diff --git a/server/data_files/gdc_values.js b/server/data_files/gdc_values.js
index 68d5806..9f70f69 100644
--- a/server/data_files/gdc_values.js
+++ b/server/data_files/gdc_values.js
@@ -1 +1 @@
-{"biospecimen.aliquot.analyte_type":[{"nm":"cfDNA","n_c":["C128274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized Normal","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE DNA","n_c":["C156435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE RNA","n_c":["C156436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GenomePlex (Rubicon) Amplified DNA","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclei RNA","n_c":["C174108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G (Qiagen) DNA","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G Pooled (Qiagen) DNA","n_c":["C156437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X (Qiagen) DNA","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A Enriched RNA","n_c":["C188352"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.aliquot.analyte_type_id":[{"nm":"D","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"E","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"G","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H","n_c":["C179446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"T","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"W","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"X","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y","n_c":"","i_c":"","i_c_s":"","term_type":""}],"metadata_file.analysis_metadata.data_category":[{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.analysis_metadata.data_type":[{"nm":"Analysis Metadata","n_c":["C165211"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.analysis_metadata.data_format":[{"nm":"SRA XML","n_c":["C184804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-TAB","n_c":["C82937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDRF","n_c":["C172211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDF","n_c":["C172212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ADF","n_c":["C172213"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.analyte_type":[{"nm":"cfDNA","n_c":["C128274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized Normal","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE DNA","n_c":["C156435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE RNA","n_c":["C156436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GenomePlex (Rubicon) Amplified DNA","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclei RNA","n_c":["C174108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G (Qiagen) DNA","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G Pooled (Qiagen) DNA","n_c":["C156437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X (Qiagen) DNA","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A Enriched RNA","n_c":["C188352"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.analyte_type_id":[{"nm":"D","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"E","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"G","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H","n_c":["C179446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"T","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"W","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"X","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y","n_c":"","i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.normal_tumor_genotype_snp_match":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"data_file.biospecimen_supplement.data_category":[{"nm":"Biospecimen","n_c":["C70699"],"i_c":"","i_c_s":"","term_type":""}],"data_file.biospecimen_supplement.data_type":[{"nm":"Biospecimen Supplement","n_c":["C164025"],"i_c":"","i_c_s":"","term_type":""}],"data_file.biospecimen_supplement.data_format":[{"nm":"BCR Auxiliary XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR Biotab","n_c":["C190164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR SSF XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR PPS XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"CDC JSON","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"FoundationOne XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XLSX","n_c":["C164050"],"i_c":"","i_c_s":"","term_type":""}],"case.case.consent_type":[{"nm":"Consent by Death","n_c":["C172262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Consent Exemption","n_c":["C79226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Consent Waiver","n_c":["C103270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Informed Consent","n_c":["C16735"],"i_c":"","i_c_s":"","term_type":""}],"case.case.disease_type":[{"nm":"Acinar Cell Neoplasms","n_c":["C4197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomas and Adenocarcinomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Adnexal and Skin Appendage Neoplasms","n_c":["C4463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Neoplasms","n_c":["C3784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel Tumors","n_c":["C7387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Myeloproliferative Disorders","n_c":["C4345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Complex Epithelial Neoplasms","n_c":["C4198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Complex Mixed and Stromal Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Cystic, Mucinous and Serous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ductal and Lobular Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Neoplasms, NOS","n_c":["C3709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroepithelial Neoplasms","n_c":["C3743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromatous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Germ Cell Neoplasms","n_c":["C3708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Giant Cell Tumors","n_c":["C3055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gliomas","n_c":["C3059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granular Cell Tumors and Alveolar Soft Part Sarcomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoproliferative Diseases","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Leukemias, NOS","n_c":["C3161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipomatous Neoplasms","n_c":["C4248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphatic Vessel Tumors","n_c":["C3723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Leukemias","n_c":["C7539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malignant Lymphomas, NOS or Diffuse","n_c":["C3208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mast Cell Tumors","n_c":["C9295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mature B-Cell Lymphomas","n_c":["C7056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mature T- and NK-Cell Lymphomas","n_c":["C3468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meningiomas","n_c":["C3230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesonephromas","n_c":["C40141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelial Neoplasms","n_c":["C3786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscellaneous Bone Tumors","n_c":["C9343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscellaneous Tumors","n_c":["C102883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucoepidermoid Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndromes","n_c":["C3247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myeloid Leukemias","n_c":["C3172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myomatous Neoplasms","n_c":["C4063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myxomatous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms, NOS","n_c":["C3262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms of Histiocytes and Accessory Lymphoid Cells","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve Sheath Tumors","n_c":["C4972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroepitheliomatous Neoplasms","n_c":["C3787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nevi and Melanomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Odontogenic Tumors","n_c":["C3286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osseous and Chondromatous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Other Hematologic Disorders","n_c":["C184783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Leukemias","n_c":["C184784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paragangliomas and Glomus Tumors","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma Cell Tumors","n_c":["C4665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Precursor Cell Lymphoblastic Lymphoma","n_c":["C9360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Tumors and Sarcomas, NOS","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Specialized Gonadal Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Cell Neoplasms","n_c":["C3792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovial-like Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Thymic Epithelial Neoplasms","n_c":["C3411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transitional Cell Papillomas and Carcinomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Trophoblastic neoplasms","n_c":["C3422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"case.case.index_date":[{"nm":"Diagnosis","n_c":["C164339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Patient Visit","n_c":["C164021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Treatment","n_c":["C164022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Initial Genomic Sequencing","n_c":["C164023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence","n_c":["C171136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sample Procurement","n_c":["C164024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Study Enrollment","n_c":["C139171"],"i_c":"","i_c_s":"","term_type":""}],"case.case.lost_to_followup":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"case.case.primary_site":[{"nm":"Accessory sinuses","n_c":["C12763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal gland","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus and anal canal","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Base of tongue","n_c":["C12228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bones, joints and articular cartilage of limbs","n_c":["C164038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bones, joints and articular cartilage of other and unspecified sites","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus and lung","n_c":["C92218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective, subcutaneous and other soft tissues","n_c":["C12964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye and adnexa","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Floor of mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart, mediastinum, and pleura","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Hematopoietic and reticuloendothelial systems","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver and intrahepatic bile ducts","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph nodes","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meninges","n_c":["C12348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal cavity and middle ear","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined digestive organs","n_c":["C148335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined sites","n_c":["C148336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined sites in lip, oral cavity and pharynx","n_c":["C148337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined sites within respiratory system and intrathoracic organs","n_c":["C148338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified female genital organs","n_c":["C148339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified major salivary glands","n_c":["C148340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified male genital organs","n_c":["C148341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified parts of biliary tract","n_c":["C148342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified parts of mouth","n_c":["C148343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified parts of tongue","n_c":["C148344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified urinary organs","n_c":["C148345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other endocrine glands and related structures","n_c":["C148346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral nerves and autonomic nervous system","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum and peritoneum","n_c":["C156712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal cord, cranial nerves, and other parts of central nervous system","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea","n_c":["C12428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"data_file.clinical_supplement.data_category":[{"nm":"Clinical","n_c":["C15783"],"i_c":"","i_c_s":"","term_type":""}],"data_file.clinical_supplement.data_type":[{"nm":"Clinical Supplement","n_c":["C164028"],"i_c":"","i_c_s":"","term_type":""}],"data_file.clinical_supplement.data_format":[{"nm":"BCR Biotab","n_c":["C190164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR OMF XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"CDC JSON","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"FoundationOne XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XLSX","n_c":["C164050"],"i_c":"","i_c_s":"","term_type":""}],"data.data_release.type":[{"nm":"data_release","n_c":["C172217"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.cause_of_death":[{"nm":"Cancer Related","n_c":["C156427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiovascular Disorder, NOS","n_c":["C2931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End-stage Renal Disease","n_c":["C9439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infection","n_c":["C26726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Cancer Related","n_c":["C156428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Disorder, NOS","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Muscular Atrophy","n_c":["C85075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical Complications","n_c":["C164157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxicity","n_c":["C27990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.cause_of_death_source":[{"nm":"Autopsy","n_c":["C25153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death Certificate","n_c":["C163970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medical Record","n_c":["C45258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social Security Death Index","n_c":["C107424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.country_of_residence_at_enrollment":[{"nm":"Afghanistan","n_c":["C16267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albania","n_c":["C16271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Algeria","n_c":["C16274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andorra","n_c":["C16289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angola","n_c":["C16292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anguilla","n_c":["C20133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antigua and Barbuda","n_c":["C16303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Argentina","n_c":["C16305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Armenia","n_c":["C16306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aruba","n_c":["C17884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Australia","n_c":["C16311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Austria","n_c":["C16312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azerbaijan","n_c":["C16316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahamas","n_c":["C16321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahrain","n_c":["C16322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bangladesh","n_c":["C16323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barbados","n_c":["C16324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belarus","n_c":["C16372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belgium","n_c":["C16329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belize","n_c":["C16331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benin","n_c":["C16333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bermuda","n_c":["C16334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bhutan","n_c":["C16336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bolivia","n_c":["C16359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosnia and Herzegovina","n_c":["C16361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botswana","n_c":["C16363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brazil","n_c":["C16364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brunei","n_c":["C16367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bulgaria","n_c":["C16368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burkina Faso","n_c":["C16369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burundi","n_c":["C16371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cambodia","n_c":["C16378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cameroon","n_c":["C16379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canada","n_c":["C16380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cape Verde","n_c":["C16382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cayman Islands","n_c":["C16391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central African Republic","n_c":["C16409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chad","n_c":["C16412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chile","n_c":["C16427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"China","n_c":["C16428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colombia","n_c":["C16449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Comoros","n_c":["C16458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congo","n_c":["C16467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cook Islands","n_c":["C16469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Costa Rica","n_c":["C16470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cote d'Ivoire","n_c":["C16762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Croatia","n_c":["C16474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cuba","n_c":["C16477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curacao","n_c":["C101225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyprus","n_c":["C16480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Czech Republic (Czechia)","n_c":["C17668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Democratic Republic of the Congo","n_c":["C17266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denmark","n_c":["C16496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Djibouti","n_c":["C16506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominica","n_c":["C16519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominican Republic","n_c":["C16520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ecuador","n_c":["C16528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Egypt","n_c":["C16530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"El Salvador","n_c":["C16532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equatorial Guinea","n_c":["C16557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eritrea","n_c":["C16558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estonia","n_c":["C16562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eswatini","n_c":["C17179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethiopia","n_c":["C16563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Falkland Islands (Malvinas)","n_c":["C17954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Faroe Islands","n_c":["C16573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Federated States of Micronesia","n_c":["C17881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fiji","n_c":["C16582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finland","n_c":["C16584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"France","n_c":["C16592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Guiana","n_c":["C16593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Polynesia","n_c":["C16594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gabon","n_c":["C16596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gambia","n_c":["C16598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Georgia","n_c":["C16634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Germany","n_c":["C16636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ghana","n_c":["C26330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gibraltar","n_c":["C16638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greece","n_c":["C16645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greenland","n_c":["C16646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grenada","n_c":["C16647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guadeloupe","n_c":["C16651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guam","n_c":["C16652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guatemala","n_c":["C16654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guernsey","n_c":["C64375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea","n_c":["C16655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea-Bissau","n_c":["C16656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guyana","n_c":["C16657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Haiti","n_c":["C16660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Holy See","n_c":["C17249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Honduras","n_c":["C16694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hong Kong","n_c":["C16695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hungary","n_c":["C16699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iceland","n_c":["C16704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"India","n_c":["C16727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indonesia","n_c":["C16728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iran","n_c":["C16755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iraq","n_c":["C16756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ireland","n_c":["C16757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isle of Man","n_c":["C44480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Israel","n_c":["C16760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Italy","n_c":["C16761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jamaica","n_c":["C16763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Japan","n_c":["C16764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jersey","n_c":["C64374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jordan","n_c":["C16765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kazakhstan","n_c":["C20107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kenya","n_c":["C16769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kiribati","n_c":["C16639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kosovo","n_c":["C123740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kuwait","n_c":["C16775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kyrgyzstan","n_c":["C16771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laos","n_c":["C16780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Latvia","n_c":["C16783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lebanon","n_c":["C16784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lesotho","n_c":["C16787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liberia","n_c":["C16791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libya","n_c":["C16793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liechtenstein","n_c":["C16794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lithuania","n_c":["C16799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luxembourg","n_c":["C16803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macau","n_c":["C16807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Madagascar","n_c":["C16808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malawi","n_c":["C16813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaysia","n_c":["C16814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maldives","n_c":["C16815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mali","n_c":["C16816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malta","n_c":["C16817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marshall Islands","n_c":["C16822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Martinique","n_c":["C16823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritania","n_c":["C16826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritius","n_c":["C16827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mayotte","n_c":["C16828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mexico","n_c":["C16850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moldova","n_c":["C16871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monaco","n_c":["C16874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mongolia","n_c":["C16875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montenegro","n_c":["C64378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montserrat","n_c":["C16876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morocco","n_c":["C16878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mozambique","n_c":["C16882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myanmar","n_c":["C16370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namibia","n_c":["C16891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nauru","n_c":["C16896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nepal","n_c":["C16901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Netherlands","n_c":["C16903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Caledonia","n_c":["C16913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Zealand","n_c":["C16914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nicaragua","n_c":["C16915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niger","n_c":["C16916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nigeria","n_c":["C16917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niue","n_c":["C16918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Korea","n_c":["C16773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Macedonia","n_c":["C17654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Northern Mariana Islands","n_c":["C17882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norway","n_c":["C16920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oman","n_c":["C16933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pakistan","n_c":["C16949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palau","n_c":["C17733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panama","n_c":["C16951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papua New Guinea","n_c":["C16952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraguay","n_c":["C16953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peru","n_c":["C16972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Philippines","n_c":["C16978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poland","n_c":["C17002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portugal","n_c":["C17006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puerto Rico","n_c":["C17043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Qatar","n_c":["C17045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reunion","n_c":["C17095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Romania","n_c":["C17108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Russia","n_c":["C17111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rwanda","n_c":["C17112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Helena, Ascension and Tristan da Cunha","n_c":["C17164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Kitts and Nevis","n_c":["C17885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Lucia","n_c":["C17113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Pierre and Miquelon","n_c":["C17165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Vincent and the Grenadines","n_c":["C17114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samoa","n_c":["C17740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"San Marino","n_c":["C17115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sao Tome and Principe","n_c":["C17116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saudi Arabia","n_c":["C17117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Senegal","n_c":["C17121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serbia","n_c":["C64377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seychelles","n_c":["C17129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sierra Leone","n_c":["C17130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Singapore","n_c":["C17134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovakia","n_c":["C17669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovenia","n_c":["C17138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solomon Islands","n_c":["C17148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somalia","n_c":["C17149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Africa","n_c":["C17151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Korea","n_c":["C16774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Sudan","n_c":["C97351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spain","n_c":["C17152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sri Lanka","n_c":["C17163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"State of Palestine","n_c":["C20110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sudan","n_c":["C17170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suriname","n_c":["C17175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Svalbard & Jan Mayen Islands","n_c":["C17178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sweden","n_c":["C17180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Switzerland","n_c":["C17181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syria","n_c":["C17182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taiwan","n_c":["C17184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tajikistan","n_c":["C17183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanzania","n_c":["C17185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thailand","n_c":["C17192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Timor-Leste","n_c":["C17200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Togo","n_c":["C17202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tokelau","n_c":["C17704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonga","n_c":["C17205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trinidad and Tobago","n_c":["C17217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tunisia","n_c":["C17221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkey","n_c":["C17222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkmenistan","n_c":["C17223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuvalu","n_c":["C17225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uganda","n_c":["C17228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ukraine","n_c":["C17229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Arab Emirates","n_c":["C17232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Kingdom","n_c":["C17233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United States","n_c":["C17234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uruguay","n_c":["C17244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uzbekistan","n_c":["C17246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vanuatu","n_c":["C17247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venezuela","n_c":["C17250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vietnam","n_c":["C17252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, British","n_c":["C17653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, U.S.","n_c":["C17255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wallis and Futuna","n_c":["C17259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Western Sahara","n_c":["C20113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yemen","n_c":["C17264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zambia","n_c":["C17267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zimbabwe","n_c":["C17268"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.ethnicity":[{"nm":"hispanic or latino","n_c":["C17459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not hispanic or latino","n_c":["C41222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not allowed to collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.gender":[{"nm":"female","n_c":["C16576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"male","n_c":["C20197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unspecified","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.premature_at_birth":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.race":[{"nm":"white","n_c":["C41261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"american indian or alaska native","n_c":["C41259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"black or african american","n_c":["C16352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"asian","n_c":["C41260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"native hawaiian or other pacific islander","n_c":["C41219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not allowed to collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.vital_status":[{"nm":"Alive","n_c":["C37987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dead","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_m":[{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_stage":[{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_t":[{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C47858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_m":[{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M2","n_c":["C188299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1d","n_c":["C188301"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_stage":[{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIID","n_c":["C137676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA1","n_c":["C139980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA2","n_c":["C139981"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_t":[{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C139415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_staging_system_edition":[{"nm":"1st","n_c":["C25509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2nd","n_c":["C25666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3rd","n_c":["C25260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4th","n_c":["C191343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5th","n_c":["C191344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6th","n_c":["C186612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7th","n_c":["C125755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8th","n_c":["C146985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.anaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.anaplasia_present_type":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse","n_c":["C14175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equivocal","n_c":["C86071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Focal","n_c":["C28224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C36113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sclerosis","n_c":["C69309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_b_symptoms":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_clinical_stage":[{"nm":"Stage I","n_c":["C125472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C125474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C125476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C125478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_extranodal_involvement":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_pathologic_stage":[{"nm":"Stage I","n_c":["C125473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C125475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C125477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C125479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.best_overall_response":[{"nm":"AJ-Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CPD-Clinical Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CR-Complete Response","n_c":["C4870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRU-Complete Response Unconfirmed","n_c":["C165198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DU-Disease Unchanged","n_c":["C71687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IMR-Immunoresponse","n_c":["C131144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IPD-Immunoprogression","n_c":["C131143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MR-Minimal/Marginal Response","n_c":["C123598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX-Mixed Response","n_c":["C165202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-CR/Non-PD-Non-CR/Non-PD","n_c":["C96700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPB-No Palliative Benefit","n_c":["C165204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR-No Response","n_c":["C123600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PA-Palliative Therapy","n_c":["C15292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PB-Palliative Benefit","n_c":["C101516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-Progressive Disease","n_c":["C8510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPD-Pseudoprogression","n_c":["C98298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PR-Partial Response","n_c":["C18058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSR-Pseudoresponse","n_c":["C131142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RD-Responsive Disease","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RP-Response","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPD-Radiographic Progressive Disease","n_c":["C165208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"sCR-Stringent Complete Response","n_c":["C123614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SD-Stable Disease","n_c":["C18213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPD-Surgical Progression","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TE-Too Early","n_c":["C133441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGPR-Very Good Partial Response","n_c":["C123618"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.burkitt_lymphoma_clinical_variant":[{"nm":"Endemic","n_c":["C27122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunodeficiency-associated, adult","n_c":["C27915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunodeficiency-associated, pediatric","n_c":["C27915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sporadic, adult","n_c":["C27914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sporadic, pediatric","n_c":["C27914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.child_pugh_classification":[{"nm":"A","n_c":["C113691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"A5","n_c":["C146790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"A6","n_c":["C146791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B","n_c":["C113692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B7","n_c":["C146792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B8","n_c":["C146793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B9","n_c":["C146794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C","n_c":["C113694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C10","n_c":["C146795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C11","n_c":["C146796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C12","n_c":["C146797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.classification_of_tumor":[{"nm":"metastasis","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premalignant","n_c":["C36032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"primary","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progression","n_c":["C17609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"recurrence","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synchronous primary","n_c":["C54621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior primary","n_c":["C156806"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_neuroblastoma_risk_group":[{"nm":"High Risk","n_c":["C102401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Risk","n_c":["C102402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Risk","n_c":["C102403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_rhabdomyosarcoma_risk_group":[{"nm":"High Risk","n_c":["C102401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Risk","n_c":["C102402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Risk","n_c":["C102403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_renal_stage":[{"nm":"Stage I","n_c":["C140301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C140303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C140305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C140307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_liver_stage":[{"nm":"Stage I","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.eln_risk_classification":[{"nm":"Adverse","n_c":["C188368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Favorable","n_c":["C188369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate","n_c":["C188370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_grade":[{"nm":"High Grade (G2)","n_c":["C140261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade (G1)","n_c":["C140260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_metastasis":[{"nm":"No Metastasis (M0)","n_c":["C147528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional or Distant Metastasis (M1)","n_c":["C147529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_stage":[{"nm":"Stage IA","n_c":["C146701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C146702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C146703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C146704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C146705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_tumor_site":[{"nm":"Extracompartmental (T2)","n_c":["C140265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intracompartmental (T1)","n_c":["C140263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.esophageal_columnar_dysplasia_degree":[{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indefinite for Dysplasia","n_c":["C164039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative/ No Dysplasia","n_c":["C164040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.esophageal_columnar_metaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.figo_stage":[{"nm":"Stage 0","n_c":["C96243"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C96244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C96245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C96246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C96247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C96248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C96249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C96250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C96251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC1","n_c":["C128099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC2","n_c":["C128100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC3","n_c":["C128101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C96252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C96253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C162223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C162224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C96254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C96255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C96256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA1","n_c":["C128102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA2","n_c":["C128105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIAi","n_c":["C128103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIAii","n_c":["C128104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C96257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C96258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C96259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C96260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C96261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C96262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C96263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.figo_staging_edition_year":[{"nm":"1988","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"1995","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"2009","n_c":"","i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.first_symptom_prior_to_diagnosis":[{"nm":"Altered Mental Status","n_c":["C121628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headaches","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motor or Movement Changes","n_c":["C157433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizures","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Visual Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.gastric_esophageal_junction_involvement":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.gleason_grade_group":[{"nm":"Group 1","n_c":["C137992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 2","n_c":["C137993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 3","n_c":["C137994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 4","n_c":["C137995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 5","n_c":["C137996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.gleason_grade_tertiary":[{"nm":"Pattern 4","n_c":["C28088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 5","n_c":["C28089"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.goblet_cells_columnar_mucosa_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.igcccg_stage":[{"nm":"Good Prognosis","n_c":["C177313","C177310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Prognosis","n_c":["C177314","C177311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poor Prognosis","n_c":["C177312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inpc_grade":[{"nm":"Differentiating","n_c":["C42048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poorly Differentiated","n_c":["C42047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undifferentiated","n_c":["C42046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undifferentiated or Poorly Differentiated","n_c":["C42047","C42046"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inpc_histologic_group":[{"nm":"Favorable","n_c":["C102560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unfavorable","n_c":["C102561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inrg_stage":[{"nm":"L1","n_c":["C133428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"L2","n_c":["C133429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M","n_c":["C133430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ms","n_c":["C133431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inss_stage":[{"nm":"Stage 1","n_c":["C85417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 2A","n_c":["C85418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 2B","n_c":["C85419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 3","n_c":["C85420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 4","n_c":["C85421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 4S","n_c":["C85422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.international_prognostic_index":[{"nm":"Low Risk","n_c":["C161806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low-Intermediate Risk","n_c":["C161807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-Intermediate Risk","n_c":["C161808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Risk","n_c":["C161809"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.irs_group":[{"nm":"Group I","n_c":["C148012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group Ia","n_c":["C148013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group Ib","n_c":["C148014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group II","n_c":["C148015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIa","n_c":["C148016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIb","n_c":["C148017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIc","n_c":["C148018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group III","n_c":["C148019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIIa","n_c":["C148020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIIb","n_c":["C148021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IV","n_c":["C148022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.irs_stage":[{"nm":"1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ishak_fibrosis_score":[{"nm":"0 - No Fibrosis","n_c":["C95150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1,2 - Portal Fibrosis","n_c":["C157159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3,4 - Fibrous Septa","n_c":["C157161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5 - Nodular Formation and Incomplete Cirrhosis","n_c":["C95155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6 - Established Cirrhosis","n_c":["C95156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.iss_stage":[{"nm":"I","n_c":["C70658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"II","n_c":["C70659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"III","n_c":["C70660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.largest_extrapelvic_peritoneal_focus":[{"nm":"Macroscopic (2cm or less)","n_c":["C53696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic (greater than 2cm)","n_c":["C51138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.last_known_disease_status":[{"nm":"Distant met recurrence/progression","n_c":["C35933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loco-regional recurrence/progression","n_c":["C8524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biochemical evidence of disease without structural correlate","n_c":["C165197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor free","n_c":["C156848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown tumor status","n_c":["C158709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"With tumor","n_c":["C156849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Midline","n_c":["C81170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unilateral","n_c":["C28012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.lymphatic_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.lymph_node_involved_site":[{"nm":"Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-external","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac, NOS","n_c":["C32761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.margins_involved_site":[{"nm":"Gerota Fascia","n_c":["C162125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parenchyma","n_c":["C74601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perinephric Fat","n_c":["C162218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Capsule","n_c":["C12885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Sinus","n_c":["C162219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Vein","n_c":["C33462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.masaoka_stage":[{"nm":"Stage I","n_c":["C112007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIa","n_c":["C112008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIb","n_c":["C112009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C112010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVa","n_c":["C112011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVb","n_c":["C112012"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.medulloblastoma_molecular_classification":[{"nm":"Not Determined","n_c":["C129447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-WNT/non-SHH Activated","n_c":["C129444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHH-Activated","n_c":["C129441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WNT-Activated","n_c":["C129440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.metastasis_at_diagnosis":[{"nm":"Distant Metastasis","n_c":["C18206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metastasis, NOS","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Metastasis","n_c":["C164041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional Metastasis","n_c":["C172220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.metastasis_at_diagnosis_site":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal Gland","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Nodes","n_c":["C172221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Organ","n_c":["C172223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, NOS","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Adnexa","n_c":["C12321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebral Canal","n_c":["C33869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Subcarinal","n_c":["C117873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.method_of_diagnosis":[{"nm":"Autopsy","n_c":["C25153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy","n_c":["C15189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Draw","n_c":["C17610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Aspirate","n_c":["C133261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Core Biopsy","n_c":["C15680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytology","n_c":["C16491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cystoscopy","n_c":["C16482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Debulking","n_c":["C15749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diagnostic Imaging","n_c":["C16502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dilation and Curettage Procedure","n_c":["C15226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enucleation","n_c":["C48601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Excisional Biopsy","n_c":["C15385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fine Needle Aspiration","n_c":["C15361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imaging","n_c":["C17369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incisional Biopsy","n_c":["C15386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopy","n_c":["C16969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparotomy","n_c":["C15266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pap Smear","n_c":["C17348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical Exam","n_c":["C20989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathologic Review","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical Resection","n_c":["C158758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracentesis","n_c":["C15392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ultrasound Guided Biopsy","n_c":["C93022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exoresection","n_c":["C118358"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.mitosis_karyorrhexis_index":[{"nm":"High","n_c":["C25227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate","n_c":["C73705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low","n_c":["C54722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.morphology":[{"nm":"8000/0","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Neoplasm, benign","Tumor, benign","Unclassified tumor, benign"],"term_type":""},{"nm":"8000/1","n_c":["C3262","C65157"],"i_c":"8000/1","i_c_s":["Neoplasm, uncertain whether benign or malignant","Neoplasm, NOS","Tumor, NOS","Unclassified tumor, borderline malignancy","Unclassified tumor, uncertain whether benign or malignant"],"term_type":""},{"nm":"8000/3","n_c":["C9305","C8997"],"i_c":"8000/3","i_c_s":["Neoplasm, malignant","Blastoma, NOS","Cancer","Malignancy","Tumor, malignant, NOS","Unclassified tumor, malignant"],"term_type":""},{"nm":"8000/6","n_c":["C36255","C3005","C3261"],"i_c":"8000/6","i_c_s":["Neoplasm, metastatic","Neoplasm, secondary","Tumor embolus","Tumor, metastatic","Tumor, secondary"],"term_type":""},{"nm":"8000/9","n_c":["C65153"],"i_c":"8000/9","i_c_s":["Neoplasm, malignant, uncertain whether primary or metastatic","Unclassified tumor, malignant, uncertain whether primary or metastatic"],"term_type":""},{"nm":"8001/0","n_c":["C36122"],"i_c":"8001/0","i_c_s":["Tumor cells, benign"],"term_type":""},{"nm":"8001/1","n_c":["C12922"],"i_c":"8001/1","i_c_s":["Tumor cells, uncertain whether benign or malignant","Tumor cells, NOS"],"term_type":""},{"nm":"8001/3","n_c":["C12917"],"i_c":"8001/3","i_c_s":["Tumor cells, malignant"],"term_type":""},{"nm":"8002/3","n_c":["C65154"],"i_c":"8002/3","i_c_s":["Malignant tumor, small cell type"],"term_type":""},{"nm":"8003/3","n_c":["C4090"],"i_c":"8003/3","i_c_s":["Malignant tumor, giant cell type"],"term_type":""},{"nm":"8004/3","n_c":["C27091"],"i_c":"8004/3","i_c_s":["Malignant tumor, spindle cell type","Malignant tumor, fusiform cell type"],"term_type":""},{"nm":"8005/0","n_c":["C66752"],"i_c":"8005/0","i_c_s":["Clear cell tumor, NOS"],"term_type":""},{"nm":"8005/3","n_c":["C40077"],"i_c":"8005/3","i_c_s":["Malignant tumor, clear cell type"],"term_type":""},{"nm":"8010/0","n_c":["C4092"],"i_c":"8010/0","i_c_s":["Epithelial tumor, benign"],"term_type":""},{"nm":"8010/2","n_c":["C2917"],"i_c":"8010/2","i_c_s":["Carcinoma in situ, NOS","Intraepithelial carcinoma, NOS"],"term_type":""},{"nm":"8010/3","n_c":["C2916"],"i_c":"8010/3","i_c_s":["Carcinoma, NOS","Epithelial tumor, malignant"],"term_type":""},{"nm":"8010/6","n_c":["C3482"],"i_c":"8010/6","i_c_s":["Carcinoma, metastatic, NOS","Secondary carcinoma"],"term_type":""},{"nm":"8010/9","n_c":["C3693"],"i_c":"8010/9","i_c_s":["Carcinomatosis"],"term_type":""},{"nm":"8011/0","n_c":["C4092"],"i_c":"8011/0","i_c_s":["Epithelioma, benign"],"term_type":""},{"nm":"8011/3","n_c":["C2916"],"i_c":"8011/3","i_c_s":["Epithelioma, malignant","Epithelioma, NOS"],"term_type":""},{"nm":"8012/3","n_c":["C3780"],"i_c":"8012/3","i_c_s":["Large cell carcinoma, NOS"],"term_type":""},{"nm":"8013/3","n_c":["C6875"],"i_c":"8013/3","i_c_s":["Large cell neuroendocrine carcinoma"],"term_type":""},{"nm":"8014/3","n_c":["C6876"],"i_c":"8014/3","i_c_s":["Large cell carcinoma with rhabdoid phenotype"],"term_type":""},{"nm":"8015/3","n_c":["C65159"],"i_c":"8015/3","i_c_s":["Glassy cell carcinoma"],"term_type":""},{"nm":"8020/3","n_c":["C3692"],"i_c":"8020/3","i_c_s":["Carcinoma, undifferentiated, NOS"],"term_type":""},{"nm":"8020/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8021/3","n_c":["C3692"],"i_c":"8021/3","i_c_s":["Carcinoma, anaplastic, NOS"],"term_type":""},{"nm":"8022/3","n_c":["C4094"],"i_c":"8022/3","i_c_s":["Pleomorphic carcinoma"],"term_type":""},{"nm":"8023/3","n_c":["C45716"],"i_c":"8023/3","i_c_s":["NUT carcinoma"],"term_type":""},{"nm":"8030/3","n_c":["C65160"],"i_c":"8030/3","i_c_s":["Giant cell and spindle cell carcinoma"],"term_type":""},{"nm":"8031/3","n_c":["C3779"],"i_c":"8031/3","i_c_s":["Giant cell carcinoma"],"term_type":""},{"nm":"8032/3","n_c":["C27004"],"i_c":"8032/3","i_c_s":["Spindle cell carcinoma, NOS"],"term_type":""},{"nm":"8033/3","n_c":["C27004"],"i_c":"8033/3","i_c_s":["Pseudosarcomatous carcinoma","Sarcomatoid carcinoma"],"term_type":""},{"nm":"8034/3","n_c":["C65161"],"i_c":"8034/3","i_c_s":["Polygonal cell carcinoma"],"term_type":""},{"nm":"8035/3","n_c":["C63622"],"i_c":"8035/3","i_c_s":["Carcinoma with osteoclast-like giant cells"],"term_type":""},{"nm":"8040/0","n_c":["C65162"],"i_c":"8040/0","i_c_s":["Tumorlet, benign"],"term_type":""},{"nm":"8040/1","n_c":["C65162"],"i_c":"8040/1","i_c_s":["Tumorlet, NOS"],"term_type":""},{"nm":"8040/3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8041/3","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Small cell carcinoma, NOS","Small cell neuroendocrine carcinoma","Reserve cell carcinoma","Round cell carcinoma"],"term_type":""},{"nm":"8041/34","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8041/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8042/3","n_c":["C3915"],"i_c":"8042/3","i_c_s":["Oat cell carcinoma"],"term_type":""},{"nm":"8043/3","n_c":["C27092"],"i_c":"8043/3","i_c_s":["Small cell carcinoma, fusiform cell"],"term_type":""},{"nm":"8044/3","n_c":["C4099"],"i_c":"8044/3","i_c_s":["Small cell carcinoma, intermediate cell"],"term_type":""},{"nm":"8045/3","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Combined small cell carcinoma","Combined small cell-adenocarcinoma","Combined small cell-large cell carcinoma","Combined small cell-squamous cell carcinoma","Mixed small cell carcinoma"],"term_type":""},{"nm":"8046/3","n_c":["C65151"],"i_c":"8046/3","i_c_s":["Non-small cell carcinoma"],"term_type":""},{"nm":"8046/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8050/0","n_c":["C7440"],"i_c":"8050/0","i_c_s":["Papilloma, NOS"],"term_type":""},{"nm":"8050/2","n_c":["C65163"],"i_c":"8050/2","i_c_s":["Papillary carcinoma in situ"],"term_type":""},{"nm":"8050/3","n_c":["C2927"],"i_c":"8050/3","i_c_s":["Papillary carcinoma, NOS"],"term_type":""},{"nm":"8051/0","n_c":["C4101"],"i_c":"8051/0","i_c_s":["Verrucous papilloma"],"term_type":""},{"nm":"8051/3","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous carcinoma, NOS","Condylomatous carcinoma","Verrucous epidermoid carcinoma","Verrucous squamous cell carcinoma","Warty carcinoma"],"term_type":""},{"nm":"8052/0","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Squamous cell papilloma, NOS","Keratotic papilloma","Squamous papilloma"],"term_type":""},{"nm":"8052/2","n_c":["C65164"],"i_c":"8052/2","i_c_s":["Papillary squamous cell carcinoma, non-invasive","Papillary squamous cell carcinoma in situ"],"term_type":""},{"nm":"8052/3","n_c":["C4102"],"i_c":"8052/3","i_c_s":["Papillary squamous cell carcinoma","Papillary epidermoid carcinoma"],"term_type":""},{"nm":"8053/0","n_c":["C65165"],"i_c":"8053/0","i_c_s":["Squamous cell papilloma, inverted"],"term_type":""},{"nm":"8060/0","n_c":["C9009","C3713"],"i_c":"8060/0","i_c_s":["Squamous papillomatosis","Papillomatosis, NOS"],"term_type":""},{"nm":"8070/2","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Squamous cell carcinoma in situ, NOS","Epidermoid carcinoma in situ, NOS","Intraepidermal carcinoma, NOS","Intraepithelial squamous cell carcinoma"],"term_type":""},{"nm":"8070/3","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous cell carcinoma, NOS","Epidermoid carcinoma, NOS","Squamous carcinoma","Squamous cell epithelioma"],"term_type":""},{"nm":"8070/33","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8070/6","n_c":["C4104"],"i_c":"8070/6","i_c_s":["Squamous cell carcinoma, metastatic, NOS"],"term_type":""},{"nm":"8071/2","n_c":["C4105"],"i_c":"8071/2","i_c_s":["Sq. cell carcinoma, keratinizing, NOS, in situ"],"term_type":""},{"nm":"8071/3","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Squamous cell carcinoma, keratinizing, NOS","Epidermoid carcinoma, keratinizing","Squamous cell carcinoma, large cell, keratinizing"],"term_type":""},{"nm":"8072/3","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Squamous cell carcinoma, large cell, nonkeratinizing, NOS","Epidermoid carcinoma, large cell, nonkeratinizing","Squamous cell carcinoma, nonkeratinizing, NOS"],"term_type":""},{"nm":"8073/3","n_c":["C65175"],"i_c":"8073/3","i_c_s":["Squamous cell carcinoma, small cell, nonkeratinizing","Epidermoid carcinoma, small cell, nonkeratinizing"],"term_type":""},{"nm":"8074/3","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Squamous cell carcinoma, spindle cell","Epidermoid carcinoma, spindle cell","Squamous cell carcinoma, sarcomatoid"],"term_type":""},{"nm":"8075/3","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, adenoid","Squamous cell carcinoma, acantholytic","Squamous cell carcinoma, pseudoglandular"],"term_type":""},{"nm":"8076/2","n_c":["C65176"],"i_c":"8076/2","i_c_s":["Squamous cell carcinoma in situ with questionable stromal invasion","Epidermoid carcinoma in situ with questionable stromal invasion"],"term_type":""},{"nm":"8076/3","n_c":["C65178"],"i_c":"8076/3","i_c_s":["Squamous cell carcinoma, microinvasive"],"term_type":""},{"nm":"8077/0","n_c":["C7351","C27427","C8335","C4630"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, low grade","Anal intraepithelial neoplasia, low grade","Cervical intraepithelial neoplasia, low grade","Esophageal squamous intraepithelial neoplasia (dysplasia), low grade","Squamous intraepithelial neoplasia, grade II","Squamous intraepithelial neoplasia, grade I"],"term_type":""},{"nm":"8077/2","n_c":["C27093","C8336","C157575","C7855","C4000","C4522"],"i_c":"8077/2","i_c_s":["Squamous intraepithelial neoplasia, high grade","Anal intraepithelial neoplasia, grade III","Cervical intraepithelial neoplasia, grade III","Esophageal squamous intraepithelial neoplasia (dysplasia), high grade","Vaginal intraepithelial neoplasia, grade III","Vulvar intraepithelial neoplasia, grade III","AIN III","CIN III with severe dysplasia","CIN III, NOS","Squamous intraepithelial neoplasia, grade III","VAIN III","VIN III"],"term_type":""},{"nm":"8078/3","n_c":["C65179"],"i_c":"8078/3","i_c_s":["Squamous cell carcinoma with horn formation"],"term_type":""},{"nm":"8080/2","n_c":["C27790"],"i_c":"8080/2","i_c_s":["Queyrat erythroplasia"],"term_type":""},{"nm":"8081/2","n_c":["C62571"],"i_c":"8081/2","i_c_s":["Bowen disease","Intraepidermal squamous cell carcinoma, Bowen type"],"term_type":""},{"nm":"8082/3","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelial carcinoma","Schmincke tumor","Lymphoepithelioma-like carcinoma","Lymphoepithelioma"],"term_type":""},{"nm":"8083/3","n_c":["C54244"],"i_c":"8083/3","i_c_s":["Basaloid squamous cell carcinoma"],"term_type":""},{"nm":"8084/3","n_c":["C65180"],"i_c":"8084/3","i_c_s":["Squamous cell carcinoma, clear cell type"],"term_type":""},{"nm":"8085/3","n_c":["C27683"],"i_c":"8085/3","i_c_s":["Squamous cell carcinoma, HPV-positive"],"term_type":""},{"nm":"8086/3","n_c":["C164250"],"i_c":"8086/3","i_c_s":["Squamous cell carcinoma, HPV-negative"],"term_type":""},{"nm":"8090/1","n_c":["C3784"],"i_c":"8090/1","i_c_s":["Basal cell tumor"],"term_type":""},{"nm":"8090/3","n_c":["C2921","C9359","C156767"],"i_c":"8090/3","i_c_s":["Basal cell carcinoma, NOS","Pigmented basal cell carcinoma","Basal cell epithelioma","Rodent ulcer"],"term_type":""},{"nm":"8091/3","n_c":["C4108"],"i_c":"8091/3","i_c_s":["Multifocal superficial basal cell carcinoma","Multicentric basal cell carcinoma"],"term_type":""},{"nm":"8092/3","n_c":["C27182","C27539"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, NOS","Infiltrating basal cell carcinoma, non-sclerosing","Infiltrating basal cell carcinoma, sclerosing","Basal cell carcinoma, desmoplastic type","Basal cell carcinoma, morpheic"],"term_type":""},{"nm":"8093/3","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Basal cell carcinoma, fibroepithelial","Fibroepithelial basal cell carcinoma, Pinkus type","Fibroepithelioma of Pinkus type","Fibroepithelioma, NOS","Pinkus tumor"],"term_type":""},{"nm":"8094/3","n_c":["C2922"],"i_c":"8094/3","i_c_s":["Basosquamous carcinoma","Mixed basal-squamous cell carcinoma"],"term_type":""},{"nm":"8095/3","n_c":["C66903"],"i_c":"8095/3","i_c_s":["Metatypical carcinoma"],"term_type":""},{"nm":"8096/0","n_c":["C4110"],"i_c":"8096/0","i_c_s":["Intraepidermal epithelioma of Jadassohn"],"term_type":""},{"nm":"8097/3","n_c":["C27541","C62282"],"i_c":"8097/3","i_c_s":["Basal cell carcinoma, nodular","Basal cell carcinoma, micronodular"],"term_type":""},{"nm":"8098/3","n_c":["C27535"],"i_c":"8098/3","i_c_s":["Adenoid basal carcinoma"],"term_type":""},{"nm":"8100/0","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Trichoepithelioma","Brooke tumor","Epithelioma adenoides cysticum"],"term_type":""},{"nm":"8101/0","n_c":["C4112"],"i_c":"8101/0","i_c_s":["Trichofolliculoma"],"term_type":""},{"nm":"8102/0","n_c":["C4113"],"i_c":"8102/0","i_c_s":["Trichilemmoma"],"term_type":""},{"nm":"8102/3","n_c":["C43326"],"i_c":"8102/3","i_c_s":["Trichilemmocarcinoma","Trichilemmal carcinoma"],"term_type":""},{"nm":"8103/0","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Pilar tumor","Proliferating trichilemmal cyst","Proliferating trichilemmal tumor"],"term_type":""},{"nm":"8110/0","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Pilomatrixoma, NOS","Calcifying epithelioma of Malherbe","Pilomatricoma, NOS"],"term_type":""},{"nm":"8110/3","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatrix carcinoma","Matrical carcinoma","Pilomatricoma, malignant","Pilomatrixoma, malignant"],"term_type":""},{"nm":"8120/0","n_c":["C4115"],"i_c":"8120/0","i_c_s":["Transitional cell papilloma, benign","Transitional papilloma"],"term_type":""},{"nm":"8120/1","n_c":["C4115","C3842"],"i_c":"8120/1","i_c_s":["Urothelial papilloma, NOS","Papilloma of bladder","Transitional cell papilloma, NOS"],"term_type":""},{"nm":"8120/2","n_c":["C4116"],"i_c":"8120/2","i_c_s":["Transitional cell carcinoma in situ","Urothelial carcinoma in situ"],"term_type":""},{"nm":"8120/3","n_c":["C2930","C4030"],"i_c":"8120/3","i_c_s":["Transitional cell carcinoma, NOS","Transitional carcinoma","Urothelial carcinoma, NOS"],"term_type":""},{"nm":"8121/0","n_c":["C4117","C4118"],"i_c":"8121/0","i_c_s":["Schneiderian papilloma, NOS","Sinonasal papilloma, exophytic","Transitional cell papilloma, inverted, benign","Transitional papilloma, inverted, benign","Sinonasal papilloma, NOS","Sinonasal papilloma, fungiform"],"term_type":""},{"nm":"8121/1","n_c":["C6871","C54345","C4118"],"i_c":"8121/1","i_c_s":["Transitional cell papilloma, inverted, NOS","Columnar cell papilloma","Cylindrical cell papilloma","Oncocytic Schneiderian papilloma","Schneiderian papilloma, inverted","Transitional papilloma, inverted, NOS"],"term_type":""},{"nm":"8121/3","n_c":["C54287"],"i_c":"8121/3","i_c_s":["Schneiderian carcinoma","Cylindrical cell carcinoma"],"term_type":""},{"nm":"8122/3","n_c":["C4120"],"i_c":"8122/3","i_c_s":["Transitional cell carcinoma, spindle cell","Transitional cell carcinoma, sarcomatoid"],"term_type":""},{"nm":"8123/3","n_c":["C4121"],"i_c":"8123/3","i_c_s":["Basaloid carcinoma"],"term_type":""},{"nm":"8124/3","n_c":["C8255"],"i_c":"8124/3","i_c_s":["Cloacogenic carcinoma"],"term_type":""},{"nm":"8130/1","n_c":["C191672"],"i_c":"8130/1","i_c_s":["Papillary transitional cell neoplasm of low malignant potential","Papillary urothelial neoplasm of low malignant potential"],"term_type":""},{"nm":"8130/2","n_c":["C65181"],"i_c":"8130/2","i_c_s":["Papillary transitional cell carcinoma, non-invasive","Papillary urothelial carcinoma, non-invasive"],"term_type":""},{"nm":"8130/3","n_c":["C4122"],"i_c":"8130/3","i_c_s":["Papillary transitional cell carcinoma","Papillary urothelial carcinoma"],"term_type":""},{"nm":"8131/3","n_c":["C65182"],"i_c":"8131/3","i_c_s":["Transitional cell carcinoma, micropapillary"],"term_type":""},{"nm":"8140/0","n_c":["C2855"],"i_c":"8140/0","i_c_s":["Adenoma, NOS"],"term_type":""},{"nm":"8140/1","n_c":["C3494","C7559"],"i_c":"8140/1","i_c_s":["Atypical adenoma","Bronchial adenoma, NOS"],"term_type":""},{"nm":"8140/2","n_c":["C4123"],"i_c":"8140/2","i_c_s":["Adenocarcinoma in situ, NOS"],"term_type":""},{"nm":"8140/3","n_c":["C2852"],"i_c":"8140/3","i_c_s":["Adenocarcinoma, NOS"],"term_type":""},{"nm":"8140/33","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8140/6","n_c":["C4124"],"i_c":"8140/6","i_c_s":["Adenocarcinoma, metastatic, NOS"],"term_type":""},{"nm":"8141/3","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Scirrhous adenocarcinoma","Carcinoma with productive fibrosis","Scirrhous carcinoma"],"term_type":""},{"nm":"8142/3","n_c":["C3190"],"i_c":"8142/3","i_c_s":["Linitis plastica"],"term_type":""},{"nm":"8143/3","n_c":["C4125"],"i_c":"8143/3","i_c_s":["Superficial spreading adenocarcinoma"],"term_type":""},{"nm":"8144/3","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Adenocarcinoma, intestinal type","Carcinoma, intestinal type"],"term_type":""},{"nm":"8145/3","n_c":["C4127"],"i_c":"8145/3","i_c_s":["Carcinoma, diffuse type","Adenocarcinoma, diffuse type"],"term_type":""},{"nm":"8146/0","n_c":["C3686"],"i_c":"8146/0","i_c_s":["Monomorphic adenoma"],"term_type":""},{"nm":"8147/0","n_c":["C5950"],"i_c":"8147/0","i_c_s":["Basal cell adenoma"],"term_type":""},{"nm":"8147/3","n_c":["C3678"],"i_c":"8147/3","i_c_s":["Basal cell adenocarcinoma"],"term_type":""},{"nm":"8148/0","n_c":["C7660","C7661","C27428"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, low grade","Biliary intraepithelial neoplasia, low grade","Esophageal glandular dysplasia (intraepithelial neoplasia), low grade","Glandular intraepithelial neoplasia, grade II","Glandular intraepithelial neoplasia, grade I"],"term_type":""},{"nm":"8148/2","n_c":["C6877","C27429","C27425","C67493","C3642","C7662"],"i_c":"8148/2","i_c_s":["Glandular intraepithelial neoplasia, high grade","Biliary intraepithelial neoplasia, high grade","Esophageal glandular dysplasia (intraepithelial neoplasia), high grade","Flat intraepithelial glandular neoplasia, high grade","Prostatic intraepithelial neoplasia, grade III","Biliary intraepithelial neoplasia, grade 3 (BilIN-3)","Esophageal intraepithelial neoplasia, high grade","Flat intraepithelial neoplasia (dysplasia), high grade","Flat intraepithelial neoplasia, high grade","Glandular intraepithelial neoplasia, grade III","PIN III"],"term_type":""},{"nm":"8149/0","n_c":["C5979"],"i_c":"8149/0","i_c_s":["Canalicular adenoma"],"term_type":""},{"nm":"8150/0","n_c":["C27720"],"i_c":"8150/0","i_c_s":["Pancreatic endocrine tumor, benign","Islet cell adenomatosis","Pancreatic microadenoma","Islet cell adenoma","Islet cell tumor, benign","Nesidioblastoma"],"term_type":""},{"nm":"8150/1","n_c":["C27031"],"i_c":"8150/1","i_c_s":["Pancreatic endocrine tumor, NOS","Islet cell tumor, NOS"],"term_type":""},{"nm":"8150/3","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Pancreatic endocrine tumor, malignant","Pancreatic endocrine tumor, nonfunctioning","Islet cell adenocarcinoma","Islet cell carcinoma"],"term_type":""},{"nm":"8151/0","n_c":["C67457","C95598"],"i_c":"8151/0","i_c_s":["Insulinoma, NOS","Beta cell adenoma"],"term_type":""},{"nm":"8151/3","n_c":["C65186"],"i_c":"8151/3","i_c_s":["Insulinoma, malignant","Beta cell tumor, malignant"],"term_type":""},{"nm":"8152/1","n_c":["C95597"],"i_c":"8152/1","i_c_s":["Glucagonoma, NOS","Enteroglucagonoma, NOS","Glucagon-like peptide-producing tumor","L-cell tumor","Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor","Alpha cell tumor, NOS","PP/PYY producing tumor"],"term_type":""},{"nm":"8152/3","n_c":["C65191","C65187"],"i_c":"8152/3","i_c_s":["Glucagonoma, malignant","Enteroglucagonoma, malignant","Alpha cell tumor, malignant"],"term_type":""},{"nm":"8153/1","n_c":["C3050"],"i_c":"8153/1","i_c_s":["Gastrinoma, NOS","G cell tumor, NOS","Gastrin cell tumor"],"term_type":""},{"nm":"8153/3","n_c":["C65188"],"i_c":"8153/3","i_c_s":["Gastrinoma, malignant","G cell tumor, malignant","Gastrin cell tumor, malignant"],"term_type":""},{"nm":"8154/3","n_c":["C164255","C45843"],"i_c":"8154/3","i_c_s":["Mixed pancreatic endocrine and exocrine tumor, malignant","Mixed acinar-endocrine carcinoma","Mixed acinar-endocrine-ductal carcinoma","Mixed ductal-endocrine carcinoma","Mixed endocrine and exocrine adenocarcinoma","Mixed islet cell and exocrine adenocarcinoma"],"term_type":""},{"nm":"8155/1","n_c":["C26749"],"i_c":"8155/1","i_c_s":["Vipoma, NOS"],"term_type":""},{"nm":"8155/3","n_c":["C65189"],"i_c":"8155/3","i_c_s":["Vipoma, malignant"],"term_type":""},{"nm":"8156/1","n_c":["C3379"],"i_c":"8156/1","i_c_s":["Somatostatinoma, NOS","Somatostatin cell tumor, NOS"],"term_type":""},{"nm":"8156/3","n_c":["C65190"],"i_c":"8156/3","i_c_s":["Somatostatinoma, malignant","Somatostatin cell tumor, malignant"],"term_type":""},{"nm":"8158/1","n_c":["C94759"],"i_c":"8158/1","i_c_s":["Endocrine tumor, functioning, NOS","ACTH-producing tumor"],"term_type":""},{"nm":"8160/0","n_c":["C2942"],"i_c":"8160/0","i_c_s":["Bile duct adenoma","Cholangioma"],"term_type":""},{"nm":"8160/3","n_c":["C4436","C27813","C27814"],"i_c":"8160/3","i_c_s":["Cholangiocarcinoma","Bile duct adenocarcinoma","Bile duct carcinoma"],"term_type":""},{"nm":"8161/0","n_c":["C4129"],"i_c":"8161/0","i_c_s":["Bile duct cystadenoma"],"term_type":""},{"nm":"8161/3","n_c":["C4130"],"i_c":"8161/3","i_c_s":["Bile duct cystadenocarcinoma"],"term_type":""},{"nm":"8162/3","n_c":["C36077"],"i_c":"8162/3","i_c_s":["Klatskin tumor"],"term_type":""},{"nm":"8163/0","n_c":["C95914","C95913"],"i_c":"8163/0","i_c_s":["Pancreatobiliary neoplasm, non-invasive","Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia","Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":""},{"nm":"8163/2","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia","Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia","Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":""},{"nm":"8163/3","n_c":["C95963"],"i_c":"8163/3","i_c_s":["Pancreatobiliary-type carcinoma","Adenocarcinoma, pancreatobiliary type"],"term_type":""},{"nm":"8170/0","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Liver cell adenoma","Hepatocellular adenoma","Hepatoma, benign"],"term_type":""},{"nm":"8170/3","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatocellular carcinoma, NOS","Hepatocarcinoma","Hepatoma, NOS","Hepatoma, malignant","Liver cell carcinoma"],"term_type":""},{"nm":"8171/3","n_c":["C4131"],"i_c":"8171/3","i_c_s":["Hepatocellular carcinoma, fibrolamellar"],"term_type":""},{"nm":"8172/3","n_c":["C27388"],"i_c":"8172/3","i_c_s":["Hepatocellular carcinoma, scirrhous","Sclerosing hepatic carcinoma"],"term_type":""},{"nm":"8173/3","n_c":["C43627"],"i_c":"8173/3","i_c_s":["Hepatocellular carcinoma, spindle cell variant","Hepatocellular carcinoma, sarcomatoid"],"term_type":""},{"nm":"8174/3","n_c":["C5754"],"i_c":"8174/3","i_c_s":["Hepatocellular carcinoma, clear cell type"],"term_type":""},{"nm":"8175/3","n_c":["C43625"],"i_c":"8175/3","i_c_s":["Hepatocellular carcinoma, pleomorphic type"],"term_type":""},{"nm":"8180/3","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Combined hepatocellular carcinoma and cholangiocarcinoma","Hepatocholangiocarcinoma","Mixed hepatocellular and bile duct carcinoma"],"term_type":""},{"nm":"8190/0","n_c":["C3688"],"i_c":"8190/0","i_c_s":["Trabecular adenoma"],"term_type":""},{"nm":"8190/3","n_c":["C4068"],"i_c":"8190/3","i_c_s":["Trabecular adenocarcinoma","Trabecular carcinoma"],"term_type":""},{"nm":"8191/0","n_c":["C27253"],"i_c":"8191/0","i_c_s":["Embryonal adenoma"],"term_type":""},{"nm":"8200/0","n_c":["C43352","C27094"],"i_c":"8200/0","i_c_s":["Eccrine dermal cylindroma","Cylindroma of skin","Turban tumor"],"term_type":""},{"nm":"8200/3","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenoid cystic carcinoma","Bronchial adenoma, cylindroid","Adenocarcinoma, cylindroid","Adenocystic carcinoma","Cylindroma, NOS"],"term_type":""},{"nm":"8201/2","n_c":["C162973"],"i_c":"8201/2","i_c_s":["Cribriform carcinoma in situ","Ductal carcinoma in situ, cribriform type"],"term_type":""},{"nm":"8201/3","n_c":["C3680"],"i_c":"8201/3","i_c_s":["Cribriform carcinoma, NOS","Cribriform comedo-type carcinoma","Adenocarcinoma, cribriform comedo-type","Ductal carcinoma, cribriform type"],"term_type":""},{"nm":"8202/0","n_c":["C3685"],"i_c":"8202/0","i_c_s":["Microcystic adenoma"],"term_type":""},{"nm":"8204/0","n_c":["C9473"],"i_c":"8204/0","i_c_s":["Lactating adenoma"],"term_type":""},{"nm":"8210/0","n_c":["C3764"],"i_c":"8210/0","i_c_s":["Adenomatous polyp, NOS","Polypoid adenoma"],"term_type":""},{"nm":"8210/2","n_c":["C7678","C7680","C7679","C7681"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in adenomatous polyp","Adenocarcinoma in situ in a polyp, NOS","Adenocarcinoma in situ in polypoid adenoma","Adenocarcinoma in situ in tubular adenoma","Carcinoma in situ in a polyp, NOS","Carcinoma in situ in adenomatous polyp"],"term_type":""},{"nm":"8210/3","n_c":["C7676","C7677","C7682"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in adenomatous polyp","Adenocarcinoma in a polyp, NOS","Adenocarcinoma in polypoid adenoma","Adenocarcinoma in tubular adenoma","Carcinoma in a polyp, NOS","Carcinoma in adenomatous polyp"],"term_type":""},{"nm":"8211/0","n_c":["C4133"],"i_c":"8211/0","i_c_s":["Tubular adenoma, NOS"],"term_type":""},{"nm":"8211/3","n_c":["C65192"],"i_c":"8211/3","i_c_s":["Tubular adenocarcinoma","Tubular carcinoma"],"term_type":""},{"nm":"8212/0","n_c":["C65193"],"i_c":"8212/0","i_c_s":["Flat adenoma"],"term_type":""},{"nm":"8213/0","n_c":["C38458","C96414"],"i_c":"8213/0","i_c_s":["Serrated adenoma","Mixed adenomatous and hyperplastic polyp","Sessile serrated adenoma","Sessile serrated polyp","Traditional sessile serrated adenoma","Traditional serrated adenoma"],"term_type":""},{"nm":"8213/3","n_c":["C96485"],"i_c":"8213/3","i_c_s":["Serrated adenocarcinoma"],"term_type":""},{"nm":"8214/3","n_c":["C65194"],"i_c":"8214/3","i_c_s":["Parietal cell carcinoma","Parietal cell adenocarcinoma"],"term_type":""},{"nm":"8215/3","n_c":["C5609"],"i_c":"8215/3","i_c_s":["Adenocarcinoma of anal glands","Adenocarcinoma of anal ducts"],"term_type":""},{"nm":"8220/0","n_c":["C3339"],"i_c":"8220/0","i_c_s":["Adenomatous polyposis coli","Adenomatosis, NOS","Familial polyposis coli"],"term_type":""},{"nm":"8220/3","n_c":["C4134"],"i_c":"8220/3","i_c_s":["Adenocarcinoma in adenomatous polyposis coli"],"term_type":""},{"nm":"8221/0","n_c":["C4135"],"i_c":"8221/0","i_c_s":["Multiple adenomatous polyps"],"term_type":""},{"nm":"8221/3","n_c":["C4136"],"i_c":"8221/3","i_c_s":["Adenocarcinoma in multiple adenomatous polyps"],"term_type":""},{"nm":"8230/2","n_c":["C66933"],"i_c":"8230/2","i_c_s":["Ductal carcinoma in situ, solid type","Intraductal carcinoma, solid type"],"term_type":""},{"nm":"8230/3","n_c":["C4137"],"i_c":"8230/3","i_c_s":["Solid carcinoma, NOS","Solid carcinoma with mucin formation","Solid adenocarcinoma with mucin formation"],"term_type":""},{"nm":"8231/3","n_c":["C65195"],"i_c":"8231/3","i_c_s":["Carcinoma simplex"],"term_type":""},{"nm":"8240/1","n_c":["C65196"],"i_c":"8240/1","i_c_s":["Carcinoid tumor of uncertain malignant potential","Carcinoid tumor, argentaffin, NOS","Argentaffinoma, NOS"],"term_type":""},{"nm":"8240/3","n_c":["C35727","C2915"],"i_c":"8240/3","i_c_s":["Carcinoid tumor, NOS","Bronchial adenoma, carcinoid","Neuroendocrine carcinoma, low grade","Neuroendocrine carcinoma, well-differentiated","Neuroendocrine tumor, grade I","Typical carcinoid","Carcinoid, NOS"],"term_type":""},{"nm":"8240/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8241/3","n_c":["C2915"],"i_c":"8241/3","i_c_s":["Enterochromaffin cell carcinoid","Argentaffinoma, malignant","Carcinoid tumor, argentaffin, malignant","EC cell carcinoid","Serotonin producing carcinoid"],"term_type":""},{"nm":"8242/1","n_c":["C27252"],"i_c":"8242/1","i_c_s":["Enterochromaffin-like cell carcinoid, NOS","ECL cell carcinoid, NOS"],"term_type":""},{"nm":"8242/3","n_c":["C27252"],"i_c":"8242/3","i_c_s":["Enterochromaffin-like cell tumor, malignant","ECL cell carcinoid, malignant"],"term_type":""},{"nm":"8243/3","n_c":["C201135"],"i_c":"8243/3","i_c_s":["Goblet cell carcinoid","Mucinous carcinoid","Mucocarcinoid tumor"],"term_type":""},{"nm":"8244/3","n_c":["C95406"],"i_c":"8244/3","i_c_s":["Mixed adenoneuroendocrine carcinoma","Combined carcinoid and adenocarcinoma","Combined/mixed carcinoid and adenocarcinoma","Composite carcinoid","MANEC","Mixed carcinoid-adenocarcinoma"],"term_type":""},{"nm":"8245/1","n_c":["C43565"],"i_c":"8245/1","i_c_s":["Tubular carcinoid"],"term_type":""},{"nm":"8245/3","n_c":["C201135"],"i_c":"8245/3","i_c_s":["Adenocarcinoid tumor"],"term_type":""},{"nm":"8246/3","n_c":["C3773"],"i_c":"8246/3","i_c_s":["Neuroendocrine carcinoma, NOS"],"term_type":""},{"nm":"8247/3","n_c":["C9231"],"i_c":"8247/3","i_c_s":["Merkel cell carcinoma","Merkel cell tumor","Primary cutaneous neuroendocrine carcinoma"],"term_type":""},{"nm":"8248/1","n_c":["C188218"],"i_c":"8248/1","i_c_s":["Apudoma"],"term_type":""},{"nm":"8249/3","n_c":["C35725","C72074"],"i_c":"8249/3","i_c_s":["Atypical carcinoid tumor","Neuroendocrine carcinoma, moderately differentiated","Neuroendocrine tumor, grade 2"],"term_type":""},{"nm":"8250/1","n_c":["C3763"],"i_c":"8250/1","i_c_s":["Pulmonary adenomatosis"],"term_type":""},{"nm":"8250/2","n_c":["C136716"],"i_c":"8250/2","i_c_s":["Adenocarcinoma in situ, non-mucinous"],"term_type":""},{"nm":"8250/3","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolo-alveolar adenocarcinoma, NOS","Alveolar cell carcinoma","Bronchiolar adenocarcinoma","Bronchiolar carcinoma","Bronchiolo-alveolar carcinoma, NOS"],"term_type":""},{"nm":"8251/0","n_c":["C4140"],"i_c":"8251/0","i_c_s":["Alveolar adenoma"],"term_type":""},{"nm":"8251/3","n_c":["C2923"],"i_c":"8251/3","i_c_s":["Alveolar adenocarcinoma","Alveolar carcinoma"],"term_type":""},{"nm":"8252/3","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma, non- mucinous","Bronchiolo-alveolar carcinoma, Clara cell","Bronchiolo-alveolar carcinoma, type II pneumocyte"],"term_type":""},{"nm":"8253/3","n_c":["C136709"],"i_c":"8253/3","i_c_s":["Bronchiolo-alveolar carcinoma, mucinous","Bronchiolo-alveolar carcinoma, goblet cell type"],"term_type":""},{"nm":"8254/3","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, mixed mucinous and non-mucinous","Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type","Bronchiolo-alveolar carcinoma, indeterminate type","Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type"],"term_type":""},{"nm":"8255/3","n_c":["C45508"],"i_c":"8255/3","i_c_s":["Adenocarcinoma with mixed subtypes","Adenocarcinoma combined with other types of carcinoma"],"term_type":""},{"nm":"8256/3","n_c":["C7269"],"i_c":"8256/3","i_c_s":["Minimally invasive adenocarcinoma, non-mucinous"],"term_type":""},{"nm":"8257/3","n_c":["C7268"],"i_c":"8257/3","i_c_s":["Minimally invasive adenocarcinoma, mucinous"],"term_type":""},{"nm":"8260/0","n_c":["C79951"],"i_c":"8260/0","i_c_s":["Papillary adenoma, NOS","Glandular papilloma"],"term_type":""},{"nm":"8260/3","n_c":["C4035","C2853","C6975"],"i_c":"8260/3","i_c_s":["Papillary adenocarcinoma, NOS","Papillary carcinoma of thyroid","Papillary renal cell carcinoma"],"term_type":""},{"nm":"8261/0","n_c":["C7399"],"i_c":"8261/0","i_c_s":["Villous adenoma, NOS","Villous papilloma"],"term_type":""},{"nm":"8261/2","n_c":["C8376"],"i_c":"8261/2","i_c_s":["Adenocarcinoma in situ in villous adenoma"],"term_type":""},{"nm":"8261/3","n_c":["C4141"],"i_c":"8261/3","i_c_s":["Adenocarcinoma in villous adenoma"],"term_type":""},{"nm":"8262/3","n_c":["C4142"],"i_c":"8262/3","i_c_s":["Villous adenocarcinoma"],"term_type":""},{"nm":"8263/0","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Tubulovillous adenoma, NOS","Papillotubular adenoma","Tubulo-papillary adenoma","Villoglandular adenoma"],"term_type":""},{"nm":"8263/2","n_c":["C4144"],"i_c":"8263/2","i_c_s":["Adenocarcinoma in situ in tubulovillous adenoma"],"term_type":""},{"nm":"8263/3","n_c":["C4145"],"i_c":"8263/3","i_c_s":["Adenocarcinoma in tubulovillous adenoma","Papillotubular adenocarcinoma","Tubulopapillary adenocarcinoma"],"term_type":""},{"nm":"8264/0","n_c":["C6881","C65198"],"i_c":"8264/0","i_c_s":["Papillomatosis, glandular","Biliary papillomatosis"],"term_type":""},{"nm":"8265/3","n_c":["C128847"],"i_c":"8265/3","i_c_s":["Micropapillary carcinoma, NOS"],"term_type":""},{"nm":"8270/0","n_c":["C2857"],"i_c":"8270/0","i_c_s":["Chromophobe adenoma"],"term_type":""},{"nm":"8270/3","n_c":["C4146"],"i_c":"8270/3","i_c_s":["Chromophobe carcinoma","Chromophobe adenocarcinoma"],"term_type":""},{"nm":"8271/0","n_c":["C3342"],"i_c":"8271/0","i_c_s":["Prolactinoma"],"term_type":""},{"nm":"8272/0","n_c":["C3329"],"i_c":"8272/0","i_c_s":["Pituitary adenoma, NOS"],"term_type":""},{"nm":"8272/3","n_c":["C4536"],"i_c":"8272/3","i_c_s":["Pituitary carcinoma, NOS"],"term_type":""},{"nm":"8280/0","n_c":["C6780"],"i_c":"8280/0","i_c_s":["Acidophil adenoma","Eosinophil adenoma"],"term_type":""},{"nm":"8280/3","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Acidophil carcinoma","Acidophil adenocarcinoma","Eosinophil adenocarcinoma","Eosinophil carcinoma"],"term_type":""},{"nm":"8281/0","n_c":["C4148"],"i_c":"8281/0","i_c_s":["Mixed acidophil-basophil adenoma"],"term_type":""},{"nm":"8281/3","n_c":["C4149"],"i_c":"8281/3","i_c_s":["Mixed acidophil-basophil carcinoma"],"term_type":""},{"nm":"8290/0","n_c":["C3759","C6042"],"i_c":"8290/0","i_c_s":["Oxyphilic adenoma","Follicular adenoma, oxyphilic cell","Hurthle cell adenoma","Hurthle cell tumor","Spindle cell oncocytoma","Oncocytic adenoma","Oncocytoma"],"term_type":""},{"nm":"8290/3","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oxyphilic adenocarcinoma","Follicular carcinoma, oxyphilic cell","Hurthle cell adenocarcinoma","Hurthle cell carcinoma","Oncocytic adenocarcinoma","Oncocytic carcinoma"],"term_type":""},{"nm":"8300/0","n_c":["C2856"],"i_c":"8300/0","i_c_s":["Basophil adenoma","Mucoid cell adenoma"],"term_type":""},{"nm":"8300/3","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Basophil carcinoma","Basophil adenocarcinoma","Mucoid cell adenocarcinoma"],"term_type":""},{"nm":"8310/0","n_c":["C4151"],"i_c":"8310/0","i_c_s":["Clear cell adenoma"],"term_type":""},{"nm":"8310/3","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell adenocarcinoma, NOS","Clear cell adenocarcinoma, mesonephroid","Clear cell carcinoma"],"term_type":""},{"nm":"8310/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8311/1","n_c":["C4033"],"i_c":"8311/1","i_c_s":["Hypernephroid tumor"],"term_type":""},{"nm":"8311/3","n_c":["C51302"],"i_c":"8311/3","i_c_s":["Hereditary leiomyomatosis & RCC-associated renal cell carcinoma"],"term_type":""},{"nm":"8311/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8312/3","n_c":["C191370","C4033"],"i_c":"8312/3","i_c_s":["Renal cell carcinoma, NOS","Grawitz tumor","Hypernephroma","Renal cell adenocarcinoma"],"term_type":""},{"nm":"8313/0","n_c":["C8988","C8987"],"i_c":"8313/0","i_c_s":["Clear cell adenofibroma","Clear cell cystadenofibroma"],"term_type":""},{"nm":"8313/1","n_c":["C40080","C40081"],"i_c":"8313/1","i_c_s":["Clear cell adenofibroma of borderline malignancy","Clear cell cystadenofibroma of borderline malignancy"],"term_type":""},{"nm":"8313/3","n_c":["C40079"],"i_c":"8313/3","i_c_s":["Clear cell adenocarcinofibroma","Clear cell cystadenocarcinofibroma"],"term_type":""},{"nm":"8314/3","n_c":["C4152"],"i_c":"8314/3","i_c_s":["Lipid-rich carcinoma"],"term_type":""},{"nm":"8315/3","n_c":["C4153"],"i_c":"8315/3","i_c_s":["Glycogen-rich carcinoma"],"term_type":""},{"nm":"8316/3","n_c":["C157718"],"i_c":"8316/3","i_c_s":["Cyst-associated renal cell carcinoma"],"term_type":""},{"nm":"8317/3","n_c":["C4146"],"i_c":"8317/3","i_c_s":["Renal cell carcinoma, chromophobe type","Chromophobe cell renal carcinoma"],"term_type":""},{"nm":"8318/3","n_c":["C27893"],"i_c":"8318/3","i_c_s":["Renal cell carcinoma, sarcomatoid","Renal cell carcinoma, spindle cell"],"term_type":""},{"nm":"8319/3","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Collecting duct carcinoma","Bellini duct carcinoma","Renal carcinoma, collecting duct type"],"term_type":""},{"nm":"8320/3","n_c":["C3681"],"i_c":"8320/3","i_c_s":["Granular cell carcinoma","Granular cell adenocarcinoma"],"term_type":""},{"nm":"8321/0","n_c":["C4154"],"i_c":"8321/0","i_c_s":["Chief cell adenoma"],"term_type":""},{"nm":"8322/0","n_c":["C4155"],"i_c":"8322/0","i_c_s":["Water-clear cell adenoma"],"term_type":""},{"nm":"8322/3","n_c":["C4156"],"i_c":"8322/3","i_c_s":["Water-clear cell adenocarcinoma","Water-clear cell carcinoma"],"term_type":""},{"nm":"8323/0","n_c":["C4157"],"i_c":"8323/0","i_c_s":["Mixed cell adenoma"],"term_type":""},{"nm":"8323/3","n_c":["C4158"],"i_c":"8323/3","i_c_s":["Mixed cell adenocarcinoma"],"term_type":""},{"nm":"8324/0","n_c":["C4159"],"i_c":"8324/0","i_c_s":["Lipoadenoma","Adenolipoma"],"term_type":""},{"nm":"8325/0","n_c":["C27253"],"i_c":"8325/0","i_c_s":["Metanephric adenoma"],"term_type":""},{"nm":"8330/0","n_c":["C3502"],"i_c":"8330/0","i_c_s":["Follicular adenoma"],"term_type":""},{"nm":"8330/1","n_c":["C27729"],"i_c":"8330/1","i_c_s":["Atypical follicular adenoma"],"term_type":""},{"nm":"8330/3","n_c":["C8054"],"i_c":"8330/3","i_c_s":["Follicular adenocarcinoma, NOS","Follicular carcinoma, NOS"],"term_type":""},{"nm":"8331/3","n_c":["C8054"],"i_c":"8331/3","i_c_s":["Follicular adenocarcinoma, well differentiated","Follicular carcinoma, well differentiated"],"term_type":""},{"nm":"8332/3","n_c":["C46095"],"i_c":"8332/3","i_c_s":["Follicular adenocarcinoma, trabecular","Follicular adenocarcinoma, moderately differentiated","Follicular carcinoma, moderately differentiated","Follicular carcinoma, trabecular"],"term_type":""},{"nm":"8333/0","n_c":["C4160"],"i_c":"8333/0","i_c_s":["Microfollicular adenoma, NOS","Fetal adenoma"],"term_type":""},{"nm":"8333/3","n_c":["C45509"],"i_c":"8333/3","i_c_s":["Fetal adenocarcinoma"],"term_type":""},{"nm":"8334/0","n_c":["C4161"],"i_c":"8334/0","i_c_s":["Macrofollicular adenoma","Colloid adenoma"],"term_type":""},{"nm":"8335/3","n_c":["C65200"],"i_c":"8335/3","i_c_s":["Follicular carcinoma, minimally invasive","Follicular carcinoma, encapsulated"],"term_type":""},{"nm":"8336/0","n_c":["C6846"],"i_c":"8336/0","i_c_s":["Hyalinizing trabecular adenoma"],"term_type":""},{"nm":"8337/3","n_c":["C6040"],"i_c":"8337/3","i_c_s":["Insular carcinoma"],"term_type":""},{"nm":"8339/3","n_c":["C156122"],"i_c":"8339/3","i_c_s":["Follicular thyroid carcinoma (FTC), encapsulated angioinvasive"],"term_type":""},{"nm":"8340/3","n_c":["C7380","C126594"],"i_c":"8340/3","i_c_s":["Papillary carcinoma, follicular variant","Papillary adenocarcinoma, follicular variant","Papillary and follicular adenocarcinoma","Papillary and follicular carcinoma"],"term_type":""},{"nm":"8341/3","n_c":["C46004"],"i_c":"8341/3","i_c_s":["Papillary microcarcinoma"],"term_type":""},{"nm":"8342/3","n_c":["C46093"],"i_c":"8342/3","i_c_s":["Papillary carcinoma, oxyphilic cell"],"term_type":""},{"nm":"8343/2","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive EFVPTC"],"term_type":""},{"nm":"8343/3","n_c":["C156034"],"i_c":"8343/3","i_c_s":["Papillary carcinoma, encapsulated"],"term_type":""},{"nm":"8344/3","n_c":["C35830","C35558"],"i_c":"8344/3","i_c_s":["Papillary carcinoma, columnar cell","Papillary carcinoma, tall cell"],"term_type":""},{"nm":"8345/3","n_c":["C4193","C3879"],"i_c":"8345/3","i_c_s":["Medullary carcinoma with amyloid stroma","C cell carcinoma","Parafollicular cell carcinoma"],"term_type":""},{"nm":"8346/3","n_c":["C46104"],"i_c":"8346/3","i_c_s":["Mixed medullary-follicular carcinoma"],"term_type":""},{"nm":"8347/3","n_c":["C46104"],"i_c":"8347/3","i_c_s":["Mixed medullary-papillary carcinoma"],"term_type":""},{"nm":"8350/3","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing carcinoma","Papillary carcinoma, diffuse sclerosing","Nonencapsulated sclerosing adenocarcinoma","Nonencapsulated sclerosing tumor"],"term_type":""},{"nm":"8360/1","n_c":["C6432"],"i_c":"8360/1","i_c_s":["Multiple endocrine adenomas","Endocrine adenomatosis"],"term_type":""},{"nm":"8361/0","n_c":["C4162"],"i_c":"8361/0","i_c_s":["Juxtaglomerular tumor","Reninoma"],"term_type":""},{"nm":"8370/0","n_c":["C9003","C2858","C9004"],"i_c":"8370/0","i_c_s":["Adrenal cortical adenoma, NOS","Adrenal cortical tumor, NOS","Adrenal cortical tumor, benign"],"term_type":""},{"nm":"8370/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8370/3","n_c":["C9325","C9327"],"i_c":"8370/3","i_c_s":["Adrenal cortical carcinoma","Adrenal cortical adenocarcinoma","Adrenal cortical tumor, malignant"],"term_type":""},{"nm":"8371/0","n_c":["C4163"],"i_c":"8371/0","i_c_s":["Adrenal cortical adenoma, compact cell"],"term_type":""},{"nm":"8372/0","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Adrenal cortical adenoma, pigmented","Black adenoma","Pigmented adenoma"],"term_type":""},{"nm":"8373/0","n_c":["C4165"],"i_c":"8373/0","i_c_s":["Adrenal cortical adenoma, clear cell"],"term_type":""},{"nm":"8374/0","n_c":["C4166"],"i_c":"8374/0","i_c_s":["Adrenal cortical adenoma, glomerulosa cell"],"term_type":""},{"nm":"8375/0","n_c":["C4167"],"i_c":"8375/0","i_c_s":["Adrenal cortical adenoma, mixed cell"],"term_type":""},{"nm":"8380/0","n_c":["C27287"],"i_c":"8380/0","i_c_s":["Endometrioid adenoma, NOS","Endometrioid cystadenoma, NOS"],"term_type":""},{"nm":"8380/1","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid adenoma, borderline malignancy","Atypical proliferative endometrioid tumor","Endometrioid cystadenoma, borderline malignancy","Endometrioid tumor of low malignant potential"],"term_type":""},{"nm":"8380/2","n_c":["C27789"],"i_c":"8380/2","i_c_s":["Atypical hyperplasia/Endometrioid intraepithelial neoplasm"],"term_type":""},{"nm":"8380/3","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid adenocarcinoma, NOS","Endometrioid cystadenocarcinoma","Endometrioid carcinoma, NOS"],"term_type":""},{"nm":"8381/0","n_c":["C27288","C27287"],"i_c":"8381/0","i_c_s":["Endometrioid adenofibroma, NOS","Endometrioid cystadenofibroma, NOS"],"term_type":""},{"nm":"8381/1","n_c":["C40069"],"i_c":"8381/1","i_c_s":["Endometrioid adenofibroma, borderline malignancy","Endometrioid cystadenofibroma, borderline malignancy"],"term_type":""},{"nm":"8381/3","n_c":["C40060"],"i_c":"8381/3","i_c_s":["Endometrioid adenofibroma, malignant","Endometrioid cystadenofibroma, malignant"],"term_type":""},{"nm":"8382/3","n_c":["C27839"],"i_c":"8382/3","i_c_s":["Endometrioid adenocarcinoma, secretory variant"],"term_type":""},{"nm":"8383/3","n_c":["C27848"],"i_c":"8383/3","i_c_s":["Endometrioid adenocarcinoma, ciliated cell variant"],"term_type":""},{"nm":"8384/3","n_c":["C66951"],"i_c":"8384/3","i_c_s":["Adenocarcinoma, endocervical type"],"term_type":""},{"nm":"8390/0","n_c":["C7580"],"i_c":"8390/0","i_c_s":["Skin appendage adenoma","Adnexal tumor, benign","Skin appendage tumor, benign"],"term_type":""},{"nm":"8390/3","n_c":["C3775"],"i_c":"8390/3","i_c_s":["Skin appendage carcinoma","Adnexal carcinoma"],"term_type":""},{"nm":"8391/0","n_c":["C4470","C43333","C43331"],"i_c":"8391/0","i_c_s":["Follicular fibroma","Fibrofolliculoma","Perifollicular fibroma","Trichodiscoma"],"term_type":""},{"nm":"8392/0","n_c":["C43356"],"i_c":"8392/0","i_c_s":["Syringofibroadenoma"],"term_type":""},{"nm":"8400/0","n_c":["C7560","C7563","C4879"],"i_c":"8400/0","i_c_s":["Sweat gland adenoma","Hidradenoma, NOS","Sweat gland tumor, benign","Syringadenoma, NOS"],"term_type":""},{"nm":"8400/1","n_c":["C3398"],"i_c":"8400/1","i_c_s":["Sweat gland tumor, NOS"],"term_type":""},{"nm":"8400/3","n_c":["C6938","C4810","C4615"],"i_c":"8400/3","i_c_s":["Sweat gland adenocarcinoma","Sweat gland carcinoma","Sweat gland tumor, malignant"],"term_type":""},{"nm":"8401/0","n_c":["C4168","C43342"],"i_c":"8401/0","i_c_s":["Apocrine adenoma","Apocrine cystadenoma"],"term_type":""},{"nm":"8401/3","n_c":["C4169"],"i_c":"8401/3","i_c_s":["Apocrine adenocarcinoma"],"term_type":""},{"nm":"8402/0","n_c":["C7568","C7563","C7567"],"i_c":"8402/0","i_c_s":["Nodular hidradenoma","Clear cell hidradenoma","Eccrine acrospiroma"],"term_type":""},{"nm":"8402/3","n_c":["C54664"],"i_c":"8402/3","i_c_s":["Nodular hidradenoma, malignant","Hidradenocarcinoma"],"term_type":""},{"nm":"8403/0","n_c":["C4170"],"i_c":"8403/0","i_c_s":["Eccrine spiradenoma","Spiradenoma, NOS"],"term_type":""},{"nm":"8403/3","n_c":["C5117"],"i_c":"8403/3","i_c_s":["Malignant eccrine spiradenoma"],"term_type":""},{"nm":"8404/0","n_c":["C3760","C7565"],"i_c":"8404/0","i_c_s":["Hidrocystoma","Eccrine cystadenoma"],"term_type":""},{"nm":"8405/0","n_c":["C4171"],"i_c":"8405/0","i_c_s":["Papillary hidradenoma","Hidradenoma papilliferum"],"term_type":""},{"nm":"8406/0","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Papillary syringadenoma","Papillary syringocystadenoma","Syringocystadenoma papilliferum"],"term_type":""},{"nm":"8407/0","n_c":["C3761"],"i_c":"8407/0","i_c_s":["Syringoma, NOS"],"term_type":""},{"nm":"8407/3","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Sclerosing sweat duct carcinoma","Microcystic adnexal carcinoma","Syringomatous carcinoma"],"term_type":""},{"nm":"8408/0","n_c":["C4173"],"i_c":"8408/0","i_c_s":["Eccrine papillary adenoma"],"term_type":""},{"nm":"8408/1","n_c":["C162848"],"i_c":"8408/1","i_c_s":["Aggressive digital papillary adenoma"],"term_type":""},{"nm":"8408/3","n_c":["C27254","C27534"],"i_c":"8408/3","i_c_s":["Eccrine papillary adenocarcinoma","Digital papillary adenocarcinoma"],"term_type":""},{"nm":"8409/0","n_c":["C27273"],"i_c":"8409/0","i_c_s":["Eccrine poroma"],"term_type":""},{"nm":"8409/3","n_c":["C5560"],"i_c":"8409/3","i_c_s":["Eccrine poroma, malignant","Porocarcinoma"],"term_type":""},{"nm":"8410/0","n_c":["C4346","C4174"],"i_c":"8410/0","i_c_s":["Sebaceous adenoma","Sebaceous epithelioma"],"term_type":""},{"nm":"8410/3","n_c":["C40310"],"i_c":"8410/3","i_c_s":["Sebaceous adenocarcinoma","Sebaceous carcinoma"],"term_type":""},{"nm":"8413/3","n_c":["C27255"],"i_c":"8413/3","i_c_s":["Eccrine adenocarcinoma"],"term_type":""},{"nm":"8420/0","n_c":["C6088"],"i_c":"8420/0","i_c_s":["Ceruminous adenoma"],"term_type":""},{"nm":"8420/3","n_c":["C4176"],"i_c":"8420/3","i_c_s":["Ceruminous adenocarcinoma","Ceruminous carcinoma"],"term_type":""},{"nm":"8430/1","n_c":["C3772"],"i_c":"8430/1","i_c_s":["Mucoepidermoid tumor"],"term_type":""},{"nm":"8430/3","n_c":["C3772"],"i_c":"8430/3","i_c_s":["Mucoepidermoid carcinoma"],"term_type":""},{"nm":"8440/0","n_c":["C2972"],"i_c":"8440/0","i_c_s":["Cystadenoma, NOS","Cystoma, NOS"],"term_type":""},{"nm":"8440/3","n_c":["C2971"],"i_c":"8440/3","i_c_s":["Cystadenocarcinoma, NOS"],"term_type":""},{"nm":"8441/0","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous cystadenoma, NOS","Serous microcystic adenoma","Serous cystoma"],"term_type":""},{"nm":"8441/2","n_c":["C126449"],"i_c":"8441/2","i_c_s":["Serous tubal intraepithelial carcinoma"],"term_type":""},{"nm":"8441/3","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous cystadenocarcinoma, NOS","Serous adenocarcinoma, NOS","Serous carcinoma, NOS"],"term_type":""},{"nm":"8441/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8442/1","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Serous cystadenoma, borderline malignancy","Atypical proliferating serous tumor","Serous tumor, NOS, of low malignant potential"],"term_type":""},{"nm":"8443/0","n_c":["C65203"],"i_c":"8443/0","i_c_s":["Clear cell cystadenoma"],"term_type":""},{"nm":"8444/1","n_c":["C40080"],"i_c":"8444/1","i_c_s":["Clear cell cystic tumor of borderline malignancy","Atypical proliferating clear cell tumor"],"term_type":""},{"nm":"8450/0","n_c":["C2974"],"i_c":"8450/0","i_c_s":["Papillary cystadenoma, NOS"],"term_type":""},{"nm":"8450/3","n_c":["C3777"],"i_c":"8450/3","i_c_s":["Papillary cystadenocarcinoma, NOS","Papillocystic adenocarcinoma"],"term_type":""},{"nm":"8451/1","n_c":["C4178"],"i_c":"8451/1","i_c_s":["Papillary cystadenoma, borderline malignancy"],"term_type":""},{"nm":"8452/1","n_c":["C201136"],"i_c":"8452/1","i_c_s":["Solid pseudopapillary tumor","Papillary cystic tumor","Solid and cystic tumor","Solid and papillary epithelial neoplasm"],"term_type":""},{"nm":"8452/3","n_c":["C37212","C5728"],"i_c":"8452/3","i_c_s":["Solid pseudopapillary carcinoma"],"term_type":""},{"nm":"8453/0","n_c":["C95514"],"i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous adenoma","Intraductal papillary-mucinous tumor with intermediate dysplasia","Intraductal papillary-mucinous tumor with low grade dysplasia","Intraductal papillary-mucinous tumor with moderate dysplasia","Intraductal papillary-mucinous neoplasm with low grade dysplasia","Intraductal papillary-mucinous neoplasm with moderate dysplasia"],"term_type":""},{"nm":"8453/2","n_c":["C41251"],"i_c":"8453/2","i_c_s":["Intraductal papillary-mucinous carcinoma, non-invasive","Intraductal papillary mucinous neoplasm with high grade dysplasia"],"term_type":""},{"nm":"8453/3","n_c":["C5726"],"i_c":"8453/3","i_c_s":["Intraductal papillary-mucinous carcinoma, invasive","Intraductal papillary mucinous neoplasm with an associated invasive carcinoma"],"term_type":""},{"nm":"8454/0","n_c":["C45754"],"i_c":"8454/0","i_c_s":["Cystic tumor of atrio-ventricular node"],"term_type":""},{"nm":"8460/0","n_c":["C4180"],"i_c":"8460/0","i_c_s":["Papillary serous cystadenoma, NOS"],"term_type":""},{"nm":"8460/2","n_c":["C122585"],"i_c":"8460/2","i_c_s":["Non-invasive low grade serous carcinoma"],"term_type":""},{"nm":"8460/3","n_c":["C8377","C6882"],"i_c":"8460/3","i_c_s":["Papillary serous cystadenocarcinoma","Micropapillary serous carcinoma","Papillary serous adenocarcinoma"],"term_type":""},{"nm":"8461/0","n_c":["C4181"],"i_c":"8461/0","i_c_s":["Serous surface papilloma"],"term_type":""},{"nm":"8461/3","n_c":["C7695","C4182"],"i_c":"8461/3","i_c_s":["Serous surface papillary carcinoma","Primary serous papillary carcinoma of peritoneum"],"term_type":""},{"nm":"8462/1","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Serous papillary cystic tumor of borderline malignancy","Atypical proliferative papillary serous tumor","Papillary serous cystadenoma, borderline malignancy","Papillary serous tumor of low malignant potential"],"term_type":""},{"nm":"8463/1","n_c":["C7315"],"i_c":"8463/1","i_c_s":["Serous surface papillary tumor of borderline malignancy"],"term_type":""},{"nm":"8470/0","n_c":["C2973","C6883"],"i_c":"8470/0","i_c_s":["Mucinous cystadenoma, NOS","Mucinous cystic neoplasm with intermediate-grade dysplasia","Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia","Mucinous cystic neoplasm with low-grade dysplasia","Mucinous cystic neoplasm with low-grade intraepithelial neoplasia","Mucinous cystic tumor with intermediate dysplasia","Mucinous cystic tumor with low-grade dysplasia","Mucinous cystic tumor with moderate dysplasia","Mucinous cystoma","Pseudomucinous cystadenoma, NOS"],"term_type":""},{"nm":"8470/2","n_c":["C41245","C95493"],"i_c":"8470/2","i_c_s":["Mucinous cystadenocarcinoma, non-invasive","Mucinous cystic tumor with high-grade dysplasia","Mucinous cystic neoplasm with high-grade dysplasia","Mucinous cystic neoplasm with high-grade intraepithelial neoplasia"],"term_type":""},{"nm":"8470/3","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Mucinous cystadenocarcinoma, NOS","Mucinous cystic tumor with an associated invasive carcinoma","Mucinous cystic neoplasm with an associated invasive carcinoma","Pseudomucinous adenocarcinoma","Pseudomucinous cystadenocarcinoma, NOS"],"term_type":""},{"nm":"8471/0","n_c":["C4184"],"i_c":"8471/0","i_c_s":["Papillary mucinous cystadenoma, NOS","Papillary pseudomucinous cystadenoma, NOS"],"term_type":""},{"nm":"8471/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8471/3","n_c":["C65204"],"i_c":"8471/3","i_c_s":["Papillary mucinous cystadenocarcinoma","Papillary pseudomucinous cystadenocarcinoma"],"term_type":""},{"nm":"8472/1","n_c":["C201978"],"i_c":"8472/1","i_c_s":["Mucinous cystic tumor of borderline malignancy","Atypical proliferative mucinous tumor","Mucinous cystadenoma, borderline malignancy","Mucinous tumor, NOS, of low malignant potential","Pseudomucinous cystadenoma, borderline malignancy"],"term_type":""},{"nm":"8473/1","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary mucinous cystadenoma, borderline malignancy","Papillary mucinous tumor of low malignant potential","Papillary pseudomucinous cystadenoma, borderline malignancy"],"term_type":""},{"nm":"8474/1","n_c":["C7281"],"i_c":"8474/1","i_c_s":["Seromucinous Borderline Tumor"],"term_type":""},{"nm":"8474/3","n_c":["C40090"],"i_c":"8474/3","i_c_s":["Seromucinous carcinoma"],"term_type":""},{"nm":"8480/0","n_c":["C2973"],"i_c":"8480/0","i_c_s":["Mucinous adenoma"],"term_type":""},{"nm":"8480/1","n_c":["C42598"],"i_c":"8480/1","i_c_s":["Low grade appendiceal mucinous neoplasm"],"term_type":""},{"nm":"8480/3","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucinous adenocarcinoma","Pseudomyxoma peritonei with unknown primary site","Gelatinous adenocarcinoma","Gelatinous carcinoma","Colloid adenocarcinoma","Colloid carcinoma","Mucinous carcinoma","Mucoid adenocarcinoma","Mucoid carcinoma","Mucous adenocarcinoma","Mucous carcinoma"],"term_type":""},{"nm":"8480/6","n_c":["C3345"],"i_c":"8480/6","i_c_s":["Pseudomyxoma peritonei"],"term_type":""},{"nm":"8481/3","n_c":["C27825","C27379"],"i_c":"8481/3","i_c_s":["Mucin-producing adenocarcinoma","Mucin-producing carcinoma","Mucin-secreting adenocarcinoma","Mucin-secreting carcinoma"],"term_type":""},{"nm":"8482/3","n_c":["C66953"],"i_c":"8482/3","i_c_s":["Mucinous adenocarcinoma, endocervical type"],"term_type":""},{"nm":"8482/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8490/3","n_c":["C3774","C4127"],"i_c":"8490/3","i_c_s":["Signet ring cell carcinoma","Poorly cohesive carcinoma","Signet ring cell adenocarcinoma"],"term_type":""},{"nm":"8490/6","n_c":["C66717","C3153"],"i_c":"8490/6","i_c_s":["Metastatic signet ring cell carcinoma","Krukenberg tumor"],"term_type":""},{"nm":"8500/2","n_c":["C2924","C7949"],"i_c":"8500/2","i_c_s":["Intraductal carcinoma, noninfiltrating, NOS","Ductal carcinoma in situ, NOS","DCIS, NOS","DIN 3","Ductal intraepithelial neoplasia 3","Intraductal adenocarcinoma, noninfiltrating, NOS","Intraductal carcinoma, NOS"],"term_type":""},{"nm":"8500/3","n_c":["C4017","C4194"],"i_c":"8500/3","i_c_s":["Infiltrating duct carcinoma, NOS","Duct adenocarcinoma, NOS","Duct carcinoma, NOS","Duct cell carcinoma","Ductal carcinoma, NOS","Infiltrating duct adenocarcinoma"],"term_type":""},{"nm":"8500/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8501/2","n_c":["C7949"],"i_c":"8501/2","i_c_s":["Comedocarcinoma, noninfiltrating","DCIS, comedo type","Ductal carcinoma in situ, comedo type"],"term_type":""},{"nm":"8501/3","n_c":["C4188"],"i_c":"8501/3","i_c_s":["Comedocarcinoma, NOS"],"term_type":""},{"nm":"8502/3","n_c":["C4189"],"i_c":"8502/3","i_c_s":["Secretory carcinoma of breast","Juvenile carcinoma of breast"],"term_type":""},{"nm":"8503/0","n_c":["C96877","C6881","C96807","C3785"],"i_c":"8503/0","i_c_s":["Intraductal papilloma","Intracystic papillary neoplasm with low grade intraepithelial neoplasia","Intraductal papillary neoplasm with low grade intraepithelial neoplasia","Intraductal papillary neoplasm, NOS","Intraductal tubular-papillary neoplasm, low grade","Duct adenoma, NOS","Ductal papilloma","Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia","Intraductal papillary neoplasm with intermediate grade neoplasia","Intraglandular papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":""},{"nm":"8503/2","n_c":["C96809","C4190"],"i_c":"8503/2","i_c_s":["Noninfiltrating intraductal papillary adenocarcinoma","Intraductal papillary neoplasm with high grade intraepithelial neoplasia","Intraductal tubular-papillary neoplasm, high grade","DCIS, papillary","Ductal carcinoma in situ, papillary","Intracystic papillary neoplasm with high grade intraepithelial neoplasia","Intracystic papillary tumor with high grade dysplasia","Intracystic papillary tumor with high grade intraepithelial neoplasia","Intraductal papillary adenocarcinoma, NOS","Intraductal papillary carcinoma, NOS","Intraductal papillary neoplasm with high grade dysplasia","Intraductal papillary tumor with high grade dysplasia","Intraductal papillary tumor with high grade intraepithelial neoplasia","Noninfiltrating intraductal papillary carcinoma"],"term_type":""},{"nm":"8503/3","n_c":["C7439","C7438"],"i_c":"8503/3","i_c_s":["Intraductal papillary adenocarcinoma with invasion","Intraductal papillary neoplasm with associated invasive carcinoma","Infiltrating and papillary adenocarcinoma","Infiltrating papillary adenocarcinoma","Intracystic papillary neoplasm with associated invasive carcinoma"],"term_type":""},{"nm":"8504/0","n_c":["C3863"],"i_c":"8504/0","i_c_s":["Intracystic papillary adenoma","Intracystic papilloma"],"term_type":""},{"nm":"8504/2","n_c":["C7645"],"i_c":"8504/2","i_c_s":["Noninfiltrating intracystic carcinoma"],"term_type":""},{"nm":"8504/3","n_c":["C7645"],"i_c":"8504/3","i_c_s":["Intracystic carcinoma, NOS","Intracystic papillary adenocarcinoma"],"term_type":""},{"nm":"8505/0","n_c":["C7363"],"i_c":"8505/0","i_c_s":["Intraductal papillomatosis, NOS","Diffuse intraductal papillomatosis"],"term_type":""},{"nm":"8506/0","n_c":["C4192"],"i_c":"8506/0","i_c_s":["Adenoma of nipple","Subareolar duct papillomatosis"],"term_type":""},{"nm":"8507/2","n_c":["C5139"],"i_c":"8507/2","i_c_s":["Intraductal micropapillary carcinoma","Intraductal carcinoma, clinging","Ductal carcinoma in situ, micropapillary"],"term_type":""},{"nm":"8507/3","n_c":["C36084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8508/3","n_c":["C4189"],"i_c":"8508/3","i_c_s":["Cystic hypersecretory carcinoma"],"term_type":""},{"nm":"8509/2","n_c":["C6870"],"i_c":"8509/2","i_c_s":["Solid papillary carcinoma in situ"],"term_type":""},{"nm":"8509/3","n_c":["C66850"],"i_c":"8509/3","i_c_s":["Solid papillary carcinoma with invasion"],"term_type":""},{"nm":"8510/3","n_c":["C66718"],"i_c":"8510/3","i_c_s":["Medullary carcinoma, NOS","Medullary adenocarcinoma"],"term_type":""},{"nm":"8512/3","n_c":["C9119"],"i_c":"8512/3","i_c_s":["Medullary carcinoma with lymphoid stroma"],"term_type":""},{"nm":"8513/3","n_c":["C66719"],"i_c":"8513/3","i_c_s":["Atypical medullary carcinoma"],"term_type":""},{"nm":"8514/3","n_c":["C7362"],"i_c":"8514/3","i_c_s":["Duct carcinoma, desmoplastic type"],"term_type":""},{"nm":"8519/2","n_c":["C137839"],"i_c":"8519/2","i_c_s":["Pleomorphic lobular carcinoma in situ"],"term_type":""},{"nm":"8520/2","n_c":["C4018"],"i_c":"8520/2","i_c_s":["Lobular carcinoma in situ, NOS","LCIS, NOS","Lobular carcinoma, noninfiltrating"],"term_type":""},{"nm":"8520/3","n_c":["C3771","C7950"],"i_c":"8520/3","i_c_s":["Lobular carcinoma, NOS","Infiltrating lobular carcinoma, NOS","Lobular adenocarcinoma"],"term_type":""},{"nm":"8521/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8521/3","n_c":["C4194"],"i_c":"8521/3","i_c_s":["Infiltrating ductular carcinoma"],"term_type":""},{"nm":"8522/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8522/2","n_c":["C4195"],"i_c":"8522/2","i_c_s":["Intraductal carcinoma and lobular carcinoma in situ"],"term_type":""},{"nm":"8522/3","n_c":["C7690","C6939","C5160","C7688","C7689"],"i_c":"8522/3","i_c_s":["Infiltrating duct and lobular carcinoma","Infiltrating duct and lobular carcinoma in situ","Infiltrating lobular carcinoma and ductal carcinoma in situ","Intraductal and lobular carcinoma","Lobular and ductal carcinoma"],"term_type":""},{"nm":"8523/3","n_c":["C7688"],"i_c":"8523/3","i_c_s":["Infiltrating duct mixed with other types of carcinoma","Infiltrating duct and colloid carcinoma","Infiltrating duct and cribriform carcinoma","Infiltrating duct and mucinous carcinoma","Infiltrating duct and tubular carcinoma"],"term_type":""},{"nm":"8524/3","n_c":["C6939"],"i_c":"8524/3","i_c_s":["Infiltrating lobular mixed with other types of carcinoma"],"term_type":""},{"nm":"8525/3","n_c":["C35702"],"i_c":"8525/3","i_c_s":["Polymorphous low grade adenocarcinoma","Terminal duct adenocarcinoma"],"term_type":""},{"nm":"8530/3","n_c":["C4001"],"i_c":"8530/3","i_c_s":["Inflammatory carcinoma","Inflammatory adenocarcinoma"],"term_type":""},{"nm":"8540/3","n_c":["C47857"],"i_c":"8540/3","i_c_s":["Paget disease, mammary","Paget disease of breast"],"term_type":""},{"nm":"8541/3","n_c":["C7951"],"i_c":"8541/3","i_c_s":["Paget disease and infiltrating duct carcinoma of breast"],"term_type":""},{"nm":"8542/3","n_c":["C3302"],"i_c":"8542/3","i_c_s":["Paget disease, extramammary"],"term_type":""},{"nm":"8543/3","n_c":["C4019"],"i_c":"8543/3","i_c_s":["Paget disease and intraductal carcinoma of breast"],"term_type":""},{"nm":"8550/0","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinar cell adenoma","Acinar adenoma","Acinic cell adenoma"],"term_type":""},{"nm":"8550/1","n_c":["C3768","C4197"],"i_c":"8550/1","i_c_s":["Acinar cell tumor","Acinic cell tumor"],"term_type":""},{"nm":"8550/3","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar cell carcinoma","Acinar adenocarcinoma","Acinar carcinoma","Acinic cell adenocarcinoma"],"term_type":""},{"nm":"8551/3","n_c":["C5727"],"i_c":"8551/3","i_c_s":["Acinar cell cystadenocarcinoma"],"term_type":""},{"nm":"8552/3","n_c":["C95458"],"i_c":"8552/3","i_c_s":["Mixed acinar-ductal carcinoma"],"term_type":""},{"nm":"8560/0","n_c":["C45602"],"i_c":"8560/0","i_c_s":["Mixed squamous cell and glandular papilloma"],"term_type":""},{"nm":"8560/3","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Adenosquamous carcinoma","Mixed adenocarcinoma and epidermoid carcinoma","Mixed adenocarcinoma and squamous cell carcinoma"],"term_type":""},{"nm":"8561/0","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Adenolymphoma","Papillary cystadenoma lymphomatosum","Warthin tumor"],"term_type":""},{"nm":"8562/3","n_c":["C4199"],"i_c":"8562/3","i_c_s":["Epithelial-myoepithelial carcinoma"],"term_type":""},{"nm":"8570/3","n_c":["C4200"],"i_c":"8570/3","i_c_s":["Adenocarcinoma with squamous metaplasia","Adenoacanthoma"],"term_type":""},{"nm":"8571/3","n_c":["C7685","C7684","C7683"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with cartilaginous and osseous metaplasia","Adenocarcinoma with cartilaginous metaplasia","Adenocarcinoma with osseous metaplasia"],"term_type":""},{"nm":"8572/3","n_c":["C4201"],"i_c":"8572/3","i_c_s":["Adenocarcinoma with spindle cell metaplasia"],"term_type":""},{"nm":"8573/3","n_c":["C4202"],"i_c":"8573/3","i_c_s":["Adenocarcinoma with apocrine metaplasia","Carcinoma with apocrine metaplasia"],"term_type":""},{"nm":"8574/3","n_c":["C66745"],"i_c":"8574/3","i_c_s":["Adenocarcinoma with neuroendocrine differentiation","Carcinoma with neuroendocrine differentiation"],"term_type":""},{"nm":"8575/3","n_c":["C27949"],"i_c":"8575/3","i_c_s":["Metaplastic carcinoma, NOS"],"term_type":""},{"nm":"8576/3","n_c":["C66950"],"i_c":"8576/3","i_c_s":["Hepatoid adenocarcinoma","Hepatoid carcinoma"],"term_type":""},{"nm":"8580/0","n_c":["C66746"],"i_c":"8580/0","i_c_s":["Thymoma, benign"],"term_type":""},{"nm":"8580/1","n_c":["C3411"],"i_c":"8580/1","i_c_s":["Thymoma, NOS"],"term_type":""},{"nm":"8580/3","n_c":["C7612"],"i_c":"8580/3","i_c_s":["Thymoma, malignant, NOS"],"term_type":""},{"nm":"8581/1","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, type A, NOS","Thymoma, medullary, NOS","Thymoma, spindle cell, NOS"],"term_type":""},{"nm":"8581/3","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, type A, malignant","Thymoma, medullary, malignant","Thymoma, spindle cell, malignant"],"term_type":""},{"nm":"8582/1","n_c":["C6885"],"i_c":"8582/1","i_c_s":["Thymoma, type AB, NOS","Thymoma, mixed type, NOS"],"term_type":""},{"nm":"8582/3","n_c":["C6886"],"i_c":"8582/3","i_c_s":["Thymoma, type AB, malignant","Thymoma, mixed type, malignant"],"term_type":""},{"nm":"8583/1","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, type B1, NOS","Thymoma, lymphocyte-rich, NOS","Thymoma, lymphocytic, NOS","Thymoma, organoid, NOS","Thymoma, predominantly cortical, NOS"],"term_type":""},{"nm":"8583/3","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, type B1, malignant","Thymoma, lymphocyte-rich, malignant","Thymoma, lymphocytic, malignant","Thymoma, organoid, malignant","Thymoma, predominantly cortical, malignant"],"term_type":""},{"nm":"8584/1","n_c":["C6888"],"i_c":"8584/1","i_c_s":["Thymoma, type B2, NOS","Thymoma, cortical, NOS"],"term_type":""},{"nm":"8584/3","n_c":["C6889"],"i_c":"8584/3","i_c_s":["Thymoma, type B2, malignant","Thymoma, cortical, malignant"],"term_type":""},{"nm":"8585/1","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, type B3, NOS","Thymoma, atypical, NOS","Thymoma, epithelial, NOS"],"term_type":""},{"nm":"8585/3","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, type B3, malignant","Thymoma, atypical, malignant","Thymoma, epithelial, malignant","Well differentiated thymic carcinoma"],"term_type":""},{"nm":"8586/3","n_c":["C7569"],"i_c":"8586/3","i_c_s":["Thymic carcinoma, NOS","Thymoma, type C"],"term_type":""},{"nm":"8587/0","n_c":["C53595"],"i_c":"8587/0","i_c_s":["Ectopic hamartomatous thymoma"],"term_type":""},{"nm":"8588/3","n_c":["C46105"],"i_c":"8588/3","i_c_s":["Spindle epithelial tumor with thymus-like element","SETTLE","Spindle epithelial tumor with thymus-like differentiation"],"term_type":""},{"nm":"8589/3","n_c":["C46106"],"i_c":"8589/3","i_c_s":["Carcinoma showing thymus-like element","CASTLE","Carcinoma showing thymus-like differentiation"],"term_type":""},{"nm":"8590/1","n_c":["C4862","C3794"],"i_c":"8590/1","i_c_s":["Sex cord-gonadal stromal tumor, NOS","Gonadal stromal tumor, NOS","Ovarian stromal tumor","Sex cord tumor, NOS","Testicular stromal tumor"],"term_type":""},{"nm":"8591/1","n_c":["C66748"],"i_c":"8591/1","i_c_s":["Sex cord-gonadal stromal tumor, incompletely differentiated"],"term_type":""},{"nm":"8592/1","n_c":["C66991"],"i_c":"8592/1","i_c_s":["Sex cord-gonadal stromal tumor, mixed forms"],"term_type":""},{"nm":"8593/1","n_c":["C66749"],"i_c":"8593/1","i_c_s":["Stromal tumor with minor sex cord elements"],"term_type":""},{"nm":"8594/1","n_c":["C5241"],"i_c":"8594/1","i_c_s":["Mixed germ cell sex cord‐stromal tumor, unclassified"],"term_type":""},{"nm":"8600/0","n_c":["C3405"],"i_c":"8600/0","i_c_s":["Thecoma, NOS","Theca cell tumor"],"term_type":""},{"nm":"8600/3","n_c":["C6929"],"i_c":"8600/3","i_c_s":["Thecoma, malignant"],"term_type":""},{"nm":"8601/0","n_c":["C4203"],"i_c":"8601/0","i_c_s":["Thecoma, luteinized"],"term_type":""},{"nm":"8602/0","n_c":["C4204"],"i_c":"8602/0","i_c_s":["Sclerosing stromal tumor"],"term_type":""},{"nm":"8610/0","n_c":["C3202"],"i_c":"8610/0","i_c_s":["Luteoma, NOS","Luteinoma"],"term_type":""},{"nm":"8620/1","n_c":["C66750","C3070"],"i_c":"8620/1","i_c_s":["Granulosa cell tumor, adult type","Granulosa cell tumor, NOS"],"term_type":""},{"nm":"8620/3","n_c":["C4205"],"i_c":"8620/3","i_c_s":["Granulosa cell tumor, malignant","Granulosa cell carcinoma","Granulosa cell tumor, sarcomatoid"],"term_type":""},{"nm":"8621/1","n_c":["C66751"],"i_c":"8621/1","i_c_s":["Granulosa cell-theca cell tumor","Theca cell-granulosa cell tumor"],"term_type":""},{"nm":"8622/1","n_c":["C4207"],"i_c":"8622/1","i_c_s":["Granulosa cell tumor, juvenile"],"term_type":""},{"nm":"8623/1","n_c":["C4208"],"i_c":"8623/1","i_c_s":["Sex cord tumor with annular tubules"],"term_type":""},{"nm":"8630/0","n_c":["C67012"],"i_c":"8630/0","i_c_s":["Androblastoma, benign","Arrhenoblastoma, benign"],"term_type":""},{"nm":"8630/1","n_c":["C39976"],"i_c":"8630/1","i_c_s":["Androblastoma, NOS","Arrhenoblastoma, NOS"],"term_type":""},{"nm":"8630/3","n_c":["C67006"],"i_c":"8630/3","i_c_s":["Androblastoma, malignant","Arrhenoblastoma, malignant"],"term_type":""},{"nm":"8631/0","n_c":["C4209"],"i_c":"8631/0","i_c_s":["Sertoli-Leydig cell tumor, well differentiated"],"term_type":""},{"nm":"8631/1","n_c":["C39968","C2880"],"i_c":"8631/1","i_c_s":["Sertoli-Leydig cell tumor of intermediate differentiation","Sertoli-Leydig cell tumor, NOS"],"term_type":""},{"nm":"8631/3","n_c":["C4210"],"i_c":"8631/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated","Sertoli-Leydig cell tumor, sarcomatoid"],"term_type":""},{"nm":"8632/1","n_c":["C3072"],"i_c":"8632/1","i_c_s":["Gynandroblastoma"],"term_type":""},{"nm":"8633/1","n_c":["C39974"],"i_c":"8633/1","i_c_s":["Sertoli-Leydig cell tumor, retiform"],"term_type":""},{"nm":"8634/1","n_c":["C39972"],"i_c":"8634/1","i_c_s":["Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements","Sertoli-Leydig cell tumor, retiform, with heterologous elements"],"term_type":""},{"nm":"8634/3","n_c":["C39973"],"i_c":"8634/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements"],"term_type":""},{"nm":"8640/1","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Sertoli cell tumor, NOS","Pick tubular adenoma","Sertoli cell adenoma","Testicular adenoma","Tubular androblastoma, NOS"],"term_type":""},{"nm":"8640/3","n_c":["C67006"],"i_c":"8640/3","i_c_s":["Sertoli cell carcinoma"],"term_type":""},{"nm":"8641/0","n_c":["C4211"],"i_c":"8641/0","i_c_s":["Sertoli cell tumor with lipid storage","Folliculome lipidique","Lipid-rich Sertoli cell tumor","Tubular androblastoma with lipid storage"],"term_type":""},{"nm":"8642/1","n_c":["C39944"],"i_c":"8642/1","i_c_s":["Large cell calcifying Sertoli cell tumor"],"term_type":""},{"nm":"8650/0","n_c":["C4212"],"i_c":"8650/0","i_c_s":["Leydig cell tumor, benign","Interstitial cell tumor, benign"],"term_type":""},{"nm":"8650/1","n_c":["C3188"],"i_c":"8650/1","i_c_s":["Leydig cell tumor, NOS","Interstitial cell tumor, NOS"],"term_type":""},{"nm":"8650/3","n_c":["C4213"],"i_c":"8650/3","i_c_s":["Leydig cell tumor, malignant","Interstitial cell tumor, malignant"],"term_type":""},{"nm":"8660/0","n_c":["C4214"],"i_c":"8660/0","i_c_s":["Hilus cell tumor","Hilar cell tumor"],"term_type":""},{"nm":"8670/0","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Lipid cell tumor of ovary","Masculinovoblastoma","Lipoid cell tumor of ovary","Steroid cell tumor, NOS"],"term_type":""},{"nm":"8670/3","n_c":["C39981"],"i_c":"8670/3","i_c_s":["Steroid cell tumor, malignant"],"term_type":""},{"nm":"8671/0","n_c":["C2860"],"i_c":"8671/0","i_c_s":["Adrenal rest tumor"],"term_type":""},{"nm":"8680/0","n_c":["C48314"],"i_c":"8680/0","i_c_s":["Paraganglioma, benign"],"term_type":""},{"nm":"8680/1","n_c":["C3308"],"i_c":"8680/1","i_c_s":["Paraganglioma, NOS"],"term_type":""},{"nm":"8680/3","n_c":["C8559"],"i_c":"8680/3","i_c_s":["Paraganglioma, malignant"],"term_type":""},{"nm":"8681/1","n_c":["C4216"],"i_c":"8681/1","i_c_s":["Sympathetic paraganglioma"],"term_type":""},{"nm":"8682/1","n_c":["C4217"],"i_c":"8682/1","i_c_s":["Parasympathetic paraganglioma"],"term_type":""},{"nm":"8683/0","n_c":["C188229"],"i_c":"8683/0","i_c_s":["Gangliocytic paraganglioma"],"term_type":""},{"nm":"8690/1","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Glomus jugulare tumor, NOS","Jugular paraganglioma","Jugulotympanic paraganglioma"],"term_type":""},{"nm":"8691/1","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aortic body tumor","Aortic body paraganglioma","Aorticopulmonary paraganglioma"],"term_type":""},{"nm":"8692/1","n_c":["C2932"],"i_c":"8692/1","i_c_s":["Carotid body tumor","Carotid body paraganglioma"],"term_type":""},{"nm":"8693/1","n_c":["C2932","C3309"],"i_c":"8693/1","i_c_s":["Extra-adrenal paraganglioma, NOS","Chemodectoma","Nonchromaffin paraganglioma, NOS"],"term_type":""},{"nm":"8693/3","n_c":["C4219"],"i_c":"8693/3","i_c_s":["Extra-adrenal paraganglioma, malignant","Nonchromaffin paraganglioma, malignant"],"term_type":""},{"nm":"8700/0","n_c":["C3326","C4216"],"i_c":"8700/0","i_c_s":["Pheochromocytoma, NOS","Adrenal medullary paraganglioma","Chromaffin paraganglioma","Chromaffin tumor","Chromaffinoma"],"term_type":""},{"nm":"8700/3","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Pheochromocytoma, malignant","Adrenal medullary paraganglioma, malignant","Pheochromoblastoma"],"term_type":""},{"nm":"8710/3","n_c":["C4221"],"i_c":"8710/3","i_c_s":["Glomangiosarcoma","Glomoid sarcoma"],"term_type":""},{"nm":"8711/0","n_c":["C3060"],"i_c":"8711/0","i_c_s":["Glomus tumor, NOS"],"term_type":""},{"nm":"8711/3","n_c":["C4221"],"i_c":"8711/3","i_c_s":["Glomus tumor, malignant"],"term_type":""},{"nm":"8712/0","n_c":["C4222"],"i_c":"8712/0","i_c_s":["Glomangioma"],"term_type":""},{"nm":"8713/0","n_c":["C4223"],"i_c":"8713/0","i_c_s":["Glomangiomyoma"],"term_type":""},{"nm":"8714/3","n_c":["C121792"],"i_c":"8714/3","i_c_s":["PEComa, malignant"],"term_type":""},{"nm":"8720/0","n_c":["C7570","C27816","C3074"],"i_c":"8720/0","i_c_s":["Pigmented nevus, NOS","Hairy nevus","Melanocytic nevus","Nevus, NOS"],"term_type":""},{"nm":"8720/2","n_c":["C8423"],"i_c":"8720/2","i_c_s":["Melanoma in situ"],"term_type":""},{"nm":"8720/3","n_c":["C3224"],"i_c":"8720/3","i_c_s":["Malignant melanoma, NOS","Melanoma, NOS"],"term_type":""},{"nm":"8720/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8721/3","n_c":["C4225"],"i_c":"8721/3","i_c_s":["Nodular melanoma"],"term_type":""},{"nm":"8722/0","n_c":["C4226"],"i_c":"8722/0","i_c_s":["Balloon cell nevus"],"term_type":""},{"nm":"8722/3","n_c":["C4227"],"i_c":"8722/3","i_c_s":["Balloon cell melanoma"],"term_type":""},{"nm":"8723/0","n_c":["C7602","C7603"],"i_c":"8723/0","i_c_s":["Halo nevus","Regressing nevus"],"term_type":""},{"nm":"8723/3","n_c":["C4228"],"i_c":"8723/3","i_c_s":["Malignant melanoma, regressing"],"term_type":""},{"nm":"8725/0","n_c":["C4229"],"i_c":"8725/0","i_c_s":["Neuronevus"],"term_type":""},{"nm":"8726/0","n_c":["C9498"],"i_c":"8726/0","i_c_s":["Magnocellular nevus","Melanocytoma, NOS","Melanocytoma, eyeball"],"term_type":""},{"nm":"8727/0","n_c":["C3694"],"i_c":"8727/0","i_c_s":["Dysplastic nevus"],"term_type":""},{"nm":"8728/0","n_c":["C6890"],"i_c":"8728/0","i_c_s":["Diffuse melanocytosis"],"term_type":""},{"nm":"8728/1","n_c":["C4662"],"i_c":"8728/1","i_c_s":["Meningeal melanocytoma"],"term_type":""},{"nm":"8728/3","n_c":["C6891"],"i_c":"8728/3","i_c_s":["Meningeal melanomatosis"],"term_type":""},{"nm":"8730/0","n_c":["C27095"],"i_c":"8730/0","i_c_s":["Nonpigmented nevus","Achromic nevus"],"term_type":""},{"nm":"8730/3","n_c":["C3802"],"i_c":"8730/3","i_c_s":["Amelanotic melanoma"],"term_type":""},{"nm":"8740/0","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Junctional nevus, NOS","Intraepidermal nevus","Junction nevus"],"term_type":""},{"nm":"8740/3","n_c":["C4232"],"i_c":"8740/3","i_c_s":["Malignant melanoma in junctional nevus"],"term_type":""},{"nm":"8741/2","n_c":["C4233"],"i_c":"8741/2","i_c_s":["Precancerous melanosis, NOS"],"term_type":""},{"nm":"8741/3","n_c":["C66753"],"i_c":"8741/3","i_c_s":["Malignant melanoma in precancerous melanosis"],"term_type":""},{"nm":"8742/2","n_c":["C43372"],"i_c":"8742/2","i_c_s":["Lentigo maligna","Hutchinson melanotic freckle, NOS"],"term_type":""},{"nm":"8742/3","n_c":["C9151"],"i_c":"8742/3","i_c_s":["Lentigo maligna melanoma","Malignant melanoma in Hutchinson melanotic freckle"],"term_type":""},{"nm":"8743/3","n_c":["C9152"],"i_c":"8743/3","i_c_s":["Superficial spreading melanoma"],"term_type":""},{"nm":"8744/3","n_c":["C4022"],"i_c":"8744/3","i_c_s":["Acral lentiginous melanoma, malignant"],"term_type":""},{"nm":"8745/3","n_c":["C37257"],"i_c":"8745/3","i_c_s":["Desmoplastic melanoma, malignant","Desmoplastic melanoma, amelanotic","Neurotropic melanoma, malignant"],"term_type":""},{"nm":"8746/3","n_c":["C48622"],"i_c":"8746/3","i_c_s":["Mucosal lentiginous melanoma"],"term_type":""},{"nm":"8750/0","n_c":["C3804"],"i_c":"8750/0","i_c_s":["Intradermal nevus","Dermal nevus"],"term_type":""},{"nm":"8760/0","n_c":["C3901"],"i_c":"8760/0","i_c_s":["Compound nevus","Dermal and epidermal nevus"],"term_type":""},{"nm":"8761/0","n_c":["C3944","C66754"],"i_c":"8761/0","i_c_s":["Small congenital nevus"],"term_type":""},{"nm":"8761/1","n_c":["C4234"],"i_c":"8761/1","i_c_s":["Giant pigmented nevus, NOS","Intermediate and giant congenital nevus"],"term_type":""},{"nm":"8761/3","n_c":["C4235"],"i_c":"8761/3","i_c_s":["Malignant melanoma in giant pigmented nevus","Malignant melanoma in congenital melanocytic nevus"],"term_type":""},{"nm":"8762/1","n_c":["C66755"],"i_c":"8762/1","i_c_s":["Proliferative dermal lesion in congenital nevus"],"term_type":""},{"nm":"8770/0","n_c":["C27007","C4751"],"i_c":"8770/0","i_c_s":["Epithelioid and spindle cell nevus","Pigmented spindle cell nevus of Reed","Juvenile melanoma","Juvenile nevus","Spitz nevus"],"term_type":""},{"nm":"8770/3","n_c":["C66756"],"i_c":"8770/3","i_c_s":["Mixed epithelioid and spindle cell melanoma"],"term_type":""},{"nm":"8771/0","n_c":["C66757"],"i_c":"8771/0","i_c_s":["Epithelioid cell nevus"],"term_type":""},{"nm":"8771/3","n_c":["C4236"],"i_c":"8771/3","i_c_s":["Epithelioid cell melanoma"],"term_type":""},{"nm":"8772/0","n_c":["C27007"],"i_c":"8772/0","i_c_s":["Spindle cell nevus, NOS"],"term_type":""},{"nm":"8772/3","n_c":["C4237"],"i_c":"8772/3","i_c_s":["Spindle cell melanoma, NOS"],"term_type":""},{"nm":"8773/3","n_c":["C4238"],"i_c":"8773/3","i_c_s":["Spindle cell melanoma, type A"],"term_type":""},{"nm":"8774/3","n_c":["C4239"],"i_c":"8774/3","i_c_s":["Spindle cell melanoma, type B"],"term_type":""},{"nm":"8780/0","n_c":["C3803"],"i_c":"8780/0","i_c_s":["Blue nevus, NOS","Jadassohn blue nevus"],"term_type":""},{"nm":"8780/3","n_c":["C4240"],"i_c":"8780/3","i_c_s":["Blue nevus, malignant"],"term_type":""},{"nm":"8790/0","n_c":["C4241"],"i_c":"8790/0","i_c_s":["Cellular blue nevus"],"term_type":""},{"nm":"8800/0","n_c":["C4242"],"i_c":"8800/0","i_c_s":["Soft tissue tumor, benign"],"term_type":""},{"nm":"8800/3","n_c":["C4867","C9118","C9306"],"i_c":"8800/3","i_c_s":["Sarcoma, NOS","Mesenchymal tumor, malignant","Soft tissue sarcoma","Soft tissue tumor, malignant"],"term_type":""},{"nm":"8800/9","n_c":["C4243"],"i_c":"8800/9","i_c_s":["Sarcomatosis, NOS"],"term_type":""},{"nm":"8801/3","n_c":["C27005"],"i_c":"8801/3","i_c_s":["Spindle cell sarcoma"],"term_type":""},{"nm":"8801/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8802/3","n_c":["C66759"],"i_c":"8802/3","i_c_s":["Giant cell sarcoma","Pleomorphic cell sarcoma"],"term_type":""},{"nm":"8803/3","n_c":["C3746"],"i_c":"8803/3","i_c_s":["Small cell sarcoma","Round cell sarcoma"],"term_type":""},{"nm":"8804/3","n_c":["C3714"],"i_c":"8804/3","i_c_s":["Epithelioid sarcoma","Epithelioid cell sarcoma"],"term_type":""},{"nm":"8804/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8805/3","n_c":["C121793"],"i_c":"8805/3","i_c_s":["Undifferentiated sarcoma"],"term_type":""},{"nm":"8806/3","n_c":["C8300"],"i_c":"8806/3","i_c_s":["Desmoplastic small round cell tumor"],"term_type":""},{"nm":"8806/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8810/0","n_c":["C3041"],"i_c":"8810/0","i_c_s":["Fibroma, NOS"],"term_type":""},{"nm":"8810/1","n_c":["C6892"],"i_c":"8810/1","i_c_s":["Cellular fibroma"],"term_type":""},{"nm":"8810/3","n_c":["C3043"],"i_c":"8810/3","i_c_s":["Fibrosarcoma, NOS"],"term_type":""},{"nm":"8811/0","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Fibromyxoma","Plexiform fibromyxoma","Myxofibroma, NOS","Myxoid fibroma"],"term_type":""},{"nm":"8811/1","n_c":["C49025"],"i_c":"8811/1","i_c_s":["Myxoinflammatory fibroblastic sarcoma (MIFS)"],"term_type":""},{"nm":"8811/3","n_c":["C6496"],"i_c":"8811/3","i_c_s":["Fibromyxosarcoma"],"term_type":""},{"nm":"8812/0","n_c":["C66761"],"i_c":"8812/0","i_c_s":["Periosteal fibroma"],"term_type":""},{"nm":"8812/3","n_c":["C66763"],"i_c":"8812/3","i_c_s":["Periosteal fibrosarcoma","Periosteal sarcoma, NOS"],"term_type":""},{"nm":"8813/0","n_c":["C66764"],"i_c":"8813/0","i_c_s":["Fascial fibroma"],"term_type":""},{"nm":"8813/3","n_c":["C66765"],"i_c":"8813/3","i_c_s":["Fascial fibrosarcoma"],"term_type":""},{"nm":"8814/3","n_c":["C4244"],"i_c":"8814/3","i_c_s":["Infantile fibrosarcoma","Congenital fibrosarcoma"],"term_type":""},{"nm":"8815/0","n_c":["C7634"],"i_c":"8815/0","i_c_s":["Solitary fibrous tumor","Localized fibrous tumor"],"term_type":""},{"nm":"8815/1","n_c":["C129528"],"i_c":"8815/1","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)"],"term_type":""},{"nm":"8815/3","n_c":["C6894"],"i_c":"8815/3","i_c_s":["Solitary fibrous tumor, malignant"],"term_type":""},{"nm":"8820/0","n_c":["C4245"],"i_c":"8820/0","i_c_s":["Elastofibroma"],"term_type":""},{"nm":"8821/1","n_c":["C6489","C9182"],"i_c":"8821/1","i_c_s":["Aggressive fibromatosis","Desmoid, NOS","Extra-abdominal desmoid","Invasive fibroma"],"term_type":""},{"nm":"8822/1","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Abdominal fibromatosis","Abdominal desmoid","Mesenteric fibromatosis","Retroperitoneal fibromatosis"],"term_type":""},{"nm":"8823/0","n_c":["C3740"],"i_c":"8823/0","i_c_s":["Desmoplastic fibroma"],"term_type":""},{"nm":"8824/0","n_c":["C7052"],"i_c":"8824/0","i_c_s":["Myofibroma"],"term_type":""},{"nm":"8824/1","n_c":["C3742"],"i_c":"8824/1","i_c_s":["Myofibromatosis","Congenital generalized fibromatosis","Infantile myofibromatosis"],"term_type":""},{"nm":"8825/0","n_c":["C49012"],"i_c":"8825/0","i_c_s":["Myofibroblastoma"],"term_type":""},{"nm":"8825/1","n_c":["C6481"],"i_c":"8825/1","i_c_s":["Myofibroblastic tumor, NOS","Inflammatory myofibroblastic tumor"],"term_type":""},{"nm":"8825/3","n_c":["C49024"],"i_c":"8825/3","i_c_s":["Myofibroblastic sarcoma"],"term_type":""},{"nm":"8826/0","n_c":["C49016"],"i_c":"8826/0","i_c_s":["Angiomyofibroblastoma"],"term_type":""},{"nm":"8827/1","n_c":["C142823","C39740"],"i_c":"8827/1","i_c_s":["Myofibroblastic tumor, peribronchial","Congenital peribronchial myofibroblastic tumor"],"term_type":""},{"nm":"8830/0","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Benign fibrous histiocytoma","Fibrous histiocytoma, NOS","Fibroxanthoma, NOS","Xanthofibroma"],"term_type":""},{"nm":"8830/1","n_c":["C4246"],"i_c":"8830/1","i_c_s":["Atypical fibrous histiocytoma","Atypical fibroxanthoma"],"term_type":""},{"nm":"8830/3","n_c":["C4247"],"i_c":"8830/3","i_c_s":["Malignant fibrous histiocytoma","Fibroxanthoma, malignant"],"term_type":""},{"nm":"8831/0","n_c":["C35765","C3356","C6492"],"i_c":"8831/0","i_c_s":["Histiocytoma, NOS","Deep histiocytoma","Juvenile histiocytoma","Reticulohistiocytoma"],"term_type":""},{"nm":"8832/0","n_c":["C7159","C6801"],"i_c":"8832/0","i_c_s":["Dermatofibroma, NOS","Cutaneous histiocytoma, NOS","Dermatofibroma lenticulare","Sclerosing hemangioma","Subepidermal nodular fibrosis"],"term_type":""},{"nm":"8832/3","n_c":["C4683"],"i_c":"8832/3","i_c_s":["Dermatofibrosarcoma, NOS","Dermatofibrosarcoma protuberans, NOS"],"term_type":""},{"nm":"8833/3","n_c":["C9430"],"i_c":"8833/3","i_c_s":["Pigmented dermatofibrosarcoma protuberans","Bednar tumor"],"term_type":""},{"nm":"8834/1","n_c":["C4700"],"i_c":"8834/1","i_c_s":["Giant cell fibroblastoma"],"term_type":""},{"nm":"8835/1","n_c":["C6493"],"i_c":"8835/1","i_c_s":["Plexiform fibrohistiocytic tumor"],"term_type":""},{"nm":"8836/1","n_c":["C6494"],"i_c":"8836/1","i_c_s":["Angiomatoid fibrous histiocytoma"],"term_type":""},{"nm":"8840/0","n_c":["C6577"],"i_c":"8840/0","i_c_s":["Myxoma, NOS"],"term_type":""},{"nm":"8840/3","n_c":["C3255"],"i_c":"8840/3","i_c_s":["Myxosarcoma"],"term_type":""},{"nm":"8841/1","n_c":["C3254","C6936"],"i_c":"8841/1","i_c_s":["Angiomyxoma","Aggressive angiomyxoma"],"term_type":""},{"nm":"8842/0","n_c":["C6582"],"i_c":"8842/0","i_c_s":["Ossifying fibromyxoid tumor"],"term_type":""},{"nm":"8842/3","n_c":["C142827"],"i_c":"8842/3","i_c_s":["Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation"],"term_type":""},{"nm":"8850/0","n_c":["C3192"],"i_c":"8850/0","i_c_s":["Lipoma, NOS"],"term_type":""},{"nm":"8850/1","n_c":["C6505"],"i_c":"8850/1","i_c_s":["Atypical lipoma","Superficial well differentated liposarcoma","Well differentiated liposarcoma of superficial soft tissue"],"term_type":""},{"nm":"8850/3","n_c":["C3194"],"i_c":"8850/3","i_c_s":["Liposarcoma, NOS","Fibroliposarcoma"],"term_type":""},{"nm":"8851/0","n_c":["C4249"],"i_c":"8851/0","i_c_s":["Fibrolipoma"],"term_type":""},{"nm":"8851/3","n_c":["C6505","C6508","C6507"],"i_c":"8851/3","i_c_s":["Liposarcoma, well differentiated","Inflammatory liposarcoma","Sclerosing liposarcoma","Lipoma-like liposarcoma","Liposarcoma, differentiated"],"term_type":""},{"nm":"8852/0","n_c":["C4251"],"i_c":"8852/0","i_c_s":["Fibromyxolipoma","Myxolipoma"],"term_type":""},{"nm":"8852/3","n_c":["C27781"],"i_c":"8852/3","i_c_s":["Myxoid liposarcoma","Myxoliposarcoma"],"term_type":""},{"nm":"8853/3","n_c":["C4252"],"i_c":"8853/3","i_c_s":["Round cell liposarcoma"],"term_type":""},{"nm":"8854/0","n_c":["C3703"],"i_c":"8854/0","i_c_s":["Pleomorphic lipoma"],"term_type":""},{"nm":"8854/3","n_c":["C3705"],"i_c":"8854/3","i_c_s":["Pleomorphic liposarcoma"],"term_type":""},{"nm":"8855/3","n_c":["C4253"],"i_c":"8855/3","i_c_s":["Mixed liposarcoma"],"term_type":""},{"nm":"8856/0","n_c":["C7451","C7450","C7449"],"i_c":"8856/0","i_c_s":["Intramuscular lipoma","Infiltrating angiolipoma","Infiltrating lipoma"],"term_type":""},{"nm":"8857/0","n_c":["C4254"],"i_c":"8857/0","i_c_s":["Spindle cell lipoma"],"term_type":""},{"nm":"8857/3","n_c":["C6509"],"i_c":"8857/3","i_c_s":["Fibroblastic liposarcoma"],"term_type":""},{"nm":"8858/3","n_c":["C3704"],"i_c":"8858/3","i_c_s":["Dedifferentiated liposarcoma"],"term_type":""},{"nm":"8860/0","n_c":["C3734"],"i_c":"8860/0","i_c_s":["Angiomyolipoma"],"term_type":""},{"nm":"8861/0","n_c":["C3733"],"i_c":"8861/0","i_c_s":["Angiolipoma, NOS"],"term_type":""},{"nm":"8862/0","n_c":["C6503"],"i_c":"8862/0","i_c_s":["Chondroid lipoma"],"term_type":""},{"nm":"8870/0","n_c":["C3736"],"i_c":"8870/0","i_c_s":["Myelolipoma"],"term_type":""},{"nm":"8880/0","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Hibernoma","Brown fat tumor","Fetal fat cell lipoma"],"term_type":""},{"nm":"8881/0","n_c":["C27483","C4255"],"i_c":"8881/0","i_c_s":["Lipoblastomatosis","Fetal lipoma, NOS","Fetal lipomatosis","Lipoblastoma"],"term_type":""},{"nm":"8890/0","n_c":["C3434","C3157"],"i_c":"8890/0","i_c_s":["Leiomyoma, NOS","Lipoleiomyoma","Plexiform leiomyoma","Fibroid uterus","Fibromyoma","Leiomyofibroma"],"term_type":""},{"nm":"8890/1","n_c":["C3748"],"i_c":"8890/1","i_c_s":["Leiomyomatosis, NOS","Intravascular leiomyomatosis"],"term_type":""},{"nm":"8890/3","n_c":["C3158"],"i_c":"8890/3","i_c_s":["Leiomyosarcoma, NOS"],"term_type":""},{"nm":"8891/0","n_c":["C40164"],"i_c":"8891/0","i_c_s":["Epithelioid leiomyoma","Leiomyoblastoma"],"term_type":""},{"nm":"8891/3","n_c":["C3700"],"i_c":"8891/3","i_c_s":["Epithelioid leiomyosarcoma"],"term_type":""},{"nm":"8892/0","n_c":["C4256"],"i_c":"8892/0","i_c_s":["Cellular leiomyoma"],"term_type":""},{"nm":"8893/0","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Bizarre leiomyoma","Atypical leiomyoma","Pleomorphic leiomyoma","Symplastic leiomyoma"],"term_type":""},{"nm":"8894/0","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Angiomyoma","Angioleiomyoma","Vascular leiomyoma"],"term_type":""},{"nm":"8894/3","n_c":["C66771"],"i_c":"8894/3","i_c_s":["Angiomyosarcoma"],"term_type":""},{"nm":"8895/0","n_c":["C4882"],"i_c":"8895/0","i_c_s":["Myoma"],"term_type":""},{"nm":"8895/3","n_c":["C4883"],"i_c":"8895/3","i_c_s":["Myosarcoma"],"term_type":""},{"nm":"8896/3","n_c":["C3701"],"i_c":"8896/3","i_c_s":["Myxoid leiomyosarcoma"],"term_type":""},{"nm":"8897/1","n_c":["C40177"],"i_c":"8897/1","i_c_s":["Smooth muscle tumor of uncertain malignant potential","Smooth muscle tumor, NOS"],"term_type":""},{"nm":"8898/1","n_c":["C40173"],"i_c":"8898/1","i_c_s":["Metastasizing leiomyoma"],"term_type":""},{"nm":"8900/0","n_c":["C3358"],"i_c":"8900/0","i_c_s":["Rhabdomyoma, NOS"],"term_type":""},{"nm":"8900/3","n_c":["C3359"],"i_c":"8900/3","i_c_s":["Rhabdomyosarcoma, NOS","Rhabdosarcoma"],"term_type":""},{"nm":"8901/3","n_c":["C4258","C27369"],"i_c":"8901/3","i_c_s":["Pleomorphic rhabdomyosarcoma, adult type","Pleomorphic rhabdomyosarcoma, NOS"],"term_type":""},{"nm":"8902/3","n_c":["C4259"],"i_c":"8902/3","i_c_s":["Mixed type rhabdomyosarcoma","Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma"],"term_type":""},{"nm":"8903/0","n_c":["C4260"],"i_c":"8903/0","i_c_s":["Fetal rhabdomyoma"],"term_type":""},{"nm":"8904/0","n_c":["C4261","C45747"],"i_c":"8904/0","i_c_s":["Adult rhabdomyoma","Glycogenic rhabdomyoma"],"term_type":""},{"nm":"8905/0","n_c":["C6517"],"i_c":"8905/0","i_c_s":["Genital rhabdomyoma"],"term_type":""},{"nm":"8910/3","n_c":["C9150","C8971"],"i_c":"8910/3","i_c_s":["Embryonal rhabdomyosarcoma, NOS","Embryonal rhabdomyosarcoma, pleomorphic","Sarcoma botryoides","Botryoid sarcoma"],"term_type":""},{"nm":"8912/3","n_c":["C6519"],"i_c":"8912/3","i_c_s":["Spindle cell rhabdomyosarcoma"],"term_type":""},{"nm":"8920/3","n_c":["C3749"],"i_c":"8920/3","i_c_s":["Alveolar rhabdomyosarcoma"],"term_type":""},{"nm":"8920/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8921/3","n_c":["C4716"],"i_c":"8921/3","i_c_s":["Rhabdomyosarcoma with ganglionic differentiation","Ectomesenchymoma"],"term_type":""},{"nm":"8930/0","n_c":["C4262"],"i_c":"8930/0","i_c_s":["Endometrial stromal nodule"],"term_type":""},{"nm":"8930/3","n_c":["C8973","C126998"],"i_c":"8930/3","i_c_s":["Endometrial stromal sarcoma, NOS","Endometrial stromal sarcoma, high grade","Endometrial sarcoma, NOS"],"term_type":""},{"nm":"8931/3","n_c":["C40223","C4263"],"i_c":"8931/3","i_c_s":["Endometrial stromal sarcoma, low grade","Endolymphatic stromal myosis","Endometrial stromatosis","Stromal endometriosis","Stromal myosis, NOS"],"term_type":""},{"nm":"8932/0","n_c":["C3726","C6895"],"i_c":"8932/0","i_c_s":["Adenomyoma","Atypical polypoid adenomyoma"],"term_type":""},{"nm":"8933/3","n_c":["C9474"],"i_c":"8933/3","i_c_s":["Adenosarcoma"],"term_type":""},{"nm":"8934/3","n_c":["C40182"],"i_c":"8934/3","i_c_s":["Carcinofibroma"],"term_type":""},{"nm":"8935/0","n_c":["C66772"],"i_c":"8935/0","i_c_s":["Stromal tumor, benign"],"term_type":""},{"nm":"8935/1","n_c":["C6781"],"i_c":"8935/1","i_c_s":["Stromal tumor, NOS"],"term_type":""},{"nm":"8935/3","n_c":["C6926"],"i_c":"8935/3","i_c_s":["Stromal sarcoma, NOS"],"term_type":""},{"nm":"8936/0","n_c":["C53998"],"i_c":"8936/0","i_c_s":["Gastrointestinal stromal tumor, benign","GIST, benign"],"term_type":""},{"nm":"8936/1","n_c":["C54000","C3868","C27940"],"i_c":"8936/1","i_c_s":["Gastrointestinal stromal tumor, NOS","Gastrointestinal autonomic nerve tumor","Gastrointestinal pacemaker cell tumor","GANT","GIST, NOS","Gastrointestinal stromal tumor, uncertain malignant potential"],"term_type":""},{"nm":"8936/3","n_c":["C53999"],"i_c":"8936/3","i_c_s":["Gastrointestinal stromal sarcoma","GIST, malignant","Gastrointestinal stromal tumor, malignant"],"term_type":""},{"nm":"8940/0","n_c":["C6930","C8602","C4474"],"i_c":"8940/0","i_c_s":["Pleomorphic adenoma","Chondroid syringoma","Mixed tumor, NOS","Mixed tumor, salivary gland type, NOS"],"term_type":""},{"nm":"8940/3","n_c":["C3729"],"i_c":"8940/3","i_c_s":["Mixed tumor, malignant, NOS","Malignant chondroid syringoma","Mixed tumor, salivary gland type, malignant"],"term_type":""},{"nm":"8941/3","n_c":["C4397"],"i_c":"8941/3","i_c_s":["Carcinoma in pleomorphic adenoma"],"term_type":""},{"nm":"8950/3","n_c":["C3730"],"i_c":"8950/3","i_c_s":["Mullerian mixed tumor"],"term_type":""},{"nm":"8950/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8951/3","n_c":["C3730"],"i_c":"8951/3","i_c_s":["Mesodermal mixed tumor"],"term_type":""},{"nm":"8959/0","n_c":["C7504"],"i_c":"8959/0","i_c_s":["Benign cystic nephroma"],"term_type":""},{"nm":"8959/1","n_c":["C6897"],"i_c":"8959/1","i_c_s":["Cystic partially differentiated nephroblastoma"],"term_type":""},{"nm":"8959/3","n_c":["C6897"],"i_c":"8959/3","i_c_s":["Malignant cystic nephroma","Malignant multilocular cystic nephroma"],"term_type":""},{"nm":"8960/1","n_c":["C6569"],"i_c":"8960/1","i_c_s":["Mesoblastic nephroma"],"term_type":""},{"nm":"8960/3","n_c":["C40407","C3267"],"i_c":"8960/3","i_c_s":["Nephroblastoma, NOS","Nephroma, NOS","Wilms tumor"],"term_type":""},{"nm":"8963/3","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Malignant rhabdoid tumor","Rhabdoid sarcoma","Rhabdoid tumor, NOS"],"term_type":""},{"nm":"8964/3","n_c":["C4264"],"i_c":"8964/3","i_c_s":["Clear cell sarcoma of kidney"],"term_type":""},{"nm":"8965/0","n_c":["C39812"],"i_c":"8965/0","i_c_s":["Nephrogenic adenofibroma"],"term_type":""},{"nm":"8966/0","n_c":["C5100"],"i_c":"8966/0","i_c_s":["Renomedullary interstitial cell tumor","Renomedullary fibroma"],"term_type":""},{"nm":"8967/0","n_c":["C66774"],"i_c":"8967/0","i_c_s":["Ossifying renal tumor"],"term_type":""},{"nm":"8970/3","n_c":["C7097","C3728"],"i_c":"8970/3","i_c_s":["Hepatoblastoma","Hepatoblastoma, epithelioid","Hepatoblastoma, mixed epithelial-mesenchymal","Embryonal hepatoma"],"term_type":""},{"nm":"8971/3","n_c":["C4265"],"i_c":"8971/3","i_c_s":["Pancreatoblastoma"],"term_type":""},{"nm":"8972/3","n_c":["C3732"],"i_c":"8972/3","i_c_s":["Pulmonary blastoma","Pneumoblastoma"],"term_type":""},{"nm":"8973/3","n_c":["C5669"],"i_c":"8973/3","i_c_s":["Pleuropulmonary blastoma"],"term_type":""},{"nm":"8974/1","n_c":["C35837"],"i_c":"8974/1","i_c_s":["Sialoblastoma"],"term_type":""},{"nm":"8975/1","n_c":["C96830"],"i_c":"8975/1","i_c_s":["Calcifying nested epithelial stromal tumor"],"term_type":""},{"nm":"8980/3","n_c":["C34448"],"i_c":"8980/3","i_c_s":["Carcinosarcoma, NOS"],"term_type":""},{"nm":"8981/3","n_c":["C8975"],"i_c":"8981/3","i_c_s":["Carcinosarcoma, embryonal"],"term_type":""},{"nm":"8982/0","n_c":["C40392","C7442"],"i_c":"8982/0","i_c_s":["Myoepithelioma","Myoepithelial adenoma","Myoepithelial tumor"],"term_type":""},{"nm":"8982/3","n_c":["C7596"],"i_c":"8982/3","i_c_s":["Malignant myoepithelioma","Myoepithelial carcinoma"],"term_type":""},{"nm":"8983/0","n_c":["C6899"],"i_c":"8983/0","i_c_s":["Adenomyoepithelioma"],"term_type":""},{"nm":"8983/3","n_c":["C5143"],"i_c":"8983/3","i_c_s":["Adenomyoepithelioma with carcinoma"],"term_type":""},{"nm":"8990/0","n_c":["C4267"],"i_c":"8990/0","i_c_s":["Mesenchymoma, benign"],"term_type":""},{"nm":"8990/1","n_c":["C3233"],"i_c":"8990/1","i_c_s":["Mesenchymoma, NOS","Mixed mesenchymal tumor"],"term_type":""},{"nm":"8990/3","n_c":["C4268"],"i_c":"8990/3","i_c_s":["Mesenchymoma, malignant","Mixed mesenchymal sarcoma"],"term_type":""},{"nm":"8991/3","n_c":["C27096"],"i_c":"8991/3","i_c_s":["Embryonal sarcoma"],"term_type":""},{"nm":"9000/0","n_c":["C39954"],"i_c":"9000/0","i_c_s":["Brenner tumor, NOS"],"term_type":""},{"nm":"9000/1","n_c":["C9459"],"i_c":"9000/1","i_c_s":["Brenner tumor, borderline malignancy","Brenner tumor, proliferating"],"term_type":""},{"nm":"9000/3","n_c":["C4270"],"i_c":"9000/3","i_c_s":["Brenner tumor, malignant"],"term_type":""},{"nm":"9010/0","n_c":["C3744"],"i_c":"9010/0","i_c_s":["Fibroadenoma, NOS"],"term_type":""},{"nm":"9011/0","n_c":["C4271"],"i_c":"9011/0","i_c_s":["Intracanalicular fibroadenoma"],"term_type":""},{"nm":"9012/0","n_c":["C4272"],"i_c":"9012/0","i_c_s":["Pericanalicular fibroadenoma"],"term_type":""},{"nm":"9013/0","n_c":["C8984","C8985","C8986"],"i_c":"9013/0","i_c_s":["Adenofibroma, NOS","Cystadenofibroma, NOS","Papillary adenofibroma"],"term_type":""},{"nm":"9014/0","n_c":["C67090"],"i_c":"9014/0","i_c_s":["Serous adenofibroma, NOS","Serous cystadenofibroma, NOS"],"term_type":""},{"nm":"9014/1","n_c":["C40028"],"i_c":"9014/1","i_c_s":["Serous adenofibroma of borderline malignancy","Serous cystadenofibroma of borderline malignancy"],"term_type":""},{"nm":"9014/3","n_c":["C67092"],"i_c":"9014/3","i_c_s":["Serous adenocarcinofibroma","Serous cystadenocarcinofibroma","Malignant serous adenofibroma","Malignant serous cystadenofibroma"],"term_type":""},{"nm":"9015/0","n_c":["C8979","C8978"],"i_c":"9015/0","i_c_s":["Mucinous adenofibroma, NOS","Mucinous cystadenofibroma, NOS"],"term_type":""},{"nm":"9015/1","n_c":["C66775"],"i_c":"9015/1","i_c_s":["Mucinous adenofibroma of borderline malignancy","Mucinous cystadenofibroma of borderline malignancy"],"term_type":""},{"nm":"9015/3","n_c":["C40034"],"i_c":"9015/3","i_c_s":["Mucinous adenocarcinofibroma","Mucinous cystadenocarcinofibroma","Malignant mucinous adenofibroma","Malignant mucinous cystadenofibroma"],"term_type":""},{"nm":"9016/0","n_c":["C4273"],"i_c":"9016/0","i_c_s":["Giant fibroadenoma"],"term_type":""},{"nm":"9020/0","n_c":["C4274"],"i_c":"9020/0","i_c_s":["Phyllodes tumor, benign","Cystosarcoma phyllodes, benign"],"term_type":""},{"nm":"9020/1","n_c":["C2977","C7503"],"i_c":"9020/1","i_c_s":["Phyllodes tumor, borderline","Cystosarcoma phyllodes, NOS","Phyllodes tumor, NOS"],"term_type":""},{"nm":"9020/3","n_c":["C4275"],"i_c":"9020/3","i_c_s":["Phyllodes tumor, malignant","Cystosarcoma phyllodes, malignant"],"term_type":""},{"nm":"9030/0","n_c":["C4276"],"i_c":"9030/0","i_c_s":["Juvenile fibroadenoma"],"term_type":""},{"nm":"9040/0","n_c":["C3829"],"i_c":"9040/0","i_c_s":["Synovioma, benign"],"term_type":""},{"nm":"9040/3","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovial sarcoma, NOS","Synovioma, NOS","Synovioma, malignant"],"term_type":""},{"nm":"9041/3","n_c":["C4277"],"i_c":"9041/3","i_c_s":["Synovial sarcoma, spindle cell","Synovial sarcoma, monophasic fibrous"],"term_type":""},{"nm":"9042/3","n_c":["C4278"],"i_c":"9042/3","i_c_s":["Synovial sarcoma, epithelioid cell"],"term_type":""},{"nm":"9043/3","n_c":["C4279"],"i_c":"9043/3","i_c_s":["Synovial sarcoma, biphasic"],"term_type":""},{"nm":"9044/3","n_c":["C3745"],"i_c":"9044/3","i_c_s":["Clear cell sarcoma, NOS","Clear cell sarcoma, of tendons and aponeuroses","Melanoma, malignant, of soft parts"],"term_type":""},{"nm":"9045/3","n_c":["C164205"],"i_c":"9045/3","i_c_s":["Biphenotypic sinonasal sarcoma"],"term_type":""},{"nm":"9050/0","n_c":["C3762"],"i_c":"9050/0","i_c_s":["Mesothelioma, benign"],"term_type":""},{"nm":"9050/3","n_c":["C4456","C3786"],"i_c":"9050/3","i_c_s":["Mesothelioma, malignant","Mesothelioma, NOS"],"term_type":""},{"nm":"9051/0","n_c":["C4457"],"i_c":"9051/0","i_c_s":["Fibrous mesothelioma, benign"],"term_type":""},{"nm":"9051/3","n_c":["C6747","C45655"],"i_c":"9051/3","i_c_s":["Fibrous mesothelioma, malignant","Desmoplastic mesothelioma","Fibrous mesothelioma, NOS","Sarcomatoid mesothelioma","Spindled mesothelioma"],"term_type":""},{"nm":"9052/0","n_c":["C3762"],"i_c":"9052/0","i_c_s":["Epithelioid mesothelioma, benign","Well differentiated papillary mesothelioma, benign","Mesothelial papilloma"],"term_type":""},{"nm":"9052/3","n_c":["C7985"],"i_c":"9052/3","i_c_s":["Epithelioid mesothelioma, malignant","Epithelioid mesothelioma, NOS"],"term_type":""},{"nm":"9053/3","n_c":["C4282"],"i_c":"9053/3","i_c_s":["Mesothelioma, biphasic, malignant","Mesothelioma, biphasic, NOS"],"term_type":""},{"nm":"9054/0","n_c":["C3762"],"i_c":"9054/0","i_c_s":["Adenomatoid tumor, NOS"],"term_type":""},{"nm":"9055/0","n_c":["C6536","C3765"],"i_c":"9055/0","i_c_s":["Multicystic mesothelioma, benign","Cystic mesothelioma, benign"],"term_type":""},{"nm":"9055/1","n_c":["C3765"],"i_c":"9055/1","i_c_s":["Cystic mesothelioma, NOS"],"term_type":""},{"nm":"9060/3","n_c":["C8106"],"i_c":"9060/3","i_c_s":["Dysgerminoma"],"term_type":""},{"nm":"9061/3","n_c":["C9309"],"i_c":"9061/3","i_c_s":["Seminoma, NOS"],"term_type":""},{"nm":"9062/3","n_c":["C39920"],"i_c":"9062/3","i_c_s":["Seminoma, anaplastic","Seminoma with high mitotic index"],"term_type":""},{"nm":"9063/3","n_c":["C39921"],"i_c":"9063/3","i_c_s":["Spermatocytic seminoma","Spermatocytoma"],"term_type":""},{"nm":"9064/2","n_c":["C40345"],"i_c":"9064/2","i_c_s":["Intratubular malignant germ cells","Intratubular germ cell neoplasia"],"term_type":""},{"nm":"9064/3","n_c":["C7009","C3708"],"i_c":"9064/3","i_c_s":["Germinoma","Germ cell tumor, NOS"],"term_type":""},{"nm":"9065/3","n_c":["C121619"],"i_c":"9065/3","i_c_s":["Germ cell tumor, nonseminomatous"],"term_type":""},{"nm":"9070/3","n_c":["C3752"],"i_c":"9070/3","i_c_s":["Embryonal carcinoma, NOS","Embryonal adenocarcinoma"],"term_type":""},{"nm":"9071/3","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Yolk sac tumor","Hepatoid yolk sac tumor","Embryonal carcinoma, infantile","Endodermal sinus tumor","Orchioblastoma","Polyvesicular vitelline tumor"],"term_type":""},{"nm":"9072/3","n_c":["C66776"],"i_c":"9072/3","i_c_s":["Polyembryoma","Embryonal carcinoma, polyembryonal type"],"term_type":""},{"nm":"9073/1","n_c":["C3754"],"i_c":"9073/1","i_c_s":["Gonadoblastoma","Gonocytoma"],"term_type":""},{"nm":"9080/0","n_c":["C9012","C9013","C9014","C67107","C9015"],"i_c":"9080/0","i_c_s":["Teratoma, benign","Adult cystic teratoma","Adult teratoma, NOS","Cystic teratoma, NOS","Mature teratoma","Teratoma, differentiated"],"term_type":""},{"nm":"9080/1","n_c":["C3403"],"i_c":"9080/1","i_c_s":["Teratoma, NOS","Solid teratoma"],"term_type":""},{"nm":"9080/3","n_c":["C4287"],"i_c":"9080/3","i_c_s":["Teratoma, malignant, NOS","Immature teratoma, malignant","Embryonal teratoma","Immature teratoma, NOS","Teratoblastoma, malignant"],"term_type":""},{"nm":"9081/3","n_c":["C3756"],"i_c":"9081/3","i_c_s":["Teratocarcinoma","Mixed embryonal carcinoma and teratoma"],"term_type":""},{"nm":"9082/3","n_c":["C4287"],"i_c":"9082/3","i_c_s":["Malignant teratoma, undifferentiated","Malignant teratoma, anaplastic"],"term_type":""},{"nm":"9083/3","n_c":["C4288"],"i_c":"9083/3","i_c_s":["Malignant teratoma, intermediate"],"term_type":""},{"nm":"9084/0","n_c":["C9011"],"i_c":"9084/0","i_c_s":["Dermoid cyst, NOS","Dermoid, NOS"],"term_type":""},{"nm":"9084/3","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Teratoma with malignant transformation","Dermoid cyst with malignant transformation","Dermoid cyst with secondary tumor"],"term_type":""},{"nm":"9085/3","n_c":["C9010","C4290"],"i_c":"9085/3","i_c_s":["Mixed germ cell tumor","Mixed teratoma and seminoma"],"term_type":""},{"nm":"9086/3","n_c":["C45733"],"i_c":"9086/3","i_c_s":["Germ cell tumors with associated hematological malignancy"],"term_type":""},{"nm":"9090/0","n_c":["C7468"],"i_c":"9090/0","i_c_s":["Struma ovarii, NOS"],"term_type":""},{"nm":"9090/3","n_c":["C4291"],"i_c":"9090/3","i_c_s":["Struma ovarii, malignant"],"term_type":""},{"nm":"9091/1","n_c":["C4292"],"i_c":"9091/1","i_c_s":["Strumal carcinoid","Struma ovarii and carcinoid"],"term_type":""},{"nm":"9100/0","n_c":["C3110","C4871"],"i_c":"9100/0","i_c_s":["Hydatidiform mole, NOS","Complete hydatidiform mole","Hydatid mole"],"term_type":""},{"nm":"9100/1","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Invasive hydatidiform mole","Chorioadenoma destruens","Chorioadenoma","Invasive mole, NOS","Malignant hydatidiform mole"],"term_type":""},{"nm":"9100/3","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Choriocarcinoma, NOS","Chorioepithelioma","Chorionepithelioma"],"term_type":""},{"nm":"9101/3","n_c":["C66777"],"i_c":"9101/3","i_c_s":["Choriocarcinoma combined with other germ cell elements","Choriocarcinoma combined with embryonal carcinoma","Choriocarcinoma combined with teratoma"],"term_type":""},{"nm":"9102/3","n_c":["C66778"],"i_c":"9102/3","i_c_s":["Malignant teratoma, trophoblastic"],"term_type":""},{"nm":"9103/0","n_c":["C4293"],"i_c":"9103/0","i_c_s":["Partial hydatidiform mole"],"term_type":""},{"nm":"9104/1","n_c":["C3757"],"i_c":"9104/1","i_c_s":["Placental site trophoblastic tumor"],"term_type":""},{"nm":"9105/3","n_c":["C40141"],"i_c":"9105/3","i_c_s":["Trophoblastic tumor, epithelioid"],"term_type":""},{"nm":"9110/0","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Mesonephroma, benign","Mesonephric adenoma","Wolffian duct adenoma"],"term_type":""},{"nm":"9110/1","n_c":["C40141"],"i_c":"9110/1","i_c_s":["Mesonephric tumor, NOS","Wolffian duct tumor"],"term_type":""},{"nm":"9110/3","n_c":["C4072","C40141"],"i_c":"9110/3","i_c_s":["Mesonephroma, malignant","Mesonephric adenocarcinoma","Mesonephroma, NOS","Wolffian duct carcinoma"],"term_type":""},{"nm":"9120/0","n_c":["C3085"],"i_c":"9120/0","i_c_s":["Hemangioma, NOS","Angioma, NOS","Chorioangioma"],"term_type":""},{"nm":"9120/3","n_c":["C3088"],"i_c":"9120/3","i_c_s":["Hemangiosarcoma","Angiosarcoma"],"term_type":""},{"nm":"9121/0","n_c":["C3086"],"i_c":"9121/0","i_c_s":["Cavernous hemangioma"],"term_type":""},{"nm":"9122/0","n_c":["C4296"],"i_c":"9122/0","i_c_s":["Venous hemangioma"],"term_type":""},{"nm":"9123/0","n_c":["C2882"],"i_c":"9123/0","i_c_s":["Racemose hemangioma","Arteriovenous hemangioma"],"term_type":""},{"nm":"9124/3","n_c":["C4438"],"i_c":"9124/3","i_c_s":["Kupffer cell sarcoma"],"term_type":""},{"nm":"9125/0","n_c":["C4298"],"i_c":"9125/0","i_c_s":["Epithelioid hemangioma","Histiocytoid hemangioma"],"term_type":""},{"nm":"9130/0","n_c":["C66779"],"i_c":"9130/0","i_c_s":["Hemangioendothelioma, benign"],"term_type":""},{"nm":"9130/1","n_c":["C3084","C27510"],"i_c":"9130/1","i_c_s":["Hemangioendothelioma, NOS","Kaposiform hemangioendothelioma","Angioendothelioma"],"term_type":""},{"nm":"9130/3","n_c":["C3088"],"i_c":"9130/3","i_c_s":["Hemangioendothelioma, malignant","Hemangioendothelial sarcoma"],"term_type":""},{"nm":"9131/0","n_c":["C6645","C7457"],"i_c":"9131/0","i_c_s":["Capillary hemangioma","Hemangioma simplex","Infantile hemangioma","Juvenile hemangioma","Plexiform hemangioma"],"term_type":""},{"nm":"9132/0","n_c":["C3699"],"i_c":"9132/0","i_c_s":["Intramuscular hemangioma"],"term_type":""},{"nm":"9133/1","n_c":["C3800"],"i_c":"9133/1","i_c_s":["Epithelioid hemangioendothelioma, NOS"],"term_type":""},{"nm":"9133/3","n_c":["C3800"],"i_c":"9133/3","i_c_s":["Epithelioid hemangioendothelioma, malignant","Intravascular bronchial alveolar tumor"],"term_type":""},{"nm":"9135/1","n_c":["C7526"],"i_c":"9135/1","i_c_s":["Endovascular papillary angioendothelioma","Dabska tumor"],"term_type":""},{"nm":"9136/1","n_c":["C4754"],"i_c":"9136/1","i_c_s":["Spindle cell hemangioendothelioma","Spindle cell angioendothelioma"],"term_type":""},{"nm":"9137/3","n_c":["C53677"],"i_c":"9137/3","i_c_s":["Intimal sarcoma"],"term_type":""},{"nm":"9140/3","n_c":["C9087"],"i_c":"9140/3","i_c_s":["Kaposi sarcoma","Multiple hemorrhagic sarcoma"],"term_type":""},{"nm":"9141/0","n_c":["C2874"],"i_c":"9141/0","i_c_s":["Angiokeratoma"],"term_type":""},{"nm":"9142/0","n_c":["C4299"],"i_c":"9142/0","i_c_s":["Verrucous keratotic hemangioma"],"term_type":""},{"nm":"9150/0","n_c":["C4300"],"i_c":"9150/0","i_c_s":["Hemangiopericytoma, benign"],"term_type":""},{"nm":"9150/1","n_c":["C3087"],"i_c":"9150/1","i_c_s":["Hemangiopericytoma, NOS","Hemangiopericytic meningioma"],"term_type":""},{"nm":"9150/3","n_c":["C4301"],"i_c":"9150/3","i_c_s":["Hemangiopericytoma, malignant"],"term_type":""},{"nm":"9160/0","n_c":["C27257","C27256","C3799"],"i_c":"9160/0","i_c_s":["Angiofibroma, NOS","Cellular angiofibroma","Giant cell angiofibroma","Fibrous papule of nose","Involuting nevus","Juvenile angiofibroma"],"term_type":""},{"nm":"9161/0","n_c":["C4487"],"i_c":"9161/0","i_c_s":["Acquired tufted hemangioma"],"term_type":""},{"nm":"9161/1","n_c":["C3801"],"i_c":"9161/1","i_c_s":["Hemangioblastoma","Angioblastoma"],"term_type":""},{"nm":"9170/0","n_c":["C8965","C3203"],"i_c":"9170/0","i_c_s":["Lymphangioma, NOS","Lymphangioendothelioma, NOS"],"term_type":""},{"nm":"9170/3","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangiosarcoma","Lymphangioendothelial sarcoma","Lymphangioendothelioma, malignant"],"term_type":""},{"nm":"9171/0","n_c":["C8965"],"i_c":"9171/0","i_c_s":["Capillary lymphangioma"],"term_type":""},{"nm":"9172/0","n_c":["C53316"],"i_c":"9172/0","i_c_s":["Cavernous lymphangioma"],"term_type":""},{"nm":"9173/0","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Cystic lymphangioma","Cystic hygroma","Hygroma, NOS"],"term_type":""},{"nm":"9174/0","n_c":["C3204"],"i_c":"9174/0","i_c_s":["Lymphangiomyoma"],"term_type":""},{"nm":"9174/1","n_c":["C3725"],"i_c":"9174/1","i_c_s":["Lymphangiomyomatosis","Lymphangioleiomyomatosis"],"term_type":""},{"nm":"9175/0","n_c":["C66792"],"i_c":"9175/0","i_c_s":["Hemolymphangioma"],"term_type":""},{"nm":"9180/0","n_c":["C3296"],"i_c":"9180/0","i_c_s":["Osteoma, NOS"],"term_type":""},{"nm":"9180/3","n_c":["C53953","C4021","C9145"],"i_c":"9180/3","i_c_s":["Osteosarcoma, NOS","Osteoblastic sarcoma","Osteochondrosarcoma","Osteogenic sarcoma, NOS"],"term_type":""},{"nm":"9180/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9181/3","n_c":["C4021"],"i_c":"9181/3","i_c_s":["Chondroblastic osteosarcoma"],"term_type":""},{"nm":"9182/3","n_c":["C4020"],"i_c":"9182/3","i_c_s":["Fibroblastic osteosarcoma","Osteofibrosarcoma"],"term_type":""},{"nm":"9183/3","n_c":["C3902"],"i_c":"9183/3","i_c_s":["Telangiectatic osteosarcoma"],"term_type":""},{"nm":"9184/3","n_c":["C6469"],"i_c":"9184/3","i_c_s":["Osteosarcoma in Paget disease of bone"],"term_type":""},{"nm":"9185/3","n_c":["C4023"],"i_c":"9185/3","i_c_s":["Small cell osteosarcoma","Round cell osteosarcoma"],"term_type":""},{"nm":"9186/3","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Central osteosarcoma","Conventional central osteosarcoma","Medullary osteosarcoma"],"term_type":""},{"nm":"9187/3","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Intraosseous well differentiated osteosarcoma","Intraosseous low grade osteosarcoma"],"term_type":""},{"nm":"9191/0","n_c":["C3297"],"i_c":"9191/0","i_c_s":["Osteoid osteoma, NOS"],"term_type":""},{"nm":"9192/3","n_c":["C8969"],"i_c":"9192/3","i_c_s":["Parosteal osteosarcoma","Juxtacortical osteosarcoma"],"term_type":""},{"nm":"9193/3","n_c":["C8970"],"i_c":"9193/3","i_c_s":["Periosteal osteosarcoma"],"term_type":""},{"nm":"9194/3","n_c":["C53958"],"i_c":"9194/3","i_c_s":["High grade surface osteosarcoma"],"term_type":""},{"nm":"9195/3","n_c":["C35870"],"i_c":"9195/3","i_c_s":["Intracortical osteosarcoma"],"term_type":""},{"nm":"9200/0","n_c":["C3294"],"i_c":"9200/0","i_c_s":["Osteoblastoma, NOS","Giant osteoid osteoma"],"term_type":""},{"nm":"9200/1","n_c":["C66796"],"i_c":"9200/1","i_c_s":["Aggressive osteoblastoma"],"term_type":""},{"nm":"9210/0","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Osteochondroma","Cartilaginous exostosis","Ecchondroma","Osteocartilaginous exostosis"],"term_type":""},{"nm":"9210/1","n_c":["C53457"],"i_c":"9210/1","i_c_s":["Osteochondromatosis, NOS","Ecchondrosis"],"term_type":""},{"nm":"9220/0","n_c":["C53459","C3007"],"i_c":"9220/0","i_c_s":["Chondroma, NOS","Enchondroma"],"term_type":""},{"nm":"9220/1","n_c":["C35259"],"i_c":"9220/1","i_c_s":["Chondromatosis, NOS"],"term_type":""},{"nm":"9220/3","n_c":["C2946"],"i_c":"9220/3","i_c_s":["Chondrosarcoma, NOS","Fibrochondrosarcoma"],"term_type":""},{"nm":"9221/0","n_c":["C4302"],"i_c":"9221/0","i_c_s":["Juxtacortical chondroma","Periosteal chondroma"],"term_type":""},{"nm":"9221/3","n_c":["C7357"],"i_c":"9221/3","i_c_s":["Juxtacortical chondrosarcoma","Periosteal chondrosarcoma"],"term_type":""},{"nm":"9230/0","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Chondroblastoma, NOS","Chondromatous giant cell tumor","Codman tumor"],"term_type":""},{"nm":"9230/3","n_c":["C66799"],"i_c":"9230/3","i_c_s":["Chondroblastoma, malignant"],"term_type":""},{"nm":"9231/3","n_c":["C27502"],"i_c":"9231/3","i_c_s":["Myxoid chondrosarcoma"],"term_type":""},{"nm":"9240/3","n_c":["C3737"],"i_c":"9240/3","i_c_s":["Mesenchymal chondrosarcoma"],"term_type":""},{"nm":"9241/0","n_c":["C3830"],"i_c":"9241/0","i_c_s":["Chondromyxoid fibroma"],"term_type":""},{"nm":"9242/3","n_c":["C6475"],"i_c":"9242/3","i_c_s":["Clear cell chondrosarcoma"],"term_type":""},{"nm":"9243/3","n_c":["C6476"],"i_c":"9243/3","i_c_s":["Dedifferentiated chondrosarcoma"],"term_type":""},{"nm":"9250/1","n_c":["C121932"],"i_c":"9250/1","i_c_s":["Giant cell tumor of bone, NOS","Osteoclastoma, NOS"],"term_type":""},{"nm":"9250/3","n_c":["C4304","C8380"],"i_c":"9250/3","i_c_s":["Giant cell tumor of bone, malignant","Giant cell sarcoma of bone","Osteoclastoma, malignant"],"term_type":""},{"nm":"9251/1","n_c":["C49107"],"i_c":"9251/1","i_c_s":["Giant cell tumor of soft parts, NOS"],"term_type":""},{"nm":"9251/3","n_c":["C8380"],"i_c":"9251/3","i_c_s":["Malignant giant cell tumor of soft parts"],"term_type":""},{"nm":"9252/0","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Tenosynovial giant cell tumor","Fibrous histiocytoma of tendon sheath","Giant cell tumor of tendon sheath"],"term_type":""},{"nm":"9252/3","n_c":["C6535"],"i_c":"9252/3","i_c_s":["Malignant tenosynovial giant cell tumor","Giant cell tumor of tendon sheath, malignant"],"term_type":""},{"nm":"9260/3","n_c":["C4817"],"i_c":"9260/3","i_c_s":["Ewing sarcoma","Ewing tumor"],"term_type":""},{"nm":"9261/3","n_c":["C7644","C8461"],"i_c":"9261/3","i_c_s":["Adamantinoma of long bones","Tibial adamantinoma"],"term_type":""},{"nm":"9262/0","n_c":["C173820"],"i_c":"9262/0","i_c_s":["Ossifying fibroma","Fibro-osteoma","Osteofibroma"],"term_type":""},{"nm":"9270/0","n_c":["C4306"],"i_c":"9270/0","i_c_s":["Odontogenic tumor, benign"],"term_type":""},{"nm":"9270/1","n_c":["C3286"],"i_c":"9270/1","i_c_s":["Odontogenic tumor, NOS"],"term_type":""},{"nm":"9270/3","n_c":["C4812","C7492"],"i_c":"9270/3","i_c_s":["Odontogenic tumor, malignant","Ameloblastic carcinoma","Odontogenic carcinoma","Odontogenic sarcoma","Primary intraosseous carcinoma"],"term_type":""},{"nm":"9271/0","n_c":["C54323","C66800"],"i_c":"9271/0","i_c_s":["Ameloblastic fibrodentinoma","Dentinoma"],"term_type":""},{"nm":"9272/0","n_c":["C173927"],"i_c":"9272/0","i_c_s":["Cementoma, NOS","Periapical cemental dysplasia","Periapical cemento-osseous dysplasia"],"term_type":""},{"nm":"9273/0","n_c":["C4308"],"i_c":"9273/0","i_c_s":["Cementoblastoma, benign"],"term_type":""},{"nm":"9274/0","n_c":["C8422"],"i_c":"9274/0","i_c_s":["Cementifying fibroma","Cemento-ossifying fibroma"],"term_type":""},{"nm":"9275/0","n_c":["C202219"],"i_c":"9275/0","i_c_s":["Gigantiform cementoma","Florid osseous dysplasia"],"term_type":""},{"nm":"9280/0","n_c":["C3287"],"i_c":"9280/0","i_c_s":["Odontoma, NOS"],"term_type":""},{"nm":"9281/0","n_c":["C3711"],"i_c":"9281/0","i_c_s":["Compound odontoma"],"term_type":""},{"nm":"9282/0","n_c":["C4309"],"i_c":"9282/0","i_c_s":["Complex odontoma"],"term_type":""},{"nm":"9290/0","n_c":["C3710"],"i_c":"9290/0","i_c_s":["Ameloblastic fibro-odontoma","Fibroameloblastic odontoma"],"term_type":""},{"nm":"9290/3","n_c":["C173740"],"i_c":"9290/3","i_c_s":["Ameloblastic odontosarcoma","Ameloblastic fibro-odontosarcoma","Ameloblastic fibrodentinosarcoma"],"term_type":""},{"nm":"9300/0","n_c":["C4310"],"i_c":"9300/0","i_c_s":["Adenomatoid odontogenic tumor","Adenoameloblastoma"],"term_type":""},{"nm":"9301/0","n_c":["C54319"],"i_c":"9301/0","i_c_s":["Calcifying odontogenic cyst"],"term_type":""},{"nm":"9302/0","n_c":["C54323"],"i_c":"9302/0","i_c_s":["Odontogenic ghost cell tumor"],"term_type":""},{"nm":"9302/3","n_c":["C4311"],"i_c":"9302/3","i_c_s":["Ghost cell odontogenic carcinoma"],"term_type":""},{"nm":"9310/0","n_c":["C4313"],"i_c":"9310/0","i_c_s":["Ameloblastoma, NOS","Adamantinoma, NOS"],"term_type":""},{"nm":"9310/3","n_c":["C54297"],"i_c":"9310/3","i_c_s":["Ameloblastoma, malignant","Adamantinoma, malignant"],"term_type":""},{"nm":"9311/0","n_c":["C54317"],"i_c":"9311/0","i_c_s":["Odontoameloblastoma"],"term_type":""},{"nm":"9312/0","n_c":["C7112"],"i_c":"9312/0","i_c_s":["Squamous odontogenic tumor"],"term_type":""},{"nm":"9320/0","n_c":["C7501","C7452"],"i_c":"9320/0","i_c_s":["Odontogenic myxoma","Odontogenic myxofibroma"],"term_type":""},{"nm":"9321/0","n_c":["C4314","C202077"],"i_c":"9321/0","i_c_s":["Central odontogenic fibroma","Odontogenic fibroma, NOS"],"term_type":""},{"nm":"9322/0","n_c":["C4315"],"i_c":"9322/0","i_c_s":["Peripheral odontogenic fibroma"],"term_type":""},{"nm":"9330/0","n_c":["C4316"],"i_c":"9330/0","i_c_s":["Ameloblastic fibroma"],"term_type":""},{"nm":"9330/3","n_c":["C4317"],"i_c":"9330/3","i_c_s":["Ameloblastic fibrosarcoma","Ameloblastic sarcoma","Odontogenic fibrosarcoma"],"term_type":""},{"nm":"9340/0","n_c":["C54301"],"i_c":"9340/0","i_c_s":["Calcifying epithelial odontogenic tumor","Pindborg tumor"],"term_type":""},{"nm":"9341/1","n_c":["C54300"],"i_c":"9341/1","i_c_s":["Clear cell odontogenic tumor"],"term_type":""},{"nm":"9341/3","n_c":["C54300"],"i_c":"9341/3","i_c_s":["Clear cell odontogenic carcinoma"],"term_type":""},{"nm":"9342/3","n_c":["C173735"],"i_c":"9342/3","i_c_s":["Odontogenic carcinosarcoma"],"term_type":""},{"nm":"9350/1","n_c":["C2964"],"i_c":"9350/1","i_c_s":["Craniopharyngioma","Rathke pouch tumor"],"term_type":""},{"nm":"9351/1","n_c":["C4726"],"i_c":"9351/1","i_c_s":["Craniopharyngioma, adamantinomatous"],"term_type":""},{"nm":"9352/1","n_c":["C4725"],"i_c":"9352/1","i_c_s":["Craniopharyngioma, papillary"],"term_type":""},{"nm":"9360/1","n_c":["C3328"],"i_c":"9360/1","i_c_s":["Pinealoma"],"term_type":""},{"nm":"9361/1","n_c":["C6966"],"i_c":"9361/1","i_c_s":["Pineocytoma"],"term_type":""},{"nm":"9362/3","n_c":["C6967","C9344"],"i_c":"9362/3","i_c_s":["Pineoblastoma","Mixed pineal tumor","Pineal parenchymal tumor of intermediate differentiation","Transitional pineal tumor","Mixed pineocytoma-pineoblastoma"],"term_type":""},{"nm":"9363/0","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanotic neuroectodermal tumor","Melanoameloblastoma","Melanotic progonoma","Retinal anlage tumor"],"term_type":""},{"nm":"9364/3","n_c":["C3716","C9341"],"i_c":"9364/3","i_c_s":["Peripheral neuroectodermal tumor","Neuroectodermal tumor, NOS","Peripheral primitive neuroectodermal tumor, NOS","PPNET"],"term_type":""},{"nm":"9365/3","n_c":["C7542"],"i_c":"9365/3","i_c_s":["Askin tumor"],"term_type":""},{"nm":"9370/3","n_c":["C2947"],"i_c":"9370/3","i_c_s":["Chordoma, NOS"],"term_type":""},{"nm":"9371/3","n_c":["C6902"],"i_c":"9371/3","i_c_s":["Chondroid chordoma"],"term_type":""},{"nm":"9372/3","n_c":["C48876"],"i_c":"9372/3","i_c_s":["Dedifferentiated chordoma"],"term_type":""},{"nm":"9373/0","n_c":["C6581"],"i_c":"9373/0","i_c_s":["Parachordoma"],"term_type":""},{"nm":"9380/3","n_c":["C4822","C3059"],"i_c":"9380/3","i_c_s":["Glioma, malignant","Glioma, NOS"],"term_type":""},{"nm":"9381/3","n_c":["C4318"],"i_c":"9381/3","i_c_s":["Gliomatosis cerebri"],"term_type":""},{"nm":"9382/3","n_c":["C4050","C3903","C6959"],"i_c":"9382/3","i_c_s":["Mixed glioma","Anaplastic oligoastrocytoma","Oligoastrocytoma"],"term_type":""},{"nm":"9383/1","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Subependymoma","Mixed subependymoma-ependymoma","Subependymal astrocytoma, NOS","Subependymal glioma"],"term_type":""},{"nm":"9384/1","n_c":["C3696"],"i_c":"9384/1","i_c_s":["Subependymal giant cell astrocytoma"],"term_type":""},{"nm":"9385/3","n_c":["C129309"],"i_c":"9385/3","i_c_s":["Diffuse midline glioma, H3 K27M-mutant"],"term_type":""},{"nm":"9390/0","n_c":["C3698"],"i_c":"9390/0","i_c_s":["Choroid plexus papilloma, NOS"],"term_type":""},{"nm":"9390/1","n_c":["C53686"],"i_c":"9390/1","i_c_s":["Atypical choroid plexus papilloma"],"term_type":""},{"nm":"9390/3","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus carcinoma","Choroid plexus papilloma, anaplastic","Choroid plexus papilloma, malignant"],"term_type":""},{"nm":"9391/3","n_c":["C6903","C4713","C4714","C3017"],"i_c":"9391/3","i_c_s":["Ependymoma, NOS","Cellular ependymoma","Clear cell ependymoma","Tanycytic ependymoma","Epithelial ependymoma"],"term_type":""},{"nm":"9392/3","n_c":["C4049","C4915"],"i_c":"9392/3","i_c_s":["Ependymoma, anaplastic","Ependymoblastoma"],"term_type":""},{"nm":"9393/3","n_c":["C4319"],"i_c":"9393/3","i_c_s":["Papillary ependymoma"],"term_type":""},{"nm":"9394/1","n_c":["C3697"],"i_c":"9394/1","i_c_s":["Myxopapillary ependymoma"],"term_type":""},{"nm":"9395/3","n_c":["C92624"],"i_c":"9395/3","i_c_s":["Papillary tumor of the pineal region"],"term_type":""},{"nm":"9396/3","n_c":["C129351"],"i_c":"9396/3","i_c_s":["Ependymoma, RELA fusion-positive"],"term_type":""},{"nm":"9400/3","n_c":["C6958","C7173","C60781"],"i_c":"9400/3","i_c_s":["Astrocytoma, NOS","Cystic astrocytoma","Astrocytoma, low grade","Diffuse astrocytoma, low grade","Diffuse astrocytoma","Astroglioma","Astrocytic glioma"],"term_type":""},{"nm":"9401/3","n_c":["C9477"],"i_c":"9401/3","i_c_s":["Astrocytoma, anaplastic"],"term_type":""},{"nm":"9410/3","n_c":["C4320"],"i_c":"9410/3","i_c_s":["Protoplasmic astrocytoma"],"term_type":""},{"nm":"9411/3","n_c":["C4321"],"i_c":"9411/3","i_c_s":["Gemistocytic astrocytoma","Gemistocytoma"],"term_type":""},{"nm":"9412/1","n_c":["C9476","C4738"],"i_c":"9412/1","i_c_s":["Desmoplastic infantile astrocytoma","Desmoplastic infantile ganglioglioma"],"term_type":""},{"nm":"9413/0","n_c":["C9505"],"i_c":"9413/0","i_c_s":["Dysembryoplastic neuroepithelial tumor"],"term_type":""},{"nm":"9420/3","n_c":["C4322"],"i_c":"9420/3","i_c_s":["Fibrillary astrocytoma","Fibrous astrocytoma"],"term_type":""},{"nm":"9421/1","n_c":["C4047","C9022"],"i_c":"9421/1","i_c_s":["Pilocytic astrocytoma","Spongioblastoma, NOS","Juvenile astrocytoma","Piloid astrocytoma"],"term_type":""},{"nm":"9423/3","n_c":["C66801"],"i_c":"9423/3","i_c_s":["Polar spongioblastoma","Primitive polar spongioblastoma","Spongioblastoma polare"],"term_type":""},{"nm":"9424/3","n_c":["C4323"],"i_c":"9424/3","i_c_s":["Pleomorphic xanthoastrocytoma"],"term_type":""},{"nm":"9425/3","n_c":["C40315"],"i_c":"9425/3","i_c_s":["Pilomyxoid astrocytoma"],"term_type":""},{"nm":"9430/3","n_c":["C4324"],"i_c":"9430/3","i_c_s":["Astroblastoma"],"term_type":""},{"nm":"9431/1","n_c":["C92552"],"i_c":"9431/1","i_c_s":["Angiocentric glioma"],"term_type":""},{"nm":"9432/1","n_c":["C94524"],"i_c":"9432/1","i_c_s":["Pituicytoma"],"term_type":""},{"nm":"9440/3","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Glioblastoma, NOS","Glioblastoma multiforme","Spongioblastoma multiforme"],"term_type":""},{"nm":"9440/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9441/3","n_c":["C4325"],"i_c":"9441/3","i_c_s":["Giant cell glioblastoma","Monstrocellular sarcoma"],"term_type":""},{"nm":"9442/1","n_c":["C5419"],"i_c":"9442/1","i_c_s":["Gliofibroma"],"term_type":""},{"nm":"9442/3","n_c":["C3796"],"i_c":"9442/3","i_c_s":["Gliosarcoma","Glioblastoma with sarcomatous component"],"term_type":""},{"nm":"9444/1","n_c":["C5592"],"i_c":"9444/1","i_c_s":["Chordoid glioma","Chordoid glioma of third ventricle"],"term_type":""},{"nm":"9445/3","n_c":["C167335"],"i_c":"9445/3","i_c_s":["Glioblastoma, IDH-mutant"],"term_type":""},{"nm":"9450/3","n_c":["C129319"],"i_c":"9450/3","i_c_s":["Oligodendroglioma, NOS"],"term_type":""},{"nm":"9451/3","n_c":["C4326"],"i_c":"9451/3","i_c_s":["Oligodendroglioma, anaplastic"],"term_type":""},{"nm":"9460/3","n_c":["C66802"],"i_c":"9460/3","i_c_s":["Oligodendroblastoma"],"term_type":""},{"nm":"9470/3","n_c":["C129447","C9497"],"i_c":"9470/3","i_c_s":["Medulloblastoma, NOS","Melanotic medulloblastoma"],"term_type":""},{"nm":"9471/3","n_c":["C5407","C4956"],"i_c":"9471/3","i_c_s":["Desmoplastic nodular medulloblastoma","Medulloblastoma with extensive nodularity","Circumscribed arachnoidal cerebellar sarcoma","Desmoplastic medulloblastoma"],"term_type":""},{"nm":"9472/3","n_c":["C3706"],"i_c":"9472/3","i_c_s":["Medullomyoblastoma"],"term_type":""},{"nm":"9473/3","n_c":["C6968","C3716","C5398"],"i_c":"9473/3","i_c_s":["Primitive neuroectodermal tumor, NOS","Central primitive neuroectodermal tumor, NOS","Supratentorial PNET","CPNET","PNET, NOS"],"term_type":""},{"nm":"9474/3","n_c":["C92625","C6904"],"i_c":"9474/3","i_c_s":["Large cell medulloblastoma","Anaplastic medulloblastoma"],"term_type":""},{"nm":"9475/3","n_c":["C129440"],"i_c":"9475/3","i_c_s":["Medulloblastoma, WNT-activated"],"term_type":""},{"nm":"9476/3","n_c":["C129442"],"i_c":"9476/3","i_c_s":["Medulloblastoma, SHH-activated and TP53-mutant"],"term_type":""},{"nm":"9477/3","n_c":["C129444"],"i_c":"9477/3","i_c_s":["Medulloblastoma, non-WNT/non-SHH"],"term_type":""},{"nm":"9478/3","n_c":["C186534","C4915"],"i_c":"9478/3","i_c_s":["Embryonal tumor with multilayered rosettes, NOS"],"term_type":""},{"nm":"9480/3","n_c":["C66803"],"i_c":"9480/3","i_c_s":["Cerebellar sarcoma, NOS"],"term_type":""},{"nm":"9490/0","n_c":["C3049"],"i_c":"9490/0","i_c_s":["Ganglioneuroma"],"term_type":""},{"nm":"9490/3","n_c":["C3790"],"i_c":"9490/3","i_c_s":["Ganglioneuroblastoma"],"term_type":""},{"nm":"9491/0","n_c":["C66804"],"i_c":"9491/0","i_c_s":["Ganglioneuromatosis"],"term_type":""},{"nm":"9492/0","n_c":["C6934"],"i_c":"9492/0","i_c_s":["Gangliocytoma"],"term_type":""},{"nm":"9493/0","n_c":["C8419"],"i_c":"9493/0","i_c_s":["Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)"],"term_type":""},{"nm":"9500/3","n_c":["C3270"],"i_c":"9500/3","i_c_s":["Neuroblastoma, NOS","Central neuroblastoma","Sympathicoblastoma"],"term_type":""},{"nm":"9501/0","n_c":["C66807"],"i_c":"9501/0","i_c_s":["Medulloepithelioma, benign","Diktyoma, benign"],"term_type":""},{"nm":"9501/3","n_c":["C66808","C4327"],"i_c":"9501/3","i_c_s":["Medulloepithelioma, NOS","Diktyoma, malignant"],"term_type":""},{"nm":"9502/0","n_c":["C66809"],"i_c":"9502/0","i_c_s":["Teratoid medulloepithelioma, benign"],"term_type":""},{"nm":"9502/3","n_c":["C66810"],"i_c":"9502/3","i_c_s":["Teratoid medulloepithelioma"],"term_type":""},{"nm":"9503/3","n_c":["C3716"],"i_c":"9503/3","i_c_s":["Neuroepithelioma, NOS"],"term_type":""},{"nm":"9504/3","n_c":["C66811"],"i_c":"9504/3","i_c_s":["Spongioneuroblastoma"],"term_type":""},{"nm":"9505/1","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Ganglioglioma, NOS","Glioneuroma","Neuroastrocytoma"],"term_type":""},{"nm":"9505/3","n_c":["C4717"],"i_c":"9505/3","i_c_s":["Ganglioglioma, anaplastic"],"term_type":""},{"nm":"9506/1","n_c":["C92555","C6905","C3791"],"i_c":"9506/1","i_c_s":["Central neurocytoma","Cerebellar liponeurocytoma","Extraventricular neurocytoma","Lipomatous medulloblastoma","Medullocytoma","Neurocytoma","Neurolipocytoma"],"term_type":""},{"nm":"9507/0","n_c":["C4328"],"i_c":"9507/0","i_c_s":["Pacinian tumor"],"term_type":""},{"nm":"9508/3","n_c":["C6906"],"i_c":"9508/3","i_c_s":["Atypical teratoid/rhabdoid tumor"],"term_type":""},{"nm":"9509/1","n_c":["C92554","C129431"],"i_c":"9509/1","i_c_s":["Papillary glioneuronal tumor","Rosette-forming glioneuronal tumor"],"term_type":""},{"nm":"9510/0","n_c":["C66812"],"i_c":"9510/0","i_c_s":["Retinocytoma"],"term_type":""},{"nm":"9510/3","n_c":["C7541"],"i_c":"9510/3","i_c_s":["Retinoblastoma, NOS"],"term_type":""},{"nm":"9511/3","n_c":["C66813"],"i_c":"9511/3","i_c_s":["Retinoblastoma, differentiated"],"term_type":""},{"nm":"9512/3","n_c":["C66814"],"i_c":"9512/3","i_c_s":["Retinoblastoma, undifferentiated"],"term_type":""},{"nm":"9513/3","n_c":["C66815"],"i_c":"9513/3","i_c_s":["Retinoblastoma, diffuse"],"term_type":""},{"nm":"9514/1","n_c":["C66816"],"i_c":"9514/1","i_c_s":["Retinoblastoma, spontaneously regressed"],"term_type":""},{"nm":"9520/3","n_c":["C67155"],"i_c":"9520/3","i_c_s":["Olfactory neurogenic tumor"],"term_type":""},{"nm":"9521/3","n_c":["C67156"],"i_c":"9521/3","i_c_s":["Olfactory neurocytoma","Esthesioneurocytoma"],"term_type":""},{"nm":"9522/3","n_c":["C3789"],"i_c":"9522/3","i_c_s":["Olfactory neuroblastoma","Esthesioneuroblastoma"],"term_type":""},{"nm":"9523/3","n_c":["C3789"],"i_c":"9523/3","i_c_s":["Olfactory neuroepithelioma","Esthesioneuroepithelioma"],"term_type":""},{"nm":"9530/0","n_c":["C6907","C4718","C4721","C4720","C3230"],"i_c":"9530/0","i_c_s":["Meningioma, NOS","Lymphoplasmacyte-rich meningioma","Metaplastic meningioma","Microcystic meningioma","Secretory meningioma"],"term_type":""},{"nm":"9530/1","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Meningiomatosis, NOS","Diffuse meningiomatosis","Multiple meningiomas"],"term_type":""},{"nm":"9530/3","n_c":["C4051","C4073","C8312"],"i_c":"9530/3","i_c_s":["Meningioma, malignant","Leptomeningeal sarcoma","Meningeal sarcoma","Meningioma, anaplastic","Meningothelial sarcoma"],"term_type":""},{"nm":"9531/0","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Meningothelial meningioma","Endotheliomatous meningioma","Syncytial meningioma"],"term_type":""},{"nm":"9532/0","n_c":["C4330"],"i_c":"9532/0","i_c_s":["Fibrous meningioma","Fibroblastic meningioma"],"term_type":""},{"nm":"9533/0","n_c":["C4331"],"i_c":"9533/0","i_c_s":["Psammomatous meningioma"],"term_type":""},{"nm":"9534/0","n_c":["C4332"],"i_c":"9534/0","i_c_s":["Angiomatous meningioma"],"term_type":""},{"nm":"9535/0","n_c":["C66817"],"i_c":"9535/0","i_c_s":["Hemangioblastic meningioma","Angioblastic meningioma"],"term_type":""},{"nm":"9537/0","n_c":["C4333"],"i_c":"9537/0","i_c_s":["Transitional meningioma","Mixed meningioma"],"term_type":""},{"nm":"9538/1","n_c":["C4722","C6908"],"i_c":"9538/1","i_c_s":["Clear cell meningioma","Chordoid meningioma"],"term_type":""},{"nm":"9538/3","n_c":["C3904","C6909"],"i_c":"9538/3","i_c_s":["Papillary meningioma","Rhabdoid meningioma"],"term_type":""},{"nm":"9539/1","n_c":["C4723"],"i_c":"9539/1","i_c_s":["Atypical meningioma"],"term_type":""},{"nm":"9539/3","n_c":["C4334"],"i_c":"9539/3","i_c_s":["Meningeal sarcomatosis"],"term_type":""},{"nm":"9540/0","n_c":["C3272"],"i_c":"9540/0","i_c_s":["Neurofibroma, NOS"],"term_type":""},{"nm":"9540/1","n_c":["C6727","C3273"],"i_c":"9540/1","i_c_s":["Neurofibromatosis, NOS","Multiple neurofibromatosis","Recklinghausen disease","Von Recklinghausen disease"],"term_type":""},{"nm":"9540/3","n_c":["C6561","C4748","C3798"],"i_c":"9540/3","i_c_s":["Malignant peripheral nerve sheath tumor","Epithelioid MPNST","MPNST with glandular differentiation","MPNST with mesenchymal differentiation","Melanotic MPNST","Melanotic psammomatous MPNST","Neurofibrosarcoma","Neurogenic sarcoma","Neurosarcoma","MPNST, NOS"],"term_type":""},{"nm":"9541/0","n_c":["C66841"],"i_c":"9541/0","i_c_s":["Melanotic neurofibroma"],"term_type":""},{"nm":"9542/3","n_c":["C6561"],"i_c":"9542/3","i_c_s":["Epithelioid malignant peripheral nerve sheath tumor"],"term_type":""},{"nm":"9550/0","n_c":["C3797"],"i_c":"9550/0","i_c_s":["Plexiform neurofibroma","Plexiform neuroma"],"term_type":""},{"nm":"9560/0","n_c":["C3276","C3269","C4724","C6970","C6969","C6556"],"i_c":"9560/0","i_c_s":["Neurilemoma, NOS","Acoustic neuroma","Ancient schwannoma","Cellular schwannoma","Degenerated schwannoma","Pigmented schwannoma","Plexiform schwannoma","Psammomatous schwannoma","Melanotic schwannoma","Neurinoma","Schwannoma, NOS"],"term_type":""},{"nm":"9560/1","n_c":["C6557"],"i_c":"9560/1","i_c_s":["Neurinomatosis"],"term_type":""},{"nm":"9560/3","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Neurilemoma, malignant","Malignant schwannoma, NOS","Neurilemosarcoma"],"term_type":""},{"nm":"9561/3","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation","MPNST with rhabdomyoblastic differentiation","Malignant schwannoma with rhabdomyoblastic differentiation","Triton tumor, malignant"],"term_type":""},{"nm":"9562/0","n_c":["C7018"],"i_c":"9562/0","i_c_s":["Neurothekeoma","Nerve sheath myxoma"],"term_type":""},{"nm":"9570/0","n_c":["C3275"],"i_c":"9570/0","i_c_s":["Neuroma, NOS"],"term_type":""},{"nm":"9571/0","n_c":["C6911","C6912","C4973"],"i_c":"9571/0","i_c_s":["Perineurioma, NOS","Intraneural perineurioma","Soft tissue perineurioma"],"term_type":""},{"nm":"9571/3","n_c":["C66845"],"i_c":"9571/3","i_c_s":["Perineurioma, malignant","Perineural MPNST"],"term_type":""},{"nm":"9580/0","n_c":["C3474"],"i_c":"9580/0","i_c_s":["Granular cell tumor, NOS","Granular cell myoblastoma, NOS"],"term_type":""},{"nm":"9580/3","n_c":["C4336"],"i_c":"9580/3","i_c_s":["Granular cell tumor, malignant","Granular cell myoblastoma, malignant"],"term_type":""},{"nm":"9581/3","n_c":["C3750"],"i_c":"9581/3","i_c_s":["Alveolar soft part sarcoma"],"term_type":""},{"nm":"9582/0","n_c":["C7017"],"i_c":"9582/0","i_c_s":["Granular cell tumor of the sellar region"],"term_type":""},{"nm":"9590/3","n_c":["C9301","C3208"],"i_c":"9590/3","i_c_s":["Malignant lymphoma, NOS","Microglioma","Lymphoma, NOS"],"term_type":""},{"nm":"9591/3","n_c":["C27258","C80308","C27822","C27824","C26919","C7401","C80309","C3211"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, non-Hodgkin, NOS","Lymphosarcoma, NOS","Malignant lymphoma, lymphocytic, intermediate differentiation, nodular","Malignant lymphoma, lymphocytic, poorly differentiated, diffuse","Malignant lymphoma, small cell, noncleaved, diffuse","Malignant lymphoma, small cleaved cell, diffuse","Reticulum cell sarcoma, NOS","B cell lymphoma, NOS","Hairy cell leukemia variant","Malignant lymphoma, diffuse, NOS","Malignant lymphoma, non-cleaved cell, NOS","Splenic B-cell lymphoma/leukemia, unclassifiable","Splenic diffuse red pulp small B-cell lymphoma","Lymphosarcoma, diffuse","Malignant lymphoma, cleaved cell, NOS","Malignant lymphoma, small cleaved cell, NOS","Malignant lymphoma, undifferentiated cell type, NOS","Malignant lymphoma, undifferentiated cell, non-Burkitt","Reticulosarcoma, NOS","Reticulosarcoma, diffuse","Reticulum cell sarcoma, diffuse","Non-Hodgkin lymphoma, NOS"],"term_type":""},{"nm":"9596/3","n_c":["C38661","C37869"],"i_c":"9596/3","i_c_s":["Composite Hodgkin and non-Hodgkin lymphoma","B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma"],"term_type":""},{"nm":"9597/3","n_c":["C7217"],"i_c":"9597/3","i_c_s":["Primary cutaneous follicle centre lymphoma"],"term_type":""},{"nm":"9650/3","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Hodgkin lymphoma, NOS","Hodgkin disease, NOS","Malignant lymphoma, Hodgkin"],"term_type":""},{"nm":"9651/3","n_c":["C6913","C8590"],"i_c":"9651/3","i_c_s":["Hodgkin lymphoma, lymphocyte-rich","Hodgkin disease, lymphocyte predominance, NOS","Hodgkin disease, lymphocyte predominance, diffuse","Hodgkin disease, lymphocytic-histiocytic predominance","Classical Hodgkin lymphoma, lymphocyte- rich"],"term_type":""},{"nm":"9652/3","n_c":["C3517"],"i_c":"9652/3","i_c_s":["Hodgkin lymphoma, mixed cellularity, NOS","Classical Hodgkin lymphoma, mixed cellularity, NOS"],"term_type":""},{"nm":"9653/3","n_c":["C9283"],"i_c":"9653/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, NOS","Classical Hodgkin lymphoma, lymphocyte depletion, NOS"],"term_type":""},{"nm":"9654/3","n_c":["C9283"],"i_c":"9654/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis","Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"],"term_type":""},{"nm":"9655/3","n_c":["C9283"],"i_c":"9655/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, reticular","Classical Hodgkin lymphoma, lymphocyte depletion, reticular"],"term_type":""},{"nm":"9659/3","n_c":["C7258","C26956"],"i_c":"9659/3","i_c_s":["Hodgkin lymphoma, nodular lymphocyte predominance","Hodgkin paragranuloma, NOS","Hodgkin paragranuloma, nodular","Hodgkin lymphoma, lymphocyte predominance, nodular"],"term_type":""},{"nm":"9661/3","n_c":["C6914"],"i_c":"9661/3","i_c_s":["Hodgkin granuloma"],"term_type":""},{"nm":"9662/3","n_c":["C164145"],"i_c":"9662/3","i_c_s":["Hodgkin sarcoma"],"term_type":""},{"nm":"9663/3","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, NOS","Classical Hodgkin lymphoma, nodular sclerosis, NOS","Hodgkin disease, nodular sclerosis, NOS"],"term_type":""},{"nm":"9664/3","n_c":["C67171"],"i_c":"9664/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, cellular phase","Classical Hodgkin lymphoma, nodular sclerosis, cellular phase"],"term_type":""},{"nm":"9665/3","n_c":["C27270","C27098","C7165"],"i_c":"9665/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 1","Classical Hodgkin lymphoma, nodular sclerosis, grade 1","Hodgkin disease, nodular sclerosis, lymphocyte predominance","Hodgkin disease, nodular sclerosis, mixed cellularity"],"term_type":""},{"nm":"9667/3","n_c":["C27808","C27807","C7166"],"i_c":"9667/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 2","Classical Hodgkin lymphoma, nodular sclerosis, grade 2","Hodgkin disease, nodular sclerosis, lymphocyte depletion","Hodgkin disease, nodular sclerosis, syncytial variant"],"term_type":""},{"nm":"9670/3","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small B lymphocytic, NOS","Malignant lymphoma, lymphocytic, NOS","Malignant lymphoma, lymphocytic, diffuse, NOS","Malignant lymphoma, lymphocytic, well differentiated, diffuse","Malignant lymphoma, small cell diffuse","Malignant lymphoma, small cell, NOS","Malignant lymphoma, small lymphocytic, NOS","Malignant lymphoma, small lymphocytic, diffuse"],"term_type":""},{"nm":"9671/3","n_c":["C3212","C3898"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, lymphoplasmacytic","Immunocytoma","Malignant lymphoma, plasmacytoid","Plasmacytic lymphoma","Malignant lymphoma, lymphoplasmacytoid"],"term_type":""},{"nm":"9673/3","n_c":["C4339","C4337"],"i_c":"9673/3","i_c_s":["Mantle cell lymphoma","Malignant lymphoma, centrocytic","Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse","Mantle zone lymphoma","Malignant lymphomatous polyposis"],"term_type":""},{"nm":"9675/3","n_c":["C4338","C3463"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed small and large cell, diffuse","Malignant lymphoma, centroblastic- centrocytic, NOS","Malignant lymphoma, centroblastic- centrocytic, diffuse","Malignant lymphoma, mixed cell type, diffuse","Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse"],"term_type":""},{"nm":"9678/3","n_c":["C6915"],"i_c":"9678/3","i_c_s":["Primary effusion lymphoma"],"term_type":""},{"nm":"9679/3","n_c":["C9280"],"i_c":"9679/3","i_c_s":["Mediastinal large B-cell lymphoma","Thymic large B-cell lymphoma"],"term_type":""},{"nm":"9680/3","n_c":["C27099","C4074","C80289","C80281","C6916","C80291","C9496","C4342","C80280","C27823","C27265","C27266","C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, NOS","Anaplastic large B-cell lymphoma","B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","Diffuse large B-cell lymphoma associated with chronic inflammation","EBV positive diffuse large B-cell lymphoma of the elderly","Intravascular large B-cell lymphoma","Malignant lymphoma, centroblastic, NOS","Malignant lymphoma, centroblastic, diffuse","Primary cutaneous DLBCL, leg type","Primary diffuse large B-cell lymphoma of the CNS","T-cell rich large B-cell lymphoma","Malignant lymphoma, histiocytic, NOS","Malignant lymphoma, large cell, cleaved and noncleaved","Malignant lymphoma, large cell, cleaved, NOS","Malignant lymphoma, large cell, diffuse, NOS","Malignant lymphoma, large cleaved cell, NOS","Malignant lymphoma, noncleaved, diffuse, NOS","Angioendotheliomatosis","Angiotropic lymphoma","Diffuse large B-cell lymphoma, NOS","Histiocyte-rich large B-cell lymphoma","Intravascular B-cell lymphoma","Malignant lymphoma, histiocytic, diffuse","Malignant lymphoma, large B-cell, NOS","Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS","Malignant lymphoma, large cell, NOS","Malignant lymphoma, large cell, cleaved, diffuse","Malignant lymphoma, large cell, noncleaved, NOS","Malignant lymphoma, large cell, noncleaved, diffuse","Malignant lymphoma, noncleaved, NOS"],"term_type":""},{"nm":"9684/3","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS","Immunoblastic sarcoma","Malignant lymphoma, immunoblastic, NOS","Malignant lymphoma, large cell, immunoblastic"],"term_type":""},{"nm":"9687/3","n_c":["C6917","C2912"],"i_c":"9687/3","i_c_s":["Burkitt lymphoma, NOS","Burkitt-like lymphoma","Burkitt tumor","Malignant lymphoma, small noncleaved, Burkitt type","Malignant lymphoma, undifferentiated, Burkitt type"],"term_type":""},{"nm":"9688/3","n_c":["C9496"],"i_c":"9688/3","i_c_s":["T-cell/histiocyte rich large B-cell lymphoma"],"term_type":""},{"nm":"9689/3","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic marginal zone B-cell lymphoma","Splenic lymphoma with villous lymphocytes","Splenic marginal zone lymphoma, NOS"],"term_type":""},{"nm":"9690/3","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Follicular lymphoma, NOS","Malignant lymphoma, centroblastic- centrocytic, follicular","Malignant lymphoma, lymphocytic, nodular, NOS","Malignant lymphoma, nodular, NOS","Malignant lymphoma, follicle center, NOS","Malignant lymphoma, follicle center, follicular","Malignant lymphoma, follicular, NOS"],"term_type":""},{"nm":"9691/3","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Follicular lymphoma, grade 2","Malignant lymphoma, mixed cell type, follicular","Malignant lymphoma, mixed cell type, nodular","Malignant lymphoma, mixed lymphocytic-histiocytic, nodular","Malignant lymphoma, mixed small cleaved and large cell, follicular"],"term_type":""},{"nm":"9695/3","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Follicular lymphoma, grade 1","Malignant lymphoma, lymphocytic, poorly differentiated, nodular","Malignant lymphoma, small cleaved cell, follicular","Follicular lymphoma, small cleaved cell"],"term_type":""},{"nm":"9698/3","n_c":["C3460","C7192","C7191","C8994"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3","Malignant lymphoma, histiocytic, nodular","Malignant lymphoma, large cell, noncleaved, follicular","Malignant lymphoma, large cleaved cell, follicular","Malignant lymphoma, lymphocytic, well differentiated, nodular","Malignant lymphoma, noncleaved cell, follicular, NOS","Follicular lymphoma, grade 3A","Follicular lymphoma, grade 3B","Malignant lymphoma, centroblastic, follicular","Malignant lymphoma, large cell, follicular, NOS"],"term_type":""},{"nm":"9699/3","n_c":["C7230","C8863","C4341","C5264","C3898"],"i_c":"9699/3","i_c_s":["Marginal zone B-cell lymphoma, NOS","Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue","BALT lymphoma","Bronchial-associated lymphoid tissue lymphoma","MALT lymphoma","Marginal zone lymphoma, NOS","Monocytoid B-cell lymphoma","Mucosal-associated lymphoid tissue lymphoma","Nodal marginal zone lymphoma","SALT lymphoma","Skin-associated lymphoid tissue lymphoma"],"term_type":""},{"nm":"9700/3","n_c":["C3246","C35794"],"i_c":"9700/3","i_c_s":["Mycosis fungoides","Pagetoid reticulosis"],"term_type":""},{"nm":"9701/3","n_c":["C3366"],"i_c":"9701/3","i_c_s":["Sezary syndrome","Sezary disease"],"term_type":""},{"nm":"9702/3","n_c":["C27352","C37194","C4340","C3466","C7205","C7204"],"i_c":"9702/3","i_c_s":["Mature T-cell lymphoma, NOS","Anaplastic large cell lymphoma, ALK negative","Lymphoepithelioid lymphoma","Lennert lymphoma","Peripheral T-cell lymphoma, NOS","Peripheral T-cell lymphoma, large cell","Peripheral T-cell lymphoma, pleomorphic medium and large cell","Peripheral T-cell lymphoma, pleomorphic small cell","T-cell lymphoma, NOS","T-zone lymphoma"],"term_type":""},{"nm":"9705/3","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Angioimmunoblastic T-cell lymphoma","Angioimmunoblastic lymphoma","Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)"],"term_type":""},{"nm":"9708/3","n_c":["C6918"],"i_c":"9708/3","i_c_s":["Subcutaneous panniculitis-like T-cell lymphoma"],"term_type":""},{"nm":"9709/3","n_c":["C7162","C3467","C45366"],"i_c":"9709/3","i_c_s":["Cutaneous T-cell lymphoma, NOS","Primary cutaneous CD4-positive small/medium T-cell lymphoma","Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma","Cutaneous lymphoma, NOS"],"term_type":""},{"nm":"9712/3","n_c":["C4342"],"i_c":"9712/3","i_c_s":["Intravascular large B-cell lymphoma"],"term_type":""},{"nm":"9714/3","n_c":["C37193","C3720"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, T cell and Null cell type","Anaplastic large cell lymphoma, ALK positive","Anaplastic large cell lymphoma, NOS","Large cell (Ki-1+) lymphoma","Anaplastic large cell lymphoma, CD30+"],"term_type":""},{"nm":"9716/3","n_c":["C8459"],"i_c":"9716/3","i_c_s":["Hepatosplenic T-cell lymphoma","Hepatosplenic gamma-delta cell lymphoma"],"term_type":""},{"nm":"9717/3","n_c":["C150495","C4737"],"i_c":"9717/3","i_c_s":["Intestinal T-cell lymphoma","Enteropathy associated T-cell lymphoma","Enteropathy type intestinal T-cell lymphoma"],"term_type":""},{"nm":"9718/3","n_c":["C3721","C6860","C7195"],"i_c":"9718/3","i_c_s":["Primary cutaneous CD30+ T-cell lymphoproliferative disorder","Lymphomatoid papulosis","Primary cutaneous CD30+ large T-cell lymphoma","Primary cutaneous anaplastic large cell lymphoma"],"term_type":""},{"nm":"9719/3","n_c":["C68692","C4684"],"i_c":"9719/3","i_c_s":["NK/T-cell lymphoma, nasal and nasal-type","Angiocentric T-cell lymphoma","Malignant midline reticulosis","Malignant reticulosis, NOS","Polymorphic reticulosis","Extranodal NK/T-cell lymphoma, nasal type","T/NK-cell lymphoma"],"term_type":""},{"nm":"9724/3","n_c":["C80374"],"i_c":"9724/3","i_c_s":["Systemic EBV positive T-cell lymphoproliferative disease of childhood"],"term_type":""},{"nm":"9725/3","n_c":["C45327"],"i_c":"9725/3","i_c_s":["Hydroa vacciniforme-like lymphoma"],"term_type":""},{"nm":"9726/3","n_c":["C45340"],"i_c":"9726/3","i_c_s":["Primary cutaneous gamma-delta T-cell lymphoma"],"term_type":""},{"nm":"9727/3","n_c":["C27821","C7203","C9360"],"i_c":"9727/3","i_c_s":["Precursor cell lymphoblastic lymphoma, NOS","Blastic NK cell lymphoma","Blastic plasmacytoid dendritic cell neoplasm","Lymphoblastoma","Malignant lymphoma, convoluted cell","Malignant lymphoma, lymphoblastic, NOS"],"term_type":""},{"nm":"9728/3","n_c":["C8868"],"i_c":"9728/3","i_c_s":["Precursor B-cell lymphoblastic lymphoma"],"term_type":""},{"nm":"9729/3","n_c":["C6919"],"i_c":"9729/3","i_c_s":["Precursor T-cell lymphoblastic lymphoma"],"term_type":""},{"nm":"9731/3","n_c":["C6932","C7812","C9349","C4665"],"i_c":"9731/3","i_c_s":["Plasmacytoma, NOS","Plasma cell tumor","Plasmacytoma of bone","Solitary myeloma","Solitary plasmacytoma"],"term_type":""},{"nm":"9732/3","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Multiple myeloma","Myeloma, NOS","Myelomatosis","Plasma cell myeloma"],"term_type":""},{"nm":"9733/3","n_c":["C3180"],"i_c":"9733/3","i_c_s":["Plasma cell leukemia","Plasmacytic leukemia"],"term_type":""},{"nm":"9734/3","n_c":["C4002"],"i_c":"9734/3","i_c_s":["Plasmacytoma, extramedullary","Extraosseous plasmacytoma"],"term_type":""},{"nm":"9735/3","n_c":["C7224"],"i_c":"9735/3","i_c_s":["Plasmablastic lymphoma"],"term_type":""},{"nm":"9737/3","n_c":["C7225"],"i_c":"9737/3","i_c_s":["ALK positive large B-cell lymphoma"],"term_type":""},{"nm":"9738/3","n_c":["C27856"],"i_c":"9738/3","i_c_s":["Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease"],"term_type":""},{"nm":"9740/1","n_c":["C7138","C7137","C9303","C7136","C3218","C3433","C9295"],"i_c":"9740/1","i_c_s":["Mastocytoma, NOS","Cutaneous mastocytosis","Diffuse cutaneous mastocytosis","Urticaria pigmentosa","Extracutaneous mastocytoma","Mast cell tumor, NOS","Solitary mastocytoma of skin"],"term_type":""},{"nm":"9740/3","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Mast cell sarcoma","Malignant mast cell tumor","Malignant mastocytoma"],"term_type":""},{"nm":"9741/1","n_c":["C9286"],"i_c":"9741/1","i_c_s":["Indolent systemic mastocytosis"],"term_type":""},{"nm":"9741/3","n_c":["C9284","C9235","C9285","C8991"],"i_c":"9741/3","i_c_s":["Malignant mastocytosis","Aggressive systemic mastocytosis","Systemic mastocytosis with AHNMD","Systemic mastocytosis with associated hematological clonal non-mast cell disorder","Systemic tissue mast cell disease"],"term_type":""},{"nm":"9742/3","n_c":["C3169"],"i_c":"9742/3","i_c_s":["Mast cell leukemia"],"term_type":""},{"nm":"9750/3","n_c":["C7202"],"i_c":"9750/3","i_c_s":["Malignant histiocytosis","Histiocytic medullary reticulosis"],"term_type":""},{"nm":"9751/1","n_c":["C3107"],"i_c":"9751/1","i_c_s":["Langerhans cell histiocytosis, NOS"],"term_type":""},{"nm":"9751/3","n_c":["C3016","C3160","C6920","C3107"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, NOS","Acute progressive histiocytosis X","Hand-Schuller-Christian disease","Histiocytosis X, NOS","Langerhans cell histiocytosis, disseminated","Langerhans cell histiocytosis, generalized","Langerhans cell histiocytosis, mono-ostotic","Langerhans cell histiocytosis, multifocal","Langerhans cell histiocytosis, poly-ostotic","Langerhans cell histiocytosis, unifocal","Letterer-Siwe disease","Nonlipid reticuloendotheliosis","Eosinophilic granuloma","Langerhans cell granulomatosis, unifocal","Langerhans cell granulomatosis"],"term_type":""},{"nm":"9752/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9753/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9754/3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9755/3","n_c":["C27349"],"i_c":"9755/3","i_c_s":["Histiocytic sarcoma","True histiocytic lymphoma"],"term_type":""},{"nm":"9756/3","n_c":["C6921"],"i_c":"9756/3","i_c_s":["Langerhans cell sarcoma"],"term_type":""},{"nm":"9757/3","n_c":["C9282","C81767"],"i_c":"9757/3","i_c_s":["Interdigitating dendritic cell sarcoma","Dendritic cell sarcoma, NOS","Indeterminate dendritic cell tumor","Interdigitating cell sarcoma"],"term_type":""},{"nm":"9758/3","n_c":["C9281"],"i_c":"9758/3","i_c_s":["Follicular dendritic cell sarcoma","Follicular dendritic cell tumor"],"term_type":""},{"nm":"9759/3","n_c":["C81758"],"i_c":"9759/3","i_c_s":["Fibroblastic reticular cell tumor"],"term_type":""},{"nm":"9760/3","n_c":["C3132"],"i_c":"9760/3","i_c_s":["Immunoproliferative disease, NOS"],"term_type":""},{"nm":"9761/3","n_c":["C80307"],"i_c":"9761/3","i_c_s":["Waldenstrom macroglobulinemia"],"term_type":""},{"nm":"9762/3","n_c":["C3892","C3083","C3132","C3082"],"i_c":"9762/3","i_c_s":["Heavy chain disease, NOS","Alpha heavy chain disease","Gamma heavy chain disease","Mu heavy chain disease","Franklin disease"],"term_type":""},{"nm":"9764/3","n_c":["C3132"],"i_c":"9764/3","i_c_s":["Immunoproliferative small intestinal disease","Mediterranean lymphoma"],"term_type":""},{"nm":"9765/1","n_c":["C3996"],"i_c":"9765/1","i_c_s":["Monoclonal gammopathy of undetermined significance","MGUS","Monoclonal gammopathy, NOS"],"term_type":""},{"nm":"9766/1","n_c":["C40970","C7930"],"i_c":"9766/1","i_c_s":["Angiocentric immunoproliferative lesion","Lymphomatoid granulomatosis"],"term_type":""},{"nm":"9767/1","n_c":["C7528"],"i_c":"9767/1","i_c_s":["Angioimmunoblastic lymphadenopathy (AIC)","Immunoblastic lymphadenopathy (IBL)"],"term_type":""},{"nm":"9768/1","n_c":["C4664"],"i_c":"9768/1","i_c_s":["T-gamma lymphoproliferative disease"],"term_type":""},{"nm":"9769/1","n_c":["C7727","C7151","C3819"],"i_c":"9769/1","i_c_s":["Immunoglobulin deposition disease","Primary amyloidosis","Systemic light chain disease"],"term_type":""},{"nm":"9800/3","n_c":["C4982","C3483","C3161"],"i_c":"9800/3","i_c_s":["Leukemia, NOS","Aleukemic leukemia, NOS","Chronic leukemia, NOS","Subacute leukemia, NOS"],"term_type":""},{"nm":"9801/3","n_c":["C9300"],"i_c":"9801/3","i_c_s":["Acute leukemia, NOS","Blast cell leukemia","Stem cell leukemia","Undifferentiated leukemia"],"term_type":""},{"nm":"9805/3","n_c":["C4673","C6923"],"i_c":"9805/3","i_c_s":["Acute biphenotypic leukemia","Acute bilineal leukemia","Acute mixed lineage leukemia"],"term_type":""},{"nm":"9806/3","n_c":["C82192"],"i_c":"9806/3","i_c_s":["Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":""},{"nm":"9807/3","n_c":["C82203"],"i_c":"9807/3","i_c_s":["Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged"],"term_type":""},{"nm":"9808/3","n_c":["C82212"],"i_c":"9808/3","i_c_s":["Mixed phenotype acute leukemia, B/myeloid, NOS"],"term_type":""},{"nm":"9809/3","n_c":["C82213"],"i_c":"9809/3","i_c_s":["Mixed phenotype acute leukemia, T/myeloid, NOS"],"term_type":""},{"nm":"9811/3","n_c":["C80326"],"i_c":"9811/3","i_c_s":["B lymphoblastic leukemia/lymphoma, NOS"],"term_type":""},{"nm":"9812/3","n_c":["C80331"],"i_c":"9812/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":""},{"nm":"9813/3","n_c":["C80332"],"i_c":"9813/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged"],"term_type":""},{"nm":"9814/3","n_c":["C80334"],"i_c":"9814/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)"],"term_type":""},{"nm":"9815/3","n_c":["C80335"],"i_c":"9815/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hyperdiploidy"],"term_type":""},{"nm":"9816/3","n_c":["C80344","C80338"],"i_c":"9816/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)"],"term_type":""},{"nm":"9817/3","n_c":["C80340"],"i_c":"9817/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH"],"term_type":""},{"nm":"9818/3","n_c":["C80341"],"i_c":"9818/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)"],"term_type":""},{"nm":"9820/3","n_c":["C7176","C4343","C7539"],"i_c":"9820/3","i_c_s":["Lymphoid leukemia, NOS","Aleukemic lymphoid leukemia","Lymphatic leukemia, NOS","Lymphocytic leukemia, NOS","Lymphosarcoma cell leukemia","Subacute lymphoid leukemia","Aleukemic lymphatic leukemia","Aleukemic lymphocytic leukemia","Subacute lymphatic leukemia","Subacute lymphocytic leukemia"],"term_type":""},{"nm":"9823/3","n_c":["C27911","C3163"],"i_c":"9823/3","i_c_s":["B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma","Chronic lymphatic leukemia","Chronic lymphocytic leukemia, B-cell type","Chronic lymphocytic leukemia","Chronic lymphoid leukemia"],"term_type":""},{"nm":"9826/3","n_c":["C7400","C8644"],"i_c":"9826/3","i_c_s":["Burkitt cell leukemia","Acute leukemia, Burkitt type","B-ALL","FAB L3","Acute lymphoblastic leukemia, mature B-cell type"],"term_type":""},{"nm":"9827/3","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell leukemia/lymphoma (HTLV-1 positive)","Adult T-cell leukemia","Adult T-cell lymphoma/leukemia","Adult T-cell lymphoma"],"term_type":""},{"nm":"9831/3","n_c":["C4664","C39591"],"i_c":"9831/3","i_c_s":["T-cell large granular lymphocytic leukemia","Chronic lymphoproliferative disorder of NK cells","Large granular lymphocytosis, NOS","NK-cell large granular lymphocytic leukemia","T-cell large granular lymphocytosis"],"term_type":""},{"nm":"9832/3","n_c":["C3181"],"i_c":"9832/3","i_c_s":["Prolymphocytic leukemia, NOS"],"term_type":""},{"nm":"9833/3","n_c":["C4753"],"i_c":"9833/3","i_c_s":["Prolymphocytic leukemia, B-cell type"],"term_type":""},{"nm":"9834/3","n_c":["C4752"],"i_c":"9834/3","i_c_s":["Prolymphocytic leukemia, T-cell type"],"term_type":""},{"nm":"9835/3","n_c":["C27290","C27281","C3167"],"i_c":"9835/3","i_c_s":["Precursor cell lymphoblastic leukemia, NOS","FAB L1","Acute lymphatic leukemia","Acute lymphoblastic leukemia, L2 type, NOS","Acute lymphoblastic leukemia, NOS","Acute lymphoblastic leukemia, precursor-cell type","Acute lymphoblastic leukemia-lymphoma, NOS","Acute lymphocytic leukemia","Acute lymphoid leukemia","FAB L2","Lymphoblastic leukemia, NOS","Precursor cell lymphoblastic leukemia, not phenotyped"],"term_type":""},{"nm":"9836/3","n_c":["C27797","C27799","C27798","C8644"],"i_c":"9836/3","i_c_s":["Precursor B-cell lymphoblastic leukemia","Common ALL","Common precursor B ALL","Pre-B ALL","Pre-pre-B ALL","Pro-B ALL","c-ALL"],"term_type":""},{"nm":"9837/3","n_c":["C27820","C27261","C8694","C3183"],"i_c":"9837/3","i_c_s":["Precursor T-cell lymphoblastic leukemia","T lymphoblastic leukemia/lymphoma","Cortical T ALL","Mature T ALL","Pre-T ALL","Pro-T ALL"],"term_type":""},{"nm":"9840/3","n_c":["C7467","C8923"],"i_c":"9840/3","i_c_s":["Acute myeloid leukemia, M6 type","Acute erythremia","Acute erythremic myelosis","Di Guglielmo disease","AML M6","Acute erythroid leukemia","Erythremic myelosis, NOS","Erythroleukemia","FAB M6","M6A","M6B"],"term_type":""},{"nm":"9860/3","n_c":["C34774","C3519","C4563","C4861","C3172"],"i_c":"9860/3","i_c_s":["Myeloid leukemia, NOS","Aleukemic monocytic leukemia","Aleukemic myeloid leukemia","Chronic monocytic leukemia","Subacute monocytic leukemia","Subacute myeloid leukemia","Eosinophilic leukemia","Monocytic leukemia, NOS","Aleukemic granulocytic leukemia","Aleukemic myelogenous leukemia","Subacute granulocytic leukemia","Subacute myelogenous leukemia","Granulocytic leukemia, NOS","Myelocytic leukemia, NOS","Myelogenous leukemia, NOS","Myelomonocytic leukemia, NOS","Non-lymphocytic leukemia, NOS"],"term_type":""},{"nm":"9861/3","n_c":["C27753","C82433","C82431","C3171"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia, NOS","Acute myeloid leukemia with mutated CEBPA","Acute myeloid leukemia with mutated NPM1","Acute granulocytic leukemia","Acute myelocytic leukemia","Acute myelogenous leukemia","Acute non-lymphocytic leukemia"],"term_type":""},{"nm":"9863/3","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic myeloid leukemia, NOS","Chronic granulocytic leukemia, NOS","Chronic myelocytic leukemia, NOS","Chronic myelogenous leukemia, NOS"],"term_type":""},{"nm":"9865/3","n_c":["C82423"],"i_c":"9865/3","i_c_s":["Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214"],"term_type":""},{"nm":"9866/3","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukemia, t(15;17)(q22;q11-12)","Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)","Acute myeloid leukemia, PML/RAR-alpha","Acute myeloid leukemia, t(15;17)(q22;q11-12)","Acute promyelocytic leukemia, NOS","Acute promyelocytic leukemia, PML/RAR-alpha","FAB M3"],"term_type":""},{"nm":"9867/3","n_c":["C7463"],"i_c":"9867/3","i_c_s":["Acute myelomonocytic leukemia","FAB M4"],"term_type":""},{"nm":"9869/3","n_c":["C82426"],"i_c":"9869/3","i_c_s":["Acute myeloid leukemia with inv(3)(q21;q26.2) or t(13.3)(q21;q26.2); RPN1-EVI1"],"term_type":""},{"nm":"9870/3","n_c":["C3164"],"i_c":"9870/3","i_c_s":["Acute basophilic leukemia"],"term_type":""},{"nm":"9871/3","n_c":["C9020","C9287"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia with abnormal marrow eosinophils","Acute myeloid leukemia, CBF-beta/MYH11","Acute myeloid leukemia, inv(16)(p13;q22)","Acute myeloid leukemia, t(16;16)(p13;q11)","Acute myelomonocytic leukemia with abnormal eosinophils","FAB M4Eo"],"term_type":""},{"nm":"9872/3","n_c":["C8460","C3171"],"i_c":"9872/3","i_c_s":["Acute myeloid leukemia, minimal differentiation","Acute myeloblastic leukemia","FAB M0"],"term_type":""},{"nm":"9873/3","n_c":["C3249"],"i_c":"9873/3","i_c_s":["Acute myeloid leukemia without maturation","FAB M1"],"term_type":""},{"nm":"9874/3","n_c":["C3250"],"i_c":"9874/3","i_c_s":["Acute myeloid leukemia with maturation","FAB M2, NOS"],"term_type":""},{"nm":"9875/3","n_c":["C9128","C3174"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, BCR/ABL positive","Chronic granulocytic leukemia, BCR/ABL","Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive","Chronic granulocytic leukemia, t(9;22)(q34;q11)","Chronic myelogenous leukemia, Philadelphia chromosome (Ph1) positive","Chronic myelogenous leukemia, t(9;22)(q34;11)"],"term_type":""},{"nm":"9876/3","n_c":["C3519"],"i_c":"9876/3","i_c_s":["Atypical chronic myeloid leukemia, BCR/ABL negative","Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative"],"term_type":""},{"nm":"9891/3","n_c":["C7318","C4861","C7171"],"i_c":"9891/3","i_c_s":["Acute monocytic leukemia","Acute monoblastic and monocytic leukemia","Acute monoblastic leukemia","FAB M5","Monoblastic leukemia, NOS"],"term_type":""},{"nm":"9895/3","n_c":["C9289","C4037","C7600"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with myelodysplasia-related changes","Acute myeloid leukemia with multilineage dysplasia","Acute myeloid leukemia with prior myelodysplastic syndrome","Acute myeloid leukemia without prior myelodysplastic syndrome"],"term_type":""},{"nm":"9896/3","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukemia, t(8;21)(q22;q22)","Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","Acute myeloid leukemia, AML1(CBF-alpha)/ETO","FAB M2, AML1(CBF-alpha)/ETO","FAB M2, t(8;21)(q22;q22)"],"term_type":""},{"nm":"9897/3","n_c":["C174129"],"i_c":"9897/3","i_c_s":["Acute myeloid leukemia, 11q23 abnormalities","Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL","Acute myeloid leukemia, MLL"],"term_type":""},{"nm":"9898/1","n_c":["C82339"],"i_c":"9898/1","i_c_s":["Transient abnormal myelopoiesis"],"term_type":""},{"nm":"9898/3","n_c":["C43223"],"i_c":"9898/3","i_c_s":["Myeloid leukemia associated with Down Syndrome"],"term_type":""},{"nm":"9910/3","n_c":["C3170"],"i_c":"9910/3","i_c_s":["Acute megakaryoblastic leukemia","FAB M7","Megakaryocytic leukemia"],"term_type":""},{"nm":"9911/3","n_c":["C82427"],"i_c":"9911/3","i_c_s":["Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1"],"term_type":""},{"nm":"9920/3","n_c":["C27754","C27912","C8252"],"i_c":"9920/3","i_c_s":["Therapy related myeloid neoplasm","Therapy-related acute myeloid leukemia, alkylating agent related","Therapy-related acute myeloid leukemia, epipodophyllotoxin-related","Therapy-related acute myeloid leukemia, NOS"],"term_type":""},{"nm":"9930/3","n_c":["C3520","C35815"],"i_c":"9930/3","i_c_s":["Myeloid sarcoma","Chloroma","Granulocytic sarcoma"],"term_type":""},{"nm":"9931/3","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute panmyelosis with myelofibrosis","Malignant myelosclerosis","Acute myelofibrosis","Acute myelosclerosis, NOS","Acute panmyelosis, NOS"],"term_type":""},{"nm":"9940/3","n_c":["C7402","C7401"],"i_c":"9940/3","i_c_s":["Hairy cell leukemia","Hairy cell leukemia variant","Leukemic reticuloendotheliosis"],"term_type":""},{"nm":"9945/3","n_c":["C3178"],"i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, NOS","Chronic myelomonocytic leukemia, Type II","Chronic myelomonocytic leukemia, Type I","Chronic myelomonocytic leukemia in transformation"],"term_type":""},{"nm":"9946/3","n_c":["C9233"],"i_c":"9946/3","i_c_s":["Juvenile myelomonocytic leukemia","Juvenile chronic myelomonocytic leukemia"],"term_type":""},{"nm":"9948/3","n_c":["C8647"],"i_c":"9948/3","i_c_s":["Aggressive NK-cell leukemia"],"term_type":""},{"nm":"9950/3","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Polycythemia vera","Chronic erythremia","Polycythemia rubra vera","Proliferative polycythemia"],"term_type":""},{"nm":"9960/3","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Myeloproliferative neoplasm, NOS","Chronic myeloproliferative disease, NOS","Chronic myeloproliferative disorder","Myeloproliferative disease, NOS"],"term_type":""},{"nm":"9961/3","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Primary myelofibrosis","Agnogenic myeloid metaplasia","Chronic idiopathic myelofibrosis","Megakaryocytic myelosclerosis","Myelofibrosis as a result of myeloproliferative disease","Myelofibrosis with myeloid metaplasia","Myelosclerosis with myeloid metaplasia"],"term_type":""},{"nm":"9962/3","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Essential thrombocythemia","Essential hemorrhagic thrombocythemia","Idiopathic hemorrhagic thrombocythemia","Idiopathic thrombocythemia"],"term_type":""},{"nm":"9963/3","n_c":["C3179"],"i_c":"9963/3","i_c_s":["Chronic neutrophilic leukemia"],"term_type":""},{"nm":"9964/3","n_c":["C4563","C27038"],"i_c":"9964/3","i_c_s":["Chronic eosinophilic leukemia, NOS","Hypereosinophilic syndrome"],"term_type":""},{"nm":"9965/3","n_c":["C84275"],"i_c":"9965/3","i_c_s":["Myeloid and lymphoid neoplasms with PDGFRA rearrangement"],"term_type":""},{"nm":"9966/3","n_c":["C84276"],"i_c":"9966/3","i_c_s":["Myeloid neoplasms with PDGFRB rearrangement"],"term_type":""},{"nm":"9967/3","n_c":["C84277"],"i_c":"9967/3","i_c_s":["Myeloid and lymphoid neoplasms with FGFR1 abnormalities"],"term_type":""},{"nm":"9970/1","n_c":["C9308"],"i_c":"9970/1","i_c_s":["Lymphoproliferative disorder, NOS","Lymphoproliferative disease, NOS"],"term_type":""},{"nm":"9971/1","n_c":["C4727"],"i_c":"9971/1","i_c_s":["Post transplant lymphoproliferative disorder, NOS","PTLD, NOS"],"term_type":""},{"nm":"9971/3","n_c":["C7183"],"i_c":"9971/3","i_c_s":["Polymorphic post transplant lymphoproliferative disorder"],"term_type":""},{"nm":"9975/3","n_c":["C27350"],"i_c":"9975/3","i_c_s":["Myloproliferative neoplasm, unclassifiable","Myelodysplastic/myeloproliferative neoplasm, unclassifiable"],"term_type":""},{"nm":"9980/3","n_c":["C2872"],"i_c":"9980/3","i_c_s":["Refractory anemia","Refractory anemia without sideroblasts"],"term_type":""},{"nm":"9982/3","n_c":["C4036","C82616"],"i_c":"9982/3","i_c_s":["Refractory anemia with sideroblasts","RARS","Refractory anemia with ring sideroblasts associated with marked thrombocytosis","Refractory anemia with ringed sideroblasts"],"term_type":""},{"nm":"9983/3","n_c":["C7506"],"i_c":"9983/3","i_c_s":["Refractory anemia with excess blasts","RAEB II","RAEB I","RAEB"],"term_type":""},{"nm":"9984/3","n_c":["C27080"],"i_c":"9984/3","i_c_s":["Refractory anemia with excess blasts in transformation","RAEB-T"],"term_type":""},{"nm":"9985/3","n_c":["C8574","C82596"],"i_c":"9985/3","i_c_s":["Refractory cytopenia with multilineage dysplasia","Refractory cytopenia of childhood"],"term_type":""},{"nm":"9986/3","n_c":["C6867"],"i_c":"9986/3","i_c_s":["Myelodysplastic syndrome with 5q deletion (5q-) syndrome","Myelodysplastic syndrome with isolated del (5q)"],"term_type":""},{"nm":"9987/3","n_c":["C7643","C7642","C27722"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, NOS","Therapy-related myelodysplastic syndrome, alkylating agent related","Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related"],"term_type":""},{"nm":"9989/3","n_c":["C198589"],"i_c":"9989/3","i_c_s":["Myelodysplastic syndrome, NOS","Preleukemia","Preleukemic syndrome","Myelodysplastic syndrome, unclassifiable"],"term_type":""},{"nm":"9991/3","n_c":["C82593"],"i_c":"9991/3","i_c_s":["Refractory neutropenia"],"term_type":""},{"nm":"9992/3","n_c":["C82594"],"i_c":"9992/3","i_c_s":["Refractory thrombocytopenia"],"term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ovarian_specimen_status":[{"nm":"Ovarian Capsule Intact","n_c":["C164042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Capsule Ruptured","n_c":["C164044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Capsule Fragmented","n_c":["C164045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ovarian_surface_involvement":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.perineural_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.peripancreatic_lymph_nodes_positive":[{"nm":"0","n_c":["C70430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1-3","n_c":["C172224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4 or More","n_c":["C172226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.peritoneal_fluid_cytological_status":[{"nm":"Atypical","n_c":["C8326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malignant","n_c":["C14143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Malignant","n_c":["C25588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unsatisfactory","n_c":["C126862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.pregnant_at_diagnosis":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.primary_diagnosis":[{"nm":"Abdominal desmoid","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Abdominal desmoid"],"term_type":"SY"},{"nm":"Abdominal fibromatosis","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Abdominal fibromatosis"],"term_type":"PT"},{"nm":"Achromic nevus","n_c":["C27095"],"i_c":"8730/0","i_c_s":["Achromic nevus"],"term_type":"SY"},{"nm":"Acidophil adenocarcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Acidophil adenocarcinoma"],"term_type":"SY"},{"nm":"Acidophil adenoma","n_c":["C6780"],"i_c":"8280/0","i_c_s":["Acidophil adenoma"],"term_type":"PT"},{"nm":"Acidophil carcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Acidophil carcinoma"],"term_type":"PT"},{"nm":"Acinar adenocarcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar adenocarcinoma"],"term_type":"SY"},{"nm":"Acinar adenocarcinoma, sarcomatoid","n_c":["C5530"],"i_c":"8572/3","i_c_s":["Acinar adenocarcinoma, sarcomatoid"],"term_type":""},{"nm":"Acinar adenoma","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinar adenoma"],"term_type":"SY"},{"nm":"Acinar carcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar carcinoma"],"term_type":"SY"},{"nm":"Acinar cell adenoma","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinar cell adenoma"],"term_type":"PT"},{"nm":"Acinar cell carcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar cell carcinoma"],"term_type":"PT"},{"nm":"Acinar cell cystadenocarcinoma","n_c":["C5727"],"i_c":"8551/3","i_c_s":["Acinar cell cystadenocarcinoma"],"term_type":"PT"},{"nm":"Acinar cell tumor","n_c":["C4197"],"i_c":"8550/1","i_c_s":["Acinar cell tumor"],"term_type":"OP"},{"nm":"Acinic cell adenocarcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinic cell adenocarcinoma"],"term_type":"SY"},{"nm":"Acinic cell adenoma","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinic cell adenoma"],"term_type":"SY"},{"nm":"Acinic cell tumor","n_c":["C4197"],"i_c":"8550/1","i_c_s":["Acinic cell tumor"],"term_type":"IS"},{"nm":"Acoustic neuroma","n_c":["C3276"],"i_c":"9560/0","i_c_s":["Acoustic neuroma"],"term_type":"RT"},{"nm":"Acquired cystic disease-associated renal cell carcinoma (RCC)","n_c":["C157718"],"i_c":"8316/3","i_c_s":["Acquired cystic disease-associated renal cell carcinoma (RCC)"],"term_type":""},{"nm":"Acquired tufted hemangioma","n_c":["C4487"],"i_c":"9161/0","i_c_s":["Acquired tufted hemangioma"],"term_type":"PT"},{"nm":"Acral lentiginous melanoma, malignant","n_c":["C4022"],"i_c":"8744/3","i_c_s":["Acral lentiginous melanoma, malignant"],"term_type":"PT"},{"nm":"ACTH-producing tumor","n_c":"","i_c":"8158/1","i_c_s":["ACTH-producing tumor"],"term_type":"RT"},{"nm":"Acute basophilic leukaemia","n_c":["C3164"],"i_c":"9870/3","i_c_s":["Acute basophilic leukaemia"],"term_type":""},{"nm":"Acute bilineal leukemia","n_c":["C6923"],"i_c":"9805/3","i_c_s":["Acute bilineal leukemia"],"term_type":"RT"},{"nm":"Acute biphenotypic leukemia","n_c":["C4673"],"i_c":"9805/3","i_c_s":["Acute biphenotypic leukemia"],"term_type":"PT"},{"nm":"Acute erythremia","n_c":["C8923"],"i_c":"9840/3","i_c_s":["Acute erythremia"],"term_type":"IS"},{"nm":"Acute erythremic myelosis","n_c":["C7467"],"i_c":"9840/3","i_c_s":["Acute erythremic myelosis"],"term_type":"IS"},{"nm":"Acute erythroid leukaemia","n_c":["C8923"],"i_c":"9840/3","i_c_s":["Acute erythroid leukaemia"],"term_type":""},{"nm":"Acute granulocytic leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute granulocytic leukemia"],"term_type":"SY"},{"nm":"Acute leukemia, Burkitt type","n_c":["C7400"],"i_c":"9826/3","i_c_s":["Acute leukemia, Burkitt type"],"term_type":"IS"},{"nm":"Acute leukemia, NOS","n_c":["C9298"],"i_c":"9801/3","i_c_s":["Acute leukemia, NOS"],"term_type":"PT"},{"nm":"Acute lymphatic leukemia","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphatic leukemia"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia-lymphoma, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia-lymphoma, NOS"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, L2 type, NOS","n_c":["C27281"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia, L2 type, NOS"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, mature B-cell type","n_c":["C7400"],"i_c":"9826/3","i_c_s":["Acute lymphoblastic leukemia, mature B-cell type"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia, NOS"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, precursor cell type","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia, precursor cell type"],"term_type":""},{"nm":"Acute lymphocytic leukemia","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphocytic leukemia"],"term_type":"SY"},{"nm":"Acute lymphoid leukemia","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoid leukemia"],"term_type":"SY"},{"nm":"Acute megakaryoblastic leukaemia","n_c":["C3170"],"i_c":"9910/3","i_c_s":["Acute megakaryoblastic leukaemia"],"term_type":""},{"nm":"Acute mixed lineage leukemia","n_c":["C6923"],"i_c":"9805/3","i_c_s":["Acute mixed lineage leukemia"],"term_type":"RT"},{"nm":"Acute monoblastic and monocytic leukemia","n_c":["C7318"],"i_c":"9891/3","i_c_s":["Acute monoblastic and monocytic leukemia"],"term_type":"RT"},{"nm":"Acute monoblastic leukemia","n_c":["C7171"],"i_c":"9891/3","i_c_s":["Acute monoblastic leukemia"],"term_type":"SY"},{"nm":"Acute monocytic leukemia","n_c":["C4861"],"i_c":"9891/3","i_c_s":["Acute monocytic leukemia"],"term_type":"PT"},{"nm":"Acute myeloblastic leukemia","n_c":["C3171"],"i_c":"9872/3","i_c_s":["Acute myeloblastic leukemia"],"term_type":"SY"},{"nm":"Acute myelocytic leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute myelocytic leukemia"],"term_type":"SY"},{"nm":"Acute myelofibrosis","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute myelofibrosis"],"term_type":"SY"},{"nm":"Acute myelogenous leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute myelogenous leukemia"],"term_type":"SY"},{"nm":"Acute myeloid leukaemia, t(8;21)(q22;q22)","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukaemia, t(8;21)(q22;q22)"],"term_type":""},{"nm":"Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1","n_c":["C82427"],"i_c":"9911/3","i_c_s":["Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)","n_c":["C9287"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)"],"term_type":""},{"nm":"Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1","n_c":["C82426"],"i_c":"9869/3","i_c_s":["Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1"],"term_type":""},{"nm":"Acute myeloid leukemia with maturation","n_c":["C3250"],"i_c":"9874/3","i_c_s":["Acute myeloid leukemia with maturation"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with multilineage dysplasia","n_c":["C9289"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with multilineage dysplasia"],"term_type":"SY"},{"nm":"Acute myeloid leukemia with mutated CEBPA","n_c":["C82433"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia with mutated CEBPA"],"term_type":"RT"},{"nm":"Acute myeloid leukemia with mutated NPM1","n_c":["C82431"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia with mutated NPM1"],"term_type":"RT"},{"nm":"Acute myeloid leukemia with myelodysplasia-related changes","n_c":["C7600"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with myelodysplasia-related changes"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with prior myelodysplastic syndrome","n_c":["C4037"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with prior myelodysplastic syndrome"],"term_type":"SY"},{"nm":"Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214","n_c":["C82423"],"i_c":"9865/3","i_c_s":["Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1"],"term_type":"SY"},{"nm":"Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL","n_c":["C82403"],"i_c":"9897/3","i_c_s":["Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL"],"term_type":"SY"},{"nm":"Acute myeloid leukemia without maturation","n_c":["C3249"],"i_c":"9873/3","i_c_s":["Acute myeloid leukemia without maturation"],"term_type":"PT"},{"nm":"Acute myeloid leukemia without prior myelodysplastic syndrome","n_c":["C4037"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia without prior myelodysplastic syndrome"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, AML1(CBF-alpha)/ETO","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukemia, AML1(CBF-alpha)/ETO"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, CBF-beta/MYH11","n_c":["C9287"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia, CBF-beta/MYH11"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, inv(16)(p13;q22)","n_c":["C9018"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia, inv(16)(p13;q22)"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, M6 type","n_c":["C8923"],"i_c":"9840/3","i_c_s":["Acute myeloid leukemia, M6 type"],"term_type":"PT"},{"nm":"Acute myeloid leukemia, minimal differentiation","n_c":["C8460"],"i_c":"9872/3","i_c_s":["Acute myeloid leukemia, minimal differentiation"],"term_type":"PT"},{"nm":"Acute myeloid leukemia, MLL","n_c":["C174129"],"i_c":"9897/3","i_c_s":["Acute myeloid leukemia, MLL"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, NOS","n_c":["C27753"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia, NOS"],"term_type":"PT"},{"nm":"Acute myeloid leukemia, PML/RAR-alpha","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute myeloid leukemia, PML/RAR-alpha"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, t(15:17)(g22;q11-12)","n_c":"","i_c":"9866/3","i_c_s":["Acute myeloid leukemia, t(15:17)(g22;q11-12)"],"term_type":""},{"nm":"Acute myeloid leukemia, t(16;16)(p 13;q 11)","n_c":["C9019"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia, t(16;16)(p 13;q 11)"],"term_type":""},{"nm":"Acute myelomonocytic leukemia","n_c":["C7463"],"i_c":"9867/3","i_c_s":["Acute myelomonocytic leukemia"],"term_type":"PT"},{"nm":"Acute myelomonocytic leukemia with abnormal eosinophils","n_c":["C9020"],"i_c":"9871/3","i_c_s":["Acute myelomonocytic leukemia with abnormal eosinophils"],"term_type":"SY"},{"nm":"Acute myelosclerosis, NOS","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute myelosclerosis, NOS"],"term_type":"SY"},{"nm":"Acute myloid leukemia, 11q23 abnormalities","n_c":["C174129"],"i_c":"9897/3","i_c_s":["Acute myloid leukemia, 11q23 abnormalities"],"term_type":"PT"},{"nm":"Acute non-lymphocytic leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute non-lymphocytic leukemia"],"term_type":"SY"},{"nm":"Acute panmyelosis with myelofibrosis","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute panmyelosis with myelofibrosis"],"term_type":"PT"},{"nm":"Acute panmyelosis, NOS","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute panmyelosis, NOS"],"term_type":"SY"},{"nm":"Acute progressive histiocytosis X","n_c":"","i_c":"9751/3","i_c_s":["Acute progressive histiocytosis X"],"term_type":"ORT"},{"nm":"Acute promyelocytic leukaemia, PML-RAR-alpha","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukaemia, PML-RAR-alpha"],"term_type":""},{"nm":"Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)"],"term_type":""},{"nm":"Acute promyelocytic leukemia, NOS","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Adamantinoma of long bones","n_c":["C7644"],"i_c":"9261/3","i_c_s":["Adamantinoma of long bones"],"term_type":"PT"},{"nm":"Adamantinoma, malignant","n_c":["C7644"],"i_c":"9310/3","i_c_s":["Adamantinoma, malignant"],"term_type":"SY"},{"nm":"Adamantinoma, NOS","n_c":["C7644"],"i_c":"9310/0","i_c_s":["Adamantinoma, NOS"],"term_type":"SY"},{"nm":"Adenoacanthoma","n_c":["C4200"],"i_c":"8570/3","i_c_s":["Adenoacanthoma"],"term_type":"SY"},{"nm":"Adenoameloblastoma","n_c":["C4310"],"i_c":"9300/0","i_c_s":["Adenoameloblastoma"],"term_type":"SY"},{"nm":"Adenocarcinoid tumor","n_c":["C201135"],"i_c":"8245/3","i_c_s":["Adenocarcinoid tumor"],"term_type":"PT"},{"nm":"Adenocarcinoma admixed with neuroendocrine carcinoma","n_c":["C127915"],"i_c":"8574/3","i_c_s":["Adenocarcinoma admixed with neuroendocrine carcinoma"],"term_type":""},{"nm":"Adenocarcinoma combined with other types of carcinoma","n_c":["C45508"],"i_c":"8255/3","i_c_s":["Adenocarcinoma combined with other types of carcinoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in a polyp, NOS","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in a polyp, NOS"],"term_type":"SY"},{"nm":"Adenocarcinoma in adenomatous polyp","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in adenomatous polyp"],"term_type":"PT"},{"nm":"Adenocarcinoma in adenomatous polyposis coli","n_c":["C4134"],"i_c":"8220/3","i_c_s":["Adenocarcinoma in adenomatous polyposis coli"],"term_type":"PT"},{"nm":"Adenocarcinoma in multiple adenomatous polyps","n_c":["C4136"],"i_c":"8221/3","i_c_s":["Adenocarcinoma in multiple adenomatous polyps"],"term_type":"PT"},{"nm":"Adenocarcinoma in polypoid adenoma","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in polypoid adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in a polyp, NOS","n_c":["C7680"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in a polyp, NOS"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in adenomatous polyp","n_c":["C7678"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in adenomatous polyp"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ in polypoid adenoma","n_c":["C7678"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in polypoid adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in tubular adenoma","n_c":["C7679"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in tubular adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in tubulovillous adenoma","n_c":["C4144"],"i_c":"8263/2","i_c_s":["Adenocarcinoma in situ in tubulovillous adenoma"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ in villous adenoma","n_c":["C8376"],"i_c":"8261/2","i_c_s":["Adenocarcinoma in situ in villous adenoma"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ, mucinous","n_c":["C136717"],"i_c":"8253/2","i_c_s":["Adenocarcinoma in situ, mucinous"],"term_type":""},{"nm":"Adenocarcinoma in situ, non-mucinous","n_c":["C136716"],"i_c":"8250/2","i_c_s":["Adenocarcinoma in situ, non-mucinous"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ, NOS","n_c":["C4123"],"i_c":"8140/2","i_c_s":["Adenocarcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Adenocarcinoma in tubolovillous adenoma","n_c":["C4145"],"i_c":"8263/3","i_c_s":["Adenocarcinoma in tubolovillous adenoma"],"term_type":""},{"nm":"Adenocarcinoma in tubular adenoma","n_c":["C7677"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in tubular adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in villous adenoma","n_c":["C4141"],"i_c":"8261/3","i_c_s":["Adenocarcinoma in villous adenoma"],"term_type":"PT"},{"nm":"Adenocarcinoma of anal ducts","n_c":["C5609"],"i_c":"8215/3","i_c_s":["Adenocarcinoma of anal ducts"],"term_type":"SY"},{"nm":"Adenocarcinoma of anal glands","n_c":["C5609"],"i_c":"8215/3","i_c_s":["Adenocarcinoma of anal glands"],"term_type":"PT"},{"nm":"Adenocarcinoma of rete ovarii","n_c":["C40017"],"i_c":"9110/3","i_c_s":["Adenocarcinoma of rete ovarii"],"term_type":""},{"nm":"Adenocarcinoma with apocrine metaplasia","n_c":["C4202"],"i_c":"8573/3","i_c_s":["Adenocarcinoma with apocrine metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma with cartilaginous and osseous metaplasia","n_c":["C7683"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with cartilaginous and osseous metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma with cartilaginous metaplasia","n_c":["C7685"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with cartilaginous metaplasia"],"term_type":"SY"},{"nm":"Adenocarcinoma with mixed subtypes","n_c":["C45508"],"i_c":"8255/3","i_c_s":["Adenocarcinoma with mixed subtypes"],"term_type":"PT"},{"nm":"Adenocarcinoma with neuroendocrine differentiation","n_c":["C66745"],"i_c":"8574/3","i_c_s":["Adenocarcinoma with neuroendocrine differentiation"],"term_type":"PT"},{"nm":"Adenocarcinoma with osseous metaplasia","n_c":["C7684"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with osseous metaplasia"],"term_type":"SY"},{"nm":"Adenocarcinoma with spindle cell metaplasia","n_c":["C4201"],"i_c":"8572/3","i_c_s":["Adenocarcinoma with spindle cell metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma with squamous metaplasia","n_c":["C4200"],"i_c":"8570/3","i_c_s":["Adenocarcinoma with squamous metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma, cribriform comedo-type","n_c":"","i_c":"8201/3","i_c_s":["Adenocarcinoma, cribriform comedo-type"],"term_type":"SY"},{"nm":"Adenocarcinoma, cylindroid","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenocarcinoma, cylindroid"],"term_type":"SY"},{"nm":"Adenocarcinoma, diffuse type","n_c":["C4127"],"i_c":"8145/3","i_c_s":["Adenocarcinoma, diffuse type"],"term_type":"SY"},{"nm":"Adenocarcinoma, endocervical type","n_c":["C66951"],"i_c":"8384/3","i_c_s":["Adenocarcinoma, endocervical type"],"term_type":"PT"},{"nm":"Adenocarcinoma, intestinal type","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Adenocarcinoma, intestinal type"],"term_type":"PT"},{"nm":"Adenocarcinoma, metastatic, NOS","n_c":["C4124"],"i_c":"8140/6","i_c_s":["Adenocarcinoma, metastatic, NOS"],"term_type":"PT"},{"nm":"Adenocarcinoma, NOS","n_c":["C2852"],"i_c":"8140/3","i_c_s":["Adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Adenocarcinoma, pancreatobiliary type","n_c":"","i_c":"8163/3","i_c_s":["Adenocarcinoma, pancreatobiliary type"],"term_type":"SY"},{"nm":"Adenocystic carcinoma","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenocystic carcinoma"],"term_type":"SY"},{"nm":"Adenofibroma, NOS","n_c":["C8984"],"i_c":"9013/0","i_c_s":["Adenofibroma, NOS"],"term_type":"PT"},{"nm":"Adenoid basal carcinoma","n_c":["C27535"],"i_c":"8098/3","i_c_s":["Adenoid basal carcinoma"],"term_type":"PT"},{"nm":"Adenoid cystic carcinoma","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenoid cystic carcinoma"],"term_type":"PT"},{"nm":"Adenolipoma","n_c":["C4159"],"i_c":"8324/0","i_c_s":["Adenolipoma"],"term_type":"SY"},{"nm":"Adenolymphoma","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Adenolymphoma"],"term_type":"PT"},{"nm":"Adenoma of nipple","n_c":["C4192"],"i_c":"8506/0","i_c_s":["Adenoma of nipple"],"term_type":"PT"},{"nm":"Adenoma, NOS","n_c":["C2855"],"i_c":"8140/0","i_c_s":["Adenoma, NOS"],"term_type":"PT"},{"nm":"Adenomatoid odontogenic tumor","n_c":["C4310"],"i_c":"9300/0","i_c_s":["Adenomatoid odontogenic tumor"],"term_type":"PT"},{"nm":"Adenomatoid tumor, NOS","n_c":["C3762"],"i_c":"9054/0","i_c_s":["Adenomatoid tumor, NOS"],"term_type":"PT"},{"nm":"Adenomatosis, NOS","n_c":"","i_c":"8220/0","i_c_s":["Adenomatosis, NOS"],"term_type":"SY"},{"nm":"Adenomatous polyp, NOS","n_c":["C3764"],"i_c":"8210/0","i_c_s":["Adenomatous polyp, NOS"],"term_type":"PT"},{"nm":"Adenomatous polyposis coli","n_c":["C3339"],"i_c":"8220/0","i_c_s":["Adenomatous polyposis coli"],"term_type":"PT"},{"nm":"Adenomyoepithelioma","n_c":["C6899"],"i_c":"8983/0","i_c_s":["Adenomyoepithelioma"],"term_type":"PT"},{"nm":"Adenomyoepithelioma with carcinoma","n_c":["C5143"],"i_c":"8983/3","i_c_s":["Adenomyoepithelioma with carcinoma"],"term_type":"PT"},{"nm":"Adenomyoma","n_c":["C3726"],"i_c":"8932/0","i_c_s":["Adenomyoma"],"term_type":"PT"},{"nm":"Adenosarcoma","n_c":["C9474"],"i_c":"8933/3","i_c_s":["Adenosarcoma"],"term_type":"PT"},{"nm":"Adenosquamous carcinoma","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Adenosquamous carcinoma"],"term_type":"PT"},{"nm":"Adnexal carcinoma","n_c":["C3775"],"i_c":"8390/3","i_c_s":["Adnexal carcinoma"],"term_type":"SY"},{"nm":"Adnexal tumor, benign","n_c":["C7580"],"i_c":"8390/0","i_c_s":["Adnexal tumor, benign"],"term_type":"SY"},{"nm":"Adrenal cortical adenocarcinoma","n_c":["C9325"],"i_c":"8370/3","i_c_s":["Adrenal cortical adenocarcinoma"],"term_type":"SY"},{"nm":"Adrenal cortical adenoma, clear cell","n_c":["C4165"],"i_c":"8373/0","i_c_s":["Adrenal cortical adenoma, clear cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, compact cell","n_c":["C4163"],"i_c":"8371/0","i_c_s":["Adrenal cortical adenoma, compact cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, glomerulosa cell","n_c":["C4166"],"i_c":"8374/0","i_c_s":["Adrenal cortical adenoma, glomerulosa cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, mixed cell","n_c":["C4167"],"i_c":"8375/0","i_c_s":["Adrenal cortical adenoma, mixed cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, NOS","n_c":["C9003"],"i_c":"8370/0","i_c_s":["Adrenal cortical adenoma, NOS"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, pigmented","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Adrenal cortical adenoma, pigmented"],"term_type":"PT"},{"nm":"Adrenal cortical carcinoma","n_c":["C9325"],"i_c":"8370/3","i_c_s":["Adrenal cortical carcinoma"],"term_type":"PT"},{"nm":"Adrenal cortical tumor, benign","n_c":["C9004"],"i_c":"8370/0","i_c_s":["Adrenal cortical tumor, benign"],"term_type":"SY"},{"nm":"Adrenal cortical tumor, malignant","n_c":["C9327"],"i_c":"8370/3","i_c_s":["Adrenal cortical tumor, malignant"],"term_type":"SY"},{"nm":"Adrenal cortical tumor, NOS","n_c":["C2858"],"i_c":"8370/0","i_c_s":["Adrenal cortical tumor, NOS"],"term_type":"SY"},{"nm":"Adrenal medullary paraganglioma","n_c":["C3326"],"i_c":"8700/0","i_c_s":["Adrenal medullary paraganglioma"],"term_type":"SY"},{"nm":"Adrenal medullary paraganglioma, malignant","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Adrenal medullary paraganglioma, malignant"],"term_type":"SY"},{"nm":"Adrenal rest tumor","n_c":["C2860"],"i_c":"8671/0","i_c_s":["Adrenal rest tumor"],"term_type":"PT"},{"nm":"Adult cystic teratoma","n_c":["C9012"],"i_c":"9080/0","i_c_s":["Adult cystic teratoma"],"term_type":"SY"},{"nm":"Adult granulosa cell tumor","n_c":["C66750"],"i_c":"8620/3","i_c_s":["Adult granulosa cell tumor"],"term_type":""},{"nm":"Adult rhabdomyoma","n_c":"","i_c":"8904/0","i_c_s":["Adult rhabdomyoma"],"term_type":"PT"},{"nm":"Adult T-cell leukemia","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell leukemia"],"term_type":"SY"},{"nm":"Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)"],"term_type":""},{"nm":"Adult T-cell lymphoma","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell lymphoma"],"term_type":"SY"},{"nm":"Adult T-cell lymphoma/leukemia","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell lymphoma/leukemia"],"term_type":"SY"},{"nm":"Adult teratoma, NOS","n_c":["C9013"],"i_c":"9080/0","i_c_s":["Adult teratoma, NOS"],"term_type":"SY"},{"nm":"Aggressive angiomyxoma","n_c":["C6936"],"i_c":"8841/1","i_c_s":["Aggressive angiomyxoma"],"term_type":"SY"},{"nm":"Aggressive digital papillary adenoma","n_c":["C162848"],"i_c":"8408/1","i_c_s":["Aggressive digital papillary adenoma"],"term_type":"PT"},{"nm":"Aggressive fibromatosis","n_c":["C9182"],"i_c":"8821/1","i_c_s":["Aggressive fibromatosis"],"term_type":"PT"},{"nm":"Aggressive NK-cell leukaemia","n_c":["C8647"],"i_c":"9948/3","i_c_s":["Aggressive NK-cell leukaemia"],"term_type":""},{"nm":"Aggressive osteoblastoma","n_c":["C66796"],"i_c":"9200/1","i_c_s":["Aggressive osteoblastoma"],"term_type":"PT"},{"nm":"Aggressive systemic mastocytosis","n_c":["C9285"],"i_c":"9741/3","i_c_s":["Aggressive systemic mastocytosis"],"term_type":"RT"},{"nm":"Agnogenic myeloid metaplasia","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Agnogenic myeloid metaplasia"],"term_type":"SY"},{"nm":"AIN III","n_c":["C157575"],"i_c":"8077/2","i_c_s":["AIN III"],"term_type":"SY"},{"nm":"Aleukemic granulocytic leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic granulocytic leukemia"],"term_type":"IS"},{"nm":"Aleukemic leukemia, NOS","n_c":["C4982"],"i_c":"9800/3","i_c_s":["Aleukemic leukemia, NOS"],"term_type":"ORT"},{"nm":"Aleukemic lymphatic leukemia","n_c":["C4343"],"i_c":"9820/3","i_c_s":["Aleukemic lymphatic leukemia"],"term_type":"IS"},{"nm":"Aleukemic lymphocytic leukemia","n_c":["C7176"],"i_c":"9820/3","i_c_s":["Aleukemic lymphocytic leukemia"],"term_type":"IS"},{"nm":"Aleukemic lymphoid leukemia","n_c":["C4343"],"i_c":"9820/3","i_c_s":["Aleukemic lymphoid leukemia"],"term_type":"ORT"},{"nm":"Aleukemic monocytic leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic monocytic leukemia"],"term_type":"ORT"},{"nm":"Aleukemic myelogenous leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic myelogenous leukemia"],"term_type":"IS"},{"nm":"Aleukemic myeloid leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic myeloid leukemia"],"term_type":"ORT"},{"nm":"ALK positive large B-cell lymphoma","n_c":["C7225"],"i_c":"9737/3","i_c_s":["ALK positive large B-cell lymphoma"],"term_type":"PT"},{"nm":"Alpha cell tumor, malignant","n_c":["C65187"],"i_c":"8152/3","i_c_s":["Alpha cell tumor, malignant"],"term_type":"SY"},{"nm":"Alpha cell tumor, NOS","n_c":"","i_c":"8152/1","i_c_s":["Alpha cell tumor, NOS"],"term_type":"SY"},{"nm":"Alpha heavy chain disease","n_c":["C3132"],"i_c":"9762/3","i_c_s":["Alpha heavy chain disease"],"term_type":"RT"},{"nm":"Alveolar adenocarcinoma","n_c":["C2923"],"i_c":"8251/3","i_c_s":["Alveolar adenocarcinoma"],"term_type":"PT"},{"nm":"Alveolar adenoma","n_c":["C4140"],"i_c":"8251/0","i_c_s":["Alveolar adenoma"],"term_type":"PT"},{"nm":"Alveolar carcinoma","n_c":["C2923"],"i_c":"8251/3","i_c_s":["Alveolar carcinoma"],"term_type":"SY"},{"nm":"Alveolar cell carcinoma","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Alveolar cell carcinoma"],"term_type":"SY"},{"nm":"Alveolar rhabdomyosarcoma","n_c":["C3749"],"i_c":"8920/3","i_c_s":["Alveolar rhabdomyosarcoma"],"term_type":"PT"},{"nm":"Alveolar soft part sarcoma","n_c":["C3750"],"i_c":"9581/3","i_c_s":["Alveolar soft part sarcoma"],"term_type":"PT"},{"nm":"Amelanotic melanoma","n_c":["C3802"],"i_c":"8730/3","i_c_s":["Amelanotic melanoma"],"term_type":"PT"},{"nm":"Ameloblastic carcinoma","n_c":["C7492"],"i_c":"9270/3","i_c_s":["Ameloblastic carcinoma"],"term_type":"SY"},{"nm":"Ameloblastic fibro-odontoma","n_c":["C3710"],"i_c":"9290/0","i_c_s":["Ameloblastic fibro-odontoma"],"term_type":"PT"},{"nm":"Ameloblastic fibro-odontosarcoma","n_c":["C173740"],"i_c":"9290/3","i_c_s":["Ameloblastic fibro-odontosarcoma"],"term_type":"SY"},{"nm":"Ameloblastic fibrodentinoma","n_c":["C66800"],"i_c":"9271/0","i_c_s":["Ameloblastic fibrodentinoma"],"term_type":"PT"},{"nm":"Ameloblastic fibrodentinosarcoma","n_c":["C173739"],"i_c":"9290/3","i_c_s":["Ameloblastic fibrodentinosarcoma"],"term_type":"SY"},{"nm":"Ameloblastic fibroma","n_c":["C4316"],"i_c":"9330/0","i_c_s":["Ameloblastic fibroma"],"term_type":"PT"},{"nm":"Ameloblastic fibrosarcoma","n_c":["C4317"],"i_c":"9330/3","i_c_s":["Ameloblastic fibrosarcoma"],"term_type":"PT"},{"nm":"Ameloblastic odontosarcoma","n_c":["C173740"],"i_c":"9290/3","i_c_s":["Ameloblastic odontosarcoma"],"term_type":"PT"},{"nm":"Ameloblastic sarcoma","n_c":["C4317"],"i_c":"9330/3","i_c_s":["Ameloblastic sarcoma"],"term_type":"SY"},{"nm":"Ameloblastoma, malignant","n_c":["C54297"],"i_c":"9310/3","i_c_s":["Ameloblastoma, malignant"],"term_type":"PT"},{"nm":"Ameloblastoma, NOS","n_c":["C4313"],"i_c":"9310/0","i_c_s":["Ameloblastoma, NOS"],"term_type":"PT"},{"nm":"AML M6","n_c":["C8923"],"i_c":"9840/3","i_c_s":["AML M6"],"term_type":"SY"},{"nm":"Anal intraepithelial neoplasia, grade III","n_c":["C157575"],"i_c":"8077/2","i_c_s":["Anal intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Anal intraepithelial neoplasia, low grade","n_c":"","i_c":"8077/0","i_c_s":["Anal intraepithelial neoplasia, low grade"],"term_type":"RT"},{"nm":"Anaplastic astrocytoma, IDH-mutant","n_c":["C129290"],"i_c":"9401/3","i_c_s":["Anaplastic astrocytoma, IDH-mutant"],"term_type":""},{"nm":"Anaplastic astrocytoma, IDH-wildtype","n_c":["C129291"],"i_c":"9401/3","i_c_s":["Anaplastic astrocytoma, IDH-wildtype"],"term_type":""},{"nm":"Anaplastic large B-cell lymphoma","n_c":["C6916"],"i_c":"9680/3","i_c_s":["Anaplastic large B-cell lymphoma"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, ALK negative","n_c":["C37194"],"i_c":"9702/3","i_c_s":["Anaplastic large cell lymphoma, ALK negative"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, ALK positive","n_c":["C37193"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, ALK positive"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, CD30+","n_c":["C3720"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, CD30+"],"term_type":"SY"},{"nm":"Anaplastic large cell lymphoma, NOS","n_c":["C3720"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, NOS"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, T cell and Null cell type","n_c":"","i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, T cell and Null cell type"],"term_type":"PT"},{"nm":"Anaplastic medulloblastoma","n_c":["C92625"],"i_c":"9474/3","i_c_s":["Anaplastic medulloblastoma"],"term_type":"RT"},{"nm":"Anaplastic oligoastrocytoma","n_c":["C6959"],"i_c":"9382/3","i_c_s":["Anaplastic oligoastrocytoma"],"term_type":"SY"},{"nm":"Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted","n_c":["C129321"],"i_c":"9451/3","i_c_s":["Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted"],"term_type":""},{"nm":"Anaplastic pleomorphic xanthroastrocytoma","n_c":["C129327"],"i_c":"9424/3","i_c_s":["Anaplastic pleomorphic xanthroastrocytoma"],"term_type":""},{"nm":"Ancient schwannoma","n_c":["C6556"],"i_c":"9560/0","i_c_s":["Ancient schwannoma"],"term_type":"RT"},{"nm":"Androblastoma, benign","n_c":["C67012"],"i_c":"8630/0","i_c_s":["Androblastoma, benign"],"term_type":"PT"},{"nm":"Androblastoma, malignant","n_c":["C67006"],"i_c":"8630/3","i_c_s":["Androblastoma, malignant"],"term_type":"PT"},{"nm":"Androblastoma, NOS","n_c":["C39976"],"i_c":"8630/1","i_c_s":["Androblastoma, NOS"],"term_type":"PT"},{"nm":"Angioblastic meningioma","n_c":"","i_c":"9535/0","i_c_s":["Angioblastic meningioma"],"term_type":"IS"},{"nm":"Angioblastoma","n_c":["C3801"],"i_c":"9161/1","i_c_s":["Angioblastoma"],"term_type":"SY"},{"nm":"Angiocentric glioma","n_c":["C92552"],"i_c":"9431/1","i_c_s":["Angiocentric glioma"],"term_type":"PT"},{"nm":"Angiocentric immunoproliferative lesion","n_c":["C40970"],"i_c":"9766/1","i_c_s":["Angiocentric immunoproliferative lesion"],"term_type":"PT"},{"nm":"Angiocentric T-cell lymphoma","n_c":["C4684"],"i_c":"9719/3","i_c_s":["Angiocentric T-cell lymphoma"],"term_type":"IS"},{"nm":"Angioendothelioma","n_c":["C3084"],"i_c":"9130/1","i_c_s":["Angioendothelioma"],"term_type":"SY"},{"nm":"Angioendotheliomatosis","n_c":["C4342"],"i_c":"9680/3","i_c_s":["Angioendotheliomatosis"],"term_type":"SY"},{"nm":"Angiofibroma, NOS","n_c":["C3799"],"i_c":"9160/0","i_c_s":["Angiofibroma, NOS"],"term_type":"PT"},{"nm":"Angioimmunoblastic lymphadenopathy","n_c":["C7528"],"i_c":"9767/1","i_c_s":["Angioimmunoblastic lymphadenopathy"],"term_type":""},{"nm":"Angioimmunoblastic lymphoma","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Angioimmunoblastic lymphoma"],"term_type":"IS"},{"nm":"Angioimmunoblastic T-cell lymphoma","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Angioimmunoblastic T-cell lymphoma"],"term_type":"PT"},{"nm":"Angiokeratoma","n_c":["C2874"],"i_c":"9141/0","i_c_s":["Angiokeratoma"],"term_type":"PT"},{"nm":"Angioleiomyoma","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Angioleiomyoma"],"term_type":"SY"},{"nm":"Angiolipoma, NOS","n_c":["C3733"],"i_c":"8861/0","i_c_s":["Angiolipoma, NOS"],"term_type":"PT"},{"nm":"Angioma, NOS","n_c":["C3085"],"i_c":"9120/0","i_c_s":["Angioma, NOS"],"term_type":"SY"},{"nm":"Angiomatoid fibrous histiocytoma","n_c":["C6494"],"i_c":"8836/1","i_c_s":["Angiomatoid fibrous histiocytoma"],"term_type":"PT"},{"nm":"Angiomatous meningioma","n_c":["C4332"],"i_c":"9534/0","i_c_s":["Angiomatous meningioma"],"term_type":"PT"},{"nm":"Angiomyofibroblastoma","n_c":["C49016"],"i_c":"8826/0","i_c_s":["Angiomyofibroblastoma"],"term_type":"PT"},{"nm":"Angiomyolipoma","n_c":["C3734"],"i_c":"8860/0","i_c_s":["Angiomyolipoma"],"term_type":"PT"},{"nm":"Angiomyoma","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Angiomyoma"],"term_type":"PT"},{"nm":"Angiomyosarcoma","n_c":["C66771"],"i_c":"8894/3","i_c_s":["Angiomyosarcoma"],"term_type":"PT"},{"nm":"Angiomyxoma","n_c":["C3254"],"i_c":"8841/1","i_c_s":["Angiomyxoma"],"term_type":"PT"},{"nm":"Angiosarcoma","n_c":["C3088"],"i_c":"9120/3","i_c_s":["Angiosarcoma"],"term_type":"SY"},{"nm":"Angiotropic lymphoma","n_c":["C4342"],"i_c":"9680/3","i_c_s":["Angiotropic lymphoma"],"term_type":"SY"},{"nm":"Aortic body paraganglioma","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aortic body paraganglioma"],"term_type":"SY"},{"nm":"Aortic body tumor","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aortic body tumor"],"term_type":"PT"},{"nm":"Aorticopulmonary paraganglioma","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aorticopulmonary paraganglioma"],"term_type":"SY"},{"nm":"Apocrine adenocarcinoma","n_c":["C4169"],"i_c":"8401/3","i_c_s":["Apocrine adenocarcinoma"],"term_type":"PT"},{"nm":"Apocrine adenoma","n_c":["C4168"],"i_c":"8401/0","i_c_s":["Apocrine adenoma"],"term_type":"PT"},{"nm":"Apocrine cystadenoma","n_c":["C43342"],"i_c":"8401/0","i_c_s":["Apocrine cystadenoma"],"term_type":"SY"},{"nm":"Apudoma","n_c":["C188218"],"i_c":"8248/1","i_c_s":["Apudoma"],"term_type":"PT"},{"nm":"Argentaffinoma, malignant","n_c":"","i_c":"8241/3","i_c_s":["Argentaffinoma, malignant"],"term_type":"IS"},{"nm":"Argentaffinoma, NOS","n_c":"","i_c":"8240/1","i_c_s":["Argentaffinoma, NOS"],"term_type":"IS"},{"nm":"Arrhenoblastoma, benign","n_c":["C67012"],"i_c":"8630/0","i_c_s":["Arrhenoblastoma, benign"],"term_type":"SY"},{"nm":"Arrhenoblastoma, malignant","n_c":["C67006"],"i_c":"8630/3","i_c_s":["Arrhenoblastoma, malignant"],"term_type":"SY"},{"nm":"Arrhenoblastoma, NOS","n_c":["C39976"],"i_c":"8630/1","i_c_s":["Arrhenoblastoma, NOS"],"term_type":"SY"},{"nm":"Arteriovenous hemangioma","n_c":["C2882"],"i_c":"9123/0","i_c_s":["Arteriovenous hemangioma"],"term_type":"SY"},{"nm":"Askin tumor","n_c":["C7542"],"i_c":"9365/3","i_c_s":["Askin tumor"],"term_type":"PT"},{"nm":"Astroblastoma","n_c":["C4324"],"i_c":"9430/3","i_c_s":["Astroblastoma"],"term_type":"PT"},{"nm":"Astrocytic glioma","n_c":["C6958"],"i_c":"9400/3","i_c_s":["Astrocytic glioma"],"term_type":"SY"},{"nm":"Astrocytoma, anaplastic","n_c":["C9477"],"i_c":"9401/3","i_c_s":["Astrocytoma, anaplastic"],"term_type":"PT"},{"nm":"Astrocytoma, low grade","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Astrocytoma, low grade"],"term_type":"RT"},{"nm":"Astrocytoma, NOS","n_c":["C60781"],"i_c":"9400/3","i_c_s":["Astrocytoma, NOS"],"term_type":"PT"},{"nm":"Astroglioma","n_c":["C6958"],"i_c":"9400/3","i_c_s":["Astroglioma"],"term_type":"IS"},{"nm":"Atypical adenoma","n_c":["C7559"],"i_c":"8140/1","i_c_s":["Atypical adenoma"],"term_type":"PT"},{"nm":"Atypical carcinoid tumor","n_c":["C72074"],"i_c":"8249/3","i_c_s":["Atypical carcinoid tumor"],"term_type":"PT"},{"nm":"Atypical choroid plexus papilloma","n_c":["C53686"],"i_c":"9390/1","i_c_s":["Atypical choroid plexus papilloma"],"term_type":"PT"},{"nm":"Atypical chronic myeloid leukemia, BCR/ABL negative","n_c":["C3519"],"i_c":"9876/3","i_c_s":["Atypical chronic myeloid leukemia, BCR/ABL negative"],"term_type":"PT"},{"nm":"Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative","n_c":["C3519"],"i_c":"9876/3","i_c_s":["Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative"],"term_type":"RT"},{"nm":"Atypical fibrous histiocytoma","n_c":["C4246"],"i_c":"8830/1","i_c_s":["Atypical fibrous histiocytoma"],"term_type":"PT"},{"nm":"Atypical fibroxanthoma","n_c":["C4246"],"i_c":"8830/1","i_c_s":["Atypical fibroxanthoma"],"term_type":"SY"},{"nm":"Atypical follicular adenoma","n_c":["C27729"],"i_c":"8330/1","i_c_s":["Atypical follicular adenoma"],"term_type":"PT"},{"nm":"Atypical hyperplasia/Endometrioid intraepithelial neoplasm","n_c":["C27789"],"i_c":"8380/2","i_c_s":["Atypical hyperplasia/Endometrioid intraepithelial neoplasm"],"term_type":""},{"nm":"Atypical leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Atypical leiomyoma"],"term_type":"SY"},{"nm":"Atypical lipoma","n_c":["C6505"],"i_c":"8850/1","i_c_s":["Atypical lipoma"],"term_type":"PT"},{"nm":"Atypical medullary carcinoma","n_c":["C66719"],"i_c":"8513/3","i_c_s":["Atypical medullary carcinoma"],"term_type":"PT"},{"nm":"Atypical meningioma","n_c":["C4723"],"i_c":"9539/1","i_c_s":["Atypical meningioma"],"term_type":"PT"},{"nm":"Atypical polypoid adenomyoma","n_c":["C6895"],"i_c":"8932/0","i_c_s":["Atypical polypoid adenomyoma"],"term_type":"RT"},{"nm":"Atypical proliferating clear cell tumor","n_c":"","i_c":"8444/1","i_c_s":["Atypical proliferating clear cell tumor"],"term_type":"SY"},{"nm":"Atypical proliferating serous tumor","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Atypical proliferating serous tumor"],"term_type":"SY"},{"nm":"Atypical proliferative endometrioid tumor","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Atypical proliferative endometrioid tumor"],"term_type":"SY"},{"nm":"Atypical proliferative mucinous tumor","n_c":"","i_c":"8472/1","i_c_s":["Atypical proliferative mucinous tumor"],"term_type":"SY"},{"nm":"Atypical proliferative papillary serous tumor","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Atypical proliferative papillary serous tumor"],"term_type":"SY"},{"nm":"Atypical teratoid/rhabdoid tumor","n_c":["C6906"],"i_c":"9508/3","i_c_s":["Atypical teratoid/rhabdoid tumor"],"term_type":"PT"},{"nm":"B cell lymphoma, NOS","n_c":"","i_c":"9591/3","i_c_s":["B cell lymphoma, NOS"],"term_type":"RT"},{"nm":"B lymphoblastic leukemia/lymphoma with hyperdiploidy","n_c":["C80335"],"i_c":"9815/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hyperdiploidy"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)","n_c":["C80338"],"i_c":"9816/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","n_c":["C80341"],"i_c":"9818/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)","n_c":["C80334"],"i_c":"9814/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH","n_c":["C80340"],"i_c":"9817/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1","n_c":["C80331"],"i_c":"9812/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged","n_c":["C80332"],"i_c":"9813/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma, NOS","n_c":["C80326"],"i_c":"9811/3","i_c_s":["B lymphoblastic leukemia/lymphoma, NOS"],"term_type":"PT"},{"nm":"B-ALL","n_c":["C8644"],"i_c":"9826/3","i_c_s":["B-ALL"],"term_type":"IS"},{"nm":"B-cell lymphocytic leukemia/small lymphocytic lymphoma","n_c":["C27911","C3163"],"i_c":"9823/3","i_c_s":["B-cell lymphocytic leukemia/small lymphocytic lymphoma"],"term_type":""},{"nm":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","n_c":["C80291"],"i_c":"9680/3","i_c_s":["B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma"],"term_type":"RT"},{"nm":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma","n_c":["C37869"],"i_c":"9596/3","i_c_s":["B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma"],"term_type":"RT"},{"nm":"Balloon cell melanoma","n_c":["C4227"],"i_c":"8722/3","i_c_s":["Balloon cell melanoma"],"term_type":"PT"},{"nm":"Balloon cell nevus","n_c":["C4226"],"i_c":"8722/0","i_c_s":["Balloon cell nevus"],"term_type":"PT"},{"nm":"BALT lymphoma","n_c":["C5264"],"i_c":"9699/3","i_c_s":["BALT lymphoma"],"term_type":"SY"},{"nm":"Basal cell adenocarcinoma","n_c":["C3678"],"i_c":"8147/3","i_c_s":["Basal cell adenocarcinoma"],"term_type":"PT"},{"nm":"Basal cell adenoma","n_c":["C5950"],"i_c":"8147/0","i_c_s":["Basal cell adenoma"],"term_type":"PT"},{"nm":"Basal cell carcinoma, desmoplastic type","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Basal cell carcinoma, desmoplastic type"],"term_type":"SY"},{"nm":"Basal cell carcinoma, fibroepithelial","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Basal cell carcinoma, fibroepithelial"],"term_type":"PT"},{"nm":"Basal cell carcinoma, micronodular","n_c":["C27541"],"i_c":"8097/3","i_c_s":["Basal cell carcinoma, micronodular"],"term_type":"RT"},{"nm":"Basal cell carcinoma, morpheic","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Basal cell carcinoma, morpheic"],"term_type":"SY"},{"nm":"Basal cell carcinoma, nodular","n_c":["C62282"],"i_c":"8097/3","i_c_s":["Basal cell carcinoma, nodular"],"term_type":"PT"},{"nm":"Basal cell carcinoma, NOS","n_c":["C2921","C156767"],"i_c":"8090/3","i_c_s":["Basal cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Basal cell epithelioma","n_c":["C2921"],"i_c":"8090/3","i_c_s":["Basal cell epithelioma"],"term_type":"SY"},{"nm":"Basal cell tumor","n_c":["C3784"],"i_c":"8090/1","i_c_s":["Basal cell tumor"],"term_type":"PT"},{"nm":"Basaloid carcinoma","n_c":["C4121"],"i_c":"8123/3","i_c_s":["Basaloid carcinoma"],"term_type":"PT"},{"nm":"Basaloid squamous cell carcinoma","n_c":["C54244"],"i_c":"8083/3","i_c_s":["Basaloid squamous cell carcinoma"],"term_type":"PT"},{"nm":"Basophil adenocarcinoma","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Basophil adenocarcinoma"],"term_type":"SY"},{"nm":"Basophil adenoma","n_c":["C2856"],"i_c":"8300/0","i_c_s":["Basophil adenoma"],"term_type":"PT"},{"nm":"Basophil carcinoma","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Basophil carcinoma"],"term_type":"PT"},{"nm":"Basosquamous carcinoma","n_c":["C2922"],"i_c":"8094/3","i_c_s":["Basosquamous carcinoma"],"term_type":"PT"},{"nm":"Bednar tumor","n_c":["C9430"],"i_c":"8833/3","i_c_s":["Bednar tumor"],"term_type":"SY"},{"nm":"Bellini duct carcinoma","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Bellini duct carcinoma"],"term_type":"SY"},{"nm":"Benign cystic nephroma","n_c":["C7504"],"i_c":"8959/0","i_c_s":["Benign cystic nephroma"],"term_type":"PT"},{"nm":"Benign fibrous histiocytoma","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Benign fibrous histiocytoma"],"term_type":"PT"},{"nm":"Beta cell adenoma","n_c":["C67457"],"i_c":"8151/0","i_c_s":["Beta cell adenoma"],"term_type":"SY"},{"nm":"Beta cell tumor, malignant","n_c":["C65186"],"i_c":"8151/3","i_c_s":["Beta cell tumor, malignant"],"term_type":"SY"},{"nm":"Bile duct adenocarcinoma","n_c":["C27813"],"i_c":"8160/3","i_c_s":["Bile duct adenocarcinoma"],"term_type":"SY"},{"nm":"Bile duct adenoma","n_c":["C2942"],"i_c":"8160/0","i_c_s":["Bile duct adenoma"],"term_type":"PT"},{"nm":"Bile duct carcinoma","n_c":["C27814"],"i_c":"8160/3","i_c_s":["Bile duct carcinoma"],"term_type":"SY"},{"nm":"Bile duct cystadenocarcinoma","n_c":["C4130"],"i_c":"8161/3","i_c_s":["Bile duct cystadenocarcinoma"],"term_type":"PT"},{"nm":"Bile duct cystadenoma","n_c":["C4129"],"i_c":"8161/0","i_c_s":["Bile duct cystadenoma"],"term_type":"PT"},{"nm":"Biliary intraepithelial neoplasia, grade 3","n_c":["C67493"],"i_c":"8148/2","i_c_s":["Biliary intraepithelial neoplasia, grade 3"],"term_type":""},{"nm":"Biliary intraepithelial neoplasia, high grade","n_c":["C67493"],"i_c":"8148/2","i_c_s":["Biliary intraepithelial neoplasia, high grade"],"term_type":"RT"},{"nm":"Biliary intraepithelial neoplasia, low grade","n_c":["C172804"],"i_c":"8148/0","i_c_s":["Biliary intraepithelial neoplasia, low grade"],"term_type":"RT"},{"nm":"Biliary papillomatosis","n_c":["C6881"],"i_c":"8264/0","i_c_s":["Biliary papillomatosis"],"term_type":"RT"},{"nm":"Biphenotypic sinonasal sarcoma","n_c":["C164205"],"i_c":"9045/3","i_c_s":["Biphenotypic sinonasal sarcoma"],"term_type":"PT"},{"nm":"Bizarre leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Bizarre leiomyoma"],"term_type":"PT"},{"nm":"Black adenoma","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Black adenoma"],"term_type":"SY"},{"nm":"Blast cell leukemia","n_c":["C9300"],"i_c":"9801/3","i_c_s":["Blast cell leukemia"],"term_type":"SY"},{"nm":"Blastic NK cell lymphoma","n_c":["C7203"],"i_c":"9727/3","i_c_s":["Blastic NK cell lymphoma"],"term_type":"ORT"},{"nm":"Blastic plasmacytoid dendritic cell neoplasm","n_c":["C7203"],"i_c":"9727/3","i_c_s":["Blastic plasmacytoid dendritic cell neoplasm"],"term_type":"RT"},{"nm":"Blastoma, NOS","n_c":["C8997"],"i_c":"8000/3","i_c_s":["Blastoma, NOS"],"term_type":"SY"},{"nm":"Blue nevus, malignant","n_c":["C4240"],"i_c":"8780/3","i_c_s":["Blue nevus, malignant"],"term_type":"PT"},{"nm":"Blue nevus, NOS","n_c":["C3803"],"i_c":"8780/0","i_c_s":["Blue nevus, NOS"],"term_type":"PT"},{"nm":"Botryoid sarcoma","n_c":["C9150"],"i_c":"8910/3","i_c_s":["Botryoid sarcoma"],"term_type":"SY"},{"nm":"Bowen disease","n_c":["C62571"],"i_c":"8081/2","i_c_s":["Bowen disease"],"term_type":"PT"},{"nm":"Brenner tumor, borderline malignancy","n_c":["C9459"],"i_c":"9000/1","i_c_s":["Brenner tumor, borderline malignancy"],"term_type":"PT"},{"nm":"Brenner tumor, malignant","n_c":["C4270"],"i_c":"9000/3","i_c_s":["Brenner tumor, malignant"],"term_type":"PT"},{"nm":"Brenner tumor, NOS","n_c":["C39954"],"i_c":"9000/0","i_c_s":["Brenner tumor, NOS"],"term_type":"PT"},{"nm":"Brenner tumor, proliferating","n_c":["C9459"],"i_c":"9000/1","i_c_s":["Brenner tumor, proliferating"],"term_type":"SY"},{"nm":"Bronchial adenoma, carcinoid","n_c":"","i_c":"8240/3","i_c_s":["Bronchial adenoma, carcinoid"],"term_type":"RT"},{"nm":"Bronchial adenoma, cylindroid","n_c":"","i_c":"8200/3","i_c_s":["Bronchial adenoma, cylindroid"],"term_type":"ORT"},{"nm":"Bronchial adenoma, NOS","n_c":["C3494"],"i_c":"8140/1","i_c_s":["Bronchial adenoma, NOS"],"term_type":"SY"},{"nm":"Bronchial-associated lymphoid tissue lymphoma","n_c":["C5264"],"i_c":"9699/3","i_c_s":["Bronchial-associated lymphoid tissue lymphoma"],"term_type":"SY"},{"nm":"Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous"],"term_type":""},{"nm":"Bronchio-alveolar carcinoma, mucinous","n_c":["C136709","C7268"],"i_c":"8253/3","i_c_s":["Bronchio-alveolar carcinoma, mucinous"],"term_type":""},{"nm":"Bronchiolar adenocarcinoma","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolar adenocarcinoma"],"term_type":"SY"},{"nm":"Bronchiolar carcinoma","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolar carcinoma"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar adenocarcinoma, NOS","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolo-alveolar adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Bronchiolo-alveolar carcinoma, Clara cell","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma, Clara cell"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, goblet cell type","n_c":["C7268"],"i_c":"8253/3","i_c_s":["Bronchiolo-alveolar carcinoma, goblet cell type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, indeterminate type","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, indeterminate type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, non-mucinous","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma, non-mucinous"],"term_type":""},{"nm":"Bronchiolo-alveolar carcinoma, NOS","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolo-alveolar carcinoma, NOS"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma; type II pneumocyte","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma; type II pneumocyte"],"term_type":""},{"nm":"Brooke tumor","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Brooke tumor"],"term_type":"SY"},{"nm":"Brown fat tumor","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Brown fat tumor"],"term_type":"SY"},{"nm":"Burkitt cell leukemia","n_c":["C7400"],"i_c":"9826/3","i_c_s":["Burkitt cell leukemia"],"term_type":"PT"},{"nm":"Burkitt lymphoma, NOS (Includes all variants)","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Burkitt lymphoma, NOS (Includes all variants)"],"term_type":""},{"nm":"Burkitt tumor","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Burkitt tumor"],"term_type":"IS"},{"nm":"Burkitt-like lymphoma","n_c":["C6917"],"i_c":"9687/3","i_c_s":["Burkitt-like lymphoma"],"term_type":"RT"},{"nm":"C cell carcinoma","n_c":["C3879"],"i_c":"8345/3","i_c_s":["C cell carcinoma"],"term_type":"SY"},{"nm":"c-ALL","n_c":["C27797"],"i_c":"9836/3","i_c_s":["c-ALL"],"term_type":"SY"},{"nm":"Calcifying epithelial odontogenic tumor","n_c":["C54301"],"i_c":"9340/0","i_c_s":["Calcifying epithelial odontogenic tumor"],"term_type":"PT"},{"nm":"Calcifying epithelioma of Malherbe","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Calcifying epithelioma of Malherbe"],"term_type":"SY"},{"nm":"Calcifying nested epithelial stromal tumor","n_c":["C96830"],"i_c":"8975/1","i_c_s":["Calcifying nested epithelial stromal tumor"],"term_type":"PT"},{"nm":"Calcifying odontogenic cyst","n_c":["C54319"],"i_c":"9301/0","i_c_s":["Calcifying odontogenic cyst"],"term_type":"PT"},{"nm":"Canalicular adenoma","n_c":["C5979"],"i_c":"8149/0","i_c_s":["Canalicular adenoma"],"term_type":"PT"},{"nm":"Cancer","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Cancer"],"term_type":"SY"},{"nm":"Capillary hemangioma","n_c":["C7457"],"i_c":"9131/0","i_c_s":["Capillary hemangioma"],"term_type":"PT"},{"nm":"Capillary lymphangioma","n_c":["C8965"],"i_c":"9171/0","i_c_s":["Capillary lymphangioma"],"term_type":"PT"},{"nm":"Carcinofibroma","n_c":"","i_c":"8934/3","i_c_s":["Carcinofibroma"],"term_type":"PT"},{"nm":"Carcinoid tumor of uncertain malignant potential","n_c":["C65196"],"i_c":"8240/1","i_c_s":["Carcinoid tumor of uncertain malignant potential"],"term_type":"PT"},{"nm":"Carcinoid tumor, argentaffin, malignant","n_c":"","i_c":"8241/3","i_c_s":["Carcinoid tumor, argentaffin, malignant"],"term_type":"SY"},{"nm":"Carcinoid tumor, argentaffin, NOS","n_c":"","i_c":"8240/1","i_c_s":["Carcinoid tumor, argentaffin, NOS"],"term_type":"RT"},{"nm":"Carcinoid tumor, NOS","n_c":["C2915"],"i_c":"8240/3","i_c_s":["Carcinoid tumor, NOS"],"term_type":"PT"},{"nm":"Carcinoid tumor, NOS, of appendix","n_c":"","i_c":"8240/1","i_c_s":["Carcinoid tumor, NOS, of appendix"],"term_type":"PT"},{"nm":"Carcinoid, NOS","n_c":["C2915"],"i_c":"8240/3","i_c_s":["Carcinoid, NOS"],"term_type":"SY"},{"nm":"Carcinoid, NOS, of appendix","n_c":"","i_c":"8240/1","i_c_s":["Carcinoid, NOS, of appendix"],"term_type":"SY"},{"nm":"Carcinoma in a polyp, NOS","n_c":["C7682"],"i_c":"8210/3","i_c_s":["Carcinoma in a polyp, NOS"],"term_type":"SY"},{"nm":"Carcinoma in adenomatous polyp","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Carcinoma in adenomatous polyp"],"term_type":"SY"},{"nm":"Carcinoma in pleomorphic adenoma","n_c":["C4397"],"i_c":"8941/3","i_c_s":["Carcinoma in pleomorphic adenoma"],"term_type":"PT"},{"nm":"Carcinoma in situ in a polyp, NOS","n_c":["C7681"],"i_c":"8210/2","i_c_s":["Carcinoma in situ in a polyp, NOS"],"term_type":"SY"},{"nm":"Carcinoma in situ in adenomatous polyp","n_c":["C7678"],"i_c":"8210/2","i_c_s":["Carcinoma in situ in adenomatous polyp"],"term_type":"SY"},{"nm":"Carcinoma in situ, NOS","n_c":["C2917"],"i_c":"8010/2","i_c_s":["Carcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Carcinoma showing thymus-like differentiation","n_c":["C46106"],"i_c":"8589/3","i_c_s":["Carcinoma showing thymus-like differentiation"],"term_type":"SY"},{"nm":"Carcinoma showing thymus-like element","n_c":["C46106"],"i_c":"8589/3","i_c_s":["Carcinoma showing thymus-like element"],"term_type":"PT"},{"nm":"Carcinoma simplex","n_c":["C65195"],"i_c":"8231/3","i_c_s":["Carcinoma simplex"],"term_type":"PT"},{"nm":"Carcinoma with apocrine metaplasia","n_c":["C4202"],"i_c":"8573/3","i_c_s":["Carcinoma with apocrine metaplasia"],"term_type":"SY"},{"nm":"Carcinoma with chondroid differentiation","n_c":["C47847"],"i_c":"8571/3","i_c_s":["Carcinoma with chondroid differentiation"],"term_type":""},{"nm":"Carcinoma with neuroendocrine differentiation","n_c":["C66745"],"i_c":"8574/3","i_c_s":["Carcinoma with neuroendocrine differentiation"],"term_type":"SY"},{"nm":"Carcinoma with osseous differentiation","n_c":["C47848"],"i_c":"8571/3","i_c_s":["Carcinoma with osseous differentiation"],"term_type":""},{"nm":"Carcinoma with osteoclast-like giant cells","n_c":["C63622"],"i_c":"8035/3","i_c_s":["Carcinoma with osteoclast-like giant cells"],"term_type":"PT"},{"nm":"Carcinoma with other types mesenchymal differentiation","n_c":"","i_c":"8575/3","i_c_s":["Carcinoma with other types mesenchymal differentiation"],"term_type":""},{"nm":"Carcinoma with productive fibrosis","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Carcinoma with productive fibrosis"],"term_type":"SY"},{"nm":"Carcinoma, anaplastic, NOS","n_c":["C3692"],"i_c":"8021/3","i_c_s":["Carcinoma, anaplastic, NOS"],"term_type":"PT"},{"nm":"Carcinoma, diffuse type","n_c":["C4127"],"i_c":"8145/3","i_c_s":["Carcinoma, diffuse type"],"term_type":"PT"},{"nm":"Carcinoma, intestinal type","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Carcinoma, intestinal type"],"term_type":"SY"},{"nm":"Carcinoma, metastatic, NOS","n_c":["C3482"],"i_c":"8010/6","i_c_s":["Carcinoma, metastatic, NOS"],"term_type":"PT"},{"nm":"Carcinoma, NOS","n_c":["C2916"],"i_c":"8010/3","i_c_s":["Carcinoma, NOS"],"term_type":"PT"},{"nm":"Carcinoma, undifferentiated, NOS","n_c":["C3692"],"i_c":"8020/3","i_c_s":["Carcinoma, undifferentiated, NOS"],"term_type":"PT"},{"nm":"Carcinomatosis","n_c":["C3693"],"i_c":"8010/9","i_c_s":["Carcinomatosis"],"term_type":"PT"},{"nm":"Carcinosarcoma, embryonal","n_c":["C8975"],"i_c":"8981/3","i_c_s":["Carcinosarcoma, embryonal"],"term_type":"PT"},{"nm":"Carcinosarcoma, NOS","n_c":["C34448"],"i_c":"8980/3","i_c_s":["Carcinosarcoma, NOS"],"term_type":"PT"},{"nm":"Carotid body paraganglioma","n_c":["C2932"],"i_c":"8692/1","i_c_s":["Carotid body paraganglioma"],"term_type":"SY"},{"nm":"Carotid body tumor","n_c":["C2932"],"i_c":"8692/1","i_c_s":["Carotid body tumor"],"term_type":"PT"},{"nm":"Cartilaginous exostosis","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Cartilaginous exostosis"],"term_type":"SY"},{"nm":"CASTLE","n_c":["C46106"],"i_c":"8589/3","i_c_s":["CASTLE"],"term_type":"SY"},{"nm":"Cavernous hemangioma","n_c":["C3086"],"i_c":"9121/0","i_c_s":["Cavernous hemangioma"],"term_type":"PT"},{"nm":"Cavernous lymphangioma","n_c":["C53316"],"i_c":"9172/0","i_c_s":["Cavernous lymphangioma"],"term_type":"PT"},{"nm":"Cellular angiofibroma","n_c":["C27257"],"i_c":"9160/0","i_c_s":["Cellular angiofibroma"],"term_type":"RT"},{"nm":"Cellular blue nevus","n_c":["C4241"],"i_c":"8790/0","i_c_s":["Cellular blue nevus"],"term_type":"PT"},{"nm":"Cellular ependymoma","n_c":["C4713"],"i_c":"9391/3","i_c_s":["Cellular ependymoma"],"term_type":"RT"},{"nm":"Cellular fibroma","n_c":["C6892"],"i_c":"8810/1","i_c_s":["Cellular fibroma"],"term_type":"PT"},{"nm":"Cellular leiomyoma","n_c":["C4256"],"i_c":"8892/0","i_c_s":["Cellular leiomyoma"],"term_type":"PT"},{"nm":"Cellular schwannoma","n_c":["C4724"],"i_c":"9560/0","i_c_s":["Cellular schwannoma"],"term_type":"RT"},{"nm":"Cementifying fibroma","n_c":["C8422"],"i_c":"9274/0","i_c_s":["Cementifying fibroma"],"term_type":"PT"},{"nm":"Cemento-ossifying fibroma","n_c":["C8422"],"i_c":"9274/0","i_c_s":["Cemento-ossifying fibroma"],"term_type":"RT"},{"nm":"Cementoblastoma, benign","n_c":["C4308"],"i_c":"9273/0","i_c_s":["Cementoblastoma, benign"],"term_type":"PT"},{"nm":"Cementoma, NOS","n_c":["C173927"],"i_c":"9272/0","i_c_s":["Cementoma, NOS"],"term_type":"PT"},{"nm":"Central neuroblastoma","n_c":["C3270"],"i_c":"9500/3","i_c_s":["Central neuroblastoma"],"term_type":"SY"},{"nm":"Central neurocytoma","n_c":["C3791"],"i_c":"9506/1","i_c_s":["Central neurocytoma"],"term_type":"PT"},{"nm":"Central odontogenic fibroma","n_c":["C202077"],"i_c":"9321/0","i_c_s":["Central odontogenic fibroma"],"term_type":"PT"},{"nm":"Central osteosarcoma","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Central osteosarcoma"],"term_type":"PT"},{"nm":"Central primitive neuroectodermal tumor, NOS","n_c":["C5398"],"i_c":"9473/3","i_c_s":["Central primitive neuroectodermal tumor, NOS"],"term_type":"RT"},{"nm":"Cerebellar liponeurocytoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Cerebellar liponeurocytoma"],"term_type":"RT"},{"nm":"Cerebellar sarcoma, NOS","n_c":["C66803"],"i_c":"9480/3","i_c_s":["Cerebellar sarcoma, NOS"],"term_type":"OP"},{"nm":"Ceruminous adenocarcinoma","n_c":["C4176"],"i_c":"8420/3","i_c_s":["Ceruminous adenocarcinoma"],"term_type":"PT"},{"nm":"Ceruminous adenoma","n_c":["C6088"],"i_c":"8420/0","i_c_s":["Ceruminous adenoma"],"term_type":"PT"},{"nm":"Ceruminous carcinoma","n_c":["C4176"],"i_c":"8420/3","i_c_s":["Ceruminous carcinoma"],"term_type":"SY"},{"nm":"Cervical intraepithelial neoplasia, grade III","n_c":["C4000"],"i_c":"8077/2","i_c_s":["Cervical intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Cervical intraepithelial neoplasia, low grade","n_c":["C4630"],"i_c":"8077/0","i_c_s":["Cervical intraepithelial neoplasia, low grade"],"term_type":"RT"},{"nm":"Chemodectoma","n_c":["C2932"],"i_c":"8693/1","i_c_s":["Chemodectoma"],"term_type":"RT"},{"nm":"Chief cell adenoma","n_c":["C4154"],"i_c":"8321/0","i_c_s":["Chief cell adenoma"],"term_type":"PT"},{"nm":"Chloroma","n_c":["C3520"],"i_c":"9930/3","i_c_s":["Chloroma"],"term_type":"SY"},{"nm":"Cholangiocarcinoma","n_c":["C4436"],"i_c":"8160/3","i_c_s":["Cholangiocarcinoma"],"term_type":"PT"},{"nm":"Cholangioma","n_c":["C2942"],"i_c":"8160/0","i_c_s":["Cholangioma"],"term_type":"SY"},{"nm":"Chondroblastic osteosarcoma","n_c":["C4021"],"i_c":"9181/3","i_c_s":["Chondroblastic osteosarcoma"],"term_type":"PT"},{"nm":"Chondroblastoma, malignant","n_c":["C66799"],"i_c":"9230/3","i_c_s":["Chondroblastoma, malignant"],"term_type":"PT"},{"nm":"Chondroblastoma, NOS","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Chondroblastoma, NOS"],"term_type":"PT"},{"nm":"Chondroid chordoma","n_c":["C6902"],"i_c":"9371/3","i_c_s":["Chondroid chordoma"],"term_type":"PT"},{"nm":"Chondroid lipoma","n_c":["C6503"],"i_c":"8862/0","i_c_s":["Chondroid lipoma"],"term_type":"PT"},{"nm":"Chondroid syringoma","n_c":["C4474"],"i_c":"8940/0","i_c_s":["Chondroid syringoma"],"term_type":"RT"},{"nm":"Chondroma, NOS","n_c":["C53459"],"i_c":"9220/0","i_c_s":["Chondroma, NOS"],"term_type":"PT"},{"nm":"Chondromatosis, NOS","n_c":["C35259"],"i_c":"9220/1","i_c_s":["Chondromatosis, NOS"],"term_type":"PT"},{"nm":"Chondromatous giant cell tumor","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Chondromatous giant cell tumor"],"term_type":"SY"},{"nm":"Chondromyxoid fibroma","n_c":["C3830"],"i_c":"9241/0","i_c_s":["Chondromyxoid fibroma"],"term_type":"PT"},{"nm":"Chondrosarcoma grade 2/3","n_c":"","i_c":"9220/3","i_c_s":["Chondrosarcoma grade 2/3"],"term_type":""},{"nm":"Chondrosarcoma, NOS","n_c":["C2946"],"i_c":"9220/3","i_c_s":["Chondrosarcoma, NOS"],"term_type":"PT"},{"nm":"Chordoid glioma","n_c":["C5592"],"i_c":"9444/1","i_c_s":["Chordoid glioma"],"term_type":"PT"},{"nm":"Chordoid glioma of third ventricle","n_c":["C5592"],"i_c":"9444/1","i_c_s":["Chordoid glioma of third ventricle"],"term_type":"RT"},{"nm":"Chordoid meningioma","n_c":["C6908"],"i_c":"9538/1","i_c_s":["Chordoid meningioma"],"term_type":"RT"},{"nm":"Chordoma, NOS","n_c":["C2947"],"i_c":"9370/3","i_c_s":["Chordoma, NOS"],"term_type":"PT"},{"nm":"Chorioadenoma","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Chorioadenoma"],"term_type":"SY"},{"nm":"Chorioadenoma destruens","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Chorioadenoma destruens"],"term_type":"SY"},{"nm":"Chorioangioma","n_c":["C4868"],"i_c":"9120/0","i_c_s":["Chorioangioma"],"term_type":"SY"},{"nm":"Choriocarcinoma combined with embryonal carcinoma","n_c":["C66777"],"i_c":"9101/3","i_c_s":["Choriocarcinoma combined with embryonal carcinoma"],"term_type":"SY"},{"nm":"Choriocarcinoma combined with other germ cell elements","n_c":["C66777"],"i_c":"9101/3","i_c_s":["Choriocarcinoma combined with other germ cell elements"],"term_type":"PT"},{"nm":"Choriocarcinoma combined with teratorna","n_c":"","i_c":"9101/3","i_c_s":["Choriocarcinoma combined with teratorna"],"term_type":""},{"nm":"Choriocarcinoma, NOS","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Choriocarcinoma, NOS"],"term_type":"PT"},{"nm":"Chorioepithelioma","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Chorioepithelioma"],"term_type":"SY"},{"nm":"Chorionepithelioma","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Chorionepithelioma"],"term_type":"SY"},{"nm":"Choroid plexus carcinoma","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus carcinoma"],"term_type":"PT"},{"nm":"Choroid plexus papilloma, anaplastic","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus papilloma, anaplastic"],"term_type":"SY"},{"nm":"Choroid plexus papilloma, malignant","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus papilloma, malignant"],"term_type":"SY"},{"nm":"Choroid plexus papilloma, NOS","n_c":["C3698"],"i_c":"9390/0","i_c_s":["Choroid plexus papilloma, NOS"],"term_type":"PT"},{"nm":"Chromaffin paraganglioma","n_c":["C3326"],"i_c":"8700/0","i_c_s":["Chromaffin paraganglioma"],"term_type":"SY"},{"nm":"Chromaffin tumor","n_c":["C4216"],"i_c":"8700/0","i_c_s":["Chromaffin tumor"],"term_type":"SY"},{"nm":"Chromaffinoma","n_c":["C4216"],"i_c":"8700/0","i_c_s":["Chromaffinoma"],"term_type":"SY"},{"nm":"Chromophobe adenocarcinoma","n_c":["C4146"],"i_c":"8270/3","i_c_s":["Chromophobe adenocarcinoma"],"term_type":"SY"},{"nm":"Chromophobe adenoma","n_c":["C2857"],"i_c":"8270/0","i_c_s":["Chromophobe adenoma"],"term_type":"PT"},{"nm":"Chromophobe carcinoma","n_c":["C4146"],"i_c":"8270/3","i_c_s":["Chromophobe carcinoma"],"term_type":"PT"},{"nm":"Chromophobe cell renal carcinoma","n_c":["C4146"],"i_c":"8317/3","i_c_s":["Chromophobe cell renal carcinoma"],"term_type":"SY"},{"nm":"Chronic eosinophilic leukemia, NOS","n_c":["C4563"],"i_c":"9964/3","i_c_s":["Chronic eosinophilic leukemia, NOS"],"term_type":"PT"},{"nm":"Chronic erythremia","n_c":"","i_c":"9950/3","i_c_s":["Chronic erythremia"],"term_type":"IS"},{"nm":"Chronic granulocytic leukemia, BCR/ABL","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic granulocytic leukemia, BCR/ABL"],"term_type":"SY"},{"nm":"Chronic granulocytic leukemia, NOS","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic granulocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive"],"term_type":"SY"},{"nm":"Chronic granulocytic leukemia, t(9;22)(q34;q11)","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic granulocytic leukemia, t(9;22)(q34;q11)"],"term_type":"SY"},{"nm":"Chronic idiopathic myelofibrosis","n_c":["C188314"],"i_c":"9961/3","i_c_s":["Chronic idiopathic myelofibrosis"],"term_type":"SY"},{"nm":"Chronic leukemia, NOS","n_c":["C3483"],"i_c":"9800/3","i_c_s":["Chronic leukemia, NOS"],"term_type":"ORT"},{"nm":"Chronic lymphatic leukemia","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphatic leukemia"],"term_type":"SY"},{"nm":"Chronic lymphocytic leukemia","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphocytic leukemia"],"term_type":"SY"},{"nm":"Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)"],"term_type":""},{"nm":"Chronic lymphoid leukemia","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphoid leukemia"],"term_type":"SY"},{"nm":"Chronic lymphoproliferative disorder of NK cells","n_c":["C39591"],"i_c":"9831/3","i_c_s":["Chronic lymphoproliferative disorder of NK cells"],"term_type":"RT"},{"nm":"Chronic monocytic leukemia","n_c":["C34774"],"i_c":"9860/3","i_c_s":["Chronic monocytic leukemia"],"term_type":"ORT"},{"nm":"Chronic myelocytic leukemia, NOS","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic myelocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Chronic myelogenous leukemia, BCR-ABL positive","n_c":["C3174"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, BCR-ABL positive"],"term_type":""},{"nm":"Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive"],"term_type":""},{"nm":"Chronic myelogenous leukemia, t(9;22)(q34;q11)","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, t(9;22)(q34;q11)"],"term_type":""},{"nm":"Chronic myeloid leukemia, NOS","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic myeloid leukemia, NOS"],"term_type":"PT"},{"nm":"Chronic myelomonocytic leukemia in transformation","n_c":["C3178"],"i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia in transformation"],"term_type":"IS"},{"nm":"Chronic myelomonocytic leukemia, NOS","n_c":["C3178"],"i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, NOS"],"term_type":"PT"},{"nm":"Chronic myelomonocytic leukemia, Type 1","n_c":"","i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, Type 1"],"term_type":""},{"nm":"Chronic myelomonocytic leukemia, Type II","n_c":"","i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, Type II"],"term_type":"RT"},{"nm":"Chronic myeloproliferative disease, NOS","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Chronic myeloproliferative disease, NOS"],"term_type":"SY"},{"nm":"Chronic myeloproliferative disorder","n_c":["C4345"],"i_c":"9960/3","i_c_s":["Chronic myeloproliferative disorder"],"term_type":"SY"},{"nm":"Chronic neutrophilic leukemia","n_c":["C3179"],"i_c":"9963/3","i_c_s":["Chronic neutrophilic leukemia"],"term_type":"PT"},{"nm":"CIN III with severe dysplasia","n_c":["C4000"],"i_c":"8077/2","i_c_s":["CIN III with severe dysplasia"],"term_type":"SY"},{"nm":"Cin III, NOS","n_c":["C4000"],"i_c":"8077/2","i_c_s":["Cin III, NOS"],"term_type":""},{"nm":"Circumscribed arachnoidal cerebellar sarcoma","n_c":["C4956"],"i_c":"9471/3","i_c_s":["Circumscribed arachnoidal cerebellar sarcoma"],"term_type":"IS"},{"nm":"Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis","n_c":["C9283"],"i_c":"9654/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, lymphocyte depletion, NOS","n_c":["C9283"],"i_c":"9653/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte depletion, NOS"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, lymphocyte depletion, reticular","n_c":"","i_c":"9655/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte depletion, reticular"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, lymphocyte-rich","n_c":["C6913"],"i_c":"9651/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte-rich"],"term_type":""},{"nm":"Classical Hodgkin lymphoma, mixed cellularity, NOS","n_c":["C3517"],"i_c":"9652/3","i_c_s":["Classical Hodgkin lymphoma, mixed cellularity, NOS"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, cellular phase","n_c":["C67171"],"i_c":"9664/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, cellular phase"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, grade 1","n_c":["C7165"],"i_c":"9665/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, grade 1"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, grade 2","n_c":["C7166"],"i_c":"9667/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, grade 2"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, NOS","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, NOS"],"term_type":"SY"},{"nm":"Clear cell (glycogen-rich) urothelial carcinoma","n_c":["C191683"],"i_c":"8120/3","i_c_s":["Clear cell (glycogen-rich) urothelial carcinoma"],"term_type":""},{"nm":"Clear cell adenocarcinofibroma","n_c":["C40079"],"i_c":"8313/3","i_c_s":["Clear cell adenocarcinofibroma"],"term_type":"PT"},{"nm":"Clear cell adenocarcinoma, mesonephroid","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell adenocarcinoma, mesonephroid"],"term_type":"RT"},{"nm":"Clear cell adenocarcinoma, NOS","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Clear cell adenofibroma","n_c":["C8987"],"i_c":"8313/0","i_c_s":["Clear cell adenofibroma"],"term_type":"PT"},{"nm":"Clear cell adenofibroma of borderline malignancy","n_c":["C40081"],"i_c":"8313/1","i_c_s":["Clear cell adenofibroma of borderline malignancy"],"term_type":"PT"},{"nm":"Clear cell adenoma","n_c":["C4151"],"i_c":"8310/0","i_c_s":["Clear cell adenoma"],"term_type":"PT"},{"nm":"Clear cell carcinoma","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell carcinoma"],"term_type":"SY"},{"nm":"Clear cell chondrosarcoma","n_c":["C6475"],"i_c":"9242/3","i_c_s":["Clear cell chondrosarcoma"],"term_type":"PT"},{"nm":"Clear cell cystadenocarcinofibroma","n_c":"","i_c":"8313/3","i_c_s":["Clear cell cystadenocarcinofibroma"],"term_type":"SY"},{"nm":"Clear cell cystadenofibroma","n_c":["C8988"],"i_c":"8313/0","i_c_s":["Clear cell cystadenofibroma"],"term_type":"SY"},{"nm":"Clear cell cystadenofibroma of borderline malignancy","n_c":"","i_c":"8313/1","i_c_s":["Clear cell cystadenofibroma of borderline malignancy"],"term_type":"SY"},{"nm":"Clear cell cystadenoma","n_c":["C65203"],"i_c":"8443/0","i_c_s":["Clear cell cystadenoma"],"term_type":"PT"},{"nm":"Clear cell cystic tumor of borderline malignancy","n_c":["C40080"],"i_c":"8444/1","i_c_s":["Clear cell cystic tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Clear cell ependymoma","n_c":["C4714"],"i_c":"9391/3","i_c_s":["Clear cell ependymoma"],"term_type":"RT"},{"nm":"Clear cell hidradenoma","n_c":["C7567"],"i_c":"8402/0","i_c_s":["Clear cell hidradenoma"],"term_type":"RT"},{"nm":"Clear cell meningioma","n_c":["C4722"],"i_c":"9538/1","i_c_s":["Clear cell meningioma"],"term_type":"PT"},{"nm":"Clear cell odontogenic carcinoma","n_c":["C54300"],"i_c":"9341/3","i_c_s":["Clear cell odontogenic carcinoma"],"term_type":""},{"nm":"Clear cell odontogenic tumor","n_c":["C54300"],"i_c":"9341/1","i_c_s":["Clear cell odontogenic tumor"],"term_type":"PT"},{"nm":"Clear cell sarcoma of kidney","n_c":["C4264"],"i_c":"8964/3","i_c_s":["Clear cell sarcoma of kidney"],"term_type":"PT"},{"nm":"Clear cell sarcoma, NOS","n_c":["C3745"],"i_c":"9044/3","i_c_s":["Clear cell sarcoma, NOS"],"term_type":"PT"},{"nm":"Clear cell sarcoma, of tendons and aponeuroses","n_c":"","i_c":"9044/3","i_c_s":["Clear cell sarcoma, of tendons and aponeuroses"],"term_type":"RT"},{"nm":"Clear cell tumor, NOS","n_c":["C66752"],"i_c":"8005/0","i_c_s":["Clear cell tumor, NOS"],"term_type":"PT"},{"nm":"Cloacogenic carcinoma","n_c":["C8255"],"i_c":"8124/3","i_c_s":["Cloacogenic carcinoma"],"term_type":"PT"},{"nm":"CNS Embryonal tumor with rhabdoid features","n_c":["C129501"],"i_c":"9508/3","i_c_s":["CNS Embryonal tumor with rhabdoid features"],"term_type":""},{"nm":"Codman tumor","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Codman tumor"],"term_type":"SY"},{"nm":"Collecting duct carcinoma","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Collecting duct carcinoma"],"term_type":"PT"},{"nm":"Colloid adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Colloid adenocarcinoma"],"term_type":"SY"},{"nm":"Colloid adenoma","n_c":["C4161"],"i_c":"8334/0","i_c_s":["Colloid adenoma"],"term_type":"SY"},{"nm":"Colloid carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Colloid carcinoma"],"term_type":"SY"},{"nm":"Columnar cell papilloma","n_c":"","i_c":"8121/1","i_c_s":["Columnar cell papilloma"],"term_type":"RT"},{"nm":"Combined carcinoid and adenocarcinoma","n_c":["C4139"],"i_c":"8244/3","i_c_s":["Combined carcinoid and adenocarcinoma"],"term_type":"SY"},{"nm":"Combined hepatocellular carcinoma and cholangiocarcinoma","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Combined hepatocellular carcinoma and cholangiocarcinoma"],"term_type":"PT"},{"nm":"Combined large cell neuroendocrine carcinoma","n_c":["C7267"],"i_c":"8013/3","i_c_s":["Combined large cell neuroendocrine carcinoma"],"term_type":""},{"nm":"Combined small cell carcinoma","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Combined small cell carcinoma"],"term_type":"PT"},{"nm":"Combined small cell-adenocarcinoma","n_c":["C9379"],"i_c":"8045/3","i_c_s":["Combined small cell-adenocarcinoma"],"term_type":"RT"},{"nm":"Combined small cell-large carcinoma","n_c":"","i_c":"8045/3","i_c_s":["Combined small cell-large carcinoma"],"term_type":""},{"nm":"Combined small cell-squamous cell carcinoma","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Combined small cell-squamous cell carcinoma"],"term_type":"RT"},{"nm":"Combined/mixed carcinoid and adenocarcinoma","n_c":["C4139"],"i_c":"8244/3","i_c_s":["Combined/mixed carcinoid and adenocarcinoma"],"term_type":"SY"},{"nm":"Comedocarcinoma, noninfiltrating","n_c":["C7949"],"i_c":"8501/2","i_c_s":["Comedocarcinoma, noninfiltrating"],"term_type":"PT"},{"nm":"Comedocarcinoma, NOS","n_c":["C4188"],"i_c":"8501/3","i_c_s":["Comedocarcinoma, NOS"],"term_type":"PT"},{"nm":"Common ALL","n_c":["C27797"],"i_c":"9836/3","i_c_s":["Common ALL"],"term_type":"SY"},{"nm":"Common precursor B ALL","n_c":["C27797"],"i_c":"9836/3","i_c_s":["Common precursor B ALL"],"term_type":"SY"},{"nm":"Complete hydatidiform mole","n_c":["C4871"],"i_c":"9100/0","i_c_s":["Complete hydatidiform mole"],"term_type":"SY"},{"nm":"Complex odontoma","n_c":["C4309"],"i_c":"9282/0","i_c_s":["Complex odontoma"],"term_type":"PT"},{"nm":"Composite carcinoid","n_c":["C201135"],"i_c":"8244/3","i_c_s":["Composite carcinoid"],"term_type":"SY"},{"nm":"Composite Hodgkin and non-Hodgkin lymphoma","n_c":"","i_c":"9596/3","i_c_s":["Composite Hodgkin and non-Hodgkin lymphoma"],"term_type":"PT"},{"nm":"Compound nevus","n_c":["C3901"],"i_c":"8760/0","i_c_s":["Compound nevus"],"term_type":"PT"},{"nm":"Compound odontoma","n_c":["C3711"],"i_c":"9281/0","i_c_s":["Compound odontoma"],"term_type":"PT"},{"nm":"Condylomatous carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Condylomatous carcinoma"],"term_type":"SY"},{"nm":"Congenital fibrosarcoma","n_c":["C4244"],"i_c":"8814/3","i_c_s":["Congenital fibrosarcoma"],"term_type":"SY"},{"nm":"Congenital generalized fibromatosis","n_c":"","i_c":"8824/1","i_c_s":["Congenital generalized fibromatosis"],"term_type":"RT"},{"nm":"Congenital peribronchial myofibroblastic tumor","n_c":["C142823"],"i_c":"8827/1","i_c_s":["Congenital peribronchial myofibroblastic tumor"],"term_type":"SY"},{"nm":"Conventional central osteosarcoma","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Conventional central osteosarcoma"],"term_type":"SY"},{"nm":"Cortical T ALL","n_c":["C27820"],"i_c":"9837/3","i_c_s":["Cortical T ALL"],"term_type":"SY"},{"nm":"CPNET","n_c":["C5398"],"i_c":"9473/3","i_c_s":["CPNET"],"term_type":"SY"},{"nm":"Craniopharyngioma","n_c":["C2964"],"i_c":"9350/1","i_c_s":["Craniopharyngioma"],"term_type":"PT"},{"nm":"Craniopharyngioma, adamantinomatous","n_c":["C4726"],"i_c":"9351/1","i_c_s":["Craniopharyngioma, adamantinomatous"],"term_type":"PT"},{"nm":"Craniopharyngioma, papillary","n_c":["C4725"],"i_c":"9352/1","i_c_s":["Craniopharyngioma, papillary"],"term_type":"PT"},{"nm":"Cribriform carcinoma in situ","n_c":["C162973"],"i_c":"8201/2","i_c_s":["Cribriform carcinoma in situ"],"term_type":"PT"},{"nm":"Cribriform carcinoma, NOS","n_c":["C3680"],"i_c":"8201/3","i_c_s":["Cribriform carcinoma, NOS"],"term_type":"PT"},{"nm":"Cribriform comedo-type carcinoma","n_c":"","i_c":"8201/3","i_c_s":["Cribriform comedo-type carcinoma"],"term_type":"RT"},{"nm":"Cutaneous histiocytoma, NOS","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Cutaneous histiocytoma, NOS"],"term_type":"SY"},{"nm":"Cutaneous lymphoma, NOS","n_c":["C7162"],"i_c":"9709/3","i_c_s":["Cutaneous lymphoma, NOS"],"term_type":"IS"},{"nm":"Cutaneous mastocytosis","n_c":["C7137"],"i_c":"9740/1","i_c_s":["Cutaneous mastocytosis"],"term_type":"RT"},{"nm":"Cutaneous T-cell lymphoma, NOS","n_c":["C3467"],"i_c":"9709/3","i_c_s":["Cutaneous T-cell lymphoma, NOS"],"term_type":"PT"},{"nm":"Cylindrical cell carcinoma","n_c":["C54287"],"i_c":"8121/3","i_c_s":["Cylindrical cell carcinoma"],"term_type":"RT"},{"nm":"Cylindrical cell papilloma","n_c":"","i_c":"8121/1","i_c_s":["Cylindrical cell papilloma"],"term_type":"RT"},{"nm":"Cylindroma of skin","n_c":["C27094"],"i_c":"8200/0","i_c_s":["Cylindroma of skin"],"term_type":"RT"},{"nm":"Cylindroma, NOS","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Cylindroma, NOS"],"term_type":"SY"},{"nm":"Cyst-associated renal cell carcinoma","n_c":["C157718"],"i_c":"8316/3","i_c_s":["Cyst-associated renal cell carcinoma"],"term_type":"PT"},{"nm":"Cystadenocarcinoma, NOS","n_c":["C2971"],"i_c":"8440/3","i_c_s":["Cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Cystadenofibroma, NOS","n_c":["C8985"],"i_c":"9013/0","i_c_s":["Cystadenofibroma, NOS"],"term_type":"RT"},{"nm":"Cystadenoma, NOS","n_c":["C2972"],"i_c":"8440/0","i_c_s":["Cystadenoma, NOS"],"term_type":"PT"},{"nm":"Cystic astrocytoma","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Cystic astrocytoma"],"term_type":"ORT"},{"nm":"Cystic hygroma","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Cystic hygroma"],"term_type":"SY"},{"nm":"Cystic hypersecretory carcinoma","n_c":["C4189"],"i_c":"8508/3","i_c_s":["Cystic hypersecretory carcinoma"],"term_type":"PT"},{"nm":"Cystic lymphangioma","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Cystic lymphangioma"],"term_type":"PT"},{"nm":"Cystic mesothelioma, benign","n_c":"","i_c":"9055/0","i_c_s":["Cystic mesothelioma, benign"],"term_type":"SY"},{"nm":"Cystic mesothelioma, NOS","n_c":["C3765"],"i_c":"9055/1","i_c_s":["Cystic mesothelioma, NOS"],"term_type":"PT"},{"nm":"Cystic partially differentiated nephroblastoma","n_c":["C6897"],"i_c":"8959/1","i_c_s":["Cystic partially differentiated nephroblastoma"],"term_type":"PT"},{"nm":"Cystic teratoma, NOS","n_c":["C9014"],"i_c":"9080/0","i_c_s":["Cystic teratoma, NOS"],"term_type":"SY"},{"nm":"Cystic tumor of atrio-ventricular node","n_c":["C45754"],"i_c":"8454/0","i_c_s":["Cystic tumor of atrio-ventricular node"],"term_type":"PT"},{"nm":"Cystoma, NOS","n_c":["C2972"],"i_c":"8440/0","i_c_s":["Cystoma, NOS"],"term_type":"SY"},{"nm":"Cystosarcoma phyllodes, benign","n_c":["C4274"],"i_c":"9020/0","i_c_s":["Cystosarcoma phyllodes, benign"],"term_type":"IS"},{"nm":"Cystosarcoma phyllodes, malignant","n_c":["C4275"],"i_c":"9020/3","i_c_s":["Cystosarcoma phyllodes, malignant"],"term_type":"SY"},{"nm":"Cystosarcoma phyllodes, NOS","n_c":["C2977"],"i_c":"9020/1","i_c_s":["Cystosarcoma phyllodes, NOS"],"term_type":"SY"},{"nm":"Dabska tumor","n_c":["C7526"],"i_c":"9135/1","i_c_s":["Dabska tumor"],"term_type":"SY"},{"nm":"DCIS, comedo type","n_c":["C176005"],"i_c":"8501/2","i_c_s":["DCIS, comedo type"],"term_type":"SY"},{"nm":"DCIS, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["DCIS, NOS"],"term_type":"SY"},{"nm":"DCIS, papillary","n_c":["C4190"],"i_c":"8503/2","i_c_s":["DCIS, papillary"],"term_type":"SY"},{"nm":"Dedifferentiated chondrosarcoma","n_c":["C6476"],"i_c":"9243/3","i_c_s":["Dedifferentiated chondrosarcoma"],"term_type":"PT"},{"nm":"Dedifferentiated chordoma","n_c":["C48876"],"i_c":"9372/3","i_c_s":["Dedifferentiated chordoma"],"term_type":"PT"},{"nm":"Dedifferentiated liposarcoma","n_c":["C3704"],"i_c":"8858/3","i_c_s":["Dedifferentiated liposarcoma"],"term_type":"PT"},{"nm":"Deep histiocytoma","n_c":["C6492"],"i_c":"8831/0","i_c_s":["Deep histiocytoma"],"term_type":"RT"},{"nm":"Degenerated schwannoma","n_c":["C6556"],"i_c":"9560/0","i_c_s":["Degenerated schwannoma"],"term_type":"RT"},{"nm":"Dendritic cell sarcoma, NOS","n_c":["C27260"],"i_c":"9757/3","i_c_s":["Dendritic cell sarcoma, NOS"],"term_type":"RT"},{"nm":"Dentinoma","n_c":["C54323"],"i_c":"9271/0","i_c_s":["Dentinoma"],"term_type":"SY"},{"nm":"Dermal and epidermal nevus","n_c":["C3901"],"i_c":"8760/0","i_c_s":["Dermal and epidermal nevus"],"term_type":"SY"},{"nm":"Dermal nevus","n_c":["C3804"],"i_c":"8750/0","i_c_s":["Dermal nevus"],"term_type":"SY"},{"nm":"Dermatofibroma lenticulare","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Dermatofibroma lenticulare"],"term_type":"SY"},{"nm":"Dermatofibroma, NOS","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Dermatofibroma, NOS"],"term_type":"PT"},{"nm":"Dermatofibrosarcoma protuberans, NOS","n_c":["C4683"],"i_c":"8832/3","i_c_s":["Dermatofibrosarcoma protuberans, NOS"],"term_type":"SY"},{"nm":"Dermatofibrosarcoma, NOS","n_c":["C4683"],"i_c":"8832/3","i_c_s":["Dermatofibrosarcoma, NOS"],"term_type":"PT"},{"nm":"Dermoid cyst with malignant transformation","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Dermoid cyst with malignant transformation"],"term_type":"SY"},{"nm":"Dermoid cyst with secondary tumor","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Dermoid cyst with secondary tumor"],"term_type":"SY"},{"nm":"Dermoid cyst, NOS","n_c":["C9011"],"i_c":"9084/0","i_c_s":["Dermoid cyst, NOS"],"term_type":"PT"},{"nm":"Dermoid, NOS","n_c":["C9011"],"i_c":"9084/0","i_c_s":["Dermoid, NOS"],"term_type":"SY"},{"nm":"Desmoid, NOS","n_c":["C9182"],"i_c":"8821/1","i_c_s":["Desmoid, NOS"],"term_type":"SY"},{"nm":"Desmoplastic fibroma","n_c":["C3740"],"i_c":"8823/0","i_c_s":["Desmoplastic fibroma"],"term_type":"PT"},{"nm":"Desmoplastic infantile astrocytoma","n_c":["C9476"],"i_c":"9412/1","i_c_s":["Desmoplastic infantile astrocytoma"],"term_type":"PT"},{"nm":"Desmoplastic infantile ganglioglioma","n_c":["C4738"],"i_c":"9412/1","i_c_s":["Desmoplastic infantile ganglioglioma"],"term_type":"RT"},{"nm":"Desmoplastic medulloblastoma","n_c":["C4956"],"i_c":"9471/3","i_c_s":["Desmoplastic medulloblastoma"],"term_type":"SY"},{"nm":"Desmoplastic melanoma, amelanotic","n_c":["C37257"],"i_c":"8745/3","i_c_s":["Desmoplastic melanoma, amelanotic"],"term_type":"RT"},{"nm":"Desmoplastic melanoma, malignant","n_c":["C37257"],"i_c":"8745/3","i_c_s":["Desmoplastic melanoma, malignant"],"term_type":"PT"},{"nm":"Desmoplastic mesothelioma","n_c":["C6747"],"i_c":"9051/3","i_c_s":["Desmoplastic mesothelioma"],"term_type":"SY"},{"nm":"Desmoplastic nodular medulloblastoma","n_c":["C4956"],"i_c":"9471/3","i_c_s":["Desmoplastic nodular medulloblastoma"],"term_type":"PT"},{"nm":"Desmoplastic small round cell tumor","n_c":["C8300"],"i_c":"8806/3","i_c_s":["Desmoplastic small round cell tumor"],"term_type":"PT"},{"nm":"Di Guglielmo disease","n_c":["C7467"],"i_c":"9840/3","i_c_s":["Di Guglielmo disease"],"term_type":"IS"},{"nm":"Differentiated penile intraepithelial neoplasia","n_c":"","i_c":"8071/2","i_c_s":["Differentiated penile intraepithelial neoplasia"],"term_type":""},{"nm":"Differentiated-type vulvar intraepithelial neoplasia","n_c":["C37272"],"i_c":"8071/2","i_c_s":["Differentiated-type vulvar intraepithelial neoplasia"],"term_type":""},{"nm":"Diffuse astrocytoma","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma"],"term_type":"RT"},{"nm":"Diffuse astrocytoma, IDH-mutant","n_c":["C129271"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma, IDH-mutant"],"term_type":""},{"nm":"Diffuse astrocytoma, IDH-wildtype","n_c":["C129274"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma, IDH-wildtype"],"term_type":""},{"nm":"Diffuse astrocytoma, low grade","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma, low grade"],"term_type":"RT"},{"nm":"Diffuse cutaneous mastocytosis","n_c":["C3218"],"i_c":"9740/1","i_c_s":["Diffuse cutaneous mastocytosis"],"term_type":"RT"},{"nm":"Diffuse intraductal papillomatosis","n_c":["C7364"],"i_c":"8505/0","i_c_s":["Diffuse intraductal papillomatosis"],"term_type":"SY"},{"nm":"Diffuse large B-cell lymphoma associated with chronic inflammation","n_c":["C80289"],"i_c":"9680/3","i_c_s":["Diffuse large B-cell lymphoma associated with chronic inflammation"],"term_type":"RT"},{"nm":"Diffuse large B-cell lymphoma, NOS","n_c":["C80280"],"i_c":"9680/3","i_c_s":["Diffuse large B-cell lymphoma, NOS"],"term_type":"SY"},{"nm":"Diffuse leptomeningeal glioneuronal tumor","n_c":["C129424"],"i_c":"9509/1","i_c_s":["Diffuse leptomeningeal glioneuronal tumor"],"term_type":""},{"nm":"Diffuse melanocytosis","n_c":["C6890"],"i_c":"8728/0","i_c_s":["Diffuse melanocytosis"],"term_type":"PT"},{"nm":"Diffuse meningiomatosis","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Diffuse meningiomatosis"],"term_type":"SY"},{"nm":"Diffuse midline glioma, H3 K27M-mutant","n_c":["C129309"],"i_c":"9385/3","i_c_s":["Diffuse midline glioma, H3 K27M-mutant"],"term_type":"PT"},{"nm":"Digital papillary adenocarcinoma","n_c":["C27534"],"i_c":"8408/3","i_c_s":["Digital papillary adenocarcinoma"],"term_type":"RT"},{"nm":"Diktyoma, benign","n_c":"","i_c":"9501/0","i_c_s":["Diktyoma, benign"],"term_type":"SY"},{"nm":"Diktyoma, malignant","n_c":["C4327"],"i_c":"9501/3","i_c_s":["Diktyoma, malignant"],"term_type":"SY"},{"nm":"DIN 3","n_c":["C7949"],"i_c":"8500/2","i_c_s":["DIN 3"],"term_type":"SY"},{"nm":"Duct adenocarcinoma, NOS","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Duct adenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Duct adenoma, NOS","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Duct adenoma, NOS"],"term_type":"SY"},{"nm":"Duct carcinoma, desmoplastic type","n_c":["C7362"],"i_c":"8514/3","i_c_s":["Duct carcinoma, desmoplastic type"],"term_type":"PT"},{"nm":"Duct carcinoma, NOS","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Duct carcinoma, NOS"],"term_type":"SY"},{"nm":"Duct cell carcinoma","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Duct cell carcinoma"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, comedo type","n_c":["C176005"],"i_c":"8501/2","i_c_s":["Ductal carcinoma in situ, comedo type"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, cribriform type","n_c":["C5138"],"i_c":"8201/2","i_c_s":["Ductal carcinoma in situ, cribriform type"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, micropapillary","n_c":["C5139"],"i_c":"8507/2","i_c_s":["Ductal carcinoma in situ, micropapillary"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Ductal carcinoma in situ, NOS"],"term_type":"RT"},{"nm":"Ductal carcinoma in situ, papillary","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Ductal carcinoma in situ, papillary"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, solid type","n_c":["C66933"],"i_c":"8230/2","i_c_s":["Ductal carcinoma in situ, solid type"],"term_type":"PT"},{"nm":"Ductal carcinoma, cribriform type","n_c":["C3680"],"i_c":"8201/3","i_c_s":["Ductal carcinoma, cribriform type"],"term_type":"SY"},{"nm":"Ductal carcinoma, NOS","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Ductal carcinoma, NOS"],"term_type":"SY"},{"nm":"Ductal intraepithelial neoplasia 3","n_c":["C7949"],"i_c":"8500/2","i_c_s":["Ductal intraepithelial neoplasia 3"],"term_type":"SY"},{"nm":"Ductal papilloma","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Ductal papilloma"],"term_type":"SY"},{"nm":"Dysembryoplastic neuroepithelial tumor","n_c":["C9505"],"i_c":"9413/0","i_c_s":["Dysembryoplastic neuroepithelial tumor"],"term_type":"PT"},{"nm":"Dysgerminoma","n_c":["C8106"],"i_c":"9060/3","i_c_s":["Dysgerminoma"],"term_type":"PT"},{"nm":"Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)","n_c":["C8419"],"i_c":"9493/0","i_c_s":["Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)"],"term_type":"PT"},{"nm":"Dysplastic nevus","n_c":["C3694"],"i_c":"8727/0","i_c_s":["Dysplastic nevus"],"term_type":"PT"},{"nm":"EBV positive diffuse large B-cell lymphoma of the elderly","n_c":["C80281"],"i_c":"9680/3","i_c_s":["EBV positive diffuse large B-cell lymphoma of the elderly"],"term_type":"RT"},{"nm":"EC cell carcinoid","n_c":"","i_c":"8241/3","i_c_s":["EC cell carcinoid"],"term_type":"SY"},{"nm":"Ecchondroma","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Ecchondroma"],"term_type":"SY"},{"nm":"Ecchondrosis","n_c":["C53457"],"i_c":"9210/1","i_c_s":["Ecchondrosis"],"term_type":"SY"},{"nm":"Eccrine acrospiroma","n_c":["C7563"],"i_c":"8402/0","i_c_s":["Eccrine acrospiroma"],"term_type":"RT"},{"nm":"Eccrine adenocarcinoma","n_c":["C27255"],"i_c":"8413/3","i_c_s":["Eccrine adenocarcinoma"],"term_type":"PT"},{"nm":"Eccrine cystadenoma","n_c":["C7565"],"i_c":"8404/0","i_c_s":["Eccrine cystadenoma"],"term_type":"SY"},{"nm":"Eccrine dermal cylindroma","n_c":["C27094"],"i_c":"8200/0","i_c_s":["Eccrine dermal cylindroma"],"term_type":"PT"},{"nm":"Eccrine papillary adenocarcinoma","n_c":["C27254","C27534"],"i_c":"8408/3","i_c_s":["Eccrine papillary adenocarcinoma"],"term_type":"PT"},{"nm":"Eccrine papillary adenoma","n_c":["C4173"],"i_c":"8408/0","i_c_s":["Eccrine papillary adenoma"],"term_type":"PT"},{"nm":"Eccrine poroma","n_c":["C27273"],"i_c":"8409/0","i_c_s":["Eccrine poroma"],"term_type":"PT"},{"nm":"Eccrine poroma, malignant","n_c":["C5560"],"i_c":"8409/3","i_c_s":["Eccrine poroma, malignant"],"term_type":"PT"},{"nm":"Eccrine spiradenoma","n_c":["C4170"],"i_c":"8403/0","i_c_s":["Eccrine spiradenoma"],"term_type":"PT"},{"nm":"ECL cell carcinoid, malignant","n_c":["C27252"],"i_c":"8242/3","i_c_s":["ECL cell carcinoid, malignant"],"term_type":"SY"},{"nm":"ECL cell carcinoid, NOS","n_c":["C27252"],"i_c":"8242/1","i_c_s":["ECL cell carcinoid, NOS"],"term_type":"SY"},{"nm":"Ectomesenchymoma","n_c":["C4716"],"i_c":"8921/3","i_c_s":["Ectomesenchymoma"],"term_type":"SY"},{"nm":"Ectopic hamartomatous thymoma","n_c":["C53595"],"i_c":"8587/0","i_c_s":["Ectopic hamartomatous thymoma"],"term_type":"PT"},{"nm":"Elastofibroma","n_c":["C4245"],"i_c":"8820/0","i_c_s":["Elastofibroma"],"term_type":"PT"},{"nm":"Embryonal adenocarcinoma","n_c":["C3752"],"i_c":"9070/3","i_c_s":["Embryonal adenocarcinoma"],"term_type":"SY"},{"nm":"Embryonal adenoma","n_c":["C27253"],"i_c":"8191/0","i_c_s":["Embryonal adenoma"],"term_type":"PT"},{"nm":"Embryonal carcinoma, infantile","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Embryonal carcinoma, infantile"],"term_type":"SY"},{"nm":"Embryonal carcinoma, NOS","n_c":["C3752"],"i_c":"9070/3","i_c_s":["Embryonal carcinoma, NOS"],"term_type":"PT"},{"nm":"Embryonal carcinoma, polyembryonal type","n_c":"","i_c":"9072/3","i_c_s":["Embryonal carcinoma, polyembryonal type"],"term_type":"SY"},{"nm":"Embryonal hepatoma","n_c":["C3728"],"i_c":"8970/3","i_c_s":["Embryonal hepatoma"],"term_type":"SY"},{"nm":"Embryonal rhabdomyosarcoma, NOS","n_c":["C8971"],"i_c":"8910/3","i_c_s":["Embryonal rhabdomyosarcoma, NOS"],"term_type":"PT"},{"nm":"Embryonal rhabdomyosarcoma, pleomorphic","n_c":"","i_c":"8910/3","i_c_s":["Embryonal rhabdomyosarcoma, pleomorphic"],"term_type":"RT"},{"nm":"Embryonal sarcoma","n_c":["C27096"],"i_c":"8991/3","i_c_s":["Embryonal sarcoma"],"term_type":"PT"},{"nm":"Embryonal teratoma","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Embryonal teratoma"],"term_type":"SY"},{"nm":"Embryonal tumor with multilayered rosettes C19MC-altered","n_c":["C4915"],"i_c":"9478/3","i_c_s":["Embryonal tumor with multilayered rosettes C19MC-altered"],"term_type":""},{"nm":"Embryonal tumor with multilayered rosettes, NOS","n_c":["C186534"],"i_c":"9478/3","i_c_s":["Embryonal tumor with multilayered rosettes, NOS"],"term_type":"PT"},{"nm":"Embryonal tumor with rhabdoid features","n_c":["C129501"],"i_c":"9508/3","i_c_s":["Embryonal tumor with rhabdoid features"],"term_type":""},{"nm":"Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)","n_c":"","i_c":"8343/3","i_c_s":["Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)"],"term_type":""},{"nm":"Encapsulated papillary carcinoma","n_c":["C156034"],"i_c":"8504/2","i_c_s":["Encapsulated papillary carcinoma"],"term_type":""},{"nm":"Encapsulated papillary carcinoma with invasion","n_c":["C66850"],"i_c":"8504/3","i_c_s":["Encapsulated papillary carcinoma with invasion"],"term_type":""},{"nm":"Enchondroma","n_c":["C3007"],"i_c":"9220/0","i_c_s":["Enchondroma"],"term_type":"RT"},{"nm":"Endocervical adenocarcinoma usual type","n_c":["C127907"],"i_c":"8140/3","i_c_s":["Endocervical adenocarcinoma usual type"],"term_type":""},{"nm":"Endocrine adenomatosis","n_c":["C6432"],"i_c":"8360/1","i_c_s":["Endocrine adenomatosis"],"term_type":"SY"},{"nm":"Endocrine tumor, functioning, NOS","n_c":["C94759"],"i_c":"8158/1","i_c_s":["Endocrine tumor, functioning, NOS"],"term_type":"PT"},{"nm":"Endodermal sinus tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Endodermal sinus tumor"],"term_type":"SY"},{"nm":"Endolymphatic stromal myosis","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Endolymphatic stromal myosis"],"term_type":"SY"},{"nm":"Endometrial sarcoma, NOS","n_c":["C8973"],"i_c":"8930/3","i_c_s":["Endometrial sarcoma, NOS"],"term_type":"SY"},{"nm":"Endometrial stromal nodule","n_c":["C4262"],"i_c":"8930/0","i_c_s":["Endometrial stromal nodule"],"term_type":"PT"},{"nm":"Endometrial stromal sarcoma, high grade","n_c":["C126998"],"i_c":"8930/3","i_c_s":["Endometrial stromal sarcoma, high grade"],"term_type":"RT"},{"nm":"Endometrial stromal sarcoma, low grade","n_c":["C40223"],"i_c":"8931/3","i_c_s":["Endometrial stromal sarcoma, low grade"],"term_type":"PT"},{"nm":"Endometrial stromal sarcoma, NOS","n_c":["C8973"],"i_c":"8930/3","i_c_s":["Endometrial stromal sarcoma, NOS"],"term_type":"PT"},{"nm":"Endometrial stromatosis","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Endometrial stromatosis"],"term_type":"SY"},{"nm":"Endometrioid adenocarcinoma, ciliated cell variant","n_c":["C27848"],"i_c":"8383/3","i_c_s":["Endometrioid adenocarcinoma, ciliated cell variant"],"term_type":"PT"},{"nm":"Endometrioid adenocarcinoma, NOS","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Endometrioid adenocarcinoma, secretory variant","n_c":["C27839"],"i_c":"8382/3","i_c_s":["Endometrioid adenocarcinoma, secretory variant"],"term_type":"PT"},{"nm":"Endometrioid adenocarcinoma, villoglandular","n_c":["C27846"],"i_c":"8263/3","i_c_s":["Endometrioid adenocarcinoma, villoglandular"],"term_type":""},{"nm":"Endometrioid adenofibroma, borderline malignancy","n_c":["C40069"],"i_c":"8381/1","i_c_s":["Endometrioid adenofibroma, borderline malignancy"],"term_type":"PT"},{"nm":"Endometrioid adenofibroma, malignant","n_c":["C40060"],"i_c":"8381/3","i_c_s":["Endometrioid adenofibroma, malignant"],"term_type":"PT"},{"nm":"Endometrioid adenofibroma, NOS","n_c":["C27287"],"i_c":"8381/0","i_c_s":["Endometrioid adenofibroma, NOS"],"term_type":"PT"},{"nm":"Endometrioid adenoma, borderline malignancy","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid adenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Endometrioid adenoma, NOS","n_c":["C27287"],"i_c":"8380/0","i_c_s":["Endometrioid adenoma, NOS"],"term_type":"PT"},{"nm":"Endometrioid carcinoma with squamous differentiation","n_c":["C6290"],"i_c":"8570/3","i_c_s":["Endometrioid carcinoma with squamous differentiation"],"term_type":""},{"nm":"Endometrioid carcinoma, NOS","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid carcinoma, NOS"],"term_type":"SY"},{"nm":"Endometrioid cystadenocarcinoma","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid cystadenocarcinoma"],"term_type":"RT"},{"nm":"Endometrioid cystadenofibroma, borderline malignancy","n_c":["C40069"],"i_c":"8381/1","i_c_s":["Endometrioid cystadenofibroma, borderline malignancy"],"term_type":"SY"},{"nm":"Endometrioid cystadenofibroma, malignant","n_c":"","i_c":"8381/3","i_c_s":["Endometrioid cystadenofibroma, malignant"],"term_type":"SY"},{"nm":"Endometrioid cystadenofibroma, NOS","n_c":["C27288"],"i_c":"8381/0","i_c_s":["Endometrioid cystadenofibroma, NOS"],"term_type":"SY"},{"nm":"Endometrioid cystadenoma, borderline malignancy","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Endometrioid cystadenoma, NOS","n_c":"","i_c":"8380/0","i_c_s":["Endometrioid cystadenoma, NOS"],"term_type":"SY"},{"nm":"Endometrioid tumor of low malignant potential","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid tumor of low malignant potential"],"term_type":"SY"},{"nm":"Endotheliomatous meningioma","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Endotheliomatous meningioma"],"term_type":"SY"},{"nm":"Endovascular papillary angioendothelioma","n_c":["C7526"],"i_c":"9135/1","i_c_s":["Endovascular papillary angioendothelioma"],"term_type":"PT"},{"nm":"Enteric adenocarcinoma","n_c":"","i_c":"8144/3","i_c_s":["Enteric adenocarcinoma"],"term_type":""},{"nm":"Enterochromaffin cell carcinoid","n_c":["C2915"],"i_c":"8241/3","i_c_s":["Enterochromaffin cell carcinoid"],"term_type":"PT"},{"nm":"Enterochromaffin-like cell carcinoid, NOS","n_c":["C27252"],"i_c":"8242/1","i_c_s":["Enterochromaffin-like cell carcinoid, NOS"],"term_type":"PT"},{"nm":"Enterochromaffin-like cell tumor, malignant","n_c":["C27252"],"i_c":"8242/3","i_c_s":["Enterochromaffin-like cell tumor, malignant"],"term_type":"PT"},{"nm":"Enteroglucagonoma, malignant","n_c":["C65191"],"i_c":"8152/3","i_c_s":["Enteroglucagonoma, malignant"],"term_type":"RT"},{"nm":"Enteroglucagonoma, NOS","n_c":["C66925"],"i_c":"8152/1","i_c_s":["Enteroglucagonoma, NOS"],"term_type":"RT"},{"nm":"Enteropathy associated T-cell lymphoma","n_c":["C4737"],"i_c":"9717/3","i_c_s":["Enteropathy associated T-cell lymphoma"],"term_type":"SY"},{"nm":"Enteropathy type intestinal T-cell lymphoma","n_c":["C4737"],"i_c":"9717/3","i_c_s":["Enteropathy type intestinal T-cell lymphoma"],"term_type":"SY"},{"nm":"Eosinophil adenocarcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Eosinophil adenocarcinoma"],"term_type":"SY"},{"nm":"Eosinophil adenoma","n_c":["C6780"],"i_c":"8280/0","i_c_s":["Eosinophil adenoma"],"term_type":"SY"},{"nm":"Eosinophil carcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Eosinophil carcinoma"],"term_type":"SY"},{"nm":"Eosinophilic granuloma","n_c":["C3016"],"i_c":"9751/3","i_c_s":["Eosinophilic granuloma"],"term_type":"RT"},{"nm":"Eosinophilic leukemia","n_c":["C4563"],"i_c":"9860/3","i_c_s":["Eosinophilic leukemia"],"term_type":"RT"},{"nm":"Ependymoblastoma","n_c":["C4915"],"i_c":"9392/3","i_c_s":["Ependymoblastoma"],"term_type":"SY"},{"nm":"Ependymoma, anaplastic","n_c":["C4049"],"i_c":"9392/3","i_c_s":["Ependymoma, anaplastic"],"term_type":"PT"},{"nm":"Ependymoma, NOS","n_c":["C3017"],"i_c":"9391/3","i_c_s":["Ependymoma, NOS"],"term_type":"PT"},{"nm":"Ependymoma, RELA fusion-positive","n_c":["C129351"],"i_c":"9396/3","i_c_s":["Ependymoma, RELA fusion-positive"],"term_type":"PT"},{"nm":"Epidermoid carcinoma in situ with questionable stromal invasion","n_c":["C65176"],"i_c":"8076/2","i_c_s":["Epidermoid carcinoma in situ with questionable stromal invasion"],"term_type":"SY"},{"nm":"Epidermoid carcinoma in situ, NOS","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Epidermoid carcinoma in situ, NOS"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, keratinizing","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Epidermoid carcinoma, keratinizing"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, large cell, nonkeratinizing","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Epidermoid carcinoma, large cell, nonkeratinizing"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, NOS","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Epidermoid carcinoma, NOS"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, small cell, nonkeratinizing","n_c":["C65175"],"i_c":"8073/3","i_c_s":["Epidermoid carcinoma, small cell, nonkeratinizing"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, spindle cell","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Epidermoid carcinoma, spindle cell"],"term_type":"SY"},{"nm":"Epithelial ependymoma","n_c":["C3017"],"i_c":"9391/3","i_c_s":["Epithelial ependymoma"],"term_type":"SY"},{"nm":"Epithelial tumor, benign","n_c":["C4092"],"i_c":"8010/0","i_c_s":["Epithelial tumor, benign"],"term_type":"PT"},{"nm":"Epithelial tumor, malignant","n_c":["C2916"],"i_c":"8010/3","i_c_s":["Epithelial tumor, malignant"],"term_type":"SY"},{"nm":"Epithelial-myoepithelial carcinoma","n_c":["C4199"],"i_c":"8562/3","i_c_s":["Epithelial-myoepithelial carcinoma"],"term_type":"PT"},{"nm":"Epithelioid and spindle cell nevus","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Epithelioid and spindle cell nevus"],"term_type":"PT"},{"nm":"Epithelioid cell melanoma","n_c":["C4236"],"i_c":"8771/3","i_c_s":["Epithelioid cell melanoma"],"term_type":"PT"},{"nm":"Epithelioid cell nevus","n_c":["C66757"],"i_c":"8771/0","i_c_s":["Epithelioid cell nevus"],"term_type":"PT"},{"nm":"Epithelioid cell sarcoma","n_c":["C3714"],"i_c":"8804/3","i_c_s":["Epithelioid cell sarcoma"],"term_type":"SY"},{"nm":"Epithelioid glioblastoma","n_c":["C129293"],"i_c":"9440/3","i_c_s":["Epithelioid glioblastoma"],"term_type":""},{"nm":"Epithelioid hemangioendothelioma, malignant","n_c":["C3800"],"i_c":"9133/3","i_c_s":["Epithelioid hemangioendothelioma, malignant"],"term_type":"PT"},{"nm":"Epithelioid hemangioendothelioma, NOS","n_c":["C3800"],"i_c":"9133/1","i_c_s":["Epithelioid hemangioendothelioma, NOS"],"term_type":"PT"},{"nm":"Epithelioid hemangioma","n_c":["C4298"],"i_c":"9125/0","i_c_s":["Epithelioid hemangioma"],"term_type":"PT"},{"nm":"Epithelioid leiomyoma","n_c":["C40164","C3486"],"i_c":"8891/0","i_c_s":["Epithelioid leiomyoma"],"term_type":"PT"},{"nm":"Epithelioid leiomyosarcoma","n_c":["C3700"],"i_c":"8891/3","i_c_s":["Epithelioid leiomyosarcoma"],"term_type":"PT"},{"nm":"Epithelioid malignant peripheral nerve sheath tumor","n_c":["C6561"],"i_c":"9542/3","i_c_s":["Epithelioid malignant peripheral nerve sheath tumor"],"term_type":"PT"},{"nm":"Epithelioid mesothelioma, benign","n_c":["C3762"],"i_c":"9052/0","i_c_s":["Epithelioid mesothelioma, benign"],"term_type":"PT"},{"nm":"Epithelioid mesothelioma, malignant","n_c":["C7985"],"i_c":"9052/3","i_c_s":["Epithelioid mesothelioma, malignant"],"term_type":"PT"},{"nm":"Epithelioid mesothelioma, NOS","n_c":["C7985"],"i_c":"9052/3","i_c_s":["Epithelioid mesothelioma, NOS"],"term_type":"SY"},{"nm":"Epithelioid MPNST","n_c":["C6561"],"i_c":"9540/3","i_c_s":["Epithelioid MPNST"],"term_type":"RT"},{"nm":"Epithelioid sarcoma","n_c":["C3714"],"i_c":"8804/3","i_c_s":["Epithelioid sarcoma"],"term_type":"PT"},{"nm":"Epithelioma adenoides cysticum","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Epithelioma adenoides cysticum"],"term_type":"SY"},{"nm":"Epithelioma, benign","n_c":["C4092"],"i_c":"8011/0","i_c_s":["Epithelioma, benign"],"term_type":"PT"},{"nm":"Epithelioma, malignant","n_c":["C3709"],"i_c":"8011/3","i_c_s":["Epithelioma, malignant"],"term_type":"PT"},{"nm":"Epithelioma, NOS","n_c":["C3709"],"i_c":"8011/3","i_c_s":["Epithelioma, NOS"],"term_type":"SY"},{"nm":"Erythremic myelosis, NOS","n_c":["C7467"],"i_c":"9840/3","i_c_s":["Erythremic myelosis, NOS"],"term_type":"SY"},{"nm":"Erythroleukemia","n_c":["C7152"],"i_c":"9840/3","i_c_s":["Erythroleukemia"],"term_type":"SY"},{"nm":"Esophageal glandular dysplasia (intraepithelial neoplasia), high grade","n_c":["C27429"],"i_c":"8148/2","i_c_s":["Esophageal glandular dysplasia (intraepithelial neoplasia), high grade"],"term_type":"RT"},{"nm":"Esophageal glandular dysplasia (intraepithelial neoplasia), low grade","n_c":["C27428"],"i_c":"8148/0","i_c_s":["Esophageal glandular dysplasia (intraepithelial neoplasia), low grade"],"term_type":"RT"},{"nm":"Esophageal intraepithelial neoplasia, high grade","n_c":["C27425"],"i_c":"8148/2","i_c_s":["Esophageal intraepithelial neoplasia, high grade"],"term_type":"SY"},{"nm":"Esophageal squamous intraepithelial neoplasia (dysplasia), high grade","n_c":["C27426"],"i_c":"8077/2","i_c_s":["Esophageal squamous intraepithelial neoplasia (dysplasia), high grade"],"term_type":"RT"},{"nm":"Esophageal squamous intraepithelial neoplasia (dysplasia), low grade","n_c":["C27427"],"i_c":"8077/0","i_c_s":["Esophageal squamous intraepithelial neoplasia (dysplasia), low grade"],"term_type":"RT"},{"nm":"Essential hemorrhagic thrombocythaemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Essential hemorrhagic thrombocythaemia"],"term_type":""},{"nm":"Essential thrombocythemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Essential thrombocythemia"],"term_type":"PT"},{"nm":"Esthesioneuroblastoma","n_c":["C3789"],"i_c":"9522/3","i_c_s":["Esthesioneuroblastoma"],"term_type":"SY"},{"nm":"Esthesioneurocytoma","n_c":"","i_c":"9521/3","i_c_s":["Esthesioneurocytoma"],"term_type":"SY"},{"nm":"Esthesioneuroepithelioma","n_c":["C3789"],"i_c":"9523/3","i_c_s":["Esthesioneuroepithelioma"],"term_type":"SY"},{"nm":"Ewing sarcoma","n_c":["C4817"],"i_c":"9260/3","i_c_s":["Ewing sarcoma"],"term_type":"PT"},{"nm":"Ewing tumor","n_c":["C4817"],"i_c":"9260/3","i_c_s":["Ewing tumor"],"term_type":"SY"},{"nm":"Extra-abdominal desmoid","n_c":["C6489"],"i_c":"8821/1","i_c_s":["Extra-abdominal desmoid"],"term_type":"SY"},{"nm":"Extra-adrenal paraganglioma, malignant","n_c":["C4219"],"i_c":"8693/3","i_c_s":["Extra-adrenal paraganglioma, malignant"],"term_type":"PT"},{"nm":"Extra-adrenal paraganglioma, NOS","n_c":["C3309"],"i_c":"8693/1","i_c_s":["Extra-adrenal paraganglioma, NOS"],"term_type":"PT"},{"nm":"Extracutaneous mastocytoma","n_c":["C7136"],"i_c":"9740/1","i_c_s":["Extracutaneous mastocytoma"],"term_type":"SY"},{"nm":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue","n_c":["C3898"],"i_c":"9699/3","i_c_s":["Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue"],"term_type":"RT"},{"nm":"Extranodal NK/T-cell lymphoma, nasal type","n_c":["C4684"],"i_c":"9719/3","i_c_s":["Extranodal NK/T-cell lymphoma, nasal type"],"term_type":"SY"},{"nm":"Extraosseous plasmacytoma","n_c":["C4002"],"i_c":"9734/3","i_c_s":["Extraosseous plasmacytoma"],"term_type":"SY"},{"nm":"Extraventricular neurocytoma","n_c":["C92555"],"i_c":"9506/1","i_c_s":["Extraventricular neurocytoma"],"term_type":"RT"},{"nm":"FAB L2","n_c":["C27281"],"i_c":"9835/3","i_c_s":["FAB L2"],"term_type":"SY"},{"nm":"FAB L3","n_c":["C7400"],"i_c":"9826/3","i_c_s":["FAB L3"],"term_type":"IS"},{"nm":"FAB Ll","n_c":["C27290"],"i_c":"9835/3","i_c_s":["FAB Ll"],"term_type":""},{"nm":"FAB M1","n_c":["C3249"],"i_c":"9873/3","i_c_s":["FAB M1"],"term_type":"SY"},{"nm":"FAB M2, AML1(CBF-alpha)/ETO","n_c":["C9288"],"i_c":"9896/3","i_c_s":["FAB M2, AML1(CBF-alpha)/ETO"],"term_type":"SY"},{"nm":"FAB M2, NOS","n_c":["C3250"],"i_c":"9874/3","i_c_s":["FAB M2, NOS"],"term_type":"SY"},{"nm":"FAB M2, t(8;21)(q22;q22)","n_c":["C9288"],"i_c":"9896/3","i_c_s":["FAB M2, t(8;21)(q22;q22)"],"term_type":"SY"},{"nm":"FAB M3 (includes all variants)","n_c":["C3182"],"i_c":"9866/3","i_c_s":["FAB M3 (includes all variants)"],"term_type":""},{"nm":"FAB M4","n_c":["C7463"],"i_c":"9867/3","i_c_s":["FAB M4"],"term_type":"SY"},{"nm":"FAB M4Eo","n_c":["C9020"],"i_c":"9871/3","i_c_s":["FAB M4Eo"],"term_type":"SY"},{"nm":"FAB M5 (includes all variants)","n_c":["C7318"],"i_c":"9891/3","i_c_s":["FAB M5 (includes all variants)"],"term_type":""},{"nm":"FAB M6","n_c":["C8923"],"i_c":"9840/3","i_c_s":["FAB M6"],"term_type":"SY"},{"nm":"FAB M7","n_c":["C3170"],"i_c":"9910/3","i_c_s":["FAB M7"],"term_type":"SY"},{"nm":"FAB MO","n_c":["C8460"],"i_c":"9872/3","i_c_s":["FAB MO"],"term_type":""},{"nm":"Familial polyposis coli","n_c":["C3339"],"i_c":"8220/0","i_c_s":["Familial polyposis coli"],"term_type":"SY"},{"nm":"Fascial fibroma","n_c":["C66764"],"i_c":"8813/0","i_c_s":["Fascial fibroma"],"term_type":"PT"},{"nm":"Fascial fibrosarcoma","n_c":["C66765"],"i_c":"8813/3","i_c_s":["Fascial fibrosarcoma"],"term_type":"PT"},{"nm":"Fetal adenocarcinoma","n_c":["C45509"],"i_c":"8333/3","i_c_s":["Fetal adenocarcinoma"],"term_type":"PT"},{"nm":"Fetal adenoma","n_c":["C4160"],"i_c":"8333/0","i_c_s":["Fetal adenoma"],"term_type":"SY"},{"nm":"Fetal fat cell lipoma","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Fetal fat cell lipoma"],"term_type":"SY"},{"nm":"Fetal lipoma, NOS","n_c":["C27483"],"i_c":"8881/0","i_c_s":["Fetal lipoma, NOS"],"term_type":"SY"},{"nm":"Fetal lipomatosis","n_c":["C4255"],"i_c":"8881/0","i_c_s":["Fetal lipomatosis"],"term_type":"SY"},{"nm":"Fetal rhabdomyoma","n_c":["C4260"],"i_c":"8903/0","i_c_s":["Fetal rhabdomyoma"],"term_type":"PT"},{"nm":"Fibrillary astrocytoma","n_c":["C4322"],"i_c":"9420/3","i_c_s":["Fibrillary astrocytoma"],"term_type":"PT"},{"nm":"Fibro-osteoma","n_c":["C173820"],"i_c":"9262/0","i_c_s":["Fibro-osteoma"],"term_type":"SY"},{"nm":"Fibroadenoma, NOS","n_c":["C3744"],"i_c":"9010/0","i_c_s":["Fibroadenoma, NOS"],"term_type":"PT"},{"nm":"Fibroameloblastic odontoma","n_c":["C3710"],"i_c":"9290/0","i_c_s":["Fibroameloblastic odontoma"],"term_type":"SY"},{"nm":"Fibroblastic liposarcoma","n_c":["C6509"],"i_c":"8857/3","i_c_s":["Fibroblastic liposarcoma"],"term_type":"PT"},{"nm":"Fibroblastic meningioma","n_c":["C4330"],"i_c":"9532/0","i_c_s":["Fibroblastic meningioma"],"term_type":"SY"},{"nm":"Fibroblastic osteosarcoma","n_c":["C4020"],"i_c":"9182/3","i_c_s":["Fibroblastic osteosarcoma"],"term_type":"PT"},{"nm":"Fibroblastic reticular cell tumor","n_c":["C81758"],"i_c":"9759/3","i_c_s":["Fibroblastic reticular cell tumor"],"term_type":"PT"},{"nm":"Fibrochondrosarcoma","n_c":["C2946"],"i_c":"9220/3","i_c_s":["Fibrochondrosarcoma"],"term_type":"RT"},{"nm":"Fibroepithelial basal cell carcinoma, Pinkus type","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Fibroepithelial basal cell carcinoma, Pinkus type"],"term_type":"SY"},{"nm":"Fibroepithelioma of Pinkus type","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Fibroepithelioma of Pinkus type"],"term_type":"SY"},{"nm":"Fibroepithelioma, NOS","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Fibroepithelioma, NOS"],"term_type":"SY"},{"nm":"Fibrofolliculoma","n_c":["C43331"],"i_c":"8391/0","i_c_s":["Fibrofolliculoma"],"term_type":"SY"},{"nm":"Fibroid uterus","n_c":["C3434"],"i_c":"8890/0","i_c_s":["Fibroid uterus"],"term_type":"SY"},{"nm":"Fibrolipoma","n_c":["C4249"],"i_c":"8851/0","i_c_s":["Fibrolipoma"],"term_type":"PT"},{"nm":"Fibroliposarcoma","n_c":["C3194"],"i_c":"8850/3","i_c_s":["Fibroliposarcoma"],"term_type":"SY"},{"nm":"Fibroma, NOS","n_c":["C3041"],"i_c":"8810/0","i_c_s":["Fibroma, NOS"],"term_type":"PT"},{"nm":"Fibromatosis-like metaplastic carcinoma","n_c":"","i_c":"8572/3","i_c_s":["Fibromatosis-like metaplastic carcinoma"],"term_type":""},{"nm":"Fibromyoma","n_c":["C3434"],"i_c":"8890/0","i_c_s":["Fibromyoma"],"term_type":"SY"},{"nm":"Fibromyxolipoma","n_c":["C4251"],"i_c":"8852/0","i_c_s":["Fibromyxolipoma"],"term_type":"PT"},{"nm":"Fibromyxoma","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Fibromyxoma"],"term_type":"PT"},{"nm":"Fibromyxosarcoma","n_c":["C6496"],"i_c":"8811/3","i_c_s":["Fibromyxosarcoma"],"term_type":"PT"},{"nm":"Fibrosarcoma, NOS","n_c":["C3043"],"i_c":"8810/3","i_c_s":["Fibrosarcoma, NOS"],"term_type":"PT"},{"nm":"Fibrosarcomatous dermatofibrosarcoma protuberans","n_c":["C27547"],"i_c":"8832/3","i_c_s":["Fibrosarcomatous dermatofibrosarcoma protuberans"],"term_type":""},{"nm":"Fibrous astrocytoma","n_c":["C4322"],"i_c":"9420/3","i_c_s":["Fibrous astrocytoma"],"term_type":"SY"},{"nm":"Fibrous histiocytoma of tendon sheath","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Fibrous histiocytoma of tendon sheath"],"term_type":"SY"},{"nm":"Fibrous histiocytoma, NOS","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Fibrous histiocytoma, NOS"],"term_type":"SY"},{"nm":"Fibrous meningioma","n_c":["C4330"],"i_c":"9532/0","i_c_s":["Fibrous meningioma"],"term_type":"PT"},{"nm":"Fibrous mesothelioma, benign","n_c":["C4457"],"i_c":"9051/0","i_c_s":["Fibrous mesothelioma, benign"],"term_type":"PT"},{"nm":"Fibrous mesothelioma, malignant","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Fibrous mesothelioma, malignant"],"term_type":"PT"},{"nm":"Fibrous mesothelioma, NOS","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Fibrous mesothelioma, NOS"],"term_type":"SY"},{"nm":"Fibrous papule of nose","n_c":"","i_c":"9160/0","i_c_s":["Fibrous papule of nose"],"term_type":"IS"},{"nm":"Fibroxanthoma, malignant","n_c":["C4247"],"i_c":"8830/3","i_c_s":["Fibroxanthoma, malignant"],"term_type":"SY"},{"nm":"Fibroxanthoma, NOS","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Fibroxanthoma, NOS"],"term_type":"SY"},{"nm":"Flat adenoma","n_c":["C65193"],"i_c":"8212/0","i_c_s":["Flat adenoma"],"term_type":"PT"},{"nm":"Flat intraepithelial glandular neoplasia, high grade","n_c":"","i_c":"8148/2","i_c_s":["Flat intraepithelial glandular neoplasia, high grade"],"term_type":"RT"},{"nm":"Flat intraepithelial neoplasia, high grade","n_c":"","i_c":"8148/2","i_c_s":["Flat intraepithelial neoplasia, high grade"],"term_type":"SY"},{"nm":"Florid osseous dysplasia","n_c":["C202219"],"i_c":"9275/0","i_c_s":["Florid osseous dysplasia"],"term_type":"SY"},{"nm":"Follicular adenocarcinoma, moderately differentiated","n_c":"","i_c":"8332/3","i_c_s":["Follicular adenocarcinoma, moderately differentiated"],"term_type":"RT"},{"nm":"Follicular adenocarcinoma, NOS","n_c":["C8054"],"i_c":"8330/3","i_c_s":["Follicular adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Follicular adenocarcinoma, trabecular","n_c":["C46095"],"i_c":"8332/3","i_c_s":["Follicular adenocarcinoma, trabecular"],"term_type":"PT"},{"nm":"Follicular adenocarcinoma, well differentiated","n_c":["C8054"],"i_c":"8331/3","i_c_s":["Follicular adenocarcinoma, well differentiated"],"term_type":"PT"},{"nm":"Follicular adenoma","n_c":["C3502"],"i_c":"8330/0","i_c_s":["Follicular adenoma"],"term_type":"PT"},{"nm":"Follicular adenoma, oxyphilic cell","n_c":["C3759"],"i_c":"8290/0","i_c_s":["Follicular adenoma, oxyphilic cell"],"term_type":"RT"},{"nm":"Follicular carcinoma, encapsulated","n_c":"","i_c":"8335/3","i_c_s":["Follicular carcinoma, encapsulated"],"term_type":"SY"},{"nm":"Follicular carcinoma, minimally invasive","n_c":["C65200"],"i_c":"8335/3","i_c_s":["Follicular carcinoma, minimally invasive"],"term_type":"PT"},{"nm":"Follicular carcinoma, moderately differentiated","n_c":"","i_c":"8332/3","i_c_s":["Follicular carcinoma, moderately differentiated"],"term_type":"SY"},{"nm":"Follicular carcinoma, NOS","n_c":["C8054"],"i_c":"8330/3","i_c_s":["Follicular carcinoma, NOS"],"term_type":"SY"},{"nm":"Follicular carcinoma, oxyphilic cell","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Follicular carcinoma, oxyphilic cell"],"term_type":"RT"},{"nm":"Follicular carcinoma, trabecular","n_c":"","i_c":"8332/3","i_c_s":["Follicular carcinoma, trabecular"],"term_type":"SY"},{"nm":"Follicular carcinoma, well differentiated","n_c":["C8054"],"i_c":"8331/3","i_c_s":["Follicular carcinoma, well differentiated"],"term_type":"SY"},{"nm":"Follicular dendritic cell sarcoma","n_c":["C9281"],"i_c":"9758/3","i_c_s":["Follicular dendritic cell sarcoma"],"term_type":"PT"},{"nm":"Follicular dendritic cell tumor","n_c":["C9281"],"i_c":"9758/3","i_c_s":["Follicular dendritic cell tumor"],"term_type":"RT"},{"nm":"Follicular fibroma","n_c":["C43331"],"i_c":"8391/0","i_c_s":["Follicular fibroma"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 1","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Follicular lymphoma, grade 1"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 2","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Follicular lymphoma, grade 2"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 3","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 3A","n_c":["C7191"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3A"],"term_type":"SY"},{"nm":"Follicular lymphoma, grade 3B","n_c":["C7192"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3B"],"term_type":"SY"},{"nm":"Follicular lymphoma, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Follicular lymphoma, NOS"],"term_type":"PT"},{"nm":"Follicular lymphoma, small cleaved cell","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Follicular lymphoma, small cleaved cell"],"term_type":"SY"},{"nm":"Follicular thyroid carcinoma (FTC), encapsulated angioinvasive","n_c":["C156122"],"i_c":"8339/3","i_c_s":["Follicular thyroid carcinoma (FTC), encapsulated angioinvasive"],"term_type":"PT"},{"nm":"Folliculome lipidique","n_c":"","i_c":"8641/0","i_c_s":["Folliculome lipidique"],"term_type":"SY"},{"nm":"Franklin disease","n_c":["C3083"],"i_c":"9762/3","i_c_s":["Franklin disease"],"term_type":"SY"},{"nm":"G cell tumor, malignant","n_c":["C65188"],"i_c":"8153/3","i_c_s":["G cell tumor, malignant"],"term_type":"SY"},{"nm":"G cell tumor, NOS","n_c":["C3050"],"i_c":"8153/1","i_c_s":["G cell tumor, NOS"],"term_type":"SY"},{"nm":"Gamma heavy chain disease","n_c":["C3083"],"i_c":"9762/3","i_c_s":["Gamma heavy chain disease"],"term_type":"RT"},{"nm":"Gangliocytic paraganglioma","n_c":["C188229"],"i_c":"8683/0","i_c_s":["Gangliocytic paraganglioma"],"term_type":"PT"},{"nm":"Gangliocytoma","n_c":["C6934"],"i_c":"9492/0","i_c_s":["Gangliocytoma"],"term_type":"PT"},{"nm":"Ganglioglioma, anaplastic","n_c":["C4717"],"i_c":"9505/3","i_c_s":["Ganglioglioma, anaplastic"],"term_type":"PT"},{"nm":"Ganglioglioma, NOS","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Ganglioglioma, NOS"],"term_type":"PT"},{"nm":"Ganglioneuroblastoma","n_c":["C3790"],"i_c":"9490/3","i_c_s":["Ganglioneuroblastoma"],"term_type":"PT"},{"nm":"Ganglioneuroma","n_c":["C3049"],"i_c":"9490/0","i_c_s":["Ganglioneuroma"],"term_type":"PT"},{"nm":"Ganglioneuromatosis","n_c":["C66804"],"i_c":"9491/0","i_c_s":["Ganglioneuromatosis"],"term_type":"PT"},{"nm":"GANT","n_c":["C27940"],"i_c":"8936/1","i_c_s":["GANT"],"term_type":"SY"},{"nm":"Gastrin cell tumor","n_c":["C3050"],"i_c":"8153/1","i_c_s":["Gastrin cell tumor"],"term_type":"SY"},{"nm":"Gastrin cell tumor, malignant","n_c":["C65188"],"i_c":"8153/3","i_c_s":["Gastrin cell tumor, malignant"],"term_type":"SY"},{"nm":"Gastrinoma, malignant","n_c":["C65188"],"i_c":"8153/3","i_c_s":["Gastrinoma, malignant"],"term_type":"PT"},{"nm":"Gastrinoma, NOS","n_c":["C3050"],"i_c":"8153/1","i_c_s":["Gastrinoma, NOS"],"term_type":"PT"},{"nm":"Gastrointestinal autonomic nerve tumor","n_c":["C27940"],"i_c":"8936/1","i_c_s":["Gastrointestinal autonomic nerve tumor"],"term_type":"RT"},{"nm":"Gastrointestinal pacemaker cell tumor","n_c":"","i_c":"8936/1","i_c_s":["Gastrointestinal pacemaker cell tumor"],"term_type":"RT"},{"nm":"Gastrointestinal stromal sarcoma","n_c":["C53999"],"i_c":"8936/3","i_c_s":["Gastrointestinal stromal sarcoma"],"term_type":"PT"},{"nm":"Gastrointestinal stromal tumor, benign","n_c":["C53998"],"i_c":"8936/0","i_c_s":["Gastrointestinal stromal tumor, benign"],"term_type":"PT"},{"nm":"Gastrointestinal stromal tumor, malignant","n_c":["C53999"],"i_c":"8936/3","i_c_s":["Gastrointestinal stromal tumor, malignant"],"term_type":"SY"},{"nm":"Gastrointestinal stromal tumor, NOS","n_c":["C3868"],"i_c":"8936/1","i_c_s":["Gastrointestinal stromal tumor, NOS"],"term_type":"PT"},{"nm":"Gastrointestinal stromal tumor, uncertain malignant potential","n_c":["C54000"],"i_c":"8936/1","i_c_s":["Gastrointestinal stromal tumor, uncertain malignant potential"],"term_type":"SY"},{"nm":"Gelatinous adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Gelatinous adenocarcinoma"],"term_type":"IS"},{"nm":"Gelatinous carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Gelatinous carcinoma"],"term_type":"IS"},{"nm":"Gemistocytic astrocytoma","n_c":["C4321"],"i_c":"9411/3","i_c_s":["Gemistocytic astrocytoma"],"term_type":"PT"},{"nm":"Gemistocytoma","n_c":["C4321"],"i_c":"9411/3","i_c_s":["Gemistocytoma"],"term_type":"SY"},{"nm":"Genital rhabdomyoma","n_c":["C6517"],"i_c":"8905/0","i_c_s":["Genital rhabdomyoma"],"term_type":"PT"},{"nm":"Germ cell tumor, nonseminomatous","n_c":["C121619"],"i_c":"9065/3","i_c_s":["Germ cell tumor, nonseminomatous"],"term_type":"PT"},{"nm":"Germ cell tumor, NOS","n_c":["C3708"],"i_c":"9064/3","i_c_s":["Germ cell tumor, NOS"],"term_type":"SY"},{"nm":"Germ cell tumors with associated hematological malignancy","n_c":["C45733"],"i_c":"9086/3","i_c_s":["Germ cell tumors with associated hematological malignancy"],"term_type":"PT"},{"nm":"Germinoma","n_c":["C7009"],"i_c":"9064/3","i_c_s":["Germinoma"],"term_type":"PT"},{"nm":"Ghost cell odontogenic carcinoma","n_c":["C4311"],"i_c":"9302/3","i_c_s":["Ghost cell odontogenic carcinoma"],"term_type":""},{"nm":"Giant cell and spindle cell carcinoma","n_c":["C65160"],"i_c":"8030/3","i_c_s":["Giant cell and spindle cell carcinoma"],"term_type":"PT"},{"nm":"Giant cell angiofibroma","n_c":["C27256"],"i_c":"9160/0","i_c_s":["Giant cell angiofibroma"],"term_type":"RT"},{"nm":"Giant cell carcinoma","n_c":["C3779"],"i_c":"8031/3","i_c_s":["Giant cell carcinoma"],"term_type":"PT"},{"nm":"Giant cell fibroblastoma","n_c":["C4700"],"i_c":"8834/1","i_c_s":["Giant cell fibroblastoma"],"term_type":"PT"},{"nm":"Giant cell glioblastoma","n_c":["C4325"],"i_c":"9441/3","i_c_s":["Giant cell glioblastoma"],"term_type":"PT"},{"nm":"Giant cell sarcoma","n_c":["C66759"],"i_c":"8802/3","i_c_s":["Giant cell sarcoma"],"term_type":"PT"},{"nm":"Giant cell sarcoma of bone","n_c":["C4304"],"i_c":"9250/3","i_c_s":["Giant cell sarcoma of bone"],"term_type":"SY"},{"nm":"Giant cell tumor of bone, malignant","n_c":["C4304"],"i_c":"9250/3","i_c_s":["Giant cell tumor of bone, malignant"],"term_type":"PT"},{"nm":"Giant cell tumor of bone, NOS","n_c":["C121932"],"i_c":"9250/1","i_c_s":["Giant cell tumor of bone, NOS"],"term_type":"PT"},{"nm":"Giant cell tumor of soft parts, NOS","n_c":["C49107"],"i_c":"9251/1","i_c_s":["Giant cell tumor of soft parts, NOS"],"term_type":"PT"},{"nm":"Giant cell tumor of tendon sheath","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Giant cell tumor of tendon sheath"],"term_type":"SY"},{"nm":"Giant cell tumor of tendon sheath, malignant","n_c":["C6535"],"i_c":"9252/3","i_c_s":["Giant cell tumor of tendon sheath, malignant"],"term_type":"SY"},{"nm":"Giant fibroadenoma","n_c":["C4273"],"i_c":"9016/0","i_c_s":["Giant fibroadenoma"],"term_type":"PT"},{"nm":"Giant osteoid osteoma","n_c":["C3294"],"i_c":"9200/0","i_c_s":["Giant osteoid osteoma"],"term_type":"SY"},{"nm":"Giant pigmented nevus, NOS","n_c":["C4234"],"i_c":"8761/1","i_c_s":["Giant pigmented nevus, NOS"],"term_type":"PT"},{"nm":"Gigantiform cementoma","n_c":["C202219"],"i_c":"9275/0","i_c_s":["Gigantiform cementoma"],"term_type":"PT"},{"nm":"GIST, benign","n_c":["C53998"],"i_c":"8936/0","i_c_s":["GIST, benign"],"term_type":"SY"},{"nm":"GIST, malignant","n_c":["C53999"],"i_c":"8936/3","i_c_s":["GIST, malignant"],"term_type":"SY"},{"nm":"GIST, NOS","n_c":["C3868"],"i_c":"8936/1","i_c_s":["GIST, NOS"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, grade I","n_c":["C7661"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, grade I"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, grade II","n_c":["C7660"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, grade II"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, grade III","n_c":["C6877"],"i_c":"8148/2","i_c_s":["Glandular intraepithelial neoplasia, grade III"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, high grade","n_c":["C7662"],"i_c":"8148/2","i_c_s":["Glandular intraepithelial neoplasia, high grade"],"term_type":"PT"},{"nm":"Glandular intraepithelial neoplasia, low grade","n_c":["C7661"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, low grade"],"term_type":"PT"},{"nm":"Glandular papilloma","n_c":["C6880"],"i_c":"8260/0","i_c_s":["Glandular papilloma"],"term_type":"RT"},{"nm":"Glassy cell carcinoma","n_c":["C65159"],"i_c":"8015/3","i_c_s":["Glassy cell carcinoma"],"term_type":"PT"},{"nm":"Glioblastoma","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Glioblastoma"],"term_type":""},{"nm":"Glioblastoma multiforme","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Glioblastoma multiforme"],"term_type":"SY"},{"nm":"Glioblastoma with sarcomatous component","n_c":["C3796"],"i_c":"9442/3","i_c_s":["Glioblastoma with sarcomatous component"],"term_type":"SY"},{"nm":"Glioblastoma, IDH wildtype","n_c":["C39750"],"i_c":"9440/3","i_c_s":["Glioblastoma, IDH wildtype"],"term_type":""},{"nm":"Glioblastoma, IDH-mutant","n_c":["C167335"],"i_c":"9445/3","i_c_s":["Glioblastoma, IDH-mutant"],"term_type":"PT"},{"nm":"Gliofibroma","n_c":["C5419"],"i_c":"9442/1","i_c_s":["Gliofibroma"],"term_type":"PT"},{"nm":"Glioma, malignant","n_c":["C4822"],"i_c":"9380/3","i_c_s":["Glioma, malignant"],"term_type":"PT"},{"nm":"Glioma, NOS","n_c":["C3059"],"i_c":"9380/3","i_c_s":["Glioma, NOS"],"term_type":"SY"},{"nm":"Gliomatosis cerebri","n_c":["C4318"],"i_c":"9381/3","i_c_s":["Gliomatosis cerebri"],"term_type":"PT"},{"nm":"Glioneuroma","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Glioneuroma"],"term_type":"IS"},{"nm":"Gliosarcoma","n_c":["C3796"],"i_c":"9442/3","i_c_s":["Gliosarcoma"],"term_type":"PT"},{"nm":"Glomangioma","n_c":["C4222"],"i_c":"8712/0","i_c_s":["Glomangioma"],"term_type":"PT"},{"nm":"Glomangiomyoma","n_c":["C4223"],"i_c":"8713/0","i_c_s":["Glomangiomyoma"],"term_type":"PT"},{"nm":"Glomangiosarcoma","n_c":["C4221"],"i_c":"8710/3","i_c_s":["Glomangiosarcoma"],"term_type":"PT"},{"nm":"Glomoid sarcoma","n_c":["C4221"],"i_c":"8710/3","i_c_s":["Glomoid sarcoma"],"term_type":"SY"},{"nm":"Glomus jugulare tumor, NOS","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Glomus jugulare tumor, NOS"],"term_type":"PT"},{"nm":"Glomus tumor, malignant","n_c":["C4221"],"i_c":"8711/3","i_c_s":["Glomus tumor, malignant"],"term_type":"PT"},{"nm":"Glomus tumor, NOS","n_c":["C3060"],"i_c":"8711/0","i_c_s":["Glomus tumor, NOS"],"term_type":"PT"},{"nm":"Glucagon-like peptide-producing tumor","n_c":"","i_c":"8152/1","i_c_s":["Glucagon-like peptide-producing tumor"],"term_type":"RT"},{"nm":"Glucagonoma, malignant","n_c":["C65187"],"i_c":"8152/3","i_c_s":["Glucagonoma, malignant"],"term_type":"PT"},{"nm":"Glucagonoma, NOS","n_c":"","i_c":"8152/1","i_c_s":["Glucagonoma, NOS"],"term_type":"PT"},{"nm":"Glycogen-rich carcinoma","n_c":["C4153"],"i_c":"8315/3","i_c_s":["Glycogen-rich carcinoma"],"term_type":"PT"},{"nm":"Glycogenic rhabdomyoma","n_c":"","i_c":"8904/0","i_c_s":["Glycogenic rhabdomyoma"],"term_type":"RT"},{"nm":"Goblet cell carcinoid","n_c":["C201135"],"i_c":"8243/3","i_c_s":["Goblet cell carcinoid"],"term_type":"PT"},{"nm":"Gonadal stromal tumor, NOS","n_c":["C3794"],"i_c":"8590/1","i_c_s":["Gonadal stromal tumor, NOS"],"term_type":"SY"},{"nm":"Gonadoblastoma","n_c":["C3754"],"i_c":"9073/1","i_c_s":["Gonadoblastoma"],"term_type":"PT"},{"nm":"Gonocytoma","n_c":["C3754"],"i_c":"9073/1","i_c_s":["Gonocytoma"],"term_type":"SY"},{"nm":"Granular cell adenocarcinoma","n_c":["C3681"],"i_c":"8320/3","i_c_s":["Granular cell adenocarcinoma"],"term_type":"SY"},{"nm":"Granular cell carcinoma","n_c":["C3681"],"i_c":"8320/3","i_c_s":["Granular cell carcinoma"],"term_type":"PT"},{"nm":"Granular cell myoblastoma, malignant","n_c":["C4336"],"i_c":"9580/3","i_c_s":["Granular cell myoblastoma, malignant"],"term_type":"SY"},{"nm":"Granular cell myoblastoma, NOS","n_c":["C3474"],"i_c":"9580/0","i_c_s":["Granular cell myoblastoma, NOS"],"term_type":"SY"},{"nm":"Granular cell tumor of the sellar region","n_c":["C7017"],"i_c":"9582/0","i_c_s":["Granular cell tumor of the sellar region"],"term_type":"PT"},{"nm":"Granular cell tumor, malignant","n_c":["C4336"],"i_c":"9580/3","i_c_s":["Granular cell tumor, malignant"],"term_type":"PT"},{"nm":"Granular cell tumor, NOS","n_c":["C3474"],"i_c":"9580/0","i_c_s":["Granular cell tumor, NOS"],"term_type":"PT"},{"nm":"Granulocytic leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Granulocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Granulocytic sarcoma","n_c":["C35815"],"i_c":"9930/3","i_c_s":["Granulocytic sarcoma"],"term_type":"SY"},{"nm":"Granulosa cell carcinoma","n_c":["C4205"],"i_c":"8620/3","i_c_s":["Granulosa cell carcinoma"],"term_type":"RT"},{"nm":"Granulosa cell tumor, adult type","n_c":["C66750"],"i_c":"8620/1","i_c_s":["Granulosa cell tumor, adult type"],"term_type":"PT"},{"nm":"Granulosa cell tumor, juvenile","n_c":["C4207"],"i_c":"8622/1","i_c_s":["Granulosa cell tumor, juvenile"],"term_type":"PT"},{"nm":"Granulosa cell tumor, malignant","n_c":["C4205"],"i_c":"8620/3","i_c_s":["Granulosa cell tumor, malignant"],"term_type":"PT"},{"nm":"Granulosa cell tumor, NOS","n_c":["C3070"],"i_c":"8620/1","i_c_s":["Granulosa cell tumor, NOS"],"term_type":"SY"},{"nm":"Granulosa cell tumor, sarcomatoid","n_c":"","i_c":"8620/3","i_c_s":["Granulosa cell tumor, sarcomatoid"],"term_type":"RT"},{"nm":"Granulosa cell-theca cell tumor","n_c":["C66751"],"i_c":"8621/1","i_c_s":["Granulosa cell-theca cell tumor"],"term_type":"PT"},{"nm":"Grawitz tumor","n_c":["C4033"],"i_c":"8312/3","i_c_s":["Grawitz tumor"],"term_type":"IS"},{"nm":"Gynandroblastoma","n_c":["C3072"],"i_c":"8632/1","i_c_s":["Gynandroblastoma"],"term_type":"PT"},{"nm":"Haemangioblastoma","n_c":["C3801"],"i_c":"9161/1","i_c_s":["Haemangioblastoma"],"term_type":""},{"nm":"Haemangiosarcoma","n_c":["C3088"],"i_c":"9120/3","i_c_s":["Haemangiosarcoma"],"term_type":""},{"nm":"Hairy cell leukaemia variant","n_c":["C7401"],"i_c":"9940/3","i_c_s":["Hairy cell leukaemia variant"],"term_type":""},{"nm":"Hairy cell leukemia","n_c":["C7402"],"i_c":"9940/3","i_c_s":["Hairy cell leukemia"],"term_type":"PT"},{"nm":"Hairy cell leukemia variant","n_c":["C7401"],"i_c":"9591/3","i_c_s":["Hairy cell leukemia variant"],"term_type":"RT"},{"nm":"Hairy nevus","n_c":["C3074"],"i_c":"8720/0","i_c_s":["Hairy nevus"],"term_type":"RT"},{"nm":"Halo nevus","n_c":["C7602"],"i_c":"8723/0","i_c_s":["Halo nevus"],"term_type":"PT"},{"nm":"Hand-Schuller-Christian disease","n_c":["C6920"],"i_c":"9751/3","i_c_s":["Hand-Schuller-Christian disease"],"term_type":"ORT"},{"nm":"Heavy chain disease, NOS","n_c":["C3082"],"i_c":"9762/3","i_c_s":["Heavy chain disease, NOS"],"term_type":"PT"},{"nm":"Hemangioblastic meningioma","n_c":["C66817"],"i_c":"9535/0","i_c_s":["Hemangioblastic meningioma"],"term_type":"OP"},{"nm":"Hemangioendothelial sarcoma","n_c":["C3088"],"i_c":"9130/3","i_c_s":["Hemangioendothelial sarcoma"],"term_type":"SY"},{"nm":"Hemangioendothelioma, benign","n_c":["C66779"],"i_c":"9130/0","i_c_s":["Hemangioendothelioma, benign"],"term_type":"PT"},{"nm":"Hemangioendothelioma, malignant","n_c":["C3088"],"i_c":"9130/3","i_c_s":["Hemangioendothelioma, malignant"],"term_type":"PT"},{"nm":"Hemangioendothelioma, NOS","n_c":["C3084"],"i_c":"9130/1","i_c_s":["Hemangioendothelioma, NOS"],"term_type":"PT"},{"nm":"Hemangioma simplex","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Hemangioma simplex"],"term_type":"SY"},{"nm":"Hemangioma, NOS","n_c":["C3085"],"i_c":"9120/0","i_c_s":["Hemangioma, NOS"],"term_type":"PT"},{"nm":"Hemangiopericytic meningioma","n_c":"","i_c":"9150/1","i_c_s":["Hemangiopericytic meningioma"],"term_type":"ORT"},{"nm":"Hemangiopericytoma, benign","n_c":["C4300"],"i_c":"9150/0","i_c_s":["Hemangiopericytoma, benign"],"term_type":"PT"},{"nm":"Hemangiopericytoma, malignant","n_c":["C4301"],"i_c":"9150/3","i_c_s":["Hemangiopericytoma, malignant"],"term_type":"PT"},{"nm":"Hemangiopericytoma, NOS","n_c":["C3087"],"i_c":"9150/1","i_c_s":["Hemangiopericytoma, NOS"],"term_type":"PT"},{"nm":"Hemolymphangioma","n_c":["C66792"],"i_c":"9175/0","i_c_s":["Hemolymphangioma"],"term_type":"PT"},{"nm":"Hepatoblastoma","n_c":["C3728"],"i_c":"8970/3","i_c_s":["Hepatoblastoma"],"term_type":"PT"},{"nm":"Hepatoblastoma, epithelioid","n_c":"","i_c":"8970/3","i_c_s":["Hepatoblastoma, epithelioid"],"term_type":"RT"},{"nm":"Hepatoblastoma, mixed epithelial-mesenchymal","n_c":["C7097"],"i_c":"8970/3","i_c_s":["Hepatoblastoma, mixed epithelial-mesenchymal"],"term_type":"RT"},{"nm":"Hepatocarcinoma","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatocarcinoma"],"term_type":"SY"},{"nm":"Hepatocellular adenoma","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Hepatocellular adenoma"],"term_type":"SY"},{"nm":"Hepatocellular carcinoma, clear cell type","n_c":["C5754"],"i_c":"8174/3","i_c_s":["Hepatocellular carcinoma, clear cell type"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, fibrolamellar","n_c":["C4131"],"i_c":"8171/3","i_c_s":["Hepatocellular carcinoma, fibrolamellar"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, NOS","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatocellular carcinoma, NOS"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, pleomorphic type","n_c":["C43625"],"i_c":"8175/3","i_c_s":["Hepatocellular carcinoma, pleomorphic type"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, sarcomatoid","n_c":["C43627"],"i_c":"8173/3","i_c_s":["Hepatocellular carcinoma, sarcomatoid"],"term_type":"SY"},{"nm":"Hepatocellular carcinoma, scirrhous","n_c":["C27388"],"i_c":"8172/3","i_c_s":["Hepatocellular carcinoma, scirrhous"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, spindle cell variant","n_c":["C43627"],"i_c":"8173/3","i_c_s":["Hepatocellular carcinoma, spindle cell variant"],"term_type":"PT"},{"nm":"Hepatocholangiocarcinoma","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Hepatocholangiocarcinoma"],"term_type":"SY"},{"nm":"Hepatoid adenocarcinoma","n_c":["C66950"],"i_c":"8576/3","i_c_s":["Hepatoid adenocarcinoma"],"term_type":"PT"},{"nm":"Hepatoid carcinoma","n_c":["C66950"],"i_c":"8576/3","i_c_s":["Hepatoid carcinoma"],"term_type":"SY"},{"nm":"Hepatoid yolk sac tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Hepatoid yolk sac tumor"],"term_type":"RT"},{"nm":"Hepatoma, benign","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Hepatoma, benign"],"term_type":"SY"},{"nm":"Hepatoma, malignant","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatoma, malignant"],"term_type":"SY"},{"nm":"Hepatoma, NOS","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatoma, NOS"],"term_type":"SY"},{"nm":"Hepatosplenic gamma-delta cell lymphoma","n_c":["C8459"],"i_c":"9716/3","i_c_s":["Hepatosplenic gamma-delta cell lymphoma"],"term_type":"SY"},{"nm":"Hepatosplenic T-cell lymphoma","n_c":["C8459"],"i_c":"9716/3","i_c_s":["Hepatosplenic T-cell lymphoma"],"term_type":"PT"},{"nm":"Hereditary leiomyomatosis & RCC-associated renal cell carcinoma","n_c":["C51302"],"i_c":"8311/3","i_c_s":["Hereditary leiomyomatosis & RCC-associated renal cell carcinoma"],"term_type":""},{"nm":"Hibernoma","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Hibernoma"],"term_type":"PT"},{"nm":"Hidradenocarcinoma","n_c":["C54664"],"i_c":"8402/3","i_c_s":["Hidradenocarcinoma"],"term_type":"SY"},{"nm":"Hidradenoma papilliferum","n_c":["C4171"],"i_c":"8405/0","i_c_s":["Hidradenoma papilliferum"],"term_type":"SY"},{"nm":"Hidradenoma, NOS","n_c":["C7563"],"i_c":"8400/0","i_c_s":["Hidradenoma, NOS"],"term_type":"SY"},{"nm":"Hidrocystoma","n_c":["C3760"],"i_c":"8404/0","i_c_s":["Hidrocystoma"],"term_type":"PT"},{"nm":"High grade surface osteosarcoma","n_c":["C53958"],"i_c":"9194/3","i_c_s":["High grade surface osteosarcoma"],"term_type":"PT"},{"nm":"High-grade neuroendocrine carcinoma","n_c":"","i_c":"8041/3","i_c_s":["High-grade neuroendocrine carcinoma"],"term_type":""},{"nm":"High-grade serous carcinoma","n_c":"","i_c":"8461/3","i_c_s":["High-grade serous carcinoma"],"term_type":""},{"nm":"Hilar cell tumor","n_c":["C4214"],"i_c":"8660/0","i_c_s":["Hilar cell tumor"],"term_type":"SY"},{"nm":"Hilus cell tumor","n_c":["C4214"],"i_c":"8660/0","i_c_s":["Hilus cell tumor"],"term_type":"PT"},{"nm":"Histiocyte-rich large B-cell lymphoma","n_c":["C9496"],"i_c":"9688/3","i_c_s":["Histiocyte-rich large B-cell lymphoma"],"term_type":""},{"nm":"Histiocytic medullary reticulosis","n_c":["C7202"],"i_c":"9750/3","i_c_s":["Histiocytic medullary reticulosis"],"term_type":"ORT"},{"nm":"Histiocytic sarcoma","n_c":["C27349"],"i_c":"9755/3","i_c_s":["Histiocytic sarcoma"],"term_type":"PT"},{"nm":"Histiocytoid hemangioma","n_c":["C4298"],"i_c":"9125/0","i_c_s":["Histiocytoid hemangioma"],"term_type":"SY"},{"nm":"Histiocytoma, NOS","n_c":["C35765"],"i_c":"8831/0","i_c_s":["Histiocytoma, NOS"],"term_type":"PT"},{"nm":"Histiocytosis X, NOS","n_c":["C3107"],"i_c":"9751/3","i_c_s":["Histiocytosis X, NOS"],"term_type":"ORT"},{"nm":"Hodgkin disease, lymphocyte predominance, diffuse","n_c":["C6913"],"i_c":"9651/3","i_c_s":["Hodgkin disease, lymphocyte predominance, diffuse"],"term_type":"IS"},{"nm":"Hodgkin disease, lymphocyte predominance, NOS","n_c":["C8590"],"i_c":"9651/3","i_c_s":["Hodgkin disease, lymphocyte predominance, NOS"],"term_type":"ORT"},{"nm":"Hodgkin disease, lymphocytic-histiocytic predominance","n_c":["C8590"],"i_c":"9651/3","i_c_s":["Hodgkin disease, lymphocytic-histiocytic predominance"],"term_type":"IS"},{"nm":"Hodgkin disease, nodular sclerosis, lymphocyte depletion","n_c":["C27808"],"i_c":"9667/3","i_c_s":["Hodgkin disease, nodular sclerosis, lymphocyte depletion"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, lymphocyte predominance","n_c":["C27270"],"i_c":"9665/3","i_c_s":["Hodgkin disease, nodular sclerosis, lymphocyte predominance"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, mixed cellularity","n_c":["C27098"],"i_c":"9665/3","i_c_s":["Hodgkin disease, nodular sclerosis, mixed cellularity"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, NOS","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Hodgkin disease, nodular sclerosis, NOS"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, syncytial variant","n_c":["C27807"],"i_c":"9667/3","i_c_s":["Hodgkin disease, nodular sclerosis, syncytial variant"],"term_type":"SY"},{"nm":"Hodgkin disease, NOS","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Hodgkin disease, NOS"],"term_type":"SY"},{"nm":"Hodgkin granuloma","n_c":["C6914"],"i_c":"9661/3","i_c_s":["Hodgkin granuloma"],"term_type":"OP"},{"nm":"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis","n_c":["C9283"],"i_c":"9654/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, lymphocyte depletion, NOS","n_c":["C9283"],"i_c":"9653/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, NOS"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, lymphocyte depletion, reticular","n_c":["C9283"],"i_c":"9655/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, reticular"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, lymphocyte predominance, nodular","n_c":["C7258"],"i_c":"9659/3","i_c_s":["Hodgkin lymphoma, lymphocyte predominance, nodular"],"term_type":"SY"},{"nm":"Hodgkin lymphoma, lymphocyte-rich","n_c":["C6913"],"i_c":"9651/3","i_c_s":["Hodgkin lymphoma, lymphocyte-rich"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, mixed cellularity, NOS","n_c":["C3517"],"i_c":"9652/3","i_c_s":["Hodgkin lymphoma, mixed cellularity, NOS"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular lymphocyte predominance","n_c":["C7258"],"i_c":"9659/3","i_c_s":["Hodgkin lymphoma, nodular lymphocyte predominance"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, cellular phase","n_c":["C67171"],"i_c":"9664/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, cellular phase"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, grade 1","n_c":["C7165"],"i_c":"9665/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 1"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, grade 2","n_c":["C7166"],"i_c":"9667/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 2"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, NOS","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, NOS"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, NOS","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Hodgkin lymphoma, NOS"],"term_type":"PT"},{"nm":"Hodgkin paragranuloma, nodular","n_c":["C26956"],"i_c":"9659/3","i_c_s":["Hodgkin paragranuloma, nodular"],"term_type":"IS"},{"nm":"Hodgkin paragranuloma, NOS","n_c":["C26956"],"i_c":"9659/3","i_c_s":["Hodgkin paragranuloma, NOS"],"term_type":"IS"},{"nm":"Hodgkin sarcoma","n_c":["C164145"],"i_c":"9662/3","i_c_s":["Hodgkin sarcoma"],"term_type":"OP"},{"nm":"Hurthle cell adenocarcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Hurthle cell adenocarcinoma"],"term_type":"RT"},{"nm":"Hurthle cell adenoma","n_c":["C6042"],"i_c":"8290/0","i_c_s":["Hurthle cell adenoma"],"term_type":"RT"},{"nm":"Hurthle cell carcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Hurthle cell carcinoma"],"term_type":"RT"},{"nm":"Hurthle cell tumor","n_c":["C46068"],"i_c":"8290/0","i_c_s":["Hurthle cell tumor"],"term_type":"RT"},{"nm":"Hutchinson melanotic freckle, NOS","n_c":["C43372"],"i_c":"8742/2","i_c_s":["Hutchinson melanotic freckle, NOS"],"term_type":"SY"},{"nm":"Hyalinizing trabecular adenoma","n_c":["C6846"],"i_c":"8336/0","i_c_s":["Hyalinizing trabecular adenoma"],"term_type":"PT"},{"nm":"Hydatid mole","n_c":["C3110"],"i_c":"9100/0","i_c_s":["Hydatid mole"],"term_type":"SY"},{"nm":"Hydatidiform mole, NOS","n_c":["C3110"],"i_c":"9100/0","i_c_s":["Hydatidiform mole, NOS"],"term_type":"PT"},{"nm":"Hydroa vacciniforme-like lymphoma","n_c":["C45327"],"i_c":"9725/3","i_c_s":["Hydroa vacciniforme-like lymphoma"],"term_type":"PT"},{"nm":"Hygroma, NOS","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Hygroma, NOS"],"term_type":"SY"},{"nm":"Hypereosinophilic syndrome","n_c":["C27038"],"i_c":"9964/3","i_c_s":["Hypereosinophilic syndrome"],"term_type":"SY"},{"nm":"Hypernephroid tumor","n_c":["C4033"],"i_c":"8311/1","i_c_s":["Hypernephroid tumor"],"term_type":"OP"},{"nm":"Hypernephroma","n_c":["C4033"],"i_c":"8312/3","i_c_s":["Hypernephroma"],"term_type":"IS"},{"nm":"Idiopathic hemorrhagic thrombocythaemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Idiopathic hemorrhagic thrombocythaemia"],"term_type":""},{"nm":"Idiopathic thrombocythemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Idiopathic thrombocythemia"],"term_type":"SY"},{"nm":"Immature teratoma, malignant","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Immature teratoma, malignant"],"term_type":"RT"},{"nm":"Immature teratoma, NOS","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Immature teratoma, NOS"],"term_type":"SY"},{"nm":"Immunoblastic sarcoma","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Immunoblastic sarcoma"],"term_type":"IS"},{"nm":"Immunocytoma","n_c":["C3898"],"i_c":"9671/3","i_c_s":["Immunocytoma"],"term_type":"ORT"},{"nm":"Immunoglobulin deposition disease","n_c":["C7151"],"i_c":"9769/1","i_c_s":["Immunoglobulin deposition disease"],"term_type":"PT"},{"nm":"Immunoproliferative disease, NOS","n_c":["C3132"],"i_c":"9760/3","i_c_s":["Immunoproliferative disease, NOS"],"term_type":"PT"},{"nm":"Immunoproliferative small intestinal disease","n_c":["C3132"],"i_c":"9764/3","i_c_s":["Immunoproliferative small intestinal disease"],"term_type":"PT"},{"nm":"Indeterminate dendritic cell tumor","n_c":["C81767"],"i_c":"9757/3","i_c_s":["Indeterminate dendritic cell tumor"],"term_type":"RT"},{"nm":"Indolent systemic mastocytosis","n_c":["C9286"],"i_c":"9741/1","i_c_s":["Indolent systemic mastocytosis"],"term_type":"PT"},{"nm":"Infantile fibrosarcoma","n_c":["C4244"],"i_c":"8814/3","i_c_s":["Infantile fibrosarcoma"],"term_type":"PT"},{"nm":"Infantile hemangioma","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Infantile hemangioma"],"term_type":"SY"},{"nm":"Infantile myofibromatosis","n_c":["C3742"],"i_c":"8824/1","i_c_s":["Infantile myofibromatosis"],"term_type":"SY"},{"nm":"Infiltrating and papillary adenocarcinoma","n_c":["C7438"],"i_c":"8503/3","i_c_s":["Infiltrating and papillary adenocarcinoma"],"term_type":"SY"},{"nm":"Infiltrating angiolipoma","n_c":["C7449"],"i_c":"8856/0","i_c_s":["Infiltrating angiolipoma"],"term_type":"RT"},{"nm":"Infiltrating basal cell carcinoma, non-sclerosing","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, non-sclerosing"],"term_type":"RT"},{"nm":"Infiltrating basal cell carcinoma, NOS","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Infiltrating basal cell carcinoma, sclerosing","n_c":["C27182"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, sclerosing"],"term_type":"RT"},{"nm":"Infiltrating duct adenocarcinoma","n_c":["C4194"],"i_c":"8500/3","i_c_s":["Infiltrating duct adenocarcinoma"],"term_type":"SY"},{"nm":"Infiltrating duct and colloid carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and colloid carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct and cribriform carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and cribriform carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct and lobular carcinoma","n_c":["C7688"],"i_c":"8522/3","i_c_s":["Infiltrating duct and lobular carcinoma"],"term_type":"PT"},{"nm":"Infiltrating duct and lobular carcinoma in situ","n_c":["C7689"],"i_c":"8522/3","i_c_s":["Infiltrating duct and lobular carcinoma in situ"],"term_type":"RT"},{"nm":"Infiltrating duct and mucinous carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and mucinous carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct and tubular carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and tubular carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct carcinoma, NOS","n_c":["C4194"],"i_c":"8500/3","i_c_s":["Infiltrating duct carcinoma, NOS"],"term_type":"PT"},{"nm":"Infiltrating duct mixed with other types of carcinoma","n_c":["C7688"],"i_c":"8523/3","i_c_s":["Infiltrating duct mixed with other types of carcinoma"],"term_type":"PT"},{"nm":"Infiltrating ductular carcinoma","n_c":["C4194"],"i_c":"8521/3","i_c_s":["Infiltrating ductular carcinoma"],"term_type":"PT"},{"nm":"Infiltrating lipoma","n_c":["C7451"],"i_c":"8856/0","i_c_s":["Infiltrating lipoma"],"term_type":"RT"},{"nm":"Infiltrating lobular carcinoma and ductal carcinoma in situ","n_c":["C6939"],"i_c":"8522/3","i_c_s":["Infiltrating lobular carcinoma and ductal carcinoma in situ"],"term_type":"RT"},{"nm":"Infiltrating lobular carcinoma, NOS","n_c":["C7950"],"i_c":"8520/3","i_c_s":["Infiltrating lobular carcinoma, NOS"],"term_type":"SY"},{"nm":"Infiltrating lobular mixed with other types of carcinoma","n_c":["C6939"],"i_c":"8524/3","i_c_s":["Infiltrating lobular mixed with other types of carcinoma"],"term_type":"PT"},{"nm":"Infiltrating papillary adenocarcinoma","n_c":["C7438"],"i_c":"8503/3","i_c_s":["Infiltrating papillary adenocarcinoma"],"term_type":"SY"},{"nm":"Inflammatory adenocarcinoma","n_c":"","i_c":"8530/3","i_c_s":["Inflammatory adenocarcinoma"],"term_type":"SY"},{"nm":"Inflammatory carcinoma","n_c":["C4001"],"i_c":"8530/3","i_c_s":["Inflammatory carcinoma"],"term_type":"PT"},{"nm":"Inflammatory liposarcoma","n_c":["C6508"],"i_c":"8851/3","i_c_s":["Inflammatory liposarcoma"],"term_type":"RT"},{"nm":"Inflammatory myofibroblastic tumor","n_c":["C6481"],"i_c":"8825/1","i_c_s":["Inflammatory myofibroblastic tumor"],"term_type":"SY"},{"nm":"Insular carcinoma","n_c":["C6040"],"i_c":"8337/3","i_c_s":["Insular carcinoma"],"term_type":"PT"},{"nm":"Insulinoma, malignant","n_c":["C65186"],"i_c":"8151/3","i_c_s":["Insulinoma, malignant"],"term_type":"PT"},{"nm":"Insulinoma, NOS","n_c":["C95598"],"i_c":"8151/0","i_c_s":["Insulinoma, NOS"],"term_type":"PT"},{"nm":"Interdigitating cell sarcoma","n_c":["C9282"],"i_c":"9757/3","i_c_s":["Interdigitating cell sarcoma"],"term_type":"SY"},{"nm":"Interdigitating dendritic cell sarcoma","n_c":["C9282"],"i_c":"9757/3","i_c_s":["Interdigitating dendritic cell sarcoma"],"term_type":"PT"},{"nm":"Intermediate and giant congenital nevus","n_c":"","i_c":"8761/1","i_c_s":["Intermediate and giant congenital nevus"],"term_type":"RT"},{"nm":"Interstitial cell tumor, benign","n_c":["C4212"],"i_c":"8650/0","i_c_s":["Interstitial cell tumor, benign"],"term_type":"SY"},{"nm":"Interstitial cell tumor, malignant","n_c":["C4213"],"i_c":"8650/3","i_c_s":["Interstitial cell tumor, malignant"],"term_type":"SY"},{"nm":"Interstitial cell tumor, NOS","n_c":["C3188"],"i_c":"8650/1","i_c_s":["Interstitial cell tumor, NOS"],"term_type":"SY"},{"nm":"Intestinal T-cell lymphoma","n_c":["C4737"],"i_c":"9717/3","i_c_s":["Intestinal T-cell lymphoma"],"term_type":"PT"},{"nm":"Intestinal-type adenocarcinoma","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Intestinal-type adenocarcinoma"],"term_type":""},{"nm":"Intimal sarcoma","n_c":["C53677"],"i_c":"9137/3","i_c_s":["Intimal sarcoma"],"term_type":"PT"},{"nm":"Intracanalicular fibroadenoma","n_c":["C4271"],"i_c":"9011/0","i_c_s":["Intracanalicular fibroadenoma"],"term_type":"PT"},{"nm":"Intracortical osteosarcoma","n_c":["C35870"],"i_c":"9195/3","i_c_s":["Intracortical osteosarcoma"],"term_type":"PT"},{"nm":"Intracystic carcinoma, NOS","n_c":["C7645"],"i_c":"8504/3","i_c_s":["Intracystic carcinoma, NOS"],"term_type":"PT"},{"nm":"Intracystic papillary adenocarcinoma","n_c":["C7645"],"i_c":"8504/3","i_c_s":["Intracystic papillary adenocarcinoma"],"term_type":"SY"},{"nm":"Intracystic papillary adenoma","n_c":["C3863"],"i_c":"8504/0","i_c_s":["Intracystic papillary adenoma"],"term_type":"PT"},{"nm":"Intracystic papillary neoplasm with associated invasive carcinoma","n_c":"","i_c":"8503/3","i_c_s":["Intracystic papillary neoplasm with associated invasive carcinoma"],"term_type":"SY"},{"nm":"Intracystic papillary neoplasm with high grade intraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia","n_c":["C96878"],"i_c":"8503/0","i_c_s":["Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intracystic papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C96877"],"i_c":"8503/0","i_c_s":["Intracystic papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intracystic papillary tumor with high grade dysplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary tumor with high grade dysplasia"],"term_type":"SY"},{"nm":"Intracystic papillary tumor with high grade entraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary tumor with high grade entraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intracystic papillary tumor with high grade intraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary tumor with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intracystic papilloma","n_c":["C3863"],"i_c":"8504/0","i_c_s":["Intracystic papilloma"],"term_type":"SY"},{"nm":"Intradermal nevus","n_c":["C3804"],"i_c":"8750/0","i_c_s":["Intradermal nevus"],"term_type":"PT"},{"nm":"Intraductal adenocarcinoma, noninfiltrating, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Intraductal adenocarcinoma, noninfiltrating, NOS"],"term_type":"SY"},{"nm":"Intraductal and lobular carcinoma","n_c":["C7690"],"i_c":"8522/3","i_c_s":["Intraductal and lobular carcinoma"],"term_type":"RT"},{"nm":"Intraductal carcinoma and lobular carcinoma in situ","n_c":["C4195"],"i_c":"8522/2","i_c_s":["Intraductal carcinoma and lobular carcinoma in situ"],"term_type":"PT"},{"nm":"Intraductal carcinoma, clinging","n_c":"","i_c":"8507/2","i_c_s":["Intraductal carcinoma, clinging"],"term_type":"RT"},{"nm":"Intraductal carcinoma, noninfiltrating, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Intraductal carcinoma, noninfiltrating, NOS"],"term_type":"PT"},{"nm":"Intraductal carcinoma, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Intraductal carcinoma, NOS"],"term_type":"SY"},{"nm":"Intraductal carcinoma, solid type","n_c":"","i_c":"8230/2","i_c_s":["Intraductal carcinoma, solid type"],"term_type":"SY"},{"nm":"Intraductal micropapillary carcinoma","n_c":["C5139"],"i_c":"8507/2","i_c_s":["Intraductal micropapillary carcinoma"],"term_type":"PT"},{"nm":"Intraductal papillary adenocarcinoma with invasion","n_c":["C7439"],"i_c":"8503/3","i_c_s":["Intraductal papillary adenocarcinoma with invasion"],"term_type":"PT"},{"nm":"Intraductal papillary adenocarcinoma, NOS","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Intraductal papillary adenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Intraductal papillary carcinoma","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Intraductal papillary carcinoma"],"term_type":""},{"nm":"Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma","n_c":["C5726"],"i_c":"8503/3","i_c_s":["Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma"],"term_type":""},{"nm":"Intraductal papillary mucinous neoplasm with an associated invasive carcinoma","n_c":["C5726"],"i_c":"8453/3","i_c_s":["Intraductal papillary mucinous neoplasm with an associated invasive carcinoma"],"term_type":"RT"},{"nm":"Intraductal papillary mucinous neoplasm with high grade dysplasia","n_c":["C41251"],"i_c":"8453/2","i_c_s":["Intraductal papillary mucinous neoplasm with high grade dysplasia"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm with associated invasive carcinoma","n_c":["C7439"],"i_c":"8503/3","i_c_s":["Intraductal papillary neoplasm with associated invasive carcinoma"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm with high grade dysplasia","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papillary neoplasm with high grade dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary neoplasm with high grade intraepithelial neoplasia","n_c":["C96809"],"i_c":"8503/2","i_c_s":["Intraductal papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm with intermediate grade neoplasia","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Intraductal papillary neoplasm with intermediate grade neoplasia"],"term_type":"SY"},{"nm":"Intraductal papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C96807"],"i_c":"8503/0","i_c_s":["Intraductal papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm, NOS","n_c":["C6881"],"i_c":"8503/0","i_c_s":["Intraductal papillary neoplasm, NOS"],"term_type":"RT"},{"nm":"Intraductal papillary tumor with high grade dysplasia","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papillary tumor with high grade dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary tumor with high grade intraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papillary tumor with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intraductal papillary-mucinous adenoma","n_c":["C95514"],"i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous adenoma"],"term_type":"PT"},{"nm":"Intraductal papillary-mucinous carcinoma, invasive","n_c":["C5726"],"i_c":"8453/3","i_c_s":["Intraductal papillary-mucinous carcinoma, invasive"],"term_type":"PT"},{"nm":"Intraductal papillary-mucinous carcinoma, non-invasive","n_c":"","i_c":"8453/2","i_c_s":["Intraductal papillary-mucinous carcinoma, non-invasive"],"term_type":"PT"},{"nm":"Intraductal papillary-mucinous neoplasm with low grade dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous neoplasm with low grade dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary-mucinous neoplasm with moderate dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous neoplasm with moderate dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary-mucinous tumor with intermediate dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous tumor with intermediate dysplasia"],"term_type":"RT"},{"nm":"Intraductal papillary-mucinous tumor with low grade dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous tumor with low grade dysplasia"],"term_type":"RT"},{"nm":"Intraductal papillary-mucinous tumor with moderate dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous tumor with moderate dysplasia"],"term_type":"RT"},{"nm":"Intraductal papilloma","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Intraductal papilloma"],"term_type":"PT"},{"nm":"Intraductal papilloma with ductal carcinoma in situ","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papilloma with ductal carcinoma in situ"],"term_type":""},{"nm":"Intraductal papilloma with lobular carcinoma in situ","n_c":"","i_c":"8520/2","i_c_s":["Intraductal papilloma with lobular carcinoma in situ"],"term_type":""},{"nm":"Intraductal papillomatosis, NOS","n_c":["C7363"],"i_c":"8505/0","i_c_s":["Intraductal papillomatosis, NOS"],"term_type":"PT"},{"nm":"Intraductal tubular-papillary neoplasm, high grade","n_c":"","i_c":"8503/2","i_c_s":["Intraductal tubular-papillary neoplasm, high grade"],"term_type":"RT"},{"nm":"Intraductal tubular-papillary neoplasm, low grade","n_c":"","i_c":"8503/0","i_c_s":["Intraductal tubular-papillary neoplasm, low grade"],"term_type":"RT"},{"nm":"Intraductal tubulopapillary neoplasm","n_c":["C95506"],"i_c":"8503/2","i_c_s":["Intraductal tubulopapillary neoplasm"],"term_type":""},{"nm":"Intraepidermal carcinoma, NOS","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Intraepidermal carcinoma, NOS"],"term_type":"SY"},{"nm":"Intraepidermal epithelioma of Jadassohn","n_c":["C4110"],"i_c":"8096/0","i_c_s":["Intraepidermal epithelioma of Jadassohn"],"term_type":"PT"},{"nm":"Intraepidermal nevus","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Intraepidermal nevus"],"term_type":"SY"},{"nm":"Intraepidermal squamous cell carcinoma, Bowen type","n_c":["C62571"],"i_c":"8081/2","i_c_s":["Intraepidermal squamous cell carcinoma, Bowen type"],"term_type":"SY"},{"nm":"Intraepithelial carcinoma, NOS","n_c":["C2917"],"i_c":"8010/2","i_c_s":["Intraepithelial carcinoma, NOS"],"term_type":"SY"},{"nm":"Intraepithelial squamous cell carcinoma","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Intraepithelial squamous cell carcinoma"],"term_type":"SY"},{"nm":"Intraglandular papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Intraglandular papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intramuscular hemangioma","n_c":["C3699"],"i_c":"9132/0","i_c_s":["Intramuscular hemangioma"],"term_type":"PT"},{"nm":"Intramuscular lipoma","n_c":["C7450"],"i_c":"8856/0","i_c_s":["Intramuscular lipoma"],"term_type":"PT"},{"nm":"Intraneural perineurioma","n_c":["C6911"],"i_c":"9571/0","i_c_s":["Intraneural perineurioma"],"term_type":"RT"},{"nm":"Intraosseous low grade osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Intraosseous low grade osteosarcoma"],"term_type":"SY"},{"nm":"Intraosseous well differentiated osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Intraosseous well differentiated osteosarcoma"],"term_type":"PT"},{"nm":"Intratubular germ cell neoplasia","n_c":["C40345"],"i_c":"9064/2","i_c_s":["Intratubular germ cell neoplasia"],"term_type":"SY"},{"nm":"Intratubular malignant germ cells","n_c":["C40345"],"i_c":"9064/2","i_c_s":["Intratubular malignant germ cells"],"term_type":"PT"},{"nm":"Intravascular B-cell lymphoma","n_c":["C4342"],"i_c":"9712/3","i_c_s":["Intravascular B-cell lymphoma"],"term_type":""},{"nm":"Intravascular bronchial alveolar tumor","n_c":"","i_c":"9133/3","i_c_s":["Intravascular bronchial alveolar tumor"],"term_type":"ORT"},{"nm":"Intravascular large B-cell lymphoma","n_c":["C4342"],"i_c":"9712/3","i_c_s":["Intravascular large B-cell lymphoma"],"term_type":"PT"},{"nm":"Intravascular leiomyomatosis","n_c":"","i_c":"8890/1","i_c_s":["Intravascular leiomyomatosis"],"term_type":"RT"},{"nm":"Invasive carcinoma of no special type","n_c":["C9480"],"i_c":"8500/3","i_c_s":["Invasive carcinoma of no special type"],"term_type":"PT"},{"nm":"Invasive carcinoma, NST","n_c":["C9480"],"i_c":"8500/3","i_c_s":["Invasive carcinoma, NST"],"term_type":""},{"nm":"Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)","n_c":["C66850"],"i_c":"8343/3","i_c_s":["Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)"],"term_type":""},{"nm":"Invasive fibroma","n_c":["C9182"],"i_c":"8821/1","i_c_s":["Invasive fibroma"],"term_type":"SY"},{"nm":"Invasive hydatidiform mole","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Invasive hydatidiform mole"],"term_type":"PT"},{"nm":"Invasive lobular carcinoma","n_c":["C7950"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma"],"term_type":""},{"nm":"Invasive lobular carcinoma, alveolar type","n_c":["C97049"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma, alveolar type"],"term_type":""},{"nm":"Invasive lobular carcinoma, solid type","n_c":["C97052"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma, solid type"],"term_type":""},{"nm":"Invasive lobular carcinoma, tubulolobular variant","n_c":["C97053"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma, tubulolobular variant"],"term_type":""},{"nm":"Invasive mammary carcinoma","n_c":["C9245"],"i_c":"8500/3","i_c_s":["Invasive mammary carcinoma"],"term_type":""},{"nm":"Invasive micropapillary carcinoma","n_c":["C36084"],"i_c":"8507/3","i_c_s":["Invasive micropapillary carcinoma"],"term_type":"PT"},{"nm":"Invasive mole, NOS","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Invasive mole, NOS"],"term_type":"SY"},{"nm":"Invasive mucinous adenocarcinoma","n_c":["C136709"],"i_c":"8253/3","i_c_s":["Invasive mucinous adenocarcinoma"],"term_type":"PT"},{"nm":"Involuting nevus","n_c":"","i_c":"9160/0","i_c_s":["Involuting nevus"],"term_type":"IS"},{"nm":"Islet cell adenocarcinoma","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Islet cell adenocarcinoma"],"term_type":"SY"},{"nm":"Islet cell adenoma","n_c":["C65184"],"i_c":"8150/0","i_c_s":["Islet cell adenoma"],"term_type":"SY"},{"nm":"Islet cell adenomatosis","n_c":["C4375"],"i_c":"8150/0","i_c_s":["Islet cell adenomatosis"],"term_type":"RT"},{"nm":"Islet cell carcinoma","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Islet cell carcinoma"],"term_type":"SY"},{"nm":"Islet cell tumor, benign","n_c":"","i_c":"8150/0","i_c_s":["Islet cell tumor, benign"],"term_type":"SY"},{"nm":"Islet cell tumor, NOS","n_c":["C27031"],"i_c":"8150/1","i_c_s":["Islet cell tumor, NOS"],"term_type":"SY"},{"nm":"Jadassohn blue nevus","n_c":["C3803"],"i_c":"8780/0","i_c_s":["Jadassohn blue nevus"],"term_type":"SY"},{"nm":"Jugular paraganglioma","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Jugular paraganglioma"],"term_type":"SY"},{"nm":"Jugulotympanic paraganglioma","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Jugulotympanic paraganglioma"],"term_type":"SY"},{"nm":"Junction nevus","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Junction nevus"],"term_type":"SY"},{"nm":"Junctional nevus, NOS","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Junctional nevus, NOS"],"term_type":"PT"},{"nm":"Juvenile angiofibroma","n_c":["C3799"],"i_c":"9160/0","i_c_s":["Juvenile angiofibroma"],"term_type":"SY"},{"nm":"Juvenile astrocytoma","n_c":["C9022"],"i_c":"9421/1","i_c_s":["Juvenile astrocytoma"],"term_type":"SY"},{"nm":"Juvenile carcinoma of breast","n_c":["C4189"],"i_c":"8502/3","i_c_s":["Juvenile carcinoma of breast"],"term_type":"SY"},{"nm":"Juvenile chronic myelomonocytic leukemia","n_c":["C9233"],"i_c":"9946/3","i_c_s":["Juvenile chronic myelomonocytic leukemia"],"term_type":"SY"},{"nm":"Juvenile fibroadenoma","n_c":["C4276"],"i_c":"9030/0","i_c_s":["Juvenile fibroadenoma"],"term_type":"PT"},{"nm":"Juvenile hemangioma","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Juvenile hemangioma"],"term_type":"SY"},{"nm":"Juvenile histiocytoma","n_c":["C6492"],"i_c":"8831/0","i_c_s":["Juvenile histiocytoma"],"term_type":"RT"},{"nm":"Juvenile melanoma","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Juvenile melanoma"],"term_type":"SY"},{"nm":"Juvenile myelomonocytic leukemia","n_c":["C9233"],"i_c":"9946/3","i_c_s":["Juvenile myelomonocytic leukemia"],"term_type":"PT"},{"nm":"Juvenile nevus","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Juvenile nevus"],"term_type":"SY"},{"nm":"Juxtacortical chondroma","n_c":["C4302"],"i_c":"9221/0","i_c_s":["Juxtacortical chondroma"],"term_type":"PT"},{"nm":"Juxtacortical chondrosarcoma","n_c":["C7357"],"i_c":"9221/3","i_c_s":["Juxtacortical chondrosarcoma"],"term_type":"PT"},{"nm":"Juxtacortical osteosarcoma","n_c":["C8969"],"i_c":"9192/3","i_c_s":["Juxtacortical osteosarcoma"],"term_type":"SY"},{"nm":"Juxtaglomerular tumor","n_c":["C4162"],"i_c":"8361/0","i_c_s":["Juxtaglomerular tumor"],"term_type":"PT"},{"nm":"Kaposi sarcoma","n_c":["C9087"],"i_c":"9140/3","i_c_s":["Kaposi sarcoma"],"term_type":"PT"},{"nm":"Kaposiform hemangioendothelioma","n_c":["C27510"],"i_c":"9130/1","i_c_s":["Kaposiform hemangioendothelioma"],"term_type":"RT"},{"nm":"Keratotoc papilloma","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Keratotoc papilloma"],"term_type":""},{"nm":"Klatskin tumor","n_c":["C36077"],"i_c":"8162/3","i_c_s":["Klatskin tumor"],"term_type":"PT"},{"nm":"Krukenberg tumor","n_c":["C3153"],"i_c":"8490/6","i_c_s":["Krukenberg tumor"],"term_type":"RT"},{"nm":"Kupffer cell sarcoma","n_c":["C4438"],"i_c":"9124/3","i_c_s":["Kupffer cell sarcoma"],"term_type":"PT"},{"nm":"L-cell tumor","n_c":"","i_c":"8152/1","i_c_s":["L-cell tumor"],"term_type":"RT"},{"nm":"Lactating adenoma","n_c":["C9473"],"i_c":"8204/0","i_c_s":["Lactating adenoma"],"term_type":"PT"},{"nm":"Langerhans cell granulomatosis","n_c":["C3107"],"i_c":"9751/3","i_c_s":["Langerhans cell granulomatosis"],"term_type":"IS"},{"nm":"Langerhans cell granulomatosis, unifocal","n_c":["C3016"],"i_c":"9751/3","i_c_s":["Langerhans cell granulomatosis, unifocal"],"term_type":"IS"},{"nm":"Langerhans cell histiocytosis, disseminated","n_c":["C150703"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, disseminated"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, generalized","n_c":["C150703"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, generalized"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, mono-ostotic","n_c":["C150701"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, mono-ostotic"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, multifocal","n_c":["C150702"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, multifocal"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, NOS","n_c":["C3107"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, NOS"],"term_type":"PT"},{"nm":"Langerhans cell histiocytosis, poly-ostotic","n_c":["C150702"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, poly-ostotic"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, unifocal","n_c":["C150701"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, unifocal"],"term_type":"ORT"},{"nm":"Langerhans cell sarcoma","n_c":["C6921"],"i_c":"9756/3","i_c_s":["Langerhans cell sarcoma"],"term_type":"PT"},{"nm":"Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease","n_c":["C27856"],"i_c":"9738/3","i_c_s":["Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease"],"term_type":"PT"},{"nm":"Large cell (Ki-1+) lymphoma","n_c":["C3720"],"i_c":"9714/3","i_c_s":["Large cell (Ki-1+) lymphoma"],"term_type":"IS"},{"nm":"Large cell calcifying Sertoli cell tumor","n_c":["C39944"],"i_c":"8642/1","i_c_s":["Large cell calcifying Sertoli cell tumor"],"term_type":"PT"},{"nm":"Large cell carcinoma with rhabdoid phenotype","n_c":["C6876"],"i_c":"8014/3","i_c_s":["Large cell carcinoma with rhabdoid phenotype"],"term_type":"PT"},{"nm":"Large cell carcinoma, NOS","n_c":["C3780"],"i_c":"8012/3","i_c_s":["Large cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Large cell medulloblastoma","n_c":["C6904"],"i_c":"9474/3","i_c_s":["Large cell medulloblastoma"],"term_type":"PT"},{"nm":"Large cell neuroendocrine carcinoma","n_c":["C6875"],"i_c":"8013/3","i_c_s":["Large cell neuroendocrine carcinoma"],"term_type":"PT"},{"nm":"Large granular lymphocytosis, NOS","n_c":"","i_c":"9831/3","i_c_s":["Large granular lymphocytosis, NOS"],"term_type":"SY"},{"nm":"LCIS, NOS","n_c":["C4018"],"i_c":"8520/2","i_c_s":["LCIS, NOS"],"term_type":"SY"},{"nm":"Leiomyoblastoma","n_c":["C3486"],"i_c":"8891/0","i_c_s":["Leiomyoblastoma"],"term_type":"SY"},{"nm":"Leiomyofibroma","n_c":["C3434"],"i_c":"8890/0","i_c_s":["Leiomyofibroma"],"term_type":"SY"},{"nm":"Leiomyoma, NOS","n_c":["C3157"],"i_c":"8890/0","i_c_s":["Leiomyoma, NOS"],"term_type":"PT"},{"nm":"Leiomyomatosis, NOS","n_c":["C3748"],"i_c":"8890/1","i_c_s":["Leiomyomatosis, NOS"],"term_type":"PT"},{"nm":"Leiomyosarcoma, NOS","n_c":["C3158"],"i_c":"8890/3","i_c_s":["Leiomyosarcoma, NOS"],"term_type":"PT"},{"nm":"Lennert lymphoma","n_c":["C7205"],"i_c":"9702/3","i_c_s":["Lennert lymphoma"],"term_type":"SY"},{"nm":"Lentigo maligna","n_c":["C43372"],"i_c":"8742/2","i_c_s":["Lentigo maligna"],"term_type":"PT"},{"nm":"Lentigo maligna melanoma","n_c":["C9151"],"i_c":"8742/3","i_c_s":["Lentigo maligna melanoma"],"term_type":"PT"},{"nm":"Lepidic adenocarcinoma","n_c":["C123160"],"i_c":"8250/3","i_c_s":["Lepidic adenocarcinoma"],"term_type":"PT"},{"nm":"Lepidic predominant adenocarcinoma","n_c":["C123160"],"i_c":"8250/3","i_c_s":["Lepidic predominant adenocarcinoma"],"term_type":""},{"nm":"Leptomeningeal sarcoma","n_c":["C8312"],"i_c":"9530/3","i_c_s":["Leptomeningeal sarcoma"],"term_type":"SY"},{"nm":"Letterer-Siwe disease","n_c":["C3160"],"i_c":"9751/3","i_c_s":["Letterer-Siwe disease"],"term_type":"ORT"},{"nm":"Leukemia, NOS","n_c":["C3161"],"i_c":"9800/3","i_c_s":["Leukemia, NOS"],"term_type":"PT"},{"nm":"Leukemic reticuloendotheliosis","n_c":["C7402"],"i_c":"9940/3","i_c_s":["Leukemic reticuloendotheliosis"],"term_type":"SY"},{"nm":"Leydig cell tumor, benign","n_c":["C4212"],"i_c":"8650/0","i_c_s":["Leydig cell tumor, benign"],"term_type":"PT"},{"nm":"Leydig cell tumor, malignant","n_c":["C4213"],"i_c":"8650/3","i_c_s":["Leydig cell tumor, malignant"],"term_type":"PT"},{"nm":"Leydig cell tumor, NOS","n_c":["C3188"],"i_c":"8650/1","i_c_s":["Leydig cell tumor, NOS"],"term_type":"PT"},{"nm":"Linitis plastica","n_c":["C3190"],"i_c":"8142/3","i_c_s":["Linitis plastica"],"term_type":"PT"},{"nm":"Lipid cell tumor of ovary","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Lipid cell tumor of ovary"],"term_type":"PT"},{"nm":"Lipid-rich carcinoma","n_c":["C4152"],"i_c":"8314/3","i_c_s":["Lipid-rich carcinoma"],"term_type":"PT"},{"nm":"Lipid-rich Sertoli cell tumor","n_c":"","i_c":"8641/0","i_c_s":["Lipid-rich Sertoli cell tumor"],"term_type":"SY"},{"nm":"Lipid-rich urothelial carcinoma","n_c":["C191684"],"i_c":"8120/3","i_c_s":["Lipid-rich urothelial carcinoma"],"term_type":""},{"nm":"Lipoadenoma","n_c":["C4159"],"i_c":"8324/0","i_c_s":["Lipoadenoma"],"term_type":"PT"},{"nm":"Lipoblastoma","n_c":["C27483"],"i_c":"8881/0","i_c_s":["Lipoblastoma"],"term_type":"SY"},{"nm":"Lipoblastomatosis","n_c":["C4255"],"i_c":"8881/0","i_c_s":["Lipoblastomatosis"],"term_type":"PT"},{"nm":"Lipoid cell tumor of ovary","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Lipoid cell tumor of ovary"],"term_type":"SY"},{"nm":"Lipoleiomyoma","n_c":["C9502"],"i_c":"8890/0","i_c_s":["Lipoleiomyoma"],"term_type":"RT"},{"nm":"Lipoma-like liposarcoma","n_c":["C176979"],"i_c":"8851/3","i_c_s":["Lipoma-like liposarcoma"],"term_type":"SY"},{"nm":"Lipoma, NOS","n_c":["C3192"],"i_c":"8850/0","i_c_s":["Lipoma, NOS"],"term_type":"PT"},{"nm":"Lipomatous medulloblastoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Lipomatous medulloblastoma"],"term_type":"SY"},{"nm":"Liposarcoma, differentiated","n_c":["C6505"],"i_c":"8851/3","i_c_s":["Liposarcoma, differentiated"],"term_type":"SY"},{"nm":"Liposarcoma, NOS","n_c":["C3194"],"i_c":"8850/3","i_c_s":["Liposarcoma, NOS"],"term_type":"PT"},{"nm":"Liposarcoma, well differentiated","n_c":["C6505"],"i_c":"8851/3","i_c_s":["Liposarcoma, well differentiated"],"term_type":"PT"},{"nm":"Liver cell adenoma","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Liver cell adenoma"],"term_type":"PT"},{"nm":"Liver cell carcinoma","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Liver cell carcinoma"],"term_type":"SY"},{"nm":"Lobular adenocarcinoma","n_c":["C3771"],"i_c":"8520/3","i_c_s":["Lobular adenocarcinoma"],"term_type":"SY"},{"nm":"Lobular and ductal carcinoma","n_c":["C5160"],"i_c":"8522/3","i_c_s":["Lobular and ductal carcinoma"],"term_type":"SY"},{"nm":"Lobular carcinoma in situ, NOS","n_c":["C4018"],"i_c":"8520/2","i_c_s":["Lobular carcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Lobular carcinoma, noninfiltrating","n_c":["C4018"],"i_c":"8520/2","i_c_s":["Lobular carcinoma, noninfiltrating"],"term_type":"SY"},{"nm":"Lobular carcinoma, NOS","n_c":["C3771"],"i_c":"8520/3","i_c_s":["Lobular carcinoma, NOS"],"term_type":"PT"},{"nm":"Localized fibrous tumor","n_c":["C7634"],"i_c":"8815/0","i_c_s":["Localized fibrous tumor"],"term_type":"SY"},{"nm":"Low grade adenosquamous carcinoma","n_c":["C40362"],"i_c":"8570/3","i_c_s":["Low grade adenosquamous carcinoma"],"term_type":""},{"nm":"Low grade appendiceal mucinous neoplasm","n_c":["C42598"],"i_c":"8480/1","i_c_s":["Low grade appendiceal mucinous neoplasm"],"term_type":"PT"},{"nm":"Low grade cribriform cystadenocarcinoma (LGCCC)","n_c":["C62192"],"i_c":"8500/2","i_c_s":["Low grade cribriform cystadenocarcinoma (LGCCC)"],"term_type":""},{"nm":"Low-grade central osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Low-grade central osteosarcoma"],"term_type":""},{"nm":"Low-grade fibromyxoid sarcoma","n_c":["C45202"],"i_c":"8840/3","i_c_s":["Low-grade fibromyxoid sarcoma"],"term_type":""},{"nm":"Low-grade intramedullary osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Low-grade intramedullary osteosarcoma"],"term_type":""},{"nm":"Low-grade myofibroblastic sarcoma","n_c":["C49024"],"i_c":"8825/3","i_c_s":["Low-grade myofibroblastic sarcoma"],"term_type":""},{"nm":"Low-grade serous carcinoma","n_c":"","i_c":"8460/3","i_c_s":["Low-grade serous carcinoma"],"term_type":""},{"nm":"Luteinoma","n_c":["C3202"],"i_c":"8610/0","i_c_s":["Luteinoma"],"term_type":"SY"},{"nm":"Luteoma, NOS","n_c":["C3202"],"i_c":"8610/0","i_c_s":["Luteoma, NOS"],"term_type":"PT"},{"nm":"Lymphangioendothelial sarcoma","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangioendothelial sarcoma"],"term_type":"SY"},{"nm":"Lymphangioendothelioma, malignant","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangioendothelioma, malignant"],"term_type":"SY"},{"nm":"Lymphangioendothelioma, NOS","n_c":["C3203"],"i_c":"9170/0","i_c_s":["Lymphangioendothelioma, NOS"],"term_type":"SY"},{"nm":"Lymphangioleiomyomatosis","n_c":["C3725"],"i_c":"9174/1","i_c_s":["Lymphangioleiomyomatosis"],"term_type":"SY"},{"nm":"Lymphangioma, NOS","n_c":["C8965"],"i_c":"9170/0","i_c_s":["Lymphangioma, NOS"],"term_type":"PT"},{"nm":"Lymphangiomyoma","n_c":["C3204"],"i_c":"9174/0","i_c_s":["Lymphangiomyoma"],"term_type":"PT"},{"nm":"Lymphangiomyomatosis","n_c":["C3725"],"i_c":"9174/1","i_c_s":["Lymphangiomyomatosis"],"term_type":"PT"},{"nm":"Lymphangiosarcoma","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangiosarcoma"],"term_type":"PT"},{"nm":"Lymphatic leukemic, NOS","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphatic leukemic, NOS"],"term_type":""},{"nm":"Lymphoblastic leukemia, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Lymphoblastic leukemia, NOS"],"term_type":"SY"},{"nm":"Lymphoblastoma","n_c":["C9360"],"i_c":"9727/3","i_c_s":["Lymphoblastoma"],"term_type":"IS"},{"nm":"Lymphocytic leukemia, NOS","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphocytic leukemia, NOS"],"term_type":"ORT"},{"nm":"Lymphoepithelial carcinoma","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelial carcinoma"],"term_type":"PT"},{"nm":"Lymphoepithelioid lymphoma","n_c":["C7205"],"i_c":"9702/3","i_c_s":["Lymphoepithelioid lymphoma"],"term_type":"RT"},{"nm":"Lymphoepithelioma","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelioma"],"term_type":"SY"},{"nm":"Lymphoepithelioma-like carcinoma","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelioma-like carcinoma"],"term_type":"SY"},{"nm":"Lymphoid leukemia, NOS","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphoid leukemia, NOS"],"term_type":"PT"},{"nm":"Lymphoma, NOS","n_c":["C3208"],"i_c":"9590/3","i_c_s":["Lymphoma, NOS"],"term_type":"SY"},{"nm":"Lymphomatoid granulomatosis","n_c":["C7930"],"i_c":"9766/1","i_c_s":["Lymphomatoid granulomatosis"],"term_type":"RT"},{"nm":"Lymphomatoid papulosis","n_c":["C3721"],"i_c":"9718/3","i_c_s":["Lymphomatoid papulosis"],"term_type":"SY"},{"nm":"Lymphoplasmacyte-rich meningioma","n_c":["C4720"],"i_c":"9530/0","i_c_s":["Lymphoplasmacyte-rich meningioma"],"term_type":"RT"},{"nm":"Lymphoproliferative disease, NOS","n_c":["C9308"],"i_c":"9970/1","i_c_s":["Lymphoproliferative disease, NOS"],"term_type":"SY"},{"nm":"Lymphoproliferative disorder, NOS","n_c":["C9308"],"i_c":"9970/1","i_c_s":["Lymphoproliferative disorder, NOS"],"term_type":"PT"},{"nm":"Lymphosarcoma cell leukemia","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphosarcoma cell leukemia"],"term_type":"ORT"},{"nm":"Lymphosarcoma, diffuse","n_c":["C26919"],"i_c":"9591/3","i_c_s":["Lymphosarcoma, diffuse"],"term_type":"IS"},{"nm":"Lymphosarcoma, NOS","n_c":["C26919"],"i_c":"9591/3","i_c_s":["Lymphosarcoma, NOS"],"term_type":"ORT"},{"nm":"M6A","n_c":["C7152"],"i_c":"9840/3","i_c_s":["M6A"],"term_type":"SY"},{"nm":"M6B","n_c":["C7467"],"i_c":"9840/3","i_c_s":["M6B"],"term_type":"SY"},{"nm":"Macrofollicular adenoma","n_c":["C4161"],"i_c":"8334/0","i_c_s":["Macrofollicular adenoma"],"term_type":"PT"},{"nm":"Magnocellular nevus","n_c":["C9498"],"i_c":"8726/0","i_c_s":["Magnocellular nevus"],"term_type":"PT"},{"nm":"Malignancy","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Malignancy"],"term_type":"SY"},{"nm":"Malignant chondroid syringoma","n_c":"","i_c":"8940/3","i_c_s":["Malignant chondroid syringoma"],"term_type":"RT"},{"nm":"Malignant cystic nephroma","n_c":["C6897"],"i_c":"8959/3","i_c_s":["Malignant cystic nephroma"],"term_type":"PT"},{"nm":"Malignant eccrine spiradenoma","n_c":["C5117"],"i_c":"8403/3","i_c_s":["Malignant eccrine spiradenoma"],"term_type":"PT"},{"nm":"Malignant fibrous histiocytoma","n_c":["C4247"],"i_c":"8830/3","i_c_s":["Malignant fibrous histiocytoma"],"term_type":"PT"},{"nm":"Malignant fibrous histiocytoma (MFH) of bone","n_c":["C8563"],"i_c":"8830/3","i_c_s":["Malignant fibrous histiocytoma (MFH) of bone"],"term_type":""},{"nm":"Malignant giant cell tumor of soft parts","n_c":["C8380"],"i_c":"9251/3","i_c_s":["Malignant giant cell tumor of soft parts"],"term_type":"PT"},{"nm":"Malignant histiocytosis","n_c":["C7202"],"i_c":"9750/3","i_c_s":["Malignant histiocytosis"],"term_type":"PT"},{"nm":"Malignant hydatidiform mole","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Malignant hydatidiform mole"],"term_type":"SY"},{"nm":"Malignant lymphoma, centroblastic, diffuse","n_c":["C4074"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, centroblastic, diffuse"],"term_type":"RT"},{"nm":"Malignant lymphoma, centroblastic, follicular","n_c":["C8994"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, centroblastic, follicular"],"term_type":"SY"},{"nm":"Malignant lymphoma, centroblastic, NOS","n_c":["C4074"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, centroblastic, NOS"],"term_type":"RT"},{"nm":"Malignant lymphoma, centroblasticcentrocytic, diffuse","n_c":["C4338"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, centroblasticcentrocytic, diffuse"],"term_type":""},{"nm":"Malignant lymphoma, centroblasticcentrocytic, follicular","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, centroblasticcentrocytic, follicular"],"term_type":""},{"nm":"Malignant lymphoma, centroblasticcentrocytic, NOS","n_c":["C4338"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, centroblasticcentrocytic, NOS"],"term_type":""},{"nm":"Malignant lymphoma, centrocytic","n_c":"","i_c":"9673/3","i_c_s":["Malignant lymphoma, centrocytic"],"term_type":"IS"},{"nm":"Malignant lymphoma, cleaved cell, NOS","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, cleaved cell, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, convoluted cell","n_c":["C27821"],"i_c":"9727/3","i_c_s":["Malignant lymphoma, convoluted cell"],"term_type":"IS"},{"nm":"Malignant lymphoma, diffuse, NOS","n_c":["C27822"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, diffuse, NOS"],"term_type":"RT"},{"nm":"Malignant lymphoma, follicle center, follicular","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, follicle center, follicular"],"term_type":"SY"},{"nm":"Malignant lymphoma, follicle center, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, follicle center, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, follicular, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, follicular, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, histiocytic, diffuse","n_c":["C27099"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, histiocytic, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, histiocytic, nodular","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, histiocytic, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, histiocytic, NOS","n_c":["C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, histiocytic, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, Hodgkin","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Malignant lymphoma, Hodgkin"],"term_type":"SY"},{"nm":"Malignant lymphoma, immunoblastic, NOS","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, immunoblastic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS","n_c":["C4074"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, large B-cell, diffuse, NOS","n_c":["C80280"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, large B-cell, NOS","n_c":["C80280"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, cleaved and noncleaved","n_c":["C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, cleaved and noncleaved"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, cleaved, diffuse","n_c":["C27265"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, cleaved, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, cleaved, NOS","n_c":["C27265"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, cleaved, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, diffuse, NOS","n_c":["C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, diffuse, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, follicular, NOS","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, large cell, follicular, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, immunoblastic","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, large cell, immunoblastic"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, noncleaved, diffuse","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, noncleaved, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, noncleaved, follicular","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, large cell, noncleaved, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, noncleaved, NOS","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, noncleaved, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, NOS","n_c":["C27823"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cleaved cell, follicular","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, large cleaved cell, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cleaved cell, NOS","n_c":["C27265"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cleaved cell, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphoblastic, NOS","n_c":["C9360"],"i_c":"9727/3","i_c_s":["Malignant lymphoma, lymphoblastic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, diffuse, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, lymphocytic, diffuse, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse","n_c":["C4337"],"i_c":"9673/3","i_c_s":["Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphocytic, intermediate differentiation, nodular","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, lymphocytic, intermediate differentiation, nodular"],"term_type":"ORT"},{"nm":"Malignant lymphoma, lymphocytic, nodular, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, lymphocytic, nodular, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphocytic, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, lymphocytic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, poorly differentiated, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, lymphocytic, poorly differentiated, diffuse"],"term_type":"ORT"},{"nm":"Malignant lymphoma, lymphocytic, poorly differentiated, nodular","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Malignant lymphoma, lymphocytic, poorly differentiated, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphocytic, well differentiated, diffuse","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, lymphocytic, well differentiated, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, well differentiated, nodular","n_c":"","i_c":"9698/3","i_c_s":["Malignant lymphoma, lymphocytic, well differentiated, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphoplasmacytic","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, lymphoplasmacytic"],"term_type":"PT"},{"nm":"Malignant lymphoma, lymphoplasmacytoid","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, lymphoplasmacytoid"],"term_type":"SY"},{"nm":"Malignant lymphoma, mixed cell type, diffuse","n_c":["C3463"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed cell type, diffuse"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed cell type, follicular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed cell type, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed cell type, nodular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed cell type, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse","n_c":"","i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed lymphocytic-histiocytic, nodular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed lymphocytic-histiocytic, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed small and large cell, diffuse","n_c":["C3463"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed small and large cell, diffuse"],"term_type":"OP"},{"nm":"Malignant lymphoma, mixed small cleaved and large cell, follicular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed small cleaved and large cell, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, nodular, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, nodular, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, non-cleaved cell, NOS","n_c":["C27258"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, non-cleaved cell, NOS"],"term_type":"RT"},{"nm":"Malignant lymphoma, non-Hodgkin, NOS","n_c":["C3211"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, non-Hodgkin, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, noncleaved cell, follicular, NOS","n_c":"","i_c":"9698/3","i_c_s":["Malignant lymphoma, noncleaved cell, follicular, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, noncleaved, diffuse, NOS","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, noncleaved, diffuse, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, noncleaved, NOS","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, noncleaved, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, NOS","n_c":["C3208"],"i_c":"9590/3","i_c_s":["Malignant lymphoma, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, plasmacytoid","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, plasmacytoid"],"term_type":"ORT"},{"nm":"Malignant lymphoma, small B lymphocytic, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small B lymphocytic, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, small cell diffuse","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small cell diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, small cell, noncleaved, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, small cell, noncleaved, diffuse"],"term_type":"ORT"},{"nm":"Malignant lymphoma, small cell, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small cell, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, small cleaved cell, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, small cleaved cell, diffuse"],"term_type":"ORT"},{"nm":"Malignant lymphoma, small cleaved cell, follicular","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Malignant lymphoma, small cleaved cell, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, small cleaved cell, NOS","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, small cleaved cell, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, small lymphocytic, diffuse","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small lymphocytic, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, small lymphocytic, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small lymphocytic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, small noncleaved, Burkitt type","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Malignant lymphoma, small noncleaved, Burkitt type"],"term_type":"IS"},{"nm":"Malignant lymphoma, undifferentiated cell type, NOS","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, undifferentiated cell type, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, undifferentiated cell, non-Burkitt","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, undifferentiated cell, non-Burkitt"],"term_type":"IS"},{"nm":"Malignant lymphoma, undifferentiated, Burkitt type","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Malignant lymphoma, undifferentiated, Burkitt type"],"term_type":"IS"},{"nm":"Malignant lymphomatous polyposis","n_c":["C4339"],"i_c":"9673/3","i_c_s":["Malignant lymphomatous polyposis"],"term_type":"SY"},{"nm":"Malignant mast cell tumor","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Malignant mast cell tumor"],"term_type":"SY"},{"nm":"Malignant mastocytoma","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Malignant mastocytoma"],"term_type":"SY"},{"nm":"Malignant mastocytosis","n_c":["C8991"],"i_c":"9741/3","i_c_s":["Malignant mastocytosis"],"term_type":"PT"},{"nm":"Malignant melanoma in congenital melanocytic nevus","n_c":["C4235"],"i_c":"8761/3","i_c_s":["Malignant melanoma in congenital melanocytic nevus"],"term_type":"SY"},{"nm":"Malignant melanoma in giant pigmented nevus","n_c":["C4235"],"i_c":"8761/3","i_c_s":["Malignant melanoma in giant pigmented nevus"],"term_type":"PT"},{"nm":"Malignant melanoma in Hutchinson melanotic freckle","n_c":["C9151"],"i_c":"8742/3","i_c_s":["Malignant melanoma in Hutchinson melanotic freckle"],"term_type":"SY"},{"nm":"Malignant melanoma in junctional nevus","n_c":["C4232"],"i_c":"8740/3","i_c_s":["Malignant melanoma in junctional nevus"],"term_type":"PT"},{"nm":"Malignant melanoma in precancerous melanosis","n_c":["C66753"],"i_c":"8741/3","i_c_s":["Malignant melanoma in precancerous melanosis"],"term_type":"PT"},{"nm":"Malignant melanoma, NOS","n_c":["C3224"],"i_c":"8720/3","i_c_s":["Malignant melanoma, NOS"],"term_type":"PT"},{"nm":"Malignant melanoma, regressing","n_c":["C4228"],"i_c":"8723/3","i_c_s":["Malignant melanoma, regressing"],"term_type":"PT"},{"nm":"Malignant midline reticulosis","n_c":"","i_c":"9719/3","i_c_s":["Malignant midline reticulosis"],"term_type":"IS"},{"nm":"Malignant mucinous adenofibroma","n_c":"","i_c":"9015/3","i_c_s":["Malignant mucinous adenofibroma"],"term_type":"SY"},{"nm":"Malignant mucinous cystadenofibroma","n_c":"","i_c":"9015/3","i_c_s":["Malignant mucinous cystadenofibroma"],"term_type":"SY"},{"nm":"Malignant multilocular cystic nephroma","n_c":["C6897"],"i_c":"8959/3","i_c_s":["Malignant multilocular cystic nephroma"],"term_type":"SY"},{"nm":"Malignant myelosclerosis","n_c":"","i_c":"9931/3","i_c_s":["Malignant myelosclerosis"],"term_type":"IS"},{"nm":"Malignant myoepithelioma","n_c":["C7596"],"i_c":"8982/3","i_c_s":["Malignant myoepithelioma"],"term_type":"PT"},{"nm":"Malignant peripheral nerve sheath tumor","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Malignant peripheral nerve sheath tumor"],"term_type":"PT"},{"nm":"Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation"],"term_type":"PT"},{"nm":"Malignant perivascular epithelial cell tumor","n_c":["C6530"],"i_c":"8714/3","i_c_s":["Malignant perivascular epithelial cell tumor"],"term_type":""},{"nm":"Malignant reticulosis, NOS","n_c":["C4684"],"i_c":"9719/3","i_c_s":["Malignant reticulosis, NOS"],"term_type":"IS"},{"nm":"Malignant rhabdoid tumor","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Malignant rhabdoid tumor"],"term_type":"PT"},{"nm":"Malignant schwannoma with rhabdomyoblastic differentiation","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Malignant schwannoma with rhabdomyoblastic differentiation"],"term_type":"SY"},{"nm":"Malignant schwannoma, NOS","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Malignant schwannoma, NOS"],"term_type":"IS"},{"nm":"Malignant serous adenofibroma","n_c":"","i_c":"9014/3","i_c_s":["Malignant serous adenofibroma"],"term_type":"SY"},{"nm":"Malignant serous cystadenofibroma","n_c":"","i_c":"9014/3","i_c_s":["Malignant serous cystadenofibroma"],"term_type":"SY"},{"nm":"Malignant tenosynovial giant cell tumor","n_c":["C6535"],"i_c":"9252/3","i_c_s":["Malignant tenosynovial giant cell tumor"],"term_type":"PT"},{"nm":"Malignant teratoma, anaplastic","n_c":["C4287"],"i_c":"9082/3","i_c_s":["Malignant teratoma, anaplastic"],"term_type":"SY"},{"nm":"Malignant teratoma, intermediate","n_c":["C4288"],"i_c":"9083/3","i_c_s":["Malignant teratoma, intermediate"],"term_type":"PT"},{"nm":"Malignant teratoma, trophoblastic","n_c":["C66778"],"i_c":"9102/3","i_c_s":["Malignant teratoma, trophoblastic"],"term_type":"PT"},{"nm":"Malignant teratoma, undifferentiated","n_c":["C4287"],"i_c":"9082/3","i_c_s":["Malignant teratoma, undifferentiated"],"term_type":"PT"},{"nm":"Malignant tumor, clear cell type","n_c":["C40077"],"i_c":"8005/3","i_c_s":["Malignant tumor, clear cell type"],"term_type":"PT"},{"nm":"Malignant tumor, fusiform cell type","n_c":["C27091"],"i_c":"8004/3","i_c_s":["Malignant tumor, fusiform cell type"],"term_type":"SY"},{"nm":"Malignant tumor, giant cell type","n_c":["C4090"],"i_c":"8003/3","i_c_s":["Malignant tumor, giant cell type"],"term_type":"PT"},{"nm":"Malignant tumor, small cell type","n_c":["C65154"],"i_c":"8002/3","i_c_s":["Malignant tumor, small cell type"],"term_type":"PT"},{"nm":"Malignant tumor, spindle cell type","n_c":["C27091"],"i_c":"8004/3","i_c_s":["Malignant tumor, spindle cell type"],"term_type":"PT"},{"nm":"MALT lymphoma","n_c":["C3898"],"i_c":"9699/3","i_c_s":["MALT lymphoma"],"term_type":"SY"},{"nm":"Mammary carcinoma, in situ","n_c":"","i_c":"8500/2","i_c_s":["Mammary carcinoma, in situ"],"term_type":""},{"nm":"MANEC","n_c":["C95406"],"i_c":"8244/3","i_c_s":["MANEC"],"term_type":"SY"},{"nm":"Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)","n_c":["C4337"],"i_c":"9673/3","i_c_s":["Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)"],"term_type":""},{"nm":"Mantle zone lymphoma","n_c":["C4337"],"i_c":"9673/3","i_c_s":["Mantle zone lymphoma"],"term_type":"IS"},{"nm":"Marginal zone B-cell lymphoma, NOS","n_c":["C4341"],"i_c":"9699/3","i_c_s":["Marginal zone B-cell lymphoma, NOS"],"term_type":"PT"},{"nm":"Marginal zone lymphoma, NOS","n_c":["C4341"],"i_c":"9699/3","i_c_s":["Marginal zone lymphoma, NOS"],"term_type":"SY"},{"nm":"Masculinovoblastoma","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Masculinovoblastoma"],"term_type":"RT"},{"nm":"Mast cell leukaemia","n_c":["C3169"],"i_c":"9742/3","i_c_s":["Mast cell leukaemia"],"term_type":""},{"nm":"Mast cell sarcoma","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Mast cell sarcoma"],"term_type":"PT"},{"nm":"Mast cell tumor, NOS","n_c":["C9295"],"i_c":"9740/1","i_c_s":["Mast cell tumor, NOS"],"term_type":"SY"},{"nm":"Mastocytoma, NOS","n_c":["C9303"],"i_c":"9740/1","i_c_s":["Mastocytoma, NOS"],"term_type":"PT"},{"nm":"Matrical carcinoma","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Matrical carcinoma"],"term_type":"SY"},{"nm":"Mature T ALL","n_c":["C27820"],"i_c":"9837/3","i_c_s":["Mature T ALL"],"term_type":"SY"},{"nm":"Mature T-cell lymphoma, NOS","n_c":["C4340"],"i_c":"9702/3","i_c_s":["Mature T-cell lymphoma, NOS"],"term_type":"PT"},{"nm":"Mature teratoma","n_c":["C9015"],"i_c":"9080/0","i_c_s":["Mature teratoma"],"term_type":"SY"},{"nm":"Mediastinal (thymic) large B-cell lymphoma","n_c":["C9280"],"i_c":"9679/3","i_c_s":["Mediastinal (thymic) large B-cell lymphoma"],"term_type":""},{"nm":"Mediterranean lymphoma","n_c":["C3132"],"i_c":"9764/3","i_c_s":["Mediterranean lymphoma"],"term_type":"SY"},{"nm":"Medullary adenocarcinoma","n_c":"","i_c":"8510/3","i_c_s":["Medullary adenocarcinoma"],"term_type":"RT"},{"nm":"Medullary carcinoma with amyloid stroma","n_c":["C4193"],"i_c":"8345/3","i_c_s":["Medullary carcinoma with amyloid stroma"],"term_type":"PT"},{"nm":"Medullary carcinoma with lymphoid stroma","n_c":["C9119"],"i_c":"8512/3","i_c_s":["Medullary carcinoma with lymphoid stroma"],"term_type":"PT"},{"nm":"Medullary carcinoma, NOS","n_c":["C66718"],"i_c":"8510/3","i_c_s":["Medullary carcinoma, NOS"],"term_type":"PT"},{"nm":"Medullary osteosarcoma","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Medullary osteosarcoma"],"term_type":"SY"},{"nm":"Medulloblastoma with extensive nodularity","n_c":["C5407"],"i_c":"9471/3","i_c_s":["Medulloblastoma with extensive nodularity"],"term_type":"RT"},{"nm":"Medulloblastoma, classic","n_c":["C54039"],"i_c":"9470/3","i_c_s":["Medulloblastoma, classic"],"term_type":""},{"nm":"Medulloblastoma, group 3","n_c":["C129445"],"i_c":"9477/3","i_c_s":["Medulloblastoma, group 3"],"term_type":""},{"nm":"Medulloblastoma, group 4","n_c":["C129446"],"i_c":"9477/3","i_c_s":["Medulloblastoma, group 4"],"term_type":""},{"nm":"Medulloblastoma, non-WNT/non-SHH","n_c":["C129444"],"i_c":"9477/3","i_c_s":["Medulloblastoma, non-WNT/non-SHH"],"term_type":"PT"},{"nm":"Medulloblastoma, NOS","n_c":["C129447"],"i_c":"9470/3","i_c_s":["Medulloblastoma, NOS"],"term_type":"PT"},{"nm":"Medulloblastoma, SHH-activated and TP53-mutant","n_c":["C129442"],"i_c":"9476/3","i_c_s":["Medulloblastoma, SHH-activated and TP53-mutant"],"term_type":"PT"},{"nm":"Medulloblastoma, SHH-activated and TP53-wildtype","n_c":["C129443"],"i_c":"9471/3","i_c_s":["Medulloblastoma, SHH-activated and TP53-wildtype"],"term_type":""},{"nm":"Medulloblastoma, WNT-activated","n_c":["C129440"],"i_c":"9475/3","i_c_s":["Medulloblastoma, WNT-activated"],"term_type":"PT"},{"nm":"Medullocytoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Medullocytoma"],"term_type":"SY"},{"nm":"Medulloepithelioma, benign","n_c":["C66807"],"i_c":"9501/0","i_c_s":["Medulloepithelioma, benign"],"term_type":"PT"},{"nm":"Medulloepithelioma, NOS","n_c":["C66808"],"i_c":"9501/3","i_c_s":["Medulloepithelioma, NOS"],"term_type":"PT"},{"nm":"Medullomyoblastoma","n_c":["C3706"],"i_c":"9472/3","i_c_s":["Medullomyoblastoma"],"term_type":"PT"},{"nm":"Megakaryocytic leukemia","n_c":["C3170"],"i_c":"9910/3","i_c_s":["Megakaryocytic leukemia"],"term_type":"SY"},{"nm":"Megakaryocytic myelosclerosis","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Megakaryocytic myelosclerosis"],"term_type":"SY"},{"nm":"Melanoameloblastoma","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanoameloblastoma"],"term_type":"SY"},{"nm":"Melanocytic nevus","n_c":["C7570"],"i_c":"8720/0","i_c_s":["Melanocytic nevus"],"term_type":"SY"},{"nm":"Melanocytoma, eyeball","n_c":["C4230"],"i_c":"8726/0","i_c_s":["Melanocytoma, eyeball"],"term_type":"SY"},{"nm":"Melanocytoma, NOS","n_c":["C9498"],"i_c":"8726/0","i_c_s":["Melanocytoma, NOS"],"term_type":"RT"},{"nm":"Melanoma in situ","n_c":["C8423"],"i_c":"8720/2","i_c_s":["Melanoma in situ"],"term_type":"PT"},{"nm":"Melanoma, malignant, of soft parts","n_c":["C3745"],"i_c":"9044/3","i_c_s":["Melanoma, malignant, of soft parts"],"term_type":"RT"},{"nm":"Melanoma, NOS","n_c":["C3224"],"i_c":"8720/3","i_c_s":["Melanoma, NOS"],"term_type":"SY"},{"nm":"Melanotic medulloblastoma","n_c":["C9497"],"i_c":"9470/3","i_c_s":["Melanotic medulloblastoma"],"term_type":"RT"},{"nm":"Melanotic MPNST","n_c":["C4748"],"i_c":"9540/3","i_c_s":["Melanotic MPNST"],"term_type":"RT"},{"nm":"Melanotic neuroectodermal tumor","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanotic neuroectodermal tumor"],"term_type":"PT"},{"nm":"Melanotic neurofibroma","n_c":["C66841"],"i_c":"9541/0","i_c_s":["Melanotic neurofibroma"],"term_type":"PT"},{"nm":"Melanotic progonoma","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanotic progonoma"],"term_type":"SY"},{"nm":"Melanotic psammomatous MPNST","n_c":["C6910"],"i_c":"9540/3","i_c_s":["Melanotic psammomatous MPNST"],"term_type":"RT"},{"nm":"Melanotic schwannoma","n_c":["C6970"],"i_c":"9560/0","i_c_s":["Melanotic schwannoma"],"term_type":"SY"},{"nm":"Meningeal melanocytoma","n_c":["C4662"],"i_c":"8728/1","i_c_s":["Meningeal melanocytoma"],"term_type":"PT"},{"nm":"Meningeal melanoma","n_c":["C5317"],"i_c":"8720/3","i_c_s":["Meningeal melanoma"],"term_type":""},{"nm":"Meningeal melanomatosis","n_c":["C6891"],"i_c":"8728/3","i_c_s":["Meningeal melanomatosis"],"term_type":"PT"},{"nm":"Meningeal sarcoma","n_c":["C4073"],"i_c":"9530/3","i_c_s":["Meningeal sarcoma"],"term_type":"SY"},{"nm":"Meningeal sarcomatosis","n_c":["C4334"],"i_c":"9539/3","i_c_s":["Meningeal sarcomatosis"],"term_type":"PT"},{"nm":"Meningioma, anaplastic","n_c":["C4051"],"i_c":"9530/3","i_c_s":["Meningioma, anaplastic"],"term_type":"SY"},{"nm":"Meningioma, malignant","n_c":["C4051"],"i_c":"9530/3","i_c_s":["Meningioma, malignant"],"term_type":"PT"},{"nm":"Meningioma, NOS","n_c":["C3230"],"i_c":"9530/0","i_c_s":["Meningioma, NOS"],"term_type":"PT"},{"nm":"Meningiomatosis, NOS","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Meningiomatosis, NOS"],"term_type":"PT"},{"nm":"Meningothelial meningioma","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Meningothelial meningioma"],"term_type":"PT"},{"nm":"Meningothelial sarcoma","n_c":["C4073"],"i_c":"9530/3","i_c_s":["Meningothelial sarcoma"],"term_type":"SY"},{"nm":"Merkel cell carcinoma","n_c":["C9231"],"i_c":"8247/3","i_c_s":["Merkel cell carcinoma"],"term_type":"PT"},{"nm":"Merkel cell tumor","n_c":["C9231"],"i_c":"8247/3","i_c_s":["Merkel cell tumor"],"term_type":"SY"},{"nm":"Mesenchymal chondrosarcoma","n_c":["C3737"],"i_c":"9240/3","i_c_s":["Mesenchymal chondrosarcoma"],"term_type":"PT"},{"nm":"Mesenchymal tumor, malignant","n_c":["C9118"],"i_c":"8800/3","i_c_s":["Mesenchymal tumor, malignant"],"term_type":"SY"},{"nm":"Mesenchymoma, benign","n_c":["C4267"],"i_c":"8990/0","i_c_s":["Mesenchymoma, benign"],"term_type":"PT"},{"nm":"Mesenchymoma, malignant","n_c":["C4268"],"i_c":"8990/3","i_c_s":["Mesenchymoma, malignant"],"term_type":"PT"},{"nm":"Mesenchymoma, NOS","n_c":["C3233"],"i_c":"8990/1","i_c_s":["Mesenchymoma, NOS"],"term_type":"PT"},{"nm":"Mesenteric fibromatosis","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Mesenteric fibromatosis"],"term_type":"SY"},{"nm":"Mesoblastic nephroma","n_c":["C6569"],"i_c":"8960/1","i_c_s":["Mesoblastic nephroma"],"term_type":"PT"},{"nm":"Mesodermal mixed tumor","n_c":["C3730"],"i_c":"8951/3","i_c_s":["Mesodermal mixed tumor"],"term_type":"PT"},{"nm":"Mesonephric adenocarcinoma","n_c":["C4072"],"i_c":"9110/3","i_c_s":["Mesonephric adenocarcinoma"],"term_type":"SY"},{"nm":"Mesonephric adenoma","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Mesonephric adenoma"],"term_type":"SY"},{"nm":"Mesonephric tumor, NOS","n_c":["C40141"],"i_c":"9110/1","i_c_s":["Mesonephric tumor, NOS"],"term_type":"PT"},{"nm":"Mesonephroma, benign","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Mesonephroma, benign"],"term_type":"PT"},{"nm":"Mesonephroma, malignant","n_c":["C4072"],"i_c":"9110/3","i_c_s":["Mesonephroma, malignant"],"term_type":"PT"},{"nm":"Mesonephroma, NOS","n_c":["C40141"],"i_c":"9110/3","i_c_s":["Mesonephroma, NOS"],"term_type":"SY"},{"nm":"Mesothelial papilloma","n_c":"","i_c":"9052/0","i_c_s":["Mesothelial papilloma"],"term_type":"SY"},{"nm":"Mesothelioma, benign","n_c":["C3762"],"i_c":"9050/0","i_c_s":["Mesothelioma, benign"],"term_type":"PT"},{"nm":"Mesothelioma, biphasic, malignant","n_c":["C4282"],"i_c":"9053/3","i_c_s":["Mesothelioma, biphasic, malignant"],"term_type":"PT"},{"nm":"Mesothelioma, biphasic, NOS","n_c":["C4282"],"i_c":"9053/3","i_c_s":["Mesothelioma, biphasic, NOS"],"term_type":"SY"},{"nm":"Mesothelioma, malignant","n_c":["C4456"],"i_c":"9050/3","i_c_s":["Mesothelioma, malignant"],"term_type":"PT"},{"nm":"Mesothelioma, NOS","n_c":["C3786"],"i_c":"9050/3","i_c_s":["Mesothelioma, NOS"],"term_type":"SY"},{"nm":"Metanephric adenoma","n_c":["C27253"],"i_c":"8325/0","i_c_s":["Metanephric adenoma"],"term_type":"PT"},{"nm":"Metaplastic carcinoma of no special type","n_c":["C27949"],"i_c":"8575/3","i_c_s":["Metaplastic carcinoma of no special type"],"term_type":""},{"nm":"Metaplastic carcinoma with chondroid differentiation","n_c":"","i_c":"8571/3","i_c_s":["Metaplastic carcinoma with chondroid differentiation"],"term_type":""},{"nm":"Metaplastic carcinoma with osseous differentiation","n_c":"","i_c":"8571/3","i_c_s":["Metaplastic carcinoma with osseous differentiation"],"term_type":""},{"nm":"Metaplastic carcinoma with other types mesenchymal differentiation","n_c":"","i_c":"8575/3","i_c_s":["Metaplastic carcinoma with other types mesenchymal differentiation"],"term_type":""},{"nm":"Metaplastic carcinoma, NOS","n_c":["C27949"],"i_c":"8575/3","i_c_s":["Metaplastic carcinoma, NOS"],"term_type":"PT"},{"nm":"Metaplastic meningioma","n_c":["C6907"],"i_c":"9530/0","i_c_s":["Metaplastic meningioma"],"term_type":"RT"},{"nm":"Metastasizing leiomyoma","n_c":"","i_c":"8898/1","i_c_s":["Metastasizing leiomyoma"],"term_type":"PT"},{"nm":"Metastatic signet ring cell carcinoma","n_c":["C66717"],"i_c":"8490/6","i_c_s":["Metastatic signet ring cell carcinoma"],"term_type":"PT"},{"nm":"Metatypical carcinoma","n_c":["C66903"],"i_c":"8095/3","i_c_s":["Metatypical carcinoma"],"term_type":"PT"},{"nm":"MGUS","n_c":["C3996"],"i_c":"9765/1","i_c_s":["MGUS"],"term_type":"SY"},{"nm":"Microcystic adenoma","n_c":["C3685"],"i_c":"8202/0","i_c_s":["Microcystic adenoma"],"term_type":"PT"},{"nm":"Microcystic adnexal carcinoma","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Microcystic adnexal carcinoma"],"term_type":"SY"},{"nm":"Microcystic meningioma","n_c":["C4721"],"i_c":"9530/0","i_c_s":["Microcystic meningioma"],"term_type":"RT"},{"nm":"Microcystic urothelial carcinoma","n_c":["C191685"],"i_c":"8120/3","i_c_s":["Microcystic urothelial carcinoma"],"term_type":""},{"nm":"Microfollicular adenoma, NOS","n_c":["C4160"],"i_c":"8333/0","i_c_s":["Microfollicular adenoma, NOS"],"term_type":"PT"},{"nm":"Microglioma","n_c":["C9301"],"i_c":"9590/3","i_c_s":["Microglioma"],"term_type":"IS"},{"nm":"Micropapillary adenocarcinoma","n_c":"","i_c":"8265/3","i_c_s":["Micropapillary adenocarcinoma"],"term_type":""},{"nm":"Micropapillary carcinoma, NOS","n_c":["C128847"],"i_c":"8265/3","i_c_s":["Micropapillary carcinoma, NOS"],"term_type":"PT"},{"nm":"Micropapillary serous carcinoma","n_c":["C6882"],"i_c":"8460/3","i_c_s":["Micropapillary serous carcinoma"],"term_type":"RT"},{"nm":"Midline carcinoma of children and young adults with NUT rearrangement","n_c":["C45716"],"i_c":"8023/3","i_c_s":["Midline carcinoma of children and young adults with NUT rearrangement"],"term_type":""},{"nm":"Minimally invasive adenocarcinoma, mucinous","n_c":["C7268"],"i_c":"8257/3","i_c_s":["Minimally invasive adenocarcinoma, mucinous"],"term_type":"PT"},{"nm":"Minimally invasive adenocarcinoma, non-mucinous","n_c":["C7269"],"i_c":"8256/3","i_c_s":["Minimally invasive adenocarcinoma, non-mucinous"],"term_type":"PT"},{"nm":"Minimally invasive adenocarcinoma, NOS","n_c":["C2923"],"i_c":"8140/3","i_c_s":["Minimally invasive adenocarcinoma, NOS"],"term_type":""},{"nm":"MiT family translocation renal cell carcinoma","n_c":["C154494"],"i_c":"8311/3","i_c_s":["MiT family translocation renal cell carcinoma"],"term_type":""},{"nm":"Mixed acidophil-basophil adenoma","n_c":["C4148"],"i_c":"8281/0","i_c_s":["Mixed acidophil-basophil adenoma"],"term_type":"PT"},{"nm":"Mixed acidophil-basophil carcinoma","n_c":["C4149"],"i_c":"8281/3","i_c_s":["Mixed acidophil-basophil carcinoma"],"term_type":"PT"},{"nm":"Mixed acinar-ductal carcinoma","n_c":["C95458"],"i_c":"8552/3","i_c_s":["Mixed acinar-ductal carcinoma"],"term_type":"PT"},{"nm":"Mixed acinar-endocrine carcinoma","n_c":"","i_c":"8154/3","i_c_s":["Mixed acinar-endocrine carcinoma"],"term_type":"RT"},{"nm":"Mixed acinar-endocrine-ductal carcinoma","n_c":["C95458"],"i_c":"8154/3","i_c_s":["Mixed acinar-endocrine-ductal carcinoma"],"term_type":"RT"},{"nm":"Mixed adenocarcinoma and epidermoid carcinoma","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Mixed adenocarcinoma and epidermoid carcinoma"],"term_type":"SY"},{"nm":"Mixed adenocarcinoma and squamous cell carcinoma","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Mixed adenocarcinoma and squamous cell carcinoma"],"term_type":"SY"},{"nm":"Mixed adenomatous and hyperplastic polyp","n_c":["C38458"],"i_c":"8213/0","i_c_s":["Mixed adenomatous and hyperplastic polyp"],"term_type":"RT"},{"nm":"Mixed adenoneuroendocrine carcinoma","n_c":["C95406"],"i_c":"8244/3","i_c_s":["Mixed adenoneuroendocrine carcinoma"],"term_type":"PT"},{"nm":"Mixed basal-squamous cell carcinoma","n_c":["C2922"],"i_c":"8094/3","i_c_s":["Mixed basal-squamous cell carcinoma"],"term_type":"SY"},{"nm":"Mixed carcinoid-adenocarcinoma","n_c":["C95406"],"i_c":"8244/3","i_c_s":["Mixed carcinoid-adenocarcinoma"],"term_type":"SY"},{"nm":"Mixed cell adenocarcinoma","n_c":["C4158"],"i_c":"8323/3","i_c_s":["Mixed cell adenocarcinoma"],"term_type":"PT"},{"nm":"Mixed cell adenoma","n_c":["C4157"],"i_c":"8323/0","i_c_s":["Mixed cell adenoma"],"term_type":"PT"},{"nm":"Mixed ductal-endocrine carcinoma","n_c":["C6879"],"i_c":"8154/3","i_c_s":["Mixed ductal-endocrine carcinoma"],"term_type":"RT"},{"nm":"Mixed embryonal carcinoma and teratoma","n_c":["C3756"],"i_c":"9081/3","i_c_s":["Mixed embryonal carcinoma and teratoma"],"term_type":"SY"},{"nm":"Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma","n_c":"","i_c":"8902/3","i_c_s":["Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma"],"term_type":"RT"},{"nm":"Mixed endocrine and exocrine adenocarcinoma","n_c":"","i_c":"8154/3","i_c_s":["Mixed endocrine and exocrine adenocarcinoma"],"term_type":"RT"},{"nm":"Mixed epithelioid and spindle cell melanoma","n_c":["C66756"],"i_c":"8770/3","i_c_s":["Mixed epithelioid and spindle cell melanoma"],"term_type":"PT"},{"nm":"Mixed germ cell sex cord-stromal tumor, unclassified","n_c":["C39912"],"i_c":"8594/1","i_c_s":["Mixed germ cell sex cord-stromal tumor, unclassified"],"term_type":"PT"},{"nm":"Mixed germ cell tumor","n_c":["C4290"],"i_c":"9085/3","i_c_s":["Mixed germ cell tumor"],"term_type":"PT"},{"nm":"Mixed glioma","n_c":["C3903"],"i_c":"9382/3","i_c_s":["Mixed glioma"],"term_type":"PT"},{"nm":"Mixed hepatocellular and bile duct carcinoma","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Mixed hepatocellular and bile duct carcinoma"],"term_type":"SY"},{"nm":"Mixed invasive mucinous and non-mucinous adenocarcinoma","n_c":"","i_c":"8254/3","i_c_s":["Mixed invasive mucinous and non-mucinous adenocarcinoma"],"term_type":"PT"},{"nm":"Mixed islet cell and exocrine adenocarcinoma","n_c":"","i_c":"8154/3","i_c_s":["Mixed islet cell and exocrine adenocarcinoma"],"term_type":"SY"},{"nm":"Mixed liposarcoma","n_c":["C4253"],"i_c":"8855/3","i_c_s":["Mixed liposarcoma"],"term_type":"PT"},{"nm":"Mixed medullary-follicular carcinoma","n_c":["C46104"],"i_c":"8346/3","i_c_s":["Mixed medullary-follicular carcinoma"],"term_type":"PT"},{"nm":"Mixed medullary-papillary carcinoma","n_c":["C46104"],"i_c":"8347/3","i_c_s":["Mixed medullary-papillary carcinoma"],"term_type":"PT"},{"nm":"Mixed meningioma","n_c":["C4333"],"i_c":"9537/0","i_c_s":["Mixed meningioma"],"term_type":"SY"},{"nm":"Mixed mesenchymal sarcoma","n_c":["C4268"],"i_c":"8990/3","i_c_s":["Mixed mesenchymal sarcoma"],"term_type":"SY"},{"nm":"Mixed mesenchymal tumor","n_c":["C3233"],"i_c":"8990/1","i_c_s":["Mixed mesenchymal tumor"],"term_type":"SY"},{"nm":"Mixed pancreatic endocrine and exocrine tumor, malignant","n_c":["C45843"],"i_c":"8154/3","i_c_s":["Mixed pancreatic endocrine and exocrine tumor, malignant"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1","n_c":["C82192"],"i_c":"9806/3","i_c_s":["Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged","n_c":["C82203"],"i_c":"9807/3","i_c_s":["Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia, B/myeloid, NOS","n_c":["C82212"],"i_c":"9808/3","i_c_s":["Mixed phenotype acute leukemia, B/myeloid, NOS"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia, T/myeloid, NOS","n_c":["C82213"],"i_c":"9809/3","i_c_s":["Mixed phenotype acute leukemia, T/myeloid, NOS"],"term_type":"PT"},{"nm":"Mixed pineal tumor","n_c":"","i_c":"9362/3","i_c_s":["Mixed pineal tumor"],"term_type":"RT"},{"nm":"Mixed pineocytoma-pineoblastoma","n_c":"","i_c":"9362/3","i_c_s":["Mixed pineocytoma-pineoblastoma"],"term_type":"SY"},{"nm":"Mixed small cell carcinoma","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Mixed small cell carcinoma"],"term_type":"SY"},{"nm":"Mixed squamous cell and glandular papilloma","n_c":["C45602"],"i_c":"8560/0","i_c_s":["Mixed squamous cell and glandular papilloma"],"term_type":"PT"},{"nm":"Mixed subependymoma-ependymoma","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Mixed subependymoma-ependymoma"],"term_type":"RT"},{"nm":"Mixed teratoma and seminoma","n_c":["C9010"],"i_c":"9085/3","i_c_s":["Mixed teratoma and seminoma"],"term_type":"RT"},{"nm":"Mixed tumor, malignant, NOS","n_c":["C3729","C8025"],"i_c":"8940/3","i_c_s":["Mixed tumor, malignant, NOS"],"term_type":"PT"},{"nm":"Mixed tumor, NOS","n_c":["C121786"],"i_c":"8940/0","i_c_s":["Mixed tumor, NOS"],"term_type":"SY"},{"nm":"Mixed tumor, salivary gland type, malignant","n_c":["C8025"],"i_c":"8940/3","i_c_s":["Mixed tumor, salivary gland type, malignant"],"term_type":"SY"},{"nm":"Mixed tumor, salivary gland type, NOS","n_c":["C8602"],"i_c":"8940/0","i_c_s":["Mixed tumor, salivary gland type, NOS"],"term_type":"SY"},{"nm":"Mixed type rhabdomyosarcoma","n_c":"","i_c":"8902/3","i_c_s":["Mixed type rhabdomyosarcoma"],"term_type":"PT"},{"nm":"Monoblastic leukemia, NOS","n_c":["C7171"],"i_c":"9891/3","i_c_s":["Monoblastic leukemia, NOS"],"term_type":"SY"},{"nm":"Monoclonal gammopathy of undetermined significance","n_c":["C3996"],"i_c":"9765/1","i_c_s":["Monoclonal gammopathy of undetermined significance"],"term_type":"PT"},{"nm":"Monoclonal gammopathy, NOS","n_c":["C3996"],"i_c":"9765/1","i_c_s":["Monoclonal gammopathy, NOS"],"term_type":"SY"},{"nm":"Monocytic leukemia, NOS","n_c":["C4861"],"i_c":"9860/3","i_c_s":["Monocytic leukemia, NOS"],"term_type":"RT"},{"nm":"Monocytoid B-cell lymphoma","n_c":["C8863"],"i_c":"9699/3","i_c_s":["Monocytoid B-cell lymphoma"],"term_type":"SY"},{"nm":"Monomorphic adenoma","n_c":["C3686"],"i_c":"8146/0","i_c_s":["Monomorphic adenoma"],"term_type":"PT"},{"nm":"Monstrocellular sarcoma","n_c":"","i_c":"9441/3","i_c_s":["Monstrocellular sarcoma"],"term_type":"IS"},{"nm":"MPNST with glandular differentiation","n_c":"","i_c":"9540/3","i_c_s":["MPNST with glandular differentiation"],"term_type":"RT"},{"nm":"MPNST with mesenchymal differentiation","n_c":"","i_c":"9540/3","i_c_s":["MPNST with mesenchymal differentiation"],"term_type":"RT"},{"nm":"MPNST with rhabdomyoblastic differentiation","n_c":["C4335"],"i_c":"9561/3","i_c_s":["MPNST with rhabdomyoblastic differentiation"],"term_type":"SY"},{"nm":"MPNST, NOS","n_c":["C3798"],"i_c":"9540/3","i_c_s":["MPNST, NOS"],"term_type":"SY"},{"nm":"Mu heavy chain disease","n_c":["C3892"],"i_c":"9762/3","i_c_s":["Mu heavy chain disease"],"term_type":"RT"},{"nm":"Mucin-producing adenocarcinoma","n_c":["C27379"],"i_c":"8481/3","i_c_s":["Mucin-producing adenocarcinoma"],"term_type":"PT"},{"nm":"Mucin-producing carcinoma","n_c":["C27825"],"i_c":"8481/3","i_c_s":["Mucin-producing carcinoma"],"term_type":"SY"},{"nm":"Mucin-secreting adenocarcinoma","n_c":["C27379"],"i_c":"8481/3","i_c_s":["Mucin-secreting adenocarcinoma"],"term_type":"SY"},{"nm":"Mucin-secreting carcinoma","n_c":["C27825"],"i_c":"8481/3","i_c_s":["Mucin-secreting carcinoma"],"term_type":"SY"},{"nm":"Mucinous adenocarcinofibroma","n_c":["C40034"],"i_c":"9015/3","i_c_s":["Mucinous adenocarcinofibroma"],"term_type":"PT"},{"nm":"Mucinous adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucinous adenocarcinoma"],"term_type":"PT"},{"nm":"Mucinous adenocarcinoma, endocervical type","n_c":["C66953"],"i_c":"8482/3","i_c_s":["Mucinous adenocarcinoma, endocervical type"],"term_type":"PT"},{"nm":"Mucinous adenofibroma of borderline malignancy","n_c":["C66775"],"i_c":"9015/1","i_c_s":["Mucinous adenofibroma of borderline malignancy"],"term_type":"PT"},{"nm":"Mucinous adenofibroma, NOS","n_c":["C8978"],"i_c":"9015/0","i_c_s":["Mucinous adenofibroma, NOS"],"term_type":"PT"},{"nm":"Mucinous adenoma","n_c":["C2973"],"i_c":"8480/0","i_c_s":["Mucinous adenoma"],"term_type":"PT"},{"nm":"Mucinous carcinoid","n_c":"","i_c":"8243/3","i_c_s":["Mucinous carcinoid"],"term_type":"SY"},{"nm":"Mucinous carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucinous carcinoma"],"term_type":"SY"},{"nm":"Mucinous carcinoma, gastric type","n_c":["C127905"],"i_c":"8482/3","i_c_s":["Mucinous carcinoma, gastric type"],"term_type":""},{"nm":"Mucinous carcinoma, intestinal type","n_c":["C40203"],"i_c":"8144/3","i_c_s":["Mucinous carcinoma, intestinal type"],"term_type":""},{"nm":"Mucinous cystadenocarcinofibroma","n_c":"","i_c":"9015/3","i_c_s":["Mucinous cystadenocarcinofibroma"],"term_type":"RT"},{"nm":"Mucinous cystadenocarcinoma, non-invasive","n_c":["C41245"],"i_c":"8470/2","i_c_s":["Mucinous cystadenocarcinoma, non-invasive"],"term_type":"PT"},{"nm":"Mucinous cystadenocarcinoma, NOS","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Mucinous cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Mucinous cystadenofibroma of borderline malignancy","n_c":"","i_c":"9015/1","i_c_s":["Mucinous cystadenofibroma of borderline malignancy"],"term_type":"RT"},{"nm":"Mucinous cystadenofibroma, NOS","n_c":["C8979"],"i_c":"9015/0","i_c_s":["Mucinous cystadenofibroma, NOS"],"term_type":"RT"},{"nm":"Mucinous cystadenoma, borderline malignancy","n_c":"","i_c":"8472/1","i_c_s":["Mucinous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Mucinous cystadenoma, NOS","n_c":["C2973"],"i_c":"8470/0","i_c_s":["Mucinous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Mucinous cystic neoplasm with an associated invasive carcinoma","n_c":"","i_c":"8470/3","i_c_s":["Mucinous cystic neoplasm with an associated invasive carcinoma"],"term_type":"SY"},{"nm":"Mucinous cystic neoplasm with high-grade dysplasia","n_c":["C95493"],"i_c":"8470/2","i_c_s":["Mucinous cystic neoplasm with high-grade dysplasia"],"term_type":"SY"},{"nm":"Mucinous cystic neoplasm with high-grade intraepithelial neoplasia","n_c":"","i_c":"8470/2","i_c_s":["Mucinous cystic neoplasm with high-grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Mucinous cystic neoplasm with intermediate-grade dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with intermediate-grade dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Mucinous cystic neoplasm with low-grade dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with low-grade dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic neoplasm with low-grade intraepithelial neoplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with low-grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Mucinous cystic tumor of borderline malignancy","n_c":["C201978"],"i_c":"8472/1","i_c_s":["Mucinous cystic tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Mucinous cystic tumor with an associated invasive carcinoma","n_c":"","i_c":"8470/3","i_c_s":["Mucinous cystic tumor with an associated invasive carcinoma"],"term_type":"RT"},{"nm":"Mucinous cystic tumor with high-grade dysplasia","n_c":"","i_c":"8470/2","i_c_s":["Mucinous cystic tumor with high-grade dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic tumor with intermediate dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic tumor with intermediate dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic tumor with low grade dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic tumor with low grade dysplasia"],"term_type":""},{"nm":"Mucinous cystic tumor with moderate dysplasia","n_c":["C6883"],"i_c":"8470/0","i_c_s":["Mucinous cystic tumor with moderate dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystoma","n_c":["C2973"],"i_c":"8470/0","i_c_s":["Mucinous cystoma"],"term_type":"SY"},{"nm":"Mucinous tubular and spindle cell carcinoma","n_c":["C39807"],"i_c":"8480/3","i_c_s":["Mucinous tubular and spindle cell carcinoma"],"term_type":""},{"nm":"Mucinous tumor, NOS, of low malignant potential","n_c":"","i_c":"8472/1","i_c_s":["Mucinous tumor, NOS, of low malignant potential"],"term_type":"SY"},{"nm":"Mucocarcinoid tumor","n_c":"","i_c":"8243/3","i_c_s":["Mucocarcinoid tumor"],"term_type":"SY"},{"nm":"Mucoepidermoid carcinoma","n_c":["C3772"],"i_c":"8430/3","i_c_s":["Mucoepidermoid carcinoma"],"term_type":"PT"},{"nm":"Mucoepidermoid tumor","n_c":["C3772"],"i_c":"8430/1","i_c_s":["Mucoepidermoid tumor"],"term_type":"OP"},{"nm":"Mucoid adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucoid adenocarcinoma"],"term_type":"SY"},{"nm":"Mucoid carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucoid carcinoma"],"term_type":"SY"},{"nm":"Mucoid cell adenocarcinoma","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Mucoid cell adenocarcinoma"],"term_type":"SY"},{"nm":"Mucoid cell adenoma","n_c":["C2856"],"i_c":"8300/0","i_c_s":["Mucoid cell adenoma"],"term_type":"SY"},{"nm":"Mucosal lentiginous melanoma","n_c":["C48622"],"i_c":"8746/3","i_c_s":["Mucosal lentiginous melanoma"],"term_type":"PT"},{"nm":"Mucosal-associated lymphoid tissue lymphoma","n_c":["C3898"],"i_c":"9699/3","i_c_s":["Mucosal-associated lymphoid tissue lymphoma"],"term_type":"SY"},{"nm":"Mucous adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucous adenocarcinoma"],"term_type":"SY"},{"nm":"Mucous carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucous carcinoma"],"term_type":"SY"},{"nm":"Mullerian adenosarcoma","n_c":["C9474"],"i_c":"8933/3","i_c_s":["Mullerian adenosarcoma"],"term_type":""},{"nm":"Mullerian mixed tumor","n_c":["C3730"],"i_c":"8950/3","i_c_s":["Mullerian mixed tumor"],"term_type":"PT"},{"nm":"Multicentric basal cell carcinoma","n_c":["C4108"],"i_c":"8091/3","i_c_s":["Multicentric basal cell carcinoma"],"term_type":"SY"},{"nm":"Multicystic mesothelioma, benign","n_c":["C3765"],"i_c":"9055/0","i_c_s":["Multicystic mesothelioma, benign"],"term_type":"PT"},{"nm":"Multifocal superficial basal cell carcinoma","n_c":["C4108"],"i_c":"8091/3","i_c_s":["Multifocal superficial basal cell carcinoma"],"term_type":"PT"},{"nm":"Multiple adenomatous polyps","n_c":["C4135"],"i_c":"8221/0","i_c_s":["Multiple adenomatous polyps"],"term_type":"PT"},{"nm":"Multiple endocrine adenomas","n_c":["C6432"],"i_c":"8360/1","i_c_s":["Multiple endocrine adenomas"],"term_type":"PT"},{"nm":"Multiple hemorrhagic sarcoma","n_c":["C9087"],"i_c":"9140/3","i_c_s":["Multiple hemorrhagic sarcoma"],"term_type":"SY"},{"nm":"Multiple meningiomas","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Multiple meningiomas"],"term_type":"SY"},{"nm":"Multiple myeloma","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Multiple myeloma"],"term_type":"PT"},{"nm":"Multiple neurofibromatosis","n_c":["C6727"],"i_c":"9540/1","i_c_s":["Multiple neurofibromatosis"],"term_type":"SY"},{"nm":"Mycosis fungoides","n_c":["C3246"],"i_c":"9700/3","i_c_s":["Mycosis fungoides"],"term_type":"PT"},{"nm":"Myelocytic leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Myelocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Myelodysplastic syndrome with 5q deletion (5q-) syndrome","n_c":["C6867"],"i_c":"9986/3","i_c_s":["Myelodysplastic syndrome with 5q deletion (5q-) syndrome"],"term_type":"PT"},{"nm":"Myelodysplastic syndrome with isolated del (5q)","n_c":["C6867"],"i_c":"9986/3","i_c_s":["Myelodysplastic syndrome with isolated del (5q)"],"term_type":"SY"},{"nm":"Myelodysplastic syndrome, NOS","n_c":["C198589"],"i_c":"9989/3","i_c_s":["Myelodysplastic syndrome, NOS"],"term_type":"PT"},{"nm":"Myelodysplastic syndrome, unclassifiable","n_c":["C8648"],"i_c":"9989/3","i_c_s":["Myelodysplastic syndrome, unclassifiable"],"term_type":"SY"},{"nm":"Myelodysplastic/myeloproliferative neoplasm, unclassifiable","n_c":["C27780"],"i_c":"9975/3","i_c_s":["Myelodysplastic/myeloproliferative neoplasm, unclassifiable"],"term_type":"SY"},{"nm":"Myelofibrosis as a result of myeloproliferative disease","n_c":["C27701"],"i_c":"9961/3","i_c_s":["Myelofibrosis as a result of myeloproliferative disease"],"term_type":"SY"},{"nm":"Myelofibrosis with myeloid metaplasia","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Myelofibrosis with myeloid metaplasia"],"term_type":"SY"},{"nm":"Myelogenous leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Myelogenous leukemia, NOS"],"term_type":"SY"},{"nm":"Myeloid and lymphoid neoplasms with FGFR1 abnormalities","n_c":["C84277"],"i_c":"9967/3","i_c_s":["Myeloid and lymphoid neoplasms with FGFR1 abnormalities"],"term_type":"PT"},{"nm":"Myeloid and lymphoid neoplasms with PDGFRA rearrangement","n_c":["C84275"],"i_c":"9965/3","i_c_s":["Myeloid and lymphoid neoplasms with PDGFRA rearrangement"],"term_type":"PT"},{"nm":"Myeloid leukemia associated with Down Syndrome","n_c":["C43223"],"i_c":"9898/3","i_c_s":["Myeloid leukemia associated with Down Syndrome"],"term_type":"PT"},{"nm":"Myeloid leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Myeloid leukemia, NOS"],"term_type":"PT"},{"nm":"Myeloid neoplasms with PDGFRB rearrangement","n_c":["C84276"],"i_c":"9966/3","i_c_s":["Myeloid neoplasms with PDGFRB rearrangement"],"term_type":"PT"},{"nm":"Myeloid sarcoma","n_c":["C3520"],"i_c":"9930/3","i_c_s":["Myeloid sarcoma"],"term_type":"PT"},{"nm":"Myelolipoma","n_c":["C3736"],"i_c":"8870/0","i_c_s":["Myelolipoma"],"term_type":"PT"},{"nm":"Myeloma, NOS","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Myeloma, NOS"],"term_type":"SY"},{"nm":"Myelomatosis","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Myelomatosis"],"term_type":"SY"},{"nm":"Myelomonocytic leukemia, NOS","n_c":"","i_c":"9860/3","i_c_s":["Myelomonocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Myeloproliferative disease, NOS","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Myeloproliferative disease, NOS"],"term_type":"SY"},{"nm":"Myeloproliferative neoplasm, NOS","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Myeloproliferative neoplasm, NOS"],"term_type":"PT"},{"nm":"Myelosclerosis with myeloid metaplasia","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Myelosclerosis with myeloid metaplasia"],"term_type":"SY"},{"nm":"Myloproliferative neoplasm, unclassifiable","n_c":["C27350"],"i_c":"9975/3","i_c_s":["Myloproliferative neoplasm, unclassifiable"],"term_type":"PT"},{"nm":"Myoepithelial adenoma","n_c":["C7442"],"i_c":"8982/0","i_c_s":["Myoepithelial adenoma"],"term_type":"SY"},{"nm":"Myoepithelial carcinoma","n_c":["C7596"],"i_c":"8982/3","i_c_s":["Myoepithelial carcinoma"],"term_type":"SY"},{"nm":"Myoepithelial tumor","n_c":["C40392"],"i_c":"8982/0","i_c_s":["Myoepithelial tumor"],"term_type":"SY"},{"nm":"Myoepithelioma","n_c":["C40392"],"i_c":"8982/0","i_c_s":["Myoepithelioma"],"term_type":"PT"},{"nm":"Myofibroblastic sarcoma","n_c":["C49024"],"i_c":"8825/3","i_c_s":["Myofibroblastic sarcoma"],"term_type":"PT"},{"nm":"Myofibroblastic tumor, NOS","n_c":["C6481"],"i_c":"8825/1","i_c_s":["Myofibroblastic tumor, NOS"],"term_type":"PT"},{"nm":"Myofibroblastic tumor, peribronchial","n_c":["C39740"],"i_c":"8827/1","i_c_s":["Myofibroblastic tumor, peribronchial"],"term_type":"PT"},{"nm":"Myofibroblastoma","n_c":["C49012"],"i_c":"8825/0","i_c_s":["Myofibroblastoma"],"term_type":"PT"},{"nm":"Myofibroma","n_c":["C7052"],"i_c":"8824/0","i_c_s":["Myofibroma"],"term_type":"PT"},{"nm":"Myofibromatosis","n_c":["C3742"],"i_c":"8824/1","i_c_s":["Myofibromatosis"],"term_type":"PT"},{"nm":"Myoma","n_c":["C4882"],"i_c":"8895/0","i_c_s":["Myoma"],"term_type":"PT"},{"nm":"Myosarcoma","n_c":["C4883"],"i_c":"8895/3","i_c_s":["Myosarcoma"],"term_type":"PT"},{"nm":"Myxofibroma, NOS","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Myxofibroma, NOS"],"term_type":"SY"},{"nm":"Myxoid chondrosarcoma","n_c":["C27502"],"i_c":"9231/3","i_c_s":["Myxoid chondrosarcoma"],"term_type":"PT"},{"nm":"Myxoid fibroma","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Myxoid fibroma"],"term_type":"SY"},{"nm":"Myxoid leiomyosarcoma","n_c":["C3701"],"i_c":"8896/3","i_c_s":["Myxoid leiomyosarcoma"],"term_type":"PT"},{"nm":"Myxoid liposarcoma","n_c":["C27781"],"i_c":"8852/3","i_c_s":["Myxoid liposarcoma"],"term_type":"PT"},{"nm":"Myxoinflammatory fibroblastic sarcoma (MIFS)","n_c":["C49025"],"i_c":"8811/1","i_c_s":["Myxoinflammatory fibroblastic sarcoma (MIFS)"],"term_type":""},{"nm":"Myxolipoma","n_c":["C4251"],"i_c":"8852/0","i_c_s":["Myxolipoma"],"term_type":"SY"},{"nm":"Myxoliposarcoma","n_c":["C27781"],"i_c":"8852/3","i_c_s":["Myxoliposarcoma"],"term_type":"SY"},{"nm":"Myxoma, NOS","n_c":["C6577"],"i_c":"8840/0","i_c_s":["Myxoma, NOS"],"term_type":"PT"},{"nm":"Myxopapillary ependymoma","n_c":["C3697"],"i_c":"9394/1","i_c_s":["Myxopapillary ependymoma"],"term_type":"PT"},{"nm":"Myxosarcoma","n_c":["C3255"],"i_c":"8840/3","i_c_s":["Myxosarcoma"],"term_type":"PT"},{"nm":"Neoplasm, benign","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Neoplasm, benign"],"term_type":"PT"},{"nm":"Neoplasm, malignant","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Neoplasm, malignant"],"term_type":"PT"},{"nm":"Neoplasm, malignant, uncertain whether primary or metastatic","n_c":["C65153"],"i_c":"8000/9","i_c_s":["Neoplasm, malignant, uncertain whether primary or metastatic"],"term_type":"PT"},{"nm":"Neoplasm, metastatic","n_c":["C3261"],"i_c":"8000/6","i_c_s":["Neoplasm, metastatic"],"term_type":"PT"},{"nm":"Neoplasm, NOS","n_c":["C3262"],"i_c":"8000/1","i_c_s":["Neoplasm, NOS"],"term_type":"SY"},{"nm":"Neoplasm, secondary","n_c":["C36255"],"i_c":"8000/6","i_c_s":["Neoplasm, secondary"],"term_type":"SY"},{"nm":"Neoplasm, uncertain whether benign or malignant","n_c":["C65157"],"i_c":"8000/1","i_c_s":["Neoplasm, uncertain whether benign or malignant"],"term_type":"PT"},{"nm":"Nephroblastoma, NOS","n_c":["C40407"],"i_c":"8960/3","i_c_s":["Nephroblastoma, NOS"],"term_type":"PT"},{"nm":"Nephrogenic adenofibroma","n_c":["C39812"],"i_c":"8965/0","i_c_s":["Nephrogenic adenofibroma"],"term_type":"PT"},{"nm":"Nephroma, NOS","n_c":["C40407"],"i_c":"8960/3","i_c_s":["Nephroma, NOS"],"term_type":"SY"},{"nm":"Nerve sheath myxoma","n_c":["C7018"],"i_c":"9562/0","i_c_s":["Nerve sheath myxoma"],"term_type":"SY"},{"nm":"Nesidioblastoma","n_c":["C65184"],"i_c":"8150/0","i_c_s":["Nesidioblastoma"],"term_type":"SY"},{"nm":"Nested urothelial carcinoma","n_c":["C191687"],"i_c":"8120/3","i_c_s":["Nested urothelial carcinoma"],"term_type":""},{"nm":"Neurilemoma, malignant","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Neurilemoma, malignant"],"term_type":"OP"},{"nm":"Neurilemoma, NOS","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Neurilemoma, NOS"],"term_type":"PT"},{"nm":"Neurilemosarcoma","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Neurilemosarcoma"],"term_type":"IS"},{"nm":"Neurinoma","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Neurinoma"],"term_type":"SY"},{"nm":"Neurinomatosis","n_c":["C6557"],"i_c":"9560/1","i_c_s":["Neurinomatosis"],"term_type":"PT"},{"nm":"Neuroastrocytoma","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Neuroastrocytoma"],"term_type":"IS"},{"nm":"Neuroblastoma, NOS","n_c":["C3270"],"i_c":"9500/3","i_c_s":["Neuroblastoma, NOS"],"term_type":"PT"},{"nm":"Neurocytoma","n_c":["C3791"],"i_c":"9506/1","i_c_s":["Neurocytoma"],"term_type":"SY"},{"nm":"Neuroectodermal tumor, NOS","n_c":["C3716"],"i_c":"9364/3","i_c_s":["Neuroectodermal tumor, NOS"],"term_type":"RT"},{"nm":"Neuroendocrine carcinoma, low grade","n_c":["C35727"],"i_c":"8240/3","i_c_s":["Neuroendocrine carcinoma, low grade"],"term_type":"RT"},{"nm":"Neuroendocrine carcinoma, moderately differentiated","n_c":["C35725"],"i_c":"8249/3","i_c_s":["Neuroendocrine carcinoma, moderately differentiated"],"term_type":"RT"},{"nm":"Neuroendocrine carcinoma, NOS","n_c":["C3773"],"i_c":"8246/3","i_c_s":["Neuroendocrine carcinoma, NOS"],"term_type":"PT"},{"nm":"Neuroendocrine carcinoma, poorly differentiated","n_c":["C155863"],"i_c":"8041/3","i_c_s":["Neuroendocrine carcinoma, poorly differentiated"],"term_type":""},{"nm":"Neuroendocrine carcinoma, well-differentiated","n_c":["C35727"],"i_c":"8240/3","i_c_s":["Neuroendocrine carcinoma, well-differentiated"],"term_type":"RT"},{"nm":"Neuroendocrine tumor, grade 1","n_c":"","i_c":"8240/3","i_c_s":["Neuroendocrine tumor, grade 1"],"term_type":""},{"nm":"Neuroendocrine tumor, grade 2","n_c":"","i_c":"8249/3","i_c_s":["Neuroendocrine tumor, grade 2"],"term_type":"SY"},{"nm":"Neuroendocrine tumor, well differentiated","n_c":["C155861"],"i_c":"8246/3","i_c_s":["Neuroendocrine tumor, well differentiated"],"term_type":""},{"nm":"Neuroepithelioma, NOS","n_c":["C3716"],"i_c":"9503/3","i_c_s":["Neuroepithelioma, NOS"],"term_type":"PT"},{"nm":"Neurofibroma, NOS","n_c":["C3272"],"i_c":"9540/0","i_c_s":["Neurofibroma, NOS"],"term_type":"PT"},{"nm":"Neurofibromatosis, NOS","n_c":["C6727"],"i_c":"9540/1","i_c_s":["Neurofibromatosis, NOS"],"term_type":"PT"},{"nm":"Neurofibrosarcoma","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Neurofibrosarcoma"],"term_type":"IS"},{"nm":"Neurogenic sarcoma","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Neurogenic sarcoma"],"term_type":"IS"},{"nm":"Neurolipocytoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Neurolipocytoma"],"term_type":"SY"},{"nm":"Neuroma, NOS","n_c":["C3275"],"i_c":"9570/0","i_c_s":["Neuroma, NOS"],"term_type":"PT"},{"nm":"Neuronevus","n_c":["C4229"],"i_c":"8725/0","i_c_s":["Neuronevus"],"term_type":"PT"},{"nm":"Neurosarcoma","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Neurosarcoma"],"term_type":"IS"},{"nm":"Neurothekeoma","n_c":["C7018"],"i_c":"9562/0","i_c_s":["Neurothekeoma"],"term_type":"PT"},{"nm":"Neurotropic melanoma, malignant","n_c":"","i_c":"8745/3","i_c_s":["Neurotropic melanoma, malignant"],"term_type":"RT"},{"nm":"Nevus, NOS","n_c":["C7570"],"i_c":"8720/0","i_c_s":["Nevus, NOS"],"term_type":"SY"},{"nm":"NK-cell large granular lymphocytic leukemia","n_c":"","i_c":"9831/3","i_c_s":["NK-cell large granular lymphocytic leukemia"],"term_type":"SY"},{"nm":"NK/T-cell lymphoma, nasal and nasal-type","n_c":["C4684"],"i_c":"9719/3","i_c_s":["NK/T-cell lymphoma, nasal and nasal-type"],"term_type":"PT"},{"nm":"Nodal marginal zone lymphoma","n_c":["C8863"],"i_c":"9699/3","i_c_s":["Nodal marginal zone lymphoma"],"term_type":"SY"},{"nm":"Nodular hidradenoma","n_c":["C7568"],"i_c":"8402/0","i_c_s":["Nodular hidradenoma"],"term_type":"PT"},{"nm":"Nodular hidradenoma, malignant","n_c":"","i_c":"8402/3","i_c_s":["Nodular hidradenoma, malignant"],"term_type":"PT"},{"nm":"Nodular melanoma","n_c":["C4225"],"i_c":"8721/3","i_c_s":["Nodular melanoma"],"term_type":"PT"},{"nm":"Non-Hodgkin lymphoma, NOS","n_c":["C3211"],"i_c":"9591/3","i_c_s":["Non-Hodgkin lymphoma, NOS"],"term_type":"SY"},{"nm":"Non-invasive EFVPTC","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive EFVPTC"],"term_type":""},{"nm":"Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)"],"term_type":""},{"nm":"Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)"],"term_type":""},{"nm":"Non-invasive FTP","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive FTP"],"term_type":""},{"nm":"Non-invasive low grade serous carcinoma","n_c":"","i_c":"8460/2","i_c_s":["Non-invasive low grade serous carcinoma"],"term_type":""},{"nm":"Non-invasive mammary carcinoma","n_c":"","i_c":"8500/2","i_c_s":["Non-invasive mammary carcinoma"],"term_type":""},{"nm":"Non-lymphocytic leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Non-lymphocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Non-small cell carcinoma","n_c":["C65151"],"i_c":"8046/3","i_c_s":["Non-small cell carcinoma"],"term_type":"PT"},{"nm":"Nonchromaffin paraganglioma, malignant","n_c":["C4219"],"i_c":"8693/3","i_c_s":["Nonchromaffin paraganglioma, malignant"],"term_type":"RT"},{"nm":"Nonchromaffin paraganglioma, NOS","n_c":"","i_c":"8693/1","i_c_s":["Nonchromaffin paraganglioma, NOS"],"term_type":"RT"},{"nm":"Nonencapsulated sclerosing adenocarcinoma","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing adenocarcinoma"],"term_type":"SY"},{"nm":"Nonencapsulated sclerosing carcinoma","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing carcinoma"],"term_type":"PT"},{"nm":"Nonencapsulated sclerosing tumor","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing tumor"],"term_type":"SY"},{"nm":"Noninfiltrating intracystic carcinoma","n_c":["C7645"],"i_c":"8504/2","i_c_s":["Noninfiltrating intracystic carcinoma"],"term_type":"PT"},{"nm":"Noninfiltrating intraductal papillary adenocarcinoma","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Noninfiltrating intraductal papillary adenocarcinoma"],"term_type":"PT"},{"nm":"Noninfiltrating intraductal papillary carcinoma","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Noninfiltrating intraductal papillary carcinoma"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia","n_c":["C95914"],"i_c":"8163/0","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C95914"],"i_c":"8163/0","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Nonlipid reticuloendotheliosis","n_c":"","i_c":"9751/3","i_c_s":["Nonlipid reticuloendotheliosis"],"term_type":"ORT"},{"nm":"Nonpigmented nevus","n_c":["C27095"],"i_c":"8730/0","i_c_s":["Nonpigmented nevus"],"term_type":"PT"},{"nm":"NUT carcinoma","n_c":["C45716"],"i_c":"8023/3","i_c_s":["NUT carcinoma"],"term_type":"PT"},{"nm":"NUT midline carcinoma","n_c":["C45716"],"i_c":"8023/3","i_c_s":["NUT midline carcinoma"],"term_type":""},{"nm":"Oat cell carcinoma","n_c":["C3915"],"i_c":"8042/3","i_c_s":["Oat cell carcinoma"],"term_type":"PT"},{"nm":"Odontoameloblastoma","n_c":["C54317"],"i_c":"9311/0","i_c_s":["Odontoameloblastoma"],"term_type":"PT"},{"nm":"Odontogenic carcinoma","n_c":["C173720"],"i_c":"9270/3","i_c_s":["Odontogenic carcinoma"],"term_type":"SY"},{"nm":"Odontogenic carcinosarcoma","n_c":["C173735"],"i_c":"9342/3","i_c_s":["Odontogenic carcinosarcoma"],"term_type":"PT"},{"nm":"Odontogenic fibroma, NOS","n_c":["C4314"],"i_c":"9321/0","i_c_s":["Odontogenic fibroma, NOS"],"term_type":"SY"},{"nm":"Odontogenic fibrosarcoma","n_c":["C173740"],"i_c":"9330/3","i_c_s":["Odontogenic fibrosarcoma"],"term_type":"SY"},{"nm":"Odontogenic ghost cell tumor","n_c":["C54323"],"i_c":"9302/0","i_c_s":["Odontogenic ghost cell tumor"],"term_type":"PT"},{"nm":"Odontogenic myxofibroma","n_c":["C7452"],"i_c":"9320/0","i_c_s":["Odontogenic myxofibroma"],"term_type":"SY"},{"nm":"Odontogenic myxoma","n_c":["C7501"],"i_c":"9320/0","i_c_s":["Odontogenic myxoma"],"term_type":"PT"},{"nm":"Odontogenic sarcoma","n_c":["C173738"],"i_c":"9270/3","i_c_s":["Odontogenic sarcoma"],"term_type":"SY"},{"nm":"Odontogenic tumor, benign","n_c":["C4306"],"i_c":"9270/0","i_c_s":["Odontogenic tumor, benign"],"term_type":"PT"},{"nm":"Odontogenic tumor, malignant","n_c":["C4812"],"i_c":"9270/3","i_c_s":["Odontogenic tumor, malignant"],"term_type":"PT"},{"nm":"Odontogenic tumor, NOS","n_c":["C3286"],"i_c":"9270/1","i_c_s":["Odontogenic tumor, NOS"],"term_type":"PT"},{"nm":"Odontoma, NOS","n_c":["C3287"],"i_c":"9280/0","i_c_s":["Odontoma, NOS"],"term_type":"PT"},{"nm":"Olfactory neuroblastoma","n_c":["C3789"],"i_c":"9522/3","i_c_s":["Olfactory neuroblastoma"],"term_type":"PT"},{"nm":"Olfactory neurocytoma","n_c":["C67156"],"i_c":"9521/3","i_c_s":["Olfactory neurocytoma"],"term_type":"PT"},{"nm":"Olfactory neuroepithelioma","n_c":["C3789"],"i_c":"9523/3","i_c_s":["Olfactory neuroepithelioma"],"term_type":"PT"},{"nm":"Olfactory neurogenic tumor","n_c":["C67155"],"i_c":"9520/3","i_c_s":["Olfactory neurogenic tumor"],"term_type":"PT"},{"nm":"Oligoastrocytoma","n_c":["C4050"],"i_c":"9382/3","i_c_s":["Oligoastrocytoma"],"term_type":"SY"},{"nm":"Oligodendroblastoma","n_c":["C66802"],"i_c":"9460/3","i_c_s":["Oligodendroblastoma"],"term_type":"OP"},{"nm":"Oligodendroglioma, anaplastic","n_c":["C4326"],"i_c":"9451/3","i_c_s":["Oligodendroglioma, anaplastic"],"term_type":"PT"},{"nm":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","n_c":["C129318"],"i_c":"9450/3","i_c_s":["Oligodendroglioma, IDH-mutant and 1p/19q-codeleted"],"term_type":""},{"nm":"Oligodendroglioma, NOS","n_c":["C129319"],"i_c":"9450/3","i_c_s":["Oligodendroglioma, NOS"],"term_type":"PT"},{"nm":"Oncocytic adenocarcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oncocytic adenocarcinoma"],"term_type":"SY"},{"nm":"Oncocytic adenoma","n_c":["C3759"],"i_c":"8290/0","i_c_s":["Oncocytic adenoma"],"term_type":"SY"},{"nm":"Oncocytic carcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oncocytic carcinoma"],"term_type":"SY"},{"nm":"Oncocytic Schneiderian papilloma","n_c":["C54345"],"i_c":"8121/1","i_c_s":["Oncocytic Schneiderian papilloma"],"term_type":"RT"},{"nm":"Oncocytoma","n_c":["C7072"],"i_c":"8290/0","i_c_s":["Oncocytoma"],"term_type":"SY"},{"nm":"Orchioblastoma","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Orchioblastoma"],"term_type":"SY"},{"nm":"Ossifying fibroma","n_c":["C173820"],"i_c":"9262/0","i_c_s":["Ossifying fibroma"],"term_type":"PT"},{"nm":"Ossifying fibromyxoid tumor","n_c":["C6582"],"i_c":"8842/0","i_c_s":["Ossifying fibromyxoid tumor"],"term_type":"PT"},{"nm":"Ossifying fibromyxoid tumor, malignant","n_c":["C121774"],"i_c":"8842/3","i_c_s":["Ossifying fibromyxoid tumor, malignant"],"term_type":""},{"nm":"Ossifying renal tumor","n_c":["C66774"],"i_c":"8967/0","i_c_s":["Ossifying renal tumor"],"term_type":"PT"},{"nm":"Osteoblastic sarcoma","n_c":["C53953"],"i_c":"9180/3","i_c_s":["Osteoblastic sarcoma"],"term_type":"SY"},{"nm":"Osteoblastoma, malignant","n_c":["C8380"],"i_c":"9250/3","i_c_s":["Osteoblastoma, malignant"],"term_type":""},{"nm":"Osteoblastoma, NOS","n_c":["C3294"],"i_c":"9200/0","i_c_s":["Osteoblastoma, NOS"],"term_type":"PT"},{"nm":"Osteocartilaginous exostosis","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Osteocartilaginous exostosis"],"term_type":"SY"},{"nm":"Osteochondroma","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Osteochondroma"],"term_type":"PT"},{"nm":"Osteochondromatosis, NOS","n_c":["C53457"],"i_c":"9210/1","i_c_s":["Osteochondromatosis, NOS"],"term_type":"PT"},{"nm":"Osteochondrosarcoma","n_c":["C4021"],"i_c":"9180/3","i_c_s":["Osteochondrosarcoma"],"term_type":"SY"},{"nm":"Osteofibroma","n_c":"","i_c":"9262/0","i_c_s":["Osteofibroma"],"term_type":"SY"},{"nm":"Osteofibrosarcoma","n_c":["C4020"],"i_c":"9182/3","i_c_s":["Osteofibrosarcoma"],"term_type":"SY"},{"nm":"Osteogenic sarcoma, NOS","n_c":["C9145"],"i_c":"9180/3","i_c_s":["Osteogenic sarcoma, NOS"],"term_type":"SY"},{"nm":"Osteoid osteoma, NOS","n_c":["C3297"],"i_c":"9191/0","i_c_s":["Osteoid osteoma, NOS"],"term_type":"PT"},{"nm":"Osteoma, NOS","n_c":["C3296"],"i_c":"9180/0","i_c_s":["Osteoma, NOS"],"term_type":"PT"},{"nm":"Osteosarcoma in Paget disease of bone","n_c":["C6469"],"i_c":"9184/3","i_c_s":["Osteosarcoma in Paget disease of bone"],"term_type":"PT"},{"nm":"Osteosarcoma, NOS","n_c":["C9145"],"i_c":"9180/3","i_c_s":["Osteosarcoma, NOS"],"term_type":"PT"},{"nm":"Ovarian stromal tumor","n_c":["C4862"],"i_c":"8590/1","i_c_s":["Ovarian stromal tumor"],"term_type":"SY"},{"nm":"Oxyphilic adenocarcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oxyphilic adenocarcinoma"],"term_type":"PT"},{"nm":"Oxyphilic adenoma","n_c":["C3759"],"i_c":"8290/0","i_c_s":["Oxyphilic adenoma"],"term_type":"PT"},{"nm":"Pacinian tumor","n_c":["C4328"],"i_c":"9507/0","i_c_s":["Pacinian tumor"],"term_type":"PT"},{"nm":"Paget disease and infiltrating duct carcinoma of breast","n_c":["C7951"],"i_c":"8541/3","i_c_s":["Paget disease and infiltrating duct carcinoma of breast"],"term_type":"PT"},{"nm":"Paget disease and intraductal carcinoma of breast","n_c":["C4019"],"i_c":"8543/3","i_c_s":["Paget disease and intraductal carcinoma of breast"],"term_type":"PT"},{"nm":"Paget disease of breast","n_c":["C47857"],"i_c":"8540/3","i_c_s":["Paget disease of breast"],"term_type":"SY"},{"nm":"Paget disease, extramammary","n_c":["C3302"],"i_c":"8542/3","i_c_s":["Paget disease, extramammary"],"term_type":"PT"},{"nm":"Paget disease, mammary","n_c":["C47857"],"i_c":"8540/3","i_c_s":["Paget disease, mammary"],"term_type":"PT"},{"nm":"Pagetoid reticulosis","n_c":["C35794"],"i_c":"9700/3","i_c_s":["Pagetoid reticulosis"],"term_type":"SY"},{"nm":"Pancreatic endocrine tumor, benign","n_c":["C27720"],"i_c":"8150/0","i_c_s":["Pancreatic endocrine tumor, benign"],"term_type":"PT"},{"nm":"Pancreatic endocrine tumor, malignant","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Pancreatic endocrine tumor, malignant"],"term_type":"PT"},{"nm":"Pancreatic endocrine tumor, nonfunctioning","n_c":["C45837"],"i_c":"Pancreatic endocrine tumor, nonfunctioning","i_c_s":["Pancreatic endocrine tumor, nonfunctioning"],"term_type":"RT"},{"nm":"Pancreatic endocrine tumor, NOS","n_c":["C27031"],"i_c":"8150/1","i_c_s":["Pancreatic endocrine tumor, NOS"],"term_type":"PT"},{"nm":"Pancreatic microadenoma","n_c":["C45834"],"i_c":"Pancreatic microadenoma","i_c_s":["Pancreatic microadenoma"],"term_type":"RT"},{"nm":"Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor","n_c":"","i_c":"8152/1","i_c_s":["Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor"],"term_type":"RT"},{"nm":"Pancreatobiliary neoplasm, non-invasive","n_c":["C95913"],"i_c":"8163/0","i_c_s":["Pancreatobiliary neoplasm, non-invasive"],"term_type":"PT"},{"nm":"Pancreatobiliary-type carcinoma","n_c":["C95963"],"i_c":"8163/3","i_c_s":["Pancreatobiliary-type carcinoma"],"term_type":"PT"},{"nm":"Pancreatoblastoma","n_c":["C4265"],"i_c":"8971/3","i_c_s":["Pancreatoblastoma"],"term_type":"PT"},{"nm":"Papillary adenocarcinoma, follicular variant","n_c":"","i_c":"8340/3","i_c_s":["Papillary adenocarcinoma, follicular variant"],"term_type":"SY"},{"nm":"Papillary adenocarcinoma, NOS","n_c":["C2853"],"i_c":"8260/3","i_c_s":["Papillary adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Papillary adenofibroma","n_c":["C8986"],"i_c":"9013/0","i_c_s":["Papillary adenofibroma"],"term_type":"RT"},{"nm":"Papillary adenoma, NOS","n_c":["C6880"],"i_c":"8260/0","i_c_s":["Papillary adenoma, NOS"],"term_type":"PT"},{"nm":"Papillary and follicular adenocarcinoma","n_c":["C7380"],"i_c":"8340/3","i_c_s":["Papillary and follicular adenocarcinoma"],"term_type":"SY"},{"nm":"Papillary and follicular carcinoma","n_c":["C7380"],"i_c":"8340/3","i_c_s":["Papillary and follicular carcinoma"],"term_type":"SY"},{"nm":"Papillary carcinoma in situ","n_c":["C65163"],"i_c":"8050/2","i_c_s":["Papillary carcinoma in situ"],"term_type":"PT"},{"nm":"Papillary carcinoma of thyroid","n_c":["C4035"],"i_c":"8260/3","i_c_s":["Papillary carcinoma of thyroid"],"term_type":"RT"},{"nm":"Papillary carcinoma, columnar cell","n_c":["C35830"],"i_c":"8344/3","i_c_s":["Papillary carcinoma, columnar cell"],"term_type":"PT"},{"nm":"Papillary carcinoma, diffuse sclerosing","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Papillary carcinoma, diffuse sclerosing"],"term_type":"RT"},{"nm":"Papillary carcinoma, encapsulated","n_c":"","i_c":"8343/3","i_c_s":["Papillary carcinoma, encapsulated"],"term_type":"PT"},{"nm":"Papillary carcinoma, follicular variant","n_c":["C126594"],"i_c":"8340/3","i_c_s":["Papillary carcinoma, follicular variant"],"term_type":"PT"},{"nm":"Papillary carcinoma, NOS","n_c":["C2927"],"i_c":"8050/3","i_c_s":["Papillary carcinoma, NOS"],"term_type":"PT"},{"nm":"Papillary carcinoma, oxyphilic cell","n_c":["C46093"],"i_c":"8342/3","i_c_s":["Papillary carcinoma, oxyphilic cell"],"term_type":"PT"},{"nm":"Papillary carcinoma, tall cell","n_c":["C35558"],"i_c":"8344/3","i_c_s":["Papillary carcinoma, tall cell"],"term_type":"SY"},{"nm":"Papillary cystadenocarcinoma, NOS","n_c":["C3777"],"i_c":"8450/3","i_c_s":["Papillary cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Papillary cystadenoma lymphomatosum","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Papillary cystadenoma lymphomatosum"],"term_type":"SY"},{"nm":"Papillary cystadenoma, borderline malignancy","n_c":["C4178"],"i_c":"8451/1","i_c_s":["Papillary cystadenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Papillary cystadenoma, NOS","n_c":["C2974"],"i_c":"8450/0","i_c_s":["Papillary cystadenoma, NOS"],"term_type":"PT"},{"nm":"Papillary cystic tumor","n_c":["C4179"],"i_c":"8452/1","i_c_s":["Papillary cystic tumor"],"term_type":"SY"},{"nm":"Papillary ependymoma","n_c":["C4319"],"i_c":"9393/3","i_c_s":["Papillary ependymoma"],"term_type":"PT"},{"nm":"Papillary epidermoid carcinoma","n_c":["C4102"],"i_c":"8052/3","i_c_s":["Papillary epidermoid carcinoma"],"term_type":"SY"},{"nm":"Papillary glioneuronal tumor","n_c":["C92554"],"i_c":"9509/1","i_c_s":["Papillary glioneuronal tumor"],"term_type":"PT"},{"nm":"Papillary hidradenoma","n_c":["C4171"],"i_c":"8405/0","i_c_s":["Papillary hidradenoma"],"term_type":"PT"},{"nm":"Papillary meningioma","n_c":["C3904"],"i_c":"9538/3","i_c_s":["Papillary meningioma"],"term_type":"PT"},{"nm":"Papillary microcarcinoma","n_c":["C46004"],"i_c":"8341/3","i_c_s":["Papillary microcarcinoma"],"term_type":"PT"},{"nm":"Papillary mucinous cystadenocarcinoma","n_c":["C65204"],"i_c":"8471/3","i_c_s":["Papillary mucinous cystadenocarcinoma"],"term_type":"PT"},{"nm":"Papillary mucinous cystadenoma, borderline malignancy","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary mucinous cystadenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Papillary mucinous cystadenoma, NOS","n_c":["C4184"],"i_c":"8471/0","i_c_s":["Papillary mucinous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Papillary mucinous tumor of low malignant potential","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary mucinous tumor of low malignant potential"],"term_type":"SY"},{"nm":"Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia"],"term_type":"PT"},{"nm":"Papillary pseudomucinous cystadenocarcinoma","n_c":["C65204"],"i_c":"8471/3","i_c_s":["Papillary pseudomucinous cystadenocarcinoma"],"term_type":"SY"},{"nm":"Papillary pseudomucinous cystadenoma, borderline malignancy","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary pseudomucinous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Papillary pseudomucinous cystadenoma, NOS","n_c":["C4184"],"i_c":"8471/0","i_c_s":["Papillary pseudomucinous cystadenoma, NOS"],"term_type":"SY"},{"nm":"Papillary renal cell carcinoma","n_c":["C6975"],"i_c":"8260/3","i_c_s":["Papillary renal cell carcinoma"],"term_type":"RT"},{"nm":"Papillary serous adenocarcinoma","n_c":["C8377"],"i_c":"8460/3","i_c_s":["Papillary serous adenocarcinoma"],"term_type":"SY"},{"nm":"Papillary serous cystadenocarcinoma","n_c":["C8377"],"i_c":"8460/3","i_c_s":["Papillary serous cystadenocarcinoma"],"term_type":"PT"},{"nm":"Papillary serous cystadenoma, borderline malignancy","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Papillary serous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Papillary serous cystadenoma, NOS","n_c":["C4180"],"i_c":"8460/0","i_c_s":["Papillary serous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Papillary serous tumor of low malignant potential","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Papillary serous tumor of low malignant potential"],"term_type":"SY"},{"nm":"Papillary squamous cell carcinoma","n_c":["C4102"],"i_c":"8052/3","i_c_s":["Papillary squamous cell carcinoma"],"term_type":"PT"},{"nm":"Papillary squamous cell carcinoma in situ","n_c":["C65164"],"i_c":"8052/2","i_c_s":["Papillary squamous cell carcinoma in situ"],"term_type":"SY"},{"nm":"Papillary squamous cell carcinoma, non-invasive","n_c":["C65164"],"i_c":"8052/2","i_c_s":["Papillary squamous cell carcinoma, non-invasive"],"term_type":"PT"},{"nm":"Papillary syringadenoma","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Papillary syringadenoma"],"term_type":"PT"},{"nm":"Papillary syringocystadenoma","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Papillary syringocystadenoma"],"term_type":"SY"},{"nm":"Papillary transitional cell carcinoma","n_c":["C4122"],"i_c":"8130/3","i_c_s":["Papillary transitional cell carcinoma"],"term_type":"PT"},{"nm":"Papillary transitional cell carcinoma, non-invasive","n_c":["C65181"],"i_c":"8130/2","i_c_s":["Papillary transitional cell carcinoma, non-invasive"],"term_type":"PT"},{"nm":"Papillary transitional cell neoplasm of low malignant potential","n_c":["C191672"],"i_c":"8130/1","i_c_s":["Papillary transitional cell neoplasm of low malignant potential"],"term_type":"PT"},{"nm":"Papillary tumor of the pineal region","n_c":["C92624"],"i_c":"9395/3","i_c_s":["Papillary tumor of the pineal region"],"term_type":"PT"},{"nm":"Papillary urothelial carcinoma","n_c":["C4122"],"i_c":"8130/3","i_c_s":["Papillary urothelial carcinoma"],"term_type":"SY"},{"nm":"Papillary urothelial carcinoma, non-invasive","n_c":["C65181"],"i_c":"8130/2","i_c_s":["Papillary urothelial carcinoma, non-invasive"],"term_type":"SY"},{"nm":"Papillary urothelial neoplasm of low malignant potential","n_c":["C191672"],"i_c":"8130/1","i_c_s":["Papillary urothelial neoplasm of low malignant potential"],"term_type":"SY"},{"nm":"Papillocystic adenocarcinoma","n_c":["C3777"],"i_c":"8450/3","i_c_s":["Papillocystic adenocarcinoma"],"term_type":"SY"},{"nm":"Papilloma of bladder","n_c":["C3842"],"i_c":"8120/1","i_c_s":["Papilloma of bladder"],"term_type":"SY"},{"nm":"Papilloma, NOS","n_c":["C7440"],"i_c":"8050/0","i_c_s":["Papilloma, NOS"],"term_type":"PT"},{"nm":"Papillomatosis, glandular","n_c":["C65198"],"i_c":"8264/0","i_c_s":["Papillomatosis, glandular"],"term_type":"PT"},{"nm":"Papillomatosis, NOS","n_c":["C3713"],"i_c":"8060/0","i_c_s":["Papillomatosis, NOS"],"term_type":"SY"},{"nm":"Papillotubular adenocarcinoma","n_c":"","i_c":"8263/3","i_c_s":["Papillotubular adenocarcinoma"],"term_type":"RT"},{"nm":"Papillotubular adenoma","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Papillotubular adenoma"],"term_type":"RT"},{"nm":"Parachordoma","n_c":["C6581"],"i_c":"9373/0","i_c_s":["Parachordoma"],"term_type":"PT"},{"nm":"Parafollicular cell carcinoma","n_c":["C3879"],"i_c":"8345/3","i_c_s":["Parafollicular cell carcinoma"],"term_type":"SY"},{"nm":"Paraganglioma, benign","n_c":["C48314"],"i_c":"8680/0","i_c_s":["Paraganglioma, benign"],"term_type":"PT"},{"nm":"Paraganglioma, malignant","n_c":["C8559"],"i_c":"8680/3","i_c_s":["Paraganglioma, malignant"],"term_type":"PT"},{"nm":"Paraganglioma, NOS","n_c":["C3308"],"i_c":"8680/1","i_c_s":["Paraganglioma, NOS"],"term_type":"PT"},{"nm":"Parasympathetic paraganglioma","n_c":["C4217"],"i_c":"8682/1","i_c_s":["Parasympathetic paraganglioma"],"term_type":"PT"},{"nm":"Parietal cell adenocarcinoma","n_c":["C65194"],"i_c":"8214/3","i_c_s":["Parietal cell adenocarcinoma"],"term_type":"SY"},{"nm":"Parietal cell carcinoma","n_c":["C65194"],"i_c":"8214/3","i_c_s":["Parietal cell carcinoma"],"term_type":"PT"},{"nm":"Parosteal osteosarcoma","n_c":["C8969"],"i_c":"9192/3","i_c_s":["Parosteal osteosarcoma"],"term_type":"PT"},{"nm":"Partial hydatidiform mole","n_c":["C4293"],"i_c":"9103/0","i_c_s":["Partial hydatidiform mole"],"term_type":"PT"},{"nm":"PEComa, malignant","n_c":["C121792"],"i_c":"8714/3","i_c_s":["PEComa, malignant"],"term_type":"PT"},{"nm":"Periapical cemental dysplasia","n_c":["C173928"],"i_c":"9272/0","i_c_s":["Periapical cemental dysplasia"],"term_type":"SY"},{"nm":"Periapical cemento-osseous dysplasia","n_c":["C173928"],"i_c":"9272/0","i_c_s":["Periapical cemento-osseous dysplasia"],"term_type":"SY"},{"nm":"Pericanalicular fibroadenoma","n_c":["C4272"],"i_c":"9012/0","i_c_s":["Pericanalicular fibroadenoma"],"term_type":"PT"},{"nm":"Periductal stromal tumor, low grade","n_c":"","i_c":"9020/3","i_c_s":["Periductal stromal tumor, low grade"],"term_type":""},{"nm":"Perifollicular fibroma","n_c":["C4470"],"i_c":"8391/0","i_c_s":["Perifollicular fibroma"],"term_type":"SY"},{"nm":"Perineural MPNST","n_c":["C66845"],"i_c":"9571/3","i_c_s":["Perineural MPNST"],"term_type":"SY"},{"nm":"Perineurioma, malignant","n_c":["C66845"],"i_c":"9571/3","i_c_s":["Perineurioma, malignant"],"term_type":"PT"},{"nm":"Perineurioma, NOS","n_c":["C4973"],"i_c":"9571/0","i_c_s":["Perineurioma, NOS"],"term_type":"PT"},{"nm":"Periosteal chondroma","n_c":["C4302"],"i_c":"9221/0","i_c_s":["Periosteal chondroma"],"term_type":"RT"},{"nm":"Periosteal chondrosarcoma","n_c":["C7357"],"i_c":"9221/3","i_c_s":["Periosteal chondrosarcoma"],"term_type":"RT"},{"nm":"Periosteal fibroma","n_c":["C66761"],"i_c":"8812/0","i_c_s":["Periosteal fibroma"],"term_type":"PT"},{"nm":"Periosteal fibrosarcoma","n_c":["C66763"],"i_c":"8812/3","i_c_s":["Periosteal fibrosarcoma"],"term_type":"PT"},{"nm":"Periosteal osteosarcoma","n_c":["C8970"],"i_c":"9193/3","i_c_s":["Periosteal osteosarcoma"],"term_type":"PT"},{"nm":"Periosteal sarcoma, NOS","n_c":"","i_c":"8812/3","i_c_s":["Periosteal sarcoma, NOS"],"term_type":"RT"},{"nm":"Peripheral neuroectodermal tumor","n_c":["C9341"],"i_c":"9364/3","i_c_s":["Peripheral neuroectodermal tumor"],"term_type":"PT"},{"nm":"Peripheral odontogenic fibroma","n_c":["C4315"],"i_c":"9322/0","i_c_s":["Peripheral odontogenic fibroma"],"term_type":"PT"},{"nm":"Peripheral primitive neuroectodermal tumor, NOS","n_c":["C9341"],"i_c":"9364/3","i_c_s":["Peripheral primitive neuroectodermal tumor, NOS"],"term_type":"RT"},{"nm":"Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)"],"term_type":"IS"},{"nm":"Peripheral T-cell lymphoma, large cell","n_c":["C27352"],"i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, large cell"],"term_type":"SY"},{"nm":"Peripheral T-cell lymphoma, NOS","n_c":["C4340"],"i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, NOS"],"term_type":"SY"},{"nm":"Peripheral T-cell lymphoma, pleomorphic medium and large cell","n_c":"","i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, pleomorphic medium and large cell"],"term_type":"SY"},{"nm":"Peripheral T-cell lymphoma, pleomorphic small cell","n_c":"","i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, pleomorphic small cell"],"term_type":"SY"},{"nm":"Perivascular epithelioid cell tumor, malignant","n_c":["C121792"],"i_c":"8714/3","i_c_s":["Perivascular epithelioid cell tumor, malignant"],"term_type":""},{"nm":"Pheochromoblastoma","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Pheochromoblastoma"],"term_type":"SY"},{"nm":"Pheochromocytoma, malignant","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Pheochromocytoma, malignant"],"term_type":"PT"},{"nm":"Pheochromocytoma, NOS","n_c":["C3326"],"i_c":"8700/0","i_c_s":["Pheochromocytoma, NOS"],"term_type":"PT"},{"nm":"Phosphaturic mesenchymal tumor, malignant","n_c":["C121789"],"i_c":"8990/3","i_c_s":["Phosphaturic mesenchymal tumor, malignant"],"term_type":""},{"nm":"Phyllodes tumor, benign","n_c":["C4274"],"i_c":"9020/0","i_c_s":["Phyllodes tumor, benign"],"term_type":"PT"},{"nm":"Phyllodes tumor, borderline","n_c":["C7503"],"i_c":"9020/1","i_c_s":["Phyllodes tumor, borderline"],"term_type":"PT"},{"nm":"Phyllodes tumor, malignant","n_c":["C4275"],"i_c":"9020/3","i_c_s":["Phyllodes tumor, malignant"],"term_type":"PT"},{"nm":"Phyllodes tumor, NOS","n_c":["C2977"],"i_c":"9020/1","i_c_s":["Phyllodes tumor, NOS"],"term_type":"SY"},{"nm":"Pick tubular adenoma","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Pick tubular adenoma"],"term_type":"SY"},{"nm":"Pigmented adenoma","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Pigmented adenoma"],"term_type":"SY"},{"nm":"Pigmented basal cell carcinoma","n_c":["C9359"],"i_c":"8090/3","i_c_s":["Pigmented basal cell carcinoma"],"term_type":"RT"},{"nm":"Pigmented dermatofibrosarcoma protuberans","n_c":["C9430"],"i_c":"8833/3","i_c_s":["Pigmented dermatofibrosarcoma protuberans"],"term_type":"PT"},{"nm":"Pigmented nevus, NOS","n_c":["C27816"],"i_c":"8720/0","i_c_s":["Pigmented nevus, NOS"],"term_type":"PT"},{"nm":"Pigmented schwannoma","n_c":["C6970"],"i_c":"9560/0","i_c_s":["Pigmented schwannoma"],"term_type":"RT"},{"nm":"Pigmented spindle cell nevus of Reed","n_c":["C4751"],"i_c":"8770/0","i_c_s":["Pigmented spindle cell nevus of Reed"],"term_type":"RT"},{"nm":"Pilar tumor","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Pilar tumor"],"term_type":"PT"},{"nm":"Pilocytic astrocytoma","n_c":["C4047"],"i_c":"9421/1","i_c_s":["Pilocytic astrocytoma"],"term_type":"PT"},{"nm":"Piloid astrocytoma","n_c":["C4047"],"i_c":"9421/1","i_c_s":["Piloid astrocytoma"],"term_type":"SY"},{"nm":"Pilomatricoma, malignant","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatricoma, malignant"],"term_type":"SY"},{"nm":"Pilomatricoma, NOS","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Pilomatricoma, NOS"],"term_type":"SY"},{"nm":"Pilomatrix carcinoma","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatrix carcinoma"],"term_type":"PT"},{"nm":"Pilomatrixoma, malignant","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatrixoma, malignant"],"term_type":"SY"},{"nm":"Pilomatrixoma, NOS","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Pilomatrixoma, NOS"],"term_type":"PT"},{"nm":"Pilomyxoid astrocytoma","n_c":["C40315"],"i_c":"9425/3","i_c_s":["Pilomyxoid astrocytoma"],"term_type":"PT"},{"nm":"PIN III","n_c":["C3642"],"i_c":"8148/2","i_c_s":["PIN III"],"term_type":"SY"},{"nm":"Pindborg tumor","n_c":["C54301"],"i_c":"9340/0","i_c_s":["Pindborg tumor"],"term_type":"SY"},{"nm":"Pineal parenchymal tumor of intermediate differentiation","n_c":["C6967"],"i_c":"9362/3","i_c_s":["Pineal parenchymal tumor of intermediate differentiation"],"term_type":"RT"},{"nm":"Pinealoma","n_c":["C3328"],"i_c":"9360/1","i_c_s":["Pinealoma"],"term_type":"PT"},{"nm":"Pineoblastoma","n_c":["C9344"],"i_c":"9362/3","i_c_s":["Pineoblastoma"],"term_type":"PT"},{"nm":"Pineocytoma","n_c":["C6966"],"i_c":"9361/1","i_c_s":["Pineocytoma"],"term_type":"PT"},{"nm":"Pinkus tumor","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Pinkus tumor"],"term_type":"SY"},{"nm":"Pituicytoma","n_c":["C94524"],"i_c":"9432/1","i_c_s":["Pituicytoma"],"term_type":"PT"},{"nm":"Pituitary adenoma, NOS","n_c":["C3329"],"i_c":"8272/0","i_c_s":["Pituitary adenoma, NOS"],"term_type":"PT"},{"nm":"Pituitary carcinoma, NOS","n_c":["C4536"],"i_c":"8272/3","i_c_s":["Pituitary carcinoma, NOS"],"term_type":"PT"},{"nm":"Placental site trophoblastic tumor","n_c":["C3757"],"i_c":"9104/1","i_c_s":["Placental site trophoblastic tumor"],"term_type":"PT"},{"nm":"Plasma cell leukemia","n_c":["C3180"],"i_c":"9733/3","i_c_s":["Plasma cell leukemia"],"term_type":"PT"},{"nm":"Plasma cell myeloma","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Plasma cell myeloma"],"term_type":"SY"},{"nm":"Plasma cell tumor","n_c":["C4665"],"i_c":"9731/3","i_c_s":["Plasma cell tumor"],"term_type":"SY"},{"nm":"Plasmablastic lymphoma","n_c":["C7224"],"i_c":"9735/3","i_c_s":["Plasmablastic lymphoma"],"term_type":"PT"},{"nm":"Plasmacytic leukemia","n_c":["C3180"],"i_c":"9733/3","i_c_s":["Plasmacytic leukemia"],"term_type":"SY"},{"nm":"Plasmacytic lymphoma","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Plasmacytic lymphoma"],"term_type":"ORT"},{"nm":"Plasmacytoma of bone","n_c":["C7812"],"i_c":"9731/3","i_c_s":["Plasmacytoma of bone"],"term_type":"SY"},{"nm":"Plasmacytoma, extramedullary","n_c":["C4002"],"i_c":"9734/3","i_c_s":["Plasmacytoma, extramedullary"],"term_type":"PT"},{"nm":"Plasmacytoma, NOS","n_c":["C9349"],"i_c":"9731/3","i_c_s":["Plasmacytoma, NOS"],"term_type":"PT"},{"nm":"Pleomorphic adenoma","n_c":["C8602"],"i_c":"8940/0","i_c_s":["Pleomorphic adenoma"],"term_type":"PT"},{"nm":"Pleomorphic carcinoma","n_c":["C4094"],"i_c":"8022/3","i_c_s":["Pleomorphic carcinoma"],"term_type":"PT"},{"nm":"Pleomorphic cell sarcoma","n_c":["C66759"],"i_c":"8802/3","i_c_s":["Pleomorphic cell sarcoma"],"term_type":"SY"},{"nm":"Pleomorphic leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Pleomorphic leiomyoma"],"term_type":"SY"},{"nm":"Pleomorphic lipoma","n_c":["C3703"],"i_c":"8854/0","i_c_s":["Pleomorphic lipoma"],"term_type":"PT"},{"nm":"Pleomorphic liposarcoma","n_c":["C3705"],"i_c":"8854/3","i_c_s":["Pleomorphic liposarcoma"],"term_type":"PT"},{"nm":"Pleomorphic lobular carcinoma","n_c":["C97051"],"i_c":"8520/3","i_c_s":["Pleomorphic lobular carcinoma"],"term_type":""},{"nm":"Pleomorphic lobular carcinoma in situ","n_c":["C137839"],"i_c":"8519/2","i_c_s":["Pleomorphic lobular carcinoma in situ"],"term_type":"PT"},{"nm":"Pleomorphic rhabdomyosarcoma, adult type","n_c":["C27369"],"i_c":"8901/3","i_c_s":["Pleomorphic rhabdomyosarcoma, adult type"],"term_type":"PT"},{"nm":"Pleomorphic rhabdomyosarcoma, NOS","n_c":["C4258"],"i_c":"8901/3","i_c_s":["Pleomorphic rhabdomyosarcoma, NOS"],"term_type":"RT"},{"nm":"Pleomorphic xanthoastrocytoma","n_c":["C4323"],"i_c":"9424/3","i_c_s":["Pleomorphic xanthoastrocytoma"],"term_type":"PT"},{"nm":"Pleuropulmonary blastoma","n_c":["C5669"],"i_c":"8973/3","i_c_s":["Pleuropulmonary blastoma"],"term_type":"PT"},{"nm":"Plexiform fibrohistiocytic tumor","n_c":["C6493"],"i_c":"8835/1","i_c_s":["Plexiform fibrohistiocytic tumor"],"term_type":"PT"},{"nm":"Plexiform fibromyxoma","n_c":"","i_c":"8811/0","i_c_s":["Plexiform fibromyxoma"],"term_type":"RT"},{"nm":"Plexiform hemangioma","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Plexiform hemangioma"],"term_type":"SY"},{"nm":"Plexiform leiomyoma","n_c":"","i_c":"8890/0","i_c_s":["Plexiform leiomyoma"],"term_type":"RT"},{"nm":"Plexiform neurofibroma","n_c":["C3797"],"i_c":"9550/0","i_c_s":["Plexiform neurofibroma"],"term_type":"PT"},{"nm":"Plexiform neuroma","n_c":["C3797"],"i_c":"9550/0","i_c_s":["Plexiform neuroma"],"term_type":"SY"},{"nm":"Plexiform schwannoma","n_c":["C6969"],"i_c":"9560/0","i_c_s":["Plexiform schwannoma"],"term_type":"RT"},{"nm":"PNET, NOS","n_c":["C3716"],"i_c":"9473/3","i_c_s":["PNET, NOS"],"term_type":"SY"},{"nm":"Pneumoblastoma","n_c":["C3732"],"i_c":"8972/3","i_c_s":["Pneumoblastoma"],"term_type":"SY"},{"nm":"Polar spongioblastoma","n_c":["C66801"],"i_c":"9423/3","i_c_s":["Polar spongioblastoma"],"term_type":"PT"},{"nm":"Polycythemia rubra vera","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Polycythemia rubra vera"],"term_type":"SY"},{"nm":"Polycythemia vera","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Polycythemia vera"],"term_type":"PT"},{"nm":"Polyembryoma","n_c":["C66776"],"i_c":"9072/3","i_c_s":["Polyembryoma"],"term_type":"PT"},{"nm":"Polygonal cell carcinoma","n_c":["C65161"],"i_c":"8034/3","i_c_s":["Polygonal cell carcinoma"],"term_type":"PT"},{"nm":"Polymorphic post transplant lymphoproliferative disorder","n_c":["C7183"],"i_c":"9971/3","i_c_s":["Polymorphic post transplant lymphoproliferative disorder"],"term_type":"PT"},{"nm":"Polymorphic reticulosis","n_c":"","i_c":"9719/3","i_c_s":["Polymorphic reticulosis"],"term_type":"IS"},{"nm":"Polymorphous low grade adenocarcinoma","n_c":["C35702"],"i_c":"8525/3","i_c_s":["Polymorphous low grade adenocarcinoma"],"term_type":"PT"},{"nm":"Polypoid adenoma","n_c":["C3764"],"i_c":"8210/0","i_c_s":["Polypoid adenoma"],"term_type":"SY"},{"nm":"Polyvesicular vitelline tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Polyvesicular vitelline tumor"],"term_type":"SY"},{"nm":"Poorly cohesive carcinoma","n_c":["C4127"],"i_c":"8490/3","i_c_s":["Poorly cohesive carcinoma"],"term_type":"RT"},{"nm":"Porocarcinoma","n_c":["C5560"],"i_c":"8409/3","i_c_s":["Porocarcinoma"],"term_type":"SY"},{"nm":"Post transplant lymphoproliferative disorder, NOS","n_c":["C4727"],"i_c":"9971/1","i_c_s":["Post transplant lymphoproliferative disorder, NOS"],"term_type":"PT"},{"nm":"PP/PYY producing tumor","n_c":"","i_c":"8152/1","i_c_s":["PP/PYY producing tumor"],"term_type":"SY"},{"nm":"PPNET","n_c":["C9341"],"i_c":"9364/3","i_c_s":["PPNET"],"term_type":"SY"},{"nm":"Pre-B ALL","n_c":["C27798"],"i_c":"9836/3","i_c_s":["Pre-B ALL"],"term_type":"SY"},{"nm":"Pre-pre-B ALL","n_c":["C27799"],"i_c":"9836/3","i_c_s":["Pre-pre-B ALL"],"term_type":"SY"},{"nm":"Pre-T ALL","n_c":["C27261"],"i_c":"9837/3","i_c_s":["Pre-T ALL"],"term_type":"SY"},{"nm":"Precancerous melanosis, NOS","n_c":["C4233"],"i_c":"8741/2","i_c_s":["Precancerous melanosis, NOS"],"term_type":"PT"},{"nm":"Precursor B-cell lymphoblastic leukemia","n_c":["C8644"],"i_c":"9836/3","i_c_s":["Precursor B-cell lymphoblastic leukemia"],"term_type":"PT"},{"nm":"Precursor B-cell lymphoblastic lymphoma","n_c":["C8868"],"i_c":"9728/3","i_c_s":["Precursor B-cell lymphoblastic lymphoma"],"term_type":"PT"},{"nm":"Precursor cell lymphoblastic leukemia, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Precursor cell lymphoblastic leukemia, NOS"],"term_type":"PT"},{"nm":"Precursor cell lymphoblastic leukemia, not phenotyped","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Precursor cell lymphoblastic leukemia, not phenotyped"],"term_type":"SY"},{"nm":"Precursor cell lymphoblastic lymphoma, NOS","n_c":["C9360"],"i_c":"9727/3","i_c_s":["Precursor cell lymphoblastic lymphoma, NOS"],"term_type":"PT"},{"nm":"Precursor T-cell lymphoblastic leukemia","n_c":["C3183"],"i_c":"9837/3","i_c_s":["Precursor T-cell lymphoblastic leukemia"],"term_type":"PT"},{"nm":"Precursor T-cell lymphoblastic lymphoma","n_c":["C6919"],"i_c":"9729/3","i_c_s":["Precursor T-cell lymphoblastic lymphoma"],"term_type":"PT"},{"nm":"Preleukemia","n_c":["C3247"],"i_c":"9989/3","i_c_s":["Preleukemia"],"term_type":"IS"},{"nm":"Preleukemic syndrome","n_c":["C3247"],"i_c":"9989/3","i_c_s":["Preleukemic syndrome"],"term_type":"IS"},{"nm":"Primary amyloidosis","n_c":["C3819"],"i_c":"9769/1","i_c_s":["Primary amyloidosis"],"term_type":"SY"},{"nm":"Primary cutaneous anaplastic large cell lymphoma","n_c":["C6860"],"i_c":"9718/3","i_c_s":["Primary cutaneous anaplastic large cell lymphoma"],"term_type":"SY"},{"nm":"Primary cutaneous CD30+ large T-cell lymphoma","n_c":["C6860"],"i_c":"9718/3","i_c_s":["Primary cutaneous CD30+ large T-cell lymphoma"],"term_type":"SY"},{"nm":"Primary cutaneous CD30+ T-cell lymphoproliferative disorder","n_c":["C7195"],"i_c":"9718/3","i_c_s":["Primary cutaneous CD30+ T-cell lymphoproliferative disorder"],"term_type":"PT"},{"nm":"Primary cutaneous CD4-positive small/medium T-cell lymphoma","n_c":["C45366"],"i_c":"9709/3","i_c_s":["Primary cutaneous CD4-positive small/medium T-cell lymphoma"],"term_type":"RT"},{"nm":"Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma","n_c":["C45339"],"i_c":"9709/3","i_c_s":["Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma"],"term_type":"RT"},{"nm":"Primary cutaneous DLBCL, leg type","n_c":["C45194"],"i_c":"9680/3","i_c_s":["Primary cutaneous DLBCL, leg type"],"term_type":"RT"},{"nm":"Primary cutaneous follicle centre lymphoma","n_c":["C7217"],"i_c":"9597/3","i_c_s":["Primary cutaneous follicle centre lymphoma"],"term_type":"PT"},{"nm":"Primary cutaneous gamma-delta T-cell lymphoma","n_c":["C45340"],"i_c":"9726/3","i_c_s":["Primary cutaneous gamma-delta T-cell lymphoma"],"term_type":"PT"},{"nm":"Primary cutaneous neuroendocrine carcinoma","n_c":["C9231"],"i_c":"8247/3","i_c_s":["Primary cutaneous neuroendocrine carcinoma"],"term_type":"SY"},{"nm":"Primary diffuse large B-cell lymphoma of the CNS","n_c":["C71720"],"i_c":"9680/3","i_c_s":["Primary diffuse large B-cell lymphoma of the CNS"],"term_type":"RT"},{"nm":"Primary effusion lymphoma","n_c":["C6915"],"i_c":"9678/3","i_c_s":["Primary effusion lymphoma"],"term_type":"PT"},{"nm":"Primary intraosseous carcinoma","n_c":"","i_c":"9270/3","i_c_s":["Primary intraosseous carcinoma"],"term_type":"SY"},{"nm":"Primary myelofibrosis","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Primary myelofibrosis"],"term_type":"PT"},{"nm":"Primary serous papillary carcinoma of peritoneum","n_c":["C7695"],"i_c":"8461/3","i_c_s":["Primary serous papillary carcinoma of peritoneum"],"term_type":"RT"},{"nm":"Primitive neuroectodermal tumor, NOS","n_c":["C3716"],"i_c":"9473/3","i_c_s":["Primitive neuroectodermal tumor, NOS"],"term_type":"PT"},{"nm":"Primitive polar spongioblastoma","n_c":"","i_c":"9423/3","i_c_s":["Primitive polar spongioblastoma"],"term_type":"IS"},{"nm":"Pro-B ALL","n_c":["C27798"],"i_c":"9836/3","i_c_s":["Pro-B ALL"],"term_type":"SY"},{"nm":"Pro-T ALL","n_c":["C27261"],"i_c":"9837/3","i_c_s":["Pro-T ALL"],"term_type":"SY"},{"nm":"Prolactinoma","n_c":["C3342"],"i_c":"8271/0","i_c_s":["Prolactinoma"],"term_type":"PT"},{"nm":"Proliferating trichilemmal cyst","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Proliferating trichilemmal cyst"],"term_type":"SY"},{"nm":"Proliferating trichilemmal tumor","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Proliferating trichilemmal tumor"],"term_type":"SY"},{"nm":"Proliferative dermal lesion in congenital nevus","n_c":["C66755"],"i_c":"8762/1","i_c_s":["Proliferative dermal lesion in congenital nevus"],"term_type":"PT"},{"nm":"Proliferative polycythemia","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Proliferative polycythemia"],"term_type":"SY"},{"nm":"Prolymphocytic leukemia, B-cell type","n_c":["C4753"],"i_c":"9833/3","i_c_s":["Prolymphocytic leukemia, B-cell type"],"term_type":"PT"},{"nm":"Prolymphocytic leukemia, NOS","n_c":["C3181"],"i_c":"9832/3","i_c_s":["Prolymphocytic leukemia, NOS"],"term_type":"PT"},{"nm":"Prolymphocytic leukemia, T-cell type","n_c":["C4752"],"i_c":"9834/3","i_c_s":["Prolymphocytic leukemia, T-cell type"],"term_type":"PT"},{"nm":"Prostatic intraepithelial neoplasia, grade III","n_c":["C3642"],"i_c":"8148/2","i_c_s":["Prostatic intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Protoplasmic astrocytoma","n_c":["C4320"],"i_c":"9410/3","i_c_s":["Protoplasmic astrocytoma"],"term_type":"PT"},{"nm":"Psammomatous meningioma","n_c":["C4331"],"i_c":"9533/0","i_c_s":["Psammomatous meningioma"],"term_type":"PT"},{"nm":"Psammomatous schwannoma","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Psammomatous schwannoma"],"term_type":"RT"},{"nm":"Pseudomucinous adenocarcinoma","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Pseudomucinous adenocarcinoma"],"term_type":"SY"},{"nm":"Pseudomucinous cystadenocarcinoma, NOS","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Pseudomucinous cystadenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Pseudomucinous cystadenoma, borderline malignancy","n_c":"","i_c":"8472/1","i_c_s":["Pseudomucinous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Pseudomucinous cystadenoma, NOS","n_c":["C2973"],"i_c":"8470/0","i_c_s":["Pseudomucinous cystadenoma, NOS"],"term_type":"SY"},{"nm":"Pseudomyxoma peritonei","n_c":["C3345"],"i_c":"8480/6","i_c_s":["Pseudomyxoma peritonei"],"term_type":"PT"},{"nm":"Pseudomyxoma peritonei with unknown primary site","n_c":["C3345"],"i_c":"8480/3","i_c_s":["Pseudomyxoma peritonei with unknown primary site"],"term_type":"RT"},{"nm":"Pseudosarcomatous carcinoma","n_c":["C27004"],"i_c":"8033/3","i_c_s":["Pseudosarcomatous carcinoma"],"term_type":"PT"},{"nm":"PTLD, NOS","n_c":["C4727"],"i_c":"9971/1","i_c_s":["PTLD, NOS"],"term_type":"SY"},{"nm":"Pulmonary adenomatosis","n_c":["C3763"],"i_c":"8250/1","i_c_s":["Pulmonary adenomatosis"],"term_type":"PT"},{"nm":"Pulmonary artery intimal sarcoma","n_c":["C142825"],"i_c":"9137/3","i_c_s":["Pulmonary artery intimal sarcoma"],"term_type":""},{"nm":"Pulmonary blastoma","n_c":["C3732"],"i_c":"8972/3","i_c_s":["Pulmonary blastoma"],"term_type":"PT"},{"nm":"Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation","n_c":["C142827"],"i_c":"8842/3","i_c_s":["Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation"],"term_type":""},{"nm":"Queyrat erythroplasia","n_c":["C27790"],"i_c":"8080/2","i_c_s":["Queyrat erythroplasia"],"term_type":"PT"},{"nm":"Racemose hemangioma","n_c":["C2882"],"i_c":"9123/0","i_c_s":["Racemose hemangioma"],"term_type":"PT"},{"nm":"RAEB","n_c":["C7506"],"i_c":"9983/3","i_c_s":["RAEB"],"term_type":"SY"},{"nm":"RAEB I","n_c":["C7506"],"i_c":"9983/3","i_c_s":["RAEB I"],"term_type":"SY"},{"nm":"RAEB II","n_c":["C7168"],"i_c":"9983/3","i_c_s":["RAEB II"],"term_type":"SY"},{"nm":"RAEB-T","n_c":["C27080"],"i_c":"9984/3","i_c_s":["RAEB-T"],"term_type":"SY"},{"nm":"RARS","n_c":["C4036"],"i_c":"9982/3","i_c_s":["RARS"],"term_type":"SY"},{"nm":"Rathke pouch tumor","n_c":["C2964"],"i_c":"9350/1","i_c_s":["Rathke pouch tumor"],"term_type":"SY"},{"nm":"Recklinghausen disease","n_c":["C3273"],"i_c":"9540/1","i_c_s":["Recklinghausen disease"],"term_type":"SY"},{"nm":"Refractory anemia","n_c":["C2872"],"i_c":"9980/3","i_c_s":["Refractory anemia"],"term_type":"PT"},{"nm":"Refractory anemia with excess blasts","n_c":["C7506"],"i_c":"9983/3","i_c_s":["Refractory anemia with excess blasts"],"term_type":"PT"},{"nm":"Refractory anemia with excess blasts in transformation","n_c":["C27080"],"i_c":"9984/3","i_c_s":["Refractory anemia with excess blasts in transformation"],"term_type":"OP"},{"nm":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis","n_c":["C82616"],"i_c":"9982/3","i_c_s":["Refractory anemia with ring sideroblasts associated with marked thrombocytosis"],"term_type":"SY"},{"nm":"Refractory anemia with ringed sideroblasts","n_c":["C4036"],"i_c":"9982/3","i_c_s":["Refractory anemia with ringed sideroblasts"],"term_type":"SY"},{"nm":"Refractory anemia with sideroblasts","n_c":["C4036"],"i_c":"9982/3","i_c_s":["Refractory anemia with sideroblasts"],"term_type":"PT"},{"nm":"Refractory anemia without sideroblasts","n_c":"","i_c":"9980/3","i_c_s":["Refractory anemia without sideroblasts"],"term_type":"SY"},{"nm":"Refractory cytopenia of childhood","n_c":["C82596"],"i_c":"9985/3","i_c_s":["Refractory cytopenia of childhood"],"term_type":"SY"},{"nm":"Refractory cytopenia with multilineage dysplasia","n_c":["C8574"],"i_c":"9985/3","i_c_s":["Refractory cytopenia with multilineage dysplasia"],"term_type":"PT"},{"nm":"Refractory neutropenia","n_c":["C82593"],"i_c":"9991/3","i_c_s":["Refractory neutropenia"],"term_type":"PT"},{"nm":"Refractory thrombocytopenia","n_c":["C82594"],"i_c":"9992/3","i_c_s":["Refractory thrombocytopenia"],"term_type":"PT"},{"nm":"Regressing nevus","n_c":["C7603"],"i_c":"8723/0","i_c_s":["Regressing nevus"],"term_type":"SY"},{"nm":"Renal carcinoma, collecting duct type","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Renal carcinoma, collecting duct type"],"term_type":"SY"},{"nm":"Renal cell adenocarcinoma","n_c":["C9385"],"i_c":"8312/3","i_c_s":["Renal cell adenocarcinoma"],"term_type":"SY"},{"nm":"Renal cell carcinoma, chromophobe type","n_c":["C4146"],"i_c":"8317/3","i_c_s":["Renal cell carcinoma, chromophobe type"],"term_type":"PT"},{"nm":"Renal cell carcinoma, NOS","n_c":["C191370"],"i_c":"8312/3","i_c_s":["Renal cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Renal cell carcinoma, sarcomatoid","n_c":["C27893"],"i_c":"8318/3","i_c_s":["Renal cell carcinoma, sarcomatoid"],"term_type":"PT"},{"nm":"Renal cell carcinoma, spindle cell","n_c":["C27893"],"i_c":"8318/3","i_c_s":["Renal cell carcinoma, spindle cell"],"term_type":"SY"},{"nm":"Renal cell carcinoma, unclassified","n_c":["C191370"],"i_c":"8312/3","i_c_s":["Renal cell carcinoma, unclassified"],"term_type":""},{"nm":"Renal medullary carcinoma","n_c":["C7572"],"i_c":"8510/3","i_c_s":["Renal medullary carcinoma"],"term_type":""},{"nm":"Reninoma","n_c":["C4162"],"i_c":"8361/0","i_c_s":["Reninoma"],"term_type":"SY"},{"nm":"Renomedullary fibroma","n_c":"","i_c":"8966/0","i_c_s":["Renomedullary fibroma"],"term_type":"SY"},{"nm":"Renomedullary interstitial cell tumor","n_c":["C5100"],"i_c":"8966/0","i_c_s":["Renomedullary interstitial cell tumor"],"term_type":"PT"},{"nm":"Reserve cell carcinoma","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Reserve cell carcinoma"],"term_type":"SY"},{"nm":"Reticulohistiocytoma","n_c":["C3356"],"i_c":"8831/0","i_c_s":["Reticulohistiocytoma"],"term_type":"RT"},{"nm":"Reticulosarcoma, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Reticulosarcoma, diffuse"],"term_type":"IS"},{"nm":"Reticulosarcoma, NOS","n_c":["C27824"],"i_c":"9591/3","i_c_s":["Reticulosarcoma, NOS"],"term_type":"IS"},{"nm":"Reticulum cell sarcoma, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Reticulum cell sarcoma, diffuse"],"term_type":"IS"},{"nm":"Reticulum cell sarcoma, NOS","n_c":["C27824"],"i_c":"9591/3","i_c_s":["Reticulum cell sarcoma, NOS"],"term_type":"ORT"},{"nm":"Retinal anlage tumor","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Retinal anlage tumor"],"term_type":"SY"},{"nm":"Retinoblastoma, differentiated","n_c":["C66813"],"i_c":"9511/3","i_c_s":["Retinoblastoma, differentiated"],"term_type":"PT"},{"nm":"Retinoblastoma, diffuse","n_c":["C66815"],"i_c":"9513/3","i_c_s":["Retinoblastoma, diffuse"],"term_type":"PT"},{"nm":"Retinoblastoma, NOS","n_c":["C7541"],"i_c":"9510/3","i_c_s":["Retinoblastoma, NOS"],"term_type":"PT"},{"nm":"Retinoblastoma, spontaneously regressed","n_c":["C66816"],"i_c":"9514/1","i_c_s":["Retinoblastoma, spontaneously regressed"],"term_type":"PT"},{"nm":"Retinoblastoma, undifferentiated","n_c":["C66814"],"i_c":"9512/3","i_c_s":["Retinoblastoma, undifferentiated"],"term_type":"PT"},{"nm":"Retinocytoma","n_c":["C66812"],"i_c":"9510/0","i_c_s":["Retinocytoma"],"term_type":"PT"},{"nm":"Retroperitoneal fibromatosis","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Retroperitoneal fibromatosis"],"term_type":"SY"},{"nm":"Rhabdoid meningioma","n_c":["C6909"],"i_c":"9538/3","i_c_s":["Rhabdoid meningioma"],"term_type":"RT"},{"nm":"Rhabdoid sarcoma","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Rhabdoid sarcoma"],"term_type":"SY"},{"nm":"Rhabdoid tumor, NOS","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Rhabdoid tumor, NOS"],"term_type":"SY"},{"nm":"Rhabdomyoma, NOS","n_c":["C3358"],"i_c":"8900/0","i_c_s":["Rhabdomyoma, NOS"],"term_type":"PT"},{"nm":"Rhabdomyosarcoma with ganglionic differentiation","n_c":["C4716"],"i_c":"8921/3","i_c_s":["Rhabdomyosarcoma with ganglionic differentiation"],"term_type":"PT"},{"nm":"Rhabdomyosarcoma, NOS","n_c":["C3359"],"i_c":"8900/3","i_c_s":["Rhabdomyosarcoma, NOS"],"term_type":"PT"},{"nm":"Rhabdosarcoma","n_c":["C3359"],"i_c":"8900/3","i_c_s":["Rhabdosarcoma"],"term_type":"SY"},{"nm":"Rodent ulcer","n_c":["C5568"],"i_c":"8090/3","i_c_s":["Rodent ulcer"],"term_type":"SY"},{"nm":"Rosette-forming glioneuronal tumor","n_c":["C129431"],"i_c":"9509/1","i_c_s":["Rosette-forming glioneuronal tumor"],"term_type":"RT"},{"nm":"Round cell carcinoma","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Round cell carcinoma"],"term_type":"SY"},{"nm":"Round cell liposarcoma","n_c":["C4252"],"i_c":"8853/3","i_c_s":["Round cell liposarcoma"],"term_type":"PT"},{"nm":"Round cell osteosarcoma","n_c":["C4023"],"i_c":"9185/3","i_c_s":["Round cell osteosarcoma"],"term_type":"SY"},{"nm":"Round cell sarcoma","n_c":"","i_c":"8803/3","i_c_s":["Round cell sarcoma"],"term_type":"SY"},{"nm":"Salivary duct carcinoma","n_c":["C5904"],"i_c":"8500/3","i_c_s":["Salivary duct carcinoma"],"term_type":""},{"nm":"SALT lymphoma","n_c":["C7230"],"i_c":"9699/3","i_c_s":["SALT lymphoma"],"term_type":"SY"},{"nm":"Sarcoma botryoides","n_c":["C9150"],"i_c":"8910/3","i_c_s":["Sarcoma botryoides"],"term_type":"RT"},{"nm":"Sarcoma, NOS","n_c":["C9118"],"i_c":"8800/3","i_c_s":["Sarcoma, NOS"],"term_type":"PT"},{"nm":"Sarcomatoid carcinoma","n_c":["C27004"],"i_c":"8033/3","i_c_s":["Sarcomatoid carcinoma"],"term_type":"SY"},{"nm":"Sarcomatoid mesothelioma","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Sarcomatoid mesothelioma"],"term_type":"SY"},{"nm":"Sarcomatosis, NOS","n_c":["C4243"],"i_c":"8800/9","i_c_s":["Sarcomatosis, NOS"],"term_type":"PT"},{"nm":"Schmincke tumor","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Schmincke tumor"],"term_type":"RT"},{"nm":"Schneiderian carcinoma","n_c":["C54287"],"i_c":"8121/3","i_c_s":["Schneiderian carcinoma"],"term_type":"PT"},{"nm":"Schneiderian papilloma, inverted","n_c":["C6871"],"i_c":"8121/1","i_c_s":["Schneiderian papilloma, inverted"],"term_type":"RT"},{"nm":"Schneiderian papilloma, NOS","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Schneiderian papilloma, NOS"],"term_type":"PT"},{"nm":"Schwannoma, NOS","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Schwannoma, NOS"],"term_type":"SY"},{"nm":"Scirrhous adenocarcinoma","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Scirrhous adenocarcinoma"],"term_type":"PT"},{"nm":"Scirrhous carcinoma","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Scirrhous carcinoma"],"term_type":"SY"},{"nm":"Sclerosing epithelioid fibrosarcoma","n_c":["C49027"],"i_c":"8840/3","i_c_s":["Sclerosing epithelioid fibrosarcoma"],"term_type":""},{"nm":"Sclerosing hemangioma","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Sclerosing hemangioma"],"term_type":"SY"},{"nm":"Sclerosing hepatic carcinoma","n_c":["C27388"],"i_c":"8172/3","i_c_s":["Sclerosing hepatic carcinoma"],"term_type":"SY"},{"nm":"Sclerosing liposarcoma","n_c":["C6507"],"i_c":"8851/3","i_c_s":["Sclerosing liposarcoma"],"term_type":"RT"},{"nm":"Sclerosing rhabdomyosarcoma","n_c":["C121655"],"i_c":"8912/3","i_c_s":["Sclerosing rhabdomyosarcoma"],"term_type":""},{"nm":"Sclerosing stromal tumor","n_c":["C4204"],"i_c":"8602/0","i_c_s":["Sclerosing stromal tumor"],"term_type":"PT"},{"nm":"Sclerosing sweat duct carcinoma","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Sclerosing sweat duct carcinoma"],"term_type":"PT"},{"nm":"Sebaceous adenocarcinoma","n_c":["C40310"],"i_c":"8410/3","i_c_s":["Sebaceous adenocarcinoma"],"term_type":"PT"},{"nm":"Sebaceous adenoma","n_c":["C4174"],"i_c":"8410/0","i_c_s":["Sebaceous adenoma"],"term_type":"PT"},{"nm":"Sebaceous carcinoma","n_c":["C40310"],"i_c":"8410/3","i_c_s":["Sebaceous carcinoma"],"term_type":"SY"},{"nm":"Sebaceous epithelioma","n_c":["C4346"],"i_c":"8410/0","i_c_s":["Sebaceous epithelioma"],"term_type":"RT"},{"nm":"Secondary carcinoma","n_c":["C36310"],"i_c":"8010/6","i_c_s":["Secondary carcinoma"],"term_type":"SY"},{"nm":"Secretory carcinoma of breast","n_c":["C4189"],"i_c":"8502/3","i_c_s":["Secretory carcinoma of breast"],"term_type":"PT"},{"nm":"Secretory meningioma","n_c":["C4718"],"i_c":"9530/0","i_c_s":["Secretory meningioma"],"term_type":"RT"},{"nm":"Seminoma with high mitotic index","n_c":["C39920"],"i_c":"9062/3","i_c_s":["Seminoma with high mitotic index"],"term_type":"SY"},{"nm":"Seminoma, anaplastic","n_c":["C39920"],"i_c":"9062/3","i_c_s":["Seminoma, anaplastic"],"term_type":"PT"},{"nm":"Seminoma, NOS","n_c":["C9309"],"i_c":"9061/3","i_c_s":["Seminoma, NOS"],"term_type":"PT"},{"nm":"Seromucinous carcinoma","n_c":["C40090"],"i_c":"8474/3","i_c_s":["Seromucinous carcinoma"],"term_type":"PT"},{"nm":"Serotonin producing carcinoid","n_c":"","i_c":"8241/3","i_c_s":["Serotonin producing carcinoid"],"term_type":"SY"},{"nm":"Serous adenocarcinofibroma","n_c":["C67092"],"i_c":"9014/3","i_c_s":["Serous adenocarcinofibroma"],"term_type":"PT"},{"nm":"Serous adenocarcinoma, NOS","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous adenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Serous adenofibroma of borderline malignancy","n_c":["C40028"],"i_c":"9014/1","i_c_s":["Serous adenofibroma of borderline malignancy"],"term_type":"PT"},{"nm":"Serous adenofibroma, NOS","n_c":["C67090"],"i_c":"9014/0","i_c_s":["Serous adenofibroma, NOS"],"term_type":"PT"},{"nm":"Serous borderline tumor-micropapillary variant","n_c":["C122585"],"i_c":"8460/2","i_c_s":["Serous borderline tumor-micropapillary variant"],"term_type":""},{"nm":"Serous carcinoma, NOS","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous carcinoma, NOS"],"term_type":"SY"},{"nm":"Serous cystadenocarcinofibroma","n_c":"","i_c":"9014/3","i_c_s":["Serous cystadenocarcinofibroma"],"term_type":"RT"},{"nm":"Serous cystadenocarcinoma, NOS","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Serous cystadenofibroma of borderline malignancy","n_c":"","i_c":"9014/1","i_c_s":["Serous cystadenofibroma of borderline malignancy"],"term_type":"RT"},{"nm":"Serous cystadenofibroma, NOS","n_c":"","i_c":"9014/0","i_c_s":["Serous cystadenofibroma, NOS"],"term_type":"RT"},{"nm":"Serous cystadenoma, borderline malignancy","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Serous cystadenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Serous cystadenoma, NOS","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Serous cystoma","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous cystoma"],"term_type":"SY"},{"nm":"Serous endometrial intraepithelial carcinoma","n_c":["C40152"],"i_c":"8441/2","i_c_s":["Serous endometrial intraepithelial carcinoma"],"term_type":""},{"nm":"Serous microcystic adenoma","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous microcystic adenoma"],"term_type":"RT"},{"nm":"Serous papillary cystic tumor of borderline malignancy","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Serous papillary cystic tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Serous surface papillary carcinoma","n_c":["C4182"],"i_c":"8461/3","i_c_s":["Serous surface papillary carcinoma"],"term_type":"PT"},{"nm":"Serous surface papillary tumor of borderline malignancy","n_c":["C7315"],"i_c":"8463/1","i_c_s":["Serous surface papillary tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Serous surface papilloma","n_c":["C4181"],"i_c":"8461/0","i_c_s":["Serous surface papilloma"],"term_type":"PT"},{"nm":"Serous tubal intraepithelial carcinoma","n_c":["C126449"],"i_c":"8441/2","i_c_s":["Serous tubal intraepithelial carcinoma"],"term_type":""},{"nm":"Serous tumor, NOS, of low malignant potential","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Serous tumor, NOS, of low malignant potential"],"term_type":"SY"},{"nm":"Serrated adenocarcinoma","n_c":["C96485"],"i_c":"8213/3","i_c_s":["Serrated adenocarcinoma"],"term_type":"PT"},{"nm":"Serrated adenoma","n_c":["C38458"],"i_c":"8213/0","i_c_s":["Serrated adenoma"],"term_type":"PT"},{"nm":"Sertoli cell adenoma","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Sertoli cell adenoma"],"term_type":"SY"},{"nm":"Sertoli cell carcinoma","n_c":["C67006"],"i_c":"8640/3","i_c_s":["Sertoli cell carcinoma"],"term_type":"PT"},{"nm":"Sertoli cell tumor with lipid storage","n_c":["C4211"],"i_c":"8641/0","i_c_s":["Sertoli cell tumor with lipid storage"],"term_type":"PT"},{"nm":"Sertoli cell tumor, NOS","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Sertoli cell tumor, NOS"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor of intermediate differentiation","n_c":["C39968"],"i_c":"8631/1","i_c_s":["Sertoli-Leydig cell tumor of intermediate differentiation"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements","n_c":["C39972"],"i_c":"8634/1","i_c_s":["Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, NOS","n_c":["C2880"],"i_c":"8631/1","i_c_s":["Sertoli-Leydig cell tumor, NOS"],"term_type":"RT"},{"nm":"Sertoli-Leydig cell tumor, poorly differentiated","n_c":["C4210"],"i_c":"8631/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements","n_c":["C39973"],"i_c":"8634/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, retiform","n_c":["C39974"],"i_c":"8633/1","i_c_s":["Sertoli-Leydig cell tumor, retiform"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, retiform, with heterologous elements","n_c":"","i_c":"8634/1","i_c_s":["Sertoli-Leydig cell tumor, retiform, with heterologous elements"],"term_type":"RT"},{"nm":"Sertoli-Leydig cell tumor, sarcomatoid","n_c":"","i_c":"8631/3","i_c_s":["Sertoli-Leydig cell tumor, sarcomatoid"],"term_type":"RT"},{"nm":"Sertoli-Leydig cell tumor, well differentiated","n_c":["C4209"],"i_c":"8631/0","i_c_s":["Sertoli-Leydig cell tumor, well differentiated"],"term_type":"PT"},{"nm":"Sessile serrated adenoma","n_c":["C96414"],"i_c":"8213/0","i_c_s":["Sessile serrated adenoma"],"term_type":"RT"},{"nm":"Sessile serrated polyp","n_c":["C96414"],"i_c":"8213/0","i_c_s":["Sessile serrated polyp"],"term_type":"RT"},{"nm":"SETTLE","n_c":["C46105"],"i_c":"8588/3","i_c_s":["SETTLE"],"term_type":"SY"},{"nm":"Sex cord tumor with annular tubules","n_c":["C4208"],"i_c":"8623/1","i_c_s":["Sex cord tumor with annular tubules"],"term_type":"PT"},{"nm":"Sex cord tumor, NOS","n_c":["C3794"],"i_c":"8590/1","i_c_s":["Sex cord tumor, NOS"],"term_type":"SY"},{"nm":"Sex cord-gonadal stromal tumor, incompletely differentiated","n_c":["C66748"],"i_c":"8591/1","i_c_s":["Sex cord-gonadal stromal tumor, incompletely differentiated"],"term_type":"PT"},{"nm":"Sex cord-gonadal stromal tumor, mixed forms","n_c":["C66991"],"i_c":"8592/1","i_c_s":["Sex cord-gonadal stromal tumor, mixed forms"],"term_type":"PT"},{"nm":"Sex cord-gonadal stromal tumor, NOS","n_c":["C3794"],"i_c":"8590/1","i_c_s":["Sex cord-gonadal stromal tumor, NOS"],"term_type":"PT"},{"nm":"Sezary disease","n_c":["C3366"],"i_c":"9701/3","i_c_s":["Sezary disease"],"term_type":"SY"},{"nm":"Sezary syndrome","n_c":["C3366"],"i_c":"9701/3","i_c_s":["Sezary syndrome"],"term_type":"PT"},{"nm":"Sialoblastoma","n_c":["C35837"],"i_c":"8974/1","i_c_s":["Sialoblastoma"],"term_type":"PT"},{"nm":"Signet ring cell adenocarcinoma","n_c":["C3774"],"i_c":"8490/3","i_c_s":["Signet ring cell adenocarcinoma"],"term_type":"SY"},{"nm":"Signet ring cell carcinoma","n_c":["C3774"],"i_c":"8490/3","i_c_s":["Signet ring cell carcinoma"],"term_type":"PT"},{"nm":"Sinonasal papilloma, exophytic","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Sinonasal papilloma, exophytic"],"term_type":"RT"},{"nm":"Sinonasal papilloma, fungiform","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Sinonasal papilloma, fungiform"],"term_type":"SY"},{"nm":"Sinonasal papilloma, NOS","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Sinonasal papilloma, NOS"],"term_type":"SY"},{"nm":"Skin appendage adenoma","n_c":["C7580"],"i_c":"8390/0","i_c_s":["Skin appendage adenoma"],"term_type":"PT"},{"nm":"Skin appendage carcinoma","n_c":["C3775"],"i_c":"8390/3","i_c_s":["Skin appendage carcinoma"],"term_type":"PT"},{"nm":"Skin appendage tumor, benign","n_c":["C4615"],"i_c":"8390/0","i_c_s":["Skin appendage tumor, benign"],"term_type":"SY"},{"nm":"Skin-associated lymphoid tissue lymphoma","n_c":["C7230"],"i_c":"9699/3","i_c_s":["Skin-associated lymphoid tissue lymphoma"],"term_type":"SY"},{"nm":"Small cell carcinoma pulmonary type","n_c":["C40440"],"i_c":"8041/3","i_c_s":["Small cell carcinoma pulmonary type"],"term_type":""},{"nm":"Small cell carcinoma, fusiform cell","n_c":["C27092"],"i_c":"8043/3","i_c_s":["Small cell carcinoma, fusiform cell"],"term_type":"PT"},{"nm":"Small cell carcinoma, hypercalcemic type","n_c":["C40439"],"i_c":"8044/3","i_c_s":["Small cell carcinoma, hypercalcemic type"],"term_type":""},{"nm":"Small cell carcinoma, intermediate cell","n_c":["C4099"],"i_c":"8044/3","i_c_s":["Small cell carcinoma, intermediate cell"],"term_type":"PT"},{"nm":"Small cell carcinoma, NOS","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Small cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Small cell neuroendocrine carcinoma","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Small cell neuroendocrine carcinoma"],"term_type":"RT"},{"nm":"Small cell osteosarcoma","n_c":["C4023"],"i_c":"9185/3","i_c_s":["Small cell osteosarcoma"],"term_type":"PT"},{"nm":"Small cell sarcoma","n_c":["C3746"],"i_c":"8803/3","i_c_s":["Small cell sarcoma"],"term_type":"PT"},{"nm":"Small congenital nevus","n_c":["C66754"],"i_c":"8761/0","i_c_s":["Small congenital nevus"],"term_type":"PT"},{"nm":"Smooth muscle tumor of uncertain malignant potential","n_c":["C40177"],"i_c":"8897/1","i_c_s":["Smooth muscle tumor of uncertain malignant potential"],"term_type":"PT"},{"nm":"Smooth muscle tumor, NOS","n_c":["C3751"],"i_c":"8897/1","i_c_s":["Smooth muscle tumor, NOS"],"term_type":"RT"},{"nm":"Soft tissue perineurioma","n_c":["C6912"],"i_c":"9571/0","i_c_s":["Soft tissue perineurioma"],"term_type":"RT"},{"nm":"Soft tissue sarcoma","n_c":["C9306"],"i_c":"8800/3","i_c_s":["Soft tissue sarcoma"],"term_type":"SY"},{"nm":"Soft tissue tumor, benign","n_c":["C4242"],"i_c":"8800/0","i_c_s":["Soft tissue tumor, benign"],"term_type":"PT"},{"nm":"Soft tissue tumor, malignant","n_c":["C4867"],"i_c":"8800/3","i_c_s":["Soft tissue tumor, malignant"],"term_type":"SY"},{"nm":"Solid adenocarcinoma with mucin formation","n_c":"","i_c":"8230/3","i_c_s":["Solid adenocarcinoma with mucin formation"],"term_type":"SY"},{"nm":"Solid and cystic tumor","n_c":["C4179"],"i_c":"8452/1","i_c_s":["Solid and cystic tumor"],"term_type":"SY"},{"nm":"Solid and papillary epithelial neoplasm","n_c":["C4179"],"i_c":"8452/1","i_c_s":["Solid and papillary epithelial neoplasm"],"term_type":"SY"},{"nm":"Solid carcinoma with mucin formation","n_c":"","i_c":"8230/3","i_c_s":["Solid carcinoma with mucin formation"],"term_type":"RT"},{"nm":"Solid carcinoma, NOS","n_c":["C4137"],"i_c":"8230/3","i_c_s":["Solid carcinoma, NOS"],"term_type":"PT"},{"nm":"Solid papillary carcinoma in situ","n_c":["C6870"],"i_c":"8509/2","i_c_s":["Solid papillary carcinoma in situ"],"term_type":"PT"},{"nm":"Solid papillary carcinoma with invasion","n_c":["C66850"],"i_c":"8509/3","i_c_s":["Solid papillary carcinoma with invasion"],"term_type":"PT"},{"nm":"Solid pseudopapillary carcinoma","n_c":["C5728"],"i_c":"8452/3","i_c_s":["Solid pseudopapillary carcinoma"],"term_type":"PT"},{"nm":"Solid pseudopapillary tumor","n_c":["C201136"],"i_c":"8452/1","i_c_s":["Solid pseudopapillary tumor"],"term_type":"PT"},{"nm":"Solid teratoma","n_c":["C3403"],"i_c":"9080/1","i_c_s":["Solid teratoma"],"term_type":"SY"},{"nm":"Solitary fibrous tumor","n_c":["C7634"],"i_c":"8815/0","i_c_s":["Solitary fibrous tumor"],"term_type":"PT"},{"nm":"Solitary fibrous tumor, malignant","n_c":["C6894"],"i_c":"8815/3","i_c_s":["Solitary fibrous tumor, malignant"],"term_type":"PT"},{"nm":"Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)","n_c":["C129530"],"i_c":"8815/0","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)"],"term_type":""},{"nm":"Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)","n_c":["C129528"],"i_c":"8815/1","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)"],"term_type":""},{"nm":"Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)","n_c":["C129527"],"i_c":"8815/3","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)"],"term_type":""},{"nm":"Solitary mastocytoma of skin","n_c":["C7138"],"i_c":"9740/1","i_c_s":["Solitary mastocytoma of skin"],"term_type":"SY"},{"nm":"Solitary myeloma","n_c":["C6932"],"i_c":"9731/3","i_c_s":["Solitary myeloma"],"term_type":"SY"},{"nm":"Solitary plasmacytoma","n_c":["C6932"],"i_c":"9731/3","i_c_s":["Solitary plasmacytoma"],"term_type":"SY"},{"nm":"Somatostatin cell tumor, malignant","n_c":["C65190"],"i_c":"8156/3","i_c_s":["Somatostatin cell tumor, malignant"],"term_type":"SY"},{"nm":"Somatostatin cell tumor, NOS","n_c":["C3379"],"i_c":"8156/1","i_c_s":["Somatostatin cell tumor, NOS"],"term_type":"SY"},{"nm":"Somatostatinoma, malignant","n_c":["C65190"],"i_c":"8156/3","i_c_s":["Somatostatinoma, malignant"],"term_type":"PT"},{"nm":"Somatostatinoma, NOS","n_c":["C3379"],"i_c":"8156/1","i_c_s":["Somatostatinoma, NOS"],"term_type":"PT"},{"nm":"Spermatocytic seminoma","n_c":["C39921"],"i_c":"9063/3","i_c_s":["Spermatocytic seminoma"],"term_type":"PT"},{"nm":"Spermatocytoma","n_c":["C39921"],"i_c":"9063/3","i_c_s":["Spermatocytoma"],"term_type":"SY"},{"nm":"Spindle cell angioendothelioma","n_c":["C4754"],"i_c":"9136/1","i_c_s":["Spindle cell angioendothelioma"],"term_type":"SY"},{"nm":"Spindle cell carcinoma, NOS","n_c":["C27004"],"i_c":"8032/3","i_c_s":["Spindle cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Spindle cell hemangioendothelioma","n_c":["C4754"],"i_c":"9136/1","i_c_s":["Spindle cell hemangioendothelioma"],"term_type":"PT"},{"nm":"Spindle cell lipoma","n_c":["C4254"],"i_c":"8857/0","i_c_s":["Spindle cell lipoma"],"term_type":"PT"},{"nm":"Spindle cell melanoma, NOS","n_c":["C4237"],"i_c":"8772/3","i_c_s":["Spindle cell melanoma, NOS"],"term_type":"PT"},{"nm":"Spindle cell melanoma, type A","n_c":["C4238"],"i_c":"8773/3","i_c_s":["Spindle cell melanoma, type A"],"term_type":"PT"},{"nm":"Spindle cell melanoma, type B","n_c":["C4239"],"i_c":"8774/3","i_c_s":["Spindle cell melanoma, type B"],"term_type":"PT"},{"nm":"Spindle cell nevus, NOS","n_c":["C27007"],"i_c":"8772/0","i_c_s":["Spindle cell nevus, NOS"],"term_type":"PT"},{"nm":"Spindle cell oncocytoma","n_c":["C94537"],"i_c":"8290/0","i_c_s":["Spindle cell oncocytoma"],"term_type":"RT"},{"nm":"Spindle cell rhabdomyosarcoma","n_c":["C6519"],"i_c":"8912/3","i_c_s":["Spindle cell rhabdomyosarcoma"],"term_type":"PT"},{"nm":"Spindle cell sarcoma","n_c":["C27005"],"i_c":"8801/3","i_c_s":["Spindle cell sarcoma"],"term_type":"PT"},{"nm":"Spindle epithelial tumor with thymus-like differentiation","n_c":["C46105"],"i_c":"8588/3","i_c_s":["Spindle epithelial tumor with thymus-like differentiation"],"term_type":"SY"},{"nm":"Spindle epithelial tumor with thymus-like element","n_c":["C46105"],"i_c":"8588/3","i_c_s":["Spindle epithelial tumor with thymus-like element"],"term_type":"PT"},{"nm":"Spindled mesothelioma","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Spindled mesothelioma"],"term_type":"SY"},{"nm":"Spiradenoma, NOS","n_c":["C4170"],"i_c":"8403/0","i_c_s":["Spiradenoma, NOS"],"term_type":"SY"},{"nm":"Spitz nevus","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Spitz nevus"],"term_type":"SY"},{"nm":"Splenic B-cell lymphoma/leukemia, unclassifiable","n_c":["C80308"],"i_c":"9591/3","i_c_s":["Splenic B-cell lymphoma/leukemia, unclassifiable"],"term_type":"RT"},{"nm":"Splenic diffuse red pulp small B-cell lymphoma","n_c":["C80309"],"i_c":"9591/3","i_c_s":["Splenic diffuse red pulp small B-cell lymphoma"],"term_type":"RT"},{"nm":"Splenic lymphoma with villous lymphocytes","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic lymphoma with villous lymphocytes"],"term_type":"SY"},{"nm":"Splenic marginal zone B-cell lymphoma","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic marginal zone B-cell lymphoma"],"term_type":"PT"},{"nm":"Splenic marginal zone lymphoma, NOS","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic marginal zone lymphoma, NOS"],"term_type":"SY"},{"nm":"Spongioblastoma multiforme","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Spongioblastoma multiforme"],"term_type":"SY"},{"nm":"Spongioblastoma polare","n_c":["C66801"],"i_c":"9423/3","i_c_s":["Spongioblastoma polare"],"term_type":"SY"},{"nm":"Spongioblastoma, NOS","n_c":"","i_c":"9421/1","i_c_s":["Spongioblastoma, NOS"],"term_type":"IS"},{"nm":"Spongioneuroblastoma","n_c":["C66811"],"i_c":"9504/3","i_c_s":["Spongioneuroblastoma"],"term_type":"PT"},{"nm":"Squamotransitional cell carcinoma","n_c":["C40194"],"i_c":"8120/3","i_c_s":["Squamotransitional cell carcinoma"],"term_type":""},{"nm":"Squamous carcinoma","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous carcinoma"],"term_type":"SY"},{"nm":"Squamous cell carcinoma in situ with questionable stromal invasion","n_c":["C65176"],"i_c":"8076/2","i_c_s":["Squamous cell carcinoma in situ with questionable stromal invasion"],"term_type":"PT"},{"nm":"Squamous cell carcinoma in situ, NOS","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Squamous cell carcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma with horn formation","n_c":["C65179"],"i_c":"8078/3","i_c_s":["Squamous cell carcinoma with horn formation"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, acantholytic","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, acantholytic"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, adenoid","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, adenoid"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, clear cell type","n_c":["C65180"],"i_c":"8084/3","i_c_s":["Squamous cell carcinoma, clear cell type"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, HPV-negative","n_c":["C164250"],"i_c":"8086/3","i_c_s":["Squamous cell carcinoma, HPV-negative"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, HPV-positive","n_c":["C27683"],"i_c":"8085/3","i_c_s":["Squamous cell carcinoma, HPV-positive"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, keratinizing, NOS","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Squamous cell carcinoma, keratinizing, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, large cell, keratinizing","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Squamous cell carcinoma, large cell, keratinizing"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, large cell, nonkeratinizing, NOS","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Squamous cell carcinoma, large cell, nonkeratinizing, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, metastatic, NOS","n_c":["C4104"],"i_c":"8070/6","i_c_s":["Squamous cell carcinoma, metastatic, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, microinvasive","n_c":["C65178"],"i_c":"8076/3","i_c_s":["Squamous cell carcinoma, microinvasive"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, nonkeratinizing, NOS","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Squamous cell carcinoma, nonkeratinizing, NOS"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, NOS","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, pseudoglandular","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, pseudoglandular"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, sarcomatoid","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Squamous cell carcinoma, sarcomatoid"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, small cell, nonkeratinizing","n_c":["C65175"],"i_c":"8073/3","i_c_s":["Squamous cell carcinoma, small cell, nonkeratinizing"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, spindle cell","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Squamous cell carcinoma, spindle cell"],"term_type":"PT"},{"nm":"Squamous cell epithelioma","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous cell epithelioma"],"term_type":"SY"},{"nm":"Squamous cell papilloma, inverted","n_c":["C65165"],"i_c":"8053/0","i_c_s":["Squamous cell papilloma, inverted"],"term_type":"PT"},{"nm":"Squamous cell papilloma, NOS","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Squamous cell papilloma, NOS"],"term_type":"PT"},{"nm":"Squamous intraepithelial neoplasia, grade I","n_c":["C8335"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, grade I"],"term_type":"SY"},{"nm":"Squamous intraepithelial neoplasia, grade II","n_c":["C7351"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, grade II"],"term_type":"SY"},{"nm":"Squamous intraepithelial neoplasia, grade III","n_c":["C27093"],"i_c":"8077/2","i_c_s":["Squamous intraepithelial neoplasia, grade III"],"term_type":"SY"},{"nm":"Squamous intraepithelial neoplasia, high grade","n_c":["C8336"],"i_c":"8077/2","i_c_s":["Squamous intraepithelial neoplasia, high grade"],"term_type":"PT"},{"nm":"Squamous intraepithelial neoplasia, low grade","n_c":["C8335"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, low grade"],"term_type":"PT"},{"nm":"Squamous odontogenic tumor","n_c":["C7112"],"i_c":"9312/0","i_c_s":["Squamous odontogenic tumor"],"term_type":"PT"},{"nm":"Squamous papilloma","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Squamous papilloma"],"term_type":"SY"},{"nm":"Squamous papillomatosis","n_c":["C9009"],"i_c":"8060/0","i_c_s":["Squamous papillomatosis"],"term_type":"PT"},{"nm":"Stem cell leukemia","n_c":["C9298"],"i_c":"9801/3","i_c_s":["Stem cell leukemia"],"term_type":"SY"},{"nm":"Steroid cell tumor, malignant","n_c":["C39981"],"i_c":"8670/3","i_c_s":["Steroid cell tumor, malignant"],"term_type":"PT"},{"nm":"Steroid cell tumor, NOS","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Steroid cell tumor, NOS"],"term_type":"SY"},{"nm":"Stromal endometriosis","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Stromal endometriosis"],"term_type":"SY"},{"nm":"Stromal myosis, NOS","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Stromal myosis, NOS"],"term_type":"SY"},{"nm":"Stromal sarcoma, NOS","n_c":["C6926"],"i_c":"8935/3","i_c_s":["Stromal sarcoma, NOS"],"term_type":"PT"},{"nm":"Stromal tumor with minor sex cord elements","n_c":["C66749"],"i_c":"8593/1","i_c_s":["Stromal tumor with minor sex cord elements"],"term_type":"PT"},{"nm":"Stromal tumor, benign","n_c":["C66772"],"i_c":"8935/0","i_c_s":["Stromal tumor, benign"],"term_type":"PT"},{"nm":"Stromal tumor, NOS","n_c":["C6781"],"i_c":"8935/1","i_c_s":["Stromal tumor, NOS"],"term_type":"PT"},{"nm":"Struma ovarii and carcinoid","n_c":["C4292"],"i_c":"9091/1","i_c_s":["Struma ovarii and carcinoid"],"term_type":"SY"},{"nm":"Struma ovarii, malignant","n_c":["C4291"],"i_c":"9090/3","i_c_s":["Struma ovarii, malignant"],"term_type":"PT"},{"nm":"Struma ovarii, NOS","n_c":["C7468"],"i_c":"9090/0","i_c_s":["Struma ovarii, NOS"],"term_type":"PT"},{"nm":"Strumal carcinoid","n_c":["C4292"],"i_c":"9091/1","i_c_s":["Strumal carcinoid"],"term_type":"PT"},{"nm":"Subacute granulocytic leukemia","n_c":["C3519"],"i_c":"9860/3","i_c_s":["Subacute granulocytic leukemia"],"term_type":"IS"},{"nm":"Subacute leukemia, NOS","n_c":"","i_c":"9800/3","i_c_s":["Subacute leukemia, NOS"],"term_type":"ORT"},{"nm":"Subacute lymphatic leukemia","n_c":"","i_c":"9820/3","i_c_s":["Subacute lymphatic leukemia"],"term_type":"IS"},{"nm":"Subacute lymphocytic leukemia","n_c":"","i_c":"9820/3","i_c_s":["Subacute lymphocytic leukemia"],"term_type":"IS"},{"nm":"Subacute lymphoid leukemia","n_c":"","i_c":"9820/3","i_c_s":["Subacute lymphoid leukemia"],"term_type":"ORT"},{"nm":"Subacute monocytic leukemia","n_c":"","i_c":"9860/3","i_c_s":["Subacute monocytic leukemia"],"term_type":"ORT"},{"nm":"Subacute myelogenous leukemia","n_c":["C3519"],"i_c":"9860/3","i_c_s":["Subacute myelogenous leukemia"],"term_type":"IS"},{"nm":"Subacute myeloid leukemia","n_c":["C3519"],"i_c":"9860/3","i_c_s":["Subacute myeloid leukemia"],"term_type":"ORT"},{"nm":"Subareolar duct papillomatosis","n_c":["C4192"],"i_c":"8506/0","i_c_s":["Subareolar duct papillomatosis"],"term_type":"SY"},{"nm":"Subcutaneous panniculitis-like T-cell lymphoma","n_c":["C6918"],"i_c":"9708/3","i_c_s":["Subcutaneous panniculitis-like T-cell lymphoma"],"term_type":"PT"},{"nm":"Subependymal astrocytoma, NOS","n_c":"","i_c":"9383/1","i_c_s":["Subependymal astrocytoma, NOS"],"term_type":"SY"},{"nm":"Subependymal giant cell astrocytoma","n_c":["C3696"],"i_c":"9384/1","i_c_s":["Subependymal giant cell astrocytoma"],"term_type":"PT"},{"nm":"Subependymal glioma","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Subependymal glioma"],"term_type":"SY"},{"nm":"Subependymoma","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Subependymoma"],"term_type":"PT"},{"nm":"Subepidermal nodular fibrosis","n_c":["C7159"],"i_c":"8832/0","i_c_s":["Subepidermal nodular fibrosis"],"term_type":"SY"},{"nm":"Superficial spreading adenocarcinoma","n_c":["C4125"],"i_c":"8143/3","i_c_s":["Superficial spreading adenocarcinoma"],"term_type":"PT"},{"nm":"Superficial spreading melanoma","n_c":["C9152"],"i_c":"8743/3","i_c_s":["Superficial spreading melanoma"],"term_type":"PT"},{"nm":"Superficial well differentiated liposarcoma","n_c":["C176980"],"i_c":"8850/1","i_c_s":["Superficial well differentiated liposarcoma"],"term_type":""},{"nm":"Supratentorial PNET","n_c":["C6968"],"i_c":"9473/3","i_c_s":["Supratentorial PNET"],"term_type":"RT"},{"nm":"Sweat gland adenocarcinoma","n_c":["C6938"],"i_c":"8400/3","i_c_s":["Sweat gland adenocarcinoma"],"term_type":"PT"},{"nm":"Sweat gland adenoma","n_c":["C7560"],"i_c":"8400/0","i_c_s":["Sweat gland adenoma"],"term_type":"PT"},{"nm":"Sweat gland carcinoma","n_c":["C6938"],"i_c":"8400/3","i_c_s":["Sweat gland carcinoma"],"term_type":"SY"},{"nm":"Sweat gland tumor, benign","n_c":["C4879"],"i_c":"8400/0","i_c_s":["Sweat gland tumor, benign"],"term_type":"SY"},{"nm":"Sweat gland tumor, malignant","n_c":["C4810"],"i_c":"8400/3","i_c_s":["Sweat gland tumor, malignant"],"term_type":"SY"},{"nm":"Sweat gland tumor, NOS","n_c":["C3398"],"i_c":"8400/1","i_c_s":["Sweat gland tumor, NOS"],"term_type":"PT"},{"nm":"Sympathetic paraganglioma","n_c":["C4216"],"i_c":"8681/1","i_c_s":["Sympathetic paraganglioma"],"term_type":"PT"},{"nm":"Sympathicoblastoma","n_c":"","i_c":"9500/3","i_c_s":["Sympathicoblastoma"],"term_type":"SY"},{"nm":"Symplastic leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Symplastic leiomyoma"],"term_type":"SY"},{"nm":"Syncytial meningioma","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Syncytial meningioma"],"term_type":"SY"},{"nm":"Synovial sarcoma, biphasic","n_c":["C4279"],"i_c":"9043/3","i_c_s":["Synovial sarcoma, biphasic"],"term_type":"PT"},{"nm":"Synovial sarcoma, epithelioid cell","n_c":["C4278"],"i_c":"9042/3","i_c_s":["Synovial sarcoma, epithelioid cell"],"term_type":"PT"},{"nm":"Synovial sarcoma, monophasic fibrous","n_c":["C4277"],"i_c":"9041/3","i_c_s":["Synovial sarcoma, monophasic fibrous"],"term_type":"SY"},{"nm":"Synovial sarcoma, NOS","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovial sarcoma, NOS"],"term_type":"PT"},{"nm":"Synovial sarcoma, spindle cell","n_c":["C4277"],"i_c":"9041/3","i_c_s":["Synovial sarcoma, spindle cell"],"term_type":"PT"},{"nm":"Synovioma, benign","n_c":["C3829"],"i_c":"9040/0","i_c_s":["Synovioma, benign"],"term_type":"PT"},{"nm":"Synovioma, malignant","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovioma, malignant"],"term_type":"SY"},{"nm":"Synovioma, NOS","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovioma, NOS"],"term_type":"SY"},{"nm":"Syringadenoma, NOS","n_c":"","i_c":"8400/0","i_c_s":["Syringadenoma, NOS"],"term_type":"SY"},{"nm":"Syringocystadenoma papilliferum","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Syringocystadenoma papilliferum"],"term_type":"SY"},{"nm":"Syringofibroadenoma","n_c":["C43356"],"i_c":"8392/0","i_c_s":["Syringofibroadenoma"],"term_type":"PT"},{"nm":"Syringoma, NOS","n_c":["C3761"],"i_c":"8407/0","i_c_s":["Syringoma, NOS"],"term_type":"PT"},{"nm":"Syringomatous carcinoma","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Syringomatous carcinoma"],"term_type":"SY"},{"nm":"Systemic EBV positive T-cell lymphoproliferative disease of childhood","n_c":["C80374"],"i_c":"9724/3","i_c_s":["Systemic EBV positive T-cell lymphoproliferative disease of childhood"],"term_type":"PT"},{"nm":"Systemic light chain disease","n_c":["C7727"],"i_c":"9769/1","i_c_s":["Systemic light chain disease"],"term_type":"SY"},{"nm":"Systemic mastocytosis with AHNMD","n_c":["C9284"],"i_c":"9741/3","i_c_s":["Systemic mastocytosis with AHNMD"],"term_type":"RT"},{"nm":"Systemic mastocytosis with associated hematological clonal non-mast cell disorder","n_c":["C9284"],"i_c":"9741/3","i_c_s":["Systemic mastocytosis with associated hematological clonal non-mast cell disorder"],"term_type":"RT"},{"nm":"Systemic tissue mast cell disease","n_c":["C9235"],"i_c":"9741/3","i_c_s":["Systemic tissue mast cell disease"],"term_type":"SY"},{"nm":"T lymphoblastic leukemia/lymphoma","n_c":["C8694"],"i_c":"9837/3","i_c_s":["T lymphoblastic leukemia/lymphoma"],"term_type":"RT"},{"nm":"T-cell large granular lymphocytic leukemia","n_c":["C4664"],"i_c":"9831/3","i_c_s":["T-cell large granular lymphocytic leukemia"],"term_type":"PT"},{"nm":"T-cell large granular lymphocytosis","n_c":["C4664"],"i_c":"9831/3","i_c_s":["T-cell large granular lymphocytosis"],"term_type":"SY"},{"nm":"T-cell lymphoma, NOS","n_c":["C3466"],"i_c":"9702/3","i_c_s":["T-cell lymphoma, NOS"],"term_type":"SY"},{"nm":"T-cell rich large B-cell lymphoma","n_c":["C9496"],"i_c":"9680/3","i_c_s":["T-cell rich large B-cell lymphoma"],"term_type":"RT"},{"nm":"T-cell rich/histiocyte-rich large B-cell lymphoma","n_c":["C9496"],"i_c":"9688/3","i_c_s":["T-cell rich/histiocyte-rich large B-cell lymphoma"],"term_type":""},{"nm":"T-gamma lymphoproliferative disease","n_c":["C4664"],"i_c":"9768/1","i_c_s":["T-gamma lymphoproliferative disease"],"term_type":"PT"},{"nm":"T-zone lymphoma","n_c":["C7204"],"i_c":"9702/3","i_c_s":["T-zone lymphoma"],"term_type":"SY"},{"nm":"T/NK-cell lymphoma","n_c":["C4684"],"i_c":"9719/3","i_c_s":["T/NK-cell lymphoma"],"term_type":"SY"},{"nm":"Tanycytic ependymoma","n_c":["C6903"],"i_c":"9391/3","i_c_s":["Tanycytic ependymoma"],"term_type":"RT"},{"nm":"Telangiectatic osteosarcoma","n_c":["C3902"],"i_c":"9183/3","i_c_s":["Telangiectatic osteosarcoma"],"term_type":"PT"},{"nm":"Tenosynovial giant cell tumor","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Tenosynovial giant cell tumor"],"term_type":"PT"},{"nm":"Teratoblastoma, malignant","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Teratoblastoma, malignant"],"term_type":"SY"},{"nm":"Teratocarcinoma","n_c":["C3756"],"i_c":"9081/3","i_c_s":["Teratocarcinoma"],"term_type":"PT"},{"nm":"Teratoid medulloepithelioma","n_c":["C66810"],"i_c":"9502/3","i_c_s":["Teratoid medulloepithelioma"],"term_type":"PT"},{"nm":"Teratoid medulloepithelioma, benign","n_c":["C66809"],"i_c":"9502/0","i_c_s":["Teratoid medulloepithelioma, benign"],"term_type":"PT"},{"nm":"Teratoma with malignant transformation","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Teratoma with malignant transformation"],"term_type":"PT"},{"nm":"Teratoma, benign","n_c":["C67107","C9015"],"i_c":"9080/0","i_c_s":["Teratoma, benign"],"term_type":"PT"},{"nm":"Teratoma, differentiated","n_c":["C9015"],"i_c":"9080/0","i_c_s":["Teratoma, differentiated"],"term_type":"SY"},{"nm":"Teratoma, malignant, NOS","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Teratoma, malignant, NOS"],"term_type":"PT"},{"nm":"Teratoma, NOS","n_c":["C3403"],"i_c":"9080/1","i_c_s":["Teratoma, NOS"],"term_type":"PT"},{"nm":"Terminal duct adenocarcinoma","n_c":"","i_c":"8525/3","i_c_s":["Terminal duct adenocarcinoma"],"term_type":"SY"},{"nm":"Testicular adenoma","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Testicular adenoma"],"term_type":"SY"},{"nm":"Testicular stromal tumor","n_c":"","i_c":"8590/1","i_c_s":["Testicular stromal tumor"],"term_type":"SY"},{"nm":"Theca cell tumor","n_c":["C3405"],"i_c":"8600/0","i_c_s":["Theca cell tumor"],"term_type":"SY"},{"nm":"Theca cell-granulosa cell tumor","n_c":["C66751"],"i_c":"8621/1","i_c_s":["Theca cell-granulosa cell tumor"],"term_type":"SY"},{"nm":"Thecoma, luteinized","n_c":["C4203"],"i_c":"8601/0","i_c_s":["Thecoma, luteinized"],"term_type":"PT"},{"nm":"Thecoma, malignant","n_c":["C6929"],"i_c":"8600/3","i_c_s":["Thecoma, malignant"],"term_type":"PT"},{"nm":"Thecoma, NOS","n_c":["C3405"],"i_c":"8600/0","i_c_s":["Thecoma, NOS"],"term_type":"PT"},{"nm":"Therapy related myeloid neoplasm","n_c":["C27912"],"i_c":"9920/3","i_c_s":["Therapy related myeloid neoplasm"],"term_type":"PT"},{"nm":"Therapy-related acute myeloid leukemia, alkylating agent related","n_c":["C27754"],"i_c":"9920/3","i_c_s":["Therapy-related acute myeloid leukemia, alkylating agent related"],"term_type":"RT"},{"nm":"Therapy-related acute myeloid leukemia, epipodophyllotoxin-related","n_c":["C27754"],"i_c":"9920/3","i_c_s":["Therapy-related acute myeloid leukemia, epipodophyllotoxin-related"],"term_type":"RT"},{"nm":"Therapy-related acute myeloid leukemia, NOS","n_c":["C8252"],"i_c":"9920/3","i_c_s":["Therapy-related acute myeloid leukemia, NOS"],"term_type":"SY"},{"nm":"Therapy-related myelodysplastic syndrome, alkylating agent related","n_c":["C7643"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, alkylating agent related"],"term_type":"SY"},{"nm":"Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related","n_c":["C7642"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related"],"term_type":"SY"},{"nm":"Therapy-related myelodysplastic syndrome, NOS","n_c":["C27722"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, NOS"],"term_type":"PT"},{"nm":"Thymic carcinoma with adenoid cystic carcinoma-like features","n_c":"","i_c":"8200/3","i_c_s":["Thymic carcinoma with adenoid cystic carcinoma-like features"],"term_type":""},{"nm":"Thymic carcinoma, NOS","n_c":["C7569"],"i_c":"8586/3","i_c_s":["Thymic carcinoma, NOS"],"term_type":"PT"},{"nm":"Thymic large B-cell lymphoma","n_c":["C9280"],"i_c":"9679/3","i_c_s":["Thymic large B-cell lymphoma"],"term_type":"SY"},{"nm":"Thymoma, atypical, malignant","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, atypical, malignant"],"term_type":"SY"},{"nm":"Thymoma, atypical, NOS","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, atypical, NOS"],"term_type":"SY"},{"nm":"Thymoma, benign","n_c":["C66746"],"i_c":"8580/0","i_c_s":["Thymoma, benign"],"term_type":"PT"},{"nm":"Thymoma, cortical, malignant","n_c":["C6889"],"i_c":"8584/3","i_c_s":["Thymoma, cortical, malignant"],"term_type":"SY"},{"nm":"Thymoma, cortical, NOS","n_c":["C6888"],"i_c":"8584/1","i_c_s":["Thymoma, cortical, NOS"],"term_type":"SY"},{"nm":"Thymoma, epithelial, malignant","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, epithelial, malignant"],"term_type":"SY"},{"nm":"Thymoma, epithelial, NOS","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, epithelial, NOS"],"term_type":"SY"},{"nm":"Thymoma, lymphocyte-rich, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, lymphocyte-rich, malignant"],"term_type":"SY"},{"nm":"Thymoma, lymphocyte-rich, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, lymphocyte-rich, NOS"],"term_type":"SY"},{"nm":"Thymoma, lymphocytic, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, lymphocytic, malignant"],"term_type":"SY"},{"nm":"Thymoma, lymphocytic, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, lymphocytic, NOS"],"term_type":"SY"},{"nm":"Thymoma, malignant, NOS","n_c":["C7612"],"i_c":"8580/3","i_c_s":["Thymoma, malignant, NOS"],"term_type":"PT"},{"nm":"Thymoma, medullary, malignant","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, medullary, malignant"],"term_type":"SY"},{"nm":"Thymoma, medullary, NOS","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, medullary, NOS"],"term_type":"SY"},{"nm":"Thymoma, mixed type, malignant","n_c":["C6886"],"i_c":"8582/3","i_c_s":["Thymoma, mixed type, malignant"],"term_type":"SY"},{"nm":"Thymoma, mixed type, NOS","n_c":["C6885"],"i_c":"8582/1","i_c_s":["Thymoma, mixed type, NOS"],"term_type":"SY"},{"nm":"Thymoma, NOS","n_c":["C3411"],"i_c":"8580/1","i_c_s":["Thymoma, NOS"],"term_type":"PT"},{"nm":"Thymoma, organoid, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, organoid, malignant"],"term_type":"SY"},{"nm":"Thymoma, organoid, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, organoid, NOS"],"term_type":"SY"},{"nm":"Thymoma, predominantly cortical, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, predominantly cortical, malignant"],"term_type":"SY"},{"nm":"Thymoma, predominantly cortical, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, predominantly cortical, NOS"],"term_type":"SY"},{"nm":"Thymoma, spindle cell, malignant","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, spindle cell, malignant"],"term_type":"SY"},{"nm":"Thymoma, spindle cell, NOS","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, spindle cell, NOS"],"term_type":"SY"},{"nm":"Thymoma, type A, malignant","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, type A, malignant"],"term_type":"PT"},{"nm":"Thymoma, type A, NOS","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, type A, NOS"],"term_type":"PT"},{"nm":"Thymoma, type AB, malignant","n_c":["C6886"],"i_c":"8582/3","i_c_s":["Thymoma, type AB, malignant"],"term_type":"PT"},{"nm":"Thymoma, type AB, NOS","n_c":["C6885"],"i_c":"8582/1","i_c_s":["Thymoma, type AB, NOS"],"term_type":"PT"},{"nm":"Thymoma, type B1, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, type B1, malignant"],"term_type":"PT"},{"nm":"Thymoma, type B1, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, type B1, NOS"],"term_type":"PT"},{"nm":"Thymoma, type B2, malignant","n_c":["C6889"],"i_c":"8584/3","i_c_s":["Thymoma, type B2, malignant"],"term_type":"PT"},{"nm":"Thymoma, type B2, NOS","n_c":["C6888"],"i_c":"8584/1","i_c_s":["Thymoma, type B2, NOS"],"term_type":"PT"},{"nm":"Thymoma, type B3, malignant","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, type B3, malignant"],"term_type":"PT"},{"nm":"Thymoma, type B3, NOS","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, type B3, NOS"],"term_type":"PT"},{"nm":"Thymoma, type C","n_c":["C7569"],"i_c":"8586/3","i_c_s":["Thymoma, type C"],"term_type":"SY"},{"nm":"Tibial adamantinoma","n_c":["C8461"],"i_c":"9261/3","i_c_s":["Tibial adamantinoma"],"term_type":"SY"},{"nm":"Trabecular adenocarcinoma","n_c":["C4068"],"i_c":"8190/3","i_c_s":["Trabecular adenocarcinoma"],"term_type":"PT"},{"nm":"Trabecular adenoma","n_c":["C3688"],"i_c":"8190/0","i_c_s":["Trabecular adenoma"],"term_type":"PT"},{"nm":"Trabecular carcinoma","n_c":["C4068"],"i_c":"8190/3","i_c_s":["Trabecular carcinoma"],"term_type":"SY"},{"nm":"Traditional serrated adenoma","n_c":["C38458"],"i_c":"8213/0","i_c_s":["Traditional serrated adenoma"],"term_type":"SY"},{"nm":"Traditional sessile serrated adenoma","n_c":"","i_c":"8213/0","i_c_s":["Traditional sessile serrated adenoma"],"term_type":"RT"},{"nm":"Transient abnormal myelopoiesis","n_c":["C82339"],"i_c":"9898/1","i_c_s":["Transient abnormal myelopoiesis"],"term_type":"PT"},{"nm":"Transitional carcinoma","n_c":["C2930"],"i_c":"8120/3","i_c_s":["Transitional carcinoma"],"term_type":"RT"},{"nm":"Transitional cell carcinoma","n_c":["C2930"],"i_c":"8120/3","i_c_s":["Transitional cell carcinoma"],"term_type":""},{"nm":"Transitional cell carcinoma in situ","n_c":["C4116"],"i_c":"8120/2","i_c_s":["Transitional cell carcinoma in situ"],"term_type":"PT"},{"nm":"Transitional cell carcinoma, micropapillary","n_c":["C65182"],"i_c":"8131/3","i_c_s":["Transitional cell carcinoma, micropapillary"],"term_type":"PT"},{"nm":"Transitional cell carcinoma, sarcomatoid","n_c":["C4120"],"i_c":"8122/3","i_c_s":["Transitional cell carcinoma, sarcomatoid"],"term_type":"SY"},{"nm":"Transitional cell carcinoma, spindle cell","n_c":["C4120"],"i_c":"8122/3","i_c_s":["Transitional cell carcinoma, spindle cell"],"term_type":"PT"},{"nm":"Transitional cell papilloma, benign","n_c":["C4115"],"i_c":"8120/0","i_c_s":["Transitional cell papilloma, benign"],"term_type":"PT"},{"nm":"Transitional cell papilloma, inverted, benign","n_c":["C4118"],"i_c":"8121/0","i_c_s":["Transitional cell papilloma, inverted, benign"],"term_type":"RT"},{"nm":"Transitional cell papilloma, inverted, NOS","n_c":["C4118"],"i_c":"8121/1","i_c_s":["Transitional cell papilloma, inverted, NOS"],"term_type":"PT"},{"nm":"Transitional cell papilloma, NOS","n_c":["C4115"],"i_c":"8120/1","i_c_s":["Transitional cell papilloma, NOS"],"term_type":"SY"},{"nm":"Transitional meningioma","n_c":["C4333"],"i_c":"9537/0","i_c_s":["Transitional meningioma"],"term_type":"PT"},{"nm":"Transitional papilloma","n_c":["C4115"],"i_c":"8120/0","i_c_s":["Transitional papilloma"],"term_type":"SY"},{"nm":"Transitional papilloma, inverted, benign","n_c":["C4118"],"i_c":"8121/0","i_c_s":["Transitional papilloma, inverted, benign"],"term_type":"RT"},{"nm":"Transitional papilloma, inverted, NOS","n_c":["C4118"],"i_c":"8121/1","i_c_s":["Transitional papilloma, inverted, NOS"],"term_type":"SY"},{"nm":"Transitional pineal tumor","n_c":"","i_c":"9362/3","i_c_s":["Transitional pineal tumor"],"term_type":"RT"},{"nm":"Trichilemmal carcinoma","n_c":["C43326"],"i_c":"8102/3","i_c_s":["Trichilemmal carcinoma"],"term_type":"SY"},{"nm":"Trichilemmocarcinoma","n_c":["C43326"],"i_c":"8102/3","i_c_s":["Trichilemmocarcinoma"],"term_type":"PT"},{"nm":"Trichilemmoma","n_c":["C4113"],"i_c":"8102/0","i_c_s":["Trichilemmoma"],"term_type":"PT"},{"nm":"Trichodiscoma","n_c":["C43333"],"i_c":"8391/0","i_c_s":["Trichodiscoma"],"term_type":"SY"},{"nm":"Trichoepithelioma","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Trichoepithelioma"],"term_type":"PT"},{"nm":"Trichofolliculoma","n_c":["C4112"],"i_c":"8101/0","i_c_s":["Trichofolliculoma"],"term_type":"PT"},{"nm":"Triton tumor, malignant","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Triton tumor, malignant"],"term_type":"SY"},{"nm":"Trophoblastic tumor, epithelioid","n_c":["C6900"],"i_c":"9105/3","i_c_s":["Trophoblastic tumor, epithelioid"],"term_type":"PT"},{"nm":"True histiocytic lymphoma","n_c":["C35382"],"i_c":"9755/3","i_c_s":["True histiocytic lymphoma"],"term_type":"RT"},{"nm":"Tubular adenocarcinoma","n_c":["C65192"],"i_c":"8211/3","i_c_s":["Tubular adenocarcinoma"],"term_type":"PT"},{"nm":"Tubular adenoma, NOS","n_c":["C4133"],"i_c":"8211/0","i_c_s":["Tubular adenoma, NOS"],"term_type":"PT"},{"nm":"Tubular androblastoma with lipid storage","n_c":"","i_c":"8641/0","i_c_s":["Tubular androblastoma with lipid storage"],"term_type":"SY"},{"nm":"Tubular androblastoma, NOS","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Tubular androblastoma, NOS"],"term_type":"SY"},{"nm":"Tubular carcinoid","n_c":["C43565"],"i_c":"8245/1","i_c_s":["Tubular carcinoid"],"term_type":"PT"},{"nm":"Tubular carcinoma","n_c":["C65192"],"i_c":"8211/3","i_c_s":["Tubular carcinoma"],"term_type":"SY"},{"nm":"Tubulo-papillary adenoma","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Tubulo-papillary adenoma"],"term_type":"SY"},{"nm":"Tubulocystic renal cell carcinoma","n_c":["C126303"],"i_c":"8316/3","i_c_s":["Tubulocystic renal cell carcinoma"],"term_type":""},{"nm":"Tubulolobular carcinoma","n_c":["C97053"],"i_c":"8520/3","i_c_s":["Tubulolobular carcinoma"],"term_type":""},{"nm":"Tubulopapillary adenocarcinoma","n_c":"","i_c":"8263/3","i_c_s":["Tubulopapillary adenocarcinoma"],"term_type":"SY"},{"nm":"Tubulovillous adenoma, NOS","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Tubulovillous adenoma, NOS"],"term_type":"PT"},{"nm":"Tumor cells, benign","n_c":["C36122"],"i_c":"8001/0","i_c_s":["Tumor cells, benign"],"term_type":"PT"},{"nm":"Tumor cells, malignant","n_c":["C12917"],"i_c":"8001/3","i_c_s":["Tumor cells, malignant"],"term_type":"PT"},{"nm":"Tumor cells, NOS","n_c":["C12922"],"i_c":"8001/1","i_c_s":["Tumor cells, NOS"],"term_type":"SY"},{"nm":"Tumor cells, uncertain whether benign or malignant","n_c":["C12922"],"i_c":"8001/1","i_c_s":["Tumor cells, uncertain whether benign or malignant"],"term_type":"PT"},{"nm":"Tumor embolus","n_c":["C3005"],"i_c":"8000/6","i_c_s":["Tumor embolus"],"term_type":"SY"},{"nm":"Tumor, benign","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Tumor, benign"],"term_type":"SY"},{"nm":"Tumor, malignant, NOS","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Tumor, malignant, NOS"],"term_type":"SY"},{"nm":"Tumor, metastatic","n_c":["C3261"],"i_c":"8000/6","i_c_s":["Tumor, metastatic"],"term_type":"SY"},{"nm":"Tumor, NOS","n_c":["C3262"],"i_c":"8000/1","i_c_s":["Tumor, NOS"],"term_type":"SY"},{"nm":"Tumor, secondary","n_c":["C36255"],"i_c":"8000/6","i_c_s":["Tumor, secondary"],"term_type":"SY"},{"nm":"Tumorlet, benign","n_c":["C65162"],"i_c":"8040/0","i_c_s":["Tumorlet, benign"],"term_type":"PT"},{"nm":"Tumorlet, NOS","n_c":["C65162"],"i_c":"8040/1","i_c_s":["Tumorlet, NOS"],"term_type":"PT"},{"nm":"Turban tumor","n_c":["C43352"],"i_c":"8200/0","i_c_s":["Turban tumor"],"term_type":"RT"},{"nm":"Typical carcinoid","n_c":"","i_c":"8240/3","i_c_s":["Typical carcinoid"],"term_type":"RT"},{"nm":"Unclassified tumor, benign","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Unclassified tumor, benign"],"term_type":"SY"},{"nm":"Unclassified tumor, borderline malignancy","n_c":["C65157"],"i_c":"8000/1","i_c_s":["Unclassified tumor, borderline malignancy"],"term_type":"SY"},{"nm":"Unclassified tumor, malignant","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Unclassified tumor, malignant"],"term_type":"SY"},{"nm":"Unclassified tumor, malignant, uncertain whether primary or metastatic","n_c":["C65153"],"i_c":"8000/9","i_c_s":["Unclassified tumor, malignant, uncertain whether primary or metastatic"],"term_type":"SY"},{"nm":"Unclassified tumor, uncertain whether benign or malignant","n_c":["C65157"],"i_c":"8000/1","i_c_s":["Unclassified tumor, uncertain whether benign or malignant"],"term_type":"SY"},{"nm":"Undifferentiated epithelioid sarcoma","n_c":["C121802"],"i_c":"8804/3","i_c_s":["Undifferentiated epithelioid sarcoma"],"term_type":""},{"nm":"Undifferentiated high-grade pleomorphic sarcoma","n_c":["C8563"],"i_c":"8830/3","i_c_s":["Undifferentiated high-grade pleomorphic sarcoma"],"term_type":""},{"nm":"Undifferentiated leukaemia","n_c":["C9300"],"i_c":"9801/3","i_c_s":["Undifferentiated leukaemia"],"term_type":""},{"nm":"Undifferentiated pleomorphic sarcoma","n_c":["C4247"],"i_c":"8802/3","i_c_s":["Undifferentiated pleomorphic sarcoma"],"term_type":""},{"nm":"Undifferentiated round cell sarcoma","n_c":["C121799"],"i_c":"8803/3","i_c_s":["Undifferentiated round cell sarcoma"],"term_type":""},{"nm":"Undifferentiated sarcoma","n_c":["C121793"],"i_c":"8805/3","i_c_s":["Undifferentiated sarcoma"],"term_type":"PT"},{"nm":"Undifferentiated spindle cell sarcoma","n_c":["C121797"],"i_c":"8801/3","i_c_s":["Undifferentiated spindle cell sarcoma"],"term_type":""},{"nm":"Undifferentiated uterine sarcoma","n_c":["C8972"],"i_c":"8805/3","i_c_s":["Undifferentiated uterine sarcoma"],"term_type":""},{"nm":"Urachal carcinoma","n_c":["C39842"],"i_c":"8010/3","i_c_s":["Urachal carcinoma"],"term_type":""},{"nm":"Urothelial carcinoma in situ","n_c":["C4116"],"i_c":"8120/2","i_c_s":["Urothelial carcinoma in situ"],"term_type":"SY"},{"nm":"Urothelial carcinoma with divergent differentiation","n_c":"","i_c":"8120/3","i_c_s":["Urothelial carcinoma with divergent differentiation"],"term_type":""},{"nm":"Urothelial carcinoma with squamous differentiation","n_c":["C191681"],"i_c":"8120/3","i_c_s":["Urothelial carcinoma with squamous differentiation"],"term_type":""},{"nm":"Urothelial carcinoma with trophoblastic differentiation","n_c":["C191682"],"i_c":"8120/3","i_c_s":["Urothelial carcinoma with trophoblastic differentiation"],"term_type":""},{"nm":"Urothelial carcinoma, NOS","n_c":["C4030"],"i_c":"8120/3","i_c_s":["Urothelial carcinoma, NOS"],"term_type":"SY"},{"nm":"Urothelial papilloma, NOS","n_c":["C3842"],"i_c":"8120/1","i_c_s":["Urothelial papilloma, NOS"],"term_type":"PT"},{"nm":"Urticaria pigmentosa","n_c":["C3433"],"i_c":"9740/1","i_c_s":["Urticaria pigmentosa"],"term_type":"RT"},{"nm":"Vaginal intraepithelial neoplasia, grade III","n_c":["C7855"],"i_c":"8077/2","i_c_s":["Vaginal intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"VAIN III","n_c":["C89476"],"i_c":"8077/2","i_c_s":["VAIN III"],"term_type":"SY"},{"nm":"Vascular leiomyoma","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Vascular leiomyoma"],"term_type":"SY"},{"nm":"Venous hemangioma","n_c":["C4296"],"i_c":"9122/0","i_c_s":["Venous hemangioma"],"term_type":"PT"},{"nm":"Verrucous carcinoma, NOS","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous carcinoma, NOS"],"term_type":"PT"},{"nm":"Verrucous epidermoid carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous epidermoid carcinoma"],"term_type":"SY"},{"nm":"Verrucous keratotic hemangioma","n_c":["C4299"],"i_c":"9142/0","i_c_s":["Verrucous keratotic hemangioma"],"term_type":"PT"},{"nm":"Verrucous papilloma","n_c":["C4101"],"i_c":"8051/0","i_c_s":["Verrucous papilloma"],"term_type":"PT"},{"nm":"Verrucous squamous cell carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous squamous cell carcinoma"],"term_type":"SY"},{"nm":"Villoglandular adenoma","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Villoglandular adenoma"],"term_type":"SY"},{"nm":"Villoglandular carcinoma","n_c":["C40208"],"i_c":"8263/3","i_c_s":["Villoglandular carcinoma"],"term_type":""},{"nm":"Villous adenocarcinoma","n_c":["C4142"],"i_c":"8262/3","i_c_s":["Villous adenocarcinoma"],"term_type":"PT"},{"nm":"Villous adenoma, NOS","n_c":["C7399"],"i_c":"8261/0","i_c_s":["Villous adenoma, NOS"],"term_type":"PT"},{"nm":"Villous papilloma","n_c":"","i_c":"8261/0","i_c_s":["Villous papilloma"],"term_type":"RT"},{"nm":"VIN III","n_c":["C4522"],"i_c":"8077/2","i_c_s":["VIN III"],"term_type":"SY"},{"nm":"Vipoma, malignant","n_c":["C65189"],"i_c":"8155/3","i_c_s":["Vipoma, malignant"],"term_type":"PT"},{"nm":"Vipoma, NOS","n_c":["C26749"],"i_c":"8155/1","i_c_s":["Vipoma, NOS"],"term_type":"PT"},{"nm":"Von Recklinghausen disease","n_c":["C3273"],"i_c":"9540/1","i_c_s":["Von Recklinghausen disease"],"term_type":"SY"},{"nm":"Vulvar intraepithelial neoplasia, grade III","n_c":["C4522"],"i_c":"8077/2","i_c_s":["Vulvar intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Waldenstrom macroglobulinemia","n_c":["C80307"],"i_c":"9761/3","i_c_s":["Waldenstrom macroglobulinemia"],"term_type":"PT"},{"nm":"Warthin tumor","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Warthin tumor"],"term_type":"SY"},{"nm":"Warty carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Warty carcinoma"],"term_type":"SY"},{"nm":"Water-clear cell adenocarcinoma","n_c":["C4156"],"i_c":"8322/3","i_c_s":["Water-clear cell adenocarcinoma"],"term_type":"PT"},{"nm":"Water-clear cell adenoma","n_c":["C4155"],"i_c":"8322/0","i_c_s":["Water-clear cell adenoma"],"term_type":"PT"},{"nm":"Water-clear cell carcinoma","n_c":["C4156"],"i_c":"8322/3","i_c_s":["Water-clear cell carcinoma"],"term_type":"SY"},{"nm":"Well differentiated liposarcoma of superficial soft tissue","n_c":["C176980"],"i_c":"8850/1","i_c_s":["Well differentiated liposarcoma of superficial soft tissue"],"term_type":"SY"},{"nm":"Well differentiated papillary mesothelioma, benign","n_c":["C7635"],"i_c":"9052/0","i_c_s":["Well differentiated papillary mesothelioma, benign"],"term_type":"RT"},{"nm":"Well differentiated thymic carcinoma","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Well differentiated thymic carcinoma"],"term_type":"SY"},{"nm":"Wilms tumor","n_c":["C3267"],"i_c":"8960/3","i_c_s":["Wilms tumor"],"term_type":"SY"},{"nm":"Wolffian duct adenoma","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Wolffian duct adenoma"],"term_type":"SY"},{"nm":"Wolffian duct carcinoma","n_c":["C4072"],"i_c":"9110/3","i_c_s":["Wolffian duct carcinoma"],"term_type":"SY"},{"nm":"Wolffian duct tumor","n_c":["C40141"],"i_c":"9110/1","i_c_s":["Wolffian duct tumor"],"term_type":"SY"},{"nm":"Xanthofibroma","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Xanthofibroma"],"term_type":"SY"},{"nm":"Yolk sac tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Yolk sac tumor"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast implant-associated anaplastic large cell lymphoma","n_c":["C139012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indolent T-cell lymphoproliferative disorder of gastrointestinal tract","n_c":["C139021"],"i_c":"9702/1","i_c_s":["Indolent T-cell lymphoproliferative disorder of gastrointestinal tract"],"term_type":"PT"},{"nm":"Diffuse Pediatric-type High Grade Glioma","n_c":["C185467"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.primary_gleason_grade":[{"nm":"Pattern 1","n_c":["C28085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 2","n_c":["C28086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 3","n_c":["C28087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 4","n_c":["C28088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 5","n_c":["C28089"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.prior_malignancy":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.prior_treatment":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.progression_or_recurrence":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.residual_disease":[{"nm":"R0","n_c":["C139578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C139579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C139580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RX","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.satellite_nodule_present":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.secondary_gleason_grade":[{"nm":"Pattern 1","n_c":["C28085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 2","n_c":["C28086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 3","n_c":["C28087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 4","n_c":["C28088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 5","n_c":["C28089"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.site_of_resection_or_biopsy":[{"nm":"Abdomen, NOS","n_c":["C12664"],"i_c":"C76.2","i_c_s":["Abdomen, NOS"],"term_type":"PT"},{"nm":"Abdominal esophagus","n_c":["C12252"],"i_c":"C15.2","i_c_s":["Abdominal esophagus"],"term_type":"PT"},{"nm":"Accessory sinus, NOS","n_c":["C12763"],"i_c":"C31.9","i_c_s":["Accessory sinus, NOS"],"term_type":"PT"},{"nm":"Acoustic nerve","n_c":["C12697"],"i_c":"C72.4","i_c_s":["Acoustic nerve"],"term_type":"PT"},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"C74.9","i_c_s":["Adrenal gland, NOS"],"term_type":"PT"},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"C24.1","i_c_s":["Ampulla of Vater"],"term_type":"PT"},{"nm":"Anal canal","n_c":["C12375"],"i_c":"C21.1","i_c_s":["Anal canal"],"term_type":"PT"},{"nm":"Anterior 2/3 of tongue, NOS","n_c":"","i_c":"C02.3","i_c_s":["Anterior 2/3 of tongue, NOS"],"term_type":"PT"},{"nm":"Anterior floor of mouth","n_c":"","i_c":"C04.0","i_c_s":["Anterior floor of mouth"],"term_type":"PT"},{"nm":"Anterior mediastinum","n_c":["C32098"],"i_c":"C38.1","i_c_s":["Anterior mediastinum"],"term_type":"PT"},{"nm":"Anterior surface of epiglottis","n_c":["C12238"],"i_c":"C10.1","i_c_s":["Anterior surface of epiglottis"],"term_type":"PT"},{"nm":"Anterior wall of bladder","n_c":["C12334"],"i_c":"C67.3","i_c_s":["Anterior wall of bladder"],"term_type":"PT"},{"nm":"Anterior wall of nasopharynx","n_c":["C12245"],"i_c":"C11.3","i_c_s":["Anterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"C21.0","i_c_s":["Anus, NOS"],"term_type":"PT"},{"nm":"Aortic body and other paraganglia","n_c":"","i_c":"C75.5","i_c_s":["Aortic body and other paraganglia"],"term_type":"PT"},{"nm":"Appendix","n_c":["C12380"],"i_c":"C18.1","i_c_s":["Appendix"],"term_type":"PT"},{"nm":"Ascending colon","n_c":["C12265"],"i_c":"C18.2","i_c_s":["Ascending colon"],"term_type":"PT"},{"nm":"Autonomic nervous system, NOS","n_c":["C12673"],"i_c":"C47.9","i_c_s":["Autonomic nervous system, NOS"],"term_type":"PT"},{"nm":"Axillary tail of breast","n_c":["C12305"],"i_c":"C50.6","i_c_s":["Axillary tail of breast"],"term_type":"PT"},{"nm":"Base of tongue, NOS","n_c":["C12228"],"i_c":"C01.9","i_c_s":["Base of tongue, NOS"],"term_type":"PT"},{"nm":"Biliary tract, NOS","n_c":["C12678"],"i_c":"C24.9","i_c_s":["Biliary tract, NOS"],"term_type":"PT"},{"nm":"Bladder neck","n_c":["C12336"],"i_c":"C67.5","i_c_s":["Bladder neck"],"term_type":"PT"},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"C67.9","i_c_s":["Bladder, NOS"],"term_type":"PT"},{"nm":"Blood","n_c":["C12434"],"i_c":"C42.0","i_c_s":["Blood"],"term_type":"PT"},{"nm":"Body of pancreas","n_c":["C12270"],"i_c":"C25.1","i_c_s":["Body of pancreas"],"term_type":"PT"},{"nm":"Body of penis","n_c":["C12325"],"i_c":"C60.2","i_c_s":["Body of penis"],"term_type":"PT"},{"nm":"Body of stomach","n_c":["C12258"],"i_c":"C16.2","i_c_s":["Body of stomach"],"term_type":"PT"},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"C42.1","i_c_s":["Bone marrow"],"term_type":"PT"},{"nm":"Bone of limb, NOS","n_c":["C32223"],"i_c":"C40.9","i_c_s":["Bone of limb, NOS"],"term_type":"PT"},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"C41.9","i_c_s":["Bone, NOS"],"term_type":"PT"},{"nm":"Bones of skull and face and associated joints","n_c":"","i_c":"C41.0","i_c_s":["Bones of skull and face and associated joints"],"term_type":"PT"},{"nm":"Border of tongue","n_c":"","i_c":"C02.1","i_c_s":["Border of tongue"],"term_type":"PT"},{"nm":"Brain stem","n_c":["C12441"],"i_c":"C71.7","i_c_s":["Brain stem"],"term_type":"PT"},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"C71.9","i_c_s":["Brain, NOS"],"term_type":"PT"},{"nm":"Branchial cleft","n_c":["C104813"],"i_c":"C10.4","i_c_s":["Branchial cleft"],"term_type":"PT"},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"C50.9","i_c_s":["Breast, NOS"],"term_type":"PT"},{"nm":"Broad ligament","n_c":["C12318"],"i_c":"C57.1","i_c_s":["Broad ligament"],"term_type":"PT"},{"nm":"Cardia, NOS","n_c":["C12256"],"i_c":"C16.0","i_c_s":["Cardia, NOS"],"term_type":"PT"},{"nm":"Carotid body","n_c":["C66852"],"i_c":"C75.4","i_c_s":["Carotid body"],"term_type":"PT"},{"nm":"Cauda equina","n_c":["C12689"],"i_c":"C72.1","i_c_s":["Cauda equina"],"term_type":"PT"},{"nm":"Cecum","n_c":["C12381"],"i_c":"C18.0","i_c_s":["Cecum"],"term_type":"PT"},{"nm":"Central portion of breast","n_c":["C12300"],"i_c":"C50.1","i_c_s":["Central portion of breast"],"term_type":"PT"},{"nm":"Cerebellum, NOS","n_c":["C12445"],"i_c":"C71.6","i_c_s":["Cerebellum, NOS"],"term_type":"PT"},{"nm":"Cerebral meninges","n_c":["C12349"],"i_c":"C70.0","i_c_s":["Cerebral meninges"],"term_type":"PT"},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"C71.0","i_c_s":["Cerebrum"],"term_type":"PT"},{"nm":"Cervical esophagus","n_c":["C12250"],"i_c":"C15.0","i_c_s":["Cervical esophagus"],"term_type":"PT"},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"C53.9","i_c_s":["Cervix uteri"],"term_type":"PT"},{"nm":"Cheek mucosa","n_c":["C12505"],"i_c":"C06.0","i_c_s":["Cheek mucosa"],"term_type":"PT"},{"nm":"Choroid","n_c":["C12344"],"i_c":"C69.3","i_c_s":["Choroid"],"term_type":"PT"},{"nm":"Ciliary body","n_c":["C12345"],"i_c":"C69.4","i_c_s":["Ciliary body"],"term_type":"PT"},{"nm":"Clitoris","n_c":["C12308"],"i_c":"C51.2","i_c_s":["Clitoris"],"term_type":"PT"},{"nm":"Cloacogenic zone","n_c":["C32072"],"i_c":"C21.2","i_c_s":["Cloacogenic zone"],"term_type":"PT"},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"C18.9","i_c_s":["Colon, NOS"],"term_type":"PT"},{"nm":"Commissure of lip","n_c":["C12227"],"i_c":"C00.6","i_c_s":["Commissure of lip"],"term_type":"PT"},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"C69.0","i_c_s":["Conjunctiva"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of abdomen","n_c":"","i_c":"C49.4","i_c_s":["Connective, subcutaneous and other soft tissues of abdomen"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of head, face, and neck","n_c":"","i_c":"C49.0","i_c_s":["Connective, subcutaneous and other soft tissues of head, face, and neck"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of lower limb and hip","n_c":"","i_c":"C49.2","i_c_s":["Connective, subcutaneous and other soft tissues of lower limb and hip"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of pelvis","n_c":"","i_c":"C49.5","i_c_s":["Connective, subcutaneous and other soft tissues of pelvis"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of thorax","n_c":"","i_c":"C49.3","i_c_s":["Connective, subcutaneous and other soft tissues of thorax"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of trunk, NOS","n_c":"","i_c":"C49.6","i_c_s":["Connective, subcutaneous and other soft tissues of trunk, NOS"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of upper limb and shoulder","n_c":"","i_c":"C49.1","i_c_s":["Connective, subcutaneous and other soft tissues of upper limb and shoulder"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues, NOS","n_c":["C12964"],"i_c":"C49.9","i_c_s":["Connective, subcutaneous and other soft tissues, NOS"],"term_type":"PT"},{"nm":"Cornea, NOS","n_c":["C12342"],"i_c":"C69.1","i_c_s":["Cornea, NOS"],"term_type":"PT"},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"C54.9","i_c_s":["Corpus uteri"],"term_type":"PT"},{"nm":"Cortex of adrenal gland","n_c":["C12396"],"i_c":"C74.0","i_c_s":["Cortex of adrenal gland"],"term_type":"PT"},{"nm":"Cranial nerve, NOS","n_c":["C12700"],"i_c":"C72.5","i_c_s":["Cranial nerve, NOS"],"term_type":"PT"},{"nm":"Craniopharyngeal duct","n_c":["C12357"],"i_c":"C75.2","i_c_s":["Craniopharyngeal duct"],"term_type":"PT"},{"nm":"Descended testis","n_c":"","i_c":"C62.1","i_c_s":["Descended testis"],"term_type":"PT"},{"nm":"Descending colon","n_c":["C12268"],"i_c":"C18.6","i_c_s":["Descending colon"],"term_type":"PT"},{"nm":"Dome of bladder","n_c":["C12332"],"i_c":"C67.1","i_c_s":["Dome of bladder"],"term_type":"PT"},{"nm":"Dorsal surface of tongue, NOS","n_c":"","i_c":"C02.0","i_c_s":["Dorsal surface of tongue, NOS"],"term_type":"PT"},{"nm":"Duodenum","n_c":["C12263"],"i_c":"C17.0","i_c_s":["Duodenum"],"term_type":"PT"},{"nm":"Endocervix","n_c":["C12309"],"i_c":"C53.0","i_c_s":["Endocervix"],"term_type":"PT"},{"nm":"Endocrine gland, NOS","n_c":["C12704"],"i_c":"C75.9","i_c_s":["Endocrine gland, NOS"],"term_type":"PT"},{"nm":"Endometrium","n_c":["C12313"],"i_c":"C54.1","i_c_s":["Endometrium"],"term_type":"PT"},{"nm":"Epididymis","n_c":["C12328"],"i_c":"C63.0","i_c_s":["Epididymis"],"term_type":"PT"},{"nm":"Esophagus, NOS","n_c":["C12389"],"i_c":"C15.9","i_c_s":["Esophagus, NOS"],"term_type":"PT"},{"nm":"Ethmoid sinus","n_c":["C12276"],"i_c":"C31.1","i_c_s":["Ethmoid sinus"],"term_type":"PT"},{"nm":"Exocervix","n_c":["C12310"],"i_c":"C53.1","i_c_s":["Exocervix"],"term_type":"PT"},{"nm":"External ear","n_c":["C12292"],"i_c":"C44.2","i_c_s":["External ear"],"term_type":"PT"},{"nm":"External lip, NOS","n_c":["C12223"],"i_c":"C00.2","i_c_s":["External lip, NOS"],"term_type":"PT"},{"nm":"External lower lip","n_c":["C12222"],"i_c":"C00.1","i_c_s":["External lower lip"],"term_type":"PT"},{"nm":"External upper lip","n_c":["C12221"],"i_c":"C00.0","i_c_s":["External upper lip"],"term_type":"PT"},{"nm":"Extrahepatic bile duct","n_c":["C32573"],"i_c":"C24.0","i_c_s":["Extrahepatic bile duct"],"term_type":"PT"},{"nm":"Eye, NOS","n_c":["C12401"],"i_c":"C69.9","i_c_s":["Eye, NOS"],"term_type":"PT"},{"nm":"Eyelid","n_c":["C12713"],"i_c":"C44.1","i_c_s":["Eyelid"],"term_type":"PT"},{"nm":"Fallopian tube","n_c":["C12403"],"i_c":"C57.0","i_c_s":["Fallopian tube"],"term_type":"PT"},{"nm":"Female genital tract, NOS","n_c":["C61600"],"i_c":"C57.9","i_c_s":["Female genital tract, NOS"],"term_type":"PT"},{"nm":"Floor of mouth, NOS","n_c":["C54187"],"i_c":"C04.9","i_c_s":["Floor of mouth, NOS"],"term_type":"PT"},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"C71.1","i_c_s":["Frontal lobe"],"term_type":"PT"},{"nm":"Frontal sinus","n_c":["C12277"],"i_c":"C31.2","i_c_s":["Frontal sinus"],"term_type":"PT"},{"nm":"Fundus of stomach","n_c":["C12257"],"i_c":"C16.1","i_c_s":["Fundus of stomach"],"term_type":"PT"},{"nm":"Fundus uteri","n_c":["C12315"],"i_c":"C54.3","i_c_s":["Fundus uteri"],"term_type":"PT"},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"C23.9","i_c_s":["Gallbladder"],"term_type":"PT"},{"nm":"Gastric antrum","n_c":["C12259"],"i_c":"C16.3","i_c_s":["Gastric antrum"],"term_type":"PT"},{"nm":"Gastrointestinal tract, NOS","n_c":["C34082"],"i_c":"C26.9","i_c_s":["Gastrointestinal tract, NOS"],"term_type":"PT"},{"nm":"Glans penis","n_c":["C12324"],"i_c":"C60.1","i_c_s":["Glans penis"],"term_type":"PT"},{"nm":"Glottis","n_c":["C12724"],"i_c":"C32.0","i_c_s":["Glottis"],"term_type":"PT"},{"nm":"Greater curvature of stomach, NOS","n_c":["C12262"],"i_c":"C16.6","i_c_s":["Greater curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Gum, NOS","n_c":["C32677"],"i_c":"C03.9","i_c_s":["Gum, NOS"],"term_type":"PT"},{"nm":"Hard palate","n_c":["C12230"],"i_c":"C05.0","i_c_s":["Hard palate"],"term_type":"PT"},{"nm":"Head of pancreas","n_c":["C12269"],"i_c":"C25.0","i_c_s":["Head of pancreas"],"term_type":"PT"},{"nm":"Head, face or neck, NOS","n_c":"","i_c":"C76.0","i_c_s":["Head, face or neck, NOS"],"term_type":"PT"},{"nm":"Heart","n_c":["C12727"],"i_c":"C38.0","i_c_s":["Heart"],"term_type":"PT"},{"nm":"Hematopoietic system, NOS","n_c":["C12909"],"i_c":"C42.4","i_c_s":["Hematopoietic system, NOS"],"term_type":"PT"},{"nm":"Hepatic flexure of colon","n_c":["C12266"],"i_c":"C18.3","i_c_s":["Hepatic flexure of colon"],"term_type":"PT"},{"nm":"Hypopharyngeal aspect of aryepiglottic fold","n_c":"","i_c":"C13.1","i_c_s":["Hypopharyngeal aspect of aryepiglottic fold"],"term_type":"PT"},{"nm":"Hypopharynx, NOS","n_c":["C12246"],"i_c":"C13.9","i_c_s":["Hypopharynx, NOS"],"term_type":"PT"},{"nm":"Ileum","n_c":["C12387"],"i_c":"C17.2","i_c_s":["Ileum"],"term_type":"PT"},{"nm":"Ill-defined sites within respiratory system","n_c":["C148338"],"i_c":"C39.9","i_c_s":["Ill-defined sites within respiratory system"],"term_type":"PT"},{"nm":"Intestinal tract, NOS","n_c":["C12736"],"i_c":"C26.0","i_c_s":["Intestinal tract, NOS"],"term_type":"PT"},{"nm":"Intra-abdominal lymph nodes","n_c":["C12360"],"i_c":"C77.2","i_c_s":["Intra-abdominal lymph nodes"],"term_type":"PT"},{"nm":"Intrahepatic bile duct","n_c":["C12677"],"i_c":"C22.1","i_c_s":["Intrahepatic bile duct"],"term_type":"PT"},{"nm":"Intrathoracic lymph nodes","n_c":["C12359"],"i_c":"C77.1","i_c_s":["Intrathoracic lymph nodes"],"term_type":"PT"},{"nm":"Islets of Langerhans","n_c":["C12608"],"i_c":"C25.4","i_c_s":["Islets of Langerhans"],"term_type":"PT"},{"nm":"Isthmus uteri","n_c":["C12312"],"i_c":"C54.0","i_c_s":["Isthmus uteri"],"term_type":"PT"},{"nm":"Jejunum","n_c":["C12388"],"i_c":"C17.1","i_c_s":["Jejunum"],"term_type":"PT"},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"C64.9","i_c_s":["Kidney, NOS"],"term_type":"PT"},{"nm":"Labium majus","n_c":["C12306"],"i_c":"C51.0","i_c_s":["Labium majus"],"term_type":"PT"},{"nm":"Labium minus","n_c":["C12307"],"i_c":"C51.1","i_c_s":["Labium minus"],"term_type":"PT"},{"nm":"Lacrimal gland","n_c":["C12346"],"i_c":"C69.5","i_c_s":["Lacrimal gland"],"term_type":"PT"},{"nm":"Laryngeal cartilage","n_c":["C12281"],"i_c":"C32.3","i_c_s":["Laryngeal cartilage"],"term_type":"PT"},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"C32.9","i_c_s":["Larynx, NOS"],"term_type":"PT"},{"nm":"Lateral floor of mouth","n_c":"","i_c":"C04.1","i_c_s":["Lateral floor of mouth"],"term_type":"PT"},{"nm":"Lateral wall of bladder","n_c":["C12333"],"i_c":"C67.2","i_c_s":["Lateral wall of bladder"],"term_type":"PT"},{"nm":"Lateral wall of nasopharynx","n_c":["C12244"],"i_c":"C11.2","i_c_s":["Lateral wall of nasopharynx"],"term_type":"PT"},{"nm":"Lateral wall of oropharynx","n_c":["C12239"],"i_c":"C10.2","i_c_s":["Lateral wall of oropharynx"],"term_type":"PT"},{"nm":"Lesser curvature of stomach, NOS","n_c":["C12261"],"i_c":"C16.5","i_c_s":["Lesser curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Lingual tonsil","n_c":["C32988"],"i_c":"C02.4","i_c_s":["Lingual tonsil"],"term_type":"PT"},{"nm":"Lip, NOS","n_c":["C12220"],"i_c":"C00.9","i_c_s":["Lip, NOS"],"term_type":"PT"},{"nm":"Liver","n_c":["C12392"],"i_c":"C22.0","i_c_s":["Liver"],"term_type":"PT"},{"nm":"Long bones of lower limb and associated joints","n_c":"","i_c":"C40.2","i_c_s":["Long bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Long bones of upper limb, scapula and associated joints","n_c":"","i_c":"C40.0","i_c_s":["Long bones of upper limb, scapula and associated joints"],"term_type":"PT"},{"nm":"Lower gum","n_c":["C54204"],"i_c":"C03.1","i_c_s":["Lower gum"],"term_type":"PT"},{"nm":"Lower limb, NOS","n_c":["C12742"],"i_c":"C76.5","i_c_s":["Lower limb, NOS"],"term_type":"PT"},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"C34.3","i_c_s":["Lower lobe, lung"],"term_type":"PT"},{"nm":"Lower third of esophagus","n_c":["C12255"],"i_c":"C15.5","i_c_s":["Lower third of esophagus"],"term_type":"PT"},{"nm":"Lower-inner quadrant of breast","n_c":["C12302"],"i_c":"C50.3","i_c_s":["Lower-inner quadrant of breast"],"term_type":"PT"},{"nm":"Lower-outer quadrant of breast","n_c":["C12304"],"i_c":"C50.5","i_c_s":["Lower-outer quadrant of breast"],"term_type":"PT"},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"C34.9","i_c_s":["Lung, NOS"],"term_type":"PT"},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"C77.9","i_c_s":["Lymph node, NOS"],"term_type":"PT"},{"nm":"Lymph nodes of axilla or arm","n_c":["C12904"],"i_c":"C77.3","i_c_s":["Lymph nodes of axilla or arm"],"term_type":"PT"},{"nm":"Lymph nodes of head, face and neck","n_c":["C12358"],"i_c":"C77.0","i_c_s":["Lymph nodes of head, face and neck"],"term_type":"PT"},{"nm":"Lymph nodes of inguinal region or leg","n_c":["C12362"],"i_c":"C77.4","i_c_s":["Lymph nodes of inguinal region or leg"],"term_type":"PT"},{"nm":"Lymph nodes of multiple regions","n_c":"","i_c":"C77.8","i_c_s":["Lymph nodes of multiple regions"],"term_type":"PT"},{"nm":"Main bronchus","n_c":["C12284"],"i_c":"C34.0","i_c_s":["Main bronchus"],"term_type":"PT"},{"nm":"Major salivary gland, NOS","n_c":["C12426"],"i_c":"C08.9","i_c_s":["Major salivary gland, NOS"],"term_type":"PT"},{"nm":"Male genital organs, NOS","n_c":["C61599"],"i_c":"C63.9","i_c_s":["Male genital organs, NOS"],"term_type":"PT"},{"nm":"Mandible","n_c":["C12290"],"i_c":"C41.1","i_c_s":["Mandible"],"term_type":"PT"},{"nm":"Maxillary sinus","n_c":["C12275"],"i_c":"C31.0","i_c_s":["Maxillary sinus"],"term_type":"PT"},{"nm":"Meckel diverticulum","n_c":["C12264"],"i_c":"C17.3","i_c_s":["Meckel diverticulum"],"term_type":"PT"},{"nm":"Mediastinum, NOS","n_c":["C12748"],"i_c":"C38.3","i_c_s":["Mediastinum, NOS"],"term_type":"PT"},{"nm":"Medulla of adrenal gland","n_c":["C12397"],"i_c":"C74.1","i_c_s":["Medulla of adrenal gland"],"term_type":"PT"},{"nm":"Meninges, NOS","n_c":["C12348"],"i_c":"C70.9","i_c_s":["Meninges, NOS"],"term_type":"PT"},{"nm":"Middle ear","n_c":["C12274"],"i_c":"C30.1","i_c_s":["Middle ear"],"term_type":"PT"},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"C34.2","i_c_s":["Middle lobe, lung"],"term_type":"PT"},{"nm":"Middle third of esophagus","n_c":["C12254"],"i_c":"C15.4","i_c_s":["Middle third of esophagus"],"term_type":"PT"},{"nm":"Mouth, NOS","n_c":["C12421"],"i_c":"C06.9","i_c_s":["Mouth, NOS"],"term_type":"PT"},{"nm":"Mucosa of lip, NOS","n_c":["C12226"],"i_c":"C00.5","i_c_s":["Mucosa of lip, NOS"],"term_type":"PT"},{"nm":"Mucosa of lower lip","n_c":["C12225"],"i_c":"C00.4","i_c_s":["Mucosa of lower lip"],"term_type":"PT"},{"nm":"Mucosa of upper lip","n_c":["C12224"],"i_c":"C00.3","i_c_s":["Mucosa of upper lip"],"term_type":"PT"},{"nm":"Myometrium","n_c":["C12314"],"i_c":"C54.2","i_c_s":["Myometrium"],"term_type":"PT"},{"nm":"Nasal cavity","n_c":["C12424"],"i_c":"C30.0","i_c_s":["Nasal cavity"],"term_type":"PT"},{"nm":"Nasopharynx, NOS","n_c":["C12423"],"i_c":"C11.9","i_c_s":["Nasopharynx, NOS"],"term_type":"PT"},{"nm":"Nervous system, NOS","n_c":["C12755"],"i_c":"C72.9","i_c_s":["Nervous system, NOS"],"term_type":"PT"},{"nm":"Nipple","n_c":["C12299"],"i_c":"C50.0","i_c_s":["Nipple"],"term_type":"PT"},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"C71.4","i_c_s":["Occipital lobe"],"term_type":"PT"},{"nm":"Olfactory nerve","n_c":["C12759"],"i_c":"C72.2","i_c_s":["Olfactory nerve"],"term_type":"PT"},{"nm":"Optic nerve","n_c":["C12761"],"i_c":"C72.3","i_c_s":["Optic nerve"],"term_type":"PT"},{"nm":"Orbit, NOS","n_c":["C12347"],"i_c":"C69.6","i_c_s":["Orbit, NOS"],"term_type":"PT"},{"nm":"Oropharynx, NOS","n_c":["C12762"],"i_c":"C10.9","i_c_s":["Oropharynx, NOS"],"term_type":"PT"},{"nm":"Other ill-defined sites","n_c":["C147919"],"i_c":"C76.7","i_c_s":["Other ill-defined sites"],"term_type":"PT"},{"nm":"Other specified parts of female genital organs","n_c":["C148339"],"i_c":"C57.7","i_c_s":["Other specified parts of female genital organs"],"term_type":"PT"},{"nm":"Other specified parts of male genital organs","n_c":["C148341"],"i_c":"C63.7","i_c_s":["Other specified parts of male genital organs"],"term_type":"PT"},{"nm":"Other specified parts of pancreas","n_c":["C12273"],"i_c":"C25.7","i_c_s":["Other specified parts of pancreas"],"term_type":"PT"},{"nm":"Ovary","n_c":["C12404"],"i_c":"C56.9","i_c_s":["Ovary"],"term_type":"PT"},{"nm":"Overlapping lesion of accessory sinuses","n_c":"","i_c":"C31.8","i_c_s":["Overlapping lesion of accessory sinuses"],"term_type":"PT"},{"nm":"Overlapping lesion of biliary tract","n_c":"","i_c":"C24.8","i_c_s":["Overlapping lesion of biliary tract"],"term_type":"PT"},{"nm":"Overlapping lesion of bladder","n_c":"","i_c":"C67.8","i_c_s":["Overlapping lesion of bladder"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage","n_c":"","i_c":"C41.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage of limbs","n_c":"","i_c":"C40.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage of limbs"],"term_type":"PT"},{"nm":"Overlapping lesion of brain","n_c":"","i_c":"C71.8","i_c_s":["Overlapping lesion of brain"],"term_type":"PT"},{"nm":"Overlapping lesion of brain and central nervous system","n_c":"","i_c":"C72.8","i_c_s":["Overlapping lesion of brain and central nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of breast","n_c":"","i_c":"C50.8","i_c_s":["Overlapping lesion of breast"],"term_type":"PT"},{"nm":"Overlapping lesion of cervix uteri","n_c":"","i_c":"C53.8","i_c_s":["Overlapping lesion of cervix uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of colon","n_c":"","i_c":"C18.8","i_c_s":["Overlapping lesion of colon"],"term_type":"PT"},{"nm":"Overlapping lesion of connective, subcutaneous and other soft tissues","n_c":"","i_c":"C49.8","i_c_s":["Overlapping lesion of connective, subcutaneous and other soft tissues"],"term_type":"PT"},{"nm":"Overlapping lesion of corpus uteri","n_c":"","i_c":"C54.8","i_c_s":["Overlapping lesion of corpus uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of digestive system","n_c":"","i_c":"C26.8","i_c_s":["Overlapping lesion of digestive system"],"term_type":"PT"},{"nm":"Overlapping lesion of endocrine glands and related structures","n_c":"","i_c":"C75.8","i_c_s":["Overlapping lesion of endocrine glands and related structures"],"term_type":"PT"},{"nm":"Overlapping lesion of esophagus","n_c":"","i_c":"C15.8","i_c_s":["Overlapping lesion of esophagus"],"term_type":"PT"},{"nm":"Overlapping lesion of eye and adnexa","n_c":"","i_c":"C69.8","i_c_s":["Overlapping lesion of eye and adnexa"],"term_type":"PT"},{"nm":"Overlapping lesion of female genital organs","n_c":"","i_c":"C57.8","i_c_s":["Overlapping lesion of female genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of floor of mouth","n_c":"","i_c":"C04.8","i_c_s":["Overlapping lesion of floor of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of heart, mediastinum and pleura","n_c":"","i_c":"C38.8","i_c_s":["Overlapping lesion of heart, mediastinum and pleura"],"term_type":"PT"},{"nm":"Overlapping lesion of hypopharynx","n_c":"","i_c":"C13.8","i_c_s":["Overlapping lesion of hypopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of ill-defined sites","n_c":"","i_c":"C76.8","i_c_s":["Overlapping lesion of ill-defined sites"],"term_type":"PT"},{"nm":"Overlapping lesion of larynx","n_c":"","i_c":"C32.8","i_c_s":["Overlapping lesion of larynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lip","n_c":"","i_c":"C00.8","i_c_s":["Overlapping lesion of lip"],"term_type":"PT"},{"nm":"Overlapping lesion of lip, oral cavity and pharynx","n_c":"","i_c":"C14.8","i_c_s":["Overlapping lesion of lip, oral cavity and pharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lung","n_c":"","i_c":"C34.8","i_c_s":["Overlapping lesion of lung"],"term_type":"PT"},{"nm":"Overlapping lesion of major salivary glands","n_c":"","i_c":"C08.8","i_c_s":["Overlapping lesion of major salivary glands"],"term_type":"PT"},{"nm":"Overlapping lesion of male genital organs","n_c":"","i_c":"C63.8","i_c_s":["Overlapping lesion of male genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of nasopharynx","n_c":"","i_c":"C11.8","i_c_s":["Overlapping lesion of nasopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of other and unspecified parts of mouth","n_c":"","i_c":"C06.8","i_c_s":["Overlapping lesion of other and unspecified parts of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of palate","n_c":"","i_c":"C05.8","i_c_s":["Overlapping lesion of palate"],"term_type":"PT"},{"nm":"Overlapping lesion of pancreas","n_c":"","i_c":"C25.8","i_c_s":["Overlapping lesion of pancreas"],"term_type":"PT"},{"nm":"Overlapping lesion of penis","n_c":"","i_c":"C60.8","i_c_s":["Overlapping lesion of penis"],"term_type":"PT"},{"nm":"Overlapping lesion of peripheral nerves and autonomic nervous system","n_c":"","i_c":"C47.8","i_c_s":["Overlapping lesion of peripheral nerves and autonomic nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of rectum, anus and anal canal","n_c":"","i_c":"C21.8","i_c_s":["Overlapping lesion of rectum, anus and anal canal"],"term_type":"PT"},{"nm":"Overlapping lesion of respiratory system and intrathoracic organs","n_c":"","i_c":"C39.8","i_c_s":["Overlapping lesion of respiratory system and intrathoracic organs"],"term_type":"PT"},{"nm":"Overlapping lesion of retroperitoneum and peritoneum","n_c":"","i_c":"C48.8","i_c_s":["Overlapping lesion of retroperitoneum and peritoneum"],"term_type":"PT"},{"nm":"Overlapping lesion of skin","n_c":"","i_c":"C44.8","i_c_s":["Overlapping lesion of skin"],"term_type":"PT"},{"nm":"Overlapping lesion of small intestine","n_c":"","i_c":"C17.8","i_c_s":["Overlapping lesion of small intestine"],"term_type":"PT"},{"nm":"Overlapping lesion of stomach","n_c":"","i_c":"C16.8","i_c_s":["Overlapping lesion of stomach"],"term_type":"PT"},{"nm":"Overlapping lesion of tongue","n_c":"","i_c":"C02.8","i_c_s":["Overlapping lesion of tongue"],"term_type":"PT"},{"nm":"Overlapping lesion of tonsil","n_c":"","i_c":"C09.8","i_c_s":["Overlapping lesion of tonsil"],"term_type":"PT"},{"nm":"Overlapping lesion of urinary organs","n_c":"","i_c":"C68.8","i_c_s":["Overlapping lesion of urinary organs"],"term_type":"PT"},{"nm":"Overlapping lesion of vulva","n_c":"","i_c":"C51.8","i_c_s":["Overlapping lesion of vulva"],"term_type":"PT"},{"nm":"Overlapping lesions of oropharynx","n_c":"","i_c":"C10.8","i_c_s":["Overlapping lesions of oropharynx"],"term_type":"PT"},{"nm":"Palate, NOS","n_c":["C12229"],"i_c":"C05.9","i_c_s":["Palate, NOS"],"term_type":"PT"},{"nm":"Pancreas, NOS","n_c":["C12393"],"i_c":"C25.9","i_c_s":["Pancreas, NOS"],"term_type":"PT"},{"nm":"Pancreatic duct","n_c":["C12272"],"i_c":"C25.3","i_c_s":["Pancreatic duct"],"term_type":"PT"},{"nm":"Pancreatic neck","n_c":["C158551"],"i_c":"C25.7","i_c_s":["Pancreatic neck"],"term_type":"RT"},{"nm":"Parametrium","n_c":["C12320"],"i_c":"C57.3","i_c_s":["Parametrium"],"term_type":"PT"},{"nm":"Parathyroid gland","n_c":["C12765"],"i_c":"C75.0","i_c_s":["Parathyroid gland"],"term_type":"PT"},{"nm":"Paraurethral gland","n_c":["C61122"],"i_c":"C68.1","i_c_s":["Paraurethral gland"],"term_type":"PT"},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"C71.3","i_c_s":["Parietal lobe"],"term_type":"PT"},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"C07.9","i_c_s":["Parotid gland"],"term_type":"PT"},{"nm":"Pelvic bones, sacrum, coccyx and associated joints","n_c":"","i_c":"C41.4","i_c_s":["Pelvic bones, sacrum, coccyx and associated joints"],"term_type":"PT"},{"nm":"Pelvic lymph nodes","n_c":["C12363"],"i_c":"C77.5","i_c_s":["Pelvic lymph nodes"],"term_type":"PT"},{"nm":"Pelvis, NOS","n_c":["C12767"],"i_c":"C76.3","i_c_s":["Pelvis, NOS"],"term_type":"PT"},{"nm":"Penis, NOS","n_c":["C12409"],"i_c":"C60.9","i_c_s":["Penis, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of abdomen","n_c":"","i_c":"C47.4","i_c_s":["Peripheral nerves and autonomic nervous system of abdomen"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of head, face, and neck","n_c":"","i_c":"C47.0","i_c_s":["Peripheral nerves and autonomic nervous system of head, face, and neck"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of lower limb and hip","n_c":"","i_c":"C47.2","i_c_s":["Peripheral nerves and autonomic nervous system of lower limb and hip"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of pelvis","n_c":"","i_c":"C47.5","i_c_s":["Peripheral nerves and autonomic nervous system of pelvis"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of thorax","n_c":"","i_c":"C47.3","i_c_s":["Peripheral nerves and autonomic nervous system of thorax"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of trunk, NOS","n_c":"","i_c":"C47.6","i_c_s":["Peripheral nerves and autonomic nervous system of trunk, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of upper limb and shoulder","n_c":"","i_c":"C47.1","i_c_s":["Peripheral nerves and autonomic nervous system of upper limb and shoulder"],"term_type":"PT"},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"C48.2","i_c_s":["Peritoneum, NOS"],"term_type":"PT"},{"nm":"Pharynx, NOS","n_c":["C12425"],"i_c":"C14.0","i_c_s":["Pharynx, NOS"],"term_type":"PT"},{"nm":"Pineal gland","n_c":["C12398"],"i_c":"C75.3","i_c_s":["Pineal gland"],"term_type":"PT"},{"nm":"Pituitary gland","n_c":["C12399"],"i_c":"C75.1","i_c_s":["Pituitary gland"],"term_type":"PT"},{"nm":"Placenta","n_c":["C13272"],"i_c":"C58.9","i_c_s":["Placenta"],"term_type":"PT"},{"nm":"Pleura, NOS","n_c":["C12469"],"i_c":"C38.4","i_c_s":["Pleura, NOS"],"term_type":"PT"},{"nm":"Postcricoid region","n_c":["C54221"],"i_c":"C13.0","i_c_s":["Postcricoid region"],"term_type":"PT"},{"nm":"Posterior mediastinum","n_c":["C33368"],"i_c":"C38.2","i_c_s":["Posterior mediastinum"],"term_type":"PT"},{"nm":"Posterior wall of bladder","n_c":["C12335"],"i_c":"C67.4","i_c_s":["Posterior wall of bladder"],"term_type":"PT"},{"nm":"Posterior wall of hypopharynx","n_c":["C12249"],"i_c":"C13.2","i_c_s":["Posterior wall of hypopharynx"],"term_type":"PT"},{"nm":"Posterior wall of nasopharynx","n_c":["C12243"],"i_c":"C11.1","i_c_s":["Posterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Posterior wall of oropharynx","n_c":["C12240"],"i_c":"C10.3","i_c_s":["Posterior wall of oropharynx"],"term_type":"PT"},{"nm":"Prepuce","n_c":["C12323"],"i_c":"C60.0","i_c_s":["Prepuce"],"term_type":"PT"},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"C61.9","i_c_s":["Prostate gland"],"term_type":"PT"},{"nm":"Pylorus","n_c":["C12260"],"i_c":"C16.4","i_c_s":["Pylorus"],"term_type":"PT"},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"C12.9","i_c_s":["Pyriform sinus"],"term_type":"PT"},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"C19.9","i_c_s":["Rectosigmoid junction"],"term_type":"PT"},{"nm":"Rectum, NOS","n_c":["C12390"],"i_c":"C20.9","i_c_s":["Rectum, NOS"],"term_type":"PT"},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"C65.9","i_c_s":["Renal pelvis"],"term_type":"PT"},{"nm":"Reticuloendothelial system, NOS","n_c":["C12780"],"i_c":"C42.3","i_c_s":["Reticuloendothelial system, NOS"],"term_type":"PT"},{"nm":"Retina","n_c":["C12343"],"i_c":"C69.2","i_c_s":["Retina"],"term_type":"PT"},{"nm":"Retromolar area","n_c":["C54223"],"i_c":"C06.2","i_c_s":["Retromolar area"],"term_type":"PT"},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"C48.0","i_c_s":["Retroperitoneum"],"term_type":"PT"},{"nm":"Rib, sternum, clavicle and associated joints","n_c":"","i_c":"C41.3","i_c_s":["Rib, sternum, clavicle and associated joints"],"term_type":"PT"},{"nm":"Round ligament","n_c":["C12319"],"i_c":"C57.2","i_c_s":["Round ligament"],"term_type":"PT"},{"nm":"Scrotum, NOS","n_c":["C12785"],"i_c":"C63.2","i_c_s":["Scrotum, NOS"],"term_type":"PT"},{"nm":"Short bones of lower limb and associated joints","n_c":"","i_c":"C40.3","i_c_s":["Short bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Short bones of upper limb and associated joints","n_c":"","i_c":"C40.1","i_c_s":["Short bones of upper limb and associated joints"],"term_type":"PT"},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"C18.7","i_c_s":["Sigmoid colon"],"term_type":"PT"},{"nm":"Skin of lip, NOS","n_c":["C12291"],"i_c":"C44.0","i_c_s":["Skin of lip, NOS"],"term_type":"PT"},{"nm":"Skin of lower limb and hip","n_c":["C12297"],"i_c":"C44.7","i_c_s":["Skin of lower limb and hip"],"term_type":"PT"},{"nm":"Skin of other and unspecified parts of face","n_c":["C33561"],"i_c":"C44.3","i_c_s":["Skin of other and unspecified parts of face"],"term_type":"PT"},{"nm":"Skin of scalp and neck","n_c":["C12294"],"i_c":"C44.4","i_c_s":["Skin of scalp and neck"],"term_type":"PT"},{"nm":"Skin of trunk","n_c":["C12295"],"i_c":"C44.5","i_c_s":["Skin of trunk"],"term_type":"RT"},{"nm":"Skin of upper limb and shoulder","n_c":["C12296"],"i_c":"C44.6","i_c_s":["Skin of upper limb and shoulder"],"term_type":"PT"},{"nm":"Skin, NOS","n_c":["C12470"],"i_c":"C44.9","i_c_s":["Skin, NOS"],"term_type":"PT"},{"nm":"Small intestine, NOS","n_c":["C12386"],"i_c":"C17.9","i_c_s":["Small intestine, NOS"],"term_type":"PT"},{"nm":"Soft palate, NOS","n_c":["C12231"],"i_c":"C05.1","i_c_s":["Soft palate, NOS"],"term_type":"PT"},{"nm":"Specified parts of peritoneum","n_c":"","i_c":"C48.1","i_c_s":["Specified parts of peritoneum"],"term_type":"PT"},{"nm":"Spermatic cord","n_c":["C12329"],"i_c":"C63.1","i_c_s":["Spermatic cord"],"term_type":"PT"},{"nm":"Sphenoid sinus","n_c":["C12278"],"i_c":"C31.3","i_c_s":["Sphenoid sinus"],"term_type":"PT"},{"nm":"Spinal cord","n_c":["C12464"],"i_c":"C72.0","i_c_s":["Spinal cord"],"term_type":"PT"},{"nm":"Spinal meninges","n_c":["C12350"],"i_c":"C70.1","i_c_s":["Spinal meninges"],"term_type":"PT"},{"nm":"Spleen","n_c":["C12432"],"i_c":"C42.2","i_c_s":["Spleen"],"term_type":"PT"},{"nm":"Splenic flexure of colon","n_c":["C12267"],"i_c":"C18.5","i_c_s":["Splenic flexure of colon"],"term_type":"PT"},{"nm":"Stomach, NOS","n_c":["C12391"],"i_c":"C16.9","i_c_s":["Stomach, NOS"],"term_type":"PT"},{"nm":"Subglottis","n_c":["C12280"],"i_c":"C32.2","i_c_s":["Subglottis"],"term_type":"PT"},{"nm":"Sublingual gland","n_c":["C12234"],"i_c":"C08.1","i_c_s":["Sublingual gland"],"term_type":"PT"},{"nm":"Submandibular gland","n_c":["C12233"],"i_c":"C08.0","i_c_s":["Submandibular gland"],"term_type":"PT"},{"nm":"Superior wall of nasopharynx","n_c":["C12242"],"i_c":"C11.0","i_c_s":["Superior wall of nasopharynx"],"term_type":"PT"},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"C32.1","i_c_s":["Supraglottis"],"term_type":"PT"},{"nm":"Tail of pancreas","n_c":["C12271"],"i_c":"C25.2","i_c_s":["Tail of pancreas"],"term_type":"PT"},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"C71.2","i_c_s":["Temporal lobe"],"term_type":"PT"},{"nm":"Testis, NOS","n_c":["C12412"],"i_c":"C62.9","i_c_s":["Testis, NOS"],"term_type":"PT"},{"nm":"Thoracic esophagus","n_c":["C12251"],"i_c":"C15.1","i_c_s":["Thoracic esophagus"],"term_type":"PT"},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"C76.1","i_c_s":["Thorax, NOS"],"term_type":"PT"},{"nm":"Thymus","n_c":["C12433"],"i_c":"C37.9","i_c_s":["Thymus"],"term_type":"PT"},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"C73.9","i_c_s":["Thyroid gland"],"term_type":"PT"},{"nm":"Tongue, NOS","n_c":["C12422"],"i_c":"C02.9","i_c_s":["Tongue, NOS"],"term_type":"PT"},{"nm":"Tonsil, NOS","n_c":["C33250"],"i_c":"C09.9","i_c_s":["Tonsil, NOS"],"term_type":"PT"},{"nm":"Tonsillar fossa","n_c":["C12235"],"i_c":"C09.0","i_c_s":["Tonsillar fossa"],"term_type":"PT"},{"nm":"Tonsillar pillar","n_c":["C12236"],"i_c":"C09.1","i_c_s":["Tonsillar pillar"],"term_type":"PT"},{"nm":"Trachea","n_c":["C12428"],"i_c":"C33.9","i_c_s":["Trachea"],"term_type":"PT"},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"C18.4","i_c_s":["Transverse colon"],"term_type":"PT"},{"nm":"Trigone of bladder","n_c":["C12331"],"i_c":"C67.0","i_c_s":["Trigone of bladder"],"term_type":"PT"},{"nm":"Undescended testis","n_c":["C12326"],"i_c":"C62.0","i_c_s":["Undescended testis"],"term_type":"PT"},{"nm":"Unknown primary site","n_c":["C48322"],"i_c":"C80.9","i_c_s":["Unknown primary site"],"term_type":"PT"},{"nm":"Upper gum","n_c":["C54205"],"i_c":"C03.0","i_c_s":["Upper gum"],"term_type":"PT"},{"nm":"Upper limb, NOS","n_c":["C12671"],"i_c":"C76.4","i_c_s":["Upper limb, NOS"],"term_type":"PT"},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"C34.1","i_c_s":["Upper lobe, lung"],"term_type":"PT"},{"nm":"Upper respiratory tract, NOS","n_c":["C33839"],"i_c":"C39.0","i_c_s":["Upper respiratory tract, NOS"],"term_type":"PT"},{"nm":"Upper third of esophagus","n_c":["C12253"],"i_c":"C15.3","i_c_s":["Upper third of esophagus"],"term_type":"PT"},{"nm":"Upper-inner quadrant of breast","n_c":["C12301"],"i_c":"C50.2","i_c_s":["Upper-inner quadrant of breast"],"term_type":"PT"},{"nm":"Upper-outer quadrant of breast","n_c":["C12303"],"i_c":"C50.4","i_c_s":["Upper-outer quadrant of breast"],"term_type":"PT"},{"nm":"Urachus","n_c":["C12338"],"i_c":"C67.7","i_c_s":["Urachus"],"term_type":"PT"},{"nm":"Ureter","n_c":["C12416"],"i_c":"C66.9","i_c_s":["Ureter"],"term_type":"PT"},{"nm":"Ureteric orifice","n_c":["C12337"],"i_c":"C67.6","i_c_s":["Ureteric orifice"],"term_type":"PT"},{"nm":"Urethra","n_c":["C12417"],"i_c":"C68.0","i_c_s":["Urethra"],"term_type":"PT"},{"nm":"Urinary system, NOS","n_c":["C12413"],"i_c":"C68.9","i_c_s":["Urinary system, NOS"],"term_type":"PT"},{"nm":"Uterine adnexa","n_c":["C12321"],"i_c":"C57.4","i_c_s":["Uterine adnexa"],"term_type":"PT"},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"C55.9","i_c_s":["Uterus, NOS"],"term_type":"PT"},{"nm":"Uvula","n_c":["C12232"],"i_c":"C05.2","i_c_s":["Uvula"],"term_type":"PT"},{"nm":"Vagina, NOS","n_c":["C12407"],"i_c":"C52.9","i_c_s":["Vagina, NOS"],"term_type":"PT"},{"nm":"Vallecula","n_c":["C12237"],"i_c":"C10.0","i_c_s":["Vallecula"],"term_type":"PT"},{"nm":"Ventral surface of tongue, NOS","n_c":"","i_c":"C02.2","i_c_s":["Ventral surface of tongue, NOS"],"term_type":"PT"},{"nm":"Ventricle, NOS","n_c":["C12356"],"i_c":"C71.5","i_c_s":["Ventricle, NOS"],"term_type":"PT"},{"nm":"Vertebral column","n_c":["C12998"],"i_c":"C41.2","i_c_s":["Vertebral column"],"term_type":"PT"},{"nm":"Vestibule of mouth","n_c":["C165195"],"i_c":"C06.1","i_c_s":["Vestibule of mouth"],"term_type":"PT"},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"C51.9","i_c_s":["Vulva, NOS"],"term_type":"PT"},{"nm":"Waldeyer ring","n_c":["C73468"],"i_c":"C14.2","i_c_s":["Waldeyer ring"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.supratentorial_localization":[{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Gray (e.g. Basal Ganglia, Thalamus)","n_c":["C158080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Matter","n_c":["C33892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.synchronous_malignancy":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tissue_or_organ_of_origin":[{"nm":"Abdomen, NOS","n_c":["C12664"],"i_c":"C76.2","i_c_s":["Abdomen, NOS"],"term_type":"PT"},{"nm":"Abdominal esophagus","n_c":["C12252"],"i_c":"C15.2","i_c_s":["Abdominal esophagus"],"term_type":"PT"},{"nm":"Accessory sinus, NOS","n_c":["C12763"],"i_c":"C31.9","i_c_s":["Accessory sinus, NOS"],"term_type":"PT"},{"nm":"Acoustic nerve","n_c":["C12697"],"i_c":"C72.4","i_c_s":["Acoustic nerve"],"term_type":"PT"},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"C74.9","i_c_s":["Adrenal gland, NOS"],"term_type":"PT"},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"C24.1","i_c_s":["Ampulla of Vater"],"term_type":"PT"},{"nm":"Anal canal","n_c":["C12375"],"i_c":"C21.1","i_c_s":["Anal canal"],"term_type":"PT"},{"nm":"Anterior 2/3 of tongue, NOS","n_c":"","i_c":"C02.3","i_c_s":["Anterior 2/3 of tongue, NOS"],"term_type":"PT"},{"nm":"Anterior floor of mouth","n_c":"","i_c":"C04.0","i_c_s":["Anterior floor of mouth"],"term_type":"PT"},{"nm":"Anterior mediastinum","n_c":["C32098"],"i_c":"C38.1","i_c_s":["Anterior mediastinum"],"term_type":"PT"},{"nm":"Anterior surface of epiglottis","n_c":["C12238"],"i_c":"C10.1","i_c_s":["Anterior surface of epiglottis"],"term_type":"PT"},{"nm":"Anterior wall of bladder","n_c":["C12334"],"i_c":"C67.3","i_c_s":["Anterior wall of bladder"],"term_type":"PT"},{"nm":"Anterior wall of nasopharynx","n_c":["C12245"],"i_c":"C11.3","i_c_s":["Anterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"C21.0","i_c_s":["Anus, NOS"],"term_type":"PT"},{"nm":"Aortic body and other paraganglia","n_c":"","i_c":"C75.5","i_c_s":["Aortic body and other paraganglia"],"term_type":"PT"},{"nm":"Appendix","n_c":["C12380"],"i_c":"C18.1","i_c_s":["Appendix"],"term_type":"PT"},{"nm":"Ascending colon","n_c":["C12265"],"i_c":"C18.2","i_c_s":["Ascending colon"],"term_type":"PT"},{"nm":"Autonomic nervous system, NOS","n_c":["C12673"],"i_c":"C47.9","i_c_s":["Autonomic nervous system, NOS"],"term_type":"PT"},{"nm":"Axillary tail of breast","n_c":["C12305"],"i_c":"C50.6","i_c_s":["Axillary tail of breast"],"term_type":"PT"},{"nm":"Base of tongue, NOS","n_c":["C12228"],"i_c":"C01.9","i_c_s":["Base of tongue, NOS"],"term_type":"PT"},{"nm":"Biliary tract, NOS","n_c":["C12678"],"i_c":"C24.9","i_c_s":["Biliary tract, NOS"],"term_type":"PT"},{"nm":"Bladder neck","n_c":["C12336"],"i_c":"C67.5","i_c_s":["Bladder neck"],"term_type":"PT"},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"C67.9","i_c_s":["Bladder, NOS"],"term_type":"PT"},{"nm":"Blood","n_c":["C12434"],"i_c":"C42.0","i_c_s":["Blood"],"term_type":"PT"},{"nm":"Body of pancreas","n_c":["C12270"],"i_c":"C25.1","i_c_s":["Body of pancreas"],"term_type":"PT"},{"nm":"Body of penis","n_c":["C12325"],"i_c":"C60.2","i_c_s":["Body of penis"],"term_type":"PT"},{"nm":"Body of stomach","n_c":["C12258"],"i_c":"C16.2","i_c_s":["Body of stomach"],"term_type":"PT"},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"C42.1","i_c_s":["Bone marrow"],"term_type":"PT"},{"nm":"Bone of limb, NOS","n_c":["C32223"],"i_c":"C40.9","i_c_s":["Bone of limb, NOS"],"term_type":"PT"},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"C41.9","i_c_s":["Bone, NOS"],"term_type":"PT"},{"nm":"Bones of skull and face and associated joints","n_c":"","i_c":"C41.0","i_c_s":["Bones of skull and face and associated joints"],"term_type":"PT"},{"nm":"Border of tongue","n_c":"","i_c":"C02.1","i_c_s":["Border of tongue"],"term_type":"PT"},{"nm":"Brain stem","n_c":["C12441"],"i_c":"C71.7","i_c_s":["Brain stem"],"term_type":"PT"},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"C71.9","i_c_s":["Brain, NOS"],"term_type":"PT"},{"nm":"Branchial cleft","n_c":["C104813"],"i_c":"C10.4","i_c_s":["Branchial cleft"],"term_type":"PT"},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"C50.9","i_c_s":["Breast, NOS"],"term_type":"PT"},{"nm":"Broad ligament","n_c":["C12318"],"i_c":"C57.1","i_c_s":["Broad ligament"],"term_type":"PT"},{"nm":"Cardia, NOS","n_c":["C12256"],"i_c":"C16.0","i_c_s":["Cardia, NOS"],"term_type":"PT"},{"nm":"Carotid body","n_c":["C66852"],"i_c":"C75.4","i_c_s":["Carotid body"],"term_type":"PT"},{"nm":"Cauda equina","n_c":["C12689"],"i_c":"C72.1","i_c_s":["Cauda equina"],"term_type":"PT"},{"nm":"Cecum","n_c":["C12381"],"i_c":"C18.0","i_c_s":["Cecum"],"term_type":"PT"},{"nm":"Central portion of breast","n_c":["C12300"],"i_c":"C50.1","i_c_s":["Central portion of breast"],"term_type":"PT"},{"nm":"Cerebellum, NOS","n_c":["C12445"],"i_c":"C71.6","i_c_s":["Cerebellum, NOS"],"term_type":"PT"},{"nm":"Cerebral meninges","n_c":["C12349"],"i_c":"C70.0","i_c_s":["Cerebral meninges"],"term_type":"PT"},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"C71.0","i_c_s":["Cerebrum"],"term_type":"PT"},{"nm":"Cervical esophagus","n_c":["C12250"],"i_c":"C15.0","i_c_s":["Cervical esophagus"],"term_type":"PT"},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"C53.9","i_c_s":["Cervix uteri"],"term_type":"PT"},{"nm":"Cheek mucosa","n_c":["C12505"],"i_c":"C06.0","i_c_s":["Cheek mucosa"],"term_type":"PT"},{"nm":"Choroid","n_c":["C12344"],"i_c":"C69.3","i_c_s":["Choroid"],"term_type":"PT"},{"nm":"Ciliary body","n_c":["C12345"],"i_c":"C69.4","i_c_s":["Ciliary body"],"term_type":"PT"},{"nm":"Clitoris","n_c":["C12308"],"i_c":"C51.2","i_c_s":["Clitoris"],"term_type":"PT"},{"nm":"Cloacogenic zone","n_c":["C32072"],"i_c":"C21.2","i_c_s":["Cloacogenic zone"],"term_type":"PT"},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"C18.9","i_c_s":["Colon, NOS"],"term_type":"PT"},{"nm":"Commissure of lip","n_c":["C12227"],"i_c":"C00.6","i_c_s":["Commissure of lip"],"term_type":"PT"},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"C69.0","i_c_s":["Conjunctiva"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of abdomen","n_c":"","i_c":"C49.4","i_c_s":["Connective, subcutaneous and other soft tissues of abdomen"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of head, face, and neck","n_c":"","i_c":"C49.0","i_c_s":["Connective, subcutaneous and other soft tissues of head, face, and neck"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of lower limb and hip","n_c":"","i_c":"C49.2","i_c_s":["Connective, subcutaneous and other soft tissues of lower limb and hip"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of pelvis","n_c":"","i_c":"C49.5","i_c_s":["Connective, subcutaneous and other soft tissues of pelvis"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of thorax","n_c":"","i_c":"C49.3","i_c_s":["Connective, subcutaneous and other soft tissues of thorax"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of trunk, NOS","n_c":"","i_c":"C49.6","i_c_s":["Connective, subcutaneous and other soft tissues of trunk, NOS"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of upper limb and shoulder","n_c":"","i_c":"C49.1","i_c_s":["Connective, subcutaneous and other soft tissues of upper limb and shoulder"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues, NOS","n_c":["C12964"],"i_c":"C49.9","i_c_s":["Connective, subcutaneous and other soft tissues, NOS"],"term_type":""},{"nm":"Cornea, NOS","n_c":["C12342"],"i_c":"C69.1","i_c_s":["Cornea, NOS"],"term_type":"PT"},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"C54.9","i_c_s":["Corpus uteri"],"term_type":"PT"},{"nm":"Cortex of adrenal gland","n_c":["C12396"],"i_c":"C74.0","i_c_s":["Cortex of adrenal gland"],"term_type":"PT"},{"nm":"Cranial nerve, NOS","n_c":["C12700"],"i_c":"C72.5","i_c_s":["Cranial nerve, NOS"],"term_type":"PT"},{"nm":"Craniopharyngeal duct","n_c":["C12357"],"i_c":"C75.2","i_c_s":["Craniopharyngeal duct"],"term_type":"PT"},{"nm":"Descended testis","n_c":"","i_c":"C62.1","i_c_s":["Descended testis"],"term_type":"PT"},{"nm":"Descending colon","n_c":["C12268"],"i_c":"C18.6","i_c_s":["Descending colon"],"term_type":"PT"},{"nm":"Dome of bladder","n_c":["C12332"],"i_c":"C67.1","i_c_s":["Dome of bladder"],"term_type":"PT"},{"nm":"Dorsal surface of tongue, NOS","n_c":"","i_c":"C02.0","i_c_s":["Dorsal surface of tongue, NOS"],"term_type":"PT"},{"nm":"Duodenum","n_c":["C12263"],"i_c":"C17.0","i_c_s":["Duodenum"],"term_type":"PT"},{"nm":"Endocervix","n_c":["C12309"],"i_c":"C53.0","i_c_s":["Endocervix"],"term_type":"PT"},{"nm":"Endocrine gland, NOS","n_c":["C12704"],"i_c":"C75.9","i_c_s":["Endocrine gland, NOS"],"term_type":"PT"},{"nm":"Endometrium","n_c":["C12313"],"i_c":"C54.1","i_c_s":["Endometrium"],"term_type":"PT"},{"nm":"Epididymis","n_c":["C12328"],"i_c":"C63.0","i_c_s":["Epididymis"],"term_type":"PT"},{"nm":"Esophagus, NOS","n_c":["C12389"],"i_c":"C15.9","i_c_s":["Esophagus, NOS"],"term_type":"PT"},{"nm":"Ethmoid sinus","n_c":["C12276"],"i_c":"C31.1","i_c_s":["Ethmoid sinus"],"term_type":"PT"},{"nm":"Exocervix","n_c":["C12310"],"i_c":"C53.1","i_c_s":["Exocervix"],"term_type":"PT"},{"nm":"External ear","n_c":["C12292"],"i_c":"C44.2","i_c_s":["External ear"],"term_type":"PT"},{"nm":"External lip, NOS","n_c":["C12223"],"i_c":"C00.2","i_c_s":["External lip, NOS"],"term_type":"PT"},{"nm":"External lower lip","n_c":["C12222"],"i_c":"C00.1","i_c_s":["External lower lip"],"term_type":"PT"},{"nm":"External upper lip","n_c":["C12221"],"i_c":"C00.0","i_c_s":["External upper lip"],"term_type":"PT"},{"nm":"Extrahepatic bile duct","n_c":["C32573"],"i_c":"C24.0","i_c_s":["Extrahepatic bile duct"],"term_type":"PT"},{"nm":"Eye, NOS","n_c":["C12401"],"i_c":"C69.9","i_c_s":["Eye, NOS"],"term_type":"PT"},{"nm":"Eyelid","n_c":["C12713"],"i_c":"C44.1","i_c_s":["Eyelid"],"term_type":"PT"},{"nm":"Fallopian tube","n_c":["C12403"],"i_c":"C57.0","i_c_s":["Fallopian tube"],"term_type":"PT"},{"nm":"Female genital tract, NOS","n_c":["C61600"],"i_c":"C57.9","i_c_s":["Female genital tract, NOS"],"term_type":"PT"},{"nm":"Floor of mouth, NOS","n_c":["C54187"],"i_c":"C04.9","i_c_s":["Floor of mouth, NOS"],"term_type":"PT"},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"C71.1","i_c_s":["Frontal lobe"],"term_type":"PT"},{"nm":"Frontal sinus","n_c":["C12277"],"i_c":"C31.2","i_c_s":["Frontal sinus"],"term_type":"PT"},{"nm":"Fundus of stomach","n_c":["C12257"],"i_c":"C16.1","i_c_s":["Fundus of stomach"],"term_type":"PT"},{"nm":"Fundus uteri","n_c":["C12315"],"i_c":"C54.3","i_c_s":["Fundus uteri"],"term_type":"PT"},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"C23.9","i_c_s":["Gallbladder"],"term_type":"PT"},{"nm":"Gastric antrum","n_c":["C12259"],"i_c":"C16.3","i_c_s":["Gastric antrum"],"term_type":"PT"},{"nm":"Gastrointestinal tract, NOS","n_c":["C34082"],"i_c":"C26.9","i_c_s":["Gastrointestinal tract, NOS"],"term_type":"PT"},{"nm":"Glans penis","n_c":["C12324"],"i_c":"C60.1","i_c_s":["Glans penis"],"term_type":"PT"},{"nm":"Glottis","n_c":["C12724"],"i_c":"C32.0","i_c_s":["Glottis"],"term_type":"PT"},{"nm":"Greater curvature of stomach, NOS","n_c":["C12262"],"i_c":"C16.6","i_c_s":["Greater curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Gum, NOS","n_c":["C32677"],"i_c":"C03.9","i_c_s":["Gum, NOS"],"term_type":"PT"},{"nm":"Hard palate","n_c":["C12230"],"i_c":"C05.0","i_c_s":["Hard palate"],"term_type":"PT"},{"nm":"Head of pancreas","n_c":["C12269"],"i_c":"C25.0","i_c_s":["Head of pancreas"],"term_type":"PT"},{"nm":"Head, face or neck, NOS","n_c":"","i_c":"C76.0","i_c_s":["Head, face or neck, NOS"],"term_type":"PT"},{"nm":"Heart","n_c":["C12727"],"i_c":"C38.0","i_c_s":["Heart"],"term_type":"PT"},{"nm":"Hematopoietic system, NOS","n_c":["C12909"],"i_c":"C42.4","i_c_s":["Hematopoietic system, NOS"],"term_type":"PT"},{"nm":"Hepatic flexure of colon","n_c":["C12266"],"i_c":"C18.3","i_c_s":["Hepatic flexure of colon"],"term_type":"PT"},{"nm":"Hypopharyngeal aspect of aryepiglottic fold","n_c":"","i_c":"C13.1","i_c_s":["Hypopharyngeal aspect of aryepiglottic fold"],"term_type":"PT"},{"nm":"Hypopharynx, NOS","n_c":["C12246"],"i_c":"C13.9","i_c_s":["Hypopharynx, NOS"],"term_type":"PT"},{"nm":"Ileum","n_c":["C12387"],"i_c":"C17.2","i_c_s":["Ileum"],"term_type":"PT"},{"nm":"Ill-defined sites within respiratory system","n_c":["C148338"],"i_c":"C39.9","i_c_s":["Ill-defined sites within respiratory system"],"term_type":"PT"},{"nm":"Intestinal tract, NOS","n_c":["C12736"],"i_c":"C26.0","i_c_s":["Intestinal tract, NOS"],"term_type":"PT"},{"nm":"Intra-abdominal lymph nodes","n_c":["C12360"],"i_c":"C77.2","i_c_s":["Intra-abdominal lymph nodes"],"term_type":"PT"},{"nm":"Intrahepatic bile duct","n_c":["C12677"],"i_c":"C22.1","i_c_s":["Intrahepatic bile duct"],"term_type":"PT"},{"nm":"Intrathoracic lymph nodes","n_c":["C12359"],"i_c":"C77.1","i_c_s":["Intrathoracic lymph nodes"],"term_type":"PT"},{"nm":"Islets of Langerhans","n_c":["C12608"],"i_c":"C25.4","i_c_s":["Islets of Langerhans"],"term_type":"PT"},{"nm":"Isthmus uteri","n_c":["C12312"],"i_c":"C54.0","i_c_s":["Isthmus uteri"],"term_type":"PT"},{"nm":"Jejunum","n_c":["C12388"],"i_c":"C17.1","i_c_s":["Jejunum"],"term_type":"PT"},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"C64.9","i_c_s":["Kidney, NOS"],"term_type":"PT"},{"nm":"Labium majus","n_c":["C12306"],"i_c":"C51.0","i_c_s":["Labium majus"],"term_type":"PT"},{"nm":"Labium minus","n_c":["C12307"],"i_c":"C51.1","i_c_s":["Labium minus"],"term_type":"PT"},{"nm":"Lacrimal gland","n_c":["C12346"],"i_c":"C69.5","i_c_s":["Lacrimal gland"],"term_type":"PT"},{"nm":"Laryngeal cartilage","n_c":["C12281"],"i_c":"C32.3","i_c_s":["Laryngeal cartilage"],"term_type":"PT"},{"nm":"Laryngeal Commissure","n_c":"","i_c":"C32.0","i_c_s":["Laryngeal Commissure"],"term_type":"RT"},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"C32.9","i_c_s":["Larynx, NOS"],"term_type":"PT"},{"nm":"Lateral floor of mouth","n_c":"","i_c":"C04.1","i_c_s":["Lateral floor of mouth"],"term_type":"PT"},{"nm":"Lateral wall of bladder","n_c":["C12333"],"i_c":"C67.2","i_c_s":["Lateral wall of bladder"],"term_type":"PT"},{"nm":"Lateral wall of nasopharynx","n_c":["C12244"],"i_c":"C11.2","i_c_s":["Lateral wall of nasopharynx"],"term_type":"PT"},{"nm":"Lateral wall of oropharynx","n_c":["C12239"],"i_c":"C10.2","i_c_s":["Lateral wall of oropharynx"],"term_type":"PT"},{"nm":"Lesser curvature of stomach, NOS","n_c":["C12261"],"i_c":"C16.5","i_c_s":["Lesser curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Lingual tonsil","n_c":["C32988"],"i_c":"C02.4","i_c_s":["Lingual tonsil"],"term_type":"PT"},{"nm":"Lip, NOS","n_c":["C12220"],"i_c":"C00.9","i_c_s":["Lip, NOS"],"term_type":"PT"},{"nm":"Liver","n_c":["C12392"],"i_c":"C22.0","i_c_s":["Liver"],"term_type":"PT"},{"nm":"Long bones of lower limb and associated joints","n_c":"","i_c":"C40.2","i_c_s":["Long bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Long bones of upper limb, scapula and associated joints","n_c":"","i_c":"C40.0","i_c_s":["Long bones of upper limb, scapula and associated joints"],"term_type":"PT"},{"nm":"Lower gum","n_c":["C54204"],"i_c":"C03.1","i_c_s":["Lower gum"],"term_type":"PT"},{"nm":"Lower limb, NOS","n_c":["C12742"],"i_c":"C76.5","i_c_s":["Lower limb, NOS"],"term_type":"PT"},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"C34.3","i_c_s":["Lower lobe, lung"],"term_type":"PT"},{"nm":"Lower third of esophagus","n_c":["C12255"],"i_c":"C15.5","i_c_s":["Lower third of esophagus"],"term_type":"PT"},{"nm":"Lower-inner quadrant of breast","n_c":["C12302"],"i_c":"C50.3","i_c_s":["Lower-inner quadrant of breast"],"term_type":"PT"},{"nm":"Lower-outer quadrant of breast","n_c":["C12304"],"i_c":"C50.5","i_c_s":["Lower-outer quadrant of breast"],"term_type":"PT"},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"C34.9","i_c_s":["Lung, NOS"],"term_type":"PT"},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"C77.9","i_c_s":["Lymph node, NOS"],"term_type":"PT"},{"nm":"Lymph nodes of axilla or arm","n_c":["C12904"],"i_c":"C77.3","i_c_s":["Lymph nodes of axilla or arm"],"term_type":"PT"},{"nm":"Lymph nodes of head, face and neck","n_c":["C12358"],"i_c":"C77.0","i_c_s":["Lymph nodes of head, face and neck"],"term_type":"PT"},{"nm":"Lymph nodes of inguinal region or leg","n_c":["C12362"],"i_c":"C77.4","i_c_s":["Lymph nodes of inguinal region or leg"],"term_type":"PT"},{"nm":"Lymph nodes of multiple regions","n_c":"","i_c":"C77.8","i_c_s":["Lymph nodes of multiple regions"],"term_type":"PT"},{"nm":"Main bronchus","n_c":["C12284"],"i_c":"C34.0","i_c_s":["Main bronchus"],"term_type":"PT"},{"nm":"Major salivary gland, NOS","n_c":["C12426"],"i_c":"C08.9","i_c_s":["Major salivary gland, NOS"],"term_type":"PT"},{"nm":"Male genital organs, NOS","n_c":["C61599"],"i_c":"C63.9","i_c_s":["Male genital organs, NOS"],"term_type":"PT"},{"nm":"Mandible","n_c":["C12290"],"i_c":"C41.1","i_c_s":["Mandible"],"term_type":"PT"},{"nm":"Maxillary sinus","n_c":["C12275"],"i_c":"C31.0","i_c_s":["Maxillary sinus"],"term_type":"PT"},{"nm":"Meckel diverticulum","n_c":["C12264"],"i_c":"C17.3","i_c_s":["Meckel diverticulum"],"term_type":"PT"},{"nm":"Mediastinum, NOS","n_c":["C12748"],"i_c":"C38.3","i_c_s":["Mediastinum, NOS"],"term_type":"PT"},{"nm":"Medulla of adrenal gland","n_c":["C12397"],"i_c":"C74.1","i_c_s":["Medulla of adrenal gland"],"term_type":"PT"},{"nm":"Meninges, NOS","n_c":["C12348"],"i_c":"C70.9","i_c_s":["Meninges, NOS"],"term_type":"PT"},{"nm":"Middle ear","n_c":["C12274"],"i_c":"C30.1","i_c_s":["Middle ear"],"term_type":"PT"},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"C34.2","i_c_s":["Middle lobe, lung"],"term_type":"PT"},{"nm":"Middle third of esophagus","n_c":["C12254"],"i_c":"C15.4","i_c_s":["Middle third of esophagus"],"term_type":"PT"},{"nm":"Mouth, NOS","n_c":["C12421"],"i_c":"C06.9","i_c_s":["Mouth, NOS"],"term_type":"PT"},{"nm":"Mucosa of lip, NOS","n_c":["C12226"],"i_c":"C00.5","i_c_s":["Mucosa of lip, NOS"],"term_type":"PT"},{"nm":"Mucosa of lower lip","n_c":["C12225"],"i_c":"C00.4","i_c_s":["Mucosa of lower lip"],"term_type":"PT"},{"nm":"Mucosa of upper lip","n_c":["C12224"],"i_c":"C00.3","i_c_s":["Mucosa of upper lip"],"term_type":"PT"},{"nm":"Myometrium","n_c":["C12314"],"i_c":"C54.2","i_c_s":["Myometrium"],"term_type":"PT"},{"nm":"Nasal cavity","n_c":["C12424"],"i_c":"C30.0","i_c_s":["Nasal cavity"],"term_type":"PT"},{"nm":"Nasopharynx, NOS","n_c":["C12423"],"i_c":"C11.9","i_c_s":["Nasopharynx, NOS"],"term_type":"PT"},{"nm":"Nervous system, NOS","n_c":["C12755"],"i_c":"C72.9","i_c_s":["Nervous system, NOS"],"term_type":"PT"},{"nm":"Nipple","n_c":["C12299"],"i_c":"C50.0","i_c_s":["Nipple"],"term_type":"PT"},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"C71.4","i_c_s":["Occipital lobe"],"term_type":"PT"},{"nm":"Olfactory nerve","n_c":["C12759"],"i_c":"C72.2","i_c_s":["Olfactory nerve"],"term_type":"PT"},{"nm":"Optic nerve","n_c":["C12761"],"i_c":"C72.3","i_c_s":["Optic nerve"],"term_type":"PT"},{"nm":"Orbit, NOS","n_c":["C12347"],"i_c":"C69.6","i_c_s":["Orbit, NOS"],"term_type":"PT"},{"nm":"Oropharynx, NOS","n_c":["C12762"],"i_c":"C10.9","i_c_s":["Oropharynx, NOS"],"term_type":"PT"},{"nm":"Other ill-defined sites","n_c":["C147919"],"i_c":"C76.7","i_c_s":["Other ill-defined sites"],"term_type":"PT"},{"nm":"Other specified parts of female genital organs","n_c":["C148339"],"i_c":"C57.7","i_c_s":["Other specified parts of female genital organs"],"term_type":"PT"},{"nm":"Other specified parts of male genital organs","n_c":["C148341"],"i_c":"C63.7","i_c_s":["Other specified parts of male genital organs"],"term_type":"PT"},{"nm":"Other specified parts of pancreas","n_c":["C12273"],"i_c":"C25.7","i_c_s":["Other specified parts of pancreas"],"term_type":"PT"},{"nm":"Ovary","n_c":["C12404"],"i_c":"C56.9","i_c_s":["Ovary"],"term_type":"PT"},{"nm":"Overlapping lesion of accessory sinuses","n_c":"","i_c":"C31.8","i_c_s":["Overlapping lesion of accessory sinuses"],"term_type":"PT"},{"nm":"Overlapping lesion of biliary tract","n_c":"","i_c":"C24.8","i_c_s":["Overlapping lesion of biliary tract"],"term_type":"PT"},{"nm":"Overlapping lesion of bladder","n_c":"","i_c":"C67.8","i_c_s":["Overlapping lesion of bladder"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage","n_c":"","i_c":"C41.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage of limbs","n_c":"","i_c":"C40.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage of limbs"],"term_type":"PT"},{"nm":"Overlapping lesion of brain","n_c":"","i_c":"C71.8","i_c_s":["Overlapping lesion of brain"],"term_type":"PT"},{"nm":"Overlapping lesion of brain and central nervous system","n_c":"","i_c":"C72.8","i_c_s":["Overlapping lesion of brain and central nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of breast","n_c":"","i_c":"C50.8","i_c_s":["Overlapping lesion of breast"],"term_type":"PT"},{"nm":"Overlapping lesion of cervix uteri","n_c":"","i_c":"C53.8","i_c_s":["Overlapping lesion of cervix uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of colon","n_c":"","i_c":"C18.8","i_c_s":["Overlapping lesion of colon"],"term_type":"PT"},{"nm":"Overlapping lesion of connective, subcutaneous and other soft tissues","n_c":"","i_c":"C49.8","i_c_s":["Overlapping lesion of connective, subcutaneous and other soft tissues"],"term_type":"PT"},{"nm":"Overlapping lesion of corpus uteri","n_c":"","i_c":"C54.8","i_c_s":["Overlapping lesion of corpus uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of digestive system","n_c":"","i_c":"C26.8","i_c_s":["Overlapping lesion of digestive system"],"term_type":"PT"},{"nm":"Overlapping lesion of endocrine glands and related structures","n_c":"","i_c":"C75.8","i_c_s":["Overlapping lesion of endocrine glands and related structures"],"term_type":"PT"},{"nm":"Overlapping lesion of esophagus","n_c":"","i_c":"C15.8","i_c_s":["Overlapping lesion of esophagus"],"term_type":"PT"},{"nm":"Overlapping lesion of eye and adnexa","n_c":"","i_c":"C69.8","i_c_s":["Overlapping lesion of eye and adnexa"],"term_type":"PT"},{"nm":"Overlapping lesion of female genital organs","n_c":"","i_c":"C57.8","i_c_s":["Overlapping lesion of female genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of floor of mouth","n_c":"","i_c":"C04.8","i_c_s":["Overlapping lesion of floor of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of heart, mediastinum and pleura","n_c":"","i_c":"C38.8","i_c_s":["Overlapping lesion of heart, mediastinum and pleura"],"term_type":"PT"},{"nm":"Overlapping lesion of hypopharynx","n_c":"","i_c":"C13.8","i_c_s":["Overlapping lesion of hypopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of ill-defined sites","n_c":"","i_c":"C76.8","i_c_s":["Overlapping lesion of ill-defined sites"],"term_type":"PT"},{"nm":"Overlapping lesion of larynx","n_c":"","i_c":"C32.8","i_c_s":["Overlapping lesion of larynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lip","n_c":"","i_c":"C00.8","i_c_s":["Overlapping lesion of lip"],"term_type":"PT"},{"nm":"Overlapping lesion of lip, oral cavity and pharynx","n_c":"","i_c":"C14.8","i_c_s":["Overlapping lesion of lip, oral cavity and pharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lung","n_c":"","i_c":"C34.8","i_c_s":["Overlapping lesion of lung"],"term_type":"PT"},{"nm":"Overlapping lesion of major salivary glands","n_c":"","i_c":"C08.8","i_c_s":["Overlapping lesion of major salivary glands"],"term_type":"PT"},{"nm":"Overlapping lesion of male genital organs","n_c":"","i_c":"C63.8","i_c_s":["Overlapping lesion of male genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of nasopharynx","n_c":"","i_c":"C11.8","i_c_s":["Overlapping lesion of nasopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of other and unspecified parts of mouth","n_c":"","i_c":"C06.8","i_c_s":["Overlapping lesion of other and unspecified parts of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of palate","n_c":"","i_c":"C05.8","i_c_s":["Overlapping lesion of palate"],"term_type":"PT"},{"nm":"Overlapping lesion of pancreas","n_c":"","i_c":"C25.8","i_c_s":["Overlapping lesion of pancreas"],"term_type":"PT"},{"nm":"Overlapping lesion of penis","n_c":"","i_c":"C60.8","i_c_s":["Overlapping lesion of penis"],"term_type":"PT"},{"nm":"Overlapping lesion of peripheral nerves and autonomic nervous system","n_c":"","i_c":"C47.8","i_c_s":["Overlapping lesion of peripheral nerves and autonomic nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of rectum, anus and anal canal","n_c":"","i_c":"C21.8","i_c_s":["Overlapping lesion of rectum, anus and anal canal"],"term_type":"PT"},{"nm":"Overlapping lesion of respiratory system and intrathoracic organs","n_c":"","i_c":"C39.8","i_c_s":["Overlapping lesion of respiratory system and intrathoracic organs"],"term_type":"PT"},{"nm":"Overlapping lesion of retroperitoneum and peritoneum","n_c":"","i_c":"C48.8","i_c_s":["Overlapping lesion of retroperitoneum and peritoneum"],"term_type":"PT"},{"nm":"Overlapping lesion of skin","n_c":"","i_c":"C44.8","i_c_s":["Overlapping lesion of skin"],"term_type":"PT"},{"nm":"Overlapping lesion of small intestine","n_c":"","i_c":"C17.8","i_c_s":["Overlapping lesion of small intestine"],"term_type":"PT"},{"nm":"Overlapping lesion of stomach","n_c":"","i_c":"C16.8","i_c_s":["Overlapping lesion of stomach"],"term_type":"PT"},{"nm":"Overlapping lesion of tongue","n_c":"","i_c":"C02.8","i_c_s":["Overlapping lesion of tongue"],"term_type":"PT"},{"nm":"Overlapping lesion of tonsil","n_c":"","i_c":"C09.8","i_c_s":["Overlapping lesion of tonsil"],"term_type":"PT"},{"nm":"Overlapping lesion of urinary organs","n_c":"","i_c":"C68.8","i_c_s":["Overlapping lesion of urinary organs"],"term_type":"PT"},{"nm":"Overlapping lesion of vulva","n_c":"","i_c":"C51.8","i_c_s":["Overlapping lesion of vulva"],"term_type":"PT"},{"nm":"Overlapping lesions of oropharynx","n_c":"","i_c":"C10.8","i_c_s":["Overlapping lesions of oropharynx"],"term_type":""},{"nm":"Palate, NOS","n_c":["C12229"],"i_c":"C05.9","i_c_s":["Palate, NOS"],"term_type":"PT"},{"nm":"Pancreas, NOS","n_c":["C12393"],"i_c":"C25.9","i_c_s":["Pancreas, NOS"],"term_type":"PT"},{"nm":"Pancreatic duct","n_c":["C12272"],"i_c":"C25.3","i_c_s":["Pancreatic duct"],"term_type":"PT"},{"nm":"Parametrium","n_c":["C12320"],"i_c":"C57.3","i_c_s":["Parametrium"],"term_type":"PT"},{"nm":"Parathyroid gland","n_c":["C12765"],"i_c":"C75.0","i_c_s":["Parathyroid gland"],"term_type":"PT"},{"nm":"Paraurethral gland","n_c":["C61122"],"i_c":"C68.1","i_c_s":["Paraurethral gland"],"term_type":"PT"},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"C71.3","i_c_s":["Parietal lobe"],"term_type":"PT"},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"C07.9","i_c_s":["Parotid gland"],"term_type":"PT"},{"nm":"Pelvic bones, sacrum, coccyx and associated joints","n_c":"","i_c":"C41.4","i_c_s":["Pelvic bones, sacrum, coccyx and associated joints"],"term_type":"PT"},{"nm":"Pelvic lymph nodes","n_c":["C12363"],"i_c":"C77.5","i_c_s":["Pelvic lymph nodes"],"term_type":"PT"},{"nm":"Pelvis, NOS","n_c":["C12767"],"i_c":"C76.3","i_c_s":["Pelvis, NOS"],"term_type":"PT"},{"nm":"Penis, NOS","n_c":["C12409"],"i_c":"C60.9","i_c_s":["Penis, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of abdomen","n_c":"","i_c":"C47.4","i_c_s":["Peripheral nerves and autonomic nervous system of abdomen"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of head, face, and neck","n_c":"","i_c":"C47.0","i_c_s":["Peripheral nerves and autonomic nervous system of head, face, and neck"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of lower limb and hip","n_c":"","i_c":"C47.2","i_c_s":["Peripheral nerves and autonomic nervous system of lower limb and hip"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of pelvis","n_c":"","i_c":"C47.5","i_c_s":["Peripheral nerves and autonomic nervous system of pelvis"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of thorax","n_c":"","i_c":"C47.3","i_c_s":["Peripheral nerves and autonomic nervous system of thorax"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of trunk, NOS","n_c":"","i_c":"C47.6","i_c_s":["Peripheral nerves and autonomic nervous system of trunk, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of upper limb and shoulder","n_c":"","i_c":"C47.1","i_c_s":["Peripheral nerves and autonomic nervous system of upper limb and shoulder"],"term_type":"PT"},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"C48.2","i_c_s":["Peritoneum, NOS"],"term_type":"PT"},{"nm":"Pharynx, NOS","n_c":["C12425"],"i_c":"C14.0","i_c_s":["Pharynx, NOS"],"term_type":"PT"},{"nm":"Pineal gland","n_c":["C12398"],"i_c":"C75.3","i_c_s":["Pineal gland"],"term_type":"PT"},{"nm":"Pituitary gland","n_c":["C12399"],"i_c":"C75.1","i_c_s":["Pituitary gland"],"term_type":"PT"},{"nm":"Placenta","n_c":["C13272"],"i_c":"C58.9","i_c_s":["Placenta"],"term_type":"PT"},{"nm":"Pleura, NOS","n_c":["C12469"],"i_c":"C38.4","i_c_s":["Pleura, NOS"],"term_type":"PT"},{"nm":"Postcricoid region","n_c":["C54221"],"i_c":"C13.0","i_c_s":["Postcricoid region"],"term_type":"PT"},{"nm":"Posterior mediastinum","n_c":["C33368"],"i_c":"C38.2","i_c_s":["Posterior mediastinum"],"term_type":"PT"},{"nm":"Posterior wall of bladder","n_c":["C12335"],"i_c":"C67.4","i_c_s":["Posterior wall of bladder"],"term_type":"PT"},{"nm":"Posterior wall of hypopharynx","n_c":["C12249"],"i_c":"C13.2","i_c_s":["Posterior wall of hypopharynx"],"term_type":"PT"},{"nm":"Posterior wall of nasopharynx","n_c":["C12243"],"i_c":"C11.1","i_c_s":["Posterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Posterior wall of oropharynx","n_c":["C12240"],"i_c":"C10.3","i_c_s":["Posterior wall of oropharynx"],"term_type":"PT"},{"nm":"Prepuce","n_c":["C12323"],"i_c":"C60.0","i_c_s":["Prepuce"],"term_type":"PT"},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"C61.9","i_c_s":["Prostate gland"],"term_type":"PT"},{"nm":"Pylorus","n_c":["C12260"],"i_c":"C16.4","i_c_s":["Pylorus"],"term_type":"PT"},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"C12.9","i_c_s":["Pyriform sinus"],"term_type":"PT"},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"C19.9","i_c_s":["Rectosigmoid junction"],"term_type":"PT"},{"nm":"Rectum, NOS","n_c":["C12390"],"i_c":"C20.9","i_c_s":["Rectum, NOS"],"term_type":"PT"},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"C65.9","i_c_s":["Renal pelvis"],"term_type":"PT"},{"nm":"Reticuloendothelial system, NOS","n_c":["C12780"],"i_c":"C42.3","i_c_s":["Reticuloendothelial system, NOS"],"term_type":"PT"},{"nm":"Retina","n_c":["C12343"],"i_c":"C69.2","i_c_s":["Retina"],"term_type":"PT"},{"nm":"Retromolar area","n_c":["C54223"],"i_c":"C06.2","i_c_s":["Retromolar area"],"term_type":"PT"},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"C48.0","i_c_s":["Retroperitoneum"],"term_type":"PT"},{"nm":"Rib, sternum, clavicle and associated joints","n_c":"","i_c":"C41.3","i_c_s":["Rib, sternum, clavicle and associated joints"],"term_type":"PT"},{"nm":"Round ligament","n_c":["C12319"],"i_c":"C57.2","i_c_s":["Round ligament"],"term_type":"PT"},{"nm":"Scrotum, NOS","n_c":["C12785"],"i_c":"C63.2","i_c_s":["Scrotum, NOS"],"term_type":"PT"},{"nm":"Short bones of lower limb and associated joints","n_c":"","i_c":"C40.3","i_c_s":["Short bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Short bones of upper limb and associated joints","n_c":"","i_c":"C40.1","i_c_s":["Short bones of upper limb and associated joints"],"term_type":"PT"},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"C18.7","i_c_s":["Sigmoid colon"],"term_type":"PT"},{"nm":"Skin of lip, NOS","n_c":["C12291"],"i_c":"C44.0","i_c_s":["Skin of lip, NOS"],"term_type":"PT"},{"nm":"Skin of lower limb and hip","n_c":["C12297"],"i_c":"C44.7","i_c_s":["Skin of lower limb and hip"],"term_type":"PT"},{"nm":"Skin of other and unspecified parts of face","n_c":["C33561"],"i_c":"C44.3","i_c_s":["Skin of other and unspecified parts of face"],"term_type":"PT"},{"nm":"Skin of scalp and neck","n_c":["C12294"],"i_c":"C44.4","i_c_s":["Skin of scalp and neck"],"term_type":"PT"},{"nm":"Skin of trunk","n_c":["C12295"],"i_c":"C44.5","i_c_s":["Skin of trunk"],"term_type":"RT"},{"nm":"Skin of upper limb and shoulder","n_c":["C12296"],"i_c":"C44.6","i_c_s":["Skin of upper limb and shoulder"],"term_type":"PT"},{"nm":"Skin, NOS","n_c":["C12470"],"i_c":"C44.9","i_c_s":["Skin, NOS"],"term_type":"PT"},{"nm":"Small intestine, NOS","n_c":["C12386"],"i_c":"C17.9","i_c_s":["Small intestine, NOS"],"term_type":"PT"},{"nm":"Soft palate, NOS","n_c":["C12231"],"i_c":"C05.1","i_c_s":["Soft palate, NOS"],"term_type":"PT"},{"nm":"Specified parts of peritoneum","n_c":"","i_c":"C48.1","i_c_s":["Specified parts of peritoneum"],"term_type":"PT"},{"nm":"Spermatic cord","n_c":["C12329"],"i_c":"C63.1","i_c_s":["Spermatic cord"],"term_type":"PT"},{"nm":"Sphenoid sinus","n_c":["C12278"],"i_c":"C31.3","i_c_s":["Sphenoid sinus"],"term_type":"PT"},{"nm":"Spinal cord","n_c":["C12464"],"i_c":"C72.0","i_c_s":["Spinal cord"],"term_type":"PT"},{"nm":"Spinal meninges","n_c":["C12350"],"i_c":"C70.1","i_c_s":["Spinal meninges"],"term_type":"PT"},{"nm":"Spleen","n_c":["C12432"],"i_c":"C42.2","i_c_s":["Spleen"],"term_type":"PT"},{"nm":"Splenic flexure of colon","n_c":["C12267"],"i_c":"C18.5","i_c_s":["Splenic flexure of colon"],"term_type":"PT"},{"nm":"Stomach, NOS","n_c":["C12391"],"i_c":"C16.9","i_c_s":["Stomach, NOS"],"term_type":"PT"},{"nm":"Subglottis","n_c":["C12280"],"i_c":"C32.2","i_c_s":["Subglottis"],"term_type":"PT"},{"nm":"Sublingual gland","n_c":["C12234"],"i_c":"C08.1","i_c_s":["Sublingual gland"],"term_type":"PT"},{"nm":"Submandibular gland","n_c":["C12233"],"i_c":"C08.0","i_c_s":["Submandibular gland"],"term_type":"PT"},{"nm":"Superior wall of nasopharynx","n_c":["C12242"],"i_c":"C11.0","i_c_s":["Superior wall of nasopharynx"],"term_type":"PT"},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"C32.1","i_c_s":["Supraglottis"],"term_type":"PT"},{"nm":"Tail of pancreas","n_c":["C12271"],"i_c":"C25.2","i_c_s":["Tail of pancreas"],"term_type":"PT"},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"C71.2","i_c_s":["Temporal lobe"],"term_type":"PT"},{"nm":"Testis, NOS","n_c":["C12412"],"i_c":"C62.9","i_c_s":["Testis, NOS"],"term_type":"PT"},{"nm":"Thoracic esophagus","n_c":["C12251"],"i_c":"C15.1","i_c_s":["Thoracic esophagus"],"term_type":"PT"},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"C76.1","i_c_s":["Thorax, NOS"],"term_type":"PT"},{"nm":"Thymus","n_c":["C12433"],"i_c":"C37.9","i_c_s":["Thymus"],"term_type":"PT"},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"C73.9","i_c_s":["Thyroid gland"],"term_type":"PT"},{"nm":"Tongue, NOS","n_c":["C12422"],"i_c":"C02.9","i_c_s":["Tongue, NOS"],"term_type":"PT"},{"nm":"Tonsil, NOS","n_c":["C33250"],"i_c":"C09.9","i_c_s":["Tonsil, NOS"],"term_type":"PT"},{"nm":"Tonsillar fossa","n_c":["C12235"],"i_c":"C09.0","i_c_s":["Tonsillar fossa"],"term_type":"PT"},{"nm":"Tonsillar pillar","n_c":["C12236"],"i_c":"C09.1","i_c_s":["Tonsillar pillar"],"term_type":"PT"},{"nm":"Trachea","n_c":["C12428"],"i_c":"C33.9","i_c_s":["Trachea"],"term_type":"PT"},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"C18.4","i_c_s":["Transverse colon"],"term_type":"PT"},{"nm":"Trigone of bladder","n_c":["C12331"],"i_c":"C67.0","i_c_s":["Trigone of bladder"],"term_type":"PT"},{"nm":"Undescended testis","n_c":["C12326"],"i_c":"C62.0","i_c_s":["Undescended testis"],"term_type":"PT"},{"nm":"Unknown primary site","n_c":["C48322"],"i_c":"C80.9","i_c_s":["Unknown primary site"],"term_type":"PT"},{"nm":"Upper Gum","n_c":["C54205"],"i_c":"C03.0","i_c_s":["Upper Gum"],"term_type":""},{"nm":"Upper limb, NOS","n_c":["C12671"],"i_c":"C76.4","i_c_s":["Upper limb, NOS"],"term_type":"PT"},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"C34.1","i_c_s":["Upper lobe, lung"],"term_type":"PT"},{"nm":"Upper respiratory tract, NOS","n_c":["C33839"],"i_c":"C39.0","i_c_s":["Upper respiratory tract, NOS"],"term_type":"PT"},{"nm":"Upper third of esophagus","n_c":["C12253"],"i_c":"C15.3","i_c_s":["Upper third of esophagus"],"term_type":"PT"},{"nm":"Upper-inner quadrant of breast","n_c":["C12301"],"i_c":"C50.2","i_c_s":["Upper-inner quadrant of breast"],"term_type":"PT"},{"nm":"Upper-outer quadrant of breast","n_c":["C12303"],"i_c":"C50.4","i_c_s":["Upper-outer quadrant of breast"],"term_type":"PT"},{"nm":"Urachus","n_c":["C12338"],"i_c":"C67.7","i_c_s":["Urachus"],"term_type":"PT"},{"nm":"Ureter","n_c":["C12416"],"i_c":"C66.9","i_c_s":["Ureter"],"term_type":"PT"},{"nm":"Ureteric orifice","n_c":["C12337"],"i_c":"C67.6","i_c_s":["Ureteric orifice"],"term_type":"PT"},{"nm":"Urethra","n_c":["C12417"],"i_c":"C68.0","i_c_s":["Urethra"],"term_type":"PT"},{"nm":"Urinary system, NOS","n_c":["C12413"],"i_c":"C68.9","i_c_s":["Urinary system, NOS"],"term_type":"PT"},{"nm":"Uterine adnexa","n_c":["C12321"],"i_c":"C57.4","i_c_s":["Uterine adnexa"],"term_type":"PT"},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"C55.9","i_c_s":["Uterus, NOS"],"term_type":"PT"},{"nm":"Uvula","n_c":["C12232"],"i_c":"C05.2","i_c_s":["Uvula"],"term_type":"PT"},{"nm":"Vagina, NOS","n_c":["C12407"],"i_c":"C52.9","i_c_s":["Vagina, NOS"],"term_type":"PT"},{"nm":"Vallecula","n_c":["C12237"],"i_c":"C10.0","i_c_s":["Vallecula"],"term_type":"PT"},{"nm":"Ventral surface of tongue, NOS","n_c":"","i_c":"C02.2","i_c_s":["Ventral surface of tongue, NOS"],"term_type":"PT"},{"nm":"Ventricle, NOS","n_c":["C12356"],"i_c":"C71.5","i_c_s":["Ventricle, NOS"],"term_type":"PT"},{"nm":"Vertebral column","n_c":["C12998"],"i_c":"C41.2","i_c_s":["Vertebral column"],"term_type":"PT"},{"nm":"Vestibule of mouth","n_c":["C165195"],"i_c":"C06.1","i_c_s":["Vestibule of mouth"],"term_type":"PT"},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"C51.9","i_c_s":["Vulva, NOS"],"term_type":"PT"},{"nm":"Waldeyer ring","n_c":["C73468"],"i_c":"C14.2","i_c_s":["Waldeyer ring"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal commissure","n_c":"","i_c":"C32.0","i_c_s":["Laryngeal commissure"],"term_type":"PT"}],"clinical.diagnosis.transglottic_extension":[{"nm":"Absent","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C160996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_confined_to_organ_of_origin":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_focality":[{"nm":"Multifocal","n_c":["C25253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unifocal","n_c":["C47862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_grade":[{"nm":"G1","n_c":["C28077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G2","n_c":["C28078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G3","n_c":["C28079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G4","n_c":["C28082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GX","n_c":["C113730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GB","n_c":["C113729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade","n_c":["C14158"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Grade","n_c":["C28083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade","n_c":["C14161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_regression_grade":[{"nm":"0","n_c":["C155941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1","n_c":["C155942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C155943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C155944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.vascular_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.vascular_invasion_type":[{"nm":"Extramural","n_c":["C44280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intramural","n_c":["C25234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macro","n_c":["C43566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micro","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Vascular Invasion","n_c":["C164046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.weiss_assessment_score":[{"nm":"0","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"5","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"7","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9","n_c":"","i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.who_cns_grade":[{"nm":"Grade I","n_c":["C62394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade II","n_c":["C62395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade III","n_c":["C62396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade IV","n_c":["C62397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade Not Assigned","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.who_nte_grade":[{"nm":"G1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"G2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"G3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"GX","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.wilms_tumor_histologic_subtype":[{"nm":"Favorable","n_c":["C102560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unfavorable","n_c":["C102561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.experiment_metadata.data_category":[{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.experiment_metadata.data_type":[{"nm":"Experiment Metadata","n_c":["C165216"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.experiment_metadata.data_format":[{"nm":"SRA XML","n_c":["C184804"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_history":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_intensity":[{"nm":"Drinker","n_c":["C126383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heavy Drinker","n_c":["C126384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifelong Non-Drinker","n_c":["C126380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Drinker","n_c":["C126379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occasional Drinker","n_c":["C126382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social Drinker","n_c":["C156429"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_type":[{"nm":"Beer","n_c":["C66824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquor","n_c":["C66826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wine","n_c":["C66822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.asbestos_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.coal_dust_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.environmental_tobacco_smoke_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.exposure_duration":[{"nm":"Six Weeks or More","n_c":["C171137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.exposure_type":[{"nm":"Marijuana","n_c":["C26659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoke","n_c":["C164057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco","n_c":["C891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood Dust","n_c":["C174115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation","n_c":["C61398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asbestos","n_c":["C55816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical","n_c":["C36290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radon","n_c":["C177573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Respirable Crystalline Silica","n_c":["C177575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smokeless Tobacco","n_c":["C189768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coal Dust","n_c":["C177574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dust, NOS","n_c":["C200417"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.radon_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.respirable_crystalline_silica_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.secondhand_smoke_as_child":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.smoking_frequency":[{"nm":"Every day","n_c":["C67145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Some days","n_c":["C67146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.time_between_waking_and_first_smoke":[{"nm":"Within 5 Minutes","n_c":["C164121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6-30 Minutes","n_c":["C164124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"31-60 Minutes","n_c":["C164126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"After 60 Minutes","n_c":["C164127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.tobacco_smoking_status":[{"nm":"1","n_c":["C65108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C67147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C156828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":["C156829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5","n_c":["C156830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6","n_c":["C164079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7","n_c":["C163971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Reformed Smoker for < or = 15 yrs","n_c":["C156829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Reformed Smoker for > 15 yrs","n_c":["C156828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Reformed Smoker, Duration Not Specified","n_c":["C156830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Smoker","n_c":["C67147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifelong Non-Smoker","n_c":["C65108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoker at Diagnosis","n_c":["C164079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking history not documented","n_c":["C163971"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.type_of_smoke_exposure":[{"nm":"Accidental building fire smoke","n_c":["C164066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental fire smoke, grass","n_c":["C164067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental fire smoke, NOS","n_c":["C164059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental forest fire smoke","n_c":["C164068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental vehicle fire smoke","n_c":["C164069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aircraft smoke","n_c":["C164072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burning tree smoke","n_c":["C164075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coal smoke, NOS","n_c":["C164060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cooking-related smoke, NOS","n_c":["C164061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrical fire smoke","n_c":["C164077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electronic cigarette smoke, NOS","n_c":["C164062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Environmental tobacco smoke","n_c":["C17140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Factory smokestack smoke","n_c":["C164081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Field burning smoke","n_c":["C164082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fire smoke, NOS","n_c":["C164058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Furnace or boiler smoke","n_c":["C164083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gas burning smoke, propane","n_c":["C164084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grease fire smoke","n_c":["C164085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grilling smoke","n_c":["C164086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashish smoke","n_c":["C164087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoor stove or fireplace smoke, coal burning","n_c":["C164088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoor stove or fireplace smoke, NOS","n_c":["C164064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoor stove or fireplace smoke, wood burning","n_c":["C164089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Machine smoke","n_c":["C164090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marijuana smoke","n_c":["C164091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Smoke Exposure","n_c":["C164092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oil burning smoke, Kerosene","n_c":["C164093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oil burning smoke, NOS","n_c":["C164063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recreational fire smoke","n_c":["C164094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoke exposure, NOS","n_c":["C164057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smokehouse smoke","n_c":["C164095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, cigar","n_c":["C164097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, cigarettes","n_c":["C164098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, NOS","n_c":["C44456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, pipe","n_c":["C164099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Volcanic smoke","n_c":["C164100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Waste burning smoke","n_c":["C164101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood burning smoke, factory","n_c":["C164102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood burning smoke, NOS","n_c":["C164065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, artificial smoke machines","n_c":["C164104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, fire fighting","n_c":["C164105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, foundry","n_c":["C164106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, generators","n_c":["C164107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, military","n_c":["C164115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, NOS","n_c":["C164103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, paint baking","n_c":["C164116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, plastics factory","n_c":["C164118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, plumbing","n_c":["C164119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, soldering/welding","n_c":["C164120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.type_of_tobacco_used":[{"nm":"Cigar","n_c":["C1813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cigarette","n_c":["C1802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electronic Cigarette","n_c":["C120482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pipe","n_c":["C86044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smokeless Tobacco","n_c":["C892"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relationship_type":[{"nm":"Adopted Brother","n_c":["C166195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adopted Daughter","n_c":["C166131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adopted Sister","n_c":["C166196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adopted Son","n_c":["C166132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adoptive Father","n_c":["C166133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adoptive Mother","n_c":["C166134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aunt","n_c":["C71405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brother","n_c":["C25289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brother-in-law","n_c":["C71406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Child","n_c":["C150886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cousin","n_c":["C71410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daughter","n_c":["C25165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daughter-in-law","n_c":["C71401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domestic Partner","n_c":["C53262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Father","n_c":["C25174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Father-in-law","n_c":["C68640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Female Cousin","n_c":["C165786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Female Sibling of Adopted Child","n_c":["C166198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Cousin","n_c":["C71411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Cousin Once Removed","n_c":["C71412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Brother","n_c":["C165788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Daughter","n_c":["C165790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Father","n_c":["C165792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Mother","n_c":["C165793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Sister","n_c":["C165794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Son","n_c":["C165795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fraternal Twin Brother","n_c":["C165796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fraternal Twin Sibling","n_c":["C73428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fraternal Twin Sister","n_c":["C165797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Full Brother","n_c":["C111201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Full Sister","n_c":["C111202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grand Nephew","n_c":["C165798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grand Niece","n_c":["C165846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandchild","n_c":["C71397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granddaughter","n_c":["C71399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandfather","n_c":["C71387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandmother","n_c":["C71386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandparent","n_c":["C71385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandson","n_c":["C71398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Great Grandchild","n_c":["C165847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Half Brother","n_c":["C71402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Half Sibling","n_c":["C71391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Half Sister","n_c":["C71403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Husband","n_c":["C71588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Identical Twin Brother","n_c":["C165848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Identical Twin Sibling","n_c":["C73429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Identical Twin Sister","n_c":["C165849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legal Guardian","n_c":["C51828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Male Cousin","n_c":["C165850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Male Sibling of Adopted Child","n_c":["C166197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Aunt","n_c":["C96575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal First Cousin","n_c":["C96576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal First Cousin Once Removed","n_c":["C165851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Grandfather","n_c":["C96577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Grandmother","n_c":["C96578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Grandparent","n_c":["C111248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Great Aunt","n_c":["C165853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Great Grandparent","n_c":["C166127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Great Uncle","n_c":["C165854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Half Brother","n_c":["C96656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Half Sibling","n_c":["C166112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Half Sister","n_c":["C96658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Uncle","n_c":["C96579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mother","n_c":["C25189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mother-in-law","n_c":["C68639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Brother","n_c":["C96570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Child","n_c":["C42708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Daughter","n_c":["C25165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Father","n_c":["C96572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandchild","n_c":["C100805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandfather","n_c":["C96573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandmother","n_c":["C96574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandparent","n_c":["C100806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Mother","n_c":["C96580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Parent","n_c":["C166114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Sibling","n_c":["C100809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Sister","n_c":["C96586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Son","n_c":["C150888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nephew","n_c":["C71409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niece","n_c":["C71408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niece Second Degree Relative","n_c":["C166115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parent","n_c":["C42709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Aunt","n_c":["C96581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal First Cousin","n_c":["C96582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal First Cousin Once Removed","n_c":["C165852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Grandfather","n_c":["C96583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Grandmother","n_c":["C96584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Grandparent","n_c":["C111286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Great Aunt","n_c":["C165856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Great Grandparent","n_c":["C166128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Great Uncle","n_c":["C165857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Half Brother","n_c":["C96655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Half Sibling","n_c":["C166113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Half Sister","n_c":["C96657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Uncle","n_c":["C96585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sibling","n_c":["C25204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sister","n_c":["C25680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sister-in-law","n_c":["C71407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Son","n_c":["C25205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Son-in-law","n_c":["C71400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spouse","n_c":["C62649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Step Child","n_c":["C166117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Step Sibling","n_c":["C166118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepbrother","n_c":["C166119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepdaughter","n_c":["C166123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepfather","n_c":["C154851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepmother","n_c":["C132450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepsister","n_c":["C166124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepson","n_c":["C166125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twin Sibling","n_c":["C73427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uncle","n_c":["C71404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unrelated","n_c":["C25328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ward","n_c":["C71413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wife","n_c":["C71587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Degree Relative, NOS","n_c":["C21481"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relationship_gender":[{"nm":"female","n_c":["C16576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"male","n_c":["C20197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unspecified","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relationship_primary_diagnosis":[{"nm":"Adrenal Gland Cancer","n_c":["C9338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Cancer","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct Cancer","n_c":["C27814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Cancer","n_c":["C4912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Cancer","n_c":["C116915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Cancer","n_c":["C4016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Cancer","n_c":["C3568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Cancer","n_c":["C4872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Cancer","n_c":["C9039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chondrosarcoma","n_c":["C2946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Cancer","n_c":["C4627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Cancer","n_c":["C2955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Cancer","n_c":["C3513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ewing Sarcoma","n_c":["C4817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Cancer","n_c":["C3844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Cancer","n_c":["C4911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioblastoma","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gynecologic Cancer","n_c":["C4913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head and Neck Cancer","n_c":["C4013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Cancer","n_c":["C27134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kaposi Sarcoma","n_c":["C9087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Cancer","n_c":["C9384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Cancer","n_c":["C4855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukemia","n_c":["C3161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cancer","n_c":["C7927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Cancer","n_c":["C4878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node Cancer","n_c":["C35812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoma","n_c":["C3208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melanoma","n_c":["C3224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelioma","n_c":["C3786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multiple Myeloma","n_c":["C3242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroblastoma","n_c":["C3270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteosarcoma","n_c":["C9145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Cancer","n_c":["C7431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Cancer","n_c":["C3850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pediatric Liver Cancer","n_c":["C7708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Cancer","n_c":["C4863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Cancer","n_c":["C9382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhabdomyosarcoma","n_c":["C3359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoma","n_c":["C9118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Cancer","n_c":["C2920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen Cancer","n_c":["C3539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Cancer","n_c":["C9063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat Cancer","n_c":["C35506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Cancer","n_c":["C4815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue Cancer","n_c":["C4824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsillar Cancer","n_c":["C4825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Cancer","n_c":["C3552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wilms Tumor","n_c":["C3267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relative_with_cancer_history":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.adverse_event":[{"nm":"Abdominal Distension","n_c":["C143253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Infection","n_c":["C143254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Pain","n_c":["C143255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Soft Tissue Necrosis","n_c":["C143256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abducens Nerve Disorder","n_c":["C143257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accessory Nerve Disorder","n_c":["C143258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acidosis","n_c":["C143259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acoustic Nerve Disorder NOS","n_c":["C143260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Activated Partial Thromboplastin Time Prolonged","n_c":["C143261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Coronary Syndrome","n_c":["C53652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Kidney Injury","n_c":["C143262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal Insufficiency","n_c":["C55748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adult Respiratory Distress Syndrome","n_c":["C58020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agitation","n_c":["C146777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akathisia","n_c":["C143266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alanine Aminotransferase Increased","n_c":["C143267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Intolerance","n_c":["C143268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alkaline Phosphatase Increased","n_c":["C143269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alkalosis","n_c":["C143270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergic Reaction","n_c":["C143271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergic Rhinitis","n_c":["C143272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alopecia","n_c":["C57898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amnesia","n_c":["C143274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Fistula","n_c":["C143275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Hemorrhage","n_c":["C143276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Mucositis","n_c":["C143277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Necrosis","n_c":["C143278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Pain","n_c":["C143279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Stenosis","n_c":["C143280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Ulcer","n_c":["C143281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anaphylaxis","n_c":["C143282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C143283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle Fracture","n_c":["C143284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectal Infection","n_c":["C143285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorexia","n_c":["C57118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorgasmia","n_c":["C143287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C146778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Injury","n_c":["C143289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Valve Disease","n_c":["C143290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aphonia","n_c":["C143291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apnea","n_c":["C55340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendicitis","n_c":["C143294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendicitis Perforated","n_c":["C143293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arachnoiditis","n_c":["C143295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arterial Injury","n_c":["C143296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arteritis Infective","n_c":["C143297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthralgia","n_c":["C143298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C143299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C143300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspartate Aminotransferase Increased","n_c":["C143301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspiration","n_c":["C28245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asystole","n_c":["C146731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia","n_c":["C146737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atelectasis","n_c":["C58022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C54767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Flutter","n_c":["C54768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrioventricular Block Complete","n_c":["C143308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrioventricular Block First Degree","n_c":["C143309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Disorder","n_c":["C143310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C143311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azoospermia","n_c":["C143312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back Pain","n_c":["C146739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct Stenosis","n_c":["C143314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Anastomotic Leak","n_c":["C143315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Fistula","n_c":["C143316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Tract Infection","n_c":["C143317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Anastomotic Leak","n_c":["C143318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Infection","n_c":["C143319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Perforation","n_c":["C146707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Spasm","n_c":["C146698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bloating","n_c":["C143322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood and Lymphatic System Disorders - Other","n_c":["C143323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Antidiuretic Hormone Abnormal","n_c":["C143324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Bilirubin Increased","n_c":["C143325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Corticotrophin Decreased","n_c":["C143326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Gonadotrophin Abnormal","n_c":["C143327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Prolactin Abnormal","n_c":["C143328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blurred Vision","n_c":["C55906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Body Odor","n_c":["C143330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Infection","n_c":["C143331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Hypocellular","n_c":["C143332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Pain","n_c":["C146741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachial Plexopathy","n_c":["C146754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Atrophy","n_c":["C143335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Infection","n_c":["C143336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Pain","n_c":["C146742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Fistula","n_c":["C143338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Infection","n_c":["C143339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Obstruction","n_c":["C143340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Stricture","n_c":["C143341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchopleural Fistula","n_c":["C143342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchopulmonary Hemorrhage","n_c":["C143343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchospasm","n_c":["C143344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruising","n_c":["C143345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bullous Dermatitis","n_c":["C143346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burn","n_c":["C57900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock Pain","n_c":["C146744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary Leak Syndrome","n_c":["C143349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbon Monoxide Diffusing Capacity Decreased","n_c":["C143350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Arrest","n_c":["C143351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Disorders - Other","n_c":["C143352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Troponin I Increased","n_c":["C143353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Troponin T Increased","n_c":["C143354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataract","n_c":["C146674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Catheter Related Infection","n_c":["C143356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD4 Lymphocytes Decreased","n_c":["C143357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecal Hemorrhage","n_c":["C143358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecal Infection","n_c":["C143359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System Necrosis","n_c":["C143360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid Leakage","n_c":["C143361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervicitis Infection","n_c":["C143362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cheilitis","n_c":["C57901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Pain - Cardiac","n_c":["C143364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall Pain","n_c":["C146743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chills","n_c":["C143366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholecystitis","n_c":["C146788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholesterol High","n_c":["C143368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C143369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chylothorax","n_c":["C58027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cognitive Disturbance","n_c":["C146746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colitis","n_c":["C57134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Fistula","n_c":["C143373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Hemorrhage","n_c":["C143374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Obstruction","n_c":["C143375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Perforation","n_c":["C143376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Stenosis","n_c":["C143377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Ulcer","n_c":["C143378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Concentration Impairment","n_c":["C143379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conduction Disorder","n_c":["C143380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Confusion","n_c":["C146785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congenital, Familial and Genetic Disorders - Other","n_c":["C143382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctivitis","n_c":["C143384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctivitis Infective","n_c":["C143383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Constipation","n_c":["C57141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Constrictive Pericarditis","n_c":["C78246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corneal Infection","n_c":["C143386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corneal Ulcer","n_c":["C143387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cough","n_c":["C58028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CPK Increased","n_c":["C143389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cranial Nerve Infection","n_c":["C143390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Creatinine Increased","n_c":["C143391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cushingoid","n_c":["C143392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cystitis Noninfective","n_c":["C143393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokine Release Syndrome","n_c":["C143394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death Neonatal","n_c":["C143395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death NOS","n_c":["C143396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dehydration","n_c":["C57787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delayed Orgasm","n_c":["C143398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delayed Puberty","n_c":["C55742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delirium","n_c":["C143400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delusions","n_c":["C143401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dental Caries","n_c":["C143402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depressed Level of Consciousness","n_c":["C143403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C55447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatitis Radiation","n_c":["C143405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Device Related Infection","n_c":["C143406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diarrhea","n_c":["C57788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Disseminated Intravascular Coagulation","n_c":["C55273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dizziness","n_c":["C146747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dry Eye","n_c":["C143410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dry Mouth","n_c":["C143411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dry Skin","n_c":["C57996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Fistula","n_c":["C57789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Hemorrhage","n_c":["C143414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Infection","n_c":["C143415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Obstruction","n_c":["C143416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Perforation","n_c":["C143417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Stenosis","n_c":["C143418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Ulcer","n_c":["C143419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysarthria","n_c":["C143420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysesthesia","n_c":["C143421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysgeusia","n_c":["C143422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysmenorrhea","n_c":["C143423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyspareunia","n_c":["C143424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyspepsia","n_c":["C143425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysphagia","n_c":["C57795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysphasia","n_c":["C143427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyspnea","n_c":["C58185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear and Labyrinth Disorders - Other","n_c":["C143429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Pain","n_c":["C143430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Cerebral","n_c":["C143431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Face","n_c":["C143432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Limbs","n_c":["C143433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Trunk","n_c":["C143434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ejaculation Disorder","n_c":["C143435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ejection Fraction Decreased","n_c":["C143436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrocardiogram QT Corrected Interval Prolonged","n_c":["C143437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalitis Infection","n_c":["C143438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalomyelitis Infection","n_c":["C143439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalopathy","n_c":["C146699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocarditis Infective","n_c":["C143441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Disorders - Other","n_c":["C143442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endophthalmitis","n_c":["C143443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterocolitis","n_c":["C143445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterocolitis Infectious","n_c":["C143444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterovesical Fistula","n_c":["C143446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epistaxis","n_c":["C143447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erectile Dysfunction","n_c":["C55615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythema Multiforme","n_c":["C143449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythroderma","n_c":["C143450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Anastomotic Leak","n_c":["C143451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Fistula","n_c":["C57798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Hemorrhage","n_c":["C143453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Infection","n_c":["C143454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Necrosis","n_c":["C143455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Obstruction","n_c":["C143456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Pain","n_c":["C143457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Perforation","n_c":["C143458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Stenosis","n_c":["C143459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Ulcer","n_c":["C143460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Varices Hemorrhage","n_c":["C146710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagitis","n_c":["C57797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Euphoria","n_c":["C146748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exostosis","n_c":["C146749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"External Ear Inflammation","n_c":["C79601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"External Ear Pain","n_c":["C146745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extraocular Muscle Paresis","n_c":["C143466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extrapyramidal Disorder","n_c":["C143467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye Disorders - Other","n_c":["C143468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye Infection","n_c":["C143469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye Pain","n_c":["C146751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eyelid Function Disorder","n_c":["C143471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Facial Muscle Weakness","n_c":["C143472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Facial Nerve Disorder","n_c":["C143473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Facial Pain","n_c":["C143474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fall","n_c":["C143475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Anastomotic Leak","n_c":["C143476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Obstruction","n_c":["C146752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Perforation","n_c":["C146714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Stenosis","n_c":["C78295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fat Atrophy","n_c":["C143479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fatigue","n_c":["C146753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Febrile Neutropenia","n_c":["C143481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fecal Incontinence","n_c":["C143482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Female Genital Tract Fistula","n_c":["C78298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feminization Acquired","n_c":["C143483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fetal Death","n_c":["C50620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fetal Growth Retardation","n_c":["C143484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fever","n_c":["C143485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrinogen Decreased","n_c":["C143486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis Deep Connective Tissue","n_c":["C143487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flank Pain","n_c":["C143488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flashing Lights","n_c":["C143489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flatulence","n_c":["C57807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floaters","n_c":["C143491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flu Like Symptoms","n_c":["C143492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flushing","n_c":["C146643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forced Expiratory Volume Decreased","n_c":["C143494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fracture","n_c":["C58382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gait Disturbance","n_c":["C143496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Fistula","n_c":["C57808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Infection","n_c":["C143497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Necrosis","n_c":["C146735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Obstruction","n_c":["C57810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Pain","n_c":["C146755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Perforation","n_c":["C146708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Anastomotic Leak","n_c":["C143498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Fistula","n_c":["C143499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Hemorrhage","n_c":["C143500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Necrosis","n_c":["C143501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Perforation","n_c":["C143502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Stenosis","n_c":["C143503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Ulcer","n_c":["C143504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C57812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C143506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Anastomotic Leak","n_c":["C143507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Disorders - Other","n_c":["C143508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Fistula","n_c":["C146637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Pain","n_c":["C143510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Stoma Necrosis","n_c":["C143511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroparesis","n_c":["C143512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"General Disorders and Administration Site Conditions - Other","n_c":["C143513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Generalized Muscle Weakness","n_c":["C143514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genital Edema","n_c":["C143515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GGT Increased","n_c":["C143516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gingival Pain","n_c":["C146626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C55842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glossopharyngeal Nerve Disorder","n_c":["C143518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucose Intolerance","n_c":["C143519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth Accelerated","n_c":["C143520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth Hormone Abnormal","n_c":["C143521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth Suppression","n_c":["C143522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum Infection","n_c":["C143523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gynecomastia","n_c":["C146685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hallucinations","n_c":["C143525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Haptoglobin Decreased","n_c":["C143526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head Soft Tissue Necrosis","n_c":["C58383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C143527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hearing Impaired","n_c":["C143528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Failure","n_c":["C143529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematoma","n_c":["C56539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematosalpinx","n_c":["C143531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematuria","n_c":["C143532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemoglobin Increased","n_c":["C143533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemoglobinuria","n_c":["C146768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemolysis","n_c":["C55992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemolytic Uremic Syndrome","n_c":["C143536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhoidal Hemorrhage","n_c":["C143537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhoids","n_c":["C146738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Failure","n_c":["C143539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Hemorrhage","n_c":["C143540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Infection","n_c":["C143541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Necrosis","n_c":["C146736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Pain","n_c":["C143542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis Viral","n_c":["C143543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatobiliary Disorders - Other","n_c":["C143544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hiccups","n_c":["C143545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip Fracture","n_c":["C143546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hirsutism","n_c":["C143547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hoarseness","n_c":["C143548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hot Flashes","n_c":["C143549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydrocephalus","n_c":["C55401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C143551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C143552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperhidrosis","n_c":["C143553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperkalemia","n_c":["C143554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypermagnesemia","n_c":["C143555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypernatremia","n_c":["C143556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperparathyroidism","n_c":["C143557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypersomnia","n_c":["C143558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C55060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperthyroidism","n_c":["C143560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertrichosis","n_c":["C143561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertriglyceridemia","n_c":["C143562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperuricemia","n_c":["C143563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoalbuminemia","n_c":["C143564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypocalcemia","n_c":["C143565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoglossal Nerve Disorder","n_c":["C143566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoglycemia","n_c":["C143567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypohidrosis","n_c":["C143568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypokalemia","n_c":["C143569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypomagnesemia","n_c":["C143570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyponatremia","n_c":["C143571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoparathyroidism","n_c":["C143572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypophosphatemia","n_c":["C143573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypotension","n_c":["C55061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothermia","n_c":["C55332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C143576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoxia","n_c":["C58188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Fistula","n_c":["C57821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Hemorrhage","n_c":["C56542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Obstruction","n_c":["C57823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Perforation","n_c":["C146633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Stenosis","n_c":["C143578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Ulcer","n_c":["C57826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileus","n_c":["C57814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immune System Disorders - Other","n_c":["C143580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infections and Infestations - Other","n_c":["C143581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infective Myositis","n_c":["C143582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infusion Related Reaction","n_c":["C143583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infusion Site Extravasation","n_c":["C143584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injection Site Reaction","n_c":["C143585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Carotid Artery","n_c":["C143586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Inferior Vena Cava","n_c":["C56735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Jugular Vein","n_c":["C143587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Superior Vena Cava","n_c":["C143588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury, Poisoning and Procedural Complications - Other","n_c":["C143589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INR Increased","n_c":["C143590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insomnia","n_c":["C146771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Stoma Leak","n_c":["C143592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Stoma Obstruction","n_c":["C143593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Stoma Site Bleeding","n_c":["C143594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intra-Abdominal Hemorrhage","n_c":["C143595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intracranial Hemorrhage","n_c":["C143596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Arterial Injury","n_c":["C143597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Breast Injury","n_c":["C143598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Cardiac Injury","n_c":["C143599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Ear Injury","n_c":["C143600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Endocrine Injury","n_c":["C143601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Gastrointestinal Injury","n_c":["C143602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Head and Neck Injury","n_c":["C143603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Hemorrhage","n_c":["C143604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Hepatobiliary Injury","n_c":["C143605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Musculoskeletal Injury","n_c":["C143606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Neurological Injury","n_c":["C143607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Ocular Injury","n_c":["C143608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Renal Injury","n_c":["C143609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Reproductive Tract Injury","n_c":["C143610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Respiratory Injury","n_c":["C143611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Skin Injury","n_c":["C78389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Splenic Injury","n_c":["C143612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Urinary Injury","n_c":["C143613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Venous Injury","n_c":["C143614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Investigations - Other","n_c":["C143615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C55993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irregular Menstruation","n_c":["C143617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irritability","n_c":["C143618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemia Cerebrovascular","n_c":["C143619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IVth Nerve Disorder","n_c":["C143235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Fistula","n_c":["C57827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Hemorrhage","n_c":["C56543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Obstruction","n_c":["C57829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Perforation","n_c":["C143622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Stenosis","n_c":["C143623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Ulcer","n_c":["C57832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Effusion","n_c":["C146760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Infection","n_c":["C143626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Range of Motion Decreased","n_c":["C143629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Range of Motion Decreased Cervical Spine","n_c":["C143627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Range of Motion Decreased Lumbar Spine","n_c":["C143628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Keratitis","n_c":["C55847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Anastomotic Leak","n_c":["C143631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Infection","n_c":["C143632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kyphosis","n_c":["C143633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lactation Disorder","n_c":["C143634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Intestinal Anastomotic Leak","n_c":["C143635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Edema","n_c":["C143636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Fistula","n_c":["C58190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Hemorrhage","n_c":["C56545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Inflammation","n_c":["C143637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Mucositis","n_c":["C143638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Obstruction","n_c":["C143639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Stenosis","n_c":["C143640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngitis","n_c":["C143641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharyngeal Dysesthesia","n_c":["C143642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngospasm","n_c":["C143643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left Ventricular Systolic Dysfunction","n_c":["C146719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lethargy","n_c":["C143645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukemia Secondary to Oncology Chemotherapy","n_c":["C143646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukocytosis","n_c":["C143647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukoencephalopathy","n_c":["C143648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libido Decreased","n_c":["C143649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libido Increased","n_c":["C143650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip Infection","n_c":["C143651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip Pain","n_c":["C146761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipase Increased","n_c":["C143652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipohypertrophy","n_c":["C143653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Localized Edema","n_c":["C143654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lordosis","n_c":["C143655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lower Gastrointestinal Hemorrhage","n_c":["C143656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Infection","n_c":["C143657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Gland Infection","n_c":["C143658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Leakage","n_c":["C143659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node Pain","n_c":["C146773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphedema","n_c":["C143660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocele","n_c":["C55705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocyte Count Decreased","n_c":["C143662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocyte Count Increased","n_c":["C143663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malabsorption","n_c":["C57838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaise","n_c":["C143665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mania","n_c":["C143666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Hemorrhage","n_c":["C56549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Infection","n_c":["C143667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Memory Impairment","n_c":["C146763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meningismus","n_c":["C143669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meningitis","n_c":["C143670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menopause","n_c":["C3231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menorrhagia","n_c":["C143671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolism and Nutrition Disorders - Other","n_c":["C143672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Ear Inflammation","n_c":["C143673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitral Valve Disease","n_c":["C143674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobitz (Type) II Atrioventricular Block","n_c":["C54772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobitz Type I","n_c":["C54771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Movements Involuntary","n_c":["C143677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucosal Infection","n_c":["C143678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucositis Oral","n_c":["C143679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-Organ Failure","n_c":["C143680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Left-Sided","n_c":["C143681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Lower Limb","n_c":["C143682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Right-Sided","n_c":["C143683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Trunk","n_c":["C143684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Upper Limb","n_c":["C143685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Musculoskeletal and Connective Tissue Disorders - Other","n_c":["C143686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Musculoskeletal Deformity","n_c":["C143687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myalgia","n_c":["C143688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelitis","n_c":["C55459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndrome","n_c":["C143690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C143691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocarditis","n_c":["C146695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myositis","n_c":["C146787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Discoloration","n_c":["C143694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Infection","n_c":["C143695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Loss","n_c":["C143696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Ridging","n_c":["C143697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Congestion","n_c":["C143698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nausea","n_c":["C146764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck Edema","n_c":["C143700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck Pain","n_c":["C146766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck Soft Tissue Necrosis","n_c":["C58394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other","n_c":["C143701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nervous System Disorders - Other","n_c":["C143702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuralgia","n_c":["C143703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neutrophil Count Decreased","n_c":["C143704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Night Blindness","n_c":["C143705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nipple Deformity","n_c":["C143706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Cardiac Chest Pain","n_c":["C143707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nystagmus","n_c":["C146775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C55334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obstruction Gastric","n_c":["C143710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oculomotor Nerve Disorder","n_c":["C143711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olfactory Nerve Disorder","n_c":["C143712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oligospermia","n_c":["C143713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Optic Nerve Disorder","n_c":["C143714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity Fistula","n_c":["C143715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Dysesthesia","n_c":["C143716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hemorrhage","n_c":["C56551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Pain","n_c":["C146627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteonecrosis of Jaw","n_c":["C143717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis","n_c":["C146767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Otitis Externa","n_c":["C143719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Otitis Media","n_c":["C143720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Hemorrhage","n_c":["C56553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Infection","n_c":["C143721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Rupture","n_c":["C143722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovulation Pain","n_c":["C146769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain","n_c":["C143725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain in Extremity","n_c":["C143723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain of Skin","n_c":["C143724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palmar-Plantar Erythrodysesthesia Syndrome","n_c":["C143726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palpitations","n_c":["C54935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Infection","n_c":["C143728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Anastomotic Leak","n_c":["C143729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Duct Stenosis","n_c":["C143730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Enzymes Decreased","n_c":["C143731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Fistula","n_c":["C57845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Hemorrhage","n_c":["C56554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Necrosis","n_c":["C143732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C146789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papilledema","n_c":["C143734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papulopustular Rash","n_c":["C143735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paresthesia","n_c":["C143736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paronychia","n_c":["C143737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paroxysmal Atrial Tachycardia","n_c":["C143738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Floor Muscle Weakness","n_c":["C143739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Infection","n_c":["C143740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Pain","n_c":["C146679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Soft Tissue Necrosis","n_c":["C58399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penile Infection","n_c":["C143741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penile Pain","n_c":["C146680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perforation Bile Duct","n_c":["C143742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardial Effusion","n_c":["C143743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardial Tamponade","n_c":["C143744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericarditis","n_c":["C55067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perineal Pain","n_c":["C146681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periodontal Disease","n_c":["C57849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Edema","n_c":["C143747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Infection","n_c":["C143748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Ischemia","n_c":["C143749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Motor Neuropathy","n_c":["C143750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Nerve Infection","n_c":["C143751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Sensory Neuropathy","n_c":["C143752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Infection","n_c":["C143753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Necrosis","n_c":["C57850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personality Change","n_c":["C143754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phantom Pain","n_c":["C146682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Anastomotic Leak","n_c":["C143755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Fistula","n_c":["C57851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Hemorrhage","n_c":["C56557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Mucositis","n_c":["C143756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Necrosis","n_c":["C57855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Stenosis","n_c":["C143757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngitis","n_c":["C143758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngolaryngeal Pain","n_c":["C143759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phlebitis","n_c":["C143761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phlebitis Infective","n_c":["C143760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photophobia","n_c":["C146770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photosensitivity","n_c":["C58005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platelet Count Decreased","n_c":["C143764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C143765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Hemorrhage","n_c":["C56558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Infection","n_c":["C143766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleuritic Pain","n_c":["C146663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonitis","n_c":["C143767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumothorax","n_c":["C58201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portal Hypertension","n_c":["C143769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portal Vein Thrombosis","n_c":["C143770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postnasal Drip","n_c":["C143771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative Hemorrhage","n_c":["C143772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative Thoracic Procedure Complication","n_c":["C143773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Precocious Puberty","n_c":["C146645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy, Puerperium and Perinatal Conditions - Other","n_c":["C143775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premature Delivery","n_c":["C143776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premature Menopause","n_c":["C143777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Presyncope","n_c":["C143778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proctitis","n_c":["C57857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Productive Cough","n_c":["C143780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolapse of Intestinal Stoma","n_c":["C143781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolapse of Urostomy","n_c":["C143782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Infection","n_c":["C143783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Hemorrhage","n_c":["C56552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Obstruction","n_c":["C143784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Pain","n_c":["C146664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proteinuria","n_c":["C146758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pruritus","n_c":["C58006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psychiatric Disorders - Other","n_c":["C143787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psychosis","n_c":["C143788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Edema","n_c":["C143789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C143790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fistula","n_c":["C143791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hypertension","n_c":["C55068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Valve Disease","n_c":["C143793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Purpura","n_c":["C143794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyramidal Tract Syndrome","n_c":["C143795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation Recall Reaction (Dermatologic)","n_c":["C143796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiculitis","n_c":["C143797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rash Acneiform","n_c":["C143798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rash Maculo-Papular","n_c":["C143799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rash Pustular","n_c":["C143800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Anastomotic Leak","n_c":["C143801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Fistula","n_c":["C57859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Hemorrhage","n_c":["C56560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Mucositis","n_c":["C143802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Necrosis","n_c":["C57863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Obstruction","n_c":["C57864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Pain","n_c":["C146631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Perforation","n_c":["C146634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Stenosis","n_c":["C143803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Ulcer","n_c":["C57867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Laryngeal Nerve Palsy","n_c":["C143804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal and Urinary Disorders - Other","n_c":["C143805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Calculi","n_c":["C143806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Colic","n_c":["C143807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Hemorrhage","n_c":["C56544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reproductive System and Breast Disorders - Other","n_c":["C143808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Respiratory Failure","n_c":["C143809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Respiratory, Thoracic and Mediastinal Disorders - Other","n_c":["C143810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Restlessness","n_c":["C143811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Restrictive Cardiomyopathy","n_c":["C55069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinal Detachment","n_c":["C146729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinal Tear","n_c":["C143814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinal Vascular Disorder","n_c":["C143815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinoic Acid Syndrome","n_c":["C56635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinopathy","n_c":["C55891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal Hemorrhage","n_c":["C146632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reversible Posterior Leukoencephalopathy Syndrome","n_c":["C143818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhinitis Infective","n_c":["C143819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right Ventricular Dysfunction","n_c":["C55070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Duct Inflammation","n_c":["C143821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland Fistula","n_c":["C57868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland Infection","n_c":["C143822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp Pain","n_c":["C146772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scleral Disorder","n_c":["C143823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scoliosis","n_c":["C143824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotal Infection","n_c":["C143825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotal Pain","n_c":["C146665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C146700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sepsis","n_c":["C143827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seroma","n_c":["C58401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Amylase Increased","n_c":["C143829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Sickness","n_c":["C146642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sick Sinus Syndrome","n_c":["C54938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Bradycardia","n_c":["C54940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Disorder","n_c":["C143831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Pain","n_c":["C146783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Tachycardia","n_c":["C146759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinusitis","n_c":["C143832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin and Subcutaneous Tissue Disorders - Other","n_c":["C143833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Atrophy","n_c":["C146644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Hyperpigmentation","n_c":["C143835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Hypopigmentation","n_c":["C143836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Induration","n_c":["C143837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Infection","n_c":["C143838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Ulceration","n_c":["C143839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep Apnea","n_c":["C143840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Anastomotic Leak","n_c":["C143841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Mucositis","n_c":["C143842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Obstruction","n_c":["C143843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Perforation","n_c":["C146635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Stenosis","n_c":["C143844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestine Infection","n_c":["C143845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestine Ulcer","n_c":["C143846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sneezing","n_c":["C143847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social Circumstances - Other","n_c":["C143848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Infection","n_c":["C143849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Necrosis Lower Limb","n_c":["C143850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Necrosis Upper Limb","n_c":["C143851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somnolence","n_c":["C143852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sore Throat","n_c":["C143853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spasticity","n_c":["C143854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spermatic Cord Anastomotic Leak","n_c":["C143855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spermatic Cord Hemorrhage","n_c":["C56563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spermatic Cord Obstruction","n_c":["C146757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Fracture","n_c":["C143856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen Disorder","n_c":["C35823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Infection","n_c":["C143857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stenosis of Gastrointestinal Stoma","n_c":["C143858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stevens-Johnson Syndrome","n_c":["C143859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stoma Site Infection","n_c":["C143860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach Pain","n_c":["C146774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomal Ulcer","n_c":["C146694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stridor","n_c":["C143861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C143862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sudden Death NOS","n_c":["C143863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suicidal Ideation","n_c":["C143864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suicide Attempt","n_c":["C143865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial Soft Tissue Fibrosis","n_c":["C143866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial Thrombophlebitis","n_c":["C143867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superior Vena Cava Syndrome","n_c":["C143868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraventricular Tachycardia","n_c":["C54945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical and Medical Procedures - Other","n_c":["C143869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syncope","n_c":["C146750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telangiectasia","n_c":["C146740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Disorder","n_c":["C143872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Hemorrhage","n_c":["C56566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Pain","n_c":["C146666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thromboembolic Event","n_c":["C143873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thrombotic Thrombocytopenic Purpura","n_c":["C143874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tinnitus","n_c":["C146690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tooth Development Disorder","n_c":["C143876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tooth Discoloration","n_c":["C143877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tooth Infection","n_c":["C143878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toothache","n_c":["C143879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxic Epidermal Necrolysis","n_c":["C143880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Fistula","n_c":["C58205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Hemorrhage","n_c":["C56567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Mucositis","n_c":["C143881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Obstruction","n_c":["C143882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Stenosis","n_c":["C143883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheitis","n_c":["C143884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheostomy Site Bleeding","n_c":["C143885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attacks","n_c":["C143886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treatment Related Secondary Malignancy","n_c":["C143887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tremor","n_c":["C146780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tricuspid Valve Disease","n_c":["C143889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trigeminal Nerve Disorder","n_c":["C143890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trismus","n_c":["C58404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Lysis Syndrome","n_c":["C146688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Pain","n_c":["C146782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Typhlitis","n_c":["C146730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unequal Limb Length","n_c":["C143894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unintended Pregnancy","n_c":["C79801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upper Gastrointestinal Hemorrhage","n_c":["C143895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upper Respiratory Infection","n_c":["C143896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureteric Anastomotic Leak","n_c":["C143897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethral Anastomotic Leak","n_c":["C143898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethral Infection","n_c":["C143899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Fistula","n_c":["C143900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Frequency","n_c":["C143901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Incontinence","n_c":["C146786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Retention","n_c":["C57097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C143904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Obstruction","n_c":["C143905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Pain","n_c":["C143906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Urgency","n_c":["C143907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urine Discoloration","n_c":["C143908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urine Output Decreased","n_c":["C143909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Leak","n_c":["C143910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Obstruction","n_c":["C143911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Site Bleeding","n_c":["C143912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Stenosis","n_c":["C143913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urticaria","n_c":["C58019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Anastomotic Leak","n_c":["C143915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Fistula","n_c":["C143916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Hemorrhage","n_c":["C56572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Infection","n_c":["C143917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Obstruction","n_c":["C143918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Pain","n_c":["C146683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Perforation","n_c":["C143919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uveitis","n_c":["C55901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Anastomotic Leak","n_c":["C143921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Discharge","n_c":["C143922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Dryness","n_c":["C146687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Fistula","n_c":["C57104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Hemorrhage","n_c":["C56573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Infection","n_c":["C143924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Inflammation","n_c":["C143925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Obstruction","n_c":["C146696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Pain","n_c":["C146684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Perforation","n_c":["C146697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Stricture","n_c":["C143926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginismus","n_c":["C78703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagus Nerve Disorder","n_c":["C143927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens Anastomotic Leak","n_c":["C143928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Access Complication","n_c":["C143929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disorders - Other","n_c":["C143930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vasculitis","n_c":["C54741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vasovagal Reaction","n_c":["C143932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous Injury","n_c":["C143933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ventricular Arrhythmia","n_c":["C146629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ventricular Fibrillation","n_c":["C146732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ventricular Tachycardia","n_c":["C146733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertigo","n_c":["C143935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vestibular Disorder","n_c":["C143936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virilization","n_c":["C143937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Visceral Arterial Ischemia","n_c":["C143938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vital Capacity Abnormal","n_c":["C143939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitreous Hemorrhage","n_c":["C146677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Voice Alteration","n_c":["C143941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vomiting","n_c":["C57896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulval Infection","n_c":["C143943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Watering Eyes","n_c":["C143944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weight Gain","n_c":["C55338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weight Loss","n_c":["C55339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wheezing","n_c":["C143947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cell Decreased","n_c":["C143948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wolff-Parkinson-White Syndrome","n_c":["C35132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wound Complication","n_c":["C143949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wound Dehiscence","n_c":["C143950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wound Infection","n_c":["C143951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist Fracture","n_c":["C143952"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.adverse_event_grade":[{"nm":"Grade 1","n_c":["C41338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 2","n_c":["C41339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 3","n_c":["C41340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 4","n_c":["C84266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 5","n_c":["C48275"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.aids_risk_factors":[{"nm":"Candidiasis","n_c":["C26711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coccidioidomycosis","n_c":["C84642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcosis","n_c":["C2967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptosporidiosis, Chronic Intestinal","n_c":["C174107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalopathy","n_c":["C26920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Simplex Virus","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histoplasmosis","n_c":["C77201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isosporiasis","n_c":["C4076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium tuberculosis","n_c":["C128377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium, NOS","n_c":["C26831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nocardiosis","n_c":["C171147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Multifocal Leukoencephalopathy","n_c":["C26815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salmonella Septicemia","n_c":["C171146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxoplasmosis","n_c":["C3418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wasting Syndrome","n_c":["C171148"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.barretts_esophagus_goblet_cells_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.cdc_hiv_risk_factors":[{"nm":"Hemophiliac","n_c":["C3093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterosexual Contact","n_c":["C154862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Homosexual Contact","n_c":["C154863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravenous Drug User","n_c":["C84367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C159672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transfusion Recipient","n_c":["C171149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.comorbidity":[{"nm":"Acute Renal Failure","n_c":["C26808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenocarcinoma","n_c":["C2852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomatous Polyposis Coli","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenocortical Insufficiency","n_c":["C26691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergies","n_c":["C114476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C26696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arrhythmia","n_c":["C2881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C2883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C50466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C118385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Carcinoma","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Disorder","n_c":["C2899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Clots","n_c":["C27083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Fracture(s)","n_c":["C3046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchitis","n_c":["C2911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Channel Blockers","n_c":["C333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataracts","n_c":["C26713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celiac Disease","n_c":["C26714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrovascular Disease","n_c":["C2938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Renal Failure","n_c":["C9438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis, Unknown Etiology","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immunodeficiency","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congestive Heart Failure (CHF)","n_c":["C3080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue Disorder","n_c":["C26729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COPD","n_c":["C3199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coronary Artery Disease","n_c":["C26732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crohn's Disease","n_c":["C2965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptogenic Organizing Pneumonia","n_c":["C62586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Vein Thrombosis / Thromboembolism","n_c":["C49343","C28195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C2982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetic Neuropathy","n_c":["C26748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet Controlled Diabetes","n_c":["C184754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DVT/PE","n_c":["C49343","C50713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyslipidemia","n_c":["C80385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epilepsy","n_c":["C3020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GERD","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C26782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycogen Storage Disease","n_c":["C61272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadal Dysfunction","n_c":["C26786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gout","n_c":["C34650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H. pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Disease","n_c":["C3079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhagic Cystitis","n_c":["C114666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, Chronic","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Non-polyposis Colon Cancer","n_c":["C120083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Liver Dysplastic Nodule","n_c":["C96768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV / AIDS","n_c":["C2851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HUS/TTP","n_c":["C75545","C78797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C3112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercholesterolemia","n_c":["C37967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C26797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperlipidemia","n_c":["C34707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C3117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammatory Bowel Disease","n_c":["C3138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin Controlled Diabetes","n_c":["C184766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interstitial Pneumontis or ARDS","n_c":["C3353","C27006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraductal Papillary Mucinous Neoplasm","n_c":["C38342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemic Heart Disease","n_c":["C50625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITP","n_c":["C3446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Replacement","n_c":["C131579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Disease","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cirrhosis (Liver Disease)","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Toxicity (Non-Infectious)","n_c":["C184773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Liver Dysplastic Nodule","n_c":["C96770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupus","n_c":["C27153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAI","n_c":["C27314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C27996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroendocrine Tumor","n_c":["C3809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ transplant (site)","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoarthritis","n_c":["C3293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis or Osteopenia","n_c":["C3298","C50910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Cancer Within 5 Years","n_c":["C184782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Nonmalignant Systemic Disease","n_c":["C184785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Pulmonary Complications","n_c":["C184786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain (Various)","n_c":["C3303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptic Ulcer (Ulcer)","n_c":["C3318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Neuropathy","n_c":["C119734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Vascular Disease","n_c":["C35136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peutz-Jeghers Disease","n_c":["C3324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy in Patient or Partner","n_c":["C124295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psoriasis","n_c":["C3346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hemorrhage","n_c":["C78578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Dialysis","n_c":["C15248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Failure (Requiring Dialysis)","n_c":["C184791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Insufficiency","n_c":["C4376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatologic Disease","n_c":["C27204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep apnea","n_c":["C26884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C3390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attack","n_c":["C50781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinemia","n_c":["C98640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulcerative Colitis","n_c":["C2952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Fatigue Syndrome","n_c":["C3037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clonal Hematopoiesis","n_c":["C162188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromyalgia","n_c":["C87497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staph Osteomyelitis","n_c":["C188353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Infection","n_c":["C27582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methicillin-Resistant Staphylococcus aureus (MRSA)","n_c":["C115248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Disease, Non-Cancer","n_c":["C27566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C50791"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.comorbidity_method_of_diagnosis":[{"nm":"Histology","n_c":["C16681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathology","n_c":["C18189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiology","n_c":["C19187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.diabetes_treatment_type":[{"nm":"Alpha-Glucosidase Inhibitor","n_c":["C139651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biguanide","n_c":["C98234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injected Insulin","n_c":["C179441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin","n_c":["C581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hypoglycemic","n_c":["C179448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulfonylurea","n_c":["C97936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiazolidinedione","n_c":["C98241"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linagliptin","n_c":["C83887"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.disease_response":[{"nm":"AJ-Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BED-Biochemical Evidence of Disease","n_c":["C165196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CPD-Clinical Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CR-Complete Response","n_c":["C4870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRU-Complete Response Unconfirmed","n_c":["C165198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DU-Disease Unchanged","n_c":["C71687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IMR-Immunoresponse","n_c":["C131144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IPD-Immunoprogression","n_c":["C131143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MR-Minimal/Marginal response","n_c":["C123598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX-Mixed Response","n_c":["C165202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-CR/Non-PD-Non-CR/Non-PD","n_c":["C96700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPB-No Palliative Benefit","n_c":["C165204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR-No Response","n_c":["C123600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PA-Palliative Therapy","n_c":["C15292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PB-Palliative Benefit","n_c":["C101516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-Progressive Disease","n_c":["C8510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDM-Persistent Distant Metastasis","n_c":["C165205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLD-Persistent Locoregional Disease","n_c":["C188367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPD-Pseudoprogression","n_c":["C98298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PR-Partial Response","n_c":["C18058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSR-Pseudoresponse","n_c":["C131142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RD-Responsive Disease","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RP-Response","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPD-Radiographic Progressive Disease","n_c":["C165208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"sCR-Stringent Complete Response","n_c":["C123614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SD-Stable Disease","n_c":["C18213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPD-Surgical Progression","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TE-Too Early","n_c":["C133441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TF-Tumor Free","n_c":["C156848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGPR-Very Good Partial Response","n_c":["C123618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT-With Tumor","n_c":["C156849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.ecog_performance_status":[{"nm":"0","n_c":["C105722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1","n_c":["C105723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C105725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C105726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":["C105727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5","n_c":["C105728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.evidence_of_recurrence_type":[{"nm":"Biopsy with Histologic Confirmation","n_c":["C158780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Convincing Image Source","n_c":["C158782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical Examination","n_c":["C83119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Positive Biomarker(s)","n_c":["C150123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histologic Confirmation","n_c":["C158780"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.haart_treatment_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hepatitis_sustained_virological_response":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hormonal_contraceptive_type":[{"nm":"Progestin","n_c":["C179455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progestin and Estrogen","n_c":["C179456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hormonal_contraceptive_use":[{"nm":"Current User","n_c":["C160671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Former User","n_c":["C160672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never Used","n_c":["C160673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hormone_replacement_therapy_type":[{"nm":"Estrogen only","n_c":["C179434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone and Estrogen","n_c":["C179452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone only","n_c":["C179453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hpv_positive_type":[{"nm":"16","n_c":["C14338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"18","n_c":["C14377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"26","n_c":["C102995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"31","n_c":["C102904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"33","n_c":["C102996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"35","n_c":["C102997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"39","n_c":["C102998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"45","n_c":["C102999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"51","n_c":["C103000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"52","n_c":["C103001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"53","n_c":["C103002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"56","n_c":["C103003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"58","n_c":["C103004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"59","n_c":["C103005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"63","n_c":["C156054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"66","n_c":["C103006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"68","n_c":["C103007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"70","n_c":["C156055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"73","n_c":["C103008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"82","n_c":["C103009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hysterectomy_margins_involved":[{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic Parametrium","n_c":["C179443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic Parametrium","n_c":["C179445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C48621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hysterectomy_type":[{"nm":"Hysterectomy, NOS","n_c":["C15256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not performed","n_c":["C141477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Hysterectomy","n_c":["C94470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_result":[{"nm":"Positive","n_c":["C38758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Performed","n_c":["C141477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_type":[{"nm":"99mTc Bone Scintigraphy","n_c":["C162575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CT Scan","n_c":["C17204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MRI","n_c":["C16809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PET","n_c":["C17007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ultrasound","n_c":["C17230"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.immunosuppressive_treatment_type":[{"nm":"Anti-TNF Therapy","n_c":["C15577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azathioprine","n_c":["C290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide","n_c":["C405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate","n_c":["C642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.karnofsky_performance_status":[{"nm":"0","n_c":["C105720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"10","n_c":["C105718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"20","n_c":["C105716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"30","n_c":["C105715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"40","n_c":["C105714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"50","n_c":["C105713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"60","n_c":["C105712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"70","n_c":["C105711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"80","n_c":["C105710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"90","n_c":["C105709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"100","n_c":["C105707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.menopause_status":[{"nm":"Premenopausal","n_c":["C15491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perimenopausal","n_c":["C15692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postmenopausal","n_c":["C15421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.pregnancy_outcome":[{"nm":"Ectopic Pregnancy","n_c":["C34945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induced Abortion","n_c":["C50613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live Birth","n_c":["C114091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscarriage","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stillbirth","n_c":["C49151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Abortion","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.procedures_performed":[{"nm":"Colonoscopy","n_c":["C16450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endoscopy","n_c":["C16546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.progression_or_recurrence":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.progression_or_recurrence_anatomic_site":[{"nm":"Abdomen, NOS","n_c":["C12664"],"i_c":"C76.2","i_c_s":["Abdomen, NOS"],"term_type":"PT"},{"nm":"Abdominal esophagus","n_c":["C12252"],"i_c":"C15.2","i_c_s":["Abdominal esophagus"],"term_type":"PT"},{"nm":"Accessory sinus, NOS","n_c":["C12763"],"i_c":"C31.9","i_c_s":["Accessory sinus, NOS"],"term_type":"PT"},{"nm":"Acoustic nerve","n_c":["C12697"],"i_c":"C72.4","i_c_s":["Acoustic nerve"],"term_type":"PT"},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"C74.9","i_c_s":["Adrenal gland, NOS"],"term_type":"PT"},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"C24.1","i_c_s":["Ampulla of Vater"],"term_type":"PT"},{"nm":"Anal canal","n_c":["C12375"],"i_c":"C21.1","i_c_s":["Anal canal"],"term_type":"PT"},{"nm":"Anterior 2/3 of tongue, NOS","n_c":"","i_c":"C02.3","i_c_s":["Anterior 2/3 of tongue, NOS"],"term_type":"PT"},{"nm":"Anterior floor of mouth","n_c":"","i_c":"C04.0","i_c_s":["Anterior floor of mouth"],"term_type":"PT"},{"nm":"Anterior mediastinum","n_c":["C32098"],"i_c":"C38.1","i_c_s":["Anterior mediastinum"],"term_type":"PT"},{"nm":"Anterior surface of epiglottis","n_c":["C12238"],"i_c":"C10.1","i_c_s":["Anterior surface of epiglottis"],"term_type":"PT"},{"nm":"Anterior wall of bladder","n_c":["C12334"],"i_c":"C67.3","i_c_s":["Anterior wall of bladder"],"term_type":"PT"},{"nm":"Anterior wall of nasopharynx","n_c":["C12245"],"i_c":"C11.3","i_c_s":["Anterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"C21.0","i_c_s":["Anus, NOS"],"term_type":"PT"},{"nm":"Aortic body and other paraganglia","n_c":"","i_c":"C75.5","i_c_s":["Aortic body and other paraganglia"],"term_type":"PT"},{"nm":"Appendix","n_c":["C12380"],"i_c":"C18.1","i_c_s":["Appendix"],"term_type":"PT"},{"nm":"Ascending colon","n_c":["C12265"],"i_c":"C18.2","i_c_s":["Ascending colon"],"term_type":"PT"},{"nm":"Autonomic nervous system, NOS","n_c":["C12673"],"i_c":"C47.9","i_c_s":["Autonomic nervous system, NOS"],"term_type":"PT"},{"nm":"Axillary tail of breast","n_c":["C12305"],"i_c":"C50.6","i_c_s":["Axillary tail of breast"],"term_type":"PT"},{"nm":"Base of tongue, NOS","n_c":["C12228"],"i_c":"C01.9","i_c_s":["Base of tongue, NOS"],"term_type":"PT"},{"nm":"Biliary tract, NOS","n_c":["C12678"],"i_c":"C24.9","i_c_s":["Biliary tract, NOS"],"term_type":"PT"},{"nm":"Bladder neck","n_c":["C12336"],"i_c":"C67.5","i_c_s":["Bladder neck"],"term_type":"PT"},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"C67.9","i_c_s":["Bladder, NOS"],"term_type":"PT"},{"nm":"Blood","n_c":["C12434"],"i_c":"C42.0","i_c_s":["Blood"],"term_type":"PT"},{"nm":"Body of pancreas","n_c":["C12270"],"i_c":"C25.1","i_c_s":["Body of pancreas"],"term_type":"PT"},{"nm":"Body of penis","n_c":["C12325"],"i_c":"C60.2","i_c_s":["Body of penis"],"term_type":"PT"},{"nm":"Body of stomach","n_c":["C12258"],"i_c":"C16.2","i_c_s":["Body of stomach"],"term_type":"PT"},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"C42.1","i_c_s":["Bone marrow"],"term_type":"PT"},{"nm":"Bone of limb, NOS","n_c":["C32223"],"i_c":"C40.9","i_c_s":["Bone of limb, NOS"],"term_type":"PT"},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"C41.9","i_c_s":["Bone, NOS"],"term_type":"PT"},{"nm":"Bones of skull and face and associated joints","n_c":"","i_c":"C41.0","i_c_s":["Bones of skull and face and associated joints"],"term_type":"PT"},{"nm":"Border of tongue","n_c":"","i_c":"C02.1","i_c_s":["Border of tongue"],"term_type":"PT"},{"nm":"Brain stem","n_c":["C12441"],"i_c":"C71.7","i_c_s":["Brain stem"],"term_type":"PT"},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"C71.9","i_c_s":["Brain, NOS"],"term_type":"PT"},{"nm":"Branchial cleft","n_c":["C104813"],"i_c":"C10.4","i_c_s":["Branchial cleft"],"term_type":"PT"},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"C50.9","i_c_s":["Breast, NOS"],"term_type":"PT"},{"nm":"Broad ligament","n_c":["C12318"],"i_c":"C57.1","i_c_s":["Broad ligament"],"term_type":"PT"},{"nm":"Cardia, NOS","n_c":["C12256"],"i_c":"C16.0","i_c_s":["Cardia, NOS"],"term_type":"PT"},{"nm":"Carotid body","n_c":["C66852"],"i_c":"C75.4","i_c_s":["Carotid body"],"term_type":"PT"},{"nm":"Cauda equina","n_c":["C12689"],"i_c":"C72.1","i_c_s":["Cauda equina"],"term_type":"PT"},{"nm":"Cecum","n_c":["C12381"],"i_c":"C18.0","i_c_s":["Cecum"],"term_type":"PT"},{"nm":"Central portion of breast","n_c":["C12300"],"i_c":"C50.1","i_c_s":["Central portion of breast"],"term_type":"PT"},{"nm":"Cerebellum, NOS","n_c":["C12445"],"i_c":"C71.6","i_c_s":["Cerebellum, NOS"],"term_type":"PT"},{"nm":"Cerebral meninges","n_c":["C12349"],"i_c":"C70.0","i_c_s":["Cerebral meninges"],"term_type":"PT"},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"C71.0","i_c_s":["Cerebrum"],"term_type":"PT"},{"nm":"Cervical esophagus","n_c":["C12250"],"i_c":"C15.0","i_c_s":["Cervical esophagus"],"term_type":"PT"},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"C53.9","i_c_s":["Cervix uteri"],"term_type":"PT"},{"nm":"Cheek mucosa","n_c":["C12505"],"i_c":"C06.0","i_c_s":["Cheek mucosa"],"term_type":"PT"},{"nm":"Choroid","n_c":["C12344"],"i_c":"C69.3","i_c_s":["Choroid"],"term_type":"PT"},{"nm":"Ciliary body","n_c":["C12345"],"i_c":"C69.4","i_c_s":["Ciliary body"],"term_type":"PT"},{"nm":"Clitoris","n_c":["C12308"],"i_c":"C51.2","i_c_s":["Clitoris"],"term_type":"PT"},{"nm":"Cloacogenic zone","n_c":["C32072"],"i_c":"C21.2","i_c_s":["Cloacogenic zone"],"term_type":"PT"},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"C18.9","i_c_s":["Colon, NOS"],"term_type":"PT"},{"nm":"Commissure of lip","n_c":["C12227"],"i_c":"C00.6","i_c_s":["Commissure of lip"],"term_type":"PT"},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"C69.0","i_c_s":["Conjunctiva"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of abdomen","n_c":"","i_c":"C49.4","i_c_s":["Connective, subcutaneous and other soft tissues of abdomen"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of head, face, and neck","n_c":"","i_c":"C49.0","i_c_s":["Connective, subcutaneous and other soft tissues of head, face, and neck"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of lower limb and hip","n_c":"","i_c":"C49.2","i_c_s":["Connective, subcutaneous and other soft tissues of lower limb and hip"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of pelvis","n_c":"","i_c":"C49.5","i_c_s":["Connective, subcutaneous and other soft tissues of pelvis"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of thorax","n_c":"","i_c":"C49.3","i_c_s":["Connective, subcutaneous and other soft tissues of thorax"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of trunk, NOS","n_c":"","i_c":"C49.6","i_c_s":["Connective, subcutaneous and other soft tissues of trunk, NOS"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of upper limb and shoulder","n_c":"","i_c":"C49.1","i_c_s":["Connective, subcutaneous and other soft tissues of upper limb and shoulder"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues, NOS","n_c":["C12964"],"i_c":"C49.9","i_c_s":["Connective, subcutaneous and other soft tissues, NOS"],"term_type":"PT"},{"nm":"Cornea, NOS","n_c":["C12342"],"i_c":"C69.1","i_c_s":["Cornea, NOS"],"term_type":"PT"},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"C54.9","i_c_s":["Corpus uteri"],"term_type":"PT"},{"nm":"Cortex of adrenal gland","n_c":["C12396"],"i_c":"C74.0","i_c_s":["Cortex of adrenal gland"],"term_type":"PT"},{"nm":"Cranial nerve, NOS","n_c":["C12700"],"i_c":"C72.5","i_c_s":["Cranial nerve, NOS"],"term_type":"PT"},{"nm":"Craniopharyngeal duct","n_c":["C12357"],"i_c":"C75.2","i_c_s":["Craniopharyngeal duct"],"term_type":"PT"},{"nm":"Descended testis","n_c":"","i_c":"C62.1","i_c_s":["Descended testis"],"term_type":"PT"},{"nm":"Descending colon","n_c":["C12268"],"i_c":"C18.6","i_c_s":["Descending colon"],"term_type":"PT"},{"nm":"Dome of bladder","n_c":["C12332"],"i_c":"C67.1","i_c_s":["Dome of bladder"],"term_type":"PT"},{"nm":"Dorsal surface of tongue, NOS","n_c":"","i_c":"C02.0","i_c_s":["Dorsal surface of tongue, NOS"],"term_type":"PT"},{"nm":"Duodenum","n_c":["C12263"],"i_c":"C17.0","i_c_s":["Duodenum"],"term_type":"PT"},{"nm":"Endocervix","n_c":["C12309"],"i_c":"C53.0","i_c_s":["Endocervix"],"term_type":"PT"},{"nm":"Endocrine gland, NOS","n_c":["C12704"],"i_c":"C75.9","i_c_s":["Endocrine gland, NOS"],"term_type":"PT"},{"nm":"Endometrium","n_c":["C12313"],"i_c":"C54.1","i_c_s":["Endometrium"],"term_type":"PT"},{"nm":"Epididymis","n_c":["C12328"],"i_c":"C63.0","i_c_s":["Epididymis"],"term_type":"PT"},{"nm":"Esophagus, NOS","n_c":["C12389"],"i_c":"C15.9","i_c_s":["Esophagus, NOS"],"term_type":"PT"},{"nm":"Ethmoid sinus","n_c":["C12276"],"i_c":"C31.1","i_c_s":["Ethmoid sinus"],"term_type":"PT"},{"nm":"Exocervix","n_c":["C12310"],"i_c":"C53.1","i_c_s":["Exocervix"],"term_type":"PT"},{"nm":"External ear","n_c":["C12292"],"i_c":"C44.2","i_c_s":["External ear"],"term_type":"PT"},{"nm":"External lip, NOS","n_c":["C12223"],"i_c":"C00.2","i_c_s":["External lip, NOS"],"term_type":"PT"},{"nm":"External lower lip","n_c":["C12222"],"i_c":"C00.1","i_c_s":["External lower lip"],"term_type":"PT"},{"nm":"External upper lip","n_c":["C12221"],"i_c":"C00.0","i_c_s":["External upper lip"],"term_type":"PT"},{"nm":"Extrahepatic bile duct","n_c":["C32573"],"i_c":"C24.0","i_c_s":["Extrahepatic bile duct"],"term_type":"PT"},{"nm":"Eye, NOS","n_c":["C12401"],"i_c":"C69.9","i_c_s":["Eye, NOS"],"term_type":"PT"},{"nm":"Eyelid","n_c":["C12713"],"i_c":"C44.1","i_c_s":["Eyelid"],"term_type":"PT"},{"nm":"Fallopian tube","n_c":["C12403"],"i_c":"C57.0","i_c_s":["Fallopian tube"],"term_type":"PT"},{"nm":"Female genital tract, NOS","n_c":["C61600"],"i_c":"C57.9","i_c_s":["Female genital tract, NOS"],"term_type":"PT"},{"nm":"Floor of mouth, NOS","n_c":["C54187"],"i_c":"C04.9","i_c_s":["Floor of mouth, NOS"],"term_type":"PT"},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"C71.1","i_c_s":["Frontal lobe"],"term_type":"PT"},{"nm":"Frontal sinus","n_c":["C12277"],"i_c":"C31.2","i_c_s":["Frontal sinus"],"term_type":"PT"},{"nm":"Fundus of stomach","n_c":["C12257"],"i_c":"C16.1","i_c_s":["Fundus of stomach"],"term_type":"PT"},{"nm":"Fundus uteri","n_c":["C12315"],"i_c":"C54.3","i_c_s":["Fundus uteri"],"term_type":"PT"},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"C23.9","i_c_s":["Gallbladder"],"term_type":"PT"},{"nm":"Gastric antrum","n_c":["C12259"],"i_c":"C16.3","i_c_s":["Gastric antrum"],"term_type":"PT"},{"nm":"Gastrointestinal tract, NOS","n_c":["C34082"],"i_c":"C26.9","i_c_s":["Gastrointestinal tract, NOS"],"term_type":"PT"},{"nm":"Glans penis","n_c":["C12324"],"i_c":"C60.1","i_c_s":["Glans penis"],"term_type":"PT"},{"nm":"Glottis","n_c":["C12724"],"i_c":"C32.0","i_c_s":["Glottis"],"term_type":"PT"},{"nm":"Greater curvature of stomach, NOS","n_c":["C12262"],"i_c":"C16.6","i_c_s":["Greater curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Gum, NOS","n_c":["C32677"],"i_c":"C03.9","i_c_s":["Gum, NOS"],"term_type":"PT"},{"nm":"Hard palate","n_c":["C12230"],"i_c":"C05.0","i_c_s":["Hard palate"],"term_type":"PT"},{"nm":"Head of pancreas","n_c":["C12269"],"i_c":"C25.0","i_c_s":["Head of pancreas"],"term_type":"PT"},{"nm":"Head, face or neck, NOS","n_c":"","i_c":"C76.0","i_c_s":["Head, face or neck, NOS"],"term_type":"PT"},{"nm":"Heart","n_c":["C12727"],"i_c":"C38.0","i_c_s":["Heart"],"term_type":"PT"},{"nm":"Hematopoietic system, NOS","n_c":["C12909"],"i_c":"C42.4","i_c_s":["Hematopoietic system, NOS"],"term_type":"PT"},{"nm":"Hepatic flexure of colon","n_c":["C12266"],"i_c":"C18.3","i_c_s":["Hepatic flexure of colon"],"term_type":"PT"},{"nm":"Hypopharyngeal aspect of aryepiglottic fold","n_c":"","i_c":"C13.1","i_c_s":["Hypopharyngeal aspect of aryepiglottic fold"],"term_type":"PT"},{"nm":"Hypopharynx, NOS","n_c":["C12246"],"i_c":"C13.9","i_c_s":["Hypopharynx, NOS"],"term_type":"PT"},{"nm":"Ileum","n_c":["C12387"],"i_c":"C17.2","i_c_s":["Ileum"],"term_type":"PT"},{"nm":"Ill-defined sites within respiratory system","n_c":["C148338"],"i_c":"C39.9","i_c_s":["Ill-defined sites within respiratory system"],"term_type":"PT"},{"nm":"Intestinal tract, NOS","n_c":["C12736"],"i_c":"C26.0","i_c_s":["Intestinal tract, NOS"],"term_type":"PT"},{"nm":"Intra-abdominal lymph nodes","n_c":["C12360"],"i_c":"C77.2","i_c_s":["Intra-abdominal lymph nodes"],"term_type":"PT"},{"nm":"Intrahepatic bile duct","n_c":["C12677"],"i_c":"C22.1","i_c_s":["Intrahepatic bile duct"],"term_type":"PT"},{"nm":"Intrathoracic lymph nodes","n_c":["C12359"],"i_c":"C77.1","i_c_s":["Intrathoracic lymph nodes"],"term_type":"PT"},{"nm":"Islets of Langerhans","n_c":["C12608"],"i_c":"C25.4","i_c_s":["Islets of Langerhans"],"term_type":"PT"},{"nm":"Isthmus uteri","n_c":["C12312"],"i_c":"C54.0","i_c_s":["Isthmus uteri"],"term_type":"PT"},{"nm":"Jejunum","n_c":["C12388"],"i_c":"C17.1","i_c_s":["Jejunum"],"term_type":"PT"},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"C64.9","i_c_s":["Kidney, NOS"],"term_type":"PT"},{"nm":"Labium majus","n_c":["C12306"],"i_c":"C51.0","i_c_s":["Labium majus"],"term_type":"PT"},{"nm":"Labium minus","n_c":["C12307"],"i_c":"C51.1","i_c_s":["Labium minus"],"term_type":"PT"},{"nm":"Lacrimal gland","n_c":["C12346"],"i_c":"C69.5","i_c_s":["Lacrimal gland"],"term_type":"PT"},{"nm":"Laryngeal cartilage","n_c":["C12281"],"i_c":"C32.3","i_c_s":["Laryngeal cartilage"],"term_type":"PT"},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"C32.9","i_c_s":["Larynx, NOS"],"term_type":"PT"},{"nm":"Lateral floor of mouth","n_c":"","i_c":"C04.1","i_c_s":["Lateral floor of mouth"],"term_type":"PT"},{"nm":"Lateral wall of bladder","n_c":["C12333"],"i_c":"C67.2","i_c_s":["Lateral wall of bladder"],"term_type":"PT"},{"nm":"Lateral wall of nasopharynx","n_c":["C12244"],"i_c":"C11.2","i_c_s":["Lateral wall of nasopharynx"],"term_type":"PT"},{"nm":"Lateral wall of oropharynx","n_c":["C12239"],"i_c":"C10.2","i_c_s":["Lateral wall of oropharynx"],"term_type":"PT"},{"nm":"Lesser curvature of stomach, NOS","n_c":["C12261"],"i_c":"C16.5","i_c_s":["Lesser curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Lingual tonsil","n_c":["C32988"],"i_c":"C02.4","i_c_s":["Lingual tonsil"],"term_type":"PT"},{"nm":"Lip, NOS","n_c":["C12220"],"i_c":"C00.9","i_c_s":["Lip, NOS"],"term_type":"PT"},{"nm":"Liver","n_c":["C12392"],"i_c":"C22.0","i_c_s":["Liver"],"term_type":"PT"},{"nm":"Long bones of lower limb and associated joints","n_c":"","i_c":"C40.2","i_c_s":["Long bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Long bones of upper limb, scapula and associated joints","n_c":"","i_c":"C40.0","i_c_s":["Long bones of upper limb, scapula and associated joints"],"term_type":"PT"},{"nm":"Lower gum","n_c":["C54204"],"i_c":"C03.1","i_c_s":["Lower gum"],"term_type":"PT"},{"nm":"Lower limb, NOS","n_c":["C12742"],"i_c":"C76.5","i_c_s":["Lower limb, NOS"],"term_type":"PT"},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"C34.3","i_c_s":["Lower lobe, lung"],"term_type":"PT"},{"nm":"Lower third of esophagus","n_c":["C12255"],"i_c":"C15.5","i_c_s":["Lower third of esophagus"],"term_type":"PT"},{"nm":"Lower-inner quadrant of breast","n_c":["C12302"],"i_c":"C50.3","i_c_s":["Lower-inner quadrant of breast"],"term_type":"PT"},{"nm":"Lower-outer quadrant of breast","n_c":["C12304"],"i_c":"C50.5","i_c_s":["Lower-outer quadrant of breast"],"term_type":"PT"},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"C34.9","i_c_s":["Lung, NOS"],"term_type":"PT"},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"C77.9","i_c_s":["Lymph node, NOS"],"term_type":"PT"},{"nm":"Lymph nodes of axilla or arm","n_c":["C12904"],"i_c":"C77.3","i_c_s":["Lymph nodes of axilla or arm"],"term_type":"PT"},{"nm":"Lymph nodes of head, face and neck","n_c":["C12358"],"i_c":"C77.0","i_c_s":["Lymph nodes of head, face and neck"],"term_type":"PT"},{"nm":"Lymph nodes of inguinal region or leg","n_c":["C12362"],"i_c":"C77.4","i_c_s":["Lymph nodes of inguinal region or leg"],"term_type":"PT"},{"nm":"Lymph nodes of multiple regions","n_c":"","i_c":"C77.8","i_c_s":["Lymph nodes of multiple regions"],"term_type":"PT"},{"nm":"Main bronchus","n_c":["C12284"],"i_c":"C34.0","i_c_s":["Main bronchus"],"term_type":"PT"},{"nm":"Major salivary gland, NOS","n_c":["C12426"],"i_c":"C08.9","i_c_s":["Major salivary gland, NOS"],"term_type":"PT"},{"nm":"Male genital organs, NOS","n_c":["C61599"],"i_c":"C63.9","i_c_s":["Male genital organs, NOS"],"term_type":"PT"},{"nm":"Mandible","n_c":["C12290"],"i_c":"C41.1","i_c_s":["Mandible"],"term_type":"PT"},{"nm":"Maxillary sinus","n_c":["C12275"],"i_c":"C31.0","i_c_s":["Maxillary sinus"],"term_type":"PT"},{"nm":"Meckel diverticulum","n_c":["C12264"],"i_c":"C17.3","i_c_s":["Meckel diverticulum"],"term_type":"PT"},{"nm":"Mediastinum, NOS","n_c":["C12748"],"i_c":"C38.3","i_c_s":["Mediastinum, NOS"],"term_type":"PT"},{"nm":"Medulla of adrenal gland","n_c":["C12397"],"i_c":"C74.1","i_c_s":["Medulla of adrenal gland"],"term_type":"PT"},{"nm":"Meninges, NOS","n_c":["C12348"],"i_c":"C70.9","i_c_s":["Meninges, NOS"],"term_type":"PT"},{"nm":"Middle ear","n_c":["C12274"],"i_c":"C30.1","i_c_s":["Middle ear"],"term_type":"PT"},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"C34.2","i_c_s":["Middle lobe, lung"],"term_type":"PT"},{"nm":"Middle third of esophagus","n_c":["C12254"],"i_c":"C15.4","i_c_s":["Middle third of esophagus"],"term_type":"PT"},{"nm":"Mouth, NOS","n_c":["C12421"],"i_c":"C06.9","i_c_s":["Mouth, NOS"],"term_type":"PT"},{"nm":"Mucosa of lip, NOS","n_c":["C12226"],"i_c":"C00.5","i_c_s":["Mucosa of lip, NOS"],"term_type":"PT"},{"nm":"Mucosa of lower lip","n_c":["C12225"],"i_c":"C00.4","i_c_s":["Mucosa of lower lip"],"term_type":"PT"},{"nm":"Mucosa of upper lip","n_c":["C12224"],"i_c":"C00.3","i_c_s":["Mucosa of upper lip"],"term_type":"PT"},{"nm":"Myometrium","n_c":["C12314"],"i_c":"C54.2","i_c_s":["Myometrium"],"term_type":"PT"},{"nm":"Nasal cavity","n_c":["C12424"],"i_c":"C30.0","i_c_s":["Nasal cavity"],"term_type":"PT"},{"nm":"Nasopharynx, NOS","n_c":["C12423"],"i_c":"C11.9","i_c_s":["Nasopharynx, NOS"],"term_type":"PT"},{"nm":"Nervous system, NOS","n_c":["C12755"],"i_c":"C72.9","i_c_s":["Nervous system, NOS"],"term_type":"PT"},{"nm":"Nipple","n_c":["C12299"],"i_c":"C50.0","i_c_s":["Nipple"],"term_type":"PT"},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"C71.4","i_c_s":["Occipital lobe"],"term_type":"PT"},{"nm":"Olfactory nerve","n_c":["C12759"],"i_c":"C72.2","i_c_s":["Olfactory nerve"],"term_type":"PT"},{"nm":"Optic nerve","n_c":["C12761"],"i_c":"C72.3","i_c_s":["Optic nerve"],"term_type":"PT"},{"nm":"Orbit, NOS","n_c":["C12347"],"i_c":"C69.6","i_c_s":["Orbit, NOS"],"term_type":"PT"},{"nm":"Oropharynx, NOS","n_c":["C12762"],"i_c":"C10.9","i_c_s":["Oropharynx, NOS"],"term_type":"PT"},{"nm":"Other ill-defined sites","n_c":["C147919"],"i_c":"C76.7","i_c_s":["Other ill-defined sites"],"term_type":"PT"},{"nm":"Other specified parts of female genital organs","n_c":["C148339"],"i_c":"C57.7","i_c_s":["Other specified parts of female genital organs"],"term_type":"PT"},{"nm":"Other specified parts of male genital organs","n_c":["C148341"],"i_c":"C63.7","i_c_s":["Other specified parts of male genital organs"],"term_type":"PT"},{"nm":"Other specified parts of pancreas","n_c":["C12273"],"i_c":"C25.7","i_c_s":["Other specified parts of pancreas"],"term_type":"PT"},{"nm":"Ovary","n_c":["C12404"],"i_c":"C56.9","i_c_s":["Ovary"],"term_type":"PT"},{"nm":"Overlapping lesion of accessory sinuses","n_c":"","i_c":"C31.8","i_c_s":["Overlapping lesion of accessory sinuses"],"term_type":"PT"},{"nm":"Overlapping lesion of biliary tract","n_c":"","i_c":"C24.8","i_c_s":["Overlapping lesion of biliary tract"],"term_type":"PT"},{"nm":"Overlapping lesion of bladder","n_c":"","i_c":"C67.8","i_c_s":["Overlapping lesion of bladder"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage","n_c":"","i_c":"C41.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage of limbs","n_c":"","i_c":"C40.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage of limbs"],"term_type":"PT"},{"nm":"Overlapping lesion of brain","n_c":"","i_c":"C71.8","i_c_s":["Overlapping lesion of brain"],"term_type":"PT"},{"nm":"Overlapping lesion of brain and central nervous system","n_c":"","i_c":"C72.8","i_c_s":["Overlapping lesion of brain and central nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of breast","n_c":"","i_c":"C50.8","i_c_s":["Overlapping lesion of breast"],"term_type":"PT"},{"nm":"Overlapping lesion of cervix uteri","n_c":"","i_c":"C53.8","i_c_s":["Overlapping lesion of cervix uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of colon","n_c":"","i_c":"C18.8","i_c_s":["Overlapping lesion of colon"],"term_type":"PT"},{"nm":"Overlapping lesion of connective, subcutaneous and other soft tissues","n_c":"","i_c":"C49.8","i_c_s":["Overlapping lesion of connective, subcutaneous and other soft tissues"],"term_type":"PT"},{"nm":"Overlapping lesion of corpus uteri","n_c":"","i_c":"C54.8","i_c_s":["Overlapping lesion of corpus uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of digestive system","n_c":"","i_c":"C26.8","i_c_s":["Overlapping lesion of digestive system"],"term_type":"PT"},{"nm":"Overlapping lesion of endocrine glands and related structures","n_c":"","i_c":"C75.8","i_c_s":["Overlapping lesion of endocrine glands and related structures"],"term_type":"PT"},{"nm":"Overlapping lesion of esophagus","n_c":"","i_c":"C15.8","i_c_s":["Overlapping lesion of esophagus"],"term_type":"PT"},{"nm":"Overlapping lesion of eye and adnexa","n_c":"","i_c":"C69.8","i_c_s":["Overlapping lesion of eye and adnexa"],"term_type":"PT"},{"nm":"Overlapping lesion of female genital organs","n_c":"","i_c":"C57.8","i_c_s":["Overlapping lesion of female genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of floor of mouth","n_c":"","i_c":"C04.8","i_c_s":["Overlapping lesion of floor of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of heart, mediastinum and pleura","n_c":"","i_c":"C38.8","i_c_s":["Overlapping lesion of heart, mediastinum and pleura"],"term_type":"PT"},{"nm":"Overlapping lesion of hypopharynx","n_c":"","i_c":"C13.8","i_c_s":["Overlapping lesion of hypopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of ill-defined sites","n_c":"","i_c":"C76.8","i_c_s":["Overlapping lesion of ill-defined sites"],"term_type":"PT"},{"nm":"Overlapping lesion of larynx","n_c":"","i_c":"C32.8","i_c_s":["Overlapping lesion of larynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lip","n_c":"","i_c":"C00.8","i_c_s":["Overlapping lesion of lip"],"term_type":"PT"},{"nm":"Overlapping lesion of lip, oral cavity and pharynx","n_c":"","i_c":"C14.8","i_c_s":["Overlapping lesion of lip, oral cavity and pharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lung","n_c":"","i_c":"C34.8","i_c_s":["Overlapping lesion of lung"],"term_type":"PT"},{"nm":"Overlapping lesion of major salivary glands","n_c":"","i_c":"C08.8","i_c_s":["Overlapping lesion of major salivary glands"],"term_type":"PT"},{"nm":"Overlapping lesion of male genital organs","n_c":"","i_c":"C63.8","i_c_s":["Overlapping lesion of male genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of nasopharynx","n_c":"","i_c":"C11.8","i_c_s":["Overlapping lesion of nasopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of other and unspecified parts of mouth","n_c":"","i_c":"C06.8","i_c_s":["Overlapping lesion of other and unspecified parts of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of palate","n_c":"","i_c":"C05.8","i_c_s":["Overlapping lesion of palate"],"term_type":"PT"},{"nm":"Overlapping lesion of pancreas","n_c":"","i_c":"C25.8","i_c_s":["Overlapping lesion of pancreas"],"term_type":"PT"},{"nm":"Overlapping lesion of penis","n_c":"","i_c":"C60.8","i_c_s":["Overlapping lesion of penis"],"term_type":"PT"},{"nm":"Overlapping lesion of peripheral nerves and autonomic nervous system","n_c":"","i_c":"C47.8","i_c_s":["Overlapping lesion of peripheral nerves and autonomic nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of rectum, anus and anal canal","n_c":"","i_c":"C21.8","i_c_s":["Overlapping lesion of rectum, anus and anal canal"],"term_type":"PT"},{"nm":"Overlapping lesion of respiratory system and intrathoracic organs","n_c":"","i_c":"C39.8","i_c_s":["Overlapping lesion of respiratory system and intrathoracic organs"],"term_type":"PT"},{"nm":"Overlapping lesion of retroperitoneum and peritoneum","n_c":"","i_c":"C48.8","i_c_s":["Overlapping lesion of retroperitoneum and peritoneum"],"term_type":"PT"},{"nm":"Overlapping lesion of skin","n_c":"","i_c":"C44.8","i_c_s":["Overlapping lesion of skin"],"term_type":"PT"},{"nm":"Overlapping lesion of small intestine","n_c":"","i_c":"C17.8","i_c_s":["Overlapping lesion of small intestine"],"term_type":"PT"},{"nm":"Overlapping lesion of stomach","n_c":"","i_c":"C16.8","i_c_s":["Overlapping lesion of stomach"],"term_type":"PT"},{"nm":"Overlapping lesion of tongue","n_c":"","i_c":"C02.8","i_c_s":["Overlapping lesion of tongue"],"term_type":"PT"},{"nm":"Overlapping lesion of tonsil","n_c":"","i_c":"C09.8","i_c_s":["Overlapping lesion of tonsil"],"term_type":"PT"},{"nm":"Overlapping lesion of urinary organs","n_c":"","i_c":"C68.8","i_c_s":["Overlapping lesion of urinary organs"],"term_type":"PT"},{"nm":"Overlapping lesion of vulva","n_c":"","i_c":"C51.8","i_c_s":["Overlapping lesion of vulva"],"term_type":"PT"},{"nm":"Overlapping lesions of oropharynx","n_c":"","i_c":"C10.8","i_c_s":["Overlapping lesions of oropharynx"],"term_type":""},{"nm":"Palate, NOS","n_c":["C12229"],"i_c":"C05.9","i_c_s":["Palate, NOS"],"term_type":"PT"},{"nm":"Pancreas, NOS","n_c":["C12393"],"i_c":"C25.9","i_c_s":["Pancreas, NOS"],"term_type":"PT"},{"nm":"Pancreatic duct","n_c":["C12272"],"i_c":"C25.3","i_c_s":["Pancreatic duct"],"term_type":"PT"},{"nm":"Parametrium","n_c":["C12320"],"i_c":"C57.3","i_c_s":["Parametrium"],"term_type":"PT"},{"nm":"Parathyroid gland","n_c":["C12765"],"i_c":"C75.0","i_c_s":["Parathyroid gland"],"term_type":"PT"},{"nm":"Paraurethral gland","n_c":["C61122"],"i_c":"C68.1","i_c_s":["Paraurethral gland"],"term_type":"PT"},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"C71.3","i_c_s":["Parietal lobe"],"term_type":"PT"},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"C07.9","i_c_s":["Parotid gland"],"term_type":"PT"},{"nm":"Pelvic bones, sacrum, coccyx and associated joints","n_c":"","i_c":"C41.4","i_c_s":["Pelvic bones, sacrum, coccyx and associated joints"],"term_type":"PT"},{"nm":"Pelvic lymph nodes","n_c":["C12363"],"i_c":"C77.5","i_c_s":["Pelvic lymph nodes"],"term_type":"PT"},{"nm":"Pelvis, NOS","n_c":["C12767"],"i_c":"C76.3","i_c_s":["Pelvis, NOS"],"term_type":"PT"},{"nm":"Penis, NOS","n_c":["C12409"],"i_c":"C60.9","i_c_s":["Penis, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of abdomen","n_c":"","i_c":"C47.4","i_c_s":["Peripheral nerves and autonomic nervous system of abdomen"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of head, face, and neck","n_c":"","i_c":"C47.0","i_c_s":["Peripheral nerves and autonomic nervous system of head, face, and neck"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of lower limb and hip","n_c":"","i_c":"C47.2","i_c_s":["Peripheral nerves and autonomic nervous system of lower limb and hip"],"term_type":""},{"nm":"Peripheral nerves and autonomic nervous system of pelvis","n_c":"","i_c":"C47.5","i_c_s":["Peripheral nerves and autonomic nervous system of pelvis"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of thorax","n_c":"","i_c":"C47.3","i_c_s":["Peripheral nerves and autonomic nervous system of thorax"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of trunk, NOS","n_c":"","i_c":"C47.6","i_c_s":["Peripheral nerves and autonomic nervous system of trunk, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of upper limb and shoulder","n_c":"","i_c":"C47.1","i_c_s":["Peripheral nerves and autonomic nervous system of upper limb and shoulder"],"term_type":"PT"},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"C48.2","i_c_s":["Peritoneum, NOS"],"term_type":"PT"},{"nm":"Pharynx, NOS","n_c":["C12425"],"i_c":"C14.0","i_c_s":["Pharynx, NOS"],"term_type":"PT"},{"nm":"Pineal gland","n_c":["C12398"],"i_c":"C75.3","i_c_s":["Pineal gland"],"term_type":"PT"},{"nm":"Pituitary gland","n_c":["C12399"],"i_c":"C75.1","i_c_s":["Pituitary gland"],"term_type":"PT"},{"nm":"Placenta","n_c":["C13272"],"i_c":"C58.9","i_c_s":["Placenta"],"term_type":"PT"},{"nm":"Pleura, NOS","n_c":["C12469"],"i_c":"C38.4","i_c_s":["Pleura, NOS"],"term_type":"PT"},{"nm":"Postcricoid region","n_c":["C54221"],"i_c":"C13.0","i_c_s":["Postcricoid region"],"term_type":"PT"},{"nm":"Posterior mediastinum","n_c":["C33368"],"i_c":"C38.2","i_c_s":["Posterior mediastinum"],"term_type":"PT"},{"nm":"Posterior wall of bladder","n_c":["C12335"],"i_c":"C67.4","i_c_s":["Posterior wall of bladder"],"term_type":"PT"},{"nm":"Posterior wall of hypopharynx","n_c":["C12249"],"i_c":"C13.2","i_c_s":["Posterior wall of hypopharynx"],"term_type":"PT"},{"nm":"Posterior wall of nasopharynx","n_c":["C12243"],"i_c":"C11.1","i_c_s":["Posterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Posterior wall of oropharynx","n_c":["C12240"],"i_c":"C10.3","i_c_s":["Posterior wall of oropharynx"],"term_type":"PT"},{"nm":"Prepuce","n_c":["C12323"],"i_c":"C60.0","i_c_s":["Prepuce"],"term_type":"PT"},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"C61.9","i_c_s":["Prostate gland"],"term_type":"PT"},{"nm":"Pylorus","n_c":["C12260"],"i_c":"C16.4","i_c_s":["Pylorus"],"term_type":"PT"},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"C12.9","i_c_s":["Pyriform sinus"],"term_type":"PT"},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"C19.9","i_c_s":["Rectosigmoid junction"],"term_type":"PT"},{"nm":"Rectum, NOS","n_c":["C12390"],"i_c":"C20.9","i_c_s":["Rectum, NOS"],"term_type":"PT"},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"C65.9","i_c_s":["Renal pelvis"],"term_type":"PT"},{"nm":"Reticuloendothelial system, NOS","n_c":["C12780"],"i_c":"C42.3","i_c_s":["Reticuloendothelial system, NOS"],"term_type":"PT"},{"nm":"Retina","n_c":["C12343"],"i_c":"C69.2","i_c_s":["Retina"],"term_type":"PT"},{"nm":"Retromolar area","n_c":["C54223"],"i_c":"C06.2","i_c_s":["Retromolar area"],"term_type":"PT"},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"C48.0","i_c_s":["Retroperitoneum"],"term_type":"PT"},{"nm":"Rib, sternum, clavicle and associated joints","n_c":"","i_c":"C41.3","i_c_s":["Rib, sternum, clavicle and associated joints"],"term_type":"PT"},{"nm":"Round ligament","n_c":["C12319"],"i_c":"C57.2","i_c_s":["Round ligament"],"term_type":"PT"},{"nm":"Scrotum, NOS","n_c":["C12785"],"i_c":"C63.2","i_c_s":["Scrotum, NOS"],"term_type":"PT"},{"nm":"Short bones of lower limb and associated joints","n_c":"","i_c":"C40.3","i_c_s":["Short bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Short bones of upper limb and associated joints","n_c":"","i_c":"C40.1","i_c_s":["Short bones of upper limb and associated joints"],"term_type":"PT"},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"C18.7","i_c_s":["Sigmoid colon"],"term_type":"PT"},{"nm":"Skin of lip, NOS","n_c":["C12291"],"i_c":"C44.0","i_c_s":["Skin of lip, NOS"],"term_type":"PT"},{"nm":"Skin of lower limb and hip","n_c":["C12297"],"i_c":"C44.7","i_c_s":["Skin of lower limb and hip"],"term_type":"PT"},{"nm":"Skin of other and unspecified parts of face","n_c":["C33561"],"i_c":"C44.3","i_c_s":["Skin of other and unspecified parts of face"],"term_type":"PT"},{"nm":"Skin of scalp and neck","n_c":["C12294"],"i_c":"C44.4","i_c_s":["Skin of scalp and neck"],"term_type":"PT"},{"nm":"Skin of trunk","n_c":["C12295"],"i_c":"C44.5","i_c_s":["Skin of trunk"],"term_type":"RT"},{"nm":"Skin of upper limb and shoulder","n_c":["C12296"],"i_c":"C44.6","i_c_s":["Skin of upper limb and shoulder"],"term_type":"PT"},{"nm":"Skin, NOS","n_c":["C12470"],"i_c":"C44.9","i_c_s":["Skin, NOS"],"term_type":"PT"},{"nm":"Small intestine, NOS","n_c":["C12386"],"i_c":"C17.9","i_c_s":["Small intestine, NOS"],"term_type":"PT"},{"nm":"Soft palate, NOS","n_c":["C12231"],"i_c":"C05.1","i_c_s":["Soft palate, NOS"],"term_type":"PT"},{"nm":"Specified parts of peritoneum","n_c":"","i_c":"C48.1","i_c_s":["Specified parts of peritoneum"],"term_type":"PT"},{"nm":"Spermatic cord","n_c":["C12329"],"i_c":"C63.1","i_c_s":["Spermatic cord"],"term_type":"PT"},{"nm":"Sphenoid sinus","n_c":["C12278"],"i_c":"C31.3","i_c_s":["Sphenoid sinus"],"term_type":"PT"},{"nm":"Spinal cord","n_c":["C12464"],"i_c":"C72.0","i_c_s":["Spinal cord"],"term_type":"PT"},{"nm":"Spinal meninges","n_c":["C12350"],"i_c":"C70.1","i_c_s":["Spinal meninges"],"term_type":"PT"},{"nm":"Spleen","n_c":["C12432"],"i_c":"C42.2","i_c_s":["Spleen"],"term_type":"PT"},{"nm":"Splenic flexure of colon","n_c":["C12267"],"i_c":"C18.5","i_c_s":["Splenic flexure of colon"],"term_type":"PT"},{"nm":"Stomach, NOS","n_c":["C12391"],"i_c":"C16.9","i_c_s":["Stomach, NOS"],"term_type":"PT"},{"nm":"Subglottis","n_c":["C12280"],"i_c":"C32.2","i_c_s":["Subglottis"],"term_type":"PT"},{"nm":"Sublingual gland","n_c":["C12234"],"i_c":"C08.1","i_c_s":["Sublingual gland"],"term_type":"PT"},{"nm":"Submandibular gland","n_c":["C12233"],"i_c":"C08.0","i_c_s":["Submandibular gland"],"term_type":"PT"},{"nm":"Superior wall of nasopharynx","n_c":["C12242"],"i_c":"C11.0","i_c_s":["Superior wall of nasopharynx"],"term_type":"PT"},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"C32.1","i_c_s":["Supraglottis"],"term_type":"PT"},{"nm":"Tail of pancreas","n_c":["C12271"],"i_c":"C25.2","i_c_s":["Tail of pancreas"],"term_type":"PT"},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"C71.2","i_c_s":["Temporal lobe"],"term_type":"PT"},{"nm":"Testis, NOS","n_c":["C12412"],"i_c":"C62.9","i_c_s":["Testis, NOS"],"term_type":"PT"},{"nm":"Thoracic esophagus","n_c":["C12251"],"i_c":"C15.1","i_c_s":["Thoracic esophagus"],"term_type":"PT"},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"C76.1","i_c_s":["Thorax, NOS"],"term_type":"PT"},{"nm":"Thymus","n_c":["C12433"],"i_c":"C37.9","i_c_s":["Thymus"],"term_type":"PT"},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"C73.9","i_c_s":["Thyroid gland"],"term_type":"PT"},{"nm":"Tongue, NOS","n_c":["C12422"],"i_c":"C02.9","i_c_s":["Tongue, NOS"],"term_type":"PT"},{"nm":"Tonsil, NOS","n_c":["C33250"],"i_c":"C09.9","i_c_s":["Tonsil, NOS"],"term_type":"PT"},{"nm":"Tonsillar fossa","n_c":["C12235"],"i_c":"C09.0","i_c_s":["Tonsillar fossa"],"term_type":"PT"},{"nm":"Tonsillar pillar","n_c":["C12236"],"i_c":"C09.1","i_c_s":["Tonsillar pillar"],"term_type":"PT"},{"nm":"Trachea","n_c":["C12428"],"i_c":"C33.9","i_c_s":["Trachea"],"term_type":"PT"},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"C18.4","i_c_s":["Transverse colon"],"term_type":"PT"},{"nm":"Trigone of bladder","n_c":["C12331"],"i_c":"C67.0","i_c_s":["Trigone of bladder"],"term_type":"PT"},{"nm":"Undescended testis","n_c":["C12326"],"i_c":"C62.0","i_c_s":["Undescended testis"],"term_type":"PT"},{"nm":"Unknown primary site","n_c":["C48322"],"i_c":"C80.9","i_c_s":["Unknown primary site"],"term_type":"PT"},{"nm":"Upper gum","n_c":["C54205"],"i_c":"C03.0","i_c_s":["Upper gum"],"term_type":"PT"},{"nm":"Upper limb, NOS","n_c":["C12671"],"i_c":"C76.4","i_c_s":["Upper limb, NOS"],"term_type":"PT"},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"C34.1","i_c_s":["Upper lobe, lung"],"term_type":"PT"},{"nm":"Upper respiratory tract, NOS","n_c":["C33839"],"i_c":"C39.0","i_c_s":["Upper respiratory tract, NOS"],"term_type":"PT"},{"nm":"Upper third of esophagus","n_c":["C12253"],"i_c":"C15.3","i_c_s":["Upper third of esophagus"],"term_type":"PT"},{"nm":"Upper-inner quadrant of breast","n_c":["C12301"],"i_c":"C50.2","i_c_s":["Upper-inner quadrant of breast"],"term_type":"PT"},{"nm":"Upper-outer quadrant of breast","n_c":["C12303"],"i_c":"C50.4","i_c_s":["Upper-outer quadrant of breast"],"term_type":"PT"},{"nm":"Urachus","n_c":["C12338"],"i_c":"C67.7","i_c_s":["Urachus"],"term_type":"PT"},{"nm":"Ureter","n_c":["C12416"],"i_c":"C66.9","i_c_s":["Ureter"],"term_type":"PT"},{"nm":"Ureteric orifice","n_c":["C12337"],"i_c":"C67.6","i_c_s":["Ureteric orifice"],"term_type":"PT"},{"nm":"Urethra","n_c":["C12417"],"i_c":"C68.0","i_c_s":["Urethra"],"term_type":"PT"},{"nm":"Urinary system, NOS","n_c":["C12413"],"i_c":"C68.9","i_c_s":["Urinary system, NOS"],"term_type":"PT"},{"nm":"Uterine adnexa","n_c":["C12321"],"i_c":"C57.4","i_c_s":["Uterine adnexa"],"term_type":"PT"},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"C55.9","i_c_s":["Uterus, NOS"],"term_type":"PT"},{"nm":"Uvula","n_c":["C12232"],"i_c":"C05.2","i_c_s":["Uvula"],"term_type":"PT"},{"nm":"Vagina, NOS","n_c":["C12407"],"i_c":"C52.9","i_c_s":["Vagina, NOS"],"term_type":"PT"},{"nm":"Vallecula","n_c":["C12237"],"i_c":"C10.0","i_c_s":["Vallecula"],"term_type":"PT"},{"nm":"Ventral surface of tongue, NOS","n_c":"","i_c":"C02.2","i_c_s":["Ventral surface of tongue, NOS"],"term_type":"PT"},{"nm":"Ventricle, NOS","n_c":["C12356"],"i_c":"C71.5","i_c_s":["Ventricle, NOS"],"term_type":"PT"},{"nm":"Vertebral column","n_c":["C12998"],"i_c":"C41.2","i_c_s":["Vertebral column"],"term_type":"PT"},{"nm":"Vestibule of mouth","n_c":["C165195"],"i_c":"C06.1","i_c_s":["Vestibule of mouth"],"term_type":"PT"},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"C51.9","i_c_s":["Vulva, NOS"],"term_type":"PT"},{"nm":"Waldeyer ring","n_c":["C73468"],"i_c":"C14.2","i_c_s":["Waldeyer ring"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.progression_or_recurrence_type":[{"nm":"Biochemical","n_c":["C165196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant","n_c":["C55073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Local","n_c":["C36162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional","n_c":["C41844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locoregional","n_c":["C25388"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.reflux_treatment_type":[{"nm":"Antacids","n_c":["C29633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2 Blockers","n_c":["C29702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medically Treated","n_c":["C165200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Treatment","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proton Pump Inhibitors","n_c":["C29723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgically Treated","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factor":[{"nm":"Adenosis (Atypical Adenomatous Hyperplasia)","n_c":["C120861","C5665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Consumption","n_c":["C16273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcoholic Liver Disease","n_c":["C34783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Animal, NOS","n_c":["C172303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Ant","n_c":["C172307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Bee","n_c":["C172308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Cat","n_c":["C172310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dairy or Lactose","n_c":["C175520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dog","n_c":["C172311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Eggs","n_c":["C172313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Food, NOS","n_c":["C172304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Fruit","n_c":["C172316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Meat","n_c":["C172317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Mold or Dust","n_c":["C172306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Nuts","n_c":["C175521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Processed Foods","n_c":["C175522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Seafood","n_c":["C172320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Wasp","n_c":["C172321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin Deficiency","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Atrophic Chronic Gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1 Tumor Predisposition Syndrome","n_c":["C172639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birt-Hogg-Dube Syndrome","n_c":["C28244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA Family History","n_c":["C172230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Hepatitis","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common variable immune deficiency (CVID)","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cowden Syndrome","n_c":["C3076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, NOS","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type I","n_c":["C2986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Hyperplasia","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Polyp(s)","n_c":["C3954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilbert's Syndrome","n_c":["C84729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular Disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hay Fever","n_c":["C92188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter Pylori-Associated Gastritis","n_c":["C27121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Disorder, NOS","n_c":["C26323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemochromatosis","n_c":["C82892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Encephalopathy","n_c":["C79596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, NOS","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Breast Cancer","n_c":["C4503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Kidney Oncocytoma","n_c":["C8960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","n_c":["C51302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Ovarian Cancer","n_c":["C36102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Papillary Renal Cell Carcinoma","n_c":["C9222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Prostate Cancer","n_c":["C103817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Renal Cell Carcinoma","n_c":["C39789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-grade Prostatic Intraepithelial Neoplasia (PIN)","n_c":["C5541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV","n_c":["C3108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation, Hyperkeratosis","n_c":["C3137","C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nodular Prostatic Hyperplasia","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Fatty Liver Disease","n_c":["C84444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Contraceptives","n_c":["C389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parasitic Disease of Biliary Tract","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Pyogenic Cholangitis","n_c":["C164213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serous tubal intraepithelial carcinoma (STIC)","n_c":["C126449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","n_c":["C156464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tattoo","n_c":["C113681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Nodular Hyperplasia","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, NOS","n_c":["C18059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smokeless","n_c":["C137998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberous Sclerosis","n_c":["C3424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulointerstitial Disease","n_c":["C123036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated Lymphoid Proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undescended Testis","n_c":["C12326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disease","n_c":["C35117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vision Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Von Hippel-Lindau Syndrome","n_c":["C3105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C80078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Rash","n_c":["C39594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-6 (HHV-6)","n_c":["C128829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-8 (HHV-8)","n_c":["C39291"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factor_treatment":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.scan_tracer_used":[{"nm":"Acetate","n_c":["C94719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axumin","n_c":["C74002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Choline","n_c":["C61674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA","n_c":["C17796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Fluoride","n_c":["C832"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.viral_hepatitis_serologies":[{"nm":"HBV Core Antibody","n_c":["C96660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV DNA","n_c":["C103404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Genotype","n_c":["C117108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Surface Antibody","n_c":["C74711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HCV Genotype","n_c":["C117109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Surface Antigen","n_c":["C64850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Antibody","n_c":["C92535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Virus RNA","n_c":["C142330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.antigen":[{"nm":"BCL6","n_c":["C26149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CA-125","n_c":["C325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CA19-9","n_c":["C327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND1","n_c":["C17988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD10","n_c":["C16836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD117","n_c":["C17328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD138","n_c":["C96914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD14","n_c":["C17488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD15","n_c":["C96898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD19","n_c":["C38894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD20","n_c":["C38896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD22","n_c":["C17279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD23","n_c":["C96902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD25","n_c":["C17073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD3","n_c":["C38897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD30","n_c":["C38906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD33","n_c":["C97246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD34","n_c":["C17280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD45","n_c":["C17282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD5","n_c":["C73124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD56","n_c":["C25276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD7","n_c":["C38935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79A","n_c":["C97423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEA","n_c":["C16384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-DR","n_c":["C16692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelin","n_c":["C20887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSE","n_c":["C62216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate-Specific Antigen (PSA)","n_c":["C17525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Cell Carcinoma Antigen (SCCA)","n_c":["C120660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ki67","n_c":["C17675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FMC-7","n_c":["C38896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kappa, Surface","n_c":["C184770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lambda, Surface","n_c":["C184771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAG-72","n_c":["C1269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin, Cytoplasmic","n_c":["C172121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin, Surface","n_c":["C573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD43","n_c":["C101153"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.biospecimen_type":[{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buffy Coat","n_c":["C84507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Embryonic Fluid","n_c":["C13398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Embryonic Tissue","n_c":["C12950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feces","n_c":["C13234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocyte","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Involved Tissue, NOS","n_c":["C18009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Tissue","n_c":["C12435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve Tissue","n_c":["C13052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Fluid","n_c":["C77612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma","n_c":["C13356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Fluid","n_c":["C77613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C13275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum","n_c":["C13325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tissue, NOS","n_c":["C12801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uninvolved Tissue, NOS","n_c":["C162623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urine","n_c":["C13283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.chromosome":[{"nm":"chr1","n_c":["C13204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr2","n_c":["C13215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr3","n_c":["C13219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr4","n_c":["C13220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr5","n_c":["C13221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr6","n_c":["C13222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr7","n_c":["C13223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr8","n_c":["C13224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr9","n_c":["C13225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr10","n_c":["C13205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr11","n_c":["C13206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr12","n_c":["C13207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr13","n_c":["C13208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr14","n_c":["C13209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr15","n_c":["C13210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr16","n_c":["C13211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr17","n_c":["C13212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr18","n_c":["C13213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr19","n_c":["C13214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr20","n_c":["C13216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr21","n_c":["C13217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr22","n_c":["C13218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr23","n_c":["C33542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chrM","n_c":["C28512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chrX","n_c":["C13285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chrY","n_c":["C13286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.clonality":[{"nm":"Clonal","n_c":["C41179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-clonal","n_c":["C172229"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.gene_symbol":[{"nm":"A1CF","n_c":["C143031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABI1","n_c":["C24824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL1","n_c":["C17346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL2","n_c":["C18451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACKR3","n_c":["C91369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL3","n_c":["C97365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL6","n_c":["C97519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR1","n_c":["C21267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR2A","n_c":["C21271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF1","n_c":["C24602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF3","n_c":["C24538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF4","n_c":["C21385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKAP9","n_c":["C21305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT1","n_c":["C18350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT2","n_c":["C18352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT3","n_c":["C20937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALDH2","n_c":["C84921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK","n_c":["C38184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AMER1","n_c":["C68718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ANK1","n_c":["C84301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APC","n_c":["C17567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APOBEC3B","n_c":["C117001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AR","n_c":["C28539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARAF","n_c":["C18354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP26","n_c":["C97504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP5","n_c":["C97279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGEF12","n_c":["C97436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1A","n_c":["C92530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1B","n_c":["C102520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID2","n_c":["C101088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARNT","n_c":["C26373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASPSCR1","n_c":["C70991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL1","n_c":["C97320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL2","n_c":["C116296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATF1","n_c":["C92177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATIC","n_c":["C97400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM","n_c":["C18583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP1A1","n_c":["C113762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP2B3","n_c":["C113765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR","n_c":["C20560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATRX","n_c":["C74976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN1","n_c":["C19969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN2","n_c":["C20763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B2M","n_c":["C62660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1","n_c":["C20766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BARD1","n_c":["C20715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL10","n_c":["C24259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11A","n_c":["C97394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11B","n_c":["C91855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2","n_c":["C17963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2L12","n_c":["C114743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL3","n_c":["C18360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL6","n_c":["C24260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL7A","n_c":["C24261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9","n_c":["C24262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9L","n_c":["C132328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCLAF1","n_c":["C115994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCOR","n_c":["C101091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCORL1","n_c":["C131268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR","n_c":["C18455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC3","n_c":["C20356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC6","n_c":["C20352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BLM","n_c":["C20805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMP5","n_c":["C21353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMPR1A","n_c":["C21366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF","n_c":["C18363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA1","n_c":["C17965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA2","n_c":["C18120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD3","n_c":["C97397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4","n_c":["C92702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRIP1","n_c":["C63526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTG1","n_c":["C80101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK","n_c":["C75013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BUB1B","n_c":["C95592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C15orf65","n_c":["C98096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CACNA1D","n_c":["C113769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CALR","n_c":["C95313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAMTA1","n_c":["C101440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CANT1","n_c":["C97375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARD11","n_c":["C60668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARS","n_c":["C97369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CASP8","n_c":["C26623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T3","n_c":["C97445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFB","n_c":["C18584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBL","n_c":["C18364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLB","n_c":["C21589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLC","n_c":["C97439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCDC6","n_c":["C18376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNB1IP1","n_c":["C97372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNC","n_c":["C105393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND1","n_c":["C18021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND2","n_c":["C39596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND3","n_c":["C97381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNE1","n_c":["C21412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR4","n_c":["C129065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR7","n_c":["C104128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD209","n_c":["C21568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD274","n_c":["C96022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD28","n_c":["C21291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD74","n_c":["C97418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79A","n_c":["C97421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79B","n_c":["C97424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD99","n_c":["C102939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC73","n_c":["C43569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH1","n_c":["C18249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH10","n_c":["C143093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH11","n_c":["C97427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH17","n_c":["C143096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK12","n_c":["C101095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4","n_c":["C18250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK6","n_c":["C97384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1A","n_c":["C17782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1B","n_c":["C20060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2A","n_c":["C18022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2C","n_c":["C24288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDX2","n_c":["C24292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEBPA","n_c":["C39598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP89","n_c":["C122887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHCHD7","n_c":["C97403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD2","n_c":["C75307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD4","n_c":["C128251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHEK2","n_c":["C40965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHIC2","n_c":["C97406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHST11","n_c":["C143061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIC","n_c":["C97912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIITA","n_c":["C96013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLIP1","n_c":["C84464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLP1","n_c":["C97528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTC","n_c":["C97412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTCL1","n_c":["C97415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBD1","n_c":["C143056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBP","n_c":["C97888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNOT3","n_c":["C107658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTNAP2","n_c":["C73461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTRL","n_c":["C97891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL1A1","n_c":["C29949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL2A1","n_c":["C75315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL3A1","n_c":["C143052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COX6C","n_c":["C24308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB1","n_c":["C38536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L1","n_c":["C95477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L2","n_c":["C95480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREBBP","n_c":["C26568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRLF2","n_c":["C97430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRNKL1","n_c":["C143049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC1","n_c":["C95449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC3","n_c":["C95276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R","n_c":["C18516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF3R","n_c":["C24313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSMD3","n_c":["C143042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTCF","n_c":["C73679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNA2","n_c":["C143115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNB1","n_c":["C20987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND1","n_c":["C79770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND2","n_c":["C82941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUL3","n_c":["C24323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUX1","n_c":["C95578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4","n_c":["C24327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYLD","n_c":["C92678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP2C8","n_c":["C46071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYSLTR2","n_c":["C143039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DAXX","n_c":["C24330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCAF12L2","n_c":["C143036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCC","n_c":["C17358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCTN1","n_c":["C122875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDB2","n_c":["C93075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDIT3","n_c":["C92539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDR2","n_c":["C24333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX10","n_c":["C97457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX3X","n_c":["C101565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX5","n_c":["C97460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX6","n_c":["C18378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DEK","n_c":["C24339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DGCR8","n_c":["C92663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DICER1","n_c":["C25956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNAJB1","n_c":["C122560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNM2","n_c":["C102796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT3A","n_c":["C73652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DROSHA","n_c":["C25955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DUX4L1","n_c":["C124048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBF1","n_c":["C80023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ECT2L","n_c":["C101452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EED","n_c":["C101721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR","n_c":["C17757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF1AX","n_c":["C131315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF3E","n_c":["C18347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF4A2","n_c":["C97467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF3","n_c":["C20899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF4","n_c":["C97470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELK4","n_c":["C97476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELL","n_c":["C97516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELN","n_c":["C75333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EML4","n_c":["C71003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP300","n_c":["C26569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPAS1","n_c":["C104303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA3","n_c":["C18384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA7","n_c":["C111841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPS15","n_c":["C24369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB2","n_c":["C17756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB3","n_c":["C18386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB4","n_c":["C18388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERC1","n_c":["C97499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC2","n_c":["C20555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC3","n_c":["C20556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC4","n_c":["C20558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC5","n_c":["C20557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERG","n_c":["C18139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ESR1","n_c":["C38349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETNK1","n_c":["C122823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV1","n_c":["C24377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV4","n_c":["C24378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV5","n_c":["C97479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV6","n_c":["C18312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EWSR1","n_c":["C18322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT1","n_c":["C18251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT2","n_c":["C18252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2","n_c":["C21327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZR","n_c":["C68722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM131B","n_c":["C106340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM135B","n_c":["C143112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM46C","n_c":["C96316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM47C","n_c":["C143109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCA","n_c":["C85995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCC","n_c":["C86025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCD2","n_c":["C86549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCE","n_c":["C86551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCF","n_c":["C86553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCG","n_c":["C24385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAS","n_c":["C21555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT1","n_c":["C18397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT3","n_c":["C143133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT4","n_c":["C128254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBLN2","n_c":["C143130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXO11","n_c":["C101104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXW7","n_c":["C20786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCGR2B","n_c":["C38554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCRL4","n_c":["C97592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEN1","n_c":["C98120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FES","n_c":["C45497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEV","n_c":["C97482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1","n_c":["C19929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1OP","n_c":["C24401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR2","n_c":["C19931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR3","n_c":["C24393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4","n_c":["C20743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FH","n_c":["C95268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FHIT","n_c":["C18524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FIP1L1","n_c":["C97454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FKBP9","n_c":["C143127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLCN","n_c":["C63514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLI1","n_c":["C18321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLNA","n_c":["C113585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3","n_c":["C24399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT4","n_c":["C24400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FNBP1","n_c":["C97540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXA1","n_c":["C101646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXL2","n_c":["C75472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO1","n_c":["C24402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO3","n_c":["C28519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO4","n_c":["C24606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXP1","n_c":["C97549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXR1","n_c":["C143124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FSTL3","n_c":["C24408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUBP1","n_c":["C99614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUS","n_c":["C91852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GAS7","n_c":["C97562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA1","n_c":["C28575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA2","n_c":["C97552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA3","n_c":["C75492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLI1","n_c":["C24432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GMPS","n_c":["C97522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNA11","n_c":["C89717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAQ","n_c":["C38316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAS","n_c":["C38317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOLGA5","n_c":["C97543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOPC","n_c":["C97546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPC3","n_c":["C88173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPHN","n_c":["C97525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRIN2A","n_c":["C98146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRM3","n_c":["C114529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3A","n_c":["C101443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3B","n_c":["C113760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HERPUD1","n_c":["C97534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HEY1","n_c":["C101107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF1A","n_c":["C26372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIP1","n_c":["C97537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H3B","n_c":["C101732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H4I","n_c":["C68734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A","n_c":["C28585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLF","n_c":["C97556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA1","n_c":["C20576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA2","n_c":["C20577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGN2P46","n_c":["C98093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNF1A","n_c":["C97825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPA2B1","n_c":["C97496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOOK3","n_c":["C97493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA11","n_c":["C97568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA13","n_c":["C97571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA9","n_c":["C24474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXB1","n_c":["C162630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC11","n_c":["C97574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC13","n_c":["C97577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD11","n_c":["C97580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD13","n_c":["C97583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HRAS","n_c":["C17060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AA1","n_c":["C97586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AB1","n_c":["C97589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ID3","n_c":["C102968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1","n_c":["C77215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH2","n_c":["C84948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGH","n_c":["C26422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGK","n_c":["C26425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGKC","n_c":["C171139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGL","n_c":["C26423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKBKB","n_c":["C96383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKZF1","n_c":["C68730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL2","n_c":["C24498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL21R","n_c":["C68736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL6ST","n_c":["C24505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL7R","n_c":["C24506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRF4","n_c":["C18430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRS4","n_c":["C24524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISX","n_c":["C116411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITGAV","n_c":["C53661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITK","n_c":["C24526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1","n_c":["C24528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2","n_c":["C24529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK3","n_c":["C24530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAZF1","n_c":["C73542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JUN","n_c":["C19531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6A","n_c":["C71429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6B","n_c":["C71431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT7","n_c":["C73660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KCNJ5","n_c":["C95838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5A","n_c":["C97595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5C","n_c":["C97598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM6A","n_c":["C96334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDR","n_c":["C24532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDSR","n_c":["C24410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KEAP1","n_c":["C112105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIAA1549","n_c":["C98017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIF5B","n_c":["C101425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIT","n_c":["C18609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF4","n_c":["C73449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF6","n_c":["C97448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLK2","n_c":["C26584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2A","n_c":["C18585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2C","n_c":["C93091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2D","n_c":["C24600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNL1","n_c":["C97378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNSTRN","n_c":["C119652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS","n_c":["C25785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRT20","n_c":["C96457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRT7","n_c":["C96444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KTN1","n_c":["C97601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LARP4B","n_c":["C143064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LASP1","n_c":["C97604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCK","n_c":["C18541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCP1","n_c":["C21294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LEF1","n_c":["C80032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LHFP","n_c":["C97607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LIFR","n_c":["C24552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMNA","n_c":["C61148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO1","n_c":["C91263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO2","n_c":["C17973"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LPP","n_c":["C97610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRIG3","n_c":["C101446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP1B","n_c":["C111830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSM14A","n_c":["C122884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LYL1","n_c":["C24564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LZTR1","n_c":["C128257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAF","n_c":["C18417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAFB","n_c":["C97671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALAT1","n_c":["C92696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALT1","n_c":["C60671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML2","n_c":["C95456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML3","n_c":["C117094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K1","n_c":["C21222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K2","n_c":["C106606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K4","n_c":["C97674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K1","n_c":["C24572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K13","n_c":["C102523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAPK1","n_c":["C21227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAX","n_c":["C18576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MB21D2","n_c":["C132170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2","n_c":["C18345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM4","n_c":["C88218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDS2","n_c":["C97615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MECOM","n_c":["C18392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MED12","n_c":["C98210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEN1","n_c":["C18254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET","n_c":["C18325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MGMT","n_c":["C21232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MIB1","n_c":["C104651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MITF","n_c":["C70584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKL1","n_c":["C97296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLF1","n_c":["C97650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH1","n_c":["C18482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH2","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT1","n_c":["C24601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT10","n_c":["C84461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT11","n_c":["C97387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT3","n_c":["C24603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT4","n_c":["C24604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT6","n_c":["C24605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MN1","n_c":["C97618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MNX1","n_c":["C97559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MPL","n_c":["C18411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH2","n_c":["C18481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH6","n_c":["C19195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSI2","n_c":["C91356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSN","n_c":["C97621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTCP1","n_c":["C24617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTOR","n_c":["C38928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC1","n_c":["C38939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC16","n_c":["C71018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC4","n_c":["C128854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUTYH","n_c":["C61056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYB","n_c":["C28569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYC","n_c":["C16887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCL","n_c":["C18407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCN","n_c":["C18405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYD88","n_c":["C90089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH11","n_c":["C29957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH9","n_c":["C97646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYO5A","n_c":["C122881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYOD1","n_c":["C93113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NAB2","n_c":["C122903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NACA","n_c":["C97653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBEA","n_c":["C143075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBN","n_c":["C21178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCKIPSD","n_c":["C97433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA1","n_c":["C20695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA2","n_c":["C20697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA4","n_c":["C18381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR1","n_c":["C28640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR2","n_c":["C28633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NDRG1","n_c":["C24625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF1","n_c":["C17424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF2","n_c":["C17425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFATC2","n_c":["C93138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFE2L2","n_c":["C54237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFIB","n_c":["C38401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKB2","n_c":["C18404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKBIE","n_c":["C38396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NIN","n_c":["C97668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NKX2-1","n_c":["C73443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NONO","n_c":["C71419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH1","n_c":["C24636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH2","n_c":["C97677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPM1","n_c":["C21185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR4A3","n_c":["C96007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRAS","n_c":["C25786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRG1","n_c":["C20174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD1","n_c":["C75876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD2","n_c":["C21416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD3","n_c":["C96341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NT5C2","n_c":["C104587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTHL1","n_c":["C106190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK1","n_c":["C18551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK3","n_c":["C24647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUMA1","n_c":["C24648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP214","n_c":["C24649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP98","n_c":["C20820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM1","n_c":["C92705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2A","n_c":["C101098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2B","n_c":["C101101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OLIG2","n_c":["C68575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OMD","n_c":["C97680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P2RY8","n_c":["C97683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PABPC1","n_c":["C143072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAFAH1B2","n_c":["C97894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PALB2","n_c":["C84945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PATZ1","n_c":["C97876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX3","n_c":["C24658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX5","n_c":["C24659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX7","n_c":["C24660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX8","n_c":["C97687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBRM1","n_c":["C95438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBX1","n_c":["C97317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCBP1","n_c":["C95865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCM1","n_c":["C97900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDCD1LG2","n_c":["C45437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDE4DIP","n_c":["C97718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFB","n_c":["C18278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRA","n_c":["C24666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRB","n_c":["C24667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PER1","n_c":["C97721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGR","n_c":["C28656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF6","n_c":["C101449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHOX2B","n_c":["C97724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PICALM","n_c":["C84434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CA","n_c":["C21220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CB","n_c":["C24672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3R1","n_c":["C97733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM1","n_c":["C18337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLAG1","n_c":["C71423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLCG1","n_c":["C104821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PML","n_c":["C24686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS1","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS2","n_c":["C18591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLD1","n_c":["C106224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLE","n_c":["C106232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLG","n_c":["C143069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLQ","n_c":["C131801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POT1","n_c":["C107655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU2AF1","n_c":["C97730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU5F1","n_c":["C61140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPARG","n_c":["C24689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPFIBP1","n_c":["C101494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPM1D","n_c":["C88179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP2R1A","n_c":["C92536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP6C","n_c":["C102901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRCC","n_c":["C70994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM1","n_c":["C24692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM16","n_c":["C97736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM2","n_c":["C143121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PREX2","n_c":["C102517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRF1","n_c":["C97739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKACA","n_c":["C38409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKAR1A","n_c":["C97742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKCB","n_c":["C39597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRPF40B","n_c":["C143090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRRX1","n_c":["C98030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSIP1","n_c":["C20676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTCH1","n_c":["C18255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTEN","n_c":["C18256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTK6","n_c":["C24701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN11","n_c":["C26337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN13","n_c":["C104212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN6","n_c":["C24708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRB","n_c":["C122909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRC","n_c":["C24711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRK","n_c":["C106113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRT","n_c":["C24716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PWWP2A","n_c":["C122890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"QKI","n_c":["C111937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RABEP1","n_c":["C97751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAC1","n_c":["C99663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD21","n_c":["C93082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD51B","n_c":["C90145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF1","n_c":["C18338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RALGDS","n_c":["C24721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RANBP2","n_c":["C114452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAP1GDS1","n_c":["C97758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RARA","n_c":["C21571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RB1","n_c":["C17360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM10","n_c":["C115382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM15","n_c":["C97293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RECQL4","n_c":["C26492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"REL","n_c":["C17084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET","n_c":["C18257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGPD3","n_c":["C143082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGS7","n_c":["C143118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOA","n_c":["C18356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOH","n_c":["C21320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RMI2","n_c":["C96027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF213","n_c":["C97390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF43","n_c":["C107649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROBO2","n_c":["C126774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROS1","n_c":["C18399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL10","n_c":["C24748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL22","n_c":["C97761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL5","n_c":["C107652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPN1","n_c":["C97290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO2","n_c":["C106067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO3","n_c":["C24397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1","n_c":["C18579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1T1","n_c":["C28570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S100A7","n_c":["C143078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SALL4","n_c":["C112905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SBDS","n_c":["C97767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDC4","n_c":["C101431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHA","n_c":["C103873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHAF2","n_c":["C97770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHB","n_c":["C97773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHC","n_c":["C97776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHD","n_c":["C97779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT5","n_c":["C97727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT6","n_c":["C97782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT9","n_c":["C97897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SET","n_c":["C24801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETBP1","n_c":["C106635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD2","n_c":["C73662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SF3B1","n_c":["C98284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFPQ","n_c":["C71417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFRP4","n_c":["C24804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SGK1","n_c":["C101559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH2B3","n_c":["C102802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH3GL1","n_c":["C97788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHTN1","n_c":["C122906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPA","n_c":["C24710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SKI","n_c":["C69184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC34A2","n_c":["C101434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC45A3","n_c":["C97791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD2","n_c":["C24566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD3","n_c":["C18504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD4","n_c":["C18258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCA4","n_c":["C19878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCB1","n_c":["C18394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCD1","n_c":["C19875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCE1","n_c":["C19874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMC1A","n_c":["C75406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMO","n_c":["C24817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SND1","n_c":["C96331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SNX29","n_c":["C97764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOCS1","n_c":["C97794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOX2","n_c":["C61136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPECC1","n_c":["C97531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPEN","n_c":["C115310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPOP","n_c":["C102534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRC","n_c":["C19917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRGAP3","n_c":["C97797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF2","n_c":["C101110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF3","n_c":["C97785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18","n_c":["C97800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18L1","n_c":["C97803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX1","n_c":["C97806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX2","n_c":["C97809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX4","n_c":["C97814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG1","n_c":["C131224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG2","n_c":["C101346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3","n_c":["C24833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT5B","n_c":["C28667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT6","n_c":["C24835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STIL","n_c":["C101126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STK11","n_c":["C18253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STRN","n_c":["C107661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUFU","n_c":["C97819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUZ12","n_c":["C73545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYK","n_c":["C26536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAF15","n_c":["C95994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL1","n_c":["C18301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL2","n_c":["C24843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBL1XR1","n_c":["C80116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBX3","n_c":["C101638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCEA1","n_c":["C97822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF12","n_c":["C97828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF3","n_c":["C24846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF7L2","n_c":["C24847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCL1A","n_c":["C92699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TEC","n_c":["C24850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TERT","n_c":["C18173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET1","n_c":["C95423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET2","n_c":["C95252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFE3","n_c":["C24854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFEB","n_c":["C94761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFG","n_c":["C97834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFPT","n_c":["C97837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFRC","n_c":["C38517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFBR2","n_c":["C18592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"THRAP3","n_c":["C97840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX1","n_c":["C18608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX3","n_c":["C98099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMEM127","n_c":["C95303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMPRSS2","n_c":["C24871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNC","n_c":["C21091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFAIP3","n_c":["C84928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF14","n_c":["C97843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF17","n_c":["C97846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP1","n_c":["C26591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP53","n_c":["C17359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP63","n_c":["C91791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM3","n_c":["C97849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM4","n_c":["C97852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPR","n_c":["C97855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRA","n_c":["C26419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRAF7","n_c":["C107646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRB","n_c":["C26418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRD","n_c":["C26420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM24","n_c":["C95280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM27","n_c":["C24733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM33","n_c":["C97858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIP11","n_c":["C97861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRRAP","n_c":["C24880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC1","n_c":["C18259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC2","n_c":["C18260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSHR","n_c":["C24881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U2AF1","n_c":["C101113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBR5","n_c":["C111928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP6","n_c":["C24892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP8","n_c":["C24893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VAV1","n_c":["C18365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VHL","n_c":["C18261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VTI1A","n_c":["C99462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WAS","n_c":["C43236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WDCP","n_c":["C101428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WIF1","n_c":["C97867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WNK2","n_c":["C143106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WRN","n_c":["C20070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1","n_c":["C18262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WWTR1","n_c":["C24844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPA","n_c":["C20361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPC","n_c":["C97870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPO1","n_c":["C99484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"YWHAE","n_c":["C101116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZBTB16","n_c":["C28635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZCCHC8","n_c":["C122878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB1","n_c":["C105605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZFHX3","n_c":["C115424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZMYM3","n_c":["C101617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF198","n_c":["C97873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF331","n_c":["C97879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF384","n_c":["C97882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF429","n_c":["C143100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF444","n_c":["C106358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF479","n_c":["C143103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF521","n_c":["C97885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNRF3","n_c":["C118319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZRSR2","n_c":["C101120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHGA","n_c":["C21167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYP","n_c":["C101144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AQP1","n_c":["C181091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CALB2","n_c":["C123856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNTT","n_c":["C26556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPCAM","n_c":["C18421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GCET1","n_c":["C106015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDPN","n_c":["C104785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTGS2","n_c":["C26598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR2","n_c":["C24863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACACA","n_c":["C103885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD1","n_c":["C185736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTBD18","n_c":["C126629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T2","n_c":["C104928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP164","n_c":["C200372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP170B","n_c":["C126611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTDP1","n_c":["C200378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DOT1L","n_c":["C73677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FRYL","n_c":["C126623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLIS2","n_c":["C105900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGB3","n_c":["C20580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPH1","n_c":["C200386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INO80D","n_c":["C125258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JARID2","n_c":["C200399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF23","n_c":["C98035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM3","n_c":["C178143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTP4A1","n_c":["C24704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPS15","n_c":["C200404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD1A","n_c":["C200408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC66A2 (aka PQLC1)","n_c":["C200414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP2B","n_c":["C26593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBB","n_c":["C38431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB2","n_c":["C75441"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.histone_family":[{"nm":"H1","n_c":["C16683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A","n_c":["C16684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2B","n_c":["C17460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3","n_c":["C16685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H4","n_c":["C16686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.histone_variant":[{"nm":"CENP-A","n_c":["C152974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A-Bbd","n_c":["C154613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.X","n_c":["C19432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z","n_c":["C126766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z.1","n_c":["C126766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z.2","n_c":["C162832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z.2.2","n_c":["C162834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.1","n_c":["C101734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.2","n_c":["C148067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.3","n_c":["C101445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.5","n_c":["C154668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.X","n_c":["C188199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.Y","n_c":["C155738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3t (H3.4)","n_c":["C154671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mH2A","n_c":["C95407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mH2A.1","n_c":["C113624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mH2A.2","n_c":["C154659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.laboratory_test":[{"nm":"5-Hydroxyindoleacetic Acid","n_c":["C112217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Absolute Neutrophil","n_c":["C63321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albumin","n_c":["C64431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha Fetoprotein","n_c":["C74732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B-cell genotyping","n_c":["C171142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basophil","n_c":["C64470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta 2 Microglobulin","n_c":["C81980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Urea Nitrogen","n_c":["C61019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C-Reactive Protein","n_c":["C64548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium","n_c":["C64488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cellularity","n_c":["C111153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromogranin A","n_c":["C122108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromogranin B","n_c":["C174116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Circulating Tumor Cells","n_c":["C96593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Creatinine","n_c":["C64547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eosinophil","n_c":["C64550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C171143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-Enolase","n_c":["C116205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucose","n_c":["C105585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematocrit","n_c":["C64796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemoglobin","n_c":["C64848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV-E6/E7","n_c":["C171144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Chorionic Gonadotropin","n_c":["C147128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus","n_c":["C171145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin A","n_c":["C81969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin G","n_c":["C81971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin M","n_c":["C81972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lactate Dehydrogenase","n_c":["C64855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukocytes","n_c":["C51948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luteinizing Hormone","n_c":["C74790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoblasts","n_c":["C102278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytes","n_c":["C51949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M Protein","n_c":["C92291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metamyelocytes","n_c":["C74615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myeloblasts","n_c":["C74632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelocytes","n_c":["C74662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neutrophil Bands","n_c":["C64830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platelets","n_c":["C51951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolymphocytes","n_c":["C74620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Promonocytes","n_c":["C74621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Promyelocytes","n_c":["C74622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Segmented Neutrophil","n_c":["C81997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Free Immunoglobulin Light Chain, Kappa","n_c":["C98730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Free Immunoglobulin Light Chain, Lambda","n_c":["C98732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Free Immunoglobulin Light Chain, NOS","n_c":["C147376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testosterone","n_c":["C74793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Bilirubin","n_c":["C38037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Protein","n_c":["C64858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BG8","n_c":["C178240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Circulating Endothelial Cells","n_c":["C96592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dopamine-Secreting","n_c":["C103871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epinephrine-Secreting","n_c":["C103869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metanephrine-Secreting","n_c":["C103870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxytyramine-Secreting","n_c":["C103872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microsatellite Instability","n_c":["C36318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norepinephrine-Secreting","n_c":["C103867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normetanephrine-Secreting","n_c":["C103868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAG-72","n_c":["C106505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokeratin 5","n_c":["C122859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokeratin 6","n_c":["C122858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Mesothelin","n_c":["C184798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythrocyte Sedimentation Rate","n_c":["C74611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prothrombin Time","n_c":["C62656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blast Count","n_c":["C74605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metaphase Nucleus Count","n_c":["C168918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Minimal Residual Disease","n_c":["C185298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monocytes","n_c":["C64823"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.mismatch_repair_mutation":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.molecular_analysis_method":[{"nm":"Comparative Genomic Hybridization","n_c":["C18084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytogenetics, NOS","n_c":["C18280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FISH","n_c":["C17563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flow Cytometry","n_c":["C16585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IHC","n_c":["C23020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunofluorescence","n_c":["C142337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISH","n_c":["C17562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Karyotype","n_c":["C16768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microarray","n_c":["C18477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microsatellite Analysis","n_c":["C63331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclear Staining","n_c":["C165224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCR","n_c":["C17003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA Sequencing","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RT-PCR","n_c":["C18136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing, NOS","n_c":["C17565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Southern Blotting","n_c":["C16356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopy, NOS","n_c":["C16853"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.molecular_consequence":[{"nm":"3 Prime UTR Variant","n_c":["C63433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5 Prime UTR Variant","n_c":["C63432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coding Sequence Variant","n_c":["C148639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Downstream Gene Variant","n_c":["C63431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feature Elongation","n_c":["C148640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feature Truncation","n_c":["C148641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frameshift Variant","n_c":["C17354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incomplete Terminal Codon Variant","n_c":["C179438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inframe Deletion","n_c":["C165225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inframe Insertion","n_c":["C165226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intergenic Variant","n_c":["C148642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intron Variant","n_c":["C63429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mature miRNA Variant","n_c":["C165227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Missense Variant","n_c":["C18133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NMD Transcript Variant","n_c":["C148643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-coding Transcript Exon Variant","n_c":["C148645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-coding Transcript Variant","n_c":["C148644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonsense","n_c":["C62198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Altering Variant","n_c":["C18133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regulatory Region Ablation","n_c":["C148647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regulatory Region Amplification","n_c":["C148648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regulatory Region Variant","n_c":["C148646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Acceptor Variant","n_c":["C45389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Donor Variant","n_c":["C45390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Region Variant","n_c":["C19798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Start Lost","n_c":["C148649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stop Gain","n_c":["C62198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stop Lost","n_c":["C148650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stop Retained Variant","n_c":["C148651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synonymous Variant","n_c":["C20629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TF Binding Site Variant","n_c":["C148652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFBS Ablation","n_c":["C148653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFBS Amplification","n_c":["C148654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transcript Ablation","n_c":["C16606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transcript Amplification","n_c":["C45581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upstream Gene Variant","n_c":["C63430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exon Variant","n_c":["C148639"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.pathogenicity":[{"nm":"Benign","n_c":["C168802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Likely Benign","n_c":["C168801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Likely Pathogenic","n_c":["C168800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathogenic","n_c":["C168799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uncertain Significance","n_c":["C94187"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.ploidy":[{"nm":"Aneuploid","n_c":["C2873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diploid","n_c":["C118941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperdiploid","n_c":["C80336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypodiploid","n_c":["C80337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Near Diploid","n_c":["C165228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetraploid","n_c":["C28450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.second_gene_symbol":[{"nm":"A1CF","n_c":["C143031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABI1","n_c":["C24824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL1","n_c":["C17346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL2","n_c":["C18451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACKR3","n_c":["C91369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL3","n_c":["C97365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL6","n_c":["C97519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR1","n_c":["C21267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR2A","n_c":["C21271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF1","n_c":["C24602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF3","n_c":["C24538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF4","n_c":["C21385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKAP9","n_c":["C21305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT1","n_c":["C18350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT2","n_c":["C18352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT3","n_c":["C20937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALDH2","n_c":["C84921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK","n_c":["C38184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AMER1","n_c":["C68718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ANK1","n_c":["C84301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APC","n_c":["C17567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APOBEC3B","n_c":["C117001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AR","n_c":["C28539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARAF","n_c":["C18354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP26","n_c":["C97504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP5","n_c":["C97279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGEF12","n_c":["C97436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1A","n_c":["C92530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1B","n_c":["C102520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID2","n_c":["C101088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARNT","n_c":["C26373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASPSCR1","n_c":["C70991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL1","n_c":["C97320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL2","n_c":["C116296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATF1","n_c":["C92177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATIC","n_c":["C97400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM","n_c":["C18583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP1A1","n_c":["C113762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP2B3","n_c":["C113765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR","n_c":["C20560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATRX","n_c":["C74976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN1","n_c":["C19969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN2","n_c":["C20763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B2M","n_c":["C62660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1","n_c":["C20766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BARD1","n_c":["C20715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL10","n_c":["C24259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11A","n_c":["C97394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11B","n_c":["C91855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2","n_c":["C17963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2L12","n_c":["C114743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL3","n_c":["C18360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL6","n_c":["C24260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL7A","n_c":["C24261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9","n_c":["C24262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9L","n_c":["C132328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCLAF1","n_c":["C115994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCOR","n_c":["C101091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCORL1","n_c":["C131268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR","n_c":["C18455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC3","n_c":["C20356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC6","n_c":["C20352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BLM","n_c":["C20805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMP5","n_c":["C21353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMPR1A","n_c":["C21366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF","n_c":["C18363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA1","n_c":["C17965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA2","n_c":["C18120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD3","n_c":["C97397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4","n_c":["C92702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRIP1","n_c":["C63526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTG1","n_c":["C80101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK","n_c":["C75013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BUB1B","n_c":["C95592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C15orf65","n_c":["C98096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CACNA1D","n_c":["C113769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CALR","n_c":["C95313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAMTA1","n_c":["C101440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CANT1","n_c":["C97375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARD11","n_c":["C60668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARS","n_c":["C97369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CASP8","n_c":["C26623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T3","n_c":["C97445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFB","n_c":["C18584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBL","n_c":["C18364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLB","n_c":["C21589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLC","n_c":["C97439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCDC6","n_c":["C18376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNB1IP1","n_c":["C97372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNC","n_c":["C105393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND1","n_c":["C18021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND2","n_c":["C39596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND3","n_c":["C97381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNE1","n_c":["C21412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR4","n_c":["C129065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR7","n_c":["C104128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD209","n_c":["C21568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD274","n_c":["C96022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD28","n_c":["C21291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD74","n_c":["C97418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79A","n_c":["C97421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79B","n_c":["C97424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD99","n_c":["C102939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC73","n_c":["C43569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH1","n_c":["C18249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH10","n_c":["C143093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH11","n_c":["C97427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH17","n_c":["C143096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK12","n_c":["C101095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4","n_c":["C18250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK6","n_c":["C97384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1A","n_c":["C17782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1B","n_c":["C20060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2A","n_c":["C18022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2C","n_c":["C24288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDX2","n_c":["C24292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEBPA","n_c":["C39598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP89","n_c":["C122887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHCHD7","n_c":["C97403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD2","n_c":["C75307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD4","n_c":["C128251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHEK2","n_c":["C40965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHIC2","n_c":["C97406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHST11","n_c":["C143061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIC","n_c":["C97912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIITA","n_c":["C96013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLIP1","n_c":["C84464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLP1","n_c":["C97528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTC","n_c":["C97412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTCL1","n_c":["C97415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBD1","n_c":["C143056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBP","n_c":["C97888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNOT3","n_c":["C107658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTNAP2","n_c":["C73461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTRL","n_c":["C97891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL1A1","n_c":["C29949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL2A1","n_c":["C75315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL3A1","n_c":["C143052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COX6C","n_c":["C24308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB1","n_c":["C38536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L1","n_c":["C95477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L2","n_c":["C95480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREBBP","n_c":["C26568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRLF2","n_c":["C97430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRNKL1","n_c":["C143049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC1","n_c":["C95449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC3","n_c":["C95276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R","n_c":["C18516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF3R","n_c":["C24313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSMD3","n_c":["C143042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTCF","n_c":["C73679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNA2","n_c":["C143115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNB1","n_c":["C20987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND1","n_c":["C79770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND2","n_c":["C82941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUL3","n_c":["C24323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUX1","n_c":["C95578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4","n_c":["C24327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYLD","n_c":["C92678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP2C8","n_c":["C46071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYSLTR2","n_c":["C143039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DAXX","n_c":["C24330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCAF12L2","n_c":["C143036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCC","n_c":["C17358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCTN1","n_c":["C122875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDB2","n_c":["C93075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDIT3","n_c":["C92539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDR2","n_c":["C24333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX10","n_c":["C97457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX3X","n_c":["C101565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX5","n_c":["C97460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX6","n_c":["C18378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DEK","n_c":["C24339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DGCR8","n_c":["C92663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DICER1","n_c":["C25956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNAJB1","n_c":["C122560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNM2","n_c":["C102796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT3A","n_c":["C73652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DROSHA","n_c":["C25955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DUX4L1","n_c":["C124048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBF1","n_c":["C80023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ECT2L","n_c":["C101452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EED","n_c":["C101721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR","n_c":["C17757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF1AX","n_c":["C131315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF3E","n_c":["C18347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF4A2","n_c":["C97467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF3","n_c":["C20899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF4","n_c":["C97470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELK4","n_c":["C97476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELL","n_c":["C97516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELN","n_c":["C75333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EML4","n_c":["C71003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP300","n_c":["C26569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPAS1","n_c":["C104303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA3","n_c":["C18384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA7","n_c":["C111841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPS15","n_c":["C24369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB2","n_c":["C17756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB3","n_c":["C18386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB4","n_c":["C18388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERC1","n_c":["C97499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC2","n_c":["C20555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC3","n_c":["C20556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC4","n_c":["C20558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC5","n_c":["C20557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERG","n_c":["C18139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ESR1","n_c":["C38349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETNK1","n_c":["C122823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV1","n_c":["C24377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV4","n_c":["C24378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV5","n_c":["C97479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV6","n_c":["C18312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EWSR1","n_c":["C18322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT1","n_c":["C18251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT2","n_c":["C18252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2","n_c":["C21327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZR","n_c":["C68722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM131B","n_c":["C106340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM135B","n_c":["C143112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM46C","n_c":["C96316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM47C","n_c":["C143109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCA","n_c":["C85995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCC","n_c":["C86025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCD2","n_c":["C86549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCE","n_c":["C86551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCF","n_c":["C86553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCG","n_c":["C24385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAS","n_c":["C21555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT1","n_c":["C18397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT3","n_c":["C143133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT4","n_c":["C128254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBLN2","n_c":["C143130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXO11","n_c":["C101104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXW7","n_c":["C20786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCGR2B","n_c":["C38554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCRL4","n_c":["C97592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEN1","n_c":["C98120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FES","n_c":["C45497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEV","n_c":["C97482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1","n_c":["C19929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1OP","n_c":["C24401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR2","n_c":["C19931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR3","n_c":["C24393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4","n_c":["C20743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FH","n_c":["C95268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FHIT","n_c":["C18524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FIP1L1","n_c":["C97454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FKBP9","n_c":["C143127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLCN","n_c":["C63514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLI1","n_c":["C18321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLNA","n_c":["C113585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3","n_c":["C24399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT4","n_c":["C24400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FNBP1","n_c":["C97540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXA1","n_c":["C101646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXL2","n_c":["C75472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO1","n_c":["C24402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO3","n_c":["C28519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO4","n_c":["C24606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXP1","n_c":["C97549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXR1","n_c":["C143124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FSTL3","n_c":["C24408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUBP1","n_c":["C99614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUS","n_c":["C91852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GAS7","n_c":["C97562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA1","n_c":["C28575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA2","n_c":["C97552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA3","n_c":["C75492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLI1","n_c":["C24432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GMPS","n_c":["C97522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNA11","n_c":["C89717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAQ","n_c":["C38316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAS","n_c":["C38317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOLGA5","n_c":["C97543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOPC","n_c":["C97546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPC3","n_c":["C88173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPHN","n_c":["C97525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRIN2A","n_c":["C98146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRM3","n_c":["C114529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3A","n_c":["C101443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3B","n_c":["C113760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HERPUD1","n_c":["C97534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HEY1","n_c":["C101107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF1A","n_c":["C26372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIP1","n_c":["C97537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H3B","n_c":["C101732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H4I","n_c":["C68734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A","n_c":["C28585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLF","n_c":["C97556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA1","n_c":["C20576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA2","n_c":["C20577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGN2P46","n_c":["C98093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNF1A","n_c":["C97825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPA2B1","n_c":["C97496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOOK3","n_c":["C97493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA11","n_c":["C97568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA13","n_c":["C97571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA9","n_c":["C24474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXB1","n_c":["C162630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC11","n_c":["C97574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC13","n_c":["C97577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD11","n_c":["C97580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD13","n_c":["C97583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HRAS","n_c":["C17060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AA1","n_c":["C97586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AB1","n_c":["C97589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ID3","n_c":["C102968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1","n_c":["C77215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH2","n_c":["C84948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGH","n_c":["C26422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGK","n_c":["C26425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGL","n_c":["C26423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKBKB","n_c":["C96383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKZF1","n_c":["C68730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL2","n_c":["C24498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL21R","n_c":["C68736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL6ST","n_c":["C24505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL7R","n_c":["C24506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRF4","n_c":["C18430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRS4","n_c":["C24524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISX","n_c":["C116411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITGAV","n_c":["C53661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITK","n_c":["C24526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1","n_c":["C24528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2","n_c":["C24529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK3","n_c":["C24530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAZF1","n_c":["C73542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JUN","n_c":["C19531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6A","n_c":["C71429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6B","n_c":["C71431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT7","n_c":["C73660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KCNJ5","n_c":["C95838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5A","n_c":["C97595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5C","n_c":["C97598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM6A","n_c":["C96334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDR","n_c":["C24532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDSR","n_c":["C24410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KEAP1","n_c":["C112105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIAA1549","n_c":["C98017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIF5B","n_c":["C101425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIT","n_c":["C18609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF4","n_c":["C73449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF6","n_c":["C97448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLK2","n_c":["C26584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2A","n_c":["C18585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2C","n_c":["C93091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2D","n_c":["C24600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNL1","n_c":["C97378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNSTRN","n_c":["C119652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS","n_c":["C25785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KTN1","n_c":["C97601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LARP4B","n_c":["C143064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LASP1","n_c":["C97604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCK","n_c":["C18541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCP1","n_c":["C21294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LEF1","n_c":["C80032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LHFP","n_c":["C97607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LIFR","n_c":["C24552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMNA","n_c":["C61148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO1","n_c":["C91263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO2","n_c":["C17973"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LPP","n_c":["C97610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRIG3","n_c":["C101446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP1B","n_c":["C111830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSM14A","n_c":["C122884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LYL1","n_c":["C24564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LZTR1","n_c":["C128257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAF","n_c":["C18417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAFB","n_c":["C97671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALAT1","n_c":["C92696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALT1","n_c":["C60671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML2","n_c":["C95456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML3","n_c":["C117094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K1","n_c":["C21222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K2","n_c":["C106606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K4","n_c":["C97674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K1","n_c":["C24572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K13","n_c":["C102523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAPK1","n_c":["C21227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAX","n_c":["C18576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MB21D2","n_c":["C132170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2","n_c":["C18345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM4","n_c":["C88218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDS2","n_c":["C97615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MECOM","n_c":["C18392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MED12","n_c":["C98210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEN1","n_c":["C18254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET","n_c":["C18325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MGMT","n_c":["C21232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MITF","n_c":["C70584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKL1","n_c":["C97296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLF1","n_c":["C97650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH1","n_c":["C18482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH2","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT1","n_c":["C24601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT10","n_c":["C84461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT11","n_c":["C97387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT3","n_c":["C24603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT4","n_c":["C24604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT6","n_c":["C24605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MN1","n_c":["C97618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MNX1","n_c":["C97559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MPL","n_c":["C18411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH2","n_c":["C18481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH6","n_c":["C19195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSI2","n_c":["C91356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSN","n_c":["C97621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTCP1","n_c":["C24617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTOR","n_c":["C38928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC1","n_c":["C38939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC16","n_c":["C71018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC4","n_c":["C128854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUTYH","n_c":["C61056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYB","n_c":["C28569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYC","n_c":["C16887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCL","n_c":["C18407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCN","n_c":["C18405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYD88","n_c":["C90089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH11","n_c":["C29957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH9","n_c":["C97646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYO5A","n_c":["C122881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYOD1","n_c":["C93113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NAB2","n_c":["C122903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NACA","n_c":["C97653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBEA","n_c":["C143075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBN","n_c":["C21178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCKIPSD","n_c":["C97433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA1","n_c":["C20695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA2","n_c":["C20697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA4","n_c":["C18381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR1","n_c":["C28640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR2","n_c":["C28633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NDRG1","n_c":["C24625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF1","n_c":["C17424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF2","n_c":["C17425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFATC2","n_c":["C93138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFE2L2","n_c":["C54237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFIB","n_c":["C38401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKB2","n_c":["C18404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKBIE","n_c":["C38396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NIN","n_c":["C97668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NKX2-1","n_c":["C73443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NONO","n_c":["C71419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH1","n_c":["C24636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH2","n_c":["C97677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPM1","n_c":["C21185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR4A3","n_c":["C96007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRAS","n_c":["C25786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRG1","n_c":["C20174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD1","n_c":["C75876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD2","n_c":["C21416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD3","n_c":["C96341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NT5C2","n_c":["C104587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTHL1","n_c":["C106190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK1","n_c":["C18551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK3","n_c":["C24647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUMA1","n_c":["C24648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP214","n_c":["C24649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP98","n_c":["C20820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM1","n_c":["C92705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2A","n_c":["C101098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2B","n_c":["C101101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OLIG2","n_c":["C68575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OMD","n_c":["C97680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P2RY8","n_c":["C97683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PABPC1","n_c":["C143072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAFAH1B2","n_c":["C97894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PALB2","n_c":["C84945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PATZ1","n_c":["C97876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX3","n_c":["C24658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX5","n_c":["C24659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX7","n_c":["C24660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX8","n_c":["C97687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBRM1","n_c":["C95438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBX1","n_c":["C97317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCBP1","n_c":["C95865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCM1","n_c":["C97900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDCD1LG2","n_c":["C45437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDE4DIP","n_c":["C97718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFB","n_c":["C18278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRA","n_c":["C24666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRB","n_c":["C24667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PER1","n_c":["C97721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGR","n_c":["C28656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF6","n_c":["C101449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHOX2B","n_c":["C97724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PICALM","n_c":["C84434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CA","n_c":["C21220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CB","n_c":["C24672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3R1","n_c":["C97733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM1","n_c":["C18337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLAG1","n_c":["C71423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLCG1","n_c":["C104821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PML","n_c":["C24686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS1","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS2","n_c":["C18591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLD1","n_c":["C106224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLE","n_c":["C106232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLG","n_c":["C143069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLQ","n_c":["C131801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POT1","n_c":["C107655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU2AF1","n_c":["C97730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU5F1","n_c":["C61140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPARG","n_c":["C24689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPFIBP1","n_c":["C101494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPM1D","n_c":["C88179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP2R1A","n_c":["C92536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP6C","n_c":["C102901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRCC","n_c":["C70994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM1","n_c":["C24692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM16","n_c":["C97736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM2","n_c":["C143121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PREX2","n_c":["C102517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRF1","n_c":["C97739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKACA","n_c":["C38409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKAR1A","n_c":["C97742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKCB","n_c":["C39597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRPF40B","n_c":["C143090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRRX1","n_c":["C98030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSIP1","n_c":["C20676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTCH1","n_c":["C18255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTEN","n_c":["C18256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTK6","n_c":["C24701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN11","n_c":["C26337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN13","n_c":["C104212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN6","n_c":["C24708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRB","n_c":["C122909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRC","n_c":["C24711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRK","n_c":["C106113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRT","n_c":["C24716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PWWP2A","n_c":["C122890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"QKI","n_c":["C111937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RABEP1","n_c":["C97751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAC1","n_c":["C99663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD21","n_c":["C93082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD51B","n_c":["C90145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF1","n_c":["C18338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RALGDS","n_c":["C24721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RANBP2","n_c":["C114452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAP1GDS1","n_c":["C97758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RARA","n_c":["C21571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RB1","n_c":["C17360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM10","n_c":["C115382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM15","n_c":["C97293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RECQL4","n_c":["C26492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"REL","n_c":["C17084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET","n_c":["C18257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGPD3","n_c":["C143082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGS7","n_c":["C143118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOA","n_c":["C18356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOH","n_c":["C21320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RMI2","n_c":["C96027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF213","n_c":["C97390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF43","n_c":["C107649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROBO2","n_c":["C126774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROS1","n_c":["C18399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL10","n_c":["C24748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL22","n_c":["C97761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL5","n_c":["C107652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPN1","n_c":["C97290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO2","n_c":["C106067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO3","n_c":["C24397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1","n_c":["C18579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1T1","n_c":["C28570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S100A7","n_c":["C143078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SALL4","n_c":["C112905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SBDS","n_c":["C97767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDC4","n_c":["C101431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHA","n_c":["C103873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHAF2","n_c":["C97770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHB","n_c":["C97773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHC","n_c":["C97776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHD","n_c":["C97779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT5","n_c":["C97727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT6","n_c":["C97782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT9","n_c":["C97897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SET","n_c":["C24801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETBP1","n_c":["C106635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD2","n_c":["C73662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SF3B1","n_c":["C98284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFPQ","n_c":["C71417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFRP4","n_c":["C24804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SGK1","n_c":["C101559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH2B3","n_c":["C102802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH3GL1","n_c":["C97788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHTN1","n_c":["C122906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPA","n_c":["C24710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SKI","n_c":["C69184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC34A2","n_c":["C101434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC45A3","n_c":["C97791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD2","n_c":["C24566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD3","n_c":["C18504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD4","n_c":["C18258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCA4","n_c":["C19878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCB1","n_c":["C18394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCD1","n_c":["C19875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCE1","n_c":["C19874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMC1A","n_c":["C75406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMO","n_c":["C24817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SND1","n_c":["C96331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SNX29","n_c":["C97764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOCS1","n_c":["C97794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOX2","n_c":["C61136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPECC1","n_c":["C97531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPEN","n_c":["C115310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPOP","n_c":["C102534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRC","n_c":["C19917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRGAP3","n_c":["C97797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF2","n_c":["C101110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF3","n_c":["C97785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18","n_c":["C97800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18L1","n_c":["C97803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX1","n_c":["C97806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX2","n_c":["C97809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX4","n_c":["C97814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG1","n_c":["C131224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG2","n_c":["C101346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3","n_c":["C24833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT5B","n_c":["C28667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT6","n_c":["C24835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STIL","n_c":["C101126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STK11","n_c":["C18253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STRN","n_c":["C107661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUFU","n_c":["C97819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUZ12","n_c":["C73545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYK","n_c":["C26536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAF15","n_c":["C95994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL1","n_c":["C18301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL2","n_c":["C24843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBL1XR1","n_c":["C80116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBX3","n_c":["C101638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCEA1","n_c":["C97822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF12","n_c":["C97828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF3","n_c":["C24846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF7L2","n_c":["C24847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCL1A","n_c":["C92699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TEC","n_c":["C24850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TERT","n_c":["C18173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET1","n_c":["C95423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET2","n_c":["C95252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFE3","n_c":["C24854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFEB","n_c":["C94761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFG","n_c":["C97834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFPT","n_c":["C97837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFRC","n_c":["C38517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFBR2","n_c":["C18592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"THRAP3","n_c":["C97840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX1","n_c":["C18608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX3","n_c":["C98099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMEM127","n_c":["C95303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMPRSS2","n_c":["C24871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNC","n_c":["C21091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFAIP3","n_c":["C84928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF14","n_c":["C97843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF17","n_c":["C97846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP1","n_c":["C26591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP53","n_c":["C17359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP63","n_c":["C91791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM3","n_c":["C97849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM4","n_c":["C97852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPR","n_c":["C97855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRA","n_c":["C26419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRAF7","n_c":["C107646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRB","n_c":["C26418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRD","n_c":["C26420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM24","n_c":["C95280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM27","n_c":["C24733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM33","n_c":["C97858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIP11","n_c":["C97861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRRAP","n_c":["C24880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC1","n_c":["C18259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC2","n_c":["C18260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSHR","n_c":["C24881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U2AF1","n_c":["C101113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBR5","n_c":["C111928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP6","n_c":["C24892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP8","n_c":["C24893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VAV1","n_c":["C18365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VHL","n_c":["C18261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VTI1A","n_c":["C99462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WAS","n_c":["C43236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WDCP","n_c":["C101428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WIF1","n_c":["C97867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WNK2","n_c":["C143106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WRN","n_c":["C20070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1","n_c":["C18262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WWTR1","n_c":["C24844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPA","n_c":["C20361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPC","n_c":["C97870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPO1","n_c":["C99484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"YWHAE","n_c":["C101116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZBTB16","n_c":["C28635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZCCHC8","n_c":["C122878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB1","n_c":["C105605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZFHX3","n_c":["C115424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZMYM3","n_c":["C101617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF198","n_c":["C97873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF331","n_c":["C97879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF384","n_c":["C97882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF429","n_c":["C143100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF444","n_c":["C106358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF479","n_c":["C143103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF521","n_c":["C97885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNRF3","n_c":["C118319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZRSR2","n_c":["C101120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHGA","n_c":["C21167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYP","n_c":["C101144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR2","n_c":["C24863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACACA","n_c":["C103885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD1","n_c":["C185736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTBD18","n_c":["C126629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T2","n_c":["C104928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP164","n_c":["C200372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP170B","n_c":["C126611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTDP1","n_c":["C200378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DOT1L","n_c":["C73677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FRYL","n_c":["C126623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLIS2","n_c":["C105900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGB3","n_c":["C20580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPH1","n_c":["C200386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INO80D","n_c":["C125258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JARID2","n_c":["C200399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF23","n_c":["C98035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM3","n_c":["C178143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTP4A1","n_c":["C24704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPS15","n_c":["C200404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD1A","n_c":["C200408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC66A2 (aka PQLC1)","n_c":["C200414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP2B","n_c":["C26593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBB","n_c":["C38431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB2","n_c":["C75441"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.test_analyte_type":[{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA","n_c":["C25966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA","n_c":["C813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein","n_c":["C17021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.test_result":[{"nm":"Abnormal, NOS","n_c":["C26683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copy Number Reported","n_c":["C49142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equivocal","n_c":["C86071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High","n_c":["C25227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate","n_c":["C73705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loss of Expression","n_c":["C165233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low","n_c":["C54722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normal","n_c":["C14165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Overexpressed","n_c":["C177693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Positive","n_c":["C38758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Test Value Reported","n_c":["C165229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stable","n_c":["C30103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amplified","n_c":["C177682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elevated","n_c":["C26683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Amplified","n_c":["C177682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotic Count Reported","n_c":["C202274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staining Intensity Value Reported","n_c":["C202275"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.variant_origin":[{"nm":"Germline","n_c":["C17666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somatic","n_c":["C18060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.variant_type":[{"nm":"Alleles","n_c":["C16277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amplification","n_c":["C45581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chrimerism","n_c":["C62582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conversion","n_c":["C165230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deletion","n_c":["C19296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deletion-Insertion","n_c":["C171175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duplication","n_c":["C45582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extension","n_c":["C148650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gain","n_c":["C37956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypermethylation","n_c":["C20102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insertion","n_c":["C19295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inversion","n_c":["C45589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loss","n_c":["C25559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylation","n_c":["C16848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mosaicism","n_c":["C92976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Methylation","n_c":["C165231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rearrangement","n_c":["C36541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repeated Sequences","n_c":["C13298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice","n_c":["C19798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Substitution","n_c":["C18133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Translocation","n_c":["C3420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fusion","n_c":["C45584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genetic Polymorphism","n_c":["C17004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Internal Tandem Duplication","n_c":["C198980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutation, NOS","n_c":["C45576"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.zygosity":[{"nm":"Hemizygous","n_c":["C64346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterozygous","n_c":["C45825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Homozygous","n_c":["C45826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nullizygous","n_c":["C148063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.anaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.anaplasia_present_type":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse","n_c":["C14175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equivocal","n_c":["C86071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Focal","n_c":["C28224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C36113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sclerosis","n_c":["C69309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.bone_marrow_malignant_cells":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.columnar_mucosa_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.dysplasia_degree":[{"nm":"High Grade","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indefinite","n_c":["C164039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Dysplasia","n_c":["C164040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mild","n_c":["C8362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate","n_c":["C8363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Severe","n_c":["C8364"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.dysplasia_type":[{"nm":"Esophageal Columnar Dysplasia","n_c":["C174120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Keratinizing","n_c":["C161017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonkeratinizing","n_c":["C161016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Mucosa Columnar Dysplasia","n_c":["C174120"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.largest_extrapelvic_peritoneal_focus":[{"nm":"Macroscopic (2cm or less)","n_c":["C53696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic (greater than 2cm)","n_c":["C51138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_involved_site":[{"nm":"Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-external","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac, NOS","n_c":["C32761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis, NOS","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical, NOS","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_involvement":[{"nm":"Positive","n_c":["C27296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative","n_c":["C36174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminant","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymphatic_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.margin_status":[{"nm":"Involved","n_c":["C48620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uninvolved","n_c":["C48621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminant","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.metaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.morphologic_architectural_pattern":[{"nm":"Cohesive","n_c":["C179432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cribiform","n_c":["C35920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micropapillary","n_c":["C36181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-cohesive","n_c":["C179447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papillary Renal Cell","n_c":["C6975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papillary, NOS","n_c":["C35911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid","n_c":["C36182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubular","n_c":["C35925"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.non_nodal_regional_disease":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.non_nodal_tumor_deposits":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.perineural_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.peripancreatic_lymph_nodes_positive":[{"nm":"0","n_c":["C70430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1-3","n_c":["C172224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4 or More","n_c":["C172226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.transglottic_extension":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.vascular_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.vascular_invasion_type":[{"nm":"Extramural","n_c":["C44280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intramural","n_c":["C25234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macro","n_c":["C43566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micro","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Vascular Invasion","n_c":["C164046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"data_file.pathology_report.data_category":[{"nm":"Clinical","n_c":["C15783"],"i_c":"","i_c_s":"","term_type":""}],"data_file.pathology_report.data_type":[{"nm":"Pathology Report","n_c":["C28277"],"i_c":"","i_c_s":"","term_type":""}],"data_file.pathology_report.data_format":[{"nm":"PDF","n_c":["C63805"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.chipseq_target":[{"nm":"H3K4me1","n_c":["C120024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K4me3","n_c":["C107153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K9me3","n_c":["C174109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K27me3","n_c":["C174110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K36me3","n_c":["C142872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K27ac","n_c":["C120023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Input Control","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.instrument_model":[{"nm":"454 GS FLX Titanium","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"AB SOLiD 2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"AB SOLiD 3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"AB SOLiD 4","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Complete Genomics","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Genome Analyzer II","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Genome Analyzer IIx","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq 2000","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq 2500","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq 4000","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq X Five","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq X Ten","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina MiSeq","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina NextSeq","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent PGM","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent Proton","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent S5","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio RS","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.library_selection":[{"nm":"Affinity Enrichment","n_c":["C163987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hybrid Selection","n_c":["C163986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA Size Fractionation","n_c":["C163991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCR","n_c":["C17003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poly-T Enrichment","n_c":["C163988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Random","n_c":["C163989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"rRNA Depletion","n_c":["C163990"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.library_strand":[{"nm":"Unstranded","n_c":["C150427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First_Stranded","n_c":["C150428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Second_Stranded","n_c":["C150426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.library_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A RNA Methylation","n_c":["C179442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.single_cell_library":[{"nm":"Chromium 3' Gene Expression v2 Library","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Chromium 3' Gene Expression v3 Library","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Smart-Seq2","n_c":"","i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.target_capture_kit":[{"nm":"Custom AmpliSeq Cancer Hotspot GENIE-MDA Augmented Panel v1 - 46 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom GENIE-DFCI OncoPanel - 275 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom GENIE-DFCI Oncopanel - 300 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom GENIE-DFCI Oncopanel - 447 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom HaloPlex DLBCL Panel - 370 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Ion AmpliSeq Hotspot GENIE-MOSC3 Augmented Panel - 74 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Large Construct Capture TARGET-OS Panel - 8 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom MSK IMPACT Panel - 341 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom MSK IMPACT Panel - 410 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom MSK IMPACT Panel - 468 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Myeloid GENIE-VICC Panel - 37 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Personalis ACEcp VAREPOP-APOLLO Panel v2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom PGDX SureSelect CancerSelect VAREPOP-APOLLO Panel - 203 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom PGDX SureSelect CancerSelect VAREPOP-APOLLO Panel - 88 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SeqCap EZ HGSC VCRome v2.1 ER Augmented v1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SeqCap EZ HGSC VCRome v2.1 ER Augmented v2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SeqCap EZ TARGET-OS Panel - 7.0 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Solid Tumor GENIE-VICC Panel - 34 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect CGCI-BLGSP Panel - 4.6 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect CGCI-HTMCP-CC KMT2D And Hotspot Panel - 37.0 Kb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect CGCI-HTMCP-CC Panel - 19.7 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect GENIE-UHN Panel - 555 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect Human All Exon v1.1 Plus 3 Boosters","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect TARGET-AML_NBL_WT Panel - 2.8 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Twist Broad Exome v1.0 - 35.0 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Twist Broad PanCancer Panel - 396 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Foundation Medicine T5a Panel - 322 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Foundation Medicine T7 Panel - 429 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion AmpliSeq Cancer Hotspot Panel v2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion AmpliSeq Comprehensive Cancer Panel","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nextera DNA Exome","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nextera Rapid Capture Exome v1.2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SeqCap EZ HGSC VCRome v2.1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SeqCap EZ Human Exome v2.0","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SeqCap EZ Human Exome v3.0","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v4","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v5","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v5 + UTR","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSeq Amplicon Cancer Panel","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSeq Exome Enrichment - 62 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSeq RNA Exome","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSight Myeloid Sequencing Panel","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"xGen Exome Research Panel v1.0","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data.root.id":[{"nm":"root","n_c":["C172256"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.run_metadata.data_category":[{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.run_metadata.data_type":[{"nm":"Run Metadata","n_c":["C165214"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.run_metadata.data_format":[{"nm":"SRA XML","n_c":["C184804"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.biospecimen_anatomic_site":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Wall","n_c":["C77608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetabulum","n_c":["C32042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoid","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adipose","n_c":["C12472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alveolar Ridge","n_c":["C89749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amniotic Fluid","n_c":["C13188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ampulla Of Vater","n_c":["C13011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Sphincter","n_c":["C165177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle","n_c":["C32078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectum","n_c":["C129464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antecubital Fossa","n_c":["C103238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrum","n_c":["C97102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aorta","n_c":["C12669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Body","n_c":["C97112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aqueous Fluid","n_c":["C13190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arm","n_c":["C32141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artery","n_c":["C12372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon","n_c":["C12265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auditory Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autonomic Nervous System","n_c":["C12673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axilla","n_c":["C12674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back","n_c":["C13062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct","n_c":["C12376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel","n_c":["C12679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bowel","n_c":["C12736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad Ligament","n_c":["C12318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchiole","n_c":["C12684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brow","n_c":["C32575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock","n_c":["C89806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calf","n_c":["C93027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary","n_c":["C12685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardia","n_c":["C12256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carina","n_c":["C25264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Artery","n_c":["C12687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Body","n_c":["C66852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cartilage","n_c":["C12373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecum","n_c":["C12381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell-Line","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebellum","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Spine","n_c":["C69313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest","n_c":["C25389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chin","n_c":["C81169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clavicle","n_c":["C12695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clitoris","n_c":["C12308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon - Mucosa Only","n_c":["C164003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Duct","n_c":["C12698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermal","n_c":["C25478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Descending Colon","n_c":["C12268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenum","n_c":["C12263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear, Pinna (External)","n_c":["C12292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Effusion","n_c":["C3003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbow","n_c":["C32497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Gland","n_c":["C12704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epidural Space","n_c":["C41449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal; Distal","n_c":["C12255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal; Mid","n_c":["C12254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal; Proximal","n_c":["C12253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagogastric Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus - Mucosa Only","n_c":["C32538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Artery","n_c":["C12715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Vein","n_c":["C12716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femur","n_c":["C12717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts","n_c":["C12482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibula","n_c":["C12718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finger","n_c":["C32608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floor Of Mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluid","n_c":["C25278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foot","n_c":["C32622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forearm","n_c":["C32628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forehead","n_c":["C89803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foreskin","n_c":["C33049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Cortex","n_c":["C177766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fundus Of Stomach","n_c":["C12257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglia","n_c":["C12719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glottis","n_c":["C12724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand","n_c":["C32712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hard Palate","n_c":["C12230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head - Face Or Neck, Nos","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Head & Neck","n_c":["C12418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic","n_c":["C13308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Duct","n_c":["C32730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Vein","n_c":["C32736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip","n_c":["C64193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hippocampus","n_c":["C12444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Humerus","n_c":["C12731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileum","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilium","n_c":["C32765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Index Finger","n_c":["C52835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischium","n_c":["C32884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Islet Cells","n_c":["C32885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jaw","n_c":["C48821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunum","n_c":["C12388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint","n_c":["C13044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Knee","n_c":["C32898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacrimal Gland","n_c":["C12346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Bowel","n_c":["C12379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leg","n_c":["C32974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ligament","n_c":["C13046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumbar Spine","n_c":["C69314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Axilla","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Distant","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-Common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-External","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Internal Mammary","n_c":["C32853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mammary","n_c":["C137678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Pelvic","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Scalene","n_c":["C89780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Subclavicular","n_c":["C63705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Nodes(s) Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Soft Tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Finger","n_c":["C52836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondria","n_c":["C13258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle","n_c":["C13056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nails","n_c":["C33156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Cavity","n_c":["C12424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Soft Tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve","n_c":["C12466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve(s) Cranial","n_c":["C12700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital Cortex","n_c":["C177767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular Orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity - Mucosa Only","n_c":["C77637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paranasal Sinuses","n_c":["C12763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraspinal Ganglion","n_c":["C97925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parathyroid","n_c":["C12765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid Gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patella","n_c":["C33282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Soft Tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharynx","n_c":["C12425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal Gland","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pituitary Gland","n_c":["C12399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal Fossa","n_c":["C103222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pylorus","n_c":["C12260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid Junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retina","n_c":["C12343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retro-Orbital Region","n_c":["C54155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rib","n_c":["C12782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ring Finger","n_c":["C52837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Round Ligament","n_c":["C12319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacrum","n_c":["C33508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scapula","n_c":["C12783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sciatic Nerve","n_c":["C52810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotum","n_c":["C12785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seminal Vesicle","n_c":["C12787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shoulder","n_c":["C25203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus(es), Maxillary","n_c":["C12275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skeletal Muscle","n_c":["C13050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skull","n_c":["C12789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel - Mucosa Only","n_c":["C33568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Finger","n_c":["C52838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Column","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Flexure","n_c":["C12267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sternum","n_c":["C12793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach - Mucosa Only","n_c":["C32656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous Tissue","n_c":["C33645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subglottis","n_c":["C12280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sublingual Gland","n_c":["C12234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular Gland","n_c":["C12233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovium","n_c":["C12473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal Cortex","n_c":["C177768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tendon","n_c":["C13045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thigh","n_c":["C33763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracic Spine","n_c":["C69315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat","n_c":["C54272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thumb","n_c":["C52834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tibia","n_c":["C12800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil (Pharyngeal)","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea / Major Bronchi","n_c":["C12961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trunk","n_c":["C33816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbilical Cord","n_c":["C34320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract","n_c":["C191741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uvula","n_c":["C12232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens","n_c":["C12813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vein","n_c":["C12814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous","n_c":["C25291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebra","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cells","n_c":["C12529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist","n_c":["C33894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.biospecimen_laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.composition":[{"nm":"2D Classical Conditionally Reprogrammed Cells","n_c":["C172257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2D Modified Conditionally Reprogrammed Cells","n_c":["C172258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Air-Liquid Interface Organoid","n_c":["C172260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Neurosphere","n_c":["C172261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Organoid","n_c":["C172259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adherent Cell Line","n_c":["C20216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Components","n_c":["C164009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Components NOS","n_c":["C164009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cells","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buffy Coat","n_c":["C84507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell","n_c":["C12508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Control Analyte","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derived Cell Line","n_c":["C156445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts from Bone Marrow Normal","n_c":["C164010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocytes","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Original Cells","n_c":["C19315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquid Suspension Cell Line","n_c":["C20217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytes","n_c":["C12535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mononuclear Cells from Bone Marrow Normal","n_c":["C164011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Blood Components NOS","n_c":["C17610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Whole Blood","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma","n_c":["C13356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C3331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C13275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum","n_c":["C13325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid Tissue","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorted Cells","n_c":["C126974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sputum","n_c":["C13278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whole Bone Marrow","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Adherent Suspension","n_c":["C174118"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.diagnosis_pathologically_confirmed":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.distance_normal_to_tumor":[{"nm":"Adjacent (< or = 2cm)","n_c":["C25408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distal (>2cm)","n_c":["C25237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.method_of_sample_procurement":[{"nm":"Abdomino-perineal Resection of Rectum","n_c":["C91826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anterior Resection of Rectum","n_c":["C113716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites Drainage","n_c":["C159342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspirate","n_c":["C13347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autopsy","n_c":["C25153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy","n_c":["C15189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Draw","n_c":["C17610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Aspirate","n_c":["C133261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosal Resection","n_c":["C172322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Core Biopsy","n_c":["C15680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cystectomy","n_c":["C15217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Parotidectomy","n_c":["C161002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endo Rectal Tumor Resection","n_c":["C165178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endolaryngeal Excision","n_c":["C160999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endoscopic Biopsy","n_c":["C15389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endoscopic Mucosal Resection (EMR)","n_c":["C103242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enucleation","n_c":["C48601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Excisional Biopsy","n_c":["C15385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fine Needle Aspiration","n_c":["C15361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Full Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glossectomy","n_c":["C51604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gross Total Resection","n_c":["C131672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand Assisted Laparoscopic Radical Nephrectomy","n_c":["C165179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hysterectomy NOS","n_c":["C15256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incisional Biopsy","n_c":["C15386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminant","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Biopsy","n_c":["C165180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Partial Nephrectomy","n_c":["C165181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Radical Nephrectomy","n_c":["C165182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Radical Prostatectomy with Robotics","n_c":["C165183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Radical Prostatectomy without Robotics","n_c":["C165184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharyngectomy","n_c":["C150660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left Hemicolectomy","n_c":["C51624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquid Biopsy","n_c":["C135727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lobectomy","n_c":["C15272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Local Resection (Exoresection; wall resection)","n_c":["C118358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumpectomy","n_c":["C15755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node Dissection","n_c":["C15275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphadenectomy","n_c":["C15275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandibulectomy","n_c":["C51664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxillectomy","n_c":["C51656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metastasectomy","n_c":["C94461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Radical Mastectomy","n_c":["C15278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Needle Biopsy","n_c":["C15190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentectomy","n_c":["C51787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oophorectomy","n_c":["C15291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Craniotomy","n_c":["C15214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Partial Nephrectomy","n_c":["C165186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Radical Nephrectomy","n_c":["C165187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Radical Prostatectomy","n_c":["C165188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orchiectomy","n_c":["C15288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Surgical Resection","n_c":["C184787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palatectomy","n_c":["C160997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-Procto Colectomy","n_c":["C103239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatectomy","n_c":["C15294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paracentesis","n_c":["C15310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotidectomy, NOS","n_c":["C51490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Hepatectomy","n_c":["C15394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Laryngectomy","n_c":["C94240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Maxillectomy","n_c":["C51657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Nephrectomy","n_c":["C51928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Lavage","n_c":["C159340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonectomy","n_c":["C15305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Punch Biopsy","n_c":["C28743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Hysterectomy","n_c":["C94470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Maxillectomy","n_c":["C172324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Nephrectomy","n_c":["C51778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Prostatectomy","n_c":["C15399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right Hemicolectomy","n_c":["C51623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salpingectomy","n_c":["C51605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salpingo-oophorectomy","n_c":["C15323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colectomy","n_c":["C91838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Mastectomy","n_c":["C15281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subtotal Prostatectomy","n_c":["C172325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subtotal Resection","n_c":["C131680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial Parotidectomy","n_c":["C51910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supracervical Hysterectomy","n_c":["C126397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supracricoid Laryngectomy","n_c":["C91839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraglottic Laryngectomy","n_c":["C51889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical Resection","n_c":["C158758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracentesis","n_c":["C15392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracoscopic Biopsy","n_c":["C163997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsillectomy","n_c":["C51679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Colectomy","n_c":["C51924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Hepatectomy","n_c":["C51781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Laryngectomy","n_c":["C51771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Mastectomy","n_c":["C15281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Nephrectomy","n_c":["C51632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transoral Laser Excision","n_c":["C91840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transplant","n_c":["C15342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transurethral resection (TURBT)","n_c":["C116651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transurethral Resection (TURP)","n_c":["C15343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colectomy","n_c":["C51612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Debulking","n_c":["C15749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Resection","n_c":["C164212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertical Hemilaryngectomy","n_c":["C51906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wedge Resection","n_c":["C51690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whipple Procedure","n_c":["C15356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.preservation_method":[{"nm":"Cryopreserved","n_c":["C16475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE","n_c":["C143028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fresh","n_c":["C84517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frozen","n_c":["C70717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OCT","n_c":["C63523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Snap Frozen","n_c":["C63521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EDTA","n_c":["C61742"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.sample_type":[{"nm":"Additional - New Primary","n_c":["C156441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Additional Metastatic","n_c":["C156440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Neoplasms","n_c":["C3677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Bone Marrow","n_c":["C164015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Bone Marrow, Post-treatment","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Peripheral Blood","n_c":["C164030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Peripheral Blood, Post-treatment","n_c":["C164031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Liquid Biopsy","n_c":["C135727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Normal","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Normal","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cell Normal","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell Line Derived Xenograft Tissue","n_c":["C156443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell Lines","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Control Analyte","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized Normal","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Expanded Next Generation Cancer Model","n_c":["C184757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE Recurrent","n_c":["C172267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE Scrolls","n_c":["C172268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts from Bone Marrow Normal","n_c":["C164010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GenomePlex (Rubicon) Amplified DNA","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocytes","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Tumor Original Cells","n_c":["C172293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"In Situ Neoplasms","n_c":["C36118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Normal","n_c":["C13049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metastatic","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Adherent Suspension","n_c":["C174118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mononuclear Cells from Bone Marrow Normal","n_c":["C164011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms of Uncertain and Unknown Behavior","n_c":["C65157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Next Generation Cancer Model","n_c":["C172295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C3331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post neo-adjuvant therapy","n_c":["C156444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Blood Derived Cancer - Bone Marrow","n_c":["C164015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Blood Derived Cancer - Peripheral Blood","n_c":["C164030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Tumor","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Xenograft Tissue","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Blood Derived Cancer - Bone Marrow","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Blood Derived Cancer - Peripheral Blood","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Tumor","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G (Qiagen) DNA","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X (Qiagen) DNA","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C174119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slides","n_c":["C172296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid Tissue Normal","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor","n_c":["C18009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Adjacent Normal - Post Neo-adjuvant Therapy","n_c":["C164033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xenograft Tissue","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Next Generation Cancer Model Expanded Under Non-conforming Conditions","n_c":["C184781"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.sample_type_id":[{"nm":"01","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"02","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"03","n_c":["C164030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"04","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"05","n_c":["C156441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"06","n_c":["C156440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"07","n_c":["C156440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"08","n_c":["C172293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"09","n_c":["C164015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"10","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"12","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"13","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"14","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"15","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"16","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"17","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"18","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"20","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"30","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"31","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"32","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"40","n_c":["C164031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"41","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"42","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"50","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"60","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"61","n_c":["C156443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"85","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"86","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"99","n_c":"","i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tissue_collection_type":[{"nm":"Prospective","n_c":["C172297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retrospective","n_c":["C172298"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tissue_type":[{"nm":"Tumor","n_c":["C18009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normal","n_c":["C14165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abnormal","n_c":["C25401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritumoral","n_c":["C119010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tumor_code":[{"nm":"Acute Leukemia of Ambiguous Lineage (ALAL)","n_c":["C7464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute lymphoblastic leukemia (ALL)","n_c":["C3167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute myeloid leukemia (AML)","n_c":["C3171"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Cancer (all types)","n_c":["C9291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Cancer (all types)","n_c":["C9039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clear cell sarcoma of the kidney (CCSK)","n_c":["C4264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, ependymoma","n_c":["C3017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, glioblastoma (GBM)","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, low grade glioma (LGG)","n_c":["C132067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, medulloblastoma","n_c":["C3222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, other","n_c":["C184750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, rhabdoid tumor","n_c":["C184751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse Large B-Cell Lymphoma (DLBCL)","n_c":["C8851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ewing sarcoma","n_c":["C4817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction Failure AML (AML-IF)","n_c":["C184765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Cancer (all types)","n_c":["C4878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroblastoma (NBL)","n_c":["C3270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NHL, anaplastic large cell lymphoma","n_c":["C3720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NHL, Burkitt lymphoma (BL)","n_c":["C2912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non cancerous tissue","n_c":["C166238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteosarcoma (OS)","n_c":["C9145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhabdoid tumor (kidney) (RT)","n_c":["C8715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhabdomyosarcoma","n_c":["C3359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft tissue sarcoma, non-rhabdomyosarcoma","n_c":["C9306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wilms tumor (WT)","n_c":["C3267"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tumor_code_id":[{"nm":"00","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"01","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"02","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"03","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"04","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"10","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"15","n_c":["C7978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"20","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"21","n_c":["C7978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"30","n_c":["C4349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"40","n_c":["C7978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"41","n_c":["C4349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"50","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"51","n_c":["C6975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"52","n_c":["C3512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"60","n_c":["C3493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"61","n_c":["C9245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"62","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"63","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"64","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"65","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"70","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"71","n_c":["C6975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"80","n_c":["C9245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"81","n_c":["C7558"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tumor_descriptor":[{"nm":"Metastatic","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOS","n_c":["C19594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premalignant","n_c":["C36032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xenograft","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Primary","n_c":["C156806"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.slide.bone_marrow_malignant_cells":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.data_category":[{"nm":"Biospecimen","n_c":["C70699"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.data_type":[{"nm":"Cell Culture Image","n_c":["C165212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slide Image","n_c":["C165215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tissue Microarray Image","n_c":["C171154"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.data_format":[{"nm":"JPEG","n_c":["C48230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SVS","n_c":["C172214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TIFF","n_c":["C70631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JPEG 2000","n_c":["C184768"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.experimental_strategy":[{"nm":"Cell Culture","n_c":["C16396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diagnostic Slide","n_c":["C165218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tissue Slide","n_c":["C165223"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.stain_type":[{"nm":"Haemotoxylin and Eosin (H&E)","n_c":["C23011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunohistochemistry (IHC)","n_c":["C23020"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.data_category":[{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.data_type":[{"nm":"Aligned Reads","n_c":["C164052"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.data_format":[{"nm":"BAM","n_c":["C153249"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A RNA Methylation","n_c":["C179442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.type":[{"nm":"submitted_genomic_profile","n_c":["C94411"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.data_category":[{"nm":"Combined Nucleotide Variation","n_c":["C171155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genomic Profiling","n_c":["C94411"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.data_type":[{"nm":"FoundationOne Report","n_c":["C184758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GENIE Report","n_c":["C184760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw CGI Variant","n_c":["C184794"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XML","n_c":["C45967"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.data_type":[{"nm":"Methylation Beta Value","n_c":["C164051"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.platform":[{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.data_type":[{"nm":"Copy Number Estimate","n_c":["C165213"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.data_category":[{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.data_type":[{"nm":"Unaligned Reads","n_c":["C164053"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.data_format":[{"nm":"BAM","n_c":["C153249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FASTQ","n_c":["C153250"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A RNA Methylation","n_c":["C179442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.read_pair_number":[{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C172301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C172302"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.chemo_concurrent_to_radiation":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.initial_disease_status":[{"nm":"Initial Diagnosis","n_c":["C156813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Disease","n_c":["C35571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Disease","n_c":["C38155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Residual Disease","n_c":["C4809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Persistent Disease","n_c":["C90169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Refractory Disease","n_c":["C39752"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.reason_treatment_ended":[{"nm":"Adverse Event","n_c":["C41331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Course of Therapy Completed","n_c":["C82568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Disease Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Withdrawal by Subject","n_c":["C49634"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_anatomic_site":[{"nm":"Abdomen, total","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Wall","n_c":["C77608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetabulum","n_c":["C32042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoid","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adipose","n_c":["C12472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alveolar Ridge","n_c":["C89749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amniotic Fluid","n_c":["C13188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Sphincter","n_c":["C165177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle","n_c":["C32078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectum","n_c":["C129464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antecubital Fossa","n_c":["C103238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrum","n_c":["C97102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aorta","n_c":["C12669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Body","n_c":["C97112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aqueous Fluid","n_c":["C13190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arm","n_c":["C32141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artery","n_c":["C12372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon","n_c":["C12265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auditory Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autonomic Nervous System","n_c":["C12673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axilla","n_c":["C12674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back","n_c":["C13062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct","n_c":["C12376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel","n_c":["C12679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Body, total","n_c":["C13041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone, non-spine","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Bowel","n_c":["C12736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad Ligament","n_c":["C12318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchiole","n_c":["C12684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brow","n_c":["C32575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock","n_c":["C89806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calf","n_c":["C93027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary","n_c":["C12685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardia","n_c":["C12256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carina","n_c":["C25264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Artery","n_c":["C12687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Body","n_c":["C66852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cartilage","n_c":["C12373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecum","n_c":["C12381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell-Line","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebellum","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Spine","n_c":["C69313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest","n_c":["C25389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chin","n_c":["C81169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clavicle","n_c":["C12695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clitoris","n_c":["C12308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon - Mucosa Only","n_c":["C164003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Duct","n_c":["C12698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermal","n_c":["C25478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Descending Colon","n_c":["C12268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Site","n_c":["C179433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenum","n_c":["C12263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear, Pinna (External)","n_c":["C12292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbow","n_c":["C32497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Gland","n_c":["C12704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epidural Space","n_c":["C41449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C165193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagogastric Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus - Mucosa Only","n_c":["C32538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Artery","n_c":["C12715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Vein","n_c":["C12716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femur","n_c":["C12717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts","n_c":["C12482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibula","n_c":["C12718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finger","n_c":["C32608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floor of Mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluid","n_c":["C25278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foot","n_c":["C32622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forearm","n_c":["C32628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forehead","n_c":["C89803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foreskin","n_c":["C33049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Cortex","n_c":["C177766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fundus of Stomach","n_c":["C12257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglia","n_c":["C12719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal, Intestine","n_c":["C13359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genitourinary, NOS","n_c":["C25350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand","n_c":["C32712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hard Palate","n_c":["C12230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head - Face Or Neck, Nos","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Head and Neck","n_c":["C12418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic","n_c":["C13308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Duct","n_c":["C32730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Vein","n_c":["C32736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C25724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip","n_c":["C64193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hippocampus","n_c":["C12444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Humerus","n_c":["C12731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileocecal Valve","n_c":["C13066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileum","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilium","n_c":["C32765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Index Finger","n_c":["C52835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischium","n_c":["C32884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Islet Cells","n_c":["C32885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jaw","n_c":["C48821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunum","n_c":["C12388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint","n_c":["C13044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Knee","n_c":["C32898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacrimal Gland","n_c":["C12346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Bowel","n_c":["C12379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leg","n_c":["C32974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ligament","n_c":["C13046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumbar Spine","n_c":["C69314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Axilla","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Distant","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-Common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-External","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Internal Mammary","n_c":["C32853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mammary","n_c":["C137678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Pelvic","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Scalene","n_c":["C89780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Subclavicular","n_c":["C63705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mantle","n_c":["C12507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Soft Tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Finger","n_c":["C52836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondria","n_c":["C13258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle","n_c":["C13056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nails","n_c":["C33156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Cavity","n_c":["C12424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Soft Tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve","n_c":["C12466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve(s) Cranial","n_c":["C12700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital Cortex","n_c":["C177767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular Orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity - Mucosa Only","n_c":["C77637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraspinal Ganglion","n_c":["C97925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parathyroid","n_c":["C12765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid Gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patella","n_c":["C33282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Soft Tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharynx","n_c":["C12425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal Gland","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pituitary Gland","n_c":["C12399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal Fossa","n_c":["C103222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pouch","n_c":["C43200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Tumor Field","n_c":["C179450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary tumor site","n_c":["C179451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Bed","n_c":["C90348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate, Seminal Vesicles and Lymph Nodes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Pylorus","n_c":["C12260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid Junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional Site","n_c":["C179457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retina","n_c":["C12343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retro-Orbital Region","n_c":["C54155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rib","n_c":["C12782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ring Finger","n_c":["C52837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Round Ligament","n_c":["C12319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacrum","n_c":["C33508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scapula","n_c":["C12783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sciatic Nerve","n_c":["C52810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotum","n_c":["C12785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seminal Vesicle","n_c":["C12787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shoulder","n_c":["C25203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus(es), Maxillary","n_c":["C12275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skeletal Muscle","n_c":["C13050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, lower extremity, local","n_c":["C164047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, total","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, trunk, local","n_c":["C12295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, upper extremity, local","n_c":["C164048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skull","n_c":["C12789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel - Mucosa Only","n_c":["C33568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Finger","n_c":["C52838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Column","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spine","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Flexure","n_c":["C12267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sternum","n_c":["C12793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach - Mucosa Only","n_c":["C32656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous Tissue","n_c":["C33645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovium","n_c":["C12473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal Cortex","n_c":["C177768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tendon","n_c":["C13045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thigh","n_c":["C33763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracic Spine","n_c":["C69315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat","n_c":["C54272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thumb","n_c":["C52834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tibia","n_c":["C12800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil (Pharyngeal)","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea / Major Bronchi","n_c":["C12961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trunk","n_c":["C33816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbilical Cord","n_c":["C34320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract","n_c":["C191741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uvula","n_c":["C12232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens","n_c":["C12813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vein","n_c":["C12814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous","n_c":["C25291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebra","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cells","n_c":["C12529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist","n_c":["C33894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locoregional Site","n_c":["C25388"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_arm":[{"nm":"A081105","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"E4512","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"EA5142","n_c":"","i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_dose_units":[{"nm":"cGy","n_c":["C64693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gy","n_c":["C18063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg","n_c":["C28253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AUC","n_c":["C64774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/day","n_c":["C67372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/m2","n_c":["C67282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IU/kg","n_c":["C67379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IU/mg","n_c":["C67380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mCi","n_c":["C48511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mEq","n_c":["C48512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/day","n_c":["C67399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/dL","n_c":["C67015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/kg","n_c":["C67401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/kg/day","n_c":["C66976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2","n_c":["C67402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2/day","n_c":["C66974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2/wk","n_c":["C88148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/mL","n_c":["C42576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/wk","n_c":["C67404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mIU","n_c":["C67316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mL","n_c":["C28254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ug","n_c":["C48152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ug/m2","n_c":["C67312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wafer","n_c":["C48552"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_effect":[{"nm":"Complete Necrosis (No Viable Tumor)","n_c":["C156234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incomplete Necrosis (Viable Tumor Present)","n_c":["C156235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Necrosis","n_c":["C168971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Known Treatment Effect","n_c":["C164134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_effect_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_frequency":[{"nm":"Every Hour","n_c":["C64510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Five Times Daily","n_c":["C98849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Four Times Daily","n_c":["C64530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Three Times Daily","n_c":["C64527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Daily","n_c":["C64496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Every 24 Hours","n_c":["C64515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Every Other Day","n_c":["C64525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Weekly","n_c":["C64497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once Weekly","n_c":["C64526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_intent_type":[{"nm":"Adjuvant","n_c":["C25722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Deprivation Therapy (ADT)","n_c":["C15481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer Control","n_c":["C15971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cure","n_c":["C62220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maintenance Therapy","n_c":["C15688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoadjuvant","n_c":["C15665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palliative","n_c":["C15292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prevention","n_c":["C15843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Consolidation Therapy","n_c":["C15679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First-Line Therapy","n_c":["C45792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction","n_c":["C158876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation Boost","n_c":["C137812"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_or_therapy":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_outcome":[{"nm":"Complete Response","n_c":["C4870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Response","n_c":["C165202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Measurable Disease","n_c":["C40413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Response","n_c":["C123600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Response","n_c":["C18058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Persistent Disease","n_c":["C90169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Disease","n_c":["C35571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stable Disease","n_c":["C18213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treatment Ongoing","n_c":["C165209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treatment Stopped Due to Toxicity","n_c":["C105741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Very Good Partial Response","n_c":["C123618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normalization of Tumor Markers","n_c":["C198983"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_type":[{"nm":"Ablation, Cryo","n_c":["C15215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Ethanol Injection","n_c":["C67444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Microwave","n_c":["C116643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, NOS","n_c":["C20985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Radiofrequency","n_c":["C15666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Radiosurgical","n_c":["C15696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ancillary Treatment","n_c":["C15747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antiseizure Treatment","n_c":["C64172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisphosphonate Therapy","n_c":["C443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blinded Study, Treatment Unknown","n_c":["C70840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachytherapy, High Dose","n_c":["C15651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachytherapy, Low Dose","n_c":["C85254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachytherapy, NOS","n_c":["C15195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemoembolization","n_c":["C15752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemoprotectant","n_c":["C15533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemotherapy","n_c":["C15632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Concurrent Chemoradiation","n_c":["C141342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryoablation","n_c":["C15215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Embolization","n_c":["C15230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethanol Injection Ablation","n_c":["C67444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"External Beam Radiation","n_c":["C15751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hormone Therapy","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I-131 Radiation Therapy","n_c":["C198584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapy (Including Vaccines)","n_c":["C15262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Internal Radiation","n_c":["C15195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isolated Limb Perfusion (ILP)","n_c":["C15393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ Transplantation","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharmaceutical Therapy, NOS","n_c":["C15986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis","n_c":["C66899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation Therapy, NOS","n_c":["C15313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, 2D Conventional","n_c":["C165189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, 3D Conformal","n_c":["C16035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Combination","n_c":["C165192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Cyberknife","n_c":["C95484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, External Beam","n_c":["C15751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Implants","n_c":["C66891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Intensity-Modulated Radiotherapy","n_c":["C16135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Internal","n_c":["C15195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Proton Beam","n_c":["C66897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Radioisotope","n_c":["C15470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Stereotactic/Gamma Knife/SRS","n_c":["C15382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Systemic","n_c":["C92991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radioactive Iodine Therapy","n_c":["C157968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radioembolization","n_c":["C93340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiosensitizing Agent","n_c":["C798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Allogeneic","n_c":["C46089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Autologous","n_c":["C16039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Double Autologous","n_c":["C116466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Haploidentical","n_c":["C138187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Non-Myeloablative","n_c":["C62714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, NOS","n_c":["C15431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Syngenic","n_c":["C93196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Treatment","n_c":["C165194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stereotactic Radiosurgery","n_c":["C15358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steroid Therapy","n_c":["C15370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Molecular Therapy","n_c":["C76243"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Hypofractionated","n_c":["C62726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Mixed Photon Beam","n_c":["C152055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Photon Beam","n_c":["C104914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis, NOS","n_c":["C66899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis, Talc","n_c":["C178422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptide Receptor Radionuclide Therapy (PRRT)","n_c":["C162449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy, Excisional","n_c":["C15385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy, Incisional","n_c":["C15386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distal Pancreatectomy","n_c":["C51647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery, Minimally Invasive","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery, NOS","n_c":["C172727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery, Open","n_c":["C126391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Pancreatectomy","n_c":["C15340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whipple","n_c":["C15356"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.therapeutic_agents":[{"nm":"10-Deacetyltaxol","n_c":["C957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11C Topotecan","n_c":["C49172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11D10 AluGel Anti-Idiotype Monoclonal Antibody","n_c":["C28781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"12-Allyldeoxoartemisinin","n_c":["C41441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"13-Deoxydoxorubicin","n_c":["C2494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"14C BMS-275183","n_c":["C62553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521","n_c":["C133224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Deoxy-D-glucose","n_c":["C116618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Ethylhydrazide","n_c":["C1165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Fluoroadenine","n_c":["C29794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Fluorofucose-containing SGN-2FF","n_c":["C131289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyestradiol","n_c":["C120474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyestrone","n_c":["C63947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyflutamide Depot","n_c":["C85482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyoleic Acid","n_c":["C105401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Methoxyestradiol","n_c":["C965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion","n_c":["C62603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Methoxyestrone","n_c":["C120472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-O, 3-O Desulfated Heparin","n_c":["C99130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2,6-Diaminopurine","n_c":["C29796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2,6-Dimethoxyquinone","n_c":["C126754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2'-F-ara-deoxyuridine","n_c":["C80036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3'-C-ethynylcytidine","n_c":["C29475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4-Nitroestrone 3-Methyl Ether","n_c":["C977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4-Thio-2-deoxycytidine","n_c":["C121828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4'-Iodo-4'-Deoxydoxorubicin","n_c":["C971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5-Aza-4'-thio-2'-deoxycytidine","n_c":["C153479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5-Fluoro-2-Deoxycytidine","n_c":["C62785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158","n_c":["C113787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7-Cyanoquinocarcinol","n_c":["C1611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7-Ethyl-10-Hydroxycamptothecin","n_c":["C61618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7-Hydroxystaurosporine","n_c":["C1271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8-Azaguanine","n_c":["C28788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"9-Ethyl 6-Mercaptopurine","n_c":["C28789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"9H-Purine-6Thio-98D","n_c":["C28793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abagovomab","n_c":["C26449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abarelix","n_c":["C2015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abemaciclib","n_c":["C97660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abemaciclib Mesylate","n_c":["C162507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abexinostat","n_c":["C68920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abexinostat Tosylate","n_c":["C160889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abiraterone","n_c":["C77333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abiraterone Acetate","n_c":["C68845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abituzumab","n_c":["C82422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acai Berry Juice","n_c":["C99901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acalabrutinib","n_c":["C113442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acalisib","n_c":["C103277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aceglatone","n_c":["C984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetylcysteine","n_c":["C200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acitretin","n_c":["C985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acivicin","n_c":["C986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aclacinomycin B","n_c":["C1861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aclarubicin","n_c":["C202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acodazole","n_c":["C988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acodazole Hydrochloride","n_c":["C71627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acolbifene Hydrochloride","n_c":["C65213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acridine","n_c":["C203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acridine Carboxamide","n_c":["C2203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acronine","n_c":["C75297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinium Ac 225 Lintuzumab","n_c":["C82414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinium Ac 225-FPI-1434","n_c":["C158815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","n_c":["C153159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinomycin C2","n_c":["C95198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinomycin C3","n_c":["C99564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinomycin F1","n_c":["C2844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Activin Type 2B Receptor Fc Fusion Protein STM 434","n_c":["C118625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968","n_c":["C151941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ad-RTS-hIL-12","n_c":["C143953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adagloxad Simolenin","n_c":["C99766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adavosertib","n_c":["C91725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adecatumumab","n_c":["C82358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist AZD4635","n_c":["C148039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist NIR178","n_c":["C142374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999","n_c":["C157489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A/A2B Receptor Antagonist AB928","n_c":["C159564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2B Receptor Antagonist PBF-1129","n_c":["C148435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","n_c":["C106242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Brachyury Vaccine ETBX-051","n_c":["C143034"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Cancer Vaccine PF-06936308","n_c":["C156015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral MUC1 Vaccine ETBX-061","n_c":["C143035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral PSA Vaccine ETBX-071","n_c":["C148142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001","n_c":["C101789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","n_c":["C162805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901","n_c":["C156925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3","n_c":["C131825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001","n_c":["C97959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aderbasib","n_c":["C76115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ADH-1","n_c":["C53399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AE37 Peptide/GM-CSF Vaccine","n_c":["C91719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AEE788","n_c":["C48369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aerosol Gemcitabine","n_c":["C153133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aerosolized Aldesleukin","n_c":["C101794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aerosolized Liposomal Rubitecan","n_c":["C61071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afatinib","n_c":["C66940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afatinib Dimaleate","n_c":["C97273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afimoxifene","n_c":["C975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afuresertib","n_c":["C82390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agatolimod Sodium","n_c":["C28580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agerafenib","n_c":["C107245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aglatimagene Besadenovec","n_c":["C73996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agonistic Anti-CD40 Monoclonal Antibody ADC-1013","n_c":["C121538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949","n_c":["C129967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469","n_c":["C117293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKR1C3-activated Prodrug OBI-3424","n_c":["C156414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT 1/2 Inhibitor BAY1125976","n_c":["C111575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT Inhibitor ARQ 092","n_c":["C99172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt Inhibitor LY2780301","n_c":["C95737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt Inhibitor MK2206","n_c":["C90581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt Inhibitor SR13668","n_c":["C85448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt/ERK Inhibitor ONC201","n_c":["C113792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alacizumab Pegol","n_c":["C61438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alanosine","n_c":["C994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albumin-binding Cisplatin Prodrug BTP-114","n_c":["C131607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aldesleukin","n_c":["C1498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aldoxorubicin","n_c":["C68921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alectinib","n_c":["C101790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alefacept","n_c":["C65220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alemtuzumab","n_c":["C1681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alestramustine","n_c":["C77370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alflutinib Mesylate","n_c":["C133719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Algenpantucel-L","n_c":["C61082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alisertib","n_c":["C71717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alitretinoin","n_c":["C1574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor","n_c":["C141136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor ASP3026","n_c":["C116727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor PLB 1003","n_c":["C148533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor RO5424802","n_c":["C101790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor WX-0593","n_c":["C154279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK-2 Inhibitor TP-0184","n_c":["C156729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK-FAK Inhibitor CEP-37440","n_c":["C111685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/c-Met Inhibitor TQ-B3139","n_c":["C148513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/FAK/Pyk2 Inhibitor CT-707","n_c":["C126648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/TRK Inhibitor TSR-011","n_c":["C114287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alkotinib","n_c":["C165556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allodepleted T Cell Immunotherapeutic ATIR101","n_c":["C123911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD19-CAR T-cells PBCAR0191","n_c":["C158558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100","n_c":["C137863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Cellular Vaccine 1650-G","n_c":["C119759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","n_c":["C146711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine","n_c":["C2525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine","n_c":["C98282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo","n_c":["C101892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo","n_c":["C101891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2","n_c":["C90577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470","n_c":["C103862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307","n_c":["C78862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Melanoma Vaccine AGI-101H","n_c":["C78861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Natural Killer Cell Line MG4101","n_c":["C94209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Natural Killer Cell Line NK-92","n_c":["C117231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601","n_c":["C95213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allovectin-7","n_c":["C1649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Almurtide","n_c":["C81667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpelisib","n_c":["C94214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha Galactosylceramide","n_c":["C1720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha V Beta 1 Inhibitor ATN-161","n_c":["C52185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801","n_c":["C120550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-Gal AGI-134","n_c":["C165548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H","n_c":["C159497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-Thioguanine Deoxyriboside","n_c":["C28795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-tocopheryloxyacetic Acid","n_c":["C117234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altiratinib","n_c":["C118290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altretamine","n_c":["C544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvespimycin","n_c":["C38142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvespimycin Hydrochloride","n_c":["C76665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvocidib","n_c":["C74940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvocidib Hydrochloride","n_c":["C1571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvocidib Prodrug TP-1287","n_c":["C165555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amatuximab","n_c":["C62483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ambamustine","n_c":["C73320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ambazone","n_c":["C72627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amblyomin-X","n_c":["C148521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amcasertib","n_c":["C104745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ametantrone","n_c":["C1342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amifostine","n_c":["C488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amino Acid Injection","n_c":["C15509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminocamptothecin","n_c":["C1488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminocamptothecin Colloidal Dispersion","n_c":["C2452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminoflavone Prodrug AFP464","n_c":["C48370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminopterin","n_c":["C235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminopterin Sodium","n_c":["C74554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amolimogene Bepiplasmid","n_c":["C90592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amonafide L-Malate","n_c":["C61306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amrubicin","n_c":["C80089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amrubicin Hydrochloride","n_c":["C47948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amsacrine","n_c":["C240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amsacrine Lactate","n_c":["C96771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amsilarotene","n_c":["C38684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amustaline","n_c":["C75926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amustaline Dihydrochloride","n_c":["C75035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amuvatinib","n_c":["C71750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amuvatinib Hydrochloride","n_c":["C95776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anakinra","n_c":["C38717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anastrozole","n_c":["C1607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anaxirone","n_c":["C950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ancitabine","n_c":["C80636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ancitabine Hydrochloride","n_c":["C403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Antagonist APC-100","n_c":["C98290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist BAY 1161116","n_c":["C148520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist SHR3680","n_c":["C175852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist TAS3681","n_c":["C137818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist TRC253","n_c":["C131874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antisense Oligonucleotide AZD5312","n_c":["C116326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antisense Oligonucleotide EZN-4176","n_c":["C96742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Degrader ARV-110","n_c":["C160788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Downregulator AZD3514","n_c":["C116726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118","n_c":["C121777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andrographolide","n_c":["C61637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androstane Steroid HE3235","n_c":["C78831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anetumab Ravtansine","n_c":["C98293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241","n_c":["C88301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiogenesis Inhibitor GT-111","n_c":["C71539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiogenesis Inhibitor JI-101","n_c":["C82413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiogenesis/Heparanase Inhibitor PG545","n_c":["C95202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiopoietin-2-specific Fusion Protein PF-04856884","n_c":["C116625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anhydrovinblastine","n_c":["C2526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aniline Mustard","n_c":["C249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anlotinib Hydrochloride","n_c":["C106428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Annamycin","n_c":["C2632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Annamycin Liposomal","n_c":["C25838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Annonaceous Acetogenins","n_c":["C118972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ansamitomicin P-3","n_c":["C97710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anthramycin","n_c":["C252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anthrapyrazole","n_c":["C2706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti c-KIT Antibody-drug Conjugate LOP628","n_c":["C117735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-5T4 Antibody-Drug Conjugate PF-06263507","n_c":["C107388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-A33 Monoclonal Antibody KRN330","n_c":["C90583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412","n_c":["C85478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087","n_c":["C129715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AG7 Antibody Drug Conjugate AbGn-107","n_c":["C133818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AGS-16 Monoclonal Antibody AGS-16M18","n_c":["C82685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME","n_c":["C92590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AGS-8 Monoclonal Antibody AGS-8M4","n_c":["C82686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B","n_c":["C164668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-alpha5beta1 Integrin Antibody MINT1526A","n_c":["C116865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ANG2 Monoclonal Antibody MEDI-3617","n_c":["C95704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-angiopoietin Monoclonal Antibody AMG 780","n_c":["C116627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-APRIL Monoclonal Antibody BION-1301","n_c":["C142822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AXL Fusion Protein AVB-S6-500","n_c":["C156017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AXL/PBD Antibody-drug Conjugate ADCT-601","n_c":["C160890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7-H3 Antibody DS-5573a","n_c":["C122924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7-H4 Monoclonal Antibody FPA150","n_c":["C155967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7H3 Antibody-drug Conjugate MGC018","n_c":["C159495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody SEA-BCMA","n_c":["C148176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody-drug Conjugate AMG 224","n_c":["C162528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody-drug Conjugate GSK2857916","n_c":["C114299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/CD3 BiTE Antibody AMG 420","n_c":["C159652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/CD3 BiTE Antibody AMG 701","n_c":["C147028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/CD3 BiTE Antibody REGN5458","n_c":["C158504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/PBD ADC MEDI2228","n_c":["C150127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-fms Monoclonal Antibody AMG 820","n_c":["C98295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-KIT Monoclonal Antibody CDX 0158","n_c":["C125620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Antibody-drug Conjugate HTI-1066","n_c":["C146667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Antibody-drug Conjugate TR1801","n_c":["C158513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Monoclonal Antibody ABT-700","n_c":["C106262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Monoclonal Antibody ARGX-111","n_c":["C113802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-MET Monoclonal Antibody LY2875358","n_c":["C95732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-C-met Monoclonal Antibody SAIT301","n_c":["C119619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-C4.4a Antibody-Drug Conjugate BAY1129980","n_c":["C116070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-C5aR Monoclonal Antibody IPH5401","n_c":["C163020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CA19-9 Monoclonal Antibody 5B1","n_c":["C125900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CA6-DM4 Immunoconjugate SAR566658","n_c":["C95764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1","n_c":["C121231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 ADC IMGN632","n_c":["C184834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 Monoclonal Antibody CSL360","n_c":["C91093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 Monoclonal Antibody KHK2823","n_c":["C123380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404","n_c":["C127120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A","n_c":["C129457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123/CD3 Bispecific Antibody APVO436","n_c":["C157257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178","n_c":["C128486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123/CD3 BiTE Antibody SAR440234","n_c":["C160348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody ADG106","n_c":["C160715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471","n_c":["C162039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD157 Monoclonal Antibody MEN1112","n_c":["C120317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD166 Probody-drug Conjugate CX-2009","n_c":["C134697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B","n_c":["C126377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody DI-B4","n_c":["C105805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody MDX-1342","n_c":["C74003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody MEDI-551","n_c":["C88283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody XmAb5574","n_c":["C95768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19-DM4 Immunoconjugate SAR3419","n_c":["C71009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL","n_c":["C82375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/CD3 BiTE Antibody AMG 562","n_c":["C153215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/CD3 Tetravalent Antibody AFM11","n_c":["C115101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody B001","n_c":["C155899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody PRO131921","n_c":["C90590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody SCT400","n_c":["C122680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody TL011","n_c":["C94206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002","n_c":["C123915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20-engineered Toxin Body MT-3724","n_c":["C120546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323","n_c":["C165166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20/CD3 Monoclonal Antibody REGN1979","n_c":["C119615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20/CD3 Monoclonal Antibody XmAb13676","n_c":["C130050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD22 ADC TRPH-222","n_c":["C156882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S","n_c":["C104167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD25-PBD Antibody-drug Conjugate ADCT-301","n_c":["C121949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD26 Monoclonal Antibody YS110","n_c":["C150677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD27L Antibody-Drug Conjugate AMG 172","n_c":["C106266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)","n_c":["C74004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957","n_c":["C136823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135","n_c":["C146860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05","n_c":["C95760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564","n_c":["C171840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/CD20 Bispecific Antibody GEN3013","n_c":["C163022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424","n_c":["C153147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30 Monoclonal Antibody MDX-1401","n_c":["C77886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30 Monoclonal Antibody XmAb2513","n_c":["C74005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30/CD16A Monoclonal Antibody AFM13","n_c":["C94219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD32B Monoclonal Antibody BI-1206","n_c":["C156458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Antibody-drug Conjugate IMGN779","n_c":["C125717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564","n_c":["C135632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Monoclonal Antibody BI 836858","n_c":["C116737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633","n_c":["C71523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 Bispecific Antibody GEM 333","n_c":["C155970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244","n_c":["C162296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 BiTE Antibody AMG 330","n_c":["C123332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 BiTE Antibody AMG 673","n_c":["C175778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A","n_c":["C131174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 Antibody-Drug Conjugate IMGN529","n_c":["C100101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E","n_c":["C119700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 Monoclonal Antibody BI 836826","n_c":["C122833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Monoclonal Antibody MOR03087","n_c":["C97954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Monoclonal Antibody TAK-079","n_c":["C148078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38-targeted IgG4-attenuated IFNa TAK-573","n_c":["C140427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342","n_c":["C147563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD39 Monoclonal Antibody TTX-030","n_c":["C162693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Agonist Monoclonal Antibody ABBV-927","n_c":["C139553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","n_c":["C150558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4","n_c":["C101366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Monoclonal Antibody SEA-CD40","n_c":["C121217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428","n_c":["C132681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40L Fc-Fusion Protein BMS-986004","n_c":["C120140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD44 Monoclonal Antibody RO5429083","n_c":["C116881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD45 Monoclonal Antibody AHN-12","n_c":["C74009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD46 Antibody-drug Conjugate FOR46","n_c":["C156416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody AO-176","n_c":["C159600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody CC-90002","n_c":["C121211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody Hu5F9-G4","n_c":["C117730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody IBI188","n_c":["C157385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody SHR-1603","n_c":["C160202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody SRF231","n_c":["C155976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody TJC4","n_c":["C163977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A","n_c":["C148103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD52 Monoclonal Antibody ALLO-647","n_c":["C160787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 Antibody-Drug Conjugate MDX-1203","n_c":["C84855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A","n_c":["C117732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 CAR-expressing T Lymphocytes","n_c":["C162699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 Monoclonal Antibody MDX-1411","n_c":["C78187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029","n_c":["C153287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody BMS-986179","n_c":["C132266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody CPI-006","n_c":["C156061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody NZV930","n_c":["C158132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody TJ4309","n_c":["C159168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD74 Antibody-drug Conjugate STRO-001","n_c":["C148066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD98 Monoclonal Antibody IGN523","n_c":["C113659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CDH6 Antibody-drug Conjugate HKT288","n_c":["C131439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEA BiTE Monoclonal Antibody AMG211","n_c":["C95728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody","n_c":["C68927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2","n_c":["C82355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM1 Monoclonal Antibody CM-24","n_c":["C120305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM5 Antibody-Drug Conjugate SAR408701","n_c":["C117229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47","n_c":["C120068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM6 Antibody BAY1834942","n_c":["C171841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CLDN6 Monoclonal Antibody ASP1650","n_c":["C114286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CLEC12A/CD3 Bispecific Antibody MCLA117","n_c":["C148141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CLEVER-1 Monoclonal Antibody FP-1305","n_c":["C159536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CSF1 Monoclonal Antibody PD-0360324","n_c":["C131301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CSF1R Monoclonal Antibody IMC-CS4","n_c":["C96801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CSF1R Monoclonal Antibody SNDX-6352","n_c":["C155813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTGF Monoclonal Antibody FG-3019","n_c":["C92577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody ADU-1604","n_c":["C162505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody AGEN1181","n_c":["C158557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody BCD-145","n_c":["C156734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody MK-1308","n_c":["C150679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody REGN4659","n_c":["C159764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841","n_c":["C159530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","n_c":["C157494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA4 Monoclonal Antibody BMS-986218","n_c":["C135633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CXCR4 Monoclonal Antibody PF-06747143","n_c":["C131572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Denatured Collagen Monoclonal Antibody TRC093","n_c":["C71749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DKK-1 Monoclonal Antibody LY2812176","n_c":["C99123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DKK1 Monoclonal Antibody BHQ880","n_c":["C80040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DLL3/CD3 BiTE Antibody AMG 757","n_c":["C147027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DLL4 Monoclonal Antibody MEDI0639","n_c":["C101521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83","n_c":["C119620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DR5 Agonist Monoclonal Antibody TRA-8","n_c":["C78826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DR5 Agonistic Antibody DS-8273a","n_c":["C121158"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DR5 Agonistic Monoclonal Antibody INBRX-109","n_c":["C157062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody CPGJ 602","n_c":["C155876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody EMD 55900","n_c":["C2714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody GC1118","n_c":["C120316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX","n_c":["C94221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody HLX-07","n_c":["C163981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody Mixture MM-151","n_c":["C99899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody RO5083945","n_c":["C78838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody SCT200","n_c":["C117726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody SYN004","n_c":["C121550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR TAP Antibody-drug Conjugate IMGN289","n_c":["C111906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/c-Met Bispecific Antibody EMB-01","n_c":["C158085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372","n_c":["C124993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100","n_c":["C148507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013","n_c":["C131175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321","n_c":["C150590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595","n_c":["C99222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFRvIII Immunotoxin MR1-1","n_c":["C88307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFRvIII/CD3 BiTE Antibody AMG 596","n_c":["C146824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGP-2 Immunotoxin MOC31-PE","n_c":["C90551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F","n_c":["C102980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F","n_c":["C116626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ep-CAM Monoclonal Antibody ING-1","n_c":["C133022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310","n_c":["C136981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EphA2 Monoclonal Antibody DS-8895a","n_c":["C118447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","n_c":["C79836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111","n_c":["C85486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Antibody ISU104","n_c":["C158746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Monoclonal Antibody AV-203","n_c":["C102535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Monoclonal Antibody CDX-3379","n_c":["C113333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Monoclonal Antibody REGN1400","n_c":["C103859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141","n_c":["C103863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A","n_c":["C116742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FAP/Interleukin-2 Fusion Protein RO6874281","n_c":["C129383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FCRH5/CD3 BiTE Antibody BFCR4350A","n_c":["C139549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FGFR2 Antibody BAY1179470","n_c":["C107683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FGFR3 Antibody-drug Conjugate LY3076226","n_c":["C123829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FGFR4 Monoclonal Antibody U3-1784","n_c":["C126334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3 Antibody-drug Conjugate AGS62P1","n_c":["C129937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM","n_c":["C129376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3 Monoclonal Antibody IMC-EB10","n_c":["C85453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3/CD3 BiTE Antibody AMG 427","n_c":["C156399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002","n_c":["C158067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012","n_c":["C118443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962","n_c":["C79795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GCC Antibody-Drug Conjugate MLN0264","n_c":["C101524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GCC Antibody-Drug Conjugate TAK-164","n_c":["C156707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody","n_c":["C158436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD2 Monoclonal Antibody hu14.18K322A","n_c":["C80042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD2 Monoclonal Antibody MORAb-028","n_c":["C91383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD3 Antibody-drug Conjugate PF-06688992","n_c":["C136426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Agonistic Monoclonal Antibody ASP1951","n_c":["C159411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156","n_c":["C132267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Agonistic Monoclonal Antibody INCAGN01876","n_c":["C126643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Monoclonal Antibody GWN 323","n_c":["C128028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Monoclonal Antibody MK-4166","n_c":["C116065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Globo H Monoclonal Antibody OBI-888","n_c":["C153261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974","n_c":["C129936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GnRH Vaccine PEP223","n_c":["C85464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-gpA33/CD3 Monoclonal Antibody MGD007","n_c":["C118442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GRP78 Monoclonal Antibody PAT-SM6","n_c":["C103857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HA Epitope Monoclonal Antibody MEDI8852","n_c":["C131295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HB-EGF Monoclonal Antibody KHK2866","n_c":["C95721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HBEGF Monoclonal Antibody U3-1565","n_c":["C95736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-hepcidin Monoclonal Antibody LY2787106","n_c":["C116630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER-2 Bispecific Antibody KN026","n_c":["C162577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 ADC DS-8201a","n_c":["C128799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate A166","n_c":["C156480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate ARX788","n_c":["C123917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate MEDI4276","n_c":["C126355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate RC48","n_c":["C130011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Bi-specific Monoclonal Antibody ZW25","n_c":["C130010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49","n_c":["C162115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395","n_c":["C160349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody CT-P6","n_c":["C1647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343","n_c":["C142890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2-vc0101 ADC PF-06804103","n_c":["C141420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A","n_c":["C156705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","n_c":["C142889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128","n_c":["C152948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522","n_c":["C132112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A","n_c":["C155940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER3 Antibody-drug Conjugate U3 1402","n_c":["C136987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER3 Monoclonal Antibody GSK2849330","n_c":["C111997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HGF Monoclonal Antibody TAK-701","n_c":["C81939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","n_c":["C68930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1","n_c":["C165547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HLA-DR Monoclonal Antibody IMMU-114","n_c":["C103860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-human GITR Monoclonal Antibody AMG 228","n_c":["C129694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-human GITR Monoclonal Antibody TRX518","n_c":["C95023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICAM-1 Monoclonal Antibody BI-505","n_c":["C88327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Agonist Antibody GSK3359609","n_c":["C126804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226","n_c":["C146762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Monoclonal Antibody KY1044","n_c":["C162521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Monoclonal Antibody MEDI-570","n_c":["C123267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IGF-1R Monoclonal Antibody AVE1642","n_c":["C79798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022","n_c":["C71530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-1 alpha Monoclonal Antibody MABp1","n_c":["C95708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-13 Humanized Monoclonal Antibody TNX-650","n_c":["C87767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-15 Monoclonal Antibody AMG 714","n_c":["C126841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-8 Monoclonal Antibody HuMax-IL8","n_c":["C124227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ILDR2 Monoclonal Antibody BAY 1905254","n_c":["C156490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ILT4 Monoclonal Antibody MK-4830","n_c":["C160204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388","n_c":["C78839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-KIR Monoclonal Antibody IPH 2101","n_c":["C78464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02","n_c":["C82391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody INCAGN02385","n_c":["C157127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody LAG525","n_c":["C122683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody REGN3767","n_c":["C132339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118","n_c":["C150734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG3 Monoclonal Antibody BI 754111","n_c":["C150403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG3 Monoclonal Antibody MK-4280","n_c":["C142077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG3 Monoclonal Antibody TSR-033","n_c":["C142978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAMP1 Antibody-drug Conjugate SAR428926","n_c":["C126275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LGR5 Monoclonal Antibody BNC101","n_c":["C126794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LIF Monoclonal Antibody MSC-1","n_c":["C156176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A","n_c":["C112001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ly6E Antibody-Drug Conjugate RG 7841","n_c":["C116745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C","n_c":["C162462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Melanin Monoclonal Antibody PTI-6D2","n_c":["C91092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin Antibody-drug Conjugate BMS-986148","n_c":["C120303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100","n_c":["C121653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A","n_c":["C116746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Met Monoclonal Antibody Mixture Sym015","n_c":["C127906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Met/EGFR Monoclonal Antibody LY3164530","n_c":["C118281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MMP-9 Monoclonal Antibody GS-5745","n_c":["C105803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC1 Monoclonal Antibody BTH1704","n_c":["C118362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC16/CD3 BiTE Antibody REGN4018","n_c":["C153129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A","n_c":["C147031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","n_c":["C78840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-myostatin Monoclonal Antibody LY2495655","n_c":["C99640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NaPi2b Monoclonal Antibody XMT-1535","n_c":["C147578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E","n_c":["C114500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A","n_c":["C91728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-nf-P2X7 Antibody Ointment BIL-010t","n_c":["C124647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Nucleolin Aptamer AS1411","n_c":["C91721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A","n_c":["C116847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso","n_c":["C153130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OFA Immunotherapeutic BB-MPI-03","n_c":["C118368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Agonist Monoclonal Antibody ABBV-368","n_c":["C161864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Agonist Monoclonal Antibody PF-04518600","n_c":["C121927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Antibody BMS 986178","n_c":["C128026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Monoclonal Antibody GSK3174998","n_c":["C124783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Monoclonal Antibody IBI101","n_c":["C158507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Checkpoint Inhibitor PF-06801591","n_c":["C124058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Fusion Protein AMP-224","n_c":["C97039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody AK105","n_c":["C155879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody AMG 404","n_c":["C161597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody BAT1306","n_c":["C162871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody BCD-100","n_c":["C148155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody BI 754091","n_c":["C132252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody CS1003","n_c":["C156726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody F520","n_c":["C162636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody GLS-010","n_c":["C159549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody HLX10","n_c":["C156738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody HX008","n_c":["C160717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody JTX-4014","n_c":["C157485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody LZM009","n_c":["C153149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody MEDI0680","n_c":["C113332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody MGA012","n_c":["C142168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody Sym021","n_c":["C142865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody TSR-042","n_c":["C126799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-CTLA4 DART Protein MGD019","n_c":["C158505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-LAG-3 DART Protein MGD013","n_c":["C143957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172","n_c":["C160605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/CTLA-4 Bispecific Antibody AK104","n_c":["C153379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/TIM-3 Bispecific Antibody RO7121661","n_c":["C160714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody A167","n_c":["C163992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody BCD-135","n_c":["C156741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody BGB-A333","n_c":["C155654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody CBT-502","n_c":["C156692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody CK-301","n_c":["C151947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody CS1001","n_c":["C154550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody FAZ053","n_c":["C131537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody GR1405","n_c":["C159538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody HLX20","n_c":["C165270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody LY3300054","n_c":["C128138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody MDX-1105","n_c":["C78852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody MSB2311","n_c":["C155931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody SHR-1316","n_c":["C148535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody TG-1501","n_c":["C151947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody ZKAB001","n_c":["C162504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105","n_c":["C159978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","n_c":["C160772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","n_c":["C157058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD1 Monoclonal Antibody AGEN2034","n_c":["C136465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD1/CTLA4 Bispecific Antibody XmAb20717","n_c":["C150463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PGF Monoclonal Antibody RO5323441","n_c":["C78486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PKN3 siRNA Atu027","n_c":["C84847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PLGF Monoclonal Antibody TB-403","n_c":["C78486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4","n_c":["C123924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PRAME Immunotherapeutic GSK2302032A","n_c":["C116848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab","n_c":["C151931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-prolactin Receptor Antibody LFA102","n_c":["C96744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSCA Monoclonal Antibody AGS-1C4D4","n_c":["C71157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA Monoclonal Antibody MDX1201-A488","n_c":["C113439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704","n_c":["C26660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate","n_c":["C95707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD28 Bispecific Antibody REGN5678","n_c":["C162936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081","n_c":["C163976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414","n_c":["C118626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/PBD ADC MEDI3726","n_c":["C140552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020","n_c":["C123828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PVRIG Monoclonal Antibody COM701","n_c":["C156791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ROR1 ADC VLS-101","n_c":["C157772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-S15 Monoclonal Antibody NC318","n_c":["C157061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-sCLU Monoclonal Antibody AB-16B5","n_c":["C121778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-SIRPa Monoclonal Antibody CC-95251","n_c":["C157501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E","n_c":["C152370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218","n_c":["C28880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TF Monoclonal Antibody ALT-836","n_c":["C96430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TGF-beta Monoclonal Antibody NIS793","n_c":["C132250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TGF-beta Monoclonal Antibody SAR-439459","n_c":["C146862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1","n_c":["C102853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody AB154","n_c":["C162875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody BMS-986207","n_c":["C131907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody OMP-313M32","n_c":["C142821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Antibody BMS-986258","n_c":["C148042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody BGB-A425","n_c":["C157242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody INCAGN02390","n_c":["C162625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody MBG453","n_c":["C124850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody Sym023","n_c":["C150560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody TSR-022","n_c":["C128627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM3 Monoclonal Antibody LY3321367","n_c":["C137820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Tissue Factor Monoclonal Antibody MORAb-066","n_c":["C104291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a","n_c":["C151967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TWEAK Monoclonal Antibody RG7212","n_c":["C97337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF Anticalin PRS-050-PEG40","n_c":["C91376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF Monoclonal Antibody hPV19","n_c":["C156139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF/ANG2 Nanobody BI 836880","n_c":["C126644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T","n_c":["C162872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFC Monoclonal Antibody VGX-100","n_c":["C99765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFR2 Monoclonal Antibody HLX06","n_c":["C156172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5","n_c":["C95734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VISTA Monoclonal Antibody JNJ 61610588","n_c":["C127124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antiangiogenic Drug Combination TL-118","n_c":["C99761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-011","n_c":["C161599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-085","n_c":["C124134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-155","n_c":["C157279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-176","n_c":["C137991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-838","n_c":["C122816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ADC XMT-1536","n_c":["C147577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014","n_c":["C129401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-Drug Conjugate DFRF4539A","n_c":["C106256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate MEDI7247","n_c":["C137821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate PF-06647263","n_c":["C118572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate PF-06664178","n_c":["C118570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-002","n_c":["C123284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-003","n_c":["C124133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-004","n_c":["C136807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-005","n_c":["C154558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-006","n_c":["C136779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-007","n_c":["C147029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008","n_c":["C90562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV","n_c":["C165256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antimetabolite FF-10502","n_c":["C125690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplastic Agent Combination SM-88","n_c":["C124051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplastic Vaccine","n_c":["C1663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplastic Vaccine GV-1301","n_c":["C2100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplaston A10","n_c":["C1004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplaston AS2-1","n_c":["C1613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antisense Oligonucleotide GTI-2040","n_c":["C26652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antitumor B Key Active Component-alpha","n_c":["C156694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrodia cinnamomea Supplement","n_c":["C95731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antroquinonol Capsule","n_c":["C119701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apalutamide","n_c":["C92574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apatorsen","n_c":["C71740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apaziquone","n_c":["C1087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APC8015F","n_c":["C48640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APE1/Ref-1 Redox Inhibitor APX3330","n_c":["C150216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aphidicoline Glycinate","n_c":["C28802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apilimod Dimesylate Capsule","n_c":["C126661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apitolisib","n_c":["C91731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apolizumab","n_c":["C2228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apomab","n_c":["C71693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apomine","n_c":["C1873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apoptosis Inducer BZL101","n_c":["C69134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apoptosis Inducer GCS-100","n_c":["C70984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apoptosis Inducer MPC-2130","n_c":["C64781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apricoxib","n_c":["C74021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aprutumab Ixadotin","n_c":["C121212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AR Antagonist BMS-641988","n_c":["C62522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arabinoxylan Compound MGN3","n_c":["C1879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aranose","n_c":["C162540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARC Fusion Protein SL-279252","n_c":["C161803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Archexin","n_c":["C88335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arcitumomab","n_c":["C1494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arfolitixorin","n_c":["C157079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arginase Inhibitor INCB001158","n_c":["C142866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arginine Butyrate","n_c":["C2570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arnebia Indigo Jade Pearl Topical Cream","n_c":["C74013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arsenic Trioxide","n_c":["C1005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arsenic Trioxide Capsule Formulation ORH 2014","n_c":["C133720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artemether Sublingual Spray","n_c":["C118504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artemisinin Dimer","n_c":["C60769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artesunate","n_c":["C73005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arugula Seed Powder","n_c":["C131020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aryl Hydrocarbon Receptor Antagonist BAY2416964","n_c":["C164317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asaley","n_c":["C1346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asciminib","n_c":["C114494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascrinvacumab","n_c":["C91073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ashwagandha Root Powder Extract","n_c":["C77883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASP4132","n_c":["C122720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asparaginase","n_c":["C286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asparaginase Erwinia chrysanthemi","n_c":["C64260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10","n_c":["C165280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","n_c":["C133190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Astuprotimut-R","n_c":["C78478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asulacrine","n_c":["C91758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asulacrine Isethionate","n_c":["C1050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"At 211 Monoclonal Antibody 81C6","n_c":["C2490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atamestane","n_c":["C1224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atezolizumab","n_c":["C106250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atiprimod","n_c":["C52184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atiprimod Dihydrochloride","n_c":["C76969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atiprimod Dimaleate","n_c":["C76970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM Inhibitor M 3541","n_c":["C138076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM Kinase Inhibitor AZD0156","n_c":["C124648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM Kinase Inhibitor AZD1390","n_c":["C150167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atorvastatin Calcium","n_c":["C28837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atorvastatin Sodium","n_c":["C78676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor BAY1895344","n_c":["C146807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor M6620","n_c":["C116355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor VX-803","n_c":["C129693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrasentan Hydrochloride","n_c":["C1779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Attenuated Listeria monocytogenes CRS-100","n_c":["C62409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001","n_c":["C74595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auranofin","n_c":["C65242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor LY3295668","n_c":["C148501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor LY3295668 Erbumine","n_c":["C165238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor MK5108","n_c":["C90585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor TAS-119","n_c":["C116068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076","n_c":["C78190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901","n_c":["C82674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora B/C Kinase Inhibitor GSK1070916A","n_c":["C91081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora kinase A/B inhibitor TT-00420","n_c":["C162532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor AMG 900","n_c":["C82349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor BI 811283","n_c":["C74014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor MLN8054","n_c":["C61075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor PF-03814735","n_c":["C66946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor SNS-314","n_c":["C70655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor TTP607","n_c":["C84846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase/VEGFR2 Inhibitor CYC116","n_c":["C70983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707","n_c":["C139730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585","n_c":["C155883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101","n_c":["C142864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125","n_c":["C147523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217","n_c":["C140310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053","n_c":["C165507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143","n_c":["C142807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR T-cells IM19","n_c":["C155888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19","n_c":["C156271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002","n_c":["C162856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01","n_c":["C153118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901","n_c":["C158604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19","n_c":["C142887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1","n_c":["C148030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3","n_c":["C162620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014","n_c":["C126639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s","n_c":["C156251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202","n_c":["C162260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1","n_c":["C155884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794","n_c":["C121379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous AXL-targeted CAR T-cells CCT301-38","n_c":["C154276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B","n_c":["C156153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M","n_c":["C162506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528","n_c":["C148498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001","n_c":["C103865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005","n_c":["C158533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006","n_c":["C160847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123","n_c":["C148526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19-targeted CAR T Cells JWCAR029","n_c":["C155878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20","n_c":["C148525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22","n_c":["C148524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38","n_c":["C148523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Deep IL-15 Primed T-cells TRQ15-01","n_c":["C158091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Dendritic Cell Vaccine ACT2001","n_c":["C121856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Dendritic Cell-based Immunotherapeutic AV0113","n_c":["C123928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa","n_c":["C150698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells","n_c":["C162804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Genetically-modified MAGE-A4 C1032 T Cells","n_c":["C175738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858","n_c":["C37448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439","n_c":["C159977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001","n_c":["C162627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718","n_c":["C135534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","n_c":["C156382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Mesenchymal Stem Cells Apceth_101","n_c":["C113803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","n_c":["C155775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01","n_c":["C121536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101","n_c":["C82361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601","n_c":["C128031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous ROR2-targeted CAR T-cells CCT301-59","n_c":["C154277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1","n_c":["C154285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCR-engineered T-cells IMA201","n_c":["C146779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCR-engineered T-cells IMA202","n_c":["C153218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCR-engineered T-cells IMA203","n_c":["C161831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes LN-144","n_c":["C120552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes LN-145","n_c":["C135634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL","n_c":["C153312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avadomide","n_c":["C160786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avadomide Hydrochloride","n_c":["C97956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avapritinib","n_c":["C123827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avelumab","n_c":["C116870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avitinib Maleate","n_c":["C118671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axicabtagene Ciloleucel","n_c":["C120309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axitinib","n_c":["C38718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL Inhibitor DS-1205c","n_c":["C152976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M","n_c":["C132025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axl/Mer Inhibitor INCB081776","n_c":["C153122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azacitidine","n_c":["C288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azapicyl","n_c":["C1007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azaribine","n_c":["C1008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azaserine","n_c":["C289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azathioprine","n_c":["C290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azimexon","n_c":["C1347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aziridinylbenzoquinone RH1","n_c":["C29404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azotomycin","n_c":["C28803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azurin:50-77 Cell Penetrating Peptide p28","n_c":["C85480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B-Raf/VEGFR-2 Inhibitor RAF265","n_c":["C61311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Babaodan Capsule","n_c":["C155974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen","n_c":["C77694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bactobolin","n_c":["C28850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bafetinib","n_c":["C62516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Balixafortide","n_c":["C91094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Baltaleucel-T","n_c":["C129374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Banoxantrone","n_c":["C79528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barasertib","n_c":["C62502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bardoxolone","n_c":["C48382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bardoxolone Methyl","n_c":["C98250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Baricitinib","n_c":["C127012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Batabulin","n_c":["C72716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Batabulin Sodium","n_c":["C1835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Batimastat","n_c":["C1529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bavituximab","n_c":["C49088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bazedoxifene","n_c":["C73598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BC-819 Plasmid/Polyethylenimine Complex","n_c":["C107685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCG Solution","n_c":["C83496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCG Tokyo-172 Strain Solution","n_c":["C126694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCG Vaccine","n_c":["C298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor APG 2575","n_c":["C156249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor BCL201","n_c":["C125603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor S65487","n_c":["C158510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-Xs Adenovirus Vaccine","n_c":["C28860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCMA x CD3 T-cell Engaging Antibody CC-93269","n_c":["C156052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcr-Abl Kinase Inhibitor K0706","n_c":["C174748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcr-Abl Kinase Inhibitor PF-114","n_c":["C130033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351","n_c":["C165549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beauvericin","n_c":["C1011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Becatecarin","n_c":["C1620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belagenpumatucel-L","n_c":["C73438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belimumab","n_c":["C91385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belinostat","n_c":["C48812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belotecan Hydrochloride","n_c":["C66954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bemarituzumab","n_c":["C120040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bemcentinib","n_c":["C121854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bempegaldesleukin","n_c":["C131019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benaxibine","n_c":["C73231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bendamustine","n_c":["C73261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bendamustine Hydrochloride","n_c":["C61565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107","n_c":["C124053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benzaldehyde Dimethane Sulfonate","n_c":["C107164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benzoylphenylurea","n_c":["C2618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Berberine Chloride","n_c":["C87331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bermekimab","n_c":["C95708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Berubicin Hydrochloride","n_c":["C61568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Bromodomain Inhibitor ZEN-3694","n_c":["C126805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor ABBV-744","n_c":["C148415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor BAY1238097","n_c":["C121213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET inhibitor BI 894999","n_c":["C160257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor BMS-986158","n_c":["C121849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor CC-90010","n_c":["C151951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor CPI-0610","n_c":["C111901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor FT-1101","n_c":["C123733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor GS-5829","n_c":["C126640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor GSK2820151","n_c":["C125391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor INCB054329","n_c":["C121948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor INCB057643","n_c":["C128622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor RO6870810","n_c":["C112500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET-bromodomain Inhibitor ODM-207","n_c":["C148138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta Alethine","n_c":["C2605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Carotene","n_c":["C1016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-elemene","n_c":["C103177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Glucan","n_c":["C2678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Glucan MM-10-001","n_c":["C82657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-lapachone Prodrug ARQ 761","n_c":["C99146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Thioguanine Deoxyriboside","n_c":["C1350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Betulinic Acid","n_c":["C38126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bevacizumab","n_c":["C2039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bexarotene","n_c":["C1635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BF-200 Gel Formulation","n_c":["C131905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BH3 Mimetic ABT-737","n_c":["C114384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bi-functional Alkylating Agent VAL-083","n_c":["C425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bicalutamide","n_c":["C1599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bimiralisib","n_c":["C111898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Binetrakin","n_c":["C589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Binimetinib","n_c":["C84865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bintrafusp Alfa","n_c":["C124229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birabresib","n_c":["C103298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birinapant","n_c":["C88295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bis(choline)tetrathiomolybdate","n_c":["C62514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisantrene","n_c":["C1019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisantrene Hydrochloride","n_c":["C77218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisnafide","n_c":["C73611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisnafide Dimesylate","n_c":["C73307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody 2B1","n_c":["C2399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody MDX-H210","n_c":["C1578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody MDX447","n_c":["C2207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisthianostat","n_c":["C163996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bivalent BRD4 Inhibitor AZD5153","n_c":["C151943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bizelesin","n_c":["C1472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BL22 Immunotoxin","n_c":["C1842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Black Cohosh","n_c":["C26647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Black Raspberry Nectar","n_c":["C122398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin","n_c":["C313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin A2","n_c":["C311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin B2","n_c":["C81672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin Sulfate","n_c":["C312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blinatumomab","n_c":["C62528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blueberry Powder Supplement","n_c":["C98108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMI1 Inhibitor PTC596","n_c":["C121645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-184476","n_c":["C1843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-188797","n_c":["C1859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-214662","n_c":["C1856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-275183","n_c":["C62639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Boanmycin Hydrochloride","n_c":["C102878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Boronophenylalanine-Fructose Complex","n_c":["C2405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bortezomib","n_c":["C1851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosutinib","n_c":["C60809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosutinib Monohydrate","n_c":["C154440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botanical Agent BEL-X-HG","n_c":["C153419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botanical Agent LEAC-102","n_c":["C129711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bovine Cartilage","n_c":["C2418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bozitinib","n_c":["C129717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BP-Cx1-Platinum Complex BP-C1","n_c":["C107387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BR96-Doxorubicin Immunoconjugate","n_c":["C1617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachyury-expressing Yeast Vaccine GI-6301","n_c":["C106267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor","n_c":["C155322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor ARQ 736","n_c":["C94224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor PLX8394","n_c":["C113330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF(V600E) Kinase Inhibitor RO5212054","n_c":["C92591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF/EGFR Inhibitor BGB-283","n_c":["C124995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAFV600/PI3K Inhibitor ASN003","n_c":["C134967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4 Inhibitor PLX2853","n_c":["C146825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4 Inhibitor PLX51107","n_c":["C125739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breflate","n_c":["C28855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brentuximab","n_c":["C2007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brentuximab Vedotin","n_c":["C66944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brequinar","n_c":["C1560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brequinar Sodium","n_c":["C1078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Briciclib Sodium","n_c":["C90541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brigatinib","n_c":["C98831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brilanestrant","n_c":["C106235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brimonidine Tartrate Nanoemulsion OCU-300","n_c":["C158723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivanib","n_c":["C67040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivanib Alaninate","n_c":["C53397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivudine","n_c":["C67088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivudine Phosphoramidate","n_c":["C1882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad-Spectrum Human Papillomavirus Vaccine V505","n_c":["C70598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broccoli Sprout/Broccoli Seed Extract Supplement","n_c":["C128293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bromacrylide","n_c":["C73259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bromebric Acid","n_c":["C72089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bromocriptine Mesylate","n_c":["C317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brontictuzumab","n_c":["C103274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brostacillin Hydrochloride","n_c":["C128040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brostallicin","n_c":["C1889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broxuridine","n_c":["C318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol A","n_c":["C1765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol B","n_c":["C1764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol C","n_c":["C1768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol D","n_c":["C1535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol E","n_c":["C1536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol F","n_c":["C1537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol G","n_c":["C1694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol H","n_c":["C1695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceantin","n_c":["C1025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bryostatin 1","n_c":["C1026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor ARQ 531","n_c":["C138066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor CT-1530","n_c":["C138164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor DTRMWXHS-12","n_c":["C130001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor ICP-022","n_c":["C156173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor LOXO-305","n_c":["C158617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor M7583","n_c":["C129710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK inhibitor TG-1701","n_c":["C175775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Budigalimab","n_c":["C137682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Budotitane","n_c":["C81555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bufalin","n_c":["C107555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buparlisib","n_c":["C90565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burixafor","n_c":["C88323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burixafor Hydrobromide","n_c":["C130049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burosumab","n_c":["C119744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buserelin","n_c":["C320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bushen Culuan Decoction","n_c":["C160712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bushen-Jianpi Decoction","n_c":["C151930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Busulfan","n_c":["C321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buthionine Sulfoximine","n_c":["C1029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BXQ-350 Nanovesicle Formulation","n_c":["C131491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Kit Inhibitor PLX9486","n_c":["C121647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor AL2846","n_c":["C129314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor AMG 208","n_c":["C82677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor AMG 337","n_c":["C95203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor HS-10241","n_c":["C128895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor JNJ-38877605","n_c":["C77893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor MK2461","n_c":["C90591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor MK8033","n_c":["C116866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor MSC2156119J","n_c":["C88314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C-myb Antisense Oligonucleotide G4460","n_c":["C1541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-raf Antisense Oligonucleotide ISIS 5132","n_c":["C2721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C-VISA BikDD:Liposome","n_c":["C88264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAB-ROR2-ADC BA3021","n_c":["C155812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabazitaxel","n_c":["C66937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabiralizumab","n_c":["C123831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabozantinib","n_c":["C52200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabozantinib S-malate","n_c":["C97938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cactinomycin","n_c":["C1032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Caffeic Acid Phenethyl Ester","n_c":["C63756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAIX Inhibitor DTP348","n_c":["C117731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAIX Inhibitor SLC-0111","n_c":["C117728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calaspargase Pegol-mknl","n_c":["C78198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcitriol","n_c":["C330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Release-activated Channels Inhibitor RP4010","n_c":["C136828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Saccharate","n_c":["C335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule","n_c":["C121642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calicheamicin Gamma 1I","n_c":["C1035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin","n_c":["C338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin Analogue TLC388","n_c":["C80047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin Glycoconjugate BAY 38-3441","n_c":["C1886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin Sodium","n_c":["C2344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin-20(S)-O-Propionate Hydrate","n_c":["C84857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camrelizumab","n_c":["C123816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camsirubicin","n_c":["C78863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancell","n_c":["C1775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer Peptide Vaccine S-588410","n_c":["C121776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canerpaturev","n_c":["C88318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canertinib Dihydrochloride","n_c":["C1880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canfosfamide","n_c":["C83581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canfosfamide Hydrochloride","n_c":["C2641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cannabidiol","n_c":["C118452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cantrixil","n_c":["C159719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cantuzumab Ravtansine","n_c":["C61576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capecitabine","n_c":["C1794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capecitabine Rapidly Disintegrating Tablet","n_c":["C99629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capivasertib","n_c":["C102564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capmatinib","n_c":["C90564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Captopril","n_c":["C340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAR T-Cells AMG 119","n_c":["C150586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Caracemide","n_c":["C1037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbendazim","n_c":["C1154"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbetimer","n_c":["C1356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbogen","n_c":["C1038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboplatin","n_c":["C1282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboquone","n_c":["C342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboxyamidotriazole","n_c":["C1141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboxyamidotriazole Orotate","n_c":["C91090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboxyphenyl Retinamide","n_c":["C1169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carfilzomib","n_c":["C52196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Caricotamide/Tretazicar","n_c":["C80048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carlumab","n_c":["C71010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmofur","n_c":["C955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine","n_c":["C349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine Implant","n_c":["C2487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine in Ethanol","n_c":["C2602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine Sustained-Release Implant Wafer","n_c":["C102847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotuximab","n_c":["C74010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carubicin","n_c":["C352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carubicin Hydrochloride","n_c":["C1582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carzelesin","n_c":["C1441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carzinophilin","n_c":["C1040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cathelicidin LL-37","n_c":["C118292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cationic Liposome-Encapsulated Paclitaxel","n_c":["C69130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Catumaxomab","n_c":["C62445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBP/beta-catenin Antagonist PRI-724","n_c":["C95894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBP/beta-catenin Modulator E7386","n_c":["C153376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR2 Antagonist CCX872-B","n_c":["C120302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR2 Antagonist PF-04136309","n_c":["C97507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR2/CCR5 Antagonist BMS-813160","n_c":["C139550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR4 Inhibitor FLX475","n_c":["C157240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD4-specific Telomerase Peptide Vaccine UCPVax","n_c":["C129596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD40 Agonist Monoclonal Antibody CP-870,893","n_c":["C119740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD40 Agonistic Monoclonal Antibody APX005M","n_c":["C123734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD44 Targeted Agent SPL-108","n_c":["C142813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD47 Antagonist ALX148","n_c":["C132851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Inhibitor TAK-931","n_c":["C126641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Kinase Inhibitor BMS-863233","n_c":["C82418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Kinase Inhibitor LY3143921 Hydrate","n_c":["C148509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Kinase Inhibitor NMS-1116354","n_c":["C88316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK Inhibitor AT7519","n_c":["C64761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK Inhibitor R547","n_c":["C64544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK Inhibitor SNS-032","n_c":["C62523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK/JAK2/FLT3 Inhibitor TG02 Citrate","n_c":["C105851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK1 Inhibitor BEY1107","n_c":["C163985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK1/2/4 Inhibitor AG-024322","n_c":["C52182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK2/4/6/FLT3 Inhibitor FN-1501","n_c":["C155956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK2/5/9 Inhibitor CYC065","n_c":["C123902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4 Inhibitor P1446A-05","n_c":["C80049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor","n_c":["C116938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor BPI-16350","n_c":["C157481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor FCN-437","n_c":["C165199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor G1T38","n_c":["C138165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor SHR6390","n_c":["C125899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK7 Inhibitor CT7001","n_c":["C155652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK7 Inhibitor SY-1365","n_c":["C139552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK9 Inhibitor AZD4573","n_c":["C153377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEA-MUC-1-TRICOM Vaccine CV301","n_c":["C131129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEA-targeting Agent RG6123","n_c":["C159892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEBPA-targeting saRNA MTL-CEBPA Liposome","n_c":["C126800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedazuridine","n_c":["C164146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedazuridine/Decitabine Combination Agent ASTX727","n_c":["C115102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedefingol","n_c":["C78081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cediranib","n_c":["C80867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cediranib Maleate","n_c":["C48379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celecoxib","n_c":["C1728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83","n_c":["C67075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cemadotin","n_c":["C75875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cemadotin Hydrochloride","n_c":["C1634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cemiplimab","n_c":["C121540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cenersen","n_c":["C37454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cenisertib","n_c":["C64540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CENP-E Inhibitor GSK-923295","n_c":["C91080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ceralasertib","n_c":["C111993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ceramide Nanoliposome","n_c":["C131434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerdulatinib","n_c":["C113173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480","n_c":["C146660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cereblon Modulator CC-90009","n_c":["C131177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cergutuzumab Amunaleukin","n_c":["C141459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ceritinib","n_c":["C115112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cesalin","n_c":["C28882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cEt KRAS Antisense Oligonucleotide AZD4785","n_c":["C147521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetrelimab","n_c":["C129448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab","n_c":["C1723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab-IR700 Conjugate RM-1929","n_c":["C121850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)","n_c":["C158083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevipabulin","n_c":["C77064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevipabulin Fumarate","n_c":["C73815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevipabulin Succinate","n_c":["C96746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cFMS Tyrosine Kinase Inhibitor ARRY-382","n_c":["C96227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chaparrin","n_c":["C1767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chaparrinone","n_c":["C1046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Checkpoint Kinase Inhibitor AZD7762","n_c":["C66961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Checkpoint Kinase Inhibitor XL844","n_c":["C61102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemotherapy","n_c":["C15632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chiauranib","n_c":["C115970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chimeric Monoclonal Antibody 81C6","n_c":["C156351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChiNing Decoction","n_c":["C119741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chk1 Inhibitor CCT245737","n_c":["C129580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chk1 Inhibitor GDC-0425","n_c":["C116756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chk1 Inhibitor GDC-0575","n_c":["C116845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHK1 Inhibitor MK-8776","n_c":["C79867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHK1 Inhibitor PF-477736","n_c":["C68820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorambucil","n_c":["C362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorodihydropyrimidine","n_c":["C2085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroquine","n_c":["C61671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroquinoxaline Sulfonamide","n_c":["C982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorotoxin","n_c":["C94723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorozotocin","n_c":["C1049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Choline Kinase Alpha Inhibitor TCD-717","n_c":["C94213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHP-NY-ESO-1 Peptide Vaccine IMF-001","n_c":["C62598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromomycin A3","n_c":["C895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement","n_c":["C1828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cibisatamab","n_c":["C120097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ciclopirox Prodrug CPX-POM","n_c":["C175786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cidan Herbal Capsule","n_c":["C118451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ciforadenant","n_c":["C125659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cilengitide","n_c":["C1834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cimetidine","n_c":["C374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinacalcet Hydrochloride","n_c":["C47450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinobufagin","n_c":["C95021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinobufotalin","n_c":["C151929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cintredekin Besudotox","n_c":["C2599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirmtuzumab","n_c":["C118284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cis-Urocanic Acid","n_c":["C99125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin","n_c":["C376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin Liposomal","n_c":["C2502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin-E Therapeutic Implant","n_c":["C17879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","n_c":["C136428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Citarinostat","n_c":["C121641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Citatuzumab Bogatox","n_c":["C71694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cixutumumab","n_c":["C79828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CK2-targeting Synthetic Peptide CIGB-300","n_c":["C102849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CL 246738","n_c":["C1052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cladribine","n_c":["C1336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clanfenur","n_c":["C78082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clarithromycin","n_c":["C1054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class 1/4 Histone Deacetylase Inhibitor OKI-179","n_c":["C160606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Trial","n_c":["C71104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Trial Agent","n_c":["C90373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clioquinol","n_c":["C65337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clivatuzumab","n_c":["C88638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clodronate Disodium","n_c":["C1418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clodronic Acid","n_c":["C61685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clofarabine","n_c":["C26638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clomesone","n_c":["C28888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clomiphene","n_c":["C61607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clomiphene Citrate","n_c":["C379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clostridium Novyi-NT Spores","n_c":["C62762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cobimetinib","n_c":["C68923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cobomarsen","n_c":["C124225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Codrituzumab","n_c":["C80043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coenzyme Q10","n_c":["C916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colchicine-Site Binding Agent ABT-751","n_c":["C2679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cold Contaminant-free Iobenguane I-131","n_c":["C82344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colloidal Gold-Bound Tumor Necrosis Factor","n_c":["C62538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","n_c":["C154278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Tumor-Associated Peptides Vaccine IMA910","n_c":["C79806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Combretastatin","n_c":["C80014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Combretastatin A-1","n_c":["C162344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Combretastatin A1 Diphosphate","n_c":["C84867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Compound Kushen Injection","n_c":["C120314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conatumumab","n_c":["C71015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conbercept","n_c":["C162879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Concentrated Lingzhi Mushroom Extract","n_c":["C165273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011","n_c":["C156141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copanlisib","n_c":["C96796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copanlisib Hydrochloride","n_c":["C138994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper Cu 64-ATSM","n_c":["C79824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper Gluconate","n_c":["C80050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cord Blood-derived Expanded Natural Killer Cells PNK-007","n_c":["C128560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cordycepin","n_c":["C1057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cordycepin Triphosphate","n_c":["C967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coriolus Versicolor Extract","n_c":["C78184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corticorelin Acetate","n_c":["C76112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cortisone Acetate","n_c":["C1058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cositecan","n_c":["C1877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coxsackievirus A21","n_c":["C61493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CpG Oligodeoxynucleotide GNKG168","n_c":["C88342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crenolanib","n_c":["C64639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crenolanib Besylate","n_c":["C106204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crizotinib","n_c":["C74061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crolibulin","n_c":["C66938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptophycin","n_c":["C1546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptophycin 52","n_c":["C1826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crystalline Genistein Formulation AXP107-11","n_c":["C95769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF-1R Inhibitor BLZ945","n_c":["C129653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R Inhibitor DCC-3014","n_c":["C136424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R Inhibitor PLX73086","n_c":["C129688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CT2584 HMS","n_c":["C1729 "," C202251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTLA-4-directed Probody BMS-986249","n_c":["C146765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curcumin","n_c":["C401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110","n_c":["C154569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cusatuzumab","n_c":["C106116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Custirsen Sodium","n_c":["C1055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXC Chemokine Receptor 2 Antagonist AZD5069","n_c":["C123383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR1/2 Inhibitor SX-682","n_c":["C150389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR2 Antagonist QBM076","n_c":["C153151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Antagonist BL-8040","n_c":["C88309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Antagonist USL311","n_c":["C131534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Inhibitor Q-122","n_c":["C74022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Peptide Antagonist LY2510924","n_c":["C106253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115","n_c":["C148166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclin-dependent Kinase Inhibitor PF-06873600","n_c":["C151988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclodextrin-Based Polymer-Camptothecin CRLX101","n_c":["C62600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclodisone","n_c":["C28899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cycloleucine","n_c":["C404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclopentenyl Cytosine","n_c":["C1359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide","n_c":["C405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide Anhydrous","n_c":["C61694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclosporine","n_c":["C406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYL-02 Plasmid DNA","n_c":["C95716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP11A1 inhibitor ODM-208","n_c":["C156744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17 Inhibitor CFG920","n_c":["C102855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17 Lyase Inhibitor ASN001","n_c":["C120310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17/Androgen Receptor Inhibitor ODM 204","n_c":["C120304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyproterone","n_c":["C407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyproterone Acetate","n_c":["C1059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytarabine","n_c":["C408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytarabine Monophosphate Prodrug MB07133","n_c":["C128888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytarabine-asparagine Prodrug BST-236","n_c":["C153327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytidine Analog RX-3117","n_c":["C113444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytochlor","n_c":["C28950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokine-based Biologic Agent IRX-2","n_c":["C53396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"D-methionine Formulation MRX-1024","n_c":["C69140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DAB389 Epidermal Growth Factor","n_c":["C2383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dabrafenib","n_c":["C82386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dabrafenib Mesylate","n_c":["C128059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacarbazine","n_c":["C411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacetuzumab","n_c":["C62179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DACH Polymer Platinate AP5346","n_c":["C64784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DACH-Platin Micelle NC-4016","n_c":["C113175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daclizumab","n_c":["C1569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacomitinib","n_c":["C53398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacplatinum","n_c":["C28955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dactinomycin","n_c":["C412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dactolisib","n_c":["C74072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dactolisib Tosylate","n_c":["C162346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dalantercept","n_c":["C88296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dalotuzumab","n_c":["C74011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daniquidone","n_c":["C66984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Danusertib","n_c":["C61587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Danvatirsen","n_c":["C101368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daporinad","n_c":["C67043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daratumumab","n_c":["C74007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daratumumab/rHuPH20","n_c":["C156401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Darinaparsin","n_c":["C61490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Darleukin","n_c":["C90546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Darolutamide","n_c":["C104748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daromun","n_c":["C154627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dasatinib","n_c":["C38713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daunorubicin","n_c":["C62091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daunorubicin Citrate","n_c":["C47471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daunorubicin Hydrochloride","n_c":["C1583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401","n_c":["C170362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Decitabine","n_c":["C981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Defactinib","n_c":["C79809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Defactinib Hydrochloride","n_c":["C128039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deferoxamine","n_c":["C416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deferoxamine Mesylate","n_c":["C417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Degarelix","n_c":["C48385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Degarelix Acetate","n_c":["C80443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delanzomib","n_c":["C74075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Demcizumab","n_c":["C80041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Demecolcine","n_c":["C419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Demplatin Pegraglumer","n_c":["C85476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendritic Cell Vaccine","n_c":["C28310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendritic Cell-Autologous Lung Tumor Vaccine","n_c":["C26446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendritic Cell-targeting Lentiviral Vector ID-LV305","n_c":["C115976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denenicokin","n_c":["C62492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denibulin","n_c":["C77065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denibulin Hydrochloride","n_c":["C72736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denileukin Diftitox","n_c":["C1476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denintuzumab Mafodotin","n_c":["C105150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denosumab","n_c":["C61313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deoxycytidine Analogue TAS-109","n_c":["C82697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deoxycytidine Analogue TAS-109 Hydrochloride","n_c":["C150430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depatuxizumab","n_c":["C95206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depatuxizumab Mafodotin","n_c":["C105612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derazantinib","n_c":["C104267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deslorelin","n_c":["C38709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deslorelin Acetate","n_c":["C82600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Detirelix","n_c":["C132693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Detorubicin","n_c":["C1066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deuteporfin","n_c":["C132685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deuterated Enzalutamide","n_c":["C158096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Devimistat","n_c":["C80039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethason","n_c":["C422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethasone","n_c":["C422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethasone Phosphate","n_c":["C77001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethasone Sodium Phosphate","n_c":["C1362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexanabinol","n_c":["C99381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexrazoxane","n_c":["C1333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexrazoxane Hydrochloride","n_c":["C66945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dezaguanine","n_c":["C968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dezaguanine Mesylate","n_c":["C80635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dezapelisib","n_c":["C107686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DHA-Paclitaxel","n_c":["C2649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DHEA Mustard","n_c":["C2707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DI-Leu16-IL2 Immunocytokine","n_c":["C78451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dianhydrogalactitol","n_c":["C425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diarylsulfonylurea Compound ILX-295501","n_c":["C1632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diazepinomicin","n_c":["C62508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaziquone","n_c":["C1363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diazooxonorleucine","n_c":["C427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dibrospidium Chloride","n_c":["C81362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dichloroallyl Lawsone","n_c":["C28959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dicycloplatin","n_c":["C107676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Didox","n_c":["C1338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dienogest","n_c":["C87238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diethylnorspermine","n_c":["C1168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Digitoxin","n_c":["C2634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Digoxin","n_c":["C28990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydro-5-Azacytidine","n_c":["C980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydrolenperone","n_c":["C1463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydroorotate Dehydrogenase Inhibitor AG-636","n_c":["C158103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydroorotate Dehydrogenase Inhibitor BAY2402234","n_c":["C153137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diindolylmethane","n_c":["C53434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dimethylmyleran","n_c":["C1073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dinaciclib","n_c":["C78854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dinutuximab","n_c":["C1570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dioscorea nipponica Makino Extract DNE3","n_c":["C115103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diphencyprone","n_c":["C28994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777","n_c":["C1476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ditiocarb","n_c":["C432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DKK1-Neutralizing Monoclonal Antibody DKN-01","n_c":["C99123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DM-CHOC-PEN","n_c":["C90539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015","n_c":["C77864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Interference Oligonucleotide PNT2258","n_c":["C92588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Minor Groove Binding Agent SG2000","n_c":["C29435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Plasmid Encoding Interleukin-12 INO-9012","n_c":["C116709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151","n_c":["C163978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457","n_c":["C123919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Vaccine VB10.16","n_c":["C123923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-dependent Protein Kinase Inhibitor VX-984","n_c":["C129061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-PK/TOR Kinase Inhibitor CC-115","n_c":["C97040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98","n_c":["C2530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel","n_c":["C1526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Anhydrous","n_c":["C61734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Emulsion ANX-514","n_c":["C78196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Formulation CKD-810","n_c":["C88322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Lipid Microspheres","n_c":["C102568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Nanoparticle CPC634","n_c":["C121961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Polymeric Micelles","n_c":["C165263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel-loaded Nanopharmaceutical CRLX301","n_c":["C121539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel-PNP","n_c":["C91087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel/Ritonavir","n_c":["C162784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dolastatin 10","n_c":["C1300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dolastatin 15","n_c":["C1439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domatinostat","n_c":["C96797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Donafenib","n_c":["C118294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dopamine-Somatostatin Chimeric Molecule BIM-23A760","n_c":["C88345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703","n_c":["C148462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dovitinib","n_c":["C76199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dovitinib Lactate","n_c":["C62435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxazosin","n_c":["C61737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxercalciferol","n_c":["C2645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxifluridine","n_c":["C978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin","n_c":["C456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin Hydrochloride","n_c":["C1326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin Prodrug L-377,202","n_c":["C1853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-Eluting Beads","n_c":["C82419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-HPMA Conjugate","n_c":["C1366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-loaded EGFR-targeting Nanocells","n_c":["C128897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-Magnetic Targeted Carrier Complex","n_c":["C2644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine","n_c":["C120213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine","n_c":["C120214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DPX-E7 HPV Vaccine","n_c":["C131494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DR5 HexaBody Agonist GEN1029","n_c":["C153259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DR5-targeting Tetrameric Nanobody Agonist TAS266","n_c":["C116886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dromostanolone Propionate","n_c":["C1077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Drozitumab","n_c":["C95784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dual IGF-1R/InsR Inhibitor BMS-754807","n_c":["C74043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dual Variable Domain Immunoglobulin ABT-165","n_c":["C116750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dual-affinity B7-H3/CD3-targeted Protein MGD009","n_c":["C136983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dubermatinib","n_c":["C127116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duborimycin","n_c":["C1062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dulanermin","n_c":["C1685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duligotuzumab","n_c":["C116628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dupilumab","n_c":["C162455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Durvalumab","n_c":["C103194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dusigitumab","n_c":["C82683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"dUTPase/DPD Inhibitor TAS-114","n_c":["C116885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duvelisib","n_c":["C99225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duvortuxizumab","n_c":["C122406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dynemicin","n_c":["C1928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dynemicin A","n_c":["C1079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"E2F1 Pathway Activator ARQ 171","n_c":["C64767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBNA-1 inhibitor VK-2019","n_c":["C159410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Echinomycin","n_c":["C462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ecromeximab","n_c":["C61095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edatrexate","n_c":["C958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edelfosine","n_c":["C956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edotecarin","n_c":["C2665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edrecolomab","n_c":["C1554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EED Inhibitor MAK683","n_c":["C133819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Efatutazone","n_c":["C83819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Efatutazone Dihydrochloride","n_c":["C64764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Efizonerimod","n_c":["C118282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eflornithine","n_c":["C226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eflornithine Hydrochloride","n_c":["C1579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eftilagimod Alpha","n_c":["C62509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205","n_c":["C90557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621","n_c":["C82694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGb761","n_c":["C26646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Antagonist Hemay022","n_c":["C123722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Antisense DNA BB-401","n_c":["C156732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor AZD3759","n_c":["C118289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor BIBX 1382","n_c":["C80868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor DBPR112","n_c":["C153427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor PD-168393","n_c":["C2727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor BPI-7711","n_c":["C154286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor CK-101","n_c":["C132023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor D-0316","n_c":["C175747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor ZN-e4","n_c":["C153173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR T790M Antagonist BPI-15086","n_c":["C131909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR T790M Inhibitor HS-10296","n_c":["C133691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/FLT3/Abl Inhibitor SKLB1028","n_c":["C131492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER1/HER2 Inhibitor PKI166","n_c":["C1871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Inhibitor AP32788","n_c":["C126752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Inhibitor AV-412","n_c":["C64627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Kinase Inhibitor TAK-285","n_c":["C90589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eicosapentaenoic Acid","n_c":["C67080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"eIF4E Antisense Oligonucleotide ISIS 183750","n_c":["C95740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elacestrant","n_c":["C120211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elacytarabine","n_c":["C53401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elagolix","n_c":["C153373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbasvir/Grazoprevir","n_c":["C159973"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elesclomol","n_c":["C75291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elesclomol Sodium","n_c":["C79840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elgemtumab","n_c":["C101895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elinafide","n_c":["C1615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elisidepsin","n_c":["C66949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elliptinium","n_c":["C90495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elliptinium Acetate","n_c":["C1367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elmustine","n_c":["C73262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elotuzumab","n_c":["C66982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elpamotide","n_c":["C74090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elsamitrucin","n_c":["C1080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eltanexor","n_c":["C125193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emactuzumab","n_c":["C125548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emapalumab","n_c":["C127123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emepepimut-S","n_c":["C2195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emitefur","n_c":["C1022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emofolin Sodium","n_c":["C29019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Empesertib","n_c":["C116074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enadenotucirev","n_c":["C113786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A","n_c":["C159599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enasidenib","n_c":["C111573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enasidenib Mesylate","n_c":["C137825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enavatuzumab","n_c":["C80045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enclomiphene","n_c":["C28211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enclomiphene Citrate","n_c":["C61745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encorafenib","n_c":["C98283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endothelin Receptor Type A Antagonist YM598","n_c":["C26678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enfortumab Vedotin","n_c":["C114500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Human Umbilical Vein Endothelial Cells AB-205","n_c":["C162248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Toxin Body Targeting HER2 MT-5111","n_c":["C162649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eniluracil/5-FU Combination Tablet","n_c":["C11252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enloplatin","n_c":["C95323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enoblituzumab","n_c":["C97510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enobosarm","n_c":["C69161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enoticumab","n_c":["C82367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enpromate","n_c":["C83689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ensartinib","n_c":["C102754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ensituximab","n_c":["C90532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride","n_c":["C82660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterococcus gallinarum Strain MRx0518","n_c":["C160293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entinostat","n_c":["C1863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entolimod","n_c":["C99166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entospletinib","n_c":["C105402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entrectinib","n_c":["C114984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Envafolimab","n_c":["C129714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enzalutamide","n_c":["C71744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enzastaurin","n_c":["C77392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enzastaurin Hydrochloride","n_c":["C26658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP4 Antagonist ONO-4578","n_c":["C150376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epacadostat","n_c":["C92582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epipodophyllotoxin Analog GL331","n_c":["C1866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epipropidine","n_c":["C78083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epirubicin","n_c":["C62028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epirubicin Hydrochloride","n_c":["C474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitinib Succinate","n_c":["C153095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitiostanol","n_c":["C1089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epothilone Analog UTD1","n_c":["C118450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epothilone KOS-1584","n_c":["C77892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epratuzumab","n_c":["C1887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epratuzumab-cys-tesirine","n_c":["C155794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471","n_c":["C165420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERa36 Modulator Icaritin","n_c":["C95720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erastin Analogue PRLX 93936","n_c":["C70625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erbulozole","n_c":["C73258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erdafitinib","n_c":["C103273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eribulin","n_c":["C96748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eribulin Mesylate","n_c":["C26644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK 1/2 Inhibitor ASTX029","n_c":["C155785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor CC-90003","n_c":["C119747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor GDC-0994","n_c":["C170364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor LTT462","n_c":["C126687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor MK-8353","n_c":["C104045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor ASN007","n_c":["C150248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor KO-947","n_c":["C141074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor LY3214996","n_c":["C131335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erlotinib","n_c":["C65530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erlotinib Hydrochloride","n_c":["C2693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ertumaxomab","n_c":["C2658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythrocyte-encapsulated L-asparaginase Suspension","n_c":["C99767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esorubicin","n_c":["C972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esorubicin Hydrochloride","n_c":["C74943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esperamicin A1","n_c":["C1301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Essiac","n_c":["C26649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esterified Estrogens","n_c":["C154677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estradiol Valerate","n_c":["C1090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estramustine","n_c":["C479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estramustine Phosphate Sodium","n_c":["C480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogen Receptor Agonist GTx-758","n_c":["C96432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogens, Conjugated","n_c":["C482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etalocib","n_c":["C1626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etanercept","n_c":["C2381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etanidazole","n_c":["C1092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etaracizumab","n_c":["C1800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etarotene","n_c":["C96705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethaselen","n_c":["C116713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethinyl Estradiol","n_c":["C486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethyleneimine","n_c":["C1009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethylnitrosourea","n_c":["C26563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etidronate-Cytarabine Conjugate MBC-11","n_c":["C125901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etirinotecan Pegol","n_c":["C74069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoglucid","n_c":["C489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoposide","n_c":["C491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoposide Phosphate","n_c":["C1093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoposide Toniribate","n_c":["C114977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoprine","n_c":["C73236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoricoxib","n_c":["C52188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ets-family Transcription Factor Inhibitor TK216","n_c":["C125657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Everolimus","n_c":["C48387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Everolimus Tablets for Oral Suspension","n_c":["C102880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Evofosfamide","n_c":["C71722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ex Vivo-expanded Autologous T Cells IMA101","n_c":["C131305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exatecan Mesylate","n_c":["C1679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exatecan Mesylate Anhydrous","n_c":["C162348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exemestane","n_c":["C1097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exisulind","n_c":["C1239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extended Release Flucytosine","n_c":["C112498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extended-release Onapristone","n_c":["C113797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH1/2 Inhibitor DS-3201","n_c":["C127114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 Inhibitor CPI-1205","n_c":["C121639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 Inhibitor PF-06821497","n_c":["C156743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 Inhibitor SHR2554","n_c":["C158742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"F16-IL2 Fusion Protein","n_c":["C91395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FACT Complex-targeting Curaxin CBL0137","n_c":["C107239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Factor VII-targeting Immunoconjugate Protein ICON-1","n_c":["C129313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Factor VIIa Inhibitor PCI-27483","n_c":["C88324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fadrozole Hydrochloride","n_c":["C1044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK Inhibitor GSK2256098","n_c":["C88346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK Inhibitor PF-00562271","n_c":["C78199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK Inhibitor VS-4718","n_c":["C107238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Falimarev","n_c":["C29316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Famitinib","n_c":["C97512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Farletuzumab","n_c":["C61503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123","n_c":["C1840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fas Receptor Agonist APO010","n_c":["C67041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fascin Inhibitor NP-G2-044","n_c":["C142086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FASN Inhibitor TVB-2640","n_c":["C118285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fazarabine","n_c":["C1096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Febuxostat","n_c":["C65629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fedratinib","n_c":["C88293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fedratinib Hydrochloride","n_c":["C162995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenebrutinib","n_c":["C116844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenretinide","n_c":["C1098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenretinide Lipid Matrix","n_c":["C63482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGF Receptor Antagonist HGS1036","n_c":["C77970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGF/FGFR Pathway Inhibitor E7090","n_c":["C118672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor ASP5878","n_c":["C122719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor AZD4547","n_c":["C88272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor Debio 1347","n_c":["C174762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor TAS-120","n_c":["C114283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","n_c":["C116894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1/2/3 Inhibitor HMPL-453","n_c":["C150383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Antagonist INCB062079","n_c":["C143067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor BLU 9931","n_c":["C162342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor FGF401","n_c":["C120102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor H3B-6527","n_c":["C128862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor ICP-105","n_c":["C162852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromun","n_c":["C166939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ficlatuzumab","n_c":["C78844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Figitumumab","n_c":["C52187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Filanesib","n_c":["C68937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Filgotinib","n_c":["C155799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Filgrastim","n_c":["C1474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fimepinostat","n_c":["C104008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Firtecan Pegol","n_c":["C70651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fisogatinib","n_c":["C123826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flanvotumab","n_c":["C91384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flotetuzumab","n_c":["C117238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floxuridine","n_c":["C504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Inhibitor FF-10101 Succinate","n_c":["C137988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Inhibitor HM43239","n_c":["C165254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Inhibitor SKI-G-801","n_c":["C155773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Tyrosine Kinase Inhibitor TTT-3002","n_c":["C123362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449","n_c":["C116858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/CDK4/6 Inhibitor FLX925","n_c":["C120209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/KIT Kinase Inhibitor AKN-028","n_c":["C101520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flt3/MerTK Inhibitor MRX-2843","n_c":["C151407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fludarabine","n_c":["C1094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fludarabine Phosphate","n_c":["C1102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flumatinib","n_c":["C138991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flumatinib Mesylate","n_c":["C117723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorodopan","n_c":["C29042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorouracil","n_c":["C505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorouracil Implant","n_c":["C90544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorouracil-E Therapeutic Implant","n_c":["C17877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluoxymesterone","n_c":["C507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flutamide","n_c":["C509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluvastatin","n_c":["C61768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluvastatin Sodium","n_c":["C29062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluzoparib","n_c":["C126274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FMS Inhibitor JNJ-40346527","n_c":["C101519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate","n_c":["C105804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor Targeted Epothilone BMS753493","n_c":["C71524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor-Targeted Tubulysin Conjugate EC1456","n_c":["C113176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor-Targeted Vinca Alkaloid EC0489","n_c":["C81935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225","n_c":["C66987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate-FITC","n_c":["C62479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folic Acid","n_c":["C510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folitixorin","n_c":["C61304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foretinib","n_c":["C80058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Formestane","n_c":["C974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forodesine Hydrochloride","n_c":["C26655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosaprepitant","n_c":["C72787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosbretabulin","n_c":["C82378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosbretabulin Disodium","n_c":["C2503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosbretabulin Tromethamine","n_c":["C83721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foslinanib","n_c":["C123824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foslinanib Disodium","n_c":["C163994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosquidone","n_c":["C1371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fostriecin","n_c":["C1372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fotemustine","n_c":["C1106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fotretamine","n_c":["C65767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FPV Vaccine CV301","n_c":["C141298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FPV-Brachyury-TRICOM Vaccine","n_c":["C148402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fresolimumab","n_c":["C63546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fruquintinib","n_c":["C102852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fulvestrant","n_c":["C1379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fumagillin-Derived Polymer Conjugate XMT-1107","n_c":["C88321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fursultiamine","n_c":["C121852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Futuximab","n_c":["C152971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Futuximab/Modotuximab Mixture","n_c":["C91381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G-Quadruplex Stabilizer BMVC","n_c":["C95893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galamustine","n_c":["C76791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galarubicin","n_c":["C81422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galectin Inhibitor GR-MD-02","n_c":["C115111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galectin-1 Inhibitor OTX008","n_c":["C103828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galeterone","n_c":["C84866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galiximab","n_c":["C26447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galocitabine","n_c":["C73254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galunisertib","n_c":["C116891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamboge Resin Extract TSB-9-W1","n_c":["C118444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-delta Tocotrienol","n_c":["C101517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-Secretase Inhibitor LY3039478","n_c":["C121535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-Secretase Inhibitor RO4929097","n_c":["C88333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gandotinib","n_c":["C116857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganetespib","n_c":["C77872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglioside GD2","n_c":["C1110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglioside GM2","n_c":["C516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganitumab","n_c":["C71531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganoderma lucidum Spores Powder Capsule","n_c":["C118365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Garlic","n_c":["C38706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrin Immunotoxin","n_c":["C1692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360","n_c":["C61329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gataparsen Sodium","n_c":["C66935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gatipotuzumab","n_c":["C94220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gedatolisib","n_c":["C91732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gefitinib","n_c":["C1855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Geldanamycin","n_c":["C1112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gelonin","n_c":["C133021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine","n_c":["C66876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Elaidate","n_c":["C79803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Hydrochloride","n_c":["C961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Hydrochloride Emulsion","n_c":["C105613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Prodrug LY2334737","n_c":["C102856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine-Phosphoramidate Hydrochloride NUC-1031","n_c":["C102752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine-Releasing Intravesical System","n_c":["C150807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemtuzumab Ozogamicin","n_c":["C1806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genistein","n_c":["C1113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gentuximab","n_c":["C154552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Geranylgeranyltransferase I Inhibitor","n_c":["C104414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GI-4000 Vaccine","n_c":["C61489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilteritinib","n_c":["C116722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilteritinib Fumarate","n_c":["C119665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gimatecan","n_c":["C65804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gimeracil","n_c":["C2416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ginsenoside Rg3 Capsule","n_c":["C103300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Girentuximab","n_c":["C1960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Girodazole","n_c":["C1373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GITR Agonist MEDI1873","n_c":["C169931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Givinostat","n_c":["C71716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glasdegib","n_c":["C84862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glasdegib Maleate","n_c":["C156894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucarubolone","n_c":["C1114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glecaprevir/Pibrentasvir","n_c":["C160484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glembatumumab Vedotin","n_c":["C78449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glesatinib","n_c":["C77876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioblastoma Cancer Vaccine ERC1671","n_c":["C107502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioblastoma Multiforme Multipeptide Vaccine IMA950","n_c":["C94211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioma Lysate Vaccine GBM6-AD","n_c":["C139000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701","n_c":["C114496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Globo H-DT Vaccine OBI-833","n_c":["C119745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucarpidase","n_c":["C346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucocorticoid Receptor Antagonist ORIC-101","n_c":["C162509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glufosfamide","n_c":["C1612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glumetinib","n_c":["C156700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutaminase Inhibitor CB-839","n_c":["C114381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutaminase Inhibitor CB-839 Hydrochloride","n_c":["C150413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101","n_c":["C106121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01","n_c":["C151952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycooptimized Trastuzumab-GEX","n_c":["C97917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102","n_c":["C98287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gold Sodium Thiomalate","n_c":["C74037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Golnerminogene Pradenovec","n_c":["C26444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Golotimod","n_c":["C76497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Golvatinib","n_c":["C82363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadotropin-releasing Hormone Analog","n_c":["C1910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goserelin","n_c":["C1374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goserelin Acetate","n_c":["C1417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goserelin Acetate Extended-release Microspheres LY01005","n_c":["C156710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gossypol","n_c":["C529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gossypol Acetic Acid","n_c":["C1118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grapiprant","n_c":["C124131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Green Tea Extract-based Antioxidant Supplement","n_c":["C97514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GS/pan-Notch Inhibitor AL101","n_c":["C116872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GS/pan-Notch Inhibitor BMS-986115","n_c":["C118573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GSK-3 Inhibitor 9-ING-41","n_c":["C156792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GSK-3 Inhibitor LY2090314","n_c":["C116849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guadecitabine","n_c":["C95209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guanabenz Acetate","n_c":["C65826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guselkumab","n_c":["C150390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gusperimus Trihydrochloride","n_c":["C1598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gutolactone","n_c":["C1532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H-ras Antisense Oligodeoxynucleotide ISIS 2503","n_c":["C2024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H1299 Tumor Cell Lysate Vaccine","n_c":["C114284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HAAH Lambda phage Vaccine SNS-301","n_c":["C148522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hafnium Oxide-containing Nanoparticles NBTXR3","n_c":["C98280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halichondrin Analogue E7130","n_c":["C156697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halichondrin B","n_c":["C1376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halofuginone","n_c":["C1120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halofuginone Hydrobromide","n_c":["C2656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HCV DNA Vaccine INO-8000","n_c":["C121570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Class I/IIb Inhibitor HG146","n_c":["C160706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor AR-42","n_c":["C116850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC inhibitor CG200745","n_c":["C94225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor CHR-2845","n_c":["C152539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor CKD-581","n_c":["C148157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor CXD101","n_c":["C112177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor MPT0E028","n_c":["C120312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor OBP-801","n_c":["C121665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC/EGFR/HER2 Inhibitor CUDC-101","n_c":["C78850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC6 Inhibitor KA2507","n_c":["C135629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC8 Inhibitor NBM-BMX","n_c":["C159496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDM2 Inhibitor HDM201","n_c":["C116325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDM2 Inhibitor MK-8242","n_c":["C116867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hedgehog Inhibitor IPI-609","n_c":["C60772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematoporphyrin Derivative","n_c":["C1071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemiasterlin Analog E7974","n_c":["C49083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Henatinib Maleate","n_c":["C97949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heparan Sulfate Glycosaminoglycan Mimetic M402","n_c":["C170206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heparin Derivative SST0001","n_c":["C104412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131","n_c":["C128283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901","n_c":["C99903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Inhibitor CP-724,714","n_c":["C26648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Inhibitor TAS0728","n_c":["C146810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-targeted DARPin MP0274","n_c":["C148491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302","n_c":["C96038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-targeting Antibody Fc Fragment FS102","n_c":["C118953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herba Scutellaria Barbata","n_c":["C2661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herbimycin","n_c":["C1124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterodimeric Interleukin-15","n_c":["C122401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hexamethylene Bisacetamide","n_c":["C1125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hexaminolevulinate","n_c":["C26654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hexylresorcinol","n_c":["C29092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF-1alpha Inhibitor PX-478","n_c":["C70953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF-2alpha Inhibitor PT2385","n_c":["C119618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF-2alpha Inhibitor PT2977","n_c":["C135627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126","n_c":["C113334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histrelin Acetate","n_c":["C77424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001","n_c":["C111689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410","n_c":["C101893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201","n_c":["C128489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HM2/MMAE Antibody-Drug Conjugate ALT-P7","n_c":["C153102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine","n_c":["C61592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres","n_c":["C88336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hormone Therapy","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPPH","n_c":["C2636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c","n_c":["C117240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV DNA Plasmids Therapeutic Vaccine VGX-3100","n_c":["C77909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV E6/E7 DNA Vaccine GX-188E","n_c":["C102787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C","n_c":["C131495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract","n_c":["C102874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106","n_c":["C123378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101","n_c":["C162459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN","n_c":["C121648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Antagonist KW-2478","n_c":["C69139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor AB-010","n_c":["C82691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor BIIB021","n_c":["C62517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor BIIB028","n_c":["C78846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor Debio 0932","n_c":["C92572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor DS-2248","n_c":["C116851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor HSP990","n_c":["C82387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor MPC-3100","n_c":["C84836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor PU-H71","n_c":["C101227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor SNX-5422 Mesylate","n_c":["C91068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor SNX-5542 Mesylate","n_c":["C74040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor XL888","n_c":["C79835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90-targeted SN-38 Conjugate PEN-866","n_c":["C151953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90alpha/beta Inhibitor TAS-116","n_c":["C134448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301","n_c":["C119616"],"i_c":"","i_c_s":"","term_type":""},{"nm":"hTERT Vaccine V934/V935","n_c":["C80055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"hTERT-encoding DNA Vaccine INVAC-1","n_c":["C119737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hu14.18-IL2 Fusion Protein EMD 273063","n_c":["C162537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HuaChanSu","n_c":["C82415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Huaier Extract Granule","n_c":["C125001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Huang Lian","n_c":["C2626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"huBC1-huIL12 Fusion Protein AS1409","n_c":["C74041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736","n_c":["C116788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104","n_c":["C66980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human MOAB LICO 28a32","n_c":["C29089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Monoclonal Antibody 216","n_c":["C62532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307","n_c":["C77858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus 16 E7 Peptide/Padre 965.10","n_c":["C2569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hycanthone","n_c":["C550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydralazine Hydrochloride","n_c":["C551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydrocortisone Sodium Succinate","n_c":["C1819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxychloroquine","n_c":["C557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxyprogesterone Caproate","n_c":["C960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxytyrosol","n_c":["C63690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxyurea","n_c":["C560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypericin","n_c":["C37456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoxia-activated Prodrug TH-4000","n_c":["C101523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Antiferritin Immunoglobulin","n_c":["C2357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody A33","n_c":["C2477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody CC49","n_c":["C26442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody F19","n_c":["C2515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody Lym-1","n_c":["C2103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IAP Inhibitor APG-1387","n_c":["C162535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IAP Inhibitor AT-406","n_c":["C90574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IAP Inhibitor HGS1029","n_c":["C78484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ibandronate Sodium","n_c":["C1670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iberdomide","n_c":["C129048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iboctadekin","n_c":["C1680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ibritumomab Tiuxetan","n_c":["C29981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ibrutinib","n_c":["C81934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Icotinib Hydrochloride","n_c":["C99160"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Icrucumab","n_c":["C79808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ICT-121 Dendritic Cell Vaccine","n_c":["C124652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idarubicin","n_c":["C562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idarubicin Hydrochloride","n_c":["C1587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idarubicin-Eluting Beads","n_c":["C90593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idasanutlin","n_c":["C99131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idecabtagene Vicleucel","n_c":["C117729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idelalisib","n_c":["C78825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1(R132) Inhibitor IDH305","n_c":["C121457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M","n_c":["C117235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020","n_c":["C74042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO Peptide Vaccine IO102","n_c":["C159498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO-1 Inhibitor LY3381916","n_c":["C143068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO/TDO Inhibitor HTI-1090","n_c":["C151945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1 Inhibitor KHK2455","n_c":["C129790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1 Inhibitor MK-7162","n_c":["C148235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1 Inhibitor PF-06840003","n_c":["C129375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1/TDO2 Inhibitor DN1406131","n_c":["C162858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idronoxil","n_c":["C2642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idronoxil Suppository NOX66","n_c":["C132257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ifabotuzumab","n_c":["C116629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ifetroban","n_c":["C81570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ifosfamide","n_c":["C564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-1R Inhibitor","n_c":["C184764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-1R Inhibitor PL225B","n_c":["C104746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-1R/IR Inhibitor KW-2450","n_c":["C84871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-methotrexate Conjugate","n_c":["C113789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-10 Immunomodulator MK-1966","n_c":["C126840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-12-expressing HSV-1 NSC 733972","n_c":["C114294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051","n_c":["C114385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-2 Recombinant Fusion Protein ALT-801","n_c":["C71743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1","n_c":["C146636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL4-Pseudomonas Exotoxin Fusion Protein MDNA55","n_c":["C79843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilixadencel","n_c":["C99902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iloprost","n_c":["C48397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilorasertib","n_c":["C116729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imalumab","n_c":["C104260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imatinib","n_c":["C62035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imatinib Mesylate","n_c":["C1687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imetelstat","n_c":["C49084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imetelstat Sodium","n_c":["C84511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imexon","n_c":["C29115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imidazole Mustard","n_c":["C2216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imidazole-Pyrazole","n_c":["C29344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imipramine Blue","n_c":["C126638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imiquimod","n_c":["C1431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immediate-release Onapristone","n_c":["C113795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immediate-release Tablet Afuresertib","n_c":["C113658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immune Checkpoint Inhibitor ASP8374","n_c":["C141421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoconjugate RO5479599","n_c":["C104058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunocytokine NHS-IL12","n_c":["C97961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunocytokine NHS-IL2-LT","n_c":["C82411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulator LAM-003","n_c":["C152979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulator OHR/AVR118","n_c":["C49092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulatory Agent CC-11006","n_c":["C101370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulatory Oligonucleotide HYB2055","n_c":["C49182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapeutic Combination Product CMB305","n_c":["C122922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapeutic GSK1572932A","n_c":["C78478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapy Regimen MKC-1106-MT","n_c":["C77971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotoxin CMD-193","n_c":["C62480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IMT-1012 Immunotherapeutic Vaccine","n_c":["C77863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inalimarev","n_c":["C29317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incyclinide","n_c":["C2454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indibulin","n_c":["C2049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indicine-N-Oxide","n_c":["C1134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indisulam","n_c":["C25797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indocyanine Green-labeled Polymeric Micelles ONM-100","n_c":["C158750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indole-3-Carbinol","n_c":["C1135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indomethacin","n_c":["C576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoximod","n_c":["C71535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoximod Prodrug NLG802","n_c":["C150393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inecalcitol","n_c":["C83818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infigratinib","n_c":["C88302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infigratinib Mesylate","n_c":["C162568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infliximab","n_c":["C1789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ingenol Mebutate","n_c":["C48398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ingenol Mebutate Gel","n_c":["C118776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iniparib","n_c":["C62526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Innate Immunostimulator rBBX-01","n_c":["C82362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INO-1001","n_c":["C61315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inodiftagene Vixteplasmid","n_c":["C157333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iNOS Dimerization Inhibitor ASP9853","n_c":["C116728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01","n_c":["C122835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944","n_c":["C49181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inositol","n_c":["C28163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inotuzumab Ozogamicin","n_c":["C71542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inproquone","n_c":["C65919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Integrin alpha-2 Inhibitor E7820","n_c":["C61501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Integrin Receptor Antagonist GLPG0187","n_c":["C96223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon","n_c":["C20493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfa-N1","n_c":["C2220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfa-N3","n_c":["C30136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfacon-1","n_c":["C1766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Beta-1A","n_c":["C1823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Gamma-1b","n_c":["C100089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002","n_c":["C66972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin Therapy","n_c":["C15543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-2 Liposome","n_c":["C2373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230","n_c":["C128107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intetumumab","n_c":["C61070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intiquinatine","n_c":["C83820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intoplicine","n_c":["C1495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inulin","n_c":["C61506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iobenguane I-131","n_c":["C970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 124 Monoclonal Antibody A33","n_c":["C2440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 124 Monoclonal Antibody M5A","n_c":["C158629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody","n_c":["C74051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP","n_c":["C91389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Derlotuximab Biotin","n_c":["C2223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Ethiodized Oil","n_c":["C2696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 MIP-1095","n_c":["C131821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody 81C6","n_c":["C2488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody BC8","n_c":["C2527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2","n_c":["C2697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody F16SIP","n_c":["C95025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody G-250","n_c":["C2449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody muJ591","n_c":["C2604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Omburtamab","n_c":["C48400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Rituximab","n_c":["C102981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Tenatumomab","n_c":["C124996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 TM-601","n_c":["C48263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Tositumomab","n_c":["C2444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I-131","n_c":["C1639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ioflubenzamide I-131","n_c":["C80056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ionomycin","n_c":["C596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipafricept","n_c":["C102565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipatasertib","n_c":["C91072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipilimumab","n_c":["C2654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipomeanol","n_c":["C976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iproplatin","n_c":["C1070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iPSC-derived CD16-expressing Natural Killer Cells FT516","n_c":["C164140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iPSC-derived Natural Killer Cells FT500","n_c":["C158438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRAK4 Inhibitor CA-4948","n_c":["C148455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iratumumab","n_c":["C26441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iridium Ir 192","n_c":["C104270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan","n_c":["C62040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan Hydrochloride","n_c":["C1381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan-Eluting Beads","n_c":["C82682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet","n_c":["C88280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irofulven","n_c":["C1717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irosustat","n_c":["C79827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isatuximab","n_c":["C90578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iso-fludelone","n_c":["C97332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isobrucein B","n_c":["C1774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isocoumarin NM-3","n_c":["C1888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isotretinoin","n_c":["C603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ispinesib","n_c":["C38131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ispinesib Mesylate","n_c":["C77518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISS 1018 CpG Oligodeoxynucleotide","n_c":["C61080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itacitinib","n_c":["C116855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itacitinib Adipate","n_c":["C158906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITK Inhibitor CPI-818","n_c":["C162010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itraconazole","n_c":["C1138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itraconazole Dispersion In Polymer Matrix","n_c":["C104048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ivosidenib","n_c":["C114383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ixabepilone","n_c":["C37452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ixazomib","n_c":["C97940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ixazomib Citrate","n_c":["C82653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK Inhibitor INCB047986","n_c":["C111761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1 Inhibitor AZD4205","n_c":["C156774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1 Inhibitor INCB052793","n_c":["C118629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2 Inhibitor AZD1480","n_c":["C91394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2 Inhibitor BMS-911543","n_c":["C95702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2 Inhibitor XL019","n_c":["C90573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2/Src Inhibitor NS-018","n_c":["C98109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jin Fu Kang","n_c":["C61316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JNK Inhibitor CC-401","n_c":["C49095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kanglaite","n_c":["C91705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ketoconazole","n_c":["C605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ketotrexate","n_c":["C77403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS G12C Inhibitor MRTX849","n_c":["C157493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS Mutant-targeting AMG 510","n_c":["C154287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS-MAPK Signaling Pathway Inhibitor JAB-3312","n_c":["C164218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRN5500","n_c":["C1614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KSP Inhibitor AZD4877","n_c":["C64522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KSP Inhibitor SB-743921","n_c":["C52199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kunecatechins Ointment","n_c":["C67049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"L-Gossypol","n_c":["C62178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"L-methylfolate","n_c":["C107240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Labetuzumab Govitecan","n_c":["C95710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lactoferrin-derived Lytic Peptide LTX-315","n_c":["C90547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacutamab","n_c":["C124999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ladirubicin","n_c":["C83861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laetrile","n_c":["C29149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laniquidar","n_c":["C28698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lanreotide Acetate","n_c":["C74584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapachone","n_c":["C28694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapatinib","n_c":["C26653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapatinib Ditosylate","n_c":["C66878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapuleucel-T","n_c":["C2057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laromustine","n_c":["C2653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotaxel","n_c":["C48427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotrectinib","n_c":["C115977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotrectinib Sulfate","n_c":["C156895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lavendustin A","n_c":["C1142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lazertinib","n_c":["C148147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lead Pb 212 TCMC-trastuzumab","n_c":["C97500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lefitolimod","n_c":["C94207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leflunomide","n_c":["C1128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenalidomide","n_c":["C2668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenalidomide Analog KPG-121","n_c":["C162878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lentinan","n_c":["C28168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenvatinib","n_c":["C95124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenvatinib Mesylate","n_c":["C48636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenzilumab","n_c":["C125081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lestaurtinib","n_c":["C48402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Letrozole","n_c":["C1527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leucovorin","n_c":["C71631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leucovorin Calcium","n_c":["C607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leuprolide","n_c":["C62042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leuprolide Acetate","n_c":["C1319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leuprolide Mesylate Injectable Suspension","n_c":["C118363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leurubicin","n_c":["C81421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levetiracetam","n_c":["C47581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levothyroxine","n_c":["C62080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levothyroxine Sodium","n_c":["C888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lexatumumab","n_c":["C64621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lexibulin","n_c":["C77882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liarozole","n_c":["C1433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liarozole Fumarate","n_c":["C1524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liarozole Hydrochloride","n_c":["C80333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Licartin","n_c":["C104275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Licorice","n_c":["C61436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifastuzumab Vedotin","n_c":["C116747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Light-activated AU-011","n_c":["C137951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Light-Emitting Oncolytic Vaccinia Virus GL-ONC1","n_c":["C79833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Limonene, (+)-","n_c":["C61714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Limonene, (+/-)-","n_c":["C61709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linifanib","n_c":["C71759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linoleyl Carbonate-Paclitaxel","n_c":["C101792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linrodostat","n_c":["C141135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linsitinib","n_c":["C70982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lintuzumab","n_c":["C1716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liothyronine I-131","n_c":["C2396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liothyronine Sodium","n_c":["C2581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1","n_c":["C116889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191","n_c":["C160867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416","n_c":["C142137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","n_c":["C157247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal c-raf Antisense Oligonucleotide","n_c":["C95718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Curcumin","n_c":["C116322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Cytarabine","n_c":["C2388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Daunorubicin Citrate","n_c":["C2213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Docetaxel","n_c":["C92581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Eribulin Mesylate","n_c":["C111899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","n_c":["C111688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Irinotecan","n_c":["C82676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Mitoxantrone Hydrochloride","n_c":["C116064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal MUC1/PET-lipid A Vaccine ONT-10","n_c":["C101262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal NDDP","n_c":["C1383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Rhenium Re 186","n_c":["C107679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal SN-38","n_c":["C95717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Topotecan FF-10850","n_c":["C165505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Vinorelbine","n_c":["C62790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Vinorelbine Tartrate","n_c":["C135619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome","n_c":["C18208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated Daunorubicin-Cytarabine","n_c":["C67504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-Encapsulated Doxorubicin Citrate","n_c":["C61317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated miR-34 Mimic MRX34","n_c":["C105802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated OSI-7904","n_c":["C38694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94","n_c":["C106271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lirilumab","n_c":["C103820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lisavanbulin","n_c":["C97664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lisocabtagene Maraleucel","n_c":["C125192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142","n_c":["C120103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Litronesib","n_c":["C88328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809","n_c":["C125631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","n_c":["C74055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623","n_c":["C111998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver X Receptor beta Agonist RGX-104","n_c":["C131910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lm-tLLO-neoantigens Vaccine ADXS-NEO","n_c":["C148380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-1 Immunotoxin","n_c":["C2499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-2 Immunotoxin","n_c":["C2513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-7 Immunotoxin","n_c":["C1619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-9 Immunotoxin","n_c":["C2472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164","n_c":["C121541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP-2:340-349 Peptide Vaccine","n_c":["C62767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP-2:419-427 Peptide Vaccine","n_c":["C62768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lobaplatin","n_c":["C1434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lometrexol","n_c":["C979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lometrexol Sodium","n_c":["C90623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lomustine","n_c":["C617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lonafarnib","n_c":["C1829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loncastuximab Tesirine","n_c":["C125549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Long Peptide Vaccine 7","n_c":["C116067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Long-acting Release Pasireotide","n_c":["C113656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lontucirev","n_c":["C2830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lorlatinib","n_c":["C113655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lorukafusp alfa","n_c":["C162537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lorvotuzumab Mertansine","n_c":["C38714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Losatuxizumab Vedotin","n_c":["C120556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Losoxantrone","n_c":["C1521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Losoxantrone Hydrochloride","n_c":["C72077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lovastatin","n_c":["C620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LOXL2 Inhibitor PAT-1251","n_c":["C160691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP5/6 Antagonist BI 905677","n_c":["C165553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor CC-90011","n_c":["C131303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor GSK2879552","n_c":["C113646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor IMG-7289","n_c":["C131827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor RO7051790","n_c":["C131908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lucanthone","n_c":["C83925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lucatumumab","n_c":["C48405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lucitanib","n_c":["C95726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luminespib","n_c":["C71467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luminespib Mesylate","n_c":["C162567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung-targeted Immunomodulator QBKPN","n_c":["C118623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lurbinectedin","n_c":["C82382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lurtotecan","n_c":["C1610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lurtotecan Liposome","n_c":["C1876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","n_c":["C142176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 DOTA-biotin","n_c":["C113801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 DOTA-N3-CTT1403","n_c":["C158044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 DOTA-Tetulomab","n_c":["C105403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Dotatate","n_c":["C95020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Lilotomab-satetraxetan","n_c":["C162565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Monoclonal Antibody CC49","n_c":["C2598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Monoclonal Antibody J591","n_c":["C38701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 PP-F11N","n_c":["C114499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Satoreotide Tetraxetan","n_c":["C124929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-DOTA-EB-TATE","n_c":["C154549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-Edotreotide","n_c":["C88277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-NeoB","n_c":["C158734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-PSMA-617","n_c":["C148145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 Capromab","n_c":["C67039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 Girentuximab","n_c":["C66978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 PSMA-R2","n_c":["C150467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 Rituximab","n_c":["C162563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1","n_c":["C78832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lyophilized Black Raspberry Lozenge","n_c":["C99163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lyophilized Black Raspberry Saliva Substitute","n_c":["C99164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lysine-specific Demethylase 1 Inhibitor INCB059872","n_c":["C126421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lyso-Thermosensitive Liposome Doxorubicin","n_c":["C61571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macimorelin","n_c":["C95123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macitentan","n_c":["C87728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maekmoondong-tang","n_c":["C154567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mafosfamide","n_c":["C1150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-10.A2","n_c":["C2681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A3 Multipeptide Vaccine GL-0817","n_c":["C166968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A3 Peptide Vaccine","n_c":["C91710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A3-specific Immunotherapeutic GSK 2132231A","n_c":["C123649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201","n_c":["C114978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Magnesium Valproate","n_c":["C71156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALT1 Inhibitor JNJ-67856633","n_c":["C160147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mannosulfan","n_c":["C83904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mannosylerythritol Lipid","n_c":["C1990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mapatumumab","n_c":["C61502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7","n_c":["C157776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marcellomycin","n_c":["C1152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MARCKS Protein Inhibitor BIO-11006","n_c":["C156733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Margetuximab","n_c":["C91733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marimastat","n_c":["C1652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marizomib","n_c":["C64634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masitinib Mesylate","n_c":["C79831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masoprocol","n_c":["C701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAT2A Inhibitor AG-270","n_c":["C153180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Matrix Metalloproteinase Inhibitor MMI270","n_c":["C2045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Matuzumab","n_c":["C2012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mavelertinib","n_c":["C120307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mavorixafor","n_c":["C126660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maytansine","n_c":["C626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MCL-1 Inhibitor AMG 176","n_c":["C127817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MCL-1 inhibitor AMG 397","n_c":["C156740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mcl-1 Inhibitor AZD5991","n_c":["C137989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mcl-1 Inhibitor MIK665","n_c":["C133174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Antagonist ASTX295","n_c":["C162749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Antagonist RO5045337","n_c":["C91724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Antagonist RO6839921","n_c":["C114980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor AMG-232","n_c":["C116624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor BI 907828","n_c":["C156709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor KRT-232","n_c":["C116624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2/MDMX Inhibitor ALRN-6924","n_c":["C118669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDR Modulator CBT-1","n_c":["C67042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mechlorethamine","n_c":["C62056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mechlorethamine Hydrochloride","n_c":["C627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mechlorethamine Hydrochloride Gel","n_c":["C119736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medorubicin","n_c":["C87599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medroxyprogesterone","n_c":["C629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medroxyprogesterone Acetate","n_c":["C1155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Megestrol Acetate","n_c":["C1156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK 1/2 Inhibitor AS703988/MSC2015103B","n_c":["C98832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor AZD8330","n_c":["C69143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor CI-1040","n_c":["C2670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK inhibitor CS3006","n_c":["C155971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor GDC-0623","n_c":["C95738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor PD0325901","n_c":["C52195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor RO4987655","n_c":["C82696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor SHR 7390","n_c":["C150680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor TAK-733","n_c":["C84858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor WX-554","n_c":["C101532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK-1/MEKK-1 Inhibitor E6201","n_c":["C79848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK/Aurora Kinase Inhibitor BI 847325","n_c":["C106126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melanoma Monoclonal Antibody hIgG2A","n_c":["C29178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melanoma TRP2 CTL Epitope Vaccine SCIB1","n_c":["C91380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melapuldencel-T","n_c":["C120183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MELK Inhibitor OTS167","n_c":["C111569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan","n_c":["C633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan Flufenamide","n_c":["C107680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan Hydrochloride","n_c":["C48002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex","n_c":["C84878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Membrane-Disrupting Peptide EP-100","n_c":["C84860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menatetrenone","n_c":["C52194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menogaril","n_c":["C1389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Merbarone","n_c":["C1390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mercaptopurine","n_c":["C195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mercaptopurine Anhydrous","n_c":["C61832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mercaptopurine Oral Suspension","n_c":["C111757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Merestinib","n_c":["C95729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesna","n_c":["C192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536","n_c":["C162935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Kinase Inhibitor OMO-1","n_c":["C148537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor BMS-777607","n_c":["C74060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor EMD 1204831","n_c":["C91097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor PF-04217903","n_c":["C78483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor SAR125844","n_c":["C97511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor SGX523","n_c":["C74062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metamelfalan","n_c":["C83946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MetAP2 Inhibitor APL-1202","n_c":["C162480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MetAP2 Inhibitor SDX-7320","n_c":["C128030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metatinib Tromethamine","n_c":["C113294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metformin","n_c":["C61612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metformin Hydrochloride","n_c":["C29251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methanol Extraction Residue of BCG","n_c":["C1159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methazolamide","n_c":["C61318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methionine Aminopeptidase 2 Inhibitor M8891","n_c":["C142831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methionine Aminopeptidase 2 Inhibitor PPI-2458","n_c":["C38129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate","n_c":["C642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate Sodium","n_c":["C1735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate-E Therapeutic Implant","n_c":["C17876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","n_c":["C125656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxsalen","n_c":["C643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxyamine","n_c":["C78084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxyamine Hydrochloride","n_c":["C78085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methyl-5-Aminolevulinate Hydrochloride Cream","n_c":["C2647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylmercaptopurine Riboside","n_c":["C2352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylprednisolone","n_c":["C647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylprednisolone Acetate","n_c":["C48003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylprednisolone Sodium Succinate","n_c":["C48004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylselenocysteine","n_c":["C63678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methyltestosterone","n_c":["C648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metoprine","n_c":["C1161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mibefradil","n_c":["C87686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mibefradil Dihydrochloride","n_c":["C87687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micellar Nanoparticle-encapsulated Epirubicin","n_c":["C139003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micro Needle Array-Doxorubicin","n_c":["C156665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300","n_c":["C64631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microtubule Inhibitor SCB01A","n_c":["C143158"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Midostaurin","n_c":["C1872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mifamurtide","n_c":["C1394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mifepristone","n_c":["C655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milademetan Tosylate","n_c":["C107384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milatuzumab","n_c":["C66983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110","n_c":["C91086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milciclib Maleate","n_c":["C88312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milk Thistle","n_c":["C29261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miltefosine","n_c":["C1170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Minretumomab","n_c":["C2567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mipsagargin","n_c":["C90554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirabegron","n_c":["C90633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirvetuximab Soravtansine","n_c":["C102566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Misonidazole","n_c":["C657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitindomide","n_c":["C29195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitobronitol","n_c":["C659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101","n_c":["C111758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoclomine","n_c":["C66164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoflaxone","n_c":["C1101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoguazone","n_c":["C661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoguazone Dihydrochloride","n_c":["C91409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitolactol","n_c":["C662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin","n_c":["C1820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin A","n_c":["C1164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin B","n_c":["C1392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin C Analog KW-2149","n_c":["C1140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitosis Inhibitor T 1101 Tosylate","n_c":["C151933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotane","n_c":["C664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotenamine","n_c":["C66167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoxantrone","n_c":["C62050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoxantrone Hydrochloride","n_c":["C665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitozolomide","n_c":["C1166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivavotinib","n_c":["C113162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivebresib","n_c":["C121829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivobulin","n_c":["C87698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivobulin Isethionate","n_c":["C1357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Bacteria Vaccine","n_c":["C74063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MK0731","n_c":["C49174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKC-1","n_c":["C2507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKNK1 Inhibitor BAY 1143269","n_c":["C121956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MMP Inhibitor S-3304","n_c":["C2671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MNK1/2 Inhibitor ETC-1907206","n_c":["C153262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mocetinostat","n_c":["C62521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Vitamin D Binding Protein Macrophage Activator EF-022","n_c":["C131824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modotuximab","n_c":["C152075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MOF Compound RiMO-301","n_c":["C148280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mofarotene","n_c":["C63667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mogamulizumab","n_c":["C62510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Molibresib","n_c":["C101538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Molibresib Besylate","n_c":["C159943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Momelotinib","n_c":["C88311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monalizumab","n_c":["C120208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monocarboxylate Transporter 1 Inhibitor AZD3965","n_c":["C105399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine","n_c":["C2648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 11D10","n_c":["C2446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine","n_c":["C2606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 14G2A","n_c":["C2368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 1F5","n_c":["C29198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 3622W94","n_c":["C2470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 3F8","n_c":["C2370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine","n_c":["C2424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine","n_c":["C2227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 7C11","n_c":["C2739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 81C6","n_c":["C1958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine","n_c":["C2436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody A27.15","n_c":["C2447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody A33","n_c":["C2410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody AbGn-7","n_c":["C99162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody AK002","n_c":["C129591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody ASP1948","n_c":["C156402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody CAL","n_c":["C2659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody CC49-delta CH2","n_c":["C2698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody CEP-37250/KHK2804","n_c":["C98296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody D6.12","n_c":["C2683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody E2.3","n_c":["C2448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody F19","n_c":["C2514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine","n_c":["C26450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HeFi-1","n_c":["C2505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody Hu3S193","n_c":["C2547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HuAFP31","n_c":["C48407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HuHMFG1","n_c":["C38697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody huJ591","n_c":["C2652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HuPAM4","n_c":["C48408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody IMMU-14","n_c":["C29224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody L6","n_c":["C2372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody Lym-1","n_c":["C1561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody m170","n_c":["C1959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody Me1-14 F(ab')2","n_c":["C2409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody muJ591","n_c":["C2476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody MX35 F(ab')2","n_c":["C2417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody NEO-201","n_c":["C156398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody R24","n_c":["C2349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody RAV12","n_c":["C48409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody SGN-14","n_c":["C2005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody TRK-950","n_c":["C142826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Microbial EDP1503","n_c":["C155907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100","n_c":["C94208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monomethyl Auristatin E","n_c":["C122637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morinda Citrifolia Fruit Extract","n_c":["C26662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morpholinodoxorubicin","n_c":["C1442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mosedipimod","n_c":["C123775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mosunetuzumab","n_c":["C129691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motesanib","n_c":["C71896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motesanib Diphosphate","n_c":["C48374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motexafin Gadolinium","n_c":["C1881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motexafin Lutetium","n_c":["C1651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motolimod","n_c":["C80521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MOv-gamma Chimeric Receptor Gene","n_c":["C2638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moxetumomab Pasudotox","n_c":["C68819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mps1 Inhibitor BAY 1217389","n_c":["C122707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mps1 Inhibitor BOS172722","n_c":["C155895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based Personalized Cancer Vaccine mRNA-4157","n_c":["C146813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based Personalized Cancer Vaccine NCI-4650","n_c":["C148239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based TriMix Melanoma Vaccine ECI-006","n_c":["C154274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902","n_c":["C156926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-derived KRAS-targeted Vaccine V941","n_c":["C162186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-derived Lung Cancer Vaccine BI 1361849","n_c":["C111574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-Derived Prostate Cancer Vaccine CV9103","n_c":["C82654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-derived Prostate Cancer Vaccine CV9104","n_c":["C106231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTF-1 Inhibitor APTO-253 HCl","n_c":["C95724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Inhibitor GDC-0349","n_c":["C133227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor AZD8055","n_c":["C78856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor CC-223","n_c":["C92575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor OSI-027","n_c":["C78476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor PP242","n_c":["C128632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR1/2 Kinase Inhibitor ME-344","n_c":["C101132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTORC 1/2 Inhibitor LXI-15029","n_c":["C148528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTORC1/2 Kinase Inhibitor BI 860585","n_c":["C122836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTORC1/mTORC2/DHFR Inhibitor ABTL0812","n_c":["C117290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC1-targeted Peptide GO-203-2C","n_c":["C95722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucoadhesive Paclitaxel Formulation","n_c":["C107188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-AGC Kinase Inhibitor AT13148","n_c":["C101786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200","n_c":["C128898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-epitope HER2 Peptide Vaccine H2NVAC","n_c":["C165292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","n_c":["C124054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-kinase Inhibitor TPX-0022","n_c":["C162676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-kinase Inhibitor XL092","n_c":["C161598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-mode Kinase Inhibitor EOC317","n_c":["C164211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-neo-epitope Vaccine OSE 2101","n_c":["C26645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multifunctional/Multitargeted Anticancer Agent OMN54","n_c":["C101260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor 4SC-203","n_c":["C90553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor AEE788","n_c":["C48369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor AT9283","n_c":["C66947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor SAR103168","n_c":["C88278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multipeptide Vaccine S-588210","n_c":["C125692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327","n_c":["C77866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muparfostat","n_c":["C38690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mureletecan","n_c":["C2234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutant IDH1 Inhibitor DS-1001","n_c":["C148134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutant p53 Activator COTI-2","n_c":["C121951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutant-selective EGFR Inhibitor PF-06459988","n_c":["C119624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","n_c":["C162806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVA-FCU1 TG4023","n_c":["C88279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1","n_c":["C123382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYC-targeting siRNA DCR-MYC","n_c":["C115108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium tuberculosis Arabinomannan Z-100","n_c":["C118445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium w","n_c":["C70969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycophenolic Acid","n_c":["C673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea","n_c":["C44168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N-Methylformamide","n_c":["C1163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N,N-Dibenzyl Daunomycin","n_c":["C2084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NA17-A Antigen","n_c":["C37450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NA17.A2 Peptide Vaccine","n_c":["C2680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nab-paclitaxel","n_c":["C2688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","n_c":["C131213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nadofaragene Firadenovec","n_c":["C71011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namirotene","n_c":["C83981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namodenoson","n_c":["C79826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NAMPT Inhibitor OT-82","n_c":["C162742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanafrocin","n_c":["C72594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanatinostat","n_c":["C78475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanocell-encapsulated miR-16-based microRNA Mimic","n_c":["C121214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Albumin-Bound Docetaxel","n_c":["C71696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Albumin-Bound Rapamycin","n_c":["C74065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404","n_c":["C116890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Paclitaxel Ointment SOR007","n_c":["C146821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle-based Paclitaxel Suspension","n_c":["C118648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle-encapsulated Doxorubicin Hydrochloride","n_c":["C102875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoscale Coordination Polymer Nanoparticles CPI-100","n_c":["C157499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanosomal Docetaxel Lipid Suspension","n_c":["C111570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Napabucasin","n_c":["C96429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naphthalimide Analogue UNBS5162","n_c":["C102850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naptumomab Estafenatox","n_c":["C95789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naquotinib","n_c":["C115110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Narnatumab","n_c":["C91382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natalizumab","n_c":["C77862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural IFN-alpha OPC-18","n_c":["C71159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Killer Cells ZRx101","n_c":["C85466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navarixin","n_c":["C156730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navitoclax","n_c":["C64776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navoximod","n_c":["C113793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navy Bean Powder","n_c":["C111687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naxitamab","n_c":["C123428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nazartinib","n_c":["C115109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ncmtRNA Oligonucleotide Andes-1537","n_c":["C123825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Necitumumab","n_c":["C88281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nedaplatin","n_c":["C61099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464","n_c":["C136418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nedisertib","n_c":["C120036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nelarabine","n_c":["C1704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nelipepimut-S","n_c":["C117985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nelipepimut-S Plus GM-CSF Vaccine","n_c":["C99228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nemorubicin","n_c":["C83999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nemorubicin Hydrochloride","n_c":["C84000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen Vaccine GEN-009","n_c":["C162874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Glioblastoma Vaccine","n_c":["C118960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Melanoma-Poly-ICLC Vaccine","n_c":["C112003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine","n_c":["C158694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903","n_c":["C165514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904","n_c":["C165515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017","n_c":["C135018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neratinib","n_c":["C49094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neratinib Maleate","n_c":["C136891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nesvacumab","n_c":["C95712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NG-nitro-L-arginine","n_c":["C96232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niacinamide","n_c":["C2327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niclosamide","n_c":["C66240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nicotinamide Riboside","n_c":["C158078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nidanilimab","n_c":["C153375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nifurtimox","n_c":["C71734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilotinib","n_c":["C48375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilotinib Hydrochloride Anhydrous","n_c":["C95223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilotinib Hydrochloride Monohydrate","n_c":["C95229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilutamide","n_c":["C1173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimesulide-Hyaluronic Acid Conjugate CA102N","n_c":["C157231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimodipine","n_c":["C692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimotuzumab","n_c":["C2733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimustine","n_c":["C693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimustine Hydrochloride","n_c":["C95325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ningetinib Tosylate","n_c":["C148529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nintedanib","n_c":["C62765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niraparib","n_c":["C80059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niraparib Tosylate Monohydrate","n_c":["C133238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nirogacestat","n_c":["C82383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative","n_c":["C61499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nitrogen Mustard Prodrug PR-104","n_c":["C61590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nitroglycerin Transdermal Patch","n_c":["C103272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nivolumab","n_c":["C68814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NLRP3 Agonist BMS-986299","n_c":["C155945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nocodazole","n_c":["C75228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nogalamycin","n_c":["C700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nolatrexed Dihydrochloride","n_c":["C1577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201","n_c":["C84872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norgestrel","n_c":["C703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North American Ginseng Extract AFX-2","n_c":["C99122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nortopixantrone","n_c":["C81423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Noscapine","n_c":["C80589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Noscapine Hydrochloride","n_c":["C61103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Otherwise Specified","n_c":["C19594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Notch Signaling Inhibitor PF-06650808","n_c":["C118569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Notch Signaling Pathway Inhibitor MK0752","n_c":["C49175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK/ROS1 Inhibitor DS-6051b","n_c":["C118948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleolin Antagonist IPP-204106N","n_c":["C103297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleoside Analog DFP-10917","n_c":["C116744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleotide Analog Prodrug NUC-3373","n_c":["C156680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleotide Analogue GS 9219","n_c":["C71742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nutlin-3a","n_c":["C74594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nutraceutical TBL-12","n_c":["C96036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611","n_c":["C62452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301","n_c":["C120557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-1/GLA-SE Vaccine ID-G305","n_c":["C113432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-B","n_c":["C26680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"O-Chloroacetylcarbamoylfumagillol","n_c":["C1298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"O6-Benzylguanine","n_c":["C1306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obatoclax Mesylate","n_c":["C62771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obinutuzumab","n_c":["C70741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oblimersen Sodium","n_c":["C66722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocaratuzumab","n_c":["C2524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocrelizumab","n_c":["C66250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Octreotide","n_c":["C711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Octreotide Acetate","n_c":["C53447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Octreotide Pamoate","n_c":["C2402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ofatumumab","n_c":["C66952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oglufanide Disodium","n_c":["C2558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olaparib","n_c":["C71721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olaptesed Pegol","n_c":["C99379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olaratumab","n_c":["C79825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oleandrin","n_c":["C90586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oleclumab","n_c":["C123914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oligonucleotide SPC2996","n_c":["C61325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olivomycin","n_c":["C715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olmutinib","n_c":["C101791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oltipraz","n_c":["C1177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olutasidenib","n_c":["C129687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omacetaxine Mepesuccinate","n_c":["C1127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ombrabulin","n_c":["C78480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omipalisib","n_c":["C88270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onalespib","n_c":["C85454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onalespib Lactate","n_c":["C129425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onartuzumab","n_c":["C82348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Adenovirus Ad5-DNX-2401","n_c":["C74067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 C134","n_c":["C162635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 G207","n_c":["C2676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 NV1020","n_c":["C2623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 rQNestin34.5v.2","n_c":["C139551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 rRp450","n_c":["C90563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV1716","n_c":["C84840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Newcastle Disease Virus MEDI5395","n_c":["C165457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Newcastle Disease Virus MTH-68H","n_c":["C91700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Newcastle Disease Virus Strain PV701","n_c":["C2799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Virus ASP9801","n_c":["C161021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Virus RP1","n_c":["C158074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ondansetron Hydrochloride","n_c":["C48007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ontuxizumab","n_c":["C82406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onvansertib","n_c":["C143162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opaganib","n_c":["C98278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","n_c":["C90545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opioid Growth Factor","n_c":["C48413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oportuzumab Monatox","n_c":["C61307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oprozomib","n_c":["C91388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Aminolevulinic Acid Hydrochloride","n_c":["C99763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Azacitidine","n_c":["C118288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cancer Vaccine V3-OVA","n_c":["C159540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Docetaxel","n_c":["C131903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Fludarabine Phosphate","n_c":["C64338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hsp90 Inhibitor IPI-493","n_c":["C78843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Ixabepilone","n_c":["C63478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Microencapsulated Diindolylmethane","n_c":["C71132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Milataxel","n_c":["C77880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Myoma Vaccine V3-myoma","n_c":["C158745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Pancreatic Cancer Vaccine V3-P","n_c":["C150400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Picoplatin","n_c":["C68924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Sodium Phenylbutyrate","n_c":["C67083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Topotecan Hydrochloride","n_c":["C63477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orantinib","n_c":["C1884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oraxol","n_c":["C112000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oregovomab","n_c":["C1784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ormaplatin","n_c":["C1250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ortataxel","n_c":["C1867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orteronel","n_c":["C90582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osilodrostat","n_c":["C131535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osimertinib","n_c":["C116377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Otlertuzumab","n_c":["C74006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovapuldencel-T","n_c":["C113651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006","n_c":["C96739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovine Submaxillary Mucin","n_c":["C2350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OX40L-expressing Oncolytic Adenovirus DNX-2440","n_c":["C160192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxaliplatin","n_c":["C1181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome","n_c":["C91074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxcarbazepine","n_c":["C47643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxeclosporin","n_c":["C132271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxidative Phosphorylation Inhibitor IACS-010759","n_c":["C130012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxidative Phosphorylation Inhibitor IM156","n_c":["C153372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxidopamine","n_c":["C1316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OxPhos Inhibitor VLX600","n_c":["C118283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ozarelix","n_c":["C95214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-cadherin Antagonist PF-03732010","n_c":["C91723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-cadherin Inhibitor PCA062","n_c":["C121216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-cadherin-targeting Agent PF-06671008","n_c":["C125607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-p68 Inhibitor RX-5902","n_c":["C113293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-TEFb Inhibitor BAY1143572","n_c":["C121456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p300/CBP Bromodomain Inhibitor CCS1477","n_c":["C160195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p38 MAPK Inhibitor LY3007113","n_c":["C99134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53 Peptide Vaccine MPS-128","n_c":["C1986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53-HDM2 Interaction Inhibitor MI-773","n_c":["C106120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53-HDM2 Protein-protein Interaction Inhibitor APG-115","n_c":["C132991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53/HDM2 Interaction Inhibitor CGM097","n_c":["C104280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p70S6K Inhibitor LY2584702","n_c":["C91393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p70S6K/Akt Inhibitor MSC2363318A","n_c":["C112004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p97 Inhibitor CB-5083","n_c":["C118287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel","n_c":["C1411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Ceribate","n_c":["C96934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Injection Concentrate for Nanodispersion","n_c":["C96037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Liposome","n_c":["C2631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Poliglumex","n_c":["C1795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Polymeric Micelle Formulation NANT-008","n_c":["C148531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel PPE Microspheres","n_c":["C2785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Trevatide","n_c":["C99461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Vitamin E-Based Emulsion","n_c":["C61079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel-Loaded Polymeric Micelle","n_c":["C48415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pacritinib","n_c":["C78837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Padeliporfin","n_c":["C78481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Padoporfin","n_c":["C61321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAK4 Inhibitor PF-03758309","n_c":["C84841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAK4/NAMPT Inhibitor KPT-9274","n_c":["C126646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palbociclib","n_c":["C49176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palbociclib Isethionate","n_c":["C120259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palifosfamide","n_c":["C66990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palifosfamide Tromethamine","n_c":["C95703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palladium Pd-103","n_c":["C2550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palonosetron Hydrochloride","n_c":["C47650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamidronate Disodium","n_c":["C1345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamidronic Acid","n_c":["C61875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamiparib","n_c":["C120553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan FGFR Inhibitor PRN1371","n_c":["C124931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514","n_c":["C68832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-AKT Inhibitor ARQ751","n_c":["C128250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-AKT Kinase Inhibitor GSK690693","n_c":["C71711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-FGFR Inhibitor LY2874455","n_c":["C139004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806","n_c":["C162573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-HER Kinase Inhibitor AC480","n_c":["C48380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-IDH Mutant Inhibitor AG-881","n_c":["C152914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-Mutant-IDH1 Inhibitor Bay-1436032","n_c":["C131690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PI3K Inhibitor CLR457","n_c":["C117230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PI3K/mTOR Inhibitor SF1126","n_c":["C85469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-PIM Inhibitor INCB053914","n_c":["C124226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PIM Kinase Inhibitor AZD1208","n_c":["C99380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PIM Kinase Inhibitor NVP-LGB-321","n_c":["C128615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-RAF Inhibitor LXH254","n_c":["C125003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-RAF Inhibitor LY3009120","n_c":["C116861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-RAF Kinase Inhibitor CCT3833","n_c":["C121952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-RAF Kinase Inhibitor TAK-580","n_c":["C106254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550","n_c":["C2062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-TRK Inhibitor ONO-7579","n_c":["C140379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981","n_c":["C82379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancratistatin","n_c":["C1184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panitumumab","n_c":["C1857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panobinostat","n_c":["C66948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panobinostat Nanoparticle Formulation MTX110","n_c":["C150717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paricalcitol","n_c":["C38693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP 1/2 Inhibitor NOV1401","n_c":["C154560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor AZD2461","n_c":["C95201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor CEP-9722","n_c":["C84880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor E7016","n_c":["C91387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP-1/2 Inhibitor ABT-767","n_c":["C96795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP/Tankyrase Inhibitor 2X-121","n_c":["C102746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parsatuzumab","n_c":["C90567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parvovirus H-1","n_c":["C96229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pasireotide","n_c":["C69131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pasotuxizumab","n_c":["C103827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patidegib","n_c":["C80063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patidegib Topical Gel","n_c":["C158420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patritumab","n_c":["C78853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patupilone","n_c":["C1623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pazopanib","n_c":["C74547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pazopanib Hydrochloride","n_c":["C60779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pbi-shRNA STMN1 Lipoplex","n_c":["C99639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBN Derivative OKN-007","n_c":["C77600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCNU","n_c":["C1186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-1 Directed Probody CX-188","n_c":["C160716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-1 Inhibitor","n_c":["C124946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1 Inhibitor INCB086550","n_c":["C158532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1/PD-L2/VISTA Antagonist CA-170","n_c":["C129594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDK1 Inhibitor AR-12","n_c":["C88271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0","n_c":["C157262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1","n_c":["C126276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEG-interleukin-2","n_c":["C1304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1","n_c":["C49178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEG-Proline-Interferon Alfa-2b","n_c":["C111892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegargiminase","n_c":["C91702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegaspargase","n_c":["C1200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegdinetanib","n_c":["C62791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegfilgrastim","n_c":["C1854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegilodecakin","n_c":["C113295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peginterferon Alfa-2a","n_c":["C33987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peginterferon Alfa-2b","n_c":["C1845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegvisomant","n_c":["C61881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Deoxycytidine Analogue DFP-14927","n_c":["C162508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Interferon Alfa","n_c":["C2491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Belotecan","n_c":["C61437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Doxorubicin Hydrochloride","n_c":["C1555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Irinotecan","n_c":["C62789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug","n_c":["C103276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Mitoxantrone Hydrochloride","n_c":["C131307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010","n_c":["C116869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Paclitaxel","n_c":["C63476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant Human Arginase I BCT-100","n_c":["C88286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant Human Hyaluronidase PH20","n_c":["C82659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant Interleukin-2 THOR-707","n_c":["C162645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant L-asparaginase Erwinia chrysanthemi","n_c":["C170297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegzilarginase","n_c":["C125143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelareorep","n_c":["C60774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peldesine","n_c":["C1650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelitinib","n_c":["C2713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelitrexol","n_c":["C2633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pembrolizumab","n_c":["C106432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemetrexed","n_c":["C61614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemetrexed Disodium","n_c":["C1533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemigatinib","n_c":["C121553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemlimogene Merolisbac","n_c":["C124843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penberol","n_c":["C1187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penclomedine","n_c":["C1188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penicillamine","n_c":["C729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentamethylmelamine","n_c":["C1189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentamustine","n_c":["C66341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentostatin","n_c":["C732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentoxifylline","n_c":["C733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEOX-based Polymer Encapsulated Paclitaxel FID-007","n_c":["C148635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEP-3-KLH Conjugate Vaccine","n_c":["C74070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pepinemab","n_c":["C96222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peplomycin","n_c":["C1399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peplomycin Sulfate","n_c":["C1400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptichemio","n_c":["C734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptide 946 Melanoma Vaccine","n_c":["C2466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine","n_c":["C2467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peretinoin","n_c":["C87202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perflenapent Emulsion","n_c":["C116804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perfosfamide","n_c":["C1423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perifosine","n_c":["C1727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perillyl Alcohol","n_c":["C1461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine","n_c":["C159601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Cancer Vaccine RO7198457","n_c":["C175745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01","n_c":["C162633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoepitope Yeast Vaccine YE-NEO-001","n_c":["C158749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Peptide Cancer Vaccine NEO-PV-01","n_c":["C129935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pertuzumab","n_c":["C38692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pevonedistat","n_c":["C77906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pexastimogene Devacirepvec","n_c":["C71533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pexidartinib","n_c":["C88303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pexmetinib","n_c":["C85481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGG Beta-Glucan","n_c":["C78463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGLA/PEG Copolymer-Based Paclitaxel","n_c":["C71692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PH20 Hyaluronidase-expressing Adenovirus VCN-01","n_c":["C113790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phaleria macrocarpa Extract DLBS-1425","n_c":["C91739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharmacological Ascorbate","n_c":["C156461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phellodendron amurense Bark Extract","n_c":["C103230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenesterin","n_c":["C1190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenethyl Isothiocyanate","n_c":["C2233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenethyl Isothiocyanate-containing Watercress Juice","n_c":["C105392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenyl Acetate","n_c":["C1501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenytoin Sodium","n_c":["C48011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphaplatin PT-112","n_c":["C121375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphatidylcholine-Bound Silybin","n_c":["C71883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phospholipid Ether-drug Conjugate CLR 131","n_c":["C84879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphoramide Mustard","n_c":["C29322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphorodiamidate Morpholino Oligomer AVI-4126","n_c":["C62518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphorus P-32","n_c":["C1698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photosensitizer LUZ 11","n_c":["C114382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex","n_c":["C126802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Alpha/Beta Inhibitor BAY1082439","n_c":["C103861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate","n_c":["C97915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor ACP-319","n_c":["C95891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor BGT226","n_c":["C74073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor GDC-0084","n_c":["C116877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor GDC0077","n_c":["C132166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor GSK1059615","n_c":["C78470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor WX-037","n_c":["C107386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor ZSTK474","n_c":["C95723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K p110beta/delta Inhibitor KA2237","n_c":["C126271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-alpha Inhibitor MEN1611","n_c":["C158603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-beta Inhibitor GSK2636771","n_c":["C106261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-beta Inhibitor SAR260301","n_c":["C116882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor AMG 319","n_c":["C95891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor HMPL 689","n_c":["C148532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor INCB050465","n_c":["C113434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor PWT143","n_c":["C123925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor SHC014748M","n_c":["C165266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor YY-20394","n_c":["C158508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-gamma Inhibitor IPI-549","n_c":["C125471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/BET Inhibitor LY294002","n_c":["C148229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor DS-7423","n_c":["C97254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor PF-04691502","n_c":["C84837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor VS-5584","n_c":["C112497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor WXFL10030390","n_c":["C159499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170","n_c":["C104292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901","n_c":["C116351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Ka/mTOR Inhibitor PKI-179","n_c":["C90291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Kalpha Inhibitor AZD8835","n_c":["C118624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Kbeta Inhibitor AZD8186","n_c":["C107684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Kdelta Inhibitor GS-9901","n_c":["C121374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pibenzimol","n_c":["C546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pibrozelesin","n_c":["C1542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pibrozelesin Hydrobromide","n_c":["C73816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picibanil","n_c":["C745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picoplatin","n_c":["C48416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picrasinoside H","n_c":["C1771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picropodophyllin","n_c":["C87736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pictilisib","n_c":["C165479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pictilisib Bismesylate","n_c":["C82380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pidilizumab","n_c":["C71014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pilaralisib","n_c":["C71705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM Kinase Inhibitor LGH447","n_c":["C106259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM Kinase Inhibitor SGI-1776","n_c":["C82404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM Kinase Inhibitor TP-3654","n_c":["C160203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM/FLT3 Kinase Inhibitor SEL24","n_c":["C133540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pimasertib","n_c":["C84864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pingyangmycin","n_c":["C1279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pinometostat","n_c":["C103179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pioglitazone","n_c":["C71633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pioglitazone Hydrochloride","n_c":["C29367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pipendoxifene","n_c":["C1874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piperazinedione","n_c":["C1401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piperine Extract (Standardized)","n_c":["C48417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pipobroman","n_c":["C750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piposulfan","n_c":["C1783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirarubicin","n_c":["C1197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirarubicin Hydrochloride","n_c":["C95319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirfenidone","n_c":["C2635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piritrexim","n_c":["C1031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piritrexim Isethionate","n_c":["C91407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirotinib","n_c":["C121960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piroxantrone","n_c":["C1182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piroxantrone Hydrochloride","n_c":["C72829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pixantrone","n_c":["C26663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pixantrone Dimaleate","n_c":["C82398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231","n_c":["C1810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521","n_c":["C1788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PKC-beta Inhibitor MS-553","n_c":["C148422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placebo","n_c":["C753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pladienolide Derivative E7107","n_c":["C69005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum","n_c":["C756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles","n_c":["C153425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum Compound","n_c":["C1450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plevitrexed","n_c":["C1629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plicamycin","n_c":["C658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plinabulin","n_c":["C62444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plitidepsin","n_c":["C1689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plk1 Inhibitor BI 2536","n_c":["C49091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLK1 Inhibitor CYC140","n_c":["C162375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLK1 Inhibitor TAK-960","n_c":["C92587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plocabulin","n_c":["C95888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plozalizumab","n_c":["C88308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pol I Inhibitor CX5461","n_c":["C126798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polatuzumab Vedotin","n_c":["C104153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polidocanol","n_c":["C158511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poliglusam","n_c":["C157372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 1 Inhibitor GSK461364","n_c":["C70948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 1 Inhibitor MK1496","n_c":["C82389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 1 Inhibitor NMS-1286937","n_c":["C143162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate","n_c":["C111990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poly-alendronate Dextran-Guanidine Conjugate","n_c":["C101894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poly-gamma Glutamic Acid","n_c":["C106124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Analog SL11093","n_c":["C38130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Analogue PG11047","n_c":["C60816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Analogue SBP-101","n_c":["C142788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate","n_c":["C148487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyandrol","n_c":["C1628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyethylene Glycol Recombinant Endostatin","n_c":["C92583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318","n_c":["C125243"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polymer-encapsulated Luteolin Nanoparticle","n_c":["C150508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polymeric Camptothecin Prodrug XMT-1001","n_c":["C69079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polypodium leucotomos Extract","n_c":["C129595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polysaccharide-K","n_c":["C1204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polysialic Acid","n_c":["C1201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyunsaturated Fatty Acid","n_c":["C67038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyvalent Melanoma Vaccine","n_c":["C1633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pomalidomide","n_c":["C72560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pomegranate Juice","n_c":["C26665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pomegranate Liquid Extract","n_c":["C78866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ponatinib","n_c":["C95777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ponatinib Hydrochloride","n_c":["C78194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor CGX1321","n_c":["C146853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor ETC-1922159","n_c":["C123830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor RXC004","n_c":["C156701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor WNT974","n_c":["C116860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porfimer Sodium","n_c":["C1071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porfiromycin","n_c":["C763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poziotinib","n_c":["C98838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PR1 Leukemia Peptide Vaccine","n_c":["C2235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pracinostat","n_c":["C71708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pralatrexate","n_c":["C2250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701","n_c":["C128029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pravastatin Sodium","n_c":["C29375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednimustine","n_c":["C768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisolone","n_c":["C769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisolone Acetate","n_c":["C1202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisolone Sodium Phosphate","n_c":["C1402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisone","n_c":["C770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prexasertib","n_c":["C91392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prexigebersen","n_c":["C91736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRIMA-1 Analog APR-246","n_c":["C85465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prime Cancer Vaccine MVA-BN-CV301","n_c":["C143059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prinomastat","n_c":["C1811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRMT1 Inhibitor GSK3368715","n_c":["C156759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRMT5 Inhibitor JNJ-64619178","n_c":["C163980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proapoptotic Sulindac Analog CP-461","n_c":["C133019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Procarbazine","n_c":["C62072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Procarbazine Hydrochloride","n_c":["C773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Procaspase Activating Compound-1 VO-100","n_c":["C120318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progestational IUD","n_c":["C184790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prohibitin-Targeting Peptide 1","n_c":["C95709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostaglandin E2 EP4 Receptor Inhibitor E7046","n_c":["C129689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Cancer Vaccine ONY-P1","n_c":["C71723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Health Cocktail Dietary Supplement","n_c":["C77860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024","n_c":["C2548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protease-activated Anti-PD-L1 Antibody Prodrug CX-072","n_c":["C132192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Arginine Methyltransferase 5 Inhibitor GSK3326595","n_c":["C142177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999","n_c":["C158100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Arginine Methyltransferase 5 Inhibitor PRT543","n_c":["C162454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Kinase C Inhibitor IDE196","n_c":["C124796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Phosphatase 2A Inhibitor LB-100","n_c":["C106430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Stabilized Liposomal Docetaxel Nanoparticles","n_c":["C90534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proxalutamide","n_c":["C130036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSA/IL-2/GM-CSF Vaccine","n_c":["C114289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSA/PSMA DNA Plasmid INO-5150","n_c":["C123283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pseudoisocytidine","n_c":["C87389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA-targeted Docetaxel Nanoparticles BIND-014","n_c":["C95892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA-targeted Tubulysin B-containing Conjugate EC1169","n_c":["C117291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424","n_c":["C156681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTEF-b/CDK9 Inhibitor BAY1251152","n_c":["C128266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pterostilbene","n_c":["C153353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pumitepa","n_c":["C73239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puquitinib","n_c":["C162555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puquitinib Mesylate","n_c":["C162556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puromycin","n_c":["C787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puromycin Hydrochloride","n_c":["C75148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PV-10","n_c":["C53412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride","n_c":["C71149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrazinamide","n_c":["C29395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrazoloacridine","n_c":["C1564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyridyl Cyanoguanidine CHS 828","n_c":["C1852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrotinib","n_c":["C111895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrotinib Dimaleate","n_c":["C162554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyroxamide","n_c":["C2801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyruvate Kinase Inhibitor TLN-232","n_c":["C67087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Qilisheng Immunoregulatory Oral Solution","n_c":["C155882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","n_c":["C61087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quarfloxin","n_c":["C71726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quinacrine Hydrochloride","n_c":["C67059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quinine","n_c":["C794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quisinostat","n_c":["C77912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quizartinib","n_c":["C68936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R-(-)-Gossypol Acetic Acid","n_c":["C78348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rabusertib","n_c":["C81937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Racotumomab","n_c":["C95024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD51 Inhibitor CYT-0851","n_c":["C165436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radioactive Iodine","n_c":["C2462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiolabeled CC49","n_c":["C2729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radium Ra 223 Dichloride","n_c":["C62535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radium Ra 224-labeled Calcium Carbonate Microparticles","n_c":["C159537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement","n_c":["C113297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radotinib Hydrochloride","n_c":["C99644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raf Kinase Inhibitor HM95573","n_c":["C121646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF Kinase Inhibitor L-779450","n_c":["C2722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF Kinase Inhibitor XL281","n_c":["C69135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ralaniten Acetate","n_c":["C124654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ralimetinib Mesylate","n_c":["C105853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raloxifene","n_c":["C1518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raloxifene Hydrochloride","n_c":["C1762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raltitrexed","n_c":["C1804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ramucirumab","n_c":["C70792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranibizumab","n_c":["C67562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranimustine","n_c":["C1515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranolazine","n_c":["C66507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranpirnase","n_c":["C1183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RARalpha Agonist IRX5183","n_c":["C77899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Inhibitor","n_c":["C1902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Peptide ASP","n_c":["C2802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Peptide CYS","n_c":["C2803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Peptide VAL","n_c":["C2804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Razoxane","n_c":["C801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Realgar-Indigo naturalis Formulation","n_c":["C117289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rebastinib Tosylate","n_c":["C82693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rebeccamycin","n_c":["C1213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rebimastat","n_c":["C1875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Receptor Tyrosine Kinase Inhibitor R1530","n_c":["C71710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Adenovirus-p53 SCH-58500","n_c":["C2423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A","n_c":["C116880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Bispecific Single-Chain Antibody rM28","n_c":["C60882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant CD40-Ligand","n_c":["C1437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Erythropoietin","n_c":["C477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Fas Ligand","n_c":["C1538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Fractalkine","n_c":["C2257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","n_c":["C1288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human 6Ckine","n_c":["C1792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Adenovirus Type 5 H101","n_c":["C107504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Angiotensin Converting Enzyme 2 APN01","n_c":["C85447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Apolipoprotein(a) Kringle V MG1102","n_c":["C116864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine","n_c":["C70674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Endostatin","n_c":["C45515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine","n_c":["C103830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Papillomavirus Bivalent Vaccine","n_c":["C48395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Papillomavirus Nonavalent Vaccine","n_c":["C119664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828","n_c":["C162524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon","n_c":["C584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa","n_c":["C225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa-1b","n_c":["C53411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa-2a","n_c":["C1952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa-2b","n_c":["C1953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alpha 2b-like Protein","n_c":["C97503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Beta","n_c":["C495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Gamma","n_c":["C583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-12","n_c":["C1380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-13","n_c":["C1489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-18","n_c":["C1680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-2","n_c":["C587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-6","n_c":["C591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant KSA Glycoprotein CO17-1A","n_c":["C28721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Leukocyte Interleukin","n_c":["C2413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Leukoregulin","n_c":["C1143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Luteinizing Hormone","n_c":["C612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Macrophage Colony-Stimulating Factor","n_c":["C1290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant MAGE-3.1 Antigen","n_c":["C38724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant MIP1-alpha Variant ECI301","n_c":["C98294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine","n_c":["C49087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Oncolytic Poliovirus PVS-RIPO","n_c":["C99459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Platelet Factor 4","n_c":["C2251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A","n_c":["C92586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207","n_c":["C82371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Super-compound Interferon","n_c":["C121542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Thyroglobulin","n_c":["C884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Thyrotropin Alfa","n_c":["C61322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Transforming Growth Factor-Beta","n_c":["C898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Transforming Growth Factor-Beta-2","n_c":["C1286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Tumor Necrosis Factor-Alpha","n_c":["C913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Tyrosinase-Related Protein-2","n_c":["C38682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","n_c":["C131580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Refametinib","n_c":["C74059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regorafenib","n_c":["C78204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relacorilant","n_c":["C127838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relatlimab","n_c":["C111999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relugolix","n_c":["C114498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Remetinostat","n_c":["C97513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Cell Carcinoma Peptides Vaccine IMA901","n_c":["C70968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reparixin","n_c":["C66515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repotrectinib","n_c":["C133821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resiquimod","n_c":["C63958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resiquimod Topical Gel","n_c":["C88259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resistant Starch","n_c":["C94233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resminostat","n_c":["C84856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resveratrol","n_c":["C1215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resveratrol Formulation SRT501","n_c":["C85484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET Inhibitor DS-5010","n_c":["C158093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET Mutation/Fusion Inhibitor BLU-667","n_c":["C132295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retaspimycin","n_c":["C80378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retaspimycin Hydrochloride","n_c":["C48401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retelliptine","n_c":["C73241"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinoic Acid Agent Ro 16-9100","n_c":["C64174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinoid 9cUAB30","n_c":["C80061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinol","n_c":["C68302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinyl Acetate","n_c":["C1216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinyl Palmitate","n_c":["C1217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retrovector Encoding Mutant Anti-Cyclin G1","n_c":["C49082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rexinoid NRX 194204","n_c":["C74076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RFT5-dgA Immunotoxin IMTOX25","n_c":["C61498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re 188 BMEDA-labeled Liposomes","n_c":["C118670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re-186 Hydroxyethylidene Diphosphonate","n_c":["C1562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re-188 Ethiodized Oil","n_c":["C91390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re-188 Etidronate","n_c":["C156698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhizoxin","n_c":["C1218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RhoC Peptide Vaccine RV001V","n_c":["C151937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribociclib","n_c":["C95701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribociclib/Letrozole","n_c":["C154675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribonuclease QBI-139","n_c":["C82689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribosome-Inactivating Protein CY503","n_c":["C78188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribozyme RPI.4610","n_c":["C1865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rice Bran","n_c":["C111686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ricolinostat","n_c":["C96431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ridaforolimus","n_c":["C49061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rigosertib","n_c":["C152216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rigosertib Sodium","n_c":["C71355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilimogene Galvacirepvec","n_c":["C38681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","n_c":["C132990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilimogene Glafolivec","n_c":["C29560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilotumumab","n_c":["C67079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rindopepimut","n_c":["C69076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RIPK1 Inhibitor GSK3145095","n_c":["C156737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ripretinib","n_c":["C124067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Risperidone Formulation in Rumenic Acid","n_c":["C131306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ritrosulfan","n_c":["C75294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rituximab","n_c":["C1702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rituximab and Hyaluronidase Human","n_c":["C136821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rituximab Conjugate CON-4619","n_c":["C148162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Riviciclib","n_c":["C64762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rivoceranib","n_c":["C152237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rivoceranib Mesylate","n_c":["C74012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNR Inhibitor COH29","n_c":["C114976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Robatumumab","n_c":["C71527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rocapuldencel-T","n_c":["C77907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rociletinib","n_c":["C99905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rodorubicin","n_c":["C97275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rofecoxib","n_c":["C1832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roflumilast","n_c":["C76890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rogaratinib","n_c":["C112205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rogletimide","n_c":["C1427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Romidepsin","n_c":["C1544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roniciclib","n_c":["C92579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ropidoxuridine","n_c":["C48813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roquinimex","n_c":["C1519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RORgamma Agonist LYC-55716","n_c":["C131294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosabulin","n_c":["C77066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rose Bengal Solution PV-10","n_c":["C53412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosiglitazone Maleate","n_c":["C2583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosmantuzumab","n_c":["C122921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosuvastatin","n_c":["C66523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rovalpituzumab Tesirine","n_c":["C107678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubitecan","n_c":["C1485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rucaparib","n_c":["C137800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rucaparib Camsylate","n_c":["C131178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rucaparib Phosphate","n_c":["C78186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruthenium Ru-106","n_c":["C38686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruthenium-based Transferrin Targeting Agent NKP-1339","n_c":["C97948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruxolitinib","n_c":["C77888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruxolitinib Phosphate","n_c":["C97937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S-Adenosylmethionine","n_c":["C63661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S-equol","n_c":["C120313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S1P Receptor Agonist KRP203","n_c":["C106368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sabarubicin","n_c":["C1706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacituzumab Govitecan","n_c":["C102783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacubitril/Valsartan","n_c":["C162629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Safingol","n_c":["C1568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sagopilone","n_c":["C61072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salirasib","n_c":["C71146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salmonella VNP20009","n_c":["C2556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sam68 Modulator CWP232291","n_c":["C97663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samalizumab","n_c":["C77891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samarium Sm 153-DOTMP","n_c":["C165558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samotolisib","n_c":["C121817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sapacitabine","n_c":["C64541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sapanisertib","n_c":["C90548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sapitinib","n_c":["C77887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saracatinib","n_c":["C48378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saracatinib Difumarate","n_c":["C95224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SarCNU","n_c":["C963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sardomozide","n_c":["C1673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sargramostim","n_c":["C1492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Satraplatin","n_c":["C1493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Savolitinib","n_c":["C104732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SBIL-2","n_c":["C29418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scopoletin","n_c":["C126100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seclidemstat","n_c":["C154328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sedoxantrone Trihydrochloride","n_c":["C1576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selatinib Ditosilate","n_c":["C111764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Androgen Receptor Modulator RAD140","n_c":["C137950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Cytokine Inhibitory Drug CC-1088","n_c":["C2210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader AZD9496","n_c":["C122834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader AZD9833","n_c":["C160603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader LSZ102","n_c":["C128280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader SRN-927","n_c":["C120037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Modulator CC-8490","n_c":["C38711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Modulator TAS-108","n_c":["C61494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Glucocorticoid Receptor Antagonist CORT125281","n_c":["C153309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","n_c":["C150363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seliciclib","n_c":["C62783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selicrelumab","n_c":["C119740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selinexor","n_c":["C102546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selitrectinib","n_c":["C138160"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selonsertib","n_c":["C121943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selpercatinib","n_c":["C134987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selumetinib","n_c":["C66939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selumetinib Sulfate","n_c":["C95225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Semaxanib","n_c":["C1831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Semuloparin","n_c":["C78447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Semustine","n_c":["C827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seneca Valley Virus-001","n_c":["C62524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seocalcitol","n_c":["C26669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sepantronium Bromide","n_c":["C61091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serabelisib","n_c":["C98844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD D-0502","n_c":["C156735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD G1T48","n_c":["C175853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD GDC-9545","n_c":["C147030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD SAR439859","n_c":["C174915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD SHR9549","n_c":["C165550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serdemetan","n_c":["C77904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sergiolide","n_c":["C1763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seribantumab","n_c":["C78859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serine/Threonine Kinase Inhibitor CBP501","n_c":["C71529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serine/Threonine Kinase Inhibitor XL418","n_c":["C68963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sevacizumab","n_c":["C122403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seviteronel","n_c":["C113652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shared Anti-Idiotype-AB-S006","n_c":["C29424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shared Anti-Idiotype-AB-S024A","n_c":["C29432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shark Cartilage","n_c":["C2318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shark Cartilage Extract AE-941","n_c":["C1798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sho-Saiko-To","n_c":["C2690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Short Chain Fatty Acid HQK-1004","n_c":["C2570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP-1 Agonist SC-43","n_c":["C156695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor JAB-3068","n_c":["C160207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor RMC-4630","n_c":["C155850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor TNO155","n_c":["C139559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shu Yu Wan Formula","n_c":["C120207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialyl Tn Antigen","n_c":["C1226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialyl Tn-KLH Vaccine","n_c":["C1690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sibrotuzumab","n_c":["C156438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"siG12D LODER","n_c":["C95772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silatecan AR-67","n_c":["C64618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silibinin","n_c":["C152359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silicon Phthalocyanine 4","n_c":["C2651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silmitasertib Sodium","n_c":["C85460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Siltuximab","n_c":["C61084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simalikalactone D","n_c":["C1227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simeprevir","n_c":["C129015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simotaxel","n_c":["C116871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simtuzumab","n_c":["C91735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sintilimab","n_c":["C132992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Siplizumab","n_c":["C38685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sipuleucel-T","n_c":["C1985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401","n_c":["C116353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sirolimus","n_c":["C1212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-Fc Fusion Protein TTI-621","n_c":["C125718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-IgG4-Fc Fusion Protein TTI-622","n_c":["C150756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sitimagene Ceradenovec","n_c":["C162553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sitravatinib","n_c":["C117734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sivifene","n_c":["C61305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sizofiran","n_c":["C824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC6A8 Inhibitor RGX-202","n_c":["C153354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLCT Inhibitor GNS561","n_c":["C184909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAC Mimetic BI 891065","n_c":["C150507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smac Mimetic GDC-0152","n_c":["C88274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smac Mimetic GDC-0917","n_c":["C103825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smac Mimetic LCL161","n_c":["C91079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMO Protein Inhibitor ZSP1602","n_c":["C159535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist BMS-833923","n_c":["C77861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist LDE225 Topical","n_c":["C88337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist LEQ506","n_c":["C91089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist TAK-441","n_c":["C116874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SN-38-Loaded Polymeric Micelles NK012","n_c":["C71521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SNS01-T Nanoparticles","n_c":["C98288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sobuzoxane","n_c":["C66540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Borocaptate","n_c":["C2208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Butyrate","n_c":["C2337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Dichloroacetate","n_c":["C73591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Iodide I-131","n_c":["C47725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Metaarsenite","n_c":["C91098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Phenylbutyrate","n_c":["C1440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Salicylate","n_c":["C834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Selenite","n_c":["C87346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Stibogluconate","n_c":["C61083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108","n_c":["C156728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sofituzumab Vedotin","n_c":["C106119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solitomab","n_c":["C77854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sonepcizumab","n_c":["C78195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sonidegib","n_c":["C82385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sonolisib","n_c":["C78848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorafenib","n_c":["C61948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorafenib Tosylate","n_c":["C2194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorghum bicolor Supplement","n_c":["C111681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotrastaurin","n_c":["C80630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotrastaurin Acetate","n_c":["C80631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soy Isoflavones","n_c":["C65152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soy Protein Isolate","n_c":["C1803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sparfosate Sodium","n_c":["C2353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sparfosic Acid","n_c":["C1398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spartalizumab","n_c":["C121625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spebrutinib","n_c":["C97037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spherical Nucleic Acid Nanoparticle NU-0129","n_c":["C131368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spirogermanium","n_c":["C1232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spiromustine","n_c":["C1233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spiroplatin","n_c":["C1234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splicing Inhibitor H3B-8800","n_c":["C129546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spongistatin","n_c":["C2051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squalamine Lactate","n_c":["C1482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SR-BP1/HSI Inhibitor SR31747A","n_c":["C61435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SR-T100 Gel","n_c":["C99460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor AP 23846","n_c":["C162533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor KX2-391","n_c":["C74077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor KX2-391 Ointment","n_c":["C120210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor M475271","n_c":["C162339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src/Abl Kinase Inhibitor AZD0424","n_c":["C102976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src/tubulin Inhibitor KX02","n_c":["C120101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ssRNA-based Immunomodulator CV8102","n_c":["C150401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSTR2-targeting Protein/DM1 Conjugate PEN-221","n_c":["C131562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"St. John's Wort","n_c":["C2589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stallimycin","n_c":["C1517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcal Enterotoxin A","n_c":["C1083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcal Enterotoxin B","n_c":["C1084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT Inhibitor OPB-111077","n_c":["C116873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor DSP-0337","n_c":["C151994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor OPB-31121","n_c":["C90588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor OPB-51602","n_c":["C95889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor TTI-101","n_c":["C151932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor WP1066","n_c":["C111042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staurosporine","n_c":["C1237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist MK-1454","n_c":["C132258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING-activating Cyclic Dinucleotide Agonist MIW815","n_c":["C125902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Streptonigrin","n_c":["C844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Streptozocin","n_c":["C845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Strontium Chloride Sr-89","n_c":["C1238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submicron Particle Paclitaxel Sterile Suspension","n_c":["C162773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulfatinib","n_c":["C116066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulforaphane","n_c":["C1424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulindac","n_c":["C850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulofenur","n_c":["C1432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sumoylation Inhibitor TAK-981","n_c":["C156270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sunitinib","n_c":["C71622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sunitinib Malate","n_c":["C26673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Super Enhancer Inhibitor GZ17-6.02","n_c":["C158082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803","n_c":["C107503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suramin","n_c":["C853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suramin Sodium","n_c":["C1848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin Antigen","n_c":["C37449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin Antigen Vaccine DPX-Survivac","n_c":["C97951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin mRNA Antagonist EZN-3042","n_c":["C92578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin-expressing CVD908ssb-TXSVN Vaccine","n_c":["C158607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sustained-release Lipid Inhaled Cisplatin","n_c":["C116884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101","n_c":["C126642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102","n_c":["C158422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syk Inhibitor HMPL-523","n_c":["C123912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synchrotope TA2M Plasmid DNA Vaccine","n_c":["C2650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synchrovax SEM Plasmid DNA Vaccine","n_c":["C28549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Alkaloid PM00104","n_c":["C62763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2","n_c":["C116332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1","n_c":["C116331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic hTERT DNA Vaccine INO-1400","n_c":["C120118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic hTERT DNA Vaccine INO-1401","n_c":["C142139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Hypericin","n_c":["C122400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201","n_c":["C129652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Long E6/E7 Peptides Vaccine HPV-01","n_c":["C111037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b","n_c":["C150809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T900607","n_c":["C26674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tabalumab","n_c":["C91727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tabelecleucel","n_c":["C143140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tacedinaline","n_c":["C2202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tagraxofusp-erzs","n_c":["C64769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talabostat","n_c":["C48264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talabostat Mesylate","n_c":["C80682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talacotuzumab","n_c":["C102784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talactoferrin Alfa","n_c":["C78460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taladegib","n_c":["C103826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talampanel","n_c":["C38139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talaporfin Sodium","n_c":["C26675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talazoparib","n_c":["C95733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talimogene Laherparepvec","n_c":["C61314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tallimustine","n_c":["C1603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talmapimod","n_c":["C79841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talotrexin","n_c":["C29341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talotrexin Ammonium","n_c":["C80159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taltobulin","n_c":["C75998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAM/c-Met Inhibitor RXDX-106","n_c":["C150585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamibarotene","n_c":["C71025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taminadenant","n_c":["C121664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamoxifen","n_c":["C62078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamoxifen Citrate","n_c":["C855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tandutinib","n_c":["C48404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanespimycin","n_c":["C37899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanibirumab","n_c":["C102877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanomastat","n_c":["C1705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tarenflurbil","n_c":["C26666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tarextumab","n_c":["C95719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tariquidar","n_c":["C2246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taselisib","n_c":["C116876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasidotin","n_c":["C77067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasisulam","n_c":["C62794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasisulam Sodium","n_c":["C88304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasquinimod","n_c":["C74080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taurolidine","n_c":["C2639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tauromustine","n_c":["C954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taurultam","n_c":["C75290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taurultam Analogue GP-2250","n_c":["C159500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tavokinogene Telseplasmid","n_c":["C156363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tavolimab","n_c":["C120041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taxane Analogue TPI 287","n_c":["C48424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taxane Compound","n_c":["C1490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taxol Analogue SID 530","n_c":["C84839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tazarotene","n_c":["C29487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tazemetostat","n_c":["C107506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tecogalan Sodium","n_c":["C1605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur","n_c":["C513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur-gimeracil-oteracil Potassium","n_c":["C1833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation","n_c":["C120099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur-Uracil","n_c":["C9506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegavivint","n_c":["C155885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teglarinad","n_c":["C90746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teglarinad Chloride","n_c":["C68931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telapristone","n_c":["C104057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telapristone Acetate","n_c":["C104055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telatinib Mesylate","n_c":["C87837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telisotuzumab Vedotin","n_c":["C118571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telomerase Inhibitor FJ5002","n_c":["C2715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telomerase-specific Type 5 Adenovirus OBP-301","n_c":["C119617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teloxantrone","n_c":["C1520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teloxantrone Hydrochloride","n_c":["C74544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telratolimod","n_c":["C124653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temarotene","n_c":["C63953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temoporfin","n_c":["C1669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temozolomide","n_c":["C1244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temsirolimus","n_c":["C1844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tenalisib","n_c":["C113433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tenifatecan","n_c":["C64772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teniposide","n_c":["C857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tepotinib","n_c":["C88314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teprotumumab","n_c":["C95797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Terameprocol","n_c":["C61441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Terfluranol","n_c":["C75292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tergenpumatucel-L","n_c":["C66985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teroxirone","n_c":["C2320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tertomotide","n_c":["C62756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tesetaxel","n_c":["C37451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tesevatinib","n_c":["C62496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tesidolumab","n_c":["C129315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testolactone","n_c":["C2301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testosterone Enanthate","n_c":["C1247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetanus Toxoid Vaccine","n_c":["C2660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetradecanoylphorbol Acetate","n_c":["C866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetrahydrouridine","n_c":["C868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetraphenyl Chlorin Disulfonate","n_c":["C88344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetrathiomolybdate","n_c":["C160684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tezacitabine","n_c":["C1539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tezacitabine Anhydrous","n_c":["C95916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGF-beta Receptor 1 Inhibitor PF-06952229","n_c":["C160258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFa-PE38 Immunotoxin","n_c":["C29483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFbeta Inhibitor LY3200882","n_c":["C132013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200","n_c":["C159817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thalicarpine","n_c":["C869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thalidomide","n_c":["C870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Theliatinib","n_c":["C162552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Theramide","n_c":["C2385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Angiotensin-(1-7)","n_c":["C68962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907","n_c":["C91077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Estradiol","n_c":["C478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Hydrocortisone","n_c":["C555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Liver Cancer Peptide Vaccine IMA970A","n_c":["C151942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiarabine","n_c":["C92589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiodiglycol","n_c":["C75295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioguanine","n_c":["C876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioguanine Anhydrous","n_c":["C61970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioinosine","n_c":["C877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioredoxin-1 Inhibitor PX-12","n_c":["C74082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiotepa","n_c":["C875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioureidobutyronitrile","n_c":["C102881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"THL-P","n_c":["C88275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anetumab","n_c":["C155977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Threonine Tyrosine Kinase Inhibitor CFI-402257","n_c":["C128288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymidylate Synthase Inhibitor DFP-11207","n_c":["C116720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymopentin","n_c":["C1294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Extract","n_c":["C2565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiazofurin","n_c":["C1254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tidutamab","n_c":["C146820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tigapotide","n_c":["C78474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tigatuzumab","n_c":["C62482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TIGIT-targeting Agent MK-7684","n_c":["C140041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tilarginine","n_c":["C1178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tilsotolimod Sodium","n_c":["C125080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Timonacic","n_c":["C2354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tin Ethyl Etiopurpurin","n_c":["C1255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tinostamustine","n_c":["C126105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tinzaparin Sodium","n_c":["C60810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiomolibdate Diammonium","n_c":["C74001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipapkinogene Sovacivec","n_c":["C88326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipifarnib","n_c":["C1703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipiracil","n_c":["C152646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipiracil Hydrochloride","n_c":["C152647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tirabrutinib","n_c":["C102876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiragolumab","n_c":["C131291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tirapazamine","n_c":["C1464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tisagenlecleucel","n_c":["C102758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tislelizumab","n_c":["C121775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tisotumab Vedotin","n_c":["C113164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tivantinib","n_c":["C62437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tivozanib","n_c":["C85444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLC ELL-12","n_c":["C2102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR Agonist BDB001","n_c":["C156395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR Agonist BSG-001","n_c":["C158747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR Agonist CADI-05","n_c":["C77884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100","n_c":["C82353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7 Agonist 852A","n_c":["C61104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7/8/9 Antagonist IMO-8400","n_c":["C114975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR8 Agonist DN1508052","n_c":["C160500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR9 Agonist AST-008","n_c":["C157771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocilizumab","n_c":["C84217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocladesine","n_c":["C2571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocotrienol","n_c":["C68318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocotrienol-rich Fraction","n_c":["C101518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toll-like Receptor 7 Agonist DSP-0509","n_c":["C153314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tolnidamine","n_c":["C75293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tomaralimab","n_c":["C120554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tomato-Soy Juice","n_c":["C88300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tomivosertib","n_c":["C125062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Betulinic Acid","n_c":["C78477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Celecoxib","n_c":["C148519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Fluorouracil","n_c":["C125194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Gemcitabine Hydrochloride","n_c":["C74085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Potassium Dobesilate","n_c":["C151946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Trichloroacetic Acid","n_c":["C125002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topixantrone","n_c":["C75124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I Inhibitor Genz-644282","n_c":["C84851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I Inhibitor LMP400","n_c":["C90594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I Inhibitor LMP776","n_c":["C90595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I/II Inhibitor NEV-801","n_c":["C128557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase-1 Inhibitor LMP744","n_c":["C127900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase-II Inhibitor Racemic XK469","n_c":["C2825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase-II-beta Inhibitor Racemic XK469","n_c":["C2662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan","n_c":["C1413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan Hydrochloride","n_c":["C2828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan Hydrochloride Liposomes","n_c":["C80065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topsalysin","n_c":["C64779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TORC1/2 Kinase Inhibitor DS-3078a","n_c":["C101795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toremifene","n_c":["C1256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toremifene Citrate","n_c":["C1756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toripalimab","n_c":["C131334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tosedostat","n_c":["C70650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tositumomab","n_c":["C2543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Androgen Blockade","n_c":["C94614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tovetumab","n_c":["C82684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tozasertib Lactate","n_c":["C61319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP40 Immunotoxin","n_c":["C2374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trabectedin","n_c":["C1691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trabedersen","n_c":["C80066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRAIL Receptor Agonist ABBV-621","n_c":["C146854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trametinib","n_c":["C77908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trametinib Dimethyl Sulfoxide","n_c":["C152711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trans Sodium Crocetinate","n_c":["C82695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transdermal 17beta-Estradiol Gel BHR-200","n_c":["C120308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transdermal 4-Hydroxytestosterone","n_c":["C114103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01","n_c":["C78450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transferrin Receptor-Targeted Liposomal p53 cDNA","n_c":["C29474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transferrin-CRM107","n_c":["C26676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tranylcypromine Sulfate","n_c":["C61980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trapoxin","n_c":["C1665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab","n_c":["C1647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Conjugate BI-CON-02","n_c":["C148165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Duocarmazine","n_c":["C118674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Emtansine","n_c":["C82492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab/Hyaluronidase-oysk","n_c":["C158060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502","n_c":["C139800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trebananib","n_c":["C91711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tremelimumab","n_c":["C49085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treosulfan","n_c":["C1257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tretazicar","n_c":["C81554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tretinoin","n_c":["C900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tretinoin Liposome","n_c":["C2398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triamcinolone Acetonide","n_c":["C48027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triamcinolone Hexacetonide","n_c":["C48026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triapine","n_c":["C2242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triazene Derivative CB10-277","n_c":["C2367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triazene Derivative TriN2755","n_c":["C95208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triazinate","n_c":["C1258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triaziquone","n_c":["C903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tributyrin","n_c":["C1260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triciribine Phosphate","n_c":["C1262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trientine Hydrochloride","n_c":["C61987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triethylenemelamine","n_c":["C29858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trifluridine","n_c":["C905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trifluridine and Tipiracil Hydrochloride","n_c":["C102554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trigriluzole","n_c":["C142847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trilaciclib","n_c":["C123281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimelamol","n_c":["C29485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimeric GITRL-Fc OMP-336B11","n_c":["C143155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimethylcolchicinic Acid","n_c":["C1264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimetrexate","n_c":["C1314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimetrexate Glucuronate","n_c":["C1265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trioxifene","n_c":["C1266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triplatin Tetranitrate","n_c":["C1827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triptolide Analog","n_c":["C111762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triptorelin","n_c":["C1267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triptorelin Pamoate","n_c":["C29523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tritylcysteine","n_c":["C1758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRK Inhibitor AZD6918","n_c":["C80491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TrkA Inhibitor VMD-928","n_c":["C153116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trodusquemine","n_c":["C123882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trofosfamide","n_c":["C1268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troglitazone","n_c":["C1522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tropomyosin Receptor Kinase Inhibitor AZD7451","n_c":["C99161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troxacitabine","n_c":["C1438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troxacitabine Nucleotide Prodrug MIV-818","n_c":["C157496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRPM8 Agonist D-3263","n_c":["C162345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRPV6 Calcium Channel Inhibitor SOR-C13","n_c":["C101525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSP-1 Mimetic ABT-510","n_c":["C37447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSP-1 Mimetic Fusion Protein CVX-045","n_c":["C82384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubercidin","n_c":["C911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Binding Agent TTI-237","n_c":["C77064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Inhibitor ALB 109564 Dihydrochloride","n_c":["C78842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Inhibitor ALB-109564","n_c":["C162527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Polymerization Inhibitor AEZS 112","n_c":["C162525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Polymerization Inhibitor CKD-516","n_c":["C101264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Polymerization Inhibitor VERU-111","n_c":["C158517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin-Binding Agent SSR97225","n_c":["C71525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tucatinib","n_c":["C77896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tucidinostat","n_c":["C97263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tucotuzumab Celmoleukin","n_c":["C2630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyroserleutide","n_c":["C77856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinase Peptide","n_c":["C2401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinase-KLH","n_c":["C2384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinase:146-156 Peptide","n_c":["C48630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor","n_c":["C1967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor OSI-930","n_c":["C70981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor SU5402","n_c":["C1725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor XL228","n_c":["C68929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UAE Inhibitor TAK-243","n_c":["C113788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ubenimex","n_c":["C1015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ubidecarenone Nanodispersion BPM31510n","n_c":["C118621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ublituximab","n_c":["C91078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulinastatin","n_c":["C102851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulixertinib","n_c":["C104744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulocuplumab","n_c":["C95755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbralisib","n_c":["C104413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uncaria tomentosa Extract","n_c":["C113799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upamostat","n_c":["C73985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uproleselan","n_c":["C119743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uprosertib","n_c":["C84870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uracil Ointment","n_c":["C91083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urelumab","n_c":["C62449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uroacitides","n_c":["C162545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urokinase-Derived Peptide A6","n_c":["C91709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP14/UCHL5 Inhibitor VLX1570","n_c":["C121215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Utomilumab","n_c":["C116619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"V930 Vaccine","n_c":["C61069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaccine-Sensitized Draining Lymph Node Cells","n_c":["C2542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules","n_c":["C102748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vactosertib","n_c":["C116357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vadacabtagene Leraleucel","n_c":["C133718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vadastuximab Talirine","n_c":["C111039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vadimezan","n_c":["C2504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valproic Acid","n_c":["C29536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valrubicin","n_c":["C1340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valspodar","n_c":["C1405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vandetanib","n_c":["C2737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vandetanib-eluting Radiopaque Bead BTG-002814","n_c":["C150384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vandortuzumab Vedotin","n_c":["C116748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vantictumab","n_c":["C96799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vanucizumab","n_c":["C118578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vapreotide","n_c":["C1429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varlilumab","n_c":["C99127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varlitinib","n_c":["C62530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varlitinib Tosylate","n_c":["C95226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disrupting Agent BNC105","n_c":["C162343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disrupting Agent BNC105P","n_c":["C88338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disrupting Agent ZD6126","n_c":["C2736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vatalanib","n_c":["C1868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vatalanib Succinate","n_c":["C74945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vecabrutinib","n_c":["C136416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vector-peptide Conjugated Paclitaxel","n_c":["C70971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vedolizumab","n_c":["C95798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGF Inhibitor PTC299","n_c":["C91100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGF/HGF-targeting DARPin MP0250","n_c":["C117236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR Inhibitor KRN951","n_c":["C88267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR-2 DNA Vaccine VXM01","n_c":["C99378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR/FGFR Inhibitor ODM-203","n_c":["C118628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593","n_c":["C79794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210","n_c":["C97950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813","n_c":["C61507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veliparib","n_c":["C60768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veltuzumab","n_c":["C48406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vemurafenib","n_c":["C64768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venetoclax","n_c":["C103147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verapamil","n_c":["C928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verpasep Caltespen","n_c":["C2811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verubulin","n_c":["C96747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verubulin Hydrochloride","n_c":["C64782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vesigenurtucel-L","n_c":["C113653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220","n_c":["C2016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820","n_c":["C49090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Viagenpumatucel-L","n_c":["C61073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vilaprisan","n_c":["C148505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinblastine","n_c":["C930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinblastine Sulfate","n_c":["C931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine","n_c":["C933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine Liposomal","n_c":["C2104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine Sulfate","n_c":["C1739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine Sulfate Liposome","n_c":["C2702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vindesine","n_c":["C934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinepidine","n_c":["C1274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinflunine","n_c":["C61564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinflunine Ditartrate","n_c":["C76266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinfosiltine","n_c":["C2378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine","n_c":["C1275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine Tartrate","n_c":["C1395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine Tartrate Emulsion","n_c":["C66943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine Tartrate Oral","n_c":["C85457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vintafolide","n_c":["C62525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinzolidine","n_c":["C1276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinzolidine Sulfate","n_c":["C87288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virulizin","n_c":["C26677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vismodegib","n_c":["C74038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vistusertib","n_c":["C88329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitamin D3 Analogue ILX23-7553","n_c":["C1883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitamin E Compound","n_c":["C942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitespen","n_c":["C2432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VLP-encapsulated TLR9 Agonist CMP-001","n_c":["C175875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vocimagene Amiretrorepvec","n_c":["C91734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vofatamab","n_c":["C116863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Volasertib","n_c":["C79844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Volociximab","n_c":["C48426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vonlerolizumab","n_c":["C121376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vopratelimab","n_c":["C129876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorinostat","n_c":["C1796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorolanib","n_c":["C95896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorsetzumab Mafodotin","n_c":["C88315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vosaroxin","n_c":["C95148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Voxtalisib","n_c":["C71704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Warfarin Sodium","n_c":["C1658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Carrot","n_c":["C126649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wnt Signaling Inhibitor SM04755","n_c":["C122693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wnt Signaling Pathway Inhibitor SM08502","n_c":["C142777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wnt-5a Mimic Hexapeptide Foxy-5","n_c":["C113435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wobe-Mugos E","n_c":["C28501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1 Peptide Vaccine OCV-501","n_c":["C106257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1 Peptide Vaccine WT2725","n_c":["C102751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1 Protein-derived Peptide Vaccine DSP-7888","n_c":["C121957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1-A10/AS01B Immunotherapeutic GSK2130579A","n_c":["C78865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401","n_c":["C148480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xanthohumol","n_c":["C121950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","n_c":["C103823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xeloda","n_c":["C1794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xentuzumab","n_c":["C106118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xiaoai Jiedu Decoction","n_c":["C165272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XIAP Antisense Oligonucleotide AEG35156","n_c":["C49180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XIAP/cIAP1 Antagonist ASTX660","n_c":["C123913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPO1 Inhibitor SL-801","n_c":["C171660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody CC49","n_c":["C2597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody HMFG1","n_c":["C2541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody Lym-1","n_c":["C2247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody m170","n_c":["C2532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody M195","n_c":["C2248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yang Yin Fu Zheng","n_c":["C132024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yangzheng Xiaoji Extract","n_c":["C111897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yiqi-yangyin-jiedu Herbal Decoction","n_c":["C132026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12","n_c":["C74092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12","n_c":["C74093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","n_c":["C95698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","n_c":["C122405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66","n_c":["C77885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Basiliximab","n_c":["C99167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Colloid","n_c":["C114495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Daclizumab","n_c":["C2600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A","n_c":["C77853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Glass Microspheres","n_c":["C38679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody B3","n_c":["C2614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody BrE-3","n_c":["C2607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody Hu3S193","n_c":["C38678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody MN-14","n_c":["C2249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Resin Microspheres","n_c":["C64539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-DOTA-Biotin","n_c":["C1808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","n_c":["C119738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-Edotreotide","n_c":["C2601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101","n_c":["C99168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Clivatuzumab Tetraxetan","n_c":["C48429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Epratuzumab Tetraxetan","n_c":["C2582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Ibritumomab Tiuxetan","n_c":["C1812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Tacatuzumab Tetraxetan","n_c":["C48428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium-90 Polycarbonate Brachytherapy Plaque","n_c":["C80739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Z-Endoxifen Hydrochloride","n_c":["C95713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zalcitabine","n_c":["C430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zalifrelimab","n_c":["C126113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zalutumumab","n_c":["C64620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zanolimumab","n_c":["C91701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zanubrutinib","n_c":["C141428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zebularine","n_c":["C37455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zibotentan","n_c":["C48430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinc Finger Nuclease ZFN-603","n_c":["C129588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinc Finger Nuclease ZFN-758","n_c":["C129589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinostatin","n_c":["C682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinostatin Stimalamer","n_c":["C162544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zirconium Zr 89 Panitumumab","n_c":["C156043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ziv-Aflibercept","n_c":["C2682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zolbetuximab","n_c":["C85475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zoledronic Acid","n_c":["C1699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zoptarelin Doxorubicin","n_c":["C74025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zorubicin","n_c":["C91365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zorubicin Hydrochloride","n_c":["C1458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zuclomiphene Citrate","n_c":["C28322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3'-dA Phosphoramidate NUC-7738","n_c":["C171381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"A2A Receptor Antagonist EOS100850","n_c":["C172109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist CS3005","n_c":["C175468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","n_c":["C173640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918","n_c":["C167360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931","n_c":["C167361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor TAE684","n_c":["C171615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/ROS1/Met Inhibitor TQ-B3101","n_c":["C173430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715","n_c":["C165779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A","n_c":["C171066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells","n_c":["C173967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD19 CAR T-cells ALLO-501A","n_c":["C172708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101","n_c":["C173959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S","n_c":["C174397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A","n_c":["C168570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22","n_c":["C165696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001","n_c":["C173877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001","n_c":["C170887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120","n_c":["C172741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130","n_c":["C173153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A","n_c":["C165661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01","n_c":["C173427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19","n_c":["C174401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allosteric ErbB Inhibitor BDTX-189","n_c":["C171059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alobresib","n_c":["C126640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alofanib","n_c":["C170744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha V Beta 8 Antagonist PF-06940434","n_c":["C172097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alsevalimab","n_c":["C155967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amivantamab","n_c":["C124993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andecaliximab","n_c":["C105803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Degrader CC-94676","n_c":["C173364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Inhibitor EPI-7386","n_c":["C173374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10","n_c":["C172104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anhydrous Enol-oxaloacetate","n_c":["C168687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-5T4 Antibody-drug Conjugate ASN004","n_c":["C173556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-5T4 Antibody-drug Conjugate SYD1875","n_c":["C175444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a","n_c":["C171577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody-drug Conjugate CC-99712","n_c":["C170915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA","n_c":["C167337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459","n_c":["C165656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BTLA Monoclonal Antibody TAB004","n_c":["C168617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01","n_c":["C175508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Monoclonal Antibody HLX55","n_c":["C174391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CCR7 Antibody-drug Conjugate JBH492","n_c":["C175477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD117 Monoclonal Antibody JSP191","n_c":["C174050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373","n_c":["C168522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017","n_c":["C173548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody LVGN6051","n_c":["C171541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003","n_c":["C172202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 iCAR NK Cells","n_c":["C170903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/CD22 CAR NK Cells","n_c":["C170904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody BAT4306F","n_c":["C173955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody MIL62","n_c":["C166140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD205 Antibody-drug Conjugate OBT076","n_c":["C165598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A","n_c":["C168772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD25 Monoclonal Antibody RO7296682","n_c":["C173969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD27 Agonistic Monoclonal Antibody MK-5890","n_c":["C172056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044","n_c":["C173369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119","n_c":["C166258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin","n_c":["C165583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30/DM1 Antibody-drug Conjugate F0002","n_c":["C172064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 Bispecific Monoclonal Antibody GEN3009","n_c":["C172443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Antibody-drug Conjugate STI-6129","n_c":["C174057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Monoclonal Antibody SAR442085","n_c":["C166376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257","n_c":["C173645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD39 Monoclonal Antibody SRF617","n_c":["C171450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042","n_c":["C168604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 ADC SGN-CD47M","n_c":["C173421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody IMC-002","n_c":["C174192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801","n_c":["C166137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-claudin18.2 Monoclonal Antibody AB011","n_c":["C173724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Claudin18.2 Monoclonal Antibody TST001","n_c":["C173726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody ADG116","n_c":["C166139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody HBM4003","n_c":["C173540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody ONC-392","n_c":["C173547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Probody BMS-986288","n_c":["C173435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","n_c":["C172196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA4 Antibody Fc Fusion Protein KN044","n_c":["C173422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/CD16A Bispecific Antibody AFM24","n_c":["C171163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202","n_c":["C173946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GARP Monoclonal Antibody ABBV-151","n_c":["C165684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999","n_c":["C165657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a","n_c":["C172987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-gremlin-1 Monoclonal Antibody UCB6114","n_c":["C173701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702","n_c":["C173076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate BAT8001","n_c":["C173966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate DP303c","n_c":["C173962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody B002","n_c":["C174121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody HLX22","n_c":["C172198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2-DM1 ADC B003","n_c":["C173420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001","n_c":["C173827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/MMAE Antibody-drug Conjugate MRG002","n_c":["C174205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HLA-G Antibody TTX-080","n_c":["C175374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-8 Monoclonal Antibody BMS-986253","n_c":["C124227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A","n_c":["C172391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IRF4 Antisense Oligonucleotide ION251","n_c":["C173725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody IBI-110","n_c":["C168603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181","n_c":["C173598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102","n_c":["C175411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LILRB4 Monoclonal Antibody IO-202","n_c":["C174485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin/MMAE Antibody-drug Conjugate RC88","n_c":["C174395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC16/CD3 Bispecific Antibody REGN4018","n_c":["C153129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC17/CD3 BiTE Antibody AMG 199","n_c":["C165588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592","n_c":["C173702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NRP1 Antibody ASP1948","n_c":["C156402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Agonist Monoclonal Antibody BGB-A445","n_c":["C175453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106","n_c":["C173983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256","n_c":["C174140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody 609A","n_c":["C172820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody SCT-I10A","n_c":["C170758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315","n_c":["C174419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669","n_c":["C173539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","n_c":["C171938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/CD47 Infusion Protein HX009","n_c":["C168600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752","n_c":["C171937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/VEGF Bispecific Antibody AK112","n_c":["C184865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody IMC-001","n_c":["C172819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody RC98","n_c":["C174520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046","n_c":["C172194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/IL-15 Fusion Protein KD033","n_c":["C173592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C","n_c":["C170976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD3 Bispecific Antibody CCW702","n_c":["C169053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-RANKL Monoclonal Antibody GB-223","n_c":["C174406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-RANKL Monoclonal Antibody JMT103","n_c":["C190458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ribonucleoprotein Antibody ATRC-101","n_c":["C172924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002","n_c":["C174012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody BGB-A1217","n_c":["C170906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody COM902","n_c":["C174037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody SGN-TGT","n_c":["C173630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM3 Monoclonal Antibody SHR-1702","n_c":["C172108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711","n_c":["C173541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TROP2 Antibody-drug Conjugate BAT8003","n_c":["C172060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TROP2 Antibody-drug Conjugate SKB264","n_c":["C166409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFR2 Monoclonal Antibody MSB0254","n_c":["C174422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antisense Oligonucleotide QR-313","n_c":["C162452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aprinocarsen","n_c":["C1788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aprutumab","n_c":["C107683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aryl Hydrocarbon Receptor Inhibitor IK-175","n_c":["C171151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspacytarabine","n_c":["C153327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asunercept","n_c":["C90562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Inhibitor RP-3500","n_c":["C174206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor M1774","n_c":["C171067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Attenuated Measles Virus Encoding SCD Transgene TMV-018","n_c":["C175440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atuveciclib","n_c":["C121456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Audencel","n_c":["C123928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055","n_c":["C173429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA CAR T-cells PHE885","n_c":["C174124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11","n_c":["C173434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088","n_c":["C170747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD123 CAR-T Cells","n_c":["C171167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx","n_c":["C173622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19","n_c":["C175465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1","n_c":["C172746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 TAC-T cells TAC01-CD19","n_c":["C172055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells","n_c":["C172057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells","n_c":["C155897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1","n_c":["C172063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes","n_c":["C173958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-FLT3 CAR T Cells AMG 553","n_c":["C172197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100","n_c":["C173378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes","n_c":["C175446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes","n_c":["C172191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101","n_c":["C175511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous BCMA-targeted CAR T Cells CC-98633","n_c":["C173699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F","n_c":["C175471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022","n_c":["C171093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1","n_c":["C172103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19-targeted CAR T Cells CC-97540","n_c":["C175049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19-targeted CAR-T Cells GC007F","n_c":["C171092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19/PD-1 Bispecific CAR-T Cells","n_c":["C172387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Clonal Neoantigen T Cells ATL001","n_c":["C171097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19","n_c":["C170914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC","n_c":["C173442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Multi-lineage Potential Cells","n_c":["C170908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Nectin-4/FAP-targeted CAR-T Cells","n_c":["C172386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous NKG2D CAR T-cells CYAD-02","n_c":["C173710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine","n_c":["C173968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001","n_c":["C167208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201","n_c":["C174405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCRm-expressing T-cells ET140203","n_c":["C175306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG","n_c":["C168775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1","n_c":["C173508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T","n_c":["C175463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avdoralimab","n_c":["C163020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aviscumine","n_c":["C78188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axalimogene Filolisbac","n_c":["C74595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axatilimab","n_c":["C155813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL Inhibitor SLC-391","n_c":["C173362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL/ FLT3/VEGFR2 Inhibitor KC1036","n_c":["C173961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axl/Mer Inhibitor PF-07265807","n_c":["C175543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azintuxizumab Vedotin","n_c":["C122816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Balstilimab","n_c":["C136465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bazlitoran","n_c":["C114975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor BGB-11417","n_c":["C175489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor LP-108","n_c":["C173536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCMA-CD19 Compound CAR T Cells","n_c":["C171631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCMA/CD3e Tri-specific T-cell Activating Construct HPN217","n_c":["C174412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belantamab Mafodotin","n_c":["C114299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belapectin","n_c":["C115111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belvarafenib","n_c":["C121646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belzutifan","n_c":["C135627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bersanlimab","n_c":["C88327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Berzosertib","n_c":["C116355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Betaglucin Gel","n_c":["C172188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bexmarilimab","n_c":["C159536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody AGEN1223","n_c":["C171161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody AMG 509","n_c":["C168580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody GS-1423","n_c":["C167206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BiTE Antibody AMG 910","n_c":["C184829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bizalimogene Ralaplasmid","n_c":["C77909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bomedemstat","n_c":["C131827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor BGB-3245","n_c":["C173633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF(V600E) Kinase Inhibitor ABM-1310","n_c":["C170951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor HZ-A-018","n_c":["C174394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor ABN401","n_c":["C170765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor GST-HG161","n_c":["C175449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C/EBP Beta Antagonist ST101","n_c":["C174169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Release-activated Channel Inhibitor CM4620","n_c":["C166417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camidanlumab Tesirine","n_c":["C121949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbon C 14-pamiparib","n_c":["C173441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cationic Peptide Cream Cypep-1","n_c":["C171374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD11b Agonist GB1275","n_c":["C165605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD123-CD33 Compound CAR T Cells","n_c":["C173970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD123-specific Targeting Module TM123","n_c":["C175461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD20-CD19 Compound CAR T Cells","n_c":["C173960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD28/ICOS Antagonist ALPN-101","n_c":["C179069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD44v6-specific CAR T-cells","n_c":["C173368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD73 Inhibitor AB680","n_c":["C167156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD73 Inhibitor LY3475070","n_c":["C170952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD80-Fc Fusion Protein ALPN-202","n_c":["C174515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD80-Fc Fusion Protein FPT155","n_c":["C169063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK2 Inhibitor PF-07104091","n_c":["C175251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor CS3002","n_c":["C174417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor HS-10342","n_c":["C170749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor TQB3616","n_c":["C171344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK7 Inhibitor SY-5609","n_c":["C172390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK8/19 Inhibitor SEL 120","n_c":["C165747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedazuridine/Azacitidine Combination Agent ASTX030","n_c":["C171649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282","n_c":["C172396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab Sarotalocan","n_c":["C121850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevostamab","n_c":["C139549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes","n_c":["C167056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ciltacabtagene Autoleucel","n_c":["C148498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinrebafusp Alfa","n_c":["C142890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cintirorgon","n_c":["C131294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51","n_c":["C169027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cobolimab","n_c":["C128627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cofetuzumab Pelidotin","n_c":["C123828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coltuximab Ravtansine","n_c":["C71009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Commensal Bacterial Strain Formulation VE800","n_c":["C167393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper Cu 67 Tyr3-octreotate","n_c":["C171370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cord Blood Derived CAR T-Cells","n_c":["C172058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cosibelimab","n_c":["C151947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coxsackievirus V937","n_c":["C61493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R Inhibitor ABSK021","n_c":["C173651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4/E-selectin Antagonist GMI-1359","n_c":["C167271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP11A1 Inhibitor ODM-209","n_c":["C172052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17/CYP11B2 Inhibitor LAE001","n_c":["C102855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daratumumab and Hyaluronidase-fihj","n_c":["C156401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Decitabine and Cedazuridine","n_c":["C115102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delolimogene Mupadenorepvec","n_c":["C148462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466","n_c":["C173660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dengue Virus Adjuvant PV-001-DV","n_c":["C173443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dilpacimab","n_c":["C116750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-PK inhibitor AZD7648","n_c":["C168692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-PK/PI3K-delta Inhibitor BR101801","n_c":["C172111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT1 Inhibitor NTX-301","n_c":["C174424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dociparstat sodium","n_c":["C99130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dostarlimab","n_c":["C126799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370","n_c":["C167221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555","n_c":["C173999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edicotinib","n_c":["C101519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edodekin alfa","n_c":["C1380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eftozanermin Alfa","n_c":["C146854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor TY-9591","n_c":["C175445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-selective  Inhibitor TQB3804","n_c":["C173415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/EGFRvIII Inhibitor WSD0922-FU","n_c":["C165778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Inhibitor DZD9008","n_c":["C167205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/TGFb Fusion Monoclonal Antibody BCA101","n_c":["C173165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/VEGFR/RET Inhibitor HA121-28","n_c":["C173436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emibetuzumab","n_c":["C95732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641","n_c":["C168790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encapsulated Rapamycin","n_c":["C173879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encelimab","n_c":["C142978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endothelin B Receptor Blocker ENB 003","n_c":["C175447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240","n_c":["C172990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Toxin Body Targeting CD38 TAK-169","n_c":["C173707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP2/EP4 Antagonist TPST-1495","n_c":["C174460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP4 Antagonist INV-1120","n_c":["C173520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epcoritamab","n_c":["C163022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EphA2-targeting Bicycle Toxin Conjugate BT5528","n_c":["C171425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor HH2710","n_c":["C172805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor JSI-1187","n_c":["C174203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etigilimab","n_c":["C142821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exicorilant","n_c":["C153309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extended Release Metformin Hydrochloride","n_c":["C173523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ezabenlimab","n_c":["C132252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH1/2 Inhibitor HH2853","n_c":["C173698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 inhibitor CPI-0209","n_c":["C167347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fadraciclib","n_c":["C123902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK/ALK/ROS1 Inhibitor APG-2449","n_c":["C172193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAP/4-1BB-targeting DARPin MP0310","n_c":["C170894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAP/4-1BB-targeting Fusion Protein RO7122290","n_c":["C175490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells","n_c":["C167326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Favezelimab","n_c":["C142077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11","n_c":["C170762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feladilimab","n_c":["C126804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Felzartamab","n_c":["C97954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenretinide Phospholipid Suspension ST-001","n_c":["C175469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor CPL304110","n_c":["C173964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR/CSF-1R Inhibitor 3D185","n_c":["C175460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR2 Inhibitor RLY-4008","n_c":["C174208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fianlimab","n_c":["C132339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fimaporfin A","n_c":["C88344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01","n_c":["C174049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279","n_c":["C174517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/KIT/CSF1R Inhibitor NMS-03592088","n_c":["C172195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorine F 18 Ara-G","n_c":["C120100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foritinib Succinate","n_c":["C175475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosgemcitabine Palabenamide","n_c":["C102752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosifloxuridine Nafalbenamide","n_c":["C156680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Futibatinib","n_c":["C114283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G Protein-coupled Estrogen Receptor Agonist LNS8801","n_c":["C165626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallium-based Bone Resorption Inhibitor AP-002","n_c":["C165650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine","n_c":["C172199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum","n_c":["C171371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Giredestrant","n_c":["C147030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glofitamab","n_c":["C148486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutaminase Inhibitor IPN60090","n_c":["C165612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutamine Antagonist DRP-104","n_c":["C174038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Inhibitor DZD1516","n_c":["C174039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Tri-specific Natural Killer Cell Engager DF1001","n_c":["C172279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-directed TLR8 Agonist SBT6050","n_c":["C174010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF2a RNAi ARO-HIF2","n_c":["C170918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202","n_c":["C173149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV E6/E7-encoding Arenavirus Vaccine HB-201","n_c":["C167349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107","n_c":["C173718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor TQB3474","n_c":["C173550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90-targeted Photosensitizer HS-201","n_c":["C172190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab","n_c":["C173339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iadademstat","n_c":["C131908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ianalumab","n_c":["C116788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idetrexed","n_c":["C120550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1 Mutant Inhibitor LY3410738","n_c":["C175542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO/TDO Inhibitor LY-01013","n_c":["C171343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1/TDO2 Inhibitor M4112","n_c":["C168808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ieramilimab","n_c":["C122683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000","n_c":["C166375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilginatinib","n_c":["C98109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imaradenant","n_c":["C148039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imgatuzumab","n_c":["C78838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imifoplatin","n_c":["C121375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inactivated Oncolytic Virus Particle GEN0101","n_c":["C170893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indatuximab Ravtansine","n_c":["C78840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Individualized MVA-based Vaccine TG4050","n_c":["C171392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indusatumab Vedotin","n_c":["C101524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inebilizumab","n_c":["C88283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iNKT Cell Agonist ABX196","n_c":["C172187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-12-Fc Fusion Protein DF6002","n_c":["C173371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15 Agonist Fusion Protein SHR1501","n_c":["C171385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15 Fusion Protein BJ-001","n_c":["C172075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306","n_c":["C170890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101","n_c":["C170516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Apamistamab","n_c":["C2527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 IPA","n_c":["C171348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","n_c":["C170800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan Sucrosofate","n_c":["C82676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iroplact","n_c":["C2251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130","n_c":["C165639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Istiratumab","n_c":["C103863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ivaltinostat","n_c":["C94225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ivuxolimab","n_c":["C121927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK Inhibitor","n_c":["C172200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kanitinib","n_c":["C168608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS G12C Inhibitor GDC-6036","n_c":["C173995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS G12C Inhibitor LY3499446","n_c":["C166410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRASG12C Inhibitor JNJ-74699157","n_c":["C167157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ladiratuzumab Vedotin","n_c":["C112001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LAIR-2 Fusion Protein NC410","n_c":["C173559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Landogrozumab","n_c":["C99640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laprituximab Emtansine","n_c":["C111906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotinib Mesylate","n_c":["C172062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lerociclib","n_c":["C138165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Letetresgene Autoleucel","n_c":["C121379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Letolizumab","n_c":["C120140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifileucel","n_c":["C120552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifirafenib","n_c":["C124995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lilotomab","n_c":["C165685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linperlisib","n_c":["C158508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006","n_c":["C170753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Bcl-2 Antisense Oligonucleotide  BP1002","n_c":["C170743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1","n_c":["C174421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes","n_c":["C172395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP7 Inhibitor M3258","n_c":["C169060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lodapolimab","n_c":["C128138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP5 Antagonist BI 905681","n_c":["C171102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor SYHA1807","n_c":["C173722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumretuzumab","n_c":["C104058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupartumab Amadotin","n_c":["C116070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-DTPA-omburtamab","n_c":["C174423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maackia amurensis Seed Lectin","n_c":["C174518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macrocycle-bridged STING Agonist E7766","n_c":["C166141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells","n_c":["C174139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Magrolimab","n_c":["C117730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Manelimab","n_c":["C156741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MCL-1 Inhibitor ABBV-467","n_c":["C174400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor AMGMDS3","n_c":["C171616"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK 1/2 Inhibitor FCN-159","n_c":["C172382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor HL-085","n_c":["C173437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menin-MLL Interaction Inhibitor SNDX-5613","n_c":["C165776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET x MET Bispecific Antibody REGN5093","n_c":["C167188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metarrestin","n_c":["C168544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylcantharidimide","n_c":["C173446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mevociclib","n_c":["C139552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mezagitamab","n_c":["C148078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microbiome GEN-001","n_c":["C171422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microbiome-derived Peptide Vaccine EO2401","n_c":["C165646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milataxel","n_c":["C77880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miptenalimab","n_c":["C150403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miransertib","n_c":["C99172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirdametinib","n_c":["C52195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirzotamab Clezutoclax","n_c":["C157279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitazalimab","n_c":["C121538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobocertinib","n_c":["C126752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modakafusp Alfa","n_c":["C140427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208","n_c":["C167362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motixafortide","n_c":["C88309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells","n_c":["C174519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-epitope HER2 Peptide Vaccine TPIV100","n_c":["C173525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Murizatoclax","n_c":["C156740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscadine Grape Extract","n_c":["C175526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVA-BN Smallpox Vaccine","n_c":["C173552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N-dihydrogalactochitosan","n_c":["C173438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nagrestipen","n_c":["C98294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naratuximab Emtansine","n_c":["C100101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navicixizumab","n_c":["C119620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nogapendekin Alfa","n_c":["C107503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Numidargistat","n_c":["C142866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nurulimab","n_c":["C156734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Odronextamab","n_c":["C119615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ofranergene Obadenovec","n_c":["C71539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oligo-fucoidan","n_c":["C170752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olinvacimab","n_c":["C102877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olvimulogene Nanivacirepvec","n_c":["C79833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onatasertib","n_c":["C92575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Adenovirus ORCA-010","n_c":["C168607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Herpes Simplex Virus-1 ONCR-177","n_c":["C171540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","n_c":["C175473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein","n_c":["C173889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ontorpacept","n_c":["C125718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onvatilimab","n_c":["C127124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opolimogene Capmilisbac","n_c":["C125631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opucolimab","n_c":["C165270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orelabrutinib","n_c":["C156173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orvacabtagene Autoleucel","n_c":["C147523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxaliplatin Eluting Beads","n_c":["C172098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p97 Inhibitor CB-5339","n_c":["C167257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p97 Inhibitor CB-5339 Tosylate","n_c":["C167262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pacmilimab","n_c":["C132192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamrevlumab","n_c":["C92577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-KRAS Inhibitor BI 1701963","n_c":["C166138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-mutation-selective EGFR Inhibitor CLN-081","n_c":["C165567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-TRK Inhibitor NOV1601","n_c":["C172394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panulisib","n_c":["C104292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP 1/2 Inhibitor IMP4297","n_c":["C168601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor NMS-03305293","n_c":["C167278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP7 Inhibitor RBN-2397","n_c":["C170764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parsaclisib","n_c":["C113434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parsaclisib Hydrochloride","n_c":["C166387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201","n_c":["C167207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patritumab Deruxtecan","n_c":["C136987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paxalisib","n_c":["C116877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1 Inhibitor GS-4224","n_c":["C170900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480","n_c":["C174020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegvorhyaluronidase Alfa","n_c":["C82659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated SN-38 Conjugate PLX038","n_c":["C167334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelabresib","n_c":["C111901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peposertib","n_c":["C120036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC","n_c":["C173152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoantigen DNA Vaccine GNOS-PV01","n_c":["C171430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoantigen DNA Vaccine GNOS-PVO2","n_c":["C170950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photodynamic Compound TLD-1433","n_c":["C172822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pimitespib","n_c":["C134448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pimurutamab","n_c":["C163981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pinatuzumab Vedotin","n_c":["C104167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pixatimod","n_c":["C95202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plamotamab","n_c":["C130050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasmid DNA Vaccine pING-hHER3FL","n_c":["C171387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pNGVL4a-CRT-E6E7L2 DNA Vaccine","n_c":["C175536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2","n_c":["C172205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255","n_c":["C165666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor XNW7201","n_c":["C172189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPAR Alpha Antagonist TPST-1120","n_c":["C169105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pralsetinib","n_c":["C132295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Praluzatamab Ravtansine","n_c":["C134697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRMT5 Inhibitor PRT811","n_c":["C168531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolgolimab","n_c":["C148155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostaglandin E2 EP4 Receptor Inhibitor AN0025","n_c":["C129689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Tyrosine Kinase 2 Inhibitor IN10018","n_c":["C166122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyruvate Kinase M2 Isoform Activator TP-1454","n_c":["C175380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88","n_c":["C124051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radgocitabine","n_c":["C82697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radgocitabine Hydrochloride","n_c":["C150430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ragifilimab","n_c":["C126643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Bacterial Minicells VAX014","n_c":["C170742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Erwinia asparaginase JZP-458","n_c":["C64260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Papillomavirus 11-valent Vaccine","n_c":["C168605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human TRAIL-Trimer Fusion Protein SCB-313","n_c":["C170907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301","n_c":["C171377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Redaporfin","n_c":["C114382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET/SRC Inhibitor TPX-0046","n_c":["C167210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retifanlimab","n_c":["C142168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Revdofilimab","n_c":["C161864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rezivertinib","n_c":["C154286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ripertamab","n_c":["C124067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roblitinib","n_c":["C120102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROBO1-targeted BiCAR-NKT Cells","n_c":["C172380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rocakinogene Sifuplasmid","n_c":["C116709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roducitabine","n_c":["C113444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rolinsatamab Talirine","n_c":["C137991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roneparstat","n_c":["C104412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ropeginterferon Alfa-2B","n_c":["C111892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ropocamptide","n_c":["C118292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosopatamab","n_c":["C2652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSK1-4 Inhibitor PMD-026","n_c":["C166135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruthenium-based Small Molecule Therapeutic BOLD-100","n_c":["C173373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruxotemitide","n_c":["C90547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sabatolimab","n_c":["C124850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samrotamab Vedotin","n_c":["C124134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samuraciclib","n_c":["C155652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sasanlimab","n_c":["C124058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDF-1 Receptor Antagonist PTX-9908","n_c":["C170746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader LX-039","n_c":["C168606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader LY3484356","n_c":["C174042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serclutamab Talirine","n_c":["C150590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD ZN-c5","n_c":["C167267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serplulimab","n_c":["C156738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shenqi Fuzheng Injection SQ001","n_c":["C171384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor RLY-1971","n_c":["C172988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simlukafusp Alfa","n_c":["C129383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simmitinib","n_c":["C170763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simurosertib","n_c":["C126641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Siremadlin","n_c":["C116325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-4-1BBL Fusion Protein DSP107","n_c":["C174171"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-Fc-CD40L Fusion Protein SL-172154","n_c":["C173706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotigalimab","n_c":["C123734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotorasib","n_c":["C154287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spanlecortemlocel","n_c":["C111571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRPK1/ABCG2 Inhibitor SCO-101","n_c":["C175512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist BMS-986301","n_c":["C167292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist GSK3745417","n_c":["C165748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist IMSA101","n_c":["C165655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist SB 11285","n_c":["C165566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist TAK-676","n_c":["C173377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING-expressing E. coli SYNB1891","n_c":["C167270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sugemalimab","n_c":["C154550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superoxide Dismutase Mimetic GC4711","n_c":["C173664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Plumbagin PCUR-101","n_c":["C166377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tafasitamab","n_c":["C95768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taletrectinib","n_c":["C118948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamrintamab Pamozirine","n_c":["C124133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tankyrase Inhibitor STP1002","n_c":["C174060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tapotoclax","n_c":["C127817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasadenoturev","n_c":["C74067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tebentafusp","n_c":["C94208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teclistamab","n_c":["C136823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tefinostat","n_c":["C152539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telaglenastat","n_c":["C114381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telaglenastat Hydrochloride","n_c":["C150413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telisotuzumab","n_c":["C106262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tepoditamab","n_c":["C148141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGF-beta Receptor 1 Kinase Inhibitor SH3051","n_c":["C173370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027","n_c":["C172107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Cancer Vaccine ATP128","n_c":["C165621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anetumab Corixetan","n_c":["C155977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439","n_c":["C168996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497","n_c":["C175301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymidylate Synthase Inhibitor CX1106","n_c":["C168609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TIGIT Inhibitor M6223","n_c":["C173891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tilogotamab","n_c":["C153259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiomolibdate Choline","n_c":["C62514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tirbanibulin","n_c":["C74077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7 agonist BNT411","n_c":["C167350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7 Agonist LHC165","n_c":["C166362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells","n_c":["C173965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tolebrutinib","n_c":["C173549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan Sustained-release Episcleral Plaque","n_c":["C173363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Deruxtecan","n_c":["C128799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Monomethyl Auristatin F","n_c":["C172821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab-TLR 7/8 Agonist BDC-1001","n_c":["C172388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tris-acryl Gelatin Microspheres","n_c":["C126803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRK Inhibitor TQB3558","n_c":["C173560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troriluzole","n_c":["C142847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor TL-895","n_c":["C172809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upifitamab","n_c":["C147578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urabrelimab","n_c":["C155976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ursolic Acid","n_c":["C172843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uzansertib","n_c":["C124226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valecobulin","n_c":["C101264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valemetostat","n_c":["C127114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vesencumab","n_c":["C91728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vibecotamab","n_c":["C127120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vibostolimab","n_c":["C140041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorasidenib","n_c":["C152914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulinacimab","n_c":["C156172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wee1 Inhibitor ZN-c3","n_c":["C167064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wee1 Kinase Inhibitor Debio 0123","n_c":["C173426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xevinapant","n_c":["C90574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xiliertinib","n_c":["C162552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xisomab 3G3","n_c":["C171173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Tabituximab Barzuxetan","n_c":["C99168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zandelisib","n_c":["C123925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zanidatamab","n_c":["C130010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zelavespib","n_c":["C101227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zorifertinib","n_c":["C118289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zotatifin","n_c":["C165746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zotiraciclib Citrate","n_c":["C105851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Giloralimab","n_c":["C139553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vosilasarm","n_c":["C137950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfa-2B","n_c":["C1953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levoleucovorin Calcium","n_c":["C66721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mistletoe Extract","n_c":["C2703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10","n_c":["C172104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-selective Inhibitor TQB3804","n_c":["C173415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Bcl-2 Antisense Oligonucleotide BP1002","n_c":["C170743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canakinumab","n_c":["C80971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rivaroxaban","n_c":["C77995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR9 Agonist SD-101","n_c":["C74084"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.experimental_protocol_type":[{"nm":"Genomplex","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"aDNA Preparation Type","n_c":["C179426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allprep FFPE DNA","n_c":["C179428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allprep RNA Extraction","n_c":["C179430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical Lysis DNA Extraction","n_c":["C179431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HighPure miRNA (Allprep DNA) FFPE RNA","n_c":["C179436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mirVana (Allprep DNA) RNA","n_c":["C179446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pre-extracted DNA received by TSS","n_c":["C179449"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_b_symptoms_described":[{"nm":"Fever","n_c":["C3038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Night Sweats","n_c":["C3279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weight Loss","n_c":["C3445"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.necrosis_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.rhabdoid_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.sarcomatoid_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.chipseq_antibody":[{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.fragmentation_enzyme":[{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.data_category":[{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.data_type":[{"nm":"Aligned Reads","n_c":["C164052"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.data_format":[{"nm":"BAM","n_c":["C153249"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Validation","n_c":["C16237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"index_file.aligned_reads_index.data_category":[{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.gender":[{"nm":"female","n_c":["C16576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"male","n_c":["C20197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unspecified","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.ethnicity":[{"nm":"hispanic or latino","n_c":["C17459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not hispanic or latino","n_c":["C41222"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.race":[{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"white","n_c":["C41261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"american indian or alaska native","n_c":["C41259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"black or african american","n_c":["C16352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"asian","n_c":["C41260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"native hawaiian or other pacific islander","n_c":["C41219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.vital_status":[{"nm":"alive","n_c":["C37987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"dead","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"lost to follow-up","n_c":["C48227"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.platform":[{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.platform":[{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSV","n_c":["C182456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDF5","n_c":["C184763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEX","n_c":["C184778"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.experimental_strategy":[{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.data_type":[{"nm":"Methylation Beta Value","n_c":["C164051"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSV","n_c":["C182456"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.experimental_strategy":[{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDF5","n_c":["C184763"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.data_format":[{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.data_category":[{"nm":"Combined Nucleotide Variation","n_c":["C171155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.data_format":[{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FASTA","n_c":["C47845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSV","n_c":["C182456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BEDPE","n_c":["C184749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GVF","n_c":["C184761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JSON","n_c":["C184769"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.experimental_strategy":[{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.test_units":[{"nm":"g/dL","n_c":["C64783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/L","n_c":["C42576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mcg/mL","n_c":["C64572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/dL","n_c":["C67015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/L","n_c":["C64572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mmol/L","n_c":["C64387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U/g Hb","n_c":["C105522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U/mL","n_c":["C77607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U/L","n_c":["C67456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ukat/L","n_c":["C67397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"umol/L","n_c":["C48508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"x10^3 cells/mcL","n_c":["C67244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"x10^9 cells/L","n_c":["C67249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mm^2","n_c":["C65104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mU/mol Hb","n_c":["C184780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ng/mL","n_c":["C67306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"percent","n_c":["C48570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cells/mL","n_c":["C74919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mcg/L","n_c":["C67306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/24 hr","n_c":["C67399"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.additional_pathology_findings":[{"nm":"Pleurodesis, Talc","n_c":["C178422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis, NOS","n_c":["C66899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asbestos bodies","n_c":["C36015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN)","n_c":["C27789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune atrophic chronic gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign endocervical polyp","n_c":["C34584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carcinoma in situ","n_c":["C2917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clostridioides difficile (c. diff)","n_c":["C180523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization; bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization; fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysplasia; high grade","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysplasia; low grade","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperkeratosis","n_c":["C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leiomyoma","n_c":["C3157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum-resistant","n_c":["C147558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary interstitial fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinonasal papilloma","n_c":["C4117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous papilloma; solitary","n_c":["C3712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous papillomatosis","n_c":["C9009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated lymphoid proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Percent follicular component <= 10%","n_c":["C188349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Percent follicular component > 10%","n_c":["C188350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1 CPS (223C LDT) - 20%","n_c":["C188351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow concordant histology","n_c":["C198920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow discordant histology","n_c":["C198921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometrial polyp","n_c":["C6433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extravascular Matrix Loops","n_c":["C111025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Complex Extravascular Matrix Patterns","n_c":["C111024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poorly Differentiated","n_c":["C14167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Well Differentiated","n_c":["C14171"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.consistent_pathology_review":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.residual_tumor":[{"nm":"RX","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R0","n_c":["C139578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C139579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C139580"],"i_c":"","i_c_s":"","term_type":""}],"case.project.state":[{"nm":"open","n_c":["C49069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"review","n_c":["C42729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"submitted","n_c":["C25695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"processing","n_c":["C48177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"closed","n_c":["C49070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"legacy","n_c":["C184772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"processed","n_c":["C184788"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.data_category":[{"nm":"Proteome Profiling","n_c":["C62669"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.data_type":[{"nm":"Protein Expression Quantification","n_c":["C63480"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.channel":[{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red","n_c":["C48326"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.data_category":[{"nm":"Transcriptome Profiling","n_c":["C153194"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.experimental_strategy":[{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.route_of_administration":[{"nm":"Intrathecal","n_c":["C38267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravenous","n_c":["C38276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral","n_c":["C38288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intrahepatic","n_c":["C38248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intramuscular","n_c":["C28161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraperitoneal","n_c":["C38258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intratumoral","n_c":["C38269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravesical","n_c":["C38278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous","n_c":["C38299"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.eye_color":[{"nm":"Amber","n_c":["C111017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blue","n_c":["C48333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brown","n_c":["C48332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gray","n_c":["C48324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hazel","n_c":["C111018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red & Violet","n_c":["C157431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C160244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.history_of_tumor":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.parent_with_radiation_exposure":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_corrected":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_corrected_laterality":[{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_corrected_method":[{"nm":"Orchiopexy","n_c":["C111066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hormones","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis Removed","n_c":["C15288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Descent","n_c":["C184803"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_history":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_history_laterality":[{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.adrenal_hormone":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.channel":[{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red","n_c":["C48326"],"i_c":"","i_c_s":"","term_type":""}],"data_file.archive.data_category":[{"nm":"Archive","n_c":["C156018"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.data_category":[{"nm":"Transcriptome Profiling","n_c":["C153194"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.data_category":[{"nm":"Transcriptome Profiling","n_c":["C153194"],"i_c":"","i_c_s":"","term_type":""}],"data_file.archive.data_format":[{"nm":"MAGETAB","n_c":["C82937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TARGZ","n_c":["C184805"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.msi_status":[{"nm":"MSI","n_c":["C36318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSS","n_c":["C131459"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.data_type":[{"nm":"Supplementary Files","n_c":["C60763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isoform Expression Quantification","n_c":["C184767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA Expression Quantification","n_c":["C184779"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.history_of_tumor_type":[{"nm":"Phenochromocytoma or Paraganglioma","n_c":["C185075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Cancer","n_c":["C198972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lower Grade Glioma","n_c":["C198973"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"index_file.somatic_mutation_index.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somatic Structural Variation","n_c":["C184801"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.data_category":[{"nm":"Somatic Structural Variation","n_c":["C184801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Structural Variation","n_c":["C2950"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.data_format":[{"nm":"IDAT","n_c":["C184762"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.data_format":[{"nm":"IDAT","n_c":["C184762"],"i_c":"","i_c_s":"","term_type":""}],"index_file.somatic_mutation_index.data_format":[{"nm":"TBI","n_c":["C184806"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.data_type":[{"nm":"Aggregated Somatic Mutation","n_c":["C184741"],"i_c":"","i_c_s":"","term_type":""}],"index_file.aligned_reads_index.data_type":[{"nm":"Aligned Reads Index","n_c":["C184742"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.data_type":[{"nm":"Allele-specific Copy Number Segment","n_c":["C184745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copy Number Segment","n_c":["C184744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masked Copy Number Segment","n_c":["C184776"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.data_type":[{"nm":"Annotated Somatic Mutation","n_c":["C184746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masked Annotated Somatic Mutation","n_c":["C184775"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.data_type":[{"nm":"Cohort Level Copy Number Scores","n_c":["C184752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gene Level Copy Number","n_c":["C181336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gene Level Copy Number Scores","n_c":["C184759"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.data_type":[{"nm":"Copy Number Segment","n_c":["C184744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masked Copy Number Segment","n_c":["C184776"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.data_type":[{"nm":"Differential Gene Expression","n_c":["C184755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Single Cell Analysis","n_c":["C184799"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.data_type":[{"nm":"Exon Expression Quantification","n_c":["C184756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gene Expression Quantification","n_c":["C135484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isoform Expression Quantification","n_c":["C184767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Junction Quantification","n_c":["C184802"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.data_type":[{"nm":"Masked Intensities","n_c":["C184774"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.data_type":[{"nm":"Masked Somatic Mutation","n_c":["C184777"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.data_type":[{"nm":"Raw CGI Variant","n_c":["C184794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Simple Somatic Mutation","n_c":["C184795"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.data_type":[{"nm":"Raw Intensities","n_c":["C184793"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.data_type":[{"nm":"Raw Intensities","n_c":["C184793"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.data_type":[{"nm":"Simple Germline Variation","n_c":["C17666"],"i_c":"","i_c_s":"","term_type":""}],"index_file.somatic_mutation_index.data_type":[{"nm":"Somatic Mutation Index","n_c":["C184800"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.data_type":[{"nm":"Structural Alteration","n_c":["C2950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Structural Rearrangement","n_c":["C36541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transcript Fusion","n_c":["C184809"],"i_c":"","i_c_s":"","term_type":""}],"data_file.archive.data_type":[{"nm":"TARGET DCC Archive","n_c":["C184807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCGA DCC Archive","n_c":["C184808"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.experimental_strategy":[{"nm":"Reverse Phase Protein Array","n_c":["C184797"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.platform":[{"nm":"RPPA","n_c":["C184797"],"i_c":"","i_c_s":"","term_type":""}],"analysis.alignment_workflow.type":[{"nm":"alignment_workflow","n_c":["C184743"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.asbestos_exposure_type":[{"nm":"Amosite","n_c":["C45527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crocidolite","n_c":["C29816"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.clinical_trial_indicator":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.double_expressor_lymphoma":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.double_hit_lymphoma":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.drug_category":[{"nm":"Glucocorticoid","n_c":["C521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth factor","n_c":["C530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP inhibitor","n_c":["C62554"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.embolic_agent":[{"nm":"Gelfoam","n_c":["C38705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipiodol","n_c":["C487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plastic Beads","n_c":["C97233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PVA Particles","n_c":["C71147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spherical Particles","n_c":["C97230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y-90 Sirsphere","n_c":["C64539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y-90 Therasphere","n_c":["C38679"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.exposure_source":[{"nm":"Secondary","n_c":["C188376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occupational","n_c":["C16929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Home","n_c":["C202294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social","n_c":["C202295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work","n_c":["C16929"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.hpv_strain":[{"nm":"HPV16","n_c":["C14338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV18","n_c":["C14377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV31","n_c":["C102904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV33","n_c":["C102996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV35","n_c":["C102997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV39","n_c":["C102998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV45","n_c":["C102999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV51","n_c":["C103000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV52","n_c":["C103001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV56","n_c":["C103003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV58","n_c":["C103004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV59","n_c":["C103005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV66","n_c":["C103006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV68","n_c":["C103007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV73","n_c":["C103008"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.max_tumor_bulk_site":[{"nm":"No known nodal involvement","n_c":["C188386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites/peritoneum","n_c":["C159203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axillary lymph nodes","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical lymph nodes","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-external","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inguinal","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal lymph nodes","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal soft tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesenteric lymph nodes","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraaortic lymph nodes","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peri-orbital soft tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal lymph nodes","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft tissue (muscle, ligaments, subcutaneous)","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic lymph nodes","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular lymph nodes","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraclavicular lymph nodes","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.sites_of_involvement":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Peritoneum","n_c":["C159355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adnexa","n_c":["C137974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central nervous system","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube, Left","n_c":["C32959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube, NOS","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube, Right","n_c":["C33475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, Lower Pole","n_c":["C93180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, Middle","n_c":["C186124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, Upper Pole","n_c":["C93179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal soft tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mouth","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal soft tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary, Left","n_c":["C32969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary, NOS","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary, Right","n_c":["C33487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Peritoneum","n_c":["C159344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perineum","n_c":["C33301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peri-orbital soft tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral blood","n_c":["C173496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral nervous system","n_c":["C12465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testes","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea","n_c":["C12428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transplanted kidney","n_c":["C26990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebrae","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Brain stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Cerebellum, NOS","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Frontal lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Occipital lobe","n_c":["C12355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Parietal","n_c":["C12354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Temporal lobe","n_c":["C12353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Ventricle, NOS","n_c":["C12356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Lung","n_c":["C159213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrosplenic Ligament","n_c":["C32671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium, Left","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium, Right","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Lymph Node(s)","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Lung","n_c":["C159212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Nodes","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Organ","n_c":["C172223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Great Blood Vessel","n_c":["C102955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inferior Vena Cava","n_c":["C12815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Subcarinal","n_c":["C117873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Vein","n_c":["C33462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebral Canal","n_c":["C33869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Gland Isthmus","n_c":["C32887"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_m":[{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_stage":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_t":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C47858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_m":[{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1d","n_c":["C188301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M2","n_c":["C188299"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_stage":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA1","n_c":["C139980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA2","n_c":["C139981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIID","n_c":["C137676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_t":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C139415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.zone_of_origin_prostate":[{"nm":"Central zone","n_c":["C128572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Overlapping/multiple zones","n_c":["C157522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral zone","n_c":["C128570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transition zone","n_c":["C128571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown zone","n_c":["C160198"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.data_format":[{"nm":"CEL","n_c":["C191737"],"i_c":"","i_c_s":"","term_type":""}],"index_file.aligned_reads_index.data_format":[{"nm":"BAI","n_c":["C190163"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_frequency":[{"nm":"Daily Drinker","n_c":["C198923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weekly Drinker","n_c":["C198924"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.aneuploidy":[{"nm":"Monosomy","n_c":["C3239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trisomy","n_c":["C3421"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cancer_detection_method":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Screening","n_c":["C15406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surveillance","n_c":["C15719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Symptomatic","n_c":["C168447"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.chemical_exposure_type":[{"nm":"Agent Orange","n_c":["C198925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aluminum","n_c":["C198926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arsenic","n_c":["C165476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asbestos","n_c":["C55816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benzene","n_c":["C36251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cadmium","n_c":["C198927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical Exposure, NOS","n_c":["C36290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromium","n_c":["C198934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coal Gas, Coal Tar, Coal Tar Pitch, and Derivatives","n_c":["C177574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coke Oven Emission","n_c":["C157008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper","n_c":["C198935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diesel Exhaust","n_c":["C198936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Disinfectant","n_c":["C198937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Formaldehyde","n_c":["C198938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylene Chloride","n_c":["C198939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occupational Soldering/Welding Smoke Exposure","n_c":["C164120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oil","n_c":["C198940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pesticide","n_c":["C198941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Petroleum Hydrocarbon Compound","n_c":["C198942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resin Fumes","n_c":["C198943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Borate","n_c":["C198944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solvent","n_c":["C198945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetrachloroethylene","n_c":["C198946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toluene","n_c":["C198947"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.chromosomal_translocation":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(10;11)(p11.2;q23)","n_c":["C168758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(11;19)(q23;p13.1)","n_c":["C36371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(3;5)(q25;q34)","n_c":["C36415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(6;11)(q27;q23)","n_c":["C36610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(6;9)","n_c":["C128650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(8;21)","n_c":["C119608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(9;11)(p22;q23)","n_c":["C36370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.chromosome_arm":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p","n_c":["C198952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"q","n_c":["C198953"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.comorbidities":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Renal Failure","n_c":["C26808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenocarcinoma","n_c":["C2852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomatous Polyposis Coli","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenocortical Insufficiency","n_c":["C26691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergies","n_c":["C114476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C26696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arrhythmia","n_c":["C2881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C2883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C50466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C118385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Carcinoma","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Disorder","n_c":["C2899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Clots","n_c":["C27083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Fracture(s)","n_c":["C3046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchitis","n_c":["C2911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Channel Blockers","n_c":["C333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataracts","n_c":["C26713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celiac Disease","n_c":["C26714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrovascular Disease","n_c":["C2938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Fatigue Syndrome","n_c":["C3037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Renal Failure","n_c":["C9438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis, Unknown Etiology","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clonal Hematopoiesis","n_c":["C162188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Infection","n_c":["C27582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immunodeficiency","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congestive Heart Failure (CHF)","n_c":["C3080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue Disorder","n_c":["C26729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COPD","n_c":["C3199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coronary Artery Disease","n_c":["C26732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crohn's Disease","n_c":["C2965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C62586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptogenic Organizing Pneumonia","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Vein Thrombosis / Thromboembolism","n_c":["C49343","C28195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C2982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetic Neuropathy","n_c":["C26748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet Controlled Diabetes","n_c":["C184754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DVT/PE","n_c":["C49343","C50713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyslipidemia","n_c":["C80385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epilepsy","n_c":["C3020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromyalgia","n_c":["C87497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GERD","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C26782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycogen Storage Disease","n_c":["C61272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadal Dysfunction","n_c":["C26786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gout","n_c":["C34650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H. pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Disease","n_c":["C3079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhagic Cystitis","n_c":["C114666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, Chronic","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Non-polyposis Colon Cancer","n_c":["C120083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Liver Dysplastic Nodule","n_c":["C96768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV / AIDS","n_c":["C2851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HUS/TTP","n_c":["C75545","C78797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C3112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercholesterolemia","n_c":["C37967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C26797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperlipidemia","n_c":["C34707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C3117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammatory Bowel Disease","n_c":["C3138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin Controlled Diabetes","n_c":["C184766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interstitial Pneumontis or ARDS","n_c":["C3353","C27006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraductal Papillary Mucinous Neoplasm","n_c":["C38342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemic Heart Disease","n_c":["C50625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITP","n_c":["C3446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Replacement","n_c":["C131579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Disease","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cirrhosis (Liver Disease)","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Toxicity (Non-Infectious)","n_c":["C184773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Liver Dysplastic Nodule","n_c":["C96770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupus","n_c":["C27153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAI","n_c":["C27314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methicillin-Resistant Staphylococcus aureus (MRSA)","n_c":["C115248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C27996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroendocrine Tumor","n_c":["C3809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ transplant (site)","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoarthritis","n_c":["C3293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis or Osteopenia","n_c":["C50910","C3298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Cancer Within 5 Years","n_c":["C184782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Nonmalignant Systemic Disease","n_c":["C184785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Pulmonary Complications","n_c":["C184786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain (Various)","n_c":["C3303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptic Ulcer (Ulcer)","n_c":["C3318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Neuropathy","n_c":["C119734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Vascular Disease","n_c":["C35136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peutz-Jeghers Disease","n_c":["C3324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy in Patient or Partner","n_c":["C124295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psoriasis","n_c":["C3346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hemorrhage","n_c":["C78578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Dialysis","n_c":["C15248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Failure (Requiring Dialysis)","n_c":["C184791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Insufficiency","n_c":["C4376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatologic Disease","n_c":["C27204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep apnea","n_c":["C26884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking","n_c":["C154329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staph Osteomyelitis","n_c":["C188353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C3390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Disease, Non-Cancer","n_c":["C27566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attack","n_c":["C50781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinemia","n_c":["C98640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulcerative Colitis","n_c":["C2952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C50791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.data_format":[{"nm":"TAR","n_c":["C190189"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.data_type":[{"nm":"Intermediate Analysis Archive","n_c":["C198955"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.evidence_of_progression_type":[{"nm":"Convincing Image Source","n_c":["C158782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histologic Confirmation","n_c":["C158780"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.experimental_strategy":[{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extracapsular_extension":[{"nm":"Extensive","n_c":["C198967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Focal","n_c":["C198968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extranodal_extension":[{"nm":"Gross Extension","n_c":["C198969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic Extension","n_c":["C198970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Extranodal Extension","n_c":["C160838"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.fab_morphology_code":[{"nm":"M0","n_c":["C8460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C3249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M2","n_c":["C3250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M3","n_c":["C3182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M4","n_c":["C7463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M5","n_c":["C4861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M6","n_c":["C8923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M7","n_c":["C3170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Classified","n_c":["C27753"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.first_event":[{"nm":"Censored","n_c":["C118962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death without Remission","n_c":["C199218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Event","n_c":["C25499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction Death","n_c":["C121972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction Failure","n_c":["C70622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relapse","n_c":["C38155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Second Malignant Neoplasm","n_c":["C95606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Presented with Metastases","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_anatomic_site":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_findings":[{"nm":"Carcinomatosis","n_c":["C3693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Involvement","n_c":["C199151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Involvement","n_c":["C199154"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Involvement","n_c":["C199155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normal","n_c":["C14165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal Lymph Node Involvement","n_c":["C199157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vena Cava Involvement/Thrombus","n_c":["C199158"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_dissection_method":[{"nm":"Functional (Limited) Neck Dissection","n_c":["C148527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Radical Neck Dissection","n_c":["C51904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Neck Dissection","n_c":["C51759"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_dissection_site":[{"nm":"Neck, Left","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck, NOS","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck, Right","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_nodes_removed":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.occupation_type":[{"nm":"Administration Professionals","n_c":["C198715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Administrative and Specialized Secretaries","n_c":["C198716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agricultural, Forestry and Fishery Labourers","n_c":["C97632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Animal Producers","n_c":["C198717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Architects, Planners, Surveyors and Designers","n_c":["C198718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Armed Forces Occupations, Other Ranks","n_c":["C198719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artistic, Cultural and Culinary Associate Professionals","n_c":["C198720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Assemblers","n_c":["C198721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Authors, Journalists and Linguists","n_c":["C198722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blacksmiths, Toolmakers and Related Trades Workers","n_c":["C198723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Building and Housekeeping Supervisors","n_c":["C198724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Building Finishers and Related Trades Workers","n_c":["C198725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Building Frame and Related Trades Workers","n_c":["C198726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Business Services Agents","n_c":["C198727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Business Services and Administration Managers","n_c":["C198728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Car, Van and Motorcycle Drivers","n_c":["C198729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cashiers and Ticket Clerks","n_c":["C198730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical and Photographic Products Plant and Machine Operators","n_c":["C198731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Child Care Workers and Teachers' Aides","n_c":["C198732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Client Information Workers","n_c":["C198733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Commissioned Armed Forces Officers","n_c":["C198734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cooks","n_c":["C122440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Creative and Performing Artists","n_c":["C80245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Database and Network Professionals","n_c":["C198735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domestic, Hotel and Office Cleaners and Helpers","n_c":["C198736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrical Equipment Installers and Repairers","n_c":["C122446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electronics and Telecommunications Installers and Repairers","n_c":["C198737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrotechnology Engineers","n_c":["C198738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineering Professionals (excluding Electrotechnology)","n_c":["C122447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finance Professionals","n_c":["C122452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Financial and Mathematical Associate Professionals","n_c":["C198739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fishery Workers, Hunters and Trappers","n_c":["C198740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Food and Related Products Machine Operators","n_c":["C198741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Food Preparation Assistants","n_c":["C198742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Food Processing and Related Trades Workers","n_c":["C198743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forestry and Related Workers","n_c":["C198744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Garment and Related Trades Workers","n_c":["C198745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"General Office Clerks","n_c":["C198746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Government Regulatory Associate Professionals","n_c":["C198747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hairdressers, Beauticians and Related Workers","n_c":["C198748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Handicraft Workers","n_c":["C198749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heavy Truck and Bus Drivers","n_c":["C198750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hotel and Restaurant Managers","n_c":["C198751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Information and Communications Technology Operations and User Support Technicians","n_c":["C198752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Information and Communications Technology Service managers","n_c":["C198753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Keyboard Operators","n_c":["C198754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legal Professionals","n_c":["C97637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legal, Social and Religious Associate Professionals","n_c":["C198822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legislators and Senior Officials","n_c":["C198755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Librarians, Archivists and Curators","n_c":["C122473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Life Science Professionals","n_c":["C122474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Life Science Technicians and Related Associate Professionals","n_c":["C198756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locomotive Engine Drivers and Related Workers","n_c":["C198757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Machinery Mechanics and Repairers","n_c":["C198758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Managing Directors and Chief Executives","n_c":["C198759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Manufacturing Labourers","n_c":["C25392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Manufacturing, Mining, Construction and Distribution Managers","n_c":["C198760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Market Gardeners and Crop Growers","n_c":["C198761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Material Recording and Transport Clerks","n_c":["C198762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mathematicians, Actuaries and Statisticians","n_c":["C198763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medical and Pharmaceutical Technicians","n_c":["C198764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medical Doctors","n_c":["C25741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metal Processing and Finishing Plant Operators","n_c":["C198765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mining and Construction Labourers","n_c":["C198766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mining and Mineral Processing Plant Operators","n_c":["C198767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mining, Manufacturing and Construction Supervisors","n_c":["C198768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Crop and Animal Producers","n_c":["C198769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobile Plant Operators","n_c":["C198770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-commissioned Armed Forces Officers","n_c":["C198771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Numerical Clerks","n_c":["C198772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nursing and Midwifery Associate Professionals","n_c":["C198773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nursing and Midwifery Professionals","n_c":["C198774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Clerical Support Workers","n_c":["C198775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Craft and Related Workers","n_c":["C198776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Elementary Workers","n_c":["C198777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Health Associate Professionals","n_c":["C198778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Health Professionals","n_c":["C198779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Personal Services Workers","n_c":["C198780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Sales Workers","n_c":["C122555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Services Managers","n_c":["C198781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Stationary Plant and Machine Operators","n_c":["C198782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Teaching Professionals","n_c":["C122556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Painters, Building Structure Cleaners and Related Trades Workers","n_c":["C198783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paramedical Practitioners","n_c":["C53420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personal Care Workers in Health Services","n_c":["C198784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical and Earth Science Professionals","n_c":["C198785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical and Engineering Science Technicians","n_c":["C198786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary School and Early Childhood Teachers","n_c":["C198787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Printing Trades Workers","n_c":["C122501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Process Control Technicians","n_c":["C198788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Production Managers in Agriculture, Forestry and Fisheries","n_c":["C198789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Professional Services Managers","n_c":["C198790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protective Services Workers","n_c":["C97643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Refuse Workers","n_c":["C198791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retail and Wholesale Trade Managers","n_c":["C198792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubber, Plastic and Paper Products Machine Operators","n_c":["C198793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sales and Purchasing Agents and Brokers","n_c":["C198794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sales, Marketing and Development Managers","n_c":["C198795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sales, Marketing and Public Relations Professionals","n_c":["C198796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Secondary Education Teachers","n_c":["C198797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Secretaries (general)","n_c":["C198798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sheet and Structural Metal Workers, Moulders and Welders, and Related Workers","n_c":["C198799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ship and Aircraft Controllers and Technicians","n_c":["C198800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ships' Deck Crews and Related Workers","n_c":["C198801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shop Salespersons","n_c":["C75553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social and Religious Professionals","n_c":["C198802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Software and Applications Developers and Analysts","n_c":["C198803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sports and Fitness Workers","n_c":["C198804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Street and Market Salespersons","n_c":["C198805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Street and Related Service Workers","n_c":["C198806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Street Vendors (excluding Food)","n_c":["C198807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Crop Farmers","n_c":["C198808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Fishers, Hunters, Trappers and Gatherers","n_c":["C198809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Livestock Farmers","n_c":["C198810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Mixed Crop and Livestock Farmers","n_c":["C198811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telecommunications and Broadcasting Technicians","n_c":["C198812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tellers, Money Collectors and Related Clerks","n_c":["C122451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Textile, Fur and Leather Products Machine Operators","n_c":["C198813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Traditional and Complementary Medicine Associate Professionals","n_c":["C198814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Traditional and Complementary Medicine Professionals","n_c":["C198815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transport and Storage Labourers","n_c":["C198816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Travel Attendants, Conductors and Guides","n_c":["C198817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"University and Higher Education Teachers","n_c":["C122499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vehicle, Window, Laundry and Other Hand Cleaning Workers","n_c":["C198818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veterinarians","n_c":["C82470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veterinary Technicians and Assistants","n_c":["C82473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vocational education teachers","n_c":["C198819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Waiters and Bartenders","n_c":["C122460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood Processing and Papermaking Plant Operators","n_c":["C198820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood Treaters, Cabinet-makers and Related Trades Workers","n_c":["C198821"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.peritoneal_washing_results":[{"nm":"Negative","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Positive","n_c":["C38758"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.platform":[{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.residual_disease":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R0","n_c":["C139578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C139579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C139580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RX","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.residual_tumor_measurement":[{"nm":">20 mm","n_c":["C199161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1-10 mm","n_c":["C199163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11-20 mm","n_c":["C199164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No macroscopic disease","n_c":["C199165"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factor_method_of_diagnosis":[{"nm":"Biochemical Assessment","n_c":["C199177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Both Clinical and Biochemical Assessments","n_c":["C199179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Assessment","n_c":["C199178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factors":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosis (Atypical Adenomatous Hyperplasia)","n_c":["C120861","C5665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Consumption","n_c":["C16273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcoholic Liver Disease","n_c":["C34783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Animal, NOS","n_c":["C172303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Ant","n_c":["C172307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Bee","n_c":["C172308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Cat","n_c":["C172310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dairy or Lactose","n_c":["C175520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dog","n_c":["C172311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Eggs","n_c":["C172313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Food, NOS","n_c":["C172304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Fruit","n_c":["C172316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Meat","n_c":["C172317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Mold or Dust","n_c":["C172306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Nuts","n_c":["C175521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Processed Foods","n_c":["C175522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Seafood","n_c":["C172320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Wasp","n_c":["C172321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin Deficiency","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altered Mental Status","n_c":["C121628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Excess","n_c":["C113215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Atrophic Chronic Gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1 Tumor Predisposition Syndrome","n_c":["C172639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birt-Hogg-Dube Syndrome","n_c":["C28244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA Family History","n_c":["C172230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Hepatitis","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C80078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common variable immune deficiency (CVID)","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cortisol Excess","n_c":["C113208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cowden Syndrome","n_c":["C3076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, NOS","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type I","n_c":["C2986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogen Excess","n_c":["C113344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Polyp(s)","n_c":["C3954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilbert's Syndrome","n_c":["C84729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular Disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H. pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hay Fever","n_c":["C92188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter Pylori-Associated Gastritis","n_c":["C27121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Disorder, NOS","n_c":["C26323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemochromatosis","n_c":["C82892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Encephalopathy","n_c":["C79596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, NOS","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Breast Cancer","n_c":["C4503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Hemorrhagic Telangiectasia","n_c":["C35064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Kidney Oncocytoma","n_c":["C8960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","n_c":["C51302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Ovarian Cancer","n_c":["C36102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Papillary Renal Cell Carcinoma","n_c":["C9222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Prostate Cancer","n_c":["C103817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Renal Cell Carcinoma","n_c":["C39789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-grade Prostatic Intraepithelial Neoplasia (PIN)","n_c":["C5541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV","n_c":["C3108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-6 (HHV-6)","n_c":["C128829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-8 (HHV-8)","n_c":["C39291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation, Hyperkeratosis","n_c":["C3137","C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inherited Genetic Syndrome, NOS","n_c":["C3101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mineralcorticoids Excess","n_c":["C198986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motor / Movement Change","n_c":["C157433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndrome","n_c":["C3247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neurocystericerosis","n_c":["C84932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Fatty Liver Disease","n_c":["C84444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Contraceptives","n_c":["C389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Pyogenic Cholangitis","n_c":["C164213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubella","n_c":["C85051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serous tubal intraepithelial carcinoma (STIC)","n_c":["C126449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Rash","n_c":["C39594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","n_c":["C156464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tattoo","n_c":["C113681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Nodular Hyperplasia","n_c":["C131437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, NOS","n_c":["C18059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smokeless","n_c":["C137998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberous Sclerosis","n_c":["C3424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulointerstitial Disease","n_c":["C123036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated Lymphoid Proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undescended Testis","n_c":["C12326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disease","n_c":["C35117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vision Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Von Hippel-Lindau Syndrome","n_c":["C3105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.specimen_type":[{"nm":"2D Classical Conditionally Reprogrammed Cells","n_c":["C172257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2D Modified Conditionally Reprogrammed Cells","n_c":["C172258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Air-Liquid Interface Organoid","n_c":["C172260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Neurosphere","n_c":["C172261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Organoid","n_c":["C172259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adherent Cell Line","n_c":["C20216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Components NOS","n_c":["C164008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow NOS","n_c":["C164009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cells","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buffy Coat","n_c":["C84507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell","n_c":["C12508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Control Analyte","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derived Cell Line","n_c":["C156445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts from Bone Marrow","n_c":["C164010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocytes","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Original Cells","n_c":["C19315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquid Suspension Cell Line","n_c":["C20217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytes","n_c":["C12535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid","n_c":["C13049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Adherent Suspension","n_c":["C174118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mononuclear Cells from Bone Marrow","n_c":["C164011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Blood Components NOS","n_c":["C199216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Blood NOS","n_c":["C173496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Whole Blood","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma","n_c":["C13356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C3331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C174119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum","n_c":["C13325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid Tissue","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorted Cells","n_c":["C126974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sputum","n_c":["C13278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whole Bone Marrow","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derived Cell Lines and Sorted Cells","n_c":["C156445","C126974"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.timepoint_category":[{"nm":"Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adolescence","n_c":["C39298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adulthood","n_c":["C199314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Childhood","n_c":["C89345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follow-up","n_c":["C16033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Initial Diagnosis","n_c":["C156813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Last Contact","n_c":["C199315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Adjuvant Therapy","n_c":["C158707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Hormone Therapy","n_c":["C199316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Secondary Therapy","n_c":["C158753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative","n_c":["C28006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Diagnosis","n_c":["C199317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence/Progression","n_c":["C158754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Within 3 Months of Surgery","n_c":["C200432"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.timepoint_category":[{"nm":"End of Consolidation Therapy","n_c":["C199318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End of Treatment Course 1","n_c":["C199320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End of Treatment Course 2","n_c":["C199321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.timepoint_category":[{"nm":"End of Consolidation Therapy","n_c":["C199318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End of Treatment Course","n_c":["C199319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Complete Response","n_c":["C199322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative","n_c":["C28006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Diagnosis","n_c":["C199317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Procurement","n_c":["C199323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Study Registration","n_c":["C199324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence","n_c":["C38155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Treatment","n_c":["C164022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_grade_category":[{"nm":"Four Tier","n_c":["C199325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Three Tier","n_c":["C199326"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_level_prostate":[{"nm":"Apex","n_c":["C13087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Base","n_c":["C13088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle","n_c":["C13094"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_staging_system_edition":[{"nm":"1st","n_c":["C25509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2nd","n_c":["C25666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3rd","n_c":["C25260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4th","n_c":["C54566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5th","n_c":["C54567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6th","n_c":["C54568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7th","n_c":["C133531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8th","n_c":["C133533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.weiss_assessment_findings":[{"nm":"Atypical Mitotic Figures","n_c":["C35962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytoplasm presence <= to 25%","n_c":["C199327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse Architecture","n_c":["C35903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Invasion of Tumor Capsule","n_c":["C199328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotic Rate > 5/50 HPF","n_c":["C54007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Necrosis","n_c":["C36184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclear Grade III or IV","n_c":["C104011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinusoid Invasion","n_c":["C39615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous Invasion","n_c":["C47849"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.clark_level":[{"nm":"I","n_c":["C94812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"II","n_c":["C94813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"III","n_c":["C94814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IV","n_c":["C94815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"V","n_c":["C94816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.contiguous_organ_invaded":[{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inferior Vena Cava","n_c":["C12815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.country_of_birth":[{"nm":"Afghanistan","n_c":["C16267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albania","n_c":["C16271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Algeria","n_c":["C16274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andorra","n_c":["C16289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angola","n_c":["C16292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anguilla","n_c":["C20133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antigua and Barbuda","n_c":["C16303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Argentina","n_c":["C16305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Armenia","n_c":["C16306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aruba","n_c":["C17884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Australia","n_c":["C16311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Austria","n_c":["C16312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azerbaijan","n_c":["C16316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahamas","n_c":["C16321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahrain","n_c":["C16322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bangladesh","n_c":["C16323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barbados","n_c":["C16324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belarus","n_c":["C16372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belgium","n_c":["C16329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belize","n_c":["C16331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benin","n_c":["C16333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bermuda","n_c":["C16334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bhutan","n_c":["C16336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bolivia","n_c":["C16359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosnia and Herzegovina","n_c":["C16361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botswana","n_c":["C16363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brazil","n_c":["C16364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brunei","n_c":["C16367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bulgaria","n_c":["C16368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burkina Faso","n_c":["C16369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burundi","n_c":["C16371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cambodia","n_c":["C16378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cameroon","n_c":["C16379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canada","n_c":["C16380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cape Verde","n_c":["C16382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cayman Islands","n_c":["C16391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central African Republic","n_c":["C16409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chad","n_c":["C16412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chile","n_c":["C16427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"China","n_c":["C16428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colombia","n_c":["C16449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Comoros","n_c":["C16458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congo","n_c":["C16467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cook Islands","n_c":["C16469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Costa Rica","n_c":["C16470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cote d'Ivoire","n_c":["C16762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Croatia","n_c":["C16474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cuba","n_c":["C16477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curacao","n_c":["C101225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyprus","n_c":["C16480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Czech Republic (Czechia)","n_c":["C17668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Democratic Republic of the Congo","n_c":["C17266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denmark","n_c":["C16496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Djibouti","n_c":["C16506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominica","n_c":["C16519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominican Republic","n_c":["C16520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ecuador","n_c":["C16528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Egypt","n_c":["C16530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"El Salvador","n_c":["C16532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equatorial Guinea","n_c":["C16557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eritrea","n_c":["C16558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estonia","n_c":["C16562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eswatini","n_c":["C17179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethiopia","n_c":["C16563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Falkland Islands (Malvinas)","n_c":["C17954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Faroe Islands","n_c":["C16573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Federated States of Micronesia","n_c":["C17881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fiji","n_c":["C16582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finland","n_c":["C16584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"France","n_c":["C16592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Guiana","n_c":["C16593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Polynesia","n_c":["C16594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gabon","n_c":["C16596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gambia","n_c":["C16598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Georgia","n_c":["C16634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Germany","n_c":["C16636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ghana","n_c":["C26330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gibraltar","n_c":["C16638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greece","n_c":["C16645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greenland","n_c":["C16646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grenada","n_c":["C16647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guadeloupe","n_c":["C16651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guam","n_c":["C16652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guatemala","n_c":["C16654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guernsey","n_c":["C64375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea","n_c":["C16655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea-Bissau","n_c":["C16656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guyana","n_c":["C16657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Haiti","n_c":["C16660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Holy See","n_c":["C17249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Honduras","n_c":["C16694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hong Kong","n_c":["C16695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hungary","n_c":["C16699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iceland","n_c":["C16704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"India","n_c":["C16727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indonesia","n_c":["C16728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iran","n_c":["C16755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iraq","n_c":["C16756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ireland","n_c":["C16757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isle of Man","n_c":["C44480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Israel","n_c":["C16760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Italy","n_c":["C16761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jamaica","n_c":["C16763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Japan","n_c":["C16764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jersey","n_c":["C64374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jordan","n_c":["C16765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kazakhstan","n_c":["C20107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kenya","n_c":["C16769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kiribati","n_c":["C16639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kosovo","n_c":["C123740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kuwait","n_c":["C16775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kyrgyzstan","n_c":["C16771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laos","n_c":["C16780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Latvia","n_c":["C16783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lebanon","n_c":["C16784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lesotho","n_c":["C16787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liberia","n_c":["C16791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libya","n_c":["C16793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liechtenstein","n_c":["C16794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lithuania","n_c":["C16799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luxembourg","n_c":["C16803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macau","n_c":["C16807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Madagascar","n_c":["C16808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malawi","n_c":["C16813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaysia","n_c":["C16814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maldives","n_c":["C16815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mali","n_c":["C16816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malta","n_c":["C16817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marshall Islands","n_c":["C16822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Martinique","n_c":["C16823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritania","n_c":["C16826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritius","n_c":["C16827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mayotte","n_c":["C16828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mexico","n_c":["C16850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moldova","n_c":["C16871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monaco","n_c":["C16874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mongolia","n_c":["C16875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montenegro","n_c":["C64378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montserrat","n_c":["C16876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morocco","n_c":["C16878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mozambique","n_c":["C16882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myanmar","n_c":["C16370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namibia","n_c":["C16891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nauru","n_c":["C16896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nepal","n_c":["C16901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Netherlands","n_c":["C16903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Caledonia","n_c":["C16913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Zealand","n_c":["C16914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nicaragua","n_c":["C16915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niger","n_c":["C16916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nigeria","n_c":["C16917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niue","n_c":["C16918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Korea","n_c":["C16773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Macedonia","n_c":["C17654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Northern Mariana Islands","n_c":["C17882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norway","n_c":["C16920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oman","n_c":["C16933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pakistan","n_c":["C16949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palau","n_c":["C17733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panama","n_c":["C16951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papua New Guinea","n_c":["C16952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraguay","n_c":["C16953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peru","n_c":["C16972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Philippines","n_c":["C16978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poland","n_c":["C17002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portugal","n_c":["C17006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puerto Rico","n_c":["C17043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Qatar","n_c":["C17045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reunion","n_c":["C17095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Romania","n_c":["C17108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Russia","n_c":["C17111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rwanda","n_c":["C17112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Helena, Ascension and Tristan da Cunha","n_c":["C17164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Kitts and Nevis","n_c":["C17885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Lucia","n_c":["C17113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Pierre and Miquelon","n_c":["C17165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Vincent and the Grenadines","n_c":["C17114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samoa","n_c":["C17740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"San Marino","n_c":["C17115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sao Tome and Principe","n_c":["C17116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saudi Arabia","n_c":["C17117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Senegal","n_c":["C17121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serbia","n_c":["C64377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seychelles","n_c":["C17129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sierra Leone","n_c":["C17130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Singapore","n_c":["C17134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovakia","n_c":["C17669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovenia","n_c":["C17138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solomon Islands","n_c":["C17148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somalia","n_c":["C17149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Africa","n_c":["C17151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Korea","n_c":["C16774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Sudan","n_c":["C97351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spain","n_c":["C17152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sri Lanka","n_c":["C17163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"State of Palestine","n_c":["C20110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sudan","n_c":["C17170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suriname","n_c":["C17175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Svalbard & Jan Mayen Islands","n_c":["C17178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sweden","n_c":["C17180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Switzerland","n_c":["C17181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syria","n_c":["C17182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taiwan","n_c":["C17184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tajikistan","n_c":["C17183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanzania","n_c":["C17185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thailand","n_c":["C17192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Timor-Leste","n_c":["C17200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Togo","n_c":["C17202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tokelau","n_c":["C17704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonga","n_c":["C17205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trinidad and Tobago","n_c":["C17217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tunisia","n_c":["C17221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkey","n_c":["C17222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkmenistan","n_c":["C17223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuvalu","n_c":["C17225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uganda","n_c":["C17228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ukraine","n_c":["C17229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Arab Emirates","n_c":["C17232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Kingdom","n_c":["C17233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United States","n_c":["C17234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uruguay","n_c":["C17244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uzbekistan","n_c":["C17246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vanuatu","n_c":["C17247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venezuela","n_c":["C17250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vietnam","n_c":["C17252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, British","n_c":["C17653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, U.S.","n_c":["C17255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wallis and Futuna","n_c":["C17259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Western Sahara","n_c":["C20113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yemen","n_c":["C17264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zambia","n_c":["C17267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zimbabwe","n_c":["C17268"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.education_level":[{"nm":"College Degree","n_c":["C159746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High School Graduate or GED","n_c":["C67136","C67135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Professional or Graduate Degree","n_c":["C70558","C168226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Some High School or Less","n_c":["C198650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vocational College or Some College","n_c":["C67141","C67137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_clinical_m":[{"nm":"M0","n_c":["C104028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C104029"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_pathologic_n":[{"nm":"N0","n_c":["C104024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C104025"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_pathologic_stage":[{"nm":"Stage I","n_c":["C104031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C104032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C104033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C104034"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_pathologic_t":[{"nm":"T1","n_c":["C104019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C104020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C104021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C104022"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.marital_status":[{"nm":"Divorced","n_c":["C51776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domestic Partnership","n_c":["C53262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Married","n_c":["C51773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never Married","n_c":["C51774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Separated","n_c":["C156541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Widowed","n_c":["C51775"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.measurement_type":[{"nm":"Pathologic","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiologic","n_c":["C93286"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.measurement_type":[{"nm":"Pathologic","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiologic","n_c":["C93286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Echographic","n_c":["C200433"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.measurement_unit":[{"nm":"Centimeters","n_c":["C49668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Millimeters","n_c":["C28251"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.melanoma_known_primary":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.platform":[{"nm":"Illumina Methylation Epic v2","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Methylation Epic","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.platform":[{"nm":"Illumina Methylation Epic v2","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Methylation Epic","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.platform":[{"nm":"Illumina Methylation Epic v2","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Methylation Epic","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relative_deceased":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relative_smoker":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_anatomic_sites":[{"nm":"Abdomen, total","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Wall","n_c":["C77608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetabulum","n_c":["C32042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoid","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adipose","n_c":["C12472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alveolar Ridge","n_c":["C89749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amniotic Fluid","n_c":["C13188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Sphincter","n_c":["C165177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle","n_c":["C32078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectum","n_c":["C129464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antecubital Fossa","n_c":["C103238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrum","n_c":["C97102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aorta","n_c":["C12669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Body","n_c":["C97112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aqueous Fluid","n_c":["C13190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arm","n_c":["C32141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artery","n_c":["C12372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon","n_c":["C12265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auditory Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autonomic Nervous System","n_c":["C12673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axilla","n_c":["C12674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back","n_c":["C13062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct","n_c":["C12376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel","n_c":["C12679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Body, total","n_c":["C13041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bowel","n_c":["C12736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad Ligament","n_c":["C12318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchiole","n_c":["C12684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brow","n_c":["C32575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock","n_c":["C89806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calf","n_c":["C93027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary","n_c":["C12685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardia","n_c":["C12256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carina","n_c":["C25264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Artery","n_c":["C12687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Body","n_c":["C66852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cartilage","n_c":["C12373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecum","n_c":["C12381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell-Line","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebellum","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Spine","n_c":["C69313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest","n_c":["C25389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chin","n_c":["C81169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clavicle","n_c":["C12695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clitoris","n_c":["C12308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon - Mucosa Only","n_c":["C164003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Duct","n_c":["C12698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermal","n_c":["C25478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Descending Colon","n_c":["C12268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Site","n_c":["C179433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenum","n_c":["C12263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear, Pinna (External)","n_c":["C12292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbow","n_c":["C32497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Gland","n_c":["C12704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epidural Space","n_c":["C41449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C165193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagogastric Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus - Mucosa Only","n_c":["C32538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Artery","n_c":["C12715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Vein","n_c":["C12716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femur","n_c":["C12717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts","n_c":["C12482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibula","n_c":["C12718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finger","n_c":["C32608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floor of Mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluid","n_c":["C25278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foot","n_c":["C32622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forearm","n_c":["C32628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forehead","n_c":["C89803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foreskin","n_c":["C33049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Cortex","n_c":["C177766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fundus of Stomach","n_c":["C12257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglia","n_c":["C12719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal, Intestine","n_c":["C13359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genitourinary, NOS","n_c":["C25350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand","n_c":["C32712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hard Palate","n_c":["C12230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head and Neck","n_c":["C12418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic","n_c":["C13308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Duct","n_c":["C32730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Vein","n_c":["C32736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C25724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip","n_c":["C64193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hippocampus","n_c":["C12444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Humerus","n_c":["C12731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileocecal Valve","n_c":["C13066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileum","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilium","n_c":["C32765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Index Finger","n_c":["C52835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inferior Vena Cava","n_c":["C12815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischium","n_c":["C32884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Islet Cells","n_c":["C32885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jaw","n_c":["C48821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunum","n_c":["C12388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint","n_c":["C13044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Knee","n_c":["C32898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacrimal Gland","n_c":["C12346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Bowel","n_c":["C12379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leg","n_c":["C32974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ligament","n_c":["C13046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locoregional Site","n_c":["C25388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumbar Spine","n_c":["C69314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Axilla","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Distant","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-Common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-External","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Internal Mammary","n_c":["C32853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mammary","n_c":["C137678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Pelvic","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Scalene","n_c":["C89780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Subclavicular","n_c":["C63705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mantle","n_c":["C12507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Soft Tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Finger","n_c":["C52836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondria","n_c":["C13258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle","n_c":["C13056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nails","n_c":["C33156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Cavity","n_c":["C12424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Soft Tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve","n_c":["C12466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve(s) Cranial","n_c":["C12700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital Cortex","n_c":["C177767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular Orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity - Mucosa Only","n_c":["C77637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraspinal Ganglion","n_c":["C97925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parathyroid","n_c":["C12765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid Gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patella","n_c":["C33282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Soft Tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharynx","n_c":["C12425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal Gland","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pituitary Gland","n_c":["C12399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal Fossa","n_c":["C103222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pouch","n_c":["C43200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Tumor Field","n_c":["C179450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary tumor site","n_c":["C179451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Bed","n_c":["C90348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pylorus","n_c":["C12260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid Junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional Site","n_c":["C179457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retina","n_c":["C12343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retro-Orbital Region","n_c":["C54155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rib","n_c":["C12782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ring Finger","n_c":["C52837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Round Ligament","n_c":["C12319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacrum","n_c":["C33508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scapula","n_c":["C12783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sciatic Nerve","n_c":["C52810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotum","n_c":["C12785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seminal Vesicle","n_c":["C12787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shoulder","n_c":["C25203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus(es), Maxillary","n_c":["C12275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skeletal Muscle","n_c":["C13050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, lower extremity, local","n_c":["C164047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, total","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, trunk, local","n_c":["C12295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, upper extremity, local","n_c":["C164048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skull","n_c":["C12789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel - Mucosa Only","n_c":["C33568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Finger","n_c":["C52838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Column","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spine","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Flexure","n_c":["C12267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sternum","n_c":["C12793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach - Mucosa Only","n_c":["C32656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous Tissue","n_c":["C33645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovium","n_c":["C12473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal Cortex","n_c":["C177768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tendon","n_c":["C13045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thigh","n_c":["C33763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracic Spine","n_c":["C69315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat","n_c":["C54272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thumb","n_c":["C52834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tibia","n_c":["C12800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil (Pharyngeal)","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea / Major Bronchi","n_c":["C12961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trunk","n_c":["C33816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbilical Cord","n_c":["C34320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract","n_c":["C191741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uvula","n_c":["C12232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens","n_c":["C12813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vein","n_c":["C12814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous","n_c":["C25291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebra","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cells","n_c":["C12529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist","n_c":["C33894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_depth_descriptor":[{"nm":"Deep","n_c":["C51137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial","n_c":["C36109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_infiltrating_lymphocytes":[{"nm":"Few","n_c":["C64942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Many","n_c":["C78728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate","n_c":["C61376"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_infiltrating_macrophages":[{"nm":"Few","n_c":["C64942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Many","n_c":["C78728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate","n_c":["C61376"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_measurement_method":[{"nm":"Echographic","n_c":["C200433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathologic","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_shape":[{"nm":"Diffuse","n_c":["C47826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dome","n_c":["C54253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mushroom","n_c":["C111029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ulceration_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.aids_risk_factors":[{"nm":"Candidiasis","n_c":["C26711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coccidioidomycosis","n_c":["C84642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcosis","n_c":["C2967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptosporidiosis, Chronic Intestinal","n_c":["C174107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalopathy","n_c":["C26920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Simplex Virus","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histoplasmosis","n_c":["C77201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isosporiasis","n_c":["C4076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium tuberculosis","n_c":["C128377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium, NOS","n_c":["C26831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nocardiosis","n_c":["C171147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Multifocal Leukoencephalopathy","n_c":["C26815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salmonella Septicemia","n_c":["C171146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxoplasmosis","n_c":["C3418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wasting Syndrome","n_c":["C171148"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.cdc_hiv_risk_factors":[{"nm":"Hemophiliac","n_c":["C3093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterosexual Contact","n_c":["C154862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Homosexual Contact","n_c":["C154863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravenous Drug User","n_c":["C84367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C159672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transfusion Recipient","n_c":["C171149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.comorbidities":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Renal Failure","n_c":["C26808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenocarcinoma","n_c":["C2852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomatous Polyposis Coli","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenocortical Insufficiency","n_c":["C26691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergies","n_c":["C114476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C26696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arrhythmia","n_c":["C2881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C2883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-Telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C50466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C118385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Carcinoma","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Thyroid Nodule","n_c":["C3415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Disorder","n_c":["C2899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Clots","n_c":["C27083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Fracture(s)","n_c":["C3046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchitis","n_c":["C2911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Channel Blockers","n_c":["C333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataracts","n_c":["C26713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celiac Disease","n_c":["C26714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrovascular Disease","n_c":["C2938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Fatigue Syndrome","n_c":["C3037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Renal Failure","n_c":["C9438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis, Unknown Etiology","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clonal Hematopoiesis","n_c":["C162188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Infection","n_c":["C27582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immunodeficiency","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congestive Heart Failure (CHF)","n_c":["C3080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue Disorder","n_c":["C26729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COPD","n_c":["C3199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coronary Artery Disease","n_c":["C26732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crohn's Disease","n_c":["C2965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptogenic Organizing Pneumonia","n_c":["C62586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Vein Thrombosis / Thromboembolism","n_c":["C49343","C28195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C2982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetic Neuropathy","n_c":["C26748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet Controlled Diabetes","n_c":["C184754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DVT/PE","n_c":["C49343","C50713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyslipidemia","n_c":["C80385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epilepsy","n_c":["C3020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromyalgia","n_c":["C87497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follicular Adenoma","n_c":["C3502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GERD","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C26782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycogen Storage Disease","n_c":["C61272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goiter","n_c":["C26785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadal Dysfunction","n_c":["C26786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gout","n_c":["C34650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Graves' Disease","n_c":["C3071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Disease","n_c":["C3079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhagic Cystitis","n_c":["C114666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, Chronic","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Non-Polyposis Colon Cancer","n_c":["C120083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Liver Dysplastic Nodule","n_c":["C96768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV/AIDS","n_c":["C2851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HUS/TTP","n_c":["C75545","C78797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C3112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercholesterolemia","n_c":["C37967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C26797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperlipidemia","n_c":["C34707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperparathyroidism","n_c":["C48259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C3117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperthyroidism","n_c":["C3123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammatory Bowel Disease","n_c":["C3138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin Controlled Diabetes","n_c":["C184766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interstitial Pneumonitis or ARDS","n_c":["C3353","C27006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraductal Papillary Mucinous Neoplasm","n_c":["C38342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemic Heart Disease","n_c":["C50625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITP","n_c":["C3446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Replacement","n_c":["C131579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Disease","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cirrhosis (Liver Disease)","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Toxicity (Non-Infectious)","n_c":["C184773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Liver Dysplastic Nodule","n_c":["C96770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupus","n_c":["C27153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Hyperplasia","n_c":["C102532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAI","n_c":["C27314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methicillin-Resistant Staphylococcus aureus (MRSA)","n_c":["C115248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C27996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroendocrine Tumor","n_c":["C3809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ Transplant (Site)","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoarthritis","n_c":["C3293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis or Osteopenia","n_c":["C50910","C3298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Cancer within 5 Years","n_c":["C184782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Nonmalignant Systemic Disease","n_c":["C184785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Pulmonary Complications","n_c":["C184786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain (Various)","n_c":["C3303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptic Ulcer (Ulcer)","n_c":["C3318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Neuropathy","n_c":["C119734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Vascular Disease","n_c":["C35136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peutz-Jeghers Disease","n_c":["C3324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy in Patient or Partner","n_c":["C124295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psoriasis","n_c":["C3346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hemorrhage","n_c":["C78578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Dialysis","n_c":["C15248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Failure (Requiring Dialysis)","n_c":["C184791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Insufficiency","n_c":["C4376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatologic Disease","n_c":["C27204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep Apnea","n_c":["C26884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking","n_c":["C154329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staph Osteomyelitis","n_c":["C188353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C3390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Disease, Non-Cancer","n_c":["C27566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attack","n_c":["C50781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinemia","n_c":["C98640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulcerative Colitis","n_c":["C2952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C50791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.comorbidity_method_of_diagnosis":[{"nm":"Histology","n_c":["C16681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathology","n_c":["C18189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiology","n_c":["C19187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.diabetes_treatment_type":[{"nm":"Alpha-Glucosidase Inhibitor","n_c":["C139651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biguanide","n_c":["C98234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injected Insulin","n_c":["C179441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin","n_c":["C581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linagliptin","n_c":["C83887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hypoglycemic","n_c":["C179448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulfonylurea","n_c":["C97936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiazolidinedione","n_c":["C98241"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.exercise_frequency_weekly":[{"nm":"5 or More Days","n_c":["C202212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3 to 4 Days","n_c":["C202213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1 to 2 Days","n_c":["C202214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extracapsular_extension_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extrathyroid_extension":[{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Minimal (T3)","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate/Advanced (T4a)","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Very Advanced (T4b)","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.eye_color":[{"nm":"Amber","n_c":["C111017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blue","n_c":["C48333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brown","n_c":["C48332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gray","n_c":["C48324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hazel","n_c":["C111018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red & Violet","n_c":["C157431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C160244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.first_symptom_longest_duration":[{"nm":"0-30 Days","n_c":["C202215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"31-90 Days","n_c":["C202216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"91-180 Days","n_c":["C202217"],"i_c":"","i_c_s":"","term_type":""},{"nm":">=181 Days","n_c":["C202218"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.haart_treatment_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hepatitis_sustained_virological_response":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.histologic_progression_type":[{"nm":"Anaplastic","n_c":["C36113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poorly differentiated","n_c":["C36132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hormonal_contraceptive_type":[{"nm":"Progestin","n_c":["C179455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progestin and Estrogen","n_c":["C179456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hormonal_contraceptive_use":[{"nm":"Current User","n_c":["C160671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Former User","n_c":["C160672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never Used","n_c":["C160673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hormone_replacement_therapy_type":[{"nm":"Estrogen only","n_c":["C179434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone and Estrogen","n_c":["C179452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone only","n_c":["C179453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hysterectomy_margins_involved":[{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic Parametrium","n_c":["C179443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic Parametrium","n_c":["C179445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C48621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hysterectomy_type":[{"nm":"Hysterectomy, NOS","n_c":["C15256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Performed","n_c":["C141477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Hysterectomy","n_c":["C94470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.immunosuppressive_treatment_type":[{"nm":"Anti-TNF Therapy","n_c":["C15577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azathioprine","n_c":["C290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide","n_c":["C405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate","n_c":["C642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.menopause_status":[{"nm":"Perimenopausal","n_c":["C15692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postmenopausal","n_c":["C15421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premenopausal","n_c":["C15491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.micrometastasis_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.myasthenia_gravis_classification":[{"nm":"Class I","n_c":["C112014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class II","n_c":["C112015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class III","n_c":["C112016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class IV","n_c":["C112017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class V","n_c":["C112018"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.nononcologic_therapeutic_agents":[{"nm":"Acetaminophen","n_c":["C198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspirin","n_c":["C287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metformin","n_c":["C61612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Statin, NOS","n_c":["C1655"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.oxygen_use_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.oxygen_use_type":[{"nm":"Continuous","n_c":["C202296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermittent","n_c":["C202297"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.platform":[{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.platform":[{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.pregnancy_outcome":[{"nm":"Ectopic Pregnancy","n_c":["C34945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induced Abortion","n_c":["C50613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live Birth","n_c":["C114091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscarriage","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Abortion","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stillbirth","n_c":["C49151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.pregnant_at_diagnosis":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.premature_at_birth":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.radiosensitizing_agent":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.reason_treatment_not_given":[{"nm":"Adverse Event/Complications","n_c":["C41331","C2959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Done per Treating Physician's Discretion","n_c":["C202267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Participant Refusal","n_c":["C192979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scheduling Problems","n_c":["C185642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.reflux_treatment_type":[{"nm":"Antacids","n_c":["C29633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2 Blockers","n_c":["C29702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medically Treated","n_c":["C165200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Treatment","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proton Pump Inhibitors","n_c":["C29723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgically Treated","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.risk_factor_method_of_diagnosis":[{"nm":"Biochemical Assessment","n_c":["C199177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Both Clinical and Biochemical Assessments","n_c":["C199179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Assessment","n_c":["C199178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.risk_factor_treatment":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.risk_factors":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosis (Atypical Adenomatous Hyperplasia)","n_c":["C120861","C5665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Consumption","n_c":["C16273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcoholic Liver Disease","n_c":["C34783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Animal, NOS","n_c":["C172303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Ant","n_c":["C172307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Bee","n_c":["C172308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Cat","n_c":["C172310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dairy or Lactose","n_c":["C175520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dog","n_c":["C172311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Eggs","n_c":["C172313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Food, NOS","n_c":["C172304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Fruit","n_c":["C172316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Meat","n_c":["C172317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Mold or Dust","n_c":["C172306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Nuts","n_c":["C175521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Processed Foods","n_c":["C175522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Seafood","n_c":["C172320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Wasp","n_c":["C172321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin Deficiency","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altered Mental Status","n_c":["C121628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Excess","n_c":["C113215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-Telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Atrophic Chronic Gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1 Tumor Predisposition Syndrome","n_c":["C172639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Thyroid Nodule","n_c":["C3415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birt-Hogg-Dube Syndrome","n_c":["C28244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA Family History","n_c":["C172230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Hepatitis","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C80078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immune Deficiency (CVID)","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cortisol Excess","n_c":["C113208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cowden Syndrome","n_c":["C3076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, NOS","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type I","n_c":["C2986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogen Excess","n_c":["C113344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follicular Adenoma","n_c":["C3502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Polyp(s)","n_c":["C3954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilbert's Syndrome","n_c":["C84729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular Disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goiter","n_c":["C26785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Graves' Disease","n_c":["C3071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hay Fever","n_c":["C92188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter pylori-Associated Gastritis","n_c":["C27121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Disorder, NOS","n_c":["C26323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemochromatosis","n_c":["C82892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Encephalopathy","n_c":["C79596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, NOS","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Breast Cancer","n_c":["C4503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Hemorrhagic Telangiectasia","n_c":["C35064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Kidney Oncocytoma","n_c":["C8960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","n_c":["C51302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Ovarian Cancer","n_c":["C36102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Papillary Renal Cell Carcinoma","n_c":["C9222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Prostate Cancer","n_c":["C103817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Renal Cell Carcinoma","n_c":["C39789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-grade Prostatic Intraepithelial Neoplasia (PIN)","n_c":["C5541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV","n_c":["C3108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-6 (HHV-6)","n_c":["C128829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-8 (HHV-8)","n_c":["C39291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperparathyroidism","n_c":["C48259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperthyroidism","n_c":["C3123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation, Hyperkeratosis","n_c":["C3137","C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inherited Genetic Syndrome, NOS","n_c":["C3101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Hyperplasia","n_c":["C102532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mineralcorticoids Excess","n_c":["C198986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motor / Movement Change","n_c":["C157433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndrome","n_c":["C3247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neurocystericerosis","n_c":["C84932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nodular Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Fatty Liver Disease","n_c":["C84444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Contraceptives","n_c":["C389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Pyogenic Cholangitis","n_c":["C164213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubella","n_c":["C85051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serous Tubal Intraepithelial Carcinoma (STIC)","n_c":["C126449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Rash","n_c":["C39594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","n_c":["C156464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tattoo","n_c":["C113681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Nodular Hyperplasia","n_c":["C131437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, NOS","n_c":["C18059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smokeless","n_c":["C137998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberous Sclerosis","n_c":["C3424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulointerstitial Disease","n_c":["C123036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated Lymphoid Proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undescended Testis","n_c":["C12326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disease","n_c":["C35117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vision Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Von Hippel-Lindau Syndrome","n_c":["C3105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.staining_intensity_scale":[{"nm":"3 Point Scale","n_c":["C202268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4 Point Scale","n_c":["C202269"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.staining_intensity_value":[{"nm":"0","n_c":["C186199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1+","n_c":["C186200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2+","n_c":["C186201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3+","n_c":["C186202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4+","n_c":["C202273"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.therapeutic_levels_achieved":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.timepoint_category":[{"nm":"Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adolescence","n_c":["C39298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adulthood","n_c":["C199314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Childhood","n_c":["C89345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follow-up","n_c":["C16033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Initial Diagnosis","n_c":["C156813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Last Contact","n_c":["C199315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Adjuvant Therapy","n_c":["C158707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Hormone Therapy","n_c":["C199316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Secondary Therapy","n_c":["C158753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative","n_c":["C28006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Diagnosis","n_c":["C199317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence/Progression","n_c":["C158754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Within 3 Months of Surgery","n_c":["C200432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.treatment_frequency":[{"nm":"Every Hour","n_c":["C64510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Five Times Daily","n_c":["C98849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Four Times Daily","n_c":["C64530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Three Times Daily","n_c":["C64527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Daily","n_c":["C64496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once Daily","n_c":["C64515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Every Other Day","n_c":["C64525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Weekly","n_c":["C64497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once Weekly","n_c":["C64526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once a Week for at Least a Year","n_c":["C202276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occasionally","n_c":["C151974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never","n_c":["C172572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_corrected":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_corrected_laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_corrected_method":[{"nm":"Hormones","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orchiopexy","n_c":["C111066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Descent","n_c":["C184803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis Removed","n_c":["C15288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_history":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_history_laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.viral_hepatitis_serologies":[{"nm":"HBV Core Antibody","n_c":["C96660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV DNA","n_c":["C103404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Genotype","n_c":["C117108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Surface Antibody","n_c":["C74711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HCV Genotype","n_c":["C117109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Surface Antigen","n_c":["C64850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Antibody","n_c":["C92535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Virus RNA","n_c":["C142330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}]}
\ No newline at end of file
+{"biospecimen.aliquot.analyte_type":[{"nm":"cfDNA","n_c":["C128274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized Normal","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE DNA","n_c":["C156435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE RNA","n_c":["C156436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GenomePlex (Rubicon) Amplified DNA","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclei RNA","n_c":["C174108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G (Qiagen) DNA","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G Pooled (Qiagen) DNA","n_c":["C156437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X (Qiagen) DNA","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A Enriched RNA","n_c":["C188352"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.aliquot.analyte_type_id":[{"nm":"D","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"E","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"G","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H","n_c":["C179446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"T","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"W","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"X","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y","n_c":"","i_c":"","i_c_s":"","term_type":""}],"metadata_file.analysis_metadata.data_category":[{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.analysis_metadata.data_type":[{"nm":"Analysis Metadata","n_c":["C165211"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.analysis_metadata.data_format":[{"nm":"SRA XML","n_c":["C184804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-TAB","n_c":["C82937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDRF","n_c":["C172211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDF","n_c":["C172212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ADF","n_c":["C172213"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.analyte_type":[{"nm":"cfDNA","n_c":["C128274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized Normal","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE DNA","n_c":["C156435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE RNA","n_c":["C156436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GenomePlex (Rubicon) Amplified DNA","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclei RNA","n_c":["C174108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G (Qiagen) DNA","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G Pooled (Qiagen) DNA","n_c":["C156437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X (Qiagen) DNA","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A Enriched RNA","n_c":["C188352"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.analyte_type_id":[{"nm":"D","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"E","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"G","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H","n_c":["C179446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"T","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"W","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"X","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y","n_c":"","i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.normal_tumor_genotype_snp_match":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"data_file.biospecimen_supplement.data_category":[{"nm":"Biospecimen","n_c":["C70699"],"i_c":"","i_c_s":"","term_type":""}],"data_file.biospecimen_supplement.data_type":[{"nm":"Biospecimen Supplement","n_c":["C164025"],"i_c":"","i_c_s":"","term_type":""}],"data_file.biospecimen_supplement.data_format":[{"nm":"BCR Auxiliary XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR Biotab","n_c":["C190164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR SSF XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR PPS XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"CDC JSON","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"FoundationOne XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XLSX","n_c":["C164050"],"i_c":"","i_c_s":"","term_type":""}],"case.case.consent_type":[{"nm":"Consent by Death","n_c":["C172262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Consent Exemption","n_c":["C79226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Consent Waiver","n_c":["C103270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Informed Consent","n_c":["C16735"],"i_c":"","i_c_s":"","term_type":""}],"case.case.disease_type":[{"nm":"Acinar Cell Neoplasms","n_c":["C4197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomas and Adenocarcinomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Adnexal and Skin Appendage Neoplasms","n_c":["C4463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Neoplasms","n_c":["C3784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel Tumors","n_c":["C7387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Myeloproliferative Disorders","n_c":["C4345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Complex Epithelial Neoplasms","n_c":["C4198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Complex Mixed and Stromal Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Cystic, Mucinous and Serous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ductal and Lobular Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Neoplasms, NOS","n_c":["C3709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroepithelial Neoplasms","n_c":["C3743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromatous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Germ Cell Neoplasms","n_c":["C3708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Giant Cell Tumors","n_c":["C3055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gliomas","n_c":["C3059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granular Cell Tumors and Alveolar Soft Part Sarcomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoproliferative Diseases","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Leukemias, NOS","n_c":["C3161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipomatous Neoplasms","n_c":["C4248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphatic Vessel Tumors","n_c":["C3723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Leukemias","n_c":["C7539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malignant Lymphomas, NOS or Diffuse","n_c":["C3208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mast Cell Tumors","n_c":["C9295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mature B-Cell Lymphomas","n_c":["C7056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mature T- and NK-Cell Lymphomas","n_c":["C3468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meningiomas","n_c":["C3230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesonephromas","n_c":["C40141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelial Neoplasms","n_c":["C3786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscellaneous Bone Tumors","n_c":["C9343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscellaneous Tumors","n_c":["C102883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucoepidermoid Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndromes","n_c":["C3247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myeloid Leukemias","n_c":["C3172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myomatous Neoplasms","n_c":["C4063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myxomatous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms, NOS","n_c":["C3262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms of Histiocytes and Accessory Lymphoid Cells","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve Sheath Tumors","n_c":["C4972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroepitheliomatous Neoplasms","n_c":["C3787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nevi and Melanomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Odontogenic Tumors","n_c":["C3286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osseous and Chondromatous Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Other Hematologic Disorders","n_c":["C184783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Leukemias","n_c":["C184784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paragangliomas and Glomus Tumors","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma Cell Tumors","n_c":["C4665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Precursor Cell Lymphoblastic Lymphoma","n_c":["C9360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Tumors and Sarcomas, NOS","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Specialized Gonadal Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Cell Neoplasms","n_c":["C3792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovial-like Neoplasms","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Thymic Epithelial Neoplasms","n_c":["C3411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transitional Cell Papillomas and Carcinomas","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Trophoblastic neoplasms","n_c":["C3422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"case.case.index_date":[{"nm":"Diagnosis","n_c":["C164339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Patient Visit","n_c":["C164021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Treatment","n_c":["C164022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Initial Genomic Sequencing","n_c":["C164023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence","n_c":["C171136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sample Procurement","n_c":["C164024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Study Enrollment","n_c":["C139171"],"i_c":"","i_c_s":"","term_type":""}],"case.case.lost_to_followup":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"case.case.primary_site":[{"nm":"Accessory sinuses","n_c":["C12763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal gland","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus and anal canal","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Base of tongue","n_c":["C12228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bones, joints and articular cartilage of limbs","n_c":["C164038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bones, joints and articular cartilage of other and unspecified sites","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus and lung","n_c":["C92218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective, subcutaneous and other soft tissues","n_c":["C12964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye and adnexa","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Floor of mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart, mediastinum, and pleura","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Hematopoietic and reticuloendothelial systems","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver and intrahepatic bile ducts","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph nodes","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meninges","n_c":["C12348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal cavity and middle ear","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined digestive organs","n_c":["C148335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined sites","n_c":["C148336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined sites in lip, oral cavity and pharynx","n_c":["C148337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and ill-defined sites within respiratory system and intrathoracic organs","n_c":["C148338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified female genital organs","n_c":["C148339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified major salivary glands","n_c":["C148340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified male genital organs","n_c":["C148341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified parts of biliary tract","n_c":["C148342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified parts of mouth","n_c":["C148343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified parts of tongue","n_c":["C148344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other and unspecified urinary organs","n_c":["C148345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other endocrine glands and related structures","n_c":["C148346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral nerves and autonomic nervous system","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum and peritoneum","n_c":["C156712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal cord, cranial nerves, and other parts of central nervous system","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea","n_c":["C12428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"data_file.clinical_supplement.data_category":[{"nm":"Clinical","n_c":["C15783"],"i_c":"","i_c_s":"","term_type":""}],"data_file.clinical_supplement.data_type":[{"nm":"Clinical Supplement","n_c":["C164028"],"i_c":"","i_c_s":"","term_type":""}],"data_file.clinical_supplement.data_format":[{"nm":"BCR Biotab","n_c":["C190164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR OMF XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"BCR XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"CDC JSON","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"FoundationOne XML","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XLSX","n_c":["C164050"],"i_c":"","i_c_s":"","term_type":""}],"data.data_release.type":[{"nm":"data_release","n_c":["C172217"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.cause_of_death":[{"nm":"Cancer Related","n_c":["C156427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiovascular Disorder, NOS","n_c":["C2931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End-stage Renal Disease","n_c":["C9439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infection","n_c":["C26726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Cancer Related","n_c":["C156428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Disorder, NOS","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Muscular Atrophy","n_c":["C85075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical Complications","n_c":["C164157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxicity","n_c":["C27990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.cause_of_death_source":[{"nm":"Autopsy","n_c":["C25153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death Certificate","n_c":["C163970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medical Record","n_c":["C45258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social Security Death Index","n_c":["C107424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.country_of_residence_at_enrollment":[{"nm":"Afghanistan","n_c":["C16267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albania","n_c":["C16271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Algeria","n_c":["C16274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andorra","n_c":["C16289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angola","n_c":["C16292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anguilla","n_c":["C20133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antigua and Barbuda","n_c":["C16303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Argentina","n_c":["C16305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Armenia","n_c":["C16306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aruba","n_c":["C17884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Australia","n_c":["C16311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Austria","n_c":["C16312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azerbaijan","n_c":["C16316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahamas","n_c":["C16321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahrain","n_c":["C16322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bangladesh","n_c":["C16323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barbados","n_c":["C16324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belarus","n_c":["C16372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belgium","n_c":["C16329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belize","n_c":["C16331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benin","n_c":["C16333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bermuda","n_c":["C16334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bhutan","n_c":["C16336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bolivia","n_c":["C16359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosnia and Herzegovina","n_c":["C16361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botswana","n_c":["C16363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brazil","n_c":["C16364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brunei","n_c":["C16367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bulgaria","n_c":["C16368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burkina Faso","n_c":["C16369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burundi","n_c":["C16371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cambodia","n_c":["C16378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cameroon","n_c":["C16379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canada","n_c":["C16380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cape Verde","n_c":["C16382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cayman Islands","n_c":["C16391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central African Republic","n_c":["C16409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chad","n_c":["C16412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chile","n_c":["C16427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"China","n_c":["C16428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colombia","n_c":["C16449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Comoros","n_c":["C16458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congo","n_c":["C16467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cook Islands","n_c":["C16469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Costa Rica","n_c":["C16470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cote d'Ivoire","n_c":["C16762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Croatia","n_c":["C16474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cuba","n_c":["C16477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curacao","n_c":["C101225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyprus","n_c":["C16480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Czech Republic (Czechia)","n_c":["C17668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Democratic Republic of the Congo","n_c":["C17266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denmark","n_c":["C16496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Djibouti","n_c":["C16506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominica","n_c":["C16519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominican Republic","n_c":["C16520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ecuador","n_c":["C16528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Egypt","n_c":["C16530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"El Salvador","n_c":["C16532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equatorial Guinea","n_c":["C16557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eritrea","n_c":["C16558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estonia","n_c":["C16562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eswatini","n_c":["C17179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethiopia","n_c":["C16563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Falkland Islands (Malvinas)","n_c":["C17954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Faroe Islands","n_c":["C16573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Federated States of Micronesia","n_c":["C17881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fiji","n_c":["C16582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finland","n_c":["C16584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"France","n_c":["C16592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Guiana","n_c":["C16593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Polynesia","n_c":["C16594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gabon","n_c":["C16596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gambia","n_c":["C16598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Georgia","n_c":["C16634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Germany","n_c":["C16636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ghana","n_c":["C26330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gibraltar","n_c":["C16638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greece","n_c":["C16645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greenland","n_c":["C16646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grenada","n_c":["C16647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guadeloupe","n_c":["C16651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guam","n_c":["C16652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guatemala","n_c":["C16654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guernsey","n_c":["C64375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea","n_c":["C16655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea-Bissau","n_c":["C16656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guyana","n_c":["C16657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Haiti","n_c":["C16660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Holy See","n_c":["C17249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Honduras","n_c":["C16694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hong Kong","n_c":["C16695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hungary","n_c":["C16699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iceland","n_c":["C16704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"India","n_c":["C16727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indonesia","n_c":["C16728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iran","n_c":["C16755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iraq","n_c":["C16756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ireland","n_c":["C16757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isle of Man","n_c":["C44480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Israel","n_c":["C16760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Italy","n_c":["C16761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jamaica","n_c":["C16763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Japan","n_c":["C16764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jersey","n_c":["C64374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jordan","n_c":["C16765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kazakhstan","n_c":["C20107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kenya","n_c":["C16769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kiribati","n_c":["C16639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kosovo","n_c":["C123740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kuwait","n_c":["C16775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kyrgyzstan","n_c":["C16771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laos","n_c":["C16780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Latvia","n_c":["C16783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lebanon","n_c":["C16784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lesotho","n_c":["C16787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liberia","n_c":["C16791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libya","n_c":["C16793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liechtenstein","n_c":["C16794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lithuania","n_c":["C16799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luxembourg","n_c":["C16803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macau","n_c":["C16807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Madagascar","n_c":["C16808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malawi","n_c":["C16813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaysia","n_c":["C16814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maldives","n_c":["C16815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mali","n_c":["C16816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malta","n_c":["C16817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marshall Islands","n_c":["C16822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Martinique","n_c":["C16823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritania","n_c":["C16826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritius","n_c":["C16827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mayotte","n_c":["C16828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mexico","n_c":["C16850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moldova","n_c":["C16871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monaco","n_c":["C16874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mongolia","n_c":["C16875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montenegro","n_c":["C64378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montserrat","n_c":["C16876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morocco","n_c":["C16878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mozambique","n_c":["C16882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myanmar","n_c":["C16370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namibia","n_c":["C16891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nauru","n_c":["C16896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nepal","n_c":["C16901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Netherlands","n_c":["C16903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Caledonia","n_c":["C16913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Zealand","n_c":["C16914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nicaragua","n_c":["C16915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niger","n_c":["C16916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nigeria","n_c":["C16917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niue","n_c":["C16918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Korea","n_c":["C16773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Macedonia","n_c":["C17654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Northern Mariana Islands","n_c":["C17882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norway","n_c":["C16920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oman","n_c":["C16933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pakistan","n_c":["C16949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palau","n_c":["C17733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panama","n_c":["C16951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papua New Guinea","n_c":["C16952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraguay","n_c":["C16953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peru","n_c":["C16972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Philippines","n_c":["C16978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poland","n_c":["C17002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portugal","n_c":["C17006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puerto Rico","n_c":["C17043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Qatar","n_c":["C17045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reunion","n_c":["C17095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Romania","n_c":["C17108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Russia","n_c":["C17111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rwanda","n_c":["C17112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Helena, Ascension and Tristan da Cunha","n_c":["C17164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Kitts and Nevis","n_c":["C17885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Lucia","n_c":["C17113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Pierre and Miquelon","n_c":["C17165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Vincent and the Grenadines","n_c":["C17114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samoa","n_c":["C17740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"San Marino","n_c":["C17115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sao Tome and Principe","n_c":["C17116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saudi Arabia","n_c":["C17117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Senegal","n_c":["C17121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serbia","n_c":["C64377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seychelles","n_c":["C17129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sierra Leone","n_c":["C17130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Singapore","n_c":["C17134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovakia","n_c":["C17669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovenia","n_c":["C17138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solomon Islands","n_c":["C17148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somalia","n_c":["C17149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Africa","n_c":["C17151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Korea","n_c":["C16774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Sudan","n_c":["C97351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spain","n_c":["C17152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sri Lanka","n_c":["C17163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"State of Palestine","n_c":["C20110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sudan","n_c":["C17170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suriname","n_c":["C17175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Svalbard & Jan Mayen Islands","n_c":["C17178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sweden","n_c":["C17180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Switzerland","n_c":["C17181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syria","n_c":["C17182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taiwan","n_c":["C17184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tajikistan","n_c":["C17183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanzania","n_c":["C17185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thailand","n_c":["C17192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Timor-Leste","n_c":["C17200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Togo","n_c":["C17202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tokelau","n_c":["C17704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonga","n_c":["C17205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trinidad and Tobago","n_c":["C17217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tunisia","n_c":["C17221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkey","n_c":["C17222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkmenistan","n_c":["C17223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuvalu","n_c":["C17225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uganda","n_c":["C17228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ukraine","n_c":["C17229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Arab Emirates","n_c":["C17232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Kingdom","n_c":["C17233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United States","n_c":["C17234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uruguay","n_c":["C17244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uzbekistan","n_c":["C17246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vanuatu","n_c":["C17247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venezuela","n_c":["C17250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vietnam","n_c":["C17252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, British","n_c":["C17653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, U.S.","n_c":["C17255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wallis and Futuna","n_c":["C17259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Western Sahara","n_c":["C20113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yemen","n_c":["C17264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zambia","n_c":["C17267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zimbabwe","n_c":["C17268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.ethnicity":[{"nm":"hispanic or latino","n_c":["C17459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not hispanic or latino","n_c":["C41222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not allowed to collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.gender":[{"nm":"female","n_c":["C16576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"male","n_c":["C20197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unspecified","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.premature_at_birth":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.race":[{"nm":"white","n_c":["C41261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"american indian or alaska native","n_c":["C41259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"black or african american","n_c":["C16352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"asian","n_c":["C41260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"native hawaiian or other pacific islander","n_c":["C41219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not allowed to collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.vital_status":[{"nm":"Alive","n_c":["C37987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dead","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_m":[{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_stage":[{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_clinical_t":[{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C47858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_m":[{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M2","n_c":["C188299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1d","n_c":["C188301"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_stage":[{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIID","n_c":["C137676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA1","n_c":["C139980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA2","n_c":["C139981"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_pathologic_t":[{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C139415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ajcc_staging_system_edition":[{"nm":"1st","n_c":["C25509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2nd","n_c":["C25666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3rd","n_c":["C25260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4th","n_c":["C191343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5th","n_c":["C191344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6th","n_c":["C186612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7th","n_c":["C125755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8th","n_c":["C146985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.anaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.anaplasia_present_type":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse","n_c":["C14175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equivocal","n_c":["C86071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Focal","n_c":["C28224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C36113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sclerosis","n_c":["C69309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_b_symptoms":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_clinical_stage":[{"nm":"Stage I","n_c":["C125472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C125474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C125476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C125478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_extranodal_involvement":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_pathologic_stage":[{"nm":"Stage I","n_c":["C125473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C125475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C125477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C125479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.best_overall_response":[{"nm":"AJ-Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CPD-Clinical Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CR-Complete Response","n_c":["C4870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRU-Complete Response Unconfirmed","n_c":["C165198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DU-Disease Unchanged","n_c":["C71687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IMR-Immunoresponse","n_c":["C131144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IPD-Immunoprogression","n_c":["C131143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MR-Minimal/Marginal Response","n_c":["C123598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX-Mixed Response","n_c":["C165202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-CR/Non-PD-Non-CR/Non-PD","n_c":["C96700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPB-No Palliative Benefit","n_c":["C165204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR-No Response","n_c":["C123600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PA-Palliative Therapy","n_c":["C15292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PB-Palliative Benefit","n_c":["C101516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-Progressive Disease","n_c":["C8510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPD-Pseudoprogression","n_c":["C98298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PR-Partial Response","n_c":["C18058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSR-Pseudoresponse","n_c":["C131142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RD-Responsive Disease","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RP-Response","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPD-Radiographic Progressive Disease","n_c":["C165208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"sCR-Stringent Complete Response","n_c":["C123614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SD-Stable Disease","n_c":["C18213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPD-Surgical Progression","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TE-Too Early","n_c":["C133441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGPR-Very Good Partial Response","n_c":["C123618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.burkitt_lymphoma_clinical_variant":[{"nm":"Endemic","n_c":["C27122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunodeficiency-associated, adult","n_c":["C27915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunodeficiency-associated, pediatric","n_c":["C27915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sporadic, adult","n_c":["C27914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sporadic, pediatric","n_c":["C27914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.child_pugh_classification":[{"nm":"A","n_c":["C113691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"A5","n_c":["C146790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"A6","n_c":["C146791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B","n_c":["C113692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B7","n_c":["C146792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B8","n_c":["C146793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B9","n_c":["C146794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C","n_c":["C113694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C10","n_c":["C146795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C11","n_c":["C146796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C12","n_c":["C146797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.classification_of_tumor":[{"nm":"metastasis","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premalignant","n_c":["C36032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"primary","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progression","n_c":["C17609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"recurrence","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synchronous primary","n_c":["C54621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior primary","n_c":["C156806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsequent Primary","n_c":["C156806"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_neuroblastoma_risk_group":[{"nm":"High Risk","n_c":["C102401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Risk","n_c":["C102402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Risk","n_c":["C102403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_rhabdomyosarcoma_risk_group":[{"nm":"High Risk","n_c":["C102401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Risk","n_c":["C102402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Risk","n_c":["C102403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_renal_stage":[{"nm":"Stage I","n_c":["C140301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C140303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C140305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C140307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cog_liver_stage":[{"nm":"Stage I","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.eln_risk_classification":[{"nm":"Adverse","n_c":["C188368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Favorable","n_c":["C188369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate","n_c":["C188370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_grade":[{"nm":"High Grade (G2)","n_c":["C140261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade (G1)","n_c":["C140260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_metastasis":[{"nm":"No Metastasis (M0)","n_c":["C147528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional or Distant Metastasis (M1)","n_c":["C147529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_stage":[{"nm":"Stage IA","n_c":["C146701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C146702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C146703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C146704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C146705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.enneking_msts_tumor_site":[{"nm":"Extracompartmental (T2)","n_c":["C140265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intracompartmental (T1)","n_c":["C140263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.esophageal_columnar_dysplasia_degree":[{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indefinite for Dysplasia","n_c":["C164039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative/ No Dysplasia","n_c":["C164040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.esophageal_columnar_metaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.figo_stage":[{"nm":"Stage 0","n_c":["C96243"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C96244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C96245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C96246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C96247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C96248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C96249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C96250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C96251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC1","n_c":["C128099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC2","n_c":["C128100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC3","n_c":["C128101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C96252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C96253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C162223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C162224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C96254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C188300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C96255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C96256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA1","n_c":["C128102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA2","n_c":["C128105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIAi","n_c":["C128103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIAii","n_c":["C128104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C96257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C96258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C96259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C96260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C96261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C96262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C96263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.figo_staging_edition_year":[{"nm":"1988","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"1995","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"2009","n_c":"","i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.first_symptom_prior_to_diagnosis":[{"nm":"Altered Mental Status","n_c":["C121628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headaches","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motor or Movement Changes","n_c":["C157433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizures","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Visual Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.gastric_esophageal_junction_involvement":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.gleason_grade_group":[{"nm":"Group 1","n_c":["C137992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 2","n_c":["C137993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 3","n_c":["C137994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 4","n_c":["C137995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group 5","n_c":["C137996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.gleason_grade_tertiary":[{"nm":"Pattern 4","n_c":["C28088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 5","n_c":["C28089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.goblet_cells_columnar_mucosa_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.igcccg_stage":[{"nm":"Good Prognosis","n_c":["C177313","C177310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Prognosis","n_c":["C177314","C177311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poor Prognosis","n_c":["C177312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inpc_grade":[{"nm":"Differentiating","n_c":["C42048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poorly Differentiated","n_c":["C42047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undifferentiated","n_c":["C42046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undifferentiated or Poorly Differentiated","n_c":["C42047","C42046"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inpc_histologic_group":[{"nm":"Favorable","n_c":["C102560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unfavorable","n_c":["C102561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inrg_stage":[{"nm":"L1","n_c":["C133428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"L2","n_c":["C133429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M","n_c":["C133430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ms","n_c":["C133431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.inss_stage":[{"nm":"Stage 1","n_c":["C85417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 2A","n_c":["C85418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 2B","n_c":["C85419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 3","n_c":["C85420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 4","n_c":["C85421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 4S","n_c":["C85422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.international_prognostic_index":[{"nm":"Low Risk","n_c":["C161806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low-Intermediate Risk","n_c":["C161807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-Intermediate Risk","n_c":["C161808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Risk","n_c":["C161809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.irs_group":[{"nm":"Group I","n_c":["C148012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group Ia","n_c":["C148013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group Ib","n_c":["C148014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group II","n_c":["C148015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIa","n_c":["C148016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIb","n_c":["C148017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIc","n_c":["C148018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group III","n_c":["C148019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIIa","n_c":["C148020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IIIb","n_c":["C148021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Group IV","n_c":["C148022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.irs_stage":[{"nm":"1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ishak_fibrosis_score":[{"nm":"0 - No Fibrosis","n_c":["C95150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1,2 - Portal Fibrosis","n_c":["C157159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3,4 - Fibrous Septa","n_c":["C157161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5 - Nodular Formation and Incomplete Cirrhosis","n_c":["C95155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6 - Established Cirrhosis","n_c":["C95156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.iss_stage":[{"nm":"I","n_c":["C70658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"II","n_c":["C70659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"III","n_c":["C70660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.largest_extrapelvic_peritoneal_focus":[{"nm":"Macroscopic (2cm or less)","n_c":["C53696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic (greater than 2cm)","n_c":["C51138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.last_known_disease_status":[{"nm":"Distant met recurrence/progression","n_c":["C35933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loco-regional recurrence/progression","n_c":["C8524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biochemical evidence of disease without structural correlate","n_c":["C165197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor free","n_c":["C156848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown tumor status","n_c":["C158709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"With tumor","n_c":["C156849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Midline","n_c":["C81170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unilateral","n_c":["C28012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.lymphatic_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.lymph_node_involved_site":[{"nm":"Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-external","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac, NOS","n_c":["C32761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.margins_involved_site":[{"nm":"Gerota Fascia","n_c":["C162125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parenchyma","n_c":["C74601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perinephric Fat","n_c":["C162218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Capsule","n_c":["C12885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Sinus","n_c":["C162219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Vein","n_c":["C33462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.masaoka_stage":[{"nm":"Stage I","n_c":["C112007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIa","n_c":["C112008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIb","n_c":["C112009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C112010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVa","n_c":["C112011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVb","n_c":["C112012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.medulloblastoma_molecular_classification":[{"nm":"Not Determined","n_c":["C129447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-WNT/non-SHH Activated","n_c":["C129444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHH-Activated","n_c":["C129441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WNT-Activated","n_c":["C129440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.metastasis_at_diagnosis":[{"nm":"Distant Metastasis","n_c":["C18206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metastasis, NOS","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Metastasis","n_c":["C164041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional Metastasis","n_c":["C172220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.metastasis_at_diagnosis_site":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal Gland","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Nodes","n_c":["C172221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Organ","n_c":["C172223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, NOS","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Adnexa","n_c":["C12321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebral Canal","n_c":["C33869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Subcarinal","n_c":["C117873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.method_of_diagnosis":[{"nm":"Autopsy","n_c":["C25153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy","n_c":["C15189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Draw","n_c":["C17610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Aspirate","n_c":["C133261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Core Biopsy","n_c":["C15680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytology","n_c":["C16491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cystoscopy","n_c":["C16482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Debulking","n_c":["C15749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diagnostic Imaging","n_c":["C16502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dilation and Curettage Procedure","n_c":["C15226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enucleation","n_c":["C48601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Excisional Biopsy","n_c":["C15385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fine Needle Aspiration","n_c":["C15361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imaging","n_c":["C17369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incisional Biopsy","n_c":["C15386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopy","n_c":["C16969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparotomy","n_c":["C15266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pap Smear","n_c":["C17348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical Exam","n_c":["C20989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathologic Review","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical Resection","n_c":["C158758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracentesis","n_c":["C15392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ultrasound Guided Biopsy","n_c":["C93022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exoresection","n_c":["C118358"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.mitosis_karyorrhexis_index":[{"nm":"High","n_c":["C25227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate","n_c":["C73705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low","n_c":["C54722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.morphology":[{"nm":"8000/0","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Neoplasm, benign","Tumor, benign","Unclassified tumor, benign"],"term_type":""},{"nm":"8000/1","n_c":["C3262","C65157"],"i_c":"8000/1","i_c_s":["Neoplasm, uncertain whether benign or malignant","Neoplasm, NOS","Tumor, NOS","Unclassified tumor, borderline malignancy","Unclassified tumor, uncertain whether benign or malignant"],"term_type":""},{"nm":"8000/3","n_c":["C9305","C8997"],"i_c":"8000/3","i_c_s":["Neoplasm, malignant","Blastoma, NOS","Cancer","Malignancy","Tumor, malignant, NOS","Unclassified tumor, malignant"],"term_type":""},{"nm":"8000/6","n_c":["C36255","C3005","C3261"],"i_c":"8000/6","i_c_s":["Neoplasm, metastatic","Neoplasm, secondary","Tumor embolus","Tumor, metastatic","Tumor, secondary"],"term_type":""},{"nm":"8000/9","n_c":["C65153"],"i_c":"8000/9","i_c_s":["Neoplasm, malignant, uncertain whether primary or metastatic","Unclassified tumor, malignant, uncertain whether primary or metastatic"],"term_type":""},{"nm":"8001/0","n_c":["C36122"],"i_c":"8001/0","i_c_s":["Tumor cells, benign"],"term_type":""},{"nm":"8001/1","n_c":["C12922"],"i_c":"8001/1","i_c_s":["Tumor cells, uncertain whether benign or malignant","Tumor cells, NOS"],"term_type":""},{"nm":"8001/3","n_c":["C12917"],"i_c":"8001/3","i_c_s":["Tumor cells, malignant"],"term_type":""},{"nm":"8002/3","n_c":["C65154"],"i_c":"8002/3","i_c_s":["Malignant tumor, small cell type"],"term_type":""},{"nm":"8003/3","n_c":["C4090"],"i_c":"8003/3","i_c_s":["Malignant tumor, giant cell type"],"term_type":""},{"nm":"8004/3","n_c":["C27091"],"i_c":"8004/3","i_c_s":["Malignant tumor, spindle cell type","Malignant tumor, fusiform cell type"],"term_type":""},{"nm":"8005/0","n_c":["C66752"],"i_c":"8005/0","i_c_s":["Clear cell tumor, NOS"],"term_type":""},{"nm":"8005/3","n_c":["C40077"],"i_c":"8005/3","i_c_s":["Malignant tumor, clear cell type"],"term_type":""},{"nm":"8010/0","n_c":["C4092"],"i_c":"8010/0","i_c_s":["Epithelial tumor, benign"],"term_type":""},{"nm":"8010/2","n_c":["C2917"],"i_c":"8010/2","i_c_s":["Carcinoma in situ, NOS","Intraepithelial carcinoma, NOS"],"term_type":""},{"nm":"8010/3","n_c":["C2916"],"i_c":"8010/3","i_c_s":["Carcinoma, NOS","Epithelial tumor, malignant"],"term_type":""},{"nm":"8010/6","n_c":["C3482"],"i_c":"8010/6","i_c_s":["Carcinoma, metastatic, NOS","Secondary carcinoma"],"term_type":""},{"nm":"8010/9","n_c":["C3693"],"i_c":"8010/9","i_c_s":["Carcinomatosis"],"term_type":""},{"nm":"8011/0","n_c":["C4092"],"i_c":"8011/0","i_c_s":["Epithelioma, benign"],"term_type":""},{"nm":"8011/3","n_c":["C2916"],"i_c":"8011/3","i_c_s":["Epithelioma, malignant","Epithelioma, NOS"],"term_type":""},{"nm":"8012/3","n_c":["C3780"],"i_c":"8012/3","i_c_s":["Large cell carcinoma, NOS"],"term_type":""},{"nm":"8013/3","n_c":["C6875"],"i_c":"8013/3","i_c_s":["Large cell neuroendocrine carcinoma"],"term_type":""},{"nm":"8014/3","n_c":["C6876"],"i_c":"8014/3","i_c_s":["Large cell carcinoma with rhabdoid phenotype"],"term_type":""},{"nm":"8015/3","n_c":["C65159"],"i_c":"8015/3","i_c_s":["Glassy cell carcinoma"],"term_type":""},{"nm":"8020/3","n_c":["C3692"],"i_c":"8020/3","i_c_s":["Carcinoma, undifferentiated, NOS"],"term_type":""},{"nm":"8020/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8021/3","n_c":["C3692"],"i_c":"8021/3","i_c_s":["Carcinoma, anaplastic, NOS"],"term_type":""},{"nm":"8022/3","n_c":["C4094"],"i_c":"8022/3","i_c_s":["Pleomorphic carcinoma"],"term_type":""},{"nm":"8023/3","n_c":["C45716"],"i_c":"8023/3","i_c_s":["NUT carcinoma"],"term_type":""},{"nm":"8030/3","n_c":["C65160"],"i_c":"8030/3","i_c_s":["Giant cell and spindle cell carcinoma"],"term_type":""},{"nm":"8031/3","n_c":["C3779"],"i_c":"8031/3","i_c_s":["Giant cell carcinoma"],"term_type":""},{"nm":"8032/3","n_c":["C27004"],"i_c":"8032/3","i_c_s":["Spindle cell carcinoma, NOS"],"term_type":""},{"nm":"8033/3","n_c":["C27004"],"i_c":"8033/3","i_c_s":["Pseudosarcomatous carcinoma","Sarcomatoid carcinoma"],"term_type":""},{"nm":"8034/3","n_c":["C65161"],"i_c":"8034/3","i_c_s":["Polygonal cell carcinoma"],"term_type":""},{"nm":"8035/3","n_c":["C63622"],"i_c":"8035/3","i_c_s":["Carcinoma with osteoclast-like giant cells"],"term_type":""},{"nm":"8040/0","n_c":["C65162"],"i_c":"8040/0","i_c_s":["Tumorlet, benign"],"term_type":""},{"nm":"8040/1","n_c":["C65162"],"i_c":"8040/1","i_c_s":["Tumorlet, NOS"],"term_type":""},{"nm":"8040/3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8041/3","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Small cell carcinoma, NOS","Small cell neuroendocrine carcinoma","Reserve cell carcinoma","Round cell carcinoma"],"term_type":""},{"nm":"8041/34","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8041/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8042/3","n_c":["C3915"],"i_c":"8042/3","i_c_s":["Oat cell carcinoma"],"term_type":""},{"nm":"8043/3","n_c":["C27092"],"i_c":"8043/3","i_c_s":["Small cell carcinoma, fusiform cell"],"term_type":""},{"nm":"8044/3","n_c":["C4099"],"i_c":"8044/3","i_c_s":["Small cell carcinoma, intermediate cell"],"term_type":""},{"nm":"8045/3","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Combined small cell carcinoma","Combined small cell-adenocarcinoma","Combined small cell-large cell carcinoma","Combined small cell-squamous cell carcinoma","Mixed small cell carcinoma"],"term_type":""},{"nm":"8046/3","n_c":["C65151"],"i_c":"8046/3","i_c_s":["Non-small cell carcinoma"],"term_type":""},{"nm":"8046/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8050/0","n_c":["C7440"],"i_c":"8050/0","i_c_s":["Papilloma, NOS"],"term_type":""},{"nm":"8050/2","n_c":["C65163"],"i_c":"8050/2","i_c_s":["Papillary carcinoma in situ"],"term_type":""},{"nm":"8050/3","n_c":["C2927"],"i_c":"8050/3","i_c_s":["Papillary carcinoma, NOS"],"term_type":""},{"nm":"8051/0","n_c":["C4101"],"i_c":"8051/0","i_c_s":["Verrucous papilloma"],"term_type":""},{"nm":"8051/3","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous carcinoma, NOS","Condylomatous carcinoma","Verrucous epidermoid carcinoma","Verrucous squamous cell carcinoma","Warty carcinoma"],"term_type":""},{"nm":"8052/0","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Squamous cell papilloma, NOS","Keratotic papilloma","Squamous papilloma"],"term_type":""},{"nm":"8052/2","n_c":["C65164"],"i_c":"8052/2","i_c_s":["Papillary squamous cell carcinoma, non-invasive","Papillary squamous cell carcinoma in situ"],"term_type":""},{"nm":"8052/3","n_c":["C4102"],"i_c":"8052/3","i_c_s":["Papillary squamous cell carcinoma","Papillary epidermoid carcinoma"],"term_type":""},{"nm":"8053/0","n_c":["C65165"],"i_c":"8053/0","i_c_s":["Squamous cell papilloma, inverted"],"term_type":""},{"nm":"8060/0","n_c":["C9009","C3713"],"i_c":"8060/0","i_c_s":["Squamous papillomatosis","Papillomatosis, NOS"],"term_type":""},{"nm":"8070/2","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Squamous cell carcinoma in situ, NOS","Epidermoid carcinoma in situ, NOS","Intraepidermal carcinoma, NOS","Intraepithelial squamous cell carcinoma"],"term_type":""},{"nm":"8070/3","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous cell carcinoma, NOS","Epidermoid carcinoma, NOS","Squamous carcinoma","Squamous cell epithelioma"],"term_type":""},{"nm":"8070/33","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8070/6","n_c":["C4104"],"i_c":"8070/6","i_c_s":["Squamous cell carcinoma, metastatic, NOS"],"term_type":""},{"nm":"8071/2","n_c":["C4105"],"i_c":"8071/2","i_c_s":["Sq. cell carcinoma, keratinizing, NOS, in situ"],"term_type":""},{"nm":"8071/3","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Squamous cell carcinoma, keratinizing, NOS","Epidermoid carcinoma, keratinizing","Squamous cell carcinoma, large cell, keratinizing"],"term_type":""},{"nm":"8072/3","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Squamous cell carcinoma, large cell, nonkeratinizing, NOS","Epidermoid carcinoma, large cell, nonkeratinizing","Squamous cell carcinoma, nonkeratinizing, NOS"],"term_type":""},{"nm":"8073/3","n_c":["C65175"],"i_c":"8073/3","i_c_s":["Squamous cell carcinoma, small cell, nonkeratinizing","Epidermoid carcinoma, small cell, nonkeratinizing"],"term_type":""},{"nm":"8074/3","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Squamous cell carcinoma, spindle cell","Epidermoid carcinoma, spindle cell","Squamous cell carcinoma, sarcomatoid"],"term_type":""},{"nm":"8075/3","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, adenoid","Squamous cell carcinoma, acantholytic","Squamous cell carcinoma, pseudoglandular"],"term_type":""},{"nm":"8076/2","n_c":["C65176"],"i_c":"8076/2","i_c_s":["Squamous cell carcinoma in situ with questionable stromal invasion","Epidermoid carcinoma in situ with questionable stromal invasion"],"term_type":""},{"nm":"8076/3","n_c":["C65178"],"i_c":"8076/3","i_c_s":["Squamous cell carcinoma, microinvasive"],"term_type":""},{"nm":"8077/0","n_c":["C7351","C27427","C8335","C4630"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, low grade","Anal intraepithelial neoplasia, low grade","Cervical intraepithelial neoplasia, low grade","Esophageal squamous intraepithelial neoplasia (dysplasia), low grade","Squamous intraepithelial neoplasia, grade II","Squamous intraepithelial neoplasia, grade I"],"term_type":""},{"nm":"8077/2","n_c":["C27093","C8336","C157575","C7855","C4000","C4522"],"i_c":"8077/2","i_c_s":["Squamous intraepithelial neoplasia, high grade","Anal intraepithelial neoplasia, grade III","Cervical intraepithelial neoplasia, grade III","Esophageal squamous intraepithelial neoplasia (dysplasia), high grade","Vaginal intraepithelial neoplasia, grade III","Vulvar intraepithelial neoplasia, grade III","AIN III","CIN III with severe dysplasia","CIN III, NOS","Squamous intraepithelial neoplasia, grade III","VAIN III","VIN III"],"term_type":""},{"nm":"8078/3","n_c":["C65179"],"i_c":"8078/3","i_c_s":["Squamous cell carcinoma with horn formation"],"term_type":""},{"nm":"8080/2","n_c":["C27790"],"i_c":"8080/2","i_c_s":["Queyrat erythroplasia"],"term_type":""},{"nm":"8081/2","n_c":["C62571"],"i_c":"8081/2","i_c_s":["Bowen disease","Intraepidermal squamous cell carcinoma, Bowen type"],"term_type":""},{"nm":"8082/3","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelial carcinoma","Schmincke tumor","Lymphoepithelioma-like carcinoma","Lymphoepithelioma"],"term_type":""},{"nm":"8083/3","n_c":["C54244"],"i_c":"8083/3","i_c_s":["Basaloid squamous cell carcinoma"],"term_type":""},{"nm":"8084/3","n_c":["C65180"],"i_c":"8084/3","i_c_s":["Squamous cell carcinoma, clear cell type"],"term_type":""},{"nm":"8085/3","n_c":["C27683"],"i_c":"8085/3","i_c_s":["Squamous cell carcinoma, HPV-positive"],"term_type":""},{"nm":"8086/3","n_c":["C164250"],"i_c":"8086/3","i_c_s":["Squamous cell carcinoma, HPV-negative"],"term_type":""},{"nm":"8090/1","n_c":["C3784"],"i_c":"8090/1","i_c_s":["Basal cell tumor"],"term_type":""},{"nm":"8090/3","n_c":["C2921","C9359","C156767"],"i_c":"8090/3","i_c_s":["Basal cell carcinoma, NOS","Pigmented basal cell carcinoma","Basal cell epithelioma","Rodent ulcer"],"term_type":""},{"nm":"8091/3","n_c":["C4108"],"i_c":"8091/3","i_c_s":["Multifocal superficial basal cell carcinoma","Multicentric basal cell carcinoma"],"term_type":""},{"nm":"8092/3","n_c":["C27182","C27539"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, NOS","Infiltrating basal cell carcinoma, non-sclerosing","Infiltrating basal cell carcinoma, sclerosing","Basal cell carcinoma, desmoplastic type","Basal cell carcinoma, morpheic"],"term_type":""},{"nm":"8093/3","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Basal cell carcinoma, fibroepithelial","Fibroepithelial basal cell carcinoma, Pinkus type","Fibroepithelioma of Pinkus type","Fibroepithelioma, NOS","Pinkus tumor"],"term_type":""},{"nm":"8094/3","n_c":["C2922"],"i_c":"8094/3","i_c_s":["Basosquamous carcinoma","Mixed basal-squamous cell carcinoma"],"term_type":""},{"nm":"8095/3","n_c":["C2922"],"i_c":"8095/3","i_c_s":["Metatypical carcinoma"],"term_type":""},{"nm":"8096/0","n_c":["C4110"],"i_c":"8096/0","i_c_s":["Intraepidermal epithelioma of Jadassohn"],"term_type":""},{"nm":"8097/3","n_c":["C27541","C62282"],"i_c":"8097/3","i_c_s":["Basal cell carcinoma, nodular","Basal cell carcinoma, micronodular"],"term_type":""},{"nm":"8098/3","n_c":["C27535"],"i_c":"8098/3","i_c_s":["Adenoid basal carcinoma"],"term_type":""},{"nm":"8100/0","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Trichoepithelioma","Brooke tumor","Epithelioma adenoides cysticum"],"term_type":""},{"nm":"8101/0","n_c":["C4112"],"i_c":"8101/0","i_c_s":["Trichofolliculoma"],"term_type":""},{"nm":"8102/0","n_c":["C4113"],"i_c":"8102/0","i_c_s":["Trichilemmoma"],"term_type":""},{"nm":"8102/3","n_c":["C43326"],"i_c":"8102/3","i_c_s":["Trichilemmocarcinoma","Trichilemmal carcinoma"],"term_type":""},{"nm":"8103/0","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Pilar tumor","Proliferating trichilemmal cyst","Proliferating trichilemmal tumor"],"term_type":""},{"nm":"8110/0","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Pilomatrixoma, NOS","Calcifying epithelioma of Malherbe","Pilomatricoma, NOS"],"term_type":""},{"nm":"8110/3","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatrix carcinoma","Matrical carcinoma","Pilomatricoma, malignant","Pilomatrixoma, malignant"],"term_type":""},{"nm":"8120/0","n_c":["C4115"],"i_c":"8120/0","i_c_s":["Transitional cell papilloma, benign","Transitional papilloma"],"term_type":""},{"nm":"8120/1","n_c":["C4115","C3842"],"i_c":"8120/1","i_c_s":["Urothelial papilloma, NOS","Papilloma of bladder","Transitional cell papilloma, NOS"],"term_type":""},{"nm":"8120/2","n_c":["C4116"],"i_c":"8120/2","i_c_s":["Transitional cell carcinoma in situ","Urothelial carcinoma in situ"],"term_type":""},{"nm":"8120/3","n_c":["C2930","C4030"],"i_c":"8120/3","i_c_s":["Transitional cell carcinoma, NOS","Transitional carcinoma","Urothelial carcinoma, NOS"],"term_type":""},{"nm":"8121/0","n_c":["C4117","C4118"],"i_c":"8121/0","i_c_s":["Schneiderian papilloma, NOS","Sinonasal papilloma, exophytic","Transitional cell papilloma, inverted, benign","Transitional papilloma, inverted, benign","Sinonasal papilloma, NOS","Sinonasal papilloma, fungiform"],"term_type":""},{"nm":"8121/1","n_c":["C6871","C54345","C4118"],"i_c":"8121/1","i_c_s":["Transitional cell papilloma, inverted, NOS","Columnar cell papilloma","Cylindrical cell papilloma","Oncocytic Schneiderian papilloma","Schneiderian papilloma, inverted","Transitional papilloma, inverted, NOS"],"term_type":""},{"nm":"8121/3","n_c":["C54287"],"i_c":"8121/3","i_c_s":["Schneiderian carcinoma","Cylindrical cell carcinoma"],"term_type":""},{"nm":"8122/3","n_c":["C4120"],"i_c":"8122/3","i_c_s":["Transitional cell carcinoma, spindle cell","Transitional cell carcinoma, sarcomatoid"],"term_type":""},{"nm":"8123/3","n_c":["C4121"],"i_c":"8123/3","i_c_s":["Basaloid carcinoma"],"term_type":""},{"nm":"8124/3","n_c":["C8255"],"i_c":"8124/3","i_c_s":["Cloacogenic carcinoma"],"term_type":""},{"nm":"8130/1","n_c":["C191672"],"i_c":"8130/1","i_c_s":["Papillary transitional cell neoplasm of low malignant potential","Papillary urothelial neoplasm of low malignant potential"],"term_type":""},{"nm":"8130/2","n_c":["C65181"],"i_c":"8130/2","i_c_s":["Papillary transitional cell carcinoma, non-invasive","Papillary urothelial carcinoma, non-invasive"],"term_type":""},{"nm":"8130/3","n_c":["C4122"],"i_c":"8130/3","i_c_s":["Papillary transitional cell carcinoma","Papillary urothelial carcinoma"],"term_type":""},{"nm":"8131/3","n_c":["C65182"],"i_c":"8131/3","i_c_s":["Transitional cell carcinoma, micropapillary"],"term_type":""},{"nm":"8140/0","n_c":["C2855"],"i_c":"8140/0","i_c_s":["Adenoma, NOS"],"term_type":""},{"nm":"8140/1","n_c":["C3494","C7559"],"i_c":"8140/1","i_c_s":["Atypical adenoma","Bronchial adenoma, NOS"],"term_type":""},{"nm":"8140/2","n_c":["C4123"],"i_c":"8140/2","i_c_s":["Adenocarcinoma in situ, NOS"],"term_type":""},{"nm":"8140/3","n_c":["C2852"],"i_c":"8140/3","i_c_s":["Adenocarcinoma, NOS"],"term_type":""},{"nm":"8140/33","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8140/6","n_c":["C4124"],"i_c":"8140/6","i_c_s":["Adenocarcinoma, metastatic, NOS"],"term_type":""},{"nm":"8141/3","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Scirrhous adenocarcinoma","Carcinoma with productive fibrosis","Scirrhous carcinoma"],"term_type":""},{"nm":"8142/3","n_c":["C3190"],"i_c":"8142/3","i_c_s":["Linitis plastica"],"term_type":""},{"nm":"8143/3","n_c":["C4125"],"i_c":"8143/3","i_c_s":["Superficial spreading adenocarcinoma"],"term_type":""},{"nm":"8144/3","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Adenocarcinoma, intestinal type","Carcinoma, intestinal type"],"term_type":""},{"nm":"8145/3","n_c":["C4127"],"i_c":"8145/3","i_c_s":["Carcinoma, diffuse type","Adenocarcinoma, diffuse type"],"term_type":""},{"nm":"8146/0","n_c":["C3686"],"i_c":"8146/0","i_c_s":["Monomorphic adenoma"],"term_type":""},{"nm":"8147/0","n_c":["C5950"],"i_c":"8147/0","i_c_s":["Basal cell adenoma"],"term_type":""},{"nm":"8147/3","n_c":["C3678"],"i_c":"8147/3","i_c_s":["Basal cell adenocarcinoma"],"term_type":""},{"nm":"8148/0","n_c":["C7660","C7661","C27428"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, low grade","Biliary intraepithelial neoplasia, low grade","Esophageal glandular dysplasia (intraepithelial neoplasia), low grade","Glandular intraepithelial neoplasia, grade II","Glandular intraepithelial neoplasia, grade I"],"term_type":""},{"nm":"8148/2","n_c":["C6877","C27429","C27425","C67493","C3642","C7662"],"i_c":"8148/2","i_c_s":["Glandular intraepithelial neoplasia, high grade","Biliary intraepithelial neoplasia, high grade","Esophageal glandular dysplasia (intraepithelial neoplasia), high grade","Flat intraepithelial glandular neoplasia, high grade","Prostatic intraepithelial neoplasia, grade III","Biliary intraepithelial neoplasia, grade 3 (BilIN-3)","Esophageal intraepithelial neoplasia, high grade","Flat intraepithelial neoplasia (dysplasia), high grade","Flat intraepithelial neoplasia, high grade","Glandular intraepithelial neoplasia, grade III","PIN III"],"term_type":""},{"nm":"8149/0","n_c":["C5979"],"i_c":"8149/0","i_c_s":["Canalicular adenoma"],"term_type":""},{"nm":"8150/0","n_c":["C27720"],"i_c":"8150/0","i_c_s":["Pancreatic endocrine tumor, benign","Islet cell adenomatosis","Pancreatic microadenoma","Islet cell adenoma","Islet cell tumor, benign","Nesidioblastoma"],"term_type":""},{"nm":"8150/1","n_c":["C27031"],"i_c":"8150/1","i_c_s":["Pancreatic endocrine tumor, NOS","Islet cell tumor, NOS"],"term_type":""},{"nm":"8150/3","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Pancreatic endocrine tumor, malignant","Pancreatic endocrine tumor, nonfunctioning","Islet cell adenocarcinoma","Islet cell carcinoma"],"term_type":""},{"nm":"8151/0","n_c":["C67457","C95598"],"i_c":"8151/0","i_c_s":["Insulinoma, NOS","Beta cell adenoma"],"term_type":""},{"nm":"8151/3","n_c":["C65186"],"i_c":"8151/3","i_c_s":["Insulinoma, malignant","Beta cell tumor, malignant"],"term_type":""},{"nm":"8152/1","n_c":["C95597"],"i_c":"8152/1","i_c_s":["Glucagonoma, NOS","Enteroglucagonoma, NOS","Glucagon-like peptide-producing tumor","L-cell tumor","Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor","Alpha cell tumor, NOS","PP/PYY producing tumor"],"term_type":""},{"nm":"8152/3","n_c":["C65191","C65187"],"i_c":"8152/3","i_c_s":["Glucagonoma, malignant","Enteroglucagonoma, malignant","Alpha cell tumor, malignant"],"term_type":""},{"nm":"8153/1","n_c":["C3050"],"i_c":"8153/1","i_c_s":["Gastrinoma, NOS","G cell tumor, NOS","Gastrin cell tumor"],"term_type":""},{"nm":"8153/3","n_c":["C65188"],"i_c":"8153/3","i_c_s":["Gastrinoma, malignant","G cell tumor, malignant","Gastrin cell tumor, malignant"],"term_type":""},{"nm":"8154/3","n_c":["C164255","C45843"],"i_c":"8154/3","i_c_s":["Mixed pancreatic endocrine and exocrine tumor, malignant","Mixed acinar-endocrine carcinoma","Mixed acinar-endocrine-ductal carcinoma","Mixed ductal-endocrine carcinoma","Mixed endocrine and exocrine adenocarcinoma","Mixed islet cell and exocrine adenocarcinoma"],"term_type":""},{"nm":"8155/1","n_c":["C26749"],"i_c":"8155/1","i_c_s":["Vipoma, NOS"],"term_type":""},{"nm":"8155/3","n_c":["C65189"],"i_c":"8155/3","i_c_s":["Vipoma, malignant"],"term_type":""},{"nm":"8156/1","n_c":["C3379"],"i_c":"8156/1","i_c_s":["Somatostatinoma, NOS","Somatostatin cell tumor, NOS"],"term_type":""},{"nm":"8156/3","n_c":["C65190"],"i_c":"8156/3","i_c_s":["Somatostatinoma, malignant","Somatostatin cell tumor, malignant"],"term_type":""},{"nm":"8158/1","n_c":["C94759"],"i_c":"8158/1","i_c_s":["Endocrine tumor, functioning, NOS","ACTH-producing tumor"],"term_type":""},{"nm":"8160/0","n_c":["C2942"],"i_c":"8160/0","i_c_s":["Bile duct adenoma","Cholangioma"],"term_type":""},{"nm":"8160/3","n_c":["C4436","C27813","C27814"],"i_c":"8160/3","i_c_s":["Cholangiocarcinoma","Bile duct adenocarcinoma","Bile duct carcinoma"],"term_type":""},{"nm":"8161/0","n_c":["C4129"],"i_c":"8161/0","i_c_s":["Bile duct cystadenoma"],"term_type":""},{"nm":"8161/3","n_c":["C4130"],"i_c":"8161/3","i_c_s":["Bile duct cystadenocarcinoma"],"term_type":""},{"nm":"8162/3","n_c":["C36077"],"i_c":"8162/3","i_c_s":["Klatskin tumor"],"term_type":""},{"nm":"8163/0","n_c":["C95914","C95913"],"i_c":"8163/0","i_c_s":["Pancreatobiliary neoplasm, non-invasive","Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia","Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":""},{"nm":"8163/2","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia","Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia","Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":""},{"nm":"8163/3","n_c":["C95963"],"i_c":"8163/3","i_c_s":["Pancreatobiliary-type carcinoma","Adenocarcinoma, pancreatobiliary type"],"term_type":""},{"nm":"8170/0","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Liver cell adenoma","Hepatocellular adenoma","Hepatoma, benign"],"term_type":""},{"nm":"8170/3","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatocellular carcinoma, NOS","Hepatocarcinoma","Hepatoma, NOS","Hepatoma, malignant","Liver cell carcinoma"],"term_type":""},{"nm":"8171/3","n_c":["C4131"],"i_c":"8171/3","i_c_s":["Hepatocellular carcinoma, fibrolamellar"],"term_type":""},{"nm":"8172/3","n_c":["C27388"],"i_c":"8172/3","i_c_s":["Hepatocellular carcinoma, scirrhous","Sclerosing hepatic carcinoma"],"term_type":""},{"nm":"8173/3","n_c":["C43627"],"i_c":"8173/3","i_c_s":["Hepatocellular carcinoma, spindle cell variant","Hepatocellular carcinoma, sarcomatoid"],"term_type":""},{"nm":"8174/3","n_c":["C5754"],"i_c":"8174/3","i_c_s":["Hepatocellular carcinoma, clear cell type"],"term_type":""},{"nm":"8175/3","n_c":["C43625"],"i_c":"8175/3","i_c_s":["Hepatocellular carcinoma, pleomorphic type"],"term_type":""},{"nm":"8180/3","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Combined hepatocellular carcinoma and cholangiocarcinoma","Hepatocholangiocarcinoma","Mixed hepatocellular and bile duct carcinoma"],"term_type":""},{"nm":"8190/0","n_c":["C3688"],"i_c":"8190/0","i_c_s":["Trabecular adenoma"],"term_type":""},{"nm":"8190/3","n_c":["C4068"],"i_c":"8190/3","i_c_s":["Trabecular adenocarcinoma","Trabecular carcinoma"],"term_type":""},{"nm":"8191/0","n_c":["C27253"],"i_c":"8191/0","i_c_s":["Embryonal adenoma"],"term_type":""},{"nm":"8200/0","n_c":["C43352","C27094"],"i_c":"8200/0","i_c_s":["Eccrine dermal cylindroma","Cylindroma of skin","Turban tumor"],"term_type":""},{"nm":"8200/3","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenoid cystic carcinoma","Bronchial adenoma, cylindroid","Adenocarcinoma, cylindroid","Adenocystic carcinoma","Cylindroma, NOS"],"term_type":""},{"nm":"8201/2","n_c":["C162973"],"i_c":"8201/2","i_c_s":["Cribriform carcinoma in situ","Ductal carcinoma in situ, cribriform type"],"term_type":""},{"nm":"8201/3","n_c":["C3680"],"i_c":"8201/3","i_c_s":["Cribriform carcinoma, NOS","Cribriform comedo-type carcinoma","Adenocarcinoma, cribriform comedo-type","Ductal carcinoma, cribriform type"],"term_type":""},{"nm":"8202/0","n_c":["C3685"],"i_c":"8202/0","i_c_s":["Microcystic adenoma"],"term_type":""},{"nm":"8204/0","n_c":["C9473"],"i_c":"8204/0","i_c_s":["Lactating adenoma"],"term_type":""},{"nm":"8210/0","n_c":["C3764"],"i_c":"8210/0","i_c_s":["Adenomatous polyp, NOS","Polypoid adenoma"],"term_type":""},{"nm":"8210/2","n_c":["C7678","C7680","C7679","C7681"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in adenomatous polyp","Adenocarcinoma in situ in a polyp, NOS","Adenocarcinoma in situ in polypoid adenoma","Adenocarcinoma in situ in tubular adenoma","Carcinoma in situ in a polyp, NOS","Carcinoma in situ in adenomatous polyp"],"term_type":""},{"nm":"8210/3","n_c":["C7676","C7677","C7682"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in adenomatous polyp","Adenocarcinoma in a polyp, NOS","Adenocarcinoma in polypoid adenoma","Adenocarcinoma in tubular adenoma","Carcinoma in a polyp, NOS","Carcinoma in adenomatous polyp"],"term_type":""},{"nm":"8211/0","n_c":["C4133"],"i_c":"8211/0","i_c_s":["Tubular adenoma, NOS"],"term_type":""},{"nm":"8211/3","n_c":["C65192"],"i_c":"8211/3","i_c_s":["Tubular adenocarcinoma","Tubular carcinoma"],"term_type":""},{"nm":"8212/0","n_c":["C65193"],"i_c":"8212/0","i_c_s":["Flat adenoma"],"term_type":""},{"nm":"8213/0","n_c":["C38458","C96414"],"i_c":"8213/0","i_c_s":["Serrated adenoma","Mixed adenomatous and hyperplastic polyp","Sessile serrated adenoma","Sessile serrated polyp","Traditional sessile serrated adenoma","Traditional serrated adenoma"],"term_type":""},{"nm":"8213/3","n_c":["C96485"],"i_c":"8213/3","i_c_s":["Serrated adenocarcinoma"],"term_type":""},{"nm":"8214/3","n_c":["C65194"],"i_c":"8214/3","i_c_s":["Parietal cell carcinoma","Parietal cell adenocarcinoma"],"term_type":""},{"nm":"8215/3","n_c":["C5609"],"i_c":"8215/3","i_c_s":["Adenocarcinoma of anal glands","Adenocarcinoma of anal ducts"],"term_type":""},{"nm":"8220/0","n_c":["C3339"],"i_c":"8220/0","i_c_s":["Adenomatous polyposis coli","Adenomatosis, NOS","Familial polyposis coli"],"term_type":""},{"nm":"8220/3","n_c":["C4134"],"i_c":"8220/3","i_c_s":["Adenocarcinoma in adenomatous polyposis coli"],"term_type":""},{"nm":"8221/0","n_c":["C4135"],"i_c":"8221/0","i_c_s":["Multiple adenomatous polyps"],"term_type":""},{"nm":"8221/3","n_c":["C4136"],"i_c":"8221/3","i_c_s":["Adenocarcinoma in multiple adenomatous polyps"],"term_type":""},{"nm":"8230/2","n_c":["C66933"],"i_c":"8230/2","i_c_s":["Ductal carcinoma in situ, solid type","Intraductal carcinoma, solid type"],"term_type":""},{"nm":"8230/3","n_c":["C4137"],"i_c":"8230/3","i_c_s":["Solid carcinoma, NOS","Solid carcinoma with mucin formation","Solid adenocarcinoma with mucin formation"],"term_type":""},{"nm":"8231/3","n_c":["C65195"],"i_c":"8231/3","i_c_s":["Carcinoma simplex"],"term_type":""},{"nm":"8240/1","n_c":["C65196"],"i_c":"8240/1","i_c_s":["Carcinoid tumor of uncertain malignant potential","Carcinoid tumor, argentaffin, NOS","Argentaffinoma, NOS"],"term_type":""},{"nm":"8240/3","n_c":["C35727","C188218"],"i_c":"8240/3","i_c_s":["Carcinoid tumor, NOS","Bronchial adenoma, carcinoid","Neuroendocrine carcinoma, low grade","Neuroendocrine carcinoma, well-differentiated","Neuroendocrine tumor, grade I","Typical carcinoid","Carcinoid, NOS"],"term_type":""},{"nm":"8240/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8241/3","n_c":["C188218"],"i_c":"8241/3","i_c_s":["Enterochromaffin cell carcinoid","Argentaffinoma, malignant","Carcinoid tumor, argentaffin, malignant","EC cell carcinoid","Serotonin producing carcinoid"],"term_type":""},{"nm":"8242/1","n_c":["C27252"],"i_c":"8242/1","i_c_s":["Enterochromaffin-like cell carcinoid, NOS","ECL cell carcinoid, NOS"],"term_type":""},{"nm":"8242/3","n_c":["C27252"],"i_c":"8242/3","i_c_s":["Enterochromaffin-like cell tumor, malignant","ECL cell carcinoid, malignant"],"term_type":""},{"nm":"8243/3","n_c":["C201135"],"i_c":"8243/3","i_c_s":["Goblet cell carcinoid","Mucinous carcinoid","Mucocarcinoid tumor"],"term_type":""},{"nm":"8244/3","n_c":["C95406"],"i_c":"8244/3","i_c_s":["Mixed adenoneuroendocrine carcinoma","Combined carcinoid and adenocarcinoma","Combined/mixed carcinoid and adenocarcinoma","Composite carcinoid","MANEC","Mixed carcinoid-adenocarcinoma"],"term_type":""},{"nm":"8245/1","n_c":["C43565"],"i_c":"8245/1","i_c_s":["Tubular carcinoid"],"term_type":""},{"nm":"8245/3","n_c":["C201135"],"i_c":"8245/3","i_c_s":["Adenocarcinoid tumor"],"term_type":""},{"nm":"8246/3","n_c":["C3773"],"i_c":"8246/3","i_c_s":["Neuroendocrine carcinoma, NOS"],"term_type":""},{"nm":"8247/3","n_c":["C9231","C173385"],"i_c":"8247/3","i_c_s":["Merkel cell carcinoma","Merkel cell tumor","Primary cutaneous neuroendocrine carcinoma"],"term_type":""},{"nm":"8248/1","n_c":["C188218"],"i_c":"8248/1","i_c_s":["Apudoma"],"term_type":""},{"nm":"8249/3","n_c":["C35725","C72074"],"i_c":"8249/3","i_c_s":["Atypical carcinoid tumor","Neuroendocrine carcinoma, moderately differentiated","Neuroendocrine tumor, grade 2"],"term_type":""},{"nm":"8250/1","n_c":["C3763"],"i_c":"8250/1","i_c_s":["Pulmonary adenomatosis"],"term_type":""},{"nm":"8250/2","n_c":["C136716"],"i_c":"8250/2","i_c_s":["Adenocarcinoma in situ, non-mucinous"],"term_type":""},{"nm":"8250/3","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolo-alveolar adenocarcinoma, NOS","Alveolar cell carcinoma","Bronchiolar adenocarcinoma","Bronchiolar carcinoma","Bronchiolo-alveolar carcinoma, NOS"],"term_type":""},{"nm":"8251/0","n_c":["C4140"],"i_c":"8251/0","i_c_s":["Alveolar adenoma"],"term_type":""},{"nm":"8251/3","n_c":["C2923"],"i_c":"8251/3","i_c_s":["Alveolar adenocarcinoma","Alveolar carcinoma"],"term_type":""},{"nm":"8252/3","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma, non- mucinous","Bronchiolo-alveolar carcinoma, Clara cell","Bronchiolo-alveolar carcinoma, type II pneumocyte"],"term_type":""},{"nm":"8253/3","n_c":["C136709"],"i_c":"8253/3","i_c_s":["Bronchiolo-alveolar carcinoma, mucinous","Bronchiolo-alveolar carcinoma, goblet cell type"],"term_type":""},{"nm":"8254/3","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, mixed mucinous and non-mucinous","Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type","Bronchiolo-alveolar carcinoma, indeterminate type","Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type"],"term_type":""},{"nm":"8255/3","n_c":["C45508"],"i_c":"8255/3","i_c_s":["Adenocarcinoma with mixed subtypes","Adenocarcinoma combined with other types of carcinoma"],"term_type":""},{"nm":"8256/3","n_c":["C7269"],"i_c":"8256/3","i_c_s":["Minimally invasive adenocarcinoma, non-mucinous"],"term_type":""},{"nm":"8257/3","n_c":["C7268"],"i_c":"8257/3","i_c_s":["Minimally invasive adenocarcinoma, mucinous"],"term_type":""},{"nm":"8260/0","n_c":["C79951"],"i_c":"8260/0","i_c_s":["Papillary adenoma, NOS","Glandular papilloma"],"term_type":""},{"nm":"8260/3","n_c":["C4035","C2853","C6975"],"i_c":"8260/3","i_c_s":["Papillary adenocarcinoma, NOS","Papillary carcinoma of thyroid","Papillary renal cell carcinoma"],"term_type":""},{"nm":"8261/0","n_c":["C7399"],"i_c":"8261/0","i_c_s":["Villous adenoma, NOS","Villous papilloma"],"term_type":""},{"nm":"8261/2","n_c":["C8376"],"i_c":"8261/2","i_c_s":["Adenocarcinoma in situ in villous adenoma"],"term_type":""},{"nm":"8261/3","n_c":["C4141"],"i_c":"8261/3","i_c_s":["Adenocarcinoma in villous adenoma"],"term_type":""},{"nm":"8262/3","n_c":["C4142"],"i_c":"8262/3","i_c_s":["Villous adenocarcinoma"],"term_type":""},{"nm":"8263/0","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Tubulovillous adenoma, NOS","Papillotubular adenoma","Tubulo-papillary adenoma","Villoglandular adenoma"],"term_type":""},{"nm":"8263/2","n_c":["C4144"],"i_c":"8263/2","i_c_s":["Adenocarcinoma in situ in tubulovillous adenoma"],"term_type":""},{"nm":"8263/3","n_c":["C4145"],"i_c":"8263/3","i_c_s":["Adenocarcinoma in tubulovillous adenoma","Papillotubular adenocarcinoma","Tubulopapillary adenocarcinoma"],"term_type":""},{"nm":"8264/0","n_c":["C6881","C65198"],"i_c":"8264/0","i_c_s":["Papillomatosis, glandular","Biliary papillomatosis"],"term_type":""},{"nm":"8265/3","n_c":["C128847"],"i_c":"8265/3","i_c_s":["Micropapillary carcinoma, NOS"],"term_type":""},{"nm":"8270/0","n_c":["C2857"],"i_c":"8270/0","i_c_s":["Chromophobe adenoma"],"term_type":""},{"nm":"8270/3","n_c":["C4146"],"i_c":"8270/3","i_c_s":["Chromophobe carcinoma","Chromophobe adenocarcinoma"],"term_type":""},{"nm":"8271/0","n_c":["C3342"],"i_c":"8271/0","i_c_s":["Prolactinoma"],"term_type":""},{"nm":"8272/0","n_c":["C3329"],"i_c":"8272/0","i_c_s":["Pituitary adenoma, NOS"],"term_type":""},{"nm":"8272/3","n_c":["C4536"],"i_c":"8272/3","i_c_s":["Pituitary carcinoma, NOS"],"term_type":""},{"nm":"8280/0","n_c":["C6780"],"i_c":"8280/0","i_c_s":["Acidophil adenoma","Eosinophil adenoma"],"term_type":""},{"nm":"8280/3","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Acidophil carcinoma","Acidophil adenocarcinoma","Eosinophil adenocarcinoma","Eosinophil carcinoma"],"term_type":""},{"nm":"8281/0","n_c":["C4148"],"i_c":"8281/0","i_c_s":["Mixed acidophil-basophil adenoma"],"term_type":""},{"nm":"8281/3","n_c":["C4149"],"i_c":"8281/3","i_c_s":["Mixed acidophil-basophil carcinoma"],"term_type":""},{"nm":"8290/0","n_c":["C3759","C6042"],"i_c":"8290/0","i_c_s":["Oxyphilic adenoma","Follicular adenoma, oxyphilic cell","Hurthle cell adenoma","Hurthle cell tumor","Spindle cell oncocytoma","Oncocytic adenoma","Oncocytoma"],"term_type":""},{"nm":"8290/3","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oxyphilic adenocarcinoma","Follicular carcinoma, oxyphilic cell","Hurthle cell adenocarcinoma","Hurthle cell carcinoma","Oncocytic adenocarcinoma","Oncocytic carcinoma"],"term_type":""},{"nm":"8300/0","n_c":["C2856"],"i_c":"8300/0","i_c_s":["Basophil adenoma","Mucoid cell adenoma"],"term_type":""},{"nm":"8300/3","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Basophil carcinoma","Basophil adenocarcinoma","Mucoid cell adenocarcinoma"],"term_type":""},{"nm":"8310/0","n_c":["C4151"],"i_c":"8310/0","i_c_s":["Clear cell adenoma"],"term_type":""},{"nm":"8310/3","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell adenocarcinoma, NOS","Clear cell adenocarcinoma, mesonephroid","Clear cell carcinoma"],"term_type":""},{"nm":"8310/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8311/1","n_c":["C4033"],"i_c":"8311/1","i_c_s":["Hypernephroid tumor"],"term_type":""},{"nm":"8311/3","n_c":["C51302"],"i_c":"8311/3","i_c_s":["Hereditary leiomyomatosis & RCC-associated renal cell carcinoma"],"term_type":""},{"nm":"8311/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8312/3","n_c":["C191370","C4033"],"i_c":"8312/3","i_c_s":["Renal cell carcinoma, NOS","Grawitz tumor","Hypernephroma","Renal cell adenocarcinoma"],"term_type":""},{"nm":"8313/0","n_c":["C8988","C8987"],"i_c":"8313/0","i_c_s":["Clear cell adenofibroma","Clear cell cystadenofibroma"],"term_type":""},{"nm":"8313/1","n_c":["C40080","C40081"],"i_c":"8313/1","i_c_s":["Clear cell adenofibroma of borderline malignancy","Clear cell cystadenofibroma of borderline malignancy"],"term_type":""},{"nm":"8313/3","n_c":["C40079"],"i_c":"8313/3","i_c_s":["Clear cell adenocarcinofibroma","Clear cell cystadenocarcinofibroma"],"term_type":""},{"nm":"8314/3","n_c":["C4152"],"i_c":"8314/3","i_c_s":["Lipid-rich carcinoma"],"term_type":""},{"nm":"8315/3","n_c":["C4153"],"i_c":"8315/3","i_c_s":["Glycogen-rich carcinoma"],"term_type":""},{"nm":"8316/3","n_c":["C157718"],"i_c":"8316/3","i_c_s":["Cyst-associated renal cell carcinoma"],"term_type":""},{"nm":"8317/3","n_c":["C4146"],"i_c":"8317/3","i_c_s":["Renal cell carcinoma, chromophobe type","Chromophobe cell renal carcinoma"],"term_type":""},{"nm":"8318/3","n_c":["C27893"],"i_c":"8318/3","i_c_s":["Renal cell carcinoma, sarcomatoid","Renal cell carcinoma, spindle cell"],"term_type":""},{"nm":"8319/3","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Collecting duct carcinoma","Bellini duct carcinoma","Renal carcinoma, collecting duct type"],"term_type":""},{"nm":"8320/3","n_c":["C3681"],"i_c":"8320/3","i_c_s":["Granular cell carcinoma","Granular cell adenocarcinoma"],"term_type":""},{"nm":"8321/0","n_c":["C4154"],"i_c":"8321/0","i_c_s":["Chief cell adenoma"],"term_type":""},{"nm":"8322/0","n_c":["C4155"],"i_c":"8322/0","i_c_s":["Water-clear cell adenoma"],"term_type":""},{"nm":"8322/3","n_c":["C4156"],"i_c":"8322/3","i_c_s":["Water-clear cell adenocarcinoma","Water-clear cell carcinoma"],"term_type":""},{"nm":"8323/0","n_c":["C4157"],"i_c":"8323/0","i_c_s":["Mixed cell adenoma"],"term_type":""},{"nm":"8323/3","n_c":["C4158"],"i_c":"8323/3","i_c_s":["Mixed cell adenocarcinoma"],"term_type":""},{"nm":"8324/0","n_c":["C4159"],"i_c":"8324/0","i_c_s":["Lipoadenoma","Adenolipoma"],"term_type":""},{"nm":"8325/0","n_c":["C27253"],"i_c":"8325/0","i_c_s":["Metanephric adenoma"],"term_type":""},{"nm":"8330/0","n_c":["C3502"],"i_c":"8330/0","i_c_s":["Follicular adenoma"],"term_type":""},{"nm":"8330/1","n_c":["C27729"],"i_c":"8330/1","i_c_s":["Atypical follicular adenoma"],"term_type":""},{"nm":"8330/3","n_c":["C8054"],"i_c":"8330/3","i_c_s":["Follicular adenocarcinoma, NOS","Follicular carcinoma, NOS"],"term_type":""},{"nm":"8331/3","n_c":["C8054"],"i_c":"8331/3","i_c_s":["Follicular adenocarcinoma, well differentiated","Follicular carcinoma, well differentiated"],"term_type":""},{"nm":"8332/3","n_c":["C46095"],"i_c":"8332/3","i_c_s":["Follicular adenocarcinoma, trabecular","Follicular adenocarcinoma, moderately differentiated","Follicular carcinoma, moderately differentiated","Follicular carcinoma, trabecular"],"term_type":""},{"nm":"8333/0","n_c":["C4160"],"i_c":"8333/0","i_c_s":["Microfollicular adenoma, NOS","Fetal adenoma"],"term_type":""},{"nm":"8333/3","n_c":["C45509"],"i_c":"8333/3","i_c_s":["Fetal adenocarcinoma"],"term_type":""},{"nm":"8334/0","n_c":["C4161"],"i_c":"8334/0","i_c_s":["Macrofollicular adenoma","Colloid adenoma"],"term_type":""},{"nm":"8335/3","n_c":["C65200"],"i_c":"8335/3","i_c_s":["Follicular carcinoma, minimally invasive","Follicular carcinoma, encapsulated"],"term_type":""},{"nm":"8336/0","n_c":["C6846"],"i_c":"8336/0","i_c_s":["Hyalinizing trabecular adenoma"],"term_type":""},{"nm":"8337/3","n_c":["C6040"],"i_c":"8337/3","i_c_s":["Insular carcinoma"],"term_type":""},{"nm":"8339/3","n_c":["C156122"],"i_c":"8339/3","i_c_s":["Follicular thyroid carcinoma (FTC), encapsulated angioinvasive"],"term_type":""},{"nm":"8340/3","n_c":["C7380","C126594"],"i_c":"8340/3","i_c_s":["Papillary carcinoma, follicular variant","Papillary adenocarcinoma, follicular variant","Papillary and follicular adenocarcinoma","Papillary and follicular carcinoma"],"term_type":""},{"nm":"8341/3","n_c":["C46004"],"i_c":"8341/3","i_c_s":["Papillary microcarcinoma"],"term_type":""},{"nm":"8342/3","n_c":["C46093"],"i_c":"8342/3","i_c_s":["Papillary carcinoma, oxyphilic cell"],"term_type":""},{"nm":"8343/2","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive EFVPTC"],"term_type":""},{"nm":"8343/3","n_c":["C156034"],"i_c":"8343/3","i_c_s":["Papillary carcinoma, encapsulated"],"term_type":""},{"nm":"8344/3","n_c":["C35830","C35558"],"i_c":"8344/3","i_c_s":["Papillary carcinoma, columnar cell","Papillary carcinoma, tall cell"],"term_type":""},{"nm":"8345/3","n_c":["C4193","C3879"],"i_c":"8345/3","i_c_s":["Medullary carcinoma with amyloid stroma","C cell carcinoma","Parafollicular cell carcinoma"],"term_type":""},{"nm":"8346/3","n_c":["C46104"],"i_c":"8346/3","i_c_s":["Mixed medullary-follicular carcinoma"],"term_type":""},{"nm":"8347/3","n_c":["C46104"],"i_c":"8347/3","i_c_s":["Mixed medullary-papillary carcinoma"],"term_type":""},{"nm":"8350/3","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing carcinoma","Papillary carcinoma, diffuse sclerosing","Nonencapsulated sclerosing adenocarcinoma","Nonencapsulated sclerosing tumor"],"term_type":""},{"nm":"8360/1","n_c":["C6432"],"i_c":"8360/1","i_c_s":["Multiple endocrine adenomas","Endocrine adenomatosis"],"term_type":""},{"nm":"8361/0","n_c":["C4162"],"i_c":"8361/0","i_c_s":["Juxtaglomerular tumor","Reninoma"],"term_type":""},{"nm":"8370/0","n_c":["C9003","C2858","C9004"],"i_c":"8370/0","i_c_s":["Adrenal cortical adenoma, NOS","Adrenal cortical tumor, NOS","Adrenal cortical tumor, benign"],"term_type":""},{"nm":"8370/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8370/3","n_c":["C9325","C9327"],"i_c":"8370/3","i_c_s":["Adrenal cortical carcinoma","Adrenal cortical adenocarcinoma","Adrenal cortical tumor, malignant"],"term_type":""},{"nm":"8371/0","n_c":["C4163"],"i_c":"8371/0","i_c_s":["Adrenal cortical adenoma, compact cell"],"term_type":""},{"nm":"8372/0","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Adrenal cortical adenoma, pigmented","Black adenoma","Pigmented adenoma"],"term_type":""},{"nm":"8373/0","n_c":["C4165"],"i_c":"8373/0","i_c_s":["Adrenal cortical adenoma, clear cell"],"term_type":""},{"nm":"8374/0","n_c":["C4166"],"i_c":"8374/0","i_c_s":["Adrenal cortical adenoma, glomerulosa cell"],"term_type":""},{"nm":"8375/0","n_c":["C4167"],"i_c":"8375/0","i_c_s":["Adrenal cortical adenoma, mixed cell"],"term_type":""},{"nm":"8380/0","n_c":["C27287"],"i_c":"8380/0","i_c_s":["Endometrioid adenoma, NOS","Endometrioid cystadenoma, NOS"],"term_type":""},{"nm":"8380/1","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid adenoma, borderline malignancy","Atypical proliferative endometrioid tumor","Endometrioid cystadenoma, borderline malignancy","Endometrioid tumor of low malignant potential"],"term_type":""},{"nm":"8380/2","n_c":["C27789"],"i_c":"8380/2","i_c_s":["Atypical hyperplasia/Endometrioid intraepithelial neoplasm"],"term_type":""},{"nm":"8380/3","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid adenocarcinoma, NOS","Endometrioid cystadenocarcinoma","Endometrioid carcinoma, NOS"],"term_type":""},{"nm":"8381/0","n_c":["C27288","C27287"],"i_c":"8381/0","i_c_s":["Endometrioid adenofibroma, NOS","Endometrioid cystadenofibroma, NOS"],"term_type":""},{"nm":"8381/1","n_c":["C40069"],"i_c":"8381/1","i_c_s":["Endometrioid adenofibroma, borderline malignancy","Endometrioid cystadenofibroma, borderline malignancy"],"term_type":""},{"nm":"8381/3","n_c":["C40060"],"i_c":"8381/3","i_c_s":["Endometrioid adenofibroma, malignant","Endometrioid cystadenofibroma, malignant"],"term_type":""},{"nm":"8382/3","n_c":["C27839"],"i_c":"8382/3","i_c_s":["Endometrioid adenocarcinoma, secretory variant"],"term_type":""},{"nm":"8383/3","n_c":["C27848"],"i_c":"8383/3","i_c_s":["Endometrioid adenocarcinoma, ciliated cell variant"],"term_type":""},{"nm":"8384/3","n_c":["C66951"],"i_c":"8384/3","i_c_s":["Adenocarcinoma, endocervical type"],"term_type":""},{"nm":"8390/0","n_c":["C7580"],"i_c":"8390/0","i_c_s":["Skin appendage adenoma","Adnexal tumor, benign","Skin appendage tumor, benign"],"term_type":""},{"nm":"8390/3","n_c":["C3775"],"i_c":"8390/3","i_c_s":["Skin appendage carcinoma","Adnexal carcinoma"],"term_type":""},{"nm":"8391/0","n_c":["C4470","C206079","C43331"],"i_c":"8391/0","i_c_s":["Follicular fibroma","Fibrofolliculoma","Perifollicular fibroma","Trichodiscoma"],"term_type":""},{"nm":"8392/0","n_c":["C43356"],"i_c":"8392/0","i_c_s":["Syringofibroadenoma"],"term_type":""},{"nm":"8400/0","n_c":["C7560","C7563","C4879"],"i_c":"8400/0","i_c_s":["Sweat gland adenoma","Hidradenoma, NOS","Sweat gland tumor, benign","Syringadenoma, NOS"],"term_type":""},{"nm":"8400/1","n_c":["C3398"],"i_c":"8400/1","i_c_s":["Sweat gland tumor, NOS"],"term_type":""},{"nm":"8400/3","n_c":["C6938","C4810","C4615"],"i_c":"8400/3","i_c_s":["Sweat gland adenocarcinoma","Sweat gland carcinoma","Sweat gland tumor, malignant"],"term_type":""},{"nm":"8401/0","n_c":["C4168","C205459"],"i_c":"8401/0","i_c_s":["Apocrine adenoma","Apocrine cystadenoma"],"term_type":""},{"nm":"8401/3","n_c":["C4169"],"i_c":"8401/3","i_c_s":["Apocrine adenocarcinoma"],"term_type":""},{"nm":"8402/0","n_c":["C7568","C7563","C7567"],"i_c":"8402/0","i_c_s":["Nodular hidradenoma","Clear cell hidradenoma","Eccrine acrospiroma"],"term_type":""},{"nm":"8402/3","n_c":["C54664"],"i_c":"8402/3","i_c_s":["Nodular hidradenoma, malignant","Hidradenocarcinoma"],"term_type":""},{"nm":"8403/0","n_c":["C4170"],"i_c":"8403/0","i_c_s":["Eccrine spiradenoma","Spiradenoma, NOS"],"term_type":""},{"nm":"8403/3","n_c":["C5117"],"i_c":"8403/3","i_c_s":["Malignant eccrine spiradenoma"],"term_type":""},{"nm":"8404/0","n_c":["C3760","C7565"],"i_c":"8404/0","i_c_s":["Hidrocystoma","Eccrine cystadenoma"],"term_type":""},{"nm":"8405/0","n_c":["C4171"],"i_c":"8405/0","i_c_s":["Papillary hidradenoma","Hidradenoma papilliferum"],"term_type":""},{"nm":"8406/0","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Papillary syringadenoma","Papillary syringocystadenoma","Syringocystadenoma papilliferum"],"term_type":""},{"nm":"8407/0","n_c":["C3761"],"i_c":"8407/0","i_c_s":["Syringoma, NOS"],"term_type":""},{"nm":"8407/3","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Sclerosing sweat duct carcinoma","Microcystic adnexal carcinoma","Syringomatous carcinoma"],"term_type":""},{"nm":"8408/0","n_c":["C27527"],"i_c":"8408/0","i_c_s":["Eccrine papillary adenoma"],"term_type":""},{"nm":"8408/1","n_c":["C27534"],"i_c":"8408/1","i_c_s":["Aggressive digital papillary adenoma"],"term_type":""},{"nm":"8408/3","n_c":["C27534"],"i_c":"8408/3","i_c_s":["Eccrine papillary adenocarcinoma","Digital papillary adenocarcinoma"],"term_type":""},{"nm":"8409/0","n_c":["C205462"],"i_c":"8409/0","i_c_s":["Eccrine poroma"],"term_type":""},{"nm":"8409/3","n_c":["C5560"],"i_c":"8409/3","i_c_s":["Eccrine poroma, malignant","Porocarcinoma"],"term_type":""},{"nm":"8410/0","n_c":["C4346","C4174"],"i_c":"8410/0","i_c_s":["Sebaceous adenoma","Sebaceous epithelioma"],"term_type":""},{"nm":"8410/3","n_c":["C40310"],"i_c":"8410/3","i_c_s":["Sebaceous adenocarcinoma","Sebaceous carcinoma"],"term_type":""},{"nm":"8413/3","n_c":["C27255"],"i_c":"8413/3","i_c_s":["Eccrine adenocarcinoma"],"term_type":""},{"nm":"8420/0","n_c":["C6088"],"i_c":"8420/0","i_c_s":["Ceruminous adenoma"],"term_type":""},{"nm":"8420/3","n_c":["C4176"],"i_c":"8420/3","i_c_s":["Ceruminous adenocarcinoma","Ceruminous carcinoma"],"term_type":""},{"nm":"8430/1","n_c":["C3772"],"i_c":"8430/1","i_c_s":["Mucoepidermoid tumor"],"term_type":""},{"nm":"8430/3","n_c":["C3772"],"i_c":"8430/3","i_c_s":["Mucoepidermoid carcinoma"],"term_type":""},{"nm":"8440/0","n_c":["C2972"],"i_c":"8440/0","i_c_s":["Cystadenoma, NOS","Cystoma, NOS"],"term_type":""},{"nm":"8440/3","n_c":["C2971"],"i_c":"8440/3","i_c_s":["Cystadenocarcinoma, NOS"],"term_type":""},{"nm":"8441/0","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous cystadenoma, NOS","Serous microcystic adenoma","Serous cystoma"],"term_type":""},{"nm":"8441/2","n_c":["C126449"],"i_c":"8441/2","i_c_s":["Serous tubal intraepithelial carcinoma"],"term_type":""},{"nm":"8441/3","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous cystadenocarcinoma, NOS","Serous adenocarcinoma, NOS","Serous carcinoma, NOS"],"term_type":""},{"nm":"8441/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8442/1","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Serous cystadenoma, borderline malignancy","Atypical proliferating serous tumor","Serous tumor, NOS, of low malignant potential"],"term_type":""},{"nm":"8443/0","n_c":["C65203"],"i_c":"8443/0","i_c_s":["Clear cell cystadenoma"],"term_type":""},{"nm":"8444/1","n_c":["C40080"],"i_c":"8444/1","i_c_s":["Clear cell cystic tumor of borderline malignancy","Atypical proliferating clear cell tumor"],"term_type":""},{"nm":"8450/0","n_c":["C2974"],"i_c":"8450/0","i_c_s":["Papillary cystadenoma, NOS"],"term_type":""},{"nm":"8450/3","n_c":["C3777"],"i_c":"8450/3","i_c_s":["Papillary cystadenocarcinoma, NOS","Papillocystic adenocarcinoma"],"term_type":""},{"nm":"8451/1","n_c":["C4178"],"i_c":"8451/1","i_c_s":["Papillary cystadenoma, borderline malignancy"],"term_type":""},{"nm":"8452/1","n_c":["C201136"],"i_c":"8452/1","i_c_s":["Solid pseudopapillary tumor","Papillary cystic tumor","Solid and cystic tumor","Solid and papillary epithelial neoplasm"],"term_type":""},{"nm":"8452/3","n_c":["C37212","C5728"],"i_c":"8452/3","i_c_s":["Solid pseudopapillary carcinoma"],"term_type":""},{"nm":"8453/0","n_c":["C95514"],"i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous adenoma","Intraductal papillary-mucinous tumor with intermediate dysplasia","Intraductal papillary-mucinous tumor with low grade dysplasia","Intraductal papillary-mucinous tumor with moderate dysplasia","Intraductal papillary-mucinous neoplasm with low grade dysplasia","Intraductal papillary-mucinous neoplasm with moderate dysplasia"],"term_type":""},{"nm":"8453/2","n_c":["C41251"],"i_c":"8453/2","i_c_s":["Intraductal papillary-mucinous carcinoma, non-invasive","Intraductal papillary mucinous neoplasm with high grade dysplasia"],"term_type":""},{"nm":"8453/3","n_c":["C5726"],"i_c":"8453/3","i_c_s":["Intraductal papillary-mucinous carcinoma, invasive","Intraductal papillary mucinous neoplasm with an associated invasive carcinoma"],"term_type":""},{"nm":"8454/0","n_c":["C45754"],"i_c":"8454/0","i_c_s":["Cystic tumor of atrio-ventricular node"],"term_type":""},{"nm":"8460/0","n_c":["C4180"],"i_c":"8460/0","i_c_s":["Papillary serous cystadenoma, NOS"],"term_type":""},{"nm":"8460/2","n_c":["C122585"],"i_c":"8460/2","i_c_s":["Non-invasive low grade serous carcinoma"],"term_type":""},{"nm":"8460/3","n_c":["C8377","C6882"],"i_c":"8460/3","i_c_s":["Papillary serous cystadenocarcinoma","Micropapillary serous carcinoma","Papillary serous adenocarcinoma"],"term_type":""},{"nm":"8461/0","n_c":["C4181"],"i_c":"8461/0","i_c_s":["Serous surface papilloma"],"term_type":""},{"nm":"8461/3","n_c":["C7695","C4182"],"i_c":"8461/3","i_c_s":["Serous surface papillary carcinoma","Primary serous papillary carcinoma of peritoneum"],"term_type":""},{"nm":"8462/1","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Serous papillary cystic tumor of borderline malignancy","Atypical proliferative papillary serous tumor","Papillary serous cystadenoma, borderline malignancy","Papillary serous tumor of low malignant potential"],"term_type":""},{"nm":"8463/1","n_c":["C7315"],"i_c":"8463/1","i_c_s":["Serous surface papillary tumor of borderline malignancy"],"term_type":""},{"nm":"8470/0","n_c":["C2973","C6883"],"i_c":"8470/0","i_c_s":["Mucinous cystadenoma, NOS","Mucinous cystic neoplasm with intermediate-grade dysplasia","Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia","Mucinous cystic neoplasm with low-grade dysplasia","Mucinous cystic neoplasm with low-grade intraepithelial neoplasia","Mucinous cystic tumor with intermediate dysplasia","Mucinous cystic tumor with low-grade dysplasia","Mucinous cystic tumor with moderate dysplasia","Mucinous cystoma","Pseudomucinous cystadenoma, NOS"],"term_type":""},{"nm":"8470/2","n_c":["C41245","C95493"],"i_c":"8470/2","i_c_s":["Mucinous cystadenocarcinoma, non-invasive","Mucinous cystic tumor with high-grade dysplasia","Mucinous cystic neoplasm with high-grade dysplasia","Mucinous cystic neoplasm with high-grade intraepithelial neoplasia"],"term_type":""},{"nm":"8470/3","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Mucinous cystadenocarcinoma, NOS","Mucinous cystic tumor with an associated invasive carcinoma","Mucinous cystic neoplasm with an associated invasive carcinoma","Pseudomucinous adenocarcinoma","Pseudomucinous cystadenocarcinoma, NOS"],"term_type":""},{"nm":"8471/0","n_c":["C4184"],"i_c":"8471/0","i_c_s":["Papillary mucinous cystadenoma, NOS","Papillary pseudomucinous cystadenoma, NOS"],"term_type":""},{"nm":"8471/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8471/3","n_c":["C65204"],"i_c":"8471/3","i_c_s":["Papillary mucinous cystadenocarcinoma","Papillary pseudomucinous cystadenocarcinoma"],"term_type":""},{"nm":"8472/1","n_c":["C201978"],"i_c":"8472/1","i_c_s":["Mucinous cystic tumor of borderline malignancy","Atypical proliferative mucinous tumor","Mucinous cystadenoma, borderline malignancy","Mucinous tumor, NOS, of low malignant potential","Pseudomucinous cystadenoma, borderline malignancy"],"term_type":""},{"nm":"8473/1","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary mucinous cystadenoma, borderline malignancy","Papillary mucinous tumor of low malignant potential","Papillary pseudomucinous cystadenoma, borderline malignancy"],"term_type":""},{"nm":"8474/1","n_c":["C7281"],"i_c":"8474/1","i_c_s":["Seromucinous Borderline Tumor"],"term_type":""},{"nm":"8474/3","n_c":["C40090"],"i_c":"8474/3","i_c_s":["Seromucinous carcinoma"],"term_type":""},{"nm":"8480/0","n_c":["C2973"],"i_c":"8480/0","i_c_s":["Mucinous adenoma"],"term_type":""},{"nm":"8480/1","n_c":["C42598"],"i_c":"8480/1","i_c_s":["Low grade appendiceal mucinous neoplasm"],"term_type":""},{"nm":"8480/3","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucinous adenocarcinoma","Pseudomyxoma peritonei with unknown primary site","Gelatinous adenocarcinoma","Gelatinous carcinoma","Colloid adenocarcinoma","Colloid carcinoma","Mucinous carcinoma","Mucoid adenocarcinoma","Mucoid carcinoma","Mucous adenocarcinoma","Mucous carcinoma"],"term_type":""},{"nm":"8480/6","n_c":["C3345"],"i_c":"8480/6","i_c_s":["Pseudomyxoma peritonei"],"term_type":""},{"nm":"8481/3","n_c":["C27825","C27379"],"i_c":"8481/3","i_c_s":["Mucin-producing adenocarcinoma","Mucin-producing carcinoma","Mucin-secreting adenocarcinoma","Mucin-secreting carcinoma"],"term_type":""},{"nm":"8482/3","n_c":["C66953"],"i_c":"8482/3","i_c_s":["Mucinous adenocarcinoma, endocervical type"],"term_type":""},{"nm":"8482/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8490/3","n_c":["C3774","C4127"],"i_c":"8490/3","i_c_s":["Signet ring cell carcinoma","Poorly cohesive carcinoma","Signet ring cell adenocarcinoma"],"term_type":""},{"nm":"8490/6","n_c":["C66717","C3153"],"i_c":"8490/6","i_c_s":["Metastatic signet ring cell carcinoma","Krukenberg tumor"],"term_type":""},{"nm":"8500/2","n_c":["C2924","C7949"],"i_c":"8500/2","i_c_s":["Intraductal carcinoma, noninfiltrating, NOS","Ductal carcinoma in situ, NOS","DCIS, NOS","DIN 3","Ductal intraepithelial neoplasia 3","Intraductal adenocarcinoma, noninfiltrating, NOS","Intraductal carcinoma, NOS"],"term_type":""},{"nm":"8500/3","n_c":["C4017","C4194"],"i_c":"8500/3","i_c_s":["Infiltrating duct carcinoma, NOS","Duct adenocarcinoma, NOS","Duct carcinoma, NOS","Duct cell carcinoma","Ductal carcinoma, NOS","Infiltrating duct adenocarcinoma"],"term_type":""},{"nm":"8500/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8501/2","n_c":["C7949"],"i_c":"8501/2","i_c_s":["Comedocarcinoma, noninfiltrating","DCIS, comedo type","Ductal carcinoma in situ, comedo type"],"term_type":""},{"nm":"8501/3","n_c":["C4188"],"i_c":"8501/3","i_c_s":["Comedocarcinoma, NOS"],"term_type":""},{"nm":"8502/3","n_c":["C4189"],"i_c":"8502/3","i_c_s":["Secretory carcinoma of breast","Juvenile carcinoma of breast"],"term_type":""},{"nm":"8503/0","n_c":["C96877","C6881","C96807","C3785"],"i_c":"8503/0","i_c_s":["Intraductal papilloma","Intracystic papillary neoplasm with low grade intraepithelial neoplasia","Intraductal papillary neoplasm with low grade intraepithelial neoplasia","Intraductal papillary neoplasm, NOS","Intraductal tubular-papillary neoplasm, low grade","Duct adenoma, NOS","Ductal papilloma","Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia","Intraductal papillary neoplasm with intermediate grade neoplasia","Intraglandular papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":""},{"nm":"8503/2","n_c":["C96809","C4190"],"i_c":"8503/2","i_c_s":["Noninfiltrating intraductal papillary adenocarcinoma","Intraductal papillary neoplasm with high grade intraepithelial neoplasia","Intraductal tubular-papillary neoplasm, high grade","DCIS, papillary","Ductal carcinoma in situ, papillary","Intracystic papillary neoplasm with high grade intraepithelial neoplasia","Intracystic papillary tumor with high grade dysplasia","Intracystic papillary tumor with high grade intraepithelial neoplasia","Intraductal papillary adenocarcinoma, NOS","Intraductal papillary carcinoma, NOS","Intraductal papillary neoplasm with high grade dysplasia","Intraductal papillary tumor with high grade dysplasia","Intraductal papillary tumor with high grade intraepithelial neoplasia","Noninfiltrating intraductal papillary carcinoma"],"term_type":""},{"nm":"8503/3","n_c":["C7439","C7438"],"i_c":"8503/3","i_c_s":["Intraductal papillary adenocarcinoma with invasion","Intraductal papillary neoplasm with associated invasive carcinoma","Infiltrating and papillary adenocarcinoma","Infiltrating papillary adenocarcinoma","Intracystic papillary neoplasm with associated invasive carcinoma"],"term_type":""},{"nm":"8504/0","n_c":["C3863"],"i_c":"8504/0","i_c_s":["Intracystic papillary adenoma","Intracystic papilloma"],"term_type":""},{"nm":"8504/2","n_c":["C7645"],"i_c":"8504/2","i_c_s":["Noninfiltrating intracystic carcinoma"],"term_type":""},{"nm":"8504/3","n_c":["C7645"],"i_c":"8504/3","i_c_s":["Intracystic carcinoma, NOS","Intracystic papillary adenocarcinoma"],"term_type":""},{"nm":"8505/0","n_c":["C7363"],"i_c":"8505/0","i_c_s":["Intraductal papillomatosis, NOS","Diffuse intraductal papillomatosis"],"term_type":""},{"nm":"8506/0","n_c":["C4192"],"i_c":"8506/0","i_c_s":["Adenoma of nipple","Subareolar duct papillomatosis"],"term_type":""},{"nm":"8507/2","n_c":["C5139"],"i_c":"8507/2","i_c_s":["Intraductal micropapillary carcinoma","Intraductal carcinoma, clinging","Ductal carcinoma in situ, micropapillary"],"term_type":""},{"nm":"8507/3","n_c":["C36084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8508/3","n_c":["C4189"],"i_c":"8508/3","i_c_s":["Cystic hypersecretory carcinoma"],"term_type":""},{"nm":"8509/2","n_c":["C6870"],"i_c":"8509/2","i_c_s":["Solid papillary carcinoma in situ"],"term_type":""},{"nm":"8509/3","n_c":["C66850"],"i_c":"8509/3","i_c_s":["Solid papillary carcinoma with invasion"],"term_type":""},{"nm":"8510/3","n_c":["C66718"],"i_c":"8510/3","i_c_s":["Medullary carcinoma, NOS","Medullary adenocarcinoma"],"term_type":""},{"nm":"8512/3","n_c":["C9119"],"i_c":"8512/3","i_c_s":["Medullary carcinoma with lymphoid stroma"],"term_type":""},{"nm":"8513/3","n_c":["C66719"],"i_c":"8513/3","i_c_s":["Atypical medullary carcinoma"],"term_type":""},{"nm":"8514/3","n_c":["C7362"],"i_c":"8514/3","i_c_s":["Duct carcinoma, desmoplastic type"],"term_type":""},{"nm":"8519/2","n_c":["C137839"],"i_c":"8519/2","i_c_s":["Pleomorphic lobular carcinoma in situ"],"term_type":""},{"nm":"8520/2","n_c":["C4018"],"i_c":"8520/2","i_c_s":["Lobular carcinoma in situ, NOS","LCIS, NOS","Lobular carcinoma, noninfiltrating"],"term_type":""},{"nm":"8520/3","n_c":["C3771","C7950"],"i_c":"8520/3","i_c_s":["Lobular carcinoma, NOS","Infiltrating lobular carcinoma, NOS","Lobular adenocarcinoma"],"term_type":""},{"nm":"8521/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8521/3","n_c":["C4194"],"i_c":"8521/3","i_c_s":["Infiltrating ductular carcinoma"],"term_type":""},{"nm":"8522/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8522/2","n_c":["C4195"],"i_c":"8522/2","i_c_s":["Intraductal carcinoma and lobular carcinoma in situ"],"term_type":""},{"nm":"8522/3","n_c":["C7690","C6939","C5160","C7688","C7689"],"i_c":"8522/3","i_c_s":["Infiltrating duct and lobular carcinoma","Infiltrating duct and lobular carcinoma in situ","Infiltrating lobular carcinoma and ductal carcinoma in situ","Intraductal and lobular carcinoma","Lobular and ductal carcinoma"],"term_type":""},{"nm":"8523/3","n_c":["C7688"],"i_c":"8523/3","i_c_s":["Infiltrating duct mixed with other types of carcinoma","Infiltrating duct and colloid carcinoma","Infiltrating duct and cribriform carcinoma","Infiltrating duct and mucinous carcinoma","Infiltrating duct and tubular carcinoma"],"term_type":""},{"nm":"8524/3","n_c":["C6939"],"i_c":"8524/3","i_c_s":["Infiltrating lobular mixed with other types of carcinoma"],"term_type":""},{"nm":"8525/3","n_c":["C35702"],"i_c":"8525/3","i_c_s":["Polymorphous low grade adenocarcinoma","Terminal duct adenocarcinoma"],"term_type":""},{"nm":"8530/3","n_c":["C4001"],"i_c":"8530/3","i_c_s":["Inflammatory carcinoma","Inflammatory adenocarcinoma"],"term_type":""},{"nm":"8540/3","n_c":["C47857"],"i_c":"8540/3","i_c_s":["Paget disease, mammary","Paget disease of breast"],"term_type":""},{"nm":"8541/3","n_c":["C7951"],"i_c":"8541/3","i_c_s":["Paget disease and infiltrating duct carcinoma of breast"],"term_type":""},{"nm":"8542/3","n_c":["C3302"],"i_c":"8542/3","i_c_s":["Paget disease, extramammary"],"term_type":""},{"nm":"8543/3","n_c":["C4019"],"i_c":"8543/3","i_c_s":["Paget disease and intraductal carcinoma of breast"],"term_type":""},{"nm":"8550/0","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinar cell adenoma","Acinar adenoma","Acinic cell adenoma"],"term_type":""},{"nm":"8550/1","n_c":["C3768","C4197"],"i_c":"8550/1","i_c_s":["Acinar cell tumor","Acinic cell tumor"],"term_type":""},{"nm":"8550/3","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar cell carcinoma","Acinar adenocarcinoma","Acinar carcinoma","Acinic cell adenocarcinoma"],"term_type":""},{"nm":"8551/3","n_c":["C5727"],"i_c":"8551/3","i_c_s":["Acinar cell cystadenocarcinoma"],"term_type":""},{"nm":"8552/3","n_c":["C95458"],"i_c":"8552/3","i_c_s":["Mixed acinar-ductal carcinoma"],"term_type":""},{"nm":"8560/0","n_c":["C45602"],"i_c":"8560/0","i_c_s":["Mixed squamous cell and glandular papilloma"],"term_type":""},{"nm":"8560/3","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Adenosquamous carcinoma","Mixed adenocarcinoma and epidermoid carcinoma","Mixed adenocarcinoma and squamous cell carcinoma"],"term_type":""},{"nm":"8561/0","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Adenolymphoma","Papillary cystadenoma lymphomatosum","Warthin tumor"],"term_type":""},{"nm":"8562/3","n_c":["C4199"],"i_c":"8562/3","i_c_s":["Epithelial-myoepithelial carcinoma"],"term_type":""},{"nm":"8570/3","n_c":["C4200"],"i_c":"8570/3","i_c_s":["Adenocarcinoma with squamous metaplasia","Adenoacanthoma"],"term_type":""},{"nm":"8571/3","n_c":["C7685","C7684","C7683"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with cartilaginous and osseous metaplasia","Adenocarcinoma with cartilaginous metaplasia","Adenocarcinoma with osseous metaplasia"],"term_type":""},{"nm":"8572/3","n_c":["C4201"],"i_c":"8572/3","i_c_s":["Adenocarcinoma with spindle cell metaplasia"],"term_type":""},{"nm":"8573/3","n_c":["C4202"],"i_c":"8573/3","i_c_s":["Adenocarcinoma with apocrine metaplasia","Carcinoma with apocrine metaplasia"],"term_type":""},{"nm":"8574/3","n_c":["C66745"],"i_c":"8574/3","i_c_s":["Adenocarcinoma with neuroendocrine differentiation","Carcinoma with neuroendocrine differentiation"],"term_type":""},{"nm":"8575/3","n_c":["C27949"],"i_c":"8575/3","i_c_s":["Metaplastic carcinoma, NOS"],"term_type":""},{"nm":"8576/3","n_c":["C66950"],"i_c":"8576/3","i_c_s":["Hepatoid adenocarcinoma","Hepatoid carcinoma"],"term_type":""},{"nm":"8580/0","n_c":["C66746"],"i_c":"8580/0","i_c_s":["Thymoma, benign"],"term_type":""},{"nm":"8580/1","n_c":["C3411"],"i_c":"8580/1","i_c_s":["Thymoma, NOS"],"term_type":""},{"nm":"8580/3","n_c":["C7612"],"i_c":"8580/3","i_c_s":["Thymoma, malignant, NOS"],"term_type":""},{"nm":"8581/1","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, type A, NOS","Thymoma, medullary, NOS","Thymoma, spindle cell, NOS"],"term_type":""},{"nm":"8581/3","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, type A, malignant","Thymoma, medullary, malignant","Thymoma, spindle cell, malignant"],"term_type":""},{"nm":"8582/1","n_c":["C6885"],"i_c":"8582/1","i_c_s":["Thymoma, type AB, NOS","Thymoma, mixed type, NOS"],"term_type":""},{"nm":"8582/3","n_c":["C6886"],"i_c":"8582/3","i_c_s":["Thymoma, type AB, malignant","Thymoma, mixed type, malignant"],"term_type":""},{"nm":"8583/1","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, type B1, NOS","Thymoma, lymphocyte-rich, NOS","Thymoma, lymphocytic, NOS","Thymoma, organoid, NOS","Thymoma, predominantly cortical, NOS"],"term_type":""},{"nm":"8583/3","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, type B1, malignant","Thymoma, lymphocyte-rich, malignant","Thymoma, lymphocytic, malignant","Thymoma, organoid, malignant","Thymoma, predominantly cortical, malignant"],"term_type":""},{"nm":"8584/1","n_c":["C6888"],"i_c":"8584/1","i_c_s":["Thymoma, type B2, NOS","Thymoma, cortical, NOS"],"term_type":""},{"nm":"8584/3","n_c":["C6889"],"i_c":"8584/3","i_c_s":["Thymoma, type B2, malignant","Thymoma, cortical, malignant"],"term_type":""},{"nm":"8585/1","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, type B3, NOS","Thymoma, atypical, NOS","Thymoma, epithelial, NOS"],"term_type":""},{"nm":"8585/3","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, type B3, malignant","Thymoma, atypical, malignant","Thymoma, epithelial, malignant","Well differentiated thymic carcinoma"],"term_type":""},{"nm":"8586/3","n_c":["C7569"],"i_c":"8586/3","i_c_s":["Thymic carcinoma, NOS","Thymoma, type C"],"term_type":""},{"nm":"8587/0","n_c":["C53595"],"i_c":"8587/0","i_c_s":["Ectopic hamartomatous thymoma"],"term_type":""},{"nm":"8588/3","n_c":["C46105"],"i_c":"8588/3","i_c_s":["Spindle epithelial tumor with thymus-like element","SETTLE","Spindle epithelial tumor with thymus-like differentiation"],"term_type":""},{"nm":"8589/3","n_c":["C46106"],"i_c":"8589/3","i_c_s":["Carcinoma showing thymus-like element","CASTLE","Carcinoma showing thymus-like differentiation"],"term_type":""},{"nm":"8590/1","n_c":["C4862","C3794"],"i_c":"8590/1","i_c_s":["Sex cord-gonadal stromal tumor, NOS","Gonadal stromal tumor, NOS","Ovarian stromal tumor","Sex cord tumor, NOS","Testicular stromal tumor"],"term_type":""},{"nm":"8591/1","n_c":["C66748"],"i_c":"8591/1","i_c_s":["Sex cord-gonadal stromal tumor, incompletely differentiated"],"term_type":""},{"nm":"8592/1","n_c":["C66991"],"i_c":"8592/1","i_c_s":["Sex cord-gonadal stromal tumor, mixed forms"],"term_type":""},{"nm":"8593/1","n_c":["C66749"],"i_c":"8593/1","i_c_s":["Stromal tumor with minor sex cord elements"],"term_type":""},{"nm":"8594/1","n_c":["C5241"],"i_c":"8594/1","i_c_s":["Mixed germ cell sex cord‐stromal tumor, unclassified"],"term_type":""},{"nm":"8600/0","n_c":["C3405"],"i_c":"8600/0","i_c_s":["Thecoma, NOS","Theca cell tumor"],"term_type":""},{"nm":"8600/3","n_c":["C6929"],"i_c":"8600/3","i_c_s":["Thecoma, malignant"],"term_type":""},{"nm":"8601/0","n_c":["C4203"],"i_c":"8601/0","i_c_s":["Thecoma, luteinized"],"term_type":""},{"nm":"8602/0","n_c":["C4204"],"i_c":"8602/0","i_c_s":["Sclerosing stromal tumor"],"term_type":""},{"nm":"8610/0","n_c":["C3202"],"i_c":"8610/0","i_c_s":["Luteoma, NOS","Luteinoma"],"term_type":""},{"nm":"8620/1","n_c":["C66750","C3070"],"i_c":"8620/1","i_c_s":["Granulosa cell tumor, adult type","Granulosa cell tumor, NOS"],"term_type":""},{"nm":"8620/3","n_c":["C4205"],"i_c":"8620/3","i_c_s":["Granulosa cell tumor, malignant","Granulosa cell carcinoma","Granulosa cell tumor, sarcomatoid"],"term_type":""},{"nm":"8621/1","n_c":["C66751"],"i_c":"8621/1","i_c_s":["Granulosa cell-theca cell tumor","Theca cell-granulosa cell tumor"],"term_type":""},{"nm":"8622/1","n_c":["C4207"],"i_c":"8622/1","i_c_s":["Granulosa cell tumor, juvenile"],"term_type":""},{"nm":"8623/1","n_c":["C4208"],"i_c":"8623/1","i_c_s":["Sex cord tumor with annular tubules"],"term_type":""},{"nm":"8630/0","n_c":["C67012"],"i_c":"8630/0","i_c_s":["Androblastoma, benign","Arrhenoblastoma, benign"],"term_type":""},{"nm":"8630/1","n_c":["C39976"],"i_c":"8630/1","i_c_s":["Androblastoma, NOS","Arrhenoblastoma, NOS"],"term_type":""},{"nm":"8630/3","n_c":["C67006"],"i_c":"8630/3","i_c_s":["Androblastoma, malignant","Arrhenoblastoma, malignant"],"term_type":""},{"nm":"8631/0","n_c":["C4209"],"i_c":"8631/0","i_c_s":["Sertoli-Leydig cell tumor, well differentiated"],"term_type":""},{"nm":"8631/1","n_c":["C39968","C2880"],"i_c":"8631/1","i_c_s":["Sertoli-Leydig cell tumor of intermediate differentiation","Sertoli-Leydig cell tumor, NOS"],"term_type":""},{"nm":"8631/3","n_c":["C4210"],"i_c":"8631/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated","Sertoli-Leydig cell tumor, sarcomatoid"],"term_type":""},{"nm":"8632/1","n_c":["C3072"],"i_c":"8632/1","i_c_s":["Gynandroblastoma"],"term_type":""},{"nm":"8633/1","n_c":["C39974"],"i_c":"8633/1","i_c_s":["Sertoli-Leydig cell tumor, retiform"],"term_type":""},{"nm":"8634/1","n_c":["C39972"],"i_c":"8634/1","i_c_s":["Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements","Sertoli-Leydig cell tumor, retiform, with heterologous elements"],"term_type":""},{"nm":"8634/3","n_c":["C39973"],"i_c":"8634/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements"],"term_type":""},{"nm":"8640/1","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Sertoli cell tumor, NOS","Pick tubular adenoma","Sertoli cell adenoma","Testicular adenoma","Tubular androblastoma, NOS"],"term_type":""},{"nm":"8640/3","n_c":["C67006"],"i_c":"8640/3","i_c_s":["Sertoli cell carcinoma"],"term_type":""},{"nm":"8641/0","n_c":["C4211"],"i_c":"8641/0","i_c_s":["Sertoli cell tumor with lipid storage","Folliculome lipidique","Lipid-rich Sertoli cell tumor","Tubular androblastoma with lipid storage"],"term_type":""},{"nm":"8642/1","n_c":["C39944"],"i_c":"8642/1","i_c_s":["Large cell calcifying Sertoli cell tumor"],"term_type":""},{"nm":"8650/0","n_c":["C4212"],"i_c":"8650/0","i_c_s":["Leydig cell tumor, benign","Interstitial cell tumor, benign"],"term_type":""},{"nm":"8650/1","n_c":["C3188"],"i_c":"8650/1","i_c_s":["Leydig cell tumor, NOS","Interstitial cell tumor, NOS"],"term_type":""},{"nm":"8650/3","n_c":["C4213"],"i_c":"8650/3","i_c_s":["Leydig cell tumor, malignant","Interstitial cell tumor, malignant"],"term_type":""},{"nm":"8660/0","n_c":["C4214"],"i_c":"8660/0","i_c_s":["Hilus cell tumor","Hilar cell tumor"],"term_type":""},{"nm":"8670/0","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Lipid cell tumor of ovary","Masculinovoblastoma","Lipoid cell tumor of ovary","Steroid cell tumor, NOS"],"term_type":""},{"nm":"8670/3","n_c":["C39981"],"i_c":"8670/3","i_c_s":["Steroid cell tumor, malignant"],"term_type":""},{"nm":"8671/0","n_c":["C2860"],"i_c":"8671/0","i_c_s":["Adrenal rest tumor"],"term_type":""},{"nm":"8680/0","n_c":["C48314"],"i_c":"8680/0","i_c_s":["Paraganglioma, benign"],"term_type":""},{"nm":"8680/1","n_c":["C3308"],"i_c":"8680/1","i_c_s":["Paraganglioma, NOS"],"term_type":""},{"nm":"8680/3","n_c":["C8559"],"i_c":"8680/3","i_c_s":["Paraganglioma, malignant"],"term_type":""},{"nm":"8681/1","n_c":["C4216"],"i_c":"8681/1","i_c_s":["Sympathetic paraganglioma"],"term_type":""},{"nm":"8682/1","n_c":["C4217"],"i_c":"8682/1","i_c_s":["Parasympathetic paraganglioma"],"term_type":""},{"nm":"8683/0","n_c":["C188229"],"i_c":"8683/0","i_c_s":["Gangliocytic paraganglioma"],"term_type":""},{"nm":"8690/1","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Glomus jugulare tumor, NOS","Jugular paraganglioma","Jugulotympanic paraganglioma"],"term_type":""},{"nm":"8691/1","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aortic body tumor","Aortic body paraganglioma","Aorticopulmonary paraganglioma"],"term_type":""},{"nm":"8692/1","n_c":["C2932"],"i_c":"8692/1","i_c_s":["Carotid body tumor","Carotid body paraganglioma"],"term_type":""},{"nm":"8693/1","n_c":["C2932","C3309"],"i_c":"8693/1","i_c_s":["Extra-adrenal paraganglioma, NOS","Chemodectoma","Nonchromaffin paraganglioma, NOS"],"term_type":""},{"nm":"8693/3","n_c":["C4219"],"i_c":"8693/3","i_c_s":["Extra-adrenal paraganglioma, malignant","Nonchromaffin paraganglioma, malignant"],"term_type":""},{"nm":"8700/0","n_c":["C3326","C4216"],"i_c":"8700/0","i_c_s":["Pheochromocytoma, NOS","Adrenal medullary paraganglioma","Chromaffin paraganglioma","Chromaffin tumor","Chromaffinoma"],"term_type":""},{"nm":"8700/3","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Pheochromocytoma, malignant","Adrenal medullary paraganglioma, malignant","Pheochromoblastoma"],"term_type":""},{"nm":"8710/3","n_c":["C4221"],"i_c":"8710/3","i_c_s":["Glomangiosarcoma","Glomoid sarcoma"],"term_type":""},{"nm":"8711/0","n_c":["C3060"],"i_c":"8711/0","i_c_s":["Glomus tumor, NOS"],"term_type":""},{"nm":"8711/3","n_c":["C4221"],"i_c":"8711/3","i_c_s":["Glomus tumor, malignant"],"term_type":""},{"nm":"8712/0","n_c":["C4222"],"i_c":"8712/0","i_c_s":["Glomangioma"],"term_type":""},{"nm":"8713/0","n_c":["C4223"],"i_c":"8713/0","i_c_s":["Glomangiomyoma"],"term_type":""},{"nm":"8714/3","n_c":["C121792"],"i_c":"8714/3","i_c_s":["PEComa, malignant"],"term_type":""},{"nm":"8720/0","n_c":["C7570","C27816","C3074"],"i_c":"8720/0","i_c_s":["Pigmented nevus, NOS","Hairy nevus","Melanocytic nevus","Nevus, NOS"],"term_type":""},{"nm":"8720/2","n_c":["C8423"],"i_c":"8720/2","i_c_s":["Melanoma in situ"],"term_type":""},{"nm":"8720/3","n_c":["C3224"],"i_c":"8720/3","i_c_s":["Malignant melanoma, NOS","Melanoma, NOS"],"term_type":""},{"nm":"8720/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8721/3","n_c":["C205125"],"i_c":"8721/3","i_c_s":["Nodular melanoma"],"term_type":""},{"nm":"8722/0","n_c":["C4226"],"i_c":"8722/0","i_c_s":["Balloon cell nevus"],"term_type":""},{"nm":"8722/3","n_c":["C4227"],"i_c":"8722/3","i_c_s":["Balloon cell melanoma"],"term_type":""},{"nm":"8723/0","n_c":["C7602","C7603"],"i_c":"8723/0","i_c_s":["Halo nevus","Regressing nevus"],"term_type":""},{"nm":"8723/3","n_c":["C4228"],"i_c":"8723/3","i_c_s":["Malignant melanoma, regressing"],"term_type":""},{"nm":"8725/0","n_c":["C4229"],"i_c":"8725/0","i_c_s":["Neuronevus"],"term_type":""},{"nm":"8726/0","n_c":["C9498"],"i_c":"8726/0","i_c_s":["Magnocellular nevus","Melanocytoma, NOS","Melanocytoma, eyeball"],"term_type":""},{"nm":"8727/0","n_c":["C3694"],"i_c":"8727/0","i_c_s":["Dysplastic nevus"],"term_type":""},{"nm":"8728/0","n_c":["C6890"],"i_c":"8728/0","i_c_s":["Diffuse melanocytosis"],"term_type":""},{"nm":"8728/1","n_c":["C4662"],"i_c":"8728/1","i_c_s":["Meningeal melanocytoma"],"term_type":""},{"nm":"8728/3","n_c":["C6891"],"i_c":"8728/3","i_c_s":["Meningeal melanomatosis"],"term_type":""},{"nm":"8730/0","n_c":["C27095"],"i_c":"8730/0","i_c_s":["Nonpigmented nevus","Achromic nevus"],"term_type":""},{"nm":"8730/3","n_c":["C3802"],"i_c":"8730/3","i_c_s":["Amelanotic melanoma"],"term_type":""},{"nm":"8740/0","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Junctional nevus, NOS","Intraepidermal nevus","Junction nevus"],"term_type":""},{"nm":"8740/3","n_c":["C4232"],"i_c":"8740/3","i_c_s":["Malignant melanoma in junctional nevus"],"term_type":""},{"nm":"8741/2","n_c":["C4233"],"i_c":"8741/2","i_c_s":["Precancerous melanosis, NOS"],"term_type":""},{"nm":"8741/3","n_c":["C66753"],"i_c":"8741/3","i_c_s":["Malignant melanoma in precancerous melanosis"],"term_type":""},{"nm":"8742/2","n_c":["C43372"],"i_c":"8742/2","i_c_s":["Lentigo maligna","Hutchinson melanotic freckle, NOS"],"term_type":""},{"nm":"8742/3","n_c":["C9151"],"i_c":"8742/3","i_c_s":["Lentigo maligna melanoma","Malignant melanoma in Hutchinson melanotic freckle"],"term_type":""},{"nm":"8743/3","n_c":["C204843"],"i_c":"8743/3","i_c_s":["Superficial spreading melanoma"],"term_type":""},{"nm":"8744/3","n_c":["C4022"],"i_c":"8744/3","i_c_s":["Acral lentiginous melanoma, malignant"],"term_type":""},{"nm":"8745/3","n_c":["C37257"],"i_c":"8745/3","i_c_s":["Desmoplastic melanoma, malignant","Desmoplastic melanoma, amelanotic","Neurotropic melanoma, malignant"],"term_type":""},{"nm":"8746/3","n_c":["C48622"],"i_c":"8746/3","i_c_s":["Mucosal lentiginous melanoma"],"term_type":""},{"nm":"8750/0","n_c":["C3804"],"i_c":"8750/0","i_c_s":["Intradermal nevus","Dermal nevus"],"term_type":""},{"nm":"8760/0","n_c":["C3901"],"i_c":"8760/0","i_c_s":["Compound nevus","Dermal and epidermal nevus"],"term_type":""},{"nm":"8761/0","n_c":["C3944","C66754"],"i_c":"8761/0","i_c_s":["Small congenital nevus"],"term_type":""},{"nm":"8761/1","n_c":["C4234"],"i_c":"8761/1","i_c_s":["Giant pigmented nevus, NOS","Intermediate and giant congenital nevus"],"term_type":""},{"nm":"8761/3","n_c":["C4235"],"i_c":"8761/3","i_c_s":["Malignant melanoma in giant pigmented nevus","Malignant melanoma in congenital melanocytic nevus"],"term_type":""},{"nm":"8762/1","n_c":["C66755"],"i_c":"8762/1","i_c_s":["Proliferative dermal lesion in congenital nevus"],"term_type":""},{"nm":"8770/0","n_c":["C27007","C4751"],"i_c":"8770/0","i_c_s":["Epithelioid and spindle cell nevus","Pigmented spindle cell nevus of Reed","Juvenile melanoma","Juvenile nevus","Spitz nevus"],"term_type":""},{"nm":"8770/3","n_c":["C66756"],"i_c":"8770/3","i_c_s":["Mixed epithelioid and spindle cell melanoma"],"term_type":""},{"nm":"8771/0","n_c":["C66757"],"i_c":"8771/0","i_c_s":["Epithelioid cell nevus"],"term_type":""},{"nm":"8771/3","n_c":["C4236"],"i_c":"8771/3","i_c_s":["Epithelioid cell melanoma"],"term_type":""},{"nm":"8772/0","n_c":["C27007"],"i_c":"8772/0","i_c_s":["Spindle cell nevus, NOS"],"term_type":""},{"nm":"8772/3","n_c":["C4237"],"i_c":"8772/3","i_c_s":["Spindle cell melanoma, NOS"],"term_type":""},{"nm":"8773/3","n_c":["C4238"],"i_c":"8773/3","i_c_s":["Spindle cell melanoma, type A"],"term_type":""},{"nm":"8774/3","n_c":["C4239"],"i_c":"8774/3","i_c_s":["Spindle cell melanoma, type B"],"term_type":""},{"nm":"8780/0","n_c":["C3803"],"i_c":"8780/0","i_c_s":["Blue nevus, NOS","Jadassohn blue nevus"],"term_type":""},{"nm":"8780/3","n_c":["C4240"],"i_c":"8780/3","i_c_s":["Blue nevus, malignant"],"term_type":""},{"nm":"8790/0","n_c":["C4241"],"i_c":"8790/0","i_c_s":["Cellular blue nevus"],"term_type":""},{"nm":"8800/0","n_c":["C4242"],"i_c":"8800/0","i_c_s":["Soft tissue tumor, benign"],"term_type":""},{"nm":"8800/3","n_c":["C4867","C9118","C9306"],"i_c":"8800/3","i_c_s":["Sarcoma, NOS","Mesenchymal tumor, malignant","Soft tissue sarcoma","Soft tissue tumor, malignant"],"term_type":""},{"nm":"8800/9","n_c":["C4243"],"i_c":"8800/9","i_c_s":["Sarcomatosis, NOS"],"term_type":""},{"nm":"8801/3","n_c":["C27005"],"i_c":"8801/3","i_c_s":["Spindle cell sarcoma"],"term_type":""},{"nm":"8801/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8802/3","n_c":["C66759"],"i_c":"8802/3","i_c_s":["Giant cell sarcoma","Pleomorphic cell sarcoma"],"term_type":""},{"nm":"8803/3","n_c":["C3746"],"i_c":"8803/3","i_c_s":["Small cell sarcoma","Round cell sarcoma"],"term_type":""},{"nm":"8804/3","n_c":["C3714"],"i_c":"8804/3","i_c_s":["Epithelioid sarcoma","Epithelioid cell sarcoma"],"term_type":""},{"nm":"8804/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8805/3","n_c":["C121793"],"i_c":"8805/3","i_c_s":["Undifferentiated sarcoma"],"term_type":""},{"nm":"8806/3","n_c":["C8300"],"i_c":"8806/3","i_c_s":["Desmoplastic small round cell tumor"],"term_type":""},{"nm":"8806/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8810/0","n_c":["C3041"],"i_c":"8810/0","i_c_s":["Fibroma, NOS"],"term_type":""},{"nm":"8810/1","n_c":["C6892"],"i_c":"8810/1","i_c_s":["Cellular fibroma"],"term_type":""},{"nm":"8810/3","n_c":["C3043"],"i_c":"8810/3","i_c_s":["Fibrosarcoma, NOS"],"term_type":""},{"nm":"8811/0","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Fibromyxoma","Plexiform fibromyxoma","Myxofibroma, NOS","Myxoid fibroma"],"term_type":""},{"nm":"8811/1","n_c":["C49025"],"i_c":"8811/1","i_c_s":["Myxoinflammatory fibroblastic sarcoma (MIFS)"],"term_type":""},{"nm":"8811/3","n_c":["C6496"],"i_c":"8811/3","i_c_s":["Fibromyxosarcoma"],"term_type":""},{"nm":"8812/0","n_c":["C66761"],"i_c":"8812/0","i_c_s":["Periosteal fibroma"],"term_type":""},{"nm":"8812/3","n_c":["C66763"],"i_c":"8812/3","i_c_s":["Periosteal fibrosarcoma","Periosteal sarcoma, NOS"],"term_type":""},{"nm":"8813/0","n_c":["C66764"],"i_c":"8813/0","i_c_s":["Fascial fibroma"],"term_type":""},{"nm":"8813/3","n_c":["C66765"],"i_c":"8813/3","i_c_s":["Fascial fibrosarcoma"],"term_type":""},{"nm":"8814/3","n_c":["C4244"],"i_c":"8814/3","i_c_s":["Infantile fibrosarcoma","Congenital fibrosarcoma"],"term_type":""},{"nm":"8815/0","n_c":["C7634"],"i_c":"8815/0","i_c_s":["Solitary fibrous tumor","Localized fibrous tumor"],"term_type":""},{"nm":"8815/1","n_c":["C129528"],"i_c":"8815/1","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)"],"term_type":""},{"nm":"8815/3","n_c":["C6894"],"i_c":"8815/3","i_c_s":["Solitary fibrous tumor, malignant"],"term_type":""},{"nm":"8820/0","n_c":["C4245"],"i_c":"8820/0","i_c_s":["Elastofibroma"],"term_type":""},{"nm":"8821/1","n_c":["C6489","C9182"],"i_c":"8821/1","i_c_s":["Aggressive fibromatosis","Desmoid, NOS","Extra-abdominal desmoid","Invasive fibroma"],"term_type":""},{"nm":"8822/1","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Abdominal fibromatosis","Abdominal desmoid","Mesenteric fibromatosis","Retroperitoneal fibromatosis"],"term_type":""},{"nm":"8823/0","n_c":["C3740"],"i_c":"8823/0","i_c_s":["Desmoplastic fibroma"],"term_type":""},{"nm":"8824/0","n_c":["C7052"],"i_c":"8824/0","i_c_s":["Myofibroma"],"term_type":""},{"nm":"8824/1","n_c":["C3742"],"i_c":"8824/1","i_c_s":["Myofibromatosis","Congenital generalized fibromatosis","Infantile myofibromatosis"],"term_type":""},{"nm":"8825/0","n_c":["C49012"],"i_c":"8825/0","i_c_s":["Myofibroblastoma"],"term_type":""},{"nm":"8825/1","n_c":["C6481"],"i_c":"8825/1","i_c_s":["Myofibroblastic tumor, NOS","Inflammatory myofibroblastic tumor"],"term_type":""},{"nm":"8825/3","n_c":["C49024"],"i_c":"8825/3","i_c_s":["Myofibroblastic sarcoma"],"term_type":""},{"nm":"8826/0","n_c":["C49016"],"i_c":"8826/0","i_c_s":["Angiomyofibroblastoma"],"term_type":""},{"nm":"8827/1","n_c":["C142823","C39740"],"i_c":"8827/1","i_c_s":["Myofibroblastic tumor, peribronchial","Congenital peribronchial myofibroblastic tumor"],"term_type":""},{"nm":"8830/0","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Benign fibrous histiocytoma","Fibrous histiocytoma, NOS","Fibroxanthoma, NOS","Xanthofibroma"],"term_type":""},{"nm":"8830/1","n_c":["C4246"],"i_c":"8830/1","i_c_s":["Atypical fibrous histiocytoma","Atypical fibroxanthoma"],"term_type":""},{"nm":"8830/3","n_c":["C4247"],"i_c":"8830/3","i_c_s":["Malignant fibrous histiocytoma","Fibroxanthoma, malignant"],"term_type":""},{"nm":"8831/0","n_c":["C35765","C3356","C6492"],"i_c":"8831/0","i_c_s":["Histiocytoma, NOS","Deep histiocytoma","Juvenile histiocytoma","Reticulohistiocytoma"],"term_type":""},{"nm":"8832/0","n_c":["C7159","C6801"],"i_c":"8832/0","i_c_s":["Dermatofibroma, NOS","Cutaneous histiocytoma, NOS","Dermatofibroma lenticulare","Sclerosing hemangioma","Subepidermal nodular fibrosis"],"term_type":""},{"nm":"8832/3","n_c":["C4683"],"i_c":"8832/3","i_c_s":["Dermatofibrosarcoma, NOS","Dermatofibrosarcoma protuberans, NOS"],"term_type":""},{"nm":"8833/3","n_c":["C9430"],"i_c":"8833/3","i_c_s":["Pigmented dermatofibrosarcoma protuberans","Bednar tumor"],"term_type":""},{"nm":"8834/1","n_c":["C4700"],"i_c":"8834/1","i_c_s":["Giant cell fibroblastoma"],"term_type":""},{"nm":"8835/1","n_c":["C6493"],"i_c":"8835/1","i_c_s":["Plexiform fibrohistiocytic tumor"],"term_type":""},{"nm":"8836/1","n_c":["C6494"],"i_c":"8836/1","i_c_s":["Angiomatoid fibrous histiocytoma"],"term_type":""},{"nm":"8840/0","n_c":["C6577"],"i_c":"8840/0","i_c_s":["Myxoma, NOS"],"term_type":""},{"nm":"8840/3","n_c":["C3255"],"i_c":"8840/3","i_c_s":["Myxosarcoma"],"term_type":""},{"nm":"8841/1","n_c":["C6936"],"i_c":"8841/1","i_c_s":["Angiomyxoma","Aggressive angiomyxoma"],"term_type":""},{"nm":"8842/0","n_c":["C6582"],"i_c":"8842/0","i_c_s":["Ossifying fibromyxoid tumor"],"term_type":""},{"nm":"8842/3","n_c":["C142827"],"i_c":"8842/3","i_c_s":["Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation"],"term_type":""},{"nm":"8850/0","n_c":["C3192"],"i_c":"8850/0","i_c_s":["Lipoma, NOS"],"term_type":""},{"nm":"8850/1","n_c":["C6505"],"i_c":"8850/1","i_c_s":["Atypical lipoma","Superficial well differentated liposarcoma","Well differentiated liposarcoma of superficial soft tissue"],"term_type":""},{"nm":"8850/3","n_c":["C3194"],"i_c":"8850/3","i_c_s":["Liposarcoma, NOS","Fibroliposarcoma"],"term_type":""},{"nm":"8851/0","n_c":["C4249"],"i_c":"8851/0","i_c_s":["Fibrolipoma"],"term_type":""},{"nm":"8851/3","n_c":["C6505","C6508","C6507"],"i_c":"8851/3","i_c_s":["Liposarcoma, well differentiated","Inflammatory liposarcoma","Sclerosing liposarcoma","Lipoma-like liposarcoma","Liposarcoma, differentiated"],"term_type":""},{"nm":"8852/0","n_c":["C4251"],"i_c":"8852/0","i_c_s":["Fibromyxolipoma","Myxolipoma"],"term_type":""},{"nm":"8852/3","n_c":["C27781"],"i_c":"8852/3","i_c_s":["Myxoid liposarcoma","Myxoliposarcoma"],"term_type":""},{"nm":"8853/3","n_c":["C4252"],"i_c":"8853/3","i_c_s":["Round cell liposarcoma"],"term_type":""},{"nm":"8854/0","n_c":["C3703"],"i_c":"8854/0","i_c_s":["Pleomorphic lipoma"],"term_type":""},{"nm":"8854/3","n_c":["C3705"],"i_c":"8854/3","i_c_s":["Pleomorphic liposarcoma"],"term_type":""},{"nm":"8855/3","n_c":["C4253"],"i_c":"8855/3","i_c_s":["Mixed liposarcoma"],"term_type":""},{"nm":"8856/0","n_c":["C7451","C7450","C7449"],"i_c":"8856/0","i_c_s":["Intramuscular lipoma","Infiltrating angiolipoma","Infiltrating lipoma"],"term_type":""},{"nm":"8857/0","n_c":["C4254"],"i_c":"8857/0","i_c_s":["Spindle cell lipoma"],"term_type":""},{"nm":"8857/3","n_c":["C6509"],"i_c":"8857/3","i_c_s":["Fibroblastic liposarcoma"],"term_type":""},{"nm":"8858/3","n_c":["C3704"],"i_c":"8858/3","i_c_s":["Dedifferentiated liposarcoma"],"term_type":""},{"nm":"8860/0","n_c":["C3734"],"i_c":"8860/0","i_c_s":["Angiomyolipoma"],"term_type":""},{"nm":"8861/0","n_c":["C3733"],"i_c":"8861/0","i_c_s":["Angiolipoma, NOS"],"term_type":""},{"nm":"8862/0","n_c":["C6503"],"i_c":"8862/0","i_c_s":["Chondroid lipoma"],"term_type":""},{"nm":"8870/0","n_c":["C3736"],"i_c":"8870/0","i_c_s":["Myelolipoma"],"term_type":""},{"nm":"8880/0","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Hibernoma","Brown fat tumor","Fetal fat cell lipoma"],"term_type":""},{"nm":"8881/0","n_c":["C27483","C4255"],"i_c":"8881/0","i_c_s":["Lipoblastomatosis","Fetal lipoma, NOS","Fetal lipomatosis","Lipoblastoma"],"term_type":""},{"nm":"8890/0","n_c":["C3434","C3157"],"i_c":"8890/0","i_c_s":["Leiomyoma, NOS","Lipoleiomyoma","Plexiform leiomyoma","Fibroid uterus","Fibromyoma","Leiomyofibroma"],"term_type":""},{"nm":"8890/1","n_c":["C3748"],"i_c":"8890/1","i_c_s":["Leiomyomatosis, NOS","Intravascular leiomyomatosis"],"term_type":""},{"nm":"8890/3","n_c":["C3158"],"i_c":"8890/3","i_c_s":["Leiomyosarcoma, NOS"],"term_type":""},{"nm":"8891/0","n_c":["C40164"],"i_c":"8891/0","i_c_s":["Epithelioid leiomyoma","Leiomyoblastoma"],"term_type":""},{"nm":"8891/3","n_c":["C3700"],"i_c":"8891/3","i_c_s":["Epithelioid leiomyosarcoma"],"term_type":""},{"nm":"8892/0","n_c":["C4256"],"i_c":"8892/0","i_c_s":["Cellular leiomyoma"],"term_type":""},{"nm":"8893/0","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Bizarre leiomyoma","Atypical leiomyoma","Pleomorphic leiomyoma","Symplastic leiomyoma"],"term_type":""},{"nm":"8894/0","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Angiomyoma","Angioleiomyoma","Vascular leiomyoma"],"term_type":""},{"nm":"8894/3","n_c":["C66771"],"i_c":"8894/3","i_c_s":["Angiomyosarcoma"],"term_type":""},{"nm":"8895/0","n_c":["C4882"],"i_c":"8895/0","i_c_s":["Myoma"],"term_type":""},{"nm":"8895/3","n_c":["C4883"],"i_c":"8895/3","i_c_s":["Myosarcoma"],"term_type":""},{"nm":"8896/3","n_c":["C3701"],"i_c":"8896/3","i_c_s":["Myxoid leiomyosarcoma"],"term_type":""},{"nm":"8897/1","n_c":["C40177"],"i_c":"8897/1","i_c_s":["Smooth muscle tumor of uncertain malignant potential","Smooth muscle tumor, NOS"],"term_type":""},{"nm":"8898/1","n_c":["C40173"],"i_c":"8898/1","i_c_s":["Metastasizing leiomyoma"],"term_type":""},{"nm":"8900/0","n_c":["C3358"],"i_c":"8900/0","i_c_s":["Rhabdomyoma, NOS"],"term_type":""},{"nm":"8900/3","n_c":["C3359"],"i_c":"8900/3","i_c_s":["Rhabdomyosarcoma, NOS","Rhabdosarcoma"],"term_type":""},{"nm":"8901/3","n_c":["C4258","C27369"],"i_c":"8901/3","i_c_s":["Pleomorphic rhabdomyosarcoma, adult type","Pleomorphic rhabdomyosarcoma, NOS"],"term_type":""},{"nm":"8902/3","n_c":["C4259"],"i_c":"8902/3","i_c_s":["Mixed type rhabdomyosarcoma","Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma"],"term_type":""},{"nm":"8903/0","n_c":["C4260"],"i_c":"8903/0","i_c_s":["Fetal rhabdomyoma"],"term_type":""},{"nm":"8904/0","n_c":["C4261","C45747"],"i_c":"8904/0","i_c_s":["Adult rhabdomyoma","Glycogenic rhabdomyoma"],"term_type":""},{"nm":"8905/0","n_c":["C6517"],"i_c":"8905/0","i_c_s":["Genital rhabdomyoma"],"term_type":""},{"nm":"8910/3","n_c":["C9150","C8971"],"i_c":"8910/3","i_c_s":["Embryonal rhabdomyosarcoma, NOS","Embryonal rhabdomyosarcoma, pleomorphic","Sarcoma botryoides","Botryoid sarcoma"],"term_type":""},{"nm":"8912/3","n_c":["C6519"],"i_c":"8912/3","i_c_s":["Spindle cell rhabdomyosarcoma"],"term_type":""},{"nm":"8920/3","n_c":["C3749"],"i_c":"8920/3","i_c_s":["Alveolar rhabdomyosarcoma"],"term_type":""},{"nm":"8920/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8921/3","n_c":["C4716"],"i_c":"8921/3","i_c_s":["Rhabdomyosarcoma with ganglionic differentiation","Ectomesenchymoma"],"term_type":""},{"nm":"8930/0","n_c":["C4262"],"i_c":"8930/0","i_c_s":["Endometrial stromal nodule"],"term_type":""},{"nm":"8930/3","n_c":["C8973","C126998"],"i_c":"8930/3","i_c_s":["Endometrial stromal sarcoma, NOS","Endometrial stromal sarcoma, high grade","Endometrial sarcoma, NOS"],"term_type":""},{"nm":"8931/3","n_c":["C40223","C4263"],"i_c":"8931/3","i_c_s":["Endometrial stromal sarcoma, low grade","Endolymphatic stromal myosis","Endometrial stromatosis","Stromal endometriosis","Stromal myosis, NOS"],"term_type":""},{"nm":"8932/0","n_c":["C3726","C6895"],"i_c":"8932/0","i_c_s":["Adenomyoma","Atypical polypoid adenomyoma"],"term_type":""},{"nm":"8933/3","n_c":["C9474"],"i_c":"8933/3","i_c_s":["Adenosarcoma"],"term_type":""},{"nm":"8934/3","n_c":["C40182"],"i_c":"8934/3","i_c_s":["Carcinofibroma"],"term_type":""},{"nm":"8935/0","n_c":["C66772"],"i_c":"8935/0","i_c_s":["Stromal tumor, benign"],"term_type":""},{"nm":"8935/1","n_c":["C6781"],"i_c":"8935/1","i_c_s":["Stromal tumor, NOS"],"term_type":""},{"nm":"8935/3","n_c":["C6926"],"i_c":"8935/3","i_c_s":["Stromal sarcoma, NOS"],"term_type":""},{"nm":"8936/0","n_c":["C53998"],"i_c":"8936/0","i_c_s":["Gastrointestinal stromal tumor, benign","GIST, benign"],"term_type":""},{"nm":"8936/1","n_c":["C54000","C3868","C27940"],"i_c":"8936/1","i_c_s":["Gastrointestinal stromal tumor, NOS","Gastrointestinal autonomic nerve tumor","Gastrointestinal pacemaker cell tumor","GANT","GIST, NOS","Gastrointestinal stromal tumor, uncertain malignant potential"],"term_type":""},{"nm":"8936/3","n_c":["C53999"],"i_c":"8936/3","i_c_s":["Gastrointestinal stromal sarcoma","GIST, malignant","Gastrointestinal stromal tumor, malignant"],"term_type":""},{"nm":"8940/0","n_c":["C6930","C8602","C4474"],"i_c":"8940/0","i_c_s":["Pleomorphic adenoma","Chondroid syringoma","Mixed tumor, NOS","Mixed tumor, salivary gland type, NOS"],"term_type":""},{"nm":"8940/3","n_c":["C3729"],"i_c":"8940/3","i_c_s":["Mixed tumor, malignant, NOS","Malignant chondroid syringoma","Mixed tumor, salivary gland type, malignant"],"term_type":""},{"nm":"8941/3","n_c":["C4397"],"i_c":"8941/3","i_c_s":["Carcinoma in pleomorphic adenoma"],"term_type":""},{"nm":"8950/3","n_c":["C3730"],"i_c":"8950/3","i_c_s":["Mullerian mixed tumor"],"term_type":""},{"nm":"8950/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"8951/3","n_c":["C3730"],"i_c":"8951/3","i_c_s":["Mesodermal mixed tumor"],"term_type":""},{"nm":"8959/0","n_c":["C7504"],"i_c":"8959/0","i_c_s":["Benign cystic nephroma"],"term_type":""},{"nm":"8959/1","n_c":["C6897"],"i_c":"8959/1","i_c_s":["Cystic partially differentiated nephroblastoma"],"term_type":""},{"nm":"8959/3","n_c":["C6897"],"i_c":"8959/3","i_c_s":["Malignant cystic nephroma","Malignant multilocular cystic nephroma"],"term_type":""},{"nm":"8960/1","n_c":["C6569"],"i_c":"8960/1","i_c_s":["Mesoblastic nephroma"],"term_type":""},{"nm":"8960/3","n_c":["C40407","C3267"],"i_c":"8960/3","i_c_s":["Nephroblastoma, NOS","Nephroma, NOS","Wilms tumor"],"term_type":""},{"nm":"8963/3","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Malignant rhabdoid tumor","Rhabdoid sarcoma","Rhabdoid tumor, NOS"],"term_type":""},{"nm":"8964/3","n_c":["C4264"],"i_c":"8964/3","i_c_s":["Clear cell sarcoma of kidney"],"term_type":""},{"nm":"8965/0","n_c":["C39812"],"i_c":"8965/0","i_c_s":["Nephrogenic adenofibroma"],"term_type":""},{"nm":"8966/0","n_c":["C5100"],"i_c":"8966/0","i_c_s":["Renomedullary interstitial cell tumor","Renomedullary fibroma"],"term_type":""},{"nm":"8967/0","n_c":["C66774"],"i_c":"8967/0","i_c_s":["Ossifying renal tumor"],"term_type":""},{"nm":"8970/3","n_c":["C7097","C3728"],"i_c":"8970/3","i_c_s":["Hepatoblastoma","Hepatoblastoma, epithelioid","Hepatoblastoma, mixed epithelial-mesenchymal","Embryonal hepatoma"],"term_type":""},{"nm":"8971/3","n_c":["C4265"],"i_c":"8971/3","i_c_s":["Pancreatoblastoma"],"term_type":""},{"nm":"8972/3","n_c":["C3732"],"i_c":"8972/3","i_c_s":["Pulmonary blastoma","Pneumoblastoma"],"term_type":""},{"nm":"8973/3","n_c":["C5669"],"i_c":"8973/3","i_c_s":["Pleuropulmonary blastoma"],"term_type":""},{"nm":"8974/1","n_c":["C35837"],"i_c":"8974/1","i_c_s":["Sialoblastoma"],"term_type":""},{"nm":"8975/1","n_c":["C96830"],"i_c":"8975/1","i_c_s":["Calcifying nested epithelial stromal tumor"],"term_type":""},{"nm":"8980/3","n_c":["C34448"],"i_c":"8980/3","i_c_s":["Carcinosarcoma, NOS"],"term_type":""},{"nm":"8981/3","n_c":["C8975"],"i_c":"8981/3","i_c_s":["Carcinosarcoma, embryonal"],"term_type":""},{"nm":"8982/0","n_c":["C40392","C7442"],"i_c":"8982/0","i_c_s":["Myoepithelioma","Myoepithelial adenoma","Myoepithelial tumor"],"term_type":""},{"nm":"8982/3","n_c":["C7596"],"i_c":"8982/3","i_c_s":["Malignant myoepithelioma","Myoepithelial carcinoma"],"term_type":""},{"nm":"8983/0","n_c":["C6899"],"i_c":"8983/0","i_c_s":["Adenomyoepithelioma"],"term_type":""},{"nm":"8983/3","n_c":["C5143"],"i_c":"8983/3","i_c_s":["Adenomyoepithelioma with carcinoma"],"term_type":""},{"nm":"8990/0","n_c":["C4267"],"i_c":"8990/0","i_c_s":["Mesenchymoma, benign"],"term_type":""},{"nm":"8990/1","n_c":["C3233"],"i_c":"8990/1","i_c_s":["Mesenchymoma, NOS","Mixed mesenchymal tumor"],"term_type":""},{"nm":"8990/3","n_c":["C4268"],"i_c":"8990/3","i_c_s":["Mesenchymoma, malignant","Mixed mesenchymal sarcoma"],"term_type":""},{"nm":"8991/3","n_c":["C27096"],"i_c":"8991/3","i_c_s":["Embryonal sarcoma"],"term_type":""},{"nm":"9000/0","n_c":["C39954"],"i_c":"9000/0","i_c_s":["Brenner tumor, NOS"],"term_type":""},{"nm":"9000/1","n_c":["C9459"],"i_c":"9000/1","i_c_s":["Brenner tumor, borderline malignancy","Brenner tumor, proliferating"],"term_type":""},{"nm":"9000/3","n_c":["C4270"],"i_c":"9000/3","i_c_s":["Brenner tumor, malignant"],"term_type":""},{"nm":"9010/0","n_c":["C3744"],"i_c":"9010/0","i_c_s":["Fibroadenoma, NOS"],"term_type":""},{"nm":"9011/0","n_c":["C4271"],"i_c":"9011/0","i_c_s":["Intracanalicular fibroadenoma"],"term_type":""},{"nm":"9012/0","n_c":["C4272"],"i_c":"9012/0","i_c_s":["Pericanalicular fibroadenoma"],"term_type":""},{"nm":"9013/0","n_c":["C8984","C8985","C8986"],"i_c":"9013/0","i_c_s":["Adenofibroma, NOS","Cystadenofibroma, NOS","Papillary adenofibroma"],"term_type":""},{"nm":"9014/0","n_c":["C67090"],"i_c":"9014/0","i_c_s":["Serous adenofibroma, NOS","Serous cystadenofibroma, NOS"],"term_type":""},{"nm":"9014/1","n_c":["C40028"],"i_c":"9014/1","i_c_s":["Serous adenofibroma of borderline malignancy","Serous cystadenofibroma of borderline malignancy"],"term_type":""},{"nm":"9014/3","n_c":["C67092"],"i_c":"9014/3","i_c_s":["Serous adenocarcinofibroma","Serous cystadenocarcinofibroma","Malignant serous adenofibroma","Malignant serous cystadenofibroma"],"term_type":""},{"nm":"9015/0","n_c":["C8979","C8978"],"i_c":"9015/0","i_c_s":["Mucinous adenofibroma, NOS","Mucinous cystadenofibroma, NOS"],"term_type":""},{"nm":"9015/1","n_c":["C66775"],"i_c":"9015/1","i_c_s":["Mucinous adenofibroma of borderline malignancy","Mucinous cystadenofibroma of borderline malignancy"],"term_type":""},{"nm":"9015/3","n_c":["C40034"],"i_c":"9015/3","i_c_s":["Mucinous adenocarcinofibroma","Mucinous cystadenocarcinofibroma","Malignant mucinous adenofibroma","Malignant mucinous cystadenofibroma"],"term_type":""},{"nm":"9016/0","n_c":["C4273"],"i_c":"9016/0","i_c_s":["Giant fibroadenoma"],"term_type":""},{"nm":"9020/0","n_c":["C4274"],"i_c":"9020/0","i_c_s":["Phyllodes tumor, benign","Cystosarcoma phyllodes, benign"],"term_type":""},{"nm":"9020/1","n_c":["C2977","C7503"],"i_c":"9020/1","i_c_s":["Phyllodes tumor, borderline","Cystosarcoma phyllodes, NOS","Phyllodes tumor, NOS"],"term_type":""},{"nm":"9020/3","n_c":["C4275"],"i_c":"9020/3","i_c_s":["Phyllodes tumor, malignant","Cystosarcoma phyllodes, malignant"],"term_type":""},{"nm":"9030/0","n_c":["C4276"],"i_c":"9030/0","i_c_s":["Juvenile fibroadenoma"],"term_type":""},{"nm":"9040/0","n_c":["C3829"],"i_c":"9040/0","i_c_s":["Synovioma, benign"],"term_type":""},{"nm":"9040/3","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovial sarcoma, NOS","Synovioma, NOS","Synovioma, malignant"],"term_type":""},{"nm":"9041/3","n_c":["C4277"],"i_c":"9041/3","i_c_s":["Synovial sarcoma, spindle cell","Synovial sarcoma, monophasic fibrous"],"term_type":""},{"nm":"9042/3","n_c":["C4278"],"i_c":"9042/3","i_c_s":["Synovial sarcoma, epithelioid cell"],"term_type":""},{"nm":"9043/3","n_c":["C4279"],"i_c":"9043/3","i_c_s":["Synovial sarcoma, biphasic"],"term_type":""},{"nm":"9044/3","n_c":["C3745"],"i_c":"9044/3","i_c_s":["Clear cell sarcoma, NOS","Clear cell sarcoma, of tendons and aponeuroses","Melanoma, malignant, of soft parts"],"term_type":""},{"nm":"9045/3","n_c":["C164205"],"i_c":"9045/3","i_c_s":["Biphenotypic sinonasal sarcoma"],"term_type":""},{"nm":"9050/0","n_c":["C3762"],"i_c":"9050/0","i_c_s":["Mesothelioma, benign"],"term_type":""},{"nm":"9050/3","n_c":["C4456","C3786"],"i_c":"9050/3","i_c_s":["Mesothelioma, malignant","Mesothelioma, NOS"],"term_type":""},{"nm":"9051/0","n_c":["C4457"],"i_c":"9051/0","i_c_s":["Fibrous mesothelioma, benign"],"term_type":""},{"nm":"9051/3","n_c":["C6747","C45655"],"i_c":"9051/3","i_c_s":["Fibrous mesothelioma, malignant","Desmoplastic mesothelioma","Fibrous mesothelioma, NOS","Sarcomatoid mesothelioma","Spindled mesothelioma"],"term_type":""},{"nm":"9052/0","n_c":["C3762"],"i_c":"9052/0","i_c_s":["Epithelioid mesothelioma, benign","Well differentiated papillary mesothelioma, benign","Mesothelial papilloma"],"term_type":""},{"nm":"9052/3","n_c":["C7985"],"i_c":"9052/3","i_c_s":["Epithelioid mesothelioma, malignant","Epithelioid mesothelioma, NOS"],"term_type":""},{"nm":"9053/3","n_c":["C4282"],"i_c":"9053/3","i_c_s":["Mesothelioma, biphasic, malignant","Mesothelioma, biphasic, NOS"],"term_type":""},{"nm":"9054/0","n_c":["C3762"],"i_c":"9054/0","i_c_s":["Adenomatoid tumor, NOS"],"term_type":""},{"nm":"9055/0","n_c":["C6536","C3765"],"i_c":"9055/0","i_c_s":["Multicystic mesothelioma, benign","Cystic mesothelioma, benign"],"term_type":""},{"nm":"9055/1","n_c":["C3765"],"i_c":"9055/1","i_c_s":["Cystic mesothelioma, NOS"],"term_type":""},{"nm":"9060/3","n_c":["C8106"],"i_c":"9060/3","i_c_s":["Dysgerminoma"],"term_type":""},{"nm":"9061/3","n_c":["C9309"],"i_c":"9061/3","i_c_s":["Seminoma, NOS"],"term_type":""},{"nm":"9062/3","n_c":["C39920"],"i_c":"9062/3","i_c_s":["Seminoma, anaplastic","Seminoma with high mitotic index"],"term_type":""},{"nm":"9063/3","n_c":["C39921"],"i_c":"9063/3","i_c_s":["Spermatocytic seminoma","Spermatocytoma"],"term_type":""},{"nm":"9064/2","n_c":["C40345"],"i_c":"9064/2","i_c_s":["Intratubular malignant germ cells","Intratubular germ cell neoplasia"],"term_type":""},{"nm":"9064/3","n_c":["C7009","C3708"],"i_c":"9064/3","i_c_s":["Germinoma","Germ cell tumor, NOS"],"term_type":""},{"nm":"9065/3","n_c":["C121619"],"i_c":"9065/3","i_c_s":["Germ cell tumor, nonseminomatous"],"term_type":""},{"nm":"9070/3","n_c":["C3752"],"i_c":"9070/3","i_c_s":["Embryonal carcinoma, NOS","Embryonal adenocarcinoma"],"term_type":""},{"nm":"9071/3","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Yolk sac tumor","Hepatoid yolk sac tumor","Embryonal carcinoma, infantile","Endodermal sinus tumor","Orchioblastoma","Polyvesicular vitelline tumor"],"term_type":""},{"nm":"9072/3","n_c":["C66776"],"i_c":"9072/3","i_c_s":["Polyembryoma","Embryonal carcinoma, polyembryonal type"],"term_type":""},{"nm":"9073/1","n_c":["C3754"],"i_c":"9073/1","i_c_s":["Gonadoblastoma","Gonocytoma"],"term_type":""},{"nm":"9080/0","n_c":["C9012","C9013","C9014","C67107","C9015"],"i_c":"9080/0","i_c_s":["Teratoma, benign","Adult cystic teratoma","Adult teratoma, NOS","Cystic teratoma, NOS","Mature teratoma","Teratoma, differentiated"],"term_type":""},{"nm":"9080/1","n_c":["C3403"],"i_c":"9080/1","i_c_s":["Teratoma, NOS","Solid teratoma"],"term_type":""},{"nm":"9080/3","n_c":["C4287"],"i_c":"9080/3","i_c_s":["Teratoma, malignant, NOS","Immature teratoma, malignant","Embryonal teratoma","Immature teratoma, NOS","Teratoblastoma, malignant"],"term_type":""},{"nm":"9081/3","n_c":["C3756"],"i_c":"9081/3","i_c_s":["Teratocarcinoma","Mixed embryonal carcinoma and teratoma"],"term_type":""},{"nm":"9082/3","n_c":["C4287"],"i_c":"9082/3","i_c_s":["Malignant teratoma, undifferentiated","Malignant teratoma, anaplastic"],"term_type":""},{"nm":"9083/3","n_c":["C4288"],"i_c":"9083/3","i_c_s":["Malignant teratoma, intermediate"],"term_type":""},{"nm":"9084/0","n_c":["C9011"],"i_c":"9084/0","i_c_s":["Dermoid cyst, NOS","Dermoid, NOS"],"term_type":""},{"nm":"9084/3","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Teratoma with malignant transformation","Dermoid cyst with malignant transformation","Dermoid cyst with secondary tumor"],"term_type":""},{"nm":"9085/3","n_c":["C9010","C4290"],"i_c":"9085/3","i_c_s":["Mixed germ cell tumor","Mixed teratoma and seminoma"],"term_type":""},{"nm":"9086/3","n_c":["C45733"],"i_c":"9086/3","i_c_s":["Germ cell tumors with associated hematological malignancy"],"term_type":""},{"nm":"9090/0","n_c":["C7468"],"i_c":"9090/0","i_c_s":["Struma ovarii, NOS"],"term_type":""},{"nm":"9090/3","n_c":["C4291"],"i_c":"9090/3","i_c_s":["Struma ovarii, malignant"],"term_type":""},{"nm":"9091/1","n_c":["C4292"],"i_c":"9091/1","i_c_s":["Strumal carcinoid","Struma ovarii and carcinoid"],"term_type":""},{"nm":"9100/0","n_c":["C3110","C4871"],"i_c":"9100/0","i_c_s":["Hydatidiform mole, NOS","Complete hydatidiform mole","Hydatid mole"],"term_type":""},{"nm":"9100/1","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Invasive hydatidiform mole","Chorioadenoma destruens","Chorioadenoma","Invasive mole, NOS","Malignant hydatidiform mole"],"term_type":""},{"nm":"9100/3","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Choriocarcinoma, NOS","Chorioepithelioma","Chorionepithelioma"],"term_type":""},{"nm":"9101/3","n_c":["C66777"],"i_c":"9101/3","i_c_s":["Choriocarcinoma combined with other germ cell elements","Choriocarcinoma combined with embryonal carcinoma","Choriocarcinoma combined with teratoma"],"term_type":""},{"nm":"9102/3","n_c":["C66778"],"i_c":"9102/3","i_c_s":["Malignant teratoma, trophoblastic"],"term_type":""},{"nm":"9103/0","n_c":["C4293"],"i_c":"9103/0","i_c_s":["Partial hydatidiform mole"],"term_type":""},{"nm":"9104/1","n_c":["C3757"],"i_c":"9104/1","i_c_s":["Placental site trophoblastic tumor"],"term_type":""},{"nm":"9105/3","n_c":["C40141"],"i_c":"9105/3","i_c_s":["Trophoblastic tumor, epithelioid"],"term_type":""},{"nm":"9110/0","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Mesonephroma, benign","Mesonephric adenoma","Wolffian duct adenoma"],"term_type":""},{"nm":"9110/1","n_c":["C40141"],"i_c":"9110/1","i_c_s":["Mesonephric tumor, NOS","Wolffian duct tumor"],"term_type":""},{"nm":"9110/3","n_c":["C4072","C40141"],"i_c":"9110/3","i_c_s":["Mesonephroma, malignant","Mesonephric adenocarcinoma","Mesonephroma, NOS","Wolffian duct carcinoma"],"term_type":""},{"nm":"9120/0","n_c":["C3085"],"i_c":"9120/0","i_c_s":["Hemangioma, NOS","Angioma, NOS","Chorioangioma"],"term_type":""},{"nm":"9120/3","n_c":["C3088"],"i_c":"9120/3","i_c_s":["Hemangiosarcoma","Angiosarcoma"],"term_type":""},{"nm":"9121/0","n_c":["C3086"],"i_c":"9121/0","i_c_s":["Cavernous hemangioma"],"term_type":""},{"nm":"9122/0","n_c":["C4296"],"i_c":"9122/0","i_c_s":["Venous hemangioma"],"term_type":""},{"nm":"9123/0","n_c":["C2882","C35479"],"i_c":"9123/0","i_c_s":["Racemose hemangioma","Arteriovenous hemangioma"],"term_type":""},{"nm":"9124/3","n_c":["C4438"],"i_c":"9124/3","i_c_s":["Kupffer cell sarcoma"],"term_type":""},{"nm":"9125/0","n_c":["C4298"],"i_c":"9125/0","i_c_s":["Epithelioid hemangioma","Histiocytoid hemangioma"],"term_type":""},{"nm":"9130/0","n_c":["C66779"],"i_c":"9130/0","i_c_s":["Hemangioendothelioma, benign"],"term_type":""},{"nm":"9130/1","n_c":["C3084","C27510"],"i_c":"9130/1","i_c_s":["Hemangioendothelioma, NOS","Kaposiform hemangioendothelioma","Angioendothelioma"],"term_type":""},{"nm":"9130/3","n_c":["C3088"],"i_c":"9130/3","i_c_s":["Hemangioendothelioma, malignant","Hemangioendothelial sarcoma"],"term_type":""},{"nm":"9131/0","n_c":["C6645","C7457"],"i_c":"9131/0","i_c_s":["Capillary hemangioma","Hemangioma simplex","Infantile hemangioma","Juvenile hemangioma","Plexiform hemangioma"],"term_type":""},{"nm":"9132/0","n_c":["C3699"],"i_c":"9132/0","i_c_s":["Intramuscular hemangioma"],"term_type":""},{"nm":"9133/1","n_c":["C3800"],"i_c":"9133/1","i_c_s":["Epithelioid hemangioendothelioma, NOS"],"term_type":""},{"nm":"9133/3","n_c":["C3800"],"i_c":"9133/3","i_c_s":["Epithelioid hemangioendothelioma, malignant","Intravascular bronchial alveolar tumor"],"term_type":""},{"nm":"9135/1","n_c":["C7526"],"i_c":"9135/1","i_c_s":["Endovascular papillary angioendothelioma","Dabska tumor"],"term_type":""},{"nm":"9136/1","n_c":["C4754"],"i_c":"9136/1","i_c_s":["Spindle cell hemangioendothelioma","Spindle cell angioendothelioma"],"term_type":""},{"nm":"9137/3","n_c":["C53677"],"i_c":"9137/3","i_c_s":["Intimal sarcoma"],"term_type":""},{"nm":"9140/3","n_c":["C9087"],"i_c":"9140/3","i_c_s":["Kaposi sarcoma","Multiple hemorrhagic sarcoma"],"term_type":""},{"nm":"9141/0","n_c":["C4488"],"i_c":"9141/0","i_c_s":["Angiokeratoma"],"term_type":""},{"nm":"9142/0","n_c":["C4299"],"i_c":"9142/0","i_c_s":["Verrucous keratotic hemangioma"],"term_type":""},{"nm":"9150/0","n_c":["C4300"],"i_c":"9150/0","i_c_s":["Hemangiopericytoma, benign"],"term_type":""},{"nm":"9150/1","n_c":["C3087"],"i_c":"9150/1","i_c_s":["Hemangiopericytoma, NOS","Hemangiopericytic meningioma"],"term_type":""},{"nm":"9150/3","n_c":["C4301"],"i_c":"9150/3","i_c_s":["Hemangiopericytoma, malignant"],"term_type":""},{"nm":"9160/0","n_c":["C27257","C27256","C3799"],"i_c":"9160/0","i_c_s":["Angiofibroma, NOS","Cellular angiofibroma","Giant cell angiofibroma","Fibrous papule of nose","Involuting nevus","Juvenile angiofibroma"],"term_type":""},{"nm":"9161/0","n_c":["C4487"],"i_c":"9161/0","i_c_s":["Acquired tufted hemangioma"],"term_type":""},{"nm":"9161/1","n_c":["C3801"],"i_c":"9161/1","i_c_s":["Hemangioblastoma","Angioblastoma"],"term_type":""},{"nm":"9170/0","n_c":["C8965","C3203"],"i_c":"9170/0","i_c_s":["Lymphangioma, NOS","Lymphangioendothelioma, NOS"],"term_type":""},{"nm":"9170/3","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangiosarcoma","Lymphangioendothelial sarcoma","Lymphangioendothelioma, malignant"],"term_type":""},{"nm":"9171/0","n_c":["C8965"],"i_c":"9171/0","i_c_s":["Capillary lymphangioma"],"term_type":""},{"nm":"9172/0","n_c":["C53316"],"i_c":"9172/0","i_c_s":["Cavernous lymphangioma"],"term_type":""},{"nm":"9173/0","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Cystic lymphangioma","Cystic hygroma","Hygroma, NOS"],"term_type":""},{"nm":"9174/0","n_c":["C3204"],"i_c":"9174/0","i_c_s":["Lymphangiomyoma"],"term_type":""},{"nm":"9174/1","n_c":["C3725"],"i_c":"9174/1","i_c_s":["Lymphangiomyomatosis","Lymphangioleiomyomatosis"],"term_type":""},{"nm":"9175/0","n_c":["C66792"],"i_c":"9175/0","i_c_s":["Hemolymphangioma"],"term_type":""},{"nm":"9180/0","n_c":["C3296"],"i_c":"9180/0","i_c_s":["Osteoma, NOS"],"term_type":""},{"nm":"9180/3","n_c":["C53953","C4021","C9145"],"i_c":"9180/3","i_c_s":["Osteosarcoma, NOS","Osteoblastic sarcoma","Osteochondrosarcoma","Osteogenic sarcoma, NOS"],"term_type":""},{"nm":"9180/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9181/3","n_c":["C4021"],"i_c":"9181/3","i_c_s":["Chondroblastic osteosarcoma"],"term_type":""},{"nm":"9182/3","n_c":["C4020"],"i_c":"9182/3","i_c_s":["Fibroblastic osteosarcoma","Osteofibrosarcoma"],"term_type":""},{"nm":"9183/3","n_c":["C3902"],"i_c":"9183/3","i_c_s":["Telangiectatic osteosarcoma"],"term_type":""},{"nm":"9184/3","n_c":["C6469"],"i_c":"9184/3","i_c_s":["Osteosarcoma in Paget disease of bone"],"term_type":""},{"nm":"9185/3","n_c":["C4023"],"i_c":"9185/3","i_c_s":["Small cell osteosarcoma","Round cell osteosarcoma"],"term_type":""},{"nm":"9186/3","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Central osteosarcoma","Conventional central osteosarcoma","Medullary osteosarcoma"],"term_type":""},{"nm":"9187/3","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Intraosseous well differentiated osteosarcoma","Intraosseous low grade osteosarcoma"],"term_type":""},{"nm":"9191/0","n_c":["C3297"],"i_c":"9191/0","i_c_s":["Osteoid osteoma, NOS"],"term_type":""},{"nm":"9192/3","n_c":["C8969"],"i_c":"9192/3","i_c_s":["Parosteal osteosarcoma","Juxtacortical osteosarcoma"],"term_type":""},{"nm":"9193/3","n_c":["C8970"],"i_c":"9193/3","i_c_s":["Periosteal osteosarcoma"],"term_type":""},{"nm":"9194/3","n_c":["C53958"],"i_c":"9194/3","i_c_s":["High grade surface osteosarcoma"],"term_type":""},{"nm":"9195/3","n_c":["C35870"],"i_c":"9195/3","i_c_s":["Intracortical osteosarcoma"],"term_type":""},{"nm":"9200/0","n_c":["C3294"],"i_c":"9200/0","i_c_s":["Osteoblastoma, NOS","Giant osteoid osteoma"],"term_type":""},{"nm":"9200/1","n_c":["C66796"],"i_c":"9200/1","i_c_s":["Aggressive osteoblastoma"],"term_type":""},{"nm":"9210/0","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Osteochondroma","Cartilaginous exostosis","Ecchondroma","Osteocartilaginous exostosis"],"term_type":""},{"nm":"9210/1","n_c":["C53457"],"i_c":"9210/1","i_c_s":["Osteochondromatosis, NOS","Ecchondrosis"],"term_type":""},{"nm":"9220/0","n_c":["C53459","C3007"],"i_c":"9220/0","i_c_s":["Chondroma, NOS","Enchondroma"],"term_type":""},{"nm":"9220/1","n_c":["C35259"],"i_c":"9220/1","i_c_s":["Chondromatosis, NOS"],"term_type":""},{"nm":"9220/3","n_c":["C2946"],"i_c":"9220/3","i_c_s":["Chondrosarcoma, NOS","Fibrochondrosarcoma"],"term_type":""},{"nm":"9221/0","n_c":["C4302"],"i_c":"9221/0","i_c_s":["Juxtacortical chondroma","Periosteal chondroma"],"term_type":""},{"nm":"9221/3","n_c":["C7357"],"i_c":"9221/3","i_c_s":["Juxtacortical chondrosarcoma","Periosteal chondrosarcoma"],"term_type":""},{"nm":"9230/0","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Chondroblastoma, NOS","Chondromatous giant cell tumor","Codman tumor"],"term_type":""},{"nm":"9230/3","n_c":["C66799"],"i_c":"9230/3","i_c_s":["Chondroblastoma, malignant"],"term_type":""},{"nm":"9231/3","n_c":["C27502"],"i_c":"9231/3","i_c_s":["Myxoid chondrosarcoma"],"term_type":""},{"nm":"9240/3","n_c":["C3737"],"i_c":"9240/3","i_c_s":["Mesenchymal chondrosarcoma"],"term_type":""},{"nm":"9241/0","n_c":["C3830"],"i_c":"9241/0","i_c_s":["Chondromyxoid fibroma"],"term_type":""},{"nm":"9242/3","n_c":["C6475"],"i_c":"9242/3","i_c_s":["Clear cell chondrosarcoma"],"term_type":""},{"nm":"9243/3","n_c":["C6476"],"i_c":"9243/3","i_c_s":["Dedifferentiated chondrosarcoma"],"term_type":""},{"nm":"9250/1","n_c":["C121932"],"i_c":"9250/1","i_c_s":["Giant cell tumor of bone, NOS","Osteoclastoma, NOS"],"term_type":""},{"nm":"9250/3","n_c":["C4304","C8380"],"i_c":"9250/3","i_c_s":["Giant cell tumor of bone, malignant","Giant cell sarcoma of bone","Osteoclastoma, malignant"],"term_type":""},{"nm":"9251/1","n_c":["C49107"],"i_c":"9251/1","i_c_s":["Giant cell tumor of soft parts, NOS"],"term_type":""},{"nm":"9251/3","n_c":["C8380"],"i_c":"9251/3","i_c_s":["Malignant giant cell tumor of soft parts"],"term_type":""},{"nm":"9252/0","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Tenosynovial giant cell tumor","Fibrous histiocytoma of tendon sheath","Giant cell tumor of tendon sheath"],"term_type":""},{"nm":"9252/3","n_c":["C6535"],"i_c":"9252/3","i_c_s":["Malignant tenosynovial giant cell tumor","Giant cell tumor of tendon sheath, malignant"],"term_type":""},{"nm":"9260/3","n_c":["C4817"],"i_c":"9260/3","i_c_s":["Ewing sarcoma","Ewing tumor"],"term_type":""},{"nm":"9261/3","n_c":["C7644","C8461"],"i_c":"9261/3","i_c_s":["Adamantinoma of long bones","Tibial adamantinoma"],"term_type":""},{"nm":"9262/0","n_c":["C173820"],"i_c":"9262/0","i_c_s":["Ossifying fibroma","Fibro-osteoma","Osteofibroma"],"term_type":""},{"nm":"9270/0","n_c":["C4306"],"i_c":"9270/0","i_c_s":["Odontogenic tumor, benign"],"term_type":""},{"nm":"9270/1","n_c":["C3286"],"i_c":"9270/1","i_c_s":["Odontogenic tumor, NOS"],"term_type":""},{"nm":"9270/3","n_c":["C4812","C7492"],"i_c":"9270/3","i_c_s":["Odontogenic tumor, malignant","Ameloblastic carcinoma","Odontogenic carcinoma","Odontogenic sarcoma","Primary intraosseous carcinoma"],"term_type":""},{"nm":"9271/0","n_c":["C54323","C66800"],"i_c":"9271/0","i_c_s":["Ameloblastic fibrodentinoma","Dentinoma"],"term_type":""},{"nm":"9272/0","n_c":["C173927"],"i_c":"9272/0","i_c_s":["Cementoma, NOS","Periapical cemental dysplasia","Periapical cemento-osseous dysplasia"],"term_type":""},{"nm":"9273/0","n_c":["C4308"],"i_c":"9273/0","i_c_s":["Cementoblastoma, benign"],"term_type":""},{"nm":"9274/0","n_c":["C8422"],"i_c":"9274/0","i_c_s":["Cementifying fibroma","Cemento-ossifying fibroma"],"term_type":""},{"nm":"9275/0","n_c":["C202219"],"i_c":"9275/0","i_c_s":["Gigantiform cementoma","Florid osseous dysplasia"],"term_type":""},{"nm":"9280/0","n_c":["C3287"],"i_c":"9280/0","i_c_s":["Odontoma, NOS"],"term_type":""},{"nm":"9281/0","n_c":["C3711"],"i_c":"9281/0","i_c_s":["Compound odontoma"],"term_type":""},{"nm":"9282/0","n_c":["C4309"],"i_c":"9282/0","i_c_s":["Complex odontoma"],"term_type":""},{"nm":"9290/0","n_c":["C3710"],"i_c":"9290/0","i_c_s":["Ameloblastic fibro-odontoma","Fibroameloblastic odontoma"],"term_type":""},{"nm":"9290/3","n_c":["C173740"],"i_c":"9290/3","i_c_s":["Ameloblastic odontosarcoma","Ameloblastic fibro-odontosarcoma","Ameloblastic fibrodentinosarcoma"],"term_type":""},{"nm":"9300/0","n_c":["C4310"],"i_c":"9300/0","i_c_s":["Adenomatoid odontogenic tumor","Adenoameloblastoma"],"term_type":""},{"nm":"9301/0","n_c":["C54319"],"i_c":"9301/0","i_c_s":["Calcifying odontogenic cyst"],"term_type":""},{"nm":"9302/0","n_c":["C54323"],"i_c":"9302/0","i_c_s":["Odontogenic ghost cell tumor"],"term_type":""},{"nm":"9302/3","n_c":["C4311"],"i_c":"9302/3","i_c_s":["Ghost cell odontogenic carcinoma"],"term_type":""},{"nm":"9310/0","n_c":["C4313"],"i_c":"9310/0","i_c_s":["Ameloblastoma, NOS","Adamantinoma, NOS"],"term_type":""},{"nm":"9310/3","n_c":["C54297"],"i_c":"9310/3","i_c_s":["Ameloblastoma, malignant","Adamantinoma, malignant"],"term_type":""},{"nm":"9311/0","n_c":["C54317"],"i_c":"9311/0","i_c_s":["Odontoameloblastoma"],"term_type":""},{"nm":"9312/0","n_c":["C7112"],"i_c":"9312/0","i_c_s":["Squamous odontogenic tumor"],"term_type":""},{"nm":"9320/0","n_c":["C7501","C7452"],"i_c":"9320/0","i_c_s":["Odontogenic myxoma","Odontogenic myxofibroma"],"term_type":""},{"nm":"9321/0","n_c":["C4314","C202077"],"i_c":"9321/0","i_c_s":["Central odontogenic fibroma","Odontogenic fibroma, NOS"],"term_type":""},{"nm":"9322/0","n_c":["C4315"],"i_c":"9322/0","i_c_s":["Peripheral odontogenic fibroma"],"term_type":""},{"nm":"9330/0","n_c":["C4316"],"i_c":"9330/0","i_c_s":["Ameloblastic fibroma"],"term_type":""},{"nm":"9330/3","n_c":["C4317"],"i_c":"9330/3","i_c_s":["Ameloblastic fibrosarcoma","Ameloblastic sarcoma","Odontogenic fibrosarcoma"],"term_type":""},{"nm":"9340/0","n_c":["C54301"],"i_c":"9340/0","i_c_s":["Calcifying epithelial odontogenic tumor","Pindborg tumor"],"term_type":""},{"nm":"9341/1","n_c":["C54300"],"i_c":"9341/1","i_c_s":["Clear cell odontogenic tumor"],"term_type":""},{"nm":"9341/3","n_c":["C54300"],"i_c":"9341/3","i_c_s":["Clear cell odontogenic carcinoma"],"term_type":""},{"nm":"9342/3","n_c":["C173735"],"i_c":"9342/3","i_c_s":["Odontogenic carcinosarcoma"],"term_type":""},{"nm":"9350/1","n_c":["C2964"],"i_c":"9350/1","i_c_s":["Craniopharyngioma","Rathke pouch tumor"],"term_type":""},{"nm":"9351/1","n_c":["C4726"],"i_c":"9351/1","i_c_s":["Craniopharyngioma, adamantinomatous"],"term_type":""},{"nm":"9352/1","n_c":["C4725"],"i_c":"9352/1","i_c_s":["Craniopharyngioma, papillary"],"term_type":""},{"nm":"9360/1","n_c":["C3328"],"i_c":"9360/1","i_c_s":["Pinealoma"],"term_type":""},{"nm":"9361/1","n_c":["C6966"],"i_c":"9361/1","i_c_s":["Pineocytoma"],"term_type":""},{"nm":"9362/3","n_c":["C6967","C9344"],"i_c":"9362/3","i_c_s":["Pineoblastoma","Mixed pineal tumor","Pineal parenchymal tumor of intermediate differentiation","Transitional pineal tumor","Mixed pineocytoma-pineoblastoma"],"term_type":""},{"nm":"9363/0","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanotic neuroectodermal tumor","Melanoameloblastoma","Melanotic progonoma","Retinal anlage tumor"],"term_type":""},{"nm":"9364/3","n_c":["C3716","C9341"],"i_c":"9364/3","i_c_s":["Peripheral neuroectodermal tumor","Neuroectodermal tumor, NOS","Peripheral primitive neuroectodermal tumor, NOS","PPNET"],"term_type":""},{"nm":"9365/3","n_c":["C7542"],"i_c":"9365/3","i_c_s":["Askin tumor"],"term_type":""},{"nm":"9370/3","n_c":["C2947"],"i_c":"9370/3","i_c_s":["Chordoma, NOS"],"term_type":""},{"nm":"9371/3","n_c":["C6902"],"i_c":"9371/3","i_c_s":["Chondroid chordoma"],"term_type":""},{"nm":"9372/3","n_c":["C48876"],"i_c":"9372/3","i_c_s":["Dedifferentiated chordoma"],"term_type":""},{"nm":"9373/0","n_c":["C6581"],"i_c":"9373/0","i_c_s":["Parachordoma"],"term_type":""},{"nm":"9380/3","n_c":["C4822","C3059"],"i_c":"9380/3","i_c_s":["Glioma, malignant","Glioma, NOS"],"term_type":""},{"nm":"9381/3","n_c":["C4318"],"i_c":"9381/3","i_c_s":["Gliomatosis cerebri"],"term_type":""},{"nm":"9382/3","n_c":["C4050","C3903","C6959"],"i_c":"9382/3","i_c_s":["Mixed glioma","Anaplastic oligoastrocytoma","Oligoastrocytoma"],"term_type":""},{"nm":"9383/1","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Subependymoma","Mixed subependymoma-ependymoma","Subependymal astrocytoma, NOS","Subependymal glioma"],"term_type":""},{"nm":"9384/1","n_c":["C3696"],"i_c":"9384/1","i_c_s":["Subependymal giant cell astrocytoma"],"term_type":""},{"nm":"9385/3","n_c":["C129309"],"i_c":"9385/3","i_c_s":["Diffuse midline glioma, H3 K27M-mutant"],"term_type":""},{"nm":"9390/0","n_c":["C3698"],"i_c":"9390/0","i_c_s":["Choroid plexus papilloma, NOS"],"term_type":""},{"nm":"9390/1","n_c":["C53686"],"i_c":"9390/1","i_c_s":["Atypical choroid plexus papilloma"],"term_type":""},{"nm":"9390/3","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus carcinoma","Choroid plexus papilloma, anaplastic","Choroid plexus papilloma, malignant"],"term_type":""},{"nm":"9391/3","n_c":["C6903","C4713","C4714","C3017"],"i_c":"9391/3","i_c_s":["Ependymoma, NOS","Cellular ependymoma","Clear cell ependymoma","Tanycytic ependymoma","Epithelial ependymoma"],"term_type":""},{"nm":"9392/3","n_c":["C4049","C4915"],"i_c":"9392/3","i_c_s":["Ependymoma, anaplastic","Ependymoblastoma"],"term_type":""},{"nm":"9393/3","n_c":["C4319"],"i_c":"9393/3","i_c_s":["Papillary ependymoma"],"term_type":""},{"nm":"9394/1","n_c":["C3697"],"i_c":"9394/1","i_c_s":["Myxopapillary ependymoma"],"term_type":""},{"nm":"9395/3","n_c":["C92624"],"i_c":"9395/3","i_c_s":["Papillary tumor of the pineal region"],"term_type":""},{"nm":"9396/3","n_c":["C129351"],"i_c":"9396/3","i_c_s":["Ependymoma, RELA fusion-positive"],"term_type":""},{"nm":"9400/3","n_c":["C6958","C7173","C60781"],"i_c":"9400/3","i_c_s":["Astrocytoma, NOS","Cystic astrocytoma","Astrocytoma, low grade","Diffuse astrocytoma, low grade","Diffuse astrocytoma","Astroglioma","Astrocytic glioma"],"term_type":""},{"nm":"9401/3","n_c":["C9477"],"i_c":"9401/3","i_c_s":["Astrocytoma, anaplastic"],"term_type":""},{"nm":"9410/3","n_c":["C4320"],"i_c":"9410/3","i_c_s":["Protoplasmic astrocytoma"],"term_type":""},{"nm":"9411/3","n_c":["C4321"],"i_c":"9411/3","i_c_s":["Gemistocytic astrocytoma","Gemistocytoma"],"term_type":""},{"nm":"9412/1","n_c":["C9476","C4738"],"i_c":"9412/1","i_c_s":["Desmoplastic infantile astrocytoma","Desmoplastic infantile ganglioglioma"],"term_type":""},{"nm":"9413/0","n_c":["C9505"],"i_c":"9413/0","i_c_s":["Dysembryoplastic neuroepithelial tumor"],"term_type":""},{"nm":"9420/3","n_c":["C4322"],"i_c":"9420/3","i_c_s":["Fibrillary astrocytoma","Fibrous astrocytoma"],"term_type":""},{"nm":"9421/1","n_c":["C4047","C9022"],"i_c":"9421/1","i_c_s":["Pilocytic astrocytoma","Spongioblastoma, NOS","Juvenile astrocytoma","Piloid astrocytoma"],"term_type":""},{"nm":"9423/3","n_c":["C66801"],"i_c":"9423/3","i_c_s":["Polar spongioblastoma","Primitive polar spongioblastoma","Spongioblastoma polare"],"term_type":""},{"nm":"9424/3","n_c":["C4323"],"i_c":"9424/3","i_c_s":["Pleomorphic xanthoastrocytoma"],"term_type":""},{"nm":"9425/3","n_c":["C40315"],"i_c":"9425/3","i_c_s":["Pilomyxoid astrocytoma"],"term_type":""},{"nm":"9430/3","n_c":["C4324"],"i_c":"9430/3","i_c_s":["Astroblastoma"],"term_type":""},{"nm":"9431/1","n_c":["C92552"],"i_c":"9431/1","i_c_s":["Angiocentric glioma"],"term_type":""},{"nm":"9432/1","n_c":["C94524"],"i_c":"9432/1","i_c_s":["Pituicytoma"],"term_type":""},{"nm":"9440/3","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Glioblastoma, NOS","Glioblastoma multiforme","Spongioblastoma multiforme"],"term_type":""},{"nm":"9440/6","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9441/3","n_c":["C4325"],"i_c":"9441/3","i_c_s":["Giant cell glioblastoma","Monstrocellular sarcoma"],"term_type":""},{"nm":"9442/1","n_c":["C5419"],"i_c":"9442/1","i_c_s":["Gliofibroma"],"term_type":""},{"nm":"9442/3","n_c":["C3796"],"i_c":"9442/3","i_c_s":["Gliosarcoma","Glioblastoma with sarcomatous component"],"term_type":""},{"nm":"9444/1","n_c":["C5592"],"i_c":"9444/1","i_c_s":["Chordoid glioma","Chordoid glioma of third ventricle"],"term_type":""},{"nm":"9445/3","n_c":["C167335"],"i_c":"9445/3","i_c_s":["Glioblastoma, IDH-mutant"],"term_type":""},{"nm":"9450/3","n_c":["C129319"],"i_c":"9450/3","i_c_s":["Oligodendroglioma, NOS"],"term_type":""},{"nm":"9451/3","n_c":["C4326"],"i_c":"9451/3","i_c_s":["Oligodendroglioma, anaplastic"],"term_type":""},{"nm":"9460/3","n_c":["C66802"],"i_c":"9460/3","i_c_s":["Oligodendroblastoma"],"term_type":""},{"nm":"9470/3","n_c":["C129447","C9497"],"i_c":"9470/3","i_c_s":["Medulloblastoma, NOS","Melanotic medulloblastoma"],"term_type":""},{"nm":"9471/3","n_c":["C5407","C4956"],"i_c":"9471/3","i_c_s":["Desmoplastic nodular medulloblastoma","Medulloblastoma with extensive nodularity","Circumscribed arachnoidal cerebellar sarcoma","Desmoplastic medulloblastoma"],"term_type":""},{"nm":"9472/3","n_c":["C3706"],"i_c":"9472/3","i_c_s":["Medullomyoblastoma"],"term_type":""},{"nm":"9473/3","n_c":["C6968","C3716","C5398"],"i_c":"9473/3","i_c_s":["Primitive neuroectodermal tumor, NOS","Central primitive neuroectodermal tumor, NOS","Supratentorial PNET","CPNET","PNET, NOS"],"term_type":""},{"nm":"9474/3","n_c":["C92625","C6904"],"i_c":"9474/3","i_c_s":["Large cell medulloblastoma","Anaplastic medulloblastoma"],"term_type":""},{"nm":"9475/3","n_c":["C129440"],"i_c":"9475/3","i_c_s":["Medulloblastoma, WNT-activated"],"term_type":""},{"nm":"9476/3","n_c":["C129442"],"i_c":"9476/3","i_c_s":["Medulloblastoma, SHH-activated and TP53-mutant"],"term_type":""},{"nm":"9477/3","n_c":["C129444"],"i_c":"9477/3","i_c_s":["Medulloblastoma, non-WNT/non-SHH"],"term_type":""},{"nm":"9478/3","n_c":["C186534","C4915"],"i_c":"9478/3","i_c_s":["Embryonal tumor with multilayered rosettes, NOS"],"term_type":""},{"nm":"9480/3","n_c":["C66803"],"i_c":"9480/3","i_c_s":["Cerebellar sarcoma, NOS"],"term_type":""},{"nm":"9490/0","n_c":["C3049"],"i_c":"9490/0","i_c_s":["Ganglioneuroma"],"term_type":""},{"nm":"9490/3","n_c":["C3790"],"i_c":"9490/3","i_c_s":["Ganglioneuroblastoma"],"term_type":""},{"nm":"9491/0","n_c":["C66804"],"i_c":"9491/0","i_c_s":["Ganglioneuromatosis"],"term_type":""},{"nm":"9492/0","n_c":["C6934"],"i_c":"9492/0","i_c_s":["Gangliocytoma"],"term_type":""},{"nm":"9493/0","n_c":["C8419"],"i_c":"9493/0","i_c_s":["Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)"],"term_type":""},{"nm":"9500/3","n_c":["C3270"],"i_c":"9500/3","i_c_s":["Neuroblastoma, NOS","Central neuroblastoma","Sympathicoblastoma"],"term_type":""},{"nm":"9501/0","n_c":["C66807"],"i_c":"9501/0","i_c_s":["Medulloepithelioma, benign","Diktyoma, benign"],"term_type":""},{"nm":"9501/3","n_c":["C66808","C4327"],"i_c":"9501/3","i_c_s":["Medulloepithelioma, NOS","Diktyoma, malignant"],"term_type":""},{"nm":"9502/0","n_c":["C66809"],"i_c":"9502/0","i_c_s":["Teratoid medulloepithelioma, benign"],"term_type":""},{"nm":"9502/3","n_c":["C66810"],"i_c":"9502/3","i_c_s":["Teratoid medulloepithelioma"],"term_type":""},{"nm":"9503/3","n_c":["C3716"],"i_c":"9503/3","i_c_s":["Neuroepithelioma, NOS"],"term_type":""},{"nm":"9504/3","n_c":["C66811"],"i_c":"9504/3","i_c_s":["Spongioneuroblastoma"],"term_type":""},{"nm":"9505/1","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Ganglioglioma, NOS","Glioneuroma","Neuroastrocytoma"],"term_type":""},{"nm":"9505/3","n_c":["C4717"],"i_c":"9505/3","i_c_s":["Ganglioglioma, anaplastic"],"term_type":""},{"nm":"9506/1","n_c":["C92555","C6905","C3791"],"i_c":"9506/1","i_c_s":["Central neurocytoma","Cerebellar liponeurocytoma","Extraventricular neurocytoma","Lipomatous medulloblastoma","Medullocytoma","Neurocytoma","Neurolipocytoma"],"term_type":""},{"nm":"9507/0","n_c":["C4328"],"i_c":"9507/0","i_c_s":["Pacinian tumor"],"term_type":""},{"nm":"9508/3","n_c":["C6906"],"i_c":"9508/3","i_c_s":["Atypical teratoid/rhabdoid tumor"],"term_type":""},{"nm":"9509/1","n_c":["C92554","C129431"],"i_c":"9509/1","i_c_s":["Papillary glioneuronal tumor","Rosette-forming glioneuronal tumor"],"term_type":""},{"nm":"9510/0","n_c":["C66812"],"i_c":"9510/0","i_c_s":["Retinocytoma"],"term_type":""},{"nm":"9510/3","n_c":["C7541"],"i_c":"9510/3","i_c_s":["Retinoblastoma, NOS"],"term_type":""},{"nm":"9511/3","n_c":["C66813"],"i_c":"9511/3","i_c_s":["Retinoblastoma, differentiated"],"term_type":""},{"nm":"9512/3","n_c":["C66814"],"i_c":"9512/3","i_c_s":["Retinoblastoma, undifferentiated"],"term_type":""},{"nm":"9513/3","n_c":["C66815"],"i_c":"9513/3","i_c_s":["Retinoblastoma, diffuse"],"term_type":""},{"nm":"9514/1","n_c":["C66816"],"i_c":"9514/1","i_c_s":["Retinoblastoma, spontaneously regressed"],"term_type":""},{"nm":"9520/3","n_c":["C67155"],"i_c":"9520/3","i_c_s":["Olfactory neurogenic tumor"],"term_type":""},{"nm":"9521/3","n_c":["C67156"],"i_c":"9521/3","i_c_s":["Olfactory neurocytoma","Esthesioneurocytoma"],"term_type":""},{"nm":"9522/3","n_c":["C3789"],"i_c":"9522/3","i_c_s":["Olfactory neuroblastoma","Esthesioneuroblastoma"],"term_type":""},{"nm":"9523/3","n_c":["C3789"],"i_c":"9523/3","i_c_s":["Olfactory neuroepithelioma","Esthesioneuroepithelioma"],"term_type":""},{"nm":"9530/0","n_c":["C6907","C4718","C4721","C4720","C3230"],"i_c":"9530/0","i_c_s":["Meningioma, NOS","Lymphoplasmacyte-rich meningioma","Metaplastic meningioma","Microcystic meningioma","Secretory meningioma"],"term_type":""},{"nm":"9530/1","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Meningiomatosis, NOS","Diffuse meningiomatosis","Multiple meningiomas"],"term_type":""},{"nm":"9530/3","n_c":["C4051","C4073","C8312"],"i_c":"9530/3","i_c_s":["Meningioma, malignant","Leptomeningeal sarcoma","Meningeal sarcoma","Meningioma, anaplastic","Meningothelial sarcoma"],"term_type":""},{"nm":"9531/0","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Meningothelial meningioma","Endotheliomatous meningioma","Syncytial meningioma"],"term_type":""},{"nm":"9532/0","n_c":["C4330"],"i_c":"9532/0","i_c_s":["Fibrous meningioma","Fibroblastic meningioma"],"term_type":""},{"nm":"9533/0","n_c":["C4331"],"i_c":"9533/0","i_c_s":["Psammomatous meningioma"],"term_type":""},{"nm":"9534/0","n_c":["C4332"],"i_c":"9534/0","i_c_s":["Angiomatous meningioma"],"term_type":""},{"nm":"9535/0","n_c":["C66817"],"i_c":"9535/0","i_c_s":["Hemangioblastic meningioma","Angioblastic meningioma"],"term_type":""},{"nm":"9537/0","n_c":["C4333"],"i_c":"9537/0","i_c_s":["Transitional meningioma","Mixed meningioma"],"term_type":""},{"nm":"9538/1","n_c":["C4722","C6908"],"i_c":"9538/1","i_c_s":["Clear cell meningioma","Chordoid meningioma"],"term_type":""},{"nm":"9538/3","n_c":["C3904","C6909"],"i_c":"9538/3","i_c_s":["Papillary meningioma","Rhabdoid meningioma"],"term_type":""},{"nm":"9539/1","n_c":["C4723"],"i_c":"9539/1","i_c_s":["Atypical meningioma"],"term_type":""},{"nm":"9539/3","n_c":["C4334"],"i_c":"9539/3","i_c_s":["Meningeal sarcomatosis"],"term_type":""},{"nm":"9540/0","n_c":["C3272"],"i_c":"9540/0","i_c_s":["Neurofibroma, NOS"],"term_type":""},{"nm":"9540/1","n_c":["C6727","C3273"],"i_c":"9540/1","i_c_s":["Neurofibromatosis, NOS","Multiple neurofibromatosis","Recklinghausen disease","Von Recklinghausen disease"],"term_type":""},{"nm":"9540/3","n_c":["C6561","C4748","C3798"],"i_c":"9540/3","i_c_s":["Malignant peripheral nerve sheath tumor","Epithelioid MPNST","MPNST with glandular differentiation","MPNST with mesenchymal differentiation","Melanotic MPNST","Melanotic psammomatous MPNST","Neurofibrosarcoma","Neurogenic sarcoma","Neurosarcoma","MPNST, NOS"],"term_type":""},{"nm":"9541/0","n_c":["C66841"],"i_c":"9541/0","i_c_s":["Melanotic neurofibroma"],"term_type":""},{"nm":"9542/3","n_c":["C6561"],"i_c":"9542/3","i_c_s":["Epithelioid malignant peripheral nerve sheath tumor"],"term_type":""},{"nm":"9550/0","n_c":["C3797"],"i_c":"9550/0","i_c_s":["Plexiform neurofibroma","Plexiform neuroma"],"term_type":""},{"nm":"9560/0","n_c":["C3276","C3269","C4724","C6970","C6969","C6556"],"i_c":"9560/0","i_c_s":["Neurilemoma, NOS","Acoustic neuroma","Ancient schwannoma","Cellular schwannoma","Degenerated schwannoma","Pigmented schwannoma","Plexiform schwannoma","Psammomatous schwannoma","Melanotic schwannoma","Neurinoma","Schwannoma, NOS"],"term_type":""},{"nm":"9560/1","n_c":["C6557"],"i_c":"9560/1","i_c_s":["Neurinomatosis"],"term_type":""},{"nm":"9560/3","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Neurilemoma, malignant","Malignant schwannoma, NOS","Neurilemosarcoma"],"term_type":""},{"nm":"9561/3","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation","MPNST with rhabdomyoblastic differentiation","Malignant schwannoma with rhabdomyoblastic differentiation","Triton tumor, malignant"],"term_type":""},{"nm":"9562/0","n_c":["C7018"],"i_c":"9562/0","i_c_s":["Neurothekeoma","Nerve sheath myxoma"],"term_type":""},{"nm":"9570/0","n_c":["C3275"],"i_c":"9570/0","i_c_s":["Neuroma, NOS"],"term_type":""},{"nm":"9571/0","n_c":["C6911","C6912","C4973"],"i_c":"9571/0","i_c_s":["Perineurioma, NOS","Intraneural perineurioma","Soft tissue perineurioma"],"term_type":""},{"nm":"9571/3","n_c":["C66845"],"i_c":"9571/3","i_c_s":["Perineurioma, malignant","Perineural MPNST"],"term_type":""},{"nm":"9580/0","n_c":["C3474"],"i_c":"9580/0","i_c_s":["Granular cell tumor, NOS","Granular cell myoblastoma, NOS"],"term_type":""},{"nm":"9580/3","n_c":["C4336"],"i_c":"9580/3","i_c_s":["Granular cell tumor, malignant","Granular cell myoblastoma, malignant"],"term_type":""},{"nm":"9581/3","n_c":["C3750"],"i_c":"9581/3","i_c_s":["Alveolar soft part sarcoma"],"term_type":""},{"nm":"9582/0","n_c":["C7017"],"i_c":"9582/0","i_c_s":["Granular cell tumor of the sellar region"],"term_type":""},{"nm":"9590/3","n_c":["C9301","C3208"],"i_c":"9590/3","i_c_s":["Malignant lymphoma, NOS","Microglioma","Lymphoma, NOS"],"term_type":""},{"nm":"9591/3","n_c":["C27258","C80308","C27822","C27824","C26919","C7401","C80309","C3211"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, non-Hodgkin, NOS","Lymphosarcoma, NOS","Malignant lymphoma, lymphocytic, intermediate differentiation, nodular","Malignant lymphoma, lymphocytic, poorly differentiated, diffuse","Malignant lymphoma, small cell, noncleaved, diffuse","Malignant lymphoma, small cleaved cell, diffuse","Reticulum cell sarcoma, NOS","B cell lymphoma, NOS","Hairy cell leukemia variant","Malignant lymphoma, diffuse, NOS","Malignant lymphoma, non-cleaved cell, NOS","Splenic B-cell lymphoma/leukemia, unclassifiable","Splenic diffuse red pulp small B-cell lymphoma","Lymphosarcoma, diffuse","Malignant lymphoma, cleaved cell, NOS","Malignant lymphoma, small cleaved cell, NOS","Malignant lymphoma, undifferentiated cell type, NOS","Malignant lymphoma, undifferentiated cell, non-Burkitt","Reticulosarcoma, NOS","Reticulosarcoma, diffuse","Reticulum cell sarcoma, diffuse","Non-Hodgkin lymphoma, NOS"],"term_type":""},{"nm":"9596/3","n_c":["C38661","C37869"],"i_c":"9596/3","i_c_s":["Composite Hodgkin and non-Hodgkin lymphoma","B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma"],"term_type":""},{"nm":"9597/3","n_c":["C7217"],"i_c":"9597/3","i_c_s":["Primary cutaneous follicle centre lymphoma"],"term_type":""},{"nm":"9650/3","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Hodgkin lymphoma, NOS","Hodgkin disease, NOS","Malignant lymphoma, Hodgkin"],"term_type":""},{"nm":"9651/3","n_c":["C6913","C8590"],"i_c":"9651/3","i_c_s":["Hodgkin lymphoma, lymphocyte-rich","Hodgkin disease, lymphocyte predominance, NOS","Hodgkin disease, lymphocyte predominance, diffuse","Hodgkin disease, lymphocytic-histiocytic predominance","Classical Hodgkin lymphoma, lymphocyte- rich"],"term_type":""},{"nm":"9652/3","n_c":["C3517"],"i_c":"9652/3","i_c_s":["Hodgkin lymphoma, mixed cellularity, NOS","Classical Hodgkin lymphoma, mixed cellularity, NOS"],"term_type":""},{"nm":"9653/3","n_c":["C9283"],"i_c":"9653/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, NOS","Classical Hodgkin lymphoma, lymphocyte depletion, NOS"],"term_type":""},{"nm":"9654/3","n_c":["C9283"],"i_c":"9654/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis","Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"],"term_type":""},{"nm":"9655/3","n_c":["C9283"],"i_c":"9655/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, reticular","Classical Hodgkin lymphoma, lymphocyte depletion, reticular"],"term_type":""},{"nm":"9659/3","n_c":["C7258","C26956"],"i_c":"9659/3","i_c_s":["Hodgkin lymphoma, nodular lymphocyte predominance","Hodgkin paragranuloma, NOS","Hodgkin paragranuloma, nodular","Hodgkin lymphoma, lymphocyte predominance, nodular"],"term_type":""},{"nm":"9661/3","n_c":["C6914"],"i_c":"9661/3","i_c_s":["Hodgkin granuloma"],"term_type":""},{"nm":"9662/3","n_c":["C164145"],"i_c":"9662/3","i_c_s":["Hodgkin sarcoma"],"term_type":""},{"nm":"9663/3","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, NOS","Classical Hodgkin lymphoma, nodular sclerosis, NOS","Hodgkin disease, nodular sclerosis, NOS"],"term_type":""},{"nm":"9664/3","n_c":["C67171"],"i_c":"9664/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, cellular phase","Classical Hodgkin lymphoma, nodular sclerosis, cellular phase"],"term_type":""},{"nm":"9665/3","n_c":["C27270","C27098","C7165"],"i_c":"9665/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 1","Classical Hodgkin lymphoma, nodular sclerosis, grade 1","Hodgkin disease, nodular sclerosis, lymphocyte predominance","Hodgkin disease, nodular sclerosis, mixed cellularity"],"term_type":""},{"nm":"9667/3","n_c":["C27808","C27807","C7166"],"i_c":"9667/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 2","Classical Hodgkin lymphoma, nodular sclerosis, grade 2","Hodgkin disease, nodular sclerosis, lymphocyte depletion","Hodgkin disease, nodular sclerosis, syncytial variant"],"term_type":""},{"nm":"9670/3","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small B lymphocytic, NOS","Malignant lymphoma, lymphocytic, NOS","Malignant lymphoma, lymphocytic, diffuse, NOS","Malignant lymphoma, lymphocytic, well differentiated, diffuse","Malignant lymphoma, small cell diffuse","Malignant lymphoma, small cell, NOS","Malignant lymphoma, small lymphocytic, NOS","Malignant lymphoma, small lymphocytic, diffuse"],"term_type":""},{"nm":"9671/3","n_c":["C3212","C3898"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, lymphoplasmacytic","Immunocytoma","Malignant lymphoma, plasmacytoid","Plasmacytic lymphoma","Malignant lymphoma, lymphoplasmacytoid"],"term_type":""},{"nm":"9673/3","n_c":["C4339","C4337"],"i_c":"9673/3","i_c_s":["Mantle cell lymphoma","Malignant lymphoma, centrocytic","Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse","Mantle zone lymphoma","Malignant lymphomatous polyposis"],"term_type":""},{"nm":"9675/3","n_c":["C4338","C3463"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed small and large cell, diffuse","Malignant lymphoma, centroblastic- centrocytic, NOS","Malignant lymphoma, centroblastic- centrocytic, diffuse","Malignant lymphoma, mixed cell type, diffuse","Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse"],"term_type":""},{"nm":"9678/3","n_c":["C6915"],"i_c":"9678/3","i_c_s":["Primary effusion lymphoma"],"term_type":""},{"nm":"9679/3","n_c":["C9280"],"i_c":"9679/3","i_c_s":["Mediastinal large B-cell lymphoma","Thymic large B-cell lymphoma"],"term_type":""},{"nm":"9680/3","n_c":["C27099","C4074","C80289","C80281","C6916","C80291","C9496","C4342","C80280","C27823","C27265","C27266","C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, NOS","Anaplastic large B-cell lymphoma","B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","Diffuse large B-cell lymphoma associated with chronic inflammation","EBV positive diffuse large B-cell lymphoma of the elderly","Intravascular large B-cell lymphoma","Malignant lymphoma, centroblastic, NOS","Malignant lymphoma, centroblastic, diffuse","Primary cutaneous DLBCL, leg type","Primary diffuse large B-cell lymphoma of the CNS","T-cell rich large B-cell lymphoma","Malignant lymphoma, histiocytic, NOS","Malignant lymphoma, large cell, cleaved and noncleaved","Malignant lymphoma, large cell, cleaved, NOS","Malignant lymphoma, large cell, diffuse, NOS","Malignant lymphoma, large cleaved cell, NOS","Malignant lymphoma, noncleaved, diffuse, NOS","Angioendotheliomatosis","Angiotropic lymphoma","Diffuse large B-cell lymphoma, NOS","Histiocyte-rich large B-cell lymphoma","Intravascular B-cell lymphoma","Malignant lymphoma, histiocytic, diffuse","Malignant lymphoma, large B-cell, NOS","Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS","Malignant lymphoma, large cell, NOS","Malignant lymphoma, large cell, cleaved, diffuse","Malignant lymphoma, large cell, noncleaved, NOS","Malignant lymphoma, large cell, noncleaved, diffuse","Malignant lymphoma, noncleaved, NOS"],"term_type":""},{"nm":"9684/3","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS","Immunoblastic sarcoma","Malignant lymphoma, immunoblastic, NOS","Malignant lymphoma, large cell, immunoblastic"],"term_type":""},{"nm":"9687/3","n_c":["C6917","C2912"],"i_c":"9687/3","i_c_s":["Burkitt lymphoma, NOS","Burkitt-like lymphoma","Burkitt tumor","Malignant lymphoma, small noncleaved, Burkitt type","Malignant lymphoma, undifferentiated, Burkitt type"],"term_type":""},{"nm":"9688/3","n_c":["C9496"],"i_c":"9688/3","i_c_s":["T-cell/histiocyte rich large B-cell lymphoma"],"term_type":""},{"nm":"9689/3","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic marginal zone B-cell lymphoma","Splenic lymphoma with villous lymphocytes","Splenic marginal zone lymphoma, NOS"],"term_type":""},{"nm":"9690/3","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Follicular lymphoma, NOS","Malignant lymphoma, centroblastic- centrocytic, follicular","Malignant lymphoma, lymphocytic, nodular, NOS","Malignant lymphoma, nodular, NOS","Malignant lymphoma, follicle center, NOS","Malignant lymphoma, follicle center, follicular","Malignant lymphoma, follicular, NOS"],"term_type":""},{"nm":"9691/3","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Follicular lymphoma, grade 2","Malignant lymphoma, mixed cell type, follicular","Malignant lymphoma, mixed cell type, nodular","Malignant lymphoma, mixed lymphocytic-histiocytic, nodular","Malignant lymphoma, mixed small cleaved and large cell, follicular"],"term_type":""},{"nm":"9695/3","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Follicular lymphoma, grade 1","Malignant lymphoma, lymphocytic, poorly differentiated, nodular","Malignant lymphoma, small cleaved cell, follicular","Follicular lymphoma, small cleaved cell"],"term_type":""},{"nm":"9698/3","n_c":["C3460","C7192","C7191","C8994"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3","Malignant lymphoma, histiocytic, nodular","Malignant lymphoma, large cell, noncleaved, follicular","Malignant lymphoma, large cleaved cell, follicular","Malignant lymphoma, lymphocytic, well differentiated, nodular","Malignant lymphoma, noncleaved cell, follicular, NOS","Follicular lymphoma, grade 3A","Follicular lymphoma, grade 3B","Malignant lymphoma, centroblastic, follicular","Malignant lymphoma, large cell, follicular, NOS"],"term_type":""},{"nm":"9699/3","n_c":["C7230","C8863","C4341","C5264","C3898"],"i_c":"9699/3","i_c_s":["Marginal zone B-cell lymphoma, NOS","Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue","BALT lymphoma","Bronchial-associated lymphoid tissue lymphoma","MALT lymphoma","Marginal zone lymphoma, NOS","Monocytoid B-cell lymphoma","Mucosal-associated lymphoid tissue lymphoma","Nodal marginal zone lymphoma","SALT lymphoma","Skin-associated lymphoid tissue lymphoma"],"term_type":""},{"nm":"9700/3","n_c":["C3246","C35794"],"i_c":"9700/3","i_c_s":["Mycosis fungoides","Pagetoid reticulosis"],"term_type":""},{"nm":"9701/3","n_c":["C3366"],"i_c":"9701/3","i_c_s":["Sezary syndrome","Sezary disease"],"term_type":""},{"nm":"9702/3","n_c":["C27352","C37194","C4340","C3466","C7205","C7204"],"i_c":"9702/3","i_c_s":["Mature T-cell lymphoma, NOS","Anaplastic large cell lymphoma, ALK negative","Lymphoepithelioid lymphoma","Lennert lymphoma","Peripheral T-cell lymphoma, NOS","Peripheral T-cell lymphoma, large cell","Peripheral T-cell lymphoma, pleomorphic medium and large cell","Peripheral T-cell lymphoma, pleomorphic small cell","T-cell lymphoma, NOS","T-zone lymphoma"],"term_type":""},{"nm":"9705/3","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Angioimmunoblastic T-cell lymphoma","Angioimmunoblastic lymphoma","Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)"],"term_type":""},{"nm":"9708/3","n_c":["C6918"],"i_c":"9708/3","i_c_s":["Subcutaneous panniculitis-like T-cell lymphoma"],"term_type":""},{"nm":"9709/3","n_c":["C7162","C3467","C45366"],"i_c":"9709/3","i_c_s":["Cutaneous T-cell lymphoma, NOS","Primary cutaneous CD4-positive small/medium T-cell lymphoma","Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma","Cutaneous lymphoma, NOS"],"term_type":""},{"nm":"9712/3","n_c":["C4342"],"i_c":"9712/3","i_c_s":["Intravascular large B-cell lymphoma"],"term_type":""},{"nm":"9714/3","n_c":["C37193","C3720"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, T cell and Null cell type","Anaplastic large cell lymphoma, ALK positive","Anaplastic large cell lymphoma, NOS","Large cell (Ki-1+) lymphoma","Anaplastic large cell lymphoma, CD30+"],"term_type":""},{"nm":"9716/3","n_c":["C8459"],"i_c":"9716/3","i_c_s":["Hepatosplenic T-cell lymphoma","Hepatosplenic gamma-delta cell lymphoma"],"term_type":""},{"nm":"9717/3","n_c":["C150495","C4737"],"i_c":"9717/3","i_c_s":["Intestinal T-cell lymphoma","Enteropathy associated T-cell lymphoma","Enteropathy type intestinal T-cell lymphoma"],"term_type":""},{"nm":"9718/3","n_c":["C3721","C6860","C7195"],"i_c":"9718/3","i_c_s":["Primary cutaneous CD30+ T-cell lymphoproliferative disorder","Lymphomatoid papulosis","Primary cutaneous CD30+ large T-cell lymphoma","Primary cutaneous anaplastic large cell lymphoma"],"term_type":""},{"nm":"9719/3","n_c":["C68692","C4684"],"i_c":"9719/3","i_c_s":["NK/T-cell lymphoma, nasal and nasal-type","Angiocentric T-cell lymphoma","Malignant midline reticulosis","Malignant reticulosis, NOS","Polymorphic reticulosis","Extranodal NK/T-cell lymphoma, nasal type","T/NK-cell lymphoma"],"term_type":""},{"nm":"9724/3","n_c":["C80374"],"i_c":"9724/3","i_c_s":["Systemic EBV positive T-cell lymphoproliferative disease of childhood"],"term_type":""},{"nm":"9725/3","n_c":["C45327"],"i_c":"9725/3","i_c_s":["Hydroa vacciniforme-like lymphoma"],"term_type":""},{"nm":"9726/3","n_c":["C45340"],"i_c":"9726/3","i_c_s":["Primary cutaneous gamma-delta T-cell lymphoma"],"term_type":""},{"nm":"9727/3","n_c":["C27821","C7203","C9360"],"i_c":"9727/3","i_c_s":["Precursor cell lymphoblastic lymphoma, NOS","Blastic NK cell lymphoma","Blastic plasmacytoid dendritic cell neoplasm","Lymphoblastoma","Malignant lymphoma, convoluted cell","Malignant lymphoma, lymphoblastic, NOS"],"term_type":""},{"nm":"9728/3","n_c":["C8868"],"i_c":"9728/3","i_c_s":["Precursor B-cell lymphoblastic lymphoma"],"term_type":""},{"nm":"9729/3","n_c":["C6919"],"i_c":"9729/3","i_c_s":["Precursor T-cell lymphoblastic lymphoma"],"term_type":""},{"nm":"9731/3","n_c":["C6932","C7812","C9349","C4665"],"i_c":"9731/3","i_c_s":["Plasmacytoma, NOS","Plasma cell tumor","Plasmacytoma of bone","Solitary myeloma","Solitary plasmacytoma"],"term_type":""},{"nm":"9732/3","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Multiple myeloma","Myeloma, NOS","Myelomatosis","Plasma cell myeloma"],"term_type":""},{"nm":"9733/3","n_c":["C3180"],"i_c":"9733/3","i_c_s":["Plasma cell leukemia","Plasmacytic leukemia"],"term_type":""},{"nm":"9734/3","n_c":["C4002"],"i_c":"9734/3","i_c_s":["Plasmacytoma, extramedullary","Extraosseous plasmacytoma"],"term_type":""},{"nm":"9735/3","n_c":["C7224"],"i_c":"9735/3","i_c_s":["Plasmablastic lymphoma"],"term_type":""},{"nm":"9737/3","n_c":["C7225"],"i_c":"9737/3","i_c_s":["ALK positive large B-cell lymphoma"],"term_type":""},{"nm":"9738/3","n_c":["C27856"],"i_c":"9738/3","i_c_s":["Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease"],"term_type":""},{"nm":"9740/1","n_c":["C7138","C7137","C9303","C7136","C3218","C3433","C9295"],"i_c":"9740/1","i_c_s":["Mastocytoma, NOS","Cutaneous mastocytosis","Diffuse cutaneous mastocytosis","Urticaria pigmentosa","Extracutaneous mastocytoma","Mast cell tumor, NOS","Solitary mastocytoma of skin"],"term_type":""},{"nm":"9740/3","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Mast cell sarcoma","Malignant mast cell tumor","Malignant mastocytoma"],"term_type":""},{"nm":"9741/1","n_c":["C9286"],"i_c":"9741/1","i_c_s":["Indolent systemic mastocytosis"],"term_type":""},{"nm":"9741/3","n_c":["C9284","C9235","C9285","C8991"],"i_c":"9741/3","i_c_s":["Malignant mastocytosis","Aggressive systemic mastocytosis","Systemic mastocytosis with AHNMD","Systemic mastocytosis with associated hematological clonal non-mast cell disorder","Systemic tissue mast cell disease"],"term_type":""},{"nm":"9742/3","n_c":["C3169"],"i_c":"9742/3","i_c_s":["Mast cell leukemia"],"term_type":""},{"nm":"9750/3","n_c":["C7202"],"i_c":"9750/3","i_c_s":["Malignant histiocytosis","Histiocytic medullary reticulosis"],"term_type":""},{"nm":"9751/1","n_c":["C3107"],"i_c":"9751/1","i_c_s":["Langerhans cell histiocytosis, NOS"],"term_type":""},{"nm":"9751/3","n_c":["C3016","C3160","C6920","C3107"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, NOS","Acute progressive histiocytosis X","Hand-Schuller-Christian disease","Histiocytosis X, NOS","Langerhans cell histiocytosis, disseminated","Langerhans cell histiocytosis, generalized","Langerhans cell histiocytosis, mono-ostotic","Langerhans cell histiocytosis, multifocal","Langerhans cell histiocytosis, poly-ostotic","Langerhans cell histiocytosis, unifocal","Letterer-Siwe disease","Nonlipid reticuloendotheliosis","Eosinophilic granuloma","Langerhans cell granulomatosis, unifocal","Langerhans cell granulomatosis"],"term_type":""},{"nm":"9752/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9753/1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9754/3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"9755/3","n_c":["C27349"],"i_c":"9755/3","i_c_s":["Histiocytic sarcoma","True histiocytic lymphoma"],"term_type":""},{"nm":"9756/3","n_c":["C6921"],"i_c":"9756/3","i_c_s":["Langerhans cell sarcoma"],"term_type":""},{"nm":"9757/3","n_c":["C9282","C81767"],"i_c":"9757/3","i_c_s":["Interdigitating dendritic cell sarcoma","Dendritic cell sarcoma, NOS","Indeterminate dendritic cell tumor","Interdigitating cell sarcoma"],"term_type":""},{"nm":"9758/3","n_c":["C9281"],"i_c":"9758/3","i_c_s":["Follicular dendritic cell sarcoma","Follicular dendritic cell tumor"],"term_type":""},{"nm":"9759/3","n_c":["C81758"],"i_c":"9759/3","i_c_s":["Fibroblastic reticular cell tumor"],"term_type":""},{"nm":"9760/3","n_c":["C3132"],"i_c":"9760/3","i_c_s":["Immunoproliferative disease, NOS"],"term_type":""},{"nm":"9761/3","n_c":["C80307"],"i_c":"9761/3","i_c_s":["Waldenstrom macroglobulinemia"],"term_type":""},{"nm":"9762/3","n_c":["C3892","C3083","C3132","C3082"],"i_c":"9762/3","i_c_s":["Heavy chain disease, NOS","Alpha heavy chain disease","Gamma heavy chain disease","Mu heavy chain disease","Franklin disease"],"term_type":""},{"nm":"9764/3","n_c":["C3132"],"i_c":"9764/3","i_c_s":["Immunoproliferative small intestinal disease","Mediterranean lymphoma"],"term_type":""},{"nm":"9765/1","n_c":["C3996"],"i_c":"9765/1","i_c_s":["Monoclonal gammopathy of undetermined significance","MGUS","Monoclonal gammopathy, NOS"],"term_type":""},{"nm":"9766/1","n_c":["C40970","C7930"],"i_c":"9766/1","i_c_s":["Angiocentric immunoproliferative lesion","Lymphomatoid granulomatosis"],"term_type":""},{"nm":"9767/1","n_c":["C7528"],"i_c":"9767/1","i_c_s":["Angioimmunoblastic lymphadenopathy (AIC)","Immunoblastic lymphadenopathy (IBL)"],"term_type":""},{"nm":"9768/1","n_c":["C4664"],"i_c":"9768/1","i_c_s":["T-gamma lymphoproliferative disease"],"term_type":""},{"nm":"9769/1","n_c":["C7727","C7151","C3819"],"i_c":"9769/1","i_c_s":["Immunoglobulin deposition disease","Primary amyloidosis","Systemic light chain disease"],"term_type":""},{"nm":"9800/3","n_c":["C4982","C3483","C3161"],"i_c":"9800/3","i_c_s":["Leukemia, NOS","Aleukemic leukemia, NOS","Chronic leukemia, NOS","Subacute leukemia, NOS"],"term_type":""},{"nm":"9801/3","n_c":["C9300"],"i_c":"9801/3","i_c_s":["Acute leukemia, NOS","Blast cell leukemia","Stem cell leukemia","Undifferentiated leukemia"],"term_type":""},{"nm":"9805/3","n_c":["C4673","C6923"],"i_c":"9805/3","i_c_s":["Acute biphenotypic leukemia","Acute bilineal leukemia","Acute mixed lineage leukemia"],"term_type":""},{"nm":"9806/3","n_c":["C82192"],"i_c":"9806/3","i_c_s":["Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":""},{"nm":"9807/3","n_c":["C82203"],"i_c":"9807/3","i_c_s":["Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged"],"term_type":""},{"nm":"9808/3","n_c":["C82212"],"i_c":"9808/3","i_c_s":["Mixed phenotype acute leukemia, B/myeloid, NOS"],"term_type":""},{"nm":"9809/3","n_c":["C82213"],"i_c":"9809/3","i_c_s":["Mixed phenotype acute leukemia, T/myeloid, NOS"],"term_type":""},{"nm":"9811/3","n_c":["C80326"],"i_c":"9811/3","i_c_s":["B lymphoblastic leukemia/lymphoma, NOS"],"term_type":""},{"nm":"9812/3","n_c":["C80331"],"i_c":"9812/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":""},{"nm":"9813/3","n_c":["C80332"],"i_c":"9813/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged"],"term_type":""},{"nm":"9814/3","n_c":["C80334"],"i_c":"9814/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)"],"term_type":""},{"nm":"9815/3","n_c":["C80335"],"i_c":"9815/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hyperdiploidy"],"term_type":""},{"nm":"9816/3","n_c":["C80344","C80338"],"i_c":"9816/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)"],"term_type":""},{"nm":"9817/3","n_c":["C80340"],"i_c":"9817/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH"],"term_type":""},{"nm":"9818/3","n_c":["C80341"],"i_c":"9818/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)"],"term_type":""},{"nm":"9820/3","n_c":["C7176","C4343","C7539"],"i_c":"9820/3","i_c_s":["Lymphoid leukemia, NOS","Aleukemic lymphoid leukemia","Lymphatic leukemia, NOS","Lymphocytic leukemia, NOS","Lymphosarcoma cell leukemia","Subacute lymphoid leukemia","Aleukemic lymphatic leukemia","Aleukemic lymphocytic leukemia","Subacute lymphatic leukemia","Subacute lymphocytic leukemia"],"term_type":""},{"nm":"9823/3","n_c":["C27911","C3163"],"i_c":"9823/3","i_c_s":["B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma","Chronic lymphatic leukemia","Chronic lymphocytic leukemia, B-cell type","Chronic lymphocytic leukemia","Chronic lymphoid leukemia"],"term_type":""},{"nm":"9826/3","n_c":["C7400","C8644"],"i_c":"9826/3","i_c_s":["Burkitt cell leukemia","Acute leukemia, Burkitt type","B-ALL","FAB L3","Acute lymphoblastic leukemia, mature B-cell type"],"term_type":""},{"nm":"9827/3","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell leukemia/lymphoma (HTLV-1 positive)","Adult T-cell leukemia","Adult T-cell lymphoma/leukemia","Adult T-cell lymphoma"],"term_type":""},{"nm":"9831/3","n_c":["C4664","C39591"],"i_c":"9831/3","i_c_s":["T-cell large granular lymphocytic leukemia","Chronic lymphoproliferative disorder of NK cells","Large granular lymphocytosis, NOS","NK-cell large granular lymphocytic leukemia","T-cell large granular lymphocytosis"],"term_type":""},{"nm":"9832/3","n_c":["C3181"],"i_c":"9832/3","i_c_s":["Prolymphocytic leukemia, NOS"],"term_type":""},{"nm":"9833/3","n_c":["C4753"],"i_c":"9833/3","i_c_s":["Prolymphocytic leukemia, B-cell type"],"term_type":""},{"nm":"9834/3","n_c":["C4752"],"i_c":"9834/3","i_c_s":["Prolymphocytic leukemia, T-cell type"],"term_type":""},{"nm":"9835/3","n_c":["C27290","C27281","C3167"],"i_c":"9835/3","i_c_s":["Precursor cell lymphoblastic leukemia, NOS","FAB L1","Acute lymphatic leukemia","Acute lymphoblastic leukemia, L2 type, NOS","Acute lymphoblastic leukemia, NOS","Acute lymphoblastic leukemia, precursor-cell type","Acute lymphoblastic leukemia-lymphoma, NOS","Acute lymphocytic leukemia","Acute lymphoid leukemia","FAB L2","Lymphoblastic leukemia, NOS","Precursor cell lymphoblastic leukemia, not phenotyped"],"term_type":""},{"nm":"9836/3","n_c":["C27797","C27799","C27798","C8644"],"i_c":"9836/3","i_c_s":["Precursor B-cell lymphoblastic leukemia","Common ALL","Common precursor B ALL","Pre-B ALL","Pre-pre-B ALL","Pro-B ALL","c-ALL"],"term_type":""},{"nm":"9837/3","n_c":["C27820","C27261","C8694","C3183"],"i_c":"9837/3","i_c_s":["Precursor T-cell lymphoblastic leukemia","T lymphoblastic leukemia/lymphoma","Cortical T ALL","Mature T ALL","Pre-T ALL","Pro-T ALL"],"term_type":""},{"nm":"9840/3","n_c":["C7467","C8923"],"i_c":"9840/3","i_c_s":["Acute myeloid leukemia, M6 type","Acute erythremia","Acute erythremic myelosis","Di Guglielmo disease","AML M6","Acute erythroid leukemia","Erythremic myelosis, NOS","Erythroleukemia","FAB M6","M6A","M6B"],"term_type":""},{"nm":"9860/3","n_c":["C34774","C3519","C4563","C4861","C3172"],"i_c":"9860/3","i_c_s":["Myeloid leukemia, NOS","Aleukemic monocytic leukemia","Aleukemic myeloid leukemia","Chronic monocytic leukemia","Subacute monocytic leukemia","Subacute myeloid leukemia","Eosinophilic leukemia","Monocytic leukemia, NOS","Aleukemic granulocytic leukemia","Aleukemic myelogenous leukemia","Subacute granulocytic leukemia","Subacute myelogenous leukemia","Granulocytic leukemia, NOS","Myelocytic leukemia, NOS","Myelogenous leukemia, NOS","Myelomonocytic leukemia, NOS","Non-lymphocytic leukemia, NOS"],"term_type":""},{"nm":"9861/3","n_c":["C27753","C82433","C82431","C3171"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia, NOS","Acute myeloid leukemia with mutated CEBPA","Acute myeloid leukemia with mutated NPM1","Acute granulocytic leukemia","Acute myelocytic leukemia","Acute myelogenous leukemia","Acute non-lymphocytic leukemia"],"term_type":""},{"nm":"9863/3","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic myeloid leukemia, NOS","Chronic granulocytic leukemia, NOS","Chronic myelocytic leukemia, NOS","Chronic myelogenous leukemia, NOS"],"term_type":""},{"nm":"9865/3","n_c":["C82423"],"i_c":"9865/3","i_c_s":["Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214"],"term_type":""},{"nm":"9866/3","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukemia, t(15;17)(q22;q11-12)","Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)","Acute myeloid leukemia, PML/RAR-alpha","Acute myeloid leukemia, t(15;17)(q22;q11-12)","Acute promyelocytic leukemia, NOS","Acute promyelocytic leukemia, PML/RAR-alpha","FAB M3"],"term_type":""},{"nm":"9867/3","n_c":["C7463"],"i_c":"9867/3","i_c_s":["Acute myelomonocytic leukemia","FAB M4"],"term_type":""},{"nm":"9869/3","n_c":["C82426"],"i_c":"9869/3","i_c_s":["Acute myeloid leukemia with inv(3)(q21;q26.2) or t(13.3)(q21;q26.2); RPN1-EVI1"],"term_type":""},{"nm":"9870/3","n_c":["C3164"],"i_c":"9870/3","i_c_s":["Acute basophilic leukemia"],"term_type":""},{"nm":"9871/3","n_c":["C9020","C9287"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia with abnormal marrow eosinophils","Acute myeloid leukemia, CBF-beta/MYH11","Acute myeloid leukemia, inv(16)(p13;q22)","Acute myeloid leukemia, t(16;16)(p13;q11)","Acute myelomonocytic leukemia with abnormal eosinophils","FAB M4Eo"],"term_type":""},{"nm":"9872/3","n_c":["C8460","C3171"],"i_c":"9872/3","i_c_s":["Acute myeloid leukemia, minimal differentiation","Acute myeloblastic leukemia","FAB M0"],"term_type":""},{"nm":"9873/3","n_c":["C3249"],"i_c":"9873/3","i_c_s":["Acute myeloid leukemia without maturation","FAB M1"],"term_type":""},{"nm":"9874/3","n_c":["C3250"],"i_c":"9874/3","i_c_s":["Acute myeloid leukemia with maturation","FAB M2, NOS"],"term_type":""},{"nm":"9875/3","n_c":["C9128","C3174"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, BCR/ABL positive","Chronic granulocytic leukemia, BCR/ABL","Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive","Chronic granulocytic leukemia, t(9;22)(q34;q11)","Chronic myelogenous leukemia, Philadelphia chromosome (Ph1) positive","Chronic myelogenous leukemia, t(9;22)(q34;11)"],"term_type":""},{"nm":"9876/3","n_c":["C3519"],"i_c":"9876/3","i_c_s":["Atypical chronic myeloid leukemia, BCR/ABL negative","Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative"],"term_type":""},{"nm":"9891/3","n_c":["C7318","C4861","C7171"],"i_c":"9891/3","i_c_s":["Acute monocytic leukemia","Acute monoblastic and monocytic leukemia","Acute monoblastic leukemia","FAB M5","Monoblastic leukemia, NOS"],"term_type":""},{"nm":"9895/3","n_c":["C9289","C4037","C7600"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with myelodysplasia-related changes","Acute myeloid leukemia with multilineage dysplasia","Acute myeloid leukemia with prior myelodysplastic syndrome","Acute myeloid leukemia without prior myelodysplastic syndrome"],"term_type":""},{"nm":"9896/3","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukemia, t(8;21)(q22;q22)","Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","Acute myeloid leukemia, AML1(CBF-alpha)/ETO","FAB M2, AML1(CBF-alpha)/ETO","FAB M2, t(8;21)(q22;q22)"],"term_type":""},{"nm":"9897/3","n_c":["C174129"],"i_c":"9897/3","i_c_s":["Acute myeloid leukemia, 11q23 abnormalities","Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL","Acute myeloid leukemia, MLL"],"term_type":""},{"nm":"9898/1","n_c":["C82339"],"i_c":"9898/1","i_c_s":["Transient abnormal myelopoiesis"],"term_type":""},{"nm":"9898/3","n_c":["C43223"],"i_c":"9898/3","i_c_s":["Myeloid leukemia associated with Down Syndrome"],"term_type":""},{"nm":"9910/3","n_c":["C3170"],"i_c":"9910/3","i_c_s":["Acute megakaryoblastic leukemia","FAB M7","Megakaryocytic leukemia"],"term_type":""},{"nm":"9911/3","n_c":["C82427"],"i_c":"9911/3","i_c_s":["Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1"],"term_type":""},{"nm":"9920/3","n_c":["C27754","C27912","C8252"],"i_c":"9920/3","i_c_s":["Therapy related myeloid neoplasm","Therapy-related acute myeloid leukemia, alkylating agent related","Therapy-related acute myeloid leukemia, epipodophyllotoxin-related","Therapy-related acute myeloid leukemia, NOS"],"term_type":""},{"nm":"9930/3","n_c":["C3520","C35815"],"i_c":"9930/3","i_c_s":["Myeloid sarcoma","Chloroma","Granulocytic sarcoma"],"term_type":""},{"nm":"9931/3","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute panmyelosis with myelofibrosis","Malignant myelosclerosis","Acute myelofibrosis","Acute myelosclerosis, NOS","Acute panmyelosis, NOS"],"term_type":""},{"nm":"9940/3","n_c":["C7402","C7401"],"i_c":"9940/3","i_c_s":["Hairy cell leukemia","Hairy cell leukemia variant","Leukemic reticuloendotheliosis"],"term_type":""},{"nm":"9945/3","n_c":["C3178"],"i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, NOS","Chronic myelomonocytic leukemia, Type II","Chronic myelomonocytic leukemia, Type I","Chronic myelomonocytic leukemia in transformation"],"term_type":""},{"nm":"9946/3","n_c":["C9233"],"i_c":"9946/3","i_c_s":["Juvenile myelomonocytic leukemia","Juvenile chronic myelomonocytic leukemia"],"term_type":""},{"nm":"9948/3","n_c":["C8647"],"i_c":"9948/3","i_c_s":["Aggressive NK-cell leukemia"],"term_type":""},{"nm":"9950/3","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Polycythemia vera","Chronic erythremia","Polycythemia rubra vera","Proliferative polycythemia"],"term_type":""},{"nm":"9960/3","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Myeloproliferative neoplasm, NOS","Chronic myeloproliferative disease, NOS","Chronic myeloproliferative disorder","Myeloproliferative disease, NOS"],"term_type":""},{"nm":"9961/3","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Primary myelofibrosis","Agnogenic myeloid metaplasia","Chronic idiopathic myelofibrosis","Megakaryocytic myelosclerosis","Myelofibrosis as a result of myeloproliferative disease","Myelofibrosis with myeloid metaplasia","Myelosclerosis with myeloid metaplasia"],"term_type":""},{"nm":"9962/3","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Essential thrombocythemia","Essential hemorrhagic thrombocythemia","Idiopathic hemorrhagic thrombocythemia","Idiopathic thrombocythemia"],"term_type":""},{"nm":"9963/3","n_c":["C3179"],"i_c":"9963/3","i_c_s":["Chronic neutrophilic leukemia"],"term_type":""},{"nm":"9964/3","n_c":["C4563","C27038"],"i_c":"9964/3","i_c_s":["Chronic eosinophilic leukemia, NOS","Hypereosinophilic syndrome"],"term_type":""},{"nm":"9965/3","n_c":["C84275"],"i_c":"9965/3","i_c_s":["Myeloid and lymphoid neoplasms with PDGFRA rearrangement"],"term_type":""},{"nm":"9966/3","n_c":["C84276"],"i_c":"9966/3","i_c_s":["Myeloid neoplasms with PDGFRB rearrangement"],"term_type":""},{"nm":"9967/3","n_c":["C84277"],"i_c":"9967/3","i_c_s":["Myeloid and lymphoid neoplasms with FGFR1 abnormalities"],"term_type":""},{"nm":"9970/1","n_c":["C9308"],"i_c":"9970/1","i_c_s":["Lymphoproliferative disorder, NOS","Lymphoproliferative disease, NOS"],"term_type":""},{"nm":"9971/1","n_c":["C4727"],"i_c":"9971/1","i_c_s":["Post transplant lymphoproliferative disorder, NOS","PTLD, NOS"],"term_type":""},{"nm":"9971/3","n_c":["C7183"],"i_c":"9971/3","i_c_s":["Polymorphic post transplant lymphoproliferative disorder"],"term_type":""},{"nm":"9975/3","n_c":["C27350"],"i_c":"9975/3","i_c_s":["Myloproliferative neoplasm, unclassifiable","Myelodysplastic/myeloproliferative neoplasm, unclassifiable"],"term_type":""},{"nm":"9980/3","n_c":["C2872"],"i_c":"9980/3","i_c_s":["Refractory anemia","Refractory anemia without sideroblasts"],"term_type":""},{"nm":"9982/3","n_c":["C4036","C82616"],"i_c":"9982/3","i_c_s":["Refractory anemia with sideroblasts","RARS","Refractory anemia with ring sideroblasts associated with marked thrombocytosis","Refractory anemia with ringed sideroblasts"],"term_type":""},{"nm":"9983/3","n_c":["C7506"],"i_c":"9983/3","i_c_s":["Refractory anemia with excess blasts","RAEB II","RAEB I","RAEB"],"term_type":""},{"nm":"9984/3","n_c":["C27080"],"i_c":"9984/3","i_c_s":["Refractory anemia with excess blasts in transformation","RAEB-T"],"term_type":""},{"nm":"9985/3","n_c":["C8574","C82596"],"i_c":"9985/3","i_c_s":["Refractory cytopenia with multilineage dysplasia","Refractory cytopenia of childhood"],"term_type":""},{"nm":"9986/3","n_c":["C6867"],"i_c":"9986/3","i_c_s":["Myelodysplastic syndrome with 5q deletion (5q-) syndrome","Myelodysplastic syndrome with isolated del (5q)"],"term_type":""},{"nm":"9987/3","n_c":["C7643","C7642","C27722"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, NOS","Therapy-related myelodysplastic syndrome, alkylating agent related","Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related"],"term_type":""},{"nm":"9989/3","n_c":["C198589"],"i_c":"9989/3","i_c_s":["Myelodysplastic syndrome, NOS","Preleukemia","Preleukemic syndrome","Myelodysplastic syndrome, unclassifiable"],"term_type":""},{"nm":"9991/3","n_c":["C82593"],"i_c":"9991/3","i_c_s":["Refractory neutropenia"],"term_type":""},{"nm":"9992/3","n_c":["C82594"],"i_c":"9992/3","i_c_s":["Refractory thrombocytopenia"],"term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ovarian_specimen_status":[{"nm":"Ovarian Capsule Intact","n_c":["C164042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Capsule Ruptured","n_c":["C164044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Capsule Fragmented","n_c":["C164045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ovarian_surface_involvement":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.perineural_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.peripancreatic_lymph_nodes_positive":[{"nm":"0","n_c":["C70430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1-3","n_c":["C172224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4 or More","n_c":["C172226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.peritoneal_fluid_cytological_status":[{"nm":"Atypical","n_c":["C8326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malignant","n_c":["C14143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Malignant","n_c":["C25588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unsatisfactory","n_c":["C126862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.pregnant_at_diagnosis":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.primary_diagnosis":[{"nm":"Abdominal desmoid","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Abdominal desmoid"],"term_type":"SY"},{"nm":"Abdominal fibromatosis","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Abdominal fibromatosis"],"term_type":"PT"},{"nm":"Achromic nevus","n_c":["C27095"],"i_c":"8730/0","i_c_s":["Achromic nevus"],"term_type":"SY"},{"nm":"Acidophil adenocarcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Acidophil adenocarcinoma"],"term_type":"SY"},{"nm":"Acidophil adenoma","n_c":["C6780"],"i_c":"8280/0","i_c_s":["Acidophil adenoma"],"term_type":"PT"},{"nm":"Acidophil carcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Acidophil carcinoma"],"term_type":"PT"},{"nm":"Acinar adenocarcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar adenocarcinoma"],"term_type":"SY"},{"nm":"Acinar adenocarcinoma, sarcomatoid","n_c":["C5530"],"i_c":"8572/3","i_c_s":["Acinar adenocarcinoma, sarcomatoid"],"term_type":""},{"nm":"Acinar adenoma","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinar adenoma"],"term_type":"SY"},{"nm":"Acinar carcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar carcinoma"],"term_type":"SY"},{"nm":"Acinar cell adenoma","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinar cell adenoma"],"term_type":"PT"},{"nm":"Acinar cell carcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinar cell carcinoma"],"term_type":"PT"},{"nm":"Acinar cell cystadenocarcinoma","n_c":["C5727"],"i_c":"8551/3","i_c_s":["Acinar cell cystadenocarcinoma"],"term_type":"PT"},{"nm":"Acinar cell tumor","n_c":["C4197"],"i_c":"8550/1","i_c_s":["Acinar cell tumor"],"term_type":"OP"},{"nm":"Acinic cell adenocarcinoma","n_c":["C3768"],"i_c":"8550/3","i_c_s":["Acinic cell adenocarcinoma"],"term_type":"SY"},{"nm":"Acinic cell adenoma","n_c":["C4196"],"i_c":"8550/0","i_c_s":["Acinic cell adenoma"],"term_type":"SY"},{"nm":"Acinic cell tumor","n_c":["C4197"],"i_c":"8550/1","i_c_s":["Acinic cell tumor"],"term_type":"IS"},{"nm":"Acoustic neuroma","n_c":["C3276"],"i_c":"9560/0","i_c_s":["Acoustic neuroma"],"term_type":"RT"},{"nm":"Acquired cystic disease-associated renal cell carcinoma (RCC)","n_c":["C157718"],"i_c":"8316/3","i_c_s":["Acquired cystic disease-associated renal cell carcinoma (RCC)"],"term_type":""},{"nm":"Acquired tufted hemangioma","n_c":["C4487"],"i_c":"9161/0","i_c_s":["Acquired tufted hemangioma"],"term_type":"PT"},{"nm":"Acral lentiginous melanoma, malignant","n_c":["C4022"],"i_c":"8744/3","i_c_s":["Acral lentiginous melanoma, malignant"],"term_type":"PT"},{"nm":"ACTH-producing tumor","n_c":"","i_c":"8158/1","i_c_s":["ACTH-producing tumor"],"term_type":"RT"},{"nm":"Acute basophilic leukaemia","n_c":["C3164"],"i_c":"9870/3","i_c_s":["Acute basophilic leukaemia"],"term_type":""},{"nm":"Acute bilineal leukemia","n_c":["C6923"],"i_c":"9805/3","i_c_s":["Acute bilineal leukemia"],"term_type":"RT"},{"nm":"Acute biphenotypic leukemia","n_c":["C4673"],"i_c":"9805/3","i_c_s":["Acute biphenotypic leukemia"],"term_type":"PT"},{"nm":"Acute erythremia","n_c":["C8923"],"i_c":"9840/3","i_c_s":["Acute erythremia"],"term_type":"IS"},{"nm":"Acute erythremic myelosis","n_c":["C7467"],"i_c":"9840/3","i_c_s":["Acute erythremic myelosis"],"term_type":"IS"},{"nm":"Acute erythroid leukaemia","n_c":["C8923"],"i_c":"9840/3","i_c_s":["Acute erythroid leukaemia"],"term_type":""},{"nm":"Acute granulocytic leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute granulocytic leukemia"],"term_type":"SY"},{"nm":"Acute leukemia, Burkitt type","n_c":["C7400"],"i_c":"9826/3","i_c_s":["Acute leukemia, Burkitt type"],"term_type":"IS"},{"nm":"Acute leukemia, NOS","n_c":["C9298"],"i_c":"9801/3","i_c_s":["Acute leukemia, NOS"],"term_type":"PT"},{"nm":"Acute lymphatic leukemia","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphatic leukemia"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia-lymphoma, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia-lymphoma, NOS"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, L2 type, NOS","n_c":["C27281"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia, L2 type, NOS"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, mature B-cell type","n_c":["C7400"],"i_c":"9826/3","i_c_s":["Acute lymphoblastic leukemia, mature B-cell type"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia, NOS"],"term_type":"SY"},{"nm":"Acute lymphoblastic leukemia, precursor cell type","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoblastic leukemia, precursor cell type"],"term_type":""},{"nm":"Acute lymphocytic leukemia","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphocytic leukemia"],"term_type":"SY"},{"nm":"Acute lymphoid leukemia","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Acute lymphoid leukemia"],"term_type":"SY"},{"nm":"Acute megakaryoblastic leukaemia","n_c":["C3170"],"i_c":"9910/3","i_c_s":["Acute megakaryoblastic leukaemia"],"term_type":""},{"nm":"Acute mixed lineage leukemia","n_c":["C6923"],"i_c":"9805/3","i_c_s":["Acute mixed lineage leukemia"],"term_type":"RT"},{"nm":"Acute monoblastic and monocytic leukemia","n_c":["C7318"],"i_c":"9891/3","i_c_s":["Acute monoblastic and monocytic leukemia"],"term_type":"RT"},{"nm":"Acute monoblastic leukemia","n_c":["C7171"],"i_c":"9891/3","i_c_s":["Acute monoblastic leukemia"],"term_type":"SY"},{"nm":"Acute monocytic leukemia","n_c":["C4861"],"i_c":"9891/3","i_c_s":["Acute monocytic leukemia"],"term_type":"PT"},{"nm":"Acute myeloblastic leukemia","n_c":["C3171"],"i_c":"9872/3","i_c_s":["Acute myeloblastic leukemia"],"term_type":"SY"},{"nm":"Acute myelocytic leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute myelocytic leukemia"],"term_type":"SY"},{"nm":"Acute myelofibrosis","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute myelofibrosis"],"term_type":"SY"},{"nm":"Acute myelogenous leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute myelogenous leukemia"],"term_type":"SY"},{"nm":"Acute myeloid leukaemia, t(8;21)(q22;q22)","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukaemia, t(8;21)(q22;q22)"],"term_type":""},{"nm":"Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1","n_c":["C82427"],"i_c":"9911/3","i_c_s":["Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)","n_c":["C9287"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)"],"term_type":""},{"nm":"Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1","n_c":["C82426"],"i_c":"9869/3","i_c_s":["Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1"],"term_type":""},{"nm":"Acute myeloid leukemia with maturation","n_c":["C3250"],"i_c":"9874/3","i_c_s":["Acute myeloid leukemia with maturation"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with multilineage dysplasia","n_c":["C9289"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with multilineage dysplasia"],"term_type":"SY"},{"nm":"Acute myeloid leukemia with mutated CEBPA","n_c":["C82433"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia with mutated CEBPA"],"term_type":"RT"},{"nm":"Acute myeloid leukemia with mutated NPM1","n_c":["C82431"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia with mutated NPM1"],"term_type":"RT"},{"nm":"Acute myeloid leukemia with myelodysplasia-related changes","n_c":["C7600"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with myelodysplasia-related changes"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with prior myelodysplastic syndrome","n_c":["C4037"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia with prior myelodysplastic syndrome"],"term_type":"SY"},{"nm":"Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214","n_c":["C82423"],"i_c":"9865/3","i_c_s":["Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214"],"term_type":"PT"},{"nm":"Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1"],"term_type":"SY"},{"nm":"Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL","n_c":["C82403"],"i_c":"9897/3","i_c_s":["Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL"],"term_type":"SY"},{"nm":"Acute myeloid leukemia without maturation","n_c":["C3249"],"i_c":"9873/3","i_c_s":["Acute myeloid leukemia without maturation"],"term_type":"PT"},{"nm":"Acute myeloid leukemia without prior myelodysplastic syndrome","n_c":["C4037"],"i_c":"9895/3","i_c_s":["Acute myeloid leukemia without prior myelodysplastic syndrome"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, AML1(CBF-alpha)/ETO","n_c":["C9288"],"i_c":"9896/3","i_c_s":["Acute myeloid leukemia, AML1(CBF-alpha)/ETO"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, CBF-beta/MYH11","n_c":["C9287"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia, CBF-beta/MYH11"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, inv(16)(p13;q22)","n_c":["C9018"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia, inv(16)(p13;q22)"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, M6 type","n_c":["C8923"],"i_c":"9840/3","i_c_s":["Acute myeloid leukemia, M6 type"],"term_type":"PT"},{"nm":"Acute myeloid leukemia, minimal differentiation","n_c":["C8460"],"i_c":"9872/3","i_c_s":["Acute myeloid leukemia, minimal differentiation"],"term_type":"PT"},{"nm":"Acute myeloid leukemia, MLL","n_c":["C174129"],"i_c":"9897/3","i_c_s":["Acute myeloid leukemia, MLL"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, NOS","n_c":["C27753"],"i_c":"9861/3","i_c_s":["Acute myeloid leukemia, NOS"],"term_type":"PT"},{"nm":"Acute myeloid leukemia, PML/RAR-alpha","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute myeloid leukemia, PML/RAR-alpha"],"term_type":"SY"},{"nm":"Acute myeloid leukemia, t(15:17)(g22;q11-12)","n_c":"","i_c":"9866/3","i_c_s":["Acute myeloid leukemia, t(15:17)(g22;q11-12)"],"term_type":""},{"nm":"Acute myeloid leukemia, t(16;16)(p 13;q 11)","n_c":["C9019"],"i_c":"9871/3","i_c_s":["Acute myeloid leukemia, t(16;16)(p 13;q 11)"],"term_type":""},{"nm":"Acute myelomonocytic leukemia","n_c":["C7463"],"i_c":"9867/3","i_c_s":["Acute myelomonocytic leukemia"],"term_type":"PT"},{"nm":"Acute myelomonocytic leukemia with abnormal eosinophils","n_c":["C9020"],"i_c":"9871/3","i_c_s":["Acute myelomonocytic leukemia with abnormal eosinophils"],"term_type":"SY"},{"nm":"Acute myelosclerosis, NOS","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute myelosclerosis, NOS"],"term_type":"SY"},{"nm":"Acute myloid leukemia, 11q23 abnormalities","n_c":["C174129"],"i_c":"9897/3","i_c_s":["Acute myloid leukemia, 11q23 abnormalities"],"term_type":"PT"},{"nm":"Acute non-lymphocytic leukemia","n_c":["C3171"],"i_c":"9861/3","i_c_s":["Acute non-lymphocytic leukemia"],"term_type":"SY"},{"nm":"Acute panmyelosis with myelofibrosis","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute panmyelosis with myelofibrosis"],"term_type":"PT"},{"nm":"Acute panmyelosis, NOS","n_c":["C4344"],"i_c":"9931/3","i_c_s":["Acute panmyelosis, NOS"],"term_type":"SY"},{"nm":"Acute progressive histiocytosis X","n_c":"","i_c":"9751/3","i_c_s":["Acute progressive histiocytosis X"],"term_type":"ORT"},{"nm":"Acute promyelocytic leukaemia, PML-RAR-alpha","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukaemia, PML-RAR-alpha"],"term_type":""},{"nm":"Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)"],"term_type":""},{"nm":"Acute promyelocytic leukemia, NOS","n_c":["C3182"],"i_c":"9866/3","i_c_s":["Acute promyelocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Adamantinoma of long bones","n_c":["C7644"],"i_c":"9261/3","i_c_s":["Adamantinoma of long bones"],"term_type":"PT"},{"nm":"Adamantinoma, malignant","n_c":["C7644"],"i_c":"9310/3","i_c_s":["Adamantinoma, malignant"],"term_type":"SY"},{"nm":"Adamantinoma, NOS","n_c":["C7644"],"i_c":"9310/0","i_c_s":["Adamantinoma, NOS"],"term_type":"SY"},{"nm":"Adenoacanthoma","n_c":["C4200"],"i_c":"8570/3","i_c_s":["Adenoacanthoma"],"term_type":"SY"},{"nm":"Adenoameloblastoma","n_c":["C4310"],"i_c":"9300/0","i_c_s":["Adenoameloblastoma"],"term_type":"SY"},{"nm":"Adenocarcinoid tumor","n_c":["C201135"],"i_c":"8245/3","i_c_s":["Adenocarcinoid tumor"],"term_type":"PT"},{"nm":"Adenocarcinoma admixed with neuroendocrine carcinoma","n_c":["C127915"],"i_c":"8574/3","i_c_s":["Adenocarcinoma admixed with neuroendocrine carcinoma"],"term_type":""},{"nm":"Adenocarcinoma combined with other types of carcinoma","n_c":["C45508"],"i_c":"8255/3","i_c_s":["Adenocarcinoma combined with other types of carcinoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in a polyp, NOS","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in a polyp, NOS"],"term_type":"SY"},{"nm":"Adenocarcinoma in adenomatous polyp","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in adenomatous polyp"],"term_type":"PT"},{"nm":"Adenocarcinoma in adenomatous polyposis coli","n_c":["C4134"],"i_c":"8220/3","i_c_s":["Adenocarcinoma in adenomatous polyposis coli"],"term_type":"PT"},{"nm":"Adenocarcinoma in multiple adenomatous polyps","n_c":["C4136"],"i_c":"8221/3","i_c_s":["Adenocarcinoma in multiple adenomatous polyps"],"term_type":"PT"},{"nm":"Adenocarcinoma in polypoid adenoma","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in polypoid adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in a polyp, NOS","n_c":["C7680"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in a polyp, NOS"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in adenomatous polyp","n_c":["C7678"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in adenomatous polyp"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ in polypoid adenoma","n_c":["C7678"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in polypoid adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in tubular adenoma","n_c":["C7679"],"i_c":"8210/2","i_c_s":["Adenocarcinoma in situ in tubular adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in situ in tubulovillous adenoma","n_c":["C4144"],"i_c":"8263/2","i_c_s":["Adenocarcinoma in situ in tubulovillous adenoma"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ in villous adenoma","n_c":["C8376"],"i_c":"8261/2","i_c_s":["Adenocarcinoma in situ in villous adenoma"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ, mucinous","n_c":["C136717"],"i_c":"8253/2","i_c_s":["Adenocarcinoma in situ, mucinous"],"term_type":""},{"nm":"Adenocarcinoma in situ, non-mucinous","n_c":["C136716"],"i_c":"8250/2","i_c_s":["Adenocarcinoma in situ, non-mucinous"],"term_type":"PT"},{"nm":"Adenocarcinoma in situ, NOS","n_c":["C4123"],"i_c":"8140/2","i_c_s":["Adenocarcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Adenocarcinoma in tubolovillous adenoma","n_c":["C4145"],"i_c":"8263/3","i_c_s":["Adenocarcinoma in tubolovillous adenoma"],"term_type":""},{"nm":"Adenocarcinoma in tubular adenoma","n_c":["C7677"],"i_c":"8210/3","i_c_s":["Adenocarcinoma in tubular adenoma"],"term_type":"SY"},{"nm":"Adenocarcinoma in villous adenoma","n_c":["C4141"],"i_c":"8261/3","i_c_s":["Adenocarcinoma in villous adenoma"],"term_type":"PT"},{"nm":"Adenocarcinoma of anal ducts","n_c":["C5609"],"i_c":"8215/3","i_c_s":["Adenocarcinoma of anal ducts"],"term_type":"SY"},{"nm":"Adenocarcinoma of anal glands","n_c":["C5609"],"i_c":"8215/3","i_c_s":["Adenocarcinoma of anal glands"],"term_type":"PT"},{"nm":"Adenocarcinoma of rete ovarii","n_c":["C40017"],"i_c":"9110/3","i_c_s":["Adenocarcinoma of rete ovarii"],"term_type":""},{"nm":"Adenocarcinoma with apocrine metaplasia","n_c":["C4202"],"i_c":"8573/3","i_c_s":["Adenocarcinoma with apocrine metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma with cartilaginous and osseous metaplasia","n_c":["C7683"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with cartilaginous and osseous metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma with cartilaginous metaplasia","n_c":["C7685"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with cartilaginous metaplasia"],"term_type":"SY"},{"nm":"Adenocarcinoma with mixed subtypes","n_c":["C45508"],"i_c":"8255/3","i_c_s":["Adenocarcinoma with mixed subtypes"],"term_type":"PT"},{"nm":"Adenocarcinoma with neuroendocrine differentiation","n_c":["C66745"],"i_c":"8574/3","i_c_s":["Adenocarcinoma with neuroendocrine differentiation"],"term_type":"PT"},{"nm":"Adenocarcinoma with osseous metaplasia","n_c":["C7684"],"i_c":"8571/3","i_c_s":["Adenocarcinoma with osseous metaplasia"],"term_type":"SY"},{"nm":"Adenocarcinoma with spindle cell metaplasia","n_c":["C4201"],"i_c":"8572/3","i_c_s":["Adenocarcinoma with spindle cell metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma with squamous metaplasia","n_c":["C4200"],"i_c":"8570/3","i_c_s":["Adenocarcinoma with squamous metaplasia"],"term_type":"PT"},{"nm":"Adenocarcinoma, cribriform comedo-type","n_c":"","i_c":"8201/3","i_c_s":["Adenocarcinoma, cribriform comedo-type"],"term_type":"SY"},{"nm":"Adenocarcinoma, cylindroid","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenocarcinoma, cylindroid"],"term_type":"SY"},{"nm":"Adenocarcinoma, diffuse type","n_c":["C4127"],"i_c":"8145/3","i_c_s":["Adenocarcinoma, diffuse type"],"term_type":"SY"},{"nm":"Adenocarcinoma, endocervical type","n_c":["C66951"],"i_c":"8384/3","i_c_s":["Adenocarcinoma, endocervical type"],"term_type":"PT"},{"nm":"Adenocarcinoma, intestinal type","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Adenocarcinoma, intestinal type"],"term_type":"PT"},{"nm":"Adenocarcinoma, metastatic, NOS","n_c":["C4124"],"i_c":"8140/6","i_c_s":["Adenocarcinoma, metastatic, NOS"],"term_type":"PT"},{"nm":"Adenocarcinoma, NOS","n_c":["C2852"],"i_c":"8140/3","i_c_s":["Adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Adenocarcinoma, pancreatobiliary type","n_c":"","i_c":"8163/3","i_c_s":["Adenocarcinoma, pancreatobiliary type"],"term_type":"SY"},{"nm":"Adenocystic carcinoma","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenocystic carcinoma"],"term_type":"SY"},{"nm":"Adenofibroma, NOS","n_c":["C8984"],"i_c":"9013/0","i_c_s":["Adenofibroma, NOS"],"term_type":"PT"},{"nm":"Adenoid basal carcinoma","n_c":["C27535"],"i_c":"8098/3","i_c_s":["Adenoid basal carcinoma"],"term_type":"PT"},{"nm":"Adenoid cystic carcinoma","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Adenoid cystic carcinoma"],"term_type":"PT"},{"nm":"Adenolipoma","n_c":["C4159"],"i_c":"8324/0","i_c_s":["Adenolipoma"],"term_type":"SY"},{"nm":"Adenolymphoma","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Adenolymphoma"],"term_type":"PT"},{"nm":"Adenoma of nipple","n_c":["C4192"],"i_c":"8506/0","i_c_s":["Adenoma of nipple"],"term_type":"PT"},{"nm":"Adenoma, NOS","n_c":["C2855"],"i_c":"8140/0","i_c_s":["Adenoma, NOS"],"term_type":"PT"},{"nm":"Adenomatoid odontogenic tumor","n_c":["C4310"],"i_c":"9300/0","i_c_s":["Adenomatoid odontogenic tumor"],"term_type":"PT"},{"nm":"Adenomatoid tumor, NOS","n_c":["C3762"],"i_c":"9054/0","i_c_s":["Adenomatoid tumor, NOS"],"term_type":"PT"},{"nm":"Adenomatosis, NOS","n_c":"","i_c":"8220/0","i_c_s":["Adenomatosis, NOS"],"term_type":"SY"},{"nm":"Adenomatous polyp, NOS","n_c":["C3764"],"i_c":"8210/0","i_c_s":["Adenomatous polyp, NOS"],"term_type":"PT"},{"nm":"Adenomatous polyposis coli","n_c":["C3339"],"i_c":"8220/0","i_c_s":["Adenomatous polyposis coli"],"term_type":"PT"},{"nm":"Adenomyoepithelioma","n_c":["C6899"],"i_c":"8983/0","i_c_s":["Adenomyoepithelioma"],"term_type":"PT"},{"nm":"Adenomyoepithelioma with carcinoma","n_c":["C5143"],"i_c":"8983/3","i_c_s":["Adenomyoepithelioma with carcinoma"],"term_type":"PT"},{"nm":"Adenomyoma","n_c":["C3726"],"i_c":"8932/0","i_c_s":["Adenomyoma"],"term_type":"PT"},{"nm":"Adenosarcoma","n_c":["C9474"],"i_c":"8933/3","i_c_s":["Adenosarcoma"],"term_type":"PT"},{"nm":"Adenosquamous carcinoma","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Adenosquamous carcinoma"],"term_type":"PT"},{"nm":"Adnexal carcinoma","n_c":["C3775"],"i_c":"8390/3","i_c_s":["Adnexal carcinoma"],"term_type":"SY"},{"nm":"Adnexal tumor, benign","n_c":["C7580"],"i_c":"8390/0","i_c_s":["Adnexal tumor, benign"],"term_type":"SY"},{"nm":"Adrenal cortical adenocarcinoma","n_c":["C9325"],"i_c":"8370/3","i_c_s":["Adrenal cortical adenocarcinoma"],"term_type":"SY"},{"nm":"Adrenal cortical adenoma, clear cell","n_c":["C4165"],"i_c":"8373/0","i_c_s":["Adrenal cortical adenoma, clear cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, compact cell","n_c":["C4163"],"i_c":"8371/0","i_c_s":["Adrenal cortical adenoma, compact cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, glomerulosa cell","n_c":["C4166"],"i_c":"8374/0","i_c_s":["Adrenal cortical adenoma, glomerulosa cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, mixed cell","n_c":["C4167"],"i_c":"8375/0","i_c_s":["Adrenal cortical adenoma, mixed cell"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, NOS","n_c":["C9003"],"i_c":"8370/0","i_c_s":["Adrenal cortical adenoma, NOS"],"term_type":"PT"},{"nm":"Adrenal cortical adenoma, pigmented","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Adrenal cortical adenoma, pigmented"],"term_type":"PT"},{"nm":"Adrenal cortical carcinoma","n_c":["C9325"],"i_c":"8370/3","i_c_s":["Adrenal cortical carcinoma"],"term_type":"PT"},{"nm":"Adrenal cortical tumor, benign","n_c":["C9004"],"i_c":"8370/0","i_c_s":["Adrenal cortical tumor, benign"],"term_type":"SY"},{"nm":"Adrenal cortical tumor, malignant","n_c":["C9327"],"i_c":"8370/3","i_c_s":["Adrenal cortical tumor, malignant"],"term_type":"SY"},{"nm":"Adrenal cortical tumor, NOS","n_c":["C2858"],"i_c":"8370/0","i_c_s":["Adrenal cortical tumor, NOS"],"term_type":"SY"},{"nm":"Adrenal medullary paraganglioma","n_c":["C3326"],"i_c":"8700/0","i_c_s":["Adrenal medullary paraganglioma"],"term_type":"SY"},{"nm":"Adrenal medullary paraganglioma, malignant","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Adrenal medullary paraganglioma, malignant"],"term_type":"SY"},{"nm":"Adrenal rest tumor","n_c":["C2860"],"i_c":"8671/0","i_c_s":["Adrenal rest tumor"],"term_type":"PT"},{"nm":"Adult cystic teratoma","n_c":["C9012"],"i_c":"9080/0","i_c_s":["Adult cystic teratoma"],"term_type":"SY"},{"nm":"Adult granulosa cell tumor","n_c":["C66750"],"i_c":"8620/3","i_c_s":["Adult granulosa cell tumor"],"term_type":""},{"nm":"Adult rhabdomyoma","n_c":"","i_c":"8904/0","i_c_s":["Adult rhabdomyoma"],"term_type":"PT"},{"nm":"Adult T-cell leukemia","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell leukemia"],"term_type":"SY"},{"nm":"Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)"],"term_type":""},{"nm":"Adult T-cell lymphoma","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell lymphoma"],"term_type":"SY"},{"nm":"Adult T-cell lymphoma/leukemia","n_c":["C3184"],"i_c":"9827/3","i_c_s":["Adult T-cell lymphoma/leukemia"],"term_type":"SY"},{"nm":"Adult teratoma, NOS","n_c":["C9013"],"i_c":"9080/0","i_c_s":["Adult teratoma, NOS"],"term_type":"SY"},{"nm":"Aggressive angiomyxoma","n_c":["C6936"],"i_c":"8841/1","i_c_s":["Aggressive angiomyxoma"],"term_type":"SY"},{"nm":"Aggressive digital papillary adenoma","n_c":["C27534"],"i_c":"8408/1","i_c_s":["Aggressive digital papillary adenoma"],"term_type":"PT"},{"nm":"Aggressive fibromatosis","n_c":["C9182"],"i_c":"8821/1","i_c_s":["Aggressive fibromatosis"],"term_type":"PT"},{"nm":"Aggressive NK-cell leukaemia","n_c":["C8647"],"i_c":"9948/3","i_c_s":["Aggressive NK-cell leukaemia"],"term_type":""},{"nm":"Aggressive osteoblastoma","n_c":["C66796"],"i_c":"9200/1","i_c_s":["Aggressive osteoblastoma"],"term_type":"PT"},{"nm":"Aggressive systemic mastocytosis","n_c":["C9285"],"i_c":"9741/3","i_c_s":["Aggressive systemic mastocytosis"],"term_type":"RT"},{"nm":"Agnogenic myeloid metaplasia","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Agnogenic myeloid metaplasia"],"term_type":"SY"},{"nm":"AIN III","n_c":["C157575"],"i_c":"8077/2","i_c_s":["AIN III"],"term_type":"SY"},{"nm":"Aleukemic granulocytic leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic granulocytic leukemia"],"term_type":"IS"},{"nm":"Aleukemic leukemia, NOS","n_c":["C4982"],"i_c":"9800/3","i_c_s":["Aleukemic leukemia, NOS"],"term_type":"ORT"},{"nm":"Aleukemic lymphatic leukemia","n_c":["C4343"],"i_c":"9820/3","i_c_s":["Aleukemic lymphatic leukemia"],"term_type":"IS"},{"nm":"Aleukemic lymphocytic leukemia","n_c":["C7176"],"i_c":"9820/3","i_c_s":["Aleukemic lymphocytic leukemia"],"term_type":"IS"},{"nm":"Aleukemic lymphoid leukemia","n_c":["C4343"],"i_c":"9820/3","i_c_s":["Aleukemic lymphoid leukemia"],"term_type":"ORT"},{"nm":"Aleukemic monocytic leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic monocytic leukemia"],"term_type":"ORT"},{"nm":"Aleukemic myelogenous leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic myelogenous leukemia"],"term_type":"IS"},{"nm":"Aleukemic myeloid leukemia","n_c":"","i_c":"9860/3","i_c_s":["Aleukemic myeloid leukemia"],"term_type":"ORT"},{"nm":"ALK positive large B-cell lymphoma","n_c":["C7225"],"i_c":"9737/3","i_c_s":["ALK positive large B-cell lymphoma"],"term_type":"PT"},{"nm":"Alpha cell tumor, malignant","n_c":["C65187"],"i_c":"8152/3","i_c_s":["Alpha cell tumor, malignant"],"term_type":"SY"},{"nm":"Alpha cell tumor, NOS","n_c":"","i_c":"8152/1","i_c_s":["Alpha cell tumor, NOS"],"term_type":"SY"},{"nm":"Alpha heavy chain disease","n_c":["C3132"],"i_c":"9762/3","i_c_s":["Alpha heavy chain disease"],"term_type":"RT"},{"nm":"Alveolar adenocarcinoma","n_c":["C2923"],"i_c":"8251/3","i_c_s":["Alveolar adenocarcinoma"],"term_type":"PT"},{"nm":"Alveolar adenoma","n_c":["C4140"],"i_c":"8251/0","i_c_s":["Alveolar adenoma"],"term_type":"PT"},{"nm":"Alveolar carcinoma","n_c":["C2923"],"i_c":"8251/3","i_c_s":["Alveolar carcinoma"],"term_type":"SY"},{"nm":"Alveolar cell carcinoma","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Alveolar cell carcinoma"],"term_type":"SY"},{"nm":"Alveolar rhabdomyosarcoma","n_c":["C3749"],"i_c":"8920/3","i_c_s":["Alveolar rhabdomyosarcoma"],"term_type":"PT"},{"nm":"Alveolar soft part sarcoma","n_c":["C3750"],"i_c":"9581/3","i_c_s":["Alveolar soft part sarcoma"],"term_type":"PT"},{"nm":"Amelanotic melanoma","n_c":["C3802"],"i_c":"8730/3","i_c_s":["Amelanotic melanoma"],"term_type":"PT"},{"nm":"Ameloblastic carcinoma","n_c":["C7492"],"i_c":"9270/3","i_c_s":["Ameloblastic carcinoma"],"term_type":"SY"},{"nm":"Ameloblastic fibro-odontoma","n_c":["C3710"],"i_c":"9290/0","i_c_s":["Ameloblastic fibro-odontoma"],"term_type":"PT"},{"nm":"Ameloblastic fibro-odontosarcoma","n_c":["C173740"],"i_c":"9290/3","i_c_s":["Ameloblastic fibro-odontosarcoma"],"term_type":"SY"},{"nm":"Ameloblastic fibrodentinoma","n_c":["C66800"],"i_c":"9271/0","i_c_s":["Ameloblastic fibrodentinoma"],"term_type":"PT"},{"nm":"Ameloblastic fibrodentinosarcoma","n_c":["C173739"],"i_c":"9290/3","i_c_s":["Ameloblastic fibrodentinosarcoma"],"term_type":"SY"},{"nm":"Ameloblastic fibroma","n_c":["C4316"],"i_c":"9330/0","i_c_s":["Ameloblastic fibroma"],"term_type":"PT"},{"nm":"Ameloblastic fibrosarcoma","n_c":["C4317"],"i_c":"9330/3","i_c_s":["Ameloblastic fibrosarcoma"],"term_type":"PT"},{"nm":"Ameloblastic odontosarcoma","n_c":["C173740"],"i_c":"9290/3","i_c_s":["Ameloblastic odontosarcoma"],"term_type":"PT"},{"nm":"Ameloblastic sarcoma","n_c":["C4317"],"i_c":"9330/3","i_c_s":["Ameloblastic sarcoma"],"term_type":"SY"},{"nm":"Ameloblastoma, malignant","n_c":["C54297"],"i_c":"9310/3","i_c_s":["Ameloblastoma, malignant"],"term_type":"PT"},{"nm":"Ameloblastoma, NOS","n_c":["C4313"],"i_c":"9310/0","i_c_s":["Ameloblastoma, NOS"],"term_type":"PT"},{"nm":"AML M6","n_c":["C8923"],"i_c":"9840/3","i_c_s":["AML M6"],"term_type":"SY"},{"nm":"Anal intraepithelial neoplasia, grade III","n_c":["C157575"],"i_c":"8077/2","i_c_s":["Anal intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Anal intraepithelial neoplasia, low grade","n_c":"","i_c":"8077/0","i_c_s":["Anal intraepithelial neoplasia, low grade"],"term_type":"RT"},{"nm":"Anaplastic astrocytoma, IDH-mutant","n_c":["C129290"],"i_c":"9401/3","i_c_s":["Anaplastic astrocytoma, IDH-mutant"],"term_type":""},{"nm":"Anaplastic astrocytoma, IDH-wildtype","n_c":["C129291"],"i_c":"9401/3","i_c_s":["Anaplastic astrocytoma, IDH-wildtype"],"term_type":""},{"nm":"Anaplastic large B-cell lymphoma","n_c":["C6916"],"i_c":"9680/3","i_c_s":["Anaplastic large B-cell lymphoma"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, ALK negative","n_c":["C37194"],"i_c":"9702/3","i_c_s":["Anaplastic large cell lymphoma, ALK negative"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, ALK positive","n_c":["C37193"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, ALK positive"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, CD30+","n_c":["C3720"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, CD30+"],"term_type":"SY"},{"nm":"Anaplastic large cell lymphoma, NOS","n_c":["C3720"],"i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, NOS"],"term_type":"RT"},{"nm":"Anaplastic large cell lymphoma, T cell and Null cell type","n_c":"","i_c":"9714/3","i_c_s":["Anaplastic large cell lymphoma, T cell and Null cell type"],"term_type":"PT"},{"nm":"Anaplastic medulloblastoma","n_c":["C92625"],"i_c":"9474/3","i_c_s":["Anaplastic medulloblastoma"],"term_type":"RT"},{"nm":"Anaplastic oligoastrocytoma","n_c":["C6959"],"i_c":"9382/3","i_c_s":["Anaplastic oligoastrocytoma"],"term_type":"SY"},{"nm":"Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted","n_c":["C129321"],"i_c":"9451/3","i_c_s":["Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted"],"term_type":""},{"nm":"Anaplastic pleomorphic xanthroastrocytoma","n_c":["C129327"],"i_c":"9424/3","i_c_s":["Anaplastic pleomorphic xanthroastrocytoma"],"term_type":""},{"nm":"Ancient schwannoma","n_c":["C6556"],"i_c":"9560/0","i_c_s":["Ancient schwannoma"],"term_type":"RT"},{"nm":"Androblastoma, benign","n_c":["C67012"],"i_c":"8630/0","i_c_s":["Androblastoma, benign"],"term_type":"PT"},{"nm":"Androblastoma, malignant","n_c":["C67006"],"i_c":"8630/3","i_c_s":["Androblastoma, malignant"],"term_type":"PT"},{"nm":"Androblastoma, NOS","n_c":["C39976"],"i_c":"8630/1","i_c_s":["Androblastoma, NOS"],"term_type":"PT"},{"nm":"Angioblastic meningioma","n_c":"","i_c":"9535/0","i_c_s":["Angioblastic meningioma"],"term_type":"IS"},{"nm":"Angioblastoma","n_c":["C3801"],"i_c":"9161/1","i_c_s":["Angioblastoma"],"term_type":"SY"},{"nm":"Angiocentric glioma","n_c":["C92552"],"i_c":"9431/1","i_c_s":["Angiocentric glioma"],"term_type":"PT"},{"nm":"Angiocentric immunoproliferative lesion","n_c":["C40970"],"i_c":"9766/1","i_c_s":["Angiocentric immunoproliferative lesion"],"term_type":"PT"},{"nm":"Angiocentric T-cell lymphoma","n_c":["C4684"],"i_c":"9719/3","i_c_s":["Angiocentric T-cell lymphoma"],"term_type":"IS"},{"nm":"Angioendothelioma","n_c":["C3084"],"i_c":"9130/1","i_c_s":["Angioendothelioma"],"term_type":"SY"},{"nm":"Angioendotheliomatosis","n_c":["C4342"],"i_c":"9680/3","i_c_s":["Angioendotheliomatosis"],"term_type":"SY"},{"nm":"Angiofibroma, NOS","n_c":["C3799"],"i_c":"9160/0","i_c_s":["Angiofibroma, NOS"],"term_type":"PT"},{"nm":"Angioimmunoblastic lymphadenopathy","n_c":["C7528"],"i_c":"9767/1","i_c_s":["Angioimmunoblastic lymphadenopathy"],"term_type":""},{"nm":"Angioimmunoblastic lymphoma","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Angioimmunoblastic lymphoma"],"term_type":"IS"},{"nm":"Angioimmunoblastic T-cell lymphoma","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Angioimmunoblastic T-cell lymphoma"],"term_type":"PT"},{"nm":"Angiokeratoma","n_c":["C4488"],"i_c":"9141/0","i_c_s":["Angiokeratoma"],"term_type":"PT"},{"nm":"Angioleiomyoma","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Angioleiomyoma"],"term_type":"SY"},{"nm":"Angiolipoma, NOS","n_c":["C3733"],"i_c":"8861/0","i_c_s":["Angiolipoma, NOS"],"term_type":"PT"},{"nm":"Angioma, NOS","n_c":["C3085"],"i_c":"9120/0","i_c_s":["Angioma, NOS"],"term_type":"SY"},{"nm":"Angiomatoid fibrous histiocytoma","n_c":["C6494"],"i_c":"8836/1","i_c_s":["Angiomatoid fibrous histiocytoma"],"term_type":"PT"},{"nm":"Angiomatous meningioma","n_c":["C4332"],"i_c":"9534/0","i_c_s":["Angiomatous meningioma"],"term_type":"PT"},{"nm":"Angiomyofibroblastoma","n_c":["C49016"],"i_c":"8826/0","i_c_s":["Angiomyofibroblastoma"],"term_type":"PT"},{"nm":"Angiomyolipoma","n_c":["C3734"],"i_c":"8860/0","i_c_s":["Angiomyolipoma"],"term_type":"PT"},{"nm":"Angiomyoma","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Angiomyoma"],"term_type":"PT"},{"nm":"Angiomyosarcoma","n_c":["C66771"],"i_c":"8894/3","i_c_s":["Angiomyosarcoma"],"term_type":"PT"},{"nm":"Angiomyxoma","n_c":["C6936"],"i_c":"8841/1","i_c_s":["Angiomyxoma"],"term_type":"PT"},{"nm":"Angiosarcoma","n_c":["C3088"],"i_c":"9120/3","i_c_s":["Angiosarcoma"],"term_type":"SY"},{"nm":"Angiotropic lymphoma","n_c":["C4342"],"i_c":"9680/3","i_c_s":["Angiotropic lymphoma"],"term_type":"SY"},{"nm":"Aortic body paraganglioma","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aortic body paraganglioma"],"term_type":"SY"},{"nm":"Aortic body tumor","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aortic body tumor"],"term_type":"PT"},{"nm":"Aorticopulmonary paraganglioma","n_c":["C4218"],"i_c":"8691/1","i_c_s":["Aorticopulmonary paraganglioma"],"term_type":"SY"},{"nm":"Apocrine adenocarcinoma","n_c":["C4169"],"i_c":"8401/3","i_c_s":["Apocrine adenocarcinoma"],"term_type":"PT"},{"nm":"Apocrine adenoma","n_c":["C4168"],"i_c":"8401/0","i_c_s":["Apocrine adenoma"],"term_type":"PT"},{"nm":"Apocrine cystadenoma","n_c":["C205459"],"i_c":"8401/0","i_c_s":["Apocrine cystadenoma"],"term_type":"SY"},{"nm":"Apudoma","n_c":["C188218"],"i_c":"8248/1","i_c_s":["Apudoma"],"term_type":"PT"},{"nm":"Argentaffinoma, malignant","n_c":"","i_c":"8241/3","i_c_s":["Argentaffinoma, malignant"],"term_type":"IS"},{"nm":"Argentaffinoma, NOS","n_c":"","i_c":"8240/1","i_c_s":["Argentaffinoma, NOS"],"term_type":"IS"},{"nm":"Arrhenoblastoma, benign","n_c":["C67012"],"i_c":"8630/0","i_c_s":["Arrhenoblastoma, benign"],"term_type":"SY"},{"nm":"Arrhenoblastoma, malignant","n_c":["C67006"],"i_c":"8630/3","i_c_s":["Arrhenoblastoma, malignant"],"term_type":"SY"},{"nm":"Arrhenoblastoma, NOS","n_c":["C39976"],"i_c":"8630/1","i_c_s":["Arrhenoblastoma, NOS"],"term_type":"SY"},{"nm":"Arteriovenous hemangioma","n_c":["C2882"],"i_c":"9123/0","i_c_s":["Arteriovenous hemangioma"],"term_type":"SY"},{"nm":"Askin tumor","n_c":["C7542"],"i_c":"9365/3","i_c_s":["Askin tumor"],"term_type":"PT"},{"nm":"Astroblastoma","n_c":["C4324"],"i_c":"9430/3","i_c_s":["Astroblastoma"],"term_type":"PT"},{"nm":"Astrocytic glioma","n_c":["C6958"],"i_c":"9400/3","i_c_s":["Astrocytic glioma"],"term_type":"SY"},{"nm":"Astrocytoma, anaplastic","n_c":["C9477"],"i_c":"9401/3","i_c_s":["Astrocytoma, anaplastic"],"term_type":"PT"},{"nm":"Astrocytoma, low grade","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Astrocytoma, low grade"],"term_type":"RT"},{"nm":"Astrocytoma, NOS","n_c":["C60781"],"i_c":"9400/3","i_c_s":["Astrocytoma, NOS"],"term_type":"PT"},{"nm":"Astroglioma","n_c":["C6958"],"i_c":"9400/3","i_c_s":["Astroglioma"],"term_type":"IS"},{"nm":"Atypical adenoma","n_c":["C7559"],"i_c":"8140/1","i_c_s":["Atypical adenoma"],"term_type":"PT"},{"nm":"Atypical carcinoid tumor","n_c":["C72074"],"i_c":"8249/3","i_c_s":["Atypical carcinoid tumor"],"term_type":"PT"},{"nm":"Atypical choroid plexus papilloma","n_c":["C53686"],"i_c":"9390/1","i_c_s":["Atypical choroid plexus papilloma"],"term_type":"PT"},{"nm":"Atypical chronic myeloid leukemia, BCR/ABL negative","n_c":["C3519"],"i_c":"9876/3","i_c_s":["Atypical chronic myeloid leukemia, BCR/ABL negative"],"term_type":"PT"},{"nm":"Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative","n_c":["C3519"],"i_c":"9876/3","i_c_s":["Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative"],"term_type":"RT"},{"nm":"Atypical fibrous histiocytoma","n_c":["C4246"],"i_c":"8830/1","i_c_s":["Atypical fibrous histiocytoma"],"term_type":"PT"},{"nm":"Atypical fibroxanthoma","n_c":["C4246"],"i_c":"8830/1","i_c_s":["Atypical fibroxanthoma"],"term_type":"SY"},{"nm":"Atypical follicular adenoma","n_c":["C27729"],"i_c":"8330/1","i_c_s":["Atypical follicular adenoma"],"term_type":"PT"},{"nm":"Atypical hyperplasia/Endometrioid intraepithelial neoplasm","n_c":["C27789"],"i_c":"8380/2","i_c_s":["Atypical hyperplasia/Endometrioid intraepithelial neoplasm"],"term_type":""},{"nm":"Atypical leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Atypical leiomyoma"],"term_type":"SY"},{"nm":"Atypical lipoma","n_c":["C6505"],"i_c":"8850/1","i_c_s":["Atypical lipoma"],"term_type":"PT"},{"nm":"Atypical medullary carcinoma","n_c":["C66719"],"i_c":"8513/3","i_c_s":["Atypical medullary carcinoma"],"term_type":"PT"},{"nm":"Atypical meningioma","n_c":["C4723"],"i_c":"9539/1","i_c_s":["Atypical meningioma"],"term_type":"PT"},{"nm":"Atypical polypoid adenomyoma","n_c":["C6895"],"i_c":"8932/0","i_c_s":["Atypical polypoid adenomyoma"],"term_type":"RT"},{"nm":"Atypical proliferating clear cell tumor","n_c":"","i_c":"8444/1","i_c_s":["Atypical proliferating clear cell tumor"],"term_type":"SY"},{"nm":"Atypical proliferating serous tumor","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Atypical proliferating serous tumor"],"term_type":"SY"},{"nm":"Atypical proliferative endometrioid tumor","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Atypical proliferative endometrioid tumor"],"term_type":"SY"},{"nm":"Atypical proliferative mucinous tumor","n_c":"","i_c":"8472/1","i_c_s":["Atypical proliferative mucinous tumor"],"term_type":"SY"},{"nm":"Atypical proliferative papillary serous tumor","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Atypical proliferative papillary serous tumor"],"term_type":"SY"},{"nm":"Atypical teratoid/rhabdoid tumor","n_c":["C6906"],"i_c":"9508/3","i_c_s":["Atypical teratoid/rhabdoid tumor"],"term_type":"PT"},{"nm":"B cell lymphoma, NOS","n_c":"","i_c":"9591/3","i_c_s":["B cell lymphoma, NOS"],"term_type":"RT"},{"nm":"B lymphoblastic leukemia/lymphoma with hyperdiploidy","n_c":["C80335"],"i_c":"9815/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hyperdiploidy"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)","n_c":["C80338"],"i_c":"9816/3","i_c_s":["B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","n_c":["C80341"],"i_c":"9818/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)","n_c":["C80334"],"i_c":"9814/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH","n_c":["C80340"],"i_c":"9817/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1","n_c":["C80331"],"i_c":"9812/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged","n_c":["C80332"],"i_c":"9813/3","i_c_s":["B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged"],"term_type":"PT"},{"nm":"B lymphoblastic leukemia/lymphoma, NOS","n_c":["C80326"],"i_c":"9811/3","i_c_s":["B lymphoblastic leukemia/lymphoma, NOS"],"term_type":"PT"},{"nm":"B-ALL","n_c":["C8644"],"i_c":"9826/3","i_c_s":["B-ALL"],"term_type":"IS"},{"nm":"B-cell lymphocytic leukemia/small lymphocytic lymphoma","n_c":["C27911","C3163"],"i_c":"9823/3","i_c_s":["B-cell lymphocytic leukemia/small lymphocytic lymphoma"],"term_type":""},{"nm":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","n_c":["C80291"],"i_c":"9680/3","i_c_s":["B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma"],"term_type":"RT"},{"nm":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma","n_c":["C37869"],"i_c":"9596/3","i_c_s":["B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma"],"term_type":"RT"},{"nm":"Balloon cell melanoma","n_c":["C4227"],"i_c":"8722/3","i_c_s":["Balloon cell melanoma"],"term_type":"PT"},{"nm":"Balloon cell nevus","n_c":["C4226"],"i_c":"8722/0","i_c_s":["Balloon cell nevus"],"term_type":"PT"},{"nm":"BALT lymphoma","n_c":["C5264"],"i_c":"9699/3","i_c_s":["BALT lymphoma"],"term_type":"SY"},{"nm":"Basal cell adenocarcinoma","n_c":["C3678"],"i_c":"8147/3","i_c_s":["Basal cell adenocarcinoma"],"term_type":"PT"},{"nm":"Basal cell adenoma","n_c":["C5950"],"i_c":"8147/0","i_c_s":["Basal cell adenoma"],"term_type":"PT"},{"nm":"Basal cell carcinoma, desmoplastic type","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Basal cell carcinoma, desmoplastic type"],"term_type":"SY"},{"nm":"Basal cell carcinoma, fibroepithelial","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Basal cell carcinoma, fibroepithelial"],"term_type":"PT"},{"nm":"Basal cell carcinoma, micronodular","n_c":["C27541"],"i_c":"8097/3","i_c_s":["Basal cell carcinoma, micronodular"],"term_type":"RT"},{"nm":"Basal cell carcinoma, morpheic","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Basal cell carcinoma, morpheic"],"term_type":"SY"},{"nm":"Basal cell carcinoma, nodular","n_c":["C62282"],"i_c":"8097/3","i_c_s":["Basal cell carcinoma, nodular"],"term_type":"PT"},{"nm":"Basal cell carcinoma, NOS","n_c":["C2921","C156767"],"i_c":"8090/3","i_c_s":["Basal cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Basal cell epithelioma","n_c":["C2921"],"i_c":"8090/3","i_c_s":["Basal cell epithelioma"],"term_type":"SY"},{"nm":"Basal cell tumor","n_c":["C3784"],"i_c":"8090/1","i_c_s":["Basal cell tumor"],"term_type":"PT"},{"nm":"Basaloid carcinoma","n_c":["C4121"],"i_c":"8123/3","i_c_s":["Basaloid carcinoma"],"term_type":"PT"},{"nm":"Basaloid squamous cell carcinoma","n_c":["C54244"],"i_c":"8083/3","i_c_s":["Basaloid squamous cell carcinoma"],"term_type":"PT"},{"nm":"Basophil adenocarcinoma","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Basophil adenocarcinoma"],"term_type":"SY"},{"nm":"Basophil adenoma","n_c":["C2856"],"i_c":"8300/0","i_c_s":["Basophil adenoma"],"term_type":"PT"},{"nm":"Basophil carcinoma","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Basophil carcinoma"],"term_type":"PT"},{"nm":"Basosquamous carcinoma","n_c":["C2922"],"i_c":"8094/3","i_c_s":["Basosquamous carcinoma"],"term_type":"PT"},{"nm":"Bednar tumor","n_c":["C9430"],"i_c":"8833/3","i_c_s":["Bednar tumor"],"term_type":"SY"},{"nm":"Bellini duct carcinoma","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Bellini duct carcinoma"],"term_type":"SY"},{"nm":"Benign cystic nephroma","n_c":["C7504"],"i_c":"8959/0","i_c_s":["Benign cystic nephroma"],"term_type":"PT"},{"nm":"Benign fibrous histiocytoma","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Benign fibrous histiocytoma"],"term_type":"PT"},{"nm":"Beta cell adenoma","n_c":["C67457"],"i_c":"8151/0","i_c_s":["Beta cell adenoma"],"term_type":"SY"},{"nm":"Beta cell tumor, malignant","n_c":["C65186"],"i_c":"8151/3","i_c_s":["Beta cell tumor, malignant"],"term_type":"SY"},{"nm":"Bile duct adenocarcinoma","n_c":["C27813"],"i_c":"8160/3","i_c_s":["Bile duct adenocarcinoma"],"term_type":"SY"},{"nm":"Bile duct adenoma","n_c":["C2942"],"i_c":"8160/0","i_c_s":["Bile duct adenoma"],"term_type":"PT"},{"nm":"Bile duct carcinoma","n_c":["C27814"],"i_c":"8160/3","i_c_s":["Bile duct carcinoma"],"term_type":"SY"},{"nm":"Bile duct cystadenocarcinoma","n_c":["C4130"],"i_c":"8161/3","i_c_s":["Bile duct cystadenocarcinoma"],"term_type":"PT"},{"nm":"Bile duct cystadenoma","n_c":["C4129"],"i_c":"8161/0","i_c_s":["Bile duct cystadenoma"],"term_type":"PT"},{"nm":"Biliary intraepithelial neoplasia, grade 3","n_c":["C67493"],"i_c":"8148/2","i_c_s":["Biliary intraepithelial neoplasia, grade 3"],"term_type":""},{"nm":"Biliary intraepithelial neoplasia, high grade","n_c":["C67493"],"i_c":"8148/2","i_c_s":["Biliary intraepithelial neoplasia, high grade"],"term_type":"RT"},{"nm":"Biliary intraepithelial neoplasia, low grade","n_c":["C172804"],"i_c":"8148/0","i_c_s":["Biliary intraepithelial neoplasia, low grade"],"term_type":"RT"},{"nm":"Biliary papillomatosis","n_c":["C6881"],"i_c":"8264/0","i_c_s":["Biliary papillomatosis"],"term_type":"RT"},{"nm":"Biphenotypic sinonasal sarcoma","n_c":["C164205"],"i_c":"9045/3","i_c_s":["Biphenotypic sinonasal sarcoma"],"term_type":"PT"},{"nm":"Bizarre leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Bizarre leiomyoma"],"term_type":"PT"},{"nm":"Black adenoma","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Black adenoma"],"term_type":"SY"},{"nm":"Blast cell leukemia","n_c":["C9300"],"i_c":"9801/3","i_c_s":["Blast cell leukemia"],"term_type":"SY"},{"nm":"Blastic NK cell lymphoma","n_c":["C7203"],"i_c":"9727/3","i_c_s":["Blastic NK cell lymphoma"],"term_type":"ORT"},{"nm":"Blastic plasmacytoid dendritic cell neoplasm","n_c":["C7203"],"i_c":"9727/3","i_c_s":["Blastic plasmacytoid dendritic cell neoplasm"],"term_type":"RT"},{"nm":"Blastoma, NOS","n_c":["C8997"],"i_c":"8000/3","i_c_s":["Blastoma, NOS"],"term_type":"SY"},{"nm":"Blue nevus, malignant","n_c":["C4240"],"i_c":"8780/3","i_c_s":["Blue nevus, malignant"],"term_type":"PT"},{"nm":"Blue nevus, NOS","n_c":["C3803"],"i_c":"8780/0","i_c_s":["Blue nevus, NOS"],"term_type":"PT"},{"nm":"Botryoid sarcoma","n_c":["C9150"],"i_c":"8910/3","i_c_s":["Botryoid sarcoma"],"term_type":"SY"},{"nm":"Bowen disease","n_c":["C62571"],"i_c":"8081/2","i_c_s":["Bowen disease"],"term_type":"PT"},{"nm":"Brenner tumor, borderline malignancy","n_c":["C9459"],"i_c":"9000/1","i_c_s":["Brenner tumor, borderline malignancy"],"term_type":"PT"},{"nm":"Brenner tumor, malignant","n_c":["C4270"],"i_c":"9000/3","i_c_s":["Brenner tumor, malignant"],"term_type":"PT"},{"nm":"Brenner tumor, NOS","n_c":["C39954"],"i_c":"9000/0","i_c_s":["Brenner tumor, NOS"],"term_type":"PT"},{"nm":"Brenner tumor, proliferating","n_c":["C9459"],"i_c":"9000/1","i_c_s":["Brenner tumor, proliferating"],"term_type":"SY"},{"nm":"Bronchial adenoma, carcinoid","n_c":"","i_c":"8240/3","i_c_s":["Bronchial adenoma, carcinoid"],"term_type":"RT"},{"nm":"Bronchial adenoma, cylindroid","n_c":"","i_c":"8200/3","i_c_s":["Bronchial adenoma, cylindroid"],"term_type":"ORT"},{"nm":"Bronchial adenoma, NOS","n_c":["C3494"],"i_c":"8140/1","i_c_s":["Bronchial adenoma, NOS"],"term_type":"SY"},{"nm":"Bronchial-associated lymphoid tissue lymphoma","n_c":["C5264"],"i_c":"9699/3","i_c_s":["Bronchial-associated lymphoid tissue lymphoma"],"term_type":"SY"},{"nm":"Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous"],"term_type":""},{"nm":"Bronchio-alveolar carcinoma, mucinous","n_c":["C136709","C7268"],"i_c":"8253/3","i_c_s":["Bronchio-alveolar carcinoma, mucinous"],"term_type":""},{"nm":"Bronchiolar adenocarcinoma","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolar adenocarcinoma"],"term_type":"SY"},{"nm":"Bronchiolar carcinoma","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolar carcinoma"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar adenocarcinoma, NOS","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolo-alveolar adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Bronchiolo-alveolar carcinoma, Clara cell","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma, Clara cell"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, goblet cell type","n_c":["C7268"],"i_c":"8253/3","i_c_s":["Bronchiolo-alveolar carcinoma, goblet cell type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, indeterminate type","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, indeterminate type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, non-mucinous","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma, non-mucinous"],"term_type":""},{"nm":"Bronchiolo-alveolar carcinoma, NOS","n_c":["C2923"],"i_c":"8250/3","i_c_s":["Bronchiolo-alveolar carcinoma, NOS"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type","n_c":["C7270"],"i_c":"8254/3","i_c_s":["Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type"],"term_type":"SY"},{"nm":"Bronchiolo-alveolar carcinoma; type II pneumocyte","n_c":["C7269"],"i_c":"8252/3","i_c_s":["Bronchiolo-alveolar carcinoma; type II pneumocyte"],"term_type":""},{"nm":"Brooke tumor","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Brooke tumor"],"term_type":"SY"},{"nm":"Brown fat tumor","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Brown fat tumor"],"term_type":"SY"},{"nm":"Burkitt cell leukemia","n_c":["C7400"],"i_c":"9826/3","i_c_s":["Burkitt cell leukemia"],"term_type":"PT"},{"nm":"Burkitt lymphoma, NOS (Includes all variants)","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Burkitt lymphoma, NOS (Includes all variants)"],"term_type":""},{"nm":"Burkitt tumor","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Burkitt tumor"],"term_type":"IS"},{"nm":"Burkitt-like lymphoma","n_c":["C6917"],"i_c":"9687/3","i_c_s":["Burkitt-like lymphoma"],"term_type":"RT"},{"nm":"C cell carcinoma","n_c":["C3879"],"i_c":"8345/3","i_c_s":["C cell carcinoma"],"term_type":"SY"},{"nm":"c-ALL","n_c":["C27797"],"i_c":"9836/3","i_c_s":["c-ALL"],"term_type":"SY"},{"nm":"Calcifying epithelial odontogenic tumor","n_c":["C54301"],"i_c":"9340/0","i_c_s":["Calcifying epithelial odontogenic tumor"],"term_type":"PT"},{"nm":"Calcifying epithelioma of Malherbe","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Calcifying epithelioma of Malherbe"],"term_type":"SY"},{"nm":"Calcifying nested epithelial stromal tumor","n_c":["C96830"],"i_c":"8975/1","i_c_s":["Calcifying nested epithelial stromal tumor"],"term_type":"PT"},{"nm":"Calcifying odontogenic cyst","n_c":["C54319"],"i_c":"9301/0","i_c_s":["Calcifying odontogenic cyst"],"term_type":"PT"},{"nm":"Canalicular adenoma","n_c":["C5979"],"i_c":"8149/0","i_c_s":["Canalicular adenoma"],"term_type":"PT"},{"nm":"Cancer","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Cancer"],"term_type":"SY"},{"nm":"Capillary hemangioma","n_c":["C7457"],"i_c":"9131/0","i_c_s":["Capillary hemangioma"],"term_type":"PT"},{"nm":"Capillary lymphangioma","n_c":["C8965"],"i_c":"9171/0","i_c_s":["Capillary lymphangioma"],"term_type":"PT"},{"nm":"Carcinofibroma","n_c":"","i_c":"8934/3","i_c_s":["Carcinofibroma"],"term_type":"PT"},{"nm":"Carcinoid tumor of uncertain malignant potential","n_c":["C65196"],"i_c":"8240/1","i_c_s":["Carcinoid tumor of uncertain malignant potential"],"term_type":"PT"},{"nm":"Carcinoid tumor, argentaffin, malignant","n_c":"","i_c":"8241/3","i_c_s":["Carcinoid tumor, argentaffin, malignant"],"term_type":"SY"},{"nm":"Carcinoid tumor, argentaffin, NOS","n_c":"","i_c":"8240/1","i_c_s":["Carcinoid tumor, argentaffin, NOS"],"term_type":"RT"},{"nm":"Carcinoid tumor, NOS","n_c":["C188218"],"i_c":"8240/3","i_c_s":["Carcinoid tumor, NOS"],"term_type":"PT"},{"nm":"Carcinoid tumor, NOS, of appendix","n_c":"","i_c":"8240/1","i_c_s":["Carcinoid tumor, NOS, of appendix"],"term_type":"PT"},{"nm":"Carcinoid, NOS","n_c":["C188218"],"i_c":"8240/3","i_c_s":["Carcinoid, NOS"],"term_type":"SY"},{"nm":"Carcinoid, NOS, of appendix","n_c":"","i_c":"8240/1","i_c_s":["Carcinoid, NOS, of appendix"],"term_type":"SY"},{"nm":"Carcinoma in a polyp, NOS","n_c":["C7682"],"i_c":"8210/3","i_c_s":["Carcinoma in a polyp, NOS"],"term_type":"SY"},{"nm":"Carcinoma in adenomatous polyp","n_c":["C7676"],"i_c":"8210/3","i_c_s":["Carcinoma in adenomatous polyp"],"term_type":"SY"},{"nm":"Carcinoma in pleomorphic adenoma","n_c":["C4397"],"i_c":"8941/3","i_c_s":["Carcinoma in pleomorphic adenoma"],"term_type":"PT"},{"nm":"Carcinoma in situ in a polyp, NOS","n_c":["C7681"],"i_c":"8210/2","i_c_s":["Carcinoma in situ in a polyp, NOS"],"term_type":"SY"},{"nm":"Carcinoma in situ in adenomatous polyp","n_c":["C7678"],"i_c":"8210/2","i_c_s":["Carcinoma in situ in adenomatous polyp"],"term_type":"SY"},{"nm":"Carcinoma in situ, NOS","n_c":["C2917"],"i_c":"8010/2","i_c_s":["Carcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Carcinoma showing thymus-like differentiation","n_c":["C46106"],"i_c":"8589/3","i_c_s":["Carcinoma showing thymus-like differentiation"],"term_type":"SY"},{"nm":"Carcinoma showing thymus-like element","n_c":["C46106"],"i_c":"8589/3","i_c_s":["Carcinoma showing thymus-like element"],"term_type":"PT"},{"nm":"Carcinoma simplex","n_c":["C65195"],"i_c":"8231/3","i_c_s":["Carcinoma simplex"],"term_type":"PT"},{"nm":"Carcinoma with apocrine metaplasia","n_c":["C4202"],"i_c":"8573/3","i_c_s":["Carcinoma with apocrine metaplasia"],"term_type":"SY"},{"nm":"Carcinoma with chondroid differentiation","n_c":["C47847"],"i_c":"8571/3","i_c_s":["Carcinoma with chondroid differentiation"],"term_type":""},{"nm":"Carcinoma with neuroendocrine differentiation","n_c":["C66745"],"i_c":"8574/3","i_c_s":["Carcinoma with neuroendocrine differentiation"],"term_type":"SY"},{"nm":"Carcinoma with osseous differentiation","n_c":["C47848"],"i_c":"8571/3","i_c_s":["Carcinoma with osseous differentiation"],"term_type":""},{"nm":"Carcinoma with osteoclast-like giant cells","n_c":["C63622"],"i_c":"8035/3","i_c_s":["Carcinoma with osteoclast-like giant cells"],"term_type":"PT"},{"nm":"Carcinoma with other types mesenchymal differentiation","n_c":"","i_c":"8575/3","i_c_s":["Carcinoma with other types mesenchymal differentiation"],"term_type":""},{"nm":"Carcinoma with productive fibrosis","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Carcinoma with productive fibrosis"],"term_type":"SY"},{"nm":"Carcinoma, anaplastic, NOS","n_c":["C3692"],"i_c":"8021/3","i_c_s":["Carcinoma, anaplastic, NOS"],"term_type":"PT"},{"nm":"Carcinoma, diffuse type","n_c":["C4127"],"i_c":"8145/3","i_c_s":["Carcinoma, diffuse type"],"term_type":"PT"},{"nm":"Carcinoma, intestinal type","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Carcinoma, intestinal type"],"term_type":"SY"},{"nm":"Carcinoma, metastatic, NOS","n_c":["C3482"],"i_c":"8010/6","i_c_s":["Carcinoma, metastatic, NOS"],"term_type":"PT"},{"nm":"Carcinoma, NOS","n_c":["C2916"],"i_c":"8010/3","i_c_s":["Carcinoma, NOS"],"term_type":"PT"},{"nm":"Carcinoma, undifferentiated, NOS","n_c":["C3692"],"i_c":"8020/3","i_c_s":["Carcinoma, undifferentiated, NOS"],"term_type":"PT"},{"nm":"Carcinomatosis","n_c":["C3693"],"i_c":"8010/9","i_c_s":["Carcinomatosis"],"term_type":"PT"},{"nm":"Carcinosarcoma, embryonal","n_c":["C8975"],"i_c":"8981/3","i_c_s":["Carcinosarcoma, embryonal"],"term_type":"PT"},{"nm":"Carcinosarcoma, NOS","n_c":["C34448"],"i_c":"8980/3","i_c_s":["Carcinosarcoma, NOS"],"term_type":"PT"},{"nm":"Carotid body paraganglioma","n_c":["C2932"],"i_c":"8692/1","i_c_s":["Carotid body paraganglioma"],"term_type":"SY"},{"nm":"Carotid body tumor","n_c":["C2932"],"i_c":"8692/1","i_c_s":["Carotid body tumor"],"term_type":"PT"},{"nm":"Cartilaginous exostosis","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Cartilaginous exostosis"],"term_type":"SY"},{"nm":"CASTLE","n_c":["C46106"],"i_c":"8589/3","i_c_s":["CASTLE"],"term_type":"SY"},{"nm":"Cavernous hemangioma","n_c":["C3086"],"i_c":"9121/0","i_c_s":["Cavernous hemangioma"],"term_type":"PT"},{"nm":"Cavernous lymphangioma","n_c":["C53316"],"i_c":"9172/0","i_c_s":["Cavernous lymphangioma"],"term_type":"PT"},{"nm":"Cellular angiofibroma","n_c":["C27257"],"i_c":"9160/0","i_c_s":["Cellular angiofibroma"],"term_type":"RT"},{"nm":"Cellular blue nevus","n_c":["C4241"],"i_c":"8790/0","i_c_s":["Cellular blue nevus"],"term_type":"PT"},{"nm":"Cellular ependymoma","n_c":["C4713"],"i_c":"9391/3","i_c_s":["Cellular ependymoma"],"term_type":"RT"},{"nm":"Cellular fibroma","n_c":["C6892"],"i_c":"8810/1","i_c_s":["Cellular fibroma"],"term_type":"PT"},{"nm":"Cellular leiomyoma","n_c":["C4256"],"i_c":"8892/0","i_c_s":["Cellular leiomyoma"],"term_type":"PT"},{"nm":"Cellular schwannoma","n_c":["C4724"],"i_c":"9560/0","i_c_s":["Cellular schwannoma"],"term_type":"RT"},{"nm":"Cementifying fibroma","n_c":["C8422"],"i_c":"9274/0","i_c_s":["Cementifying fibroma"],"term_type":"PT"},{"nm":"Cemento-ossifying fibroma","n_c":["C8422"],"i_c":"9274/0","i_c_s":["Cemento-ossifying fibroma"],"term_type":"RT"},{"nm":"Cementoblastoma, benign","n_c":["C4308"],"i_c":"9273/0","i_c_s":["Cementoblastoma, benign"],"term_type":"PT"},{"nm":"Cementoma, NOS","n_c":["C173927"],"i_c":"9272/0","i_c_s":["Cementoma, NOS"],"term_type":"PT"},{"nm":"Central neuroblastoma","n_c":["C3270"],"i_c":"9500/3","i_c_s":["Central neuroblastoma"],"term_type":"SY"},{"nm":"Central neurocytoma","n_c":["C3791"],"i_c":"9506/1","i_c_s":["Central neurocytoma"],"term_type":"PT"},{"nm":"Central odontogenic fibroma","n_c":["C202077"],"i_c":"9321/0","i_c_s":["Central odontogenic fibroma"],"term_type":"PT"},{"nm":"Central osteosarcoma","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Central osteosarcoma"],"term_type":"PT"},{"nm":"Central primitive neuroectodermal tumor, NOS","n_c":["C5398"],"i_c":"9473/3","i_c_s":["Central primitive neuroectodermal tumor, NOS"],"term_type":"RT"},{"nm":"Cerebellar liponeurocytoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Cerebellar liponeurocytoma"],"term_type":"RT"},{"nm":"Cerebellar sarcoma, NOS","n_c":["C66803"],"i_c":"9480/3","i_c_s":["Cerebellar sarcoma, NOS"],"term_type":"OP"},{"nm":"Ceruminous adenocarcinoma","n_c":["C4176"],"i_c":"8420/3","i_c_s":["Ceruminous adenocarcinoma"],"term_type":"PT"},{"nm":"Ceruminous adenoma","n_c":["C6088"],"i_c":"8420/0","i_c_s":["Ceruminous adenoma"],"term_type":"PT"},{"nm":"Ceruminous carcinoma","n_c":["C4176"],"i_c":"8420/3","i_c_s":["Ceruminous carcinoma"],"term_type":"SY"},{"nm":"Cervical intraepithelial neoplasia, grade III","n_c":["C4000"],"i_c":"8077/2","i_c_s":["Cervical intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Cervical intraepithelial neoplasia, low grade","n_c":["C4630"],"i_c":"8077/0","i_c_s":["Cervical intraepithelial neoplasia, low grade"],"term_type":"RT"},{"nm":"Chemodectoma","n_c":["C2932"],"i_c":"8693/1","i_c_s":["Chemodectoma"],"term_type":"RT"},{"nm":"Chief cell adenoma","n_c":["C4154"],"i_c":"8321/0","i_c_s":["Chief cell adenoma"],"term_type":"PT"},{"nm":"Chloroma","n_c":["C3520"],"i_c":"9930/3","i_c_s":["Chloroma"],"term_type":"SY"},{"nm":"Cholangiocarcinoma","n_c":["C4436"],"i_c":"8160/3","i_c_s":["Cholangiocarcinoma"],"term_type":"PT"},{"nm":"Cholangioma","n_c":["C2942"],"i_c":"8160/0","i_c_s":["Cholangioma"],"term_type":"SY"},{"nm":"Chondroblastic osteosarcoma","n_c":["C4021"],"i_c":"9181/3","i_c_s":["Chondroblastic osteosarcoma"],"term_type":"PT"},{"nm":"Chondroblastoma, malignant","n_c":["C66799"],"i_c":"9230/3","i_c_s":["Chondroblastoma, malignant"],"term_type":"PT"},{"nm":"Chondroblastoma, NOS","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Chondroblastoma, NOS"],"term_type":"PT"},{"nm":"Chondroid chordoma","n_c":["C6902"],"i_c":"9371/3","i_c_s":["Chondroid chordoma"],"term_type":"PT"},{"nm":"Chondroid lipoma","n_c":["C6503"],"i_c":"8862/0","i_c_s":["Chondroid lipoma"],"term_type":"PT"},{"nm":"Chondroid syringoma","n_c":["C4474"],"i_c":"8940/0","i_c_s":["Chondroid syringoma"],"term_type":"RT"},{"nm":"Chondroma, NOS","n_c":["C53459"],"i_c":"9220/0","i_c_s":["Chondroma, NOS"],"term_type":"PT"},{"nm":"Chondromatosis, NOS","n_c":["C35259"],"i_c":"9220/1","i_c_s":["Chondromatosis, NOS"],"term_type":"PT"},{"nm":"Chondromatous giant cell tumor","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Chondromatous giant cell tumor"],"term_type":"SY"},{"nm":"Chondromyxoid fibroma","n_c":["C3830"],"i_c":"9241/0","i_c_s":["Chondromyxoid fibroma"],"term_type":"PT"},{"nm":"Chondrosarcoma grade 2/3","n_c":"","i_c":"9220/3","i_c_s":["Chondrosarcoma grade 2/3"],"term_type":""},{"nm":"Chondrosarcoma, NOS","n_c":["C2946"],"i_c":"9220/3","i_c_s":["Chondrosarcoma, NOS"],"term_type":"PT"},{"nm":"Chordoid glioma","n_c":["C5592"],"i_c":"9444/1","i_c_s":["Chordoid glioma"],"term_type":"PT"},{"nm":"Chordoid glioma of third ventricle","n_c":["C5592"],"i_c":"9444/1","i_c_s":["Chordoid glioma of third ventricle"],"term_type":"RT"},{"nm":"Chordoid meningioma","n_c":["C6908"],"i_c":"9538/1","i_c_s":["Chordoid meningioma"],"term_type":"RT"},{"nm":"Chordoma, NOS","n_c":["C2947"],"i_c":"9370/3","i_c_s":["Chordoma, NOS"],"term_type":"PT"},{"nm":"Chorioadenoma","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Chorioadenoma"],"term_type":"SY"},{"nm":"Chorioadenoma destruens","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Chorioadenoma destruens"],"term_type":"SY"},{"nm":"Chorioangioma","n_c":["C4868"],"i_c":"9120/0","i_c_s":["Chorioangioma"],"term_type":"SY"},{"nm":"Choriocarcinoma combined with embryonal carcinoma","n_c":["C66777"],"i_c":"9101/3","i_c_s":["Choriocarcinoma combined with embryonal carcinoma"],"term_type":"SY"},{"nm":"Choriocarcinoma combined with other germ cell elements","n_c":["C66777"],"i_c":"9101/3","i_c_s":["Choriocarcinoma combined with other germ cell elements"],"term_type":"PT"},{"nm":"Choriocarcinoma combined with teratorna","n_c":"","i_c":"9101/3","i_c_s":["Choriocarcinoma combined with teratorna"],"term_type":""},{"nm":"Choriocarcinoma, NOS","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Choriocarcinoma, NOS"],"term_type":"PT"},{"nm":"Chorioepithelioma","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Chorioepithelioma"],"term_type":"SY"},{"nm":"Chorionepithelioma","n_c":["C2948"],"i_c":"9100/3","i_c_s":["Chorionepithelioma"],"term_type":"SY"},{"nm":"Choroid plexus carcinoma","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus carcinoma"],"term_type":"PT"},{"nm":"Choroid plexus papilloma, anaplastic","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus papilloma, anaplastic"],"term_type":"SY"},{"nm":"Choroid plexus papilloma, malignant","n_c":["C4715"],"i_c":"9390/3","i_c_s":["Choroid plexus papilloma, malignant"],"term_type":"SY"},{"nm":"Choroid plexus papilloma, NOS","n_c":["C3698"],"i_c":"9390/0","i_c_s":["Choroid plexus papilloma, NOS"],"term_type":"PT"},{"nm":"Chromaffin paraganglioma","n_c":["C3326"],"i_c":"8700/0","i_c_s":["Chromaffin paraganglioma"],"term_type":"SY"},{"nm":"Chromaffin tumor","n_c":["C4216"],"i_c":"8700/0","i_c_s":["Chromaffin tumor"],"term_type":"SY"},{"nm":"Chromaffinoma","n_c":["C4216"],"i_c":"8700/0","i_c_s":["Chromaffinoma"],"term_type":"SY"},{"nm":"Chromophobe adenocarcinoma","n_c":["C4146"],"i_c":"8270/3","i_c_s":["Chromophobe adenocarcinoma"],"term_type":"SY"},{"nm":"Chromophobe adenoma","n_c":["C2857"],"i_c":"8270/0","i_c_s":["Chromophobe adenoma"],"term_type":"PT"},{"nm":"Chromophobe carcinoma","n_c":["C4146"],"i_c":"8270/3","i_c_s":["Chromophobe carcinoma"],"term_type":"PT"},{"nm":"Chromophobe cell renal carcinoma","n_c":["C4146"],"i_c":"8317/3","i_c_s":["Chromophobe cell renal carcinoma"],"term_type":"SY"},{"nm":"Chronic eosinophilic leukemia, NOS","n_c":["C4563"],"i_c":"9964/3","i_c_s":["Chronic eosinophilic leukemia, NOS"],"term_type":"PT"},{"nm":"Chronic erythremia","n_c":"","i_c":"9950/3","i_c_s":["Chronic erythremia"],"term_type":"IS"},{"nm":"Chronic granulocytic leukemia, BCR/ABL","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic granulocytic leukemia, BCR/ABL"],"term_type":"SY"},{"nm":"Chronic granulocytic leukemia, NOS","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic granulocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive"],"term_type":"SY"},{"nm":"Chronic granulocytic leukemia, t(9;22)(q34;q11)","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic granulocytic leukemia, t(9;22)(q34;q11)"],"term_type":"SY"},{"nm":"Chronic idiopathic myelofibrosis","n_c":["C188314"],"i_c":"9961/3","i_c_s":["Chronic idiopathic myelofibrosis"],"term_type":"SY"},{"nm":"Chronic leukemia, NOS","n_c":["C3483"],"i_c":"9800/3","i_c_s":["Chronic leukemia, NOS"],"term_type":"ORT"},{"nm":"Chronic lymphatic leukemia","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphatic leukemia"],"term_type":"SY"},{"nm":"Chronic lymphocytic leukemia","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphocytic leukemia"],"term_type":"SY"},{"nm":"Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)"],"term_type":""},{"nm":"Chronic lymphoid leukemia","n_c":["C3163"],"i_c":"9823/3","i_c_s":["Chronic lymphoid leukemia"],"term_type":"SY"},{"nm":"Chronic lymphoproliferative disorder of NK cells","n_c":["C39591"],"i_c":"9831/3","i_c_s":["Chronic lymphoproliferative disorder of NK cells"],"term_type":"RT"},{"nm":"Chronic monocytic leukemia","n_c":["C34774"],"i_c":"9860/3","i_c_s":["Chronic monocytic leukemia"],"term_type":"ORT"},{"nm":"Chronic myelocytic leukemia, NOS","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic myelocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Chronic myelogenous leukemia, BCR-ABL positive","n_c":["C3174"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, BCR-ABL positive"],"term_type":""},{"nm":"Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive"],"term_type":""},{"nm":"Chronic myelogenous leukemia, t(9;22)(q34;q11)","n_c":["C9128"],"i_c":"9875/3","i_c_s":["Chronic myelogenous leukemia, t(9;22)(q34;q11)"],"term_type":""},{"nm":"Chronic myeloid leukemia, NOS","n_c":["C3174"],"i_c":"9863/3","i_c_s":["Chronic myeloid leukemia, NOS"],"term_type":"PT"},{"nm":"Chronic myelomonocytic leukemia in transformation","n_c":["C3178"],"i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia in transformation"],"term_type":"IS"},{"nm":"Chronic myelomonocytic leukemia, NOS","n_c":["C3178"],"i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, NOS"],"term_type":"PT"},{"nm":"Chronic myelomonocytic leukemia, Type 1","n_c":"","i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, Type 1"],"term_type":""},{"nm":"Chronic myelomonocytic leukemia, Type II","n_c":"","i_c":"9945/3","i_c_s":["Chronic myelomonocytic leukemia, Type II"],"term_type":"RT"},{"nm":"Chronic myeloproliferative disease, NOS","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Chronic myeloproliferative disease, NOS"],"term_type":"SY"},{"nm":"Chronic myeloproliferative disorder","n_c":["C4345"],"i_c":"9960/3","i_c_s":["Chronic myeloproliferative disorder"],"term_type":"SY"},{"nm":"Chronic neutrophilic leukemia","n_c":["C3179"],"i_c":"9963/3","i_c_s":["Chronic neutrophilic leukemia"],"term_type":"PT"},{"nm":"CIN III with severe dysplasia","n_c":["C4000"],"i_c":"8077/2","i_c_s":["CIN III with severe dysplasia"],"term_type":"SY"},{"nm":"Cin III, NOS","n_c":["C4000"],"i_c":"8077/2","i_c_s":["Cin III, NOS"],"term_type":""},{"nm":"Circumscribed arachnoidal cerebellar sarcoma","n_c":["C4956"],"i_c":"9471/3","i_c_s":["Circumscribed arachnoidal cerebellar sarcoma"],"term_type":"IS"},{"nm":"Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis","n_c":["C9283"],"i_c":"9654/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, lymphocyte depletion, NOS","n_c":["C9283"],"i_c":"9653/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte depletion, NOS"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, lymphocyte depletion, reticular","n_c":"","i_c":"9655/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte depletion, reticular"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, lymphocyte-rich","n_c":["C6913"],"i_c":"9651/3","i_c_s":["Classical Hodgkin lymphoma, lymphocyte-rich"],"term_type":""},{"nm":"Classical Hodgkin lymphoma, mixed cellularity, NOS","n_c":["C3517"],"i_c":"9652/3","i_c_s":["Classical Hodgkin lymphoma, mixed cellularity, NOS"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, cellular phase","n_c":["C67171"],"i_c":"9664/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, cellular phase"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, grade 1","n_c":["C7165"],"i_c":"9665/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, grade 1"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, grade 2","n_c":["C7166"],"i_c":"9667/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, grade 2"],"term_type":"SY"},{"nm":"Classical Hodgkin lymphoma, nodular sclerosis, NOS","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Classical Hodgkin lymphoma, nodular sclerosis, NOS"],"term_type":"SY"},{"nm":"Clear cell (glycogen-rich) urothelial carcinoma","n_c":["C191683"],"i_c":"8120/3","i_c_s":["Clear cell (glycogen-rich) urothelial carcinoma"],"term_type":""},{"nm":"Clear cell adenocarcinofibroma","n_c":["C40079"],"i_c":"8313/3","i_c_s":["Clear cell adenocarcinofibroma"],"term_type":"PT"},{"nm":"Clear cell adenocarcinoma, mesonephroid","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell adenocarcinoma, mesonephroid"],"term_type":"RT"},{"nm":"Clear cell adenocarcinoma, NOS","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Clear cell adenofibroma","n_c":["C8987"],"i_c":"8313/0","i_c_s":["Clear cell adenofibroma"],"term_type":"PT"},{"nm":"Clear cell adenofibroma of borderline malignancy","n_c":["C40081"],"i_c":"8313/1","i_c_s":["Clear cell adenofibroma of borderline malignancy"],"term_type":"PT"},{"nm":"Clear cell adenoma","n_c":["C4151"],"i_c":"8310/0","i_c_s":["Clear cell adenoma"],"term_type":"PT"},{"nm":"Clear cell carcinoma","n_c":["C3766"],"i_c":"8310/3","i_c_s":["Clear cell carcinoma"],"term_type":"SY"},{"nm":"Clear cell chondrosarcoma","n_c":["C6475"],"i_c":"9242/3","i_c_s":["Clear cell chondrosarcoma"],"term_type":"PT"},{"nm":"Clear cell cystadenocarcinofibroma","n_c":"","i_c":"8313/3","i_c_s":["Clear cell cystadenocarcinofibroma"],"term_type":"SY"},{"nm":"Clear cell cystadenofibroma","n_c":["C8988"],"i_c":"8313/0","i_c_s":["Clear cell cystadenofibroma"],"term_type":"SY"},{"nm":"Clear cell cystadenofibroma of borderline malignancy","n_c":"","i_c":"8313/1","i_c_s":["Clear cell cystadenofibroma of borderline malignancy"],"term_type":"SY"},{"nm":"Clear cell cystadenoma","n_c":["C65203"],"i_c":"8443/0","i_c_s":["Clear cell cystadenoma"],"term_type":"PT"},{"nm":"Clear cell cystic tumor of borderline malignancy","n_c":["C40080"],"i_c":"8444/1","i_c_s":["Clear cell cystic tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Clear cell ependymoma","n_c":["C4714"],"i_c":"9391/3","i_c_s":["Clear cell ependymoma"],"term_type":"RT"},{"nm":"Clear cell hidradenoma","n_c":["C7567"],"i_c":"8402/0","i_c_s":["Clear cell hidradenoma"],"term_type":"RT"},{"nm":"Clear cell meningioma","n_c":["C4722"],"i_c":"9538/1","i_c_s":["Clear cell meningioma"],"term_type":"PT"},{"nm":"Clear cell odontogenic carcinoma","n_c":["C54300"],"i_c":"9341/3","i_c_s":["Clear cell odontogenic carcinoma"],"term_type":""},{"nm":"Clear cell odontogenic tumor","n_c":["C54300"],"i_c":"9341/1","i_c_s":["Clear cell odontogenic tumor"],"term_type":"PT"},{"nm":"Clear cell sarcoma of kidney","n_c":["C4264"],"i_c":"8964/3","i_c_s":["Clear cell sarcoma of kidney"],"term_type":"PT"},{"nm":"Clear cell sarcoma, NOS","n_c":["C3745"],"i_c":"9044/3","i_c_s":["Clear cell sarcoma, NOS"],"term_type":"PT"},{"nm":"Clear cell sarcoma, of tendons and aponeuroses","n_c":"","i_c":"9044/3","i_c_s":["Clear cell sarcoma, of tendons and aponeuroses"],"term_type":"RT"},{"nm":"Clear cell tumor, NOS","n_c":["C66752"],"i_c":"8005/0","i_c_s":["Clear cell tumor, NOS"],"term_type":"PT"},{"nm":"Cloacogenic carcinoma","n_c":["C8255"],"i_c":"8124/3","i_c_s":["Cloacogenic carcinoma"],"term_type":"PT"},{"nm":"CNS Embryonal tumor with rhabdoid features","n_c":["C129501"],"i_c":"9508/3","i_c_s":["CNS Embryonal tumor with rhabdoid features"],"term_type":""},{"nm":"Codman tumor","n_c":["C2945"],"i_c":"9230/0","i_c_s":["Codman tumor"],"term_type":"SY"},{"nm":"Collecting duct carcinoma","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Collecting duct carcinoma"],"term_type":"PT"},{"nm":"Colloid adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Colloid adenocarcinoma"],"term_type":"SY"},{"nm":"Colloid adenoma","n_c":["C4161"],"i_c":"8334/0","i_c_s":["Colloid adenoma"],"term_type":"SY"},{"nm":"Colloid carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Colloid carcinoma"],"term_type":"SY"},{"nm":"Columnar cell papilloma","n_c":"","i_c":"8121/1","i_c_s":["Columnar cell papilloma"],"term_type":"RT"},{"nm":"Combined carcinoid and adenocarcinoma","n_c":["C4139"],"i_c":"8244/3","i_c_s":["Combined carcinoid and adenocarcinoma"],"term_type":"SY"},{"nm":"Combined hepatocellular carcinoma and cholangiocarcinoma","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Combined hepatocellular carcinoma and cholangiocarcinoma"],"term_type":"PT"},{"nm":"Combined large cell neuroendocrine carcinoma","n_c":["C7267"],"i_c":"8013/3","i_c_s":["Combined large cell neuroendocrine carcinoma"],"term_type":""},{"nm":"Combined small cell carcinoma","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Combined small cell carcinoma"],"term_type":"PT"},{"nm":"Combined small cell-adenocarcinoma","n_c":["C9379"],"i_c":"8045/3","i_c_s":["Combined small cell-adenocarcinoma"],"term_type":"RT"},{"nm":"Combined small cell-large carcinoma","n_c":"","i_c":"8045/3","i_c_s":["Combined small cell-large carcinoma"],"term_type":""},{"nm":"Combined small cell-squamous cell carcinoma","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Combined small cell-squamous cell carcinoma"],"term_type":"RT"},{"nm":"Combined/mixed carcinoid and adenocarcinoma","n_c":["C4139"],"i_c":"8244/3","i_c_s":["Combined/mixed carcinoid and adenocarcinoma"],"term_type":"SY"},{"nm":"Comedocarcinoma, noninfiltrating","n_c":["C7949"],"i_c":"8501/2","i_c_s":["Comedocarcinoma, noninfiltrating"],"term_type":"PT"},{"nm":"Comedocarcinoma, NOS","n_c":["C4188"],"i_c":"8501/3","i_c_s":["Comedocarcinoma, NOS"],"term_type":"PT"},{"nm":"Common ALL","n_c":["C27797"],"i_c":"9836/3","i_c_s":["Common ALL"],"term_type":"SY"},{"nm":"Common precursor B ALL","n_c":["C27797"],"i_c":"9836/3","i_c_s":["Common precursor B ALL"],"term_type":"SY"},{"nm":"Complete hydatidiform mole","n_c":["C4871"],"i_c":"9100/0","i_c_s":["Complete hydatidiform mole"],"term_type":"SY"},{"nm":"Complex odontoma","n_c":["C4309"],"i_c":"9282/0","i_c_s":["Complex odontoma"],"term_type":"PT"},{"nm":"Composite carcinoid","n_c":["C201135"],"i_c":"8244/3","i_c_s":["Composite carcinoid"],"term_type":"SY"},{"nm":"Composite Hodgkin and non-Hodgkin lymphoma","n_c":"","i_c":"9596/3","i_c_s":["Composite Hodgkin and non-Hodgkin lymphoma"],"term_type":"PT"},{"nm":"Compound nevus","n_c":["C3901"],"i_c":"8760/0","i_c_s":["Compound nevus"],"term_type":"PT"},{"nm":"Compound odontoma","n_c":["C3711"],"i_c":"9281/0","i_c_s":["Compound odontoma"],"term_type":"PT"},{"nm":"Condylomatous carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Condylomatous carcinoma"],"term_type":"SY"},{"nm":"Congenital fibrosarcoma","n_c":["C4244"],"i_c":"8814/3","i_c_s":["Congenital fibrosarcoma"],"term_type":"SY"},{"nm":"Congenital generalized fibromatosis","n_c":"","i_c":"8824/1","i_c_s":["Congenital generalized fibromatosis"],"term_type":"RT"},{"nm":"Congenital peribronchial myofibroblastic tumor","n_c":["C142823"],"i_c":"8827/1","i_c_s":["Congenital peribronchial myofibroblastic tumor"],"term_type":"SY"},{"nm":"Conventional central osteosarcoma","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Conventional central osteosarcoma"],"term_type":"SY"},{"nm":"Cortical T ALL","n_c":["C27820"],"i_c":"9837/3","i_c_s":["Cortical T ALL"],"term_type":"SY"},{"nm":"CPNET","n_c":["C5398"],"i_c":"9473/3","i_c_s":["CPNET"],"term_type":"SY"},{"nm":"Craniopharyngioma","n_c":["C2964"],"i_c":"9350/1","i_c_s":["Craniopharyngioma"],"term_type":"PT"},{"nm":"Craniopharyngioma, adamantinomatous","n_c":["C4726"],"i_c":"9351/1","i_c_s":["Craniopharyngioma, adamantinomatous"],"term_type":"PT"},{"nm":"Craniopharyngioma, papillary","n_c":["C4725"],"i_c":"9352/1","i_c_s":["Craniopharyngioma, papillary"],"term_type":"PT"},{"nm":"Cribriform carcinoma in situ","n_c":["C162973"],"i_c":"8201/2","i_c_s":["Cribriform carcinoma in situ"],"term_type":"PT"},{"nm":"Cribriform carcinoma, NOS","n_c":["C3680"],"i_c":"8201/3","i_c_s":["Cribriform carcinoma, NOS"],"term_type":"PT"},{"nm":"Cribriform comedo-type carcinoma","n_c":"","i_c":"8201/3","i_c_s":["Cribriform comedo-type carcinoma"],"term_type":"RT"},{"nm":"Cutaneous histiocytoma, NOS","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Cutaneous histiocytoma, NOS"],"term_type":"SY"},{"nm":"Cutaneous lymphoma, NOS","n_c":["C7162"],"i_c":"9709/3","i_c_s":["Cutaneous lymphoma, NOS"],"term_type":"IS"},{"nm":"Cutaneous mastocytosis","n_c":["C7137"],"i_c":"9740/1","i_c_s":["Cutaneous mastocytosis"],"term_type":"RT"},{"nm":"Cutaneous T-cell lymphoma, NOS","n_c":["C3467"],"i_c":"9709/3","i_c_s":["Cutaneous T-cell lymphoma, NOS"],"term_type":"PT"},{"nm":"Cylindrical cell carcinoma","n_c":["C54287"],"i_c":"8121/3","i_c_s":["Cylindrical cell carcinoma"],"term_type":"RT"},{"nm":"Cylindrical cell papilloma","n_c":"","i_c":"8121/1","i_c_s":["Cylindrical cell papilloma"],"term_type":"RT"},{"nm":"Cylindroma of skin","n_c":["C27094"],"i_c":"8200/0","i_c_s":["Cylindroma of skin"],"term_type":"RT"},{"nm":"Cylindroma, NOS","n_c":["C2970"],"i_c":"8200/3","i_c_s":["Cylindroma, NOS"],"term_type":"SY"},{"nm":"Cyst-associated renal cell carcinoma","n_c":["C157718"],"i_c":"8316/3","i_c_s":["Cyst-associated renal cell carcinoma"],"term_type":"PT"},{"nm":"Cystadenocarcinoma, NOS","n_c":["C2971"],"i_c":"8440/3","i_c_s":["Cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Cystadenofibroma, NOS","n_c":["C8985"],"i_c":"9013/0","i_c_s":["Cystadenofibroma, NOS"],"term_type":"RT"},{"nm":"Cystadenoma, NOS","n_c":["C2972"],"i_c":"8440/0","i_c_s":["Cystadenoma, NOS"],"term_type":"PT"},{"nm":"Cystic astrocytoma","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Cystic astrocytoma"],"term_type":"ORT"},{"nm":"Cystic hygroma","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Cystic hygroma"],"term_type":"SY"},{"nm":"Cystic hypersecretory carcinoma","n_c":["C4189"],"i_c":"8508/3","i_c_s":["Cystic hypersecretory carcinoma"],"term_type":"PT"},{"nm":"Cystic lymphangioma","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Cystic lymphangioma"],"term_type":"PT"},{"nm":"Cystic mesothelioma, benign","n_c":"","i_c":"9055/0","i_c_s":["Cystic mesothelioma, benign"],"term_type":"SY"},{"nm":"Cystic mesothelioma, NOS","n_c":["C3765"],"i_c":"9055/1","i_c_s":["Cystic mesothelioma, NOS"],"term_type":"PT"},{"nm":"Cystic partially differentiated nephroblastoma","n_c":["C6897"],"i_c":"8959/1","i_c_s":["Cystic partially differentiated nephroblastoma"],"term_type":"PT"},{"nm":"Cystic teratoma, NOS","n_c":["C9014"],"i_c":"9080/0","i_c_s":["Cystic teratoma, NOS"],"term_type":"SY"},{"nm":"Cystic tumor of atrio-ventricular node","n_c":["C45754"],"i_c":"8454/0","i_c_s":["Cystic tumor of atrio-ventricular node"],"term_type":"PT"},{"nm":"Cystoma, NOS","n_c":["C2972"],"i_c":"8440/0","i_c_s":["Cystoma, NOS"],"term_type":"SY"},{"nm":"Cystosarcoma phyllodes, benign","n_c":["C4274"],"i_c":"9020/0","i_c_s":["Cystosarcoma phyllodes, benign"],"term_type":"IS"},{"nm":"Cystosarcoma phyllodes, malignant","n_c":["C4275"],"i_c":"9020/3","i_c_s":["Cystosarcoma phyllodes, malignant"],"term_type":"SY"},{"nm":"Cystosarcoma phyllodes, NOS","n_c":["C2977"],"i_c":"9020/1","i_c_s":["Cystosarcoma phyllodes, NOS"],"term_type":"SY"},{"nm":"Dabska tumor","n_c":["C7526"],"i_c":"9135/1","i_c_s":["Dabska tumor"],"term_type":"SY"},{"nm":"DCIS, comedo type","n_c":["C176005"],"i_c":"8501/2","i_c_s":["DCIS, comedo type"],"term_type":"SY"},{"nm":"DCIS, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["DCIS, NOS"],"term_type":"SY"},{"nm":"DCIS, papillary","n_c":["C4190"],"i_c":"8503/2","i_c_s":["DCIS, papillary"],"term_type":"SY"},{"nm":"Dedifferentiated chondrosarcoma","n_c":["C6476"],"i_c":"9243/3","i_c_s":["Dedifferentiated chondrosarcoma"],"term_type":"PT"},{"nm":"Dedifferentiated chordoma","n_c":["C48876"],"i_c":"9372/3","i_c_s":["Dedifferentiated chordoma"],"term_type":"PT"},{"nm":"Dedifferentiated liposarcoma","n_c":["C3704"],"i_c":"8858/3","i_c_s":["Dedifferentiated liposarcoma"],"term_type":"PT"},{"nm":"Deep histiocytoma","n_c":["C6492"],"i_c":"8831/0","i_c_s":["Deep histiocytoma"],"term_type":"RT"},{"nm":"Degenerated schwannoma","n_c":["C6556"],"i_c":"9560/0","i_c_s":["Degenerated schwannoma"],"term_type":"RT"},{"nm":"Dendritic cell sarcoma, NOS","n_c":["C27260"],"i_c":"9757/3","i_c_s":["Dendritic cell sarcoma, NOS"],"term_type":"RT"},{"nm":"Dentinoma","n_c":["C54323"],"i_c":"9271/0","i_c_s":["Dentinoma"],"term_type":"SY"},{"nm":"Dermal and epidermal nevus","n_c":["C3901"],"i_c":"8760/0","i_c_s":["Dermal and epidermal nevus"],"term_type":"SY"},{"nm":"Dermal nevus","n_c":["C3804"],"i_c":"8750/0","i_c_s":["Dermal nevus"],"term_type":"SY"},{"nm":"Dermatofibroma lenticulare","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Dermatofibroma lenticulare"],"term_type":"SY"},{"nm":"Dermatofibroma, NOS","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Dermatofibroma, NOS"],"term_type":"PT"},{"nm":"Dermatofibrosarcoma protuberans, NOS","n_c":["C4683"],"i_c":"8832/3","i_c_s":["Dermatofibrosarcoma protuberans, NOS"],"term_type":"SY"},{"nm":"Dermatofibrosarcoma, NOS","n_c":["C4683"],"i_c":"8832/3","i_c_s":["Dermatofibrosarcoma, NOS"],"term_type":"PT"},{"nm":"Dermoid cyst with malignant transformation","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Dermoid cyst with malignant transformation"],"term_type":"SY"},{"nm":"Dermoid cyst with secondary tumor","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Dermoid cyst with secondary tumor"],"term_type":"SY"},{"nm":"Dermoid cyst, NOS","n_c":["C9011"],"i_c":"9084/0","i_c_s":["Dermoid cyst, NOS"],"term_type":"PT"},{"nm":"Dermoid, NOS","n_c":["C9011"],"i_c":"9084/0","i_c_s":["Dermoid, NOS"],"term_type":"SY"},{"nm":"Desmoid, NOS","n_c":["C9182"],"i_c":"8821/1","i_c_s":["Desmoid, NOS"],"term_type":"SY"},{"nm":"Desmoplastic fibroma","n_c":["C3740"],"i_c":"8823/0","i_c_s":["Desmoplastic fibroma"],"term_type":"PT"},{"nm":"Desmoplastic infantile astrocytoma","n_c":["C9476"],"i_c":"9412/1","i_c_s":["Desmoplastic infantile astrocytoma"],"term_type":"PT"},{"nm":"Desmoplastic infantile ganglioglioma","n_c":["C4738"],"i_c":"9412/1","i_c_s":["Desmoplastic infantile ganglioglioma"],"term_type":"RT"},{"nm":"Desmoplastic medulloblastoma","n_c":["C4956"],"i_c":"9471/3","i_c_s":["Desmoplastic medulloblastoma"],"term_type":"SY"},{"nm":"Desmoplastic melanoma, amelanotic","n_c":["C37257"],"i_c":"8745/3","i_c_s":["Desmoplastic melanoma, amelanotic"],"term_type":"RT"},{"nm":"Desmoplastic melanoma, malignant","n_c":["C37257"],"i_c":"8745/3","i_c_s":["Desmoplastic melanoma, malignant"],"term_type":"PT"},{"nm":"Desmoplastic mesothelioma","n_c":["C6747"],"i_c":"9051/3","i_c_s":["Desmoplastic mesothelioma"],"term_type":"SY"},{"nm":"Desmoplastic nodular medulloblastoma","n_c":["C4956"],"i_c":"9471/3","i_c_s":["Desmoplastic nodular medulloblastoma"],"term_type":"PT"},{"nm":"Desmoplastic small round cell tumor","n_c":["C8300"],"i_c":"8806/3","i_c_s":["Desmoplastic small round cell tumor"],"term_type":"PT"},{"nm":"Di Guglielmo disease","n_c":["C7467"],"i_c":"9840/3","i_c_s":["Di Guglielmo disease"],"term_type":"IS"},{"nm":"Differentiated penile intraepithelial neoplasia","n_c":"","i_c":"8071/2","i_c_s":["Differentiated penile intraepithelial neoplasia"],"term_type":""},{"nm":"Differentiated-type vulvar intraepithelial neoplasia","n_c":["C37272"],"i_c":"8071/2","i_c_s":["Differentiated-type vulvar intraepithelial neoplasia"],"term_type":""},{"nm":"Diffuse astrocytoma","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma"],"term_type":"RT"},{"nm":"Diffuse astrocytoma, IDH-mutant","n_c":["C129271"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma, IDH-mutant"],"term_type":""},{"nm":"Diffuse astrocytoma, IDH-wildtype","n_c":["C129274"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma, IDH-wildtype"],"term_type":""},{"nm":"Diffuse astrocytoma, low grade","n_c":["C7173"],"i_c":"9400/3","i_c_s":["Diffuse astrocytoma, low grade"],"term_type":"RT"},{"nm":"Diffuse cutaneous mastocytosis","n_c":["C3218"],"i_c":"9740/1","i_c_s":["Diffuse cutaneous mastocytosis"],"term_type":"RT"},{"nm":"Diffuse intraductal papillomatosis","n_c":["C7364"],"i_c":"8505/0","i_c_s":["Diffuse intraductal papillomatosis"],"term_type":"SY"},{"nm":"Diffuse large B-cell lymphoma associated with chronic inflammation","n_c":["C80289"],"i_c":"9680/3","i_c_s":["Diffuse large B-cell lymphoma associated with chronic inflammation"],"term_type":"RT"},{"nm":"Diffuse large B-cell lymphoma, NOS","n_c":["C80280"],"i_c":"9680/3","i_c_s":["Diffuse large B-cell lymphoma, NOS"],"term_type":"SY"},{"nm":"Diffuse leptomeningeal glioneuronal tumor","n_c":["C129424"],"i_c":"9509/1","i_c_s":["Diffuse leptomeningeal glioneuronal tumor"],"term_type":""},{"nm":"Diffuse melanocytosis","n_c":["C6890"],"i_c":"8728/0","i_c_s":["Diffuse melanocytosis"],"term_type":"PT"},{"nm":"Diffuse meningiomatosis","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Diffuse meningiomatosis"],"term_type":"SY"},{"nm":"Diffuse midline glioma, H3 K27M-mutant","n_c":["C129309"],"i_c":"9385/3","i_c_s":["Diffuse midline glioma, H3 K27M-mutant"],"term_type":"PT"},{"nm":"Digital papillary adenocarcinoma","n_c":["C27534"],"i_c":"8408/3","i_c_s":["Digital papillary adenocarcinoma"],"term_type":"RT"},{"nm":"Diktyoma, benign","n_c":"","i_c":"9501/0","i_c_s":["Diktyoma, benign"],"term_type":"SY"},{"nm":"Diktyoma, malignant","n_c":["C4327"],"i_c":"9501/3","i_c_s":["Diktyoma, malignant"],"term_type":"SY"},{"nm":"DIN 3","n_c":["C7949"],"i_c":"8500/2","i_c_s":["DIN 3"],"term_type":"SY"},{"nm":"Duct adenocarcinoma, NOS","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Duct adenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Duct adenoma, NOS","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Duct adenoma, NOS"],"term_type":"SY"},{"nm":"Duct carcinoma, desmoplastic type","n_c":["C7362"],"i_c":"8514/3","i_c_s":["Duct carcinoma, desmoplastic type"],"term_type":"PT"},{"nm":"Duct carcinoma, NOS","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Duct carcinoma, NOS"],"term_type":"SY"},{"nm":"Duct cell carcinoma","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Duct cell carcinoma"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, comedo type","n_c":["C176005"],"i_c":"8501/2","i_c_s":["Ductal carcinoma in situ, comedo type"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, cribriform type","n_c":["C5138"],"i_c":"8201/2","i_c_s":["Ductal carcinoma in situ, cribriform type"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, micropapillary","n_c":["C5139"],"i_c":"8507/2","i_c_s":["Ductal carcinoma in situ, micropapillary"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Ductal carcinoma in situ, NOS"],"term_type":"RT"},{"nm":"Ductal carcinoma in situ, papillary","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Ductal carcinoma in situ, papillary"],"term_type":"SY"},{"nm":"Ductal carcinoma in situ, solid type","n_c":["C66933"],"i_c":"8230/2","i_c_s":["Ductal carcinoma in situ, solid type"],"term_type":"PT"},{"nm":"Ductal carcinoma, cribriform type","n_c":["C3680"],"i_c":"8201/3","i_c_s":["Ductal carcinoma, cribriform type"],"term_type":"SY"},{"nm":"Ductal carcinoma, NOS","n_c":["C4017"],"i_c":"8500/3","i_c_s":["Ductal carcinoma, NOS"],"term_type":"SY"},{"nm":"Ductal intraepithelial neoplasia 3","n_c":["C7949"],"i_c":"8500/2","i_c_s":["Ductal intraepithelial neoplasia 3"],"term_type":"SY"},{"nm":"Ductal papilloma","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Ductal papilloma"],"term_type":"SY"},{"nm":"Dysembryoplastic neuroepithelial tumor","n_c":["C9505"],"i_c":"9413/0","i_c_s":["Dysembryoplastic neuroepithelial tumor"],"term_type":"PT"},{"nm":"Dysgerminoma","n_c":["C8106"],"i_c":"9060/3","i_c_s":["Dysgerminoma"],"term_type":"PT"},{"nm":"Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)","n_c":["C8419"],"i_c":"9493/0","i_c_s":["Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)"],"term_type":"PT"},{"nm":"Dysplastic nevus","n_c":["C3694"],"i_c":"8727/0","i_c_s":["Dysplastic nevus"],"term_type":"PT"},{"nm":"EBV positive diffuse large B-cell lymphoma of the elderly","n_c":["C80281"],"i_c":"9680/3","i_c_s":["EBV positive diffuse large B-cell lymphoma of the elderly"],"term_type":"RT"},{"nm":"EC cell carcinoid","n_c":"","i_c":"8241/3","i_c_s":["EC cell carcinoid"],"term_type":"SY"},{"nm":"Ecchondroma","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Ecchondroma"],"term_type":"SY"},{"nm":"Ecchondrosis","n_c":["C53457"],"i_c":"9210/1","i_c_s":["Ecchondrosis"],"term_type":"SY"},{"nm":"Eccrine acrospiroma","n_c":["C7563"],"i_c":"8402/0","i_c_s":["Eccrine acrospiroma"],"term_type":"RT"},{"nm":"Eccrine adenocarcinoma","n_c":["C27255"],"i_c":"8413/3","i_c_s":["Eccrine adenocarcinoma"],"term_type":"PT"},{"nm":"Eccrine cystadenoma","n_c":["C7565"],"i_c":"8404/0","i_c_s":["Eccrine cystadenoma"],"term_type":"SY"},{"nm":"Eccrine dermal cylindroma","n_c":["C27094"],"i_c":"8200/0","i_c_s":["Eccrine dermal cylindroma"],"term_type":"PT"},{"nm":"Eccrine papillary adenocarcinoma","n_c":["C27534"],"i_c":"8408/3","i_c_s":["Eccrine papillary adenocarcinoma"],"term_type":"PT"},{"nm":"Eccrine papillary adenoma","n_c":["C27527"],"i_c":"8408/0","i_c_s":["Eccrine papillary adenoma"],"term_type":"PT"},{"nm":"Eccrine poroma","n_c":["C205462"],"i_c":"8409/0","i_c_s":["Eccrine poroma"],"term_type":"PT"},{"nm":"Eccrine poroma, malignant","n_c":["C5560"],"i_c":"8409/3","i_c_s":["Eccrine poroma, malignant"],"term_type":"PT"},{"nm":"Eccrine spiradenoma","n_c":["C4170"],"i_c":"8403/0","i_c_s":["Eccrine spiradenoma"],"term_type":"PT"},{"nm":"ECL cell carcinoid, malignant","n_c":["C27252"],"i_c":"8242/3","i_c_s":["ECL cell carcinoid, malignant"],"term_type":"SY"},{"nm":"ECL cell carcinoid, NOS","n_c":["C27252"],"i_c":"8242/1","i_c_s":["ECL cell carcinoid, NOS"],"term_type":"SY"},{"nm":"Ectomesenchymoma","n_c":["C4716"],"i_c":"8921/3","i_c_s":["Ectomesenchymoma"],"term_type":"SY"},{"nm":"Ectopic hamartomatous thymoma","n_c":["C53595"],"i_c":"8587/0","i_c_s":["Ectopic hamartomatous thymoma"],"term_type":"PT"},{"nm":"Elastofibroma","n_c":["C4245"],"i_c":"8820/0","i_c_s":["Elastofibroma"],"term_type":"PT"},{"nm":"Embryonal adenocarcinoma","n_c":["C3752"],"i_c":"9070/3","i_c_s":["Embryonal adenocarcinoma"],"term_type":"SY"},{"nm":"Embryonal adenoma","n_c":["C27253"],"i_c":"8191/0","i_c_s":["Embryonal adenoma"],"term_type":"PT"},{"nm":"Embryonal carcinoma, infantile","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Embryonal carcinoma, infantile"],"term_type":"SY"},{"nm":"Embryonal carcinoma, NOS","n_c":["C3752"],"i_c":"9070/3","i_c_s":["Embryonal carcinoma, NOS"],"term_type":"PT"},{"nm":"Embryonal carcinoma, polyembryonal type","n_c":"","i_c":"9072/3","i_c_s":["Embryonal carcinoma, polyembryonal type"],"term_type":"SY"},{"nm":"Embryonal hepatoma","n_c":["C3728"],"i_c":"8970/3","i_c_s":["Embryonal hepatoma"],"term_type":"SY"},{"nm":"Embryonal rhabdomyosarcoma, NOS","n_c":["C8971"],"i_c":"8910/3","i_c_s":["Embryonal rhabdomyosarcoma, NOS"],"term_type":"PT"},{"nm":"Embryonal rhabdomyosarcoma, pleomorphic","n_c":"","i_c":"8910/3","i_c_s":["Embryonal rhabdomyosarcoma, pleomorphic"],"term_type":"RT"},{"nm":"Embryonal sarcoma","n_c":["C27096"],"i_c":"8991/3","i_c_s":["Embryonal sarcoma"],"term_type":"PT"},{"nm":"Embryonal teratoma","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Embryonal teratoma"],"term_type":"SY"},{"nm":"Embryonal tumor with multilayered rosettes C19MC-altered","n_c":["C4915"],"i_c":"9478/3","i_c_s":["Embryonal tumor with multilayered rosettes C19MC-altered"],"term_type":""},{"nm":"Embryonal tumor with multilayered rosettes, NOS","n_c":["C186534"],"i_c":"9478/3","i_c_s":["Embryonal tumor with multilayered rosettes, NOS"],"term_type":"PT"},{"nm":"Embryonal tumor with rhabdoid features","n_c":["C129501"],"i_c":"9508/3","i_c_s":["Embryonal tumor with rhabdoid features"],"term_type":""},{"nm":"Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)","n_c":"","i_c":"8343/3","i_c_s":["Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)"],"term_type":""},{"nm":"Encapsulated papillary carcinoma","n_c":["C156034"],"i_c":"8504/2","i_c_s":["Encapsulated papillary carcinoma"],"term_type":""},{"nm":"Encapsulated papillary carcinoma with invasion","n_c":["C66850"],"i_c":"8504/3","i_c_s":["Encapsulated papillary carcinoma with invasion"],"term_type":""},{"nm":"Enchondroma","n_c":["C3007"],"i_c":"9220/0","i_c_s":["Enchondroma"],"term_type":"RT"},{"nm":"Endocervical adenocarcinoma usual type","n_c":["C127907"],"i_c":"8140/3","i_c_s":["Endocervical adenocarcinoma usual type"],"term_type":""},{"nm":"Endocrine adenomatosis","n_c":["C6432"],"i_c":"8360/1","i_c_s":["Endocrine adenomatosis"],"term_type":"SY"},{"nm":"Endocrine tumor, functioning, NOS","n_c":["C94759"],"i_c":"8158/1","i_c_s":["Endocrine tumor, functioning, NOS"],"term_type":"PT"},{"nm":"Endodermal sinus tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Endodermal sinus tumor"],"term_type":"SY"},{"nm":"Endolymphatic stromal myosis","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Endolymphatic stromal myosis"],"term_type":"SY"},{"nm":"Endometrial sarcoma, NOS","n_c":["C8973"],"i_c":"8930/3","i_c_s":["Endometrial sarcoma, NOS"],"term_type":"SY"},{"nm":"Endometrial stromal nodule","n_c":["C4262"],"i_c":"8930/0","i_c_s":["Endometrial stromal nodule"],"term_type":"PT"},{"nm":"Endometrial stromal sarcoma, high grade","n_c":["C126998"],"i_c":"8930/3","i_c_s":["Endometrial stromal sarcoma, high grade"],"term_type":"RT"},{"nm":"Endometrial stromal sarcoma, low grade","n_c":["C40223"],"i_c":"8931/3","i_c_s":["Endometrial stromal sarcoma, low grade"],"term_type":"PT"},{"nm":"Endometrial stromal sarcoma, NOS","n_c":["C8973"],"i_c":"8930/3","i_c_s":["Endometrial stromal sarcoma, NOS"],"term_type":"PT"},{"nm":"Endometrial stromatosis","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Endometrial stromatosis"],"term_type":"SY"},{"nm":"Endometrioid adenocarcinoma, ciliated cell variant","n_c":["C27848"],"i_c":"8383/3","i_c_s":["Endometrioid adenocarcinoma, ciliated cell variant"],"term_type":"PT"},{"nm":"Endometrioid adenocarcinoma, NOS","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Endometrioid adenocarcinoma, secretory variant","n_c":["C27839"],"i_c":"8382/3","i_c_s":["Endometrioid adenocarcinoma, secretory variant"],"term_type":"PT"},{"nm":"Endometrioid adenocarcinoma, villoglandular","n_c":["C27846"],"i_c":"8263/3","i_c_s":["Endometrioid adenocarcinoma, villoglandular"],"term_type":""},{"nm":"Endometrioid adenofibroma, borderline malignancy","n_c":["C40069"],"i_c":"8381/1","i_c_s":["Endometrioid adenofibroma, borderline malignancy"],"term_type":"PT"},{"nm":"Endometrioid adenofibroma, malignant","n_c":["C40060"],"i_c":"8381/3","i_c_s":["Endometrioid adenofibroma, malignant"],"term_type":"PT"},{"nm":"Endometrioid adenofibroma, NOS","n_c":["C27287"],"i_c":"8381/0","i_c_s":["Endometrioid adenofibroma, NOS"],"term_type":"PT"},{"nm":"Endometrioid adenoma, borderline malignancy","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid adenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Endometrioid adenoma, NOS","n_c":["C27287"],"i_c":"8380/0","i_c_s":["Endometrioid adenoma, NOS"],"term_type":"PT"},{"nm":"Endometrioid carcinoma with squamous differentiation","n_c":["C6290"],"i_c":"8570/3","i_c_s":["Endometrioid carcinoma with squamous differentiation"],"term_type":""},{"nm":"Endometrioid carcinoma, NOS","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid carcinoma, NOS"],"term_type":"SY"},{"nm":"Endometrioid cystadenocarcinoma","n_c":["C3769"],"i_c":"8380/3","i_c_s":["Endometrioid cystadenocarcinoma"],"term_type":"RT"},{"nm":"Endometrioid cystadenofibroma, borderline malignancy","n_c":["C40069"],"i_c":"8381/1","i_c_s":["Endometrioid cystadenofibroma, borderline malignancy"],"term_type":"SY"},{"nm":"Endometrioid cystadenofibroma, malignant","n_c":"","i_c":"8381/3","i_c_s":["Endometrioid cystadenofibroma, malignant"],"term_type":"SY"},{"nm":"Endometrioid cystadenofibroma, NOS","n_c":["C27288"],"i_c":"8381/0","i_c_s":["Endometrioid cystadenofibroma, NOS"],"term_type":"SY"},{"nm":"Endometrioid cystadenoma, borderline malignancy","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Endometrioid cystadenoma, NOS","n_c":"","i_c":"8380/0","i_c_s":["Endometrioid cystadenoma, NOS"],"term_type":"SY"},{"nm":"Endometrioid tumor of low malignant potential","n_c":["C7983"],"i_c":"8380/1","i_c_s":["Endometrioid tumor of low malignant potential"],"term_type":"SY"},{"nm":"Endotheliomatous meningioma","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Endotheliomatous meningioma"],"term_type":"SY"},{"nm":"Endovascular papillary angioendothelioma","n_c":["C7526"],"i_c":"9135/1","i_c_s":["Endovascular papillary angioendothelioma"],"term_type":"PT"},{"nm":"Enteric adenocarcinoma","n_c":"","i_c":"8144/3","i_c_s":["Enteric adenocarcinoma"],"term_type":""},{"nm":"Enterochromaffin cell carcinoid","n_c":["C188218"],"i_c":"8241/3","i_c_s":["Enterochromaffin cell carcinoid"],"term_type":"PT"},{"nm":"Enterochromaffin-like cell carcinoid, NOS","n_c":["C27252"],"i_c":"8242/1","i_c_s":["Enterochromaffin-like cell carcinoid, NOS"],"term_type":"PT"},{"nm":"Enterochromaffin-like cell tumor, malignant","n_c":["C27252"],"i_c":"8242/3","i_c_s":["Enterochromaffin-like cell tumor, malignant"],"term_type":"PT"},{"nm":"Enteroglucagonoma, malignant","n_c":["C65191"],"i_c":"8152/3","i_c_s":["Enteroglucagonoma, malignant"],"term_type":"RT"},{"nm":"Enteroglucagonoma, NOS","n_c":["C66925"],"i_c":"8152/1","i_c_s":["Enteroglucagonoma, NOS"],"term_type":"RT"},{"nm":"Enteropathy associated T-cell lymphoma","n_c":["C4737"],"i_c":"9717/3","i_c_s":["Enteropathy associated T-cell lymphoma"],"term_type":"SY"},{"nm":"Enteropathy type intestinal T-cell lymphoma","n_c":["C4737"],"i_c":"9717/3","i_c_s":["Enteropathy type intestinal T-cell lymphoma"],"term_type":"SY"},{"nm":"Eosinophil adenocarcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Eosinophil adenocarcinoma"],"term_type":"SY"},{"nm":"Eosinophil adenoma","n_c":["C6780"],"i_c":"8280/0","i_c_s":["Eosinophil adenoma"],"term_type":"SY"},{"nm":"Eosinophil carcinoma","n_c":["C4147"],"i_c":"8280/3","i_c_s":["Eosinophil carcinoma"],"term_type":"SY"},{"nm":"Eosinophilic granuloma","n_c":["C3016"],"i_c":"9751/3","i_c_s":["Eosinophilic granuloma"],"term_type":"RT"},{"nm":"Eosinophilic leukemia","n_c":["C4563"],"i_c":"9860/3","i_c_s":["Eosinophilic leukemia"],"term_type":"RT"},{"nm":"Ependymoblastoma","n_c":["C4915"],"i_c":"9392/3","i_c_s":["Ependymoblastoma"],"term_type":"SY"},{"nm":"Ependymoma, anaplastic","n_c":["C4049"],"i_c":"9392/3","i_c_s":["Ependymoma, anaplastic"],"term_type":"PT"},{"nm":"Ependymoma, NOS","n_c":["C3017"],"i_c":"9391/3","i_c_s":["Ependymoma, NOS"],"term_type":"PT"},{"nm":"Ependymoma, RELA fusion-positive","n_c":["C129351"],"i_c":"9396/3","i_c_s":["Ependymoma, RELA fusion-positive"],"term_type":"PT"},{"nm":"Epidermoid carcinoma in situ with questionable stromal invasion","n_c":["C65176"],"i_c":"8076/2","i_c_s":["Epidermoid carcinoma in situ with questionable stromal invasion"],"term_type":"SY"},{"nm":"Epidermoid carcinoma in situ, NOS","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Epidermoid carcinoma in situ, NOS"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, keratinizing","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Epidermoid carcinoma, keratinizing"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, large cell, nonkeratinizing","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Epidermoid carcinoma, large cell, nonkeratinizing"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, NOS","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Epidermoid carcinoma, NOS"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, small cell, nonkeratinizing","n_c":["C65175"],"i_c":"8073/3","i_c_s":["Epidermoid carcinoma, small cell, nonkeratinizing"],"term_type":"SY"},{"nm":"Epidermoid carcinoma, spindle cell","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Epidermoid carcinoma, spindle cell"],"term_type":"SY"},{"nm":"Epithelial ependymoma","n_c":["C3017"],"i_c":"9391/3","i_c_s":["Epithelial ependymoma"],"term_type":"SY"},{"nm":"Epithelial tumor, benign","n_c":["C4092"],"i_c":"8010/0","i_c_s":["Epithelial tumor, benign"],"term_type":"PT"},{"nm":"Epithelial tumor, malignant","n_c":["C2916"],"i_c":"8010/3","i_c_s":["Epithelial tumor, malignant"],"term_type":"SY"},{"nm":"Epithelial-myoepithelial carcinoma","n_c":["C4199"],"i_c":"8562/3","i_c_s":["Epithelial-myoepithelial carcinoma"],"term_type":"PT"},{"nm":"Epithelioid and spindle cell nevus","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Epithelioid and spindle cell nevus"],"term_type":"PT"},{"nm":"Epithelioid cell melanoma","n_c":["C4236"],"i_c":"8771/3","i_c_s":["Epithelioid cell melanoma"],"term_type":"PT"},{"nm":"Epithelioid cell nevus","n_c":["C66757"],"i_c":"8771/0","i_c_s":["Epithelioid cell nevus"],"term_type":"PT"},{"nm":"Epithelioid cell sarcoma","n_c":["C3714"],"i_c":"8804/3","i_c_s":["Epithelioid cell sarcoma"],"term_type":"SY"},{"nm":"Epithelioid glioblastoma","n_c":["C129293"],"i_c":"9440/3","i_c_s":["Epithelioid glioblastoma"],"term_type":""},{"nm":"Epithelioid hemangioendothelioma, malignant","n_c":["C3800"],"i_c":"9133/3","i_c_s":["Epithelioid hemangioendothelioma, malignant"],"term_type":"PT"},{"nm":"Epithelioid hemangioendothelioma, NOS","n_c":["C3800"],"i_c":"9133/1","i_c_s":["Epithelioid hemangioendothelioma, NOS"],"term_type":"PT"},{"nm":"Epithelioid hemangioma","n_c":["C4298"],"i_c":"9125/0","i_c_s":["Epithelioid hemangioma"],"term_type":"PT"},{"nm":"Epithelioid leiomyoma","n_c":["C40164","C3486"],"i_c":"8891/0","i_c_s":["Epithelioid leiomyoma"],"term_type":"PT"},{"nm":"Epithelioid leiomyosarcoma","n_c":["C3700"],"i_c":"8891/3","i_c_s":["Epithelioid leiomyosarcoma"],"term_type":"PT"},{"nm":"Epithelioid malignant peripheral nerve sheath tumor","n_c":["C6561"],"i_c":"9542/3","i_c_s":["Epithelioid malignant peripheral nerve sheath tumor"],"term_type":"PT"},{"nm":"Epithelioid mesothelioma, benign","n_c":["C3762"],"i_c":"9052/0","i_c_s":["Epithelioid mesothelioma, benign"],"term_type":"PT"},{"nm":"Epithelioid mesothelioma, malignant","n_c":["C7985"],"i_c":"9052/3","i_c_s":["Epithelioid mesothelioma, malignant"],"term_type":"PT"},{"nm":"Epithelioid mesothelioma, NOS","n_c":["C7985"],"i_c":"9052/3","i_c_s":["Epithelioid mesothelioma, NOS"],"term_type":"SY"},{"nm":"Epithelioid MPNST","n_c":["C6561"],"i_c":"9540/3","i_c_s":["Epithelioid MPNST"],"term_type":"RT"},{"nm":"Epithelioid sarcoma","n_c":["C3714"],"i_c":"8804/3","i_c_s":["Epithelioid sarcoma"],"term_type":"PT"},{"nm":"Epithelioma adenoides cysticum","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Epithelioma adenoides cysticum"],"term_type":"SY"},{"nm":"Epithelioma, benign","n_c":["C4092"],"i_c":"8011/0","i_c_s":["Epithelioma, benign"],"term_type":"PT"},{"nm":"Epithelioma, malignant","n_c":["C3709"],"i_c":"8011/3","i_c_s":["Epithelioma, malignant"],"term_type":"PT"},{"nm":"Epithelioma, NOS","n_c":["C3709"],"i_c":"8011/3","i_c_s":["Epithelioma, NOS"],"term_type":"SY"},{"nm":"Erythremic myelosis, NOS","n_c":["C7467"],"i_c":"9840/3","i_c_s":["Erythremic myelosis, NOS"],"term_type":"SY"},{"nm":"Erythroleukemia","n_c":["C7152"],"i_c":"9840/3","i_c_s":["Erythroleukemia"],"term_type":"SY"},{"nm":"Esophageal glandular dysplasia (intraepithelial neoplasia), high grade","n_c":["C27429"],"i_c":"8148/2","i_c_s":["Esophageal glandular dysplasia (intraepithelial neoplasia), high grade"],"term_type":"RT"},{"nm":"Esophageal glandular dysplasia (intraepithelial neoplasia), low grade","n_c":["C27428"],"i_c":"8148/0","i_c_s":["Esophageal glandular dysplasia (intraepithelial neoplasia), low grade"],"term_type":"RT"},{"nm":"Esophageal intraepithelial neoplasia, high grade","n_c":["C27425"],"i_c":"8148/2","i_c_s":["Esophageal intraepithelial neoplasia, high grade"],"term_type":"SY"},{"nm":"Esophageal squamous intraepithelial neoplasia (dysplasia), high grade","n_c":["C27426"],"i_c":"8077/2","i_c_s":["Esophageal squamous intraepithelial neoplasia (dysplasia), high grade"],"term_type":"RT"},{"nm":"Esophageal squamous intraepithelial neoplasia (dysplasia), low grade","n_c":["C27427"],"i_c":"8077/0","i_c_s":["Esophageal squamous intraepithelial neoplasia (dysplasia), low grade"],"term_type":"RT"},{"nm":"Essential hemorrhagic thrombocythaemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Essential hemorrhagic thrombocythaemia"],"term_type":""},{"nm":"Essential thrombocythemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Essential thrombocythemia"],"term_type":"PT"},{"nm":"Esthesioneuroblastoma","n_c":["C3789"],"i_c":"9522/3","i_c_s":["Esthesioneuroblastoma"],"term_type":"SY"},{"nm":"Esthesioneurocytoma","n_c":"","i_c":"9521/3","i_c_s":["Esthesioneurocytoma"],"term_type":"SY"},{"nm":"Esthesioneuroepithelioma","n_c":["C3789"],"i_c":"9523/3","i_c_s":["Esthesioneuroepithelioma"],"term_type":"SY"},{"nm":"Ewing sarcoma","n_c":["C4817"],"i_c":"9260/3","i_c_s":["Ewing sarcoma"],"term_type":"PT"},{"nm":"Ewing tumor","n_c":["C4817"],"i_c":"9260/3","i_c_s":["Ewing tumor"],"term_type":"SY"},{"nm":"Extra-abdominal desmoid","n_c":["C6489"],"i_c":"8821/1","i_c_s":["Extra-abdominal desmoid"],"term_type":"SY"},{"nm":"Extra-adrenal paraganglioma, malignant","n_c":["C4219"],"i_c":"8693/3","i_c_s":["Extra-adrenal paraganglioma, malignant"],"term_type":"PT"},{"nm":"Extra-adrenal paraganglioma, NOS","n_c":["C3309"],"i_c":"8693/1","i_c_s":["Extra-adrenal paraganglioma, NOS"],"term_type":"PT"},{"nm":"Extracutaneous mastocytoma","n_c":["C7136"],"i_c":"9740/1","i_c_s":["Extracutaneous mastocytoma"],"term_type":"SY"},{"nm":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue","n_c":["C3898"],"i_c":"9699/3","i_c_s":["Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue"],"term_type":"RT"},{"nm":"Extranodal NK/T-cell lymphoma, nasal type","n_c":["C4684"],"i_c":"9719/3","i_c_s":["Extranodal NK/T-cell lymphoma, nasal type"],"term_type":"SY"},{"nm":"Extraosseous plasmacytoma","n_c":["C4002"],"i_c":"9734/3","i_c_s":["Extraosseous plasmacytoma"],"term_type":"SY"},{"nm":"Extraventricular neurocytoma","n_c":["C92555"],"i_c":"9506/1","i_c_s":["Extraventricular neurocytoma"],"term_type":"RT"},{"nm":"FAB L2","n_c":["C27281"],"i_c":"9835/3","i_c_s":["FAB L2"],"term_type":"SY"},{"nm":"FAB L3","n_c":["C7400"],"i_c":"9826/3","i_c_s":["FAB L3"],"term_type":"IS"},{"nm":"FAB Ll","n_c":["C27290"],"i_c":"9835/3","i_c_s":["FAB Ll"],"term_type":""},{"nm":"FAB M1","n_c":["C3249"],"i_c":"9873/3","i_c_s":["FAB M1"],"term_type":"SY"},{"nm":"FAB M2, AML1(CBF-alpha)/ETO","n_c":["C9288"],"i_c":"9896/3","i_c_s":["FAB M2, AML1(CBF-alpha)/ETO"],"term_type":"SY"},{"nm":"FAB M2, NOS","n_c":["C3250"],"i_c":"9874/3","i_c_s":["FAB M2, NOS"],"term_type":"SY"},{"nm":"FAB M2, t(8;21)(q22;q22)","n_c":["C9288"],"i_c":"9896/3","i_c_s":["FAB M2, t(8;21)(q22;q22)"],"term_type":"SY"},{"nm":"FAB M3 (includes all variants)","n_c":["C3182"],"i_c":"9866/3","i_c_s":["FAB M3 (includes all variants)"],"term_type":""},{"nm":"FAB M4","n_c":["C7463"],"i_c":"9867/3","i_c_s":["FAB M4"],"term_type":"SY"},{"nm":"FAB M4Eo","n_c":["C9020"],"i_c":"9871/3","i_c_s":["FAB M4Eo"],"term_type":"SY"},{"nm":"FAB M5 (includes all variants)","n_c":["C7318"],"i_c":"9891/3","i_c_s":["FAB M5 (includes all variants)"],"term_type":""},{"nm":"FAB M6","n_c":["C8923"],"i_c":"9840/3","i_c_s":["FAB M6"],"term_type":"SY"},{"nm":"FAB M7","n_c":["C3170"],"i_c":"9910/3","i_c_s":["FAB M7"],"term_type":"SY"},{"nm":"FAB MO","n_c":["C8460"],"i_c":"9872/3","i_c_s":["FAB MO"],"term_type":""},{"nm":"Familial polyposis coli","n_c":["C3339"],"i_c":"8220/0","i_c_s":["Familial polyposis coli"],"term_type":"SY"},{"nm":"Fascial fibroma","n_c":["C66764"],"i_c":"8813/0","i_c_s":["Fascial fibroma"],"term_type":"PT"},{"nm":"Fascial fibrosarcoma","n_c":["C66765"],"i_c":"8813/3","i_c_s":["Fascial fibrosarcoma"],"term_type":"PT"},{"nm":"Fetal adenocarcinoma","n_c":["C45509"],"i_c":"8333/3","i_c_s":["Fetal adenocarcinoma"],"term_type":"PT"},{"nm":"Fetal adenoma","n_c":["C4160"],"i_c":"8333/0","i_c_s":["Fetal adenoma"],"term_type":"SY"},{"nm":"Fetal fat cell lipoma","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Fetal fat cell lipoma"],"term_type":"SY"},{"nm":"Fetal lipoma, NOS","n_c":["C27483"],"i_c":"8881/0","i_c_s":["Fetal lipoma, NOS"],"term_type":"SY"},{"nm":"Fetal lipomatosis","n_c":["C4255"],"i_c":"8881/0","i_c_s":["Fetal lipomatosis"],"term_type":"SY"},{"nm":"Fetal rhabdomyoma","n_c":["C4260"],"i_c":"8903/0","i_c_s":["Fetal rhabdomyoma"],"term_type":"PT"},{"nm":"Fibrillary astrocytoma","n_c":["C4322"],"i_c":"9420/3","i_c_s":["Fibrillary astrocytoma"],"term_type":"PT"},{"nm":"Fibro-osteoma","n_c":["C173820"],"i_c":"9262/0","i_c_s":["Fibro-osteoma"],"term_type":"SY"},{"nm":"Fibroadenoma, NOS","n_c":["C3744"],"i_c":"9010/0","i_c_s":["Fibroadenoma, NOS"],"term_type":"PT"},{"nm":"Fibroameloblastic odontoma","n_c":["C3710"],"i_c":"9290/0","i_c_s":["Fibroameloblastic odontoma"],"term_type":"SY"},{"nm":"Fibroblastic liposarcoma","n_c":["C6509"],"i_c":"8857/3","i_c_s":["Fibroblastic liposarcoma"],"term_type":"PT"},{"nm":"Fibroblastic meningioma","n_c":["C4330"],"i_c":"9532/0","i_c_s":["Fibroblastic meningioma"],"term_type":"SY"},{"nm":"Fibroblastic osteosarcoma","n_c":["C4020"],"i_c":"9182/3","i_c_s":["Fibroblastic osteosarcoma"],"term_type":"PT"},{"nm":"Fibroblastic reticular cell tumor","n_c":["C81758"],"i_c":"9759/3","i_c_s":["Fibroblastic reticular cell tumor"],"term_type":"PT"},{"nm":"Fibrochondrosarcoma","n_c":["C2946"],"i_c":"9220/3","i_c_s":["Fibrochondrosarcoma"],"term_type":"RT"},{"nm":"Fibroepithelial basal cell carcinoma, Pinkus type","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Fibroepithelial basal cell carcinoma, Pinkus type"],"term_type":"SY"},{"nm":"Fibroepithelioma of Pinkus type","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Fibroepithelioma of Pinkus type"],"term_type":"SY"},{"nm":"Fibroepithelioma, NOS","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Fibroepithelioma, NOS"],"term_type":"SY"},{"nm":"Fibrofolliculoma","n_c":["C43331"],"i_c":"8391/0","i_c_s":["Fibrofolliculoma"],"term_type":"SY"},{"nm":"Fibroid uterus","n_c":["C3434"],"i_c":"8890/0","i_c_s":["Fibroid uterus"],"term_type":"SY"},{"nm":"Fibrolipoma","n_c":["C4249"],"i_c":"8851/0","i_c_s":["Fibrolipoma"],"term_type":"PT"},{"nm":"Fibroliposarcoma","n_c":["C3194"],"i_c":"8850/3","i_c_s":["Fibroliposarcoma"],"term_type":"SY"},{"nm":"Fibroma, NOS","n_c":["C3041"],"i_c":"8810/0","i_c_s":["Fibroma, NOS"],"term_type":"PT"},{"nm":"Fibromatosis-like metaplastic carcinoma","n_c":"","i_c":"8572/3","i_c_s":["Fibromatosis-like metaplastic carcinoma"],"term_type":""},{"nm":"Fibromyoma","n_c":["C3434"],"i_c":"8890/0","i_c_s":["Fibromyoma"],"term_type":"SY"},{"nm":"Fibromyxolipoma","n_c":["C4251"],"i_c":"8852/0","i_c_s":["Fibromyxolipoma"],"term_type":"PT"},{"nm":"Fibromyxoma","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Fibromyxoma"],"term_type":"PT"},{"nm":"Fibromyxosarcoma","n_c":["C6496"],"i_c":"8811/3","i_c_s":["Fibromyxosarcoma"],"term_type":"PT"},{"nm":"Fibrosarcoma, NOS","n_c":["C3043"],"i_c":"8810/3","i_c_s":["Fibrosarcoma, NOS"],"term_type":"PT"},{"nm":"Fibrosarcomatous dermatofibrosarcoma protuberans","n_c":["C27547"],"i_c":"8832/3","i_c_s":["Fibrosarcomatous dermatofibrosarcoma protuberans"],"term_type":""},{"nm":"Fibrous astrocytoma","n_c":["C4322"],"i_c":"9420/3","i_c_s":["Fibrous astrocytoma"],"term_type":"SY"},{"nm":"Fibrous histiocytoma of tendon sheath","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Fibrous histiocytoma of tendon sheath"],"term_type":"SY"},{"nm":"Fibrous histiocytoma, NOS","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Fibrous histiocytoma, NOS"],"term_type":"SY"},{"nm":"Fibrous meningioma","n_c":["C4330"],"i_c":"9532/0","i_c_s":["Fibrous meningioma"],"term_type":"PT"},{"nm":"Fibrous mesothelioma, benign","n_c":["C4457"],"i_c":"9051/0","i_c_s":["Fibrous mesothelioma, benign"],"term_type":"PT"},{"nm":"Fibrous mesothelioma, malignant","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Fibrous mesothelioma, malignant"],"term_type":"PT"},{"nm":"Fibrous mesothelioma, NOS","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Fibrous mesothelioma, NOS"],"term_type":"SY"},{"nm":"Fibrous papule of nose","n_c":"","i_c":"9160/0","i_c_s":["Fibrous papule of nose"],"term_type":"IS"},{"nm":"Fibroxanthoma, malignant","n_c":["C4247"],"i_c":"8830/3","i_c_s":["Fibroxanthoma, malignant"],"term_type":"SY"},{"nm":"Fibroxanthoma, NOS","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Fibroxanthoma, NOS"],"term_type":"SY"},{"nm":"Flat adenoma","n_c":["C65193"],"i_c":"8212/0","i_c_s":["Flat adenoma"],"term_type":"PT"},{"nm":"Flat intraepithelial glandular neoplasia, high grade","n_c":"","i_c":"8148/2","i_c_s":["Flat intraepithelial glandular neoplasia, high grade"],"term_type":"RT"},{"nm":"Flat intraepithelial neoplasia, high grade","n_c":"","i_c":"8148/2","i_c_s":["Flat intraepithelial neoplasia, high grade"],"term_type":"SY"},{"nm":"Florid osseous dysplasia","n_c":["C202219"],"i_c":"9275/0","i_c_s":["Florid osseous dysplasia"],"term_type":"SY"},{"nm":"Follicular adenocarcinoma, moderately differentiated","n_c":"","i_c":"8332/3","i_c_s":["Follicular adenocarcinoma, moderately differentiated"],"term_type":"RT"},{"nm":"Follicular adenocarcinoma, NOS","n_c":["C8054"],"i_c":"8330/3","i_c_s":["Follicular adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Follicular adenocarcinoma, trabecular","n_c":["C46095"],"i_c":"8332/3","i_c_s":["Follicular adenocarcinoma, trabecular"],"term_type":"PT"},{"nm":"Follicular adenocarcinoma, well differentiated","n_c":["C8054"],"i_c":"8331/3","i_c_s":["Follicular adenocarcinoma, well differentiated"],"term_type":"PT"},{"nm":"Follicular adenoma","n_c":["C3502"],"i_c":"8330/0","i_c_s":["Follicular adenoma"],"term_type":"PT"},{"nm":"Follicular adenoma, oxyphilic cell","n_c":["C3759"],"i_c":"8290/0","i_c_s":["Follicular adenoma, oxyphilic cell"],"term_type":"RT"},{"nm":"Follicular carcinoma, encapsulated","n_c":"","i_c":"8335/3","i_c_s":["Follicular carcinoma, encapsulated"],"term_type":"SY"},{"nm":"Follicular carcinoma, minimally invasive","n_c":["C65200"],"i_c":"8335/3","i_c_s":["Follicular carcinoma, minimally invasive"],"term_type":"PT"},{"nm":"Follicular carcinoma, moderately differentiated","n_c":"","i_c":"8332/3","i_c_s":["Follicular carcinoma, moderately differentiated"],"term_type":"SY"},{"nm":"Follicular carcinoma, NOS","n_c":["C8054"],"i_c":"8330/3","i_c_s":["Follicular carcinoma, NOS"],"term_type":"SY"},{"nm":"Follicular carcinoma, oxyphilic cell","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Follicular carcinoma, oxyphilic cell"],"term_type":"RT"},{"nm":"Follicular carcinoma, trabecular","n_c":"","i_c":"8332/3","i_c_s":["Follicular carcinoma, trabecular"],"term_type":"SY"},{"nm":"Follicular carcinoma, well differentiated","n_c":["C8054"],"i_c":"8331/3","i_c_s":["Follicular carcinoma, well differentiated"],"term_type":"SY"},{"nm":"Follicular dendritic cell sarcoma","n_c":["C9281"],"i_c":"9758/3","i_c_s":["Follicular dendritic cell sarcoma"],"term_type":"PT"},{"nm":"Follicular dendritic cell tumor","n_c":["C9281"],"i_c":"9758/3","i_c_s":["Follicular dendritic cell tumor"],"term_type":"RT"},{"nm":"Follicular fibroma","n_c":["C43331"],"i_c":"8391/0","i_c_s":["Follicular fibroma"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 1","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Follicular lymphoma, grade 1"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 2","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Follicular lymphoma, grade 2"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 3","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3"],"term_type":"PT"},{"nm":"Follicular lymphoma, grade 3A","n_c":["C7191"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3A"],"term_type":"SY"},{"nm":"Follicular lymphoma, grade 3B","n_c":["C7192"],"i_c":"9698/3","i_c_s":["Follicular lymphoma, grade 3B"],"term_type":"SY"},{"nm":"Follicular lymphoma, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Follicular lymphoma, NOS"],"term_type":"PT"},{"nm":"Follicular lymphoma, small cleaved cell","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Follicular lymphoma, small cleaved cell"],"term_type":"SY"},{"nm":"Follicular thyroid carcinoma (FTC), encapsulated angioinvasive","n_c":["C156122"],"i_c":"8339/3","i_c_s":["Follicular thyroid carcinoma (FTC), encapsulated angioinvasive"],"term_type":"PT"},{"nm":"Folliculome lipidique","n_c":"","i_c":"8641/0","i_c_s":["Folliculome lipidique"],"term_type":"SY"},{"nm":"Franklin disease","n_c":["C3083"],"i_c":"9762/3","i_c_s":["Franklin disease"],"term_type":"SY"},{"nm":"G cell tumor, malignant","n_c":["C65188"],"i_c":"8153/3","i_c_s":["G cell tumor, malignant"],"term_type":"SY"},{"nm":"G cell tumor, NOS","n_c":["C3050"],"i_c":"8153/1","i_c_s":["G cell tumor, NOS"],"term_type":"SY"},{"nm":"Gamma heavy chain disease","n_c":["C3083"],"i_c":"9762/3","i_c_s":["Gamma heavy chain disease"],"term_type":"RT"},{"nm":"Gangliocytic paraganglioma","n_c":["C188229"],"i_c":"8683/0","i_c_s":["Gangliocytic paraganglioma"],"term_type":"PT"},{"nm":"Gangliocytoma","n_c":["C6934"],"i_c":"9492/0","i_c_s":["Gangliocytoma"],"term_type":"PT"},{"nm":"Ganglioglioma, anaplastic","n_c":["C4717"],"i_c":"9505/3","i_c_s":["Ganglioglioma, anaplastic"],"term_type":"PT"},{"nm":"Ganglioglioma, NOS","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Ganglioglioma, NOS"],"term_type":"PT"},{"nm":"Ganglioneuroblastoma","n_c":["C3790"],"i_c":"9490/3","i_c_s":["Ganglioneuroblastoma"],"term_type":"PT"},{"nm":"Ganglioneuroma","n_c":["C3049"],"i_c":"9490/0","i_c_s":["Ganglioneuroma"],"term_type":"PT"},{"nm":"Ganglioneuromatosis","n_c":["C66804"],"i_c":"9491/0","i_c_s":["Ganglioneuromatosis"],"term_type":"PT"},{"nm":"GANT","n_c":["C27940"],"i_c":"8936/1","i_c_s":["GANT"],"term_type":"SY"},{"nm":"Gastrin cell tumor","n_c":["C3050"],"i_c":"8153/1","i_c_s":["Gastrin cell tumor"],"term_type":"SY"},{"nm":"Gastrin cell tumor, malignant","n_c":["C65188"],"i_c":"8153/3","i_c_s":["Gastrin cell tumor, malignant"],"term_type":"SY"},{"nm":"Gastrinoma, malignant","n_c":["C65188"],"i_c":"8153/3","i_c_s":["Gastrinoma, malignant"],"term_type":"PT"},{"nm":"Gastrinoma, NOS","n_c":["C3050"],"i_c":"8153/1","i_c_s":["Gastrinoma, NOS"],"term_type":"PT"},{"nm":"Gastrointestinal autonomic nerve tumor","n_c":["C27940"],"i_c":"8936/1","i_c_s":["Gastrointestinal autonomic nerve tumor"],"term_type":"RT"},{"nm":"Gastrointestinal pacemaker cell tumor","n_c":"","i_c":"8936/1","i_c_s":["Gastrointestinal pacemaker cell tumor"],"term_type":"RT"},{"nm":"Gastrointestinal stromal sarcoma","n_c":["C53999"],"i_c":"8936/3","i_c_s":["Gastrointestinal stromal sarcoma"],"term_type":"PT"},{"nm":"Gastrointestinal stromal tumor, benign","n_c":["C53998"],"i_c":"8936/0","i_c_s":["Gastrointestinal stromal tumor, benign"],"term_type":"PT"},{"nm":"Gastrointestinal stromal tumor, malignant","n_c":["C53999"],"i_c":"8936/3","i_c_s":["Gastrointestinal stromal tumor, malignant"],"term_type":"SY"},{"nm":"Gastrointestinal stromal tumor, NOS","n_c":["C3868"],"i_c":"8936/1","i_c_s":["Gastrointestinal stromal tumor, NOS"],"term_type":"PT"},{"nm":"Gastrointestinal stromal tumor, uncertain malignant potential","n_c":["C54000"],"i_c":"8936/1","i_c_s":["Gastrointestinal stromal tumor, uncertain malignant potential"],"term_type":"SY"},{"nm":"Gelatinous adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Gelatinous adenocarcinoma"],"term_type":"IS"},{"nm":"Gelatinous carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Gelatinous carcinoma"],"term_type":"IS"},{"nm":"Gemistocytic astrocytoma","n_c":["C4321"],"i_c":"9411/3","i_c_s":["Gemistocytic astrocytoma"],"term_type":"PT"},{"nm":"Gemistocytoma","n_c":["C4321"],"i_c":"9411/3","i_c_s":["Gemistocytoma"],"term_type":"SY"},{"nm":"Genital rhabdomyoma","n_c":["C6517"],"i_c":"8905/0","i_c_s":["Genital rhabdomyoma"],"term_type":"PT"},{"nm":"Germ cell tumor, nonseminomatous","n_c":["C121619"],"i_c":"9065/3","i_c_s":["Germ cell tumor, nonseminomatous"],"term_type":"PT"},{"nm":"Germ cell tumor, NOS","n_c":["C3708"],"i_c":"9064/3","i_c_s":["Germ cell tumor, NOS"],"term_type":"SY"},{"nm":"Germ cell tumors with associated hematological malignancy","n_c":["C45733"],"i_c":"9086/3","i_c_s":["Germ cell tumors with associated hematological malignancy"],"term_type":"PT"},{"nm":"Germinoma","n_c":["C7009"],"i_c":"9064/3","i_c_s":["Germinoma"],"term_type":"PT"},{"nm":"Ghost cell odontogenic carcinoma","n_c":["C4311"],"i_c":"9302/3","i_c_s":["Ghost cell odontogenic carcinoma"],"term_type":""},{"nm":"Giant cell and spindle cell carcinoma","n_c":["C65160"],"i_c":"8030/3","i_c_s":["Giant cell and spindle cell carcinoma"],"term_type":"PT"},{"nm":"Giant cell angiofibroma","n_c":["C27256"],"i_c":"9160/0","i_c_s":["Giant cell angiofibroma"],"term_type":"RT"},{"nm":"Giant cell carcinoma","n_c":["C3779"],"i_c":"8031/3","i_c_s":["Giant cell carcinoma"],"term_type":"PT"},{"nm":"Giant cell fibroblastoma","n_c":["C4700"],"i_c":"8834/1","i_c_s":["Giant cell fibroblastoma"],"term_type":"PT"},{"nm":"Giant cell glioblastoma","n_c":["C4325"],"i_c":"9441/3","i_c_s":["Giant cell glioblastoma"],"term_type":"PT"},{"nm":"Giant cell sarcoma","n_c":["C66759"],"i_c":"8802/3","i_c_s":["Giant cell sarcoma"],"term_type":"PT"},{"nm":"Giant cell sarcoma of bone","n_c":["C4304"],"i_c":"9250/3","i_c_s":["Giant cell sarcoma of bone"],"term_type":"SY"},{"nm":"Giant cell tumor of bone, malignant","n_c":["C4304"],"i_c":"9250/3","i_c_s":["Giant cell tumor of bone, malignant"],"term_type":"PT"},{"nm":"Giant cell tumor of bone, NOS","n_c":["C121932"],"i_c":"9250/1","i_c_s":["Giant cell tumor of bone, NOS"],"term_type":"PT"},{"nm":"Giant cell tumor of soft parts, NOS","n_c":["C49107"],"i_c":"9251/1","i_c_s":["Giant cell tumor of soft parts, NOS"],"term_type":"PT"},{"nm":"Giant cell tumor of tendon sheath","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Giant cell tumor of tendon sheath"],"term_type":"SY"},{"nm":"Giant cell tumor of tendon sheath, malignant","n_c":["C6535"],"i_c":"9252/3","i_c_s":["Giant cell tumor of tendon sheath, malignant"],"term_type":"SY"},{"nm":"Giant fibroadenoma","n_c":["C4273"],"i_c":"9016/0","i_c_s":["Giant fibroadenoma"],"term_type":"PT"},{"nm":"Giant osteoid osteoma","n_c":["C3294"],"i_c":"9200/0","i_c_s":["Giant osteoid osteoma"],"term_type":"SY"},{"nm":"Giant pigmented nevus, NOS","n_c":["C4234"],"i_c":"8761/1","i_c_s":["Giant pigmented nevus, NOS"],"term_type":"PT"},{"nm":"Gigantiform cementoma","n_c":["C202219"],"i_c":"9275/0","i_c_s":["Gigantiform cementoma"],"term_type":"PT"},{"nm":"GIST, benign","n_c":["C53998"],"i_c":"8936/0","i_c_s":["GIST, benign"],"term_type":"SY"},{"nm":"GIST, malignant","n_c":["C53999"],"i_c":"8936/3","i_c_s":["GIST, malignant"],"term_type":"SY"},{"nm":"GIST, NOS","n_c":["C3868"],"i_c":"8936/1","i_c_s":["GIST, NOS"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, grade I","n_c":["C7661"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, grade I"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, grade II","n_c":["C7660"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, grade II"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, grade III","n_c":["C6877"],"i_c":"8148/2","i_c_s":["Glandular intraepithelial neoplasia, grade III"],"term_type":"SY"},{"nm":"Glandular intraepithelial neoplasia, high grade","n_c":["C7662"],"i_c":"8148/2","i_c_s":["Glandular intraepithelial neoplasia, high grade"],"term_type":"PT"},{"nm":"Glandular intraepithelial neoplasia, low grade","n_c":["C7661"],"i_c":"8148/0","i_c_s":["Glandular intraepithelial neoplasia, low grade"],"term_type":"PT"},{"nm":"Glandular papilloma","n_c":["C6880"],"i_c":"8260/0","i_c_s":["Glandular papilloma"],"term_type":"RT"},{"nm":"Glassy cell carcinoma","n_c":["C65159"],"i_c":"8015/3","i_c_s":["Glassy cell carcinoma"],"term_type":"PT"},{"nm":"Glioblastoma","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Glioblastoma"],"term_type":""},{"nm":"Glioblastoma multiforme","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Glioblastoma multiforme"],"term_type":"SY"},{"nm":"Glioblastoma with sarcomatous component","n_c":["C3796"],"i_c":"9442/3","i_c_s":["Glioblastoma with sarcomatous component"],"term_type":"SY"},{"nm":"Glioblastoma, IDH wildtype","n_c":["C39750"],"i_c":"9440/3","i_c_s":["Glioblastoma, IDH wildtype"],"term_type":""},{"nm":"Glioblastoma, IDH-mutant","n_c":["C167335"],"i_c":"9445/3","i_c_s":["Glioblastoma, IDH-mutant"],"term_type":"PT"},{"nm":"Gliofibroma","n_c":["C5419"],"i_c":"9442/1","i_c_s":["Gliofibroma"],"term_type":"PT"},{"nm":"Glioma, malignant","n_c":["C4822"],"i_c":"9380/3","i_c_s":["Glioma, malignant"],"term_type":"PT"},{"nm":"Glioma, NOS","n_c":["C3059"],"i_c":"9380/3","i_c_s":["Glioma, NOS"],"term_type":"SY"},{"nm":"Gliomatosis cerebri","n_c":["C4318"],"i_c":"9381/3","i_c_s":["Gliomatosis cerebri"],"term_type":"PT"},{"nm":"Glioneuroma","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Glioneuroma"],"term_type":"IS"},{"nm":"Gliosarcoma","n_c":["C3796"],"i_c":"9442/3","i_c_s":["Gliosarcoma"],"term_type":"PT"},{"nm":"Glomangioma","n_c":["C4222"],"i_c":"8712/0","i_c_s":["Glomangioma"],"term_type":"PT"},{"nm":"Glomangiomyoma","n_c":["C4223"],"i_c":"8713/0","i_c_s":["Glomangiomyoma"],"term_type":"PT"},{"nm":"Glomangiosarcoma","n_c":["C4221"],"i_c":"8710/3","i_c_s":["Glomangiosarcoma"],"term_type":"PT"},{"nm":"Glomoid sarcoma","n_c":["C4221"],"i_c":"8710/3","i_c_s":["Glomoid sarcoma"],"term_type":"SY"},{"nm":"Glomus jugulare tumor, NOS","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Glomus jugulare tumor, NOS"],"term_type":"PT"},{"nm":"Glomus tumor, malignant","n_c":["C4221"],"i_c":"8711/3","i_c_s":["Glomus tumor, malignant"],"term_type":"PT"},{"nm":"Glomus tumor, NOS","n_c":["C3060"],"i_c":"8711/0","i_c_s":["Glomus tumor, NOS"],"term_type":"PT"},{"nm":"Glucagon-like peptide-producing tumor","n_c":"","i_c":"8152/1","i_c_s":["Glucagon-like peptide-producing tumor"],"term_type":"RT"},{"nm":"Glucagonoma, malignant","n_c":["C65187"],"i_c":"8152/3","i_c_s":["Glucagonoma, malignant"],"term_type":"PT"},{"nm":"Glucagonoma, NOS","n_c":"","i_c":"8152/1","i_c_s":["Glucagonoma, NOS"],"term_type":"PT"},{"nm":"Glycogen-rich carcinoma","n_c":["C4153"],"i_c":"8315/3","i_c_s":["Glycogen-rich carcinoma"],"term_type":"PT"},{"nm":"Glycogenic rhabdomyoma","n_c":"","i_c":"8904/0","i_c_s":["Glycogenic rhabdomyoma"],"term_type":"RT"},{"nm":"Goblet cell carcinoid","n_c":["C201135"],"i_c":"8243/3","i_c_s":["Goblet cell carcinoid"],"term_type":"PT"},{"nm":"Gonadal stromal tumor, NOS","n_c":["C3794"],"i_c":"8590/1","i_c_s":["Gonadal stromal tumor, NOS"],"term_type":"SY"},{"nm":"Gonadoblastoma","n_c":["C3754"],"i_c":"9073/1","i_c_s":["Gonadoblastoma"],"term_type":"PT"},{"nm":"Gonocytoma","n_c":["C3754"],"i_c":"9073/1","i_c_s":["Gonocytoma"],"term_type":"SY"},{"nm":"Granular cell adenocarcinoma","n_c":["C3681"],"i_c":"8320/3","i_c_s":["Granular cell adenocarcinoma"],"term_type":"SY"},{"nm":"Granular cell carcinoma","n_c":["C3681"],"i_c":"8320/3","i_c_s":["Granular cell carcinoma"],"term_type":"PT"},{"nm":"Granular cell myoblastoma, malignant","n_c":["C4336"],"i_c":"9580/3","i_c_s":["Granular cell myoblastoma, malignant"],"term_type":"SY"},{"nm":"Granular cell myoblastoma, NOS","n_c":["C3474"],"i_c":"9580/0","i_c_s":["Granular cell myoblastoma, NOS"],"term_type":"SY"},{"nm":"Granular cell tumor of the sellar region","n_c":["C7017"],"i_c":"9582/0","i_c_s":["Granular cell tumor of the sellar region"],"term_type":"PT"},{"nm":"Granular cell tumor, malignant","n_c":["C4336"],"i_c":"9580/3","i_c_s":["Granular cell tumor, malignant"],"term_type":"PT"},{"nm":"Granular cell tumor, NOS","n_c":["C3474"],"i_c":"9580/0","i_c_s":["Granular cell tumor, NOS"],"term_type":"PT"},{"nm":"Granulocytic leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Granulocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Granulocytic sarcoma","n_c":["C35815"],"i_c":"9930/3","i_c_s":["Granulocytic sarcoma"],"term_type":"SY"},{"nm":"Granulosa cell carcinoma","n_c":["C4205"],"i_c":"8620/3","i_c_s":["Granulosa cell carcinoma"],"term_type":"RT"},{"nm":"Granulosa cell tumor, adult type","n_c":["C66750"],"i_c":"8620/1","i_c_s":["Granulosa cell tumor, adult type"],"term_type":"PT"},{"nm":"Granulosa cell tumor, juvenile","n_c":["C4207"],"i_c":"8622/1","i_c_s":["Granulosa cell tumor, juvenile"],"term_type":"PT"},{"nm":"Granulosa cell tumor, malignant","n_c":["C4205"],"i_c":"8620/3","i_c_s":["Granulosa cell tumor, malignant"],"term_type":"PT"},{"nm":"Granulosa cell tumor, NOS","n_c":["C3070"],"i_c":"8620/1","i_c_s":["Granulosa cell tumor, NOS"],"term_type":"SY"},{"nm":"Granulosa cell tumor, sarcomatoid","n_c":"","i_c":"8620/3","i_c_s":["Granulosa cell tumor, sarcomatoid"],"term_type":"RT"},{"nm":"Granulosa cell-theca cell tumor","n_c":["C66751"],"i_c":"8621/1","i_c_s":["Granulosa cell-theca cell tumor"],"term_type":"PT"},{"nm":"Grawitz tumor","n_c":["C4033"],"i_c":"8312/3","i_c_s":["Grawitz tumor"],"term_type":"IS"},{"nm":"Gynandroblastoma","n_c":["C3072"],"i_c":"8632/1","i_c_s":["Gynandroblastoma"],"term_type":"PT"},{"nm":"Haemangioblastoma","n_c":["C3801"],"i_c":"9161/1","i_c_s":["Haemangioblastoma"],"term_type":""},{"nm":"Haemangiosarcoma","n_c":["C3088"],"i_c":"9120/3","i_c_s":["Haemangiosarcoma"],"term_type":""},{"nm":"Hairy cell leukaemia variant","n_c":["C7401"],"i_c":"9940/3","i_c_s":["Hairy cell leukaemia variant"],"term_type":""},{"nm":"Hairy cell leukemia","n_c":["C7402"],"i_c":"9940/3","i_c_s":["Hairy cell leukemia"],"term_type":"PT"},{"nm":"Hairy cell leukemia variant","n_c":["C7401"],"i_c":"9591/3","i_c_s":["Hairy cell leukemia variant"],"term_type":"RT"},{"nm":"Hairy nevus","n_c":["C3074"],"i_c":"8720/0","i_c_s":["Hairy nevus"],"term_type":"RT"},{"nm":"Halo nevus","n_c":["C7602"],"i_c":"8723/0","i_c_s":["Halo nevus"],"term_type":"PT"},{"nm":"Hand-Schuller-Christian disease","n_c":["C6920"],"i_c":"9751/3","i_c_s":["Hand-Schuller-Christian disease"],"term_type":"ORT"},{"nm":"Heavy chain disease, NOS","n_c":["C3082"],"i_c":"9762/3","i_c_s":["Heavy chain disease, NOS"],"term_type":"PT"},{"nm":"Hemangioblastic meningioma","n_c":["C66817"],"i_c":"9535/0","i_c_s":["Hemangioblastic meningioma"],"term_type":"OP"},{"nm":"Hemangioendothelial sarcoma","n_c":["C3088"],"i_c":"9130/3","i_c_s":["Hemangioendothelial sarcoma"],"term_type":"SY"},{"nm":"Hemangioendothelioma, benign","n_c":["C66779"],"i_c":"9130/0","i_c_s":["Hemangioendothelioma, benign"],"term_type":"PT"},{"nm":"Hemangioendothelioma, malignant","n_c":["C3088"],"i_c":"9130/3","i_c_s":["Hemangioendothelioma, malignant"],"term_type":"PT"},{"nm":"Hemangioendothelioma, NOS","n_c":["C3084"],"i_c":"9130/1","i_c_s":["Hemangioendothelioma, NOS"],"term_type":"PT"},{"nm":"Hemangioma simplex","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Hemangioma simplex"],"term_type":"SY"},{"nm":"Hemangioma, NOS","n_c":["C3085"],"i_c":"9120/0","i_c_s":["Hemangioma, NOS"],"term_type":"PT"},{"nm":"Hemangiopericytic meningioma","n_c":"","i_c":"9150/1","i_c_s":["Hemangiopericytic meningioma"],"term_type":"ORT"},{"nm":"Hemangiopericytoma, benign","n_c":["C4300"],"i_c":"9150/0","i_c_s":["Hemangiopericytoma, benign"],"term_type":"PT"},{"nm":"Hemangiopericytoma, malignant","n_c":["C4301"],"i_c":"9150/3","i_c_s":["Hemangiopericytoma, malignant"],"term_type":"PT"},{"nm":"Hemangiopericytoma, NOS","n_c":["C3087"],"i_c":"9150/1","i_c_s":["Hemangiopericytoma, NOS"],"term_type":"PT"},{"nm":"Hemolymphangioma","n_c":["C66792"],"i_c":"9175/0","i_c_s":["Hemolymphangioma"],"term_type":"PT"},{"nm":"Hepatoblastoma","n_c":["C3728"],"i_c":"8970/3","i_c_s":["Hepatoblastoma"],"term_type":"PT"},{"nm":"Hepatoblastoma, epithelioid","n_c":"","i_c":"8970/3","i_c_s":["Hepatoblastoma, epithelioid"],"term_type":"RT"},{"nm":"Hepatoblastoma, mixed epithelial-mesenchymal","n_c":["C7097"],"i_c":"8970/3","i_c_s":["Hepatoblastoma, mixed epithelial-mesenchymal"],"term_type":"RT"},{"nm":"Hepatocarcinoma","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatocarcinoma"],"term_type":"SY"},{"nm":"Hepatocellular adenoma","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Hepatocellular adenoma"],"term_type":"SY"},{"nm":"Hepatocellular carcinoma, clear cell type","n_c":["C5754"],"i_c":"8174/3","i_c_s":["Hepatocellular carcinoma, clear cell type"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, fibrolamellar","n_c":["C4131"],"i_c":"8171/3","i_c_s":["Hepatocellular carcinoma, fibrolamellar"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, NOS","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatocellular carcinoma, NOS"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, pleomorphic type","n_c":["C43625"],"i_c":"8175/3","i_c_s":["Hepatocellular carcinoma, pleomorphic type"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, sarcomatoid","n_c":["C43627"],"i_c":"8173/3","i_c_s":["Hepatocellular carcinoma, sarcomatoid"],"term_type":"SY"},{"nm":"Hepatocellular carcinoma, scirrhous","n_c":["C27388"],"i_c":"8172/3","i_c_s":["Hepatocellular carcinoma, scirrhous"],"term_type":"PT"},{"nm":"Hepatocellular carcinoma, spindle cell variant","n_c":["C43627"],"i_c":"8173/3","i_c_s":["Hepatocellular carcinoma, spindle cell variant"],"term_type":"PT"},{"nm":"Hepatocholangiocarcinoma","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Hepatocholangiocarcinoma"],"term_type":"SY"},{"nm":"Hepatoid adenocarcinoma","n_c":["C66950"],"i_c":"8576/3","i_c_s":["Hepatoid adenocarcinoma"],"term_type":"PT"},{"nm":"Hepatoid carcinoma","n_c":["C66950"],"i_c":"8576/3","i_c_s":["Hepatoid carcinoma"],"term_type":"SY"},{"nm":"Hepatoid yolk sac tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Hepatoid yolk sac tumor"],"term_type":"RT"},{"nm":"Hepatoma, benign","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Hepatoma, benign"],"term_type":"SY"},{"nm":"Hepatoma, malignant","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatoma, malignant"],"term_type":"SY"},{"nm":"Hepatoma, NOS","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Hepatoma, NOS"],"term_type":"SY"},{"nm":"Hepatosplenic gamma-delta cell lymphoma","n_c":["C8459"],"i_c":"9716/3","i_c_s":["Hepatosplenic gamma-delta cell lymphoma"],"term_type":"SY"},{"nm":"Hepatosplenic T-cell lymphoma","n_c":["C8459"],"i_c":"9716/3","i_c_s":["Hepatosplenic T-cell lymphoma"],"term_type":"PT"},{"nm":"Hereditary leiomyomatosis & RCC-associated renal cell carcinoma","n_c":["C51302"],"i_c":"8311/3","i_c_s":["Hereditary leiomyomatosis & RCC-associated renal cell carcinoma"],"term_type":""},{"nm":"Hibernoma","n_c":["C3702"],"i_c":"8880/0","i_c_s":["Hibernoma"],"term_type":"PT"},{"nm":"Hidradenocarcinoma","n_c":["C54664"],"i_c":"8402/3","i_c_s":["Hidradenocarcinoma"],"term_type":"SY"},{"nm":"Hidradenoma papilliferum","n_c":["C4171"],"i_c":"8405/0","i_c_s":["Hidradenoma papilliferum"],"term_type":"SY"},{"nm":"Hidradenoma, NOS","n_c":["C7563"],"i_c":"8400/0","i_c_s":["Hidradenoma, NOS"],"term_type":"SY"},{"nm":"Hidrocystoma","n_c":["C3760"],"i_c":"8404/0","i_c_s":["Hidrocystoma"],"term_type":"PT"},{"nm":"High grade surface osteosarcoma","n_c":["C53958"],"i_c":"9194/3","i_c_s":["High grade surface osteosarcoma"],"term_type":"PT"},{"nm":"High-grade neuroendocrine carcinoma","n_c":"","i_c":"8041/3","i_c_s":["High-grade neuroendocrine carcinoma"],"term_type":""},{"nm":"High-grade serous carcinoma","n_c":"","i_c":"8461/3","i_c_s":["High-grade serous carcinoma"],"term_type":""},{"nm":"Hilar cell tumor","n_c":["C4214"],"i_c":"8660/0","i_c_s":["Hilar cell tumor"],"term_type":"SY"},{"nm":"Hilus cell tumor","n_c":["C4214"],"i_c":"8660/0","i_c_s":["Hilus cell tumor"],"term_type":"PT"},{"nm":"Histiocyte-rich large B-cell lymphoma","n_c":["C9496"],"i_c":"9688/3","i_c_s":["Histiocyte-rich large B-cell lymphoma"],"term_type":""},{"nm":"Histiocytic medullary reticulosis","n_c":["C7202"],"i_c":"9750/3","i_c_s":["Histiocytic medullary reticulosis"],"term_type":"ORT"},{"nm":"Histiocytic sarcoma","n_c":["C27349"],"i_c":"9755/3","i_c_s":["Histiocytic sarcoma"],"term_type":"PT"},{"nm":"Histiocytoid hemangioma","n_c":["C4298"],"i_c":"9125/0","i_c_s":["Histiocytoid hemangioma"],"term_type":"SY"},{"nm":"Histiocytoma, NOS","n_c":["C35765"],"i_c":"8831/0","i_c_s":["Histiocytoma, NOS"],"term_type":"PT"},{"nm":"Histiocytosis X, NOS","n_c":["C3107"],"i_c":"9751/3","i_c_s":["Histiocytosis X, NOS"],"term_type":"ORT"},{"nm":"Hodgkin disease, lymphocyte predominance, diffuse","n_c":["C6913"],"i_c":"9651/3","i_c_s":["Hodgkin disease, lymphocyte predominance, diffuse"],"term_type":"IS"},{"nm":"Hodgkin disease, lymphocyte predominance, NOS","n_c":["C8590"],"i_c":"9651/3","i_c_s":["Hodgkin disease, lymphocyte predominance, NOS"],"term_type":"ORT"},{"nm":"Hodgkin disease, lymphocytic-histiocytic predominance","n_c":["C8590"],"i_c":"9651/3","i_c_s":["Hodgkin disease, lymphocytic-histiocytic predominance"],"term_type":"IS"},{"nm":"Hodgkin disease, nodular sclerosis, lymphocyte depletion","n_c":["C27808"],"i_c":"9667/3","i_c_s":["Hodgkin disease, nodular sclerosis, lymphocyte depletion"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, lymphocyte predominance","n_c":["C27270"],"i_c":"9665/3","i_c_s":["Hodgkin disease, nodular sclerosis, lymphocyte predominance"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, mixed cellularity","n_c":["C27098"],"i_c":"9665/3","i_c_s":["Hodgkin disease, nodular sclerosis, mixed cellularity"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, NOS","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Hodgkin disease, nodular sclerosis, NOS"],"term_type":"SY"},{"nm":"Hodgkin disease, nodular sclerosis, syncytial variant","n_c":["C27807"],"i_c":"9667/3","i_c_s":["Hodgkin disease, nodular sclerosis, syncytial variant"],"term_type":"SY"},{"nm":"Hodgkin disease, NOS","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Hodgkin disease, NOS"],"term_type":"SY"},{"nm":"Hodgkin granuloma","n_c":["C6914"],"i_c":"9661/3","i_c_s":["Hodgkin granuloma"],"term_type":"OP"},{"nm":"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis","n_c":["C9283"],"i_c":"9654/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, lymphocyte depletion, NOS","n_c":["C9283"],"i_c":"9653/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, NOS"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, lymphocyte depletion, reticular","n_c":["C9283"],"i_c":"9655/3","i_c_s":["Hodgkin lymphoma, lymphocyte depletion, reticular"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, lymphocyte predominance, nodular","n_c":["C7258"],"i_c":"9659/3","i_c_s":["Hodgkin lymphoma, lymphocyte predominance, nodular"],"term_type":"SY"},{"nm":"Hodgkin lymphoma, lymphocyte-rich","n_c":["C6913"],"i_c":"9651/3","i_c_s":["Hodgkin lymphoma, lymphocyte-rich"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, mixed cellularity, NOS","n_c":["C3517"],"i_c":"9652/3","i_c_s":["Hodgkin lymphoma, mixed cellularity, NOS"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular lymphocyte predominance","n_c":["C7258"],"i_c":"9659/3","i_c_s":["Hodgkin lymphoma, nodular lymphocyte predominance"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, cellular phase","n_c":["C67171"],"i_c":"9664/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, cellular phase"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, grade 1","n_c":["C7165"],"i_c":"9665/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 1"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, grade 2","n_c":["C7166"],"i_c":"9667/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, grade 2"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, nodular sclerosis, NOS","n_c":["C3518"],"i_c":"9663/3","i_c_s":["Hodgkin lymphoma, nodular sclerosis, NOS"],"term_type":"PT"},{"nm":"Hodgkin lymphoma, NOS","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Hodgkin lymphoma, NOS"],"term_type":"PT"},{"nm":"Hodgkin paragranuloma, nodular","n_c":["C26956"],"i_c":"9659/3","i_c_s":["Hodgkin paragranuloma, nodular"],"term_type":"IS"},{"nm":"Hodgkin paragranuloma, NOS","n_c":["C26956"],"i_c":"9659/3","i_c_s":["Hodgkin paragranuloma, NOS"],"term_type":"IS"},{"nm":"Hodgkin sarcoma","n_c":["C164145"],"i_c":"9662/3","i_c_s":["Hodgkin sarcoma"],"term_type":"OP"},{"nm":"Hurthle cell adenocarcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Hurthle cell adenocarcinoma"],"term_type":"RT"},{"nm":"Hurthle cell adenoma","n_c":["C6042"],"i_c":"8290/0","i_c_s":["Hurthle cell adenoma"],"term_type":"RT"},{"nm":"Hurthle cell carcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Hurthle cell carcinoma"],"term_type":"RT"},{"nm":"Hurthle cell tumor","n_c":["C46068"],"i_c":"8290/0","i_c_s":["Hurthle cell tumor"],"term_type":"RT"},{"nm":"Hutchinson melanotic freckle, NOS","n_c":["C43372"],"i_c":"8742/2","i_c_s":["Hutchinson melanotic freckle, NOS"],"term_type":"SY"},{"nm":"Hyalinizing trabecular adenoma","n_c":["C6846"],"i_c":"8336/0","i_c_s":["Hyalinizing trabecular adenoma"],"term_type":"PT"},{"nm":"Hydatid mole","n_c":["C3110"],"i_c":"9100/0","i_c_s":["Hydatid mole"],"term_type":"SY"},{"nm":"Hydatidiform mole, NOS","n_c":["C3110"],"i_c":"9100/0","i_c_s":["Hydatidiform mole, NOS"],"term_type":"PT"},{"nm":"Hydroa vacciniforme-like lymphoma","n_c":["C45327"],"i_c":"9725/3","i_c_s":["Hydroa vacciniforme-like lymphoma"],"term_type":"PT"},{"nm":"Hygroma, NOS","n_c":["C3724"],"i_c":"9173/0","i_c_s":["Hygroma, NOS"],"term_type":"SY"},{"nm":"Hypereosinophilic syndrome","n_c":["C27038"],"i_c":"9964/3","i_c_s":["Hypereosinophilic syndrome"],"term_type":"SY"},{"nm":"Hypernephroid tumor","n_c":["C4033"],"i_c":"8311/1","i_c_s":["Hypernephroid tumor"],"term_type":"OP"},{"nm":"Hypernephroma","n_c":["C4033"],"i_c":"8312/3","i_c_s":["Hypernephroma"],"term_type":"IS"},{"nm":"Idiopathic hemorrhagic thrombocythaemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Idiopathic hemorrhagic thrombocythaemia"],"term_type":""},{"nm":"Idiopathic thrombocythemia","n_c":["C3407"],"i_c":"9962/3","i_c_s":["Idiopathic thrombocythemia"],"term_type":"SY"},{"nm":"Immature teratoma, malignant","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Immature teratoma, malignant"],"term_type":"RT"},{"nm":"Immature teratoma, NOS","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Immature teratoma, NOS"],"term_type":"SY"},{"nm":"Immunoblastic sarcoma","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Immunoblastic sarcoma"],"term_type":"IS"},{"nm":"Immunocytoma","n_c":["C3898"],"i_c":"9671/3","i_c_s":["Immunocytoma"],"term_type":"ORT"},{"nm":"Immunoglobulin deposition disease","n_c":["C7151"],"i_c":"9769/1","i_c_s":["Immunoglobulin deposition disease"],"term_type":"PT"},{"nm":"Immunoproliferative disease, NOS","n_c":["C3132"],"i_c":"9760/3","i_c_s":["Immunoproliferative disease, NOS"],"term_type":"PT"},{"nm":"Immunoproliferative small intestinal disease","n_c":["C3132"],"i_c":"9764/3","i_c_s":["Immunoproliferative small intestinal disease"],"term_type":"PT"},{"nm":"Indeterminate dendritic cell tumor","n_c":["C81767"],"i_c":"9757/3","i_c_s":["Indeterminate dendritic cell tumor"],"term_type":"RT"},{"nm":"Indolent systemic mastocytosis","n_c":["C9286"],"i_c":"9741/1","i_c_s":["Indolent systemic mastocytosis"],"term_type":"PT"},{"nm":"Infantile fibrosarcoma","n_c":["C4244"],"i_c":"8814/3","i_c_s":["Infantile fibrosarcoma"],"term_type":"PT"},{"nm":"Infantile hemangioma","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Infantile hemangioma"],"term_type":"SY"},{"nm":"Infantile myofibromatosis","n_c":["C3742"],"i_c":"8824/1","i_c_s":["Infantile myofibromatosis"],"term_type":"SY"},{"nm":"Infiltrating and papillary adenocarcinoma","n_c":["C7438"],"i_c":"8503/3","i_c_s":["Infiltrating and papillary adenocarcinoma"],"term_type":"SY"},{"nm":"Infiltrating angiolipoma","n_c":["C7449"],"i_c":"8856/0","i_c_s":["Infiltrating angiolipoma"],"term_type":"RT"},{"nm":"Infiltrating basal cell carcinoma, non-sclerosing","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, non-sclerosing"],"term_type":"RT"},{"nm":"Infiltrating basal cell carcinoma, NOS","n_c":["C27539"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Infiltrating basal cell carcinoma, sclerosing","n_c":["C27182"],"i_c":"8092/3","i_c_s":["Infiltrating basal cell carcinoma, sclerosing"],"term_type":"RT"},{"nm":"Infiltrating duct adenocarcinoma","n_c":["C4194"],"i_c":"8500/3","i_c_s":["Infiltrating duct adenocarcinoma"],"term_type":"SY"},{"nm":"Infiltrating duct and colloid carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and colloid carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct and cribriform carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and cribriform carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct and lobular carcinoma","n_c":["C7688"],"i_c":"8522/3","i_c_s":["Infiltrating duct and lobular carcinoma"],"term_type":"PT"},{"nm":"Infiltrating duct and lobular carcinoma in situ","n_c":["C7689"],"i_c":"8522/3","i_c_s":["Infiltrating duct and lobular carcinoma in situ"],"term_type":"RT"},{"nm":"Infiltrating duct and mucinous carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and mucinous carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct and tubular carcinoma","n_c":"","i_c":"8523/3","i_c_s":["Infiltrating duct and tubular carcinoma"],"term_type":"RT"},{"nm":"Infiltrating duct carcinoma, NOS","n_c":["C4194"],"i_c":"8500/3","i_c_s":["Infiltrating duct carcinoma, NOS"],"term_type":"PT"},{"nm":"Infiltrating duct mixed with other types of carcinoma","n_c":["C7688"],"i_c":"8523/3","i_c_s":["Infiltrating duct mixed with other types of carcinoma"],"term_type":"PT"},{"nm":"Infiltrating ductular carcinoma","n_c":["C4194"],"i_c":"8521/3","i_c_s":["Infiltrating ductular carcinoma"],"term_type":"PT"},{"nm":"Infiltrating lipoma","n_c":["C7451"],"i_c":"8856/0","i_c_s":["Infiltrating lipoma"],"term_type":"RT"},{"nm":"Infiltrating lobular carcinoma and ductal carcinoma in situ","n_c":["C6939"],"i_c":"8522/3","i_c_s":["Infiltrating lobular carcinoma and ductal carcinoma in situ"],"term_type":"RT"},{"nm":"Infiltrating lobular carcinoma, NOS","n_c":["C7950"],"i_c":"8520/3","i_c_s":["Infiltrating lobular carcinoma, NOS"],"term_type":"SY"},{"nm":"Infiltrating lobular mixed with other types of carcinoma","n_c":["C6939"],"i_c":"8524/3","i_c_s":["Infiltrating lobular mixed with other types of carcinoma"],"term_type":"PT"},{"nm":"Infiltrating papillary adenocarcinoma","n_c":["C7438"],"i_c":"8503/3","i_c_s":["Infiltrating papillary adenocarcinoma"],"term_type":"SY"},{"nm":"Inflammatory adenocarcinoma","n_c":"","i_c":"8530/3","i_c_s":["Inflammatory adenocarcinoma"],"term_type":"SY"},{"nm":"Inflammatory carcinoma","n_c":["C4001"],"i_c":"8530/3","i_c_s":["Inflammatory carcinoma"],"term_type":"PT"},{"nm":"Inflammatory liposarcoma","n_c":["C6508"],"i_c":"8851/3","i_c_s":["Inflammatory liposarcoma"],"term_type":"RT"},{"nm":"Inflammatory myofibroblastic tumor","n_c":["C6481"],"i_c":"8825/1","i_c_s":["Inflammatory myofibroblastic tumor"],"term_type":"SY"},{"nm":"Insular carcinoma","n_c":["C6040"],"i_c":"8337/3","i_c_s":["Insular carcinoma"],"term_type":"PT"},{"nm":"Insulinoma, malignant","n_c":["C65186"],"i_c":"8151/3","i_c_s":["Insulinoma, malignant"],"term_type":"PT"},{"nm":"Insulinoma, NOS","n_c":["C95598"],"i_c":"8151/0","i_c_s":["Insulinoma, NOS"],"term_type":"PT"},{"nm":"Interdigitating cell sarcoma","n_c":["C9282"],"i_c":"9757/3","i_c_s":["Interdigitating cell sarcoma"],"term_type":"SY"},{"nm":"Interdigitating dendritic cell sarcoma","n_c":["C9282"],"i_c":"9757/3","i_c_s":["Interdigitating dendritic cell sarcoma"],"term_type":"PT"},{"nm":"Intermediate and giant congenital nevus","n_c":"","i_c":"8761/1","i_c_s":["Intermediate and giant congenital nevus"],"term_type":"RT"},{"nm":"Interstitial cell tumor, benign","n_c":["C4212"],"i_c":"8650/0","i_c_s":["Interstitial cell tumor, benign"],"term_type":"SY"},{"nm":"Interstitial cell tumor, malignant","n_c":["C4213"],"i_c":"8650/3","i_c_s":["Interstitial cell tumor, malignant"],"term_type":"SY"},{"nm":"Interstitial cell tumor, NOS","n_c":["C3188"],"i_c":"8650/1","i_c_s":["Interstitial cell tumor, NOS"],"term_type":"SY"},{"nm":"Intestinal T-cell lymphoma","n_c":["C4737"],"i_c":"9717/3","i_c_s":["Intestinal T-cell lymphoma"],"term_type":"PT"},{"nm":"Intestinal-type adenocarcinoma","n_c":["C4126"],"i_c":"8144/3","i_c_s":["Intestinal-type adenocarcinoma"],"term_type":""},{"nm":"Intimal sarcoma","n_c":["C53677"],"i_c":"9137/3","i_c_s":["Intimal sarcoma"],"term_type":"PT"},{"nm":"Intracanalicular fibroadenoma","n_c":["C4271"],"i_c":"9011/0","i_c_s":["Intracanalicular fibroadenoma"],"term_type":"PT"},{"nm":"Intracortical osteosarcoma","n_c":["C35870"],"i_c":"9195/3","i_c_s":["Intracortical osteosarcoma"],"term_type":"PT"},{"nm":"Intracystic carcinoma, NOS","n_c":["C7645"],"i_c":"8504/3","i_c_s":["Intracystic carcinoma, NOS"],"term_type":"PT"},{"nm":"Intracystic papillary adenocarcinoma","n_c":["C7645"],"i_c":"8504/3","i_c_s":["Intracystic papillary adenocarcinoma"],"term_type":"SY"},{"nm":"Intracystic papillary adenoma","n_c":["C3863"],"i_c":"8504/0","i_c_s":["Intracystic papillary adenoma"],"term_type":"PT"},{"nm":"Intracystic papillary neoplasm with associated invasive carcinoma","n_c":"","i_c":"8503/3","i_c_s":["Intracystic papillary neoplasm with associated invasive carcinoma"],"term_type":"SY"},{"nm":"Intracystic papillary neoplasm with high grade intraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia","n_c":["C96878"],"i_c":"8503/0","i_c_s":["Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intracystic papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C96877"],"i_c":"8503/0","i_c_s":["Intracystic papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intracystic papillary tumor with high grade dysplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary tumor with high grade dysplasia"],"term_type":"SY"},{"nm":"Intracystic papillary tumor with high grade entraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary tumor with high grade entraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intracystic papillary tumor with high grade intraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intracystic papillary tumor with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intracystic papilloma","n_c":["C3863"],"i_c":"8504/0","i_c_s":["Intracystic papilloma"],"term_type":"SY"},{"nm":"Intradermal nevus","n_c":["C3804"],"i_c":"8750/0","i_c_s":["Intradermal nevus"],"term_type":"PT"},{"nm":"Intraductal adenocarcinoma, noninfiltrating, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Intraductal adenocarcinoma, noninfiltrating, NOS"],"term_type":"SY"},{"nm":"Intraductal and lobular carcinoma","n_c":["C7690"],"i_c":"8522/3","i_c_s":["Intraductal and lobular carcinoma"],"term_type":"RT"},{"nm":"Intraductal carcinoma and lobular carcinoma in situ","n_c":["C4195"],"i_c":"8522/2","i_c_s":["Intraductal carcinoma and lobular carcinoma in situ"],"term_type":"PT"},{"nm":"Intraductal carcinoma, clinging","n_c":"","i_c":"8507/2","i_c_s":["Intraductal carcinoma, clinging"],"term_type":"RT"},{"nm":"Intraductal carcinoma, noninfiltrating, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Intraductal carcinoma, noninfiltrating, NOS"],"term_type":"PT"},{"nm":"Intraductal carcinoma, NOS","n_c":["C2924"],"i_c":"8500/2","i_c_s":["Intraductal carcinoma, NOS"],"term_type":"SY"},{"nm":"Intraductal carcinoma, solid type","n_c":"","i_c":"8230/2","i_c_s":["Intraductal carcinoma, solid type"],"term_type":"SY"},{"nm":"Intraductal micropapillary carcinoma","n_c":["C5139"],"i_c":"8507/2","i_c_s":["Intraductal micropapillary carcinoma"],"term_type":"PT"},{"nm":"Intraductal papillary adenocarcinoma with invasion","n_c":["C7439"],"i_c":"8503/3","i_c_s":["Intraductal papillary adenocarcinoma with invasion"],"term_type":"PT"},{"nm":"Intraductal papillary adenocarcinoma, NOS","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Intraductal papillary adenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Intraductal papillary carcinoma","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Intraductal papillary carcinoma"],"term_type":""},{"nm":"Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma","n_c":["C5726"],"i_c":"8503/3","i_c_s":["Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma"],"term_type":""},{"nm":"Intraductal papillary mucinous neoplasm with an associated invasive carcinoma","n_c":["C5726"],"i_c":"8453/3","i_c_s":["Intraductal papillary mucinous neoplasm with an associated invasive carcinoma"],"term_type":"RT"},{"nm":"Intraductal papillary mucinous neoplasm with high grade dysplasia","n_c":["C41251"],"i_c":"8453/2","i_c_s":["Intraductal papillary mucinous neoplasm with high grade dysplasia"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm with associated invasive carcinoma","n_c":["C7439"],"i_c":"8503/3","i_c_s":["Intraductal papillary neoplasm with associated invasive carcinoma"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm with high grade dysplasia","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papillary neoplasm with high grade dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary neoplasm with high grade intraepithelial neoplasia","n_c":["C96809"],"i_c":"8503/2","i_c_s":["Intraductal papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm with intermediate grade neoplasia","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Intraductal papillary neoplasm with intermediate grade neoplasia"],"term_type":"SY"},{"nm":"Intraductal papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C96807"],"i_c":"8503/0","i_c_s":["Intraductal papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Intraductal papillary neoplasm, NOS","n_c":["C6881"],"i_c":"8503/0","i_c_s":["Intraductal papillary neoplasm, NOS"],"term_type":"RT"},{"nm":"Intraductal papillary tumor with high grade dysplasia","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papillary tumor with high grade dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary tumor with high grade intraepithelial neoplasia","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papillary tumor with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intraductal papillary-mucinous adenoma","n_c":["C95514"],"i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous adenoma"],"term_type":"PT"},{"nm":"Intraductal papillary-mucinous carcinoma, invasive","n_c":["C5726"],"i_c":"8453/3","i_c_s":["Intraductal papillary-mucinous carcinoma, invasive"],"term_type":"PT"},{"nm":"Intraductal papillary-mucinous carcinoma, non-invasive","n_c":"","i_c":"8453/2","i_c_s":["Intraductal papillary-mucinous carcinoma, non-invasive"],"term_type":"PT"},{"nm":"Intraductal papillary-mucinous neoplasm with low grade dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous neoplasm with low grade dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary-mucinous neoplasm with moderate dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous neoplasm with moderate dysplasia"],"term_type":"SY"},{"nm":"Intraductal papillary-mucinous tumor with intermediate dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous tumor with intermediate dysplasia"],"term_type":"RT"},{"nm":"Intraductal papillary-mucinous tumor with low grade dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous tumor with low grade dysplasia"],"term_type":"RT"},{"nm":"Intraductal papillary-mucinous tumor with moderate dysplasia","n_c":"","i_c":"8453/0","i_c_s":["Intraductal papillary-mucinous tumor with moderate dysplasia"],"term_type":"RT"},{"nm":"Intraductal papilloma","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Intraductal papilloma"],"term_type":"PT"},{"nm":"Intraductal papilloma with ductal carcinoma in situ","n_c":"","i_c":"8503/2","i_c_s":["Intraductal papilloma with ductal carcinoma in situ"],"term_type":""},{"nm":"Intraductal papilloma with lobular carcinoma in situ","n_c":"","i_c":"8520/2","i_c_s":["Intraductal papilloma with lobular carcinoma in situ"],"term_type":""},{"nm":"Intraductal papillomatosis, NOS","n_c":["C7363"],"i_c":"8505/0","i_c_s":["Intraductal papillomatosis, NOS"],"term_type":"PT"},{"nm":"Intraductal tubular-papillary neoplasm, high grade","n_c":"","i_c":"8503/2","i_c_s":["Intraductal tubular-papillary neoplasm, high grade"],"term_type":"RT"},{"nm":"Intraductal tubular-papillary neoplasm, low grade","n_c":"","i_c":"8503/0","i_c_s":["Intraductal tubular-papillary neoplasm, low grade"],"term_type":"RT"},{"nm":"Intraductal tubulopapillary neoplasm","n_c":["C95506"],"i_c":"8503/2","i_c_s":["Intraductal tubulopapillary neoplasm"],"term_type":""},{"nm":"Intraepidermal carcinoma, NOS","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Intraepidermal carcinoma, NOS"],"term_type":"SY"},{"nm":"Intraepidermal epithelioma of Jadassohn","n_c":["C4110"],"i_c":"8096/0","i_c_s":["Intraepidermal epithelioma of Jadassohn"],"term_type":"PT"},{"nm":"Intraepidermal nevus","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Intraepidermal nevus"],"term_type":"SY"},{"nm":"Intraepidermal squamous cell carcinoma, Bowen type","n_c":["C62571"],"i_c":"8081/2","i_c_s":["Intraepidermal squamous cell carcinoma, Bowen type"],"term_type":"SY"},{"nm":"Intraepithelial carcinoma, NOS","n_c":["C2917"],"i_c":"8010/2","i_c_s":["Intraepithelial carcinoma, NOS"],"term_type":"SY"},{"nm":"Intraepithelial squamous cell carcinoma","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Intraepithelial squamous cell carcinoma"],"term_type":"SY"},{"nm":"Intraglandular papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C3785"],"i_c":"8503/0","i_c_s":["Intraglandular papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Intramuscular hemangioma","n_c":["C3699"],"i_c":"9132/0","i_c_s":["Intramuscular hemangioma"],"term_type":"PT"},{"nm":"Intramuscular lipoma","n_c":["C7450"],"i_c":"8856/0","i_c_s":["Intramuscular lipoma"],"term_type":"PT"},{"nm":"Intraneural perineurioma","n_c":["C6911"],"i_c":"9571/0","i_c_s":["Intraneural perineurioma"],"term_type":"RT"},{"nm":"Intraosseous low grade osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Intraosseous low grade osteosarcoma"],"term_type":"SY"},{"nm":"Intraosseous well differentiated osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Intraosseous well differentiated osteosarcoma"],"term_type":"PT"},{"nm":"Intratubular germ cell neoplasia","n_c":["C40345"],"i_c":"9064/2","i_c_s":["Intratubular germ cell neoplasia"],"term_type":"SY"},{"nm":"Intratubular malignant germ cells","n_c":["C40345"],"i_c":"9064/2","i_c_s":["Intratubular malignant germ cells"],"term_type":"PT"},{"nm":"Intravascular B-cell lymphoma","n_c":["C4342"],"i_c":"9712/3","i_c_s":["Intravascular B-cell lymphoma"],"term_type":""},{"nm":"Intravascular bronchial alveolar tumor","n_c":"","i_c":"9133/3","i_c_s":["Intravascular bronchial alveolar tumor"],"term_type":"ORT"},{"nm":"Intravascular large B-cell lymphoma","n_c":["C4342"],"i_c":"9712/3","i_c_s":["Intravascular large B-cell lymphoma"],"term_type":"PT"},{"nm":"Intravascular leiomyomatosis","n_c":"","i_c":"8890/1","i_c_s":["Intravascular leiomyomatosis"],"term_type":"RT"},{"nm":"Invasive carcinoma of no special type","n_c":["C9480"],"i_c":"8500/3","i_c_s":["Invasive carcinoma of no special type"],"term_type":"PT"},{"nm":"Invasive carcinoma, NST","n_c":["C9480"],"i_c":"8500/3","i_c_s":["Invasive carcinoma, NST"],"term_type":""},{"nm":"Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)","n_c":["C66850"],"i_c":"8343/3","i_c_s":["Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)"],"term_type":""},{"nm":"Invasive fibroma","n_c":["C9182"],"i_c":"8821/1","i_c_s":["Invasive fibroma"],"term_type":"SY"},{"nm":"Invasive hydatidiform mole","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Invasive hydatidiform mole"],"term_type":"PT"},{"nm":"Invasive lobular carcinoma","n_c":["C7950"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma"],"term_type":""},{"nm":"Invasive lobular carcinoma, alveolar type","n_c":["C97049"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma, alveolar type"],"term_type":""},{"nm":"Invasive lobular carcinoma, solid type","n_c":["C97052"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma, solid type"],"term_type":""},{"nm":"Invasive lobular carcinoma, tubulolobular variant","n_c":["C97053"],"i_c":"8520/3","i_c_s":["Invasive lobular carcinoma, tubulolobular variant"],"term_type":""},{"nm":"Invasive mammary carcinoma","n_c":["C9245"],"i_c":"8500/3","i_c_s":["Invasive mammary carcinoma"],"term_type":""},{"nm":"Invasive micropapillary carcinoma","n_c":["C36084"],"i_c":"8507/3","i_c_s":["Invasive micropapillary carcinoma"],"term_type":"PT"},{"nm":"Invasive mole, NOS","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Invasive mole, NOS"],"term_type":"SY"},{"nm":"Invasive mucinous adenocarcinoma","n_c":["C136709"],"i_c":"8253/3","i_c_s":["Invasive mucinous adenocarcinoma"],"term_type":"PT"},{"nm":"Involuting nevus","n_c":"","i_c":"9160/0","i_c_s":["Involuting nevus"],"term_type":"IS"},{"nm":"Islet cell adenocarcinoma","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Islet cell adenocarcinoma"],"term_type":"SY"},{"nm":"Islet cell adenoma","n_c":["C65184"],"i_c":"8150/0","i_c_s":["Islet cell adenoma"],"term_type":"SY"},{"nm":"Islet cell adenomatosis","n_c":["C4375"],"i_c":"8150/0","i_c_s":["Islet cell adenomatosis"],"term_type":"RT"},{"nm":"Islet cell carcinoma","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Islet cell carcinoma"],"term_type":"SY"},{"nm":"Islet cell tumor, benign","n_c":"","i_c":"8150/0","i_c_s":["Islet cell tumor, benign"],"term_type":"SY"},{"nm":"Islet cell tumor, NOS","n_c":["C27031"],"i_c":"8150/1","i_c_s":["Islet cell tumor, NOS"],"term_type":"SY"},{"nm":"Jadassohn blue nevus","n_c":["C3803"],"i_c":"8780/0","i_c_s":["Jadassohn blue nevus"],"term_type":"SY"},{"nm":"Jugular paraganglioma","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Jugular paraganglioma"],"term_type":"SY"},{"nm":"Jugulotympanic paraganglioma","n_c":["C3061"],"i_c":"8690/1","i_c_s":["Jugulotympanic paraganglioma"],"term_type":"SY"},{"nm":"Junction nevus","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Junction nevus"],"term_type":"SY"},{"nm":"Junctional nevus, NOS","n_c":["C4231"],"i_c":"8740/0","i_c_s":["Junctional nevus, NOS"],"term_type":"PT"},{"nm":"Juvenile angiofibroma","n_c":["C3799"],"i_c":"9160/0","i_c_s":["Juvenile angiofibroma"],"term_type":"SY"},{"nm":"Juvenile astrocytoma","n_c":["C9022"],"i_c":"9421/1","i_c_s":["Juvenile astrocytoma"],"term_type":"SY"},{"nm":"Juvenile carcinoma of breast","n_c":["C4189"],"i_c":"8502/3","i_c_s":["Juvenile carcinoma of breast"],"term_type":"SY"},{"nm":"Juvenile chronic myelomonocytic leukemia","n_c":["C9233"],"i_c":"9946/3","i_c_s":["Juvenile chronic myelomonocytic leukemia"],"term_type":"SY"},{"nm":"Juvenile fibroadenoma","n_c":["C4276"],"i_c":"9030/0","i_c_s":["Juvenile fibroadenoma"],"term_type":"PT"},{"nm":"Juvenile hemangioma","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Juvenile hemangioma"],"term_type":"SY"},{"nm":"Juvenile histiocytoma","n_c":["C6492"],"i_c":"8831/0","i_c_s":["Juvenile histiocytoma"],"term_type":"RT"},{"nm":"Juvenile melanoma","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Juvenile melanoma"],"term_type":"SY"},{"nm":"Juvenile myelomonocytic leukemia","n_c":["C9233"],"i_c":"9946/3","i_c_s":["Juvenile myelomonocytic leukemia"],"term_type":"PT"},{"nm":"Juvenile nevus","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Juvenile nevus"],"term_type":"SY"},{"nm":"Juxtacortical chondroma","n_c":["C4302"],"i_c":"9221/0","i_c_s":["Juxtacortical chondroma"],"term_type":"PT"},{"nm":"Juxtacortical chondrosarcoma","n_c":["C7357"],"i_c":"9221/3","i_c_s":["Juxtacortical chondrosarcoma"],"term_type":"PT"},{"nm":"Juxtacortical osteosarcoma","n_c":["C8969"],"i_c":"9192/3","i_c_s":["Juxtacortical osteosarcoma"],"term_type":"SY"},{"nm":"Juxtaglomerular tumor","n_c":["C4162"],"i_c":"8361/0","i_c_s":["Juxtaglomerular tumor"],"term_type":"PT"},{"nm":"Kaposi sarcoma","n_c":["C9087"],"i_c":"9140/3","i_c_s":["Kaposi sarcoma"],"term_type":"PT"},{"nm":"Kaposiform hemangioendothelioma","n_c":["C27510"],"i_c":"9130/1","i_c_s":["Kaposiform hemangioendothelioma"],"term_type":"RT"},{"nm":"Keratotoc papilloma","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Keratotoc papilloma"],"term_type":""},{"nm":"Klatskin tumor","n_c":["C36077"],"i_c":"8162/3","i_c_s":["Klatskin tumor"],"term_type":"PT"},{"nm":"Krukenberg tumor","n_c":["C3153"],"i_c":"8490/6","i_c_s":["Krukenberg tumor"],"term_type":"RT"},{"nm":"Kupffer cell sarcoma","n_c":["C4438"],"i_c":"9124/3","i_c_s":["Kupffer cell sarcoma"],"term_type":"PT"},{"nm":"L-cell tumor","n_c":"","i_c":"8152/1","i_c_s":["L-cell tumor"],"term_type":"RT"},{"nm":"Lactating adenoma","n_c":["C9473"],"i_c":"8204/0","i_c_s":["Lactating adenoma"],"term_type":"PT"},{"nm":"Langerhans cell granulomatosis","n_c":["C3107"],"i_c":"9751/3","i_c_s":["Langerhans cell granulomatosis"],"term_type":"IS"},{"nm":"Langerhans cell granulomatosis, unifocal","n_c":["C3016"],"i_c":"9751/3","i_c_s":["Langerhans cell granulomatosis, unifocal"],"term_type":"IS"},{"nm":"Langerhans cell histiocytosis, disseminated","n_c":["C150703"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, disseminated"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, generalized","n_c":["C150703"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, generalized"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, mono-ostotic","n_c":["C150701"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, mono-ostotic"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, multifocal","n_c":["C150702"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, multifocal"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, NOS","n_c":["C3107"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, NOS"],"term_type":"PT"},{"nm":"Langerhans cell histiocytosis, poly-ostotic","n_c":["C150702"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, poly-ostotic"],"term_type":"ORT"},{"nm":"Langerhans cell histiocytosis, unifocal","n_c":["C150701"],"i_c":"9751/3","i_c_s":["Langerhans cell histiocytosis, unifocal"],"term_type":"ORT"},{"nm":"Langerhans cell sarcoma","n_c":["C6921"],"i_c":"9756/3","i_c_s":["Langerhans cell sarcoma"],"term_type":"PT"},{"nm":"Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease","n_c":["C27856"],"i_c":"9738/3","i_c_s":["Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease"],"term_type":"PT"},{"nm":"Large cell (Ki-1+) lymphoma","n_c":["C3720"],"i_c":"9714/3","i_c_s":["Large cell (Ki-1+) lymphoma"],"term_type":"IS"},{"nm":"Large cell calcifying Sertoli cell tumor","n_c":["C39944"],"i_c":"8642/1","i_c_s":["Large cell calcifying Sertoli cell tumor"],"term_type":"PT"},{"nm":"Large cell carcinoma with rhabdoid phenotype","n_c":["C6876"],"i_c":"8014/3","i_c_s":["Large cell carcinoma with rhabdoid phenotype"],"term_type":"PT"},{"nm":"Large cell carcinoma, NOS","n_c":["C3780"],"i_c":"8012/3","i_c_s":["Large cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Large cell medulloblastoma","n_c":["C6904"],"i_c":"9474/3","i_c_s":["Large cell medulloblastoma"],"term_type":"PT"},{"nm":"Large cell neuroendocrine carcinoma","n_c":["C6875"],"i_c":"8013/3","i_c_s":["Large cell neuroendocrine carcinoma"],"term_type":"PT"},{"nm":"Large granular lymphocytosis, NOS","n_c":"","i_c":"9831/3","i_c_s":["Large granular lymphocytosis, NOS"],"term_type":"SY"},{"nm":"LCIS, NOS","n_c":["C4018"],"i_c":"8520/2","i_c_s":["LCIS, NOS"],"term_type":"SY"},{"nm":"Leiomyoblastoma","n_c":["C3486"],"i_c":"8891/0","i_c_s":["Leiomyoblastoma"],"term_type":"SY"},{"nm":"Leiomyofibroma","n_c":["C3434"],"i_c":"8890/0","i_c_s":["Leiomyofibroma"],"term_type":"SY"},{"nm":"Leiomyoma, NOS","n_c":["C3157"],"i_c":"8890/0","i_c_s":["Leiomyoma, NOS"],"term_type":"PT"},{"nm":"Leiomyomatosis, NOS","n_c":["C3748"],"i_c":"8890/1","i_c_s":["Leiomyomatosis, NOS"],"term_type":"PT"},{"nm":"Leiomyosarcoma, NOS","n_c":["C3158"],"i_c":"8890/3","i_c_s":["Leiomyosarcoma, NOS"],"term_type":"PT"},{"nm":"Lennert lymphoma","n_c":["C7205"],"i_c":"9702/3","i_c_s":["Lennert lymphoma"],"term_type":"SY"},{"nm":"Lentigo maligna","n_c":["C43372"],"i_c":"8742/2","i_c_s":["Lentigo maligna"],"term_type":"PT"},{"nm":"Lentigo maligna melanoma","n_c":["C9151"],"i_c":"8742/3","i_c_s":["Lentigo maligna melanoma"],"term_type":"PT"},{"nm":"Lepidic adenocarcinoma","n_c":["C123160"],"i_c":"8250/3","i_c_s":["Lepidic adenocarcinoma"],"term_type":"PT"},{"nm":"Lepidic predominant adenocarcinoma","n_c":["C123160"],"i_c":"8250/3","i_c_s":["Lepidic predominant adenocarcinoma"],"term_type":""},{"nm":"Leptomeningeal sarcoma","n_c":["C8312"],"i_c":"9530/3","i_c_s":["Leptomeningeal sarcoma"],"term_type":"SY"},{"nm":"Letterer-Siwe disease","n_c":["C3160"],"i_c":"9751/3","i_c_s":["Letterer-Siwe disease"],"term_type":"ORT"},{"nm":"Leukemia, NOS","n_c":["C3161"],"i_c":"9800/3","i_c_s":["Leukemia, NOS"],"term_type":"PT"},{"nm":"Leukemic reticuloendotheliosis","n_c":["C7402"],"i_c":"9940/3","i_c_s":["Leukemic reticuloendotheliosis"],"term_type":"SY"},{"nm":"Leydig cell tumor, benign","n_c":["C4212"],"i_c":"8650/0","i_c_s":["Leydig cell tumor, benign"],"term_type":"PT"},{"nm":"Leydig cell tumor, malignant","n_c":["C4213"],"i_c":"8650/3","i_c_s":["Leydig cell tumor, malignant"],"term_type":"PT"},{"nm":"Leydig cell tumor, NOS","n_c":["C3188"],"i_c":"8650/1","i_c_s":["Leydig cell tumor, NOS"],"term_type":"PT"},{"nm":"Linitis plastica","n_c":["C3190"],"i_c":"8142/3","i_c_s":["Linitis plastica"],"term_type":"PT"},{"nm":"Lipid cell tumor of ovary","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Lipid cell tumor of ovary"],"term_type":"PT"},{"nm":"Lipid-rich carcinoma","n_c":["C4152"],"i_c":"8314/3","i_c_s":["Lipid-rich carcinoma"],"term_type":"PT"},{"nm":"Lipid-rich Sertoli cell tumor","n_c":"","i_c":"8641/0","i_c_s":["Lipid-rich Sertoli cell tumor"],"term_type":"SY"},{"nm":"Lipid-rich urothelial carcinoma","n_c":["C191684"],"i_c":"8120/3","i_c_s":["Lipid-rich urothelial carcinoma"],"term_type":""},{"nm":"Lipoadenoma","n_c":["C4159"],"i_c":"8324/0","i_c_s":["Lipoadenoma"],"term_type":"PT"},{"nm":"Lipoblastoma","n_c":["C27483"],"i_c":"8881/0","i_c_s":["Lipoblastoma"],"term_type":"SY"},{"nm":"Lipoblastomatosis","n_c":["C4255"],"i_c":"8881/0","i_c_s":["Lipoblastomatosis"],"term_type":"PT"},{"nm":"Lipoid cell tumor of ovary","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Lipoid cell tumor of ovary"],"term_type":"SY"},{"nm":"Lipoleiomyoma","n_c":["C9502"],"i_c":"8890/0","i_c_s":["Lipoleiomyoma"],"term_type":"RT"},{"nm":"Lipoma-like liposarcoma","n_c":["C176979"],"i_c":"8851/3","i_c_s":["Lipoma-like liposarcoma"],"term_type":"SY"},{"nm":"Lipoma, NOS","n_c":["C3192"],"i_c":"8850/0","i_c_s":["Lipoma, NOS"],"term_type":"PT"},{"nm":"Lipomatous medulloblastoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Lipomatous medulloblastoma"],"term_type":"SY"},{"nm":"Liposarcoma, differentiated","n_c":["C6505"],"i_c":"8851/3","i_c_s":["Liposarcoma, differentiated"],"term_type":"SY"},{"nm":"Liposarcoma, NOS","n_c":["C3194"],"i_c":"8850/3","i_c_s":["Liposarcoma, NOS"],"term_type":"PT"},{"nm":"Liposarcoma, well differentiated","n_c":["C6505"],"i_c":"8851/3","i_c_s":["Liposarcoma, well differentiated"],"term_type":"PT"},{"nm":"Liver cell adenoma","n_c":["C3758"],"i_c":"8170/0","i_c_s":["Liver cell adenoma"],"term_type":"PT"},{"nm":"Liver cell carcinoma","n_c":["C3099"],"i_c":"8170/3","i_c_s":["Liver cell carcinoma"],"term_type":"SY"},{"nm":"Lobular adenocarcinoma","n_c":["C3771"],"i_c":"8520/3","i_c_s":["Lobular adenocarcinoma"],"term_type":"SY"},{"nm":"Lobular and ductal carcinoma","n_c":["C5160"],"i_c":"8522/3","i_c_s":["Lobular and ductal carcinoma"],"term_type":"SY"},{"nm":"Lobular carcinoma in situ, NOS","n_c":["C4018"],"i_c":"8520/2","i_c_s":["Lobular carcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Lobular carcinoma, noninfiltrating","n_c":["C4018"],"i_c":"8520/2","i_c_s":["Lobular carcinoma, noninfiltrating"],"term_type":"SY"},{"nm":"Lobular carcinoma, NOS","n_c":["C3771"],"i_c":"8520/3","i_c_s":["Lobular carcinoma, NOS"],"term_type":"PT"},{"nm":"Localized fibrous tumor","n_c":["C7634"],"i_c":"8815/0","i_c_s":["Localized fibrous tumor"],"term_type":"SY"},{"nm":"Low grade adenosquamous carcinoma","n_c":["C40362"],"i_c":"8570/3","i_c_s":["Low grade adenosquamous carcinoma"],"term_type":""},{"nm":"Low grade appendiceal mucinous neoplasm","n_c":["C42598"],"i_c":"8480/1","i_c_s":["Low grade appendiceal mucinous neoplasm"],"term_type":"PT"},{"nm":"Low grade cribriform cystadenocarcinoma (LGCCC)","n_c":["C62192"],"i_c":"8500/2","i_c_s":["Low grade cribriform cystadenocarcinoma (LGCCC)"],"term_type":""},{"nm":"Low-grade central osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Low-grade central osteosarcoma"],"term_type":""},{"nm":"Low-grade fibromyxoid sarcoma","n_c":["C45202"],"i_c":"8840/3","i_c_s":["Low-grade fibromyxoid sarcoma"],"term_type":""},{"nm":"Low-grade intramedullary osteosarcoma","n_c":["C6474"],"i_c":"9187/3","i_c_s":["Low-grade intramedullary osteosarcoma"],"term_type":""},{"nm":"Low-grade myofibroblastic sarcoma","n_c":["C49024"],"i_c":"8825/3","i_c_s":["Low-grade myofibroblastic sarcoma"],"term_type":""},{"nm":"Low-grade serous carcinoma","n_c":"","i_c":"8460/3","i_c_s":["Low-grade serous carcinoma"],"term_type":""},{"nm":"Luteinoma","n_c":["C3202"],"i_c":"8610/0","i_c_s":["Luteinoma"],"term_type":"SY"},{"nm":"Luteoma, NOS","n_c":["C3202"],"i_c":"8610/0","i_c_s":["Luteoma, NOS"],"term_type":"PT"},{"nm":"Lymphangioendothelial sarcoma","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangioendothelial sarcoma"],"term_type":"SY"},{"nm":"Lymphangioendothelioma, malignant","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangioendothelioma, malignant"],"term_type":"SY"},{"nm":"Lymphangioendothelioma, NOS","n_c":["C3203"],"i_c":"9170/0","i_c_s":["Lymphangioendothelioma, NOS"],"term_type":"SY"},{"nm":"Lymphangioleiomyomatosis","n_c":["C3725"],"i_c":"9174/1","i_c_s":["Lymphangioleiomyomatosis"],"term_type":"SY"},{"nm":"Lymphangioma, NOS","n_c":["C8965"],"i_c":"9170/0","i_c_s":["Lymphangioma, NOS"],"term_type":"PT"},{"nm":"Lymphangiomyoma","n_c":["C3204"],"i_c":"9174/0","i_c_s":["Lymphangiomyoma"],"term_type":"PT"},{"nm":"Lymphangiomyomatosis","n_c":["C3725"],"i_c":"9174/1","i_c_s":["Lymphangiomyomatosis"],"term_type":"PT"},{"nm":"Lymphangiosarcoma","n_c":["C3205"],"i_c":"9170/3","i_c_s":["Lymphangiosarcoma"],"term_type":"PT"},{"nm":"Lymphatic leukemic, NOS","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphatic leukemic, NOS"],"term_type":""},{"nm":"Lymphoblastic leukemia, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Lymphoblastic leukemia, NOS"],"term_type":"SY"},{"nm":"Lymphoblastoma","n_c":["C9360"],"i_c":"9727/3","i_c_s":["Lymphoblastoma"],"term_type":"IS"},{"nm":"Lymphocytic leukemia, NOS","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphocytic leukemia, NOS"],"term_type":"ORT"},{"nm":"Lymphoepithelial carcinoma","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelial carcinoma"],"term_type":"PT"},{"nm":"Lymphoepithelioid lymphoma","n_c":["C7205"],"i_c":"9702/3","i_c_s":["Lymphoepithelioid lymphoma"],"term_type":"RT"},{"nm":"Lymphoepithelioma","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelioma"],"term_type":"SY"},{"nm":"Lymphoepithelioma-like carcinoma","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Lymphoepithelioma-like carcinoma"],"term_type":"SY"},{"nm":"Lymphoid leukemia, NOS","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphoid leukemia, NOS"],"term_type":"PT"},{"nm":"Lymphoma, NOS","n_c":["C3208"],"i_c":"9590/3","i_c_s":["Lymphoma, NOS"],"term_type":"SY"},{"nm":"Lymphomatoid granulomatosis","n_c":["C7930"],"i_c":"9766/1","i_c_s":["Lymphomatoid granulomatosis"],"term_type":"RT"},{"nm":"Lymphomatoid papulosis","n_c":["C3721"],"i_c":"9718/3","i_c_s":["Lymphomatoid papulosis"],"term_type":"SY"},{"nm":"Lymphoplasmacyte-rich meningioma","n_c":["C4720"],"i_c":"9530/0","i_c_s":["Lymphoplasmacyte-rich meningioma"],"term_type":"RT"},{"nm":"Lymphoproliferative disease, NOS","n_c":["C9308"],"i_c":"9970/1","i_c_s":["Lymphoproliferative disease, NOS"],"term_type":"SY"},{"nm":"Lymphoproliferative disorder, NOS","n_c":["C9308"],"i_c":"9970/1","i_c_s":["Lymphoproliferative disorder, NOS"],"term_type":"PT"},{"nm":"Lymphosarcoma cell leukemia","n_c":["C7539"],"i_c":"9820/3","i_c_s":["Lymphosarcoma cell leukemia"],"term_type":"ORT"},{"nm":"Lymphosarcoma, diffuse","n_c":["C26919"],"i_c":"9591/3","i_c_s":["Lymphosarcoma, diffuse"],"term_type":"IS"},{"nm":"Lymphosarcoma, NOS","n_c":["C26919"],"i_c":"9591/3","i_c_s":["Lymphosarcoma, NOS"],"term_type":"ORT"},{"nm":"M6A","n_c":["C7152"],"i_c":"9840/3","i_c_s":["M6A"],"term_type":"SY"},{"nm":"M6B","n_c":["C7467"],"i_c":"9840/3","i_c_s":["M6B"],"term_type":"SY"},{"nm":"Macrofollicular adenoma","n_c":["C4161"],"i_c":"8334/0","i_c_s":["Macrofollicular adenoma"],"term_type":"PT"},{"nm":"Magnocellular nevus","n_c":["C9498"],"i_c":"8726/0","i_c_s":["Magnocellular nevus"],"term_type":"PT"},{"nm":"Malignancy","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Malignancy"],"term_type":"SY"},{"nm":"Malignant chondroid syringoma","n_c":"","i_c":"8940/3","i_c_s":["Malignant chondroid syringoma"],"term_type":"RT"},{"nm":"Malignant cystic nephroma","n_c":["C6897"],"i_c":"8959/3","i_c_s":["Malignant cystic nephroma"],"term_type":"PT"},{"nm":"Malignant eccrine spiradenoma","n_c":["C5117"],"i_c":"8403/3","i_c_s":["Malignant eccrine spiradenoma"],"term_type":"PT"},{"nm":"Malignant fibrous histiocytoma","n_c":["C4247"],"i_c":"8830/3","i_c_s":["Malignant fibrous histiocytoma"],"term_type":"PT"},{"nm":"Malignant fibrous histiocytoma (MFH) of bone","n_c":["C8563"],"i_c":"8830/3","i_c_s":["Malignant fibrous histiocytoma (MFH) of bone"],"term_type":""},{"nm":"Malignant giant cell tumor of soft parts","n_c":["C8380"],"i_c":"9251/3","i_c_s":["Malignant giant cell tumor of soft parts"],"term_type":"PT"},{"nm":"Malignant histiocytosis","n_c":["C7202"],"i_c":"9750/3","i_c_s":["Malignant histiocytosis"],"term_type":"PT"},{"nm":"Malignant hydatidiform mole","n_c":["C6985"],"i_c":"9100/1","i_c_s":["Malignant hydatidiform mole"],"term_type":"SY"},{"nm":"Malignant lymphoma, centroblastic, diffuse","n_c":["C4074"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, centroblastic, diffuse"],"term_type":"RT"},{"nm":"Malignant lymphoma, centroblastic, follicular","n_c":["C8994"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, centroblastic, follicular"],"term_type":"SY"},{"nm":"Malignant lymphoma, centroblastic, NOS","n_c":["C4074"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, centroblastic, NOS"],"term_type":"RT"},{"nm":"Malignant lymphoma, centroblasticcentrocytic, diffuse","n_c":["C4338"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, centroblasticcentrocytic, diffuse"],"term_type":""},{"nm":"Malignant lymphoma, centroblasticcentrocytic, follicular","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, centroblasticcentrocytic, follicular"],"term_type":""},{"nm":"Malignant lymphoma, centroblasticcentrocytic, NOS","n_c":["C4338"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, centroblasticcentrocytic, NOS"],"term_type":""},{"nm":"Malignant lymphoma, centrocytic","n_c":"","i_c":"9673/3","i_c_s":["Malignant lymphoma, centrocytic"],"term_type":"IS"},{"nm":"Malignant lymphoma, cleaved cell, NOS","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, cleaved cell, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, convoluted cell","n_c":["C27821"],"i_c":"9727/3","i_c_s":["Malignant lymphoma, convoluted cell"],"term_type":"IS"},{"nm":"Malignant lymphoma, diffuse, NOS","n_c":["C27822"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, diffuse, NOS"],"term_type":"RT"},{"nm":"Malignant lymphoma, follicle center, follicular","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, follicle center, follicular"],"term_type":"SY"},{"nm":"Malignant lymphoma, follicle center, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, follicle center, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, follicular, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, follicular, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, histiocytic, diffuse","n_c":["C27099"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, histiocytic, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, histiocytic, nodular","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, histiocytic, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, histiocytic, NOS","n_c":["C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, histiocytic, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, Hodgkin","n_c":["C9357"],"i_c":"9650/3","i_c_s":["Malignant lymphoma, Hodgkin"],"term_type":"SY"},{"nm":"Malignant lymphoma, immunoblastic, NOS","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, immunoblastic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS","n_c":["C4074"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, large B-cell, diffuse, NOS","n_c":["C80280"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, diffuse, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, large B-cell, NOS","n_c":["C80280"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large B-cell, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, cleaved and noncleaved","n_c":["C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, cleaved and noncleaved"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, cleaved, diffuse","n_c":["C27265"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, cleaved, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, cleaved, NOS","n_c":["C27265"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, cleaved, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, diffuse, NOS","n_c":["C8851"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, diffuse, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, follicular, NOS","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, large cell, follicular, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, immunoblastic","n_c":["C3461"],"i_c":"9684/3","i_c_s":["Malignant lymphoma, large cell, immunoblastic"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, noncleaved, diffuse","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, noncleaved, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, noncleaved, follicular","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, large cell, noncleaved, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cell, noncleaved, NOS","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, noncleaved, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cell, NOS","n_c":["C27823"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cell, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, large cleaved cell, follicular","n_c":["C3460"],"i_c":"9698/3","i_c_s":["Malignant lymphoma, large cleaved cell, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, large cleaved cell, NOS","n_c":["C27265"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, large cleaved cell, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphoblastic, NOS","n_c":["C9360"],"i_c":"9727/3","i_c_s":["Malignant lymphoma, lymphoblastic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, diffuse, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, lymphocytic, diffuse, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse","n_c":["C4337"],"i_c":"9673/3","i_c_s":["Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphocytic, intermediate differentiation, nodular","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, lymphocytic, intermediate differentiation, nodular"],"term_type":"ORT"},{"nm":"Malignant lymphoma, lymphocytic, nodular, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, lymphocytic, nodular, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphocytic, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, lymphocytic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, poorly differentiated, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, lymphocytic, poorly differentiated, diffuse"],"term_type":"ORT"},{"nm":"Malignant lymphoma, lymphocytic, poorly differentiated, nodular","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Malignant lymphoma, lymphocytic, poorly differentiated, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphocytic, well differentiated, diffuse","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, lymphocytic, well differentiated, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, lymphocytic, well differentiated, nodular","n_c":"","i_c":"9698/3","i_c_s":["Malignant lymphoma, lymphocytic, well differentiated, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, lymphoplasmacytic","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, lymphoplasmacytic"],"term_type":"PT"},{"nm":"Malignant lymphoma, lymphoplasmacytoid","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, lymphoplasmacytoid"],"term_type":"SY"},{"nm":"Malignant lymphoma, mixed cell type, diffuse","n_c":["C3463"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed cell type, diffuse"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed cell type, follicular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed cell type, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed cell type, nodular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed cell type, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse","n_c":"","i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed lymphocytic-histiocytic, nodular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed lymphocytic-histiocytic, nodular"],"term_type":"IS"},{"nm":"Malignant lymphoma, mixed small and large cell, diffuse","n_c":["C3463"],"i_c":"9675/3","i_c_s":["Malignant lymphoma, mixed small and large cell, diffuse"],"term_type":"OP"},{"nm":"Malignant lymphoma, mixed small cleaved and large cell, follicular","n_c":["C8968"],"i_c":"9691/3","i_c_s":["Malignant lymphoma, mixed small cleaved and large cell, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, nodular, NOS","n_c":["C3209"],"i_c":"9690/3","i_c_s":["Malignant lymphoma, nodular, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, non-cleaved cell, NOS","n_c":["C27258"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, non-cleaved cell, NOS"],"term_type":"RT"},{"nm":"Malignant lymphoma, non-Hodgkin, NOS","n_c":["C3211"],"i_c":"9591/3","i_c_s":["Malignant lymphoma, non-Hodgkin, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, noncleaved cell, follicular, NOS","n_c":"","i_c":"9698/3","i_c_s":["Malignant lymphoma, noncleaved cell, follicular, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, noncleaved, diffuse, NOS","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, noncleaved, diffuse, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, noncleaved, NOS","n_c":["C27266"],"i_c":"9680/3","i_c_s":["Malignant lymphoma, noncleaved, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, NOS","n_c":["C3208"],"i_c":"9590/3","i_c_s":["Malignant lymphoma, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, plasmacytoid","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Malignant lymphoma, plasmacytoid"],"term_type":"ORT"},{"nm":"Malignant lymphoma, small B lymphocytic, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small B lymphocytic, NOS"],"term_type":"PT"},{"nm":"Malignant lymphoma, small cell diffuse","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small cell diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, small cell, noncleaved, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, small cell, noncleaved, diffuse"],"term_type":"ORT"},{"nm":"Malignant lymphoma, small cell, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small cell, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, small cleaved cell, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, small cleaved cell, diffuse"],"term_type":"ORT"},{"nm":"Malignant lymphoma, small cleaved cell, follicular","n_c":["C3465"],"i_c":"9695/3","i_c_s":["Malignant lymphoma, small cleaved cell, follicular"],"term_type":"IS"},{"nm":"Malignant lymphoma, small cleaved cell, NOS","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, small cleaved cell, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, small lymphocytic, diffuse","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small lymphocytic, diffuse"],"term_type":"SY"},{"nm":"Malignant lymphoma, small lymphocytic, NOS","n_c":["C7540"],"i_c":"9670/3","i_c_s":["Malignant lymphoma, small lymphocytic, NOS"],"term_type":"SY"},{"nm":"Malignant lymphoma, small noncleaved, Burkitt type","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Malignant lymphoma, small noncleaved, Burkitt type"],"term_type":"IS"},{"nm":"Malignant lymphoma, undifferentiated cell type, NOS","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, undifferentiated cell type, NOS"],"term_type":"IS"},{"nm":"Malignant lymphoma, undifferentiated cell, non-Burkitt","n_c":"","i_c":"9591/3","i_c_s":["Malignant lymphoma, undifferentiated cell, non-Burkitt"],"term_type":"IS"},{"nm":"Malignant lymphoma, undifferentiated, Burkitt type","n_c":["C2912"],"i_c":"9687/3","i_c_s":["Malignant lymphoma, undifferentiated, Burkitt type"],"term_type":"IS"},{"nm":"Malignant lymphomatous polyposis","n_c":["C4339"],"i_c":"9673/3","i_c_s":["Malignant lymphomatous polyposis"],"term_type":"SY"},{"nm":"Malignant mast cell tumor","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Malignant mast cell tumor"],"term_type":"SY"},{"nm":"Malignant mastocytoma","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Malignant mastocytoma"],"term_type":"SY"},{"nm":"Malignant mastocytosis","n_c":["C8991"],"i_c":"9741/3","i_c_s":["Malignant mastocytosis"],"term_type":"PT"},{"nm":"Malignant melanoma in congenital melanocytic nevus","n_c":["C4235"],"i_c":"8761/3","i_c_s":["Malignant melanoma in congenital melanocytic nevus"],"term_type":"SY"},{"nm":"Malignant melanoma in giant pigmented nevus","n_c":["C4235"],"i_c":"8761/3","i_c_s":["Malignant melanoma in giant pigmented nevus"],"term_type":"PT"},{"nm":"Malignant melanoma in Hutchinson melanotic freckle","n_c":["C9151"],"i_c":"8742/3","i_c_s":["Malignant melanoma in Hutchinson melanotic freckle"],"term_type":"SY"},{"nm":"Malignant melanoma in junctional nevus","n_c":["C4232"],"i_c":"8740/3","i_c_s":["Malignant melanoma in junctional nevus"],"term_type":"PT"},{"nm":"Malignant melanoma in precancerous melanosis","n_c":["C66753"],"i_c":"8741/3","i_c_s":["Malignant melanoma in precancerous melanosis"],"term_type":"PT"},{"nm":"Malignant melanoma, NOS","n_c":["C3224"],"i_c":"8720/3","i_c_s":["Malignant melanoma, NOS"],"term_type":"PT"},{"nm":"Malignant melanoma, regressing","n_c":["C4228"],"i_c":"8723/3","i_c_s":["Malignant melanoma, regressing"],"term_type":"PT"},{"nm":"Malignant midline reticulosis","n_c":"","i_c":"9719/3","i_c_s":["Malignant midline reticulosis"],"term_type":"IS"},{"nm":"Malignant mucinous adenofibroma","n_c":"","i_c":"9015/3","i_c_s":["Malignant mucinous adenofibroma"],"term_type":"SY"},{"nm":"Malignant mucinous cystadenofibroma","n_c":"","i_c":"9015/3","i_c_s":["Malignant mucinous cystadenofibroma"],"term_type":"SY"},{"nm":"Malignant multilocular cystic nephroma","n_c":["C6897"],"i_c":"8959/3","i_c_s":["Malignant multilocular cystic nephroma"],"term_type":"SY"},{"nm":"Malignant myelosclerosis","n_c":"","i_c":"9931/3","i_c_s":["Malignant myelosclerosis"],"term_type":"IS"},{"nm":"Malignant myoepithelioma","n_c":["C7596"],"i_c":"8982/3","i_c_s":["Malignant myoepithelioma"],"term_type":"PT"},{"nm":"Malignant peripheral nerve sheath tumor","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Malignant peripheral nerve sheath tumor"],"term_type":"PT"},{"nm":"Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation"],"term_type":"PT"},{"nm":"Malignant perivascular epithelial cell tumor","n_c":["C6530"],"i_c":"8714/3","i_c_s":["Malignant perivascular epithelial cell tumor"],"term_type":""},{"nm":"Malignant reticulosis, NOS","n_c":["C4684"],"i_c":"9719/3","i_c_s":["Malignant reticulosis, NOS"],"term_type":"IS"},{"nm":"Malignant rhabdoid tumor","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Malignant rhabdoid tumor"],"term_type":"PT"},{"nm":"Malignant schwannoma with rhabdomyoblastic differentiation","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Malignant schwannoma with rhabdomyoblastic differentiation"],"term_type":"SY"},{"nm":"Malignant schwannoma, NOS","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Malignant schwannoma, NOS"],"term_type":"IS"},{"nm":"Malignant serous adenofibroma","n_c":"","i_c":"9014/3","i_c_s":["Malignant serous adenofibroma"],"term_type":"SY"},{"nm":"Malignant serous cystadenofibroma","n_c":"","i_c":"9014/3","i_c_s":["Malignant serous cystadenofibroma"],"term_type":"SY"},{"nm":"Malignant tenosynovial giant cell tumor","n_c":["C6535"],"i_c":"9252/3","i_c_s":["Malignant tenosynovial giant cell tumor"],"term_type":"PT"},{"nm":"Malignant teratoma, anaplastic","n_c":["C4287"],"i_c":"9082/3","i_c_s":["Malignant teratoma, anaplastic"],"term_type":"SY"},{"nm":"Malignant teratoma, intermediate","n_c":["C4288"],"i_c":"9083/3","i_c_s":["Malignant teratoma, intermediate"],"term_type":"PT"},{"nm":"Malignant teratoma, trophoblastic","n_c":["C66778"],"i_c":"9102/3","i_c_s":["Malignant teratoma, trophoblastic"],"term_type":"PT"},{"nm":"Malignant teratoma, undifferentiated","n_c":["C4287"],"i_c":"9082/3","i_c_s":["Malignant teratoma, undifferentiated"],"term_type":"PT"},{"nm":"Malignant tumor, clear cell type","n_c":["C40077"],"i_c":"8005/3","i_c_s":["Malignant tumor, clear cell type"],"term_type":"PT"},{"nm":"Malignant tumor, fusiform cell type","n_c":["C27091"],"i_c":"8004/3","i_c_s":["Malignant tumor, fusiform cell type"],"term_type":"SY"},{"nm":"Malignant tumor, giant cell type","n_c":["C4090"],"i_c":"8003/3","i_c_s":["Malignant tumor, giant cell type"],"term_type":"PT"},{"nm":"Malignant tumor, small cell type","n_c":["C65154"],"i_c":"8002/3","i_c_s":["Malignant tumor, small cell type"],"term_type":"PT"},{"nm":"Malignant tumor, spindle cell type","n_c":["C27091"],"i_c":"8004/3","i_c_s":["Malignant tumor, spindle cell type"],"term_type":"PT"},{"nm":"MALT lymphoma","n_c":["C3898"],"i_c":"9699/3","i_c_s":["MALT lymphoma"],"term_type":"SY"},{"nm":"Mammary carcinoma, in situ","n_c":"","i_c":"8500/2","i_c_s":["Mammary carcinoma, in situ"],"term_type":""},{"nm":"MANEC","n_c":["C95406"],"i_c":"8244/3","i_c_s":["MANEC"],"term_type":"SY"},{"nm":"Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)","n_c":["C4337"],"i_c":"9673/3","i_c_s":["Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)"],"term_type":""},{"nm":"Mantle zone lymphoma","n_c":["C4337"],"i_c":"9673/3","i_c_s":["Mantle zone lymphoma"],"term_type":"IS"},{"nm":"Marginal zone B-cell lymphoma, NOS","n_c":["C4341"],"i_c":"9699/3","i_c_s":["Marginal zone B-cell lymphoma, NOS"],"term_type":"PT"},{"nm":"Marginal zone lymphoma, NOS","n_c":["C4341"],"i_c":"9699/3","i_c_s":["Marginal zone lymphoma, NOS"],"term_type":"SY"},{"nm":"Masculinovoblastoma","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Masculinovoblastoma"],"term_type":"RT"},{"nm":"Mast cell leukaemia","n_c":["C3169"],"i_c":"9742/3","i_c_s":["Mast cell leukaemia"],"term_type":""},{"nm":"Mast cell sarcoma","n_c":["C9348"],"i_c":"9740/3","i_c_s":["Mast cell sarcoma"],"term_type":"PT"},{"nm":"Mast cell tumor, NOS","n_c":["C9295"],"i_c":"9740/1","i_c_s":["Mast cell tumor, NOS"],"term_type":"SY"},{"nm":"Mastocytoma, NOS","n_c":["C9303"],"i_c":"9740/1","i_c_s":["Mastocytoma, NOS"],"term_type":"PT"},{"nm":"Matrical carcinoma","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Matrical carcinoma"],"term_type":"SY"},{"nm":"Mature T ALL","n_c":["C27820"],"i_c":"9837/3","i_c_s":["Mature T ALL"],"term_type":"SY"},{"nm":"Mature T-cell lymphoma, NOS","n_c":["C4340"],"i_c":"9702/3","i_c_s":["Mature T-cell lymphoma, NOS"],"term_type":"PT"},{"nm":"Mature teratoma","n_c":["C9015"],"i_c":"9080/0","i_c_s":["Mature teratoma"],"term_type":"SY"},{"nm":"Mediastinal (thymic) large B-cell lymphoma","n_c":["C9280"],"i_c":"9679/3","i_c_s":["Mediastinal (thymic) large B-cell lymphoma"],"term_type":""},{"nm":"Mediterranean lymphoma","n_c":["C3132"],"i_c":"9764/3","i_c_s":["Mediterranean lymphoma"],"term_type":"SY"},{"nm":"Medullary adenocarcinoma","n_c":"","i_c":"8510/3","i_c_s":["Medullary adenocarcinoma"],"term_type":"RT"},{"nm":"Medullary carcinoma with amyloid stroma","n_c":["C4193"],"i_c":"8345/3","i_c_s":["Medullary carcinoma with amyloid stroma"],"term_type":"PT"},{"nm":"Medullary carcinoma with lymphoid stroma","n_c":["C9119"],"i_c":"8512/3","i_c_s":["Medullary carcinoma with lymphoid stroma"],"term_type":"PT"},{"nm":"Medullary carcinoma, NOS","n_c":["C66718"],"i_c":"8510/3","i_c_s":["Medullary carcinoma, NOS"],"term_type":"PT"},{"nm":"Medullary osteosarcoma","n_c":["C35870"],"i_c":"9186/3","i_c_s":["Medullary osteosarcoma"],"term_type":"SY"},{"nm":"Medulloblastoma with extensive nodularity","n_c":["C5407"],"i_c":"9471/3","i_c_s":["Medulloblastoma with extensive nodularity"],"term_type":"RT"},{"nm":"Medulloblastoma, classic","n_c":["C54039"],"i_c":"9470/3","i_c_s":["Medulloblastoma, classic"],"term_type":""},{"nm":"Medulloblastoma, group 3","n_c":["C129445"],"i_c":"9477/3","i_c_s":["Medulloblastoma, group 3"],"term_type":""},{"nm":"Medulloblastoma, group 4","n_c":["C129446"],"i_c":"9477/3","i_c_s":["Medulloblastoma, group 4"],"term_type":""},{"nm":"Medulloblastoma, non-WNT/non-SHH","n_c":["C129444"],"i_c":"9477/3","i_c_s":["Medulloblastoma, non-WNT/non-SHH"],"term_type":"PT"},{"nm":"Medulloblastoma, NOS","n_c":["C129447"],"i_c":"9470/3","i_c_s":["Medulloblastoma, NOS"],"term_type":"PT"},{"nm":"Medulloblastoma, SHH-activated and TP53-mutant","n_c":["C129442"],"i_c":"9476/3","i_c_s":["Medulloblastoma, SHH-activated and TP53-mutant"],"term_type":"PT"},{"nm":"Medulloblastoma, SHH-activated and TP53-wildtype","n_c":["C129443"],"i_c":"9471/3","i_c_s":["Medulloblastoma, SHH-activated and TP53-wildtype"],"term_type":""},{"nm":"Medulloblastoma, WNT-activated","n_c":["C129440"],"i_c":"9475/3","i_c_s":["Medulloblastoma, WNT-activated"],"term_type":"PT"},{"nm":"Medullocytoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Medullocytoma"],"term_type":"SY"},{"nm":"Medulloepithelioma, benign","n_c":["C66807"],"i_c":"9501/0","i_c_s":["Medulloepithelioma, benign"],"term_type":"PT"},{"nm":"Medulloepithelioma, NOS","n_c":["C66808"],"i_c":"9501/3","i_c_s":["Medulloepithelioma, NOS"],"term_type":"PT"},{"nm":"Medullomyoblastoma","n_c":["C3706"],"i_c":"9472/3","i_c_s":["Medullomyoblastoma"],"term_type":"PT"},{"nm":"Megakaryocytic leukemia","n_c":["C3170"],"i_c":"9910/3","i_c_s":["Megakaryocytic leukemia"],"term_type":"SY"},{"nm":"Megakaryocytic myelosclerosis","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Megakaryocytic myelosclerosis"],"term_type":"SY"},{"nm":"Melanoameloblastoma","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanoameloblastoma"],"term_type":"SY"},{"nm":"Melanocytic nevus","n_c":["C7570"],"i_c":"8720/0","i_c_s":["Melanocytic nevus"],"term_type":"SY"},{"nm":"Melanocytoma, eyeball","n_c":["C4230"],"i_c":"8726/0","i_c_s":["Melanocytoma, eyeball"],"term_type":"SY"},{"nm":"Melanocytoma, NOS","n_c":["C9498"],"i_c":"8726/0","i_c_s":["Melanocytoma, NOS"],"term_type":"RT"},{"nm":"Melanoma in situ","n_c":["C8423"],"i_c":"8720/2","i_c_s":["Melanoma in situ"],"term_type":"PT"},{"nm":"Melanoma, malignant, of soft parts","n_c":["C3745"],"i_c":"9044/3","i_c_s":["Melanoma, malignant, of soft parts"],"term_type":"RT"},{"nm":"Melanoma, NOS","n_c":["C3224"],"i_c":"8720/3","i_c_s":["Melanoma, NOS"],"term_type":"SY"},{"nm":"Melanotic medulloblastoma","n_c":["C9497"],"i_c":"9470/3","i_c_s":["Melanotic medulloblastoma"],"term_type":"RT"},{"nm":"Melanotic MPNST","n_c":["C4748"],"i_c":"9540/3","i_c_s":["Melanotic MPNST"],"term_type":"RT"},{"nm":"Melanotic neuroectodermal tumor","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanotic neuroectodermal tumor"],"term_type":"PT"},{"nm":"Melanotic neurofibroma","n_c":["C66841"],"i_c":"9541/0","i_c_s":["Melanotic neurofibroma"],"term_type":"PT"},{"nm":"Melanotic progonoma","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Melanotic progonoma"],"term_type":"SY"},{"nm":"Melanotic psammomatous MPNST","n_c":["C6910"],"i_c":"9540/3","i_c_s":["Melanotic psammomatous MPNST"],"term_type":"RT"},{"nm":"Melanotic schwannoma","n_c":["C6970"],"i_c":"9560/0","i_c_s":["Melanotic schwannoma"],"term_type":"SY"},{"nm":"Meningeal melanocytoma","n_c":["C4662"],"i_c":"8728/1","i_c_s":["Meningeal melanocytoma"],"term_type":"PT"},{"nm":"Meningeal melanoma","n_c":["C5317"],"i_c":"8720/3","i_c_s":["Meningeal melanoma"],"term_type":""},{"nm":"Meningeal melanomatosis","n_c":["C6891"],"i_c":"8728/3","i_c_s":["Meningeal melanomatosis"],"term_type":"PT"},{"nm":"Meningeal sarcoma","n_c":["C4073"],"i_c":"9530/3","i_c_s":["Meningeal sarcoma"],"term_type":"SY"},{"nm":"Meningeal sarcomatosis","n_c":["C4334"],"i_c":"9539/3","i_c_s":["Meningeal sarcomatosis"],"term_type":"PT"},{"nm":"Meningioma, anaplastic","n_c":["C4051"],"i_c":"9530/3","i_c_s":["Meningioma, anaplastic"],"term_type":"SY"},{"nm":"Meningioma, malignant","n_c":["C4051"],"i_c":"9530/3","i_c_s":["Meningioma, malignant"],"term_type":"PT"},{"nm":"Meningioma, NOS","n_c":["C3230"],"i_c":"9530/0","i_c_s":["Meningioma, NOS"],"term_type":"PT"},{"nm":"Meningiomatosis, NOS","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Meningiomatosis, NOS"],"term_type":"PT"},{"nm":"Meningothelial meningioma","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Meningothelial meningioma"],"term_type":"PT"},{"nm":"Meningothelial sarcoma","n_c":["C4073"],"i_c":"9530/3","i_c_s":["Meningothelial sarcoma"],"term_type":"SY"},{"nm":"Merkel cell carcinoma","n_c":["C9231"],"i_c":"8247/3","i_c_s":["Merkel cell carcinoma"],"term_type":"PT"},{"nm":"Merkel cell tumor","n_c":["C9231"],"i_c":"8247/3","i_c_s":["Merkel cell tumor"],"term_type":"SY"},{"nm":"Mesenchymal chondrosarcoma","n_c":["C3737"],"i_c":"9240/3","i_c_s":["Mesenchymal chondrosarcoma"],"term_type":"PT"},{"nm":"Mesenchymal tumor, malignant","n_c":["C9118"],"i_c":"8800/3","i_c_s":["Mesenchymal tumor, malignant"],"term_type":"SY"},{"nm":"Mesenchymoma, benign","n_c":["C4267"],"i_c":"8990/0","i_c_s":["Mesenchymoma, benign"],"term_type":"PT"},{"nm":"Mesenchymoma, malignant","n_c":["C4268"],"i_c":"8990/3","i_c_s":["Mesenchymoma, malignant"],"term_type":"PT"},{"nm":"Mesenchymoma, NOS","n_c":["C3233"],"i_c":"8990/1","i_c_s":["Mesenchymoma, NOS"],"term_type":"PT"},{"nm":"Mesenteric fibromatosis","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Mesenteric fibromatosis"],"term_type":"SY"},{"nm":"Mesoblastic nephroma","n_c":["C6569"],"i_c":"8960/1","i_c_s":["Mesoblastic nephroma"],"term_type":"PT"},{"nm":"Mesodermal mixed tumor","n_c":["C3730"],"i_c":"8951/3","i_c_s":["Mesodermal mixed tumor"],"term_type":"PT"},{"nm":"Mesonephric adenocarcinoma","n_c":["C4072"],"i_c":"9110/3","i_c_s":["Mesonephric adenocarcinoma"],"term_type":"SY"},{"nm":"Mesonephric adenoma","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Mesonephric adenoma"],"term_type":"SY"},{"nm":"Mesonephric tumor, NOS","n_c":["C40141"],"i_c":"9110/1","i_c_s":["Mesonephric tumor, NOS"],"term_type":"PT"},{"nm":"Mesonephroma, benign","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Mesonephroma, benign"],"term_type":"PT"},{"nm":"Mesonephroma, malignant","n_c":["C4072"],"i_c":"9110/3","i_c_s":["Mesonephroma, malignant"],"term_type":"PT"},{"nm":"Mesonephroma, NOS","n_c":["C40141"],"i_c":"9110/3","i_c_s":["Mesonephroma, NOS"],"term_type":"SY"},{"nm":"Mesothelial papilloma","n_c":"","i_c":"9052/0","i_c_s":["Mesothelial papilloma"],"term_type":"SY"},{"nm":"Mesothelioma, benign","n_c":["C3762"],"i_c":"9050/0","i_c_s":["Mesothelioma, benign"],"term_type":"PT"},{"nm":"Mesothelioma, biphasic, malignant","n_c":["C4282"],"i_c":"9053/3","i_c_s":["Mesothelioma, biphasic, malignant"],"term_type":"PT"},{"nm":"Mesothelioma, biphasic, NOS","n_c":["C4282"],"i_c":"9053/3","i_c_s":["Mesothelioma, biphasic, NOS"],"term_type":"SY"},{"nm":"Mesothelioma, malignant","n_c":["C4456"],"i_c":"9050/3","i_c_s":["Mesothelioma, malignant"],"term_type":"PT"},{"nm":"Mesothelioma, NOS","n_c":["C3786"],"i_c":"9050/3","i_c_s":["Mesothelioma, NOS"],"term_type":"SY"},{"nm":"Metanephric adenoma","n_c":["C27253"],"i_c":"8325/0","i_c_s":["Metanephric adenoma"],"term_type":"PT"},{"nm":"Metaplastic carcinoma of no special type","n_c":["C27949"],"i_c":"8575/3","i_c_s":["Metaplastic carcinoma of no special type"],"term_type":""},{"nm":"Metaplastic carcinoma with chondroid differentiation","n_c":"","i_c":"8571/3","i_c_s":["Metaplastic carcinoma with chondroid differentiation"],"term_type":""},{"nm":"Metaplastic carcinoma with osseous differentiation","n_c":"","i_c":"8571/3","i_c_s":["Metaplastic carcinoma with osseous differentiation"],"term_type":""},{"nm":"Metaplastic carcinoma with other types mesenchymal differentiation","n_c":"","i_c":"8575/3","i_c_s":["Metaplastic carcinoma with other types mesenchymal differentiation"],"term_type":""},{"nm":"Metaplastic carcinoma, NOS","n_c":["C27949"],"i_c":"8575/3","i_c_s":["Metaplastic carcinoma, NOS"],"term_type":"PT"},{"nm":"Metaplastic meningioma","n_c":["C6907"],"i_c":"9530/0","i_c_s":["Metaplastic meningioma"],"term_type":"RT"},{"nm":"Metastasizing leiomyoma","n_c":"","i_c":"8898/1","i_c_s":["Metastasizing leiomyoma"],"term_type":"PT"},{"nm":"Metastatic signet ring cell carcinoma","n_c":["C66717"],"i_c":"8490/6","i_c_s":["Metastatic signet ring cell carcinoma"],"term_type":"PT"},{"nm":"Metatypical carcinoma","n_c":["C2922"],"i_c":"8095/3","i_c_s":["Metatypical carcinoma"],"term_type":"PT"},{"nm":"MGUS","n_c":["C3996"],"i_c":"9765/1","i_c_s":["MGUS"],"term_type":"SY"},{"nm":"Microcystic adenoma","n_c":["C3685"],"i_c":"8202/0","i_c_s":["Microcystic adenoma"],"term_type":"PT"},{"nm":"Microcystic adnexal carcinoma","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Microcystic adnexal carcinoma"],"term_type":"SY"},{"nm":"Microcystic meningioma","n_c":["C4721"],"i_c":"9530/0","i_c_s":["Microcystic meningioma"],"term_type":"RT"},{"nm":"Microcystic urothelial carcinoma","n_c":["C191685"],"i_c":"8120/3","i_c_s":["Microcystic urothelial carcinoma"],"term_type":""},{"nm":"Microfollicular adenoma, NOS","n_c":["C4160"],"i_c":"8333/0","i_c_s":["Microfollicular adenoma, NOS"],"term_type":"PT"},{"nm":"Microglioma","n_c":["C9301"],"i_c":"9590/3","i_c_s":["Microglioma"],"term_type":"IS"},{"nm":"Micropapillary adenocarcinoma","n_c":"","i_c":"8265/3","i_c_s":["Micropapillary adenocarcinoma"],"term_type":""},{"nm":"Micropapillary carcinoma, NOS","n_c":["C128847"],"i_c":"8265/3","i_c_s":["Micropapillary carcinoma, NOS"],"term_type":"PT"},{"nm":"Micropapillary serous carcinoma","n_c":["C6882"],"i_c":"8460/3","i_c_s":["Micropapillary serous carcinoma"],"term_type":"RT"},{"nm":"Midline carcinoma of children and young adults with NUT rearrangement","n_c":["C45716"],"i_c":"8023/3","i_c_s":["Midline carcinoma of children and young adults with NUT rearrangement"],"term_type":""},{"nm":"Minimally invasive adenocarcinoma, mucinous","n_c":["C7268"],"i_c":"8257/3","i_c_s":["Minimally invasive adenocarcinoma, mucinous"],"term_type":"PT"},{"nm":"Minimally invasive adenocarcinoma, non-mucinous","n_c":["C7269"],"i_c":"8256/3","i_c_s":["Minimally invasive adenocarcinoma, non-mucinous"],"term_type":"PT"},{"nm":"Minimally invasive adenocarcinoma, NOS","n_c":["C2923"],"i_c":"8140/3","i_c_s":["Minimally invasive adenocarcinoma, NOS"],"term_type":""},{"nm":"MiT family translocation renal cell carcinoma","n_c":["C154494"],"i_c":"8311/3","i_c_s":["MiT family translocation renal cell carcinoma"],"term_type":""},{"nm":"Mixed acidophil-basophil adenoma","n_c":["C4148"],"i_c":"8281/0","i_c_s":["Mixed acidophil-basophil adenoma"],"term_type":"PT"},{"nm":"Mixed acidophil-basophil carcinoma","n_c":["C4149"],"i_c":"8281/3","i_c_s":["Mixed acidophil-basophil carcinoma"],"term_type":"PT"},{"nm":"Mixed acinar-ductal carcinoma","n_c":["C95458"],"i_c":"8552/3","i_c_s":["Mixed acinar-ductal carcinoma"],"term_type":"PT"},{"nm":"Mixed acinar-endocrine carcinoma","n_c":"","i_c":"8154/3","i_c_s":["Mixed acinar-endocrine carcinoma"],"term_type":"RT"},{"nm":"Mixed acinar-endocrine-ductal carcinoma","n_c":["C95458"],"i_c":"8154/3","i_c_s":["Mixed acinar-endocrine-ductal carcinoma"],"term_type":"RT"},{"nm":"Mixed adenocarcinoma and epidermoid carcinoma","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Mixed adenocarcinoma and epidermoid carcinoma"],"term_type":"SY"},{"nm":"Mixed adenocarcinoma and squamous cell carcinoma","n_c":["C3727"],"i_c":"8560/3","i_c_s":["Mixed adenocarcinoma and squamous cell carcinoma"],"term_type":"SY"},{"nm":"Mixed adenomatous and hyperplastic polyp","n_c":["C38458"],"i_c":"8213/0","i_c_s":["Mixed adenomatous and hyperplastic polyp"],"term_type":"RT"},{"nm":"Mixed adenoneuroendocrine carcinoma","n_c":["C95406"],"i_c":"8244/3","i_c_s":["Mixed adenoneuroendocrine carcinoma"],"term_type":"PT"},{"nm":"Mixed basal-squamous cell carcinoma","n_c":["C2922"],"i_c":"8094/3","i_c_s":["Mixed basal-squamous cell carcinoma"],"term_type":"SY"},{"nm":"Mixed carcinoid-adenocarcinoma","n_c":["C95406"],"i_c":"8244/3","i_c_s":["Mixed carcinoid-adenocarcinoma"],"term_type":"SY"},{"nm":"Mixed cell adenocarcinoma","n_c":["C4158"],"i_c":"8323/3","i_c_s":["Mixed cell adenocarcinoma"],"term_type":"PT"},{"nm":"Mixed cell adenoma","n_c":["C4157"],"i_c":"8323/0","i_c_s":["Mixed cell adenoma"],"term_type":"PT"},{"nm":"Mixed ductal-endocrine carcinoma","n_c":["C6879"],"i_c":"8154/3","i_c_s":["Mixed ductal-endocrine carcinoma"],"term_type":"RT"},{"nm":"Mixed embryonal carcinoma and teratoma","n_c":["C3756"],"i_c":"9081/3","i_c_s":["Mixed embryonal carcinoma and teratoma"],"term_type":"SY"},{"nm":"Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma","n_c":"","i_c":"8902/3","i_c_s":["Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma"],"term_type":"RT"},{"nm":"Mixed endocrine and exocrine adenocarcinoma","n_c":"","i_c":"8154/3","i_c_s":["Mixed endocrine and exocrine adenocarcinoma"],"term_type":"RT"},{"nm":"Mixed epithelioid and spindle cell melanoma","n_c":["C66756"],"i_c":"8770/3","i_c_s":["Mixed epithelioid and spindle cell melanoma"],"term_type":"PT"},{"nm":"Mixed germ cell sex cord-stromal tumor, unclassified","n_c":["C39912"],"i_c":"8594/1","i_c_s":["Mixed germ cell sex cord-stromal tumor, unclassified"],"term_type":"PT"},{"nm":"Mixed germ cell tumor","n_c":["C4290"],"i_c":"9085/3","i_c_s":["Mixed germ cell tumor"],"term_type":"PT"},{"nm":"Mixed glioma","n_c":["C3903"],"i_c":"9382/3","i_c_s":["Mixed glioma"],"term_type":"PT"},{"nm":"Mixed hepatocellular and bile duct carcinoma","n_c":["C3828"],"i_c":"8180/3","i_c_s":["Mixed hepatocellular and bile duct carcinoma"],"term_type":"SY"},{"nm":"Mixed invasive mucinous and non-mucinous adenocarcinoma","n_c":"","i_c":"8254/3","i_c_s":["Mixed invasive mucinous and non-mucinous adenocarcinoma"],"term_type":"PT"},{"nm":"Mixed islet cell and exocrine adenocarcinoma","n_c":"","i_c":"8154/3","i_c_s":["Mixed islet cell and exocrine adenocarcinoma"],"term_type":"SY"},{"nm":"Mixed liposarcoma","n_c":["C4253"],"i_c":"8855/3","i_c_s":["Mixed liposarcoma"],"term_type":"PT"},{"nm":"Mixed medullary-follicular carcinoma","n_c":["C46104"],"i_c":"8346/3","i_c_s":["Mixed medullary-follicular carcinoma"],"term_type":"PT"},{"nm":"Mixed medullary-papillary carcinoma","n_c":["C46104"],"i_c":"8347/3","i_c_s":["Mixed medullary-papillary carcinoma"],"term_type":"PT"},{"nm":"Mixed meningioma","n_c":["C4333"],"i_c":"9537/0","i_c_s":["Mixed meningioma"],"term_type":"SY"},{"nm":"Mixed mesenchymal sarcoma","n_c":["C4268"],"i_c":"8990/3","i_c_s":["Mixed mesenchymal sarcoma"],"term_type":"SY"},{"nm":"Mixed mesenchymal tumor","n_c":["C3233"],"i_c":"8990/1","i_c_s":["Mixed mesenchymal tumor"],"term_type":"SY"},{"nm":"Mixed pancreatic endocrine and exocrine tumor, malignant","n_c":["C45843"],"i_c":"8154/3","i_c_s":["Mixed pancreatic endocrine and exocrine tumor, malignant"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1","n_c":["C82192"],"i_c":"9806/3","i_c_s":["Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged","n_c":["C82203"],"i_c":"9807/3","i_c_s":["Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia, B/myeloid, NOS","n_c":["C82212"],"i_c":"9808/3","i_c_s":["Mixed phenotype acute leukemia, B/myeloid, NOS"],"term_type":"PT"},{"nm":"Mixed phenotype acute leukemia, T/myeloid, NOS","n_c":["C82213"],"i_c":"9809/3","i_c_s":["Mixed phenotype acute leukemia, T/myeloid, NOS"],"term_type":"PT"},{"nm":"Mixed pineal tumor","n_c":"","i_c":"9362/3","i_c_s":["Mixed pineal tumor"],"term_type":"RT"},{"nm":"Mixed pineocytoma-pineoblastoma","n_c":"","i_c":"9362/3","i_c_s":["Mixed pineocytoma-pineoblastoma"],"term_type":"SY"},{"nm":"Mixed small cell carcinoma","n_c":["C9137"],"i_c":"8045/3","i_c_s":["Mixed small cell carcinoma"],"term_type":"SY"},{"nm":"Mixed squamous cell and glandular papilloma","n_c":["C45602"],"i_c":"8560/0","i_c_s":["Mixed squamous cell and glandular papilloma"],"term_type":"PT"},{"nm":"Mixed subependymoma-ependymoma","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Mixed subependymoma-ependymoma"],"term_type":"RT"},{"nm":"Mixed teratoma and seminoma","n_c":["C9010"],"i_c":"9085/3","i_c_s":["Mixed teratoma and seminoma"],"term_type":"RT"},{"nm":"Mixed tumor, malignant, NOS","n_c":["C3729","C8025"],"i_c":"8940/3","i_c_s":["Mixed tumor, malignant, NOS"],"term_type":"PT"},{"nm":"Mixed tumor, NOS","n_c":["C121786"],"i_c":"8940/0","i_c_s":["Mixed tumor, NOS"],"term_type":"SY"},{"nm":"Mixed tumor, salivary gland type, malignant","n_c":["C8025"],"i_c":"8940/3","i_c_s":["Mixed tumor, salivary gland type, malignant"],"term_type":"SY"},{"nm":"Mixed tumor, salivary gland type, NOS","n_c":["C8602"],"i_c":"8940/0","i_c_s":["Mixed tumor, salivary gland type, NOS"],"term_type":"SY"},{"nm":"Mixed type rhabdomyosarcoma","n_c":"","i_c":"8902/3","i_c_s":["Mixed type rhabdomyosarcoma"],"term_type":"PT"},{"nm":"Monoblastic leukemia, NOS","n_c":["C7171"],"i_c":"9891/3","i_c_s":["Monoblastic leukemia, NOS"],"term_type":"SY"},{"nm":"Monoclonal gammopathy of undetermined significance","n_c":["C3996"],"i_c":"9765/1","i_c_s":["Monoclonal gammopathy of undetermined significance"],"term_type":"PT"},{"nm":"Monoclonal gammopathy, NOS","n_c":["C3996"],"i_c":"9765/1","i_c_s":["Monoclonal gammopathy, NOS"],"term_type":"SY"},{"nm":"Monocytic leukemia, NOS","n_c":["C4861"],"i_c":"9860/3","i_c_s":["Monocytic leukemia, NOS"],"term_type":"RT"},{"nm":"Monocytoid B-cell lymphoma","n_c":["C8863"],"i_c":"9699/3","i_c_s":["Monocytoid B-cell lymphoma"],"term_type":"SY"},{"nm":"Monomorphic adenoma","n_c":["C3686"],"i_c":"8146/0","i_c_s":["Monomorphic adenoma"],"term_type":"PT"},{"nm":"Monstrocellular sarcoma","n_c":"","i_c":"9441/3","i_c_s":["Monstrocellular sarcoma"],"term_type":"IS"},{"nm":"MPNST with glandular differentiation","n_c":"","i_c":"9540/3","i_c_s":["MPNST with glandular differentiation"],"term_type":"RT"},{"nm":"MPNST with mesenchymal differentiation","n_c":"","i_c":"9540/3","i_c_s":["MPNST with mesenchymal differentiation"],"term_type":"RT"},{"nm":"MPNST with rhabdomyoblastic differentiation","n_c":["C4335"],"i_c":"9561/3","i_c_s":["MPNST with rhabdomyoblastic differentiation"],"term_type":"SY"},{"nm":"MPNST, NOS","n_c":["C3798"],"i_c":"9540/3","i_c_s":["MPNST, NOS"],"term_type":"SY"},{"nm":"Mu heavy chain disease","n_c":["C3892"],"i_c":"9762/3","i_c_s":["Mu heavy chain disease"],"term_type":"RT"},{"nm":"Mucin-producing adenocarcinoma","n_c":["C27379"],"i_c":"8481/3","i_c_s":["Mucin-producing adenocarcinoma"],"term_type":"PT"},{"nm":"Mucin-producing carcinoma","n_c":["C27825"],"i_c":"8481/3","i_c_s":["Mucin-producing carcinoma"],"term_type":"SY"},{"nm":"Mucin-secreting adenocarcinoma","n_c":["C27379"],"i_c":"8481/3","i_c_s":["Mucin-secreting adenocarcinoma"],"term_type":"SY"},{"nm":"Mucin-secreting carcinoma","n_c":["C27825"],"i_c":"8481/3","i_c_s":["Mucin-secreting carcinoma"],"term_type":"SY"},{"nm":"Mucinous adenocarcinofibroma","n_c":["C40034"],"i_c":"9015/3","i_c_s":["Mucinous adenocarcinofibroma"],"term_type":"PT"},{"nm":"Mucinous adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucinous adenocarcinoma"],"term_type":"PT"},{"nm":"Mucinous adenocarcinoma, endocervical type","n_c":["C66953"],"i_c":"8482/3","i_c_s":["Mucinous adenocarcinoma, endocervical type"],"term_type":"PT"},{"nm":"Mucinous adenofibroma of borderline malignancy","n_c":["C66775"],"i_c":"9015/1","i_c_s":["Mucinous adenofibroma of borderline malignancy"],"term_type":"PT"},{"nm":"Mucinous adenofibroma, NOS","n_c":["C8978"],"i_c":"9015/0","i_c_s":["Mucinous adenofibroma, NOS"],"term_type":"PT"},{"nm":"Mucinous adenoma","n_c":["C2973"],"i_c":"8480/0","i_c_s":["Mucinous adenoma"],"term_type":"PT"},{"nm":"Mucinous carcinoid","n_c":"","i_c":"8243/3","i_c_s":["Mucinous carcinoid"],"term_type":"SY"},{"nm":"Mucinous carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucinous carcinoma"],"term_type":"SY"},{"nm":"Mucinous carcinoma, gastric type","n_c":["C127905"],"i_c":"8482/3","i_c_s":["Mucinous carcinoma, gastric type"],"term_type":""},{"nm":"Mucinous carcinoma, intestinal type","n_c":["C40203"],"i_c":"8144/3","i_c_s":["Mucinous carcinoma, intestinal type"],"term_type":""},{"nm":"Mucinous cystadenocarcinofibroma","n_c":"","i_c":"9015/3","i_c_s":["Mucinous cystadenocarcinofibroma"],"term_type":"RT"},{"nm":"Mucinous cystadenocarcinoma, non-invasive","n_c":["C41245"],"i_c":"8470/2","i_c_s":["Mucinous cystadenocarcinoma, non-invasive"],"term_type":"PT"},{"nm":"Mucinous cystadenocarcinoma, NOS","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Mucinous cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Mucinous cystadenofibroma of borderline malignancy","n_c":"","i_c":"9015/1","i_c_s":["Mucinous cystadenofibroma of borderline malignancy"],"term_type":"RT"},{"nm":"Mucinous cystadenofibroma, NOS","n_c":["C8979"],"i_c":"9015/0","i_c_s":["Mucinous cystadenofibroma, NOS"],"term_type":"RT"},{"nm":"Mucinous cystadenoma, borderline malignancy","n_c":"","i_c":"8472/1","i_c_s":["Mucinous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Mucinous cystadenoma, NOS","n_c":["C2973"],"i_c":"8470/0","i_c_s":["Mucinous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Mucinous cystic neoplasm with an associated invasive carcinoma","n_c":"","i_c":"8470/3","i_c_s":["Mucinous cystic neoplasm with an associated invasive carcinoma"],"term_type":"SY"},{"nm":"Mucinous cystic neoplasm with high-grade dysplasia","n_c":["C95493"],"i_c":"8470/2","i_c_s":["Mucinous cystic neoplasm with high-grade dysplasia"],"term_type":"SY"},{"nm":"Mucinous cystic neoplasm with high-grade intraepithelial neoplasia","n_c":"","i_c":"8470/2","i_c_s":["Mucinous cystic neoplasm with high-grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Mucinous cystic neoplasm with intermediate-grade dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with intermediate-grade dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Mucinous cystic neoplasm with low-grade dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with low-grade dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic neoplasm with low-grade intraepithelial neoplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic neoplasm with low-grade intraepithelial neoplasia"],"term_type":"RT"},{"nm":"Mucinous cystic tumor of borderline malignancy","n_c":["C201978"],"i_c":"8472/1","i_c_s":["Mucinous cystic tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Mucinous cystic tumor with an associated invasive carcinoma","n_c":"","i_c":"8470/3","i_c_s":["Mucinous cystic tumor with an associated invasive carcinoma"],"term_type":"RT"},{"nm":"Mucinous cystic tumor with high-grade dysplasia","n_c":"","i_c":"8470/2","i_c_s":["Mucinous cystic tumor with high-grade dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic tumor with intermediate dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic tumor with intermediate dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystic tumor with low grade dysplasia","n_c":"","i_c":"8470/0","i_c_s":["Mucinous cystic tumor with low grade dysplasia"],"term_type":""},{"nm":"Mucinous cystic tumor with moderate dysplasia","n_c":["C6883"],"i_c":"8470/0","i_c_s":["Mucinous cystic tumor with moderate dysplasia"],"term_type":"RT"},{"nm":"Mucinous cystoma","n_c":["C2973"],"i_c":"8470/0","i_c_s":["Mucinous cystoma"],"term_type":"SY"},{"nm":"Mucinous tubular and spindle cell carcinoma","n_c":["C39807"],"i_c":"8480/3","i_c_s":["Mucinous tubular and spindle cell carcinoma"],"term_type":""},{"nm":"Mucinous tumor, NOS, of low malignant potential","n_c":"","i_c":"8472/1","i_c_s":["Mucinous tumor, NOS, of low malignant potential"],"term_type":"SY"},{"nm":"Mucocarcinoid tumor","n_c":"","i_c":"8243/3","i_c_s":["Mucocarcinoid tumor"],"term_type":"SY"},{"nm":"Mucoepidermoid carcinoma","n_c":["C3772"],"i_c":"8430/3","i_c_s":["Mucoepidermoid carcinoma"],"term_type":"PT"},{"nm":"Mucoepidermoid tumor","n_c":["C3772"],"i_c":"8430/1","i_c_s":["Mucoepidermoid tumor"],"term_type":"OP"},{"nm":"Mucoid adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucoid adenocarcinoma"],"term_type":"SY"},{"nm":"Mucoid carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucoid carcinoma"],"term_type":"SY"},{"nm":"Mucoid cell adenocarcinoma","n_c":["C4150"],"i_c":"8300/3","i_c_s":["Mucoid cell adenocarcinoma"],"term_type":"SY"},{"nm":"Mucoid cell adenoma","n_c":["C2856"],"i_c":"8300/0","i_c_s":["Mucoid cell adenoma"],"term_type":"SY"},{"nm":"Mucosal lentiginous melanoma","n_c":["C48622"],"i_c":"8746/3","i_c_s":["Mucosal lentiginous melanoma"],"term_type":"PT"},{"nm":"Mucosal-associated lymphoid tissue lymphoma","n_c":["C3898"],"i_c":"9699/3","i_c_s":["Mucosal-associated lymphoid tissue lymphoma"],"term_type":"SY"},{"nm":"Mucous adenocarcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucous adenocarcinoma"],"term_type":"SY"},{"nm":"Mucous carcinoma","n_c":["C26712"],"i_c":"8480/3","i_c_s":["Mucous carcinoma"],"term_type":"SY"},{"nm":"Mullerian adenosarcoma","n_c":["C9474"],"i_c":"8933/3","i_c_s":["Mullerian adenosarcoma"],"term_type":""},{"nm":"Mullerian mixed tumor","n_c":["C3730"],"i_c":"8950/3","i_c_s":["Mullerian mixed tumor"],"term_type":"PT"},{"nm":"Multicentric basal cell carcinoma","n_c":["C4108"],"i_c":"8091/3","i_c_s":["Multicentric basal cell carcinoma"],"term_type":"SY"},{"nm":"Multicystic mesothelioma, benign","n_c":["C3765"],"i_c":"9055/0","i_c_s":["Multicystic mesothelioma, benign"],"term_type":"PT"},{"nm":"Multifocal superficial basal cell carcinoma","n_c":["C4108"],"i_c":"8091/3","i_c_s":["Multifocal superficial basal cell carcinoma"],"term_type":"PT"},{"nm":"Multiple adenomatous polyps","n_c":["C4135"],"i_c":"8221/0","i_c_s":["Multiple adenomatous polyps"],"term_type":"PT"},{"nm":"Multiple endocrine adenomas","n_c":["C6432"],"i_c":"8360/1","i_c_s":["Multiple endocrine adenomas"],"term_type":"PT"},{"nm":"Multiple hemorrhagic sarcoma","n_c":["C9087"],"i_c":"9140/3","i_c_s":["Multiple hemorrhagic sarcoma"],"term_type":"SY"},{"nm":"Multiple meningiomas","n_c":["C3707"],"i_c":"9530/1","i_c_s":["Multiple meningiomas"],"term_type":"SY"},{"nm":"Multiple myeloma","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Multiple myeloma"],"term_type":"PT"},{"nm":"Multiple neurofibromatosis","n_c":["C6727"],"i_c":"9540/1","i_c_s":["Multiple neurofibromatosis"],"term_type":"SY"},{"nm":"Mycosis fungoides","n_c":["C3246"],"i_c":"9700/3","i_c_s":["Mycosis fungoides"],"term_type":"PT"},{"nm":"Myelocytic leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Myelocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Myelodysplastic syndrome with 5q deletion (5q-) syndrome","n_c":["C6867"],"i_c":"9986/3","i_c_s":["Myelodysplastic syndrome with 5q deletion (5q-) syndrome"],"term_type":"PT"},{"nm":"Myelodysplastic syndrome with isolated del (5q)","n_c":["C6867"],"i_c":"9986/3","i_c_s":["Myelodysplastic syndrome with isolated del (5q)"],"term_type":"SY"},{"nm":"Myelodysplastic syndrome, NOS","n_c":["C198589"],"i_c":"9989/3","i_c_s":["Myelodysplastic syndrome, NOS"],"term_type":"PT"},{"nm":"Myelodysplastic syndrome, unclassifiable","n_c":["C8648"],"i_c":"9989/3","i_c_s":["Myelodysplastic syndrome, unclassifiable"],"term_type":"SY"},{"nm":"Myelodysplastic/myeloproliferative neoplasm, unclassifiable","n_c":["C27780"],"i_c":"9975/3","i_c_s":["Myelodysplastic/myeloproliferative neoplasm, unclassifiable"],"term_type":"SY"},{"nm":"Myelofibrosis as a result of myeloproliferative disease","n_c":["C27701"],"i_c":"9961/3","i_c_s":["Myelofibrosis as a result of myeloproliferative disease"],"term_type":"SY"},{"nm":"Myelofibrosis with myeloid metaplasia","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Myelofibrosis with myeloid metaplasia"],"term_type":"SY"},{"nm":"Myelogenous leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Myelogenous leukemia, NOS"],"term_type":"SY"},{"nm":"Myeloid and lymphoid neoplasms with FGFR1 abnormalities","n_c":["C84277"],"i_c":"9967/3","i_c_s":["Myeloid and lymphoid neoplasms with FGFR1 abnormalities"],"term_type":"PT"},{"nm":"Myeloid and lymphoid neoplasms with PDGFRA rearrangement","n_c":["C84275"],"i_c":"9965/3","i_c_s":["Myeloid and lymphoid neoplasms with PDGFRA rearrangement"],"term_type":"PT"},{"nm":"Myeloid leukemia associated with Down Syndrome","n_c":["C43223"],"i_c":"9898/3","i_c_s":["Myeloid leukemia associated with Down Syndrome"],"term_type":"PT"},{"nm":"Myeloid leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Myeloid leukemia, NOS"],"term_type":"PT"},{"nm":"Myeloid neoplasms with PDGFRB rearrangement","n_c":["C84276"],"i_c":"9966/3","i_c_s":["Myeloid neoplasms with PDGFRB rearrangement"],"term_type":"PT"},{"nm":"Myeloid sarcoma","n_c":["C3520"],"i_c":"9930/3","i_c_s":["Myeloid sarcoma"],"term_type":"PT"},{"nm":"Myelolipoma","n_c":["C3736"],"i_c":"8870/0","i_c_s":["Myelolipoma"],"term_type":"PT"},{"nm":"Myeloma, NOS","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Myeloma, NOS"],"term_type":"SY"},{"nm":"Myelomatosis","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Myelomatosis"],"term_type":"SY"},{"nm":"Myelomonocytic leukemia, NOS","n_c":"","i_c":"9860/3","i_c_s":["Myelomonocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Myeloproliferative disease, NOS","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Myeloproliferative disease, NOS"],"term_type":"SY"},{"nm":"Myeloproliferative neoplasm, NOS","n_c":["C27350"],"i_c":"9960/3","i_c_s":["Myeloproliferative neoplasm, NOS"],"term_type":"PT"},{"nm":"Myelosclerosis with myeloid metaplasia","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Myelosclerosis with myeloid metaplasia"],"term_type":"SY"},{"nm":"Myloproliferative neoplasm, unclassifiable","n_c":["C27350"],"i_c":"9975/3","i_c_s":["Myloproliferative neoplasm, unclassifiable"],"term_type":"PT"},{"nm":"Myoepithelial adenoma","n_c":["C7442"],"i_c":"8982/0","i_c_s":["Myoepithelial adenoma"],"term_type":"SY"},{"nm":"Myoepithelial carcinoma","n_c":["C7596"],"i_c":"8982/3","i_c_s":["Myoepithelial carcinoma"],"term_type":"SY"},{"nm":"Myoepithelial tumor","n_c":["C40392"],"i_c":"8982/0","i_c_s":["Myoepithelial tumor"],"term_type":"SY"},{"nm":"Myoepithelioma","n_c":["C40392"],"i_c":"8982/0","i_c_s":["Myoepithelioma"],"term_type":"PT"},{"nm":"Myofibroblastic sarcoma","n_c":["C49024"],"i_c":"8825/3","i_c_s":["Myofibroblastic sarcoma"],"term_type":"PT"},{"nm":"Myofibroblastic tumor, NOS","n_c":["C6481"],"i_c":"8825/1","i_c_s":["Myofibroblastic tumor, NOS"],"term_type":"PT"},{"nm":"Myofibroblastic tumor, peribronchial","n_c":["C39740"],"i_c":"8827/1","i_c_s":["Myofibroblastic tumor, peribronchial"],"term_type":"PT"},{"nm":"Myofibroblastoma","n_c":["C49012"],"i_c":"8825/0","i_c_s":["Myofibroblastoma"],"term_type":"PT"},{"nm":"Myofibroma","n_c":["C7052"],"i_c":"8824/0","i_c_s":["Myofibroma"],"term_type":"PT"},{"nm":"Myofibromatosis","n_c":["C3742"],"i_c":"8824/1","i_c_s":["Myofibromatosis"],"term_type":"PT"},{"nm":"Myoma","n_c":["C4882"],"i_c":"8895/0","i_c_s":["Myoma"],"term_type":"PT"},{"nm":"Myosarcoma","n_c":["C4883"],"i_c":"8895/3","i_c_s":["Myosarcoma"],"term_type":"PT"},{"nm":"Myxofibroma, NOS","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Myxofibroma, NOS"],"term_type":"SY"},{"nm":"Myxoid chondrosarcoma","n_c":["C27502"],"i_c":"9231/3","i_c_s":["Myxoid chondrosarcoma"],"term_type":"PT"},{"nm":"Myxoid fibroma","n_c":["C66760"],"i_c":"8811/0","i_c_s":["Myxoid fibroma"],"term_type":"SY"},{"nm":"Myxoid leiomyosarcoma","n_c":["C3701"],"i_c":"8896/3","i_c_s":["Myxoid leiomyosarcoma"],"term_type":"PT"},{"nm":"Myxoid liposarcoma","n_c":["C27781"],"i_c":"8852/3","i_c_s":["Myxoid liposarcoma"],"term_type":"PT"},{"nm":"Myxoinflammatory fibroblastic sarcoma (MIFS)","n_c":["C49025"],"i_c":"8811/1","i_c_s":["Myxoinflammatory fibroblastic sarcoma (MIFS)"],"term_type":""},{"nm":"Myxolipoma","n_c":["C4251"],"i_c":"8852/0","i_c_s":["Myxolipoma"],"term_type":"SY"},{"nm":"Myxoliposarcoma","n_c":["C27781"],"i_c":"8852/3","i_c_s":["Myxoliposarcoma"],"term_type":"SY"},{"nm":"Myxoma, NOS","n_c":["C6577"],"i_c":"8840/0","i_c_s":["Myxoma, NOS"],"term_type":"PT"},{"nm":"Myxopapillary ependymoma","n_c":["C3697"],"i_c":"9394/1","i_c_s":["Myxopapillary ependymoma"],"term_type":"PT"},{"nm":"Myxosarcoma","n_c":["C3255"],"i_c":"8840/3","i_c_s":["Myxosarcoma"],"term_type":"PT"},{"nm":"Neoplasm, benign","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Neoplasm, benign"],"term_type":"PT"},{"nm":"Neoplasm, malignant","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Neoplasm, malignant"],"term_type":"PT"},{"nm":"Neoplasm, malignant, uncertain whether primary or metastatic","n_c":["C65153"],"i_c":"8000/9","i_c_s":["Neoplasm, malignant, uncertain whether primary or metastatic"],"term_type":"PT"},{"nm":"Neoplasm, metastatic","n_c":["C3261"],"i_c":"8000/6","i_c_s":["Neoplasm, metastatic"],"term_type":"PT"},{"nm":"Neoplasm, NOS","n_c":["C3262"],"i_c":"8000/1","i_c_s":["Neoplasm, NOS"],"term_type":"SY"},{"nm":"Neoplasm, secondary","n_c":["C36255"],"i_c":"8000/6","i_c_s":["Neoplasm, secondary"],"term_type":"SY"},{"nm":"Neoplasm, uncertain whether benign or malignant","n_c":["C65157"],"i_c":"8000/1","i_c_s":["Neoplasm, uncertain whether benign or malignant"],"term_type":"PT"},{"nm":"Nephroblastoma, NOS","n_c":["C40407"],"i_c":"8960/3","i_c_s":["Nephroblastoma, NOS"],"term_type":"PT"},{"nm":"Nephrogenic adenofibroma","n_c":["C39812"],"i_c":"8965/0","i_c_s":["Nephrogenic adenofibroma"],"term_type":"PT"},{"nm":"Nephroma, NOS","n_c":["C40407"],"i_c":"8960/3","i_c_s":["Nephroma, NOS"],"term_type":"SY"},{"nm":"Nerve sheath myxoma","n_c":["C7018"],"i_c":"9562/0","i_c_s":["Nerve sheath myxoma"],"term_type":"SY"},{"nm":"Nesidioblastoma","n_c":["C65184"],"i_c":"8150/0","i_c_s":["Nesidioblastoma"],"term_type":"SY"},{"nm":"Nested urothelial carcinoma","n_c":["C191687"],"i_c":"8120/3","i_c_s":["Nested urothelial carcinoma"],"term_type":""},{"nm":"Neurilemoma, malignant","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Neurilemoma, malignant"],"term_type":"OP"},{"nm":"Neurilemoma, NOS","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Neurilemoma, NOS"],"term_type":"PT"},{"nm":"Neurilemosarcoma","n_c":["C3798"],"i_c":"9560/3","i_c_s":["Neurilemosarcoma"],"term_type":"IS"},{"nm":"Neurinoma","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Neurinoma"],"term_type":"SY"},{"nm":"Neurinomatosis","n_c":["C6557"],"i_c":"9560/1","i_c_s":["Neurinomatosis"],"term_type":"PT"},{"nm":"Neuroastrocytoma","n_c":["C3788"],"i_c":"9505/1","i_c_s":["Neuroastrocytoma"],"term_type":"IS"},{"nm":"Neuroblastoma, NOS","n_c":["C3270"],"i_c":"9500/3","i_c_s":["Neuroblastoma, NOS"],"term_type":"PT"},{"nm":"Neurocytoma","n_c":["C3791"],"i_c":"9506/1","i_c_s":["Neurocytoma"],"term_type":"SY"},{"nm":"Neuroectodermal tumor, NOS","n_c":["C3716"],"i_c":"9364/3","i_c_s":["Neuroectodermal tumor, NOS"],"term_type":"RT"},{"nm":"Neuroendocrine carcinoma, low grade","n_c":["C35727"],"i_c":"8240/3","i_c_s":["Neuroendocrine carcinoma, low grade"],"term_type":"RT"},{"nm":"Neuroendocrine carcinoma, moderately differentiated","n_c":["C35725"],"i_c":"8249/3","i_c_s":["Neuroendocrine carcinoma, moderately differentiated"],"term_type":"RT"},{"nm":"Neuroendocrine carcinoma, NOS","n_c":["C3773"],"i_c":"8246/3","i_c_s":["Neuroendocrine carcinoma, NOS"],"term_type":"PT"},{"nm":"Neuroendocrine carcinoma, poorly differentiated","n_c":["C155863"],"i_c":"8041/3","i_c_s":["Neuroendocrine carcinoma, poorly differentiated"],"term_type":""},{"nm":"Neuroendocrine carcinoma, well-differentiated","n_c":["C35727"],"i_c":"8240/3","i_c_s":["Neuroendocrine carcinoma, well-differentiated"],"term_type":"RT"},{"nm":"Neuroendocrine tumor, grade 1","n_c":"","i_c":"8240/3","i_c_s":["Neuroendocrine tumor, grade 1"],"term_type":""},{"nm":"Neuroendocrine tumor, grade 2","n_c":"","i_c":"8249/3","i_c_s":["Neuroendocrine tumor, grade 2"],"term_type":"SY"},{"nm":"Neuroendocrine tumor, well differentiated","n_c":["C155861"],"i_c":"8246/3","i_c_s":["Neuroendocrine tumor, well differentiated"],"term_type":""},{"nm":"Neuroepithelioma, NOS","n_c":["C3716"],"i_c":"9503/3","i_c_s":["Neuroepithelioma, NOS"],"term_type":"PT"},{"nm":"Neurofibroma, NOS","n_c":["C3272"],"i_c":"9540/0","i_c_s":["Neurofibroma, NOS"],"term_type":"PT"},{"nm":"Neurofibromatosis, NOS","n_c":["C6727"],"i_c":"9540/1","i_c_s":["Neurofibromatosis, NOS"],"term_type":"PT"},{"nm":"Neurofibrosarcoma","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Neurofibrosarcoma"],"term_type":"IS"},{"nm":"Neurogenic sarcoma","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Neurogenic sarcoma"],"term_type":"IS"},{"nm":"Neurolipocytoma","n_c":["C6905"],"i_c":"9506/1","i_c_s":["Neurolipocytoma"],"term_type":"SY"},{"nm":"Neuroma, NOS","n_c":["C3275"],"i_c":"9570/0","i_c_s":["Neuroma, NOS"],"term_type":"PT"},{"nm":"Neuronevus","n_c":["C4229"],"i_c":"8725/0","i_c_s":["Neuronevus"],"term_type":"PT"},{"nm":"Neurosarcoma","n_c":["C3798"],"i_c":"9540/3","i_c_s":["Neurosarcoma"],"term_type":"IS"},{"nm":"Neurothekeoma","n_c":["C7018"],"i_c":"9562/0","i_c_s":["Neurothekeoma"],"term_type":"PT"},{"nm":"Neurotropic melanoma, malignant","n_c":"","i_c":"8745/3","i_c_s":["Neurotropic melanoma, malignant"],"term_type":"RT"},{"nm":"Nevus, NOS","n_c":["C7570"],"i_c":"8720/0","i_c_s":["Nevus, NOS"],"term_type":"SY"},{"nm":"NK-cell large granular lymphocytic leukemia","n_c":"","i_c":"9831/3","i_c_s":["NK-cell large granular lymphocytic leukemia"],"term_type":"SY"},{"nm":"NK/T-cell lymphoma, nasal and nasal-type","n_c":["C4684"],"i_c":"9719/3","i_c_s":["NK/T-cell lymphoma, nasal and nasal-type"],"term_type":"PT"},{"nm":"Nodal marginal zone lymphoma","n_c":["C8863"],"i_c":"9699/3","i_c_s":["Nodal marginal zone lymphoma"],"term_type":"SY"},{"nm":"Nodular hidradenoma","n_c":["C7568"],"i_c":"8402/0","i_c_s":["Nodular hidradenoma"],"term_type":"PT"},{"nm":"Nodular hidradenoma, malignant","n_c":"","i_c":"8402/3","i_c_s":["Nodular hidradenoma, malignant"],"term_type":"PT"},{"nm":"Nodular melanoma","n_c":["C205125"],"i_c":"8721/3","i_c_s":["Nodular melanoma"],"term_type":"PT"},{"nm":"Non-Hodgkin lymphoma, NOS","n_c":["C3211"],"i_c":"9591/3","i_c_s":["Non-Hodgkin lymphoma, NOS"],"term_type":"SY"},{"nm":"Non-invasive EFVPTC","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive EFVPTC"],"term_type":""},{"nm":"Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)"],"term_type":""},{"nm":"Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)"],"term_type":""},{"nm":"Non-invasive FTP","n_c":["C126598"],"i_c":"8343/2","i_c_s":["Non-invasive FTP"],"term_type":""},{"nm":"Non-invasive low grade serous carcinoma","n_c":"","i_c":"8460/2","i_c_s":["Non-invasive low grade serous carcinoma"],"term_type":""},{"nm":"Non-invasive mammary carcinoma","n_c":"","i_c":"8500/2","i_c_s":["Non-invasive mammary carcinoma"],"term_type":""},{"nm":"Non-lymphocytic leukemia, NOS","n_c":["C3172"],"i_c":"9860/3","i_c_s":["Non-lymphocytic leukemia, NOS"],"term_type":"SY"},{"nm":"Non-small cell carcinoma","n_c":["C65151"],"i_c":"8046/3","i_c_s":["Non-small cell carcinoma"],"term_type":"PT"},{"nm":"Nonchromaffin paraganglioma, malignant","n_c":["C4219"],"i_c":"8693/3","i_c_s":["Nonchromaffin paraganglioma, malignant"],"term_type":"RT"},{"nm":"Nonchromaffin paraganglioma, NOS","n_c":"","i_c":"8693/1","i_c_s":["Nonchromaffin paraganglioma, NOS"],"term_type":"RT"},{"nm":"Nonencapsulated sclerosing adenocarcinoma","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing adenocarcinoma"],"term_type":"SY"},{"nm":"Nonencapsulated sclerosing carcinoma","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing carcinoma"],"term_type":"PT"},{"nm":"Nonencapsulated sclerosing tumor","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Nonencapsulated sclerosing tumor"],"term_type":"SY"},{"nm":"Noninfiltrating intracystic carcinoma","n_c":["C7645"],"i_c":"8504/2","i_c_s":["Noninfiltrating intracystic carcinoma"],"term_type":"PT"},{"nm":"Noninfiltrating intraductal papillary adenocarcinoma","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Noninfiltrating intraductal papillary adenocarcinoma"],"term_type":"PT"},{"nm":"Noninfiltrating intraductal papillary carcinoma","n_c":["C4190"],"i_c":"8503/2","i_c_s":["Noninfiltrating intraductal papillary carcinoma"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia","n_c":["C95914"],"i_c":"8163/0","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia"],"term_type":"SY"},{"nm":"Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia","n_c":["C95914"],"i_c":"8163/0","i_c_s":["Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia"],"term_type":"SY"},{"nm":"Nonlipid reticuloendotheliosis","n_c":"","i_c":"9751/3","i_c_s":["Nonlipid reticuloendotheliosis"],"term_type":"ORT"},{"nm":"Nonpigmented nevus","n_c":["C27095"],"i_c":"8730/0","i_c_s":["Nonpigmented nevus"],"term_type":"PT"},{"nm":"NUT carcinoma","n_c":["C45716"],"i_c":"8023/3","i_c_s":["NUT carcinoma"],"term_type":"PT"},{"nm":"NUT midline carcinoma","n_c":["C45716"],"i_c":"8023/3","i_c_s":["NUT midline carcinoma"],"term_type":""},{"nm":"Oat cell carcinoma","n_c":["C3915"],"i_c":"8042/3","i_c_s":["Oat cell carcinoma"],"term_type":"PT"},{"nm":"Odontoameloblastoma","n_c":["C54317"],"i_c":"9311/0","i_c_s":["Odontoameloblastoma"],"term_type":"PT"},{"nm":"Odontogenic carcinoma","n_c":["C173720"],"i_c":"9270/3","i_c_s":["Odontogenic carcinoma"],"term_type":"SY"},{"nm":"Odontogenic carcinosarcoma","n_c":["C173735"],"i_c":"9342/3","i_c_s":["Odontogenic carcinosarcoma"],"term_type":"PT"},{"nm":"Odontogenic fibroma, NOS","n_c":["C4314"],"i_c":"9321/0","i_c_s":["Odontogenic fibroma, NOS"],"term_type":"SY"},{"nm":"Odontogenic fibrosarcoma","n_c":["C173740"],"i_c":"9330/3","i_c_s":["Odontogenic fibrosarcoma"],"term_type":"SY"},{"nm":"Odontogenic ghost cell tumor","n_c":["C54323"],"i_c":"9302/0","i_c_s":["Odontogenic ghost cell tumor"],"term_type":"PT"},{"nm":"Odontogenic myxofibroma","n_c":["C7452"],"i_c":"9320/0","i_c_s":["Odontogenic myxofibroma"],"term_type":"SY"},{"nm":"Odontogenic myxoma","n_c":["C7501"],"i_c":"9320/0","i_c_s":["Odontogenic myxoma"],"term_type":"PT"},{"nm":"Odontogenic sarcoma","n_c":["C173738"],"i_c":"9270/3","i_c_s":["Odontogenic sarcoma"],"term_type":"SY"},{"nm":"Odontogenic tumor, benign","n_c":["C4306"],"i_c":"9270/0","i_c_s":["Odontogenic tumor, benign"],"term_type":"PT"},{"nm":"Odontogenic tumor, malignant","n_c":["C4812"],"i_c":"9270/3","i_c_s":["Odontogenic tumor, malignant"],"term_type":"PT"},{"nm":"Odontogenic tumor, NOS","n_c":["C3286"],"i_c":"9270/1","i_c_s":["Odontogenic tumor, NOS"],"term_type":"PT"},{"nm":"Odontoma, NOS","n_c":["C3287"],"i_c":"9280/0","i_c_s":["Odontoma, NOS"],"term_type":"PT"},{"nm":"Olfactory neuroblastoma","n_c":["C3789"],"i_c":"9522/3","i_c_s":["Olfactory neuroblastoma"],"term_type":"PT"},{"nm":"Olfactory neurocytoma","n_c":["C67156"],"i_c":"9521/3","i_c_s":["Olfactory neurocytoma"],"term_type":"PT"},{"nm":"Olfactory neuroepithelioma","n_c":["C3789"],"i_c":"9523/3","i_c_s":["Olfactory neuroepithelioma"],"term_type":"PT"},{"nm":"Olfactory neurogenic tumor","n_c":["C67155"],"i_c":"9520/3","i_c_s":["Olfactory neurogenic tumor"],"term_type":"PT"},{"nm":"Oligoastrocytoma","n_c":["C4050"],"i_c":"9382/3","i_c_s":["Oligoastrocytoma"],"term_type":"SY"},{"nm":"Oligodendroblastoma","n_c":["C66802"],"i_c":"9460/3","i_c_s":["Oligodendroblastoma"],"term_type":"OP"},{"nm":"Oligodendroglioma, anaplastic","n_c":["C4326"],"i_c":"9451/3","i_c_s":["Oligodendroglioma, anaplastic"],"term_type":"PT"},{"nm":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","n_c":["C129318"],"i_c":"9450/3","i_c_s":["Oligodendroglioma, IDH-mutant and 1p/19q-codeleted"],"term_type":""},{"nm":"Oligodendroglioma, NOS","n_c":["C129319"],"i_c":"9450/3","i_c_s":["Oligodendroglioma, NOS"],"term_type":"PT"},{"nm":"Oncocytic adenocarcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oncocytic adenocarcinoma"],"term_type":"SY"},{"nm":"Oncocytic adenoma","n_c":["C3759"],"i_c":"8290/0","i_c_s":["Oncocytic adenoma"],"term_type":"SY"},{"nm":"Oncocytic carcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oncocytic carcinoma"],"term_type":"SY"},{"nm":"Oncocytic Schneiderian papilloma","n_c":["C54345"],"i_c":"8121/1","i_c_s":["Oncocytic Schneiderian papilloma"],"term_type":"RT"},{"nm":"Oncocytoma","n_c":["C7072"],"i_c":"8290/0","i_c_s":["Oncocytoma"],"term_type":"SY"},{"nm":"Orchioblastoma","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Orchioblastoma"],"term_type":"SY"},{"nm":"Ossifying fibroma","n_c":["C173820"],"i_c":"9262/0","i_c_s":["Ossifying fibroma"],"term_type":"PT"},{"nm":"Ossifying fibromyxoid tumor","n_c":["C6582"],"i_c":"8842/0","i_c_s":["Ossifying fibromyxoid tumor"],"term_type":"PT"},{"nm":"Ossifying fibromyxoid tumor, malignant","n_c":["C121774"],"i_c":"8842/3","i_c_s":["Ossifying fibromyxoid tumor, malignant"],"term_type":""},{"nm":"Ossifying renal tumor","n_c":["C66774"],"i_c":"8967/0","i_c_s":["Ossifying renal tumor"],"term_type":"PT"},{"nm":"Osteoblastic sarcoma","n_c":["C53953"],"i_c":"9180/3","i_c_s":["Osteoblastic sarcoma"],"term_type":"SY"},{"nm":"Osteoblastoma, malignant","n_c":["C8380"],"i_c":"9250/3","i_c_s":["Osteoblastoma, malignant"],"term_type":""},{"nm":"Osteoblastoma, NOS","n_c":["C3294"],"i_c":"9200/0","i_c_s":["Osteoblastoma, NOS"],"term_type":"PT"},{"nm":"Osteocartilaginous exostosis","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Osteocartilaginous exostosis"],"term_type":"SY"},{"nm":"Osteochondroma","n_c":["C3295"],"i_c":"9210/0","i_c_s":["Osteochondroma"],"term_type":"PT"},{"nm":"Osteochondromatosis, NOS","n_c":["C53457"],"i_c":"9210/1","i_c_s":["Osteochondromatosis, NOS"],"term_type":"PT"},{"nm":"Osteochondrosarcoma","n_c":["C4021"],"i_c":"9180/3","i_c_s":["Osteochondrosarcoma"],"term_type":"SY"},{"nm":"Osteofibroma","n_c":"","i_c":"9262/0","i_c_s":["Osteofibroma"],"term_type":"SY"},{"nm":"Osteofibrosarcoma","n_c":["C4020"],"i_c":"9182/3","i_c_s":["Osteofibrosarcoma"],"term_type":"SY"},{"nm":"Osteogenic sarcoma, NOS","n_c":["C9145"],"i_c":"9180/3","i_c_s":["Osteogenic sarcoma, NOS"],"term_type":"SY"},{"nm":"Osteoid osteoma, NOS","n_c":["C3297"],"i_c":"9191/0","i_c_s":["Osteoid osteoma, NOS"],"term_type":"PT"},{"nm":"Osteoma, NOS","n_c":["C3296"],"i_c":"9180/0","i_c_s":["Osteoma, NOS"],"term_type":"PT"},{"nm":"Osteosarcoma in Paget disease of bone","n_c":["C6469"],"i_c":"9184/3","i_c_s":["Osteosarcoma in Paget disease of bone"],"term_type":"PT"},{"nm":"Osteosarcoma, NOS","n_c":["C9145"],"i_c":"9180/3","i_c_s":["Osteosarcoma, NOS"],"term_type":"PT"},{"nm":"Ovarian stromal tumor","n_c":["C4862"],"i_c":"8590/1","i_c_s":["Ovarian stromal tumor"],"term_type":"SY"},{"nm":"Oxyphilic adenocarcinoma","n_c":["C3679"],"i_c":"8290/3","i_c_s":["Oxyphilic adenocarcinoma"],"term_type":"PT"},{"nm":"Oxyphilic adenoma","n_c":["C3759"],"i_c":"8290/0","i_c_s":["Oxyphilic adenoma"],"term_type":"PT"},{"nm":"Pacinian tumor","n_c":["C4328"],"i_c":"9507/0","i_c_s":["Pacinian tumor"],"term_type":"PT"},{"nm":"Paget disease and infiltrating duct carcinoma of breast","n_c":["C7951"],"i_c":"8541/3","i_c_s":["Paget disease and infiltrating duct carcinoma of breast"],"term_type":"PT"},{"nm":"Paget disease and intraductal carcinoma of breast","n_c":["C4019"],"i_c":"8543/3","i_c_s":["Paget disease and intraductal carcinoma of breast"],"term_type":"PT"},{"nm":"Paget disease of breast","n_c":["C47857"],"i_c":"8540/3","i_c_s":["Paget disease of breast"],"term_type":"SY"},{"nm":"Paget disease, extramammary","n_c":["C3302"],"i_c":"8542/3","i_c_s":["Paget disease, extramammary"],"term_type":"PT"},{"nm":"Paget disease, mammary","n_c":["C47857"],"i_c":"8540/3","i_c_s":["Paget disease, mammary"],"term_type":"PT"},{"nm":"Pagetoid reticulosis","n_c":["C35794"],"i_c":"9700/3","i_c_s":["Pagetoid reticulosis"],"term_type":"SY"},{"nm":"Pancreatic endocrine tumor, benign","n_c":["C27720"],"i_c":"8150/0","i_c_s":["Pancreatic endocrine tumor, benign"],"term_type":"PT"},{"nm":"Pancreatic endocrine tumor, malignant","n_c":["C3770"],"i_c":"8150/3","i_c_s":["Pancreatic endocrine tumor, malignant"],"term_type":"PT"},{"nm":"Pancreatic endocrine tumor, nonfunctioning","n_c":["C45837"],"i_c":"Pancreatic endocrine tumor, nonfunctioning","i_c_s":["Pancreatic endocrine tumor, nonfunctioning"],"term_type":"RT"},{"nm":"Pancreatic endocrine tumor, NOS","n_c":["C27031"],"i_c":"8150/1","i_c_s":["Pancreatic endocrine tumor, NOS"],"term_type":"PT"},{"nm":"Pancreatic microadenoma","n_c":["C45834"],"i_c":"Pancreatic microadenoma","i_c_s":["Pancreatic microadenoma"],"term_type":"RT"},{"nm":"Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor","n_c":"","i_c":"8152/1","i_c_s":["Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor"],"term_type":"RT"},{"nm":"Pancreatobiliary neoplasm, non-invasive","n_c":["C95913"],"i_c":"8163/0","i_c_s":["Pancreatobiliary neoplasm, non-invasive"],"term_type":"PT"},{"nm":"Pancreatobiliary-type carcinoma","n_c":["C95963"],"i_c":"8163/3","i_c_s":["Pancreatobiliary-type carcinoma"],"term_type":"PT"},{"nm":"Pancreatoblastoma","n_c":["C4265"],"i_c":"8971/3","i_c_s":["Pancreatoblastoma"],"term_type":"PT"},{"nm":"Papillary adenocarcinoma, follicular variant","n_c":"","i_c":"8340/3","i_c_s":["Papillary adenocarcinoma, follicular variant"],"term_type":"SY"},{"nm":"Papillary adenocarcinoma, NOS","n_c":["C2853"],"i_c":"8260/3","i_c_s":["Papillary adenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Papillary adenofibroma","n_c":["C8986"],"i_c":"9013/0","i_c_s":["Papillary adenofibroma"],"term_type":"RT"},{"nm":"Papillary adenoma, NOS","n_c":["C6880"],"i_c":"8260/0","i_c_s":["Papillary adenoma, NOS"],"term_type":"PT"},{"nm":"Papillary and follicular adenocarcinoma","n_c":["C7380"],"i_c":"8340/3","i_c_s":["Papillary and follicular adenocarcinoma"],"term_type":"SY"},{"nm":"Papillary and follicular carcinoma","n_c":["C7380"],"i_c":"8340/3","i_c_s":["Papillary and follicular carcinoma"],"term_type":"SY"},{"nm":"Papillary carcinoma in situ","n_c":["C65163"],"i_c":"8050/2","i_c_s":["Papillary carcinoma in situ"],"term_type":"PT"},{"nm":"Papillary carcinoma of thyroid","n_c":["C4035"],"i_c":"8260/3","i_c_s":["Papillary carcinoma of thyroid"],"term_type":"RT"},{"nm":"Papillary carcinoma, columnar cell","n_c":["C35830"],"i_c":"8344/3","i_c_s":["Papillary carcinoma, columnar cell"],"term_type":"PT"},{"nm":"Papillary carcinoma, diffuse sclerosing","n_c":["C7427"],"i_c":"8350/3","i_c_s":["Papillary carcinoma, diffuse sclerosing"],"term_type":"RT"},{"nm":"Papillary carcinoma, encapsulated","n_c":"","i_c":"8343/3","i_c_s":["Papillary carcinoma, encapsulated"],"term_type":"PT"},{"nm":"Papillary carcinoma, follicular variant","n_c":["C126594"],"i_c":"8340/3","i_c_s":["Papillary carcinoma, follicular variant"],"term_type":"PT"},{"nm":"Papillary carcinoma, NOS","n_c":["C2927"],"i_c":"8050/3","i_c_s":["Papillary carcinoma, NOS"],"term_type":"PT"},{"nm":"Papillary carcinoma, oxyphilic cell","n_c":["C46093"],"i_c":"8342/3","i_c_s":["Papillary carcinoma, oxyphilic cell"],"term_type":"PT"},{"nm":"Papillary carcinoma, tall cell","n_c":["C35558"],"i_c":"8344/3","i_c_s":["Papillary carcinoma, tall cell"],"term_type":"SY"},{"nm":"Papillary cystadenocarcinoma, NOS","n_c":["C3777"],"i_c":"8450/3","i_c_s":["Papillary cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Papillary cystadenoma lymphomatosum","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Papillary cystadenoma lymphomatosum"],"term_type":"SY"},{"nm":"Papillary cystadenoma, borderline malignancy","n_c":["C4178"],"i_c":"8451/1","i_c_s":["Papillary cystadenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Papillary cystadenoma, NOS","n_c":["C2974"],"i_c":"8450/0","i_c_s":["Papillary cystadenoma, NOS"],"term_type":"PT"},{"nm":"Papillary cystic tumor","n_c":["C4179"],"i_c":"8452/1","i_c_s":["Papillary cystic tumor"],"term_type":"SY"},{"nm":"Papillary ependymoma","n_c":["C4319"],"i_c":"9393/3","i_c_s":["Papillary ependymoma"],"term_type":"PT"},{"nm":"Papillary epidermoid carcinoma","n_c":["C4102"],"i_c":"8052/3","i_c_s":["Papillary epidermoid carcinoma"],"term_type":"SY"},{"nm":"Papillary glioneuronal tumor","n_c":["C92554"],"i_c":"9509/1","i_c_s":["Papillary glioneuronal tumor"],"term_type":"PT"},{"nm":"Papillary hidradenoma","n_c":["C4171"],"i_c":"8405/0","i_c_s":["Papillary hidradenoma"],"term_type":"PT"},{"nm":"Papillary meningioma","n_c":["C3904"],"i_c":"9538/3","i_c_s":["Papillary meningioma"],"term_type":"PT"},{"nm":"Papillary microcarcinoma","n_c":["C46004"],"i_c":"8341/3","i_c_s":["Papillary microcarcinoma"],"term_type":"PT"},{"nm":"Papillary mucinous cystadenocarcinoma","n_c":["C65204"],"i_c":"8471/3","i_c_s":["Papillary mucinous cystadenocarcinoma"],"term_type":"PT"},{"nm":"Papillary mucinous cystadenoma, borderline malignancy","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary mucinous cystadenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Papillary mucinous cystadenoma, NOS","n_c":["C4184"],"i_c":"8471/0","i_c_s":["Papillary mucinous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Papillary mucinous tumor of low malignant potential","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary mucinous tumor of low malignant potential"],"term_type":"SY"},{"nm":"Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia","n_c":["C95915"],"i_c":"8163/2","i_c_s":["Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia"],"term_type":"PT"},{"nm":"Papillary pseudomucinous cystadenocarcinoma","n_c":["C65204"],"i_c":"8471/3","i_c_s":["Papillary pseudomucinous cystadenocarcinoma"],"term_type":"SY"},{"nm":"Papillary pseudomucinous cystadenoma, borderline malignancy","n_c":["C4186"],"i_c":"8473/1","i_c_s":["Papillary pseudomucinous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Papillary pseudomucinous cystadenoma, NOS","n_c":["C4184"],"i_c":"8471/0","i_c_s":["Papillary pseudomucinous cystadenoma, NOS"],"term_type":"SY"},{"nm":"Papillary renal cell carcinoma","n_c":["C6975"],"i_c":"8260/3","i_c_s":["Papillary renal cell carcinoma"],"term_type":"RT"},{"nm":"Papillary serous adenocarcinoma","n_c":["C8377"],"i_c":"8460/3","i_c_s":["Papillary serous adenocarcinoma"],"term_type":"SY"},{"nm":"Papillary serous cystadenocarcinoma","n_c":["C8377"],"i_c":"8460/3","i_c_s":["Papillary serous cystadenocarcinoma"],"term_type":"PT"},{"nm":"Papillary serous cystadenoma, borderline malignancy","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Papillary serous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Papillary serous cystadenoma, NOS","n_c":["C4180"],"i_c":"8460/0","i_c_s":["Papillary serous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Papillary serous tumor of low malignant potential","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Papillary serous tumor of low malignant potential"],"term_type":"SY"},{"nm":"Papillary squamous cell carcinoma","n_c":["C4102"],"i_c":"8052/3","i_c_s":["Papillary squamous cell carcinoma"],"term_type":"PT"},{"nm":"Papillary squamous cell carcinoma in situ","n_c":["C65164"],"i_c":"8052/2","i_c_s":["Papillary squamous cell carcinoma in situ"],"term_type":"SY"},{"nm":"Papillary squamous cell carcinoma, non-invasive","n_c":["C65164"],"i_c":"8052/2","i_c_s":["Papillary squamous cell carcinoma, non-invasive"],"term_type":"PT"},{"nm":"Papillary syringadenoma","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Papillary syringadenoma"],"term_type":"PT"},{"nm":"Papillary syringocystadenoma","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Papillary syringocystadenoma"],"term_type":"SY"},{"nm":"Papillary transitional cell carcinoma","n_c":["C4122"],"i_c":"8130/3","i_c_s":["Papillary transitional cell carcinoma"],"term_type":"PT"},{"nm":"Papillary transitional cell carcinoma, non-invasive","n_c":["C65181"],"i_c":"8130/2","i_c_s":["Papillary transitional cell carcinoma, non-invasive"],"term_type":"PT"},{"nm":"Papillary transitional cell neoplasm of low malignant potential","n_c":["C191672"],"i_c":"8130/1","i_c_s":["Papillary transitional cell neoplasm of low malignant potential"],"term_type":"PT"},{"nm":"Papillary tumor of the pineal region","n_c":["C92624"],"i_c":"9395/3","i_c_s":["Papillary tumor of the pineal region"],"term_type":"PT"},{"nm":"Papillary urothelial carcinoma","n_c":["C4122"],"i_c":"8130/3","i_c_s":["Papillary urothelial carcinoma"],"term_type":"SY"},{"nm":"Papillary urothelial carcinoma, non-invasive","n_c":["C65181"],"i_c":"8130/2","i_c_s":["Papillary urothelial carcinoma, non-invasive"],"term_type":"SY"},{"nm":"Papillary urothelial neoplasm of low malignant potential","n_c":["C191672"],"i_c":"8130/1","i_c_s":["Papillary urothelial neoplasm of low malignant potential"],"term_type":"SY"},{"nm":"Papillocystic adenocarcinoma","n_c":["C3777"],"i_c":"8450/3","i_c_s":["Papillocystic adenocarcinoma"],"term_type":"SY"},{"nm":"Papilloma of bladder","n_c":["C3842"],"i_c":"8120/1","i_c_s":["Papilloma of bladder"],"term_type":"SY"},{"nm":"Papilloma, NOS","n_c":["C7440"],"i_c":"8050/0","i_c_s":["Papilloma, NOS"],"term_type":"PT"},{"nm":"Papillomatosis, glandular","n_c":["C65198"],"i_c":"8264/0","i_c_s":["Papillomatosis, glandular"],"term_type":"PT"},{"nm":"Papillomatosis, NOS","n_c":["C3713"],"i_c":"8060/0","i_c_s":["Papillomatosis, NOS"],"term_type":"SY"},{"nm":"Papillotubular adenocarcinoma","n_c":"","i_c":"8263/3","i_c_s":["Papillotubular adenocarcinoma"],"term_type":"RT"},{"nm":"Papillotubular adenoma","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Papillotubular adenoma"],"term_type":"RT"},{"nm":"Parachordoma","n_c":["C6581"],"i_c":"9373/0","i_c_s":["Parachordoma"],"term_type":"PT"},{"nm":"Parafollicular cell carcinoma","n_c":["C3879"],"i_c":"8345/3","i_c_s":["Parafollicular cell carcinoma"],"term_type":"SY"},{"nm":"Paraganglioma, benign","n_c":["C48314"],"i_c":"8680/0","i_c_s":["Paraganglioma, benign"],"term_type":"PT"},{"nm":"Paraganglioma, malignant","n_c":["C8559"],"i_c":"8680/3","i_c_s":["Paraganglioma, malignant"],"term_type":"PT"},{"nm":"Paraganglioma, NOS","n_c":["C3308"],"i_c":"8680/1","i_c_s":["Paraganglioma, NOS"],"term_type":"PT"},{"nm":"Parasympathetic paraganglioma","n_c":["C4217"],"i_c":"8682/1","i_c_s":["Parasympathetic paraganglioma"],"term_type":"PT"},{"nm":"Parietal cell adenocarcinoma","n_c":["C65194"],"i_c":"8214/3","i_c_s":["Parietal cell adenocarcinoma"],"term_type":"SY"},{"nm":"Parietal cell carcinoma","n_c":["C65194"],"i_c":"8214/3","i_c_s":["Parietal cell carcinoma"],"term_type":"PT"},{"nm":"Parosteal osteosarcoma","n_c":["C8969"],"i_c":"9192/3","i_c_s":["Parosteal osteosarcoma"],"term_type":"PT"},{"nm":"Partial hydatidiform mole","n_c":["C4293"],"i_c":"9103/0","i_c_s":["Partial hydatidiform mole"],"term_type":"PT"},{"nm":"PEComa, malignant","n_c":["C121792"],"i_c":"8714/3","i_c_s":["PEComa, malignant"],"term_type":"PT"},{"nm":"Periapical cemental dysplasia","n_c":["C173928"],"i_c":"9272/0","i_c_s":["Periapical cemental dysplasia"],"term_type":"SY"},{"nm":"Periapical cemento-osseous dysplasia","n_c":["C173928"],"i_c":"9272/0","i_c_s":["Periapical cemento-osseous dysplasia"],"term_type":"SY"},{"nm":"Pericanalicular fibroadenoma","n_c":["C4272"],"i_c":"9012/0","i_c_s":["Pericanalicular fibroadenoma"],"term_type":"PT"},{"nm":"Periductal stromal tumor, low grade","n_c":"","i_c":"9020/3","i_c_s":["Periductal stromal tumor, low grade"],"term_type":""},{"nm":"Perifollicular fibroma","n_c":["C4470"],"i_c":"8391/0","i_c_s":["Perifollicular fibroma"],"term_type":"SY"},{"nm":"Perineural MPNST","n_c":["C66845"],"i_c":"9571/3","i_c_s":["Perineural MPNST"],"term_type":"SY"},{"nm":"Perineurioma, malignant","n_c":["C66845"],"i_c":"9571/3","i_c_s":["Perineurioma, malignant"],"term_type":"PT"},{"nm":"Perineurioma, NOS","n_c":["C4973"],"i_c":"9571/0","i_c_s":["Perineurioma, NOS"],"term_type":"PT"},{"nm":"Periosteal chondroma","n_c":["C4302"],"i_c":"9221/0","i_c_s":["Periosteal chondroma"],"term_type":"RT"},{"nm":"Periosteal chondrosarcoma","n_c":["C7357"],"i_c":"9221/3","i_c_s":["Periosteal chondrosarcoma"],"term_type":"RT"},{"nm":"Periosteal fibroma","n_c":["C66761"],"i_c":"8812/0","i_c_s":["Periosteal fibroma"],"term_type":"PT"},{"nm":"Periosteal fibrosarcoma","n_c":["C66763"],"i_c":"8812/3","i_c_s":["Periosteal fibrosarcoma"],"term_type":"PT"},{"nm":"Periosteal osteosarcoma","n_c":["C8970"],"i_c":"9193/3","i_c_s":["Periosteal osteosarcoma"],"term_type":"PT"},{"nm":"Periosteal sarcoma, NOS","n_c":"","i_c":"8812/3","i_c_s":["Periosteal sarcoma, NOS"],"term_type":"RT"},{"nm":"Peripheral neuroectodermal tumor","n_c":["C9341"],"i_c":"9364/3","i_c_s":["Peripheral neuroectodermal tumor"],"term_type":"PT"},{"nm":"Peripheral odontogenic fibroma","n_c":["C4315"],"i_c":"9322/0","i_c_s":["Peripheral odontogenic fibroma"],"term_type":"PT"},{"nm":"Peripheral primitive neuroectodermal tumor, NOS","n_c":["C9341"],"i_c":"9364/3","i_c_s":["Peripheral primitive neuroectodermal tumor, NOS"],"term_type":"RT"},{"nm":"Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)","n_c":["C7528"],"i_c":"9705/3","i_c_s":["Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)"],"term_type":"IS"},{"nm":"Peripheral T-cell lymphoma, large cell","n_c":["C27352"],"i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, large cell"],"term_type":"SY"},{"nm":"Peripheral T-cell lymphoma, NOS","n_c":["C4340"],"i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, NOS"],"term_type":"SY"},{"nm":"Peripheral T-cell lymphoma, pleomorphic medium and large cell","n_c":"","i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, pleomorphic medium and large cell"],"term_type":"SY"},{"nm":"Peripheral T-cell lymphoma, pleomorphic small cell","n_c":"","i_c":"9702/3","i_c_s":["Peripheral T-cell lymphoma, pleomorphic small cell"],"term_type":"SY"},{"nm":"Perivascular epithelioid cell tumor, malignant","n_c":["C121792"],"i_c":"8714/3","i_c_s":["Perivascular epithelioid cell tumor, malignant"],"term_type":""},{"nm":"Pheochromoblastoma","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Pheochromoblastoma"],"term_type":"SY"},{"nm":"Pheochromocytoma, malignant","n_c":["C4220"],"i_c":"8700/3","i_c_s":["Pheochromocytoma, malignant"],"term_type":"PT"},{"nm":"Pheochromocytoma, NOS","n_c":["C3326"],"i_c":"8700/0","i_c_s":["Pheochromocytoma, NOS"],"term_type":"PT"},{"nm":"Phosphaturic mesenchymal tumor, malignant","n_c":["C121789"],"i_c":"8990/3","i_c_s":["Phosphaturic mesenchymal tumor, malignant"],"term_type":""},{"nm":"Phyllodes tumor, benign","n_c":["C4274"],"i_c":"9020/0","i_c_s":["Phyllodes tumor, benign"],"term_type":"PT"},{"nm":"Phyllodes tumor, borderline","n_c":["C7503"],"i_c":"9020/1","i_c_s":["Phyllodes tumor, borderline"],"term_type":"PT"},{"nm":"Phyllodes tumor, malignant","n_c":["C4275"],"i_c":"9020/3","i_c_s":["Phyllodes tumor, malignant"],"term_type":"PT"},{"nm":"Phyllodes tumor, NOS","n_c":["C2977"],"i_c":"9020/1","i_c_s":["Phyllodes tumor, NOS"],"term_type":"SY"},{"nm":"Pick tubular adenoma","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Pick tubular adenoma"],"term_type":"SY"},{"nm":"Pigmented adenoma","n_c":["C4164"],"i_c":"8372/0","i_c_s":["Pigmented adenoma"],"term_type":"SY"},{"nm":"Pigmented basal cell carcinoma","n_c":["C9359"],"i_c":"8090/3","i_c_s":["Pigmented basal cell carcinoma"],"term_type":"RT"},{"nm":"Pigmented dermatofibrosarcoma protuberans","n_c":["C9430"],"i_c":"8833/3","i_c_s":["Pigmented dermatofibrosarcoma protuberans"],"term_type":"PT"},{"nm":"Pigmented nevus, NOS","n_c":["C27816"],"i_c":"8720/0","i_c_s":["Pigmented nevus, NOS"],"term_type":"PT"},{"nm":"Pigmented schwannoma","n_c":["C6970"],"i_c":"9560/0","i_c_s":["Pigmented schwannoma"],"term_type":"RT"},{"nm":"Pigmented spindle cell nevus of Reed","n_c":["C4751"],"i_c":"8770/0","i_c_s":["Pigmented spindle cell nevus of Reed"],"term_type":"RT"},{"nm":"Pilar tumor","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Pilar tumor"],"term_type":"PT"},{"nm":"Pilocytic astrocytoma","n_c":["C4047"],"i_c":"9421/1","i_c_s":["Pilocytic astrocytoma"],"term_type":"PT"},{"nm":"Piloid astrocytoma","n_c":["C4047"],"i_c":"9421/1","i_c_s":["Piloid astrocytoma"],"term_type":"SY"},{"nm":"Pilomatricoma, malignant","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatricoma, malignant"],"term_type":"SY"},{"nm":"Pilomatricoma, NOS","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Pilomatricoma, NOS"],"term_type":"SY"},{"nm":"Pilomatrix carcinoma","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatrix carcinoma"],"term_type":"PT"},{"nm":"Pilomatrixoma, malignant","n_c":["C4114"],"i_c":"8110/3","i_c_s":["Pilomatrixoma, malignant"],"term_type":"SY"},{"nm":"Pilomatrixoma, NOS","n_c":["C7368"],"i_c":"8110/0","i_c_s":["Pilomatrixoma, NOS"],"term_type":"PT"},{"nm":"Pilomyxoid astrocytoma","n_c":["C40315"],"i_c":"9425/3","i_c_s":["Pilomyxoid astrocytoma"],"term_type":"PT"},{"nm":"PIN III","n_c":["C3642"],"i_c":"8148/2","i_c_s":["PIN III"],"term_type":"SY"},{"nm":"Pindborg tumor","n_c":["C54301"],"i_c":"9340/0","i_c_s":["Pindborg tumor"],"term_type":"SY"},{"nm":"Pineal parenchymal tumor of intermediate differentiation","n_c":["C6967"],"i_c":"9362/3","i_c_s":["Pineal parenchymal tumor of intermediate differentiation"],"term_type":"RT"},{"nm":"Pinealoma","n_c":["C3328"],"i_c":"9360/1","i_c_s":["Pinealoma"],"term_type":"PT"},{"nm":"Pineoblastoma","n_c":["C9344"],"i_c":"9362/3","i_c_s":["Pineoblastoma"],"term_type":"PT"},{"nm":"Pineocytoma","n_c":["C6966"],"i_c":"9361/1","i_c_s":["Pineocytoma"],"term_type":"PT"},{"nm":"Pinkus tumor","n_c":["C4109"],"i_c":"8093/3","i_c_s":["Pinkus tumor"],"term_type":"SY"},{"nm":"Pituicytoma","n_c":["C94524"],"i_c":"9432/1","i_c_s":["Pituicytoma"],"term_type":"PT"},{"nm":"Pituitary adenoma, NOS","n_c":["C3329"],"i_c":"8272/0","i_c_s":["Pituitary adenoma, NOS"],"term_type":"PT"},{"nm":"Pituitary carcinoma, NOS","n_c":["C4536"],"i_c":"8272/3","i_c_s":["Pituitary carcinoma, NOS"],"term_type":"PT"},{"nm":"Placental site trophoblastic tumor","n_c":["C3757"],"i_c":"9104/1","i_c_s":["Placental site trophoblastic tumor"],"term_type":"PT"},{"nm":"Plasma cell leukemia","n_c":["C3180"],"i_c":"9733/3","i_c_s":["Plasma cell leukemia"],"term_type":"PT"},{"nm":"Plasma cell myeloma","n_c":["C3242"],"i_c":"9732/3","i_c_s":["Plasma cell myeloma"],"term_type":"SY"},{"nm":"Plasma cell tumor","n_c":["C4665"],"i_c":"9731/3","i_c_s":["Plasma cell tumor"],"term_type":"SY"},{"nm":"Plasmablastic lymphoma","n_c":["C7224"],"i_c":"9735/3","i_c_s":["Plasmablastic lymphoma"],"term_type":"PT"},{"nm":"Plasmacytic leukemia","n_c":["C3180"],"i_c":"9733/3","i_c_s":["Plasmacytic leukemia"],"term_type":"SY"},{"nm":"Plasmacytic lymphoma","n_c":["C3212"],"i_c":"9671/3","i_c_s":["Plasmacytic lymphoma"],"term_type":"ORT"},{"nm":"Plasmacytoma of bone","n_c":["C7812"],"i_c":"9731/3","i_c_s":["Plasmacytoma of bone"],"term_type":"SY"},{"nm":"Plasmacytoma, extramedullary","n_c":["C4002"],"i_c":"9734/3","i_c_s":["Plasmacytoma, extramedullary"],"term_type":"PT"},{"nm":"Plasmacytoma, NOS","n_c":["C9349"],"i_c":"9731/3","i_c_s":["Plasmacytoma, NOS"],"term_type":"PT"},{"nm":"Pleomorphic adenoma","n_c":["C8602"],"i_c":"8940/0","i_c_s":["Pleomorphic adenoma"],"term_type":"PT"},{"nm":"Pleomorphic carcinoma","n_c":["C4094"],"i_c":"8022/3","i_c_s":["Pleomorphic carcinoma"],"term_type":"PT"},{"nm":"Pleomorphic cell sarcoma","n_c":["C66759"],"i_c":"8802/3","i_c_s":["Pleomorphic cell sarcoma"],"term_type":"SY"},{"nm":"Pleomorphic leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Pleomorphic leiomyoma"],"term_type":"SY"},{"nm":"Pleomorphic lipoma","n_c":["C3703"],"i_c":"8854/0","i_c_s":["Pleomorphic lipoma"],"term_type":"PT"},{"nm":"Pleomorphic liposarcoma","n_c":["C3705"],"i_c":"8854/3","i_c_s":["Pleomorphic liposarcoma"],"term_type":"PT"},{"nm":"Pleomorphic lobular carcinoma","n_c":["C97051"],"i_c":"8520/3","i_c_s":["Pleomorphic lobular carcinoma"],"term_type":""},{"nm":"Pleomorphic lobular carcinoma in situ","n_c":["C137839"],"i_c":"8519/2","i_c_s":["Pleomorphic lobular carcinoma in situ"],"term_type":"PT"},{"nm":"Pleomorphic rhabdomyosarcoma, adult type","n_c":["C27369"],"i_c":"8901/3","i_c_s":["Pleomorphic rhabdomyosarcoma, adult type"],"term_type":"PT"},{"nm":"Pleomorphic rhabdomyosarcoma, NOS","n_c":["C4258"],"i_c":"8901/3","i_c_s":["Pleomorphic rhabdomyosarcoma, NOS"],"term_type":"RT"},{"nm":"Pleomorphic xanthoastrocytoma","n_c":["C4323"],"i_c":"9424/3","i_c_s":["Pleomorphic xanthoastrocytoma"],"term_type":"PT"},{"nm":"Pleuropulmonary blastoma","n_c":["C5669"],"i_c":"8973/3","i_c_s":["Pleuropulmonary blastoma"],"term_type":"PT"},{"nm":"Plexiform fibrohistiocytic tumor","n_c":["C6493"],"i_c":"8835/1","i_c_s":["Plexiform fibrohistiocytic tumor"],"term_type":"PT"},{"nm":"Plexiform fibromyxoma","n_c":"","i_c":"8811/0","i_c_s":["Plexiform fibromyxoma"],"term_type":"RT"},{"nm":"Plexiform hemangioma","n_c":["C6645"],"i_c":"9131/0","i_c_s":["Plexiform hemangioma"],"term_type":"SY"},{"nm":"Plexiform leiomyoma","n_c":"","i_c":"8890/0","i_c_s":["Plexiform leiomyoma"],"term_type":"RT"},{"nm":"Plexiform neurofibroma","n_c":["C3797"],"i_c":"9550/0","i_c_s":["Plexiform neurofibroma"],"term_type":"PT"},{"nm":"Plexiform neuroma","n_c":["C3797"],"i_c":"9550/0","i_c_s":["Plexiform neuroma"],"term_type":"SY"},{"nm":"Plexiform schwannoma","n_c":["C6969"],"i_c":"9560/0","i_c_s":["Plexiform schwannoma"],"term_type":"RT"},{"nm":"PNET, NOS","n_c":["C3716"],"i_c":"9473/3","i_c_s":["PNET, NOS"],"term_type":"SY"},{"nm":"Pneumoblastoma","n_c":["C3732"],"i_c":"8972/3","i_c_s":["Pneumoblastoma"],"term_type":"SY"},{"nm":"Polar spongioblastoma","n_c":["C66801"],"i_c":"9423/3","i_c_s":["Polar spongioblastoma"],"term_type":"PT"},{"nm":"Polycythemia rubra vera","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Polycythemia rubra vera"],"term_type":"SY"},{"nm":"Polycythemia vera","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Polycythemia vera"],"term_type":"PT"},{"nm":"Polyembryoma","n_c":["C66776"],"i_c":"9072/3","i_c_s":["Polyembryoma"],"term_type":"PT"},{"nm":"Polygonal cell carcinoma","n_c":["C65161"],"i_c":"8034/3","i_c_s":["Polygonal cell carcinoma"],"term_type":"PT"},{"nm":"Polymorphic post transplant lymphoproliferative disorder","n_c":["C7183"],"i_c":"9971/3","i_c_s":["Polymorphic post transplant lymphoproliferative disorder"],"term_type":"PT"},{"nm":"Polymorphic reticulosis","n_c":"","i_c":"9719/3","i_c_s":["Polymorphic reticulosis"],"term_type":"IS"},{"nm":"Polymorphous low grade adenocarcinoma","n_c":["C35702"],"i_c":"8525/3","i_c_s":["Polymorphous low grade adenocarcinoma"],"term_type":"PT"},{"nm":"Polypoid adenoma","n_c":["C3764"],"i_c":"8210/0","i_c_s":["Polypoid adenoma"],"term_type":"SY"},{"nm":"Polyvesicular vitelline tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Polyvesicular vitelline tumor"],"term_type":"SY"},{"nm":"Poorly cohesive carcinoma","n_c":["C4127"],"i_c":"8490/3","i_c_s":["Poorly cohesive carcinoma"],"term_type":"RT"},{"nm":"Porocarcinoma","n_c":["C5560"],"i_c":"8409/3","i_c_s":["Porocarcinoma"],"term_type":"SY"},{"nm":"Post transplant lymphoproliferative disorder, NOS","n_c":["C4727"],"i_c":"9971/1","i_c_s":["Post transplant lymphoproliferative disorder, NOS"],"term_type":"PT"},{"nm":"PP/PYY producing tumor","n_c":"","i_c":"8152/1","i_c_s":["PP/PYY producing tumor"],"term_type":"SY"},{"nm":"PPNET","n_c":["C9341"],"i_c":"9364/3","i_c_s":["PPNET"],"term_type":"SY"},{"nm":"Pre-B ALL","n_c":["C27798"],"i_c":"9836/3","i_c_s":["Pre-B ALL"],"term_type":"SY"},{"nm":"Pre-pre-B ALL","n_c":["C27799"],"i_c":"9836/3","i_c_s":["Pre-pre-B ALL"],"term_type":"SY"},{"nm":"Pre-T ALL","n_c":["C27261"],"i_c":"9837/3","i_c_s":["Pre-T ALL"],"term_type":"SY"},{"nm":"Precancerous melanosis, NOS","n_c":["C4233"],"i_c":"8741/2","i_c_s":["Precancerous melanosis, NOS"],"term_type":"PT"},{"nm":"Precursor B-cell lymphoblastic leukemia","n_c":["C8644"],"i_c":"9836/3","i_c_s":["Precursor B-cell lymphoblastic leukemia"],"term_type":"PT"},{"nm":"Precursor B-cell lymphoblastic lymphoma","n_c":["C8868"],"i_c":"9728/3","i_c_s":["Precursor B-cell lymphoblastic lymphoma"],"term_type":"PT"},{"nm":"Precursor cell lymphoblastic leukemia, NOS","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Precursor cell lymphoblastic leukemia, NOS"],"term_type":"PT"},{"nm":"Precursor cell lymphoblastic leukemia, not phenotyped","n_c":["C3167"],"i_c":"9835/3","i_c_s":["Precursor cell lymphoblastic leukemia, not phenotyped"],"term_type":"SY"},{"nm":"Precursor cell lymphoblastic lymphoma, NOS","n_c":["C9360"],"i_c":"9727/3","i_c_s":["Precursor cell lymphoblastic lymphoma, NOS"],"term_type":"PT"},{"nm":"Precursor T-cell lymphoblastic leukemia","n_c":["C3183"],"i_c":"9837/3","i_c_s":["Precursor T-cell lymphoblastic leukemia"],"term_type":"PT"},{"nm":"Precursor T-cell lymphoblastic lymphoma","n_c":["C6919"],"i_c":"9729/3","i_c_s":["Precursor T-cell lymphoblastic lymphoma"],"term_type":"PT"},{"nm":"Preleukemia","n_c":["C3247"],"i_c":"9989/3","i_c_s":["Preleukemia"],"term_type":"IS"},{"nm":"Preleukemic syndrome","n_c":["C3247"],"i_c":"9989/3","i_c_s":["Preleukemic syndrome"],"term_type":"IS"},{"nm":"Primary amyloidosis","n_c":["C3819"],"i_c":"9769/1","i_c_s":["Primary amyloidosis"],"term_type":"SY"},{"nm":"Primary cutaneous anaplastic large cell lymphoma","n_c":["C6860"],"i_c":"9718/3","i_c_s":["Primary cutaneous anaplastic large cell lymphoma"],"term_type":"SY"},{"nm":"Primary cutaneous CD30+ large T-cell lymphoma","n_c":["C6860"],"i_c":"9718/3","i_c_s":["Primary cutaneous CD30+ large T-cell lymphoma"],"term_type":"SY"},{"nm":"Primary cutaneous CD30+ T-cell lymphoproliferative disorder","n_c":["C7195"],"i_c":"9718/3","i_c_s":["Primary cutaneous CD30+ T-cell lymphoproliferative disorder"],"term_type":"PT"},{"nm":"Primary cutaneous CD4-positive small/medium T-cell lymphoma","n_c":["C45366"],"i_c":"9709/3","i_c_s":["Primary cutaneous CD4-positive small/medium T-cell lymphoma"],"term_type":"RT"},{"nm":"Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma","n_c":["C45339"],"i_c":"9709/3","i_c_s":["Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma"],"term_type":"RT"},{"nm":"Primary cutaneous DLBCL, leg type","n_c":["C45194"],"i_c":"9680/3","i_c_s":["Primary cutaneous DLBCL, leg type"],"term_type":"RT"},{"nm":"Primary cutaneous follicle centre lymphoma","n_c":["C7217"],"i_c":"9597/3","i_c_s":["Primary cutaneous follicle centre lymphoma"],"term_type":"PT"},{"nm":"Primary cutaneous gamma-delta T-cell lymphoma","n_c":["C45340"],"i_c":"9726/3","i_c_s":["Primary cutaneous gamma-delta T-cell lymphoma"],"term_type":"PT"},{"nm":"Primary cutaneous neuroendocrine carcinoma","n_c":["C173385"],"i_c":"8247/3","i_c_s":["Primary cutaneous neuroendocrine carcinoma"],"term_type":"SY"},{"nm":"Primary diffuse large B-cell lymphoma of the CNS","n_c":["C71720"],"i_c":"9680/3","i_c_s":["Primary diffuse large B-cell lymphoma of the CNS"],"term_type":"RT"},{"nm":"Primary effusion lymphoma","n_c":["C6915"],"i_c":"9678/3","i_c_s":["Primary effusion lymphoma"],"term_type":"PT"},{"nm":"Primary intraosseous carcinoma","n_c":"","i_c":"9270/3","i_c_s":["Primary intraosseous carcinoma"],"term_type":"SY"},{"nm":"Primary myelofibrosis","n_c":["C2862"],"i_c":"9961/3","i_c_s":["Primary myelofibrosis"],"term_type":"PT"},{"nm":"Primary serous papillary carcinoma of peritoneum","n_c":["C7695"],"i_c":"8461/3","i_c_s":["Primary serous papillary carcinoma of peritoneum"],"term_type":"RT"},{"nm":"Primitive neuroectodermal tumor, NOS","n_c":["C3716"],"i_c":"9473/3","i_c_s":["Primitive neuroectodermal tumor, NOS"],"term_type":"PT"},{"nm":"Primitive polar spongioblastoma","n_c":"","i_c":"9423/3","i_c_s":["Primitive polar spongioblastoma"],"term_type":"IS"},{"nm":"Pro-B ALL","n_c":["C27798"],"i_c":"9836/3","i_c_s":["Pro-B ALL"],"term_type":"SY"},{"nm":"Pro-T ALL","n_c":["C27261"],"i_c":"9837/3","i_c_s":["Pro-T ALL"],"term_type":"SY"},{"nm":"Prolactinoma","n_c":["C3342"],"i_c":"8271/0","i_c_s":["Prolactinoma"],"term_type":"PT"},{"nm":"Proliferating trichilemmal cyst","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Proliferating trichilemmal cyst"],"term_type":"SY"},{"nm":"Proliferating trichilemmal tumor","n_c":["C27125"],"i_c":"8103/0","i_c_s":["Proliferating trichilemmal tumor"],"term_type":"SY"},{"nm":"Proliferative dermal lesion in congenital nevus","n_c":["C66755"],"i_c":"8762/1","i_c_s":["Proliferative dermal lesion in congenital nevus"],"term_type":"PT"},{"nm":"Proliferative polycythemia","n_c":["C3336"],"i_c":"9950/3","i_c_s":["Proliferative polycythemia"],"term_type":"SY"},{"nm":"Prolymphocytic leukemia, B-cell type","n_c":["C4753"],"i_c":"9833/3","i_c_s":["Prolymphocytic leukemia, B-cell type"],"term_type":"PT"},{"nm":"Prolymphocytic leukemia, NOS","n_c":["C3181"],"i_c":"9832/3","i_c_s":["Prolymphocytic leukemia, NOS"],"term_type":"PT"},{"nm":"Prolymphocytic leukemia, T-cell type","n_c":["C4752"],"i_c":"9834/3","i_c_s":["Prolymphocytic leukemia, T-cell type"],"term_type":"PT"},{"nm":"Prostatic intraepithelial neoplasia, grade III","n_c":["C3642"],"i_c":"8148/2","i_c_s":["Prostatic intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Protoplasmic astrocytoma","n_c":["C4320"],"i_c":"9410/3","i_c_s":["Protoplasmic astrocytoma"],"term_type":"PT"},{"nm":"Psammomatous meningioma","n_c":["C4331"],"i_c":"9533/0","i_c_s":["Psammomatous meningioma"],"term_type":"PT"},{"nm":"Psammomatous schwannoma","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Psammomatous schwannoma"],"term_type":"RT"},{"nm":"Pseudomucinous adenocarcinoma","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Pseudomucinous adenocarcinoma"],"term_type":"SY"},{"nm":"Pseudomucinous cystadenocarcinoma, NOS","n_c":["C3776"],"i_c":"8470/3","i_c_s":["Pseudomucinous cystadenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Pseudomucinous cystadenoma, borderline malignancy","n_c":"","i_c":"8472/1","i_c_s":["Pseudomucinous cystadenoma, borderline malignancy"],"term_type":"SY"},{"nm":"Pseudomucinous cystadenoma, NOS","n_c":["C2973"],"i_c":"8470/0","i_c_s":["Pseudomucinous cystadenoma, NOS"],"term_type":"SY"},{"nm":"Pseudomyxoma peritonei","n_c":["C3345"],"i_c":"8480/6","i_c_s":["Pseudomyxoma peritonei"],"term_type":"PT"},{"nm":"Pseudomyxoma peritonei with unknown primary site","n_c":["C3345"],"i_c":"8480/3","i_c_s":["Pseudomyxoma peritonei with unknown primary site"],"term_type":"RT"},{"nm":"Pseudosarcomatous carcinoma","n_c":["C27004"],"i_c":"8033/3","i_c_s":["Pseudosarcomatous carcinoma"],"term_type":"PT"},{"nm":"PTLD, NOS","n_c":["C4727"],"i_c":"9971/1","i_c_s":["PTLD, NOS"],"term_type":"SY"},{"nm":"Pulmonary adenomatosis","n_c":["C3763"],"i_c":"8250/1","i_c_s":["Pulmonary adenomatosis"],"term_type":"PT"},{"nm":"Pulmonary artery intimal sarcoma","n_c":["C142825"],"i_c":"9137/3","i_c_s":["Pulmonary artery intimal sarcoma"],"term_type":""},{"nm":"Pulmonary blastoma","n_c":["C3732"],"i_c":"8972/3","i_c_s":["Pulmonary blastoma"],"term_type":"PT"},{"nm":"Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation","n_c":["C142827"],"i_c":"8842/3","i_c_s":["Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation"],"term_type":""},{"nm":"Queyrat erythroplasia","n_c":["C27790"],"i_c":"8080/2","i_c_s":["Queyrat erythroplasia"],"term_type":"PT"},{"nm":"Racemose hemangioma","n_c":["C35479"],"i_c":"9123/0","i_c_s":["Racemose hemangioma"],"term_type":"PT"},{"nm":"RAEB","n_c":["C7506"],"i_c":"9983/3","i_c_s":["RAEB"],"term_type":"SY"},{"nm":"RAEB I","n_c":["C7506"],"i_c":"9983/3","i_c_s":["RAEB I"],"term_type":"SY"},{"nm":"RAEB II","n_c":["C7168"],"i_c":"9983/3","i_c_s":["RAEB II"],"term_type":"SY"},{"nm":"RAEB-T","n_c":["C27080"],"i_c":"9984/3","i_c_s":["RAEB-T"],"term_type":"SY"},{"nm":"RARS","n_c":["C4036"],"i_c":"9982/3","i_c_s":["RARS"],"term_type":"SY"},{"nm":"Rathke pouch tumor","n_c":["C2964"],"i_c":"9350/1","i_c_s":["Rathke pouch tumor"],"term_type":"SY"},{"nm":"Recklinghausen disease","n_c":["C3273"],"i_c":"9540/1","i_c_s":["Recklinghausen disease"],"term_type":"SY"},{"nm":"Refractory anemia","n_c":["C2872"],"i_c":"9980/3","i_c_s":["Refractory anemia"],"term_type":"PT"},{"nm":"Refractory anemia with excess blasts","n_c":["C7506"],"i_c":"9983/3","i_c_s":["Refractory anemia with excess blasts"],"term_type":"PT"},{"nm":"Refractory anemia with excess blasts in transformation","n_c":["C27080"],"i_c":"9984/3","i_c_s":["Refractory anemia with excess blasts in transformation"],"term_type":"OP"},{"nm":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis","n_c":["C82616"],"i_c":"9982/3","i_c_s":["Refractory anemia with ring sideroblasts associated with marked thrombocytosis"],"term_type":"SY"},{"nm":"Refractory anemia with ringed sideroblasts","n_c":["C4036"],"i_c":"9982/3","i_c_s":["Refractory anemia with ringed sideroblasts"],"term_type":"SY"},{"nm":"Refractory anemia with sideroblasts","n_c":["C4036"],"i_c":"9982/3","i_c_s":["Refractory anemia with sideroblasts"],"term_type":"PT"},{"nm":"Refractory anemia without sideroblasts","n_c":"","i_c":"9980/3","i_c_s":["Refractory anemia without sideroblasts"],"term_type":"SY"},{"nm":"Refractory cytopenia of childhood","n_c":["C82596"],"i_c":"9985/3","i_c_s":["Refractory cytopenia of childhood"],"term_type":"SY"},{"nm":"Refractory cytopenia with multilineage dysplasia","n_c":["C8574"],"i_c":"9985/3","i_c_s":["Refractory cytopenia with multilineage dysplasia"],"term_type":"PT"},{"nm":"Refractory neutropenia","n_c":["C82593"],"i_c":"9991/3","i_c_s":["Refractory neutropenia"],"term_type":"PT"},{"nm":"Refractory thrombocytopenia","n_c":["C82594"],"i_c":"9992/3","i_c_s":["Refractory thrombocytopenia"],"term_type":"PT"},{"nm":"Regressing nevus","n_c":["C7603"],"i_c":"8723/0","i_c_s":["Regressing nevus"],"term_type":"SY"},{"nm":"Renal carcinoma, collecting duct type","n_c":["C6194"],"i_c":"8319/3","i_c_s":["Renal carcinoma, collecting duct type"],"term_type":"SY"},{"nm":"Renal cell adenocarcinoma","n_c":["C9385"],"i_c":"8312/3","i_c_s":["Renal cell adenocarcinoma"],"term_type":"SY"},{"nm":"Renal cell carcinoma, chromophobe type","n_c":["C4146"],"i_c":"8317/3","i_c_s":["Renal cell carcinoma, chromophobe type"],"term_type":"PT"},{"nm":"Renal cell carcinoma, NOS","n_c":["C191370"],"i_c":"8312/3","i_c_s":["Renal cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Renal cell carcinoma, sarcomatoid","n_c":["C27893"],"i_c":"8318/3","i_c_s":["Renal cell carcinoma, sarcomatoid"],"term_type":"PT"},{"nm":"Renal cell carcinoma, spindle cell","n_c":["C27893"],"i_c":"8318/3","i_c_s":["Renal cell carcinoma, spindle cell"],"term_type":"SY"},{"nm":"Renal cell carcinoma, unclassified","n_c":["C191370"],"i_c":"8312/3","i_c_s":["Renal cell carcinoma, unclassified"],"term_type":""},{"nm":"Renal medullary carcinoma","n_c":["C7572"],"i_c":"8510/3","i_c_s":["Renal medullary carcinoma"],"term_type":""},{"nm":"Reninoma","n_c":["C4162"],"i_c":"8361/0","i_c_s":["Reninoma"],"term_type":"SY"},{"nm":"Renomedullary fibroma","n_c":"","i_c":"8966/0","i_c_s":["Renomedullary fibroma"],"term_type":"SY"},{"nm":"Renomedullary interstitial cell tumor","n_c":["C5100"],"i_c":"8966/0","i_c_s":["Renomedullary interstitial cell tumor"],"term_type":"PT"},{"nm":"Reserve cell carcinoma","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Reserve cell carcinoma"],"term_type":"SY"},{"nm":"Reticulohistiocytoma","n_c":["C3356"],"i_c":"8831/0","i_c_s":["Reticulohistiocytoma"],"term_type":"RT"},{"nm":"Reticulosarcoma, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Reticulosarcoma, diffuse"],"term_type":"IS"},{"nm":"Reticulosarcoma, NOS","n_c":["C27824"],"i_c":"9591/3","i_c_s":["Reticulosarcoma, NOS"],"term_type":"IS"},{"nm":"Reticulum cell sarcoma, diffuse","n_c":"","i_c":"9591/3","i_c_s":["Reticulum cell sarcoma, diffuse"],"term_type":"IS"},{"nm":"Reticulum cell sarcoma, NOS","n_c":["C27824"],"i_c":"9591/3","i_c_s":["Reticulum cell sarcoma, NOS"],"term_type":"ORT"},{"nm":"Retinal anlage tumor","n_c":["C3717"],"i_c":"9363/0","i_c_s":["Retinal anlage tumor"],"term_type":"SY"},{"nm":"Retinoblastoma, differentiated","n_c":["C66813"],"i_c":"9511/3","i_c_s":["Retinoblastoma, differentiated"],"term_type":"PT"},{"nm":"Retinoblastoma, diffuse","n_c":["C66815"],"i_c":"9513/3","i_c_s":["Retinoblastoma, diffuse"],"term_type":"PT"},{"nm":"Retinoblastoma, NOS","n_c":["C7541"],"i_c":"9510/3","i_c_s":["Retinoblastoma, NOS"],"term_type":"PT"},{"nm":"Retinoblastoma, spontaneously regressed","n_c":["C66816"],"i_c":"9514/1","i_c_s":["Retinoblastoma, spontaneously regressed"],"term_type":"PT"},{"nm":"Retinoblastoma, undifferentiated","n_c":["C66814"],"i_c":"9512/3","i_c_s":["Retinoblastoma, undifferentiated"],"term_type":"PT"},{"nm":"Retinocytoma","n_c":["C66812"],"i_c":"9510/0","i_c_s":["Retinocytoma"],"term_type":"PT"},{"nm":"Retroperitoneal fibromatosis","n_c":["C3741"],"i_c":"8822/1","i_c_s":["Retroperitoneal fibromatosis"],"term_type":"SY"},{"nm":"Rhabdoid meningioma","n_c":["C6909"],"i_c":"9538/3","i_c_s":["Rhabdoid meningioma"],"term_type":"RT"},{"nm":"Rhabdoid sarcoma","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Rhabdoid sarcoma"],"term_type":"SY"},{"nm":"Rhabdoid tumor, NOS","n_c":["C3808"],"i_c":"8963/3","i_c_s":["Rhabdoid tumor, NOS"],"term_type":"SY"},{"nm":"Rhabdomyoma, NOS","n_c":["C3358"],"i_c":"8900/0","i_c_s":["Rhabdomyoma, NOS"],"term_type":"PT"},{"nm":"Rhabdomyosarcoma with ganglionic differentiation","n_c":["C4716"],"i_c":"8921/3","i_c_s":["Rhabdomyosarcoma with ganglionic differentiation"],"term_type":"PT"},{"nm":"Rhabdomyosarcoma, NOS","n_c":["C3359"],"i_c":"8900/3","i_c_s":["Rhabdomyosarcoma, NOS"],"term_type":"PT"},{"nm":"Rhabdosarcoma","n_c":["C3359"],"i_c":"8900/3","i_c_s":["Rhabdosarcoma"],"term_type":"SY"},{"nm":"Rodent ulcer","n_c":["C5568"],"i_c":"8090/3","i_c_s":["Rodent ulcer"],"term_type":"SY"},{"nm":"Rosette-forming glioneuronal tumor","n_c":["C129431"],"i_c":"9509/1","i_c_s":["Rosette-forming glioneuronal tumor"],"term_type":"RT"},{"nm":"Round cell carcinoma","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Round cell carcinoma"],"term_type":"SY"},{"nm":"Round cell liposarcoma","n_c":["C4252"],"i_c":"8853/3","i_c_s":["Round cell liposarcoma"],"term_type":"PT"},{"nm":"Round cell osteosarcoma","n_c":["C4023"],"i_c":"9185/3","i_c_s":["Round cell osteosarcoma"],"term_type":"SY"},{"nm":"Round cell sarcoma","n_c":"","i_c":"8803/3","i_c_s":["Round cell sarcoma"],"term_type":"SY"},{"nm":"Salivary duct carcinoma","n_c":["C5904"],"i_c":"8500/3","i_c_s":["Salivary duct carcinoma"],"term_type":""},{"nm":"SALT lymphoma","n_c":["C7230"],"i_c":"9699/3","i_c_s":["SALT lymphoma"],"term_type":"SY"},{"nm":"Sarcoma botryoides","n_c":["C9150"],"i_c":"8910/3","i_c_s":["Sarcoma botryoides"],"term_type":"RT"},{"nm":"Sarcoma, NOS","n_c":["C9118"],"i_c":"8800/3","i_c_s":["Sarcoma, NOS"],"term_type":"PT"},{"nm":"Sarcomatoid carcinoma","n_c":["C27004"],"i_c":"8033/3","i_c_s":["Sarcomatoid carcinoma"],"term_type":"SY"},{"nm":"Sarcomatoid mesothelioma","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Sarcomatoid mesothelioma"],"term_type":"SY"},{"nm":"Sarcomatosis, NOS","n_c":["C4243"],"i_c":"8800/9","i_c_s":["Sarcomatosis, NOS"],"term_type":"PT"},{"nm":"Schmincke tumor","n_c":["C4107"],"i_c":"8082/3","i_c_s":["Schmincke tumor"],"term_type":"RT"},{"nm":"Schneiderian carcinoma","n_c":["C54287"],"i_c":"8121/3","i_c_s":["Schneiderian carcinoma"],"term_type":"PT"},{"nm":"Schneiderian papilloma, inverted","n_c":["C6871"],"i_c":"8121/1","i_c_s":["Schneiderian papilloma, inverted"],"term_type":"RT"},{"nm":"Schneiderian papilloma, NOS","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Schneiderian papilloma, NOS"],"term_type":"PT"},{"nm":"Schwannoma, NOS","n_c":["C3269"],"i_c":"9560/0","i_c_s":["Schwannoma, NOS"],"term_type":"SY"},{"nm":"Scirrhous adenocarcinoma","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Scirrhous adenocarcinoma"],"term_type":"PT"},{"nm":"Scirrhous carcinoma","n_c":["C2928"],"i_c":"8141/3","i_c_s":["Scirrhous carcinoma"],"term_type":"SY"},{"nm":"Sclerosing epithelioid fibrosarcoma","n_c":["C49027"],"i_c":"8840/3","i_c_s":["Sclerosing epithelioid fibrosarcoma"],"term_type":""},{"nm":"Sclerosing hemangioma","n_c":["C6801"],"i_c":"8832/0","i_c_s":["Sclerosing hemangioma"],"term_type":"SY"},{"nm":"Sclerosing hepatic carcinoma","n_c":["C27388"],"i_c":"8172/3","i_c_s":["Sclerosing hepatic carcinoma"],"term_type":"SY"},{"nm":"Sclerosing liposarcoma","n_c":["C6507"],"i_c":"8851/3","i_c_s":["Sclerosing liposarcoma"],"term_type":"RT"},{"nm":"Sclerosing rhabdomyosarcoma","n_c":["C121655"],"i_c":"8912/3","i_c_s":["Sclerosing rhabdomyosarcoma"],"term_type":""},{"nm":"Sclerosing stromal tumor","n_c":["C4204"],"i_c":"8602/0","i_c_s":["Sclerosing stromal tumor"],"term_type":"PT"},{"nm":"Sclerosing sweat duct carcinoma","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Sclerosing sweat duct carcinoma"],"term_type":"PT"},{"nm":"Sebaceous adenocarcinoma","n_c":["C40310"],"i_c":"8410/3","i_c_s":["Sebaceous adenocarcinoma"],"term_type":"PT"},{"nm":"Sebaceous adenoma","n_c":["C4174"],"i_c":"8410/0","i_c_s":["Sebaceous adenoma"],"term_type":"PT"},{"nm":"Sebaceous carcinoma","n_c":["C40310"],"i_c":"8410/3","i_c_s":["Sebaceous carcinoma"],"term_type":"SY"},{"nm":"Sebaceous epithelioma","n_c":["C4346"],"i_c":"8410/0","i_c_s":["Sebaceous epithelioma"],"term_type":"RT"},{"nm":"Secondary carcinoma","n_c":["C36310"],"i_c":"8010/6","i_c_s":["Secondary carcinoma"],"term_type":"SY"},{"nm":"Secretory carcinoma of breast","n_c":["C4189"],"i_c":"8502/3","i_c_s":["Secretory carcinoma of breast"],"term_type":"PT"},{"nm":"Secretory meningioma","n_c":["C4718"],"i_c":"9530/0","i_c_s":["Secretory meningioma"],"term_type":"RT"},{"nm":"Seminoma with high mitotic index","n_c":["C39920"],"i_c":"9062/3","i_c_s":["Seminoma with high mitotic index"],"term_type":"SY"},{"nm":"Seminoma, anaplastic","n_c":["C39920"],"i_c":"9062/3","i_c_s":["Seminoma, anaplastic"],"term_type":"PT"},{"nm":"Seminoma, NOS","n_c":["C9309"],"i_c":"9061/3","i_c_s":["Seminoma, NOS"],"term_type":"PT"},{"nm":"Seromucinous carcinoma","n_c":["C40090"],"i_c":"8474/3","i_c_s":["Seromucinous carcinoma"],"term_type":"PT"},{"nm":"Serotonin producing carcinoid","n_c":"","i_c":"8241/3","i_c_s":["Serotonin producing carcinoid"],"term_type":"SY"},{"nm":"Serous adenocarcinofibroma","n_c":["C67092"],"i_c":"9014/3","i_c_s":["Serous adenocarcinofibroma"],"term_type":"PT"},{"nm":"Serous adenocarcinoma, NOS","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous adenocarcinoma, NOS"],"term_type":"SY"},{"nm":"Serous adenofibroma of borderline malignancy","n_c":["C40028"],"i_c":"9014/1","i_c_s":["Serous adenofibroma of borderline malignancy"],"term_type":"PT"},{"nm":"Serous adenofibroma, NOS","n_c":["C67090"],"i_c":"9014/0","i_c_s":["Serous adenofibroma, NOS"],"term_type":"PT"},{"nm":"Serous borderline tumor-micropapillary variant","n_c":["C122585"],"i_c":"8460/2","i_c_s":["Serous borderline tumor-micropapillary variant"],"term_type":""},{"nm":"Serous carcinoma, NOS","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous carcinoma, NOS"],"term_type":"SY"},{"nm":"Serous cystadenocarcinofibroma","n_c":"","i_c":"9014/3","i_c_s":["Serous cystadenocarcinofibroma"],"term_type":"RT"},{"nm":"Serous cystadenocarcinoma, NOS","n_c":["C3778"],"i_c":"8441/3","i_c_s":["Serous cystadenocarcinoma, NOS"],"term_type":"PT"},{"nm":"Serous cystadenofibroma of borderline malignancy","n_c":"","i_c":"9014/1","i_c_s":["Serous cystadenofibroma of borderline malignancy"],"term_type":"RT"},{"nm":"Serous cystadenofibroma, NOS","n_c":"","i_c":"9014/0","i_c_s":["Serous cystadenofibroma, NOS"],"term_type":"RT"},{"nm":"Serous cystadenoma, borderline malignancy","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Serous cystadenoma, borderline malignancy"],"term_type":"PT"},{"nm":"Serous cystadenoma, NOS","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous cystadenoma, NOS"],"term_type":"PT"},{"nm":"Serous cystoma","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous cystoma"],"term_type":"SY"},{"nm":"Serous endometrial intraepithelial carcinoma","n_c":["C40152"],"i_c":"8441/2","i_c_s":["Serous endometrial intraepithelial carcinoma"],"term_type":""},{"nm":"Serous microcystic adenoma","n_c":["C3783"],"i_c":"8441/0","i_c_s":["Serous microcystic adenoma"],"term_type":"RT"},{"nm":"Serous papillary cystic tumor of borderline malignancy","n_c":["C4183"],"i_c":"8462/1","i_c_s":["Serous papillary cystic tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Serous surface papillary carcinoma","n_c":["C4182"],"i_c":"8461/3","i_c_s":["Serous surface papillary carcinoma"],"term_type":"PT"},{"nm":"Serous surface papillary tumor of borderline malignancy","n_c":["C7315"],"i_c":"8463/1","i_c_s":["Serous surface papillary tumor of borderline malignancy"],"term_type":"PT"},{"nm":"Serous surface papilloma","n_c":["C4181"],"i_c":"8461/0","i_c_s":["Serous surface papilloma"],"term_type":"PT"},{"nm":"Serous tubal intraepithelial carcinoma","n_c":["C126449"],"i_c":"8441/2","i_c_s":["Serous tubal intraepithelial carcinoma"],"term_type":""},{"nm":"Serous tumor, NOS, of low malignant potential","n_c":["C4177"],"i_c":"8442/1","i_c_s":["Serous tumor, NOS, of low malignant potential"],"term_type":"SY"},{"nm":"Serrated adenocarcinoma","n_c":["C96485"],"i_c":"8213/3","i_c_s":["Serrated adenocarcinoma"],"term_type":"PT"},{"nm":"Serrated adenoma","n_c":["C38458"],"i_c":"8213/0","i_c_s":["Serrated adenoma"],"term_type":"PT"},{"nm":"Sertoli cell adenoma","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Sertoli cell adenoma"],"term_type":"SY"},{"nm":"Sertoli cell carcinoma","n_c":["C67006"],"i_c":"8640/3","i_c_s":["Sertoli cell carcinoma"],"term_type":"PT"},{"nm":"Sertoli cell tumor with lipid storage","n_c":["C4211"],"i_c":"8641/0","i_c_s":["Sertoli cell tumor with lipid storage"],"term_type":"PT"},{"nm":"Sertoli cell tumor, NOS","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Sertoli cell tumor, NOS"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor of intermediate differentiation","n_c":["C39968"],"i_c":"8631/1","i_c_s":["Sertoli-Leydig cell tumor of intermediate differentiation"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements","n_c":["C39972"],"i_c":"8634/1","i_c_s":["Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, NOS","n_c":["C2880"],"i_c":"8631/1","i_c_s":["Sertoli-Leydig cell tumor, NOS"],"term_type":"RT"},{"nm":"Sertoli-Leydig cell tumor, poorly differentiated","n_c":["C4210"],"i_c":"8631/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements","n_c":["C39973"],"i_c":"8634/3","i_c_s":["Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, retiform","n_c":["C39974"],"i_c":"8633/1","i_c_s":["Sertoli-Leydig cell tumor, retiform"],"term_type":"PT"},{"nm":"Sertoli-Leydig cell tumor, retiform, with heterologous elements","n_c":"","i_c":"8634/1","i_c_s":["Sertoli-Leydig cell tumor, retiform, with heterologous elements"],"term_type":"RT"},{"nm":"Sertoli-Leydig cell tumor, sarcomatoid","n_c":"","i_c":"8631/3","i_c_s":["Sertoli-Leydig cell tumor, sarcomatoid"],"term_type":"RT"},{"nm":"Sertoli-Leydig cell tumor, well differentiated","n_c":["C4209"],"i_c":"8631/0","i_c_s":["Sertoli-Leydig cell tumor, well differentiated"],"term_type":"PT"},{"nm":"Sessile serrated adenoma","n_c":["C96414"],"i_c":"8213/0","i_c_s":["Sessile serrated adenoma"],"term_type":"RT"},{"nm":"Sessile serrated polyp","n_c":["C96414"],"i_c":"8213/0","i_c_s":["Sessile serrated polyp"],"term_type":"RT"},{"nm":"SETTLE","n_c":["C46105"],"i_c":"8588/3","i_c_s":["SETTLE"],"term_type":"SY"},{"nm":"Sex cord tumor with annular tubules","n_c":["C4208"],"i_c":"8623/1","i_c_s":["Sex cord tumor with annular tubules"],"term_type":"PT"},{"nm":"Sex cord tumor, NOS","n_c":["C3794"],"i_c":"8590/1","i_c_s":["Sex cord tumor, NOS"],"term_type":"SY"},{"nm":"Sex cord-gonadal stromal tumor, incompletely differentiated","n_c":["C66748"],"i_c":"8591/1","i_c_s":["Sex cord-gonadal stromal tumor, incompletely differentiated"],"term_type":"PT"},{"nm":"Sex cord-gonadal stromal tumor, mixed forms","n_c":["C66991"],"i_c":"8592/1","i_c_s":["Sex cord-gonadal stromal tumor, mixed forms"],"term_type":"PT"},{"nm":"Sex cord-gonadal stromal tumor, NOS","n_c":["C3794"],"i_c":"8590/1","i_c_s":["Sex cord-gonadal stromal tumor, NOS"],"term_type":"PT"},{"nm":"Sezary disease","n_c":["C3366"],"i_c":"9701/3","i_c_s":["Sezary disease"],"term_type":"SY"},{"nm":"Sezary syndrome","n_c":["C3366"],"i_c":"9701/3","i_c_s":["Sezary syndrome"],"term_type":"PT"},{"nm":"Sialoblastoma","n_c":["C35837"],"i_c":"8974/1","i_c_s":["Sialoblastoma"],"term_type":"PT"},{"nm":"Signet ring cell adenocarcinoma","n_c":["C3774"],"i_c":"8490/3","i_c_s":["Signet ring cell adenocarcinoma"],"term_type":"SY"},{"nm":"Signet ring cell carcinoma","n_c":["C3774"],"i_c":"8490/3","i_c_s":["Signet ring cell carcinoma"],"term_type":"PT"},{"nm":"Sinonasal papilloma, exophytic","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Sinonasal papilloma, exophytic"],"term_type":"RT"},{"nm":"Sinonasal papilloma, fungiform","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Sinonasal papilloma, fungiform"],"term_type":"SY"},{"nm":"Sinonasal papilloma, NOS","n_c":["C4117"],"i_c":"8121/0","i_c_s":["Sinonasal papilloma, NOS"],"term_type":"SY"},{"nm":"Skin appendage adenoma","n_c":["C7580"],"i_c":"8390/0","i_c_s":["Skin appendage adenoma"],"term_type":"PT"},{"nm":"Skin appendage carcinoma","n_c":["C3775"],"i_c":"8390/3","i_c_s":["Skin appendage carcinoma"],"term_type":"PT"},{"nm":"Skin appendage tumor, benign","n_c":["C4615"],"i_c":"8390/0","i_c_s":["Skin appendage tumor, benign"],"term_type":"SY"},{"nm":"Skin-associated lymphoid tissue lymphoma","n_c":["C7230"],"i_c":"9699/3","i_c_s":["Skin-associated lymphoid tissue lymphoma"],"term_type":"SY"},{"nm":"Small cell carcinoma pulmonary type","n_c":["C40440"],"i_c":"8041/3","i_c_s":["Small cell carcinoma pulmonary type"],"term_type":""},{"nm":"Small cell carcinoma, fusiform cell","n_c":["C27092"],"i_c":"8043/3","i_c_s":["Small cell carcinoma, fusiform cell"],"term_type":"PT"},{"nm":"Small cell carcinoma, hypercalcemic type","n_c":["C40439"],"i_c":"8044/3","i_c_s":["Small cell carcinoma, hypercalcemic type"],"term_type":""},{"nm":"Small cell carcinoma, intermediate cell","n_c":["C4099"],"i_c":"8044/3","i_c_s":["Small cell carcinoma, intermediate cell"],"term_type":"PT"},{"nm":"Small cell carcinoma, NOS","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Small cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Small cell neuroendocrine carcinoma","n_c":["C3915"],"i_c":"8041/3","i_c_s":["Small cell neuroendocrine carcinoma"],"term_type":"RT"},{"nm":"Small cell osteosarcoma","n_c":["C4023"],"i_c":"9185/3","i_c_s":["Small cell osteosarcoma"],"term_type":"PT"},{"nm":"Small cell sarcoma","n_c":["C3746"],"i_c":"8803/3","i_c_s":["Small cell sarcoma"],"term_type":"PT"},{"nm":"Small congenital nevus","n_c":["C66754"],"i_c":"8761/0","i_c_s":["Small congenital nevus"],"term_type":"PT"},{"nm":"Smooth muscle tumor of uncertain malignant potential","n_c":["C40177"],"i_c":"8897/1","i_c_s":["Smooth muscle tumor of uncertain malignant potential"],"term_type":"PT"},{"nm":"Smooth muscle tumor, NOS","n_c":["C3751"],"i_c":"8897/1","i_c_s":["Smooth muscle tumor, NOS"],"term_type":"RT"},{"nm":"Soft tissue perineurioma","n_c":["C6912"],"i_c":"9571/0","i_c_s":["Soft tissue perineurioma"],"term_type":"RT"},{"nm":"Soft tissue sarcoma","n_c":["C9306"],"i_c":"8800/3","i_c_s":["Soft tissue sarcoma"],"term_type":"SY"},{"nm":"Soft tissue tumor, benign","n_c":["C4242"],"i_c":"8800/0","i_c_s":["Soft tissue tumor, benign"],"term_type":"PT"},{"nm":"Soft tissue tumor, malignant","n_c":["C4867"],"i_c":"8800/3","i_c_s":["Soft tissue tumor, malignant"],"term_type":"SY"},{"nm":"Solid adenocarcinoma with mucin formation","n_c":"","i_c":"8230/3","i_c_s":["Solid adenocarcinoma with mucin formation"],"term_type":"SY"},{"nm":"Solid and cystic tumor","n_c":["C4179"],"i_c":"8452/1","i_c_s":["Solid and cystic tumor"],"term_type":"SY"},{"nm":"Solid and papillary epithelial neoplasm","n_c":["C4179"],"i_c":"8452/1","i_c_s":["Solid and papillary epithelial neoplasm"],"term_type":"SY"},{"nm":"Solid carcinoma with mucin formation","n_c":"","i_c":"8230/3","i_c_s":["Solid carcinoma with mucin formation"],"term_type":"RT"},{"nm":"Solid carcinoma, NOS","n_c":["C4137"],"i_c":"8230/3","i_c_s":["Solid carcinoma, NOS"],"term_type":"PT"},{"nm":"Solid papillary carcinoma in situ","n_c":["C6870"],"i_c":"8509/2","i_c_s":["Solid papillary carcinoma in situ"],"term_type":"PT"},{"nm":"Solid papillary carcinoma with invasion","n_c":["C66850"],"i_c":"8509/3","i_c_s":["Solid papillary carcinoma with invasion"],"term_type":"PT"},{"nm":"Solid pseudopapillary carcinoma","n_c":["C5728"],"i_c":"8452/3","i_c_s":["Solid pseudopapillary carcinoma"],"term_type":"PT"},{"nm":"Solid pseudopapillary tumor","n_c":["C201136"],"i_c":"8452/1","i_c_s":["Solid pseudopapillary tumor"],"term_type":"PT"},{"nm":"Solid teratoma","n_c":["C3403"],"i_c":"9080/1","i_c_s":["Solid teratoma"],"term_type":"SY"},{"nm":"Solitary fibrous tumor","n_c":["C7634"],"i_c":"8815/0","i_c_s":["Solitary fibrous tumor"],"term_type":"PT"},{"nm":"Solitary fibrous tumor, malignant","n_c":["C6894"],"i_c":"8815/3","i_c_s":["Solitary fibrous tumor, malignant"],"term_type":"PT"},{"nm":"Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)","n_c":["C129530"],"i_c":"8815/0","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)"],"term_type":""},{"nm":"Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)","n_c":["C129528"],"i_c":"8815/1","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)"],"term_type":""},{"nm":"Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)","n_c":["C129527"],"i_c":"8815/3","i_c_s":["Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)"],"term_type":""},{"nm":"Solitary mastocytoma of skin","n_c":["C7138"],"i_c":"9740/1","i_c_s":["Solitary mastocytoma of skin"],"term_type":"SY"},{"nm":"Solitary myeloma","n_c":["C6932"],"i_c":"9731/3","i_c_s":["Solitary myeloma"],"term_type":"SY"},{"nm":"Solitary plasmacytoma","n_c":["C6932"],"i_c":"9731/3","i_c_s":["Solitary plasmacytoma"],"term_type":"SY"},{"nm":"Somatostatin cell tumor, malignant","n_c":["C65190"],"i_c":"8156/3","i_c_s":["Somatostatin cell tumor, malignant"],"term_type":"SY"},{"nm":"Somatostatin cell tumor, NOS","n_c":["C3379"],"i_c":"8156/1","i_c_s":["Somatostatin cell tumor, NOS"],"term_type":"SY"},{"nm":"Somatostatinoma, malignant","n_c":["C65190"],"i_c":"8156/3","i_c_s":["Somatostatinoma, malignant"],"term_type":"PT"},{"nm":"Somatostatinoma, NOS","n_c":["C3379"],"i_c":"8156/1","i_c_s":["Somatostatinoma, NOS"],"term_type":"PT"},{"nm":"Spermatocytic seminoma","n_c":["C39921"],"i_c":"9063/3","i_c_s":["Spermatocytic seminoma"],"term_type":"PT"},{"nm":"Spermatocytoma","n_c":["C39921"],"i_c":"9063/3","i_c_s":["Spermatocytoma"],"term_type":"SY"},{"nm":"Spindle cell angioendothelioma","n_c":["C4754"],"i_c":"9136/1","i_c_s":["Spindle cell angioendothelioma"],"term_type":"SY"},{"nm":"Spindle cell carcinoma, NOS","n_c":["C27004"],"i_c":"8032/3","i_c_s":["Spindle cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Spindle cell hemangioendothelioma","n_c":["C4754"],"i_c":"9136/1","i_c_s":["Spindle cell hemangioendothelioma"],"term_type":"PT"},{"nm":"Spindle cell lipoma","n_c":["C4254"],"i_c":"8857/0","i_c_s":["Spindle cell lipoma"],"term_type":"PT"},{"nm":"Spindle cell melanoma, NOS","n_c":["C4237"],"i_c":"8772/3","i_c_s":["Spindle cell melanoma, NOS"],"term_type":"PT"},{"nm":"Spindle cell melanoma, type A","n_c":["C4238"],"i_c":"8773/3","i_c_s":["Spindle cell melanoma, type A"],"term_type":"PT"},{"nm":"Spindle cell melanoma, type B","n_c":["C4239"],"i_c":"8774/3","i_c_s":["Spindle cell melanoma, type B"],"term_type":"PT"},{"nm":"Spindle cell nevus, NOS","n_c":["C27007"],"i_c":"8772/0","i_c_s":["Spindle cell nevus, NOS"],"term_type":"PT"},{"nm":"Spindle cell oncocytoma","n_c":["C94537"],"i_c":"8290/0","i_c_s":["Spindle cell oncocytoma"],"term_type":"RT"},{"nm":"Spindle cell rhabdomyosarcoma","n_c":["C6519"],"i_c":"8912/3","i_c_s":["Spindle cell rhabdomyosarcoma"],"term_type":"PT"},{"nm":"Spindle cell sarcoma","n_c":["C27005"],"i_c":"8801/3","i_c_s":["Spindle cell sarcoma"],"term_type":"PT"},{"nm":"Spindle epithelial tumor with thymus-like differentiation","n_c":["C46105"],"i_c":"8588/3","i_c_s":["Spindle epithelial tumor with thymus-like differentiation"],"term_type":"SY"},{"nm":"Spindle epithelial tumor with thymus-like element","n_c":["C46105"],"i_c":"8588/3","i_c_s":["Spindle epithelial tumor with thymus-like element"],"term_type":"PT"},{"nm":"Spindled mesothelioma","n_c":["C45655"],"i_c":"9051/3","i_c_s":["Spindled mesothelioma"],"term_type":"SY"},{"nm":"Spiradenoma, NOS","n_c":["C4170"],"i_c":"8403/0","i_c_s":["Spiradenoma, NOS"],"term_type":"SY"},{"nm":"Spitz nevus","n_c":["C27007"],"i_c":"8770/0","i_c_s":["Spitz nevus"],"term_type":"SY"},{"nm":"Splenic B-cell lymphoma/leukemia, unclassifiable","n_c":["C80308"],"i_c":"9591/3","i_c_s":["Splenic B-cell lymphoma/leukemia, unclassifiable"],"term_type":"RT"},{"nm":"Splenic diffuse red pulp small B-cell lymphoma","n_c":["C80309"],"i_c":"9591/3","i_c_s":["Splenic diffuse red pulp small B-cell lymphoma"],"term_type":"RT"},{"nm":"Splenic lymphoma with villous lymphocytes","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic lymphoma with villous lymphocytes"],"term_type":"SY"},{"nm":"Splenic marginal zone B-cell lymphoma","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic marginal zone B-cell lymphoma"],"term_type":"PT"},{"nm":"Splenic marginal zone lymphoma, NOS","n_c":["C4663"],"i_c":"9689/3","i_c_s":["Splenic marginal zone lymphoma, NOS"],"term_type":"SY"},{"nm":"Spongioblastoma multiforme","n_c":["C3058"],"i_c":"9440/3","i_c_s":["Spongioblastoma multiforme"],"term_type":"SY"},{"nm":"Spongioblastoma polare","n_c":["C66801"],"i_c":"9423/3","i_c_s":["Spongioblastoma polare"],"term_type":"SY"},{"nm":"Spongioblastoma, NOS","n_c":"","i_c":"9421/1","i_c_s":["Spongioblastoma, NOS"],"term_type":"IS"},{"nm":"Spongioneuroblastoma","n_c":["C66811"],"i_c":"9504/3","i_c_s":["Spongioneuroblastoma"],"term_type":"PT"},{"nm":"Squamotransitional cell carcinoma","n_c":["C40194"],"i_c":"8120/3","i_c_s":["Squamotransitional cell carcinoma"],"term_type":""},{"nm":"Squamous carcinoma","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous carcinoma"],"term_type":"SY"},{"nm":"Squamous cell carcinoma in situ with questionable stromal invasion","n_c":["C65176"],"i_c":"8076/2","i_c_s":["Squamous cell carcinoma in situ with questionable stromal invasion"],"term_type":"PT"},{"nm":"Squamous cell carcinoma in situ, NOS","n_c":["C27093"],"i_c":"8070/2","i_c_s":["Squamous cell carcinoma in situ, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma with horn formation","n_c":["C65179"],"i_c":"8078/3","i_c_s":["Squamous cell carcinoma with horn formation"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, acantholytic","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, acantholytic"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, adenoid","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, adenoid"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, clear cell type","n_c":["C65180"],"i_c":"8084/3","i_c_s":["Squamous cell carcinoma, clear cell type"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, HPV-negative","n_c":["C164250"],"i_c":"8086/3","i_c_s":["Squamous cell carcinoma, HPV-negative"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, HPV-positive","n_c":["C27683"],"i_c":"8085/3","i_c_s":["Squamous cell carcinoma, HPV-positive"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, keratinizing, NOS","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Squamous cell carcinoma, keratinizing, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, large cell, keratinizing","n_c":["C4105"],"i_c":"8071/3","i_c_s":["Squamous cell carcinoma, large cell, keratinizing"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, large cell, nonkeratinizing, NOS","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Squamous cell carcinoma, large cell, nonkeratinizing, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, metastatic, NOS","n_c":["C4104"],"i_c":"8070/6","i_c_s":["Squamous cell carcinoma, metastatic, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, microinvasive","n_c":["C65178"],"i_c":"8076/3","i_c_s":["Squamous cell carcinoma, microinvasive"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, nonkeratinizing, NOS","n_c":["C65173"],"i_c":"8072/3","i_c_s":["Squamous cell carcinoma, nonkeratinizing, NOS"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, NOS","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous cell carcinoma, NOS"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, pseudoglandular","n_c":["C4106"],"i_c":"8075/3","i_c_s":["Squamous cell carcinoma, pseudoglandular"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, sarcomatoid","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Squamous cell carcinoma, sarcomatoid"],"term_type":"SY"},{"nm":"Squamous cell carcinoma, small cell, nonkeratinizing","n_c":["C65175"],"i_c":"8073/3","i_c_s":["Squamous cell carcinoma, small cell, nonkeratinizing"],"term_type":"PT"},{"nm":"Squamous cell carcinoma, spindle cell","n_c":["C27084"],"i_c":"8074/3","i_c_s":["Squamous cell carcinoma, spindle cell"],"term_type":"PT"},{"nm":"Squamous cell epithelioma","n_c":["C2929"],"i_c":"8070/3","i_c_s":["Squamous cell epithelioma"],"term_type":"SY"},{"nm":"Squamous cell papilloma, inverted","n_c":["C65165"],"i_c":"8053/0","i_c_s":["Squamous cell papilloma, inverted"],"term_type":"PT"},{"nm":"Squamous cell papilloma, NOS","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Squamous cell papilloma, NOS"],"term_type":"PT"},{"nm":"Squamous intraepithelial neoplasia, grade I","n_c":["C8335"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, grade I"],"term_type":"SY"},{"nm":"Squamous intraepithelial neoplasia, grade II","n_c":["C7351"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, grade II"],"term_type":"SY"},{"nm":"Squamous intraepithelial neoplasia, grade III","n_c":["C27093"],"i_c":"8077/2","i_c_s":["Squamous intraepithelial neoplasia, grade III"],"term_type":"SY"},{"nm":"Squamous intraepithelial neoplasia, high grade","n_c":["C8336"],"i_c":"8077/2","i_c_s":["Squamous intraepithelial neoplasia, high grade"],"term_type":"PT"},{"nm":"Squamous intraepithelial neoplasia, low grade","n_c":["C8335"],"i_c":"8077/0","i_c_s":["Squamous intraepithelial neoplasia, low grade"],"term_type":"PT"},{"nm":"Squamous odontogenic tumor","n_c":["C7112"],"i_c":"9312/0","i_c_s":["Squamous odontogenic tumor"],"term_type":"PT"},{"nm":"Squamous papilloma","n_c":["C3712"],"i_c":"8052/0","i_c_s":["Squamous papilloma"],"term_type":"SY"},{"nm":"Squamous papillomatosis","n_c":["C9009"],"i_c":"8060/0","i_c_s":["Squamous papillomatosis"],"term_type":"PT"},{"nm":"Stem cell leukemia","n_c":["C9298"],"i_c":"9801/3","i_c_s":["Stem cell leukemia"],"term_type":"SY"},{"nm":"Steroid cell tumor, malignant","n_c":["C39981"],"i_c":"8670/3","i_c_s":["Steroid cell tumor, malignant"],"term_type":"PT"},{"nm":"Steroid cell tumor, NOS","n_c":["C4215"],"i_c":"8670/0","i_c_s":["Steroid cell tumor, NOS"],"term_type":"SY"},{"nm":"Stromal endometriosis","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Stromal endometriosis"],"term_type":"SY"},{"nm":"Stromal myosis, NOS","n_c":["C4263"],"i_c":"8931/3","i_c_s":["Stromal myosis, NOS"],"term_type":"SY"},{"nm":"Stromal sarcoma, NOS","n_c":["C6926"],"i_c":"8935/3","i_c_s":["Stromal sarcoma, NOS"],"term_type":"PT"},{"nm":"Stromal tumor with minor sex cord elements","n_c":["C66749"],"i_c":"8593/1","i_c_s":["Stromal tumor with minor sex cord elements"],"term_type":"PT"},{"nm":"Stromal tumor, benign","n_c":["C66772"],"i_c":"8935/0","i_c_s":["Stromal tumor, benign"],"term_type":"PT"},{"nm":"Stromal tumor, NOS","n_c":["C6781"],"i_c":"8935/1","i_c_s":["Stromal tumor, NOS"],"term_type":"PT"},{"nm":"Struma ovarii and carcinoid","n_c":["C4292"],"i_c":"9091/1","i_c_s":["Struma ovarii and carcinoid"],"term_type":"SY"},{"nm":"Struma ovarii, malignant","n_c":["C4291"],"i_c":"9090/3","i_c_s":["Struma ovarii, malignant"],"term_type":"PT"},{"nm":"Struma ovarii, NOS","n_c":["C7468"],"i_c":"9090/0","i_c_s":["Struma ovarii, NOS"],"term_type":"PT"},{"nm":"Strumal carcinoid","n_c":["C4292"],"i_c":"9091/1","i_c_s":["Strumal carcinoid"],"term_type":"PT"},{"nm":"Subacute granulocytic leukemia","n_c":["C3519"],"i_c":"9860/3","i_c_s":["Subacute granulocytic leukemia"],"term_type":"IS"},{"nm":"Subacute leukemia, NOS","n_c":"","i_c":"9800/3","i_c_s":["Subacute leukemia, NOS"],"term_type":"ORT"},{"nm":"Subacute lymphatic leukemia","n_c":"","i_c":"9820/3","i_c_s":["Subacute lymphatic leukemia"],"term_type":"IS"},{"nm":"Subacute lymphocytic leukemia","n_c":"","i_c":"9820/3","i_c_s":["Subacute lymphocytic leukemia"],"term_type":"IS"},{"nm":"Subacute lymphoid leukemia","n_c":"","i_c":"9820/3","i_c_s":["Subacute lymphoid leukemia"],"term_type":"ORT"},{"nm":"Subacute monocytic leukemia","n_c":"","i_c":"9860/3","i_c_s":["Subacute monocytic leukemia"],"term_type":"ORT"},{"nm":"Subacute myelogenous leukemia","n_c":["C3519"],"i_c":"9860/3","i_c_s":["Subacute myelogenous leukemia"],"term_type":"IS"},{"nm":"Subacute myeloid leukemia","n_c":["C3519"],"i_c":"9860/3","i_c_s":["Subacute myeloid leukemia"],"term_type":"ORT"},{"nm":"Subareolar duct papillomatosis","n_c":["C4192"],"i_c":"8506/0","i_c_s":["Subareolar duct papillomatosis"],"term_type":"SY"},{"nm":"Subcutaneous panniculitis-like T-cell lymphoma","n_c":["C6918"],"i_c":"9708/3","i_c_s":["Subcutaneous panniculitis-like T-cell lymphoma"],"term_type":"PT"},{"nm":"Subependymal astrocytoma, NOS","n_c":"","i_c":"9383/1","i_c_s":["Subependymal astrocytoma, NOS"],"term_type":"SY"},{"nm":"Subependymal giant cell astrocytoma","n_c":["C3696"],"i_c":"9384/1","i_c_s":["Subependymal giant cell astrocytoma"],"term_type":"PT"},{"nm":"Subependymal glioma","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Subependymal glioma"],"term_type":"SY"},{"nm":"Subependymoma","n_c":["C3795"],"i_c":"9383/1","i_c_s":["Subependymoma"],"term_type":"PT"},{"nm":"Subepidermal nodular fibrosis","n_c":["C7159"],"i_c":"8832/0","i_c_s":["Subepidermal nodular fibrosis"],"term_type":"SY"},{"nm":"Superficial spreading adenocarcinoma","n_c":["C4125"],"i_c":"8143/3","i_c_s":["Superficial spreading adenocarcinoma"],"term_type":"PT"},{"nm":"Superficial spreading melanoma","n_c":["C204843"],"i_c":"8743/3","i_c_s":["Superficial spreading melanoma"],"term_type":"PT"},{"nm":"Superficial well differentiated liposarcoma","n_c":["C176980"],"i_c":"8850/1","i_c_s":["Superficial well differentiated liposarcoma"],"term_type":""},{"nm":"Supratentorial PNET","n_c":["C6968"],"i_c":"9473/3","i_c_s":["Supratentorial PNET"],"term_type":"RT"},{"nm":"Sweat gland adenocarcinoma","n_c":["C6938"],"i_c":"8400/3","i_c_s":["Sweat gland adenocarcinoma"],"term_type":"PT"},{"nm":"Sweat gland adenoma","n_c":["C7560"],"i_c":"8400/0","i_c_s":["Sweat gland adenoma"],"term_type":"PT"},{"nm":"Sweat gland carcinoma","n_c":["C6938"],"i_c":"8400/3","i_c_s":["Sweat gland carcinoma"],"term_type":"SY"},{"nm":"Sweat gland tumor, benign","n_c":["C4879"],"i_c":"8400/0","i_c_s":["Sweat gland tumor, benign"],"term_type":"SY"},{"nm":"Sweat gland tumor, malignant","n_c":["C4810"],"i_c":"8400/3","i_c_s":["Sweat gland tumor, malignant"],"term_type":"SY"},{"nm":"Sweat gland tumor, NOS","n_c":["C3398"],"i_c":"8400/1","i_c_s":["Sweat gland tumor, NOS"],"term_type":"PT"},{"nm":"Sympathetic paraganglioma","n_c":["C4216"],"i_c":"8681/1","i_c_s":["Sympathetic paraganglioma"],"term_type":"PT"},{"nm":"Sympathicoblastoma","n_c":"","i_c":"9500/3","i_c_s":["Sympathicoblastoma"],"term_type":"SY"},{"nm":"Symplastic leiomyoma","n_c":["C4257"],"i_c":"8893/0","i_c_s":["Symplastic leiomyoma"],"term_type":"SY"},{"nm":"Syncytial meningioma","n_c":["C4329"],"i_c":"9531/0","i_c_s":["Syncytial meningioma"],"term_type":"SY"},{"nm":"Synovial sarcoma, biphasic","n_c":["C4279"],"i_c":"9043/3","i_c_s":["Synovial sarcoma, biphasic"],"term_type":"PT"},{"nm":"Synovial sarcoma, epithelioid cell","n_c":["C4278"],"i_c":"9042/3","i_c_s":["Synovial sarcoma, epithelioid cell"],"term_type":"PT"},{"nm":"Synovial sarcoma, monophasic fibrous","n_c":["C4277"],"i_c":"9041/3","i_c_s":["Synovial sarcoma, monophasic fibrous"],"term_type":"SY"},{"nm":"Synovial sarcoma, NOS","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovial sarcoma, NOS"],"term_type":"PT"},{"nm":"Synovial sarcoma, spindle cell","n_c":["C4277"],"i_c":"9041/3","i_c_s":["Synovial sarcoma, spindle cell"],"term_type":"PT"},{"nm":"Synovioma, benign","n_c":["C3829"],"i_c":"9040/0","i_c_s":["Synovioma, benign"],"term_type":"PT"},{"nm":"Synovioma, malignant","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovioma, malignant"],"term_type":"SY"},{"nm":"Synovioma, NOS","n_c":["C3400"],"i_c":"9040/3","i_c_s":["Synovioma, NOS"],"term_type":"SY"},{"nm":"Syringadenoma, NOS","n_c":"","i_c":"8400/0","i_c_s":["Syringadenoma, NOS"],"term_type":"SY"},{"nm":"Syringocystadenoma papilliferum","n_c":["C4172"],"i_c":"8406/0","i_c_s":["Syringocystadenoma papilliferum"],"term_type":"SY"},{"nm":"Syringofibroadenoma","n_c":["C43356"],"i_c":"8392/0","i_c_s":["Syringofibroadenoma"],"term_type":"PT"},{"nm":"Syringoma, NOS","n_c":["C3761"],"i_c":"8407/0","i_c_s":["Syringoma, NOS"],"term_type":"PT"},{"nm":"Syringomatous carcinoma","n_c":["C7581"],"i_c":"8407/3","i_c_s":["Syringomatous carcinoma"],"term_type":"SY"},{"nm":"Systemic EBV positive T-cell lymphoproliferative disease of childhood","n_c":["C80374"],"i_c":"9724/3","i_c_s":["Systemic EBV positive T-cell lymphoproliferative disease of childhood"],"term_type":"PT"},{"nm":"Systemic light chain disease","n_c":["C7727"],"i_c":"9769/1","i_c_s":["Systemic light chain disease"],"term_type":"SY"},{"nm":"Systemic mastocytosis with AHNMD","n_c":["C9284"],"i_c":"9741/3","i_c_s":["Systemic mastocytosis with AHNMD"],"term_type":"RT"},{"nm":"Systemic mastocytosis with associated hematological clonal non-mast cell disorder","n_c":["C9284"],"i_c":"9741/3","i_c_s":["Systemic mastocytosis with associated hematological clonal non-mast cell disorder"],"term_type":"RT"},{"nm":"Systemic tissue mast cell disease","n_c":["C9235"],"i_c":"9741/3","i_c_s":["Systemic tissue mast cell disease"],"term_type":"SY"},{"nm":"T lymphoblastic leukemia/lymphoma","n_c":["C8694"],"i_c":"9837/3","i_c_s":["T lymphoblastic leukemia/lymphoma"],"term_type":"RT"},{"nm":"T-cell large granular lymphocytic leukemia","n_c":["C4664"],"i_c":"9831/3","i_c_s":["T-cell large granular lymphocytic leukemia"],"term_type":"PT"},{"nm":"T-cell large granular lymphocytosis","n_c":["C4664"],"i_c":"9831/3","i_c_s":["T-cell large granular lymphocytosis"],"term_type":"SY"},{"nm":"T-cell lymphoma, NOS","n_c":["C3466"],"i_c":"9702/3","i_c_s":["T-cell lymphoma, NOS"],"term_type":"SY"},{"nm":"T-cell rich large B-cell lymphoma","n_c":["C9496"],"i_c":"9680/3","i_c_s":["T-cell rich large B-cell lymphoma"],"term_type":"RT"},{"nm":"T-cell rich/histiocyte-rich large B-cell lymphoma","n_c":["C9496"],"i_c":"9688/3","i_c_s":["T-cell rich/histiocyte-rich large B-cell lymphoma"],"term_type":""},{"nm":"T-gamma lymphoproliferative disease","n_c":["C4664"],"i_c":"9768/1","i_c_s":["T-gamma lymphoproliferative disease"],"term_type":"PT"},{"nm":"T-zone lymphoma","n_c":["C7204"],"i_c":"9702/3","i_c_s":["T-zone lymphoma"],"term_type":"SY"},{"nm":"T/NK-cell lymphoma","n_c":["C4684"],"i_c":"9719/3","i_c_s":["T/NK-cell lymphoma"],"term_type":"SY"},{"nm":"Tanycytic ependymoma","n_c":["C6903"],"i_c":"9391/3","i_c_s":["Tanycytic ependymoma"],"term_type":"RT"},{"nm":"Telangiectatic osteosarcoma","n_c":["C3902"],"i_c":"9183/3","i_c_s":["Telangiectatic osteosarcoma"],"term_type":"PT"},{"nm":"Tenosynovial giant cell tumor","n_c":["C3402"],"i_c":"9252/0","i_c_s":["Tenosynovial giant cell tumor"],"term_type":"PT"},{"nm":"Teratoblastoma, malignant","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Teratoblastoma, malignant"],"term_type":"SY"},{"nm":"Teratocarcinoma","n_c":["C3756"],"i_c":"9081/3","i_c_s":["Teratocarcinoma"],"term_type":"PT"},{"nm":"Teratoid medulloepithelioma","n_c":["C66810"],"i_c":"9502/3","i_c_s":["Teratoid medulloepithelioma"],"term_type":"PT"},{"nm":"Teratoid medulloepithelioma, benign","n_c":["C66809"],"i_c":"9502/0","i_c_s":["Teratoid medulloepithelioma, benign"],"term_type":"PT"},{"nm":"Teratoma with malignant transformation","n_c":["C4289"],"i_c":"9084/3","i_c_s":["Teratoma with malignant transformation"],"term_type":"PT"},{"nm":"Teratoma, benign","n_c":["C67107","C9015"],"i_c":"9080/0","i_c_s":["Teratoma, benign"],"term_type":"PT"},{"nm":"Teratoma, differentiated","n_c":["C9015"],"i_c":"9080/0","i_c_s":["Teratoma, differentiated"],"term_type":"SY"},{"nm":"Teratoma, malignant, NOS","n_c":["C4286"],"i_c":"9080/3","i_c_s":["Teratoma, malignant, NOS"],"term_type":"PT"},{"nm":"Teratoma, NOS","n_c":["C3403"],"i_c":"9080/1","i_c_s":["Teratoma, NOS"],"term_type":"PT"},{"nm":"Terminal duct adenocarcinoma","n_c":"","i_c":"8525/3","i_c_s":["Terminal duct adenocarcinoma"],"term_type":"SY"},{"nm":"Testicular adenoma","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Testicular adenoma"],"term_type":"SY"},{"nm":"Testicular stromal tumor","n_c":"","i_c":"8590/1","i_c_s":["Testicular stromal tumor"],"term_type":"SY"},{"nm":"Theca cell tumor","n_c":["C3405"],"i_c":"8600/0","i_c_s":["Theca cell tumor"],"term_type":"SY"},{"nm":"Theca cell-granulosa cell tumor","n_c":["C66751"],"i_c":"8621/1","i_c_s":["Theca cell-granulosa cell tumor"],"term_type":"SY"},{"nm":"Thecoma, luteinized","n_c":["C4203"],"i_c":"8601/0","i_c_s":["Thecoma, luteinized"],"term_type":"PT"},{"nm":"Thecoma, malignant","n_c":["C6929"],"i_c":"8600/3","i_c_s":["Thecoma, malignant"],"term_type":"PT"},{"nm":"Thecoma, NOS","n_c":["C3405"],"i_c":"8600/0","i_c_s":["Thecoma, NOS"],"term_type":"PT"},{"nm":"Therapy related myeloid neoplasm","n_c":["C27912"],"i_c":"9920/3","i_c_s":["Therapy related myeloid neoplasm"],"term_type":"PT"},{"nm":"Therapy-related acute myeloid leukemia, alkylating agent related","n_c":["C27754"],"i_c":"9920/3","i_c_s":["Therapy-related acute myeloid leukemia, alkylating agent related"],"term_type":"RT"},{"nm":"Therapy-related acute myeloid leukemia, epipodophyllotoxin-related","n_c":["C27754"],"i_c":"9920/3","i_c_s":["Therapy-related acute myeloid leukemia, epipodophyllotoxin-related"],"term_type":"RT"},{"nm":"Therapy-related acute myeloid leukemia, NOS","n_c":["C8252"],"i_c":"9920/3","i_c_s":["Therapy-related acute myeloid leukemia, NOS"],"term_type":"SY"},{"nm":"Therapy-related myelodysplastic syndrome, alkylating agent related","n_c":["C7643"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, alkylating agent related"],"term_type":"SY"},{"nm":"Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related","n_c":["C7642"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related"],"term_type":"SY"},{"nm":"Therapy-related myelodysplastic syndrome, NOS","n_c":["C27722"],"i_c":"9987/3","i_c_s":["Therapy-related myelodysplastic syndrome, NOS"],"term_type":"PT"},{"nm":"Thymic carcinoma with adenoid cystic carcinoma-like features","n_c":"","i_c":"8200/3","i_c_s":["Thymic carcinoma with adenoid cystic carcinoma-like features"],"term_type":""},{"nm":"Thymic carcinoma, NOS","n_c":["C7569"],"i_c":"8586/3","i_c_s":["Thymic carcinoma, NOS"],"term_type":"PT"},{"nm":"Thymic large B-cell lymphoma","n_c":["C9280"],"i_c":"9679/3","i_c_s":["Thymic large B-cell lymphoma"],"term_type":"SY"},{"nm":"Thymoma, atypical, malignant","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, atypical, malignant"],"term_type":"SY"},{"nm":"Thymoma, atypical, NOS","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, atypical, NOS"],"term_type":"SY"},{"nm":"Thymoma, benign","n_c":["C66746"],"i_c":"8580/0","i_c_s":["Thymoma, benign"],"term_type":"PT"},{"nm":"Thymoma, cortical, malignant","n_c":["C6889"],"i_c":"8584/3","i_c_s":["Thymoma, cortical, malignant"],"term_type":"SY"},{"nm":"Thymoma, cortical, NOS","n_c":["C6888"],"i_c":"8584/1","i_c_s":["Thymoma, cortical, NOS"],"term_type":"SY"},{"nm":"Thymoma, epithelial, malignant","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, epithelial, malignant"],"term_type":"SY"},{"nm":"Thymoma, epithelial, NOS","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, epithelial, NOS"],"term_type":"SY"},{"nm":"Thymoma, lymphocyte-rich, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, lymphocyte-rich, malignant"],"term_type":"SY"},{"nm":"Thymoma, lymphocyte-rich, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, lymphocyte-rich, NOS"],"term_type":"SY"},{"nm":"Thymoma, lymphocytic, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, lymphocytic, malignant"],"term_type":"SY"},{"nm":"Thymoma, lymphocytic, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, lymphocytic, NOS"],"term_type":"SY"},{"nm":"Thymoma, malignant, NOS","n_c":["C7612"],"i_c":"8580/3","i_c_s":["Thymoma, malignant, NOS"],"term_type":"PT"},{"nm":"Thymoma, medullary, malignant","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, medullary, malignant"],"term_type":"SY"},{"nm":"Thymoma, medullary, NOS","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, medullary, NOS"],"term_type":"SY"},{"nm":"Thymoma, mixed type, malignant","n_c":["C6886"],"i_c":"8582/3","i_c_s":["Thymoma, mixed type, malignant"],"term_type":"SY"},{"nm":"Thymoma, mixed type, NOS","n_c":["C6885"],"i_c":"8582/1","i_c_s":["Thymoma, mixed type, NOS"],"term_type":"SY"},{"nm":"Thymoma, NOS","n_c":["C3411"],"i_c":"8580/1","i_c_s":["Thymoma, NOS"],"term_type":"PT"},{"nm":"Thymoma, organoid, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, organoid, malignant"],"term_type":"SY"},{"nm":"Thymoma, organoid, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, organoid, NOS"],"term_type":"SY"},{"nm":"Thymoma, predominantly cortical, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, predominantly cortical, malignant"],"term_type":"SY"},{"nm":"Thymoma, predominantly cortical, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, predominantly cortical, NOS"],"term_type":"SY"},{"nm":"Thymoma, spindle cell, malignant","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, spindle cell, malignant"],"term_type":"SY"},{"nm":"Thymoma, spindle cell, NOS","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, spindle cell, NOS"],"term_type":"SY"},{"nm":"Thymoma, type A, malignant","n_c":["C7999"],"i_c":"8581/3","i_c_s":["Thymoma, type A, malignant"],"term_type":"PT"},{"nm":"Thymoma, type A, NOS","n_c":["C6454"],"i_c":"8581/1","i_c_s":["Thymoma, type A, NOS"],"term_type":"PT"},{"nm":"Thymoma, type AB, malignant","n_c":["C6886"],"i_c":"8582/3","i_c_s":["Thymoma, type AB, malignant"],"term_type":"PT"},{"nm":"Thymoma, type AB, NOS","n_c":["C6885"],"i_c":"8582/1","i_c_s":["Thymoma, type AB, NOS"],"term_type":"PT"},{"nm":"Thymoma, type B1, malignant","n_c":["C7996"],"i_c":"8583/3","i_c_s":["Thymoma, type B1, malignant"],"term_type":"PT"},{"nm":"Thymoma, type B1, NOS","n_c":["C6887"],"i_c":"8583/1","i_c_s":["Thymoma, type B1, NOS"],"term_type":"PT"},{"nm":"Thymoma, type B2, malignant","n_c":["C6889"],"i_c":"8584/3","i_c_s":["Thymoma, type B2, malignant"],"term_type":"PT"},{"nm":"Thymoma, type B2, NOS","n_c":["C6888"],"i_c":"8584/1","i_c_s":["Thymoma, type B2, NOS"],"term_type":"PT"},{"nm":"Thymoma, type B3, malignant","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Thymoma, type B3, malignant"],"term_type":"PT"},{"nm":"Thymoma, type B3, NOS","n_c":["C7997"],"i_c":"8585/1","i_c_s":["Thymoma, type B3, NOS"],"term_type":"PT"},{"nm":"Thymoma, type C","n_c":["C7569"],"i_c":"8586/3","i_c_s":["Thymoma, type C"],"term_type":"SY"},{"nm":"Tibial adamantinoma","n_c":["C8461"],"i_c":"9261/3","i_c_s":["Tibial adamantinoma"],"term_type":"SY"},{"nm":"Trabecular adenocarcinoma","n_c":["C4068"],"i_c":"8190/3","i_c_s":["Trabecular adenocarcinoma"],"term_type":"PT"},{"nm":"Trabecular adenoma","n_c":["C3688"],"i_c":"8190/0","i_c_s":["Trabecular adenoma"],"term_type":"PT"},{"nm":"Trabecular carcinoma","n_c":["C4068"],"i_c":"8190/3","i_c_s":["Trabecular carcinoma"],"term_type":"SY"},{"nm":"Traditional serrated adenoma","n_c":["C38458"],"i_c":"8213/0","i_c_s":["Traditional serrated adenoma"],"term_type":"SY"},{"nm":"Traditional sessile serrated adenoma","n_c":"","i_c":"8213/0","i_c_s":["Traditional sessile serrated adenoma"],"term_type":"RT"},{"nm":"Transient abnormal myelopoiesis","n_c":["C82339"],"i_c":"9898/1","i_c_s":["Transient abnormal myelopoiesis"],"term_type":"PT"},{"nm":"Transitional carcinoma","n_c":["C2930"],"i_c":"8120/3","i_c_s":["Transitional carcinoma"],"term_type":"RT"},{"nm":"Transitional cell carcinoma","n_c":["C2930"],"i_c":"8120/3","i_c_s":["Transitional cell carcinoma"],"term_type":""},{"nm":"Transitional cell carcinoma in situ","n_c":["C4116"],"i_c":"8120/2","i_c_s":["Transitional cell carcinoma in situ"],"term_type":"PT"},{"nm":"Transitional cell carcinoma, micropapillary","n_c":["C65182"],"i_c":"8131/3","i_c_s":["Transitional cell carcinoma, micropapillary"],"term_type":"PT"},{"nm":"Transitional cell carcinoma, sarcomatoid","n_c":["C4120"],"i_c":"8122/3","i_c_s":["Transitional cell carcinoma, sarcomatoid"],"term_type":"SY"},{"nm":"Transitional cell carcinoma, spindle cell","n_c":["C4120"],"i_c":"8122/3","i_c_s":["Transitional cell carcinoma, spindle cell"],"term_type":"PT"},{"nm":"Transitional cell papilloma, benign","n_c":["C4115"],"i_c":"8120/0","i_c_s":["Transitional cell papilloma, benign"],"term_type":"PT"},{"nm":"Transitional cell papilloma, inverted, benign","n_c":["C4118"],"i_c":"8121/0","i_c_s":["Transitional cell papilloma, inverted, benign"],"term_type":"RT"},{"nm":"Transitional cell papilloma, inverted, NOS","n_c":["C4118"],"i_c":"8121/1","i_c_s":["Transitional cell papilloma, inverted, NOS"],"term_type":"PT"},{"nm":"Transitional cell papilloma, NOS","n_c":["C4115"],"i_c":"8120/1","i_c_s":["Transitional cell papilloma, NOS"],"term_type":"SY"},{"nm":"Transitional meningioma","n_c":["C4333"],"i_c":"9537/0","i_c_s":["Transitional meningioma"],"term_type":"PT"},{"nm":"Transitional papilloma","n_c":["C4115"],"i_c":"8120/0","i_c_s":["Transitional papilloma"],"term_type":"SY"},{"nm":"Transitional papilloma, inverted, benign","n_c":["C4118"],"i_c":"8121/0","i_c_s":["Transitional papilloma, inverted, benign"],"term_type":"RT"},{"nm":"Transitional papilloma, inverted, NOS","n_c":["C4118"],"i_c":"8121/1","i_c_s":["Transitional papilloma, inverted, NOS"],"term_type":"SY"},{"nm":"Transitional pineal tumor","n_c":"","i_c":"9362/3","i_c_s":["Transitional pineal tumor"],"term_type":"RT"},{"nm":"Trichilemmal carcinoma","n_c":["C43326"],"i_c":"8102/3","i_c_s":["Trichilemmal carcinoma"],"term_type":"SY"},{"nm":"Trichilemmocarcinoma","n_c":["C43326"],"i_c":"8102/3","i_c_s":["Trichilemmocarcinoma"],"term_type":"PT"},{"nm":"Trichilemmoma","n_c":["C4113"],"i_c":"8102/0","i_c_s":["Trichilemmoma"],"term_type":"PT"},{"nm":"Trichodiscoma","n_c":["C206079"],"i_c":"8391/0","i_c_s":["Trichodiscoma"],"term_type":"SY"},{"nm":"Trichoepithelioma","n_c":["C27132"],"i_c":"8100/0","i_c_s":["Trichoepithelioma"],"term_type":"PT"},{"nm":"Trichofolliculoma","n_c":["C4112"],"i_c":"8101/0","i_c_s":["Trichofolliculoma"],"term_type":"PT"},{"nm":"Triton tumor, malignant","n_c":["C4335"],"i_c":"9561/3","i_c_s":["Triton tumor, malignant"],"term_type":"SY"},{"nm":"Trophoblastic tumor, epithelioid","n_c":["C6900"],"i_c":"9105/3","i_c_s":["Trophoblastic tumor, epithelioid"],"term_type":"PT"},{"nm":"True histiocytic lymphoma","n_c":["C35382"],"i_c":"9755/3","i_c_s":["True histiocytic lymphoma"],"term_type":"RT"},{"nm":"Tubular adenocarcinoma","n_c":["C65192"],"i_c":"8211/3","i_c_s":["Tubular adenocarcinoma"],"term_type":"PT"},{"nm":"Tubular adenoma, NOS","n_c":["C4133"],"i_c":"8211/0","i_c_s":["Tubular adenoma, NOS"],"term_type":"PT"},{"nm":"Tubular androblastoma with lipid storage","n_c":"","i_c":"8641/0","i_c_s":["Tubular androblastoma with lipid storage"],"term_type":"SY"},{"nm":"Tubular androblastoma, NOS","n_c":["C39976"],"i_c":"8640/1","i_c_s":["Tubular androblastoma, NOS"],"term_type":"SY"},{"nm":"Tubular carcinoid","n_c":["C43565"],"i_c":"8245/1","i_c_s":["Tubular carcinoid"],"term_type":"PT"},{"nm":"Tubular carcinoma","n_c":["C65192"],"i_c":"8211/3","i_c_s":["Tubular carcinoma"],"term_type":"SY"},{"nm":"Tubulo-papillary adenoma","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Tubulo-papillary adenoma"],"term_type":"SY"},{"nm":"Tubulocystic renal cell carcinoma","n_c":["C126303"],"i_c":"8316/3","i_c_s":["Tubulocystic renal cell carcinoma"],"term_type":""},{"nm":"Tubulolobular carcinoma","n_c":["C97053"],"i_c":"8520/3","i_c_s":["Tubulolobular carcinoma"],"term_type":""},{"nm":"Tubulopapillary adenocarcinoma","n_c":"","i_c":"8263/3","i_c_s":["Tubulopapillary adenocarcinoma"],"term_type":"SY"},{"nm":"Tubulovillous adenoma, NOS","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Tubulovillous adenoma, NOS"],"term_type":"PT"},{"nm":"Tumor cells, benign","n_c":["C36122"],"i_c":"8001/0","i_c_s":["Tumor cells, benign"],"term_type":"PT"},{"nm":"Tumor cells, malignant","n_c":["C12917"],"i_c":"8001/3","i_c_s":["Tumor cells, malignant"],"term_type":"PT"},{"nm":"Tumor cells, NOS","n_c":["C12922"],"i_c":"8001/1","i_c_s":["Tumor cells, NOS"],"term_type":"SY"},{"nm":"Tumor cells, uncertain whether benign or malignant","n_c":["C12922"],"i_c":"8001/1","i_c_s":["Tumor cells, uncertain whether benign or malignant"],"term_type":"PT"},{"nm":"Tumor embolus","n_c":["C3005"],"i_c":"8000/6","i_c_s":["Tumor embolus"],"term_type":"SY"},{"nm":"Tumor, benign","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Tumor, benign"],"term_type":"SY"},{"nm":"Tumor, malignant, NOS","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Tumor, malignant, NOS"],"term_type":"SY"},{"nm":"Tumor, metastatic","n_c":["C3261"],"i_c":"8000/6","i_c_s":["Tumor, metastatic"],"term_type":"SY"},{"nm":"Tumor, NOS","n_c":["C3262"],"i_c":"8000/1","i_c_s":["Tumor, NOS"],"term_type":"SY"},{"nm":"Tumor, secondary","n_c":["C36255"],"i_c":"8000/6","i_c_s":["Tumor, secondary"],"term_type":"SY"},{"nm":"Tumorlet, benign","n_c":["C65162"],"i_c":"8040/0","i_c_s":["Tumorlet, benign"],"term_type":"PT"},{"nm":"Tumorlet, NOS","n_c":["C65162"],"i_c":"8040/1","i_c_s":["Tumorlet, NOS"],"term_type":"PT"},{"nm":"Turban tumor","n_c":["C43352"],"i_c":"8200/0","i_c_s":["Turban tumor"],"term_type":"RT"},{"nm":"Typical carcinoid","n_c":"","i_c":"8240/3","i_c_s":["Typical carcinoid"],"term_type":"RT"},{"nm":"Unclassified tumor, benign","n_c":["C3677"],"i_c":"8000/0","i_c_s":["Unclassified tumor, benign"],"term_type":"SY"},{"nm":"Unclassified tumor, borderline malignancy","n_c":["C65157"],"i_c":"8000/1","i_c_s":["Unclassified tumor, borderline malignancy"],"term_type":"SY"},{"nm":"Unclassified tumor, malignant","n_c":["C9305"],"i_c":"8000/3","i_c_s":["Unclassified tumor, malignant"],"term_type":"SY"},{"nm":"Unclassified tumor, malignant, uncertain whether primary or metastatic","n_c":["C65153"],"i_c":"8000/9","i_c_s":["Unclassified tumor, malignant, uncertain whether primary or metastatic"],"term_type":"SY"},{"nm":"Unclassified tumor, uncertain whether benign or malignant","n_c":["C65157"],"i_c":"8000/1","i_c_s":["Unclassified tumor, uncertain whether benign or malignant"],"term_type":"SY"},{"nm":"Undifferentiated epithelioid sarcoma","n_c":["C121802"],"i_c":"8804/3","i_c_s":["Undifferentiated epithelioid sarcoma"],"term_type":""},{"nm":"Undifferentiated high-grade pleomorphic sarcoma","n_c":["C8563"],"i_c":"8830/3","i_c_s":["Undifferentiated high-grade pleomorphic sarcoma"],"term_type":""},{"nm":"Undifferentiated leukaemia","n_c":["C9300"],"i_c":"9801/3","i_c_s":["Undifferentiated leukaemia"],"term_type":""},{"nm":"Undifferentiated pleomorphic sarcoma","n_c":["C4247"],"i_c":"8802/3","i_c_s":["Undifferentiated pleomorphic sarcoma"],"term_type":""},{"nm":"Undifferentiated round cell sarcoma","n_c":["C121799"],"i_c":"8803/3","i_c_s":["Undifferentiated round cell sarcoma"],"term_type":""},{"nm":"Undifferentiated sarcoma","n_c":["C121793"],"i_c":"8805/3","i_c_s":["Undifferentiated sarcoma"],"term_type":"PT"},{"nm":"Undifferentiated spindle cell sarcoma","n_c":["C121797"],"i_c":"8801/3","i_c_s":["Undifferentiated spindle cell sarcoma"],"term_type":""},{"nm":"Undifferentiated uterine sarcoma","n_c":["C8972"],"i_c":"8805/3","i_c_s":["Undifferentiated uterine sarcoma"],"term_type":""},{"nm":"Urachal carcinoma","n_c":["C39842"],"i_c":"8010/3","i_c_s":["Urachal carcinoma"],"term_type":""},{"nm":"Urothelial carcinoma in situ","n_c":["C4116"],"i_c":"8120/2","i_c_s":["Urothelial carcinoma in situ"],"term_type":"SY"},{"nm":"Urothelial carcinoma with divergent differentiation","n_c":"","i_c":"8120/3","i_c_s":["Urothelial carcinoma with divergent differentiation"],"term_type":""},{"nm":"Urothelial carcinoma with squamous differentiation","n_c":["C191681"],"i_c":"8120/3","i_c_s":["Urothelial carcinoma with squamous differentiation"],"term_type":""},{"nm":"Urothelial carcinoma with trophoblastic differentiation","n_c":["C191682"],"i_c":"8120/3","i_c_s":["Urothelial carcinoma with trophoblastic differentiation"],"term_type":""},{"nm":"Urothelial carcinoma, NOS","n_c":["C4030"],"i_c":"8120/3","i_c_s":["Urothelial carcinoma, NOS"],"term_type":"SY"},{"nm":"Urothelial papilloma, NOS","n_c":["C3842"],"i_c":"8120/1","i_c_s":["Urothelial papilloma, NOS"],"term_type":"PT"},{"nm":"Urticaria pigmentosa","n_c":["C3433"],"i_c":"9740/1","i_c_s":["Urticaria pigmentosa"],"term_type":"RT"},{"nm":"Vaginal intraepithelial neoplasia, grade III","n_c":["C7855"],"i_c":"8077/2","i_c_s":["Vaginal intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"VAIN III","n_c":["C89476"],"i_c":"8077/2","i_c_s":["VAIN III"],"term_type":"SY"},{"nm":"Vascular leiomyoma","n_c":["C3747"],"i_c":"8894/0","i_c_s":["Vascular leiomyoma"],"term_type":"SY"},{"nm":"Venous hemangioma","n_c":["C4296"],"i_c":"9122/0","i_c_s":["Venous hemangioma"],"term_type":"PT"},{"nm":"Verrucous carcinoma, NOS","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous carcinoma, NOS"],"term_type":"PT"},{"nm":"Verrucous epidermoid carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous epidermoid carcinoma"],"term_type":"SY"},{"nm":"Verrucous keratotic hemangioma","n_c":["C4299"],"i_c":"9142/0","i_c_s":["Verrucous keratotic hemangioma"],"term_type":"PT"},{"nm":"Verrucous papilloma","n_c":["C4101"],"i_c":"8051/0","i_c_s":["Verrucous papilloma"],"term_type":"PT"},{"nm":"Verrucous squamous cell carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Verrucous squamous cell carcinoma"],"term_type":"SY"},{"nm":"Villoglandular adenoma","n_c":["C4143"],"i_c":"8263/0","i_c_s":["Villoglandular adenoma"],"term_type":"SY"},{"nm":"Villoglandular carcinoma","n_c":["C40208"],"i_c":"8263/3","i_c_s":["Villoglandular carcinoma"],"term_type":""},{"nm":"Villous adenocarcinoma","n_c":["C4142"],"i_c":"8262/3","i_c_s":["Villous adenocarcinoma"],"term_type":"PT"},{"nm":"Villous adenoma, NOS","n_c":["C7399"],"i_c":"8261/0","i_c_s":["Villous adenoma, NOS"],"term_type":"PT"},{"nm":"Villous papilloma","n_c":"","i_c":"8261/0","i_c_s":["Villous papilloma"],"term_type":"RT"},{"nm":"VIN III","n_c":["C4522"],"i_c":"8077/2","i_c_s":["VIN III"],"term_type":"SY"},{"nm":"Vipoma, malignant","n_c":["C65189"],"i_c":"8155/3","i_c_s":["Vipoma, malignant"],"term_type":"PT"},{"nm":"Vipoma, NOS","n_c":["C26749"],"i_c":"8155/1","i_c_s":["Vipoma, NOS"],"term_type":"PT"},{"nm":"Von Recklinghausen disease","n_c":["C3273"],"i_c":"9540/1","i_c_s":["Von Recklinghausen disease"],"term_type":"SY"},{"nm":"Vulvar intraepithelial neoplasia, grade III","n_c":["C4522"],"i_c":"8077/2","i_c_s":["Vulvar intraepithelial neoplasia, grade III"],"term_type":"RT"},{"nm":"Waldenstrom macroglobulinemia","n_c":["C80307"],"i_c":"9761/3","i_c_s":["Waldenstrom macroglobulinemia"],"term_type":"PT"},{"nm":"Warthin tumor","n_c":["C2854"],"i_c":"8561/0","i_c_s":["Warthin tumor"],"term_type":"SY"},{"nm":"Warty carcinoma","n_c":["C3781"],"i_c":"8051/3","i_c_s":["Warty carcinoma"],"term_type":"SY"},{"nm":"Water-clear cell adenocarcinoma","n_c":["C4156"],"i_c":"8322/3","i_c_s":["Water-clear cell adenocarcinoma"],"term_type":"PT"},{"nm":"Water-clear cell adenoma","n_c":["C4155"],"i_c":"8322/0","i_c_s":["Water-clear cell adenoma"],"term_type":"PT"},{"nm":"Water-clear cell carcinoma","n_c":["C4156"],"i_c":"8322/3","i_c_s":["Water-clear cell carcinoma"],"term_type":"SY"},{"nm":"Well differentiated liposarcoma of superficial soft tissue","n_c":["C176980"],"i_c":"8850/1","i_c_s":["Well differentiated liposarcoma of superficial soft tissue"],"term_type":"SY"},{"nm":"Well differentiated papillary mesothelioma, benign","n_c":["C7635"],"i_c":"9052/0","i_c_s":["Well differentiated papillary mesothelioma, benign"],"term_type":"RT"},{"nm":"Well differentiated thymic carcinoma","n_c":["C7997"],"i_c":"8585/3","i_c_s":["Well differentiated thymic carcinoma"],"term_type":"SY"},{"nm":"Wilms tumor","n_c":["C3267"],"i_c":"8960/3","i_c_s":["Wilms tumor"],"term_type":"SY"},{"nm":"Wolffian duct adenoma","n_c":["C40141"],"i_c":"9110/0","i_c_s":["Wolffian duct adenoma"],"term_type":"SY"},{"nm":"Wolffian duct carcinoma","n_c":["C4072"],"i_c":"9110/3","i_c_s":["Wolffian duct carcinoma"],"term_type":"SY"},{"nm":"Wolffian duct tumor","n_c":["C40141"],"i_c":"9110/1","i_c_s":["Wolffian duct tumor"],"term_type":"SY"},{"nm":"Xanthofibroma","n_c":["C3739"],"i_c":"8830/0","i_c_s":["Xanthofibroma"],"term_type":"SY"},{"nm":"Yolk sac tumor","n_c":["C3011"],"i_c":"9071/3","i_c_s":["Yolk sac tumor"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast implant-associated anaplastic large cell lymphoma","n_c":["C139012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indolent T-cell lymphoproliferative disorder of gastrointestinal tract","n_c":["C139021"],"i_c":"9702/1","i_c_s":["Indolent T-cell lymphoproliferative disorder of gastrointestinal tract"],"term_type":"PT"},{"nm":"Diffuse Pediatric-type High Grade Glioma","n_c":["C185467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse intrinsic pontine glioma, H3 K27M-mutant","n_c":["C94764"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.primary_gleason_grade":[{"nm":"Pattern 1","n_c":["C28085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 2","n_c":["C28086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 3","n_c":["C28087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 4","n_c":["C28088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 5","n_c":["C28089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.prior_malignancy":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.prior_treatment":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.progression_or_recurrence":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.residual_disease":[{"nm":"R0","n_c":["C139578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C139579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C139580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RX","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.satellite_nodule_present":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.secondary_gleason_grade":[{"nm":"Pattern 1","n_c":["C28085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 2","n_c":["C28086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 3","n_c":["C28087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 4","n_c":["C28088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pattern 5","n_c":["C28089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.site_of_resection_or_biopsy":[{"nm":"Abdomen, NOS","n_c":["C12664"],"i_c":"C76.2","i_c_s":["Abdomen, NOS"],"term_type":"PT"},{"nm":"Abdominal esophagus","n_c":["C12252"],"i_c":"C15.2","i_c_s":["Abdominal esophagus"],"term_type":"PT"},{"nm":"Accessory sinus, NOS","n_c":["C12763"],"i_c":"C31.9","i_c_s":["Accessory sinus, NOS"],"term_type":"PT"},{"nm":"Acoustic nerve","n_c":["C12697"],"i_c":"C72.4","i_c_s":["Acoustic nerve"],"term_type":"PT"},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"C74.9","i_c_s":["Adrenal gland, NOS"],"term_type":"PT"},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"C24.1","i_c_s":["Ampulla of Vater"],"term_type":"PT"},{"nm":"Anal canal","n_c":["C12375"],"i_c":"C21.1","i_c_s":["Anal canal"],"term_type":"PT"},{"nm":"Anterior 2/3 of tongue, NOS","n_c":"","i_c":"C02.3","i_c_s":["Anterior 2/3 of tongue, NOS"],"term_type":"PT"},{"nm":"Anterior floor of mouth","n_c":"","i_c":"C04.0","i_c_s":["Anterior floor of mouth"],"term_type":"PT"},{"nm":"Anterior mediastinum","n_c":["C32098"],"i_c":"C38.1","i_c_s":["Anterior mediastinum"],"term_type":"PT"},{"nm":"Anterior surface of epiglottis","n_c":["C12238"],"i_c":"C10.1","i_c_s":["Anterior surface of epiglottis"],"term_type":"PT"},{"nm":"Anterior wall of bladder","n_c":["C12334"],"i_c":"C67.3","i_c_s":["Anterior wall of bladder"],"term_type":"PT"},{"nm":"Anterior wall of nasopharynx","n_c":["C12245"],"i_c":"C11.3","i_c_s":["Anterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"C21.0","i_c_s":["Anus, NOS"],"term_type":"PT"},{"nm":"Aortic body and other paraganglia","n_c":"","i_c":"C75.5","i_c_s":["Aortic body and other paraganglia"],"term_type":"PT"},{"nm":"Appendix","n_c":["C12380"],"i_c":"C18.1","i_c_s":["Appendix"],"term_type":"PT"},{"nm":"Ascending colon","n_c":["C12265"],"i_c":"C18.2","i_c_s":["Ascending colon"],"term_type":"PT"},{"nm":"Autonomic nervous system, NOS","n_c":["C12673"],"i_c":"C47.9","i_c_s":["Autonomic nervous system, NOS"],"term_type":"PT"},{"nm":"Axillary tail of breast","n_c":["C12305"],"i_c":"C50.6","i_c_s":["Axillary tail of breast"],"term_type":"PT"},{"nm":"Base of tongue, NOS","n_c":["C12228"],"i_c":"C01.9","i_c_s":["Base of tongue, NOS"],"term_type":"PT"},{"nm":"Biliary tract, NOS","n_c":["C12678"],"i_c":"C24.9","i_c_s":["Biliary tract, NOS"],"term_type":"PT"},{"nm":"Bladder neck","n_c":["C12336"],"i_c":"C67.5","i_c_s":["Bladder neck"],"term_type":"PT"},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"C67.9","i_c_s":["Bladder, NOS"],"term_type":"PT"},{"nm":"Blood","n_c":["C12434"],"i_c":"C42.0","i_c_s":["Blood"],"term_type":"PT"},{"nm":"Body of pancreas","n_c":["C12270"],"i_c":"C25.1","i_c_s":["Body of pancreas"],"term_type":"PT"},{"nm":"Body of penis","n_c":["C12325"],"i_c":"C60.2","i_c_s":["Body of penis"],"term_type":"PT"},{"nm":"Body of stomach","n_c":["C12258"],"i_c":"C16.2","i_c_s":["Body of stomach"],"term_type":"PT"},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"C42.1","i_c_s":["Bone marrow"],"term_type":"PT"},{"nm":"Bone of limb, NOS","n_c":["C32223"],"i_c":"C40.9","i_c_s":["Bone of limb, NOS"],"term_type":"PT"},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"C41.9","i_c_s":["Bone, NOS"],"term_type":"PT"},{"nm":"Bones of skull and face and associated joints","n_c":"","i_c":"C41.0","i_c_s":["Bones of skull and face and associated joints"],"term_type":"PT"},{"nm":"Border of tongue","n_c":"","i_c":"C02.1","i_c_s":["Border of tongue"],"term_type":"PT"},{"nm":"Brain stem","n_c":["C12441"],"i_c":"C71.7","i_c_s":["Brain stem"],"term_type":"PT"},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"C71.9","i_c_s":["Brain, NOS"],"term_type":"PT"},{"nm":"Branchial cleft","n_c":["C104813"],"i_c":"C10.4","i_c_s":["Branchial cleft"],"term_type":"PT"},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"C50.9","i_c_s":["Breast, NOS"],"term_type":"PT"},{"nm":"Broad ligament","n_c":["C12318"],"i_c":"C57.1","i_c_s":["Broad ligament"],"term_type":"PT"},{"nm":"Cardia, NOS","n_c":["C12256"],"i_c":"C16.0","i_c_s":["Cardia, NOS"],"term_type":"PT"},{"nm":"Carotid body","n_c":["C66852"],"i_c":"C75.4","i_c_s":["Carotid body"],"term_type":"PT"},{"nm":"Cauda equina","n_c":["C12689"],"i_c":"C72.1","i_c_s":["Cauda equina"],"term_type":"PT"},{"nm":"Cecum","n_c":["C12381"],"i_c":"C18.0","i_c_s":["Cecum"],"term_type":"PT"},{"nm":"Central portion of breast","n_c":["C12300"],"i_c":"C50.1","i_c_s":["Central portion of breast"],"term_type":"PT"},{"nm":"Cerebellum, NOS","n_c":["C12445"],"i_c":"C71.6","i_c_s":["Cerebellum, NOS"],"term_type":"PT"},{"nm":"Cerebral meninges","n_c":["C12349"],"i_c":"C70.0","i_c_s":["Cerebral meninges"],"term_type":"PT"},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"C71.0","i_c_s":["Cerebrum"],"term_type":"PT"},{"nm":"Cervical esophagus","n_c":["C12250"],"i_c":"C15.0","i_c_s":["Cervical esophagus"],"term_type":"PT"},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"C53.9","i_c_s":["Cervix uteri"],"term_type":"PT"},{"nm":"Cheek mucosa","n_c":["C12505"],"i_c":"C06.0","i_c_s":["Cheek mucosa"],"term_type":"PT"},{"nm":"Choroid","n_c":["C12344"],"i_c":"C69.3","i_c_s":["Choroid"],"term_type":"PT"},{"nm":"Ciliary body","n_c":["C12345"],"i_c":"C69.4","i_c_s":["Ciliary body"],"term_type":"PT"},{"nm":"Clitoris","n_c":["C12308"],"i_c":"C51.2","i_c_s":["Clitoris"],"term_type":"PT"},{"nm":"Cloacogenic zone","n_c":["C32072"],"i_c":"C21.2","i_c_s":["Cloacogenic zone"],"term_type":"PT"},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"C18.9","i_c_s":["Colon, NOS"],"term_type":"PT"},{"nm":"Commissure of lip","n_c":["C12227"],"i_c":"C00.6","i_c_s":["Commissure of lip"],"term_type":"PT"},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"C69.0","i_c_s":["Conjunctiva"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of abdomen","n_c":"","i_c":"C49.4","i_c_s":["Connective, subcutaneous and other soft tissues of abdomen"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of head, face, and neck","n_c":"","i_c":"C49.0","i_c_s":["Connective, subcutaneous and other soft tissues of head, face, and neck"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of lower limb and hip","n_c":"","i_c":"C49.2","i_c_s":["Connective, subcutaneous and other soft tissues of lower limb and hip"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of pelvis","n_c":"","i_c":"C49.5","i_c_s":["Connective, subcutaneous and other soft tissues of pelvis"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of thorax","n_c":"","i_c":"C49.3","i_c_s":["Connective, subcutaneous and other soft tissues of thorax"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of trunk, NOS","n_c":"","i_c":"C49.6","i_c_s":["Connective, subcutaneous and other soft tissues of trunk, NOS"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of upper limb and shoulder","n_c":"","i_c":"C49.1","i_c_s":["Connective, subcutaneous and other soft tissues of upper limb and shoulder"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues, NOS","n_c":["C12964"],"i_c":"C49.9","i_c_s":["Connective, subcutaneous and other soft tissues, NOS"],"term_type":"PT"},{"nm":"Cornea, NOS","n_c":["C12342"],"i_c":"C69.1","i_c_s":["Cornea, NOS"],"term_type":"PT"},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"C54.9","i_c_s":["Corpus uteri"],"term_type":"PT"},{"nm":"Cortex of adrenal gland","n_c":["C12396"],"i_c":"C74.0","i_c_s":["Cortex of adrenal gland"],"term_type":"PT"},{"nm":"Cranial nerve, NOS","n_c":["C12700"],"i_c":"C72.5","i_c_s":["Cranial nerve, NOS"],"term_type":"PT"},{"nm":"Craniopharyngeal duct","n_c":["C12357"],"i_c":"C75.2","i_c_s":["Craniopharyngeal duct"],"term_type":"PT"},{"nm":"Descended testis","n_c":"","i_c":"C62.1","i_c_s":["Descended testis"],"term_type":"PT"},{"nm":"Descending colon","n_c":["C12268"],"i_c":"C18.6","i_c_s":["Descending colon"],"term_type":"PT"},{"nm":"Dome of bladder","n_c":["C12332"],"i_c":"C67.1","i_c_s":["Dome of bladder"],"term_type":"PT"},{"nm":"Dorsal surface of tongue, NOS","n_c":"","i_c":"C02.0","i_c_s":["Dorsal surface of tongue, NOS"],"term_type":"PT"},{"nm":"Duodenum","n_c":["C12263"],"i_c":"C17.0","i_c_s":["Duodenum"],"term_type":"PT"},{"nm":"Endocervix","n_c":["C12309"],"i_c":"C53.0","i_c_s":["Endocervix"],"term_type":"PT"},{"nm":"Endocrine gland, NOS","n_c":["C12704"],"i_c":"C75.9","i_c_s":["Endocrine gland, NOS"],"term_type":"PT"},{"nm":"Endometrium","n_c":["C12313"],"i_c":"C54.1","i_c_s":["Endometrium"],"term_type":"PT"},{"nm":"Epididymis","n_c":["C12328"],"i_c":"C63.0","i_c_s":["Epididymis"],"term_type":"PT"},{"nm":"Esophagus, NOS","n_c":["C12389"],"i_c":"C15.9","i_c_s":["Esophagus, NOS"],"term_type":"PT"},{"nm":"Ethmoid sinus","n_c":["C12276"],"i_c":"C31.1","i_c_s":["Ethmoid sinus"],"term_type":"PT"},{"nm":"Exocervix","n_c":["C12310"],"i_c":"C53.1","i_c_s":["Exocervix"],"term_type":"PT"},{"nm":"External ear","n_c":["C12292"],"i_c":"C44.2","i_c_s":["External ear"],"term_type":"PT"},{"nm":"External lip, NOS","n_c":["C12223"],"i_c":"C00.2","i_c_s":["External lip, NOS"],"term_type":"PT"},{"nm":"External lower lip","n_c":["C12222"],"i_c":"C00.1","i_c_s":["External lower lip"],"term_type":"PT"},{"nm":"External upper lip","n_c":["C12221"],"i_c":"C00.0","i_c_s":["External upper lip"],"term_type":"PT"},{"nm":"Extrahepatic bile duct","n_c":["C32573"],"i_c":"C24.0","i_c_s":["Extrahepatic bile duct"],"term_type":"PT"},{"nm":"Eye, NOS","n_c":["C12401"],"i_c":"C69.9","i_c_s":["Eye, NOS"],"term_type":"PT"},{"nm":"Eyelid","n_c":["C12713"],"i_c":"C44.1","i_c_s":["Eyelid"],"term_type":"PT"},{"nm":"Fallopian tube","n_c":["C12403"],"i_c":"C57.0","i_c_s":["Fallopian tube"],"term_type":"PT"},{"nm":"Female genital tract, NOS","n_c":["C61600"],"i_c":"C57.9","i_c_s":["Female genital tract, NOS"],"term_type":"PT"},{"nm":"Floor of mouth, NOS","n_c":["C54187"],"i_c":"C04.9","i_c_s":["Floor of mouth, NOS"],"term_type":"PT"},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"C71.1","i_c_s":["Frontal lobe"],"term_type":"PT"},{"nm":"Frontal sinus","n_c":["C12277"],"i_c":"C31.2","i_c_s":["Frontal sinus"],"term_type":"PT"},{"nm":"Fundus of stomach","n_c":["C12257"],"i_c":"C16.1","i_c_s":["Fundus of stomach"],"term_type":"PT"},{"nm":"Fundus uteri","n_c":["C12315"],"i_c":"C54.3","i_c_s":["Fundus uteri"],"term_type":"PT"},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"C23.9","i_c_s":["Gallbladder"],"term_type":"PT"},{"nm":"Gastric antrum","n_c":["C12259"],"i_c":"C16.3","i_c_s":["Gastric antrum"],"term_type":"PT"},{"nm":"Gastrointestinal tract, NOS","n_c":["C34082"],"i_c":"C26.9","i_c_s":["Gastrointestinal tract, NOS"],"term_type":"PT"},{"nm":"Glans penis","n_c":["C12324"],"i_c":"C60.1","i_c_s":["Glans penis"],"term_type":"PT"},{"nm":"Glottis","n_c":["C12724"],"i_c":"C32.0","i_c_s":["Glottis"],"term_type":"PT"},{"nm":"Greater curvature of stomach, NOS","n_c":["C12262"],"i_c":"C16.6","i_c_s":["Greater curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Gum, NOS","n_c":["C32677"],"i_c":"C03.9","i_c_s":["Gum, NOS"],"term_type":"PT"},{"nm":"Hard palate","n_c":["C12230"],"i_c":"C05.0","i_c_s":["Hard palate"],"term_type":"PT"},{"nm":"Head of pancreas","n_c":["C12269"],"i_c":"C25.0","i_c_s":["Head of pancreas"],"term_type":"PT"},{"nm":"Head, face or neck, NOS","n_c":"","i_c":"C76.0","i_c_s":["Head, face or neck, NOS"],"term_type":"PT"},{"nm":"Heart","n_c":["C12727"],"i_c":"C38.0","i_c_s":["Heart"],"term_type":"PT"},{"nm":"Hematopoietic system, NOS","n_c":["C12909"],"i_c":"C42.4","i_c_s":["Hematopoietic system, NOS"],"term_type":"PT"},{"nm":"Hepatic flexure of colon","n_c":["C12266"],"i_c":"C18.3","i_c_s":["Hepatic flexure of colon"],"term_type":"PT"},{"nm":"Hypopharyngeal aspect of aryepiglottic fold","n_c":"","i_c":"C13.1","i_c_s":["Hypopharyngeal aspect of aryepiglottic fold"],"term_type":"PT"},{"nm":"Hypopharynx, NOS","n_c":["C12246"],"i_c":"C13.9","i_c_s":["Hypopharynx, NOS"],"term_type":"PT"},{"nm":"Ileum","n_c":["C12387"],"i_c":"C17.2","i_c_s":["Ileum"],"term_type":"PT"},{"nm":"Ill-defined sites within respiratory system","n_c":["C148338"],"i_c":"C39.9","i_c_s":["Ill-defined sites within respiratory system"],"term_type":"PT"},{"nm":"Intestinal tract, NOS","n_c":["C12736"],"i_c":"C26.0","i_c_s":["Intestinal tract, NOS"],"term_type":"PT"},{"nm":"Intra-abdominal lymph nodes","n_c":["C12360"],"i_c":"C77.2","i_c_s":["Intra-abdominal lymph nodes"],"term_type":"PT"},{"nm":"Intrahepatic bile duct","n_c":["C12677"],"i_c":"C22.1","i_c_s":["Intrahepatic bile duct"],"term_type":"PT"},{"nm":"Intrathoracic lymph nodes","n_c":["C12359"],"i_c":"C77.1","i_c_s":["Intrathoracic lymph nodes"],"term_type":"PT"},{"nm":"Islets of Langerhans","n_c":["C12608"],"i_c":"C25.4","i_c_s":["Islets of Langerhans"],"term_type":"PT"},{"nm":"Isthmus uteri","n_c":["C12312"],"i_c":"C54.0","i_c_s":["Isthmus uteri"],"term_type":"PT"},{"nm":"Jejunum","n_c":["C12388"],"i_c":"C17.1","i_c_s":["Jejunum"],"term_type":"PT"},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"C64.9","i_c_s":["Kidney, NOS"],"term_type":"PT"},{"nm":"Labium majus","n_c":["C12306"],"i_c":"C51.0","i_c_s":["Labium majus"],"term_type":"PT"},{"nm":"Labium minus","n_c":["C12307"],"i_c":"C51.1","i_c_s":["Labium minus"],"term_type":"PT"},{"nm":"Lacrimal gland","n_c":["C12346"],"i_c":"C69.5","i_c_s":["Lacrimal gland"],"term_type":"PT"},{"nm":"Laryngeal cartilage","n_c":["C12281"],"i_c":"C32.3","i_c_s":["Laryngeal cartilage"],"term_type":"PT"},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"C32.9","i_c_s":["Larynx, NOS"],"term_type":"PT"},{"nm":"Lateral floor of mouth","n_c":"","i_c":"C04.1","i_c_s":["Lateral floor of mouth"],"term_type":"PT"},{"nm":"Lateral wall of bladder","n_c":["C12333"],"i_c":"C67.2","i_c_s":["Lateral wall of bladder"],"term_type":"PT"},{"nm":"Lateral wall of nasopharynx","n_c":["C12244"],"i_c":"C11.2","i_c_s":["Lateral wall of nasopharynx"],"term_type":"PT"},{"nm":"Lateral wall of oropharynx","n_c":["C12239"],"i_c":"C10.2","i_c_s":["Lateral wall of oropharynx"],"term_type":"PT"},{"nm":"Lesser curvature of stomach, NOS","n_c":["C12261"],"i_c":"C16.5","i_c_s":["Lesser curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Lingual tonsil","n_c":["C32988"],"i_c":"C02.4","i_c_s":["Lingual tonsil"],"term_type":"PT"},{"nm":"Lip, NOS","n_c":["C12220"],"i_c":"C00.9","i_c_s":["Lip, NOS"],"term_type":"PT"},{"nm":"Liver","n_c":["C12392"],"i_c":"C22.0","i_c_s":["Liver"],"term_type":"PT"},{"nm":"Long bones of lower limb and associated joints","n_c":"","i_c":"C40.2","i_c_s":["Long bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Long bones of upper limb, scapula and associated joints","n_c":"","i_c":"C40.0","i_c_s":["Long bones of upper limb, scapula and associated joints"],"term_type":"PT"},{"nm":"Lower gum","n_c":["C54204"],"i_c":"C03.1","i_c_s":["Lower gum"],"term_type":"PT"},{"nm":"Lower limb, NOS","n_c":["C12742"],"i_c":"C76.5","i_c_s":["Lower limb, NOS"],"term_type":"PT"},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"C34.3","i_c_s":["Lower lobe, lung"],"term_type":"PT"},{"nm":"Lower third of esophagus","n_c":["C12255"],"i_c":"C15.5","i_c_s":["Lower third of esophagus"],"term_type":"PT"},{"nm":"Lower-inner quadrant of breast","n_c":["C12302"],"i_c":"C50.3","i_c_s":["Lower-inner quadrant of breast"],"term_type":"PT"},{"nm":"Lower-outer quadrant of breast","n_c":["C12304"],"i_c":"C50.5","i_c_s":["Lower-outer quadrant of breast"],"term_type":"PT"},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"C34.9","i_c_s":["Lung, NOS"],"term_type":"PT"},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"C77.9","i_c_s":["Lymph node, NOS"],"term_type":"PT"},{"nm":"Lymph nodes of axilla or arm","n_c":["C12904"],"i_c":"C77.3","i_c_s":["Lymph nodes of axilla or arm"],"term_type":"PT"},{"nm":"Lymph nodes of head, face and neck","n_c":["C12358"],"i_c":"C77.0","i_c_s":["Lymph nodes of head, face and neck"],"term_type":"PT"},{"nm":"Lymph nodes of inguinal region or leg","n_c":["C12362"],"i_c":"C77.4","i_c_s":["Lymph nodes of inguinal region or leg"],"term_type":"PT"},{"nm":"Lymph nodes of multiple regions","n_c":"","i_c":"C77.8","i_c_s":["Lymph nodes of multiple regions"],"term_type":"PT"},{"nm":"Main bronchus","n_c":["C12284"],"i_c":"C34.0","i_c_s":["Main bronchus"],"term_type":"PT"},{"nm":"Major salivary gland, NOS","n_c":["C12999"],"i_c":"C08.9","i_c_s":["Major salivary gland, NOS"],"term_type":"PT"},{"nm":"Male genital organs, NOS","n_c":["C61599"],"i_c":"C63.9","i_c_s":["Male genital organs, NOS"],"term_type":"PT"},{"nm":"Mandible","n_c":["C12290"],"i_c":"C41.1","i_c_s":["Mandible"],"term_type":"PT"},{"nm":"Maxillary sinus","n_c":["C12275"],"i_c":"C31.0","i_c_s":["Maxillary sinus"],"term_type":"PT"},{"nm":"Meckel diverticulum","n_c":["C12264"],"i_c":"C17.3","i_c_s":["Meckel diverticulum"],"term_type":"PT"},{"nm":"Mediastinum, NOS","n_c":["C12748"],"i_c":"C38.3","i_c_s":["Mediastinum, NOS"],"term_type":"PT"},{"nm":"Medulla of adrenal gland","n_c":["C12397"],"i_c":"C74.1","i_c_s":["Medulla of adrenal gland"],"term_type":"PT"},{"nm":"Meninges, NOS","n_c":["C12348"],"i_c":"C70.9","i_c_s":["Meninges, NOS"],"term_type":"PT"},{"nm":"Middle ear","n_c":["C12274"],"i_c":"C30.1","i_c_s":["Middle ear"],"term_type":"PT"},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"C34.2","i_c_s":["Middle lobe, lung"],"term_type":"PT"},{"nm":"Middle third of esophagus","n_c":["C12254"],"i_c":"C15.4","i_c_s":["Middle third of esophagus"],"term_type":"PT"},{"nm":"Mouth, NOS","n_c":["C12421"],"i_c":"C06.9","i_c_s":["Mouth, NOS"],"term_type":"PT"},{"nm":"Mucosa of lip, NOS","n_c":["C12226"],"i_c":"C00.5","i_c_s":["Mucosa of lip, NOS"],"term_type":"PT"},{"nm":"Mucosa of lower lip","n_c":["C12225"],"i_c":"C00.4","i_c_s":["Mucosa of lower lip"],"term_type":"PT"},{"nm":"Mucosa of upper lip","n_c":["C12224"],"i_c":"C00.3","i_c_s":["Mucosa of upper lip"],"term_type":"PT"},{"nm":"Myometrium","n_c":["C12314"],"i_c":"C54.2","i_c_s":["Myometrium"],"term_type":"PT"},{"nm":"Nasal cavity","n_c":["C12424"],"i_c":"C30.0","i_c_s":["Nasal cavity"],"term_type":"PT"},{"nm":"Nasopharynx, NOS","n_c":["C12423"],"i_c":"C11.9","i_c_s":["Nasopharynx, NOS"],"term_type":"PT"},{"nm":"Nervous system, NOS","n_c":["C12755"],"i_c":"C72.9","i_c_s":["Nervous system, NOS"],"term_type":"PT"},{"nm":"Nipple","n_c":["C12299"],"i_c":"C50.0","i_c_s":["Nipple"],"term_type":"PT"},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"C71.4","i_c_s":["Occipital lobe"],"term_type":"PT"},{"nm":"Olfactory nerve","n_c":["C12759"],"i_c":"C72.2","i_c_s":["Olfactory nerve"],"term_type":"PT"},{"nm":"Optic nerve","n_c":["C12761"],"i_c":"C72.3","i_c_s":["Optic nerve"],"term_type":"PT"},{"nm":"Orbit, NOS","n_c":["C12347"],"i_c":"C69.6","i_c_s":["Orbit, NOS"],"term_type":"PT"},{"nm":"Oropharynx, NOS","n_c":["C12762"],"i_c":"C10.9","i_c_s":["Oropharynx, NOS"],"term_type":"PT"},{"nm":"Other ill-defined sites","n_c":["C147919"],"i_c":"C76.7","i_c_s":["Other ill-defined sites"],"term_type":"PT"},{"nm":"Other specified parts of female genital organs","n_c":["C148339"],"i_c":"C57.7","i_c_s":["Other specified parts of female genital organs"],"term_type":"PT"},{"nm":"Other specified parts of male genital organs","n_c":["C148341"],"i_c":"C63.7","i_c_s":["Other specified parts of male genital organs"],"term_type":"PT"},{"nm":"Other specified parts of pancreas","n_c":["C12273"],"i_c":"C25.7","i_c_s":["Other specified parts of pancreas"],"term_type":"PT"},{"nm":"Ovary","n_c":["C12404"],"i_c":"C56.9","i_c_s":["Ovary"],"term_type":"PT"},{"nm":"Overlapping lesion of accessory sinuses","n_c":"","i_c":"C31.8","i_c_s":["Overlapping lesion of accessory sinuses"],"term_type":"PT"},{"nm":"Overlapping lesion of biliary tract","n_c":"","i_c":"C24.8","i_c_s":["Overlapping lesion of biliary tract"],"term_type":"PT"},{"nm":"Overlapping lesion of bladder","n_c":"","i_c":"C67.8","i_c_s":["Overlapping lesion of bladder"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage","n_c":"","i_c":"C41.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage of limbs","n_c":"","i_c":"C40.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage of limbs"],"term_type":"PT"},{"nm":"Overlapping lesion of brain","n_c":"","i_c":"C71.8","i_c_s":["Overlapping lesion of brain"],"term_type":"PT"},{"nm":"Overlapping lesion of brain and central nervous system","n_c":"","i_c":"C72.8","i_c_s":["Overlapping lesion of brain and central nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of breast","n_c":"","i_c":"C50.8","i_c_s":["Overlapping lesion of breast"],"term_type":"PT"},{"nm":"Overlapping lesion of cervix uteri","n_c":"","i_c":"C53.8","i_c_s":["Overlapping lesion of cervix uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of colon","n_c":"","i_c":"C18.8","i_c_s":["Overlapping lesion of colon"],"term_type":"PT"},{"nm":"Overlapping lesion of connective, subcutaneous and other soft tissues","n_c":"","i_c":"C49.8","i_c_s":["Overlapping lesion of connective, subcutaneous and other soft tissues"],"term_type":"PT"},{"nm":"Overlapping lesion of corpus uteri","n_c":"","i_c":"C54.8","i_c_s":["Overlapping lesion of corpus uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of digestive system","n_c":"","i_c":"C26.8","i_c_s":["Overlapping lesion of digestive system"],"term_type":"PT"},{"nm":"Overlapping lesion of endocrine glands and related structures","n_c":"","i_c":"C75.8","i_c_s":["Overlapping lesion of endocrine glands and related structures"],"term_type":"PT"},{"nm":"Overlapping lesion of esophagus","n_c":"","i_c":"C15.8","i_c_s":["Overlapping lesion of esophagus"],"term_type":"PT"},{"nm":"Overlapping lesion of eye and adnexa","n_c":"","i_c":"C69.8","i_c_s":["Overlapping lesion of eye and adnexa"],"term_type":"PT"},{"nm":"Overlapping lesion of female genital organs","n_c":"","i_c":"C57.8","i_c_s":["Overlapping lesion of female genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of floor of mouth","n_c":"","i_c":"C04.8","i_c_s":["Overlapping lesion of floor of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of heart, mediastinum and pleura","n_c":"","i_c":"C38.8","i_c_s":["Overlapping lesion of heart, mediastinum and pleura"],"term_type":"PT"},{"nm":"Overlapping lesion of hypopharynx","n_c":"","i_c":"C13.8","i_c_s":["Overlapping lesion of hypopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of ill-defined sites","n_c":"","i_c":"C76.8","i_c_s":["Overlapping lesion of ill-defined sites"],"term_type":"PT"},{"nm":"Overlapping lesion of larynx","n_c":"","i_c":"C32.8","i_c_s":["Overlapping lesion of larynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lip","n_c":"","i_c":"C00.8","i_c_s":["Overlapping lesion of lip"],"term_type":"PT"},{"nm":"Overlapping lesion of lip, oral cavity and pharynx","n_c":"","i_c":"C14.8","i_c_s":["Overlapping lesion of lip, oral cavity and pharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lung","n_c":"","i_c":"C34.8","i_c_s":["Overlapping lesion of lung"],"term_type":"PT"},{"nm":"Overlapping lesion of major salivary glands","n_c":"","i_c":"C08.8","i_c_s":["Overlapping lesion of major salivary glands"],"term_type":"PT"},{"nm":"Overlapping lesion of male genital organs","n_c":"","i_c":"C63.8","i_c_s":["Overlapping lesion of male genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of nasopharynx","n_c":"","i_c":"C11.8","i_c_s":["Overlapping lesion of nasopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of other and unspecified parts of mouth","n_c":"","i_c":"C06.8","i_c_s":["Overlapping lesion of other and unspecified parts of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of palate","n_c":"","i_c":"C05.8","i_c_s":["Overlapping lesion of palate"],"term_type":"PT"},{"nm":"Overlapping lesion of pancreas","n_c":"","i_c":"C25.8","i_c_s":["Overlapping lesion of pancreas"],"term_type":"PT"},{"nm":"Overlapping lesion of penis","n_c":"","i_c":"C60.8","i_c_s":["Overlapping lesion of penis"],"term_type":"PT"},{"nm":"Overlapping lesion of peripheral nerves and autonomic nervous system","n_c":"","i_c":"C47.8","i_c_s":["Overlapping lesion of peripheral nerves and autonomic nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of rectum, anus and anal canal","n_c":"","i_c":"C21.8","i_c_s":["Overlapping lesion of rectum, anus and anal canal"],"term_type":"PT"},{"nm":"Overlapping lesion of respiratory system and intrathoracic organs","n_c":"","i_c":"C39.8","i_c_s":["Overlapping lesion of respiratory system and intrathoracic organs"],"term_type":"PT"},{"nm":"Overlapping lesion of retroperitoneum and peritoneum","n_c":"","i_c":"C48.8","i_c_s":["Overlapping lesion of retroperitoneum and peritoneum"],"term_type":"PT"},{"nm":"Overlapping lesion of skin","n_c":"","i_c":"C44.8","i_c_s":["Overlapping lesion of skin"],"term_type":"PT"},{"nm":"Overlapping lesion of small intestine","n_c":"","i_c":"C17.8","i_c_s":["Overlapping lesion of small intestine"],"term_type":"PT"},{"nm":"Overlapping lesion of stomach","n_c":"","i_c":"C16.8","i_c_s":["Overlapping lesion of stomach"],"term_type":"PT"},{"nm":"Overlapping lesion of tongue","n_c":"","i_c":"C02.8","i_c_s":["Overlapping lesion of tongue"],"term_type":"PT"},{"nm":"Overlapping lesion of tonsil","n_c":"","i_c":"C09.8","i_c_s":["Overlapping lesion of tonsil"],"term_type":"PT"},{"nm":"Overlapping lesion of urinary organs","n_c":"","i_c":"C68.8","i_c_s":["Overlapping lesion of urinary organs"],"term_type":"PT"},{"nm":"Overlapping lesion of vulva","n_c":"","i_c":"C51.8","i_c_s":["Overlapping lesion of vulva"],"term_type":"PT"},{"nm":"Overlapping lesions of oropharynx","n_c":"","i_c":"C10.8","i_c_s":["Overlapping lesions of oropharynx"],"term_type":"PT"},{"nm":"Palate, NOS","n_c":["C12229"],"i_c":"C05.9","i_c_s":["Palate, NOS"],"term_type":"PT"},{"nm":"Pancreas, NOS","n_c":["C12393"],"i_c":"C25.9","i_c_s":["Pancreas, NOS"],"term_type":"PT"},{"nm":"Pancreatic duct","n_c":["C12272"],"i_c":"C25.3","i_c_s":["Pancreatic duct"],"term_type":"PT"},{"nm":"Pancreatic neck","n_c":["C158551"],"i_c":"C25.7","i_c_s":["Pancreatic neck"],"term_type":"RT"},{"nm":"Parametrium","n_c":["C12320"],"i_c":"C57.3","i_c_s":["Parametrium"],"term_type":"PT"},{"nm":"Parathyroid gland","n_c":["C12765"],"i_c":"C75.0","i_c_s":["Parathyroid gland"],"term_type":"PT"},{"nm":"Paraurethral gland","n_c":["C61122"],"i_c":"C68.1","i_c_s":["Paraurethral gland"],"term_type":"PT"},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"C71.3","i_c_s":["Parietal lobe"],"term_type":"PT"},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"C07.9","i_c_s":["Parotid gland"],"term_type":"PT"},{"nm":"Pelvic bones, sacrum, coccyx and associated joints","n_c":"","i_c":"C41.4","i_c_s":["Pelvic bones, sacrum, coccyx and associated joints"],"term_type":"PT"},{"nm":"Pelvic lymph nodes","n_c":["C12363"],"i_c":"C77.5","i_c_s":["Pelvic lymph nodes"],"term_type":"PT"},{"nm":"Pelvis, NOS","n_c":["C12767"],"i_c":"C76.3","i_c_s":["Pelvis, NOS"],"term_type":"PT"},{"nm":"Penis, NOS","n_c":["C12409"],"i_c":"C60.9","i_c_s":["Penis, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of abdomen","n_c":"","i_c":"C47.4","i_c_s":["Peripheral nerves and autonomic nervous system of abdomen"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of head, face, and neck","n_c":"","i_c":"C47.0","i_c_s":["Peripheral nerves and autonomic nervous system of head, face, and neck"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of lower limb and hip","n_c":"","i_c":"C47.2","i_c_s":["Peripheral nerves and autonomic nervous system of lower limb and hip"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of pelvis","n_c":"","i_c":"C47.5","i_c_s":["Peripheral nerves and autonomic nervous system of pelvis"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of thorax","n_c":"","i_c":"C47.3","i_c_s":["Peripheral nerves and autonomic nervous system of thorax"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of trunk, NOS","n_c":"","i_c":"C47.6","i_c_s":["Peripheral nerves and autonomic nervous system of trunk, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of upper limb and shoulder","n_c":"","i_c":"C47.1","i_c_s":["Peripheral nerves and autonomic nervous system of upper limb and shoulder"],"term_type":"PT"},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"C48.2","i_c_s":["Peritoneum, NOS"],"term_type":"PT"},{"nm":"Pharynx, NOS","n_c":["C12425"],"i_c":"C14.0","i_c_s":["Pharynx, NOS"],"term_type":"PT"},{"nm":"Pineal gland","n_c":["C12398"],"i_c":"C75.3","i_c_s":["Pineal gland"],"term_type":"PT"},{"nm":"Pituitary gland","n_c":["C12399"],"i_c":"C75.1","i_c_s":["Pituitary gland"],"term_type":"PT"},{"nm":"Placenta","n_c":["C13272"],"i_c":"C58.9","i_c_s":["Placenta"],"term_type":"PT"},{"nm":"Pleura, NOS","n_c":["C12469"],"i_c":"C38.4","i_c_s":["Pleura, NOS"],"term_type":"PT"},{"nm":"Postcricoid region","n_c":["C54221"],"i_c":"C13.0","i_c_s":["Postcricoid region"],"term_type":"PT"},{"nm":"Posterior mediastinum","n_c":["C33368"],"i_c":"C38.2","i_c_s":["Posterior mediastinum"],"term_type":"PT"},{"nm":"Posterior wall of bladder","n_c":["C12335"],"i_c":"C67.4","i_c_s":["Posterior wall of bladder"],"term_type":"PT"},{"nm":"Posterior wall of hypopharynx","n_c":["C12249"],"i_c":"C13.2","i_c_s":["Posterior wall of hypopharynx"],"term_type":"PT"},{"nm":"Posterior wall of nasopharynx","n_c":["C12243"],"i_c":"C11.1","i_c_s":["Posterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Posterior wall of oropharynx","n_c":["C12240"],"i_c":"C10.3","i_c_s":["Posterior wall of oropharynx"],"term_type":"PT"},{"nm":"Prepuce","n_c":["C12323"],"i_c":"C60.0","i_c_s":["Prepuce"],"term_type":"PT"},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"C61.9","i_c_s":["Prostate gland"],"term_type":"PT"},{"nm":"Pylorus","n_c":["C12260"],"i_c":"C16.4","i_c_s":["Pylorus"],"term_type":"PT"},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"C12.9","i_c_s":["Pyriform sinus"],"term_type":"PT"},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"C19.9","i_c_s":["Rectosigmoid junction"],"term_type":"PT"},{"nm":"Rectum, NOS","n_c":["C12390"],"i_c":"C20.9","i_c_s":["Rectum, NOS"],"term_type":"PT"},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"C65.9","i_c_s":["Renal pelvis"],"term_type":"PT"},{"nm":"Reticuloendothelial system, NOS","n_c":["C12780"],"i_c":"C42.3","i_c_s":["Reticuloendothelial system, NOS"],"term_type":"PT"},{"nm":"Retina","n_c":["C12343"],"i_c":"C69.2","i_c_s":["Retina"],"term_type":"PT"},{"nm":"Retromolar area","n_c":["C54223"],"i_c":"C06.2","i_c_s":["Retromolar area"],"term_type":"PT"},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"C48.0","i_c_s":["Retroperitoneum"],"term_type":"PT"},{"nm":"Rib, sternum, clavicle and associated joints","n_c":"","i_c":"C41.3","i_c_s":["Rib, sternum, clavicle and associated joints"],"term_type":"PT"},{"nm":"Round ligament","n_c":["C12319"],"i_c":"C57.2","i_c_s":["Round ligament"],"term_type":"PT"},{"nm":"Scrotum, NOS","n_c":["C12785"],"i_c":"C63.2","i_c_s":["Scrotum, NOS"],"term_type":"PT"},{"nm":"Short bones of lower limb and associated joints","n_c":"","i_c":"C40.3","i_c_s":["Short bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Short bones of upper limb and associated joints","n_c":"","i_c":"C40.1","i_c_s":["Short bones of upper limb and associated joints"],"term_type":"PT"},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"C18.7","i_c_s":["Sigmoid colon"],"term_type":"PT"},{"nm":"Skin of lip, NOS","n_c":["C12291"],"i_c":"C44.0","i_c_s":["Skin of lip, NOS"],"term_type":"PT"},{"nm":"Skin of lower limb and hip","n_c":["C12297"],"i_c":"C44.7","i_c_s":["Skin of lower limb and hip"],"term_type":"PT"},{"nm":"Skin of other and unspecified parts of face","n_c":["C33561"],"i_c":"C44.3","i_c_s":["Skin of other and unspecified parts of face"],"term_type":"PT"},{"nm":"Skin of scalp and neck","n_c":["C12294"],"i_c":"C44.4","i_c_s":["Skin of scalp and neck"],"term_type":"PT"},{"nm":"Skin of trunk","n_c":["C12295"],"i_c":"C44.5","i_c_s":["Skin of trunk"],"term_type":"RT"},{"nm":"Skin of upper limb and shoulder","n_c":["C12296"],"i_c":"C44.6","i_c_s":["Skin of upper limb and shoulder"],"term_type":"PT"},{"nm":"Skin, NOS","n_c":["C12470"],"i_c":"C44.9","i_c_s":["Skin, NOS"],"term_type":"PT"},{"nm":"Small intestine, NOS","n_c":["C12386"],"i_c":"C17.9","i_c_s":["Small intestine, NOS"],"term_type":"PT"},{"nm":"Soft palate, NOS","n_c":["C12231"],"i_c":"C05.1","i_c_s":["Soft palate, NOS"],"term_type":"PT"},{"nm":"Specified parts of peritoneum","n_c":"","i_c":"C48.1","i_c_s":["Specified parts of peritoneum"],"term_type":"PT"},{"nm":"Spermatic cord","n_c":["C12329"],"i_c":"C63.1","i_c_s":["Spermatic cord"],"term_type":"PT"},{"nm":"Sphenoid sinus","n_c":["C12278"],"i_c":"C31.3","i_c_s":["Sphenoid sinus"],"term_type":"PT"},{"nm":"Spinal cord","n_c":["C12464"],"i_c":"C72.0","i_c_s":["Spinal cord"],"term_type":"PT"},{"nm":"Spinal meninges","n_c":["C12350"],"i_c":"C70.1","i_c_s":["Spinal meninges"],"term_type":"PT"},{"nm":"Spleen","n_c":["C12432"],"i_c":"C42.2","i_c_s":["Spleen"],"term_type":"PT"},{"nm":"Splenic flexure of colon","n_c":["C12267"],"i_c":"C18.5","i_c_s":["Splenic flexure of colon"],"term_type":"PT"},{"nm":"Stomach, NOS","n_c":["C12391"],"i_c":"C16.9","i_c_s":["Stomach, NOS"],"term_type":"PT"},{"nm":"Subglottis","n_c":["C12280"],"i_c":"C32.2","i_c_s":["Subglottis"],"term_type":"PT"},{"nm":"Sublingual gland","n_c":["C12234"],"i_c":"C08.1","i_c_s":["Sublingual gland"],"term_type":"PT"},{"nm":"Submandibular gland","n_c":["C12233"],"i_c":"C08.0","i_c_s":["Submandibular gland"],"term_type":"PT"},{"nm":"Superior wall of nasopharynx","n_c":["C12242"],"i_c":"C11.0","i_c_s":["Superior wall of nasopharynx"],"term_type":"PT"},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"C32.1","i_c_s":["Supraglottis"],"term_type":"PT"},{"nm":"Tail of pancreas","n_c":["C12271"],"i_c":"C25.2","i_c_s":["Tail of pancreas"],"term_type":"PT"},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"C71.2","i_c_s":["Temporal lobe"],"term_type":"PT"},{"nm":"Testis, NOS","n_c":["C12412"],"i_c":"C62.9","i_c_s":["Testis, NOS"],"term_type":"PT"},{"nm":"Thoracic esophagus","n_c":["C12251"],"i_c":"C15.1","i_c_s":["Thoracic esophagus"],"term_type":"PT"},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"C76.1","i_c_s":["Thorax, NOS"],"term_type":"PT"},{"nm":"Thymus","n_c":["C12433"],"i_c":"C37.9","i_c_s":["Thymus"],"term_type":"PT"},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"C73.9","i_c_s":["Thyroid gland"],"term_type":"PT"},{"nm":"Tongue, NOS","n_c":["C12422"],"i_c":"C02.9","i_c_s":["Tongue, NOS"],"term_type":"PT"},{"nm":"Tonsil, NOS","n_c":["C33250"],"i_c":"C09.9","i_c_s":["Tonsil, NOS"],"term_type":"PT"},{"nm":"Tonsillar fossa","n_c":["C12235"],"i_c":"C09.0","i_c_s":["Tonsillar fossa"],"term_type":"PT"},{"nm":"Tonsillar pillar","n_c":["C12236"],"i_c":"C09.1","i_c_s":["Tonsillar pillar"],"term_type":"PT"},{"nm":"Trachea","n_c":["C12428"],"i_c":"C33.9","i_c_s":["Trachea"],"term_type":"PT"},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"C18.4","i_c_s":["Transverse colon"],"term_type":"PT"},{"nm":"Trigone of bladder","n_c":["C12331"],"i_c":"C67.0","i_c_s":["Trigone of bladder"],"term_type":"PT"},{"nm":"Undescended testis","n_c":["C12326"],"i_c":"C62.0","i_c_s":["Undescended testis"],"term_type":"PT"},{"nm":"Unknown primary site","n_c":["C48322"],"i_c":"C80.9","i_c_s":["Unknown primary site"],"term_type":"PT"},{"nm":"Upper gum","n_c":["C54205"],"i_c":"C03.0","i_c_s":["Upper gum"],"term_type":"PT"},{"nm":"Upper limb, NOS","n_c":["C12671"],"i_c":"C76.4","i_c_s":["Upper limb, NOS"],"term_type":"PT"},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"C34.1","i_c_s":["Upper lobe, lung"],"term_type":"PT"},{"nm":"Upper respiratory tract, NOS","n_c":["C33839"],"i_c":"C39.0","i_c_s":["Upper respiratory tract, NOS"],"term_type":"PT"},{"nm":"Upper third of esophagus","n_c":["C12253"],"i_c":"C15.3","i_c_s":["Upper third of esophagus"],"term_type":"PT"},{"nm":"Upper-inner quadrant of breast","n_c":["C12301"],"i_c":"C50.2","i_c_s":["Upper-inner quadrant of breast"],"term_type":"PT"},{"nm":"Upper-outer quadrant of breast","n_c":["C12303"],"i_c":"C50.4","i_c_s":["Upper-outer quadrant of breast"],"term_type":"PT"},{"nm":"Urachus","n_c":["C12338"],"i_c":"C67.7","i_c_s":["Urachus"],"term_type":"PT"},{"nm":"Ureter","n_c":["C12416"],"i_c":"C66.9","i_c_s":["Ureter"],"term_type":"PT"},{"nm":"Ureteric orifice","n_c":["C12337"],"i_c":"C67.6","i_c_s":["Ureteric orifice"],"term_type":"PT"},{"nm":"Urethra","n_c":["C12417"],"i_c":"C68.0","i_c_s":["Urethra"],"term_type":"PT"},{"nm":"Urinary system, NOS","n_c":["C12413"],"i_c":"C68.9","i_c_s":["Urinary system, NOS"],"term_type":"PT"},{"nm":"Uterine adnexa","n_c":["C12321"],"i_c":"C57.4","i_c_s":["Uterine adnexa"],"term_type":"PT"},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"C55.9","i_c_s":["Uterus, NOS"],"term_type":"PT"},{"nm":"Uvula","n_c":["C12232"],"i_c":"C05.2","i_c_s":["Uvula"],"term_type":"PT"},{"nm":"Vagina, NOS","n_c":["C12407"],"i_c":"C52.9","i_c_s":["Vagina, NOS"],"term_type":"PT"},{"nm":"Vallecula","n_c":["C12237"],"i_c":"C10.0","i_c_s":["Vallecula"],"term_type":"PT"},{"nm":"Ventral surface of tongue, NOS","n_c":"","i_c":"C02.2","i_c_s":["Ventral surface of tongue, NOS"],"term_type":"PT"},{"nm":"Ventricle, NOS","n_c":["C12356"],"i_c":"C71.5","i_c_s":["Ventricle, NOS"],"term_type":"PT"},{"nm":"Vertebral column","n_c":["C12998"],"i_c":"C41.2","i_c_s":["Vertebral column"],"term_type":"PT"},{"nm":"Vestibule of mouth","n_c":["C165195"],"i_c":"C06.1","i_c_s":["Vestibule of mouth"],"term_type":"PT"},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"C51.9","i_c_s":["Vulva, NOS"],"term_type":"PT"},{"nm":"Waldeyer ring","n_c":["C73468"],"i_c":"C14.2","i_c_s":["Waldeyer ring"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.supratentorial_localization":[{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Gray (e.g. Basal Ganglia, Thalamus)","n_c":["C158080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Matter","n_c":["C33892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.synchronous_malignancy":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tissue_or_organ_of_origin":[{"nm":"Abdomen, NOS","n_c":["C12664"],"i_c":"C76.2","i_c_s":["Abdomen, NOS"],"term_type":"PT"},{"nm":"Abdominal esophagus","n_c":["C12252"],"i_c":"C15.2","i_c_s":["Abdominal esophagus"],"term_type":"PT"},{"nm":"Accessory sinus, NOS","n_c":["C12763"],"i_c":"C31.9","i_c_s":["Accessory sinus, NOS"],"term_type":"PT"},{"nm":"Acoustic nerve","n_c":["C12697"],"i_c":"C72.4","i_c_s":["Acoustic nerve"],"term_type":"PT"},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"C74.9","i_c_s":["Adrenal gland, NOS"],"term_type":"PT"},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"C24.1","i_c_s":["Ampulla of Vater"],"term_type":"PT"},{"nm":"Anal canal","n_c":["C12375"],"i_c":"C21.1","i_c_s":["Anal canal"],"term_type":"PT"},{"nm":"Anterior 2/3 of tongue, NOS","n_c":"","i_c":"C02.3","i_c_s":["Anterior 2/3 of tongue, NOS"],"term_type":"PT"},{"nm":"Anterior floor of mouth","n_c":"","i_c":"C04.0","i_c_s":["Anterior floor of mouth"],"term_type":"PT"},{"nm":"Anterior mediastinum","n_c":["C32098"],"i_c":"C38.1","i_c_s":["Anterior mediastinum"],"term_type":"PT"},{"nm":"Anterior surface of epiglottis","n_c":["C12238"],"i_c":"C10.1","i_c_s":["Anterior surface of epiglottis"],"term_type":"PT"},{"nm":"Anterior wall of bladder","n_c":["C12334"],"i_c":"C67.3","i_c_s":["Anterior wall of bladder"],"term_type":"PT"},{"nm":"Anterior wall of nasopharynx","n_c":["C12245"],"i_c":"C11.3","i_c_s":["Anterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"C21.0","i_c_s":["Anus, NOS"],"term_type":"PT"},{"nm":"Aortic body and other paraganglia","n_c":"","i_c":"C75.5","i_c_s":["Aortic body and other paraganglia"],"term_type":"PT"},{"nm":"Appendix","n_c":["C12380"],"i_c":"C18.1","i_c_s":["Appendix"],"term_type":"PT"},{"nm":"Ascending colon","n_c":["C12265"],"i_c":"C18.2","i_c_s":["Ascending colon"],"term_type":"PT"},{"nm":"Autonomic nervous system, NOS","n_c":["C12673"],"i_c":"C47.9","i_c_s":["Autonomic nervous system, NOS"],"term_type":"PT"},{"nm":"Axillary tail of breast","n_c":["C12305"],"i_c":"C50.6","i_c_s":["Axillary tail of breast"],"term_type":"PT"},{"nm":"Base of tongue, NOS","n_c":["C12228"],"i_c":"C01.9","i_c_s":["Base of tongue, NOS"],"term_type":"PT"},{"nm":"Biliary tract, NOS","n_c":["C12678"],"i_c":"C24.9","i_c_s":["Biliary tract, NOS"],"term_type":"PT"},{"nm":"Bladder neck","n_c":["C12336"],"i_c":"C67.5","i_c_s":["Bladder neck"],"term_type":"PT"},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"C67.9","i_c_s":["Bladder, NOS"],"term_type":"PT"},{"nm":"Blood","n_c":["C12434"],"i_c":"C42.0","i_c_s":["Blood"],"term_type":"PT"},{"nm":"Body of pancreas","n_c":["C12270"],"i_c":"C25.1","i_c_s":["Body of pancreas"],"term_type":"PT"},{"nm":"Body of penis","n_c":["C12325"],"i_c":"C60.2","i_c_s":["Body of penis"],"term_type":"PT"},{"nm":"Body of stomach","n_c":["C12258"],"i_c":"C16.2","i_c_s":["Body of stomach"],"term_type":"PT"},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"C42.1","i_c_s":["Bone marrow"],"term_type":"PT"},{"nm":"Bone of limb, NOS","n_c":["C32223"],"i_c":"C40.9","i_c_s":["Bone of limb, NOS"],"term_type":"PT"},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"C41.9","i_c_s":["Bone, NOS"],"term_type":"PT"},{"nm":"Bones of skull and face and associated joints","n_c":"","i_c":"C41.0","i_c_s":["Bones of skull and face and associated joints"],"term_type":"PT"},{"nm":"Border of tongue","n_c":"","i_c":"C02.1","i_c_s":["Border of tongue"],"term_type":"PT"},{"nm":"Brain stem","n_c":["C12441"],"i_c":"C71.7","i_c_s":["Brain stem"],"term_type":"PT"},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"C71.9","i_c_s":["Brain, NOS"],"term_type":"PT"},{"nm":"Branchial cleft","n_c":["C104813"],"i_c":"C10.4","i_c_s":["Branchial cleft"],"term_type":"PT"},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"C50.9","i_c_s":["Breast, NOS"],"term_type":"PT"},{"nm":"Broad ligament","n_c":["C12318"],"i_c":"C57.1","i_c_s":["Broad ligament"],"term_type":"PT"},{"nm":"Cardia, NOS","n_c":["C12256"],"i_c":"C16.0","i_c_s":["Cardia, NOS"],"term_type":"PT"},{"nm":"Carotid body","n_c":["C66852"],"i_c":"C75.4","i_c_s":["Carotid body"],"term_type":"PT"},{"nm":"Cauda equina","n_c":["C12689"],"i_c":"C72.1","i_c_s":["Cauda equina"],"term_type":"PT"},{"nm":"Cecum","n_c":["C12381"],"i_c":"C18.0","i_c_s":["Cecum"],"term_type":"PT"},{"nm":"Central portion of breast","n_c":["C12300"],"i_c":"C50.1","i_c_s":["Central portion of breast"],"term_type":"PT"},{"nm":"Cerebellum, NOS","n_c":["C12445"],"i_c":"C71.6","i_c_s":["Cerebellum, NOS"],"term_type":"PT"},{"nm":"Cerebral meninges","n_c":["C12349"],"i_c":"C70.0","i_c_s":["Cerebral meninges"],"term_type":"PT"},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"C71.0","i_c_s":["Cerebrum"],"term_type":"PT"},{"nm":"Cervical esophagus","n_c":["C12250"],"i_c":"C15.0","i_c_s":["Cervical esophagus"],"term_type":"PT"},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"C53.9","i_c_s":["Cervix uteri"],"term_type":"PT"},{"nm":"Cheek mucosa","n_c":["C12505"],"i_c":"C06.0","i_c_s":["Cheek mucosa"],"term_type":"PT"},{"nm":"Choroid","n_c":["C12344"],"i_c":"C69.3","i_c_s":["Choroid"],"term_type":"PT"},{"nm":"Ciliary body","n_c":["C12345"],"i_c":"C69.4","i_c_s":["Ciliary body"],"term_type":"PT"},{"nm":"Clitoris","n_c":["C12308"],"i_c":"C51.2","i_c_s":["Clitoris"],"term_type":"PT"},{"nm":"Cloacogenic zone","n_c":["C32072"],"i_c":"C21.2","i_c_s":["Cloacogenic zone"],"term_type":"PT"},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"C18.9","i_c_s":["Colon, NOS"],"term_type":"PT"},{"nm":"Commissure of lip","n_c":["C12227"],"i_c":"C00.6","i_c_s":["Commissure of lip"],"term_type":"PT"},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"C69.0","i_c_s":["Conjunctiva"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of abdomen","n_c":"","i_c":"C49.4","i_c_s":["Connective, subcutaneous and other soft tissues of abdomen"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of head, face, and neck","n_c":"","i_c":"C49.0","i_c_s":["Connective, subcutaneous and other soft tissues of head, face, and neck"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of lower limb and hip","n_c":"","i_c":"C49.2","i_c_s":["Connective, subcutaneous and other soft tissues of lower limb and hip"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of pelvis","n_c":"","i_c":"C49.5","i_c_s":["Connective, subcutaneous and other soft tissues of pelvis"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of thorax","n_c":"","i_c":"C49.3","i_c_s":["Connective, subcutaneous and other soft tissues of thorax"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of trunk, NOS","n_c":"","i_c":"C49.6","i_c_s":["Connective, subcutaneous and other soft tissues of trunk, NOS"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of upper limb and shoulder","n_c":"","i_c":"C49.1","i_c_s":["Connective, subcutaneous and other soft tissues of upper limb and shoulder"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues, NOS","n_c":["C12964"],"i_c":"C49.9","i_c_s":["Connective, subcutaneous and other soft tissues, NOS"],"term_type":""},{"nm":"Cornea, NOS","n_c":["C12342"],"i_c":"C69.1","i_c_s":["Cornea, NOS"],"term_type":"PT"},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"C54.9","i_c_s":["Corpus uteri"],"term_type":"PT"},{"nm":"Cortex of adrenal gland","n_c":["C12396"],"i_c":"C74.0","i_c_s":["Cortex of adrenal gland"],"term_type":"PT"},{"nm":"Cranial nerve, NOS","n_c":["C12700"],"i_c":"C72.5","i_c_s":["Cranial nerve, NOS"],"term_type":"PT"},{"nm":"Craniopharyngeal duct","n_c":["C12357"],"i_c":"C75.2","i_c_s":["Craniopharyngeal duct"],"term_type":"PT"},{"nm":"Descended testis","n_c":"","i_c":"C62.1","i_c_s":["Descended testis"],"term_type":"PT"},{"nm":"Descending colon","n_c":["C12268"],"i_c":"C18.6","i_c_s":["Descending colon"],"term_type":"PT"},{"nm":"Dome of bladder","n_c":["C12332"],"i_c":"C67.1","i_c_s":["Dome of bladder"],"term_type":"PT"},{"nm":"Dorsal surface of tongue, NOS","n_c":"","i_c":"C02.0","i_c_s":["Dorsal surface of tongue, NOS"],"term_type":"PT"},{"nm":"Duodenum","n_c":["C12263"],"i_c":"C17.0","i_c_s":["Duodenum"],"term_type":"PT"},{"nm":"Endocervix","n_c":["C12309"],"i_c":"C53.0","i_c_s":["Endocervix"],"term_type":"PT"},{"nm":"Endocrine gland, NOS","n_c":["C12704"],"i_c":"C75.9","i_c_s":["Endocrine gland, NOS"],"term_type":"PT"},{"nm":"Endometrium","n_c":["C12313"],"i_c":"C54.1","i_c_s":["Endometrium"],"term_type":"PT"},{"nm":"Epididymis","n_c":["C12328"],"i_c":"C63.0","i_c_s":["Epididymis"],"term_type":"PT"},{"nm":"Esophagus, NOS","n_c":["C12389"],"i_c":"C15.9","i_c_s":["Esophagus, NOS"],"term_type":"PT"},{"nm":"Ethmoid sinus","n_c":["C12276"],"i_c":"C31.1","i_c_s":["Ethmoid sinus"],"term_type":"PT"},{"nm":"Exocervix","n_c":["C12310"],"i_c":"C53.1","i_c_s":["Exocervix"],"term_type":"PT"},{"nm":"External ear","n_c":["C12292"],"i_c":"C44.2","i_c_s":["External ear"],"term_type":"PT"},{"nm":"External lip, NOS","n_c":["C12223"],"i_c":"C00.2","i_c_s":["External lip, NOS"],"term_type":"PT"},{"nm":"External lower lip","n_c":["C12222"],"i_c":"C00.1","i_c_s":["External lower lip"],"term_type":"PT"},{"nm":"External upper lip","n_c":["C12221"],"i_c":"C00.0","i_c_s":["External upper lip"],"term_type":"PT"},{"nm":"Extrahepatic bile duct","n_c":["C32573"],"i_c":"C24.0","i_c_s":["Extrahepatic bile duct"],"term_type":"PT"},{"nm":"Eye, NOS","n_c":["C12401"],"i_c":"C69.9","i_c_s":["Eye, NOS"],"term_type":"PT"},{"nm":"Eyelid","n_c":["C12713"],"i_c":"C44.1","i_c_s":["Eyelid"],"term_type":"PT"},{"nm":"Fallopian tube","n_c":["C12403"],"i_c":"C57.0","i_c_s":["Fallopian tube"],"term_type":"PT"},{"nm":"Female genital tract, NOS","n_c":["C61600"],"i_c":"C57.9","i_c_s":["Female genital tract, NOS"],"term_type":"PT"},{"nm":"Floor of mouth, NOS","n_c":["C54187"],"i_c":"C04.9","i_c_s":["Floor of mouth, NOS"],"term_type":"PT"},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"C71.1","i_c_s":["Frontal lobe"],"term_type":"PT"},{"nm":"Frontal sinus","n_c":["C12277"],"i_c":"C31.2","i_c_s":["Frontal sinus"],"term_type":"PT"},{"nm":"Fundus of stomach","n_c":["C12257"],"i_c":"C16.1","i_c_s":["Fundus of stomach"],"term_type":"PT"},{"nm":"Fundus uteri","n_c":["C12315"],"i_c":"C54.3","i_c_s":["Fundus uteri"],"term_type":"PT"},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"C23.9","i_c_s":["Gallbladder"],"term_type":"PT"},{"nm":"Gastric antrum","n_c":["C12259"],"i_c":"C16.3","i_c_s":["Gastric antrum"],"term_type":"PT"},{"nm":"Gastrointestinal tract, NOS","n_c":["C34082"],"i_c":"C26.9","i_c_s":["Gastrointestinal tract, NOS"],"term_type":"PT"},{"nm":"Glans penis","n_c":["C12324"],"i_c":"C60.1","i_c_s":["Glans penis"],"term_type":"PT"},{"nm":"Glottis","n_c":["C12724"],"i_c":"C32.0","i_c_s":["Glottis"],"term_type":"PT"},{"nm":"Greater curvature of stomach, NOS","n_c":["C12262"],"i_c":"C16.6","i_c_s":["Greater curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Gum, NOS","n_c":["C32677"],"i_c":"C03.9","i_c_s":["Gum, NOS"],"term_type":"PT"},{"nm":"Hard palate","n_c":["C12230"],"i_c":"C05.0","i_c_s":["Hard palate"],"term_type":"PT"},{"nm":"Head of pancreas","n_c":["C12269"],"i_c":"C25.0","i_c_s":["Head of pancreas"],"term_type":"PT"},{"nm":"Head, face or neck, NOS","n_c":"","i_c":"C76.0","i_c_s":["Head, face or neck, NOS"],"term_type":"PT"},{"nm":"Heart","n_c":["C12727"],"i_c":"C38.0","i_c_s":["Heart"],"term_type":"PT"},{"nm":"Hematopoietic system, NOS","n_c":["C12909"],"i_c":"C42.4","i_c_s":["Hematopoietic system, NOS"],"term_type":"PT"},{"nm":"Hepatic flexure of colon","n_c":["C12266"],"i_c":"C18.3","i_c_s":["Hepatic flexure of colon"],"term_type":"PT"},{"nm":"Hypopharyngeal aspect of aryepiglottic fold","n_c":"","i_c":"C13.1","i_c_s":["Hypopharyngeal aspect of aryepiglottic fold"],"term_type":"PT"},{"nm":"Hypopharynx, NOS","n_c":["C12246"],"i_c":"C13.9","i_c_s":["Hypopharynx, NOS"],"term_type":"PT"},{"nm":"Ileum","n_c":["C12387"],"i_c":"C17.2","i_c_s":["Ileum"],"term_type":"PT"},{"nm":"Ill-defined sites within respiratory system","n_c":["C148338"],"i_c":"C39.9","i_c_s":["Ill-defined sites within respiratory system"],"term_type":"PT"},{"nm":"Intestinal tract, NOS","n_c":["C12736"],"i_c":"C26.0","i_c_s":["Intestinal tract, NOS"],"term_type":"PT"},{"nm":"Intra-abdominal lymph nodes","n_c":["C12360"],"i_c":"C77.2","i_c_s":["Intra-abdominal lymph nodes"],"term_type":"PT"},{"nm":"Intrahepatic bile duct","n_c":["C12677"],"i_c":"C22.1","i_c_s":["Intrahepatic bile duct"],"term_type":"PT"},{"nm":"Intrathoracic lymph nodes","n_c":["C12359"],"i_c":"C77.1","i_c_s":["Intrathoracic lymph nodes"],"term_type":"PT"},{"nm":"Islets of Langerhans","n_c":["C12608"],"i_c":"C25.4","i_c_s":["Islets of Langerhans"],"term_type":"PT"},{"nm":"Isthmus uteri","n_c":["C12312"],"i_c":"C54.0","i_c_s":["Isthmus uteri"],"term_type":"PT"},{"nm":"Jejunum","n_c":["C12388"],"i_c":"C17.1","i_c_s":["Jejunum"],"term_type":"PT"},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"C64.9","i_c_s":["Kidney, NOS"],"term_type":"PT"},{"nm":"Labium majus","n_c":["C12306"],"i_c":"C51.0","i_c_s":["Labium majus"],"term_type":"PT"},{"nm":"Labium minus","n_c":["C12307"],"i_c":"C51.1","i_c_s":["Labium minus"],"term_type":"PT"},{"nm":"Lacrimal gland","n_c":["C12346"],"i_c":"C69.5","i_c_s":["Lacrimal gland"],"term_type":"PT"},{"nm":"Laryngeal cartilage","n_c":["C12281"],"i_c":"C32.3","i_c_s":["Laryngeal cartilage"],"term_type":"PT"},{"nm":"Laryngeal Commissure","n_c":"","i_c":"C32.0","i_c_s":["Laryngeal Commissure"],"term_type":"RT"},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"C32.9","i_c_s":["Larynx, NOS"],"term_type":"PT"},{"nm":"Lateral floor of mouth","n_c":"","i_c":"C04.1","i_c_s":["Lateral floor of mouth"],"term_type":"PT"},{"nm":"Lateral wall of bladder","n_c":["C12333"],"i_c":"C67.2","i_c_s":["Lateral wall of bladder"],"term_type":"PT"},{"nm":"Lateral wall of nasopharynx","n_c":["C12244"],"i_c":"C11.2","i_c_s":["Lateral wall of nasopharynx"],"term_type":"PT"},{"nm":"Lateral wall of oropharynx","n_c":["C12239"],"i_c":"C10.2","i_c_s":["Lateral wall of oropharynx"],"term_type":"PT"},{"nm":"Lesser curvature of stomach, NOS","n_c":["C12261"],"i_c":"C16.5","i_c_s":["Lesser curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Lingual tonsil","n_c":["C32988"],"i_c":"C02.4","i_c_s":["Lingual tonsil"],"term_type":"PT"},{"nm":"Lip, NOS","n_c":["C12220"],"i_c":"C00.9","i_c_s":["Lip, NOS"],"term_type":"PT"},{"nm":"Liver","n_c":["C12392"],"i_c":"C22.0","i_c_s":["Liver"],"term_type":"PT"},{"nm":"Long bones of lower limb and associated joints","n_c":"","i_c":"C40.2","i_c_s":["Long bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Long bones of upper limb, scapula and associated joints","n_c":"","i_c":"C40.0","i_c_s":["Long bones of upper limb, scapula and associated joints"],"term_type":"PT"},{"nm":"Lower gum","n_c":["C54204"],"i_c":"C03.1","i_c_s":["Lower gum"],"term_type":"PT"},{"nm":"Lower limb, NOS","n_c":["C12742"],"i_c":"C76.5","i_c_s":["Lower limb, NOS"],"term_type":"PT"},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"C34.3","i_c_s":["Lower lobe, lung"],"term_type":"PT"},{"nm":"Lower third of esophagus","n_c":["C12255"],"i_c":"C15.5","i_c_s":["Lower third of esophagus"],"term_type":"PT"},{"nm":"Lower-inner quadrant of breast","n_c":["C12302"],"i_c":"C50.3","i_c_s":["Lower-inner quadrant of breast"],"term_type":"PT"},{"nm":"Lower-outer quadrant of breast","n_c":["C12304"],"i_c":"C50.5","i_c_s":["Lower-outer quadrant of breast"],"term_type":"PT"},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"C34.9","i_c_s":["Lung, NOS"],"term_type":"PT"},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"C77.9","i_c_s":["Lymph node, NOS"],"term_type":"PT"},{"nm":"Lymph nodes of axilla or arm","n_c":["C12904"],"i_c":"C77.3","i_c_s":["Lymph nodes of axilla or arm"],"term_type":"PT"},{"nm":"Lymph nodes of head, face and neck","n_c":["C12358"],"i_c":"C77.0","i_c_s":["Lymph nodes of head, face and neck"],"term_type":"PT"},{"nm":"Lymph nodes of inguinal region or leg","n_c":["C12362"],"i_c":"C77.4","i_c_s":["Lymph nodes of inguinal region or leg"],"term_type":"PT"},{"nm":"Lymph nodes of multiple regions","n_c":"","i_c":"C77.8","i_c_s":["Lymph nodes of multiple regions"],"term_type":"PT"},{"nm":"Main bronchus","n_c":["C12284"],"i_c":"C34.0","i_c_s":["Main bronchus"],"term_type":"PT"},{"nm":"Major salivary gland, NOS","n_c":["C12999"],"i_c":"C08.9","i_c_s":["Major salivary gland, NOS"],"term_type":"PT"},{"nm":"Male genital organs, NOS","n_c":["C61599"],"i_c":"C63.9","i_c_s":["Male genital organs, NOS"],"term_type":"PT"},{"nm":"Mandible","n_c":["C12290"],"i_c":"C41.1","i_c_s":["Mandible"],"term_type":"PT"},{"nm":"Maxillary sinus","n_c":["C12275"],"i_c":"C31.0","i_c_s":["Maxillary sinus"],"term_type":"PT"},{"nm":"Meckel diverticulum","n_c":["C12264"],"i_c":"C17.3","i_c_s":["Meckel diverticulum"],"term_type":"PT"},{"nm":"Mediastinum, NOS","n_c":["C12748"],"i_c":"C38.3","i_c_s":["Mediastinum, NOS"],"term_type":"PT"},{"nm":"Medulla of adrenal gland","n_c":["C12397"],"i_c":"C74.1","i_c_s":["Medulla of adrenal gland"],"term_type":"PT"},{"nm":"Meninges, NOS","n_c":["C12348"],"i_c":"C70.9","i_c_s":["Meninges, NOS"],"term_type":"PT"},{"nm":"Middle ear","n_c":["C12274"],"i_c":"C30.1","i_c_s":["Middle ear"],"term_type":"PT"},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"C34.2","i_c_s":["Middle lobe, lung"],"term_type":"PT"},{"nm":"Middle third of esophagus","n_c":["C12254"],"i_c":"C15.4","i_c_s":["Middle third of esophagus"],"term_type":"PT"},{"nm":"Mouth, NOS","n_c":["C12421"],"i_c":"C06.9","i_c_s":["Mouth, NOS"],"term_type":"PT"},{"nm":"Mucosa of lip, NOS","n_c":["C12226"],"i_c":"C00.5","i_c_s":["Mucosa of lip, NOS"],"term_type":"PT"},{"nm":"Mucosa of lower lip","n_c":["C12225"],"i_c":"C00.4","i_c_s":["Mucosa of lower lip"],"term_type":"PT"},{"nm":"Mucosa of upper lip","n_c":["C12224"],"i_c":"C00.3","i_c_s":["Mucosa of upper lip"],"term_type":"PT"},{"nm":"Myometrium","n_c":["C12314"],"i_c":"C54.2","i_c_s":["Myometrium"],"term_type":"PT"},{"nm":"Nasal cavity","n_c":["C12424"],"i_c":"C30.0","i_c_s":["Nasal cavity"],"term_type":"PT"},{"nm":"Nasopharynx, NOS","n_c":["C12423"],"i_c":"C11.9","i_c_s":["Nasopharynx, NOS"],"term_type":"PT"},{"nm":"Nervous system, NOS","n_c":["C12755"],"i_c":"C72.9","i_c_s":["Nervous system, NOS"],"term_type":"PT"},{"nm":"Nipple","n_c":["C12299"],"i_c":"C50.0","i_c_s":["Nipple"],"term_type":"PT"},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"C71.4","i_c_s":["Occipital lobe"],"term_type":"PT"},{"nm":"Olfactory nerve","n_c":["C12759"],"i_c":"C72.2","i_c_s":["Olfactory nerve"],"term_type":"PT"},{"nm":"Optic nerve","n_c":["C12761"],"i_c":"C72.3","i_c_s":["Optic nerve"],"term_type":"PT"},{"nm":"Orbit, NOS","n_c":["C12347"],"i_c":"C69.6","i_c_s":["Orbit, NOS"],"term_type":"PT"},{"nm":"Oropharynx, NOS","n_c":["C12762"],"i_c":"C10.9","i_c_s":["Oropharynx, NOS"],"term_type":"PT"},{"nm":"Other ill-defined sites","n_c":["C147919"],"i_c":"C76.7","i_c_s":["Other ill-defined sites"],"term_type":"PT"},{"nm":"Other specified parts of female genital organs","n_c":["C148339"],"i_c":"C57.7","i_c_s":["Other specified parts of female genital organs"],"term_type":"PT"},{"nm":"Other specified parts of male genital organs","n_c":["C148341"],"i_c":"C63.7","i_c_s":["Other specified parts of male genital organs"],"term_type":"PT"},{"nm":"Other specified parts of pancreas","n_c":["C12273"],"i_c":"C25.7","i_c_s":["Other specified parts of pancreas"],"term_type":"PT"},{"nm":"Ovary","n_c":["C12404"],"i_c":"C56.9","i_c_s":["Ovary"],"term_type":"PT"},{"nm":"Overlapping lesion of accessory sinuses","n_c":"","i_c":"C31.8","i_c_s":["Overlapping lesion of accessory sinuses"],"term_type":"PT"},{"nm":"Overlapping lesion of biliary tract","n_c":"","i_c":"C24.8","i_c_s":["Overlapping lesion of biliary tract"],"term_type":"PT"},{"nm":"Overlapping lesion of bladder","n_c":"","i_c":"C67.8","i_c_s":["Overlapping lesion of bladder"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage","n_c":"","i_c":"C41.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage of limbs","n_c":"","i_c":"C40.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage of limbs"],"term_type":"PT"},{"nm":"Overlapping lesion of brain","n_c":"","i_c":"C71.8","i_c_s":["Overlapping lesion of brain"],"term_type":"PT"},{"nm":"Overlapping lesion of brain and central nervous system","n_c":"","i_c":"C72.8","i_c_s":["Overlapping lesion of brain and central nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of breast","n_c":"","i_c":"C50.8","i_c_s":["Overlapping lesion of breast"],"term_type":"PT"},{"nm":"Overlapping lesion of cervix uteri","n_c":"","i_c":"C53.8","i_c_s":["Overlapping lesion of cervix uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of colon","n_c":"","i_c":"C18.8","i_c_s":["Overlapping lesion of colon"],"term_type":"PT"},{"nm":"Overlapping lesion of connective, subcutaneous and other soft tissues","n_c":"","i_c":"C49.8","i_c_s":["Overlapping lesion of connective, subcutaneous and other soft tissues"],"term_type":"PT"},{"nm":"Overlapping lesion of corpus uteri","n_c":"","i_c":"C54.8","i_c_s":["Overlapping lesion of corpus uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of digestive system","n_c":"","i_c":"C26.8","i_c_s":["Overlapping lesion of digestive system"],"term_type":"PT"},{"nm":"Overlapping lesion of endocrine glands and related structures","n_c":"","i_c":"C75.8","i_c_s":["Overlapping lesion of endocrine glands and related structures"],"term_type":"PT"},{"nm":"Overlapping lesion of esophagus","n_c":"","i_c":"C15.8","i_c_s":["Overlapping lesion of esophagus"],"term_type":"PT"},{"nm":"Overlapping lesion of eye and adnexa","n_c":"","i_c":"C69.8","i_c_s":["Overlapping lesion of eye and adnexa"],"term_type":"PT"},{"nm":"Overlapping lesion of female genital organs","n_c":"","i_c":"C57.8","i_c_s":["Overlapping lesion of female genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of floor of mouth","n_c":"","i_c":"C04.8","i_c_s":["Overlapping lesion of floor of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of heart, mediastinum and pleura","n_c":"","i_c":"C38.8","i_c_s":["Overlapping lesion of heart, mediastinum and pleura"],"term_type":"PT"},{"nm":"Overlapping lesion of hypopharynx","n_c":"","i_c":"C13.8","i_c_s":["Overlapping lesion of hypopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of ill-defined sites","n_c":"","i_c":"C76.8","i_c_s":["Overlapping lesion of ill-defined sites"],"term_type":"PT"},{"nm":"Overlapping lesion of larynx","n_c":"","i_c":"C32.8","i_c_s":["Overlapping lesion of larynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lip","n_c":"","i_c":"C00.8","i_c_s":["Overlapping lesion of lip"],"term_type":"PT"},{"nm":"Overlapping lesion of lip, oral cavity and pharynx","n_c":"","i_c":"C14.8","i_c_s":["Overlapping lesion of lip, oral cavity and pharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lung","n_c":"","i_c":"C34.8","i_c_s":["Overlapping lesion of lung"],"term_type":"PT"},{"nm":"Overlapping lesion of major salivary glands","n_c":"","i_c":"C08.8","i_c_s":["Overlapping lesion of major salivary glands"],"term_type":"PT"},{"nm":"Overlapping lesion of male genital organs","n_c":"","i_c":"C63.8","i_c_s":["Overlapping lesion of male genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of nasopharynx","n_c":"","i_c":"C11.8","i_c_s":["Overlapping lesion of nasopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of other and unspecified parts of mouth","n_c":"","i_c":"C06.8","i_c_s":["Overlapping lesion of other and unspecified parts of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of palate","n_c":"","i_c":"C05.8","i_c_s":["Overlapping lesion of palate"],"term_type":"PT"},{"nm":"Overlapping lesion of pancreas","n_c":"","i_c":"C25.8","i_c_s":["Overlapping lesion of pancreas"],"term_type":"PT"},{"nm":"Overlapping lesion of penis","n_c":"","i_c":"C60.8","i_c_s":["Overlapping lesion of penis"],"term_type":"PT"},{"nm":"Overlapping lesion of peripheral nerves and autonomic nervous system","n_c":"","i_c":"C47.8","i_c_s":["Overlapping lesion of peripheral nerves and autonomic nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of rectum, anus and anal canal","n_c":"","i_c":"C21.8","i_c_s":["Overlapping lesion of rectum, anus and anal canal"],"term_type":"PT"},{"nm":"Overlapping lesion of respiratory system and intrathoracic organs","n_c":"","i_c":"C39.8","i_c_s":["Overlapping lesion of respiratory system and intrathoracic organs"],"term_type":"PT"},{"nm":"Overlapping lesion of retroperitoneum and peritoneum","n_c":"","i_c":"C48.8","i_c_s":["Overlapping lesion of retroperitoneum and peritoneum"],"term_type":"PT"},{"nm":"Overlapping lesion of skin","n_c":"","i_c":"C44.8","i_c_s":["Overlapping lesion of skin"],"term_type":"PT"},{"nm":"Overlapping lesion of small intestine","n_c":"","i_c":"C17.8","i_c_s":["Overlapping lesion of small intestine"],"term_type":"PT"},{"nm":"Overlapping lesion of stomach","n_c":"","i_c":"C16.8","i_c_s":["Overlapping lesion of stomach"],"term_type":"PT"},{"nm":"Overlapping lesion of tongue","n_c":"","i_c":"C02.8","i_c_s":["Overlapping lesion of tongue"],"term_type":"PT"},{"nm":"Overlapping lesion of tonsil","n_c":"","i_c":"C09.8","i_c_s":["Overlapping lesion of tonsil"],"term_type":"PT"},{"nm":"Overlapping lesion of urinary organs","n_c":"","i_c":"C68.8","i_c_s":["Overlapping lesion of urinary organs"],"term_type":"PT"},{"nm":"Overlapping lesion of vulva","n_c":"","i_c":"C51.8","i_c_s":["Overlapping lesion of vulva"],"term_type":"PT"},{"nm":"Overlapping lesions of oropharynx","n_c":"","i_c":"C10.8","i_c_s":["Overlapping lesions of oropharynx"],"term_type":""},{"nm":"Palate, NOS","n_c":["C12229"],"i_c":"C05.9","i_c_s":["Palate, NOS"],"term_type":"PT"},{"nm":"Pancreas, NOS","n_c":["C12393"],"i_c":"C25.9","i_c_s":["Pancreas, NOS"],"term_type":"PT"},{"nm":"Pancreatic duct","n_c":["C12272"],"i_c":"C25.3","i_c_s":["Pancreatic duct"],"term_type":"PT"},{"nm":"Parametrium","n_c":["C12320"],"i_c":"C57.3","i_c_s":["Parametrium"],"term_type":"PT"},{"nm":"Parathyroid gland","n_c":["C12765"],"i_c":"C75.0","i_c_s":["Parathyroid gland"],"term_type":"PT"},{"nm":"Paraurethral gland","n_c":["C61122"],"i_c":"C68.1","i_c_s":["Paraurethral gland"],"term_type":"PT"},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"C71.3","i_c_s":["Parietal lobe"],"term_type":"PT"},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"C07.9","i_c_s":["Parotid gland"],"term_type":"PT"},{"nm":"Pelvic bones, sacrum, coccyx and associated joints","n_c":"","i_c":"C41.4","i_c_s":["Pelvic bones, sacrum, coccyx and associated joints"],"term_type":"PT"},{"nm":"Pelvic lymph nodes","n_c":["C12363"],"i_c":"C77.5","i_c_s":["Pelvic lymph nodes"],"term_type":"PT"},{"nm":"Pelvis, NOS","n_c":["C12767"],"i_c":"C76.3","i_c_s":["Pelvis, NOS"],"term_type":"PT"},{"nm":"Penis, NOS","n_c":["C12409"],"i_c":"C60.9","i_c_s":["Penis, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of abdomen","n_c":"","i_c":"C47.4","i_c_s":["Peripheral nerves and autonomic nervous system of abdomen"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of head, face, and neck","n_c":"","i_c":"C47.0","i_c_s":["Peripheral nerves and autonomic nervous system of head, face, and neck"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of lower limb and hip","n_c":"","i_c":"C47.2","i_c_s":["Peripheral nerves and autonomic nervous system of lower limb and hip"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of pelvis","n_c":"","i_c":"C47.5","i_c_s":["Peripheral nerves and autonomic nervous system of pelvis"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of thorax","n_c":"","i_c":"C47.3","i_c_s":["Peripheral nerves and autonomic nervous system of thorax"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of trunk, NOS","n_c":"","i_c":"C47.6","i_c_s":["Peripheral nerves and autonomic nervous system of trunk, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of upper limb and shoulder","n_c":"","i_c":"C47.1","i_c_s":["Peripheral nerves and autonomic nervous system of upper limb and shoulder"],"term_type":"PT"},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"C48.2","i_c_s":["Peritoneum, NOS"],"term_type":"PT"},{"nm":"Pharynx, NOS","n_c":["C12425"],"i_c":"C14.0","i_c_s":["Pharynx, NOS"],"term_type":"PT"},{"nm":"Pineal gland","n_c":["C12398"],"i_c":"C75.3","i_c_s":["Pineal gland"],"term_type":"PT"},{"nm":"Pituitary gland","n_c":["C12399"],"i_c":"C75.1","i_c_s":["Pituitary gland"],"term_type":"PT"},{"nm":"Placenta","n_c":["C13272"],"i_c":"C58.9","i_c_s":["Placenta"],"term_type":"PT"},{"nm":"Pleura, NOS","n_c":["C12469"],"i_c":"C38.4","i_c_s":["Pleura, NOS"],"term_type":"PT"},{"nm":"Postcricoid region","n_c":["C54221"],"i_c":"C13.0","i_c_s":["Postcricoid region"],"term_type":"PT"},{"nm":"Posterior mediastinum","n_c":["C33368"],"i_c":"C38.2","i_c_s":["Posterior mediastinum"],"term_type":"PT"},{"nm":"Posterior wall of bladder","n_c":["C12335"],"i_c":"C67.4","i_c_s":["Posterior wall of bladder"],"term_type":"PT"},{"nm":"Posterior wall of hypopharynx","n_c":["C12249"],"i_c":"C13.2","i_c_s":["Posterior wall of hypopharynx"],"term_type":"PT"},{"nm":"Posterior wall of nasopharynx","n_c":["C12243"],"i_c":"C11.1","i_c_s":["Posterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Posterior wall of oropharynx","n_c":["C12240"],"i_c":"C10.3","i_c_s":["Posterior wall of oropharynx"],"term_type":"PT"},{"nm":"Prepuce","n_c":["C12323"],"i_c":"C60.0","i_c_s":["Prepuce"],"term_type":"PT"},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"C61.9","i_c_s":["Prostate gland"],"term_type":"PT"},{"nm":"Pylorus","n_c":["C12260"],"i_c":"C16.4","i_c_s":["Pylorus"],"term_type":"PT"},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"C12.9","i_c_s":["Pyriform sinus"],"term_type":"PT"},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"C19.9","i_c_s":["Rectosigmoid junction"],"term_type":"PT"},{"nm":"Rectum, NOS","n_c":["C12390"],"i_c":"C20.9","i_c_s":["Rectum, NOS"],"term_type":"PT"},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"C65.9","i_c_s":["Renal pelvis"],"term_type":"PT"},{"nm":"Reticuloendothelial system, NOS","n_c":["C12780"],"i_c":"C42.3","i_c_s":["Reticuloendothelial system, NOS"],"term_type":"PT"},{"nm":"Retina","n_c":["C12343"],"i_c":"C69.2","i_c_s":["Retina"],"term_type":"PT"},{"nm":"Retromolar area","n_c":["C54223"],"i_c":"C06.2","i_c_s":["Retromolar area"],"term_type":"PT"},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"C48.0","i_c_s":["Retroperitoneum"],"term_type":"PT"},{"nm":"Rib, sternum, clavicle and associated joints","n_c":"","i_c":"C41.3","i_c_s":["Rib, sternum, clavicle and associated joints"],"term_type":"PT"},{"nm":"Round ligament","n_c":["C12319"],"i_c":"C57.2","i_c_s":["Round ligament"],"term_type":"PT"},{"nm":"Scrotum, NOS","n_c":["C12785"],"i_c":"C63.2","i_c_s":["Scrotum, NOS"],"term_type":"PT"},{"nm":"Short bones of lower limb and associated joints","n_c":"","i_c":"C40.3","i_c_s":["Short bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Short bones of upper limb and associated joints","n_c":"","i_c":"C40.1","i_c_s":["Short bones of upper limb and associated joints"],"term_type":"PT"},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"C18.7","i_c_s":["Sigmoid colon"],"term_type":"PT"},{"nm":"Skin of lip, NOS","n_c":["C12291"],"i_c":"C44.0","i_c_s":["Skin of lip, NOS"],"term_type":"PT"},{"nm":"Skin of lower limb and hip","n_c":["C12297"],"i_c":"C44.7","i_c_s":["Skin of lower limb and hip"],"term_type":"PT"},{"nm":"Skin of other and unspecified parts of face","n_c":["C33561"],"i_c":"C44.3","i_c_s":["Skin of other and unspecified parts of face"],"term_type":"PT"},{"nm":"Skin of scalp and neck","n_c":["C12294"],"i_c":"C44.4","i_c_s":["Skin of scalp and neck"],"term_type":"PT"},{"nm":"Skin of trunk","n_c":["C12295"],"i_c":"C44.5","i_c_s":["Skin of trunk"],"term_type":"RT"},{"nm":"Skin of upper limb and shoulder","n_c":["C12296"],"i_c":"C44.6","i_c_s":["Skin of upper limb and shoulder"],"term_type":"PT"},{"nm":"Skin, NOS","n_c":["C12470"],"i_c":"C44.9","i_c_s":["Skin, NOS"],"term_type":"PT"},{"nm":"Small intestine, NOS","n_c":["C12386"],"i_c":"C17.9","i_c_s":["Small intestine, NOS"],"term_type":"PT"},{"nm":"Soft palate, NOS","n_c":["C12231"],"i_c":"C05.1","i_c_s":["Soft palate, NOS"],"term_type":"PT"},{"nm":"Specified parts of peritoneum","n_c":"","i_c":"C48.1","i_c_s":["Specified parts of peritoneum"],"term_type":"PT"},{"nm":"Spermatic cord","n_c":["C12329"],"i_c":"C63.1","i_c_s":["Spermatic cord"],"term_type":"PT"},{"nm":"Sphenoid sinus","n_c":["C12278"],"i_c":"C31.3","i_c_s":["Sphenoid sinus"],"term_type":"PT"},{"nm":"Spinal cord","n_c":["C12464"],"i_c":"C72.0","i_c_s":["Spinal cord"],"term_type":"PT"},{"nm":"Spinal meninges","n_c":["C12350"],"i_c":"C70.1","i_c_s":["Spinal meninges"],"term_type":"PT"},{"nm":"Spleen","n_c":["C12432"],"i_c":"C42.2","i_c_s":["Spleen"],"term_type":"PT"},{"nm":"Splenic flexure of colon","n_c":["C12267"],"i_c":"C18.5","i_c_s":["Splenic flexure of colon"],"term_type":"PT"},{"nm":"Stomach, NOS","n_c":["C12391"],"i_c":"C16.9","i_c_s":["Stomach, NOS"],"term_type":"PT"},{"nm":"Subglottis","n_c":["C12280"],"i_c":"C32.2","i_c_s":["Subglottis"],"term_type":"PT"},{"nm":"Sublingual gland","n_c":["C12234"],"i_c":"C08.1","i_c_s":["Sublingual gland"],"term_type":"PT"},{"nm":"Submandibular gland","n_c":["C12233"],"i_c":"C08.0","i_c_s":["Submandibular gland"],"term_type":"PT"},{"nm":"Superior wall of nasopharynx","n_c":["C12242"],"i_c":"C11.0","i_c_s":["Superior wall of nasopharynx"],"term_type":"PT"},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"C32.1","i_c_s":["Supraglottis"],"term_type":"PT"},{"nm":"Tail of pancreas","n_c":["C12271"],"i_c":"C25.2","i_c_s":["Tail of pancreas"],"term_type":"PT"},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"C71.2","i_c_s":["Temporal lobe"],"term_type":"PT"},{"nm":"Testis, NOS","n_c":["C12412"],"i_c":"C62.9","i_c_s":["Testis, NOS"],"term_type":"PT"},{"nm":"Thoracic esophagus","n_c":["C12251"],"i_c":"C15.1","i_c_s":["Thoracic esophagus"],"term_type":"PT"},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"C76.1","i_c_s":["Thorax, NOS"],"term_type":"PT"},{"nm":"Thymus","n_c":["C12433"],"i_c":"C37.9","i_c_s":["Thymus"],"term_type":"PT"},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"C73.9","i_c_s":["Thyroid gland"],"term_type":"PT"},{"nm":"Tongue, NOS","n_c":["C12422"],"i_c":"C02.9","i_c_s":["Tongue, NOS"],"term_type":"PT"},{"nm":"Tonsil, NOS","n_c":["C33250"],"i_c":"C09.9","i_c_s":["Tonsil, NOS"],"term_type":"PT"},{"nm":"Tonsillar fossa","n_c":["C12235"],"i_c":"C09.0","i_c_s":["Tonsillar fossa"],"term_type":"PT"},{"nm":"Tonsillar pillar","n_c":["C12236"],"i_c":"C09.1","i_c_s":["Tonsillar pillar"],"term_type":"PT"},{"nm":"Trachea","n_c":["C12428"],"i_c":"C33.9","i_c_s":["Trachea"],"term_type":"PT"},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"C18.4","i_c_s":["Transverse colon"],"term_type":"PT"},{"nm":"Trigone of bladder","n_c":["C12331"],"i_c":"C67.0","i_c_s":["Trigone of bladder"],"term_type":"PT"},{"nm":"Undescended testis","n_c":["C12326"],"i_c":"C62.0","i_c_s":["Undescended testis"],"term_type":"PT"},{"nm":"Unknown primary site","n_c":["C48322"],"i_c":"C80.9","i_c_s":["Unknown primary site"],"term_type":"PT"},{"nm":"Upper Gum","n_c":["C54205"],"i_c":"C03.0","i_c_s":["Upper Gum"],"term_type":""},{"nm":"Upper limb, NOS","n_c":["C12671"],"i_c":"C76.4","i_c_s":["Upper limb, NOS"],"term_type":"PT"},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"C34.1","i_c_s":["Upper lobe, lung"],"term_type":"PT"},{"nm":"Upper respiratory tract, NOS","n_c":["C33839"],"i_c":"C39.0","i_c_s":["Upper respiratory tract, NOS"],"term_type":"PT"},{"nm":"Upper third of esophagus","n_c":["C12253"],"i_c":"C15.3","i_c_s":["Upper third of esophagus"],"term_type":"PT"},{"nm":"Upper-inner quadrant of breast","n_c":["C12301"],"i_c":"C50.2","i_c_s":["Upper-inner quadrant of breast"],"term_type":"PT"},{"nm":"Upper-outer quadrant of breast","n_c":["C12303"],"i_c":"C50.4","i_c_s":["Upper-outer quadrant of breast"],"term_type":"PT"},{"nm":"Urachus","n_c":["C12338"],"i_c":"C67.7","i_c_s":["Urachus"],"term_type":"PT"},{"nm":"Ureter","n_c":["C12416"],"i_c":"C66.9","i_c_s":["Ureter"],"term_type":"PT"},{"nm":"Ureteric orifice","n_c":["C12337"],"i_c":"C67.6","i_c_s":["Ureteric orifice"],"term_type":"PT"},{"nm":"Urethra","n_c":["C12417"],"i_c":"C68.0","i_c_s":["Urethra"],"term_type":"PT"},{"nm":"Urinary system, NOS","n_c":["C12413"],"i_c":"C68.9","i_c_s":["Urinary system, NOS"],"term_type":"PT"},{"nm":"Uterine adnexa","n_c":["C12321"],"i_c":"C57.4","i_c_s":["Uterine adnexa"],"term_type":"PT"},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"C55.9","i_c_s":["Uterus, NOS"],"term_type":"PT"},{"nm":"Uvula","n_c":["C12232"],"i_c":"C05.2","i_c_s":["Uvula"],"term_type":"PT"},{"nm":"Vagina, NOS","n_c":["C12407"],"i_c":"C52.9","i_c_s":["Vagina, NOS"],"term_type":"PT"},{"nm":"Vallecula","n_c":["C12237"],"i_c":"C10.0","i_c_s":["Vallecula"],"term_type":"PT"},{"nm":"Ventral surface of tongue, NOS","n_c":"","i_c":"C02.2","i_c_s":["Ventral surface of tongue, NOS"],"term_type":"PT"},{"nm":"Ventricle, NOS","n_c":["C12356"],"i_c":"C71.5","i_c_s":["Ventricle, NOS"],"term_type":"PT"},{"nm":"Vertebral column","n_c":["C12998"],"i_c":"C41.2","i_c_s":["Vertebral column"],"term_type":"PT"},{"nm":"Vestibule of mouth","n_c":["C165195"],"i_c":"C06.1","i_c_s":["Vestibule of mouth"],"term_type":"PT"},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"C51.9","i_c_s":["Vulva, NOS"],"term_type":"PT"},{"nm":"Waldeyer ring","n_c":["C73468"],"i_c":"C14.2","i_c_s":["Waldeyer ring"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal commissure","n_c":"","i_c":"C32.0","i_c_s":["Laryngeal commissure"],"term_type":"PT"}],"clinical.diagnosis.transglottic_extension":[{"nm":"Absent","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C160996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_confined_to_organ_of_origin":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_focality":[{"nm":"Multifocal","n_c":["C25253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unifocal","n_c":["C47862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_grade":[{"nm":"G1","n_c":["C28077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G2","n_c":["C28078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G3","n_c":["C28079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G4","n_c":["C28082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GX","n_c":["C113730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GB","n_c":["C113729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade","n_c":["C14158"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate Grade","n_c":["C28083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade","n_c":["C14161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_regression_grade":[{"nm":"0","n_c":["C155941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1","n_c":["C155942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C155943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C155944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.vascular_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.vascular_invasion_type":[{"nm":"Extramural","n_c":["C44280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intramural","n_c":["C25234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macro","n_c":["C43566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micro","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Vascular Invasion","n_c":["C164046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.weiss_assessment_score":[{"nm":"0","n_c":["C70430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1","n_c":["C66832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C66833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C66834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":["C66835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5","n_c":["C66836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6","n_c":["C66837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7","n_c":["C66838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8","n_c":["C66839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"9","n_c":["C66840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.who_cns_grade":[{"nm":"Grade I","n_c":["C62394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade II","n_c":["C62395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade III","n_c":["C62396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade IV","n_c":["C62397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade Not Assigned","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.who_nte_grade":[{"nm":"G1","n_c":["C203250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G2","n_c":["C72074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G3","n_c":["C203251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GX","n_c":["C113730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.wilms_tumor_histologic_subtype":[{"nm":"Favorable","n_c":["C102560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unfavorable","n_c":["C102561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.experiment_metadata.data_category":[{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.experiment_metadata.data_type":[{"nm":"Experiment Metadata","n_c":["C165216"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.experiment_metadata.data_format":[{"nm":"SRA XML","n_c":["C184804"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_history":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_intensity":[{"nm":"Drinker","n_c":["C126383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heavy Drinker","n_c":["C126384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifelong Non-Drinker","n_c":["C126380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Drinker","n_c":["C126379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occasional Drinker","n_c":["C126382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social Drinker","n_c":["C156429"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_type":[{"nm":"Beer","n_c":["C66824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquor","n_c":["C66826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wine","n_c":["C66822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.asbestos_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.coal_dust_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.environmental_tobacco_smoke_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.exposure_duration":[{"nm":"Six Weeks or More","n_c":["C171137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.exposure_type":[{"nm":"Marijuana","n_c":["C26659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoke","n_c":["C164057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco","n_c":["C891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood Dust","n_c":["C174115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation","n_c":["C61398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asbestos","n_c":["C55816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical","n_c":["C36290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radon","n_c":["C177573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Respirable Crystalline Silica","n_c":["C177575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smokeless Tobacco","n_c":["C189768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coal Dust","n_c":["C177574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dust, NOS","n_c":["C200417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.radon_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.respirable_crystalline_silica_exposure":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.secondhand_smoke_as_child":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.smoking_frequency":[{"nm":"Every day","n_c":["C67145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Some days","n_c":["C67146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.time_between_waking_and_first_smoke":[{"nm":"Within 5 Minutes","n_c":["C164121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6-30 Minutes","n_c":["C164124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"31-60 Minutes","n_c":["C164126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"After 60 Minutes","n_c":["C164127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.tobacco_smoking_status":[{"nm":"1","n_c":["C65108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C67147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C156828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":["C156829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5","n_c":["C156830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6","n_c":["C164079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7","n_c":["C163971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Reformed Smoker for < or = 15 yrs","n_c":["C156829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Reformed Smoker for > 15 yrs","n_c":["C156828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Reformed Smoker, Duration Not Specified","n_c":["C156830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Current Smoker","n_c":["C67147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifelong Non-Smoker","n_c":["C65108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoker at Diagnosis","n_c":["C164079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking history not documented","n_c":["C163971"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.type_of_smoke_exposure":[{"nm":"Accidental building fire smoke","n_c":["C164066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental fire smoke, grass","n_c":["C164067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental fire smoke, NOS","n_c":["C164059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental forest fire smoke","n_c":["C164068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accidental vehicle fire smoke","n_c":["C164069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aircraft smoke","n_c":["C164072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burning tree smoke","n_c":["C164075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coal smoke, NOS","n_c":["C164060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cooking-related smoke, NOS","n_c":["C164061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrical fire smoke","n_c":["C164077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electronic cigarette smoke, NOS","n_c":["C164062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Environmental tobacco smoke","n_c":["C17140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Factory smokestack smoke","n_c":["C164081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Field burning smoke","n_c":["C164082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fire smoke, NOS","n_c":["C164058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Furnace or boiler smoke","n_c":["C164083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gas burning smoke, propane","n_c":["C164084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grease fire smoke","n_c":["C164085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grilling smoke","n_c":["C164086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashish smoke","n_c":["C164087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoor stove or fireplace smoke, coal burning","n_c":["C164088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoor stove or fireplace smoke, NOS","n_c":["C164064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoor stove or fireplace smoke, wood burning","n_c":["C164089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Machine smoke","n_c":["C164090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marijuana smoke","n_c":["C164091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Smoke Exposure","n_c":["C164092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oil burning smoke, Kerosene","n_c":["C164093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oil burning smoke, NOS","n_c":["C164063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recreational fire smoke","n_c":["C164094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoke exposure, NOS","n_c":["C164057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smokehouse smoke","n_c":["C164095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, cigar","n_c":["C164097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, cigarettes","n_c":["C164098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, NOS","n_c":["C44456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco smoke, pipe","n_c":["C164099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Volcanic smoke","n_c":["C164100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Waste burning smoke","n_c":["C164101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood burning smoke, factory","n_c":["C164102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood burning smoke, NOS","n_c":["C164065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, artificial smoke machines","n_c":["C164104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, fire fighting","n_c":["C164105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, foundry","n_c":["C164106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, generators","n_c":["C164107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, military","n_c":["C164115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, NOS","n_c":["C164103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, paint baking","n_c":["C164116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, plastics factory","n_c":["C164118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, plumbing","n_c":["C164119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work-related smoke, soldering/welding","n_c":["C164120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.type_of_tobacco_used":[{"nm":"Cigar","n_c":["C1813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cigarette","n_c":["C1802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electronic Cigarette","n_c":["C120482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pipe","n_c":["C86044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smokeless Tobacco","n_c":["C892"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relationship_type":[{"nm":"Adopted Brother","n_c":["C166195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adopted Daughter","n_c":["C166131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adopted Sister","n_c":["C166196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adopted Son","n_c":["C166132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adoptive Father","n_c":["C166133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adoptive Mother","n_c":["C166134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aunt","n_c":["C71405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brother","n_c":["C25289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brother-in-law","n_c":["C71406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Child","n_c":["C150886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cousin","n_c":["C71410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daughter","n_c":["C25165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daughter-in-law","n_c":["C71401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domestic Partner","n_c":["C53262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Father","n_c":["C25174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Father-in-law","n_c":["C68640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Female Cousin","n_c":["C165786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Female Sibling of Adopted Child","n_c":["C166198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Cousin","n_c":["C71411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Cousin Once Removed","n_c":["C71412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Brother","n_c":["C165788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Daughter","n_c":["C165790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Father","n_c":["C165792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Mother","n_c":["C165793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Sister","n_c":["C165794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foster Son","n_c":["C165795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fraternal Twin Brother","n_c":["C165796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fraternal Twin Sibling","n_c":["C73428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fraternal Twin Sister","n_c":["C165797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Full Brother","n_c":["C111201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Full Sister","n_c":["C111202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grand Nephew","n_c":["C165798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grand Niece","n_c":["C165846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandchild","n_c":["C71397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granddaughter","n_c":["C71399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandfather","n_c":["C71387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandmother","n_c":["C71386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandparent","n_c":["C71385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grandson","n_c":["C71398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Great Grandchild","n_c":["C165847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Half Brother","n_c":["C71402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Half Sibling","n_c":["C71391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Half Sister","n_c":["C71403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Husband","n_c":["C71588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Identical Twin Brother","n_c":["C165848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Identical Twin Sibling","n_c":["C73429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Identical Twin Sister","n_c":["C165849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legal Guardian","n_c":["C51828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Male Cousin","n_c":["C165850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Male Sibling of Adopted Child","n_c":["C166197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Aunt","n_c":["C96575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal First Cousin","n_c":["C96576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal First Cousin Once Removed","n_c":["C165851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Grandfather","n_c":["C96577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Grandmother","n_c":["C96578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Grandparent","n_c":["C111248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Great Aunt","n_c":["C165853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Great Grandparent","n_c":["C166127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Great Uncle","n_c":["C165854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Half Brother","n_c":["C96656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Half Sibling","n_c":["C166112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Half Sister","n_c":["C96658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maternal Uncle","n_c":["C96579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mother","n_c":["C25189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mother-in-law","n_c":["C68639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Brother","n_c":["C96570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Child","n_c":["C42708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Daughter","n_c":["C25165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Father","n_c":["C96572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandchild","n_c":["C100805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandfather","n_c":["C96573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandmother","n_c":["C96574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Grandparent","n_c":["C100806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Mother","n_c":["C96580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Parent","n_c":["C166114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Sibling","n_c":["C100809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Sister","n_c":["C96586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Son","n_c":["C150888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nephew","n_c":["C71409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niece","n_c":["C71408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niece Second Degree Relative","n_c":["C166115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parent","n_c":["C42709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Aunt","n_c":["C96581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal First Cousin","n_c":["C96582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal First Cousin Once Removed","n_c":["C165852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Grandfather","n_c":["C96583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Grandmother","n_c":["C96584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Grandparent","n_c":["C111286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Great Aunt","n_c":["C165856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Great Grandparent","n_c":["C166128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Great Uncle","n_c":["C165857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Half Brother","n_c":["C96655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Half Sibling","n_c":["C166113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Half Sister","n_c":["C96657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paternal Uncle","n_c":["C96585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sibling","n_c":["C25204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sister","n_c":["C25680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sister-in-law","n_c":["C71407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Son","n_c":["C25205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Son-in-law","n_c":["C71400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spouse","n_c":["C62649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Step Child","n_c":["C166117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Step Sibling","n_c":["C166118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepbrother","n_c":["C166119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepdaughter","n_c":["C166123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepfather","n_c":["C154851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepmother","n_c":["C132450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepsister","n_c":["C166124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stepson","n_c":["C166125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twin Sibling","n_c":["C73427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uncle","n_c":["C71404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unrelated","n_c":["C25328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ward","n_c":["C71413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wife","n_c":["C71587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Degree Relative, NOS","n_c":["C21481"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relationship_gender":[{"nm":"female","n_c":["C16576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"male","n_c":["C20197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unspecified","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relationship_primary_diagnosis":[{"nm":"Adrenal Gland Cancer","n_c":["C9338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Cancer","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct Cancer","n_c":["C27814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Cancer","n_c":["C4912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Cancer","n_c":["C116915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Cancer","n_c":["C4016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Cancer","n_c":["C3568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Cancer","n_c":["C4872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Cancer","n_c":["C9039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chondrosarcoma","n_c":["C2946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Cancer","n_c":["C4627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Cancer","n_c":["C2955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Cancer","n_c":["C3513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ewing Sarcoma","n_c":["C4817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Cancer","n_c":["C3844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Cancer","n_c":["C4911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioblastoma","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gynecologic Cancer","n_c":["C4913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head and Neck Cancer","n_c":["C4013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Cancer","n_c":["C27134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kaposi Sarcoma","n_c":["C9087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Cancer","n_c":["C9384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Cancer","n_c":["C4855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukemia","n_c":["C3161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cancer","n_c":["C7927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Cancer","n_c":["C4878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node Cancer","n_c":["C35812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoma","n_c":["C3208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melanoma","n_c":["C3224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelioma","n_c":["C3786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multiple Myeloma","n_c":["C3242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroblastoma","n_c":["C3270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteosarcoma","n_c":["C9145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Cancer","n_c":["C7431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Cancer","n_c":["C3850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pediatric Liver Cancer","n_c":["C7708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Cancer","n_c":["C4863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Cancer","n_c":["C9382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhabdomyosarcoma","n_c":["C3359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoma","n_c":["C9118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Cancer","n_c":["C2920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen Cancer","n_c":["C3539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Cancer","n_c":["C9063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat Cancer","n_c":["C35506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Cancer","n_c":["C4815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue Cancer","n_c":["C4824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsillar Cancer","n_c":["C4825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Cancer","n_c":["C3552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wilms Tumor","n_c":["C3267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relative_with_cancer_history":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.adverse_event":[{"nm":"Abdominal Distension","n_c":["C143253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Infection","n_c":["C143254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Pain","n_c":["C143255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Soft Tissue Necrosis","n_c":["C143256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abducens Nerve Disorder","n_c":["C143257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Accessory Nerve Disorder","n_c":["C143258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acidosis","n_c":["C143259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acoustic Nerve Disorder NOS","n_c":["C143260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Activated Partial Thromboplastin Time Prolonged","n_c":["C143261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Coronary Syndrome","n_c":["C53652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Kidney Injury","n_c":["C143262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal Insufficiency","n_c":["C55748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adult Respiratory Distress Syndrome","n_c":["C58020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agitation","n_c":["C146777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akathisia","n_c":["C143266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alanine Aminotransferase Increased","n_c":["C143267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Intolerance","n_c":["C143268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alkaline Phosphatase Increased","n_c":["C143269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alkalosis","n_c":["C143270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergic Reaction","n_c":["C143271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergic Rhinitis","n_c":["C143272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alopecia","n_c":["C57898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amnesia","n_c":["C143274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Fistula","n_c":["C143275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Hemorrhage","n_c":["C143276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Mucositis","n_c":["C143277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Necrosis","n_c":["C143278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Pain","n_c":["C143279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Stenosis","n_c":["C143280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Ulcer","n_c":["C143281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anaphylaxis","n_c":["C143282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C143283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle Fracture","n_c":["C143284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectal Infection","n_c":["C143285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorexia","n_c":["C57118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorgasmia","n_c":["C143287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C146778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Injury","n_c":["C143289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Valve Disease","n_c":["C143290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aphonia","n_c":["C143291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apnea","n_c":["C55340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendicitis","n_c":["C143294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendicitis Perforated","n_c":["C143293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arachnoiditis","n_c":["C143295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arterial Injury","n_c":["C143296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arteritis Infective","n_c":["C143297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthralgia","n_c":["C143298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C143299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C143300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspartate Aminotransferase Increased","n_c":["C143301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspiration","n_c":["C28245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asystole","n_c":["C146731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia","n_c":["C146737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atelectasis","n_c":["C58022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C54767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Flutter","n_c":["C54768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrioventricular Block Complete","n_c":["C143308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrioventricular Block First Degree","n_c":["C143309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Disorder","n_c":["C143310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C143311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azoospermia","n_c":["C143312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back Pain","n_c":["C146739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct Stenosis","n_c":["C143314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Anastomotic Leak","n_c":["C143315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Fistula","n_c":["C143316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Tract Infection","n_c":["C143317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Anastomotic Leak","n_c":["C143318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Infection","n_c":["C143319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Perforation","n_c":["C146707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder Spasm","n_c":["C146698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bloating","n_c":["C143322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood and Lymphatic System Disorders - Other","n_c":["C143323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Antidiuretic Hormone Abnormal","n_c":["C143324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Bilirubin Increased","n_c":["C143325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Corticotrophin Decreased","n_c":["C143326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Gonadotrophin Abnormal","n_c":["C143327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Prolactin Abnormal","n_c":["C143328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blurred Vision","n_c":["C55906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Body Odor","n_c":["C143330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Infection","n_c":["C143331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Hypocellular","n_c":["C143332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Pain","n_c":["C146741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachial Plexopathy","n_c":["C146754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Atrophy","n_c":["C143335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Infection","n_c":["C143336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast Pain","n_c":["C146742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Fistula","n_c":["C143338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Infection","n_c":["C143339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Obstruction","n_c":["C143340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchial Stricture","n_c":["C143341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchopleural Fistula","n_c":["C143342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchopulmonary Hemorrhage","n_c":["C143343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchospasm","n_c":["C143344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruising","n_c":["C143345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bullous Dermatitis","n_c":["C143346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burn","n_c":["C57900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock Pain","n_c":["C146744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary Leak Syndrome","n_c":["C143349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbon Monoxide Diffusing Capacity Decreased","n_c":["C143350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Arrest","n_c":["C143351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Disorders - Other","n_c":["C143352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Troponin I Increased","n_c":["C143353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Troponin T Increased","n_c":["C143354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataract","n_c":["C146674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Catheter Related Infection","n_c":["C143356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD4 Lymphocytes Decreased","n_c":["C143357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecal Hemorrhage","n_c":["C143358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecal Infection","n_c":["C143359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System Necrosis","n_c":["C143360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid Leakage","n_c":["C143361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervicitis Infection","n_c":["C143362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cheilitis","n_c":["C57901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Pain - Cardiac","n_c":["C143364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall Pain","n_c":["C146743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chills","n_c":["C143366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholecystitis","n_c":["C146788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholesterol High","n_c":["C143368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C143369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chylothorax","n_c":["C58027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cognitive Disturbance","n_c":["C146746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colitis","n_c":["C57134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Fistula","n_c":["C143373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Hemorrhage","n_c":["C143374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Obstruction","n_c":["C143375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Perforation","n_c":["C143376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Stenosis","n_c":["C143377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonic Ulcer","n_c":["C143378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Concentration Impairment","n_c":["C143379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conduction Disorder","n_c":["C143380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Confusion","n_c":["C146785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congenital, Familial and Genetic Disorders - Other","n_c":["C143382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctivitis","n_c":["C143384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctivitis Infective","n_c":["C143383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Constipation","n_c":["C57141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Constrictive Pericarditis","n_c":["C78246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corneal Infection","n_c":["C143386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corneal Ulcer","n_c":["C143387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cough","n_c":["C58028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CPK Increased","n_c":["C143389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cranial Nerve Infection","n_c":["C143390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Creatinine Increased","n_c":["C143391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cushingoid","n_c":["C143392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cystitis Noninfective","n_c":["C143393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokine Release Syndrome","n_c":["C143394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death Neonatal","n_c":["C143395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death NOS","n_c":["C143396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dehydration","n_c":["C57787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delayed Orgasm","n_c":["C143398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delayed Puberty","n_c":["C55742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delirium","n_c":["C143400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delusions","n_c":["C143401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dental Caries","n_c":["C143402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depressed Level of Consciousness","n_c":["C143403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C55447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatitis Radiation","n_c":["C143405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Device Related Infection","n_c":["C143406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diarrhea","n_c":["C57788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Disseminated Intravascular Coagulation","n_c":["C55273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dizziness","n_c":["C146747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dry Eye","n_c":["C143410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dry Mouth","n_c":["C143411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dry Skin","n_c":["C57996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Fistula","n_c":["C57789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Hemorrhage","n_c":["C143414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Infection","n_c":["C143415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Obstruction","n_c":["C143416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Perforation","n_c":["C143417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Stenosis","n_c":["C143418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenal Ulcer","n_c":["C143419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysarthria","n_c":["C143420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysesthesia","n_c":["C143421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysgeusia","n_c":["C143422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysmenorrhea","n_c":["C143423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyspareunia","n_c":["C143424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyspepsia","n_c":["C143425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysphagia","n_c":["C57795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysphasia","n_c":["C143427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyspnea","n_c":["C58185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear and Labyrinth Disorders - Other","n_c":["C143429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Pain","n_c":["C143430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Cerebral","n_c":["C143431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Face","n_c":["C143432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Limbs","n_c":["C143433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edema Trunk","n_c":["C143434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ejaculation Disorder","n_c":["C143435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ejection Fraction Decreased","n_c":["C143436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrocardiogram QT Corrected Interval Prolonged","n_c":["C143437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalitis Infection","n_c":["C143438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalomyelitis Infection","n_c":["C143439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalopathy","n_c":["C146699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocarditis Infective","n_c":["C143441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Disorders - Other","n_c":["C143442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endophthalmitis","n_c":["C143443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterocolitis","n_c":["C143445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterocolitis Infectious","n_c":["C143444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterovesical Fistula","n_c":["C143446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epistaxis","n_c":["C143447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erectile Dysfunction","n_c":["C55615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythema Multiforme","n_c":["C143449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythroderma","n_c":["C143450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Anastomotic Leak","n_c":["C143451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Fistula","n_c":["C57798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Hemorrhage","n_c":["C143453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Infection","n_c":["C143454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Necrosis","n_c":["C143455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Obstruction","n_c":["C143456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Pain","n_c":["C143457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Perforation","n_c":["C143458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Stenosis","n_c":["C143459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Ulcer","n_c":["C143460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Varices Hemorrhage","n_c":["C146710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagitis","n_c":["C57797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Euphoria","n_c":["C146748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exostosis","n_c":["C146749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"External Ear Inflammation","n_c":["C79601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"External Ear Pain","n_c":["C146745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extraocular Muscle Paresis","n_c":["C143466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extrapyramidal Disorder","n_c":["C143467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye Disorders - Other","n_c":["C143468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye Infection","n_c":["C143469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye Pain","n_c":["C146751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eyelid Function Disorder","n_c":["C143471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Facial Muscle Weakness","n_c":["C143472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Facial Nerve Disorder","n_c":["C143473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Facial Pain","n_c":["C143474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fall","n_c":["C143475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Anastomotic Leak","n_c":["C143476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Obstruction","n_c":["C146752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Perforation","n_c":["C146714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube Stenosis","n_c":["C78295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fat Atrophy","n_c":["C143479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fatigue","n_c":["C146753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Febrile Neutropenia","n_c":["C143481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fecal Incontinence","n_c":["C143482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Female Genital Tract Fistula","n_c":["C78298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feminization Acquired","n_c":["C143483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fetal Death","n_c":["C50620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fetal Growth Retardation","n_c":["C143484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fever","n_c":["C143485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrinogen Decreased","n_c":["C143486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis Deep Connective Tissue","n_c":["C143487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flank Pain","n_c":["C143488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flashing Lights","n_c":["C143489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flatulence","n_c":["C57807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floaters","n_c":["C143491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flu Like Symptoms","n_c":["C143492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flushing","n_c":["C146643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forced Expiratory Volume Decreased","n_c":["C143494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fracture","n_c":["C58382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gait Disturbance","n_c":["C143496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Fistula","n_c":["C57808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Infection","n_c":["C143497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Necrosis","n_c":["C146735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Obstruction","n_c":["C57810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Pain","n_c":["C146755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder Perforation","n_c":["C146708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Anastomotic Leak","n_c":["C143498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Fistula","n_c":["C143499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Hemorrhage","n_c":["C143500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Necrosis","n_c":["C143501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Perforation","n_c":["C143502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Stenosis","n_c":["C143503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Ulcer","n_c":["C143504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C57812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C143506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Anastomotic Leak","n_c":["C143507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Disorders - Other","n_c":["C143508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Fistula","n_c":["C146637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Pain","n_c":["C143510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Stoma Necrosis","n_c":["C143511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroparesis","n_c":["C143512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"General Disorders and Administration Site Conditions - Other","n_c":["C143513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Generalized Muscle Weakness","n_c":["C143514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genital Edema","n_c":["C143515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GGT Increased","n_c":["C143516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gingival Pain","n_c":["C146626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C55842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glossopharyngeal Nerve Disorder","n_c":["C143518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucose Intolerance","n_c":["C143519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth Accelerated","n_c":["C143520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth Hormone Abnormal","n_c":["C143521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth Suppression","n_c":["C143522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum Infection","n_c":["C143523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gynecomastia","n_c":["C146685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hallucinations","n_c":["C143525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Haptoglobin Decreased","n_c":["C143526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head Soft Tissue Necrosis","n_c":["C58383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C143527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hearing Impaired","n_c":["C143528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Failure","n_c":["C143529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematoma","n_c":["C56539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematosalpinx","n_c":["C143531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematuria","n_c":["C143532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemoglobin Increased","n_c":["C143533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemoglobinuria","n_c":["C146768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemolysis","n_c":["C55992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemolytic Uremic Syndrome","n_c":["C143536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhoidal Hemorrhage","n_c":["C143537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhoids","n_c":["C146738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Failure","n_c":["C143539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Hemorrhage","n_c":["C143540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Infection","n_c":["C143541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Necrosis","n_c":["C146736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Pain","n_c":["C143542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis Viral","n_c":["C143543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatobiliary Disorders - Other","n_c":["C143544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hiccups","n_c":["C143545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip Fracture","n_c":["C143546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hirsutism","n_c":["C143547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hoarseness","n_c":["C143548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hot Flashes","n_c":["C143549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydrocephalus","n_c":["C55401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C143551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C143552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperhidrosis","n_c":["C143553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperkalemia","n_c":["C143554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypermagnesemia","n_c":["C143555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypernatremia","n_c":["C143556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperparathyroidism","n_c":["C143557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypersomnia","n_c":["C143558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C55060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperthyroidism","n_c":["C143560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertrichosis","n_c":["C143561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertriglyceridemia","n_c":["C143562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperuricemia","n_c":["C143563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoalbuminemia","n_c":["C143564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypocalcemia","n_c":["C143565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoglossal Nerve Disorder","n_c":["C143566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoglycemia","n_c":["C143567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypohidrosis","n_c":["C143568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypokalemia","n_c":["C143569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypomagnesemia","n_c":["C143570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyponatremia","n_c":["C143571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoparathyroidism","n_c":["C143572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypophosphatemia","n_c":["C143573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypotension","n_c":["C55061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothermia","n_c":["C55332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C143576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoxia","n_c":["C58188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Fistula","n_c":["C57821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Hemorrhage","n_c":["C56542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Obstruction","n_c":["C57823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Perforation","n_c":["C146633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Stenosis","n_c":["C143578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileal Ulcer","n_c":["C57826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileus","n_c":["C57814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immune System Disorders - Other","n_c":["C143580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infections and Infestations - Other","n_c":["C143581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infective Myositis","n_c":["C143582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infusion Related Reaction","n_c":["C143583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infusion Site Extravasation","n_c":["C143584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injection Site Reaction","n_c":["C143585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Carotid Artery","n_c":["C143586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Inferior Vena Cava","n_c":["C56735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Jugular Vein","n_c":["C143587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury to Superior Vena Cava","n_c":["C143588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injury, Poisoning and Procedural Complications - Other","n_c":["C143589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INR Increased","n_c":["C143590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insomnia","n_c":["C146771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Stoma Leak","n_c":["C143592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Stoma Obstruction","n_c":["C143593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Stoma Site Bleeding","n_c":["C143594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intra-Abdominal Hemorrhage","n_c":["C143595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intracranial Hemorrhage","n_c":["C143596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Arterial Injury","n_c":["C143597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Breast Injury","n_c":["C143598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Cardiac Injury","n_c":["C143599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Ear Injury","n_c":["C143600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Endocrine Injury","n_c":["C143601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Gastrointestinal Injury","n_c":["C143602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Head and Neck Injury","n_c":["C143603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Hemorrhage","n_c":["C143604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Hepatobiliary Injury","n_c":["C143605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Musculoskeletal Injury","n_c":["C143606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Neurological Injury","n_c":["C143607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Ocular Injury","n_c":["C143608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Renal Injury","n_c":["C143609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Reproductive Tract Injury","n_c":["C143610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Respiratory Injury","n_c":["C143611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Skin Injury","n_c":["C78389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Splenic Injury","n_c":["C143612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Urinary Injury","n_c":["C143613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraoperative Venous Injury","n_c":["C143614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Investigations - Other","n_c":["C143615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C55993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irregular Menstruation","n_c":["C143617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irritability","n_c":["C143618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemia Cerebrovascular","n_c":["C143619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IVth Nerve Disorder","n_c":["C143235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Fistula","n_c":["C57827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Hemorrhage","n_c":["C56543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Obstruction","n_c":["C57829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Perforation","n_c":["C143622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Stenosis","n_c":["C143623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunal Ulcer","n_c":["C57832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Effusion","n_c":["C146760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Infection","n_c":["C143626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Range of Motion Decreased","n_c":["C143629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Range of Motion Decreased Cervical Spine","n_c":["C143627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Range of Motion Decreased Lumbar Spine","n_c":["C143628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Keratitis","n_c":["C55847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Anastomotic Leak","n_c":["C143631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Infection","n_c":["C143632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kyphosis","n_c":["C143633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lactation Disorder","n_c":["C143634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Intestinal Anastomotic Leak","n_c":["C143635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Edema","n_c":["C143636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Fistula","n_c":["C58190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Hemorrhage","n_c":["C56545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Inflammation","n_c":["C143637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Mucositis","n_c":["C143638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Obstruction","n_c":["C143639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngeal Stenosis","n_c":["C143640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngitis","n_c":["C143641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharyngeal Dysesthesia","n_c":["C143642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngospasm","n_c":["C143643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left Ventricular Systolic Dysfunction","n_c":["C146719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lethargy","n_c":["C143645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukemia Secondary to Oncology Chemotherapy","n_c":["C143646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukocytosis","n_c":["C143647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukoencephalopathy","n_c":["C143648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libido Decreased","n_c":["C143649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libido Increased","n_c":["C143650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip Infection","n_c":["C143651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip Pain","n_c":["C146761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipase Increased","n_c":["C143652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipohypertrophy","n_c":["C143653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Localized Edema","n_c":["C143654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lordosis","n_c":["C143655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lower Gastrointestinal Hemorrhage","n_c":["C143656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Infection","n_c":["C143657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Gland Infection","n_c":["C143658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Leakage","n_c":["C143659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node Pain","n_c":["C146773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphedema","n_c":["C143660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocele","n_c":["C55705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocyte Count Decreased","n_c":["C143662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocyte Count Increased","n_c":["C143663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malabsorption","n_c":["C57838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaise","n_c":["C143665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mania","n_c":["C143666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Hemorrhage","n_c":["C56549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Infection","n_c":["C143667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Memory Impairment","n_c":["C146763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meningismus","n_c":["C143669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Meningitis","n_c":["C143670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menopause","n_c":["C3231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menorrhagia","n_c":["C143671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolism and Nutrition Disorders - Other","n_c":["C143672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Ear Inflammation","n_c":["C143673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitral Valve Disease","n_c":["C143674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobitz (Type) II Atrioventricular Block","n_c":["C54772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobitz Type I","n_c":["C54771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Movements Involuntary","n_c":["C143677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucosal Infection","n_c":["C143678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucositis Oral","n_c":["C143679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-Organ Failure","n_c":["C143680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Left-Sided","n_c":["C143681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Lower Limb","n_c":["C143682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Right-Sided","n_c":["C143683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Trunk","n_c":["C143684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Weakness Upper Limb","n_c":["C143685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Musculoskeletal and Connective Tissue Disorders - Other","n_c":["C143686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Musculoskeletal Deformity","n_c":["C143687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myalgia","n_c":["C143688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelitis","n_c":["C55459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndrome","n_c":["C143690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C143691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocarditis","n_c":["C146695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myositis","n_c":["C146787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Discoloration","n_c":["C143694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Infection","n_c":["C143695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Loss","n_c":["C143696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nail Ridging","n_c":["C143697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Congestion","n_c":["C143698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nausea","n_c":["C146764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck Edema","n_c":["C143700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck Pain","n_c":["C146766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck Soft Tissue Necrosis","n_c":["C58394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other","n_c":["C143701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nervous System Disorders - Other","n_c":["C143702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuralgia","n_c":["C143703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neutrophil Count Decreased","n_c":["C143704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Night Blindness","n_c":["C143705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nipple Deformity","n_c":["C143706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Cardiac Chest Pain","n_c":["C143707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nystagmus","n_c":["C146775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C55334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obstruction Gastric","n_c":["C143710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oculomotor Nerve Disorder","n_c":["C143711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olfactory Nerve Disorder","n_c":["C143712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oligospermia","n_c":["C143713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Optic Nerve Disorder","n_c":["C143714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity Fistula","n_c":["C143715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Dysesthesia","n_c":["C143716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hemorrhage","n_c":["C56551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Pain","n_c":["C146627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteonecrosis of Jaw","n_c":["C143717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis","n_c":["C146767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Otitis Externa","n_c":["C143719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Otitis Media","n_c":["C143720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Hemorrhage","n_c":["C56553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Infection","n_c":["C143721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Rupture","n_c":["C143722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovulation Pain","n_c":["C146769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain","n_c":["C143725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain in Extremity","n_c":["C143723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain of Skin","n_c":["C143724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palmar-Plantar Erythrodysesthesia Syndrome","n_c":["C143726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palpitations","n_c":["C54935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Infection","n_c":["C143728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Anastomotic Leak","n_c":["C143729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Duct Stenosis","n_c":["C143730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Enzymes Decreased","n_c":["C143731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Fistula","n_c":["C57845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Hemorrhage","n_c":["C56554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatic Necrosis","n_c":["C143732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C146789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papilledema","n_c":["C143734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papulopustular Rash","n_c":["C143735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paresthesia","n_c":["C143736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paronychia","n_c":["C143737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paroxysmal Atrial Tachycardia","n_c":["C143738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Floor Muscle Weakness","n_c":["C143739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Infection","n_c":["C143740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Pain","n_c":["C146679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Soft Tissue Necrosis","n_c":["C58399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penile Infection","n_c":["C143741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penile Pain","n_c":["C146680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perforation Bile Duct","n_c":["C143742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardial Effusion","n_c":["C143743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardial Tamponade","n_c":["C143744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericarditis","n_c":["C55067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perineal Pain","n_c":["C146681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periodontal Disease","n_c":["C57849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Edema","n_c":["C143747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Infection","n_c":["C143748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Ischemia","n_c":["C143749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Motor Neuropathy","n_c":["C143750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Nerve Infection","n_c":["C143751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Sensory Neuropathy","n_c":["C143752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Infection","n_c":["C143753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Necrosis","n_c":["C57850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personality Change","n_c":["C143754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phantom Pain","n_c":["C146682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Anastomotic Leak","n_c":["C143755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Fistula","n_c":["C57851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Hemorrhage","n_c":["C56557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Mucositis","n_c":["C143756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Necrosis","n_c":["C57855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngeal Stenosis","n_c":["C143757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngitis","n_c":["C143758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharyngolaryngeal Pain","n_c":["C143759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phlebitis","n_c":["C143761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phlebitis Infective","n_c":["C143760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photophobia","n_c":["C146770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photosensitivity","n_c":["C58005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platelet Count Decreased","n_c":["C143764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C143765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Hemorrhage","n_c":["C56558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Infection","n_c":["C143766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleuritic Pain","n_c":["C146663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonitis","n_c":["C143767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumothorax","n_c":["C58201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portal Hypertension","n_c":["C143769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portal Vein Thrombosis","n_c":["C143770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postnasal Drip","n_c":["C143771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative Hemorrhage","n_c":["C143772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative Thoracic Procedure Complication","n_c":["C143773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Precocious Puberty","n_c":["C146645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy, Puerperium and Perinatal Conditions - Other","n_c":["C143775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premature Delivery","n_c":["C143776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premature Menopause","n_c":["C143777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Presyncope","n_c":["C143778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proctitis","n_c":["C57857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Productive Cough","n_c":["C143780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolapse of Intestinal Stoma","n_c":["C143781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolapse of Urostomy","n_c":["C143782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Infection","n_c":["C143783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Hemorrhage","n_c":["C56552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Obstruction","n_c":["C143784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Pain","n_c":["C146664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proteinuria","n_c":["C146758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pruritus","n_c":["C58006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psychiatric Disorders - Other","n_c":["C143787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psychosis","n_c":["C143788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Edema","n_c":["C143789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C143790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fistula","n_c":["C143791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hypertension","n_c":["C55068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Valve Disease","n_c":["C143793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Purpura","n_c":["C143794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyramidal Tract Syndrome","n_c":["C143795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation Recall Reaction (Dermatologic)","n_c":["C143796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiculitis","n_c":["C143797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rash Acneiform","n_c":["C143798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rash Maculo-Papular","n_c":["C143799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rash Pustular","n_c":["C143800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Anastomotic Leak","n_c":["C143801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Fistula","n_c":["C57859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Hemorrhage","n_c":["C56560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Mucositis","n_c":["C143802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Necrosis","n_c":["C57863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Obstruction","n_c":["C57864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Pain","n_c":["C146631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Perforation","n_c":["C146634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Stenosis","n_c":["C143803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectal Ulcer","n_c":["C57867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Laryngeal Nerve Palsy","n_c":["C143804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal and Urinary Disorders - Other","n_c":["C143805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Calculi","n_c":["C143806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Colic","n_c":["C143807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Hemorrhage","n_c":["C56544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reproductive System and Breast Disorders - Other","n_c":["C143808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Respiratory Failure","n_c":["C143809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Respiratory, Thoracic and Mediastinal Disorders - Other","n_c":["C143810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Restlessness","n_c":["C143811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Restrictive Cardiomyopathy","n_c":["C55069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinal Detachment","n_c":["C146729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinal Tear","n_c":["C143814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinal Vascular Disorder","n_c":["C143815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinoic Acid Syndrome","n_c":["C56635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinopathy","n_c":["C55891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal Hemorrhage","n_c":["C146632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reversible Posterior Leukoencephalopathy Syndrome","n_c":["C143818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhinitis Infective","n_c":["C143819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right Ventricular Dysfunction","n_c":["C55070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Duct Inflammation","n_c":["C143821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland Fistula","n_c":["C57868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland Infection","n_c":["C143822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp Pain","n_c":["C146772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scleral Disorder","n_c":["C143823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scoliosis","n_c":["C143824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotal Infection","n_c":["C143825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotal Pain","n_c":["C146665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C146700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sepsis","n_c":["C143827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seroma","n_c":["C58401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Amylase Increased","n_c":["C143829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Sickness","n_c":["C146642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sick Sinus Syndrome","n_c":["C54938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Bradycardia","n_c":["C54940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Disorder","n_c":["C143831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Pain","n_c":["C146783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus Tachycardia","n_c":["C146759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinusitis","n_c":["C143832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin and Subcutaneous Tissue Disorders - Other","n_c":["C143833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Atrophy","n_c":["C146644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Hyperpigmentation","n_c":["C143835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Hypopigmentation","n_c":["C143836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Induration","n_c":["C143837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Infection","n_c":["C143838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Ulceration","n_c":["C143839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep Apnea","n_c":["C143840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Anastomotic Leak","n_c":["C143841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Mucositis","n_c":["C143842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Obstruction","n_c":["C143843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Perforation","n_c":["C146635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestinal Stenosis","n_c":["C143844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestine Infection","n_c":["C143845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Intestine Ulcer","n_c":["C143846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sneezing","n_c":["C143847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social Circumstances - Other","n_c":["C143848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Infection","n_c":["C143849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Necrosis Lower Limb","n_c":["C143850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue Necrosis Upper Limb","n_c":["C143851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somnolence","n_c":["C143852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sore Throat","n_c":["C143853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spasticity","n_c":["C143854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spermatic Cord Anastomotic Leak","n_c":["C143855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spermatic Cord Hemorrhage","n_c":["C56563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spermatic Cord Obstruction","n_c":["C146757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Fracture","n_c":["C143856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen Disorder","n_c":["C35823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Infection","n_c":["C143857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stenosis of Gastrointestinal Stoma","n_c":["C143858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stevens-Johnson Syndrome","n_c":["C143859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stoma Site Infection","n_c":["C143860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach Pain","n_c":["C146774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomal Ulcer","n_c":["C146694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stridor","n_c":["C143861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C143862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sudden Death NOS","n_c":["C143863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suicidal Ideation","n_c":["C143864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suicide Attempt","n_c":["C143865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial Soft Tissue Fibrosis","n_c":["C143866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial Thrombophlebitis","n_c":["C143867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superior Vena Cava Syndrome","n_c":["C143868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraventricular Tachycardia","n_c":["C54945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical and Medical Procedures - Other","n_c":["C143869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syncope","n_c":["C146750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telangiectasia","n_c":["C146740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Disorder","n_c":["C143872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Hemorrhage","n_c":["C56566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testicular Pain","n_c":["C146666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thromboembolic Event","n_c":["C143873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thrombotic Thrombocytopenic Purpura","n_c":["C143874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tinnitus","n_c":["C146690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tooth Development Disorder","n_c":["C143876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tooth Discoloration","n_c":["C143877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tooth Infection","n_c":["C143878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toothache","n_c":["C143879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxic Epidermal Necrolysis","n_c":["C143880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Fistula","n_c":["C58205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Hemorrhage","n_c":["C56567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Mucositis","n_c":["C143881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Obstruction","n_c":["C143882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheal Stenosis","n_c":["C143883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheitis","n_c":["C143884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tracheostomy Site Bleeding","n_c":["C143885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attacks","n_c":["C143886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treatment Related Secondary Malignancy","n_c":["C143887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tremor","n_c":["C146780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tricuspid Valve Disease","n_c":["C143889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trigeminal Nerve Disorder","n_c":["C143890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trismus","n_c":["C58404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Lysis Syndrome","n_c":["C146688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Pain","n_c":["C146782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Typhlitis","n_c":["C146730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unequal Limb Length","n_c":["C143894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unintended Pregnancy","n_c":["C79801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upper Gastrointestinal Hemorrhage","n_c":["C143895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upper Respiratory Infection","n_c":["C143896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureteric Anastomotic Leak","n_c":["C143897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethral Anastomotic Leak","n_c":["C143898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethral Infection","n_c":["C143899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Fistula","n_c":["C143900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Frequency","n_c":["C143901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Incontinence","n_c":["C146786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Retention","n_c":["C57097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C143904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Obstruction","n_c":["C143905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Pain","n_c":["C143906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Urgency","n_c":["C143907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urine Discoloration","n_c":["C143908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urine Output Decreased","n_c":["C143909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Leak","n_c":["C143910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Obstruction","n_c":["C143911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Site Bleeding","n_c":["C143912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urostomy Stenosis","n_c":["C143913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urticaria","n_c":["C58019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Anastomotic Leak","n_c":["C143915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Fistula","n_c":["C143916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Hemorrhage","n_c":["C56572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Infection","n_c":["C143917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Obstruction","n_c":["C143918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Pain","n_c":["C146683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterine Perforation","n_c":["C143919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uveitis","n_c":["C55901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Anastomotic Leak","n_c":["C143921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Discharge","n_c":["C143922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Dryness","n_c":["C146687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Fistula","n_c":["C57104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Hemorrhage","n_c":["C56573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Infection","n_c":["C143924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Inflammation","n_c":["C143925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Obstruction","n_c":["C146696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Pain","n_c":["C146684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Perforation","n_c":["C146697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginal Stricture","n_c":["C143926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaginismus","n_c":["C78703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagus Nerve Disorder","n_c":["C143927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens Anastomotic Leak","n_c":["C143928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Access Complication","n_c":["C143929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disorders - Other","n_c":["C143930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vasculitis","n_c":["C54741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vasovagal Reaction","n_c":["C143932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous Injury","n_c":["C143933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ventricular Arrhythmia","n_c":["C146629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ventricular Fibrillation","n_c":["C146732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ventricular Tachycardia","n_c":["C146733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertigo","n_c":["C143935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vestibular Disorder","n_c":["C143936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virilization","n_c":["C143937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Visceral Arterial Ischemia","n_c":["C143938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vital Capacity Abnormal","n_c":["C143939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitreous Hemorrhage","n_c":["C146677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Voice Alteration","n_c":["C143941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vomiting","n_c":["C57896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulval Infection","n_c":["C143943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Watering Eyes","n_c":["C143944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weight Gain","n_c":["C55338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weight Loss","n_c":["C55339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wheezing","n_c":["C143947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cell Decreased","n_c":["C143948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wolff-Parkinson-White Syndrome","n_c":["C35132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wound Complication","n_c":["C143949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wound Dehiscence","n_c":["C143950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wound Infection","n_c":["C143951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist Fracture","n_c":["C143952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardiac Ischemia","n_c":["C54986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular Filtration Rate Decreased","n_c":["C55159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Pain","n_c":["C56095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rash/Desquamation","n_c":["C58010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Failure","n_c":["C57074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureteral Obstruction","n_c":["C57086"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.adverse_event_grade":[{"nm":"Grade 1","n_c":["C41338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 2","n_c":["C41339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 3","n_c":["C41340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 4","n_c":["C84266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grade 5","n_c":["C48275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.aids_risk_factors":[{"nm":"Candidiasis","n_c":["C26711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coccidioidomycosis","n_c":["C84642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcosis","n_c":["C2967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptosporidiosis, Chronic Intestinal","n_c":["C174107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalopathy","n_c":["C26920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Simplex Virus","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histoplasmosis","n_c":["C77201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isosporiasis","n_c":["C4076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium tuberculosis","n_c":["C128377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium, NOS","n_c":["C26831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nocardiosis","n_c":["C171147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Multifocal Leukoencephalopathy","n_c":["C26815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salmonella Septicemia","n_c":["C171146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxoplasmosis","n_c":["C3418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wasting Syndrome","n_c":["C171148"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.barretts_esophagus_goblet_cells_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.cdc_hiv_risk_factors":[{"nm":"Hemophiliac","n_c":["C3093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterosexual Contact","n_c":["C154862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Homosexual Contact","n_c":["C154863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravenous Drug User","n_c":["C84367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C159672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transfusion Recipient","n_c":["C171149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.comorbidity":[{"nm":"Acute Renal Failure","n_c":["C26808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenocarcinoma","n_c":["C2852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomatous Polyposis Coli","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenocortical Insufficiency","n_c":["C26691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergies","n_c":["C114476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C26696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arrhythmia","n_c":["C2881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C2883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C50466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C118385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Carcinoma","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Disorder","n_c":["C2899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Clots","n_c":["C27083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Fracture(s)","n_c":["C3046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchitis","n_c":["C2911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Channel Blockers","n_c":["C333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataracts","n_c":["C26713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celiac Disease","n_c":["C26714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrovascular Disease","n_c":["C2938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Renal Failure","n_c":["C9438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis, Unknown Etiology","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immunodeficiency","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congestive Heart Failure (CHF)","n_c":["C3080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue Disorder","n_c":["C26729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COPD","n_c":["C3199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coronary Artery Disease","n_c":["C26732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crohn's Disease","n_c":["C2965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptogenic Organizing Pneumonia","n_c":["C62586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Vein Thrombosis / Thromboembolism","n_c":["C49343","C28195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C2982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetic Neuropathy","n_c":["C26748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet Controlled Diabetes","n_c":["C184754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DVT/PE","n_c":["C49343","C50713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyslipidemia","n_c":["C80385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epilepsy","n_c":["C3020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GERD","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C26782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycogen Storage Disease","n_c":["C61272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadal Dysfunction","n_c":["C26786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gout","n_c":["C34650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H. pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Disease","n_c":["C3079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhagic Cystitis","n_c":["C114666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, Chronic","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Non-polyposis Colon Cancer","n_c":["C120083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Liver Dysplastic Nodule","n_c":["C96768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV / AIDS","n_c":["C2851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HUS/TTP","n_c":["C75545","C78797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C3112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercholesterolemia","n_c":["C37967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C26797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperlipidemia","n_c":["C34707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C3117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammatory Bowel Disease","n_c":["C3138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin Controlled Diabetes","n_c":["C184766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interstitial Pneumontis or ARDS","n_c":["C3353","C27006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraductal Papillary Mucinous Neoplasm","n_c":["C38342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemic Heart Disease","n_c":["C50625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITP","n_c":["C3446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Replacement","n_c":["C131579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Disease","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cirrhosis (Liver Disease)","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Toxicity (Non-Infectious)","n_c":["C184773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Liver Dysplastic Nodule","n_c":["C96770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupus","n_c":["C27153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAI","n_c":["C27314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C27996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroendocrine Tumor","n_c":["C3809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ transplant (site)","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoarthritis","n_c":["C3293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis or Osteopenia","n_c":["C3298","C50910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Cancer Within 5 Years","n_c":["C184782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Nonmalignant Systemic Disease","n_c":["C184785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Pulmonary Complications","n_c":["C184786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain (Various)","n_c":["C3303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptic Ulcer (Ulcer)","n_c":["C3318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Neuropathy","n_c":["C119734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Vascular Disease","n_c":["C35136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peutz-Jeghers Disease","n_c":["C3324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy in Patient or Partner","n_c":["C124295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psoriasis","n_c":["C3346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hemorrhage","n_c":["C78578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Dialysis","n_c":["C15248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Failure (Requiring Dialysis)","n_c":["C184791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Insufficiency","n_c":["C4376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatologic Disease","n_c":["C27204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep apnea","n_c":["C26884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C3390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attack","n_c":["C50781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinemia","n_c":["C98640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulcerative Colitis","n_c":["C2952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Fatigue Syndrome","n_c":["C3037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clonal Hematopoiesis","n_c":["C162188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromyalgia","n_c":["C87497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staph Osteomyelitis","n_c":["C188353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Infection","n_c":["C27582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methicillin-Resistant Staphylococcus aureus (MRSA)","n_c":["C115248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Disease, Non-Cancer","n_c":["C27566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C50791"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.comorbidity_method_of_diagnosis":[{"nm":"Histology","n_c":["C16681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathology","n_c":["C18189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiology","n_c":["C19187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.diabetes_treatment_type":[{"nm":"Alpha-Glucosidase Inhibitor","n_c":["C139651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biguanide","n_c":["C98234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injected Insulin","n_c":["C179441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin","n_c":["C581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hypoglycemic","n_c":["C179448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulfonylurea","n_c":["C97936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiazolidinedione","n_c":["C98241"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linagliptin","n_c":["C83887"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.disease_response":[{"nm":"AJ-Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BED-Biochemical Evidence of Disease","n_c":["C165196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CPD-Clinical Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CR-Complete Response","n_c":["C4870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRU-Complete Response Unconfirmed","n_c":["C165198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DU-Disease Unchanged","n_c":["C71687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IMR-Immunoresponse","n_c":["C131144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IPD-Immunoprogression","n_c":["C131143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MR-Minimal/Marginal response","n_c":["C123598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX-Mixed Response","n_c":["C165202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-CR/Non-PD-Non-CR/Non-PD","n_c":["C96700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPB-No Palliative Benefit","n_c":["C165204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR-No Response","n_c":["C123600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PA-Palliative Therapy","n_c":["C15292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PB-Palliative Benefit","n_c":["C101516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-Progressive Disease","n_c":["C8510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDM-Persistent Distant Metastasis","n_c":["C165205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLD-Persistent Locoregional Disease","n_c":["C188367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPD-Pseudoprogression","n_c":["C98298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PR-Partial Response","n_c":["C18058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSR-Pseudoresponse","n_c":["C131142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RD-Responsive Disease","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RP-Response","n_c":["C165206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPD-Radiographic Progressive Disease","n_c":["C165208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"sCR-Stringent Complete Response","n_c":["C123614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SD-Stable Disease","n_c":["C18213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPD-Surgical Progression","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TE-Too Early","n_c":["C133441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TF-Tumor Free","n_c":["C156848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGPR-Very Good Partial Response","n_c":["C123618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT-With Tumor","n_c":["C156849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.ecog_performance_status":[{"nm":"0","n_c":["C105722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1","n_c":["C105723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C105725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C105726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4","n_c":["C105727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5","n_c":["C105728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.evidence_of_recurrence_type":[{"nm":"Biopsy with Histologic Confirmation","n_c":["C158780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Convincing Image Source","n_c":["C158782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical Examination","n_c":["C83119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Positive Biomarker(s)","n_c":["C150123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histologic Confirmation","n_c":["C158780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.haart_treatment_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hepatitis_sustained_virological_response":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hormonal_contraceptive_type":[{"nm":"Progestin","n_c":["C179455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progestin and Estrogen","n_c":["C179456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hormonal_contraceptive_use":[{"nm":"Current User","n_c":["C160671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Former User","n_c":["C160672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never Used","n_c":["C160673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hormone_replacement_therapy_type":[{"nm":"Estrogen only","n_c":["C179434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone and Estrogen","n_c":["C179452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone only","n_c":["C179453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hpv_positive_type":[{"nm":"16","n_c":["C14338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"18","n_c":["C14377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"26","n_c":["C102995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"31","n_c":["C102904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"33","n_c":["C102996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"35","n_c":["C102997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"39","n_c":["C102998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"45","n_c":["C102999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"51","n_c":["C103000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"52","n_c":["C103001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"53","n_c":["C103002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"56","n_c":["C103003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"58","n_c":["C103004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"59","n_c":["C103005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"63","n_c":["C156054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"66","n_c":["C103006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"68","n_c":["C103007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"70","n_c":["C156055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"73","n_c":["C103008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"82","n_c":["C103009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hysterectomy_margins_involved":[{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic Parametrium","n_c":["C179443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic Parametrium","n_c":["C179445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C48621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.hysterectomy_type":[{"nm":"Hysterectomy, NOS","n_c":["C15256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not performed","n_c":["C141477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Hysterectomy","n_c":["C94470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_result":[{"nm":"Positive","n_c":["C38758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Performed","n_c":["C141477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_type":[{"nm":"99mTc Bone Scintigraphy","n_c":["C162575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CT Scan","n_c":["C17204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MRI","n_c":["C16809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PET","n_c":["C17007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ultrasound","n_c":["C17230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Scan, NOS","n_c":["C17646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.immunosuppressive_treatment_type":[{"nm":"Anti-TNF Therapy","n_c":["C15577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azathioprine","n_c":["C290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide","n_c":["C405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate","n_c":["C642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.karnofsky_performance_status":[{"nm":"0","n_c":["C105720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"10","n_c":["C105718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"20","n_c":["C105716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"30","n_c":["C105715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"40","n_c":["C105714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"50","n_c":["C105713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"60","n_c":["C105712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"70","n_c":["C105711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"80","n_c":["C105710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"90","n_c":["C105709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"100","n_c":["C105707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.menopause_status":[{"nm":"Premenopausal","n_c":["C15491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perimenopausal","n_c":["C15692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postmenopausal","n_c":["C15421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.pregnancy_outcome":[{"nm":"Ectopic Pregnancy","n_c":["C34945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induced Abortion","n_c":["C50613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live Birth","n_c":["C114091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscarriage","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stillbirth","n_c":["C49151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Abortion","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.procedures_performed":[{"nm":"Colonoscopy","n_c":["C16450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endoscopy","n_c":["C16546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.progression_or_recurrence":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.progression_or_recurrence_anatomic_site":[{"nm":"Abdomen, NOS","n_c":["C12664"],"i_c":"C76.2","i_c_s":["Abdomen, NOS"],"term_type":"PT"},{"nm":"Abdominal esophagus","n_c":["C12252"],"i_c":"C15.2","i_c_s":["Abdominal esophagus"],"term_type":"PT"},{"nm":"Accessory sinus, NOS","n_c":["C12763"],"i_c":"C31.9","i_c_s":["Accessory sinus, NOS"],"term_type":"PT"},{"nm":"Acoustic nerve","n_c":["C12697"],"i_c":"C72.4","i_c_s":["Acoustic nerve"],"term_type":"PT"},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"C74.9","i_c_s":["Adrenal gland, NOS"],"term_type":"PT"},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"C24.1","i_c_s":["Ampulla of Vater"],"term_type":"PT"},{"nm":"Anal canal","n_c":["C12375"],"i_c":"C21.1","i_c_s":["Anal canal"],"term_type":"PT"},{"nm":"Anterior 2/3 of tongue, NOS","n_c":"","i_c":"C02.3","i_c_s":["Anterior 2/3 of tongue, NOS"],"term_type":"PT"},{"nm":"Anterior floor of mouth","n_c":"","i_c":"C04.0","i_c_s":["Anterior floor of mouth"],"term_type":"PT"},{"nm":"Anterior mediastinum","n_c":["C32098"],"i_c":"C38.1","i_c_s":["Anterior mediastinum"],"term_type":"PT"},{"nm":"Anterior surface of epiglottis","n_c":["C12238"],"i_c":"C10.1","i_c_s":["Anterior surface of epiglottis"],"term_type":"PT"},{"nm":"Anterior wall of bladder","n_c":["C12334"],"i_c":"C67.3","i_c_s":["Anterior wall of bladder"],"term_type":"PT"},{"nm":"Anterior wall of nasopharynx","n_c":["C12245"],"i_c":"C11.3","i_c_s":["Anterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"C21.0","i_c_s":["Anus, NOS"],"term_type":"PT"},{"nm":"Aortic body and other paraganglia","n_c":"","i_c":"C75.5","i_c_s":["Aortic body and other paraganglia"],"term_type":"PT"},{"nm":"Appendix","n_c":["C12380"],"i_c":"C18.1","i_c_s":["Appendix"],"term_type":"PT"},{"nm":"Ascending colon","n_c":["C12265"],"i_c":"C18.2","i_c_s":["Ascending colon"],"term_type":"PT"},{"nm":"Autonomic nervous system, NOS","n_c":["C12673"],"i_c":"C47.9","i_c_s":["Autonomic nervous system, NOS"],"term_type":"PT"},{"nm":"Axillary tail of breast","n_c":["C12305"],"i_c":"C50.6","i_c_s":["Axillary tail of breast"],"term_type":"PT"},{"nm":"Base of tongue, NOS","n_c":["C12228"],"i_c":"C01.9","i_c_s":["Base of tongue, NOS"],"term_type":"PT"},{"nm":"Biliary tract, NOS","n_c":["C12678"],"i_c":"C24.9","i_c_s":["Biliary tract, NOS"],"term_type":"PT"},{"nm":"Bladder neck","n_c":["C12336"],"i_c":"C67.5","i_c_s":["Bladder neck"],"term_type":"PT"},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"C67.9","i_c_s":["Bladder, NOS"],"term_type":"PT"},{"nm":"Blood","n_c":["C12434"],"i_c":"C42.0","i_c_s":["Blood"],"term_type":"PT"},{"nm":"Body of pancreas","n_c":["C12270"],"i_c":"C25.1","i_c_s":["Body of pancreas"],"term_type":"PT"},{"nm":"Body of penis","n_c":["C12325"],"i_c":"C60.2","i_c_s":["Body of penis"],"term_type":"PT"},{"nm":"Body of stomach","n_c":["C12258"],"i_c":"C16.2","i_c_s":["Body of stomach"],"term_type":"PT"},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"C42.1","i_c_s":["Bone marrow"],"term_type":"PT"},{"nm":"Bone of limb, NOS","n_c":["C32223"],"i_c":"C40.9","i_c_s":["Bone of limb, NOS"],"term_type":"PT"},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"C41.9","i_c_s":["Bone, NOS"],"term_type":"PT"},{"nm":"Bones of skull and face and associated joints","n_c":"","i_c":"C41.0","i_c_s":["Bones of skull and face and associated joints"],"term_type":"PT"},{"nm":"Border of tongue","n_c":"","i_c":"C02.1","i_c_s":["Border of tongue"],"term_type":"PT"},{"nm":"Brain stem","n_c":["C12441"],"i_c":"C71.7","i_c_s":["Brain stem"],"term_type":"PT"},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"C71.9","i_c_s":["Brain, NOS"],"term_type":"PT"},{"nm":"Branchial cleft","n_c":["C104813"],"i_c":"C10.4","i_c_s":["Branchial cleft"],"term_type":"PT"},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"C50.9","i_c_s":["Breast, NOS"],"term_type":"PT"},{"nm":"Broad ligament","n_c":["C12318"],"i_c":"C57.1","i_c_s":["Broad ligament"],"term_type":"PT"},{"nm":"Cardia, NOS","n_c":["C12256"],"i_c":"C16.0","i_c_s":["Cardia, NOS"],"term_type":"PT"},{"nm":"Carotid body","n_c":["C66852"],"i_c":"C75.4","i_c_s":["Carotid body"],"term_type":"PT"},{"nm":"Cauda equina","n_c":["C12689"],"i_c":"C72.1","i_c_s":["Cauda equina"],"term_type":"PT"},{"nm":"Cecum","n_c":["C12381"],"i_c":"C18.0","i_c_s":["Cecum"],"term_type":"PT"},{"nm":"Central portion of breast","n_c":["C12300"],"i_c":"C50.1","i_c_s":["Central portion of breast"],"term_type":"PT"},{"nm":"Cerebellum, NOS","n_c":["C12445"],"i_c":"C71.6","i_c_s":["Cerebellum, NOS"],"term_type":"PT"},{"nm":"Cerebral meninges","n_c":["C12349"],"i_c":"C70.0","i_c_s":["Cerebral meninges"],"term_type":"PT"},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"C71.0","i_c_s":["Cerebrum"],"term_type":"PT"},{"nm":"Cervical esophagus","n_c":["C12250"],"i_c":"C15.0","i_c_s":["Cervical esophagus"],"term_type":"PT"},{"nm":"Cervix uteri","n_c":["C12311"],"i_c":"C53.9","i_c_s":["Cervix uteri"],"term_type":"PT"},{"nm":"Cheek mucosa","n_c":["C12505"],"i_c":"C06.0","i_c_s":["Cheek mucosa"],"term_type":"PT"},{"nm":"Choroid","n_c":["C12344"],"i_c":"C69.3","i_c_s":["Choroid"],"term_type":"PT"},{"nm":"Ciliary body","n_c":["C12345"],"i_c":"C69.4","i_c_s":["Ciliary body"],"term_type":"PT"},{"nm":"Clitoris","n_c":["C12308"],"i_c":"C51.2","i_c_s":["Clitoris"],"term_type":"PT"},{"nm":"Cloacogenic zone","n_c":["C32072"],"i_c":"C21.2","i_c_s":["Cloacogenic zone"],"term_type":"PT"},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"C18.9","i_c_s":["Colon, NOS"],"term_type":"PT"},{"nm":"Commissure of lip","n_c":["C12227"],"i_c":"C00.6","i_c_s":["Commissure of lip"],"term_type":"PT"},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"C69.0","i_c_s":["Conjunctiva"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of abdomen","n_c":"","i_c":"C49.4","i_c_s":["Connective, subcutaneous and other soft tissues of abdomen"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of head, face, and neck","n_c":"","i_c":"C49.0","i_c_s":["Connective, subcutaneous and other soft tissues of head, face, and neck"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of lower limb and hip","n_c":"","i_c":"C49.2","i_c_s":["Connective, subcutaneous and other soft tissues of lower limb and hip"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of pelvis","n_c":"","i_c":"C49.5","i_c_s":["Connective, subcutaneous and other soft tissues of pelvis"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues of thorax","n_c":"","i_c":"C49.3","i_c_s":["Connective, subcutaneous and other soft tissues of thorax"],"term_type":"RT"},{"nm":"Connective, subcutaneous and other soft tissues of trunk, NOS","n_c":"","i_c":"C49.6","i_c_s":["Connective, subcutaneous and other soft tissues of trunk, NOS"],"term_type":""},{"nm":"Connective, subcutaneous and other soft tissues of upper limb and shoulder","n_c":"","i_c":"C49.1","i_c_s":["Connective, subcutaneous and other soft tissues of upper limb and shoulder"],"term_type":"PT"},{"nm":"Connective, subcutaneous and other soft tissues, NOS","n_c":["C12964"],"i_c":"C49.9","i_c_s":["Connective, subcutaneous and other soft tissues, NOS"],"term_type":"PT"},{"nm":"Cornea, NOS","n_c":["C12342"],"i_c":"C69.1","i_c_s":["Cornea, NOS"],"term_type":"PT"},{"nm":"Corpus uteri","n_c":["C12316"],"i_c":"C54.9","i_c_s":["Corpus uteri"],"term_type":"PT"},{"nm":"Cortex of adrenal gland","n_c":["C12396"],"i_c":"C74.0","i_c_s":["Cortex of adrenal gland"],"term_type":"PT"},{"nm":"Cranial nerve, NOS","n_c":["C12700"],"i_c":"C72.5","i_c_s":["Cranial nerve, NOS"],"term_type":"PT"},{"nm":"Craniopharyngeal duct","n_c":["C12357"],"i_c":"C75.2","i_c_s":["Craniopharyngeal duct"],"term_type":"PT"},{"nm":"Descended testis","n_c":"","i_c":"C62.1","i_c_s":["Descended testis"],"term_type":"PT"},{"nm":"Descending colon","n_c":["C12268"],"i_c":"C18.6","i_c_s":["Descending colon"],"term_type":"PT"},{"nm":"Dome of bladder","n_c":["C12332"],"i_c":"C67.1","i_c_s":["Dome of bladder"],"term_type":"PT"},{"nm":"Dorsal surface of tongue, NOS","n_c":"","i_c":"C02.0","i_c_s":["Dorsal surface of tongue, NOS"],"term_type":"PT"},{"nm":"Duodenum","n_c":["C12263"],"i_c":"C17.0","i_c_s":["Duodenum"],"term_type":"PT"},{"nm":"Endocervix","n_c":["C12309"],"i_c":"C53.0","i_c_s":["Endocervix"],"term_type":"PT"},{"nm":"Endocrine gland, NOS","n_c":["C12704"],"i_c":"C75.9","i_c_s":["Endocrine gland, NOS"],"term_type":"PT"},{"nm":"Endometrium","n_c":["C12313"],"i_c":"C54.1","i_c_s":["Endometrium"],"term_type":"PT"},{"nm":"Epididymis","n_c":["C12328"],"i_c":"C63.0","i_c_s":["Epididymis"],"term_type":"PT"},{"nm":"Esophagus, NOS","n_c":["C12389"],"i_c":"C15.9","i_c_s":["Esophagus, NOS"],"term_type":"PT"},{"nm":"Ethmoid sinus","n_c":["C12276"],"i_c":"C31.1","i_c_s":["Ethmoid sinus"],"term_type":"PT"},{"nm":"Exocervix","n_c":["C12310"],"i_c":"C53.1","i_c_s":["Exocervix"],"term_type":"PT"},{"nm":"External ear","n_c":["C12292"],"i_c":"C44.2","i_c_s":["External ear"],"term_type":"PT"},{"nm":"External lip, NOS","n_c":["C12223"],"i_c":"C00.2","i_c_s":["External lip, NOS"],"term_type":"PT"},{"nm":"External lower lip","n_c":["C12222"],"i_c":"C00.1","i_c_s":["External lower lip"],"term_type":"PT"},{"nm":"External upper lip","n_c":["C12221"],"i_c":"C00.0","i_c_s":["External upper lip"],"term_type":"PT"},{"nm":"Extrahepatic bile duct","n_c":["C32573"],"i_c":"C24.0","i_c_s":["Extrahepatic bile duct"],"term_type":"PT"},{"nm":"Eye, NOS","n_c":["C12401"],"i_c":"C69.9","i_c_s":["Eye, NOS"],"term_type":"PT"},{"nm":"Eyelid","n_c":["C12713"],"i_c":"C44.1","i_c_s":["Eyelid"],"term_type":"PT"},{"nm":"Fallopian tube","n_c":["C12403"],"i_c":"C57.0","i_c_s":["Fallopian tube"],"term_type":"PT"},{"nm":"Female genital tract, NOS","n_c":["C61600"],"i_c":"C57.9","i_c_s":["Female genital tract, NOS"],"term_type":"PT"},{"nm":"Floor of mouth, NOS","n_c":["C54187"],"i_c":"C04.9","i_c_s":["Floor of mouth, NOS"],"term_type":"PT"},{"nm":"Frontal lobe","n_c":["C12352"],"i_c":"C71.1","i_c_s":["Frontal lobe"],"term_type":"PT"},{"nm":"Frontal sinus","n_c":["C12277"],"i_c":"C31.2","i_c_s":["Frontal sinus"],"term_type":"PT"},{"nm":"Fundus of stomach","n_c":["C12257"],"i_c":"C16.1","i_c_s":["Fundus of stomach"],"term_type":"PT"},{"nm":"Fundus uteri","n_c":["C12315"],"i_c":"C54.3","i_c_s":["Fundus uteri"],"term_type":"PT"},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"C23.9","i_c_s":["Gallbladder"],"term_type":"PT"},{"nm":"Gastric antrum","n_c":["C12259"],"i_c":"C16.3","i_c_s":["Gastric antrum"],"term_type":"PT"},{"nm":"Gastrointestinal tract, NOS","n_c":["C34082"],"i_c":"C26.9","i_c_s":["Gastrointestinal tract, NOS"],"term_type":"PT"},{"nm":"Glans penis","n_c":["C12324"],"i_c":"C60.1","i_c_s":["Glans penis"],"term_type":"PT"},{"nm":"Glottis","n_c":["C12724"],"i_c":"C32.0","i_c_s":["Glottis"],"term_type":"PT"},{"nm":"Greater curvature of stomach, NOS","n_c":["C12262"],"i_c":"C16.6","i_c_s":["Greater curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Gum, NOS","n_c":["C32677"],"i_c":"C03.9","i_c_s":["Gum, NOS"],"term_type":"PT"},{"nm":"Hard palate","n_c":["C12230"],"i_c":"C05.0","i_c_s":["Hard palate"],"term_type":"PT"},{"nm":"Head of pancreas","n_c":["C12269"],"i_c":"C25.0","i_c_s":["Head of pancreas"],"term_type":"PT"},{"nm":"Head, face or neck, NOS","n_c":"","i_c":"C76.0","i_c_s":["Head, face or neck, NOS"],"term_type":"PT"},{"nm":"Heart","n_c":["C12727"],"i_c":"C38.0","i_c_s":["Heart"],"term_type":"PT"},{"nm":"Hematopoietic system, NOS","n_c":["C12909"],"i_c":"C42.4","i_c_s":["Hematopoietic system, NOS"],"term_type":"PT"},{"nm":"Hepatic flexure of colon","n_c":["C12266"],"i_c":"C18.3","i_c_s":["Hepatic flexure of colon"],"term_type":"PT"},{"nm":"Hypopharyngeal aspect of aryepiglottic fold","n_c":"","i_c":"C13.1","i_c_s":["Hypopharyngeal aspect of aryepiglottic fold"],"term_type":"PT"},{"nm":"Hypopharynx, NOS","n_c":["C12246"],"i_c":"C13.9","i_c_s":["Hypopharynx, NOS"],"term_type":"PT"},{"nm":"Ileum","n_c":["C12387"],"i_c":"C17.2","i_c_s":["Ileum"],"term_type":"PT"},{"nm":"Ill-defined sites within respiratory system","n_c":["C148338"],"i_c":"C39.9","i_c_s":["Ill-defined sites within respiratory system"],"term_type":"PT"},{"nm":"Intestinal tract, NOS","n_c":["C12736"],"i_c":"C26.0","i_c_s":["Intestinal tract, NOS"],"term_type":"PT"},{"nm":"Intra-abdominal lymph nodes","n_c":["C12360"],"i_c":"C77.2","i_c_s":["Intra-abdominal lymph nodes"],"term_type":"PT"},{"nm":"Intrahepatic bile duct","n_c":["C12677"],"i_c":"C22.1","i_c_s":["Intrahepatic bile duct"],"term_type":"PT"},{"nm":"Intrathoracic lymph nodes","n_c":["C12359"],"i_c":"C77.1","i_c_s":["Intrathoracic lymph nodes"],"term_type":"PT"},{"nm":"Islets of Langerhans","n_c":["C12608"],"i_c":"C25.4","i_c_s":["Islets of Langerhans"],"term_type":"PT"},{"nm":"Isthmus uteri","n_c":["C12312"],"i_c":"C54.0","i_c_s":["Isthmus uteri"],"term_type":"PT"},{"nm":"Jejunum","n_c":["C12388"],"i_c":"C17.1","i_c_s":["Jejunum"],"term_type":"PT"},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"C64.9","i_c_s":["Kidney, NOS"],"term_type":"PT"},{"nm":"Labium majus","n_c":["C12306"],"i_c":"C51.0","i_c_s":["Labium majus"],"term_type":"PT"},{"nm":"Labium minus","n_c":["C12307"],"i_c":"C51.1","i_c_s":["Labium minus"],"term_type":"PT"},{"nm":"Lacrimal gland","n_c":["C12346"],"i_c":"C69.5","i_c_s":["Lacrimal gland"],"term_type":"PT"},{"nm":"Laryngeal cartilage","n_c":["C12281"],"i_c":"C32.3","i_c_s":["Laryngeal cartilage"],"term_type":"PT"},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"C32.9","i_c_s":["Larynx, NOS"],"term_type":"PT"},{"nm":"Lateral floor of mouth","n_c":"","i_c":"C04.1","i_c_s":["Lateral floor of mouth"],"term_type":"PT"},{"nm":"Lateral wall of bladder","n_c":["C12333"],"i_c":"C67.2","i_c_s":["Lateral wall of bladder"],"term_type":"PT"},{"nm":"Lateral wall of nasopharynx","n_c":["C12244"],"i_c":"C11.2","i_c_s":["Lateral wall of nasopharynx"],"term_type":"PT"},{"nm":"Lateral wall of oropharynx","n_c":["C12239"],"i_c":"C10.2","i_c_s":["Lateral wall of oropharynx"],"term_type":"PT"},{"nm":"Lesser curvature of stomach, NOS","n_c":["C12261"],"i_c":"C16.5","i_c_s":["Lesser curvature of stomach, NOS"],"term_type":"PT"},{"nm":"Lingual tonsil","n_c":["C32988"],"i_c":"C02.4","i_c_s":["Lingual tonsil"],"term_type":"PT"},{"nm":"Lip, NOS","n_c":["C12220"],"i_c":"C00.9","i_c_s":["Lip, NOS"],"term_type":"PT"},{"nm":"Liver","n_c":["C12392"],"i_c":"C22.0","i_c_s":["Liver"],"term_type":"PT"},{"nm":"Long bones of lower limb and associated joints","n_c":"","i_c":"C40.2","i_c_s":["Long bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Long bones of upper limb, scapula and associated joints","n_c":"","i_c":"C40.0","i_c_s":["Long bones of upper limb, scapula and associated joints"],"term_type":"PT"},{"nm":"Lower gum","n_c":["C54204"],"i_c":"C03.1","i_c_s":["Lower gum"],"term_type":"PT"},{"nm":"Lower limb, NOS","n_c":["C12742"],"i_c":"C76.5","i_c_s":["Lower limb, NOS"],"term_type":"PT"},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"C34.3","i_c_s":["Lower lobe, lung"],"term_type":"PT"},{"nm":"Lower third of esophagus","n_c":["C12255"],"i_c":"C15.5","i_c_s":["Lower third of esophagus"],"term_type":"PT"},{"nm":"Lower-inner quadrant of breast","n_c":["C12302"],"i_c":"C50.3","i_c_s":["Lower-inner quadrant of breast"],"term_type":"PT"},{"nm":"Lower-outer quadrant of breast","n_c":["C12304"],"i_c":"C50.5","i_c_s":["Lower-outer quadrant of breast"],"term_type":"PT"},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"C34.9","i_c_s":["Lung, NOS"],"term_type":"PT"},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"C77.9","i_c_s":["Lymph node, NOS"],"term_type":"PT"},{"nm":"Lymph nodes of axilla or arm","n_c":["C12904"],"i_c":"C77.3","i_c_s":["Lymph nodes of axilla or arm"],"term_type":"PT"},{"nm":"Lymph nodes of head, face and neck","n_c":["C12358"],"i_c":"C77.0","i_c_s":["Lymph nodes of head, face and neck"],"term_type":"PT"},{"nm":"Lymph nodes of inguinal region or leg","n_c":["C12362"],"i_c":"C77.4","i_c_s":["Lymph nodes of inguinal region or leg"],"term_type":"PT"},{"nm":"Lymph nodes of multiple regions","n_c":"","i_c":"C77.8","i_c_s":["Lymph nodes of multiple regions"],"term_type":"PT"},{"nm":"Main bronchus","n_c":["C12284"],"i_c":"C34.0","i_c_s":["Main bronchus"],"term_type":"PT"},{"nm":"Major salivary gland, NOS","n_c":["C12999"],"i_c":"C08.9","i_c_s":["Major salivary gland, NOS"],"term_type":"PT"},{"nm":"Male genital organs, NOS","n_c":["C61599"],"i_c":"C63.9","i_c_s":["Male genital organs, NOS"],"term_type":"PT"},{"nm":"Mandible","n_c":["C12290"],"i_c":"C41.1","i_c_s":["Mandible"],"term_type":"PT"},{"nm":"Maxillary sinus","n_c":["C12275"],"i_c":"C31.0","i_c_s":["Maxillary sinus"],"term_type":"PT"},{"nm":"Meckel diverticulum","n_c":["C12264"],"i_c":"C17.3","i_c_s":["Meckel diverticulum"],"term_type":"PT"},{"nm":"Mediastinum, NOS","n_c":["C12748"],"i_c":"C38.3","i_c_s":["Mediastinum, NOS"],"term_type":"PT"},{"nm":"Medulla of adrenal gland","n_c":["C12397"],"i_c":"C74.1","i_c_s":["Medulla of adrenal gland"],"term_type":"PT"},{"nm":"Meninges, NOS","n_c":["C12348"],"i_c":"C70.9","i_c_s":["Meninges, NOS"],"term_type":"PT"},{"nm":"Middle ear","n_c":["C12274"],"i_c":"C30.1","i_c_s":["Middle ear"],"term_type":"PT"},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"C34.2","i_c_s":["Middle lobe, lung"],"term_type":"PT"},{"nm":"Middle third of esophagus","n_c":["C12254"],"i_c":"C15.4","i_c_s":["Middle third of esophagus"],"term_type":"PT"},{"nm":"Mouth, NOS","n_c":["C12421"],"i_c":"C06.9","i_c_s":["Mouth, NOS"],"term_type":"PT"},{"nm":"Mucosa of lip, NOS","n_c":["C12226"],"i_c":"C00.5","i_c_s":["Mucosa of lip, NOS"],"term_type":"PT"},{"nm":"Mucosa of lower lip","n_c":["C12225"],"i_c":"C00.4","i_c_s":["Mucosa of lower lip"],"term_type":"PT"},{"nm":"Mucosa of upper lip","n_c":["C12224"],"i_c":"C00.3","i_c_s":["Mucosa of upper lip"],"term_type":"PT"},{"nm":"Myometrium","n_c":["C12314"],"i_c":"C54.2","i_c_s":["Myometrium"],"term_type":"PT"},{"nm":"Nasal cavity","n_c":["C12424"],"i_c":"C30.0","i_c_s":["Nasal cavity"],"term_type":"PT"},{"nm":"Nasopharynx, NOS","n_c":["C12423"],"i_c":"C11.9","i_c_s":["Nasopharynx, NOS"],"term_type":"PT"},{"nm":"Nervous system, NOS","n_c":["C12755"],"i_c":"C72.9","i_c_s":["Nervous system, NOS"],"term_type":"PT"},{"nm":"Nipple","n_c":["C12299"],"i_c":"C50.0","i_c_s":["Nipple"],"term_type":"PT"},{"nm":"Occipital lobe","n_c":["C12355"],"i_c":"C71.4","i_c_s":["Occipital lobe"],"term_type":"PT"},{"nm":"Olfactory nerve","n_c":["C12759"],"i_c":"C72.2","i_c_s":["Olfactory nerve"],"term_type":"PT"},{"nm":"Optic nerve","n_c":["C12761"],"i_c":"C72.3","i_c_s":["Optic nerve"],"term_type":"PT"},{"nm":"Orbit, NOS","n_c":["C12347"],"i_c":"C69.6","i_c_s":["Orbit, NOS"],"term_type":"PT"},{"nm":"Oropharynx, NOS","n_c":["C12762"],"i_c":"C10.9","i_c_s":["Oropharynx, NOS"],"term_type":"PT"},{"nm":"Other ill-defined sites","n_c":["C147919"],"i_c":"C76.7","i_c_s":["Other ill-defined sites"],"term_type":"PT"},{"nm":"Other specified parts of female genital organs","n_c":["C148339"],"i_c":"C57.7","i_c_s":["Other specified parts of female genital organs"],"term_type":"PT"},{"nm":"Other specified parts of male genital organs","n_c":["C148341"],"i_c":"C63.7","i_c_s":["Other specified parts of male genital organs"],"term_type":"PT"},{"nm":"Other specified parts of pancreas","n_c":["C12273"],"i_c":"C25.7","i_c_s":["Other specified parts of pancreas"],"term_type":"PT"},{"nm":"Ovary","n_c":["C12404"],"i_c":"C56.9","i_c_s":["Ovary"],"term_type":"PT"},{"nm":"Overlapping lesion of accessory sinuses","n_c":"","i_c":"C31.8","i_c_s":["Overlapping lesion of accessory sinuses"],"term_type":"PT"},{"nm":"Overlapping lesion of biliary tract","n_c":"","i_c":"C24.8","i_c_s":["Overlapping lesion of biliary tract"],"term_type":"PT"},{"nm":"Overlapping lesion of bladder","n_c":"","i_c":"C67.8","i_c_s":["Overlapping lesion of bladder"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage","n_c":"","i_c":"C41.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage"],"term_type":"PT"},{"nm":"Overlapping lesion of bones, joints and articular cartilage of limbs","n_c":"","i_c":"C40.8","i_c_s":["Overlapping lesion of bones, joints and articular cartilage of limbs"],"term_type":"PT"},{"nm":"Overlapping lesion of brain","n_c":"","i_c":"C71.8","i_c_s":["Overlapping lesion of brain"],"term_type":"PT"},{"nm":"Overlapping lesion of brain and central nervous system","n_c":"","i_c":"C72.8","i_c_s":["Overlapping lesion of brain and central nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of breast","n_c":"","i_c":"C50.8","i_c_s":["Overlapping lesion of breast"],"term_type":"PT"},{"nm":"Overlapping lesion of cervix uteri","n_c":"","i_c":"C53.8","i_c_s":["Overlapping lesion of cervix uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of colon","n_c":"","i_c":"C18.8","i_c_s":["Overlapping lesion of colon"],"term_type":"PT"},{"nm":"Overlapping lesion of connective, subcutaneous and other soft tissues","n_c":"","i_c":"C49.8","i_c_s":["Overlapping lesion of connective, subcutaneous and other soft tissues"],"term_type":"PT"},{"nm":"Overlapping lesion of corpus uteri","n_c":"","i_c":"C54.8","i_c_s":["Overlapping lesion of corpus uteri"],"term_type":"PT"},{"nm":"Overlapping lesion of digestive system","n_c":"","i_c":"C26.8","i_c_s":["Overlapping lesion of digestive system"],"term_type":"PT"},{"nm":"Overlapping lesion of endocrine glands and related structures","n_c":"","i_c":"C75.8","i_c_s":["Overlapping lesion of endocrine glands and related structures"],"term_type":"PT"},{"nm":"Overlapping lesion of esophagus","n_c":"","i_c":"C15.8","i_c_s":["Overlapping lesion of esophagus"],"term_type":"PT"},{"nm":"Overlapping lesion of eye and adnexa","n_c":"","i_c":"C69.8","i_c_s":["Overlapping lesion of eye and adnexa"],"term_type":"PT"},{"nm":"Overlapping lesion of female genital organs","n_c":"","i_c":"C57.8","i_c_s":["Overlapping lesion of female genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of floor of mouth","n_c":"","i_c":"C04.8","i_c_s":["Overlapping lesion of floor of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of heart, mediastinum and pleura","n_c":"","i_c":"C38.8","i_c_s":["Overlapping lesion of heart, mediastinum and pleura"],"term_type":"PT"},{"nm":"Overlapping lesion of hypopharynx","n_c":"","i_c":"C13.8","i_c_s":["Overlapping lesion of hypopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of ill-defined sites","n_c":"","i_c":"C76.8","i_c_s":["Overlapping lesion of ill-defined sites"],"term_type":"PT"},{"nm":"Overlapping lesion of larynx","n_c":"","i_c":"C32.8","i_c_s":["Overlapping lesion of larynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lip","n_c":"","i_c":"C00.8","i_c_s":["Overlapping lesion of lip"],"term_type":"PT"},{"nm":"Overlapping lesion of lip, oral cavity and pharynx","n_c":"","i_c":"C14.8","i_c_s":["Overlapping lesion of lip, oral cavity and pharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of lung","n_c":"","i_c":"C34.8","i_c_s":["Overlapping lesion of lung"],"term_type":"PT"},{"nm":"Overlapping lesion of major salivary glands","n_c":"","i_c":"C08.8","i_c_s":["Overlapping lesion of major salivary glands"],"term_type":"PT"},{"nm":"Overlapping lesion of male genital organs","n_c":"","i_c":"C63.8","i_c_s":["Overlapping lesion of male genital organs"],"term_type":"PT"},{"nm":"Overlapping lesion of nasopharynx","n_c":"","i_c":"C11.8","i_c_s":["Overlapping lesion of nasopharynx"],"term_type":"PT"},{"nm":"Overlapping lesion of other and unspecified parts of mouth","n_c":"","i_c":"C06.8","i_c_s":["Overlapping lesion of other and unspecified parts of mouth"],"term_type":"PT"},{"nm":"Overlapping lesion of palate","n_c":"","i_c":"C05.8","i_c_s":["Overlapping lesion of palate"],"term_type":"PT"},{"nm":"Overlapping lesion of pancreas","n_c":"","i_c":"C25.8","i_c_s":["Overlapping lesion of pancreas"],"term_type":"PT"},{"nm":"Overlapping lesion of penis","n_c":"","i_c":"C60.8","i_c_s":["Overlapping lesion of penis"],"term_type":"PT"},{"nm":"Overlapping lesion of peripheral nerves and autonomic nervous system","n_c":"","i_c":"C47.8","i_c_s":["Overlapping lesion of peripheral nerves and autonomic nervous system"],"term_type":"PT"},{"nm":"Overlapping lesion of rectum, anus and anal canal","n_c":"","i_c":"C21.8","i_c_s":["Overlapping lesion of rectum, anus and anal canal"],"term_type":"PT"},{"nm":"Overlapping lesion of respiratory system and intrathoracic organs","n_c":"","i_c":"C39.8","i_c_s":["Overlapping lesion of respiratory system and intrathoracic organs"],"term_type":"PT"},{"nm":"Overlapping lesion of retroperitoneum and peritoneum","n_c":"","i_c":"C48.8","i_c_s":["Overlapping lesion of retroperitoneum and peritoneum"],"term_type":"PT"},{"nm":"Overlapping lesion of skin","n_c":"","i_c":"C44.8","i_c_s":["Overlapping lesion of skin"],"term_type":"PT"},{"nm":"Overlapping lesion of small intestine","n_c":"","i_c":"C17.8","i_c_s":["Overlapping lesion of small intestine"],"term_type":"PT"},{"nm":"Overlapping lesion of stomach","n_c":"","i_c":"C16.8","i_c_s":["Overlapping lesion of stomach"],"term_type":"PT"},{"nm":"Overlapping lesion of tongue","n_c":"","i_c":"C02.8","i_c_s":["Overlapping lesion of tongue"],"term_type":"PT"},{"nm":"Overlapping lesion of tonsil","n_c":"","i_c":"C09.8","i_c_s":["Overlapping lesion of tonsil"],"term_type":"PT"},{"nm":"Overlapping lesion of urinary organs","n_c":"","i_c":"C68.8","i_c_s":["Overlapping lesion of urinary organs"],"term_type":"PT"},{"nm":"Overlapping lesion of vulva","n_c":"","i_c":"C51.8","i_c_s":["Overlapping lesion of vulva"],"term_type":"PT"},{"nm":"Overlapping lesions of oropharynx","n_c":"","i_c":"C10.8","i_c_s":["Overlapping lesions of oropharynx"],"term_type":""},{"nm":"Palate, NOS","n_c":["C12229"],"i_c":"C05.9","i_c_s":["Palate, NOS"],"term_type":"PT"},{"nm":"Pancreas, NOS","n_c":["C12393"],"i_c":"C25.9","i_c_s":["Pancreas, NOS"],"term_type":"PT"},{"nm":"Pancreatic duct","n_c":["C12272"],"i_c":"C25.3","i_c_s":["Pancreatic duct"],"term_type":"PT"},{"nm":"Parametrium","n_c":["C12320"],"i_c":"C57.3","i_c_s":["Parametrium"],"term_type":"PT"},{"nm":"Parathyroid gland","n_c":["C12765"],"i_c":"C75.0","i_c_s":["Parathyroid gland"],"term_type":"PT"},{"nm":"Paraurethral gland","n_c":["C61122"],"i_c":"C68.1","i_c_s":["Paraurethral gland"],"term_type":"PT"},{"nm":"Parietal lobe","n_c":["C12354"],"i_c":"C71.3","i_c_s":["Parietal lobe"],"term_type":"PT"},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"C07.9","i_c_s":["Parotid gland"],"term_type":"PT"},{"nm":"Pelvic bones, sacrum, coccyx and associated joints","n_c":"","i_c":"C41.4","i_c_s":["Pelvic bones, sacrum, coccyx and associated joints"],"term_type":"PT"},{"nm":"Pelvic lymph nodes","n_c":["C12363"],"i_c":"C77.5","i_c_s":["Pelvic lymph nodes"],"term_type":"PT"},{"nm":"Pelvis, NOS","n_c":["C12767"],"i_c":"C76.3","i_c_s":["Pelvis, NOS"],"term_type":"PT"},{"nm":"Penis, NOS","n_c":["C12409"],"i_c":"C60.9","i_c_s":["Penis, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of abdomen","n_c":"","i_c":"C47.4","i_c_s":["Peripheral nerves and autonomic nervous system of abdomen"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of head, face, and neck","n_c":"","i_c":"C47.0","i_c_s":["Peripheral nerves and autonomic nervous system of head, face, and neck"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of lower limb and hip","n_c":"","i_c":"C47.2","i_c_s":["Peripheral nerves and autonomic nervous system of lower limb and hip"],"term_type":""},{"nm":"Peripheral nerves and autonomic nervous system of pelvis","n_c":"","i_c":"C47.5","i_c_s":["Peripheral nerves and autonomic nervous system of pelvis"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of thorax","n_c":"","i_c":"C47.3","i_c_s":["Peripheral nerves and autonomic nervous system of thorax"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of trunk, NOS","n_c":"","i_c":"C47.6","i_c_s":["Peripheral nerves and autonomic nervous system of trunk, NOS"],"term_type":"PT"},{"nm":"Peripheral nerves and autonomic nervous system of upper limb and shoulder","n_c":"","i_c":"C47.1","i_c_s":["Peripheral nerves and autonomic nervous system of upper limb and shoulder"],"term_type":"PT"},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"C48.2","i_c_s":["Peritoneum, NOS"],"term_type":"PT"},{"nm":"Pharynx, NOS","n_c":["C12425"],"i_c":"C14.0","i_c_s":["Pharynx, NOS"],"term_type":"PT"},{"nm":"Pineal gland","n_c":["C12398"],"i_c":"C75.3","i_c_s":["Pineal gland"],"term_type":"PT"},{"nm":"Pituitary gland","n_c":["C12399"],"i_c":"C75.1","i_c_s":["Pituitary gland"],"term_type":"PT"},{"nm":"Placenta","n_c":["C13272"],"i_c":"C58.9","i_c_s":["Placenta"],"term_type":"PT"},{"nm":"Pleura, NOS","n_c":["C12469"],"i_c":"C38.4","i_c_s":["Pleura, NOS"],"term_type":"PT"},{"nm":"Postcricoid region","n_c":["C54221"],"i_c":"C13.0","i_c_s":["Postcricoid region"],"term_type":"PT"},{"nm":"Posterior mediastinum","n_c":["C33368"],"i_c":"C38.2","i_c_s":["Posterior mediastinum"],"term_type":"PT"},{"nm":"Posterior wall of bladder","n_c":["C12335"],"i_c":"C67.4","i_c_s":["Posterior wall of bladder"],"term_type":"PT"},{"nm":"Posterior wall of hypopharynx","n_c":["C12249"],"i_c":"C13.2","i_c_s":["Posterior wall of hypopharynx"],"term_type":"PT"},{"nm":"Posterior wall of nasopharynx","n_c":["C12243"],"i_c":"C11.1","i_c_s":["Posterior wall of nasopharynx"],"term_type":"PT"},{"nm":"Posterior wall of oropharynx","n_c":["C12240"],"i_c":"C10.3","i_c_s":["Posterior wall of oropharynx"],"term_type":"PT"},{"nm":"Prepuce","n_c":["C12323"],"i_c":"C60.0","i_c_s":["Prepuce"],"term_type":"PT"},{"nm":"Prostate gland","n_c":["C12410"],"i_c":"C61.9","i_c_s":["Prostate gland"],"term_type":"PT"},{"nm":"Pylorus","n_c":["C12260"],"i_c":"C16.4","i_c_s":["Pylorus"],"term_type":"PT"},{"nm":"Pyriform sinus","n_c":["C33439"],"i_c":"C12.9","i_c_s":["Pyriform sinus"],"term_type":"PT"},{"nm":"Rectosigmoid junction","n_c":["C54188"],"i_c":"C19.9","i_c_s":["Rectosigmoid junction"],"term_type":"PT"},{"nm":"Rectum, NOS","n_c":["C12390"],"i_c":"C20.9","i_c_s":["Rectum, NOS"],"term_type":"PT"},{"nm":"Renal pelvis","n_c":["C12887"],"i_c":"C65.9","i_c_s":["Renal pelvis"],"term_type":"PT"},{"nm":"Reticuloendothelial system, NOS","n_c":["C12780"],"i_c":"C42.3","i_c_s":["Reticuloendothelial system, NOS"],"term_type":"PT"},{"nm":"Retina","n_c":["C12343"],"i_c":"C69.2","i_c_s":["Retina"],"term_type":"PT"},{"nm":"Retromolar area","n_c":["C54223"],"i_c":"C06.2","i_c_s":["Retromolar area"],"term_type":"PT"},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"C48.0","i_c_s":["Retroperitoneum"],"term_type":"PT"},{"nm":"Rib, sternum, clavicle and associated joints","n_c":"","i_c":"C41.3","i_c_s":["Rib, sternum, clavicle and associated joints"],"term_type":"PT"},{"nm":"Round ligament","n_c":["C12319"],"i_c":"C57.2","i_c_s":["Round ligament"],"term_type":"PT"},{"nm":"Scrotum, NOS","n_c":["C12785"],"i_c":"C63.2","i_c_s":["Scrotum, NOS"],"term_type":"PT"},{"nm":"Short bones of lower limb and associated joints","n_c":"","i_c":"C40.3","i_c_s":["Short bones of lower limb and associated joints"],"term_type":"PT"},{"nm":"Short bones of upper limb and associated joints","n_c":"","i_c":"C40.1","i_c_s":["Short bones of upper limb and associated joints"],"term_type":"PT"},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"C18.7","i_c_s":["Sigmoid colon"],"term_type":"PT"},{"nm":"Skin of lip, NOS","n_c":["C12291"],"i_c":"C44.0","i_c_s":["Skin of lip, NOS"],"term_type":"PT"},{"nm":"Skin of lower limb and hip","n_c":["C12297"],"i_c":"C44.7","i_c_s":["Skin of lower limb and hip"],"term_type":"PT"},{"nm":"Skin of other and unspecified parts of face","n_c":["C33561"],"i_c":"C44.3","i_c_s":["Skin of other and unspecified parts of face"],"term_type":"PT"},{"nm":"Skin of scalp and neck","n_c":["C12294"],"i_c":"C44.4","i_c_s":["Skin of scalp and neck"],"term_type":"PT"},{"nm":"Skin of trunk","n_c":["C12295"],"i_c":"C44.5","i_c_s":["Skin of trunk"],"term_type":"RT"},{"nm":"Skin of upper limb and shoulder","n_c":["C12296"],"i_c":"C44.6","i_c_s":["Skin of upper limb and shoulder"],"term_type":"PT"},{"nm":"Skin, NOS","n_c":["C12470"],"i_c":"C44.9","i_c_s":["Skin, NOS"],"term_type":"PT"},{"nm":"Small intestine, NOS","n_c":["C12386"],"i_c":"C17.9","i_c_s":["Small intestine, NOS"],"term_type":"PT"},{"nm":"Soft palate, NOS","n_c":["C12231"],"i_c":"C05.1","i_c_s":["Soft palate, NOS"],"term_type":"PT"},{"nm":"Specified parts of peritoneum","n_c":"","i_c":"C48.1","i_c_s":["Specified parts of peritoneum"],"term_type":"PT"},{"nm":"Spermatic cord","n_c":["C12329"],"i_c":"C63.1","i_c_s":["Spermatic cord"],"term_type":"PT"},{"nm":"Sphenoid sinus","n_c":["C12278"],"i_c":"C31.3","i_c_s":["Sphenoid sinus"],"term_type":"PT"},{"nm":"Spinal cord","n_c":["C12464"],"i_c":"C72.0","i_c_s":["Spinal cord"],"term_type":"PT"},{"nm":"Spinal meninges","n_c":["C12350"],"i_c":"C70.1","i_c_s":["Spinal meninges"],"term_type":"PT"},{"nm":"Spleen","n_c":["C12432"],"i_c":"C42.2","i_c_s":["Spleen"],"term_type":"PT"},{"nm":"Splenic flexure of colon","n_c":["C12267"],"i_c":"C18.5","i_c_s":["Splenic flexure of colon"],"term_type":"PT"},{"nm":"Stomach, NOS","n_c":["C12391"],"i_c":"C16.9","i_c_s":["Stomach, NOS"],"term_type":"PT"},{"nm":"Subglottis","n_c":["C12280"],"i_c":"C32.2","i_c_s":["Subglottis"],"term_type":"PT"},{"nm":"Sublingual gland","n_c":["C12234"],"i_c":"C08.1","i_c_s":["Sublingual gland"],"term_type":"PT"},{"nm":"Submandibular gland","n_c":["C12233"],"i_c":"C08.0","i_c_s":["Submandibular gland"],"term_type":"PT"},{"nm":"Superior wall of nasopharynx","n_c":["C12242"],"i_c":"C11.0","i_c_s":["Superior wall of nasopharynx"],"term_type":"PT"},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"C32.1","i_c_s":["Supraglottis"],"term_type":"PT"},{"nm":"Tail of pancreas","n_c":["C12271"],"i_c":"C25.2","i_c_s":["Tail of pancreas"],"term_type":"PT"},{"nm":"Temporal lobe","n_c":["C12353"],"i_c":"C71.2","i_c_s":["Temporal lobe"],"term_type":"PT"},{"nm":"Testis, NOS","n_c":["C12412"],"i_c":"C62.9","i_c_s":["Testis, NOS"],"term_type":"PT"},{"nm":"Thoracic esophagus","n_c":["C12251"],"i_c":"C15.1","i_c_s":["Thoracic esophagus"],"term_type":"PT"},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"C76.1","i_c_s":["Thorax, NOS"],"term_type":"PT"},{"nm":"Thymus","n_c":["C12433"],"i_c":"C37.9","i_c_s":["Thymus"],"term_type":"PT"},{"nm":"Thyroid gland","n_c":["C12400"],"i_c":"C73.9","i_c_s":["Thyroid gland"],"term_type":"PT"},{"nm":"Tongue, NOS","n_c":["C12422"],"i_c":"C02.9","i_c_s":["Tongue, NOS"],"term_type":"PT"},{"nm":"Tonsil, NOS","n_c":["C33250"],"i_c":"C09.9","i_c_s":["Tonsil, NOS"],"term_type":"PT"},{"nm":"Tonsillar fossa","n_c":["C12235"],"i_c":"C09.0","i_c_s":["Tonsillar fossa"],"term_type":"PT"},{"nm":"Tonsillar pillar","n_c":["C12236"],"i_c":"C09.1","i_c_s":["Tonsillar pillar"],"term_type":"PT"},{"nm":"Trachea","n_c":["C12428"],"i_c":"C33.9","i_c_s":["Trachea"],"term_type":"PT"},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"C18.4","i_c_s":["Transverse colon"],"term_type":"PT"},{"nm":"Trigone of bladder","n_c":["C12331"],"i_c":"C67.0","i_c_s":["Trigone of bladder"],"term_type":"PT"},{"nm":"Undescended testis","n_c":["C12326"],"i_c":"C62.0","i_c_s":["Undescended testis"],"term_type":"PT"},{"nm":"Unknown primary site","n_c":["C48322"],"i_c":"C80.9","i_c_s":["Unknown primary site"],"term_type":"PT"},{"nm":"Upper gum","n_c":["C54205"],"i_c":"C03.0","i_c_s":["Upper gum"],"term_type":"PT"},{"nm":"Upper limb, NOS","n_c":["C12671"],"i_c":"C76.4","i_c_s":["Upper limb, NOS"],"term_type":"PT"},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"C34.1","i_c_s":["Upper lobe, lung"],"term_type":"PT"},{"nm":"Upper respiratory tract, NOS","n_c":["C33839"],"i_c":"C39.0","i_c_s":["Upper respiratory tract, NOS"],"term_type":"PT"},{"nm":"Upper third of esophagus","n_c":["C12253"],"i_c":"C15.3","i_c_s":["Upper third of esophagus"],"term_type":"PT"},{"nm":"Upper-inner quadrant of breast","n_c":["C12301"],"i_c":"C50.2","i_c_s":["Upper-inner quadrant of breast"],"term_type":"PT"},{"nm":"Upper-outer quadrant of breast","n_c":["C12303"],"i_c":"C50.4","i_c_s":["Upper-outer quadrant of breast"],"term_type":"PT"},{"nm":"Urachus","n_c":["C12338"],"i_c":"C67.7","i_c_s":["Urachus"],"term_type":"PT"},{"nm":"Ureter","n_c":["C12416"],"i_c":"C66.9","i_c_s":["Ureter"],"term_type":"PT"},{"nm":"Ureteric orifice","n_c":["C12337"],"i_c":"C67.6","i_c_s":["Ureteric orifice"],"term_type":"PT"},{"nm":"Urethra","n_c":["C12417"],"i_c":"C68.0","i_c_s":["Urethra"],"term_type":"PT"},{"nm":"Urinary system, NOS","n_c":["C12413"],"i_c":"C68.9","i_c_s":["Urinary system, NOS"],"term_type":"PT"},{"nm":"Uterine adnexa","n_c":["C12321"],"i_c":"C57.4","i_c_s":["Uterine adnexa"],"term_type":"PT"},{"nm":"Uterus, NOS","n_c":["C12405"],"i_c":"C55.9","i_c_s":["Uterus, NOS"],"term_type":"PT"},{"nm":"Uvula","n_c":["C12232"],"i_c":"C05.2","i_c_s":["Uvula"],"term_type":"PT"},{"nm":"Vagina, NOS","n_c":["C12407"],"i_c":"C52.9","i_c_s":["Vagina, NOS"],"term_type":"PT"},{"nm":"Vallecula","n_c":["C12237"],"i_c":"C10.0","i_c_s":["Vallecula"],"term_type":"PT"},{"nm":"Ventral surface of tongue, NOS","n_c":"","i_c":"C02.2","i_c_s":["Ventral surface of tongue, NOS"],"term_type":"PT"},{"nm":"Ventricle, NOS","n_c":["C12356"],"i_c":"C71.5","i_c_s":["Ventricle, NOS"],"term_type":"PT"},{"nm":"Vertebral column","n_c":["C12998"],"i_c":"C41.2","i_c_s":["Vertebral column"],"term_type":"PT"},{"nm":"Vestibule of mouth","n_c":["C165195"],"i_c":"C06.1","i_c_s":["Vestibule of mouth"],"term_type":"PT"},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"C51.9","i_c_s":["Vulva, NOS"],"term_type":"PT"},{"nm":"Waldeyer ring","n_c":["C73468"],"i_c":"C14.2","i_c_s":["Waldeyer ring"],"term_type":"PT"},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.progression_or_recurrence_type":[{"nm":"Biochemical","n_c":["C165196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant","n_c":["C55073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Local","n_c":["C36162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional","n_c":["C41844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locoregional","n_c":["C25388"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.reflux_treatment_type":[{"nm":"Antacids","n_c":["C29633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2 Blockers","n_c":["C29702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medically Treated","n_c":["C165200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Treatment","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proton Pump Inhibitors","n_c":["C29723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgically Treated","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factor":[{"nm":"Adenosis (Atypical Adenomatous Hyperplasia)","n_c":["C120861","C5665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Consumption","n_c":["C16273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcoholic Liver Disease","n_c":["C34783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Animal, NOS","n_c":["C172303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Ant","n_c":["C172307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Bee","n_c":["C172308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Cat","n_c":["C172310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dairy or Lactose","n_c":["C175520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dog","n_c":["C172311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Eggs","n_c":["C172313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Food, NOS","n_c":["C172304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Fruit","n_c":["C172316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Meat","n_c":["C172317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Mold or Dust","n_c":["C172306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Nuts","n_c":["C175521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Processed Foods","n_c":["C175522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Seafood","n_c":["C172320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Wasp","n_c":["C172321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin Deficiency","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Atrophic Chronic Gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1 Tumor Predisposition Syndrome","n_c":["C172639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birt-Hogg-Dube Syndrome","n_c":["C28244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA Family History","n_c":["C172230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Hepatitis","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common variable immune deficiency (CVID)","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cowden Syndrome","n_c":["C3076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, NOS","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type I","n_c":["C2986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Hyperplasia","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Polyp(s)","n_c":["C3954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilbert's Syndrome","n_c":["C84729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular Disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hay Fever","n_c":["C92188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter Pylori-Associated Gastritis","n_c":["C27121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Disorder, NOS","n_c":["C26323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemochromatosis","n_c":["C82892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Encephalopathy","n_c":["C79596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, NOS","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Breast Cancer","n_c":["C4503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Kidney Oncocytoma","n_c":["C8960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","n_c":["C51302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Ovarian Cancer","n_c":["C36102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Papillary Renal Cell Carcinoma","n_c":["C9222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Prostate Cancer","n_c":["C103817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Renal Cell Carcinoma","n_c":["C39789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-grade Prostatic Intraepithelial Neoplasia (PIN)","n_c":["C5541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV","n_c":["C3108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation, Hyperkeratosis","n_c":["C3137","C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nodular Prostatic Hyperplasia","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Fatty Liver Disease","n_c":["C84444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Contraceptives","n_c":["C389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parasitic Disease of Biliary Tract","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Pyogenic Cholangitis","n_c":["C164213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serous tubal intraepithelial carcinoma (STIC)","n_c":["C126449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","n_c":["C156464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tattoo","n_c":["C113681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Nodular Hyperplasia","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, NOS","n_c":["C18059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smokeless","n_c":["C137998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberous Sclerosis","n_c":["C3424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulointerstitial Disease","n_c":["C123036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated Lymphoid Proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undescended Testis","n_c":["C12326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disease","n_c":["C35117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vision Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Von Hippel-Lindau Syndrome","n_c":["C3105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C80078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Rash","n_c":["C39594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-6 (HHV-6)","n_c":["C128829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-8 (HHV-8)","n_c":["C39291"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factor_treatment":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.scan_tracer_used":[{"nm":"Acetate","n_c":["C94719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axumin","n_c":["C74002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Choline","n_c":["C61674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA","n_c":["C17796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Fluoride","n_c":["C832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.viral_hepatitis_serologies":[{"nm":"HBV Core Antibody","n_c":["C96660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV DNA","n_c":["C103404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Genotype","n_c":["C117108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Surface Antibody","n_c":["C74711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HCV Genotype","n_c":["C117109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Surface Antigen","n_c":["C64850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Antibody","n_c":["C92535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Virus RNA","n_c":["C142330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.antigen":[{"nm":"BCL6","n_c":["C26149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CA-125","n_c":["C325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CA19-9","n_c":["C327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND1","n_c":["C17988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD10","n_c":["C16836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD117","n_c":["C17328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD138","n_c":["C96914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD14","n_c":["C17488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD15","n_c":["C96898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD19","n_c":["C38894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD20","n_c":["C38896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD22","n_c":["C17279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD23","n_c":["C96902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD25","n_c":["C17073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD3","n_c":["C38897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD30","n_c":["C38906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD33","n_c":["C97246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD34","n_c":["C17280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD45","n_c":["C17282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD5","n_c":["C73124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD56","n_c":["C25276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD7","n_c":["C38935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79A","n_c":["C97423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEA","n_c":["C16384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-DR","n_c":["C16692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelin","n_c":["C20887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSE","n_c":["C62216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate-Specific Antigen (PSA)","n_c":["C17525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Cell Carcinoma Antigen (SCCA)","n_c":["C120660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ki67","n_c":["C17675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FMC-7","n_c":["C38896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kappa, Surface","n_c":["C184770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lambda, Surface","n_c":["C184771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAG-72","n_c":["C1269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin, Cytoplasmic","n_c":["C172121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin, Surface","n_c":["C573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD43","n_c":["C101153"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.biospecimen_type":[{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buffy Coat","n_c":["C84507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Embryonic Fluid","n_c":["C13398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Embryonic Tissue","n_c":["C12950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feces","n_c":["C13234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocyte","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Involved Tissue, NOS","n_c":["C18009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle Tissue","n_c":["C12435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve Tissue","n_c":["C13052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Fluid","n_c":["C77612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma","n_c":["C13356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Fluid","n_c":["C77613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C13275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum","n_c":["C13325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tissue, NOS","n_c":["C12801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uninvolved Tissue, NOS","n_c":["C162623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urine","n_c":["C13283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.chromosome":[{"nm":"chr1","n_c":["C13204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr2","n_c":["C13215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr3","n_c":["C13219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr4","n_c":["C13220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr5","n_c":["C13221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr6","n_c":["C13222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr7","n_c":["C13223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr8","n_c":["C13224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr9","n_c":["C13225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr10","n_c":["C13205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr11","n_c":["C13206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr12","n_c":["C13207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr13","n_c":["C13208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr14","n_c":["C13209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr15","n_c":["C13210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr16","n_c":["C13211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr17","n_c":["C13212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr18","n_c":["C13213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr19","n_c":["C13214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr20","n_c":["C13216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr21","n_c":["C13217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr22","n_c":["C13218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chr23","n_c":["C33542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chrM","n_c":["C28512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chrX","n_c":["C13285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"chrY","n_c":["C13286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.clonality":[{"nm":"Clonal","n_c":["C41179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-clonal","n_c":["C172229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.gene_symbol":[{"nm":"A1CF","n_c":["C143031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABI1","n_c":["C24824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL1","n_c":["C17346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL2","n_c":["C18451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACKR3","n_c":["C91369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL3","n_c":["C97365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL6","n_c":["C97519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR1","n_c":["C21267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR2A","n_c":["C21271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF1","n_c":["C24602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF3","n_c":["C24538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF4","n_c":["C21385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKAP9","n_c":["C21305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT1","n_c":["C18350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT2","n_c":["C18352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT3","n_c":["C20937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALDH2","n_c":["C84921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK","n_c":["C38184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AMER1","n_c":["C68718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ANK1","n_c":["C84301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APC","n_c":["C17567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APOBEC3B","n_c":["C117001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AR","n_c":["C28539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARAF","n_c":["C18354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP26","n_c":["C97504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP5","n_c":["C97279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGEF12","n_c":["C97436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1A","n_c":["C92530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1B","n_c":["C102520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID2","n_c":["C101088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARNT","n_c":["C26373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASPSCR1","n_c":["C70991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL1","n_c":["C97320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL2","n_c":["C116296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATF1","n_c":["C92177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATIC","n_c":["C97400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM","n_c":["C18583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP1A1","n_c":["C113762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP2B3","n_c":["C113765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR","n_c":["C20560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATRX","n_c":["C74976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN1","n_c":["C19969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN2","n_c":["C20763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B2M","n_c":["C62660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1","n_c":["C20766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BARD1","n_c":["C20715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL10","n_c":["C24259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11A","n_c":["C97394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11B","n_c":["C91855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2","n_c":["C17963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2L12","n_c":["C114743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL3","n_c":["C18360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL6","n_c":["C24260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL7A","n_c":["C24261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9","n_c":["C24262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9L","n_c":["C132328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCLAF1","n_c":["C115994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCOR","n_c":["C101091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCORL1","n_c":["C131268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR","n_c":["C18455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC3","n_c":["C20356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC6","n_c":["C20352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BLM","n_c":["C20805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMP5","n_c":["C21353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMPR1A","n_c":["C21366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF","n_c":["C18363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA1","n_c":["C17965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA2","n_c":["C18120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD3","n_c":["C97397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4","n_c":["C92702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRIP1","n_c":["C63526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTG1","n_c":["C80101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK","n_c":["C75013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BUB1B","n_c":["C95592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C15orf65","n_c":["C98096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CACNA1D","n_c":["C113769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CALR","n_c":["C95313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAMTA1","n_c":["C101440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CANT1","n_c":["C97375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARD11","n_c":["C60668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARS","n_c":["C97369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CASP8","n_c":["C26623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T3","n_c":["C97445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFB","n_c":["C18584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBL","n_c":["C18364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLB","n_c":["C21589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLC","n_c":["C97439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCDC6","n_c":["C18376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNB1IP1","n_c":["C97372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNC","n_c":["C105393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND1","n_c":["C18021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND2","n_c":["C39596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND3","n_c":["C97381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNE1","n_c":["C21412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR4","n_c":["C129065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR7","n_c":["C104128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD209","n_c":["C21568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD274","n_c":["C96022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD28","n_c":["C21291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD74","n_c":["C97418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79A","n_c":["C97421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79B","n_c":["C97424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD99","n_c":["C102939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC73","n_c":["C43569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH1","n_c":["C18249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH10","n_c":["C143093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH11","n_c":["C97427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH17","n_c":["C143096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK12","n_c":["C101095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4","n_c":["C18250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK6","n_c":["C97384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1A","n_c":["C17782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1B","n_c":["C20060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2A","n_c":["C18022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2C","n_c":["C24288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDX2","n_c":["C24292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEBPA","n_c":["C39598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP89","n_c":["C122887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHCHD7","n_c":["C97403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD2","n_c":["C75307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD4","n_c":["C128251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHEK2","n_c":["C40965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHIC2","n_c":["C97406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHST11","n_c":["C143061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIC","n_c":["C97912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIITA","n_c":["C96013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLIP1","n_c":["C84464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLP1","n_c":["C97528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTC","n_c":["C97412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTCL1","n_c":["C97415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBD1","n_c":["C143056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBP","n_c":["C97888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNOT3","n_c":["C107658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTNAP2","n_c":["C73461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTRL","n_c":["C97891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL1A1","n_c":["C29949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL2A1","n_c":["C75315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL3A1","n_c":["C143052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COX6C","n_c":["C24308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB1","n_c":["C38536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L1","n_c":["C95477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L2","n_c":["C95480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREBBP","n_c":["C26568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRLF2","n_c":["C97430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRNKL1","n_c":["C143049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC1","n_c":["C95449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC3","n_c":["C95276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R","n_c":["C18516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF3R","n_c":["C24313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSMD3","n_c":["C143042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTCF","n_c":["C73679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNA2","n_c":["C143115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNB1","n_c":["C20987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND1","n_c":["C79770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND2","n_c":["C82941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUL3","n_c":["C24323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUX1","n_c":["C95578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4","n_c":["C24327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYLD","n_c":["C92678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP2C8","n_c":["C46071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYSLTR2","n_c":["C143039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DAXX","n_c":["C24330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCAF12L2","n_c":["C143036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCC","n_c":["C17358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCTN1","n_c":["C122875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDB2","n_c":["C93075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDIT3","n_c":["C92539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDR2","n_c":["C24333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX10","n_c":["C97457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX3X","n_c":["C101565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX5","n_c":["C97460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX6","n_c":["C18378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DEK","n_c":["C24339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DGCR8","n_c":["C92663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DICER1","n_c":["C25956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNAJB1","n_c":["C122560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNM2","n_c":["C102796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT3A","n_c":["C73652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DROSHA","n_c":["C25955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DUX4L1","n_c":["C124048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBF1","n_c":["C80023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ECT2L","n_c":["C101452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EED","n_c":["C101721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR","n_c":["C17757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF1AX","n_c":["C131315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF3E","n_c":["C18347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF4A2","n_c":["C97467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF3","n_c":["C20899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF4","n_c":["C97470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELK4","n_c":["C97476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELL","n_c":["C97516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELN","n_c":["C75333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EML4","n_c":["C71003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP300","n_c":["C26569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPAS1","n_c":["C104303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA3","n_c":["C18384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA7","n_c":["C111841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPS15","n_c":["C24369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB2","n_c":["C17756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB3","n_c":["C18386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB4","n_c":["C18388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERC1","n_c":["C97499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC2","n_c":["C20555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC3","n_c":["C20556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC4","n_c":["C20558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC5","n_c":["C20557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERG","n_c":["C18139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ESR1","n_c":["C38349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETNK1","n_c":["C122823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV1","n_c":["C24377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV4","n_c":["C24378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV5","n_c":["C97479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV6","n_c":["C18312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EWSR1","n_c":["C18322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT1","n_c":["C18251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT2","n_c":["C18252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2","n_c":["C21327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZR","n_c":["C68722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM131B","n_c":["C106340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM135B","n_c":["C143112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM46C","n_c":["C96316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM47C","n_c":["C143109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCA","n_c":["C85995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCC","n_c":["C86025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCD2","n_c":["C86549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCE","n_c":["C86551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCF","n_c":["C86553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCG","n_c":["C24385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAS","n_c":["C21555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT1","n_c":["C18397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT3","n_c":["C143133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT4","n_c":["C128254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBLN2","n_c":["C143130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXO11","n_c":["C101104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXW7","n_c":["C20786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCGR2B","n_c":["C38554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCRL4","n_c":["C97592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEN1","n_c":["C98120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FES","n_c":["C45497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEV","n_c":["C97482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1","n_c":["C19929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1OP","n_c":["C24401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR2","n_c":["C19931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR3","n_c":["C24393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4","n_c":["C20743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FH","n_c":["C95268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FHIT","n_c":["C18524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FIP1L1","n_c":["C97454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FKBP9","n_c":["C143127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLCN","n_c":["C63514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLI1","n_c":["C18321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLNA","n_c":["C113585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3","n_c":["C24399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT4","n_c":["C24400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FNBP1","n_c":["C97540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXA1","n_c":["C101646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXL2","n_c":["C75472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO1","n_c":["C24402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO3","n_c":["C28519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO4","n_c":["C24606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXP1","n_c":["C97549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXR1","n_c":["C143124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FSTL3","n_c":["C24408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUBP1","n_c":["C99614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUS","n_c":["C91852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GAS7","n_c":["C97562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA1","n_c":["C28575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA2","n_c":["C97552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA3","n_c":["C75492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLI1","n_c":["C24432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GMPS","n_c":["C97522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNA11","n_c":["C89717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAQ","n_c":["C38316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAS","n_c":["C38317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOLGA5","n_c":["C97543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOPC","n_c":["C97546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPC3","n_c":["C88173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPHN","n_c":["C97525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRIN2A","n_c":["C98146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRM3","n_c":["C114529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3A","n_c":["C101443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3B","n_c":["C113760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HERPUD1","n_c":["C97534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HEY1","n_c":["C101107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF1A","n_c":["C26372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIP1","n_c":["C97537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H3B","n_c":["C101732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H4I","n_c":["C68734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A","n_c":["C28585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLF","n_c":["C97556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA1","n_c":["C20576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA2","n_c":["C20577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGN2P46","n_c":["C98093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNF1A","n_c":["C97825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPA2B1","n_c":["C97496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOOK3","n_c":["C97493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA11","n_c":["C97568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA13","n_c":["C97571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA9","n_c":["C24474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXB1","n_c":["C162630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC11","n_c":["C97574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC13","n_c":["C97577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD11","n_c":["C97580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD13","n_c":["C97583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HRAS","n_c":["C17060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AA1","n_c":["C97586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AB1","n_c":["C97589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ID3","n_c":["C102968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1","n_c":["C77215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH2","n_c":["C84948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGH","n_c":["C26422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGK","n_c":["C26425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGKC","n_c":["C171139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGL","n_c":["C26423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKBKB","n_c":["C96383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKZF1","n_c":["C68730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL2","n_c":["C24498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL21R","n_c":["C68736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL6ST","n_c":["C24505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL7R","n_c":["C24506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRF4","n_c":["C18430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRS4","n_c":["C24524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISX","n_c":["C116411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITGAV","n_c":["C53661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITK","n_c":["C24526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1","n_c":["C24528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2","n_c":["C24529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK3","n_c":["C24530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAZF1","n_c":["C73542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JUN","n_c":["C19531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6A","n_c":["C71429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6B","n_c":["C71431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT7","n_c":["C73660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KCNJ5","n_c":["C95838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5A","n_c":["C97595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5C","n_c":["C97598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM6A","n_c":["C96334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDR","n_c":["C24532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDSR","n_c":["C24410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KEAP1","n_c":["C112105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIAA1549","n_c":["C98017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIF5B","n_c":["C101425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIT","n_c":["C18609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF4","n_c":["C73449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF6","n_c":["C97448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLK2","n_c":["C26584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2A","n_c":["C18585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2C","n_c":["C93091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2D","n_c":["C24600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNL1","n_c":["C97378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNSTRN","n_c":["C119652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS","n_c":["C25785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRT20","n_c":["C96457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRT7","n_c":["C96444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KTN1","n_c":["C97601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LARP4B","n_c":["C143064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LASP1","n_c":["C97604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCK","n_c":["C18541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCP1","n_c":["C21294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LEF1","n_c":["C80032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LHFP","n_c":["C97607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LIFR","n_c":["C24552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMNA","n_c":["C61148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO1","n_c":["C91263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO2","n_c":["C17973"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LPP","n_c":["C97610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRIG3","n_c":["C101446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP1B","n_c":["C111830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSM14A","n_c":["C122884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LYL1","n_c":["C24564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LZTR1","n_c":["C128257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAF","n_c":["C18417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAFB","n_c":["C97671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALAT1","n_c":["C92696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALT1","n_c":["C60671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML2","n_c":["C95456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML3","n_c":["C117094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K1","n_c":["C21222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K2","n_c":["C106606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K4","n_c":["C97674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K1","n_c":["C24572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K13","n_c":["C102523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAPK1","n_c":["C21227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAX","n_c":["C18576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MB21D2","n_c":["C132170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2","n_c":["C18345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM4","n_c":["C88218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDS2","n_c":["C97615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MECOM","n_c":["C18392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MED12","n_c":["C98210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEN1","n_c":["C18254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET","n_c":["C18325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MGMT","n_c":["C21232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MIB1","n_c":["C104651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MITF","n_c":["C70584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKL1","n_c":["C97296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLF1","n_c":["C97650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH1","n_c":["C18482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH2","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT1","n_c":["C24601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT10","n_c":["C84461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT11","n_c":["C97387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT3","n_c":["C24603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT4","n_c":["C24604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT6","n_c":["C24605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MN1","n_c":["C97618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MNX1","n_c":["C97559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MPL","n_c":["C18411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH2","n_c":["C18481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH6","n_c":["C19195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSI2","n_c":["C91356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSN","n_c":["C97621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTCP1","n_c":["C24617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTOR","n_c":["C38928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC1","n_c":["C38939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC16","n_c":["C71018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC4","n_c":["C128854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUTYH","n_c":["C61056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYB","n_c":["C28569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYC","n_c":["C16887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCL","n_c":["C18407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCN","n_c":["C18405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYD88","n_c":["C90089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH11","n_c":["C29957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH9","n_c":["C97646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYO5A","n_c":["C122881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYOD1","n_c":["C93113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NAB2","n_c":["C122903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NACA","n_c":["C97653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBEA","n_c":["C143075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBN","n_c":["C21178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCKIPSD","n_c":["C97433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA1","n_c":["C20695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA2","n_c":["C20697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA4","n_c":["C18381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR1","n_c":["C28640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR2","n_c":["C28633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NDRG1","n_c":["C24625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF1","n_c":["C17424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF2","n_c":["C17425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFATC2","n_c":["C93138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFE2L2","n_c":["C54237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFIB","n_c":["C38401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKB2","n_c":["C18404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKBIE","n_c":["C38396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NIN","n_c":["C97668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NKX2-1","n_c":["C73443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NONO","n_c":["C71419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH1","n_c":["C24636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH2","n_c":["C97677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPM1","n_c":["C21185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR4A3","n_c":["C96007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRAS","n_c":["C25786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRG1","n_c":["C20174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD1","n_c":["C75876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD2","n_c":["C21416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD3","n_c":["C96341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NT5C2","n_c":["C104587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTHL1","n_c":["C106190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK1","n_c":["C18551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK3","n_c":["C24647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUMA1","n_c":["C24648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP214","n_c":["C24649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP98","n_c":["C20820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM1","n_c":["C92705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2A","n_c":["C101098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2B","n_c":["C101101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OLIG2","n_c":["C68575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OMD","n_c":["C97680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P2RY8","n_c":["C97683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PABPC1","n_c":["C143072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAFAH1B2","n_c":["C97894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PALB2","n_c":["C84945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PATZ1","n_c":["C97876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX3","n_c":["C24658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX5","n_c":["C24659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX7","n_c":["C24660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX8","n_c":["C97687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBRM1","n_c":["C95438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBX1","n_c":["C97317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCBP1","n_c":["C95865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCM1","n_c":["C97900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDCD1LG2","n_c":["C45437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDE4DIP","n_c":["C97718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFB","n_c":["C18278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRA","n_c":["C24666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRB","n_c":["C24667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PER1","n_c":["C97721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGR","n_c":["C28656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF6","n_c":["C101449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHOX2B","n_c":["C97724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PICALM","n_c":["C84434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CA","n_c":["C21220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CB","n_c":["C24672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3R1","n_c":["C97733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM1","n_c":["C18337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLAG1","n_c":["C71423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLCG1","n_c":["C104821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PML","n_c":["C24686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS1","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS2","n_c":["C18591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLD1","n_c":["C106224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLE","n_c":["C106232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLG","n_c":["C143069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLQ","n_c":["C131801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POT1","n_c":["C107655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU2AF1","n_c":["C97730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU5F1","n_c":["C61140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPARG","n_c":["C24689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPFIBP1","n_c":["C101494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPM1D","n_c":["C88179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP2R1A","n_c":["C92536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP6C","n_c":["C102901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRCC","n_c":["C70994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM1","n_c":["C24692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM16","n_c":["C97736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM2","n_c":["C143121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PREX2","n_c":["C102517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRF1","n_c":["C97739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKACA","n_c":["C38409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKAR1A","n_c":["C97742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKCB","n_c":["C39597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRPF40B","n_c":["C143090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRRX1","n_c":["C98030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSIP1","n_c":["C20676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTCH1","n_c":["C18255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTEN","n_c":["C18256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTK6","n_c":["C24701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN11","n_c":["C26337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN13","n_c":["C104212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN6","n_c":["C24708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRB","n_c":["C122909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRC","n_c":["C24711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRK","n_c":["C106113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRT","n_c":["C24716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PWWP2A","n_c":["C122890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"QKI","n_c":["C111937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RABEP1","n_c":["C97751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAC1","n_c":["C99663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD21","n_c":["C93082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD51B","n_c":["C90145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF1","n_c":["C18338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RALGDS","n_c":["C24721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RANBP2","n_c":["C114452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAP1GDS1","n_c":["C97758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RARA","n_c":["C21571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RB1","n_c":["C17360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM10","n_c":["C115382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM15","n_c":["C97293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RECQL4","n_c":["C26492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"REL","n_c":["C17084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET","n_c":["C18257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGPD3","n_c":["C143082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGS7","n_c":["C143118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOA","n_c":["C18356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOH","n_c":["C21320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RMI2","n_c":["C96027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF213","n_c":["C97390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF43","n_c":["C107649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROBO2","n_c":["C126774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROS1","n_c":["C18399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL10","n_c":["C24748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL22","n_c":["C97761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL5","n_c":["C107652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPN1","n_c":["C97290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO2","n_c":["C106067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO3","n_c":["C24397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1","n_c":["C18579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1T1","n_c":["C28570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S100A7","n_c":["C143078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SALL4","n_c":["C112905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SBDS","n_c":["C97767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDC4","n_c":["C101431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHA","n_c":["C103873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHAF2","n_c":["C97770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHB","n_c":["C97773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHC","n_c":["C97776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHD","n_c":["C97779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT5","n_c":["C97727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT6","n_c":["C97782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT9","n_c":["C97897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SET","n_c":["C24801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETBP1","n_c":["C106635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD2","n_c":["C73662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SF3B1","n_c":["C98284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFPQ","n_c":["C71417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFRP4","n_c":["C24804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SGK1","n_c":["C101559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH2B3","n_c":["C102802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH3GL1","n_c":["C97788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHTN1","n_c":["C122906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPA","n_c":["C24710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SKI","n_c":["C69184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC34A2","n_c":["C101434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC45A3","n_c":["C97791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD2","n_c":["C24566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD3","n_c":["C18504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD4","n_c":["C18258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCA4","n_c":["C19878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCB1","n_c":["C18394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCD1","n_c":["C19875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCE1","n_c":["C19874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMC1A","n_c":["C75406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMO","n_c":["C24817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SND1","n_c":["C96331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SNX29","n_c":["C97764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOCS1","n_c":["C97794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOX2","n_c":["C61136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPECC1","n_c":["C97531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPEN","n_c":["C115310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPOP","n_c":["C102534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRC","n_c":["C19917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRGAP3","n_c":["C97797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF2","n_c":["C101110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF3","n_c":["C97785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18","n_c":["C97800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18L1","n_c":["C97803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX1","n_c":["C97806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX2","n_c":["C97809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX4","n_c":["C97814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG1","n_c":["C131224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG2","n_c":["C101346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3","n_c":["C24833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT5B","n_c":["C28667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT6","n_c":["C24835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STIL","n_c":["C101126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STK11","n_c":["C18253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STRN","n_c":["C107661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUFU","n_c":["C97819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUZ12","n_c":["C73545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYK","n_c":["C26536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAF15","n_c":["C95994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL1","n_c":["C18301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL2","n_c":["C24843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBL1XR1","n_c":["C80116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBX3","n_c":["C101638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCEA1","n_c":["C97822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF12","n_c":["C97828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF3","n_c":["C24846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF7L2","n_c":["C24847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCL1A","n_c":["C92699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TEC","n_c":["C24850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TERT","n_c":["C18173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET1","n_c":["C95423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET2","n_c":["C95252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFE3","n_c":["C24854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFEB","n_c":["C94761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFG","n_c":["C97834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFPT","n_c":["C97837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFRC","n_c":["C38517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFBR2","n_c":["C18592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"THRAP3","n_c":["C97840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX1","n_c":["C18608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX3","n_c":["C98099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMEM127","n_c":["C95303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMPRSS2","n_c":["C24871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNC","n_c":["C21091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFAIP3","n_c":["C84928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF14","n_c":["C97843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF17","n_c":["C97846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP1","n_c":["C26591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP53","n_c":["C17359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP63","n_c":["C91791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM3","n_c":["C97849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM4","n_c":["C97852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPR","n_c":["C97855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRA","n_c":["C26419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRAF7","n_c":["C107646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRB","n_c":["C26418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRD","n_c":["C26420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM24","n_c":["C95280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM27","n_c":["C24733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM33","n_c":["C97858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIP11","n_c":["C97861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRRAP","n_c":["C24880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC1","n_c":["C18259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC2","n_c":["C18260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSHR","n_c":["C24881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U2AF1","n_c":["C101113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBR5","n_c":["C111928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP6","n_c":["C24892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP8","n_c":["C24893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VAV1","n_c":["C18365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VHL","n_c":["C18261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VTI1A","n_c":["C99462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WAS","n_c":["C43236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WDCP","n_c":["C101428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WIF1","n_c":["C97867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WNK2","n_c":["C143106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WRN","n_c":["C20070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1","n_c":["C18262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WWTR1","n_c":["C24844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPA","n_c":["C20361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPC","n_c":["C97870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPO1","n_c":["C99484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"YWHAE","n_c":["C101116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZBTB16","n_c":["C28635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZCCHC8","n_c":["C122878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB1","n_c":["C105605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZFHX3","n_c":["C115424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZMYM3","n_c":["C101617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF198","n_c":["C97873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF331","n_c":["C97879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF384","n_c":["C97882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF429","n_c":["C143100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF444","n_c":["C106358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF479","n_c":["C143103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF521","n_c":["C97885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNRF3","n_c":["C118319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZRSR2","n_c":["C101120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHGA","n_c":["C21167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYP","n_c":["C101144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AQP1","n_c":["C181091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CALB2","n_c":["C123856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNTT","n_c":["C26556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPCAM","n_c":["C18421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GCET1","n_c":["C106015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDPN","n_c":["C104785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTGS2","n_c":["C26598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR2","n_c":["C24863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACACA","n_c":["C103885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD1","n_c":["C185736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTBD18","n_c":["C126629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T2","n_c":["C104928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP164","n_c":["C200372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP170B","n_c":["C126611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTDP1","n_c":["C200378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DOT1L","n_c":["C73677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FRYL","n_c":["C126623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLIS2","n_c":["C105900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGB3","n_c":["C20580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPH1","n_c":["C200386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INO80D","n_c":["C125258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JARID2","n_c":["C200399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF23","n_c":["C98035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM3","n_c":["C178143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTP4A1","n_c":["C24704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPS15","n_c":["C200404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD1A","n_c":["C200408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC66A2 (aka PQLC1)","n_c":["C200414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP2B","n_c":["C26593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBB","n_c":["C38431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB2","n_c":["C75441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MPO","n_c":["C91742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAS, NOS","n_c":["C25784"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.histone_family":[{"nm":"H1","n_c":["C16683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A","n_c":["C16684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2B","n_c":["C17460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3","n_c":["C16685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H4","n_c":["C16686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.histone_variant":[{"nm":"CENP-A","n_c":["C152974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A-Bbd","n_c":["C154613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.X","n_c":["C19432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z","n_c":["C126766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z.1","n_c":["C126766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z.2","n_c":["C162832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2A.Z.2.2","n_c":["C162834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.1","n_c":["C101734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.2","n_c":["C148067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.3","n_c":["C101445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.5","n_c":["C154668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.X","n_c":["C188199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3.Y","n_c":["C155738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3t (H3.4)","n_c":["C154671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mH2A","n_c":["C95407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mH2A.1","n_c":["C113624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mH2A.2","n_c":["C154659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.laboratory_test":[{"nm":"5-Hydroxyindoleacetic Acid","n_c":["C112217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Absolute Neutrophil","n_c":["C63321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albumin","n_c":["C64431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha Fetoprotein","n_c":["C74732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B-cell genotyping","n_c":["C171142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basophil","n_c":["C64470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta 2 Microglobulin","n_c":["C81980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Urea Nitrogen","n_c":["C61019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C-Reactive Protein","n_c":["C64548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium","n_c":["C64488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cellularity","n_c":["C111153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromogranin A","n_c":["C122108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromogranin B","n_c":["C174116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Circulating Tumor Cells","n_c":["C96593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Creatinine","n_c":["C64547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eosinophil","n_c":["C64550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C171143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-Enolase","n_c":["C116205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucose","n_c":["C105585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematocrit","n_c":["C64796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemoglobin","n_c":["C64848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV-E6/E7","n_c":["C171144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Chorionic Gonadotropin","n_c":["C147128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus","n_c":["C171145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin A","n_c":["C81969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin G","n_c":["C81971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin M","n_c":["C81972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lactate Dehydrogenase","n_c":["C64855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leukocytes","n_c":["C51948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luteinizing Hormone","n_c":["C74790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoblasts","n_c":["C102278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytes","n_c":["C51949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M Protein","n_c":["C92291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metamyelocytes","n_c":["C74615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myeloblasts","n_c":["C74632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelocytes","n_c":["C74662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neutrophil Bands","n_c":["C64830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platelets","n_c":["C51951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolymphocytes","n_c":["C74620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Promonocytes","n_c":["C74621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Promyelocytes","n_c":["C74622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Segmented Neutrophil","n_c":["C81997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Free Immunoglobulin Light Chain, Kappa","n_c":["C98730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Free Immunoglobulin Light Chain, Lambda","n_c":["C98732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Free Immunoglobulin Light Chain, NOS","n_c":["C147376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testosterone","n_c":["C74793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Bilirubin","n_c":["C38037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Protein","n_c":["C64858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BG8","n_c":["C178240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Circulating Endothelial Cells","n_c":["C96592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dopamine-Secreting","n_c":["C103871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epinephrine-Secreting","n_c":["C103869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metanephrine-Secreting","n_c":["C103870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxytyramine-Secreting","n_c":["C103872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microsatellite Instability","n_c":["C36318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norepinephrine-Secreting","n_c":["C103867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normetanephrine-Secreting","n_c":["C103868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAG-72","n_c":["C106505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokeratin 5","n_c":["C122859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokeratin 6","n_c":["C122858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum Mesothelin","n_c":["C184798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythrocyte Sedimentation Rate","n_c":["C74611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prothrombin Time","n_c":["C62656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blast Count","n_c":["C74605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metaphase Nucleus Count","n_c":["C168918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Minimal Residual Disease","n_c":["C185298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monocytes","n_c":["C64823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abnormal Cells","n_c":["C111124"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.mismatch_repair_mutation":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.molecular_analysis_method":[{"nm":"Comparative Genomic Hybridization","n_c":["C18084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytogenetics, NOS","n_c":["C18280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FISH","n_c":["C17563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flow Cytometry","n_c":["C16585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IHC","n_c":["C23020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunofluorescence","n_c":["C142337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISH","n_c":["C17562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Karyotype","n_c":["C16768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microarray","n_c":["C18477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microsatellite Analysis","n_c":["C63331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclear Staining","n_c":["C165224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCR","n_c":["C17003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA Sequencing","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RT-PCR","n_c":["C18136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing, NOS","n_c":["C17565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Southern Blotting","n_c":["C16356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopy, NOS","n_c":["C16853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunophenotyping, NOS","n_c":["C181250"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.molecular_consequence":[{"nm":"3 Prime UTR Variant","n_c":["C63433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5 Prime UTR Variant","n_c":["C63432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coding Sequence Variant","n_c":["C148639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Downstream Gene Variant","n_c":["C63431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feature Elongation","n_c":["C148640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feature Truncation","n_c":["C148641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frameshift Variant","n_c":["C17354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incomplete Terminal Codon Variant","n_c":["C179438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inframe Deletion","n_c":["C165225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inframe Insertion","n_c":["C165226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intergenic Variant","n_c":["C148642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intron Variant","n_c":["C63429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mature miRNA Variant","n_c":["C165227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Missense Variant","n_c":["C18133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NMD Transcript Variant","n_c":["C148643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-coding Transcript Exon Variant","n_c":["C148645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-coding Transcript Variant","n_c":["C148644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonsense","n_c":["C62198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Altering Variant","n_c":["C18133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regulatory Region Ablation","n_c":["C148647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regulatory Region Amplification","n_c":["C148648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regulatory Region Variant","n_c":["C148646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Acceptor Variant","n_c":["C45389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Donor Variant","n_c":["C45390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Region Variant","n_c":["C19798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Start Lost","n_c":["C148649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stop Gain","n_c":["C62198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stop Lost","n_c":["C148650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stop Retained Variant","n_c":["C148651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synonymous Variant","n_c":["C20629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TF Binding Site Variant","n_c":["C148652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFBS Ablation","n_c":["C148653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFBS Amplification","n_c":["C148654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transcript Ablation","n_c":["C16606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transcript Amplification","n_c":["C45581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upstream Gene Variant","n_c":["C63430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exon Variant","n_c":["C148639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.pathogenicity":[{"nm":"Benign","n_c":["C168802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Likely Benign","n_c":["C168801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Likely Pathogenic","n_c":["C168800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathogenic","n_c":["C168799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uncertain Significance","n_c":["C94187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.ploidy":[{"nm":"Aneuploid","n_c":["C2873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diploid","n_c":["C118941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperdiploid","n_c":["C80336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypodiploid","n_c":["C80337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Near Diploid","n_c":["C165228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetraploid","n_c":["C28450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.second_gene_symbol":[{"nm":"A1CF","n_c":["C143031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABI1","n_c":["C24824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL1","n_c":["C17346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ABL2","n_c":["C18451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACKR3","n_c":["C91369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL3","n_c":["C97365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACSL6","n_c":["C97519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR1","n_c":["C21267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACVR2A","n_c":["C21271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF1","n_c":["C24602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF3","n_c":["C24538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AFF4","n_c":["C21385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKAP9","n_c":["C21305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT1","n_c":["C18350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT2","n_c":["C18352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT3","n_c":["C20937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALDH2","n_c":["C84921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK","n_c":["C38184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AMER1","n_c":["C68718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ANK1","n_c":["C84301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APC","n_c":["C17567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APOBEC3B","n_c":["C117001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AR","n_c":["C28539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARAF","n_c":["C18354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP26","n_c":["C97504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGAP5","n_c":["C97279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARHGEF12","n_c":["C97436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1A","n_c":["C92530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID1B","n_c":["C102520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARID2","n_c":["C101088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARNT","n_c":["C26373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASPSCR1","n_c":["C70991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL1","n_c":["C97320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASXL2","n_c":["C116296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATF1","n_c":["C92177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATIC","n_c":["C97400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM","n_c":["C18583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP1A1","n_c":["C113762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATP2B3","n_c":["C113765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR","n_c":["C20560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATRX","n_c":["C74976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN1","n_c":["C19969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXIN2","n_c":["C20763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B2M","n_c":["C62660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1","n_c":["C20766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BARD1","n_c":["C20715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL10","n_c":["C24259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11A","n_c":["C97394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL11B","n_c":["C91855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2","n_c":["C17963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL2L12","n_c":["C114743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL3","n_c":["C18360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL6","n_c":["C24260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL7A","n_c":["C24261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9","n_c":["C24262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCL9L","n_c":["C132328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCLAF1","n_c":["C115994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCOR","n_c":["C101091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCORL1","n_c":["C131268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR","n_c":["C18455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC3","n_c":["C20356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BIRC6","n_c":["C20352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BLM","n_c":["C20805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMP5","n_c":["C21353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMPR1A","n_c":["C21366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF","n_c":["C18363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA1","n_c":["C17965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA2","n_c":["C18120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD3","n_c":["C97397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4","n_c":["C92702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRIP1","n_c":["C63526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTG1","n_c":["C80101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK","n_c":["C75013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BUB1B","n_c":["C95592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C15orf65","n_c":["C98096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CACNA1D","n_c":["C113769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CALR","n_c":["C95313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAMTA1","n_c":["C101440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CANT1","n_c":["C97375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARD11","n_c":["C60668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CARS","n_c":["C97369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CASP8","n_c":["C26623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T3","n_c":["C97445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFB","n_c":["C18584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBL","n_c":["C18364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLB","n_c":["C21589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBLC","n_c":["C97439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCDC6","n_c":["C18376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNB1IP1","n_c":["C97372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNC","n_c":["C105393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND1","n_c":["C18021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND2","n_c":["C39596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCND3","n_c":["C97381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCNE1","n_c":["C21412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR4","n_c":["C129065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR7","n_c":["C104128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD209","n_c":["C21568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD274","n_c":["C96022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD28","n_c":["C21291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD74","n_c":["C97418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79A","n_c":["C97421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD79B","n_c":["C97424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD99","n_c":["C102939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC73","n_c":["C43569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH1","n_c":["C18249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH10","n_c":["C143093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH11","n_c":["C97427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDH17","n_c":["C143096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK12","n_c":["C101095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4","n_c":["C18250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK6","n_c":["C97384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1A","n_c":["C17782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN1B","n_c":["C20060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2A","n_c":["C18022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDKN2C","n_c":["C24288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDX2","n_c":["C24292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEBPA","n_c":["C39598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP89","n_c":["C122887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHCHD7","n_c":["C97403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD2","n_c":["C75307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHD4","n_c":["C128251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHEK2","n_c":["C40965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHIC2","n_c":["C97406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHST11","n_c":["C143061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIC","n_c":["C97912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CIITA","n_c":["C96013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLIP1","n_c":["C84464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLP1","n_c":["C97528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTC","n_c":["C97412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CLTCL1","n_c":["C97415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBD1","n_c":["C143056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNBP","n_c":["C97888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNOT3","n_c":["C107658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTNAP2","n_c":["C73461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNTRL","n_c":["C97891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL1A1","n_c":["C29949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL2A1","n_c":["C75315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COL3A1","n_c":["C143052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COX6C","n_c":["C24308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB1","n_c":["C38536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L1","n_c":["C95477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREB3L2","n_c":["C95480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CREBBP","n_c":["C26568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRLF2","n_c":["C97430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRNKL1","n_c":["C143049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC1","n_c":["C95449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CRTC3","n_c":["C95276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R","n_c":["C18516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF3R","n_c":["C24313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSMD3","n_c":["C143042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTCF","n_c":["C73679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNA2","n_c":["C143115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNNB1","n_c":["C20987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND1","n_c":["C79770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTNND2","n_c":["C82941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUL3","n_c":["C24323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CUX1","n_c":["C95578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4","n_c":["C24327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYLD","n_c":["C92678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP2C8","n_c":["C46071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYSLTR2","n_c":["C143039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DAXX","n_c":["C24330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCAF12L2","n_c":["C143036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCC","n_c":["C17358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DCTN1","n_c":["C122875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDB2","n_c":["C93075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDIT3","n_c":["C92539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDR2","n_c":["C24333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX10","n_c":["C97457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX3X","n_c":["C101565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX5","n_c":["C97460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DDX6","n_c":["C18378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DEK","n_c":["C24339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DGCR8","n_c":["C92663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DICER1","n_c":["C25956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNAJB1","n_c":["C122560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNM2","n_c":["C102796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT3A","n_c":["C73652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DROSHA","n_c":["C25955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DUX4L1","n_c":["C124048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBF1","n_c":["C80023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ECT2L","n_c":["C101452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EED","n_c":["C101721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR","n_c":["C17757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF1AX","n_c":["C131315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF3E","n_c":["C18347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EIF4A2","n_c":["C97467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF3","n_c":["C20899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELF4","n_c":["C97470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELK4","n_c":["C97476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELL","n_c":["C97516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ELN","n_c":["C75333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EML4","n_c":["C71003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP300","n_c":["C26569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPAS1","n_c":["C104303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA3","n_c":["C18384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPHA7","n_c":["C111841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EPS15","n_c":["C24369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB2","n_c":["C17756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB3","n_c":["C18386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERBB4","n_c":["C18388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERC1","n_c":["C97499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC2","n_c":["C20555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC3","n_c":["C20556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC4","n_c":["C20558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERCC5","n_c":["C20557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERG","n_c":["C18139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ESR1","n_c":["C38349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETNK1","n_c":["C122823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV1","n_c":["C24377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV4","n_c":["C24378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV5","n_c":["C97479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ETV6","n_c":["C18312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EWSR1","n_c":["C18322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT1","n_c":["C18251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EXT2","n_c":["C18252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2","n_c":["C21327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZR","n_c":["C68722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM131B","n_c":["C106340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM135B","n_c":["C143112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM46C","n_c":["C96316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAM47C","n_c":["C143109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCA","n_c":["C85995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCC","n_c":["C86025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCD2","n_c":["C86549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCE","n_c":["C86551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCF","n_c":["C86553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FANCG","n_c":["C24385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAS","n_c":["C21555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT1","n_c":["C18397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT3","n_c":["C143133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAT4","n_c":["C128254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBLN2","n_c":["C143130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXO11","n_c":["C101104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FBXW7","n_c":["C20786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCGR2B","n_c":["C38554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FCRL4","n_c":["C97592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEN1","n_c":["C98120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FES","n_c":["C45497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FEV","n_c":["C97482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1","n_c":["C19929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1OP","n_c":["C24401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR2","n_c":["C19931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR3","n_c":["C24393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4","n_c":["C20743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FH","n_c":["C95268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FHIT","n_c":["C18524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FIP1L1","n_c":["C97454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FKBP9","n_c":["C143127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLCN","n_c":["C63514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLI1","n_c":["C18321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLNA","n_c":["C113585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3","n_c":["C24399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT4","n_c":["C24400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FNBP1","n_c":["C97540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXA1","n_c":["C101646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXL2","n_c":["C75472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO1","n_c":["C24402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO3","n_c":["C28519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXO4","n_c":["C24606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXP1","n_c":["C97549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FOXR1","n_c":["C143124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FSTL3","n_c":["C24408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUBP1","n_c":["C99614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FUS","n_c":["C91852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GAS7","n_c":["C97562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA1","n_c":["C28575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA2","n_c":["C97552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GATA3","n_c":["C75492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLI1","n_c":["C24432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GMPS","n_c":["C97522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNA11","n_c":["C89717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAQ","n_c":["C38316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GNAS","n_c":["C38317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOLGA5","n_c":["C97543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GOPC","n_c":["C97546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPC3","n_c":["C88173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GPHN","n_c":["C97525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRIN2A","n_c":["C98146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GRM3","n_c":["C114529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3A","n_c":["C101443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3F3B","n_c":["C113760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HERPUD1","n_c":["C97534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HEY1","n_c":["C101107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF1A","n_c":["C26372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIP1","n_c":["C97537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H3B","n_c":["C101732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIST1H4I","n_c":["C68734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A","n_c":["C28585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLF","n_c":["C97556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA1","n_c":["C20576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGA2","n_c":["C20577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGN2P46","n_c":["C98093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNF1A","n_c":["C97825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPA2B1","n_c":["C97496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOOK3","n_c":["C97493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA11","n_c":["C97568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA13","n_c":["C97571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXA9","n_c":["C24474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXB1","n_c":["C162630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC11","n_c":["C97574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXC13","n_c":["C97577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD11","n_c":["C97580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HOXD13","n_c":["C97583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HRAS","n_c":["C17060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AA1","n_c":["C97586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90AB1","n_c":["C97589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ID3","n_c":["C102968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1","n_c":["C77215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH2","n_c":["C84948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGH","n_c":["C26422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGK","n_c":["C26425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGL","n_c":["C26423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKBKB","n_c":["C96383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IKZF1","n_c":["C68730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL2","n_c":["C24498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL21R","n_c":["C68736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL6ST","n_c":["C24505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL7R","n_c":["C24506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRF4","n_c":["C18430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRS4","n_c":["C24524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISX","n_c":["C116411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITGAV","n_c":["C53661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITK","n_c":["C24526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1","n_c":["C24528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2","n_c":["C24529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK3","n_c":["C24530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAZF1","n_c":["C73542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JUN","n_c":["C19531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6A","n_c":["C71429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT6B","n_c":["C71431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KAT7","n_c":["C73660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KCNJ5","n_c":["C95838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5A","n_c":["C97595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM5C","n_c":["C97598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDM6A","n_c":["C96334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDR","n_c":["C24532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KDSR","n_c":["C24410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KEAP1","n_c":["C112105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIAA1549","n_c":["C98017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIF5B","n_c":["C101425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KIT","n_c":["C18609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF4","n_c":["C73449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLF6","n_c":["C97448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KLK2","n_c":["C26584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2A","n_c":["C18585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2C","n_c":["C93091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KMT2D","n_c":["C24600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNL1","n_c":["C97378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KNSTRN","n_c":["C119652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS","n_c":["C25785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KTN1","n_c":["C97601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LARP4B","n_c":["C143064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LASP1","n_c":["C97604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCK","n_c":["C18541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LCP1","n_c":["C21294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LEF1","n_c":["C80032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LHFP","n_c":["C97607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LIFR","n_c":["C24552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMNA","n_c":["C61148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO1","n_c":["C91263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMO2","n_c":["C17973"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LPP","n_c":["C97610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRIG3","n_c":["C101446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP1B","n_c":["C111830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSM14A","n_c":["C122884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LYL1","n_c":["C24564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LZTR1","n_c":["C128257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAF","n_c":["C18417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAFB","n_c":["C97671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALAT1","n_c":["C92696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALT1","n_c":["C60671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML2","n_c":["C95456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAML3","n_c":["C117094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K1","n_c":["C21222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K2","n_c":["C106606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP2K4","n_c":["C97674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K1","n_c":["C24572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAP3K13","n_c":["C102523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAPK1","n_c":["C21227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAX","n_c":["C18576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MB21D2","n_c":["C132170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2","n_c":["C18345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM4","n_c":["C88218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDS2","n_c":["C97615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MECOM","n_c":["C18392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MED12","n_c":["C98210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEN1","n_c":["C18254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET","n_c":["C18325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MGMT","n_c":["C21232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MITF","n_c":["C70584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKL1","n_c":["C97296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLF1","n_c":["C97650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH1","n_c":["C18482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLH2","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT1","n_c":["C24601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT10","n_c":["C84461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT11","n_c":["C97387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT3","n_c":["C24603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT4","n_c":["C24604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MLLT6","n_c":["C24605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MN1","n_c":["C97618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MNX1","n_c":["C97559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MPL","n_c":["C18411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH2","n_c":["C18481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSH6","n_c":["C19195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSI2","n_c":["C91356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSN","n_c":["C97621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTCP1","n_c":["C24617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTOR","n_c":["C38928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC1","n_c":["C38939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC16","n_c":["C71018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC4","n_c":["C128854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUTYH","n_c":["C61056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYB","n_c":["C28569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYC","n_c":["C16887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCL","n_c":["C18407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYCN","n_c":["C18405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYD88","n_c":["C90089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH11","n_c":["C29957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYH9","n_c":["C97646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYO5A","n_c":["C122881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYOD1","n_c":["C93113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NAB2","n_c":["C122903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NACA","n_c":["C97653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBEA","n_c":["C143075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NBN","n_c":["C21178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCKIPSD","n_c":["C97433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA1","n_c":["C20695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA2","n_c":["C20697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOA4","n_c":["C18381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR1","n_c":["C28640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NCOR2","n_c":["C28633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NDRG1","n_c":["C24625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF1","n_c":["C17424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NF2","n_c":["C17425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFATC2","n_c":["C93138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFE2L2","n_c":["C54237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFIB","n_c":["C38401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKB2","n_c":["C18404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NFKBIE","n_c":["C38396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NIN","n_c":["C97668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NKX2-1","n_c":["C73443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NONO","n_c":["C71419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH1","n_c":["C24636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOTCH2","n_c":["C97677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NPM1","n_c":["C21185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NR4A3","n_c":["C96007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRAS","n_c":["C25786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NRG1","n_c":["C20174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD1","n_c":["C75876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD2","n_c":["C21416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NSD3","n_c":["C96341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NT5C2","n_c":["C104587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTHL1","n_c":["C106190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK1","n_c":["C18551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK3","n_c":["C24647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUMA1","n_c":["C24648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP214","n_c":["C24649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUP98","n_c":["C20820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM1","n_c":["C92705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2A","n_c":["C101098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NUTM2B","n_c":["C101101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OLIG2","n_c":["C68575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OMD","n_c":["C97680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P2RY8","n_c":["C97683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PABPC1","n_c":["C143072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAFAH1B2","n_c":["C97894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PALB2","n_c":["C84945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PATZ1","n_c":["C97876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX3","n_c":["C24658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX5","n_c":["C24659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX7","n_c":["C24660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAX8","n_c":["C97687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBRM1","n_c":["C95438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBX1","n_c":["C97317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCBP1","n_c":["C95865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCM1","n_c":["C97900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDCD1LG2","n_c":["C45437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDE4DIP","n_c":["C97718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFB","n_c":["C18278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRA","n_c":["C24666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDGFRB","n_c":["C24667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PER1","n_c":["C97721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGR","n_c":["C28656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF6","n_c":["C101449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHOX2B","n_c":["C97724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PICALM","n_c":["C84434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CA","n_c":["C21220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3CB","n_c":["C24672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIK3R1","n_c":["C97733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM1","n_c":["C18337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLAG1","n_c":["C71423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLCG1","n_c":["C104821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PML","n_c":["C24686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS1","n_c":["C18590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PMS2","n_c":["C18591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLD1","n_c":["C106224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLE","n_c":["C106232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLG","n_c":["C143069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POLQ","n_c":["C131801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POT1","n_c":["C107655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU2AF1","n_c":["C97730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"POU5F1","n_c":["C61140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPARG","n_c":["C24689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPFIBP1","n_c":["C101494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPM1D","n_c":["C88179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP2R1A","n_c":["C92536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPP6C","n_c":["C102901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRCC","n_c":["C70994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM1","n_c":["C24692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM16","n_c":["C97736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRDM2","n_c":["C143121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PREX2","n_c":["C102517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRF1","n_c":["C97739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKACA","n_c":["C38409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKAR1A","n_c":["C97742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRKCB","n_c":["C39597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRPF40B","n_c":["C143090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRRX1","n_c":["C98030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSIP1","n_c":["C20676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTCH1","n_c":["C18255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTEN","n_c":["C18256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTK6","n_c":["C24701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN11","n_c":["C26337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN13","n_c":["C104212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPN6","n_c":["C24708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRB","n_c":["C122909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRC","n_c":["C24711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRK","n_c":["C106113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTPRT","n_c":["C24716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PWWP2A","n_c":["C122890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"QKI","n_c":["C111937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RABEP1","n_c":["C97751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAC1","n_c":["C99663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD21","n_c":["C93082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD51B","n_c":["C90145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF1","n_c":["C18338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RALGDS","n_c":["C24721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RANBP2","n_c":["C114452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAP1GDS1","n_c":["C97758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RARA","n_c":["C21571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RB1","n_c":["C17360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM10","n_c":["C115382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RBM15","n_c":["C97293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RECQL4","n_c":["C26492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"REL","n_c":["C17084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET","n_c":["C18257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGPD3","n_c":["C143082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RGS7","n_c":["C143118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOA","n_c":["C18356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RHOH","n_c":["C21320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RMI2","n_c":["C96027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF213","n_c":["C97390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNF43","n_c":["C107649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROBO2","n_c":["C126774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROS1","n_c":["C18399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL10","n_c":["C24748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL22","n_c":["C97761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPL5","n_c":["C107652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPN1","n_c":["C97290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO2","n_c":["C106067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSPO3","n_c":["C24397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1","n_c":["C18579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RUNX1T1","n_c":["C28570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S100A7","n_c":["C143078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SALL4","n_c":["C112905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SBDS","n_c":["C97767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDC4","n_c":["C101431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHA","n_c":["C103873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHAF2","n_c":["C97770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHB","n_c":["C97773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHC","n_c":["C97776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDHD","n_c":["C97779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT5","n_c":["C97727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT6","n_c":["C97782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SEPT9","n_c":["C97897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SET","n_c":["C24801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETBP1","n_c":["C106635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD2","n_c":["C73662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SF3B1","n_c":["C98284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFPQ","n_c":["C71417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SFRP4","n_c":["C24804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SGK1","n_c":["C101559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH2B3","n_c":["C102802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SH3GL1","n_c":["C97788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHTN1","n_c":["C122906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPA","n_c":["C24710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SKI","n_c":["C69184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC34A2","n_c":["C101434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC45A3","n_c":["C97791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD2","n_c":["C24566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD3","n_c":["C18504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAD4","n_c":["C18258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCA4","n_c":["C19878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCB1","n_c":["C18394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCD1","n_c":["C19875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMARCE1","n_c":["C19874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMC1A","n_c":["C75406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMO","n_c":["C24817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SND1","n_c":["C96331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SNX29","n_c":["C97764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOCS1","n_c":["C97794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOX2","n_c":["C61136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPECC1","n_c":["C97531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPEN","n_c":["C115310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SPOP","n_c":["C102534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRC","n_c":["C19917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRGAP3","n_c":["C97797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF2","n_c":["C101110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRSF3","n_c":["C97785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18","n_c":["C97800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SS18L1","n_c":["C97803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX1","n_c":["C97806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX2","n_c":["C97809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSX4","n_c":["C97814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG1","n_c":["C131224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAG2","n_c":["C101346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3","n_c":["C24833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT5B","n_c":["C28667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT6","n_c":["C24835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STIL","n_c":["C101126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STK11","n_c":["C18253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STRN","n_c":["C107661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUFU","n_c":["C97819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SUZ12","n_c":["C73545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYK","n_c":["C26536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAF15","n_c":["C95994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL1","n_c":["C18301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAL2","n_c":["C24843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBL1XR1","n_c":["C80116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TBX3","n_c":["C101638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCEA1","n_c":["C97822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF12","n_c":["C97828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF3","n_c":["C24846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCF7L2","n_c":["C24847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCL1A","n_c":["C92699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TEC","n_c":["C24850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TERT","n_c":["C18173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET1","n_c":["C95423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TET2","n_c":["C95252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFE3","n_c":["C24854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFEB","n_c":["C94761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFG","n_c":["C97834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFPT","n_c":["C97837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TFRC","n_c":["C38517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFBR2","n_c":["C18592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"THRAP3","n_c":["C97840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX1","n_c":["C18608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLX3","n_c":["C98099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMEM127","n_c":["C95303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TMPRSS2","n_c":["C24871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNC","n_c":["C21091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFAIP3","n_c":["C84928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF14","n_c":["C97843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TNFRSF17","n_c":["C97846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP1","n_c":["C26591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP53","n_c":["C17359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP63","n_c":["C91791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM3","n_c":["C97849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPM4","n_c":["C97852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TPR","n_c":["C97855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRA","n_c":["C26419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRAF7","n_c":["C107646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRB","n_c":["C26418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRD","n_c":["C26420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM24","n_c":["C95280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM27","n_c":["C24733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIM33","n_c":["C97858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRIP11","n_c":["C97861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRRAP","n_c":["C24880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC1","n_c":["C18259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSC2","n_c":["C18260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSHR","n_c":["C24881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U2AF1","n_c":["C101113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBR5","n_c":["C111928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP6","n_c":["C24892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP8","n_c":["C24893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VAV1","n_c":["C18365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VHL","n_c":["C18261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VTI1A","n_c":["C99462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WAS","n_c":["C43236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WDCP","n_c":["C101428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WIF1","n_c":["C97867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WNK2","n_c":["C143106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WRN","n_c":["C20070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1","n_c":["C18262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WWTR1","n_c":["C24844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPA","n_c":["C20361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPC","n_c":["C97870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPO1","n_c":["C99484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"YWHAE","n_c":["C101116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZBTB16","n_c":["C28635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZCCHC8","n_c":["C122878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB1","n_c":["C105605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZFHX3","n_c":["C115424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZMYM3","n_c":["C101617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF198","n_c":["C97873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF331","n_c":["C97879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF384","n_c":["C97882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF429","n_c":["C143100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF444","n_c":["C106358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF479","n_c":["C143103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNF521","n_c":["C97885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZNRF3","n_c":["C118319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZRSR2","n_c":["C101120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHGA","n_c":["C21167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SYP","n_c":["C101144"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR2","n_c":["C24863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ACACA","n_c":["C103885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD1","n_c":["C185736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTBD18","n_c":["C126629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBFA2T2","n_c":["C104928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP164","n_c":["C200372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEP170B","n_c":["C126611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTDP1","n_c":["C200378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DOT1L","n_c":["C73677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FRYL","n_c":["C126623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GLIS2","n_c":["C105900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HMGB3","n_c":["C20580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HNRNPH1","n_c":["C200386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INO80D","n_c":["C125258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JARID2","n_c":["C200399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PHF23","n_c":["C98035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM3","n_c":["C178143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTP4A1","n_c":["C24704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RPS15","n_c":["C200404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SETD1A","n_c":["C200408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC66A2 (aka PQLC1)","n_c":["C200414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TOP2B","n_c":["C26593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UBB","n_c":["C38431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ZEB2","n_c":["C75441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MPO","n_c":["C91742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAS, NOS","n_c":["C25784"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.test_analyte_type":[{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA","n_c":["C25966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA","n_c":["C813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein","n_c":["C17021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.test_result":[{"nm":"Abnormal, NOS","n_c":["C26683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copy Number Reported","n_c":["C49142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equivocal","n_c":["C86071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High","n_c":["C25227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate","n_c":["C73705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loss of Expression","n_c":["C165233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low","n_c":["C54722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normal","n_c":["C14165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Overexpressed","n_c":["C177693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Positive","n_c":["C38758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Test Value Reported","n_c":["C165229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stable","n_c":["C30103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amplified","n_c":["C177682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elevated","n_c":["C26683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Amplified","n_c":["C177682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotic Count Reported","n_c":["C202274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staining Intensity Value Reported","n_c":["C202275"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.variant_origin":[{"nm":"Germline","n_c":["C17666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somatic","n_c":["C18060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.variant_type":[{"nm":"Alleles","n_c":["C16277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amplification","n_c":["C45581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chrimerism","n_c":["C62582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conversion","n_c":["C165230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deletion","n_c":["C19296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deletion-Insertion","n_c":["C171175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duplication","n_c":["C45582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extension","n_c":["C148650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gain","n_c":["C37956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypermethylation","n_c":["C20102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insertion","n_c":["C19295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inversion","n_c":["C45589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loss","n_c":["C25559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylation","n_c":["C16848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mosaicism","n_c":["C92976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Methylation","n_c":["C165231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rearrangement","n_c":["C36541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repeated Sequences","n_c":["C13298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice","n_c":["C19798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Substitution","n_c":["C18133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Translocation","n_c":["C3420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fusion","n_c":["C45584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genetic Polymorphism","n_c":["C17004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Internal Tandem Duplication","n_c":["C198980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutation, NOS","n_c":["C45576"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.zygosity":[{"nm":"Hemizygous","n_c":["C64346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterozygous","n_c":["C45825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Homozygous","n_c":["C45826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nullizygous","n_c":["C148063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.anaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.anaplasia_present_type":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse","n_c":["C14175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equivocal","n_c":["C86071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Focal","n_c":["C28224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C36113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sclerosis","n_c":["C69309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.bone_marrow_malignant_cells":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.columnar_mucosa_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.dysplasia_degree":[{"nm":"High Grade","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indefinite","n_c":["C164039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Dysplasia","n_c":["C164040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mild","n_c":["C8362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate","n_c":["C8363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Severe","n_c":["C8364"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.dysplasia_type":[{"nm":"Esophageal Columnar Dysplasia","n_c":["C174120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Keratinizing","n_c":["C161017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonkeratinizing","n_c":["C161016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal Mucosa Columnar Dysplasia","n_c":["C174120"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.largest_extrapelvic_peritoneal_focus":[{"nm":"Macroscopic (2cm or less)","n_c":["C53696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic (greater than 2cm)","n_c":["C51138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_involved_site":[{"nm":"Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-external","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac, NOS","n_c":["C32761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis, NOS","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical, NOS","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_involvement":[{"nm":"Positive","n_c":["C27296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Negative","n_c":["C36174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminant","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymphatic_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.margin_status":[{"nm":"Involved","n_c":["C48620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uninvolved","n_c":["C48621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminant","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.metaplasia_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.morphologic_architectural_pattern":[{"nm":"Cohesive","n_c":["C179432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cribiform","n_c":["C35920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micropapillary","n_c":["C36181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-cohesive","n_c":["C179447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papillary Renal Cell","n_c":["C6975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papillary, NOS","n_c":["C35911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid","n_c":["C36182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubular","n_c":["C35925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.non_nodal_regional_disease":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminate","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.non_nodal_tumor_deposits":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.perineural_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.peripancreatic_lymph_nodes_positive":[{"nm":"0","n_c":["C70430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1-3","n_c":["C172224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4 or More","n_c":["C172226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.transglottic_extension":[{"nm":"Absent","n_c":["C48190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Present","n_c":["C25626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.vascular_invasion_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.vascular_invasion_type":[{"nm":"Extramural","n_c":["C44280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intramural","n_c":["C25234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macro","n_c":["C43566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micro","n_c":["C25252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Vascular Invasion","n_c":["C164046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"data_file.pathology_report.data_category":[{"nm":"Clinical","n_c":["C15783"],"i_c":"","i_c_s":"","term_type":""}],"data_file.pathology_report.data_type":[{"nm":"Pathology Report","n_c":["C28277"],"i_c":"","i_c_s":"","term_type":""}],"data_file.pathology_report.data_format":[{"nm":"PDF","n_c":["C63805"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.chipseq_target":[{"nm":"H3K4me1","n_c":["C120024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K4me3","n_c":["C107153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K9me3","n_c":["C174109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K27me3","n_c":["C174110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K36me3","n_c":["C142872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H3K27ac","n_c":["C120023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Input Control","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.instrument_model":[{"nm":"454 GS FLX Titanium","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"AB SOLiD 2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"AB SOLiD 3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"AB SOLiD 4","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Complete Genomics","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Genome Analyzer II","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Genome Analyzer IIx","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq 2000","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq 2500","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq 4000","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq X Five","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina HiSeq X Ten","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina MiSeq","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina NextSeq","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent PGM","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent Proton","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent S5","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio RS","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.library_selection":[{"nm":"Affinity Enrichment","n_c":["C163987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hybrid Selection","n_c":["C163986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA Size Fractionation","n_c":["C163991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCR","n_c":["C17003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poly-T Enrichment","n_c":["C163988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Random","n_c":["C163989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"rRNA Depletion","n_c":["C163990"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.library_strand":[{"nm":"Unstranded","n_c":["C150427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First_Stranded","n_c":["C150428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Second_Stranded","n_c":["C150426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.library_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A RNA Methylation","n_c":["C179442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.single_cell_library":[{"nm":"Chromium 3' Gene Expression v2 Library","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Chromium 3' Gene Expression v3 Library","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Smart-Seq2","n_c":"","i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.target_capture_kit":[{"nm":"Custom AmpliSeq Cancer Hotspot GENIE-MDA Augmented Panel v1 - 46 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom GENIE-DFCI OncoPanel - 275 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom GENIE-DFCI Oncopanel - 300 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom GENIE-DFCI Oncopanel - 447 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom HaloPlex DLBCL Panel - 370 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Ion AmpliSeq Hotspot GENIE-MOSC3 Augmented Panel - 74 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Large Construct Capture TARGET-OS Panel - 8 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom MSK IMPACT Panel - 341 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom MSK IMPACT Panel - 410 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom MSK IMPACT Panel - 468 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Myeloid GENIE-VICC Panel - 37 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Personalis ACEcp VAREPOP-APOLLO Panel v2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom PGDX SureSelect CancerSelect VAREPOP-APOLLO Panel - 203 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom PGDX SureSelect CancerSelect VAREPOP-APOLLO Panel - 88 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SeqCap EZ HGSC VCRome v2.1 ER Augmented v1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SeqCap EZ HGSC VCRome v2.1 ER Augmented v2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SeqCap EZ TARGET-OS Panel - 7.0 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Solid Tumor GENIE-VICC Panel - 34 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect CGCI-BLGSP Panel - 4.6 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect CGCI-HTMCP-CC KMT2D And Hotspot Panel - 37.0 Kb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect CGCI-HTMCP-CC Panel - 19.7 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect GENIE-UHN Panel - 555 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect Human All Exon v1.1 Plus 3 Boosters","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom SureSelect TARGET-AML_NBL_WT Panel - 2.8 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Twist Broad Exome v1.0 - 35.0 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Custom Twist Broad PanCancer Panel - 396 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Foundation Medicine T5a Panel - 322 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Foundation Medicine T7 Panel - 429 Genes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion AmpliSeq Cancer Hotspot Panel v2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Ion AmpliSeq Comprehensive Cancer Panel","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nextera DNA Exome","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Nextera Rapid Capture Exome v1.2","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SeqCap EZ HGSC VCRome v2.1","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SeqCap EZ Human Exome v2.0","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SeqCap EZ Human Exome v3.0","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v3","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v4","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v5","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"SureSelect Human All Exon v5 + UTR","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSeq Amplicon Cancer Panel","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSeq Exome Enrichment - 62 Mb","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSeq RNA Exome","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"TruSight Myeloid Sequencing Panel","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"xGen Exome Research Panel v1.0","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data.root.id":[{"nm":"root","n_c":["C172256"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.run_metadata.data_category":[{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.run_metadata.data_type":[{"nm":"Run Metadata","n_c":["C165214"],"i_c":"","i_c_s":"","term_type":""}],"metadata_file.run_metadata.data_format":[{"nm":"SRA XML","n_c":["C184804"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.biospecimen_anatomic_site":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Wall","n_c":["C77608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetabulum","n_c":["C32042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoid","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adipose","n_c":["C12472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alveolar Ridge","n_c":["C89749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amniotic Fluid","n_c":["C13188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ampulla Of Vater","n_c":["C13011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Sphincter","n_c":["C165177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle","n_c":["C32078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectum","n_c":["C129464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antecubital Fossa","n_c":["C103238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrum","n_c":["C97102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aorta","n_c":["C12669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Body","n_c":["C97112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aqueous Fluid","n_c":["C13190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arm","n_c":["C32141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artery","n_c":["C12372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon","n_c":["C12265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auditory Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autonomic Nervous System","n_c":["C12673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axilla","n_c":["C12674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back","n_c":["C13062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct","n_c":["C12376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel","n_c":["C12679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bowel","n_c":["C12736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad Ligament","n_c":["C12318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchiole","n_c":["C12684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brow","n_c":["C32575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock","n_c":["C89806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calf","n_c":["C93027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary","n_c":["C12685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardia","n_c":["C12256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carina","n_c":["C25264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Artery","n_c":["C12687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Body","n_c":["C66852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cartilage","n_c":["C12373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecum","n_c":["C12381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell-Line","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebellum","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Spine","n_c":["C69313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest","n_c":["C25389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chin","n_c":["C81169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clavicle","n_c":["C12695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clitoris","n_c":["C12308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon - Mucosa Only","n_c":["C164003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Duct","n_c":["C12698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermal","n_c":["C25478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Descending Colon","n_c":["C12268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenum","n_c":["C12263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear, Pinna (External)","n_c":["C12292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Effusion","n_c":["C3003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbow","n_c":["C32497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Gland","n_c":["C12704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epidural Space","n_c":["C41449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal; Distal","n_c":["C12255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal; Mid","n_c":["C12254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophageal; Proximal","n_c":["C12253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagogastric Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus - Mucosa Only","n_c":["C32538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Artery","n_c":["C12715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Vein","n_c":["C12716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femur","n_c":["C12717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts","n_c":["C12482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibula","n_c":["C12718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finger","n_c":["C32608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floor Of Mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluid","n_c":["C25278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foot","n_c":["C32622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forearm","n_c":["C32628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forehead","n_c":["C89803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foreskin","n_c":["C33049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Cortex","n_c":["C177766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fundus Of Stomach","n_c":["C12257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglia","n_c":["C12719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glottis","n_c":["C12724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand","n_c":["C32712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hard Palate","n_c":["C12230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head - Face Or Neck, Nos","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Head & Neck","n_c":["C12418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic","n_c":["C13308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Duct","n_c":["C32730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Vein","n_c":["C32736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip","n_c":["C64193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hippocampus","n_c":["C12444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Humerus","n_c":["C12731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileum","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilium","n_c":["C32765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Index Finger","n_c":["C52835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischium","n_c":["C32884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Islet Cells","n_c":["C32885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jaw","n_c":["C48821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunum","n_c":["C12388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint","n_c":["C13044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Knee","n_c":["C32898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacrimal Gland","n_c":["C12346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Bowel","n_c":["C12379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leg","n_c":["C32974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ligament","n_c":["C13046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumbar Spine","n_c":["C69314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Axilla","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Distant","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-Common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-External","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Internal Mammary","n_c":["C32853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mammary","n_c":["C137678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Pelvic","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Scalene","n_c":["C89780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Subclavicular","n_c":["C63705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Nodes(s) Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Soft Tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Finger","n_c":["C52836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondria","n_c":["C13258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle","n_c":["C13056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nails","n_c":["C33156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Cavity","n_c":["C12424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Soft Tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve","n_c":["C12466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve(s) Cranial","n_c":["C12700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital Cortex","n_c":["C177767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular Orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity - Mucosa Only","n_c":["C77637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paranasal Sinuses","n_c":["C12763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraspinal Ganglion","n_c":["C97925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parathyroid","n_c":["C12765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid Gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patella","n_c":["C33282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Soft Tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharynx","n_c":["C12425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal Gland","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pituitary Gland","n_c":["C12399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal Fossa","n_c":["C103222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pylorus","n_c":["C12260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid Junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retina","n_c":["C12343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retro-Orbital Region","n_c":["C54155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rib","n_c":["C12782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ring Finger","n_c":["C52837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Round Ligament","n_c":["C12319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacrum","n_c":["C33508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scapula","n_c":["C12783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sciatic Nerve","n_c":["C52810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotum","n_c":["C12785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seminal Vesicle","n_c":["C12787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shoulder","n_c":["C25203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus(es), Maxillary","n_c":["C12275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skeletal Muscle","n_c":["C13050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skull","n_c":["C12789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel - Mucosa Only","n_c":["C33568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Finger","n_c":["C52838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Column","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Flexure","n_c":["C12267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sternum","n_c":["C12793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach - Mucosa Only","n_c":["C32656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous Tissue","n_c":["C33645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subglottis","n_c":["C12280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sublingual Gland","n_c":["C12234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular Gland","n_c":["C12233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraglottis","n_c":["C12279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovium","n_c":["C12473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal Cortex","n_c":["C177768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tendon","n_c":["C13045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thigh","n_c":["C33763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracic Spine","n_c":["C69315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat","n_c":["C54272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thumb","n_c":["C52834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tibia","n_c":["C12800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil (Pharyngeal)","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea / Major Bronchi","n_c":["C12961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trunk","n_c":["C33816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbilical Cord","n_c":["C34320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract","n_c":["C191741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uvula","n_c":["C12232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens","n_c":["C12813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vein","n_c":["C12814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous","n_c":["C25291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebra","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cells","n_c":["C12529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist","n_c":["C33894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.biospecimen_laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.composition":[{"nm":"2D Classical Conditionally Reprogrammed Cells","n_c":["C172257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2D Modified Conditionally Reprogrammed Cells","n_c":["C172258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Air-Liquid Interface Organoid","n_c":["C172260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Neurosphere","n_c":["C172261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Organoid","n_c":["C172259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adherent Cell Line","n_c":["C20216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Components","n_c":["C164009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Components NOS","n_c":["C164009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cells","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buffy Coat","n_c":["C84507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell","n_c":["C12508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Control Analyte","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derived Cell Line","n_c":["C156445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts from Bone Marrow Normal","n_c":["C164010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocytes","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Original Cells","n_c":["C19315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquid Suspension Cell Line","n_c":["C20217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytes","n_c":["C12535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mononuclear Cells from Bone Marrow Normal","n_c":["C164011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Blood Components NOS","n_c":["C17610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Whole Blood","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma","n_c":["C13356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C3331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C13275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum","n_c":["C13325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid Tissue","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorted Cells","n_c":["C126974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sputum","n_c":["C13278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whole Bone Marrow","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Adherent Suspension","n_c":["C174118"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.diagnosis_pathologically_confirmed":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.distance_normal_to_tumor":[{"nm":"Adjacent (< or = 2cm)","n_c":["C25408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distal (>2cm)","n_c":["C25237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.method_of_sample_procurement":[{"nm":"Abdomino-perineal Resection of Rectum","n_c":["C91826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anterior Resection of Rectum","n_c":["C113716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites Drainage","n_c":["C159342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspirate","n_c":["C13347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autopsy","n_c":["C25153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy","n_c":["C15189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Draw","n_c":["C17610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Aspirate","n_c":["C133261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosal Resection","n_c":["C172322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Core Biopsy","n_c":["C15680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cystectomy","n_c":["C15217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Parotidectomy","n_c":["C161002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endo Rectal Tumor Resection","n_c":["C165178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endolaryngeal Excision","n_c":["C160999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endoscopic Biopsy","n_c":["C15389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endoscopic Mucosal Resection (EMR)","n_c":["C103242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enucleation","n_c":["C48601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Excisional Biopsy","n_c":["C15385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fine Needle Aspiration","n_c":["C15361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Full Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glossectomy","n_c":["C51604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gross Total Resection","n_c":["C131672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand Assisted Laparoscopic Radical Nephrectomy","n_c":["C165179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hysterectomy NOS","n_c":["C15256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incisional Biopsy","n_c":["C15386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indeterminant","n_c":["C48658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Biopsy","n_c":["C165180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Partial Nephrectomy","n_c":["C165181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Radical Nephrectomy","n_c":["C165182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Radical Prostatectomy with Robotics","n_c":["C165183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laparoscopic Radical Prostatectomy without Robotics","n_c":["C165184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharyngectomy","n_c":["C150660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left Hemicolectomy","n_c":["C51624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquid Biopsy","n_c":["C135727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lobectomy","n_c":["C15272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Local Resection (Exoresection; wall resection)","n_c":["C118358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumpectomy","n_c":["C15755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node Dissection","n_c":["C15275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphadenectomy","n_c":["C15275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandibulectomy","n_c":["C51664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxillectomy","n_c":["C51656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metastasectomy","n_c":["C94461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Radical Mastectomy","n_c":["C15278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Needle Biopsy","n_c":["C15190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentectomy","n_c":["C51787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oophorectomy","n_c":["C15291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Craniotomy","n_c":["C15214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Partial Nephrectomy","n_c":["C165186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Radical Nephrectomy","n_c":["C165187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Open Radical Prostatectomy","n_c":["C165188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orchiectomy","n_c":["C15288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Surgical Resection","n_c":["C184787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palatectomy","n_c":["C160997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-Procto Colectomy","n_c":["C103239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatectomy","n_c":["C15294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paracentesis","n_c":["C15310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotidectomy, NOS","n_c":["C51490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Hepatectomy","n_c":["C15394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Laryngectomy","n_c":["C94240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Maxillectomy","n_c":["C51657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Nephrectomy","n_c":["C51928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Lavage","n_c":["C159340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonectomy","n_c":["C15305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Punch Biopsy","n_c":["C28743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Hysterectomy","n_c":["C94470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Maxillectomy","n_c":["C172324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Nephrectomy","n_c":["C51778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Prostatectomy","n_c":["C15399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right Hemicolectomy","n_c":["C51623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salpingectomy","n_c":["C51605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salpingo-oophorectomy","n_c":["C15323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colectomy","n_c":["C91838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Mastectomy","n_c":["C15281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subtotal Prostatectomy","n_c":["C172325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subtotal Resection","n_c":["C131680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial Parotidectomy","n_c":["C51910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supracervical Hysterectomy","n_c":["C126397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supracricoid Laryngectomy","n_c":["C91839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraglottic Laryngectomy","n_c":["C51889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgical Resection","n_c":["C158758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracentesis","n_c":["C15392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracoscopic Biopsy","n_c":["C163997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsillectomy","n_c":["C51679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Colectomy","n_c":["C51924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Hepatectomy","n_c":["C51781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Laryngectomy","n_c":["C51771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Mastectomy","n_c":["C15281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Nephrectomy","n_c":["C51632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transoral Laser Excision","n_c":["C91840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transplant","n_c":["C15342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transurethral resection (TURBT)","n_c":["C116651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transurethral Resection (TURP)","n_c":["C15343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colectomy","n_c":["C51612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Debulking","n_c":["C15749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Resection","n_c":["C164212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertical Hemilaryngectomy","n_c":["C51906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wedge Resection","n_c":["C51690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whipple Procedure","n_c":["C15356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.preservation_method":[{"nm":"Cryopreserved","n_c":["C16475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE","n_c":["C143028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fresh","n_c":["C84517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frozen","n_c":["C70717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OCT","n_c":["C63523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Snap Frozen","n_c":["C63521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EDTA","n_c":["C61742"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.sample_type":[{"nm":"Additional - New Primary","n_c":["C156441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Additional Metastatic","n_c":["C156440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Neoplasms","n_c":["C3677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Bone Marrow","n_c":["C164015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Bone Marrow, Post-treatment","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Peripheral Blood","n_c":["C164030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Cancer - Peripheral Blood, Post-treatment","n_c":["C164031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Liquid Biopsy","n_c":["C135727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Derived Normal","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Normal","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cell Normal","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell Line Derived Xenograft Tissue","n_c":["C156443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell Lines","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Control Analyte","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA","n_c":["C449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized Normal","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Expanded Next Generation Cancer Model","n_c":["C184757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE Recurrent","n_c":["C172267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FFPE Scrolls","n_c":["C172268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts from Bone Marrow Normal","n_c":["C164010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GenomePlex (Rubicon) Amplified DNA","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocytes","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Tumor Original Cells","n_c":["C172293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"In Situ Neoplasms","n_c":["C36118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Normal","n_c":["C13049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metastatic","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Adherent Suspension","n_c":["C174118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mononuclear Cells from Bone Marrow Normal","n_c":["C164011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoplasms of Uncertain and Unknown Behavior","n_c":["C65157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Next Generation Cancer Model","n_c":["C172295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Allowed To Collect","n_c":["C141478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C3331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post neo-adjuvant therapy","n_c":["C156444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Blood Derived Cancer - Bone Marrow","n_c":["C164015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Blood Derived Cancer - Peripheral Blood","n_c":["C164030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Tumor","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Xenograft Tissue","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Blood Derived Cancer - Bone Marrow","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Blood Derived Cancer - Peripheral Blood","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Tumor","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G (Qiagen) DNA","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X (Qiagen) DNA","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA","n_c":["C812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C174119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slides","n_c":["C172296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid Tissue Normal","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor","n_c":["C18009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor Adjacent Normal - Post Neo-adjuvant Therapy","n_c":["C164033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xenograft Tissue","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Next Generation Cancer Model Expanded Under Non-conforming Conditions","n_c":["C184781"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.sample_type_id":[{"nm":"01","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"02","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"03","n_c":["C164030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"04","n_c":["C164017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"05","n_c":["C156441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"06","n_c":["C156440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"07","n_c":["C156440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"08","n_c":["C172293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"09","n_c":["C164015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"10","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"12","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"13","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"14","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"15","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"16","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"17","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"18","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"20","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"30","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"31","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"32","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"40","n_c":["C164031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"41","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"42","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"50","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"60","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"61","n_c":["C156443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"85","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"86","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"99","n_c":"","i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tissue_collection_type":[{"nm":"Prospective","n_c":["C172297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retrospective","n_c":["C172298"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tissue_type":[{"nm":"Tumor","n_c":["C18009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normal","n_c":["C14165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abnormal","n_c":["C25401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritumoral","n_c":["C119010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tumor_code":[{"nm":"Acute Leukemia of Ambiguous Lineage (ALAL)","n_c":["C7464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute lymphoblastic leukemia (ALL)","n_c":["C3167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute myeloid leukemia (AML)","n_c":["C3171"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Cancer (all types)","n_c":["C9291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Cancer (all types)","n_c":["C9039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clear cell sarcoma of the kidney (CCSK)","n_c":["C4264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, ependymoma","n_c":["C3017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, glioblastoma (GBM)","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, low grade glioma (LGG)","n_c":["C132067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, medulloblastoma","n_c":["C3222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, other","n_c":["C184750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS, rhabdoid tumor","n_c":["C184751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse Large B-Cell Lymphoma (DLBCL)","n_c":["C8851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ewing sarcoma","n_c":["C4817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction Failure AML (AML-IF)","n_c":["C184765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Cancer (all types)","n_c":["C4878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroblastoma (NBL)","n_c":["C3270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NHL, anaplastic large cell lymphoma","n_c":["C3720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NHL, Burkitt lymphoma (BL)","n_c":["C2912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non cancerous tissue","n_c":["C166238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteosarcoma (OS)","n_c":["C9145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhabdoid tumor (kidney) (RT)","n_c":["C8715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhabdomyosarcoma","n_c":["C3359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft tissue sarcoma, non-rhabdomyosarcoma","n_c":["C9306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wilms tumor (WT)","n_c":["C3267"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tumor_code_id":[{"nm":"00","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"01","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"02","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"03","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"04","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"10","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"15","n_c":["C7978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"20","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"21","n_c":["C7978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"30","n_c":["C4349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"40","n_c":["C7978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"41","n_c":["C4349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"50","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"51","n_c":["C6975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"52","n_c":["C3512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"60","n_c":["C3493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"61","n_c":["C9245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"62","n_c":["C3058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"63","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"64","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"65","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"70","n_c":["C4033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"71","n_c":["C6975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"80","n_c":["C9245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"81","n_c":["C7558"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.tumor_descriptor":[{"nm":"Metastatic","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NOS","n_c":["C19594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premalignant","n_c":["C36032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary","n_c":["C8509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence","n_c":["C4798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xenograft","n_c":["C12932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Primary","n_c":["C156806"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.slide.bone_marrow_malignant_cells":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.data_category":[{"nm":"Biospecimen","n_c":["C70699"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.data_type":[{"nm":"Cell Culture Image","n_c":["C165212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slide Image","n_c":["C165215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tissue Microarray Image","n_c":["C171154"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.data_format":[{"nm":"JPEG","n_c":["C48230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SVS","n_c":["C172214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TIFF","n_c":["C70631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JPEG 2000","n_c":["C184768"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.experimental_strategy":[{"nm":"Cell Culture","n_c":["C16396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diagnostic Slide","n_c":["C165218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tissue Slide","n_c":["C165223"],"i_c":"","i_c_s":"","term_type":""}],"data_file.slide_image.stain_type":[{"nm":"Haemotoxylin and Eosin (H&E)","n_c":["C23011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunohistochemistry (IHC)","n_c":["C23020"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.data_category":[{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.data_type":[{"nm":"Aligned Reads","n_c":["C164052"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.data_format":[{"nm":"BAM","n_c":["C153249"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_aligned_reads.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A RNA Methylation","n_c":["C179442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.type":[{"nm":"submitted_genomic_profile","n_c":["C94411"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.data_category":[{"nm":"Combined Nucleotide Variation","n_c":["C171155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genomic Profiling","n_c":["C94411"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.data_type":[{"nm":"FoundationOne Report","n_c":["C184758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GENIE Report","n_c":["C184760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw CGI Variant","n_c":["C184794"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XML","n_c":["C45967"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genomic_profile.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.data_type":[{"nm":"Methylation Beta Value","n_c":["C164051"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_methylation_beta_value.platform":[{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.data_type":[{"nm":"Copy Number Estimate","n_c":["C165213"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_tangent_copy_number.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.data_category":[{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.data_type":[{"nm":"Unaligned Reads","n_c":["C164053"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.data_format":[{"nm":"BAM","n_c":["C153249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FASTQ","n_c":["C153250"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A RNA Methylation","n_c":["C179442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_unaligned_reads.read_pair_number":[{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C172301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C172302"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.chemo_concurrent_to_radiation":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.initial_disease_status":[{"nm":"Initial Diagnosis","n_c":["C156813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Disease","n_c":["C35571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Disease","n_c":["C38155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Residual Disease","n_c":["C4809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Persistent Disease","n_c":["C90169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Refractory Disease","n_c":["C39752"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.reason_treatment_ended":[{"nm":"Adverse Event","n_c":["C41331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Course of Therapy Completed","n_c":["C82568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Disease Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Withdrawal by Subject","n_c":["C49634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_anatomic_site":[{"nm":"Abdomen, total","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Wall","n_c":["C77608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetabulum","n_c":["C32042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoid","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adipose","n_c":["C12472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alveolar Ridge","n_c":["C89749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amniotic Fluid","n_c":["C13188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Sphincter","n_c":["C165177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle","n_c":["C32078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectum","n_c":["C129464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antecubital Fossa","n_c":["C103238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrum","n_c":["C97102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aorta","n_c":["C12669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Body","n_c":["C97112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aqueous Fluid","n_c":["C13190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arm","n_c":["C32141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artery","n_c":["C12372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon","n_c":["C12265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auditory Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autonomic Nervous System","n_c":["C12673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axilla","n_c":["C12674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back","n_c":["C13062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct","n_c":["C12376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel","n_c":["C12679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Body, total","n_c":["C13041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone, non-spine","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Bowel","n_c":["C12736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad Ligament","n_c":["C12318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchiole","n_c":["C12684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brow","n_c":["C32575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock","n_c":["C89806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calf","n_c":["C93027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary","n_c":["C12685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardia","n_c":["C12256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carina","n_c":["C25264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Artery","n_c":["C12687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Body","n_c":["C66852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cartilage","n_c":["C12373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecum","n_c":["C12381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell-Line","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebellum","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Spine","n_c":["C69313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest","n_c":["C25389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chin","n_c":["C81169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clavicle","n_c":["C12695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clitoris","n_c":["C12308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon - Mucosa Only","n_c":["C164003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Duct","n_c":["C12698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermal","n_c":["C25478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Descending Colon","n_c":["C12268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Site","n_c":["C179433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenum","n_c":["C12263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear, Pinna (External)","n_c":["C12292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbow","n_c":["C32497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Gland","n_c":["C12704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epidural Space","n_c":["C41449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C165193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagogastric Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus - Mucosa Only","n_c":["C32538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Artery","n_c":["C12715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Vein","n_c":["C12716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femur","n_c":["C12717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts","n_c":["C12482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibula","n_c":["C12718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finger","n_c":["C32608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floor of Mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluid","n_c":["C25278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foot","n_c":["C32622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forearm","n_c":["C32628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forehead","n_c":["C89803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foreskin","n_c":["C33049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Cortex","n_c":["C177766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fundus of Stomach","n_c":["C12257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglia","n_c":["C12719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal, Intestine","n_c":["C13359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genitourinary, NOS","n_c":["C25350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand","n_c":["C32712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hard Palate","n_c":["C12230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head - Face Or Neck, Nos","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Head and Neck","n_c":["C12418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic","n_c":["C13308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Duct","n_c":["C32730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Vein","n_c":["C32736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C25724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip","n_c":["C64193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hippocampus","n_c":["C12444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Humerus","n_c":["C12731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileocecal Valve","n_c":["C13066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileum","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilium","n_c":["C32765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Index Finger","n_c":["C52835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischium","n_c":["C32884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Islet Cells","n_c":["C32885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jaw","n_c":["C48821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunum","n_c":["C12388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint","n_c":["C13044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Knee","n_c":["C32898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacrimal Gland","n_c":["C12346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Bowel","n_c":["C12379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leg","n_c":["C32974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ligament","n_c":["C13046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumbar Spine","n_c":["C69314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Axilla","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Distant","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-Common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-External","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Internal Mammary","n_c":["C32853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mammary","n_c":["C137678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Pelvic","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Scalene","n_c":["C89780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Subclavicular","n_c":["C63705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mantle","n_c":["C12507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Soft Tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Finger","n_c":["C52836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondria","n_c":["C13258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle","n_c":["C13056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nails","n_c":["C33156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Cavity","n_c":["C12424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Soft Tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve","n_c":["C12466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve(s) Cranial","n_c":["C12700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital Cortex","n_c":["C177767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular Orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity - Mucosa Only","n_c":["C77637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraspinal Ganglion","n_c":["C97925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parathyroid","n_c":["C12765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid Gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patella","n_c":["C33282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Soft Tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharynx","n_c":["C12425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal Gland","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pituitary Gland","n_c":["C12399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal Fossa","n_c":["C103222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pouch","n_c":["C43200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Tumor Field","n_c":["C179450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary tumor site","n_c":["C179451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Bed","n_c":["C90348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate, Seminal Vesicles and Lymph Nodes","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"Pylorus","n_c":["C12260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid Junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional Site","n_c":["C179457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retina","n_c":["C12343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retro-Orbital Region","n_c":["C54155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rib","n_c":["C12782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ring Finger","n_c":["C52837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Round Ligament","n_c":["C12319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacrum","n_c":["C33508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scapula","n_c":["C12783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sciatic Nerve","n_c":["C52810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotum","n_c":["C12785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seminal Vesicle","n_c":["C12787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shoulder","n_c":["C25203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus(es), Maxillary","n_c":["C12275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skeletal Muscle","n_c":["C13050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, lower extremity, local","n_c":["C164047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, total","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, trunk, local","n_c":["C12295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, upper extremity, local","n_c":["C164048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skull","n_c":["C12789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel - Mucosa Only","n_c":["C33568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Finger","n_c":["C52838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Column","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spine","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Flexure","n_c":["C12267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sternum","n_c":["C12793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach - Mucosa Only","n_c":["C32656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous Tissue","n_c":["C33645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovium","n_c":["C12473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal Cortex","n_c":["C177768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tendon","n_c":["C13045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thigh","n_c":["C33763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracic Spine","n_c":["C69315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat","n_c":["C54272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thumb","n_c":["C52834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tibia","n_c":["C12800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil (Pharyngeal)","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea / Major Bronchi","n_c":["C12961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trunk","n_c":["C33816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbilical Cord","n_c":["C34320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract","n_c":["C191741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uvula","n_c":["C12232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens","n_c":["C12813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vein","n_c":["C12814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous","n_c":["C25291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebra","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cells","n_c":["C12529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist","n_c":["C33894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locoregional Site","n_c":["C25388"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_arm":[{"nm":"A081105","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"E4512","n_c":"","i_c":"","i_c_s":"","term_type":""},{"nm":"EA5142","n_c":"","i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_dose_units":[{"nm":"cGy","n_c":["C64693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gy","n_c":["C18063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg","n_c":["C28253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AUC","n_c":["C64774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/day","n_c":["C67372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/m2","n_c":["C67282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IU/kg","n_c":["C67379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IU/mg","n_c":["C67380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mCi","n_c":["C48511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mEq","n_c":["C48512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/day","n_c":["C67399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/dL","n_c":["C67015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/kg","n_c":["C67401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/kg/day","n_c":["C66976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2","n_c":["C67402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2/day","n_c":["C66974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2/wk","n_c":["C88148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/mL","n_c":["C42576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/wk","n_c":["C67404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mIU","n_c":["C67316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mL","n_c":["C28254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ug","n_c":["C48152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ug/m2","n_c":["C67312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wafer","n_c":["C48552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_effect":[{"nm":"Complete Necrosis (No Viable Tumor)","n_c":["C156234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incomplete Necrosis (Viable Tumor Present)","n_c":["C156235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Necrosis","n_c":["C168971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Known Treatment Effect","n_c":["C164134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_effect_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_frequency":[{"nm":"Every Hour","n_c":["C64510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Five Times Daily","n_c":["C98849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Four Times Daily","n_c":["C64530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Three Times Daily","n_c":["C64527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Daily","n_c":["C64496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Every 24 Hours","n_c":["C64515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Every Other Day","n_c":["C64525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Weekly","n_c":["C64497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once Weekly","n_c":["C64526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_intent_type":[{"nm":"Adjuvant","n_c":["C25722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Deprivation Therapy (ADT)","n_c":["C15481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer Control","n_c":["C15971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cure","n_c":["C62220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maintenance Therapy","n_c":["C15688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoadjuvant","n_c":["C15665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palliative","n_c":["C15292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prevention","n_c":["C15843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Consolidation Therapy","n_c":["C15679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First-Line Therapy","n_c":["C45792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction","n_c":["C158876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation Boost","n_c":["C137812"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_or_therapy":[{"nm":"yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"no","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_outcome":[{"nm":"Complete Response","n_c":["C4870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Response","n_c":["C165202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Measurable Disease","n_c":["C40413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Response","n_c":["C123600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partial Response","n_c":["C18058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Persistent Disease","n_c":["C90169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Disease","n_c":["C35571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stable Disease","n_c":["C18213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treatment Ongoing","n_c":["C165209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treatment Stopped Due to Toxicity","n_c":["C105741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Very Good Partial Response","n_c":["C123618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normalization of Tumor Markers","n_c":["C198983"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_type":[{"nm":"Ablation, Cryo","n_c":["C15215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Ethanol Injection","n_c":["C67444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Microwave","n_c":["C116643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, NOS","n_c":["C20985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Radiofrequency","n_c":["C15666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation, Radiosurgical","n_c":["C15696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ancillary Treatment","n_c":["C15747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antiseizure Treatment","n_c":["C64172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisphosphonate Therapy","n_c":["C443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blinded Study, Treatment Unknown","n_c":["C70840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachytherapy, High Dose","n_c":["C15651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachytherapy, Low Dose","n_c":["C85254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachytherapy, NOS","n_c":["C15195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemoembolization","n_c":["C15752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemoprotectant","n_c":["C15533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemotherapy","n_c":["C15632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Concurrent Chemoradiation","n_c":["C141342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryoablation","n_c":["C15215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Embolization","n_c":["C15230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethanol Injection Ablation","n_c":["C67444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"External Beam Radiation","n_c":["C15751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hormone Therapy","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I-131 Radiation Therapy","n_c":["C198584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapy (Including Vaccines)","n_c":["C15262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Internal Radiation","n_c":["C15195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isolated Limb Perfusion (ILP)","n_c":["C15393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ Transplantation","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharmaceutical Therapy, NOS","n_c":["C15986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis","n_c":["C66899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation Therapy, NOS","n_c":["C15313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, 2D Conventional","n_c":["C165189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, 3D Conformal","n_c":["C16035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Combination","n_c":["C165192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Cyberknife","n_c":["C95484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, External Beam","n_c":["C15751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Implants","n_c":["C66891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Intensity-Modulated Radiotherapy","n_c":["C16135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Internal","n_c":["C15195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Proton Beam","n_c":["C66897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Radioisotope","n_c":["C15470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Stereotactic/Gamma Knife/SRS","n_c":["C15382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Systemic","n_c":["C92991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radioactive Iodine Therapy","n_c":["C157968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radioembolization","n_c":["C93340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiosensitizing Agent","n_c":["C798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Allogeneic","n_c":["C46089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Autologous","n_c":["C16039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Double Autologous","n_c":["C116466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Haploidentical","n_c":["C138187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Non-Myeloablative","n_c":["C62714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, NOS","n_c":["C15431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Transplantation, Syngenic","n_c":["C93196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stem Cell Treatment","n_c":["C165194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stereotactic Radiosurgery","n_c":["C15358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steroid Therapy","n_c":["C15370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Molecular Therapy","n_c":["C76243"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Hypofractionated","n_c":["C62726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Mixed Photon Beam","n_c":["C152055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiation, Photon Beam","n_c":["C104914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis, NOS","n_c":["C66899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis, Talc","n_c":["C178422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptide Receptor Radionuclide Therapy (PRRT)","n_c":["C162449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy, Excisional","n_c":["C15385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biopsy, Incisional","n_c":["C15386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distal Pancreatectomy","n_c":["C51647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery, Minimally Invasive","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery, NOS","n_c":["C172727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgery, Open","n_c":["C126391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Pancreatectomy","n_c":["C15340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whipple","n_c":["C15356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ablation or Embolization, NOS","n_c":["C20985","C15230"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.therapeutic_agents":[{"nm":"10-Deacetyltaxol","n_c":["C957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11C Topotecan","n_c":["C49172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11D10 AluGel Anti-Idiotype Monoclonal Antibody","n_c":["C28781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"12-Allyldeoxoartemisinin","n_c":["C41441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"13-Deoxydoxorubicin","n_c":["C2494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"14C BMS-275183","n_c":["C62553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521","n_c":["C133224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Deoxy-D-glucose","n_c":["C116618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Ethylhydrazide","n_c":["C1165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Fluoroadenine","n_c":["C29794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Fluorofucose-containing SGN-2FF","n_c":["C131289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyestradiol","n_c":["C120474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyestrone","n_c":["C63947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyflutamide Depot","n_c":["C85482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Hydroxyoleic Acid","n_c":["C105401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Methoxyestradiol","n_c":["C965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion","n_c":["C62603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-Methoxyestrone","n_c":["C120472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2-O, 3-O Desulfated Heparin","n_c":["C99130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2,6-Diaminopurine","n_c":["C29796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2,6-Dimethoxyquinone","n_c":["C126754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2'-F-ara-deoxyuridine","n_c":["C80036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3'-C-ethynylcytidine","n_c":["C29475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4-Nitroestrone 3-Methyl Ether","n_c":["C977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4-Thio-2-deoxycytidine","n_c":["C121828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4'-Iodo-4'-Deoxydoxorubicin","n_c":["C971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5-Aza-4'-thio-2'-deoxycytidine","n_c":["C153479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5-Fluoro-2-Deoxycytidine","n_c":["C62785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158","n_c":["C113787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7-Cyanoquinocarcinol","n_c":["C1611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7-Ethyl-10-Hydroxycamptothecin","n_c":["C61618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7-Hydroxystaurosporine","n_c":["C1271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8-Azaguanine","n_c":["C28788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"9-Ethyl 6-Mercaptopurine","n_c":["C28789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"9H-Purine-6Thio-98D","n_c":["C28793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abagovomab","n_c":["C26449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abarelix","n_c":["C2015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abemaciclib","n_c":["C97660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abemaciclib Mesylate","n_c":["C162507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abexinostat","n_c":["C68920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abexinostat Tosylate","n_c":["C160889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abiraterone","n_c":["C77333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abiraterone Acetate","n_c":["C68845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abituzumab","n_c":["C82422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acai Berry Juice","n_c":["C99901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acalabrutinib","n_c":["C113442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acalisib","n_c":["C103277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aceglatone","n_c":["C984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetylcysteine","n_c":["C200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acitretin","n_c":["C985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acivicin","n_c":["C986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aclacinomycin B","n_c":["C1861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aclarubicin","n_c":["C202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acodazole","n_c":["C988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acodazole Hydrochloride","n_c":["C71627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acolbifene Hydrochloride","n_c":["C65213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acridine","n_c":["C203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acridine Carboxamide","n_c":["C2203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acronine","n_c":["C75297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinium Ac 225 Lintuzumab","n_c":["C82414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinium Ac 225-FPI-1434","n_c":["C158815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","n_c":["C153159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinomycin C2","n_c":["C95198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinomycin C3","n_c":["C99564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Actinomycin F1","n_c":["C2844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Activin Type 2B Receptor Fc Fusion Protein STM 434","n_c":["C118625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968","n_c":["C151941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ad-RTS-hIL-12","n_c":["C143953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adagloxad Simolenin","n_c":["C99766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adavosertib","n_c":["C91725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adecatumumab","n_c":["C82358"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist AZD4635","n_c":["C148039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist NIR178","n_c":["C142374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999","n_c":["C157489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A/A2B Receptor Antagonist AB928","n_c":["C159564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2B Receptor Antagonist PBF-1129","n_c":["C148435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","n_c":["C106242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Brachyury Vaccine ETBX-051","n_c":["C143034"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Cancer Vaccine PF-06936308","n_c":["C156015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral MUC1 Vaccine ETBX-061","n_c":["C143035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral PSA Vaccine ETBX-071","n_c":["C148142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001","n_c":["C101789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","n_c":["C162805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901","n_c":["C156925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3","n_c":["C131825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001","n_c":["C97959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aderbasib","n_c":["C76115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ADH-1","n_c":["C53399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AE37 Peptide/GM-CSF Vaccine","n_c":["C91719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AEE788","n_c":["C48369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aerosol Gemcitabine","n_c":["C153133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aerosolized Aldesleukin","n_c":["C101794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aerosolized Liposomal Rubitecan","n_c":["C61071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afatinib","n_c":["C66940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afatinib Dimaleate","n_c":["C97273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afimoxifene","n_c":["C975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Afuresertib","n_c":["C82390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agatolimod Sodium","n_c":["C28580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agerafenib","n_c":["C107245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aglatimagene Besadenovec","n_c":["C73996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agonistic Anti-CD40 Monoclonal Antibody ADC-1013","n_c":["C121538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949","n_c":["C129967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469","n_c":["C117293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKR1C3-activated Prodrug OBI-3424","n_c":["C156414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT 1/2 Inhibitor BAY1125976","n_c":["C111575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AKT Inhibitor ARQ 092","n_c":["C99172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt Inhibitor LY2780301","n_c":["C95737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt Inhibitor MK2206","n_c":["C90581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt Inhibitor SR13668","n_c":["C85448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Akt/ERK Inhibitor ONC201","n_c":["C113792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alacizumab Pegol","n_c":["C61438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alanosine","n_c":["C994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albumin-binding Cisplatin Prodrug BTP-114","n_c":["C131607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aldesleukin","n_c":["C1498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aldoxorubicin","n_c":["C68921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alectinib","n_c":["C101790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alefacept","n_c":["C65220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alemtuzumab","n_c":["C1681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alestramustine","n_c":["C77370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alflutinib Mesylate","n_c":["C133719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Algenpantucel-L","n_c":["C61082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alisertib","n_c":["C71717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alitretinoin","n_c":["C1574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor","n_c":["C141136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor ASP3026","n_c":["C116727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor PLB 1003","n_c":["C148533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor RO5424802","n_c":["C101790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor WX-0593","n_c":["C154279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK-2 Inhibitor TP-0184","n_c":["C156729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK-FAK Inhibitor CEP-37440","n_c":["C111685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/c-Met Inhibitor TQ-B3139","n_c":["C148513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/FAK/Pyk2 Inhibitor CT-707","n_c":["C126648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/TRK Inhibitor TSR-011","n_c":["C114287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alkotinib","n_c":["C165556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allodepleted T Cell Immunotherapeutic ATIR101","n_c":["C123911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD19-CAR T-cells PBCAR0191","n_c":["C158558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100","n_c":["C137863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Cellular Vaccine 1650-G","n_c":["C119759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","n_c":["C146711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine","n_c":["C2525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine","n_c":["C98282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo","n_c":["C101892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo","n_c":["C101891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2","n_c":["C90577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470","n_c":["C103862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307","n_c":["C78862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Melanoma Vaccine AGI-101H","n_c":["C78861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Natural Killer Cell Line MG4101","n_c":["C94209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Natural Killer Cell Line NK-92","n_c":["C117231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601","n_c":["C95213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allovectin-7","n_c":["C1649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Almurtide","n_c":["C81667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpelisib","n_c":["C94214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha Galactosylceramide","n_c":["C1720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha V Beta 1 Inhibitor ATN-161","n_c":["C52185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801","n_c":["C120550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-Gal AGI-134","n_c":["C165548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H","n_c":["C159497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-Thioguanine Deoxyriboside","n_c":["C28795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-tocopheryloxyacetic Acid","n_c":["C117234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altiratinib","n_c":["C118290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altretamine","n_c":["C544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvespimycin","n_c":["C38142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvespimycin Hydrochloride","n_c":["C76665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvocidib","n_c":["C74940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvocidib Hydrochloride","n_c":["C1571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alvocidib Prodrug TP-1287","n_c":["C165555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amatuximab","n_c":["C62483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ambamustine","n_c":["C73320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ambazone","n_c":["C72627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amblyomin-X","n_c":["C148521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amcasertib","n_c":["C104745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ametantrone","n_c":["C1342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amifostine","n_c":["C488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amino Acid Injection","n_c":["C15509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminocamptothecin","n_c":["C1488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminocamptothecin Colloidal Dispersion","n_c":["C2452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminoflavone Prodrug AFP464","n_c":["C48370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminopterin","n_c":["C235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aminopterin Sodium","n_c":["C74554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amolimogene Bepiplasmid","n_c":["C90592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amonafide L-Malate","n_c":["C61306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amrubicin","n_c":["C80089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amrubicin Hydrochloride","n_c":["C47948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amsacrine","n_c":["C240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amsacrine Lactate","n_c":["C96771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amsilarotene","n_c":["C38684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amustaline","n_c":["C75926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amustaline Dihydrochloride","n_c":["C75035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amuvatinib","n_c":["C71750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amuvatinib Hydrochloride","n_c":["C95776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anakinra","n_c":["C38717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anastrozole","n_c":["C1607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anaxirone","n_c":["C950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ancitabine","n_c":["C80636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ancitabine Hydrochloride","n_c":["C403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Antagonist APC-100","n_c":["C98290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist BAY 1161116","n_c":["C148520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist SHR3680","n_c":["C175852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist TAS3681","n_c":["C137818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antagonist TRC253","n_c":["C131874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antisense Oligonucleotide AZD5312","n_c":["C116326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Antisense Oligonucleotide EZN-4176","n_c":["C96742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Degrader ARV-110","n_c":["C160788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Downregulator AZD3514","n_c":["C116726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118","n_c":["C121777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andrographolide","n_c":["C61637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androstane Steroid HE3235","n_c":["C78831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anetumab Ravtansine","n_c":["C98293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241","n_c":["C88301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiogenesis Inhibitor GT-111","n_c":["C71539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiogenesis Inhibitor JI-101","n_c":["C82413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiogenesis/Heparanase Inhibitor PG545","n_c":["C95202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angiopoietin-2-specific Fusion Protein PF-04856884","n_c":["C116625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anhydrovinblastine","n_c":["C2526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aniline Mustard","n_c":["C249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anlotinib Hydrochloride","n_c":["C106428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Annamycin","n_c":["C2632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Annamycin Liposomal","n_c":["C25838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Annonaceous Acetogenins","n_c":["C118972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ansamitomicin P-3","n_c":["C97710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anthramycin","n_c":["C252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anthrapyrazole","n_c":["C2706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti c-KIT Antibody-drug Conjugate LOP628","n_c":["C117735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-5T4 Antibody-Drug Conjugate PF-06263507","n_c":["C107388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-A33 Monoclonal Antibody KRN330","n_c":["C90583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412","n_c":["C85478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087","n_c":["C129715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AG7 Antibody Drug Conjugate AbGn-107","n_c":["C133818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AGS-16 Monoclonal Antibody AGS-16M18","n_c":["C82685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME","n_c":["C92590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AGS-8 Monoclonal Antibody AGS-8M4","n_c":["C82686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B","n_c":["C164668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-alpha5beta1 Integrin Antibody MINT1526A","n_c":["C116865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ANG2 Monoclonal Antibody MEDI-3617","n_c":["C95704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-angiopoietin Monoclonal Antibody AMG 780","n_c":["C116627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-APRIL Monoclonal Antibody BION-1301","n_c":["C142822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AXL Fusion Protein AVB-S6-500","n_c":["C156017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-AXL/PBD Antibody-drug Conjugate ADCT-601","n_c":["C160890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7-H3 Antibody DS-5573a","n_c":["C122924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7-H4 Monoclonal Antibody FPA150","n_c":["C155967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7H3 Antibody-drug Conjugate MGC018","n_c":["C159495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody SEA-BCMA","n_c":["C148176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody-drug Conjugate AMG 224","n_c":["C162528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody-drug Conjugate GSK2857916","n_c":["C114299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/CD3 BiTE Antibody AMG 420","n_c":["C159652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/CD3 BiTE Antibody AMG 701","n_c":["C147028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/CD3 BiTE Antibody REGN5458","n_c":["C158504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/PBD ADC MEDI2228","n_c":["C150127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-fms Monoclonal Antibody AMG 820","n_c":["C98295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-KIT Monoclonal Antibody CDX 0158","n_c":["C125620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Antibody-drug Conjugate HTI-1066","n_c":["C146667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Antibody-drug Conjugate TR1801","n_c":["C158513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Monoclonal Antibody ABT-700","n_c":["C106262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Monoclonal Antibody ARGX-111","n_c":["C113802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-MET Monoclonal Antibody LY2875358","n_c":["C95732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-C-met Monoclonal Antibody SAIT301","n_c":["C119619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-C4.4a Antibody-Drug Conjugate BAY1129980","n_c":["C116070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-C5aR Monoclonal Antibody IPH5401","n_c":["C163020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CA19-9 Monoclonal Antibody 5B1","n_c":["C125900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CA6-DM4 Immunoconjugate SAR566658","n_c":["C95764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1","n_c":["C121231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 ADC IMGN632","n_c":["C184834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 Monoclonal Antibody CSL360","n_c":["C91093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 Monoclonal Antibody KHK2823","n_c":["C123380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404","n_c":["C127120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A","n_c":["C129457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123/CD3 Bispecific Antibody APVO436","n_c":["C157257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178","n_c":["C128486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD123/CD3 BiTE Antibody SAR440234","n_c":["C160348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody ADG106","n_c":["C160715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471","n_c":["C162039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD157 Monoclonal Antibody MEN1112","n_c":["C120317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD166 Probody-drug Conjugate CX-2009","n_c":["C134697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B","n_c":["C126377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody DI-B4","n_c":["C105805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody MDX-1342","n_c":["C74003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody MEDI-551","n_c":["C88283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Monoclonal Antibody XmAb5574","n_c":["C95768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19-DM4 Immunoconjugate SAR3419","n_c":["C71009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL","n_c":["C82375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/CD3 BiTE Antibody AMG 562","n_c":["C153215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/CD3 Tetravalent Antibody AFM11","n_c":["C115101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody B001","n_c":["C155899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody PRO131921","n_c":["C90590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody SCT400","n_c":["C122680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody TL011","n_c":["C94206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002","n_c":["C123915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20-engineered Toxin Body MT-3724","n_c":["C120546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323","n_c":["C165166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20/CD3 Monoclonal Antibody REGN1979","n_c":["C119615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20/CD3 Monoclonal Antibody XmAb13676","n_c":["C130050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD22 ADC TRPH-222","n_c":["C156882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S","n_c":["C104167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD25-PBD Antibody-drug Conjugate ADCT-301","n_c":["C121949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD26 Monoclonal Antibody YS110","n_c":["C150677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD27L Antibody-Drug Conjugate AMG 172","n_c":["C106266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)","n_c":["C74004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957","n_c":["C136823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135","n_c":["C146860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05","n_c":["C95760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564","n_c":["C171840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/CD20 Bispecific Antibody GEN3013","n_c":["C163022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424","n_c":["C153147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30 Monoclonal Antibody MDX-1401","n_c":["C77886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30 Monoclonal Antibody XmAb2513","n_c":["C74005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30/CD16A Monoclonal Antibody AFM13","n_c":["C94219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD32B Monoclonal Antibody BI-1206","n_c":["C156458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Antibody-drug Conjugate IMGN779","n_c":["C125717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564","n_c":["C135632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Monoclonal Antibody BI 836858","n_c":["C116737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633","n_c":["C71523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 Bispecific Antibody GEM 333","n_c":["C155970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244","n_c":["C162296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 BiTE Antibody AMG 330","n_c":["C123332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD33/CD3 BiTE Antibody AMG 673","n_c":["C175778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A","n_c":["C131174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 Antibody-Drug Conjugate IMGN529","n_c":["C100101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E","n_c":["C119700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 Monoclonal Antibody BI 836826","n_c":["C122833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Monoclonal Antibody MOR03087","n_c":["C97954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Monoclonal Antibody TAK-079","n_c":["C148078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38-targeted IgG4-attenuated IFNa TAK-573","n_c":["C140427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342","n_c":["C147563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD39 Monoclonal Antibody TTX-030","n_c":["C162693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Agonist Monoclonal Antibody ABBV-927","n_c":["C139553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","n_c":["C150558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4","n_c":["C101366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40 Monoclonal Antibody SEA-CD40","n_c":["C121217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428","n_c":["C132681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40L Fc-Fusion Protein BMS-986004","n_c":["C120140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD44 Monoclonal Antibody RO5429083","n_c":["C116881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD45 Monoclonal Antibody AHN-12","n_c":["C74009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD46 Antibody-drug Conjugate FOR46","n_c":["C156416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody AO-176","n_c":["C159600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody CC-90002","n_c":["C121211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody Hu5F9-G4","n_c":["C117730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody IBI188","n_c":["C157385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody SHR-1603","n_c":["C160202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody SRF231","n_c":["C155976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody TJC4","n_c":["C163977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A","n_c":["C148103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD52 Monoclonal Antibody ALLO-647","n_c":["C160787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 Antibody-Drug Conjugate MDX-1203","n_c":["C84855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A","n_c":["C117732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 CAR-expressing T Lymphocytes","n_c":["C162699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD70 Monoclonal Antibody MDX-1411","n_c":["C78187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029","n_c":["C153287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody BMS-986179","n_c":["C132266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody CPI-006","n_c":["C156061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody NZV930","n_c":["C158132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD73 Monoclonal Antibody TJ4309","n_c":["C159168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD74 Antibody-drug Conjugate STRO-001","n_c":["C148066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD98 Monoclonal Antibody IGN523","n_c":["C113659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CDH6 Antibody-drug Conjugate HKT288","n_c":["C131439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEA BiTE Monoclonal Antibody AMG211","n_c":["C95728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody","n_c":["C68927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2","n_c":["C82355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM1 Monoclonal Antibody CM-24","n_c":["C120305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM5 Antibody-Drug Conjugate SAR408701","n_c":["C117229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47","n_c":["C120068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CEACAM6 Antibody BAY1834942","n_c":["C171841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CLDN6 Monoclonal Antibody ASP1650","n_c":["C114286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CLEC12A/CD3 Bispecific Antibody MCLA117","n_c":["C148141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CLEVER-1 Monoclonal Antibody FP-1305","n_c":["C159536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CSF1 Monoclonal Antibody PD-0360324","n_c":["C131301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CSF1R Monoclonal Antibody IMC-CS4","n_c":["C96801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CSF1R Monoclonal Antibody SNDX-6352","n_c":["C155813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTGF Monoclonal Antibody FG-3019","n_c":["C92577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody ADU-1604","n_c":["C162505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody AGEN1181","n_c":["C158557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody BCD-145","n_c":["C156734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody MK-1308","n_c":["C150679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody REGN4659","n_c":["C159764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841","n_c":["C159530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","n_c":["C157494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA4 Monoclonal Antibody BMS-986218","n_c":["C135633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CXCR4 Monoclonal Antibody PF-06747143","n_c":["C131572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Denatured Collagen Monoclonal Antibody TRC093","n_c":["C71749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DKK-1 Monoclonal Antibody LY2812176","n_c":["C99123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DKK1 Monoclonal Antibody BHQ880","n_c":["C80040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DLL3/CD3 BiTE Antibody AMG 757","n_c":["C147027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DLL4 Monoclonal Antibody MEDI0639","n_c":["C101521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83","n_c":["C119620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DR5 Agonist Monoclonal Antibody TRA-8","n_c":["C78826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DR5 Agonistic Antibody DS-8273a","n_c":["C121158"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-DR5 Agonistic Monoclonal Antibody INBRX-109","n_c":["C157062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody CPGJ 602","n_c":["C155876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody EMD 55900","n_c":["C2714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody GC1118","n_c":["C120316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX","n_c":["C94221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody HLX-07","n_c":["C163981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody Mixture MM-151","n_c":["C99899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody RO5083945","n_c":["C78838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody SCT200","n_c":["C117726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR Monoclonal Antibody SYN004","n_c":["C121550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR TAP Antibody-drug Conjugate IMGN289","n_c":["C111906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/c-Met Bispecific Antibody EMB-01","n_c":["C158085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372","n_c":["C124993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100","n_c":["C148507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013","n_c":["C131175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321","n_c":["C150590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595","n_c":["C99222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFRvIII Immunotoxin MR1-1","n_c":["C88307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFRvIII/CD3 BiTE Antibody AMG 596","n_c":["C146824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGP-2 Immunotoxin MOC31-PE","n_c":["C90551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F","n_c":["C102980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F","n_c":["C116626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ep-CAM Monoclonal Antibody ING-1","n_c":["C133022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310","n_c":["C136981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EphA2 Monoclonal Antibody DS-8895a","n_c":["C118447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","n_c":["C79836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111","n_c":["C85486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Antibody ISU104","n_c":["C158746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Monoclonal Antibody AV-203","n_c":["C102535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Monoclonal Antibody CDX-3379","n_c":["C113333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3 Monoclonal Antibody REGN1400","n_c":["C103859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141","n_c":["C103863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A","n_c":["C116742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FAP/Interleukin-2 Fusion Protein RO6874281","n_c":["C129383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FCRH5/CD3 BiTE Antibody BFCR4350A","n_c":["C139549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FGFR2 Antibody BAY1179470","n_c":["C107683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FGFR3 Antibody-drug Conjugate LY3076226","n_c":["C123829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FGFR4 Monoclonal Antibody U3-1784","n_c":["C126334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3 Antibody-drug Conjugate AGS62P1","n_c":["C129937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM","n_c":["C129376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3 Monoclonal Antibody IMC-EB10","n_c":["C85453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FLT3/CD3 BiTE Antibody AMG 427","n_c":["C156399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002","n_c":["C158067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012","n_c":["C118443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962","n_c":["C79795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GCC Antibody-Drug Conjugate MLN0264","n_c":["C101524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GCC Antibody-Drug Conjugate TAK-164","n_c":["C156707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody","n_c":["C158436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD2 Monoclonal Antibody hu14.18K322A","n_c":["C80042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD2 Monoclonal Antibody MORAb-028","n_c":["C91383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GD3 Antibody-drug Conjugate PF-06688992","n_c":["C136426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Agonistic Monoclonal Antibody ASP1951","n_c":["C159411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156","n_c":["C132267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Agonistic Monoclonal Antibody INCAGN01876","n_c":["C126643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Monoclonal Antibody GWN 323","n_c":["C128028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GITR Monoclonal Antibody MK-4166","n_c":["C116065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Globo H Monoclonal Antibody OBI-888","n_c":["C153261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974","n_c":["C129936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GnRH Vaccine PEP223","n_c":["C85464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-gpA33/CD3 Monoclonal Antibody MGD007","n_c":["C118442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GRP78 Monoclonal Antibody PAT-SM6","n_c":["C103857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HA Epitope Monoclonal Antibody MEDI8852","n_c":["C131295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HB-EGF Monoclonal Antibody KHK2866","n_c":["C95721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HBEGF Monoclonal Antibody U3-1565","n_c":["C95736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-hepcidin Monoclonal Antibody LY2787106","n_c":["C116630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER-2 Bispecific Antibody KN026","n_c":["C162577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 ADC DS-8201a","n_c":["C128799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate A166","n_c":["C156480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate ARX788","n_c":["C123917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate MEDI4276","n_c":["C126355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate RC48","n_c":["C130011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Bi-specific Monoclonal Antibody ZW25","n_c":["C130010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49","n_c":["C162115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395","n_c":["C160349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody CT-P6","n_c":["C1647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343","n_c":["C142890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2-vc0101 ADC PF-06804103","n_c":["C141420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A","n_c":["C156705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","n_c":["C142889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128","n_c":["C152948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522","n_c":["C132112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A","n_c":["C155940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER3 Antibody-drug Conjugate U3 1402","n_c":["C136987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER3 Monoclonal Antibody GSK2849330","n_c":["C111997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HGF Monoclonal Antibody TAK-701","n_c":["C81939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","n_c":["C68930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1","n_c":["C165547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HLA-DR Monoclonal Antibody IMMU-114","n_c":["C103860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-human GITR Monoclonal Antibody AMG 228","n_c":["C129694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-human GITR Monoclonal Antibody TRX518","n_c":["C95023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICAM-1 Monoclonal Antibody BI-505","n_c":["C88327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Agonist Antibody GSK3359609","n_c":["C126804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226","n_c":["C146762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Monoclonal Antibody KY1044","n_c":["C162521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ICOS Monoclonal Antibody MEDI-570","n_c":["C123267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IGF-1R Monoclonal Antibody AVE1642","n_c":["C79798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022","n_c":["C71530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-1 alpha Monoclonal Antibody MABp1","n_c":["C95708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-13 Humanized Monoclonal Antibody TNX-650","n_c":["C87767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-15 Monoclonal Antibody AMG 714","n_c":["C126841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-8 Monoclonal Antibody HuMax-IL8","n_c":["C124227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ILDR2 Monoclonal Antibody BAY 1905254","n_c":["C156490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ILT4 Monoclonal Antibody MK-4830","n_c":["C160204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388","n_c":["C78839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-KIR Monoclonal Antibody IPH 2101","n_c":["C78464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02","n_c":["C82391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody INCAGN02385","n_c":["C157127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody LAG525","n_c":["C122683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody REGN3767","n_c":["C132339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118","n_c":["C150734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG3 Monoclonal Antibody BI 754111","n_c":["C150403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG3 Monoclonal Antibody MK-4280","n_c":["C142077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG3 Monoclonal Antibody TSR-033","n_c":["C142978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAMP1 Antibody-drug Conjugate SAR428926","n_c":["C126275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LGR5 Monoclonal Antibody BNC101","n_c":["C126794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LIF Monoclonal Antibody MSC-1","n_c":["C156176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A","n_c":["C112001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ly6E Antibody-Drug Conjugate RG 7841","n_c":["C116745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C","n_c":["C162462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Melanin Monoclonal Antibody PTI-6D2","n_c":["C91092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin Antibody-drug Conjugate BMS-986148","n_c":["C120303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100","n_c":["C121653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A","n_c":["C116746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Met Monoclonal Antibody Mixture Sym015","n_c":["C127906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Met/EGFR Monoclonal Antibody LY3164530","n_c":["C118281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MMP-9 Monoclonal Antibody GS-5745","n_c":["C105803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC1 Monoclonal Antibody BTH1704","n_c":["C118362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC16/CD3 BiTE Antibody REGN4018","n_c":["C153129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A","n_c":["C147031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","n_c":["C78840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-myostatin Monoclonal Antibody LY2495655","n_c":["C99640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NaPi2b Monoclonal Antibody XMT-1535","n_c":["C147578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E","n_c":["C114500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A","n_c":["C91728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-nf-P2X7 Antibody Ointment BIL-010t","n_c":["C124647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Nucleolin Aptamer AS1411","n_c":["C91721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A","n_c":["C116847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso","n_c":["C153130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OFA Immunotherapeutic BB-MPI-03","n_c":["C118368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Agonist Monoclonal Antibody ABBV-368","n_c":["C161864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Agonist Monoclonal Antibody PF-04518600","n_c":["C121927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Antibody BMS 986178","n_c":["C128026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Monoclonal Antibody GSK3174998","n_c":["C124783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Monoclonal Antibody IBI101","n_c":["C158507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Checkpoint Inhibitor PF-06801591","n_c":["C124058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Fusion Protein AMP-224","n_c":["C97039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody AK105","n_c":["C155879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody AMG 404","n_c":["C161597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody BAT1306","n_c":["C162871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody BCD-100","n_c":["C148155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody BI 754091","n_c":["C132252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody CS1003","n_c":["C156726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody F520","n_c":["C162636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody GLS-010","n_c":["C159549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody HLX10","n_c":["C156738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody HX008","n_c":["C160717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody JTX-4014","n_c":["C157485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody LZM009","n_c":["C153149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody MEDI0680","n_c":["C113332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody MGA012","n_c":["C142168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody Sym021","n_c":["C142865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody TSR-042","n_c":["C126799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-CTLA4 DART Protein MGD019","n_c":["C158505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-LAG-3 DART Protein MGD013","n_c":["C143957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172","n_c":["C160605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/CTLA-4 Bispecific Antibody AK104","n_c":["C153379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/TIM-3 Bispecific Antibody RO7121661","n_c":["C160714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody A167","n_c":["C163992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody BCD-135","n_c":["C156741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody BGB-A333","n_c":["C155654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody CBT-502","n_c":["C156692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody CK-301","n_c":["C151947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody CS1001","n_c":["C154550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody FAZ053","n_c":["C131537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody GR1405","n_c":["C159538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody HLX20","n_c":["C165270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody LY3300054","n_c":["C128138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody MDX-1105","n_c":["C78852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody MSB2311","n_c":["C155931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody SHR-1316","n_c":["C148535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody TG-1501","n_c":["C151947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody ZKAB001","n_c":["C162504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105","n_c":["C159978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","n_c":["C160772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","n_c":["C157058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD1 Monoclonal Antibody AGEN2034","n_c":["C136465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD1/CTLA4 Bispecific Antibody XmAb20717","n_c":["C150463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PGF Monoclonal Antibody RO5323441","n_c":["C78486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PKN3 siRNA Atu027","n_c":["C84847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PLGF Monoclonal Antibody TB-403","n_c":["C78486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4","n_c":["C123924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PRAME Immunotherapeutic GSK2302032A","n_c":["C116848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab","n_c":["C151931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-prolactin Receptor Antibody LFA102","n_c":["C96744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSCA Monoclonal Antibody AGS-1C4D4","n_c":["C71157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA Monoclonal Antibody MDX1201-A488","n_c":["C113439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704","n_c":["C26660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate","n_c":["C95707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD28 Bispecific Antibody REGN5678","n_c":["C162936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081","n_c":["C163976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414","n_c":["C118626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/PBD ADC MEDI3726","n_c":["C140552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020","n_c":["C123828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PVRIG Monoclonal Antibody COM701","n_c":["C156791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ROR1 ADC VLS-101","n_c":["C157772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-S15 Monoclonal Antibody NC318","n_c":["C157061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-sCLU Monoclonal Antibody AB-16B5","n_c":["C121778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-SIRPa Monoclonal Antibody CC-95251","n_c":["C157501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E","n_c":["C152370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218","n_c":["C28880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TF Monoclonal Antibody ALT-836","n_c":["C96430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TGF-beta Monoclonal Antibody NIS793","n_c":["C132250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TGF-beta Monoclonal Antibody SAR-439459","n_c":["C146862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1","n_c":["C102853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody AB154","n_c":["C162875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody BMS-986207","n_c":["C131907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody OMP-313M32","n_c":["C142821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Antibody BMS-986258","n_c":["C148042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody BGB-A425","n_c":["C157242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody INCAGN02390","n_c":["C162625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody MBG453","n_c":["C124850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody Sym023","n_c":["C150560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM-3 Monoclonal Antibody TSR-022","n_c":["C128627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM3 Monoclonal Antibody LY3321367","n_c":["C137820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Tissue Factor Monoclonal Antibody MORAb-066","n_c":["C104291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a","n_c":["C151967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TWEAK Monoclonal Antibody RG7212","n_c":["C97337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF Anticalin PRS-050-PEG40","n_c":["C91376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF Monoclonal Antibody hPV19","n_c":["C156139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF/ANG2 Nanobody BI 836880","n_c":["C126644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T","n_c":["C162872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFC Monoclonal Antibody VGX-100","n_c":["C99765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFR2 Monoclonal Antibody HLX06","n_c":["C156172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5","n_c":["C95734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VISTA Monoclonal Antibody JNJ 61610588","n_c":["C127124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antiangiogenic Drug Combination TL-118","n_c":["C99761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-011","n_c":["C161599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-085","n_c":["C124134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-155","n_c":["C157279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-176","n_c":["C137991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ABBV-838","n_c":["C122816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate ADC XMT-1536","n_c":["C147577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014","n_c":["C129401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-Drug Conjugate DFRF4539A","n_c":["C106256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate MEDI7247","n_c":["C137821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate PF-06647263","n_c":["C118572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate PF-06664178","n_c":["C118570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-002","n_c":["C123284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-003","n_c":["C124133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-004","n_c":["C136807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-005","n_c":["C154558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-006","n_c":["C136779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-drug Conjugate SC-007","n_c":["C147029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008","n_c":["C90562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV","n_c":["C165256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antimetabolite FF-10502","n_c":["C125690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplastic Agent Combination SM-88","n_c":["C124051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplastic Vaccine","n_c":["C1663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplastic Vaccine GV-1301","n_c":["C2100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplaston A10","n_c":["C1004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antineoplaston AS2-1","n_c":["C1613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antisense Oligonucleotide GTI-2040","n_c":["C26652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antitumor B Key Active Component-alpha","n_c":["C156694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrodia cinnamomea Supplement","n_c":["C95731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antroquinonol Capsule","n_c":["C119701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apalutamide","n_c":["C92574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apatorsen","n_c":["C71740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apaziquone","n_c":["C1087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APC8015F","n_c":["C48640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"APE1/Ref-1 Redox Inhibitor APX3330","n_c":["C150216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aphidicoline Glycinate","n_c":["C28802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apilimod Dimesylate Capsule","n_c":["C126661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apitolisib","n_c":["C91731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apolizumab","n_c":["C2228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apomab","n_c":["C71693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apomine","n_c":["C1873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apoptosis Inducer BZL101","n_c":["C69134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apoptosis Inducer GCS-100","n_c":["C70984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apoptosis Inducer MPC-2130","n_c":["C64781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Apricoxib","n_c":["C74021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aprutumab Ixadotin","n_c":["C121212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AR Antagonist BMS-641988","n_c":["C62522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arabinoxylan Compound MGN3","n_c":["C1879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aranose","n_c":["C162540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ARC Fusion Protein SL-279252","n_c":["C161803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Archexin","n_c":["C88335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arcitumomab","n_c":["C1494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arfolitixorin","n_c":["C157079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arginase Inhibitor INCB001158","n_c":["C142866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arginine Butyrate","n_c":["C2570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arnebia Indigo Jade Pearl Topical Cream","n_c":["C74013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arsenic Trioxide","n_c":["C1005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arsenic Trioxide Capsule Formulation ORH 2014","n_c":["C133720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artemether Sublingual Spray","n_c":["C118504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artemisinin Dimer","n_c":["C60769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artesunate","n_c":["C73005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arugula Seed Powder","n_c":["C131020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aryl Hydrocarbon Receptor Antagonist BAY2416964","n_c":["C164317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asaley","n_c":["C1346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asciminib","n_c":["C114494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascrinvacumab","n_c":["C91073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ashwagandha Root Powder Extract","n_c":["C77883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ASP4132","n_c":["C122720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asparaginase","n_c":["C286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asparaginase Erwinia chrysanthemi","n_c":["C64260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10","n_c":["C165280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","n_c":["C133190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Astuprotimut-R","n_c":["C78478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asulacrine","n_c":["C91758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asulacrine Isethionate","n_c":["C1050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"At 211 Monoclonal Antibody 81C6","n_c":["C2490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atamestane","n_c":["C1224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atezolizumab","n_c":["C106250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atiprimod","n_c":["C52184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atiprimod Dihydrochloride","n_c":["C76969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atiprimod Dimaleate","n_c":["C76970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM Inhibitor M 3541","n_c":["C138076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM Kinase Inhibitor AZD0156","n_c":["C124648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATM Kinase Inhibitor AZD1390","n_c":["C150167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atorvastatin Calcium","n_c":["C28837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atorvastatin Sodium","n_c":["C78676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor BAY1895344","n_c":["C146807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor M6620","n_c":["C116355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor VX-803","n_c":["C129693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrasentan Hydrochloride","n_c":["C1779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Attenuated Listeria monocytogenes CRS-100","n_c":["C62409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001","n_c":["C74595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auranofin","n_c":["C65242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor LY3295668","n_c":["C148501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor LY3295668 Erbumine","n_c":["C165238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor MK5108","n_c":["C90585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase Inhibitor TAS-119","n_c":["C116068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076","n_c":["C78190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901","n_c":["C82674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora B/C Kinase Inhibitor GSK1070916A","n_c":["C91081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora kinase A/B inhibitor TT-00420","n_c":["C162532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor AMG 900","n_c":["C82349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor BI 811283","n_c":["C74014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor MLN8054","n_c":["C61075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor PF-03814735","n_c":["C66946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor SNS-314","n_c":["C70655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase Inhibitor TTP607","n_c":["C84846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aurora Kinase/VEGFR2 Inhibitor CYC116","n_c":["C70983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707","n_c":["C139730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585","n_c":["C155883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101","n_c":["C142864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125","n_c":["C147523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217","n_c":["C140310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053","n_c":["C165507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143","n_c":["C142807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR T-cells IM19","n_c":["C155888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19","n_c":["C156271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002","n_c":["C162856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01","n_c":["C153118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901","n_c":["C158604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19","n_c":["C142887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1","n_c":["C148030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3","n_c":["C162620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014","n_c":["C126639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s","n_c":["C156251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202","n_c":["C162260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1","n_c":["C155884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794","n_c":["C121379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous AXL-targeted CAR T-cells CCT301-38","n_c":["C154276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B","n_c":["C156153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M","n_c":["C162506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528","n_c":["C148498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001","n_c":["C103865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005","n_c":["C158533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006","n_c":["C160847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123","n_c":["C148526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19-targeted CAR T Cells JWCAR029","n_c":["C155878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20","n_c":["C148525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22","n_c":["C148524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38","n_c":["C148523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Deep IL-15 Primed T-cells TRQ15-01","n_c":["C158091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Dendritic Cell Vaccine ACT2001","n_c":["C121856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Dendritic Cell-based Immunotherapeutic AV0113","n_c":["C123928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa","n_c":["C150698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells","n_c":["C162804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Genetically-modified MAGE-A4 C1032 T Cells","n_c":["C175738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858","n_c":["C37448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439","n_c":["C159977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001","n_c":["C162627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718","n_c":["C135534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","n_c":["C156382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Mesenchymal Stem Cells Apceth_101","n_c":["C113803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","n_c":["C155775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01","n_c":["C121536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101","n_c":["C82361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601","n_c":["C128031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous ROR2-targeted CAR T-cells CCT301-59","n_c":["C154277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1","n_c":["C154285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCR-engineered T-cells IMA201","n_c":["C146779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCR-engineered T-cells IMA202","n_c":["C153218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCR-engineered T-cells IMA203","n_c":["C161831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes LN-144","n_c":["C120552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes LN-145","n_c":["C135634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL","n_c":["C153312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avadomide","n_c":["C160786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avadomide Hydrochloride","n_c":["C97956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avapritinib","n_c":["C123827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avelumab","n_c":["C116870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avitinib Maleate","n_c":["C118671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axicabtagene Ciloleucel","n_c":["C120309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axitinib","n_c":["C38718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL Inhibitor DS-1205c","n_c":["C152976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M","n_c":["C132025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axl/Mer Inhibitor INCB081776","n_c":["C153122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azacitidine","n_c":["C288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azapicyl","n_c":["C1007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azaribine","n_c":["C1008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azaserine","n_c":["C289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azathioprine","n_c":["C290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azimexon","n_c":["C1347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aziridinylbenzoquinone RH1","n_c":["C29404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azotomycin","n_c":["C28803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azurin:50-77 Cell Penetrating Peptide p28","n_c":["C85480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"B-Raf/VEGFR-2 Inhibitor RAF265","n_c":["C61311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Babaodan Capsule","n_c":["C155974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen","n_c":["C77694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bactobolin","n_c":["C28850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bafetinib","n_c":["C62516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Balixafortide","n_c":["C91094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Baltaleucel-T","n_c":["C129374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Banoxantrone","n_c":["C79528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barasertib","n_c":["C62502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bardoxolone","n_c":["C48382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bardoxolone Methyl","n_c":["C98250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Baricitinib","n_c":["C127012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Batabulin","n_c":["C72716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Batabulin Sodium","n_c":["C1835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Batimastat","n_c":["C1529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bavituximab","n_c":["C49088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bazedoxifene","n_c":["C73598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BC-819 Plasmid/Polyethylenimine Complex","n_c":["C107685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCG Solution","n_c":["C83496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCG Tokyo-172 Strain Solution","n_c":["C126694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCG Vaccine","n_c":["C298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor APG 2575","n_c":["C156249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor BCL201","n_c":["C125603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor S65487","n_c":["C158510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-Xs Adenovirus Vaccine","n_c":["C28860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCMA x CD3 T-cell Engaging Antibody CC-93269","n_c":["C175740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcr-Abl Kinase Inhibitor K0706","n_c":["C174748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcr-Abl Kinase Inhibitor PF-114","n_c":["C130033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351","n_c":["C165549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beauvericin","n_c":["C1011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Becatecarin","n_c":["C1620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belagenpumatucel-L","n_c":["C73438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belimumab","n_c":["C91385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belinostat","n_c":["C48812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belotecan Hydrochloride","n_c":["C66954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bemarituzumab","n_c":["C120040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bemcentinib","n_c":["C121854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bempegaldesleukin","n_c":["C131019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benaxibine","n_c":["C73231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bendamustine","n_c":["C73261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bendamustine Hydrochloride","n_c":["C61565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107","n_c":["C124053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benzaldehyde Dimethane Sulfonate","n_c":["C107164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benzoylphenylurea","n_c":["C2618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Berberine Chloride","n_c":["C87331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bermekimab","n_c":["C95708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Berubicin Hydrochloride","n_c":["C61568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Bromodomain Inhibitor ZEN-3694","n_c":["C126805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor ABBV-744","n_c":["C148415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor BAY1238097","n_c":["C121213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET inhibitor BI 894999","n_c":["C160257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor BMS-986158","n_c":["C121849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor CC-90010","n_c":["C151951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor CPI-0610","n_c":["C111901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor FT-1101","n_c":["C123733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor GS-5829","n_c":["C126640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor GSK2820151","n_c":["C125391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor INCB054329","n_c":["C121948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor INCB057643","n_c":["C128622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET Inhibitor RO6870810","n_c":["C112500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BET-bromodomain Inhibitor ODM-207","n_c":["C148138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta Alethine","n_c":["C2605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Carotene","n_c":["C1016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-elemene","n_c":["C103177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Glucan","n_c":["C2678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Glucan MM-10-001","n_c":["C82657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-lapachone Prodrug ARQ 761","n_c":["C99146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beta-Thioguanine Deoxyriboside","n_c":["C1350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Betulinic Acid","n_c":["C38126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bevacizumab","n_c":["C2039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bexarotene","n_c":["C1635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BF-200 Gel Formulation","n_c":["C131905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BH3 Mimetic ABT-737","n_c":["C114384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bi-functional Alkylating Agent VAL-083","n_c":["C425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bicalutamide","n_c":["C1599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bimiralisib","n_c":["C111898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Binetrakin","n_c":["C589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Binimetinib","n_c":["C84865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bintrafusp Alfa","n_c":["C124229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birabresib","n_c":["C103298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birinapant","n_c":["C88295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bis(choline)tetrathiomolybdate","n_c":["C62514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisantrene","n_c":["C1019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisantrene Hydrochloride","n_c":["C77218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisnafide","n_c":["C73611"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisnafide Dimesylate","n_c":["C73307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody 2B1","n_c":["C2399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody MDX-H210","n_c":["C1578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody MDX447","n_c":["C2207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisthianostat","n_c":["C163996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bivalent BRD4 Inhibitor AZD5153","n_c":["C151943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bizelesin","n_c":["C1472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BL22 Immunotoxin","n_c":["C1842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Black Cohosh","n_c":["C26647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Black Raspberry Nectar","n_c":["C122398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin","n_c":["C313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin A2","n_c":["C311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin B2","n_c":["C81672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bleomycin Sulfate","n_c":["C312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blinatumomab","n_c":["C62528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blueberry Powder Supplement","n_c":["C98108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMI1 Inhibitor PTC596","n_c":["C121645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-184476","n_c":["C1843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-188797","n_c":["C1859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-214662","n_c":["C1856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BMS-275183","n_c":["C62639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Boanmycin Hydrochloride","n_c":["C102878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Boronophenylalanine-Fructose Complex","n_c":["C2405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bortezomib","n_c":["C1851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosutinib","n_c":["C60809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosutinib Monohydrate","n_c":["C154440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botanical Agent BEL-X-HG","n_c":["C153419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botanical Agent LEAC-102","n_c":["C129711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bovine Cartilage","n_c":["C2418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bozitinib","n_c":["C129717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BP-Cx1-Platinum Complex BP-C1","n_c":["C107387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BR96-Doxorubicin Immunoconjugate","n_c":["C1617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brachyury-expressing Yeast Vaccine GI-6301","n_c":["C106267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor","n_c":["C155322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor ARQ 736","n_c":["C94224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor PLX8394","n_c":["C113330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF(V600E) Kinase Inhibitor RO5212054","n_c":["C92591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF/EGFR Inhibitor BGB-283","n_c":["C124995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAFV600/PI3K Inhibitor ASN003","n_c":["C134967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4 Inhibitor PLX2853","n_c":["C146825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRD4 Inhibitor PLX51107","n_c":["C125739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breflate","n_c":["C28855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brentuximab","n_c":["C2007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brentuximab Vedotin","n_c":["C66944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brequinar","n_c":["C1560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brequinar Sodium","n_c":["C1078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Briciclib Sodium","n_c":["C90541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brigatinib","n_c":["C98831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brilanestrant","n_c":["C106235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brimonidine Tartrate Nanoemulsion OCU-300","n_c":["C158723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivanib","n_c":["C67040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivanib Alaninate","n_c":["C53397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivudine","n_c":["C67088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brivudine Phosphoramidate","n_c":["C1882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad-Spectrum Human Papillomavirus Vaccine V505","n_c":["C70598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broccoli Sprout/Broccoli Seed Extract Supplement","n_c":["C128293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bromacrylide","n_c":["C73259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bromebric Acid","n_c":["C72089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bromocriptine Mesylate","n_c":["C317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brontictuzumab","n_c":["C103274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brostacillin Hydrochloride","n_c":["C128040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brostallicin","n_c":["C1889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broxuridine","n_c":["C318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol A","n_c":["C1765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol B","n_c":["C1764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol C","n_c":["C1768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol D","n_c":["C1535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol E","n_c":["C1536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol F","n_c":["C1537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol G","n_c":["C1694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceanol H","n_c":["C1695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bruceantin","n_c":["C1025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bryostatin 1","n_c":["C1026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor ARQ 531","n_c":["C138066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor CT-1530","n_c":["C138164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor DTRMWXHS-12","n_c":["C130001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor ICP-022","n_c":["C156173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor LOXO-305","n_c":["C158617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor M7583","n_c":["C129710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK inhibitor TG-1701","n_c":["C175775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Budigalimab","n_c":["C137682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Budotitane","n_c":["C81555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bufalin","n_c":["C107555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buparlisib","n_c":["C90565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burixafor","n_c":["C88323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burixafor Hydrobromide","n_c":["C130049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burosumab","n_c":["C119744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buserelin","n_c":["C320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bushen Culuan Decoction","n_c":["C160712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bushen-Jianpi Decoction","n_c":["C151930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Busulfan","n_c":["C321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buthionine Sulfoximine","n_c":["C1029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BXQ-350 Nanovesicle Formulation","n_c":["C131491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Kit Inhibitor PLX9486","n_c":["C121647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor AL2846","n_c":["C129314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor AMG 208","n_c":["C82677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor AMG 337","n_c":["C95203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor HS-10241","n_c":["C128895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor JNJ-38877605","n_c":["C77893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor MK2461","n_c":["C90591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor MK8033","n_c":["C116866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor MSC2156119J","n_c":["C88314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C-myb Antisense Oligonucleotide G4460","n_c":["C1541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-raf Antisense Oligonucleotide ISIS 5132","n_c":["C2721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C-VISA BikDD:Liposome","n_c":["C88264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAB-ROR2-ADC BA3021","n_c":["C155812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabazitaxel","n_c":["C66937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabiralizumab","n_c":["C123831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabozantinib","n_c":["C52200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cabozantinib S-malate","n_c":["C97938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cactinomycin","n_c":["C1032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Caffeic Acid Phenethyl Ester","n_c":["C63756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAIX Inhibitor DTP348","n_c":["C117731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAIX Inhibitor SLC-0111","n_c":["C117728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calaspargase Pegol-mknl","n_c":["C78198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcitriol","n_c":["C330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Release-activated Channels Inhibitor RP4010","n_c":["C136828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Saccharate","n_c":["C335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule","n_c":["C121642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calicheamicin Gamma 1I","n_c":["C1035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin","n_c":["C338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin Analogue TLC388","n_c":["C80047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin Glycoconjugate BAY 38-3441","n_c":["C1886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin Sodium","n_c":["C2344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camptothecin-20(S)-O-Propionate Hydrate","n_c":["C84857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camrelizumab","n_c":["C123816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camsirubicin","n_c":["C78863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancell","n_c":["C1775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer Peptide Vaccine S-588410","n_c":["C121776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canerpaturev","n_c":["C88318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canertinib Dihydrochloride","n_c":["C1880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canfosfamide","n_c":["C83581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canfosfamide Hydrochloride","n_c":["C2641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cannabidiol","n_c":["C118452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cantrixil","n_c":["C159719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cantuzumab Ravtansine","n_c":["C61576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capecitabine","n_c":["C1794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capecitabine Rapidly Disintegrating Tablet","n_c":["C99629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capivasertib","n_c":["C102564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capmatinib","n_c":["C90564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Captopril","n_c":["C340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CAR T-Cells AMG 119","n_c":["C150586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Caracemide","n_c":["C1037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbendazim","n_c":["C1154"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbetimer","n_c":["C1356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbogen","n_c":["C1038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboplatin","n_c":["C1282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboquone","n_c":["C342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboxyamidotriazole","n_c":["C1141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboxyamidotriazole Orotate","n_c":["C91090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carboxyphenyl Retinamide","n_c":["C1169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carfilzomib","n_c":["C52196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Caricotamide/Tretazicar","n_c":["C80048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carlumab","n_c":["C71010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmofur","n_c":["C955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine","n_c":["C349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine Implant","n_c":["C2487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine in Ethanol","n_c":["C2602"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carmustine Sustained-Release Implant Wafer","n_c":["C102847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotuximab","n_c":["C74010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carubicin","n_c":["C352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carubicin Hydrochloride","n_c":["C1582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carzelesin","n_c":["C1441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carzinophilin","n_c":["C1040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cathelicidin LL-37","n_c":["C118292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cationic Liposome-Encapsulated Paclitaxel","n_c":["C69130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Catumaxomab","n_c":["C62445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBP/beta-catenin Antagonist PRI-724","n_c":["C95894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CBP/beta-catenin Modulator E7386","n_c":["C153376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR2 Antagonist CCX872-B","n_c":["C120302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR2 Antagonist PF-04136309","n_c":["C97507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR2/CCR5 Antagonist BMS-813160","n_c":["C139550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CCR4 Inhibitor FLX475","n_c":["C157240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD4-specific Telomerase Peptide Vaccine UCPVax","n_c":["C129596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD40 Agonist Monoclonal Antibody CP-870,893","n_c":["C119740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD40 Agonistic Monoclonal Antibody APX005M","n_c":["C123734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD44 Targeted Agent SPL-108","n_c":["C142813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD47 Antagonist ALX148","n_c":["C132851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Inhibitor TAK-931","n_c":["C126641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Kinase Inhibitor BMS-863233","n_c":["C82418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Kinase Inhibitor LY3143921 Hydrate","n_c":["C148509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDC7 Kinase Inhibitor NMS-1116354","n_c":["C88316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK Inhibitor AT7519","n_c":["C64761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK Inhibitor R547","n_c":["C64544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK Inhibitor SNS-032","n_c":["C62523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK/JAK2/FLT3 Inhibitor TG02 Citrate","n_c":["C105851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK1 Inhibitor BEY1107","n_c":["C163985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK1/2/4 Inhibitor AG-024322","n_c":["C52182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK2/4/6/FLT3 Inhibitor FN-1501","n_c":["C155956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK2/5/9 Inhibitor CYC065","n_c":["C123902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4 Inhibitor P1446A-05","n_c":["C80049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor","n_c":["C116938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor BPI-16350","n_c":["C157481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor FCN-437","n_c":["C165199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor G1T38","n_c":["C138165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor SHR6390","n_c":["C125899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK7 Inhibitor CT7001","n_c":["C155652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK7 Inhibitor SY-1365","n_c":["C139552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK9 Inhibitor AZD4573","n_c":["C153377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEA-MUC-1-TRICOM Vaccine CV301","n_c":["C131129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEA-targeting Agent RG6123","n_c":["C159892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CEBPA-targeting saRNA MTL-CEBPA Liposome","n_c":["C126800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedazuridine","n_c":["C164146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedazuridine/Decitabine Combination Agent ASTX727","n_c":["C115102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedefingol","n_c":["C78081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cediranib","n_c":["C80867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cediranib Maleate","n_c":["C48379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celecoxib","n_c":["C1728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83","n_c":["C67075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cemadotin","n_c":["C75875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cemadotin Hydrochloride","n_c":["C1634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cemiplimab","n_c":["C121540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cenersen","n_c":["C37454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cenisertib","n_c":["C64540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CENP-E Inhibitor GSK-923295","n_c":["C91080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ceralasertib","n_c":["C111993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ceramide Nanoliposome","n_c":["C131434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerdulatinib","n_c":["C113173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480","n_c":["C146660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cereblon Modulator CC-90009","n_c":["C131177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cergutuzumab Amunaleukin","n_c":["C141459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ceritinib","n_c":["C115112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cesalin","n_c":["C28882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cEt KRAS Antisense Oligonucleotide AZD4785","n_c":["C147521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetrelimab","n_c":["C129448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab","n_c":["C1723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab-IR700 Conjugate RM-1929","n_c":["C121850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)","n_c":["C158083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevipabulin","n_c":["C77064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevipabulin Fumarate","n_c":["C73815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevipabulin Succinate","n_c":["C96746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cFMS Tyrosine Kinase Inhibitor ARRY-382","n_c":["C96227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chaparrin","n_c":["C1767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chaparrinone","n_c":["C1046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Checkpoint Kinase Inhibitor AZD7762","n_c":["C66961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Checkpoint Kinase Inhibitor XL844","n_c":["C61102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemotherapy","n_c":["C15632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chiauranib","n_c":["C115970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chimeric Monoclonal Antibody 81C6","n_c":["C156351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChiNing Decoction","n_c":["C119741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chk1 Inhibitor CCT245737","n_c":["C129580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chk1 Inhibitor GDC-0425","n_c":["C116756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chk1 Inhibitor GDC-0575","n_c":["C116845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHK1 Inhibitor MK-8776","n_c":["C79867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHK1 Inhibitor PF-477736","n_c":["C68820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorambucil","n_c":["C362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorodihydropyrimidine","n_c":["C2085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroquine","n_c":["C61671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroquinoxaline Sulfonamide","n_c":["C982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorotoxin","n_c":["C94723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorozotocin","n_c":["C1049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Choline Kinase Alpha Inhibitor TCD-717","n_c":["C94213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CHP-NY-ESO-1 Peptide Vaccine IMF-001","n_c":["C62598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromomycin A3","n_c":["C895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement","n_c":["C1828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cibisatamab","n_c":["C120097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ciclopirox Prodrug CPX-POM","n_c":["C175786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cidan Herbal Capsule","n_c":["C118451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ciforadenant","n_c":["C125659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cilengitide","n_c":["C1834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cimetidine","n_c":["C374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinacalcet Hydrochloride","n_c":["C47450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinobufagin","n_c":["C95021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinobufotalin","n_c":["C151929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cintredekin Besudotox","n_c":["C2599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirmtuzumab","n_c":["C118284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cis-Urocanic Acid","n_c":["C99125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin","n_c":["C376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin Liposomal","n_c":["C2502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin-E Therapeutic Implant","n_c":["C17879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","n_c":["C136428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Citarinostat","n_c":["C121641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Citatuzumab Bogatox","n_c":["C71694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cixutumumab","n_c":["C79828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CK2-targeting Synthetic Peptide CIGB-300","n_c":["C102849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CL 246738","n_c":["C1052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cladribine","n_c":["C1336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clanfenur","n_c":["C78082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clarithromycin","n_c":["C1054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class 1/4 Histone Deacetylase Inhibitor OKI-179","n_c":["C160606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Trial","n_c":["C71104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Trial Agent","n_c":["C90373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clioquinol","n_c":["C65337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clivatuzumab","n_c":["C88638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clodronate Disodium","n_c":["C1418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clodronic Acid","n_c":["C61685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clofarabine","n_c":["C26638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clomesone","n_c":["C28888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clomiphene","n_c":["C61607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clomiphene Citrate","n_c":["C379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clostridium Novyi-NT Spores","n_c":["C62762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cobimetinib","n_c":["C68923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cobomarsen","n_c":["C124225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Codrituzumab","n_c":["C80043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coenzyme Q10","n_c":["C916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colchicine-Site Binding Agent ABT-751","n_c":["C2679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cold Contaminant-free Iobenguane I-131","n_c":["C82344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colloidal Gold-Bound Tumor Necrosis Factor","n_c":["C62538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","n_c":["C154278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Tumor-Associated Peptides Vaccine IMA910","n_c":["C79806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Combretastatin","n_c":["C80014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Combretastatin A-1","n_c":["C162344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Combretastatin A1 Diphosphate","n_c":["C84867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Compound Kushen Injection","n_c":["C120314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conatumumab","n_c":["C71015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conbercept","n_c":["C162879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Concentrated Lingzhi Mushroom Extract","n_c":["C165273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011","n_c":["C156141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copanlisib","n_c":["C96796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copanlisib Hydrochloride","n_c":["C138994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper Cu 64-ATSM","n_c":["C79824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper Gluconate","n_c":["C80050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cord Blood-derived Expanded Natural Killer Cells PNK-007","n_c":["C173877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cordycepin","n_c":["C1057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cordycepin Triphosphate","n_c":["C967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coriolus Versicolor Extract","n_c":["C78184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Corticorelin Acetate","n_c":["C76112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cortisone Acetate","n_c":["C1058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cositecan","n_c":["C1877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coxsackievirus A21","n_c":["C61493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CpG Oligodeoxynucleotide GNKG168","n_c":["C88342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crenolanib","n_c":["C64639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crenolanib Besylate","n_c":["C106204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crizotinib","n_c":["C74061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crolibulin","n_c":["C66938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptophycin","n_c":["C1546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptophycin 52","n_c":["C1826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crystalline Genistein Formulation AXP107-11","n_c":["C95769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF-1R Inhibitor BLZ945","n_c":["C129653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R Inhibitor DCC-3014","n_c":["C136424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R Inhibitor PLX73086","n_c":["C129688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CT2584 HMS","n_c":["C202251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CTLA-4-directed Probody BMS-986249","n_c":["C146765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curcumin","n_c":["C401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110","n_c":["C154569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cusatuzumab","n_c":["C106116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Custirsen Sodium","n_c":["C1055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXC Chemokine Receptor 2 Antagonist AZD5069","n_c":["C123383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR1/2 Inhibitor SX-682","n_c":["C150389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR2 Antagonist QBM076","n_c":["C153151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Antagonist BL-8040","n_c":["C88309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Antagonist USL311","n_c":["C131534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Inhibitor Q-122","n_c":["C74022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4 Peptide Antagonist LY2510924","n_c":["C106253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115","n_c":["C148166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclin-dependent Kinase Inhibitor PF-06873600","n_c":["C151988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclodextrin-Based Polymer-Camptothecin CRLX101","n_c":["C62600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclodisone","n_c":["C28899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cycloleucine","n_c":["C404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclopentenyl Cytosine","n_c":["C1359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide","n_c":["C405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide Anhydrous","n_c":["C61694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclosporine","n_c":["C406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYL-02 Plasmid DNA","n_c":["C95716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP11A1 inhibitor ODM-208","n_c":["C156744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17 Inhibitor CFG920","n_c":["C102855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17 Lyase Inhibitor ASN001","n_c":["C120310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17/Androgen Receptor Inhibitor ODM 204","n_c":["C120304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyproterone","n_c":["C407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyproterone Acetate","n_c":["C1059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytarabine","n_c":["C408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytarabine Monophosphate Prodrug MB07133","n_c":["C128888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytarabine-asparagine Prodrug BST-236","n_c":["C153327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytidine Analog RX-3117","n_c":["C113444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytochlor","n_c":["C28950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytokine-based Biologic Agent IRX-2","n_c":["C53396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"D-methionine Formulation MRX-1024","n_c":["C69140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DAB389 Epidermal Growth Factor","n_c":["C2383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dabrafenib","n_c":["C82386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dabrafenib Mesylate","n_c":["C128059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacarbazine","n_c":["C411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacetuzumab","n_c":["C62179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DACH Polymer Platinate AP5346","n_c":["C64784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DACH-Platin Micelle NC-4016","n_c":["C113175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daclizumab","n_c":["C1569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacomitinib","n_c":["C53398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dacplatinum","n_c":["C28955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dactinomycin","n_c":["C412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dactolisib","n_c":["C74072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dactolisib Tosylate","n_c":["C162346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dalantercept","n_c":["C88296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dalotuzumab","n_c":["C74011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daniquidone","n_c":["C66984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Danusertib","n_c":["C61587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Danvatirsen","n_c":["C101368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daporinad","n_c":["C67043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daratumumab","n_c":["C74007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daratumumab/rHuPH20","n_c":["C156401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Darinaparsin","n_c":["C61490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Darleukin","n_c":["C90546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Darolutamide","n_c":["C104748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daromun","n_c":["C154627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dasatinib","n_c":["C38713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daunorubicin","n_c":["C62091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daunorubicin Citrate","n_c":["C47471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daunorubicin Hydrochloride","n_c":["C1583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401","n_c":["C170362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Decitabine","n_c":["C981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Defactinib","n_c":["C79809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Defactinib Hydrochloride","n_c":["C128039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deferoxamine","n_c":["C416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deferoxamine Mesylate","n_c":["C417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Degarelix","n_c":["C48385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Degarelix Acetate","n_c":["C80443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delanzomib","n_c":["C74075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Demcizumab","n_c":["C80041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Demecolcine","n_c":["C419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Demplatin Pegraglumer","n_c":["C85476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendritic Cell Vaccine","n_c":["C28310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendritic Cell-Autologous Lung Tumor Vaccine","n_c":["C26446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendritic Cell-targeting Lentiviral Vector ID-LV305","n_c":["C115976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denenicokin","n_c":["C62492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denibulin","n_c":["C77065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denibulin Hydrochloride","n_c":["C72736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denileukin Diftitox","n_c":["C1476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denintuzumab Mafodotin","n_c":["C105150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denosumab","n_c":["C61313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deoxycytidine Analogue TAS-109","n_c":["C82697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deoxycytidine Analogue TAS-109 Hydrochloride","n_c":["C150430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depatuxizumab","n_c":["C95206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depatuxizumab Mafodotin","n_c":["C105612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derazantinib","n_c":["C104267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deslorelin","n_c":["C38709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deslorelin Acetate","n_c":["C82600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Detirelix","n_c":["C132693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Detorubicin","n_c":["C1066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deuteporfin","n_c":["C132685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deuterated Enzalutamide","n_c":["C158096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Devimistat","n_c":["C80039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethason","n_c":["C422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethasone","n_c":["C422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethasone Phosphate","n_c":["C77001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexamethasone Sodium Phosphate","n_c":["C1362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexanabinol","n_c":["C99381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexrazoxane","n_c":["C1333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dexrazoxane Hydrochloride","n_c":["C66945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dezaguanine","n_c":["C968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dezaguanine Mesylate","n_c":["C80635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dezapelisib","n_c":["C107686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DHA-Paclitaxel","n_c":["C2649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DHEA Mustard","n_c":["C2707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DI-Leu16-IL2 Immunocytokine","n_c":["C78451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dianhydrogalactitol","n_c":["C425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diarylsulfonylurea Compound ILX-295501","n_c":["C1632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diazepinomicin","n_c":["C62508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaziquone","n_c":["C1363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diazooxonorleucine","n_c":["C427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dibrospidium Chloride","n_c":["C81362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dichloroallyl Lawsone","n_c":["C28959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dicycloplatin","n_c":["C107676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Didox","n_c":["C1338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dienogest","n_c":["C87238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diethylnorspermine","n_c":["C1168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Digitoxin","n_c":["C2634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Digoxin","n_c":["C28990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydro-5-Azacytidine","n_c":["C980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydrolenperone","n_c":["C1463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydroorotate Dehydrogenase Inhibitor AG-636","n_c":["C158103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dihydroorotate Dehydrogenase Inhibitor BAY2402234","n_c":["C153137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diindolylmethane","n_c":["C53434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dimethylmyleran","n_c":["C1073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dinaciclib","n_c":["C78854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dinutuximab","n_c":["C1570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dioscorea nipponica Makino Extract DNE3","n_c":["C115103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diphencyprone","n_c":["C28994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777","n_c":["C1476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ditiocarb","n_c":["C432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DKK1-Neutralizing Monoclonal Antibody DKN-01","n_c":["C99123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DM-CHOC-PEN","n_c":["C90539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015","n_c":["C77864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Interference Oligonucleotide PNT2258","n_c":["C92588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Minor Groove Binding Agent SG2000","n_c":["C29435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Plasmid Encoding Interleukin-12 INO-9012","n_c":["C116709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151","n_c":["C163978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457","n_c":["C123919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA Vaccine VB10.16","n_c":["C123923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-dependent Protein Kinase Inhibitor VX-984","n_c":["C129061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-PK/TOR Kinase Inhibitor CC-115","n_c":["C97040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98","n_c":["C2530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel","n_c":["C1526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Anhydrous","n_c":["C61734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Emulsion ANX-514","n_c":["C78196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Formulation CKD-810","n_c":["C88322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Lipid Microspheres","n_c":["C102568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Nanoparticle CPC634","n_c":["C121961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel Polymeric Micelles","n_c":["C165263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel-loaded Nanopharmaceutical CRLX301","n_c":["C121539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel-PNP","n_c":["C91087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Docetaxel/Ritonavir","n_c":["C162784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dolastatin 10","n_c":["C1300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dolastatin 15","n_c":["C1439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domatinostat","n_c":["C96797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Donafenib","n_c":["C118294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dopamine-Somatostatin Chimeric Molecule BIM-23A760","n_c":["C88345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703","n_c":["C148462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dovitinib","n_c":["C76199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dovitinib Lactate","n_c":["C62435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxazosin","n_c":["C61737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxercalciferol","n_c":["C2645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxifluridine","n_c":["C978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin","n_c":["C456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin Hydrochloride","n_c":["C1326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin Prodrug L-377,202","n_c":["C1853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-Eluting Beads","n_c":["C82419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-HPMA Conjugate","n_c":["C1366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-loaded EGFR-targeting Nanocells","n_c":["C128897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin-Magnetic Targeted Carrier Complex","n_c":["C2644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine","n_c":["C120213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine","n_c":["C120214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DPX-E7 HPV Vaccine","n_c":["C131494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DR5 HexaBody Agonist GEN1029","n_c":["C153259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DR5-targeting Tetrameric Nanobody Agonist TAS266","n_c":["C116886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dromostanolone Propionate","n_c":["C1077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Drozitumab","n_c":["C95784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dual IGF-1R/InsR Inhibitor BMS-754807","n_c":["C74043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dual Variable Domain Immunoglobulin ABT-165","n_c":["C116750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dual-affinity B7-H3/CD3-targeted Protein MGD009","n_c":["C136983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dubermatinib","n_c":["C127116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duborimycin","n_c":["C1062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dulanermin","n_c":["C1685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duligotuzumab","n_c":["C116628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dupilumab","n_c":["C162455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Durvalumab","n_c":["C103194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dusigitumab","n_c":["C82683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"dUTPase/DPD Inhibitor TAS-114","n_c":["C116885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duvelisib","n_c":["C99225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duvortuxizumab","n_c":["C122406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dynemicin","n_c":["C1928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dynemicin A","n_c":["C1079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"E2F1 Pathway Activator ARQ 171","n_c":["C64767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBNA-1 inhibitor VK-2019","n_c":["C159410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Echinomycin","n_c":["C462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ecromeximab","n_c":["C61095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edatrexate","n_c":["C958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edelfosine","n_c":["C956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edotecarin","n_c":["C2665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edrecolomab","n_c":["C1554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EED Inhibitor MAK683","n_c":["C133819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Efatutazone","n_c":["C83819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Efatutazone Dihydrochloride","n_c":["C64764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Efizonerimod","n_c":["C118282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eflornithine","n_c":["C226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eflornithine Hydrochloride","n_c":["C1579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eftilagimod Alpha","n_c":["C62509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205","n_c":["C90557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621","n_c":["C82694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGb761","n_c":["C26646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Antagonist Hemay022","n_c":["C123722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Antisense DNA BB-401","n_c":["C156732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor AZD3759","n_c":["C118289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor BIBX 1382","n_c":["C80868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor DBPR112","n_c":["C153427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor PD-168393","n_c":["C2727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor BPI-7711","n_c":["C154286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor CK-101","n_c":["C132023"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor D-0316","n_c":["C175747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-specific Inhibitor ZN-e4","n_c":["C153173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR T790M Antagonist BPI-15086","n_c":["C131909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR T790M Inhibitor HS-10296","n_c":["C133691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/FLT3/Abl Inhibitor SKLB1028","n_c":["C131492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER1/HER2 Inhibitor PKI166","n_c":["C1871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Inhibitor AP32788","n_c":["C126752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Inhibitor AV-412","n_c":["C64627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Kinase Inhibitor TAK-285","n_c":["C90589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eicosapentaenoic Acid","n_c":["C67080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"eIF4E Antisense Oligonucleotide ISIS 183750","n_c":["C95740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elacestrant","n_c":["C120211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elacytarabine","n_c":["C53401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elagolix","n_c":["C153373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbasvir/Grazoprevir","n_c":["C159973"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elesclomol","n_c":["C75291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elesclomol Sodium","n_c":["C79840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elgemtumab","n_c":["C101895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elinafide","n_c":["C1615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elisidepsin","n_c":["C66949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elliptinium","n_c":["C90495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elliptinium Acetate","n_c":["C1367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elmustine","n_c":["C73262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elotuzumab","n_c":["C66982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elpamotide","n_c":["C74090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elsamitrucin","n_c":["C1080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eltanexor","n_c":["C125193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emactuzumab","n_c":["C125548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emapalumab","n_c":["C127123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emepepimut-S","n_c":["C2195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emitefur","n_c":["C1022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emofolin Sodium","n_c":["C29019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Empesertib","n_c":["C116074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enadenotucirev","n_c":["C113786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A","n_c":["C159599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enasidenib","n_c":["C111573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enasidenib Mesylate","n_c":["C137825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enavatuzumab","n_c":["C80045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enclomiphene","n_c":["C28211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enclomiphene Citrate","n_c":["C61745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encorafenib","n_c":["C98283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endothelin Receptor Type A Antagonist YM598","n_c":["C26678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enfortumab Vedotin","n_c":["C114500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Human Umbilical Vein Endothelial Cells AB-205","n_c":["C162248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Toxin Body Targeting HER2 MT-5111","n_c":["C162649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eniluracil/5-FU Combination Tablet","n_c":["C11252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enloplatin","n_c":["C95323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enoblituzumab","n_c":["C97510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enobosarm","n_c":["C69161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enoticumab","n_c":["C82367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enpromate","n_c":["C83689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ensartinib","n_c":["C102754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ensituximab","n_c":["C90532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride","n_c":["C82660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enterococcus gallinarum Strain MRx0518","n_c":["C160293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entinostat","n_c":["C1863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entolimod","n_c":["C99166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entospletinib","n_c":["C105402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Entrectinib","n_c":["C114984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Envafolimab","n_c":["C129714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enzalutamide","n_c":["C71744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enzastaurin","n_c":["C77392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enzastaurin Hydrochloride","n_c":["C26658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP4 Antagonist ONO-4578","n_c":["C150376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epacadostat","n_c":["C92582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epipodophyllotoxin Analog GL331","n_c":["C1866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epipropidine","n_c":["C78083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epirubicin","n_c":["C62028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epirubicin Hydrochloride","n_c":["C474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitinib Succinate","n_c":["C153095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitiostanol","n_c":["C1089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epothilone Analog UTD1","n_c":["C118450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epothilone KOS-1584","n_c":["C77892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epratuzumab","n_c":["C1887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epratuzumab-cys-tesirine","n_c":["C155794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471","n_c":["C165420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERa36 Modulator Icaritin","n_c":["C95720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erastin Analogue PRLX 93936","n_c":["C70625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erbulozole","n_c":["C73258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erdafitinib","n_c":["C103273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eribulin","n_c":["C96748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eribulin Mesylate","n_c":["C26644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK 1/2 Inhibitor ASTX029","n_c":["C155785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor CC-90003","n_c":["C119747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor GDC-0994","n_c":["C170364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor LTT462","n_c":["C126687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK Inhibitor MK-8353","n_c":["C104045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor ASN007","n_c":["C150248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor KO-947","n_c":["C141074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor LY3214996","n_c":["C131335"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erlotinib","n_c":["C65530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erlotinib Hydrochloride","n_c":["C2693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ertumaxomab","n_c":["C2658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Erythrocyte-encapsulated L-asparaginase Suspension","n_c":["C99767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esorubicin","n_c":["C972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esorubicin Hydrochloride","n_c":["C74943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esperamicin A1","n_c":["C1301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Essiac","n_c":["C26649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esterified Estrogens","n_c":["C154677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estradiol Valerate","n_c":["C1090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estramustine","n_c":["C479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estramustine Phosphate Sodium","n_c":["C480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogen Receptor Agonist GTx-758","n_c":["C96432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogens, Conjugated","n_c":["C482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etalocib","n_c":["C1626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etanercept","n_c":["C2381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etanidazole","n_c":["C1092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etaracizumab","n_c":["C1800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etarotene","n_c":["C96705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethaselen","n_c":["C116713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethinyl Estradiol","n_c":["C486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethyleneimine","n_c":["C1009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethylnitrosourea","n_c":["C26563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etidronate-Cytarabine Conjugate MBC-11","n_c":["C125901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etirinotecan Pegol","n_c":["C74069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoglucid","n_c":["C489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoposide","n_c":["C491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoposide Phosphate","n_c":["C1093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoposide Toniribate","n_c":["C114977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoprine","n_c":["C73236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etoricoxib","n_c":["C52188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ets-family Transcription Factor Inhibitor TK216","n_c":["C125657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Everolimus","n_c":["C48387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Everolimus Tablets for Oral Suspension","n_c":["C102880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Evofosfamide","n_c":["C71722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ex Vivo-expanded Autologous T Cells IMA101","n_c":["C131305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exatecan Mesylate","n_c":["C1679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exatecan Mesylate Anhydrous","n_c":["C162348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exemestane","n_c":["C1097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exisulind","n_c":["C1239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extended Release Flucytosine","n_c":["C112498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extended-release Onapristone","n_c":["C113797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH1/2 Inhibitor DS-3201","n_c":["C127114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 Inhibitor CPI-1205","n_c":["C121639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 Inhibitor PF-06821497","n_c":["C156743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 Inhibitor SHR2554","n_c":["C158742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"F16-IL2 Fusion Protein","n_c":["C91395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FACT Complex-targeting Curaxin CBL0137","n_c":["C107239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Factor VII-targeting Immunoconjugate Protein ICON-1","n_c":["C129313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Factor VIIa Inhibitor PCI-27483","n_c":["C88324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fadrozole Hydrochloride","n_c":["C1044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK Inhibitor GSK2256098","n_c":["C88346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK Inhibitor PF-00562271","n_c":["C78199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK Inhibitor VS-4718","n_c":["C107238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Falimarev","n_c":["C29316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Famitinib","n_c":["C97512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Farletuzumab","n_c":["C61503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123","n_c":["C1840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fas Receptor Agonist APO010","n_c":["C67041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fascin Inhibitor NP-G2-044","n_c":["C142086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FASN Inhibitor TVB-2640","n_c":["C118285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fazarabine","n_c":["C1096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Febuxostat","n_c":["C65629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fedratinib","n_c":["C88293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fedratinib Hydrochloride","n_c":["C162995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenebrutinib","n_c":["C116844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenretinide","n_c":["C1098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenretinide Lipid Matrix","n_c":["C63482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGF Receptor Antagonist HGS1036","n_c":["C77970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGF/FGFR Pathway Inhibitor E7090","n_c":["C118672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor ASP5878","n_c":["C122719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor AZD4547","n_c":["C88272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor Debio 1347","n_c":["C174762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor TAS-120","n_c":["C114283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","n_c":["C116894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR1/2/3 Inhibitor HMPL-453","n_c":["C150383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Antagonist INCB062079","n_c":["C143067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor BLU 9931","n_c":["C162342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor FGF401","n_c":["C120102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor H3B-6527","n_c":["C128862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR4 Inhibitor ICP-105","n_c":["C162852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromun","n_c":["C166939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ficlatuzumab","n_c":["C78844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Figitumumab","n_c":["C52187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Filanesib","n_c":["C68937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Filgotinib","n_c":["C155799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Filgrastim","n_c":["C1474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fimepinostat","n_c":["C104008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Firtecan Pegol","n_c":["C70651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fisogatinib","n_c":["C123826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flanvotumab","n_c":["C91384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flotetuzumab","n_c":["C117238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floxuridine","n_c":["C504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Inhibitor FF-10101 Succinate","n_c":["C137988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Inhibitor HM43239","n_c":["C165254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Inhibitor SKI-G-801","n_c":["C155773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3 Tyrosine Kinase Inhibitor TTT-3002","n_c":["C123362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449","n_c":["C116858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/CDK4/6 Inhibitor FLX925","n_c":["C120209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/KIT Kinase Inhibitor AKN-028","n_c":["C101520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flt3/MerTK Inhibitor MRX-2843","n_c":["C151407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fludarabine","n_c":["C1094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fludarabine Phosphate","n_c":["C1102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flumatinib","n_c":["C138991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flumatinib Mesylate","n_c":["C117723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorodopan","n_c":["C29042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorouracil","n_c":["C505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorouracil Implant","n_c":["C90544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorouracil-E Therapeutic Implant","n_c":["C17877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluoxymesterone","n_c":["C507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flutamide","n_c":["C509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluvastatin","n_c":["C61768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluvastatin Sodium","n_c":["C29062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluzoparib","n_c":["C126274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FMS Inhibitor JNJ-40346527","n_c":["C101519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate","n_c":["C105804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor Targeted Epothilone BMS753493","n_c":["C71524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor-Targeted Tubulysin Conjugate EC1456","n_c":["C113176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor-Targeted Vinca Alkaloid EC0489","n_c":["C81935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225","n_c":["C66987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folate-FITC","n_c":["C62479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folic Acid","n_c":["C510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Folitixorin","n_c":["C61304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foretinib","n_c":["C80058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Formestane","n_c":["C974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forodesine Hydrochloride","n_c":["C26655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosaprepitant","n_c":["C72787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosbretabulin","n_c":["C82378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosbretabulin Disodium","n_c":["C2503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosbretabulin Tromethamine","n_c":["C83721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foslinanib","n_c":["C123824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foslinanib Disodium","n_c":["C163994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosquidone","n_c":["C1371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fostriecin","n_c":["C1372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fotemustine","n_c":["C1106"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fotretamine","n_c":["C65767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FPV Vaccine CV301","n_c":["C141298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FPV-Brachyury-TRICOM Vaccine","n_c":["C148402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fresolimumab","n_c":["C63546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fruquintinib","n_c":["C102852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fulvestrant","n_c":["C1379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fumagillin-Derived Polymer Conjugate XMT-1107","n_c":["C88321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fursultiamine","n_c":["C121852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Futuximab","n_c":["C152971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Futuximab/Modotuximab Mixture","n_c":["C91381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G-Quadruplex Stabilizer BMVC","n_c":["C95893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galamustine","n_c":["C76791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galarubicin","n_c":["C81422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galectin Inhibitor GR-MD-02","n_c":["C115111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galectin-1 Inhibitor OTX008","n_c":["C103828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galeterone","n_c":["C84866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galiximab","n_c":["C26447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galocitabine","n_c":["C73254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Galunisertib","n_c":["C116891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamboge Resin Extract TSB-9-W1","n_c":["C118444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-delta Tocotrienol","n_c":["C101517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-Secretase Inhibitor LY3039478","n_c":["C121535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gamma-Secretase Inhibitor RO4929097","n_c":["C88333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gandotinib","n_c":["C116857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganetespib","n_c":["C77872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglioside GD2","n_c":["C1110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglioside GM2","n_c":["C516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganitumab","n_c":["C71531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganoderma lucidum Spores Powder Capsule","n_c":["C118365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Garlic","n_c":["C38706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrin Immunotoxin","n_c":["C1692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360","n_c":["C61329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gataparsen Sodium","n_c":["C66935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gatipotuzumab","n_c":["C94220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gedatolisib","n_c":["C91732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gefitinib","n_c":["C1855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Geldanamycin","n_c":["C1112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gelonin","n_c":["C133021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine","n_c":["C66876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Elaidate","n_c":["C79803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Hydrochloride","n_c":["C961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Hydrochloride Emulsion","n_c":["C105613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine Prodrug LY2334737","n_c":["C102856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine-Phosphoramidate Hydrochloride NUC-1031","n_c":["C102752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemcitabine-Releasing Intravesical System","n_c":["C150807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gemtuzumab Ozogamicin","n_c":["C1806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genistein","n_c":["C1113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gentuximab","n_c":["C154552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Geranylgeranyltransferase I Inhibitor","n_c":["C104414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GI-4000 Vaccine","n_c":["C61489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilteritinib","n_c":["C116722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilteritinib Fumarate","n_c":["C119665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gimatecan","n_c":["C65804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gimeracil","n_c":["C2416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ginsenoside Rg3 Capsule","n_c":["C103300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Girentuximab","n_c":["C1960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Girodazole","n_c":["C1373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GITR Agonist MEDI1873","n_c":["C169931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Givinostat","n_c":["C71716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glasdegib","n_c":["C84862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glasdegib Maleate","n_c":["C156894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucarubolone","n_c":["C1114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glecaprevir/Pibrentasvir","n_c":["C160484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glembatumumab Vedotin","n_c":["C78449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glesatinib","n_c":["C77876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioblastoma Cancer Vaccine ERC1671","n_c":["C107502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioblastoma Multiforme Multipeptide Vaccine IMA950","n_c":["C94211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioma Lysate Vaccine GBM6-AD","n_c":["C139000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701","n_c":["C114496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Globo H-DT Vaccine OBI-833","n_c":["C119745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucarpidase","n_c":["C346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glucocorticoid Receptor Antagonist ORIC-101","n_c":["C162509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glufosfamide","n_c":["C1612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glumetinib","n_c":["C156700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutaminase Inhibitor CB-839","n_c":["C114381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutaminase Inhibitor CB-839 Hydrochloride","n_c":["C150413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101","n_c":["C106121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01","n_c":["C151952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycooptimized Trastuzumab-GEX","n_c":["C97917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102","n_c":["C98287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gold Sodium Thiomalate","n_c":["C74037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Golnerminogene Pradenovec","n_c":["C26444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Golotimod","n_c":["C76497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Golvatinib","n_c":["C82363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadotropin-releasing Hormone Analog","n_c":["C1910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goserelin","n_c":["C1374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goserelin Acetate","n_c":["C1417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goserelin Acetate Extended-release Microspheres LY01005","n_c":["C156710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gossypol","n_c":["C529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gossypol Acetic Acid","n_c":["C1118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grapiprant","n_c":["C124131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Green Tea Extract-based Antioxidant Supplement","n_c":["C97514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GS/pan-Notch Inhibitor AL101","n_c":["C116872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GS/pan-Notch Inhibitor BMS-986115","n_c":["C118573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GSK-3 Inhibitor 9-ING-41","n_c":["C156792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GSK-3 Inhibitor LY2090314","n_c":["C116849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guadecitabine","n_c":["C95209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guanabenz Acetate","n_c":["C65826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guselkumab","n_c":["C150390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gusperimus Trihydrochloride","n_c":["C1598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gutolactone","n_c":["C1532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H-ras Antisense Oligodeoxynucleotide ISIS 2503","n_c":["C2024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H1299 Tumor Cell Lysate Vaccine","n_c":["C114284"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HAAH Lambda phage Vaccine SNS-301","n_c":["C148522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hafnium Oxide-containing Nanoparticles NBTXR3","n_c":["C98280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halichondrin Analogue E7130","n_c":["C156697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halichondrin B","n_c":["C1376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halofuginone","n_c":["C1120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Halofuginone Hydrobromide","n_c":["C2656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HCV DNA Vaccine INO-8000","n_c":["C121570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Class I/IIb Inhibitor HG146","n_c":["C160706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor AR-42","n_c":["C116850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC inhibitor CG200745","n_c":["C94225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor CHR-2845","n_c":["C152539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor CKD-581","n_c":["C148157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor CXD101","n_c":["C112177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor MPT0E028","n_c":["C120312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC Inhibitor OBP-801","n_c":["C121665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC/EGFR/HER2 Inhibitor CUDC-101","n_c":["C78850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC6 Inhibitor KA2507","n_c":["C135629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDAC8 Inhibitor NBM-BMX","n_c":["C159496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDM2 Inhibitor HDM201","n_c":["C116325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDM2 Inhibitor MK-8242","n_c":["C116867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hedgehog Inhibitor IPI-609","n_c":["C60772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematoporphyrin Derivative","n_c":["C1071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemiasterlin Analog E7974","n_c":["C49083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Henatinib Maleate","n_c":["C97949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heparan Sulfate Glycosaminoglycan Mimetic M402","n_c":["C170206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heparin Derivative SST0001","n_c":["C104412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131","n_c":["C128283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901","n_c":["C99903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Inhibitor CP-724,714","n_c":["C26648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Inhibitor TAS0728","n_c":["C146810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-targeted DARPin MP0274","n_c":["C148491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302","n_c":["C96038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-targeting Antibody Fc Fragment FS102","n_c":["C118953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herba Scutellaria Barbata","n_c":["C2661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herbimycin","n_c":["C1124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterodimeric Interleukin-15","n_c":["C122401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hexamethylene Bisacetamide","n_c":["C1125"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hexaminolevulinate","n_c":["C26654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hexylresorcinol","n_c":["C29092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF-1alpha Inhibitor PX-478","n_c":["C70953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF-2alpha Inhibitor PT2385","n_c":["C119618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF-2alpha Inhibitor PT2977","n_c":["C135627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126","n_c":["C113334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histrelin Acetate","n_c":["C77424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001","n_c":["C111689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410","n_c":["C101893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201","n_c":["C128489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HM2/MMAE Antibody-Drug Conjugate ALT-P7","n_c":["C153102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine","n_c":["C61592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres","n_c":["C88336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hormone Therapy","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPPH","n_c":["C2636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c","n_c":["C117240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV DNA Plasmids Therapeutic Vaccine VGX-3100","n_c":["C77909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV E6/E7 DNA Vaccine GX-188E","n_c":["C102787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C","n_c":["C131495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract","n_c":["C102874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106","n_c":["C123378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101","n_c":["C162459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN","n_c":["C121648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Antagonist KW-2478","n_c":["C69139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor AB-010","n_c":["C82691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor BIIB021","n_c":["C62517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor BIIB028","n_c":["C78846"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor Debio 0932","n_c":["C92572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor DS-2248","n_c":["C116851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor HSP990","n_c":["C82387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor MPC-3100","n_c":["C84836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor PU-H71","n_c":["C101227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor SNX-5422 Mesylate","n_c":["C91068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor SNX-5542 Mesylate","n_c":["C74040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor XL888","n_c":["C79835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90-targeted SN-38 Conjugate PEN-866","n_c":["C151953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HSP90alpha/beta Inhibitor TAS-116","n_c":["C134448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301","n_c":["C119616"],"i_c":"","i_c_s":"","term_type":""},{"nm":"hTERT Vaccine V934/V935","n_c":["C80055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"hTERT-encoding DNA Vaccine INVAC-1","n_c":["C119737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hu14.18-IL2 Fusion Protein EMD 273063","n_c":["C162537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HuaChanSu","n_c":["C82415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Huaier Extract Granule","n_c":["C125001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Huang Lian","n_c":["C2626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"huBC1-huIL12 Fusion Protein AS1409","n_c":["C74041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736","n_c":["C116788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104","n_c":["C66980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human MOAB LICO 28a32","n_c":["C29089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Monoclonal Antibody 216","n_c":["C62532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307","n_c":["C77858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus 16 E7 Peptide/Padre 965.10","n_c":["C2569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hycanthone","n_c":["C550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydralazine Hydrochloride","n_c":["C551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydrocortisone Sodium Succinate","n_c":["C1819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxychloroquine","n_c":["C557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxyprogesterone Caproate","n_c":["C960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxytyrosol","n_c":["C63690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hydroxyurea","n_c":["C560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypericin","n_c":["C37456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypoxia-activated Prodrug TH-4000","n_c":["C101523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Antiferritin Immunoglobulin","n_c":["C2357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody A33","n_c":["C2477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody CC49","n_c":["C26442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody F19","n_c":["C2515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"I 131 Monoclonal Antibody Lym-1","n_c":["C2103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IAP Inhibitor APG-1387","n_c":["C162535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IAP Inhibitor AT-406","n_c":["C90574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IAP Inhibitor HGS1029","n_c":["C78484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ibandronate Sodium","n_c":["C1670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iberdomide","n_c":["C129048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iboctadekin","n_c":["C1680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ibritumomab Tiuxetan","n_c":["C29981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ibrutinib","n_c":["C81934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Icotinib Hydrochloride","n_c":["C99160"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Icrucumab","n_c":["C79808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ICT-121 Dendritic Cell Vaccine","n_c":["C124652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idarubicin","n_c":["C562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idarubicin Hydrochloride","n_c":["C1587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idarubicin-Eluting Beads","n_c":["C90593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idasanutlin","n_c":["C99131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idecabtagene Vicleucel","n_c":["C117729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idelalisib","n_c":["C78825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1(R132) Inhibitor IDH305","n_c":["C121457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M","n_c":["C117235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020","n_c":["C74042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO Peptide Vaccine IO102","n_c":["C159498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO-1 Inhibitor LY3381916","n_c":["C143068"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO/TDO Inhibitor HTI-1090","n_c":["C151945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1 Inhibitor KHK2455","n_c":["C129790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1 Inhibitor MK-7162","n_c":["C148235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1 Inhibitor PF-06840003","n_c":["C129375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1/TDO2 Inhibitor DN1406131","n_c":["C162858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idronoxil","n_c":["C2642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idronoxil Suppository NOX66","n_c":["C132257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ifabotuzumab","n_c":["C116629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ifetroban","n_c":["C81570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ifosfamide","n_c":["C564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-1R Inhibitor","n_c":["C184764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-1R Inhibitor PL225B","n_c":["C104746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-1R/IR Inhibitor KW-2450","n_c":["C84871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IGF-methotrexate Conjugate","n_c":["C113789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-10 Immunomodulator MK-1966","n_c":["C126840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-12-expressing HSV-1 NSC 733972","n_c":["C114294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051","n_c":["C114385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-2 Recombinant Fusion Protein ALT-801","n_c":["C71743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1","n_c":["C146636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL4-Pseudomonas Exotoxin Fusion Protein MDNA55","n_c":["C79843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilixadencel","n_c":["C99902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iloprost","n_c":["C48397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilorasertib","n_c":["C116729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imalumab","n_c":["C104260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imatinib","n_c":["C62035"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imatinib Mesylate","n_c":["C1687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imetelstat","n_c":["C49084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imetelstat Sodium","n_c":["C84511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imexon","n_c":["C29115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imidazole Mustard","n_c":["C2216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imidazole-Pyrazole","n_c":["C29344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imipramine Blue","n_c":["C126638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imiquimod","n_c":["C1431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immediate-release Onapristone","n_c":["C113795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immediate-release Tablet Afuresertib","n_c":["C113658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immune Checkpoint Inhibitor ASP8374","n_c":["C141421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoconjugate RO5479599","n_c":["C104058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunocytokine NHS-IL12","n_c":["C97961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunocytokine NHS-IL2-LT","n_c":["C82411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulator LAM-003","n_c":["C152979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulator OHR/AVR118","n_c":["C49092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulatory Agent CC-11006","n_c":["C101370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunomodulatory Oligonucleotide HYB2055","n_c":["C49182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapeutic Combination Product CMB305","n_c":["C122922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapeutic GSK1572932A","n_c":["C78478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotherapy Regimen MKC-1106-MT","n_c":["C77971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunotoxin CMD-193","n_c":["C62480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IMT-1012 Immunotherapeutic Vaccine","n_c":["C77863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inalimarev","n_c":["C29317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Incyclinide","n_c":["C2454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indibulin","n_c":["C2049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indicine-N-Oxide","n_c":["C1134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indisulam","n_c":["C25797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indocyanine Green-labeled Polymeric Micelles ONM-100","n_c":["C158750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indole-3-Carbinol","n_c":["C1135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indomethacin","n_c":["C576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoximod","n_c":["C71535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indoximod Prodrug NLG802","n_c":["C150393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inecalcitol","n_c":["C83818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infigratinib","n_c":["C88302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infigratinib Mesylate","n_c":["C162568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Infliximab","n_c":["C1789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ingenol Mebutate","n_c":["C48398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ingenol Mebutate Gel","n_c":["C118776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iniparib","n_c":["C62526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Innate Immunostimulator rBBX-01","n_c":["C82362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"INO-1001","n_c":["C61315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inodiftagene Vixteplasmid","n_c":["C157333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iNOS Dimerization Inhibitor ASP9853","n_c":["C116728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01","n_c":["C122835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944","n_c":["C49181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inositol","n_c":["C28163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inotuzumab Ozogamicin","n_c":["C71542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inproquone","n_c":["C65919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Integrin alpha-2 Inhibitor E7820","n_c":["C61501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Integrin Receptor Antagonist GLPG0187","n_c":["C96223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon","n_c":["C20493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfa-N1","n_c":["C2220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfa-N3","n_c":["C30136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfacon-1","n_c":["C1766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Beta-1A","n_c":["C1823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Gamma-1b","n_c":["C100089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002","n_c":["C66972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin Therapy","n_c":["C15543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-2 Liposome","n_c":["C2373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230","n_c":["C128107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intetumumab","n_c":["C61070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intiquinatine","n_c":["C83820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intoplicine","n_c":["C1495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inulin","n_c":["C61506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iobenguane I-131","n_c":["C970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 124 Monoclonal Antibody A33","n_c":["C2440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 124 Monoclonal Antibody M5A","n_c":["C158629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody","n_c":["C74051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP","n_c":["C91389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Derlotuximab Biotin","n_c":["C2223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Ethiodized Oil","n_c":["C2696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 MIP-1095","n_c":["C131821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody 81C6","n_c":["C2488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody BC8","n_c":["C2527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2","n_c":["C2697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody F16SIP","n_c":["C95025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody G-250","n_c":["C2449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Monoclonal Antibody muJ591","n_c":["C2604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Omburtamab","n_c":["C48400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Rituximab","n_c":["C102981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Tenatumomab","n_c":["C124996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 TM-601","n_c":["C48263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Tositumomab","n_c":["C2444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I-131","n_c":["C1639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ioflubenzamide I-131","n_c":["C80056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ionomycin","n_c":["C596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipafricept","n_c":["C102565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipatasertib","n_c":["C91072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipilimumab","n_c":["C2654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ipomeanol","n_c":["C976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iproplatin","n_c":["C1070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iPSC-derived CD16-expressing Natural Killer Cells FT516","n_c":["C164140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iPSC-derived Natural Killer Cells FT500","n_c":["C158438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IRAK4 Inhibitor CA-4948","n_c":["C148455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iratumumab","n_c":["C26441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iridium Ir 192","n_c":["C104270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan","n_c":["C62040"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan Hydrochloride","n_c":["C1381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan-Eluting Beads","n_c":["C82682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet","n_c":["C88280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irofulven","n_c":["C1717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irosustat","n_c":["C79827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isatuximab","n_c":["C90578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iso-fludelone","n_c":["C97332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isobrucein B","n_c":["C1774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isocoumarin NM-3","n_c":["C1888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isotretinoin","n_c":["C603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ispinesib","n_c":["C38131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ispinesib Mesylate","n_c":["C77518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ISS 1018 CpG Oligodeoxynucleotide","n_c":["C61080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itacitinib","n_c":["C116855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itacitinib Adipate","n_c":["C158906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITK Inhibitor CPI-818","n_c":["C162010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itraconazole","n_c":["C1138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Itraconazole Dispersion In Polymer Matrix","n_c":["C104048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ivosidenib","n_c":["C114383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ixabepilone","n_c":["C37452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ixazomib","n_c":["C97940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ixazomib Citrate","n_c":["C82653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK Inhibitor INCB047986","n_c":["C111761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1 Inhibitor AZD4205","n_c":["C156774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK1 Inhibitor INCB052793","n_c":["C118629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2 Inhibitor AZD1480","n_c":["C91394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2 Inhibitor BMS-911543","n_c":["C95702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2 Inhibitor XL019","n_c":["C90573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK2/Src Inhibitor NS-018","n_c":["C98109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jin Fu Kang","n_c":["C61316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JNK Inhibitor CC-401","n_c":["C49095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kanglaite","n_c":["C91705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ketoconazole","n_c":["C605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ketotrexate","n_c":["C77403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS G12C Inhibitor MRTX849","n_c":["C157493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS Mutant-targeting AMG 510","n_c":["C154287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS-MAPK Signaling Pathway Inhibitor JAB-3312","n_c":["C164218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRN5500","n_c":["C1614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KSP Inhibitor AZD4877","n_c":["C64522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KSP Inhibitor SB-743921","n_c":["C52199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kunecatechins Ointment","n_c":["C67049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"L-Gossypol","n_c":["C62178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"L-methylfolate","n_c":["C107240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Labetuzumab Govitecan","n_c":["C95710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lactoferrin-derived Lytic Peptide LTX-315","n_c":["C90547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacutamab","n_c":["C124999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ladirubicin","n_c":["C83861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laetrile","n_c":["C29149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laniquidar","n_c":["C28698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lanreotide Acetate","n_c":["C74584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapachone","n_c":["C28694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapatinib","n_c":["C26653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapatinib Ditosylate","n_c":["C66878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lapuleucel-T","n_c":["C2057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laromustine","n_c":["C2653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotaxel","n_c":["C48427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotrectinib","n_c":["C115977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotrectinib Sulfate","n_c":["C156895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lavendustin A","n_c":["C1142"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lazertinib","n_c":["C148147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lead Pb 212 TCMC-trastuzumab","n_c":["C97500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lefitolimod","n_c":["C94207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leflunomide","n_c":["C1128"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenalidomide","n_c":["C2668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenalidomide Analog KPG-121","n_c":["C162878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lentinan","n_c":["C28168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenvatinib","n_c":["C95124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenvatinib Mesylate","n_c":["C48636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lenzilumab","n_c":["C125081"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lestaurtinib","n_c":["C48402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Letrozole","n_c":["C1527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leucovorin","n_c":["C71631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leucovorin Calcium","n_c":["C607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leuprolide","n_c":["C62042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leuprolide Acetate","n_c":["C1319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leuprolide Mesylate Injectable Suspension","n_c":["C118363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leurubicin","n_c":["C81421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levetiracetam","n_c":["C47581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levothyroxine","n_c":["C62080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levothyroxine Sodium","n_c":["C888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lexatumumab","n_c":["C64621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lexibulin","n_c":["C77882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liarozole","n_c":["C1433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liarozole Fumarate","n_c":["C1524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liarozole Hydrochloride","n_c":["C80333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Licartin","n_c":["C104275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Licorice","n_c":["C61436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifastuzumab Vedotin","n_c":["C116747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Light-activated AU-011","n_c":["C137951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Light-Emitting Oncolytic Vaccinia Virus GL-ONC1","n_c":["C79833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Limonene, (+)-","n_c":["C61714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Limonene, (+/-)-","n_c":["C61709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linifanib","n_c":["C71759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linoleyl Carbonate-Paclitaxel","n_c":["C101792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linrodostat","n_c":["C141135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linsitinib","n_c":["C70982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lintuzumab","n_c":["C1716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liothyronine I-131","n_c":["C2396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liothyronine Sodium","n_c":["C2581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1","n_c":["C116889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191","n_c":["C160867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416","n_c":["C142137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","n_c":["C157247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal c-raf Antisense Oligonucleotide","n_c":["C95718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Curcumin","n_c":["C116322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Cytarabine","n_c":["C2388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Daunorubicin Citrate","n_c":["C2213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Docetaxel","n_c":["C92581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Eribulin Mesylate","n_c":["C111899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","n_c":["C111688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Irinotecan","n_c":["C82676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Mitoxantrone Hydrochloride","n_c":["C116064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal MUC1/PET-lipid A Vaccine ONT-10","n_c":["C101262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal NDDP","n_c":["C1383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Rhenium Re 186","n_c":["C188608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal SN-38","n_c":["C95717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Topotecan FF-10850","n_c":["C165505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Vinorelbine","n_c":["C62790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Vinorelbine Tartrate","n_c":["C135619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome","n_c":["C18208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated Daunorubicin-Cytarabine","n_c":["C67504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-Encapsulated Doxorubicin Citrate","n_c":["C61317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated miR-34 Mimic MRX34","n_c":["C105802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated OSI-7904","n_c":["C38694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94","n_c":["C106271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lirilumab","n_c":["C103820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lisavanbulin","n_c":["C97664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lisocabtagene Maraleucel","n_c":["C125192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142","n_c":["C120103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Litronesib","n_c":["C88328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809","n_c":["C125631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","n_c":["C74055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623","n_c":["C111998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver X Receptor beta Agonist RGX-104","n_c":["C131910"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lm-tLLO-neoantigens Vaccine ADXS-NEO","n_c":["C148380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-1 Immunotoxin","n_c":["C2499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-2 Immunotoxin","n_c":["C2513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-7 Immunotoxin","n_c":["C1619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMB-9 Immunotoxin","n_c":["C2472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164","n_c":["C121541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP-2:340-349 Peptide Vaccine","n_c":["C62767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP-2:419-427 Peptide Vaccine","n_c":["C62768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lobaplatin","n_c":["C1434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lometrexol","n_c":["C979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lometrexol Sodium","n_c":["C90623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lomustine","n_c":["C617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lonafarnib","n_c":["C1829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Loncastuximab Tesirine","n_c":["C125549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Long Peptide Vaccine 7","n_c":["C116067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Long-acting Release Pasireotide","n_c":["C113656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lontucirev","n_c":["C2830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lorlatinib","n_c":["C113655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lorukafusp alfa","n_c":["C162537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lorvotuzumab Mertansine","n_c":["C38714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Losatuxizumab Vedotin","n_c":["C120556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Losoxantrone","n_c":["C1521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Losoxantrone Hydrochloride","n_c":["C72077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lovastatin","n_c":["C620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LOXL2 Inhibitor PAT-1251","n_c":["C160691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP5/6 Antagonist BI 905677","n_c":["C165553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor CC-90011","n_c":["C131303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor GSK2879552","n_c":["C113646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor IMG-7289","n_c":["C131827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor RO7051790","n_c":["C131908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lucanthone","n_c":["C83925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lucatumumab","n_c":["C48405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lucitanib","n_c":["C95726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luminespib","n_c":["C71467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luminespib Mesylate","n_c":["C162567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung-targeted Immunomodulator QBKPN","n_c":["C118623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lurbinectedin","n_c":["C82382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lurtotecan","n_c":["C1610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lurtotecan Liposome","n_c":["C1876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","n_c":["C142176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 DOTA-biotin","n_c":["C113801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 DOTA-N3-CTT1403","n_c":["C158044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 DOTA-Tetulomab","n_c":["C105403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Dotatate","n_c":["C95020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Lilotomab-satetraxetan","n_c":["C162565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Monoclonal Antibody CC49","n_c":["C2598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Monoclonal Antibody J591","n_c":["C38701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 PP-F11N","n_c":["C114499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177 Satoreotide Tetraxetan","n_c":["C124929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-DOTA-EB-TATE","n_c":["C154549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-Edotreotide","n_c":["C88277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-NeoB","n_c":["C158734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-PSMA-617","n_c":["C148145"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 Capromab","n_c":["C67039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 Girentuximab","n_c":["C66978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 PSMA-R2","n_c":["C150467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu-177 Rituximab","n_c":["C162563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1","n_c":["C78832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lyophilized Black Raspberry Lozenge","n_c":["C99163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lyophilized Black Raspberry Saliva Substitute","n_c":["C99164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lysine-specific Demethylase 1 Inhibitor INCB059872","n_c":["C126421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lyso-Thermosensitive Liposome Doxorubicin","n_c":["C61571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macimorelin","n_c":["C95123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macitentan","n_c":["C87728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maekmoondong-tang","n_c":["C154567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mafosfamide","n_c":["C1150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-10.A2","n_c":["C2681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A3 Multipeptide Vaccine GL-0817","n_c":["C166968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A3 Peptide Vaccine","n_c":["C91710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A3-specific Immunotherapeutic GSK 2132231A","n_c":["C123649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201","n_c":["C114978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Magnesium Valproate","n_c":["C71156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MALT1 Inhibitor JNJ-67856633","n_c":["C160147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mannosulfan","n_c":["C83904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mannosylerythritol Lipid","n_c":["C1990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mapatumumab","n_c":["C61502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7","n_c":["C157776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marcellomycin","n_c":["C1152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MARCKS Protein Inhibitor BIO-11006","n_c":["C156733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Margetuximab","n_c":["C91733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marimastat","n_c":["C1652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marizomib","n_c":["C64634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masitinib Mesylate","n_c":["C79831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masoprocol","n_c":["C701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAT2A Inhibitor AG-270","n_c":["C153180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Matrix Metalloproteinase Inhibitor MMI270","n_c":["C2045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Matuzumab","n_c":["C2012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mavelertinib","n_c":["C120307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mavorixafor","n_c":["C126660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maytansine","n_c":["C626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MCL-1 Inhibitor AMG 176","n_c":["C127817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MCL-1 inhibitor AMG 397","n_c":["C156740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mcl-1 Inhibitor AZD5991","n_c":["C137989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mcl-1 Inhibitor MIK665","n_c":["C133174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Antagonist ASTX295","n_c":["C162749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Antagonist RO5045337","n_c":["C91724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Antagonist RO6839921","n_c":["C114980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor AMG-232","n_c":["C116624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor BI 907828","n_c":["C156709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor KRT-232","n_c":["C116624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2/MDMX Inhibitor ALRN-6924","n_c":["C118669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDR Modulator CBT-1","n_c":["C67042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mechlorethamine","n_c":["C62056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mechlorethamine Hydrochloride","n_c":["C627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mechlorethamine Hydrochloride Gel","n_c":["C119736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medorubicin","n_c":["C87599"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medroxyprogesterone","n_c":["C629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medroxyprogesterone Acetate","n_c":["C1155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Megestrol Acetate","n_c":["C1156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK 1/2 Inhibitor AS703988/MSC2015103B","n_c":["C98832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor AZD8330","n_c":["C69143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor CI-1040","n_c":["C2670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK inhibitor CS3006","n_c":["C155971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor GDC-0623","n_c":["C95738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor PD0325901","n_c":["C52195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor RO4987655","n_c":["C82696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor SHR 7390","n_c":["C150680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor TAK-733","n_c":["C84858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor WX-554","n_c":["C101532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK-1/MEKK-1 Inhibitor E6201","n_c":["C79848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK/Aurora Kinase Inhibitor BI 847325","n_c":["C106126"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melanoma Monoclonal Antibody hIgG2A","n_c":["C29178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melanoma TRP2 CTL Epitope Vaccine SCIB1","n_c":["C91380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melapuldencel-T","n_c":["C120183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MELK Inhibitor OTS167","n_c":["C111569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan","n_c":["C633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan Flufenamide","n_c":["C107680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan Hydrochloride","n_c":["C48002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex","n_c":["C84878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Membrane-Disrupting Peptide EP-100","n_c":["C84860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menatetrenone","n_c":["C52194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menogaril","n_c":["C1389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Merbarone","n_c":["C1390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mercaptopurine","n_c":["C195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mercaptopurine Anhydrous","n_c":["C61832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mercaptopurine Oral Suspension","n_c":["C111757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Merestinib","n_c":["C95729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesna","n_c":["C192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536","n_c":["C162935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Kinase Inhibitor OMO-1","n_c":["C148537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor BMS-777607","n_c":["C74060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor EMD 1204831","n_c":["C91097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor PF-04217903","n_c":["C78483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor SAR125844","n_c":["C97511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET Tyrosine Kinase Inhibitor SGX523","n_c":["C74062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metamelfalan","n_c":["C83946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MetAP2 Inhibitor APL-1202","n_c":["C162480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MetAP2 Inhibitor SDX-7320","n_c":["C128030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metatinib Tromethamine","n_c":["C113294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metformin","n_c":["C61612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metformin Hydrochloride","n_c":["C29251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methanol Extraction Residue of BCG","n_c":["C1159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methazolamide","n_c":["C61318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methionine Aminopeptidase 2 Inhibitor M8891","n_c":["C142831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methionine Aminopeptidase 2 Inhibitor PPI-2458","n_c":["C38129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate","n_c":["C642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate Sodium","n_c":["C1735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate-E Therapeutic Implant","n_c":["C17876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","n_c":["C125656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxsalen","n_c":["C643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxyamine","n_c":["C78084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methoxyamine Hydrochloride","n_c":["C78085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methyl-5-Aminolevulinate Hydrochloride Cream","n_c":["C2647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylmercaptopurine Riboside","n_c":["C2352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylprednisolone","n_c":["C647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylprednisolone Acetate","n_c":["C48003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylprednisolone Sodium Succinate","n_c":["C48004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylselenocysteine","n_c":["C63678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methyltestosterone","n_c":["C648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metoprine","n_c":["C1161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mibefradil","n_c":["C87686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mibefradil Dihydrochloride","n_c":["C87687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micellar Nanoparticle-encapsulated Epirubicin","n_c":["C139003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Micro Needle Array-Doxorubicin","n_c":["C156665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300","n_c":["C64631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microtubule Inhibitor SCB01A","n_c":["C143158"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Midostaurin","n_c":["C1872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mifamurtide","n_c":["C1394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mifepristone","n_c":["C655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milademetan Tosylate","n_c":["C107384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milatuzumab","n_c":["C66983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110","n_c":["C91086"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milciclib Maleate","n_c":["C88312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milk Thistle","n_c":["C29261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miltefosine","n_c":["C1170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Minretumomab","n_c":["C2567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mipsagargin","n_c":["C90554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirabegron","n_c":["C90633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirvetuximab Soravtansine","n_c":["C102566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Misonidazole","n_c":["C657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitindomide","n_c":["C29195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitobronitol","n_c":["C659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101","n_c":["C111758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoclomine","n_c":["C66164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoflaxone","n_c":["C1101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoguazone","n_c":["C661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoguazone Dihydrochloride","n_c":["C91409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitolactol","n_c":["C662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin","n_c":["C1820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin A","n_c":["C1164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin B","n_c":["C1392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitomycin C Analog KW-2149","n_c":["C1140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitosis Inhibitor T 1101 Tosylate","n_c":["C151933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotane","n_c":["C664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotenamine","n_c":["C66167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoxantrone","n_c":["C62050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitoxantrone Hydrochloride","n_c":["C665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitozolomide","n_c":["C1166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivavotinib","n_c":["C113162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivebresib","n_c":["C121829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivobulin","n_c":["C87698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mivobulin Isethionate","n_c":["C1357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Bacteria Vaccine","n_c":["C74063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MK0731","n_c":["C49174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKC-1","n_c":["C2507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MKNK1 Inhibitor BAY 1143269","n_c":["C121956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MMP Inhibitor S-3304","n_c":["C2671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MNK1/2 Inhibitor ETC-1907206","n_c":["C153262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mocetinostat","n_c":["C62521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Vitamin D Binding Protein Macrophage Activator EF-022","n_c":["C131824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modotuximab","n_c":["C152075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MOF Compound RiMO-301","n_c":["C148280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mofarotene","n_c":["C63667"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mogamulizumab","n_c":["C62510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Molibresib","n_c":["C101538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Molibresib Besylate","n_c":["C159943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Momelotinib","n_c":["C88311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monalizumab","n_c":["C120208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monocarboxylate Transporter 1 Inhibitor AZD3965","n_c":["C105399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine","n_c":["C2648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 11D10","n_c":["C2446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine","n_c":["C2606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 14G2A","n_c":["C2368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 1F5","n_c":["C29198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 3622W94","n_c":["C2470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 3F8","n_c":["C2370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine","n_c":["C2424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine","n_c":["C2227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 7C11","n_c":["C2739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody 81C6","n_c":["C1958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine","n_c":["C2436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody A27.15","n_c":["C2447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody A33","n_c":["C2410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody AbGn-7","n_c":["C99162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody AK002","n_c":["C129591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody ASP1948","n_c":["C156402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody CAL","n_c":["C2659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody CC49-delta CH2","n_c":["C2698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody CEP-37250/KHK2804","n_c":["C98296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody D6.12","n_c":["C2683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody E2.3","n_c":["C2448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody F19","n_c":["C2514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine","n_c":["C26450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HeFi-1","n_c":["C2505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody Hu3S193","n_c":["C2547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HuAFP31","n_c":["C48407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HuHMFG1","n_c":["C38697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody huJ591","n_c":["C2652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody HuPAM4","n_c":["C48408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody IMMU-14","n_c":["C29224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody L6","n_c":["C2372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody Lym-1","n_c":["C1561"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody m170","n_c":["C1959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody Me1-14 F(ab')2","n_c":["C2409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody muJ591","n_c":["C2476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody MX35 F(ab')2","n_c":["C2417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody NEO-201","n_c":["C156398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody R24","n_c":["C2349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody RAV12","n_c":["C48409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody SGN-14","n_c":["C2005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Antibody TRK-950","n_c":["C142826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal Microbial EDP1503","n_c":["C155907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100","n_c":["C94208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monomethyl Auristatin E","n_c":["C122637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morinda Citrifolia Fruit Extract","n_c":["C26662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morpholinodoxorubicin","n_c":["C1442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mosedipimod","n_c":["C123775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mosunetuzumab","n_c":["C129691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motesanib","n_c":["C71896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motesanib Diphosphate","n_c":["C48374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motexafin Gadolinium","n_c":["C1881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motexafin Lutetium","n_c":["C1651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motolimod","n_c":["C80521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MOv-gamma Chimeric Receptor Gene","n_c":["C2638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moxetumomab Pasudotox","n_c":["C68819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mps1 Inhibitor BAY 1217389","n_c":["C122707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mps1 Inhibitor BOS172722","n_c":["C155895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based Personalized Cancer Vaccine mRNA-4157","n_c":["C146813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based Personalized Cancer Vaccine NCI-4650","n_c":["C148239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based TriMix Melanoma Vaccine ECI-006","n_c":["C154274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902","n_c":["C156926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-derived KRAS-targeted Vaccine V941","n_c":["C162186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-derived Lung Cancer Vaccine BI 1361849","n_c":["C111574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-Derived Prostate Cancer Vaccine CV9103","n_c":["C82654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mRNA-derived Prostate Cancer Vaccine CV9104","n_c":["C106231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MTF-1 Inhibitor APTO-253 HCl","n_c":["C95724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Inhibitor GDC-0349","n_c":["C133227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor AZD8055","n_c":["C78856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor CC-223","n_c":["C92575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor OSI-027","n_c":["C78476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR Kinase Inhibitor PP242","n_c":["C128632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTOR1/2 Kinase Inhibitor ME-344","n_c":["C101132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTORC 1/2 Inhibitor LXI-15029","n_c":["C148528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTORC1/2 Kinase Inhibitor BI 860585","n_c":["C122836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mTORC1/mTORC2/DHFR Inhibitor ABTL0812","n_c":["C117290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC1-targeted Peptide GO-203-2C","n_c":["C95722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mucoadhesive Paclitaxel Formulation","n_c":["C107188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-AGC Kinase Inhibitor AT13148","n_c":["C101786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200","n_c":["C128898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-epitope HER2 Peptide Vaccine H2NVAC","n_c":["C165292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","n_c":["C124054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-kinase Inhibitor TPX-0022","n_c":["C162676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-kinase Inhibitor XL092","n_c":["C161598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-mode Kinase Inhibitor EOC317","n_c":["C164211"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-neo-epitope Vaccine OSE 2101","n_c":["C26645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multifunctional/Multitargeted Anticancer Agent OMN54","n_c":["C101260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor 4SC-203","n_c":["C90553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor AEE788","n_c":["C48369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor AT9283","n_c":["C66947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multikinase Inhibitor SAR103168","n_c":["C88278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multipeptide Vaccine S-588210","n_c":["C125692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327","n_c":["C77866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muparfostat","n_c":["C38690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mureletecan","n_c":["C2234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutant IDH1 Inhibitor DS-1001","n_c":["C148134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutant p53 Activator COTI-2","n_c":["C121951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mutant-selective EGFR Inhibitor PF-06459988","n_c":["C119624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","n_c":["C162806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVA-FCU1 TG4023","n_c":["C88279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1","n_c":["C123382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MYC-targeting siRNA DCR-MYC","n_c":["C115108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium tuberculosis Arabinomannan Z-100","n_c":["C118445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium w","n_c":["C70969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycophenolic Acid","n_c":["C673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea","n_c":["C44168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N-Methylformamide","n_c":["C1163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N,N-Dibenzyl Daunomycin","n_c":["C2084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NA17-A Antigen","n_c":["C37450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NA17.A2 Peptide Vaccine","n_c":["C2680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nab-paclitaxel","n_c":["C2688"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","n_c":["C131213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nadofaragene Firadenovec","n_c":["C71011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namirotene","n_c":["C83981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namodenoson","n_c":["C79826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NAMPT Inhibitor OT-82","n_c":["C162742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanafrocin","n_c":["C72594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanatinostat","n_c":["C78475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanocell-encapsulated miR-16-based microRNA Mimic","n_c":["C121214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Albumin-Bound Docetaxel","n_c":["C71696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Albumin-Bound Rapamycin","n_c":["C74065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404","n_c":["C116890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle Paclitaxel Ointment SOR007","n_c":["C146821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle-based Paclitaxel Suspension","n_c":["C118648"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoparticle-encapsulated Doxorubicin Hydrochloride","n_c":["C102875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanoscale Coordination Polymer Nanoparticles CPI-100","n_c":["C157499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nanosomal Docetaxel Lipid Suspension","n_c":["C111570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Napabucasin","n_c":["C96429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naphthalimide Analogue UNBS5162","n_c":["C102850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naptumomab Estafenatox","n_c":["C95789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naquotinib","n_c":["C115110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Narnatumab","n_c":["C91382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natalizumab","n_c":["C77862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural IFN-alpha OPC-18","n_c":["C71159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Natural Killer Cells ZRx101","n_c":["C85466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navarixin","n_c":["C156730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navitoclax","n_c":["C64776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navoximod","n_c":["C113793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navy Bean Powder","n_c":["C111687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naxitamab","n_c":["C123428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nazartinib","n_c":["C115109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ncmtRNA Oligonucleotide Andes-1537","n_c":["C123825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Necitumumab","n_c":["C88281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nedaplatin","n_c":["C61099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464","n_c":["C136418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nedisertib","n_c":["C120036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nelarabine","n_c":["C1704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nelipepimut-S","n_c":["C117985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nelipepimut-S Plus GM-CSF Vaccine","n_c":["C99228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nemorubicin","n_c":["C83999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nemorubicin Hydrochloride","n_c":["C84000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen Vaccine GEN-009","n_c":["C162874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Glioblastoma Vaccine","n_c":["C118960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Melanoma-Poly-ICLC Vaccine","n_c":["C112003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine","n_c":["C158694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903","n_c":["C165514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904","n_c":["C165515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017","n_c":["C135018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neratinib","n_c":["C49094"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neratinib Maleate","n_c":["C136891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nesvacumab","n_c":["C95712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NG-nitro-L-arginine","n_c":["C96232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niacinamide","n_c":["C2327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niclosamide","n_c":["C66240"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nicotinamide Riboside","n_c":["C158078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nidanilimab","n_c":["C153375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nifurtimox","n_c":["C71734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilotinib","n_c":["C48375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilotinib Hydrochloride Anhydrous","n_c":["C95223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilotinib Hydrochloride Monohydrate","n_c":["C95229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nilutamide","n_c":["C1173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimesulide-Hyaluronic Acid Conjugate CA102N","n_c":["C157231"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimodipine","n_c":["C692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimotuzumab","n_c":["C2733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimustine","n_c":["C693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nimustine Hydrochloride","n_c":["C95325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ningetinib Tosylate","n_c":["C148529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nintedanib","n_c":["C62765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niraparib","n_c":["C80059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niraparib Tosylate Monohydrate","n_c":["C133238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nirogacestat","n_c":["C82383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative","n_c":["C61499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nitrogen Mustard Prodrug PR-104","n_c":["C61590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nitroglycerin Transdermal Patch","n_c":["C103272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nivolumab","n_c":["C68814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NLRP3 Agonist BMS-986299","n_c":["C155945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nocodazole","n_c":["C75228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nogalamycin","n_c":["C700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nolatrexed Dihydrochloride","n_c":["C1577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201","n_c":["C84872"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norgestrel","n_c":["C703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North American Ginseng Extract AFX-2","n_c":["C99122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nortopixantrone","n_c":["C81423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Noscapine","n_c":["C80589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Noscapine Hydrochloride","n_c":["C61103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Otherwise Specified","n_c":["C19594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Notch Signaling Inhibitor PF-06650808","n_c":["C118569"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Notch Signaling Pathway Inhibitor MK0752","n_c":["C49175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NTRK/ROS1 Inhibitor DS-6051b","n_c":["C118948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleolin Antagonist IPP-204106N","n_c":["C103297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleoside Analog DFP-10917","n_c":["C116744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleotide Analog Prodrug NUC-3373","n_c":["C156680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nucleotide Analogue GS 9219","n_c":["C71742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nutlin-3a","n_c":["C74594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nutraceutical TBL-12","n_c":["C96036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611","n_c":["C62452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301","n_c":["C120557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-1/GLA-SE Vaccine ID-G305","n_c":["C113432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NY-ESO-B","n_c":["C26680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"O-Chloroacetylcarbamoylfumagillol","n_c":["C1298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"O6-Benzylguanine","n_c":["C1306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obatoclax Mesylate","n_c":["C62771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obinutuzumab","n_c":["C70741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oblimersen Sodium","n_c":["C66722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocaratuzumab","n_c":["C2524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocrelizumab","n_c":["C66250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Octreotide","n_c":["C711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Octreotide Acetate","n_c":["C53447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Octreotide Pamoate","n_c":["C2402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ofatumumab","n_c":["C66952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oglufanide Disodium","n_c":["C2558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olaparib","n_c":["C71721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olaptesed Pegol","n_c":["C99379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olaratumab","n_c":["C79825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oleandrin","n_c":["C90586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oleclumab","n_c":["C123914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oligonucleotide SPC2996","n_c":["C61325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olivomycin","n_c":["C715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olmutinib","n_c":["C101791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oltipraz","n_c":["C1177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olutasidenib","n_c":["C129687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omacetaxine Mepesuccinate","n_c":["C1127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ombrabulin","n_c":["C78480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omipalisib","n_c":["C88270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onalespib","n_c":["C85454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onalespib Lactate","n_c":["C129425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onartuzumab","n_c":["C82348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Adenovirus Ad5-DNX-2401","n_c":["C74067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 C134","n_c":["C162635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 G207","n_c":["C2676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 NV1020","n_c":["C2623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 rQNestin34.5v.2","n_c":["C139551"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 rRp450","n_c":["C90563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV1716","n_c":["C84840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Newcastle Disease Virus MEDI5395","n_c":["C165457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Newcastle Disease Virus MTH-68H","n_c":["C91700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Newcastle Disease Virus Strain PV701","n_c":["C2799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Virus ASP9801","n_c":["C161021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Virus RP1","n_c":["C158074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ondansetron Hydrochloride","n_c":["C48007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ontuxizumab","n_c":["C82406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onvansertib","n_c":["C143162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opaganib","n_c":["C98278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","n_c":["C90545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opioid Growth Factor","n_c":["C48413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oportuzumab Monatox","n_c":["C61307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oprozomib","n_c":["C91388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Aminolevulinic Acid Hydrochloride","n_c":["C99763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Azacitidine","n_c":["C118288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cancer Vaccine V3-OVA","n_c":["C159540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Docetaxel","n_c":["C131903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Fludarabine Phosphate","n_c":["C64338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hsp90 Inhibitor IPI-493","n_c":["C78843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Ixabepilone","n_c":["C63478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Microencapsulated Diindolylmethane","n_c":["C71132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Milataxel","n_c":["C77880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Myoma Vaccine V3-myoma","n_c":["C158745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Pancreatic Cancer Vaccine V3-P","n_c":["C150400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Picoplatin","n_c":["C68924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Sodium Phenylbutyrate","n_c":["C67083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Topotecan Hydrochloride","n_c":["C63477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orantinib","n_c":["C1884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oraxol","n_c":["C112000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oregovomab","n_c":["C1784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ormaplatin","n_c":["C1250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ortataxel","n_c":["C1867"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orteronel","n_c":["C90582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osilodrostat","n_c":["C131535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osimertinib","n_c":["C116377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Otlertuzumab","n_c":["C74006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovapuldencel-T","n_c":["C113651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006","n_c":["C96739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovine Submaxillary Mucin","n_c":["C2350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OX40L-expressing Oncolytic Adenovirus DNX-2440","n_c":["C160192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxaliplatin","n_c":["C1181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome","n_c":["C91074"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxcarbazepine","n_c":["C47643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxeclosporin","n_c":["C132271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxidative Phosphorylation Inhibitor IACS-010759","n_c":["C130012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxidative Phosphorylation Inhibitor IM156","n_c":["C153372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxidopamine","n_c":["C1316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"OxPhos Inhibitor VLX600","n_c":["C118283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ozarelix","n_c":["C95214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-cadherin Antagonist PF-03732010","n_c":["C91723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-cadherin Inhibitor PCA062","n_c":["C121216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-cadherin-targeting Agent PF-06671008","n_c":["C125607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-p68 Inhibitor RX-5902","n_c":["C113293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"P-TEFb Inhibitor BAY1143572","n_c":["C121456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p300/CBP Bromodomain Inhibitor CCS1477","n_c":["C160195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p38 MAPK Inhibitor LY3007113","n_c":["C99134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53 Peptide Vaccine MPS-128","n_c":["C1986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53-HDM2 Interaction Inhibitor MI-773","n_c":["C106120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53-HDM2 Protein-protein Interaction Inhibitor APG-115","n_c":["C132991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p53/HDM2 Interaction Inhibitor CGM097","n_c":["C104280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p70S6K Inhibitor LY2584702","n_c":["C91393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p70S6K/Akt Inhibitor MSC2363318A","n_c":["C112004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p97 Inhibitor CB-5083","n_c":["C118287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel","n_c":["C1411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Ceribate","n_c":["C96934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Injection Concentrate for Nanodispersion","n_c":["C96037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Liposome","n_c":["C2631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Poliglumex","n_c":["C1795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Polymeric Micelle Formulation NANT-008","n_c":["C148531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel PPE Microspheres","n_c":["C2785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Trevatide","n_c":["C99461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel Vitamin E-Based Emulsion","n_c":["C61079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paclitaxel-Loaded Polymeric Micelle","n_c":["C48415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pacritinib","n_c":["C78837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Padeliporfin","n_c":["C78481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Padoporfin","n_c":["C61321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAK4 Inhibitor PF-03758309","n_c":["C84841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PAK4/NAMPT Inhibitor KPT-9274","n_c":["C126646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palbociclib","n_c":["C49176"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palbociclib Isethionate","n_c":["C120259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palifosfamide","n_c":["C66990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palifosfamide Tromethamine","n_c":["C95703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palladium Pd-103","n_c":["C2550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palonosetron Hydrochloride","n_c":["C47650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamidronate Disodium","n_c":["C1345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamidronic Acid","n_c":["C61875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamiparib","n_c":["C120553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan FGFR Inhibitor PRN1371","n_c":["C124931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514","n_c":["C68832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-AKT Inhibitor ARQ751","n_c":["C128250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-AKT Kinase Inhibitor GSK690693","n_c":["C71711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-FGFR Inhibitor LY2874455","n_c":["C139004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806","n_c":["C162573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-HER Kinase Inhibitor AC480","n_c":["C48380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-IDH Mutant Inhibitor AG-881","n_c":["C152914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-Mutant-IDH1 Inhibitor Bay-1436032","n_c":["C131690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PI3K Inhibitor CLR457","n_c":["C117230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PI3K/mTOR Inhibitor SF1126","n_c":["C85469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-PIM Inhibitor INCB053914","n_c":["C124226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PIM Kinase Inhibitor AZD1208","n_c":["C99380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-PIM Kinase Inhibitor NVP-LGB-321","n_c":["C128615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-RAF Inhibitor LXH254","n_c":["C125003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-RAF Inhibitor LY3009120","n_c":["C116861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-RAF Kinase Inhibitor CCT3833","n_c":["C121952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pan-RAF Kinase Inhibitor TAK-580","n_c":["C106254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550","n_c":["C2062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-TRK Inhibitor ONO-7579","n_c":["C140379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981","n_c":["C82379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancratistatin","n_c":["C1184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panitumumab","n_c":["C1857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panobinostat","n_c":["C66948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panobinostat Nanoparticle Formulation MTX110","n_c":["C150717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paricalcitol","n_c":["C38693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP 1/2 Inhibitor NOV1401","n_c":["C154560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor AZD2461","n_c":["C95201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor CEP-9722","n_c":["C84880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor E7016","n_c":["C91387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP-1/2 Inhibitor ABT-767","n_c":["C96795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP/Tankyrase Inhibitor 2X-121","n_c":["C102746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parsatuzumab","n_c":["C90567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parvovirus H-1","n_c":["C96229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pasireotide","n_c":["C69131"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pasotuxizumab","n_c":["C103827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patidegib","n_c":["C80063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patidegib Topical Gel","n_c":["C158420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patritumab","n_c":["C78853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patupilone","n_c":["C1623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pazopanib","n_c":["C74547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pazopanib Hydrochloride","n_c":["C60779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pbi-shRNA STMN1 Lipoplex","n_c":["C99639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PBN Derivative OKN-007","n_c":["C77600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PCNU","n_c":["C1186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-1 Directed Probody CX-188","n_c":["C160716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-1 Inhibitor","n_c":["C124946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1 Inhibitor INCB086550","n_c":["C158532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1/PD-L2/VISTA Antagonist CA-170","n_c":["C129594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDK1 Inhibitor AR-12","n_c":["C88271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0","n_c":["C157262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1","n_c":["C126276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEG-interleukin-2","n_c":["C1304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1","n_c":["C49178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEG-Proline-Interferon Alfa-2b","n_c":["C111892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegargiminase","n_c":["C91702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegaspargase","n_c":["C1200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegdinetanib","n_c":["C62791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegfilgrastim","n_c":["C1854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegilodecakin","n_c":["C113295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peginterferon Alfa-2a","n_c":["C33987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peginterferon Alfa-2b","n_c":["C1845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegvisomant","n_c":["C61881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Deoxycytidine Analogue DFP-14927","n_c":["C162508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Interferon Alfa","n_c":["C2491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Belotecan","n_c":["C61437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Doxorubicin Hydrochloride","n_c":["C1555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Irinotecan","n_c":["C62789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug","n_c":["C103276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Mitoxantrone Hydrochloride","n_c":["C131307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010","n_c":["C116869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Paclitaxel","n_c":["C63476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant Human Arginase I BCT-100","n_c":["C88286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant Human Hyaluronidase PH20","n_c":["C82659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant Interleukin-2 THOR-707","n_c":["C162645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated Recombinant L-asparaginase Erwinia chrysanthemi","n_c":["C170297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegzilarginase","n_c":["C125143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelareorep","n_c":["C60774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peldesine","n_c":["C1650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelitinib","n_c":["C2713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelitrexol","n_c":["C2633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pembrolizumab","n_c":["C106432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemetrexed","n_c":["C61614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemetrexed Disodium","n_c":["C1533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemigatinib","n_c":["C121553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pemlimogene Merolisbac","n_c":["C124843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penberol","n_c":["C1187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penclomedine","n_c":["C1188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penicillamine","n_c":["C729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentamethylmelamine","n_c":["C1189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentamustine","n_c":["C66341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentostatin","n_c":["C732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pentoxifylline","n_c":["C733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEOX-based Polymer Encapsulated Paclitaxel FID-007","n_c":["C148635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PEP-3-KLH Conjugate Vaccine","n_c":["C74070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pepinemab","n_c":["C96222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peplomycin","n_c":["C1399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peplomycin Sulfate","n_c":["C1400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptichemio","n_c":["C734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptide 946 Melanoma Vaccine","n_c":["C2466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine","n_c":["C2467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peretinoin","n_c":["C87202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perflenapent Emulsion","n_c":["C116804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perfosfamide","n_c":["C1423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perifosine","n_c":["C1727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perillyl Alcohol","n_c":["C1461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine","n_c":["C159601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Cancer Vaccine RO7198457","n_c":["C175745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01","n_c":["C162633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoepitope Yeast Vaccine YE-NEO-001","n_c":["C158749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Peptide Cancer Vaccine NEO-PV-01","n_c":["C129935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pertuzumab","n_c":["C38692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pevonedistat","n_c":["C77906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pexastimogene Devacirepvec","n_c":["C71533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pexidartinib","n_c":["C88303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pexmetinib","n_c":["C85481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGG Beta-Glucan","n_c":["C78463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PGLA/PEG Copolymer-Based Paclitaxel","n_c":["C71692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PH20 Hyaluronidase-expressing Adenovirus VCN-01","n_c":["C113790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phaleria macrocarpa Extract DLBS-1425","n_c":["C91739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharmacological Ascorbate","n_c":["C156461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phellodendron amurense Bark Extract","n_c":["C103230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenesterin","n_c":["C1190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenethyl Isothiocyanate","n_c":["C2233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenethyl Isothiocyanate-containing Watercress Juice","n_c":["C105392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenyl Acetate","n_c":["C1501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phenytoin Sodium","n_c":["C48011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphaplatin PT-112","n_c":["C121375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphatidylcholine-Bound Silybin","n_c":["C71883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phospholipid Ether-drug Conjugate CLR 131","n_c":["C84879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphoramide Mustard","n_c":["C29322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphorodiamidate Morpholino Oligomer AVI-4126","n_c":["C62518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phosphorus P-32","n_c":["C1698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photosensitizer LUZ 11","n_c":["C114382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex","n_c":["C126802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Alpha/Beta Inhibitor BAY1082439","n_c":["C103861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate","n_c":["C97915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor ACP-319","n_c":["C95891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor BGT226","n_c":["C74073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor GDC-0084","n_c":["C116877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor GDC0077","n_c":["C132166"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor GSK1059615","n_c":["C78470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor WX-037","n_c":["C107386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K Inhibitor ZSTK474","n_c":["C95723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K p110beta/delta Inhibitor KA2237","n_c":["C126271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-alpha Inhibitor MEN1611","n_c":["C158603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-beta Inhibitor GSK2636771","n_c":["C106261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-beta Inhibitor SAR260301","n_c":["C116882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor AMG 319","n_c":["C95891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor HMPL 689","n_c":["C148532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor INCB050465","n_c":["C113434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor PWT143","n_c":["C123925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor SHC014748M","n_c":["C165266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-delta Inhibitor YY-20394","n_c":["C158508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K-gamma Inhibitor IPI-549","n_c":["C125471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/BET Inhibitor LY294002","n_c":["C148229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor DS-7423","n_c":["C97254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor PF-04691502","n_c":["C84837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor VS-5584","n_c":["C112497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR Kinase Inhibitor WXFL10030390","n_c":["C159499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170","n_c":["C104292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901","n_c":["C116351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Ka/mTOR Inhibitor PKI-179","n_c":["C90291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Kalpha Inhibitor AZD8835","n_c":["C118624"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Kbeta Inhibitor AZD8186","n_c":["C107684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PI3Kdelta Inhibitor GS-9901","n_c":["C121374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pibenzimol","n_c":["C546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pibrozelesin","n_c":["C1542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pibrozelesin Hydrobromide","n_c":["C73816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picibanil","n_c":["C745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picoplatin","n_c":["C48416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picrasinoside H","n_c":["C1771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Picropodophyllin","n_c":["C87736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pictilisib","n_c":["C165479"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pictilisib Bismesylate","n_c":["C82380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pidilizumab","n_c":["C71014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pilaralisib","n_c":["C71705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM Kinase Inhibitor LGH447","n_c":["C106259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM Kinase Inhibitor SGI-1776","n_c":["C82404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM Kinase Inhibitor TP-3654","n_c":["C160203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PIM/FLT3 Kinase Inhibitor SEL24","n_c":["C133540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pimasertib","n_c":["C84864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pingyangmycin","n_c":["C1279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pinometostat","n_c":["C103179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pioglitazone","n_c":["C71633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pioglitazone Hydrochloride","n_c":["C29367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pipendoxifene","n_c":["C1874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piperazinedione","n_c":["C1401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piperine Extract (Standardized)","n_c":["C48417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pipobroman","n_c":["C750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piposulfan","n_c":["C1783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirarubicin","n_c":["C1197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirarubicin Hydrochloride","n_c":["C95319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirfenidone","n_c":["C2635"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piritrexim","n_c":["C1031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piritrexim Isethionate","n_c":["C91407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pirotinib","n_c":["C121960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piroxantrone","n_c":["C1182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Piroxantrone Hydrochloride","n_c":["C72829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pixantrone","n_c":["C26663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pixantrone Dimaleate","n_c":["C82398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231","n_c":["C1810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521","n_c":["C1788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PKC-beta Inhibitor MS-553","n_c":["C148422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placebo","n_c":["C753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pladienolide Derivative E7107","n_c":["C69005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum","n_c":["C756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles","n_c":["C153425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum Compound","n_c":["C1450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plevitrexed","n_c":["C1629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plicamycin","n_c":["C658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plinabulin","n_c":["C62444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plitidepsin","n_c":["C1689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plk1 Inhibitor BI 2536","n_c":["C49091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLK1 Inhibitor CYC140","n_c":["C162375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PLK1 Inhibitor TAK-960","n_c":["C92587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plocabulin","n_c":["C95888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plozalizumab","n_c":["C88308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pol I Inhibitor CX5461","n_c":["C126798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polatuzumab Vedotin","n_c":["C104153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polidocanol","n_c":["C158511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poliglusam","n_c":["C157372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 1 Inhibitor GSK461364","n_c":["C70948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 1 Inhibitor MK1496","n_c":["C82389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 1 Inhibitor NMS-1286937","n_c":["C143162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate","n_c":["C111990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poly-alendronate Dextran-Guanidine Conjugate","n_c":["C101894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poly-gamma Glutamic Acid","n_c":["C106124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Analog SL11093","n_c":["C38130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Analogue PG11047","n_c":["C60816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Analogue SBP-101","n_c":["C142788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate","n_c":["C148487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyandrol","n_c":["C1628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyethylene Glycol Recombinant Endostatin","n_c":["C92583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318","n_c":["C125243"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polymer-encapsulated Luteolin Nanoparticle","n_c":["C150508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polymeric Camptothecin Prodrug XMT-1001","n_c":["C69079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polypodium leucotomos Extract","n_c":["C129595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polysaccharide-K","n_c":["C1204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polysialic Acid","n_c":["C1201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyunsaturated Fatty Acid","n_c":["C67038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polyvalent Melanoma Vaccine","n_c":["C1633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pomalidomide","n_c":["C72560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pomegranate Juice","n_c":["C26665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pomegranate Liquid Extract","n_c":["C78866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ponatinib","n_c":["C95777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ponatinib Hydrochloride","n_c":["C78194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor CGX1321","n_c":["C146853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor ETC-1922159","n_c":["C123830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor RXC004","n_c":["C156701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor WNT974","n_c":["C116860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porfimer Sodium","n_c":["C1071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porfiromycin","n_c":["C763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poziotinib","n_c":["C98838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PR1 Leukemia Peptide Vaccine","n_c":["C2235"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pracinostat","n_c":["C71708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pralatrexate","n_c":["C2250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701","n_c":["C128029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pravastatin Sodium","n_c":["C29375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednimustine","n_c":["C768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisolone","n_c":["C769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisolone Acetate","n_c":["C1202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisolone Sodium Phosphate","n_c":["C1402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisone","n_c":["C770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prexasertib","n_c":["C91392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prexigebersen","n_c":["C91736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRIMA-1 Analog APR-246","n_c":["C85465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prime Cancer Vaccine MVA-BN-CV301","n_c":["C143059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prinomastat","n_c":["C1811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRMT1 Inhibitor GSK3368715","n_c":["C156759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRMT5 Inhibitor JNJ-64619178","n_c":["C163980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proapoptotic Sulindac Analog CP-461","n_c":["C133019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Procarbazine","n_c":["C62072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Procarbazine Hydrochloride","n_c":["C773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Procaspase Activating Compound-1 VO-100","n_c":["C120318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progestational IUD","n_c":["C184790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prohibitin-Targeting Peptide 1","n_c":["C95709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostaglandin E2 EP4 Receptor Inhibitor E7046","n_c":["C129689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Cancer Vaccine ONY-P1","n_c":["C71723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Health Cocktail Dietary Supplement","n_c":["C77860"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024","n_c":["C2548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protease-activated Anti-PD-L1 Antibody Prodrug CX-072","n_c":["C132192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Arginine Methyltransferase 5 Inhibitor GSK3326595","n_c":["C142177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999","n_c":["C158100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Arginine Methyltransferase 5 Inhibitor PRT543","n_c":["C162454"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Kinase C Inhibitor IDE196","n_c":["C124796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Phosphatase 2A Inhibitor LB-100","n_c":["C106430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Stabilized Liposomal Docetaxel Nanoparticles","n_c":["C90534"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proxalutamide","n_c":["C130036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSA/IL-2/GM-CSF Vaccine","n_c":["C114289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSA/PSMA DNA Plasmid INO-5150","n_c":["C123283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pseudoisocytidine","n_c":["C87389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA-targeted Docetaxel Nanoparticles BIND-014","n_c":["C95892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA-targeted Tubulysin B-containing Conjugate EC1169","n_c":["C117291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424","n_c":["C156681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PTEF-b/CDK9 Inhibitor BAY1251152","n_c":["C128266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pterostilbene","n_c":["C153353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pumitepa","n_c":["C73239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puquitinib","n_c":["C162555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puquitinib Mesylate","n_c":["C162556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puromycin","n_c":["C787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puromycin Hydrochloride","n_c":["C75148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PV-10","n_c":["C53412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride","n_c":["C71149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrazinamide","n_c":["C29395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrazoloacridine","n_c":["C1564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyridyl Cyanoguanidine CHS 828","n_c":["C1852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrotinib","n_c":["C111895"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyrotinib Dimaleate","n_c":["C162554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyroxamide","n_c":["C2801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyruvate Kinase Inhibitor TLN-232","n_c":["C67087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Qilisheng Immunoregulatory Oral Solution","n_c":["C155882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","n_c":["C61087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quarfloxin","n_c":["C71726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quinacrine Hydrochloride","n_c":["C67059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quinine","n_c":["C794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quisinostat","n_c":["C77912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Quizartinib","n_c":["C68936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R-(-)-Gossypol Acetic Acid","n_c":["C78348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rabusertib","n_c":["C81937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Racotumomab","n_c":["C95024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAD51 Inhibitor CYT-0851","n_c":["C165436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radioactive Iodine","n_c":["C2462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiolabeled CC49","n_c":["C2729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radium Ra 223 Dichloride","n_c":["C62535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radium Ra 224-labeled Calcium Carbonate Microparticles","n_c":["C159537"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement","n_c":["C113297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radotinib Hydrochloride","n_c":["C99644"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raf Kinase Inhibitor HM95573","n_c":["C121646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF Kinase Inhibitor L-779450","n_c":["C2722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RAF Kinase Inhibitor XL281","n_c":["C69135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ralaniten Acetate","n_c":["C124654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ralimetinib Mesylate","n_c":["C105853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raloxifene","n_c":["C1518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raloxifene Hydrochloride","n_c":["C1762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raltitrexed","n_c":["C1804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ramucirumab","n_c":["C70792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranibizumab","n_c":["C67562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranimustine","n_c":["C1515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranolazine","n_c":["C66507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ranpirnase","n_c":["C1183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RARalpha Agonist IRX5183","n_c":["C77899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Inhibitor","n_c":["C1902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Peptide ASP","n_c":["C2802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Peptide CYS","n_c":["C2803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ras Peptide VAL","n_c":["C2804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Razoxane","n_c":["C801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Realgar-Indigo naturalis Formulation","n_c":["C117289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rebastinib Tosylate","n_c":["C82693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rebeccamycin","n_c":["C1213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rebimastat","n_c":["C1875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Receptor Tyrosine Kinase Inhibitor R1530","n_c":["C71710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Adenovirus-p53 SCH-58500","n_c":["C2423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A","n_c":["C116880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Bispecific Single-Chain Antibody rM28","n_c":["C60882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant CD40-Ligand","n_c":["C1437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Erythropoietin","n_c":["C477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Fas Ligand","n_c":["C1538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Fractalkine","n_c":["C2257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","n_c":["C1288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human 6Ckine","n_c":["C1792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Adenovirus Type 5 H101","n_c":["C107504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Angiotensin Converting Enzyme 2 APN01","n_c":["C85447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Apolipoprotein(a) Kringle V MG1102","n_c":["C116864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine","n_c":["C70674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Endostatin","n_c":["C45515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine","n_c":["C103830"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Papillomavirus Bivalent Vaccine","n_c":["C48395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Papillomavirus Nonavalent Vaccine","n_c":["C119664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828","n_c":["C162524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon","n_c":["C584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa","n_c":["C225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa-1b","n_c":["C53411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa-2a","n_c":["C1952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alfa-2b","n_c":["C1953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Alpha 2b-like Protein","n_c":["C97503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Beta","n_c":["C495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interferon Gamma","n_c":["C583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-12","n_c":["C1380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-13","n_c":["C1489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-18","n_c":["C1680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-2","n_c":["C587"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Interleukin-6","n_c":["C591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant KSA Glycoprotein CO17-1A","n_c":["C28721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Leukocyte Interleukin","n_c":["C2413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Leukoregulin","n_c":["C1143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Luteinizing Hormone","n_c":["C612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Macrophage Colony-Stimulating Factor","n_c":["C1290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant MAGE-3.1 Antigen","n_c":["C38724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant MIP1-alpha Variant ECI301","n_c":["C98294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine","n_c":["C49087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Oncolytic Poliovirus PVS-RIPO","n_c":["C184921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Platelet Factor 4","n_c":["C2251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A","n_c":["C92586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207","n_c":["C82371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Super-compound Interferon","n_c":["C121542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Thyroglobulin","n_c":["C884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Thyrotropin Alfa","n_c":["C61322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Transforming Growth Factor-Beta","n_c":["C898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Transforming Growth Factor-Beta-2","n_c":["C1286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Tumor Necrosis Factor-Alpha","n_c":["C913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Tyrosinase-Related Protein-2","n_c":["C38682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","n_c":["C131580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Refametinib","n_c":["C74059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regorafenib","n_c":["C78204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relacorilant","n_c":["C127838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relatlimab","n_c":["C111999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relugolix","n_c":["C114498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Remetinostat","n_c":["C97513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Cell Carcinoma Peptides Vaccine IMA901","n_c":["C70968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reparixin","n_c":["C66515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repotrectinib","n_c":["C133821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resiquimod","n_c":["C63958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resiquimod Topical Gel","n_c":["C88259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resistant Starch","n_c":["C94233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resminostat","n_c":["C84856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resveratrol","n_c":["C1215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resveratrol Formulation SRT501","n_c":["C85484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET Inhibitor DS-5010","n_c":["C158093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET Mutation/Fusion Inhibitor BLU-667","n_c":["C132295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retaspimycin","n_c":["C80378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retaspimycin Hydrochloride","n_c":["C48401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retelliptine","n_c":["C73241"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinoic Acid Agent Ro 16-9100","n_c":["C64174"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinoid 9cUAB30","n_c":["C80061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinol","n_c":["C68302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinyl Acetate","n_c":["C1216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retinyl Palmitate","n_c":["C1217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retrovector Encoding Mutant Anti-Cyclin G1","n_c":["C49082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rexinoid NRX 194204","n_c":["C74076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RFT5-dgA Immunotoxin IMTOX25","n_c":["C61498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re 188 BMEDA-labeled Liposomes","n_c":["C118670"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re-186 Hydroxyethylidene Diphosphonate","n_c":["C1562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re-188 Ethiodized Oil","n_c":["C91390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhenium Re-188 Etidronate","n_c":["C156698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rhizoxin","n_c":["C1218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RhoC Peptide Vaccine RV001V","n_c":["C151937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribociclib","n_c":["C95701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribociclib/Letrozole","n_c":["C154675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribonuclease QBI-139","n_c":["C82689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribosome-Inactivating Protein CY503","n_c":["C78188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ribozyme RPI.4610","n_c":["C1865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rice Bran","n_c":["C111686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ricolinostat","n_c":["C96431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ridaforolimus","n_c":["C49061"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rigosertib","n_c":["C152216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rigosertib Sodium","n_c":["C71355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilimogene Galvacirepvec","n_c":["C38681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","n_c":["C132990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilimogene Glafolivec","n_c":["C29560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rilotumumab","n_c":["C67079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rindopepimut","n_c":["C69076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RIPK1 Inhibitor GSK3145095","n_c":["C156737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ripretinib","n_c":["C124067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Risperidone Formulation in Rumenic Acid","n_c":["C131306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ritrosulfan","n_c":["C75294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rituximab","n_c":["C1702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rituximab and Hyaluronidase Human","n_c":["C136821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rituximab Conjugate CON-4619","n_c":["C148162"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Riviciclib","n_c":["C64762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rivoceranib","n_c":["C152237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rivoceranib Mesylate","n_c":["C74012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNR Inhibitor COH29","n_c":["C114976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Robatumumab","n_c":["C71527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rocapuldencel-T","n_c":["C77907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rociletinib","n_c":["C99905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rodorubicin","n_c":["C97275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rofecoxib","n_c":["C1832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roflumilast","n_c":["C76890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rogaratinib","n_c":["C112205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rogletimide","n_c":["C1427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Romidepsin","n_c":["C1544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roniciclib","n_c":["C92579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ropidoxuridine","n_c":["C48813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roquinimex","n_c":["C1519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RORgamma Agonist LYC-55716","n_c":["C131294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosabulin","n_c":["C77066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rose Bengal Solution PV-10","n_c":["C53412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosiglitazone Maleate","n_c":["C2583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosmantuzumab","n_c":["C122921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosuvastatin","n_c":["C66523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rovalpituzumab Tesirine","n_c":["C107678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubitecan","n_c":["C1485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rucaparib","n_c":["C137800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rucaparib Camsylate","n_c":["C131178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rucaparib Phosphate","n_c":["C78186"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruthenium Ru-106","n_c":["C38686"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruthenium-based Transferrin Targeting Agent NKP-1339","n_c":["C97948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruxolitinib","n_c":["C77888"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruxolitinib Phosphate","n_c":["C97937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S-Adenosylmethionine","n_c":["C63661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S-equol","n_c":["C120313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"S1P Receptor Agonist KRP203","n_c":["C106368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sabarubicin","n_c":["C1706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacituzumab Govitecan","n_c":["C102783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacubitril/Valsartan","n_c":["C162629"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Safingol","n_c":["C1568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sagopilone","n_c":["C61072"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salirasib","n_c":["C71146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salmonella VNP20009","n_c":["C2556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sam68 Modulator CWP232291","n_c":["C97663"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samalizumab","n_c":["C77891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samarium Sm 153-DOTMP","n_c":["C165558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samotolisib","n_c":["C121817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sapacitabine","n_c":["C64541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sapanisertib","n_c":["C90548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sapitinib","n_c":["C77887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saracatinib","n_c":["C48378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saracatinib Difumarate","n_c":["C95224"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SarCNU","n_c":["C963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sardomozide","n_c":["C1673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sargramostim","n_c":["C1492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Satraplatin","n_c":["C1493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Savolitinib","n_c":["C104732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SBIL-2","n_c":["C29418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scopoletin","n_c":["C126100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seclidemstat","n_c":["C154328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sedoxantrone Trihydrochloride","n_c":["C1576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selatinib Ditosilate","n_c":["C111764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Androgen Receptor Modulator RAD140","n_c":["C137950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Cytokine Inhibitory Drug CC-1088","n_c":["C2210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader AZD9496","n_c":["C122834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader AZD9833","n_c":["C160603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader LSZ102","n_c":["C128280"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader SRN-927","n_c":["C120037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Modulator CC-8490","n_c":["C38711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Modulator TAS-108","n_c":["C61494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Glucocorticoid Receptor Antagonist CORT125281","n_c":["C153309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","n_c":["C150363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seliciclib","n_c":["C62783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selicrelumab","n_c":["C119740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selinexor","n_c":["C102546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selitrectinib","n_c":["C138160"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selonsertib","n_c":["C121943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selpercatinib","n_c":["C134987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selumetinib","n_c":["C66939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selumetinib Sulfate","n_c":["C95225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Semaxanib","n_c":["C1831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Semuloparin","n_c":["C78447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Semustine","n_c":["C827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seneca Valley Virus-001","n_c":["C62524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seocalcitol","n_c":["C26669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sepantronium Bromide","n_c":["C61091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serabelisib","n_c":["C98844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD D-0502","n_c":["C156735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD G1T48","n_c":["C175853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD GDC-9545","n_c":["C147030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD SAR439859","n_c":["C174915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD SHR9549","n_c":["C165550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serdemetan","n_c":["C77904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sergiolide","n_c":["C1763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seribantumab","n_c":["C78859"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serine/Threonine Kinase Inhibitor CBP501","n_c":["C71529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serine/Threonine Kinase Inhibitor XL418","n_c":["C68963"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sevacizumab","n_c":["C122403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seviteronel","n_c":["C113652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shared Anti-Idiotype-AB-S006","n_c":["C29424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shared Anti-Idiotype-AB-S024A","n_c":["C29432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shark Cartilage","n_c":["C2318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shark Cartilage Extract AE-941","n_c":["C1798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sho-Saiko-To","n_c":["C2690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Short Chain Fatty Acid HQK-1004","n_c":["C2570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP-1 Agonist SC-43","n_c":["C156695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor JAB-3068","n_c":["C160207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor RMC-4630","n_c":["C155850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor TNO155","n_c":["C139559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shu Yu Wan Formula","n_c":["C120207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialyl Tn Antigen","n_c":["C1226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialyl Tn-KLH Vaccine","n_c":["C1690"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sibrotuzumab","n_c":["C156438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"siG12D LODER","n_c":["C95772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silatecan AR-67","n_c":["C64618"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silibinin","n_c":["C152359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silicon Phthalocyanine 4","n_c":["C2651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Silmitasertib Sodium","n_c":["C85460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Siltuximab","n_c":["C61084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simalikalactone D","n_c":["C1227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simeprevir","n_c":["C129015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simotaxel","n_c":["C116871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simtuzumab","n_c":["C91735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sintilimab","n_c":["C132992"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Siplizumab","n_c":["C38685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sipuleucel-T","n_c":["C1985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401","n_c":["C116353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sirolimus","n_c":["C1212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-Fc Fusion Protein TTI-621","n_c":["C125718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-IgG4-Fc Fusion Protein TTI-622","n_c":["C150756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sitimagene Ceradenovec","n_c":["C162553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sitravatinib","n_c":["C117734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sivifene","n_c":["C61305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sizofiran","n_c":["C824"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLC6A8 Inhibitor RGX-202","n_c":["C153354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SLCT Inhibitor GNS561","n_c":["C184909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMAC Mimetic BI 891065","n_c":["C150507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smac Mimetic GDC-0152","n_c":["C88274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smac Mimetic GDC-0917","n_c":["C103825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smac Mimetic LCL161","n_c":["C91079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SMO Protein Inhibitor ZSP1602","n_c":["C159535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist BMS-833923","n_c":["C77861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist LDE225 Topical","n_c":["C88337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist LEQ506","n_c":["C91089"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoothened Antagonist TAK-441","n_c":["C116874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SN-38-Loaded Polymeric Micelles NK012","n_c":["C71521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SNS01-T Nanoparticles","n_c":["C98288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sobuzoxane","n_c":["C66540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Borocaptate","n_c":["C2208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Butyrate","n_c":["C2337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Dichloroacetate","n_c":["C73591"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Iodide I-131","n_c":["C47725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Metaarsenite","n_c":["C91098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Phenylbutyrate","n_c":["C1440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Salicylate","n_c":["C834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Selenite","n_c":["C87346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Stibogluconate","n_c":["C61083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108","n_c":["C156728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sofituzumab Vedotin","n_c":["C106119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solitomab","n_c":["C77854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sonepcizumab","n_c":["C78195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sonidegib","n_c":["C82385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sonolisib","n_c":["C78848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorafenib","n_c":["C61948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorafenib Tosylate","n_c":["C2194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorghum bicolor Supplement","n_c":["C111681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotrastaurin","n_c":["C80630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotrastaurin Acetate","n_c":["C80631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soy Isoflavones","n_c":["C65152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soy Protein Isolate","n_c":["C1803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sparfosate Sodium","n_c":["C2353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sparfosic Acid","n_c":["C1398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spartalizumab","n_c":["C121625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spebrutinib","n_c":["C97037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spherical Nucleic Acid Nanoparticle NU-0129","n_c":["C131368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spirogermanium","n_c":["C1232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spiromustine","n_c":["C1233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spiroplatin","n_c":["C1234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splicing Inhibitor H3B-8800","n_c":["C129546"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spongistatin","n_c":["C2051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squalamine Lactate","n_c":["C1482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SR-BP1/HSI Inhibitor SR31747A","n_c":["C61435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SR-T100 Gel","n_c":["C99460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor AP 23846","n_c":["C162533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor KX2-391","n_c":["C74077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor KX2-391 Ointment","n_c":["C120210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src Kinase Inhibitor M475271","n_c":["C162339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src/Abl Kinase Inhibitor AZD0424","n_c":["C102976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Src/tubulin Inhibitor KX02","n_c":["C120101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ssRNA-based Immunomodulator CV8102","n_c":["C150401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SSTR2-targeting Protein/DM1 Conjugate PEN-221","n_c":["C131562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"St. John's Wort","n_c":["C2589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stallimycin","n_c":["C1517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcal Enterotoxin A","n_c":["C1083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcal Enterotoxin B","n_c":["C1084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT Inhibitor OPB-111077","n_c":["C116873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor DSP-0337","n_c":["C151994"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor OPB-31121","n_c":["C90588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor OPB-51602","n_c":["C95889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor TTI-101","n_c":["C151932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STAT3 Inhibitor WP1066","n_c":["C111042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staurosporine","n_c":["C1237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist MK-1454","n_c":["C132258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING-activating Cyclic Dinucleotide Agonist MIW815","n_c":["C125902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Streptonigrin","n_c":["C844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Streptozocin","n_c":["C845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Strontium Chloride Sr-89","n_c":["C1238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submicron Particle Paclitaxel Sterile Suspension","n_c":["C162773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulfatinib","n_c":["C116066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulforaphane","n_c":["C1424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulindac","n_c":["C850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulofenur","n_c":["C1432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sumoylation Inhibitor TAK-981","n_c":["C156270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sunitinib","n_c":["C71622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sunitinib Malate","n_c":["C26673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Super Enhancer Inhibitor GZ17-6.02","n_c":["C158082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803","n_c":["C107503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suramin","n_c":["C853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suramin Sodium","n_c":["C1848"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin Antigen","n_c":["C37449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin Antigen Vaccine DPX-Survivac","n_c":["C97951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin mRNA Antagonist EZN-3042","n_c":["C92578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Survivin-expressing CVD908ssb-TXSVN Vaccine","n_c":["C158607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sustained-release Lipid Inhaled Cisplatin","n_c":["C116884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101","n_c":["C126642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102","n_c":["C158422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syk Inhibitor HMPL-523","n_c":["C123912"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synchrotope TA2M Plasmid DNA Vaccine","n_c":["C2650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synchrovax SEM Plasmid DNA Vaccine","n_c":["C28549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Alkaloid PM00104","n_c":["C62763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2","n_c":["C116332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1","n_c":["C116331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic hTERT DNA Vaccine INO-1400","n_c":["C120118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic hTERT DNA Vaccine INO-1401","n_c":["C142139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Hypericin","n_c":["C122400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201","n_c":["C129652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Long E6/E7 Peptides Vaccine HPV-01","n_c":["C111037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b","n_c":["C150809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T900607","n_c":["C26674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tabalumab","n_c":["C91727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tabelecleucel","n_c":["C143140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tacedinaline","n_c":["C2202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tagraxofusp-erzs","n_c":["C64769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talabostat","n_c":["C48264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talabostat Mesylate","n_c":["C80682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talacotuzumab","n_c":["C102784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talactoferrin Alfa","n_c":["C78460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taladegib","n_c":["C103826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talampanel","n_c":["C38139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talaporfin Sodium","n_c":["C26675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talazoparib","n_c":["C95733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talimogene Laherparepvec","n_c":["C61314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tallimustine","n_c":["C1603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talmapimod","n_c":["C79841"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talotrexin","n_c":["C29341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Talotrexin Ammonium","n_c":["C80159"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taltobulin","n_c":["C75998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TAM/c-Met Inhibitor RXDX-106","n_c":["C150585"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamibarotene","n_c":["C71025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taminadenant","n_c":["C121664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamoxifen","n_c":["C62078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamoxifen Citrate","n_c":["C855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tandutinib","n_c":["C48404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanespimycin","n_c":["C37899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanibirumab","n_c":["C102877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanomastat","n_c":["C1705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tarenflurbil","n_c":["C26666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tarextumab","n_c":["C95719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tariquidar","n_c":["C2246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taselisib","n_c":["C116876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasidotin","n_c":["C77067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasisulam","n_c":["C62794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasisulam Sodium","n_c":["C88304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasquinimod","n_c":["C74080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taurolidine","n_c":["C2639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tauromustine","n_c":["C954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taurultam","n_c":["C75290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taurultam Analogue GP-2250","n_c":["C159500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tavokinogene Telseplasmid","n_c":["C156363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tavolimab","n_c":["C120041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taxane Analogue TPI 287","n_c":["C48424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taxane Compound","n_c":["C1490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taxol Analogue SID 530","n_c":["C84839"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tazarotene","n_c":["C29487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tazemetostat","n_c":["C107506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tecogalan Sodium","n_c":["C1605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur","n_c":["C513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur-gimeracil-oteracil Potassium","n_c":["C1833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation","n_c":["C120099"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegafur-Uracil","n_c":["C9506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tegavivint","n_c":["C155885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teglarinad","n_c":["C90746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teglarinad Chloride","n_c":["C68931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telapristone","n_c":["C104057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telapristone Acetate","n_c":["C104055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telatinib Mesylate","n_c":["C87837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telisotuzumab Vedotin","n_c":["C118571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telomerase Inhibitor FJ5002","n_c":["C2715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telomerase-specific Type 5 Adenovirus OBP-301","n_c":["C119617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teloxantrone","n_c":["C1520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teloxantrone Hydrochloride","n_c":["C74544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telratolimod","n_c":["C124653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temarotene","n_c":["C63953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temoporfin","n_c":["C1669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temozolomide","n_c":["C1244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temsirolimus","n_c":["C1844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tenalisib","n_c":["C113433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tenifatecan","n_c":["C64772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teniposide","n_c":["C857"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tepotinib","n_c":["C88314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teprotumumab","n_c":["C95797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Terameprocol","n_c":["C61441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Terfluranol","n_c":["C75292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tergenpumatucel-L","n_c":["C66985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teroxirone","n_c":["C2320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tertomotide","n_c":["C62756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tesetaxel","n_c":["C37451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tesevatinib","n_c":["C62496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tesidolumab","n_c":["C129315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testolactone","n_c":["C2301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testosterone Enanthate","n_c":["C1247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetanus Toxoid Vaccine","n_c":["C2660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetradecanoylphorbol Acetate","n_c":["C866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetrahydrouridine","n_c":["C868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetraphenyl Chlorin Disulfonate","n_c":["C88344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetrathiomolybdate","n_c":["C160684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tezacitabine","n_c":["C1539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tezacitabine Anhydrous","n_c":["C95916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGF-beta Receptor 1 Inhibitor PF-06952229","n_c":["C160258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFa-PE38 Immunotoxin","n_c":["C29483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFbeta Inhibitor LY3200882","n_c":["C132013"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200","n_c":["C159817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thalicarpine","n_c":["C869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thalidomide","n_c":["C870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Theliatinib","n_c":["C162552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Theramide","n_c":["C2385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Angiotensin-(1-7)","n_c":["C68962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907","n_c":["C91077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Estradiol","n_c":["C478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Hydrocortisone","n_c":["C555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Liver Cancer Peptide Vaccine IMA970A","n_c":["C151942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiarabine","n_c":["C92589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiodiglycol","n_c":["C75295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioguanine","n_c":["C876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioguanine Anhydrous","n_c":["C61970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioinosine","n_c":["C877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioredoxin-1 Inhibitor PX-12","n_c":["C74082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiotepa","n_c":["C875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thioureidobutyronitrile","n_c":["C102881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"THL-P","n_c":["C88275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anetumab","n_c":["C155977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Threonine Tyrosine Kinase Inhibitor CFI-402257","n_c":["C128288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymidylate Synthase Inhibitor DFP-11207","n_c":["C116720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymopentin","n_c":["C1294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Extract","n_c":["C2565"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiazofurin","n_c":["C1254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tidutamab","n_c":["C146820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tigapotide","n_c":["C78474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tigatuzumab","n_c":["C62482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TIGIT-targeting Agent MK-7684","n_c":["C140041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tilarginine","n_c":["C1178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tilsotolimod Sodium","n_c":["C125080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Timonacic","n_c":["C2354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tin Ethyl Etiopurpurin","n_c":["C1255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tinostamustine","n_c":["C126105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tinzaparin Sodium","n_c":["C60810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiomolibdate Diammonium","n_c":["C74001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipapkinogene Sovacivec","n_c":["C88326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipifarnib","n_c":["C1703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipiracil","n_c":["C152646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tipiracil Hydrochloride","n_c":["C152647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tirabrutinib","n_c":["C102876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiragolumab","n_c":["C131291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tirapazamine","n_c":["C1464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tisagenlecleucel","n_c":["C102758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tislelizumab","n_c":["C121775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tisotumab Vedotin","n_c":["C113164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tivantinib","n_c":["C62437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tivozanib","n_c":["C85444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLC ELL-12","n_c":["C2102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR Agonist BDB001","n_c":["C156395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR Agonist BSG-001","n_c":["C158747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR Agonist CADI-05","n_c":["C77884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100","n_c":["C82353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7 Agonist 852A","n_c":["C61104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7/8/9 Antagonist IMO-8400","n_c":["C114975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR8 Agonist DN1508052","n_c":["C160500"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR9 Agonist AST-008","n_c":["C157771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocilizumab","n_c":["C84217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocladesine","n_c":["C2571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocotrienol","n_c":["C68318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tocotrienol-rich Fraction","n_c":["C101518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toll-like Receptor 7 Agonist DSP-0509","n_c":["C153314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tolnidamine","n_c":["C75293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tomaralimab","n_c":["C120554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tomato-Soy Juice","n_c":["C88300"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tomivosertib","n_c":["C125062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Betulinic Acid","n_c":["C78477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Celecoxib","n_c":["C148519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Fluorouracil","n_c":["C125194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Gemcitabine Hydrochloride","n_c":["C74085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Potassium Dobesilate","n_c":["C151946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topical Trichloroacetic Acid","n_c":["C125002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topixantrone","n_c":["C75124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I Inhibitor Genz-644282","n_c":["C84851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I Inhibitor LMP400","n_c":["C90594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I Inhibitor LMP776","n_c":["C90595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase I/II Inhibitor NEV-801","n_c":["C128557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase-1 Inhibitor LMP744","n_c":["C127900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase-II Inhibitor Racemic XK469","n_c":["C2825"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topoisomerase-II-beta Inhibitor Racemic XK469","n_c":["C2662"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan","n_c":["C1413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan Hydrochloride","n_c":["C2828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan Hydrochloride Liposomes","n_c":["C80065"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topsalysin","n_c":["C64779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TORC1/2 Kinase Inhibitor DS-3078a","n_c":["C101795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toremifene","n_c":["C1256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toremifene Citrate","n_c":["C1756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toripalimab","n_c":["C131334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tosedostat","n_c":["C70650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tositumomab","n_c":["C2543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total Androgen Blockade","n_c":["C94614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tovetumab","n_c":["C82684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tozasertib Lactate","n_c":["C61319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TP40 Immunotoxin","n_c":["C2374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trabectedin","n_c":["C1691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trabedersen","n_c":["C80066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRAIL Receptor Agonist ABBV-621","n_c":["C146854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trametinib","n_c":["C77908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trametinib Dimethyl Sulfoxide","n_c":["C152711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trans Sodium Crocetinate","n_c":["C82695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transdermal 17beta-Estradiol Gel BHR-200","n_c":["C120308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transdermal 4-Hydroxytestosterone","n_c":["C114103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01","n_c":["C78450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transferrin Receptor-Targeted Liposomal p53 cDNA","n_c":["C29474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transferrin-CRM107","n_c":["C26676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tranylcypromine Sulfate","n_c":["C61980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trapoxin","n_c":["C1665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab","n_c":["C1647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Conjugate BI-CON-02","n_c":["C148165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Duocarmazine","n_c":["C118674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Emtansine","n_c":["C82492"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab/Hyaluronidase-oysk","n_c":["C158060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502","n_c":["C139800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trebananib","n_c":["C91711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tremelimumab","n_c":["C49085"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treosulfan","n_c":["C1257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tretazicar","n_c":["C81554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tretinoin","n_c":["C900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tretinoin Liposome","n_c":["C2398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triamcinolone Acetonide","n_c":["C48027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triamcinolone Hexacetonide","n_c":["C48026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triapine","n_c":["C2242"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triazene Derivative CB10-277","n_c":["C2367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triazene Derivative TriN2755","n_c":["C95208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triazinate","n_c":["C1258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triaziquone","n_c":["C903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tributyrin","n_c":["C1260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triciribine Phosphate","n_c":["C1262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trientine Hydrochloride","n_c":["C61987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triethylenemelamine","n_c":["C29858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trifluridine","n_c":["C905"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trifluridine and Tipiracil Hydrochloride","n_c":["C102554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trigriluzole","n_c":["C142847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trilaciclib","n_c":["C123281"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimelamol","n_c":["C29485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimeric GITRL-Fc OMP-336B11","n_c":["C169928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimethylcolchicinic Acid","n_c":["C1264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimetrexate","n_c":["C1314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trimetrexate Glucuronate","n_c":["C1265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trioxifene","n_c":["C1266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triplatin Tetranitrate","n_c":["C1827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triptolide Analog","n_c":["C111762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triptorelin","n_c":["C1267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Triptorelin Pamoate","n_c":["C29523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tritylcysteine","n_c":["C1758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRK Inhibitor AZD6918","n_c":["C80491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TrkA Inhibitor VMD-928","n_c":["C153116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trodusquemine","n_c":["C123882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trofosfamide","n_c":["C1268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troglitazone","n_c":["C1522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tropomyosin Receptor Kinase Inhibitor AZD7451","n_c":["C99161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troxacitabine","n_c":["C1438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troxacitabine Nucleotide Prodrug MIV-818","n_c":["C157496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRPM8 Agonist D-3263","n_c":["C162345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRPV6 Calcium Channel Inhibitor SOR-C13","n_c":["C101525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSP-1 Mimetic ABT-510","n_c":["C37447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSP-1 Mimetic Fusion Protein CVX-045","n_c":["C82384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubercidin","n_c":["C911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Binding Agent TTI-237","n_c":["C77064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Inhibitor ALB 109564 Dihydrochloride","n_c":["C78842"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Inhibitor ALB-109564","n_c":["C162527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Polymerization Inhibitor AEZS 112","n_c":["C162525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Polymerization Inhibitor CKD-516","n_c":["C101264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin Polymerization Inhibitor VERU-111","n_c":["C158517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulin-Binding Agent SSR97225","n_c":["C71525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tucatinib","n_c":["C77896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tucidinostat","n_c":["C97263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tucotuzumab Celmoleukin","n_c":["C2630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyroserleutide","n_c":["C77856"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinase Peptide","n_c":["C2401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinase-KLH","n_c":["C2384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinase:146-156 Peptide","n_c":["C48630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor","n_c":["C1967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor OSI-930","n_c":["C70981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor SU5402","n_c":["C1725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor XL228","n_c":["C68929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"UAE Inhibitor TAK-243","n_c":["C113788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ubenimex","n_c":["C1015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ubidecarenone Nanodispersion BPM31510n","n_c":["C118621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ublituximab","n_c":["C91078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulinastatin","n_c":["C102851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulixertinib","n_c":["C104744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulocuplumab","n_c":["C95755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbralisib","n_c":["C104413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uncaria tomentosa Extract","n_c":["C113799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upamostat","n_c":["C73985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uproleselan","n_c":["C119743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uprosertib","n_c":["C84870"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uracil Ointment","n_c":["C91083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urelumab","n_c":["C62449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uroacitides","n_c":["C162545"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urokinase-Derived Peptide A6","n_c":["C91709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"USP14/UCHL5 Inhibitor VLX1570","n_c":["C121215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Utomilumab","n_c":["C116619"],"i_c":"","i_c_s":"","term_type":""},{"nm":"V930 Vaccine","n_c":["C61069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaccine-Sensitized Draining Lymph Node Cells","n_c":["C2542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules","n_c":["C102748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vactosertib","n_c":["C116357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vadacabtagene Leraleucel","n_c":["C133718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vadastuximab Talirine","n_c":["C111039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vadimezan","n_c":["C2504"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valproic Acid","n_c":["C29536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valrubicin","n_c":["C1340"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valspodar","n_c":["C1405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vandetanib","n_c":["C2737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vandetanib-eluting Radiopaque Bead BTG-002814","n_c":["C150384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vandortuzumab Vedotin","n_c":["C116748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vantictumab","n_c":["C96799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vanucizumab","n_c":["C118578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vapreotide","n_c":["C1429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varlilumab","n_c":["C99127"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varlitinib","n_c":["C62530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varlitinib Tosylate","n_c":["C95226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disrupting Agent BNC105","n_c":["C162343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disrupting Agent BNC105P","n_c":["C88338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disrupting Agent ZD6126","n_c":["C2736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vatalanib","n_c":["C1868"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vatalanib Succinate","n_c":["C74945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vecabrutinib","n_c":["C136416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vector-peptide Conjugated Paclitaxel","n_c":["C70971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vedolizumab","n_c":["C95798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGF Inhibitor PTC299","n_c":["C91100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGF/HGF-targeting DARPin MP0250","n_c":["C117236"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR Inhibitor KRN951","n_c":["C88267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR-2 DNA Vaccine VXM01","n_c":["C99378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR/FGFR Inhibitor ODM-203","n_c":["C118628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593","n_c":["C79794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210","n_c":["C97950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813","n_c":["C61507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veliparib","n_c":["C60768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veltuzumab","n_c":["C48406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vemurafenib","n_c":["C64768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venetoclax","n_c":["C103147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verapamil","n_c":["C928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verpasep Caltespen","n_c":["C2811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verubulin","n_c":["C96747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Verubulin Hydrochloride","n_c":["C64782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vesigenurtucel-L","n_c":["C113653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220","n_c":["C2016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820","n_c":["C49090"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Viagenpumatucel-L","n_c":["C61073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vilaprisan","n_c":["C148505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinblastine","n_c":["C930"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinblastine Sulfate","n_c":["C931"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine","n_c":["C933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine Liposomal","n_c":["C2104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine Sulfate","n_c":["C1739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vincristine Sulfate Liposome","n_c":["C2702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vindesine","n_c":["C934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinepidine","n_c":["C1274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinflunine","n_c":["C61564"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinflunine Ditartrate","n_c":["C76266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinfosiltine","n_c":["C2378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine","n_c":["C1275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine Tartrate","n_c":["C1395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine Tartrate Emulsion","n_c":["C66943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinorelbine Tartrate Oral","n_c":["C85457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vintafolide","n_c":["C62525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinzolidine","n_c":["C1276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vinzolidine Sulfate","n_c":["C87288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virulizin","n_c":["C26677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vismodegib","n_c":["C74038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vistusertib","n_c":["C88329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitamin D3 Analogue ILX23-7553","n_c":["C1883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitamin E Compound","n_c":["C942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vitespen","n_c":["C2432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VLP-encapsulated TLR9 Agonist CMP-001","n_c":["C175875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vocimagene Amiretrorepvec","n_c":["C91734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vofatamab","n_c":["C116863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Volasertib","n_c":["C79844"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Volociximab","n_c":["C48426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vonlerolizumab","n_c":["C121376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vopratelimab","n_c":["C129876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorinostat","n_c":["C1796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorolanib","n_c":["C95896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorsetzumab Mafodotin","n_c":["C88315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vosaroxin","n_c":["C95148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Voxtalisib","n_c":["C71704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Warfarin Sodium","n_c":["C1658"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Carrot","n_c":["C126649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wnt Signaling Inhibitor SM04755","n_c":["C122693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wnt Signaling Pathway Inhibitor SM08502","n_c":["C142777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wnt-5a Mimic Hexapeptide Foxy-5","n_c":["C113435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wobe-Mugos E","n_c":["C28501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1 Peptide Vaccine OCV-501","n_c":["C106257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1 Peptide Vaccine WT2725","n_c":["C102751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1 Protein-derived Peptide Vaccine DSP-7888","n_c":["C121957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1-A10/AS01B Immunotherapeutic GSK2130579A","n_c":["C78865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401","n_c":["C148480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xanthohumol","n_c":["C121950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","n_c":["C103823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xeloda","n_c":["C1794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xentuzumab","n_c":["C106118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xiaoai Jiedu Decoction","n_c":["C165272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XIAP Antisense Oligonucleotide AEG35156","n_c":["C49180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XIAP/cIAP1 Antagonist ASTX660","n_c":["C123913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"XPO1 Inhibitor SL-801","n_c":["C171660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody CC49","n_c":["C2597"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody HMFG1","n_c":["C2541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody Lym-1","n_c":["C2247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody m170","n_c":["C2532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y 90 Monoclonal Antibody M195","n_c":["C2248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yang Yin Fu Zheng","n_c":["C132024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yangzheng Xiaoji Extract","n_c":["C111897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yiqi-yangyin-jiedu Herbal Decoction","n_c":["C132026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12","n_c":["C74092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12","n_c":["C74093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","n_c":["C95698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","n_c":["C122405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66","n_c":["C77885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Basiliximab","n_c":["C99167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Colloid","n_c":["C114495"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Daclizumab","n_c":["C2600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A","n_c":["C77853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Glass Microspheres","n_c":["C38679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody B3","n_c":["C2614"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody BrE-3","n_c":["C2607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody Hu3S193","n_c":["C38678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Monoclonal Antibody MN-14","n_c":["C2249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Resin Microspheres","n_c":["C64539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-DOTA-Biotin","n_c":["C1808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","n_c":["C119738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-Edotreotide","n_c":["C2601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101","n_c":["C99168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Clivatuzumab Tetraxetan","n_c":["C48429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Epratuzumab Tetraxetan","n_c":["C2582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Ibritumomab Tiuxetan","n_c":["C1812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y-90 Tacatuzumab Tetraxetan","n_c":["C48428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium-90 Polycarbonate Brachytherapy Plaque","n_c":["C80739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Z-Endoxifen Hydrochloride","n_c":["C95713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zalcitabine","n_c":["C430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zalifrelimab","n_c":["C126113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zalutumumab","n_c":["C64620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zanolimumab","n_c":["C91701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zanubrutinib","n_c":["C141428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zebularine","n_c":["C37455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zibotentan","n_c":["C48430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinc Finger Nuclease ZFN-603","n_c":["C129588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinc Finger Nuclease ZFN-758","n_c":["C129589"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinostatin","n_c":["C682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zinostatin Stimalamer","n_c":["C162544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zirconium Zr 89 Panitumumab","n_c":["C156043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ziv-Aflibercept","n_c":["C2682"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zolbetuximab","n_c":["C85475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zoledronic Acid","n_c":["C1699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zoptarelin Doxorubicin","n_c":["C74025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zorubicin","n_c":["C91365"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zorubicin Hydrochloride","n_c":["C1458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zuclomiphene Citrate","n_c":["C28322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3'-dA Phosphoramidate NUC-7738","n_c":["C171381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"A2A Receptor Antagonist EOS100850","n_c":["C172109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosine A2A Receptor Antagonist CS3005","n_c":["C175468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","n_c":["C173640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918","n_c":["C167360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931","n_c":["C167361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK Inhibitor TAE684","n_c":["C171615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ALK/ROS1/Met Inhibitor TQ-B3101","n_c":["C173430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715","n_c":["C165779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A","n_c":["C171066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells","n_c":["C173967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD19 CAR T-cells ALLO-501A","n_c":["C172708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101","n_c":["C173959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S","n_c":["C174397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A","n_c":["C168570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22","n_c":["C165696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001","n_c":["C173877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001","n_c":["C170887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120","n_c":["C172741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130","n_c":["C173153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A","n_c":["C165661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01","n_c":["C173427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19","n_c":["C174401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allosteric ErbB Inhibitor BDTX-189","n_c":["C171059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alobresib","n_c":["C126640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alofanib","n_c":["C170744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha V Beta 8 Antagonist PF-06940434","n_c":["C172097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alsevalimab","n_c":["C155967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amivantamab","n_c":["C124993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andecaliximab","n_c":["C105803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Degrader CC-94676","n_c":["C173364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor Inhibitor EPI-7386","n_c":["C173374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10","n_c":["C172104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anhydrous Enol-oxaloacetate","n_c":["C168687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-5T4 Antibody-drug Conjugate ASN004","n_c":["C173556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-5T4 Antibody-drug Conjugate SYD1875","n_c":["C175444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a","n_c":["C171577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA Antibody-drug Conjugate CC-99712","n_c":["C170915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA","n_c":["C167337"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459","n_c":["C165656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BTLA Monoclonal Antibody TAB004","n_c":["C168617"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01","n_c":["C175508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-c-Met Monoclonal Antibody HLX55","n_c":["C174391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CCR7 Antibody-drug Conjugate JBH492","n_c":["C175477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD117 Monoclonal Antibody JSP191","n_c":["C174050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373","n_c":["C168522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017","n_c":["C173548"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD137 Agonistic Monoclonal Antibody LVGN6051","n_c":["C171541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003","n_c":["C172202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19 iCAR NK Cells","n_c":["C170903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD19/CD22 CAR NK Cells","n_c":["C170904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody BAT4306F","n_c":["C173955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD20 Monoclonal Antibody MIL62","n_c":["C166140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD205 Antibody-drug Conjugate OBT076","n_c":["C165598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A","n_c":["C168772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD25 Monoclonal Antibody RO7296682","n_c":["C173969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD27 Agonistic Monoclonal Antibody MK-5890","n_c":["C172056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044","n_c":["C173369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119","n_c":["C166258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin","n_c":["C165583"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD30/DM1 Antibody-drug Conjugate F0002","n_c":["C172064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD37 Bispecific Monoclonal Antibody GEN3009","n_c":["C172443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Antibody-drug Conjugate STI-6129","n_c":["C174057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38 Monoclonal Antibody SAR442085","n_c":["C166376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257","n_c":["C173645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD39 Monoclonal Antibody SRF617","n_c":["C171450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042","n_c":["C168604"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 ADC SGN-CD47M","n_c":["C173421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47 Monoclonal Antibody IMC-002","n_c":["C174192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801","n_c":["C166137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-claudin18.2 Monoclonal Antibody AB011","n_c":["C173724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Claudin18.2 Monoclonal Antibody TST001","n_c":["C173726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody ADG116","n_c":["C166139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody HBM4003","n_c":["C173540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Monoclonal Antibody ONC-392","n_c":["C173547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4 Probody BMS-986288","n_c":["C173435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","n_c":["C172196"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-CTLA4 Antibody Fc Fusion Protein KN044","n_c":["C173422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-EGFR/CD16A Bispecific Antibody AFM24","n_c":["C171163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202","n_c":["C173946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GARP Monoclonal Antibody ABBV-151","n_c":["C165684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999","n_c":["C165657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a","n_c":["C172987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-gremlin-1 Monoclonal Antibody UCB6114","n_c":["C173701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702","n_c":["C173076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate BAT8001","n_c":["C173966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Antibody-drug Conjugate DP303c","n_c":["C173962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody B002","n_c":["C174121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2 Monoclonal Antibody HLX22","n_c":["C172198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2-DM1 ADC B003","n_c":["C173420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001","n_c":["C173827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HER2/MMAE Antibody-drug Conjugate MRG002","n_c":["C174205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-HLA-G Antibody TTX-080","n_c":["C175374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IL-8 Monoclonal Antibody BMS-986253","n_c":["C124227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A","n_c":["C172391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-IRF4 Antisense Oligonucleotide ION251","n_c":["C173725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LAG-3 Monoclonal Antibody IBI-110","n_c":["C168603"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181","n_c":["C173598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102","n_c":["C175411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-LILRB4 Monoclonal Antibody IO-202","n_c":["C174485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-mesothelin/MMAE Antibody-drug Conjugate RC88","n_c":["C174395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC16/CD3 Bispecific Antibody REGN4018","n_c":["C153129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-MUC17/CD3 BiTE Antibody AMG 199","n_c":["C165588"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592","n_c":["C173702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-NRP1 Antibody ASP1948","n_c":["C156402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Agonist Monoclonal Antibody BGB-A445","n_c":["C175453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106","n_c":["C173983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256","n_c":["C174140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody 609A","n_c":["C172820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1 Monoclonal Antibody SCT-I10A","n_c":["C170758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315","n_c":["C174419"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669","n_c":["C173539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","n_c":["C171938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/CD47 Infusion Protein HX009","n_c":["C168600"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752","n_c":["C171937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-1/VEGF Bispecific Antibody AK112","n_c":["C184865"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody IMC-001","n_c":["C172819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1 Monoclonal Antibody RC98","n_c":["C174520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046","n_c":["C172194"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PD-L1/IL-15 Fusion Protein KD033","n_c":["C173592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C","n_c":["C170976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-PSMA/CD3 Bispecific Antibody CCW702","n_c":["C169053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-RANKL Monoclonal Antibody GB-223","n_c":["C174406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-RANKL Monoclonal Antibody JMT103","n_c":["C190458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-Ribonucleoprotein Antibody ATRC-101","n_c":["C172924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002","n_c":["C174012"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody BGB-A1217","n_c":["C170906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody COM902","n_c":["C174037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIGIT Monoclonal Antibody SGN-TGT","n_c":["C173630"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TIM3 Monoclonal Antibody SHR-1702","n_c":["C172108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711","n_c":["C173541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TROP2 Antibody-drug Conjugate BAT8003","n_c":["C172060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-TROP2 Antibody-drug Conjugate SKB264","n_c":["C166409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anti-VEGFR2 Monoclonal Antibody MSB0254","n_c":["C174422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antisense Oligonucleotide QR-313","n_c":["C162452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aprinocarsen","n_c":["C1788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aprutumab","n_c":["C107683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aryl Hydrocarbon Receptor Inhibitor IK-175","n_c":["C171151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspacytarabine","n_c":["C153327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asunercept","n_c":["C90562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Inhibitor RP-3500","n_c":["C174206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ATR Kinase Inhibitor M1774","n_c":["C171067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Attenuated Measles Virus Encoding SCD Transgene TMV-018","n_c":["C175440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atuveciclib","n_c":["C121456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Audencel","n_c":["C123928"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055","n_c":["C173429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA CAR T-cells PHE885","n_c":["C174124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11","n_c":["C173434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088","n_c":["C170747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD123 CAR-T Cells","n_c":["C171167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx","n_c":["C173622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19","n_c":["C175465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1","n_c":["C172746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19 TAC-T cells TAC01-CD19","n_c":["C172055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells","n_c":["C172057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells","n_c":["C155897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1","n_c":["C172063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes","n_c":["C173958"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-FLT3 CAR T Cells AMG 553","n_c":["C172197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100","n_c":["C173378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes","n_c":["C175446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes","n_c":["C172191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101","n_c":["C175511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous BCMA-targeted CAR T Cells CC-98633","n_c":["C173699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F","n_c":["C175471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022","n_c":["C171093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1","n_c":["C172103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19-targeted CAR T Cells CC-97540","n_c":["C175049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19-targeted CAR-T Cells GC007F","n_c":["C171092"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CD19/PD-1 Bispecific CAR-T Cells","n_c":["C172387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Clonal Neoantigen T Cells ATL001","n_c":["C171097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19","n_c":["C170914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC","n_c":["C173442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Multi-lineage Potential Cells","n_c":["C170908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Nectin-4/FAP-targeted CAR-T Cells","n_c":["C172386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous NKG2D CAR T-cells CYAD-02","n_c":["C173710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine","n_c":["C173968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001","n_c":["C167208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201","n_c":["C174405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous TCRm-expressing T-cells ET140203","n_c":["C175306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG","n_c":["C168775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1","n_c":["C173508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T","n_c":["C175463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avdoralimab","n_c":["C163020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aviscumine","n_c":["C78188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axalimogene Filolisbac","n_c":["C74595"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axatilimab","n_c":["C155813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL Inhibitor SLC-391","n_c":["C173362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"AXL/ FLT3/VEGFR2 Inhibitor KC1036","n_c":["C173961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axl/Mer Inhibitor PF-07265807","n_c":["C175543"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azintuxizumab Vedotin","n_c":["C122816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Balstilimab","n_c":["C136465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bazlitoran","n_c":["C114975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor BGB-11417","n_c":["C175489"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bcl-2 Inhibitor LP-108","n_c":["C203075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCMA-CD19 Compound CAR T Cells","n_c":["C174412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BCMA/CD3e Tri-specific T-cell Activating Construct HPN217","n_c":["C171631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belantamab Mafodotin","n_c":["C114299"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belapectin","n_c":["C115111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belvarafenib","n_c":["C121646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belzutifan","n_c":["C135627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bersanlimab","n_c":["C88327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Berzosertib","n_c":["C116355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Betaglucin Gel","n_c":["C172188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bexmarilimab","n_c":["C159536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody AGEN1223","n_c":["C171161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody AMG 509","n_c":["C168580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bispecific Antibody GS-1423","n_c":["C167206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BiTE Antibody AMG 910","n_c":["C184829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bizalimogene Ralaplasmid","n_c":["C77909"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bomedemstat","n_c":["C131827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF Inhibitor BGB-3245","n_c":["C173633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRAF(V600E) Kinase Inhibitor ABM-1310","n_c":["C170951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BTK Inhibitor HZ-A-018","n_c":["C174394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor ABN401","n_c":["C170765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"c-Met Inhibitor GST-HG161","n_c":["C175449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"C/EBP Beta Antagonist ST101","n_c":["C174169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Release-activated Channel Inhibitor CM4620","n_c":["C166417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Camidanlumab Tesirine","n_c":["C121949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carbon C 14-pamiparib","n_c":["C173441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cationic Peptide Cream Cypep-1","n_c":["C171374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD11b Agonist GB1275","n_c":["C165605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD123-CD33 Compound CAR T Cells","n_c":["C173970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD123-specific Targeting Module TM123","n_c":["C175461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD20-CD19 Compound CAR T Cells","n_c":["C173960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD28/ICOS Antagonist ALPN-101","n_c":["C179069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD44v6-specific CAR T-cells","n_c":["C173368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD73 Inhibitor AB680","n_c":["C167156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD73 Inhibitor LY3475070","n_c":["C170952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD80-Fc Fusion Protein ALPN-202","n_c":["C174515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CD80-Fc Fusion Protein FPT155","n_c":["C169063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK2 Inhibitor PF-07104091","n_c":["C175251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor CS3002","n_c":["C174417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor HS-10342","n_c":["C170749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK4/6 Inhibitor TQB3616","n_c":["C171344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK7 Inhibitor SY-5609","n_c":["C172390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CDK8/19 Inhibitor SEL 120","n_c":["C165747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cedazuridine/Azacitidine Combination Agent ASTX030","n_c":["C171649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282","n_c":["C172396"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab Sarotalocan","n_c":["C121850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cevostamab","n_c":["C139549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes","n_c":["C167056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ciltacabtagene Autoleucel","n_c":["C148498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cinrebafusp Alfa","n_c":["C142890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cintirorgon","n_c":["C131294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51","n_c":["C169027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cobolimab","n_c":["C128627"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cofetuzumab Pelidotin","n_c":["C123828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coltuximab Ravtansine","n_c":["C71009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Commensal Bacterial Strain Formulation VE800","n_c":["C167393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper Cu 67 Tyr3-octreotate","n_c":["C171370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cord Blood Derived CAR T-Cells","n_c":["C172058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cosibelimab","n_c":["C151947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coxsackievirus V937","n_c":["C61493"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSF1R Inhibitor ABSK021","n_c":["C173651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CXCR4/E-selectin Antagonist GMI-1359","n_c":["C167271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP11A1 Inhibitor ODM-209","n_c":["C172052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CYP17/CYP11B2 Inhibitor LAE001","n_c":["C102855"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Daratumumab and Hyaluronidase-fihj","n_c":["C156401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Decitabine and Cedazuridine","n_c":["C115102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Delolimogene Mupadenorepvec","n_c":["C148462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466","n_c":["C173660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dengue Virus Adjuvant PV-001-DV","n_c":["C173443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dilpacimab","n_c":["C116750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-PK inhibitor AZD7648","n_c":["C168692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNA-PK/PI3K-delta Inhibitor BR101801","n_c":["C172111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DNMT1 Inhibitor NTX-301","n_c":["C174424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dociparstat sodium","n_c":["C99130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dostarlimab","n_c":["C126799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370","n_c":["C167221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555","n_c":["C173999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edicotinib","n_c":["C101519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Edodekin alfa","n_c":["C1380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eftozanermin Alfa","n_c":["C146854"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Inhibitor TY-9591","n_c":["C175445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-selective  Inhibitor TQB3804","n_c":["C173415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/EGFRvIII Inhibitor WSD0922-FU","n_c":["C165778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/HER2 Inhibitor DZD9008","n_c":["C167205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/TGFb Fusion Monoclonal Antibody BCA101","n_c":["C173165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR/VEGFR/RET Inhibitor HA121-28","n_c":["C173436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Emibetuzumab","n_c":["C95732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641","n_c":["C168790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encapsulated Rapamycin","n_c":["C173879"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encelimab","n_c":["C142978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endothelin B Receptor Blocker ENB 003","n_c":["C175447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240","n_c":["C172990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineered Toxin Body Targeting CD38 TAK-169","n_c":["C173707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP2/EP4 Antagonist TPST-1495","n_c":["C174460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EP4 Antagonist INV-1120","n_c":["C173520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epcoritamab","n_c":["C163022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EphA2-targeting Bicycle Toxin Conjugate BT5528","n_c":["C171425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor HH2710","n_c":["C172805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ERK1/2 Inhibitor JSI-1187","n_c":["C174203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Etigilimab","n_c":["C142821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Exicorilant","n_c":["C153309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extended Release Metformin Hydrochloride","n_c":["C173523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ezabenlimab","n_c":["C132252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH1/2 Inhibitor HH2853","n_c":["C173698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EZH2 inhibitor CPI-0209","n_c":["C167347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fadraciclib","n_c":["C123902"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAK/ALK/ROS1 Inhibitor APG-2449","n_c":["C172193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAP/4-1BB-targeting DARPin MP0310","n_c":["C170894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FAP/4-1BB-targeting Fusion Protein RO7122290","n_c":["C175490"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells","n_c":["C167326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Favezelimab","n_c":["C142077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11","n_c":["C170762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Feladilimab","n_c":["C126804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Felzartamab","n_c":["C97954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fenretinide Phospholipid Suspension ST-001","n_c":["C175469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR Inhibitor CPL304110","n_c":["C173964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR/CSF-1R Inhibitor 3D185","n_c":["C175460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FGFR2 Inhibitor RLY-4008","n_c":["C174208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fianlimab","n_c":["C132339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fimaporfin A","n_c":["C88344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01","n_c":["C174049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279","n_c":["C174517"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FLT3/KIT/CSF1R Inhibitor NMS-03592088","n_c":["C172195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluorine F 18 Ara-G","n_c":["C120100"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foritinib Succinate","n_c":["C175475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosgemcitabine Palabenamide","n_c":["C102752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fosifloxuridine Nafalbenamide","n_c":["C156680"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Futibatinib","n_c":["C114283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"G Protein-coupled Estrogen Receptor Agonist LNS8801","n_c":["C165626"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallium-based Bone Resorption Inhibitor AP-002","n_c":["C165650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine","n_c":["C172199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum","n_c":["C171371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Giredestrant","n_c":["C147030"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glofitamab","n_c":["C148486"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutaminase Inhibitor IPN60090","n_c":["C165612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glutamine Antagonist DRP-104","n_c":["C174038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Inhibitor DZD1516","n_c":["C174039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2 Tri-specific Natural Killer Cell Engager DF1001","n_c":["C172279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HER2-directed TLR8 Agonist SBT6050","n_c":["C174010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIF2a RNAi ARO-HIF2","n_c":["C170918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202","n_c":["C173149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV E6/E7-encoding Arenavirus Vaccine HB-201","n_c":["C167349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107","n_c":["C173718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90 Inhibitor TQB3474","n_c":["C173550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hsp90-targeted Photosensitizer HS-201","n_c":["C172190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab","n_c":["C173339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iadademstat","n_c":["C131908"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ianalumab","n_c":["C116788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Idetrexed","n_c":["C120550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDH1 Mutant Inhibitor LY3410738","n_c":["C175542"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO/TDO Inhibitor LY-01013","n_c":["C171343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IDO1/TDO2 Inhibitor M4112","n_c":["C168808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ieramilimab","n_c":["C122683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000","n_c":["C166375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilginatinib","n_c":["C98109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imaradenant","n_c":["C148039"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imgatuzumab","n_c":["C78838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Imifoplatin","n_c":["C121375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inactivated Oncolytic Virus Particle GEN0101","n_c":["C170893"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indatuximab Ravtansine","n_c":["C78840"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Individualized MVA-based Vaccine TG4050","n_c":["C171392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indusatumab Vedotin","n_c":["C101524"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inebilizumab","n_c":["C88283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iNKT Cell Agonist ABX196","n_c":["C172187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-12-Fc Fusion Protein DF6002","n_c":["C173371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15 Agonist Fusion Protein SHR1501","n_c":["C171385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15 Fusion Protein BJ-001","n_c":["C172075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306","n_c":["C170890"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101","n_c":["C170516"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 Apamistamab","n_c":["C2527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iodine I 131 IPA","n_c":["C171348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","n_c":["C170800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irinotecan Sucrosofate","n_c":["C82676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iroplact","n_c":["C2251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130","n_c":["C165639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Istiratumab","n_c":["C103863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ivaltinostat","n_c":["C94225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ivuxolimab","n_c":["C121927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JAK Inhibitor","n_c":["C172200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kanitinib","n_c":["C168608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS G12C Inhibitor GDC-6036","n_c":["C173995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRAS G12C Inhibitor LY3499446","n_c":["C166410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"KRASG12C Inhibitor JNJ-74699157","n_c":["C167157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ladiratuzumab Vedotin","n_c":["C112001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LAIR-2 Fusion Protein NC410","n_c":["C173559"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Landogrozumab","n_c":["C99640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laprituximab Emtansine","n_c":["C111906"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larotinib Mesylate","n_c":["C172062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lerociclib","n_c":["C138165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Letetresgene Autoleucel","n_c":["C121379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Letolizumab","n_c":["C120140"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifileucel","n_c":["C120552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lifirafenib","n_c":["C124995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lilotomab","n_c":["C165685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linperlisib","n_c":["C158508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006","n_c":["C170753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Bcl-2 Antisense Oligonucleotide  BP1002","n_c":["C170743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1","n_c":["C174421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes","n_c":["C172395"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LMP7 Inhibitor M3258","n_c":["C169060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lodapolimab","n_c":["C128138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LRP5 Antagonist BI 905681","n_c":["C171102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LSD1 Inhibitor SYHA1807","n_c":["C173722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumretuzumab","n_c":["C104058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupartumab Amadotin","n_c":["C116070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lutetium Lu 177-DTPA-omburtamab","n_c":["C174423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maackia amurensis Seed Lectin","n_c":["C174518"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macrocycle-bridged STING Agonist E7766","n_c":["C166141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells","n_c":["C174139"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Magrolimab","n_c":["C117730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Manelimab","n_c":["C156741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MCL-1 Inhibitor ABBV-467","n_c":["C174400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MDM2 Inhibitor AMGMDS3","n_c":["C171616"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK 1/2 Inhibitor FCN-159","n_c":["C172382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEK Inhibitor HL-085","n_c":["C173437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Menin-MLL Interaction Inhibitor SNDX-5613","n_c":["C165776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MET x MET Bispecific Antibody REGN5093","n_c":["C167188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metarrestin","n_c":["C168544"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylcantharidimide","n_c":["C173446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mevociclib","n_c":["C139552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mezagitamab","n_c":["C148078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microbiome GEN-001","n_c":["C171422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microbiome-derived Peptide Vaccine EO2401","n_c":["C165646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Milataxel","n_c":["C77880"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miptenalimab","n_c":["C150403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miransertib","n_c":["C99172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirdametinib","n_c":["C52195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mirzotamab Clezutoclax","n_c":["C157279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitazalimab","n_c":["C121538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobocertinib","n_c":["C126752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modakafusp Alfa","n_c":["C140427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208","n_c":["C167362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motixafortide","n_c":["C88309"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells","n_c":["C174519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Multi-epitope HER2 Peptide Vaccine TPIV100","n_c":["C173525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Murizatoclax","n_c":["C156740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscadine Grape Extract","n_c":["C175526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MVA-BN Smallpox Vaccine","n_c":["C173552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N-dihydrogalactochitosan","n_c":["C173438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nagrestipen","n_c":["C98294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Naratuximab Emtansine","n_c":["C100101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Navicixizumab","n_c":["C119620"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nogapendekin Alfa","n_c":["C107503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Numidargistat","n_c":["C142866"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nurulimab","n_c":["C156734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Odronextamab","n_c":["C119615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ofranergene Obadenovec","n_c":["C71539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oligo-fucoidan","n_c":["C170752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olinvacimab","n_c":["C102877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Olvimulogene Nanivacirepvec","n_c":["C79833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onatasertib","n_c":["C92575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Adenovirus ORCA-010","n_c":["C168607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Herpes Simplex Virus-1 ONCR-177","n_c":["C171540"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","n_c":["C175473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein","n_c":["C173889"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ontorpacept","n_c":["C125718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Onvatilimab","n_c":["C127124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opolimogene Capmilisbac","n_c":["C125631"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Opucolimab","n_c":["C165270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orelabrutinib","n_c":["C156173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orvacabtagene Autoleucel","n_c":["C147523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oxaliplatin Eluting Beads","n_c":["C172098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p97 Inhibitor CB-5339","n_c":["C167257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p97 Inhibitor CB-5339 Tosylate","n_c":["C167262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pacmilimab","n_c":["C132192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pamrevlumab","n_c":["C92577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-KRAS Inhibitor BI 1701963","n_c":["C166138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-mutation-selective EGFR Inhibitor CLN-081","n_c":["C165567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pan-TRK Inhibitor NOV1601","n_c":["C172394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panulisib","n_c":["C104292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP 1/2 Inhibitor IMP4297","n_c":["C168601"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP Inhibitor NMS-03305293","n_c":["C167278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP7 Inhibitor RBN-2397","n_c":["C170764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parsaclisib","n_c":["C113434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parsaclisib Hydrochloride","n_c":["C166387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201","n_c":["C167207"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patritumab Deruxtecan","n_c":["C136987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paxalisib","n_c":["C116877"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1 Inhibitor GS-4224","n_c":["C170900"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480","n_c":["C174020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegvorhyaluronidase Alfa","n_c":["C82659"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pegylated SN-38 Conjugate PLX038","n_c":["C167334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelabresib","n_c":["C111901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peposertib","n_c":["C120036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC","n_c":["C173152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoantigen DNA Vaccine GNOS-PV01","n_c":["C171430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personalized Neoantigen DNA Vaccine GNOS-PVO2","n_c":["C170950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Photodynamic Compound TLD-1433","n_c":["C172822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pimitespib","n_c":["C134448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pimurutamab","n_c":["C163981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pinatuzumab Vedotin","n_c":["C104167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pixatimod","n_c":["C95202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plamotamab","n_c":["C130050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasmid DNA Vaccine pING-hHER3FL","n_c":["C171387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pNGVL4a-CRT-E6E7L2 DNA Vaccine","n_c":["C175536"],"i_c":"","i_c_s":"","term_type":""},{"nm":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2","n_c":["C172205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255","n_c":["C165666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Porcupine Inhibitor XNW7201","n_c":["C172189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PPAR Alpha Antagonist TPST-1120","n_c":["C169105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pralsetinib","n_c":["C132295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Praluzatamab Ravtansine","n_c":["C134697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PRMT5 Inhibitor PRT811","n_c":["C168531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prolgolimab","n_c":["C148155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostaglandin E2 EP4 Receptor Inhibitor AN0025","n_c":["C129689"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protein Tyrosine Kinase 2 Inhibitor IN10018","n_c":["C166122"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pyruvate Kinase M2 Isoform Activator TP-1454","n_c":["C175380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88","n_c":["C124051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radgocitabine","n_c":["C82697"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radgocitabine Hydrochloride","n_c":["C150430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ragifilimab","n_c":["C126643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Bacterial Minicells VAX014","n_c":["C170742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Erwinia asparaginase JZP-458","n_c":["C64260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human Papillomavirus 11-valent Vaccine","n_c":["C168605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Human TRAIL-Trimer Fusion Protein SCB-313","n_c":["C170907"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301","n_c":["C171377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Redaporfin","n_c":["C114382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RET/SRC Inhibitor TPX-0046","n_c":["C167210"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retifanlimab","n_c":["C142168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Revdofilimab","n_c":["C161864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rezivertinib","n_c":["C154286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ripertamab","n_c":["C124067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roblitinib","n_c":["C120102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ROBO1-targeted BiCAR-NKT Cells","n_c":["C172380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rocakinogene Sifuplasmid","n_c":["C116709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roducitabine","n_c":["C113444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rolinsatamab Talirine","n_c":["C137991"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Roneparstat","n_c":["C104412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ropeginterferon Alfa-2B","n_c":["C111892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ropocamptide","n_c":["C118292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rosopatamab","n_c":["C2652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RSK1-4 Inhibitor PMD-026","n_c":["C166135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruthenium-based Small Molecule Therapeutic BOLD-100","n_c":["C173373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ruxotemitide","n_c":["C90547"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sabatolimab","n_c":["C124850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samrotamab Vedotin","n_c":["C124134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samuraciclib","n_c":["C155652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sasanlimab","n_c":["C124058"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SDF-1 Receptor Antagonist PTX-9908","n_c":["C170746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader LX-039","n_c":["C168606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Selective Estrogen Receptor Degrader LY3484356","n_c":["C174042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serclutamab Talirine","n_c":["C150590"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SERD ZN-c5","n_c":["C167267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serplulimab","n_c":["C156738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shenqi Fuzheng Injection SQ001","n_c":["C171384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SHP2 Inhibitor RLY-1971","n_c":["C172988"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simlukafusp Alfa","n_c":["C129383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simmitinib","n_c":["C170763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simurosertib","n_c":["C126641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Siremadlin","n_c":["C116325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-4-1BBL Fusion Protein DSP107","n_c":["C174171"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SIRPa-Fc-CD40L Fusion Protein SL-172154","n_c":["C173706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotigalimab","n_c":["C123734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sotorasib","n_c":["C154287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spanlecortemlocel","n_c":["C111571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SRPK1/ABCG2 Inhibitor SCO-101","n_c":["C175512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist BMS-986301","n_c":["C167292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist GSK3745417","n_c":["C165748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist IMSA101","n_c":["C165655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist SB 11285","n_c":["C165566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING Agonist TAK-676","n_c":["C173377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"STING-expressing E. coli SYNB1891","n_c":["C167270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sugemalimab","n_c":["C154550"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superoxide Dismutase Mimetic GC4711","n_c":["C173664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synthetic Plumbagin PCUR-101","n_c":["C166377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tafasitamab","n_c":["C95768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taletrectinib","n_c":["C118948"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tamrintamab Pamozirine","n_c":["C124133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tankyrase Inhibitor STP1002","n_c":["C174060"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tapotoclax","n_c":["C127817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tasadenoturev","n_c":["C74067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tebentafusp","n_c":["C94208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Teclistamab","n_c":["C136823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tefinostat","n_c":["C152539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telaglenastat","n_c":["C114381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telaglenastat Hydrochloride","n_c":["C150413"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telisotuzumab","n_c":["C106262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tepoditamab","n_c":["C148141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGF-beta Receptor 1 Kinase Inhibitor SH3051","n_c":["C173370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027","n_c":["C172107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Therapeutic Cancer Vaccine ATP128","n_c":["C165621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anetumab Corixetan","n_c":["C155977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439","n_c":["C168996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497","n_c":["C175301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymidylate Synthase Inhibitor CX1106","n_c":["C168609"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TIGIT Inhibitor M6223","n_c":["C173891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tilogotamab","n_c":["C153259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tiomolibdate Choline","n_c":["C62514"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tirbanibulin","n_c":["C74077"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7 agonist BNT411","n_c":["C167350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR7 Agonist LHC165","n_c":["C166362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells","n_c":["C173965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tolebrutinib","n_c":["C173549"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Topotecan Sustained-release Episcleral Plaque","n_c":["C173363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Deruxtecan","n_c":["C128799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab Monomethyl Auristatin F","n_c":["C172821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trastuzumab-TLR 7/8 Agonist BDC-1001","n_c":["C172388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tris-acryl Gelatin Microspheres","n_c":["C126803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TRK Inhibitor TQB3558","n_c":["C173560"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Troriluzole","n_c":["C142847"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosine Kinase Inhibitor TL-895","n_c":["C129710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upifitamab","n_c":["C147578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urabrelimab","n_c":["C155976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ursolic Acid","n_c":["C172843"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uzansertib","n_c":["C124226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valecobulin","n_c":["C101264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Valemetostat","n_c":["C127114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vesencumab","n_c":["C91728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vibecotamab","n_c":["C127120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vibostolimab","n_c":["C140041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vorasidenib","n_c":["C152914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulinacimab","n_c":["C156172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wee1 Inhibitor ZN-c3","n_c":["C167064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wee1 Kinase Inhibitor Debio 0123","n_c":["C173426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xevinapant","n_c":["C90574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xiliertinib","n_c":["C162552"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Xisomab 3G3","n_c":["C171173"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yttrium Y 90 Tabituximab Barzuxetan","n_c":["C99168"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zandelisib","n_c":["C123925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zanidatamab","n_c":["C130010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zelavespib","n_c":["C101227"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zorifertinib","n_c":["C118289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zotatifin","n_c":["C165746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zotiraciclib Citrate","n_c":["C105851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Giloralimab","n_c":["C139553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vosilasarm","n_c":["C137950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interferon Alfa-2B","n_c":["C1953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Levoleucovorin Calcium","n_c":["C66721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mistletoe Extract","n_c":["C2703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10","n_c":["C172104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EGFR Mutant-selective Inhibitor TQB3804","n_c":["C173415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liposomal Bcl-2 Antisense Oligonucleotide BP1002","n_c":["C170743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canakinumab","n_c":["C80971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rivaroxaban","n_c":["C77995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TLR9 Agonist SD-101","n_c":["C74084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alextatug","n_c":["C172924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide","n_c":["C158083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CT2584","n_c":["C1729"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.analyte.experimental_protocol_type":[{"nm":"Genomplex","n_c":["C128787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G","n_c":["C128788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Repli-G X","n_c":["C156439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA","n_c":["C163995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"aDNA Preparation Type","n_c":["C179426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allprep FFPE DNA","n_c":["C179428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allprep RNA Extraction","n_c":["C179430"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical Lysis DNA Extraction","n_c":["C179431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HighPure miRNA (Allprep DNA) FFPE RNA","n_c":["C179436"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mirVana (Allprep DNA) RNA","n_c":["C179446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pre-extracted DNA received by TSS","n_c":["C179449"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ann_arbor_b_symptoms_described":[{"nm":"Fever","n_c":["C3038"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Night Sweats","n_c":["C3279"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weight Loss","n_c":["C3445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.necrosis_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.rhabdoid_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.sarcomatoid_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.chipseq_antibody":[{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.read_group.fragmentation_enzyme":[{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.data_category":[{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.data_type":[{"nm":"Aligned Reads","n_c":["C164052"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.data_format":[{"nm":"BAM","n_c":["C153249"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HiChIP","n_c":["C179435"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scATAC-Seq","n_c":["C179458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Validation","n_c":["C16237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"index_file.aligned_reads_index.data_category":[{"nm":"Sequencing Data","n_c":["C153329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sequencing Reads","n_c":["C153349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Sequencing Data","n_c":["C165232"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.gender":[{"nm":"female","n_c":["C16576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"male","n_c":["C20197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"unspecified","n_c":["C38046"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.ethnicity":[{"nm":"hispanic or latino","n_c":["C17459"],"i_c":"","i_c_s":"","term_type":""},{"nm":"not hispanic or latino","n_c":["C41222"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.race":[{"nm":"not reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"white","n_c":["C41261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"american indian or alaska native","n_c":["C41259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"black or african american","n_c":["C16352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"asian","n_c":["C41260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"native hawaiian or other pacific islander","n_c":["C41219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""}],"clinical.clinical.vital_status":[{"nm":"alive","n_c":["C37987"],"i_c":"","i_c_s":"","term_type":""},{"nm":"dead","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"lost to follow-up","n_c":["C48227"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.platform":[{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.platform":[{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSV","n_c":["C182456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDF5","n_c":["C184763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MEX","n_c":["C184778"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.experimental_strategy":[{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Total RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"m6A MeRIP-Seq","n_c":["C188371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Expression Array","n_c":["C93207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.data_format":[{"nm":"MAF","n_c":["C172215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.data_type":[{"nm":"Methylation Beta Value","n_c":["C164051"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.data_format":[{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSV","n_c":["C182456"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.experimental_strategy":[{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.data_category":[{"nm":"DNA Methylation","n_c":["C63328"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.experimental_strategy":[{"nm":"Methylation Array","n_c":["C165222"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HDF5","n_c":["C184763"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.data_format":[{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"gVCF","n_c":["C204352"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.data_category":[{"nm":"Combined Nucleotide Variation","n_c":["C171155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.data_format":[{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.experimental_strategy":[{"nm":"ATAC-Seq","n_c":["C156056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bisulfite-Seq","n_c":["C106054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ChIP-Seq","n_c":["C106049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Pass WGS","n_c":["C165220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA-Seq","n_c":["C156057"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.data_format":[{"nm":"TSV","n_c":["C164049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TXT","n_c":["C85873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"VCF","n_c":["C172216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"FASTA","n_c":["C47845"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CSV","n_c":["C182456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BEDPE","n_c":["C184749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GVF","n_c":["C184761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"JSON","n_c":["C184769"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.experimental_strategy":[{"nm":"RNA-Seq","n_c":["C124261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Targeted Sequencing","n_c":["C130177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"WXS","n_c":["C101295"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.experimental_strategy":[{"nm":"Genotyping Array","n_c":["C165219"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.test_units":[{"nm":"g/dL","n_c":["C64783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/L","n_c":["C42576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mcg/mL","n_c":["C64572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/dL","n_c":["C67015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/L","n_c":["C64572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mmol/L","n_c":["C64387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U/g Hb","n_c":["C105522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U/mL","n_c":["C77607"],"i_c":"","i_c_s":"","term_type":""},{"nm":"U/L","n_c":["C67456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ukat/L","n_c":["C67397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"umol/L","n_c":["C48508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"x10^3 cells/mcL","n_c":["C67244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"x10^9 cells/L","n_c":["C67249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mm^2","n_c":["C65104"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mU/mol Hb","n_c":["C184780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ng/mL","n_c":["C67306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"percent","n_c":["C48570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cells/mL","n_c":["C74919"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mcg/L","n_c":["C67306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/24 hr","n_c":["C67399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IU","n_c":["C48579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"nmol/L","n_c":["C67432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seconds","n_c":["C42535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"x10^6 cells/mcL","n_c":["C67251"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.additional_pathology_findings":[{"nm":"Pleurodesis, Talc","n_c":["C178422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleurodesis, NOS","n_c":["C66899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asbestos bodies","n_c":["C36015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN)","n_c":["C27789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune atrophic chronic gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign endocervical polyp","n_c":["C34584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carcinoma in situ","n_c":["C2917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clostridioides difficile (c. diff)","n_c":["C180523"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization; bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization; fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysplasia; high grade","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dysplasia; low grade","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperkeratosis","n_c":["C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leiomyoma","n_c":["C3157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Platinum-resistant","n_c":["C147558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary interstitial fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinonasal papilloma","n_c":["C4117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous papilloma; solitary","n_c":["C3712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous papillomatosis","n_c":["C9009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated lymphoid proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Percent follicular component <= 10%","n_c":["C188349"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Percent follicular component > 10%","n_c":["C188350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PD-L1 CPS (223C LDT) - 20%","n_c":["C188351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow concordant histology","n_c":["C198920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow discordant histology","n_c":["C198921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometrial polyp","n_c":["C6433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extravascular Matrix Loops","n_c":["C111025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Complex Extravascular Matrix Patterns","n_c":["C111024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poorly Differentiated","n_c":["C14167"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Well Differentiated","n_c":["C14171"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.consistent_pathology_review":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.residual_tumor":[{"nm":"RX","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R0","n_c":["C139578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C139579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C139580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"case.project.state":[{"nm":"open","n_c":["C49069"],"i_c":"","i_c_s":"","term_type":""},{"nm":"review","n_c":["C42729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"submitted","n_c":["C25695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"processing","n_c":["C48177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"closed","n_c":["C49070"],"i_c":"","i_c_s":"","term_type":""},{"nm":"legacy","n_c":["C184772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"processed","n_c":["C184788"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.data_category":[{"nm":"Proteome Profiling","n_c":["C62669"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.data_type":[{"nm":"Protein Expression Quantification","n_c":["C63480"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.channel":[{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red","n_c":["C48326"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.data_category":[{"nm":"Transcriptome Profiling","n_c":["C153189"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.experimental_strategy":[{"nm":"scRNA-Seq","n_c":["C171152"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.route_of_administration":[{"nm":"Intrathecal","n_c":["C38267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravenous","n_c":["C38276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral","n_c":["C38288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intrahepatic","n_c":["C38248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intramuscular","n_c":["C28161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraperitoneal","n_c":["C38258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intratumoral","n_c":["C38269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravesical","n_c":["C38278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous","n_c":["C38299"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.eye_color":[{"nm":"Amber","n_c":["C111017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blue","n_c":["C48333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brown","n_c":["C48332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gray","n_c":["C48324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hazel","n_c":["C111018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red & Violet","n_c":["C157431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C160244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.history_of_tumor":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.parent_with_radiation_exposure":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_corrected":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_corrected_laterality":[{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_corrected_method":[{"nm":"Orchiopexy","n_c":["C111066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hormones","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis Removed","n_c":["C15288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Descent","n_c":["C184803"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_history":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.undescended_testis_history_laterality":[{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.adrenal_hormone":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.channel":[{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red","n_c":["C48326"],"i_c":"","i_c_s":"","term_type":""}],"data_file.archive.data_category":[{"nm":"Archive","n_c":["C156018"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.data_category":[{"nm":"Transcriptome Profiling","n_c":["C153189"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.data_category":[{"nm":"Transcriptome Profiling","n_c":["C153189"],"i_c":"","i_c_s":"","term_type":""}],"data_file.archive.data_format":[{"nm":"MAGETAB","n_c":["C82937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TARGZ","n_c":["C184805"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.msi_status":[{"nm":"MSI","n_c":["C36318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MSS","n_c":["C131459"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.data_type":[{"nm":"Supplementary Files","n_c":["C60763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isoform Expression Quantification","n_c":["C184767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"miRNA Expression Quantification","n_c":["C184779"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.history_of_tumor_type":[{"nm":"Phenochromocytoma or Paraganglioma","n_c":["C185075"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colorectal Cancer","n_c":["C198972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lower Grade Glioma","n_c":["C198973"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"index_file.somatic_mutation_index.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somatic Structural Variation","n_c":["C184801"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.data_category":[{"nm":"Somatic Structural Variation","n_c":["C184801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Structural Variation","n_c":["C2950"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.data_format":[{"nm":"IDAT","n_c":["C184762"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.data_format":[{"nm":"IDAT","n_c":["C184762"],"i_c":"","i_c_s":"","term_type":""}],"index_file.somatic_mutation_index.data_format":[{"nm":"TBI","n_c":["C184806"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.data_type":[{"nm":"Aggregated Somatic Mutation","n_c":["C184741"],"i_c":"","i_c_s":"","term_type":""}],"index_file.aligned_reads_index.data_type":[{"nm":"Aligned Reads Index","n_c":["C184742"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_segment.data_type":[{"nm":"Allele-specific Copy Number Segment","n_c":["C184745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copy Number Segment","n_c":["C184744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masked Copy Number Segment","n_c":["C184776"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.data_type":[{"nm":"Annotated Somatic Mutation","n_c":["C184746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masked Annotated Somatic Mutation","n_c":["C184775"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_estimate.data_type":[{"nm":"Cohort Level Copy Number Scores","n_c":["C184752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gene Level Copy Number","n_c":["C181336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gene Level Copy Number Scores","n_c":["C184759"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.data_type":[{"nm":"Copy Number Segment","n_c":["C184744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Masked Copy Number Segment","n_c":["C184776"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.data_type":[{"nm":"Differential Gene Expression","n_c":["C184755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Single Cell Analysis","n_c":["C184799"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.data_type":[{"nm":"Exon Expression Quantification","n_c":["C184756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gene Expression Quantification","n_c":["C135484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isoform Expression Quantification","n_c":["C184767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splice Junction Quantification","n_c":["C184802"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.data_type":[{"nm":"Masked Intensities","n_c":["C184774"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.data_type":[{"nm":"Masked Somatic Mutation","n_c":["C184777"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.data_type":[{"nm":"Raw CGI Variant","n_c":["C184794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Raw Simple Somatic Mutation","n_c":["C184795"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.data_type":[{"nm":"Raw Intensities","n_c":["C184793"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.data_type":[{"nm":"Raw Intensities","n_c":["C184793"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.data_type":[{"nm":"Simple Germline Variation","n_c":["C17666"],"i_c":"","i_c_s":"","term_type":""}],"index_file.somatic_mutation_index.data_type":[{"nm":"Somatic Mutation Index","n_c":["C206457"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.data_type":[{"nm":"Structural Alteration","n_c":["C2950"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Structural Rearrangement","n_c":["C36541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transcript Fusion","n_c":["C184809"],"i_c":"","i_c_s":"","term_type":""}],"data_file.archive.data_type":[{"nm":"TARGET DCC Archive","n_c":["C184807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TCGA DCC Archive","n_c":["C184808"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.experimental_strategy":[{"nm":"Reverse Phase Protein Array","n_c":["C184797"],"i_c":"","i_c_s":"","term_type":""}],"data_file.protein_expression.platform":[{"nm":"RPPA","n_c":["C184797"],"i_c":"","i_c_s":"","term_type":""}],"analysis.alignment_workflow.type":[{"nm":"alignment_workflow","n_c":["C184743"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.asbestos_exposure_type":[{"nm":"Amosite","n_c":["C45527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crocidolite","n_c":["C29816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.clinical_trial_indicator":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.double_expressor_lymphoma":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.double_hit_lymphoma":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.drug_category":[{"nm":"Glucocorticoid","n_c":["C521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Growth factor","n_c":["C530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PARP inhibitor","n_c":["C62554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.embolic_agent":[{"nm":"Gelfoam","n_c":["C38705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lipiodol","n_c":["C487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plastic Beads","n_c":["C97233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PVA Particles","n_c":["C71147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spherical Particles","n_c":["C97230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y-90 Sirsphere","n_c":["C64539"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Y-90 Therasphere","n_c":["C38679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.exposure_source":[{"nm":"Secondary","n_c":["C188376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occupational","n_c":["C16929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Home","n_c":["C202294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social","n_c":["C202295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Work","n_c":["C16929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.hpv_strain":[{"nm":"HPV16","n_c":["C14338"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV18","n_c":["C14377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV31","n_c":["C102904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV33","n_c":["C102996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV35","n_c":["C102997"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV39","n_c":["C102998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV45","n_c":["C102999"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV51","n_c":["C103000"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV52","n_c":["C103001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV56","n_c":["C103003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV58","n_c":["C103004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV59","n_c":["C103005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV66","n_c":["C103006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV68","n_c":["C103007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HPV73","n_c":["C103008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.max_tumor_bulk_site":[{"nm":"No known nodal involvement","n_c":["C188386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites/peritoneum","n_c":["C159203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axillary lymph nodes","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical lymph nodes","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iliac-external","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inguinal","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal lymph nodes","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal soft tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesenteric lymph nodes","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraaortic lymph nodes","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peri-orbital soft tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal lymph nodes","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft tissue (muscle, ligaments, subcutaneous)","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic lymph nodes","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Submandibular lymph nodes","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Supraclavicular lymph nodes","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.sites_of_involvement":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Peritoneum","n_c":["C159355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adnexa","n_c":["C137974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal gland, NOS","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus, NOS","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder, NOS","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone, NOS","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, NOS","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast, NOS","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central nervous system","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon, NOS","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube, Left","n_c":["C32959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube, NOS","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube, Right","n_c":["C33475"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, Lower Pole","n_c":["C93180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, Middle","n_c":["C186124"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, NOS","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney, Upper Pole","n_c":["C93179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx, NOS","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lower lobe, lung","n_c":["C12287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung, NOS","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph node, NOS","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal soft tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle lobe, lung","n_c":["C12286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mouth","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal soft tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary, Left","n_c":["C32969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary, NOS","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary, Right","n_c":["C33487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Peritoneum","n_c":["C159344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Perineum","n_c":["C33301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peri-orbital soft tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral blood","n_c":["C173496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral nervous system","n_c":["C12465"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum, NOS","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small intestine","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testes","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea","n_c":["C12428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transplanted kidney","n_c":["C26990"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Upper lobe, lung","n_c":["C12285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebrae","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Brain stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Cerebellum, NOS","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Frontal lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Occipital lobe","n_c":["C12355"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Parietal","n_c":["C12354"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Temporal lobe","n_c":["C12353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain, Ventricle, NOS","n_c":["C12356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Lung","n_c":["C159213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrosplenic Ligament","n_c":["C32671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium, Left","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium, Right","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvic Lymph Node(s)","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Lung","n_c":["C159212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax, NOS","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Nodes","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Organ","n_c":["C172223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Great Blood Vessel","n_c":["C102955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inferior Vena Cava","n_c":["C12815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Axillary","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Subcarinal","n_c":["C117873"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Vein","n_c":["C33462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebral Canal","n_c":["C33869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva, NOS","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Gland Isthmus","n_c":["C32887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dura Mater","n_c":["C32488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus, Lower Third","n_c":["C12255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus, Middle Third","n_c":["C12254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus, NOS","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus, Upper Third","n_c":["C12253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Iliac-Common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Iliac-External","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Para-Aortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node, Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Body","n_c":["C12270"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Duct","n_c":["C12272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Head","n_c":["C12269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas Tail","n_c":["C12271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas, NOS","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium, NOS","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_m":[{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_stage":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_clinical_t":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C47858"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_m":[{"nm":"cM0 (i+)","n_c":["C95956"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M0","n_c":["C48699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C48700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1a","n_c":["C48701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1b","n_c":["C48702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1c","n_c":["C48703"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MX","n_c":["C48704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1d","n_c":["C188301"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M2","n_c":["C188299"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_n":[{"nm":"N0","n_c":["C48705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i-)","n_c":["C95921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (i+)","n_c":["C95922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol-)","n_c":["C95923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N0 (mol+)","n_c":["C95925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C48706"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1a","n_c":["C48707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1b","n_c":["C48708"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bI","n_c":["C95929"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bII","n_c":["C95935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIII","n_c":["C95936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1bIV","n_c":["C95937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1c","n_c":["C48709"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1mi","n_c":["C95955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2","n_c":["C48786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2a","n_c":["C48711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2b","n_c":["C48712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N2c","n_c":["C48713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3","n_c":["C48714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3a","n_c":["C48715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3b","n_c":["C48716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N3c","n_c":["C48717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N4","n_c":["C96026"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"NX","n_c":["C48718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_stage":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0","n_c":["C28051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0a","n_c":["C27964"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage 0is","n_c":["C27965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage I","n_c":["C27966"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA","n_c":["C27975"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA1","n_c":["C27983"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA2","n_c":["C27984"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IA3","n_c":["C136485"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB","n_c":["C27976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB1","n_c":["C28052"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IB2","n_c":["C28053"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IC","n_c":["C27981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C28054"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA","n_c":["C27967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA1","n_c":["C95177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIA2","n_c":["C95178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIB","n_c":["C27968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIC","n_c":["C27969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C27970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA","n_c":["C27977"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA1","n_c":["C139980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIA2","n_c":["C139981"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIB","n_c":["C27978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC","n_c":["C27982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC1","n_c":["C95179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIIC2","n_c":["C95180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IIID","n_c":["C137676"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IS","n_c":["C28285"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C27971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVA","n_c":["C27979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVB","n_c":["C27980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IVC","n_c":["C28055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage X","n_c":["C95957"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_pathologic_t":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T0","n_c":["C48719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1","n_c":["C48720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a","n_c":["C48721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a1","n_c":["C188292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1a2","n_c":["C188293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b","n_c":["C48722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b1","n_c":["C188294"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1b2","n_c":["C188295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1c","n_c":["C48723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T1mi","n_c":["C95805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C48724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a","n_c":["C48725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a1","n_c":["C188296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2a2","n_c":["C188297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2b","n_c":["C48726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2c","n_c":["C48727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2d","n_c":["C148411"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3a","n_c":["C48729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3b","n_c":["C48730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3c","n_c":["C48731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3d","n_c":["C148412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C48732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4a","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4b","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4c","n_c":["C48735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4d","n_c":["C48736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4e","n_c":["C188298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ta","n_c":["C96025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis","n_c":["C48738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (DCIS)","n_c":["C139414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (LCIS)","n_c":["C48976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tis (Paget's)","n_c":["C139415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"TX","n_c":["C48737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.zone_of_origin_prostate":[{"nm":"Central zone","n_c":["C128572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Overlapping/multiple zones","n_c":["C157522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral zone","n_c":["C128570"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transition zone","n_c":["C128571"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown zone","n_c":["C160198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.data_format":[{"nm":"CEL","n_c":["C191737"],"i_c":"","i_c_s":"","term_type":""}],"index_file.aligned_reads_index.data_format":[{"nm":"BAI","n_c":["C190163"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.alcohol_frequency":[{"nm":"Daily Drinker","n_c":["C198923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Weekly Drinker","n_c":["C198924"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.aneuploidy":[{"nm":"Monosomy","n_c":["C3239"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trisomy","n_c":["C3421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.cancer_detection_method":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Screening","n_c":["C15406"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surveillance","n_c":["C15719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Symptomatic","n_c":["C168447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.chemical_exposure_type":[{"nm":"Agent Orange","n_c":["C198925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aluminum","n_c":["C198926"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arsenic","n_c":["C165476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asbestos","n_c":["C55816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benzene","n_c":["C36251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cadmium","n_c":["C198927"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical Exposure, NOS","n_c":["C36290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chromium","n_c":["C198934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coal Gas, Coal Tar, Coal Tar Pitch, and Derivatives","n_c":["C177574"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coke Oven Emission","n_c":["C157008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Copper","n_c":["C198935"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diesel Exhaust","n_c":["C198936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Disinfectant","n_c":["C198937"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Formaldehyde","n_c":["C198938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methylene Chloride","n_c":["C198939"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occupational Soldering/Welding Smoke Exposure","n_c":["C164120"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oil","n_c":["C198940"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pesticide","n_c":["C198941"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Petroleum Hydrocarbon Compound","n_c":["C198942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Resin Fumes","n_c":["C198943"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sodium Borate","n_c":["C198944"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solvent","n_c":["C198945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tetrachloroethylene","n_c":["C198946"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toluene","n_c":["C198947"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.chromosomal_translocation":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(10;11)(p11.2;q23)","n_c":["C168758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(11;19)(q23;p13.1)","n_c":["C36371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(3;5)(q25;q34)","n_c":["C36415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(6;11)(q27;q23)","n_c":["C36610"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(6;9)","n_c":["C128650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(8;21)","n_c":["C119608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(9;11)(p22;q23)","n_c":["C36370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(15;17)","n_c":["C128656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(4;11)","n_c":["C128652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(9;11)","n_c":["C113505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"t(9;22)","n_c":["C117116"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.chromosome_arm":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"p","n_c":["C198952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"q","n_c":["C198953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.comorbidities":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Renal Failure","n_c":["C26808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenocarcinoma","n_c":["C2852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomatous Polyposis Coli","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenocortical Insufficiency","n_c":["C26691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergies","n_c":["C114476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C26696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arrhythmia","n_c":["C2881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C2883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C50466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C118385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Carcinoma","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Disorder","n_c":["C2899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Clots","n_c":["C27083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Fracture(s)","n_c":["C3046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchitis","n_c":["C2911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Channel Blockers","n_c":["C333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataracts","n_c":["C26713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celiac Disease","n_c":["C26714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrovascular Disease","n_c":["C2938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Fatigue Syndrome","n_c":["C3037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Renal Failure","n_c":["C9438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis, Unknown Etiology","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clonal Hematopoiesis","n_c":["C162188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Infection","n_c":["C27582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immunodeficiency","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congestive Heart Failure (CHF)","n_c":["C3080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue Disorder","n_c":["C26729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COPD","n_c":["C3199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coronary Artery Disease","n_c":["C26732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crohn's Disease","n_c":["C2965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C62586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptogenic Organizing Pneumonia","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Vein Thrombosis / Thromboembolism","n_c":["C49343","C28195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C2982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetic Neuropathy","n_c":["C26748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet Controlled Diabetes","n_c":["C184754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DVT/PE","n_c":["C49343","C50713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyslipidemia","n_c":["C80385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epilepsy","n_c":["C3020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromyalgia","n_c":["C87497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GERD","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C26782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycogen Storage Disease","n_c":["C61272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadal Dysfunction","n_c":["C26786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gout","n_c":["C34650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H. pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Disease","n_c":["C3079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhagic Cystitis","n_c":["C114666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, Chronic","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Non-polyposis Colon Cancer","n_c":["C120083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Liver Dysplastic Nodule","n_c":["C96768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV / AIDS","n_c":["C2851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HUS/TTP","n_c":["C75545","C78797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C3112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercholesterolemia","n_c":["C37967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C26797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperlipidemia","n_c":["C34707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C3117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammatory Bowel Disease","n_c":["C3138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin Controlled Diabetes","n_c":["C184766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interstitial Pneumontis or ARDS","n_c":["C3353","C27006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraductal Papillary Mucinous Neoplasm","n_c":["C38342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemic Heart Disease","n_c":["C50625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITP","n_c":["C3446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Replacement","n_c":["C131579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Disease","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cirrhosis (Liver Disease)","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Toxicity (Non-Infectious)","n_c":["C184773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Liver Dysplastic Nodule","n_c":["C96770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupus","n_c":["C27153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAI","n_c":["C27314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methicillin-Resistant Staphylococcus aureus (MRSA)","n_c":["C115248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C27996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroendocrine Tumor","n_c":["C3809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ transplant (site)","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoarthritis","n_c":["C3293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis or Osteopenia","n_c":["C50910","C3298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Cancer Within 5 Years","n_c":["C184782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Nonmalignant Systemic Disease","n_c":["C184785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Pulmonary Complications","n_c":["C184786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain (Various)","n_c":["C3303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptic Ulcer (Ulcer)","n_c":["C3318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Neuropathy","n_c":["C119734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Vascular Disease","n_c":["C35136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peutz-Jeghers Disease","n_c":["C3324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy in Patient or Partner","n_c":["C124295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psoriasis","n_c":["C3346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hemorrhage","n_c":["C78578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Dialysis","n_c":["C15248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Failure (Requiring Dialysis)","n_c":["C184791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Insufficiency","n_c":["C4376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatologic Disease","n_c":["C27204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep apnea","n_c":["C26884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking","n_c":["C154329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staph Osteomyelitis","n_c":["C188353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C3390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Disease, Non-Cancer","n_c":["C27566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attack","n_c":["C50781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinemia","n_c":["C98640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulcerative Colitis","n_c":["C2952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C50791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.data_category":[{"nm":"Copy Number Variation","n_c":["C40207"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.data_format":[{"nm":"TAR","n_c":["C190189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PDF","n_c":["C63805"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.data_type":[{"nm":"Intermediate Analysis Archive","n_c":["C198955"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNV Model","n_c":["C206460"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.evidence_of_progression_type":[{"nm":"Convincing Image Source","n_c":["C158782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histologic Confirmation","n_c":["C158780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.experimental_strategy":[{"nm":"WGS","n_c":["C101294"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extracapsular_extension":[{"nm":"Extensive","n_c":["C198967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Focal","n_c":["C198968"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extranodal_extension":[{"nm":"Gross Extension","n_c":["C198969"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic Extension","n_c":["C198970"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Extranodal Extension","n_c":["C160838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.fab_morphology_code":[{"nm":"M0","n_c":["C8460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C3249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M2","n_c":["C3250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M3","n_c":["C3182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M4","n_c":["C7463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M5","n_c":["C4861"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M6","n_c":["C8923"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M7","n_c":["C3170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Classified","n_c":["C27753"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.first_event":[{"nm":"Censored","n_c":["C118962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death","n_c":["C28554"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Death without Remission","n_c":["C199218"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Event","n_c":["C25499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction Death","n_c":["C121972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induction Failure","n_c":["C70622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Relapse","n_c":["C38155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Second Malignant Neoplasm","n_c":["C95606"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Presented with Metastases","n_c":["C40557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence","n_c":["C38155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_anatomic_site":[{"nm":"Abdomen","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.imaging_findings":[{"nm":"Carcinomatosis","n_c":["C3693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Involvement","n_c":["C199151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Involvement","n_c":["C199154"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung Involvement","n_c":["C199155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Normal","n_c":["C14165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneal Lymph Node Involvement","n_c":["C199157"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vena Cava Involvement/Thrombus","n_c":["C199158"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Metastasis","n_c":["C18206"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equivocal","n_c":["C86071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extraprostatic Extension, Localized","n_c":["C206461"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Extraprostatic Extension, Regional Lymphadenopathy","n_c":["C206462"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Evidence of Extraprostatic Extension","n_c":["C206463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_dissection_method":[{"nm":"Functional (Limited) Neck Dissection","n_c":["C148527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Modified Radical Neck Dissection","n_c":["C51904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Neck Dissection","n_c":["C51759"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_node_dissection_site":[{"nm":"Neck, Left","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck, NOS","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck, Right","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.lymph_nodes_removed":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.exposure.occupation_type":[{"nm":"Administration Professionals","n_c":["C198715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Administrative and Specialized Secretaries","n_c":["C198716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Agricultural, Forestry and Fishery Labourers","n_c":["C97632"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Animal Producers","n_c":["C198717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Architects, Planners, Surveyors and Designers","n_c":["C198718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Armed Forces Occupations, Other Ranks","n_c":["C198719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artistic, Cultural and Culinary Associate Professionals","n_c":["C198720"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Assemblers","n_c":["C198721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Authors, Journalists and Linguists","n_c":["C198722"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blacksmiths, Toolmakers and Related Trades Workers","n_c":["C198723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Building and Housekeeping Supervisors","n_c":["C198724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Building Finishers and Related Trades Workers","n_c":["C198725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Building Frame and Related Trades Workers","n_c":["C198726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Business Services Agents","n_c":["C198727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Business Services and Administration Managers","n_c":["C198728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Car, Van and Motorcycle Drivers","n_c":["C198729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cashiers and Ticket Clerks","n_c":["C198730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chemical and Photographic Products Plant and Machine Operators","n_c":["C198731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Child Care Workers and Teachers' Aides","n_c":["C198732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Client Information Workers","n_c":["C198733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Commissioned Armed Forces Officers","n_c":["C198734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cooks","n_c":["C122440"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Creative and Performing Artists","n_c":["C80245"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Database and Network Professionals","n_c":["C198735"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domestic, Hotel and Office Cleaners and Helpers","n_c":["C198736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrical Equipment Installers and Repairers","n_c":["C122446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electronics and Telecommunications Installers and Repairers","n_c":["C198737"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Electrotechnology Engineers","n_c":["C198738"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Engineering Professionals (excluding Electrotechnology)","n_c":["C122447"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finance Professionals","n_c":["C122452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Financial and Mathematical Associate Professionals","n_c":["C198739"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fishery Workers, Hunters and Trappers","n_c":["C198740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Food and Related Products Machine Operators","n_c":["C198741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Food Preparation Assistants","n_c":["C198742"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Food Processing and Related Trades Workers","n_c":["C198743"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forestry and Related Workers","n_c":["C198744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Garment and Related Trades Workers","n_c":["C198745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"General Office Clerks","n_c":["C198746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Government Regulatory Associate Professionals","n_c":["C198747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hairdressers, Beauticians and Related Workers","n_c":["C198748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Handicraft Workers","n_c":["C198749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heavy Truck and Bus Drivers","n_c":["C198750"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hotel and Restaurant Managers","n_c":["C198751"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Information and Communications Technology Operations and User Support Technicians","n_c":["C198752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Information and Communications Technology Service managers","n_c":["C198753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Keyboard Operators","n_c":["C198754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legal Professionals","n_c":["C97637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legal, Social and Religious Associate Professionals","n_c":["C198822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Legislators and Senior Officials","n_c":["C198755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Librarians, Archivists and Curators","n_c":["C122473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Life Science Professionals","n_c":["C122474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Life Science Technicians and Related Associate Professionals","n_c":["C198756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locomotive Engine Drivers and Related Workers","n_c":["C198757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Machinery Mechanics and Repairers","n_c":["C198758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Managing Directors and Chief Executives","n_c":["C198759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Manufacturing Labourers","n_c":["C25392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Manufacturing, Mining, Construction and Distribution Managers","n_c":["C198760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Market Gardeners and Crop Growers","n_c":["C198761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Material Recording and Transport Clerks","n_c":["C198762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mathematicians, Actuaries and Statisticians","n_c":["C198763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medical and Pharmaceutical Technicians","n_c":["C198764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medical Doctors","n_c":["C25741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metal Processing and Finishing Plant Operators","n_c":["C198765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mining and Construction Labourers","n_c":["C198766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mining and Mineral Processing Plant Operators","n_c":["C198767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mining, Manufacturing and Construction Supervisors","n_c":["C198768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Crop and Animal Producers","n_c":["C198769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mobile Plant Operators","n_c":["C198770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Non-commissioned Armed Forces Officers","n_c":["C198771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Numerical Clerks","n_c":["C198772"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nursing and Midwifery Associate Professionals","n_c":["C198773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nursing and Midwifery Professionals","n_c":["C198774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Clerical Support Workers","n_c":["C198775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Craft and Related Workers","n_c":["C198776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Elementary Workers","n_c":["C198777"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Health Associate Professionals","n_c":["C198778"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Health Professionals","n_c":["C198779"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Personal Services Workers","n_c":["C198780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Sales Workers","n_c":["C122555"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Services Managers","n_c":["C198781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Stationary Plant and Machine Operators","n_c":["C198782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Teaching Professionals","n_c":["C122556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Painters, Building Structure Cleaners and Related Trades Workers","n_c":["C198783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paramedical Practitioners","n_c":["C53420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Personal Care Workers in Health Services","n_c":["C198784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical and Earth Science Professionals","n_c":["C198785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Physical and Engineering Science Technicians","n_c":["C198786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary School and Early Childhood Teachers","n_c":["C198787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Printing Trades Workers","n_c":["C122501"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Process Control Technicians","n_c":["C198788"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Production Managers in Agriculture, Forestry and Fisheries","n_c":["C198789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Professional Services Managers","n_c":["C198790"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Protective Services Workers","n_c":["C97643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Refuse Workers","n_c":["C198791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retail and Wholesale Trade Managers","n_c":["C198792"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubber, Plastic and Paper Products Machine Operators","n_c":["C198793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sales and Purchasing Agents and Brokers","n_c":["C198794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sales, Marketing and Development Managers","n_c":["C198795"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sales, Marketing and Public Relations Professionals","n_c":["C198796"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Secondary Education Teachers","n_c":["C198797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Secretaries (general)","n_c":["C198798"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sheet and Structural Metal Workers, Moulders and Welders, and Related Workers","n_c":["C198799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ship and Aircraft Controllers and Technicians","n_c":["C198800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ships' Deck Crews and Related Workers","n_c":["C198801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shop Salespersons","n_c":["C75553"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Social and Religious Professionals","n_c":["C198802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Software and Applications Developers and Analysts","n_c":["C198803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sports and Fitness Workers","n_c":["C198804"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Street and Market Salespersons","n_c":["C198805"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Street and Related Service Workers","n_c":["C198806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Street Vendors (excluding Food)","n_c":["C198807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Crop Farmers","n_c":["C198808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Fishers, Hunters, Trappers and Gatherers","n_c":["C198809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Livestock Farmers","n_c":["C198810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subsistence Mixed Crop and Livestock Farmers","n_c":["C198811"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Telecommunications and Broadcasting Technicians","n_c":["C198812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tellers, Money Collectors and Related Clerks","n_c":["C122451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Textile, Fur and Leather Products Machine Operators","n_c":["C198813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Traditional and Complementary Medicine Associate Professionals","n_c":["C198814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Traditional and Complementary Medicine Professionals","n_c":["C198815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transport and Storage Labourers","n_c":["C198816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Travel Attendants, Conductors and Guides","n_c":["C198817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"University and Higher Education Teachers","n_c":["C122499"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vehicle, Window, Laundry and Other Hand Cleaning Workers","n_c":["C198818"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veterinarians","n_c":["C82470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Veterinary Technicians and Assistants","n_c":["C82473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vocational education teachers","n_c":["C198819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Waiters and Bartenders","n_c":["C122460"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood Processing and Papermaking Plant Operators","n_c":["C198820"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wood Treaters, Cabinet-makers and Related Trades Workers","n_c":["C198821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.peritoneal_washing_results":[{"nm":"Negative","n_c":["C38757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Positive","n_c":["C38758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data_file.copy_number_auxiliary_file.platform":[{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.residual_disease":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R0","n_c":["C139578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R1","n_c":["C139579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"R2","n_c":["C139580"],"i_c":"","i_c_s":"","term_type":""},{"nm":"RX","n_c":["C139581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.residual_tumor_measurement":[{"nm":">20 mm","n_c":["C199161"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1-10 mm","n_c":["C199163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"11-20 mm","n_c":["C199164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No macroscopic disease","n_c":["C199165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factor_method_of_diagnosis":[{"nm":"Biochemical Assessment","n_c":["C199177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Both Clinical and Biochemical Assessments","n_c":["C199179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Assessment","n_c":["C199178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.risk_factors":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosis (Atypical Adenomatous Hyperplasia)","n_c":["C120861","C5665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Consumption","n_c":["C16273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcoholic Liver Disease","n_c":["C34783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Animal, NOS","n_c":["C172303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Ant","n_c":["C172307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Bee","n_c":["C172308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Cat","n_c":["C172310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dairy or Lactose","n_c":["C175520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dog","n_c":["C172311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Eggs","n_c":["C172313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Food, NOS","n_c":["C172304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Fruit","n_c":["C172316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Meat","n_c":["C172317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Mold or Dust","n_c":["C172306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Nuts","n_c":["C175521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Processed Foods","n_c":["C175522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Seafood","n_c":["C172320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Wasp","n_c":["C172321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin Deficiency","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altered Mental Status","n_c":["C121628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Excess","n_c":["C113215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Atrophic Chronic Gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1 Tumor Predisposition Syndrome","n_c":["C172639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birt-Hogg-Dube Syndrome","n_c":["C28244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA Family History","n_c":["C172230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Hepatitis","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C80078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common variable immune deficiency (CVID)","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cortisol Excess","n_c":["C113208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cowden Syndrome","n_c":["C3076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, NOS","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type I","n_c":["C2986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogen Excess","n_c":["C113344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Polyp(s)","n_c":["C3954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilbert's Syndrome","n_c":["C84729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular Disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H. pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hay Fever","n_c":["C92188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter Pylori-Associated Gastritis","n_c":["C27121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Disorder, NOS","n_c":["C26323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemochromatosis","n_c":["C82892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Encephalopathy","n_c":["C79596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, NOS","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Breast Cancer","n_c":["C4503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Hemorrhagic Telangiectasia","n_c":["C35064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Kidney Oncocytoma","n_c":["C8960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","n_c":["C51302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Ovarian Cancer","n_c":["C36102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Papillary Renal Cell Carcinoma","n_c":["C9222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Prostate Cancer","n_c":["C103817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Renal Cell Carcinoma","n_c":["C39789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-grade Prostatic Intraepithelial Neoplasia (PIN)","n_c":["C5541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV","n_c":["C3108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-6 (HHV-6)","n_c":["C128829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-8 (HHV-8)","n_c":["C39291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation, Hyperkeratosis","n_c":["C3137","C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inherited Genetic Syndrome, NOS","n_c":["C3101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mineralcorticoids Excess","n_c":["C198986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motor / Movement Change","n_c":["C157433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndrome","n_c":["C3247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neurocystericerosis","n_c":["C84932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Fatty Liver Disease","n_c":["C84444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Contraceptives","n_c":["C389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Pyogenic Cholangitis","n_c":["C164213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubella","n_c":["C85051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serous tubal intraepithelial carcinoma (STIC)","n_c":["C126449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Rash","n_c":["C39594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","n_c":["C156464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tattoo","n_c":["C113681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Nodular Hyperplasia","n_c":["C131437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, NOS","n_c":["C18059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smokeless","n_c":["C137998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberous Sclerosis","n_c":["C3424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulointerstitial Disease","n_c":["C123036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated Lymphoid Proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undescended Testis","n_c":["C12326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disease","n_c":["C35117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vision Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Von Hippel-Lindau Syndrome","n_c":["C3105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""}],"biospecimen.sample.specimen_type":[{"nm":"2D Classical Conditionally Reprogrammed Cells","n_c":["C172257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2D Modified Conditionally Reprogrammed Cells","n_c":["C172258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Air-Liquid Interface Organoid","n_c":["C172260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Neurosphere","n_c":["C172261"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3D Organoid","n_c":["C172259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adherent Cell Line","n_c":["C20216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow Components NOS","n_c":["C164008"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow NOS","n_c":["C164009"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cells","n_c":["C172264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buffy Coat","n_c":["C84507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell","n_c":["C12508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Control Analyte","n_c":["C156442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derived Cell Line","n_c":["C156445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Immortalized","n_c":["C163993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts from Bone Marrow","n_c":["C164010"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Granulocytes","n_c":["C12530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Original Cells","n_c":["C19315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liquid Suspension Cell Line","n_c":["C20217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytes","n_c":["C12535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid","n_c":["C13049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mixed Adherent Suspension","n_c":["C174118"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mononuclear Cells from Bone Marrow","n_c":["C164011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Blood Components NOS","n_c":["C199216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Blood NOS","n_c":["C173496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Whole Blood","n_c":["C41067"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Plasma","n_c":["C13356"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleural Effusion","n_c":["C3331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saliva","n_c":["C174119"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serum","n_c":["C13325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solid Tissue","n_c":["C164014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sorted Cells","n_c":["C126974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sputum","n_c":["C13278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Whole Bone Marrow","n_c":["C84513"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Derived Cell Lines and Sorted Cells","n_c":["C156445","C126974"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.timepoint_category":[{"nm":"Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adolescence","n_c":["C39298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adulthood","n_c":["C199314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Childhood","n_c":["C89345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follow-up","n_c":["C16033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Initial Diagnosis","n_c":["C156813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Last Contact","n_c":["C199315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Adjuvant Therapy","n_c":["C158707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Hormone Therapy","n_c":["C199316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Secondary Therapy","n_c":["C158753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative","n_c":["C28006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Diagnosis","n_c":["C199317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence/Progression","n_c":["C158754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Within 3 Months of Surgery","n_c":["C200432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Adjuvant Therapy","n_c":["C206464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Within 2 Months After Completion of First-Course Treatment","n_c":["C206465"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.timepoint_category":[{"nm":"End of Consolidation Therapy","n_c":["C199318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End of Treatment Course 1","n_c":["C199320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End of Treatment Course 2","n_c":["C199321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Initial Diagnosis","n_c":["C156813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sample Procurement","n_c":["C164024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.timepoint_category":[{"nm":"End of Consolidation Therapy","n_c":["C199318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"End of Treatment Course","n_c":["C199319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Complete Response","n_c":["C199322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative","n_c":["C28006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Diagnosis","n_c":["C199317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Procurement","n_c":["C199323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Study Registration","n_c":["C199324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progression","n_c":["C17747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence","n_c":["C38155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"First Treatment","n_c":["C164022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.tumor_grade_category":[{"nm":"Four Tier","n_c":["C199325"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Three Tier","n_c":["C199326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_level_prostate":[{"nm":"Apex","n_c":["C13087"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Base","n_c":["C13088"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle","n_c":["C13094"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.uicc_staging_system_edition":[{"nm":"1st","n_c":["C25509"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2nd","n_c":["C25666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3rd","n_c":["C25260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4th","n_c":["C54566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"5th","n_c":["C54567"],"i_c":"","i_c_s":"","term_type":""},{"nm":"6th","n_c":["C54568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"7th","n_c":["C133531"],"i_c":"","i_c_s":"","term_type":""},{"nm":"8th","n_c":["C133533"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.weiss_assessment_findings":[{"nm":"Atypical Mitotic Figures","n_c":["C35962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytoplasm presence <= to 25%","n_c":["C199327"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diffuse Architecture","n_c":["C35903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Invasion of Tumor Capsule","n_c":["C199328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitotic Rate > 5/50 HPF","n_c":["C54007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Necrosis","n_c":["C36184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nuclear Grade III or IV","n_c":["C104011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinusoid Invasion","n_c":["C39615"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous Invasion","n_c":["C47849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.clark_level":[{"nm":"I","n_c":["C94812"],"i_c":"","i_c_s":"","term_type":""},{"nm":"II","n_c":["C94813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"III","n_c":["C94814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IV","n_c":["C94815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"V","n_c":["C94816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.contiguous_organ_invaded":[{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inferior Vena Cava","n_c":["C12815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.country_of_birth":[{"nm":"Afghanistan","n_c":["C16267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Albania","n_c":["C16271"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Algeria","n_c":["C16274"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Andorra","n_c":["C16289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Angola","n_c":["C16292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anguilla","n_c":["C20133"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antigua and Barbuda","n_c":["C16303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Argentina","n_c":["C16305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Armenia","n_c":["C16306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aruba","n_c":["C17884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Australia","n_c":["C16311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Austria","n_c":["C16312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azerbaijan","n_c":["C16316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahamas","n_c":["C16321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bahrain","n_c":["C16322"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bangladesh","n_c":["C16323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barbados","n_c":["C16324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belarus","n_c":["C16372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belgium","n_c":["C16329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Belize","n_c":["C16331"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benin","n_c":["C16333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bermuda","n_c":["C16334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bhutan","n_c":["C16336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bolivia","n_c":["C16359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bosnia and Herzegovina","n_c":["C16361"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Botswana","n_c":["C16363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brazil","n_c":["C16364"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brunei","n_c":["C16367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bulgaria","n_c":["C16368"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burkina Faso","n_c":["C16369"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Burundi","n_c":["C16371"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cambodia","n_c":["C16378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cameroon","n_c":["C16379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Canada","n_c":["C16380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cape Verde","n_c":["C16382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cayman Islands","n_c":["C16391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central African Republic","n_c":["C16409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chad","n_c":["C16412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chile","n_c":["C16427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"China","n_c":["C16428"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colombia","n_c":["C16449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Comoros","n_c":["C16458"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congo","n_c":["C16467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cook Islands","n_c":["C16469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Costa Rica","n_c":["C16470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cote d'Ivoire","n_c":["C16762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Croatia","n_c":["C16474"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cuba","n_c":["C16477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Curacao","n_c":["C101225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyprus","n_c":["C16480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Czech Republic (Czechia)","n_c":["C17668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Democratic Republic of the Congo","n_c":["C17266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denmark","n_c":["C16496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Djibouti","n_c":["C16506"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominica","n_c":["C16519"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dominican Republic","n_c":["C16520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ecuador","n_c":["C16528"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Egypt","n_c":["C16530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"El Salvador","n_c":["C16532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Equatorial Guinea","n_c":["C16557"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eritrea","n_c":["C16558"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estonia","n_c":["C16562"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eswatini","n_c":["C17179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ethiopia","n_c":["C16563"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Falkland Islands (Malvinas)","n_c":["C17954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Faroe Islands","n_c":["C16573"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Federated States of Micronesia","n_c":["C17881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fiji","n_c":["C16582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finland","n_c":["C16584"],"i_c":"","i_c_s":"","term_type":""},{"nm":"France","n_c":["C16592"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Guiana","n_c":["C16593"],"i_c":"","i_c_s":"","term_type":""},{"nm":"French Polynesia","n_c":["C16594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gabon","n_c":["C16596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gambia","n_c":["C16598"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Georgia","n_c":["C16634"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Germany","n_c":["C16636"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ghana","n_c":["C26330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gibraltar","n_c":["C16638"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greece","n_c":["C16645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Greenland","n_c":["C16646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Grenada","n_c":["C16647"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guadeloupe","n_c":["C16651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guam","n_c":["C16652"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guatemala","n_c":["C16654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guernsey","n_c":["C64375"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea","n_c":["C16655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guinea-Bissau","n_c":["C16656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Guyana","n_c":["C16657"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Haiti","n_c":["C16660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Holy See","n_c":["C17249"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Honduras","n_c":["C16694"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hong Kong","n_c":["C16695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hungary","n_c":["C16699"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iceland","n_c":["C16704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"India","n_c":["C16727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Indonesia","n_c":["C16728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iran","n_c":["C16755"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iraq","n_c":["C16756"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ireland","n_c":["C16757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isle of Man","n_c":["C44480"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Israel","n_c":["C16760"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Italy","n_c":["C16761"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jamaica","n_c":["C16763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Japan","n_c":["C16764"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jersey","n_c":["C64374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jordan","n_c":["C16765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kazakhstan","n_c":["C20107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kenya","n_c":["C16769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kiribati","n_c":["C16639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kosovo","n_c":["C123740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kuwait","n_c":["C16775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kyrgyzstan","n_c":["C16771"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laos","n_c":["C16780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Latvia","n_c":["C16783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lebanon","n_c":["C16784"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lesotho","n_c":["C16787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liberia","n_c":["C16791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Libya","n_c":["C16793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liechtenstein","n_c":["C16794"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lithuania","n_c":["C16799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Luxembourg","n_c":["C16803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macau","n_c":["C16807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Madagascar","n_c":["C16808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malawi","n_c":["C16813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaysia","n_c":["C16814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maldives","n_c":["C16815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mali","n_c":["C16816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malta","n_c":["C16817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Marshall Islands","n_c":["C16822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Martinique","n_c":["C16823"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritania","n_c":["C16826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mauritius","n_c":["C16827"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mayotte","n_c":["C16828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mexico","n_c":["C16850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moldova","n_c":["C16871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Monaco","n_c":["C16874"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mongolia","n_c":["C16875"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montenegro","n_c":["C64378"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Montserrat","n_c":["C16876"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Morocco","n_c":["C16878"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mozambique","n_c":["C16882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myanmar","n_c":["C16370"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Namibia","n_c":["C16891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nauru","n_c":["C16896"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nepal","n_c":["C16901"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Netherlands","n_c":["C16903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Caledonia","n_c":["C16913"],"i_c":"","i_c_s":"","term_type":""},{"nm":"New Zealand","n_c":["C16914"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nicaragua","n_c":["C16915"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niger","n_c":["C16916"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nigeria","n_c":["C16917"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Niue","n_c":["C16918"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Korea","n_c":["C16773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"North Macedonia","n_c":["C17654"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Northern Mariana Islands","n_c":["C17882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Norway","n_c":["C16920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oman","n_c":["C16933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pakistan","n_c":["C16949"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palau","n_c":["C17733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Panama","n_c":["C16951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Papua New Guinea","n_c":["C16952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraguay","n_c":["C16953"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peru","n_c":["C16972"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Philippines","n_c":["C16978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poland","n_c":["C17002"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Portugal","n_c":["C17006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Puerto Rico","n_c":["C17043"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Qatar","n_c":["C17045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reunion","n_c":["C17095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Romania","n_c":["C17108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Russia","n_c":["C17111"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rwanda","n_c":["C17112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Helena, Ascension and Tristan da Cunha","n_c":["C17164"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Kitts and Nevis","n_c":["C17885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Lucia","n_c":["C17113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Pierre and Miquelon","n_c":["C17165"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saint Vincent and the Grenadines","n_c":["C17114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Samoa","n_c":["C17740"],"i_c":"","i_c_s":"","term_type":""},{"nm":"San Marino","n_c":["C17115"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sao Tome and Principe","n_c":["C17116"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Saudi Arabia","n_c":["C17117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Senegal","n_c":["C17121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serbia","n_c":["C64377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seychelles","n_c":["C17129"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sierra Leone","n_c":["C17130"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Singapore","n_c":["C17134"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovakia","n_c":["C17669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Slovenia","n_c":["C17138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Solomon Islands","n_c":["C17148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Somalia","n_c":["C17149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Africa","n_c":["C17151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Korea","n_c":["C16774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"South Sudan","n_c":["C97351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spain","n_c":["C17152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sri Lanka","n_c":["C17163"],"i_c":"","i_c_s":"","term_type":""},{"nm":"State of Palestine","n_c":["C20110"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sudan","n_c":["C17170"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Suriname","n_c":["C17175"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Svalbard & Jan Mayen Islands","n_c":["C17178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sweden","n_c":["C17180"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Switzerland","n_c":["C17181"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syria","n_c":["C17182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Taiwan","n_c":["C17184"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tajikistan","n_c":["C17183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tanzania","n_c":["C17185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thailand","n_c":["C17192"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Timor-Leste","n_c":["C17200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Togo","n_c":["C17202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tokelau","n_c":["C17704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonga","n_c":["C17205"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trinidad and Tobago","n_c":["C17217"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tunisia","n_c":["C17221"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkey","n_c":["C17222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turkmenistan","n_c":["C17223"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuvalu","n_c":["C17225"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uganda","n_c":["C17228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ukraine","n_c":["C17229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Arab Emirates","n_c":["C17232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United Kingdom","n_c":["C17233"],"i_c":"","i_c_s":"","term_type":""},{"nm":"United States","n_c":["C17234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uruguay","n_c":["C17244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uzbekistan","n_c":["C17246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vanuatu","n_c":["C17247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venezuela","n_c":["C17250"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vietnam","n_c":["C17252"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, British","n_c":["C17653"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Virgin Islands, U.S.","n_c":["C17255"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wallis and Futuna","n_c":["C17259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Western Sahara","n_c":["C20113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yemen","n_c":["C17264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zambia","n_c":["C17267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Zimbabwe","n_c":["C17268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.education_level":[{"nm":"College Degree","n_c":["C159746"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High School Graduate or GED","n_c":["C67136","C67135"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Professional or Graduate Degree","n_c":["C70558","C168226"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Some High School or Less","n_c":["C198650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vocational College or Some College","n_c":["C67141","C67137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_clinical_m":[{"nm":"M0","n_c":["C104028"],"i_c":"","i_c_s":"","term_type":""},{"nm":"M1","n_c":["C104029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_pathologic_n":[{"nm":"N0","n_c":["C104024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N1","n_c":["C104025"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_pathologic_stage":[{"nm":"Stage I","n_c":["C104031"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage II","n_c":["C104032"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage III","n_c":["C104033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stage IV","n_c":["C104034"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ensat_pathologic_t":[{"nm":"T1","n_c":["C104019"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T2","n_c":["C104020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T3","n_c":["C104021"],"i_c":"","i_c_s":"","term_type":""},{"nm":"T4","n_c":["C104022"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.demographic.marital_status":[{"nm":"Divorced","n_c":["C51776"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Domestic Partnership","n_c":["C53262"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Married","n_c":["C51773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never Married","n_c":["C51774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Separated","n_c":["C156541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Widowed","n_c":["C51775"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.measurement_type":[{"nm":"Pathologic","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiologic","n_c":["C93286"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.measurement_type":[{"nm":"Pathologic","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiologic","n_c":["C93286"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Echographic","n_c":["C200433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.measurement_unit":[{"nm":"Centimeters","n_c":["C49668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Millimeters","n_c":["C28251"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.melanoma_known_primary":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_methylation_array.platform":[{"nm":"Illumina Methylation Epic v2","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Methylation Epic","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"data_file.methylation_beta_value.platform":[{"nm":"Illumina Methylation Epic v2","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Methylation Epic","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"data_file.raw_methylation_array.platform":[{"nm":"Illumina Methylation Epic v2","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 27","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Human Methylation 450","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina Methylation Epic","n_c":["C200431"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relative_deceased":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.family_history.relative_smoker":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.treatment_anatomic_sites":[{"nm":"Abdomen, total","n_c":["C12664"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Abdominal Wall","n_c":["C77608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acetabulum","n_c":["C32042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenoid","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adipose","n_c":["C12472"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenal","n_c":["C12666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alveolar Ridge","n_c":["C89749"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Amniotic Fluid","n_c":["C13188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ampulla of Vater","n_c":["C13011"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anal Sphincter","n_c":["C165177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ankle","n_c":["C32078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anorectum","n_c":["C129464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antecubital Fossa","n_c":["C103238"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Antrum","n_c":["C97102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anus","n_c":["C43362"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aorta","n_c":["C12669"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aortic Body","n_c":["C97112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Appendix","n_c":["C12380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aqueous Fluid","n_c":["C13190"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arm","n_c":["C32141"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Artery","n_c":["C12372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon","n_c":["C12265"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascending Colon Hepatic Flexure","n_c":["C12266"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ascites","n_c":["C2885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Auditory Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autonomic Nervous System","n_c":["C12673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Axilla","n_c":["C12674"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Back","n_c":["C13062"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bile Duct","n_c":["C12376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood","n_c":["C12434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Vessel","n_c":["C12679"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Body, total","n_c":["C13041"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone","n_c":["C12366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Marrow","n_c":["C12431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bowel","n_c":["C12736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain","n_c":["C12439"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brain Stem","n_c":["C12441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Breast","n_c":["C12971"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Broad Ligament","n_c":["C12318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchiole","n_c":["C12684"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchus","n_c":["C12683"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brow","n_c":["C32575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buccal Mucosa","n_c":["C12505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Buttock","n_c":["C89806"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calf","n_c":["C93027"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Capillary","n_c":["C12685"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cardia","n_c":["C12256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carina","n_c":["C25264"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Artery","n_c":["C12687"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Carotid Body","n_c":["C66852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cartilage","n_c":["C12373"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cecum","n_c":["C12381"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cell-Line","n_c":["C16403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Central Nervous System","n_c":["C12438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebellum","n_c":["C12445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebral Cortex","n_c":["C12443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrospinal Fluid","n_c":["C12692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrum","n_c":["C12351"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervical Spine","n_c":["C69313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cervix","n_c":["C12311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest","n_c":["C25389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chest Wall","n_c":["C62484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chin","n_c":["C81169"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clavicle","n_c":["C12695"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clitoris","n_c":["C12308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon","n_c":["C12382"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon - Mucosa Only","n_c":["C164003"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Duct","n_c":["C12698"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Conjunctiva","n_c":["C12341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue","n_c":["C12374"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermal","n_c":["C25478"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Descending Colon","n_c":["C12268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diaphragm","n_c":["C12702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Distant Site","n_c":["C179433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Duodenum","n_c":["C12263"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear","n_c":["C12394"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear Canal","n_c":["C12498"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ear, Pinna (External)","n_c":["C12292"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Elbow","n_c":["C32497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endocrine Gland","n_c":["C12704"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epididymis","n_c":["C12328"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epidural Space","n_c":["C41449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epitrochlear","n_c":["C165193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagogastric Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus","n_c":["C12389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Esophagus - Mucosa Only","n_c":["C32538"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eye","n_c":["C12401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fallopian Tube","n_c":["C12403"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Artery","n_c":["C12715"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femoral Vein","n_c":["C12716"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Femur","n_c":["C12717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibroblasts","n_c":["C12482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibula","n_c":["C12718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Finger","n_c":["C32608"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Floor of Mouth","n_c":["C54187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fluid","n_c":["C25278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foot","n_c":["C32622"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forearm","n_c":["C32628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Forehead","n_c":["C89803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Foreskin","n_c":["C33049"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Cortex","n_c":["C177766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Frontal Lobe","n_c":["C12352"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fundus of Stomach","n_c":["C12257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gallbladder","n_c":["C12377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ganglia","n_c":["C12719"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Junction","n_c":["C32668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal Tract","n_c":["C34082"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastrointestinal, Intestine","n_c":["C13359"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Genitourinary, NOS","n_c":["C25350"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Groin","n_c":["C12726"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gum","n_c":["C32677"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hand","n_c":["C32712"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hard Palate","n_c":["C12230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Head and Neck","n_c":["C12418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart","n_c":["C12727"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic","n_c":["C13308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Duct","n_c":["C32730"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Vein","n_c":["C32736"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hilar","n_c":["C25724"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hip","n_c":["C64193"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hippocampus","n_c":["C12444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Humerus","n_c":["C12731"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileocecal Valve","n_c":["C13066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ileum","n_c":["C12387"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ilium","n_c":["C32765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Index Finger","n_c":["C52835"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inferior Vena Cava","n_c":["C12815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischium","n_c":["C32884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Islet Cells","n_c":["C32885"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jaw","n_c":["C48821"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Jejunum","n_c":["C12388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint","n_c":["C13044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney","n_c":["C12415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Knee","n_c":["C32898"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lacrimal Gland","n_c":["C12346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Large Bowel","n_c":["C12379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Laryngopharynx","n_c":["C12246"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Larynx","n_c":["C12420"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leg","n_c":["C32974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Leptomeninges","n_c":["C32979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ligament","n_c":["C13046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lip","n_c":["C12220"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver","n_c":["C12392"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Locoregional Site","n_c":["C25388"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lumbar Spine","n_c":["C69314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lung","n_c":["C12468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node","n_c":["C12745"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Axilla","n_c":["C12904"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Cervical","n_c":["C32298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Distant","n_c":["C106042"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Epitrochlear","n_c":["C98182"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Femoral","n_c":["C98183"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Hilar","n_c":["C102330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-Common","n_c":["C103384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Iliac-External","n_c":["C88143"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Inguinal","n_c":["C32801"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Internal Mammary","n_c":["C32853"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mammary","n_c":["C137678"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mediastinal","n_c":["C33073"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Mesenteric","n_c":["C77641"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Occipital","n_c":["C98188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Paraaortic","n_c":["C77643"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Parotid","n_c":["C33278"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Pelvic","n_c":["C12363"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Popliteal","n_c":["C53146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Regional","n_c":["C49018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Retroperitoneal","n_c":["C98189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Scalene","n_c":["C89780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Splenic","n_c":["C142320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Subclavicular","n_c":["C63705"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Submandibular","n_c":["C77650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymph Node(s) Supraclavicular","n_c":["C12903"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mandible","n_c":["C12290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mantle","n_c":["C12507"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Maxilla","n_c":["C26470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinal Soft Tissue","n_c":["C164004"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mediastinum","n_c":["C12748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesentery","n_c":["C33103"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mesothelium","n_c":["C33105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Middle Finger","n_c":["C52836"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mitochondria","n_c":["C13258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Muscle","n_c":["C13056"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nails","n_c":["C33156"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Cavity","n_c":["C12424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasal Soft Tissue","n_c":["C164006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nasopharynx","n_c":["C12423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neck","n_c":["C13063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve","n_c":["C12466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nerve(s) Cranial","n_c":["C12700"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occipital Cortex","n_c":["C177767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ocular Orbits","n_c":["C12347"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Omentum","n_c":["C33209"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity","n_c":["C12421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Cavity - Mucosa Only","n_c":["C77637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oropharynx","n_c":["C12762"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ovary","n_c":["C12404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Palate","n_c":["C12229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreas","n_c":["C12393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parametrium","n_c":["C12320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Paraspinal Ganglion","n_c":["C97925"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parathyroid","n_c":["C12765"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Parotid Gland","n_c":["C12427"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patella","n_c":["C33282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pelvis","n_c":["C12767"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Penis","n_c":["C12409"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pericardium","n_c":["C13005"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Periorbital Soft Tissue","n_c":["C164007"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneal Cavity","n_c":["C12769"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peritoneum","n_c":["C12770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pharynx","n_c":["C12425"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pineal Gland","n_c":["C12398"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pituitary Gland","n_c":["C12399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Placenta","n_c":["C13272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pleura","n_c":["C12469"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Popliteal Fossa","n_c":["C103222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pouch","n_c":["C43200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Tumor Field","n_c":["C179450"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary tumor site","n_c":["C179451"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate","n_c":["C12410"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prostate Bed","n_c":["C90348"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pylorus","n_c":["C12260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectosigmoid Junction","n_c":["C54188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rectum","n_c":["C12390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Regional Site","n_c":["C179457"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retina","n_c":["C12343"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retro-Orbital Region","n_c":["C54155"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Retroperitoneum","n_c":["C12298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rib","n_c":["C12782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ring Finger","n_c":["C52837"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Round Ligament","n_c":["C12319"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sacrum","n_c":["C33508"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salivary Gland","n_c":["C12426"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scalp","n_c":["C89807"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scapula","n_c":["C12783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sciatic Nerve","n_c":["C52810"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scrotum","n_c":["C12785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seminal Vesicle","n_c":["C12787"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shoulder","n_c":["C25203"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sigmoid Colon","n_c":["C12384"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus","n_c":["C33556"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sinus(es), Maxillary","n_c":["C12275"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skeletal Muscle","n_c":["C13050"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, lower extremity, local","n_c":["C164047"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, total","n_c":["C12470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, trunk, local","n_c":["C12295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin, upper extremity, local","n_c":["C164048"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skull","n_c":["C12789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel","n_c":["C12386"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Bowel - Mucosa Only","n_c":["C33568"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Small Finger","n_c":["C52838"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Soft Tissue","n_c":["C12471"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Column","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spinal Cord","n_c":["C12464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spine","n_c":["C12998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spleen","n_c":["C12432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Splenic Flexure","n_c":["C12267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sternum","n_c":["C12793"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach","n_c":["C12391"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stomach - Mucosa Only","n_c":["C32656"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Subcutaneous Tissue","n_c":["C33645"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Synovium","n_c":["C12473"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Temporal Cortex","n_c":["C177768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tendon","n_c":["C13045"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis","n_c":["C12412"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thigh","n_c":["C33763"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thoracic Spine","n_c":["C69315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thorax","n_c":["C12799"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Throat","n_c":["C54272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thumb","n_c":["C52834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thymus","n_c":["C12433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid","n_c":["C12400"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tibia","n_c":["C12800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tongue","n_c":["C12422"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil","n_c":["C12802"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tonsil (Pharyngeal)","n_c":["C33318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trachea / Major Bronchi","n_c":["C12961"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transverse Colon","n_c":["C12385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Trunk","n_c":["C33816"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Umbilical Cord","n_c":["C34320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ureter","n_c":["C12416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urethra","n_c":["C12417"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract","n_c":["C191741"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uterus","n_c":["C12405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Uvula","n_c":["C12232"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vas Deferens","n_c":["C12813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vein","n_c":["C12814"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Venous","n_c":["C25291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vertebra","n_c":["C12933"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vulva","n_c":["C12408"],"i_c":"","i_c_s":"","term_type":""},{"nm":"White Blood Cells","n_c":["C12529"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wrist","n_c":["C33894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_depth_descriptor":[{"nm":"Deep","n_c":["C51137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Superficial","n_c":["C36109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_infiltrating_lymphocytes":[{"nm":"Few","n_c":["C64942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Many","n_c":["C78728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate","n_c":["C61376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_infiltrating_macrophages":[{"nm":"Few","n_c":["C64942"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Many","n_c":["C78728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate","n_c":["C61376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_measurement_method":[{"nm":"Echographic","n_c":["C200433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathologic","n_c":["C125006"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.tumor_shape":[{"nm":"Diffuse","n_c":["C47826"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dome","n_c":["C54253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mushroom","n_c":["C111029"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.ulceration_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.aids_risk_factors":[{"nm":"Candidiasis","n_c":["C26711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coccidioidomycosis","n_c":["C84642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcosis","n_c":["C2967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptosporidiosis, Chronic Intestinal","n_c":["C174107"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Encephalopathy","n_c":["C26920"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Simplex Virus","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Histoplasmosis","n_c":["C77201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Isosporiasis","n_c":["C4076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium tuberculosis","n_c":["C128377"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium, NOS","n_c":["C26831"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nocardiosis","n_c":["C171147"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progressive Multifocal Leukoencephalopathy","n_c":["C26815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Salmonella Septicemia","n_c":["C171146"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Toxoplasmosis","n_c":["C3418"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wasting Syndrome","n_c":["C171148"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.cdc_hiv_risk_factors":[{"nm":"Hemophiliac","n_c":["C3093"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heterosexual Contact","n_c":["C154862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Homosexual Contact","n_c":["C154863"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intravenous Drug User","n_c":["C84367"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C159672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transfusion Recipient","n_c":["C171149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.comorbidities":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Acute Renal Failure","n_c":["C26808"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenocarcinoma","n_c":["C2852"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomatous Polyposis Coli","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adrenocortical Insufficiency","n_c":["C26691"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergies","n_c":["C114476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anxiety","n_c":["C26696"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arrhythmia","n_c":["C2881"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Arthritis","n_c":["C2883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-Telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Atrial Fibrillation","n_c":["C50466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Avascular Necrosis","n_c":["C118385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Basal Cell Carcinoma","n_c":["C2921"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Thyroid Nodule","n_c":["C3415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biliary Disorder","n_c":["C2899"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blood Clots","n_c":["C27083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bone Fracture(s)","n_c":["C3046"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bronchitis","n_c":["C2911"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Calcium Channel Blockers","n_c":["C333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cataracts","n_c":["C26713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Celiac Disease","n_c":["C26714"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cerebrovascular Disease","n_c":["C2938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Fatigue Syndrome","n_c":["C3037"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Renal Failure","n_c":["C9438"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis, Unknown Etiology","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clonal Hematopoiesis","n_c":["C162188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"CNS Infection","n_c":["C27582"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immunodeficiency","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Congestive Heart Failure (CHF)","n_c":["C3080"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Connective Tissue Disorder","n_c":["C26729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"COPD","n_c":["C3199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Coronary Artery Disease","n_c":["C26732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Crohn's Disease","n_c":["C2965"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptogenic Organizing Pneumonia","n_c":["C62586"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Deep Vein Thrombosis / Thromboembolism","n_c":["C49343","C28195"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Depression","n_c":["C2982"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetic Neuropathy","n_c":["C26748"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet Controlled Diabetes","n_c":["C184754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"DVT/PE","n_c":["C49343","C50713"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dyslipidemia","n_c":["C80385"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epilepsy","n_c":["C3020"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibromyalgia","n_c":["C87497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follicular Adenoma","n_c":["C3502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastroesophageal Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GERD","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glaucoma","n_c":["C26782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glycogen Storage Disease","n_c":["C61272"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goiter","n_c":["C26785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gonadal Dysfunction","n_c":["C26786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gout","n_c":["C34650"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Graves' Disease","n_c":["C3071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Heart Disease","n_c":["C3079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemorrhagic Cystitis","n_c":["C114666"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, Chronic","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Non-Polyposis Colon Cancer","n_c":["C120083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes","n_c":["C155871"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Liver Dysplastic Nodule","n_c":["C96768"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV/AIDS","n_c":["C2851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HUS/TTP","n_c":["C75545","C78797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercalcemia","n_c":["C3112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercholesterolemia","n_c":["C37967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperglycemia","n_c":["C26797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperlipidemia","n_c":["C34707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperparathyroidism","n_c":["C48259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C3117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperthyroidism","n_c":["C3123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammatory Bowel Disease","n_c":["C3138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin Controlled Diabetes","n_c":["C184766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Interstitial Pneumonitis or ARDS","n_c":["C3353","C27006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intraductal Papillary Mucinous Neoplasm","n_c":["C38342"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ischemic Heart Disease","n_c":["C50625"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ITP","n_c":["C3446"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Joint Replacement","n_c":["C131579"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Kidney Disease","n_c":["C3149"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Cirrhosis (Liver Disease)","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Liver Toxicity (Non-Infectious)","n_c":["C184773"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Liver Dysplastic Nodule","n_c":["C96770"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lupus","n_c":["C27153"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Hyperplasia","n_c":["C102532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"MAI","n_c":["C27314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methicillin-Resistant Staphylococcus aureus (MRSA)","n_c":["C115248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myocardial Infarction","n_c":["C27996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neuroendocrine Tumor","n_c":["C3809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Organ Transplant (Site)","n_c":["C15289"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoarthritis","n_c":["C3293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Osteoporosis or Osteopenia","n_c":["C50910","C3298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Cancer within 5 Years","n_c":["C184782"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Nonmalignant Systemic Disease","n_c":["C184785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other Pulmonary Complications","n_c":["C184786"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pain (Various)","n_c":["C3303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peptic Ulcer (Ulcer)","n_c":["C3318"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Neuropathy","n_c":["C119734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peripheral Vascular Disease","n_c":["C35136"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Peutz-Jeghers Disease","n_c":["C3324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pregnancy in Patient or Partner","n_c":["C124295"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Psoriasis","n_c":["C3346"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Fibrosis","n_c":["C26869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pulmonary Hemorrhage","n_c":["C78578"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Dialysis","n_c":["C15248"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Failure (Requiring Dialysis)","n_c":["C184791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Renal Insufficiency","n_c":["C4376"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatologic Disease","n_c":["C27204"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sleep Apnea","n_c":["C26884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Smoking","n_c":["C154329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staph Osteomyelitis","n_c":["C188353"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stroke","n_c":["C3390"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Disease, Non-Cancer","n_c":["C27566"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Transient Ischemic Attack","n_c":["C50781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tyrosinemia","n_c":["C98640"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulcerative Colitis","n_c":["C2952"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Urinary Tract Infection","n_c":["C50791"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.comorbidity_method_of_diagnosis":[{"nm":"Histology","n_c":["C16681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pathology","n_c":["C18189"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radiology","n_c":["C19187"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.diabetes_treatment_type":[{"nm":"Alpha-Glucosidase Inhibitor","n_c":["C139651"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Biguanide","n_c":["C98234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15383"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Injected Insulin","n_c":["C179441"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Insulin","n_c":["C581"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Linagliptin","n_c":["C83887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Hypoglycemic","n_c":["C179448"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sulfonylurea","n_c":["C97936"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thiazolidinedione","n_c":["C98241"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.exercise_frequency_weekly":[{"nm":"5 or More Days","n_c":["C202212"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3 to 4 Days","n_c":["C202213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1 to 2 Days","n_c":["C202214"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extracapsular_extension_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.extrathyroid_extension":[{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Minimal (T3)","n_c":["C48728"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Moderate/Advanced (T4a)","n_c":["C48733"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Very Advanced (T4b)","n_c":["C48734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.eye_color":[{"nm":"Amber","n_c":["C111017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Blue","n_c":["C48333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Brown","n_c":["C48332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gray","n_c":["C48324"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Green","n_c":["C48329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hazel","n_c":["C111018"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Red & Violet","n_c":["C157431"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C160244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.first_symptom_longest_duration":[{"nm":"0-30 Days","n_c":["C202215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"31-90 Days","n_c":["C202216"],"i_c":"","i_c_s":"","term_type":""},{"nm":"91-180 Days","n_c":["C202217"],"i_c":"","i_c_s":"","term_type":""},{"nm":">=181 Days","n_c":["C202218"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.haart_treatment_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hepatitis_sustained_virological_response":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.histologic_progression_type":[{"nm":"Anaplastic","n_c":["C36113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poorly differentiated","n_c":["C36132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hormonal_contraceptive_type":[{"nm":"Progestin","n_c":["C179455"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progestin and Estrogen","n_c":["C179456"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hormonal_contraceptive_use":[{"nm":"Current User","n_c":["C160671"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Former User","n_c":["C160672"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never Used","n_c":["C160673"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hormone_replacement_therapy_type":[{"nm":"Estrogen only","n_c":["C179434"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone and Estrogen","n_c":["C179452"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Progesterone only","n_c":["C179453"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hysterectomy_margins_involved":[{"nm":"Bladder","n_c":["C12414"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Macroscopic Parametrium","n_c":["C179443"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Microscopic Parametrium","n_c":["C179445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C48621"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vagina","n_c":["C12407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hysterectomy_type":[{"nm":"Hysterectomy, NOS","n_c":["C15256"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Performed","n_c":["C141477"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Radical Hysterectomy","n_c":["C94470"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Simple Hysterectomy","n_c":["C15701"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.immunosuppressive_treatment_type":[{"nm":"Anti-TNF Therapy","n_c":["C15577"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Azathioprine","n_c":["C290"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyclophosphamide","n_c":["C405"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Methotrexate","n_c":["C642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Immunoglobulin","n_c":["C62710"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prednisone","n_c":["C770"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.menopause_status":[{"nm":"Perimenopausal","n_c":["C15692"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postmenopausal","n_c":["C15421"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Premenopausal","n_c":["C15491"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.micrometastasis_present":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.myasthenia_gravis_classification":[{"nm":"Class I","n_c":["C112014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class II","n_c":["C112015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class III","n_c":["C112016"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class IV","n_c":["C112017"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Class V","n_c":["C112018"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.nononcologic_therapeutic_agents":[{"nm":"Acetaminophen","n_c":["C198"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Aspirin","n_c":["C287"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metformin","n_c":["C61612"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Statin, NOS","n_c":["C1655"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.oxygen_use_indicator":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.oxygen_use_type":[{"nm":"Continuous","n_c":["C202296"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermittent","n_c":["C202297"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_germline_variation.platform":[{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_genotyping_array.platform":[{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.pregnancy_outcome":[{"nm":"Ectopic Pregnancy","n_c":["C34945"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Induced Abortion","n_c":["C50613"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Live Birth","n_c":["C114091"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Miscarriage","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Abortion","n_c":["C34336"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Stillbirth","n_c":["C49151"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Full Term Birth, NOS","n_c":["C114095"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.pregnant_at_diagnosis":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.premature_at_birth":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.radiosensitizing_agent":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.reason_treatment_not_given":[{"nm":"Adverse Event/Complications","n_c":["C41331","C2959"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Done per Treating Physician's Discretion","n_c":["C202267"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Participant Refusal","n_c":["C192979"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scheduling Problems","n_c":["C185642"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Patient Ineligible","n_c":["C40412"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.reflux_treatment_type":[{"nm":"Antacids","n_c":["C29633"],"i_c":"","i_c_s":"","term_type":""},{"nm":"H2 Blockers","n_c":["C29702"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Medically Treated","n_c":["C165200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No Treatment","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Proton Pump Inhibitors","n_c":["C29723"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Surgically Treated","n_c":["C15329"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.risk_factor_method_of_diagnosis":[{"nm":"Biochemical Assessment","n_c":["C199177"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Both Clinical and Biochemical Assessments","n_c":["C199179"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Clinical Assessment","n_c":["C199178"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.risk_factor_treatment":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.risk_factors":[{"nm":"Abnormal Glucose Level","n_c":["C179424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenomyosis","n_c":["C6996"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adenosis (Atypical Adenomatous Hyperplasia)","n_c":["C120861","C5665"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcohol Consumption","n_c":["C16273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alcoholic Liver Disease","n_c":["C34783"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Animal, NOS","n_c":["C172303"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Ant","n_c":["C172307"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Bee","n_c":["C172308"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Cat","n_c":["C172310"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dairy or Lactose","n_c":["C175520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Dog","n_c":["C172311"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Eggs","n_c":["C172313"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Food, NOS","n_c":["C172304"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Fruit","n_c":["C172316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Meat","n_c":["C172317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Mold or Dust","n_c":["C172306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Nuts","n_c":["C175521"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Processed Foods","n_c":["C175522"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Seafood","n_c":["C172320"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Allergy, Wasp","n_c":["C172321"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Alpha-1 Antitrypsin Deficiency","n_c":["C84397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Altered Mental Status","n_c":["C121628"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Androgen Excess","n_c":["C113215"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Anemia","n_c":["C2869"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Asthma","n_c":["C28397"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ataxia-Telangiectasia","n_c":["C2887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Atrophic Chronic Gastritis","n_c":["C156076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Autoimmune Lymphoproliferative Syndrome (ALPS)","n_c":["C37864"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Bacteroides fragilis","n_c":["C86172"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BAP1 Tumor Predisposition Syndrome","n_c":["C172639"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Barrett's Esophagus","n_c":["C2891"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Beckwith-Wiedemann","n_c":["C34415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Behcet's Disease","n_c":["C34416"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Benign Thyroid Nodule","n_c":["C3415"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Birt-Hogg-Dube Syndrome","n_c":["C28244"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BRCA Family History","n_c":["C172230"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cancer","n_c":["C9305"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chlamydia","n_c":["C34463"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chloroma","n_c":["C3520"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cholelithiasis","n_c":["C122822"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Hepatitis","n_c":["C82978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Kidney Disease","n_c":["C80078"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Pancreatitis","n_c":["C84637"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Chronic Systemic Steroid Use","n_c":["C174112"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cirrhosis","n_c":["C2951"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colon Polyps","n_c":["C2954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Bacterial","n_c":["C171138"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Colonization, Fungal","n_c":["C82980"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Common Variable Immune Deficiency (CVID)","n_c":["C26725"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cortisol Excess","n_c":["C113208"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cowden Syndrome","n_c":["C3076"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cryptococcal Meningitis","n_c":["C174113"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cyst(s)","n_c":["C2978"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Cytomegalovirus (CMV)","n_c":["C53649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Denys-Drash Syndrome","n_c":["C84668"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Dermatomyosis","n_c":["C26744"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, NOS","n_c":["C2985"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type I","n_c":["C2986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diabetes, Type II","n_c":["C26747"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diet","n_c":["C15222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulitis","n_c":["C26752"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Down Syndrome","n_c":["C2993"],"i_c":"","i_c_s":"","term_type":""},{"nm":"EBV Lymphoproliferation","n_c":["C159717"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Eczema","n_c":["C3001"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endometriosis","n_c":["C3014"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Endosalpingiosis","n_c":["C179646"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epithelial Dysplasia","n_c":["C8366"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Epstein-Barr Virus","n_c":["C38759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Escherichia coli","n_c":["C34594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Estrogen Excess","n_c":["C113344"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Familial Adenomatous Polyposis","n_c":["C3339"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fanconi Anemia","n_c":["C62505"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Fibrosis","n_c":["C3044"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follicular Adenoma","n_c":["C3502"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastric Polyp(s)","n_c":["C3954"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gastritis","n_c":["C26780"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gilbert's Syndrome","n_c":["C84729"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Glomerular Disease","n_c":["C35605"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Goiter","n_c":["C26785"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gorlin Syndrome","n_c":["C2892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Graves' Disease","n_c":["C3071"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hashimoto's Thyroiditis","n_c":["C27191"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hay Fever","n_c":["C92188"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Headache","n_c":["C34661"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter pylori Infection","n_c":["C39293"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Helicobacter pylori-Associated Gastritis","n_c":["C27121"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hematologic Disorder, NOS","n_c":["C26323"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemihypertrophy","n_c":["C88541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hemochromatosis","n_c":["C82892"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatic Encephalopathy","n_c":["C79596"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis A Infection","n_c":["C3096"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Infection","n_c":["C3097"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Infection","n_c":["C3098"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis, NOS","n_c":["C3095"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Breast Cancer","n_c":["C4503"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Hemorrhagic Telangiectasia","n_c":["C35064"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Kidney Oncocytoma","n_c":["C8960"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","n_c":["C51302"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Ovarian Cancer","n_c":["C36102"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Papillary Renal Cell Carcinoma","n_c":["C9222"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Prostate Cancer","n_c":["C103817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hereditary Renal Cell Carcinoma","n_c":["C39789"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Herpes Zoster","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High Grade Dysplasia","n_c":["C156083"],"i_c":"","i_c_s":"","term_type":""},{"nm":"High-grade Prostatic Intraepithelial Neoplasia (PIN)","n_c":["C5541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HIV","n_c":["C3108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hodgkin Lymphoma","n_c":["C9357"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-6 (HHV-6)","n_c":["C128829"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Herpesvirus-8 (HHV-8)","n_c":["C39291"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Human Papillomavirus Infection","n_c":["C27851"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperparathyroidism","n_c":["C48259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hyperthyroidism","n_c":["C3123"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypospadias","n_c":["C40341"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypothyroidism","n_c":["C26800"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation","n_c":["C3137"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inflammation, Hyperkeratosis","n_c":["C3137","C35541"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Inherited Genetic Syndrome, NOS","n_c":["C3101"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intestinal Metaplasia","n_c":["C8360"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Iron Overload","n_c":["C78393"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Li-Fraumeni Syndrome","n_c":["C3476"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Low Grade Dysplasia","n_c":["C156084"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphamatoid Papulosis","n_c":["C3721"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Meningitis","n_c":["C174114"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphocytic Thyroiditis","n_c":["C38766"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lymphoid Hyperplasia","n_c":["C102532"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Lynch Syndrome","n_c":["C8494"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Malaria","n_c":["C34797"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Metabolic Syndrome","n_c":["C84442"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mineralcorticoids Excess","n_c":["C198986"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Motor / Movement Change","n_c":["C157433"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myasthenia Gravis","n_c":["C60989"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Mycobacterium avium Complex","n_c":["C36197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Myelodysplastic Syndrome","n_c":["C3247"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Neurocystericerosis","n_c":["C84932"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nodular Prostatic Hyperplasia","n_c":["C2897"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Fatty Liver Disease","n_c":["C84444"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Nonalcoholic Steatohepatitis","n_c":["C84445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"None","n_c":["C41132"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Obesity","n_c":["C3283"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Oral Contraceptives","n_c":["C389"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pancreatitis","n_c":["C3306"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumocystis Pneumonia","n_c":["C3334"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Pneumonia, NOS","n_c":["C3333"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Polycystic Ovarian Syndrome (PCOS)","n_c":["C26862"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Primary Sclerosing Cholangitis","n_c":["C4828"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrent Pyogenic Cholangitis","n_c":["C164213"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Reflux Disease","n_c":["C26781"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rheumatoid Arthritis","n_c":["C2884"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubella","n_c":["C85051"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Rubinstein-Taybi Syndrome","n_c":["C75466"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sarcoidosis","n_c":["C34995"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Seizure","n_c":["C2962"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sensory Changes","n_c":["C157429"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Serous Tubal Intraepithelial Carcinoma (STIC)","n_c":["C126449"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Shingles","n_c":["C71079"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sialadenitis","n_c":["C26882"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sjogren's Syndrome","n_c":["C26883"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Skin Rash","n_c":["C39594"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Squamous Metaplasia","n_c":["C3237"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Staphylococcus aureus","n_c":["C122576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Steatosis","n_c":["C36185"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","n_c":["C156464"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Syphilis","n_c":["C35055"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tattoo","n_c":["C113681"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Thyroid Nodular Hyperplasia","n_c":["C131437"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, NOS","n_c":["C18059"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smokeless","n_c":["C137998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tobacco, Smoking","n_c":["C17934"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Treponema pallidum","n_c":["C85197"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberculosis","n_c":["C3423"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tuberous Sclerosis","n_c":["C3424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tubulointerstitial Disease","n_c":["C123036"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Tumor-associated Lymphoid Proliferation","n_c":["C171150"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Turcot Syndrome","n_c":["C3938"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Undescended Testis","n_c":["C12326"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Varicella Zoster Virus","n_c":["C96407"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vascular Disease","n_c":["C35117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Vision Changes","n_c":["C157424"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Von Hippel-Lindau Syndrome","n_c":["C3105"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wagr Syndrome","n_c":["C3718"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"BK Virus","n_c":["C123276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Diverticulosis","n_c":["C4922"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypercholesterolemia","n_c":["C37967"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hypertension","n_c":["C3117"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Scarlet Fever","n_c":["C94575"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ulcerative Colitis","n_c":["C2952"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.staining_intensity_scale":[{"nm":"3 Point Scale","n_c":["C202268"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4 Point Scale","n_c":["C202269"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.staining_intensity_value":[{"nm":"0","n_c":["C186199"],"i_c":"","i_c_s":"","term_type":""},{"nm":"1+","n_c":["C186200"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2+","n_c":["C186201"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3+","n_c":["C186202"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4+","n_c":["C202273"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.therapeutic_levels_achieved":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.timepoint_category":[{"nm":"Adjuvant Therapy","n_c":["C15675"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adolescence","n_c":["C39298"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Adulthood","n_c":["C199314"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Childhood","n_c":["C89345"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Follow-up","n_c":["C16033"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Initial Diagnosis","n_c":["C156813"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Last Contact","n_c":["C199315"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Adjuvant Therapy","n_c":["C158707"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Hormone Therapy","n_c":["C199316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Post Secondary Therapy","n_c":["C158753"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Postoperative","n_c":["C28006"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Preoperative","n_c":["C54732"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Diagnosis","n_c":["C199317"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Prior to Treatment","n_c":["C54734"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Recurrence/Progression","n_c":["C158754"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Within 3 Months of Surgery","n_c":["C200432"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Sample Procurement","n_c":["C164024"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.treatment_frequency":[{"nm":"Every Hour","n_c":["C64510"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Five Times Daily","n_c":["C98849"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Four Times Daily","n_c":["C64530"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Three Times Daily","n_c":["C64527"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Daily","n_c":["C64496"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once Daily","n_c":["C64515"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Every Other Day","n_c":["C64525"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Twice Weekly","n_c":["C64497"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once Weekly","n_c":["C64526"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Once a Week for at Least a Year","n_c":["C202276"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Occasionally","n_c":["C151974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Never","n_c":["C172572"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_corrected":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_corrected_laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_corrected_method":[{"nm":"Hormones","n_c":["C15445"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Orchiopexy","n_c":["C111066"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Spontaneous Descent","n_c":["C184803"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Testis Removed","n_c":["C15288"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_history":[{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""},{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.undescended_testis_history_laterality":[{"nm":"Bilateral","n_c":["C13332"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Left","n_c":["C25229"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Right","n_c":["C25228"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.viral_hepatitis_serologies":[{"nm":"HBV Core Antibody","n_c":["C96660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV DNA","n_c":["C103404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Genotype","n_c":["C117108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Surface Antibody","n_c":["C74711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HCV Genotype","n_c":["C117109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Surface Antigen","n_c":["C64850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Antibody","n_c":["C92535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Virus RNA","n_c":["C142330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""}],"clinical.diagnosis.calgb_risk_group":[{"nm":"Favorable","n_c":["C160757"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Intermediate/Normal","n_c":["C160758"],"i_c":"","i_c_s":"","term_type":""},{"nm":"N/A","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Poor","n_c":["C160759"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"index_file.germline_mutation_index.data_category":[{"nm":"Simple Nucleotide Variation","n_c":["C97927"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_expression_array.data_category":[{"nm":"Transcriptome Profiling","n_c":["C153189"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_expression_array.data_format":[{"nm":"CEL","n_c":["C191737"],"i_c":"","i_c_s":"","term_type":""}],"index_file.germline_mutation_index.data_format":[{"nm":"TBI","n_c":["C184806"],"i_c":"","i_c_s":"","term_type":""}],"index_file.germline_mutation_index.data_type":[{"nm":"Germline Mutation Index","n_c":["C206459"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_expression_array.data_type":[{"nm":"Raw Intensities","n_c":["C184793"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_expression_array.experimental_strategy":[{"nm":"Expression Array","n_c":["C93207"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.hormonal_replacement_therapy_status":[{"nm":"No","n_c":["C49487"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Yes","n_c":["C49488"],"i_c":"","i_c_s":"","term_type":""}],"clinical.molecular_test.mutation_codon":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.number_of_pregnancies":[{"nm":"1","n_c":["C66832"],"i_c":"","i_c_s":"","term_type":""},{"nm":"2","n_c":["C66833"],"i_c":"","i_c_s":"","term_type":""},{"nm":"3","n_c":["C66834"],"i_c":"","i_c_s":"","term_type":""},{"nm":"4+","n_c":["C158623"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"index_file.germline_mutation_index.platform":[{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""}],"data_file.filtered_copy_number_segment.platform":[{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""}],"data_file.structural_variation.platform":[{"nm":"Affymetrix SNP 6.0","n_c":["C202277"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aggregated_somatic_mutation.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"data_file.annotated_somatic_mutation.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"data_file.gene_expression.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GeneChip U133 Plus 2.0","n_c":["C206467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GeneChip U133A","n_c":["C206468"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""}],"data_file.masked_somatic_mutation.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"data_file.mirna_expression.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"data_file.simple_somatic_mutation.platform":[{"nm":"Complete Genomics","n_c":["C146815"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Ion Torrent","n_c":["C125894"],"i_c":"","i_c_s":"","term_type":""},{"nm":"LS454","n_c":["C146809"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""},{"nm":"PacBio","n_c":["C146819"],"i_c":"","i_c_s":"","term_type":""},{"nm":"SOLiD","n_c":["C146811"],"i_c":"","i_c_s":"","term_type":""}],"data_file.submitted_expression_array.platform":[{"nm":"GeneChip U133 Plus 2.0","n_c":["C206467"],"i_c":"","i_c_s":"","term_type":""},{"nm":"GeneChip U133A","n_c":["C206468"],"i_c":"","i_c_s":"","term_type":""}],"data_file.secondary_expression_analysis.platform":[{"nm":"Illumina","n_c":["C146817"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Other","n_c":["C17649"],"i_c":"","i_c_s":"","term_type":""}],"clinical.pathology_detail.prcc_type":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Type 1","n_c":["C27886"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Type 2","n_c":["C27887"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.prescribed_dose_units":[{"nm":"AUC","n_c":["C64774"],"i_c":"","i_c_s":"","term_type":""},{"nm":"cGy","n_c":["C64693"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/day","n_c":["C67372"],"i_c":"","i_c_s":"","term_type":""},{"nm":"g/m2","n_c":["C67282"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Gy","n_c":["C18063"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IU/kg","n_c":["C67379"],"i_c":"","i_c_s":"","term_type":""},{"nm":"IU/mg","n_c":["C67380"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mCi","n_c":["C48511"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mEq","n_c":["C48512"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg","n_c":["C28253"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/day","n_c":["C67399"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/dL","n_c":["C67015"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/kg","n_c":["C67401"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/kg/day","n_c":["C66976"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2","n_c":["C67402"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2/day","n_c":["C66974"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/m2/wk","n_c":["C88148"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/mL","n_c":["C42576"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mg/wk","n_c":["C67404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mIU","n_c":["C67316"],"i_c":"","i_c_s":"","term_type":""},{"nm":"mL","n_c":["C28254"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ug","n_c":["C48152"],"i_c":"","i_c_s":"","term_type":""},{"nm":"ug/m2","n_c":["C67312"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Wafer","n_c":["C48552"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.protocol_identifier":[{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.treatment.therapeutic_target_level":[{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"clinical.follow_up.treatment_emergent_adverse_event":[{"nm":"Definitely","n_c":["C53260"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Possibly","n_c":["C53258"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Probably","n_c":["C53259"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unlikely","n_c":["C53257"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unrelated","n_c":["C53256"],"i_c":"","i_c_s":"","term_type":""}],"clinical.other_clinical_attribute.viral_hepatitis_serology_tests":[{"nm":"HBV Core Antibody","n_c":["C96660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV DNA","n_c":["C103404"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Genotype","n_c":["C117108"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HBV Surface Antibody","n_c":["C74711"],"i_c":"","i_c_s":"","term_type":""},{"nm":"HCV Genotype","n_c":["C117109"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis B Surface Antigen","n_c":["C64850"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Antibody","n_c":["C92535"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Hepatitis C Virus RNA","n_c":["C142330"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Reported","n_c":["C43234"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}],"data_file.aligned_reads.wgs_coverage":[{"nm":"16","n_c":["C206483"],"i_c":"","i_c_s":"","term_type":""},{"nm":"10x-25x","n_c":["C206481"],"i_c":"","i_c_s":"","term_type":""},{"nm":"150x+","n_c":["C206482"],"i_c":"","i_c_s":"","term_type":""},{"nm":"25x-150x","n_c":["C206484"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Not Applicable","n_c":["C48660"],"i_c":"","i_c_s":"","term_type":""},{"nm":"Unknown","n_c":["C17998"],"i_c":"","i_c_s":"","term_type":""}]}
\ No newline at end of file
diff --git a/server/data_files/ncit_details.js b/server/data_files/ncit_details.js
index 14b9c5a..e117850 100644
--- a/server/data_files/ncit_details.js
+++ b/server/data_files/ncit_details.js
@@ -1 +1 @@
-{"C128274":{"preferredName":"Circulating Cell-Free DNA","code":"C128274","definitions":[{"definition":"DNA found in blood plasma and other bodily fluids that is not associated with cells.","type":"DEFINITION","source":"NCI"},{"definition":"DNA in blood plasma and other body fluids that has been released from a cell due to a biological process.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Circulating Cell-Free DNA","termGroup":"PT","termSource":"NCI"},{"termName":"cfDNA","termGroup":"AB","termSource":"NCI"},{"termName":"Circulating DNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"cfDNA"},{"name":"NCI_META_CUI","value":"CL509041"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C449":{"preferredName":"DNA","code":"C449","definitions":[{"definition":"A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone and found in the nucleus of a cell; associated with the transmission of genetic information.","type":"DEFINITION","source":"NCI"},{"definition":"A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone; associated with the transmission of genetic information.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The molecules inside cells that carry genetic information and pass it from one generation to the next.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Deoxyribonucleic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9007-49-2"},{"name":"CHEBI_ID","value":"CHEBI:16991"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"DNA is a double-stranded molecule held together by weak bonds between base pairs of nucleotides. DNA contain the four nucleotide bases adenine (A), guanine (G), cytosine (C), and thymine (T). In nature, base pairs form only between A and T and between G and C; thus the base sequence of each single strand can be deduced from that of its partner."},{"name":"Legacy Concept Name","value":"Deoxyribonucleic_Acid"},{"name":"Maps_To","value":"DNA"},{"name":"NSC Number","value":"77460"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0012854"}]}}{"C163993":{"preferredName":"EBV Immortalized Lymphocytes","code":"C163993","definitions":[{"definition":"A biospecimen consisting of lymphocytes that have been isolated from whole blood and are then infected in vitro by Epstein-Barr virus (EBV; HHV4). The infected cells are then cultured to select indefinitely proliferating colonies that can be maintained in tissue culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV Immortalized Lymphocytes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EBV Immortalized"},{"name":"Maps_To","value":"EBV Immortalized Lymphocytes"},{"name":"NCI_META_CUI","value":"CL977260"},{"name":"Semantic_Type","value":"Cell"}]}}{"C156435":{"preferredName":"Formalin-Fixed Paraffin-Embedded DNA","code":"C156435","definitions":[{"definition":"A DNA sample derived from a formalin-fixed paraffin-embedded tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded DNA","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE DNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE DNA"},{"name":"NCI_META_CUI","value":"CL563154"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C156436":{"preferredName":"Formalin-Fixed Paraffin-Embedded RNA","code":"C156436","definitions":[{"definition":"An RNA sample derived from a formalin-fixed paraffin-embedded tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded RNA","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE RNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE RNA"},{"name":"NCI_META_CUI","value":"CL563155"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C128787":{"preferredName":"GenomePlex Whole Genome Amplification","code":"C128787","definitions":[{"definition":"A proprietary method for whole genome amplification (WGA) from very small samples using random fragmentation of genomic DNA and conversion of the resulting small fragments to a library of PCR-amplifiable molecules flanked by universal priming sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GenomePlex Whole Genome Amplification","termGroup":"PT","termSource":"NCI"},{"termName":"GenomePlex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genomeplex"},{"name":"Maps_To","value":"GenomePlex (Rubicon) Amplified DNA"},{"name":"NCI_META_CUI","value":"CL509071"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C174108":{"preferredName":"Nucleic RNA Sample","code":"C174108","definitions":[{"definition":"A biological specimen comprised of the RNA isolated from the nuclei of cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleic RNA Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleic RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nuclei RNA"},{"name":"NCI_META_CUI","value":"CL1407752"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C128788":{"preferredName":"REPLI-g Whole Genome Amplification","code":"C128788","definitions":[{"definition":"A proprietary method for whole genome amplification (WGA) from small samples using high-fidelity enzyme Phi 29 polymerase to amplify complex genomic DNA using Multiple Displacement Amplification (MDA) technology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REPLI-g Whole Genome Amplification","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Repli-G"},{"name":"Maps_To","value":"Repli-G (Qiagen) DNA"},{"name":"NCI_META_CUI","value":"CL509311"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C156437":{"preferredName":"REPLI-g Pooled DNA","code":"C156437","definitions":[{"definition":"A genomic DNA sample produced from a pool of samples from several subjects that is amplified using REPLI-g technology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REPLI-g Pooled DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Repli-G Pooled (Qiagen) DNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Repli-G Pooled (Qiagen) DNA"},{"name":"NCI_META_CUI","value":"CL563156"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C156439":{"preferredName":"REPLI-g X DNA","code":"C156439","definitions":[{"definition":"A genomic DNA sample that has been produced by two rounds of REPLI-g amplification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REPLI-g X DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Repli-G X (Qiagen) DNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Repli-G X"},{"name":"Maps_To","value":"Repli-G X (Qiagen) DNA"},{"name":"NCI_META_CUI","value":"CL563177"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C812":{"preferredName":"Ribonucleic Acid","code":"C812","definitions":[{"definition":"One of two types of nucleic acid made by cells. Ribonucleic acid contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of ribonucleic acid, and each form has a specific job in the cell. Many forms of ribonucleic acid have functions related to making proteins. Ribonucleic acid is also the genetic material of some viruses instead of DNA. Ribonucleic acid can be made in the laboratory and used in research studies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Single-stranded long chain of nucleotides containing ribose. It is the end product of DNA transcription by the enzyme RNA polymerase. It is essential in protein synthesis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Single-stranded long chain of nucleotides containing ribose. It is the end product of DNA transcription by the enzyme RNA polymerase. It is essential in protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribonucleic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63231-63-0"},{"name":"CHEBI_ID","value":"CHEBI:33697"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ribonucleic_Acid"},{"name":"Maps_To","value":"RNA"},{"name":"NSC Number","value":"77461"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0035668"}]}}{"C163995":{"preferredName":"Total RNA","code":"C163995","definitions":[{"definition":"A biological sample comprised of all of the RNA collected from an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total RNA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Total RNA"},{"name":"NCI_META_CUI","value":"CL973034"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C188352":{"preferredName":"N6-Methyladenine Enriched RNA","code":"C188352","definitions":[{"definition":"A biological sample comprised of RNA that has subjected to an immunoprecipitation procedure using an antibody designed to select for sequences containing N6-methyladenine modifications.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N6-Methyladenine Enriched RNA","termGroup":"PT","termSource":"NCI"},{"termName":"m6A Enriched RNA","termGroup":"SY","termSource":"NCI"},{"termName":"m6A-Enriched RNA","termGroup":"SY","termSource":"NCI"},{"termName":"N6-Methyladenine-Enriched RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"m6A Enriched RNA"},{"name":"NCI_META_CUI","value":"CL1793611"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C179446":{"preferredName":"mirVana RNA Isolation","code":"C179446","definitions":[{"definition":"A proprietary, rapid procedure using a glass fiber filter (GFF)-based method to purify total RNA from a sample. The total RNA can then be reapplied to a second GFF to purify small RNAs (miRNAs, siRNAs, and/or snRNAs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mirVana RNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"mirVana RNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"mirVana RNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mirVana (Allprep DNA) RNA"},{"name":"NCI_META_CUI","value":"CL1662297"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C153329":{"preferredName":"Sequencing Data","code":"C153329","definitions":[{"definition":"A collection of digital nucleic acid sequences, protein sequences, or other polymer sequences stored on a computer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Sequence Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sequencing Data"},{"name":"NCI_META_CUI","value":"CL554436"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C153349":{"preferredName":"Nucleotide Sequence Read","code":"C153349","definitions":[{"definition":"The manual or automated determination of the nucleotide order in a nucleic acid fragment obtained after the completion of a sequencing process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleotide Sequence Read","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleotide Sequencing Read","termGroup":"SY","termSource":"NCI"},{"termName":"Read","termGroup":"SY","termSource":"NCI"},{"termName":"Sequence Read","termGroup":"SY","termSource":"NCI"},{"termName":"Sequencing Read","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sequencing Reads"},{"name":"NCI_META_CUI","value":"CL554563"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C165232":{"preferredName":"Raw Sequencing Data","code":"C165232","definitions":[{"definition":"Nucleic acid sequence data that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw Nucleic Acid Sequencing Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw Nucleotide Sequencing Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw Sequencing Data"},{"name":"NCI_META_CUI","value":"CL978384"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C165211":{"preferredName":"Analysis Metadata","code":"C165211","definitions":[{"definition":"Supporting information that describes the processes used to analyze the experimental data in a study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Analysis Metadata","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Analysis Metadata"},{"name":"NCI_META_CUI","value":"CL978393"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184804":{"preferredName":"SRA-XML Format","code":"C184804","definitions":[{"definition":"An XML-based electronic file format used by the NCBI Sequence Read Archive (SRA) and the European Nucleotide Archive (ENA) to store raw sequencing data from next generation sequencing platforms and any corresponding sequence analysis data and associated metadata for the study, sample and experiment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution"}]}],"synonyms":[{"termName":"SRA-XML Format","termGroup":"PT","termSource":"NCI"},{"termName":"Short Read Archive eXtensible Markup Language Format","termGroup":"SY","termSource":"NCI"},{"termName":"SRA-XML","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SRA XML"},{"name":"NCI_META_CUI","value":"CL1772998"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C82937":{"preferredName":"MAGE-TAB","code":"C82937","definitions":[{"definition":"A tab-delimited, spreadsheet-based format that can be used for annotating and communicating microarray data with experimental details in a MIAME (Minimum Information About a Microarray Experiment) compliant fashion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-TAB","termGroup":"PT","termSource":"NCI"},{"termName":"MicroArray Gene Expression Tabular","termGroup":"SY","termSource":"NCI"},{"termName":"MicroArray Gene Expression Tabular Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MAGE-TAB"},{"name":"Maps_To","value":"MAGE-TAB"},{"name":"Maps_To","value":"MAGETAB"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2826580"}]}}{"C172211":{"preferredName":"Sample and Data Relationship Format","code":"C172211","definitions":[{"definition":"A tab-delimited file describing the relationships between samples, arrays, data and other objects used or produced during a microarray experiment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sample and Data Relationship Format","termGroup":"PT","termSource":"NCI"},{"termName":"SDRF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SDRF"},{"name":"NCI_META_CUI","value":"CL1406086"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172212":{"preferredName":"Investigation Description Format","code":"C172212","definitions":[{"definition":"A a tab-delimited containing information about an investigation, including its name, a description, the investigator's contact details, bibliographic references, and free text descriptions of any relevant protocols.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"BMC Bioinformatics. 2006; 7. https://doi.org/10.1186/1471-2105-7-489."}]}],"synonyms":[{"termName":"Investigation Description Format","termGroup":"PT","termSource":"NCI"},{"termName":"IDF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDF"},{"name":"NCI_META_CUI","value":"CL1406085"},{"name":"PubMedID_Primary_Reference","value":"17087822"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172213":{"preferredName":"Array Design Format","code":"C172213","definitions":[{"definition":"A tab-delimited file defining how each array in an investigation is used. This data includes what sequence is located at each position in an array and what the annotation of this sequence is; cross-references to entries in a public repository can be used if available.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"BMC Bioinformatics. 2006; 7. https://doi.org/10.1186/1471-2105-7-489."}]}],"synonyms":[{"termName":"Array Design Format","termGroup":"PT","termSource":"NCI"},{"termName":"ADF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ADF"},{"name":"NCI_META_CUI","value":"CL1406109"},{"name":"PubMedID_Primary_Reference","value":"17087822"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C49488":{"preferredName":"Yes","code":"C49488","definitions":[{"definition":"ICD: a battery-powered electrical impulse generator implanted in patients at risk of sudden cardiac death to detect cardiac arrhythmia and correct it by delivering a jolt of electricity. This would include BiV-ICDs.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The affirmative response to a question.","type":"DEFINITION","source":"NCI"},{"definition":"The affirmative response to a question. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Yes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Yes"},{"name":"Maps_To","value":"yes"},{"name":"Maps_To","value":"Yes"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C1298907"}]}}{"C49487":{"preferredName":"No","code":"C49487","definitions":[{"definition":"The non-affirmative response to a question.","type":"DEFINITION","source":"NCI"},{"definition":"The non-affirmative response to a question. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"No","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"No"},{"name":"Maps_To","value":"No"},{"name":"Maps_To","value":"no"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1298908"}]}}{"C17998":{"preferredName":"Unknown","code":"C17998","definitions":[{"definition":"A proper value is applicable but not known.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Not known, not observed, not recorded, or refused.","type":"ALT_DEFINITION","source":"PQCMC"},{"definition":"Not known, not observed, not recorded, or refused.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"SPL"}]},{"definition":"Not known, not observed, not recorded, or refused. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","type":"DEFINITION","source":"NCI"},{"definition":"Reported as unknown by the data contributor.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]}],"synonyms":[{"termName":"Unknown","termGroup":"PT","termSource":"NCI"},{"termName":"Not Known","termGroup":"SY","termSource":"NCI"},{"termName":"Unknown/Not Stated","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Contributing_Source","value":"UCUM"},{"name":"DesignNote","value":"Used for Cancer Activities Coding when cancer activity is not specified."},{"name":"Legacy Concept Name","value":"Unknown"},{"name":"Maps_To","value":"unknown"},{"name":"Maps_To","value":"Unknown"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C0439673"},{"name":"Use_For","value":"Nonspecific"}]}}{"C43234":{"preferredName":"Not Reported","code":"C43234","definitions":[{"definition":"Not provided or available.","type":"DEFINITION","source":"NCI"},{"definition":"Not provided or available.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Not Reported","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Not_Stated"},{"name":"Maps_To","value":"not reported"},{"name":"Maps_To","value":"Not Reported"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1706613"}]}}{"C141478":{"preferredName":"Not Allowed To Collect","code":"C141478","definitions":[{"definition":"An indicator that specifies that a collection event was not permitted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Not Allowed To Collect","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"not allowed to collect"},{"name":"Maps_To","value":"Not Allowed To Collect"},{"name":"NCI_META_CUI","value":"CL539590"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C70699":{"preferredName":"Biospecimen","code":"C70699","definitions":[{"definition":"A substance or portion of material originally obtained from an entity for use in testing, examination, or study.  EXAMPLE(S): Blood obtained by a specimen collection activity performed on a study subject. A few grains of cattle feed obtained from a feed sack. A randomly selected pill from a blister pack. A serum specimen that resulted from Centrifugation procedure performed on a blood specimen. A DNA specimen extraction from a saliva specimen. A Formalin-Fixed, Paraffin-Embedded (FFPE) block that resulted from a paraffin embedding procedure performed on a formalin fixed tissue specimen. A pooled blood sample that resulted from a mixing procedure performed on several blood samples taken from individual animals.  OTHER NAME(S): Biologic specimen Product specimen  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"A substance or portion of material originally obtained from an entity for use in testing, examination, or study. EXAMPLE(S): Blood obtained by a specimen collection activity performed on a study subject. A few grains of cattle feed obtained from a feed sack. A randomly selected pill from a blister pack. A serum specimen that resulted from Centrifugation procedure performed on a blood specimen. A DNA specimen extraction from a saliva specimen. A Formalin-Fixed, Paraffin-Embedded (FFPE) block that resulted from a paraffin embedding procedure performed on a formalin fixed tissue specimen. A pooled blood sample that resulted from a mixing procedure performed on several blood samples taken from individual animals. OTHER NAME(S): Biologic specimen; Product specimen.","type":"ALT_DEFINITION","source":"BRIDG 3.0.3"},{"definition":"Any material collected from a biological entity for testing, diagnostic, propagation, treatment, or research purposes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","type":"DEFINITION","source":"NCI"},{"definition":"Samples of material, such as urine, blood, tissue, cells, DNA, RNA, and protein from humans, animals, or plants. Biospecimens are stored in a biorepository and are used for laboratory research. If the samples are from people, medical information may also be stored along with a written consent to use the samples in laboratory studies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Biospecimen","termGroup":"PT","termSource":"NCI"},{"termName":"Bio-Specimen","termGroup":"SY","termSource":"NCI"},{"termName":"Biological Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Biological Specimen","termGroup":"SY","termSource":"NCI"},{"termName":"Biospecimen","termGroup":"SY","termSource":"NCI"},{"termName":"Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Biospecimen"},{"name":"Maps_To","value":"Biospecimen"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C2347026"}]}}{"C164025":{"preferredName":"Biospecimen Data Supplement","code":"C164025","definitions":[{"definition":"Additional documentation or textual matter added to a study report that contains biospecimen data or related information.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biospecimen Data Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Biospecimen Supplement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biospecimen Supplement"},{"name":"NCI_META_CUI","value":"CL977234"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C190164":{"preferredName":"BCR Biotab Format","code":"C190164","definitions":[{"definition":"Files that consist of aggregate clinical and biospecimen data across all cases of the given project. Biotab files are supplemental files that are available in the Genomic Data Commons (GDC) Legacy Archive as tab-delimited files on a project level basis. These may also include fields that are not available in the GDC application programming interface (API).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCR Biotab Format","termGroup":"PT","termSource":"NCI"},{"termName":"BCR Biotab","termGroup":"SY","termSource":"NCI"},{"termName":"BCR Biotab File Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BCR Biotab"},{"name":"NCI_META_CUI","value":"CL1798764"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C164049":{"preferredName":"Tab-Separated Value Format","code":"C164049","definitions":[{"definition":"A file format where each line in the file contains a single piece of data and where each field or value in a line of data is separated from the next by a tab character.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tab-Separated Value Format","termGroup":"PT","termSource":"NCI"},{"termName":"Tab-Delimited File Format","termGroup":"SY","termSource":"NCI"},{"termName":"Tab-Delimited Format","termGroup":"SY","termSource":"NCI"},{"termName":"Tab-Delimited Value Format","termGroup":"SY","termSource":"NCI"},{"termName":"Tab-Delimited Values","termGroup":"SY","termSource":"NCI"},{"termName":"TSV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TSV"},{"name":"NCI_META_CUI","value":"CL977213"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C164050":{"preferredName":"Excel Open XML Format","code":"C164050","definitions":[{"definition":"A proprietary file format developed by Microsoft that allows the user to save a spreadsheet created in Excel in an open XML-format. The file then can be read and opened by other spreadsheet-compatible applications.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Excel Open XML Format","termGroup":"PT","termSource":"NCI"},{"termName":"XLSX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"XLSX"},{"name":"NCI_META_CUI","value":"CL977212"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172262":{"preferredName":"Consent Exemption for Use of Post-mortem Samples","code":"C172262","definitions":[{"definition":"An exemption that allows research sponsors to use samples obtained from a subject after his/her death because these samples are not subject to human subject use regulations and do not require documentation of informed consent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Consent Exemption for Use of Post-mortem Samples","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Consent by Death"},{"name":"NCI_META_CUI","value":"CL1406151"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C79226":{"preferredName":"Exemption from Informed Consent for Research","code":"C79226","synonyms":[{"termName":"Exemption from Informed Consent for Research","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Exemption_From_Informed_Consent_For_Research"},{"name":"Maps_To","value":"Consent Exemption"},{"name":"Semantic_Type","value":"Regulation or Law"},{"name":"UMLS_CUI","value":"C2700032"}]}}{"C103270":{"preferredName":"Consent Waiver","code":"C103270","definitions":[{"definition":"The release from the requirement to obtain informed consent during a study that is granted by Human Subject Protection committee for a research institution for a protocol that is being reviewed by the Institutional Review Board.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Consent Waiver","termGroup":"PT","termSource":"NCI"},{"termName":"Waiver Of Informed Consent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Consent Waiver"},{"name":"Semantic_Type","value":"Governmental or Regulatory Activity"},{"name":"UMLS_CUI","value":"C3641166"}]}}{"C16735":{"preferredName":"Informed Consent","code":"C16735","definitions":[{"definition":"A process in which a person is given important facts about a medical procedure or treatment, a clinical trial, or genetic testing before deciding whether or not to participate. It also includes informing the patient when there is new information that may affect his or her decision to continue. Informed consent includes information about the possible risks, benefits, and limits of the procedure, treatment, trial, or genetic testing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An ongoing process that provides the subject with explanations that will help in making educated decisions about whether to begin or continue participating in a trial. informed consent is an ongoing, interactive process rather than a one-time information session. NOTE: Under 21 CFR 50.20, no informed consent form may include any \"language through which the subject or the representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability for negligence.\" In some cases, when the prospective subject is unable to provide legal consent, permission to participate may be obtained from a legally-authorized representative. See also consent form.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.","type":"DEFINITION","source":"NCI"},{"definition":"Consent given by a subject, or in the case of an individual that can only give assent, by a parent or legal guardian, for the participation in a clinical study only after having achieved an understanding of both the relevant medical facts and the relevant risks involved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The process of learning and discussing the details of a research study before deciding whether to take part. (https://mrctcenter.org/glossaryterm/informed-consent/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Informed Consent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Informed_Consent"},{"name":"Maps_To","value":"Informed Consent"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0021430"}]}}{"C4197":{"preferredName":"Acinar Cell Neoplasm","code":"C4197","definitions":[{"definition":"A benign or malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. It includes the acinar cell adenoma and acinar cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acinar Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8550/1"},{"name":"Legacy Concept Name","value":"Acinar_Cell_Neoplasm"},{"name":"Maps_To","value":"8550/1"},{"name":"Maps_To","value":"Acinar Cell Neoplasms"},{"name":"Maps_To","value":"Acinar cell tumor"},{"name":"Maps_To","value":"Acinic cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334390"}]}}{"C4463":{"preferredName":"Skin Appendage Neoplasm","code":"C4463","definitions":[{"definition":"A benign or malignant neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Appendage Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Adnexal Neoplasm of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Neoplasm of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Tumor of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Tumor of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Appendageal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Adnexal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendage Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendageal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_Appendage_Neoplasm"},{"name":"Maps_To","value":"Adnexal and Skin Appendage Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0345988"}]}}{"C3784":{"preferredName":"Basal Cell Neoplasm","code":"C3784","definitions":[{"definition":"A neoplastic proliferation of basal cells in the epidermis (part of the skin) or other anatomic sites (most frequently the salivary glands).  The basal cell neoplastic proliferation in the epidermis results in basal cell carcinomas.  The basal cell neoplastic proliferation in the salivary glands can be benign, resulting in basal cell adenomas or malignant, resulting in basal cell adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basal Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8090/1"},{"name":"Legacy Concept Name","value":"Basal_Cell_Neoplasm"},{"name":"Maps_To","value":"8090/1"},{"name":"Maps_To","value":"Basal Cell Neoplasms"},{"name":"Maps_To","value":"Basal cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206710"}]}}{"C7387":{"preferredName":"Blood Vessel Neoplasm","code":"C7387","definitions":[{"definition":"A neoplasm arising from arteries or veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Vessel Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Vessel Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blood_Vessel_Neoplasm"},{"name":"Maps_To","value":"Blood Vessel Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0282607"}]}}{"C4345":{"preferredName":"Myeloproliferative Neoplasm","code":"C4345","definitions":[{"definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","type":"DEFINITION","source":"NCI"},{"definition":"A group of slow growing blood cancers, including chronic myelogenous leukemia, in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Myeloproliferative Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"CMPD","termGroup":"AB","termSource":"NCI"},{"termName":"MPN","termGroup":"AB","termSource":"NCI"},{"termName":"Myeloproliferative Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloproliferative Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9960/3"},{"name":"ICD-O-3_Code","value":"9975/1"},{"name":"Legacy Concept Name","value":"Chronic_Myeloproliferative_Disorder"},{"name":"Maps_To","value":"Chronic myeloproliferative disease"},{"name":"Maps_To","value":"Chronic myeloproliferative disorder"},{"name":"Maps_To","value":"Chronic Myeloproliferative Disorders"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292778"}]}}{"C4198":{"preferredName":"Complex Epithelial Neoplasm","code":"C4198","synonyms":[{"termName":"Complex Epithelial Neoplasm","termGroup":"AQ","termSource":"NCI"},{"termName":"Complex Epithelial Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Neoplasm of Epithelium","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Neoplasm of the Epithelium","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Tumor of Epithelium","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Tumor of the Epithelium","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Complex_Epithelial_Neoplasm"},{"name":"Maps_To","value":"Complex Epithelial Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334391"}]}}{"C3709":{"preferredName":"Epithelial Neoplasm","code":"C3709","definitions":[{"definition":"A benign, borderline, or malignant neoplasm that arises from and is composed of epithelial cells. Representative examples include adenomas and carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Neoplasms, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epithelial_Neoplasm"},{"name":"Maps_To","value":"Epithelial Neoplasms, NOS"},{"name":"Maps_To","value":"Epithelioma, malignant"},{"name":"Maps_To","value":"Epithelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368683"}]}}{"C3743":{"preferredName":"Fibroepithelial Neoplasm","code":"C3743","definitions":[{"definition":"A benign, borderline, or malignant neoplasm characterized by the presence of an epithelial and a fibrous component.  Representative examples are fibroadenoma and phyllodes tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroepithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroepithelial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fibroepithelial_Neoplasm"},{"name":"Maps_To","value":"Fibroepithelial Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206649"}]}}{"C3708":{"preferredName":"Germ Cell Tumor","code":"C3708","definitions":[{"definition":"A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","type":"DEFINITION","source":"NCI"},{"definition":"A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, dysgerminoma, and germinoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of tumor that begins in the cells that give rise to sperm or eggs. Germ cell tumors can occur almost anywhere in the body and can be either benign or malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Germ Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Germ Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Germ Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Germ Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Germ_Cell_Neoplasm"},{"name":"Maps_To","value":"9064/3"},{"name":"Maps_To","value":"Germ Cell Neoplasms"},{"name":"Maps_To","value":"Germ cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205851"}]}}{"C3055":{"preferredName":"Giant Cell Tumor","code":"C3055","definitions":[{"definition":"A benign, intermediate, or malignant tumor that arises from the bone or soft tissue. It is characterized by the presence of multinucleated osteoclast-like giant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Giant_Cell_Tumor"},{"name":"Maps_To","value":"Giant Cell Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017525"}]}}{"C3059":{"preferredName":"Glioma","code":"C3059","definitions":[{"definition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","type":"DEFINITION","source":"NCI"},{"definition":"A general term for tumors of the central nervous system, including astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroectodermal tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Glial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Neuroglia","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Neuroglia","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroglial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Neuroglia","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Neuroglia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Neuroglial_Tumor"},{"name":"Maps_To","value":"9380/3"},{"name":"Maps_To","value":"Glioma, NOS"},{"name":"Maps_To","value":"Gliomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017638"}]}}{"C9357":{"preferredName":"Hodgkin Lymphoma","code":"C9357","definitions":[{"definition":"A cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Symptoms include the painless enlargement of lymph nodes, spleen, or other immune tissue. Other symptoms include fever, weight loss, fatigue, or night sweats.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the lymphatic system that is comprised of abnormal lymphocytes and is characterized by the presence of Reed-Sternberg cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"HL","termGroup":"AB","termSource":"NCI"},{"termName":"Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9650/3"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9650/3"},{"name":"Maps_To","value":"Hodgkin disease, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma"},{"name":"Maps_To","value":"Hodgkin Lymphoma"},{"name":"Maps_To","value":"Hodgkin lymphoma, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified, unspecified site"},{"name":"Maps_To","value":"Hodgkin's disease"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving intrapelvic lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Hodgkin's lymphoma"},{"name":"Maps_To","value":"Malignant lymphoma, Hodgkin"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019829"}]}}{"C3161":{"preferredName":"Leukemia","code":"C3161","definitions":[{"definition":"A cancer of the blood or bone marrow that is characterized by increased production of abnormal blood cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells, originating from myeloid or lymphoid stem cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of blood cells to be produced and enter the bloodstream.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Blood (Leukemia)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9800/3"},{"name":"Legacy Concept Name","value":"Leukemia"},{"name":"Maps_To","value":"9800/3"},{"name":"Maps_To","value":"Leukaemia of unspecified cell type"},{"name":"Maps_To","value":"Leukaemia, unspecified"},{"name":"Maps_To","value":"Leukemia"},{"name":"Maps_To","value":"Leukemia of unspecified cell type"},{"name":"Maps_To","value":"Leukemia, NOS"},{"name":"Maps_To","value":"Leukemia, unspecified not having achieved remission"},{"name":"Maps_To","value":"Leukemias, NOS"},{"name":"Maps_To","value":"Other leukaemias of specified cell type"},{"name":"Maps_To","value":"Other leukemia of unspecified cell type"},{"name":"Maps_To","value":"Other leukemia of unspecified cell type without mention of having achieved remission"},{"name":"Maps_To","value":"Other specified leukaemias"},{"name":"Maps_To","value":"Other specified leukemia"},{"name":"Maps_To","value":"Other specified leukemias"},{"name":"Maps_To","value":"Other specified leukemias not having achieved remission"},{"name":"Maps_To","value":"Unspecified leukemia"},{"name":"Maps_To","value":"Unspecified leukemia without mention of having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023418"}]}}{"C4248":{"preferredName":"Lipomatous Neoplasm","code":"C4248","definitions":[{"definition":"A benign, intermediate, or malignant mesenchymal neoplasm composed of adipose (fatty) tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipomatous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Adipose Tissue Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adipose Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Lipomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Adipose Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lipomatous_Neoplasm"},{"name":"Maps_To","value":"Lipomatous Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206631"}]}}{"C3723":{"preferredName":"Lymphatic Vessel Neoplasm","code":"C3723","definitions":[{"definition":"A benign or malignant neoplasm arising from the lymphatic vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphatic Vessel Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Vessel Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Vessel Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphatic Vessel Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Lymphatic Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Lymphatic Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Lymphatic Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Lymphatic Vessel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphatic_Vessel_Neoplasm"},{"name":"Maps_To","value":"Lymphatic Vessel Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206619"}]}}{"C7539":{"preferredName":"Lymphoid Leukemia","code":"C7539","definitions":[{"definition":"A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood.  This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells, originating from lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer in which the bone marrow makes too many lymphocytes (white blood cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphoid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"981-983"},{"name":"ICD-O-3_Code","value":"9820/3"},{"name":"Legacy Concept Name","value":"Lymphoid_Leukemia"},{"name":"Maps_To","value":"9820/3"},{"name":"Maps_To","value":"Lymphatic leukemic, NOS"},{"name":"Maps_To","value":"Lymphocytic leukemia, NOS"},{"name":"Maps_To","value":"Lymphoid leukaemia"},{"name":"Maps_To","value":"Lymphoid leukaemia, unspecified"},{"name":"Maps_To","value":"Lymphoid leukemia"},{"name":"Maps_To","value":"Lymphoid leukemia, NOS"},{"name":"Maps_To","value":"Lymphoid leukemia, subacute"},{"name":"Maps_To","value":"Lymphoid leukemia, unspecified not having achieved remission"},{"name":"Maps_To","value":"Lymphoid Leukemias"},{"name":"Maps_To","value":"Lymphosarcoma cell leukemia"},{"name":"Maps_To","value":"Other lymphoid leukemia"},{"name":"Maps_To","value":"Other lymphoid leukemia not having achieved remission"},{"name":"Maps_To","value":"Other lymphoid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Unspecified lymphoid leukemia"},{"name":"Maps_To","value":"Unspecified lymphoid leukemia without mention of having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023448"}]}}{"C3208":{"preferredName":"Lymphoma","code":"C3208","definitions":[{"definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A malignant neoplasm composed of lymphocytes of B- or T/NK-cell phenotype.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm of the lymphatic system that is comprised of abnormal lymphocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphoma (Hodgkin and Non-Hodgkin)","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoma (Hodgkin's and Non-Hodgkin's)","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphomatous","termGroup":"AD","termSource":"NCI"},{"termName":"Malignant Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9590/3"},{"name":"Legacy Concept Name","value":"Lymphoma"},{"name":"Maps_To","value":"9590/3"},{"name":"Maps_To","value":"Lymphoma"},{"name":"Maps_To","value":"Lymphoma, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, NOS"},{"name":"Maps_To","value":"Malignant Lymphomas, NOS or Diffuse"},{"name":"Maps_To","value":"Other malignant lymphomas"},{"name":"Maps_To","value":"Other malignant lymphomas involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Other malignant lymphomas involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Other malignant lymphomas involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Other malignant lymphomas involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Other malignant lymphomas involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Other malignant lymphomas, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4227552"},{"name":"xRef","value":"IMDRF:E180104"}]}}{"C9295":{"preferredName":"Mast Cell Neoplasm","code":"C9295","definitions":[{"definition":"A growth or lump of mast cells (a type of white blood cell). Mast cell tumors can involve the skin, subcutaneous tissue, and muscle tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A heterogeneous group of disorders characterized by the abnormal growth and accumulation of mast cells in one or more organ systems.  Recent data suggest that most variants of mast cell neoplasms are clonal disorders. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Mast Cell Proliferative Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Mast Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Mast Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Mast Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Mast Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Mast Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mast_Cell_Neoplasm"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Mast cell tumor, NOS"},{"name":"Maps_To","value":"Mast Cell Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334664"}]}}{"C7056":{"preferredName":"Mature B-Cell Non-Hodgkin Lymphoma","code":"C7056","definitions":[{"definition":"A non-Hodgkin lymphoma that originates from mature B lymphocytes. Representative examples include diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mature B-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mature B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature B-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mature_B-Cell_Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"Mature B-Cell Lymphomas"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334634"}]}}{"C3468":{"preferredName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","code":"C3468","definitions":[{"definition":"One of a group of aggressive (fast-growing) non-Hodgkin lymphomas that begins in mature T lymphocytes (T cells that have matured in the thymus gland and goes to other lymphatic sites in the body, including lymph nodes, bone marrow, and spleen.)","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative disease entities include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mature T-and NK-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature T-Cell and NK-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature T-Cell and NK-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PTCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9702/3"},{"name":"Legacy Concept Name","value":"Mature_T-Cell_and_NK-Cell_Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"Mature T- and NK-Cell Lymphomas"},{"name":"Maps_To","value":"Mature T/NK-cell lymphoma, unspecified"},{"name":"Maps_To","value":"Mature T/NK-cell lymphomas"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079774"}]}}{"C3230":{"preferredName":"Meningioma","code":"C3230","definitions":[{"definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A type of slow-growing tumor that forms in the meninges (thin layers of tissue that cover and protect the brain and spinal cord). Meningiomas usually occur in adults.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually benign tumor that develops in the meninges.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9530/0"},{"name":"Legacy Concept Name","value":"Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Meningioma"},{"name":"Maps_To","value":"Meningioma, NOS"},{"name":"Maps_To","value":"Meningiomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4012135"}]}}{"C40141":{"preferredName":"Wolffian Tumor","code":"C40141","definitions":[{"definition":"An adnexal epithelial neoplasm of Wolffian (mesonephric) origin. It predominantly affects the broad ligament and presents as a unilateral adnexal mass. Most tumors behave in a benign fashion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wolffian Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"FATWO","termGroup":"AB","termSource":"NCI"},{"termName":"Female Adnexal Tumor of Probable Wolffian Origin","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephric Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephroma","termGroup":"SY","termSource":"NCI"},{"termName":"Retiform Wolffian Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"WAT","termGroup":"AB","termSource":"NCI"},{"termName":"Wolffian Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Adnexal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Adnexal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Duct Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Duct Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Duct Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9110/0"},{"name":"ICD-O-3_Code","value":"9110/1"},{"name":"Legacy Concept Name","value":"Wolffian_Adnexal_Tumor"},{"name":"Maps_To","value":"9110/0"},{"name":"Maps_To","value":"9110/1"},{"name":"Maps_To","value":"Mesonephric adenoma"},{"name":"Maps_To","value":"Mesonephric tumor, NOS"},{"name":"Maps_To","value":"Mesonephroma, benign"},{"name":"Maps_To","value":"Mesonephroma, NOS"},{"name":"Maps_To","value":"Mesonephromas"},{"name":"Maps_To","value":"Wolffian duct adenoma"},{"name":"Maps_To","value":"Wolffian duct tumor"},{"name":"Maps_To","value":"Wolffian tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1520159"}]}}{"C3786":{"preferredName":"Mesothelial Neoplasm","code":"C3786","definitions":[{"definition":"A benign (noncancerous) or malignant (cancerous) tumor affecting the lining of the chest or abdomen.  Exposure to asbestos particles in the air increases the risk of developing malignant mesothelioma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm characterized by the proliferation of neoplastic mesothelial cells. It usually arises from the pleura or peritoneum. This category includes malignant mesothelioma, adenomatoid tumor (benign mesothelioma), well differentiated papillary mesothelial tumor, and multicystic mesothelioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesothelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mesothelial_Neoplasm"},{"name":"Maps_To","value":"9050/3"},{"name":"Maps_To","value":"Mesothelial Neoplasms"},{"name":"Maps_To","value":"Mesothelioma"},{"name":"Maps_To","value":"Mesothelioma of other sites"},{"name":"Maps_To","value":"Mesothelioma, NOS"},{"name":"Maps_To","value":"Mesothelioma, unspecified"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3714739"}]}}{"C9343":{"preferredName":"Bone Neoplasm","code":"C9343","definitions":[{"definition":"A benign, intermediate, or malignant neoplasm involving the bone or articular cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Tumors","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bone_Neoplasm"},{"name":"Maps_To","value":"Miscellaneous Bone Tumors"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of bone and articular cartilage"},{"name":"Maps_To","value":"Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0005967"}]}}{"C102883":{"preferredName":"Miscellaneous Neoplasm","code":"C102883","definitions":[{"definition":"A benign or malignant neoplasm which is not further characterized.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miscellaneous Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Miscellaneous Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3540828"}]}}{"C3247":{"preferredName":"Myelodysplastic Syndrome","code":"C3247","definitions":[{"definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A group of diseases in which the bone marrow does not make enough healthy blood cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pre-malignant disorder characterized by blood cytopenias and abnormalities in bone marrow morphology.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Dysmyelopoietic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"MDN","termGroup":"AB","termSource":"NCI"},{"termName":"MDS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome/Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Oligoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Preleukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Smoldering Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9989/3"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"High grade myelodysplastic syndrome lesions"},{"name":"Maps_To","value":"Low grade myelodysplastic syndrome lesions"},{"name":"Maps_To","value":"Myelodysplastic syndrome"},{"name":"Maps_To","value":"Myelodysplastic Syndrome"},{"name":"Maps_To","value":"Myelodysplastic syndrome, unspecified"},{"name":"Maps_To","value":"Myelodysplastic Syndromes"},{"name":"Maps_To","value":"Myelodysplastic syndromes"},{"name":"Maps_To","value":"Other myelodysplastic syndromes"},{"name":"Maps_To","value":"Preleukemia"},{"name":"Maps_To","value":"Preleukemic syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3463824"}]}}{"C3172":{"preferredName":"Myeloid Leukemia","code":"C3172","definitions":[{"definition":"A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells, originating from immature granulocytes.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Lymphoblastic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9860/3"},{"name":"Legacy Concept Name","value":"Myeloid_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"Granulocytic leukemia, NOS"},{"name":"Maps_To","value":"Myelocytic leukemia, NOS"},{"name":"Maps_To","value":"Myelogenous leukemia, NOS"},{"name":"Maps_To","value":"Myeloid leukaemia"},{"name":"Maps_To","value":"Myeloid leukaemia, unspecified"},{"name":"Maps_To","value":"Myeloid leukemia"},{"name":"Maps_To","value":"Myeloid leukemia, NOS"},{"name":"Maps_To","value":"Myeloid leukemia, subacute"},{"name":"Maps_To","value":"Myeloid Leukemias"},{"name":"Maps_To","value":"Non-lymphocytic leukemia, NOS"},{"name":"Maps_To","value":"Other myeloid leukaemia"},{"name":"Maps_To","value":"Other myeloid leukemia"},{"name":"Maps_To","value":"Other myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Subacute myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Unspecified myeloid leukemia"},{"name":"Maps_To","value":"Unspecified myeloid leukemia without mention of having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023470"}]}}{"C4063":{"preferredName":"Myomatous Neoplasm","code":"C4063","definitions":[{"definition":"A benign or malignant mesenchymal neoplasm arising from smooth, skeletal, or cardiac muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myomatous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Muscle Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Myomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Muscle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myomatous_Neoplasm"},{"name":"Maps_To","value":"Myomatous Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0282606"}]}}{"C3262":{"preferredName":"Neoplasm","code":"C3262","definitions":[{"definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","type":"DEFINITION","source":"NCI"},{"definition":"An abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Neoplasms may be benign (not cancer), or malignant (cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplastic Growth","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Neoplasm"},{"name":"Maps_To","value":"8000/1"},{"name":"Maps_To","value":"Neoplasm of unspecified nature, site unspecified"},{"name":"Maps_To","value":"Neoplasm, NOS"},{"name":"Maps_To","value":"Neoplasms of unspecified nature"},{"name":"Maps_To","value":"Neoplasms, NOS"},{"name":"Maps_To","value":"Tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Publish_Value_Set","value":"Yes"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0375111"},{"name":"xRef","value":"IMDRF:E18"}]}}{"C4972":{"preferredName":"Nerve Sheath Neoplasm","code":"C4972","definitions":[{"definition":"A benign or malignant neoplasm arising from the perineural cells in the sheaths surrounding the nerves. Representative examples include neurofibroma, schwannoma, and malignant peripheral nerve sheath tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve Sheath Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Nerve Sheath","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peripheral_Nerve_Sheath_Neoplasm"},{"name":"Maps_To","value":"Nerve sheath tumor, NOS"},{"name":"Maps_To","value":"Nerve Sheath Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206727"}]}}{"C3787":{"preferredName":"Neuroepithelial Neoplasm","code":"C3787","definitions":[{"definition":"A neoplasm of the nervous system that arises from the neuroepithelial tissues.  Representative examples include astrocytic tumors, oligodendroglial tumors, ependymal tumors, and primitive neuroectodermal tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroepithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Neuroepithelial Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Neuroepithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Neuroepithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tissue Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tumors","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Neuroepithelial Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Neuroepithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Neuroepithelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neuroepithelial_Neoplasm"},{"name":"Maps_To","value":"Neuroepitheliomatous Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206715"}]}}{"C3286":{"preferredName":"Odontogenic Neoplasm","code":"C3286","definitions":[{"definition":"A benign or malignant neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Benign neoplasms are slow growing and are not associated with specific clinical symptoms. Pain is absent or slight. Malignant neoplasms are usually associated with rapid swelling and pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9270/1"},{"name":"Legacy Concept Name","value":"Odontogenic_Neoplasm"},{"name":"Maps_To","value":"9270/1"},{"name":"Maps_To","value":"Odontogenic tumor, NOS"},{"name":"Maps_To","value":"Odontogenic Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0028880"}]}}{"C184783":{"preferredName":"Personal History of Other Hematologic Disorder","code":"C184783","definitions":[{"definition":"An individual history of a hematologic disorder, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Hematologic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Hematologic Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Hematologic Disorders"},{"name":"NCI_META_CUI","value":"CL1773110"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184784":{"preferredName":"Personal History of Other Leukemia","code":"C184784","definitions":[{"definition":"An individual history of leukemia, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Personal History of Other Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Leukemias"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0260442"}]}}{"C4665":{"preferredName":"Plasma Cell Neoplasm","code":"C4665","definitions":[{"definition":"A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes multiple myeloma, plasma cell leukemia, plasmacytoma, and plasma cell post-transplant lymphoproliferative disorder.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of plasma cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tumor that begins in plasma cells (white blood cells that produce antibodies). Multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), and plasmacytoma are types of plasma cell tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plasma Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Plasma Cell Dyscrasia","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytic Tumour","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Plasma_Cell_Neoplasm"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Multiple myeloma and malignant plasma cell neoplasms"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of plasma cells"},{"name":"Maps_To","value":"Plasma cell tumor"},{"name":"Maps_To","value":"Plasma Cell Tumors"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1136084"}]}}{"C9360":{"preferredName":"Lymphoblastic Lymphoma","code":"C9360","definitions":[{"definition":"A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of lymphoblasts (lymphoid precursor cells).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive (fast-growing) type of non-Hodgkin lymphoma in which too many lymphoblasts (immature white blood cells) are found in the lymph nodes and the thymus gland. These lymphoblasts may spread to other places in the body. It is most common in teenagers and young adults and affects more males than females. It may be a T or B cell type.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphoblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"LBL","termGroup":"AB","termSource":"NCI"},{"termName":"Precursor Cell Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9727/3"},{"name":"Legacy Concept Name","value":"Precursor_Lymphoblastic_Lymphoma"},{"name":"Maps_To","value":"9727/3"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, unspecified site"},{"name":"Maps_To","value":"Lymphoblastoma"},{"name":"Maps_To","value":"Malignant lymphoma, lymphoblastic, NOS"},{"name":"Maps_To","value":"Precursor Cell Lymphoblastic Lymphoma"},{"name":"Maps_To","value":"Precursor cell lymphoblastic lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079748"}]}}{"C3792":{"preferredName":"Squamous Cell Neoplasm","code":"C3792","definitions":[{"definition":"A neoplasm that is composed of squamous epithelial cells.  Squamous cell carcinoma is a representative example.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Neoplasm"},{"name":"Maps_To","value":"Squamous Cell Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206720"}]}}{"C3411":{"preferredName":"Thymoma","code":"C3411","definitions":[{"definition":"A neoplasm arising from the epithelial cells of the thymus.  Although thymomas are usually encapsulated tumors, they may invade the capsule and infiltrate the surrounding tissues or even metastasize to distant anatomic sites.  The following morphologic subtypes are currently recognized: type A, type B, type AB, metaplastic, micronodular, microscopic, and sclerosing thymoma.  Thymomas type B are further subdivided into types B1, B2, and B3. Thymoma type B3 usually has the most aggressive clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor of the thymus, an organ that is part of the lymphatic system and is located in the chest, behind the breastbone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8580/1"},{"name":"Legacy Concept Name","value":"Thymoma"},{"name":"Maps_To","value":"8580/1"},{"name":"Maps_To","value":"Thymic Epithelial Neoplasms"},{"name":"Maps_To","value":"Thymoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040100"}]}}{"C3422":{"preferredName":"Trophoblastic Tumor","code":"C3422","definitions":[{"definition":"A gestational or non-gestational neoplasm characterized by excessive proliferation of trophoblastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trophoblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Trophoblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Trophoblastic Neoplasms","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trophoblastic_Neoplasm"},{"name":"Maps_To","value":"Trophoblastic neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0041182"}]}}{"C48660":{"preferredName":"Not Applicable","code":"C48660","definitions":[{"definition":"A report has been received but the description provided does not appear to relate to an adverse event. This code allows a report to be recorded for administration purposes, even if it doesn't meet the requirements for adverse event reporting.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Determination of a value is not relevant in the current context.","type":"DEFINITION","source":"NCI"},{"definition":"Determination of a value is not relevant in the current context.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"SPL"}]},{"definition":"Determination of a value is not relevant in the current context.","type":"ALT_DEFINITION","source":"PQCMC"},{"definition":"Determination of a value is not relevant in the current context. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Not Applicable","termGroup":"PT","termSource":"NCI"},{"termName":"Does Not Apply","termGroup":"SY","termSource":"NCI"},{"termName":"N/A","termGroup":"SY","termSource":"NCI"},{"termName":"not applicable","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Device Problem Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Not_Applicable"},{"name":"Maps_To","value":"Not Applicable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1272460"},{"name":"xRef","value":"IMDRF:A25"}]}}{"C164339":{"preferredName":"Date of Diagnosis","code":"C164339","definitions":[{"definition":"The date on which a diagnosis of disease was made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Date of Diagnosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"Diagnosis"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C2316983"}]}}{"C164021":{"preferredName":"First Patient Visit Date","code":"C164021","definitions":[{"definition":"The date for the first patient visit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Patient Visit Date","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First Patient Visit"},{"name":"NCI_META_CUI","value":"CL977238"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C164022":{"preferredName":"First Treatment Date","code":"C164022","definitions":[{"definition":"The date for the initiation of a patient treatment plan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Treatment Date","termGroup":"PT","termSource":"NCI"},{"termName":"Date of First Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Date of First Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Date of Initial Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Initial Treatment Date","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First Treatment"},{"name":"NCI_META_CUI","value":"CL977237"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C164023":{"preferredName":"Initial Genomic Sequencing Date","code":"C164023","definitions":[{"definition":"The date for the first round of genomic sequencing of a subject's DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Initial Genomic Sequencing Date","termGroup":"PT","termSource":"NCI"},{"termName":"Date of Initial Genomic Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Initial Genomic Sequencing"},{"name":"NCI_META_CUI","value":"CL977236"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C171136":{"preferredName":"Date of Recurrence","code":"C171136","definitions":[{"definition":"The date on which diagnosis of a recurring disease was made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Date of Recurrence","termGroup":"PT","termSource":"NCI"},{"termName":"Date of Diagnosis of Recurrence","termGroup":"SY","termSource":"NCI"},{"termName":"Recurrence Date","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrence"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0807712"}]}}{"C164024":{"preferredName":"Sample Procurement Date","code":"C164024","definitions":[{"definition":"The date that a sample was collected or obtained.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sample Procurement Date","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sample Procurement"},{"name":"NCI_META_CUI","value":"CL977235"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C139171":{"preferredName":"Date of First Enrollment into Study","code":"C139171","definitions":[{"definition":"Date or date and time of first subject enrollment into a study, as verifiable by a convention that is consistent with authoritative regulatory criteria. [Modified from ICH E3] (CDISC Glossary)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Date or date and time of first subject enrollment into a study, as verifiable by a convention that is consistent with authoritative regulatory criteria. [Modified from ICH E3] Compare to study start date.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"The calendar date on which the first subject was enrolled into a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Date of First Enrollment into Study","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Study Enrollment"},{"name":"NCI_META_CUI","value":"CL526607"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C12763":{"preferredName":"Paranasal Sinus","code":"C12763","definitions":[{"definition":"Any one of the air-filled spaces within the ethmoid, frontal, maxillary, or sphenoid bones, which communicate with the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"One of many small hollow spaces in the bones around the nose. Paranasal sinuses are named after the bones that contain them: frontal (the lower forehead), maxillary (cheekbones), ethmoid (beside the upper nose), and sphenoid (behind the nose). The paranasal sinuses open into the nasal cavity (space inside the nose) and are lined with cells that make mucus to keep the nose from drying out during breathing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The air-filled cavities adjacent to the nasal cavity lined by a mucous membrane and located in the bones of the skull.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The paired air-filled cavities surrounded by the bones of the face that are lined by mucous membranes and are continuous with the nasal cavity.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Paranasal Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Accessory Sinus","termGroup":"SY","termSource":"NCI"},{"termName":"Accessory Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Nasal and Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Nasal Sinus","termGroup":"SY","termSource":"NCI"},{"termName":"Nasal Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Paranasal Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Sinuses, Nasal","termGroup":"SY","termSource":"NCI"},{"termName":"Sinuses, Paranasal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Paranasal_Sinus"},{"name":"Maps_To","value":"Accessory sinus, NOS"},{"name":"Maps_To","value":"Accessory sinuses"},{"name":"Maps_To","value":"Paranasal Sinuses"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0030471"},{"name":"xRef","value":"UBERON:0001825"}]}}{"C12666":{"preferredName":"Adrenal Gland","code":"C12666","definitions":[{"definition":"A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).","type":"DEFINITION","source":"NCI"},{"definition":"A small gland that makes steroid hormones, adrenaline, and noradrenaline. These hormones help control heart rate, blood pressure, and other important body functions. There are two adrenal glands, one on top of each kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Either of a pair of complex endocrine organs near the anterior medial border of the kidney consisting of a mesodermal cortex that produces glucocorticoid, mineralocorticoid, and androgenic hormones and an ectodermal medulla that produces epinephrine and norepinephrine.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The endocrine glands adjacent to the kidneys that consist of the outer adrenal cortex and the inner adrenal medulla in mammals.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adrenal Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Glands","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenals","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Adrenal_Gland"},{"name":"Maps_To","value":"Adrenal"},{"name":"Maps_To","value":"Adrenal gland"},{"name":"Maps_To","value":"Adrenal gland, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0001625"},{"name":"xRef","value":"UBERON:0002369"}]}}{"C12228":{"preferredName":"Base of Tongue","code":"C12228","definitions":[{"definition":"The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oro-pharynx responsible for swallowing and modification of the voice in speech.","type":"DEFINITION","source":"NCI"},{"definition":"The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oro-pharynx.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Base of Tongue","termGroup":"PT","termSource":"NCI"},{"termName":"Base of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Posterior Tongue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Base_of_the_Tongue"},{"name":"Maps_To","value":"Base of tongue"},{"name":"Maps_To","value":"Base of tongue, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226958"}]}}{"C12414":{"preferredName":"Bladder","code":"C12414","definitions":[{"definition":"Distensible musculomembranous organ situated in the anterior part of the pelvic cavity in which urine collects before excretion.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.","type":"DEFINITION","source":"NCI"},{"definition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organ that stores urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary System, Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bladder"},{"name":"Maps_To","value":"Bladder"},{"name":"Maps_To","value":"Bladder, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005682"},{"name":"xRef","value":"UBERON:0001255"}]}}{"C164038":{"preferredName":"Limb Skeletal System","code":"C164038","definitions":[{"definition":"The bones, joints, ligaments and cartilage found in the limbs (extremities).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Limb Skeletal System","termGroup":"PT","termSource":"NCI"},{"termName":"Skeletal System of the Extremities","termGroup":"SY","termSource":"NCI"},{"termName":"Skeletal System of the Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bones, joints and articular cartilage of limbs"},{"name":"NCI_META_CUI","value":"CL977192"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C12439":{"preferredName":"Brain","code":"C12439","definitions":[{"definition":"An organ composed of gray and white matter that is the center for intelligence and reasoning. It is protected by the bony cranium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.","type":"DEFINITION","source":"NCI"},{"definition":"The brain is the center of the nervous system in all vertebrate, and most invertebrate, animals. Some primitive animals such as jellyfish and starfish have a decentralized nervous system without a brain, while sponges lack any nervous system at all. In vertebrates, the brain is located in the head, protected by the skull and close to the primary sensory apparatus of vision, hearing, balance, taste, and smell.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Brain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Brain"},{"name":"Maps_To","value":"Brain"},{"name":"Maps_To","value":"Brain, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006104"},{"name":"xRef","value":"UBERON:0000955"}]}}{"C12971":{"preferredName":"Breast","code":"C12971","definitions":[{"definition":"Glandular organ located on the chest. The breast is made up of connective tissue, fat, and breast tissue that contains the glands that can make milk.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","type":"DEFINITION","source":"NCI"},{"definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Breasts","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Breast"},{"name":"Maps_To","value":"Breast"},{"name":"Maps_To","value":"Breast, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006141"}]}}{"C92218":{"preferredName":"Lung/Bronchus","code":"C92218","definitions":[{"definition":"A sample that contains lung and bronchial tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A specimen that contains lung and bronchial tissues.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lung/Bronchus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchus and lung"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0545675"}]}}{"C12311":{"preferredName":"Cervix Uteri","code":"C12311","definitions":[{"definition":"Lower, narrow portion of the uterus where it joins with the top end of the vagina.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.","type":"DEFINITION","source":"NCI"},{"definition":"The lower, narrow end of the uterus that forms a canal between the uterus and vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the uterus (or uterine horns) that empties into the vagina.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cervix Uteri","termGroup":"PT","termSource":"NCI"},{"termName":"Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Genital System, Female, Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Uterus, Cervix","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cervix"},{"name":"Maps_To","value":"Cervix"},{"name":"Maps_To","value":"Cervix uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007874"},{"name":"xRef","value":"UBERON:0000002"}]}}{"C12382":{"preferredName":"Colon","code":"C12382","definitions":[{"definition":"The longest part of the large intestine, which is a tube-like organ connected to the small intestine at one end and the anus at the other. The colon removes water and some nutrients and electrolytes from partially digested food. The remaining material, solid waste called stool, moves through the colon to the rectum and leaves the body through the anus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the large intestine which extends from the cecum (or small intestine in animals that don't have a cecum) to the rectum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Colon"},{"name":"Maps_To","value":"Colon"},{"name":"Maps_To","value":"Colon, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009368"},{"name":"xRef","value":"UBERON:0001155"}]}}{"C12964":{"preferredName":"Connective and Soft Tissue","code":"C12964","definitions":[{"definition":"The supporting connective tissue of an organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Connective and Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Connective_and_Soft_Tissue"},{"name":"Maps_To","value":"Connective, subcutaneous and other soft tissues"},{"name":"Maps_To","value":"Connective, subcutaneous and other soft tissues, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C1516798"}]}}{"C12316":{"preferredName":"Corpus Uteri","code":"C12316","definitions":[{"definition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.","type":"DEFINITION","source":"NCI"},{"definition":"The body of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The body of the uterus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Corpus Uteri","termGroup":"PT","termSource":"NCI"},{"termName":"Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Uterus, Corpus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Corpus_Uteri"},{"name":"Maps_To","value":"Corpus uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227813"}]}}{"C12389":{"preferredName":"Esophagus","code":"C12389","definitions":[{"definition":"The muscular tube through which food passes from the throat to the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the digestive tract between the pharynx and stomach.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tube that connects the pharynx to the stomach. In mammals, the esophagus connects the buccal cavity with the stomach. The stratified squamous non-keratinized epithelium lining the buccal cavity is continued through the pharynx down into the esophagus. The lowest part of the esophagus (ca. 2 cm) is lined with gastric mucosa and covered by peritoneum. The main body of the esophagus is lined with small, simple mucous glands. Each gland opens into the lumen by a long duct which pierces the muscularis mucosae (Wilson and Washington, 1989). A sphincter is situated at the point where the esophagus enters the stomach to prevent gastro-esophageal reflux, i.e. to prevent acidic gastric contents from reaching stratified epithelia of the esophagus, where they can cause inflammation and irritation (Wilson and Washington, 1989; Brown et al., 1993).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Esophagus"},{"name":"Maps_To","value":"Esophagus"},{"name":"Maps_To","value":"Esophagus, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014876"},{"name":"xRef","value":"UBERON:0001043"}]}}{"C54187":{"preferredName":"Floor of Mouth","code":"C54187","definitions":[{"definition":"The area of the mouth under the ventral surface of the tongue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The horseshoe-shaped part of the oral cavity bounded superiorly by the ventral surface of the tongue, inferiorly by the mylohyoid muscle, anterolaterally by the gingival surfaces of the mandible, and posteriorly by the anterior tonsillar pillar.","type":"DEFINITION","source":"NCI"},{"definition":"The ventral area of the mouth. In organisms with a tongue, this is the area under the ventral surface of the tongue.","type":"ALT_DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Floor of Mouth","termGroup":"PT","termSource":"NCI"},{"termName":"Floor of the Mouth","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Floor_of_the_Mouth"},{"name":"Maps_To","value":"Floor of Mouth"},{"name":"Maps_To","value":"Floor Of Mouth"},{"name":"Maps_To","value":"Floor of mouth"},{"name":"Maps_To","value":"Floor of mouth, NOS"},{"name":"NCI_META_CUI","value":"CL435388"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"xRef","value":"UBERON:0003679"}]}}{"C12377":{"preferredName":"Gallbladder","code":"C12377","definitions":[{"definition":"A pear-shaped organ located under the liver that stores and concentrates bile secreted by the liver. From the gallbladder the bile is delivered through the bile ducts into the intestine thereby aiding the digestion of fat-containing foods.","type":"DEFINITION","source":"NCI"},{"definition":"A sac-like organ located adjacent to the liver that stores and concentrates bile produced by the liver.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ that aids digestion and stores bile produced by the liver.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The pear-shaped organ found below the liver. Bile is concentrated and stored in the gallbladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gallbladder","termGroup":"PT","termSource":"NCI"},{"termName":"Gallbladder / Biliar","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Gall Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gallbladder"},{"name":"Maps_To","value":"Gallbladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016976"},{"name":"xRef","value":"UBERON:0002110"}]}}{"C32677":{"preferredName":"Gingiva","code":"C32677","definitions":[{"definition":"The fibrous investing tissue, covered by keratinized epithelium, that immediately surrounds a tooth and is contiguous with its periodontal ligament and with the mucosal tissues of the mouth.","type":"ALT_DEFINITION","source":"NCI"},{"definition":"The soft tissue surrounding the neck of individual teeth as well as covering the alveolar bone. The tissue is fibrous and continuous with the periodontal ligament and mucosal covering.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue surrounding the neck of individual teeth as well as covering the alveolar bone. The tissue is fibrous and continuous with the periodontal ligament and mucosal covering. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissue of the upper and lower jaws that surrounds the base of the teeth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gingiva","termGroup":"PT","termSource":"NCI"},{"termName":"Gingival","termGroup":"AD","termSource":"NCI"},{"termName":"Gum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gingiva"},{"name":"Maps_To","value":"Gum"},{"name":"Maps_To","value":"Gum, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0017562"},{"name":"xRef","value":"UBERON:0001828"}]}}{"C12246":{"preferredName":"Hypopharynx","code":"C12246","definitions":[{"definition":"Bottom part of the pharynx that connects to the esophagus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bottom part of the throat. Cancer of the hypopharynx is also called hypopharyngeal cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lower part of the pharynx that connects to the esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"The lower part of the pharynx that connects to the esophagus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hypopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Laryngopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hypopharynx"},{"name":"Maps_To","value":"Hypopharynx"},{"name":"Maps_To","value":"Hypopharynx, NOS"},{"name":"Maps_To","value":"Laryngopharynx"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020629"},{"name":"xRef","value":"UBERON:0001051"}]}}{"C12415":{"preferredName":"Kidney","code":"C12415","definitions":[{"definition":"A paired organ of the urinary tract which has the production of urine as its primary function.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of organs in the abdomen. Kidneys remove waste from the blood (as urine), produce erythropoietin (a substance that stimulates red blood cell production), and play a role in blood pressure regulation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secrete metabolic products and minerals from the blood, thus maintaining homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.","type":"DEFINITION","source":"NCI"},{"definition":"The organs of the urinary tract located in the retroperitoneal cavity adjacent to the spine and composed of the renal cortex and the renal medulla.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Kidneys","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary System, Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Kidney"},{"name":"Maps_To","value":"Kidney"},{"name":"Maps_To","value":"Kidney, NOS"},{"name":"Maps_To","value":"Renal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022646"},{"name":"xRef","value":"UBERON:0002113"}]}}{"C12420":{"preferredName":"Larynx","code":"C12420","definitions":[{"definition":"A continuation of the pharynx that is involved in breathing, sound production, and protecting the trachea against food aspiration.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The area of the throat containing the vocal cords and used for breathing, swallowing, and talking.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The cartilaginous structure of the respiratory tract between the pharynx and the trachea.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larynx","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Larynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Larynx"},{"name":"Maps_To","value":"Larynx"},{"name":"Maps_To","value":"Larynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0023078"},{"name":"xRef","value":"UBERON:0001737"}]}}{"C12220":{"preferredName":"Lip","code":"C12220","definitions":[{"definition":"Fleshy fold which surrounds the opening of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"Fleshy fold which surrounds the opening of the mouth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the two fleshy folds which surround the opening of the mouth.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lip"},{"name":"Maps_To","value":"Lip"},{"name":"Maps_To","value":"Lip, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0023759"},{"name":"xRef","value":"UBERON:0001833"}]}}{"C12745":{"preferredName":"Lymph Node","code":"C12745","definitions":[{"definition":"A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","type":"DEFINITION","source":"NCI"},{"definition":"A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Lymph nodes filter lymph (lymphatic fluid), and they store lymphocytes (white blood cells). They are located along lymphatic vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any of the rounded masses of lymphoid tissue that are surrounded by a capsule of connective tissue, are distributed along the lymphatic vessels, and contain numerous lymphocytes which filter the flow of lymph.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Secondary lymphoid organ associated with lymphatic vessels and consisting of an outer cortex, inner medulla and sinuses.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Nodes","termGroup":"SY","termSource":"NCI"},{"termName":"Reticuloendothelial System, Lymph Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lymph_Node"},{"name":"Maps_To","value":"Lymph Noce"},{"name":"Maps_To","value":"Lymph Node"},{"name":"Maps_To","value":"Lymph node, NOS"},{"name":"Maps_To","value":"Lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024204"},{"name":"xRef","value":"UBERON:0000029"}]}}{"C12348":{"preferredName":"Meninges","code":"C12348","definitions":[{"definition":"Any one of three membranes that surround the brain and spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"Any one of three membranes that surround the brain and spinal cord. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The three thin layers of tissue that cover and protect the brain and spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Meninges","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Meninges"},{"name":"Maps_To","value":"Meninges"},{"name":"Maps_To","value":"Meninges, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0025285"}]}}{"C12423":{"preferredName":"Nasopharynx","code":"C12423","definitions":[{"definition":"The part of the pharynx above the soft palate, which is continuous with the nasal cavity and extends to the oropharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.","type":"DEFINITION","source":"NCI"},{"definition":"The section of the pharynx that lies above the soft palate.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper part of the throat behind the nose. An opening on each side of the nasopharynx leads into the ear.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nasopharynx","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Nasopharynx"},{"name":"Maps_To","value":"Nasopharynx"},{"name":"Maps_To","value":"Nasopharynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0027442"},{"name":"xRef","value":"UBERON:0001728"}]}}{"C12762":{"preferredName":"Oropharynx","code":"C12762","definitions":[{"definition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the throat at the back of the mouth behind the oral cavity. It includes the back third of the tongue, the soft palate, the side and back walls of the throat, and the tonsils.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the pharynx that lies between the soft palate and the upper edge of the epiglottis.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Oropharynx","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Oropharynx"},{"name":"Maps_To","value":"Oropharynx"},{"name":"Maps_To","value":"Oropharynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0521367"},{"name":"xRef","value":"UBERON:0001729"}]}}{"C148335":{"preferredName":"Other and Ill Defined Digestive Organs ICD-O-3","code":"C148335","definitions":[{"definition":"Digestive organs that are referenced in topographic category C26 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill Defined Digestive Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill Defined Digestive Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and ill-defined digestive organs"},{"name":"NCI_META_CUI","value":"CL018352"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148336":{"preferredName":"Other and Ill-Defined Sites ICD-O-3","code":"C148336","definitions":[{"definition":"Other anatomic sites that are referenced in topographic category C76 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill-Defined Sites ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill-Defined Sites","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and ill-defined sites"},{"name":"NCI_META_CUI","value":"CL018612"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148337":{"preferredName":"Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx ICD-O-3","code":"C148337","definitions":[{"definition":"Anatomic sites in the lip, oral cavity and pharynx that are referenced in topographic category C14 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and ill-defined sites in lip, oral cavity and pharynx"},{"name":"NCI_META_CUI","value":"CL025608"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148338":{"preferredName":"Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs ICD-O-3","code":"C148338","definitions":[{"definition":"Anatomic sites within the respiratory system and intrathoracic organs that are referenced in topographic category C39 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ill-defined sites within respiratory system"},{"name":"Maps_To","value":"Other and ill-defined sites within respiratory system and intrathoracic organs"},{"name":"NCI_META_CUI","value":"CL025607"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148339":{"preferredName":"Other and Unspecified Female Genital Organs ICD-O-3","code":"C148339","definitions":[{"definition":"Female genital organs that are referenced in topographic category C57 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Female Genital Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Female Genital Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified female genital organs"},{"name":"Maps_To","value":"Other specified parts of female genital organs"},{"name":"NCI_META_CUI","value":"CL025605"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148340":{"preferredName":"Other and Unspecified Major Salivary Glands ICD-O-3","code":"C148340","definitions":[{"definition":"Major salivary glands that are referenced in topographic category C08 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Major Salivary Glands ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Major Salivary Glands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified major salivary glands"},{"name":"NCI_META_CUI","value":"CL018317"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148341":{"preferredName":"Other and Unspecified Male Genital Organs ICD-O-3","code":"C148341","definitions":[{"definition":"Male genital organs that are referenced in topographic category C63 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Male Genital Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Male Genital Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified male genital organs"},{"name":"Maps_To","value":"Other specified parts of male genital organs"},{"name":"NCI_META_CUI","value":"CL365219"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148342":{"preferredName":"Other and Unspecified Parts of Biliary Tract ICD-O-3","code":"C148342","definitions":[{"definition":"Components of the biliary tract that are referenced in topographic category C24 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Parts of Biliary Tract ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Parts of Biliary Tract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified parts of biliary tract"},{"name":"NCI_META_CUI","value":"CL018343"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148343":{"preferredName":"Other and Unspecified Parts of Mouth ICD-O-3","code":"C148343","definitions":[{"definition":"Components of the mouth that are referenced in topographic category C06 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Parts of Mouth ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Parts of Mouth","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified parts of mouth"},{"name":"NCI_META_CUI","value":"CL025603"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148344":{"preferredName":"Other and Unspecified Parts of Tongue ICD-O-3","code":"C148344","definitions":[{"definition":"Components of the tongue that are referenced in topographic category C02 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Parts of Tongue ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Parts of Tongue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified parts of tongue"},{"name":"NCI_META_CUI","value":"CL018300"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148345":{"preferredName":"Other and Unspecified Urinary Organs ICD-O-3","code":"C148345","definitions":[{"definition":"Urinary organs that are referenced in topographic category C68 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Urinary Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Urinary Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified urinary organs"},{"name":"NCI_META_CUI","value":"CL550961"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148346":{"preferredName":"Other Endocrine Glands and Related Structures ICD-O-3","code":"C148346","definitions":[{"definition":"Endocrine glands and related structures that are referenced in topographic category C75 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Endocrine Glands and Related Structures ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other Endocrine Glands and Related Structures","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other endocrine glands and related structures"},{"name":"NCI_META_CUI","value":"CL025599"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C12404":{"preferredName":"Ovary","code":"C12404","definitions":[{"definition":"One of the paired female reproductive glands containing the ova or germ cells; the ovary's stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.","type":"DEFINITION","source":"NCI"},{"definition":"The female gonad.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The gonad of a female organism which contains germ cells.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The pair of female reproductive glands in which the ova, or eggs, are formed. The ovaries are located in the pelvis, one on each side of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ovary","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Female, Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovaries","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ovary"},{"name":"Maps_To","value":"Ovary"},{"name":"Maps_To","value":"Ovary, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0029939"},{"name":"xRef","value":"UBERON:0000992"}]}}{"C12229":{"preferredName":"Palate","code":"C12229","definitions":[{"definition":"The roof of the mouth. The front portion is bony (hard palate), and the back portion is muscular (soft palate).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The roof of the oral cavity. It separates the oral cavity from the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The roof of the oral cavity. It separates the oral cavity from the nasal cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Palate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palate"},{"name":"Maps_To","value":"Palate"},{"name":"Maps_To","value":"Palate, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0700374"}]}}{"C12393":{"preferredName":"Pancreas","code":"C12393","definitions":[{"definition":"A digestive organ in the abdomen that has both endocrine and exocrine functions.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A glandular organ located in the abdomen. It makes pancreatic juices, which contain enzymes that aid in digestion, and it produces several hormones, including insulin. The pancreas is surrounded by the stomach, intestines, and other organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating hormones.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from Diabetes Dictionary: http://www.childrenwithdiabetes.com/dictionary"}]}],"synonyms":[{"termName":"Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pancreas"},{"name":"Maps_To","value":"Pancreas"},{"name":"Maps_To","value":"Pancreas, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030274"},{"name":"xRef","value":"UBERON:0001264"}]}}{"C12427":{"preferredName":"Parotid Gland","code":"C12427","definitions":[{"definition":"The largest of the three paired salivary glands, located in front of the ear.","type":"DEFINITION","source":"NCI"},{"definition":"The parotid gland is the largest of the salivary glands. It is found wrapped around the mandibular ramus, and it secretes saliva through Stensen's duct into the oral cavity, to facilitate mastication and swallowing. [WP,unvetted].","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The salivary gland located adjacent to the ear.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Parotid Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Parotid Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Parotid_Gland"},{"name":"Maps_To","value":"Parotid gland"},{"name":"Maps_To","value":"Parotid Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030580"},{"name":"xRef","value":"UBERON:0001831"}]}}{"C12409":{"preferredName":"Penis","code":"C12409","definitions":[{"definition":"An external male reproductive organ. It contains a tube called the urethra, which carries semen and urine to the outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intromittent organ in certain biologically male organisms. In placental mammals, this also serves as the organ of urination.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The male organ of urination and copulation.","type":"DEFINITION","source":"NCI"},{"definition":"The male organ of urination and copulation. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Penis","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Male, Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Penis"},{"name":"Maps_To","value":"Penis"},{"name":"Maps_To","value":"Penis, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030851"},{"name":"xRef","value":"UBERON:0000989"}]}}{"C13272":{"preferredName":"Placenta","code":"C13272","definitions":[{"definition":"An organ present in some vertebrates during embryonic gestation that surrounds the fetus and provides it with nutrients and oxygen, facilitates gas and waste exchange between the fetus and mother, and provides parasitic cloaking from the mother's immune system by excretion of neurokinin B.","type":"DEFINITION","source":"NCI"},{"definition":"An organ present in true mammals during embryonic developmen that provides the fetus with nutrients and oxygen, facilitates gas and waste exchange between the fetus and mother.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin[GO]. The fetal portion of the placenta is known as the villous chorion. The maternal portion is known as the decidua basalis. The two portions are held together by anchoring villi that are anchored to the decidua basalis by the cytotrophoblastic shell.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The organ that nourishes the developing fetus in the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Placenta","termGroup":"PT","termSource":"NCI"},{"termName":"Placental","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Placenta"},{"name":"Maps_To","value":"Placenta"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0032043"},{"name":"xRef","value":"UBERON:0001987"}]}}{"C12410":{"preferredName":"Prostate Gland","code":"C12410","definitions":[{"definition":"A gland in the male reproductive system. The prostate surrounds the part of the urethra (the tube that empties the bladder) just below the bladder, and produces a fluid that forms part of the semen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The male reproductive accessory gland that produces prostatic fluid and is located adjacent to or around the urethra distal to the urinary bladder in mammals.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The prostate gland is a partly muscular, partly glandular body that is situated near the base of the mammalian male urethra and secretes an alkaline viscid fluid which is a major constituent of the ejaculatory fluid.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Male, Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Prostatic Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Prostate_Gland"},{"name":"Maps_To","value":"Prostate"},{"name":"Maps_To","value":"Prostate gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0033572"},{"name":"xRef","value":"UBERON:0002367"}]}}{"C33439":{"preferredName":"Pyriform Sinus","code":"C33439","definitions":[{"definition":"A pear-shaped fossa in the wall of the laryngeal pharynx lateral to the arytenoid cartilage and medial to the lamina of the thyroid cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyriform Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Piriform Recess","termGroup":"SY","termSource":"NCI"},{"termName":"Piriform Sinus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pyriform_Sinus"},{"name":"Maps_To","value":"Pyriform sinus"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227170"}]}}{"C54188":{"preferredName":"Rectosigmoid Region","code":"C54188","definitions":[{"definition":"An anatomical junction that is between the sigmoid colon and rectum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The area where the sigmoid colon joins the rectum.","type":"DEFINITION","source":"NCI"},{"definition":"The area where the sigmoid colon joins the rectum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Rectosigmoid Region","termGroup":"PT","termSource":"NCI"},{"termName":"Rectosigmoid Junction","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Rectosigmoid_Region"},{"name":"Maps_To","value":"Rectosigmoid Junction"},{"name":"Maps_To","value":"Rectosigmoid junction"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1709868"},{"name":"xRef","value":"UBERON:0036214"}]}}{"C12390":{"preferredName":"Rectum","code":"C12390","definitions":[{"definition":"The last several inches of the large intestine closest to the anus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.","type":"DEFINITION","source":"NCI"},{"definition":"The terminal portion of the intestinal tube, terminating with the anus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The terminal portion of the large intestine extending from the terminus of the colon to the anus or anal canal.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Rectum","termGroup":"PT","termSource":"NCI"},{"termName":"Hemorrhoidal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Rectum"},{"name":"Maps_To","value":"Rectum"},{"name":"Maps_To","value":"Rectum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0034896"},{"name":"xRef","value":"UBERON:0001052"}]}}{"C12887":{"preferredName":"Renal Pelvis","code":"C12887","definitions":[{"definition":"The area at the center of the kidney. Urine collects here and is funneled into the ureter, the tube that connects the kidney to the bladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The funnel-shaped proximal portion of the ureter located within the kidney into which urine is secreted, from the collecting duct system of the kidney.","type":"DEFINITION","source":"NCI"},{"definition":"The funnel-shaped proximal portion of the ureter located within the kidney into which urine is secreted, from the collecting duct system of the kidney. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Renal Pelvis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Renal_Pelvis"},{"name":"Maps_To","value":"Renal pelvis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227666"}]}}{"C156712":{"preferredName":"Peritoneum and Retroperitoneum","code":"C156712","definitions":[{"definition":"A term that refers to the peritoneum and the space behind it (retroperitoneum).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneum and Retroperitoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retroperitoneum and peritoneum"},{"name":"NCI_META_CUI","value":"CL018479"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C12470":{"preferredName":"Skin","code":"C12470","definitions":[{"definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.","type":"DEFINITION","source":"NCI"},{"definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organ covering the body that consists of the dermis and epidermis.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Integument","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"DesignNote","value":"ICDO3: excludes skin of vulva C51._, skin of penis C60.9, skin of scrotum C63.2"},{"name":"Legacy Concept Name","value":"Skin"},{"name":"Maps_To","value":"Skin"},{"name":"Maps_To","value":"Skin, NOS"},{"name":"Maps_To","value":"Skin, total"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1123023"},{"name":"xRef","value":"UBERON:0000014"},{"name":"xRef","value":"UBERON:0002097"}]}}{"C12386":{"preferredName":"Small Intestine","code":"C12386","definitions":[{"definition":"Subdivision of digestive tract that connects the stomach to the large intestine and is where much of the digestion and absorption of food takes place (with the exception of ruminants). The mammalian small intestine is long and coiled and can be differentiated histologically into: duodenum, jejunum, ileum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the digestive tract that is located between the stomach and the large intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The section of the intestines between the pylorus and cecum. The small intestine is approximately 20 feet long and consists of the duodenum, the jejunum, and the ileum. Its main function is to absorb nutrients from food as the food is transported to the large intestine.","type":"DEFINITION","source":"NCI"},{"definition":"The villous section of the intestine extending from the pylorus to the proximal large intestine.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Small Intestine","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Small Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Small Bowel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Small_Intestine"},{"name":"Maps_To","value":"Small Bowel"},{"name":"Maps_To","value":"Small intestine"},{"name":"Maps_To","value":"Small intestine, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0021852"},{"name":"xRef","value":"UBERON:0002108"}]}}{"C12391":{"preferredName":"Stomach","code":"C12391","definitions":[{"definition":"An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An organ that is part of the digestive system. It helps in the digestion of food by mixing it with digestive juices and churning it into a thin liquid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the gastrointestinal tract located between the esophagus and the proximal duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The primary organ of food digestion. It is located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stomach","termGroup":"PT","termSource":"NCI"},{"termName":"Gastric","termGroup":"AD","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Stomach"},{"name":"Maps_To","value":"Stomach"},{"name":"Maps_To","value":"Stomach, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0038351"},{"name":"xRef","value":"UBERON:0000945"}]}}{"C12412":{"preferredName":"Testis","code":"C12412","definitions":[{"definition":"A gonad of a male animal. A gonad produces and releases sperm.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Either of the paired male reproductive glands that produce the male germ cells and the male hormones.","type":"DEFINITION","source":"NCI"},{"definition":"One of two egg-shaped glands inside the scrotum that produce sperm and male hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The male gonad.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Testis","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Male, Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Testes","termGroup":"SY","termSource":"NCI"},{"termName":"Testicle","termGroup":"SY","termSource":"NCI"},{"termName":"Testicles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Testis"},{"name":"Maps_To","value":"Testes"},{"name":"Maps_To","value":"Testis"},{"name":"Maps_To","value":"Testis, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0039597"},{"name":"xRef","value":"UBERON:0000473"}]}}{"C12433":{"preferredName":"Thymus Gland","code":"C12433","definitions":[{"definition":"A bi-lobed organ surrounded by a connective tissue capsule. It is located in the upper anterior portion of the chest, behind the sternum. It is composed predominantly of lymphocytes and fewer epithelial cells. Connective tissue septa separate the lobes into lobules. The lobules contain an outer portion (cortical zone) which is rich in lymphocytes and an inner portion (medullary zone) which is rich in epithelial cells. It is an organ essential for the development of the immune system. Its function is the maturation of the progenitor lymphoid cells to thymocytes and subsequently to mature T-cells. It reaches its greatest weight at puberty and subsequently begins to involute.","type":"DEFINITION","source":"NCI"},{"definition":"A primary lymphoid organ generally located in the mediastinum near the thoracic inlet and/or along lateral aspects of the neck.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ that is part of the lymphatic system, in which T lymphocytes grow and multiply. The thymus is in the chest behind the breastbone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Anatomical structure of largely lymphoid tissue that functions in cell-mediated immunity by being the site where T cells develop.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Thymus Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Thymus","termGroup":"SY","termSource":"NCI"},{"termName":"Thymus","termGroup":"SY","termSource":"NCI"},{"termName":"Thymus Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thymus_Gland"},{"name":"Maps_To","value":"Thymus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040113"},{"name":"xRef","value":"UBERON:0002370"}]}}{"C12400":{"preferredName":"Thyroid Gland","code":"C12400","definitions":[{"definition":"A gland located beneath the larynx (voice box) that makes thyroid hormone and calcitonin. The thyroid gland helps regulate growth and metabolism.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A two-lobed endocrine gland found in all vertebrates, located in front of and on either side of the trachea in humans, and producing various hormones, such as triiodothyronine and calcitonin.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.","type":"DEFINITION","source":"NCI"},{"definition":"Endocrine gland(s) adjacent to the trachea in mammals that produce thyroxine and other hormones.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thyroid Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thyroid_Gland"},{"name":"Maps_To","value":"Thyroid"},{"name":"Maps_To","value":"Thyroid gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040132"},{"name":"xRef","value":"UBERON:0002046"}]}}{"C12802":{"preferredName":"Tonsil","code":"C12802","definitions":[{"definition":"A secondary lymphoid tissue in the mucosa of the pharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of the two small almond-shaped masses of lymph tissue found on either side of the oropharynx.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of two small masses of lymphoid tissue on either side of the throat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.","type":"DEFINITION","source":"NCI"},{"definition":"excludes lingual tonsil C02.4 and pharyngeal tonsil C11.1","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Tonsil","termGroup":"PT","termSource":"NCI"},{"termName":"Tonsils","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tonsil"},{"name":"Maps_To","value":"Tonsil"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0836921"},{"name":"xRef","value":"UBERON:0002372"}]}}{"C12428":{"preferredName":"Trachea","code":"C12428","definitions":[{"definition":"The airway that leads from the larynx (voice box) to the bronchi (large airways that lead to the lungs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fibrocartilaginous tube extending from the larynx to the bronchi.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fibrocartilaginous, mucous-lined tube passing from the larynx to the bronchi.","type":"DEFINITION","source":"NCI"},{"definition":"The trachea is the portion of the airway that attaches to the bronchi as it branches.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Trachea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Trachea"},{"name":"Maps_To","value":"Trachea"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040578"},{"name":"xRef","value":"UBERON:0003126"}]}}{"C12416":{"preferredName":"Ureter","code":"C12416","definitions":[{"definition":"Muscular duct that propels urine from the kidneys to the urinary bladder, or related organs.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The thick-walled tube that carries urine from each kidney to the bladder.","type":"DEFINITION","source":"NCI"},{"definition":"The tube that carries urine from the kidney to the bladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tube that extends from each kidney to the urinary bladder.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ureter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ureter"},{"name":"Maps_To","value":"Ureter"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0041951"},{"name":"xRef","value":"UBERON:0000056"}]}}{"C12405":{"preferredName":"Uterus","code":"C12405","definitions":[{"definition":"A hollow muscular organ within which the fertilized egg implants and the embryo/fetus develops during pregnancy.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.","type":"DEFINITION","source":"NCI"},{"definition":"The female muscular organ of gestation in which the developing embryo or fetus is nourished until birth.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The small, hollow, pear-shaped organ in a woman's pelvis. This is the organ in which a fetus develops.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Uterus","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Female, Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine","termGroup":"AD","termSource":"NCI"},{"termName":"Utero","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Uterus"},{"name":"Maps_To","value":"Uterus"},{"name":"Maps_To","value":"Uterus, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042149"},{"name":"xRef","value":"UBERON:0000995"}]}}{"C12407":{"preferredName":"Vagina","code":"C12407","definitions":[{"definition":"A fibromuscular tubular tract leading from the uterus to the exterior of the body in female placental mammals and marsupials, or to the cloaca in female birds, monotremes, and some reptiles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The female genital canal, extending from the uterus to the vulva.","type":"DEFINITION","source":"NCI"},{"definition":"The female genital canal, extending from the uterus to the vulva. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The muscular canal extending from the uterus to the exterior of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vagina","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Female, Vagina","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vagina"},{"name":"Maps_To","value":"Vagina"},{"name":"Maps_To","value":"Vagina, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042232"},{"name":"xRef","value":"UBERON:0000996"}]}}{"C12408":{"preferredName":"Vulva","code":"C12408","definitions":[{"definition":"External genital organs of the female mammal.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The external, visible part of the female genitalia surrounding the urethral and vaginal opening(s).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external, visible part of the female genitalia surrounding the urethral and vaginal opening. The vulva includes the clitoris and inner as well as outer labia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vulva","termGroup":"PT","termSource":"NCI"},{"termName":"External Genitalia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vulva"},{"name":"Maps_To","value":"Vulva"},{"name":"Maps_To","value":"Vulva, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042993"},{"name":"xRef","value":"UBERON:0000997"}]}}{"C15783":{"preferredName":"Clinical Data","code":"C15783","definitions":[{"definition":"Data obtained through patient examination or treatment.","type":"DEFINITION","source":"NCI"},{"definition":"Data pertaining to the medical well-being or status of a patient. Category also includes clinical reports and individual patient data (IPD) as defined in the EMA Policy 0070 Implementation Guide. [http://www.ema.eoropa.eu/docs/en_GB/document_library/REPORT/2014/10/WC500174378.PDF]","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Clinical Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clinical_Data"},{"name":"Maps_To","value":"Clinical"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C1516606"}]}}{"C164028":{"preferredName":"Clincal Data Supplement","code":"C164028","definitions":[{"definition":"Additional documentation or textual matter added to a study report that contains clinical data or related information.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clincal Data Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical Supplement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clinical Supplement"},{"name":"NCI_META_CUI","value":"CL977231"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C172217":{"preferredName":"Data Release","code":"C172217","definitions":[{"definition":"The act of making data or other structured information accessible to the public or to the user group of a database.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Data Release","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"data_release"},{"name":"NCI_META_CUI","value":"CL1406105"},{"name":"Semantic_Type","value":"Activity"}]}}{"C156427":{"preferredName":"Cancer-Related Death","code":"C156427","definitions":[{"definition":"A death attributed to the progression of a cancer-related pathologic condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer-Related Death","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Death","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Related Death","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cancer Related"},{"name":"NCI_META_CUI","value":"CL563161"},{"name":"Semantic_Type","value":"Finding"}]}}{"C2931":{"preferredName":"Cardiovascular Disorder","code":"C2931","definitions":[{"definition":"A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cardiovascular Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiovascular Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Cardiovascular Disease (CVD)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Cardiovascular_Disorder"},{"name":"Maps_To","value":"Cardiovascular Disorder, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007222"}]}}{"C9439":{"preferredName":"Chronic Kidney Disease, Stage 5","code":"C9439","definitions":[{"definition":"Long-standing and persistent renal disease with glomerular filtration rate (GFR) less than 15 ml/min.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Kidney Disease, Stage 5","termGroup":"PT","termSource":"NCI"},{"termName":"End Stage Kidney Disease","termGroup":"SY","termSource":"NCI"},{"termName":"End Stage Kidney Failure","termGroup":"SY","termSource":"NCI"},{"termName":"End Stage Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"End Stage Renal Failure","termGroup":"SY","termSource":"NCI"},{"termName":"ESRD","termGroup":"AB","termSource":"NCI"},{"termName":"ESRD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"End_Stage_Renal_Disease"},{"name":"Maps_To","value":"End-stage Renal Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4015547"}]}}{"C26726":{"preferredName":"Infectious Disorder","code":"C26726","definitions":[{"definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Invasion and multiplication of germs in the body. Infections can occur in any part of the body and can spread throughout the body. The germs may be bacteria, viruses, yeast, or fungi. They can cause a fever and other problems, depending on where the infection occurs. When the body's natural defense system is strong, it can often fight the germs and prevent infection. Some cancer treatments can weaken the natural defense system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The report describes a non-specific or unidentified infection. Note: Please use the appropriate term if the report describes a specific infection. i.e. Bacterial Infection E1901, Fungal Infection E1902, Viral Infection E1907, or a relevant Level 3 term where more detail is available.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Infectious Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Infectious","termGroup":"AD","termSource":"NCI"},{"termName":"Infectious Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Infectious Diseases and Manifestations","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Infectious_Disorder"},{"name":"Maps_To","value":"Infection"},{"name":"Maps_To","value":"Other and unspecified infectious diseases"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009450"},{"name":"xRef","value":"IMDRF:E1906"}]}}{"C156428":{"preferredName":"Non-Cancer Related Death","code":"C156428","definitions":[{"definition":"A death attributed to any cause other than the progression of a cancer-related pathologic condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Cancer Related Death","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Cancer Death","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Not Cancer Related"},{"name":"NCI_META_CUI","value":"CL563162"},{"name":"Semantic_Type","value":"Finding"}]}}{"C3149":{"preferredName":"Kidney Disorder","code":"C3149","definitions":[{"definition":"A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kidney Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Renal_Disorder"},{"name":"Maps_To","value":"Kidney Disease"},{"name":"Maps_To","value":"Renal Disorder, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014900"}]}}{"C85075":{"preferredName":"Spinal Muscular Atrophy","code":"C85075","definitions":[{"definition":"An inherited disorder characterized by degeneration of the spinal cord and the cerebellum. Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spinal Muscular Atrophy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Spinal Muscular Atrophy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026847"}]}}{"C164157":{"preferredName":"Surgical Complication","code":"C164157","definitions":[{"definition":"A disease or disorder that occurs during, soon after or as a result of a surgical procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surgical Complication","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Surgical Complications"},{"name":"NCI_META_CUI","value":"CL977348"},{"name":"Semantic_Type","value":"Finding"}]}}{"C27990":{"preferredName":"Toxicity","code":"C27990","definitions":[{"definition":"The extent to which something is poisonous or harmful.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The finding of bodily harm due to the poisonous effects of something.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toxicity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Toxicity"},{"name":"Maps_To","value":"Toxicity"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0600688"}]}}{"C25153":{"preferredName":"Autopsy","code":"C25153","definitions":[{"definition":"A postmortem examination of the body that includes an examination of the internal organs and structures after dissection to determine the cause of death and the nature of pathological changes.","type":"DEFINITION","source":"NCI"},{"definition":"A postmortem examination of the body.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Autopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Autopsy"},{"name":"Maps_To","value":"Autopsy"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0004398"}]}}{"C163970":{"preferredName":"Death Certificate","code":"C163970","definitions":[{"definition":"A certified document issued by either a medical practitioner or a governmental agency that details the date, location and cause of a death of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Death Certificate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death Certificate"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C0011066"}]}}{"C45258":{"preferredName":"Medical Record","code":"C45258","definitions":[{"definition":"A chronological written account of a patient's examination and treatment that includes the patient's medical history and complaints, the physician's physical findings, the results of diagnostic tests and procedures, and medications and therapeutic procedures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medical Record","termGroup":"PT","termSource":"NCI"},{"termName":"Medical Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Medical_Record"},{"name":"Maps_To","value":"Medical Record"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0025102"}]}}{"C107424":{"preferredName":"Social Security Death Index","code":"C107424","definitions":[{"definition":"A publically-accessible database derived from the Social Security Administration's (SSA) Death Master File Extract. It includes a listing of the vital statistics of a majority of decedents reported to the SSA since 1962.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Social Security Death Index","termGroup":"PT","termSource":"NCI"},{"termName":"SSDI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social Security Death Index"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3814049"}]}}{"C16267":{"preferredName":"Afghanistan","code":"C16267","definitions":[{"definition":"A country in Southern Asia, north and west of Pakistan, east of Iran. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, north and west of Pakistan, east of Iran.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Afghanistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Afghanistan"},{"name":"Maps_To","value":"Afghanistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0001732"}]}}{"C16271":{"preferredName":"Albania","code":"C16271","definitions":[{"definition":"A country in Southeastern Europe, bordering the Adriatic Sea and Ionian Sea, between Greece and Serbia and Montenegro. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Adriatic and Ionian Seas, between Greece and Montenegro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Albania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Albania"},{"name":"Maps_To","value":"Albania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0001909"}]}}{"C16274":{"preferredName":"Algeria","code":"C16274","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Algeria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Algeria"},{"name":"Maps_To","value":"Algeria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0002037"}]}}{"C16289":{"preferredName":"Andorra","code":"C16289","definitions":[{"definition":"A country in Southwestern Europe, between France and Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Europe, between France and Spain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Andorra","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Andorra"},{"name":"Maps_To","value":"Andorra"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0002838"}]}}{"C16292":{"preferredName":"Angola","code":"C16292","definitions":[{"definition":"A country in Southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Angola","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Angola"},{"name":"Maps_To","value":"Angola"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003023"}]}}{"C20133":{"preferredName":"Anguilla","code":"C20133","definitions":[{"definition":"A group of islands in the Caribbean Sea, east of the Virgin Islands and north of Saint Kitts and Nevis.","type":"DEFINITION","source":"NCI"},{"definition":"An island in the Caribbean Sea, east of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Anguilla","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anguilla"},{"name":"Maps_To","value":"Anguilla"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003353"}]}}{"C16303":{"preferredName":"Antigua and Barbuda","code":"C16303","definitions":[{"definition":"A group of islands in the Caribbean Sea, east of Saint Kitts and Nevis.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, east-southeast of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Antigua and Barbuda","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antigua_and_Barbuda"},{"name":"Maps_To","value":"Antigua and Barbuda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003354"}]}}{"C16305":{"preferredName":"Argentina","code":"C16305","definitions":[{"definition":"A country in Southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Argentina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Argentina"},{"name":"Maps_To","value":"Argentina"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003761"}]}}{"C16306":{"preferredName":"Armenia","code":"C16306","definitions":[{"definition":"A country in Southwestern Asia, east of Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Asia, east of Turkey and south of Georgia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Armenia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Armenia"},{"name":"Maps_To","value":"Armenia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003798"}]}}{"C17884":{"preferredName":"Aruba","code":"C17884","definitions":[{"definition":"An island in the Caribbean Sea, north of Venezuela and west of Curacao.","type":"DEFINITION","source":"NCI"},{"definition":"Island in the Caribbean Sea, north of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Aruba","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aruba"},{"name":"Maps_To","value":"Aruba"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282379"}]}}{"C16311":{"preferredName":"Australia","code":"C16311","definitions":[{"definition":"The continent and country between the Indian Ocean and the South Pacific Ocean, south of Asia.","type":"DEFINITION","source":"NCI"},{"definition":"The continent between the Indian Ocean and the South Pacific Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Australia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The US State Department considers Ashmore and Cartier Islands and the Coral Sea Islands as a separate entities, each with its own code (AT and CR, respectively)."},{"name":"Legacy Concept Name","value":"Australia"},{"name":"Maps_To","value":"Australia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004340"}]}}{"C16312":{"preferredName":"Austria","code":"C16312","definitions":[{"definition":"A country in Central Europe, north of Italy and Slovenia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, northeast of Italy and southeast of Germany.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Austria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Austria"},{"name":"Maps_To","value":"Austria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004348"}]}}{"C16316":{"preferredName":"Azerbaijan","code":"C16316","definitions":[{"definition":"A country in Southwestern Asia, bordering the Caspian Sea, between Iran and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Asia, bordering the Caspian Sea, between Iran and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Azerbaijan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Azerbaijan"},{"name":"Maps_To","value":"Azerbaijan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004486"}]}}{"C16321":{"preferredName":"Bahamas","code":"C16321","definitions":[{"definition":"A chain of islands in the North Atlantic Ocean, southeast of Florida and north of Cuba.","type":"DEFINITION","source":"NCI"},{"definition":"A chain of islands in the North Atlantic Ocean, southeast of Florida. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bahamas","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bahamas"},{"name":"Maps_To","value":"Bahamas"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004683"}]}}{"C16322":{"preferredName":"Bahrain","code":"C16322","definitions":[{"definition":"An archipelago in the Persian Gulf, east of Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An archipelago in the Persian Gulf, on the east coast of Saudi Arabia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bahrain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bahrain"},{"name":"Maps_To","value":"Bahrain"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004684"}]}}{"C16323":{"preferredName":"Bangladesh","code":"C16323","definitions":[{"definition":"A country in Southern Asia, bordering the Bay of Bengal, between Burma and India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, bordering the Bay of Bengal, between Burma and India.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Bangladesh","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bangladesh"},{"name":"Maps_To","value":"Bangladesh"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004732"}]}}{"C16324":{"preferredName":"Barbados","code":"C16324","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, east of Saint Vincent and the Grenadines.","type":"DEFINITION","source":"NCI"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Barbados","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Barbados"},{"name":"Maps_To","value":"Barbados"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004739"}]}}{"C16372":{"preferredName":"Belarus","code":"C16372","definitions":[{"definition":"A country in Eastern Europe, east of Poland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, east of Poland and north of Ukraine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belarus","termGroup":"PT","termSource":"NCI"},{"termName":"Byelarus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Belarus"},{"name":"Maps_To","value":"Belarus"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006539"}]}}{"C16329":{"preferredName":"Belgium","code":"C16329","definitions":[{"definition":"A country in Western Europe, bordering the North Sea, between France and the Netherlands. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the North Sea, between France and the Netherlands.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Belgium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Belgium"},{"name":"Maps_To","value":"Belgium"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004950"}]}}{"C16331":{"preferredName":"Belize","code":"C16331","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea, between Guatemala and Mexico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central America, bordering the Caribbean Sea, between Guatemala and Mexico.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Belize","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Belize"},{"name":"Maps_To","value":"Belize"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004952"}]}}{"C16333":{"preferredName":"Benin","code":"C16333","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Benin","termGroup":"PT","termSource":"NCI"},{"termName":"Benin Republic","termGroup":"SY","termSource":"NCI"},{"termName":"Bénin","termGroup":"SY","termSource":"NCI"},{"termName":"Bénin Republic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benin_Republic"},{"name":"Maps_To","value":"Benin"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005005"}]}}{"C16334":{"preferredName":"Bermuda","code":"C16334","definitions":[{"definition":"A group of islands in the North Atlantic Ocean, east of South Carolina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A group of islands in the North Atlantic Ocean, east of South Carolina. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bermuda","termGroup":"PT","termSource":"NCI"},{"termName":"Bermuda Islands","termGroup":"SY","termSource":"NCI"},{"termName":"Bermudas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bermuda"},{"name":"Maps_To","value":"Bermuda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005126"}]}}{"C16336":{"preferredName":"Bhutan","code":"C16336","definitions":[{"definition":"A country in Southern Asia, between China and India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, between China and India, east of Nepal and north of Bangladesh.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bhutan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bhutan"},{"name":"Maps_To","value":"Bhutan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005341"}]}}{"C16359":{"preferredName":"Bolivia, Plurinational State of","code":"C16359","definitions":[{"definition":"A country in Central South America, southwest of Brazil. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central South America, southwest of Brazil.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Bolivia, Plurinational State of","termGroup":"PT","termSource":"NCI"},{"termName":"Bolivia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bolivia"},{"name":"Maps_To","value":"Bolivia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005918"}]}}{"C16361":{"preferredName":"Bosnia and Herzegovina","code":"C16361","definitions":[{"definition":"A country in Southeastern Europe, bordering the Adriatic Sea and Croatia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Adriatic Sea, between Croatia and Serbia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bosnia and Herzegovina","termGroup":"PT","termSource":"NCI"},{"termName":"Bosnia-Herzegovina","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bosnia-Herzegovina"},{"name":"Maps_To","value":"Bosnia and Herzegovina"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006036"}]}}{"C16363":{"preferredName":"Botswana","code":"C16363","definitions":[{"definition":"A country in Southern Africa, north of South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, north of South Africa and east of Namibia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botswana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Botswana"},{"name":"Maps_To","value":"Botswana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006041"}]}}{"C16364":{"preferredName":"Brazil","code":"C16364","definitions":[{"definition":"A country in Eastern South America, bordering the Atlantic Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern South America, bordering the Atlantic Ocean.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Brazil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brazil"},{"name":"Maps_To","value":"Brazil"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006137"}]}}{"C16367":{"preferredName":"Brunei Darussalam","code":"C16367","definitions":[{"definition":"A country in Southeastern Asia, bordering the South China Sea and Malaysia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the South China Sea and surrounded by Malaysia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brunei Darussalam","termGroup":"PT","termSource":"NCI"},{"termName":"Brunei","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brunei"},{"name":"Maps_To","value":"Brunei"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006320"}]}}{"C16368":{"preferredName":"Bulgaria","code":"C16368","definitions":[{"definition":"A country in Southeastern Europe, bordering the Black Sea, between Romania and Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Black Sea, between Romania and Turkey.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Bulgaria","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Bulgaria","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bulgaria"},{"name":"Maps_To","value":"Bulgaria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006368"}]}}{"C16369":{"preferredName":"Burkina Faso","code":"C16369","definitions":[{"definition":"A country in Western Africa, north of Ghana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, between Mali and Ghana.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burkina Faso","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Burkina_Faso"},{"name":"Maps_To","value":"Burkina Faso"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006409"}]}}{"C16371":{"preferredName":"Burundi","code":"C16371","definitions":[{"definition":"A country in Central Africa, east of Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, east of the Democratic Republic of the Congo and south of Rwanda.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burundi","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Burundi"},{"name":"Maps_To","value":"Burundi"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006448"}]}}{"C16378":{"preferredName":"Cambodia","code":"C16378","definitions":[{"definition":"A country in Southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Cambodia","termGroup":"PT","termSource":"NCI"},{"termName":"Kampuchea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cambodia"},{"name":"Maps_To","value":"Cambodia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006797"}]}}{"C16379":{"preferredName":"Cameroon","code":"C16379","definitions":[{"definition":"A country in Western Africa, bordering the Bight of Biafra, between Equatorial Guinea and Nigeria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Equatorial Guinea and Nigeria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cameroon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cameroon"},{"name":"Maps_To","value":"Cameroon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006802"}]}}{"C16380":{"preferredName":"Canada","code":"C16380","definitions":[{"definition":"A country in Northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Canada","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Canada"},{"name":"Maps_To","value":"Canada"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006823"}]}}{"C16382":{"preferredName":"Cabo Verde","code":"C16382","definitions":[{"definition":"A group of islands in the North Atlantic Ocean, west of Senegal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A group of islands in the North Atlantic Ocean, west of Senegal. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cabo Verde","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cape_Verde"},{"name":"Maps_To","value":"Cape Verde"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006893"}]}}{"C16391":{"preferredName":"Cayman Islands","code":"C16391","definitions":[{"definition":"An island group in the Caribbean Sea, nearly one-half of the way from Cuba to Honduras. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island group in the Caribbean Sea, south of Cuba and west of Jamaica.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cayman Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cayman_Islands"},{"name":"Maps_To","value":"Cayman Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0007481"}]}}{"C16409":{"preferredName":"Central African Republic","code":"C16409","definitions":[{"definition":"A country in Central Africa, north of Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, north of Democratic Republic of the Congo, between Cameroon and South Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central African Republic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_African_Republic"},{"name":"Maps_To","value":"Central African Republic"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0007673"}]}}{"C16412":{"preferredName":"Chad","code":"C16412","definitions":[{"definition":"A country in Central Africa, south of Libya. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, south of Libya, between Niger and Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chad","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chad"},{"name":"Maps_To","value":"Chad"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0007928"}]}}{"C16427":{"preferredName":"Chile","code":"C16427","definitions":[{"definition":"A country in Southern South America, bordering the South Atlantic Ocean and South Pacific Ocean, between Argentina and Peru. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern South America, bordering the South Pacific Ocean, between Argentina and Peru.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chile","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chile"},{"name":"Maps_To","value":"Chile"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0008107"}]}}{"C16428":{"preferredName":"China","code":"C16428","definitions":[{"definition":"A country in Eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, between North Korea and Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, south of Kazakhstan, Mongolia and Russia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"China","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"China"},{"name":"Maps_To","value":"China"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0008115"}]}}{"C16449":{"preferredName":"Colombia","code":"C16449","definitions":[{"definition":"A country in Northern South America, bordering the Caribbean Sea, between Panama and Venezuela, and bordering the North Pacific Ocean, between Ecuador and Panama. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the Caribbean Sea and the North Pacific Ocean, between Ecuador and Venezuela.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colombia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colombia"},{"name":"Maps_To","value":"Colombia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C3245499"}]}}{"C16458":{"preferredName":"Comoros","code":"C16458","definitions":[{"definition":"A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique, northwest of Mayotte.","type":"DEFINITION","source":"NCI"},{"definition":"A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Comoros","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Comoros"},{"name":"Maps_To","value":"Comoros"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0009490"}]}}{"C16467":{"preferredName":"Congo","code":"C16467","definitions":[{"definition":"A country in Western Africa, bordering the South Atlantic Ocean, between Angola and Gabon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the South Atlantic Ocean, between Gabon and the Democratic Republic of the Congo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Congo","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of the Congo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Congo"},{"name":"Maps_To","value":"Congo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0009738"}]}}{"C16469":{"preferredName":"Cook Islands","code":"C16469","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of islands in the South Pacific Ocean, east of Australia, between Tonga and French Polynesia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cook Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cook_Islands"},{"name":"Maps_To","value":"Cook Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0009956"}]}}{"C16470":{"preferredName":"Costa Rica","code":"C16470","definitions":[{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Costa Rica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Costa_Rica"},{"name":"Maps_To","value":"Costa Rica"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010182"}]}}{"C16762":{"preferredName":"Cote d'Ivoire","code":"C16762","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Cote d'Ivoire","termGroup":"PT","termSource":"NCI"},{"termName":"Côte d'Ivoire","termGroup":"SY","termSource":"NCI"},{"termName":"Ivory Coast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cote_dIvoire"},{"name":"Maps_To","value":"Cote d'Ivoire"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022326"}]}}{"C16474":{"preferredName":"Croatia","code":"C16474","definitions":[{"definition":"A country in Southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Croatia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Croatia"},{"name":"Maps_To","value":"Croatia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010343"}]}}{"C16477":{"preferredName":"Cuba","code":"C16477","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cuba","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cuba"},{"name":"Maps_To","value":"Cuba"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010435"}]}}{"C101225":{"preferredName":"Curacao","code":"C101225","definitions":[{"definition":"An island in the Caribbean Sea, north of Venezuela and east of Aruba, a constituent country of the Kingdom of the Netherlands.","type":"DEFINITION","source":"NCI"},{"definition":"An island nation located in the Caribbean Sea off the coast of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Curacao","termGroup":"PT","termSource":"NCI"},{"termName":"Curaçao","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Curacao"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0454665"}]}}{"C16480":{"preferredName":"Cyprus","code":"C16480","definitions":[{"definition":"An island in the Mediterranean Sea, south of Turkey.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island in the Mediterranean Sea, south of Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cyprus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cyprus"},{"name":"Maps_To","value":"Cyprus"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010622"}]}}{"C17668":{"preferredName":"Czechia","code":"C17668","definitions":[{"definition":"A country in Central Europe, southeast of Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, southeast of Germany and southwest of Poland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Czechia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Czech_Republic"},{"name":"Maps_To","value":"Czech Republic (Czechia)"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0206578"}]}}{"C17266":{"preferredName":"Congo, the Democratic Republic of the","code":"C17266","definitions":[{"definition":"A country in Central Africa, northeast of Angola. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, northeast of Angola.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Congo, the Democratic Republic of the","termGroup":"PT","termSource":"NCI"},{"termName":"Democratic Republic of the Congo","termGroup":"SY","termSource":"NCI"},{"termName":"Zaire","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Democratic_Republic_of_the_Congo"},{"name":"Maps_To","value":"Democratic Republic of the Congo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043444"}]}}{"C16496":{"preferredName":"Denmark","code":"C16496","definitions":[{"definition":"A country in Northern Europe, bordering the Baltic Sea and the North Sea, on a peninsula north of Germany (Jutland); also includes two major islands (Sjaelland and Fyn). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the Baltic Sea and the North Sea, consisting of a peninsula on the north coast of Germany and several major islands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denmark","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Denmark"},{"name":"Maps_To","value":"Denmark"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0011318"}]}}{"C16506":{"preferredName":"Djibouti","code":"C16506","definitions":[{"definition":"A country in Eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Djibouti","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Djibouti"},{"name":"Maps_To","value":"Djibouti"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0012836"}]}}{"C16519":{"preferredName":"Dominica","code":"C16519","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, about one-half of the way from Puerto Rico to Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, south of Guadeloupe and north of Martinique.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dominica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dominica"},{"name":"Maps_To","value":"Dominica"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013013"}]}}{"C16520":{"preferredName":"Dominican Republic","code":"C16520","definitions":[{"definition":"A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Dominican Republic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dominican_Republic"},{"name":"Maps_To","value":"Dominican Republic"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013014"}]}}{"C16528":{"preferredName":"Ecuador","code":"C16528","definitions":[{"definition":"A country in Western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ecuador","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ecuador"},{"name":"Maps_To","value":"Ecuador"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013593"}]}}{"C16530":{"preferredName":"Egypt","code":"C16530","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, east of Libya and north of Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Egypt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Egypt"},{"name":"Maps_To","value":"Egypt"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013715"}]}}{"C16532":{"preferredName":"El Salvador","code":"C16532","definitions":[{"definition":"A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"El Salvador","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"El_Salvador"},{"name":"Maps_To","value":"El Salvador"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013754"}]}}{"C16557":{"preferredName":"Equatorial Guinea","code":"C16557","definitions":[{"definition":"A country in Western Africa, bordering the Bight of Biafra, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Equatorial Guinea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Equatorial_Guinea"},{"name":"Maps_To","value":"Equatorial Guinea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0014651"}]}}{"C16558":{"preferredName":"Eritrea","code":"C16558","definitions":[{"definition":"A country in Eastern Africa, bordering the Red Sea, between Djibouti and Sudan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Red Sea, between Sudan and Ethiopia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eritrea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eritrea"},{"name":"Maps_To","value":"Eritrea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C2711724"}]}}{"C16562":{"preferredName":"Estonia","code":"C16562","definitions":[{"definition":"A country in Eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Finland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estonia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Estonia"},{"name":"Maps_To","value":"Estonia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0014908"}]}}{"C17179":{"preferredName":"Eswatini","code":"C17179","definitions":[{"definition":"A country in Southern Africa, between Mozambique and South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, between Mozambique and South Africa.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Eswatini","termGroup":"PT","termSource":"NCI"},{"termName":"Eswatini","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Swaziland"},{"name":"Maps_To","value":"Eswatini"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038983"}]}}{"C16563":{"preferredName":"Ethiopia","code":"C16563","definitions":[{"definition":"A country in Eastern Africa, west of Somalia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, between Somalia and Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethiopia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ethiopia"},{"name":"Maps_To","value":"Ethiopia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0015024"}]}}{"C17954":{"preferredName":"Falkland Islands (Malvinas)","code":"C17954","definitions":[{"definition":"A group of islands in the South Atlantic Ocean, east of southern Argentina.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the South Atlantic Ocean, east of southern Argentina. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Falkland Islands (Malvinas)","termGroup":"PT","termSource":"NCI"},{"termName":"Falkland Islands","termGroup":"SY","termSource":"NCI"},{"termName":"Islas Malvinas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Falkland_Islands"},{"name":"Maps_To","value":"Falkland Islands (Malvinas)"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0349396"}]}}{"C16573":{"preferredName":"Faroe Islands","code":"C16573","definitions":[{"definition":"An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Faroe Islands","termGroup":"PT","termSource":"NCI"},{"termName":"Faeroe Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Faroe_Islands"},{"name":"Maps_To","value":"Faroe Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0015541"}]}}{"C17881":{"preferredName":"Micronesia, Federated States of","code":"C17881","definitions":[{"definition":"An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia, west of the Marshall Islands and north of the Solomon Islands.","type":"DEFINITION","source":"NCI"},{"definition":"An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Micronesia, Federated States of","termGroup":"PT","termSource":"NCI"},{"termName":"Federated States of Micronesia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Federated_States_of_Micronesia"},{"name":"Maps_To","value":"Federated States of Micronesia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282244"}]}}{"C16582":{"preferredName":"Fiji","code":"C16582","definitions":[{"definition":"A group of islands in the South Pacific Ocean, southwest of Wallis and Fortuna and east of Vanuatu.","type":"DEFINITION","source":"NCI"},{"definition":"An island group in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fiji","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Fiji","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fiji"},{"name":"Maps_To","value":"Fiji"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016080"}]}}{"C16584":{"preferredName":"Finland","code":"C16584","definitions":[{"definition":"A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the Baltic Sea, between Sweden and Russia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Finland","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Finland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Finland"},{"name":"Maps_To","value":"Finland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016132"}]}}{"C16592":{"preferredName":"France","code":"C16592","definitions":[{"definition":"A country in Western Europe, bordering the Bay of Biscay and English Channel, between Belgium and Spain, southeast of the UK; bordering the Mediterranean Sea, between Italy and Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the Bay of Biscay and the English Channel, between Germany and Spain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"France","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"France"},{"name":"Maps_To","value":"France"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016674"}]}}{"C16593":{"preferredName":"French Guiana","code":"C16593","definitions":[{"definition":"A country in Northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"French Guiana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"French_Guiana"},{"name":"Maps_To","value":"French Guiana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016703"}]}}{"C16594":{"preferredName":"French Polynesia","code":"C16594","definitions":[{"definition":"An archipelago in the South Pacific Ocean, about one-half of the way from South America to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An archipelago in the South Pacific Ocean, east of the Cook Islands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"French Polynesia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"French_Polynesia"},{"name":"Maps_To","value":"French Polynesia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016704"}]}}{"C16596":{"preferredName":"Gabon","code":"C16596","definitions":[{"definition":"A country in Western Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gabon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gabon"},{"name":"Maps_To","value":"Gabon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016910"}]}}{"C16598":{"preferredName":"The Gambia","code":"C16598","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean and Senegal. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean and surrounded by Senegal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"The Gambia","termGroup":"PT","termSource":"NCI"},{"termName":"Gambia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gambia"},{"name":"Maps_To","value":"Gambia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016993"}]}}{"C16634":{"preferredName":"Georgia (Republic)","code":"C16634","definitions":[{"definition":"A country in Southwestern Asia, bordering the Black Sea, between Turkey and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Asia, bordering the Black Sea, between Turkey and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Georgia (Republic)","termGroup":"PT","termSource":"NCI"},{"termName":"Georgia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Georgia"},{"name":"Maps_To","value":"Georgia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017454"}]}}{"C16636":{"preferredName":"Germany","code":"C16636","definitions":[{"definition":"A country in Central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Germany","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Germany"},{"name":"Maps_To","value":"Germany"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017480"}]}}{"C26330":{"preferredName":"Ghana","code":"C26330","definitions":[{"definition":"A country in Western Africa, bordering the Gulf of Guinea, between Cote d'Ivoire and Togo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Cote d'Ivoire and Togo.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ghana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ghana"},{"name":"Maps_To","value":"Ghana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017516"}]}}{"C16638":{"preferredName":"Gibraltar","code":"C16638","definitions":[{"definition":"A dependency in Southwestern Europe, bordering the Strait of Gibraltar, on the southern coast of Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A dependency in southwestern Europe, on the southern coast of Spain, bordering the Strait of Gibraltar.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gibraltar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gibraltar"},{"name":"Maps_To","value":"Gibraltar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017540"}]}}{"C16645":{"preferredName":"Greece","code":"C16645","definitions":[{"definition":"A country in Southern Europe, bordering the Aegean Sea, Ionian Sea, and the Mediterranean Sea, between Albania and Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, bordering the Aegean, Ionian, and Mediterranean Seas, between Albania and Turkey.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Greece","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Greece"},{"name":"Maps_To","value":"Greece"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018226"}]}}{"C16646":{"preferredName":"Greenland","code":"C16646","definitions":[{"definition":"An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Greenland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Greenland"},{"name":"Maps_To","value":"Greenland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018229"}]}}{"C16647":{"preferredName":"Grenada","code":"C16647","definitions":[{"definition":"An island between the Caribbean Sea and Atlantic Ocean, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island between the Caribbean Sea and Atlantic Ocean, south of Saint Vincent and the Grenadines and north of Trinidad and Tobago.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grenada","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grenada"},{"name":"Maps_To","value":"Grenada"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018232"}]}}{"C16651":{"preferredName":"Guadeloupe","code":"C16651","definitions":[{"definition":"A group of islands in the Caribbean Seas, southeast of Montserrat.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the eastern Caribbean Sea, southeast of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guadeloupe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guadeloupe"},{"name":"Maps_To","value":"Guadeloupe"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018301"}]}}{"C16652":{"preferredName":"Guam","code":"C16652","definitions":[{"definition":"An island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines, south of the Northern Mariana Islands.","type":"DEFINITION","source":"NCI"},{"definition":"Island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guam","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Guam"},{"name":"Maps_To","value":"Guam"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018309"}]}}{"C16654":{"preferredName":"Guatemala","code":"C16654","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea and the North Pacific Ocean, east of Mexico and west of Belize and Honduras.","type":"DEFINITION","source":"NCI"},{"definition":"A country in Central America, bordering the Caribbean Sea, between Honduras and Belize and bordering the North Pacific Ocean, between El Salvador and Mexico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guatemala","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guatemala"},{"name":"Maps_To","value":"Guatemala"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018367"}]}}{"C64375":{"preferredName":"Guernsey","code":"C64375","definitions":[{"definition":"A British Crown dependency in the English Channel, between England and France.","type":"DEFINITION","source":"NCI"},{"definition":"The island of Guernsey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy, which held sway in both France and England. Guernsey is a British crown dependency, but is not part of the UK. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guernsey","termGroup":"PT","termSource":"NCI"},{"termName":"Bailiwick of Guernsey","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guernsey"},{"name":"Maps_To","value":"Guernsey"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018370"}]}}{"C16655":{"preferredName":"Guinea","code":"C16655","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Guinea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guinea"},{"name":"Maps_To","value":"Guinea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018381"}]}}{"C16656":{"preferredName":"Guinea-Bissau","code":"C16656","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Guinea-Bissau","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guinea-Bissau"},{"name":"Maps_To","value":"Guinea-Bissau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018387"}]}}{"C16657":{"preferredName":"Guyana","code":"C16657","definitions":[{"definition":"A country in Northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Guyana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guyana"},{"name":"Maps_To","value":"Guyana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018408"}]}}{"C16660":{"preferredName":"Haiti","code":"C16660","definitions":[{"definition":"A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Haiti","termGroup":"PT","termSource":"NCI"},{"termName":"Haïti","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Haiti"},{"name":"Maps_To","value":"Haiti"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018510"}]}}{"C17249":{"preferredName":"Holy See (Vatican City State)","code":"C17249","definitions":[{"definition":"An enclave of Rome (Italy).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An enclave of Rome (Italy). (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Holy See (Vatican City State)","termGroup":"PT","termSource":"NCI"},{"termName":"Holy See","termGroup":"SY","termSource":"NCI"},{"termName":"Vatican City","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vatican_City"},{"name":"Maps_To","value":"Holy See"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042427"}]}}{"C16694":{"preferredName":"Honduras","code":"C16694","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua and bordering the North Pacific Ocean, between El Salvador and Nicaragua. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Honduras","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Honduras"},{"name":"Maps_To","value":"Honduras"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0019905"}]}}{"C16695":{"preferredName":"Hong Kong","code":"C16695","definitions":[{"definition":"A special administrative region of China, bordering the South China Sea and China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A special administrative region of China, bordering the South China Sea, east of Macao.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hong Kong","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hong_Kong"},{"name":"Maps_To","value":"Hong Kong"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0019907"}]}}{"C16699":{"preferredName":"Hungary","code":"C16699","definitions":[{"definition":"A country in Central Europe, northwest of Romania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, northwest of Romania and south of Slovakia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hungary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hungary"},{"name":"Maps_To","value":"Hungary"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0020174"}]}}{"C16704":{"preferredName":"Iceland","code":"C16704","definitions":[{"definition":"A country in Northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Iceland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iceland"},{"name":"Maps_To","value":"Iceland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0020750"}]}}{"C16727":{"preferredName":"India","code":"C16727","definitions":[{"definition":"A country in Southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Pakistan and China.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"India","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"India"},{"name":"Maps_To","value":"India"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0021201"}]}}{"C16728":{"preferredName":"Indonesia","code":"C16728","definitions":[{"definition":"A country in Southeastern Asia, comprising the archipelago between the Indian Ocean and the Pacific Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprising the archipelago and islands between the Indian Ocean and the Pacific Ocean, north of Australia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indonesia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Indonesia"},{"name":"Maps_To","value":"Indonesia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0021247"}]}}{"C16755":{"preferredName":"Iran, Islamic Republic of","code":"C16755","definitions":[{"definition":"A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Iran, Islamic Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Iran","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iran"},{"name":"Maps_To","value":"Iran"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022065"}]}}{"C16756":{"preferredName":"Iraq","code":"C16756","definitions":[{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iran and Kuwait. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iran and Syria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iraq","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iraq"},{"name":"Maps_To","value":"Iraq"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022066"}]}}{"C16757":{"preferredName":"Ireland","code":"C16757","definitions":[{"definition":"A country in Western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ireland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ireland"},{"name":"Maps_To","value":"Ireland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022067"}]}}{"C44480":{"preferredName":"Isle of Man","code":"C44480","definitions":[{"definition":"An island in the Irish Sea, between Great Britain and Ireland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island in the Irish Sea, between Great Britain and Ireland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Isle of Man","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isle_of_Man"},{"name":"Maps_To","value":"Isle of Man"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022132"}]}}{"C16760":{"preferredName":"Israel","code":"C16760","definitions":[{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Israel","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Israel"},{"name":"Maps_To","value":"Israel"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022271"}]}}{"C16761":{"preferredName":"Italy","code":"C16761","definitions":[{"definition":"A country in Southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Italy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Italy"},{"name":"Maps_To","value":"Italy"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022277"}]}}{"C16763":{"preferredName":"Jamaica","code":"C16763","definitions":[{"definition":"An island in the Caribbean Sea, south of Cuba, between the Cayman Islands and Haiti.","type":"DEFINITION","source":"NCI"},{"definition":"An island in the Caribbean Sea, south of Cuba. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jamaica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jamaica"},{"name":"Maps_To","value":"Jamaica"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022337"}]}}{"C16764":{"preferredName":"Japan","code":"C16764","definitions":[{"definition":"A country in Eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Japan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Japan"},{"name":"Maps_To","value":"Japan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022341"}]}}{"C64374":{"preferredName":"Jersey","code":"C64374","definitions":[{"definition":"A British Crown dependency in the English Channel southeast of Guernsey.","type":"DEFINITION","source":"NCI"},{"definition":"Jersey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy that held sway in both France and England. Jersey is a British crown dependency, but is not part of the UK. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jersey","termGroup":"PT","termSource":"NCI"},{"termName":"Bailiwick of Jersey","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jersey"},{"name":"Maps_To","value":"Jersey"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0454673"}]}}{"C16765":{"preferredName":"Jordan","code":"C16765","definitions":[{"definition":"A country in the Middle East, northwest of Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, northwest of Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jordan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jordan"},{"name":"Maps_To","value":"Jordan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022418"}]}}{"C20107":{"preferredName":"Kazakhstan","code":"C20107","definitions":[{"definition":"A country in Central Asia, northwest of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, northwest of China and south of Russia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kazakhstan","termGroup":"PT","termSource":"NCI"},{"termName":"Kazakstan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kazakhstan"},{"name":"Maps_To","value":"Kazakhstan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022537"}]}}{"C16769":{"preferredName":"Kenya","code":"C16769","definitions":[{"definition":"A country in Eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Kenya","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kenya"},{"name":"Maps_To","value":"Kenya"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022558"}]}}{"C16639":{"preferredName":"Kiribati","code":"C16639","definitions":[{"definition":"A group of 33 coral atolls in the Pacific Ocean, south of Hawaii and northeast of Jarvis Island.","type":"DEFINITION","source":"NCI"},{"definition":"A group of 33 coral atolls in the Pacific Ocean, straddling the equator; the capital Tarawa is about one-half of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kiribati","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kiribati"},{"name":"Maps_To","value":"Kiribati"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017550"}]}}{"C123740":{"preferredName":"Kosovo","code":"C123740","definitions":[{"definition":"A southeastern European country between Servia and Macedonia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kosovo","termGroup":"PT","termSource":"NCI"},{"termName":"901","termGroup":"CNU","termSource":"NCI"},{"termName":"XK","termGroup":"CA2","termSource":"NCI"},{"termName":"XKS","termGroup":"CA3","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kosovo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0206003"}]}}{"C16775":{"preferredName":"Kuwait","code":"C16775","definitions":[{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kuwait","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kuwait"},{"name":"Maps_To","value":"Kuwait"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022804"}]}}{"C16771":{"preferredName":"Kyrgyzstan","code":"C16771","definitions":[{"definition":"A country in Central Asia, west of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, between southern Kazakhstan and western China.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kyrgyzstan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kyrgyzstan"},{"name":"Maps_To","value":"Kyrgyzstan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022718"}]}}{"C16780":{"preferredName":"Lao People's Democratic Republic","code":"C16780","definitions":[{"definition":"A country in Southeastern Asia, northeast of Thailand, west of Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, north and east of Thailand, west of Vietnam.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lao People's Democratic Republic","termGroup":"PT","termSource":"NCI"},{"termName":"Laos","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lao_Peoples_Democratic_Republic"},{"name":"Maps_To","value":"Laos"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023034"}]}}{"C16783":{"preferredName":"Latvia","code":"C16783","definitions":[{"definition":"A country in Eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Latvia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Latvia"},{"name":"Maps_To","value":"Latvia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023128"}]}}{"C16784":{"preferredName":"Lebanon","code":"C16784","definitions":[{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lebanon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lebanon"},{"name":"Maps_To","value":"Lebanon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023190"}]}}{"C16787":{"preferredName":"Lesotho","code":"C16787","definitions":[{"definition":"A country in Southern Africa, an enclave of South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, an enclave of South Africa.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Lesotho","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesotho"},{"name":"Maps_To","value":"Lesotho"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023376"}]}}{"C16791":{"preferredName":"Liberia","code":"C16791","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Liberia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liberia"},{"name":"Maps_To","value":"Liberia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023617"}]}}{"C16793":{"preferredName":"Libya","code":"C16793","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Egypt and Tunisia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, between Egypt and Algeria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Libya","termGroup":"PT","termSource":"NCI"},{"termName":"Libyan Arab Jamahiriya","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Libyan_Arab_Jamahiriya"},{"name":"Maps_To","value":"Libya"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023634"}]}}{"C16794":{"preferredName":"Liechtenstein","code":"C16794","definitions":[{"definition":"A country in Central Europe, between Austria and Switzerland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, between Austria and Switzerland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Liechtenstein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liechtenstein"},{"name":"Maps_To","value":"Liechtenstein"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023668"}]}}{"C16799":{"preferredName":"Lithuania","code":"C16799","definitions":[{"definition":"A country in Eastern Europe, bordering the Baltic Sea, between Latvia and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Baltic Sea, between Latvia and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Lithuania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lithuania"},{"name":"Maps_To","value":"Lithuania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023879"}]}}{"C16803":{"preferredName":"Luxembourg","code":"C16803","definitions":[{"definition":"A country in Western Europe, between France, Belgium, and Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, between France, Belgium, and Germany.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Luxembourg","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Luxembourg"},{"name":"Maps_To","value":"Luxembourg"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024176"}]}}{"C16807":{"preferredName":"Macau","code":"C16807","definitions":[{"definition":"A country in Eastern Asia, bordering the South China Sea and China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A special administrative region of China, bordering the South China Sea, west of Hong Kong.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macau","termGroup":"PT","termSource":"NCI"},{"termName":"Macao","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Macau"},{"name":"Maps_To","value":"Macau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024403"}]}}{"C16808":{"preferredName":"Madagascar","code":"C16808","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Indian Ocean, east of Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Indian Ocean, east of Mozambique.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Madagascar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Madagascar"},{"name":"Maps_To","value":"Madagascar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024443"}]}}{"C16813":{"preferredName":"Malawi","code":"C16813","definitions":[{"definition":"A country in Southern Africa, east of Zambia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, east of Zambia and west of Mozambique and Tanzania.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malawi","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malawi"},{"name":"Maps_To","value":"Malawi"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024548"}]}}{"C16814":{"preferredName":"Malaysia","code":"C16814","definitions":[{"definition":"A country in Southeastern Asia, occupying a peninsula and the northern one-third of the island of Borneo, bordering Indonesia and the South China Sea, south of Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia bordering Indonesia and the South China Sea, occupying a peninsula south of Thailand and the northern one-third of the island of Borneo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malaysia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malaysia"},{"name":"Maps_To","value":"Malaysia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024552"}]}}{"C16815":{"preferredName":"Maldives","code":"C16815","definitions":[{"definition":"A country in Southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India and north of the British Indian Ocean Territory.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maldives","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Maldives"},{"name":"Maps_To","value":"Maldives"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024553"}]}}{"C16816":{"preferredName":"Mali","code":"C16816","definitions":[{"definition":"A country in Western Africa, southwest of Algeria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, southwest of Algeria and east of Mauritania.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mali","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mali"},{"name":"Maps_To","value":"Mali"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024581"}]}}{"C16817":{"preferredName":"Malta","code":"C16817","definitions":[{"definition":"A country in Southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Malta","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malta"},{"name":"Maps_To","value":"Malta"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024653"}]}}{"C16822":{"preferredName":"Marshall Islands","code":"C16822","definitions":[{"definition":"A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia, south of Wake Island and north of Nauru.","type":"DEFINITION","source":"NCI"},{"definition":"A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Marshall Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Marshall_Islands"},{"name":"Maps_To","value":"Marshall Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C2711078"}]}}{"C16823":{"preferredName":"Martinique","code":"C16823","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, south of Dominica and north of Saint Lucia.","type":"DEFINITION","source":"NCI"},{"definition":"An island in the Caribbean Sea, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Martinique","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Martinique"},{"name":"Maps_To","value":"Martinique"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0454677"}]}}{"C16826":{"preferredName":"Mauritania","code":"C16826","definitions":[{"definition":"A country in Northern Africa, bordering the North Atlantic Ocean, between Senegal and Western Sahara. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the North Atlantic Ocean, between Senegal, Western Sahara, and Mali.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mauritania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mauritania"},{"name":"Maps_To","value":"Mauritania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024943"}]}}{"C16827":{"preferredName":"Mauritius","code":"C16827","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Indian Ocean, off the coast of Madagascar, east of Reunion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mauritius","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mauritius"},{"name":"Maps_To","value":"Mauritius"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024944"}]}}{"C16828":{"preferredName":"Mayotte","code":"C16828","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique, southeast of Comoros.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mayotte","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mayotte"},{"name":"Maps_To","value":"Mayotte"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024974"}]}}{"C16850":{"preferredName":"Mexico","code":"C16850","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea and the Gulf of Mexico, between Belize and the US and bordering the North Pacific Ocean, between Guatemala and the US. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern North America, bordering the North Pacific Ocean and the Gulf of Mexico, south of the US.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mexico","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mexico"},{"name":"Maps_To","value":"Mexico"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0025885"}]}}{"C16871":{"preferredName":"Moldova, Republic of","code":"C16871","definitions":[{"definition":"A country in Eastern Europe, northeast of Romania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, northeast of Romania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Moldova, Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Moldova","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Moldova","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Moldova"},{"name":"Maps_To","value":"Moldova"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026374"}]}}{"C16874":{"preferredName":"Monaco","code":"C16874","definitions":[{"definition":"A country in Western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Monaco","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monaco"},{"name":"Maps_To","value":"Monaco"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026405"}]}}{"C16875":{"preferredName":"Mongolia","code":"C16875","definitions":[{"definition":"A country in Northern Asia, between China and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Asia, between China and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Mongolia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mongolia"},{"name":"Maps_To","value":"Mongolia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026410"}]}}{"C64378":{"preferredName":"Montenegro","code":"C64378","definitions":[{"definition":"A country in southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina.","type":"DEFINITION","source":"NCI"},{"definition":"A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Montenegro","termGroup":"PT","termSource":"NCI"},{"termName":"People's Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Socialist Republic of Serbia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Montenegro"},{"name":"Maps_To","value":"Montenegro"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026510"}]}}{"C16876":{"preferredName":"Montserrat","code":"C16876","definitions":[{"definition":"A country in the Caribbean, occupying an island in the Caribbean Sea, southeast of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island in the Caribbean Seas, southeast of Saint Kitts and Nevis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Montserrat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Montserrat"},{"name":"Maps_To","value":"Montserrat"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026514"}]}}{"C16878":{"preferredName":"Morocco","code":"C16878","definitions":[{"definition":"A country in Northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, between Algeria and Western Sahara. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, south of Spain and between Algeria and Western Sahara.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Morocco","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Morocco"},{"name":"Maps_To","value":"Morocco"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026544"}]}}{"C16882":{"preferredName":"Mozambique","code":"C16882","definitions":[{"definition":"A country in Southern Africa, bordering the Mozambique Channel, between South Africa and Tanzania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Africa, bordering the Mozambique Channel, between South Africa and Tanzania.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mozambique","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mozambique"},{"name":"Maps_To","value":"Mozambique"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026655"}]}}{"C16370":{"preferredName":"Myanmar","code":"C16370","definitions":[{"definition":"A country in Southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, between Bangladesh and Thailand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, southwest of China, between Bangladesh and Thailand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myanmar","termGroup":"PT","termSource":"NCI"},{"termName":"Burma","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of the Union of Myanmar","termGroup":"SY","termSource":"NCI"},{"termName":"Union of Burma","termGroup":"SY","termSource":"NCI"},{"termName":"Union of Myanmar","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myanmar"},{"name":"Maps_To","value":"Myanmar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006416"}]}}{"C16891":{"preferredName":"Namibia","code":"C16891","definitions":[{"definition":"A country in Southern Africa, bordering the South Atlantic Ocean, between Angola and South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Africa, bordering the South Atlantic Ocean, between Angola and South Africa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Namibia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Namibia"},{"name":"Maps_To","value":"Namibia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027366"}]}}{"C16896":{"preferredName":"Nauru","code":"C16896","definitions":[{"definition":"A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nauru","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nauru"},{"name":"Maps_To","value":"Nauru"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027496"}]}}{"C16901":{"preferredName":"Nepal","code":"C16901","definitions":[{"definition":"A country in Southern Asia, between China and India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, between China and India, west of Bhutan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nepal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nepal"},{"name":"Maps_To","value":"Nepal"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027689"}]}}{"C16903":{"preferredName":"Netherlands","code":"C16903","definitions":[{"definition":"A country in Western Europe, bordering the North Sea, between Belgium and Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the North Sea, between Belgium and Germany.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Netherlands","termGroup":"PT","termSource":"NCI"},{"termName":"Kingdom of the Netherlands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Netherlands"},{"name":"Maps_To","value":"Netherlands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027778"}]}}{"C16913":{"preferredName":"New Caledonia","code":"C16913","definitions":[{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"New Caledonia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"New_Caledonia"},{"name":"Maps_To","value":"New Caledonia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027964"}]}}{"C16914":{"preferredName":"New Zealand","code":"C16914","definitions":[{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"New Zealand","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"New_Zealand"},{"name":"Maps_To","value":"New Zealand"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027978"}]}}{"C16915":{"preferredName":"Nicaragua","code":"C16915","definitions":[{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nicaragua","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nicaragua"},{"name":"Maps_To","value":"Nicaragua"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028002"}]}}{"C16916":{"preferredName":"Niger","code":"C16916","definitions":[{"definition":"A country in Western Africa, southeast of Algeria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, southeast of Algeria and north of Nigeria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niger","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Niger"},{"name":"Maps_To","value":"Niger"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028074"}]}}{"C16917":{"preferredName":"Nigeria","code":"C16917","definitions":[{"definition":"A country in Western Africa, bordering the Gulf of Guinea, between Benin and Cameroon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Benin and Cameroon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Nigeria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nigeria"},{"name":"Maps_To","value":"Nigeria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028075"}]}}{"C16918":{"preferredName":"Niue","code":"C16918","definitions":[{"definition":"A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga and south of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Niue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Niue"},{"name":"Maps_To","value":"Niue"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028219"}]}}{"C16773":{"preferredName":"Korea, Democratic People's Republic of","code":"C16773","definitions":[{"definition":"A country in Eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Korea, Democratic People's Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"North Korea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"North_Korea"},{"name":"Maps_To","value":"North Korea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022772"}]}}{"C17654":{"preferredName":"North Macedonia","code":"C17654","definitions":[{"definition":"A country in Southeastern Europe, north of Greece. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, north of Greece, between Albania and Bulgaria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"North Macedonia","termGroup":"PT","termSource":"NCI"},{"termName":"Macedonia","termGroup":"SY","termSource":"NCI"},{"termName":"Macedonia (Republic)","termGroup":"SY","termSource":"NCI"},{"termName":"Macedonia, Former Yugoslav Republic of","termGroup":"SY","termSource":"NCI"},{"termName":"Macedonia, the Former Yugoslav Republic of","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Macedonia","termGroup":"SY","termSource":"NCI"},{"termName":"The Former Yugoslav Republic of Macedonia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"The_Former_Yugoslav_Republic_of_Macedonia"},{"name":"Maps_To","value":"North Macedonia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0700290"}]}}{"C17882":{"preferredName":"Northern Mariana Islands","code":"C17882","definitions":[{"definition":"A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines, north of Guam.","type":"DEFINITION","source":"NCI"},{"definition":"A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Northern Mariana Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Northern_Mariana_Islands"},{"name":"Maps_To","value":"Northern Mariana Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282245"}]}}{"C16920":{"preferredName":"Norway","code":"C16920","definitions":[{"definition":"A country in Northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Norway","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Norway"},{"name":"Maps_To","value":"Norway"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028423"}]}}{"C16933":{"preferredName":"Oman","code":"C16933","definitions":[{"definition":"A country in the Middle East, bordering the Arabian Sea, Gulf of Oman, and Persian Gulf, between Yemen and the United Arab Emirates. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in the Middle East, bordering the Arabian Sea, southeast of Saudi Arabia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oman","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oman"},{"name":"Maps_To","value":"Oman"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028971"}]}}{"C16949":{"preferredName":"Pakistan","code":"C16949","definitions":[{"definition":"A country in Southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Pakistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pakistan"},{"name":"Maps_To","value":"Pakistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030211"}]}}{"C17733":{"preferredName":"Palau","code":"C17733","definitions":[{"definition":"A country in the Pacific, comprising a group of islands in the North Pacific Ocean, southeast of the Philippines and northwest of Papua New Guinea.","type":"DEFINITION","source":"NCI"},{"definition":"A country in the Pacific, comprising a group of islands in the North Pacific Ocean, southeast of the Philippines. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Palau","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palau"},{"name":"Maps_To","value":"Palau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C2711193"}]}}{"C16951":{"preferredName":"Panama","code":"C16951","definitions":[{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Panama","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Panama"},{"name":"Maps_To","value":"Panama"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030266"}]}}{"C16952":{"preferredName":"Papua New Guinea","code":"C16952","definitions":[{"definition":"A country in Southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Papua New Guinea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papua_New_Guinea"},{"name":"Maps_To","value":"Papua New Guinea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030375"}]}}{"C16953":{"preferredName":"Paraguay","code":"C16953","definitions":[{"definition":"A country in Central South America, northeast of Argentina. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central South America, northeast of Argentina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Paraguay","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paraguay"},{"name":"Maps_To","value":"Paraguay"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030428"}]}}{"C16972":{"preferredName":"Peru","code":"C16972","definitions":[{"definition":"A country in Western South America, bordering the South Pacific Ocean, between Chile and Ecuador. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western South America, bordering the South Pacific Ocean, between Chile and Ecuador.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Peru","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peru"},{"name":"Maps_To","value":"Peru"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0031238"}]}}{"C16978":{"preferredName":"Philippines","code":"C16978","definitions":[{"definition":"A country in Southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Philippines","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Philippines"},{"name":"Maps_To","value":"Philippines"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0031529"}]}}{"C17002":{"preferredName":"Poland","code":"C17002","definitions":[{"definition":"A country in Central Europe, east of Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, east of Germany.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Poland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poland"},{"name":"Maps_To","value":"Poland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0032356"}]}}{"C17006":{"preferredName":"Portugal","code":"C17006","definitions":[{"definition":"A country in Southwestern Europe, bordering the North Atlantic Ocean, west of Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Europe, bordering the North Atlantic Ocean, west of Spain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Portugal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Portugal"},{"name":"Maps_To","value":"Portugal"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0032729"}]}}{"C17043":{"preferredName":"Puerto Rico","code":"C17043","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic and west of the British Virgin Islands.","type":"DEFINITION","source":"NCI"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Puerto Rico","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Puerto_Rico"},{"name":"Maps_To","value":"Puerto Rico"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0034044"}]}}{"C17045":{"preferredName":"Qatar","code":"C17045","definitions":[{"definition":"A country in the Middle East, occupying a peninsula bordering the Persian Gulf and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, occupying a peninsula bordering the Persian Gulf and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Qatar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Qatar"},{"name":"Maps_To","value":"Qatar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0034366"}]}}{"C17095":{"preferredName":"Reunion","code":"C17095","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Indian Ocean, east of Madagascar and west of Mauritius.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reunion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Reunion"},{"name":"Maps_To","value":"Reunion"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035373"}]}}{"C17108":{"preferredName":"Romania","code":"C17108","definitions":[{"definition":"A country in Southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Romania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Romania"},{"name":"Maps_To","value":"Romania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035826"}]}}{"C17111":{"preferredName":"Russian Federation","code":"C17111","definitions":[{"definition":"A country in Northern Asia (that part west of the Urals is sometimes included with Europe), bordering the Arctic Ocean, between Europe and the North Pacific Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Asia, bordering the Arctic Ocean, between Europe and the North Pacific Ocean.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Russian Federation","termGroup":"PT","termSource":"NCI"},{"termName":"Russia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The part of Russia west of the Urals is sometimes included with Europe."},{"name":"Legacy Concept Name","value":"Russia"},{"name":"Maps_To","value":"Russia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035970"}]}}{"C17112":{"preferredName":"Rwanda","code":"C17112","definitions":[{"definition":"A country in Central Africa, east of Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, between the Democratic Republic of the Congo and Tanzania and north of Burundi.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rwanda","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rwanda"},{"name":"Maps_To","value":"Rwanda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035978"}]}}{"C17164":{"preferredName":"Saint Helena, Ascension and Tristan da Cunha","code":"C17164","definitions":[{"definition":"A group of islands in the South Atlantic Ocean, about midway between South America and Africa, west of Angola and South Africa.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the South Atlantic Ocean, about midway between South America and Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Saint Helena, Ascension and Tristan da Cunha","termGroup":"PT","termSource":"NCI"},{"termName":"Saint Helena","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Helena"},{"name":"Maps_To","value":"Saint Helena, Ascension and Tristan da Cunha"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038108"}]}}{"C17885":{"preferredName":"Saint Kitts and Nevis","code":"C17885","definitions":[{"definition":"A group of islands in the Caribbean Sea, east of the Virgin Islands and south of Anguilla.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the Caribbean Sea, about one-third of the way from Puerto Rico to Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Saint Kitts and Nevis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Kitts_and_Nevis"},{"name":"Maps_To","value":"Saint Kitts and Nevis"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282380"}]}}{"C17113":{"preferredName":"Saint Lucia","code":"C17113","definitions":[{"definition":"A country in the Caribbean, occupying an island between the Caribbean Sea and North Atlantic Ocean, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, south of Martinique and north of Saint Vincent and the Grenadines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saint Lucia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Lucia"},{"name":"Maps_To","value":"Saint Lucia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036056"}]}}{"C17165":{"preferredName":"Saint Pierre and Miquelon","code":"C17165","definitions":[{"definition":"A country in Northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Saint Pierre and Miquelon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Pierre_and_Miquelon"},{"name":"Maps_To","value":"Saint Pierre and Miquelon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038111"}]}}{"C17114":{"preferredName":"Saint Vincent and the Grenadines","code":"C17114","definitions":[{"definition":"A country in the Caribbean, comprised of islands in the Caribbean Sea, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, south of Saint Lucia and north of Granada.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saint Vincent and the Grenadines","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Vincent_and_the_Grenadines"},{"name":"Maps_To","value":"Saint Vincent and the Grenadines"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036057"}]}}{"C17740":{"preferredName":"Samoa","code":"C17740","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about half way from Hawaii to New Zealand, west of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Samoa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Samoa"},{"name":"Maps_To","value":"Samoa"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0242537"}]}}{"C17115":{"preferredName":"San Marino","code":"C17115","definitions":[{"definition":"A country in Southern Europe, an enclave in central Italy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, an enclave in central Italy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"San Marino","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"San_Marino"},{"name":"Maps_To","value":"San Marino"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036154"}]}}{"C17116":{"preferredName":"Sao Tome and Principe","code":"C17116","definitions":[{"definition":"A country in Western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Sao Tome and Principe","termGroup":"PT","termSource":"NCI"},{"termName":"São Tomé and Príncipe","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sao_Tome_and_Principe"},{"name":"Maps_To","value":"Sao Tome and Principe"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036183"}]}}{"C17117":{"preferredName":"Saudi Arabia","code":"C17117","definitions":[{"definition":"A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Saudi Arabia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saudi_Arabia"},{"name":"Maps_To","value":"Saudi Arabia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036243"}]}}{"C17121":{"preferredName":"Senegal","code":"C17121","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Mauritania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Mauritania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Senegal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Senegal"},{"name":"Maps_To","value":"Senegal"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036644"}]}}{"C64377":{"preferredName":"Serbia","code":"C64377","definitions":[{"definition":"A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A republic in southeastern Europe, between Romania and Bosnia and Herzegovina.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serbia","termGroup":"PT","termSource":"NCI"},{"termName":"People's Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Socialist Republic of Serbia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Serbia"},{"name":"Maps_To","value":"Serbia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036708"}]}}{"C17129":{"preferredName":"Seychelles","code":"C17129","definitions":[{"definition":"A country in Eastern Africa, comprised of a group of islands in the Indian Ocean, northeast of Madagascar. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, comprised of a group of islands in the Indian Ocean, northeast of Madagascar and east of Kenya.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seychelles","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Seychelles"},{"name":"Maps_To","value":"Seychelles"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036919"}]}}{"C17130":{"preferredName":"Sierra Leone","code":"C17130","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Liberia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea and Liberia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Sierra Leone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sierra_Leone"},{"name":"Maps_To","value":"Sierra Leone"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037063"}]}}{"C17134":{"preferredName":"Singapore","code":"C17134","definitions":[{"definition":"A country in Southeastern Asia, comprised of islands between Malaysia and Indonesia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprised of the southern tip of the Malaysian peninsula and nearby islands between Malaysia and Indonesia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Singapore","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Singapore"},{"name":"Maps_To","value":"Singapore"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037173"}]}}{"C17669":{"preferredName":"Slovakia","code":"C17669","definitions":[{"definition":"A country in Central Europe, south of Poland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, south of Poland and north of Hungary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Slovakia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Slovakia"},{"name":"Maps_To","value":"Slovakia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0206579"}]}}{"C17138":{"preferredName":"Slovenia","code":"C17138","definitions":[{"definition":"A country in Central Europe, bordering the Adriatic Sea, between Austria and Croatia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, bordering the Adriatic Sea, between Austria and Croatia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Slovenia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Slovenia"},{"name":"Maps_To","value":"Slovenia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037334"}]}}{"C17148":{"preferredName":"Solomon Islands","code":"C17148","definitions":[{"definition":"A group of islands in the South Pacific Ocean, east of Papua New Guinea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A group of islands in the South Pacific Ocean, east of Papua New Guinea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Solomon Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solomon_Islands"},{"name":"Maps_To","value":"Solomon Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037623"}]}}{"C17149":{"preferredName":"Somalia","code":"C17149","definitions":[{"definition":"A country in Eastern Africa, bordering the Gulf of Aden and the Indian Ocean, east of Ethiopia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Gulf of Aden and the Indian Ocean, east of Ethiopia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Somalia","termGroup":"PT","termSource":"NCI"},{"termName":"Federal Republic of Somalia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Somalia"},{"name":"Maps_To","value":"Somalia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037640"}]}}{"C17151":{"preferredName":"South Africa","code":"C17151","definitions":[{"definition":"A country in Southern Africa, at the southern tip of the continent of Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, at the southern tip of the continent of Africa.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"South Africa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"South_Africa"},{"name":"Maps_To","value":"South Africa"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037712"}]}}{"C16774":{"preferredName":"Korea, Republic of","code":"C16774","definitions":[{"definition":"A country in Eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Korea, Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Korea","termGroup":"SY","termSource":"NCI"},{"termName":"South Korea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"South_Korea"},{"name":"Maps_To","value":"South Korea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022773"}]}}{"C97351":{"preferredName":"South Sudan","code":"C97351","definitions":[{"definition":"A country in east central Africa south of Sudan, north of Uganda and Kenya, and west of Ethiopia.","type":"DEFINITION","source":"NCI"},{"definition":"A northeastern African country located in the Sahel region and bordered by Sudan in the north, Uganda and Kenya in the south and Ethiopia in the west. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"South Sudan","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of South Sudan","termGroup":"SY","termSource":"NCI"},{"termName":"Southern Sudan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"South Sudan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C3273373"}]}}{"C17152":{"preferredName":"Spain","code":"C17152","definitions":[{"definition":"A country in Southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, North Atlantic Ocean, and Pyrenees Mountains, southwest of France. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, and North Atlantic Ocean, southwest of France.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spain"},{"name":"Maps_To","value":"Spain"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037747"}]}}{"C17163":{"preferredName":"Sri Lanka","code":"C17163","definitions":[{"definition":"A country in Southern Asia, occupying an island in the Indian Ocean, south of India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, occupying an island in the Indian Ocean, southeast of India.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sri Lanka","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sri_Lanka"},{"name":"Maps_To","value":"Sri Lanka"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038088"}]}}{"C20110":{"preferredName":"State of Palestine","code":"C20110","definitions":[{"definition":"A collective name for the West Bank and the Gaza Strip, two territories in Palestine. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sovereign state in western Africa consisting of the West Bank and the Gaza Strip. Its capital is Jerusalem.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"State of Palestine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palestinian_Territory_Occupied"},{"name":"Maps_To","value":"State of Palestine"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1518860"}]}}{"C17170":{"preferredName":"Sudan","code":"C17170","definitions":[{"definition":"A country in Northern Africa, bordering the Red Sea, between Egypt and Eritrea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northeastern Africa, bordering the Red Sea, between Egypt and Eritrea.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sudan","termGroup":"PT","termSource":"NCI"},{"termName":"736","termGroup":"AQS","termSource":"NCI"},{"termName":"Republic of the Sudan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sudan"},{"name":"Maps_To","value":"Sudan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038642"}]}}{"C17175":{"preferredName":"Suriname","code":"C17175","definitions":[{"definition":"A country in Northern South America, bordering the North Atlantic Ocean, between French Guiana and Guyana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the North Atlantic Ocean, between French Guiana and Guyana.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Suriname","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Suriname"},{"name":"Maps_To","value":"Suriname"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038944"}]}}{"C17178":{"preferredName":"Svalbard and Jan Mayen","code":"C17178","definitions":[{"definition":"A group of islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Svalbard and Jan Mayen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The US State Department considers these as separate entities, each with its own code: Svalbard (SV), and Jan Mayen (JN)"},{"name":"Legacy Concept Name","value":"Svalbard_and_Jan_Mayen"},{"name":"Maps_To","value":"Svalbard & Jan Mayen Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1515101"}]}}{"C17180":{"preferredName":"Sweden","code":"C17180","definitions":[{"definition":"A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, Kattegat, and Skagerrak, between Finland and Norway. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the Baltic Sea, between Finland and Norway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sweden","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sweden"},{"name":"Maps_To","value":"Sweden"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038995"}]}}{"C17181":{"preferredName":"Switzerland","code":"C17181","definitions":[{"definition":"A country in Central Europe, east of France, north of Italy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, east of France and north of Italy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Switzerland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Switzerland"},{"name":"Maps_To","value":"Switzerland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039021"}]}}{"C17182":{"preferredName":"Syrian Arab Republic","code":"C17182","definitions":[{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Lebanon and Turkey.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook"}]},{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Lebanon and Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Syrian Arab Republic","termGroup":"PT","termSource":"NCI"},{"termName":"Syria","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Syria"},{"name":"Maps_To","value":"Syria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039138"}]}}{"C17184":{"preferredName":"Taiwan","code":"C17184","definitions":[{"definition":"A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, north of the Philippines, off the southeastern coast of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, off the southeastern coast of China north of the Philippines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taiwan","termGroup":"PT","termSource":"NCI"},{"termName":"Taiwan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Taiwan"},{"name":"Maps_To","value":"Taiwan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039260"}]}}{"C17183":{"preferredName":"Tajikistan","code":"C17183","definitions":[{"definition":"A country in Central Asia, west of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, south of Kyrgyzstan and west of China.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tajikistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tajikistan"},{"name":"Maps_To","value":"Tajikistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039247"}]}}{"C17185":{"preferredName":"Tanzania, United Republic of","code":"C17185","definitions":[{"definition":"A country in Eastern Africa, bordering the Indian Ocean, between Kenya and Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Indian Ocean, between Kenya and Mozambique.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Tanzania, United Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Tanzania","termGroup":"SY","termSource":"NCI"},{"termName":"United Republic of Tanzania","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tanzania"},{"name":"Maps_To","value":"Tanzania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039298"}]}}{"C17192":{"preferredName":"Thailand","code":"C17192","definitions":[{"definition":"A country in Southeastern Asia, bordering the Andaman Sea and the Gulf of Thailand, southeast of Burma. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Andaman Sea and the Gulf of Thailand, southeast of Burma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Thailand","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thailand"},{"name":"Maps_To","value":"Thailand"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039725"}]}}{"C17200":{"preferredName":"Timor-Leste","code":"C17200","definitions":[{"definition":"A country in Southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Timor-Leste","termGroup":"PT","termSource":"NCI"},{"termName":"East Timor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"East_Timor"},{"name":"Maps_To","value":"Timor-Leste"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1452561"}]}}{"C17202":{"preferredName":"Togo","code":"C17202","definitions":[{"definition":"A country in Western Africa, bordering the Bight of Benin, between Benin and Ghana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Benin and Ghana.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Togo","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Togo"},{"name":"Maps_To","value":"Togo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0040363"}]}}{"C17704":{"preferredName":"Tokelau","code":"C17704","definitions":[{"definition":"A group of three atolls in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand, west of Tuvalu and north of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"A group of three atolls in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tokelau","termGroup":"PT","termSource":"NCI"},{"termName":"Union Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tokelau"},{"name":"Maps_To","value":"Tokelau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0220928"}]}}{"C17205":{"preferredName":"Tonga","code":"C17205","definitions":[{"definition":"An archipelago in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand, southeast of Fiji.","type":"DEFINITION","source":"NCI"},{"definition":"An archipelago in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tonga","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonga"},{"name":"Maps_To","value":"Tonga"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0040407"}]}}{"C17217":{"preferredName":"Trinidad and Tobago","code":"C17217","definitions":[{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, off the northeast coast of Venezuela.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Trinidad and Tobago","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trinidad_and_Tobago"},{"name":"Maps_To","value":"Trinidad and Tobago"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041061"}]}}{"C17221":{"preferredName":"Tunisia","code":"C17221","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Algeria and Libya. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, between Algeria and Libya.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Tunisia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tunisia"},{"name":"Maps_To","value":"Tunisia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041388"}]}}{"C17222":{"preferredName":"Turkey","code":"C17222","definitions":[{"definition":"A country in southeastern Europe and southwestern Asia (that portion of Turkey west of the Bosporus is geographically part of Europe), bordering the Black Sea, between Bulgaria and Georgia, and bordering the Aegean Sea and the Mediterranean Sea, between Greece and Syria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe and southwestern Asia, between the Black Sea and Mediterranean Sea, east of Greece and north of Syria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Turkey","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Turkey","termGroup":"SY","termSource":"NCI"},{"termName":"Turkiye","termGroup":"SY","termSource":"NCI"},{"termName":"Turkiye Cumhuriyeti","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The portion of Turkey west of the Bosporus is geographically part of Europe."},{"name":"Legacy Concept Name","value":"Turkey"},{"name":"Maps_To","value":"Turkey"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041400"}]}}{"C17223":{"preferredName":"Turkmenistan","code":"C17223","definitions":[{"definition":"A country in Central Asia, bordering the Caspian Sea, between Iran and Kazakhstan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, bordering the Caspian Sea, between Iran and Kazakhstan.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Turkmenistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Turkmenistan"},{"name":"Maps_To","value":"Turkmenistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041403"}]}}{"C17225":{"preferredName":"Tuvalu","code":"C17225","definitions":[{"definition":"A group of islands consisting of nine coral atolls in the South Pacific Ocean, about one-half of the way from Hawaii to Australia, west of Tokelau and north of Fiji.","type":"DEFINITION","source":"NCI"},{"definition":"An island group consisting of nine coral atolls in the South Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tuvalu","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tuvalu"},{"name":"Maps_To","value":"Tuvalu"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041413"}]}}{"C17228":{"preferredName":"Uganda","code":"C17228","definitions":[{"definition":"A country in Eastern Africa, west of Kenya. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, west of Kenya.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Uganda","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uganda"},{"name":"Maps_To","value":"Uganda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041573"}]}}{"C17229":{"preferredName":"Ukraine","code":"C17229","definitions":[{"definition":"A country in Eastern Europe, bordering the Black Sea, between Poland and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Black Sea, between Poland and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ukraine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ukraine"},{"name":"Maps_To","value":"Ukraine"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041580"}]}}{"C17232":{"preferredName":"United Arab Emirates","code":"C17232","definitions":[{"definition":"A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"United Arab Emirates","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"United_Arab_Emirates"},{"name":"Maps_To","value":"United Arab Emirates"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041698"}]}}{"C17233":{"preferredName":"United Kingdom","code":"C17233","definitions":[{"definition":"A country in Western Europe, comprising islands, including the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, comprising islands, including England, Scotland, Wales, and the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from CIA World Factbook 2002"}]}],"synonyms":[{"termName":"United Kingdom","termGroup":"PT","termSource":"NCI"},{"termName":"United Kingdom of Great Britain and Northern Ireland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"United_Kingdom"},{"name":"Maps_To","value":"United Kingdom"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041700"}]}}{"C17234":{"preferredName":"United States","code":"C17234","definitions":[{"definition":"A country in North America, between Canada and Mexico, bordering both the North Atlantic Ocean and the North Pacific Ocean.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in North America, bordering both the North Atlantic Ocean and the North Pacific Ocean, between Canada and Mexico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"United States","termGroup":"PT","termSource":"NCI"},{"termName":"United States of America","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"United_States"},{"name":"Maps_To","value":"United States"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041703"}]}}{"C17244":{"preferredName":"Uruguay","code":"C17244","definitions":[{"definition":"A country in Southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Uruguay","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uruguay"},{"name":"Maps_To","value":"Uruguay"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042113"}]}}{"C17246":{"preferredName":"Uzbekistan","code":"C17246","definitions":[{"definition":"A country in Central Asia, north of Afghanistan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, north of Afghanistan, between Turkmenistan and Kazakhstan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uzbekistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uzbekistan"},{"name":"Maps_To","value":"Uzbekistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042177"}]}}{"C17247":{"preferredName":"Vanuatu","code":"C17247","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about three-quarters of the way from Hawaii to Australia.","type":"DEFINITION","source":"NCI"},{"definition":"A group of islands in the South Pacific Ocean, about three-quarters of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Vanuatu","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vanuatu"},{"name":"Maps_To","value":"Vanuatu"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042321"}]}}{"C17250":{"preferredName":"Venezuela, Bolivarian Republic of","code":"C17250","definitions":[{"definition":"A country in Northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Venezuela, Bolivarian Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Venezuela","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Venezuela"},{"name":"Maps_To","value":"Venezuela"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042469"}]}}{"C17252":{"preferredName":"Viet Nam","code":"C17252","definitions":[{"definition":"A country in Southeastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, alongside China, Laos, and Cambodia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, alongside China, Laos, and Cambodia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Viet Nam","termGroup":"PT","termSource":"NCI"},{"termName":"Vietnam","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vietnam"},{"name":"Maps_To","value":"Vietnam"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042658"}]}}{"C17653":{"preferredName":"Virgin Islands, British","code":"C17653","definitions":[{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of the US Virgin Islands.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Virgin Islands, British","termGroup":"PT","termSource":"NCI"},{"termName":"British Virgin Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"British_Virgin_Islands"},{"name":"Maps_To","value":"Virgin Islands, British"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0205999"}]}}{"C17255":{"preferredName":"Virgin Islands, U.S.","code":"C17255","definitions":[{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico and west of the British Virgin Islands.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Virgin Islands, U.S.","termGroup":"PT","termSource":"NCI"},{"termName":"United States Virgin Islands","termGroup":"SY","termSource":"NCI"},{"termName":"Virgin Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"United_States_Virgin_Islands"},{"name":"Maps_To","value":"Virgin Islands, U.S."},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042752"}]}}{"C17259":{"preferredName":"Wallis and Futuna","code":"C17259","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand, northeast of Fiji and west of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Wallis and Futuna","termGroup":"PT","termSource":"NCI"},{"termName":"Wallis and Futuna Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Wallis_and_Futuna_Islands"},{"name":"Maps_To","value":"Wallis and Futuna"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043021"}]}}{"C20113":{"preferredName":"Western Sahara","code":"C20113","definitions":[{"definition":"A country in Northern Africa, bordering the North Atlantic Ocean, between Mauritania and Morocco. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the North Atlantic Ocean, between Mauritania and Morocco.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Western Sahara","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Western_Sahara"},{"name":"Maps_To","value":"Western Sahara"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1520135"}]}}{"C17264":{"preferredName":"Yemen","code":"C17264","definitions":[{"definition":"A country in the Middle East, bordering the Arabian Sea, Gulf of Aden, and Red Sea, between Oman and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Arabian Sea, Gulf of Aden, and Red Sea, between Oman and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Yemen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yemen"},{"name":"Maps_To","value":"Yemen"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043402"}]}}{"C17267":{"preferredName":"Zambia","code":"C17267","definitions":[{"definition":"A country in Southern Africa, east of Angola. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, east of Angola and north of Zimbabwe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zambia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Zambia"},{"name":"Maps_To","value":"Zambia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043445"}]}}{"C17268":{"preferredName":"Zimbabwe","code":"C17268","definitions":[{"definition":"A country in Southern Africa, between South Africa and Zambia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, between South Africa and Zambia, west of Mozambique.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zimbabwe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Zimbabwe"},{"name":"Maps_To","value":"Zimbabwe"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043476"}]}}{"C17459":{"preferredName":"Hispanic or Latino","code":"C17459","definitions":[{"definition":"A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Includes individuals of Mexican, Puerto Rican, Salvadoran, Cuban, Dominican, Guatemalan, and other Central or South American or Spanish culture or origin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Hispanic or Latino","termGroup":"PT","termSource":"NCI"},{"termName":"Hispanic","termGroup":"SY","termSource":"NCI"},{"termName":"Hispanic Populations","termGroup":"SY","termSource":"NCI"},{"termName":"Hispanics or Latinos","termGroup":"SY","termSource":"NCI"},{"termName":"Latino Population","termGroup":"SY","termSource":"NCI"},{"termName":"Spanish Origin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Hispanic"},{"name":"Maps_To","value":"hispanic or latino"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0086409"}]}}{"C41222":{"preferredName":"Not Hispanic or Latino","code":"C41222","definitions":[{"definition":"A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.","type":"DEFINITION","source":"NCI"},{"definition":"A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Not Hispanic or Latino","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Hispanic","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Hispanic or Latino","termGroup":"SY","termSource":"NCI"},{"termName":"Not Hispanic/Spanish origin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Not_Hispanic_or_Latino"},{"name":"Maps_To","value":"not hispanic or latino"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C1518424"}]}}{"C16576":{"preferredName":"Female","code":"C16576","definitions":[{"definition":"A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.","type":"DEFINITION","source":"NCI"},{"definition":"A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Female","termGroup":"PT","termSource":"NCI"},{"termName":"F","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Female"},{"name":"Maps_To","value":"female"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0015780"}]}}{"C20197":{"preferredName":"Male","code":"C20197","definitions":[{"definition":"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.","type":"DEFINITION","source":"NCI"},{"definition":"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Male","termGroup":"PT","termSource":"NCI"},{"termName":"Human, Male","termGroup":"SY","termSource":"NCI"},{"termName":"M","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Male"},{"name":"Maps_To","value":"male"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0086582"}]}}{"C38046":{"preferredName":"Unspecified","code":"C38046","definitions":[{"definition":"Not stated explicitly or in detail.","type":"DEFINITION","source":"NCI"},{"definition":"Not stated explicitly or in detail.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Unspecified","termGroup":"PT","termSource":"NCI"},{"termName":"Not Assigned","termGroup":"SY","termSource":"NCI"},{"termName":"Not Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Unspecified"},{"name":"Maps_To","value":"Grade Not Assigned"},{"name":"Maps_To","value":"unspecified"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205370"}]}}{"C41261":{"preferredName":"White","code":"C41261","definitions":[{"definition":"Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of Europe, including for example, English, German, Irish, Italian, Polish, and Scottish.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"White","termGroup":"PT","termSource":"NCI"},{"termName":"Caucasian","termGroup":"SY","termSource":"NCI"},{"termName":"Caucasians","termGroup":"SY","termSource":"NCI"},{"termName":"Caucasoid","termGroup":"SY","termSource":"NCI"},{"termName":"Occidental","termGroup":"SY","termSource":"NCI"},{"termName":"Whites","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"White"},{"name":"Maps_To","value":"white"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0043157"}]}}{"C41259":{"preferredName":"American Indian or Alaska Native","code":"C41259","definitions":[{"definition":"A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of North, Central, and South America, including, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Marrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, and Maya.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"American Indian or Alaska Native","termGroup":"PT","termSource":"NCI"},{"termName":"First Nations","termGroup":"SY","termSource":"NCI"},{"termName":"Native American","termGroup":"SY","termSource":"NCI"},{"termName":"Native Americans","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"American_Indian_or_Alaska_Native"},{"name":"Maps_To","value":"american indian or alaska native"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0282204"}]}}{"C16352":{"preferredName":"Black or African American","code":"C16352","definitions":[{"definition":"A person having origins in any of the black racial groups of Africa. Terms such as \"Haitian\" or \"Negro\" can be used in addition to \"Black or African American.\" (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the Black racial groups of Africa, including, for example, African American, Jamaican, Haitian, Nigerian, Ethiopian. and Somali.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Black or African American","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"African_American"},{"name":"Maps_To","value":"black or african american"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0085756"}]}}{"C41260":{"preferredName":"Asian","code":"C41260","definitions":[{"definition":"A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of Central or East Asia, Southeast Asia, or South Asia including, for example, Chinese, Asian Indian, Filipino, Vietnamese, Korean, and Japanese.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Asian","termGroup":"PT","termSource":"NCI"},{"termName":"Asian Ancestry","termGroup":"SY","termSource":"NCI"},{"termName":"Asians","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Asian"},{"name":"Maps_To","value":"asian"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0078988"}]}}{"C41219":{"preferredName":"Native Hawaiian or Other Pacific Islander","code":"C41219","definitions":[{"definition":"Denotes a person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. The term covers particularly people who identify themselves as part-Hawaiian, Native Hawaiian, Guamanian or Chamorro, Carolinian, Samoan, Chuu. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands, including, for example, Native Hawaiian, Samoan, Chamorro, Tongan, Fijian, and Marshallese.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Native Hawaiian or Other Pacific Islander","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Native_Hawaiian_or_Other_Pacific_Islander"},{"name":"Maps_To","value":"native hawaiian or other pacific islander"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C1513907"}]}}{"C17649":{"preferredName":"Other","code":"C17649","definitions":[{"definition":"A proper value is applicable but not known.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Different than the one(s) previously specified or mentioned.","type":"DEFINITION","source":"NCI"},{"definition":"Different than the one(s) previously specified or mentioned. (NCI)","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Different than the one(s) previously specified or mentioned. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Other (COT/POT/OM)","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"eCTD"}]}],"synonyms":[{"termName":"Other","termGroup":"PT","termSource":"NCI"},{"termName":"Other or Miscellaneous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Device Problem Code (Appendix B)"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Other"},{"name":"Maps_To","value":"Other"},{"name":"Maps_To","value":"other"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205394"}]}}{"C37987":{"preferredName":"Alive","code":"C37987","definitions":[{"definition":"Living; showing characteristics of life.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Showing characteristics of life; displaying signs of life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alive","termGroup":"PT","termSource":"NCI"},{"termName":"Living","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Life"},{"name":"Maps_To","value":"Alive"},{"name":"Maps_To","value":"alive"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0376558"}]}}{"C28554":{"preferredName":"Dead","code":"C28554","definitions":[{"definition":"A cessation of life that cannot be attributed to a CTCAE term associated with Grade 5.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Dead.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The absence of life or state of being dead. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cessation of life.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The cessation of life.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The cessation of life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dead","termGroup":"PT","termSource":"NCI"},{"termName":"Deceased","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Death"},{"name":"Maps_To","value":"dead"},{"name":"Maps_To","value":"Dead"},{"name":"Maps_To","value":"Death"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0011065"},{"name":"xRef","value":"IMDRF:F02"}]}}{"C48699":{"preferredName":"M0 TNM Finding","code":"C48699","definitions":[{"definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M0 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M0","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Cancer Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M0_Stage_Finding"},{"name":"Maps_To","value":"M0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445034"}]}}{"C48700":{"preferredName":"M1 TNM Finding","code":"C48700","definitions":[{"definition":"A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1_Stage_Finding"},{"name":"Maps_To","value":"M1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441971"}]}}{"C48701":{"preferredName":"M1a TNM Finding","code":"C48701","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1a TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node); for prostate cancer it refers to metastasis to non-regional lymph node(s); for bone cancer it refers to metastasis to the lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1a","termGroup":"SY","termSource":"NCI"},{"termName":"M1a Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1a Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1a_Stage_Finding"},{"name":"Maps_To","value":"M1a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445036"}]}}{"C48702":{"preferredName":"M1b TNM Finding","code":"C48702","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1b","termGroup":"SY","termSource":"NCI"},{"termName":"M1b Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1b Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1b_Stage_Finding"},{"name":"Maps_To","value":"M1b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445064"}]}}{"C48703":{"preferredName":"M1c TNM Finding","code":"C48703","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to metastasis to anatomic site(s) other than bone, with or without bone disease; for retinoblastoma it refers to central nervous system metastasis; for melanoma of the uvea it refers to distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1c","termGroup":"SY","termSource":"NCI"},{"termName":"M1c Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1c Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1c_Stage_Finding"},{"name":"Maps_To","value":"M1c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445037"}]}}{"C48704":{"preferredName":"MX TNM Finding","code":"C48704","definitions":[{"definition":"A distant metastasis TNM finding indicating that the status of distant metastasis cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MX TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"MX","termGroup":"SY","termSource":"NCI"},{"termName":"MX Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"MX Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MX_Stage_Finding"},{"name":"Maps_To","value":"MX"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445039"}]}}{"C95956":{"preferredName":"cM0 (i+) TNM Finding","code":"C95956","definitions":[{"definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis clinically or by radiologic studies, but there are small numbers of cells detected by special studies in the blood and bone marrow, or there is tiny metastasis (no larger than 0.2 mm) detected in nonregional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cM0 (i+) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"cM0 (i+) Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"cM0 (i+)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272458"}]}}{"C48705":{"preferredName":"N0 TNM Finding","code":"C48705","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N0 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0","termGroup":"SY","termSource":"NCI"},{"termName":"N0 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N0 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N0 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N0_Stage_Finding"},{"name":"Maps_To","value":"N0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441959"}]}}{"C95922":{"preferredName":"pN0 (i+) TNM Finding","code":"C95922","definitions":[{"definition":"A regional lymph node TNM finding indicating that there are malignant cells in regional lymph node(s) no greater than 0.2 mm and are detected by hematoxylin and eosin stain or immunohistochemistry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (i+) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (i+)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (i+) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (i+)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272441"}]}}{"C95921":{"preferredName":"pN0 (i-) TNM Finding","code":"C95921","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically, and immunohistochemistry is negative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (i-) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (i-)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (i-) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (i-)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272440"}]}}{"C95925":{"preferredName":"pN0 (mol+) TNM Finding","code":"C95925","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and by immunohistochemistry, but the molecular analysis (RT-PCR) is positive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (mol+) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (mol+)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (mol+) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (mol+)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272443"}]}}{"C95923":{"preferredName":"pN0 (mol-) TNM Finding","code":"C95923","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and molecular analysis (RT-PCR) is negative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (mol-) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (mol-)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (mol-) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (mol-)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272442"}]}}{"C48706":{"preferredName":"N1 TNM Finding","code":"C48706","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1","termGroup":"SY","termSource":"NCI"},{"termName":"N1 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1_Stage_Finding"},{"name":"Maps_To","value":"N1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441962"}]}}{"C48707":{"preferredName":"N1a TNM Finding","code":"C48707","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastasis in 1 to 3 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in one regional lymph node.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1a","termGroup":"SY","termSource":"NCI"},{"termName":"N1a Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1a Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1a Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1a_Stage_Finding"},{"name":"Maps_To","value":"N1a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0456906"}]}}{"C48708":{"preferredName":"N1b TNM Finding","code":"C48708","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for cutaneous melanoma it refers to macrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in 2-3 regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1b","termGroup":"SY","termSource":"NCI"},{"termName":"N1b Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1b Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1b Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1b_Stage_Finding"},{"name":"Maps_To","value":"N1b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0456908"}]}}{"C95929":{"preferredName":"N1bI Stage Finding","code":"C95929","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is metastasis to 1-3 nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bI Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bI"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272446"}]}}{"C95935":{"preferredName":"N1bII Stage Finding","code":"C95935","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is metastasis to four or more nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bII Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bII"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272449"}]}}{"C95936":{"preferredName":"N1bIII Stage Finding","code":"C95936","definitions":[{"definition":"A regional lymph node TNM finding indicating that the tumor extends beyond the lymph node capsule and is less than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bIII Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bIII"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272450"}]}}{"C95937":{"preferredName":"N1bIV Stage Finding","code":"C95937","definitions":[{"definition":"A regional lymph node TNM finding indicating that the metastases to the lymph nodes are more than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bIV Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bIV"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272451"}]}}{"C48709":{"preferredName":"N1c TNM Finding","code":"C48709","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 1 to 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for colorectal cancer it refers to tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1c","termGroup":"SY","termSource":"NCI"},{"termName":"N1c Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1c Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1c Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1c_Stage_Finding"},{"name":"Maps_To","value":"N1c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709107"}]}}{"C95955":{"preferredName":"N1mi TNM Finding","code":"C95955","definitions":[{"definition":"A regional lymph node TNM finding indicating the presence of micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1mi TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1mi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1mi"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869928"}]}}{"C48786":{"preferredName":"N2 TNM Finding","code":"C48786","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes. The definition of N2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4-9 axillary lymph nodes; for cutaneous melanoma it refers to metastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4 or more regional lymph nodes; and for bladder cancer it refers to metastases in multiple regional lymph nodes in the true pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2","termGroup":"SY","termSource":"NCI"},{"termName":"N2 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2_Stage_Finding"},{"name":"Maps_To","value":"N2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441960"}]}}{"C48711":{"preferredName":"N2a TNM Finding","code":"C48711","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4-6 regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2a","termGroup":"SY","termSource":"NCI"},{"termName":"N2a Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2a Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2a Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2a_Stage_Finding"},{"name":"Maps_To","value":"N2a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445079"}]}}{"C48712":{"preferredName":"N2b TNM Finding","code":"C48712","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases only in clinically detected ipsilateral internal mammary nodes and in the absence of clinically evident level I, II axillary lymph node metastases; for cutaneous melanoma it refers to macrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in seven or more regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2b","termGroup":"SY","termSource":"NCI"},{"termName":"N2b Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2b Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2b Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2b_Stage_Finding"},{"name":"Maps_To","value":"N2b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445080"}]}}{"C48713":{"preferredName":"N2c TNM Finding","code":"C48713","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2c TNM finding depends on the specific type of cancer that it refers to; for example, for cutaneous melanoma it refers to intralymphatic metastases (in transit or satellite metastases) without metastatic nodes; for lip and oral cavity cancer it refers to metastases in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2c","termGroup":"SY","termSource":"NCI"},{"termName":"N2c Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2c Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2c Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2c_Stage_Finding"},{"name":"Maps_To","value":"N2c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833426"}]}}{"C48714":{"preferredName":"N3 TNM Finding","code":"C48714","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes; for cutaneous melanoma it refers to metastases in 4 or more regional lymph nodes; for gastric cancer it refers to metastases in 7 or more regional lymph nodes; and for bladder cancer it refers to metastases in common iliac lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3","termGroup":"SY","termSource":"NCI"},{"termName":"N3 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3_Stage_Finding"},{"name":"Maps_To","value":"N3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441961"}]}}{"C48715":{"preferredName":"N3a TNM Finding","code":"C48715","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm) or metastases to the infraclavicular (level III axillary) lymph nodes; for gastric cancer it refers to metastases in 7-15 regional lymph nodes; for nasopharyngeal cancer it refers to metastases to one or more lymph nodes greater than 6 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3a","termGroup":"SY","termSource":"NCI"},{"termName":"N3a Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3a Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3a Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3a_Stage_Finding"},{"name":"Maps_To","value":"N3a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3831805"}]}}{"C48716":{"preferredName":"N3b TNM Finding","code":"C48716","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in clinically detected ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes, or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for gastric cancer it refers to metastases in sixteen or more regional lymph nodes; for nasopharyngeal cancer it refers to extension to the supraclavicular fossa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3b","termGroup":"SY","termSource":"NCI"},{"termName":"N3b Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3b Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3b Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3b_Stage_Finding"},{"name":"Maps_To","value":"N3b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833393"}]}}{"C48717":{"preferredName":"N3c TNM Finding","code":"C48717","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in ipsilateral supraclavicular lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3c","termGroup":"SY","termSource":"NCI"},{"termName":"N3c Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3c Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3c Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3c_Stage_Finding"},{"name":"Maps_To","value":"N3c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709110"}]}}{"C96026":{"preferredName":"N4 TNM Finding","code":"C96026","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N4 TNM finding depends on the specific type of cancer that it refers to; for example, for ocular adnexal lymphoma it refers to metastases to central lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N4 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0332382"}]}}{"C48718":{"preferredName":"NX TNM Finding","code":"C48718","definitions":[{"definition":"A regional lymph node TNM finding indicating that the status of regional lymph nodes cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NX TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"NX","termGroup":"SY","termSource":"NCI"},{"termName":"NX Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"NX Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"NX Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NX_Stage_Finding"},{"name":"Maps_To","value":"NX"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445085"}]}}{"C28051":{"preferredName":"Stage 0","code":"C28051","definitions":[{"definition":"Cancer confined to the epithelium without invasion of the basement membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0"},{"name":"Maps_To","value":"Stage 0"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441763"}]}}{"C27964":{"preferredName":"Stage 0a","code":"C27964","definitions":[{"definition":"Cancer confined to the epithelium with formation of papillary structures without invasion of the basement membrane or noninvasive localized squamous cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0a","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0a"},{"name":"Maps_To","value":"Stage 0a"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441764"}]}}{"C27965":{"preferredName":"Stage 0is","code":"C27965","definitions":[{"definition":"Cancer confined to the epithelium with formation of a flat surface without invasion of the basement membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0is","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0is"},{"name":"Maps_To","value":"Stage 0is"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441765"}]}}{"C27966":{"preferredName":"Stage I","code":"C27966","definitions":[{"definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage I","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_I"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441766"}]}}{"C27975":{"preferredName":"Stage IA","code":"C27975","definitions":[{"definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IA is defined as follows: T1, N0, M0. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IA is defined as follows: T1, N0, M0, G1, GX. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 8th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IA"},{"name":"Maps_To","value":"Stage IA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456595"}]}}{"C27983":{"preferredName":"Stage IA1","code":"C27983","definitions":[{"definition":"A stage term referring to invasive cervical and lung cancer.  For cervical cancer, it includes: T1a1, N0, M0.  T1a1: Tumor with stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IA1"},{"name":"Maps_To","value":"Stage IA1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0458828"}]}}{"C27984":{"preferredName":"Stage IA2","code":"C27984","definitions":[{"definition":"A stage term referring to invasive cervical cancer and invasive lung cancer. For cervical cancer, it includes: T1a2, N0, M0.  T1a2: Tumor with stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IA2"},{"name":"Maps_To","value":"Stage IA2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0458829"}]}}{"C27976":{"preferredName":"Stage IB","code":"C27976","definitions":[{"definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IB is defined as follows: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IB is defined as follows: (T2, N0, M0, G1, G2, GX); (T3, N0, M0, G1, G2, GX). T2: Tumor more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. G2: Moderately differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IB"},{"name":"Maps_To","value":"Stage IB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456597"}]}}{"C28052":{"preferredName":"Stage IB1","code":"C28052","definitions":[{"definition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0. (partially adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IB1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IB1"},{"name":"Maps_To","value":"Stage IB1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C1519505"}]}}{"C28053":{"preferredName":"Stage IB2","code":"C28053","definitions":[{"definition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b2, N0, M0.  (partially adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IB2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IB2"},{"name":"Maps_To","value":"Stage IB2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C1519506"}]}}{"C27981":{"preferredName":"Stage IC","code":"C27981","definitions":[{"definition":"A cancer stage generally indicating the local invasion of tissues by cancer at the primary site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IC"},{"name":"Maps_To","value":"Stage IC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456607"}]}}{"C28054":{"preferredName":"Stage II","code":"C28054","definitions":[{"definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage II","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_II"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441767"}]}}{"C27967":{"preferredName":"Stage IIA","code":"C27967","definitions":[{"definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIA is defined as follows: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIA is defined as follows: T1, N0, M0, G3, G4. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIA"},{"name":"Maps_To","value":"Stage IIA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441768"}]}}{"C95177":{"preferredName":"Stage IIA1","code":"C95177","definitions":[{"definition":"A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures 4.0 cm or less in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986966"}]}}{"C95178":{"preferredName":"Stage IIA2","code":"C95178","definitions":[{"definition":"A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures more than 4.0 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986967"}]}}{"C27968":{"preferredName":"Stage IIB","code":"C27968","definitions":[{"definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIB is defined as follows: (T2, N1, MO); (T3, NO, MO). T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIB is defined as follows: T2, N0, M0, G3, G4. T2: Tumor more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIB"},{"name":"Maps_To","value":"Stage IIB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441769"}]}}{"C27969":{"preferredName":"Stage IIC","code":"C27969","definitions":[{"definition":"A cancer stage generally indicating the invasion of adjacent structures by cancer without distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIC"},{"name":"Maps_To","value":"Stage IIC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441770"}]}}{"C27970":{"preferredName":"Stage III","code":"C27970","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage III","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_III"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441771"}]}}{"C27977":{"preferredName":"Stage IIIA","code":"C27977","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIIA"},{"name":"Maps_To","value":"Stage IIIA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456598"}]}}{"C27978":{"preferredName":"Stage IIIB","code":"C27978","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIIB"},{"name":"Maps_To","value":"Stage IIIB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456599"}]}}{"C27982":{"preferredName":"Stage IIIC","code":"C27982","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIC depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIC is defined as follows: Any T, N3, M0. N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for appendix carcinoma, stage IIIC is defined as follows: Any T, N2, M0. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIIC"},{"name":"Maps_To","value":"Stage IIIC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456608"}]}}{"C95179":{"preferredName":"Stage IIIC1","code":"C95179","definitions":[{"definition":"A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades the stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue. There is regional lymph node metastasis to the pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIC1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986968"}]}}{"C95180":{"preferredName":"Stage IIIC2","code":"C95180","definitions":[{"definition":"A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue.  There is regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIC2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986969"}]}}{"C28285":{"preferredName":"Stage IS","code":"C28285","definitions":[{"definition":"Testicular cancer found in the testicle, spermatic cord and scrotum, associated with slightly elevated levels of all tumor markers or moderately/highly elevated levels of one or more tumor markers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IS","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 1S","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_Is"},{"name":"Maps_To","value":"Stage IS"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0730490"}]}}{"C27971":{"preferredName":"Stage IV","code":"C27971","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IV","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_IV"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441772"}]}}{"C27979":{"preferredName":"Stage IVA","code":"C27979","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVA depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVA is defined as follows: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Distant metastasis to lung; for vaginal cancer, stage IVA is defined as follows: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IVA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IVA"},{"name":"Maps_To","value":"Stage IVA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456600"}]}}{"C27980":{"preferredName":"Stage IVB","code":"C27980","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVB depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVB is defined as follows: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis to other distant sites; for vaginal cancer, stage IVB is defined as follows: Any T, Any N, M1. M1: Distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IVB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IVB"},{"name":"Maps_To","value":"Stage IVB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456601"}]}}{"C28055":{"preferredName":"Stage IVC","code":"C28055","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVC depends on the particular type of cancer that it refers to; for example, for head and neck carcinomas (lip and oral cavity carcinoma, laryngeal carcinoma, nasal cavity and paranasal sinus carcinoma, pharynx carcinoma, thyroid gland carcinoma, and major salivary gland carcinoma) and head and neck mucosal melanoma, stage IVC is defined as follows: any T, any N, M1; for appendix carcinoma, stage IVC is defined as follows: any T, any N, M1b, any G. M1: Distant metastasis.  M1b: Nonperitoneal metastasis.  G: Grade (cellular differentiation).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IVC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IVC"},{"name":"Maps_To","value":"Stage IVC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441774"}]}}{"C48738":{"preferredName":"pTis TNM Finding","code":"C48738","definitions":[{"definition":"A term that refers to a TNM finding of a primary tumor microscopically defined as carcinoma in situ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pTis TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Tis","termGroup":"SY","termSource":"NCI"},{"termName":"Tis Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Tis TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Tis Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tis_Stage_Finding"},{"name":"Maps_To","value":"Stage Tis"},{"name":"Maps_To","value":"Tis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475413"}]}}{"C95957":{"preferredName":"Stage X","code":"C95957","definitions":[{"definition":"A stage term that is applied to patients who have not been evaluated, but are presumed to have cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage X","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage X"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272459"}]}}{"C136485":{"preferredName":"Stage IA3","code":"C136485","definitions":[{"definition":"A stage term referring to invasive lung cancer. It includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA3"},{"name":"NCI_META_CUI","value":"CL523788"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C48719":{"preferredName":"T0 TNM Finding","code":"C48719","definitions":[{"definition":"A primary tumor TNM finding indicating that there is no evidence of primary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T0 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T0","termGroup":"SY","termSource":"NCI"},{"termName":"T0 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T0 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T0_Stage_Finding"},{"name":"Maps_To","value":"T0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475371"}]}}{"C48720":{"preferredName":"T1 TNM Finding","code":"C48720","definitions":[{"definition":"A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1","termGroup":"SY","termSource":"NCI"},{"termName":"T1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1_Stage_Finding"},{"name":"Maps_To","value":"T1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475372"}]}}{"C48721":{"preferredName":"T1a TNM Finding","code":"C48721","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.1cm, but not more than 0.5 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is 4 cm or less in greatest dimension; and for thyroid cancer it refers to a primary tumor that is 1 cm or less in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1a","termGroup":"SY","termSource":"NCI"},{"termName":"T1a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1a_Stage_Finding"},{"name":"Maps_To","value":"T1a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475383"}]}}{"C188292":{"preferredName":"T1a1 Stage Finding","code":"C188292","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1a1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion equal or less than 3 mm in depth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1a1 Stage Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1a1","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Cancer Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Primary Tumor Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Stage","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Tumor Stage","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Stage T1a1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1a1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3846406"}]}}{"C188293":{"preferredName":"T1a2 Stage Finding","code":"C188293","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1a2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion of more than 3.0 mm and equal or less than 5.0 mm in depth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1a2 Stage Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1a2","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Cancer Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Primary Tumor Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Stage","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Tumor Stage","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Stage T1a2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1a2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3811917"}]}}{"C48722":{"preferredName":"T1b TNM Finding","code":"C48722","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is more than 4 cm, but not more than 7 cm in greatest dimension; and for thyroid cancer it refers to a primary tumor that is more than 1 cm but not more than 2 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1b","termGroup":"SY","termSource":"NCI"},{"termName":"T1b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1b_Stage_Finding"},{"name":"Maps_To","value":"T1b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475385"}]}}{"C188294":{"preferredName":"T1b1 TNM Finding","code":"C188294","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1b1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion measuring more than 5 mm in depth and equal or less than 2 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1b1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1b1","termGroup":"SY","termSource":"NCI"},{"termName":"T1b1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1b1 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1b1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3846407"}]}}{"C188295":{"preferredName":"T1b2 TNM Finding","code":"C188295","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1b2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates stromal invasion measuring more than 2 cm and equal or less than 4 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1b2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1b2","termGroup":"SY","termSource":"NCI"},{"termName":"T1b2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1b2 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1b2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3846408"}]}}{"C48723":{"preferredName":"T1c TNM Finding","code":"C48723","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1c","termGroup":"SY","termSource":"NCI"},{"termName":"T1c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1c_Stage_Finding"},{"name":"Maps_To","value":"T1c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3834244"}]}}{"C95805":{"preferredName":"T1mi TNM Finding","code":"C95805","definitions":[{"definition":"A term that refers to a TNM finding of a primary tumor limited to the site of growth and indicates microinvasion only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1mi TNM Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1mi"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869913"}]}}{"C48724":{"preferredName":"T2 TNM Finding","code":"C48724","definitions":[{"definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2","termGroup":"SY","termSource":"NCI"},{"termName":"T2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2_Stage_Finding"},{"name":"Maps_To","value":"T2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475373"}]}}{"C48725":{"preferredName":"T2a TNM Finding","code":"C48725","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 7 cm but less than or equal to 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the superficial muscularis propria (inner half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is no parametrial invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2a","termGroup":"SY","termSource":"NCI"},{"termName":"T2a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2a Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2a_Stage_Finding"},{"name":"Maps_To","value":"T2a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475387"}]}}{"C188296":{"preferredName":"T2a1 TNM Finding","code":"C188296","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T2a1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates involvement limited to the upper two-thirds of the vagina without parametrial invasion measuring 4.0 cm or less in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2a1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2a1","termGroup":"SY","termSource":"NCI"},{"termName":"T2a1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2a1 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2a1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869936"}]}}{"C188297":{"preferredName":"T2a2 TNM Finding","code":"C188297","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T2a2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates involvement limited to the upper two-thirds of the vagina without parametrial invasion measuring more than 4.0 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2a2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2a2","termGroup":"SY","termSource":"NCI"},{"termName":"T2a2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2a2 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2a2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869849"}]}}{"C48726":{"preferredName":"T2b TNM Finding","code":"C48726","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2b","termGroup":"SY","termSource":"NCI"},{"termName":"T2b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2b_Stage_Finding"},{"name":"Maps_To","value":"T2b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833471"}]}}{"C48727":{"preferredName":"T2c TNM Finding","code":"C48727","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to a primary tumor that involves both lobes of the prostate gland; for ovarian cancer it refers to a primary tumor that involves one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings; for fallopian tube cancer it refers to a primary tumor with pelvic extension and malignant cells in ascites or peritoneal washings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2c","termGroup":"SY","termSource":"NCI"},{"termName":"T2c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2c_Stage_Finding"},{"name":"Maps_To","value":"T2c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475389"}]}}{"C148411":{"preferredName":"T2d TNM Finding","code":"C148411","definitions":[{"definition":"A TNM stage finding term that refers to choroidal and ciliary body melanoma or conjunctival melanoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 2 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means caruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2d","termGroup":"SY","termSource":"NCI"},{"termName":"T2d Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2d Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3854130"}]}}{"C48728":{"preferredName":"T3 TNM Finding","code":"C48728","definitions":[{"definition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3","termGroup":"SY","termSource":"NCI"},{"termName":"T3 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3_Stage_Finding"},{"name":"Maps_To","value":"Minimal (T3)"},{"name":"Maps_To","value":"T3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475374"}]}}{"C48729":{"preferredName":"T3a TNM Finding","code":"C48729","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the renal vein or its segmental (muscle containing) branches or the tumor invades perirenal and/or renal sinus fat but does not extends beyond Gerota's fascia; for cervical cancer it refers to a primary tumor that involves the lower third of vagina, without extension to pelvic wall; for liver cancer it refers to the presence of multiple tumors measuring more than 5 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3a","termGroup":"SY","termSource":"NCI"},{"termName":"T3a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3a Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3a_Stage_Finding"},{"name":"Maps_To","value":"T3a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475390"}]}}{"C48730":{"preferredName":"T3b TNM Finding","code":"C48730","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava below the diaphragm; for cervical cancer it refers to a primary tumor that extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney; for liver cancer it refers to a single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3b","termGroup":"SY","termSource":"NCI"},{"termName":"T3b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3b_Stage_Finding"},{"name":"Maps_To","value":"T3b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475391"}]}}{"C48731":{"preferredName":"T3c TNM Finding","code":"C48731","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3c TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava above the diaphragm, or invades the wall of the vena cava; for fallopian tube cancer it refers to a primary tumor with peritoneal metastasis outside the pelvis measuring more than 2 cm in diameter; for melanoma of the conjunctiva it refers to a primary tumor invading the orbit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3c","termGroup":"SY","termSource":"NCI"},{"termName":"T3c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3c_Stage_Finding"},{"name":"Maps_To","value":"T3c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475394"}]}}{"C148412":{"preferredName":"T3d TNM Finding","code":"C148412","definitions":[{"definition":"A TNM finding term that refers to choroidal and ciliary body melanoma, conjunctival melanoma, or retinoblastoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 3 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. For retinoblastoma it means hyphema and/or massive vitreous hemorrhage (clinical) or full-thickness invasion into the outer third of the sclera and/or invasion into or around emissary channels (pathologic). (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3d","termGroup":"SY","termSource":"NCI"},{"termName":"T3d Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3d Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T3d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3854131"}]}}{"C48732":{"preferredName":"T4 TNM Finding","code":"C48732","definitions":[{"definition":"A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4","termGroup":"SY","termSource":"NCI"},{"termName":"T4 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4_Stage_Finding"},{"name":"Maps_To","value":"T4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475751"}]}}{"C48733":{"preferredName":"T4a TNM Finding","code":"C48733","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4a TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the prostatic stroma, uterus, and vagina; for gastric cancer it refers to a primary tumor that invades the serosa (visceral peritoneum); for colorectal cancer it refers to a primary tumor that penetrates to the surface of the visceral peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4a","termGroup":"SY","termSource":"NCI"},{"termName":"T4a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4a Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4a_Stage_Finding"},{"name":"Maps_To","value":"Moderate/Advanced (T4a)"},{"name":"Maps_To","value":"T4a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475395"}]}}{"C48734":{"preferredName":"T4b TNM Finding","code":"C48734","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4b TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the pelvic wall and abdominal wall; for gastric cancer it refers to a primary tumor that invades adjacent structures; for colorectal cancer it refers to a primary tumor with direct invasion or adherence to other organs or structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4b","termGroup":"SY","termSource":"NCI"},{"termName":"T4b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4b_Stage_Finding"},{"name":"Maps_To","value":"T4b"},{"name":"Maps_To","value":"Very Advanced (T4b)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475396"}]}}{"C48735":{"preferredName":"T4c TNM Finding","code":"C48735","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that extends to the chest wall, not including the pectoralis muscle, and with edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin nodules confined to the same breast; for ocular adnexal lymphoma it refers to a primary tumor that Involves the maxillofacial, ethmoidal, and/or frontal sinuses; for carcinoma of the conjunctiva it refers to a primary tumor that invades adjacent paranasal sinuses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4c","termGroup":"SY","termSource":"NCI"},{"termName":"T4c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4c_Stage_Finding"},{"name":"Maps_To","value":"T4c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475397"}]}}{"C48736":{"preferredName":"T4d TNM Finding","code":"C48736","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4d TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that meets the clinical-pathologic criteria of inflammatory carcinoma; for ocular adnexal lymphoma it refers to a primary tumor with intracranial spread; for carcinoma of the conjunctiva it refers to a primary tumor that invades the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4d","termGroup":"SY","termSource":"NCI"},{"termName":"T4d Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4d Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4d_Stage_Finding"},{"name":"Maps_To","value":"T4d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833423"}]}}{"C188298":{"preferredName":"T4e TNM Finding","code":"C188298","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4e TNM finding depends on the specific type of cancer that it refers: for example, for choroidal and ciliary body melanoma it indicates any tumor size category with extraocular extension more than 5 mm in largest diameter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4e TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4e","termGroup":"SY","termSource":"NCI"},{"termName":"T4e Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4e Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T4e"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C5703412"}]}}{"C48737":{"preferredName":"TX TNM Finding","code":"C48737","definitions":[{"definition":"A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TX TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"TX","termGroup":"SY","termSource":"NCI"},{"termName":"TX Primary Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TX_Stage_Finding"},{"name":"Maps_To","value":"TX"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0332377"}]}}{"C96025":{"preferredName":"pTa TNM Finding","code":"C96025","definitions":[{"definition":"A term that refers to a TNM finding of a primary, non-invasive, papillary cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pTa TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Ta TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ta"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272501"}]}}{"C139414":{"preferredName":"Breast Cancer pTis (DCIS) TNM Finding v8","code":"C139414","definitions":[{"definition":"Breast cancer with a finding of ductal carcinoma in situ. Lobular carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Cancer pTis (DCIS) TNM Finding v8","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Carcinoma pTis (DCIS) TNM Finding v8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tis (DCIS)"},{"name":"NCI_META_CUI","value":"CL526812"},{"name":"Semantic_Type","value":"Finding"}]}}{"C48976":{"preferredName":"Breast Cancer pTis (LCIS) TNM Finding v6 and v7","code":"C48976","definitions":[{"definition":"Breast cancer with a finding of lobular carcinoma in situ. (from AJCC 6th and 7th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Cancer pTis (LCIS) TNM Finding v6 and v7","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Cancer pTis (LCIS) TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer pTis (LCIS) TNM Finding v6","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer pTis (LCIS) TNM Finding v7","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Breast Cancer v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Breast Carcinoma v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Cancer of Breast v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Cancer of the Breast v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Carcinoma of Breast v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Carcinoma of the Breast v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Breast_Cancer_pTis_LCIS_TNM_Finding"},{"name":"Maps_To","value":"Tis (LCIS)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1707040"}]}}{"C47858":{"preferredName":"Breast Paget Disease without Invasive Carcinoma","code":"C47858","definitions":[{"definition":"Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease without Invasive Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Paget Disease of the Breast without Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast without Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tis (Paget)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_of_the_Breast_without_Invasive_Carcinoma"},{"name":"Maps_To","value":"Tis (Paget's)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709447"}]}}{"C188299":{"preferredName":"Stage M2","code":"C188299","definitions":[{"definition":"A stage term that refers to central nervous system embryonal tumor or ependymoma in which visible metastasis is present in the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage M2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M2"},{"name":"NCI_META_CUI","value":"CL1794622"},{"name":"Semantic_Type","value":"Classification"}]}}{"C188301":{"preferredName":"M1d TNM Finding","code":"C188301","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites. The definition of M1d TNM finding depends on the specific type of cancer to which it refers: for example, for cutaneous melanoma it indicates distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease. LDH level not recorded or unspecified.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1d","termGroup":"SY","termSource":"NCI"},{"termName":"M1d Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1d Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M1d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869910"}]}}{"C137676":{"preferredName":"Stage IIID","code":"C137676","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIID depends on the particular type of cancer that it refers to; for example, for cutaneous melanoma, stage IIID is defined as follows: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (partially adapted from AJCC 8th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIID","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIID"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3846374"}]}}{"C139980":{"preferredName":"Stage IIIA1","code":"C139980","definitions":[{"definition":"A stage term that applies to ovarian and fallopian tube carcinoma and indicates that the tumor is limited to ovaries (one or both) or fallopian tube(s) or the tumor involves one or both ovaries or fallopian tubes with pelvic extension below pelvic brim. There are positive retroperitoneal lymph nodes only (histologically confirmed) and no distant metastasis. (adapted from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1"},{"name":"NCI_META_CUI","value":"CL538160"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C139981":{"preferredName":"Stage IIIA2","code":"C139981","definitions":[{"definition":"A stage term that applies to ovarian and fallopian tube carcinoma and indicates the presence of microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. There is no distant metastasis. (adapted from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA2"},{"name":"NCI_META_CUI","value":"CL538159"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C139415":{"preferredName":"Breast Cancer pTis (Paget) TNM Finding v8","code":"C139415","definitions":[{"definition":"Paget disease of the nipple not associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted. (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Cancer pTis (Paget) TNM Finding v8","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Carcinoma pTis (Paget) TNM Finding v8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tis (Paget's)"},{"name":"NCI_META_CUI","value":"CL526811"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25509":{"preferredName":"First","code":"C25509","definitions":[{"definition":"Preceding all others in time or space or degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First","termGroup":"PT","termSource":"NCI"},{"termName":"Initial","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First"},{"name":"Maps_To","value":"1st"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205435"}]}}{"C25666":{"preferredName":"Second","code":"C25666","definitions":[{"definition":"Coming next after the first in position in space or time or degree or magnitude.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Second","termGroup":"PT","termSource":"NCI"},{"termName":"Second Ordinal","termGroup":"SY","termSource":"NCI"},{"termName":"Secondary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Second"},{"name":"Maps_To","value":"2nd"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205436"}]}}{"C25260":{"preferredName":"Third","code":"C25260","definitions":[{"definition":"Following the second position in an ordering or series; coming next after the second and just before the fourth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Third","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Third"},{"name":"Maps_To","value":"3rd"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205437"}]}}{"C191343":{"preferredName":"AJCC Cancer Staging Manual 4th Edition","code":"C191343","definitions":[{"definition":"AJCC Manual for Staging of Cancer 4th Edition (AJCC V4) (Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. AJCC manual for staging of cancer (4th ed). Philadelphia, PA: J.B. Lippincott; 1992). No part of the AJCC V4 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright J.B. Lippincott Company 1992. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"AJCC Manual for Staging of Cancer 4th Edition (AJCC V4) (Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. AJCC manual for staging of cancer (4th ed). Philadelphia, PA: J.B. Lippincott; 1992). No part of the AJCC V4 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright J.B. Lippincott Company 1992. All rights reserved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 4th Edition","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"4th"},{"name":"NCI_META_CUI","value":"CL1904801"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C191344":{"preferredName":"AJCC Cancer Staging Manual 5th Edition","code":"C191344","definitions":[{"definition":"AJCC Cancer Staging Manual 5th Edition (AJCC V5) (Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbo JW, editors. AJCC cancer staging manual (5th ed). Philadelphia, PA: Lippincott-Raven; 1997). No part of the AJCC V5 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Lippincott-Raven 1997. All rights reserved.","type":"DEFINITION","source":"NCI"},{"definition":"AJCC Cancer Staging Manual 5th Edition (AJCC V5) (Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbo JW, editors. AJCC cancer staging manual (5th ed). Philadelphia, PA: Lippincott-Raven; 1997). No part of the AJCC V5 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Lippincott-Raven 1997. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 5th Edition","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5th"},{"name":"NCI_META_CUI","value":"CL1904800"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C186612":{"preferredName":"AJCC Cancer Staging Manual 6th Edition","code":"C186612","definitions":[{"definition":"AJCC Cancer Staging Manual 6th Edition (AJCC V6) (Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. AJCC cancer staging manual (6th ed). New York, NY: Springer; 2002). No part of the AJCC V6 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Springer 2002. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The 6th edition of the criteria developed by the American Joint Committee on Cancer (AJCC) and used for the classification and staging of neoplastic diseases. It was published in 2002 and was in effect 2003-2009.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 6th Edition","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6th"},{"name":"NCI_META_CUI","value":"CL1778764"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C125755":{"preferredName":"AJCC Cancer Staging Manual 7th Edition","code":"C125755","definitions":[{"definition":"AJCC TNM Staging System 7th Edition (AJCC V7) (Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010). No part of the AJCC V7 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Springer 2010. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The 7th edition of the criteria developed by the American Joint Committee on Cancer (AJCC) in 2010, used for the classification and staging of neoplastic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 7th Edition","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC v7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"7th"},{"name":"NCI_META_CUI","value":"CL504410"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146985":{"preferredName":"AJCC Cancer Staging Manual 8th Edition","code":"C146985","definitions":[{"definition":"AJCC TNM Staging System 8th Edition (AJCC V8) (Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017. AJCC Cancer Staging Manual, Eighth Edition. Copyright 2017 American College of Surgeons. All rights reserved). No part of the AJCC V8 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright American College of Surgeons 2017. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The 8th edition of the criteria developed by the American Joint Committee on Cancer (AJCC), implemented in 2018, used for the classification and staging of neoplastic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 8th Edition","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC Ed. 8","termGroup":"SY","termSource":"NCI"},{"termName":"AJCC Edition 8","termGroup":"SY","termSource":"NCI"},{"termName":"AJCC v8","termGroup":"SY","termSource":"NCI"},{"termName":"American Joint Committee on Cancer Staging Manual, Edition 8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"8th"},{"name":"NCI_META_CUI","value":"CL544955"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C48190":{"preferredName":"Absent","code":"C48190","definitions":[{"definition":"Not existing in a specified place at a specified time.","type":"DEFINITION","source":"NCI"},{"definition":"Not existing in a specified place at a specified time. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Absent","termGroup":"PT","termSource":"NCI"},{"termName":"Not Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Absent"},{"name":"Maps_To","value":"Absent"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0332197"}]}}{"C14175":{"preferredName":"Diffuse","code":"C14175","definitions":[{"definition":"Widely spread; not localized or confined.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Widely spread; not localized or confined.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Widely spread; not localized or confined.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse"},{"name":"Maps_To","value":"Diffuse"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205219"}]}}{"C86071":{"preferredName":"Equivocal","code":"C86071","definitions":[{"definition":"Open to question.","type":"DEFINITION","source":"NCI"},{"definition":"Open to question.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Equivocal","termGroup":"PT","termSource":"NCI"},{"termName":"Questionable","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Equivocal"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0332241"}]}}{"C28224":{"preferredName":"Focal","code":"C28224","definitions":[{"definition":"In terms of cancer, limited to a specific area.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Limited to a specific area.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Limited to a specific area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Focal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Focal"},{"name":"Maps_To","value":"Focal"},{"name":"Semantic_Type","value":"Spatial Concept"},{"name":"UMLS_CUI","value":"C0205234"}]}}{"C36113":{"preferredName":"Anaplastic Lesion","code":"C36113","definitions":[{"definition":"A morphologic finding indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Lesion","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Anaplastic Change","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anaplastic_Lesion"},{"name":"Maps_To","value":"Anaplastic"},{"name":"Maps_To","value":"Present"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0002793"}]}}{"C69309":{"preferredName":"Sclerosis","code":"C69309","definitions":[{"definition":"A pathological hardening or thickening of tissue, especially that of the interstitial substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosis","termGroup":"PT","termSource":"NCI"},{"termName":"Sclerotic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sclerosis"},{"name":"Maps_To","value":"Sclerosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0036429"}]}}{"C125472":{"preferredName":"Ann Arbor Clinical Stage I","code":"C125472","definitions":[{"definition":"A clinical stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085956"}]}}{"C125474":{"preferredName":"Ann Arbor Clinical Stage II","code":"C125474","definitions":[{"definition":"A clinical stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085954"}]}}{"C125476":{"preferredName":"Ann Arbor Clinical Stage III","code":"C125476","definitions":[{"definition":"A clinical stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085953"}]}}{"C125478":{"preferredName":"Ann Arbor Clinical Stage IV","code":"C125478","definitions":[{"definition":"A clinical stage that refers to diffuse extralymphatic involvement by lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085955"}]}}{"C125473":{"preferredName":"Ann Arbor Pathologic Stage I","code":"C125473","definitions":[{"definition":"A pathologic stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085960"}]}}{"C125475":{"preferredName":"Ann Arbor Pathologic Stage II","code":"C125475","definitions":[{"definition":"A pathologic stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085958"}]}}{"C125477":{"preferredName":"Ann Arbor Pathologic Stage III","code":"C125477","definitions":[{"definition":"A pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085957"}]}}{"C125479":{"preferredName":"Ann Arbor Pathologic Stage IV","code":"C125479","definitions":[{"definition":"A pathologic stage that refers to diffuse extralymphatic involvement by lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085959"}]}}{"C15675":{"preferredName":"Adjuvant Therapy","code":"C15675","definitions":[{"definition":"Another treatment used together with the primary treatment. Its purpose is to assist the primary treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adjuvant Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Legacy Concept Name","value":"Adjuvant_Therapy"},{"name":"Maps_To","value":"Adjuvant Therapy"},{"name":"Maps_To","value":"AJ-Adjuvant Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0677850"}]}}{"C17747":{"preferredName":"Disease Progression","code":"C17747","definitions":[{"definition":"A disease, condition, or injury that is increasing in extent or severity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A process that manifests as the worsening of a disease over time.","type":"DEFINITION","source":"NCI"},{"definition":"An illness getting worse over time. (https://mrctcenter.org/glossaryterm/disease-progression/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"In medicine, the course of a disease, such as cancer, as it becomes worse or spreads in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Disease Progression","termGroup":"PT","termSource":"NCI"},{"termName":"Progression","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis."},{"name":"Legacy Concept Name","value":"Disease_Progression"},{"name":"Maps_To","value":"CPD-Clinical Progression"},{"name":"Maps_To","value":"Disease Progression"},{"name":"Maps_To","value":"Progression"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0242656"}]}}{"C4870":{"preferredName":"Complete Remission","code":"C4870","definitions":[{"definition":"The disappearance of all signs of cancer in response to treatment.","type":"DEFINITION","source":"NCI"},{"definition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disappearance of all signs of cancer in response to treatment. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Complete Remission","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer-Free","termGroup":"SY","termSource":"NCI"},{"termName":"CR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Complete_Remission"},{"name":"Maps_To","value":"Complete Response"},{"name":"Maps_To","value":"CR-Complete Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0677874"}]}}{"C165198":{"preferredName":"Complete Response Unconfirmed","code":"C165198","definitions":[{"definition":"An indication that a finding of complete response to treatment has not been confirmed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complete Response Unconfirmed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"CRU-Complete Response Unconfirmed"},{"name":"NCI_META_CUI","value":"CL978410"},{"name":"Semantic_Type","value":"Finding"}]}}{"C71687":{"preferredName":"Unchanged","code":"C71687","definitions":[{"definition":"In an unchanged or similar condition.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The status is unaltered or similar to the previous state.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unchanged","termGroup":"PT","termSource":"NCI"},{"termName":"About The Same","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"About_The_Same"},{"name":"Maps_To","value":"DU-Disease Unchanged"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2346711"}]}}{"C131144":{"preferredName":"Immunoresponse","code":"C131144","definitions":[{"definition":"A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoresponse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IMR-Immunoresponse"},{"name":"NCI_META_CUI","value":"CL514173"},{"name":"Semantic_Type","value":"Finding"}]}}{"C131143":{"preferredName":"Immunoprogression","code":"C131143","definitions":[{"definition":"A marked increase in contrast enhancement that is not due to actual tumor growth, but that may be due to a reaction to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoprogression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IPD-Immunoprogression"},{"name":"NCI_META_CUI","value":"CL514172"},{"name":"Semantic_Type","value":"Finding"}]}}{"C123598":{"preferredName":"Minimal Response","code":"C123598","definitions":[{"definition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","type":"DEFINITION","source":"NCI"},{"definition":"A finding that refers to hematologic and solid malignancies and indicates that there is a minor improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Minimal Response","termGroup":"PT","termSource":"NCI"},{"termName":"MR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MR-Minimal/Marginal Response"},{"name":"Maps_To","value":"MR-Minimal/Marginal response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4050513"}]}}{"C165202":{"preferredName":"Mixed Response","code":"C165202","definitions":[{"definition":"An indication that some disease characteristics are improving while others are worsening over time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Response","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed Response"},{"name":"Maps_To","value":"MX-Mixed Response"},{"name":"NCI_META_CUI","value":"CL978414"},{"name":"Semantic_Type","value":"Finding"}]}}{"C96700":{"preferredName":"Non Complete Response/Non Progressive Disease","code":"C96700","definitions":[{"definition":"Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (RECIST)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non Complete Response/Non Progressive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-CR/Non-PD-Non-CR/Non-PD"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272974"}]}}{"C165204":{"preferredName":"No Palliative Benefit","code":"C165204","definitions":[{"definition":"An indication that the treatment for a patient is not relieving symptoms or providing comfort.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Palliative Benefit","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NPB-No Palliative Benefit"},{"name":"NCI_META_CUI","value":"CL978416"},{"name":"Semantic_Type","value":"Finding"}]}}{"C123600":{"preferredName":"No Response","code":"C123600","definitions":[{"definition":"No apparent change or worsening in lesion staging classification.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"No apparent change or worsening in lesion staging classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Response","termGroup":"PT","termSource":"NCI"},{"termName":"NR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Response"},{"name":"Maps_To","value":"NR-No Response"},{"name":"NCI_META_CUI","value":"CL498430"},{"name":"Semantic_Type","value":"Finding"}]}}{"C15292":{"preferredName":"Palliative Therapy","code":"C15292","definitions":[{"definition":"The patient- and family-centered active holistic care of patients with advanced, progressive disease. Essential components of palliative care are: pain and symptom control, communication regarding treatment and alternatives, prognosis, and available services, rehabilitation services, care that addresses treatment and palliative concerns, intellectual, emotional, social, and spiritual needs, terminal care, support in bereavement. The goal of palliative care is an achievement of the best quality of life for patients and their families.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment given to relieve the symptoms and reduce the suffering caused by cancer and other life-threatening diseases. Palliative cancer therapies are given together with other cancer treatments, from the time of diagnosis, through treatment, survivorship, recurrent or advanced disease, and at the end of life.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Palliative Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Comfort Care","termGroup":"SY","termSource":"NCI"},{"termName":"Palliative Care","termGroup":"SY","termSource":"NCI"},{"termName":"Palliative Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Symptom Management","termGroup":"SY","termSource":"NCI"},{"termName":"Symptoms Management","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Palliative_Care"},{"name":"Maps_To","value":"PA-Palliative Therapy"},{"name":"Maps_To","value":"Palliative"},{"name":"Maps_To","value":"Palliative care"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0030231"}]}}{"C101516":{"preferredName":"Palliative","code":"C101516","definitions":[{"definition":"Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.","type":"DEFINITION","source":"NCI"},{"definition":"Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Palliative","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Maps_To","value":"PB-Palliative Benefit"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1285530"}]}}{"C8510":{"preferredName":"Progressive Neoplastic Disease","code":"C8510","definitions":[{"definition":"Cancer that is growing, spreading, or getting worse.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Progressive Neoplastic Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Legacy Concept Name","value":"Progressive_Neoplastic_Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0677932"}]}}{"C98298":{"preferredName":"Pseudoprogression","code":"C98298","definitions":[{"definition":"A radiologic finding observed during magnetic resonance imaging of brain glioblastoma, following concurrent radiotherapy and temozolomide treatment or vaccine therapy. It refers to the false positive finding of progression and enhancement of the lesion. It is considered a treatment effect due to tumor cell necrosis and subsequent edema formation and increased vascular permeability.","type":"DEFINITION","source":"NCI"},{"definition":"Apparent increase in lesion burden, not proven to be disease progression.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pseudoprogression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PPD-Pseudoprogression"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3273948"}]}}{"C18058":{"preferredName":"Partial Remission","code":"C18058","definitions":[{"definition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A finding indicating that there is a decrease based on a predetermined threshold in the size and the extent of tissue involvement by cancer.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Remission","termGroup":"PT","termSource":"NCI"},{"termName":"Partial Response","termGroup":"SY","termSource":"NCI"},{"termName":"PR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Partial_Remission"},{"name":"Maps_To","value":"Partial Response"},{"name":"Maps_To","value":"PR-Partial Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1521726"}]}}{"C131142":{"preferredName":"Pseudoresponse","code":"C131142","definitions":[{"definition":"A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to anti-angiogenic therapy or an increase in steroid dosage.","type":"DEFINITION","source":"NCI"},{"definition":"Apparent decrease in lesion burden, not proven to be favorable treatment response.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pseudoresponse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSR-Pseudoresponse"},{"name":"NCI_META_CUI","value":"CL513188"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165206":{"preferredName":"Responsive Disease","code":"C165206","definitions":[{"definition":"An indication that a patient's disease is responding to treatment.","type":"DEFINITION","source":"NCI"},{"definition":"In medicine, an improvement related to treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Responsive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RD-Responsive Disease"},{"name":"Maps_To","value":"RP-Response"},{"name":"NCI_META_CUI","value":"CL978418"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165208":{"preferredName":"Radiographic Progressive Disease","code":"C165208","definitions":[{"definition":"An indication that the radiographically detectable signs of disease are becoming more prominent over time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiographic Progressive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RPD-Radiographic Progressive Disease"},{"name":"NCI_META_CUI","value":"CL978420"},{"name":"Semantic_Type","value":"Finding"}]}}{"C123614":{"preferredName":"Stringent Complete Response","code":"C123614","definitions":[{"definition":"The confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the CR.","type":"DEFINITION","source":"NCI"},{"definition":"The disappearance of all signs of cancer, including the absence of molecular or cytogenetic markers of disease, supported by additional biochemical, immunological and histopathological analyses.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Stringent Complete Response","termGroup":"PT","termSource":"NCI"},{"termName":"sCR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"sCR-Stringent Complete Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4050416"}]}}{"C18213":{"preferredName":"Stable Disease","code":"C18213","definitions":[{"definition":"A disease that is neither decreasing nor increasing in extent or severity.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that is neither decreasing nor increasing in extent or severity based on predetermined boundaries. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that is neither decreasing nor increasing in extent or severity.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stable Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stable_Disease"},{"name":"Maps_To","value":"SD-Stable Disease"},{"name":"Maps_To","value":"Stable Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0677946"}]}}{"C133441":{"preferredName":"Too Early","code":"C133441","definitions":[{"definition":"At a point before the usual, expected, or specified time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Too Early","termGroup":"PT","termSource":"NCI"},{"termName":"Premature","termGroup":"SY","termSource":"NCI"},{"termName":"Too Soon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TE-Too Early"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C4018905"}]}}{"C123618":{"preferredName":"Very Good Partial Response","code":"C123618","definitions":[{"definition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Very Good Partial Response","termGroup":"PT","termSource":"NCI"},{"termName":"VGPR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Very Good Partial Response"},{"name":"Maps_To","value":"VGPR-Very Good Partial Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4053871"}]}}{"C27122":{"preferredName":"Endemic Burkitt Lymphoma","code":"C27122","definitions":[{"definition":"A clinical variant of Burkitt lymphoma that occurs in equatorial Africa.  The Epstein-Barr virus has been detected in all patients.  It is the most common malignancy of childhood in this area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endemic Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"African Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"African Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Endemic Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endemic_Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"Endemic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0343640"}]}}{"C27915":{"preferredName":"Immunodeficiency-Related Burkitt Lymphoma","code":"C27915","definitions":[{"definition":"Burkitt lymphoma in a patient with immunodeficiency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunodeficiency-Related Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Immunodeficiency Associated Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency Associated Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency Related Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency Related Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency-Associated Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency-Associated Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency-Related Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Immunodeficiency-Related_Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"Immunodeficiency-associated, adult"},{"name":"Maps_To","value":"Immunodeficiency-associated, pediatric"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334158"}]}}{"C27914":{"preferredName":"Sporadic Burkitt Lymphoma","code":"C27914","definitions":[{"definition":"A clinical variant of Burkitt lymphoma that occurs throughout the world.  It affects both children and adults and is more frequently seen in males.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sporadic Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sporadic Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sporadic_Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"Sporadic, adult"},{"name":"Maps_To","value":"Sporadic, pediatric"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336077"}]}}{"C113691":{"preferredName":"Child-Pugh Class A","code":"C113691","definitions":[{"definition":"Child-Pugh score indicating one-year survival of 100% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"A"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3831117"}]}}{"C146790":{"preferredName":"Child-Pugh Class A5","code":"C146790","definitions":[{"definition":"A total score of 5 for hepatic function, corresponding to class A in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class A5","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade A5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"A5"},{"name":"NCI_META_CUI","value":"CL544764"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146791":{"preferredName":"Child-Pugh Class A6","code":"C146791","definitions":[{"definition":"A total score of 6 for hepatic function, corresponding to class A in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class A6","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade A6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"A6"},{"name":"NCI_META_CUI","value":"CL544765"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C113692":{"preferredName":"Child-Pugh Class B","code":"C113692","definitions":[{"definition":"Child-Pugh score indicating one-year survival of 80% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3831116"}]}}{"C146792":{"preferredName":"Child-Pugh Class B7","code":"C146792","definitions":[{"definition":"A total score of 7 for hepatic function, corresponding to class B in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B7","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade B7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B7"},{"name":"NCI_META_CUI","value":"CL544766"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146793":{"preferredName":"Child-Pugh Class B8","code":"C146793","definitions":[{"definition":"A total score of 8 for hepatic function, corresponding to class B in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B8","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade B8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B8"},{"name":"NCI_META_CUI","value":"CL544767"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146794":{"preferredName":"Child-Pugh Class B9","code":"C146794","definitions":[{"definition":"A total score of 9 for hepatic function, corresponding to class B in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B9","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade B9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B9"},{"name":"NCI_META_CUI","value":"CL544768"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C113694":{"preferredName":"Child-Pugh Class C","code":"C113694","definitions":[{"definition":"Child-Pugh score indicating one-year survival of 45% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3831115"}]}}{"C146795":{"preferredName":"Child-Pugh Class C10","code":"C146795","definitions":[{"definition":"A total score of 10 for hepatic function, corresponding to class C in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C10","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade C10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C10"},{"name":"NCI_META_CUI","value":"CL544769"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146796":{"preferredName":"Child-Pugh Class C11","code":"C146796","definitions":[{"definition":"A total score of 11 for hepatic function, corresponding to class C in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C11","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade C11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C11"},{"name":"NCI_META_CUI","value":"CL544770"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146797":{"preferredName":"Child-Pugh Class C12","code":"C146797","definitions":[{"definition":"A total score of 12 for hepatic function, corresponding to class C in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C12","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade C12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C12"},{"name":"NCI_META_CUI","value":"CL544771"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C40557":{"preferredName":"Metastatic Lesion","code":"C40557","definitions":[{"definition":"A tumor arising at a location distant to the primary lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Lesion","termGroup":"PT","termSource":"NCI"},{"termName":"Metastases","termGroup":"SY","termSource":"NCI"},{"termName":"Metastasis","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Metastatic_Lesion"},{"name":"Maps_To","value":"metastasis"},{"name":"Maps_To","value":"Metastasis, NOS"},{"name":"Maps_To","value":"Metastatic"},{"name":"Maps_To","value":"Presented with Metastases"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1513183"}]}}{"C36032":{"preferredName":"Premalignant Neoplasm","code":"C36032","definitions":[{"definition":"A neoplasm that is composed of dysplastic cells and there is no morphologic evidence of infiltration of the surrounding tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Premalignant Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Premalignant_Neoplasm"},{"name":"Maps_To","value":"Premalignant"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335472"}]}}{"C8509":{"preferredName":"Primary Neoplasm","code":"C8509","definitions":[{"definition":"A tumor at the original site of origin.","type":"DEFINITION","source":"NCI"},{"definition":"The original tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Primary_Neoplasm"},{"name":"Maps_To","value":"primary"},{"name":"Maps_To","value":"Primary"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677930"}]}}{"C17609":{"preferredName":"Tumor Progression","code":"C17609","definitions":[{"definition":"A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a neoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Progression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The process of tumor progression is thought to be driven by clonal evolution. The initiating event is a mutation that gives a cell the ability to divide when it shouldn't.  As a result a small group of related cells, called a clone because they are identical to each other, grows. Clonal evolution occurs like a tree with mutations causing many clones to branch off continuously."},{"name":"Legacy Concept Name","value":"Tumor_Progression"},{"name":"Maps_To","value":"Progression"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0178874"}]}}{"C4798":{"preferredName":"Recurrent Neoplasm","code":"C4798","definitions":[{"definition":"The reemergence of a neoplasm after a period of remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recurrent Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm Recurrence","termGroup":"SY","termSource":"NCI"},{"termName":"Recurrent Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recurrent_Neoplasm"},{"name":"Maps_To","value":"recurrence"},{"name":"Maps_To","value":"Recurrence"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0521158"}]}}{"C54621":{"preferredName":"Synchronous Lesion","code":"C54621","definitions":[{"definition":"Two or more primary lesions that are diagnosed at the same time in the same patient, or soon after the diagnosis of the first primary lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synchronous Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synchronous_Lesion"},{"name":"Maps_To","value":"Synchronous primary"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1883252"}]}}{"C156806":{"preferredName":"New Primary Tumor","code":"C156806","definitions":[{"definition":"A finding indicating the development of a tumor in a patient with a history of a previously diagnosed tumor with a different histopathologic profile in another anatomic site as compared to the most recent one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"New Primary Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"New Primary"},{"name":"Maps_To","value":"Prior primary"},{"name":"NCI_META_CUI","value":"CL935850"},{"name":"Semantic_Type","value":"Finding"}]}}{"C102401":{"preferredName":"High Risk","code":"C102401","definitions":[{"definition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","type":"DEFINITION","source":"NCI"},{"definition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"High Risk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Risk"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0332167"}]}}{"C102402":{"preferredName":"Intermediate Risk","code":"C102402","definitions":[{"definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","type":"DEFINITION","source":"NCI"},{"definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intermediate Risk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate Risk"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C3640764"}]}}{"C102403":{"preferredName":"Low Risk","code":"C102403","definitions":[{"definition":"The potential future harm that may arise from some present action or attribute or condition is small.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The potential future harm that may arise from some present action or attribute or condition is small.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Risk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Risk"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C3538919"}]}}{"C140301":{"preferredName":"SIOP/COG/NWTSG Stage I","code":"C140301","definitions":[{"definition":"Wilms' tumor is limited to the kidney and completely excised; the tumor was not ruptured before or during removal; the vessels of the renal sinus are not involved beyond 2 mm; there is no residual tumor present beyond the margins of excision.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"NCI_META_CUI","value":"CL538470"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140303":{"preferredName":"SIOP/COG/NWTSG Stage II","code":"C140303","definitions":[{"definition":"Wilms' tumor extends beyond the kidney but is completely excised; no residual tumor is apparent at or beyond the margins of the excision; tumor thrombus in vessels outside the kidney is Stage II if the thrombus is removed en bloc with the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"NCI_META_CUI","value":"CL538468"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140305":{"preferredName":"SIOP/COG/NWTSG Stage III","code":"C140305","definitions":[{"definition":"Residual Wilms' tumor confined to the abdomen; Lymph nodes in the renal hilum, the periaortic chains, or beyond are found to contain tumor; diffuse peritoneal contamination by the tumor; implants are found on the peritoneal surfaces; tumor extends beyond the surgical margins either microscopically or grossly; tumor is not completely resectable because of local infiltration into vital structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"NCI_META_CUI","value":"CL538466"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140307":{"preferredName":"SIOP/COG/NWTSG Stage IV","code":"C140307","definitions":[{"definition":"Presence of hematogenous metastases or metastases to distant lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"NCI_META_CUI","value":"CL538464"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C188368":{"preferredName":"ELN Adverse-Risk Category","code":"C188368","definitions":[{"definition":"A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating unfavorable cytogenetics and a poor prognosis, which includes an unfavorable disease response to conventional consolidation therapy. In these cases, autologous or allogeneic hematopoietic stem cell transplantation is recommended.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Adverse-Risk Category","termGroup":"PT","termSource":"NCI"},{"termName":"ELN Adverse Risk Category","termGroup":"SY","termSource":"NCI"},{"termName":"ELN Adverse-Risk","termGroup":"SY","termSource":"NCI"},{"termName":"European LeukemiaNet Adverse Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adverse"},{"name":"NCI_META_CUI","value":"CL1793644"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C188369":{"preferredName":"ELN Favorable-Risk Category","code":"C188369","definitions":[{"definition":"A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating a favorable prognosis following conventional consolidation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Favorable-Risk Category","termGroup":"PT","termSource":"NCI"},{"termName":"ELN Favorable Risk Category","termGroup":"SY","termSource":"NCI"},{"termName":"ELN Favorable-Risk","termGroup":"SY","termSource":"NCI"},{"termName":"European LeukemiaNet Favorable Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Favorable"},{"name":"NCI_META_CUI","value":"CL1793643"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C188370":{"preferredName":"ELN Intermediate-Risk Category","code":"C188370","definitions":[{"definition":"A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating an intermediate chance for relapse following treatment and remission. Subjects in this risk group are recommended to receive conventional consolidation therapy followed by allogeneic hematopoietic stem cell transplantation to achieve remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Intermediate-Risk Category","termGroup":"PT","termSource":"NCI"},{"termName":"ELN Intermediate Risk Category","termGroup":"SY","termSource":"NCI"},{"termName":"ELN Intermediate-Risk","termGroup":"SY","termSource":"NCI"},{"termName":"European LeukemiaNet Intermediate Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate"},{"name":"NCI_META_CUI","value":"CL1794623"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140261":{"preferredName":"Enneking High Surgical Grade","code":"C140261","definitions":[{"definition":"A high-grade lesion, corresponding to Broder's Grades 3 and 4, having a higher incidence of metastasis and characterized histologically by mitotic figures, prominent nucleoli, and pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking High Surgical Grade","termGroup":"PT","termSource":"NCI"},{"termName":"G2","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS High Surgical Grade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Grade (G2)"},{"name":"NCI_META_CUI","value":"CL538400"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140260":{"preferredName":"Enneking Low Surgical Grade","code":"C140260","definitions":[{"definition":"A low-grade lesion, corresponding to Broder's Grades 1 or 2, with a low risk for distant spread (< 25%). These tumors are characterized by low mitotic rates, low nuclear to cytoplasmic ratio, and limited pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Low Surgical Grade","termGroup":"PT","termSource":"NCI"},{"termName":"G1","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS Low Surgical Grade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Grade (G1)"},{"name":"NCI_META_CUI","value":"CL538401"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C147528":{"preferredName":"Enneking Metastasis M0","code":"C147528","definitions":[{"definition":"No metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Metastasis M0","termGroup":"PT","termSource":"NCI"},{"termName":"M0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Metastasis (M0)"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3869912"}]}}{"C147529":{"preferredName":"Enneking Metastasis M1","code":"C147529","definitions":[{"definition":"Regional or distant metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Metastasis M1","termGroup":"PT","termSource":"NCI"},{"termName":"M1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regional or Distant Metastasis (M1)"},{"name":"NCI_META_CUI","value":"CL545425"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146701":{"preferredName":"Enneking Stage IA","code":"C146701","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by low grade (G1), intracomparmental site (T1), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA"},{"name":"NCI_META_CUI","value":"CL544728"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146702":{"preferredName":"Enneking Stage IB","code":"C146702","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by low grade (G1), extracomparmental site (T2), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB"},{"name":"NCI_META_CUI","value":"CL544729"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146703":{"preferredName":"Enneking Stage IIA","code":"C146703","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T1), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA"},{"name":"NCI_META_CUI","value":"CL544730"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146704":{"preferredName":"Enneking Stage IIB","code":"C146704","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T2), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIB"},{"name":"NCI_META_CUI","value":"CL544731"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146705":{"preferredName":"Enneking Stage III","code":"C146705","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by any grade, any site, and regional or distant metastasis (M1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"NCI_META_CUI","value":"CL544732"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140265":{"preferredName":"Extracompartmental Tumor","code":"C140265","definitions":[{"definition":"Bone tumors extend beyond the bone cortex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extracompartmental Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Extracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS Extracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"T2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extracompartmental (T2)"},{"name":"NCI_META_CUI","value":"CL545898"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140263":{"preferredName":"Intracompartmental Tumor","code":"C140263","definitions":[{"definition":"Bone tumors are confined within the cortex of the bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intracompartmental Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Intracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS Intracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"T1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intracompartmental (T1)"},{"name":"NCI_META_CUI","value":"CL541312"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C156083":{"preferredName":"High Grade Dysplasia","code":"C156083","definitions":[{"definition":"A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysplasia; high grade"},{"name":"Maps_To","value":"High Grade"},{"name":"Maps_To","value":"High Grade Dysplasia"},{"name":"NCI_META_CUI","value":"CL562934"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164039":{"preferredName":"Indefinite Dysplasia","code":"C164039","definitions":[{"definition":"An indication that there is an ambiguous morphological pattern in a tissue sample such that the presence or absence of dysplasia cannot be determined.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indefinite Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Indefinite for Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indefinite"},{"name":"Maps_To","value":"Indefinite for Dysplasia"},{"name":"NCI_META_CUI","value":"CL977191"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156084":{"preferredName":"Low Grade Dysplasia","code":"C156084","definitions":[{"definition":"A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be low.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysplasia; low grade"},{"name":"Maps_To","value":"Low Grade"},{"name":"Maps_To","value":"Low Grade Dysplasia"},{"name":"NCI_META_CUI","value":"CL562935"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164040":{"preferredName":"Dysplasia Negative","code":"C164040","definitions":[{"definition":"An indication that signs of dysplasia were not found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dysplasia Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Negative for Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"No Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Negative/ No Dysplasia"},{"name":"Maps_To","value":"No Dysplasia"},{"name":"NCI_META_CUI","value":"CL977190"},{"name":"Semantic_Type","value":"Finding"}]}}{"C96243":{"preferredName":"FIGO Stage 0","code":"C96243","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers and refers to carcinoma in situ.  For cervical cancer, it used to refer to cancer that is confined to the cervical epithelium without stromal invasion; for endometrial cancer, it used to refer to cancer that is confined to the endometrium without myometrial invasion.  FIGO no longer includes stage 0 cervical or endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 0"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272670"}]}}{"C96244":{"preferredName":"FIGO Stage I","code":"C96244","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is confined to the cervix; for endometrial cancer, it refers to cancer confined to the corpus uteri with no or less than one-half myometrial invasion (IA) or invasion of one-half or more of the myometrium (IB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage I","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272671"}]}}{"C96245":{"preferredName":"FIGO Stage IA","code":"C96245","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion has a maximum depth of 5.00 mm and a horizontal spread of 7.00 mm or less; for endometrial cancer, it refers to cancer limited to endometrium or invades less than one-half of the myometrium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272672"}]}}{"C96246":{"preferredName":"FIGO Stage IA1","code":"C96246","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion has a maximum depth of 3.00 mm and a horizontal spread of 7.00 mm or less; there is no FIGO stage IA1 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272673"}]}}{"C96247":{"preferredName":"FIGO Stage IA2","code":"C96247","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion is more than 3.00 mm but no more than 5.00 mm with a horizontal spread of 7.00 mm or less; there is no FIGO stage A2 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272674"}]}}{"C96248":{"preferredName":"FIGO Stage IB","code":"C96248","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is clinically visible and is confined to the cervix or it is diagnosed microscopically and the stromal invasion is more than 5.00 mm and the horizontal spread is more than 7.00 mm; for endometrial cancer, it refers to cancer that is confined to the uterine body and invades one-half or more of the myometrium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272675"}]}}{"C96249":{"preferredName":"FIGO Stage IB1","code":"C96249","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to clinically visible lesions that measure 4.0 cm or less in diameter; there is no FIGO stage IB1 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IB1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272676"}]}}{"C96250":{"preferredName":"FIGO Stage IB2","code":"C96250","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to clinically visible lesions that measure more than 4.0 cm in diameter; there is no FIGO stage IB2 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IB2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272677"}]}}{"C96251":{"preferredName":"FIGO Stage IC","code":"C96251","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, there is no FIGO stage IC; for endometrial cancer, in the older FIGO classification stage scheme, it referred to invasion of more than a half of the myometrium.  Stage IC for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272678"}]}}{"C128099":{"preferredName":"FIGO Stage IC1","code":"C128099","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with surgical spill.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC1"},{"name":"NCI_META_CUI","value":"CL508831"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128100":{"preferredName":"FIGO Stage IC2","code":"C128100","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with capsule rupture before surgery or tumor on ovarian surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC2"},{"name":"NCI_META_CUI","value":"CL508833"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128101":{"preferredName":"FIGO Stage IC3","code":"C128101","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with malignant cells in the ascites or peritoneal washings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC3"},{"name":"NCI_META_CUI","value":"CL508835"},{"name":"Semantic_Type","value":"Classification"}]}}{"C96252":{"preferredName":"FIGO Stage II","code":"C96252","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina; for endometrial cancer, it refers to cancer that invades the stromal connective tissue of the cervix, but it does not extend beyond the uterus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage II","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272679"}]}}{"C96253":{"preferredName":"FIGO Stage IIA","code":"C96253","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina and there is no parametrial invasion; for endometrial cancer, in the older FIGO classification stage scheme, it referred to endocervical glandular involvement only.  Stage IIA for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272680"}]}}{"C162223":{"preferredName":"FIGO Stage IIA1","code":"C162223","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, less than 4 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA1"},{"name":"NCI_META_CUI","value":"CL970741"},{"name":"Semantic_Type","value":"Classification"}]}}{"C162224":{"preferredName":"FIGO Stage IIA2","code":"C162224","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA2"},{"name":"NCI_META_CUI","value":"CL970753"},{"name":"Semantic_Type","value":"Classification"}]}}{"C96254":{"preferredName":"FIGO Stage IIB","code":"C96254","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina and there is parametrial invasion; for endometrial cancer, in the older FIGO classification stage scheme, it referred to cervical stromal invasion.  Stage IIB for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272681"}]}}{"C96255":{"preferredName":"FIGO Stage III","code":"C96255","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that extends to the pelvic wall, and/or involves the lower third of vagina, and/or causes hydronephrosis or non-functioning kidney; for endometrial cancer, FIGO stage III is subdivided into stages IIIA and IIIB; in FIGO stage IIIA, there is involvement of the serosa and/or the adnexa; for FIGO stage IIIB, there is vaginal or parametrial involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage III","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272682"}]}}{"C96256":{"preferredName":"FIGO Stage IIIA","code":"C96256","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that involves the lower third of vagina and there is no extension to the pelvic wall; for endometrial cancer, it refers to cancer with involvement of the serosa and/or the adnexa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272683"}]}}{"C128102":{"preferredName":"FIGO Stage IIIA1","code":"C128102","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1"},{"name":"NCI_META_CUI","value":"CL508844"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128105":{"preferredName":"FIGO Stage IIIA2","code":"C128105","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with microscopic, extrapelvic (above the brim) peritoneal involvement +/- positive retroperitoneal lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA2"},{"name":"NCI_META_CUI","value":"CL508846"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128103":{"preferredName":"FIGO Stage IIIA1(i)","code":"C128103","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA1(i)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1(i)"},{"name":"NCI_META_CUI","value":"CL508841"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128104":{"preferredName":"FIGO Stage IIIA1(ii)","code":"C128104","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA1(ii)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1(ii)"},{"name":"NCI_META_CUI","value":"CL508843"},{"name":"Semantic_Type","value":"Classification"}]}}{"C96257":{"preferredName":"FIGO Stage IIIB","code":"C96257","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that extends to the pelvic wall, and/or causes hydronephrosis or non-functioning kidney; for endometrial cancer, it refers to cancer with vaginal or parametrial involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272684"}]}}{"C96258":{"preferredName":"FIGO Stage IIIC","code":"C96258","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  There is no FIGO stage IIIC for cervical cancer; for endometrial cancer, FIGO stage IIIC is subdivided into stages IIIC1 and IIIC2; in FIGO stage IIIC1, there is regional metastasis to pelvic lymph nodes; for FIGO stage IIIC2, there is regional metastasis to para-aortic lymph nodes with or without metastasis to pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272685"}]}}{"C96259":{"preferredName":"FIGO Stage IIIC1","code":"C96259","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  There is no FIGO stage IIIC1 for cervical cancer; for endometrial cancer, it refers to regional metastasis to pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIC1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272686"}]}}{"C96260":{"preferredName":"FIGO Stage IIIC2","code":"C96260","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  There is no FIGO stage IIIC2 for cervical cancer; for endometrial cancer, it refers to regional metastasis to para-aortic lymph nodes with or without metastasis to pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIC2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272687"}]}}{"C96261":{"preferredName":"FIGO Stage IV","code":"C96261","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades the mucosa of bladder or rectum, and/or extends beyond the true pelvis (FIGO stage IVA), or to cancer with distant metastases (FIGO stage IVB); for endometrial cancer, it refers to cancer that invades the bladder mucosa and/or the bowel mucosa (FIGO stage IVA), or to cancer with distant metastases (FIGO stage IVB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IV","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272688"}]}}{"C96262":{"preferredName":"FIGO Stage IVA","code":"C96262","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades the mucosa of bladder or rectum, and/or extends beyond the true pelvis; for endometrial cancer, it refers to cancer that invades the bladder mucosa and/or the bowel mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IVA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272689"}]}}{"C96263":{"preferredName":"FIGO Stage IVB","code":"C96263","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer with distant metastases, including peritoneal involvement, involvement of the supraclavicular or mediastinal lymph nodes, and metastases to the lung, bone, or liver; for endometrial cancer, it refers to cancer with distant metastases, including metastases to the inguinal lymph nodes, intraperitoneal involvement, or metastases to the lung, bone, or liver.  Endometrial cancer metastases to the para-aortic lymph nodes, vagina, adnexa, or pelvic serosa are excluded from this stage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IVB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272690"}]}}{"C121628":{"preferredName":"Altered Mental Status","code":"C121628","definitions":[{"definition":"A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Altered Mental Status","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Altered Mental Status"},{"name":"Maps_To","value":"Mental status changes"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0278061"}]}}{"C34661":{"preferredName":"Headache","code":"C34661","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Head pain or discomfort.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Pain in any region of the head.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Pain in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Pain in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Pain in various parts of the head, not confined to the area of distribution of any nerve.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Headache","termGroup":"PT","termSource":"NCI"},{"termName":"Cephalalgia","termGroup":"SY","termSource":"NCI"},{"termName":"Cephalgia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Headache"},{"name":"Maps_To","value":"Headache"},{"name":"Maps_To","value":"Headaches"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0018681"},{"name":"xRef","value":"IMDRF:E0116"}]}}{"C157433":{"preferredName":"Motor / Movement Change","code":"C157433","definitions":[{"definition":"An alteration in the motor/movement of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motor / Movement Change","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Motor / Movement Change"},{"name":"Maps_To","value":"Motor or Movement Changes"},{"name":"NCI_META_CUI","value":"CL937125"},{"name":"Semantic_Type","value":"Finding"}]}}{"C2962":{"preferredName":"Seizure","code":"C2962","definitions":[{"definition":"A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A paroxysmal surge of electrical activity in the brain that may result in physical or behavioral changes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Convulsion; a sudden, involuntary movement of the muscles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Convulsions, sensory, cognitive disturbances, or loss of consciousness resulting from abnormal electrical discharges in the brain in a patient with probable or confirmed COVID-19.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seizure","termGroup":"PT","termSource":"NCI"},{"termName":"Convulsion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Seizure"},{"name":"Maps_To","value":"Other convulsions"},{"name":"Maps_To","value":"Seizure"},{"name":"Maps_To","value":"Seizures"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2748942"},{"name":"xRef","value":"IMDRF:E0109"}]}}{"C157429":{"preferredName":"Sensory Change","code":"C157429","definitions":[{"definition":"An alteration in the perceptual senses an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sensory Change","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sensory Changes"},{"name":"NCI_META_CUI","value":"CL937129"},{"name":"Semantic_Type","value":"Finding"}]}}{"C157424":{"preferredName":"Visual Change","code":"C157424","definitions":[{"definition":"An alteration in the visual system of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Visual Change","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vision Changes"},{"name":"Maps_To","value":"Visual Changes"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0750280"}]}}{"C137992":{"preferredName":"Gleason Grade Group 1","code":"C137992","definitions":[{"definition":"Gleason grade defined by Gleason score less than or equal to 6. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 1","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 1"},{"name":"NCI_META_CUI","value":"CL525030"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137993":{"preferredName":"Gleason Grade Group 2","code":"C137993","definitions":[{"definition":"Gleason grade defined by Gleason score 3+4=7. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 2","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 2"},{"name":"NCI_META_CUI","value":"CL525029"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137994":{"preferredName":"Gleason Grade Group 3","code":"C137994","definitions":[{"definition":"Gleason grade defined by Gleason score 4+3=7. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 3","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 3"},{"name":"NCI_META_CUI","value":"CL525028"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137995":{"preferredName":"Gleason Grade Group 4","code":"C137995","definitions":[{"definition":"Gleason grade defined by Gleason score 4+4=8, Gleason score 3+5=8, or Gleason score 5+3=8. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 4","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 4"},{"name":"NCI_META_CUI","value":"CL525035"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137996":{"preferredName":"Gleason Grade Group 5","code":"C137996","definitions":[{"definition":"Gleason grade defined by Gleason score 9-10. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 5","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 5"},{"name":"NCI_META_CUI","value":"CL525034"},{"name":"Semantic_Type","value":"Classification"}]}}{"C28088":{"preferredName":"Gleason Pattern 4","code":"C28088","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of fused, cribriform, or poorly defined glands. There is partial loss of normal epithelial polarity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 4","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_4"},{"name":"Maps_To","value":"Pattern 4"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0332329"}]}}{"C28089":{"preferredName":"Gleason Pattern 5","code":"C28089","definitions":[{"definition":"A pattern of prostate carcinoma characterized by almost complete loss of epithelial polarity and luminal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 5","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_5"},{"name":"Maps_To","value":"Pattern 5"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276443"}]}}{"C177313":{"preferredName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Good","code":"C177313","definitions":[{"definition":"The good prognosis category refers to any primary site and no nonpulmonary visceral metastases and normal AFP, any hCG, any LDH.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Good","termGroup":"PT","termSource":"NCI"},{"termName":"Seminoma IGCCC, Good","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Good Prognosis"},{"name":"NCI_META_CUI","value":"CL1643274"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177310":{"preferredName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Good","code":"C177310","definitions":[{"definition":"The good prognosis category refers to testes/retroperitoneal primary and no nonpulmonary visceral metastases and the following markers: AFP less than 1,000 ng/mL, hCG less than 5,000 IU/L and LDH less than 1.5 x ULN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Good","termGroup":"PT","termSource":"NCI"},{"termName":"NSGCT IGCCC, Good","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Good Prognosis"},{"name":"NCI_META_CUI","value":"CL1643273"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177314":{"preferredName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Intermediate","code":"C177314","definitions":[{"definition":"The intermediate prognosis category refers to any primary site and nonpulmonary visceral metastases and normal AFP, any hCG, any LDH.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Intermediate","termGroup":"PT","termSource":"NCI"},{"termName":"Seminoma IGCCC, Intermediate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate Prognosis"},{"name":"NCI_META_CUI","value":"CL1643277"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177311":{"preferredName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Intermediate","code":"C177311","definitions":[{"definition":"The intermediate risk group refers to testes/retroperitoneal primary and no nonpulmonary visceral metastases and the following markers: AFP greater than or equal to 1,000 ng/mL and less than or equal to 10,000 ng/mL, or hCG greater than or equal to 5,000 IU/L and less than or equal to 50,000 ng/mL or LDH greater than or equal to 1.5 x ULN and less than or equal to 10 x ULN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Intermediate","termGroup":"PT","termSource":"NCI"},{"termName":"NSGCT IGCCC, Intermediate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Intermediate Prognosis"},{"name":"NCI_META_CUI","value":"CL1643272"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177312":{"preferredName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Poor","code":"C177312","definitions":[{"definition":"The poor prognosis category refers to mediastinal primary or nonpulmonary visceral metastases or markers with the following: AFP greater than 10,000 ng/mL or hCG  greater than 50,000 IU/L or LDH greater than 10 x ULN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Poor","termGroup":"PT","termSource":"NCI"},{"termName":"NSGCT IGCCC, Poor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Poor Prognosis"},{"name":"NCI_META_CUI","value":"CL1643275"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C42048":{"preferredName":"Differentiating Neuroblastoma","code":"C42048","definitions":[{"definition":"A neuroblastoma in which the differentiating neuroblasts constitute more than five-percent of the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Differentiating Neuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Differentiating_Neuroblastoma"},{"name":"Maps_To","value":"Differentiating"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511934"}]}}{"C42047":{"preferredName":"Poorly Differentiated Neuroblastoma","code":"C42047","definitions":[{"definition":"A neuroblastoma in which the differentiating neuroblasts constitute less than five-percent of the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Neuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Neuroblastoma"},{"name":"Maps_To","value":"Poorly Differentiated"},{"name":"Maps_To","value":"Undifferentiated or Poorly Differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1514225"}]}}{"C42046":{"preferredName":"Undifferentiated Neuroblastoma","code":"C42046","definitions":[{"definition":"A neuroblastoma characterized by the absence of differentiating neuroblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Neuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Undifferentiated_Neuroblastoma"},{"name":"Maps_To","value":"Undifferentiated"},{"name":"Maps_To","value":"Undifferentiated or Poorly Differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519787"}]}}{"C102560":{"preferredName":"Favorable","code":"C102560","definitions":[{"definition":"Expressing something as positive, advantageous or desired.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Favorable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Favorable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3640814"}]}}{"C102561":{"preferredName":"Unfavorable","code":"C102561","definitions":[{"definition":"Expressing something as negative, undesired or adverse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unfavorable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unfavorable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3640815"}]}}{"C133428":{"preferredName":"INRG Stage L1","code":"C133428","definitions":[{"definition":"Locoregional neuroblastoma without image defined risk factors (IDRFs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage L1","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"L1"},{"name":"NCI_META_CUI","value":"CL520040"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C133429":{"preferredName":"INRG Stage L2","code":"C133429","definitions":[{"definition":"Locoregional neuroblastoma with one or more image defined risk factors (IDRFs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage L2","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage L2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"L2"},{"name":"NCI_META_CUI","value":"CL520041"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C133430":{"preferredName":"INRG Stage M","code":"C133430","definitions":[{"definition":"Neuroblastoma with distant metastatic disease (except MS).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage M","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage M","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M"},{"name":"NCI_META_CUI","value":"CL520043"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C133431":{"preferredName":"INRG Stage MS","code":"C133431","definitions":[{"definition":"INRG stage L1 or L2 neuroblastoma with metastatic disease confined to the skin and/or liver and/or bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage MS","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage MS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ms"},{"name":"NCI_META_CUI","value":"CL520042"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C85417":{"preferredName":"INSS Stage 1","code":"C85417","definitions":[{"definition":"The tumor is confined to the original site of growth; no metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 1"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827642"}]}}{"C85418":{"preferredName":"INSS Stage 2A","code":"C85418","definitions":[{"definition":"The tumor is unilateral and the resection is grossly incomplete; no evidence of lymph node involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 2A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 2A"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827643"}]}}{"C85419":{"preferredName":"INSS Stage 2B","code":"C85419","definitions":[{"definition":"The tumor is unilateral and the resection is complete or incomplete; ipsilateral lymph nodes are involved by tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 2B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 2B"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827644"}]}}{"C85420":{"preferredName":"INSS Stage 3","code":"C85420","definitions":[{"definition":"The tumor extends across the midline and the regional lymph nodes may or may not be involved by tumor; or the tumor is unilateral and the contralateral lymph nodes are involved by tumor; or the tumor is in midline and there is bilateral lymph node involvement by tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 3"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827645"}]}}{"C85421":{"preferredName":"INSS Stage 4","code":"C85421","definitions":[{"definition":"Tumor spread to distant lymph nodes, bone marrow, bones, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 4","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 4"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827646"}]}}{"C85422":{"preferredName":"INSS Stage 4S","code":"C85422","definitions":[{"definition":"Patients are less than one year old with localized primary tumor and dissemination limited to the following specific anatomic sites: liver, skin, or bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 4S","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 4S"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827647"}]}}{"C161806":{"preferredName":"International Prognostic Index Low Risk Group","code":"C161806","definitions":[{"definition":"A risk group associated with a total score of 0 or 1 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 73%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index Low Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"IPI Low Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI Low Risk Group","termGroup":"SY","termSource":"NCI"},{"termName":"Low Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Risk"},{"name":"NCI_META_CUI","value":"CL970425"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C161807":{"preferredName":"International Prognostic Index Low-Intermediate Risk Group","code":"C161807","definitions":[{"definition":"A risk group associated with a total score of 2 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 69%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index Low-Intermediate Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"IPI Low-Intermediate Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI Low-Intermediate Risk Group","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Intermediate Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low-Intermediate Risk"},{"name":"NCI_META_CUI","value":"CL970424"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C161808":{"preferredName":"International Prognostic Index High-Intermediate Risk Group","code":"C161808","definitions":[{"definition":"A risk group associated with a total score of 3 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 46%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index High-Intermediate Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"High-Intermediate Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI High-Intermediate Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI High-Intermediate Risk Group","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High-Intermediate Risk"},{"name":"NCI_META_CUI","value":"CL970423"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C161809":{"preferredName":"International Prognostic Index High Risk Group","code":"C161809","definitions":[{"definition":"A risk group associated with a total score of 4 or 5 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 32%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index High Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"High Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI High Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI Low High Group","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Risk"},{"name":"NCI_META_CUI","value":"CL970375"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148012":{"preferredName":"Intergroup Rhabdomyosarcoma Group I","code":"C148012","definitions":[{"definition":"Localized disease, excised.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group I","termGroup":"PT","termSource":"NCI"},{"termName":"Group I","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group I"},{"name":"NCI_META_CUI","value":"CL546054"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148013":{"preferredName":"Intergroup Rhabdomyosarcoma Group Ia","code":"C148013","definitions":[{"definition":"Confined to site of origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group Ia","termGroup":"PT","termSource":"NCI"},{"termName":"Group Ia","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group Ia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group Ia"},{"name":"NCI_META_CUI","value":"CL545835"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148014":{"preferredName":"Intergroup Rhabdomyosarcoma Group Ib","code":"C148014","definitions":[{"definition":"Infiltrative, beyond site of origin; negative lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group Ib","termGroup":"PT","termSource":"NCI"},{"termName":"Group Ib","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group Ib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group Ib"},{"name":"NCI_META_CUI","value":"CL545836"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148015":{"preferredName":"Intergroup Rhabdomyosarcoma Group II","code":"C148015","definitions":[{"definition":"Total gross resection with regional disease spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group II","termGroup":"PT","termSource":"NCI"},{"termName":"Group II","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group II"},{"name":"NCI_META_CUI","value":"CL545823"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148016":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIa","code":"C148016","definitions":[{"definition":"Localized tumor with microscopic residual disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIa","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIa","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIa"},{"name":"NCI_META_CUI","value":"CL545824"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148017":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIb","code":"C148017","definitions":[{"definition":"Regional disease with positive lymph nodes, excised.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIb","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIb","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIb"},{"name":"NCI_META_CUI","value":"CL545825"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148018":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIc","code":"C148018","definitions":[{"definition":"Regional disease with positive lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIc","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIc","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIc","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIc"},{"name":"NCI_META_CUI","value":"CL545826"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148019":{"preferredName":"Intergroup Rhabdomyosarcoma Group III","code":"C148019","definitions":[{"definition":"Gross residual disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group III","termGroup":"PT","termSource":"NCI"},{"termName":"Group III","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group III"},{"name":"NCI_META_CUI","value":"CL545827"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148020":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIIa","code":"C148020","definitions":[{"definition":"Localized or regional disease; biopsy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIIa","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIIa","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIIa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIIa"},{"name":"NCI_META_CUI","value":"CL545828"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148021":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIIb","code":"C148021","definitions":[{"definition":"Localized or regional disease; resection (debulking of more than 50% of tumor).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIIb","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIIb","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIIb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIIb"},{"name":"NCI_META_CUI","value":"CL545829"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148022":{"preferredName":"Intergroup Rhabdomyosarcoma Group IV","code":"C148022","definitions":[{"definition":"Distant metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IV","termGroup":"PT","termSource":"NCI"},{"termName":"Group IV","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IV"},{"name":"NCI_META_CUI","value":"CL545830"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C95150":{"preferredName":"Ishak Score 0","code":"C95150","definitions":[{"definition":"No evidence of fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0 - No Fibrosis"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C2986946"}]}}{"C157159":{"preferredName":"Ishak Score 1-2","code":"C157159","definitions":[{"definition":"Portal fibrosis is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 1-2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1,2 - Portal Fibrosis"},{"name":"NCI_META_CUI","value":"CL936900"},{"name":"Semantic_Type","value":"Classification"}]}}{"C157161":{"preferredName":"Ishak Score 3-4","code":"C157161","definitions":[{"definition":"Fibrosis extends beyond the portal areas and bridging fibrosis is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 3-4","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3,4 - Fibrous Septa"},{"name":"NCI_META_CUI","value":"CL936896"},{"name":"Semantic_Type","value":"Classification"}]}}{"C95155":{"preferredName":"Ishak Score 5","code":"C95155","definitions":[{"definition":"Marked bridging fibrosis with formation of occasional hepatic nodules is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 5","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5 - Nodular Formation and Incomplete Cirrhosis"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C2986951"}]}}{"C95156":{"preferredName":"Ishak Score 6","code":"C95156","definitions":[{"definition":"Marked fibrosis with cirrhosis is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 6","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6 - Established Cirrhosis"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C2986952"}]}}{"C70658":{"preferredName":"ISS Stage I Multiple Myeloma","code":"C70658","definitions":[{"definition":"Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS Stage I Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"International Staging System Stage I Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"International Staging System Stage I Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"ISS Stage I Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Myeloma Stage I","termGroup":"SY","termSource":"NCI"},{"termName":"Stage I Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage I Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ISS_Stage_I_Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"I"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2346458"}]}}{"C70659":{"preferredName":"ISS Stage II Multiple Myeloma","code":"C70659","definitions":[{"definition":"Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS Stage II Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"International Staging System Stage II Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"International Staging System Stage II Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"ISS Stage II Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Myeloma Stage II","termGroup":"SY","termSource":"NCI"},{"termName":"Stage II Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage II Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ISS_Stage_II_Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"II"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2346457"}]}}{"C70660":{"preferredName":"ISS Stage III Multiple Myeloma","code":"C70660","definitions":[{"definition":"Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS Stage III Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"International Staging System Stage III Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"International Staging System Stage III Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"ISS Stage III Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Myeloma Stage III","termGroup":"SY","termSource":"NCI"},{"termName":"Stage III Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage III Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ISS_Stage_III_Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2346456"}]}}{"C53696":{"preferredName":"Lesion with Diameter of 2 cm or Less","code":"C53696","synonyms":[{"termName":"Lesion with Diameter of 2 cm or Less","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesion_with_Diameter_of_2cm_or_Less"},{"name":"Maps_To","value":"Macroscopic (2cm or less)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1708687"}]}}{"C51138":{"preferredName":"Lesion with Diameter Greater than 2 cm","code":"C51138","synonyms":[{"termName":"Lesion with Diameter Greater than 2 cm","termGroup":"PT","termSource":"NCI"},{"termName":"Lesion with Diameter of More than 2 cm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesion_with_Diameter_of_More_than_2cm"},{"name":"Maps_To","value":"Macroscopic (greater than 2cm)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1708689"}]}}{"C25252":{"preferredName":"Microscopic","code":"C25252","definitions":[{"definition":"Too small to be seen except under a microscope.","type":"DEFINITION","source":"NCI"},{"definition":"Too small to be seen without a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Microscopic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microscopic"},{"name":"Maps_To","value":"Micro"},{"name":"Maps_To","value":"Microscopic"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0205288"}]}}{"C35933":{"preferredName":"Distantly Metastatic Malignant Neoplasm","code":"C35933","definitions":[{"definition":"A malignant tumor that has spread from its original (primary) site of growth to another site distant from the primary site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Distantly Metastatic Malignant Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Distantly_Metastatic_Neoplasm"},{"name":"Maps_To","value":"Distant met recurrence/progression"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333309"}]}}{"C8524":{"preferredName":"Locally Advanced Malignant Neoplasm","code":"C8524","definitions":[{"definition":"A malignant neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that has spread from where it started to nearby tissue or lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Refers to cancer that has grown beyond the original (primary) tumor to nearby lymph nodes or organs and tissues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Locally Advanced Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Locally Advanced Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Locally Metastatic Malignant Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Locally_Advanced_Malignant_Neoplasm"},{"name":"Legacy Concept Name","value":"Locally_Metastatic_Neoplasm"},{"name":"Maps_To","value":"Loco-regional recurrence/progression"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677984"}]}}{"C165197":{"preferredName":"Biochemical Evidence of Disease without Structural Correlate","code":"C165197","definitions":[{"definition":"An indication that biochemical markers of a disease are present but morphological markers are absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biochemical Evidence of Disease without Structural Correlate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biochemical evidence of disease without structural correlate"},{"name":"NCI_META_CUI","value":"CL978409"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156848":{"preferredName":"Tumor Free","code":"C156848","definitions":[{"definition":"There is no evidence of a tumor in the individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Free","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TF-Tumor Free"},{"name":"Maps_To","value":"Tumor free"},{"name":"NCI_META_CUI","value":"CL935966"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C158709":{"preferredName":"Unknown Tumor Status","code":"C158709","definitions":[{"definition":"The tumor status is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unknown Tumor Status","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unknown tumor status"},{"name":"NCI_META_CUI","value":"CL950740"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C156849":{"preferredName":"With Tumor","code":"C156849","definitions":[{"definition":"There is evidence of a tumor in an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"With Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"With tumor"},{"name":"Maps_To","value":"WT-With Tumor"},{"name":"NCI_META_CUI","value":"CL935963"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C13332":{"preferredName":"Bilateral","code":"C13332","definitions":[{"definition":"Affecting both sides of the body or a matched pair of organs.","type":"DEFINITION","source":"NCI"},{"definition":"Affecting both sides of the body, or a pair of organs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Affecting both the right and left sides of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bilateral","termGroup":"PT","termSource":"NCI"},{"termName":"Right and Left","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Bilateral"},{"name":"Maps_To","value":"Bilateral"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0238767"}]}}{"C25229":{"preferredName":"Left","code":"C25229","definitions":[{"definition":"Being or located on or directed toward the side of the body to the west when facing north.","type":"DEFINITION","source":"NCI"},{"definition":"Being or located on or directed toward the side of the body to the west when facing north.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Left","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Left"},{"name":"Maps_To","value":"Left"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205091"}]}}{"C81170":{"preferredName":"Midline","code":"C81170","definitions":[{"definition":"A medial line, especially the medial line or medial plane of the body (or some part of the body).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A medial line, especially the medial line or medial plane of the body (or some part of the body).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Midline","termGroup":"PT","termSource":"NCI"},{"termName":"Mesial","termGroup":"AD","termSource":"NCI"},{"termName":"Midplane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Midline"},{"name":"Maps_To","value":"Midline"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0549183"}]}}{"C25228":{"preferredName":"Right","code":"C25228","definitions":[{"definition":"Being or located on or directed toward the side of the body to the east when facing north.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Being or located on or directed toward the side of the body to the east when facing north.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Right","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Right"},{"name":"Maps_To","value":"Right"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205090"}]}}{"C28012":{"preferredName":"Unilateral","code":"C28012","definitions":[{"definition":"Affecting one side of the body or one of a pair of organs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Having to do with one side of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Unilateral","termGroup":"PT","termSource":"NCI"},{"termName":"Unilateral Anatomic Qualifier","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"unilateral"},{"name":"Maps_To","value":"Unilateral"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205092"}]}}{"C12904":{"preferredName":"Axillary Lymph Node","code":"C12904","definitions":[{"definition":"A lymph node in the armpit region that drains lymph from the breast and nearby areas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Lymph node(s) in the axillary region.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axillary Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"ALN","termGroup":"AB","termSource":"NCI"},{"termName":"Axillary Lymph Nodes","termGroup":"SY","termSource":"NCI"},{"termName":"Axillary Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Axillary_Lymph_Node"},{"name":"Maps_To","value":"Axillary"},{"name":"Maps_To","value":"Axillary lymph nodes"},{"name":"Maps_To","value":"Lymph Node(s) Axilla"},{"name":"Maps_To","value":"Lymph Node, Axillary"},{"name":"Maps_To","value":"Lymph nodes of axilla or arm"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0729594"}]}}{"C32298":{"preferredName":"Cervical Lymph Node","code":"C32298","definitions":[{"definition":"Any of the lymph nodes located in the neck.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in the cervical region, or neck.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cervical Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Cervical_Lymph_Node"},{"name":"Maps_To","value":"Cervical lymph nodes"},{"name":"Maps_To","value":"Cervical, NOS"},{"name":"Maps_To","value":"Lymph Node(s) Cervical"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0588054"}]}}{"C98182":{"preferredName":"Epitrochlear Lymph Node","code":"C98182","definitions":[{"definition":"A lymph node located above and adjacent to the elbow.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located above and adjacent to the elbow. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Epitrochlear Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Epitrochlear"},{"name":"Maps_To","value":"Lymph Node(s) Epitrochlear"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229847"}]}}{"C98183":{"preferredName":"Femoral Lymph Node","code":"C98183","definitions":[{"definition":"A lymph node located in the upper inner portion of the thigh.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the upper inner portion of the thigh. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Femoral Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Femoral"},{"name":"Maps_To","value":"Lymph Node(s) Femoral"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0877794"}]}}{"C102330":{"preferredName":"Perihilar Lymph Node","code":"C102330","definitions":[{"definition":"A lymph node located in the area around the hilum of an organ.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the area around the hilum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Perihilar Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Hilar"},{"name":"Maps_To","value":"Lymph Node(s) Hilar"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3640700"}]}}{"C103384":{"preferredName":"Common Iliac Lymph Node","code":"C103384","definitions":[{"definition":"A lymph node located adjacent to the common iliac artery. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A lymph node located adjacent to the common iliac artery. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Common Iliac Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Iliac-common"},{"name":"Maps_To","value":"Lymph Node(s) Iliac-Common"},{"name":"NCI_META_CUI","value":"CL438194"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"xRef","value":"UBERON:0015878"}]}}{"C88143":{"preferredName":"External Iliac Lymph Node","code":"C88143","definitions":[{"definition":"A lymph node located along the external iliac artery.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located along the external iliac artery. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external iliac lymph nodes, from eight to ten in number, lie along the external iliac vessels. They are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent. Their principal afferents are derived from the inguinal lymph nodes, the deep lymphatics of the abdominal wall below the umbilicus and of the adductor region of the thigh, and the lymphatics from the glans penis vel clitoridis, the membranous urethra, the prostate, the fundus of the urinary bladder, the cervix uteri, and upper part of the vagina.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"External Iliac Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Iliac-external"},{"name":"Maps_To","value":"Lymph Node(s) Iliac-External"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229815"},{"name":"xRef","value":"UBERON:0015880"}]}}{"C32761":{"preferredName":"Iliac Lymph Node","code":"C32761","definitions":[{"definition":"Lymph node(s) adjacent to the iliac vessels in the iliosacral region and cranial to the iliofemoral lymph node.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the three lymph nodes of the pelvis: the superior gluteal, interior gluteal or sacral.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iliac Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Iliac_Lymph_Node"},{"name":"Maps_To","value":"Iliac, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229807"}]}}{"C32801":{"preferredName":"Inguinal Lymph Node","code":"C32801","definitions":[{"definition":"A superficial or deep lymph node located in the inguinal area.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in the inguinal region.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Inguinal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Inguinal_Lymph_Node"},{"name":"Maps_To","value":"Inguinal"},{"name":"Maps_To","value":"Lymph Node(s) Inguinal"},{"name":"Maps_To","value":"Lymph Node, Inguinal"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0729596"}]}}{"C33073":{"preferredName":"Mediastinal Lymph Node","code":"C33073","definitions":[{"definition":"A lymph node located in the mediastinum. Mediastinal lymph nodes are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node that is part of a mediastinum. Each consists of several lymph node groups, especially along the trachea (5 groups), along the esophagus and between the lung and the diaphragm. In the mediastinal lymph nodes arises lymphatic ducts, which drains the lymph to the left subclavian vein (to the venous angle in the confluence of the subclavian and deep jugular veins). The mediastinal lymph nodes along the esophagus are in tight connection with the abdominal lymph nodes along the esophagus and the stomach. That fact facilitates spreading of tumors cells through these lymphatics in cases of cancers of the stomach and particularly of the esophagus. Through the mediastinum, the main lymphatic drainage from the abdominal organs goes via the thoracic duct (ductus thoracicus), which drains majority of the lymph from the abdomen to the above mentioned left venous angle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Lymph node(s) in the mediastinal region.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mediastinal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mediastinal_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Mediastinal"},{"name":"Maps_To","value":"Lymph Nodes(s) Mediastinal"},{"name":"Maps_To","value":"Mediastinal"},{"name":"Maps_To","value":"Mediastinal lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0588055"},{"name":"xRef","value":"UBERON:0002524"}]}}{"C77641":{"preferredName":"Mesenteric Lymph Node","code":"C77641","definitions":[{"definition":"A lymph node located in the mesentery.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in or adjacent to the mesentery.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymph nodes located in the mesentery, of which there are 3 classes: ileocolic, juxtaintestinal mesenteric, and central superior group.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Mesenteric Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mesenteric_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Mesenteric"},{"name":"Maps_To","value":"Mesenteric"},{"name":"Maps_To","value":"Mesenteric lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229792"},{"name":"xRef","value":"UBERON:0002509"}]}}{"C41132":{"preferredName":"None","code":"C41132","definitions":[{"definition":"No person or thing, nobody, not any.","type":"DEFINITION","source":"NCI"},{"definition":"No person or thing, nobody, not any. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"None","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"None"},{"name":"Maps_To","value":"No Treatment"},{"name":"Maps_To","value":"None"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0549184"}]}}{"C98188":{"preferredName":"Occipital Lymph Node","code":"C98188","definitions":[{"definition":"A lymph node located in the back of the head adjacent to the trapezius muscle.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A lymph node located in the back of the head adjacent to the trapezius muscle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located in the back of the head adjacent to the trapezius muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occipital Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Lymph Node(s) Occipital"},{"name":"Maps_To","value":"Occipital"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229711"},{"name":"xRef","value":"UBERON:0035204"}]}}{"C77643":{"preferredName":"Paraaortic Lymph Node","code":"C77643","definitions":[{"definition":"A lymph node located adjacent to the lumbar region of the spine.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) adjacent to the lumbar vertebral column.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The paraaortic lymph nodes (also known as para-aortic, periaortic, and peri-aortic) are a group of lymph nodes that lie in front of the lumbar vertebral bodies near the aorta. These lymph nodes receive drainage from the lower gastrointestinal tract and the pelvic organs.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Paraaortic Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Aortic Lymph Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Paraaortic_Lymph_Node"},{"name":"Maps_To","value":"Aortic"},{"name":"Maps_To","value":"Lymph Node(s) Paraaortic"},{"name":"Maps_To","value":"Paraaortic"},{"name":"Maps_To","value":"Paraaortic lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229789"},{"name":"xRef","value":"UBERON:0016386"}]}}{"C33278":{"preferredName":"Parotid Gland Lymph Node","code":"C33278","definitions":[{"definition":"A lymph node found near the parotid gland.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located close to, on, or within the parotid gland.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in or adjacent to the parotid gland.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Parotid Gland Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Parotid_Gland_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Parotid"},{"name":"Maps_To","value":"Parotid"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229715"},{"name":"xRef","value":"UBERON:0015857"}]}}{"C53146":{"preferredName":"Popliteal Lymph Node","code":"C53146","definitions":[{"definition":"Lymph node located within the fat layer of the knee joint.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) adjacent to the femorotibial joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymph nodes which drain the legs; contained in the popliteal fossa.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Popliteal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Popliteal_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Popliteal"},{"name":"Maps_To","value":"Popliteal"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0588057"},{"name":"xRef","value":"UBERON:0001543"}]}}{"C98189":{"preferredName":"Retroperitoneal Lymph Node","code":"C98189","definitions":[{"definition":"A lymph node located in the retroperitoneal space.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located in the retroperitoneal space.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the retroperitoneal space. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Retroperitoneal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Lymph Node(s) Retroperitoneal"},{"name":"Maps_To","value":"Retroperitoneal"},{"name":"Maps_To","value":"Retroperitoneal lymph nodes"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229802"},{"name":"xRef","value":"UBERON:0035371"}]}}{"C142320":{"preferredName":"Splenic Lymph Node","code":"C142320","definitions":[{"definition":"Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes.","type":"DEFINITION","source":"NCI"},{"definition":"The splenic lymph nodes (or pancreaticolienal) accompany the lienal (splenic) artery, and are situated in relation to the posterior surface and upper border of the pancreas; one or two members of this group are found in the gastrolienal ligament. Their afferents are derived from the stomach, spleen, and pancreas, their efferents join the celiac group of preaortic glands.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Splenic Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Lymph Node(s) Splenic"},{"name":"Maps_To","value":"Splenic"},{"name":"Maps_To","value":"Splenic lymph nodes"},{"name":"NCI_META_CUI","value":"CL540362"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"xRef","value":"UBERON:0015469"}]}}{"C77650":{"preferredName":"Submandibular Lymph Node","code":"C77650","definitions":[{"definition":"A lymph node located beneath the floor of the oral cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) adjacent to the mandible.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The submandibular lymph nodes (submaxillary glands in older texts), three to six in number, are placed beneath the body of the mandible in the submaxillary triangle, and rest on the superficial surface of the submaxillary salivary gland. One gland, the middle gland of Stahr, which lies on the external maxillary artery as it turns over the mandible, is the most constant of the series; small lymph glands are sometimes found on the deep surface of the submaxillary salivary glands. The afferents of the submaxillary glands drain the medial palpebral commissure, the cheek, the side of the nose, the upper lip, the lateral part of the lower lip, the gums, and the anterior part of the margin of the tongue. Efferent vessels from the facial and submental glands also enter the submaxillary glands. Their efferent vessels pass to the superior deep cervical glands.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Submandibular Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Submandibular_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Submandibular"},{"name":"Maps_To","value":"Submandibular"},{"name":"Maps_To","value":"Submandibular lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229722"},{"name":"xRef","value":"UBERON:0002520"}]}}{"C12903":{"preferredName":"Supraclavicular Lymph Node","code":"C12903","definitions":[{"definition":"A lymph node which is located above the clavicle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node which is located above the clavicle.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node which is located above the clavicle. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Lymph nodes located above the clavicle (collarbone).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Supraclavicular Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Supraclavicular Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Supraclavicular_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Supraclavicular"},{"name":"Maps_To","value":"Supraclavicular"},{"name":"Maps_To","value":"Supraclavicular lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229730"},{"name":"xRef","value":"UBERON:0035279"}]}}{"C162125":{"preferredName":"Gerota Fascia","code":"C162125","definitions":[{"definition":"A fibrous connective tissue covering the kidney and adrenal gland, which separates the perinephric fat from paranephric fat.","type":"DEFINITION","source":"NCI"},{"definition":"A fibrous envelope of tissue that surrounds the kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gerota Fascia","termGroup":"PT","termSource":"NCI"},{"termName":"Anterior Perirenal Fascia","termGroup":"SY","termSource":"NCI"},{"termName":"Gerota's Fascia","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Fascia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gerota Fascia"},{"name":"NCI_META_CUI","value":"CL970599"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"}]}}{"C74601":{"preferredName":"Parenchyma","code":"C74601","definitions":[{"definition":"The essential or functional elements of an organ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tissue that constitutes the essential part of an organ as contrasted with e.g., connective tissue and blood vessels.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Parenchyma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Parenchyma"},{"name":"Maps_To","value":"Parenchyma"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0933845"}]}}{"C162218":{"preferredName":"Perinephric Fat","code":"C162218","definitions":[{"definition":"A layer of fatty tissue surrounding the kidney, bounded by the renal capsule and the renal fascia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perinephric Fat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perinephric Fat"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227617"}]}}{"C12885":{"preferredName":"Renal Capsule","code":"C12885","definitions":[{"definition":"A layer of dense connective tissue that covers the outer surface of each kidney.","type":"DEFINITION","source":"NCI"},{"definition":"The fibrous connective tissue that surrounds each kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Renal Capsule","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Capsule"},{"name":"Maps_To","value":"Renal Capsule"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227637"}]}}{"C162219":{"preferredName":"Renal Sinus","code":"C162219","definitions":[{"definition":"A cavity in the kidney containing the pelvicalyceal system, blood vessels, nerves and fat. It communicates with the perinephric space.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Sinus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Sinus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227672"}]}}{"C33462":{"preferredName":"Renal Vein","code":"C33462","definitions":[{"definition":"A vein arising from the kidney; in general it drains into the caudal vena cava vein.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The veins which return blood from the kidneys to the vena cava.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Vein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Vein"},{"name":"Maps_To","value":"Renal Vein"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0035092"}]}}{"C112007":{"preferredName":"Masaoka-Koga Stage I","code":"C112007","definitions":[{"definition":"The tumor is completely encapsulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829188"}]}}{"C112008":{"preferredName":"Masaoka-Koga Stage IIa","code":"C112008","definitions":[{"definition":"The tumor shows microscopic invasion into the capsule.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IIa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIa"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829187"}]}}{"C112009":{"preferredName":"Masaoka-Koga Stage IIb","code":"C112009","definitions":[{"definition":"The tumor shows invasion through the capsule and into the surrounding fatty tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IIb","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage IIb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIb"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829186"}]}}{"C112010":{"preferredName":"Masaoka-Koga Stage III","code":"C112010","definitions":[{"definition":"The tumor shows invasion into the neighboring tissues and organs of the lower neck or upper chest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage III","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829185"}]}}{"C112011":{"preferredName":"Masaoka-Koga Stage IVa","code":"C112011","definitions":[{"definition":"The tumor shows metastasis throughout the pleural and/or pericardial spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IVa","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage IVa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVa"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829184"}]}}{"C112012":{"preferredName":"Masaoka-Koga Stage IVb","code":"C112012","definitions":[{"definition":"The tumor shows lymphogenous or hematogenous metastasis to distant sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IVb","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage IVb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVb"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829183"}]}}{"C129447":{"preferredName":"Medulloblastoma, Not Otherwise Specified","code":"C129447","definitions":[{"definition":"A medulloblastoma which has not been further characterized.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Medulloblastoma, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9470/3"},{"name":"Maps_To","value":"Medulloblastoma, NOS"},{"name":"Maps_To","value":"Not Determined"},{"name":"NCI_META_CUI","value":"CL512714"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129444":{"preferredName":"Medulloblastoma, Non-WNT/Non-SHH","code":"C129444","definitions":[{"definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. TP53 mutations are absent. This molecular subtype includes medulloblastomas numerically designated as \"group 3\" and \"group 4\".","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Non-WNT/Non-SHH","termGroup":"PT","termSource":"NCI"},{"termName":"Non-WNT/Non-SHH Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9477/3"},{"name":"Maps_To","value":"Medulloblastoma, non-WNT/non-SHH"},{"name":"Maps_To","value":"Non-WNT/non-SHH Activated"},{"name":"NCI_META_CUI","value":"CL512713"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129441":{"preferredName":"Medulloblastoma, SHH-Activated","code":"C129441","definitions":[{"definition":"A molecular subtype of medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway. TP53 mutations may be present or absent. Patients in this group are young children and adults. Overall survival is variable and depends on the presence or absence of metastatic disease, histology, and the age at diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, SHH-Activated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SHH-Activated"},{"name":"NCI_META_CUI","value":"CL512717"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129440":{"preferredName":"Medulloblastoma, WNT-Activated","code":"C129440","definitions":[{"definition":"A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, WNT-Activated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9475/3"},{"name":"Maps_To","value":"Medulloblastoma, WNT-activated"},{"name":"Maps_To","value":"Medulloblastoma, WNT-activated, NOS"},{"name":"Maps_To","value":"WNT-Activated"},{"name":"NCI_META_CUI","value":"CL512718"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C18206":{"preferredName":"Distant Metastasis","code":"C18206","definitions":[{"definition":"A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Distant Metastasis","termGroup":"PT","termSource":"NCI"},{"termName":"Distant","termGroup":"SY","termSource":"NCI"},{"termName":"Distant Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Distant_Metastasis"},{"name":"Maps_To","value":"Distant Metastasis"},{"name":"NCI_META_CUI","value":"CL1793019"},{"name":"Semantic_Type","value":"Pathologic Function"}]}}{"C164041":{"preferredName":"Metastasis Negative","code":"C164041","definitions":[{"definition":"An indication that signs of metastasis were not found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasis Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Negative for Metastasis","termGroup":"SY","termSource":"NCI"},{"termName":"No Metastasis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Metastasis"},{"name":"NCI_META_CUI","value":"CL979263"},{"name":"Semantic_Type","value":"Finding"}]}}{"C172220":{"preferredName":"Regional Metastasis Present","code":"C172220","definitions":[{"definition":"An indication that cancer cells have migrated from the primary tumor site and have been detected in adjacent tissues and/or regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regional Metastasis Present","termGroup":"PT","termSource":"NCI"},{"termName":"Regional Metastasis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regional Metastasis"},{"name":"NCI_META_CUI","value":"CL1406102"},{"name":"Semantic_Type","value":"Finding"}]}}{"C12664":{"preferredName":"Abdomen","code":"C12664","definitions":[{"definition":"The area of the body that contains the pancreas, stomach, intestine, liver, gallbladder, and other organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The body cavity between the thoracic and pelvic cavities in mammals.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.","type":"DEFINITION","source":"NCI"},{"definition":"The subdivision of the vertebrate body between the thorax and pelvis. The ventral part of the abdomen contains the abdominal cavity and visceral organs. The dorsal part includes the abdominal section of the vertebral column.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Abdomen","termGroup":"PT","termSource":"NCI"},{"termName":"Abdominal Cavity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Abdominal_Cavity"},{"name":"Maps_To","value":"Abdomen"},{"name":"Maps_To","value":"Abdomen, NOS"},{"name":"Maps_To","value":"Abdomen, total"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0230168"},{"name":"xRef","value":"UBERON:0003684"}]}}{"C2885":{"preferredName":"Peritoneal Effusion","code":"C2885","definitions":[{"definition":"A clinical finding in which there is accumulation of interstitial fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormal buildup of fluid in the abdomen that may cause swelling. In late-stage cancer, tumor cells may be found in the fluid in the abdomen. Ascites also occurs in patients with liver disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Abnormal collection of fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Accumulation of fluid in the peritoneal cavity. The fluid may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Intra-abdominal fluid accumulation as determined by physical examination.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneal Effusion","termGroup":"PT","termSource":"NCI"},{"termName":"Ascites","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Ascites"},{"name":"Legacy Concept Name","value":"Peritoneal_Effusion"},{"name":"Maps_To","value":"Ascites"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3554541"},{"name":"xRef","value":"IMDRF:E1004"}]}}{"C12366":{"preferredName":"Bone","code":"C12366","definitions":[{"definition":"Calcified connective tissue that forms the skeletal components of the body. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Bones","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Bone"},{"name":"Maps_To","value":"Bone"},{"name":"Maps_To","value":"Bone, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0262950"},{"name":"xRef","value":"UBERON:0001474"},{"name":"xRef","value":"UBERON:0002481"}]}}{"C12431":{"preferredName":"Bone Marrow","code":"C12431","definitions":[{"definition":"The soft tissue that fills the cavities of bones.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","type":"DEFINITION","source":"NCI"},{"definition":"The tissue occupying the spaces of some bones. It consists of blood vessel sinuses and a network of hematopoietic cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bone Marrow","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Bone Marrow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bone_Marrow"},{"name":"Maps_To","value":"Bone marrow"},{"name":"Maps_To","value":"Bone Marrow"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005953"},{"name":"xRef","value":"UBERON:0002371"}]}}{"C12438":{"preferredName":"Central Nervous System","code":"C12438","definitions":[{"definition":"The brain and spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the neural tube derivatives: the brain and spinal cord. In invertebrates it includes central ganglia plus nerve cord.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Central Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Nervous System, CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Central_Nervous_System"},{"name":"Maps_To","value":"Central nervous system"},{"name":"Maps_To","value":"Central Nervous System"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C3714787"},{"name":"xRef","value":"UBERON:0001017"}]}}{"C12692":{"preferredName":"Cerebrospinal Fluid","code":"C12692","definitions":[{"definition":"A clear, colorless, bodily fluid, that occupies the subarachnoid space and the ventricular system around and inside the brain and spinal cord.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fluid that flows in and around the hollow spaces of the brain and spinal cord, and between two of the meninges (the thin layers of tissue that cover and protect the brain and spinal cord). CSF is made by tissue called the choroid plexus in the ventricles (hollow spaces) in the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cerebrospinal Fluid","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebral Spinal Fluid","termGroup":"SY","termSource":"NCI"},{"termName":"CSF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cerebrospinal_Fluid"},{"name":"Maps_To","value":"Cerebrospinal Fluid"},{"name":"Maps_To","value":"Cerebrospinal fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0007806"},{"name":"xRef","value":"UBERON:0001359"}]}}{"C172221":{"preferredName":"Metastasis Present in Distant Lymph Node","code":"C172221","definitions":[{"definition":"An indication that cancer cells have migrated from the primary tumor site and have been detected in one or more distant lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasis Present in Distant Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Metastasis in Distant Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Metastasis in Distant Lymph Node Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Nodes"},{"name":"NCI_META_CUI","value":"CL1406101"},{"name":"Semantic_Type","value":"Finding"}]}}{"C172223":{"preferredName":"Metastasis Present in Distant Organ","code":"C172223","definitions":[{"definition":"An indication that cancer cells have migrated and spread to one or more organs that are distant from the primary tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasis Present in Distant Organ","termGroup":"PT","termSource":"NCI"},{"termName":"Metastasis in Distant Organ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Organ"},{"name":"NCI_META_CUI","value":"CL1406099"},{"name":"Semantic_Type","value":"Finding"}]}}{"C12726":{"preferredName":"Inguinal Region","code":"C12726","definitions":[{"definition":"The area where the thigh meets the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The external junctural region between the lower part of the abdomen and the thigh.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower region of the anterior abdominal wall located laterally to the pubic region.","type":"DEFINITION","source":"NCI"},{"definition":"The lower region of the anterior abdominal wall located laterally to the pubic region. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Inguinal Region","termGroup":"PT","termSource":"NCI"},{"termName":"Groin","termGroup":"SY","termSource":"NCI"},{"termName":"Inguinal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Inguinal_Region"},{"name":"Maps_To","value":"Groin"},{"name":"Maps_To","value":"Inguinal"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0018246"},{"name":"xRef","value":"UBERON:0008337"}]}}{"C12392":{"preferredName":"Liver","code":"C12392","definitions":[{"definition":"A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.","type":"DEFINITION","source":"NCI"},{"definition":"An abdominal organ that has variable lobation which are composed mainly of hepatic lobules.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Liver","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Hepatic","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Hepatic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Liver"},{"name":"Maps_To","value":"Liver"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0023884"},{"name":"xRef","value":"UBERON:0002107"}]}}{"C12468":{"preferredName":"Lung","code":"C12468","definitions":[{"definition":"A thoracic organ that has variable lobation and is the primary respiratory organ of mammals.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of a pair of organs in the chest that supplies the body with oxygen, and removes carbon dioxide from the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.","type":"DEFINITION","source":"NCI"},{"definition":"Respiration organ that develops as an outpocketing of the esophagus.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lungs","termGroup":"SY","termSource":"NCI"},{"termName":"Respiratory System, Lung","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lung"},{"name":"Maps_To","value":"Lung"},{"name":"Maps_To","value":"Lung, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024109"},{"name":"xRef","value":"UBERON:0002048"}]}}{"C12748":{"preferredName":"Mediastinum","code":"C12748","definitions":[{"definition":"An anatomic site along the midline and under the sternum that contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.","type":"DEFINITION","source":"NCI"},{"definition":"The area between the lungs. The organs in this area include the heart and its large blood vessels, the trachea, the esophagus, the thymus, and lymph nodes but not the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The central part of the thoracic cavity enclosed by the left and right pleurae.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The central region of the thoracic cavity of mammals containing a group of organs surrounded by loose connective tissue, which separates the two pleural sacs.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mediastinum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mediastinum"},{"name":"Maps_To","value":"Mediastinum"},{"name":"Maps_To","value":"Mediastinum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0025066"},{"name":"xRef","value":"UBERON:0003728"}]}}{"C33209":{"preferredName":"Omentum","code":"C33209","definitions":[{"definition":"A double layer of peritoneum covering abdominal organs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A fold of peritoneum originating at the stomach and supporting the viscera.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A fold of peritoneum originating at the stomach and supporting the viscera.","type":"DEFINITION","source":"NCI"},{"definition":"A fold of the peritoneum (the thin tissue that lines the abdomen) that surrounds the stomach and other organs in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Omentum","termGroup":"PT","termSource":"NCI"},{"termName":"Omental Fat","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Omentum"},{"name":"Maps_To","value":"Omentum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0028977"},{"name":"xRef","value":"UBERON:0003688"}]}}{"C12767":{"preferredName":"Pelvis","code":"C12767","definitions":[{"definition":"The bony, basin-shaped structure formed by the bones of the pelvis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.","type":"DEFINITION","source":"NCI"},{"definition":"The lower part of the abdomen, located between the hip bones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lower segment of the trunk, inferoposterior to the abdomen proper, in the transition area between the trunk and the lower limbs.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pelvis","termGroup":"PT","termSource":"NCI"},{"termName":"Pelvic","termGroup":"SY","termSource":"NCI"},{"termName":"Pelvic Cavity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pelvis"},{"name":"Maps_To","value":"Pelvis"},{"name":"Maps_To","value":"Pelvis, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0030797"},{"name":"xRef","value":"UBERON:0001270"},{"name":"xRef","value":"UBERON:0002355"}]}}{"C12769":{"preferredName":"Peritoneal Cavity","code":"C12769","definitions":[{"definition":"A part of the abdominal cavity that lies between the visceral and parietal peritoneum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Anatomical cavity bounded by visceral and parietal peritoneum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The potential space located between the parietal and visceral layers of the peritoneum.","type":"DEFINITION","source":"NCI"},{"definition":"The space within the abdomen that contains the intestines, the stomach, and the liver. It is bound by thin membranes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peritoneal Cavity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Peritoneal_Cavity"},{"name":"Maps_To","value":"Peritoneal Cavity"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C1704247"},{"name":"xRef","value":"UBERON:0001179"}]}}{"C12770":{"preferredName":"Peritoneum","code":"C12770","definitions":[{"definition":"A serous membrane that lines the peritoneal cavity.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The membrane that lines the abdominal and pelvic cavities.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissue that lines the abdominal wall and covers most of the organs in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tissue that lines the wall of the abdominal cavity, intestine, mesentery, and pelvic organs. It consists of the parietal peritoneum and the visceral peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Peritoneum"},{"name":"Maps_To","value":"Peritoneum"},{"name":"Maps_To","value":"Peritoneum, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0031153"},{"name":"xRef","value":"UBERON:0002358"}]}}{"C12469":{"preferredName":"Pleura","code":"C12469","definitions":[{"definition":"A thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity. It protects and cushions the lungs. This tissue secretes a small amount of fluid that acts as a lubricant, allowing the lungs to move smoothly in the chest cavity while breathing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The invaginated serous membrane that surrounds the lungs (the visceral portion) and lines the walls of the pleural cavity (parietal portion).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The serous membrane that lines the wall of the thoracic cavity and the surface of the lungs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissue that lines the wall of the thoracic cavity and the surface of the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleura","termGroup":"PT","termSource":"NCI"},{"termName":"PLEURA","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pleural_Tissue"},{"name":"Maps_To","value":"Pleura"},{"name":"Maps_To","value":"Pleura, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0032225"},{"name":"xRef","value":"UBERON:0000977"}]}}{"C89807":{"preferredName":"Scalp","code":"C89807","definitions":[{"definition":"The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendonous galea aponeurotica; Loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The skin which covers the top of the head and which is usually covered by hair.","type":"DEFINITION","source":"NCI"},{"definition":"The skin which covers the top of the head and which is usually covered by hair. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Scalp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Scalp"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036270"},{"name":"xRef","value":"UBERON:0000403"}]}}{"C12471":{"preferredName":"Soft Tissue","code":"C12471","definitions":[{"definition":"A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Refers to muscle, fat, fibrous tissue, blood vessels, organ parenchyma, or other supporting tissue of the body.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Soft_Tissue"},{"name":"Maps_To","value":"Soft Tissue"},{"name":"Maps_To","value":"Soft tissue"},{"name":"Maps_To","value":"Soft tissue (muscle, ligaments, subcutaneous)"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0225317"},{"name":"xRef","value":"UBERON:0034929"}]}}{"C12464":{"preferredName":"Spinal Cord","code":"C12464","definitions":[{"definition":"A column of nerve tissue that runs from the base of the skull down the back. It is surrounded by three protective membranes, and is enclosed within the vertebrae (back bones). The spinal cord and the brain make up the central nervous system, and spinal cord nerves carry most messages between the brain and the rest of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Part of the central nervous system located in the vertebral canal continuous with and caudal to the brain; demarcated from brain by plane of foramen magnum. It is composed of an inner core of gray matter in which nerve cells predominate, and an outer layer of white matter in which myelinated nerve fibers predominate, and surrounds the central canal.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The elongated, approximately cylindrical part of the central nervous system of vertebrates that lies in the vertebral canal and from which the spinal nerves emerge.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The portion of the central nervous system that lies within the vertebral canal and from which the spinal nerves emerge.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Spinal Cord","termGroup":"PT","termSource":"NCI"},{"termName":"Medulla Spinalis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Spinal_Cord"},{"name":"Maps_To","value":"Spinal Cord"},{"name":"Maps_To","value":"Spinal cord"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037925"},{"name":"xRef","value":"UBERON:0002240"}]}}{"C34082":{"preferredName":"Gastrointestinal Tract","code":"C34082","definitions":[{"definition":"A tube extending from the mouth to the anus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff.","type":"DEFINITION","source":"NCI"},{"definition":"The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gastrointestinal Tract","termGroup":"PT","termSource":"NCI"},{"termName":"Alimentary Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Digestive Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Gut","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Tract"},{"name":"Maps_To","value":"Gastrointestinal Tract"},{"name":"Maps_To","value":"Gastrointestinal tract, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0017189"},{"name":"xRef","value":"UBERON:0001555"}]}}{"C12727":{"preferredName":"Heart","code":"C12727","definitions":[{"definition":"A hollow muscular organ which receives the blood from the veins and pumps it into the arteries.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A hollow organ located slightly to the left of the middle portion of the chest. It is composed of muscle and it is divided by a septum into two sides: the right side which receives de-oxygenated blood from the body and the left side which sends newly oxygenated blood to the body. Each side is composed of two chambers: the atrium (receiving blood) and ventricle (ejecting blood).","type":"DEFINITION","source":"NCI"},{"definition":"A myogenic muscular circulatory organ found in the vertebrate cardiovascular system composed of chambers of cardiac muscle. It is the primary circulatory organ.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Heart","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiac","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Heart"},{"name":"Maps_To","value":"Heart"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0018787"},{"name":"xRef","value":"IMDRF:E06"},{"name":"xRef","value":"UBERON:0000948"}]}}{"C13063":{"preferredName":"Neck","code":"C13063","definitions":[{"definition":"An organism subdivision that extends from the head to the pectoral girdle, encompassing the cervical vertebral column.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region that connects the head to the rest of the body.","type":"DEFINITION","source":"NCI"},{"definition":"The region that connects the head to the rest of the body. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Neck","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Neck"},{"name":"Maps_To","value":"Neck"},{"name":"Maps_To","value":"Neck, Left"},{"name":"Maps_To","value":"Neck, NOS"},{"name":"Maps_To","value":"Neck, Right"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0027530"},{"name":"xRef","value":"UBERON:0000974"}]}}{"C12298":{"preferredName":"Retroperitoneum","code":"C12298","definitions":[{"definition":"Anatomical space in the abdominal cavity behind (retro) the peritoneum. It has no specific delineating anatomical structures. Organs are retroperitoneal if they only have peritoneum on their anterior side.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The back of the abdomen where the kidneys lie and the great blood vessels run.","type":"DEFINITION","source":"NCI"},{"definition":"The region of the abdomen outside the peritoneum, where the kidneys lie and the great blood vessels run.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Retroperitoneum","termGroup":"PT","termSource":"NCI"},{"termName":"Retroperitoneal Cavity","termGroup":"SY","termSource":"NCI"},{"termName":"Retroperitoneal Space","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Retroperitoneum"},{"name":"Maps_To","value":"Retroperitoneum"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0035359"},{"name":"xRef","value":"UBERON:0003693"}]}}{"C12417":{"preferredName":"Urethra","code":"C12417","definitions":[{"definition":"The fibromuscular tubular canal through which urine is discharged from the bladder to the exterior via the external urinary meatus; in males, the urethra is joined by the ejaculatory ducts and serves as a passageway for semen during ejaculation, as well as a canal for urine during voiding; in females, the urethra is shorter and emerges above the vaginal opening.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The tube carrying urine from the bladder to outside of the body.","type":"DEFINITION","source":"NCI"},{"definition":"The tube that extends from the urinary bladder to the urethral opening.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tube through which urine leaves the body. It empties urine from the bladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Urethra","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Urethra"},{"name":"Maps_To","value":"Urethra"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0041967"},{"name":"xRef","value":"UBERON:0000057"}]}}{"C12321":{"preferredName":"Appendage of the Uterus","code":"C12321","definitions":[{"definition":"The accessory structures of the uterus, including the ovaries, fallopian tubes, broad ligament, and the ovarian and uterine ligaments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Appendage of the Uterus","termGroup":"PT","termSource":"NCI"},{"termName":"Uterine Adnexa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Appendage_of_the_Uterus"},{"name":"Maps_To","value":"Uterine adnexa"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0001575"}]}}{"C33869":{"preferredName":"Vertebral Canal","code":"C33869","definitions":[{"definition":"The space formed by the series of vertebral foramina that courses the length of the vertebral column, and which houses the spinal cord and meninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vertebral Canal","termGroup":"PT","termSource":"NCI"},{"termName":"Spinal Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Vertebral_Canal"},{"name":"Maps_To","value":"Vertebral Canal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037922"}]}}{"C117873":{"preferredName":"Subcarinal Lymph Node","code":"C117873","definitions":[{"definition":"A lymph node located in the thoracic cavity between the lungs. It is bordered by the carina of the trachea, lower lobe bronchus on the left and the bronchus intermedius on the right.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the thoracic cavity between the lungs. It is bordered by the carina of the trachea, lower lobe bronchus on the left and the bronchus intermedius on the right. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Subcarinal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node, Subcarinal"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229753"}]}}{"C12683":{"preferredName":"Bronchus","code":"C12683","definitions":[{"definition":"The large air passages that lead from the trachea (windpipe) to the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The upper conducting airways of the lung; these airways arise from the terminus of the trachea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole).","type":"DEFINITION","source":"NCI"},{"definition":"Tubular structure in continuation with the trachea, serving as an air passage.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bronchus","termGroup":"PT","termSource":"NCI"},{"termName":"Bronchi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bronchus"},{"name":"Maps_To","value":"Bronchus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006255"},{"name":"xRef","value":"UBERON:0002185"}]}}{"C49018":{"preferredName":"Regional Lymph Node","code":"C49018","definitions":[{"definition":"A lymph node that drains lymph from a region of interest.","type":"DEFINITION","source":"NCI"},{"definition":"In oncology, a lymph node that drains lymph from the region around a tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Lymph node(s) that drains the lymph from a region of interest.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Regional Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Regional_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Regional"},{"name":"Maps_To","value":"Lymph Node, Regional"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1184738"}]}}{"C12432":{"preferredName":"Spleen","code":"C12432","definitions":[{"definition":"An abdominal organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule. It is located in the left hypochondriac region. Its functions include lymphocyte production, blood cell storage, and blood cell destruction.","type":"DEFINITION","source":"NCI"},{"definition":"An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The organ that functions to filter blood and to store red corpuscles and platelets.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Spleen","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Spleen"},{"name":"Maps_To","value":"Spleen"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037993"},{"name":"xRef","value":"UBERON:0002106"}]}}{"C15189":{"preferredName":"Biopsy","code":"C15189","definitions":[{"definition":"Patient required removal of tissue or fluid specimen to establish a diagnosis.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Bx","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Biopsy"},{"name":"Maps_To","value":"Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0005558"},{"name":"xRef","value":"IMDRF:F2201"}]}}{"C17610":{"preferredName":"Blood Sample","code":"C17610","definitions":[{"definition":"A small volume of blood removed for testing or storage.","type":"DEFINITION","source":"NCI"},{"definition":"Taking a sample of blood by using a needle. (https://mrctcenter.org/glossaryterm/blood-draw/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Blood Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Blood_Sample"},{"name":"Maps_To","value":"Blood Draw"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0178913"}]}}{"C133261":{"preferredName":"Bone Marrow Aspirate","code":"C133261","definitions":[{"definition":"Aspirate from bone marrow.","type":"DEFINITION","source":"NCI"},{"definition":"The liquid portion of bone marrow, consisting of small tissue fragments, hematopoietic cells, and peripheral blood.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bone Marrow Aspirate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone Marrow Aspirate"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0857285"}]}}{"C15680":{"preferredName":"Core Biopsy","code":"C15680","definitions":[{"definition":"A type of biopsy in which a tissue sample is removed using a needle with a relatively large diameter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of a tissue sample with a wide needle for examination under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Core Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Core Needle Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Core_Biopsy"},{"name":"Maps_To","value":"Core Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C1318309"}]}}{"C16491":{"preferredName":"Cytology","code":"C16491","definitions":[{"definition":"The light microscopic study of normal and abnormal cells in fine needle aspirates (FNAs), body cavity fluids, and smears.","type":"DEFINITION","source":"NCI"},{"definition":"The study of cells using a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cytology","termGroup":"PT","termSource":"NCI"},{"termName":"Histology, Cytology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Cytology"},{"name":"Maps_To","value":"Cytology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0010819"}]}}{"C16482":{"preferredName":"Cystoscopy","code":"C16482","definitions":[{"definition":"Endoscopic examination of the urinary bladder or urethra.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Endoscopic examination of the urinary bladder or urethra.","type":"DEFINITION","source":"NCI"},{"definition":"Examination of the bladder and urethra using a cystoscope, inserted into the urethra. A cystoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cystoscopy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystoscopy"},{"name":"Maps_To","value":"Cystoscopy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0553652"}]}}{"C15749":{"preferredName":"Tumor Debulking","code":"C15749","definitions":[{"definition":"Surgical removal of as much of a tumor as possible. Tumor debulking may increase the chance that chemotherapy or radiation therapy will kill all the tumor cells. It may also be done to relieve symptoms or help the patient live longer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of as much of a malignant tumor as is reasonably possible. This procedure increases the effectiveness of the subsequent administration of chemotherapy and/or radiation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Debulking","termGroup":"PT","termSource":"NCI"},{"termName":"Debulking","termGroup":"SY","termSource":"NCI"},{"termName":"Debulking Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Debulking Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tumor_Debulking"},{"name":"Maps_To","value":"Debulking"},{"name":"Maps_To","value":"Tumor Debulking"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0439805"}]}}{"C16502":{"preferredName":"Diagnostic Imaging","code":"C16502","definitions":[{"definition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diagnostic Imaging","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diagnostic_Imaging"},{"name":"Maps_To","value":"Diagnostic Imaging"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0011923"}]}}{"C15226":{"preferredName":"Dilation and Curettage","code":"C15226","definitions":[{"definition":"A minor operation in which the cervix is expanded enough (dilation) to permit the cervical canal and uterine lining to be scraped with a spoon-shaped instrument called a curette (curettage).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A surgical scraping and removal of the inner lining of the uterus through direct dilation of the uterine cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dilation and Curettage","termGroup":"PT","termSource":"NCI"},{"termName":"D and C","termGroup":"SY","termSource":"NCI"},{"termName":"Dilation and Curettage of the Uterus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dilation_and_Curettage"},{"name":"Maps_To","value":"Dilation and Curettage Procedure"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C4067681"}]}}{"C48601":{"preferredName":"Enucleation","code":"C48601","definitions":[{"definition":"A surgical procedure by which tissue or an organ (usually containing a tumor) is removed without rupture from a specific anatomic site.","type":"DEFINITION","source":"NCI"},{"definition":"In medicine, the removal of an organ or tumor in such a way that it comes out clean and whole, like a nut from its shell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Enucleation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Enucleation"},{"name":"Maps_To","value":"Enucleation"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0014392"}]}}{"C15385":{"preferredName":"Excisional Biopsy","code":"C15385","definitions":[{"definition":"A surgical procedure in which an entire lesion is removed for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"A surgical procedure in which an entire lump or suspicious area is removed for diagnosis. The tissue is then examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of biopsy in which an entire lesion is removed for microscopic examination.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Excisional Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Excisional_Biopsy"},{"name":"Maps_To","value":"Biopsy, Excisional"},{"name":"Maps_To","value":"Excisional Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0184921"}]}}{"C15361":{"preferredName":"Fine-Needle Aspiration","code":"C15361","definitions":[{"definition":"The removal of tissue or fluid with a thin needle for examination under a microscope.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of tissue or fluid with a thin needle for examination under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of tissue specimens or fluid from the living body with a thin needle.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fine-Needle Aspiration","termGroup":"PT","termSource":"NCI"},{"termName":"Aspirate, Fine Needle","termGroup":"SY","termSource":"NCI"},{"termName":"Fine Needle Aspiration","termGroup":"SY","termSource":"NCI"},{"termName":"Fine Needle Biopsy","termGroup":"SY","termSource":"NCI"},{"termName":"FNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Fine-Needle_Aspiration"},{"name":"Maps_To","value":"Fine Needle Aspiration"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C1510483"}]}}{"C17369":{"preferredName":"Imaging Technique","code":"C17369","definitions":[{"definition":"A method of producing pictures of areas inside the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.","type":"DEFINITION","source":"NCI"},{"definition":"Method of imaging used to visualize and aspect of the patient for use in diagnosis or treatment.","type":"ALT_DEFINITION","source":"OORO","qualifiers":[{"type":"attribution","value":"PC"}]}],"synonyms":[{"termName":"Imaging Technique","termGroup":"PT","termSource":"NCI"},{"termName":"Diagnostic Imaging Technique","termGroup":"SY","termSource":"NCI"},{"termName":"Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"Imaging Procedures","termGroup":"SY","termSource":"NCI"},{"termName":"Imaging Technique","termGroup":"SY","termSource":"NCI"},{"termName":"Medical Imaging","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Imaging_Technique"},{"name":"Maps_To","value":"Imaging"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0079595"}]}}{"C15386":{"preferredName":"Incisional Biopsy","code":"C15386","definitions":[{"definition":"A procedure in which a surgical incision (cut) is made through the skin to expose and remove tissues. The biopsy tissue is examined under a microscope by a pathologist. An open biopsy may be done in the doctor's office or in the hospital, and may use local anesthesia or general anesthesia. A lumpectomy to remove a breast tumor is a type of open biopsy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A surgical procedure in which part of a lesion is removed for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"A type of biopsy in which part of a lesion is removed for microscopic examination.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Incisional Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Open Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Incisional_Biopsy"},{"name":"Maps_To","value":"Biopsy, Incisional"},{"name":"Maps_To","value":"Incisional Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0184922"}]}}{"C16969":{"preferredName":"Laparoscopy","code":"C16969","definitions":[{"definition":"A procedure that uses a laparoscope, inserted through the abdominal wall, to examine the inside of the abdomen. A laparoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A surgical procedure during which a laparoscope is inserted into the abdomen to view the abdominopelvic contents for diagnostic and/or therapeutic purposes.","type":"DEFINITION","source":"NCI"},{"definition":"A technique used to examine the abdominopelvic region with a laparoscope.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Laparoscopy","termGroup":"PT","termSource":"NCI"},{"termName":"Laparoscopic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laparoscopy"},{"name":"Maps_To","value":"Laparoscopy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0031150"}]}}{"C15266":{"preferredName":"Laparotomy","code":"C15266","definitions":[{"definition":"A surgical incision made in the wall of the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Creation of a surgical opening into the abdominal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparotomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laparotomy"},{"name":"Maps_To","value":"Laparotomy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0023038"}]}}{"C17348":{"preferredName":"Pap Smear","code":"C17348","definitions":[{"definition":"A biospecimen collection and staining procedure in which secretions and superficial cells of the cervix are collected and stained with the Papanicolaou stain followed by microscopic examination to identify the presence of abnormal cells.","type":"DEFINITION","source":"NCI"},{"definition":"A biospecimen collection and staining procedure in which secretions and superficial cells of the cervix are collected and stained with the Papanicolaou stain followed by microscopic examination to identify the presence of abnormal cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A procedure in which cells are scraped from the cervix for examination under a microscope. It is used to detect cancer and changes that may lead to cancer. A Pap smear can also show conditions, such as infection or inflammation, that are not cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pap Smear","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical Smear Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Smear Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Pap Smear Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Pap Test","termGroup":"SY","termSource":"NCI"},{"termName":"Papanicolaou Smear Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Papanicolaou Test","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Smears","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pap_Smear"},{"name":"Maps_To","value":"Pap Smear"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0079104"}]}}{"C20989":{"preferredName":"Physical Examination","code":"C20989","definitions":[{"definition":"A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment.","type":"DEFINITION","source":"NCI"},{"definition":"An exam of the body to check for general signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Physical Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Assessment","termGroup":"SY","termSource":"NCI"},{"termName":"Physical","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Assessment","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Exam","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Physical_Examination"},{"name":"Maps_To","value":"Physical Exam"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0031809"}]}}{"C125006":{"preferredName":"Pathologic Examination","code":"C125006","definitions":[{"definition":"An appraisal by a pathologist that is based on microscopic and macroscopic structural and functional changes that result from disease processes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An assessment of disease process to include cause, development, and/or structural and functional changes associated with the disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pathologic Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Pathology Examination","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pathologic"},{"name":"Maps_To","value":"Pathologic Review"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C4086729"}]}}{"C158758":{"preferredName":"Resection","code":"C158758","definitions":[{"definition":"A surgical procedure in which tissue is removed from the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Removal by surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of an organ or a part of an organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resection","termGroup":"PT","termSource":"NCI"},{"termName":"Surgical Resection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgical Resection"},{"name":"NCI_META_CUI","value":"CL950724"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C15392":{"preferredName":"Thoracentesis","code":"C15392","definitions":[{"definition":"Removal of fluid from the pleural cavity through a needle inserted between the ribs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of excess fluid via needle puncture from the thoracic cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The removal of excess fluid via needle puncture from the thoracic cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thoracentesis","termGroup":"PT","termSource":"NCI"},{"termName":"Chest Aspiration","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Cavity Tap","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Tap","termGroup":"SY","termSource":"NCI"},{"termName":"Pleurocentesis","termGroup":"SY","termSource":"NCI"},{"termName":"Puncture of Pleural Cavity for Aspiration","termGroup":"SY","termSource":"NCI"},{"termName":"Thoracic Paracentesis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thoracentesis"},{"name":"Maps_To","value":"Thoracentesis"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189477"}]}}{"C93022":{"preferredName":"Ultrasound-Guided Biopsy","code":"C93022","definitions":[{"definition":"A biopsy procedure that uses an ultrasound imaging device to find an abnormal area of tissue and guide its removal for examination under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Biopsy of tissue using ultrasound imaging as an aid in directing a biopsy needle into the area of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ultrasound-Guided Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Ultrasound Guided Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0456900"}]}}{"C118358":{"preferredName":"Exoresection","code":"C118358","definitions":[{"definition":"A surgical technique for the transscleral resection of large, anteriorly located uveal melanomas with ciliary body and/or iris involvement. This approach is most common when conservative therapy is either unlikely to help, or likely to cause complications.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exoresection","termGroup":"PT","termSource":"NCI"},{"termName":"Exoresection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Exoresection"},{"name":"Maps_To","value":"Local Resection (Exoresection; wall resection)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3899237"}]}}{"C25227":{"preferredName":"High","code":"C25227","definitions":[{"definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High","termGroup":"PT","termSource":"NCI"},{"termName":"Higher","termGroup":"AD","termSource":"NCI"},{"termName":"Highly","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"High"},{"name":"Maps_To","value":"High"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1561957"}]}}{"C73705":{"preferredName":"Intermediate","code":"C73705","definitions":[{"definition":"Located between two points or extremes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Lying between two extremes in time or space or degree.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Intermediate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intermediate"},{"name":"Maps_To","value":"Intermediate"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205103"}]}}{"C54722":{"preferredName":"Low","code":"C54722","definitions":[{"definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Low"},{"name":"Maps_To","value":"Low"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205251"}]}}{"C3677":{"preferredName":"Benign Neoplasm","code":"C3677","definitions":[{"definition":"A general term used to describe autonomous growth of tissue where the originating cell type has not been characterized. The term benign indicates the absence of morphologic features associated with malignancy (for instance severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A growth that is not cancer. It does not invade nearby tissue or spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8000/0"},{"name":"Legacy Concept Name","value":"Benign_Neoplasm"},{"name":"Maps_To","value":"8000/0"},{"name":"Maps_To","value":"Benign neoplasm of other and unspecified sites"},{"name":"Maps_To","value":"Benign neoplasm: Other specified sites"},{"name":"Maps_To","value":"Neoplasm, benign"},{"name":"Maps_To","value":"Tumor, benign"},{"name":"Maps_To","value":"Unclassified tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0086692"}]}}{"C65157":{"preferredName":"Neoplasm, Uncertain Whether Benign or Malignant","code":"C65157","definitions":[{"definition":"A neoplasm which, on morphologic grounds, can not be classified with certainty as benign or malignant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoplasm, Uncertain Whether Benign or Malignant","termGroup":"HD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8000/1"},{"name":"Legacy Concept Name","value":"Neoplasm_Uncertain_Whether_Primary_or_Metastatic"},{"name":"Maps_To","value":"8000/1"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of other and unspecified sites and tissues"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of other specified sites"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior, site unspecified"},{"name":"Maps_To","value":"Neoplasm of uncertain or unknown behaviour of other and unspecified sites"},{"name":"Maps_To","value":"Neoplasm of unspecified behavior of other specified sites"},{"name":"Maps_To","value":"Neoplasm of unspecified behavior of unspecified site"},{"name":"Maps_To","value":"Neoplasm, uncertain whether benign or malignant"},{"name":"Maps_To","value":"Unclassified tumor, borderline malignancy"},{"name":"Maps_To","value":"Unclassified tumor, uncertain whether benign or malignant"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677041"}]}}{"C9305":{"preferredName":"Malignant Neoplasm","code":"C9305","definitions":[{"definition":"A general term for autonomous tissue growth exhibiting morphologic features of malignancy (e.g. severe atypia, nuclear pleomorphism, tumor cell necrosis, abnormal mitoses, tissue invasiveness) and for which the transformed cell type has not been specifically identified.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of diseases in which abnormal cells divide without control, invade nearby tissues and may also spread to other parts of the body through the blood and lymph systems.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","type":"DEFINITION","source":"NCI"},{"definition":"A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Malignant cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of malignancy. Carcinoma is a malignancy that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are malignancies that begin in the cells of the immune system. Central nervous system cancers are malignancies that begin in the tissues of the brain and spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Uncontrolled growth of abnormal cells with potential for metastatic spread.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"CA","termGroup":"AB","termSource":"NCI"},{"termName":"Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"ICD-O-3_Code","value":"8000/3"},{"name":"Legacy Concept Name","value":"Malignant_Neoplasm"},{"name":"Maps_To","value":"8000/3"},{"name":"Maps_To","value":"Cancer"},{"name":"Maps_To","value":"Malignancy"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites: Lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites: Overlapping lesion of other and ill-defined sites"},{"name":"Maps_To","value":"Malignant neoplasm of other specified sites"},{"name":"Maps_To","value":"Malignant neoplasm without specification of site"},{"name":"Maps_To","value":"Malignant neoplasm, primary site unknown, so stated"},{"name":"Maps_To","value":"Malignant neoplasm, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm, without specification of site"},{"name":"Maps_To","value":"Neoplasm, malignant"},{"name":"Maps_To","value":"Other malignant neoplasm of unspecified site"},{"name":"Maps_To","value":"Tumor, malignant, NOS"},{"name":"Maps_To","value":"Unclassified tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1861853"},{"name":"xRef","value":"IMDRF:E1801"}]}}{"C8997":{"preferredName":"Blastoma","code":"C8997","definitions":[{"definition":"A mass of rapidly growing cells that begins in embryonic (fetal) tissue. Embryomas may be benign or malignant, and include neuroblastomas and Wilms tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare embryonal neoplasm affecting children. It is associated with DICER1 gene mutation. This category includes pituitary gland blastoma and pleuropulmonary blastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Embryoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8981/3"},{"name":"Legacy Concept Name","value":"Blastoma"},{"name":"Maps_To","value":"8000/3"},{"name":"Maps_To","value":"Blastoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0936282"}]}}{"C36255":{"preferredName":"Secondary Neoplasm","code":"C36255","definitions":[{"definition":"A neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Secondary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secondary_Neoplasm"},{"name":"Maps_To","value":"8000/6"},{"name":"Maps_To","value":"Neoplasm, secondary"},{"name":"Maps_To","value":"Tumor, secondary"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2939419"}]}}{"C3005":{"preferredName":"Tumor Embolism","code":"C3005","definitions":[{"definition":"A tumor embolism involves sudden blockage of an artery by a clot or by other material from tumor fragments transported by the blood stream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Embolism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tumor_Embolism"},{"name":"Maps_To","value":"8000/6"},{"name":"Maps_To","value":"Tumor embolus"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0013930"}]}}{"C3261":{"preferredName":"Metastatic Neoplasm","code":"C3261","definitions":[{"definition":"A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Metastatic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Related_Lash_Concept: metastasis"},{"name":"ICD-O-3_Code","value":"8000/6"},{"name":"Legacy Concept Name","value":"Metastatic_Neoplasm"},{"name":"Maps_To","value":"8000/6"},{"name":"Maps_To","value":"Neoplasm, metastatic"},{"name":"Maps_To","value":"Tumor, metastatic"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2939420"}]}}{"C65153":{"preferredName":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","code":"C65153","definitions":[{"definition":"A malignant neoplasm in which the examined tissue can not be determined with certainty if it represents the primary site of tumor growth or tumor spread from another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8000/9"},{"name":"Legacy Concept Name","value":"Malignant_Neoplasm_Uncertain_Whether_Primary_or_Metastatic"},{"name":"Maps_To","value":"8000/9"},{"name":"Maps_To","value":"Neoplasm, malignant, uncertain whether primary or metastatic"},{"name":"Maps_To","value":"Unclassified tumor, malignant, uncertain whether primary or metastatic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334224"}]}}{"C36122":{"preferredName":"Benign Cellular Infiltrate","code":"C36122","definitions":[{"definition":"A morphologic finding indicating the presence of a cellular infiltrate without atypia in a tumor sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Cellular Infiltrate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Cellular_Infiltrate"},{"name":"Maps_To","value":"8001/0"},{"name":"Maps_To","value":"Tumor cells, benign"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1332480"}]}}{"C12922":{"preferredName":"Neoplastic Cell","code":"C12922","definitions":[{"definition":"Cells of, or derived from, a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoplastic Cell","termGroup":"PT","termSource":"NCI"},{"termName":"Tumor Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neoplastic_Cell"},{"name":"Maps_To","value":"8001/1"},{"name":"Maps_To","value":"Tumor cells, NOS"},{"name":"Maps_To","value":"Tumor cells, uncertain whether benign or malignant"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0597032"}]}}{"C12917":{"preferredName":"Malignant Cell","code":"C12917","definitions":[{"definition":"Cells of, or derived from, a malignant tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Cell","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Malignant_Cell"},{"name":"Maps_To","value":"8001/3"},{"name":"Maps_To","value":"Tumor cells, malignant"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0334227"}]}}{"C65154":{"preferredName":"Malignant Tumor, Small Cell Type","code":"C65154","definitions":[{"definition":"A malignant neoplasm characterized by the presence of small atypical cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Tumor, Small Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8002/3"},{"name":"Legacy Concept Name","value":"Malignant_Tumor_Small_Cell_Type"},{"name":"Maps_To","value":"8002/3"},{"name":"Maps_To","value":"Malignant tumor, small cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334228"}]}}{"C4090":{"preferredName":"Malignant Giant Cell Neoplasm","code":"C4090","definitions":[{"definition":"A malignant neoplasm characterized by then presence of atypical giant cells.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of bone comprised of giant cells (osteoclast-like) and mononuclear cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Giant Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8003/3"},{"name":"Legacy Concept Name","value":"Malignant_Giant_Cell_Neoplasm"},{"name":"Maps_To","value":"8003/3"},{"name":"Maps_To","value":"Malignant tumor, giant cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334229"}]}}{"C27091":{"preferredName":"Malignant Spindle Cell Neoplasm","code":"C27091","definitions":[{"definition":"A neoplasm characterized by the presence of malignant spindle cells.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that begins in the skin or in tissues that line or cover internal organs and that contains long spindle-shaped cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Spindle Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8004/3"},{"name":"Legacy Concept Name","value":"Malignant_Spindle_Cell_Neoplasm"},{"name":"Maps_To","value":"8004/3"},{"name":"Maps_To","value":"Malignant tumor, fusiform cell type"},{"name":"Maps_To","value":"Malignant tumor, spindle cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334230"}]}}{"C66752":{"preferredName":"Clear Cell Neoplasm","code":"C66752","definitions":[{"definition":"A purely morphologic term that describes a neoplasm in which all or the majority of the neoplastic cells have a clear cytoplasm, when examined under light microscopy, using the conventional staining method (H-E). This term does not provide any information about the nature of the neoplasm (benign or malignant), cell of origin (e.g. epithelial versus mesenchymal versus hematopoietic), or prognosis. Further examination using special stains and/or immunohistochemistry is required to appropriately classify this tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Neoplasm","termGroup":"AQ","termSource":"NCI"},{"termName":"Clear Cell Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8005/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Tumor"},{"name":"Maps_To","value":"8005/0"},{"name":"Maps_To","value":"Clear cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265994"}]}}{"C40077":{"preferredName":"Malignant Ovarian Clear Cell Tumor","code":"C40077","definitions":[{"definition":"An invasive malignant neoplasm that arises from the ovary and is characterized by a predominance of clear and hobnail malignant epithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Clear Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ovarian Clear Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Clear_Cell_Tumor"},{"name":"Maps_To","value":"8005/3"},{"name":"Maps_To","value":"Malignant tumor, clear cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265995"}]}}{"C4092":{"preferredName":"Benign Epithelial Neoplasm","code":"C4092","definitions":[{"definition":"A benign neoplasm arising from epithelial cells of the skin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm that arises from epithelial cells and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Epithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Epithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of Epithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Epithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Epithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Epithelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/0"},{"name":"ICD-O-3_Code","value":"8011/0"},{"name":"Legacy Concept Name","value":"Benign_Epithelial_Neoplasm"},{"name":"Maps_To","value":"8010/0"},{"name":"Maps_To","value":"8011/0"},{"name":"Maps_To","value":"Epithelial tumor, benign"},{"name":"Maps_To","value":"Epithelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334232"}]}}{"C2917":{"preferredName":"Carcinoma In Situ","code":"C2917","definitions":[{"definition":"A group of abnormal cells that remain in the place where they first formed. They have not spread. These abnormal cells may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant epithelial neoplasm confined to the epithelial layer and without evidence of further tissue invasion.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"CIS","termGroup":"AB","termSource":"NCI"},{"termName":"Intraepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-invasive Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8010/2"},{"name":"Legacy Concept Name","value":"Carcinoma_in_situ"},{"name":"Maps_To","value":"8010/2"},{"name":"Maps_To","value":"Carcinoma in situ"},{"name":"Maps_To","value":"Carcinoma in situ of other and unspecified genital organs"},{"name":"Maps_To","value":"Carcinoma in situ of other and unspecified sites"},{"name":"Maps_To","value":"Carcinoma in situ of unspecified female genital organs"},{"name":"Maps_To","value":"Carcinoma in situ, NOS"},{"name":"Maps_To","value":"Carcinoma in situ, site unspecified"},{"name":"Maps_To","value":"Carcinoma in situ, unspecified"},{"name":"Maps_To","value":"Carcinoma in situ: Thyroid and other endocrine glands"},{"name":"Maps_To","value":"Intraepithelial carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0851135"}]}}{"C2916":{"preferredName":"Carcinoma","code":"C2916","definitions":[{"definition":"A malignant epithelial neoplasm.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that begins in the skin or in tissues that line or cover internal organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/3"},{"name":"ICD-O-3_Code","value":"8011/3"},{"name":"Legacy Concept Name","value":"Carcinoma"},{"name":"Maps_To","value":"8010/3"},{"name":"Maps_To","value":"8011/3"},{"name":"Maps_To","value":"Carcinoma, NOS"},{"name":"Maps_To","value":"Epithelial tumor, malignant"},{"name":"Maps_To","value":"Epithelioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007097"}]}}{"C3482":{"preferredName":"Metastatic Carcinoma","code":"C3482","definitions":[{"definition":"Carcinoma that has spread from its original site of growth to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/6"},{"name":"Legacy Concept Name","value":"Metastatic_Carcinoma"},{"name":"Maps_To","value":"8010/6"},{"name":"Maps_To","value":"Carcinoma, metastatic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384494"}]}}{"C3693":{"preferredName":"Carcinomatosis","code":"C3693","definitions":[{"definition":"A condition in which cancer is spread widely throughout the body, or, in some cases, to a relatively large region of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma that has spread diffusely to an anatomic site or throughout the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/9"},{"name":"Legacy Concept Name","value":"Carcinomatosis"},{"name":"Maps_To","value":"8010/9"},{"name":"Maps_To","value":"Carcinomatosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205699"}]}}{"C3780":{"preferredName":"Large Cell Carcinoma","code":"C3780","definitions":[{"definition":"A malignant epithelial neoplasm composed of large, atypical cells.","type":"DEFINITION","source":"NCI"},{"definition":"Lung cancer in which the cells are large and look abnormal when viewed under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Large Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma, Large Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8012/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Carcinoma"},{"name":"Maps_To","value":"8012/3"},{"name":"Maps_To","value":"Large cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206704"}]}}{"C6875":{"preferredName":"Large Cell Neuroendocrine Carcinoma","code":"C6875","definitions":[{"definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant large cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Large Cell Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Large Cell NEC","termGroup":"SY","termSource":"NCI"},{"termName":"Large-cell neuroendocrine carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LCNEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8013/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8013/3"},{"name":"Maps_To","value":"Large cell neuroendocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265996"}]}}{"C6876":{"preferredName":"Lung Large Cell Carcinoma with Rhabdoid Phenotype","code":"C6876","definitions":[{"definition":"A large cell lung carcinoma characterized by the presence of rhabdoid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Large Cell Carcinoma with Rhabdoid Phenotype","termGroup":"PT","termSource":"NCI"},{"termName":"Large Cell Carcinoma with Rhabdoid Phenotype","termGroup":"SY","termSource":"NCI"},{"termName":"Large Cell Lung Carcinoma with Rhabdoid Phenotype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8014/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Lung_Carcinoma_with_Rhabdoid_Phenotype"},{"name":"Maps_To","value":"8014/3"},{"name":"Maps_To","value":"Large cell carcinoma with rhabdoid phenotype"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265997"}]}}{"C65159":{"preferredName":"Glassy Cell Carcinoma","code":"C65159","definitions":[{"definition":"A malignant epithelial neoplasm composed of atypical cells with glassy cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glassy Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8015/3"},{"name":"Legacy Concept Name","value":"Glassy_Cell_Carcinoma"},{"name":"Maps_To","value":"8015/3"},{"name":"Maps_To","value":"Glassy cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265998"}]}}{"C3692":{"preferredName":"Undifferentiated Carcinoma","code":"C3692","definitions":[{"definition":"A malignant epithelial neoplasm exhibiting poor differentiation (anaplasia).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma, Undifferentiated","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8020/3"},{"name":"ICD-O-3_Code","value":"8021/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Carcinoma"},{"name":"Maps_To","value":"8020/3"},{"name":"Maps_To","value":"8021/3"},{"name":"Maps_To","value":"Carcinoma, anaplastic, NOS"},{"name":"Maps_To","value":"Carcinoma, undifferentiated, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205698"}]}}{"C4094":{"preferredName":"Pleomorphic Carcinoma","code":"C4094","definitions":[{"definition":"A usually aggressive malignant epithelial neoplasm composed of cells with significant cytologic atypia and nuclear pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8022/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Carcinoma"},{"name":"Maps_To","value":"8022/3"},{"name":"Maps_To","value":"Pleomorphic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334233"}]}}{"C45716":{"preferredName":"NUT Carcinoma","code":"C45716","definitions":[{"definition":"A rare, highly aggressive and lethal carcinoma that affects children and young adults.  It arises from midline epithelial structures, most commonly the head, neck, and mediastinum.  It is a poorly differentiated carcinoma and is characterized by mutations and rearrangement of the NUT gene.  A balanced translocation t(15;19) is present that results in the creation of a fusion gene involving the NUT gene, most commonly BRD4-NUT fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUT Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma with t(15;19)(q13;p13.1) Translocation","termGroup":"SY","termSource":"NCI"},{"termName":"Midline Carcinoma of Children and Young Adults with NUT Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"NMC","termGroup":"AB","termSource":"NCI"},{"termName":"Nuclear Protein in Testis (NUT) Midline Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Protein in Testis Midline Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Midline Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carcinoma_with_t_15_19_q13_p13_1_Translocation"},{"name":"Maps_To","value":"Midline carcinoma of children and young adults with NUT rearrangement"},{"name":"Maps_To","value":"Nuclear protein in testis (NUT)-associated carcinoma"},{"name":"Maps_To","value":"NUT carcinoma"},{"name":"Maps_To","value":"NUT midline carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707291"}]}}{"C65160":{"preferredName":"Giant Cell and Spindle Cell Carcinoma","code":"C65160","definitions":[{"definition":"A malignant epithelial neoplasm composed of giant, pleomorphic cells and spindle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell and Spindle Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8030/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_and_Spindle_Cell_Carcinoma"},{"name":"Maps_To","value":"8030/3"},{"name":"Maps_To","value":"Giant cell and spindle cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334234"}]}}{"C3779":{"preferredName":"Giant Cell Carcinoma","code":"C3779","definitions":[{"definition":"A malignant epithelial neoplasm composed of giant, pleomorphic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma, Giant Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8031/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Carcinoma"},{"name":"Maps_To","value":"8031/3"},{"name":"Maps_To","value":"Giant cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206703"}]}}{"C27004":{"preferredName":"Sarcomatoid Carcinoma","code":"C27004","definitions":[{"definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that begins in the skin or in tissues that line or cover internal organs and that contains long spindle-shaped cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sarcomatoid Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pseudosarcomatous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8032/3"},{"name":"ICD-O-3_Code","value":"8033/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Carcinoma"},{"name":"Maps_To","value":"8032/3"},{"name":"Maps_To","value":"8033/3"},{"name":"Maps_To","value":"Pseudosarcomatous carcinoma"},{"name":"Maps_To","value":"Sarcomatoid carcinoma"},{"name":"Maps_To","value":"Spindle cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205697"}]}}{"C65161":{"preferredName":"Polygonal Cell Carcinoma","code":"C65161","definitions":[{"definition":"A malignant epithelial neoplasm composed of atypical polygonal cells with a large amount of eosinophilic cytoplasm. A representative example is the fibrolamellar hepatocellular carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polygonal Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8034/3"},{"name":"Legacy Concept Name","value":"Polygonal_Cell_Carcinoma"},{"name":"Maps_To","value":"8034/3"},{"name":"Maps_To","value":"Polygonal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334236"}]}}{"C63622":{"preferredName":"Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","code":"C63622","definitions":[{"definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular or squamous differentiation and giant cells resembling osteoclasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8035/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Carcinoma_with_Osteoclast-Like_Giant_Cells"},{"name":"Maps_To","value":"8035/3"},{"name":"Maps_To","value":"Carcinoma with osteoclast-like giant cells"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1883424"}]}}{"C65162":{"preferredName":"Tumorlet","code":"C65162","definitions":[{"definition":"A tiny localized pulmonary nodule characterized by neuroendocrine cell proliferation. It is usually discovered as an incidental finding during routine histologic examination of tissue sections or during radiologic examination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumorlet","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Tumorlet","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8040/0"},{"name":"ICD-O-3_Code","value":"8040/1"},{"name":"Legacy Concept Name","value":"Tumorlet"},{"name":"Maps_To","value":"8040/0"},{"name":"Maps_To","value":"8040/1"},{"name":"Maps_To","value":"Tumorlet, benign"},{"name":"Maps_To","value":"Tumorlet, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1266001"}]}}{"C3915":{"preferredName":"Small Cell Neuroendocrine Carcinoma","code":"C3915","definitions":[{"definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant small cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Oat Cell Cancer","termGroup":"AQS","termSource":"NCI"},{"termName":"Oat Cell Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"SCNEC","termGroup":"AB","termSource":"NCI"},{"termName":"Small Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell NEC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8041/3"},{"name":"ICD-O-3_Code","value":"8042/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Carcinoma"},{"name":"Maps_To","value":"8041/3"},{"name":"Maps_To","value":"8042/3"},{"name":"Maps_To","value":"Oat cell carcinoma"},{"name":"Maps_To","value":"Reserve cell carcinoma"},{"name":"Maps_To","value":"Round cell carcinoma"},{"name":"Maps_To","value":"Small cell carcinoma, NOS"},{"name":"Maps_To","value":"Small cell neuroendocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0262584"}]}}{"C27092":{"preferredName":"Small Cell Carcinoma, Fusiform Cell Type","code":"C27092","definitions":[{"definition":"A neuroendocrine carcinoma composed of malignant fusiform small cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Carcinoma, Fusiform Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8043/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Carcinoma_Fusiform_Cell_Type"},{"name":"Maps_To","value":"8043/3"},{"name":"Maps_To","value":"Small cell carcinoma, fusiform cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334238"}]}}{"C4099":{"preferredName":"Small Cell Intermediate Cell Carcinoma","code":"C4099","definitions":[{"definition":"A neuroendocrine carcinoma composed of malignant small cells of intermediate shape.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Carcinoma, Intermediate Cell","termGroup":"AQS","termSource":"NCI"},{"termName":"Small Cell Intermediate Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8044/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Intermediate_Cell_Carcinoma"},{"name":"Maps_To","value":"8044/3"},{"name":"Maps_To","value":"Small cell carcinoma, intermediate cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334239"}]}}{"C9137":{"preferredName":"Combined Lung Small Cell Carcinoma","code":"C9137","definitions":[{"definition":"A morphologic variant of small cell lung carcinoma in combination with a non-small cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Lung Small Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Small and Large Cell Lung Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell-Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell-Large Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Type Small Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Type Small Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Type Small Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Small Cell and Large Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Small Cell and Large Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Small Cell and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell and Large Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell and Large Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8045/3"},{"name":"Legacy Concept Name","value":"Combined_Type_Small_Cell_Lung_Carcinoma"},{"name":"Maps_To","value":"8045/3"},{"name":"Maps_To","value":"Combined small cell carcinoma"},{"name":"Maps_To","value":"Combined small cell-squamous cell carcinoma"},{"name":"Maps_To","value":"Mixed small cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334240"}]}}{"C65151":{"preferredName":"Non-Small Cell Carcinoma","code":"C65151","definitions":[{"definition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Small Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8046/3"},{"name":"Legacy Concept Name","value":"Non-Small_Cell_Carcinoma"},{"name":"Maps_To","value":"8046/3"},{"name":"Maps_To","value":"Non-small cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266002"}]}}{"C7440":{"preferredName":"Papilloma","code":"C7440","definitions":[{"definition":"A benign epithelial neoplasm that projects above the surrounding epithelial surface and consists of villous or arborescent outgrowths of fibrovascular stroma.","type":"DEFINITION","source":"NCI"},{"definition":"A benign epithelial neoplasm that projects above the surrounding epithelial surface.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8050/0"},{"name":"Legacy Concept Name","value":"Papilloma"},{"name":"Maps_To","value":"8050/0"},{"name":"Maps_To","value":"Papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030354"}]}}{"C65163":{"preferredName":"Papillary Carcinoma In Situ","code":"C65163","definitions":[{"definition":"An epithelial neoplasm with a papillary growth pattern in which the malignant cells are confined to the epithelium, without evidence of invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Carcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8050/2"},{"name":"Legacy Concept Name","value":"Papillary_Carcinoma_In_Situ"},{"name":"Maps_To","value":"8050/2"},{"name":"Maps_To","value":"Papillary carcinoma in situ"},{"name":"Maps_To","value":"Papillary carcinoma in situ, NOS"},{"name":"Maps_To","value":"Solid papillary carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334242"}]}}{"C2927":{"preferredName":"Papillary Carcinoma","code":"C2927","definitions":[{"definition":"A malignant epithelial neoplasm characterized by a papillary growth pattern. A papillary carcinoma may be composed of glandular cells (papillary adenocarcinoma), squamous cells (papillary squamous cell carcinoma), or transitional cells (papillary transitional cell carcinoma). Bladder carcinoma is a representative example of papillary transitional cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8050/3"},{"name":"Legacy Concept Name","value":"Papillary_Carcinoma"},{"name":"Maps_To","value":"8050/3"},{"name":"Maps_To","value":"Papillary carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007133"}]}}{"C4101":{"preferredName":"Verrucous Papilloma","code":"C4101","definitions":[{"definition":"A benign epithelial neoplasm characterized by a papillary growth pattern, lack of significant cytologic atypia, and a wart-like appearance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verrucous Papilloma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8051/0"},{"name":"Legacy Concept Name","value":"Verrucous_Papilloma"},{"name":"Maps_To","value":"8051/0"},{"name":"Maps_To","value":"Verrucous papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334243"}]}}{"C3781":{"preferredName":"Verrucous Carcinoma","code":"C3781","definitions":[{"definition":"A well differentiated squamous cell carcinoma characterized by a papillary growth pattern, acanthosis, mild cytologic atypia, and pushing tumor margins. The most commonly affected anatomic sites are the oral cavity, nasal cavity, larynx, esophagus, anus, vagina, vulva, and the plantar region of the foot.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verrucous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Verrucous Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Verrucous Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Verrucous Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Verrucous Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8051/3"},{"name":"Legacy Concept Name","value":"Verrucous_Carcinoma"},{"name":"Maps_To","value":"8051/3"},{"name":"Maps_To","value":"Condylomatous carcinoma"},{"name":"Maps_To","value":"Verrucous carcinoma, NOS"},{"name":"Maps_To","value":"Verrucous epidermoid carcinoma"},{"name":"Maps_To","value":"Verrucous squamous cell carcinoma"},{"name":"Maps_To","value":"Warty carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206706"}]}}{"C3712":{"preferredName":"Squamous Papilloma","code":"C3712","definitions":[{"definition":"A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells without morphologic evidence of malignancy. Most frequently it arises in the oral cavity, nasopharynx, larynx, esophagus, vagina, and vulva.","type":"DEFINITION","source":"NCI"},{"definition":"A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Squamous Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Cell Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Keratotic Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8052/0"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Papilloma"},{"name":"Maps_To","value":"8052/0"},{"name":"Maps_To","value":"Keratotoc papilloma"},{"name":"Maps_To","value":"Squamous cell papilloma, NOS"},{"name":"Maps_To","value":"Squamous papilloma"},{"name":"Maps_To","value":"Squamous papilloma; solitary"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205874"}]}}{"C65164":{"preferredName":"Non-Invasive Papillary Squamous Cell Carcinoma","code":"C65164","definitions":[{"definition":"A well differentiated squamous cell carcinoma characterized by a papillary, exophytic growth pattern, hyperkeratosis, and absence of invasion of adjacent tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Invasive Papillary Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8052/2"},{"name":"Legacy Concept Name","value":"Non-Invasive_Papillary_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8052/2"},{"name":"Maps_To","value":"Papillary squamous cell carcinoma in situ"},{"name":"Maps_To","value":"Papillary squamous cell carcinoma, non-invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266003"}]}}{"C4102":{"preferredName":"Papillary Squamous Cell Carcinoma","code":"C4102","definitions":[{"definition":"A well differentiated squamous cell carcinoma characterized by a papillary, exophytic growth pattern and hyperkeratosis. The most commonly affected anatomic sites are the larynx, penis, cervix, vagina, and vulva.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Squamous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8052/3"},{"name":"Legacy Concept Name","value":"Papillary_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8052/3"},{"name":"Maps_To","value":"Papillary epidermoid carcinoma"},{"name":"Maps_To","value":"Papillary squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334244"}]}}{"C65165":{"preferredName":"Inverted Squamous Papilloma","code":"C65165","definitions":[{"definition":"A benign epithelial neoplasm characterized by an endophytic growth, papillary pattern, and proliferation of neoplastic squamous cells without morphologic evidence of malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inverted Squamous Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Inverted Squamous Cell Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8053/0"},{"name":"Legacy Concept Name","value":"Inverted_Squamous_Cell_Papilloma"},{"name":"Maps_To","value":"8053/0"},{"name":"Maps_To","value":"Squamous cell papilloma, inverted"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881254"}]}}{"C9009":{"preferredName":"Squamous Papillomatosis","code":"C9009","definitions":[{"definition":"A benign squamous neoplasm characterized by a papillary growth pattern, diffusely involving a specific anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8060/0"},{"name":"Legacy Concept Name","value":"Squamous_Papillomatosis"},{"name":"Maps_To","value":"8060/0"},{"name":"Maps_To","value":"Squamous papillomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378340"}]}}{"C3713":{"preferredName":"Papillomatosis","code":"C3713","definitions":[{"definition":"Glandular or squamous cell neoplastic proliferations characterized by the formation of multiple papillary structures diffusely involving a specific anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillomatosis"},{"name":"Maps_To","value":"8060/0"},{"name":"Maps_To","value":"Papillomatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205875"}]}}{"C27093":{"preferredName":"Stage 0 Squamous Cell Carcinoma","code":"C27093","definitions":[{"definition":"A malignant epithelial neoplasm confined to the squamous epithelium, without invasion of the underlying tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant epithelial neoplasm confined to the squamous epithelium, without invasion of underlying tissues.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Stage 0 Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 SIN","termGroup":"AB","termSource":"NCI"},{"termName":"Grade 3 Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III SIN","termGroup":"AB","termSource":"NCI"},{"termName":"Grade III Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SCC in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma in-situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8070/2"},{"name":"ICD-O-3_Code","value":"8077/2"},{"name":"Legacy Concept Name","value":"Stage_0_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Epidermoid carcinoma in situ, NOS"},{"name":"Maps_To","value":"Intraepidermal carcinoma, NOS"},{"name":"Maps_To","value":"Intraepithelial squamous cell carcinoma"},{"name":"Maps_To","value":"Squamous cell carcinoma in situ, NOS"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334245"}]}}{"C2929":{"preferredName":"Squamous Cell Carcinoma","code":"C2929","definitions":[{"definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from squamous epithelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epidermoid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epidermoid Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Squamous Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Squamous Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"SCC","termGroup":"AB","termSource":"NCI"},{"termName":"Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8070/3"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8070/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, NOS"},{"name":"Maps_To","value":"Squamous carcinoma"},{"name":"Maps_To","value":"Squamous cell carcinoma, NOS"},{"name":"Maps_To","value":"Squamous cell epithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3151392"}]}}{"C4104":{"preferredName":"Metastatic Squamous Cell Carcinoma","code":"C4104","definitions":[{"definition":"A carcinoma that arises from squamous cells and has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8070/6"},{"name":"Legacy Concept Name","value":"Metastatic_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8070/6"},{"name":"Maps_To","value":"Squamous cell carcinoma, metastatic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334246"}]}}{"C4105":{"preferredName":"Keratinizing Squamous Cell Carcinoma","code":"C4105","definitions":[{"definition":"Squamous cell carcinomas with morphologically prominent production of keratin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Keratinizing Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8071/3"},{"name":"Legacy Concept Name","value":"Keratinizing_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8071/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, keratinizing"},{"name":"Maps_To","value":"Squamous cell carcinoma, keratinizing, NOS"},{"name":"Maps_To","value":"Squamous cell carcinoma, large cell, keratinizing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334247"}]}}{"C65173":{"preferredName":"Non-Keratinizing Large Cell Squamous Cell Carcinoma","code":"C65173","definitions":[{"definition":"A squamous cell carcinoma composed of large atypical cells, without morphologic evidence of keratin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Keratinizing Large Cell Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8072/3"},{"name":"Legacy Concept Name","value":"Non-Keratinizing_Large_Cell_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8072/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, large cell, nonkeratinizing"},{"name":"Maps_To","value":"Squamous cell carcinoma, large cell, nonkeratinizing, NOS"},{"name":"Maps_To","value":"Squamous cell carcinoma, nonkeratinizing, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334248"}]}}{"C65175":{"preferredName":"Non-Keratinizing Small Cell Squamous Cell Carcinoma","code":"C65175","definitions":[{"definition":"A squamous cell carcinoma composed of small atypical cells, without morphologic evidence of keratin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Keratinizing Small Cell Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8073/3"},{"name":"Legacy Concept Name","value":"Non-Keratinizing_Small_Cell_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8073/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, small cell, nonkeratinizing"},{"name":"Maps_To","value":"Squamous cell carcinoma, small cell, nonkeratinizing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334249"}]}}{"C27084":{"preferredName":"Spindle Cell Squamous Carcinoma","code":"C27084","definitions":[{"definition":"A poorly differentiated squamous cell carcinoma characterized by the presence of malignant cells with spindle cell features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Squamous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatoid Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell (Sarcomatoid) Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma, Sarcomatoid","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma, Spindle Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma, Spindle Cell Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8074/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8074/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, spindle cell"},{"name":"Maps_To","value":"Squamous cell carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Squamous cell carcinoma, spindle cell"},{"name":"NCI_META_CUI","value":"CL388688"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4106":{"preferredName":"Pseudoglandular Squamous Cell Carcinoma","code":"C4106","definitions":[{"definition":"A squamous cell carcinoma characterized by the formation of gland-like structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pseudoglandular Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoid Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoid Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudoglandular Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudoglandular Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudoglandular Squamous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8075/3"},{"name":"Legacy Concept Name","value":"Pseudoglandular_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8075/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, acantholytic"},{"name":"Maps_To","value":"Squamous cell carcinoma, adenoid"},{"name":"Maps_To","value":"Squamous cell carcinoma, pseudoglandular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334250"}]}}{"C65176":{"preferredName":"Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion","code":"C65176","definitions":[{"definition":"A malignant epithelial neoplasm involving all the layers of the squamous epithelium, but it is not certain if it is confined to the squamous epithelium or it has invaded the basement membrane and the underlying stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8076/2"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma_In_Situ_with_Questionable_Stromal_Invasion"},{"name":"Maps_To","value":"8076/2"},{"name":"Maps_To","value":"Epidermoid carcinoma in situ with questionable stromal invasion"},{"name":"Maps_To","value":"Squamous cell carcinoma in situ with questionable stromal invasion"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334251"}]}}{"C65178":{"preferredName":"Microinvasive Squamous Cell Carcinoma","code":"C65178","definitions":[{"definition":"A squamous cell carcinoma with minimal stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microinvasive Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8076/3"},{"name":"Legacy Concept Name","value":"Microinvasive_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8076/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, microinvasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334252"}]}}{"C7351":{"preferredName":"Grade II Squamous Intraepithelial Neoplasia","code":"C7351","synonyms":[{"termName":"Grade II Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Grade_II_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, grade II"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302798"}]}}{"C27427":{"preferredName":"Low Grade Esophageal Squamous Intraepithelial Neoplasia","code":"C27427","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities are confined to the lower half of the esophageal squamous epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Esophageal Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal Low Grade Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade Esophageal Squamous Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Esophageal_Low-Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Esophageal squamous intraepithelial neoplasia (dysplasia), low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333458"}]}}{"C8335":{"preferredName":"Low Grade Squamous Intraepithelial Neoplasia","code":"C8335","definitions":[{"definition":"A condition in which the cells of the uterine cervix are slightly abnormal. Low-grade squamous intraepithelial lesion is not cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A precancerous neoplastic process characterized by the presence of mild dysplastic cytological changes which are usually present in the lower part of the squamous epithelium.  Representative examples include the low grade esophageal squamous intraepithelial neoplasia, low grade cervical squamous intraepithelial neoplasia, low grade vaginal intraepithelial neoplasia, and low grade vulvar intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"},{"termName":"LSIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Low_Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, grade I"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302773"}]}}{"C4630":{"preferredName":"Low Grade Cervical Intraepithelial Neoplasia","code":"C4630","definitions":[{"definition":"Squamous or glandular cervical intraepithelial neoplasia characterized by the presence of mild dysplastic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Cervical Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Low-Grade Cervix Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Cervix Uteri Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of the Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Uterine Cervix Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Low-Grade_Cervical_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Cervical intraepithelial neoplasia, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349458"}]}}{"C8336":{"preferredName":"High Grade Squamous Intraepithelial Neoplasia","code":"C8336","definitions":[{"definition":"A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Cells of the uterine cervix that are moderately or severely abnormal and may become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"High Grade Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"High-Grade Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"},{"termName":"HSIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/2"},{"name":"Legacy Concept Name","value":"High-Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0333875"}]}}{"C157575":{"preferredName":"Anal Intraepithelial Neoplasia 3","code":"C157575","definitions":[{"definition":"Anal canal or perianal skin intraepithelial neoplasia with severe dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Intraepithelial Neoplasia 3","termGroup":"PT","termSource":"NCI"},{"termName":"AIN3","termGroup":"AB","termSource":"NCI"},{"termName":"Anal Squamous Intraepithelial Neoplasia 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"AIN III"},{"name":"Maps_To","value":"Anal intraepithelial neoplasia, grade III"},{"name":"NCI_META_CUI","value":"CL937283"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7855":{"preferredName":"Stage 0 Vaginal Cancer AJCC v6","code":"C7855","definitions":[{"definition":"Stage 0 includes: (Tis, N0, M0).  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Vaginal Cancer AJCC v6","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC Stage 0 Vaginal Cancer v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Vagina AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Vagina AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Vagina","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Vagina","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vagina Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vaginal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Vaginal Intraepithelial Neoplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Vaginal Intraepithelial Neoplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Vagina Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Vagina Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vagina Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Cancer Stage 0 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"VAIN 3 AJCC v6","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"VAIN III AJCC v6","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0_Vaginal_Cancer"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Vaginal intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0686277"}]}}{"C4000":{"preferredName":"Stage 0 Cervical Cancer AJCC v6","code":"C4000","definitions":[{"definition":"Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Cervical Cancer AJCC v6","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma in situ of Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical cancer stage 0 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"CIN 3 AJCC v6","termGroup":"AB","termSource":"NCI"},{"termName":"CIN Grade 3 AJCC v6","termGroup":"AB","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Cervical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Cervix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Cervix Uteri Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Uterine Cervix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Cervical Intraepithelial Neoplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Cervix Uteri Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Cervix Uteri Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Uterine Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Uterine Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Cervical Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of the Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of the Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of the Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0_Cervical_Cancer"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Cervical intraepithelial neoplasia, grade III"},{"name":"Maps_To","value":"CIN III with severe dysplasia"},{"name":"Maps_To","value":"Cin III, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0851140"}]}}{"C4522":{"preferredName":"Stage 0 Vulvar Cancer AJCC v6","code":"C4522","definitions":[{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (preinvasive carcinoma. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Vulvar Cancer AJCC v6","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC Stage 0 Vulvar Cancer v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vulva Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vulvar Carcinoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vulval Cancer AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vulval Carcinoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vulvar Carcinoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vulva Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Cancer Stage 0 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0_Vulvar_Cancer"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"VIN III"},{"name":"Maps_To","value":"Vulvar intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278729"}]}}{"C65179":{"preferredName":"Squamous Cell Carcinoma with Horn Formation","code":"C65179","definitions":[{"definition":"A keratinizing squamous cell carcinoma characterized by the presence of horn pearls. Representative examples include squamous cell carcinomas of the face presenting as a cutaneous horn.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma with Horn Formation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8078/3"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma_with_Horn_Formation"},{"name":"Maps_To","value":"8078/3"},{"name":"Maps_To","value":"Squamous cell carcinoma with horn formation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266004"}]}}{"C27790":{"preferredName":"Penile Carcinoma In Situ","code":"C27790","definitions":[{"definition":"Abnormal cells are found on the surface of the skin of the penis. These abnormal cells may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penile Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Bowen Disease of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Bowen's Disease of Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Bowen's Disease of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Erythroplasia of Queyrat","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Penile Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Squamous Intraepithelial Lesion of Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Squamous Intraepithelial Lesion of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Penile Carcinoma In Situ AJCC v7","termGroup":"SY","termSource":"NCI"},{"termName":"Queyrat Erythroplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Queyrat's Erythroplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8080/2"},{"name":"Legacy Concept Name","value":"Penile_Carcinoma_in_situ"},{"name":"Maps_To","value":"8080/2"},{"name":"Maps_To","value":"Queyrat erythroplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0154089"}]}}{"C62571":{"preferredName":"Bowen Disease of the Skin","code":"C62571","definitions":[{"definition":"A form of squamous cell carcinoma in situ. It is a distinct clinicopathological entity and arises from the skin or the mucocutaneous junction. It affects predominantly white males in their 6-8th decades of life. Exposed and non-exposed skin sites are equally affected. UV damage and ingestion of inorganic arsenic may play a role in the development of the disease. On the skin surface, it presents as a single or multiple erythematous, scaly, keratotic patches or plaques. The clinical entity of erythroplasia of Queyrat is regarded as Bowen disease of the penis and it presents as an asymptomatic, red, circumscribed plaque. Morphologically, Bowen disease is characterized by the presence of hyperkeratosis, parakeratosis, dyskeratosis, and acanthosis. The keratotic squamous cells are atypical and display hyperchromatism and abnormal mitotic figures. The dermoepidermal basement membrane is intact. Complete surgical removal of the lesion may be curative.","type":"DEFINITION","source":"NCI"},{"definition":"A skin disease marked by scaly or thickened patches on the skin and often caused by prolonged exposure to arsenic. The patches often occur on sun-exposed areas of the skin and in older white men. These patches may become malignant (cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bowen Disease of the Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Bowen Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Bowen's Disease of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepidermal Squamous Cell Carcinoma, Bowen Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8081/2"},{"name":"Legacy Concept Name","value":"Bowen_Disease_of_the_Skin"},{"name":"Maps_To","value":"8081/2"},{"name":"Maps_To","value":"Bowen disease"},{"name":"Maps_To","value":"Intraepidermal squamous cell carcinoma, Bowen type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0006079"}]}}{"C4107":{"preferredName":"Nasopharyngeal-Type Undifferentiated Carcinoma","code":"C4107","definitions":[{"definition":"A nonkeratinizing carcinoma which occurs predominantly in the nasopharynx but also in the tonsils and rarely in other anatomic sites.  It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nasopharyngeal-Type Undifferentiated Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphoepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioma-Like Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nasopharyngeal Type Undifferentiated Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Schmincke Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8082/3"},{"name":"Legacy Concept Name","value":"Nasopharyngeal_Type_Undifferentiated_Carcinoma"},{"name":"Maps_To","value":"8082/3"},{"name":"Maps_To","value":"Lymphoepithelial carcinoma"},{"name":"Maps_To","value":"Lymphoepithelioma"},{"name":"Maps_To","value":"Lymphoepithelioma-like carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334254"}]}}{"C54244":{"preferredName":"Basaloid Squamous Cell Carcinoma","code":"C54244","definitions":[{"definition":"A squamous cell carcinoma characterized by the presence of cells with hyperchromatic nuclei, scant amount of cytoplasm, and peripheral nuclear palisading.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basaloid Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8083/3"},{"name":"Legacy Concept Name","value":"Basaloid_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8083/3"},{"name":"Maps_To","value":"Basaloid squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266005"}]}}{"C65180":{"preferredName":"Squamous Cell Carcinoma, Clear Cell Type","code":"C65180","definitions":[{"definition":"A squamous cell carcinoma characterized by the presence of malignant cells with clear cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma, Clear Cell Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8084/3"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma_Clear_Cell_Type"},{"name":"Maps_To","value":"8084/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, clear cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266006"}]}}{"C27683":{"preferredName":"Human Papillomavirus-Related Squamous Cell Carcinoma","code":"C27683","definitions":[{"definition":"A squamous cell carcinoma associated with the presence of human papillomavirus infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-Related Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-Related Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus Related Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus-Related Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papilloma_Virus-Related_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV positive"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV-positive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334057"}]}}{"C164250":{"preferredName":"Human Papillomavirus-Independent Squamous Cell Carcinoma","code":"C164250","definitions":[{"definition":"A squamous cell carcinoma not associated with human papilloma virus infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-Independent Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-Independent Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-Negative Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus-Negative Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8086/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV negative"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV-negative"},{"name":"NCI_META_CUI","value":"CL973823"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2921":{"preferredName":"Skin Basal Cell Carcinoma","code":"C2921","definitions":[{"definition":"Cancer that begins in the lower part of the epidermis (the outer layer of the skin). It may appear as a small white or flesh-colored bump that grows slowly and may bleed. Basal cell cancers are usually found on areas of the body exposed to the sun. Basal cell cancers rarely metastasize (spread) to other parts of the body. They are the most common form of skin cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Carcinoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Carcinoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Skin Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"BCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8090/3"},{"name":"Legacy Concept Name","value":"Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8090/3"},{"name":"Maps_To","value":"Basal Cell Cancer"},{"name":"Maps_To","value":"Basal Cell Carcinoma"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of left eyelid, including canthus"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of other and unspecified parts of face"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of other part of trunk"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of other parts of face"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of right eyelid, including canthus"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of trunk, except scrotum"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of unspecified eyelid, including canthus"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of unspecified parts of face"},{"name":"Maps_To","value":"Basal cell carcinoma of skin, site unspecified"},{"name":"Maps_To","value":"Basal cell carcinoma of skin, unspecified"},{"name":"Maps_To","value":"Basal cell carcinoma, NOS"},{"name":"Maps_To","value":"Basal cell epithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007117"}]}}{"C9359":{"preferredName":"Skin Pigmented Basal Cell Carcinoma","code":"C9359","definitions":[{"definition":"A basal cell carcinoma that contains large amounts of melanin.  The melanin is produced by symbiotic nontumoral proliferating melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Pigmented Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pigmented Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pigmented_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8090/3"},{"name":"Maps_To","value":"Pigmented basal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368275"}]}}{"C156767":{"preferredName":"Basal Cell Carcinoma","code":"C156767","definitions":[{"definition":"A carcinoma involving the basal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Basal_Cell_Neoplasm"},{"name":"Maps_To","value":"8090/3"},{"name":"Maps_To","value":"Basal cell carcinoma, NOS"},{"name":"NCI_META_CUI","value":"CL935818"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4108":{"preferredName":"Superficial Multifocal Basal Cell Carcinoma","code":"C4108","definitions":[{"definition":"A superficial basal cell carcinoma of the skin characterized by the presence of lobules of basaloid cells which are separated by large distances and represent multifocal discrete tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Multifocal Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Multicentric Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8091/3"},{"name":"Legacy Concept Name","value":"Superficial_Multifocal_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8091/3"},{"name":"Maps_To","value":"Multicentric basal cell carcinoma"},{"name":"Maps_To","value":"Multifocal superficial basal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334256"}]}}{"C27182":{"preferredName":"Skin Sclerosing/Morphoeic Basal Cell Carcinoma","code":"C27182","definitions":[{"definition":"A histologic variant of basal cell carcinoma of the skin characterized by the presence of strands and nests of malignant cells that are embedded in a dense fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Sclerosing/Morphoeic Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Carcinoma Sclerosing Type","termGroup":"SY","termSource":"NCI"},{"termName":"Morphea-Type (Sclerosing) Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Morphea-Type Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Morpheaform Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Type Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Morphea-Type (Sclerosing) Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Morphea-Type_Sclerosing_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8092/3"},{"name":"Maps_To","value":"Infiltrating basal cell carcinoma, sclerosing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0555191"}]}}{"C27539":{"preferredName":"Skin Infiltrating Basal Cell Carcinoma","code":"C27539","definitions":[{"definition":"A variant of basal cell carcinoma presenting as a pale, indurated plaque, usually in the upper trunk or face. Morphologically, it is characterized by the presence of strands, cords, and columns of basaloid cells infiltrating the dermis. Perineural invasion may be present and the basaloid cell infiltrate may extend into deeper tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Infiltrating Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8092/3"},{"name":"Legacy Concept Name","value":"Infiltrating_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8092/3"},{"name":"Maps_To","value":"Basal cell carcinoma, desmoplastic type"},{"name":"Maps_To","value":"Basal cell carcinoma, morpheic"},{"name":"Maps_To","value":"Infiltrating basal cell carcinoma, non-sclerosing"},{"name":"Maps_To","value":"Infiltrating basal cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334257"}]}}{"C4109":{"preferredName":"Skin Fibroepithelial Basal Cell Carcinoma","code":"C4109","definitions":[{"definition":"A variant of basal cell carcinoma presenting as an elevated or erythematous nodular lesion usually in the back. Morphologically, it is characterized by the presence of cords of basaloid cells extending from the epidermis into the dermis, creating a fenestrating pattern. It follows an indolent course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Fibroepithelial Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroepithelial Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroepithelioma of Pinkus","termGroup":"SY","termSource":"NCI"},{"termName":"Pinkus Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8093/3"},{"name":"Legacy Concept Name","value":"Fibroepithelioma_of_Pinkus"},{"name":"Maps_To","value":"8093/3"},{"name":"Maps_To","value":"Basal cell carcinoma, fibroepithelial"},{"name":"Maps_To","value":"Fibroepithelial basal cell carcinoma, Pinkus type"},{"name":"Maps_To","value":"Fibroepithelioma of Pinkus type"},{"name":"Maps_To","value":"Fibroepithelioma, NOS"},{"name":"Maps_To","value":"Pinkus tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346013"}]}}{"C2922":{"preferredName":"Skin Basosquamous Cell Carcinoma","code":"C2922","definitions":[{"definition":"A basal cell carcinoma (skin neoplasm) which displays squamous differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A basal cell carcinoma which displays squamous differentiation. The neoplastic cells have more abundant cytoplasm with more marked keratinization than typical basal cell carcinomas. It usually has a more aggressive clinical course compared to typical basal cell carcinoma, and it may produce regional or widespread metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Basosquamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basosquamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Basosquamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Metatypical Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Metatypical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Mixed Basal and Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8094/3"},{"name":"ICD-O-3_Code","value":"8095/3"},{"name":"Legacy Concept Name","value":"Basosquamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8094/3"},{"name":"Maps_To","value":"8095/3"},{"name":"Maps_To","value":"Basosquamous carcinoma"},{"name":"Maps_To","value":"Metatypical carcinoma"},{"name":"Maps_To","value":"Mixed basal-squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007118"}]}}{"C66903":{"preferredName":"Skin Metatypical Carcinoma","code":"C66903","synonyms":[{"termName":"Skin Metatypical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Skin Metatypical Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Fri Mar 01 13:50:59 EST 2024 - See 'Skin Basosquamous Cell Carcinoma(C2922)'"},{"name":"ICD-O-3_Code","value":"8095/3"},{"name":"Legacy Concept Name","value":"Skin_Metatypical_Carcinoma"},{"name":"Maps_To","value":"Metatypical carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"OLD_ASSOCIATION","value":"A32|C176985"},{"name":"OLD_ASSOCIATION","value":"A32|C177621"},{"name":"OLD_ASSOCIATION","value":"A8|C157711"},{"name":"OLD_ASSOCIATION","value":"A8|C168655"},{"name":"OLD_ASSOCIATION","value":"A8|C168656"},{"name":"OLD_ASSOCIATION","value":"A8|C168657"},{"name":"OLD_ASSOCIATION","value":"A8|C168658"},{"name":"OLD_ASSOCIATION","value":"A8|C168661"},{"name":"OLD_ASSOCIATION","value":"A8|C168662"},{"name":"OLD_ASSOCIATION","value":"A8|C177537"},{"name":"OLD_PARENT","value":"C2922"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1883040"}]}}{"C4110":{"preferredName":"Intraepidermal Epithelioma of Jadassohn","code":"C4110","definitions":[{"definition":"A rare cutaneous lesion presenting as a scaly verrucous plaque. Morphologically, the plaque contains nests of basaloid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borst-Jadassohn Intraepidermal Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intraepidermal Epithelioma of Jadassohn","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8096/0"},{"name":"Legacy Concept Name","value":"Intraepidermal_Epithelioma_of_Jadassohn"},{"name":"Maps_To","value":"8096/0"},{"name":"Maps_To","value":"Intraepidermal epithelioma of Jadassohn"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2937231"}]}}{"C27541":{"preferredName":"Skin Micronodular Basal Cell Carcinoma","code":"C27541","definitions":[{"definition":"A basal cell carcinoma of the skin characterized by the presence of small nodules that permeate the dermis.  It presents as an elevated or flat infiltrating tumor, usually in the back.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Micronodular Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Micronodular Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Micronodular_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8097/3"},{"name":"Maps_To","value":"Basal cell carcinoma, micronodular"},{"name":"NCI_META_CUI","value":"CL331352"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C62282":{"preferredName":"Skin Nodular Basal Cell Carcinoma","code":"C62282","definitions":[{"definition":"A basal cell carcinoma of the skin that often appears as elevated nodules which may become ulcerated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Nodular Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Nodular Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Basal Cell Carcinoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Basal Cell Carcinoma of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_Nodular_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8097/3"},{"name":"Maps_To","value":"Basal cell carcinoma, nodular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367861"}]}}{"C27535":{"preferredName":"Skin Adenoid Basal Cell Carcinoma","code":"C27535","definitions":[{"definition":"A variant of basal cell carcinoma morphologically characterized by the presence of thin strands of basaloid cells forming a reticulate pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Adenoid Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoid Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8098/3"},{"name":"Legacy Concept Name","value":"Adenoid_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8098/3"},{"name":"Maps_To","value":"Adenoid basal carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266007"}]}}{"C27132":{"preferredName":"Trichoblastoma","code":"C27132","definitions":[{"definition":"A benign hair follicle neoplasm with trichoblastic differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign hair follicle neoplasm with trichoblastic differentiation. It usually presents as a solitary papular lesion It most often presents on the head and neck area, but it may develop in any anatomic site containing hair follicles. Because of its benign nature, treatment usually is not required, provided that the diagnosis has been established with certainty.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Brooke's Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Trichoblastic Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Trichoepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Trichogenic Adnexal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Trichogenic Trichoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8100/0"},{"name":"Legacy Concept Name","value":"Trichogenic_Trichoblastoma"},{"name":"Maps_To","value":"8100/0"},{"name":"Maps_To","value":"Brooke tumor"},{"name":"Maps_To","value":"Epithelioma adenoides cysticum"},{"name":"Maps_To","value":"Trichoepithelioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349658"}]}}{"C4112":{"preferredName":"Trichofolliculoma","code":"C4112","definitions":[{"definition":"A skin appendage neoplasm with follicular differentiation. It usually occurs in the head and neck region, particularly the face. It presents as a solitary dome-shaped small lesion. The clinical course is benign.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichofolliculoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8101/0"},{"name":"Legacy Concept Name","value":"Trichofolliculoma"},{"name":"Maps_To","value":"8101/0"},{"name":"Maps_To","value":"Trichofolliculoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334262"}]}}{"C4113":{"preferredName":"Trichilemmoma","code":"C4113","definitions":[{"definition":"A benign hair follicle neoplasm in the outer hair sheath and infundibulum, characterized by central cells showing highly eosinophilic amorphous keratin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm arising from the outer hair sheath and infundibulum. It occurs in the head and neck, usually on the face. It usually presents as an exophytic wart-like lesion or a dome-shaped lesion with a smooth surface. Morphologically, it is characterized by the proliferation of cuboidal cells with clear or eosinophilic cytoplasm in the dermis with connection to the epidermis/hair follicle. There is peripheral cellular palisading, and the lesion is surrounded by a hyaline band.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichilemmoma","termGroup":"PT","termSource":"NCI"},{"termName":"Tricholemmoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8102/0"},{"name":"ICD-O-3_Code","value":"8102/2"},{"name":"Legacy Concept Name","value":"Trichilemmoma"},{"name":"Maps_To","value":"8102/0"},{"name":"Maps_To","value":"Trichilemmoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334263"}]}}{"C43326":{"preferredName":"Trichilemmal Carcinoma","code":"C43326","definitions":[{"definition":"A rare malignant tumor arising from the outer hair sheath and infundibulum on the face. It is considered the malignant counterpart of tricholemmoma. Complete surgical excision is required.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichilemmal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Trichilemmocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8102/3"},{"name":"Legacy Concept Name","value":"Trichilemmal_Carcinoma"},{"name":"Maps_To","value":"8102/3"},{"name":"Maps_To","value":"Trichilemmal carcinoma"},{"name":"Maps_To","value":"Trichilemmocarcinoma"},{"name":"Maps_To","value":"Trichoblastic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266009"}]}}{"C27125":{"preferredName":"Proliferating Trichilemmal Tumor","code":"C27125","definitions":[{"definition":"A neoplasm with tricholemmal differentiation. It affects women more frequently than men. It usually presents on the scalp as a solitary, multilobular, large, exophytic mass. Morphologically, it may display benign cytological features and appear as a circumscribed solid-cystic neoplasm or it may display malignant characteristics and invasive features. Cases without malignant characteristics usually have an indolent course. Complete surgical excision is recommended in such cases to avoid recurrences and to allow complete examination of the specimen. Cases with malignant characteristics may have a locally aggressive clinical course, recur, or metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proliferating Trichilemmal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Pilar Cyst","termGroup":"SY","termSource":"NCI"},{"termName":"Pilar Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Pilar Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Trichilemmal Cyst","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Trichilemmal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Tricholemmal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8103/0"},{"name":"ICD-O-3_Code","value":"8103/1"},{"name":"Legacy Concept Name","value":"Pilar_Tumor"},{"name":"Maps_To","value":"8103/0"},{"name":"Maps_To","value":"Pilar tumor"},{"name":"Maps_To","value":"Proliferating trichilemmal cyst"},{"name":"Maps_To","value":"Proliferating trichilemmal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0086809"}]}}{"C7368":{"preferredName":"Pilomatricoma","code":"C7368","definitions":[{"definition":"A benign adnexal neoplasm arising from hair-bearing skin surfaces, usually the head and neck and upper extremities. It usually presents as a solitary, slow-growing nodular mass. Morphologically, it displays differentiation towards the matrix and inner sheath of the normal hair follicle and the hair cortex. Complete surgical excision is usually curative. Occasionally, it may recur.","type":"DEFINITION","source":"NCI"},{"definition":"A benign hair follicle neoplasm in the outer hair sheath and infundibulum, characterized by abrupt keratinization and central lumen with ghost cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pilomatricoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Pilomatricoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Pilomatrixoma","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Epithelioma of Malherbe","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrixoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8110/0"},{"name":"Legacy Concept Name","value":"Pilomatricoma"},{"name":"Maps_To","value":"8110/0"},{"name":"Maps_To","value":"Calcifying epithelioma of Malherbe"},{"name":"Maps_To","value":"Pilomatricoma, NOS"},{"name":"Maps_To","value":"Pilomatrixoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206711"}]}}{"C4114":{"preferredName":"Pilomatrical Carcinoma","code":"C4114","definitions":[{"definition":"A very rare, locally aggressive, malignant neoplasm of the hair follicle. The majority of the cases arise de novo, however malignant transformation from a pre-existing pilomatricoma has been reported. It usually presents as a solitary nodule in the head and neck, upper extremities, or buttocks. Morphologically, it is characterized by the presence of aggregates of basaloid cells infiltrating the dermis. Masses of ghost cells are present in the cellular aggregates. Complete surgical excision is the treatment of choice. If it is not completely removed, it usually recurs, but it rarely metastasizes to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilomatrical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Pilomatrixoma","termGroup":"SY","termSource":"NCI"},{"termName":"Matrical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Carcinoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Carcinoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Skin Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8110/3"},{"name":"Legacy Concept Name","value":"Pilomatrix_Carcinoma"},{"name":"Maps_To","value":"8110/3"},{"name":"Maps_To","value":"Matrical carcinoma"},{"name":"Maps_To","value":"Pilomatrical carcinoma"},{"name":"Maps_To","value":"Pilomatricoma, malignant"},{"name":"Maps_To","value":"Pilomatrix carcinoma"},{"name":"Maps_To","value":"Pilomatrixoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0585475"}]}}{"C4115":{"preferredName":"Transitional Cell Papilloma","code":"C4115","definitions":[{"definition":"A benign papillary neoplasm composed of transitional cells which show preservation of the nuclear polarity.","type":"DEFINITION","source":"NCI"},{"definition":"A benign papillary neoplasm composed of urothelial cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Transitional Cell Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8120/0"},{"name":"Legacy Concept Name","value":"Transitional_Cell_Papilloma"},{"name":"Maps_To","value":"8120/1"},{"name":"Maps_To","value":"Transitional cell papilloma, benign"},{"name":"Maps_To","value":"Transitional cell papilloma, NOS"},{"name":"Maps_To","value":"Transitional papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334266"}]}}{"C3842":{"preferredName":"Urothelial Papilloma","code":"C3842","definitions":[{"definition":"A rare benign neoplasm that arises from the urinary tract and is characterized by the presence of a papillary growth with a central fibrovascular core. The latter is lined by normal urothelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urothelial Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8120/1"},{"name":"Legacy Concept Name","value":"Urothelial_Papilloma"},{"name":"Maps_To","value":"8120/1"},{"name":"Maps_To","value":"Papilloma of bladder"},{"name":"Maps_To","value":"Urothelial papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0235754"}]}}{"C4116":{"preferredName":"Stage 0 Transitional Cell Carcinoma","code":"C4116","definitions":[{"definition":"A lesion in which the surface epithelium of the bladder or the renal pelvis and ureter contains transitional cells which display malignant cytologic characteristics.  There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Transitional Cell Carcinoma in situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8120/2"},{"name":"Legacy Concept Name","value":"Stage_0_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8120/2"},{"name":"Maps_To","value":"Transitional cell carcinoma in situ"},{"name":"Maps_To","value":"Urothelial carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334267"}]}}{"C2930":{"preferredName":"Transitional Cell Carcinoma","code":"C2930","definitions":[{"definition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from transitional epithelium.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that forms in transitional cells in the lining of the bladder, ureter, or renal pelvis (the part of the kidney that collects, holds, and drains urine). Transitional cells are cells that can change shape and stretch without breaking apart.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8120/3"},{"name":"Legacy Concept Name","value":"Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8120/3"},{"name":"Maps_To","value":"Transitional carcinoma"},{"name":"Maps_To","value":"Transitional cell carcinoma"},{"name":"Maps_To","value":"Transitional cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007138"}]}}{"C4030":{"preferredName":"Urothelial Carcinoma","code":"C4030","definitions":[{"definition":"A carcinoma arising from the urothelial lining of the urinary tract (bladder, renal pelvis, ureter, or urethra).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Cell Carcinoma of the Urinary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Uroepithelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urothelial_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8120/3"},{"name":"Maps_To","value":"Urothelial carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2145472"}]}}{"C4117":{"preferredName":"Sinonasal Papilloma","code":"C4117","definitions":[{"definition":"A benign neoplasm that arises from the ciliated respiratory mucosa that lines the nasal cavity and paranasal sinuses.  It is classified as inverted papilloma, oncocytic papilloma, and exophytic papilloma. Clinical manifestations include nasal obstruction, epistaxis, and anosmia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8121/0"},{"name":"Legacy Concept Name","value":"Schneiderian_Papilloma"},{"name":"Maps_To","value":"8121/0"},{"name":"Maps_To","value":"Schneiderian papilloma, NOS"},{"name":"Maps_To","value":"Sinonasal papilloma"},{"name":"Maps_To","value":"Sinonasal papilloma, exophytic"},{"name":"Maps_To","value":"Sinonasal papilloma, fungiform"},{"name":"Maps_To","value":"Sinonasal papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334268"}]}}{"C4118":{"preferredName":"Inverted Transitional Cell Papilloma","code":"C4118","definitions":[{"definition":"A benign papillary neoplasm composed of transitional cells and characterized by an endophytic growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inverted Transitional Cell Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Inverted Transitional Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8121/1"},{"name":"Legacy Concept Name","value":"Inverted_Transitional_Cell_Papilloma"},{"name":"Maps_To","value":"8121/0"},{"name":"Maps_To","value":"8121/1"},{"name":"Maps_To","value":"Transitional cell papilloma, inverted, benign"},{"name":"Maps_To","value":"Transitional cell papilloma, inverted, NOS"},{"name":"Maps_To","value":"Transitional papilloma, inverted, benign"},{"name":"Maps_To","value":"Transitional papilloma, inverted, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334269"}]}}{"C6871":{"preferredName":"Sinonasal Inverted Papilloma","code":"C6871","definitions":[{"definition":"A benign neoplasm that arises from the ciliated respiratory mucosa that lines the nasal cavity or paranasal sinuses.  It results from the invagination and proliferation of epithelial cells in the underlying stroma.  Clinical manifestations include nasal obstruction, epistaxis, and anosmia. It has the tendency to recur and extend to adjacent structures.  Inverted papillomas are occasionally associated with the development or presence of carcinomas, usually squamous cell carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Inverted Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Inverted Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Inverted Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Papilloma, Inverted Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inverted_Schneiderian_Papilloma"},{"name":"Maps_To","value":"8121/1"},{"name":"Maps_To","value":"Schneiderian papilloma, inverted"},{"name":"Maps_To","value":"Sinonasal papilloma, inverted"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1537102"}]}}{"C54345":{"preferredName":"Sinonasal Oncocytic Papilloma","code":"C54345","definitions":[{"definition":"A benign neoplasm with exophytic and endophytic growth arising from the lateral nasal wall or the paranasal sinuses. It is characterized by the proliferation of columnar cells with oncocytic features. Microcysts containing mucin and neutrophils are present in the epithelium. Clinical manifestations include nasal obstruction and epistaxis. Occasionally, it is associated with the development or presence of a carcinoma, usually squamous cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Oncocytic Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Oncocytic Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Oncocytic Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Papilloma, Oncocytic Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oncocytic_Schneiderian_Papilloma"},{"name":"Maps_To","value":"8121/1"},{"name":"Maps_To","value":"Oncocytic Schneiderian papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704453"}]}}{"C54287":{"preferredName":"Sinonasal Non-Keratinizing Squamous Cell Carcinoma","code":"C54287","definitions":[{"definition":"A squamous cell carcinoma of the sinonasal tract characterized by a plexiform or ribbon-like growth pattern, cytological atypia, and lack of histological evidence of keratinization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Non-Keratinizing Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Keratinizing Sinonasal Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ringertz Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Schneiderian Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Cylindrical Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Schneiderian Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Transitional Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8121/3"},{"name":"Legacy Concept Name","value":"Non-Keratinizing_Sinonasal_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8121/3"},{"name":"Maps_To","value":"Cylindrical cell carcinoma"},{"name":"Maps_To","value":"Schneiderian carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334270"}]}}{"C4120":{"preferredName":"Sarcomatoid Transitional Cell Carcinoma","code":"C4120","definitions":[{"definition":"A poorly differentiated transitional cell carcinoma characterized by the presence of malignant cells with spindle cell morphologic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Cell Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Transitional Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8122/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8122/3"},{"name":"Maps_To","value":"Transitional cell carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Transitional cell carcinoma, spindle cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334271"}]}}{"C4121":{"preferredName":"Basaloid Carcinoma","code":"C4121","definitions":[{"definition":"A malignant epithelial neoplasm characterized by the presence of neoplastic cells with hyperchromatic nuclei, small amount of cytoplasm, and peripheral nuclear palisading.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basaloid Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8123/3"},{"name":"Legacy Concept Name","value":"Basaloid_Carcinoma"},{"name":"Maps_To","value":"8123/3"},{"name":"Maps_To","value":"Basaloid carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704216"}]}}{"C8255":{"preferredName":"Anal Canal Cloacogenic Carcinoma","code":"C8255","definitions":[{"definition":"An anal carcinoma arising from the transitional zone of the anal canal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Canal Cloacogenic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anal Canal Transitional Zone Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Anal Cloacogenic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Anal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Carcinoma of Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Carcinoma of the Anus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8124/3"},{"name":"Legacy Concept Name","value":"Anal_Cloacogenic_Carcinoma"},{"name":"Maps_To","value":"8124/3"},{"name":"Maps_To","value":"Cloacogenic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334273"}]}}{"C191672":{"preferredName":"Papillary Urothelial Neoplasm of Low Malignant Potential","code":"C191672","definitions":[{"definition":"A papillary neoplasm of the urothelium. The papillary structures exhibit minimal architectural distortion and minimal atypia. Mitoses are infrequent. It usually occurs in the urinary bladder, but it can arise from other sites in the urinary tract. Patients are at an increased risk of developing new papillary lesions. Occasionally, the new lesions are urothelial carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Urothelial Neoplasm of Low Malignant Potential","termGroup":"PT","termSource":"NCI"},{"termName":"PUNLMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8130/1"},{"name":"Maps_To","value":"Papillary transitional cell neoplasm of low malignant potential"},{"name":"Maps_To","value":"Papillary urothelial neoplasm of low malignant potential"},{"name":"NCI_META_CUI","value":"CL1905256"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C65181":{"preferredName":"Non-Invasive Papillary Transitional Cell Carcinoma","code":"C65181","definitions":[{"definition":"A transitional cell carcinoma characterized by a papillary growth pattern and lack of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Invasive Papillary Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8130/2"},{"name":"Legacy Concept Name","value":"Non-Invasive_Papillary_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8130/2"},{"name":"Maps_To","value":"Papillary transitional cell carcinoma, non-invasive"},{"name":"Maps_To","value":"Papillary urothelial carcinoma, non-invasive"},{"name":"NCI_META_CUI","value":"CL017895"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4122":{"preferredName":"Papillary Transitional Cell Carcinoma","code":"C4122","definitions":[{"definition":"A non-invasive or invasive transitional cell carcinoma characterized by a papillary growth pattern. It may occur in the bladder or the renal pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Transitional Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8130/3"},{"name":"Legacy Concept Name","value":"Papillary_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8130/3"},{"name":"Maps_To","value":"Papillary transitional cell carcinoma"},{"name":"Maps_To","value":"Papillary urothelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334274"}]}}{"C65182":{"preferredName":"Micropapillary Transitional Cell Carcinoma","code":"C65182","definitions":[{"definition":"A transitional cell carcinoma characterized by a micropapillary growth pattern. Typical example is the micropapillary variant of infiltrating bladder urothelial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micropapillary Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8131/3"},{"name":"Legacy Concept Name","value":"Micropapillary_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8131/3"},{"name":"Maps_To","value":"Transitional cell carcinoma, micropapillary"},{"name":"Maps_To","value":"Urothelial carcinoma, micropapillary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266012"}]}}{"C2855":{"preferredName":"Adenoma","code":"C2855","definitions":[{"definition":"A benign neoplasm arising from epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that is not cancer. It starts in gland-like cells of the epithelial tissue (thin layer of tissue that covers organs, glands, and other structures within the body).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/0"},{"name":"Legacy Concept Name","value":"Adenoma"},{"name":"Maps_To","value":"8140/0"},{"name":"Maps_To","value":"Adenoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001430"}]}}{"C3494":{"preferredName":"Lung Papillary Adenoma","code":"C3494","definitions":[{"definition":"A benign lung neoplasm characterized by the presence of a fibrovascular stroma lined by cuboidal to columnar cells. Patients are usually asymptomatic and it is incidentally discovered as a pulmonary nodule during chest X-ray examination. Surgical excision is curative.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasia of the lung, arising from bronchial epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that forms in tissues of the bronchi (large air passages in the lungs including those that lead to the lungs from the windpipe).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lung Papillary Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Bronchus","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Bronchus","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchial Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Adenoma of Type II Pneumocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Papillary Tumor of Type II Pneumocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Type II Pneumocyte Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8260/0"},{"name":"Legacy Concept Name","value":"Bronchial_Adenoma"},{"name":"Maps_To","value":"8140/1"},{"name":"Maps_To","value":"Bronchial adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0149845"}]}}{"C7559":{"preferredName":"Atypical Adenoma","code":"C7559","definitions":[{"definition":"An adenoma characterized by increased cellularity and nuclear atypia without evidence of vascular or capsular invasion. A representative example is thyroid gland atypical follicular adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/1"},{"name":"Legacy Concept Name","value":"Atypical_Adenoma"},{"name":"Maps_To","value":"8140/1"},{"name":"Maps_To","value":"Atypical adenoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1305409"}]}}{"C4123":{"preferredName":"Adenocarcinoma In Situ","code":"C4123","definitions":[{"definition":"A lesion in which the normally situated glands are partially or completely replaced by atypical cells with malignant characteristics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ"},{"name":"Maps_To","value":"8140/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334276"}]}}{"C2852":{"preferredName":"Adenocarcinoma","code":"C2852","definitions":[{"definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from glandular cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8140/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma"},{"name":"Maps_To","value":"8140/3"},{"name":"Maps_To","value":"Adenocarcinoma"},{"name":"Maps_To","value":"Adenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2750272"}]}}{"C4124":{"preferredName":"Metastatic Adenocarcinoma","code":"C4124","definitions":[{"definition":"An adenocarcinoma that has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/6"},{"name":"Legacy Concept Name","value":"Metastatic_Adenocarcinoma"},{"name":"Maps_To","value":"8140/6"},{"name":"Maps_To","value":"Adenocarcinoma, metastatic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334277"}]}}{"C2928":{"preferredName":"Scirrhous Adenocarcinoma","code":"C2928","definitions":[{"definition":"A malignant neoplasm originating from glandular cells with a fibrous or fibroblastic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating adenocarcinoma characterized by the presence of desmoplastic stromal reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scirrhous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma with Productive Fibrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8141/3"},{"name":"Legacy Concept Name","value":"Scirrhous_Adenocarcinoma"},{"name":"Maps_To","value":"8141/3"},{"name":"Maps_To","value":"Carcinoma with productive fibrosis"},{"name":"Maps_To","value":"Scirrhous adenocarcinoma"},{"name":"Maps_To","value":"Scirrhous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007135"}]}}{"C3190":{"preferredName":"Linitis Plastica","code":"C3190","definitions":[{"definition":"A cancer-related condition in which the gastric wall becomes thickened and rubbery (leather-bottle stomach). It is most often associated with diffuse gastric adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linitis Plastica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8142/3"},{"name":"Legacy Concept Name","value":"Linitis_Plastica"},{"name":"Maps_To","value":"8142/3"},{"name":"Maps_To","value":"Linitis plastica"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0023743"}]}}{"C4125":{"preferredName":"Superficial Spreading Adenocarcinoma","code":"C4125","definitions":[{"definition":"An adenocarcinoma which has spread within the mucosa without further invasion of the underlying tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Spreading Adenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8143/3"},{"name":"Legacy Concept Name","value":"Superficial_Spreading_Adenocarcinoma"},{"name":"Maps_To","value":"8143/3"},{"name":"Maps_To","value":"Superficial spreading adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334278"}]}}{"C4126":{"preferredName":"Intestinal-Type Adenocarcinoma","code":"C4126","definitions":[{"definition":"An adenocarcinoma arising from epithelium which has undergone intestinal metaplasia. Representative examples include gastric, gallbladder, and ampulla of Vater intestinal type adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intestinal-Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma, Intestinal Type","termGroup":"SY","termSource":"NCI"},{"termName":"Intestinal Type Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8144/3"},{"name":"Legacy Concept Name","value":"Intestinal_Type_Adenocarcinoma"},{"name":"Maps_To","value":"8144/3"},{"name":"Maps_To","value":"Adenocarcinoma, intestinal type"},{"name":"Maps_To","value":"Carcinoma, intestinal type"},{"name":"Maps_To","value":"Intestinal-type adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334279"}]}}{"C4127":{"preferredName":"Diffuse Type Adenocarcinoma","code":"C4127","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a diffuse cellular infiltrate which is composed of poorly cohesive cells with minimal or no glandular formations. Representative example is the gastric diffuse adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma, Diffuse Type","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Type Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8145/3"},{"name":"Legacy Concept Name","value":"Diffuse_Type_Adenocarcinoma"},{"name":"Maps_To","value":"8145/3"},{"name":"Maps_To","value":"Adenocarcinoma, diffuse type"},{"name":"Maps_To","value":"Carcinoma, diffuse type"},{"name":"Maps_To","value":"Poorly cohesive carcinoma"},{"name":"NCI_META_CUI","value":"CL523903"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3686":{"preferredName":"Salivary Gland Monomorphic Adenoma","code":"C3686","definitions":[{"definition":"A benign epithelial neoplasm arising from the salivary glands. It is characterized by the presence of a monomorphic cellular infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Monomorphic Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8146/0"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Monomorphic_Adenoma"},{"name":"Maps_To","value":"8146/0"},{"name":"Maps_To","value":"Monomorphic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205649"}]}}{"C5950":{"preferredName":"Basal Cell Adenoma","code":"C5950","definitions":[{"definition":"A salivary gland benign epithelial neoplasm with a uniform, monomorphic appearance that is dominated by basal cells forming trabecular structures. It is rare and occurs mostly on the parotid gland. The average age of patients has been reported to be 58 years. Swelling is the most constant clinical finding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basal Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Adenoma of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Adenoma of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"BCA","termGroup":"AB","termSource":"NCI"},{"termName":"Salivary Gland Basal Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8147/0"},{"name":"Legacy Concept Name","value":"Benign_Basal_Cell_Neoplasm"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Basal_Cell_Adenoma"},{"name":"Maps_To","value":"8147/0"},{"name":"Maps_To","value":"Basal cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205646"}]}}{"C3678":{"preferredName":"Salivary Gland Basal Cell Adenocarcinoma","code":"C3678","definitions":[{"definition":"A rare adenocarcinoma of the major and minor salivary glands, originating from basaloid, myoepithelial and ductal cells.  While morphologically resembling basal cell carcinomas, it is a distinct entity.  The tumor is not encapsulated, may invade locally, and less frequently may metastasize.  It usually occurs in older patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Basal Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Adenocarcinoma of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Adenocarcinoma of the Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8147/3"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Basal_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8147/3"},{"name":"Maps_To","value":"Basal cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205641"}]}}{"C7660":{"preferredName":"Grade II Glandular Intraepithelial Neoplasia","code":"C7660","synonyms":[{"termName":"Grade II Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Moderate Glandular Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/0"},{"name":"Legacy Concept Name","value":"Grade_II_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/0"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, grade II"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333861"}]}}{"C7661":{"preferredName":"Low Grade Glandular Intraepithelial Neoplasia","code":"C7661","synonyms":[{"termName":"Low Grade Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/0"},{"name":"Legacy Concept Name","value":"Low_Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/0"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, grade I"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334423"}]}}{"C27428":{"preferredName":"Low Grade Esophageal Glandular Intraepithelial Neoplasia","code":"C27428","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities are confined to the lower half of the esophageal glandular epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Esophageal Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal Low Grade Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade Esophageal Glandular Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/0"},{"name":"Legacy Concept Name","value":"Esophageal_Low-Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/0"},{"name":"Maps_To","value":"Esophageal glandular dysplasia (intraepithelial neoplasia), low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333457"}]}}{"C6877":{"preferredName":"Grade III Glandular Intraepithelial Neoplasia","code":"C6877","definitions":[{"definition":"A high grade intraepithelial neoplasia in which there is marked architectural distortion and crowding of the glands, associated with severe cellular atypia. The neoplastic cells display pleomorphic and hyperchromatic nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade III Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Grade_III_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266013"}]}}{"C27429":{"preferredName":"High Grade Esophageal Glandular Intraepithelial Neoplasia","code":"C27429","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities involve both the lower and the upper half of the esophageal glandular epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Esophageal Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal High-Grade Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Glandular Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Esophageal_High-Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Esophageal glandular dysplasia (intraepithelial neoplasia), high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333449"}]}}{"C27425":{"preferredName":"Esophageal High Grade Intraepithelial Neoplasia","code":"C27425","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities involve both the lower and the upper half of the esophageal mucosa.  It includes lesions termed moderate dysplasia, and carcinoma in situ (severe dysplasia).  (WHO, 2000)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esophageal High Grade Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal High-Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Esophageal High-Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Esophageal_High-Grade_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Esophageal intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333450"}]}}{"C67493":{"preferredName":"High-Grade Biliary Intraepithelial Neoplasia","code":"C67493","definitions":[{"definition":"Biliary intraepithelial neoplasia characterized by the presence of high grade epithelial dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High-Grade Biliary Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Biliary Intraepithelial Neoplasia-3","termGroup":"SY","termSource":"NCI"},{"termName":"BilIN-3","termGroup":"AB","termSource":"NCI"},{"termName":"Grade 3 Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade BilIN","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade BilIN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Grade_3_Biliary_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Biliary intraepithelial neoplasia, grade 3"},{"name":"Maps_To","value":"Biliary intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2348875"}]}}{"C3642":{"preferredName":"Grade III Prostatic Intraepithelial Neoplasia","code":"C3642","definitions":[{"definition":"High grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade III Prostatic Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma in situ of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma in situ of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 PIN","termGroup":"AB","termSource":"NCI"},{"termName":"Grade 3 Prostatic Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III PIN","termGroup":"AB","termSource":"NCI"},{"termName":"Prostate Adenocarcinoma in situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Grade_III_Prostatic_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Carcinoma in situ of prostate"},{"name":"Maps_To","value":"Carcinoma in situ: Prostate"},{"name":"Maps_To","value":"PIN III"},{"name":"Maps_To","value":"Prostatic intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0154088"}]}}{"C7662":{"preferredName":"High Grade Glandular Intraepithelial Neoplasia","code":"C7662","definitions":[{"definition":"This lesion shows moderate or marked architectural distortion with glandular crowding and prominent cellular atypia.  It includes moderate dysplasia and severe dysplasia.  (WHO, 2000)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"High_Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334014"}]}}{"C5979":{"preferredName":"Salivary Gland Canalicular Adenoma","code":"C5979","definitions":[{"definition":"A benign epithelial neoplasm primarily composed of branching and interconnecting cords of single and double-cell thick rows of columnar epithelium in a very loose stroma. It often occurs in the upper lip, where only pleomorphic adenoma is more frequent. Asymptomatic swelling of the upper lip is the most common clinical finding. It may present clinically and histologically as a multifocal lesion, a feature not generally seen with other intraoral salivary gland tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Canalicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Canalicular Adenoma of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Canalicular Adenoma of the Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8149/0"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Canalicular_Adenoma"},{"name":"Maps_To","value":"8149/0"},{"name":"Maps_To","value":"Canalicular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266014"}]}}{"C27720":{"preferredName":"Pancreatic Neuroendocrine Tumor","code":"C27720","definitions":[{"definition":"A mass of abnormal cells that forms in the endocrine (hormone-producing) tissues of the pancreas. Islet cell tumors may be benign (not cancer) or malignant (cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Islet Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Well Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Well-Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"PanNET","termGroup":"AB","termSource":"NCI"},{"termName":"Well Differentiated Pancreatic Endocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well Differentiated Pancreatic Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Pancreatic Endocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Pancreatic Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/1"},{"name":"Legacy Concept Name","value":"Well-Differentiated_Pancreatic_Endocrine_Neoplasm"},{"name":"Maps_To","value":"8150/0"},{"name":"Maps_To","value":"Benign neoplasm: Endocrine pancreas"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, benign"},{"name":"NCI_META_CUI","value":"CL480914"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27031":{"preferredName":"Pancreatic Neuroendocrine Neoplasm","code":"C27031","definitions":[{"definition":"A neoplasm with neuroendocrine differentiation that arises from the pancreas.  It includes neuroendocrine tumors and neuroendocrine carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Endocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"PanNEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/1"},{"name":"Legacy Concept Name","value":"Pancreatic_Endocrine_Neoplasm"},{"name":"Maps_To","value":"8150/1"},{"name":"Maps_To","value":"Islet cell tumor, NOS"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, NOS"},{"name":"NCI_META_CUI","value":"CL973078"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3770":{"preferredName":"Pancreatic Neuroendocrine Carcinoma","code":"C3770","definitions":[{"definition":"A malignant endocrine neoplasm arising from islets of Langerhans of the pancreas.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer arising from cells in the islets of Langerhans, which are found in the pancreas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"High Grade Pancreatic Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Pancreatic Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Islet Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Endocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic NEC","termGroup":"SY","termSource":"NCI"},{"termName":"PanNEC","termGroup":"AB","termSource":"NCI"},{"termName":"Poorly Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Poorly Differentiated Pancreatic Endocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/3"},{"name":"Legacy Concept Name","value":"Pancreatic_Endocrine_Carcinoma"},{"name":"Maps_To","value":"8150/3"},{"name":"Maps_To","value":"Islet cell adenocarcinoma"},{"name":"Maps_To","value":"Islet cell carcinoma"},{"name":"Maps_To","value":"Malignant neoplasm of islets of Langerhans"},{"name":"Maps_To","value":"Malignant neoplasm: Endocrine pancreas"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1328479"}]}}{"C67457":{"preferredName":"Pancreatic Beta Cell Adenoma","code":"C67457","definitions":[{"definition":"An adenoma arising from the beta cells of the pancreas.  It produces insulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Beta Cell Adenoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Pancreatic Beta Islet Cell Adenoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Beta_Cell_Adenoma"},{"name":"Maps_To","value":"8151/0"},{"name":"Maps_To","value":"Beta cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279719"}]}}{"C95598":{"preferredName":"Pancreatic Insulinoma","code":"C95598","definitions":[{"definition":"A usually benign tumor of insulin secreting pancreatic beta cells, associated with hypoglycemia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An abnormal mass that grows in the beta cells of the pancreas that make insulin. Beta cell neoplasms are usually benign (not cancer). They secrete insulin and are the most common cause of low blood sugar caused by having too much insulin in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas. Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Insulinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Insulinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"8151/0"},{"name":"Maps_To","value":"Insulinoma"},{"name":"Maps_To","value":"Insulinoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0021670"}]}}{"C65186":{"preferredName":"Malignant Pancreatic Insulinoma","code":"C65186","definitions":[{"definition":"An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Pancreatic Insulinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Insulinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Beta Islet Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Insulin Producing Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8151/3"},{"name":"Legacy Concept Name","value":"Malignant_Insulinoma"},{"name":"Maps_To","value":"8151/3"},{"name":"Maps_To","value":"Beta cell tumor, malignant"},{"name":"Maps_To","value":"Insulinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334281"}]}}{"C95597":{"preferredName":"Pancreatic Glucagonoma","code":"C95597","definitions":[{"definition":"A rare pancreatic tumor that produces a hormone called glucagon. Glucagonomas can produce symptoms similar to diabetes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually malignant, glucagon-producing neuroendocrine tumor arising from the pancreatic alpha cells. It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia. Almost 25% of patients experience thromboembolic complications, and 50% have liver metastases at the time of diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Glucagonoma","termGroup":"PT","termSource":"NCI"},{"termName":"Glucagonoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8152/1"},{"name":"Maps_To","value":"Glucagonoma"},{"name":"Maps_To","value":"Glucagonoma, NOS"},{"name":"NCI_META_CUI","value":"CL428078"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C65191":{"preferredName":"Malignant Enteroglucagonoma","code":"C65191","definitions":[{"definition":"A glucagon-producing malignant endocrine neoplasm. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Enteroglucagonoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8152/3"},{"name":"ICD-O-3_Code","value":"8157/3"},{"name":"Legacy Concept Name","value":"Malignant_Enteroglucagonoma"},{"name":"Maps_To","value":"8152/3"},{"name":"Maps_To","value":"Enteroglucagonoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266017"}]}}{"C65187":{"preferredName":"Malignant Pancreatic Glucagonoma","code":"C65187","definitions":[{"definition":"A glucagon-producing neuroendocrine tumor arising from the alpha cells of the pancreas.  It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia.  It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Pancreatic Glucagonoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Glucagonoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Alpha Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8152/3"},{"name":"Legacy Concept Name","value":"Malignant_Glucagonoma"},{"name":"Maps_To","value":"8152/3"},{"name":"Maps_To","value":"Alpha cell tumor, malignant"},{"name":"Maps_To","value":"Glucagonoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334282"}]}}{"C3050":{"preferredName":"Gastrin-Producing Neuroendocrine Tumor","code":"C3050","definitions":[{"definition":"A gastrin-producing neuroendocrine tumor. It is usually located in the pancreas but it is also found at other anatomic sites, including the stomach and small intestine.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that causes overproduction of gastric acid. It usually begins in the duodenum (first part of the small intestine that connects to the stomach) or the islet cells of the pancreas. Rarely, it may also begin in other organs, including the stomach, liver, jejunum (the middle part of the small intestine), biliary tract (organs and ducts that make and store bile), mesentery, or heart. It is a type of neuroendocrine tumor, and it may metastasize (spread) to the liver and the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastrin-Producing Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"G Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"G-Cell Gastrin Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"G-Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrin Secreting Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrin-Producing NET","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8153/1"},{"name":"Legacy Concept Name","value":"G-Cell_Gastrin_Producing_Neoplasm"},{"name":"Maps_To","value":"8153/1"},{"name":"Maps_To","value":"G cell tumor, NOS"},{"name":"Maps_To","value":"Gastrin cell tumor"},{"name":"Maps_To","value":"Gastrinoma"},{"name":"Maps_To","value":"Gastrinoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017150"}]}}{"C65188":{"preferredName":"Malignant Gastrinoma","code":"C65188","definitions":[{"definition":"A gastrin-producing neuroendocrine tumor.  It is characterized by inappropriate secretion of gastrin and associated with Zollinger Ellison syndrome.  It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Gastrinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8153/3"},{"name":"Legacy Concept Name","value":"Malignant_Gastrinoma"},{"name":"Maps_To","value":"8153/3"},{"name":"Maps_To","value":"G cell tumor, malignant"},{"name":"Maps_To","value":"Gastrin cell tumor, malignant"},{"name":"Maps_To","value":"Gastrinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334283"}]}}{"C164255":{"preferredName":"Mixed Neuroendocrine Non-Neuroendocrine Neoplasm","code":"C164255","definitions":[{"definition":"A rare neoplasm that consists of neuroendocrine and non-neuroendocrine cellular components. At least 30% of either component should be present for the diagnosis to be made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Neuroendocrine Non-Neuroendocrine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"MiNEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8154/3"},{"name":"Maps_To","value":"Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334284"}]}}{"C45843":{"preferredName":"Pancreatic Mixed Adenoneuroendocrine Carcinoma","code":"C45843","definitions":[{"definition":"A rare carcinoma with a poor prognosis, characterized by the presence of a mixture of exocrine and neuroendocrine malignant epithelial cells in both the pancreas and metastatic sites.  Symptoms include jaundice, abdominal pain, and weight loss.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mixed Adenoneuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Exocrine-Endocrine Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Carcinoma with Mixed Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mixed Neuroendocrine-Non-Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8154/3"},{"name":"Legacy Concept Name","value":"Mixed_Exocrine-Endocrine_Carcinoma"},{"name":"Maps_To","value":"8154/3"},{"name":"Maps_To","value":"Mixed pancreatic endocrine and exocrine tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709050"}]}}{"C26749":{"preferredName":"VIP-Producing Neuroendocrine Tumor","code":"C26749","definitions":[{"definition":"An often clinically aggressive neuroendocrine tumor located in the pancreas or small intestine.  It is composed of cells containing vasoactive intestinal peptide.  It may cause intractable diarrhea and metabolic disturbances.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VIP-Producing Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Vasoactive Intestinal Peptide Producing Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Vasoactive Intestinal Peptide Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Vasoactive Intestinal Peptide Secreting Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"VIP Producing Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"VIP- Secreting Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"VIP- Secreting Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"VIP-Producing NET","termGroup":"SY","termSource":"NCI"},{"termName":"VIPoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8155/1"},{"name":"Legacy Concept Name","value":"Vasoactive_Intestinal_Peptide_Producing_Neoplasm"},{"name":"Maps_To","value":"8155/1"},{"name":"Maps_To","value":"Vipoma"},{"name":"Maps_To","value":"Vipoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0011993"}]}}{"C65189":{"preferredName":"Malignant Vipoma","code":"C65189","definitions":[{"definition":"An aggressive neuroendocrine tumor located in the pancreas or small intestine. It is composed of cells containing vasoactive intestinal peptide.  It is associated with watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Vipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8155/3"},{"name":"Legacy Concept Name","value":"Malignant_Vipoma"},{"name":"Maps_To","value":"8155/3"},{"name":"Maps_To","value":"Vipoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881600"}]}}{"C3379":{"preferredName":"Somatostatin-Producing Neuroendocrine Tumor","code":"C3379","definitions":[{"definition":"A rare, usually malignant neuroendocrine tumor arizing from delta cells.  This neoplasm produces large amounts of somatostatin, which may result in a syndrome characterized by diarrhea, steatorrhea, weight loss, and gastric hyposecretion. Sixty percent are found in the pancreas and 40% in the duodenum or jejunum. The peak incidence occurs between 40 and 60 years of age; women are affected more than men by 2:1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Somatostatin-Producing Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Delta Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin-Producing NET","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin-Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Delta Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Delta Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8156/1"},{"name":"Legacy Concept Name","value":"Delta_Cell_Somatostatin_Producing_Neoplasm"},{"name":"Maps_To","value":"8156/1"},{"name":"Maps_To","value":"Somatostatin cell tumor, NOS"},{"name":"Maps_To","value":"Somatostatinoma"},{"name":"Maps_To","value":"Somatostatinoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0037661"}]}}{"C65190":{"preferredName":"Malignant Somatostatinoma","code":"C65190","definitions":[{"definition":"A neuroendocrine tumor arising from delta cells which produce somatostatin. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Somatostatinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Delta Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8156/3"},{"name":"Legacy Concept Name","value":"Malignant_Somatostatinoma"},{"name":"Maps_To","value":"8156/3"},{"name":"Maps_To","value":"Somatostatin cell tumor, malignant"},{"name":"Maps_To","value":"Somatostatinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266015"}]}}{"C94759":{"preferredName":"Functioning Endocrine Neoplasm","code":"C94759","definitions":[{"definition":"A hormone producing endocrine neoplasm, associated with a hormonal syndrome.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that is found in endocrine tissue and makes hormones (chemicals that travel in the bloodstream and control the actions of other cells or organs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Functioning Endocrine Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8158/1"},{"name":"Maps_To","value":"8158/1"},{"name":"Maps_To","value":"Endocrine tumor, functioning, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2986655"}]}}{"C2942":{"preferredName":"Bile Duct Adenoma","code":"C2942","definitions":[{"definition":"A benign neoplasm arising from/comprising cells resembling those of bile ducts.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well-demarcated polypoid neoplasm arising from the bile duct epithelium. According to the growth pattern, it is classified as tubular, papillary, or tubulopapillary. Adenomas arising from the extrahepatic bile ducts usually produce symptoms related to biliary obstruction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"BDA","termGroup":"AB","termSource":"NCI"},{"termName":"Cholangioadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cholangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8160/0"},{"name":"Legacy Concept Name","value":"Bile_Duct_Adenoma"},{"name":"Maps_To","value":"8160/0"},{"name":"Maps_To","value":"Bile duct adenoma"},{"name":"Maps_To","value":"Cholangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008309"}]}}{"C4436":{"preferredName":"Cholangiocarcinoma","code":"C4436","definitions":[{"definition":"A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from/comprising cells resembling those of bile ducts.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare type of cancer that develops in cells that line the bile ducts in the liver. Cancer that forms where the right and left ducts meet is called Klatskin tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cholangiocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"CC","termGroup":"AB","termSource":"NCI"},{"termName":"Cholangiocellular Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8160/3"},{"name":"Legacy Concept Name","value":"Cholangiocarcinoma"},{"name":"Maps_To","value":"8160/3"},{"name":"Maps_To","value":"Cholangiocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206698"}]}}{"C27813":{"preferredName":"Bile Duct Adenocarcinoma","code":"C27813","definitions":[{"definition":"An adenocarcinoma arising from the intrahepatic or extrahepatic bile ducts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bile_Duct_Adenocarcinoma"},{"name":"Maps_To","value":"8160/3"},{"name":"Maps_To","value":"Bile duct adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370800"}]}}{"C27814":{"preferredName":"Bile Duct Carcinoma","code":"C27814","definitions":[{"definition":"A carcinoma arising from the intrahepatic or extrahepatic bile ducts.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in a bile duct. A bile duct is a tube that carries bile (fluid made by the liver that helps digest fat) between the liver and gallbladder and the intestine. Bile ducts include the common hepatic, cystic, and common bile ducts. Bile duct cancer may be found inside the liver (intrahepatic) or outside the liver (extrahepatic).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bile Duct Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bile_Duct_Carcinoma"},{"name":"Maps_To","value":"8160/3"},{"name":"Maps_To","value":"Bile Duct Cancer"},{"name":"Maps_To","value":"Bile duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0740277"}]}}{"C4129":{"preferredName":"Bile Duct Mucinous Cystic Neoplasm","code":"C4129","definitions":[{"definition":"An epithelial, usually multiloculated neoplasm arising from the intrahepatic or extrahepatic bile ducts. It occurs predominantly in females. Signs and symptoms include abdominal mass, abdominal pain, and jaundice. Morphologically, the cystic spaces are lined by columnar epithelium and contain mucinous or serous fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Mucinous Cystic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct MCN","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenoma of Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenoma of the Bile Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8161/0"},{"name":"Legacy Concept Name","value":"Bile_Duct_Cystadenoma"},{"name":"Maps_To","value":"8161/0"},{"name":"Maps_To","value":"Bile duct cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334285"}]}}{"C4130":{"preferredName":"Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma","code":"C4130","definitions":[{"definition":"A mucinous cystic neoplasm that arises from the intrahepatic or extrahepatic bile ducts and it is associated with an invasive carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct MCN with an Associated Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenocarcinoma of Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenocarcinoma of the Bile Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8161/3"},{"name":"Legacy Concept Name","value":"Biliary_Cystadenocarcinoma"},{"name":"Maps_To","value":"8161/3"},{"name":"Maps_To","value":"Bile duct cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334286"}]}}{"C36077":{"preferredName":"Hilar Cholangiocarcinoma","code":"C36077","definitions":[{"definition":"A carcinoma that arises from the junction, or adjacent to the junction, of the right and left hepatic ducts.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that develops in cells that line the bile ducts in the liver, where the right and left ducts meet. It is a type of cholangiocarcinoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hilar Cholangiocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hilar CC","termGroup":"SY","termSource":"NCI"},{"termName":"Klatskin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Perihilar Cholangiocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hilar_Cholangiocarcinoma"},{"name":"Maps_To","value":"8162/3"},{"name":"Maps_To","value":"Klatskin tumor"},{"name":"Maps_To","value":"Perihilar cholangiocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206702"}]}}{"C95914":{"preferredName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia","code":"C95914","definitions":[{"definition":"An ampullary noninvasive papillary neoplasm of the pancreatobiliary type characterized by the presence of low grade dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Ampullary Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/0"},{"name":"Maps_To","value":"8163/0"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3272434"}]}}{"C95913":{"preferredName":"Ampullary Noninvasive Papillary Neoplasm, Pancreatobiliary Type","code":"C95913","definitions":[{"definition":"An exophytic, preinvasive, papillary epithelial neoplasm that arises from the ampulla of Vater.  Histologically it resembles the papillary neoplasms of the biliary tree.  This category includes neoplasms with low grade dysplasia and high grade dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampullary Noninvasive Papillary Neoplasm, Pancreatobiliary Type","termGroup":"PT","termSource":"NCI"},{"termName":"Noninvasive Papillary Neoplasm, Pancreatobiliary Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/0"},{"name":"Maps_To","value":"8163/0"},{"name":"Maps_To","value":"Pancreatobiliary neoplasm, non-invasive"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3272433"}]}}{"C95915":{"preferredName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia","code":"C95915","definitions":[{"definition":"An ampullary noninvasive papillary neoplasm of the pancreatobiliary type characterized by the presence of high grade dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Ampullary High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/2"},{"name":"Maps_To","value":"8163/2"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia"},{"name":"Maps_To","value":"Papillary neoplasm, pancreatobiliary type, with high grade intraepithelial neoplasia"},{"name":"Maps_To","value":"Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472606"}]}}{"C95963":{"preferredName":"Ampulla of Vater Pancreatobiliary Type Adenocarcinoma","code":"C95963","definitions":[{"definition":"An invasive adenocarcinoma that arises from the ampulla of Vater. It is characterized by the presence of malignant cells that resemble the malignant cells of the pancreatic ductal or extrahepatic bile duct carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampulla of Vater Pancreatobiliary Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/3"},{"name":"Maps_To","value":"8163/3"},{"name":"Maps_To","value":"Pancreatobiliary type carcinoma"},{"name":"Maps_To","value":"Pancreatobiliary-type carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472607"}]}}{"C3758":{"preferredName":"Hepatocellular Adenoma","code":"C3758","definitions":[{"definition":"A benign epithelial neoplasm arising from hepatocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign epithelial neoplasm arising from the hepatocytes. Grossly, it appears as a soft, round mass which often contains areas of hemorrhage and necrosis. Morphologically, the neoplastic cells resemble normal hepatocytes and form plates separated by sinusoids. Most patients have a history of contraceptive or anabolic steroids use.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatocellular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"HCA","termGroup":"AB","termSource":"NCI"},{"termName":"Liver Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8170/0"},{"name":"Legacy Concept Name","value":"Hepatocellular_Adenoma"},{"name":"Maps_To","value":"8170/0"},{"name":"Maps_To","value":"Hepatocellular adenoma"},{"name":"Maps_To","value":"Hepatoma, benign"},{"name":"Maps_To","value":"Liver cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206669"}]}}{"C3099":{"preferredName":"Hepatocellular Carcinoma","code":"C3099","definitions":[{"definition":"A malignant neoplasm arising from hepatocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","type":"DEFINITION","source":"NCI"},{"definition":"A type of adenocarcinoma and the most common type of liver tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"HCC","termGroup":"AB","termSource":"NCI"},{"termName":"Hepatoma","termGroup":"SY","termSource":"NCI"},{"termName":"LIHC","termGroup":"AB","termSource":"NCI"},{"termName":"Liver Cell Cancer (Hepatocellular Carcinoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8170/3"},{"name":"Legacy Concept Name","value":"Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8170/3"},{"name":"Maps_To","value":"Hepatocarcinoma"},{"name":"Maps_To","value":"Hepatocellular carcinoma, NOS"},{"name":"Maps_To","value":"Hepatoma, malignant"},{"name":"Maps_To","value":"Hepatoma, NOS"},{"name":"Maps_To","value":"Liver cell carcinoma"},{"name":"Maps_To","value":"Malignant neoplasm: Liver cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019204"}]}}{"C4131":{"preferredName":"Fibrolamellar Carcinoma","code":"C4131","definitions":[{"definition":"A distinctive type of liver cell carcinoma that arises in non-cirrhotic livers and is seen predominantly in young patients.  The tumor cells are polygonal and deeply eosinophilic, and are embedded in a fibrous stroma.  The prognosis is similar to classical hepatocellular carcinoma that arises in non-cirrhotic livers, and better than hepatocellular carcinoma that arises in cirrhotic livers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrolamellar Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibrolamellar Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrolamellar Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrolamellar Hepatocellular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FLC","termGroup":"AB","termSource":"NCI"},{"termName":"Hepatocellular Fibrolamellar Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cell Fibrolamellar Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Hepatocellular Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Polygonal Cell Type Hepatocellular Carcinoma with Fibrous Stroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8171/3"},{"name":"Legacy Concept Name","value":"Fibrolamellar_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8171/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, fibrolamellar"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334287"}]}}{"C27388":{"preferredName":"Scirrhous Hepatocellular Carcinoma","code":"C27388","definitions":[{"definition":"An uncommon type of hepatocelluar carcinoma, morphologically characterized by significant fibrosis around the sinusoid-like spaces and atrophy of the tumor trabeculae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scirrhous Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sclerosing Hepatic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Hepatocellular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8172/3"},{"name":"Legacy Concept Name","value":"Sclerosing_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8172/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, scirrhous"},{"name":"Maps_To","value":"Sclerosing hepatic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266018"}]}}{"C43627":{"preferredName":"Sarcomatoid Hepatocellular Carcinoma","code":"C43627","definitions":[{"definition":"A morphologic variant of hepatocellular carcinoma characterized by the presence of malignant spindle cells or atypical giant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcomatous Hepatocellular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8173/3"},{"name":"Legacy Concept Name","value":"Sarcomatous_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8173/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Hepatocellular carcinoma, spindle cell variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1710014"}]}}{"C5754":{"preferredName":"Clear Cell Hepatocellular Carcinoma","code":"C5754","definitions":[{"definition":"A morphologic variant of hepatocellular carcinoma characterized by the presence of clear cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatocellular Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cell Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8174/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8174/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, clear cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333067"}]}}{"C43625":{"preferredName":"Pleomorphic Hepatocellular Carcinoma","code":"C43625","definitions":[{"definition":"A morphologic variant of hepatocellular carcinoma, characterized by the presence of malignant cells which show marked variation in their size and shape. Bizarre mononuclear or multinucleated giant cells are often present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8175/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8175/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, pleomorphic type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709568"}]}}{"C3828":{"preferredName":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma","code":"C3828","definitions":[{"definition":"A rare tumor containing unequivocal elements of both hepatocellular and cholangiocarcinoma that are intimately admixed.  This tumor should be distinguished from separate hepatocellular carcinoma and cholangiocarcinoma arising in the same liver.  The prognosis of this tumor is poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"cHCC-CCA","termGroup":"AB","termSource":"NCI"},{"termName":"Cholangiohepatoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatocholangiocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Biliary Tract Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Hepatocellular Cholangiocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8180/3"},{"name":"Legacy Concept Name","value":"Combined_Hepatocellular_Carcinoma_and_Cholangiocarcinoma"},{"name":"Maps_To","value":"8180/3"},{"name":"Maps_To","value":"Combined hepatocellular carcinoma and cholangiocarcinoma"},{"name":"Maps_To","value":"Hepatocholangiocarcinoma"},{"name":"Maps_To","value":"Mixed hepatocellular and bile duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221287"}]}}{"C3688":{"preferredName":"Trabecular Adenoma","code":"C3688","definitions":[{"definition":"A benign epithelial neoplasm characterized by the presence of a trabecular glandular architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabecular Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8190/0"},{"name":"Legacy Concept Name","value":"Trabecular_Adenoma"},{"name":"Maps_To","value":"8190/0"},{"name":"Maps_To","value":"Trabecular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205651"}]}}{"C4068":{"preferredName":"Trabecular Adenocarcinoma","code":"C4068","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a trabecular glandular architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabecular Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Trabecular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8190/3"},{"name":"ICD-O-3_Code","value":"8332/3"},{"name":"Legacy Concept Name","value":"Trabecular_Adenocarcinoma"},{"name":"Maps_To","value":"8190/3"},{"name":"Maps_To","value":"Trabecular adenocarcinoma"},{"name":"Maps_To","value":"Trabecular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302182"}]}}{"C27253":{"preferredName":"Metanephric Adenoma","code":"C27253","definitions":[{"definition":"A benign, well-circumscribed renal cortical neoplasm affecting females more often than males.  Polycythemia has been reported in twelve-percent of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metanephric Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Embryonal Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8191/0"},{"name":"ICD-O-3_Code","value":"8325/0"},{"name":"Legacy Concept Name","value":"Metanephric_Adenoma"},{"name":"Maps_To","value":"8191/0"},{"name":"Maps_To","value":"Embryonal adenoma"},{"name":"Maps_To","value":"Metanephric adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266045"}]}}{"C43352":{"preferredName":"Turban Tumor Syndrome","code":"C43352","definitions":[{"definition":"A rare autosomal dominant genodermatosis associated with germline mutations of the CYLD tumor suppressor gene. It is characterized by the development of multiple adnexal tumors (usually cylindromas and trichoepitheliomas), typically in the skin of the scalp. It manifests with numerous papules and/or large dome-shaped nodules on the scalp, resembling a turban.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Turban Tumor Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Ancell-Spiegler Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Brooke-Spiegler Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"TTS","termGroup":"AB","termSource":"NCI"},{"termName":"Turban Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Turban_Tumor"},{"name":"Maps_To","value":"8200/0"},{"name":"Maps_To","value":"Turban tumor"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1851526"}]}}{"C27094":{"preferredName":"Cylindroma","code":"C27094","definitions":[{"definition":"A benign sweat gland neoplasm usually occurring in the scalp or the face. It may present as solitary or multiple papular or nodular lesions. It may be a sporadic lesion or part of Brooke-Spiegler syndrome. It arises from the dermis and has a multinodular, circumscribed appearance. The nodules contain basaloid cells with small, dark nuclei. Complete excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cylindroma","termGroup":"PT","termSource":"NCI"},{"termName":"Cylindroma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Cylindroma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Dermal Cylindroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8200/0"},{"name":"Legacy Concept Name","value":"Cylindroma"},{"name":"Maps_To","value":"8200/0"},{"name":"Maps_To","value":"Cylindroma of skin"},{"name":"Maps_To","value":"Eccrine dermal cylindroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1305968"}]}}{"C2970":{"preferredName":"Adenoid Cystic Carcinoma","code":"C2970","definitions":[{"definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of cancer that usually begins in the salivary glands.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenoid Cystic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocystic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cylindroid Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8200/3"},{"name":"Legacy Concept Name","value":"Adenoid_Cystic_Carcinoma"},{"name":"Maps_To","value":"8200/3"},{"name":"Maps_To","value":"Adenocarcinoma, cylindroid"},{"name":"Maps_To","value":"Adenocystic carcinoma"},{"name":"Maps_To","value":"Adenoid cystic carcinoma"},{"name":"Maps_To","value":"Cylindroma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010606"}]}}{"C162973":{"preferredName":"Non-Invasive Cribriform Carcinoma","code":"C162973","definitions":[{"definition":"A carcinoma characterized by the presence of a cribriform architectural pattern. There is no evidence of surrounding stromal invasion by the malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Invasive Cribriform Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8201/2"},{"name":"Maps_To","value":"Cribriform carcinoma in situ"},{"name":"NCI_META_CUI","value":"CL973264"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3680":{"preferredName":"Cribriform Carcinoma","code":"C3680","definitions":[{"definition":"A carcinoma characterized by the presence of a cribriform architectural pattern. Representative examples include the intraductal cribriform breast carcinoma and invasive cribriform breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cribriform Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8201/3"},{"name":"Legacy Concept Name","value":"Cribriform_Carcinoma"},{"name":"Maps_To","value":"8201/3"},{"name":"Maps_To","value":"Cribriform carcinoma, NOS"},{"name":"Maps_To","value":"Ductal carcinoma, cribriform type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205643"}]}}{"C3685":{"preferredName":"Microcystic Adenoma","code":"C3685","definitions":[{"definition":"A benign epithelial neoplasm characterized by a microcystic pattern. The cystic spaces are lined by small cuboidal cells without evidence of significant cytologic atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microcystic Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8202/0"},{"name":"Legacy Concept Name","value":"Microcystic_Adenoma"},{"name":"Maps_To","value":"8202/0"},{"name":"Maps_To","value":"Microcystic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205648"}]}}{"C9473":{"preferredName":"Lactating Adenoma","code":"C9473","definitions":[{"definition":"A tubular type adenoma of the breast in which, during pregnancy and lactation, the epithelial cells show extensive secretory changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lactating Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pregnancy Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8204/0"},{"name":"Legacy Concept Name","value":"Lactating_Adenoma"},{"name":"Maps_To","value":"8204/0"},{"name":"Maps_To","value":"Lactating adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266023"}]}}{"C3764":{"preferredName":"Adenomatous Polyp","code":"C3764","definitions":[{"definition":"A polypoid neoplasm arising from the glandular epithelium of the gastrointestinal tract. There is proliferation of glandular cells which may display dysplastic cytologic features. Representative examples include the adenomatous polyps of the colon and rectum..","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenomatous Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Adenomatous Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Adenomatous Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Polypoid Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8210/0"},{"name":"Legacy Concept Name","value":"Adenomatous_Polyp"},{"name":"Maps_To","value":"8210/0"},{"name":"Maps_To","value":"Adenomatous polyp, NOS"},{"name":"Maps_To","value":"Polypoid adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206677"}]}}{"C7678":{"preferredName":"Adenocarcinoma In Situ in Adenomatous Polyp","code":"C7678","definitions":[{"definition":"A non-invasive adenocarcinoma arising from the neoplastic glandular cells in an adenomatous polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Adenomatous Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8210/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Adenomatous_Polyp"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in adenomatous polyp"},{"name":"Maps_To","value":"Adenocarcinoma in situ in polypoid adenoma"},{"name":"Maps_To","value":"Carcinoma in situ in adenomatous polyp"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334290"}]}}{"C7680":{"preferredName":"Adenocarcinoma In Situ in a Polyp","code":"C7680","definitions":[{"definition":"An adenocarcinoma arising in a polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in a Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_a_Polyp"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in a polyp, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377630"}]}}{"C7679":{"preferredName":"Adenocarcinoma In Situ in Tubular Adenoma","code":"C7679","definitions":[{"definition":"An intraepithelial adenocarcinoma arising from a tubular adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Tubular Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Tubular_Adenoma"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in tubular adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377632"}]}}{"C7681":{"preferredName":"Carcinoma In Situ in a Polyp","code":"C7681","definitions":[{"definition":"An intraepithelial adenocarcinoma arising in a polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma In Situ in a Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carcinoma_in_situ_in_a_Polyp"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Carcinoma in situ in a polyp, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377629"}]}}{"C7676":{"preferredName":"Adenocarcinoma in Adenomatous Polyp","code":"C7676","definitions":[{"definition":"A non-invasive or invasive adenocarcinoma arising from the neoplastic glandular cells in an adenomatous polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Adenomatous Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8210/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Adenomatous_Polyp"},{"name":"Maps_To","value":"8210/3"},{"name":"Maps_To","value":"Adenocarcinoma in a polyp, NOS"},{"name":"Maps_To","value":"Adenocarcinoma in adenomatous polyp"},{"name":"Maps_To","value":"Adenocarcinoma in polypoid adenoma"},{"name":"Maps_To","value":"Carcinoma in adenomatous polyp"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321861"}]}}{"C7677":{"preferredName":"Adenocarcinoma in Tubular Adenoma","code":"C7677","definitions":[{"definition":"An adenocarcinoma arising from a tubular adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Tubular Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Tubular_Adenoma"},{"name":"Maps_To","value":"8210/3"},{"name":"Maps_To","value":"Adenocarcinoma in tubular adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377621"}]}}{"C7682":{"preferredName":"Carcinoma in a Polyp","code":"C7682","definitions":[{"definition":"Carcinoma arising in a polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma in a Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carcinoma_in_a_Polyp"},{"name":"Maps_To","value":"8210/3"},{"name":"Maps_To","value":"Carcinoma in a polyp, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377617"}]}}{"C4133":{"preferredName":"Tubular Adenoma","code":"C4133","definitions":[{"definition":"A benign neoplasm arising from glandular epithelium, characterized by a tubular architectural pattern.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Tubular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Tubular Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8211/0"},{"name":"Legacy Concept Name","value":"Tubular_Adenoma"},{"name":"Maps_To","value":"8211/0"},{"name":"Maps_To","value":"Tubular adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334292"}]}}{"C65192":{"preferredName":"Tubular Adenocarcinoma","code":"C65192","definitions":[{"definition":"A malignant glandular neoplasm exhibiting tubular structures.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating adenocarcinoma in which the malignant cells form tubular structures. Representative examples include the tubular breast carcinoma and the gastric tubular adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubular Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8211/3"},{"name":"Legacy Concept Name","value":"Tubular_Carcinoma"},{"name":"Maps_To","value":"8211/3"},{"name":"Maps_To","value":"Tubular adenocarcinoma"},{"name":"Maps_To","value":"Tubular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205645"}]}}{"C65193":{"preferredName":"Flat Adenoma","code":"C65193","definitions":[{"definition":"An adenoma of the gastrointestinal tract mucosa which grossly and morphologically does not appear as an elevated or polypoid lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flat Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Flat Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Flat Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8212/0"},{"name":"Legacy Concept Name","value":"Flat_Adenoma"},{"name":"Maps_To","value":"8212/0"},{"name":"Maps_To","value":"Flat adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266024"}]}}{"C38458":{"preferredName":"Traditional Serrated Adenoma","code":"C38458","definitions":[{"definition":"An adenoma that arises from the large intestine and the appendix.  It is characterized by prominent serration of the glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Traditional Serrated Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Serrated Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Serrated Adenoma Type II","termGroup":"SY","termSource":"NCI"},{"termName":"Traditional Serrated Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"TSA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8213/0"},{"name":"Legacy Concept Name","value":"Serrated_Adenoma"},{"name":"Maps_To","value":"8213/0"},{"name":"Maps_To","value":"Mixed adenomatous and hyperplastic polyp"},{"name":"Maps_To","value":"Serrated adenoma"},{"name":"Maps_To","value":"Serrated adenoma, NOS"},{"name":"Maps_To","value":"Traditional serrated adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266025"}]}}{"C96414":{"preferredName":"Serrated Lesions and Polyps","code":"C96414","definitions":[{"definition":"Polyps that arises from the large intestine and the appendix. They are characterized by the presence of serrated glands and the absence of generalized dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serrated Lesions and Polyps","termGroup":"PT","termSource":"NCI"},{"termName":"Serrated Adenoma Type I","termGroup":"SY","termSource":"NCI"},{"termName":"Serrated Lesions and Polyps","termGroup":"SY","termSource":"NCI"},{"termName":"Serrated Polyp with Abnormal Proliferation","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Adenoma/Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Polyp/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"SSA","termGroup":"AB","termSource":"NCI"},{"termName":"SSA/P","termGroup":"AB","termSource":"NCI"},{"termName":"SSP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8213/0"},{"name":"Maps_To","value":"8213/0"},{"name":"Maps_To","value":"Sessile serrated adenoma"},{"name":"Maps_To","value":"Sessile serrated polyp"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2732618"}]}}{"C96485":{"preferredName":"Colorectal Serrated Adenocarcinoma","code":"C96485","definitions":[{"definition":"A rare, invasive colorectal adenocarcinoma characterized by the presence of a malignant infiltrate with serrated glandular architecture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colorectal Serrated Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8213/3"},{"name":"Maps_To","value":"8213/3"},{"name":"Maps_To","value":"Serrated adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472623"}]}}{"C65194":{"preferredName":"Gastric Parietal Cell Adenocarcinoma","code":"C65194","definitions":[{"definition":"An adenocarcinoma of the stomach arising from the parietal cells. It is characterized by the presence of malignant cells with eosinophilic, finely granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastric Parietal Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Parietal Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8214/3"},{"name":"Legacy Concept Name","value":"Parietal_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8214/3"},{"name":"Maps_To","value":"Parietal cell adenocarcinoma"},{"name":"Maps_To","value":"Parietal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266026"}]}}{"C5609":{"preferredName":"Anal Glands Adenocarcinoma","code":"C5609","definitions":[{"definition":"An anal adenocarcinoma arising from the epithelium of the anal glands.  The overlying anal mucosa does not show evidence of neoplastic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Glands Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Anal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of Anal Glands","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Anal Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8215/3"},{"name":"Legacy Concept Name","value":"Anal_Glands_Adenocarcinoma"},{"name":"Maps_To","value":"8215/3"},{"name":"Maps_To","value":"Adenocarcinoma of anal ducts"},{"name":"Maps_To","value":"Adenocarcinoma of anal glands"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266027"}]}}{"C3339":{"preferredName":"Familial Adenomatous Polyposis","code":"C3339","definitions":[{"definition":"An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited condition in which numerous polyps (growths that protrude from mucous membranes) form on the inside walls of the colon and rectum. It increases the risk for colon cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Familial Adenomatous Polyposis","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"APC - Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Adenomatous Polyposis 1","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Adenomatous Polyposis Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"FAP","termGroup":"AB","termSource":"NCI"},{"termName":"Hereditary Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Polyposis Coli","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8220/0"},{"name":"Legacy Concept Name","value":"Familial_Adenomatous_Polyposis"},{"name":"Maps_To","value":"8220/0"},{"name":"Maps_To","value":"Adenomatous polyposis coli"},{"name":"Maps_To","value":"Adenomatous Polyposis Coli"},{"name":"Maps_To","value":"Familial Adenomatous Polyposis"},{"name":"Maps_To","value":"Familial polyposis coli"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0032580"}]}}{"C4134":{"preferredName":"Adenocarcinoma in Adenomatous Polyposis Coli","code":"C4134","definitions":[{"definition":"Adenocarcinomas developing in colorectal adenomas in patients with a history of adenomatous polyposis coli. The mean age of development of adenocarcinoma is about 40 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Adenomatous Polyposis Coli","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8220/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Adenomatous_Polyposis_Coli"},{"name":"Maps_To","value":"8220/3"},{"name":"Maps_To","value":"Adenocarcinoma in adenomatous polyposis coli"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334293"}]}}{"C4135":{"preferredName":"Multiple Adenomatous Polyps","code":"C4135","definitions":[{"definition":"A condition in which multiple adenomas develop in the gastrointestinal tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multiple Adenomatous Polyps","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Multiple Adenomatous Polyps","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Multiple Adenomatous Polyps","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8221/0"},{"name":"Legacy Concept Name","value":"Multiple_Adenomatous_Polyps"},{"name":"Maps_To","value":"8221/0"},{"name":"Maps_To","value":"Multiple adenomatous polyps"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334294"}]}}{"C4136":{"preferredName":"Adenocarcinoma in Multiple Adenomatous Polyps","code":"C4136","definitions":[{"definition":"Adenocarcinomas developing in gastrointestinal tract adenomas in patients with multiple adenomatous polyps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Multiple Adenomatous Polyps","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8221/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Multiple_Adenomatous_Polyps"},{"name":"Maps_To","value":"8221/3"},{"name":"Maps_To","value":"Adenocarcinoma in multiple adenomatous polyps"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334295"}]}}{"C66933":{"preferredName":"Breast Ductal Carcinoma In Situ, Solid Type","code":"C66933","definitions":[{"definition":"Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, Solid Type","termGroup":"PT","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma in Situ, Solid Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8230/2"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_of_the_Breast_Solid_Type"},{"name":"Maps_To","value":"8230/2"},{"name":"Maps_To","value":"Ductal carcinoma in situ, solid type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1880424"}]}}{"C4137":{"preferredName":"Solid Carcinoma","code":"C4137","definitions":[{"definition":"A carcinoma morphologically characterized by the presence of solid sheets of malignant epithelial cells in tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8230/3"},{"name":"Legacy Concept Name","value":"Solid_Carcinoma"},{"name":"Maps_To","value":"8230/3"},{"name":"Maps_To","value":"Solid carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334296"}]}}{"C65195":{"preferredName":"Carcinoma Simplex","code":"C65195","definitions":[{"definition":"An undifferentiated malignant epithelial neoplasm which tends to infiltrate the surrounding tissues and spread to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma Simplex","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8231/3"},{"name":"Legacy Concept Name","value":"Carcinoma_Simplex"},{"name":"Maps_To","value":"8231/3"},{"name":"Maps_To","value":"Carcinoma simplex"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334297"}]}}{"C65196":{"preferredName":"Carcinoid Tumor of Uncertain Malignant Potential","code":"C65196","definitions":[{"definition":"A carcinoid tumor that shows atypical characteristics and has borderline malignant potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoid Tumor of Uncertain Malignant Potential","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8240/1"},{"name":"Legacy Concept Name","value":"Carcinoid_Tumor_of_Uncertain_Malignant_Potential"},{"name":"Maps_To","value":"8240/1"},{"name":"Maps_To","value":"Carcinoid tumor of uncertain malignant potential"},{"name":"NCI_META_CUI","value":"CL017920"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C35727":{"preferredName":"Grade I Neuroendocrine Carcinoma","code":"C35727","synonyms":[{"termName":"Grade I Neuroendocrine Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8240/3"},{"name":"Legacy Concept Name","value":"Grade_I_Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8240/3"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, low grade"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, well-differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266147"}]}}{"C2915":{"preferredName":"Carcinoid Tumor","code":"C2915","definitions":[{"definition":"A slow-growing type of tumor usually found in the gastrointestinal system (most often in the appendix), and sometimes in the lungs or other sites. Carcinoid tumors may spread to the liver or other sites in the body, and they may secrete substances such as serotonin or prostaglandins, causing carcinoid syndrome.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carcinoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoid","termGroup":"SY","termSource":"NCI"},{"termName":"Enterochromaffin Cell Carcinoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Mon Dec 18 18:00:30 EST 2023 - See 'Neuroendocrine Tumor(C188218)'"},{"name":"ICD-O-3_Code","value":"8240/3"},{"name":"ICD-O-3_Code","value":"8241/3"},{"name":"Legacy Concept Name","value":"Carcinoid_Tumor"},{"name":"Maps_To","value":"Benign carcinoid tumor of unknown primary site"},{"name":"Maps_To","value":"Benign carcinoid tumor of unspecified site"},{"name":"Maps_To","value":"Carcinoid tumor, NOS"},{"name":"Maps_To","value":"Enterochromaffin cell carcinoid"},{"name":"Maps_To","value":"Other benign neuroendocrine tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"OLD_ASSOCIATION","value":"A32|C176985"},{"name":"OLD_ASSOCIATION","value":"A32|C177621"},{"name":"OLD_ASSOCIATION","value":"A8|C102905"},{"name":"OLD_ASSOCIATION","value":"A8|C103057"},{"name":"OLD_ASSOCIATION","value":"A8|C116977"},{"name":"OLD_ASSOCIATION","value":"A8|C118168"},{"name":"OLD_ASSOCIATION","value":"A8|C126659"},{"name":"OLD_ASSOCIATION","value":"A8|C156952"},{"name":"OLD_ASSOCIATION","value":"A8|C156966"},{"name":"OLD_ASSOCIATION","value":"A8|C157711"},{"name":"OLD_ASSOCIATION","value":"A8|C158520"},{"name":"OLD_ASSOCIATION","value":"A8|C168655"},{"name":"OLD_ASSOCIATION","value":"A8|C168656"},{"name":"OLD_ASSOCIATION","value":"A8|C168657"},{"name":"OLD_ASSOCIATION","value":"A8|C168658"},{"name":"OLD_ASSOCIATION","value":"A8|C168661"},{"name":"OLD_ASSOCIATION","value":"A8|C168662"},{"name":"OLD_ASSOCIATION","value":"A8|C177537"},{"name":"OLD_PARENT","value":"C188218"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007095"}]}}{"C27252":{"preferredName":"Enterochromaffin-Like Cell Neuroendocrine Tumor G1","code":"C27252","definitions":[{"definition":"A well differentiated, low grade neuroendocrine neoplasm (carcinoid tumor) arising from the gastrointestinal tract. It is characterized by the presence of enterochromaffin-like type granules in the neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enterochromaffin-Like Cell Neuroendocrine Tumor G1","termGroup":"PT","termSource":"NCI"},{"termName":"ECL Cell NET G1","termGroup":"SY","termSource":"NCI"},{"termName":"Enterochromaffin-Like Cell Carcinoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Enterochromaffin-Like Cell NET G1","termGroup":"SY","termSource":"NCI"},{"termName":"Enterochromaffin-Like Cell Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8242/1"},{"name":"ICD-O-3_Code","value":"8242/3"},{"name":"Legacy Concept Name","value":"Enterochromaffin-Like_Cell_Carcinoid_Tumor"},{"name":"Maps_To","value":"8242/1"},{"name":"Maps_To","value":"8242/3"},{"name":"Maps_To","value":"ECL cell carcinoid, malignant"},{"name":"Maps_To","value":"ECL cell carcinoid, NOS"},{"name":"Maps_To","value":"Enterochromaffin-like cell carcinoid, NOS"},{"name":"Maps_To","value":"Enterochromaffin-like cell tumor"},{"name":"Maps_To","value":"Enterochromaffin-like cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266030"}]}}{"C201135":{"preferredName":"Goblet Cell Adenocarcinoma","code":"C201135","definitions":[{"definition":"A rare adenocarcinoma that exhibits neuroendocrine differentiation and is associated with the presence of neoplastic signet-ring cells resembling goblet cells of the intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goblet Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Composite Carcinoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"GCA","termGroup":"AB","termSource":"NCI"},{"termName":"Goblet Cell Carcinoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8244/3"},{"name":"ICD-O-3_Code","value":"8245/3"},{"name":"Maps_To","value":"8243/3"},{"name":"Maps_To","value":"8245/3"},{"name":"Maps_To","value":"Adenocarcinoid tumor"},{"name":"Maps_To","value":"Composite carcinoid"},{"name":"Maps_To","value":"Goblet Cell Carcinoid"},{"name":"Maps_To","value":"Goblet cell carcinoid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205695"}]}}{"C95406":{"preferredName":"Digestive System Mixed Adenoneuroendocrine Carcinoma","code":"C95406","definitions":[{"definition":"A carcinoma that arises from the digestive system and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component. At least 30% of either component should be present for the diagnosis to be made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Digestive System Mixed Adenoneuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal MANEC","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrointestinal Mixed Adenoneuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MANEC","termGroup":"AB","termSource":"NCI"},{"termName":"Mixed Adenoneuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8244/3"},{"name":"Maps_To","value":"8244/3"},{"name":"Maps_To","value":"MANEC"},{"name":"Maps_To","value":"Mixed adenoneuroendocrine carcinoma"},{"name":"Maps_To","value":"Mixed carcinoid-adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2987129"}]}}{"C43565":{"preferredName":"Appendix Tubular Carcinoid","code":"C43565","definitions":[{"definition":"A neuroendocrine tumor that arises from the appendix.  It does not show the morphologic characteristics of typical carcinoid tumors (neoplastic cells forming solid nests). In contrast, the tumor cells form small discrete tubules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Appendix Tubular Carcinoid","termGroup":"PT","termSource":"NCI"},{"termName":"Appendix Tubular Carcinoid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8245/1"},{"name":"Legacy Concept Name","value":"Appendix_Tubular_Carcinoid"},{"name":"Maps_To","value":"8245/1"},{"name":"Maps_To","value":"Tubular carcinoid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266031"}]}}{"C3773":{"preferredName":"Neuroendocrine Carcinoma","code":"C3773","definitions":[{"definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"High-Grade Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"NEC","termGroup":"AB","termSource":"NCI"},{"termName":"Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8246/3"},{"name":"Legacy Concept Name","value":"Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8246/3"},{"name":"Maps_To","value":"Malignant neuroendocrine tumors"},{"name":"Maps_To","value":"Malignant poorly differentiated neuroendocrine carcinoma, any site"},{"name":"Maps_To","value":"Malignant poorly differentiated neuroendocrine tumors"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, NOS"},{"name":"Maps_To","value":"Other malignant neuroendocrine tumors"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206695"}]}}{"C9231":{"preferredName":"Merkel Cell Carcinoma","code":"C9231","definitions":[{"definition":"A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Merkel Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"MCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8247/3"},{"name":"Legacy Concept Name","value":"Neuroendocrine_Carcinoma_of_the_Skin"},{"name":"Maps_To","value":"8247/3"},{"name":"Maps_To","value":"Merkel cell carcinoma"},{"name":"Maps_To","value":"Merkel cell carcinoma of other sites"},{"name":"Maps_To","value":"Merkel cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007129"}]}}{"C188218":{"preferredName":"Neuroendocrine Tumor","code":"C188218","definitions":[{"definition":"A slow-growing type of tumor usually found in the gastrointestinal system (most often in the appendix), and sometimes in the lungs or other sites. Carcinoid tumors may spread to the liver or other sites in the body, and they may secrete substances such as serotonin or prostaglandins, causing carcinoid syndrome.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A well-differentiated neuroendocrine neoplasm of low, intermediate, or high grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"APUDoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Carcinoid Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Enterochromaffin Cell Carcinoid","termGroup":"AQS","termSource":"NCI"},{"termName":"Well Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8240/3"},{"name":"ICD-O-3_Code","value":"8241/3"},{"name":"ICD-O-3_Code","value":"8248/1"},{"name":"Legacy Concept Name","value":"Carcinoid_Tumor"},{"name":"Legacy Concept Name","value":"Neoplasm_of_the_Diffuse_Neuroendocrine_System"},{"name":"Maps_To","value":"8240/3"},{"name":"Maps_To","value":"8241/3"},{"name":"Maps_To","value":"8248/1"},{"name":"Maps_To","value":"Apudoma"},{"name":"Maps_To","value":"Carcinoid tumor, NOS"},{"name":"Maps_To","value":"Carcinoid, NOS"},{"name":"Maps_To","value":"Enterochromaffin cell carcinoid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0003650"}]}}{"C35725":{"preferredName":"Grade II Neuroendocrine Carcinoma","code":"C35725","synonyms":[{"termName":"Grade II Neuroendocrine Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8249/3"},{"name":"Legacy Concept Name","value":"Grade_II_Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8249/3"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, moderately differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266148"}]}}{"C72074":{"preferredName":"Neuroendocrine Tumor G2","code":"C72074","definitions":[{"definition":"A well-differentiated, intermediate-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system, lung, and head and neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Tumor G2","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Carcinoid Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"NET G2","termGroup":"AB","termSource":"NCI"},{"termName":"Neuroendocrine Tumor Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Atypical_Carcinoid_Tumor"},{"name":"Maps_To","value":"8249/3"},{"name":"Maps_To","value":"Atypical carcinoid tumor"},{"name":"Maps_To","value":"Malignant carcinoid tumor of unknown primary site"},{"name":"Maps_To","value":"Malignant carcinoid tumor of unspecified site"},{"name":"Maps_To","value":"Malignant carcinoid tumors of other and unspecified sites"},{"name":"Maps_To","value":"Malignant carcinoid tumors of other sites"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0391970"}]}}{"C3763":{"preferredName":"Pulmonary Adenomatosis","code":"C3763","definitions":[{"definition":"This is a non-human neoplastic process described in sheep.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Adenomatosis","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8250/1"},{"name":"Legacy Concept Name","value":"Pulmonary_Adenomatosis"},{"name":"Maps_To","value":"8250/1"},{"name":"Maps_To","value":"Pulmonary adenomatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206676"}]}}{"C136716":{"preferredName":"Lung Non-Mucinous Adenocarcinoma In Situ","code":"C136716","definitions":[{"definition":"Lung adenocarcinoma in situ characterized by the presence of type II pneumocyte and/or Clara cell differentiation. Almost all cases of lung adenocarcinoma in situ are non-mucinous.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Non-Mucinous Adenocarcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenocarcinoma in situ of lung, non-mucinous"},{"name":"Maps_To","value":"Adenocarcinoma in situ, non-mucinous"},{"name":"NCI_META_CUI","value":"CL554697"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2923":{"preferredName":"Minimally Invasive Lung Adenocarcinoma","code":"C2923","definitions":[{"definition":"A malignant lung neoplasm originating from the alveolar/bronchiolar epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"BAC","termGroup":"AB","termSource":"NCI"},{"termName":"Bronchioalveolar Adenocarcinoma of Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioalveolar Adenocarcinoma of the Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchiolo-Alveolar Carcinoma of Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchiolo-Alveolar Carcinoma of the Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchiolo-Alveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Adenocarcinoma of Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Adenocarcinoma of the Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Lung Adenocarcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8250/3"},{"name":"ICD-O-3_Code","value":"8251/3"},{"name":"Legacy Concept Name","value":"Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"8250/3"},{"name":"Maps_To","value":"8251/3"},{"name":"Maps_To","value":"Alveolar adenocarcinoma"},{"name":"Maps_To","value":"Alveolar carcinoma"},{"name":"Maps_To","value":"Alveolar cell carcinoma"},{"name":"Maps_To","value":"Bronchiolar adenocarcinoma"},{"name":"Maps_To","value":"Bronchiolar carcinoma"},{"name":"Maps_To","value":"Bronchiolo-alveolar adenocarcinoma, NOS"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, NOS"},{"name":"Maps_To","value":"Minimally invasive adenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2750265"}]}}{"C4140":{"preferredName":"Alveolar Adenoma","code":"C4140","definitions":[{"definition":"A benign lung neoplasm arising from the alveolar/bronchiolar epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well circumscribed lung neoplasm morphologically characterized by the presence of cystic spaces resembling alveoli, lined by a simple cuboidal epithelium. The cystic spaces are surrounded by a spindle cell stroma which may show myxoid changes. It is a solitary, usually peripheral lung lesion. Patients are usually asymptomatic and its discovery is an incidental finding during chest X-ray examination. Surgical excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alveolar Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Alveoli","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Alveoli","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8251/0"},{"name":"Legacy Concept Name","value":"Alveolar_Adenoma"},{"name":"Maps_To","value":"8251/0"},{"name":"Maps_To","value":"Alveolar adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334303"}]}}{"C7269":{"preferredName":"Minimally Invasive Lung Non-Mucinous Adenocarcinoma","code":"C7269","definitions":[{"definition":"A morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of Clara cells and/or type II cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Non-Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Mucinous Bronchioloalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Mucinous Bronchoalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Mucinous Minimally Invasive Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8252/3"},{"name":"Legacy Concept Name","value":"Non-Mucinous_Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"8252/3"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, Clara cell"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, non- mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, non-mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma; type II pneumocyte"},{"name":"Maps_To","value":"Minimally invasive adenocarcinoma, non-mucinous"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266034"}]}}{"C136709":{"preferredName":"Invasive Lung Mucinous Adenocarcinoma","code":"C136709","definitions":[{"definition":"An invasive adenocarcinoma that arises from the lung. It is characterized by the presence of tall columnar cells and mucin production. This category refers to cases formerly classified as mucinous bronchioloalveolar carcinoma, excluding cases that meet the criteria for adenocarcinoma in situ or mucinous minimally invasive adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Lung Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Invasive Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8253/3"},{"name":"Maps_To","value":"Adenocarcinoma of lung, mucinous"},{"name":"Maps_To","value":"Bronchio-alveolar carcinoma, mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, mucinous"},{"name":"Maps_To","value":"Invasive mucinous adenocarcinoma"},{"name":"NCI_META_CUI","value":"CL524517"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7270":{"preferredName":"Minimally Invasive Lung Mixed Non-Mucinous and Mucinous Adenocarcinoma","code":"C7270","definitions":[{"definition":"A morphologic variant of minimally invasive lung adenocarcinoma characterized by the presence of Clara cells and/or type II cells, tall columnar cells, and mucin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Mixed Non-Mucinous and Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Indeterminate Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Mucinous and Non-Mucinous Bronchioloalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Mucinous and Non-Mucinous Bronchoalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8254/3"},{"name":"Legacy Concept Name","value":"Mixed_Mucinous_and_Non-Mucinous_Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"8254/3"},{"name":"Maps_To","value":"Adenocarcinoma of lung, mixed mucinous and non-mucinous"},{"name":"Maps_To","value":"Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, indeterminate type"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, mixed mucinous and non-mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266036"}]}}{"C45508":{"preferredName":"Lung Adenocarcinoma, Mixed Subtype","code":"C45508","definitions":[{"definition":"The most frequently seen morphologic variant of lung adenocarcinoma characterized by a mixture of architectural patterns, including acinar, papillary, bronchioloalveolar, and solid pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Adenocarcinoma, Mixed Subtype","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Adenocarcinoma_Mixed_Subtype"},{"name":"Maps_To","value":"8255/3"},{"name":"Maps_To","value":"Adenocarcinoma combined with other types of carcinoma"},{"name":"Maps_To","value":"Adenocarcinoma with mixed subtypes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708765"}]}}{"C7268":{"preferredName":"Minimally Invasive Lung Mucinous Adenocarcinoma","code":"C7268","definitions":[{"definition":"A morphologic variant of minimally invasive lung adenocarcinoma characterized by tall columnar cells and mucin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Bronchioloalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Bronchoalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Minimally Invasive Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8253/3"},{"name":"Legacy Concept Name","value":"Mucinous_Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"Bronchio-alveolar carcinoma, mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, goblet cell type"},{"name":"Maps_To","value":"Minimally invasive adenocarcinoma, mucinous"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266035"}]}}{"C79951":{"preferredName":"Papillary Adenoma","code":"C79951","definitions":[{"definition":"A benign epithelial neoplasm characterized by the presence of papillary epithelial patterns.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenoma characterized by the presence of papillary epithelial patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Adenomatous_Lesion"},{"name":"Maps_To","value":"8260/0"},{"name":"Maps_To","value":"Papillary adenoma, NOS"},{"name":"NCI_META_CUI","value":"CL388631"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4035":{"preferredName":"Thyroid Gland Papillary Carcinoma","code":"C4035","definitions":[{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.","type":"DEFINITION","source":"NCI"},{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei. The nuclei also display clearing or have a ground glass appearance.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that forms in follicular cells in the thyroid and grows in small finger-like shapes. It grows slowly, is more common in women than in men, and often occurs before age 45. It is the most common type of thyroid cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Cancer of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cancer of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cancer of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cancer of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"PTC","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Papillary_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8260/3"},{"name":"Maps_To","value":"Papillary carcinoma of thyroid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3149311"}]}}{"C2853":{"preferredName":"Papillary Adenocarcinoma","code":"C2853","definitions":[{"definition":"A morphologic variant of adenocarcinoma. It is characterized by the presence of a papillary growth pattern. Representative examples include thyroid gland papillary carcinoma, invasive papillary breast carcinoma, and ovarian serous surface papillary adenocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"An adenocarcinoma with papillary growth pattern.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8260/3"},{"name":"Legacy Concept Name","value":"Papillary_Adenocarcinoma"},{"name":"Maps_To","value":"8260/3"},{"name":"Maps_To","value":"Papillary adenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001420"}]}}{"C6975":{"preferredName":"Papillary Renal Cell Carcinoma","code":"C6975","definitions":[{"definition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chromophil Carcinoma of Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophil Carcinoma of the Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophil Renal Cell Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary (Chromophil) Renal Cell Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary RCC","termGroup":"SY","termSource":"NCI"},{"termName":"PRCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"51"},{"name":"Maps_To","value":"71"},{"name":"Maps_To","value":"8260/3"},{"name":"Maps_To","value":"Papillary Renal Cell"},{"name":"Maps_To","value":"Papillary renal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306837"}]}}{"C7399":{"preferredName":"Villous Adenoma","code":"C7399","definitions":[{"definition":"A neoplasm that grows in the colon and other places in the gastrointestinal tract and sometimes in other parts of the body. These adenomas may become malignant (cancerous).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Villous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Villous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Villous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8261/0"},{"name":"Legacy Concept Name","value":"Villous_Adenoma"},{"name":"Maps_To","value":"8261/0"},{"name":"Maps_To","value":"Villous adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206674"}]}}{"C8376":{"preferredName":"Adenocarcinoma In Situ in Villous Adenoma","code":"C8376","definitions":[{"definition":"A non-invasive adenocarcinoma arising from a villous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Villous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8261/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Villous_Adenoma"},{"name":"Maps_To","value":"8261/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in villous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334304"}]}}{"C4141":{"preferredName":"Adenocarcinoma in Villous Adenoma","code":"C4141","definitions":[{"definition":"A non-invasive or invasive adenocarcinoma arising from a villous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Villous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8261/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Villous_Adenoma"},{"name":"Maps_To","value":"8261/3"},{"name":"Maps_To","value":"Adenocarcinoma in villous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334305"}]}}{"C4142":{"preferredName":"Villous Adenocarcinoma","code":"C4142","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a villous architectural pattern. It may arise from a villous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Villous Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8262/3"},{"name":"Legacy Concept Name","value":"Villous_Adenocarcinoma"},{"name":"Maps_To","value":"8262/3"},{"name":"Maps_To","value":"Villous adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334306"}]}}{"C4143":{"preferredName":"Tubulovillous Adenoma","code":"C4143","definitions":[{"definition":"A neoplasm that grows in the colon and other places in the gastrointestinal tract and sometimes in other parts of the body. These adenomas may become malignant (cancerous).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular and a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulovillous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Tubulovillous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Tubulovillous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8263/0"},{"name":"Legacy Concept Name","value":"Tubulovillous_Adenoma"},{"name":"Maps_To","value":"8263/0"},{"name":"Maps_To","value":"Papillotubular adenoma"},{"name":"Maps_To","value":"Tubulo-papillary adenoma"},{"name":"Maps_To","value":"Tubulovillous adenoma, NOS"},{"name":"Maps_To","value":"Villoglandular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334307"}]}}{"C4144":{"preferredName":"Adenocarcinoma In Situ in Tubulovillous Adenoma","code":"C4144","definitions":[{"definition":"A non-invasive adenocarcinoma arising from a tubulovillous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Tubulovillous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8263/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Tubulovillous_Adenoma"},{"name":"Maps_To","value":"8263/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in tubulovillous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334308"}]}}{"C4145":{"preferredName":"Adenocarcinoma in Tubulovillous Adenoma","code":"C4145","definitions":[{"definition":"A non-invasive or invasive adenocarcinoma arising from a tubulovillous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Tubulovillous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8263/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Tubulovillous_Adenoma"},{"name":"Maps_To","value":"8263/3"},{"name":"Maps_To","value":"Adenocarcinoma in tubolovillous adenoma"},{"name":"Maps_To","value":"Adenocarcinoma in tubulovillous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334309"}]}}{"C6881":{"preferredName":"Bile Duct Intraductal Papillary Neoplasm","code":"C6881","definitions":[{"definition":"An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Intraductal Papillary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct IPN","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Papillomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary Papillomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Legacy Concept Name","value":"Bile_Duct_Papillomatosis"},{"name":"Maps_To","value":"8264/0"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Biliary papillomatosis"},{"name":"Maps_To","value":"Intraductal papillary neoplasm, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879344"}]}}{"C65198":{"preferredName":"Glandular Papillomatosis","code":"C65198","definitions":[{"definition":"Multifocal neoplastic proliferations of the glandular epithelium displaying a papillary pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glandular Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8264/0"},{"name":"Legacy Concept Name","value":"Glandular_Papillomatosis"},{"name":"Maps_To","value":"8264/0"},{"name":"Maps_To","value":"Papillomatosis, glandular"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266038"}]}}{"C128847":{"preferredName":"Lung Micropapillary Adenocarcinoma","code":"C128847","definitions":[{"definition":"An aggressive variant of lung adenocarcinoma that exhibits a micropapillary architectural pattern. The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Micropapillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8265/3"},{"name":"Maps_To","value":"Micropapillary carcinoma, NOS"},{"name":"NCI_META_CUI","value":"CL536215"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2857":{"preferredName":"Pituitary Gland Chromophobe Adenoma","code":"C2857","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells do not stain with acidic or basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromophobe Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophobe Adenoma of Pituitary Gland","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophobe Adenoma of the Pituitary Gland","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Chromophobe Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Chromophobe Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8270/0"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Chromophobe_Adenoma"},{"name":"Maps_To","value":"8270/0"},{"name":"Maps_To","value":"Chromophobe adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001432"}]}}{"C4146":{"preferredName":"Chromophobe Renal Cell Carcinoma","code":"C4146","definitions":[{"definition":"A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical), eosinophilic, or oncocytic.  It has a much better prognosis than other renal cell carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromophobe Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chromophobe Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Cell Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Cell Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe RCC","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Chromophobe Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8270/3"},{"name":"ICD-O-3_Code","value":"8317/3"},{"name":"Legacy Concept Name","value":"Chromophobe_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"8270/3"},{"name":"Maps_To","value":"8317/3"},{"name":"Maps_To","value":"Chromophobe adenocarcinoma"},{"name":"Maps_To","value":"Chromophobe carcinoma"},{"name":"Maps_To","value":"Chromophobe cell renal carcinoma"},{"name":"Maps_To","value":"Renal cell carcinoma, chromophobe type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266042"}]}}{"C3342":{"preferredName":"Lactotroph Pituitary Neuroendocrine Tumor","code":"C3342","definitions":[{"definition":"A pituitary neuroendocrine tumor that produces prolactin.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A pituitary neuroendocrine tumor that produces prolactin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lactotroph Pituitary Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Lactotrope Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lactotroph Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lactotroph PitNET/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lactotroph Pituitary Neuroendocrine Tumor/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Gland Prolactinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Prolactinoma","termGroup":"SY","termSource":"NCI"},{"termName":"PRL Producing Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Pituitary Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Pituitary Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin-Producing Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8271/0"},{"name":"Legacy Concept Name","value":"Prolactin_Secreting_Pituitary_Gland_Adenoma"},{"name":"Maps_To","value":"8271/0"},{"name":"Maps_To","value":"Lactotroph adenoma"},{"name":"Maps_To","value":"Prolactinoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0033375"}]}}{"C3329":{"preferredName":"Pituitary Neuroendocrine Tumor","code":"C3329","definitions":[{"definition":"A benign neoplasm of the anterior lobe of the pituitary gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-metastasizing tumor that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A well-differentiated neuroendocrine neoplasm that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. It has a low frequency of metastatic spread. When metastatic, the term metastatic pituitary neuroendocrine tumor is endorsed instead of pituitary carcinoma. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pituitary Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"PitNET","termGroup":"AB","termSource":"NCI"},{"termName":"PitNET/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Neuroendocrine Tumor (Formerly Pituitary Adenoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Neuroendocrine Tumor/Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8272/0"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Adenoma"},{"name":"Maps_To","value":"8272/0"},{"name":"Maps_To","value":"Pituitary adenoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0032000"}]}}{"C4536":{"preferredName":"Metastatic Pituitary Neuroendocrine Tumor","code":"C4536","definitions":[{"definition":"Pituitary neuroendocrine tumor that has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Pituitary Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic PitNET","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Pituitary Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Gland Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Gland Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8272/3"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Carcinoma"},{"name":"Maps_To","value":"8272/3"},{"name":"Maps_To","value":"Pituitary carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346300"}]}}{"C6780":{"preferredName":"Pituitary Gland Acidophil Adenoma","code":"C6780","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acidophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eosinophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Acidophil Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8280/0"},{"name":"Legacy Concept Name","value":"Acidophil_Adenoma"},{"name":"Maps_To","value":"8280/0"},{"name":"Maps_To","value":"Acidophil adenoma"},{"name":"Maps_To","value":"Eosinophil adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001433"}]}}{"C4147":{"preferredName":"Pituitary Gland Acidophil Carcinoma","code":"C4147","definitions":[{"definition":"A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acidophil Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Acidophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eosinophil Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eosinophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Acidophil Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8280/3"},{"name":"Legacy Concept Name","value":"Acidophil_Adenocarcinoma"},{"name":"Maps_To","value":"8280/3"},{"name":"Maps_To","value":"Acidophil adenocarcinoma"},{"name":"Maps_To","value":"Acidophil carcinoma"},{"name":"Maps_To","value":"Eosinophil adenocarcinoma"},{"name":"Maps_To","value":"Eosinophil carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334311"}]}}{"C4148":{"preferredName":"Pituitary Gland Mixed Acidophil-Basophil Adenoma","code":"C4148","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic and basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Acidophil-Basophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Eosinophil-Basophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Mixed Acidophil-Basophil Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8281/0"},{"name":"Legacy Concept Name","value":"Mixed_Acidophil-Basophil_Adenoma"},{"name":"Maps_To","value":"8281/0"},{"name":"Maps_To","value":"Mixed acidophil-basophil adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334312"}]}}{"C4149":{"preferredName":"Pituitary Gland Mixed Acidophil-Basophil Carcinoma","code":"C4149","definitions":[{"definition":"A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic and basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Acidophil-Basophil Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Acidophil-Basophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Eosinophil-Basophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Mixed Acidophil-Basophil Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8281/3"},{"name":"Legacy Concept Name","value":"Mixed_Acidophil-Basophil_Carcinoma"},{"name":"Maps_To","value":"8281/3"},{"name":"Maps_To","value":"Mixed acidophil-basophil carcinoma"},{"name":"NCI_META_CUI","value":"CL448681"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3759":{"preferredName":"Oncocytic Adenoma","code":"C3759","definitions":[{"definition":"A benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.  Representative examples include oncocytic adenomas of the thyroid gland, parathyroid gland, and pituitary gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Oxyphilic Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8290/0"},{"name":"Legacy Concept Name","value":"Oxyphilic_Adenoma"},{"name":"Maps_To","value":"8290/0"},{"name":"Maps_To","value":"Follicular adenoma, oxyphilic cell"},{"name":"Maps_To","value":"Oncocytic adenoma"},{"name":"Maps_To","value":"Oxyphilic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1510502"}]}}{"C6042":{"preferredName":"Thyroid Gland Oncocytic Adenoma","code":"C6042","definitions":[{"definition":"A thyroid gland adenoma composed of large cells with abundant granular eosinophilic cytoplasm and large nuclei with prominent nucleoli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Oncocytic Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Oncocytoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Oncocytoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Oncocytoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Oncocytoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Thyroid Gland Oncocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Thyroid Oncocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid Gland of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid Gland of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Follicular Adenoma of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Follicular Adenoma of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Follicular Adenoma of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Follicular Adenoma of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Hurthle Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Oncocytic Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Hurthle_Cell_Adenoma"},{"name":"Maps_To","value":"8290/0"},{"name":"Maps_To","value":"Hurthle cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336750"}]}}{"C3679":{"preferredName":"Oncocytic Adenocarcinoma","code":"C3679","definitions":[{"definition":"A malignant neoplasm composed of large epithelial cells with abundant granular eosinophilic cytoplasm (oncocytes).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenocarcinoma characterized by the presence of large malignant epithelial cells with abundant granular eosinophilic cytoplasm (oncocytes). Representative examples include thyroid gland oncocytic follicular carcinoma, oncocytic breast carcinoma, and salivary gland oncocytic carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hurthle Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Oxyphilic Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8290/3"},{"name":"Legacy Concept Name","value":"Oxyphilic_Adenocarcinoma"},{"name":"Maps_To","value":"8290/3"},{"name":"Maps_To","value":"Follicular carcinoma, oxyphilic cell"},{"name":"Maps_To","value":"Hurthle cell adenocarcinoma"},{"name":"Maps_To","value":"Hurthle cell carcinoma"},{"name":"Maps_To","value":"Oncocytic adenocarcinoma"},{"name":"Maps_To","value":"Oncocytic carcinoma"},{"name":"Maps_To","value":"Oxyphilic adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205642"}]}}{"C2856":{"preferredName":"Pituitary Gland Basophil Adenoma","code":"C2856","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basophilic Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Basophilic Pituitary Gland Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucoid Cell Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Basophilic Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Basophil Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8300/0"},{"name":"Legacy Concept Name","value":"Basophilic_Adenoma"},{"name":"Maps_To","value":"8300/0"},{"name":"Maps_To","value":"Basophil adenoma"},{"name":"Maps_To","value":"Mucoid cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001431"}]}}{"C4150":{"preferredName":"Basophilic Adenocarcinoma","code":"C4150","definitions":[{"definition":"A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basophilic Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basophilic Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8300/3"},{"name":"Legacy Concept Name","value":"Basophilic_Adenocarcinoma"},{"name":"Maps_To","value":"8300/3"},{"name":"Maps_To","value":"Basophil adenocarcinoma"},{"name":"Maps_To","value":"Basophil carcinoma"},{"name":"Maps_To","value":"Mucoid cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334314"}]}}{"C4151":{"preferredName":"Clear Cell Adenoma","code":"C4151","definitions":[{"definition":"A benign neoplasm composed of glands containing epithelial clear cells.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm comprising glands containing epithelial clear cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Clear Cell Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8310/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adenoma"},{"name":"Maps_To","value":"8310/0"},{"name":"Maps_To","value":"Clear cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334315"}]}}{"C3766":{"preferredName":"Clear Cell Adenocarcinoma","code":"C3766","definitions":[{"definition":"A malignant neoplasm composed of glandular epithelial clear cells.  Various architectural patterns may be seen, including papillary, tubulocystic, and solid.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm comprising glandular epithelial clear cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare type of tumor, usually of the female genital tract, in which the insides of the cells look clear when viewed under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephroid Clear Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephroid Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8310/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8310/3"},{"name":"Maps_To","value":"Clear cell adenocarcinoma, mesonephroid"},{"name":"Maps_To","value":"Clear cell adenocarcinoma, NOS"},{"name":"Maps_To","value":"Clear cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206681"}]}}{"C4033":{"preferredName":"Clear Cell Renal Cell Carcinoma","code":"C4033","definitions":[{"definition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","type":"DEFINITION","source":"NCI"},{"definition":"The most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"CCRCC","termGroup":"AB","termSource":"NCI"},{"termName":"Clear Cell Adenocarcinoma of Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Clear Cell Adenocarcinoma of the Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Clear Cell Adenocarcinoma, Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell RCC","termGroup":"SY","termSource":"NCI"},{"termName":"Conventional (Clear Cell) Renal Cell Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Conventional (Clear Cell) Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Conventional Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grawitz Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Hypernephroma","termGroup":"AQS","termSource":"NCI"},{"termName":"Kidney Clear Cell Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Kidney Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Clear Cell Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Renal Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Conventional_Clear_Cell_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"50"},{"name":"Maps_To","value":"63"},{"name":"Maps_To","value":"64"},{"name":"Maps_To","value":"65"},{"name":"Maps_To","value":"70"},{"name":"Maps_To","value":"8311/1"},{"name":"Maps_To","value":"8312/3"},{"name":"Maps_To","value":"Grawitz tumor"},{"name":"Maps_To","value":"Hypernephroid tumor"},{"name":"Maps_To","value":"Hypernephroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4225533"}]}}{"C51302":{"preferredName":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","code":"C51302","definitions":[{"definition":"A rare inherited disorder that increases the risk of developing benign (not cancer) tumors of the skin and the uterus (leiomyomas) and malignant (cancer) tumors of the uterus (leiomyosarcoma) and the kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant inherited syndrome caused by germline mutations in the FH gene. It is characterized by predisposition to renal cell carcinoma, leiomyomas of the skin and uterus, and leiomyosarcoma of the uterus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"FH Deficiency","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Leiomyomatosis and Renal Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"HLRCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Leiomyomatosis_and_Renal_Cell_Cancer"},{"name":"Maps_To","value":"Hereditary leiomyomatosis & RCC-associated renal cell carcinoma"},{"name":"Maps_To","value":"Hereditary Leiomyomatosis and Renal Cell Carcinoma"},{"name":"Maps_To","value":"Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated renal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708350"}]}}{"C191370":{"preferredName":"Renal Cell Carcinoma, Not Otherwise Specified","code":"C191370","definitions":[{"definition":"A renal cell carcinoma that cannot be classified into one of the established subtypes of renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Cell Carcinoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"RCC-NEC","termGroup":"SY","termSource":"NCI"},{"termName":"RCC-NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Not Elsewhere Classified","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Unclassified","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unclassified_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"8312/3"},{"name":"Maps_To","value":"Renal cell carcinoma, NOS"},{"name":"Maps_To","value":"Renal cell carcinoma, unclassified"},{"name":"NCI_META_CUI","value":"CL1904778"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8988":{"preferredName":"Clear Cell Cystadenofibroma","code":"C8988","definitions":[{"definition":"A benign or borderline neoplasm characterized by the presence of cystic glandular and fibrous tissues and clear cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clear_Cell_Cystadenofibroma"},{"name":"Maps_To","value":"8313/0"},{"name":"Maps_To","value":"Clear cell cystadenofibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377853"}]}}{"C8987":{"preferredName":"Clear Cell Adenofibroma","code":"C8987","definitions":[{"definition":"A benign or borderline neoplasm characterized by the presence of glandular structures which contain clear cells and a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8313/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adenofibroma"},{"name":"Maps_To","value":"8313/0"},{"name":"Maps_To","value":"Clear cell adenofibroma"},{"name":"NCI_META_CUI","value":"CL448546"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40080":{"preferredName":"Borderline Ovarian Clear Cell Tumor","code":"C40080","definitions":[{"definition":"An epithelial neoplasm with low malignant potential affecting the ovary.  It is characterized by the presence of clear or hobnail cells.  In some cases, the cells may display nuclear atypia and prominent nucleoli.  When such cells are present, they remain confined to the glands.  There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Clear Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Ovarian Clear Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Clear_Cell_Tumor"},{"name":"Maps_To","value":"8313/1"},{"name":"Maps_To","value":"8444/1"},{"name":"Maps_To","value":"Clear cell borderline tumor"},{"name":"Maps_To","value":"Clear cell cystic tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279676"}]}}{"C40081":{"preferredName":"Borderline Ovarian Clear Cell Adenofibroma","code":"C40081","definitions":[{"definition":"An epithelial neoplasm with low malignant potential affecting the ovary. It is characterized by the presence of atypical glands and/or cystic spaces lined with clear or hobnail cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Clear Cell Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8313/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Clear_Cell_Adenofibroma"},{"name":"Maps_To","value":"8313/1"},{"name":"Maps_To","value":"Clear cell adenofibroma of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266039"}]}}{"C40079":{"preferredName":"Ovarian Clear Cell Adenocarcinofibroma","code":"C40079","definitions":[{"definition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells with clear cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Clear Cell Adenocarcinofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Clear Cell Malignant Adenofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8313/3"},{"name":"Legacy Concept Name","value":"Ovarian_Clear_Cell_Adenocarcinofibroma"},{"name":"Maps_To","value":"8313/3"},{"name":"Maps_To","value":"Clear cell adenocarcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266040"}]}}{"C4152":{"preferredName":"Lipid-Rich Carcinoma","code":"C4152","definitions":[{"definition":"A carcinoma characterized by the presence of malignant epithelial cells with clear cytoplasm which contains neutral lipids. A representative example is the lipid-rich breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid-Rich Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8314/3"},{"name":"Legacy Concept Name","value":"Lipid-Rich_Carcinoma"},{"name":"Maps_To","value":"8314/3"},{"name":"Maps_To","value":"Lipid-rich carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334318"}]}}{"C4153":{"preferredName":"Glycogen-Rich Carcinoma","code":"C4153","definitions":[{"definition":"A carcinoma characterized by the presence of malignant epithelial cells with abundant clear cytoplasm which contains glycogen. A representative example is the glycogen-rich, clear cell breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glycogen-Rich Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8315/3"},{"name":"Legacy Concept Name","value":"Glycogen-Rich_Carcinoma"},{"name":"Maps_To","value":"8315/3"},{"name":"Maps_To","value":"Glycogen-rich carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334319"}]}}{"C157718":{"preferredName":"Acquired Cystic Disease-Associated Renal Cell Carcinoma","code":"C157718","definitions":[{"definition":"The most common renal cell carcinoma that develops in patients with end-stage renal disease and acquired cystic disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acquired Cystic Disease-Associated Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ACD-RCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8316/3"},{"name":"Maps_To","value":"Acquired cystic disease-associated renal cell carcinoma (RCC)"},{"name":"Maps_To","value":"Cyst-associated renal cell carcinoma"},{"name":"NCI_META_CUI","value":"CL558162"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27893":{"preferredName":"Sarcomatoid Renal Cell Carcinoma","code":"C27893","definitions":[{"definition":"A high grade carcinoma of the kidney.  It is not a distinct clinicopathological entity and includes a diverse group of renal cell carcinomas which have been transformed from a lower to a higher grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Sarcomatoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8318/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"8318/3"},{"name":"Maps_To","value":"Renal cell carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Renal cell carcinoma, spindle cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266043"}]}}{"C6194":{"preferredName":"Collecting Duct Carcinoma","code":"C6194","definitions":[{"definition":"A rare type of kidney cancer that grows and spreads quickly. It begins in the duct of Bellini in the kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Collecting Duct Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bellini Duct Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Carcinoma of Collecting Ducts of Bellini","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Kidney Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Renal Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Kidney Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Renal Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Collecting Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Collecting Duct Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8319/3"},{"name":"Legacy Concept Name","value":"Collecting_Duct_Carcinoma"},{"name":"Maps_To","value":"8319/3"},{"name":"Maps_To","value":"Bellini duct carcinoma"},{"name":"Maps_To","value":"Collecting duct carcinoma"},{"name":"Maps_To","value":"Renal carcinoma, collecting duct type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266044"}]}}{"C3681":{"preferredName":"Granular Cell Carcinoma","code":"C3681","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant epithelial cells with granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granular Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Granular Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8320/3"},{"name":"Legacy Concept Name","value":"Granular_Cell_Carcinoma"},{"name":"Maps_To","value":"8320/3"},{"name":"Maps_To","value":"Granular cell adenocarcinoma"},{"name":"Maps_To","value":"Granular cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205644"}]}}{"C4154":{"preferredName":"Parathyroid Gland Chief Cell Adenoma","code":"C4154","definitions":[{"definition":"A parathyroid gland adenoma composed predominantly of neoplastic chief cells.  These cells have either slightly eosinophilic or vacuolated cytoplasm, and round nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parathyroid Gland Chief Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chief Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of Parathyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of Parathyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of the Parathyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of the Parathyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Parathyroid Chief Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8321/0"},{"name":"Legacy Concept Name","value":"Parathyroid_Chief_Cell_Adenoma"},{"name":"Maps_To","value":"8321/0"},{"name":"Maps_To","value":"Chief cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334320"}]}}{"C4155":{"preferredName":"Parathyroid Gland Water-Clear Cell Adenoma","code":"C4155","definitions":[{"definition":"A rare parathyroid gland adenoma composed of neoplastic cells with abundant cytoplasm.  The cytoplasm of the neoplastic cells is usually not entirely clear, and is often variably vacuolated, foamy, and granular.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parathyroid Gland Water-Clear Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Water-Clear Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8322/0"},{"name":"Legacy Concept Name","value":"Water-Clear_Cell_Adenoma"},{"name":"Maps_To","value":"8322/0"},{"name":"Maps_To","value":"Water-clear cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334321"}]}}{"C4156":{"preferredName":"Water-Clear Cell Adenocarcinoma","code":"C4156","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant epithelial cells with clear, often vacuolated or foamy cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Water-Clear Cell Adenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8322/3"},{"name":"Legacy Concept Name","value":"Water-Clear_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8322/3"},{"name":"Maps_To","value":"Water-clear cell adenocarcinoma"},{"name":"Maps_To","value":"Water-clear cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334322"}]}}{"C4157":{"preferredName":"Mixed Cell Adenoma","code":"C4157","definitions":[{"definition":"An adenoma characterized by the presence of a mixed epithelial cell population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Cell Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8323/0"},{"name":"Legacy Concept Name","value":"Mixed_Cell_Adenoma"},{"name":"Maps_To","value":"8323/0"},{"name":"Maps_To","value":"Mixed cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334323"}]}}{"C4158":{"preferredName":"Mixed Cell Adenocarcinoma","code":"C4158","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a mixed malignant glandular cell population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Cell Adenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8323/3"},{"name":"Legacy Concept Name","value":"Mixed_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8323/3"},{"name":"Maps_To","value":"Mixed cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334324"}]}}{"C4159":{"preferredName":"Lipoadenoma","code":"C4159","definitions":[{"definition":"An adenoma in which the neoplastic epithelial cells are admixed with adipose tissue cells.","type":"DEFINITION","source":"NCI"},{"definition":"Benign mixed neoplasm comprised of epithelial/glandular and lipomatous structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lipoadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8324/0"},{"name":"Legacy Concept Name","value":"Lipoadenoma"},{"name":"Maps_To","value":"8324/0"},{"name":"Maps_To","value":"Adenolipoma"},{"name":"Maps_To","value":"Lipoadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334325"}]}}{"C3502":{"preferredName":"Thyroid Gland Follicular Adenoma","code":"C3502","definitions":[{"definition":"A benign neoplasm arising from follicular cells of the thyroid gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, encapsulated neoplasm arising from the follicular cells of the thyroid gland. It may be associated with thyroid hormone secretion but it does not have malignant characteristics.","type":"DEFINITION","source":"NCI"},{"definition":"A non-malignant neoplasm of the thyroid gland arising from epithelial cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Thyroid Gland Follicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8330/0"},{"name":"Legacy Concept Name","value":"Thyroid_Adenoma"},{"name":"Maps_To","value":"8330/0"},{"name":"Maps_To","value":"Follicular Adenoma"},{"name":"Maps_To","value":"Follicular adenoma"},{"name":"Maps_To","value":"Follicular adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0151468"}]}}{"C27729":{"preferredName":"Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential","code":"C27729","definitions":[{"definition":"An encapsulated or well-circumscribed thyroid gland tumor composed of well-differentiated follicular cells with well-developed or partially developed nuclear features of papillary thyroid carcinoma and with questionable capsular or vascular invasion. This is a tumor indeterminate between follicular adenoma and follicular carcinoma. Tumors in which vascular invasion has been excluded by all means are called non-invasive follicular thyroid neoplasms with papillary-like nuclear features. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Atypical Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Well-Differentiated Neoplasm of Uncertain Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"WDT-UMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8330/1"},{"name":"Legacy Concept Name","value":"Atypical_Follicular_Adenoma"},{"name":"Maps_To","value":"8330/1"},{"name":"Maps_To","value":"Atypical follicular adenoma"},{"name":"Maps_To","value":"Well differentiated tumor of uncertain malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266046"}]}}{"C8054":{"preferredName":"Thyroid Gland Follicular Carcinoma","code":"C8054","definitions":[{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  The nuclear features which characterize the thyroid gland papillary carcinoma are absent.  Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers.  Clinically, it usually presents as a solitary mass in the thyroid gland.  It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.","type":"DEFINITION","source":"NCI"},{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The nuclear features which characterize the thyroid gland papillary carcinoma are absent.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neoplasia arising from follicular cells of the thyroid gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that forms in follicular cells in the thyroid. It grows slowly and is highly treatable.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Follicular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FTC","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Follicular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Follicular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Follicular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8330/3"},{"name":"ICD-O-3_Code","value":"8331/3"},{"name":"Legacy Concept Name","value":"Follicular_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8330/3"},{"name":"Maps_To","value":"8331/3"},{"name":"Maps_To","value":"Follicular adenocarcinoma, NOS"},{"name":"Maps_To","value":"Follicular adenocarcinoma, well differentiated"},{"name":"Maps_To","value":"Follicular carcinoma, NOS"},{"name":"Maps_To","value":"Follicular carcinoma, well differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206682"}]}}{"C46095":{"preferredName":"Solid/Trabecular Variant Thyroid Gland Papillary Carcinoma","code":"C46095","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland that predominantly affects children.  It is characterized by the presence of a solid growth pattern.  The malignant cells have nuclear features that are characteristic of papillary carcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid/Trabecular Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Variant_Thyroid_Gland_Papillary_Carcinoma"},{"name":"Maps_To","value":"8332/3"},{"name":"Maps_To","value":"Follicular adenocarcinoma, trabecular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334327"}]}}{"C4160":{"preferredName":"Thyroid Gland Microfollicular Adenoma","code":"C4160","definitions":[{"definition":"A thyroid gland adenoma composed of microfollicular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Microfollicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Microfollicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Fetal Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8333/0"},{"name":"Legacy Concept Name","value":"Microfollicular_Adenoma"},{"name":"Maps_To","value":"8333/0"},{"name":"Maps_To","value":"Fetal adenoma"},{"name":"Maps_To","value":"Microfollicular adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334328"}]}}{"C45509":{"preferredName":"Lung Fetal Adenocarcinoma","code":"C45509","definitions":[{"definition":"A rare morphologic variant of lung adenocarcinoma characterized by the presence of glandular structures containing glycogen-rich cells forming tubules that resemble fetal lung tubules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Fetal Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Adenocarcinoma of Fetal Type","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Endodermal Tumor Resembling Fetal Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Fetal Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8333/3"},{"name":"Legacy Concept Name","value":"Fetal_Lung_Adenocarcinoma"},{"name":"Maps_To","value":"8333/3"},{"name":"Maps_To","value":"Fetal adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708045"}]}}{"C4161":{"preferredName":"Thyroid Gland Macrofollicular Adenoma","code":"C4161","definitions":[{"definition":"A thyroid gland adenoma composed of large size follicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Macrofollicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Colloid Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Macrofollicular Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8334/0"},{"name":"Legacy Concept Name","value":"Macrofollicular_Adenoma"},{"name":"Maps_To","value":"8334/0"},{"name":"Maps_To","value":"Colloid adenoma"},{"name":"Maps_To","value":"Macrofollicular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334329"}]}}{"C65200":{"preferredName":"Thyroid Gland Follicular Carcinoma, Minimally Invasive","code":"C65200","definitions":[{"definition":"A follicular carcinoma of the thyroid gland showing capsular invasion only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Follicular Carcinoma, Minimally Invasive","termGroup":"PT","termSource":"NCI"},{"termName":"FTC, Minimally Invasive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8335/3"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Follicular_Carcinoma_Minimally_Invasive"},{"name":"Maps_To","value":"8335/3"},{"name":"Maps_To","value":"Follicular carcinoma, minimally invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266048"}]}}{"C6846":{"preferredName":"Thyroid Gland Hyalinizing Trabecular Tumor","code":"C6846","definitions":[{"definition":"A rare, circumscribed or encapsulated tumor arising from the follicular cells of the thyroid gland.  It is characterized by a trabecular growth pattern and hyalinized stroma formation.  The vast majority of cases have a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Hyalinizing Trabecular Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"HTT","termGroup":"AB","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma-like Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"PLAT","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Hyalinizing Trabecular Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8336/0"},{"name":"Legacy Concept Name","value":"Thyroid_Hyalinizing_Trabecular_Adenoma"},{"name":"Maps_To","value":"8336/0"},{"name":"Maps_To","value":"Hyalinizing trabecular adenoma"},{"name":"Maps_To","value":"Hyalinizing trabecular tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266049"}]}}{"C6040":{"preferredName":"Poorly Differentiated Thyroid Gland Carcinoma","code":"C6040","definitions":[{"definition":"A follicular-derived thyroid gland carcinoma that is histologically poorly differentiated and has high-grade features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Thyroid Gland Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Insular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"PDTC","termGroup":"AB","termSource":"NCI"},{"termName":"Poorly Differentiated Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Poorly Differentiated Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Poorly Differentiated Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Poorly Differentiated Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8337/3"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8337/3"},{"name":"Maps_To","value":"Insular carcinoma"},{"name":"Maps_To","value":"Poorly differentiated thyroid carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266050"}]}}{"C156122":{"preferredName":"Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive","code":"C156122","definitions":[{"definition":"An encapsulated follicular carcinoma of the thyroid gland which shows angioinvasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive","termGroup":"PT","termSource":"NCI"},{"termName":"FTC, Encapsulated Angioinvasive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Follicular carcinoma, encapsulated, angioinvasive"},{"name":"Maps_To","value":"Follicular thyroid carcinoma (FTC), encapsulated angioinvasive"},{"name":"NCI_META_CUI","value":"CL562836"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7380":{"preferredName":"Thyroid Gland Papillary and Follicular Carcinoma","code":"C7380","synonyms":[{"termName":"Papillary and Follicular Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary and Follicular Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Thyroid Gland Papillary and Follicular Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_and_Follicular_Adenocarcinoma"},{"name":"Maps_To","value":"8340/3"},{"name":"Maps_To","value":"Papillary and follicular adenocarcinoma"},{"name":"Maps_To","value":"Papillary and follicular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206683"}]}}{"C126594":{"preferredName":"Follicular Variant Thyroid Gland Papillary Carcinoma","code":"C126594","definitions":[{"definition":"An encapsulated or nonencapsulated variant of papillary carcinoma of the thyroid gland characterized by the predominance of follicular structures. The malignant follicular cells display the nuclear features that characterize the papillary adenocarcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follicular Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"FVPTC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8340/3"},{"name":"Maps_To","value":"Papillary carcinoma, follicular variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346398"}]}}{"C46004":{"preferredName":"Thyroid Gland Papillary Microcarcinoma","code":"C46004","definitions":[{"definition":"A papillary carcinoma of the thyroid gland measuring 10mm or less in diameter.  The survival rates of patients with this type of carcinoma are the same with those of the normal population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Papillary Microcarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Microcarcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Microcarcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Gland Microcarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Microcarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8341/3"},{"name":"Legacy Concept Name","value":"Papillary_Thyroid_Gland_Microcarcinoma"},{"name":"Maps_To","value":"8341/3"},{"name":"Maps_To","value":"Papillary microcarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709457"}]}}{"C46093":{"preferredName":"Oncocytic Variant Thyroid Gland Papillary Carcinoma","code":"C46093","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of papillary or follicular structures, containing malignant follicular cells with abundant granular eosinophilic cytoplasm. These cells have the nuclear features that characterize the papillary carcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Oxyphilic Variant Thyroid Gland Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8342/3"},{"name":"Legacy Concept Name","value":"Oncocytic_Variant_Thyroid_Gland_Papillary_Carcinoma"},{"name":"Maps_To","value":"8342/3"},{"name":"Maps_To","value":"Papillary carcinoma, oncocytic variant"},{"name":"Maps_To","value":"Papillary carcinoma, oxyphilic cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709312"}]}}{"C126598":{"preferredName":"Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features","code":"C126598","definitions":[{"definition":"A benign or malignant thyroid tumor arising from follicular cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A non-invasive neoplasm of thyroid follicular cells with a follicular growth pattern and nuclear features of papillary thyroid carcinoma that has an extremely low malignant potential. These tumors were formerly classified as non-invasive encapsulated follicular variant of papillary thyroid carcinoma or well-differentiated tumor of uncertain malignant potential. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features","termGroup":"PT","termSource":"NCI"},{"termName":"NIEFVPTC","termGroup":"AB","termSource":"NCI"},{"termName":"NIFTP","termGroup":"AB","termSource":"NCI"},{"termName":"Noninvasive Encapsulated Follicular Variant Papillary Thyroid Gland Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Noninvasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Noninvasive Follicular Thyroid Gland Neoplasm with Papillary-Like Nuclear Features","termGroup":"SY","termSource":"NCI"},{"termName":"Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Noninvasive Follicular Tumor with Papillary-Like Nuclear Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Non-invasive EFVPTC"},{"name":"Maps_To","value":"Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)"},{"name":"Maps_To","value":"Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)"},{"name":"Maps_To","value":"Non-invasive FTP"},{"name":"NCI_META_CUI","value":"CL505049"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C156034":{"preferredName":"Encapsulated Variant Thyroid Gland Papillary Carcinoma","code":"C156034","definitions":[{"definition":"A typical papillary thyroid gland carcinoma that is totally surrounded by a fibrous capsule, which may be intact or only focally infiltrated by tumor growth. It accounts for about 10% of all cases of papillary thyroid gland carcinoma and has an excellent prognosis. Regional nodal metastases may be present, but bloodborne metastases are rare. The survival rate is nearly 100%. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encapsulated Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8343/3"},{"name":"Maps_To","value":"Encapsulated papillary carcinoma"},{"name":"Maps_To","value":"Papillary carcinoma, encapsulated"},{"name":"Maps_To","value":"Papillary carcinoma, encapsulated, of thyroid"},{"name":"NCI_META_CUI","value":"CL562888"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C35830":{"preferredName":"Columnar Cell Variant Thyroid Gland Papillary Carcinoma","code":"C35830","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of pseudostratified malignant follicular cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Columnar Cell Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Columnar Cell Variant Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Columnar Cell Variant Papillary Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8344/3"},{"name":"Legacy Concept Name","value":"Columnar_Cell_Variant_Papillary_Carcinoma"},{"name":"Maps_To","value":"8344/3"},{"name":"Maps_To","value":"Papillary carcinoma, columnar cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266054"}]}}{"C35558":{"preferredName":"Tall Cell Variant Thyroid Gland Papillary Carcinoma","code":"C35558","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of tall malignant follicular cells, arranged in papillary and trabecular patterns.  Necrotic changes and high mitotic activity are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tall Cell Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Tall Cell Variant Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tall_Cell_Variant_Papillary_Carcinoma"},{"name":"Maps_To","value":"8344/3"},{"name":"Maps_To","value":"Papillary carcinoma, tall cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336695"}]}}{"C4193":{"preferredName":"Thyroid Gland Medullary Carcinoma with Amyloid Stroma","code":"C4193","definitions":[{"definition":"A medullary thyroid gland carcinoma characterized by the presence of amyloid stroma.  The majority of medullary carcinomas of the thyroid gland are associated with amyloid deposits.  The latter are highlighted with Congo red staining method.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Medullary Carcinoma with Amyloid Stroma","termGroup":"PT","termSource":"NCI"},{"termName":"C Cell Adenocarcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"C Cell Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Adenocarcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Gland Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Parafollicular Cell Adenocarcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Parafollicular Cell Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8345/3"},{"name":"Legacy Concept Name","value":"Medullary_Carcinoma_with_Amyloid_Stroma"},{"name":"Maps_To","value":"8345/3"},{"name":"Maps_To","value":"Medullary carcinoma with amyloid stroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334379"}]}}{"C3879":{"preferredName":"Thyroid Gland Medullary Carcinoma","code":"C3879","definitions":[{"definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","type":"DEFINITION","source":"NCI"},{"definition":"A neuroendocrine malignant epithelial neoplasm arising from C-cells of the thyroid gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that develops in C cells of the thyroid. The C cells make a hormone (calcitonin) that helps maintain a healthy level of calcium in the blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma arising from the C-cells of the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Thyroid Gland Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"C Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"C-Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MTC","termGroup":"AB","termSource":"NCI"},{"termName":"Parafollicular Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Medullary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Medullary_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8345/3"},{"name":"Maps_To","value":"C cell carcinoma"},{"name":"Maps_To","value":"Medullary thyroid carcinoma"},{"name":"Maps_To","value":"Parafollicular cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0238462"}]}}{"C46104":{"preferredName":"Thyroid Gland Mixed Medullary and Follicular Cell-Derived Carcinoma","code":"C46104","definitions":[{"definition":"A primary carcinoma of the thyroid gland containing a medullary carcinoma component that is immunohistochemically positive for calcitonin, and follicular cell-derived carcinoma component that is immunohistochemically positive for thyroglobulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Mixed Medullary and Follicular Cell-Derived Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Medullary and Follicular Cell-Derived Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MMFCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Legacy Concept Name","value":"Thyroid_Gland_Mixed_Medullary_and_Follicular_Cell_Carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1710414"}]}}{"C7427":{"preferredName":"Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma","code":"C7427","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland that more often affects young patients and commonly metastasizing to the lungs.  It is characterized by a diffuse infiltration of the thyroid gland by malignant follicular cells, squamous metaplasia, stromal fibrosis, and lymphocytic infiltration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Papillary Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Diffuse Sclerosing Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8350/3"},{"name":"Legacy Concept Name","value":"Nonencapsulated_Sclerosing_Carcinoma"},{"name":"Maps_To","value":"8350/3"},{"name":"Maps_To","value":"Nonencapsulated sclerosing adenocarcinoma"},{"name":"Maps_To","value":"Nonencapsulated sclerosing carcinoma"},{"name":"Maps_To","value":"Nonencapsulated sclerosing tumor"},{"name":"Maps_To","value":"Papillary carcinoma, diffuse sclerosing"},{"name":"NCI_META_CUI","value":"CL017960"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6432":{"preferredName":"Multiple Endocrine Neoplasia","code":"C6432","definitions":[{"definition":"A genetically heterogenous group of autosomal dominant neoplastic syndromes characterized by the development of neoplasms in various endocrine organs.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An autosomal dominant inherited neoplastic syndrome characterized by the development of various endocrine neoplasms and abnormalities in various anatomic sites. There are four types recognized: type 1 (MEN 1), caused by inactivation of the tumor suppressor gene MEN-1, type 2A (MEN 2A), caused by mutation of the RET gene, type 2B (MEN 2B) also caused by mutation of the RET gene, and type 4 (MEN 4) caused by mutation of the CDKN1B gene. Patients with MEN 1 may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. Patients with MEN 2A develop medullary thyroid carcinomas and may also develop pheochromocytomas and parathyroid gland hyperplasia. Patients with MEN 2B develop medullary thyroid carcinomas and numerous neural defects including neuromas. Patients with MEN 4 develop endocrine neoplasms, particularly in the parathyroid glands, pituitary, and pancreas.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited condition that may result in the development of cancers of the endocrine system. There are several types of multiple endocrine neoplasia syndrome, and patients with each type may develop different types of cancer. The altered genes that cause each type can be detected with a blood test.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multiple Endocrine Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"MEN","termGroup":"AB","termSource":"NCI"},{"termName":"Multiple Endocrine Adenomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Endocrine Neoplasia Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8360/1"},{"name":"Legacy Concept Name","value":"Multiple_Endocrine_Neoplasia"},{"name":"Maps_To","value":"8360/1"},{"name":"Maps_To","value":"Endocrine adenomatosis"},{"name":"Maps_To","value":"Multiple endocrine adenomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1955745"}]}}{"C4162":{"preferredName":"Juxtaglomerular Cell Tumor","code":"C4162","definitions":[{"definition":"A benign, well circumscribed neoplasm arising from the cortex of the kidney. It secrets renin and the patients usually present with severe hypertension and marked hypokalemia. Morphologically, it is characterized by the presence of sheets of polygonal or spindle-shaped neoplastic cells forming a hemangiopericytic pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Juxtaglomerular Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtaglomerular Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Juxtaglomerular Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Reninoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8361/0"},{"name":"Legacy Concept Name","value":"Juxtaglomerular_Cell_Tumor"},{"name":"Maps_To","value":"8361/0"},{"name":"Maps_To","value":"Juxtaglomerular tumor"},{"name":"Maps_To","value":"Reninoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334331"}]}}{"C9003":{"preferredName":"Adrenal Cortical Adenoma","code":"C9003","definitions":[{"definition":"A benign neoplasm arising from any of the adrenal cortical layers.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm that can arise from any of the adrenal cortical layers.  It can be associated with the overproduction of glucocorticoids (Cushing's syndrome), androgenic or estrogenic steroids (adrenogenital syndrome), or mineralocorticoids (Conn's syndrome). (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adenoma of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adenoma of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adrenal Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adrenal Gland Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8370/0"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex_Adenoma"},{"name":"Maps_To","value":"8370/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206667"}]}}{"C2858":{"preferredName":"Adrenal Cortical Neoplasm","code":"C2858","definitions":[{"definition":"A benign or malignant (primary or metastatic) neoplasm affecting the adrenal cortex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex_Neoplasm"},{"name":"Maps_To","value":"8370/0"},{"name":"Maps_To","value":"Adrenal cortical tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001618"}]}}{"C9004":{"preferredName":"Benign Adrenal Cortical Neoplasm","code":"C9004","definitions":[{"definition":"A neoplasm that arises from the adrenal cortex and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Adrenal Cortical Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Adrenal Cortex Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adrenal Cortex Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Adrenal_Cortex_Neoplasm"},{"name":"Maps_To","value":"8370/0"},{"name":"Maps_To","value":"Adrenal cortical tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368669"}]}}{"C9325":{"preferredName":"Adrenal Cortical Carcinoma","code":"C9325","definitions":[{"definition":"A malignant epithelial neoplasm arising from adrenal cortical cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare cancer that forms in the outer layer of tissue of the adrenal gland (a small organ on top of each kidney that makes steroid hormones, adrenaline, and noradrenaline to control heart rate, blood pressure, and other body functions).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortical Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8370/3"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex_Carcinoma"},{"name":"Maps_To","value":"8370/3"},{"name":"Maps_To","value":"Adrenal cortical adenocarcinoma"},{"name":"Maps_To","value":"Adrenal cortical carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206686"}]}}{"C9327":{"preferredName":"Malignant Adrenal Cortical Neoplasm","code":"C9327","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the adrenal cortex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Adrenal Cortical Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Adrenal Cortex Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Cortex Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenocortical Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenocortical Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Adrenal_Cortex_Neoplasm"},{"name":"Maps_To","value":"8370/3"},{"name":"Maps_To","value":"Adrenal cortical tumor, malignant"},{"name":"Maps_To","value":"Malignant neoplasm of cortex of left adrenal gland"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346402"}]}}{"C4163":{"preferredName":"Adrenal Cortical Compact Cell Adenoma","code":"C4163","definitions":[{"definition":"An adenoma of the adrenal cortex composed of neoplastic compact cells with eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Compact Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Compact Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Compact Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Compact Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Compact Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Compact Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8371/0"},{"name":"Legacy Concept Name","value":"Compact_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8371/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, compact cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334332"}]}}{"C4164":{"preferredName":"Pigmented Adrenal Cortical Adenoma","code":"C4164","definitions":[{"definition":"A usually functioning adenoma of the adrenal cortex. Grossly, it has a dark brown appearance and is characterized by the presence of neoplastic cells containing abundant intracytoplasmic lipofuscin. It may be associated with Cushing syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Adrenal Cortical Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Black Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Heavily Pigmented Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Heavily Pigmented Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Heavily Pigmented Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Adrenal Gland Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8372/0"},{"name":"Legacy Concept Name","value":"Heavily_Pigmented_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8372/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, pigmented"},{"name":"Maps_To","value":"Black adenoma"},{"name":"Maps_To","value":"Pigmented adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334333"}]}}{"C4165":{"preferredName":"Adrenal Cortical Clear Cell Adenoma","code":"C4165","definitions":[{"definition":"An adenoma of the adrenal cortex composed of neoplastic clear cells containing intracytoplasmic lipid droplets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Clear Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Clear Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Clear Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8373/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8373/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, clear cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334334"}]}}{"C4166":{"preferredName":"Adrenal Cortical Glomerulosa Cell Adenoma","code":"C4166","definitions":[{"definition":"An adenoma of the adrenal cortex composed of neoplastic cells with cytologic features of glomerulosa cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Glomerulosa Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Glomerulosa Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Glomerulosa Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Glomerulosa Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Glomerulosa Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Glomerulosa Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8374/0"},{"name":"Legacy Concept Name","value":"Glomerulosa_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8374/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, glomerulosa cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334335"}]}}{"C4167":{"preferredName":"Adrenal Cortical Mixed Cell Adenoma","code":"C4167","definitions":[{"definition":"An adenoma of the adrenal cortex composed of a mixed neoplastic cellular population, including varying numbers of neoplastic clear and compact cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Mixed Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Mixed Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Mixed Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8375/0"},{"name":"Legacy Concept Name","value":"Mixed_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8375/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, mixed cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334336"}]}}{"C27287":{"preferredName":"Ovarian Endometrioid Adenofibroma","code":"C27287","definitions":[{"definition":"A benign neoplasm of the ovary characterized by the presence of glandular structures with endometrial-type well-differentiated cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Endometrioid Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8380/0"},{"name":"ICD-O-3_Code","value":"8381/0"},{"name":"Legacy Concept Name","value":"Ovarian_Endometrioid_Adenofibroma"},{"name":"Maps_To","value":"8380/0"},{"name":"Maps_To","value":"8381/0"},{"name":"Maps_To","value":"Endometrioid adenofibroma, NOS"},{"name":"Maps_To","value":"Endometrioid adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334337"}]}}{"C7983":{"preferredName":"Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor","code":"C7983","definitions":[{"definition":"An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is often fibrotic. There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Endometrioid Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Endometrioid Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Endometrioid Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Endometrioid Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Endometrioid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Endometrioid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"EBT/APET","termGroup":"AB","termSource":"NCI"},{"termName":"Endometrioid Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrioid Neoplasm with Proliferating Activity, Ovarian","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrioid Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrioid Tumor with Proliferating Activity, Ovarian","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Ovarian Endometrioid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Ovarian Endometrioid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Borderline Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Borderline Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Neoplasm with Proliferating Activity","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Tumor with Proliferating Activity","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Endometrioid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Endometrioid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8380/1"},{"name":"ICD-O-3_Code","value":"8381/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Endometrioid_Tumor"},{"name":"Maps_To","value":"8380/1"},{"name":"Maps_To","value":"Atypical proliferative endometrioid tumor"},{"name":"Maps_To","value":"Endometrioid adenoma, borderline malignancy"},{"name":"Maps_To","value":"Endometrioid cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Endometrioid tumor of low malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334338"}]}}{"C27789":{"preferredName":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","code":"C27789","definitions":[{"definition":"A neoplastic clonal expansion of endometrial glands characterized by cytologic changes of the epithelium and the presence of an increased number of endometrial glands. The glands form crowded aggregates with tubular or branching patterns which are cytologically distinct from the background architectural and cytological pattern. It is associated with molecular changes seen in endometrioid endometrial carcinoma, including microsatellite instability, PAX2 inactivation, and PTEN, KRAS, and CTNNB1 gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Endometrial Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Hyperplasia of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Hyperplasia of the Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"EAH/EIN","termGroup":"AB","termSource":"NCI"},{"termName":"EIN","termGroup":"AB","termSource":"NCI"},{"termName":"EmGD","termGroup":"AB","termSource":"NCI"},{"termName":"Endometrial Glandular Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Hyperplasia with Atypia","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Endometrial_Hyperplasia"},{"name":"Legacy Concept Name","value":"Endometrial_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8380/2"},{"name":"Maps_To","value":"Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN)"},{"name":"Maps_To","value":"Atypical hyperplasia/Endometrioid intraepithelial neoplasm"},{"name":"Maps_To","value":"Endometrioid intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349579"}]}}{"C3769":{"preferredName":"Endometrioid Adenocarcinoma","code":"C3769","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrioid Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrioid Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8380/3"},{"name":"Legacy Concept Name","value":"Endometrioid_Carcinoma"},{"name":"Maps_To","value":"8380/3"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, NOS"},{"name":"Maps_To","value":"Endometrioid carcinoma, NOS"},{"name":"Maps_To","value":"Endometrioid cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206687"}]}}{"C27288":{"preferredName":"Ovarian Endometrioid Cystadenofibroma","code":"C27288","definitions":[{"definition":"A benign neoplasm of the ovary characterized by the presence of cystic structures lined by endometrial-type well-differentiated cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Endometrioid Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Endometrioid_Cystadenofibroma"},{"name":"Maps_To","value":"8381/0"},{"name":"Maps_To","value":"Endometrioid cystadenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335158"}]}}{"C40069":{"preferredName":"Borderline Ovarian Endometrioid Adenofibroma","code":"C40069","definitions":[{"definition":"An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Endometrioid Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Endometrioid_Adenofibroma"},{"name":"Maps_To","value":"8381/1"},{"name":"Maps_To","value":"Endometrioid adenofibroma, borderline malignancy"},{"name":"Maps_To","value":"Endometrioid cystadenofibroma, borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511262"}]}}{"C40060":{"preferredName":"Ovarian Endometrioid Adenocarcinofibroma","code":"C40060","definitions":[{"definition":"A malignant neoplasm of the ovary characterized by the presence of malignant glandular cells resembling endometrial cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Endometrioid Adenocarcinofibroma","termGroup":"AQ","termSource":"NCI"},{"termName":"Ovarian Endometrioid Malignant Adenofibroma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8381/3"},{"name":"Legacy Concept Name","value":"Ovarian_Endometrioid_Adenocarcinofibroma"},{"name":"Maps_To","value":"8381/3"},{"name":"Maps_To","value":"Endometrioid adenofibroma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518711"}]}}{"C27839":{"preferredName":"Endometrial Endometrioid Adenocarcinoma, Secretory Variant","code":"C27839","definitions":[{"definition":"An endometrioid adenocarcinoma arising from the endometrium. Morphologically it is characterized by the presence of malignant glandular cells containing glycogen vacuoles which are usually subnuclear and reminiscent of early secretory endometrium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Endometrioid Adenocarcinoma, Secretory Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Secretory Uterine Corpus Endometrioid Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8382/3"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Endometrioid_Adenocarcinoma_Secretory_Variant"},{"name":"Maps_To","value":"8382/3"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, secretory variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266057"}]}}{"C27848":{"preferredName":"Endometrial Endometrioid Adenocarcinoma, Ciliated Variant","code":"C27848","definitions":[{"definition":"An endometrioid adenocarcinoma arising from the endometrium, in which ciliated cells line the majority of the malignant glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Endometrioid Adenocarcinoma, Ciliated Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Ciliated Uterine Corpus Endometrioid Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8383/3"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Endometrioid_Adenocarcinoma_Ciliated_Variant"},{"name":"Maps_To","value":"8383/3"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, ciliated cell variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266058"}]}}{"C66951":{"preferredName":"Adenocarcinoma, Endocervical Type","code":"C66951","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant glandular epithelium resembling the endocervical epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma, Endocervical Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Jul 21 16:11:01 EDT 2021 - See 'Cervical Adenocarcinoma, Usual-Type(C127907)'"},{"name":"ICD-O-3_Code","value":"8384/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_Endocervical_Type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"OLD_PARENT","value":"C127907"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7580":{"preferredName":"Skin Appendage Adenoma","code":"C7580","definitions":[{"definition":"A benign epithelial neoplasm arising from the sebaceous or sweat glands.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign epithelial neoplasm arising from the sebaceous or sweat glands. Representative examples include sebaceous adenoma, tubular apocrine adenoma, and hidradenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Appendage Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Adnexa","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Skin Appendage","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8390/0"},{"name":"Legacy Concept Name","value":"Skin_Appendage_Adenoma"},{"name":"Maps_To","value":"8390/0"},{"name":"Maps_To","value":"Adnexal tumor, benign"},{"name":"Maps_To","value":"Skin appendage adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334342"}]}}{"C3775":{"preferredName":"Adnexal Carcinoma","code":"C3775","definitions":[{"definition":"A carcinoma arising from the sebaceous glands, sweat glands, or the hair follicles. Representative examples include sebaceous carcinoma, apocrine carcinoma, eccrine carcinoma, and pilomatrical carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant epithelial neoplasm arising from sebaceous or sweat glands or from hair follicles.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adnexal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Adnexa","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Skin Appendage","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendage Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8390/3"},{"name":"Legacy Concept Name","value":"Adnexal_Carcinoma"},{"name":"Maps_To","value":"8390/3"},{"name":"Maps_To","value":"Adnexal carcinoma"},{"name":"Maps_To","value":"Skin appendage carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206697"}]}}{"C4470":{"preferredName":"Perifollicular Fibroma","code":"C4470","definitions":[{"definition":"A benign neoplasm characterized by the presence of spindle-shaped fibroblasts surrounding the hair follicle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perifollicular Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Trichoblastic Fibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Perifollicular_Fibroma"},{"name":"Maps_To","value":"8391/0"},{"name":"Maps_To","value":"Perifollicular fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704236"}]}}{"C43333":{"preferredName":"Spindle-Cell Predominant Trichodiscoma","code":"C43333","definitions":[{"definition":"A benign tumor usually arising in the face, trunk or thighs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle-Cell Predominant Trichodiscoma","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofollicular Hamartoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Trichodiscoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trichodiscoma"},{"name":"Maps_To","value":"8391/0"},{"name":"Maps_To","value":"Trichodiscoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704237"}]}}{"C43331":{"preferredName":"Fibrofolliculoma","code":"C43331","definitions":[{"definition":"A rare, pilar-associated mesenchyme neoplasm with follicular differentiation. It usually occurs in the face, neck, and chest. It presents as a dome-shaped papular lesion. It is composed of epithelial and mesenchymal cells. Patients with Birt-Hogg-Dube syndrome may develop follicular fibromas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrofolliculoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8391/0"},{"name":"Legacy Concept Name","value":"Fibrofolliculoma"},{"name":"Maps_To","value":"8391/0"},{"name":"Maps_To","value":"Fibrofolliculoma"},{"name":"Maps_To","value":"Follicular fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346011"}]}}{"C43356":{"preferredName":"Syringofibroadenoma","code":"C43356","definitions":[{"definition":"A rare benign eccrine lesion usually arising on acral areas as a solitary papule or nodule. Multiple lesions are referred as syringofibroadenomatosis. It is characterized by the presence of epithelial cuboidal cells forming anastomosing cords in a fibrovascular stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syringofibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acrosyringeal Adenomatosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Acrosyringeal Nevus","termGroup":"AQS","termSource":"NCI"},{"termName":"Eccrine Poromatosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Eccrine Syringofibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Syringofibroadenoma of Mascaro","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Syringofibroadenomatous Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"ESFA","termGroup":"AB","termSource":"NCI"},{"termName":"Linear Eccrine Poroma","termGroup":"AQS","termSource":"NCI"},{"termName":"SFA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8392/0"},{"name":"Legacy Concept Name","value":"Eccrine_Syringofibroadenoma"},{"name":"Maps_To","value":"8392/0"},{"name":"Maps_To","value":"Syringofibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266060"}]}}{"C7560":{"preferredName":"Sweat Gland Adenoma","code":"C7560","definitions":[{"definition":"A benign epithelial neoplasm arising from the sweat glands. Representative examples include tubular apocrine adenoma, syringofibroadenoma, and hidradenoma.","type":"DEFINITION","source":"NCI"},{"definition":"A benign epithelias neoplasm arising from sweat glands.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sweat Gland Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Sweat Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8400/0"},{"name":"Legacy Concept Name","value":"Sweat_Gland_Adenoma"},{"name":"Maps_To","value":"8400/0"},{"name":"Maps_To","value":"Sweat gland adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019522"}]}}{"C7563":{"preferredName":"Hidradenoma","code":"C7563","definitions":[{"definition":"A benign epithelial neoplasm arising from the sweat glands. Variants include the clear cell, nodular, and solid cystic hidradenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidradenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acrospiroma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eccrine Acrospiroma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hidradenoma"},{"name":"Maps_To","value":"8400/0"},{"name":"Maps_To","value":"8402/0"},{"name":"Maps_To","value":"Eccrine acrospiroma"},{"name":"Maps_To","value":"Hidradenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206671"}]}}{"C4879":{"preferredName":"Benign Sweat Gland Neoplasm","code":"C4879","definitions":[{"definition":"An epithelial neoplasm that arises from the sweat gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Sweat Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasm of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Sweat Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Neoplasm, Benign","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Sweat_Gland_Neoplasm"},{"name":"Maps_To","value":"8400/0"},{"name":"Maps_To","value":"Sweat gland tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0684354"}]}}{"C3398":{"preferredName":"Sweat Gland Neoplasm","code":"C3398","definitions":[{"definition":"A benign or malignant neoplasm arising from the sweat glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sweat Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Sweat Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8400/1"},{"name":"Legacy Concept Name","value":"Sweat_Gland_Neoplasm"},{"name":"Maps_To","value":"8400/1"},{"name":"Maps_To","value":"Sweat gland tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0038987"}]}}{"C6938":{"preferredName":"Sweat Gland Carcinoma","code":"C6938","definitions":[{"definition":"A carcinoma arising from the sweat glands. Representative examples include tubular carcinoma, spiradenocarcinoma, eccrine carcinoma, hidradenocarcinoma, and apocrine carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from sweat glands.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sweat Gland Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8400/3"},{"name":"Legacy Concept Name","value":"Sweat_Gland_Carcinoma"},{"name":"Maps_To","value":"8400/3"},{"name":"Maps_To","value":"Sweat gland adenocarcinoma"},{"name":"Maps_To","value":"Sweat gland carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1412016"}]}}{"C4810":{"preferredName":"Malignant Sweat Gland Neoplasm","code":"C4810","definitions":[{"definition":"A malignant neoplasm that arises from the sweat glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Sweat Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Sweat_Gland_Neoplasm"},{"name":"Maps_To","value":"8400/3"},{"name":"Maps_To","value":"Sweat gland tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321904"}]}}{"C4615":{"preferredName":"Benign Skin Appendage Neoplasm","code":"C4615","definitions":[{"definition":"A neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands. It is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include cylindroma, hidrocystoma, hidradenoma, and sebaceoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Skin Appendage Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Appendageal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Cutaneous Adnexal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Skin Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Skin Appendageal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Skin_Appendage_Neoplasm"},{"name":"Maps_To","value":"8400/3"},{"name":"Maps_To","value":"Skin appendage tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0347391"}]}}{"C4168":{"preferredName":"Apocrine Adenoma","code":"C4168","definitions":[{"definition":"A benign epithelial neoplasm arising from the apocrine sweat glands. Representative examples include tubular apocrine adenoma and external auditory canal ceruminous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apocrine Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8401/0"},{"name":"Legacy Concept Name","value":"Apocrine_Adenoma"},{"name":"Maps_To","value":"8401/0"},{"name":"Maps_To","value":"Apocrine adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334345"}]}}{"C43342":{"preferredName":"Apocrine Hidrocystoma","code":"C43342","definitions":[{"definition":"A slow-growing, usually solitary, dome-shaped benign sweat gland adenoma, most frequently located on the eyelid.  It is characterized by a cystic proliferation of apocrine glands. Surgical excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apocrine Hidrocystoma","termGroup":"PT","termSource":"NCI"},{"termName":"Apocrine Hydrocystoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Apocrine_Hydrocystoma"},{"name":"Maps_To","value":"8401/0"},{"name":"Maps_To","value":"Apocrine cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704335"}]}}{"C4169":{"preferredName":"Apocrine Carcinoma","code":"C4169","definitions":[{"definition":"A carcinoma with apocrine differentiation arising from the sweat glands. It presents as single or multiple nodular lesions which may be ulcerated or hemorrhagic and is usually in the axilla and less often in the anogenital region. It grows in the dermis and infiltrates subcutaneous tissues. It is characterized by the presence of large cells with abundant eosinophilic cytoplasm and large often vesicular nuclei. Most cases are slow growing tumors and have a prolonged course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Apocrine Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Apocrine Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Apocrine Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8401/3"},{"name":"Legacy Concept Name","value":"Apocrine_Carcinoma"},{"name":"Maps_To","value":"8401/3"},{"name":"Maps_To","value":"Apocrine adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1706827"}]}}{"C7568":{"preferredName":"Nodular Hidradenoma","code":"C7568","definitions":[{"definition":"A hidradenoma characterized by a nodular growth pattern. It presents as a nodular lesion usually in the scalp, trunk, and proximal extremities. Complete excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Hidradenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8402/0"},{"name":"Legacy Concept Name","value":"Nodular_Hidradenoma"},{"name":"Maps_To","value":"8402/0"},{"name":"Maps_To","value":"Nodular hidradenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370700"}]}}{"C7567":{"preferredName":"Clear Cell Hidradenoma","code":"C7567","definitions":[{"definition":"A hidradenoma with apocrine differentiation. It is characterized by the presence of cells with vesicular nuclei and eosinophilic cytoplasm and cells with clear cytoplasm and often eccentrically located nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Hidradenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hidradenoma with Apocrine Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clear_Cell_Hidradenoma"},{"name":"Maps_To","value":"8402/0"},{"name":"Maps_To","value":"Clear cell hidradenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370701"}]}}{"C54664":{"preferredName":"Hidradenocarcinoma","code":"C54664","definitions":[{"definition":"A carcinoma with apocrine and less often eccrine differentiation, arising from the sweat glands. It usually presents as a solitary slow growing nodule in the dermis or subcutaneous tissues. It is characterized by a nodular growth pattern and it is often associated with necrotic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidradenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8402/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Eccrine_Carcinoma"},{"name":"Maps_To","value":"8402/3"},{"name":"Maps_To","value":"Hidradenocarcinoma"},{"name":"Maps_To","value":"Nodular hidradenoma, malignant"},{"name":"NCI_META_CUI","value":"CL480948"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4170":{"preferredName":"Spiradenoma","code":"C4170","definitions":[{"definition":"A benign epithelial neoplasm with eccrine or apocrine differentiation, arising from the sweat glands. It usually presents as a solitary, well circumscribed, firm nodule in the face and upper trunk. It is characterized by the presence of basaloid cells forming nodules in the dermis. Cases of carcinoma arising from long standing spiradenomas have been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spiradenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8403/0"},{"name":"Legacy Concept Name","value":"Eccrine_Spiradenoma"},{"name":"Maps_To","value":"8403/0"},{"name":"Maps_To","value":"Eccrine spiradenoma"},{"name":"Maps_To","value":"Spiradenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334347"}]}}{"C5117":{"preferredName":"Spiradenocarcinoma","code":"C5117","definitions":[{"definition":"A very rare, aggressive carcinoma of the sweat glands arising from malignant transformation of a long standing spiradenoma. It usually grows in the upper extremities, lower extremities, trunk, and head and neck. It has the tendency to recur and metastasize most often to the lymph nodes, bones, and lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spiradenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma ex Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Spiradenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8403/3"},{"name":"Legacy Concept Name","value":"Malignant_Eccrine_Spiradenoma"},{"name":"Maps_To","value":"8403/3"},{"name":"Maps_To","value":"Malignant eccrine spiradenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266063"}]}}{"C3760":{"preferredName":"Hidrocystoma","code":"C3760","definitions":[{"definition":"A benign cystic proliferation of the sweat glands with apocrine or eccrine differentiation. It usually presents as a dome-shaped, cystic papular or nodular lesion usually in the face and neck. It is a unilocular or mutlilocular lesion lined by an inner and an outer layer of epithelium. Complete excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidrocystoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hydrocystoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8404/0"},{"name":"Legacy Concept Name","value":"Hidrocystoma"},{"name":"Maps_To","value":"8404/0"},{"name":"Maps_To","value":"Hidrocystoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206672"}]}}{"C7565":{"preferredName":"Eccrine Hidrocystoma","code":"C7565","definitions":[{"definition":"A benign sweat gland cystic lesion that arises from the dermis. It is lined by a thin epithelial layer of cells with a slightly eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eccrine Hidrocystoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eccrine_Cystadenoma"},{"name":"Maps_To","value":"8404/0"},{"name":"Maps_To","value":"Eccrine cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704334"}]}}{"C4171":{"preferredName":"Hidradenoma Papilliferum","code":"C4171","definitions":[{"definition":"A benign neoplasm arising from the sweat glands. It presents as a slow growing cystic nodular lesion most often in the skin of the vulva and the perianal region. It is characterized by the presence of cystic and large papillary structures. The papillary structures contain connective tissue and are covered by two layers of epithelium. Complete excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidradenoma Papilliferum","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Hidradenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8405/0"},{"name":"Legacy Concept Name","value":"Papillary_Hidradenoma_Hidradenoma_Papilliferum"},{"name":"Maps_To","value":"8405/0"},{"name":"Maps_To","value":"Hidradenoma papilliferum"},{"name":"Maps_To","value":"Papillary hidradenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334348"}]}}{"C4172":{"preferredName":"Syringocystadenoma Papilliferum","code":"C4172","definitions":[{"definition":"A benign adnexal neoplasm occurring during childhood or adolescence. It usually presents as a papular lesion or a plaque on the head and neck. It may arise in an organoid nevus such as sebaceous. It is characterized by an endophytic invagination of the epithelium into the dermis. There are dermal cystic spaces present, containing villous projections. Complete excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syringocystadenoma Papilliferum","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Syringadenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary Syringocystadenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"SCAP","termGroup":"AB","termSource":"NCI"},{"termName":"Syringadenoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8406/0"},{"name":"Legacy Concept Name","value":"Papillary_Syringadenoma_Syringocystadenoma_Papilliferum"},{"name":"Maps_To","value":"8406/0"},{"name":"Maps_To","value":"Papillary syringadenoma"},{"name":"Maps_To","value":"Papillary syringocystadenoma"},{"name":"Maps_To","value":"Syringocystadenoma papilliferum"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0406803"}]}}{"C3761":{"preferredName":"Syringoma","code":"C3761","definitions":[{"definition":"A benign sweat gland neoplasm usually affecting the lower eyelids and upper cheeks. The lesions are papular and are usually numerous. Morphologically, there are nests, cords, and tubules of epithelial cells present, surrounded by a dense stroma in the reticular dermis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syringoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Syringoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8407/0"},{"name":"Legacy Concept Name","value":"Syringoma"},{"name":"Maps_To","value":"8407/0"},{"name":"Maps_To","value":"Syringoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206673"}]}}{"C7581":{"preferredName":"Microcystic Adnexal Carcinoma","code":"C7581","definitions":[{"definition":"A low grade adenocarcinoma with ductal differentiation, arising from the sweat glands. It presents as a scar usually in the face. It is characterized by the formation of small ducts and it frequently involves nerves and perineural spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microcystic Adnexal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Syringomatous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8407/3"},{"name":"Legacy Concept Name","value":"Microcystic_Adnexal_Carcinoma"},{"name":"Maps_To","value":"8407/3"},{"name":"Maps_To","value":"Microcystic adnexal carcinoma"},{"name":"Maps_To","value":"Sclerosing sweat duct carcinoma"},{"name":"Maps_To","value":"Syringomatous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346027"}]}}{"C4173":{"preferredName":"Papillary Eccrine Adenoma","code":"C4173","synonyms":[{"termName":"Papillary Eccrine Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Thu Apr 25 18:10:46 EDT 2024 - See 'Tubular Apocrine Adenoma(C27527)'"},{"name":"ICD-O-3_Code","value":"8408/0"},{"name":"Legacy Concept Name","value":"Papillary_Eccrine_Adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"OLD_ASSOCIATION","value":"A32|C176985"},{"name":"OLD_ASSOCIATION","value":"A32|C177621"},{"name":"OLD_ASSOCIATION","value":"A8|C157711"},{"name":"OLD_ASSOCIATION","value":"A8|C168655"},{"name":"OLD_ASSOCIATION","value":"A8|C168656"},{"name":"OLD_ASSOCIATION","value":"A8|C168657"},{"name":"OLD_ASSOCIATION","value":"A8|C168658"},{"name":"OLD_ASSOCIATION","value":"A8|C168661"},{"name":"OLD_ASSOCIATION","value":"A8|C168662"},{"name":"OLD_ASSOCIATION","value":"A8|C177537"},{"name":"OLD_PARENT","value":"C27527"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334350"}]}}{"C162848":{"preferredName":"Digital Papillary Adenoma","code":"C162848","synonyms":[{"termName":"Digital Papillary Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive Digital Papillary Adenoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Tue Apr 23 19:32:51 EDT 2024 - See 'Digital Papillary Adenocarcinoma(C27534)'"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"OLD_ASSOCIATION","value":"A32|C176985"},{"name":"OLD_ASSOCIATION","value":"A32|C177621"},{"name":"OLD_ASSOCIATION","value":"A8|C157711"},{"name":"OLD_ASSOCIATION","value":"A8|C168655"},{"name":"OLD_ASSOCIATION","value":"A8|C168657"},{"name":"OLD_ASSOCIATION","value":"A8|C168658"},{"name":"OLD_ASSOCIATION","value":"A8|C177537"},{"name":"OLD_PARENT","value":"C27534"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266064"}]}}{"C27254":{"preferredName":"Papillary Eccrine Carcinoma","code":"C27254","definitions":[{"definition":"A carcinoma of the eccrine glands. It consists of dilated ducts with papillary projections.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Eccrine Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eccrine_Papillary_Adenocarcinoma"},{"name":"Maps_To","value":"8408/3"},{"name":"Maps_To","value":"Eccrine papillary adenocarcinoma"},{"name":"Maps_To","value":"Syringocystadenocarcinoma papilliferum"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367789"}]}}{"C27534":{"preferredName":"Digital Papillary Adenocarcinoma","code":"C27534","definitions":[{"definition":"An adenocarcinoma arising from the sweat glands. Most cases present as nodular lesions on the digits, usually in the hands. It is characterized by the presence of epithelial cells in the dermis forming nodules. Cystic structures containing papillary projections are also present. It may recur and metastasize, most commonly to the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Digital Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive Digital Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Aggressive Digital Papillary Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Digital Papillary Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Digital Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Digital Papillary Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Digital Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8408/1"},{"name":"ICD-O-3_Code","value":"8408/3"},{"name":"Legacy Concept Name","value":"Aggressive_Digital_Papillary_Adenocarcinoma"},{"name":"Maps_To","value":"8408/1"},{"name":"Maps_To","value":"8408/3"},{"name":"Maps_To","value":"Aggressive digital papillary adenoma"},{"name":"Maps_To","value":"Digital papillary adenocarcinoma"},{"name":"Maps_To","value":"Eccrine papillary adenocarcinoma"},{"name":"NCI_META_CUI","value":"CL053818"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266064"}]}}{"C27273":{"preferredName":"Poroma","code":"C27273","definitions":[{"definition":"A benign, well circumscribed adnexal neoplasm arising from the intraepidermal portion of the sweat gland duct. It usually presents as a solitary, dome-shaped papule, nodule, or plaque on acral sites. It is characterized by a proliferation of uniform basaloid cells in the dermis and is associated with the presence of focal ductal and cystic structures. Complete excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poroma","termGroup":"PT","termSource":"NCI"},{"termName":"Poroid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8409/0"},{"name":"Legacy Concept Name","value":"Poroma_Acrospiroma"},{"name":"Maps_To","value":"8409/0"},{"name":"Maps_To","value":"Poroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1533161"}]}}{"C5560":{"preferredName":"Porocarcinoma","code":"C5560","definitions":[{"definition":"A carcinoma with eccrine differentiation arising from the sweat glands. It may arise de novo or as a malignant transformation of a pre-existing poroma. It usually grows in the legs, buttocks, feet, and trunk and usually presents as an ulcerative plaque. It is characterized by the presence of intraepidermal and dermal nests of malignant epithelial cells. It may recur after excision and metastasize to the lymph nodes and less frequently to distal anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Porocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermotropic Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Eccrine Poroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8409/3"},{"name":"Legacy Concept Name","value":"Eccrine_Porocarcinoma"},{"name":"Maps_To","value":"8409/3"},{"name":"Maps_To","value":"Eccrine poroma, malignant"},{"name":"Maps_To","value":"Porocarcinoma"},{"name":"Maps_To","value":"Porocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266065"}]}}{"C4346":{"preferredName":"Skin Basal Cell Carcinoma with Sebaceous Differentiation","code":"C4346","definitions":[{"definition":"A basal cell carcinoma of the skin that is characterized by sebaceous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Basal Cell Carcinoma with Sebaceous Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Carcinoma with Sebaceous Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Epithelioma with Sebaceous Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Basosebaceous Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sebaceous_Epithelioma"},{"name":"Maps_To","value":"8410/0"},{"name":"Maps_To","value":"Sebaceous epithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334683"}]}}{"C4174":{"preferredName":"Sebaceous Adenoma","code":"C4174","definitions":[{"definition":"A benign adenoma neoplasm with sebaceous differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well circumscribed neoplasm arising from the sebaceous glands. It usually presents as a small yellowish tumor in the sun exposed skin of head and neck. It is characterized by the presence of sebaceous cells aggregates with a peripheral rim of basaloid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sebaceous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendage Sebaceous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8410/0"},{"name":"Legacy Concept Name","value":"Sebaceous_Adenoma"},{"name":"Maps_To","value":"8410/0"},{"name":"Maps_To","value":"Sebaceous adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368816"}]}}{"C40310":{"preferredName":"Sebaceous Carcinoma","code":"C40310","definitions":[{"definition":"A malignant adenocarcinoma with sebaceous differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenocarcinoma with sebaceous differentiation. It presents as a painless mass and it may be multifocal. It grows in the ocular adnexae and in the skin of head and neck, trunk, genitals, and extremities. It is characterized by the presence of malignant cells with multivesicular and clear cytoplasm. It may recur and metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sebaceous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Gland Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8410/3"},{"name":"Legacy Concept Name","value":"Sebaceous_Carcinoma"},{"name":"Maps_To","value":"8410/3"},{"name":"Maps_To","value":"Sebaceous adenocarcinoma"},{"name":"Maps_To","value":"Sebaceous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206684"}]}}{"C27255":{"preferredName":"Eccrine Carcinoma","code":"C27255","definitions":[{"definition":"A malignant carcinoma with eccrine differentiation arising from the sweat glands.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenocarcinoma with eccrine differentiation arising from the sweat glands. It includes the following subtypes: ductal eccrine adenocarcinoma, papillary eccrine carcinoma, and eccrine porocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eccrine Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8413/3"},{"name":"Legacy Concept Name","value":"Eccrine_Adenocarcinoma"},{"name":"Maps_To","value":"8413/3"},{"name":"Maps_To","value":"Eccrine adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302864"}]}}{"C6088":{"preferredName":"Ceruminous Adenoma","code":"C6088","definitions":[{"definition":"A benign epithelial neoplasm derived from ceruminous glands in the external auditory canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign epithelial neoplasm derived from ceruminous glands in the external auditory canal. It presents as a grey mass covered by skin. It is characterized by a proliferation of glands composed of cells with abundant eosinophilic and granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceruminous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ceruminoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ceruminous Adenoma of External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Ceruminous Adenoma of the External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"External Auditory Canal Ceruminous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8420/0"},{"name":"Legacy Concept Name","value":"External_Auditory_Canal_Ceruminous_Adenoma"},{"name":"Maps_To","value":"8420/0"},{"name":"Maps_To","value":"Ceruminous adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334352"}]}}{"C4176":{"preferredName":"Ceruminous Adenocarcinoma","code":"C4176","definitions":[{"definition":"A malignant neoplasm derived from ceruminous glands in the external auditory canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating adenocarcinoma derived from ceruminous glands in the external auditory canal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceruminous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ceruminous Adenocarcinoma of the External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"External Auditory Canal Ceruminous Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8420/3"},{"name":"Legacy Concept Name","value":"Ceruminous_Adenocarcinoma"},{"name":"Maps_To","value":"8420/3"},{"name":"Maps_To","value":"Ceruminous adenocarcinoma"},{"name":"Maps_To","value":"Ceruminous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334353"}]}}{"C3772":{"preferredName":"Mucoepidermoid Carcinoma","code":"C3772","definitions":[{"definition":"A carcinoma morphologically characterized the presence of cuboidal mucous cells, goblet-like mucous cells, squamoid cells, cystic changes, and a fibrotic stromal formation. It can occur in several anatomic sites, including parotid gland, oral cavity, paranasal sinus, skin, breast, lung, larynx, and lacrimal ducts. It is classified as low or high grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucoepidermoid Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"MEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8430/1"},{"name":"ICD-O-3_Code","value":"8430/3"},{"name":"Legacy Concept Name","value":"Mucoepidermoid_Carcinoma"},{"name":"Maps_To","value":"8430/1"},{"name":"Maps_To","value":"Mucoepidermoid carcinoma"},{"name":"Maps_To","value":"Mucoepidermoid tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206694"}]}}{"C2972":{"preferredName":"Cystadenoma","code":"C2972","definitions":[{"definition":"A benign cystic epithelial neoplasm arising from glandular epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign or borderline cystic epithelial neoplasm arising from the glandular epithelium.  The epithelial cells line the cystic spaces which contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cystoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8440/0"},{"name":"Legacy Concept Name","value":"Cystadenoma"},{"name":"Maps_To","value":"8440/0"},{"name":"Maps_To","value":"Cystadenoma, NOS"},{"name":"Maps_To","value":"Cystoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010633"}]}}{"C2971":{"preferredName":"Cystadenocarcinoma","code":"C2971","definitions":[{"definition":"A malignant cystic epithelial neoplasm arising from glandular epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant cystic epithelial neoplasm arising from the glandular epithelium.  The malignant epithelial cells invade the stroma.  The cystic spaces contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8440/3"},{"name":"Legacy Concept Name","value":"Cystadenocarcinoma"},{"name":"Maps_To","value":"8440/3"},{"name":"Maps_To","value":"Cystadenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010631"}]}}{"C3783":{"preferredName":"Serous Cystadenoma","code":"C3783","definitions":[{"definition":"A serous neoplasm in which the cysts and papillae are lined by a single layer of cells without atypia, architectural complexity or invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Serous Cystoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8441/0"},{"name":"Legacy Concept Name","value":"Serous_Cystadenoma"},{"name":"Maps_To","value":"8441/0"},{"name":"Maps_To","value":"Serous cystadenoma, NOS"},{"name":"Maps_To","value":"Serous cystoma"},{"name":"Maps_To","value":"Serous microcystic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206709"}]}}{"C126449":{"preferredName":"Serous Tubal Intraepithelial Carcinoma","code":"C126449","definitions":[{"definition":"A non-invasive serous carcinoma arising from the fallopian tube.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Tubal Intraepithelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"STIC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serous tubal intraepithelial carcinoma"},{"name":"Maps_To","value":"Serous tubal intraepithelial carcinoma (STIC)"},{"name":"NCI_META_CUI","value":"CL504982"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3778":{"preferredName":"Serous Cystadenocarcinoma","code":"C3778","definitions":[{"definition":"A malignant serous cystic neoplasm usually involving the ovary or the pancreas. It is characterized by the presence of invasive malignant glandular epithelial cells which often form papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Serous Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8441/3"},{"name":"Legacy Concept Name","value":"Serous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8441/3"},{"name":"Maps_To","value":"Serous adenocarcinoma, NOS"},{"name":"Maps_To","value":"Serous carcinoma, NOS"},{"name":"Maps_To","value":"Serous cystadenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206701"}]}}{"C4177":{"preferredName":"Borderline Serous Cystadenoma","code":"C4177","definitions":[{"definition":"A serous cystic glandular epithelial neoplasm of low malignant potential. It is characterized by the presence of atypical or malignant glandular epithelial cells with an absence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Serous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Serous Tumor of Borderline Malignant Potential","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8442/1"},{"name":"Legacy Concept Name","value":"Borderline_Serous_Cystadenoma"},{"name":"Maps_To","value":"8442/1"},{"name":"Maps_To","value":"Atypical proliferating serous tumor"},{"name":"Maps_To","value":"Serous cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Serous tumor, NOS, of low malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334355"}]}}{"C65203":{"preferredName":"Clear Cell Papillary Cystadenoma","code":"C65203","definitions":[{"definition":"A benign cystic glandular epithelial neoplasm characterized by the presence of neoplastic clear or hobnail cells which form papillary structures. There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Papillary Cystadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8443/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Papillary_Cystadenoma"},{"name":"Maps_To","value":"8443/0"},{"name":"Maps_To","value":"Clear cell cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266068"}]}}{"C2974":{"preferredName":"Papillary Cystadenoma","code":"C2974","definitions":[{"definition":"A benign cystic epithelial neoplasm arising from glandular epithelium exhibiting papillary structures.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A serous or mucinous benign or low malignant potential cystic epithelial neoplasm. It is characterized by the presence of glandular epithelial cells forming papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Cystadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8450/0"},{"name":"Legacy Concept Name","value":"Papillary_Cystadenoma"},{"name":"Maps_To","value":"8450/0"},{"name":"Maps_To","value":"Papillary cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010636"}]}}{"C3777":{"preferredName":"Papillary Cystadenocarcinoma","code":"C3777","definitions":[{"definition":"A malignant cystic epithelial neoplasm arising from glandular epithelium exhibiting papillary structures.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant cystic serous or mucinous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8450/3"},{"name":"Legacy Concept Name","value":"Papillary_Cystadenocarcinoma"},{"name":"Maps_To","value":"8450/3"},{"name":"Maps_To","value":"Papillary cystadenocarcinoma, NOS"},{"name":"Maps_To","value":"Papillocystic adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206700"}]}}{"C4178":{"preferredName":"Borderline Papillary Cystadenoma","code":"C4178","definitions":[{"definition":"A serous or mucinous cystic glandular epithelial neoplasm of low malignant potential. It is characterized by the presence of atypical or malignant glandular epithelial cells forming papillary structures with an absence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Papillary Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8451/1"},{"name":"Legacy Concept Name","value":"Borderline_Papillary_Cystadenoma"},{"name":"Maps_To","value":"8451/1"},{"name":"Maps_To","value":"Papillary cystadenoma, borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334356"}]}}{"C201136":{"preferredName":"Solid Pseudopapillary Neoplasm","code":"C201136","definitions":[{"definition":"A low-grade malignant neoplasm that arises from the exocrine pancreas. Rare cases arising from ectopic pancreatic tissue in the ovary have also been described. It is characterized by the presence of uniform cells that form solid and pseudopapillary patterns, cystic changes, and hemorrhage. It usually presents as an encapsulated, solitary, and lobulated mass. It occurs predominantly in young women. Complete removal of the tumor is curative in the majority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Pseudopapillary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Frantz Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Solid Pseudopapillary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8452/1"},{"name":"Maps_To","value":"8452/1"},{"name":"Maps_To","value":"Solid pseudopapillary tumor"},{"name":"NCI_META_CUI","value":"CL1920478"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C37212":{"preferredName":"Solid Pseudopapillary Neoplasm of the Pancreas","code":"C37212","definitions":[{"definition":"A low-grade malignant neoplasm that arises from the exocrine pancreas. It is characterized by the presence of uniform cells that form solid and pseudopapillary patterns, cystic changes, and hemorrhage. Perineural invasion, vascular invasion, and invasion into surrounding tissues may be present. It usually presents as an encapsulated, solitary, and lobulated pancreatic mass. It is usually found incidentally during physical examination or it may present with abdominal discomfort and pain. It occurs predominantly in young women. Complete removal of the tumor is curative in the majority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Pseudopapillary Neoplasm of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Pseudopapillary Tumor of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Pseudopapillary_Tumor_of_the_Pancreas"},{"name":"Maps_To","value":"8452/3"},{"name":"Maps_To","value":"Solid pseudopapillary neoplasm of pancreas"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336030"}]}}{"C5728":{"preferredName":"Solid Pseudopapillary Carcinoma of the Pancreas","code":"C5728","definitions":[{"definition":"A malignant neoplasm arising from the exocrine pancreas. It occurs predominantly in young women. It is characterized by the presence of extensive necrosis and hemorrhage and is composed of polyhedral cells forming solid and pseudopapillary patterns. There is morphologic evidence of perineural invasion, vascular invasion, or extensive invasion into the surrounding tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Solid Pseudopapillary Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Solid Pseudopapillary Carcinoma of Pancreas","termGroup":"AQS","termSource":"NCI"},{"termName":"Solid Pseudopapillary Carcinoma of the Pancreas","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8452/3"},{"name":"Legacy Concept Name","value":"Solid_Pseudopapillary_Carcinoma_of_the_Pancreas"},{"name":"Maps_To","value":"8452/3"},{"name":"Maps_To","value":"Solid pseudopapillary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336029"}]}}{"C95514":{"preferredName":"Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type","code":"C95514","definitions":[{"definition":"A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells with abundant eosinophilic granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Oncocytic Papillary Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic IOPN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8453/0"},{"name":"Maps_To","value":"Intraductal papillary mucinous adenoma"},{"name":"Maps_To","value":"Intraductal papillary-mucinous adenoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2987197"}]}}{"C41251":{"preferredName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm, High Grade","code":"C41251","definitions":[{"definition":"A non-invasive pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that exhibit loss of polarity, nuclear stratification, hyperchromasia, and pleomorphism.  There is severe architectural atypia and frequent mitotic figures present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary Mucinous Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm, High-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Non-Invasive Intraductal Papillary-Mucinous Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8453/2"},{"name":"Legacy Concept Name","value":"Pancreatic_Non-Invasive_Intraductal_Papillary-Mucinous_Carcinoma"},{"name":"Maps_To","value":"8453/2"},{"name":"Maps_To","value":"Intraductal papillary mucinous neoplasm with high grade dysplasia"},{"name":"Maps_To","value":"Intraductal papillary-mucinous carcinoma, non-invasive"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3532881"}]}}{"C5726":{"preferredName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma","code":"C5726","definitions":[{"definition":"A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of a focal or multifocal invasive carcinomatous component.  The invasive carcinoma is either colloid or ductal adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary Mucinous Neoplasm with an Associated Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Invasive Intraductal Papillary-Mucinous Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8453/3"},{"name":"Legacy Concept Name","value":"Pancreatic_Invasive_Papillary-Mucinous_Carcinoma"},{"name":"Maps_To","value":"8453/3"},{"name":"Maps_To","value":"Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma"},{"name":"Maps_To","value":"Intraductal papillary mucinous neoplasm with an associated invasive carcinoma"},{"name":"Maps_To","value":"Intraductal papillary-mucinous carcinoma, invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518871"}]}}{"C45754":{"preferredName":"Cystic Tumor of the Atrioventricular Node","code":"C45754","definitions":[{"definition":"A multicystic tumor arising in the inferior interatrial septum in the region of the atrioventricular node. The vast majority of patients present with complete heart block and a minority with partial heart block. Sudden death is reported in approximately 10% of the cases. It is a morphologically benign tumor composed of cuboidal, transitional, or squamoid cells. The cells may also show sebaceous differentiation and originate from the endoderm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystic Tumor of the Atrioventricular Node","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Mesothelioma of Mahaim","termGroup":"SY","termSource":"NCI"},{"termName":"Cystic Tumor of Atrioventricular Node","termGroup":"SY","termSource":"NCI"},{"termName":"Endodermal Rest","termGroup":"SY","termSource":"NCI"},{"termName":"Intracardiac Endodermal Heterotopia","termGroup":"SY","termSource":"NCI"},{"termName":"Mesothelioma of Atrioventricular Node","termGroup":"SY","termSource":"NCI"},{"termName":"Tawarian Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8454/0"},{"name":"Legacy Concept Name","value":"Cystic_Tumor_of_Atrioventricular_Node"},{"name":"Maps_To","value":"8454/0"},{"name":"Maps_To","value":"Cystic tumor of atrio-ventricular node"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266075"}]}}{"C4180":{"preferredName":"Papillary Serous Cystadenoma","code":"C4180","definitions":[{"definition":"A serous benign or low malignant potential cystic epithelial neoplasm characterized by the presence of glandular epithelial cells forming papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Serous Cystadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8460/0"},{"name":"Legacy Concept Name","value":"Papillary_Serous_Cystadenoma"},{"name":"Maps_To","value":"8460/0"},{"name":"Maps_To","value":"Papillary serous cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334358"}]}}{"C122585":{"preferredName":"Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma","code":"C122585","definitions":[{"definition":"A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low grade serous carcinoma"},{"name":"Maps_To","value":"Serous borderline tumor-micropapillary variant"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4055371"}]}}{"C8377":{"preferredName":"Papillary Serous Cystadenocarcinoma","code":"C8377","definitions":[{"definition":"A malignant cystic serous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive cancer that usually affects the uterus/endometrium, peritoneum, or ovary.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Papillary Serous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Serous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Serous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8460/3"},{"name":"Legacy Concept Name","value":"Papillary_Serous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8460/3"},{"name":"Maps_To","value":"Papillary serous adenocarcinoma"},{"name":"Maps_To","value":"Papillary serous cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334359"}]}}{"C6882":{"preferredName":"Micropapillary Serous Carcinoma","code":"C6882","definitions":[{"definition":"An adenocarcinoma usually arising from the ovary. It is characterized by the presence of complex micropapillary structures covered by round and cuboidal cells with a high nuclear to cytoplasmic ratio.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micropapillary Serous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Micropapillary Variant of Serous Borderline Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"MPSC","termGroup":"AB","termSource":"NCI"},{"termName":"SBT-MP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Micropapillary_Serous_Carcinoma"},{"name":"Maps_To","value":"8460/3"},{"name":"Maps_To","value":"Micropapillary serous carcinoma"},{"name":"Maps_To","value":"Serous borderline tumor, micropapillary variant"},{"name":"NCI_META_CUI","value":"CL017991"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4181":{"preferredName":"Serous Surface Papilloma","code":"C4181","definitions":[{"definition":"A non-invasive papillary serous epithelial neoplasm usually arising from the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Surface Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8461/0"},{"name":"Legacy Concept Name","value":"Serous_Surface_Papilloma"},{"name":"Maps_To","value":"8461/0"},{"name":"Maps_To","value":"Serous surface papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334360"}]}}{"C7695":{"preferredName":"Primary Peritoneal Serous Papillary Adenocarcinoma","code":"C7695","definitions":[{"definition":"A rare, serous papillary adenocarcinoma that arises from the lining of the peritoneum. It affects females. The clinical behavior and pathologic characteristics are similar to the serous papillary adenocarcinoma that arises from the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Peritoneal Serous Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Peritoneal Serous Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Serous Papillary Carcinoma of Peritoneum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Serous_Papillary_Carcinoma_of_Peritoneum"},{"name":"Maps_To","value":"8461/3"},{"name":"Maps_To","value":"Primary serous papillary carcinoma of peritoneum"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368918"}]}}{"C4182":{"preferredName":"Serous Surface Papillary Carcinoma","code":"C4182","definitions":[{"definition":"An invasive serous adenocarcinoma arising from the ovary and rarely the peritoneum. Morphologically, it may be a well, moderately, or poorly differentiated neoplasm. It is characterized by a papillary growth pattern often associated with the presence of psammoma bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Surface Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8461/3"},{"name":"Legacy Concept Name","value":"Serous_Surface_Papillary_Carcinoma"},{"name":"Maps_To","value":"8461/3"},{"name":"Maps_To","value":"Serous surface papillary carcinoma"},{"name":"NCI_META_CUI","value":"CL512816"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4183":{"preferredName":"Borderline Papillary Serous Cystadenoma","code":"C4183","definitions":[{"definition":"A low malignant potential cystic serous epithelial neoplasm arising from the ovary. Cases with identical morphology have been described arising from the peritoneum as well. It is characterized by an atypical epithelial proliferation and a papillary growth pattern. There is no evidence of destructive stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Papillary Serous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Papillary Serous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Papillary Serous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Serous Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Serous Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8462/1"},{"name":"Legacy Concept Name","value":"Borderline_Papillary_Serous_Cystadenoma"},{"name":"Maps_To","value":"8462/1"},{"name":"Maps_To","value":"Atypical proliferative papillary serous tumor"},{"name":"Maps_To","value":"Papillary serous cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Papillary serous tumor of low malignant potential"},{"name":"Maps_To","value":"Serous papillary cystic tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334362"}]}}{"C7315":{"preferredName":"Borderline Ovarian Serous Surface Papillary Tumor","code":"C7315","definitions":[{"definition":"A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of papillary proliferations that contain atypical serous epithelial cells in the outer surface of the ovary.  There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Serous Surface Papillary Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Borderline Ovarian Serous Surface Papillary Tumor","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8463/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Serous_Papillary_Neoplasm"},{"name":"Maps_To","value":"8463/1"},{"name":"Maps_To","value":"Serous surface papillary tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511269"}]}}{"C2973":{"preferredName":"Mucinous Cystadenoma","code":"C2973","definitions":[{"definition":"A benign or low malignant potential cystic epithelial neoplasm composed of cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","type":"DEFINITION","source":"NCI"},{"definition":"A benign, cystic epithelial neoplasm comprising cells containing intracytoplasmic mucin.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mucinous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucinous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Cystoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/0"},{"name":"ICD-O-3_Code","value":"8480/0"},{"name":"Legacy Concept Name","value":"Mucinous_Cystadenoma"},{"name":"Maps_To","value":"8470/0"},{"name":"Maps_To","value":"Mucinous adenoma"},{"name":"Maps_To","value":"Mucinous cystadenoma, NOS"},{"name":"Maps_To","value":"Mucinous cystoma"},{"name":"Maps_To","value":"Pseudomucinous cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010635"}]}}{"C6883":{"preferredName":"Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia","code":"C6883","definitions":[{"definition":"A non-invasive mucinous cystic neoplasm that arises from the pancreas and is characterized by the presence of moderate dysplasia.  The neoplastic columnar mucin-producing epithelial cells form papillary projections or crypt-like invaginations. There is cellular pseudostratification and mitotic activity present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/0"},{"name":"ICD-O-3_Code","value":"8470/1"},{"name":"ICD-O-3_Code","value":"8472/1"},{"name":"Legacy Concept Name","value":"Pancreatic_Mucinous_Cystic_Neoplasm_with_Moderate_Dysplasia"},{"name":"Maps_To","value":"8470/0"},{"name":"Maps_To","value":"Mucinous cystic tumor with moderate dysplasia"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2063870"}]}}{"C41245":{"preferredName":"Pancreatic Non-Invasive Mucinous Cystadenocarcinoma","code":"C41245","definitions":[{"definition":"A non-invasive malignant cystic epithelial neoplasm arising from the exocrine pancreas. It occurs almost exclusively in women. Small tumors are usually found incidentally. Larger tumors usually produce symptoms related to compression of the adjacent structures. It is characterized by the presence of columnar, mucin-producing epithelial cells which often form papillary projections with irregular branching and budding. There is cellular stratification, severe dysplasia, and high mitotic activity present. Complete surgical removal is usually associated with an excellent prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Non-Invasive Mucinous Cystadenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/2"},{"name":"Legacy Concept Name","value":"Pancreatic_Non-Invasive_Mucinous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8470/2"},{"name":"Maps_To","value":"Mucinous cystadenocarcinoma, non-invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518874"}]}}{"C95493":{"preferredName":"Pancreatic Mucinous-Cystic Neoplasm, High Grade","code":"C95493","definitions":[{"definition":"A non-invasive mucinous cystic neoplasm that arises from the pancreas and is characterized by the presence of severe dysplasia.  The neoplastic columnar mucin-producing epithelial cells form papillae with irregular branching and budding.  There is nuclear stratification, prominent nucleoli, and cellular pleomorphism.  Mitotic activity is present and the mitoses may be atypical.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mucinous-Cystic Neoplasm, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Mucinous Cystic Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mucinous-Cystic Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mucinous-Cystic Neoplasm, High-Grade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/2"},{"name":"Maps_To","value":"8470/2"},{"name":"Maps_To","value":"Mucinous cystic neoplasm with high grade dysplasia"},{"name":"Maps_To","value":"Mucinous cystic neoplasm with high-grade dysplasia"},{"name":"NCI_META_CUI","value":"CL497910"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3776":{"preferredName":"Mucinous Cystadenocarcinoma","code":"C3776","definitions":[{"definition":"An invasive adenocarcinoma characterized by cystic changes and the presence of malignant glandular cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pseudomucinous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudomucinous Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/3"},{"name":"Legacy Concept Name","value":"Mucinous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8470/3"},{"name":"Maps_To","value":"Mucinous cystadenocarcinoma, NOS"},{"name":"Maps_To","value":"Pseudomucinous adenocarcinoma"},{"name":"Maps_To","value":"Pseudomucinous cystadenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206699"}]}}{"C4184":{"preferredName":"Papillary Mucinous Cystadenoma","code":"C4184","definitions":[{"definition":"A usually benign and less often low malignant potential cystic epithelial neoplasm composed of cells which contain intracytoplasmic mucin. It is characterized by the presence of papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Mucinous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8471/0"},{"name":"Legacy Concept Name","value":"Papillary_Mucinous_Cystadenoma"},{"name":"Maps_To","value":"8471/0"},{"name":"Maps_To","value":"Papillary mucinous cystadenoma, NOS"},{"name":"Maps_To","value":"Papillary pseudomucinous cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334363"}]}}{"C65204":{"preferredName":"Papillary Mucinous Cystadenocarcinoma","code":"C65204","definitions":[{"definition":"An invasive adenocarcinoma characterized by cystic changes, papillary growth pattern, and the presence of malignant glandular cells which contain intracytoplasmic mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Mucinous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8471/3"},{"name":"Legacy Concept Name","value":"Papillary_Mucinous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8471/3"},{"name":"Maps_To","value":"Papillary mucinous cystadenocarcinoma"},{"name":"Maps_To","value":"Papillary pseudomucinous cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334364"}]}}{"C201978":{"preferredName":"Pulmonary Mucinous Cystic Tumor of Borderline Malignancy","code":"C201978","definitions":[{"definition":"A very rare, non-invasive epithelial neoplasm that arises from the lung. It is composed of multilocular cysts filled with mucus. The cysts are lined with columnar mucinous epithelium. Focal cellular atypia is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Mucinous Cystic Tumor of Borderline Malignancy","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Mucinous Cystic Tumor of Borderline Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Mucinous Cystic Tumor of Low or Borderline Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Mucinous Cystic Tumor of Low or Borderline Malignancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8472/1"},{"name":"Maps_To","value":"Mucinous cystic tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334365"}]}}{"C4186":{"preferredName":"Borderline Papillary Mucinous Cystadenoma","code":"C4186","definitions":[{"definition":"A low malignant potential cystic epithelial neoplasm usually arising from the ovary. It is composed of glandular cells with intracytoplasmic mucin. It is characterized by an atypical epithelial proliferation and a papillary growth pattern. There is no evidence of destructive stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Papillary Mucinous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Mucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Mucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Mucinous Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Mucinous Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8473/1"},{"name":"Legacy Concept Name","value":"Borderline_Papillary_Mucinous_Cystadenoma"},{"name":"Maps_To","value":"8473/1"},{"name":"Maps_To","value":"Papillary mucinous cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Papillary mucinous tumor of low malignant potential"},{"name":"Maps_To","value":"Papillary pseudomucinous cystadenoma, borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334366"}]}}{"C7281":{"preferredName":"Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor","code":"C7281","definitions":[{"definition":"A low grade, non-invasive ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"ICD-O-3_Code","value":"8323/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Mixed_Epithelial_Neoplasm"},{"name":"Maps_To","value":"Seromucinous borderline tumor"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332596"}]}}{"C40090":{"preferredName":"Ovarian Seromucinous Carcinoma","code":"C40090","definitions":[{"definition":"A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Seromucinous Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Mixed_Epithelial_Tumor"},{"name":"Maps_To","value":"Seromucinous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279392"}]}}{"C42598":{"preferredName":"Low Grade Appendix Mucinous Neoplasm","code":"C42598","definitions":[{"definition":"A well differentiated mucinous neoplasm that arises from the appendix.  It is characterized by slow growth and it is associated with the development of pseudomyxoma peritonei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Appendix Mucinous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Appendix Well Differentiated Mucinous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LAMN","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Appendiceal Mucinous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Appendiceal Mucinous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Appendix Mucinous Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8480/1"},{"name":"Legacy Concept Name","value":"Low_Grade_Appendix_Mucinous_Neoplasm"},{"name":"Maps_To","value":"8480/1"},{"name":"Maps_To","value":"Low grade appendiceal mucinous neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708747"}]}}{"C26712":{"preferredName":"Mucinous Adenocarcinoma","code":"C26712","definitions":[{"definition":"A type of cancer that begins in cells that line certain internal organs and produce mucin (the main component of mucus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An adenocarcinoma comprising neoplastic glandular cells containing intracytoplasmic mucin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Colloid Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Colloid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gelatinous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gelatinous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucoid Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8480/3"},{"name":"Legacy Concept Name","value":"Mucinous_Adenocarcinoma"},{"name":"Maps_To","value":"8480/3"},{"name":"Maps_To","value":"Colloid adenocarcinoma"},{"name":"Maps_To","value":"Colloid carcinoma"},{"name":"Maps_To","value":"Gelatinous adenocarcinoma"},{"name":"Maps_To","value":"Gelatinous carcinoma"},{"name":"Maps_To","value":"Mucinous adenocarcinoma"},{"name":"Maps_To","value":"Mucinous carcinoma"},{"name":"Maps_To","value":"Mucoid adenocarcinoma"},{"name":"Maps_To","value":"Mucoid carcinoma"},{"name":"Maps_To","value":"Mucous adenocarcinoma"},{"name":"Maps_To","value":"Mucous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007130"}]}}{"C3345":{"preferredName":"Pseudomyxoma Peritonei","code":"C3345","definitions":[{"definition":"A build-up of mucus in the peritoneal cavity. The mucus may come from ruptured ovarian cysts, from the appendix, or from other abdominal tissues. Mucus-secreting cells may attach to the peritoneal lining and continue to secrete mucus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually well differentiated mucinous adenocarcinoma of the peritoneum.  The majority of cases represent tumor spread from a primary low grade mucinous neoplasm of the appendix.  Cases of pseudomyxoma peritonei associated with mucinous adenocarcinomas of the gallbladder, stomach, colon, rectum, pancreas, lung, breast, and fallopian tubes have also been reported.  In the past, the ovary has been considered as a common primary site associated with pseudomyxoma peritonei.  However, there is recent evidence based on immunohistochemistry and molecular genetic analysis suggesting that most cases of pseudomyxoma peritonei probably represent metastasis from an appendiceal and not ovarian primary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pseudomyxoma Peritonei","termGroup":"PT","termSource":"NCI"},{"termName":"Gelatinous Ascites","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Ascites","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Carcinoma Peritonei","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoma Peritonei","termGroup":"SY","termSource":"NCI"},{"termName":"Peritoneal Cavity Pseudomyxoma Peritonei","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8480/6"},{"name":"Legacy Concept Name","value":"Pseudomyxoma_Peritonei"},{"name":"Maps_To","value":"8480/6"},{"name":"Maps_To","value":"Pseudomyxoma peritonei"},{"name":"Maps_To","value":"Pseudomyxoma peritonei with unknown primary site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0033822"}]}}{"C27825":{"preferredName":"Mucin-Producing Carcinoma","code":"C27825","definitions":[{"definition":"A carcinoma that produces mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucin-Producing Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucin-Secreting_Carcinoma"},{"name":"Maps_To","value":"8481/3"},{"name":"Maps_To","value":"Mucin-producing carcinoma"},{"name":"Maps_To","value":"Mucin-secreting carcinoma"},{"name":"NCI_META_CUI","value":"CL054990"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27379":{"preferredName":"Mucin-Producing Adenocarcinoma","code":"C27379","definitions":[{"definition":"An invasive adenocarcinoma composed of malignant glandular cells which produce mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucin-Producing Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8481/3"},{"name":"Legacy Concept Name","value":"Mucin-Secreting_Adenocarcinoma"},{"name":"Maps_To","value":"8481/3"},{"name":"Maps_To","value":"Mucin-producing adenocarcinoma"},{"name":"Maps_To","value":"Mucin-secreting adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334368"}]}}{"C66953":{"preferredName":"Mucinous Adenocarcinoma, Endocervical Type","code":"C66953","definitions":[{"definition":"A mucinous adenocarcinoma characterized by the presence of malignant glandular cells which resemble the endocervical epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Adenocarcinoma, Endocervical Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Tue Jul 20 15:15:35 EDT 2021 - See 'Cervical Mucinous Adenocarcinoma, Not Otherwise Specified(C40202)'"},{"name":"ICD-O-3_Code","value":"8482/3"},{"name":"Legacy Concept Name","value":"Mucinous_Adenocarcinoma_Endocervical_Type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"OLD_PARENT","value":"C127907"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3774":{"preferredName":"Signet Ring Cell Carcinoma","code":"C3774","definitions":[{"definition":"A highly malignant type of cancer typically found in glandular cells that line the digestive organs. The cells resemble signet rings when examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Signet Ring Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Signet Ring Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Signet-Ring Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8490/3"},{"name":"Legacy Concept Name","value":"Signet_Ring_Cell_Carcinoma"},{"name":"Maps_To","value":"8490/3"},{"name":"Maps_To","value":"Signet ring cell adenocarcinoma"},{"name":"Maps_To","value":"Signet ring cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206696"}]}}{"C66717":{"preferredName":"Metastatic Signet Ring Cell Carcinoma","code":"C66717","definitions":[{"definition":"A signet ring cell carcinoma that has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Signet Ring Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Metastatic Signet-Ring Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8490/6"},{"name":"Legacy Concept Name","value":"Metastatic_Signet_Ring_Cell_Carcinoma"},{"name":"Maps_To","value":"8490/6"},{"name":"Maps_To","value":"Metastatic signet ring cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881801"}]}}{"C3153":{"preferredName":"Krukenberg Tumor","code":"C3153","definitions":[{"definition":"A tumor in the ovary caused by the spread of stomach cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Metastatic signet-ring cell carcinoma in the ovary. The primary site is the gastrointestinal tract or breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Krukenberg Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Krukenberg Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Krukenberg_Tumor"},{"name":"Maps_To","value":"8490/6"},{"name":"Maps_To","value":"Krukenberg tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0022790"}]}}{"C2924":{"preferredName":"Breast Ductal Carcinoma In Situ","code":"C2924","definitions":[{"definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","type":"DEFINITION","source":"NCI"},{"definition":"A noninvasive condition in which abnormal cells are found in the lining of a breast duct. The abnormal cells have not spread outside the duct to other tissues in the breast. In some cases, ductal carcinoma in situ may become invasive cancer and spread to other tissues, although it is not known at this time how to predict which lesions will become invasive.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Ductal Carcinoma In Situ, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS","termGroup":"AB","termSource":"NCI"},{"termName":"DCIS, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma In Situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma In Situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8500/2"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_of_the_Breast"},{"name":"Maps_To","value":"8500/2"},{"name":"Maps_To","value":"DCIS, NOS"},{"name":"Maps_To","value":"Ductal carcinoma in situ, NOS"},{"name":"Maps_To","value":"Intraductal adenocarcinoma, noninfiltrating, NOS"},{"name":"Maps_To","value":"Intraductal carcinoma in situ of left breast"},{"name":"Maps_To","value":"Intraductal carcinoma in situ of right breast"},{"name":"Maps_To","value":"Intraductal carcinoma in situ of unspecified breast"},{"name":"Maps_To","value":"Intraductal carcinoma, noninfiltrating, NOS"},{"name":"Maps_To","value":"Intraductal carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007124"}]}}{"C7949":{"preferredName":"Breast Ductal Carcinoma In Situ, High Grade","code":"C7949","definitions":[{"definition":"A condition in which cells that look very different from normal cells under a microscope are found in the lining of a breast duct. There may also be areas of dead cells in the abnormal tissue. The abnormal cells have not spread outside the duct to other tissues in the breast. Grade III ductal carcinoma in situ tends to grow more quickly than grade I or grade II ductal carcinoma in situ and is more likely to come back or spread to other tissues. Also called grade III DCIS, high-grade DCIS, and high-grade ductal carcinoma in situ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"DCIS Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"DIN 3","termGroup":"AB","termSource":"NCI"},{"termName":"Ductal Intraepithelial Neoplasia, Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Ductal Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade DCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade DCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Ductal Carcinoma In Situ of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8501/2"},{"name":"Legacy Concept Name","value":"High-Grade_Ductal_Carcinoma_In_Situ_of_the_Breast"},{"name":"Maps_To","value":"8500/2"},{"name":"Maps_To","value":"DIN 3"},{"name":"Maps_To","value":"Ductal intraepithelial neoplasia 3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334002"}]}}{"C4017":{"preferredName":"Breast Ductal Carcinoma","code":"C4017","definitions":[{"definition":"A breast carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive breast carcinoma of no special type. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.","type":"DEFINITION","source":"NCI"},{"definition":"The most common type of breast cancer. It begins in the cells that line the milk ducts in the breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Ductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Duct Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ductal_Breast_Carcinoma"},{"name":"Maps_To","value":"8500/3"},{"name":"Maps_To","value":"Duct adenocarcinoma, NOS"},{"name":"Maps_To","value":"Duct carcinoma, NOS"},{"name":"Maps_To","value":"Duct cell carcinoma"},{"name":"Maps_To","value":"Ductal carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1527349"}]}}{"C4194":{"preferredName":"Invasive Breast Carcinoma of No Special Type","code":"C4194","definitions":[{"definition":"A term that refers to a large and heterogeneous group of invasive breast carcinomas that cannot be classified morphologically as any of the special histological types. (WHO 2019)","type":"DEFINITION","source":"NCI"},{"definition":"The most common type of invasive breast cancer. It starts in the cells that line the milk ducts in the breast, grows outside the ducts, and often spreads to the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Invasive Breast Carcinoma of No Special Type","termGroup":"PT","termSource":"NCI"},{"termName":"IBC NST","termGroup":"AB","termSource":"NCI"},{"termName":"Infiltrating Ductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, No Specific Type","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, NST","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8500/3"},{"name":"ICD-O-3_Code","value":"8521/3"},{"name":"Legacy Concept Name","value":"Invasive_Ductal_Carcinoma_not_Otherwise_Specified"},{"name":"Maps_To","value":"8500/3"},{"name":"Maps_To","value":"Infiltrating duct adenocarcinoma"},{"name":"Maps_To","value":"Infiltrating duct carcinoma, NOS"},{"name":"Maps_To","value":"Infiltrating ductular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1134719"}]}}{"C4188":{"preferredName":"Comedo-Type Adenocarcinoma","code":"C4188","definitions":[{"definition":"A high grade carcinoma characterized by the presence of comedo-type tumor cell necrosis in which the necrotic areas are surrounded by a solid proliferation of malignant pleomorphic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Comedo-Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Comedocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8501/3"},{"name":"Legacy Concept Name","value":"Comedocarcinoma"},{"name":"Maps_To","value":"8501/3"},{"name":"Maps_To","value":"Comedocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334370"}]}}{"C4189":{"preferredName":"Breast Secretory Carcinoma","code":"C4189","definitions":[{"definition":"A rare, low grade invasive adenocarcinoma of the breast characterized by the presence of cells that secrete milk-like material. Morphologically, it usually appears as a circumscribed lesion, composed of cystic spaces, tubular structures, and solid areas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Secretory Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cystic Hypersecretory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cystic Hypersecretory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cystic Hypersecretory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Cystic Hypersecretory Duct Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Cystic Hypersecretory Duct Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Secretory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Secretory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Secretory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8502/3"},{"name":"ICD-O-3_Code","value":"8508/3"},{"name":"Legacy Concept Name","value":"Secretory_Breast_Carcinoma"},{"name":"Maps_To","value":"8508/3"},{"name":"Maps_To","value":"Cystic hypersecretory carcinoma"},{"name":"Maps_To","value":"Juvenile carcinoma of breast"},{"name":"Maps_To","value":"Secretory carcinoma"},{"name":"Maps_To","value":"Secretory carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334371"}]}}{"C96877":{"preferredName":"Gallbladder Intracholecystic Papillary Neoplasm, Low Grade","code":"C96877","definitions":[{"definition":"An intracholecystic papillary neoplasm that arises from the epithelium of the gallbladder. It is characterized by the presence of mild epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gallbladder Intracholecystic Papillary Neoplasm, Low Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Gallbladder ICPN with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracholecystic Papillary (Tubular) Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracholecystic Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracholecystic Papillary Neoplasm, Low-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracystic/Intaductal Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"AQS","termSource":"NCI"},{"termName":"Intracystic Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Intracystic papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273093"}]}}{"C96807":{"preferredName":"Bile Duct Intraductal Papillary Neoplasm, Low Grade","code":"C96807","definitions":[{"definition":"An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts. It is characterized by the presence of mild epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Intraductal Papillary Neoplasm, Low Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm, Low-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct IPN with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273049"}]}}{"C3785":{"preferredName":"Intraductal Papilloma","code":"C3785","definitions":[{"definition":"A benign (not cancer), wart-like growth in a milk duct of the breast. It is usually found close to the nipple and may cause a discharge from the nipple. It may also cause pain and a lump in the breast that can be felt. It usually affects women aged 35-55 years. Having a single papilloma does not increase the risk of breast cancer. When there are multiple intraductal papillomas, they are usually found farther from the nipple. There may not be a nipple discharge and the papillomas may not be felt. Having multiple intraductal papillomas may increase the risk of breast cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intraluminal papillary epithelial neoplasm arising within the ducts. Representative examples are the intraductal breast papilloma and the salivary gland intraductal papilloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraductal Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Duct Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Ductal Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Legacy Concept Name","value":"Intraductal_Papilloma"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Duct adenoma, NOS"},{"name":"Maps_To","value":"Ductal papilloma"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with intermediate grade neoplasia"},{"name":"Maps_To","value":"Intraductal papilloma"},{"name":"Maps_To","value":"Intraglandular papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206713"}]}}{"C96809":{"preferredName":"Bile Duct Intraductal Papillary Neoplasm, High Grade","code":"C96809","definitions":[{"definition":"An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts. It is characterized by the presence of severe epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Intraductal Papillary Neoplasm, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm, High-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct IPN with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Papillary Neoplasm with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Neoplasm with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/2"},{"name":"Maps_To","value":"8503/2"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with high grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273051"}]}}{"C4190":{"preferredName":"Breast Papillary Ductal Carcinoma In Situ","code":"C4190","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Papillary Ductal Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intracystic Papillary Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Breast Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Papillary DCIS","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Papillary Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Papillary Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary DCIS","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Ductal Carcinoma In Situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/2"},{"name":"Legacy Concept Name","value":"Intraductal_Papillary_Breast_Carcinoma"},{"name":"Maps_To","value":"8503/2"},{"name":"Maps_To","value":"DCIS, papillary"},{"name":"Maps_To","value":"Ductal carcinoma in situ, papillary"},{"name":"Maps_To","value":"Intraductal papillary adenocarcinoma, NOS"},{"name":"Maps_To","value":"Intraductal papillary carcinoma"},{"name":"Maps_To","value":"Noninfiltrating intraductal papillary adenocarcinoma"},{"name":"Maps_To","value":"Noninfiltrating intraductal papillary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334372"}]}}{"C7439":{"preferredName":"Breast Papillary Ductal Carcinoma In Situ with Invasion","code":"C7439","definitions":[{"definition":"A breast adenocarcinoma characterized by the presence of intraductal and invasive papillary carcinomatous components.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Papillary Ductal Carcinoma In Situ with Invasion","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal Papillary Adenocarcinoma with Invasion","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Adenocarcinoma with Invasion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/3"},{"name":"Legacy Concept Name","value":"Intraductal_Papillary_Adenocarcinoma_with_Invasion"},{"name":"Maps_To","value":"8503/3"},{"name":"Maps_To","value":"Intraductal papillary adenocarcinoma with invasion"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with associated invasive carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334373"}]}}{"C7438":{"preferredName":"Invasive Papillary Adenocarcinoma","code":"C7438","definitions":[{"definition":"A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Papillary_Adenocarcinoma"},{"name":"Maps_To","value":"8503/3"},{"name":"Maps_To","value":"Infiltrating and papillary adenocarcinoma"},{"name":"Maps_To","value":"Infiltrating papillary adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321863"}]}}{"C3863":{"preferredName":"Breast Intraductal Papilloma","code":"C3863","definitions":[{"definition":"A benign (not cancer), wart-like growth in a milk duct of the breast. It is usually found close to the nipple and may cause a discharge from the nipple. It may also cause pain and a lump in the breast that can be felt. It usually affects women aged 35-55 years. Having a single papilloma does not increase the risk of breast cancer. When there are multiple intraductal breast papillomas, they are usually found farther from the nipple. There may not be a nipple discharge and the papillomas may not be felt. Having multiple intraductal breast papillomas may increase the risk of breast cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign papillary neoplasm that arises anywhere in the ductal system of the breast. It is characterized by the presence of fibrovascular structures lined by benign epithelial and myoepithelial proliferations.  Intraductal breast papillomas are classified as central, when they arise in large ducts, or peripheral, when they arise in the terminal ductal lobular units.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Intraductal Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intracystic Papilloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Breast Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Duct Papilloma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Duct Papilloma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracystic Papilloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intraductal Breast Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papilloma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papilloma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Papilloma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Papilloma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8504/0"},{"name":"Legacy Concept Name","value":"Intracystic_Papilloma"},{"name":"Legacy Concept Name","value":"Intraductal_Breast_Papilloma"},{"name":"Maps_To","value":"8504/0"},{"name":"Maps_To","value":"Intracystic papillary adenoma"},{"name":"Maps_To","value":"Intracystic papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0238034"}]}}{"C7645":{"preferredName":"Breast Intracystic Papillary Carcinoma","code":"C7645","definitions":[{"definition":"An intraductal breast carcinoma characterized by a papillary growth within a large cystic duct. There is no evidence of invasion of the breast parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Intracystic Papillary Carcinoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Intracystic Breast Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intracystic Papillary Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intracystic Papillary Breast Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Noninfiltrating Intracystic Breast Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8504/2"},{"name":"ICD-O-3_Code","value":"8504/3"},{"name":"Legacy Concept Name","value":"Intracystic_Papillary_Carcinoma"},{"name":"Maps_To","value":"8504/2"},{"name":"Maps_To","value":"8504/3"},{"name":"Maps_To","value":"Intracystic carcinoma, NOS"},{"name":"Maps_To","value":"Intracystic papillary adenocarcinoma"},{"name":"Maps_To","value":"Noninfiltrating intracystic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334376"}]}}{"C7363":{"preferredName":"Intraductal Papillomatosis","code":"C7363","definitions":[{"definition":"A neoplastic process characterized by the presence of multiple intraductal papillomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraductal Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8505/0"},{"name":"Legacy Concept Name","value":"Intraductal_Papillomatosis"},{"name":"Maps_To","value":"8505/0"},{"name":"Maps_To","value":"Intraductal papillomatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334377"}]}}{"C4192":{"preferredName":"Nipple Adenoma","code":"C4192","definitions":[{"definition":"A benign epithelial neoplasm arising from the nipple. Signs and symptoms include serous or sanguineous nipple discharge and nipple erosion. It is characterized by the presence of aggregates of small tubules replacing the nipple stroma. The tubules are lined by epithelial and myoepithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nipple Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Nipple","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Nipple","termGroup":"SY","termSource":"NCI"},{"termName":"Erosive Nipple Adenomatosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Subareolar Duct Papillomatosis","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8506/0"},{"name":"Legacy Concept Name","value":"Nipple_Adenoma"},{"name":"Maps_To","value":"8506/0"},{"name":"Maps_To","value":"Adenoma of nipple"},{"name":"Maps_To","value":"Subareolar duct papillomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334378"}]}}{"C5139":{"preferredName":"Breast Micropapillary Ductal Carcinoma In Situ","code":"C5139","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Micropapillary Ductal Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal Micropapillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Micropapillary DCIS","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary DCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary DCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8507/2"},{"name":"Legacy Concept Name","value":"Intraductal_Micropapillary_Breast_Carcinoma"},{"name":"Maps_To","value":"8507/2"},{"name":"Maps_To","value":"Intraductal micropapillary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334249"}]}}{"C36084":{"preferredName":"Invasive Breast Micropapillary Carcinoma","code":"C36084","definitions":[{"definition":"An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Micropapillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Micropapillary_Breast_Carcinoma"},{"name":"Maps_To","value":"8507/3"},{"name":"Maps_To","value":"Invasive micropapillary carcinoma"},{"name":"Maps_To","value":"Invasive micropapillary carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3838947"}]}}{"C6870":{"preferredName":"Breast Solid Papillary Carcinoma","code":"C6870","definitions":[{"definition":"A well circumscribed, low grade neoplasm that arises from the breast.  It is characterized by the presence of sheets of malignant epithelial cells that are supported by fibrovascular structures.  When there is an invasive component present, it is usually a mucinous carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Solid Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Solid Papillary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Papillary_Carcinoma_of_the_Breast"},{"name":"Maps_To","value":"Solid papillary carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336027"}]}}{"C66850":{"preferredName":"Invasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma","code":"C66850","definitions":[{"definition":"A papillary carcinoma of the thyroid gland which is encapsulated and resembles an encapsulated follicular neoplasm. Capsular invasion is present. The malignant follicular cells display the nuclear features that characterize the papillary adenocarcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Variant Thyroid Gland Papillary Carcinoma, Encapsulated Subtype with Invasion","termGroup":"SY","termSource":"NCI"},{"termName":"IEFVPTC","termGroup":"AB","termSource":"NCI"},{"termName":"Invasive Encapsulated Follicular Variant Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8343/3"},{"name":"Legacy Concept Name","value":"Encapsulated_Thyroid_Gland_Papillary_Carcinoma"},{"name":"Maps_To","value":"8509/3"},{"name":"Maps_To","value":"Encapsulated papillary carcinoma with invasion"},{"name":"Maps_To","value":"Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)"},{"name":"Maps_To","value":"Solid papillary carcinoma with invasion"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1880498"}]}}{"C66718":{"preferredName":"Medullary Carcinoma, Not Otherwise Specified","code":"C66718","definitions":[{"definition":"A term referring to medullary carcinomas which can develop in various anatomic sites such as the thyroid gland, breast, colon, rectum, and small intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medullary Carcinoma, NOS","termGroup":"AQS","termSource":"NCI"},{"termName":"Medullary Carcinoma, Not Otherwise Specified","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8510/3"},{"name":"Legacy Concept Name","value":"Medullary_Carcinoma_NOS"},{"name":"Maps_To","value":"8510/3"},{"name":"Maps_To","value":"Medullary carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206693"}]}}{"C9119":{"preferredName":"Breast Medullary Carcinoma","code":"C9119","definitions":[{"definition":"A rare type of breast cancer that often can be treated successfully. It is marked by lymphocytes (a type of white blood cell) in and around the tumor that can be seen when viewed under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An infiltrating breast carcinoma with a relatively favorable prognosis.  It is an uncommon carcinoma, accounting for less than 1% of all infiltrating breast carcinomas.  It is well circumscribed, with soft cut surface and often of considerable size.  Microscopically, the predominant growth pattern is syncytial with broad anastomosing bands or sheets of malignant cells.  The malignant cells are round with abundant cytoplasm and vesicular nuclei.  The sheets of malignant cells are associated with a marked lymphoplasmacytic infiltrate.  Glandular or tubular structures are absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Medullary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Medullary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Medullary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Medullary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Medullary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Breast Carcinoma with Lymphoid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8512/3"},{"name":"Legacy Concept Name","value":"Medullary_Breast_Carcinoma"},{"name":"Maps_To","value":"8512/3"},{"name":"Maps_To","value":"Medullary carcinoma with lymphoid stroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0860580"}]}}{"C66719":{"preferredName":"Breast Atypical Medullary Carcinoma","code":"C66719","definitions":[{"definition":"An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Atypical Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Medullary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Breast Carcinoma with Medullary Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8513/3"},{"name":"Legacy Concept Name","value":"Atypical_Medullary_Breast_Carcinoma"},{"name":"Maps_To","value":"8513/3"},{"name":"Maps_To","value":"Atypical medullary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879758"}]}}{"C7362":{"preferredName":"Breast Scirrhous Carcinoma","code":"C7362","definitions":[{"definition":"An infiltrating ductal breast carcinoma associated with stromal fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Scirrhous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of Breast with Fibrotic Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of the Breast with Fibrotic Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Scirrhous Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Scirrhous Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Scirrhous Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8514/3"},{"name":"Legacy Concept Name","value":"Scirrhous_Carcinoma_of_the_Breast"},{"name":"Maps_To","value":"8514/3"},{"name":"Maps_To","value":"Duct carcinoma, desmoplastic type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346151"}]}}{"C137839":{"preferredName":"Breast Pleomorphic Lobular Carcinoma In Situ","code":"C137839","definitions":[{"definition":"Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Pleomorphic Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Invasive Pleomorphic Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"pLCIS","termGroup":"AB","termSource":"NCI"},{"termName":"Pleomorphic Lobular Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Pleomorphic Lobular Carcinoma in Situ of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Maps_To","value":"Lobular carcinoma in situ, pleomorphic"},{"name":"Maps_To","value":"Pleomorphic lobular carcinoma in situ"},{"name":"NCI_META_CUI","value":"CL524883"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4018":{"preferredName":"Breast Lobular Carcinoma In Situ","code":"C4018","definitions":[{"definition":"A condition in which abnormal cells are found in the lobules of the breast. Lobular carcinoma in situ seldom becomes invasive cancer; however, having it in one breast increases the risk of developing breast cancer in either breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"LCIS","termGroup":"AB","termSource":"NCI"},{"termName":"Lobular Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Ca in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Ca in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma In Situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma In Situ of the Breast (LCIS)","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8520/2"},{"name":"Legacy Concept Name","value":"Lobular_Carcinoma_in_situ_of_the_Breast"},{"name":"Maps_To","value":"8520/2"},{"name":"Maps_To","value":"LCIS, NOS"},{"name":"Maps_To","value":"Lobular carcinoma in situ, NOS"},{"name":"Maps_To","value":"Lobular carcinoma, noninfiltrating"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279563"}]}}{"C3771":{"preferredName":"Breast Lobular Carcinoma","code":"C3771","definitions":[{"definition":"An adenocarcinoma of the breast arising from the lobules.  This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that begins in the lobules (the glands that make milk) of the breast. Lobular carcinoma in situ (LCIS) is a condition in which abnormal cells are found only in the lobules. When cancer has spread from the lobules to surrounding tissues, it is invasive lobular carcinoma. LCIS does not become invasive lobular carcinoma very often, but having LCIS in one breast increases the risk of developing invasive cancer in either breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lobular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8520/3"},{"name":"Legacy Concept Name","value":"Lobular_Breast_Carcinoma"},{"name":"Maps_To","value":"8520/3"},{"name":"Maps_To","value":"Lobular adenocarcinoma"},{"name":"Maps_To","value":"Lobular carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206692"}]}}{"C7950":{"preferredName":"Invasive Breast Lobular Carcinoma","code":"C7950","definitions":[{"definition":"An infiltrating lobular adenocarcinoma of the breast.  The malignant cells lack cohesion and are arranged individually or in a linear manner (Indian files), or as narrow trabeculae within the stroma.  The malignant cells are usually smaller than those of ductal carcinoma, are less pleomorphic, and have fewer mitotic figures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Classic Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma, Classic Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Lobular_Breast_Carcinoma"},{"name":"Maps_To","value":"8520/3"},{"name":"Maps_To","value":"Infiltrating lobular carcinoma, NOS"},{"name":"Maps_To","value":"Invasive lobular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279565"}]}}{"C4195":{"preferredName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma In Situ","code":"C4195","definitions":[{"definition":"The co-existence of ductal and lobular carcinoma in situ in the breast, without evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"DCIS and LCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS and LCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal and Lobular Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal and Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal and Lobular Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ with Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ with Lobular Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma and Lobular Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal and Non-Infiltrating Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal with Non-Infiltrating Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal with Non-Infiltrating Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal and Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal and Non-Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Breast Carcinoma with Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma with Non-Invasive Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma with Non-Invasive Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal with Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8522/2"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_and_Lobular_Carcinoma_in_situ"},{"name":"Maps_To","value":"8522/2"},{"name":"Maps_To","value":"Intraductal carcinoma and lobular carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334383"}]}}{"C7690":{"preferredName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma","code":"C7690","definitions":[{"definition":"A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraductal_and_Lobular_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"Intraductal and lobular carcinoma"},{"name":"NCI_META_CUI","value":"CL028597"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6939":{"preferredName":"Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma","code":"C6939","definitions":[{"definition":"A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"DCIS and ILC","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS and Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma In Situ and Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ and Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma and ILC","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_and_Infiltrating_Lobular_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"8524/3"},{"name":"Maps_To","value":"Infiltrating lobular carcinoma and ductal carcinoma in situ"},{"name":"Maps_To","value":"Infiltrating lobular mixed with other types of carcinoma"},{"name":"NCI_META_CUI","value":"CL018755"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C5160":{"preferredName":"Breast Mixed Ductal and Lobular Carcinoma","code":"C5160","definitions":[{"definition":"A breast carcinoma characterized by the presence of a lobular and a ductal component. The ductal component comprises less than 50 percent of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Mixed Ductal and Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Lobular_and_Ductal_Breast_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"Lobular and ductal carcinoma"},{"name":"NCI_META_CUI","value":"CL007210"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7688":{"preferredName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma","code":"C7688","definitions":[{"definition":"An invasive ductal breast carcinoma associated with a lobular carcinomatous component. The lobular carcinomatous component may be in situ or invasive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Duct and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8522/3"},{"name":"Legacy Concept Name","value":"Invasive_Ductal_and_Lobular_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"8523/3"},{"name":"Maps_To","value":"Infiltrating duct and lobular carcinoma"},{"name":"Maps_To","value":"Infiltrating duct mixed with other types of carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334277"}]}}{"C7689":{"preferredName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma In Situ","code":"C7689","definitions":[{"definition":"An invasive ductal breast carcinoma associated with an in situ lobular carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Ductal and Lobular Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal and Lobular Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"LCIS and Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ and Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ and Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Ductal_and_Lobular_Carcinoma_in_situ"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"Infiltrating duct and lobular carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334384"}]}}{"C35702":{"preferredName":"Salivary Gland Polymorphous Adenocarcinoma","code":"C35702","definitions":[{"definition":"A low grade malignant epithelial neoplasm arising from the salivary gland. It usually arises from the oral cavity, with approximately 60% of the cases involving the palate. The most common presenting sign is a painless mass in the palate. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern. There is a variety of morphologic patterns which may be present within an individual tumor, including lobular, papillary, papillary-cystic, cribriform, and trabecular pattern. It usually has a favorable clinical outcome and a low metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Polymorphous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Salivary Gland PmA","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Polymorphous Adenocarcinoma, Classical Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Polymorphous Low Grade Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Terminal Duct Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8525/3"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Polymorphous_Low-Grade_Adenocarcinoma"},{"name":"Maps_To","value":"8525/3"},{"name":"Maps_To","value":"Polymorphous adenocarcinoma"},{"name":"Maps_To","value":"Polymorphous low grade adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335907"}]}}{"C4001":{"preferredName":"Breast Inflammatory Carcinoma","code":"C4001","definitions":[{"definition":"A type of breast cancer in which the breast looks red and swollen and feels warm. The skin of the breast may also show the pitted appearance called peau d'orange (like the skin of an orange). The redness and warmth occur because the cancer cells block the lymph vessels in the skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Inflammatory Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Inflammatory Breast Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mastitis Carcinomatosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8530/3"},{"name":"Legacy Concept Name","value":"Inflammatory_Breast_Carcinoma"},{"name":"Maps_To","value":"8530/3"},{"name":"Maps_To","value":"Inflammatory carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278601"}]}}{"C47857":{"preferredName":"Breast Paget Disease","code":"C47857","definitions":[{"definition":"A malignant neoplasm in which there is infiltration of the skin overlying the breast by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It is almost always associated with an intraductal or invasive ductal carcinoma of the breast. The clinical features include focal skin reddening, and eczema. Retraction of the nipple may sometimes occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Mammary Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8540/3"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_of_the_Breast"},{"name":"Maps_To","value":"8540/3"},{"name":"Maps_To","value":"Paget disease of breast"},{"name":"Maps_To","value":"Paget disease, mammary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030185"}]}}{"C7951":{"preferredName":"Breast Paget Disease with Invasive Ductal Carcinoma","code":"C7951","definitions":[{"definition":"Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease with Invasive Ductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Paget Disease and Infiltrating Duct Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease of the Breast with Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Infiltrating Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Infiltrating Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Invasive Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Invasive Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast with Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast with Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast with Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast with Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8541/3"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_of_the_Breast_with_Invasive_Ductal_Carcinoma"},{"name":"Maps_To","value":"8541/3"},{"name":"Maps_To","value":"Paget disease and infiltrating duct carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279567"}]}}{"C3302":{"preferredName":"Extramammary Paget Disease","code":"C3302","definitions":[{"definition":"A malignant neoplasm in which there is infiltration of the skin by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It may affect the anus, penis, scrotum, and vulva.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extramammary Paget Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Extramammary Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease Extramammary","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease, Extramammary","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Skin Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8542/3"},{"name":"Legacy Concept Name","value":"Extramammary_Paget_s_Disease"},{"name":"Maps_To","value":"8542/3"},{"name":"Maps_To","value":"Paget disease, extramammary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030186"}]}}{"C4019":{"preferredName":"Breast Paget Disease and Intraductal Carcinoma","code":"C4019","definitions":[{"definition":"Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease and Intraductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Paget Disease and Intraductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Intraductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Intraductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast with Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast with Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8543/3"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_and_Intraductal_Carcinoma_of_the_Breast"},{"name":"Maps_To","value":"8543/3"},{"name":"Maps_To","value":"Paget disease and intraductal carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279566"}]}}{"C4196":{"preferredName":"Acinar Cell Adenoma","code":"C4196","definitions":[{"definition":"A benign glandular epithelial neoplasm comprising secretory cells forming acinar patterns.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign glandular epithelial neoplasm consisting of secretory cells forming acinar patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acinar Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinic Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8550/0"},{"name":"Legacy Concept Name","value":"Acinar_Cell_Adenoma"},{"name":"Maps_To","value":"8550/0"},{"name":"Maps_To","value":"Acinar adenoma"},{"name":"Maps_To","value":"Acinar cell adenoma"},{"name":"Maps_To","value":"Acinic cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334389"}]}}{"C3768":{"preferredName":"Acinar Cell Carcinoma","code":"C3768","definitions":[{"definition":"A malignant glandular epithelial neoplasm comprising secretory cells forming acinar patterns.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acinar Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinic Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinic Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8550/3"},{"name":"Legacy Concept Name","value":"Acinar_Cell_Carcinoma"},{"name":"Maps_To","value":"8550/1"},{"name":"Maps_To","value":"Acinar adenocarcinoma"},{"name":"Maps_To","value":"Acinar carcinoma"},{"name":"Maps_To","value":"Acinar cell carcinoma"},{"name":"Maps_To","value":"Acinic cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206685"}]}}{"C5727":{"preferredName":"Pancreatic Acinar Cell Cystadenocarcinoma","code":"C5727","definitions":[{"definition":"A cystic adenocarcinoma characterized by the presence of relatively uniform neoplastic cells which produce pancreatic enzymes and are arranged in acinar patterns. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It usually has an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Acinar Cell Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Cell Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Cell Cystadenocarcinoma of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Cell Cystadenocarcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8551/3"},{"name":"Legacy Concept Name","value":"Pancreatic_Acinar_Cell_Cystadenocarcinoma"},{"name":"Maps_To","value":"8551/3"},{"name":"Maps_To","value":"Acinar cell cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266087"}]}}{"C95458":{"preferredName":"Pancreatic Mixed Acinar-Ductal Carcinoma","code":"C95458","definitions":[{"definition":"A carcinoma that arises from the pancreas showing either extensive mucin accumulation and acinar neoplastic cells or a mixture of columnar or signet-ring cells and acinar neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mixed Acinar-Ductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Acinar-Ductal Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8552/3"},{"name":"Maps_To","value":"8552/3"},{"name":"Maps_To","value":"Mixed acinar-ductal carcinoma"},{"name":"Maps_To","value":"Mixed acinar-endocrine-ductal carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472609"}]}}{"C45602":{"preferredName":"Bronchial Mixed Squamous Cell and Glandular Papilloma","code":"C45602","definitions":[{"definition":"An exceedingly rare benign endobronchial neoplasm characterized by the presence of fibrovascular cores which are lined by both squamous and glandular epithelium. Patients present with obstructive symptoms. Complete resection is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bronchial Mixed Squamous Cell and Glandular Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Mixed Squamous and Glandular Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Mixed Squamous Cell and Glandular Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8560/0"},{"name":"Legacy Concept Name","value":"Lung_Mixed_Squamous_and_Glandular_Papilloma"},{"name":"Maps_To","value":"8560/0"},{"name":"Maps_To","value":"Mixed squamous cell and glandular papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1314684"}]}}{"C3727":{"preferredName":"Adenosquamous Carcinoma","code":"C3727","definitions":[{"definition":"A type of cancer that contains two types of cells: squamous cells (thin, flat cells that line certain organs) and gland-like cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An epithelial neoplasm composed of malignant glandular and malignant squamous cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosquamous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8560/3"},{"name":"Legacy Concept Name","value":"Adenosquamous_Carcinoma"},{"name":"Maps_To","value":"8560/3"},{"name":"Maps_To","value":"Adenosquamous carcinoma"},{"name":"Maps_To","value":"Mixed adenocarcinoma and epidermoid carcinoma"},{"name":"Maps_To","value":"Mixed adenocarcinoma and squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206623"}]}}{"C2854":{"preferredName":"Warthin Tumor","code":"C2854","definitions":[{"definition":"An adenoma characterized by an oncocytic, often papillary, epithelial component, dense lymphoid stroma, and cystic spaces. It occurs primarily in the parotid gland, and is the second most common benign parotid salivary gland tumor. A strong association with smoking has been reported. It typically presents as a painless swelling in the lower portion of the parotid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Warthin Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adenolymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cystadenoma Lymphomatosum","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Warthin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Warthin's Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8561/0"},{"name":"Legacy Concept Name","value":"Warthin_s_Tumor"},{"name":"Maps_To","value":"8561/0"},{"name":"Maps_To","value":"Adenolymphoma"},{"name":"Maps_To","value":"Papillary cystadenoma lymphomatosum"},{"name":"Maps_To","value":"Warthin tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001429"}]}}{"C4199":{"preferredName":"Epithelial-Myoepithelial Carcinoma","code":"C4199","definitions":[{"definition":"A malignant neoplasm which occurs mostly in the major salivary glands (most frequently in the parotid gland), but also in the minor salivary glands of the oral mucosa and the tracheobronchial tree. It is characterized by the presence of ductal structures which are lined by an inner layer of cuboidal epithelial-type cells and an outer layer of myoepithelial cells with clear or eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelial-Myoepithelial Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8562/3"},{"name":"Legacy Concept Name","value":"Epithelial-Myoepithelial_Carcinoma"},{"name":"Maps_To","value":"8562/3"},{"name":"Maps_To","value":"Epithelial-myoepithelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334392"}]}}{"C4200":{"preferredName":"Adenocarcinoma with Squamous Metaplasia","code":"C4200","definitions":[{"definition":"A malignant neoplasm arising from glandular cells that includes focal or extensive areas of squamous metaplasia.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An invasive adenocarcinoma characterized by the presence of focal or extensive transformation of malignant glandular cells to squamous epithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Squamous Metaplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoacanthoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8570/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Squamous_Metaplasia"},{"name":"Maps_To","value":"8570/3"},{"name":"Maps_To","value":"Adenoacanthoma"},{"name":"Maps_To","value":"Adenocarcinoma with squamous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334393"}]}}{"C7685":{"preferredName":"Adenocarcinoma with Cartilaginous Metaplasia","code":"C7685","definitions":[{"definition":"An adenocarcinoma characterized by the presence of cartilaginous metaplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Cartilaginous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Cartilaginous_Metaplasia"},{"name":"Maps_To","value":"8571/3"},{"name":"Maps_To","value":"Adenocarcinoma with cartilaginous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377647"}]}}{"C7684":{"preferredName":"Adenocarcinoma with Osseous Metaplasia","code":"C7684","definitions":[{"definition":"An adenocarcinoma characterized by the presence of osseous metaplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Osseous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Osseous_Metaplasia"},{"name":"Maps_To","value":"8571/3"},{"name":"Maps_To","value":"Adenocarcinoma with osseous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377648"}]}}{"C7683":{"preferredName":"Adenocarcinoma with Cartilaginous and Osseous Metaplasia","code":"C7683","definitions":[{"definition":"An invasive adenocarcinoma characterized by focal or extensive cartilage and/or bone formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Cartilaginous and Osseous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8571/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Cartilaginous_and_Osseous_Metaplasia"},{"name":"Maps_To","value":"8571/3"},{"name":"Maps_To","value":"Adenocarcinoma with cartilaginous and osseous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334394"}]}}{"C4201":{"preferredName":"Adenocarcinoma with Spindle Cell Metaplasia","code":"C4201","definitions":[{"definition":"An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to spindle-shaped cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Spindle Cell Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8572/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Spindle_Cell_Metaplasia"},{"name":"Maps_To","value":"8572/3"},{"name":"Maps_To","value":"Adenocarcinoma with spindle cell metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334395"}]}}{"C4202":{"preferredName":"Adenocarcinoma with Apocrine Metaplasia","code":"C4202","definitions":[{"definition":"An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to cells with abundant, usually granular eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Apocrine Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8573/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Apocrine_Metaplasia"},{"name":"Maps_To","value":"8573/3"},{"name":"Maps_To","value":"Adenocarcinoma with apocrine metaplasia"},{"name":"Maps_To","value":"Carcinoma with apocrine metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334396"}]}}{"C66745":{"preferredName":"Adenocarcinoma with Neuroendocrine Differentiation","code":"C66745","definitions":[{"definition":"An invasive adenocarcinoma characterized by the presence of focal or extensive neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Neuroendocrine Differentiation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8574/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Neuroendocrine_Differentiation"},{"name":"Maps_To","value":"8574/3"},{"name":"Maps_To","value":"Adenocarcinoma with neuroendocrine differentiation"},{"name":"Maps_To","value":"Carcinoma with neuroendocrine differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266088"}]}}{"C27949":{"preferredName":"Metaplastic Carcinoma","code":"C27949","definitions":[{"definition":"A general term used to describe cancer that begins in cells that have changed into another cell type (for example, a squamous cell of the esophagus changing to resemble a cell of the stomach).  In some cases, metaplastic changes alone may mean there is an increased chance of cancer developing at the site.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cells type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metaplastic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8575/3"},{"name":"Legacy Concept Name","value":"Metaplastic_Carcinoma"},{"name":"Maps_To","value":"8575/3"},{"name":"Maps_To","value":"Metaplastic carcinoma of no special type"},{"name":"Maps_To","value":"Metaplastic carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266089"}]}}{"C66950":{"preferredName":"Hepatoid Adenocarcinoma","code":"C66950","definitions":[{"definition":"An adenocarcinoma with morphologic characteristics similar to hepatocellular carcinoma, arising from an anatomic site other than the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatoid Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatoid Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8576/3"},{"name":"Legacy Concept Name","value":"Hepatoid_Carcinoma"},{"name":"Maps_To","value":"8576/3"},{"name":"Maps_To","value":"Hepatoid adenocarcinoma"},{"name":"Maps_To","value":"Hepatoid carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266090"}]}}{"C66746":{"preferredName":"Benign Thymoma","code":"C66746","definitions":[{"definition":"A thymoma that is completely surrounded by a capsule, without evidence of capsular invasion, infiltration of the surrounding tissues, and metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Thymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8580/0"},{"name":"Legacy Concept Name","value":"Benign_Thymoma"},{"name":"Maps_To","value":"8580/0"},{"name":"Maps_To","value":"Thymoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040101"}]}}{"C7612":{"preferredName":"Malignant Thymoma","code":"C7612","definitions":[{"definition":"A malignant neoplasm of the thymus, originating from epithelial thymus cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thymoma that has an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.  Although any morphologic subtype of thymoma may eventually have a malignant clinical course, this term is most often associated with thymoma types B3 and C.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8580/3"},{"name":"Legacy Concept Name","value":"Malignant_Thymoma"},{"name":"Maps_To","value":"8580/3"},{"name":"Maps_To","value":"Thymoma, malignant, NOS"},{"name":"NCI_META_CUI","value":"CL371354"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6454":{"preferredName":"Thymoma Type A","code":"C6454","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of spindle and/or oval neoplastic epithelial cells. Lymphocytic infiltration is minimal or absent. It may be associated with myasthenia gravis or pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. Approximately 20% of the cases occur as stage II or stage III tumors. Type A thymoma generally behaves as a benign tumor and the overall survival is reported to be 100% at 5 and 10 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type A","termGroup":"PT","termSource":"NCI"},{"termName":"Medullary Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8581/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_A"},{"name":"Maps_To","value":"8581/1"},{"name":"Maps_To","value":"Thymoma, medullary, NOS"},{"name":"Maps_To","value":"Thymoma, spindle cell, NOS"},{"name":"Maps_To","value":"Thymoma, type A, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266091"}]}}{"C7999":{"preferredName":"Malignant Type A Thymoma","code":"C7999","definitions":[{"definition":"A type A thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type A Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8581/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_A_Thymoma"},{"name":"Maps_To","value":"8581/3"},{"name":"Maps_To","value":"Thymoma, medullary, malignant"},{"name":"Maps_To","value":"Thymoma, spindle cell, malignant"},{"name":"Maps_To","value":"Thymoma, type A"},{"name":"Maps_To","value":"Thymoma, type A, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279707"}]}}{"C6885":{"preferredName":"Thymoma Type AB","code":"C6885","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of a lymphocyte-poor component similar to that seen in type A thymoma and a lymphocyte-rich component which contains neoplastic small polygonal epithelial cells. It may be associated with myasthenia gravis and pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II or stage III tumors. The overall survival is reported to be 80-100% at 5 and 10 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type AB","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Type Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8582/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_AB"},{"name":"Maps_To","value":"8582/1"},{"name":"Maps_To","value":"Thymoma, mixed type, NOS"},{"name":"Maps_To","value":"Thymoma, type AB, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266092"}]}}{"C6886":{"preferredName":"Malignant Type AB Thymoma","code":"C6886","definitions":[{"definition":"A type AB thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type AB Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8582/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_AB_Thymoma"},{"name":"Maps_To","value":"8582/3"},{"name":"Maps_To","value":"Thymoma, mixed type, malignant"},{"name":"Maps_To","value":"Thymoma, type AB"},{"name":"Maps_To","value":"Thymoma, type AB, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266093"}]}}{"C6887":{"preferredName":"Thymoma Type B1","code":"C6887","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of expanded areas which resemble the normal thymic cortex. The neoplastic epithelial cells are small and scant and there is a dense T-lymphocytic component present. Areas of medullary differentiation with or without Hassall's corpuscles are also present. It may be associated with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia. It has a low grade malignant potential. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type B1","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphocyte-Predominant Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Rich Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Organoid Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Predominantly Cortical Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8583/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_B1"},{"name":"Maps_To","value":"8583/1"},{"name":"Maps_To","value":"Thymoma, lymphocyte-rich, NOS"},{"name":"Maps_To","value":"Thymoma, lymphocytic, NOS"},{"name":"Maps_To","value":"Thymoma, organoid, NOS"},{"name":"Maps_To","value":"Thymoma, predominantly cortical, NOS"},{"name":"Maps_To","value":"Thymoma, type B1, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266094"}]}}{"C7996":{"preferredName":"Malignant Type B1 Thymoma","code":"C7996","definitions":[{"definition":"A type B1 thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type B1 Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8583/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_B1_Thymoma"},{"name":"Maps_To","value":"8583/3"},{"name":"Maps_To","value":"Thymoma, lymphocyte-rich, malignant"},{"name":"Maps_To","value":"Thymoma, lymphocytic, malignant"},{"name":"Maps_To","value":"Thymoma, organoid, malignant"},{"name":"Maps_To","value":"Thymoma, predominantly cortical, malignant"},{"name":"Maps_To","value":"Thymoma, type B1"},{"name":"Maps_To","value":"Thymoma, type B1, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279704"}]}}{"C6888":{"preferredName":"Thymoma Type B2","code":"C6888","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of neoplastic large, polygonal epithelial cells with large vesicular nuclei and prominent nucleoli. The neoplastic cells are arranged around perivascular spaces and along septa. Immature T-lymphocytes are also present. It may be associated with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia. It is a tumor of moderate malignancy. The majority of cases occur in the anterior mediastinum as Masaoka stage I, stage II, or stage III tumors. Metastatic, stage IV tumors occur less frequently.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type B2","termGroup":"PT","termSource":"NCI"},{"termName":"Cortical Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Polygonal Cell Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8584/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_B2"},{"name":"Maps_To","value":"8584/1"},{"name":"Maps_To","value":"Thymoma, cortical, NOS"},{"name":"Maps_To","value":"Thymoma, type B2, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266095"}]}}{"C6889":{"preferredName":"Malignant Type B2 Thymoma","code":"C6889","definitions":[{"definition":"A type B2 thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type B2 Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8584/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_B2_Thymoma"},{"name":"Maps_To","value":"8584/3"},{"name":"Maps_To","value":"Thymoma, cortical, malignant"},{"name":"Maps_To","value":"Thymoma, type B2"},{"name":"Maps_To","value":"Thymoma, type B2, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266096"}]}}{"C7997":{"preferredName":"Thymoma Type B3","code":"C7997","definitions":[{"definition":"Also known as well-differentiated thymic carcinoma, atypical thymoma, or epithelial thymoma, this type of thymoma displays morphologic characteristics of a well-differentiated carcinoma.  The majority of cases occur in the anterior mediastinum as Masaoka stage II or stage III tumors.  It is almost always invasive, it recurs frequently, and metastasizes in approximately 20% of the cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type B3","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Malignant Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thymoma Type B3","termGroup":"SY","termSource":"NCI"},{"termName":"Squamoid Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well Differentiated Thymic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Thymic Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8585/1"},{"name":"ICD-O-3_Code","value":"8585/3"},{"name":"Legacy Concept Name","value":"Thymoma_Type_B3"},{"name":"Maps_To","value":"8585/1"},{"name":"Maps_To","value":"8585/3"},{"name":"Maps_To","value":"Thymoma, atypical, malignant"},{"name":"Maps_To","value":"Thymoma, atypical, NOS"},{"name":"Maps_To","value":"Thymoma, epithelial, malignant"},{"name":"Maps_To","value":"Thymoma, epithelial, NOS"},{"name":"Maps_To","value":"Thymoma, type B3"},{"name":"Maps_To","value":"Thymoma, type B3, malignant"},{"name":"Maps_To","value":"Thymoma, type B3, NOS"},{"name":"Maps_To","value":"Well differentiated thymic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279705"}]}}{"C7569":{"preferredName":"Thymic Carcinoma","code":"C7569","definitions":[{"definition":"A diverse group of carcinomas of the thymus gland, previously known as thymoma type C.  It includes morphologic variants derived from purely epithelial cells, as well as from cells with neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of thymus gland cancer. It usually spreads, has a high risk of recurrence, and has a poor survival rate. Thymic carcinoma is divided into subtypes, depending on the types of cells in which the cancer began.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thymic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Thymic Carcinoma (Excluding Well Differentiated Thymic Carcinoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Thymic Carcinoma Excluding Well Differentiated Thymic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thymoma Type C","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8586/3"},{"name":"Legacy Concept Name","value":"Thymoma_Type_C"},{"name":"Maps_To","value":"8586/3"},{"name":"Maps_To","value":"Thymic carcinoma, NOS"},{"name":"Maps_To","value":"Thymoma, type C"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205969"}]}}{"C53595":{"preferredName":"Branchioma","code":"C53595","definitions":[{"definition":"A rare, benign, well-circumscribed or encapsulated tumor that arises from the neck and occurs in adults. It is characterized by the presence of spindle cells, epithelial islands, and adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Branchioma","termGroup":"PT","termSource":"NCI"},{"termName":"Biphenotypic Branchioma","termGroup":"SY","termSource":"NCI"},{"termName":"Branchial Anlage Mixed Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Ectopic Hamartomatous Thymoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Neck Branchioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8587/0"},{"name":"Legacy Concept Name","value":"Ectopic_Hamartomatous_Thymoma"},{"name":"Maps_To","value":"8587/0"},{"name":"Maps_To","value":"Ectopic hamartomatous thymoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266098"}]}}{"C46105":{"preferredName":"Thyroid Gland Spindle Epithelial Tumor with Thymus-Like Elements","code":"C46105","definitions":[{"definition":"A rare, slow growing malignant tumor of the thyroid gland arising from intrathyroidal thymic tissue. It is characterized by a lobulated architectural pattern and the presence of a biphasic cellular population composed of spindle epithelial cells and glandular cells.  A small number of cases are composed exclusively of spindle epithelial cells or glandular cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Spindle Epithelial Tumor with Thymus-Like Elements","termGroup":"PT","termSource":"NCI"},{"termName":"SETTLE","termGroup":"AB","termSource":"NCI"},{"termName":"Spindle Epithelial Tumor with Thymus-Like Elements","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8588/3"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Spindle_Cell_Tumor_with_Thymus-Like_Differentiation"},{"name":"Maps_To","value":"8588/3"},{"name":"Maps_To","value":"SETTLE"},{"name":"Maps_To","value":"Spindle epithelial tumor with thymus-like differentiation"},{"name":"Maps_To","value":"Spindle epithelial tumor with thymus-like element"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266099"}]}}{"C46106":{"preferredName":"Intrathyroid Thymic Carcinoma","code":"C46106","definitions":[{"definition":"A rare primary carcinoma of the thyroid gland, composed of groups of carcinoma cells with thymic epithelial differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intrathyroid Thymic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"CASTLE","termGroup":"AB","termSource":"NCI"},{"termName":"CD5-Positive Thyroid Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intrathyroidal Carcinoma Showing Thymus-Like Elements","termGroup":"AQS","termSource":"NCI"},{"termName":"Thyroid Gland Carcinoma Showing Thymus-Like Differentiation","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8589/3"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Carcinoma_Showing_Thymus-Like_Differentiation"},{"name":"Maps_To","value":"8589/3"},{"name":"Maps_To","value":"Carcinoma showing thymus-like differentiation"},{"name":"Maps_To","value":"Carcinoma showing thymus-like element"},{"name":"Maps_To","value":"CASTLE"},{"name":"Maps_To","value":"Intrathyroid thymic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266100"}]}}{"C4862":{"preferredName":"Ovarian Sex Cord-Stromal Tumor","code":"C4862","definitions":[{"definition":"A benign or malignant neoplasm that arises from the ovary and is composed of granulosa cells, Sertoli cells, Leydig cells, theca cells, and fibroblasts.  Representative examples include thecoma, fibroma, Sertoli cell tumor, and granulosa cell tumor.","type":"DEFINITION","source":"NCI"},{"definition":"A sex cord-stromal tumor that occurs in the ovary.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Ovarian Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Sex Cord-Stromal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Tumor of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Ovarian_Sex_Cord-Stromal_Tumor"},{"name":"Maps_To","value":"8590/1"},{"name":"Maps_To","value":"Ovarian stromal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0600113"}]}}{"C3794":{"preferredName":"Sex Cord-Stromal Tumor","code":"C3794","definitions":[{"definition":"A neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, 10% of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of cancer that forms in the tissues that support the ovaries or testes. These tumors may release sex hormones. Sex cord-gonadal stromal tumors include granulosa cell, Sertoli cell, and Leydig cell tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor arising in the ovary or testis. It is composed of one or more of the following: granulosa cells, Leydig cells, Sertoli cells, and/or fibroblasts.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Sex Cord-Stromal Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8590/1"},{"name":"Legacy Concept Name","value":"Sex_Cord-Stromal_Tumor"},{"name":"Maps_To","value":"8590/1"},{"name":"Maps_To","value":"Gonadal stromal tumor, NOS"},{"name":"Maps_To","value":"Sex cord tumor, NOS"},{"name":"Maps_To","value":"Sex cord-gonadal stromal tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206724"}]}}{"C66748":{"preferredName":"Testicular Sex Cord-Stromal Tumor, Not Otherwise Specified","code":"C66748","definitions":[{"definition":"A sex cord-stromal tumor of the testis in which the neoplastic cells do not show specific differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Sex Cord-Stromal Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Gonadal Stromal Tumor with Indeterminate Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Stromal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Testicular Sex Cord-Gonadal Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Testicular Sex Cord-Stromal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8591/1"},{"name":"Legacy Concept Name","value":"Sex_Cord-Gonadal_Stromal_Tumor_Incompletely_Differentiated"},{"name":"Maps_To","value":"8591/1"},{"name":"Maps_To","value":"Sex cord-gonadal stromal tumor, incompletely differentiated"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266102"}]}}{"C66991":{"preferredName":"Testicular Mixed Sex Cord-Stromal Tumor","code":"C66991","definitions":[{"definition":"A sex cord-stromal tumor of the testis which may contain any combination of cell types, for example Sertoli cells, Leydig cells, and granulosa cells. Symptoms include testicular swelling and gynecomastia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Mixed Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Testicular Sex Cord-Gonadal Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Testicular Sex Cord-Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Gonadal Stromal Tumor, Mixed Forms","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Gonadal Stromal Tumor, Mixed Forms","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8592/1"},{"name":"Legacy Concept Name","value":"Testicular_Sex_Cord-Gonadal_Stromal_Tumor_Mixed_Forms"},{"name":"Maps_To","value":"8592/1"},{"name":"Maps_To","value":"Sex cord-gonadal stromal tumor, mixed forms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266103"}]}}{"C66749":{"preferredName":"Ovarian Stromal Tumor with Minor Sex Cord Elements","code":"C66749","definitions":[{"definition":"A rare, benign sex cord-stromal tumor of the ovary characterized by the presence of a fibrothecomatous stroma and scattered sex cord elements. Although it is usually hormonally inactive, cases associated with endometrial hyperplasia or adenocarcinoma have been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Stromal Tumor with Minor Sex Cord Elements","termGroup":"PT","termSource":"NCI"},{"termName":"Stromal Tumor with Minor Sex Cord Elements","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8593/1"},{"name":"Legacy Concept Name","value":"Stromal_Tumor_with_Minor_Sex_Cord_Elements"},{"name":"Maps_To","value":"8593/1"},{"name":"Maps_To","value":"Stromal tumor with minor sex cord elements"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1883177"}]}}{"C5241":{"preferredName":"Mixed Germ Cell-Sex Cord-Stromal Tumor","code":"C5241","definitions":[{"definition":"A biphasic neoplasm that arises from the ovary or the testis. It is characterized by the presence of neoplastic germ cells and neoplastic sex cord-stromal cells. It includes the gonadoblastoma and mixed germ cell-sex cord stromal tumor, unclassifiable.","type":"DEFINITION","source":"NCI"},{"definition":"A biphasic tumor that arises from the ovary or the testis. It is characterized by the presence of neoplastic germ cells and neoplastic sex cord-stromal cells; examples include the gonadoblastoma and mixed germ cell-sex cord stromal tumor, unclassifiable.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Mixed Germ Cell-Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Germ Cell-Sex Cord Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Germ Cell-Sex Cord Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Germ Cell-Sex Cord-Stromal Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Mixed_Germ_Cell-Sex_Cord-Stromal_Tumor"},{"name":"Maps_To","value":"8594/1"},{"name":"Maps_To","value":"Mixed germ cell-sex cord-stromal tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321220"}]}}{"C3405":{"preferredName":"Thecoma","code":"C3405","definitions":[{"definition":"An ovarian or testicular stromal tumor characterized by the presence of lipid-rich neoplastic spindle cells. In females, uterine bleeding is the most common symptom. A minority of post-menopausal women with thecoma have an associated endometrial adenocarcinoma or rarely a malignant mixed mullerian tumor or endometrial stromal sarcoma. Rare cases with nuclear atypia and mitotic activity may metastasize. In males, thecomas are rare and they usually present as slow growing, sometimes painful masses. Metastases have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thecoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8600/0"},{"name":"Legacy Concept Name","value":"Thecoma"},{"name":"Maps_To","value":"8600/0"},{"name":"Maps_To","value":"Theca cell tumor"},{"name":"Maps_To","value":"Thecoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0039747"}]}}{"C6929":{"preferredName":"Malignant Ovarian Thecoma","code":"C6929","definitions":[{"definition":"A malignant sex-cord neoplasm of the ovary, originating from theca cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thecoma of the ovary which may metastasize to another anatomic site. It is usually characterized by nuclear atypia and mitotic activity. Malignant thecomas are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Thecoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ovarian Thecal Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ovarian Thecal Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecoma of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8600/3"},{"name":"Legacy Concept Name","value":"Malignant_Thecoma"},{"name":"Maps_To","value":"8600/3"},{"name":"Maps_To","value":"Thecoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334398"}]}}{"C4203":{"preferredName":"Ovarian Luteinized Thecoma","code":"C4203","definitions":[{"definition":"A variant of ovarian thecoma characterized by the presence of lutein cells. It is associated with a lower frequency of estrogenic manifestations compared to typical thecomas. In a minority of cases androgenic manifestations are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Luteinized Thecoma","termGroup":"PT","termSource":"NCI"},{"termName":"Luteinized Ovarian Thecoma","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinized Thecoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinized Thecoma of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8601/0"},{"name":"Legacy Concept Name","value":"Luteinized_Thecoma"},{"name":"Maps_To","value":"8601/0"},{"name":"Maps_To","value":"Thecoma, luteinized"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334399"}]}}{"C4204":{"preferredName":"Ovarian Sclerosing Stromal Tumor","code":"C4204","definitions":[{"definition":"A benign ovarian stromal tumor characterized by the presence of cellular areas which contain fibroblasts and round cells. The cellular areas are separated by sclerotic or edematous hypocellular tissue. Symptoms include abdominal discomfort and menstrual abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sclerosing Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Sclerosing Stromal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Tumor of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8602/0"},{"name":"Legacy Concept Name","value":"Ovarian_Sclerosing_Stromal_Tumor"},{"name":"Maps_To","value":"8602/0"},{"name":"Maps_To","value":"Sclerosing stromal tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334400"}]}}{"C3202":{"preferredName":"Ovarian Stromal Luteoma","code":"C3202","definitions":[{"definition":"A benign neoplasm of the ovary, composed of leuteinized granulosa-theca cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign ovarian stromal tumor in which more than 90% of the tumor cells resemble steroid hormone-secreting cells. Crystals of Reinke are not present. It occurs in post-menopausal women and it is usually associated with estrogenic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Stromal Luteoma","termGroup":"PT","termSource":"NCI"},{"termName":"Luteal Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Luteal Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Luteoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8610/0"},{"name":"Legacy Concept Name","value":"Luteoma"},{"name":"Maps_To","value":"8610/0"},{"name":"Maps_To","value":"Luteinoma"},{"name":"Maps_To","value":"Luteoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024167"}]}}{"C66750":{"preferredName":"Adult Granulosa Cell Tumor","code":"C66750","definitions":[{"definition":"A low-grade malignant sex cord-stromal tumor occurring in the ovary and rarely in the testis. It is composed of granulosa cells in an often fibrothecomatous stroma. The neoplastic cells may form various patterns including the microfollicular, which is characterized by the presence of Call-Exner bodies, macrofollicular, insular, trabecular, and diffuse pattern. In females, it affects middle aged to post-menopausal women. Signs and symptoms include abdominal mass, hemoperitoneum, and ascites. Estrogenic and rarely androgenic manifestations may be present. The vast majority of cases present as stage I tumors; however, all tumors have a potential for aggressive clinical course. In males, it is reported in the age range of 16-76 years and the average age at presentation is 44 years. A minority of patients have gynecomastia. Metastases have been reported in a minority of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Type Granulosa Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8620/1"},{"name":"Legacy Concept Name","value":"Adult_Type_Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8620/1"},{"name":"Maps_To","value":"Adult granulosa cell tumor"},{"name":"Maps_To","value":"Granulosa cell tumor, adult type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879643"}]}}{"C3070":{"preferredName":"Granulosa Cell Tumor","code":"C3070","definitions":[{"definition":"A slow-growing sex cord-stromal tumor characterized by the presence of granulosa-like cells and Call-Exner bodies. It is almost always found in the ovary and rarely in the testis. There are two types of granulosa cell tumors: the adult and the juvenile.","type":"DEFINITION","source":"NCI"},{"definition":"A slow-growing, malignant tumor that is characterized by the presence of granulosa-like cells, and which is almost always found in the ovary. In rare cases, it has also been found in the testicle.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of slow-growing, malignant tumor that usually affects the ovary.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Granulosa Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8620/1"},{"name":"Maps_To","value":"Granulosa cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018206"}]}}{"C4205":{"preferredName":"Malignant Granulosa Cell Tumor","code":"C4205","definitions":[{"definition":"A granulosa cell tumor which has an aggressive clinical course and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the ovary, originating from granulosa cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Granulosa Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8620/3"},{"name":"Legacy Concept Name","value":"Malignant_Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8620/3"},{"name":"Maps_To","value":"Granulosa cell carcinoma"},{"name":"Maps_To","value":"Granulosa cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334401"}]}}{"C66751":{"preferredName":"Granulosa Cell-Theca Cell Tumor","code":"C66751","definitions":[{"definition":"A general term used to describe sex cord-stromal tumors characterized by the presence of granulosa cells in a thecomatous/fibrothecomatous background.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granulosa Cell-Theca Cell Tumor","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8621/1"},{"name":"Legacy Concept Name","value":"Granulosa_Cell-Theca_Cell_Neoplasm"},{"name":"Maps_To","value":"8621/1"},{"name":"Maps_To","value":"Granulosa cell-theca cell tumor"},{"name":"Maps_To","value":"Theca cell-granulosa cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334402"}]}}{"C4207":{"preferredName":"Juvenile Granulosa Cell Tumor","code":"C4207","definitions":[{"definition":"A rare type of tumor derived from the granulosa cells in the ovary or testis. Ninety percent of girls with the tumor will have low stage disease, which is curable with surgery alone. In males, it usually presents in infancy (median age, 6 days), which is treated with surgery alone.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A sex cord-stromal tumor occurring in the ovary and testis. In females it occurs predominantly in the first three decades of life and presents unilaterally as stage I disease in the vast majority of cases. It is characterized by the presence of granulosa cells forming macrofollicular structures. The majority of cases have a good prognosis. In males it represents the most frequent congenital testicular neoplasm, and the vast majority of cases occur in the perinatal period. It presents as a scrotal or abdominal mass, and it more often affects the left testis. Approximately 20% of the patients have ambiguous external genitalia. It is characterized by the presence of cystic spaces lined by granulosa cells and cells resembling theca cells. Metastases have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Juvenile Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Juvenile Type Granulosa Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Type Granulosa Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8622/1"},{"name":"Legacy Concept Name","value":"Juvenile_Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8622/1"},{"name":"Maps_To","value":"Granulosa cell tumor, juvenile"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334403"}]}}{"C4208":{"preferredName":"Ovarian Sex Cord Tumor with Annular Tubules","code":"C4208","definitions":[{"definition":"An ovarian sex cord-stromal tumor characterized by the presence of Sertoli cells forming annular tubules. It may be associated with Peutz-Jeghers syndrome. Cases associated with Peutz-Jeghers syndrome have followed a benign clinical course. Cases which are not associated with Peutz-Jeghers syndrome have been reported having a clinically malignant course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sex Cord Tumor with Annular Tubules","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Sertoli Cell Tumor, Annular Tubular Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Sex Cord Neoplasm with Annular Tubules","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8623/1"},{"name":"Legacy Concept Name","value":"Sex_Cord_Tumor_with_Annular_Tubules"},{"name":"Maps_To","value":"8623/1"},{"name":"Maps_To","value":"Sex cord tumor with annular tubules"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519276"}]}}{"C67012":{"preferredName":"Benign Sertoli Cell Tumor","code":"C67012","definitions":[{"definition":"A Sertoli cell tumor of the testis or the ovary which remains localized and does not metastasize to another anatomic site.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the testis or ovary, originating from Sertoli cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Benign Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8630/0"},{"name":"Legacy Concept Name","value":"Benign_Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8630/0"},{"name":"Maps_To","value":"Androblastoma, benign"},{"name":"Maps_To","value":"Arrhenoblastoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334405"}]}}{"C39976":{"preferredName":"Sertoli Cell Tumor","code":"C39976","definitions":[{"definition":"A sex cord-stromal tumor of the testis or the ovary. It is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent. It may be associated with Peutz-Jeghers syndrome.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A sex cord-stromal tumor of the testis or the ovary. It is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent. It may be associated with Peutz-Jeghers syndrome. In males, the presenting symptom is a slow growing testicular mass. Most cases follow a benign clinical course. In females it may present with estrogenic or androgenic manifestations. The vast majority of cases have a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8630/1"},{"name":"ICD-O-3_Code","value":"8640/1"},{"name":"Legacy Concept Name","value":"Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8640/1"},{"name":"Maps_To","value":"Androblastoma, NOS"},{"name":"Maps_To","value":"Arrhenoblastoma, NOS"},{"name":"Maps_To","value":"Pick tubular adenoma"},{"name":"Maps_To","value":"Sertoli cell adenoma"},{"name":"Maps_To","value":"Sertoli cell tumor, NOS"},{"name":"Maps_To","value":"Testicular adenoma"},{"name":"Maps_To","value":"Tubular androblastoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036769"}]}}{"C67006":{"preferredName":"Malignant Sertoli Cell Tumor","code":"C67006","definitions":[{"definition":"A Sertoli cell tumor that arises from the testis or the ovary. It is characterized by nuclear pleomorphism, increased mitotic activity and necrotic changes. Metastases may be present at diagnosis.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the testis or ovary, originating from Sertoli cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8630/3"},{"name":"ICD-O-3_Code","value":"8640/3"},{"name":"Legacy Concept Name","value":"Malignant_Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8640/3"},{"name":"Maps_To","value":"Androblastoma, malignant"},{"name":"Maps_To","value":"Arrhenoblastoma, malignant"},{"name":"Maps_To","value":"Sertoli cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334406"}]}}{"C4209":{"preferredName":"Well Differentiated Ovarian Sertoli-Leydig Cell Tumor","code":"C4209","definitions":[{"definition":"A Sertoli-Leydig tumor of the ovary characterized by the presence of Sertoli cells in tubules without evidence of significant nuclear atypia or mitotic activity. Primitive gonadal stromal cells are not present. It usually follows a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8631/0"},{"name":"Legacy Concept Name","value":"Benign_Androblastoma"},{"name":"Maps_To","value":"8631/0"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, well differentiated"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1314745"}]}}{"C39968":{"preferredName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor","code":"C39968","definitions":[{"definition":"A Sertoli-Leydig cell tumor of the ovary characterized by the presence of spindle-shaped gonadal stromal cells and Sertoli cells, some of which are atypical. Leydig cells are also present forming clusters at the periphery of the cellular aggregates. Metastases have been reported in a minority of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Intermediate Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8631/1"},{"name":"Legacy Concept Name","value":"Intermediate_Differentiated_Ovarian_Sertoli-Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8631/1"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor of intermediate differentiation"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor of intermediate differentiation, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1318541"}]}}{"C2880":{"preferredName":"Ovarian Sertoli-Leydig Cell Tumor","code":"C2880","definitions":[{"definition":"A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. It may be associated with trisomy 8.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. Signs and symptoms include hirsutism, menorrhagia and metrorrhagia. It may be associated with trisomy 8.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of ovarian tumor in which the tumor cells secrete a male sex hormone. This may cause virilization (the appearance of male physical characteristics in females).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Androblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Arrhenoblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Sertoli-Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Androblastoma"},{"name":"Maps_To","value":"8631/1"},{"name":"Maps_To","value":"Androblastoma, NOS"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0003810"}]}}{"C4210":{"preferredName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor","code":"C4210","definitions":[{"definition":"A Sertoli-Leydig tumor of the ovary characterized by the presence of a sarcomatoid stroma which contains primitive gonadal stromal cells. It may behave in a malignant fashion and metastasize to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8631/3"},{"name":"Legacy Concept Name","value":"Malignant_Androblastoma"},{"name":"Maps_To","value":"8631/3"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, poorly differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266105"}]}}{"C3072":{"preferredName":"Ovarian Gynandroblastoma","code":"C3072","definitions":[{"definition":"A rare neoplasm arising from the ovary. Although it may occur at any age, it is more often seen in young females. Morphologically, it is characterized by a mixture of two cellular populations: well differentiated Sertoli cells and granulosa cells, with the latter constituting at least ten percent of the neoplasm. The vast majority of cases are stage I lesions at presentation and produce either estrogenic or androgenic manifestations. Although it may present as a massive ovarian tumor, it usually follows a benign clinical course. Very rare case reports of testicular lesions morphologically resembling gynandroblastomas are in fact variants of juvenile granulose cell tumor, or Sertoli cell tumor, or a combination of both.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Gynandroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gynandroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gynandroblastoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Gynandroblastoma of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8632/1"},{"name":"Legacy Concept Name","value":"Gynandroblastoma"},{"name":"Maps_To","value":"8632/1"},{"name":"Maps_To","value":"Gynandroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018413"}]}}{"C39974":{"preferredName":"Ovarian Sertoli-Leydig Cell Tumor with Retiform Elements","code":"C39974","definitions":[{"definition":"A Sertoli-Leydig cell tumor characterized by the presence of spaces that resemble rete testis (retiform elements).  These spaces form anastomosing patterns and comprise at least ten percent but less than ninety percent of the tumor.  When the retiform elements comprise ninety percent or more of the tumor, the term retiform Sertoli-Leydig cell tumor is used.  A minority of patients may have an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sertoli-Leydig Cell Tumor with Retiform Elements","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Sertoli-Leydig_Cell_Tumor_with_Retiform_Elements"},{"name":"Maps_To","value":"8633/1"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, retiform"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266106"}]}}{"C39972":{"preferredName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","code":"C39972","definitions":[{"definition":"An ovarian Sertoli-Leydig cell tumor of intermediate differentiation, characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","termGroup":"PT","termSource":"NCI"},{"termName":"Intermediate Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8634/1"},{"name":"Legacy Concept Name","value":"Intermediate_Differentiated_Ovarian_Sertoli-Leydig_Cell_Tumor_Variant_with_Heterologous_Elements"},{"name":"Maps_To","value":"8634/1"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266107"}]}}{"C39973":{"preferredName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","code":"C39973","definitions":[{"definition":"An ovarian poorly differentiated Sertoli-Leydig cell tumor. It is characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8634/3"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Ovarian_Sertoli-Leydig_Cell_Tumor_Variant_with_Heterologous_Elements"},{"name":"Maps_To","value":"8634/3"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266108"}]}}{"C4211":{"preferredName":"Ovarian Sertoli Cell Tumor with Lipid Storage","code":"C4211","definitions":[{"definition":"A Sertoli cell tumor that arises from the ovary and is characterized by the presence of cells that are distended by the presence of intracytoplasmic lipid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sertoli Cell Tumor with Lipid Storage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tubular_Androblastoma_with_Lipid_Storage"},{"name":"Maps_To","value":"8641/0"},{"name":"Maps_To","value":"Sertoli cell tumor with lipid storage"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334408"}]}}{"C39944":{"preferredName":"Testicular Large Cell Calcifying Sertoli Cell Tumor","code":"C39944","definitions":[{"definition":"A testicular Sertoli cell tumor characterized by the presence of large polygonal cells with eosinophilic cytoplasm in a myxoid and hyalinized stroma. Calcifications may be present in the stroma. Malignant behavior is uncommon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Large Cell Calcifying Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"LCCSCT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8642/1"},{"name":"Legacy Concept Name","value":"Testicular_Large_Cell_Calcifying_Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8642/1"},{"name":"Maps_To","value":"Large cell calcifying Sertoli cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266109"}]}}{"C4212":{"preferredName":"Benign Leydig Cell Tumor","code":"C4212","definitions":[{"definition":"A Leydig cell tumor which does not recur or metastasize. Morphologically, there is no evidence of cellular atypia, increased mitotic activity, necrosis, or vascular invasion.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the testis originating from interstitial (Leydig) cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Benign Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Interstitial Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Interstitial Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8650/0"},{"name":"Legacy Concept Name","value":"Benign_Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8650/0"},{"name":"Maps_To","value":"Interstitial cell tumor, benign"},{"name":"Maps_To","value":"Leydig cell tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334409"}]}}{"C3188":{"preferredName":"Leydig Cell Tumor","code":"C3188","definitions":[{"definition":"A sex cord-stromal tumor occurring in the testis and rarely in the ovary. It is predominantly or completely composed of Leydig cells which may contain crystals of Reinke. In males it usually presents as a painless testicular enlargement and it may be associated with gynecomastia and decreased libido. The majority of the cases have a benign clinical course. Approximately 10% of the cases have a malignant clinical course and metastasize. In females it may be associated with androgenic manifestations and it follows a benign clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"A sex cord-stromal tumor, comprising Leydig cells, either predominantly or completely, occurring in the testis and rarely in the ovary.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Interstitial Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Interstitial Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8650/1"},{"name":"Legacy Concept Name","value":"Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8650/1"},{"name":"Maps_To","value":"Interstitial cell tumor, NOS"},{"name":"Maps_To","value":"Leydig cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023601"}]}}{"C4213":{"preferredName":"Malignant Leydig Cell Tumor","code":"C4213","definitions":[{"definition":"A Leydig cell tumor characterized by large tumor size, the presence of cytologic atypia, increased mitotic activity, necrosis, and vascular invasion. Approximately 10% of the testicular Leydig cell tumors show malignant characteristics and metastasize. Leydig cell tumors of the ovary follow a benign clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the testis originating from interstitial (Leydig) cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Interstitial Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Interstitial Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8650/3"},{"name":"Legacy Concept Name","value":"Malignant_Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8650/3"},{"name":"Maps_To","value":"Interstitial cell tumor, malignant"},{"name":"Maps_To","value":"Leydig cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334410"}]}}{"C4214":{"preferredName":"Ovarian Hilus Cell Tumor","code":"C4214","definitions":[{"definition":"A benign Leydig cell tumor which arises in the hilar area of the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Hilus Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Hilar Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hilar Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Hilar Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Hilus Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hilus Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Hilar Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8660/0"},{"name":"Legacy Concept Name","value":"Hilar_Cell_Tumor"},{"name":"Maps_To","value":"8660/0"},{"name":"Maps_To","value":"Hilar cell tumor"},{"name":"Maps_To","value":"Hilus cell tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346179"}]}}{"C4215":{"preferredName":"Ovarian Steroid Cell Tumor","code":"C4215","definitions":[{"definition":"An ovarian tumor in which the vast majority of the cells (more than 90% of the tumor cells) resemble steroid hormone-secreting cells. It usually presents with androgenic manifestations. Approximately one-third of the cases follow a malignant clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Steroid Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Cell Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Cell Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Lipid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Lipid Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Lipoid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Steroid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Steroid Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Steroid Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8670/0"},{"name":"Legacy Concept Name","value":"Steroid_Cell_Tumor_of_the_Ovary"},{"name":"Maps_To","value":"8670/0"},{"name":"Maps_To","value":"Lipid cell tumor of ovary"},{"name":"Maps_To","value":"Lipoid cell tumor of ovary"},{"name":"Maps_To","value":"Masculinovoblastoma"},{"name":"Maps_To","value":"Steroid cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334412"}]}}{"C39981":{"preferredName":"Malignant Ovarian Steroid Cell Tumor","code":"C39981","definitions":[{"definition":"A steroid tumor of the ovary which has an aggressive clinical course and metastasizes to other anatomic sites. It is usually of large size and is characterized by nuclear atypia, increased mitotic activity, hemorrhage, and necrosis. Sometimes, patients have abdominal metastases at presentation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Steroid Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8670/3"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Steroid_Cell_Tumor"},{"name":"Maps_To","value":"8670/3"},{"name":"Maps_To","value":"Steroid cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266110"}]}}{"C2860":{"preferredName":"Adrenal Rest Tumor","code":"C2860","definitions":[{"definition":"A benign, testicular or ovarian tumor, derived from adrenal embryonic rest cells. It is composed of hyperplastic adrenal cortical tissue, and it is associated with congenital adrenal hyperplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Rest Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Rest Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8671/0"},{"name":"Legacy Concept Name","value":"Adrenal_Rest_Neoplasm"},{"name":"Maps_To","value":"8671/0"},{"name":"Maps_To","value":"Adrenal rest tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001630"}]}}{"C48314":{"preferredName":"Non-Metastatic Paraganglioma","code":"C48314","definitions":[{"definition":"A benign neoplasm arising from paraganglia located along nerves composed of neoplastic neuroectodermal chromaffin cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A paraganglioma that is confined to the site of origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Metastatic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8680/0"},{"name":"Legacy Concept Name","value":"Benign_Paraganglionic_Neoplasm"},{"name":"Maps_To","value":"8680/0"},{"name":"Maps_To","value":"Paraganglioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346416"}]}}{"C3308":{"preferredName":"Paraganglioma","code":"C3308","definitions":[{"definition":"A neoplasm arising from paraganglia located along the sympathetic or parasympathetic nerves.  Infrequently, it may arise outside the usual distribution of the sympathetic and parasympathetic paraganglia.  Tumors arising from the adrenal gland medulla are called pheochromocytomas.  Morphologically, paragangliomas usually display a nesting (Zellballen) growth pattern.  There are no reliable morphologic criteria to distinguish between benign and malignant paragangliomas.  The only definitive indicator of malignancy is the presence of regional or distant metastases.","type":"DEFINITION","source":"NCI"},{"definition":"A rare, usually benign tumor that develops from cells of the paraganglia. Paraganglia are a collection of cells that came from embryonic nervous tissue, and are found near the adrenal glands and some blood vessels and nerves. Paragangliomas that develop in the adrenal gland are called pheochromocytomas. Those that develop outside of the adrenal glands near blood vessels or nerves are called glomus tumors or chemodectomas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglion Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglion Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglionic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Paraganglion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8680/1"},{"name":"Legacy Concept Name","value":"Paraganglionic_Neoplasm"},{"name":"Maps_To","value":"8680/1"},{"name":"Maps_To","value":"Paraganglioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030421"}]}}{"C8559":{"preferredName":"Metastatic Paraganglioma","code":"C8559","definitions":[{"definition":"A malignant neoplasm arising from paraganglia located along nerves composed of neoplastic neuroectodermal chromaffin cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A paraganglioma that metastasizes to regional or distant anatomic sites.  Extraadrenal paragangliomas have a higher tendency to metastasize, as compared to pheochromocytomas.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglion Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglion Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglionic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglion Neoplasm, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8680/3"},{"name":"Legacy Concept Name","value":"Malignant_Paraganglionic_Neoplasm"},{"name":"Maps_To","value":"8680/3"},{"name":"Maps_To","value":"Malignant neoplasm of aortic body and other paraganglia"},{"name":"Maps_To","value":"Malignant neoplasm: Aortic body and other paraganglia"},{"name":"Maps_To","value":"Paraganglioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1533592"}]}}{"C4216":{"preferredName":"Sympathetic Paraganglioma","code":"C4216","definitions":[{"definition":"A paraganglioma arising from the chromaffin cells of the paraganglia that are located along the sympathetic nerves.  It includes extra-adrenal paragangliomas and paragangliomas that arise from the adrenal medulla.  The latter are commonly referred to as pheochromocytomas.  Representative examples of extra-adrenal sympathetic paragangliomas include the bladder, and superior and inferior paraaortic paragangliomas.  Clinical signs are related to the secretion of catecholamines resulting in hypertension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sympathetic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Chromaffin Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Chromaffin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Chromaffinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sympathetic Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8681/1"},{"name":"Legacy Concept Name","value":"Sympathetic_Paraganglioma"},{"name":"Maps_To","value":"8700/0"},{"name":"Maps_To","value":"Chromaffin tumor"},{"name":"Maps_To","value":"Chromaffinoma"},{"name":"Maps_To","value":"Sympathetic paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334415"}]}}{"C4217":{"preferredName":"Parasympathetic Paraganglioma","code":"C4217","definitions":[{"definition":"An extra-adrenal paraganglioma that arises from paraganglia located along the parasympathetic nerves.  Representative examples include aorticopulmonary, carotid body, jugulotympanic, and mediastinal paragangliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parasympathetic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Parasympathetic Extra-Adrenal Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Parasympathetic Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8682/1"},{"name":"Legacy Concept Name","value":"Parasympathetic_Paraganglioma"},{"name":"Maps_To","value":"8682/1"},{"name":"Maps_To","value":"Parasympathetic paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334416"}]}}{"C188229":{"preferredName":"Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor","code":"C188229","definitions":[{"definition":"A usually indolent neuroendocrine neoplasm that almost exclusively arises in the second part of the duodenum. Rare sites of involvement include jejunum, pylorus, appendix, thymus, and lung. It is a triphasic tumor consisting of a mixture of epithelioid neuroendocrine cells, Schwann-like cells, and ganglion cell-like elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"CoGNET","termGroup":"AB","termSource":"NCI"},{"termName":"Gangliocytic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Gangliocytic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Gangliocytic Paraganglioma","termGroup":"AQS","termSource":"NCI"},{"termName":"MiGNeN","termGroup":"AB","termSource":"NCI"},{"termName":"Mixed Ganglioneuroma-Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8683/0"},{"name":"Maps_To","value":"Gangliocytic paraganglioma"},{"name":"NCI_META_CUI","value":"CL1793076"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3061":{"preferredName":"Jugulotympanic Paraganglioma","code":"C3061","definitions":[{"definition":"An extra-adrenal parasympathetic paraganglioma arising from paraganglia in the base of the skull and middle ear.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Jugulotympanic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Glomus Jugulare Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Glomus Jugulare Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Jugular Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Glomus Jugulare","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Glomus Jugulare","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Glomus Jugulare","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Glomus Jugulare","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8690/1"},{"name":"Legacy Concept Name","value":"Jugulotympanic_Paraganglioma"},{"name":"Maps_To","value":"8690/1"},{"name":"Maps_To","value":"Glomus jugulare tumor, NOS"},{"name":"Maps_To","value":"Jugular paraganglioma"},{"name":"Maps_To","value":"Jugulotympanic paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017671"}]}}{"C4218":{"preferredName":"Aorticopulmonary Paraganglioma","code":"C4218","definitions":[{"definition":"An extra-adrenal parasympathetic paraganglioma that arises from paraganglia adjacent to the base of the heart and great vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aorticopulmonary Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Aortic Body Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Aortic Body Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Aortic Body Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of the Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Aortic Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8691/1"},{"name":"Legacy Concept Name","value":"Aortic_Body_Paraganglioma"},{"name":"Maps_To","value":"8691/1"},{"name":"Maps_To","value":"Aortic body paraganglioma"},{"name":"Maps_To","value":"Aortic body tumor"},{"name":"Maps_To","value":"Aorticopulmonary paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334417"}]}}{"C2932":{"preferredName":"Carotid Body Paraganglioma","code":"C2932","definitions":[{"definition":"A parasympathetic paraganglioma arising from paraganglia adjacent to or in the bifurcation of the common carotid artery.  Most patients present with a slow growing, painless mass in the neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carotid Body Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Carotid Body Chemodectoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carotid Body Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Chemodectoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of Carotid Body","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of the Carotid Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Carotid Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Carotid Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8692/1"},{"name":"Legacy Concept Name","value":"Carotid_Body_Paraganglioma"},{"name":"Maps_To","value":"8693/1"},{"name":"Maps_To","value":"Carotid body paraganglioma"},{"name":"Maps_To","value":"Carotid body tumor"},{"name":"Maps_To","value":"Chemodectoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1866553"}]}}{"C3309":{"preferredName":"Extra-Adrenal Paraganglioma","code":"C3309","definitions":[{"definition":"A paraganglioma arising from sympathetic or parasympathetic paraganglia outside the adrenal gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extra-Adrenal Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Extra-Adrenal Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Extraadrenal Paraganglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8693/1"},{"name":"Legacy Concept Name","value":"Extra-Adrenal_Paraganglioma"},{"name":"Maps_To","value":"8693/1"},{"name":"Maps_To","value":"Extra-adrenal paraganglioma, NOS"},{"name":"NCI_META_CUI","value":"CL497918"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4219":{"preferredName":"Metastatic Extra-Adrenal Paraganglioma","code":"C4219","definitions":[{"definition":"An extra-adrenal paraganglioma that metastasizes to regional or distant anatomic sites.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Extra-Adrenal Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Extra-Adrenal Paraganglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8693/3"},{"name":"Legacy Concept Name","value":"Malignant_Extra-Adrenal_Paraganglioma"},{"name":"Maps_To","value":"8693/3"},{"name":"Maps_To","value":"Extra-adrenal paraganglioma, malignant"},{"name":"Maps_To","value":"Nonchromaffin paraganglioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334418"}]}}{"C3326":{"preferredName":"Adrenal Gland Pheochromocytoma","code":"C3326","definitions":[{"definition":"A neuroendocrine neoplasm of the sympathetic nervous system that arises from the chromaffin cells of the adrenal medulla and secretes catecholamines. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","type":"DEFINITION","source":"NCI"},{"definition":"Tumor that forms in the center of the adrenal gland (gland located above the kidney) that causes it to make too much adrenaline. Pheochromocytomas are usually benign (not cancer) but can cause high blood pressure, pounding headaches, heart palpitations, flushing of the face, nausea, and vomiting.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adrenal Gland Pheochromocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Gland Chromaffin Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Chromaffinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Medullary Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Medullary Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chromaffin Paraganglioma of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Intraadrenal Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"PCC","termGroup":"AB","termSource":"NCI"},{"termName":"Pheochromocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8700/0"},{"name":"Legacy Concept Name","value":"Pheochromocytoma"},{"name":"Maps_To","value":"8700/0"},{"name":"Maps_To","value":"Adrenal medullary paraganglioma"},{"name":"Maps_To","value":"Chromaffin paraganglioma"},{"name":"Maps_To","value":"Pheochromocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1861851"}]}}{"C4220":{"preferredName":"Metastatic Adrenal Gland Pheochromocytoma","code":"C4220","definitions":[{"definition":"A malignant neoplasm of the adrenal gland medulla.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A pheochromocytoma that metastasizes to other anatomic sites.  Common sites of metastasis include lymph nodes, bones, liver, and lung.  Morphologic features associated with malignant pheochromocytomas include: atypical mitotic figures, capsular and vascular invasion, tumor cell necrosis, and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Adrenal Gland Pheochromocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffin Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffin Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Medullary Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Medullary Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pheochromoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8700/3"},{"name":"Legacy Concept Name","value":"Malignant_Pheochromocytoma"},{"name":"Legacy Concept Name","value":"Metastatic_Pheochromocytoma"},{"name":"Maps_To","value":"8700/3"},{"name":"Maps_To","value":"Adrenal medullary paraganglioma, malignant"},{"name":"Maps_To","value":"Pheochromoblastoma"},{"name":"Maps_To","value":"Pheochromocytoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708998"}]}}{"C4221":{"preferredName":"Malignant Glomus Tumor","code":"C4221","definitions":[{"definition":"A very rare morphologic variant of glomus tumor with a size greater than 2 cm.  The tumor arises in subfascial or visceral tissues. It is characterized by the presence of atypical mitotic figures, or marked nuclear atypia, or the combination of both.  It has an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Glomus Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Glomangiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Glomus Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8710/3"},{"name":"ICD-O-3_Code","value":"8711/3"},{"name":"Legacy Concept Name","value":"Malignant_Glomus_Tumor"},{"name":"Maps_To","value":"8710/3"},{"name":"Maps_To","value":"8711/3"},{"name":"Maps_To","value":"Glomangiosarcoma"},{"name":"Maps_To","value":"Glomoid sarcoma"},{"name":"Maps_To","value":"Glomus tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266111"}]}}{"C3060":{"preferredName":"Glomus Tumor","code":"C3060","definitions":[{"definition":"A rare benign or malignant mesenchymal neoplasm arising from cells that resemble the modified smooth muscle cells of the glomus body. The majority of glomus tumors occur in the distal extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomus Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Glomus Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8711/0"},{"name":"Legacy Concept Name","value":"Glomus_Tumor"},{"name":"Maps_To","value":"8711/0"},{"name":"Maps_To","value":"Glomus tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017653"}]}}{"C4222":{"preferredName":"Glomangioma","code":"C4222","definitions":[{"definition":"A morphologic variant of the glomus tumor characterized by the presence of dilated veins, surrounded by small clusters of glomus cells. Glomangiomas are most often present in patients with multiple lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Glomuvenous Malformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8712/0"},{"name":"Legacy Concept Name","value":"Glomangioma"},{"name":"Maps_To","value":"8712/0"},{"name":"Maps_To","value":"Glomangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334421"}]}}{"C4223":{"preferredName":"Glomangiomyoma","code":"C4223","definitions":[{"definition":"A morphologic variant of the glomus tumor with architectural features similar to solid glomus tumor.  It is characterized by the presence of elongated glomus cells which resemble mature smooth muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomangiomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8713/0"},{"name":"Legacy Concept Name","value":"Glomangiomyoma"},{"name":"Maps_To","value":"8713/0"},{"name":"Maps_To","value":"Glomangiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334422"}]}}{"C121792":{"preferredName":"Malignant PEComa","code":"C121792","definitions":[{"definition":"A usually large and aggressive tumor with perivascular epithelioid cell differentiation characterized by the presence of marked nuclear atypia, pleomorphism, increased mitotic activity, necrosis, and infiltrative margins.  The most common metastatic sites are liver, lungs, lymph nodes, and bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant PEComa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PEComa, malignant"},{"name":"Maps_To","value":"Perivascular epithelioid cell tumor, malignant"},{"name":"Maps_To","value":"Perivascular epithelioid tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839062"}]}}{"C7570":{"preferredName":"Melanocytic Nevus","code":"C7570","definitions":[{"definition":"A benign (not cancer) growth on the skin that is formed by a cluster of melanocytes (cells that make a substance called melanin, which gives color to skin and eyes). A mole is usually dark and may be raised from the skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm composed of melanocytes that usually appears as a dark spot on the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Melanotic Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanocytic_Nevus"},{"name":"Maps_To","value":"8720/0"},{"name":"Maps_To","value":"Melanocytic nevus"},{"name":"Maps_To","value":"Nevus, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027960"}]}}{"C27816":{"preferredName":"Pigmented Nevus","code":"C27816","definitions":[{"definition":"A nevus characterised by the presence of excessive pigment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8720/0"},{"name":"Legacy Concept Name","value":"Pigmented_Nevus"},{"name":"Maps_To","value":"8720/0"},{"name":"Maps_To","value":"Pigmented nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3553699"}]}}{"C3074":{"preferredName":"Hairy Nevus","code":"C3074","definitions":[{"definition":"A usually benign congenital skin growth that is often pigmented and sometimes develop coarse surface hair. There is a lifetime risk of transformation to malignant melanoma which varies depending on the size of the lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hairy Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Hair Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Nevoid Hypertrichosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hairy_Nevus"},{"name":"Maps_To","value":"8720/0"},{"name":"Maps_To","value":"Hairy nevus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018508"}]}}{"C8423":{"preferredName":"Stage 0 Cutaneous Melanoma AJCC v6 and v7","code":"C8423","definitions":[{"definition":"Abnormal melanocytes (cells that make melanin, the pigment that gives skin its color) are found in the epidermis (outer layer of the skin). These abnormal melanocytes may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Melanoma in situ.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Cutaneous Melanoma AJCC v6 and v7","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Cutaneous Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma in situ of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma in situ of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Cutaneous Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Malignant Cutaneous Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Malignant Skin Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Melanoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Melanoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Skin Melanoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Skin Melanoma AJCC v6 and v7","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Skin Melanoma AJCC v7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8720/2"},{"name":"Legacy Concept Name","value":"Stage_0_Melanoma_of_the_Skin"},{"name":"Maps_To","value":"8720/2"},{"name":"Maps_To","value":"Melanoma in situ"},{"name":"Maps_To","value":"Melanoma in situ of other part of trunk"},{"name":"Maps_To","value":"Melanoma in situ of other sites"},{"name":"Maps_To","value":"Melanoma in situ of scalp and neck"},{"name":"Maps_To","value":"Melanoma in situ, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346040"}]}}{"C3224":{"preferredName":"Melanoma","code":"C3224","definitions":[{"definition":"A form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm composed of melanocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm comprised of melanocytes typically arising in the skin.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8720/3"},{"name":"Legacy Concept Name","value":"Melanoma"},{"name":"Maps_To","value":"8720/3"},{"name":"Maps_To","value":"Malignant melanoma, NOS"},{"name":"Maps_To","value":"Melanoma"},{"name":"Maps_To","value":"Melanoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025202"}]}}{"C4225":{"preferredName":"Cutaneous Nodular Melanoma","code":"C4225","definitions":[{"definition":"Nodular melanoma that arises from the skin. It may or may not arise from a pre-existing nevus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cutaneous Nodular Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Nodular Malignant Melanoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Malignant Melanoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Malignant Skin Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"ICD-O-3_Code","value":"8721/3"},{"name":"Legacy Concept Name","value":"Nodular_Melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334424"}]}}{"C4226":{"preferredName":"Balloon Cell Nevus","code":"C4226","definitions":[{"definition":"An uncommon variant of melanocytic nevus. It presents as a small pigmented skin lesion. It is characterized by the presence of large melanocytes with clear, foamy or finely vacuolated cytoplasm. It may recur if it is not completely excised.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balloon Cell Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8722/0"},{"name":"Legacy Concept Name","value":"Balloon_Cell_Nevus"},{"name":"Maps_To","value":"8722/0"},{"name":"Maps_To","value":"Balloon cell nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334425"}]}}{"C4227":{"preferredName":"Balloon Cell Melanoma","code":"C4227","definitions":[{"definition":"A rare variant of melanoma with a vertical growth phase. It presents as a nodular or polypoid skin lesion. It is characterized by the presence of nodules which contain large melanoma cells with clear, foamy or finely vacuolated cytoplasm. The prognosis is similar to that of other melanomas matched for depth of invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balloon Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Balloon Cell Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Malignant Melanoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Malignant Melanoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Malignant Skin Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Skin Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8722/3"},{"name":"Legacy Concept Name","value":"Balloon_Cell_Malignant_Skin_Melanoma"},{"name":"Maps_To","value":"8722/3"},{"name":"Maps_To","value":"Balloon cell melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334426"}]}}{"C7602":{"preferredName":"Halo Nevus","code":"C7602","definitions":[{"definition":"A melanocytic nevus characterized by circumferential depigmentation. It is usually associated with a brisk lymphocytic infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halo Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Leukoderma Acquisitum Centrifugum","termGroup":"SY","termSource":"NCI"},{"termName":"Perinevoid Leukoderma","termGroup":"SY","termSource":"NCI"},{"termName":"Perinevoid Vitiligo","termGroup":"SY","termSource":"NCI"},{"termName":"Sutton Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8723/0"},{"name":"Legacy Concept Name","value":"Halo_Nevus"},{"name":"Maps_To","value":"8723/0"},{"name":"Maps_To","value":"Halo nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474824"}]}}{"C7603":{"preferredName":"Regressing Nevus","code":"C7603","definitions":[{"definition":"A nevus associated with focal regression-like changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regressing Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Regressing_Nevus"},{"name":"Maps_To","value":"8723/0"},{"name":"Maps_To","value":"Regressing nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377589"}]}}{"C4228":{"preferredName":"Regressing Melanoma","code":"C4228","definitions":[{"definition":"A skin lesion characterized by the disappearance of the melanoma cells from the primary melanoma site. The disappearance of the malignant cells is associated with fibroplasia of the papillary dermis. According to some authors, complete regression of the primary melanoma may occur in 4-8% of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regressing Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Regressing Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8723/3"},{"name":"Legacy Concept Name","value":"Regressing_Melanoma"},{"name":"Maps_To","value":"8723/3"},{"name":"Maps_To","value":"Malignant melanoma, regressing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334427"}]}}{"C4229":{"preferredName":"Neuronevus","code":"C4229","definitions":[{"definition":"An intradermal nevus characterized by the presence of nests of atrophic nevus cells which are hyalinized and resemble nerve bundles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuronevus","termGroup":"PT","termSource":"NCI"},{"termName":"Neural Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8725/0"},{"name":"Legacy Concept Name","value":"Neuronevus"},{"name":"Maps_To","value":"8725/0"},{"name":"Maps_To","value":"Neuronevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334430"}]}}{"C9498":{"preferredName":"Melanocytoma","code":"C9498","definitions":[{"definition":"A usually benign neoplasm that arises from the sun-exposed skin, eye, and meninges. It is composed of spindle and/or epithelioid melanocytes and melanophages. It rarely progresses to melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Magnocellular Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanocytoma"},{"name":"Maps_To","value":"8726/0"},{"name":"Maps_To","value":"Magnocellular nevus"},{"name":"Maps_To","value":"Melanocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334431"}]}}{"C3694":{"preferredName":"Dysplastic Nevus","code":"C3694","definitions":[{"definition":"A type of nevus (mole) that looks different from a common mole. A dysplastic nevus is often larger with borders that are not easy to see. Its color is usually uneven and can range from pink to dark brown. Parts of the mole may be raised above the skin surface. A dysplastic nevus may develop into malignant melanoma (a type of skin cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Solitary or multiple, slightly raised pigmented melanocytic lesions with irregular borders, usually measuring more than 0.6cm in greatest dimension. Morphologically, there is melanocytic atypia and the differential diagnosis from melanoma may be difficult. Patients are at an increased risk for the development of melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dysplastic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Clark Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Clark's Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"NAD","termGroup":"AB","termSource":"NCI"},{"termName":"Nevus with Architectural Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Nevus with Architectural Disorder and Cytologic Atypia of Melanocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8727/0"},{"name":"Legacy Concept Name","value":"Dysplastic_Nevus"},{"name":"Maps_To","value":"8727/0"},{"name":"Maps_To","value":"Dysplastic nevus"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205748"}]}}{"C6890":{"preferredName":"Meningeal Melanocytosis","code":"C6890","definitions":[{"definition":"A diffuse or multifocal proliferation of uniform nevoid polygonal cells in the leptomeninges. Cells may spread into the Virchow-Robin spaces without frank invasion of the brain. Diffuse melanocytosis carries a poor prognosis even in the absence of histologic malignancy. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Melanocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Melanosis","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Meningeal Melanocytosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8728/0"},{"name":"Legacy Concept Name","value":"Diffuse_Melanocytosis"},{"name":"Maps_To","value":"8728/0"},{"name":"Maps_To","value":"Diffuse melanocytosis"},{"name":"Maps_To","value":"Meningeal melanocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266112"}]}}{"C4662":{"preferredName":"Meningeal Melanocytoma","code":"C4662","definitions":[{"definition":"A usually well differentiated melanocytic neoplasm arising from the meninges. It is characterized by the presence of epithelioid, fusiform, polyhedral, and spindle melanocytes without evidence of hemorrhage, necrosis, or high mitotic activity. Presenting symptoms include headache, vomiting, and neurological manifestations. Complete excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Leptomeningeal Melanocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytoma of Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytoma of the Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Meninges Melanocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8728/1"},{"name":"Legacy Concept Name","value":"Meningeal_Melanocytoma"},{"name":"Maps_To","value":"8728/1"},{"name":"Maps_To","value":"Meningeal melanocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266113"}]}}{"C6891":{"preferredName":"Meningeal Melanomatosis","code":"C6891","definitions":[{"definition":"A rare condition in patients with leptomeningeal melanoma characterized by diffuse or multifocal proliferation of melanoma cells in the leptomeninges. It is often associated with invasion of the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Leptomeningeal Melanomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Melanomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8728/3"},{"name":"Legacy Concept Name","value":"Melanomatosis"},{"name":"Legacy Concept Name","value":"Meningeal_Melanomatosis"},{"name":"Maps_To","value":"8728/3"},{"name":"Maps_To","value":"Meningeal melanomatosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266114"},{"name":"UMLS_CUI","value":"C1334691"}]}}{"C27095":{"preferredName":"Nonpigmented Nevus","code":"C27095","definitions":[{"definition":"A benign nevus characterized by the absence of melanin pigment in the melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonpigmented Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8730/0"},{"name":"Legacy Concept Name","value":"Nonpigmented_Nevus"},{"name":"Maps_To","value":"8730/0"},{"name":"Maps_To","value":"Achromic nevus"},{"name":"Maps_To","value":"Nonpigmented nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334432"}]}}{"C3802":{"preferredName":"Amelanotic Melanoma","code":"C3802","definitions":[{"definition":"A malignant neoplasm composed of melanocytes, which lack melanin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A melanoma characterized by the complete absence of melanin pigment in the melanoma cells. It occurs more frequently on the face and it is often associated with desmoplastic reaction.","type":"DEFINITION","source":"NCI"},{"definition":"A type of skin cancer in which the cells do not make melanin. Skin lesions are often irregular and may be pink, red, or have light brown, tan, or gray at the edges.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Amelanotic Melanoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8730/3"},{"name":"Legacy Concept Name","value":"Amelanotic_Melanoma"},{"name":"Maps_To","value":"8730/3"},{"name":"Maps_To","value":"Amelanotic melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206735"}]}}{"C4231":{"preferredName":"Junctional Nevus","code":"C4231","definitions":[{"definition":"A nevus characterized by the presence of an intraepidermal proliferation of nevus cells. The nevus cells form multiple nests in the dermal-epidermal junction. It presents as a small, slightly raised, pigmented skin lesion.","type":"DEFINITION","source":"NCI"},{"definition":"A type of nevus (mole) found at the junction (border) between the epidermis (outer) and the dermis (inner) layers of the skin. These moles may be colored and slightly raised.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Junctional Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Intraepidermal Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepidermal Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepidermal Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Junction Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Melanocytic Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Skin Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8740/0"},{"name":"Legacy Concept Name","value":"Junction_Nevus"},{"name":"Maps_To","value":"8740/0"},{"name":"Maps_To","value":"Intraepidermal nevus"},{"name":"Maps_To","value":"Junction nevus"},{"name":"Maps_To","value":"Junctional nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334433"}]}}{"C4232":{"preferredName":"Melanoma in Junctional Nevus","code":"C4232","definitions":[{"definition":"A melanoma arising from a melanocytic nevus which involves the dermal-epidermal junction of the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma in Junctional Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanoma in Junctional Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanoma of Skin in Junctional Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanoma of the Skin in Junctional Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Melanoma in Junctional Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8740/3"},{"name":"Legacy Concept Name","value":"Melanoma_in_Junctional_Nevus"},{"name":"Maps_To","value":"8740/3"},{"name":"Maps_To","value":"Malignant melanoma in junctional nevus"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334434"}]}}{"C4233":{"preferredName":"Precancerous Melanosis","code":"C4233","synonyms":[{"termName":"Precancerous Melanosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8741/2"},{"name":"Legacy Concept Name","value":"Precancerous_Melanosis"},{"name":"Maps_To","value":"8741/2"},{"name":"Maps_To","value":"Precancerous melanosis, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334435"}]}}{"C66753":{"preferredName":"Melanoma in Precancerous Melanosis","code":"C66753","definitions":[{"definition":"A melanoma arising from an atypical intraepithelial melanocytic hyperplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma in Precancerous Melanosis","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanoma in Precancerous Melanosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8741/3"},{"name":"Legacy Concept Name","value":"Malignant_Melanoma_in_Precancerous_Melanosis"},{"name":"Maps_To","value":"8741/3"},{"name":"Maps_To","value":"Malignant melanoma in precancerous melanosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431098"}]}}{"C43372":{"preferredName":"Lentigo Maligna","code":"C43372","definitions":[{"definition":"An atypical proliferation of atypical melanocytes in the dermal-epidermal junction, without infiltration of the papillary or reticular dermis. The melanocytic proliferation is associated with actinic damage and epidermal atrophy.  It usually occurs in the sun-exposed skin of elderly people.  It is a form of melanoma in situ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lentigo Maligna","termGroup":"PT","termSource":"NCI"},{"termName":"Hutchinson Melanotic Freckle","termGroup":"AQS","termSource":"NCI"},{"termName":"Hutchinson's Melanotic Freckle","termGroup":"AQS","termSource":"NCI"},{"termName":"Lentigo Maligna Melanoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"LMM In Situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8742/2"},{"name":"Legacy Concept Name","value":"Lentigo_Maligna"},{"name":"Maps_To","value":"8742/2"},{"name":"Maps_To","value":"Hutchinson melanotic freckle, NOS"},{"name":"Maps_To","value":"Lentigo maligna"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0149722"}]}}{"C9151":{"preferredName":"Lentigo Maligna Melanoma","code":"C9151","definitions":[{"definition":"A melanoma of the skin characterized by single cell infiltration of the papillary dermis by atypical melanocytes, in a background of lentigo maligna changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lentigo Maligna Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"LMM","termGroup":"AB","termSource":"NCI"},{"termName":"Malignant Lentigo Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma in Hutchinson Melanotic Freckle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8742/3"},{"name":"Legacy Concept Name","value":"Lentigo_Maligna_Melanoma"},{"name":"Maps_To","value":"8742/3"},{"name":"Maps_To","value":"Lentigo maligna melanoma"},{"name":"Maps_To","value":"Malignant melanoma in Hutchinson melanotic freckle"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2739810"}]}}{"C9152":{"preferredName":"Low-CSD Melanoma","code":"C9152","definitions":[{"definition":"A cutaneous melanoma that develops on sun-exposed sites with low cumulative sun damage (CSD). It typically occurs in light-skinned individuals ranging in age from young adults to the elderly. It arises from any cutaneous site, except the palms and soles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low-CSD Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Low Degree of Cumulative Sun Damage Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-CSD Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"ICD-O-3_Code","value":"8743/3"},{"name":"Legacy Concept Name","value":"Superficial_Spreading_Melanoma_of_the_Skin"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334438"}]}}{"C4022":{"preferredName":"Acral Lentiginous Melanoma","code":"C4022","definitions":[{"definition":"A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin.  It presents as a pigmented macular lesion with irregular borders.  Morphologically, it consists of atypical spindled and dendritic melanocytes.  The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acral Lentiginous Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acral Lentiginous Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acral Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8744/3"},{"name":"Legacy Concept Name","value":"Acral_Lentiginous_Malignant_Melanoma"},{"name":"Maps_To","value":"8744/3"},{"name":"Maps_To","value":"Acral lentiginous melanoma, malignant"},{"name":"Maps_To","value":"Acral melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346037"}]}}{"C37257":{"preferredName":"Desmoplastic Melanoma","code":"C37257","definitions":[{"definition":"A melanoma of the skin characterized by a proliferation of atypical spindled melanocytes in the dermis, in a background of abundant collagen. It usually presents as an amelanotic raised nodular lesion.","type":"DEFINITION","source":"NCI"},{"definition":"A rare form of malignant melanoma marked by nonpigmented lesions on sun-exposed areas of the body, most commonly on the head and neck.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Desmoplastic Melanoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8745/3"},{"name":"Legacy Concept Name","value":"Desmoplastic_Melanoma"},{"name":"Maps_To","value":"8745/3"},{"name":"Maps_To","value":"Desmoplastic melanoma, amelanotic"},{"name":"Maps_To","value":"Desmoplastic melanoma, malignant"},{"name":"Maps_To","value":"Desmoplastic melanoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334439"}]}}{"C48622":{"preferredName":"Mucosal Lentiginous Melanoma","code":"C48622","definitions":[{"definition":"An acral lentiginous melanoma affecting mucosal surfaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucosal Lentiginous Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucosal Lentiginous Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8746/3"},{"name":"Legacy Concept Name","value":"Mucosal_Lentiginous_Melanoma"},{"name":"Maps_To","value":"8746/3"},{"name":"Maps_To","value":"Mucosal lentiginous melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266115"}]}}{"C3804":{"preferredName":"Dermal Nevus","code":"C3804","definitions":[{"definition":"A nevus characterized by the proliferation of nevus cells in the dermis without involvement of the dermal-epidermal junction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dermal Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Intradermal Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8750/0"},{"name":"Legacy Concept Name","value":"Intradermal_Nevus"},{"name":"Maps_To","value":"8750/0"},{"name":"Maps_To","value":"Dermal nevus"},{"name":"Maps_To","value":"Intradermal nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206737"}]}}{"C3901":{"preferredName":"Compound Nevus","code":"C3901","definitions":[{"definition":"A nevus composed of neoplastic melanocytes that infiltrate both the epidermis and the dermis.","type":"DEFINITION","source":"NCI"},{"definition":"A type of mole formed by groups of nevus cells found in the epidermis and dermis (the two main layers of tissue that make up the skin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Compound Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Compound Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Compound Nevus of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8760/0"},{"name":"Legacy Concept Name","value":"Compound_Nevus"},{"name":"Maps_To","value":"8760/0"},{"name":"Maps_To","value":"Compound nevus"},{"name":"Maps_To","value":"Dermal and epidermal nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259781"}]}}{"C3944":{"preferredName":"Congenital Melanocytic Nevus","code":"C3944","definitions":[{"definition":"A melanocytic nevus that is present at birth. It may present as a small macular, papular, or plaque-like lesion or as a large brown to black hairy skin lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"CMN","termGroup":"AB","termSource":"NCI"},{"termName":"Congenital Melanocytic Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Melanocytic Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pigmented Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pigmented Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pigmented Skin Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Skin Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Congenital_Melanocytic_Skin_Nevus"},{"name":"Maps_To","value":"8761/0"},{"name":"Maps_To","value":"Congenital melanocytic nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1318558"}]}}{"C66754":{"preferredName":"Small Congenital Melanocytic Nevus","code":"C66754","definitions":[{"definition":"A congenital melanocytic nevus of small size, with a diameter smaller than 15 mm. It presents as a macular, papular or plaque-like lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Small Congenital Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8761/0"},{"name":"Legacy Concept Name","value":"Small_Congenital_Melanocytic_Nevus"},{"name":"Maps_To","value":"8761/0"},{"name":"Maps_To","value":"Small congenital nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1883045"}]}}{"C4234":{"preferredName":"Giant Congenital Melanocytic Nevus","code":"C4234","definitions":[{"definition":"A congenital melanocytic nevus that measures more than 200 mm or is unresectable. It usually presents as a dark brown to black hairy lesion. Morphologically, it is characterized by the presence of a compound or intradermal nevus. There is an increased risk of malignant transformation to melanoma, rhabdomyosarcoma, and poorly differentiated malignant tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Bathing Trunk Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"GCN","termGroup":"AB","termSource":"NCI"},{"termName":"Giant Congenital Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Pigmented Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Pigmented Nevus of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8761/1"},{"name":"Legacy Concept Name","value":"Giant_Pigmented_Nevus"},{"name":"Maps_To","value":"8761/1"},{"name":"Maps_To","value":"Giant pigmented nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1842036"}]}}{"C4235":{"preferredName":"Melanoma Arising in Giant Congenital Nevus","code":"C4235","definitions":[{"definition":"A melanoma arising in a giant congenital melanocytic nevus. The risk of developing a melanoma in a giant congenital melanocytic nevus has been reported to be between 5% and 50%. The incidence of developing melanoma is higher before the age of 10 and in adult life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma Arising in Giant Congenital Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8761/3"},{"name":"Legacy Concept Name","value":"Skin_Melanoma_in_Giant_Pigmented_Nevus"},{"name":"Maps_To","value":"8761/3"},{"name":"Maps_To","value":"Malignant melanoma arising in giant congenital nevus"},{"name":"Maps_To","value":"Malignant melanoma in congenital melanocytic nevus"},{"name":"Maps_To","value":"Malignant melanoma in giant pigmented nevus"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334441"}]}}{"C66755":{"preferredName":"Proliferative Nodules in Congenital Melanocytic Nevus","code":"C66755","definitions":[{"definition":"A benign proliferation of epithelioid or spindled melanocytes usually in the upper or mid dermis in a background of congenital melanocytic nevus. The congenital melanocytic nevus is usually of the deep type, involving the dermis and extending into the subcutaneous tissue. It presents as a dark plaque or nodule above a giant congenital melanocytic nevus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proliferative Nodules in Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Proliferative Dermal Lesion in Congenital Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8762/1"},{"name":"Legacy Concept Name","value":"Proliferative_Dermal_Lesion_in_Congenital_Nevus"},{"name":"Maps_To","value":"8762/1"},{"name":"Maps_To","value":"Proliferative dermal lesion in congenital nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266117"}]}}{"C27007":{"preferredName":"Spitz Nevus","code":"C27007","definitions":[{"definition":"An acquired or congenital benign skin melanocytic neoplasm. It can occur on any area of the body, but most commonly occurs on the face of children and the thighs of young females. It is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes in the dermal-epidermal junction. The melanocytic proliferation subsequently extends into the dermis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spitz Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Juvenile Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle and/ or Epithelioid Cell Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8770/0"},{"name":"Legacy Concept Name","value":"Spitz_Spindle_Cell_Nevus"},{"name":"Maps_To","value":"8770/0"},{"name":"Maps_To","value":"Epithelioid and spindle cell nevus"},{"name":"Maps_To","value":"Juvenile melanoma"},{"name":"Maps_To","value":"Juvenile nevus"},{"name":"Maps_To","value":"Spindle cell nevus, NOS"},{"name":"Maps_To","value":"Spitz nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206739"}]}}{"C4751":{"preferredName":"Pigmented Spindle Cell Nevus","code":"C4751","definitions":[{"definition":"A subtype of Spitz nevus characterized by the presence of heavily pigmented spindle-shaped melanocytes that proliferate in the epidermis or in the epidermis and superficial dermis. It presents as a small and slightly elevated brown or black skin lesion with usually well-demarcated borders. Sometimes the clinical and morphologic features may be difficult to distinguish from melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Spindle Cell Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Pigmented Spindle Cell Nevus of Reed","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Spindle Cell Spitz Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Spindle Cell Variant of Spitz Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"PSCN","termGroup":"AB","termSource":"NCI"},{"termName":"Reed Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Nevus of Reed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pigmented_Spindle_Cell_Nevus"},{"name":"Maps_To","value":"8770/0"},{"name":"Maps_To","value":"Pigmented spindle cell nevus of Reed"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474967"}]}}{"C66756":{"preferredName":"Mixed Epithelioid and Spindle Cell Melanoma","code":"C66756","definitions":[{"definition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes and malignant spindle-shaped melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Epithelioid and Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8770/3"},{"name":"Legacy Concept Name","value":"Mixed_Epithelioid_and_Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8770/3"},{"name":"Maps_To","value":"Mixed epithelioid and spindle cell melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334442"}]}}{"C66757":{"preferredName":"Epithelioid Cell Nevus","code":"C66757","definitions":[{"definition":"A Spitz nevus characterized by the presence of large epithelioid melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Cell Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8771/0"},{"name":"Legacy Concept Name","value":"Epithelioid_Cell_Nevus"},{"name":"Maps_To","value":"8771/0"},{"name":"Maps_To","value":"Epithelioid cell nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259820"}]}}{"C4236":{"preferredName":"Epithelioid Cell Melanoma","code":"C4236","definitions":[{"definition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Cell Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8771/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Cell_Melanoma"},{"name":"Maps_To","value":"8771/3"},{"name":"Maps_To","value":"Epithelioid cell melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334443"}]}}{"C4237":{"preferredName":"Spindle Cell Melanoma","code":"C4237","definitions":[{"definition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8772/3"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8772/3"},{"name":"Maps_To","value":"Spindle cell melanoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334444"}]}}{"C4238":{"preferredName":"Type A Spindle Cell Melanoma","code":"C4238","definitions":[{"definition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes with slender nuclei and no visible nucleoli. Representative example is the type A spindle cell uveal melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Type A Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Type A Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Type A Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8773/3"},{"name":"Legacy Concept Name","value":"Type_A_Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8773/3"},{"name":"Maps_To","value":"Spindle cell melanoma, type A"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334445"}]}}{"C4239":{"preferredName":"Type B Spindle Cell Melanoma","code":"C4239","definitions":[{"definition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes with larger nuclei and distinct nucleoli. Representative example is the type B spindle cell uveal melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Type B Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Type B Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Type B Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8774/3"},{"name":"Legacy Concept Name","value":"Type_B_Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8774/3"},{"name":"Maps_To","value":"Spindle cell melanoma, type B"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334446"}]}}{"C3803":{"preferredName":"Blue Nevus","code":"C3803","definitions":[{"definition":"An intradermal nevus characterized by the presence of benign pigmented dendritic spindle-shaped melanocytes. It most frequently occurs in the skin of the distal upper extremities, followed by the lower extremities, scalp, face, and buttocks. It usually presents as a single blue or blue-black papular lesion less than 1cm in diameter. Simple excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blue Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Blue Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Blue Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Blue Skin Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8780/0"},{"name":"Legacy Concept Name","value":"Blue_Nevus"},{"name":"Maps_To","value":"8780/0"},{"name":"Maps_To","value":"Blue nevus, NOS"},{"name":"Maps_To","value":"Jadassohn blue nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206736"}]}}{"C4240":{"preferredName":"Melanoma Arising in Blue Nevus","code":"C4240","definitions":[{"definition":"A rare melanoma which develops in a pre-existing blue nevus. It occurs more frequently on the scalp, face, orbit, back, buttocks, extremities, hands, and feet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma Arising in Blue Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Blue Nevus-Like Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Blue Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Blue Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Blue Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Cutaneous Blue Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Blue Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"MBN","termGroup":"AB","termSource":"NCI"},{"termName":"Melanoma Arising from Blue Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8780/3"},{"name":"Legacy Concept Name","value":"Blue_Nevus-Like_Melanoma"},{"name":"Maps_To","value":"8780/3"},{"name":"Maps_To","value":"Blue nevus, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334447"}]}}{"C4241":{"preferredName":"Cellular Blue Nevus","code":"C4241","definitions":[{"definition":"A blue nevus characterized by a multinodular cellular infiltrate with a dumb-bell architecture occupying the reticular dermis. The cellular infiltrate often extends into the subcutaneous tissue. The cellular infiltrate is composed of spindle-shaped melanocytes with pale cytoplasm alternating with bundles of pigmented spindle-shaped melanocytes. In occasional cases an increased mitotic activity, focal necrosis, and nuclear pleomorphism may be seen. Such cases with atypical features may have an uncertain malignant potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Blue Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"CBN","termGroup":"AB","termSource":"NCI"},{"termName":"Cellular Blue Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Cellular Blue Nevus of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8790/0"},{"name":"Legacy Concept Name","value":"Cellular_Blue_Nevus"},{"name":"Maps_To","value":"8790/0"},{"name":"Maps_To","value":"Cellular blue nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334448"}]}}{"C4242":{"preferredName":"Benign Soft Tissue Neoplasm","code":"C4242","definitions":[{"definition":"A neoplasm that arises from soft tissue and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Soft Tissue Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasm of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Soft Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8800/0"},{"name":"Legacy Concept Name","value":"Benign_Soft_Tissue_Neoplasm"},{"name":"Maps_To","value":"8800/0"},{"name":"Maps_To","value":"Soft tissue tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334450"}]}}{"C4867":{"preferredName":"Malignant Soft Tissue Neoplasm","code":"C4867","definitions":[{"definition":"A malignant neoplasm arising exclusively from the soft tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Soft Tissue Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Soft Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Soft_Tissue_Neoplasm"},{"name":"Maps_To","value":"8800/3"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of abdomen"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of head, face, and neck"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of pelvis"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of thorax"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of trunk, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue, site unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of left lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of right lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of other connective and soft tissue"},{"name":"Maps_To","value":"Malignant neoplasm of other specified sites of connective and other soft tissue"},{"name":"Maps_To","value":"Malignant neoplasm of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of abdomen"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of head, face and neck"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of pelvis"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of thorax"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of trunk, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Overlapping lesion of connective and soft tissue"},{"name":"Maps_To","value":"Soft tissue tumor, malignant"},{"name":"NCI_META_CUI","value":"CL336320"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9118":{"preferredName":"Sarcoma","code":"C9118","definitions":[{"definition":"A cancer of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant mesenchymal neoplasm. A general term for which the transformed cell type has not been specified.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"SAR","termGroup":"AB","termSource":"NCI"},{"termName":"Sarcoma of Soft Tissue and Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Soft Tissue and Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8800/3"},{"name":"Legacy Concept Name","value":"Sarcoma_of_the_Soft_Tissue_and_Bone"},{"name":"Maps_To","value":"8800/3"},{"name":"Maps_To","value":"Mesenchymal tumor, malignant"},{"name":"Maps_To","value":"Sarcoma"},{"name":"Maps_To","value":"Sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1261473"}]}}{"C9306":{"preferredName":"Soft Tissue Sarcoma","code":"C9306","definitions":[{"definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","type":"DEFINITION","source":"NCI"},{"definition":"A solid, malignant neoplasm originating in muscle, tendon, fat, blood vessels, nerves, connective or joint tissue.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Soft Tissue Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcoma of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Soft_Tissue_Sarcoma"},{"name":"Maps_To","value":"8800/3"},{"name":"Maps_To","value":"Soft tissue sarcoma"},{"name":"Maps_To","value":"Soft tissue sarcoma, non-rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2211494"}]}}{"C4243":{"preferredName":"Sarcomatosis","code":"C4243","definitions":[{"definition":"The occurrence of several sarcomas in different anatomic locations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8800/9"},{"name":"Legacy Concept Name","value":"Sarcomatosis"},{"name":"Maps_To","value":"8800/9"},{"name":"Maps_To","value":"Sarcomatosis, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334451"}]}}{"C27005":{"preferredName":"Spindle Cell Sarcoma","code":"C27005","definitions":[{"definition":"A malignant mesenchymal neoplasm composed of spindle-shaped cells.  This is a morphologic term which can be applied to a wide range of sarcomas.","type":"DEFINITION","source":"NCI"},{"definition":"A type of connective tissue cancer in which the cells are spindle-shaped when examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Spindle Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8801/3"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Sarcoma"},{"name":"Maps_To","value":"8801/3"},{"name":"Maps_To","value":"Spindle cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205945"}]}}{"C66759":{"preferredName":"Giant Cell Sarcoma","code":"C66759","definitions":[{"definition":"A sarcoma characterized by the presence of large, anaplastic malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Sarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8802/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Sarcoma"},{"name":"Maps_To","value":"8802/3"},{"name":"Maps_To","value":"Giant cell sarcoma"},{"name":"Maps_To","value":"Pleomorphic cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1261358"}]}}{"C3746":{"preferredName":"Small Cell Sarcoma","code":"C3746","definitions":[{"definition":"A sarcoma characterized by the presence of small round or elongated malignant cells with a small amount of cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Small Cell Sarcomas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8803/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Sarcoma"},{"name":"Maps_To","value":"8803/3"},{"name":"Maps_To","value":"Small cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206652"}]}}{"C3714":{"preferredName":"Epithelioid Sarcoma","code":"C3714","definitions":[{"definition":"An aggressive malignant neoplasm of uncertain differentiation, characterized by the presence of epithelioid cells forming nodular patterns.  The nodules often undergo central necrosis, resulting in a pseudogranulomatous growth pattern.  It usually occurs in young adults.  The most common sites of involvement are the extremities (distal-type epithelioid sarcoma), and less frequently the pelvis, perineum, and genital organs (proximal-type epithelioid sarcoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"ES","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8804/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Sarcoma"},{"name":"Maps_To","value":"8804/3"},{"name":"Maps_To","value":"Epithelioid cell sarcoma"},{"name":"Maps_To","value":"Epithelioid sarcoma"},{"name":"Maps_To","value":"Epithelioid sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205944"}]}}{"C121793":{"preferredName":"Undifferentiated Soft Tissue Sarcoma","code":"C121793","definitions":[{"definition":"A term that refers to a heterogeneous group of uncommon soft tissue sarcomas that do not show an identifiable line of differentiation using currently available technologies.  This is a diagnosis of exclusion and includes undifferentiated pleomorphic sarcoma (also known as malignant fibrous histiocytoma), undifferentiated spindle cell sarcoma, undifferentiated round cell sarcoma, and undifferentiated epithelioid sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Soft Tissue Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Undifferentiated Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated/Unclassified Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated/Unclassified Soft Tissue Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"USTS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8805/3"},{"name":"Maps_To","value":"Undifferentiated sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2188153"}]}}{"C8300":{"preferredName":"Desmoplastic Small Round Cell Tumor","code":"C8300","definitions":[{"definition":"A rare, aggressive cancer that usually affects young males and usually is located in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant soft tissue neoplasm of uncertain differentiation.  It is characterized by a recurrent chromosomal translocation t(11;22)(p13;q12) and the presence of small round cells in a desmoplastic stroma.  It usually affects children and young adults.  The most common site of involvement is the abdomen.  Patients usually present with abdominal distention, pain, ascites, and a palpable abdominal mass.  The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Small Round Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Desmoplastic Small Round-Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoplastic Small Round-Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"DSRCT","termGroup":"AB","termSource":"NCI"},{"termName":"Polyphenotypic Small Round Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8806/3"},{"name":"Legacy Concept Name","value":"Desmoplastic_Small_Round_Cell_Tumor"},{"name":"Maps_To","value":"8806/3"},{"name":"Maps_To","value":"Desmoplastic small round cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0281508"}]}}{"C3041":{"preferredName":"Fibroma","code":"C3041","definitions":[{"definition":"A benign neoplasm arising from fibrous tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-metastasizing neoplasm arising from the fibrous tissue. It is characterized by the presence of spindle-shaped fibroblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8810/0"},{"name":"Legacy Concept Name","value":"Fibroma"},{"name":"Maps_To","value":"8810/0"},{"name":"Maps_To","value":"Fibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0016045"}]}}{"C6892":{"preferredName":"Cellular Fibroma","code":"C6892","definitions":[{"definition":"A morphologic variant of fibroma characterized by increased cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8810/1"},{"name":"Legacy Concept Name","value":"Cellular_Fibroma"},{"name":"Maps_To","value":"8810/1"},{"name":"Maps_To","value":"Cellular fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266118"}]}}{"C3043":{"preferredName":"Fibrosarcoma","code":"C3043","definitions":[{"definition":"A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant mesenchymal neoplasm of the soft tissue and bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fibrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8810/3"},{"name":"Legacy Concept Name","value":"Fibrosarcoma"},{"name":"Maps_To","value":"8810/3"},{"name":"Maps_To","value":"Fibrosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0016057"}]}}{"C66760":{"preferredName":"Fibromyxoid Tumor","code":"C66760","definitions":[{"definition":"A benign soft-tissue neoplasm of uncertain lineage, characterized by the presence of neoplastic spindle-shaped to round cells and a fibromyxoid stroma.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A soft tissue tumor of uncertain lineage characterized by the presence of neoplastic spindle-shaped to round cells in a fibromyxoid stroma. Metaplastic bone formation may or may not be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibromyxoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibromyxoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Fibromyxoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8811/0"},{"name":"Legacy Concept Name","value":"Fibromyxoid_Neoplasm"},{"name":"Maps_To","value":"8811/0"},{"name":"Maps_To","value":"Fibromyxoma"},{"name":"Maps_To","value":"Fibromyxoma, NOS"},{"name":"Maps_To","value":"Myxofibroma, NOS"},{"name":"Maps_To","value":"Myxoid fibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205766"}]}}{"C49025":{"preferredName":"Myxoinflammatory Fibroblastic Sarcoma","code":"C49025","definitions":[{"definition":"A low grade, locally aggressive, fibroblastic neoplasm that occurs primarily in the distal extremities.  It is characterized by the presence of spindle-shaped fibroblasts, multivacuolated lipoblast-like cells, bizarre ganglion-like cells with inclusion-like nuclei, myxoid stroma formation, and a mixture of acute and chronic inflammatory cells.  Distant metastases are very rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxoinflammatory Fibroblastic Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acral Myxoinflammatory Fibroblastic Sarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Inflammatory Myxohyaline Tumor of the Distal Extremities with Virocyte/Reed-Sternberg-Like Cells","termGroup":"AQS","termSource":"NCI"},{"termName":"Inflammatory Myxoid Tumor of the Soft Parts with Bizarre Giant Cells","termGroup":"AQS","termSource":"NCI"},{"termName":"MIFS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myxoinflammatory_Fibroblastic_Sarcoma"},{"name":"Maps_To","value":"Myxoinflammatory fibroblastic sarcoma"},{"name":"Maps_To","value":"Myxoinflammatory fibroblastic sarcoma (MIFS)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709103"}]}}{"C6496":{"preferredName":"Myxofibrosarcoma","code":"C6496","definitions":[{"definition":"A malignant fibroblastic neoplasm arising from the soft tissue. It is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxofibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Myxoid Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Myxoid MFH","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8811/3"},{"name":"Legacy Concept Name","value":"Myxoid_Malignant_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8811/3"},{"name":"Maps_To","value":"Fibromyxosarcoma"},{"name":"Maps_To","value":"Myxofibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334454"}]}}{"C66761":{"preferredName":"Periosteal Fibroma","code":"C66761","definitions":[{"definition":"A benign fibrous neoplasm arising from the periosteal connective tissue that surrounds a bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8812/0"},{"name":"Legacy Concept Name","value":"Periosteal_Fibroma"},{"name":"Maps_To","value":"8812/0"},{"name":"Maps_To","value":"Periosteal fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334455"}]}}{"C66763":{"preferredName":"Periosteal Fibrosarcoma","code":"C66763","definitions":[{"definition":"A malignant fibroblastic tumor arising from the periosteal connective tissue that surrounds a bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Fibrosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8812/3"},{"name":"Legacy Concept Name","value":"Periosteal_Fibrosarcoma"},{"name":"Maps_To","value":"8812/3"},{"name":"Maps_To","value":"Periosteal fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334456"}]}}{"C66764":{"preferredName":"Fascial Fibroma","code":"C66764","definitions":[{"definition":"A benign fibrous tumor arising from the fascial connective tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fascial Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8813/0"},{"name":"Legacy Concept Name","value":"Fascial_Fibroma"},{"name":"Maps_To","value":"8813/0"},{"name":"Maps_To","value":"Fascial fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334457"}]}}{"C66765":{"preferredName":"Fascial Fibrosarcoma","code":"C66765","definitions":[{"definition":"A malignant fibroblastic neoplasm arising from the fascial connective tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fascial Fibrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8813/3"},{"name":"Legacy Concept Name","value":"Fascial_Fibrosarcoma"},{"name":"Maps_To","value":"8813/3"},{"name":"Maps_To","value":"Fascial fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334458"}]}}{"C4244":{"preferredName":"Infantile Fibrosarcoma","code":"C4244","definitions":[{"definition":"A fibrosarcoma that occurs in infants.  It shares identical morphologic features with adult fibrosarcoma but carries the t(12;15)(p13;q25) translocation that results in ETV6-NTRK3 gene fusion.  It usually affects the superficial and deep soft tissues of the extremities.  The prognosis is generally much more favorable than for adult fibrosarcoma, and it rarely metastasizes.","type":"DEFINITION","source":"NCI"},{"definition":"A fibrosarcoma typically congenital, and occurring most commonly within the first three months of life, sharing identical morphologic features with adult fibrosarcoma but rarely metastatic. It usually affects the superficial and deep soft tissues of the extremities. The majority of infantile fibrosarcomas carry the t(12;15)(p13;q25) translocation.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Infantile Fibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Congenital Fibrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"IFS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8814/3"},{"name":"Legacy Concept Name","value":"Infantile_Fibrosarcoma"},{"name":"Maps_To","value":"8814/3"},{"name":"Maps_To","value":"Congenital fibrosarcoma"},{"name":"Maps_To","value":"Infantile fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334459"}]}}{"C7634":{"preferredName":"Solitary Fibrous Tumor","code":"C7634","definitions":[{"definition":"A localized neoplasm of probable fibroblastic derivation. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Fibrous Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Localized Fibrous Mesothelioma","termGroup":"AQS","termSource":"NCI"},{"termName":"Localized Fibrous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"SFT","termGroup":"AB","termSource":"NCI"},{"termName":"Submesothelial Fibroma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8815/0"},{"name":"ICD-O-3_Code","value":"8815/1"},{"name":"ICD-O-3_Code","value":"9051/0"},{"name":"Legacy Concept Name","value":"Solitary_Fibrous_Tumor"},{"name":"Maps_To","value":"8815/0"},{"name":"Maps_To","value":"Localized fibrous tumor"},{"name":"Maps_To","value":"Solitary fibrous tumor"},{"name":"Maps_To","value":"Solitary fibrous tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266119"}]}}{"C129528":{"preferredName":"Central Nervous System Solitary Fibrous Tumor, Grade 2","code":"C129528","definitions":[{"definition":"A solitary fibrous tumor that arises from the central nervous system. It corresponds to the more cellular, less collagenous tumor with plump cells and staghorn vasculature which was diagnosed as central nervous system hemangiopericytoma in the past.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Solitary Fibrous Tumor, Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor, Grade 2","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)"},{"name":"NCI_META_CUI","value":"CL512611"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6894":{"preferredName":"Malignant Solitary Fibrous Tumor","code":"C6894","definitions":[{"definition":"A malignant neoplasm of probable fibroblastic derivation. It is characterized by the presence of atypical round to spindle-shaped cells, increased cellularity, necrotic change and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Solitary Fibrous Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8815/3"},{"name":"Legacy Concept Name","value":"Malignant_Solitary_Fibrous_Tumor"},{"name":"Maps_To","value":"8815/3"},{"name":"Maps_To","value":"Solitary fibrous tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266120"}]}}{"C4245":{"preferredName":"Elastofibroma","code":"C4245","definitions":[{"definition":"A benign, slow-growing tumor arising from the soft tissues usually in the mid-thoracic region of the elderly. It is characterized by the presence of paucicellular collagenous tissue, adipocytes and a predominance of large coarse elastic fibers arranged in globules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elastofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Elastofibroma Dorsi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8820/0"},{"name":"Legacy Concept Name","value":"Elastofibroma"},{"name":"Maps_To","value":"8820/0"},{"name":"Maps_To","value":"Elastofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334460"}]}}{"C6489":{"preferredName":"Extraabdominal Fibromatosis","code":"C6489","definitions":[{"definition":"An insidious poorly circumscribed neoplasm arising from the soft tissues outside the abdomen. It is characterized by the presence of elongated spindle-shaped fibroblasts, vascular collagenous stroma formation, and an infiltrative growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraabdominal Fibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Extraabdominal Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Extraabdominal Desmoid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Extraabdominal_Fibromatosis"},{"name":"Maps_To","value":"8821/1"},{"name":"Maps_To","value":"Extra-abdominal desmoid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275420"}]}}{"C9182":{"preferredName":"Desmoid Fibromatosis","code":"C9182","definitions":[{"definition":"A tumor of the tissue that surrounds muscles, usually in the abdomen. A desmoid tumor rarely metastasizes (spreads to other parts of the body).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An insidious, locally aggressive, poorly circumscribed neoplasm arising from the deep soft tissues. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern. It lacks metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoid Fibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Fibromatosis/Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoid-Type Fibromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8821/1"},{"name":"Legacy Concept Name","value":"Deep_Fibromatosis_Desmoid_Tumor"},{"name":"Maps_To","value":"8821/1"},{"name":"Maps_To","value":"Aggressive fibromatosis"},{"name":"Maps_To","value":"Desmoid, NOS"},{"name":"Maps_To","value":"Invasive fibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079218"}]}}{"C3741":{"preferredName":"Abdominal (Mesenteric) Fibromatosis","code":"C3741","definitions":[{"definition":"An insidious poorly circumscribed neoplasm arising from the deep soft tissues of the abdomen. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abdominal (Mesenteric) Fibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Abdominal Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Abdominal Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Abdominal Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Intraabdominal Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Intraabdominal Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Intraabdominal Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Mesenteric Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Mesenteric Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mesenteric Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Peritoneal Desmoid Fibromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8822/1"},{"name":"Legacy Concept Name","value":"Abdominal_Fibromatosis"},{"name":"Maps_To","value":"8822/1"},{"name":"Maps_To","value":"Abdominal desmoid"},{"name":"Maps_To","value":"Abdominal fibromatosis"},{"name":"Maps_To","value":"Mesenteric fibromatosis"},{"name":"Maps_To","value":"Retroperitoneal fibromatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206646"}]}}{"C3740":{"preferredName":"Desmoplastic Fibroma","code":"C3740","definitions":[{"definition":"A benign neoplasm characterized by osteolysis and the presence of a rich collagenous stroma and spindle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, benign, locally aggressive osteolytic neoplasm. It is characterized by the presence of a rich collagenous stroma and spindle cells with minimal cellular atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Desmoplastic Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoid Tumor of Bone","termGroup":"AQS","termSource":"NCI"},{"termName":"Desmoplastic Fibroma of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoplastic Fibroma of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Desmoplastic Fibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8823/0"},{"name":"Legacy Concept Name","value":"Bone_Desmoplastic_Fibroma"},{"name":"Maps_To","value":"8823/0"},{"name":"Maps_To","value":"Desmoplastic fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206645"}]}}{"C7052":{"preferredName":"Myofibroma","code":"C7052","definitions":[{"definition":"A benign, localized, nodular and well-circumscribed neoplasm usually seen as a congenital neoplasm or in the first year of life. It is characterized by a biphasic growth pattern and is composed of small, undifferentiated mesenchymal cells associated with branching thin-walled vessels and more mature neoplastic spindle cells with abundant eosinophilic cytoplasm in a collagenous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8824/0"},{"name":"Legacy Concept Name","value":"Solitary_Myofibromatosis"},{"name":"Maps_To","value":"8824/0"},{"name":"Maps_To","value":"Myofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4228279"}]}}{"C3742":{"preferredName":"Myofibromatosis","code":"C3742","definitions":[{"definition":"A benign, multifocal, nodular and well-circumscribed neoplasm usually seen as a congenital neoplasm or in the first year of life. It is characterized by a biphasic growth pattern and is composed of small, undifferentiated mesenchymal cells associated with branching thin-walled vessels and more mature neoplastic spindle cells with abundant eosinophilic cytoplasm in a collagenous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myofibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Infantile Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Infantile Myofibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Multicentric Myofibromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8824/1"},{"name":"Legacy Concept Name","value":"Myofibromatosis"},{"name":"Maps_To","value":"8824/1"},{"name":"Maps_To","value":"Infantile myofibromatosis"},{"name":"Maps_To","value":"Myofibromatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206648"}]}}{"C49012":{"preferredName":"Myofibroblastoma","code":"C49012","definitions":[{"definition":"A benign, well circumscribed soft tissue neoplasm characterized by the presence of spindle shaped myofibroblasts and mast cells in a collagenous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myofibroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8825/0"},{"name":"Legacy Concept Name","value":"Myofibroblastoma"},{"name":"Maps_To","value":"8825/0"},{"name":"Maps_To","value":"Myofibroblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0242404"}]}}{"C6481":{"preferredName":"Inflammatory Myofibroblastic Tumor","code":"C6481","definitions":[{"definition":"A multinodular intermediate fibroblastic neoplasm that arises from soft tissue or viscera, in children and young adults.  It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes, and plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inflammatory Myofibroblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"IMT","termGroup":"AB","termSource":"NCI"},{"termName":"Inflammatory Fibrosarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Inflammatory Myofibroblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Pseudotumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8825/1"},{"name":"Legacy Concept Name","value":"Inflammatory_Myofibroblastic_Tumor"},{"name":"Maps_To","value":"Inflammatory myofibroblastic tumor"},{"name":"Maps_To","value":"Myofibroblastic tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334121"}]}}{"C49024":{"preferredName":"Low Grade Myofibroblastic Sarcoma","code":"C49024","definitions":[{"definition":"A low-grade malignant neoplasm arising from the soft tissue and rarely bone. It is characterized by the presence of spindle-shaped myofibroblasts and collagenous stroma formation in a storiform growth pattern. Metastasis is very rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Myofibroblastic Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Low-Grade Myofibroblastic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myofibroblastic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myofibrosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8825/3"},{"name":"Legacy Concept Name","value":"Low_Grade_Myofibroblastic_Sarcoma"},{"name":"Maps_To","value":"8825/3"},{"name":"Maps_To","value":"Low-grade myofibroblastic sarcoma"},{"name":"Maps_To","value":"Myofibroblastic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708751"}]}}{"C49016":{"preferredName":"Angiomyofibroblastoma","code":"C49016","definitions":[{"definition":"A benign myofibroblastic neoplasm, usually arising in the pelviperineal region. It is characterized by the presence of neoplastic spindle to round cells, dilated thin walled vessels, and stromal edema.  Most patients present with painless circumscribed masses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomyofibroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8826/0"},{"name":"Legacy Concept Name","value":"Angiomyofibroblastoma"},{"name":"Maps_To","value":"8826/0"},{"name":"Maps_To","value":"Angiomyofibroblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266123"}]}}{"C142823":{"preferredName":"Congenital Peribronchial Myofibroblastic Tumor","code":"C142823","definitions":[{"definition":"A rare lung neoplasm that occurs in the intrauterine and perinatal period. It is characterized by the proliferation of spindle cells in an interstitial, peribronchial pattern. Surgical resection of the involved lung parenchyma is the treatment of choice.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Congenital Peribronchial Myofibroblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Congenital Bronchopulmonary Leiomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Fibrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Mesenchymal Malformation of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pulmonary Myofibroblastic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neonatal Pulmonary Hamartoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8827/1"},{"name":"Maps_To","value":"Congenital peribronchial myofibroblastic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266124"}]}}{"C39740":{"preferredName":"Lung Inflammatory Myofibroblastic Tumor","code":"C39740","definitions":[{"definition":"An intermediate fibroblastic neoplasm arising from the lung.  It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes and plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Inflammatory Myofibroblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Myofibroblastic Tumor, Peribronchial","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8827/1"},{"name":"Legacy Concept Name","value":"Lung_Inflammatory_Myofibroblastic_Tumor"},{"name":"Maps_To","value":"8827/1"},{"name":"Maps_To","value":"Myofibroblastic tumor, peribronchial"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518038"}]}}{"C3739":{"preferredName":"Fibrous Histiocytoma","code":"C3739","definitions":[{"definition":"A benign neoplasm composed of a fibroblastic and a histiocytic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm composed of fibroblastic spindle cells in a whorled storiform pattern.  It is characterized by the presence of foam cells, inflammatory cells, hemosiderin deposition and stromal hemorrhage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8830/0"},{"name":"Legacy Concept Name","value":"Benign_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8830/0"},{"name":"Maps_To","value":"Benign fibrous histiocytoma"},{"name":"Maps_To","value":"Benign fibrous histiocytoma, NOS"},{"name":"Maps_To","value":"Fibrous histiocytoma, NOS"},{"name":"Maps_To","value":"Fibroxanthoma, NOS"},{"name":"Maps_To","value":"Xanthofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206644"}]}}{"C4246":{"preferredName":"Atypical Fibroxanthoma","code":"C4246","definitions":[{"definition":"An intermediate cutaneous mesenchymal neoplasm of uncertain differentiation, usually affecting the actinic-damaged skin of the elderly.  The tumor presents as a single cutaneous nodule which is often ulcerated.  Microscopically, it is characterized by the presence of highly atypical cytologic features, pleomorphism and abundant mitotic figures. The vast majority of patients have an excellent prognosis following conservative therapy. Recurrences are infrequent, and metastasis is rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Fibroxanthoma","termGroup":"PT","termSource":"NCI"},{"termName":"AFX","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Cutaneous Fibroxanthoma","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Fibroxanthoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Fibroxanthoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Skin Fibroxanthoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8830/1"},{"name":"Legacy Concept Name","value":"Atypical_Fibroxanthoma"},{"name":"Maps_To","value":"8830/1"},{"name":"Maps_To","value":"Atypical fibrous histiocytoma"},{"name":"Maps_To","value":"Atypical fibroxanthoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346053"}]}}{"C4247":{"preferredName":"Undifferentiated Pleomorphic Sarcoma","code":"C4247","definitions":[{"definition":"A malignant neoplasm composed of a fibroblastic and a histiocytic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A soft tissue sarcoma that usually occurs in the limbs, most commonly the legs, and may also occur in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate.  It is also known as malignant fibrous histiocytoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Pleomorphic Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroxanthosarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibroxanthoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MFH","termGroup":"AB","termSource":"NCI"},{"termName":"Storiform-Pleomorphic Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Storiform-Pleomorphic Malignant Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Storiform-Pleomorphic MFH","termGroup":"AQS","termSource":"NCI"},{"termName":"Unclassified Pleomorphic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Pleomorphic Sarcoma (Formerly \"Malignant Fibrous Histiocytoma\")","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Pleomorphic Sarcoma (Formerly \"MFH\")","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Pleomorphic Soft Tissue Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"UPS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8830/3"},{"name":"Legacy Concept Name","value":"Malignant_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8830/3"},{"name":"Maps_To","value":"Fibroxanthoma, malignant"},{"name":"Maps_To","value":"Malignant fibrous histiocytoma"},{"name":"Maps_To","value":"Undifferentiated pleomorphic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3549501"}]}}{"C35765":{"preferredName":"Histiocytoma","code":"C35765","definitions":[{"definition":"A mesenchymal tumor composed of fibroblastic and histiocytic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histiocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8831/0"},{"name":"Legacy Concept Name","value":"Histiocytoma"},{"name":"Maps_To","value":"8831/0"},{"name":"Maps_To","value":"Histiocytoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1509147"}]}}{"C3356":{"preferredName":"Solitary Reticulohistiocytoma","code":"C3356","definitions":[{"definition":"A rare cutaneous lesion composed of eosinophilic histiocytes, which are often multinucleated.  The lesions are yellow-brown papules affecting any part of the body.  Patients are usually adult men.  The prognosis is excellent. -- 2003","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Reticulohistiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Reticulohistiocytic Granuloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solitary_Reticulohistiocytoma"},{"name":"Maps_To","value":"8831/0"},{"name":"Maps_To","value":"Reticulohistiocytoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035290"}]}}{"C6492":{"preferredName":"Deep Fibrous Histiocytoma","code":"C6492","definitions":[{"definition":"A rare, well-circumscribed, pseudo-encapsulated benign fibrous histiocytoma that arises entirely within the subcutaneous tissue or deep soft tissue.  It usually affects the extremities or the head and neck region.  It recurs locally in a minority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Deep Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Benign Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Deep_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8831/0"},{"name":"Maps_To","value":"Deep histiocytoma"},{"name":"Maps_To","value":"Juvenile histiocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266125"}]}}{"C7159":{"preferredName":"Subepidermal Nodular Fibrosis","code":"C7159","synonyms":[{"termName":"Subepidermal Nodular Fibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Subepidermal_Nodular_Fibrosis"},{"name":"Maps_To","value":"8832/0"},{"name":"Maps_To","value":"Subepidermal nodular fibrosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1509149"}]}}{"C6801":{"preferredName":"Skin Fibrous Histiocytoma","code":"C6801","definitions":[{"definition":"A solitary, slowly growing, nodular tumor most often affecting the extremities. It is composed of fibrous and histiocytic cells which infiltrate the dermis and occasionally the underlying subcutaneous tissue.  Usually local excision is curative. Recurrences are reported only in a small minority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cutaneous Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Fibrous Cutaneous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Fibrous Histiocytoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Fibrous Histiocytoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Skin Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Dermatofibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrous Histiocytoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrous Histiocytoma of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8832/0"},{"name":"Legacy Concept Name","value":"Cutaneous_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8832/0"},{"name":"Maps_To","value":"Cutaneous histiocytoma, NOS"},{"name":"Maps_To","value":"Dermatofibroma lenticulare"},{"name":"Maps_To","value":"Dermatofibroma, NOS"},{"name":"Maps_To","value":"Sclerosing hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002991"}]}}{"C4683":{"preferredName":"Dermatofibrosarcoma Protuberans","code":"C4683","definitions":[{"definition":"A low grade fibroblastic neoplasm presenting as a nodular cutaneous mass, most often on the trunk and the proximal extremities.  The tumor diffusely infiltrates the dermis and the subcutaneous tissues.  It is considered a locally aggressive neoplasm, which often recurs but rarely metastasizes.","type":"DEFINITION","source":"NCI"},{"definition":"A type of tumor that begins as a hard nodule and grows slowly. These tumors are usually found in the dermis (the inner layer of the two main layers of tissue that make up the skin) of the limbs or trunk of the body. They can grow into surrounding tissue but do not spread to other parts of the body. These tumors are related to giant cell fibroblastomas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dermatofibrosarcoma Protuberans","termGroup":"PT","termSource":"NCI"},{"termName":"Dermatofibrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"DFSP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8832/3"},{"name":"Legacy Concept Name","value":"Dermatofibrosarcoma_Protuberans"},{"name":"Maps_To","value":"8832/3"},{"name":"Maps_To","value":"Dermatofibrosarcoma protuberans, NOS"},{"name":"Maps_To","value":"Dermatofibrosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0392784"}]}}{"C9430":{"preferredName":"Pigmented Dermatofibrosarcoma Protuberans","code":"C9430","definitions":[{"definition":"A morphologic variant of dermatofibrosarcoma protuberans characterized by the presence of melanin-pigmented dendritic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Dermatofibrosarcoma Protuberans","termGroup":"PT","termSource":"NCI"},{"termName":"Bednar Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Dermatofibrosarcoma Protuberans (Bednar Tumor)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8833/3"},{"name":"Legacy Concept Name","value":"Pigmented_Dermatofibrosarcoma_Protuberans_Bednar_Tumor"},{"name":"Maps_To","value":"8833/3"},{"name":"Maps_To","value":"Bednar tumor"},{"name":"Maps_To","value":"Pigmented dermatofibrosarcoma protuberans"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334464"}]}}{"C4700":{"preferredName":"Giant Cell Fibroblastoma","code":"C4700","definitions":[{"definition":"A rare type of soft tissue tumor marked by painless nodules in the dermis (the inner layer of the two main layers of tissue that make up the skin) and subcutaneous (beneath the skin) tissue. These tumors may come back after surgery, but they do not spread to other parts of the body. They occur mostly in boys and are related to dermatofibrosarcoma protuberans.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare, locally aggressive fibroblastic neoplasm typically affecting young patients (predominantly boys).  It manifests with painless nodules in the dermis or subcutaneous tissues. Morphologically, it contains giant cells and wide vessel-like spaces.  This tumor can recur but metastases have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Fibroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"GCF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8834/1"},{"name":"Legacy Concept Name","value":"Giant_Cell_Fibroblastoma"},{"name":"Maps_To","value":"8834/1"},{"name":"Maps_To","value":"Giant cell fibroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0406579"}]}}{"C6493":{"preferredName":"Plexiform Fibrohistiocytic Tumor","code":"C6493","definitions":[{"definition":"An intermediate fibrohistiocytic neoplasm of the skin that usually affects children and young adults. It is a multinodular, poorly circumscribed tumor characterized by the presence of multinucleated giant cells, mononuclear histiocyte-like cells, and spindle fibroblast-like cells arranged in a plexiform pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plexiform Fibrohistiocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"PFHT","termGroup":"AB","termSource":"NCI"},{"termName":"Plexiform Fibrohistiocytic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8835/1"},{"name":"Legacy Concept Name","value":"Plexiform_Fibrohistiocytic_Tumor"},{"name":"Maps_To","value":"8835/1"},{"name":"Maps_To","value":"Plexiform fibrohistiocytic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266126"}]}}{"C6494":{"preferredName":"Angiomatoid Fibrous Histiocytoma","code":"C6494","definitions":[{"definition":"A low malignant potential soft tissue neoplasm of uncertain differentiation.  It typically affects young patients, presenting as a slowly growing nodular or cystic tumor mass, most often in the subcutaneous tissues of the extremities.  Occasionally, patients have systemic symptoms (anemia, fever, and weight loss).  This tumor has a relatively good prognosis.  A minority of patients develop local recurrences.  Metastases are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomatoid Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"AFH","termGroup":"AB","termSource":"NCI"},{"termName":"Angiomatoid Malignant Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8836/1"},{"name":"Legacy Concept Name","value":"Angiomatoid_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8836/1"},{"name":"Maps_To","value":"Angiomatoid fibrous histiocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266127"}]}}{"C6577":{"preferredName":"Myxoma","code":"C6577","definitions":[{"definition":"A benign soft tissue neoplasm characterized by the presence of spindle and stellate cells, lobulated growth pattern, and myxoid stroma formation.","type":"DEFINITION","source":"NCI"},{"definition":"A benign soft tissue neoplasm with a myxoid stroma formation.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Myxoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8840/0"},{"name":"Legacy Concept Name","value":"Myxoma"},{"name":"Maps_To","value":"8840/0"},{"name":"Maps_To","value":"Myxoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027149"}]}}{"C3255":{"preferredName":"Myxosarcoma","code":"C3255","definitions":[{"definition":"A malignant soft tissue neoplasm with a myxoid stroma formation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating malignant soft tissue neoplasm characterized by the presence of immature undifferentiated cells and abundant myxoid stroma formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8840/3"},{"name":"Legacy Concept Name","value":"Myxosarcoma"},{"name":"Maps_To","value":"8840/3"},{"name":"Maps_To","value":"Myxosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027155"}]}}{"C3254":{"preferredName":"Angiomyxoma","code":"C3254","definitions":[{"definition":"A benign soft tissue neoplasm characterized by the presence of neoplastic spindle and stellate cells, and vascular proliferation in a myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomyxoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8841/0"},{"name":"ICD-O-3_Code","value":"8841/1"},{"name":"Legacy Concept Name","value":"Angiomyxoma"},{"name":"Maps_To","value":"8841/1"},{"name":"Maps_To","value":"Angiomyxoma"},{"name":"Maps_To","value":"Angiomyxoma, NOS"},{"name":"NCI_META_CUI","value":"CL329980"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6936":{"preferredName":"Deep (Aggressive) Angiomyxoma","code":"C6936","definitions":[{"definition":"A locally infiltrating, non-metastasizing angiomyxoma arising from the pelviperineal region.  It may recur following resection","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep (Aggressive) Angiomyxoma","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive Angiomyxoma","termGroup":"SY","termSource":"NCI"},{"termName":"Deep \"Aggressive\" Angiomyxoma","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Angiomyxoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aggressive_Angiomyxoma"},{"name":"Maps_To","value":"8841/1"},{"name":"Maps_To","value":"Aggressive angiomyxoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306242"}]}}{"C6582":{"preferredName":"Ossifying Fibromyxoid Tumor","code":"C6582","definitions":[{"definition":"A rare soft tissue tumor of uncertain lineage characterized by the presence of neoplastic spindle to round cells forming cords in a fibromyxoid stroma.  The lesions are associated with the formation of metaplastic bone.  Most patients present with painless subcutaneous masses.  Recurrences have been reported in a minority of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ossifying Fibromyxoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"OFMT","termGroup":"AB","termSource":"NCI"},{"termName":"Ossifying Fibromyxoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ossifying Fibromyxoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8842/0"},{"name":"Legacy Concept Name","value":"Ossifying_Fibromyxoid_Neoplasm"},{"name":"Maps_To","value":"8842/0"},{"name":"Maps_To","value":"Ossifying fibromyxoid tumor"},{"name":"Maps_To","value":"Ossifying fibromyxoid tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266128"}]}}{"C142827":{"preferredName":"Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion","code":"C142827","definitions":[{"definition":"A sarcoma that arises from the lung. It is related to a bronchus and is often predominantly endobronchial. It is characterized by the proliferation of round and spindle cells within a myxoid stroma. It is associated with the presence of an EWSR1::CREB1 fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion","termGroup":"PT","termSource":"NCI"},{"termName":"Low-Grade Malignant Myxoid Endobronchial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"PPMS","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Pulmonary Myxoid Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Pulmonary Myxoid Sarcoma with EWSR1::CREB1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation"},{"name":"NCI_META_CUI","value":"CL536391"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3192":{"preferredName":"Lipoma","code":"C3192","definitions":[{"definition":"A benign (not cancer) tumor made of fat cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign neoplasm composed of adipose tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8850/0"},{"name":"Legacy Concept Name","value":"Lipoma"},{"name":"Maps_To","value":"8850/0"},{"name":"Maps_To","value":"Lipoma of other specified sites"},{"name":"Maps_To","value":"Lipoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023798"}]}}{"C6505":{"preferredName":"Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C6505","definitions":[{"definition":"A locally aggressive mesenchymal neoplasm composed either entirely or partly of an adipocytic proliferation showing at least focal nuclear atypia in both adipocytes and stromal cells. \"Atypical lipomatous tumor\" and \"well-differentiated liposarcoma\" are synonyms describing lesions that are morphologically and genetically identical. Amplification of MDM2 and/or CDK4 is almost always present. (WHO 2020)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ALT","termGroup":"AB","termSource":"NCI"},{"termName":"ALT/WDLPS","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Lipoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Atypical Lipomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8850/1"},{"name":"ICD-O-3_Code","value":"8851/3"},{"name":"Legacy Concept Name","value":"Atypical_Lipoma"},{"name":"Legacy Concept Name","value":"Well-Differentiated_Liposarcoma"},{"name":"Maps_To","value":"8851/3"},{"name":"Maps_To","value":"Atypical lipoma"},{"name":"Maps_To","value":"Atypical lipomatous tumor"},{"name":"Maps_To","value":"Liposarcoma, differentiated"},{"name":"Maps_To","value":"Liposarcoma, well differentiated"},{"name":"Maps_To","value":"Liposarcoma, well differentiated, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266129"}]}}{"C3194":{"preferredName":"Liposarcoma","code":"C3194","definitions":[{"definition":"A malignant neoplasm composed of adipose tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Lipomatous Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8850/3"},{"name":"Legacy Concept Name","value":"Liposarcoma"},{"name":"Legacy Concept Name","value":"Malignant_Lipomatous_Neoplasm"},{"name":"Maps_To","value":"8850/3"},{"name":"Maps_To","value":"Fibroliposarcoma"},{"name":"Maps_To","value":"Liposarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346117"}]}}{"C4249":{"preferredName":"Fibrolipoma","code":"C4249","definitions":[{"definition":"A benign neoplasm comprising mature adipocytes, characterized by areas of abundant fibrous tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign well-circumscribed tumor composed of mature adipocytes, characterized by areas of abundant fibrous tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8851/0"},{"name":"Legacy Concept Name","value":"Fibrolipoma"},{"name":"Maps_To","value":"8851/0"},{"name":"Maps_To","value":"Fibrolipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334467"}]}}{"C6508":{"preferredName":"Inflammatory Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C6508","definitions":[{"definition":"A rare morphologic variant of atypical lipomatous tumor/well differentiated liposarcoma occurring most often in the retroperitoneum. It is characterized by the presence of a predominant chronic inflammatory infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inflammatory Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Inflammatory ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inflammatory_Liposarcoma"},{"name":"Maps_To","value":"8851/3"},{"name":"Maps_To","value":"Inflammatory liposarcoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370890"}]}}{"C6507":{"preferredName":"Sclerosing Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C6507","definitions":[{"definition":"An atypical lipomatous tumor/well differentiated liposarcoma characterized by the presence of bizarre hyperchromatic stromal cells and rare multivacuolated lipoblasts within a fibrous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosing Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sclerosing ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sclerosing_Liposarcoma"},{"name":"Maps_To","value":"8851/3"},{"name":"Maps_To","value":"Sclerosing liposarcoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334469"}]}}{"C4251":{"preferredName":"Fibromyxolipoma","code":"C4251","definitions":[{"definition":"A benign well-circumscribed tumor composed of mature adipocytes, characterized by areas of abundant fibrous tissue and extensive myxoid change.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibromyxolipoma","termGroup":"PT","termSource":"NCI"},{"termName":"Myxolipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8852/0"},{"name":"Legacy Concept Name","value":"Fibromyxolipoma"},{"name":"Maps_To","value":"8852/0"},{"name":"Maps_To","value":"Fibromyxolipoma"},{"name":"Maps_To","value":"Myxolipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334470"}]}}{"C27781":{"preferredName":"Myxoid Liposarcoma","code":"C27781","definitions":[{"definition":"A liposarcoma characterized by the presence of round non-lipogenic primitive mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a branching vascular pattern.  This category includes hypercellular lesions with round cell morphology, formerly known as round cell liposarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxoid Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"MLPS","termGroup":"AB","termSource":"NCI"},{"termName":"Myxoid Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid/Round Cell Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8852/3"},{"name":"Legacy Concept Name","value":"Myxoid_Round_Cell_Liposarcoma"},{"name":"Maps_To","value":"8852/3"},{"name":"Maps_To","value":"Myxoid liposarcoma"},{"name":"Maps_To","value":"Myxoliposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206634"}]}}{"C4252":{"preferredName":"Round Cell Liposarcoma","code":"C4252","definitions":[{"definition":"A poorly differentiated liposarcoma, characterized by the presence of solid sheets of primitive round mesenchymal cells and the absence of myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Myxoid Liposarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Round Cell Liposarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8853/3"},{"name":"Legacy Concept Name","value":"Round_Cell_Liposarcoma"},{"name":"Maps_To","value":"8853/3"},{"name":"Maps_To","value":"Round cell liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334471"}]}}{"C3703":{"preferredName":"Pleomorphic Lipoma","code":"C3703","definitions":[{"definition":"A benign circumscribed tumor characterized by small spindle cells, rounded hyperchromatic cells and multinucleated giant cells with radially arranged nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Lipoma","termGroup":"PT","termSource":"NCI"},{"termName":"PL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8854/0"},{"name":"Legacy Concept Name","value":"Pleomorphic_Lipoma"},{"name":"Maps_To","value":"8854/0"},{"name":"Maps_To","value":"Pleomorphic lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205823"}]}}{"C3705":{"preferredName":"Pleomorphic Liposarcoma","code":"C3705","definitions":[{"definition":"A rare, aggressive liposarcoma characterized by the presence of varying proportions of pleomorphic lipoblasts in a background that resembles undifferentiated pleomorphic sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Liposarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8854/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Liposarcoma"},{"name":"Maps_To","value":"8854/3"},{"name":"Maps_To","value":"Pleomorphic liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205825"}]}}{"C4253":{"preferredName":"Mixed Liposarcoma","code":"C4253","definitions":[{"definition":"A malignant neoplasm characterized by the presence of a combination of liposarcomatous morphologic subtypes: myxoid/round cell and well differentiated/dedifferentiated liposarcoma or myxoid/round cell and pleomorphic liposarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Liposarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8855/3"},{"name":"Legacy Concept Name","value":"Mixed_Liposarcoma"},{"name":"Maps_To","value":"8855/3"},{"name":"Maps_To","value":"Mixed liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334472"}]}}{"C7451":{"preferredName":"Infiltrating Lipoma","code":"C7451","definitions":[{"definition":"A benign tumor, composed of lobules of mature adipocytes, that penetrates the surrounding tissue from which it arises. There is usually a higher local recurrence rate when compared with non-infiltrating lipomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infiltrating Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Lipoma"},{"name":"Maps_To","value":"8856/0"},{"name":"Maps_To","value":"Infiltrating lipoma"},{"name":"NCI_META_CUI","value":"CL028013"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7450":{"preferredName":"Intramuscular Lipoma","code":"C7450","definitions":[{"definition":"A benign tumor, composed of mature adipocytes, that arises within skeletal muscle fibers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramuscular Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8856/0"},{"name":"Legacy Concept Name","value":"Intramuscular_Lipoma"},{"name":"Maps_To","value":"8856/0"},{"name":"Maps_To","value":"Intramuscular lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334473"}]}}{"C7449":{"preferredName":"Infiltrating Angiolipoma","code":"C7449","definitions":[{"definition":"An uncommon lipoma characterized by prominent vascularity that invades the surrounding deep tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infiltrating Angiolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Angiolipoma"},{"name":"Maps_To","value":"8856/0"},{"name":"Maps_To","value":"Infiltrating angiolipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1305256"}]}}{"C4254":{"preferredName":"Spindle Cell Lipoma","code":"C4254","definitions":[{"definition":"A benign circumscribed tumor composed of spindled cells, adipocytes, and collagen bundles.  There is no evidence of nuclear hyperchromasia or mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Lipoma","termGroup":"PT","termSource":"NCI"},{"termName":"SCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8857/0"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Lipoma"},{"name":"Maps_To","value":"8857/0"},{"name":"Maps_To","value":"Spindle cell lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334474"}]}}{"C6509":{"preferredName":"Fibroblastic Liposarcoma","code":"C6509","definitions":[{"definition":"A liposarcoma characterized by the presence of a fibroblastic component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroblastic Liposarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8857/3"},{"name":"Legacy Concept Name","value":"Fibroblastic_Liposarcoma"},{"name":"Maps_To","value":"8857/3"},{"name":"Maps_To","value":"Fibroblastic liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266130"}]}}{"C3704":{"preferredName":"Dedifferentiated Liposarcoma","code":"C3704","definitions":[{"definition":"An atypical lipomatous tumor/well differentiated liposarcoma that shows progression to a usually non-lipomatous, high grade sarcoma.  The non-lipomatous sarcoma component may be present in the primary lesion or at the site of recurrence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dedifferentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"DDLPS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8858/3"},{"name":"Legacy Concept Name","value":"Dedifferentiated_Liposarcoma"},{"name":"Maps_To","value":"8858/3"},{"name":"Maps_To","value":"Dedifferentiated liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205824"}]}}{"C3734":{"preferredName":"Angiomyolipoma","code":"C3734","definitions":[{"definition":"A benign (noncancer) tumor of fat and muscle tissue that usually is found in the kidney. Angiomyolipomas rarely cause symptoms, but may bleed or grow large enough to be painful or cause kidney failure. They are common in patients with tuberous sclerosis (a genetic disorder in which benign tumors grow in the kidneys, brain, eyes, heart, lungs, and skin, causing seizures, mental problems, and skin lesions).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm with perivascular epithelioid cell differentiation often associated with tuberous sclerosis.  It is characterized by a mixture of epithelioid cells, smooth muscle, vessels, and mature adipose tissue.  The kidney is the most common site of involvement.  Other sites of involvement include the liver, lung, lymph nodes, and retroperitoneum.  The vast majority of cases follow a benign clinical course.  However, cases of metastatic angiomyolipomas with sarcomatoid features have been described.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomyolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8860/0"},{"name":"Legacy Concept Name","value":"Angiomyolipoma"},{"name":"Maps_To","value":"8860/0"},{"name":"Maps_To","value":"Angiomyolipoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206633"}]}}{"C3733":{"preferredName":"Angiolipoma","code":"C3733","definitions":[{"definition":"A lipoma characterized by prominent vascularization.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A lipoma with prominent vascularity. The vascular tissue is more abundant at the periphery of the tumor and contains fibrin thrombi. It occurs more frequently in younger individuals as a painful subcutaneous nodule, often on the arms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8861/0"},{"name":"Legacy Concept Name","value":"Angiolipoma"},{"name":"Maps_To","value":"8861/0"},{"name":"Maps_To","value":"Angiolipoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206632"}]}}{"C6503":{"preferredName":"Chondroid Lipoma","code":"C6503","definitions":[{"definition":"A rare benign adipose tissue neoplasm characterized by nests and cord of abundant univacuolated and multivacuolated lipoblasts and mature adipocytes in a prominent myxoid to hyalinized chondroid matrix admix. It predominantly affects females.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroid Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8862/0"},{"name":"Legacy Concept Name","value":"Chondroid_Lipoma"},{"name":"Maps_To","value":"8862/0"},{"name":"Maps_To","value":"Chondroid lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266131"}]}}{"C3736":{"preferredName":"Adrenal Gland Myelolipoma","code":"C3736","definitions":[{"definition":"A benign soft tissue lesion arising from the adrenal gland.  It is composed of mature adipose and hematopoietic/lymphoid tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A benign tumor of the adrenal gland composed of adipocytes and hematopoietic/lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adrenal Gland Myelolipoma","termGroup":"PT","termSource":"NCI"},{"termName":"Myelolipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8870/0"},{"name":"Legacy Concept Name","value":"Myelolipoma"},{"name":"Maps_To","value":"8870/0"},{"name":"Maps_To","value":"Myelolipoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0206635"}]}}{"C3702":{"preferredName":"Hibernoma","code":"C3702","definitions":[{"definition":"A benign neoplasm of the brown adipose tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare benign slow growing adipose tissue tumor, characterized by the presence of polygonal brown fat cells with multivacuolated and/or granular cytoplasm.  The tumor is usually painless and is most often seen in young adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hibernoma","termGroup":"PT","termSource":"NCI"},{"termName":"Brown Fat Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Brown Fat Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Fetal Fat Cell Lipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8880/0"},{"name":"Legacy Concept Name","value":"Hibernoma"},{"name":"Maps_To","value":"8880/0"},{"name":"Maps_To","value":"Brown fat tumor"},{"name":"Maps_To","value":"Fetal fat cell lipoma"},{"name":"Maps_To","value":"Hibernoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205822"}]}}{"C27483":{"preferredName":"Lipoblastoma","code":"C27483","definitions":[{"definition":"A lipoma usually occurring in the extremities of young children (usually boys). It is characterized by lobules of adipose tissue, separated by fibrous septa.  The adipose tissue is composed of mature adipocytes and lipoblasts. The lipoblasts may be scarce, depending on the age of the patient.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonic Lipoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fetal Lipoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infantile Lipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lipoblastoma"},{"name":"Maps_To","value":"8881/0"},{"name":"Maps_To","value":"Fetal lipoma, NOS"},{"name":"Maps_To","value":"Lipoblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260965"}]}}{"C4255":{"preferredName":"Lipoblastomatosis","code":"C4255","definitions":[{"definition":"A neoplastic process characterized by the presence of multiple lipoblastomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoblastomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Lipomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8881/0"},{"name":"Legacy Concept Name","value":"Lipoblastomatosis"},{"name":"Maps_To","value":"8881/0"},{"name":"Maps_To","value":"Fetal lipomatosis"},{"name":"Maps_To","value":"Lipoblastomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334475"}]}}{"C3434":{"preferredName":"Uterine Corpus Leiomyoma","code":"C3434","definitions":[{"definition":"A benign smooth muscle neoplasm arising from the body of the uterus. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Body of Uterus Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Body of Uterus Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Corpus Uteri Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Corpus Uteri Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Body Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Body Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Leiomyomata","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Fibroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Leiomyoma"},{"name":"Maps_To","value":"8890/0"},{"name":"Maps_To","value":"Fibroid uterus"},{"name":"Maps_To","value":"Fibromyoma"},{"name":"Maps_To","value":"Leiomyofibroma"},{"name":"Maps_To","value":"Leiomyoma of uterus, unspecified"},{"name":"Maps_To","value":"Submucous leiomyoma of uterus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0042133"}]}}{"C3157":{"preferredName":"Leiomyoma","code":"C3157","definitions":[{"definition":"A benign neoplasm, originating from smooth muscle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign smooth muscle tumor, usually in the uterus or gastrointestinal tract.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A well-circumscribed benign smooth muscle neoplasm characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyomatous Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8890/0"},{"name":"Legacy Concept Name","value":"Leiomyoma"},{"name":"Maps_To","value":"8890/0"},{"name":"Maps_To","value":"Leiomyoma"},{"name":"Maps_To","value":"Leiomyoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302742"}]}}{"C3748":{"preferredName":"Leiomyomatosis","code":"C3748","definitions":[{"definition":"A condition characterized by the presence of numerous small benign smooth muscle neoplasms located throughout the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leiomyomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8890/1"},{"name":"Legacy Concept Name","value":"Leiomyomatosis"},{"name":"Maps_To","value":"8890/1"},{"name":"Maps_To","value":"Leiomyomatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206654"}]}}{"C3158":{"preferredName":"Leiomyosarcoma","code":"C3158","definitions":[{"definition":"A malignant (cancer) tumor of smooth muscle cells that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm, originating from smooth muscle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor of smooth muscle cells that can arise almost anywhere in the body but is most common in the uterus, abdomen, or pelvis.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leiomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8890/3"},{"name":"Legacy Concept Name","value":"Leiomyosarcoma"},{"name":"Maps_To","value":"8890/3"},{"name":"Maps_To","value":"Leiomyosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023269"},{"name":"xRef","value":"IMDRF:E180103"}]}}{"C40164":{"preferredName":"Uterine Corpus Epithelioid Leiomyoma","code":"C40164","definitions":[{"definition":"A morphologic variant of uterine corpus leiomyoma characterized by the presence of round or polygonal epithelioid smooth muscle cells forming clusters.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Epithelioid Leiomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Epithelioid_Leiomyoma"},{"name":"Maps_To","value":"8891/0"},{"name":"Maps_To","value":"Epithelioid leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519850"}]}}{"C3700":{"preferredName":"Epithelioid Leiomyosarcoma","code":"C3700","definitions":[{"definition":"A morphologic variant of leiomyosarcoma characterized by the presence of epithelioid round cells with eosinophilic to clear cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Leiomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8891/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Leiomyosarcoma"},{"name":"Maps_To","value":"8891/3"},{"name":"Maps_To","value":"Epithelioid leiomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205815"}]}}{"C4256":{"preferredName":"Cellular Leiomyoma","code":"C4256","definitions":[{"definition":"A morphologic variant of classic leiomyoma characterized by a dense cellular infiltrate composed of spindle or round cells with scant cytoplasm and a less obvious interlacing fascicle pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Leiomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8892/0"},{"name":"Legacy Concept Name","value":"Cellular_Leiomyoma"},{"name":"Maps_To","value":"8892/0"},{"name":"Maps_To","value":"Cellular leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334477"}]}}{"C4257":{"preferredName":"Bizarre Leiomyoma","code":"C4257","definitions":[{"definition":"A morphologic variant of leiomyoma characterized by the presence of pleomorphic muscle cells with bizarre hyperchromatic nuclei and eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bizarre Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pleomorphic Leiomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8893/0"},{"name":"Legacy Concept Name","value":"Bizarre_Leiomyoma"},{"name":"Maps_To","value":"8893/0"},{"name":"Maps_To","value":"Atypical leiomyoma"},{"name":"Maps_To","value":"Bizarre leiomyoma"},{"name":"Maps_To","value":"Pleomorphic leiomyoma"},{"name":"Maps_To","value":"Symplastic leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334478"}]}}{"C3747":{"preferredName":"Angioleiomyoma","code":"C3747","definitions":[{"definition":"A benign, slow-growing neoplasm that arises from the dermis or subcutaneous tissue. It is characterized by the presence of well-differentiated smooth muscle cells which are arranged around numerous vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angioleiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Vascular Leiomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8894/0"},{"name":"Legacy Concept Name","value":"Angiomyoma"},{"name":"Maps_To","value":"8894/0"},{"name":"Maps_To","value":"Angioleiomyoma"},{"name":"Maps_To","value":"Angiomyoma"},{"name":"Maps_To","value":"Vascular leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206653"}]}}{"C66771":{"preferredName":"Angiomyosarcoma","code":"C66771","definitions":[{"definition":"A malignant smooth muscle neoplasm characterized by the presence of atypical spindle cells and formation of vascular channels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomyosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8894/3"},{"name":"Legacy Concept Name","value":"Angiomyosarcoma"},{"name":"Maps_To","value":"8894/3"},{"name":"Maps_To","value":"Angiomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334479"}]}}{"C4882":{"preferredName":"Benign Muscle Neoplasm","code":"C4882","definitions":[{"definition":"A mesenchymal neoplasm that arises from smooth, skeletal, or cardiac muscle and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Muscle Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Myoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8895/0"},{"name":"Legacy Concept Name","value":"Benign_Muscle_Neoplasm"},{"name":"Maps_To","value":"8895/0"},{"name":"Maps_To","value":"Myoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027086"}]}}{"C4883":{"preferredName":"Malignant Muscle Neoplasm","code":"C4883","definitions":[{"definition":"A malignant neoplasm affecting the skeletal or smooth muscles.  Malignant neoplasms arising from the skeletal muscles are called rhabdomyosarcomas.  Malignant neoplasms arising from the smooth muscles are called leiomyosarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Muscle Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Myosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8895/3"},{"name":"Legacy Concept Name","value":"Malignant_Muscle_Neoplasm"},{"name":"Maps_To","value":"8895/3"},{"name":"Maps_To","value":"Myosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0684743"}]}}{"C3701":{"preferredName":"Myxoid Leiomyosarcoma","code":"C3701","definitions":[{"definition":"A morphologic variant of leiomyosarcoma characterized by the presence of cellular pleomorphism, malignant cells with large nuclei, and a myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxoid Leiomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8896/3"},{"name":"Legacy Concept Name","value":"Myxoid_Leiomyosarcoma"},{"name":"Maps_To","value":"8896/3"},{"name":"Maps_To","value":"Myxoid leiomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205816"}]}}{"C40177":{"preferredName":"Uterine Corpus Smooth Muscle Tumor of Uncertain Malignant Potential","code":"C40177","definitions":[{"definition":"A smooth muscle neoplasm that arises from the uterine corpus and cannot be reliably diagnosed as benign or malignant because of the presence of ambiguous morphologic findings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Smooth Muscle Tumor of Uncertain Malignant Potential","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Uterine Corpus Smooth Muscle Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Smooth Muscle Neoplasm of Uncertain Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus STUMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8897/1"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Smooth_Muscle_Neoplasm_of_Uncertain_Malignant_Potential"},{"name":"Maps_To","value":"8897/1"},{"name":"Maps_To","value":"Smooth muscle tumor of uncertain malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519864"}]}}{"C40173":{"preferredName":"Uterine Corpus Metastasizing Leiomyoma","code":"C40173","definitions":[{"definition":"A cytologically benign smooth muscle neoplasm that arises from the uterine corpus and has metastasized to the lungs, abdomen, or lymph nodes. It usually presents in women with a history of benign uterine leiomyomas that have been surgically removed years before the extrauterine neoplasm spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Metastasizing Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Metastasizing Leiomyoma of the Uterine Corpus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8898/1"},{"name":"Legacy Concept Name","value":"Benign_Metastasizing_Leiomyoma"},{"name":"Maps_To","value":"8898/1"},{"name":"Maps_To","value":"Metastasizing leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511090"}]}}{"C3358":{"preferredName":"Rhabdomyoma","code":"C3358","definitions":[{"definition":"A benign mesenchymal tumor arising from skeletal or cardiac muscle.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm arising from skeletal or cardiac muscle, characterized by the presence of rhabdomyoblasts.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Rhabdomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8900/0"},{"name":"Legacy Concept Name","value":"Rhabdomyoma"},{"name":"Maps_To","value":"8900/0"},{"name":"Maps_To","value":"Rhabdomyoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0035411"}]}}{"C3359":{"preferredName":"Rhabdomyosarcoma","code":"C3359","definitions":[{"definition":"A malignant mesenchymal neoplasm arising from skeletal muscle.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from skeletal myocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the soft tissues in a type of muscle called striated muscle. Rhabdomyosarcoma can occur anywhere in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8900/3"},{"name":"Legacy Concept Name","value":"Rhabdomyosarcoma"},{"name":"Maps_To","value":"8900/3"},{"name":"Maps_To","value":"Rhabdomyosarcoma"},{"name":"Maps_To","value":"Rhabdomyosarcoma, NOS"},{"name":"Maps_To","value":"Rhabdosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1276181"}]}}{"C4258":{"preferredName":"Pleomorphic Rhabdomyosarcoma","code":"C4258","definitions":[{"definition":"An aggressive malignant mesenchymal neoplasm with skeletal muscle differentiation, occurring in adults and rarely in children.  The tumor is characterized by the presence of bizarre round, spindle, and polygonal cells.  Clinical presentation includes a rapidly enlarging painful mass usually of the lower extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleomorphic_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8901/3"},{"name":"Maps_To","value":"Pleomorphic rhabdomyosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334480"}]}}{"C27369":{"preferredName":"Adult Pleomorphic Rhabdomyosarcoma","code":"C27369","definitions":[{"definition":"An aggressive rhabdomyosarcoma occurring in adults.  The neoplasm is characterized by the presence of bizarre round, spindle, and polygonal cells.  Clinical presentation includes a rapidly enlarging painful mass usually in the lower extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Pleomorphic Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8901/3"},{"name":"Legacy Concept Name","value":"Adult_Pleomorphic_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8901/3"},{"name":"Maps_To","value":"Pleomorphic rhabdomyosarcoma, adult type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332211"}]}}{"C4259":{"preferredName":"Rhabdomyosarcoma with Mixed Embryonal and Alveolar Features","code":"C4259","definitions":[{"definition":"A rhabdomyosarcoma composed of embryonic and alveolar components. It is characterized by the presence of spindle cells with myoblastic differentiation, a myxoid stroma, and fibrous septa.  These tumors were previously considered variants of alveolar rhabdomyosarcoma.  The lack of PAX3-FOXO1 fusions in most of these tumors suggests that are biologically and clinically related to embryonal rhabdomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhabdomyosarcoma with Mixed Embryonal and Alveolar Features","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Alveolar Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Type Alveolar Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8902/3"},{"name":"Legacy Concept Name","value":"Mixed_Type_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8902/3"},{"name":"Maps_To","value":"Mixed type rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709053"}]}}{"C4260":{"preferredName":"Fetal Rhabdomyoma","code":"C4260","definitions":[{"definition":"A rare benign mesenchymal neoplasm arising from skeletal muscle. It is characterized by the presence of immature spindle and polygonal cells within a scant myxoid stroma. It usually develops in the head and neck region of young children.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fetal Rhabdomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8903/0"},{"name":"Legacy Concept Name","value":"Fetal_Rhabdomyoma"},{"name":"Maps_To","value":"8903/0"},{"name":"Maps_To","value":"Fetal rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334482"}]}}{"C4261":{"preferredName":"Adult Extracardiac Rhabdomyoma","code":"C4261","definitions":[{"definition":"A benign mesenchymal neoplasm arising from skeletal muscle and occurring in adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Extracardiac Rhabdomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Extracardiac Rhabdomyomatous Hamartoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8904/0"},{"name":"Legacy Concept Name","value":"Adult_Rhabdomyoma"},{"name":"Maps_To","value":"8904/0"},{"name":"Maps_To","value":"Adult rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4055487"}]}}{"C45747":{"preferredName":"Adult Cardiac Cellular Rhabdomyoma","code":"C45747","definitions":[{"definition":"A rare cardiac rhabdomyoma occurring in adults.  It is characterized by the presence of neoplastic striated muscle cells with eosinophilic granular cytoplasm and increased cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Cardiac Cellular Rhabdomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Heart Cellular Rhabdomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Cardiac_Cellular_Rhabdomyoma"},{"name":"Maps_To","value":"8904/0"},{"name":"Maps_To","value":"Adult cellular rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1706729"}]}}{"C6517":{"preferredName":"Genital Rhabdomyoma","code":"C6517","definitions":[{"definition":"A rare benign skeletal muscle neoplasm arising from the female genital tract. It is characterized by the presence of small nucleated rhabdomyoblasts within a fibrous and myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genital Rhabdomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8905/0"},{"name":"Legacy Concept Name","value":"Genital_Rhabdomyoma"},{"name":"Maps_To","value":"8905/0"},{"name":"Maps_To","value":"Genital rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266133"}]}}{"C9150":{"preferredName":"Botryoid-Type Embryonal Rhabdomyosarcoma","code":"C9150","definitions":[{"definition":"A morphologic variant of embryonal rhabdomyosarcoma arising from organs with a mucosal epithelial surface.  It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botryoid-Type Embryonal Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Botryoid Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma Botryoides","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Botryoid-Type_Embryonal_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8910/3"},{"name":"Maps_To","value":"Botryoid sarcoma"},{"name":"Maps_To","value":"Sarcoma botryoides"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306573"}]}}{"C8971":{"preferredName":"Embryonal Rhabdomyosarcoma","code":"C8971","definitions":[{"definition":"A poorly circumscribed morphologic variant of rhabdomyosarcoma.  It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that is most common in infants and young children. It begins in muscles, usually in the head, neck, or genitourinary tract.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Embryonal Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ERMS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8910/3"},{"name":"Legacy Concept Name","value":"Embryonal_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8910/3"},{"name":"Maps_To","value":"Embryonal rhabdomyosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206656"}]}}{"C6519":{"preferredName":"Spindle Cell Rhabdomyosarcoma","code":"C6519","definitions":[{"definition":"An uncommon variant of rhabdomyosarcoma characterized by the presence of whorls of spindle cells forming a storiform pattern. In children it usually arises in the paratesticular region. In adults it usually arises from the deep soft tissues in the head and neck.","type":"DEFINITION","source":"NCI"},{"definition":"An uncommon variant of rhabdomyosarcoma that is characterized by the presence of whorls of spindle cells forming a storiform pattern. In children, it usually arises in the paratesticular region; in adults it usually arises from the deep soft tissues in the head and neck.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Spindle Cell Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8912/3"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8912/3"},{"name":"Maps_To","value":"Spindle cell rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266134"}]}}{"C3749":{"preferredName":"Alveolar Rhabdomyosarcoma","code":"C3749","definitions":[{"definition":"A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that is most common in older children and teenagers. It begins in embryonic muscle cells (cells that develop into muscles in the body). It can occur at many places in the body, but usually occurs in the trunk, arms, or legs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alveolar Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ARMS","termGroup":"AB","termSource":"NCI"},{"termName":"Monomorphous Round Cell Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8920/3"},{"name":"Legacy Concept Name","value":"Alveolar_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8920/3"},{"name":"Maps_To","value":"Alveolar rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206655"}]}}{"C4716":{"preferredName":"Ectomesenchymoma","code":"C4716","definitions":[{"definition":"A rare, fast-growing tumor of the nervous system or soft tissue that occurs in children and young adults. Ectomesenchymomas may form in the head and neck, abdomen, perineum, scrotum, or limbs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An exceedingly rare, aggressive malignant mesenchymal neoplasm characterized by the presence of a sarcomatous component and a ganglionic or a neuroectodermal component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ectomesenchymoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ectomesenchymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma with Ganglionic or Neuroectodermal Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8921/3"},{"name":"Legacy Concept Name","value":"Rhabdomyosarcoma_with_Ganglionic_Differentiation"},{"name":"Maps_To","value":"8921/3"},{"name":"Maps_To","value":"Ectomesenchymoma"},{"name":"Maps_To","value":"Rhabdomyosarcoma with ganglionic differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431111"}]}}{"C4262":{"preferredName":"Endometrial Stromal Nodule","code":"C4262","definitions":[{"definition":"A non-infiltrating, benign mesenchymal neoplasm arising from the uterine corpus. It is characterized by the presence of neoplastic cells that resemble the cells of the proliferative phase of endometrial stroma and numerous thin-walled small vessels. It usually presents with abnormal uterine bleeding and menorrhagia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Stromal Nodule","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8930/0"},{"name":"Legacy Concept Name","value":"Endometrial_Stromal_Nodule"},{"name":"Maps_To","value":"8930/0"},{"name":"Maps_To","value":"Endometrial stromal nodule"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334485"}]}}{"C8973":{"preferredName":"Endometrioid Stromal Sarcoma","code":"C8973","definitions":[{"definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant, mesenchymal tumor of the uterine stroma.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endometrioid Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"ESS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8930/3"},{"name":"Legacy Concept Name","value":"Endometrial_Stromal_Sarcoma"},{"name":"Maps_To","value":"8930/3"},{"name":"Maps_To","value":"Endometrial sarcoma, NOS"},{"name":"Maps_To","value":"Endometrial stromal sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206630"}]}}{"C126998":{"preferredName":"Uterine Corpus High Grade Endometrial Stromal Sarcoma","code":"C126998","definitions":[{"definition":"A rare, high grade sarcoma that arises from the endometrial stroma. It is characterized by round cell morphology. It was previously also known as undifferentiated uterine sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. It appears to have a prognosis that falls between low grade endometrial stromal sarcoma and undifferentiated sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus High Grade Endometrial Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrial Stromal Sarcoma, High Grade","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade ESS","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus High Grade ESS","termGroup":"SY","termSource":"NCI"},{"termName":"YWHAE-FAM22 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"YWHAE-FAM22 ESS","termGroup":"AB","termSource":"NCI"},{"termName":"YWHAE::FAM22 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8930/3"},{"name":"Maps_To","value":"Endometrial stromal sarcoma, high grade"},{"name":"NCI_META_CUI","value":"CL508195"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40223":{"preferredName":"Uterine Corpus Low Grade Endometrial Stromal Sarcoma","code":"C40223","definitions":[{"definition":"A rare, indolent, invasive mesenchymal tumor that arises from the endometrial stroma. It is characterized by the presence of a plexiform vasculature, infrequent mitoses, and insignificant cytologic atypia. Late recurrences may occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Low Grade Endometrial Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"JAZF1-SUZ12 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"JAZF1-SUZ12 ESS","termGroup":"AB","termSource":"NCI"},{"termName":"JAZF1::SUZ12 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Low Grade ESS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Low_Grade_Endometrial_Stromal_Sarcoma"},{"name":"Maps_To","value":"8931/3"},{"name":"Maps_To","value":"Endometrial stromal sarcoma, low grade"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519857"}]}}{"C4263":{"preferredName":"Low Grade Endometrioid Stromal Sarcoma","code":"C4263","definitions":[{"definition":"An infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. It is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. It is usually characterized by indolent growth and late recurrences.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Endometrioid Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endolymphatic Stromal Myosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8931/3"},{"name":"Legacy Concept Name","value":"Low_Grade_Endometrial_Stromal_Sarcoma"},{"name":"Maps_To","value":"8931/3"},{"name":"Maps_To","value":"Endolymphatic stromal myosis"},{"name":"Maps_To","value":"Endometrial stromatosis"},{"name":"Maps_To","value":"Stromal endometriosis"},{"name":"Maps_To","value":"Stromal myosis, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334486"}]}}{"C3726":{"preferredName":"Adenomyoma","code":"C3726","definitions":[{"definition":"A benign neoplasm characterized by the presence of a glandular and a mesenchymal (fibromyomatous) component. It occurs in the uterine corpus, cervix, and uterine ligaments. A variant of adenomyoma associated with glandular architectural complexity is called atypical polypoid adenomyoma. Simple polypectomy is usually curative. Atypical polypoid adenomyoma may recur following polypectomy.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm characterized by the presence of a glandular and a mesenchymal component.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adenomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8932/0"},{"name":"Legacy Concept Name","value":"Adenomyoma"},{"name":"Maps_To","value":"8932/0"},{"name":"Maps_To","value":"Adenomyoma"},{"name":"Maps_To","value":"Adenomyoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206622"}]}}{"C6895":{"preferredName":"Atypical Polypoid Adenomyoma","code":"C6895","definitions":[{"definition":"An adenomyoma characterized by the presence of marked glandular architectural complexity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Polypoid Adenomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Polypoid_Adenomyoma"},{"name":"Maps_To","value":"8932/0"},{"name":"Maps_To","value":"Atypical polypoid adenomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1300347"}]}}{"C9474":{"preferredName":"Adenosarcoma","code":"C9474","definitions":[{"definition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that is a mixture of an adenoma (a tumor that starts in the gland-like cells of epithelial tissue) and a sarcoma (a tumor that starts in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue). An example of an adenosarcoma is Wilms tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mullerian Adenosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Müllerian Adenosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8933/3"},{"name":"Legacy Concept Name","value":"Mullerian_Adenosarcoma"},{"name":"Maps_To","value":"8933/3"},{"name":"Maps_To","value":"Adenosarcoma"},{"name":"Maps_To","value":"Mullerian adenosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001442"}]}}{"C40182":{"preferredName":"Uterine Corpus Carcinofibroma","code":"C40182","definitions":[{"definition":"An uncommon malignant neoplasm arising from the uterine corpus. It is characterized by the presence of a malignant epithelial component and a benign mesenchymal (usually fibrous) component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Carcinofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8934/3"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Adenocarcinofibroma"},{"name":"Maps_To","value":"8934/3"},{"name":"Maps_To","value":"Carcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1883485"}]}}{"C66772":{"preferredName":"Benign Stromal Tumor","code":"C66772","definitions":[{"definition":"A benign neoplasm composed of mesenchymal stromal cells without evidence of cellular atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Stromal Tumor","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8935/0"},{"name":"Legacy Concept Name","value":"Benign_Stromal_Tumor"},{"name":"Maps_To","value":"8935/0"},{"name":"Maps_To","value":"Stromal tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474833"}]}}{"C6781":{"preferredName":"Stromal Neoplasm","code":"C6781","definitions":[{"definition":"A benign or malignant mesenchymal neoplasm composed of stromal cells.  Representative examples include gastrointestinal stromal tumor, endometrial stromal sarcoma, and prostate stromal sarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that arises in the supporting connective tissue of an organ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stromal Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Stromal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8935/1"},{"name":"Legacy Concept Name","value":"Stromal_Neoplasm"},{"name":"Maps_To","value":"8935/1"},{"name":"Maps_To","value":"Stromal tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0879615"}]}}{"C6926":{"preferredName":"Stromal Sarcoma","code":"C6926","definitions":[{"definition":"A malignant neoplasm characterized by the presence of atypical mesenchymal-stromal cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm characterized by the presence of atypical mesenchymal-stromal cells. Representative examples include endometrial stromal sarcoma and prostate stromal sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stromal Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8935/3"},{"name":"Legacy Concept Name","value":"Stromal_Sarcoma"},{"name":"Maps_To","value":"8935/3"},{"name":"Maps_To","value":"Stromal sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370723"}]}}{"C53998":{"preferredName":"Benign Gastrointestinal Stromal Tumor","code":"C53998","definitions":[{"definition":"A benign neoplasm arising from specialized smooth muscle cells (i.e., interstitial cells of Cajal) in the tunica muscularis or myenteric plexus. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A gastrointestinal stromal tumor that is characterized by a maximum diameter equal or less than 5 cm (gastric localization), or equal or less than 2 cm (intestinal localization) and no more than 5 mitotic figures per 50 high power fields.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8936/0"},{"name":"Legacy Concept Name","value":"Probably_Benign_Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"8936/0"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, benign"},{"name":"Maps_To","value":"GIST, benign"},{"name":"NCI_META_CUI","value":"CL449186"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C54000":{"preferredName":"Gastrointestinal Stromal Tumor of Uncertain Malignant Potential","code":"C54000","definitions":[{"definition":"A gastrointestinal stromal tumor that is characterized by a maximum diameter greater than 5 cm and equal or less than 10 cm (gastric localization), or greater than 2 cm and equal or less than 5 cm (intestinal localization) and no more than 5 mitotic figures per 50 high power fields.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrointestinal Stromal Tumor of Uncertain Malignant Potential","termGroup":"HD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Stromal_Tumor_of_Uncertain_Malignant_Potential"},{"name":"Maps_To","value":"8936/1"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, uncertain malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704399"}]}}{"C3868":{"preferredName":"Gastrointestinal Stromal Tumor","code":"C3868","definitions":[{"definition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","type":"DEFINITION","source":"NCI"},{"definition":"A type of tumor that usually begins in cells in the wall of the gastrointestinal tract. It can be benign or malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Stromal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"GIST","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8936/1"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"8936/1"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, NOS"},{"name":"Maps_To","value":"GIST, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3149028"}]}}{"C27940":{"preferredName":"Gastrointestinal Autonomic Nerve Tumor","code":"C27940","definitions":[{"definition":"A variant of gastrointestinal stromal tumor with ultrastructural features of neural differentiation.  It is composed of spindle or epithelioid neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrointestinal Autonomic Nerve Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"GANT","termGroup":"AB","termSource":"NCI"},{"termName":"Gastrointestinal Stromal Tumor with Neurogenic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Plexosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Autonomic_Nerve_Tumor"},{"name":"Maps_To","value":"8936/1"},{"name":"Maps_To","value":"GANT"},{"name":"Maps_To","value":"Gastrointestinal autonomic nerve tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2931518"}]}}{"C53999":{"preferredName":"Malignant Gastrointestinal Stromal Tumor","code":"C53999","definitions":[{"definition":"A gastrointestinal stromal tumor that is characterized by large size (diameter greater than 10 cm for gastric localization and greater than 5 cm for intestinal localization) or more than 5 mitotic figures per 50 high power fields.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from specialized smooth muscle cells (i.e., interstitial cells of Cajal) in the tunica muscularis or myenteric plexus. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8936/3"},{"name":"Legacy Concept Name","value":"Probably_Malignant_Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"8936/3"},{"name":"Maps_To","value":"Gastrointestinal stromal sarcoma"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, malignant"},{"name":"Maps_To","value":"GIST, malignant"},{"name":"NCI_META_CUI","value":"CL497447"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6930":{"preferredName":"Mixed Neoplasm","code":"C6930","definitions":[{"definition":"A neoplasm composed of at least two distinct cellular populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8940/1"},{"name":"Legacy Concept Name","value":"Mixed_Neoplasm"},{"name":"Maps_To","value":"8940/0"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368354"}]}}{"C8602":{"preferredName":"Pleomorphic Adenoma","code":"C8602","definitions":[{"definition":"A benign neoplasm composed of epithelial and/or myoepithelial cells and a mesenchymal component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm characterized by the presence of benign epithelial and myoepithelial cells and a mesenchymal component that may contain mucoid, myxoid, cartilaginous, or osseous areas. It may be completely or partially encapsulated. It occurs in the parotid gland, submandibular gland, minor salivary glands in the oral cavity, upper respiratory tract, and nasal cavity and paranasal sinuses. It usually presents as a slow growing painless mass. Infrequently, patients may present with pain and facial palsy. It may recur after excision or transform to a malignant neoplasm (carcinoma ex pleomorphic adenoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8940/0"},{"name":"Legacy Concept Name","value":"Pleomorphic_Adenoma"},{"name":"Maps_To","value":"8940/0"},{"name":"Maps_To","value":"Mixed tumor, salivary gland type, NOS"},{"name":"Maps_To","value":"Pleomorphic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026277"}]}}{"C4474":{"preferredName":"Benign Mixed Tumor of the Skin","code":"C4474","definitions":[{"definition":"A rare, benign, slow-growing and painless neoplasm of sweat glands. It usually arises in the head and neck. It is characterized by the presence of a mesenchymal chondroid stroma, fibrosis, and epithelial structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Mixed Tumor of the Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Mixed Tumor of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mixed Tumor of Skin (Chondroid Syringoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mixed Tumor of the Skin (Chondroid Syringoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Chondroid Syringoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Tumor of the Skin (Chondroid Syringoma)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Mixed_Tumor_of_the_Skin_Chondroid_Syringoma"},{"name":"Maps_To","value":"8940/0"},{"name":"Maps_To","value":"Chondroid syringoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346026"}]}}{"C3729":{"preferredName":"Malignant Mixed Neoplasm","code":"C3729","definitions":[{"definition":"A malignant neoplasm composed of a carcinomatous epithelial component and a sarcomatous mesenchymal component. Representative examples include malignant mixed mesodermal (Mullerian) tumor of the female reproductive system and carcinosarcoma of the salivary gland and the lung.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of epithelial and/or myoepithelial cells and a mesenchymal component. A general term for which the transformed cell types have not been specified.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Mixed Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mixed Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8940/3"},{"name":"Legacy Concept Name","value":"Malignant_Mixed_Neoplasm"},{"name":"Maps_To","value":"8940/3"},{"name":"Maps_To","value":"Mixed tumor, malignant, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206625"}]}}{"C4397":{"preferredName":"Carcinoma ex Pleomorphic Adenoma","code":"C4397","definitions":[{"definition":"A carcinoma arising in a pre-existing pleomorphic adenoma. It most often occurs in the parotid gland and less often in the submandibular gland and minor salivary gland. Patients usually present with a history of a long-standing mass which recently had undergone rapid growth. The prognosis depends on the invasiveness of the malignant component. Patients with non-invasive or minimally invasive tumors usually have a good prognosis following surgical resection. Invasive tumors are usually aggressive and are associated with recurrences and metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma ex Pleomorphic Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma in Pleomorphic Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"CXPA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8941/3"},{"name":"Legacy Concept Name","value":"Carcinoma_Ex_Pleomorphic_Adenoma"},{"name":"Maps_To","value":"8941/3"},{"name":"Maps_To","value":"Carcinoma ex pleomorphic adenoma"},{"name":"Maps_To","value":"Carcinoma in pleomorphic adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0344460"}]}}{"C3730":{"preferredName":"Mixed Mesodermal (Mullerian) Tumor","code":"C3730","definitions":[{"definition":"A group of tumors affecting the female reproductive system, characterized by the presence of epithelial and stromal elements. It includes the following clinicopathological entities: adenofibroma, adenomyoma, Mullerian adenosarcoma, and malignant mixed mesodermal (Mullerian) tumor.","type":"DEFINITION","source":"NCI"},{"definition":"A rare cancer of the uterus, ovary, or fallopian tubes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mixed Mesodermal (Mullerian) Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Mesodermal Mixed Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesodermal (Mullerian) Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesodermal (Müllerian) Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesodermal (Müllerian) Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mullerian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Müllerian Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8950/3"},{"name":"ICD-O-3_Code","value":"8951/3"},{"name":"Legacy Concept Name","value":"Mixed_Mesodermal_Mullerian_Tumor"},{"name":"Maps_To","value":"8950/3"},{"name":"Maps_To","value":"8951/3"},{"name":"Maps_To","value":"Mesodermal mixed tumor"},{"name":"Maps_To","value":"Mullerian mixed tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206627"}]}}{"C7504":{"preferredName":"Adult Cystic Nephroma","code":"C7504","definitions":[{"definition":"A localized, well-circumscribed multilocular tumor lined by hobnail epithelium. It was previously classified along with pediatric cystic nephroma, as a separate entity from mixed epithelial and stromal tumors. Now it is classified within the spectrum of the mixed epithelial and stromal tumor family. Most of these tumors are benign. (WHO 2016).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Cystic Nephroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8959/0"},{"name":"Legacy Concept Name","value":"Cystic_Nephroma"},{"name":"Maps_To","value":"8959/0"},{"name":"Maps_To","value":"Benign cystic nephroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266138"}]}}{"C6897":{"preferredName":"Cystic Partially Differentiated Kidney Nephroblastoma","code":"C6897","definitions":[{"definition":"A rare, cystic variant of Wilms tumor wholly comprising cysts in which their thin septa form the only solid portion of the tumor.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A variant of Wilms tumor of the kidney characterized by the presence of cystic spaces separated by septa.  The septa contain immature epithelial cells, immature stromal cells, and blastema cells.  Surgical resection is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystic Partially Differentiated Kidney Nephroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Cystic Nephroma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Multilocular Cystic Nephroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8959/1"},{"name":"ICD-O-3_Code","value":"8959/3"},{"name":"Legacy Concept Name","value":"Cystic_Partially_Differentiated_Nephroblastoma"},{"name":"Maps_To","value":"8959/1"},{"name":"Maps_To","value":"8959/3"},{"name":"Maps_To","value":"Cystic partially differentiated nephroblastoma"},{"name":"Maps_To","value":"Malignant cystic nephroma"},{"name":"Maps_To","value":"Malignant multilocular cystic nephroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266139"}]}}{"C6569":{"preferredName":"Congenital Mesoblastic Nephroma","code":"C6569","definitions":[{"definition":"A congenital malignant neoplasm of the kidney characterized by the presence of fibroblastic cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A low grade childhood congenital malignant neoplasm arising from the kidney, which is characterized by the presence of fibroblastic cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A low grade childhood congenital malignant neoplasm arising from the kidney. It is characterized by the presence of fibroblastic cells. The majority of cases occur in the first year of life. Complete excision is usually associated with an excellent prognosis.","type":"DEFINITION","source":"NCI"},{"definition":"A type of kidney tumor that is usually found before birth by ultrasound or within the first 3 months of life. It contains fibroblastic cells (connective tissue cells), and may spread to the other kidney or to nearby tissue. Congenital mesoblastic nephroma is more common in males.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Congenital Mesoblastic Nephroma","termGroup":"PT","termSource":"NCI"},{"termName":"CMN","termGroup":"AB","termSource":"NCI"},{"termName":"Mesoblastic Nephroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8960/1"},{"name":"Legacy Concept Name","value":"Childhood_Congenital_Mesoblastic_Nephroma"},{"name":"Maps_To","value":"8960/1"},{"name":"Maps_To","value":"Mesoblastic nephroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332965"}]}}{"C40407":{"preferredName":"Kidney Wilms Tumor","code":"C40407","definitions":[{"definition":"A disease in which malignant (cancer) cells are found in the kidney, and may spread to the lungs, liver, or nearby lymph nodes. Wilms tumor usually occurs in children younger than 5 years old.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant embryonal neoplasm of the kidney.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An embryonal pediatric tumor of the kidney which may also be seen rarely in adults. The peak incidence of Wilms tumor is between the second and fifth year of life. Microscopically, it is composed of a mixture of cellular elements (blastemal, stromal, and epithelial). The most common sites of metastasis include the regional lymph nodes, lungs, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kidney Wilms Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Nephroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Wilms Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Wilms' Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Wilms Tumor of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Wilms' Tumor of the Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8960/3"},{"name":"Legacy Concept Name","value":"Renal_Wilms_Tumor"},{"name":"Maps_To","value":"8960/3"},{"name":"Maps_To","value":"Nephroblastoma, NOS"},{"name":"Maps_To","value":"Nephroma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027708"}]}}{"C3267":{"preferredName":"Wilms Tumor","code":"C3267","definitions":[{"definition":"A malignant neoplasm of embryonal origin arising within the kidney.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wilms Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Nephroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Wilms' Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Wilms_Tumor"},{"name":"Maps_To","value":"8960/3"},{"name":"Maps_To","value":"Nephroblastoma, NOS"},{"name":"Maps_To","value":"Wilms Tumor"},{"name":"Maps_To","value":"Wilms tumor"},{"name":"Maps_To","value":"Wilms tumor (WT)"},{"name":"NCI_META_CUI","value":"CL505178"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3808":{"preferredName":"Rhabdoid Tumor","code":"C3808","definitions":[{"definition":"A malignant tumor of either the central nervous system (CNS) or the kidney. Malignant rhabdoid tumors of the CNS often have an abnormality of chromosome 22. These tumors usually occur in children younger than 2 years.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive cancer of the central nervous system, kidney, or liver that occurs in very young children.\"","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant embryonal neoplasm usually occurring during childhood.  It is characterized by the presence of large cells with abundant cytoplasm, large eccentric nucleus, and a prominent nucleolus and it is associated with abnormalities of chromosome 22.  It can arise from the central nervous system, kidney, and the soft tissues.  The prognosis is poor.","type":"DEFINITION","source":"NCI"},{"definition":"Extremely aggressive malignancies that generally occur in infants and young children. The most common locations are the kidney and central nervous system (CNS), although they can also arise in most soft tissue sites. Approximately two-thirds of patients will present with advanced-stage disease. Rhabdoid tumors of the kidney tend to metastasize to the CNS and lungs. Rhabdoid tumors are associated with mutations of SMARCB1 (INI-1), a tumor suppressor gene.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Rhabdoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Rhabdoid Sarcoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8963/3"},{"name":"Legacy Concept Name","value":"Rhabdoid_Tumor"},{"name":"Maps_To","value":"8963/3"},{"name":"Maps_To","value":"Malignant rhabdoid tumor"},{"name":"Maps_To","value":"Rhabdoid sarcoma"},{"name":"Maps_To","value":"Rhabdoid tumor, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206743"}]}}{"C4264":{"preferredName":"Clear Cell Sarcoma of the Kidney","code":"C4264","definitions":[{"definition":"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. It metastasizes to lung, bone, brain and soft tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A rare primary renal tumor characterized by nests or cords of cells that are separated by regularly spaced fibrovascular septa, and which are known to metastasize to lung, bone, brain and soft tissue. It is associated with internal tandem duplications in the BCOR gene.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare type of kidney cancer, in which the inside of the cells look clear when viewed under a microscope. Clear cell sarcoma can spread from the kidney to other organs, most commonly the bone, but also including the lungs, brain, and soft tissues of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Sarcoma of the Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"CCSK","termGroup":"AB","termSource":"NCI"},{"termName":"Childhood Clear Cell Sarcoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Kidney Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Renal Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Sarcoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Kidney Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Renal Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8964/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Sarcoma_of_the_Kidney"},{"name":"Maps_To","value":"8964/3"},{"name":"Maps_To","value":"Clear cell sarcoma of kidney"},{"name":"Maps_To","value":"Clear cell sarcoma of the kidney (CCSK)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334488"}]}}{"C39812":{"preferredName":"Metanephric Adenofibroma","code":"C39812","definitions":[{"definition":"A benign, solitary, and partially cystic neoplasm arising from the kidney. It occurs in children and adults. Presenting symptoms include hematuria and polycythemia. It is characterized by the presence of epithelial nodules embedded in a stroma containing spindle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metanephric Adenofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Nephrogenic Adenofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8965/0"},{"name":"Legacy Concept Name","value":"Metanephric_Adenofibroma"},{"name":"Maps_To","value":"8965/0"},{"name":"Maps_To","value":"Nephrogenic adenofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266141"}]}}{"C5100":{"preferredName":"Renomedullary Interstitial Cell Tumor","code":"C5100","definitions":[{"definition":"A benign, asymptomatic kidney tumor arising from renomedullary interstitial cells. It is often found incidentally at the time of nephrectomy in adults. These tumors are either single or multiple and usually measure 1-10 mm in diameter. Microscopically the tumor cells are small, stellate, or spindled cells, embedded in a faintly basophilic stroma reminiscent of renal medullary stroma. (WHO 2016)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renomedullary Interstitial Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroma of Renal Medulla","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Hamartoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8966/0"},{"name":"Legacy Concept Name","value":"Renal_Fibroma"},{"name":"Maps_To","value":"8966/0"},{"name":"Maps_To","value":"Renomedullary interstitial cell tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335742"}]}}{"C66774":{"preferredName":"Ossifying Renal Tumor of Infancy","code":"C66774","definitions":[{"definition":"A benign neoplasm of the kidney occurring in infants. It develops as an intracalyceal mass and is characterized by the presence of osteoid formation, osteoblast-like cells, and spindle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ossifying Renal Tumor of Infancy","termGroup":"PT","termSource":"NCI"},{"termName":"ORTI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8967/0"},{"name":"Legacy Concept Name","value":"Ossifying_Renal_Tumor_of_Infancy"},{"name":"Maps_To","value":"8967/0"},{"name":"Maps_To","value":"Ossifying renal tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1882198"}]}}{"C7097":{"preferredName":"Mixed Epithelial and Mesenchymal Hepatoblastoma","code":"C7097","definitions":[{"definition":"A subtype of hepatoblastoma characterized by the presence of epithelial and mesenchymal components.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A subtype of hepatoblastoma characterized by the presence of epithelial and mesenchymal components.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Epithelial and Mesenchymal Hepatoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8970/3"},{"name":"Legacy Concept Name","value":"Mixed_Epithelial_and_Mesenchymal_Hepatoblastoma"},{"name":"Maps_To","value":"8970/3"},{"name":"Maps_To","value":"Hepatoblastoma, mixed epithelial-mesenchymal"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334784"}]}}{"C3728":{"preferredName":"Hepatoblastoma","code":"C3728","definitions":[{"definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant liver neoplasm composed of immature hepatocytic elements.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant liver tumor that arises from precursors of hepatocytes. It occurs almost exclusively in infants. The lungs are the most common site of metastasis.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of liver tumor that occurs in infants and children.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hepatoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"HBL","termGroup":"AB","termSource":"NCI"},{"termName":"Pediatric Embryonal Hepatoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Hepatoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8970/3"},{"name":"Legacy Concept Name","value":"Hepatoblastoma"},{"name":"Maps_To","value":"8970/3"},{"name":"Maps_To","value":"Embryonal hepatoma"},{"name":"Maps_To","value":"Hepatoblastoma"},{"name":"Maps_To","value":"Hepatoblastoma, NOS"},{"name":"Maps_To","value":"Malignant neoplasm: Hepatoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206624"}]}}{"C4265":{"preferredName":"Pancreatoblastoma","code":"C4265","definitions":[{"definition":"A rare malignant epithelial neoplasm arising from the pancreas. The vast majority of cases occur during childhood. It is characterized by acinar differentiation, the formation of squamoid corpuscles, and the formation of stromal bands. Patients may present with an abdominal mass. Symptoms include pain, weight loss, and diarrhea. It may metastasize to lymph nodes, liver, and distant anatomic sites. Children who do not have metastatic disease at the time of diagnosis usually have a favorable clinical outcome when treated with a combination of surgery and chemotherapy. However, children with metastatic disease at presentation or adult patients usually have a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8971/3"},{"name":"Legacy Concept Name","value":"Pancreatoblastoma"},{"name":"Maps_To","value":"8971/3"},{"name":"Maps_To","value":"Pancreatoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334489"}]}}{"C3732":{"preferredName":"Pulmonary Blastoma","code":"C3732","definitions":[{"definition":"A biphasic tumor that consists of fetal adenocarcinoma (typically low-grade) and primitive mesenchymal stroma. Foci of specific mesenchymal differentiation (osteosarcoma, chondrosarcoma, or rhabdomyosarcoma) may also be present, but are not required for the diagnosis. Most patients are smokers.  The prognosis is very poor. (WHO 2015)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Blastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Blastoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Blastoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Blastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pneumoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8972/3"},{"name":"Legacy Concept Name","value":"Pulmonary_Blastoma"},{"name":"Maps_To","value":"8972/3"},{"name":"Maps_To","value":"Pneumoblastoma"},{"name":"Maps_To","value":"Pulmonary blastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206629"}]}}{"C5669":{"preferredName":"Pleuropulmonary Blastoma","code":"C5669","definitions":[{"definition":"A malignant neoplasm affecting the lungs and/or the pleura. Pleuropulmonary blastoma is seen in children. Microscopically, the tumor may show features of chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, or undifferentiated sarcoma. In approximately 25% of patients there is a predisposition for other tumors. Heterozygous germline mutations in DICER1 gene have been identified in families harboring pleuropulmonary blastomas.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neoplasm affecting the lungs and/or the pleura. Pleuropulmonary blastoma is seen in children. Microscopically, the tumor may show features of chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, or undifferentiated sarcoma. In approximately 25% of patients with pleuropulmonary blastoma, there are other lesions or neoplasms that may affect patients or their families, including lung or kidney cysts, and ovarian or testicular neoplasms. Heterozygous germline mutations in DICER1 gene have been identified in families harboring pleuropulmonary blastomas.","type":"DEFINITION","source":"NCI"},{"definition":"A rare and very aggressive (fast-growing) cancer that forms in tissues of the lung and pleura (a thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity). Pleuropulmonary blastoma is most common in children.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pleuropulmonary Blastoma","termGroup":"PT","termSource":"NCI"},{"termName":"PPB","termGroup":"AB","termSource":"NCI"},{"termName":"Pulmonary Blastoma of Childhood","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8973/3"},{"name":"Legacy Concept Name","value":"Pleuropulmonary_Blastoma"},{"name":"Maps_To","value":"8973/3"},{"name":"Maps_To","value":"Pleuropulmonary blastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266144"}]}}{"C35837":{"preferredName":"Sialoblastoma","code":"C35837","definitions":[{"definition":"A rare, malignant primitive neoplasm that occurs in the salivary glands. Most tumors arise from the parotid gland, followed by the submandibular gland, and rarely the minor salivary glands. It is usually diagnosed during the neonatal period and presents with painless face swelling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Salivary Gland Sialoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8974/1"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Sialoblastoma"},{"name":"Maps_To","value":"8974/1"},{"name":"Maps_To","value":"Sialoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266145"}]}}{"C96830":{"preferredName":"Calcifying Nested Stromal-Epithelial Tumor","code":"C96830","definitions":[{"definition":"A rare malignant tumor that arises from the liver and occurs in children.  It is characterized by the presence of nested epithelioid and spindle cells.  Desmoplasia, calcifications, and bone formation may also be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcifying Nested Stromal-Epithelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Calcifying Nested Epithelial Stromal Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Nested Epithelial-Stromal Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Nested Stromal Epithelial Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Nested Stromal-Epithelial Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"CNSET","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8975/1"},{"name":"Maps_To","value":"8975/1"},{"name":"Maps_To","value":"Calcifying fibrous tumor"},{"name":"Maps_To","value":"Calcifying nested epithelial stromal tumor"},{"name":"Maps_To","value":"Calcifying nested stromal-epithelial tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273067"}]}}{"C34448":{"preferredName":"Carcinosarcoma","code":"C34448","definitions":[{"definition":"A malignant neoplasm comprising a mixture of carcinomatous and sarcomatous elements.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant tumor that is a mixture of carcinoma (cancer of epithelial tissue, which is skin and tissue that lines or covers the internal organs) and sarcoma (cancer of connective tissue, such as bone, cartilage, and fat).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carcinosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8980/3"},{"name":"Legacy Concept Name","value":"Carcinosarcoma"},{"name":"Maps_To","value":"8980/3"},{"name":"Maps_To","value":"Carcinosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007140"}]}}{"C8975":{"preferredName":"Malignant Mixed Mesodermal (Mullerian) Tumor","code":"C8975","definitions":[{"definition":"A malignant neoplasm of the female reproductive tract (mostly uterus and ovaries) originating from the Mullerian ducts and composed of carcinomatous and sarcomatous elements.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare type of tumor that is a mixture of carcinoma and sarcoma cells. MMMT usually occurs in the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant tumor of the female reproductive system, affecting predominantly elderly menopausal women.  The endometrium and ovary are the most common sites of tumor origin.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mixed Mesodermal (Mullerian) Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mixed Mesodermal (Müllerian) Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Mesodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Mullerian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Müllerian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"MMMT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Mixed_Mesodermal_Mullerian_Tumor"},{"name":"Maps_To","value":"8981/3"},{"name":"Maps_To","value":"Carcinosarcoma, embryonal"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334603"}]}}{"C40392":{"preferredName":"Myoepithelial Tumor","code":"C40392","definitions":[{"definition":"A benign or malignant tumor characterized by the presence of cells that show myoepithelial differentiation. Based on its morphologic features, it is classified as benign or malignant. A representative example of benign myoepithelioma is benign salivary gland myoepithelioma. Representative examples of malignant myoepithelioma or myoepithelial carcinoma are malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myoepithelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Myoepithelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Myoepithelial Tumor of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Myoepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8982/0"},{"name":"ICD-O-3_Code","value":"8982/1"},{"name":"Legacy Concept Name","value":"Myoepithelial_Neoplasm"},{"name":"Maps_To","value":"8982/0"},{"name":"Maps_To","value":"Myoepithelial tumor"},{"name":"Maps_To","value":"Myoepithelioma"},{"name":"Maps_To","value":"Myoepithelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027070"}]}}{"C7442":{"preferredName":"Benign Myoepithelioma","code":"C7442","definitions":[{"definition":"A benign neoplasm composed of myoepithelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tumor with myoepithelial differentiation that lacks an infiltrative growth pattern and does not metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Myoepithelioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Myoepithelioma"},{"name":"Maps_To","value":"8982/0"},{"name":"Maps_To","value":"Myoepithelial adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1947949"}]}}{"C7596":{"preferredName":"Malignant Myoepithelioma","code":"C7596","definitions":[{"definition":"A malignant neoplasm composed of myoepithelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating malignant tumor characterized by the presence of atypical cells with myoepithelial differentiation. Representative examples include malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Myoepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Myoepithelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8982/3"},{"name":"Legacy Concept Name","value":"Myoepithelial_Carcinoma"},{"name":"Maps_To","value":"8982/3"},{"name":"Maps_To","value":"Malignant myoepithelioma"},{"name":"Maps_To","value":"Myoepithelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334699"}]}}{"C6899":{"preferredName":"Breast Adenomyoepithelioma","code":"C6899","definitions":[{"definition":"A usually benign tumor arising from the breast. It is characterized by the proliferation of cells with myoepithelial differentiation around spaces which are lined by epithelial cells. Rarely, the epithelial and/or myoepithelial cells may undergo malignant transformation. Cases with malignant transformation may follow an aggressive clinical course, including recurrences and local and distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Adenomyoepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomyoepithelioma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8983/0"},{"name":"Legacy Concept Name","value":"Adenomyoepithelioma"},{"name":"Maps_To","value":"8983/0"},{"name":"Maps_To","value":"Adenomyoepithelioma"},{"name":"Maps_To","value":"Adenomyoepithelioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266146"}]}}{"C5143":{"preferredName":"Malignant Breast Adenomyoepithelioma","code":"C5143","definitions":[{"definition":"An adenomyoepithelioma of the breast in which the epithelial, myoepithelial, or both components have undergone malignant transformation.  Such cases may follow an aggressive clinical course, including recurrences and local and distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Breast Adenomyoepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Adenomyoepithelioma with Malignant Change","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adenomyoepithelioma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adenomyoepithelioma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Breast_Adenomyoepithelioma"},{"name":"Maps_To","value":"8983/3"},{"name":"Maps_To","value":"Adenomyoepithelioma with carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839546"}]}}{"C4267":{"preferredName":"Benign Mesenchymoma","code":"C4267","definitions":[{"definition":"A benign soft-tissue neoplasm comprising two or more non-fibroblastic mesenchymal lines of differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A term describing a benign soft tissue tumor which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Mesenchymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8990/0"},{"name":"Legacy Concept Name","value":"Benign_Mesenchymoma"},{"name":"Maps_To","value":"8990/0"},{"name":"Maps_To","value":"Mesenchymoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334491"}]}}{"C3233":{"preferredName":"Mesenchymoma","code":"C3233","definitions":[{"definition":"A term describing a soft tissue tumor which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesenchymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8990/1"},{"name":"Legacy Concept Name","value":"Mesenchymoma"},{"name":"Maps_To","value":"8990/1"},{"name":"Maps_To","value":"Mesenchymoma, NOS"},{"name":"Maps_To","value":"Mixed mesenchymal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025464"}]}}{"C4268":{"preferredName":"Malignant Mesenchymoma","code":"C4268","definitions":[{"definition":"A malignant soft tissue neoplasm which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A term describing a malignant soft tissue tumor which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mesenchymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8990/3"},{"name":"Legacy Concept Name","value":"Malignant_Mesenchymoma"},{"name":"Maps_To","value":"8990/3"},{"name":"Maps_To","value":"Mesenchymoma, malignant"},{"name":"Maps_To","value":"Mixed mesenchymal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334492"}]}}{"C27096":{"preferredName":"Liver Embryonal Sarcoma","code":"C27096","definitions":[{"definition":"An aggressive malignant mesenchymal neoplasm that arises from the liver and usually occurs in older children.  It is composed of immature spindle, stellate, polymorphous, and giant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liver Embryonal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Sarcoma (Undifferentiated Sarcoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Sarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"ESL","termGroup":"AB","termSource":"NCI"},{"termName":"UES","termGroup":"AB","termSource":"NCI"},{"termName":"Undifferentiated (Embryonal) Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated (Embryonal) Sarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8805/3"},{"name":"ICD-O-3_Code","value":"8991/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Embryonal_Sarcoma"},{"name":"Maps_To","value":"8991/3"},{"name":"Maps_To","value":"Embryonal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855073"}]}}{"C39954":{"preferredName":"Brenner Tumor","code":"C39954","definitions":[{"definition":"A tumor composed of solid and cystic nests of neoplastic urothelial-type cells in an abundant stromal component that is dense and fibroblastic in nature. It arises from the ovary and very rarely the paratesticular structures. It includes benign Brenner tumor, borderline Brenner tumor, and malignant Brenner tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brenner Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9000/0"},{"name":"Legacy Concept Name","value":"Brenner_Tumor"},{"name":"Maps_To","value":"9000/0"},{"name":"Maps_To","value":"Brenner tumor, NOS"},{"name":"NCI_META_CUI","value":"CL323981"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9459":{"preferredName":"Borderline Ovarian Brenner Tumor","code":"C9459","definitions":[{"definition":"A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of neoplastic atypical urothelial-type cells in a fibrotic stroma without evidence of invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Brenner Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Brenner Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Brenner Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Brenner Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Transitional Cell Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Borderline Ovarian Transitional Cell Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Ovarian Brenner Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Brenner Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9000/1"},{"name":"Legacy Concept Name","value":"Borderline_Brenner_Tumor"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Transitional_Cell_Tumor"},{"name":"Maps_To","value":"9000/1"},{"name":"Maps_To","value":"Brenner tumor, borderline malignancy"},{"name":"Maps_To","value":"Brenner tumor, proliferating"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334494"}]}}{"C4270":{"preferredName":"Malignant Ovarian Brenner Tumor","code":"C4270","definitions":[{"definition":"A malignant neoplasm that arises from the ovary. It is characterized by the presence of an invasive malignant urothelial-type cellular component and nests of benign urothelial-type cells in a fibrotic stroma. When the neoplasm is confined to the ovary, the prognosis is good.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Brenner Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ovarian Transitional Cell Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Ovarian Transitional Cell Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9000/3"},{"name":"Legacy Concept Name","value":"Malignant_Brenner_Tumor"},{"name":"Maps_To","value":"9000/3"},{"name":"Maps_To","value":"Brenner tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518237"}]}}{"C3744":{"preferredName":"Breast Fibroadenoma","code":"C3744","definitions":[{"definition":"A benign (not cancer) tumor that usually forms in the breast from both fibrous and glandular tissue. Fibroadenomas are the most common benign breast tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign neoplasm originating from glandular cells with a fibrous or fibroblastic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign tumor of the breast characterized by the presence of stromal and epithelial elements. It presents as a painless, solitary, slow growing, firm, and mobile mass. It is the most common benign breast lesion. It usually occurs in women of childbearing age. The majority of fibroadenomas do not recur after complete excision. A slightly increased risk of developing cancer within fibroadenomas or in the breast tissue of patients previously treated for fibroadenomas has been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9010/0"},{"name":"Legacy Concept Name","value":"Fibroadenoma"},{"name":"Maps_To","value":"9010/0"},{"name":"Maps_To","value":"Fibroadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206650"}]}}{"C4271":{"preferredName":"Breast Intracanalicular Fibroadenoma","code":"C4271","definitions":[{"definition":"A morphologic variant of breast fibroadenoma without clinical significance. It is characterized by distortion and compression of the ducts by proliferating stromal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Intracanalicular Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Intracanalicular Breast Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracanalicular Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracanalicular Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intracanalicular Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9011/0"},{"name":"Legacy Concept Name","value":"Intracanalicular_Fibroadenoma"},{"name":"Maps_To","value":"9011/0"},{"name":"Maps_To","value":"Intracanalicular fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334496"}]}}{"C4272":{"preferredName":"Breast Pericanalicular Fibroadenoma","code":"C4272","definitions":[{"definition":"A morphologic variant of breast fibroadenoma without clinical significance. It is characterized by circumferential proliferation of stromal cells around the ducts. This results in the formation of rounded ductal-epithelial structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Pericanalicular Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pericanalicular Breast Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pericanalicular Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pericanalicular Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Pericanalicular Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9012/0"},{"name":"Legacy Concept Name","value":"Pericanalicular_Fibroadenoma"},{"name":"Maps_To","value":"9012/0"},{"name":"Maps_To","value":"Pericanalicular fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334497"}]}}{"C8984":{"preferredName":"Female Reproductive System Adenofibroma","code":"C8984","definitions":[{"definition":"A benign or borderline neoplasm characterized by the presence of connective tissue stroma and epithelial structures. It occurs in the ovary, fallopian tube, uterine corpus, and cervix.","type":"DEFINITION","source":"NCI"},{"definition":"Benign mixed neoplasm comprised of epithelial/glandular and mesenchymal structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Female Reproductive System Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9013/0"},{"name":"Legacy Concept Name","value":"Adenofibroma"},{"name":"Maps_To","value":"9013/0"},{"name":"Maps_To","value":"Adenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001422"}]}}{"C8985":{"preferredName":"Cystadenofibroma","code":"C8985","definitions":[{"definition":"A benign or borderline neoplasm that arises from the ovaries and the fallopian tubes. It is characterized by the presence of cystic glandular structures and fibrous tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystadenofibroma"},{"name":"Maps_To","value":"9013/0"},{"name":"Maps_To","value":"Cystadenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334317"}]}}{"C8986":{"preferredName":"Papillary Adenofibroma","code":"C8986","definitions":[{"definition":"A biphasic polypoid neoplasm characterized by the presence of papillary projections that are lined by epithelial cells and fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Adenofibroma"},{"name":"Maps_To","value":"9013/0"},{"name":"Maps_To","value":"Papillary adenofibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377850"}]}}{"C67090":{"preferredName":"Serous Adenofibroma","code":"C67090","definitions":[{"definition":"A benign or borderline adenofibroma characterized by the presence of serous secretory cells and minute cystic spaces filled with watery fluid. A representative example is the ovarian serous adenofibroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9014/0"},{"name":"Legacy Concept Name","value":"Serous_Adenofibroma"},{"name":"Maps_To","value":"9014/0"},{"name":"Maps_To","value":"Serous adenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334498"}]}}{"C40028":{"preferredName":"Borderline Ovarian Serous Adenofibroma","code":"C40028","definitions":[{"definition":"A low malignant potential adenofibroma arising from the ovary. It is characterized by an atypical epithelial hyperplasia. The epithelial cells are of serous type. There is no evidence of stromal destructive invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Serous Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9014/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Serous_Adenofibroma"},{"name":"Maps_To","value":"9014/1"},{"name":"Maps_To","value":"Serous adenofibroma of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266152"}]}}{"C67092":{"preferredName":"Ovarian Serous Adenocarcinofibroma","code":"C67092","definitions":[{"definition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells of serous type, forming glandular, papillary, and solid patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Serous Adenocarcinofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9014/3"},{"name":"Legacy Concept Name","value":"Ovarian_Serous_Adenocarcinofibroma"},{"name":"Maps_To","value":"9014/3"},{"name":"Maps_To","value":"Serous adenocarcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266153"}]}}{"C8979":{"preferredName":"Mucinous Cystadenofibroma","code":"C8979","definitions":[{"definition":"A benign neoplasm characterized by the presence of cystic structures lined by mucinous columnar epithelial cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucinous_Cystadenofibroma"},{"name":"Maps_To","value":"9015/0"},{"name":"Maps_To","value":"Mucinous cystadenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377844"}]}}{"C8978":{"preferredName":"Mucinous Adenofibroma","code":"C8978","definitions":[{"definition":"A benign or borderline adenofibroma characterized by the presence of epithelial cells which contain intracytoplasmic mucin and a fibrotic stroma. A representative example is the ovarian mucinous adenofibroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9015/0"},{"name":"Legacy Concept Name","value":"Mucinous_Adenofibroma"},{"name":"Maps_To","value":"9015/0"},{"name":"Maps_To","value":"Mucinous adenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334499"}]}}{"C66775":{"preferredName":"Borderline Ovarian Mucinous Adenofibroma","code":"C66775","definitions":[{"definition":"A low malignant potential adenofibroma of the ovary It is characterized by an atypical epithelial hyperplasia. The epithelial cells contain intracytoplasmic mucin. There is no evidence of stromal destructive invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Mucinous Adenofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Mucinous Adenofibroma of Borderline Malignancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9015/1"},{"name":"Legacy Concept Name","value":"Mucinous_Adenofibroma_of_Borderline_Malignancy"},{"name":"Maps_To","value":"9015/1"},{"name":"Maps_To","value":"Mucinous adenofibroma of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266154"}]}}{"C40034":{"preferredName":"Ovarian Mucinous Adenocarcinofibroma","code":"C40034","definitions":[{"definition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells with intracytoplasmic mucin. Cystic spaces are also present which contain mucoid material.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Mucinous Adenocarcinofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Mucinous Malignant Adenofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9015/3"},{"name":"Legacy Concept Name","value":"Ovarian_Mucinous_Adenocarcinofibroma"},{"name":"Maps_To","value":"9015/3"},{"name":"Maps_To","value":"Mucinous adenocarcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266155"}]}}{"C4273":{"preferredName":"Breast Giant Fibroadenoma","code":"C4273","definitions":[{"definition":"A breast fibroadenoma characterized by a very large size. This term has also been used as a synonym for juvenile fibroadenoma by some authors. The latter is characterized by epithelial hyperplasia and an increased stromal cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Giant Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Giant Breast Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9016/0"},{"name":"Legacy Concept Name","value":"Giant_Fibroadenoma"},{"name":"Maps_To","value":"9016/0"},{"name":"Maps_To","value":"Giant fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334500"}]}}{"C4274":{"preferredName":"Benign Phyllodes Tumor","code":"C4274","definitions":[{"definition":"A benign, circumscribed fibroepithelial neoplasm arising from the breast and rarely the prostate gland. It is characterized by the presence of epithelial structures which are arranged in clefts and by a hypercellular mesenchymal stroma which is organized in leaf-like structures. There is no evidence of cellular atypia or sarcomatous features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cystosarcoma Phyllodes","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9020/0"},{"name":"Legacy Concept Name","value":"Benign_Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/0"},{"name":"Maps_To","value":"Cystosarcoma phyllodes, benign"},{"name":"Maps_To","value":"Phyllodes tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334501"}]}}{"C2977":{"preferredName":"Phyllodes Tumor","code":"C2977","definitions":[{"definition":"A benign, borderline, or malignant fibroepithelial neoplasm arising from the breast and rarely the prostate gland.  It may recur following resection.  The recurrence rates are higher for borderline and malignant phyllodes tumors.  In borderline and malignant phyllodes tumors metastases to distant anatomic sites can occur.  The incidence of metastases is higher in malignant phyllodes tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A type of tumor found in breast or prostate tissue. It is often large and bulky and grows quickly. It may be benign (not cancer) or malignant (cancer) and may spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Cystosarcoma Phyllodes","termGroup":"SY","termSource":"NCI"},{"termName":"Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/1"},{"name":"Maps_To","value":"Cystosarcoma phyllodes, NOS"},{"name":"Maps_To","value":"Phyllodes tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010701"}]}}{"C7503":{"preferredName":"Borderline Phyllodes Tumor","code":"C7503","definitions":[{"definition":"A phyllodes tumor with morphologic characteristics which are intermediate between a benign and a malignant phyllodes tumor. The stromal sarcomatous changes are of low grade and are often reminiscent of low grade fibrosarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9020/1"},{"name":"Legacy Concept Name","value":"Borderline_Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/1"},{"name":"Maps_To","value":"Phyllodes tumor, borderline"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370913"}]}}{"C4275":{"preferredName":"Malignant Phyllodes Tumor","code":"C4275","definitions":[{"definition":"A phyllodes tumor with sarcomatous stroma. The sarcomatous component is usually of the fibrosarcomatous type. Liposarcomatous, chondrosarcomatous, osteosarcomatous, or rhabdomyosarcomatous differentiation may also occur in the stroma. It may recur and metastasize following surgical resection. The lung and skeleton are the anatomic sites most frequently involved by metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Cystosarcoma Phyllodes","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9020/3"},{"name":"Legacy Concept Name","value":"Malignant_Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/3"},{"name":"Maps_To","value":"Cystosarcoma phyllodes, malignant"},{"name":"Maps_To","value":"Phyllodes tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0600066"}]}}{"C4276":{"preferredName":"Juvenile Breast Fibroadenoma","code":"C4276","definitions":[{"definition":"A breast fibroadenoma that usually occurs in young women. It is characterized by epithelial hyperplasia and an increased stromal cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Juvenile Breast Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Juvenile Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9030/0"},{"name":"Legacy Concept Name","value":"Juvenile_Fibroadenoma"},{"name":"Maps_To","value":"9030/0"},{"name":"Maps_To","value":"Juvenile fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346158"}]}}{"C3829":{"preferredName":"Benign Synovial Neoplasm","code":"C3829","definitions":[{"definition":"A benign neoplasm arising from the synovial membrane.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm arising from the synovial membrane.  Examples include the diffuse giant cell tumor of tendon sheath and localized giant cell tumor of tendon sheath.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Synovial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasm of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Synovial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Synovioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Synovium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9040/0"},{"name":"Legacy Concept Name","value":"Benign_Synovial_Neoplasm"},{"name":"Maps_To","value":"9040/0"},{"name":"Maps_To","value":"Synovioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221289"}]}}{"C3400":{"preferredName":"Synovial Sarcoma","code":"C3400","definitions":[{"definition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm that usually arises in the synovial membranes of the joints and the synovial cells of the tendons and bursae.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that develops in the synovial membrane of the joints.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"SS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9040/3"},{"name":"Legacy Concept Name","value":"Synovial_Sarcoma"},{"name":"Maps_To","value":"9040/3"},{"name":"Maps_To","value":"Synovial sarcoma, NOS"},{"name":"Maps_To","value":"Synovioma, malignant"},{"name":"Maps_To","value":"Synovioma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0039101"}]}}{"C4277":{"preferredName":"Spindle Cell Synovial Sarcoma","code":"C4277","definitions":[{"definition":"A synovial sarcoma characterized by the presence of a spindle cell component only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Synovial Sarcoma with Spindle Cell Components","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9041/3"},{"name":"Legacy Concept Name","value":"Synovial_Sarcoma_with_Spindle_Cell_Components"},{"name":"Maps_To","value":"9041/3"},{"name":"Maps_To","value":"Synovial sarcoma, monophasic fibrous"},{"name":"Maps_To","value":"Synovial sarcoma, spindle cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334505"}]}}{"C4278":{"preferredName":"Epithelial Synovial Sarcoma","code":"C4278","definitions":[{"definition":"A synovial sarcoma characterized by the presence of an epithelial cell component only. The epithelial cells are arranged in glandular or papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelial Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Sarcoma of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Sarcoma of the Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Cell Sarcoma of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Cell Sarcoma of the Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Cell Synovial Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Synovial Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9042/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Synovial_Sarcoma"},{"name":"Maps_To","value":"9042/3"},{"name":"Maps_To","value":"Synovial sarcoma, epithelioid cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334506"}]}}{"C4279":{"preferredName":"Biphasic Synovial Sarcoma","code":"C4279","definitions":[{"definition":"A synovial sarcoma characterized by the presence of both an epithelial and a spindle cell component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biphasic Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Biphasic Sarcoma of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Biphasic Sarcoma of the Synovium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9043/3"},{"name":"Legacy Concept Name","value":"Biphasic_Synovial_Sarcoma"},{"name":"Maps_To","value":"9043/3"},{"name":"Maps_To","value":"Synovial sarcoma, biphasic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334507"}]}}{"C3745":{"preferredName":"Clear Cell Sarcoma of Soft Tissue","code":"C3745","definitions":[{"definition":"A rare malignant neoplasm with melanocytic differentiation characterized by the presence of polygonal or spindle shaped clear cells. This sarcoma usually affects the tendons and aponeuroses and is associated with a poor prognosis due to recurrences and metastases.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that begins in a tendon (tough, fibrous, cord-like tissue that connects muscle to bone or to another structure). Clear cell sarcoma of soft tissue has certain markers that are also found on malignant melanoma (a type of skin cancer). It usually occurs in the leg or arm.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Sarcoma of Soft Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Sarcoma of Soft Parts","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Sarcoma of Tendons and Aponeuroses","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma of Soft Parts","termGroup":"AQS","termSource":"NCI"},{"termName":"Melanoma of the Soft Parts","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9044/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Sarcoma_of_Soft_Parts"},{"name":"Maps_To","value":"9044/3"},{"name":"Maps_To","value":"Clear cell sarcoma, NOS"},{"name":"Maps_To","value":"Melanoma, malignant, of soft parts"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206651"}]}}{"C164205":{"preferredName":"Biphenotypic Sinonasal Sarcoma","code":"C164205","definitions":[{"definition":"A rare, slow-growing, low-grade soft tissue sarcoma arising from the sinonasal tract. It presents with non-specific obstructive nasal symptoms. Morphologically, it is an infiltrative, cellular spindle cell neoplasm. It is associated with rearrangement of the PAX3 gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biphenotypic Sinonasal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"BSNS","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Biphenotypic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9045/3"},{"name":"Maps_To","value":"Biphenotypic sinonasal sarcoma"},{"name":"NCI_META_CUI","value":"CL977505"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3762":{"preferredName":"Adenomatoid Tumor","code":"C3762","definitions":[{"definition":"A benign neoplasm arising from mesothelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well-circumscribed neoplasm arising from mesothelial cells. It is characterized by the formation of glandular and tubular patterns. It usually involves the paratesticular region, uterus, and fallopian tube. Rare cases involving the pleura, peritoneum, adrenal gland, and liver have also been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenomatoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Mesothelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9050/0"},{"name":"ICD-O-3_Code","value":"9052/0"},{"name":"ICD-O-3_Code","value":"9054/0"},{"name":"Legacy Concept Name","value":"Adenomatoid_Tumor"},{"name":"Maps_To","value":"9054/0"},{"name":"Maps_To","value":"Adenomatoid tumor, NOS"},{"name":"Maps_To","value":"Epithelioid mesothelioma, benign"},{"name":"Maps_To","value":"Mesothelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206675"}]}}{"C4456":{"preferredName":"Malignant Mesothelioma","code":"C4456","definitions":[{"definition":"A malignant neoplasm originating from mesothelial cells of the pleura or peritoneum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm that arises from mesothelial cells, usually in the pleura or peritoneum. It is associated with exposure to asbestos.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of cancer in which malignant cells are found in the sac lining the chest or abdomen. Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mesothelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Mesothelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9050/3"},{"name":"Legacy Concept Name","value":"Malignant_Mesothelioma"},{"name":"Maps_To","value":"9050/3"},{"name":"Maps_To","value":"Mesothelioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0345967"}]}}{"C4457":{"preferredName":"Pleural Solitary Fibrous Tumor","code":"C4457","definitions":[{"definition":"A localized neoplasm of probable fibroblastic derivation, that arises from the pleura. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleural Solitary Fibrous Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroma of Pleura","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroma of the Pleura","termGroup":"SY","termSource":"NCI"},{"termName":"Localized Fibrous Mesothelioma of Pleura","termGroup":"AQS","termSource":"NCI"},{"termName":"Localized Fibrous Mesothelioma of the Pleura","termGroup":"AQS","termSource":"NCI"},{"termName":"Pleural Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Submesothelial Fibroma","termGroup":"AQS","termSource":"NCI"},{"termName":"Solitary Fibrous Tumor of Pleura","termGroup":"SY","termSource":"NCI"},{"termName":"Solitary Fibrous Tumor of the Pleura","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleural_Fibroma"},{"name":"Maps_To","value":"9051/0"},{"name":"Maps_To","value":"Fibrous mesothelioma, benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334511"}]}}{"C6747":{"preferredName":"Desmoplastic Mesothelioma","code":"C6747","definitions":[{"definition":"A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of a dense collagenous tissue and atypical neoplastic cells. Sarcomatoid features, collagenous necrosis, and infiltration of muscle and adipose tissue may be present. It occurs in the pleura and less commonly in the peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Mesothelioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9051/3"},{"name":"Legacy Concept Name","value":"Malignant_Fibrous_Mesothelioma"},{"name":"Maps_To","value":"9051/3"},{"name":"Maps_To","value":"Desmoplastic mesothelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1270206"}]}}{"C45655":{"preferredName":"Sarcomatoid Mesothelioma","code":"C45655","definitions":[{"definition":"A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of spindle cells. Anaplastic morphologic features and multinucleated malignant cells may also be seen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Mesothelioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Mesothelioma"},{"name":"Maps_To","value":"9051/3"},{"name":"Maps_To","value":"Fibrous mesothelioma, malignant"},{"name":"Maps_To","value":"Fibrous mesothelioma, NOS"},{"name":"Maps_To","value":"Sarcomatoid mesothelioma"},{"name":"Maps_To","value":"Spindled mesothelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334513"}]}}{"C7985":{"preferredName":"Epithelioid Mesothelioma","code":"C7985","definitions":[{"definition":"A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of cells with epithelioid morphology. The epithelioid cells usually have eosinophilic cytoplasm, bland nuclei, and form tubulopapillary, microglandular, or sheet-like patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelial Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9052/3"},{"name":"Legacy Concept Name","value":"Epithelial_Mesothelioma"},{"name":"Maps_To","value":"9052/3"},{"name":"Maps_To","value":"Epithelioid mesothelioma, malignant"},{"name":"Maps_To","value":"Epithelioid mesothelioma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862312"}]}}{"C4282":{"preferredName":"Biphasic Mesothelioma","code":"C4282","definitions":[{"definition":"A malignant mesothelioma characterized by the presence of epithelioid and sarcomatoid components, with each component representing at least 10% of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biphasic Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Biphasic Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9053/3"},{"name":"Legacy Concept Name","value":"Mixed_Mesothelioma"},{"name":"Maps_To","value":"9053/3"},{"name":"Maps_To","value":"Mesothelioma, biphasic, malignant"},{"name":"Maps_To","value":"Mesothelioma, biphasic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334515"}]}}{"C6536":{"preferredName":"Peritoneal Multicystic Mesothelioma","code":"C6536","definitions":[{"definition":"A mesothelial neoplasm that arises from the peritoneum and usually affects young to middle aged females. Grossly, it presents as a large multiloculated tumor mass, usually in the pelvic peritoneum. Histologically it is characterized by the presence of multiple cysts that are lined by one or more layers of mesothelial cells that do not show atypia. Patients usually present with abdominal or pelvic mass and pain. The clinical course is indolent. The tumor may reoccur, but transformation to malignant mesothelioma is rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneal Multicystic Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Multicystic Mesothelioma of Peritoneum","termGroup":"SY","termSource":"NCI"},{"termName":"Multicystic Mesothelioma of the Peritoneum","termGroup":"SY","termSource":"NCI"},{"termName":"Multilocular Peritoneal Inclusion Cyst","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Multicystic_Peritoneal_Mesothelioma"},{"name":"Maps_To","value":"9055/0"},{"name":"Maps_To","value":"Peritoneal inclusion cysts"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334818"}]}}{"C3765":{"preferredName":"Multicystic Mesothelioma","code":"C3765","definitions":[{"definition":"A mesothelial neoplasm that arises from the peritoneum and rarely the pleura. It is characterized by the presence of multiple cysts lined by flattened or cuboidal mesothelial cells. There is no evidence of significant cytologic atypia or increased mitotic activity. It may reoccur. Rare cases of transformation to malignant mesothelioma have been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multicystic Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Cystic Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Intermediate Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9055/0"},{"name":"ICD-O-3_Code","value":"9055/1"},{"name":"Legacy Concept Name","value":"Cystic_Mesothelioma"},{"name":"Maps_To","value":"9055/0"},{"name":"Maps_To","value":"Cystic mesothelioma, NOS"},{"name":"Maps_To","value":"Multicystic mesothelioma, benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206680"}]}}{"C8106":{"preferredName":"Ovarian Dysgerminoma","code":"C8106","definitions":[{"definition":"A malignant germ cell neoplasm characterized by the presence of a monotonous primitive germ cell population, primarily in the ovary.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant germ cell tumor arising from the ovary.  Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei.  The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumor stage.","type":"DEFINITION","source":"NCI"},{"definition":"A seminomatous germ cell tumor originating in the ovary.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of tumor that begins in the type of cells that give rise to egg cells and is most often found in the ovaries. Dysgerminomas may also occur in other places in the body, including the central nervous system. They are the most common type of ovarian germ cell tumor and can spread to other parts of the body. They are most common in females who are younger than 20 years old.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ovarian Dysgerminoma","termGroup":"PT","termSource":"NCI"},{"termName":"Dysgerminoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Dysgerminoma of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Germ Cell Dysgerminoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Germ Cell Dysgerminoma of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Germ Cell Dysgerminoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9060/3"},{"name":"Legacy Concept Name","value":"Ovarian_Dysgerminoma"},{"name":"Maps_To","value":"9060/3"},{"name":"Maps_To","value":"Dysgerminoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346185"}]}}{"C9309":{"preferredName":"Seminoma","code":"C9309","definitions":[{"definition":"A germinomatous germ cell tumor originating in the testis.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant germ cell neoplasm of the testis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer of the testicles. Seminomas may spread to the lung, bone, liver, or brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Seminoma","termGroup":"PT","termSource":"NCI"},{"termName":"Seminoma, Pure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9061/3"},{"name":"Legacy Concept Name","value":"Seminoma"},{"name":"Maps_To","value":"9061/3"},{"name":"Maps_To","value":"Seminoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036631"}]}}{"C39920":{"preferredName":"Testicular Seminoma with High Mitotic Index","code":"C39920","definitions":[{"definition":"A seminoma of the testis characterized by increased cellular pleomorphism, high mitotic activity, and a non-prominent stromal lymphocytic infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Seminoma with High Mitotic Index","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Seminoma","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Seminoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9062/3"},{"name":"Legacy Concept Name","value":"Testicular_Seminoma_with_High_Mitotic_Index"},{"name":"Maps_To","value":"9062/3"},{"name":"Maps_To","value":"Seminoma with high mitotic index"},{"name":"Maps_To","value":"Seminoma, anaplastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334516"}]}}{"C39921":{"preferredName":"Testicular Spermatocytic Tumor","code":"C39921","definitions":[{"definition":"A testicular germ cell tumor derived from postpubertal-type germ cells. It is characterized by the presence of three cell types: round cells with eosinophilic cytoplasm, small cells with dark nucleus and a small amount of cytoplasm, and mono-or multinucleated giant cells. The neoplastic cells are not cohesive. There is an edematous stroma present; lymphocytic infiltrates are rarely seen. Most patients are older males.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Spermatocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Spermatocytic Seminoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Spermatocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Spermatocytic Seminoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9063/3"},{"name":"Legacy Concept Name","value":"Testicular_Spermatocytic_Seminoma"},{"name":"Maps_To","value":"9063/3"},{"name":"Maps_To","value":"Spermatocytic seminoma"},{"name":"Maps_To","value":"Spermatocytoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334517"}]}}{"C40345":{"preferredName":"Testicular Germ Cell Neoplasia In Situ","code":"C40345","definitions":[{"definition":"A non-invasive lesion of the testis, characterized by the presence of malignant large germ cells with abundant cytoplasm in the seminiferous tubules. It may be associated with undescended or atrophic testis and infertility. The vast majority of cases progress to invasive germ cell tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Germ Cell Neoplasia In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"GCNIS","termGroup":"AB","termSource":"NCI"},{"termName":"Gonocytoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"IGCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Testicular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Intratubular Germ Cell Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Intratubular Germ Cell Neoplasia of the Unclassified Type","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Intratubular Germ Cell Neoplasia of Unclassified Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9064/2"},{"name":"Legacy Concept Name","value":"Testicular_Intratubular_Germ_Cell_Neoplasia_Unclassified"},{"name":"Maps_To","value":"9064/2"},{"name":"Maps_To","value":"Intratubular malignant germ cells"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1515286"}]}}{"C7009":{"preferredName":"Central Nervous System Germinoma","code":"C7009","definitions":[{"definition":"A germinomatous germ cell tumor arising in the central nervous system; it is histologically identical to the dysgerminoma and seminoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant germ cell tumor arising from the central nervous system.  It is composed of uniform cells resembling primitive germ cells.  These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm.  Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells.  (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Germinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Germinoma of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Germinoma of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Germinoma of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Germinoma of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9064/3"},{"name":"Legacy Concept Name","value":"Germinoma_of_the_Central_Nervous_System"},{"name":"Maps_To","value":"9064/3"},{"name":"Maps_To","value":"Germinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333813"}]}}{"C121619":{"preferredName":"Nongerminomatous Germ Cell Tumor","code":"C121619","definitions":[{"definition":"A germ cell tumor other than a pure germinoma. These tumors (choriocarcinoma, embryonal carcinoma, teratoma, yolk sac tumor, and mixed germ cell tumor) are histologically distinct from one another.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A term that refers to teratoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, or mixed forms of these tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nongerminomatous Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Nongerminomatous Germ Cell Tumor Including Central Nervous System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"9065/3"},{"name":"Maps_To","value":"Germ cell tumor, nonseminomatous"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266158"}]}}{"C3752":{"preferredName":"Embryonal Carcinoma","code":"C3752","definitions":[{"definition":"A non-seminomatous malignant germ cell neoplasm of the testis or ovary.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonal Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9070/3"},{"name":"Legacy Concept Name","value":"Embryonal_Carcinoma"},{"name":"Maps_To","value":"9070/3"},{"name":"Maps_To","value":"Embryonal adenocarcinoma"},{"name":"Maps_To","value":"Embryonal carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206659"}]}}{"C3011":{"preferredName":"Yolk Sac Tumor","code":"C3011","definitions":[{"definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells and which produce an eosinophilic substance (alpha-fetoprotein).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yolk Sac Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Endodermal Sinus Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Endodermal Sinus Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Yolk Sac Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Yolk Sac Tumour Site Unspecified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9071/3"},{"name":"Legacy Concept Name","value":"Yolk_Sac_Tumor"},{"name":"Maps_To","value":"9071/3"},{"name":"Maps_To","value":"Embryonal carcinoma, infantile"},{"name":"Maps_To","value":"Endodermal sinus tumor"},{"name":"Maps_To","value":"Hepatoid yolk sac tumor"},{"name":"Maps_To","value":"Orchioblastoma"},{"name":"Maps_To","value":"Polyvesicular vitelline tumor"},{"name":"Maps_To","value":"Yolk sac tumor"},{"name":"Maps_To","value":"Yolk sac tumor, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4228805"}]}}{"C66776":{"preferredName":"Gonadal Polyembryoma","code":"C66776","definitions":[{"definition":"A rare malignant germ cell tumor arising from the testis and less often from the ovary. It is characterized by the presence of embryoid bodies which resemble early embryos.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadal Polyembryoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9072/3"},{"name":"Legacy Concept Name","value":"Gonadal_Polyembryoma"},{"name":"Maps_To","value":"9072/3"},{"name":"Maps_To","value":"Polyembryoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1880996"}]}}{"C3754":{"preferredName":"Gonadoblastoma","code":"C3754","definitions":[{"definition":"A mixed germ cell/sex cord-stromal tumor characterized by the presence of large germ cells that resemble seminoma cells and small cells that resemble Sertoli or granulosa cells. It occurs in the testis and the ovary, and is identified in children and adults. It is often associated with gonadal dysgenesis and abnormal karyotype.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A mixed germ cell/sex cord-stromal tumor characterized by the presence of large germ cells which resemble seminoma cells and small cells which resemble Sertoli or granulosa cells. It occurs in the testis and the ovary and is identified in children and adults. It is often associated with gonadal dysgenesis and abnormal karyotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9073/1"},{"name":"Legacy Concept Name","value":"Gonadoblastoma"},{"name":"Maps_To","value":"9073/1"},{"name":"Maps_To","value":"Gonadoblastoma"},{"name":"Maps_To","value":"Gonocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206661"}]}}{"C9012":{"preferredName":"Adult Cystic Teratoma","code":"C9012","synonyms":[{"termName":"Adult Cystic Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Cystic_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Adult cystic teratoma"},{"name":"NCI_META_CUI","value":"CL033098"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9013":{"preferredName":"Adult Teratoma","code":"C9013","synonyms":[{"termName":"Adult Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Adult teratoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368888"}]}}{"C9014":{"preferredName":"Cystic Teratoma","code":"C9014","synonyms":[{"termName":"Cystic Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystic_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Cystic teratoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368903"}]}}{"C67107":{"preferredName":"Benign Teratoma","code":"C67107","definitions":[{"definition":"A teratoma that contains only mature tissue elements (mature teratoma or grade 0 teratoma) or a limited amount of immature tissue elements (grade 1 teratoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Teratoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879828"}]}}{"C9015":{"preferredName":"Mature Teratoma","code":"C9015","definitions":[{"definition":"A teratoma which may be cystic; it is composed entirely of well differentiated, adult-type mature tissues, without evidence of fetal-type immature tissues (grade 0 teratoma).","type":"DEFINITION","source":"NCI"},{"definition":"A type of benign (not cancer) germ cell tumor (type of tumor that begins in the cells that give rise to sperm or eggs) that often contains several different types of tissue such as hair, muscle, and bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mature Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 0 Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9080/0"},{"name":"Legacy Concept Name","value":"Mature_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Mature teratoma"},{"name":"Maps_To","value":"Teratoma, benign"},{"name":"Maps_To","value":"Teratoma, differentiated"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368910"}]}}{"C3403":{"preferredName":"Teratoma","code":"C3403","definitions":[{"definition":"A non-germinomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as mature or immature. Mature teratomas are composed of well differentiated, adult-type tissues. Immature teratomas are composed of immature, fetal-type tissues.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as benign (grade 0 or 1), immature (grade 2), and malignant (grade 3). Grade 0 teratomas contain only mature elements; grade 1 teratomas have a limited degree of immaturity; grade 2 teratomas have a more extensive degree of immaturity; grade 3 teratomas are composed exclusively of immature tissues. The prognosis depends on patient age, tumor size and grade, and stage.","type":"DEFINITION","source":"NCI"},{"definition":"A type of germ cell tumor that may contain several different types of tissue, such as hair, muscle, and bone.  Teratomas occur most often in the ovaries in women, the testicles in men, and the tailbone in children.  Not all teratomas are malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9080/1"},{"name":"Legacy Concept Name","value":"Teratoma"},{"name":"Maps_To","value":"9080/1"},{"name":"Maps_To","value":"Solid teratoma"},{"name":"Maps_To","value":"Teratoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0039538"}]}}{"C4287":{"preferredName":"Malignant Teratoma","code":"C4287","definitions":[{"definition":"A malignant germ-cell neoplasm derived from pluripotent cells and consisting of components from one or more of the three germ-cell layers.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A teratoma composed exclusively of immature tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 3 Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9082/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Immature_Teratoma"},{"name":"Maps_To","value":"9080/3"},{"name":"Maps_To","value":"9082/3"},{"name":"Maps_To","value":"Malignant teratoma, anaplastic"},{"name":"Maps_To","value":"Malignant teratoma, undifferentiated"},{"name":"Maps_To","value":"Teratoma, malignant, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334521"}]}}{"C3756":{"preferredName":"Mixed Embryonal Carcinoma and Teratoma","code":"C3756","definitions":[{"definition":"A germ cell tumor characterized by the presence of an embryonal carcinoma component and a teratoma component.","type":"DEFINITION","source":"NCI"},{"definition":"A type of germ cell cancer that usually forms in the testes (testicles).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mixed Embryonal Carcinoma and Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Teratocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9081/3"},{"name":"Legacy Concept Name","value":"Mixed_Embryonal_Carcinoma_and_Teratoma"},{"name":"Maps_To","value":"9081/3"},{"name":"Maps_To","value":"Mixed embryonal carcinoma and teratoma"},{"name":"Maps_To","value":"Teratocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206664"}]}}{"C4288":{"preferredName":"Intermediate Immature Teratoma","code":"C4288","definitions":[{"definition":"An immature teratoma characterized by the presence of an intermediate amount of undifferentiated tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermediate Immature Teratoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Intermediate Malignant Teratoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9083/3"},{"name":"Legacy Concept Name","value":"Intermediate_Immature_Teratoma"},{"name":"Maps_To","value":"9083/3"},{"name":"Maps_To","value":"Malignant teratoma, intermediate"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334522"}]}}{"C9011":{"preferredName":"Dermoid Cyst","code":"C9011","definitions":[{"definition":"A benign hamartomatous tumor that possesses various epidermal derivatives and is due to sequestration of skin along the lines of embryonic closure. In neonates, it is most commonly congenital and located in the subcutaneous tissues of the head, neck, or trunk.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A benign neoplasm comprised of a cyst, lined by mature epidermis-like tissue with dermal appendages.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A mature teratoma characterized by the presence of a cyst which is lined by mature tissue resembling the epidermis and the epidermal appendages. It occurs in the ovary, testis, and extragonadal sites including central nervous system and skin.","type":"DEFINITION","source":"NCI"},{"definition":"A type of benign (not cancer) germ cell tumor (type of tumor that begins in the cells that give rise to sperm or eggs) that often contains several different types of tissue such as hair, muscle, and bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dermoid Cyst","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cystic Teratoma","termGroup":"SY","termSource":"NCI"},{"termName":"Dermoid","termGroup":"SY","termSource":"NCI"},{"termName":"Dermoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mature Cystic Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9084/0"},{"name":"Legacy Concept Name","value":"Dermoid_Cyst"},{"name":"Maps_To","value":"9084/0"},{"name":"Maps_To","value":"Dermoid cyst, NOS"},{"name":"Maps_To","value":"Dermoid, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0011649"}]}}{"C4289":{"preferredName":"Teratoma with Somatic-Type Malignancy","code":"C4289","definitions":[{"definition":"A teratoma which is characterized by morphologic transformation to malignancy and an aggressive clinical course. The malignant component most often is sarcomatous or carcinomatous.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teratoma with Somatic-Type Malignancy","termGroup":"PT","termSource":"NCI"},{"termName":"Dermoid Cyst with Malignant Transformation","termGroup":"SY","termSource":"NCI"},{"termName":"Teratoma with Malignant Transformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9084/3"},{"name":"Legacy Concept Name","value":"Teratoma_with_Malignant_Transformation"},{"name":"Maps_To","value":"9084/3"},{"name":"Maps_To","value":"Dermoid cyst with malignant transformation"},{"name":"Maps_To","value":"Dermoid cyst with secondary tumor"},{"name":"Maps_To","value":"Teratoma with malignant transformation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334523"}]}}{"C9010":{"preferredName":"Mixed Teratoma and Seminoma","code":"C9010","synonyms":[{"termName":"Mixed Teratoma and Seminoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Teratoma_and_Seminoma"},{"name":"Maps_To","value":"9085/3"},{"name":"Maps_To","value":"Mixed teratoma and seminoma"},{"name":"NCI_META_CUI","value":"CL033096"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4290":{"preferredName":"Mixed Germ Cell Tumor","code":"C4290","definitions":[{"definition":"A malignant germ cell tumor characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Germ Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9085/3"},{"name":"Legacy Concept Name","value":"Mixed_Germ_Cell_Neoplasm"},{"name":"Maps_To","value":"9085/3"},{"name":"Maps_To","value":"Mixed germ cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334524"}]}}{"C45733":{"preferredName":"Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy","code":"C45733","definitions":[{"definition":"An extragonadal non-seminomatous malignant germ cell tumor that arises from the mediastinum and is associated with a hematologic malignancy.  The hematologic malignancies are clonally related to the malignant germ cell tumor and include acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, and mastocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy","termGroup":"PT","termSource":"NCI"},{"termName":"Germ Cell Tumor with Associated Hematological Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mediastinal Germ Cell Tumor with Associated Hematological Malignancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mediastinal_Malignant_Germ_Cell_Tumor_with_Associated_Hematologic_Malignancy"},{"name":"Maps_To","value":"Germ cell tumor with associated hematological malignancy"},{"name":"Maps_To","value":"Germ cell tumors with associated hematological malignancy"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708955"}]}}{"C7468":{"preferredName":"Struma Ovarii","code":"C7468","definitions":[{"definition":"An ovarian mature teratoma characterized by the presence of aberrant thyroid tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Struma Ovarii","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9090/0"},{"name":"Legacy Concept Name","value":"Struma_Ovarii"},{"name":"Maps_To","value":"9090/0"},{"name":"Maps_To","value":"Struma ovarii, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0038478"}]}}{"C4291":{"preferredName":"Thyroid Carcinoma Arising in Struma Ovarii","code":"C4291","definitions":[{"definition":"A carcinoma with histological features identical to thyroid carcinoma, arising in ovarian mature teratoma with aberrant thyroid tissue (struma ovarii).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Carcinoma Arising in Struma Ovarii","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Struma Ovarii","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9090/3"},{"name":"Legacy Concept Name","value":"Malignant_Struma_Ovarii"},{"name":"Maps_To","value":"9090/3"},{"name":"Maps_To","value":"Struma ovarii, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334525"}]}}{"C4292":{"preferredName":"Strumal Carcinoid","code":"C4292","definitions":[{"definition":"An ovarian neoplasm characterized by the presence of aberrant thyroid tissue and a carcinoid tumor. A minority of patients develop symptoms of functioning thyroid tissue. The neuroendocrine carcinoid cells infiltrate the aberrant thyroid tissue and progressively replace the follicular lining cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Strumal Carcinoid","termGroup":"PT","termSource":"NCI"},{"termName":"Struma Ovarii and Carcinoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9091/1"},{"name":"Legacy Concept Name","value":"Strumal_Carcinoid_Neoplasm"},{"name":"Maps_To","value":"9091/1"},{"name":"Maps_To","value":"Struma ovarii and carcinoid"},{"name":"Maps_To","value":"Strumal carcinoid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334526"}]}}{"C3110":{"preferredName":"Hydatidiform Mole","code":"C3110","definitions":[{"definition":"A gestational trophoblastic disorder characterized by marked enlargement of the chorionic villi, hyperplasia of the villous trophoblastic cells and hydropic changes.","type":"DEFINITION","source":"NCI"},{"definition":"A placental disorder characterized by abnormal development with marked enlargement of the chorionic villi and hydropic changes which consist of hyperplasia of the villous trophoblastic cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A slow-growing tumor that develops from trophoblastic cells (cells that help an embryo attach to the uterus and help form the placenta) after fertilization of an egg by a sperm. A hydatidiform mole contains many cysts (sacs of fluid). It is usually benign (not cancer) but it may spread to nearby tissues (invasive mole). It may also become a malignant tumor called choriocarcinoma. Hydatidiform mole is the most common type of gestational trophoblastic tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Molar Pregnancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9100/0"},{"name":"Legacy Concept Name","value":"Hydatidiform_Mole"},{"name":"Maps_To","value":"9100/0"},{"name":"Maps_To","value":"Hydatid mole"},{"name":"Maps_To","value":"Hydatidiform mole, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0020217"}]}}{"C4871":{"preferredName":"Complete Hydatidiform Mole","code":"C4871","definitions":[{"definition":"A gestational trophoblastic disorder in which there is no embryo or normal placental tissue and the chorionic villi are hydropic.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A placental disorder where the majority of the chorionic villi are hydropic.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Complete Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Complete Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Complete Molar Pregnancy","termGroup":"SY","termSource":"NCI"},{"termName":"Complete Mole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Complete_Hydatidiform_Mole"},{"name":"Maps_To","value":"9100/0"},{"name":"Maps_To","value":"Complete hydatidiform mole"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0678213"}]}}{"C6985":{"preferredName":"Invasive Hydatidiform Mole","code":"C6985","definitions":[{"definition":"A complete hydatidiform mole or very rarely a partial mole that invades the myometrium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A complete hydatidiform mole or very rarely a partial mole that invades the myometrium.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of cancer that grows into the muscular wall of the uterus. It is formed after conception (fertilization of an egg by a sperm). It may spread to other parts of the body, such as the vagina, vulva, and lung.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Invasive Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Chorioadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chorioadenoma Destruens","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Gestational Trophoblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Mole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9100/1"},{"name":"Legacy Concept Name","value":"Invasive_Hydatidiform_Mole"},{"name":"Maps_To","value":"9100/1"},{"name":"Maps_To","value":"Chorioadenoma"},{"name":"Maps_To","value":"Chorioadenoma destruens"},{"name":"Maps_To","value":"Invasive hydatidiform mole"},{"name":"Maps_To","value":"Invasive mole, NOS"},{"name":"Maps_To","value":"Malignant hydatidiform mole"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008493"}]}}{"C2948":{"preferredName":"Choriocarcinoma","code":"C2948","definitions":[{"definition":"A malignant neoplasm arising from placental trophoblast cells. They generally arise in the uterus.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant, fast-growing tumor that develops from trophoblastic cells (cells that help an embryo attach to the uterus and help form the placenta). Almost all choriocarcinomas form in the uterus after fertilization of an egg by a sperm, but a small number form in a testis or an ovary. Choriocarcinomas spread through the blood to other organs, especially the lungs. They are a type of gestational trophoblastic disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choriocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chorioepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9100/3"},{"name":"Legacy Concept Name","value":"Choriocarcinoma"},{"name":"Maps_To","value":"9100/3"},{"name":"Maps_To","value":"Choriocarcinoma, NOS"},{"name":"Maps_To","value":"Chorioepithelioma"},{"name":"Maps_To","value":"Chorionepithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008497"}]}}{"C66777":{"preferredName":"Choriocarcinoma Combined with Other Germ Cell Elements","code":"C66777","definitions":[{"definition":"A malignant mixed germ cell tumor characterized by the presence of a choriocarcinomatous component admixed with another germ cell component (e.g. embryonal carcinoma, teratoma, or seminoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choriocarcinoma Combined with Other Germ Cell Elements","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9101/3"},{"name":"Legacy Concept Name","value":"Choriocarcinoma_Combined_with_Other_Germ_Cell_Elements"},{"name":"Maps_To","value":"9101/3"},{"name":"Maps_To","value":"Choriocarcinoma combined with embryonal carcinoma"},{"name":"Maps_To","value":"Choriocarcinoma combined with other germ cell elements"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334527"}]}}{"C66778":{"preferredName":"Malignant Trophoblastic Teratoma","code":"C66778","definitions":[{"definition":"A malignant germ cell tumor which metastasizes widely and produces high levels of human chorionic gonadotropin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Trophoblastic Teratoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9102/3"},{"name":"Legacy Concept Name","value":"Malignant_Trophoblastic_Teratoma"},{"name":"Maps_To","value":"9102/3"},{"name":"Maps_To","value":"Malignant teratoma, trophoblastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334528"}]}}{"C4293":{"preferredName":"Partial Hydatidiform Mole","code":"C4293","definitions":[{"definition":"A gestational trophoblastic disorder characterized by the presence of an abnormal fetus and two populations of chorionic villi: one population which is unremarkable and a second one which shows hydropic changes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A placental disorder characterized by the presence of two populations of chorionic villi: one population which is of unremarkable development and a second one which shows hydropic changes.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Partial Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Incomplete Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Incomplete Hydatidiform Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Incomplete Molar Pregnancy","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Molar Pregnancy","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Mole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9103/0"},{"name":"Legacy Concept Name","value":"Partial_Hydatidiform_Mole"},{"name":"Maps_To","value":"9103/0"},{"name":"Maps_To","value":"Partial hydatidiform mole"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334529"}]}}{"C3757":{"preferredName":"Placental Site Trophoblastic Tumor","code":"C3757","definitions":[{"definition":"A rare gestational trophoblastic tumor characterized by the presence of a diffuse cellular infiltrate composed of intermediate trophoblasts and cytotrophoblasts and by the absense of a significant population of syncytiotrophoblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Placental Site Trophoblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Placental Site Gestational Trophoblastic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Placental-Site Gestational Trophoblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Placental-Site Gestational Trophoblastic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Placental-Site GTT","termGroup":"SY","termSource":"NCI"},{"termName":"PSTT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9104/1"},{"name":"Legacy Concept Name","value":"Placental-Site_Gestational_Trophoblastic_Tumor"},{"name":"Maps_To","value":"9104/1"},{"name":"Maps_To","value":"Placental site trophoblastic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206666"}]}}{"C4072":{"preferredName":"Mesonephric Adenocarcinoma","code":"C4072","definitions":[{"definition":"An adenocarcinoma of the cervix or the vagina that derives from Wolffian duct remnants and shows mesonephric differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesonephric Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mesonephroma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephric Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MNAC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9110/3"},{"name":"Legacy Concept Name","value":"Mesonephric_Adenocarcinoma"},{"name":"Maps_To","value":"9110/3"},{"name":"Maps_To","value":"Mesonephric adenocarcinoma"},{"name":"Maps_To","value":"Mesonephroma, malignant"},{"name":"Maps_To","value":"Wolffian duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025490"}]}}{"C3085":{"preferredName":"Hemangioma","code":"C3085","definitions":[{"definition":"A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.","type":"DEFINITION","source":"NCI"},{"definition":"A benign vascular neoplasm characterized by the formation of capillary-sized or cavernous vascular channels.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, vascular neoplasm characterized by the formation of capillary-sized vascular channels.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Hemangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9120/0"},{"name":"Legacy Concept Name","value":"Hemangioma"},{"name":"Maps_To","value":"9120/0"},{"name":"Maps_To","value":"Angioma, NOS"},{"name":"Maps_To","value":"Hemangioma"},{"name":"Maps_To","value":"Hemangioma unspecified site"},{"name":"Maps_To","value":"Hemangioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018916"}]}}{"C3088":{"preferredName":"Angiosarcoma","code":"C3088","definitions":[{"definition":"A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant vascular neoplasm arising from endothelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that begins in the cells that line blood vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Angiosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hemangiosarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Angioendothelioma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Hemangioendothelioma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9120/3"},{"name":"Legacy Concept Name","value":"Angiosarcoma"},{"name":"Maps_To","value":"9130/3"},{"name":"Maps_To","value":"Angiosarcoma"},{"name":"Maps_To","value":"Haemangiosarcoma"},{"name":"Maps_To","value":"Hemangioendothelial sarcoma"},{"name":"Maps_To","value":"Hemangioendothelioma, malignant"},{"name":"Maps_To","value":"Hemangiosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018923"}]}}{"C3086":{"preferredName":"Cavernous Hemangioma","code":"C3086","definitions":[{"definition":"A hemangioma characterized by the presence of cavernous vascular spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cavernous Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Cavernoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cavernous Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9121/0"},{"name":"Legacy Concept Name","value":"Cavernous_Hemangioma"},{"name":"Maps_To","value":"9121/0"},{"name":"Maps_To","value":"Cavernous hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018920"}]}}{"C4296":{"preferredName":"Venous Hemangioma","code":"C4296","definitions":[{"definition":"A hemangioma composed of veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venous Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Venous Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Venous Malformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9122/0"},{"name":"Legacy Concept Name","value":"Venous_Hemangioma"},{"name":"Maps_To","value":"9122/0"},{"name":"Maps_To","value":"Venous hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334532"}]}}{"C2882":{"preferredName":"Arteriovenous Malformation/Hemangioma","code":"C2882","definitions":[{"definition":"A benign vascular lesion characterized by the presence of a complex network of communicating arterial and venous vascular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arteriovenous Malformation/Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Arteriovenous Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Arteriovenous Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Arteriovenous Hemangioma/Malformation","termGroup":"SY","termSource":"NCI"},{"termName":"Arteriovenous Malformation","termGroup":"SY","termSource":"NCI"},{"termName":"AVM/H","termGroup":"AB","termSource":"NCI"},{"termName":"Racemose Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Racemose Hemangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9123/0"},{"name":"Legacy Concept Name","value":"Arteriovenous_Malformation"},{"name":"Maps_To","value":"9123/0"},{"name":"Maps_To","value":"Arteriovenous hemangioma"},{"name":"Maps_To","value":"Racemose hemangioma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0003857"}]}}{"C4438":{"preferredName":"Liver Angiosarcoma","code":"C4438","definitions":[{"definition":"A malignant vascular neoplasm arising from the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liver Angiosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiosarcoma of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Angiosarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangiosarcoma of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangiosarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Angiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Hemangiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Hemangiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Angiosarcoma of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Angiosarcoma of the Liver","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9124/3"},{"name":"Legacy Concept Name","value":"Hepatic_Angiosarcoma"},{"name":"Maps_To","value":"9124/3"},{"name":"Maps_To","value":"Kupffer cell sarcoma"},{"name":"Maps_To","value":"Malignant neoplasm: Angiosarcoma of liver"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0345907"}]}}{"C4298":{"preferredName":"Epithelioid Hemangioma","code":"C4298","definitions":[{"definition":"A hemangioma characterized by the presence of epithelioid endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiolymphoid Hyperplasia with Eosinophilia","termGroup":"SY","termSource":"NCI"},{"termName":"Histiocytoid Hemangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9125/0"},{"name":"Legacy Concept Name","value":"Epithelioid_Hemangioma"},{"name":"Maps_To","value":"9125/0"},{"name":"Maps_To","value":"Epithelioid hemangioma"},{"name":"Maps_To","value":"Histiocytoid hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368797"}]}}{"C66779":{"preferredName":"Benign Hemangioendothelioma","code":"C66779","definitions":[{"definition":"A benign vascular proliferation characterized by the presence of prominent endothelial cells and the formation of vascular channels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Hemangioendothelioma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9130/0"},{"name":"Legacy Concept Name","value":"Benign_Hemangioendothelioma"},{"name":"Maps_To","value":"9130/0"},{"name":"Maps_To","value":"Hemangioendothelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334536"}]}}{"C3084":{"preferredName":"Hemangioendothelioma","code":"C3084","definitions":[{"definition":"A vascular proliferation characterized by the presence of prominent endothelial cells and the formation of vascular channels. Hemangioendotheliomas may display borderline or low grade characteristics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioendothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9130/1"},{"name":"Legacy Concept Name","value":"Hemangioendothelioma"},{"name":"Maps_To","value":"9130/1"},{"name":"Maps_To","value":"Angioendothelioma"},{"name":"Maps_To","value":"Hemangioendothelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018915"}]}}{"C27510":{"preferredName":"Kaposiform Hemangioendothelioma","code":"C27510","definitions":[{"definition":"An intermediate, locally aggressive blood vessel neoplasm characterized by the presence of spindle endothelial cells, and formation of capillary-sized and slit-like vascular channels.  It is often associated with hemorrhage and hemosiderin deposition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kaposiform Hemangioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"KHE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kaposiform_Hemangioendothelioma"},{"name":"Maps_To","value":"9130/1"},{"name":"Maps_To","value":"Kaposiform hemangioendothelioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367420"}]}}{"C6645":{"preferredName":"Infantile Hemangioma","code":"C6645","definitions":[{"definition":"A capillary hemangioma that may regress spontaneously.  It occurs in infants and children.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infantile Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Cellular Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Infantile Hemangioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Capillary Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Strawberry Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infantile_Hemangioendothelioma"},{"name":"Maps_To","value":"9131/0"},{"name":"Maps_To","value":"Hemangioma simplex"},{"name":"Maps_To","value":"Infantile hemangioma"},{"name":"Maps_To","value":"Juvenile hemangioma"},{"name":"Maps_To","value":"Plexiform hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206733"}]}}{"C7457":{"preferredName":"Capillary Hemangioma","code":"C7457","definitions":[{"definition":"A common hemangioma characterized by the presence of capillary-sized vascular channels without prominent epithelioid endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capillary Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Capillary Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9131/0"},{"name":"Legacy Concept Name","value":"Capillary_Hemangioma"},{"name":"Maps_To","value":"9131/0"},{"name":"Maps_To","value":"Capillary hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2748741"}]}}{"C3699":{"preferredName":"Intramuscular Hemangioma","code":"C3699","definitions":[{"definition":"A hemangioma arising from skeletal muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramuscular Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Intramuscular Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9132/0"},{"name":"Legacy Concept Name","value":"Intramuscular_Hemangioma"},{"name":"Maps_To","value":"9132/0"},{"name":"Maps_To","value":"Intramuscular hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205789"}]}}{"C3800":{"preferredName":"Epithelioid Hemangioendothelioma","code":"C3800","definitions":[{"definition":"A low-grade malignant blood vessel neoplasm.  It is characterized by the presence of epithelioid endothelial cells.  The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Hemangioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Angioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Angiosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9130/3"},{"name":"ICD-O-3_Code","value":"9133/1"},{"name":"ICD-O-3_Code","value":"9133/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Hemangioendothelioma"},{"name":"Maps_To","value":"9133/1"},{"name":"Maps_To","value":"9133/3"},{"name":"Maps_To","value":"Epithelioid hemangioendothelioma, malignant"},{"name":"Maps_To","value":"Epithelioid hemangioendothelioma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206732"}]}}{"C7526":{"preferredName":"Papillary Intralymphatic Angioendothelioma","code":"C7526","definitions":[{"definition":"An intermediate, rarely metastasizing blood vessel neoplasm. It is characterized by the presence of lymphatic-like vascular channels and papillary endothelial proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Intralymphatic Angioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Dabska Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Endothelial Papillary Angioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Endovascular Angioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"PILA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9135/1"},{"name":"Legacy Concept Name","value":"Endovascular_Papillary_Angioendothelioma"},{"name":"Maps_To","value":"9135/1"},{"name":"Maps_To","value":"Dabska tumor"},{"name":"Maps_To","value":"Endovascular papillary angioendothelioma"},{"name":"Maps_To","value":"Papillary intralymphatic angioendothelioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346087"}]}}{"C4754":{"preferredName":"Spindle Cell Hemangioma","code":"C4754","definitions":[{"definition":"A hemangioma characterized by the presence of spindle endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"SCH","termGroup":"AB","termSource":"NCI"},{"termName":"Spindle -Cell Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Hemangioendothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9136/0"},{"name":"ICD-O-3_Code","value":"9136/1"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Hemangioma"},{"name":"Maps_To","value":"9136/1"},{"name":"Maps_To","value":"Spindle cell angioendothelioma"},{"name":"Maps_To","value":"Spindle cell hemangioendothelioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1304508"}]}}{"C53677":{"preferredName":"Intimal Sarcoma","code":"C53677","definitions":[{"definition":"A malignant neoplasm arising from the large blood vessels.  It is characterized by the presence of tumor cells that grow within the lumen of the blood vessels.  The intraluminal tumor growth may result in vascular obstruction and spread of tumor emboli to peripheral organs.  The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intimal Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intimal_Sarcoma"},{"name":"Maps_To","value":"9137/3"},{"name":"Maps_To","value":"Intimal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708550"}]}}{"C9087":{"preferredName":"Kaposi Sarcoma","code":"C9087","definitions":[{"definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer characterized by the abnormal growth of blood vessels that develop into skin lesions or occur internally.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Kaposi Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Kaposi's Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"KS","termGroup":"AB","termSource":"NCI"},{"termName":"Multiple Hemorrhagic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9140/3"},{"name":"Legacy Concept Name","value":"Kaposi_s_Sarcoma"},{"name":"Maps_To","value":"9140/3"},{"name":"Maps_To","value":"Kaposi sarcoma"},{"name":"Maps_To","value":"Kaposi Sarcoma"},{"name":"Maps_To","value":"Kaposi sarcoma of soft tissue"},{"name":"Maps_To","value":"Kaposi's sarcoma"},{"name":"Maps_To","value":"Kaposi's sarcoma of gastrointestinal sites"},{"name":"Maps_To","value":"Kaposi's sarcoma, gastrointestinal sites"},{"name":"Maps_To","value":"Multiple hemorrhagic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3552576"}]}}{"C2874":{"preferredName":"Angiokeratoma","code":"C2874","definitions":[{"definition":"A vascular lesion in the papillary dermis resulting from ectasia of pre-existing vessels. It is associated with secondary proliferative changes in the overlying epidermis (hyperkeratosis). It can present with widespread lesions (angiokeratoma corporis diffusum, often associated with inborn errors of metabolism) or as a localized lesion (angiokeratoma of Fordyce, angiokeratoma circumscriptum, and angiokeratoma of Mibelli).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiokeratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9141/0"},{"name":"Legacy Concept Name","value":"Angiokeratoma"},{"name":"Maps_To","value":"9141/0"},{"name":"Maps_To","value":"Angiokeratoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0002985"}]}}{"C4299":{"preferredName":"Verrucous Hemangioma","code":"C4299","definitions":[{"definition":"A skin hemangioma characterized by the presence of epidermal hyperplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verrucous Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Verrucous Keratotic Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Verrucous Venous Malformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9142/0"},{"name":"Legacy Concept Name","value":"Verrucous_Keratotic_Hemangioma"},{"name":"Maps_To","value":"9142/0"},{"name":"Maps_To","value":"Verrucous keratotic hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334540"}]}}{"C4300":{"preferredName":"Benign Hemangiopericytoma","code":"C4300","definitions":[{"definition":"A benign neoplasm originating from vascular pericytes (cells in the periphery of vessels).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A hemangiopericytoma without malignant morphologic or clinical characteristics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Hemangiopericytoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9150/0"},{"name":"Legacy Concept Name","value":"Benign_Hemangiopericytoma"},{"name":"Maps_To","value":"9150/0"},{"name":"Maps_To","value":"Hemangiopericytoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334541"}]}}{"C3087":{"preferredName":"Hemangiopericytoma","code":"C3087","definitions":[{"definition":"A type of cancer involving blood vessels and soft tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antiquated term that refers to benign or malignant mesenchymal neoplasms characterized by the presence of neoplastic spindle-shaped to round cells arranged around thin-walled branching vascular spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangiopericytoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9150/1"},{"name":"Legacy Concept Name","value":"Hemangiopericytoma"},{"name":"Maps_To","value":"9150/1"},{"name":"Maps_To","value":"Hemangiopericytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018922"}]}}{"C4301":{"preferredName":"Malignant Hemangiopericytoma","code":"C4301","definitions":[{"definition":"A malignant neoplasm originating from vascular pericytes (cells in the periphery of vessels).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An uncommon malignant neoplasm arising from pericytes.  Distinction between benign and malignant hemangiopericytoma may be difficult or even impossible on morphologic grounds alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Hemangiopericytoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Malignant Hemangiopericytoma NOS","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9150/3"},{"name":"Legacy Concept Name","value":"Malignant_Hemangiopericytoma"},{"name":"Maps_To","value":"9150/3"},{"name":"Maps_To","value":"Hemangiopericytoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334542"}]}}{"C27257":{"preferredName":"Cellular Angiofibroma","code":"C27257","definitions":[{"definition":"A benign mesenchymal neoplasm that usually arises in the superficial soft tissues of the vulva or inguinal and scrotal regions.  It is characterized by the presence of a cellular fibroblastic proliferation in an edematous to fibrous stroma containing numerous vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Angiofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cellular_Angiofibroma"},{"name":"Maps_To","value":"9160/0"},{"name":"Maps_To","value":"Cellular angiofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367534"}]}}{"C27256":{"preferredName":"Giant Cell Angiofibroma","code":"C27256","definitions":[{"definition":"A morphologic variant of angiofibroma characterized by the presence of multinucleated giant cells, collagenous or myxoid stroma, focal sclerotic areas, and angiectoid spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Angiofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Giant_Cell_Angiofibroma"},{"name":"Maps_To","value":"9160/0"},{"name":"Maps_To","value":"Giant cell angiofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367539"}]}}{"C3799":{"preferredName":"Angiofibroma","code":"C3799","definitions":[{"definition":"A benign, morphologic variant of fibroma characterized by the presence of numerous dilated vascular channels.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic variant of fibroma characterized by the presence of numerous dilated vascular channels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiofibromatous Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrous Papule","termGroup":"SY","termSource":"NCI"},{"termName":"Telangiectatic Fibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9160/0"},{"name":"Legacy Concept Name","value":"Angiofibroma"},{"name":"Maps_To","value":"9160/0"},{"name":"Maps_To","value":"Angiofibroma, NOS"},{"name":"Maps_To","value":"Juvenile angiofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206731"}]}}{"C4487":{"preferredName":"Tufted Angioma","code":"C4487","definitions":[{"definition":"A capillary hemangioma of the skin usually presenting with patches or plaques.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tufted Angioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioblastoma of Nakagawa","termGroup":"SY","termSource":"NCI"},{"termName":"TA","termGroup":"AB","termSource":"NCI"},{"termName":"Tufted Angioma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Angioma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Hemangioma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Hemangioma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Skin Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9161/0"},{"name":"Legacy Concept Name","value":"Tufted_Hemangioma"},{"name":"Maps_To","value":"9161/0"},{"name":"Maps_To","value":"Acquired tufted hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346073"}]}}{"C3801":{"preferredName":"Hemangioblastoma","code":"C3801","definitions":[{"definition":"A rare, slow-growing tumor of uncertain histogenesis. It affects the central nervous system and infrequently other sites. It is composed of stromal cells and abundant capillaries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangioblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Capillary Hemangioblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9161/1"},{"name":"Legacy Concept Name","value":"Hemangioblastoma"},{"name":"Maps_To","value":"9161/1"},{"name":"Maps_To","value":"Angioblastoma"},{"name":"Maps_To","value":"Haemangioblastoma"},{"name":"Maps_To","value":"Hemangioblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206734"}]}}{"C8965":{"preferredName":"Lymphangioma","code":"C8965","definitions":[{"definition":"A benign lesion composed of dilated lymphatic channels. Painless swelling is the usual clinical manifestation.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm arising from the lymphatics.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymphangioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9170/0"},{"name":"Legacy Concept Name","value":"Lymphangioma"},{"name":"Maps_To","value":"9170/0"},{"name":"Maps_To","value":"9171/0"},{"name":"Maps_To","value":"Capillary lymphangioma"},{"name":"Maps_To","value":"Lymphangioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024221"}]}}{"C3203":{"preferredName":"Acquired Progressive Lymphangioma","code":"C3203","definitions":[{"definition":"A lymphangioma characterized by the presence of collagen bundle formation.  It has an indolent clinical course and may be associated with skin plaques.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acquired Progressive Lymphangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangioendothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphangioendothelioma"},{"name":"Maps_To","value":"9170/0"},{"name":"Maps_To","value":"Lymphangioendothelioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024217"}]}}{"C3205":{"preferredName":"Lymphangiosarcoma","code":"C3205","definitions":[{"definition":"A malignant neoplasm arising from the endothelial cells of the lymphatic vessels.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from the endothelial cells of the lymphatic vessels.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that begins in the cells that line lymph vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphangiosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangioendothelial Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Lymphangioendothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9170/3"},{"name":"Legacy Concept Name","value":"Lymphangiosarcoma"},{"name":"Maps_To","value":"9170/3"},{"name":"Maps_To","value":"Lymphangioendothelial sarcoma"},{"name":"Maps_To","value":"Lymphangioendothelioma, malignant"},{"name":"Maps_To","value":"Lymphangiosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024224"}]}}{"C53316":{"preferredName":"Cavernous Lymphangioma","code":"C53316","definitions":[{"definition":"A lymphangioma characterized by the presence of thin-walled cavernous lymphatic spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cavernous Lymphangioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9172/0"},{"name":"Legacy Concept Name","value":"Cavernous_Lymphangioma"},{"name":"Maps_To","value":"9172/0"},{"name":"Maps_To","value":"Cavernous lymphangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205828"}]}}{"C3724":{"preferredName":"Cystic Hygroma","code":"C3724","definitions":[{"definition":"A benign lymphatic neoplasm usually arising from the neck and characterized by cystic dilation of the lymphatic vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystic Hygroma","termGroup":"PT","termSource":"NCI"},{"termName":"Cystic Lymphangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Hygroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9173/0"},{"name":"Legacy Concept Name","value":"Cystic_Lymphangioma"},{"name":"Maps_To","value":"9173/0"},{"name":"Maps_To","value":"Cystic hygroma"},{"name":"Maps_To","value":"Cystic lymphangioma"},{"name":"Maps_To","value":"Hygroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206620"}]}}{"C3204":{"preferredName":"Lymphangioleiomyoma","code":"C3204","definitions":[{"definition":"A neoplasm with perivascular epithelioid cell differentiation, often associated with tuberous sclerosis. It is characterized by the presence of smooth muscle and epithelioid cells and by the proliferation of lymphatic vessels. Sites of involvement include the lymph nodes, lung, mediastinum, and retroperitoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphangioleiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangiomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9174/0"},{"name":"Legacy Concept Name","value":"Lymphangiomyoma"},{"name":"Maps_To","value":"9174/0"},{"name":"Maps_To","value":"Lymphangiomyoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024223"}]}}{"C3725":{"preferredName":"Lymphangioleiomyomatosis","code":"C3725","definitions":[{"definition":"A multifocal neoplasm with perivascular epithelioid cell differentiation affecting almost exclusively females of child-bearing age. It is characterized by the presence of smooth muscle and epithelioid cells and by the proliferation of lymphatic vessels. Sites of involvement include the lungs, mediastinum, and the retroperitoneum. It usually presents with chylous pleural effusion or ascites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphangioleiomyomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"LAM","termGroup":"AB","termSource":"NCI"},{"termName":"Lymphangiomyomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9174/1"},{"name":"Legacy Concept Name","value":"Lymphangiomyomatosis"},{"name":"Maps_To","value":"9174/1"},{"name":"Maps_To","value":"Lymphangioleiomyomatosis"},{"name":"Maps_To","value":"Lymphangiomyomatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751674"}]}}{"C66792":{"preferredName":"Hemolymphangioma","code":"C66792","definitions":[{"definition":"A hemorrhagic lymphatic lesion characterized by the presence of dilated lymphatic spaces, extravasation of red blood cells, hemosiderin deposition, and fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemolymphangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangioma with Hemorrhage","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9175/0"},{"name":"Legacy Concept Name","value":"Lymphangioma_with_Hemorrhage"},{"name":"Maps_To","value":"9175/0"},{"name":"Maps_To","value":"Hemolymphangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334544"}]}}{"C3296":{"preferredName":"Osteoma","code":"C3296","definitions":[{"definition":"A benign well-differentiated neoplasm of bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well-circumscribed, bone-forming neoplasm predominantly composed of lamellar bone. It usually arises from the calvarial, facial, or jaw bones.  It is usually asymptomatic but it may cause local swelling or obstruction of the paranasal sinuses.  Asymptomatic cases have an indolent clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9180/0"},{"name":"Legacy Concept Name","value":"Osteoma"},{"name":"Maps_To","value":"9180/0"},{"name":"Maps_To","value":"Osteoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029440"}]}}{"C53953":{"preferredName":"Osteoblastic Osteosarcoma","code":"C53953","definitions":[{"definition":"A conventional osteosarcoma characterized by the predominance of osteoid matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoblastic Osteosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Osteoblastic_Osteosarcoma"},{"name":"Maps_To","value":"9180/3"},{"name":"Maps_To","value":"Osteoblastic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704328"}]}}{"C4021":{"preferredName":"Chondroblastic Osteosarcoma","code":"C4021","definitions":[{"definition":"An osteosarcoma characterised by the presence of atypical cartilage of variable cellularity.  It may or may not be associated with the presence of myxoid areas or focal bone formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroblastic Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chondroblastic Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9181/3"},{"name":"Legacy Concept Name","value":"Chondrosarcomatous_Osteosarcoma"},{"name":"Maps_To","value":"9180/3"},{"name":"Maps_To","value":"9181/3"},{"name":"Maps_To","value":"Chondroblastic osteosarcoma"},{"name":"Maps_To","value":"Osteochondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279603"}]}}{"C9145":{"preferredName":"Osteosarcoma","code":"C9145","definitions":[{"definition":"A cancer of the bone that usually affects the large bones of the arm or leg. It occurs most commonly in young people and affects more males than females.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm of connective tissue origin that produces bone or osteoid.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neoplasm usually arising from bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9180/3"},{"name":"Legacy Concept Name","value":"Osteosarcoma"},{"name":"Maps_To","value":"9180/3"},{"name":"Maps_To","value":"Osteogenic sarcoma, NOS"},{"name":"Maps_To","value":"Osteosarcoma"},{"name":"Maps_To","value":"Osteosarcoma (OS)"},{"name":"Maps_To","value":"Osteosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029463"}]}}{"C4020":{"preferredName":"Fibroblastic Osteosarcoma","code":"C4020","definitions":[{"definition":"A conventional osteosarcoma characterized by the presence of spindle shaped cells.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant fibrosarcoma characterized by pleomorphic cells intermixed with variable amounts of collagenous matrix.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fibroblastic Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblastic Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrosarcomatous Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrosarcomatous Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9182/3"},{"name":"Legacy Concept Name","value":"Fibroblastic_Osteosarcoma"},{"name":"Maps_To","value":"9182/3"},{"name":"Maps_To","value":"Fibroblastic osteosarcoma"},{"name":"Maps_To","value":"Osteofibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279602"}]}}{"C3902":{"preferredName":"Telangiectatic Osteosarcoma","code":"C3902","definitions":[{"definition":"An osteosarcoma usually arising from the metaphysis of long bones. It is characterized by the presence of a cystic architecture with blood-filled spaces. The prognosis is similar to that of conventional osteosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telangiectatic Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Bone Aneurysm","termGroup":"SY","termSource":"NCI"},{"termName":"Telangiectatic Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9183/3"},{"name":"Legacy Concept Name","value":"Telangiectatic_Osteosarcoma"},{"name":"Maps_To","value":"9183/3"},{"name":"Maps_To","value":"Telangiectatic osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259782"}]}}{"C6469":{"preferredName":"Osteosarcoma Arising in Paget Disease of Bone","code":"C6469","definitions":[{"definition":"A sarcomatous transformation of pre-existing Paget disease of the bone. Osteosarcomas arising from Paget disease of the bone are high grade lesions and usually have a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteosarcoma Arising in Paget Disease of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Bone Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Osseous Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Osteitis Deformans","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Paget's Disease of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma in Paget Disease of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9184/3"},{"name":"Legacy Concept Name","value":"Osteosarcoma_Arising_in_Paget_s_Disease_of_Bone"},{"name":"Maps_To","value":"9184/3"},{"name":"Maps_To","value":"Osteosarcoma in Paget disease of bone"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334546"}]}}{"C4023":{"preferredName":"Small Cell Osteosarcoma","code":"C4023","definitions":[{"definition":"An osteosarcoma usually arising from the metaphysis of long bones. It is characterized by the presence of small cells and osteoid production. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Small Cell Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9185/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Osteosarcoma"},{"name":"Maps_To","value":"9185/3"},{"name":"Maps_To","value":"Round cell osteosarcoma"},{"name":"Maps_To","value":"Small cell osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279622"}]}}{"C35870":{"preferredName":"Conventional Osteosarcoma","code":"C35870","definitions":[{"definition":"A high grade malignant bone-forming mesenchymal neoplasm producing osteoid. The tumor arises from the medullary portion of the bone. It affects the long bones and most commonly, the distal femur, proximal tibia, and proximal humerus. Pain with or without a palpable mass is the most common clinical presentation. It usually has an aggressive growth and may metastasize through the hematogenous route. The lung is the most frequent site of metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conventional Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Conventional Central Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"COS","termGroup":"AB","termSource":"NCI"},{"termName":"Intracortical Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracortical Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9186/3"},{"name":"ICD-O-3_Code","value":"9195/3"},{"name":"Legacy Concept Name","value":"Conventional_Osteosarcoma"},{"name":"Maps_To","value":"9186/3"},{"name":"Maps_To","value":"9195/3"},{"name":"Maps_To","value":"Central osteosarcoma"},{"name":"Maps_To","value":"Central osteosarcoma, NOS"},{"name":"Maps_To","value":"Conventional central osteosarcoma"},{"name":"Maps_To","value":"Intracortical osteosarcoma"},{"name":"Maps_To","value":"Medullary osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266166"}]}}{"C6474":{"preferredName":"Low Grade Central Osteosarcoma","code":"C6474","definitions":[{"definition":"A low grade osteosarcoma arising from the medullary portion of the bone. It affects the long bones and is characterized by the presence of fibroblastic stroma and osteoid production. Pain and swelling are the usual sign and symptom. The prognosis is more favorable than conventional osteosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Central Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Intraosseous Well Differentiated Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraosseous Well-Differentiated Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraosseous Well-Differentiated Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"LGCOS","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Intramedullary Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intramedullary Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9187/3"},{"name":"Legacy Concept Name","value":"Low_Grade_Central_Osteosarcoma"},{"name":"Maps_To","value":"9187/3"},{"name":"Maps_To","value":"Intraosseous low grade osteosarcoma"},{"name":"Maps_To","value":"Intraosseous well differentiated osteosarcoma"},{"name":"Maps_To","value":"Low grade central osteosarcoma"},{"name":"Maps_To","value":"Low-grade central osteosarcoma"},{"name":"Maps_To","value":"Low-grade intramedullary osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266163"}]}}{"C3297":{"preferredName":"Osteoid Osteoma","code":"C3297","definitions":[{"definition":"A small, benign, bone-forming neoplasm that can arise from any bone but more frequently affects the long bones. The central portion of the neoplasm (nidus) contains differentiated osteoblasts which produce osteoid and sometimes bone. The lesion is usually surrounded by hypervascular sclerotic bone and has limited growth potential. Clinical signs and symptoms include pain and localized tenderness, at the site of the lesion. The pain may be intense but in the majority of cases it is completely alleviated by non-steroidal anti-inflammatory drugs. Prognosis is excellent and recurrences are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoid Osteoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9191/0"},{"name":"Legacy Concept Name","value":"Osteoid_Osteoma"},{"name":"Maps_To","value":"9191/0"},{"name":"Maps_To","value":"Osteoid osteoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029441"}]}}{"C8969":{"preferredName":"Parosteal Osteosarcoma","code":"C8969","definitions":[{"definition":"A low grade malignant bone-forming mesenchymal neoplasm arising from the surface of the bone. It usually affects the distal posterior femur, the proximal tibia, and proximal humerus. Painless swelling is the usual clinical sign. Most patients are young adults and the prognosis is usually excellent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parosteal Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juxtacortical Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Parosteal Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9192/3"},{"name":"Legacy Concept Name","value":"Parosteal_Osteosarcoma"},{"name":"Maps_To","value":"9192/3"},{"name":"Maps_To","value":"Juxtacortical osteosarcoma"},{"name":"Maps_To","value":"Parosteal osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206642"}]}}{"C8970":{"preferredName":"Periosteal Osteosarcoma","code":"C8970","definitions":[{"definition":"An intermediate grade malignant bone-forming mesenchymal neoplasm with chondroblastic differentiation.  It arises from the surface of the bone and affects the diaphysis or diaphyseal- metaphyseal portion of the long bones.  A painless mass or swelling is the most common clinical sign.  It is associated with a better prognosis than conventional osteosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Chondroblastic Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9193/3"},{"name":"Legacy Concept Name","value":"Periosteal_Osteosarcoma"},{"name":"Maps_To","value":"9193/3"},{"name":"Maps_To","value":"Periosteal osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377843"}]}}{"C53958":{"preferredName":"High Grade Surface Osteosarcoma","code":"C53958","definitions":[{"definition":"A usually aggressive high grade malignant bone-forming mesenchymal neoplasm arising from the surface of the bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Surface Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"High-Grade Surface Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9194/3"},{"name":"Legacy Concept Name","value":"High_Grade_Surface_Osteosarcoma"},{"name":"Maps_To","value":"9194/3"},{"name":"Maps_To","value":"High grade surface osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266165"}]}}{"C3294":{"preferredName":"Osteoblastoma","code":"C3294","definitions":[{"definition":"A benign neoplasm of bone, characterized by the formation of osteoid tissue and large osteoblast-like cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare benign bone-forming neoplasm usually arising from the spine. It is a well-circumscribed lytic tumor that varies in size. The tumor is composed of woven bone trabeculae and shares similar histologic characteristics with the osteoid osteoma. Surgical curettage is the treatment of choice. The prognosis is excellent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Giant Osteoid Osteoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ossifying Giant Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9200/0"},{"name":"Legacy Concept Name","value":"Osteoblastoma"},{"name":"Maps_To","value":"9200/0"},{"name":"Maps_To","value":"Giant osteoid osteoma"},{"name":"Maps_To","value":"Osteoblastoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029417"}]}}{"C66796":{"preferredName":"Aggressive Osteoblastoma","code":"C66796","definitions":[{"definition":"An osteoblastoma characterized by the presence of prominent epithelioid osteoblasts and recurrences.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggressive Osteoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9200/1"},{"name":"Legacy Concept Name","value":"Aggressive_Osteoblastoma"},{"name":"Maps_To","value":"9200/1"},{"name":"Maps_To","value":"Aggressive osteoblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334547"}]}}{"C3295":{"preferredName":"Osteochondroma","code":"C3295","definitions":[{"definition":"A benign cartiliginous neoplasm arising from the metaphysis of bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A common, benign cartiliginous neoplasm arising from the metaphysis of bone. The tumor grows on the surface of the bone; it may be pedunculated or sessile. It is characterized by the presence of chondrocytes, a cartilage cap, and a fibrous perichondrium that extends to the periosteum of the bone. In some cases, there is deletion of 8q24.1 chromosome locus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteochondroma","termGroup":"PT","termSource":"NCI"},{"termName":"Osteocartilaginous Exostosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9210/0"},{"name":"Legacy Concept Name","value":"Osteochondroma"},{"name":"Maps_To","value":"9210/0"},{"name":"Maps_To","value":"Cartilaginous exostosis"},{"name":"Maps_To","value":"Ecchondroma"},{"name":"Maps_To","value":"Osteocartilaginous exostosis"},{"name":"Maps_To","value":"Osteochondroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029423"}]}}{"C53457":{"preferredName":"Multiple Osteochondromas","code":"C53457","definitions":[{"definition":"An autosomal dominant neoplastic chondrogenic process affecting multiple sites. It is caused by mutations in the EXT1 or EXT2 genes.  Grossly and microscopically, the lesions resemble an osteochondroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multiple Osteochondromas","termGroup":"PT","termSource":"NCI"},{"termName":"Osteochondromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9210/1"},{"name":"Legacy Concept Name","value":"Multiple_Osteochondromas"},{"name":"Maps_To","value":"9210/1"},{"name":"Maps_To","value":"Ecchondrosis"},{"name":"Maps_To","value":"Osteochondromatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206641"}]}}{"C53459":{"preferredName":"Chondroma","code":"C53459","definitions":[{"definition":"A benign well circumscribed neoplasm of hyaline cartilage arising from bone or soft tissue. It is characterized by the presence of chondrocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A benign, well circumscribed neoplasm arising from the hyaline cartilage in soft tissue or bone. It is characterized by the presence of chondrocytes.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Chondroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9220/0"},{"name":"Legacy Concept Name","value":"Chondroma"},{"name":"Maps_To","value":"9220/0"},{"name":"Maps_To","value":"Chondroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0936248"}]}}{"C3007":{"preferredName":"Enchondroma","code":"C3007","definitions":[{"definition":"A benign (noncancerous) growth of cartilage in bones or in other areas where cartilage is not normally found.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A common benign hyaline cartilage neoplasm arising in the intramedullary bone.  It is characterized by the presence of chondrocytes, low mitotic activity, and in some cases, a nodular pattern and calcification. The small bones of the hands and feet are the most frequently affected sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enchondroma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Chondroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Enchondroma"},{"name":"Maps_To","value":"9220/0"},{"name":"Maps_To","value":"Enchondroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704356"}]}}{"C35259":{"preferredName":"Chondromatosis","code":"C35259","definitions":[{"definition":"A multifocal benign neoplasm arising from bone or soft tissue.  It is characterized by the presence of chondrocytes and is composed of hyaline cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondromatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9220/1"},{"name":"Legacy Concept Name","value":"Chondromatosis"},{"name":"Maps_To","value":"9220/1"},{"name":"Maps_To","value":"Chondromatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206636"}]}}{"C2946":{"preferredName":"Chondrosarcoma","code":"C2946","definitions":[{"definition":"A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue.  It usually affects middle-aged to elderly adults.  The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant mesenchymal neoplasm arising from cartilage-forming tissues.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that forms in bone cartilage. It usually starts in the pelvis (between the hip bones), the shoulder, the ribs, or at the ends of the long bones of the arms and legs. A rare type of chondrosarcoma called extraskeletal chondrosarcoma does not form in bone cartilage. Instead, it forms in the soft tissues of the upper part of the arms and legs. Chondrosarcoma can occur at any age but is more common in people older than 40 years. It is a type of bone cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9220/3"},{"name":"Legacy Concept Name","value":"Chondrosarcoma"},{"name":"Maps_To","value":"9220/3"},{"name":"Maps_To","value":"Chondrosarcoma"},{"name":"Maps_To","value":"Chondrosarcoma, NOS"},{"name":"Maps_To","value":"Fibrochondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008479"}]}}{"C4302":{"preferredName":"Periosteal Chondroma","code":"C4302","definitions":[{"definition":"A benign neoplasm of bone surface composed of hyaline cartilage.  It arises beneath the periosteum and is characterized by the presence of chondrocytes, a lobulated growth pattern, and calcification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Chondroma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Chondroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9221/0"},{"name":"Legacy Concept Name","value":"Periosteal_Chondroma"},{"name":"Maps_To","value":"9221/0"},{"name":"Maps_To","value":"Juxtacortical chondroma"},{"name":"Maps_To","value":"Periosteal chondroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4076530"}]}}{"C7357":{"preferredName":"Periosteal Chondrosarcoma","code":"C7357","definitions":[{"definition":"A chondrosarcoma arising from the surface of bone. It is characterized by a lobulated growth pattern, high mitotic activity, myxoid stroma formation, and necrotic changes. It occurs in adults. Clinical presentation includes pain, and sometimes swelling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Chondrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Chondrosarcoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9221/3"},{"name":"Legacy Concept Name","value":"Periosteal_Chondrosarcoma"},{"name":"Maps_To","value":"9221/3"},{"name":"Maps_To","value":"Juxtacortical chondrosarcoma"},{"name":"Maps_To","value":"Periosteal chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334549"}]}}{"C2945":{"preferredName":"Chondroblastoma","code":"C2945","definitions":[{"definition":"A benign, chondroid-producing, well-circumscribed, lytic neoplasm usually arising from the epiphysis of long bones.  It is characterized by the presence of chondroblasts, osteoclast-like giant cells, chondroid formation, calcification, and mitotic activity. In aggressive cases, there is rearrangement of the 8q21 chromosome band.  It occurs most frequently in children and young adults and rarely metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chondroblastoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9230/0"},{"name":"Legacy Concept Name","value":"Chondroblastoma"},{"name":"Maps_To","value":"9230/0"},{"name":"Maps_To","value":"Chondroblastoma, NOS"},{"name":"Maps_To","value":"Chondromatous giant cell tumor"},{"name":"Maps_To","value":"Codman tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008441"}]}}{"C66799":{"preferredName":"Metastasizing Chondroblastoma","code":"C66799","definitions":[{"definition":"A rare chondroblastoma that has metastasized to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasizing Chondroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9230/3"},{"name":"Legacy Concept Name","value":"Malignant_Chondroblastoma"},{"name":"Maps_To","value":"9230/3"},{"name":"Maps_To","value":"Chondroblastoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334550"}]}}{"C27502":{"preferredName":"Extraskeletal Myxoid Chondrosarcoma","code":"C27502","definitions":[{"definition":"A rare malignant soft tissue neoplasm of uncertain differentiation, characterized by the presence of chondroblast-like cells in a myxoid stroma and a multinodular growth pattern.  The most common sites of involvement are the deep soft tissues of the extremities, particularly the thigh.  It usually presents as an enlarging soft tissue mass.  Patients may have long survivals, but local recurrences and metastases occur in approximately half of the cases.  The most common site of metastasis is the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraskeletal Myxoid Chondrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"EMC","termGroup":"AB","termSource":"NCI"},{"termName":"Extraosseous Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extraskeletal Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid Extraosseous Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid Extraskeletal Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"NR4A3-Rearranged Myxoid Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9231/3"},{"name":"Legacy Concept Name","value":"Myxoid_Extraskeletal_Chondrosarcoma"},{"name":"Maps_To","value":"9231/3"},{"name":"Maps_To","value":"Myxoid chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334551"}]}}{"C3737":{"preferredName":"Mesenchymal Chondrosarcoma","code":"C3737","definitions":[{"definition":"A morphologic variant of chondrosarcoma arising from bone and soft tissue. It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling. The clinical course is aggressive, with local recurrences and distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesenchymal Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9240/3"},{"name":"Legacy Concept Name","value":"Mesenchymal_Chondrosarcoma"},{"name":"Maps_To","value":"9240/3"},{"name":"Maps_To","value":"Mesenchymal chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206637"}]}}{"C3830":{"preferredName":"Chondromyxoid Fibroma","code":"C3830","definitions":[{"definition":"An uncommon benign cartilaginous neoplasm arising from the bone. It is characterized by the presence of spindle-shaped or stellate chondrocytes, a lobulated growth pattern, myxoid stroma formation, and sometimes multinucleated giant cells. It has been associated with chromosomal rearrangement of 6q13 and 6q25 bands. The most common clinical symptom is mild, localized pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondromyxoid Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9241/0"},{"name":"Legacy Concept Name","value":"Chondromyxoid_Fibroma"},{"name":"Maps_To","value":"9241/0"},{"name":"Maps_To","value":"Chondromyxoid fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221290"}]}}{"C6475":{"preferredName":"Clear Cell Chondrosarcoma","code":"C6475","definitions":[{"definition":"A rare, usually low grade chondrosarcoma characterized by the presence of tumor cells with clear cytoplasm. It usually arises in the epiphyseal ends of long bones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9242/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Chondrosarcoma"},{"name":"Maps_To","value":"9242/3"},{"name":"Maps_To","value":"Clear cell chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266167"}]}}{"C6476":{"preferredName":"Dedifferentiated Chondrosarcoma","code":"C6476","definitions":[{"definition":"An aggressive morphologic variant of chondrosarcoma. It is composed of a low grade chondrosarcoma and a high grade non-cartilagenous sarcomatous component. Due to the aggressive nature of the disease, its prognosis is poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dedifferentiated Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9243/3"},{"name":"Legacy Concept Name","value":"Dedifferentiated_Chondrosarcoma"},{"name":"Maps_To","value":"9243/3"},{"name":"Maps_To","value":"Dedifferentiated chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862878"}]}}{"C121932":{"preferredName":"Giant Cell Tumor of Bone","code":"C121932","definitions":[{"definition":"A benign but locally aggressive tumor that arises from the bone and is composed of mononuclear cells admixed with macrophages and osteoclast-like giant cells.  It usually arises from the ends of long bones or the vertebrae.  Clinical presentation includes pain, edema, and decreased range of motion in the affected joint.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of bone comprised of giant cells (osteoclast-like) and mononuclear cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Giant Cell Tumor of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"GCTB","termGroup":"AB","termSource":"NCI"},{"termName":"Giant Cell Tumor of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osteoclastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9250/1"},{"name":"Maps_To","value":"Giant cell tumor of bone, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206638"}]}}{"C4304":{"preferredName":"Malignancy in Giant Cell Tumor of Bone","code":"C4304","definitions":[{"definition":"A malignant neoplasm of bone comprised of osteoclast-like giant cells and mononuclear cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that arises from the bone.  It is characterized by the presence of an area of high grade sarcoma in an otherwise typical giant cell tumor (primary malignancy in giant cell tumor), or the presence of sarcoma in which the pre-existing giant cell tumor may or may not be apparent (secondary malignancy in giant cell tumor).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignancy in Giant Cell Tumor of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Dedifferentiated Giant Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Bone Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Sarcoma of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Sarcoma of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignancy in Giant Cell Tumor of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9250/3"},{"name":"Legacy Concept Name","value":"Malignant_Giant_Cell_Tumor_of_Bone"},{"name":"Maps_To","value":"9250/3"},{"name":"Maps_To","value":"Giant cell sarcoma of bone"},{"name":"Maps_To","value":"Giant cell tumor of bone, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334552"}]}}{"C8380":{"preferredName":"Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells","code":"C8380","definitions":[{"definition":"An undifferentiated pleomorphic sarcoma characterized by the presence of osteoclast-like giant cells and cellular pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Giant Cell Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Giant Cell Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Giant Cell Neoplasm of Soft Parts","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of Soft Parts","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9251/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"9250/3"},{"name":"Maps_To","value":"9251/3"},{"name":"Maps_To","value":"Malignant giant cell tumor of soft parts"},{"name":"Maps_To","value":"Osteoblastoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334554"}]}}{"C49107":{"preferredName":"Giant Cell Tumor of Soft Tissue","code":"C49107","definitions":[{"definition":"A painless, well circumscribed tumor arising in soft tissue, usually of the upper and lower extremities. Morphologically, it is characterized by a multinodular growth pattern. The cellular infiltrate is composed of mononuclear round or oval cells and multinucleated osteoclast-like giant cells, in a rich vascular stroma.  It rarely metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Tumor of Soft Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"GCT-ST","termGroup":"AB","termSource":"NCI"},{"termName":"Giant Cell Tumor of Low Malignant Potential","termGroup":"AQS","termSource":"NCI"},{"termName":"Osteoclastoma of Soft Tissue","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9251/1"},{"name":"Legacy Concept Name","value":"Giant_Cell_Tumor_of_Soft_Tissue"},{"name":"Maps_To","value":"9251/1"},{"name":"Maps_To","value":"Giant cell tumor of soft parts, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334553"}]}}{"C3402":{"preferredName":"Tenosynovial Giant Cell Tumor","code":"C3402","definitions":[{"definition":"A tumor usually arising in the synovium of joints, bursa or tendon sheath. It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. According to the growth pattern, it is classified as localized or diffuse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tenosynovial Giant Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibrous Histiocytoma of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Neoplasm of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Neoplasm of Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Neoplasm of the Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Tumor of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Tumor of Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Tumor of the Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Tendon Sheath Giant Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Tendon Sheath Giant Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tenosynovial Giant Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9252/0"},{"name":"Legacy Concept Name","value":"Giant_Cell_Tumor_of_Tendon_Sheath"},{"name":"Maps_To","value":"9252/0"},{"name":"Maps_To","value":"Fibrous histiocytoma of tendon sheath"},{"name":"Maps_To","value":"Giant cell tumor of tendon sheath"},{"name":"Maps_To","value":"Tenosynovial giant cell tumor"},{"name":"Maps_To","value":"Tenosynovial giant cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1318543"}]}}{"C6535":{"preferredName":"Malignant Tenosynovial Giant Cell Tumor","code":"C6535","definitions":[{"definition":"An uncommon malignant tumor arising from the tendon sheath. Morphologically, it is characterized by the presence of a cellular infiltrate reminiscent of a giant cell tumor with prominent malignant characteristics. Recurrent giant cell tumors with a sarcomatous dedifferentiation are included in this category as well.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Tenosynovial Giant Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Giant Cell Neoplasm of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Neoplasm of the Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of the Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tendon Sheath Giant Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tendon Sheath Giant Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9252/3"},{"name":"Legacy Concept Name","value":"Malignant_Giant_Cell_Tumor_of_Tendon_Sheath"},{"name":"Maps_To","value":"9252/3"},{"name":"Maps_To","value":"Giant cell tumor of tendon sheath, malignant"},{"name":"Maps_To","value":"Malignant tenosynovial giant cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266168"}]}}{"C4817":{"preferredName":"Ewing Sarcoma","code":"C4817","definitions":[{"definition":"A malignant neoplasm of the bone, or the soft tissue adjacent to bone, that is comprised of primitive neuroectodermal cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that forms in bone or soft tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ewing Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ES","termGroup":"SY","termSource":"NCI"},{"termName":"Ewing's Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ewing's Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9260/3"},{"name":"Legacy Concept Name","value":"Ewing_s_Sarcoma"},{"name":"Maps_To","value":"9260/3"},{"name":"Maps_To","value":"Ewing sarcoma"},{"name":"Maps_To","value":"Ewing Sarcoma"},{"name":"Maps_To","value":"Ewing tumor"},{"name":"Maps_To","value":"Ewing's sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0553580"}]}}{"C7644":{"preferredName":"Adamantinoma","code":"C7644","definitions":[{"definition":"A low grade malignant neoplasm arising from the long bones. The tibia is the most frequently affected bone site. Patients present with swelling which may or may not be associated with pain. Morphologically, it is characterized by a biphasic pattern consisting of an epithelial and an osteofibrous component. The vast majority of cases recur if they are not treated with radical surgery. In a minority of cases the tumor may metastasize to other anatomic sites including lymph nodes, lungs, liver, brain, and skeleton.","type":"DEFINITION","source":"NCI"},{"definition":"A low-grade malignant neoplasm composed of epithelial cells and a spindle cell osteo-fibrous proliferation.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adamantinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adamantinoma of Long Bones","termGroup":"SY","termSource":"NCI"},{"termName":"Extragnathic Adamantinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9261/3"},{"name":"Legacy Concept Name","value":"Adamantinoma"},{"name":"Maps_To","value":"9261/3"},{"name":"Maps_To","value":"Adamantinoma of long bones"},{"name":"Maps_To","value":"Adamantinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334556"}]}}{"C8461":{"preferredName":"Tibial Adamantinoma","code":"C8461","definitions":[{"definition":"An adamantinoma arising from the tibia.  The tibia is the site which is more frequently involved by adamantinoma (80-90% of cases).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tibial Adamantinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tibial_Adamantinoma"},{"name":"Maps_To","value":"9261/3"},{"name":"Maps_To","value":"Tibial adamantinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1273017"}]}}{"C173820":{"preferredName":"Ossifying Fibroma","code":"C173820","definitions":[{"definition":"A benign fibro-osseous neoplasm affecting the jaws and the craniofacial skeleton. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ossifying Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ossifying Fibroma of the Jaws and Craniofacial Skeleton","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9262/0"},{"name":"Maps_To","value":"Fibro-osteoma"},{"name":"Maps_To","value":"Ossifying fibroma"},{"name":"NCI_META_CUI","value":"CL1407622"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4306":{"preferredName":"Benign Odontogenic Neoplasm","code":"C4306","definitions":[{"definition":"A benign neoplasm arising from tooth-forming tissues.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Representative examples include adenomatoid odontogenic tumor, calcifying cystic odontogenic tumor, and squamous odontogenic tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Odontogenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9270/0"},{"name":"Legacy Concept Name","value":"Benign_Odontogenic_Neoplasm"},{"name":"Maps_To","value":"9270/0"},{"name":"Maps_To","value":"Odontogenic tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334557"}]}}{"C4812":{"preferredName":"Malignant Odontogenic Neoplasm","code":"C4812","definitions":[{"definition":"A malignant neoplasm of tooth origin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Symptoms include swelling, pain, bleeding, mobility of affected teeth, and oral mucosa ulcerations. It may metastasize to lymph nodes and distant anatomic sites early.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Odontogenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9270/3"},{"name":"ICD-O-3_Code","value":"9342/3"},{"name":"Legacy Concept Name","value":"Malignant_Odontogenic_Neoplasm"},{"name":"Maps_To","value":"9270/3"},{"name":"Maps_To","value":"Odontogenic tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334558"}]}}{"C7492":{"preferredName":"Ameloblastic Carcinoma","code":"C7492","definitions":[{"definition":"A malignant neoplasm arising from tooth-forming tissues with-enamel organ differentiation (but without enamel formation).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, cytologically malignant ameloblastoma that may metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"AC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ameloblastic_Carcinoma"},{"name":"Maps_To","value":"9270/3"},{"name":"Maps_To","value":"Ameloblastic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1314678"}]}}{"C54323":{"preferredName":"Dentinogenic Ghost Cell Tumor","code":"C54323","definitions":[{"definition":"A benign but locally infiltrating neoplasm arising from tooth-forming tissues. It is more often intraosseous and less frequently extraosseous and occurs in the jaw. It is characterized by the presence of ameloblastoma-like epithelium, connective tissue stroma, ghost cells, and dysplastic dentin. Wide local resection is recommended for intraosseous neoplasms and enucleation for extraosseous neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dentinogenic Ghost Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Calcifying Ghost Cell Odontogenic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Dentinoameloblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Dentinoma","termGroup":"SY","termSource":"NCI"},{"termName":"DGCT","termGroup":"AB","termSource":"NCI"},{"termName":"Odontogenic Ghost Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9302/0"},{"name":"Legacy Concept Name","value":"Dentinogenic_Ghost_Cell_Tumor"},{"name":"Maps_To","value":"9271/0"},{"name":"Maps_To","value":"9302/0"},{"name":"Maps_To","value":"Dentinogenic ghost cell tumor"},{"name":"Maps_To","value":"Dentinoma"},{"name":"Maps_To","value":"Odontogenic ghost cell tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704219"}]}}{"C66800":{"preferredName":"Ameloblastic Fibrodentinoma","code":"C66800","definitions":[{"definition":"A rare neoplasm arising from tooth-forming tissues. It usually arises from the posterior mandible. It is characterized by the presence of an epithelial component, fibromyxoid stroma, and dentin formation. It is treated with enucleation and curettage. Recurrences may occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibrodentinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9271/0"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibrodentinoma"},{"name":"Maps_To","value":"9271/0"},{"name":"Maps_To","value":"Ameloblastic fibrodentinoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0457520"}]}}{"C173927":{"preferredName":"Cemento-Osseous Dysplasia","code":"C173927","definitions":[{"definition":"A non-neoplastic fibro-osseous lesion of the tooth-bearing regions of the gnathic bones. It is characterized by a variably cellular fibrous stroma with areas of swirling and/or loose collagen. Within the stroma are mineralizing tissues consisting of osteoid, bone, and cementum-like material. As the lesions mature, they become increasingly calcified. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemento-Osseous Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Cemental Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Cementoma","termGroup":"SY","termSource":"NCI"},{"termName":"COD","termGroup":"AB","termSource":"NCI"},{"termName":"Osseous Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9272/0"},{"name":"Maps_To","value":"Cementoma, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334068"}]}}{"C4308":{"preferredName":"Cementoblastoma","code":"C4308","definitions":[{"definition":"A rare benign bone-forming neoplasm usually arising from the jaw. It is a well-circumscribed lytic tumor that varies in size. The cell of origin is the cementoblast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cementoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cementoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9273/0"},{"name":"Legacy Concept Name","value":"Benign_Cementoblastoma"},{"name":"Maps_To","value":"9273/0"},{"name":"Maps_To","value":"Cementoblastoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007659"}]}}{"C8422":{"preferredName":"Cemento-Ossifying Fibroma","code":"C8422","definitions":[{"definition":"A benign fibrous neoplasm characterized by a mineralized component (woven bone, lamellar bone, or cementum-like material).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A well circumscribed lesion of the bone, most frequently arising from the posterior mandible. It is characterized by the presence of fibrous tissue and a mineralized component which may be woven bone, lamellar bone, or cementum-like material. Complete removal is recommended, since it continues to enlarge if left untreated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemento-Ossifying Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"COF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9262/0"},{"name":"ICD-O-3_Code","value":"9274/0"},{"name":"Legacy Concept Name","value":"Cementifying_Fibroma"},{"name":"Maps_To","value":"9274/0"},{"name":"Maps_To","value":"Cementifying fibroma"},{"name":"Maps_To","value":"Cemento-ossifying fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206640"}]}}{"C202219":{"preferredName":"Gigantiform Cementoma","code":"C202219","definitions":[{"definition":"An extremely rare, benign, rapidly progressing fibro-osseous lesion that arises from the jaws as a multifocal expansile growth in children or adolescents. It results in significant deformity, orbital distortion, and possible airway involvement. An autosomal dominant inheritance has been proposed. Histologically, it is characterized by the presence of immature bony trabeculae and cementum-like calcifications within a hypercellular fibroblastic stroma. It shares morphological features with florid cemento-osseous dysplasia, but in florid cemento-osseous dysplasia the degree of expansion is less prominent and patients are usually older.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gigantiform Cementoma","termGroup":"PT","termSource":"NCI"},{"termName":"Expansive Osseous Dysplasia","termGroup":"AQS","termSource":"NCI"},{"termName":"Familial Gigantiform Cementoma","termGroup":"SY","termSource":"NCI"},{"termName":"FGC","termGroup":"AB","termSource":"NCI"},{"termName":"Florid Osseous Dysplasia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9275/0"},{"name":"Maps_To","value":"Florid osseous dysplasia"},{"name":"Maps_To","value":"Gigantiform cementoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3495361"}]}}{"C3287":{"preferredName":"Odontoma","code":"C3287","definitions":[{"definition":"A benign neoplasm of tooth origin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing, and painless hamartomatous tumor occurring in tooth-bearing areas of the jaws. According to the presence or absence of tooth-like structures, it is classified as complex type or compound type. Odontoma of complex type is characterized by the presence of enamel and dentin and the absence of tooth-like structures. It is treated with local excision. If it is incompletely removed, it may recur. Odontoma of compound type is characterized by the presence of tooth-like structures. It is treated by local excision. Recurrences have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibro-Odontoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroodontoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9280/0"},{"name":"Legacy Concept Name","value":"Odontoma"},{"name":"Maps_To","value":"9280/0"},{"name":"Maps_To","value":"Odontoma, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0028882"}]}}{"C3711":{"preferredName":"Compound Odontoma","code":"C3711","definitions":[{"definition":"A benign, slow growing, and painless hamartomatous tumor occurring in tooth-bearing areas of the jaws. It usually affects children and adolescents. It is characterized by the presence of tooth-like structures. Treatment consists of local excision. Recurrences have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Compound Odontoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9281/0"},{"name":"Legacy Concept Name","value":"Compound_Odontoma"},{"name":"Maps_To","value":"9281/0"},{"name":"Maps_To","value":"Compound odontoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0205866"}]}}{"C4309":{"preferredName":"Complex Odontoma","code":"C4309","definitions":[{"definition":"A benign, slow growing, and painless hamartomatous tumor occurring in tooth-bearing areas of the jaws. It is one of the most common odontogenic tumors and it usually affects children, adolescents, and young adults. It is characterized by the presence of enamel and dentin and the absence of tooth-like structures. It is treated with local excision. If it is incompletely removed, it may recur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complex Odontoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9282/0"},{"name":"Legacy Concept Name","value":"Complex_Odontoma"},{"name":"Maps_To","value":"9282/0"},{"name":"Maps_To","value":"Complex odontoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334563"}]}}{"C3710":{"preferredName":"Ameloblastic Fibro-Odontoma","code":"C3710","definitions":[{"definition":"A benign neoplasm arising from tooth-forming tissues with-enamel organ differentiation (but without enamel formation).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare benign neoplasm arising from tooth-forming tissues. It is characterized by the presence of a fibromyxoid stroma, epithelial component, dentin, and enamel. Recurrences are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibro-Odontoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ameloblastic Fibroodontoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroameloblastic Odontoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9290/0"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibro-Odontoma"},{"name":"Maps_To","value":"9290/0"},{"name":"Maps_To","value":"Ameloblastic fibro-odontoma"},{"name":"Maps_To","value":"Fibroameloblastic odontoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205865"}]}}{"C173740":{"preferredName":"Ameloblastic Fibro-Odontosarcoma","code":"C173740","definitions":[{"definition":"An odontogenic sarcoma producing enamel/enameloid and dentin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibro-Odontosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ameloblastic Fibroodontosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9290/3"},{"name":"Maps_To","value":"9290/3"},{"name":"Maps_To","value":"Ameloblastic fibro-odontosarcoma"},{"name":"Maps_To","value":"Ameloblastic odontosarcoma"},{"name":"Maps_To","value":"Odontogenic fibrosarcoma"},{"name":"NCI_META_CUI","value":"CL1407559"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4310":{"preferredName":"Adenomatoid Odontogenic Tumor","code":"C4310","definitions":[{"definition":"A benign, slow growing neoplasm arising from tooth-forming tissues. The vast majority of cases are intraosseous and most often grow in the maxilla. It is characterized by the presence of odontogenic epithelium which is embedded in a connective tissue stroma. Local excision is curative and recurrences are very rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenomatoid Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomatoid Odontogenic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"AOT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9300/0"},{"name":"Legacy Concept Name","value":"Adenomatoid_Odontogenic_Tumor"},{"name":"Maps_To","value":"9300/0"},{"name":"Maps_To","value":"Adenoameloblastoma"},{"name":"Maps_To","value":"Adenomatoid odontogenic tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334565"}]}}{"C54319":{"preferredName":"Calcifying Cystic Odontogenic Tumor","code":"C54319","definitions":[{"definition":"A benign, intraosseous or extraosseous cystic neoplasm arising from tooth-forming tissues. It is characterized by the presence of a cyst lined by an ameloblastoma-like epithelium and ghost cells formation. The ghost cells may undergo calcification. It is treated with enucleation. Few recurrences have been reported for intraosseous neoplasms whereas no recurrences have been reported for extraosseous neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcifying Cystic Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Calcifying Odontogenic Cyst","termGroup":"SY","termSource":"NCI"},{"termName":"Gorlin Cyst","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9301/0"},{"name":"Legacy Concept Name","value":"Calcifying_Cystic_Odontogenic_Tumor"},{"name":"Maps_To","value":"9301/0"},{"name":"Maps_To","value":"Calcifying odontogenic cyst"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Finding"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206740"}]}}{"C4311":{"preferredName":"Ghost Cell Odontogenic Carcinoma","code":"C4311","definitions":[{"definition":"A carcinoma usually arising from the maxilla and less often the mandible.  Symptoms include swelling and paresthesia.  It is characterized by the presence of rounded islands of malignant epithelial cells in a fibrous stroma and the benign features of calcifying cystic odontogenic tumor.  The clinical course varies from slow growing and locally invasive to rapidly growing and highly aggressive with metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ghost Cell Odontogenic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"GCOC","termGroup":"AB","termSource":"NCI"},{"termName":"Odontogenic Ghost Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9302/3"},{"name":"Legacy Concept Name","value":"Odontogenic_Ghost_Cell_Neoplasm"},{"name":"Maps_To","value":"9302/3"},{"name":"Maps_To","value":"Ghost cell odontogenic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334566"}]}}{"C4313":{"preferredName":"Ameloblastoma","code":"C4313","definitions":[{"definition":"The most common odontogenic tumor, arising from the epithelial component of the embryonic tooth and usually affecting the molar-ramus region of the mandible or maxilla.  Although most ameloblastomas are morphologically and clinically benign, they may cause extensive local destruction, recur, or metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9310/0"},{"name":"Legacy Concept Name","value":"Ameloblastoma"},{"name":"Maps_To","value":"9310/0"},{"name":"Maps_To","value":"Ameloblastoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002448"}]}}{"C54297":{"preferredName":"Metastasizing Ameloblastoma","code":"C54297","definitions":[{"definition":"A malignant odontogenic neoplasm arising from the epithelial component of the embryonic tooth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, well differentiated, cytologically benign ameloblastoma which paradoxically metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasizing Ameloblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ameloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9310/3"},{"name":"Legacy Concept Name","value":"Metastasizing_Ameloblastoma"},{"name":"Maps_To","value":"9310/3"},{"name":"Maps_To","value":"Ameloblastoma, malignant"},{"name":"Maps_To","value":"Ameloblastoma, metastasizing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334567"}]}}{"C54317":{"preferredName":"Odontoameloblastoma","code":"C54317","definitions":[{"definition":"A rare, locally aggressive neoplasm arising from tooth-forming tissues. It occurs in the mandible and maxilla. It is characterized by the presence of odontogenic epithelium and adjacent myxoid tissue, fibrous stroma, and mineralized dental tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Odontoma","termGroup":"AQS","termSource":"NCI"},{"termName":"OA","termGroup":"AB","termSource":"NCI"},{"termName":"Odontoameloblastoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Odontoblastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9311/0"},{"name":"Legacy Concept Name","value":"Odontoameloblastoma"},{"name":"Maps_To","value":"9311/0"},{"name":"Maps_To","value":"Odontoameloblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704220"}]}}{"C7112":{"preferredName":"Squamous Odontogenic Tumor","code":"C7112","definitions":[{"definition":"A rare, locally invasive neoplasm arising from tooth-forming tissues. It usually grows intraosseously in the mandible. The maxilla is less frequently involved. It is characterized by the presence of well differentiated squamous cells which form islands. Recurrences may rarely occur and probably are related to incomplete excision of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"SOT","termGroup":"AB","termSource":"NCI"},{"termName":"Squamous Odontogenic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9312/0"},{"name":"Legacy Concept Name","value":"Squamous_Odontogenic_Tumor"},{"name":"Maps_To","value":"9312/0"},{"name":"Maps_To","value":"Squamous odontogenic tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1458142"}]}}{"C7501":{"preferredName":"Odontogenic Myxoma","code":"C7501","definitions":[{"definition":"An intraosseous odontogenic neoplasm with good prognosis, arising from the mandible and less frequently from the maxilla. It is characterized by the presence of stellate cells and abundant myxoid stroma formation. Small tumors may be cured with enucleation. Complete excision may be required for larger tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Myxoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9320/0"},{"name":"Legacy Concept Name","value":"Odontogenic_Myxoma"},{"name":"Maps_To","value":"9320/0"},{"name":"Maps_To","value":"Odontogenic myxoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334569"}]}}{"C7452":{"preferredName":"Odontogenic Myxofibroma","code":"C7452","definitions":[{"definition":"An intraosseous odontogenic neoplasm with good prognosis, arising from the mandible and less frequently from the maxilla. It is characterized by the presence of stellate cells, myxoid stroma formation, and prominent collagen. Small tumors may be cured with enucleation. Complete excision may be required for larger tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Myxofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Odontogenic_Myxofibroma"},{"name":"Maps_To","value":"9320/0"},{"name":"Maps_To","value":"Odontogenic myxofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377940"}]}}{"C4314":{"preferredName":"Odontogenic Fibroma","code":"C4314","definitions":[{"definition":"A benign intraosseous neoplasm arising from tooth-forming tissues in the mandible and maxilla, characterized by the presence of islands of odontogenic epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, benign neoplasm arising from tooth-forming tissues in the mandible and maxilla (central odontogenic fibroma); and rarely from extraosseous tissues, usually in the gingiva (peripheral odontogenic fibroma). It is characterized by the presence of odontogenic epithelium that is embedded in a fibrous stroma. Local enucleation of the tumor is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"OdF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9321/0"},{"name":"Legacy Concept Name","value":"Odontogenic_Fibroma"},{"name":"Maps_To","value":"9321/0"},{"name":"Maps_To","value":"Odontogenic fibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260966"}]}}{"C202077":{"preferredName":"Central Odontogenic Fibroma","code":"C202077","definitions":[{"definition":"An odontogenic fibroma that arises from tooth-forming tissues in the mandible and maxilla.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Odontogenic Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9321/0"},{"name":"Maps_To","value":"Central odontogenic fibroma"},{"name":"NCI_META_CUI","value":"CL1921478"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4315":{"preferredName":"Peripheral Odontogenic Fibroma","code":"C4315","definitions":[{"definition":"A rare, benign, extraosseous neoplasm arising from tooth-forming tissues. It usually presents as a slow growing exophytic mass in the gingiva. It is characterized by the presence of odontogenic epithelium that is embedded in a fibrous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Odontogenic Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9322/0"},{"name":"Legacy Concept Name","value":"Peripheral_Odontogenic_Fibroma"},{"name":"Maps_To","value":"9322/0"},{"name":"Maps_To","value":"Peripheral odontogenic fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334571"}]}}{"C4316":{"preferredName":"Ameloblastic Fibroma","code":"C4316","definitions":[{"definition":"A rare neoplasm arising from tooth-forming tissues. It usually arises from the posterior mandible. It is characterized by the presence of an epithelial component and fibromyxoid stroma. It may recur and rarely shows malignant transformation to ameloblastic fibrosarcoma. It is treated with enucleation and curettage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibrodentinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9330/0"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibroma"},{"name":"Maps_To","value":"9330/0"},{"name":"Maps_To","value":"Ameloblastic fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334572"}]}}{"C4317":{"preferredName":"Ameloblastic Fibrosarcoma","code":"C4317","definitions":[{"definition":"A locally aggressive malignant neoplasm arising from odontogenic tissue. It occurs in the mandible and less often in the maxilla.  It is characterized by the presence of a malignant connective tissue component and a benign epithelial component.  The frequency of distal metastases is low.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"AFS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9330/3"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibrosarcoma"},{"name":"Maps_To","value":"9330/3"},{"name":"Maps_To","value":"Ameloblastic fibrosarcoma"},{"name":"Maps_To","value":"Ameloblastic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334573"}]}}{"C54301":{"preferredName":"Calcifying Epithelial Odontogenic Tumor","code":"C54301","definitions":[{"definition":"A slow growing, locally invasive neoplasm arising from tooth-forming tissues. It most often grows intraosseously in the mandible and less frequently in the maxilla. In a minority of cases it grows extraosseously in the gingiva. It is characterized by the presence of a fibrous stroma, epithelial cells with abundant eosinophilic cytoplasm, and amyloid material which is often calcified. Small tumors may be successfully treated with enucleation. Local resection is usually required for larger tumors. Recurrences have been reported in a minority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcifying Epithelial Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"CEOT","termGroup":"AB","termSource":"NCI"},{"termName":"Pindborg Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9340/0"},{"name":"Legacy Concept Name","value":"Calcifying_Epithelial_Odontogenic_Tumor"},{"name":"Maps_To","value":"9340/0"},{"name":"Maps_To","value":"Calcifying epithelial odontogenic tumor"},{"name":"Maps_To","value":"Pindborg tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334574"}]}}{"C54300":{"preferredName":"Clear Cell Odontogenic Carcinoma","code":"C54300","definitions":[{"definition":"A usually aggressive malignant neoplasm arising from tooth-forming tissues. It more often affects older females and more frequently occurs in the mandible. It is characterized by the presence of malignant epithelial cells with clear cytoplasm and a fibrotic stroma formation. It may recur and metastasize. Metastases may occur in the lymph nodes, lungs, and bones. Treatment of choice is resection with clean margins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Odontogenic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Ameloblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9341/1"},{"name":"ICD-O-3_Code","value":"9341/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Odontogenic_Carcinoma"},{"name":"Maps_To","value":"9341/1"},{"name":"Maps_To","value":"9341/3"},{"name":"Maps_To","value":"Clear cell odontogenic carcinoma"},{"name":"Maps_To","value":"Clear cell odontogenic tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0475829"}]}}{"C173735":{"preferredName":"Odontogenic Carcinosarcoma","code":"C173735","definitions":[{"definition":"An extremely rare malignant mixed odontogenic neoplasm in which both the epithelial and the mesenchymal components are cytologically malignant. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Carcinosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ameloblastic Carcinosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Odontogenic Mixed Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"OCS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9342/3"},{"name":"Maps_To","value":"Odontogenic Carcinosarcoma"},{"name":"Maps_To","value":"Odontogenic carcinosarcoma"},{"name":"NCI_META_CUI","value":"CL1407549"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2964":{"preferredName":"Craniopharyngioma","code":"C2964","definitions":[{"definition":"A benign brain tumor that may be considered malignant because it can damage the hypothalamus, the area of the brain that controls body temperature, hunger, and thirst.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign epithelial neoplasm of the sellar region, presumably derived from Rathke pouch epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A histologically benign, but locally destructive, partly cystic, epithelial tumor of the sellar region, derived from Rathke pouch epithelium.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Craniopharyngioma","termGroup":"PT","termSource":"NCI"},{"termName":"Craniopharyngioma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Craniopharyngioma (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke's Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke's Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Rathke's Pouch","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9350/1"},{"name":"Legacy Concept Name","value":"Craniopharyngioma"},{"name":"Maps_To","value":"9350/1"},{"name":"Maps_To","value":"Craniopharyngioma"},{"name":"Maps_To","value":"Craniopharyngioma, NOS"},{"name":"Maps_To","value":"Neoplasm of uncertain or unknown behaviour: Craniopharyngeal duct"},{"name":"Maps_To","value":"Rathke pouch tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010276"}]}}{"C4726":{"preferredName":"Adamantinomatous Craniopharyngioma","code":"C4726","definitions":[{"definition":"A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adamantinomatous Craniopharyngioma","termGroup":"PT","termSource":"NCI"},{"termName":"ACP","termGroup":"AB","termSource":"NCI"},{"termName":"Adamantinous Craniopharyngioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Neoplasm of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Rathke's Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Rathke's Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Tumor of Rathke's Pouch","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9351/1"},{"name":"Legacy Concept Name","value":"Adamantinous_Craniopharyngioma"},{"name":"Maps_To","value":"9351/1"},{"name":"Maps_To","value":"Craniopharyngioma, adamantinomatous"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431129"}]}}{"C4725":{"preferredName":"Papillary Craniopharyngioma","code":"C4725","definitions":[{"definition":"A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Craniopharyngioma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Neoplasm of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Rathke Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Rathke's Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Rathke's Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Tumor of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"PCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9352/1"},{"name":"Legacy Concept Name","value":"Papillary_Craniopharyngioma"},{"name":"Maps_To","value":"9352/1"},{"name":"Maps_To","value":"Craniopharyngioma, papillary"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431128"}]}}{"C3328":{"preferredName":"Pineal Region Neoplasm","code":"C3328","definitions":[{"definition":"A benign or malignant neoplasm that affects the pineal region.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor arising in the pineal region, the majority of which are malignant germ cell tumors. A minority of pinealomas are benign, and comprise neoplastic cells that resemble normal pineocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of brain tumor that occurs in or around the pineal gland, a tiny organ near the center of the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pineal Region Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Pineal Region","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Pineal Region","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Area Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Area Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Body Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Body Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Region Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pinealoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Pineal Region","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Pineal Region","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pineal_Region_Neoplasm"},{"name":"Maps_To","value":"9360/1"},{"name":"Maps_To","value":"Pinealoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1412004"}]}}{"C6966":{"preferredName":"Pineocytoma","code":"C6966","definitions":[{"definition":"A WHO grade 1 slow growing tumor, more frequently affecting young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes. It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the brain arising from the pineal gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing, pineal parenchymal tumor that more frequently affects young adults.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A slow growing type of brain tumor that occurs in or around the pineal gland, a tiny organ near the center of the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pineocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pineocytoma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Pineocytoma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9361/1"},{"name":"Legacy Concept Name","value":"Pineocytoma"},{"name":"Maps_To","value":"9361/1"},{"name":"Maps_To","value":"Pineocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0917890"}]}}{"C6967":{"preferredName":"Pineal Parenchymal Tumor of Intermediate Differentiation","code":"C6967","definitions":[{"definition":"A WHO grade 2 or 3 pineal parenchymal neoplasm of intermediate-grade malignancy, affecting all ages.  It is composed of diffuse sheets or large lobules of uniform cells with mild to moderate nuclear atypia and low to moderate level mitotic activity.  (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pineal Parenchymal Tumor of Intermediate Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"PPTID","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pineal_Parenchymal_Tumor_of_Intermediate_Differentiation"},{"name":"Maps_To","value":"9362/3"},{"name":"Maps_To","value":"Pineal parenchymal tumor of intermediate differentiation"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367859"}]}}{"C9344":{"preferredName":"Pineoblastoma","code":"C9344","definitions":[{"definition":"A fast growing type of brain tumor that occurs in or around the pineal gland, a tiny organ near the center of the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region of the brain.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region.  It usually occurs in children and it is characterized by the presence of small immature neuroepithelial cells.  It may follow an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pineoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pineal Gland PNET","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Gland Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Gland Primitive Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal PNET","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Primitive Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineoblastoma (WHO Grade 4)","termGroup":"SY","termSource":"NCI"},{"termName":"Pineoblastoma (WHO Grade IV)","termGroup":"SY","termSource":"NCI"},{"termName":"PNET of Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"PNET of the Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Neoplasm of Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Neoplasm of the Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Tumor of Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Tumor of the Pineal Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9362/3"},{"name":"Legacy Concept Name","value":"Pineoblastoma"},{"name":"Maps_To","value":"9362/3"},{"name":"Maps_To","value":"Pineoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205898"}]}}{"C3717":{"preferredName":"Melanotic Neuroectodermal Tumor","code":"C3717","definitions":[{"definition":"A rare neoplasm usually occurring in infants.  It is characterized by the presence of a mixture of melanin-containing epithelial cells and smaller neuroblast-like cells.  It may involve the skull and facial bones, or the epididymis.  It usually has a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanotic Neuroectodermal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Infantile Melanotic Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Neuroectodermal Tumor of Infancy","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Progonoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MNTI","termGroup":"AB","termSource":"NCI"},{"termName":"Pigmented Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Retinal Anlage Neoplasm","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9363/0"},{"name":"Legacy Concept Name","value":"Infantile_Melanotic_Neuroectodermal_Neoplasm"},{"name":"Maps_To","value":"9363/0"},{"name":"Maps_To","value":"Melanoameloblastoma"},{"name":"Maps_To","value":"Melanotic neuroectodermal tumor"},{"name":"Maps_To","value":"Melanotic progonoma"},{"name":"Maps_To","value":"Retinal anlage tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206094"}]}}{"C3716":{"preferredName":"Primitive Neuroectodermal Tumor","code":"C3716","definitions":[{"definition":"A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of cancers that develop from the same type of early cells, and share certain biochemical and genetic features. Some PNETs develop in the brain and central nervous system (CNS-PNET), and others develop in sites outside of the brain such as the limbs, pelvis, and chest wall (peripheral PNET).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primitive Neuroectodermal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"PNET","termGroup":"AB","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9473/3"},{"name":"ICD-O-3_Code","value":"9503/3"},{"name":"Legacy Concept Name","value":"Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9364/3"},{"name":"Maps_To","value":"9473/3"},{"name":"Maps_To","value":"9503/3"},{"name":"Maps_To","value":"Neuroectodermal tumor, NOS"},{"name":"Maps_To","value":"Neuroepithelioma, NOS"},{"name":"Maps_To","value":"PNET, NOS"},{"name":"Maps_To","value":"Primitive neuroectodermal tumor, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206663"}]}}{"C9341":{"preferredName":"Peripheral Primitive Neuroectodermal Tumor","code":"C9341","definitions":[{"definition":"A small round cell tumor with neural differentiation arising from the soft tissues or bone.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that forms in bone or soft tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peripheral Primitive Neuroectodermal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Peripheral Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neuroepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral PNET","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"pPNET","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9364/3"},{"name":"Legacy Concept Name","value":"Peripheral_Primitive_Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9364/3"},{"name":"Maps_To","value":"Peripheral neuroectodermal tumor"},{"name":"Maps_To","value":"Peripheral primitive neuroectodermal tumor, NOS"},{"name":"Maps_To","value":"PPNET"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3489398"}]}}{"C7542":{"preferredName":"Askin Tumor","code":"C7542","definitions":[{"definition":"A primitive neuroectodermal tumor (small round blue cell tumor) of the thorax which can involve the periosteum, thoracic wall and/or pleura though it spares the lung parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Askin Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Askin's Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neuroectodermal Tumor of Thoracopulmonary Region","termGroup":"SY","termSource":"NCI"},{"termName":"PNET of Thoracopulmonary Region","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell Tumor of Thoracopulmonary Region","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9365/3"},{"name":"Legacy Concept Name","value":"Askin_s_Tumor"},{"name":"Maps_To","value":"9365/3"},{"name":"Maps_To","value":"Askin tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0877849"}]}}{"C2947":{"preferredName":"Chordoma","code":"C2947","definitions":[{"definition":"A malignant bone neoplasm arising from the remnants of the fetal notochord.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant bone tumor arising from the remnants of the fetal notochord. Although it can occur at all ages, it is more frequently seen in middle-aged adults. The most frequent sites of involvement are the sacrococcygeal area, spheno-occipital area, and cervico-thoraco-lumbar spine. Chordomas tend to recur and may metastasize. The most common sites of metastasis are lung, bone, lymph nodes, and subcutaneous tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A type of bone cancer that usually starts in the lower spinal column or at the base of the skull.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chordoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9370/3"},{"name":"Legacy Concept Name","value":"Chordoma"},{"name":"Maps_To","value":"9370/3"},{"name":"Maps_To","value":"Chordoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008487"}]}}{"C6902":{"preferredName":"Chondroid Chordoma","code":"C6902","definitions":[{"definition":"A slow-growing malignant bone tumor arising from the remnants of the notochord and occurring in the base of the skull. The tumor is characterized by a lobulated growth pattern, myxoid stroma formation, and the presence of physaliphorous cells and cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroid Chordoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9371/3"},{"name":"Legacy Concept Name","value":"Chondroid_Chordoma"},{"name":"Maps_To","value":"9371/3"},{"name":"Maps_To","value":"Chondroid chordoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266173"}]}}{"C48876":{"preferredName":"Dedifferentiated Chordoma","code":"C48876","definitions":[{"definition":"A high-grade malignant bone tumor arising from the remnants of the notochord. It is characterized by a lobulated growth pattern, myxoid stroma formation, the presence of physaliphorous cells, and a sarcomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dedifferentiated Chordoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcomatoid Chordoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9372/3"},{"name":"Legacy Concept Name","value":"Dedifferentiated_Chordoma"},{"name":"Maps_To","value":"9372/3"},{"name":"Maps_To","value":"Dedifferentiated chordoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266174"}]}}{"C6581":{"preferredName":"Parachordoma","code":"C6581","definitions":[{"definition":"A rare, usually benign myoepithelial tumor characterized by the presence of epithelioid, often vacuolated neoplastic cells. Most patients present with painless swelling in the subcutaneous or subfascial soft tissues of the extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parachordoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9373/0"},{"name":"ICD-O-3_Code","value":"9373/1"},{"name":"Legacy Concept Name","value":"Parachordoma"},{"name":"Maps_To","value":"9373/0"},{"name":"Maps_To","value":"Parachordoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266175"}]}}{"C4822":{"preferredName":"Malignant Glioma","code":"C4822","definitions":[{"definition":"A grade 3 or grade 4 glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neuroglial neoplasm. The term can apply to several primary neoplasm of the brain and spinal cord, including astrocytoma and oligodendroglioma in addition to others.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"High Grade Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Glial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neuroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neuroglial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9380/3"},{"name":"Legacy Concept Name","value":"Malignant_Glioma"},{"name":"Maps_To","value":"9380/3"},{"name":"Maps_To","value":"Glioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0555198"}]}}{"C4318":{"preferredName":"Gliomatosis Cerebri","code":"C4318","definitions":[{"definition":"A diffuse glial tumor which infiltrates the brain extensively, involving more than two lobes. It is frequently bilateral and often extends to the infratentorial structures, even to the spinal cord. It is probably of astrocytic origin, although GFAP expression may be scant or absent. (Adapted from WHO.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gliomatosis Cerebri","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytosis cerebri","termGroup":"SY","termSource":"NCI"},{"termName":"Gliomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9381/3"},{"name":"Legacy Concept Name","value":"Gliomatosis_Cerebri"},{"name":"Maps_To","value":"9381/3"},{"name":"Maps_To","value":"Gliomatosis cerebri"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334576"}]}}{"C4050":{"preferredName":"Oligoastrocytoma","code":"C4050","definitions":[{"definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the central nervous system with an astrocytic and oligodendrocytic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A brain tumor that forms from both oligodendrocytes and astrocytes, which are types of glial cells (cells that cover and protect nerve cells in the brain and spinal cord and help them work the way they should). An oligoastrocytoma is a type of mixed glioma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Oligoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Astrocytic-Oligodendroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Astrocytic-Oligodendroglial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Astrocytoma-Oligodendroglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Oligo-Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 2 Mixed Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Mixed Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Astrocytoma-Oligodendroglioma"},{"name":"Maps_To","value":"9382/3"},{"name":"Maps_To","value":"Oligoastrocytoma"},{"name":"Maps_To","value":"Oligoastrocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280793"}]}}{"C3903":{"preferredName":"Mixed Glioma","code":"C3903","definitions":[{"definition":"A brain tumor that forms from more than one type of brain cell, usually astrocytes and oligodendrocytes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm comprising two or more glial cell types (e.g., astrocytes, ependymal cells, oligodendrocytes).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tumor composed of two or more glial cell types (astrocytes, ependymal cells, and oligodendrocytes).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Glial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Neuroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Neuroglial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9382/3"},{"name":"Legacy Concept Name","value":"Mixed_Glioma"},{"name":"Maps_To","value":"9382/3"},{"name":"Maps_To","value":"Mixed glioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259783"}]}}{"C6959":{"preferredName":"Anaplastic Oligoastrocytoma","code":"C6959","definitions":[{"definition":"An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Oligoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Mixed Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Mixed Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Mixed Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anaplastic_Oligoastrocytoma"},{"name":"Maps_To","value":"9382/3"},{"name":"Maps_To","value":"Anaplastic oligoastrocytoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431108"}]}}{"C3795":{"preferredName":"Subependymoma","code":"C3795","definitions":[{"definition":"A benign neoplasm of the brain localized in the vicinity of a ventricular wall and is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic changes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subependymoma","termGroup":"PT","termSource":"NCI"},{"termName":"Subependymal Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Subependymal Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 1 Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 1 Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade I Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade I Ependymal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9383/1"},{"name":"Legacy Concept Name","value":"Subependymoma"},{"name":"Maps_To","value":"9383/1"},{"name":"Maps_To","value":"Mixed subependymoma-ependymoma"},{"name":"Maps_To","value":"Subependymal glioma"},{"name":"Maps_To","value":"Subependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206725"}]}}{"C3696":{"preferredName":"Subependymal Giant Cell Astrocytoma","code":"C3696","definitions":[{"definition":"A benign, slowly growing tumor (WHO grade I) typically arising in the wall of the lateral ventricles and composed of large ganglioid astrocytes. It is the most common CNS neoplasm in patients with tuberous sclerosis complex and typically occurs during the first two decades of life. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subependymal Giant Cell Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"SEGA","termGroup":"AB","termSource":"NCI"},{"termName":"Subependymal Giant Cell Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Subependymal Giant Cell Astrocytic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9384/1"},{"name":"Legacy Concept Name","value":"Subependymal_Giant_Cell_Astrocytoma"},{"name":"Maps_To","value":"9384/1"},{"name":"Maps_To","value":"Subependymal giant cell astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205768"}]}}{"C129309":{"preferredName":"Diffuse Midline Glioma, H3 K27M-Mutant","code":"C129309","definitions":[{"definition":"A diffuse midline glioma characterized by the presence of histone H3 K27M mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Midline Glioma, H3 K27M-Mutant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9385/3"},{"name":"Maps_To","value":"Diffuse midline glioma, H3 K27M-mutant"},{"name":"NCI_META_CUI","value":"CL512144"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3698":{"preferredName":"Choroid Plexus Papilloma","code":"C3698","definitions":[{"definition":"A benign neoplasm of the choroid plexus of the central nervous system.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing tumor which may cause symptoms by blocking cerebrospinal fluid pathways.  It is characterized by the presence of delicate fibrovascular connective tissue fronds covered by a single layer of epithelial cells.  Mitotic activity is extremely low.  Surgical resection is usually curative. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choroid Plexus Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Papilloma of Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Papilloma of the Choroid Plexus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9390/0"},{"name":"Legacy Concept Name","value":"Choroid_Plexus_Papilloma"},{"name":"Maps_To","value":"9390/0"},{"name":"Maps_To","value":"Choroid plexus papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4012134"}]}}{"C53686":{"preferredName":"Atypical Choroid Plexus Papilloma","code":"C53686","definitions":[{"definition":"A choroid plexus papilloma characterized by increased mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Choroid Plexus Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9390/1"},{"name":"Legacy Concept Name","value":"Atypical_Choroid_Plexus_Papilloma"},{"name":"Maps_To","value":"9390/1"},{"name":"Maps_To","value":"Atypical choroid plexus papilloma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266176"}]}}{"C4715":{"preferredName":"Choroid Plexus Carcinoma","code":"C4715","definitions":[{"definition":"A malignant neoplasm arising from the choroid plexus of the brain.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choroid Plexus Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Choroid Plexus Papilloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Cancer of Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Choroid Plexus Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9390/3"},{"name":"Legacy Concept Name","value":"Choroid_Plexus_Carcinoma"},{"name":"Maps_To","value":"9390/3"},{"name":"Maps_To","value":"Choroid plexus carcinoma"},{"name":"Maps_To","value":"Choroid plexus papilloma, anaplastic"},{"name":"Maps_To","value":"Choroid plexus papilloma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431109"}]}}{"C6903":{"preferredName":"Tanycytic Ependymoma","code":"C6903","definitions":[{"definition":"A variant of ependymoma, often found in the spinal cord, with tumor cells arranged in fascicles of variable width and cell density. Ependymal rosettes are generally absent, so this lesion must be distinguished from astrocytic neoplasms, but its EM characteristics are ependymal. (Adapted from WHO.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tanycytic Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tanycytic_Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"Tanycytic ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370500"}]}}{"C4713":{"preferredName":"Cellular Ependymoma","code":"C4713","definitions":[{"definition":"An ependymoma which shows conspicuous cellularity without a significant increase in mitotic rate. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cellular_Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"Cellular ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384403"}]}}{"C4714":{"preferredName":"Clear Cell Ependymoma","code":"C4714","definitions":[{"definition":"An ependymoma, often supratentorial in location, characterized by the presence of ependymal cells with a perinuclear halo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clear_Cell_Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"Clear cell ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384404"}]}}{"C3017":{"preferredName":"Ependymoma","code":"C3017","definitions":[{"definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from WHO"}]},{"definition":"A malignant neoplasm arising from ependymal cells that line the ventricles of the brain and the central canal of the spinal cord.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of brain tumor that begins in cells lining the spinal cord central canal (fluid-filled space down the center) or the ventricles (fluid-filled spaces of the brain). Ependymomas may also form in the choroid plexus (tissue in the ventricles that makes cerebrospinal fluid).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ependymoma","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Grade 2 Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 2 Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Ependymal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9391/3"},{"name":"Legacy Concept Name","value":"Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"CNS, ependymoma"},{"name":"Maps_To","value":"Ependymoma"},{"name":"Maps_To","value":"Ependymoma, NOS"},{"name":"Maps_To","value":"Epithelial ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0014474"}]}}{"C4049":{"preferredName":"Anaplastic Ependymoma","code":"C4049","definitions":[{"definition":"A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Ependymoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Anaplastic Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ependymoma with Anaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ependymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Ependymoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Ependymal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9392/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Ependymoma"},{"name":"Maps_To","value":"9392/3"},{"name":"Maps_To","value":"Ependymoma, anaplastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280788"}]}}{"C4915":{"preferredName":"Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","code":"C4915","definitions":[{"definition":"An aggressive embryonal tumor with multilayered rosettes characterized by the presence of amplification of the C19MC region on chromosome 19 (19q13.42).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonal Tumor with Abundant Neuropil and True Rosettes","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Tumor with Multilayered Rosettes","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Tumor with Multilayered Rosettes with C19MC Amplification","termGroup":"SY","termSource":"NCI"},{"termName":"Ependymoblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"ETMR, C19MC-Altered","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ependymoblastoma"},{"name":"Maps_To","value":"9392/3"},{"name":"Maps_To","value":"9478/3"},{"name":"Maps_To","value":"Embryonal tumor with multilayered rosettes C19MC-altered"},{"name":"Maps_To","value":"Embryonal tumor with multilayered rosettes with C19MC alteration"},{"name":"Maps_To","value":"Ependymoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0700367"}]}}{"C4319":{"preferredName":"Papillary Ependymoma","code":"C4319","definitions":[{"definition":"A rare variant of ependymoma characterized by well formed papillae. Tumor cell processes abutting capillaries are usually GFAP-positive. Differential diagnoses include choroid plexus papilloma, papillary meningioma and metastatic papillary carcinoma. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9393/3"},{"name":"Legacy Concept Name","value":"Papillary_Ependymoma"},{"name":"Maps_To","value":"9393/3"},{"name":"Maps_To","value":"Papillary ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334578"}]}}{"C3697":{"preferredName":"Myxopapillary Ependymoma","code":"C3697","definitions":[{"definition":"A benign neoplasm of ependymal origin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A slow growing, WHO grade I glioma which generally occurs in young adults.  It arises almost exclusively in the conus medullaris, cauda equina, and filum terminale of the spinal cord. It generally has a favorable prognosis and is characterized histologically by tumor cells arranged in a papillary manner around vascularized mucoid stromal cores. (Adapted from WHO).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxopapillary Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9394/1"},{"name":"Legacy Concept Name","value":"Myxopapillary_Ependymoma"},{"name":"Maps_To","value":"9394/1"},{"name":"Maps_To","value":"Myxopapillary ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205769"}]}}{"C92624":{"preferredName":"Papillary Tumor of the Pineal Region","code":"C92624","definitions":[{"definition":"A rare tumor that arises from the pineal region and affects adults.  It is characterized by the presence of neuroepithelial cells and a papillary architecture.  Electron microscopic studies suggest ependymal differentiation.  The clinical course is variable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Tumor of the Pineal Region","termGroup":"PT","termSource":"NCI"},{"termName":"PTPR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9395/3"},{"name":"Maps_To","value":"9395/3"},{"name":"Maps_To","value":"Papillary tumor of pineal region"},{"name":"Maps_To","value":"Papillary tumor of the pineal region"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985219"}]}}{"C129351":{"preferredName":"Supratentorial Ependymoma, ZFTA-RELA Fusion-Positive","code":"C129351","definitions":[{"definition":"A supratentorial ependymoma characterized by a gene fusion involving ZFTA and RELA genes. It accounts for the majority of supratentorial ependymomas in children. It has an unfavorable outcome when compared to other ependymoma subtypes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supratentorial Ependymoma, ZFTA-RELA Fusion-Positive","termGroup":"PT","termSource":"NCI"},{"termName":"Ependymoma, RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Ependymoma, ZFTA-RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Supratentorial Ependymoma, RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Supratentorial Ependymoma, ZFTA::RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9396/3"},{"name":"Maps_To","value":"Ependymoma, RELA fusion positive"},{"name":"Maps_To","value":"Ependymoma, RELA fusion-positive"},{"name":"NCI_META_CUI","value":"CL512399"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6958":{"preferredName":"Astrocytic Tumor","code":"C6958","definitions":[{"definition":"A glial tumor of the brain or spinal cord showing astrocytic differentiation.  It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and glioblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Astroglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Astrocytic_Tumor"},{"name":"Maps_To","value":"9400/3"},{"name":"Maps_To","value":"Astrocytic glioma"},{"name":"Maps_To","value":"Astroglioma"},{"name":"NCI_META_CUI","value":"CL357919"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7173":{"preferredName":"Diffuse Astrocytoma","code":"C7173","definitions":[{"definition":"A low-grade (WHO grade 2) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant astrocytic neoplasm characterized by a high degree of cellular differentiation, slow growth, and diffuse infiltration of neighboring brain structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Diffuse Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 2 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Astrocytoma"},{"name":"Maps_To","value":"9400/3"},{"name":"Maps_To","value":"Astrocytoma, low grade"},{"name":"Maps_To","value":"Cystic astrocytoma"},{"name":"Maps_To","value":"Diffuse astrocytoma"},{"name":"Maps_To","value":"Diffuse astrocytoma, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280785"}]}}{"C60781":{"preferredName":"Astrocytoma","code":"C60781","definitions":[{"definition":"A malignant neoplasm of the central nervous system that arises from astrocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that begins in the brain or spinal cord in small, star-shaped cells called astrocytes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9400/3"},{"name":"Legacy Concept Name","value":"Astrocytoma"},{"name":"Maps_To","value":"9400/3"},{"name":"Maps_To","value":"Astrocytoma"},{"name":"Maps_To","value":"Astrocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0004114"}]}}{"C9477":{"preferredName":"Anaplastic Astrocytoma","code":"C9477","definitions":[{"definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 3 Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9401/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Astrocytoma"},{"name":"Maps_To","value":"9401/3"},{"name":"Maps_To","value":"Astrocytoma, anaplastic"},{"name":"Maps_To","value":"Astrocytoma, anaplastic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334579"}]}}{"C4320":{"preferredName":"Protoplasmic Astrocytoma","code":"C4320","definitions":[{"definition":"A rare variant of diffuse astrocytoma. It is predominantly composed of neoplastic astrocytes showing a small cell body with few, flaccid processes with a low content of glial filaments and scant GFAP expression. This lesion is not well defined and is considered by some authors as an occasional histopathological feature rather than a reproducibly identifiable variant. When occurring in children, this neoplasm may be difficult to separate from pilocytic juvenile astrocytoma. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protoplasmic Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9410/3"},{"name":"Legacy Concept Name","value":"Protoplasmic_Astrocytoma"},{"name":"Maps_To","value":"9410/3"},{"name":"Maps_To","value":"Protoplasmic astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334580"}]}}{"C4321":{"preferredName":"Gemistocytic Astrocytoma","code":"C4321","definitions":[{"definition":"A rare variant of diffuse astrocytoma. It is characterized by the presence of a conspicuous, though variable, fraction of gemistocytic neoplastic astrocytes. Gemistocytes are round to oval astrocytes with abundant, glassy, non-fibrillary cytoplasm which appears to displace the dark, angulated nucleus to the periphery of the cell. To make the diagnosis of gemistocytic astrocytoma, gemistocytes should amount to more than approximately 20% of all tumor cells. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemistocytic Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gemistocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9411/3"},{"name":"Legacy Concept Name","value":"Gemistocytic_Astrocytoma"},{"name":"Maps_To","value":"9411/3"},{"name":"Maps_To","value":"Gemistocytic astrocytoma"},{"name":"Maps_To","value":"Gemistocytic astrocytoma, NOS"},{"name":"Maps_To","value":"Gemistocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334581"}]}}{"C9476":{"preferredName":"Desmoplastic Infantile Astrocytoma","code":"C9476","definitions":[{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, and which involves the superficial cerebral cortex and leptomeninges.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population consisting mainly of neoplastic astrocytes. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura. Although clinically it presents as large tumor, it generally has a good prognosis following surgical resection. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Infantile Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Desmoplastic Astrocytoma of Infancy","termGroup":"SY","termSource":"NCI"},{"termName":"DIA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9412/1"},{"name":"Legacy Concept Name","value":"Desmoplastic_Infantile_Astrocytoma"},{"name":"Maps_To","value":"9412/1"},{"name":"Maps_To","value":"Desmoplastic infantile astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0457179"}]}}{"C4738":{"preferredName":"Desmoplastic Infantile Ganglioglioma","code":"C4738","definitions":[{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population of neoplastic astrocytes together with a variable neuronal component. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura. Although clinically it presents as a large tumor, it generally has a good prognosis following surgical resection. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Desmoplastic Infantile Ganglioglioma","termGroup":"PT","termSource":"NCI"},{"termName":"DIG","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Desmoplastic_Infantile_Ganglioglioma"},{"name":"Maps_To","value":"9412/1"},{"name":"Maps_To","value":"Desmoplastic infantile ganglioglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321878"}]}}{"C9505":{"preferredName":"Dysembryoplastic Neuroepithelial Tumor","code":"C9505","definitions":[{"definition":"A glial-neuronal neoplasm located in the cortex. It occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dysembryoplastic Neuroepithelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"DNET","termGroup":"AQS","termSource":"NCI"},{"termName":"DNT","termGroup":"AB","termSource":"NCI"},{"termName":"Dysembryoplastic Neuroepithelial Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9413/0"},{"name":"Legacy Concept Name","value":"Dysembryoplastic_Neuroepithelial_Tumor"},{"name":"Maps_To","value":"9413/0"},{"name":"Maps_To","value":"Dysembryoplastic neuroepithelial tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266177"}]}}{"C4322":{"preferredName":"Fibrillary Astrocytoma","code":"C4322","definitions":[{"definition":"The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrillary Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9420/3"},{"name":"Legacy Concept Name","value":"Fibrillary_Astrocytoma"},{"name":"Maps_To","value":"9420/3"},{"name":"Maps_To","value":"Fibrillary astrocytoma"},{"name":"Maps_To","value":"Fibrous astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334582"}]}}{"C4047":{"preferredName":"Pilocytic Astrocytoma","code":"C4047","definitions":[{"definition":"A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilocytic Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9421/1"},{"name":"Legacy Concept Name","value":"Pilocytic_Astrocytoma"},{"name":"Maps_To","value":"9421/1"},{"name":"Maps_To","value":"Pilocytic astrocytoma"},{"name":"Maps_To","value":"Piloid astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334583"}]}}{"C9022":{"preferredName":"Childhood Astrocytic Tumor","code":"C9022","definitions":[{"definition":"An astrocytic tumor appearing before the age of twenty one without designation of benign or malignant nor designated location.","type":"DEFINITION","source":"NCI"},{"definition":"An astrocytic tumor arising during childhood, without designation of benign or malignant, nor a designated location.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood Astrocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytic Tumors, Childhood","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Astrocytic Tumour","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Astrocytic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Childhood_Astrocytic_Tumor"},{"name":"Maps_To","value":"9421/1"},{"name":"Maps_To","value":"Juvenile astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321865"}]}}{"C66801":{"preferredName":"Polar Spongioblastoma","code":"C66801","definitions":[{"definition":"A lesion characterized by the presence of neoplastic neuroepithelial cells with palisading nuclei. This lesion implies a morphologic growth pattern and it is not considered a clinicopathological entity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polar Spongioblastoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9423/3"},{"name":"Legacy Concept Name","value":"Polar_Spongioblastoma"},{"name":"Maps_To","value":"9423/3"},{"name":"Maps_To","value":"Polar spongioblastoma"},{"name":"Maps_To","value":"Spongioblastoma polare"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334589"}]}}{"C4323":{"preferredName":"Pleomorphic Xanthoastrocytoma","code":"C4323","definitions":[{"definition":"A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Xanthoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pleomorphic Xantho-Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"PXA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9424/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Xanthoastrocytoma"},{"name":"Maps_To","value":"9424/3"},{"name":"Maps_To","value":"Pleomorphic xanthoastrocytoma"},{"name":"Maps_To","value":"Pleomorphic xanthoastrocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334586"}]}}{"C40315":{"preferredName":"Pilomyxoid Astrocytoma","code":"C40315","definitions":[{"definition":"An astrocytic tumor of uncertain relation to pilocytic astrocytoma.  It occurs predominantly in infants and young children.  It is characterized by a monomorphic architectural pattern, usually associated with the absence of Rosenthal fibers and eosinophilic granular bodies.  The clinical course is usually aggressive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilomyxoid Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9425/3"},{"name":"Legacy Concept Name","value":"Pilomyxoid_Astrocytoma"},{"name":"Maps_To","value":"9425/3"},{"name":"Maps_To","value":"Pilomyxoid astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519086"}]}}{"C4324":{"preferredName":"Astroblastoma, MN1-Altered","code":"C4324","definitions":[{"definition":"A rare glial neoplasm characterized by structural rearrangements of the MN1 gene at chromosome band 22q12.1. It is usually found in the cerebral hemispheres of young adults and children and predominantly affects females. Morphologically, it consists of elongated glial cells with abundant eosinophilic cytoplasm and GFAP-positive processes, arranged perivascularly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astroblastoma, MN1-Altered","termGroup":"PT","termSource":"NCI"},{"termName":"Astroblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9430/3"},{"name":"Legacy Concept Name","value":"Astroblastoma"},{"name":"Maps_To","value":"9430/3"},{"name":"Maps_To","value":"Astroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334587"}]}}{"C92552":{"preferredName":"Angiocentric Glioma","code":"C92552","definitions":[{"definition":"A WHO grade 1, slow-growing brain neoplasm of children and young adults, associated with epilepsy.  Morphologically it is characterized by an angiocentric pattern, monomorphic cellular infiltrate, and ependymal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiocentric Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiocentric Glioma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Angiocentric Glioma (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Angiocentric Neuroepithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Monomorphus Angiocentric Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9431/1"},{"name":"Maps_To","value":"9431/1"},{"name":"Maps_To","value":"Angiocentric glioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2363903"}]}}{"C94524":{"preferredName":"Pituicytoma","code":"C94524","definitions":[{"definition":"A benign neoplasm arising from the posterior lobe of the pituitary gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An extremely rare, WHO grade 1, circumscribed and slow-growing tumor that arises from the neurohypophysis or infundibulum and described in adults.  It is characterized by the presence of elongated, spindle-shaped neoplastic glial cells that form storiform patterns or interlacing fascicular arrangements.  Signs and symptoms include visual disturbances, headache, amenorrhea, and decreased libido.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pituicytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pituicytoma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Pituicytoma (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Posterior Pituitary Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9432/1"},{"name":"Maps_To","value":"9432/1"},{"name":"Maps_To","value":"Pituicytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2986550"}]}}{"C3058":{"preferredName":"Glioblastoma","code":"C3058","definitions":[{"definition":"A fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. GBM usually occurs in adults and affects the brain more often than the spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"GBM","termGroup":"AB","termSource":"NCI"},{"termName":"GBM (Glioblastoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Glioblastoma Multiforme","termGroup":"AQS","termSource":"NCI"},{"termName":"Spongioblastoma Multiforme","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Glioblastoma is not an astrocytoma. It is an astrocytic tumor. The latter includes astrocytomas and glioblastomas.  However, when an anaplastic astrocytoma progresses to grade IV tumor, it is called a glioblastoma."},{"name":"ICD-O-3_Code","value":"9440/3"},{"name":"Legacy Concept Name","value":"Glioblastoma"},{"name":"Maps_To","value":"01"},{"name":"Maps_To","value":"02"},{"name":"Maps_To","value":"03"},{"name":"Maps_To","value":"04"},{"name":"Maps_To","value":"10"},{"name":"Maps_To","value":"20"},{"name":"Maps_To","value":"62"},{"name":"Maps_To","value":"9440/3"},{"name":"Maps_To","value":"CNS, glioblastoma (GBM)"},{"name":"Maps_To","value":"Glioblastoma"},{"name":"Maps_To","value":"Glioblastoma multiforme"},{"name":"Maps_To","value":"Glioblastoma, NOS"},{"name":"Maps_To","value":"Spongioblastoma multiforme"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017636"}]}}{"C4325":{"preferredName":"Giant Cell Glioblastoma","code":"C4325","definitions":[{"definition":"A rare histological variant of glioblastoma with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network, and a high frequency of TP53 mutations. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Glioblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9441/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Glioblastoma"},{"name":"Maps_To","value":"9441/3"},{"name":"Maps_To","value":"Giant cell glioblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334588"}]}}{"C5419":{"preferredName":"Gliofibroma","code":"C5419","definitions":[{"definition":"An astrocytic tumor affecting young people.  Morphologically, it is characterized by the presence of collagenous tissue surrounding neoplastic astrocytes.  In some cases the collagen is produced by the tumor cells (desmoplastic astrocytoma), whereas in others it is produced by mesenchymal cells (mixed glioma/fibroma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gliofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9442/1"},{"name":"Legacy Concept Name","value":"Gliofibroma"},{"name":"Maps_To","value":"9442/1"},{"name":"Maps_To","value":"Gliofibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266178"}]}}{"C3796":{"preferredName":"Gliosarcoma","code":"C3796","definitions":[{"definition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","type":"DEFINITION","source":"NCI"},{"definition":"A type of glioma (cancer of the brain that comes from glial, or supportive, cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gliosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Glioblastoma with a Sarcomatous Component","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9442/3"},{"name":"Legacy Concept Name","value":"Gliosarcoma"},{"name":"Maps_To","value":"9442/3"},{"name":"Maps_To","value":"Glioblastoma with sarcomatous component"},{"name":"Maps_To","value":"Gliosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206726"}]}}{"C5592":{"preferredName":"Chordoid Glioma","code":"C5592","definitions":[{"definition":"A rare, slow-growing neuroepithelial neoplasm of uncertain origin affecting adults. It is located in the third ventricle. It is characterized by the presence of epithelioid cells which express GFAP, and mucinous stroma which contains lymphoplasmacytic infiltrates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chordoid Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Chordoid Glioma of 3rd Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the 3rd Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the Third Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the Third Ventricle (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the Third Ventricle (WHO Grade II)","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of Third Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Third Ventricle Chordoid Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9444/1"},{"name":"Legacy Concept Name","value":"Chordoid_Glioma"},{"name":"Maps_To","value":"9444/1"},{"name":"Maps_To","value":"Chordoid glioma"},{"name":"Maps_To","value":"Chordoid glioma of third ventricle"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1322252"}]}}{"C167335":{"preferredName":"Astrocytoma, IDH-Mutant, Grade 4","code":"C167335","definitions":[{"definition":"IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytoma, IDH-Mutant, Grade 4","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytoma, IDH-Mutant, Grade IV","termGroup":"SY","termSource":"NCI"},{"termName":"Glioblastoma, IDH-Mutant","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9445/3"},{"name":"Maps_To","value":"Glioblastoma, IDH-mutant"},{"name":"NCI_META_CUI","value":"CL972314"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129319":{"preferredName":"Oligodendroglioma, Not Otherwise Specified","code":"C129319","definitions":[{"definition":"A central nervous system tumor with morphological features of oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligodendroglioma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Oligodendroglioma, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9450/3"},{"name":"Maps_To","value":"Oligodendroglioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2732301"}]}}{"C4326":{"preferredName":"Anaplastic Oligodendroglioma","code":"C4326","definitions":[{"definition":"A WHO grade 3 oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Oligodendroglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Oligodendroglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Oligodendroglioma, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Oligodendroglioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Oligodendroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Oligodendroglial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Oligodendroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Oligodendroglial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9451/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Oligodendroglioma"},{"name":"Maps_To","value":"9451/3"},{"name":"Maps_To","value":"Oligodendroglioma, anaplastic"},{"name":"Maps_To","value":"Oligodendroglioma, anaplastic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334590"}]}}{"C66802":{"preferredName":"Oligodendroblastoma","code":"C66802","definitions":[{"definition":"An obsolete term referring to neoplasms arising from oligodendrocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligodendroblastoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9460/3"},{"name":"Legacy Concept Name","value":"Oligodendroblastoma"},{"name":"Maps_To","value":"9460/3"},{"name":"Maps_To","value":"Oligodendroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0344461"}]}}{"C9497":{"preferredName":"Melanocytic Medulloblastoma","code":"C9497","definitions":[{"definition":"A rare malignant embryonal neoplasm characterized by the presence of small cells which resemble the cells of classic medulloblastoma and a minor population of melanin-forming neuroepithelial cells.  It usually has an unfavorable clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanocytic Medulloblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Medulloblastoma with Melanotic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanotic_Medulloblastoma"},{"name":"Maps_To","value":"9470/3"},{"name":"Maps_To","value":"Melanotic medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275668"}]}}{"C5407":{"preferredName":"Medulloblastoma with Extensive Nodularity","code":"C5407","definitions":[{"definition":"A medulloblastoma characterized by nodularity and neuronal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma with Extensive Nodularity","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebellar Neuroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medulloblastoma with Extensive Nodularity and Advanced Neuronal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9471/3"},{"name":"Legacy Concept Name","value":"Nodular_Medulloblastoma"},{"name":"Maps_To","value":"9471/3"},{"name":"Maps_To","value":"Medulloblastoma with extensive nodularity"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334970"}]}}{"C4956":{"preferredName":"Desmoplastic/Nodular Medulloblastoma","code":"C4956","definitions":[{"definition":"A medulloblastoma characterized by the presence of nodular, collagenous areas which do not contain reticulin, surrounded by hypercellular areas which contain an intercellular reticulin fiber network.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic/Nodular Medulloblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Desmoplastic Medulloblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoplastic Nodular Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9471/3"},{"name":"Legacy Concept Name","value":"Desmoplastic_Medulloblastoma"},{"name":"Maps_To","value":"9471/3"},{"name":"Maps_To","value":"Circumscribed arachnoidal cerebellar sarcoma"},{"name":"Maps_To","value":"Desmoplastic medulloblastoma"},{"name":"Maps_To","value":"Desmoplastic nodular medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751291"}]}}{"C3706":{"preferredName":"Medullomyoblastoma","code":"C3706","definitions":[{"definition":"A rare malignant embryonal neoplasm arising from the cerebellum.  It is characterized by the morphologic features of a medulloblastoma and the presence of a striated muscle component.  Its clinical behavior is similar to medulloblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medullomyoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Medullomyoblastoma with Myogenic Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9472/3"},{"name":"Legacy Concept Name","value":"Medullomyoblastoma"},{"name":"Maps_To","value":"9472/3"},{"name":"Maps_To","value":"Medullomyoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205833"}]}}{"C6968":{"preferredName":"Supratentorial Embryonal Tumor, Not Otherwise Specified","code":"C6968","definitions":[{"definition":"A central nervous system embryonal tumor, not otherwise specified arising from the supratentorial region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supratentorial Embryonal Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"CNS/Supratentorial PNET","termGroup":"AQS","termSource":"NCI"},{"termName":"Supratentorial Embryonal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Supratentorial PNET","termGroup":"AQS","termSource":"NCI"},{"termName":"Supratentorial Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supratentorial_Primitive_Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9473/3"},{"name":"Maps_To","value":"Supratentorial PNET"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336538"}]}}{"C5398":{"preferredName":"Central Nervous System Embryonal Tumor, Not Otherwise Specified","code":"C5398","definitions":[{"definition":"A term that refers to central nervous system embryonal tumors which are not fully characterized.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that arises from a particular type of cell within the brain or spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Central Nervous System Embryonal Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Embryonal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System PNET","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Primitive Neuroectodermal Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Primitive Neuroectodermal Tumor (WHO Grade IV)","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Primitive Neuroectodermal Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"CNS Embryonal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Embryonal Tumor, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"CNS PNET","termGroup":"AB","termSource":"NCI"},{"termName":"CNS Primitive Neuroectodermal Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"CNS Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Primitive_Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9473/3"},{"name":"Maps_To","value":"Central primitive neuroectodermal tumor, NOS"},{"name":"Maps_To","value":"CPNET"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3887678"}]}}{"C92625":{"preferredName":"Anaplastic Medulloblastoma","code":"C92625","definitions":[{"definition":"A medulloblastoma characterized by marked nuclear pleomorphism, and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9474/3"},{"name":"Maps_To","value":"9474/3"},{"name":"Maps_To","value":"Anaplastic medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985220"}]}}{"C6904":{"preferredName":"Large Cell Medulloblastoma","code":"C6904","definitions":[{"definition":"A medulloblastoma composed of large cells with prominent nucleoli and a larger amount of cytoplasm in contrast with the cells of the classic medulloblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Large Cell Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9474/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Medulloblastoma"},{"name":"Maps_To","value":"9474/3"},{"name":"Maps_To","value":"Large cell medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266180"}]}}{"C129442":{"preferredName":"Medulloblastoma, SHH-Activated, TP53-Mutant","code":"C129442","definitions":[{"definition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the presence of TP53 mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, SHH-Activated, TP53-Mutant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9476/3"},{"name":"Maps_To","value":"Medulloblastoma, SHH-activated and TP53-mutant"},{"name":"NCI_META_CUI","value":"CL512715"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C186534":{"preferredName":"Embryonal Tumor with Multilayered Rosettes","code":"C186534","definitions":[{"definition":"A central nervous system embryonal tumor characterized by the presence of multilayered rosette formation and typically the presence of amplification of the C19MC region on chromosome 19 (19q13.42) or rarely a DICER1 mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonal Tumor with Multilayered Rosettes","termGroup":"PT","termSource":"NCI"},{"termName":"ETMR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9478/3"},{"name":"Maps_To","value":"Embryonal tumor with multilayered rosettes, NOS"},{"name":"NCI_META_CUI","value":"CL1778829"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C66803":{"preferredName":"Cerebellar Sarcoma","code":"C66803","definitions":[{"definition":"An obsolete term referring to desmoplastic medulloblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebellar Sarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9480/3"},{"name":"Legacy Concept Name","value":"Cerebellar_Sarcoma"},{"name":"Maps_To","value":"9480/3"},{"name":"Maps_To","value":"Cerebellar sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334592"}]}}{"C3049":{"preferredName":"Ganglioneuroma","code":"C3049","definitions":[{"definition":"A benign neoplasm characterized by the presence of ganglion cells and spindle cell proliferation, located primarily in the brain, ganglia, or adrenal medulla.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neuroblastic tumor of the sympathetic nervous system that occurs in childhood. Ganglioneuroma typically arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. Common presenting features include a palpable abdominal mass, hepatomegaly, and a thoracic mass detected on routine chest X-ray.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioneuroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ganglioneuroma (Schwannian Stroma-Dominant)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9490/0"},{"name":"Legacy Concept Name","value":"Ganglioneuroma"},{"name":"Maps_To","value":"9490/0"},{"name":"Maps_To","value":"Ganglioneuroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017075"}]}}{"C3790":{"preferredName":"Ganglioneuroblastoma","code":"C3790","definitions":[{"definition":"A malignant neoplasm characterized by the presence of neuroblastic and ganglion cells and a stroma with Schwannian differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume.  There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioneuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9490/3"},{"name":"Legacy Concept Name","value":"Ganglioneuroblastoma"},{"name":"Maps_To","value":"9490/3"},{"name":"Maps_To","value":"Ganglioneuroblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206718"}]}}{"C66804":{"preferredName":"Ganglioneuromatosis","code":"C66804","definitions":[{"definition":"Extensive and diffuse infiltration of tissues by ganglioneuroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioneuromatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9491/0"},{"name":"Legacy Concept Name","value":"Ganglioneuromatosis"},{"name":"Maps_To","value":"9491/0"},{"name":"Maps_To","value":"Ganglioneuromatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334595"}]}}{"C6934":{"preferredName":"Gangliocytoma","code":"C6934","definitions":[{"definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gangliocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9492/0"},{"name":"Legacy Concept Name","value":"Gangliocytoma"},{"name":"Maps_To","value":"9492/0"},{"name":"Maps_To","value":"Gangliocytoma"},{"name":"Maps_To","value":"Gangliocytoma, NOS"},{"name":"NCI_META_CUI","value":"CL378224"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8419":{"preferredName":"Dysplastic Cerebellar Gangliocytoma","code":"C8419","definitions":[{"definition":"A benign, WHO grade I cerebellar mass, which occurs in young adults and is composed of dysplastic ganglion cells.  It is the major CNS manifestation of Cowden disease, an autosomal dominant condition that causes a variety of hamartomas and neoplasms.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from WHO"}]}],"synonyms":[{"termName":"Dysplastic Cerebellar Gangliocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease)","termGroup":"SY","termSource":"NCI"},{"termName":"Dysplastic Gangliocytoma of Cerebellum","termGroup":"SY","termSource":"NCI"},{"termName":"Dysplastic Gangliocytoma of the Cerebellum","termGroup":"SY","termSource":"NCI"},{"termName":"Lhermitte-Duclos Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9493/0"},{"name":"Legacy Concept Name","value":"Dysplastic_Cerebellar_Gangliocytoma"},{"name":"Maps_To","value":"9493/0"},{"name":"Maps_To","value":"Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0391826"}]}}{"C3270":{"preferredName":"Neuroblastoma","code":"C3270","definitions":[{"definition":"A malignant neoplasm composed of neuroblastic cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm comprised of neuroblasts that commonly arises in or near the adrenal glands.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that arises in immature nerve cells and affects mostly infants and children.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Neuroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Neuroblastoma (Schwannian Stroma-Poor)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9500/3"},{"name":"Legacy Concept Name","value":"Neuroblastoma"},{"name":"Maps_To","value":"9500/3"},{"name":"Maps_To","value":"Central neuroblastoma"},{"name":"Maps_To","value":"Neuroblastoma"},{"name":"Maps_To","value":"Neuroblastoma (NBL)"},{"name":"Maps_To","value":"Neuroblastoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2751421"}]}}{"C66807":{"preferredName":"Ciliary Body Benign Medulloepithelioma","code":"C66807","definitions":[{"definition":"A rare, unilateral, benign embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body Benign Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Ciliary Body Medulloepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Intraocular Medulloepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9501/0"},{"name":"Legacy Concept Name","value":"Benign_Intraocular_Medulloepithelioma"},{"name":"Maps_To","value":"9501/0"},{"name":"Maps_To","value":"Medulloepithelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879808"}]}}{"C66808":{"preferredName":"Medulloepithelioma Not Otherwise Specified","code":"C66808","definitions":[{"definition":"A rare, unilateral, benign or malignant embryonic neoplasm typically presenting as a cilliary body mass during childhood. It is composed of medullary epithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloepithelioma Not Otherwise Specified","termGroup":"AQ","termSource":"NCI"},{"termName":"Medulloepithelioma, NOS","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9501/3"},{"name":"Legacy Concept Name","value":"Medulloepithelioma_not_Otherwise_Specified"},{"name":"Maps_To","value":"9501/3"},{"name":"Maps_To","value":"Medulloepithelioma, NOS"},{"name":"NCI_META_CUI","value":"CL505197"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4327":{"preferredName":"Central Nervous System Medulloepithelioma","code":"C4327","definitions":[{"definition":"A rare malignant embryonal neoplasm of the central nervous system, occurring in children. It is characterized by the presence of neuroepithelial cells that form papillary, trabecular, or tubular structures.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare, usually aggressive malignant embryonal neoplasm of the central nervous system occurring in children. It is characterized by the presence of neuroepithelial cells which form papillary, trabecular, or tubular structures and absence of C19MC amplification. Symptoms include headache, nausea, and vomiting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Medulloepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Medulloepithelioma, Central Nervous System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Medulloepithelioma"},{"name":"Maps_To","value":"9501/3"},{"name":"Maps_To","value":"Diktyoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334596"}]}}{"C66809":{"preferredName":"Ciliary Body Benign Teratoid Medulloepithelioma","code":"C66809","definitions":[{"definition":"A rare, unilateral, benign embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium and contains heterologous elements, particularly cartilage, skeletal muscle, and brain tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body Benign Teratoid Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Intraocular Teratoid Medulloepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9502/0"},{"name":"Legacy Concept Name","value":"Benign_Intraocular_Teratoid_Medulloepithelioma"},{"name":"Maps_To","value":"9502/0"},{"name":"Maps_To","value":"Teratoid medulloepithelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879809"}]}}{"C66810":{"preferredName":"Ciliary Body Teratoid Medulloepithelioma","code":"C66810","definitions":[{"definition":"A rare, unilateral, benign or malignant embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium and contains heterologous elements, particularly cartilage, skeletal muscle, and brain tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body Teratoid Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Intraocular Teratoid Medulloepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9502/3"},{"name":"Legacy Concept Name","value":"Intraocular_Teratoid_Medulloepithelioma"},{"name":"Maps_To","value":"9502/3"},{"name":"Maps_To","value":"Teratoid medulloepithelioma"},{"name":"Maps_To","value":"Teratoid medulloepithelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881244"}]}}{"C66811":{"preferredName":"Spongioneuroblastoma","code":"C66811","definitions":[{"definition":"A neuroectodermal tumor composed of neoplastic neural elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spongioneuroblastoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9504/3"},{"name":"Legacy Concept Name","value":"Spongioneuroblastoma"},{"name":"Maps_To","value":"9504/3"},{"name":"Maps_To","value":"Spongioneuroblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334598"}]}}{"C3788":{"preferredName":"Ganglioglioma","code":"C3788","definitions":[{"definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and neoplastic glial cells. Some gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III. Rare cases of newly diagnosed gangliogliomas with grade IV (glioblastoma) changes in the glial component have also been reported. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioglioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9505/1"},{"name":"Legacy Concept Name","value":"Ganglioglioma"},{"name":"Maps_To","value":"9505/1"},{"name":"Maps_To","value":"Ganglioglioma, NOS"},{"name":"Maps_To","value":"Glioneuroma"},{"name":"Maps_To","value":"Neuroastrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206716"}]}}{"C4717":{"preferredName":"Anaplastic Ganglioglioma","code":"C4717","definitions":[{"definition":"A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Ganglioglioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9505/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Ganglioglioma"},{"name":"Maps_To","value":"9505/3"},{"name":"Maps_To","value":"Ganglioglioma, anaplastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431112"}]}}{"C92555":{"preferredName":"Extraventricular Neurocytoma","code":"C92555","definitions":[{"definition":"A WHO grade 2 neoplasm that arises from the brain parenchyma. Morphologically it is characterized by the presence of neoplastic uniform, round cells with neuronal differentiation. Unlike central neurocytoma, it does not involve the lateral ventricles. It usually affects young adults and has a favorable prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraventricular Neurocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Extraventricular Neurocytoma (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Extraventricular Neurocytoma (WHO Grade II)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9506/1"},{"name":"Maps_To","value":"9506/1"},{"name":"Maps_To","value":"Extraventricular neurocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985175"}]}}{"C6905":{"preferredName":"Cerebellar Liponeurocytoma","code":"C6905","definitions":[{"definition":"A rare, WHO grade II cerebellar neoplasm which shows consistent neuronal, variable astrocytic and focal lipomatous differentiation. It occurs in adults, has a low proliferative potential and usually has a favorable prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebellar Liponeurocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebellar Liponeurocytoma (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Cerebellar Liponeurocytoma (WHO Grade II)","termGroup":"SY","termSource":"NCI"},{"termName":"Lipomatous Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"0000/0"},{"name":"Legacy Concept Name","value":"Cerebellar_Liponeurocytoma"},{"name":"Maps_To","value":"9506/1"},{"name":"Maps_To","value":"Cerebellar liponeurocytoma"},{"name":"Maps_To","value":"Lipomatous medulloblastoma"},{"name":"Maps_To","value":"Medullocytoma"},{"name":"Maps_To","value":"Neurolipocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370507"}]}}{"C3791":{"preferredName":"Central Neurocytoma","code":"C3791","definitions":[{"definition":"An intraventricular neuronal neoplasm composed of uniform round cells with neuronal differentiation. It is typically located in the lateral ventricles in the region of the foramen of Monro. It generally affects young adults and has a favorable prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Neurocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Neurocytoma (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Central Neurocytoma (WHO Grade II)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9506/1"},{"name":"Legacy Concept Name","value":"Neurocytoma"},{"name":"Maps_To","value":"9506/1"},{"name":"Maps_To","value":"Central neurocytoma"},{"name":"Maps_To","value":"Neurocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206719"}]}}{"C4328":{"preferredName":"Pacinian Neurofibroma","code":"C4328","definitions":[{"definition":"A neurofibroma characterized by the presence of structures which resemble Vater-Pacini corpuscles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacinian Neurofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9507/0"},{"name":"Legacy Concept Name","value":"Pacinian_Neurofibroma"},{"name":"Maps_To","value":"9507/0"},{"name":"Maps_To","value":"Pacinian tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334599"}]}}{"C6906":{"preferredName":"Atypical Teratoid/Rhabdoid Tumor","code":"C6906","definitions":[{"definition":"An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Teratoid/Rhabdoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"AT/RT","termGroup":"AB","termSource":"NCI"},{"termName":"ATRT","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Teratoid/Rhabdoid Tumor (WHO Grade 4)","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Teratoid/Rhabdoid Tumor (WHO Grade IV)","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brain Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brain Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Neoplasm of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Neoplasm of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Brain Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Brain Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Neoplasm of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Neoplasm of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Tumor of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Tumor of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9508/3"},{"name":"Legacy Concept Name","value":"Atypical_Teratoid_Rhabdoid_Tumor"},{"name":"Maps_To","value":"9508/3"},{"name":"Maps_To","value":"Atypical teratoid/rhabdoid tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266184"}]}}{"C92554":{"preferredName":"Papillary Glioneuronal Tumor","code":"C92554","definitions":[{"definition":"A WHO grade 1, indolent and relatively circumscribed brain tumor.  Morphologically it is characterized by the presence of astrocytes that line vascular and hyalinized pseudopapillae.  In between the pseudopapillae aggregates of neurocytes, large neurons, and ganglioid cells are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Glioneuronal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Glioneuronal Tumor (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Glioneuronal Tumor (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"PGNT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9509/1"},{"name":"Maps_To","value":"9509/1"},{"name":"Maps_To","value":"Papillary glioneuronal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985174"}]}}{"C129431":{"preferredName":"Rosette-Forming Glioneuronal Tumor","code":"C129431","definitions":[{"definition":"A central nervous system neoplasm mostly occurring in the fourth ventricle region. It is characterized by the presence of neurocytes forming pseudorosettes and astrocytes which contain Rosenthal fibers. Cytologic atypia is minimal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosette-Forming Glioneuronal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"RGNT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9509/1"},{"name":"Maps_To","value":"Rosette-forming glioneuronal tumor"},{"name":"NCI_META_CUI","value":"CL497922"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C66812":{"preferredName":"Retinocytoma","code":"C66812","definitions":[{"definition":"A rare, unilateral or bilateral benign neoplasm that arises from the retina. There is an increased risk of malignant transformation to retinoblastoma; therefore, patients with a diagnosis of retinocytoma should be closely observed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Retinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9510/0"},{"name":"Legacy Concept Name","value":"Retinocytoma"},{"name":"Maps_To","value":"9510/0"},{"name":"Maps_To","value":"Retinocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346396"}]}}{"C7541":{"preferredName":"Retinoblastoma","code":"C7541","definitions":[{"definition":"A malignant neoplasm originating in the nuclear layer of the retina.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the retina (the light-sensitive layers of nerve tissue at the back of the eye). Retinoblastoma usually occurs in children younger than 5 years. It may be hereditary or nonhereditary (sporadic).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Retinoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"RB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9510/3"},{"name":"Legacy Concept Name","value":"Retinoblastoma"},{"name":"Maps_To","value":"9510/3"},{"name":"Maps_To","value":"Retinoblastoma"},{"name":"Maps_To","value":"Retinoblastoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0035335"}]}}{"C66813":{"preferredName":"Differentiated Retinoblastoma","code":"C66813","definitions":[{"definition":"A retinoblastoma with well differentiated features. It often produces Flexner-Wintersteiner rosettes or Homer-Wright rosettes. In some cases the tumor cells form fleurettes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Differentiated Retinoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9511/3"},{"name":"Legacy Concept Name","value":"Differentiated_Retinoblastoma"},{"name":"Maps_To","value":"9511/3"},{"name":"Maps_To","value":"Retinoblastoma, differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334600"}]}}{"C66814":{"preferredName":"Undifferentiated Retinoblastoma","code":"C66814","definitions":[{"definition":"A retinoblastoma composed of small, undifferentiated cells. It is often associated with necrotic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Retinoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9512/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Retinoblastoma"},{"name":"Maps_To","value":"9512/3"},{"name":"Maps_To","value":"Retinoblastoma, undifferentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334601"}]}}{"C66815":{"preferredName":"Diffuse Retinoblastoma","code":"C66815","definitions":[{"definition":"A retinoblastoma characterized by the absence of a distinct retinal mass and the presence of malignant cells diffusely infiltrating the retina. It is often confused with uveitis and endophthalmitis, resulting in delayed diagnosis of the malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Retinoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9513/3"},{"name":"Legacy Concept Name","value":"Diffuse_Retinoblastoma"},{"name":"Maps_To","value":"9513/3"},{"name":"Maps_To","value":"Retinoblastoma, diffuse"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266185"}]}}{"C66816":{"preferredName":"Spontaneously Regressed Retinoblastoma","code":"C66816","definitions":[{"definition":"An archaic term that refers to benign, non-progressive retinal lesions in patients with mutation of the RB1 gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spontaneously Regressed Retinoblastoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Spontaneously Regressing Retinoblastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9514/1"},{"name":"Legacy Concept Name","value":"Spontaneously_Regressing_Retinoblastoma"},{"name":"Maps_To","value":"9514/1"},{"name":"Maps_To","value":"Retinoblastoma, spontaneously regressed"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266186"}]}}{"C67155":{"preferredName":"Olfactory Neurogenic Tumor","code":"C67155","definitions":[{"definition":"A rare, benign (olfactory neurocytoma) or malignant (olfactory neuroblastoma) neuroectodermal tumor originating from olfactory receptor cells in the nasal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Neurogenic Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9520/3"},{"name":"Legacy Concept Name","value":"Olfactory_Neurogenic_Tumor"},{"name":"Maps_To","value":"9520/3"},{"name":"Maps_To","value":"Olfactory neurogenic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334602"}]}}{"C67156":{"preferredName":"Olfactory Neurocytoma","code":"C67156","definitions":[{"definition":"A rare benign neuroectodermal tumor originating from olfactory receptor cells in the nasal cavity. Microscopically, it is characterized by the absence of malignant characteristics and the absence of rosettes formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Neurocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9521/3"},{"name":"Legacy Concept Name","value":"Olfactory_Neurocytoma"},{"name":"Maps_To","value":"9521/3"},{"name":"Maps_To","value":"Olfactory neurocytoma"},{"name":"NCI_META_CUI","value":"CL031140"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3789":{"preferredName":"Olfactory Neuroblastoma","code":"C3789","definitions":[{"definition":"A rare neuroectodermal tumor originating from olfactory receptor cells in the nasal cavity or paranasal sinuses. Microscopically, it is characterized by neuroblastic differentiation with occasional formation of rosettes. If the tumor is not resected at an early stage, the prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Neuroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Esthesioneuroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Esthesioneuroepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Olfactory Esthesioneuroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Olfactory Neuroepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9522/3"},{"name":"ICD-O-3_Code","value":"9523/3"},{"name":"Legacy Concept Name","value":"Olfactory_Neuroblastoma"},{"name":"Maps_To","value":"9522/3"},{"name":"Maps_To","value":"9523/3"},{"name":"Maps_To","value":"Esthesioneuroblastoma"},{"name":"Maps_To","value":"Esthesioneuroepithelioma"},{"name":"Maps_To","value":"Olfactory neuroblastoma"},{"name":"Maps_To","value":"Olfactory neuroepithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206717"}]}}{"C6907":{"preferredName":"Metaplastic Meningioma","code":"C6907","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of a prominent mesenchymal component. The mesenchymal component may be osseous, cartilaginous, myxoid, lipomatous, or a mixture of mesenchymal elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metaplastic Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Metaplastic_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Metaplastic meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384407"}]}}{"C4718":{"preferredName":"Secretory Meningioma","code":"C4718","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of epithelial differentiation and numerous intracellular PAS positive bodies that are rich in glycogen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secretory Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secretory_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Secretory meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384406"}]}}{"C4721":{"preferredName":"Microcystic Meningioma","code":"C4721","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of intercellular microcystic spaces that contain mucinous fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microcystic Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microcystic_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Microcystic meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384408"}]}}{"C4720":{"preferredName":"Lymphoplasmacyte-Rich Meningioma","code":"C4720","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of prominent chronic inflammatory infiltrates that predominate over the meningioma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoplasmacyte-Rich Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphoplasmacyte-Rich_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Lymphoplasmacyte-rich meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431119"}]}}{"C3707":{"preferredName":"Meningiomatosis","code":"C3707","definitions":[{"definition":"The presence of multiple meningiomas in the leptomeninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningiomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Meningiomas, Multiple","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9530/1"},{"name":"Legacy Concept Name","value":"Meningiomatosis"},{"name":"Maps_To","value":"9530/1"},{"name":"Maps_To","value":"Diffuse meningiomatosis"},{"name":"Maps_To","value":"Meningiomatosis, NOS"},{"name":"Maps_To","value":"Multiple meningiomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205834"}]}}{"C4051":{"preferredName":"Anaplastic (Malignant) Meningioma","code":"C4051","definitions":[{"definition":"A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","type":"DEFINITION","source":"NCI"},{"definition":"A rare, fast-growing tumor that forms in one of the inner layers of the meninges (thin layers of tissue that cover and protect the brain and spinal cord). Malignant meningioma often spreads to other areas of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anaplastic (Malignant) Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Meningioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Meningioma","termGroup":"SY","termSource":"NCI"},{"termName":"Meningioma, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9530/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Malignant_Meningioma"},{"name":"Maps_To","value":"9530/3"},{"name":"Maps_To","value":"Meningioma, anaplastic"},{"name":"Maps_To","value":"Meningioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259785"}]}}{"C4073":{"preferredName":"Meningeal Sarcoma","code":"C4073","definitions":[{"definition":"A rare sarcoma arising from the meninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Meninges Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Meninges","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Meningeal_Sarcoma"},{"name":"Maps_To","value":"9530/3"},{"name":"Maps_To","value":"Meningeal sarcoma"},{"name":"Maps_To","value":"Meningothelial sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302327"}]}}{"C8312":{"preferredName":"Leptomeningeal Sarcoma","code":"C8312","definitions":[{"definition":"A malignant mesenchymal neoplasm arising from the leptomeninges.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sarcoma arising from the leptomeninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leptomeningeal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcoma of Leptomeninges","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Leptomeninges","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Leptomeningeal_Sarcoma"},{"name":"Maps_To","value":"9530/3"},{"name":"Maps_To","value":"Leptomeningeal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384416"}]}}{"C4329":{"preferredName":"Meningothelial Meningioma","code":"C4329","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of tumor cells that form lobules. The tumor cells are generally uniform. Whorls and psammoma bodies are usually not present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningothelial Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Meningotheliomatous Meningioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9531/0"},{"name":"Legacy Concept Name","value":"Meningothelial_Meningioma"},{"name":"Maps_To","value":"9531/0"},{"name":"Maps_To","value":"Endotheliomatous meningioma"},{"name":"Maps_To","value":"Meningothelial meningioma"},{"name":"Maps_To","value":"Syncytial meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334605"}]}}{"C4330":{"preferredName":"Fibrous Meningioma","code":"C4330","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of spindle cells that form bundles in a collagen matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrous Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblastic Meningioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9532/0"},{"name":"Legacy Concept Name","value":"Fibrous_Meningioma"},{"name":"Maps_To","value":"9532/0"},{"name":"Maps_To","value":"Fibroblastic meningioma"},{"name":"Maps_To","value":"Fibrous meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334606"}]}}{"C4331":{"preferredName":"Psammomatous Meningioma","code":"C4331","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of psammoma bodies that predominate over the meningeal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Psammomatous Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9533/0"},{"name":"Legacy Concept Name","value":"Psammomatous_Meningioma"},{"name":"Maps_To","value":"9533/0"},{"name":"Maps_To","value":"Psammomatous meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334607"}]}}{"C4332":{"preferredName":"Angiomatous Meningioma","code":"C4332","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of small and medium sized vessels that predominate over the meningioma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomatous Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9534/0"},{"name":"Legacy Concept Name","value":"Angiomatous_Meningioma"},{"name":"Maps_To","value":"9534/0"},{"name":"Maps_To","value":"Angiomatous meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334608"}]}}{"C66817":{"preferredName":"Hemangioblastic Meningioma","code":"C66817","definitions":[{"definition":"An obsolete term referring to hemangiopericytoma of the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangioblastic Meningioma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9535/0"},{"name":"Legacy Concept Name","value":"Hemangioblastic_Meningioma"},{"name":"Maps_To","value":"9535/0"},{"name":"Maps_To","value":"Hemangioblastic meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334609"}]}}{"C4333":{"preferredName":"Transitional Meningioma","code":"C4333","definitions":[{"definition":"A WHO grade I meningioma characterized by the coexistence of meningothelial cells and fibrous architectural patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transitional Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Meningioma","termGroup":"SY","termSource":"NCI"},{"termName":"Transitional (Mixed) Meningioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9537/0"},{"name":"Legacy Concept Name","value":"Transitional_Meningioma"},{"name":"Maps_To","value":"9537/0"},{"name":"Maps_To","value":"Mixed meningioma"},{"name":"Maps_To","value":"Transitional meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334611"}]}}{"C4722":{"preferredName":"Clear Cell Meningioma","code":"C4722","definitions":[{"definition":"A WHO grade II morphologic variant of meningioma characterized by the presence of clear glycogen-rich polygonal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9538/1"},{"name":"Legacy Concept Name","value":"Clear_Cell_Meningioma"},{"name":"Maps_To","value":"9538/1"},{"name":"Maps_To","value":"Clear cell meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431121"}]}}{"C6908":{"preferredName":"Chordoid Meningioma","code":"C6908","definitions":[{"definition":"A WHO grade II, usually recurring meningioma characterized by the predominance of tissues that are histologically similar to chordoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chordoid Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chordoid_Meningioma"},{"name":"Maps_To","value":"9538/1"},{"name":"Maps_To","value":"Chordoid meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370510"}]}}{"C3904":{"preferredName":"Papillary Meningioma","code":"C3904","definitions":[{"definition":"A WHO grade III meningioma characterized by the predominance of a perivascular pseudopapillary pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9538/3"},{"name":"Legacy Concept Name","value":"Papillary_Meningioma"},{"name":"Maps_To","value":"9538/3"},{"name":"Maps_To","value":"Papillary meningioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3163622"}]}}{"C6909":{"preferredName":"Rhabdoid Meningioma","code":"C6909","definitions":[{"definition":"A WHO grade III meningioma characterized by the predominant presence of rhabdoid cells forming sheets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhabdoid Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rhabdoid_Meningioma"},{"name":"Maps_To","value":"9538/3"},{"name":"Maps_To","value":"Rhabdoid meningioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259786"}]}}{"C4723":{"preferredName":"Atypical Meningioma","code":"C4723","definitions":[{"definition":"A WHO grade II meningioma characterized by the presence of brain invasion and an increased mitotic activity, or at least three of the following morphologic features: small cells, high cellularity, prominent nucleoli, lack of architectural pattern, and necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9539/1"},{"name":"Legacy Concept Name","value":"Atypical_Meningioma"},{"name":"Maps_To","value":"9539/1"},{"name":"Maps_To","value":"Atypical meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431122"}]}}{"C4334":{"preferredName":"Meningeal Sarcomatosis","code":"C4334","definitions":[{"definition":"A rare condition characterized by diffuse spread of sarcoma cells throughout the meninges. The neoplastic cells are derived from meningeal connective tissue. Clinically, this disorder may present as a fulminant pachymeningitis and/or encephalitis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Sarcomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Meninges Sarcomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatosis of Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatosis of the Meninges","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9539/3"},{"name":"Legacy Concept Name","value":"Meningeal_Sarcomatosis"},{"name":"Maps_To","value":"9539/3"},{"name":"Maps_To","value":"Meningeal sarcomatosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334612"}]}}{"C3272":{"preferredName":"Neurofibroma","code":"C3272","definitions":[{"definition":"A benign tumor that develops from the cells and tissues that cover nerves.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths, composed of perineurial-like fibroblasts and Schwann cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibroma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9540/0"},{"name":"Legacy Concept Name","value":"Neurofibroma"},{"name":"Maps_To","value":"9540/0"},{"name":"Maps_To","value":"Neurofibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027830"}]}}{"C6727":{"preferredName":"Neurofibromatosis","code":"C6727","definitions":[{"definition":"An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurofibromatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9540/1"},{"name":"Legacy Concept Name","value":"Neurofibromatosis"},{"name":"Maps_To","value":"9540/1"},{"name":"Maps_To","value":"Multiple neurofibromatosis"},{"name":"Maps_To","value":"Neurofibromatosis (nonmalignant)"},{"name":"Maps_To","value":"Neurofibromatosis, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0162678"}]}}{"C3273":{"preferredName":"Neurofibromatosis Type 1","code":"C3273","definitions":[{"definition":"A rare genetic condition that causes brown spots and tumors on the skin, freckling in skin areas not exposed to the sun, tumors on the nerves, and developmental changes in the nervous system, muscles, bone, and skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant form of neurofibromatosis caused by mutation(s) in the NF1 gene, encoding neurofibromin. The clinical features of this condition may include smooth bordered areas of hyperpigmentation, known as cafe-au-lait spots, axillary freckling, Lisch nodules, short stature, cutaneous and subcutaneous tumors (neurofibromas), optic nerve gliomas, precocious puberty, and growth hormone excess.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The most common type of neurofibromatosis.  It is characterized clinically by cutaneous and subcutaneous tumors with patches of hyperpigmentation. The hyperpigmented skin areas, are present from birth and found anywhere on the body surface.  They can vary markedly in size and color.  The dark brown areas are called cafe-au-lait spots. The multiple cutaneous and subcutaneous tumors are nerve sheath tumors, called neurofibromas.  They can develop anywhere along the peripheral nerve fibers. Neurofibromas can become quite large, causing a major disfigurement, eroding bone, and compressing various peripheral nerve structures.  Type 1 neurofibromatosis has dominant inheritance, with a gene locus on the proximal long arm of chromosome 17.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurofibromatosis Type 1","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibromatosis 1","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neurofibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Von Recklinghausen Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Neurofibromatosis_Type_1"},{"name":"Maps_To","value":"9540/1"},{"name":"Maps_To","value":"Recklinghausen disease"},{"name":"Maps_To","value":"Von Recklinghausen disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0027831"}]}}{"C6561":{"preferredName":"Epithelioid Malignant Peripheral Nerve Sheath Tumor","code":"C6561","definitions":[{"definition":"A rare variant of malignant peripheral nerve sheath tumor composed predominantly or exclusively of epithelioid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Malignant Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid MPNST","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Neoplasm of Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Neoplasm of the Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Peripheral Nerve Sheath Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Tumor of Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Tumor of the Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epithelioid_Malignant_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"9540/3"},{"name":"Maps_To","value":"9542/3"},{"name":"Maps_To","value":"Epithelioid malignant peripheral nerve sheath tumor"},{"name":"Maps_To","value":"Epithelioid MPNST"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor, epithelioid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321427"}]}}{"C4748":{"preferredName":"Malignant Melanotic Peripheral Nerve Sheath Tumor","code":"C4748","definitions":[{"definition":"A rare variant of malignant peripheral nerve sheath tumor.  It is characterized by the presence of malignant cells that contain melanin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Melanotic Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanocytic Neoplasm of Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanocytic Neoplasm of the Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanocytic Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanotic Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanotic Schwannian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytic MPNST","termGroup":"SY","termSource":"NCI"},{"termName":"MMNST","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Melanocytic_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"9540/3"},{"name":"Maps_To","value":"Melanotic MPNST"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474847"}]}}{"C3798":{"preferredName":"Malignant Peripheral Nerve Sheath Tumor","code":"C3798","definitions":[{"definition":"A malignant neoplasm, originating from the sheaths of the peripheral nerve.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of soft tissue sarcoma that develops in cells that form a protective sheath (covering) around peripheral nerves, which are nerves that are outside of the central nervous system (brain and spinal cord).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neurilemmoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Peripheral Nerve Sheath Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Schwannoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MPNST","termGroup":"AB","termSource":"NCI"},{"termName":"Neurofibrosarcoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9540/3"},{"name":"ICD-O-3_Code","value":"9560/3"},{"name":"Legacy Concept Name","value":"Malignant_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"9540/3"},{"name":"Maps_To","value":"9560/3"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor, NOS"},{"name":"Maps_To","value":"Malignant schwannoma, NOS"},{"name":"Maps_To","value":"MPNST, NOS"},{"name":"Maps_To","value":"Neurilemoma, malignant"},{"name":"Maps_To","value":"Neurilemosarcoma"},{"name":"Maps_To","value":"Neurofibrosarcoma"},{"name":"Maps_To","value":"Neurogenic sarcoma"},{"name":"Maps_To","value":"Neurosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3279060"}]}}{"C66841":{"preferredName":"Melanotic Neurofibroma","code":"C66841","definitions":[{"definition":"A rare neurofibroma characterized by the presence of melanin-laden cells and the absence of atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanotic Neurofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Pigmented Neurofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9541/0"},{"name":"Legacy Concept Name","value":"Melanotic_Neurofibroma"},{"name":"Maps_To","value":"9541/0"},{"name":"Maps_To","value":"Melanotic neurofibroma"},{"name":"NCI_META_CUI","value":"CL497402"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3797":{"preferredName":"Plexiform Neurofibroma","code":"C3797","definitions":[{"definition":"A nerve that has become thick and misshapen due to the abnormal growth of cells and tissues that cover the nerve.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plexiform Neurofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9550/0"},{"name":"Legacy Concept Name","value":"Plexiform_Neurofibroma"},{"name":"Maps_To","value":"9550/0"},{"name":"Maps_To","value":"Plexiform neurofibroma"},{"name":"Maps_To","value":"Plexiform neuroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3279070"}]}}{"C3276":{"preferredName":"Vestibular Schwannoma","code":"C3276","definitions":[{"definition":"A benign peripheral nerve sheath neoplasm that arises from the vestibular division of the vestibulocochlear nerve (eight cranial nerve) in the auditory canal or within the labyrinth. It is composed almost entirely of differentiated neoplastic Schwann cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vestibular Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acoustic Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acoustic Neuroma","termGroup":"SY","termSource":"NCI"},{"termName":"Acoustic Schwannoma","termGroup":"SY","termSource":"NCI"},{"termName":"Neurilemoma, Acoustic","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroma, Acoustic","termGroup":"SY","termSource":"NCI"},{"termName":"Vestibular Neurilemmoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acoustic_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Acoustic neuroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3549435"}]}}{"C3269":{"preferredName":"Schwannoma","code":"C3269","definitions":[{"definition":"A benign neoplasm of the peripheral nervous system composed of well-differentiated Schwann cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, usually encapsulated slow growing tumor composed of Schwann cells.  It affects peripheral and cranial nerves.  It recurs infrequently and only rare cases associated with malignant transformation have been reported.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor of the peripheral nervous system that arises in the nerve sheath (protective covering).  It is almost always benign, but rare malignant schwannomas have been reported.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Schwannoma","termGroup":"SY","termSource":"NCI"},{"termName":"Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Neurinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Schwannoma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9560/0"},{"name":"Legacy Concept Name","value":"Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Neurilemoma, NOS"},{"name":"Maps_To","value":"Neurinoma"},{"name":"Maps_To","value":"Psammomatous schwannoma"},{"name":"Maps_To","value":"Schwannoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027809"}]}}{"C4724":{"preferredName":"Cellular Schwannoma","code":"C4724","definitions":[{"definition":"A morphologic variant of schwannoma characterized by hypercellularity, Antoni A pattern, and the absence of well-formed Verocay bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cellular Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cellular Neurinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cellular_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Cellular schwannoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431124"}]}}{"C6970":{"preferredName":"Melanotic Schwannoma","code":"C6970","definitions":[{"definition":"A rare circumscribed, non-encapsulated and grossly pigmented nerve sheath tumor. It is composed of cells with the immunophenotypic and electron microscopic features of Schwann cells which contain melanosomes and are positive for melanoma markers. It usually involves spinal nerve roots but may occur in other locations. It may be associated with PRKAR1A gene mutation and Carney complex. Malignant behavior has been reported in a significant number of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanotic Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocytic Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytic Schwannoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Neurinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Schwannoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanocytic_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Melanotic schwannoma"},{"name":"Maps_To","value":"Pigmented schwannoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306247"}]}}{"C6969":{"preferredName":"Plexiform Schwannoma","code":"C6969","definitions":[{"definition":"A schwannoma characterized by a plexiform or multinodular growth pattern.  It usually arises from the skin or subcutaneous tissues in the extremities, trunk, and head and neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plexiform Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Plexiform Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Plexiform Neurinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Plexiform_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Plexiform schwannoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370659"}]}}{"C6556":{"preferredName":"Ancient Schwannoma","code":"C6556","definitions":[{"definition":"A schwannoma that is characterized by degenerative changes such as hyalinization, hemorrhage, calcification and cystic change.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancient Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ancient Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Degenerated Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Degenerated Schwannoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Degenerated_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Ancient schwannoma"},{"name":"Maps_To","value":"Degenerated schwannoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1536561"}]}}{"C6557":{"preferredName":"Schwannomatosis","code":"C6557","definitions":[{"definition":"Rare genetic disorder caused by mutations in the SMARCB1 and LZTR1 genes. It is characterized by the presence of multiple Schwannomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Schwannomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Neurilemmomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Neurinomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9560/1"},{"name":"Legacy Concept Name","value":"Schwannomatosis"},{"name":"Maps_To","value":"9560/1"},{"name":"Maps_To","value":"Neurinomatosis"},{"name":"Maps_To","value":"Schwannomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335929"}]}}{"C4335":{"preferredName":"Malignant Triton Tumor","code":"C4335","definitions":[{"definition":"A malignant peripheral nerve sheath tumor which shows rhabdomyosarcomatous differentiation. More than half of the patients have neurofibromatosis type 1. The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Triton Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Peripheral Nerve Sheath Neoplasm with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Peripheral Nerve Sheath Tumor with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"MPNST with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9561/3"},{"name":"Legacy Concept Name","value":"Malignant_Triton_Tumor"},{"name":"Maps_To","value":"9561/3"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation"},{"name":"Maps_To","value":"Malignant schwannoma with rhabdomyoblastic differentiation"},{"name":"Maps_To","value":"MPNST with rhabdomyoblastic differentiation"},{"name":"Maps_To","value":"Triton tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334616"}]}}{"C7018":{"preferredName":"Nerve Sheath Myxoma","code":"C7018","definitions":[{"definition":"A benign neoplasm arising from nerve sheaths. It is characterized by the presence of a myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve Sheath Myxoma","termGroup":"PT","termSource":"NCI"},{"termName":"Neurothekeoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9562/0"},{"name":"Legacy Concept Name","value":"Neurothekeoma"},{"name":"Maps_To","value":"9562/0"},{"name":"Maps_To","value":"Nerve sheath myxoma"},{"name":"Maps_To","value":"Neurothekeoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206730"}]}}{"C3275":{"preferredName":"Neuroma","code":"C3275","definitions":[{"definition":"A tumor that arises in nerve cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor that grows from a nerve or is composed of nerve cells and nerve fibers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9570/0"},{"name":"Legacy Concept Name","value":"Neuroma"},{"name":"Maps_To","value":"9570/0"},{"name":"Maps_To","value":"Neuroma, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0027858"}]}}{"C6911":{"preferredName":"Intraneural Perineurioma","code":"C6911","definitions":[{"definition":"A WHO grade I perineurioma that arises within the endoneurium.  It is characterized by the formation of pseudo-onion bulbs by the proliferating perineural cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraneural Perineurioma","termGroup":"PT","termSource":"NCI"},{"termName":"Intraneural Perineurioma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraneural_Perineurioma"},{"name":"Maps_To","value":"9571/0"},{"name":"Maps_To","value":"Intraneural perineurioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370658"}]}}{"C6912":{"preferredName":"Soft Tissue Perineurioma","code":"C6912","definitions":[{"definition":"A perineurioma not associated with a nerve, arising from the soft tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soft Tissue Perineurioma","termGroup":"PT","termSource":"NCI"},{"termName":"Soft Tissue Perineurioma (WHO Grades I, II, or III)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Soft_Tissue_Perineurioma"},{"name":"Maps_To","value":"9571/0"},{"name":"Maps_To","value":"Soft tissue perineurioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370657"}]}}{"C4973":{"preferredName":"Perineurioma","code":"C4973","definitions":[{"definition":"A rare benign tumor composed entirely of neoplastic perineurial cells. It may occur in the soft tissues, intraneurally or in mucosal sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perineurioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9571/0"},{"name":"Legacy Concept Name","value":"Perineurioma"},{"name":"Maps_To","value":"9571/0"},{"name":"Maps_To","value":"Perineurioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751691"}]}}{"C66845":{"preferredName":"Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation","code":"C66845","definitions":[{"definition":"A very rare malignant tumor with morphologic features similar to those of benign perineurioma of soft tissue along with hypercellularity, nuclear atypia, hyperchromasia, and a high mitotic rate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Perineurioma","termGroup":"SY","termSource":"NCI"},{"termName":"Perineurial Malignant Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9571/3"},{"name":"Legacy Concept Name","value":"Malignant_Peripheral_Nerve_Sheath_Tumor_with_Perineurial_Differentiation"},{"name":"Maps_To","value":"9571/3"},{"name":"Maps_To","value":"Perineural MPNST"},{"name":"Maps_To","value":"Perineurioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266188"}]}}{"C3474":{"preferredName":"Granular Cell Tumor","code":"C3474","definitions":[{"definition":"An unusual benign or malignant neoplasm characterized by the presence of neoplastic large polygonal cells with granular, eosinophilic cytoplasm which contains abundant lysosomes. It was originally thought to be a tumor originating from muscle cells and was named granular cell myoblastoma. Subsequent studies have suggested a derivation from Schwann cells. It affects females more often than males and it usually presents as a solitary mass. A minority of patients have multiple tumors. It can arise from many anatomic sites including the posterior pituitary gland, skin, oral cavity, esophagus, stomach, heart, mediastinum, and breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granular Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Abrikossoff Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Abrikossoff's Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Granular Cell Myoblastoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Granular Cell Nerve Sheath Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Granular Cell Schwannoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9580/0"},{"name":"Legacy Concept Name","value":"Granular_Cell_Tumor"},{"name":"Maps_To","value":"9580/0"},{"name":"Maps_To","value":"Granular cell myoblastoma, NOS"},{"name":"Maps_To","value":"Granular cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0085167"}]}}{"C4336":{"preferredName":"Malignant Granular Cell Tumor","code":"C4336","definitions":[{"definition":"A malignant neoplasm, comprised of large cells with cytoplasmatic granules, occurring in various organs/tissues.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An uncommon granular cell tumor which may metastasize to other anatomic sites. Morphologic characteristics include the presence of spindling neoplastic cells, necrosis, extensive pleomorphism, prominent nucleoli, and increased mitiotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Granular Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Granular Cell Myoblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Granular Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9580/3"},{"name":"Legacy Concept Name","value":"Malignant_Granular_Cell_Tumor"},{"name":"Maps_To","value":"9580/3"},{"name":"Maps_To","value":"Granular cell myoblastoma, malignant"},{"name":"Maps_To","value":"Granular cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334618"}]}}{"C3750":{"preferredName":"Alveolar Soft Part Sarcoma","code":"C3750","definitions":[{"definition":"A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults the most common sites of involvement are the extremities, and in infants and children, the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that is most common in older children and teenagers. It begins in the soft supporting tissue that connects and surrounds the organs and other tissues. Alveolar soft part sarcoma usually occurs in the legs, but can also occur in the arms, hands, head, or neck. It can cause the growth of new blood vessels that help the tumor grow and spread.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alveolar Soft Part Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ASPS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9581/3"},{"name":"Legacy Concept Name","value":"Alveolar_Soft_Part_Sarcoma"},{"name":"Maps_To","value":"9581/3"},{"name":"Maps_To","value":"Alveolar soft part sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206657"}]}}{"C7017":{"preferredName":"Granular Cell Tumor of the Sellar Region","code":"C7017","definitions":[{"definition":"A generally benign intrasellar and/or suprasellar mass arising from the neurohypophysis or infundibulum.  It is composed of nests of large cells with granular, eosinophilic cytoplasm due to abundant intracytoplasmic lysosomes. It generally has a slow progression and lacks invasive growth. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granular Cell Tumor of the Sellar Region","termGroup":"PT","termSource":"NCI"},{"termName":"Granular Cell Tumor of Neurohypophysis","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Neurohypophysis","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Neurohypophysis (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Neurohypophysis (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Posterior Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumour of the Sellar Region/Granular Cell Pituicytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9582/0"},{"name":"Legacy Concept Name","value":"Granular_Cell_Tumor_of_the_Neurohypophysis"},{"name":"Maps_To","value":"9582/0"},{"name":"Maps_To","value":"Granular cell tumor of sellar region"},{"name":"Maps_To","value":"Granular cell tumor of the sellar region"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333873"}]}}{"C9301":{"preferredName":"Central Nervous System Lymphoma","code":"C9301","definitions":[{"definition":"A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the lymph tissue of the brain, spinal cord, meninges (outer covering of the brain), or eye (called ocular lymphoma).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Central Nervous System Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"CNS Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Lymphomas of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Lymphomas of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Central Nervous System Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary CNS Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Lymphoma"},{"name":"Maps_To","value":"9590/3"},{"name":"Maps_To","value":"Microglioma"},{"name":"Maps_To","value":"Primary central nervous system lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280803"}]}}{"C27258":{"preferredName":"Malignant Lymphoma, Non-Cleaved Cell Type","code":"C27258","synonyms":[{"termName":"Malignant Lymphoma, Non-Cleaved Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Non-Cleaved_Cell_Type"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Malignant lymphoma, non-cleaved cell, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1518190"}]}}{"C80308":{"preferredName":"Splenic B-Cell Lymphoma/Leukemia, Unclassifiable","code":"C80308","definitions":[{"definition":"A small B-cell clonal lymphoproliferative disorder of the spleen that does not fall into any of the other categories of mature B-cell neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic B-Cell Lymphoma/Leukemia, Unclassifiable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Splenic_B-Cell_Lymphoma_Leukemia_Unclassifiable"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Splenic B-cell lymphoma/leukemia, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699507"}]}}{"C27822":{"preferredName":"Diffuse Malignant Lymphoma","code":"C27822","definitions":[{"definition":"An antiquated term referring to non-Hodgkin lymphomas with a diffuse architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Malignant Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Malignant_Lymphoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Malignant lymphoma, diffuse, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334620"}]}}{"C27824":{"preferredName":"Reticulosarcoma","code":"C27824","definitions":[{"definition":"An antiquated term that refers to a non-Hodgkin lymphoma composed of diffuse infiltrates of large, often anaplastic lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reticulosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Reticulosarcoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Reticulosarcoma, NOS"},{"name":"Maps_To","value":"Reticulum cell sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024302"}]}}{"C26919":{"preferredName":"Lymphosarcoma","code":"C26919","definitions":[{"definition":"An antiquated term that refers to a non-Hodgkin lymphoma composed of small and medium sized lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"An obsolete term for a malignant tumor of lymphatic tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphosarcoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Lymphosarcoma, diffuse"},{"name":"Maps_To","value":"Lymphosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3714542"}]}}{"C7401":{"preferredName":"Hairy Cell Leukemia Variant","code":"C7401","definitions":[{"definition":"An indolent chronic B-cell leukemia resembling classic hairy cell leukemia but shows variant cytologic, hematologic, and immunophenotypic features and is resistant to the conventional therapy applied to hairy cell leukemia.  Biologically, it is not related to hairy cell leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hairy Cell Leukemia Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Hairy Cell Leukemia-Variant","termGroup":"SY","termSource":"NCI"},{"termName":"HCL-V","termGroup":"AB","termSource":"NCI"},{"termName":"Prolymphocytic Variant of Hairy Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic B-Cell Lymphoma/Leukemia with Prominent Nucleoli","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Hairy_Cell_Leukemia_Variant"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"9940/3"},{"name":"Maps_To","value":"Hairy cell leukaemia variant"},{"name":"Maps_To","value":"Hairy cell leukemia variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349633"}]}}{"C80309":{"preferredName":"Splenic Diffuse Red Pulp Small B-Cell Lymphoma","code":"C80309","definitions":[{"definition":"An uncommon, indolent B-cell non-Hodgkin lymphoma composed of small B-lymphocytes involving the red pulp of the spleen, bone marrow, and peripheral blood.  Patients often have massive splenomegaly.  The peripheral blood examination reveals villous lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic Diffuse Red Pulp Small B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Splenic_Diffuse_Red_Pulp_Small_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Splenic diffuse red pulp small B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699508"}]}}{"C3211":{"preferredName":"Non-Hodgkin Lymphoma","code":"C3211","definitions":[{"definition":"A malignant neoplasm of the lymphatic system that is comprised of abnormal lymphocytes in the absence of Reed-Sternberg cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any of a large group of cancers of lymphocytes (white blood cells). NHLs can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of NHL. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and they can be formed from either B-cells or T-cells. B-cell NHLs include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell NHLs include mycosis fungoides, anaplastic large cell lymphoma, and precursor T-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or stem cell transplantation are usually B-cell NHLs. Prognosis and treatment depend on the stage and type of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"NHL","termGroup":"AB","termSource":"NCI"},{"termName":"Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Hodgkin's Lymphoma (NHL)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Large cell lymphoma"},{"name":"Maps_To","value":"Large cell lymphoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Large cell lymphoma involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Large cell lymphoma involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Large cell lymphoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Large cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Lymphosarcoma"},{"name":"Maps_To","value":"Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue"},{"name":"Maps_To","value":"Lymphosarcoma involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Lymphosarcoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Lymphosarcoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Malignant lymphoma, non-Hodgkin, NOS"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, NOS"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, unspecified"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, unspecified, unspecified site"},{"name":"Maps_To","value":"Non-Hodgkin's lymphoma"},{"name":"Maps_To","value":"Other and unspecified types of non-Hodgkin lymphoma"},{"name":"Maps_To","value":"Other named variants of lymphosarcoma and reticulosarcoma"},{"name":"Maps_To","value":"Other named variants of lymphosarcoma and reticulosarcoma, unspecified site"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, unspecified site"},{"name":"Maps_To","value":"Reticulosarcoma"},{"name":"Maps_To","value":"Reticulosarcoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Reticulosarcoma involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Reticulosarcoma, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024305"}]}}{"C38661":{"preferredName":"Composite Lymphoma","code":"C38661","definitions":[{"definition":"A rare form of lymphoma (cancer that begins in cells of the immune system) in which different types of lymphoma cells occur at the same time. The different lymphoma cells may form in the same tissue or organ or in many different tissues or organs. The composite lymphoma may contain different types of non-Hodgkin lymphoma cells or both Hodgkin and non-Hodgkin lymphoma cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Coexistence of Hodgkin and non-Hodgkin lymphoma in the same anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Composite Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9596/3"},{"name":"Legacy Concept Name","value":"Composite_Lymphoma"},{"name":"Maps_To","value":"9596/3"},{"name":"Maps_To","value":"Composite Hodgkin and non-Hodgkin lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0545080"}]}}{"C37869":{"preferredName":"Gray-Zone Lymphoma","code":"C37869","definitions":[{"definition":"A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classic Hodgkin lymphoma and diffuse large B-cell lymphoma.  This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classic Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gray-Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gray Zone Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hodgkin-Like Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma with Hodgkin Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9596/3"},{"name":"Legacy Concept Name","value":"Gray_Zone_Lymphoma"},{"name":"Maps_To","value":"9596/3"},{"name":"Maps_To","value":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333878"}]}}{"C7217":{"preferredName":"Primary Cutaneous Follicle Center Lymphoma","code":"C7217","definitions":[{"definition":"A primary lymphoma of the skin composed of various numbers of small and large irregular neoplastic follicle center cells.  Its morphologic pattern can be nodular, diffuse, or nodular and diffuse.  It presents with solitary or grouped plaques and tumors, and it usually involves the scalp, forehead, or trunk.  It rarely involves the legs.  This type of cutaneous lymphoma tends to remain localized to the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Follicle Center Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Crosti's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Follicle Center Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Follicle Centre Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PCFCL","termGroup":"AB","termSource":"NCI"},{"termName":"Reticulohistiocytoma of the Dorsum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9597/3"},{"name":"Legacy Concept Name","value":"Cutaneous_Follicle_Center_Lymphoma"},{"name":"Maps_To","value":"9597/3"},{"name":"Maps_To","value":"Primary cutaneous follicle center lymphoma"},{"name":"Maps_To","value":"Primary cutaneous follicle centre lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333171"}]}}{"C6913":{"preferredName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","code":"C6913","definitions":[{"definition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"LRCHL","termGroup":"AB","termSource":"NCI"},{"termName":"Lymphocyte Rich Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Rich Classical Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte Rich Classical Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Rich Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Rich Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte Rich Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Rich Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Rich Classical Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9651/3"},{"name":"Legacy Concept Name","value":"Lymphocyte_Rich_Classical_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9651/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, lymphocyte-rich"},{"name":"Maps_To","value":"Hodgkin disease, lymphocyte predominance, diffuse"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte-rich"},{"name":"Maps_To","value":"Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Lymphocyte-rich classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266194"}]}}{"C8590":{"preferredName":"Lymphocyte Predominant Type Hodgkin's Disease","code":"C8590","definitions":[{"definition":"An antiquated term that refers either to nodular lymphocyte predominant Hodgkin lymphoma or to lymphocyte-rich classical Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte Predominant Type Hodgkin's Disease","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocyte_Predominant_Type_Hodgkin_s_Disease"},{"name":"Maps_To","value":"9651/3"},{"name":"Maps_To","value":"Hodgkin disease, lymphocyte predominance, NOS"},{"name":"Maps_To","value":"Hodgkin disease, lymphocytic-histiocytic predominance"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0852444"}]}}{"C3517":{"preferredName":"Mixed Cellularity Classic Hodgkin Lymphoma","code":"C3517","definitions":[{"definition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Cellularity Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Disease Mixed Cellularity","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Lymphoma Mixed Cellularity","termGroup":"SY","termSource":"NCI"},{"termName":"MCCHL","termGroup":"AB","termSource":"NCI"},{"termName":"MCHL","termGroup":"AB","termSource":"NCI"},{"termName":"Mixed Cellularity Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cellularity Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cellularity Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Cellularity Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9652/3"},{"name":"Legacy Concept Name","value":"Mixed_Cellularity_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9652/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, mixed cellularity, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, mixed cellularity, NOS"},{"name":"Maps_To","value":"Hodgkin's disease, mixed cellularity"},{"name":"Maps_To","value":"Hodgkin's disease, mixed cellularity, involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, mixed cellularity, involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152266"}]}}{"C9283":{"preferredName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","code":"C9283","definitions":[{"definition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin Lymphoma Lymphocyte Depleted","termGroup":"SY","termSource":"NCI"},{"termName":"Hodgkin's Disease Lymphocyte Depletion","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Lymphoma Lymphocyte Depleted","termGroup":"SY","termSource":"NCI"},{"termName":"LDCHL","termGroup":"AB","termSource":"NCI"},{"termName":"LDHL","termGroup":"AB","termSource":"NCI"},{"termName":"Lymphocyte Depleted Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Depleted Classical Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Depleted Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Depleted Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte Depleted Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Depleted Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Depleted Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte-Depleted Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9653/3"},{"name":"ICD-O-3_Code","value":"9662/3"},{"name":"Legacy Concept Name","value":"Lymphocyte_Depleted_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9653/3"},{"name":"Maps_To","value":"9654/3"},{"name":"Maps_To","value":"9655/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, lymphocyte depletion, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte depletion, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte depletion, reticular"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic depletion"},{"name":"Maps_To","value":"Hodgkin's sarcoma"},{"name":"Maps_To","value":"Hodgkin's sarcoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Lymphocyte depleted classical Hodgkin lymphoma"},{"name":"Maps_To","value":"Lymphocyte depleted classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152267"}]}}{"C7258":{"preferredName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","code":"C7258","definitions":[{"definition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of Hodgkin lymphoma, which is a cancer of the immune system. It is marked by the presence of a type of cell called a popcorn cell, which is different from the typical Reed-Sternberg cell found in classical Hodgkin lymphoma. This type of Hodgkin lymphoma may change into diffuse large B-cell lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"NLP-BCL","termGroup":"AB","termSource":"NCI"},{"termName":"NLPBL","termGroup":"AB","termSource":"NCI"},{"termName":"NLPHL","termGroup":"AB","termSource":"NCI"},{"termName":"Nodular Lymphocyte Predominant B-Cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Lymphocyte Predominant Hodgkin's Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9659/3"},{"name":"Legacy Concept Name","value":"Nodular_Lymphocyte_Predominant_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9659/3"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte predominance, nodular"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular lymphocyte predominance"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular lymphocyte predominant"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334968"}]}}{"C26956":{"preferredName":"Hodgkin's Paragranuloma","code":"C26956","definitions":[{"definition":"An obsolete term that includes cases currently classified as nodular lymphocyte predominant Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin's Paragranuloma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Paragranuloma"},{"name":"Maps_To","value":"9659/3"},{"name":"Maps_To","value":"Hodgkin paragranuloma, nodular"},{"name":"Maps_To","value":"Hodgkin paragranuloma, NOS"},{"name":"Maps_To","value":"Hodgkin's paragranuloma"},{"name":"Maps_To","value":"Hodgkin's paragranuloma, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2239290"}]}}{"C6914":{"preferredName":"Hodgkin's Granuloma","code":"C6914","definitions":[{"definition":"An obsolete term that refers to cases of Hodgkin lymphoma excluding cases that were classified as Hodgkin's paragranuloma and Hodgkin's sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin Granuloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Granuloma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9661/3"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Granuloma"},{"name":"Maps_To","value":"9661/3"},{"name":"Maps_To","value":"Hodgkin granuloma"},{"name":"Maps_To","value":"Hodgkin's granuloma"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0334626"}]}}{"C164145":{"preferredName":"Hodgkin's Sarcoma","code":"C164145","definitions":[{"definition":"An obsolete term referring to a Hodgkin lymphoma that lacks inflammatory elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin's Sarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9662/3"},{"name":"Maps_To","value":"Hodgkin sarcoma"},{"name":"NCI_META_CUI","value":"CL977332"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3518":{"preferredName":"Nodular Sclerosis Classic Hodgkin Lymphoma","code":"C3518","definitions":[{"definition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Sclerosis Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Nodular Sclerosis","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"NSCHL","termGroup":"AB","termSource":"NCI"},{"termName":"NSHD","termGroup":"AQS","termSource":"NCI"},{"termName":"NSHL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9663/3"},{"name":"Legacy Concept Name","value":"Nodular_Sclerosis_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9663/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, NOS"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, NOS"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152268"}]}}{"C67171":{"preferredName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase","code":"C67171","definitions":[{"definition":"A nodular sclerosis Hodgkin lymphoma characterized by the presence of lacunar cells, nodular growth, and the absence of fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Disease Nodular Sclerosis, Cellular Phase","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Sclerosis Classical Hodgkin Lymphoma, Cellular Phase","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin Lymphoma, Cellular Phase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9664/3"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Cellular_Phase"},{"name":"Maps_To","value":"9664/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, cellular phase"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, cellular phase"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334627"}]}}{"C27270":{"preferredName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance","code":"C27270","synonyms":[{"termName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Lymphocyte_Predominance"},{"name":"Maps_To","value":"9665/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, lymphocyte predominance"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1264183"}]}}{"C27098":{"preferredName":"Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity","code":"C27098","synonyms":[{"termName":"Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Mixed_Cellularity"},{"name":"Maps_To","value":"9665/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, mixed cellularity"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334629"}]}}{"C7165":{"preferredName":"Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma","code":"C7165","definitions":[{"definition":"Nodular sclerosis Hodgkin lymphoma in which at least 75% of the tumor nodules contain scattered Reed-Sternberg cells. The background cellular infiltrate is lymphocytic, mixed, or fibrohistiocytic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Nodular Sclerosis Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Nodular Sclerosis Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9665/3"},{"name":"Legacy Concept Name","value":"Grade_1_Nodular_Sclerosis_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9665/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, grade 1"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, grade 1"},{"name":"Maps_To","value":"Hodgkin lymphoma,nodular sclerosis,  grade 1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1521899"}]}}{"C27808":{"preferredName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion","code":"C27808","synonyms":[{"termName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Lymphocyte_Depletion"},{"name":"Maps_To","value":"9667/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, lymphocyte depletion"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334630"}]}}{"C27807":{"preferredName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant","code":"C27807","synonyms":[{"termName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Disease, Nodular Sclerosis, Syncytial Variant","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Sclerosis Classical Hodgkin Lymphoma, Syncytial Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin Lymphoma, Syncytial Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Syncytial_Variant"},{"name":"Maps_To","value":"9667/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, syncytial variant"},{"name":"NCI_META_CUI","value":"CL054962"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7166":{"preferredName":"Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma","code":"C7166","definitions":[{"definition":"Nodular sclerosis Hodgkin lymphoma in which at least 25% of the tumor nodules contain increased numbers of Reed-Sternberg cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Nodular Sclerosis Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Nodular Sclerosis Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9667/3"},{"name":"Legacy Concept Name","value":"Grade_2_Nodular_Sclerosis_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9667/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, grade 2"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, grade 2"},{"name":"NCI_META_CUI","value":"CL448834"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7540":{"preferredName":"Small Lymphocytic Lymphoma","code":"C7540","definitions":[{"definition":"A malignant neoplasm composed of small lymphocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of lymphoma in which too many immature lymphocytes (white blood cells) are found mostly in the lymph nodes. This causes the lymph nodes to become larger than normal. Sometimes cancer cells are found in the blood and bone marrow, and the disease is called chronic lymphocytic leukemia. The disease is most often seen in people older than 50 years. SLL is a type of non-Hodgkin Lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Small Lymphocytic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Small Lymphocytic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Well Differentiated Lymphocytic Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"SLL","termGroup":"AB","termSource":"NCI"},{"termName":"Small B-Cell Lymphocytic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9670/3"},{"name":"Legacy Concept Name","value":"Small_Lymphocytic_Lymphoma"},{"name":"Maps_To","value":"9670/3"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, diffuse, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, well differentiated, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, small B lymphocytic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, small cell diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, small cell, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, small lymphocytic, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, small lymphocytic, NOS"},{"name":"Maps_To","value":"Small cell B-cell lymphoma"},{"name":"Maps_To","value":"Small cell B-cell lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855095"}]}}{"C3212":{"preferredName":"Lymphoplasmacytic Lymphoma","code":"C3212","definitions":[{"definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of lymphocytes (B-cells), lymphoplasmacytoid cells, and plasma cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymphoplasmacytic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Immunocytoma, Lymphoplasmacytic Type","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphoplasmacytoid Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9671/3"},{"name":"ICD-O-3_Code","value":"9761/3"},{"name":"Legacy Concept Name","value":"Lymphoplasmacytic_Lymphoma_Waldenstrom_s_Macroglobulinemia"},{"name":"Maps_To","value":"9671/3"},{"name":"Maps_To","value":"Lymphoplasmacytic lymphoma"},{"name":"Maps_To","value":"Malignant lymphoma, lymphoplasmacytic"},{"name":"Maps_To","value":"Malignant lymphoma, lymphoplasmacytoid"},{"name":"Maps_To","value":"Malignant lymphoma, plasmacytoid"},{"name":"Maps_To","value":"Plasmacytic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334633"}]}}{"C3898":{"preferredName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","code":"C3898","definitions":[{"definition":"A type of cancer that arises in cells in mucosal tissue that are involved in antibody production.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Immunocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"MALToma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9699/3"},{"name":"Legacy Concept Name","value":"Extranodal_Marginal_Zone_B-Cell_Lymphoma_of_Mucosa-Associated_Lymphoid_Tissue"},{"name":"Maps_To","value":"9671/3"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue"},{"name":"Maps_To","value":"Immunocytoma"},{"name":"Maps_To","value":"MALT lymphoma"},{"name":"Maps_To","value":"Marginal zone lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mucosal-associated lymphoid tissue lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0242647"}]}}{"C4339":{"preferredName":"Multifocal Lymphomatous Polyposis","code":"C4339","definitions":[{"definition":"A clinico-pathological entity reflecting the multiple polyps throughout the gastrointestinal tract created as a result of involvement by a non-Hodgkin lymphoma. Typically, mantle cell lymphomas involving the gastrointestinal tract give rise to multifocal lymphomatous polyposis. Importantly, other histologic subtypes of non-Hodgkin lymphoma can also produce this clinico-pathological entity.  (WHO, 2000)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multifocal Lymphomatous Polyposis","termGroup":"PT","termSource":"NCI"},{"termName":"Multiple Lymphomatous Polyposis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Multifocal_Lymphomatous_Polyposis"},{"name":"Maps_To","value":"9673/3"},{"name":"Maps_To","value":"Malignant lymphomatous polyposis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334638"}]}}{"C4337":{"preferredName":"Mantle Cell Lymphoma","code":"C4337","definitions":[{"definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma that usually occurs in middle-aged or older adults. It is marked by small- to medium-size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood, and gastrointestinal system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mantle Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Classical Mantle Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mantle Zone Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9673/3"},{"name":"Legacy Concept Name","value":"Mantle_Cell_Lymphoma"},{"name":"Maps_To","value":"9673/3"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"},{"name":"Maps_To","value":"Mantle cell lymphoma"},{"name":"Maps_To","value":"Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)"},{"name":"Maps_To","value":"Mantle cell lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mantle cell lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mantle cell lymphoma, unspecified site"},{"name":"Maps_To","value":"Mantle cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mantle zone lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334634"}]}}{"C4338":{"preferredName":"Diffuse Centroblastic-Centrocytic Lymphoma","code":"C4338","synonyms":[{"termName":"CB/CC","termGroup":"AB","termSource":"NCI"},{"termName":"Diffuse Centroblastic-Centrocytic Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Centroblastic-Centrocytic_Lymphoma"},{"name":"Maps_To","value":"9675/3"},{"name":"Maps_To","value":"Malignant lymphoma, centroblasticcentrocytic, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, centroblasticcentrocytic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334637"}]}}{"C3463":{"preferredName":"Diffuse Mixed Cell Lymphoma","code":"C3463","definitions":[{"definition":"An antiquated term referring to non-Hodgkin lymphomas with a mixed cellular composition. This term applies to both B- and T- cell non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Mixed Cell Lymphoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Diffuse Mixed Large and Small Cell Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9675/3"},{"name":"Legacy Concept Name","value":"Diffuse_Mixed_Cell_Lymphoma"},{"name":"Maps_To","value":"9675/3"},{"name":"Maps_To","value":"Malignant lymphoma, mixed cell type, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, mixed small and large cell, diffuse"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079757"}]}}{"C6915":{"preferredName":"Primary Effusion Lymphoma","code":"C6915","definitions":[{"definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","type":"DEFINITION","source":"NCI"},{"definition":"A rare, aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma marked by an abnormal build-up of fluids in a body cavity. It usually occurs together with a human herpesvirus in people who have weakened immune systems, such as in AIDS.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Effusion Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"PEL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9678/3"},{"name":"Legacy Concept Name","value":"Primary_Effusion_Lymphoma"},{"name":"Maps_To","value":"9678/3"},{"name":"Maps_To","value":"Primary effusion lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292753"}]}}{"C9280":{"preferredName":"Primary Mediastinal Large B-Cell Lymphoma","code":"C9280","definitions":[{"definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Mediastinal Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Diffuse Large Cell Lymphoma of Mediastinum","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Diffuse Large Cell Lymphoma of the Mediastinum","termGroup":"SY","termSource":"NCI"},{"termName":"Mediastinal (Thymic) Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mediastinal B-Cell Diffuse Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mediastinal Diffuse Large Cell Lymphoma with Sclerosis","termGroup":"AQS","termSource":"NCI"},{"termName":"PMBL","termGroup":"AB","termSource":"NCI"},{"termName":"PMLCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Mediastinal Clear Cell Lymphoma of B-Cell Type","termGroup":"AQS","termSource":"NCI"},{"termName":"Primary Mediastinal Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9679/3"},{"name":"Legacy Concept Name","value":"Mediastinal_Thymic_Large_B-Cell_Cell_Lymphoma"},{"name":"Maps_To","value":"9679/3"},{"name":"Maps_To","value":"Mediastinal (thymic) large B-cell lymphoma"},{"name":"Maps_To","value":"Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Mediastinal large B-cell lymphoma"},{"name":"Maps_To","value":"Thymic large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292754"}]}}{"C27099":{"preferredName":"Malignant Lymphoma, Histiocytic, Diffuse","code":"C27099","synonyms":[{"termName":"Malignant Lymphoma, Histiocytic, Diffuse","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Histiocytic_Diffuse"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, histiocytic, diffuse"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1521844"}]}}{"C4074":{"preferredName":"Centroblastic Lymphoma","code":"C4074","definitions":[{"definition":"A B-cell non-Hodgkin lymphoma composed of large noncleaved cells. This is a subtype of diffuse large B-cell non-Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Centroblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Centroblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Centroblastic_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, centroblastic, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, centroblastic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302329"}]}}{"C80289":{"preferredName":"Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation","code":"C80289","definitions":[{"definition":"A diffuse large B-cell lymphoma arising in body cavities or narrow spaces of long standing chronic inflammation.  The classic example is the pyothorax-associated lymphoma that arises in the pleural cavity of patients with a history of long standing pyothorax.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation","termGroup":"PT","termSource":"NCI"},{"termName":"DLBCL-CI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma_Associated_with_Chronic_Inflammation"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma associated with chronic inflammation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699776"}]}}{"C80281":{"preferredName":"EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","code":"C80281","definitions":[{"definition":"A diffuse large B-cell lymphoma originally described in patients older than 50 years, but it has been increasingly recognized in younger patients. Epstein-Barr virus is present in all cases. There is no known history of immunodeficiency or prior lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Age-Related EBV Positive B-Cell Lymphoproliferative Disorder","termGroup":"AQS","termSource":"NCI"},{"termName":"EBV Positive Diffuse Large B-Cell Lymphoma of the Elderly","termGroup":"AQS","termSource":"NCI"},{"termName":"EBV-Positive Diffuse Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"EBV-Positive DLBCL, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly","termGroup":"AQS","termSource":"NCI"},{"termName":"Epstein-Barr Virus Positive DLBCL, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Senile EBV-Associated B-Cell Lymphoproliferative Disorder","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Epstein-Barr_Virus_Positive_Diffuse_Large_B-Cell_Lymphoma_of_the_Elderly"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"EBV positive diffuse large B-cell lymphoma of the elderly"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2700007"}]}}{"C6916":{"preferredName":"Anaplastic Lymphoma","code":"C6916","definitions":[{"definition":"A diffuse large B-cell lymphoma variant characterized by the presence of large round, oval, or polygonal cells with bizarre pleomorphic nuclei resembling Hodgkin or Reed-Sternberg cells. It is unrelated to anaplastic large cell lymphoma which is a T-cell non-Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anaplastic_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Anaplastic large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321546"}]}}{"C80291":{"preferredName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","code":"C80291","definitions":[{"definition":"High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"BCLU","termGroup":"AB","termSource":"NCI"},{"termName":"HGBL, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"High Grade B-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade B-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade B-Cell Lymphoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"B-Cell_Lymphoma_Unclassifiable_with_Features_Intermediate_between_Diffuse_Large_B-Cell_Lymphoma_and_Burkitt_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698294"}]}}{"C9496":{"preferredName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","code":"C9496","definitions":[{"definition":"A large B-cell lymphoma characterized by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"T-Cell Rich/Histiocyte-Rich Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell/Histiocyte Rich Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"THRLBCL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"ICD-O-3_Code","value":"9688/3"},{"name":"Legacy Concept Name","value":"T-Cell_Histiocyte_Rich_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"9688/3"},{"name":"Maps_To","value":"Histiocyte-rich large B-cell lymphoma"},{"name":"Maps_To","value":"T-cell rich large B-cell lymphoma"},{"name":"Maps_To","value":"T-cell rich/histiocyte-rich large B-cell lymphoma"},{"name":"Maps_To","value":"T-cell/histiocyte rich large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321547"}]}}{"C4342":{"preferredName":"Intravascular Large B-Cell Lymphoma","code":"C4342","definitions":[{"definition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intravascular Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiotropic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Angiotropic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intravascular B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"IVLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Malignant Angioendotheliomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9712/3"},{"name":"Legacy Concept Name","value":"Intravascular_Large_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"9712/3"},{"name":"Maps_To","value":"Angioendotheliomatosis"},{"name":"Maps_To","value":"Angiotropic lymphoma"},{"name":"Maps_To","value":"Intravascular B-cell lymphoma"},{"name":"Maps_To","value":"Intravascular large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334660"}]}}{"C80280":{"preferredName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","code":"C80280","definitions":[{"definition":"A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous. These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, diffuse, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699777"}]}}{"C27823":{"preferredName":"Malignant Lymphoma, Large Cell Type","code":"C27823","definitions":[{"definition":"An antiquated term that refers to a morphologic variant of non-Hodgkin lymphoma which is composed predominantly or exclusively of large neoplastic lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma, Large Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Large_Cell_Type"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518189"}]}}{"C27265":{"preferredName":"Malignant Lymphoma, Large Cell, Cleaved","code":"C27265","definitions":[{"definition":"Antiquated term describing non-Hodgkin lymphomas that are usually diffuse and are composed of large cells with irregular nuclei, invisible nucleoli and a small amount of cytoplasm.  This morphologic category includes both mature B- and mature T-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma, Large Cell, Cleaved","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Large_Cell_Cleaved"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, cleaved, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, cleaved, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cleaved cell, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334641"}]}}{"C27266":{"preferredName":"Malignant Lymphoma, Non-Cleaved, Diffuse","code":"C27266","definitions":[{"definition":"Antiquated term for diffuse non-Hodgkin lymphomas composed of non-cleaved cells.  The vast majority of cases are mature B-cell lymphomas (Burkitts or diffuse large B-cell lymphomas).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma, Non-Cleaved, Diffuse","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Non-Cleaved_Diffuse"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, noncleaved, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, noncleaved, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, noncleaved, diffuse, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, noncleaved, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334642"}]}}{"C8851":{"preferredName":"Diffuse Large B-Cell Lymphoma","code":"C8851","definitions":[{"definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually aggressive (fast-growing). It is the most common type of non-Hodgkin lymphoma, and is marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. Other symptoms include fever, night sweats, and weight loss. There are several subtypes of diffuse large B-cell lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"DLBCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma"},{"name":"Maps_To","value":"Diffuse Large B-Cell Lymphoma (DLBCL)"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, unspecified site"},{"name":"Maps_To","value":"Malignant lymphoma, histiocytic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, cleaved and noncleaved"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, diffuse, NOS"},{"name":"Maps_To","value":"Non-follicular lymphoma"},{"name":"Maps_To","value":"Other non-follicular lymphoma, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079744"}]}}{"C3461":{"preferredName":"Immunoblastic Lymphoma","code":"C3461","definitions":[{"definition":"A diffuse large B-cell lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, a prominent nucleolus, and abundant cytoplasm.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of immunoblasts (large B cells).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Immunoblastic Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9684/3"},{"name":"Legacy Concept Name","value":"Immunoblastic_Lymphoma"},{"name":"Maps_To","value":"9684/3"},{"name":"Maps_To","value":"Immunoblastic sarcoma"},{"name":"Maps_To","value":"Malignant lymphoma, immunoblastic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, immunoblastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079746"}]}}{"C6917":{"preferredName":"Atypical Burkitt/Burkitt-Like Lymphoma","code":"C6917","definitions":[{"definition":"A morphologic variant of Burkitt lymphoma characterized by marked nuclear pleomorphism, abundant apoptotic debris, and the presence of tangible body macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Burkitt/Burkitt-Like Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Burkitt's/Burkitt's-Like Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Burkitt's-like Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Burkitt-like Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Burkitt_s_Burkitt_s-Like_Lymphoma"},{"name":"Maps_To","value":"9687/3"},{"name":"Maps_To","value":"Burkitt-like lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368771"}]}}{"C2912":{"preferredName":"Burkitt Lymphoma","code":"C2912","definitions":[{"definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma that occurs most often in children and young adults. The disease may affect the jaw, central nervous system, bowel, kidneys, ovaries, or other organs. There are three main types of Burkitt lymphoma (sporadic, endemic, and immunodeficiency related). Sporadic Burkitt lymphoma occurs throughout the world, and endemic Burkitt lymphoma occurs in Africa. Immunodeficiency-related Burkitt lymphoma is most often seen in AIDS patients.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Small Non-Cleaved Cell Lymphoma, Burkitt's Type","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9687/3"},{"name":"Legacy Concept Name","value":"Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"9687/3"},{"name":"Maps_To","value":"Burkitt lymphoma"},{"name":"Maps_To","value":"Burkitt lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Burkitt lymphoma, intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Burkitt lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Burkitt lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Burkitt lymphoma, NOS"},{"name":"Maps_To","value":"Burkitt lymphoma, NOS (Includes all variants)"},{"name":"Maps_To","value":"Burkitt lymphoma, unspecified site"},{"name":"Maps_To","value":"Burkitt tumor"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Malignant lymphoma, small noncleaved, Burkitt type"},{"name":"Maps_To","value":"Malignant lymphoma, undifferentiated, Burkitt type"},{"name":"Maps_To","value":"NHL, Burkitt lymphoma (BL)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0006413"}]}}{"C4663":{"preferredName":"Splenic Marginal Zone Lymphoma","code":"C4663","definitions":[{"definition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic Marginal Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Marginal Zone Lymphoma of Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Marginal Zone Lymphoma of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"SLVL","termGroup":"AB","termSource":"NCI"},{"termName":"SMZL","termGroup":"AB","termSource":"NCI"},{"termName":"Splenic Lymphoma with Circulating Villous Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Marginal Zone B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Marginal Zone B-Cell Lymphoma with Villous Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Marginal Zone Lymphoma with Villous Lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9689/3"},{"name":"Legacy Concept Name","value":"Splenic_Marginal_Zone_Lymphoma"},{"name":"Maps_To","value":"9689/3"},{"name":"Maps_To","value":"Splenic marginal zone B-cell lymphoma"},{"name":"Maps_To","value":"Splenic marginal zone lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349632"}]}}{"C3209":{"preferredName":"Follicular Lymphoma","code":"C3209","definitions":[{"definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","type":"DEFINITION","source":"NCI"},{"definition":"A neoplasm of lymphoid cells which has at least a partial follicular pattern.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually indolent (slow-growing). The tumor cells grow as groups to form nodules. There are several subtypes of follicular lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicle Center Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Non-Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9690/3"},{"name":"Legacy Concept Name","value":"Follicular_Lymphoma"},{"name":"Maps_To","value":"9690/3"},{"name":"Maps_To","value":"Follicular lymphoma"},{"name":"Maps_To","value":"Follicular lymphoma, NOS"},{"name":"Maps_To","value":"Follicular lymphoma, unspecified"},{"name":"Maps_To","value":"Follicular lymphoma, unspecified, unspecified site"},{"name":"Maps_To","value":"Malignant lymphoma, centroblasticcentrocytic, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, follicle center, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, follicle center, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, follicular, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, nodular, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, nodular, NOS"},{"name":"Maps_To","value":"Nodular lymphoma"},{"name":"Maps_To","value":"Nodular lymphoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Nodular lymphoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Nodular lymphoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Nodular lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Other types of follicular lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024301"}]}}{"C8968":{"preferredName":"Grade 2 Follicular Lymphoma","code":"C8968","definitions":[{"definition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of B-cell non-Hodgkin lymphoma (cancer of the lymphatic system) in which there are both small and large cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Grade 2 Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 2","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Mixed Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Mixed Lymphocytic-Histiocytic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Follicular Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Follicular Mixed Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Mixed Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9691/3"},{"name":"Legacy Concept Name","value":"Grade_2_Follicular_Lymphoma"},{"name":"Maps_To","value":"9691/3"},{"name":"Maps_To","value":"Follicular lymphoma grade II, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Follicular lymphoma grade II, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Follicular lymphoma, grade 2"},{"name":"Maps_To","value":"Malignant lymphoma, mixed cell type, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, mixed cell type, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, mixed lymphocytic-histiocytic, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, mixed small cleaved and large cell, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079758"}]}}{"C3465":{"preferredName":"Grade 1 Follicular Lymphoma","code":"C3465","definitions":[{"definition":"A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of non-Hodgkin lymphoma marked by enlarged lymph nodes and small cells that have cleaved (u-shaped) nuclei.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Grade 1 Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 1","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Small Cleaved Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Grade I Follicular Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Follicular Small Cleaved Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Poorly Differentiated Nodular Lymphocytic Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9695/3"},{"name":"Legacy Concept Name","value":"Grade_1_Follicular_Lymphoma"},{"name":"Maps_To","value":"9695/3"},{"name":"Maps_To","value":"Follicular lymphoma grade I, unspecified site"},{"name":"Maps_To","value":"Follicular lymphoma, grade 1"},{"name":"Maps_To","value":"Follicular lymphoma, small cleaved cell"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, poorly differentiated, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, small cleaved cell, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079765"}]}}{"C3460":{"preferredName":"Grade 3 Follicular Lymphoma","code":"C3460","definitions":[{"definition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","type":"DEFINITION","source":"NCI"},{"definition":"A type of non-Hodgkin lymphoma marked by large cells and enlarged lymph nodes. Grade 3 follicular lymphoma is less common, and more aggressive than grades 1 or 2 follicular lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Grade 3 Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Lymphoma, Predominantly Large Cell","termGroup":"AQS","termSource":"NCI"},{"termName":"Grade III Follicular Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Follicular Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Histiocytic Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9698/3"},{"name":"Legacy Concept Name","value":"Grade_3_Follicular_Lymphoma"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Follicular lymphoma grade III, unspecified"},{"name":"Maps_To","value":"Follicular lymphoma, grade 3"},{"name":"Maps_To","value":"Malignant lymphoma, histiocytic, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, follicular, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, noncleaved, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, large cleaved cell, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079745"}]}}{"C7192":{"preferredName":"Grade 3b Follicular Lymphoma","code":"C7192","definitions":[{"definition":"A grade 3 follicular lymphoma composed of solid sheets of centroblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 3b Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"FLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Follicular Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 3b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9698/3"},{"name":"Legacy Concept Name","value":"Grade_3b_Follicular_Lymphoma"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Follicular lymphoma, grade 3B"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2853827"}]}}{"C7191":{"preferredName":"Grade 3a Follicular Lymphoma","code":"C7191","definitions":[{"definition":"A grade 3 follicular lymphoma in which centrocytes are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 3a Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 3a","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 3a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9698/3"},{"name":"Legacy Concept Name","value":"Grade_3a_Follicular_Lymphoma"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Follicular lymphoma grade IIIa, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Follicular lymphoma grade IIIa, unspecified site"},{"name":"Maps_To","value":"Follicular lymphoma, grade 3A"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333846"}]}}{"C8994":{"preferredName":"Malignant Lymphoma Centroblastic, Follicular","code":"C8994","definitions":[{"definition":"An antiquated term that refers to a follicular non-Hodgkin lymphoma composed predominantly of large B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma Centroblastic, Follicular","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Centroblastic_Follicular"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Malignant lymphoma, centroblastic, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862984"}]}}{"C7230":{"preferredName":"Primary Cutaneous Marginal Zone Lymphoproliferative Disorder","code":"C7230","definitions":[{"definition":"A B-cell lymphoproliferative disorder that arises from the skin. It was previously known as primary cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue. Two subtypes are recognized: heavy chain class-switched primary cutaneous marginal zone lymphoproliferative disorder and IgM-positive primary cutaneous marginal zone lymphoproliferative disorder. The majority of cases are class-switched and predominantly IgG-positive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Marginal Zone Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"C-MALT","termGroup":"AB","termSource":"NCI"},{"termName":"Cutaneous Immunocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Marginal Zone B Cell Lymphoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Marginal Zone B Cell Lymphoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"PCMZL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous Marginal Zone B Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"SALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cutaneous_Marginal_Zone_B_Cell_Lymphoma_of_Mucosa-Associated_Lymphoid_Tissue"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"SALT lymphoma"},{"name":"Maps_To","value":"Skin-associated lymphoid tissue lymphoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275321"}]}}{"C8863":{"preferredName":"Nodal Marginal Zone Lymphoma","code":"C8863","definitions":[{"definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodal Marginal Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Monocytoid B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodal Marginal Zone B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nodal_Marginal_Zone_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"Monocytoid B-cell lymphoma"},{"name":"Maps_To","value":"Nodal marginal zone lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855139"}]}}{"C4341":{"preferredName":"Marginal Zone Lymphoma","code":"C4341","definitions":[{"definition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of B-cell non-Hodgkin lymphoma that begins forming in certain areas (the marginal zones) of lymph tissue. There are three types based on whether it forms in the spleen, lymph nodes, or other lymphoid tissue that contains a lot of B cells (a type of white blood cell).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Marginal Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Marginal Zone B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"MZBCL","termGroup":"AB","termSource":"NCI"},{"termName":"MZL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9699/3"},{"name":"Legacy Concept Name","value":"Marginal_Zone_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"Marginal zone B-cell lymphoma, NOS"},{"name":"Maps_To","value":"Marginal zone lymphoma"},{"name":"Maps_To","value":"Marginal zone lymphoma involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Marginal zone lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367654"}]}}{"C5264":{"preferredName":"Lung Mucosa-Associated Lymphoid Tissue Lymphoma","code":"C5264","definitions":[{"definition":"An extranodal marginal zone lymphoma that arises from the lung.  It is characterized by the neoplastic proliferation of small B-lymphocytes, monocytoid cells and cells with plasma cell differentiation in the marginal zones of reactive lymphoid follicles.  The neoplastic cells infiltrate the interfollicular areas and the bronchial epithelium forming lymphoepithelial lesions.  The neoplasm is usually discovered as a mass in a chest x-ray in asymptomatic patients.  When symptoms occur, they include cough, dyspnea, hemoptysis, and chest pain.  If the lung lesions are resectable, surgery can result in prolonged remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"BALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"BALToma","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchial MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchus-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Lung MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bronchial_Mucosa-Associated_Lymphoid_Tissue_Lymphoma"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"BALT lymphoma"},{"name":"Maps_To","value":"Bronchial-associated lymphoid tissue lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367652"}]}}{"C3246":{"preferredName":"Mycosis Fungoides","code":"C3246","definitions":[{"definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A type of non-Hodgkin's lymphoma that first appears on the skin and can spread to the lymph nodes or other organs such as the spleen, liver, or lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mycosis Fungoides","termGroup":"PT","termSource":"NCI"},{"termName":"MF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9700/3"},{"name":"Legacy Concept Name","value":"Mycosis_Fungoides"},{"name":"Maps_To","value":"9700/3"},{"name":"Maps_To","value":"Mycosis fungoides"},{"name":"Maps_To","value":"Mycosis fungoides involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mycosis fungoides, unspecified site"},{"name":"Maps_To","value":"Mycosis fungoides, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026948"}]}}{"C35794":{"preferredName":"Pagetoid Reticulosis","code":"C35794","definitions":[{"definition":"A variant of mycosis fungoides, characterized by an exclusively intraepidermal atypical (cerebriform) lymphocytic infiltrate.  Patients present with a localized psoriasiform or hyperkeratotic patch or plaque, usually in the extremities.  Extracutaneous dissemination of the disease has never been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pagetoid Reticulosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pagetoid_Reticulosis"},{"name":"Maps_To","value":"9700/3"},{"name":"Maps_To","value":"Pagetoid reticulosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367970"}]}}{"C3366":{"preferredName":"Sezary Syndrome","code":"C3366","definitions":[{"definition":"A form of cutaneous T-cell lymphoma, a cancerous disease that affects the skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sezary Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Sezary's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Sézary Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9701/3"},{"name":"Legacy Concept Name","value":"Sezary_Syndrome"},{"name":"Maps_To","value":"9701/3"},{"name":"Maps_To","value":"Sezary disease"},{"name":"Maps_To","value":"Sezary disease, unspecified site"},{"name":"Maps_To","value":"Sezary syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036920"}]}}{"C27352":{"preferredName":"Peripheral T-Cell Lymphoma, Large Cell","code":"C27352","synonyms":[{"termName":"Peripheral T-Cell Lymphoma, Large Cell","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peripheral_T-Cell_Lymphoma_Large_Cell"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, large cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1337079"}]}}{"C37194":{"preferredName":"Anaplastic Large Cell Lymphoma, ALK-Negative","code":"C37194","definitions":[{"definition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Large Cell Lymphoma, ALK-Negative","termGroup":"PT","termSource":"NCI"},{"termName":"ALCL, ALK-","termGroup":"AB","termSource":"NCI"},{"termName":"ALK-Negative Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9702/3"},{"name":"Legacy Concept Name","value":"ALK-Negative_Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK negative"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-negative"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332078"}]}}{"C4340":{"preferredName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","code":"C4340","definitions":[{"definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Mature T-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral T-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral T-Cell Lymphoma, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"PTCL, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"PTCL-NOS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Unspecified_Peripheral_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Mature T-cell lymphoma, NOS"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, NOS"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, not classified"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, not classified, unspecified site"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2853959"}]}}{"C3466":{"preferredName":"T-Cell Non-Hodgkin Lymphoma","code":"C3466","definitions":[{"definition":"A disease in which certain cells of the lymph system (called T lymphocytes) become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Hodgkin's T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell and NK-Cell Non-Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell and NK-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T-Cell_Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"T-cell lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079772"}]}}{"C7205":{"preferredName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma, Not Otherwise Specified","code":"C7205","definitions":[{"definition":"A variant of peripheral T-cell lymphoma, not otherwise specified. It is characterized by the presence of neoplastic small lymphocytes infiltrating the lymph nodes in a diffuse and less frequently interfollicular pattern. There is an associated proliferation of epithelioid histiocytes forming confluent clusters.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Lennert Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lennert Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lennert's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lennert's Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioid Cell Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphoepithelioid_Cell_Variant_Peripheral_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Lennert lymphoma"},{"name":"Maps_To","value":"Lymphoepithelioid lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1621719"}]}}{"C7204":{"preferredName":"T-Zone Variant Peripheral T-Cell Lymphoma","code":"C7204","definitions":[{"definition":"An obsolete variant of peripheral T-cell lymphoma, not otherwise specified included in the 2008 WHO classification. These lymphomas usually have a T follicular helper (TFH) cell phenotype and have been moved to the category of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin in the 2017 WHO update. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Zone Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"T-Zone Variant Peripheral T-Cell Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T-Zone_Variant_Peripheral_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"T-zone lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334655"}]}}{"C7528":{"preferredName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","code":"C7528","definitions":[{"definition":"An aggressive (fast-growing) type of T-cell non-Hodgkin lymphoma marked by enlarged lymph nodes and hypergammaglobulinemia (increased antibodies in the blood). Other symptoms may include a skin rash, fever, weight loss, or night sweats.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","termGroup":"PT","termSource":"NCI"},{"termName":"AILD","termGroup":"AB","termSource":"NCI"},{"termName":"AITL","termGroup":"AB","termSource":"NCI"},{"termName":"Angioimmunoblastic Lymphadenopathy","termGroup":"AQS","termSource":"NCI"},{"termName":"Angioimmunoblastic Lymphadenopathy Type T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Angioimmunoblastic Lymphadenopathy with Dysproteinemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Angioimmunoblastic T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic Type (Angioimmunoblastic T-Cell Lymphoma)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9705/3"},{"name":"ICD-O-3_Code","value":"9767/1"},{"name":"Legacy Concept Name","value":"Angioimmunoblastic_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9705/3"},{"name":"Maps_To","value":"9767/1"},{"name":"Maps_To","value":"Angioimmunoblastic lymphadenopathy"},{"name":"Maps_To","value":"Angioimmunoblastic lymphadenopathy (AIC)"},{"name":"Maps_To","value":"Angioimmunoblastic lymphadenopathy (AIL)"},{"name":"Maps_To","value":"Angioimmunoblastic lymphoma"},{"name":"Maps_To","value":"Angioimmunoblastic T-cell lymphoma"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0020981"}]}}{"C6918":{"preferredName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","code":"C6918","definitions":[{"definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"SPTCL","termGroup":"AB","termSource":"NCI"},{"termName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma (Alpha/Beta Type)","termGroup":"SY","termSource":"NCI"},{"termName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma, Alpha/Beta Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9708/3"},{"name":"Legacy Concept Name","value":"Subcutaneous_Panniculitis-Like_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9708/3"},{"name":"Maps_To","value":"Subcutaneous panniculitis-like T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522624"}]}}{"C7162":{"preferredName":"Primary Cutaneous Lymphoma","code":"C7162","synonyms":[{"termName":"Primary Cutaneous Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Skin Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cutaneous_Lymphoma"},{"name":"Maps_To","value":"9709/3"},{"name":"Maps_To","value":"Cutaneous lymphoma, NOS"},{"name":"NCI_META_CUI","value":"CL524081"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3467":{"preferredName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","code":"C3467","definitions":[{"definition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"Any of a group of T-cell non-Hodgkin lymphomas that begins in the skin as an itchy, red rash that can thicken or form a tumor. The most common types are mycosis fungoides and Sezary syndrome.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"CTCL","termGroup":"AB","termSource":"NCI"},{"termName":"Cutaneous T Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous T-Cell Non-Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PCTCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Non-Hodgkin's Lymphoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Non-Hodgkin's Lymphoma of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9709/3"},{"name":"Legacy Concept Name","value":"Cutaneous_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9709/3"},{"name":"Maps_To","value":"Cutaneous T-cell lymphoma, NOS"},{"name":"Maps_To","value":"Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079773"}]}}{"C45366":{"preferredName":"Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder","code":"C45366","definitions":[{"definition":"A primary cutaneous T-cell lymphoproliferative disorder.  It usually presents with a solitary plaque or tumor on the face, neck, or upper trunk.  Morphologically, it is composed of small to medium-sized CD4-positive, CD8-negative, and CD30-negative pleomorphic T-lymphocytes.  A small number of large pleomorphic T-lymphocytes may also be present.  The lymphocytic infiltrate is dermal.  Focal epidermotropism and subcutaneous involvement may be present.  The clinical behavior is almost always indolent and most patients present with localized disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Cutaneous CD4-Positive Small or Medium T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD4-Positive Small/Medium-Sized Pleomorphic T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD4-Positive Small/Medium-Sized T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9709/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_CD4-Positive_Small_Medium-Sized_Pleomorphic_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9709/3"},{"name":"Maps_To","value":"Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder"},{"name":"Maps_To","value":"Primary cutaneous CD4-positive small/medium T-cell lymphoma"},{"name":"NCI_META_CUI","value":"CL524855"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C37193":{"preferredName":"Anaplastic Large Cell Lymphoma, ALK-Positive","code":"C37193","definitions":[{"definition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm. It is characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein. Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Large Cell Lymphoma, ALK-Positive","termGroup":"PT","termSource":"NCI"},{"termName":"ALCL, ALK+","termGroup":"AB","termSource":"NCI"},{"termName":"ALK-Positive Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"ALKoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9714/3"},{"name":"Legacy Concept Name","value":"ALK-Positive_Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9714/3"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK positive"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332079"}]}}{"C3720":{"preferredName":"Anaplastic Large Cell Lymphoma","code":"C3720","definitions":[{"definition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of non-Hodgkin lymphoma that is usually of the T-cell type. The cancer cells express a marker called CD30 or Ki-1 on the surface, and may appear in the lymph nodes, skin, bones, soft tissues, lungs, or liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anaplastic Large Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"ALCL","termGroup":"AB","termSource":"NCI"},{"termName":"Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type","termGroup":"AQS","termSource":"NCI"},{"termName":"CD30 Positive Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ki-1 Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Ki-1+ ALCL","termGroup":"AQS","termSource":"NCI"},{"termName":"Ki-1+ Anaplastic Large Cell Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9714/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9714/3"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, CD30+"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, NOS"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, T cell and Null cell type"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, T-cell and Null-cell type"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Large cell (Ki-1+) lymphoma"},{"name":"Maps_To","value":"NHL, anaplastic large cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206180"}]}}{"C8459":{"preferredName":"Hepatosplenic T-Cell Lymphoma","code":"C8459","definitions":[{"definition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatosplenic T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatosplenic Gamma/Delta T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9716/3"},{"name":"Legacy Concept Name","value":"Hepatosplenic_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9716/3"},{"name":"Maps_To","value":"Hepatosplenic gamma-delta cell lymphoma"},{"name":"Maps_To","value":"Hepatosplenic T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522627"}]}}{"C150495":{"preferredName":"Intestinal T-Cell Lymphoma","code":"C150495","definitions":[{"definition":"A group of mature T-cell and NK-cell non-Hodgkin lymphomas that includes enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, and intestinal T-cell lymphoma, not otherwise specified. Most of these lymphomas arise from the small intestine and a minority from the large intestine or stomach.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intestinal T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9717/3"},{"name":"Maps_To","value":"Intestinal T-cell lymphoma"},{"name":"NCI_META_CUI","value":"CL552301"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4737":{"preferredName":"Enteropathy-Associated T-Cell Lymphoma","code":"C4737","definitions":[{"definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enteropathy-Associated T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"EATL","termGroup":"AB","termSource":"NCI"},{"termName":"Enteropathy Associated T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Enteropathy-Type T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9717/3"},{"name":"Legacy Concept Name","value":"Enteropathy-Type_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9717/3"},{"name":"Maps_To","value":"Enteropathy associated T-cell lymphoma"},{"name":"Maps_To","value":"Enteropathy type intestinal T-cell lymphoma"},{"name":"Maps_To","value":"Intestinal T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0456889"}]}}{"C3721":{"preferredName":"Lymphomatoid Papulosis","code":"C3721","definitions":[{"definition":"A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphomatoid Papulosis","termGroup":"PT","termSource":"NCI"},{"termName":"LyP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9718/1"},{"name":"Legacy Concept Name","value":"Lymphomatoid_Papulosis"},{"name":"Maps_To","value":"9718/3"},{"name":"Maps_To","value":"Lymphomatoid Papulosis"},{"name":"Maps_To","value":"Lymphomatoid papulosis"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206182"}]}}{"C6860":{"preferredName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","code":"C6860","definitions":[{"definition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"C-ALCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Anaplastic Large Cell Lymphoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Anaplastic Large Cell Lymphoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD30 Positive Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD30+ ALCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9718/3"},{"name":"Maps_To","value":"Primary cutaneous anaplastic large cell lymphoma"},{"name":"Maps_To","value":"Primary cutaneous CD30+ large T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301362"}]}}{"C7195":{"preferredName":"Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","code":"C7195","definitions":[{"definition":"A spectrum of lymphoproliferative disorders characterized by CD30 (Ki-1)-positive cutaneous T-cell infiltrates. The two ends of the spectrum include lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9718/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_CD30-Positive_T-Cell_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9718/3"},{"name":"Maps_To","value":"Primary cutaneous CD30 positive T-cell lymphoproliferative disorder"},{"name":"Maps_To","value":"Primary cutaneous CD30+ T-cell lymphoproliferative disorder"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1371159"}]}}{"C68692":{"preferredName":"Childhood Nasal Type Extranodal NK/T-Cell Lymphoma","code":"C68692","definitions":[{"definition":"A nasal type extranodal NK/T-cell lymphoma occurring in childhood.","type":"DEFINITION","source":"NCI"},{"definition":"A nasal type of non-anaplastic peripheral NK/T cell lymphoma occurring during childhood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood Nasal Type Extranodal NK/T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Childhood_Nasal_Type_Extranodal_NK_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9719/3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879280"}]}}{"C4684":{"preferredName":"Nasal Type Extranodal NK/T-Cell Lymphoma","code":"C4684","definitions":[{"definition":"A malignant lymphoid neoplasm composed of EBV-positive NK/T cells arranged in an angiocentric pattern.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nasal Type Extranodal NK/T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiocentric T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extranodal NK/T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extranodal NK/T-Cell Lymphoma, Nasal Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9719/3"},{"name":"Legacy Concept Name","value":"Nasal_Type_Extranodal_NK_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9719/3"},{"name":"Maps_To","value":"Angiocentric T-cell lymphoma"},{"name":"Maps_To","value":"Extranodal NK/T-cell lymphoma, nasal type"},{"name":"Maps_To","value":"Malignant reticulosis, NOS"},{"name":"Maps_To","value":"NK/T-cell lymphoma, nasal and nasal type"},{"name":"Maps_To","value":"NK/T-cell lymphoma, nasal and nasal-type"},{"name":"Maps_To","value":"T/NK-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0392788"}]}}{"C80374":{"preferredName":"Systemic EBV-Positive T-Cell Lymphoma of Childhood","code":"C80374","definitions":[{"definition":"An aggressive and life-threatening, EBV-positive T-cell lymphoma affecting children.  It is more prevalent in Taiwan and Japan.  Clinically, it presents with acute onset of fever and generalized malaise, followed by hepatosplenomegaly and liver failure.  Morphologically it is characterized by the presence of infiltrating T-lymphocytes which are usually small and erythrophagocytosis.  Most patients have a fulminant clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive, life-threatening, EBV-positive T-cell lymphoproliferative disorder affecting children.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Systemic EBV-Positive T-Cell Lymphoma of Childhood","termGroup":"PT","termSource":"NCI"},{"termName":"Systemic EBV-Positive T-Cell Lymphoproliferative Disorder of Childhood","termGroup":"AQS","termSource":"NCI"},{"termName":"Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9724/3"},{"name":"Legacy Concept Name","value":"Systemic_EBV-Positive_T-Cell_Lymphoproliferative_Disease_of_Childhood"},{"name":"Maps_To","value":"9724/3"},{"name":"Maps_To","value":"Systemic EBV positive T-cell lymphoproliferative disease of childhood"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699747"}]}}{"C45327":{"preferredName":"Hydroa Vacciniforme Lymphoproliferative Disorder","code":"C45327","definitions":[{"definition":"A rare, EBV-positive cutaneous T-cell lymphoproliferative disorder, composed of CD8 positive cytotoxic T-lymphocytes.  It affects children, almost exclusively in Latin America and Asia. Patients present with papulovesicular skin lesions, clinically resembling hydroa vacciniforme, in areas of sun-exposed skin.","type":"DEFINITION","source":"NCI"},{"definition":"In contrast to hydroa vacciniforme (HV), HV-like lymphoma is not induced by sun exposure and the lesions can occur in both sun-exposed and covered body areas. It affects children, almost exclusively in Latin America and Asia.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hydroa Vacciniforme Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"HV LPD","termGroup":"AB","termSource":"NCI"},{"termName":"HV-Like LPD","termGroup":"SY","termSource":"NCI"},{"termName":"HV-LPD","termGroup":"AB","termSource":"NCI"},{"termName":"Hydroa Vacciniforme-Like Cutaneous T-Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Hydroa Vacciniforme-Like Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Hydroa Vacciniforme-Like Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9725/3"},{"name":"Legacy Concept Name","value":"Hydroa_Vacciniforme-Like_Cutaneous_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9725/3"},{"name":"Maps_To","value":"Hydroa vacciniforme-like lymphoma"},{"name":"Maps_To","value":"Hydroa vacciniforme-like lymphoproliferative disorder"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708397"}]}}{"C45340":{"preferredName":"Primary Cutaneous Gamma-Delta T-Cell Lymphoma","code":"C45340","definitions":[{"definition":"An aggressive cutaneous lymphoma of mature, activated gamma/delta T-lymphocytes.  It usually presents with disseminated plaques and nodules.  Involvement of mucosal sites is frequent.  However, involvement of lymph nodes, spleen, or bone marrow is uncommon.  Morphologically, there are three patterns of cutaneous involvement: epidermotropic, dermal, and subcutaneous.  Often, more than one pattern may co-exist in a single biopsy specimen, or may be present in different biopsy specimens from the same patient.  The lymphocytic infiltrate is composed of medium- to large-sized lymphocytes expressing CD56.  Most cases lack both CD4 and CD8, although CD8 may be present in some cases.  This group of lymphomas includes cases previously known as subcutaneous panniculitis-like T-cell lymphoma with a gamma/delta phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Gamma-Delta T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Gamma/Delta T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Gamma-Delta T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9726/3"},{"name":"Legacy Concept Name","value":"Cutaneous_Gamma_Delta_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9726/3"},{"name":"Maps_To","value":"Primary cutaneous gamma-delta T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707547"}]}}{"C27821":{"preferredName":"Malignant Lymphoma, Convoluted","code":"C27821","synonyms":[{"termName":"Malignant Lymphoma, Convoluted","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Convoluted"},{"name":"Maps_To","value":"9727/3"},{"name":"Maps_To","value":"Malignant lymphoma, convoluted cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518186"}]}}{"C7203":{"preferredName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","code":"C7203","definitions":[{"definition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Agranular CD4+ CD56+ Hematodermic Neoplasm/Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Agranular CD4+ Natural Killer Cell Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Blastic Natural Killer Leukemia/Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Blastic NK Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Blastic NK-Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"BPDCN","termGroup":"AB","termSource":"NCI"},{"termName":"CD4+/CD56+ Hematodermic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Monomorphic NK-Cell Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9727/3"},{"name":"Legacy Concept Name","value":"Blastic_NK-Cell_Lymphoma"},{"name":"Maps_To","value":"9727/3"},{"name":"Maps_To","value":"Blastic NK cell lymphoma"},{"name":"Maps_To","value":"Blastic plasmacytoid dendritic cell neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301363"}]}}{"C8868":{"preferredName":"B Lymphoblastic Lymphoma","code":"C8868","definitions":[{"definition":"An uncommon type of lymphoma.  It constitutes approximately 10% of cases of lymphoblastic lymphoma.  Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age.  The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes.  It has a high remission rate with a median survival of approximately 60 months.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor B-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9728/3"},{"name":"Legacy Concept Name","value":"Precursor_B_Lymphoblastic_Lymphoma"},{"name":"Maps_To","value":"9728/3"},{"name":"Maps_To","value":"Precursor B-cell lymphoblastic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292757"}]}}{"C6919":{"preferredName":"T Lymphoblastic Lymphoma","code":"C6919","definitions":[{"definition":"A type of non-Hodgkin lymphoma in which too many T-cell lymphoblasts (immature white blood cells) are found in the lymph nodes and spleen. It is most common in young men.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most frequent type of lymphoblastic lymphoma.  It comprises approximately 85-90% of cases.  It is more frequently seen in adolescent males.  It frequently presents with a mass lesion in the mediastinum.  Pleural effusions are common.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T Lymphoblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Precursor T Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Cell Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9729/3"},{"name":"Legacy Concept Name","value":"Precursor_T_Lymphoblastic_Lymphoma"},{"name":"Maps_To","value":"9729/3"},{"name":"Maps_To","value":"Precursor T-cell lymphoblastic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292758"}]}}{"C6932":{"preferredName":"Solitary Plasmacytoma","code":"C6932","definitions":[{"definition":"A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Plasmacytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solitary_Plasmacytoma"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Solitary myeloma"},{"name":"Maps_To","value":"Solitary plasmacytoma"},{"name":"NCI_META_CUI","value":"CL018710"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7812":{"preferredName":"Solitary Plasmacytoma of Bone","code":"C7812","definitions":[{"definition":"A localized malignant neoplasm that arises in the bone. It is composed of clonal (malignant) plasma cells forming a tumor mass. The most commonly affected bones are the vertebrae, ribs, skull, pelvis, and femur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Plasmacytoma of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Solitary Plasmacytoma","termGroup":"SY","termSource":"NCI"},{"termName":"SPB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solitary_Osseous_Plasmacytoma"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Plasmacytoma of bone"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0272256"}]}}{"C9349":{"preferredName":"Plasmacytoma","code":"C9349","definitions":[{"definition":"A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that begins in plasma cells (white blood cells that produce antibodies). A plasmacytoma may turn into multiple myeloma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plasmacytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9731/3"},{"name":"Legacy Concept Name","value":"Plasmacytoma"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Plasmacytoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0032131"}]}}{"C3242":{"preferredName":"Multiple Myeloma","code":"C3242","definitions":[{"definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the bone marrow composed of plasma cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that begins in plasma cells (white blood cells that produce antibodies).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"Multiple Myeloma/Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Cell Myeloma/Multiple Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9732/3"},{"name":"Legacy Concept Name","value":"Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"9732/3"},{"name":"Maps_To","value":"Multiple Myeloma"},{"name":"Maps_To","value":"Multiple myeloma"},{"name":"Maps_To","value":"Multiple myeloma and immunoproliferative neoplasms"},{"name":"Maps_To","value":"Multiple myeloma not having achieved remission"},{"name":"Maps_To","value":"Multiple myeloma without mention of having achieved remission"},{"name":"Maps_To","value":"Myeloma, NOS"},{"name":"Maps_To","value":"Myelomatosis"},{"name":"Maps_To","value":"Plasma cell myeloma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026764"}]}}{"C3180":{"preferredName":"Plasma Cell Leukemia","code":"C3180","definitions":[{"definition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plasma Cell Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Plasmacytic","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9733/3"},{"name":"Legacy Concept Name","value":"Plasma_Cell_Leukemia"},{"name":"Maps_To","value":"9733/3"},{"name":"Maps_To","value":"Plasma cell leukemia"},{"name":"Maps_To","value":"Plasmacytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023484"}]}}{"C4002":{"preferredName":"Extraosseous Plasmacytoma","code":"C4002","definitions":[{"definition":"A localized malignant neoplasm arising in an extraosseous site. It is composed of clonal (malignant) plasma cells forming a tumor mass. It most frequently involves the oropharynx, nasopharynx, sinuses, and larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraosseous Plasmacytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Extramedullary Plasmacytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9734/3"},{"name":"Legacy Concept Name","value":"Extramedullary_Plasmacytoma"},{"name":"Maps_To","value":"9734/3"},{"name":"Maps_To","value":"Extraosseous plasmacytoma"},{"name":"Maps_To","value":"Plasmacytoma, extramedullary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278619"}]}}{"C7224":{"preferredName":"Plasmablastic Lymphoma","code":"C7224","definitions":[{"definition":"An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells.  Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plasmablastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"PBL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9684/3"},{"name":"ICD-O-3_Code","value":"9735/3"},{"name":"Legacy Concept Name","value":"Plasmablastic_Lymphoma"},{"name":"Maps_To","value":"9735/3"},{"name":"Maps_To","value":"Plasmablastic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472614"}]}}{"C7225":{"preferredName":"ALK-Positive Large B-Cell Lymphoma","code":"C7225","definitions":[{"definition":"A usually aggressive large B-cell lymphoma characterized by the presence of monomorphic immunoblast-like neoplastic B-lymphocytes in a sinusoidal growth pattern.  The neoplastic B-lymphocytes express the ALK kinase but they lack the 2;5 translocation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK-Positive Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"ALK-DLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Diffuse Large B-Cell Lymphoma with Expression of Full-Length ALK","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Large B-Cell Lymphoma with Expression of Full-Length Anaplastic Lymphoma Kinase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9737/3"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma_with_Expression_of_Full-Length_ALK"},{"name":"Maps_To","value":"9737/3"},{"name":"Maps_To","value":"ALK positive large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333294"}]}}{"C27856":{"preferredName":"Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease","code":"C27856","definitions":[{"definition":"An aggressive diffuse large B-cell lymphoma occurring in patients with HHV8-positive multicentric Castleman disease. It is characterized by the presence of human herpesvirus 8-infected large B-lymphocytes that resemble plasmablasts. It is usually seen in patients with HIV infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease","termGroup":"AQ","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma Arising in HHV 8-Associated Multicentric Castleman Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma Arising in HHV8-Associated Multicentric Castleman Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma Arising in Human Herpes Virus 8-Associated Multicentric Castleman Disease","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9738/3"},{"name":"Legacy Concept Name","value":"Kaposi_s_Sarcoma-Associated_Human_Herpes_Virus_8_Positive_Extracavity_Lymphoma"},{"name":"Maps_To","value":"9738/3"},{"name":"Maps_To","value":"Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334319"}]}}{"C7138":{"preferredName":"Solitary Mastocytoma of the Skin","code":"C7138","definitions":[{"definition":"A benign, solitary, well-demarcated, yellow-brown or reddish-brown mast cell neoplasm that arises from the skin, most commonly in infants and children. The lesions are typically 2-5 cm in size, are characterized by infiltration of the dermis by neoplastic mast cells, and occasionally resolve spontaneously.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Mastocytoma of the Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Solitary Mastocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Solitary Mastocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Solitary Mastocytoma of Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Solitary_Mastocytoma_of_the_Skin"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Solitary mastocytoma of skin"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0343115"}]}}{"C7137":{"preferredName":"Cutaneous Mastocytosis","code":"C7137","definitions":[{"definition":"A form of mastocytosis characterized by mast cell infiltration of the skin.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cutaneous Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"CM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Cutaneous_Mastocytosis"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Cutaneous mastocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1136033"}]}}{"C9303":{"preferredName":"Mastocytoma","code":"C9303","definitions":[{"definition":"A growth or lump of mast cells (a type of white blood cell). Mast cell tumors can involve the skin, subcutaneous tissue, and muscle tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A localized tumor composed of sheets of mast cells without atypia. It includes the cutaneous mastocytoma which involves the dermis and subcutaneous tissue, and the extracutaneous mastocytoma. Most cases of extracutaneous mastocytoma have been reported in the lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mastocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Mastocytoma"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Mastocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024897"}]}}{"C7136":{"preferredName":"Extracutaneous Mastocytoma","code":"C7136","definitions":[{"definition":"A localized mast cell neoplasm involving extracutaneous sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extracutaneous Mastocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Extracutaneous_Mastocytoma"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Extracutaneous mastocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0272202"}]}}{"C3218":{"preferredName":"Diffuse Cutaneous Mastocytosis","code":"C3218","definitions":[{"definition":"A variant of cutaneous mastocytosis which is seen almost exclusively in children. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Cutaneous Mastocytosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Diffuse_Cutaneous_Mastocytosis"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Diffuse cutaneous mastocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024901"}]}}{"C3433":{"preferredName":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","code":"C3433","definitions":[{"definition":"The most frequent form of cutaneous mastocytosis.  In children, the lesions tend to be papular, and are characterized by aggregates of elongated or spindle-shaped mast cells which fill the papillary dermis and extend into the reticular dermis.  In adults, the lesions tend to have fewer mast cells compared to those in children.  The lesions are located most commonly on the trunk, but they can be seen on the extremities, head and neck. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"UP/MPCM","termGroup":"AB","termSource":"NCI"},{"termName":"Urticaria Pigmentosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Urticaria_Pigmentosa_Maculopapular_Cutaneous_Mastocytosis"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Urticaria pigmentosa"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0042111"}]}}{"C9348":{"preferredName":"Mast Cell Sarcoma","code":"C9348","definitions":[{"definition":"A rare malignant neoplasm characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"MCS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9740/3"},{"name":"Legacy Concept Name","value":"Mast_Cell_Sarcoma"},{"name":"Maps_To","value":"9740/3"},{"name":"Maps_To","value":"Malignant mast cell tumor"},{"name":"Maps_To","value":"Malignant mastocytoma"},{"name":"Maps_To","value":"Mast cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036221"}]}}{"C9286":{"preferredName":"Indolent Systemic Mastocytosis","code":"C9286","definitions":[{"definition":"An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indolent Systemic Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"ISM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9741/1"},{"name":"Legacy Concept Name","value":"Indolent_Systemic_Mastocytosis"},{"name":"Maps_To","value":"9741/1"},{"name":"Maps_To","value":"Indolent systemic mastocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0272203"}]}}{"C9284":{"preferredName":"Systemic Mastocytosis with an Associated Myeloid Neoplasm","code":"C9284","definitions":[{"definition":"A disorder characterized by systemic infiltration of internal organs by aggregates of clonal mast cells and the presence of a clonal non-mast cell myeloid neoplasm (e.g., myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Systemic Mastocytosis with an Associated Myeloid Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"SM-AHN","termGroup":"AB","termSource":"NCI"},{"termName":"SM-AHNMD","termGroup":"AB","termSource":"NCI"},{"termName":"SM-AMN","termGroup":"AB","termSource":"NCI"},{"termName":"Systemic Mastocytosis with an Associated Hematologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Systemic Mastocytosis with an Associated Hematological Neoplasm (SM-AHN)","termGroup":"SY","termSource":"NCI"},{"termName":"Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9741/3"},{"name":"Legacy Concept Name","value":"Systemic_Mastocytosis_with_Associated_Clonal_Hematological_non-Mast-Cell_Lineage_Disease"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Systemic mastocytosis with AHNMD"},{"name":"Maps_To","value":"Systemic mastocytosis with associated hematological clonal non-mast cell disorder"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301365"}]}}{"C9235":{"preferredName":"Systemic Mastocytosis","code":"C9235","definitions":[{"definition":"A rare disease in which too many mast cells (a type of immune system cell) are found in the skin, bones, joints, lymph nodes, liver, spleen, and gastrointestinal tract. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Systemic Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Systemic Tissue Mast Cell Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Primary_Systemic_Mastocytosis"},{"name":"Legacy Concept Name","value":"Systemic_Mastocytosis"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Systemic tissue mast cell disease"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221013"}]}}{"C9285":{"preferredName":"Aggressive Systemic Mastocytosis","code":"C9285","definitions":[{"definition":"An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggressive Systemic Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Advanced Systemic Mastocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"ASM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9741/3"},{"name":"Legacy Concept Name","value":"Aggressive_Systemic_Mastocytosis"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Aggressive systemic mastocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1112486"}]}}{"C8991":{"preferredName":"Malignant Mastocytosis","code":"C8991","definitions":[{"definition":"A group of malignant mast cell disorders including aggressive systemic mastocytosis, mast cell leukemia, mast cell sarcoma, and systemic mastocytosis with an associated myeloid neoplasm. Individuals with advanced systemic mastocytosis have a reduced life expectancy, with median survival measured in months to years.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of mast cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Mastocytosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9741/3"},{"name":"Legacy Concept Name","value":"Malignant_Mastocytosis"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Malignant mast cell tumors"},{"name":"Maps_To","value":"Malignant mastocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1541840"}]}}{"C3169":{"preferredName":"Mast Cell Leukemia","code":"C3169","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from mast cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast Cell Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9742/3"},{"name":"Legacy Concept Name","value":"Mast_Cell_Leukemia"},{"name":"Maps_To","value":"9742/3"},{"name":"Maps_To","value":"Mast cell leukaemia"},{"name":"Maps_To","value":"Mast cell leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023461"}]}}{"C7202":{"preferredName":"Malignant Histiocytosis","code":"C7202","definitions":[{"definition":"An antiquated term referring to cases of systemic non-Hodgkin lymphomas which are composed of large, atypical neoplastic lymphoid cells and cases of hemophagocytic syndromes. In the past, cases of anaplastic large cells lymphoma were called malignant histiocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histiocytic Medullary Reticulosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Histiocytosis","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9750/3"},{"name":"Legacy Concept Name","value":"Malignant_Histiocytosis"},{"name":"Maps_To","value":"9750/3"},{"name":"Maps_To","value":"Histiocytic medullary reticulosis"},{"name":"Maps_To","value":"Malignant histiocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019623"}]}}{"C3107":{"preferredName":"Langerhans Cell Histiocytosis","code":"C3107","definitions":[{"definition":"A group of rare disorders in which too many Langerhans cells (a type of white blood cell) grow in certain tissues and organs including the bones, skin, and lungs, and damage them. Langerhans cell histiocytosis may also affect the pituitary gland (which makes hormones that control other glands and many body functions, especially growth). Langerhans cell histiocytosis is most common in children and young adults.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"Tissue infiltration by Langerhans cells (histiocytes). When infiltration involves the pituitary stalk or gland, presentation includes diabetes insipidus, which is sometimes accompanied by other pituitary dysfunction.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Histiocytosis X","termGroup":"AQS","termSource":"NCI"},{"termName":"Langerhans Cell Granulomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"LCH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9751/1"},{"name":"ICD-O-3_Code","value":"9751/3"},{"name":"ICD-O-3_Code","value":"9752/1"},{"name":"ICD-O-3_Code","value":"9753/1"},{"name":"ICD-O-3_Code","value":"9754/3"},{"name":"Legacy Concept Name","value":"Langerhans_Cell_Histiocytosis"},{"name":"Maps_To","value":"9751/1"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Histiocytosis X, NOS"},{"name":"Maps_To","value":"Langerhans cell granulomatosis"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019621"}]}}{"C3016":{"preferredName":"Eosinophilic Granuloma","code":"C3016","definitions":[{"definition":"A clinical variant of Langerhans cell histiocytosis characterized by unifocal involvement of a bone (most often), skin, or lung.  Patients are usually older children or adults usually presenting with a lytic bone lesion.  The etiology is unknown.  Morphologically, eosinophilic granuloma is characterized by the presence of Langerhans cells in a characteristic milieu which includes histiocytes, eosinophils, neutrophils, and small, mature lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A clinical variant of Langerhans cell histiocytosis that is characterized by unifocal involvement of a bone (most often), skin, or lung. Patients are usually older children or adults, often presenting with a lytic bone lesion of an unknown etiology. Morphologically, eosinophilic granuloma is characterized by the presence of Langerhans cells in a characteristic milieu that includes histiocytes, eosinophils, neutrophils, and small, mature lymphocytes.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Eosinophilic Granuloma","termGroup":"PT","termSource":"NCI"},{"termName":"Eosinophilic Xanthomatous Granuloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9752/1"},{"name":"Legacy Concept Name","value":"Eosinophilic_Granuloma"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Eosinophilic granuloma"},{"name":"Maps_To","value":"Langerhans cell granulomatosis, unifocal"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0014461"}]}}{"C3160":{"preferredName":"Letterer-Siwe Disease","code":"C3160","definitions":[{"definition":"A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems including the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.","type":"DEFINITION","source":"NCI"},{"definition":"A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems that may include the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Letterer-Siwe Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9754/3"},{"name":"Legacy Concept Name","value":"Letterer-Siwe_Disease"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Letterer-Siwe disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023381"}]}}{"C6920":{"preferredName":"Hand-Schuller-Christian Disease","code":"C6920","definitions":[{"definition":"A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hand-Schuller-Christian Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9753/1"},{"name":"Legacy Concept Name","value":"Hand-Schuller-Christian_Disease"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Hand-Schuller-Christian disease"},{"name":"Maps_To","value":"Multifocal and unisystemic Langerhans-cell histiocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0268205"}]}}{"C27349":{"preferredName":"Histiocytic Sarcoma","code":"C27349","definitions":[{"definition":"A malignant neoplasm composed of cells resembling histiocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histiocytic Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9755/3"},{"name":"Legacy Concept Name","value":"Histiocytic_Sarcoma"},{"name":"Maps_To","value":"9755/3"},{"name":"Maps_To","value":"Histiocytic sarcoma"},{"name":"Maps_To","value":"Malignant histiocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334663"}]}}{"C6921":{"preferredName":"Langerhans Cell Sarcoma","code":"C6921","definitions":[{"definition":"A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features.  It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9756/3"},{"name":"Legacy Concept Name","value":"Langerhans_Cell_Sarcoma"},{"name":"Maps_To","value":"9756/3"},{"name":"Maps_To","value":"Langerhans cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260327"}]}}{"C9282":{"preferredName":"Interdigitating Dendritic Cell Sarcoma","code":"C9282","definitions":[{"definition":"A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells.  The clinical course is generally aggressive. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interdigitating Dendritic Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Interdigitating Cell Sarcoma/Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Interdigitating Dendritic Cell Sarcoma/Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9757/1"},{"name":"ICD-O-3_Code","value":"9757/3"},{"name":"Legacy Concept Name","value":"Interdigitating_Dendritic_Cell_Sarcoma"},{"name":"Maps_To","value":"9757/3"},{"name":"Maps_To","value":"Interdigitating cell sarcoma"},{"name":"Maps_To","value":"Interdigitating dendritic cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260326"}]}}{"C81767":{"preferredName":"Indeterminate Dendritic Cell Histiocytosis","code":"C81767","definitions":[{"definition":"A very rare dendritic cell tumor composed of spindle to ovoid cells with a phenotype that is similar to the Langerhans cells.  Patients usually present with cutaneous papules, nodules, and plaques.  Systemic symptoms are usually absent.  The clinical course is variable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indeterminate Dendritic Cell Histiocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"IDCT","termGroup":"AB","termSource":"NCI"},{"termName":"Indeterminate Cell Histiocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Indeterminate Dendritic Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9757/3"},{"name":"Legacy Concept Name","value":"Indeterminate_Dendritic_Cell_Tumor"},{"name":"Maps_To","value":"9757/3"},{"name":"Maps_To","value":"Indeterminate dendritic cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825741"}]}}{"C9281":{"preferredName":"Follicular Dendritic Cell Sarcoma","code":"C9281","definitions":[{"definition":"A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Treatment options include complete surgical removal of the tumor with or without adjuvant chemotherapy or radiotherapy. Recurrences have been reported in up to half of the cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follicular Dendritic Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"FDCS","termGroup":"AB","termSource":"NCI"},{"termName":"Follicular Dendritic Cell Sarcoma/Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9758/1"},{"name":"ICD-O-3_Code","value":"9758/3"},{"name":"Legacy Concept Name","value":"Follicular_Dendritic_Cell_Sarcoma"},{"name":"Maps_To","value":"9758/3"},{"name":"Maps_To","value":"Follicular dendritic cell sarcoma"},{"name":"Maps_To","value":"Follicular dendritic cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260325"}]}}{"C81758":{"preferredName":"Fibroblastic Reticular Cell Sarcoma","code":"C81758","definitions":[{"definition":"A very rare dendritic cell sarcoma affecting the lymph nodes, spleen, and soft tissues. Morphologically it is similar to the interdigitating dendritic cell sarcoma or follicular dendritic cell sarcoma. The tumor cells are positive for cytokeratin and CD68.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroblastic Reticular Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblastic Dendritic Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblastic Reticular Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9759/3"},{"name":"Legacy Concept Name","value":"Fibroblastic_Reticular_Cell_Tumor"},{"name":"Maps_To","value":"9759/3"},{"name":"Maps_To","value":"Fibroblastic reticular cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825739"}]}}{"C3132":{"preferredName":"Alpha Heavy Chain Disease","code":"C3132","definitions":[{"definition":"A clonal disorder, also known as immunoproliferative small intestinal disease or Mediterranean lymphoma, characterized by the secretion of a defective alpha heavy chain. It predominantly affects young people in the Mediterranean region. It involves the small intestine, and patients usually present with malabsorption syndrome, abdominal pain, weight loss, and fever. There is extensive villous atrophy of the small intestinal mucosa, which is heavily infiltrated by small lymphocytes and plasma cells. The small intestinal morphologic changes are consistent with a mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha Heavy Chain Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoproliferative Small Intestinal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"IPSID","termGroup":"AB","termSource":"NCI"},{"termName":"Mediterranean Abdominal Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mediterranean Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9760/3"},{"name":"ICD-O-3_Code","value":"9764/3"},{"name":"Legacy Concept Name","value":"Alpha_Heavy_Chain_Disease"},{"name":"Maps_To","value":"9760/3"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"9764/3"},{"name":"Maps_To","value":"Alpha heavy chain disease"},{"name":"Maps_To","value":"Immunoproliferative disease, NOS"},{"name":"Maps_To","value":"Immunoproliferative small intestinal disease"},{"name":"Maps_To","value":"Mediterranean lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0021071"}]}}{"C80307":{"preferredName":"Waldenstrom Macroglobulinemia","code":"C80307","definitions":[{"definition":"An indolent (slow-growing) type of non-Hodgkin lymphoma marked by abnormal levels of IgM antibodies in the blood and an enlarged liver, spleen, or lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Waldenstrom Macroglobulinemia","termGroup":"PT","termSource":"NCI"},{"termName":"Waldenstrom's Macroglobulinemia","termGroup":"SY","termSource":"NCI"},{"termName":"Waldenström Macroglobulinemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Waldenstrom_Macroglobulinemia"},{"name":"Maps_To","value":"9761/3"},{"name":"Maps_To","value":"Waldenstrom macroglobulinemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024419"}]}}{"C3892":{"preferredName":"Mu Heavy Chain Disease","code":"C3892","definitions":[{"definition":"A clonal disorder characterized by the secretion of a mu heavy chain that lacks a variable region. Most patients present with slowly progressive chronic lymphocytic leukemia (CLL). In contrast to most cases of CLL, Mu heavy chain disease is associated with hepatosplenomegaly and absence of lymphadenopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mu Heavy Chain Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mu_Heavy_Chain_Disease"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"Mu heavy chain disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0242310"}]}}{"C3083":{"preferredName":"Gamma Heavy Chain Disease","code":"C3083","definitions":[{"definition":"A clonal disorder characterized by the secretion of a truncated gamma chain.  In most cases, it is associated with morphologic changes also seen in lymphoplasmacytic lymphomas, but the clinical course is typically more aggressive than in lymphoplasmacytic lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma Heavy Chain Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Franklin Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Franklin's Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gamma_Heavy_Chain_Disease"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"Franklin disease"},{"name":"Maps_To","value":"Gamma heavy chain disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018854"}]}}{"C3082":{"preferredName":"Heavy Chain Disease","code":"C3082","definitions":[{"definition":"A group of rare clonal disorders of immunoglobulin synthesis associated with B-cell proliferative disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heavy Chain Disease","termGroup":"PT","termSource":"NCI"},{"termName":"HCD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9762/3"},{"name":"Legacy Concept Name","value":"Heavy_Chain_Disease"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"Heavy chain disease, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018852"}]}}{"C3996":{"preferredName":"Monoclonal Gammopathy of Undetermined Significance","code":"C3996","definitions":[{"definition":"A benign condition in which there is a higher-than-normal level of a protein called M protein in the blood. Patients with MGUS are at an increased risk of developing cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Gammopathy of Undetermined Significance","termGroup":"PT","termSource":"NCI"},{"termName":"MGUS","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Gammopathy of Undetermined Significance (MGUS)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9765/1"},{"name":"Legacy Concept Name","value":"Monoclonal_Gammopathy_of_Undetermined_Significance"},{"name":"Maps_To","value":"9765/1"},{"name":"Maps_To","value":"MGUS"},{"name":"Maps_To","value":"Monoclonal gammopathy of undetermined significance"},{"name":"Maps_To","value":"Monoclonal gammopathy of undetermined significance, NOS"},{"name":"Maps_To","value":"Monoclonal gammopathy, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026470"}]}}{"C40970":{"preferredName":"Angiocentric Immunoproliferative Lesion","code":"C40970","definitions":[{"definition":"A neoplastic lymphoproliferative process characterized by an angiocentric arrangement of tumor cells and associated angiodestruction. It includes lymphomatoid granulomatosis which is a lymphoproliferative lesion derived from mature B-lymphocytes and cases of extranodal NK/T-cell lymphomas of nasal type.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiocentric Immunoproliferative Lesion","termGroup":"PT","termSource":"NCI"},{"termName":"AIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9766/1"},{"name":"Legacy Concept Name","value":"Angiocentric_Immunoproliferative_Lesion"},{"name":"Maps_To","value":"9766/1"},{"name":"Maps_To","value":"Angiocentric immunoproliferative lesion"},{"name":"NCI_META_CUI","value":"CL331771"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7930":{"preferredName":"Lymphomatoid Granulomatosis","code":"C7930","definitions":[{"definition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"Destructive growth of lymph cells, usually involving the lungs, skin, kidneys, and central nervous system. Grades I and II are not considered cancerous, but grade III is considered a lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphomatoid Granulomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"LYG","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9766/1"},{"name":"Legacy Concept Name","value":"Lymphomatoid_Granulomatosis"},{"name":"Maps_To","value":"9766/1"},{"name":"Maps_To","value":"Lymphomatoid granulomatosis"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024307"}]}}{"C4664":{"preferredName":"T-Cell Large Granular Lymphocyte Leukemia","code":"C4664","definitions":[{"definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells which are large and granular, originating from lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of leukemia in which large T lymphocytes (a type of white blood cell) that contain granules (small particles) are found in the blood. It is a chronic disease that may last for a long time and get worse.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"T-Cell Large Granular Lymphocyte Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Large Cell Granular Lymphoid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Large Granular Lymphocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"LGLL","termGroup":"AB","termSource":"NCI"},{"termName":"T Gamma Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"T Large Granular Lymphocyte Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Gamma Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"T-Large Granular Lymphocyte Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9768/1"},{"name":"ICD-O-3_Code","value":"9831/1"},{"name":"ICD-O-3_Code","value":"9831/3"},{"name":"Legacy Concept Name","value":"T-Cell_Large_Granular_Lymphocyte_Leukemia"},{"name":"Maps_To","value":"9768/1"},{"name":"Maps_To","value":"9831/3"},{"name":"Maps_To","value":"T-cell large granular lymphocytic leukemia"},{"name":"Maps_To","value":"T-cell large granular lymphocytosis"},{"name":"Maps_To","value":"T-gamma lymphoproliferative disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1955861"}]}}{"C7727":{"preferredName":"Light Chain Deposition Disease","code":"C7727","definitions":[{"definition":"A condition in which plasma cells secrete immunoglobulin light chains of only one type, kappa or lambda. Light chain deposition disease is often associated with multiple myeloma or lymphoproliferative disease, but as many as 50% of patients have no evidence of neoplastic plasma cell proliferation. Light chains excreted in the urine are known as Bence Jones protein. Amyloidosis and severe renal failure occur more frequently than in multiple myeloma. Also known as Bence Jones myeloma. L-chain disease, L-chain myeloma, and LCDD.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Light Chain Deposition Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Bence Jones Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Light Chain Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Light Chain Gammopathy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Light_Chain_Deposition_Disease"},{"name":"Maps_To","value":"9769/1"},{"name":"Maps_To","value":"Systemic light chain disease"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0238239"}]}}{"C7151":{"preferredName":"Monoclonal Immunoglobulin Deposition Disease","code":"C7151","definitions":[{"definition":"A mature B-cell neoplasm characterized by the deposition of immunoglobulin in tissues, resulting in impaired organ function. It includes the following entities: primary amyloidosis, heavy chain deposition disease, and light chain deposition disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Immunoglobulin Deposition Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin Deposition Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9769/1"},{"name":"Legacy Concept Name","value":"Monoclonal_Immunoglobulin_Deposition_Disease"},{"name":"Maps_To","value":"9769/1"},{"name":"Maps_To","value":"Immunoglobulin deposition disease"},{"name":"NCI_META_CUI","value":"CL357425"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3819":{"preferredName":"Primary Amyloidosis","code":"C3819","definitions":[{"definition":"A plasma cell neoplasm that secretes an abnormal immunoglobulin, which deposits in tissues and forms a beta-pleated sheet structure that binds Congo red dye with characteristic birefringence. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Amyloidosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Amyloidosis"},{"name":"Maps_To","value":"9769/1"},{"name":"Maps_To","value":"Primary amyloidosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0268381"}]}}{"C4982":{"preferredName":"Aleukemic Leukemia","code":"C4982","definitions":[{"definition":"A leukemia characterized by the absence of leukemic cells in the peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aleukemic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aleukemic_Leukemia"},{"name":"Maps_To","value":"9800/3"},{"name":"Maps_To","value":"Aleukemic leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0877858"}]}}{"C3483":{"preferredName":"Chronic Leukemia","code":"C3483","definitions":[{"definition":"A slowly progressing cancer that starts in blood-forming tissues such as the bone marrow, and causes large numbers of white blood cells to be produced and enter the blood stream.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A slowly progressing leukemia characterized by a clonal (malignant) proliferation of maturing and mature myeloid cells or mature lymphocytes.  When the clonal cellular population is composed of myeloid cells, the process is called chronic myelogenous leukemia.  When the clonal cellular population is composed of lymphocytes, it is classified as chronic lymphocytic leukemia, hairy cell leukemia, or T-cell large granular lymphocyte leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chronic_Leukemia"},{"name":"Maps_To","value":"9800/3"},{"name":"Maps_To","value":"Chronic leukemia of unspecified cell type not having achieved remission"},{"name":"Maps_To","value":"Chronic leukemia of unspecified cell type without mention of having achieved remission"},{"name":"Maps_To","value":"Chronic leukemia, NOS"},{"name":"Maps_To","value":"Leukemia of unspecified cell type, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1279296"}]}}{"C9300":{"preferredName":"Acute Leukemia","code":"C9300","definitions":[{"definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","type":"DEFINITION","source":"NCI"},{"definition":"A rapidly progressing cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of white blood cells to be produced and enter the blood stream.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Acute Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9801/3"},{"name":"Legacy Concept Name","value":"Acute_Leukemia"},{"name":"Maps_To","value":"9801/3"},{"name":"Maps_To","value":"Acute leukaemia of unspecified cell type"},{"name":"Maps_To","value":"Acute leukemia of unspecified cell type not having achieved remission"},{"name":"Maps_To","value":"Acute leukemia of unspecified cell type without mention of having achieved remission"},{"name":"Maps_To","value":"Acute leukemia, NOS"},{"name":"Maps_To","value":"Blast cell leukemia"},{"name":"Maps_To","value":"Leukemia of unspecified cell type, acute"},{"name":"Maps_To","value":"Undifferentiated leukaemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0085669"}]}}{"C4673":{"preferredName":"Acute Biphenotypic Leukemia","code":"C4673","definitions":[{"definition":"An acute leukemia characterized by a single population of blasts that coexpress myeloid and lymphoid antigens.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Biphenotypic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9805/3"},{"name":"Legacy Concept Name","value":"Acute_Biphenotypic_Leukemia"},{"name":"Maps_To","value":"9805/3"},{"name":"Maps_To","value":"Acute biphenotypic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023464"}]}}{"C6923":{"preferredName":"Acute Bilineal Leukemia","code":"C6923","definitions":[{"definition":"An acute leukemia in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute leukemia of ambiguous lineage in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte).  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Bilineal Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Acute_Bilineal_Leukemia"},{"name":"Maps_To","value":"9805/3"},{"name":"Maps_To","value":"Acute bilineal leukemia"},{"name":"Maps_To","value":"Acute mixed lineage leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349680"}]}}{"C82192":{"preferredName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","code":"C82192","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR::ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(9;22)(q34;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed-Phenotype Acute Leukemia with BCR-ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed-Phenotype Acute Leukemia with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL with t(9;22)(q34.1;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL with t(9;22)(q34.1;q11.2); BCR::ABL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9806/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_with_t_9_22_q34_q11_2_BCR-ABL1"},{"name":"Maps_To","value":"9806/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826037"}]}}{"C82203":{"preferredName":"Mixed Phenotype Acute Leukemia with KMT2A Rearrangement","code":"C82203","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts carry a translocation between the KMT2A gene at 11q23.3 and another gene partner. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia with KMT2A Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(v;11q23); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(v;11q23.3); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed-Phenotype Acute Leukemia with KMT2A Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL with t(v;11q23.3); KMT2A Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL, with t(v;11q23.3); KMT2A Rearranged","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9807/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_with_t_v_11q23_MLL_Rearranged"},{"name":"Maps_To","value":"9807/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826048"}]}}{"C82212":{"preferredName":"Mixed Phenotype Acute Leukemia, B/Myeloid","code":"C82212","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts express B-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia, B/Myeloid","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, B/Myeloid, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL, B/Myeloid, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9808/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_B_Myeloid_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9808/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia, B/myeloid, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472616"}]}}{"C82213":{"preferredName":"Mixed Phenotype Acute Leukemia, T/Myeloid","code":"C82213","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts express T-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia, T/Myeloid","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, T/Myeloid, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL, T/Myeloid, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9809/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_T_Myeloid_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9809/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia, T/myeloid, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826055"}]}}{"C80326":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","code":"C80326","definitions":[{"definition":"B-lymphoblastic leukemias/lymphomas characterized by the absence of recurrent genetic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9811/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9811/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698310"}]}}{"C80331":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1","code":"C80331","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with BCR-ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR::ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with BCR-ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9812/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_9_22_q34_q11_2_BCR-ABL_1"},{"name":"Maps_To","value":"9812/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698317"}]}}{"C80332":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged","code":"C80332","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of an KMT2A related fusion protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with KMT2A Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with T(V;11Q23); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with KMT2A Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); MLL Rearranged","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9813/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemi_Lymphoma_with_t_v_11q23_MLL_Rearranged"},{"name":"Maps_To","value":"9813/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698309"}]}}{"C80334":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","code":"C80334","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the TEL gene on chromosome 12 and the AML1 gene on chromosome 21, (p13.2;q22.1). It results in the production of the TEL-AML1 (ETV6-RUNX1) fusion protein. It has a favorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with ETV6::RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6::RUNX1","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with ETV6::RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9814/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_12-21_p13_q22_TEL-AML1_ETV6-RUNX1"},{"name":"Maps_To","value":"9814/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698314"}]}}{"C80335":{"preferredName":"Hyperdiploid B Lymphoblastic Leukemia/Lymphoma","code":"C80335","definitions":[{"definition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It has a favorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperdiploid B Lymphoblastic Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9815/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_Hyperdiploidy"},{"name":"Maps_To","value":"9815/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with hyperdiploidy"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698311"}]}}{"C80344":{"preferredName":"Hyperdiploid B Acute Lymphoblastic Leukemia","code":"C80344","definitions":[{"definition":"A B-cell acute leukemia characterized by the presence of lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It is commonly seen in children and rarely in adults. It has a favorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperdiploid B Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"B Acute Lymphoblastic Leukemia with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Acute Lymphoblastic Leukemia with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid ALL","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid B-Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid B-Cell Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperdiploid_B_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9816/3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2697636"}]}}{"C80338":{"preferredName":"Hypodiploid B Lymphoblastic Leukemia/Lymphoma","code":"C80338","definitions":[{"definition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain less than 46 chromosomes. It has an unfavorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypodiploid B Lymphoblastic Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9816/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_Hypodiploidy"},{"name":"Maps_To","value":"9816/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698312"}]}}{"C80340":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH","code":"C80340","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the IL3 gene on chromosome 5 and the IGH locus on chromosome 14, (q31.1;q32.3). It results in eosinophilia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IGH-IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IGH::IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IL3-IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IL3::IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3::IGH","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31;q32); IL3-IGH","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IGH-IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IGH::IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IL3-IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IL3::IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31;q32); IL3-IGH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9817/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_5_14_q31_q32_IL3-IGH"},{"name":"Maps_To","value":"9817/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698316"}]}}{"C80341":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1","code":"C80341","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3::PBX1","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with TCF3-PBX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with TCF3::PBX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with TCF3-PBX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with TCF3::PBX1 Fusion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9818/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_1_19_q23_p13_3_E2A-PBX1_TCF3-PBX1"},{"name":"Maps_To","value":"9818/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698315"}]}}{"C7176":{"preferredName":"Aleukemic Chronic Lymphocytic Leukemia","code":"C7176","synonyms":[{"termName":"Aleukemic Chronic Lymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aleukemic Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aleukemic_Lymphocytic_Leukemia"},{"name":"Maps_To","value":"9820/3"},{"name":"Maps_To","value":"Aleukemic lymphocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3282876"}]}}{"C4343":{"preferredName":"Aleukemic Lymphoid Leukemia","code":"C4343","synonyms":[{"termName":"Aleukemic Lymphoid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aleukemic Lymphatic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Aleukemic Lymphogenous Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aleukemic_Lymphoid_Leukemia"},{"name":"Maps_To","value":"9820/3"},{"name":"Maps_To","value":"Aleukemic lymphatic leukemia"},{"name":"Maps_To","value":"Aleukemic lymphoid leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334667"}]}}{"C27911":{"preferredName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","code":"C27911","definitions":[{"definition":"An indolent (slow-growing) cancer in which immature lymphocytes (white blood cells) are found in the blood and bone marrow and/or in the lymph nodes. Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are the same disease, but in CLL cancer cells are found mostly in the blood and bone marrow. In SLL cancer cells are found mostly in the lymph nodes. Chronic lymphocytic leukemia/small lymphocytic lymphoma is a type of non-Hodgkin lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"CLL/SLL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9823/3"},{"name":"Legacy Concept Name","value":"Chronic_Lymphocytic_Leukemia_Small_Lymphocytic_Lymphoma"},{"name":"Maps_To","value":"9823/3"},{"name":"Maps_To","value":"B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma"},{"name":"Maps_To","value":"B-cell lymphocytic leukemia/small lymphocytic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302547"}]}}{"C3163":{"preferredName":"Chronic Lymphocytic Leukemia","code":"C3163","definitions":[{"definition":"An indolent (slow-growing) cancer in which too many immature lymphocytes (white blood cells) are found mostly in the blood and bone marrow. Sometimes, in later stages of the disease, cancer cells are found in the lymph nodes and the disease is called small lymphocytic lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Lymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"B Cell Chronic Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B Cell CLL","termGroup":"SY","termSource":"NCI"},{"termName":"B Cell Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Chronic Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Chronic Lymphoid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell CLL","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"BCLL","termGroup":"AB","termSource":"NCI"},{"termName":"Chronic B-Cell Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"CLL","termGroup":"AB","termSource":"NCI"},{"termName":"Hematopoeitic - Chronic Lymphocytic Leukemia (CLL)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chronic_Lymphocytic_Leukemia"},{"name":"Maps_To","value":"9823/3"},{"name":"Maps_To","value":"B-cell lymphocytic leukemia/small lymphocytic lymphoma"},{"name":"Maps_To","value":"Chronic lymphatic leukemia"},{"name":"Maps_To","value":"Chronic lymphocytic leukaemia of B-cell type"},{"name":"Maps_To","value":"Chronic lymphocytic leukemia"},{"name":"Maps_To","value":"Chronic lymphocytic leukemia of B-cell type not having achieved remission"},{"name":"Maps_To","value":"Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)"},{"name":"Maps_To","value":"Chronic lymphoid leukemia"},{"name":"Maps_To","value":"Chronic lymphoid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Lymphoid leukemia, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023434"}]}}{"C7400":{"preferredName":"Burkitt Leukemia","code":"C7400","definitions":[{"definition":"A rare, fast-growing type of leukemia (blood cancer) in which too many white blood cells called B lymphocytes form in the blood and bone marrow. It may start in the lymph nodes as Burkitt lymphoma and then spread to the blood and bone marrow, or it may start in the blood and bone marrow without involvement of the lymph nodes. Both Burkitt leukemia and Burkitt lymphoma have been linked to infection with the Epstein-Barr virus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burkitt Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Burkitt's Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Burkitt's Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB L3","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphoblastic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphoid Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9826/3"},{"name":"Legacy Concept Name","value":"Burkitt_s_Cell_Leukemia"},{"name":"Maps_To","value":"9826/3"},{"name":"Maps_To","value":"Acute leukemia, Burkitt type"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, mature B-cell type"},{"name":"Maps_To","value":"Burkitt cell leukemia"},{"name":"Maps_To","value":"FAB L3"},{"name":"Maps_To","value":"Mature B-cell leukemia Burkitt-type not having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023435"}]}}{"C8644":{"preferredName":"B Acute Lymphoblastic Leukemia","code":"C8644","definitions":[{"definition":"An acute lymphoblastic leukemia of B-lineage origin.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) type of leukemia (blood cancer) in which too many B-cell lymphoblasts (immature white blood cells) are found in the bone marrow and blood. It is the most common type of acute lymphoblastic leukemia (ALL).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute B Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute B-Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"B Cell Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"B Cell Precursor Type Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-ALL","termGroup":"AB","termSource":"NCI"},{"termName":"B-Cell Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"B-Cell ALL","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Precursor Type Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Type Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor B-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor B-Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9836/3"},{"name":"Legacy Concept Name","value":"Precursor_B_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9826/3"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"B-ALL"},{"name":"Maps_To","value":"Precursor B-cell lymphoblastic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4227542"}]}}{"C3184":{"preferredName":"Adult T-Cell Leukemia/Lymphoma","code":"C3184","definitions":[{"definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of T-cell non-Hodgkin lymphoma caused by the human T-cell leukemia virus type 1 (HTLV-1). It is marked by bone and skin lesions, high calcium levels, and enlarged lymph nodes, spleen, and liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adult T-Cell Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adult T Cell Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Adult T-Cell Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"ATLL","termGroup":"SY","termSource":"NCI"},{"termName":"HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"HTLV-I Associated Adult T-Cell Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9827/3"},{"name":"Legacy Concept Name","value":"Adult_T-Cell_Lymphoma_Leukemia"},{"name":"Maps_To","value":"9827/3"},{"name":"Maps_To","value":"Adult T-cell leukemia"},{"name":"Maps_To","value":"Adult T-cell leukemia/lymphoma (HTLV-1 positive)"},{"name":"Maps_To","value":"Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)"},{"name":"Maps_To","value":"Adult T-cell lymphoma"},{"name":"Maps_To","value":"Adult T-cell lymphoma/leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023493"}]}}{"C39591":{"preferredName":"Chronic Lymphoproliferative Disorder of NK-Cells","code":"C39591","definitions":[{"definition":"A type of leukemia in which large natural killer (NK) cells (a type of white blood cell) that contain granules (small particles) are found in the blood. It is a chronic disease that may last for a long time and get worse.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An Epstein-Barr virus negative disorder with a chronic clinical course affecting predominantly adults and characterized by the proliferation of large granular lymphocytes with natural killer cell immunophenotype.  The T-cell receptor genes are not rearranged.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Lymphoproliferative Disorder of NK-Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic NK-Cell Lymphocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic NK-Large Granular Lymphocyte Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic NK-LGL Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"CLPD-NK","termGroup":"AB","termSource":"NCI"},{"termName":"Indolent Large Granular NK-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Indolent NK-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"NK Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Cell Large Granular Lymphocyte Lymphocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Type Lymphoproliferative Disorder of Granular Lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9831/3"},{"name":"Legacy Concept Name","value":"Indolent_NK-Cell_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9831/3"},{"name":"Maps_To","value":"Chronic lymphoproliferative disorder of NK cells"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1512709"}]}}{"C3181":{"preferredName":"Prolymphocytic Leukemia","code":"C3181","definitions":[{"definition":"A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","type":"DEFINITION","source":"NCI"},{"definition":"A type of chronic lymphocytic leukemia (CLL) in which too many immature white blood cells (prolymphocytes) are found in the blood and bone marrow. PLL usually progresses more rapidly than classic CLL.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Prolymphocytic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9832/3"},{"name":"Legacy Concept Name","value":"Prolymphocytic_Leukemia"},{"name":"Maps_To","value":"9832/3"},{"name":"Maps_To","value":"Prolymphocytic leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023486"}]}}{"C4753":{"preferredName":"B-Cell Prolymphocytic Leukemia","code":"C4753","definitions":[{"definition":"A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen.  The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli.  The B-prolymphocytes must exceed 55% of lymphoid cells in the blood.  Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded.  The prognosis is poor.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Prolymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"B Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9833/3"},{"name":"Legacy Concept Name","value":"B-Cell_Prolymphocytic_Leukemia"},{"name":"Maps_To","value":"9833/3"},{"name":"Maps_To","value":"Prolymphocytic leukemia, B-cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0475801"}]}}{"C4752":{"preferredName":"T-Cell Prolymphocytic Leukemia","code":"C4752","definitions":[{"definition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Prolymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9834/3"},{"name":"Legacy Concept Name","value":"T-Cell_Prolymphocytic_Leukemia"},{"name":"Maps_To","value":"9834/3"},{"name":"Maps_To","value":"Prolymphocytic leukemia, T-cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2363142"}]}}{"C27290":{"preferredName":"L1 Acute Lymphoblastic Leukemia","code":"C27290","definitions":[{"definition":"An acute lymphoblastic leukemia (current term: precursor lymphoblastic leukemia) of B-or T-cell origin which according to the FAB classification is characterized by the presence of more mature-appearing lymphoblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"L1 Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"L1_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9835/3"},{"name":"Maps_To","value":"FAB Ll"},{"name":"NCI_META_CUI","value":"CL033103"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27281":{"preferredName":"L2 Acute Lymphoblastic Leukemia","code":"C27281","definitions":[{"definition":"An antiquated term that refers to acute lymphoblastic leukemia with large and irregular lymphoblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAB L2","termGroup":"AQS","termSource":"NCI"},{"termName":"L2 Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"FAB_L2"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, L2 type, NOS"},{"name":"Maps_To","value":"FAB L2"},{"name":"NCI_META_CUI","value":"CL031627"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3167":{"preferredName":"Acute Lymphoblastic Leukemia","code":"C3167","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rapidly progressive cancer of the blood and bone marrow consisting of the proliferation of lymphoblasts, which are immature, dysfunctional white blood cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) type of leukemia (blood cancer) in which too many lymphoblasts (immature white blood cells) are found in the blood and bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Lymphocytic Leukaemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphocytic Leukemias","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphoid Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"ALL","termGroup":"AB","termSource":"NCI"},{"termName":"ALL - Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9835/3"},{"name":"Legacy Concept Name","value":"Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9835/3"},{"name":"Maps_To","value":"Acute lymphatic leukemia"},{"name":"Maps_To","value":"Acute lymphoblastic leukaemia [ALL]"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia (ALL)"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia not having achieved remission"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, NOS"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, precursor cell type"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia-lymphoma, NOS"},{"name":"Maps_To","value":"Acute lymphocytic leukemia"},{"name":"Maps_To","value":"Acute lymphoid leukemia"},{"name":"Maps_To","value":"Acute lymphoid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Lymphoblastic leukemia, NOS"},{"name":"Maps_To","value":"Lymphoid leukemia, acute"},{"name":"Maps_To","value":"Precursor cell lymphoblastic leukemia, NOS"},{"name":"Maps_To","value":"Precursor cell lymphoblastic leukemia, not phenotyped"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3550748"}]}}{"C27797":{"preferredName":"Common Acute Lymphoblastic Leukemia","code":"C27797","synonyms":[{"termName":"Common Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Common_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"c-ALL"},{"name":"Maps_To","value":"Common ALL"},{"name":"Maps_To","value":"Common precursor B ALL"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0349637"}]}}{"C27799":{"preferredName":"Pre-Pre-B Acute Lymphoblastic Leukemia","code":"C27799","definitions":[{"definition":"Acute lymphoblastic leukemia of early B-lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Pre-B Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pre-Pre-B_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"Pre-pre-B ALL"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1514294"}]}}{"C27798":{"preferredName":"Pre-B Acute Lymphoblastic Leukemia","code":"C27798","definitions":[{"definition":"An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-B Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pre-B_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"Pre-B ALL"},{"name":"Maps_To","value":"Pro-B ALL"},{"name":"NCI_META_CUI","value":"CL054934"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C27820":{"preferredName":"Mature T-ALL","code":"C27820","synonyms":[{"termName":"Mature T-ALL","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mature_T-ALL"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"Cortical T ALL"},{"name":"Maps_To","value":"Mature T ALL"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1521897"}]}}{"C27261":{"preferredName":"Pre T-ALL","code":"C27261","synonyms":[{"termName":"Pre T-ALL","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pre_T-ALL"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"Pre-T ALL"},{"name":"Maps_To","value":"Pro-T ALL"},{"name":"NCI_META_CUI","value":"CL301529"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8694":{"preferredName":"T Lymphoblastic Leukemia/Lymphoma","code":"C8694","definitions":[{"definition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T Lymphoblastic Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Precursor T Lymphoblastic Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T Lymphoblastic Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Lymphoblastic Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Lymphoblastic Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Lymphoblastic Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9837/3"},{"name":"Legacy Concept Name","value":"Precursor_T_Lymphoblastic_Leukemia_Lymphoma"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"T lymphoblastic leukemia/lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301359"}]}}{"C3183":{"preferredName":"T Acute Lymphoblastic Leukemia","code":"C3183","definitions":[{"definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute lymphoblastic leukemia of T-lineage origin.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) type of leukemia (blood cancer) in which too many T-cell lymphoblasts (immature white blood cells) are found in the bone marrow and blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"T Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute T Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute T-Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T-Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Precursor T-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-ALL","termGroup":"AB","termSource":"NCI"},{"termName":"T-Cell Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Type Acute Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9837/3"},{"name":"Legacy Concept Name","value":"Precursor_T_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"Precursor T-cell lymphoblastic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1961099"}]}}{"C7467":{"preferredName":"Pure Erythroid Leukemia","code":"C7467","definitions":[{"definition":"Acute erythroid leukemia characterized by the presence of immature erythroid cells in the bone marrow (at least 80% of the cellular component), without evidence of a significant myeloblastic cell population present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pure Erythroid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Erythremic Myelosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia M6b","termGroup":"SY","termSource":"NCI"},{"termName":"Di Guglielmo Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Di Guglielmo's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Erythremic Myelosis","termGroup":"SY","termSource":"NCI"},{"termName":"M6b","termGroup":"AB","termSource":"NCI"},{"termName":"PEL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pure_Erythroid_Leukemia"},{"name":"Maps_To","value":"9840/3"},{"name":"Maps_To","value":"Acute erythremic myelosis"},{"name":"Maps_To","value":"Di Guglielmo disease"},{"name":"Maps_To","value":"Erythremic myelosis, NOS"},{"name":"Maps_To","value":"M6B"},{"name":"NCI_META_CUI","value":"CL028054"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8923":{"preferredName":"Acute Erythroid Leukemia","code":"C8923","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature erythroid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Erythroid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Erythroblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"AEL","termGroup":"AB","termSource":"NCI"},{"termName":"Erythroblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M6","termGroup":"AB","termSource":"NCI"},{"termName":"M6 Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9840/3"},{"name":"Legacy Concept Name","value":"Acute_Erythroid_Leukemia"},{"name":"Maps_To","value":"9840/3"},{"name":"Maps_To","value":"Acute erythremia"},{"name":"Maps_To","value":"Acute erythremia and erythroleukemia"},{"name":"Maps_To","value":"Acute erythremia and erythroleukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Acute erythroid leukaemia"},{"name":"Maps_To","value":"Acute erythroid leukemia"},{"name":"Maps_To","value":"Acute erythroid leukemia, not having achieved remission"},{"name":"Maps_To","value":"Acute myeloid leukemia, M6 type"},{"name":"Maps_To","value":"AML M6"},{"name":"Maps_To","value":"FAB M6"},{"name":"Maps_To","value":"M6"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023440"}]}}{"C34774":{"preferredName":"Chronic Monocytic Leukemia","code":"C34774","synonyms":[{"termName":"Chronic Monocytic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chronic_Monocytic_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"Chronic monocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023466"}]}}{"C3519":{"preferredName":"Atypical Chronic Myeloid Leukemia","code":"C3519","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Chronic Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"aCML","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Chronic Myeloid Leukemia, BCR::ABL1 Negative","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical CML","termGroup":"SY","termSource":"NCI"},{"termName":"MDS/MPN-N","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Neutrophilia","termGroup":"SY","termSource":"NCI"},{"termName":"Subacute Granulocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Subacute Myelogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Subacute Myeloid Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9876/3"},{"name":"Legacy Concept Name","value":"Atypical_Chronic_Myeloid_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"9876/3"},{"name":"Maps_To","value":"Atypical chronic myeloid leukemia, BCR/ABL negative"},{"name":"Maps_To","value":"Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative"},{"name":"Maps_To","value":"Subacute granulocytic leukemia"},{"name":"Maps_To","value":"Subacute myelogenous leukemia"},{"name":"Maps_To","value":"Subacute myeloid leukemia"},{"name":"NCI_META_CUI","value":"CL1779346"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4563":{"preferredName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","code":"C4563","definitions":[{"definition":"A disease in which too many eosinophils (a type of white blood cell) are found in the bone marrow, blood, and other tissues. Chronic eosinophilic leukemia may stay the same for many years, or it may progress quickly to acute leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"CEL","termGroup":"AB","termSource":"NCI"},{"termName":"CEL, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Chronic Eosinophilic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Eosinophilic Leukemia, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Eosinophilic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9964/3"},{"name":"Legacy Concept Name","value":"Chronic_Eosinophilic_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"9964/3"},{"name":"Maps_To","value":"Chronic eosinophilic leukemia"},{"name":"Maps_To","value":"Chronic eosinophilic leukemia, NOS"},{"name":"Maps_To","value":"Eosinophilic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346421"}]}}{"C4861":{"preferredName":"Acute Monocytic Leukemia","code":"C4861","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature monocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Monocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Monocytic Leukemia (FAB M5b)","termGroup":"SY","termSource":"NCI"},{"termName":"Monocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9891/3"},{"name":"Legacy Concept Name","value":"Monocytic_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"9891/3"},{"name":"Maps_To","value":"Acute monocytic leukemia"},{"name":"Maps_To","value":"Acute monocytic leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Monocytic leukaemia"},{"name":"Maps_To","value":"Monocytic leukaemia, unspecified"},{"name":"Maps_To","value":"Monocytic leukemia"},{"name":"Maps_To","value":"Monocytic leukemia, acute"},{"name":"Maps_To","value":"Monocytic leukemia, NOS"},{"name":"Maps_To","value":"Other monocytic leukemia"},{"name":"Maps_To","value":"Other monocytic leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Other monocytic leukemia, not having achieved remission"},{"name":"Maps_To","value":"Unspecified monocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023465"}]}}{"C27753":{"preferredName":"Acute Myeloid Leukemia, Not Otherwise Specified","code":"C27753","definitions":[{"definition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia Not Otherwise Categorized","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"AML, NOS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_not_Otherwise_Categorized"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"Acute myeloid leukemia, NOS"},{"name":"Maps_To","value":"Not Classified"},{"name":"NCI_META_CUI","value":"CL054841"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C82433":{"preferredName":"Acute Myeloid Leukemia with CEBPA Mutation","code":"C82433","definitions":[{"definition":"An acute myeloid leukemia (AML) with mutation of the CEBPA gene. It is usually associated with normal karyotype, and most cases meet the criteria for AML with or without maturation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with non-germline mutations of the CEBPA gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with CEBPA Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Mutated CEBPA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Non-Germline Mutated CEBPA","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Mutated CEBPA","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Familial Acute Myeloid Leukemia with Mutated CEBPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9861/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Mutated_CEBPA"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with mutated CEBPA"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826178"}]}}{"C82431":{"preferredName":"Acute Myeloid Leukemia with NPM1 Mutation","code":"C82431","definitions":[{"definition":"An acute myeloid leukemia (AML) with mutation of the nucleophosmin gene. It is usually associated with normal karyotype. It is seen in 8% of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with NPM1 Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Cytoplasmic Nucleophosmin","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Mutated NPM1","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Mutated NPM1","termGroup":"SY","termSource":"NCI"},{"termName":"NPMc+ AML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9861/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Mutated_NPM1"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with mutated NPM1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826177"}]}}{"C3171":{"preferredName":"Acute Myeloid Leukemia","code":"C3171","definitions":[{"definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","type":"DEFINITION","source":"NCI"},{"definition":"A rapidly progressive cancer of the blood and bone marrow consisting of the proliferation of abnormal myeloblasts, which are immature, dysfunctional white blood cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Acute Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemias","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Nonlymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"AML","termGroup":"AB","termSource":"NCI"},{"termName":"AML - Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"ANLL","termGroup":"AB","termSource":"NCI"},{"termName":"Hematopoeitic - Acute Myleogenous Leukemia (AML)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9861/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"9872/3"},{"name":"Maps_To","value":"Acute granulocytic leukemia"},{"name":"Maps_To","value":"Acute myeloblastic leukaemia [AML]"},{"name":"Maps_To","value":"Acute myeloblastic leukemia"},{"name":"Maps_To","value":"Acute myeloblastic leukemia, not having achieved remission"},{"name":"Maps_To","value":"Acute myelocytic leukemia"},{"name":"Maps_To","value":"Acute myelogenous leukemia"},{"name":"Maps_To","value":"Acute myeloid leukemia"},{"name":"Maps_To","value":"Acute myeloid leukemia (AML)"},{"name":"Maps_To","value":"Acute myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Acute non-lymphocytic leukemia"},{"name":"Maps_To","value":"Myeloid leukemia, acute"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4015937"}]}}{"C3174":{"preferredName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","code":"C3174","definitions":[{"definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","type":"DEFINITION","source":"NCI"},{"definition":"A slowly progressing disease in which too many white blood cells are made in the bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","termGroup":"PT","termSource":"NCI"},{"termName":"BCR-ABL Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemia, BCR::ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemias","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia, BCR::ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"CML","termGroup":"AB","termSource":"NCI"},{"termName":"CML - Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoeitic - Chronic Myelocytic Leukemia (CML)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9863/3"},{"name":"ICD-O-3_Code","value":"9875/3"},{"name":"Legacy Concept Name","value":"Chronic_Myelogenous_Leukemia"},{"name":"Maps_To","value":"9863/3"},{"name":"Maps_To","value":"9875/3"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, NOS"},{"name":"Maps_To","value":"Chronic myelocytic leukemia, NOS"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, BCR-ABL positive"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, BCR/ABL positive"},{"name":"Maps_To","value":"Chronic myeloid leukaemia [CML], BCR/ABL-positive"},{"name":"Maps_To","value":"Chronic myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission"},{"name":"Maps_To","value":"Chronic myeloid leukemia, NOS"},{"name":"Maps_To","value":"Myeloid leukemia, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023473"}]}}{"C82423":{"preferredName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","code":"C82423","definitions":[{"definition":"An acute myeloid leukemia associated with t(6;9)(p22.3;q34), resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It is rare in children.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9) (p22.3;q34.1); DEK-NUP214 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9) (p22.3;q34.1); DEK::NUP214 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34); DEK-NUP214","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK::NUP214","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9865/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_6_9_p23_q34_DEK-NUP214"},{"name":"Maps_To","value":"9865/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826169"}]}}{"C3182":{"preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","code":"C3182","definitions":[{"definition":"Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), and it is treated differently than other types of AML because of its marked sensitivity to differentiating effects of all trans-retinoic acid. APL is characterized by a severe coagulopathy which may be present at diagnosis. APL occurs in 7 % of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of acute myeloid leukemia in which there are too many immature blood-forming cells in the blood and bone marrow. It is usually marked by an exchange of parts of chromosomes 15 and 17.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with PML-RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with PML::RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"AML with t(15;17)(q24.1;q21.2)","termGroup":"SY","termSource":"NCI"},{"termName":"APL","termGroup":"AB","termSource":"NCI"},{"termName":"APML","termGroup":"AB","termSource":"NCI"},{"termName":"APML - Acute promyelocytic leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M3","termGroup":"SY","termSource":"NCI"},{"termName":"Promyelocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9866/3"},{"name":"Legacy Concept Name","value":"Acute_Promyelocytic_Leukemia"},{"name":"Maps_To","value":"9866/3"},{"name":"Maps_To","value":"Acute myeloid leukemia, PML/RAR-alpha"},{"name":"Maps_To","value":"Acute promyelocytic leukaemia [PML]"},{"name":"Maps_To","value":"Acute promyelocytic leukaemia, PML-RAR-alpha"},{"name":"Maps_To","value":"Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)"},{"name":"Maps_To","value":"Acute promyelocytic leukemia, NOS"},{"name":"Maps_To","value":"Acute promyelocytic leukemia, t(15;17)(q22;q11-12)"},{"name":"Maps_To","value":"FAB M3 (includes all variants)"},{"name":"Maps_To","value":"M3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023487"}]}}{"C7463":{"preferredName":"Acute Myelomonocytic Leukemia","code":"C7463","definitions":[{"definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myelomonocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M4 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelomonocytic Leukemia (FAB Type M4)","termGroup":"SY","termSource":"NCI"},{"termName":"AMML","termGroup":"AB","termSource":"NCI"},{"termName":"M4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9867/3"},{"name":"Legacy Concept Name","value":"Acute_Myelomonocytic_Leukemia"},{"name":"Maps_To","value":"9867/3"},{"name":"Maps_To","value":"Acute myelomonocytic leukaemia"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia, NOS"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia, not having achieved remission"},{"name":"Maps_To","value":"FAB M4"},{"name":"Maps_To","value":"M4"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023479"}]}}{"C82426":{"preferredName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","code":"C82426","definitions":[{"definition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia associated with inv(3)(q21q26.2) or t(3;3)(q21;q26.2), resulting in the expression of RPN1-EVI1 fusion protein. There have been rare cases in children that have been reported in the literature.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, EVI1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2::MECOM","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with MECOM Rearrangements","termGroup":"SY","termSource":"NCI"},{"termName":"AML with MECOM Rearrangements","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9869/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_inv_3_q2_q26_2_or_t_3_3_q21_q26_2_RPN1-EVI1"},{"name":"Maps_To","value":"9869/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3.3)(q21;q26.2); RPN1-EVI1"},{"name":"Maps_To","value":"Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1"},{"name":"Maps_To","value":"Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826172"}]}}{"C3164":{"preferredName":"Acute Basophilic Leukemia","code":"C3164","definitions":[{"definition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","type":"DEFINITION","source":"NCI"},{"definition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Basophilic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Basophilic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Leukemia Basophilic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9870/3"},{"name":"Legacy Concept Name","value":"Acute_Basophilic_Leukemia"},{"name":"Maps_To","value":"9870/3"},{"name":"Maps_To","value":"Acute basophilic leukaemia"},{"name":"Maps_To","value":"Acute basophilic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023437"}]}}{"C9020":{"preferredName":"Acute Myelomonocytic Leukemia with Abnormal Eosinophils","code":"C9020","definitions":[{"definition":"Acute myelomonocytic leukemia characterized by the presence of abnormal bone marrow eosinophils. It is associated with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22). It has a favorable prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myelomonocytic Leukemia with Abnormal Eosinophils","termGroup":"PT","termSource":"NCI"},{"termName":"AMML Eo","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M4Eo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Myelomonocytic_Leukemia_with_Abnormal_Eosinophils"},{"name":"Maps_To","value":"9871/3"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia with abnormal eosinophils"},{"name":"Maps_To","value":"FAB M4Eo"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332156"}]}}{"C9287":{"preferredName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11","code":"C9287","definitions":[{"definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) or  t(16;16)(p13.1;q22), which results in the expression of the fusion protein CBFB-MYH11. This is seen in 7-9% of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the bone marrow.  This type of acute myeloid leukemia has a favorable prognosis.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Abnormal Marrow Eosinophils","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, CBF-beta/MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, CBFB-MYH11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9871/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Abnormal_Marrow_Eosinophils"},{"name":"Maps_To","value":"9871/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with abnormal marrow eosinophils"},{"name":"Maps_To","value":"Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)"},{"name":"Maps_To","value":"Acute myeloid leukemia, CBF-beta/MYH11"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522630"}]}}{"C8460":{"preferredName":"Acute Myeloid Leukemia with Minimal Differentiation","code":"C8460","definitions":[{"definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with Minimal Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia, Minimally Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Minimal Differentiation (MO)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, Minimally Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Acute Myelogenous Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Myeloid Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9872/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_Minimally_Differentiated"},{"name":"Maps_To","value":"9872/3"},{"name":"Maps_To","value":"Acute myeloid leukemia, minimal differentiation"},{"name":"Maps_To","value":"FAB MO"},{"name":"Maps_To","value":"M0"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522631"}]}}{"C3249":{"preferredName":"Acute Myeloid Leukemia without Maturation","code":"C3249","definitions":[{"definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of significant maturation in the neutrophilic lineage.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia without Maturation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M1 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia without Maturation (FAB M1)","termGroup":"SY","termSource":"NCI"},{"termName":"AML without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M1","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloblastic Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myelogenous Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloid Leukemia without Maturation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9873/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_without_Maturation"},{"name":"Maps_To","value":"9873/3"},{"name":"Maps_To","value":"Acute myeloid leukemia without maturation"},{"name":"Maps_To","value":"FAB M1"},{"name":"Maps_To","value":"M1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026998"}]}}{"C3250":{"preferredName":"Acute Myeloid Leukemia with Maturation","code":"C3250","definitions":[{"definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of significant maturation in the neutrophilic lineage.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with Maturation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M2 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelocytic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (AML-M2)","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M2","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloblastic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myelocytic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myelogenous Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloid Leukemia with Maturation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9874/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Maturation"},{"name":"Maps_To","value":"9874/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with maturation"},{"name":"Maps_To","value":"FAB M2, NOS"},{"name":"Maps_To","value":"M2"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879321"}]}}{"C9128":{"preferredName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive","code":"C9128","definitions":[{"definition":"A chronic myeloid leukemia characterized by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia t(9;22) (q34;q11), BCR/ABL Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR::ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Chromosome Positive Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Chromosome Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Chromosome Positive Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Positive Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Chromosome Positive Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Chromosome Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Chromosome Positive Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Positive Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive CML","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive, BCR::ABL1 Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Philadelphia_Chromosome_Positive_Chronic_Myelogenous_Leukemia"},{"name":"Maps_To","value":"9875/3"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, BCR/ABL"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, t(9;22)(q34;q11)"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, t(9;22)(q34;q11)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292771"}]}}{"C7318":{"preferredName":"Acute Monoblastic and Monocytic Leukemia","code":"C7318","definitions":[{"definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Monoblastic and Monocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Monoblastic Leukemia and Acute Monocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia M5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9891/3"},{"name":"Legacy Concept Name","value":"Acute_Monoblastic_Leukemia_and_Acute_Monocytic_Leukemia"},{"name":"Maps_To","value":"9891/3"},{"name":"Maps_To","value":"Acute monoblastic and monocytic leukemia"},{"name":"Maps_To","value":"Acute monoblastic/monocytic leukaemia"},{"name":"Maps_To","value":"Acute monoblastic/monocytic leukemia, not having achieved remission"},{"name":"Maps_To","value":"FAB M5 (includes all variants)"},{"name":"Maps_To","value":"M5"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3831784"}]}}{"C7171":{"preferredName":"Acute Monoblastic Leukemia","code":"C7171","definitions":[{"definition":"An acute myeloid leukemia in which the monoblasts represent 80% or more of the total cellular population.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Monoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Monoblastic Leukemia (FAB M5a)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Monoblastic_Leukemia"},{"name":"Maps_To","value":"9891/3"},{"name":"Maps_To","value":"Acute monoblastic leukemia"},{"name":"Maps_To","value":"Monoblastic leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0457334"}]}}{"C9289":{"preferredName":"Acute Myeloid Leukemia with Multilineage Dysplasia","code":"C9289","definitions":[{"definition":"An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with Multilineage Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"AML with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"AML-MLD","termGroup":"AB","termSource":"NCI"},{"termName":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9895/3"},{"name":"Legacy Concept Name","value":"De_novo_Acute_Myeloid_Leukemia_with_Multilineage_Dysplasia"},{"name":"Maps_To","value":"9895/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with multilineage dysplasia"},{"name":"Maps_To","value":"Acute myeloid leukemia with multilineage dysplasia, not having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292773"}]}}{"C4037":{"preferredName":"Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome","code":"C4037","definitions":[{"definition":"An acute myeloid leukemia developing in patients with a prior history of myelodysplastic syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Multilineage Dysplasia following Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"AML/MDS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Multilineage_Dysplasia_following_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9895/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with prior myelodysplastic syndrome"},{"name":"Maps_To","value":"Acute myeloid leukemia without prior myelodysplastic syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321721"}]}}{"C7600":{"preferredName":"Acute Myeloid Leukemia, Myelodysplasia-Related","code":"C7600","definitions":[{"definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood and one of the following: a previous history of myelodysplastic syndrome; multilineage dysplasia; or myelodysplastic syndrome-related cytogenetic abnormalities.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia, Myelodysplasia-Related","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Myelodysplasia-Related Changes","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Myelodysplasia-Related Changes","termGroup":"SY","termSource":"NCI"},{"termName":"AML-MRC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9895/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Multilineage_Dysplasia"},{"name":"Maps_To","value":"9895/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with myelodysplasia-related changes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825139"}]}}{"C9288":{"preferredName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","code":"C9288","definitions":[{"definition":"An acute myeloid leukemia (AML) associated with t(8;21)(q22;q22) resulting in RUNX1-RUNX1T1 fusion protein expression. This is seen in 12% of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1::RUNX1T1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1::RUNX1T1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22;q22)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22;q22)(AML1(CBFa)/ETO)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, t(8;21)(q22;q22)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9896/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_8_21_q22_q22_AML1_CBFa_ETO"},{"name":"Maps_To","value":"9896/3"},{"name":"Maps_To","value":"Acute myeloid leukaemia, t(8;21)(q22;q22)"},{"name":"Maps_To","value":"Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1"},{"name":"Maps_To","value":"Acute myeloid leukemia, AML1(CBF-alpha)/ETO"},{"name":"Maps_To","value":"Acute myeloid leukemia, t(8;21)(q22;q22)"},{"name":"Maps_To","value":"FAB M2, AML1(CBF-alpha)/ETO"},{"name":"Maps_To","value":"FAB M2, t(8;21)(q22;q22)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292774"}]}}{"C174129":{"preferredName":"Acute Myeloid Leukemia with KMT2A Rearrangement","code":"C174129","definitions":[{"definition":"An acute myeloid leukemia characterized by rearrangement of the KMT2A gene. It affects infants, children and adults. It is usually associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with KMT2A Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with 11q23 Abnormalities","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with KMT2A/MLL Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with MLL Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with MLLr","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, MLL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9897/3"},{"name":"Maps_To","value":"Acute myeloid leukaemia with 11q23-abnormality"},{"name":"Maps_To","value":"Acute myeloid leukemia with 11q23-abnormality not having achieved remission"},{"name":"Maps_To","value":"Acute myeloid leukemia, 11q23 abnormalities"},{"name":"Maps_To","value":"Acute myeloid leukemia, MLL"},{"name":"NCI_META_CUI","value":"CL1407773"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C82339":{"preferredName":"Transient Abnormal Myelopoiesis Associated with Down Syndrome","code":"C82339","definitions":[{"definition":"A myeloid proliferation occurring in newborns with Down syndrome.  It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.  The blasts display morphologic and immunophenotypic features of megakaryocytic lineage.  In the majority of patients the myeloid proliferation undergoes spontaneous remission.","type":"DEFINITION","source":"NCI"},{"definition":"A myeloid proliferation occurring in newborns with Down syndrome. It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations. The blasts display morphologic and immunophenotypic features of megakaryocytic lineage. In the majority of patients, the myeloid proliferation undergoes spontaneous remission.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"AML diagnosed within four years of a diagnosis of Transient Abnormal Myelopoiesis Associated with Down Syndrome (a myeloid proliferation occurring in newborns with Down syndrome). Transient Abnormal Myelopoiesis Associated with Down Syndrome is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]}],"synonyms":[{"termName":"Transient Abnormal Myelopoiesis Associated with Down Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"TAM","termGroup":"AB","termSource":"NCI"},{"termName":"Transient Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9898/1"},{"name":"Legacy Concept Name","value":"Transient_Abnormal_Myelopoiesis"},{"name":"Maps_To","value":"9898/1"},{"name":"Maps_To","value":"Transient abnormal myelopoiesis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1834582"}]}}{"C43223":{"preferredName":"Myeloid Leukemia Associated with Down Syndrome","code":"C43223","definitions":[{"definition":"Acute myeloid leukemia occurring in children with Down syndrome. During the first 3 years of life, it is usually the megakaryoblastic subtype, and is associated with GATA1 gene mutation. After age 4 this is no longer the case.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Acute myeloid leukemia or myelodysplastic syndrome occurring in children with Down syndrome.  The acute myeloid leukemia is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid Leukemia Associated with Down Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9898/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_Transient_Myeloproliferative_Disorder_in_Down_Syndrome"},{"name":"Maps_To","value":"9898/3"},{"name":"Maps_To","value":"Myeloid leukemia associated with Down syndrome"},{"name":"Maps_To","value":"Myeloid leukemia associated with Down Syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825149"}]}}{"C3170":{"preferredName":"Acute Megakaryoblastic Leukemia","code":"C3170","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature megakaryocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Megakaryoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M7 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Megakaryoblastic Leukemia (FAB Type M7)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Megakaryocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9910/3"},{"name":"Legacy Concept Name","value":"Acute_Megakaryoblastic_Leukemia"},{"name":"Maps_To","value":"9910/3"},{"name":"Maps_To","value":"Acute megakaryoblastic leukaemia"},{"name":"Maps_To","value":"Acute megakaryoblastic leukemia"},{"name":"Maps_To","value":"Acute megakaryoblastic leukemia not having achieved remission"},{"name":"Maps_To","value":"FAB M7"},{"name":"Maps_To","value":"M7"},{"name":"Maps_To","value":"Megakaryocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023462"}]}}{"C82427":{"preferredName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","code":"C82427","definitions":[{"definition":"An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia typically showing megakaryocytic maturation and associated with t(1;22)(p13;q13), resulting in the expression of RBM15-MKL1 fusion protein.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15- MRTFA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15::MLK1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15::MRTFA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9911/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_Megakaryoblastic_with_t_1_22_p13_q13_RBM15-MKL1"},{"name":"Maps_To","value":"9911/3"},{"name":"Maps_To","value":"Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826173"}]}}{"C27754":{"preferredName":"Alkylating Agent-Related Acute Myeloid Leukemia","code":"C27754","definitions":[{"definition":"Acute myeloid leukemia occurring as late complication of prior therapy with alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alkylating Agent-Related Acute Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Alkylating Agent Related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Alkylating Agent-Related AML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alkylating_Agent-Related_Acute_Myeloid_Leukemia"},{"name":"Maps_To","value":"9920/3"},{"name":"Maps_To","value":"Therapy-related acute myeloid leukemia, alkylating agent related"},{"name":"Maps_To","value":"Therapy-related acute myeloid leukemia, epipodophyllotoxin-related"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321724"}]}}{"C27912":{"preferredName":"Myeloid Neoplasm Post Cytotoxic Therapy","code":"C27912","definitions":[{"definition":"Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid Neoplasm Post Cytotoxic Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukaemias and Myelodysplastic Syndromes, Therapy-Related","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related AML and MDS","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related Myeloid Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9920/3"},{"name":"Legacy Concept Name","value":"Therapy-Related_Acute_Myeloid_Leukemia_and_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9920/3"},{"name":"Maps_To","value":"Therapy related myeloid neoplasm"},{"name":"Maps_To","value":"Therapy-related myeloid neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292776"}]}}{"C8252":{"preferredName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","code":"C8252","definitions":[{"definition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"t-AML","termGroup":"AB","termSource":"NCI"},{"termName":"Therapy-Related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment Related Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment Related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment Related AML","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment-Related Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment-related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment-Related AML","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9920/3"},{"name":"Legacy Concept Name","value":"Therapy-Related_Acute_Myeloid_Leukemia"},{"name":"Maps_To","value":"9920/3"},{"name":"Maps_To","value":"Therapy-related acute myeloid leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336735"}]}}{"C3520":{"preferredName":"Myeloid Sarcoma","code":"C3520","definitions":[{"definition":"A malignant neoplasm composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant, green-colored tumor of myeloid cells (a type of immature white blood cell). This tumor is usually associated with myelogenous leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A tumor mass composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Myeloid Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chloroma","termGroup":"SY","termSource":"NCI"},{"termName":"Extramedullary Myeloid Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extramedullary Myeloid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9930/3"},{"name":"Legacy Concept Name","value":"Myeloid_Sarcoma"},{"name":"Maps_To","value":"9930/3"},{"name":"Maps_To","value":"Chloroma"},{"name":"Maps_To","value":"Myeloid sarcoma"},{"name":"Maps_To","value":"Myeloid sarcoma without mention of having achieved remission"},{"name":"Maps_To","value":"Myeloid sarcoma, not having achieved remission"},{"name":"NCI_META_CUI","value":"CL414320"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C35815":{"preferredName":"Granulocytic Sarcoma","code":"C35815","definitions":[{"definition":"A malignant neoplasm composed of myeloblasts, neutrophils and neutrophil precursors.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant, green-colored tumor of myeloid cells (a type of immature white blood cell). This tumor is usually associated with myelogenous leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor mass composed of myeloblasts, neutrophils and neutrophil precursors.  Granulocytic sarcoma is the most common type of myeloid sarcoma.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granulocytic Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Granulocytic_Sarcoma"},{"name":"Maps_To","value":"9930/3"},{"name":"Maps_To","value":"Granulocytic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152276"}]}}{"C4344":{"preferredName":"Acute Panmyelosis with Myelofibrosis","code":"C4344","definitions":[{"definition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Panmyelosis with Myelofibrosis","termGroup":"PT","termSource":"NCI"},{"termName":"Acute (Malignant) Myelofibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute (Malignant) Myelosclerosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelofibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelosclerosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Panmyelosis","termGroup":"SY","termSource":"NCI"},{"termName":"APMF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9931/3"},{"name":"Legacy Concept Name","value":"Acute_Panmyelosis_with_Myelofibrosis"},{"name":"Maps_To","value":"9931/3"},{"name":"Maps_To","value":"Acute myelofibrosis"},{"name":"Maps_To","value":"Acute myelosclerosis, NOS"},{"name":"Maps_To","value":"Acute panmyelosis with myelofibrosis"},{"name":"Maps_To","value":"Acute panmyelosis, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334674"}]}}{"C7402":{"preferredName":"Hairy Cell Leukemia","code":"C7402","definitions":[{"definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of leukemia in which abnormal B-lymphocytes (a type of white blood cell) are present in the bone marrow, spleen, and peripheral blood. When viewed under a microscope, these cells appear to be covered with tiny hair-like projections.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hairy Cell Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"HCL","termGroup":"AB","termSource":"NCI"},{"termName":"Leukemic Reticuloendotheliosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9940/3"},{"name":"Legacy Concept Name","value":"Hairy_Cell_Leukemia"},{"name":"Maps_To","value":"9940/3"},{"name":"Maps_To","value":"Hairy cell leukemia"},{"name":"Maps_To","value":"Hairy cell leukemia, NOS"},{"name":"Maps_To","value":"Leukemic reticuloendotheliosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023443"}]}}{"C3178":{"preferredName":"Chronic Myelomonocytic Leukemia","code":"C3178","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","type":"DEFINITION","source":"NCI"},{"definition":"A slowly progressing type of myelodysplastic/myeloproliferative disease in which too many myelomonocytes (a type of white blood cell) are in the bone marrow, crowding out other normal blood cells, such as other white blood cells, red blood cells, and platelets.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chronic Myelomonocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"CMML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9945/3"},{"name":"Legacy Concept Name","value":"Chronic_Myelomonocytic_Leukemia"},{"name":"Maps_To","value":"9945/3"},{"name":"Maps_To","value":"Chronic monocytic leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Chronic myelomonocytic leukaemia"},{"name":"Maps_To","value":"Chronic myelomonocytic leukemia in transformation"},{"name":"Maps_To","value":"Chronic myelomonocytic leukemia not having achieved remission"},{"name":"Maps_To","value":"Chronic myelomonocytic leukemia, NOS"},{"name":"Maps_To","value":"Monocytic leukemia, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023480"}]}}{"C9233":{"preferredName":"Juvenile Myelomonocytic Leukemia","code":"C9233","definitions":[{"definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","type":"DEFINITION","source":"NCI"},{"definition":"A myelodysplastic/myeloproliferative neoplasm of childhood that is principally characterized by proliferation of the granulocytic and monocytic lineages.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare form of childhood leukemia in which cancer cells often spread into tissues such as the skin, lung, and intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Juvenile Myelomonocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"JCML","termGroup":"AB","termSource":"NCI"},{"termName":"JMML","termGroup":"AB","termSource":"NCI"},{"termName":"Juvenile Chronic Myelogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Juvenile Chronic Myeloid Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9946/3"},{"name":"Legacy Concept Name","value":"Juvenile_Myelomonocytic_Leukemia"},{"name":"Maps_To","value":"9946/3"},{"name":"Maps_To","value":"Juvenile chronic myelomonocytic leukemia"},{"name":"Maps_To","value":"Juvenile myelomonocytic leukemia"},{"name":"Maps_To","value":"Juvenile myelomonocytic leukemia, NOS"},{"name":"Maps_To","value":"Juvenile myelomonocytic leukemia, not having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349639"}]}}{"C8647":{"preferredName":"Aggressive NK-Cell Leukemia","code":"C8647","definitions":[{"definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggressive NK-Cell Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive NK-Cell Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Natural Killer Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Cell Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9948/3"},{"name":"Legacy Concept Name","value":"Aggressive_NK-Cell_Leukemia"},{"name":"Maps_To","value":"9948/3"},{"name":"Maps_To","value":"Aggressive NK-cell leukaemia"},{"name":"Maps_To","value":"Aggressive NK-cell leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292777"}]}}{"C3336":{"preferredName":"Polycythemia Vera","code":"C3336","definitions":[{"definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","type":"DEFINITION","source":"NCI"},{"definition":"A disease in which there are too many red blood cells in the bone marrow and blood, causing the blood to thicken. The number of white blood cells and platelets may also increase. The extra blood cells may collect in the spleen and cause it to become enlarged. They may also cause bleeding problems and make clots form in blood vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Polycythemia Vera","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Erythremia","termGroup":"AQS","termSource":"NCI"},{"termName":"Polycythemia Rubra Vera","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9950/3"},{"name":"Legacy Concept Name","value":"Polycythemia_Vera"},{"name":"Maps_To","value":"9950/3"},{"name":"Maps_To","value":"Polycythemia rubra vera"},{"name":"Maps_To","value":"Polycythemia vera"},{"name":"Maps_To","value":"Proliferative polycythemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0032463"}]}}{"C27350":{"preferredName":"Myeloproliferative Neoplasm, Not Otherwise Specified","code":"C27350","definitions":[{"definition":"This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloproliferative Neoplasm, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Disease, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Disorder, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"CMPD, U","termGroup":"AB","termSource":"NCI"},{"termName":"CMPD-U","termGroup":"AB","termSource":"NCI"},{"termName":"MPN, U","termGroup":"AB","termSource":"NCI"},{"termName":"MPN-NOS","termGroup":"AB","termSource":"NCI"},{"termName":"MPN-U","termGroup":"AB","termSource":"NCI"},{"termName":"Myeloproliferative Neoplasm, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloproliferative Neoplasm, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassifiable Chronic Myeloproliferative Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassifiable Chronic Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9975/3"},{"name":"Legacy Concept Name","value":"Chronic_Myeloproliferative_Disease_Unclassifiable"},{"name":"Maps_To","value":"9960/3"},{"name":"Maps_To","value":"9975/3"},{"name":"Maps_To","value":"Chronic myeloproliferative disease, NOS"},{"name":"Maps_To","value":"Myeloproliferative disease, NOS"},{"name":"Maps_To","value":"Myeloproliferative neoplasm, NOS"},{"name":"Maps_To","value":"Myeloproliferative neoplasm, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333046"}]}}{"C2862":{"preferredName":"Primary Myelofibrosis","code":"C2862","definitions":[{"definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, chronic disease in which the bone marrow is replaced by fibrous tissue and blood is made in organs such as the liver and the spleen, instead of in the bone marrow. This disease is marked by an enlarged spleen and progressive anemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Myelofibrosis","termGroup":"PT","termSource":"NCI"},{"termName":"Agnogenic Myeloid Metaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"AMM","termGroup":"AB","termSource":"NCI"},{"termName":"Idiopathic Bone Marrow Fibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Myelofibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Myelosclerosis with Myeloid Metaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"PMF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9961/3"},{"name":"Legacy Concept Name","value":"Chronic_Idiopathic_Myelofibrosis"},{"name":"Maps_To","value":"9961/3"},{"name":"Maps_To","value":"Agnogenic myeloid metaplasia"},{"name":"Maps_To","value":"Megakaryocytic myelosclerosis"},{"name":"Maps_To","value":"Myelofibrosis with myeloid metaplasia"},{"name":"Maps_To","value":"Myelosclerosis with myeloid metaplasia"},{"name":"Maps_To","value":"Primary myelofibrosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001815"}]}}{"C3407":{"preferredName":"Essential Thrombocythemia","code":"C3407","definitions":[{"definition":"A chronic condition that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and elevated risk for thrombosis and/or hemorrhage.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","type":"DEFINITION","source":"NCI"},{"definition":"An increased number of thrombocytes (platelets) in the blood, without a known cause.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Essential Thrombocythemia","termGroup":"PT","termSource":"NCI"},{"termName":"Essential Thrombocytemia","termGroup":"SY","termSource":"NCI"},{"termName":"Essential Thrombocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Thrombocythemia","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Thrombocythemia","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Thrombocytosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9962/3"},{"name":"Legacy Concept Name","value":"Essential_Thrombocythemia"},{"name":"Maps_To","value":"9962/3"},{"name":"Maps_To","value":"Essential (haemorrhagic) thrombocythaemia"},{"name":"Maps_To","value":"Essential hemorrhagic thrombocythaemia"},{"name":"Maps_To","value":"Essential thrombocythemia"},{"name":"Maps_To","value":"Idiopathic hemorrhagic thrombocythaemia"},{"name":"Maps_To","value":"Idiopathic thrombocythemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040028"}]}}{"C3179":{"preferredName":"Chronic Neutrophilic Leukemia","code":"C3179","definitions":[{"definition":"A disease in which too many neutrophils (a type of white blood cell) are found in the blood. The extra neutrophils may cause the spleen and liver to become enlarged. Chronic neutrophilic leukemia may stay the same for many years or it may progress quickly to acute leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Neutrophilic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Neutrophilic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9963/3"},{"name":"Legacy Concept Name","value":"Chronic_Neutrophilic_Leukemia"},{"name":"Maps_To","value":"9963/3"},{"name":"Maps_To","value":"Chronic neutrophilic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023481"}]}}{"C27038":{"preferredName":"Idiopathic Hypereosinophilic Syndrome","code":"C27038","definitions":[{"definition":"A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idiopathic Hypereosinophilic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Hyper Eosinophilic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hypereosinophilic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"iHES","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9964/3"},{"name":"Legacy Concept Name","value":"Hypereosinophilic_Syndrome"},{"name":"Maps_To","value":"9964/3"},{"name":"Maps_To","value":"Hypereosinophilic syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1540912"}]}}{"C84275":{"preferredName":"Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","code":"C84275","definitions":[{"definition":"Hematologic neoplasms characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts. Patients usually present with chronic eosinophilic leukemia, and less often with acute myeloid leukemia or T-lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"M/LN-eo with PDGFRA Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid Neoplasm with PDGFRA Rearrangement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9965/3"},{"name":"Maps_To","value":"9965/3"},{"name":"Maps_To","value":"Myeloid and lymphoid neoplasms with PDGFRA rearrangement"},{"name":"Maps_To","value":"Myeloid or lymphoid neoplasm with PDGFRA rearrangement"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2827360"}]}}{"C84276":{"preferredName":"Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","code":"C84276","definitions":[{"definition":"Myeloid and rarely lymphoid neoplasms characterized by the rearrangement of the PDGFRB gene, most often resulting in the formation of ETV6-PDGFRB fusion transcripts. Patients usually present with chronic myelomonocytic leukemia and less often with atypical chronic myeloid leukemia, or chronic eosinophilic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"M/LN-eo with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Neoplasms with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9966/3"},{"name":"Maps_To","value":"9966/3"},{"name":"Maps_To","value":"Myeloid neoplasms with PDGFRB rearrangement"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472621"}]}}{"C84277":{"preferredName":"Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","code":"C84277","definitions":[{"definition":"Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"8p11 Myeloproliferative Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"8p11 Stem Cell Leukemia/Lymphoma Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"8p11 Stem Cell Lymphoma/Leukemia Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"8p11 Stem Cell Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"M/LN-eo with FGFR1 Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9967/3"},{"name":"Maps_To","value":"9967/3"},{"name":"Maps_To","value":"Myeloid and lymphoid neoplasms with FGFR1 abnormalities"},{"name":"Maps_To","value":"Myeloid or lymphoid neoplasm with FGFR1 abnormalities"},{"name":"NCI_META_CUI","value":"CL497893"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9308":{"preferredName":"Lymphoproliferative Disorder","code":"C9308","definitions":[{"definition":"A disease in which cells of the lymphatic system grow excessively. Lymphoproliferative disorders are often treated like cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9970/1"},{"name":"Legacy Concept Name","value":"Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9970/1"},{"name":"Maps_To","value":"Lymphoproliferative disease, NOS"},{"name":"Maps_To","value":"Lymphoproliferative disorder, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3554543"}]}}{"C4727":{"preferredName":"Post-Transplant Lymphoproliferative Disorder","code":"C4727","definitions":[{"definition":"A condition in which a group of B-cells grow out of control after an organ transplant in patients with weakened immune systems. This usually happens if the patient has also been infected with Epstein-Barr virus. Post-transplant lymphoproliferative disorder may progress to non-Hodgkin lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Abnormal proliferation of B lymphocytes as a complication of immunosuppression occurring after solid organ or allogenic stem cell transplantation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post-Transplant Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"PTLD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9971/1"},{"name":"Legacy Concept Name","value":"Post-Transplant_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9971/1"},{"name":"Maps_To","value":"Post transplant lymphoproliferative disorder"},{"name":"Maps_To","value":"Post transplant lymphoproliferative disorder, NOS"},{"name":"Maps_To","value":"Post-transplant lymphoproliferative disorder, NOS"},{"name":"Maps_To","value":"PTLD, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0432487"}]}}{"C7183":{"preferredName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","code":"C7183","definitions":[{"definition":"A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Polymorphic B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphic B-Cell Post-Transplant Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphic PTLD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9971/3"},{"name":"Legacy Concept Name","value":"Polymorphic_Post-Transplant_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9971/3"},{"name":"Maps_To","value":"Polymorphic post transplant lymphoproliferative disorder"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301361"}]}}{"C2872":{"preferredName":"Refractory Anemia","code":"C2872","definitions":[{"definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Anemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aregenerative Anemia","termGroup":"SY","termSource":"NCI"},{"termName":"RA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9980/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia"},{"name":"Maps_To","value":"9980/3"},{"name":"Maps_To","value":"Refractory anaemia, unspecified"},{"name":"Maps_To","value":"Refractory anemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002893"}]}}{"C4036":{"preferredName":"Myelodysplastic Syndrome with Ring Sideroblasts","code":"C4036","definitions":[{"definition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDS-RS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Ring Sideroblasts","termGroup":"AQ","termSource":"NCI"},{"termName":"Pure Sideroblastic Anemia","termGroup":"AQS","termSource":"NCI"},{"termName":"RARS","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with Ring Sideroblasts","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9982/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Ringed_Sideroblasts"},{"name":"Maps_To","value":"9982/3"},{"name":"Maps_To","value":"RARS"},{"name":"Maps_To","value":"Refractory anemia with ringed sideroblasts"},{"name":"Maps_To","value":"Refractory anemia with sideroblasts"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1264195"}]}}{"C82616":{"preferredName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","code":"C82616","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm characterized by marked thrombocytosis, anemia, erythroid lineage dysplasia, presence or absence of multilineage dysplasia, 15% or more ring sideroblasts, blasts less than 5% in bone marrow and less than 1% in peripheral blood, absence of BCR/ABL fusion, absence of SF3B1 mutation, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Essential Thrombocythemia with Ring Sideroblasts","termGroup":"SY","termSource":"NCI"},{"termName":"MDS/MPN with Ring Sideroblasts and Thrombocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"MDS/MPN-RS-T","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/MPN-RS-T, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"RARS-T","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9982/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Ring_Sideroblasts_Associated_with_Marked_Thrombocytosis"},{"name":"Maps_To","value":"9982/3"},{"name":"Maps_To","value":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826330"}]}}{"C7506":{"preferredName":"Myelodysplastic Syndrome with Excess Blasts","code":"C7506","definitions":[{"definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome with Excess Blasts","termGroup":"PT","termSource":"NCI"},{"termName":"MDS-EB","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-EB-1","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB-1","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB1","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm with Increased Blasts","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Excess Blasts-1","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Increased Blasts","termGroup":"SY","termSource":"NCI"},{"termName":"RAEB","termGroup":"AB","termSource":"NCI"},{"termName":"RAEB I","termGroup":"SY","termSource":"NCI"},{"termName":"RAEB-I","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with an Excess of Blasts","termGroup":"SY","termSource":"NCI"},{"termName":"Refractory Anemia with Excess Blasts","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9983/3"},{"name":"Legacy Concept Name","value":"RAEB-1"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Excess_Blasts"},{"name":"Maps_To","value":"9983/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome with excess blasts"},{"name":"Maps_To","value":"RAEB"},{"name":"Maps_To","value":"RAEB I"},{"name":"Maps_To","value":"Refractory anaemia with excess of blasts"},{"name":"Maps_To","value":"Refractory anemia with excess blasts"},{"name":"Maps_To","value":"Refractory anemia with excess of blasts, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002894"}]}}{"C27080":{"preferredName":"Refractory Anemia with Excess Blasts in Transformation","code":"C27080","definitions":[{"definition":"Refractory anemia with excess blasts in transformation (RAEB-T) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood.  The peripheral blood blast count ranges from 20% to 30%.  RAEB-T used to be a subcategory of myelodysplastic syndromes in the past.  Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes.  The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%.  The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments.  Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome).  A minority of cases are part of RAEB-2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAEB-T","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with Excess Blasts in Transformation","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9984/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Excess_Blasts_in_Transformation"},{"name":"Maps_To","value":"9984/3"},{"name":"Maps_To","value":"RAEB-T"},{"name":"Maps_To","value":"Refractory anemia with excess blasts in transformation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280028"}]}}{"C8574":{"preferredName":"Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","code":"C8574","definitions":[{"definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"MDS, NOS with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-LB-MLD","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-MLD","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm with Low Blasts and Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Low Blasts and Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"RCMD","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Cytopenia with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9985/3"},{"name":"Legacy Concept Name","value":"Refractory_Cytopenia_with_Multilineage_Dysplasia"},{"name":"Maps_To","value":"9985/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome with multilineage dysplasia"},{"name":"Maps_To","value":"Refractory cytopenia with multilineage dysplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0796466"}]}}{"C82596":{"preferredName":"Refractory Cytopenia of Childhood","code":"C82596","definitions":[{"definition":"A myeloid disorder that occurs in childhood and is characterized by persistent cytopenia, dysplastic changes in at least two hematopoietic lineages or in 10% or more of cells in one hematopoietic lineage, less than 5% blasts in bone marrow, and less than 2% blasts in peripheral blood, absence of bone marrow fibrosis, and absence of history of prior cytotoxic chemotherapy or radiation therapy. In a subset of cases, somatic mutations or cytogenetic abnormalities can be identified. Other cases are the result of pre-existing disorders with germline mutations, including Fanconi anemia, Shwachman-Diamond syndrome, and dyskeratosis congenita.","type":"DEFINITION","source":"NCI"},{"definition":"The most common subtype of the myelodysplastic syndromes affecting children. It is characterized by persistent cytopenia with less than 5% blasts in the bone marrow and less than 2% blasts in the peripheral blood. Most cases are associated with a normal karyotype, however, when abnormal, monosomy 7 is the most frequently seen cytogenetic abnormality.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Refractory Cytopenia of Childhood","termGroup":"PT","termSource":"NCI"},{"termName":"RCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9985/3"},{"name":"Legacy Concept Name","value":"Refractory_Cytopenia_of_Childhood"},{"name":"Maps_To","value":"9985/3"},{"name":"Maps_To","value":"Refractory cytopenia of childhood"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826323"}]}}{"C6867":{"preferredName":"Myelodysplastic Syndrome with del(5q)","code":"C6867","definitions":[{"definition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A rare disorder caused by loss of part of the long arm (Q arm) of human chromosome 5. This syndrome affects myeloid (bone marrow) cells, causing treatment-resistant anemia, and myelodysplastic syndromes that may lead to acute myelogenous leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Myelodysplastic Syndrome with del(5q)","termGroup":"PT","termSource":"NCI"},{"termName":"5q- Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-del(5q)","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm with Low Blasts and 5q Deletion","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with 5q Deletion","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Isolated Del (5Q)","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Isolated del(5q)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9986/3"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Syndrome_Associated_with_Isolated_del_5q_Chromosome_Abnormality"},{"name":"Maps_To","value":"9986/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome with 5q deletion"},{"name":"Maps_To","value":"Myelodysplastic syndrome with 5q deletion (5q-) syndrome"},{"name":"Maps_To","value":"Myelodysplastic syndrome with isolated del (5q)"},{"name":"Maps_To","value":"Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292779"}]}}{"C7643":{"preferredName":"Alkylating Agent-Related Myelodysplastic Syndrome","code":"C7643","definitions":[{"definition":"A disorder seen following cancer chemotherapy. It is the most common cause of therapy-related myelodysplastic syndromes. It typically manifests several years after initiation of single or multi-agent chemotherapy with alkylators. Mutagenic potential of alkylating agents is believed to be age and cumulative dose-dependent. Deletions in chromosomes 5 and 7 are associated with susceptibility to this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course may progress to bone marrow failure or acute myeloid leukemia that is refractory to treatment. Prognosis is dismal with survivability usually less than one year.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alkylating Agent-Related Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Alkylating Agent Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alkylating_Agent-Related_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9987/3"},{"name":"Maps_To","value":"Therapy-related myelodysplastic syndrome, alkylating agent related"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332235"}]}}{"C7642":{"preferredName":"Epipodophyllotoxin-Related Myelodysplastic Syndrome","code":"C7642","definitions":[{"definition":"A disorder seen following cancer chemotherapy. It typically manifests a few years after initiation of epipodophyllotoxin chemotherapy. Mutagenic potential of these non-intercalating DNA topoisomerase II inhibitors is believed to be increased with concurrent use of asparaginase or granulocyte colony-stimulating factor. Balanced translocations involving chromosomal bands 11q23 and 21q22 are commonly associated with this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course usually progresses to acute myeloid leukemia though most epipodophyllotoxin-related leukemias do not have an antecedent myelodysplastic phase. Prognosis is dismal with survivability usually less than one year.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epipodophyllotoxin-Related Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Epipodophyllotoxin Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epipodophyllotoxin-Related_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9987/3"},{"name":"Maps_To","value":"Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333418"}]}}{"C27722":{"preferredName":"Myelodysplastic Syndrome Post Cytotoxic Therapy","code":"C27722","definitions":[{"definition":"A myelodysplastic syndrome resulting from chemotherapy or radiation therapy for cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome Post Cytotoxic Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"MDS Post Cytotoxic Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-pCT","termGroup":"AB","termSource":"NCI"},{"termName":"t-MDS","termGroup":"AB","termSource":"NCI"},{"termName":"Therapy Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related MDS","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9987/3"},{"name":"Legacy Concept Name","value":"Therapy-Related_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9987/3"},{"name":"Maps_To","value":"Therapy-related myelodysplastic syndrome, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292780"}]}}{"C198589":{"preferredName":"Myelodysplastic Syndrome, Not Otherwise Specified","code":"C198589","definitions":[{"definition":"Myelodysplastic syndrome with low blasts characterized by the absence of defining genetic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"MDS, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Low Blasts, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Ringed Sideroblasts","termGroup":"AQS","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9989/3"},{"name":"Maps_To","value":"9989/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome, NOS"},{"name":"NCI_META_CUI","value":"CL1905772"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C82593":{"preferredName":"Refractory Neutropenia","code":"C82593","definitions":[{"definition":"A myelodysplastic syndrome characterized by the presence of at least 10% dysplastic neutrophils in the bone marrow or the peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Neutropenia","termGroup":"PT","termSource":"NCI"},{"termName":"RN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9991/3"},{"name":"Legacy Concept Name","value":"Refractory_Neutropenia"},{"name":"Maps_To","value":"9991/3"},{"name":"Maps_To","value":"Refractory neutropenia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826320"}]}}{"C82594":{"preferredName":"Refractory Thrombocytopenia","code":"C82594","definitions":[{"definition":"A myelodysplastic syndrome characterized by the presence of at least 10% dysplastic megakaryocytes, found within at least 30 megakaryocytes examined in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Thrombocytopenia","termGroup":"PT","termSource":"NCI"},{"termName":"RT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9992/3"},{"name":"Legacy Concept Name","value":"Refractory_Thrombocytopenia"},{"name":"Maps_To","value":"9992/3"},{"name":"Maps_To","value":"Refractory thrombocytopenia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826321"}]}}{"C164042":{"preferredName":"Ovarian Capsule Intact","code":"C164042","definitions":[{"definition":"A microscopy finding indicating that the ovarian capsule in a biopsy is intact.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Capsule Intact","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Capsule Intact"},{"name":"NCI_META_CUI","value":"CL977189"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164044":{"preferredName":"Ovarian Capsule Ruptured","code":"C164044","definitions":[{"definition":"A microscopy finding indicating that a portion of the ovarian capsule in a biopsy has ruptured.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Capsule Ruptured","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Capsule Ruptured"},{"name":"NCI_META_CUI","value":"CL977187"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164045":{"preferredName":"Ovarian Capsule Fragmented","code":"C164045","definitions":[{"definition":"A microscopy finding indicating that a portion of the ovarian capsule in a biopsy was fragmented.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Capsule Fragmented","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Capsule Fragmented"},{"name":"NCI_META_CUI","value":"CL977186"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25626":{"preferredName":"Present","code":"C25626","definitions":[{"definition":"Being or existing in a specified place or at the specified time.","type":"DEFINITION","source":"NCI"},{"definition":"Being or existing in a specified place or at the specified time. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Present","termGroup":"PT","termSource":"NCI"},{"termName":"Found","termGroup":"SY","termSource":"NCI"},{"termName":"In","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Present"},{"name":"Maps_To","value":"Present"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0150312"}]}}{"C48658":{"preferredName":"Indeterminate","code":"C48658","definitions":[{"definition":"Cannot distinguish between two or more possible values in the current context.","type":"DEFINITION","source":"NCI"},{"definition":"Cannot distinguish between two or more possible values in the current context. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Indeterminate","termGroup":"PT","termSource":"NCI"},{"termName":"Cannot Be Determined","termGroup":"SY","termSource":"NCI"},{"termName":"Inconclusive","termGroup":"SY","termSource":"NCI"},{"termName":"Unable to Determine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Indeterminate"},{"name":"Maps_To","value":"Indeterminant"},{"name":"Maps_To","value":"Indeterminate"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205258"}]}}{"C70430":{"preferredName":"Zero","code":"C70430","definitions":[{"definition":"A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zero","termGroup":"PT","termSource":"NCI"},{"termName":"0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Zero"},{"name":"Maps_To","value":"0"},{"name":"NCI_META_CUI","value":"CL938212"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C172224":{"preferredName":"One to Three Positive Lymph Nodes","code":"C172224","definitions":[{"definition":"An indication that cancer cells have been detected in one, two or three lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"One to Three Positive Lymph Nodes","termGroup":"PT","termSource":"NCI"},{"termName":"1-3 Lymph Nodes Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1-3"},{"name":"NCI_META_CUI","value":"CL1406306"},{"name":"Semantic_Type","value":"Finding"}]}}{"C172226":{"preferredName":"Four or More Positive Lymph Nodes","code":"C172226","definitions":[{"definition":"An indication that cancer cells have been detected in four or more lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Four or More Positive Lymph Nodes","termGroup":"PT","termSource":"NCI"},{"termName":"4 or More Lymph Nodes Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"4 or More"},{"name":"NCI_META_CUI","value":"CL1406327"},{"name":"Semantic_Type","value":"Finding"}]}}{"C8326":{"preferredName":"Cytologic Atypia","code":"C8326","definitions":[{"definition":"The presence of irregularly shaped or sized cells as compared to the cells that are normally present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytologic Atypia","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Cell Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cytologic_Atypia"},{"name":"Maps_To","value":"Atypical"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0333865"}]}}{"C14143":{"preferredName":"Malignant","code":"C14143","definitions":[{"definition":"Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Malignant"},{"name":"Maps_To","value":"Malignant"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"Subsource","value":"IMT"},{"name":"UMLS_CUI","value":"C0205282"}]}}{"C25588":{"preferredName":"Non-Malignant","code":"C25588","definitions":[{"definition":"For neoplasms, a neoplastic process that, at the time of the pathologic diagnosis, does not show evidence of tissue infiltration and may or may not show evidence of atypical morphologic features (e.g., cellular atypia, formation of complex structures, cellular pseudostratification, and increased mitotic activity).  This term encompasses benign neoplastic processes, neoplastic processes with dysplastic features, and borderline processes.  The former do not metastasize and the latter two are associated with a future risk of stromal invasion and metastasis. For other conditions, a process that is not seriously resistant to treatment or dangerous to health.","type":"DEFINITION","source":"NCI"},{"definition":"Not cancerous. Nonmalignant tumors may grow larger but do not spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Non-Malignant","termGroup":"PT","termSource":"NCI"},{"termName":"Non Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Nonmalignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Non-Malignant"},{"name":"Maps_To","value":"Non-Malignant"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1518371"}]}}{"C126862":{"preferredName":"Unsatisfactory","code":"C126862","definitions":[{"definition":"Failing to meet the quantitative or qualitative measures for the needs of a situation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unsatisfactory","termGroup":"PT","termSource":"NCI"},{"termName":"Inadequate","termGroup":"SY","termSource":"NCI"},{"termName":"Insufficient","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unsatisfactory"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0439856"}]}}{"C5530":{"preferredName":"Prostate Acinar Sarcomatoid Carcinoma","code":"C5530","definitions":[{"definition":"A rare acinar adenocarcinoma of the prostate gland with unfavorable prognosis. It is composed of both malignant glandular and sarcomatous components. The sarcomatous component contains a malignant spindle cell proliferation or specific mesenchymal elements including osteosarcoma, chondrosarcoma, and leiomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Acinar Sarcomatoid Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Prostate Carcinosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Sarcomatoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatoid Carcinoma of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatoid Carcinoma of the Prostate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Prostate_Sarcomatoid_Carcinoma"},{"name":"Maps_To","value":"Acinar adenocarcinoma, sarcomatoid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335519"}]}}{"C9298":{"preferredName":"Acute Undifferentiated Leukemia","code":"C9298","definitions":[{"definition":"A rare acute leukemia in which the blasts do not express markers specific to myeloid or lymphoid lineage.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare acute leukemia of ambiguous lineage in which the blasts do not express markers specific to myeloid or lymphoid lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Undifferentiated Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Stem Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Stem Cell Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Stem Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Acute Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Stem_Cell_Leukemia"},{"name":"Maps_To","value":"Acute leukemia, NOS"},{"name":"Maps_To","value":"Stem cell leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378511"}]}}{"C82403":{"preferredName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","code":"C82403","definitions":[{"definition":"An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3 (AF9)-KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-MLL","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::MLL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9897/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_9_11_p22_q23_MLLT3-MLL"},{"name":"Maps_To","value":"Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2919692"}]}}{"C9018":{"preferredName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","code":"C9018","definitions":[{"definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13q22)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13q22)(CBFb/MYH11)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, inv(16)(p13q22)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_inv_16_p13_q22"},{"name":"Maps_To","value":"Acute myeloid leukemia, inv(16)(p13;q22)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332154"}]}}{"C9019":{"preferredName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11","code":"C9019","definitions":[{"definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality t(16;16)(p13.1;q22) which results in the expression of the fusion protein CBFB-MYH11.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB::MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB::MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13;q22)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, t(16;16)(p13;q22)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_16_16_p13_q22"},{"name":"Maps_To","value":"Acute myeloid leukemia, t(16;16)(p 13;q 11)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332155"}]}}{"C127915":{"preferredName":"Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma","code":"C127915","definitions":[{"definition":"A carcinoma that arises from the cervix and is characterized by the presence of a cervical adenocarcinoma variant and a neuroendocrine carcinoma component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenocarcinoma admixed with neuroendocrine carcinoma"},{"name":"NCI_META_CUI","value":"CL509697"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C136717":{"preferredName":"Lung Mucinous Adenocarcinoma In Situ","code":"C136717","definitions":[{"definition":"A very rare lung adenocarcinoma in situ variant characterized by the presence of tall columnar cells with basal nuclei and abundant cytoplasmic mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Mucinous Adenocarcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenocarcinoma in situ of lung, mucinous"},{"name":"Maps_To","value":"Adenocarcinoma in situ, mucinous"},{"name":"NCI_META_CUI","value":"CL554698"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40017":{"preferredName":"Rete Ovarii Adenocarcinoma","code":"C40017","definitions":[{"definition":"An exceptionally rare adenocarcinoma that arises from the rete ovarii.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rete Ovarii Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rete_Ovarii_Adenocarcinoma"},{"name":"Maps_To","value":"9110/3"},{"name":"Maps_To","value":"Adenocarcinoma of rete ovarii"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3840223"}]}}{"C173739":{"preferredName":"Ameloblastic Fibrodentinosarcoma","code":"C173739","definitions":[{"definition":"An odontogenic sarcoma producing dentin/dentinoid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibrodentinosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ameloblastic fibrodentinosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334564"}]}}{"C129290":{"preferredName":"Astrocytoma, IDH-Mutant, Grade 3","code":"C129290","definitions":[{"definition":"IDH-mutant astrocytoma characterized by the presence of increased mitotic activity and anaplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytoma, IDH-Mutant, Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Astrocytoma, IDH-Mutant","termGroup":"SY","termSource":"NCI"},{"termName":"Astrocytoma, IDH-Mutant, Grade III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic astrocytoma, IDH-mutant"},{"name":"NCI_META_CUI","value":"CL512333"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129291":{"preferredName":"Anaplastic Astrocytoma, IDH-Wildtype","code":"C129291","definitions":[{"definition":"Anaplastic astrocytoma lacking mutations in IDH1 or IDH2 genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Astrocytoma, IDH-Wildtype","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic astrocytoma, IDH-wildtype"},{"name":"NCI_META_CUI","value":"CL512334"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129321":{"preferredName":"Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","code":"C129321","definitions":[{"definition":"An anaplastic oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted"},{"name":"NCI_META_CUI","value":"CL512337"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129327":{"preferredName":"Anaplastic Pleomorphic Xanthoastrocytoma","code":"C129327","definitions":[{"definition":"A WHO grade 3 pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade 2 pleomorphic xanthoastrocytoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Pleomorphic Xanthoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"APX","termGroup":"AB","termSource":"NCI"},{"termName":"WHO Grade 3 Pleomorphic Xanthoastrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Pleomorphic Xanthoastrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic pleomorphic xanthroastrocytoma"},{"name":"NCI_META_CUI","value":"CL512339"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C172804":{"preferredName":"Low Grade Biliary Intraepithelial Neoplasia","code":"C172804","definitions":[{"definition":"Biliary intraepithelial neoplasia characterized by the presence of low grade epithelial dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Biliary Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Low Grade BilIN","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade BilIN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary intraepithelial neoplasia, low grade"},{"name":"NCI_META_CUI","value":"CL497897"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C47847":{"preferredName":"Breast Carcinoma with Chondroid Metaplasia","code":"C47847","definitions":[{"definition":"An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Carcinoma with Chondroid Metaplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Carcinoma with Cartilaginous Metaplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Breast_Carcinoma_with_Chondroid_Metaplasia"},{"name":"Maps_To","value":"Carcinoma with chondroid differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707042"}]}}{"C47848":{"preferredName":"Breast Carcinoma with Osseous Metaplasia","code":"C47848","definitions":[{"definition":"An invasive breast carcinoma showing differentiation towards bone structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Carcinoma with Osseous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Breast_Carcinoma_with_Osseous_Metaplasia"},{"name":"Maps_To","value":"Carcinoma with osseous differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1711312"}]}}{"C4868":{"preferredName":"Placental Hemangioma","code":"C4868","definitions":[{"definition":"A hemangioma arising from the fetal blood vessels in the placental villi.","type":"DEFINITION","source":"NCI"},{"definition":"A hemangioma arising from the fetal blood vessels in the placental villi.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Placental Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioma of Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Angioma of the Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Chorangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Chorangioma of the Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Chorangioma Placentae","termGroup":"SY","termSource":"NCI"},{"termName":"Chorioangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangioma of Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangioma of the Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Placental Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Placental_Hemangioma"},{"name":"Maps_To","value":"Chorioangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677608"}]}}{"C188314":{"preferredName":"Chronic Phase Primary Myelofibrosis","code":"C188314","definitions":[{"definition":"Primary myelofibrosis characterized by the presence of less than 10% blasts in the peripheral blood or bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Phase Primary Myelofibrosis","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Idiopathic Myelofibrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic idiopathic myelofibrosis"},{"name":"NCI_META_CUI","value":"CL1793031"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C191683":{"preferredName":"Invasive Clear Cell (Glycogen-Rich) Urothelial Carcinoma","code":"C191683","definitions":[{"definition":"An invasive urothelial carcinoma characterized by the presence of clear (glycogen-rich) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Clear Cell (Glycogen-Rich) Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell (Glycogen-Rich) Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Clear Cell Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clear cell (glycogen-rich) urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1797870"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129501":{"preferredName":"Central Nervous System Embryonal Tumor with Rhabdoid Features","code":"C129501","definitions":[{"definition":"A central nervous system embryonal neoplasm characterized by the presence of histological features consistent with atypical teratoid/rhabdoid tumor and absence of mutations of the INI1 gene or SMARCA4 (BRG1) gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Embryonal Tumor with Rhabdoid Features","termGroup":"PT","termSource":"NCI"},{"termName":"CNS Embryonal Tumor with Rhabdoid Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS Embryonal tumor with rhabdoid features"},{"name":"Maps_To","value":"Embryonal tumor with rhabdoid features"},{"name":"NCI_META_CUI","value":"CL512681"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4139":{"preferredName":"Combined Carcinoid and Adenocarcinoma","code":"C4139","definitions":[{"definition":"A malignant epithelial neoplasm composed of a mixture of neuroendocrine cells with morphologic and immunohistochemical characteristics of carcinoid tumor and malignant glandular cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Carcinoid and Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Carcinoid Neoplasm and Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Carcinoid Tumor and Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Composite Carcinoid Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Combined_Carcinoid_and_Adenocarcinoma"},{"name":"Maps_To","value":"Combined carcinoid and adenocarcinoma"},{"name":"Maps_To","value":"Combined/mixed carcinoid and adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334302"}]}}{"C7267":{"preferredName":"Combined Lung Large Cell Neuroendocrine Carcinoma","code":"C7267","definitions":[{"definition":"A subtype of large cell neuroendocrine lung carcinoma characterized by the presence of large neuroendocrine cells in combination with adenocarcinoma, squamous cell carcinoma, giant cell carcinoma and/ or spindle cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Lung Large Cell Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Large Cell Lung Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Large Cell Neuroendocrine Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Large Cell Neuroendocrine Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Combined Large Cell Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Combined Large Cell Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Combined_Large_Cell_Neuroendocrine_Carcinoma_of_the_Lung"},{"name":"Maps_To","value":"Combined large cell neuroendocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333122"}]}}{"C9379":{"preferredName":"Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma","code":"C9379","definitions":[{"definition":"A lung carcinoma characterized by a combination of small cell carcinoma and adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma and Small Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma and Small Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma and Small Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Lung Carcinoma and Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_and_Small_Cell_Lung_Carcinoma"},{"name":"Maps_To","value":"Combined small cell-adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332165"}]}}{"C176005":{"preferredName":"Breast Ductal Carcinoma In Situ, Comedo Type","code":"C176005","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, Comedo Type","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal Comedo Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS - Comedo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8501/2"},{"name":"Maps_To","value":"Comedocarcinoma, noninfiltrating"},{"name":"Maps_To","value":"DCIS, comedo type"},{"name":"Maps_To","value":"Ductal carcinoma in situ, comedo type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334369"}]}}{"C27260":{"preferredName":"Dendritic Cell Tumor, Not Otherwise Specified","code":"C27260","definitions":[{"definition":"A dendritic cell neoplasm that does not fall into well-defined categories or shows hybrid features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendritic Cell Sarcoma, NOS","termGroup":"AQS","termSource":"NCI"},{"termName":"Dendritic Cell Tumor, Not Otherwise Specified","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Dendritic_Cell_Sarcoma_Not_Otherwise_Specified"},{"name":"Maps_To","value":"Dendritic cell sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301364"}]}}{"C37272":{"preferredName":"Vulvar Intraepithelial Neoplasia, HPV-Independent","code":"C37272","definitions":[{"definition":"HPV-negative vulvar squamous intraepithelial proliferation characterized by atypia of the basal and parabasal keratinocytes in an otherwise well-differentiated epithelium. Despite its subtle appearance, it has a high risk of malignant transformation. (WHO 2020)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vulvar Intraepithelial Neoplasia, HPV-Independent","termGroup":"PT","termSource":"NCI"},{"termName":"d-VIN","termGroup":"AB","termSource":"NCI"},{"termName":"Differentiated Vulvar Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"dVIN","termGroup":"AB","termSource":"NCI"},{"termName":"Simplex (Differentiated) Vulvar Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"SxVIN","termGroup":"AB","termSource":"NCI"},{"termName":"Vulvar Carcinoma In Situ of Simplex Type","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated (Simplex)","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated (Simplex) Type","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated Type","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Simplex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Simplex_Differentiated_Type_of_Vulvar_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"Differentiated-type vulvar intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335968"}]}}{"C129271":{"preferredName":"Astrocytoma, IDH-Mutant, Grade 2","code":"C129271","definitions":[{"definition":"IDH-mutant astrocytoma characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytoma, IDH-Mutant, Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytoma, IDH-Mutant, Grade II","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Astrocytoma, IDH-Mutant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse astrocytoma, IDH-mutant"},{"name":"NCI_META_CUI","value":"CL512140"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129274":{"preferredName":"Diffuse Astrocytoma, IDH-Wildtype","code":"C129274","definitions":[{"definition":"Diffuse astrocytoma lacking mutations in IDH1 or IDH2 genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Astrocytoma, IDH-Wildtype","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse astrocytoma, IDH-wildtype"},{"name":"NCI_META_CUI","value":"CL512141"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7364":{"preferredName":"Diffuse Intraductal Papillomatosis","code":"C7364","synonyms":[{"termName":"Diffuse Intraductal Papillomatosis","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Intraductal_Papillomatosis"},{"name":"Maps_To","value":"Diffuse intraductal papillomatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377912"}]}}{"C129424":{"preferredName":"Diffuse Leptomeningeal Glioneuronal Tumor","code":"C129424","definitions":[{"definition":"A relatively slow growing diffuse leptomeningeal neoplasm usually affecting children and adolescents. It is characterized by the presence of clear glial neoplastic cells reminiscent of oligodendroglioma. A neuronal component may be present. The prognosis is variable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Leptomeningeal Glioneuronal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Disseminated Oligodendroglial-Like Leptomeningeal Tumor of Childhood","termGroup":"SY","termSource":"NCI"},{"termName":"DLGNT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse leptomeningeal glioneuronal tumor"},{"name":"NCI_META_CUI","value":"CL512526"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C5138":{"preferredName":"Breast Ductal Carcinoma In Situ, Cribriform Pattern","code":"C5138","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of a cribriform architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, Cribriform Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Ductal Carcinoma In Situ with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Ductal Carcinoma In Situ, Cribriform Type","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Intraductal Cribriform Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform DCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform DCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform Ductal Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform Ductal Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform Ductal Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS of Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS of the Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ of Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ of the Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Cribriform Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Cribriform Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Cribriform Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8201/2"},{"name":"Legacy Concept Name","value":"Intraductal_Cribriform_Breast_Adenocarcinoma"},{"name":"Maps_To","value":"Ductal carcinoma in situ, cribriform type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334248"}]}}{"C4286":{"preferredName":"Immature Teratoma","code":"C4286","definitions":[{"definition":"A rare type of malignant (cancer) germ cell tumor (type of tumor that begins in the cells that give rise to sperm or eggs) that often contains several different types of tissue such as hair, muscle, and bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A teratoma characterized by the presence of an extensive component of immature, fetal-type tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immature Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9080/3"},{"name":"Legacy Concept Name","value":"Immature_Teratoma"},{"name":"Maps_To","value":"Embryonal teratoma"},{"name":"Maps_To","value":"Immature teratoma, malignant"},{"name":"Maps_To","value":"Immature teratoma, NOS"},{"name":"Maps_To","value":"Teratoblastoma, malignant"},{"name":"Maps_To","value":"Teratoma, malignant, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334520"}]}}{"C127907":{"preferredName":"Endocervical Adenocarcinoma, Usual-Type","code":"C127907","definitions":[{"definition":"A cervical adenocarcinoma in which 0-50% of malignant cells contain intracytoplasmic mucin. It is the most common subtype of cervical adenocarcinoma and represents 75% of all invasive cervical adenocarcinomas. The neoplastic epithelium shows a pseudostratified architecture and the malignant cells have enlarged, elongated, and hyperchromatic nuclei. Historically, usual-type cervical adenocarcinomas were termed \"endocervical-type\".","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endocervical Adenocarcinoma, Usual-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma, Endocervical Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Adenocarcinoma, Usual Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Adenocarcinoma, Usual-Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Endocervical Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Endocervical-Type","termGroup":"SY","termSource":"NCI"},{"termName":"Endocervical Adenocarcinoma, Usual Type","termGroup":"SY","termSource":"NCI"},{"termName":"UEA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8384/3"},{"name":"ICD-O-3_Code","value":"8482/3"},{"name":"Maps_To","value":"8384/3"},{"name":"Maps_To","value":"8482/3"},{"name":"Maps_To","value":"Adenocarcinoma, endocervical type"},{"name":"Maps_To","value":"Adenocarcinoma, endocervical type, NOS"},{"name":"Maps_To","value":"Endocervical adenocarcinoma usual type"},{"name":"Maps_To","value":"Mucinous adenocarcinoma, endocervical type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266079"}]}}{"C27846":{"preferredName":"Villoglandular Endometrial Endometrioid Adenocarcinoma","code":"C27846","definitions":[{"definition":"A primary endometrioid adenocarcinoma of the endometrium characterized by the presence of numerous finger-like villi lined by neoplastic columnar cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Villoglandular Endometrial Endometrioid Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Villoglandular_Uterine_Corpus_Endometrioid_Adenocarcinoma"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, villoglandular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336962"}]}}{"C6290":{"preferredName":"Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation","code":"C6290","definitions":[{"definition":"An endometrioid adenocarcinoma of the endometrium showing squamous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocanthoma of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocanthoma of the Endometrium","termGroup":"AQS","termSource":"NCI"},{"termName":"Endometrial Adenoacanthoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrial_Adenosquamous_Carcinoma"},{"name":"Maps_To","value":"Endometrioid carcinoma with squamous differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279763"}]}}{"C66925":{"preferredName":"Enteroglucagonoma","code":"C66925","definitions":[{"definition":"An endocrine neoplasm producing glucagon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enteroglucagonoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8152/1"},{"name":"ICD-O-3_Code","value":"8157/1"},{"name":"Legacy Concept Name","value":"Enteroglucagonoma"},{"name":"Maps_To","value":"Enteroglucagonoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266016"}]}}{"C129293":{"preferredName":"Epithelioid Glioblastoma","code":"C129293","definitions":[{"definition":"An IDH-wildtype glioblastoma characterized by the presence of large epithelioid cells with abundant eosinophilic cytoplasm, vesicular chromatin, and prominent nucleoli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Glioblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"e-GB","termGroup":"AB","termSource":"NCI"},{"termName":"e-GBM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epithelioid glioblastoma"},{"name":"NCI_META_CUI","value":"CL512400"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3486":{"preferredName":"Epithelioid Cell Type Gastrointestinal Stromal Tumor","code":"C3486","definitions":[{"definition":"A benign or malignant gastrointestinal stromal tumor with epithelioid morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Cell Type Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Cell Type GIST","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoblastoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Stout's Leiomyoblastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8891/0"},{"name":"Legacy Concept Name","value":"Epithelioid_Cell_Type_Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"Epithelioid leiomyoma"},{"name":"Maps_To","value":"Leiomyoblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0086533"}]}}{"C7152":{"preferredName":"Erythroleukemia","code":"C7152","definitions":[{"definition":"Acute erythroid leukemia characterised by the presence of at least 50% erythroid precursors and at least 20% myeloblasts in the bone marrow.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer of the blood-forming tissues in which large numbers of immature, abnormal red blood cells are found in the blood and bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Erythroleukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Erythroleukemia (Erythroid/Myeloid)","termGroup":"SY","termSource":"NCI"},{"termName":"Erythroleukemia, Erythroid/Myeloid","termGroup":"SY","termSource":"NCI"},{"termName":"M6a","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Erythroleukemia"},{"name":"Maps_To","value":"Erythroleukemia"},{"name":"Maps_To","value":"M6A"},{"name":"NCI_META_CUI","value":"CL432980"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27426":{"preferredName":"High Grade Esophageal Squamous Intraepithelial Neoplasia","code":"C27426","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities involve both the lower and the upper half of the esophageal squamous epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Esophageal Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal High-Grade Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Squamous Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/2"},{"name":"Legacy Concept Name","value":"Esophageal_High-Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"Esophageal squamous intraepithelial neoplasia (dysplasia), high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333451"}]}}{"C27547":{"preferredName":"Fibrosarcomatous Dermatofibrosarcoma Protuberans","code":"C27547","definitions":[{"definition":"A morphologic variant of dermatofibrosarcoma protuberans characterized by the presence of a fibrosarcomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrosarcomatous Dermatofibrosarcoma Protuberans","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fibrosarcomatous_Dermatofibrosarcoma_Protuberans"},{"name":"Maps_To","value":"Dermatofibrosarcoma protuberans, fibrosarcomatous"},{"name":"Maps_To","value":"Fibrosarcomatous dermatofibrosarcoma protuberans"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3665732"}]}}{"C6880":{"preferredName":"Glandular Papilloma","code":"C6880","synonyms":[{"termName":"Glandular Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glandular_Papilloma"},{"name":"Maps_To","value":"Glandular papilloma"},{"name":"Maps_To","value":"Papillary adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205650"}]}}{"C39750":{"preferredName":"Glioblastoma, IDH-Wildtype","code":"C39750","definitions":[{"definition":"A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma, IDH-Wildtype","termGroup":"PT","termSource":"NCI"},{"termName":"Glioblastoma, IDH Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Glioblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Glioblastoma Multiforme","termGroup":"AQS","termSource":"NCI"},{"termName":"Primary Glioblastoma, IDH-Wildtype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Glioblastoma"},{"name":"Maps_To","value":"Glioblastoma, IDH wildtype"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1514422"}]}}{"C46068":{"preferredName":"Thyroid Gland Oncocytic Neoplasm","code":"C46068","definitions":[{"definition":"An adenoma or carcinoma arising from the follicular cells of the thyroid gland.  It is composed of large oncocytic cells with abundant granular eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"},{"definition":"An uncommon type of thyroid tumor that can be benign or malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Oncocytic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Hurthle Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle (Oncocytic) Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Oncocytic_Neoplasm"},{"name":"Maps_To","value":"Hurthle cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0949541"}]}}{"C96878":{"preferredName":"Gallbladder Intracholecystic Papillary (Tubular) Neoplasm with Intermediate Grade Intraepithelial Neoplasia","code":"C96878","definitions":[{"definition":"An intracholecystic papillary neoplasm that arises from the epithelium of the gallbladder. It is characterized by the presence of moderate epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gallbladder Intracholecystic Papillary (Tubular) Neoplasm with Intermediate Grade Intraepithelial Neoplasia","termGroup":"AQ","termSource":"NCI"},{"termName":"Gallbladder Papillary Neoplasm with Intermediate Grade Intraepithelial Neoplasia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Maps_To","value":"Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273094"}]}}{"C95506":{"preferredName":"Pancreatic Intraductal Tubulopapillary Neoplasm","code":"C95506","definitions":[{"definition":"An epithelial neoplasm that arises from the exocrine pancreas characterized by the formation of tubular structures, high grade dysplasia, and ductal differentiation. Grossly, it is characterized by the presence of intraductal nodular masses. Morphologically, there are nodules of tubular glands and occasional papillary structures growing in dilated ducts.  There is no significant mucin production. Signs and symptoms include epigastric pain, weight loss, vomiting, steatorrhea, and diabetes mellitus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Tubulopapillary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"ITPN","termGroup":"AB","termSource":"NCI"},{"termName":"Pancreatic Intraductal Tubular Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic ITPN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"ICD-O-3_Code","value":"8503/2"},{"name":"Maps_To","value":"Intraductal tubulopapillary neoplasm"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2987189"}]}}{"C9480":{"preferredName":"Invasive Carcinoma","code":"C9480","definitions":[{"definition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Carcinoma"},{"name":"Maps_To","value":"Invasive carcinoma of no special type"},{"name":"Maps_To","value":"Invasive carcinoma, NST"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334274"}]}}{"C97049":{"preferredName":"Invasive Breast Lobular Carcinoma, Alveolar Variant","code":"C97049","definitions":[{"definition":"A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Alveolar Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Alveolar Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasive lobular carcinoma, alveolar type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273215"}]}}{"C97052":{"preferredName":"Invasive Breast Lobular Carcinoma, Solid Variant","code":"C97052","definitions":[{"definition":"A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Solid Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Solid Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasive lobular carcinoma, solid type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273217"}]}}{"C97053":{"preferredName":"Invasive Breast Lobular Carcinoma, Tubulolobular Variant","code":"C97053","definitions":[{"definition":"An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Tubulolobular Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Tubulolobular Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasive lobular carcinoma, tubulolobular variant"},{"name":"Maps_To","value":"Tubulolobular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273218"}]}}{"C9245":{"preferredName":"Invasive Breast Carcinoma","code":"C9245","definitions":[{"definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that has spread from where it started in the breast into surrounding, healthy tissue. Most invasive breast cancers start in the ducts (tubes that carry milk from the lobules to the nipple). Invasive breast cancer can spread to other parts of the body through the blood and lymph systems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Invasive Breast Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Breast Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Mammary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Breast_Carcinoma"},{"name":"Maps_To","value":"61"},{"name":"Maps_To","value":"80"},{"name":"Maps_To","value":"Invasive mammary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0853879"}]}}{"C65184":{"preferredName":"Islet Cell Adenoma","code":"C65184","definitions":[{"definition":"A benign endocrine neoplasm arising from the pancreas. It is separated from the normal pancreatic tissues by a thin collagenous capsule. It may secrete a hormone (e.g. insulin, gastrin) or it may be non-functional.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Islet Cell Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/0"},{"name":"Legacy Concept Name","value":"Islet_Cell_Adenoma"},{"name":"Maps_To","value":"Islet cell adenoma"},{"name":"Maps_To","value":"Nesidioblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0022134"}]}}{"C4375":{"preferredName":"Nesidioblastosis","code":"C4375","definitions":[{"definition":"A sporadic or inherited disorder characterized by the focal or diffuse proliferation of the cells of the islets of Langerhans in the pancreas. It results in hyperinsulinemia and hypoglycemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nesidioblastosis","termGroup":"PT","termSource":"NCI"},{"termName":"Islet Cell Adenomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Islet_Cell_Adenomatosis"},{"name":"Maps_To","value":"Islet cell adenomatosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0027773"}]}}{"C150703":{"preferredName":"Langerhans Cell Histiocytosis, Disseminated","code":"C150703","definitions":[{"definition":"Langerhans cell histiocytosis presenting with disseminated disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis, Disseminated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, disseminated"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, generalized"},{"name":"NCI_META_CUI","value":"CL480899"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C150701":{"preferredName":"Langerhans Cell Histiocytosis, Monostotic","code":"C150701","definitions":[{"definition":"Langerhans cell histiocytosis presenting as a solitary lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis, Monostotic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, mono-ostotic"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, unifocal"},{"name":"NCI_META_CUI","value":"CL552503"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C150702":{"preferredName":"Langerhans Cell Histiocytosis, Polyostotic","code":"C150702","definitions":[{"definition":"Langerhans cell histiocytosis presenting with multiple sites of involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis, Polyostotic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, multifocal"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, poly-ostotic"},{"name":"NCI_META_CUI","value":"CL552504"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C123160":{"preferredName":"Lepidic Adenocarcinoma","code":"C123160","definitions":[{"definition":"A lung adenocarcinoma characterized by the presence of mildly and moderately differentiated adenocarcinoma cells across the alveolar walls with at least one focus of invasive carcinoma measuring more than 5 mm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lepidic Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lepidic Predominant Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lepidic Predominant Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LPA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lepidic adenocarcinoma"},{"name":"Maps_To","value":"Lepidic predominant adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4049711"}]}}{"C191684":{"preferredName":"Invasive Lipid-Rich Urothelial Carcinoma","code":"C191684","definitions":[{"definition":"Invasive urothelial carcinoma characterized by the presence of lipid laden tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Lipid-Rich Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid-Rich Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid-rich urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1905265"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9502":{"preferredName":"Myolipoma","code":"C9502","definitions":[{"definition":"A benign extrauterine tumor composed of mature adipocytes and smooth muscle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myolipoma","termGroup":"PT","termSource":"NCI"},{"termName":"Extrauterine Lipoleiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myolipoma of Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myolipoma"},{"name":"Maps_To","value":"Lipoleiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1096309"}]}}{"C176979":{"preferredName":"Lipoma-Like Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C176979","definitions":[{"definition":"An atypical lipomatous tumor/well differentiated liposarcoma composed of mature adipocytes in which, unlike in benign lipoma, substantial variation in cell size is appreciated alongside nuclear atypia in fat cells or stromal spindle cells. (WHO 2020)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoma-Like Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lipoma-Like ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Lipoma-Like Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lipoma-Like Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipoma-like liposarcoma"},{"name":"NCI_META_CUI","value":"CL1642762"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40362":{"preferredName":"Low Grade Breast Adenosquamous Carcinoma","code":"C40362","definitions":[{"definition":"A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Breast Adenosquamous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Breast Syringomatous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade Adenosquamous Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Low_Grade_Adenosquamous_Breast_Carcinoma"},{"name":"Maps_To","value":"Low grade adenosquamous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518013"}]}}{"C62192":{"preferredName":"Salivary Gland Intraductal Carcinoma","code":"C62192","definitions":[{"definition":"A rare, low-grade adenocarcinoma that arises from the salivary glands.  It is characterized by the presence of cystic structures lined by ductal cells which are arranged in cribriform patterns.  Adjacent ducts show intraductal proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Intraductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Low Grade Salivary Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Low Grade Cribriform Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Low_Grade_Cribriform_Cystadenocarcinoma"},{"name":"Maps_To","value":"Low grade cribriform cystadenocarcinoma (LGCCC)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1882972"}]}}{"C45202":{"preferredName":"Low Grade Fibromyxoid Sarcoma","code":"C45202","definitions":[{"definition":"A low-grade, late-metastasizing variant of fibrosarcoma characterized by alternating fibrous and myxoid areas and a whorling growth pattern.  The neoplastic cells have a spindle morphology, and lack hyperchromasia or significant nuclear atypia.  Approximately 40% of cases show the focal presence of collagen rosettes.  A t(7;16)(q33;p11) translocation has been identified in the majority of cases, associated with the presence of FUS-CREB3L2 fusion protein.  Rare cases carry the t(11;16)(p11;p11) translocation which is associated with the presence of the FUS-CREB3L1 fusion protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Fibromyxoid Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Low_Grade_Fibromyxoid_Sarcoma"},{"name":"Maps_To","value":"Low-grade fibromyxoid sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275282"}]}}{"C8563":{"preferredName":"Undifferentiated High Grade Pleomorphic Sarcoma of Bone","code":"C8563","definitions":[{"definition":"A rare, high-grade pleomorphic malignant neoplasm arising from the bone.  It usually presents with pain which may or may not be associated with swelling in the affected area.  It is characterized by the presence of spindle-shaped cells, polygonal or epithelioid cells, multinucleated giant cells, and inflammatory cells.  The neoplastic cells exhibit nuclear pleomorphism and high mitotic activity.  It metastasizes frequently, most often in the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated High Grade Pleomorphic Sarcoma of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Bone Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibrous Histiocytoma of Bone","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibrous Histiocytoma of the Bone","termGroup":"AQS","termSource":"NCI"},{"termName":"Undifferentiated High Grade Pleomorphic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated High-Grade Pleomorphic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Bone_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"Malignant fibrous histiocytoma (MFH) of bone"},{"name":"Maps_To","value":"Undifferentiated high-grade pleomorphic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0740479"}]}}{"C6530":{"preferredName":"Malignant Pericytic Neoplasm","code":"C6530","definitions":[{"definition":"A malignant mesenchymal neoplasm arising from the perivascular cells of the connective and soft tissues.  It is characterized by the presence of pericytes that grow in a circumferential pattern around vessels, and cytologic atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Pericytic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Pericytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Perivascular Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Perivascular Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Perivascular_Neoplasm"},{"name":"Maps_To","value":"Malignant perivascular epithelial cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334611"}]}}{"C54039":{"preferredName":"Classic Medulloblastoma","code":"C54039","definitions":[{"definition":"A medulloblastoma composed of malignant cells with hyperchromatic nucleus and scanty cytoplasm.  Homer Wright rosettes may be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Classic Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Classic_Medulloblastoma"},{"name":"Maps_To","value":"Medulloblastoma, classic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707400"}]}}{"C129445":{"preferredName":"Medulloblastoma, Non-WNT/Non-SHH, Group 3","code":"C129445","definitions":[{"definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications may be present. TP53 mutations are absent. Patients in this group are usually young children. The overall survival is the worst among all the molecular groups.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Non-WNT/Non-SHH, Group 3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medulloblastoma, group 3"},{"name":"NCI_META_CUI","value":"CL512711"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129446":{"preferredName":"Medulloblastoma, Non-WNT/Non-SHH, Group 4","code":"C129446","definitions":[{"definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications are absent. TP53 mutations are absent. Chromosome 17 abnormalities may be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Non-WNT/Non-SHH, Group 4","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medulloblastoma, group 4"},{"name":"NCI_META_CUI","value":"CL512712"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129443":{"preferredName":"Medulloblastoma, SHH-Activated, TP53-Wildtype","code":"C129443","definitions":[{"definition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the absence of TP53 mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, SHH-Activated, TP53-Wildtype","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medulloblastoma, SHH-activated and TP53-wildtype"},{"name":"NCI_META_CUI","value":"CL512716"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4230":{"preferredName":"Optic Disc Melanocytoma","code":"C4230","definitions":[{"definition":"A benign neoplastic melanocytic proliferation within or adjacent to the optic disk. It presents as a pigmented, intraocular tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Optic Disc Melanocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocytoma of Eyeball","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytoma of the Eyeball","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8726/0"},{"name":"Legacy Concept Name","value":"Melanocytoma_of_the_Eyeball"},{"name":"Maps_To","value":"Melanocytoma, eyeball"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2004458"}]}}{"C6910":{"preferredName":"Malignant Melanotic Psammomatous Peripheral Nerve Sheath Tumor","code":"C6910","definitions":[{"definition":"A malignant peripheral nerve sheath tumor characterized by the presence of malignant cells that contain melanin and formation of psammoma bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Melanotic Psammomatous Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocytic Psammomatous Malignant Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytic Psammomatous MPNST","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Psammomatous Malignant Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanotic_Psammomatous_Malignant_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"Melanotic psammomatous MPNST"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321709"}]}}{"C5317":{"preferredName":"Meningeal Melanoma","code":"C5317","definitions":[{"definition":"A melanoma that arises from leptomeningeal melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Leptomeningeal Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma of Leptomeninges","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma of the Leptomeninges","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Central Nervous System Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Melanoma"},{"name":"Legacy Concept Name","value":"Leptomeningeal_Melanoma"},{"name":"Maps_To","value":"Meningeal melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332888"},{"name":"UMLS_CUI","value":"C1334386"}]}}{"C191685":{"preferredName":"Invasive Microcystic Urothelial Carcinoma","code":"C191685","definitions":[{"definition":"Invasive urothelial carcinoma characterized by microcysts formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Microcystic Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Microcystic Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microcystic urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1905264"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C154494":{"preferredName":"Renal Cell Carcinoma with MiT Translocations","code":"C154494","definitions":[{"definition":"A renal cell carcinoma usually seen in children or young adults. It is characterized by papillary, alveolar and nested growth patterns with clear and eosinophilic cells. The carcinomas range from microscopic lesions to clinically symptomatic tumors. It is associated with translocations/gene fusions involving members of the MiT family of transcription factors. There are two subtypes: TFE3-rearranged renal cell carcinoma [Xp11 translocation renal cell carcinoma] and TFEB-rearranged renal cell carcinoma [t(6;11) renal cell carcinoma].","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Cell Carcinoma with MiT Translocations","termGroup":"PT","termSource":"NCI"},{"termName":"MiT Family Translocation-Associated Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MiT family translocation renal cell carcinoma"},{"name":"NCI_META_CUI","value":"CL557969"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6879":{"preferredName":"Pancreatic Mixed Ductal Adenocarcinoma-Neuroendocrine Carcinoma","code":"C6879","definitions":[{"definition":"A carcinoma that arises from the pancreas and is composed of ductal adenocarcinoma and neuroendocrine carcinoma components in both the primary tumor and the metastatic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mixed Ductal Adenocarcinoma-Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Ductal-Endocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal-Endocrine Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mixed Ductal Adenocarcinoma-NEC","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mixed Ductal-Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Ductal-Endocrine_Carcinoma"},{"name":"Maps_To","value":"Mixed ductal-endocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301048"}]}}{"C39912":{"preferredName":"Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified","code":"C39912","definitions":[{"definition":"A testicular mixed germ cell-sex cord-stromal tumor in which the neoplastic germ cells and the neoplastic sex cord-stromal cells do not form nests and are instead arranged in a diffuse pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Testicular_Mixed_Germ_Cell-Sex_Cord-Stromal_Tumor_Unclassified"},{"name":"Maps_To","value":"Mixed germ cell sex cord-stromal tumor, unclassified"},{"name":"NCI_META_CUI","value":"CL448662"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8025":{"preferredName":"Malignant Mixed Tumor of the Salivary Gland","code":"C8025","definitions":[{"definition":"A malignant tumor arising from the salivary gland.  It includes carcinoma ex pleomorphic adenoma, a malignant epithelial tumor arising from a pre-existing pleomorphic adenoma and carcinosarcoma which is characterized by a mixture of malignant epithelial and sarcomatous elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mixed Tumor of the Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mixed Cell Type Neoplasm of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Cell Type Neoplasm of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Neoplasm of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Neoplasm of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Tumor of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Cell Type Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Cell Type Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Neoplasm of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Neoplasm of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Salivary Gland Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Salivary Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Tumor of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Tumor of the Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Mixed_Tumor_of_the_Salivary_Gland"},{"name":"Maps_To","value":"Mixed tumor, malignant, NOS"},{"name":"Maps_To","value":"Mixed tumor, salivary gland type, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0344459"}]}}{"C121786":{"preferredName":"Mixed Tumor, Not Otherwise Specified","code":"C121786","definitions":[{"definition":"A benign myoepithelioma characterized by the presence of a minor ductal component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Tumor, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed tumor, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4049618"}]}}{"C127905":{"preferredName":"Cervical Mucinous Adenocarcinoma, Gastric Type","code":"C127905","definitions":[{"definition":"A cervical mucinous adenocarcinoma showing gastric differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Mucinous Adenocarcinoma, Gastric Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Mon Jul 19 15:28:50 EDT 2021 - See 'Human Papillomavirus-Independent Cervical Adenocarcinoma, Gastric-Type(C40206)'"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"OLD_PARENT","value":"C180848"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40203":{"preferredName":"Cervical Mucinous Adenocarcinoma, Intestinal-Type","code":"C40203","definitions":[{"definition":"A cervical mucinous adenocarcinoma that resembles a large intestinal adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Mucinous Adenocarcinoma, Intestinal-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Intestinal Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Intestinal Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cervical_Mucinous_Adenocarcinoma_Intestinal_Variant"},{"name":"Maps_To","value":"Mucinous carcinoma, intestinal type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516422"}]}}{"C39807":{"preferredName":"Mucinous Tubular and Spindle Cell Carcinoma of the Kidney","code":"C39807","definitions":[{"definition":"A low grade carcinoma of the kidney characterized by the presence of tubules which are separated by mucinous stroma. Often the tubular structures have a spindle cell appearance.  Patients are usually asymptomatic and occasionally they may present with hematuria or flank pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Tubular and Spindle Cell Carcinoma of the Kidney","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"0000/0"},{"name":"Legacy Concept Name","value":"Mucinous_Tubular_and_Spindle_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Mucinous tubular and spindle cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1513719"}]}}{"C8648":{"preferredName":"Myelodysplastic Syndrome, Unclassifiable","code":"C8648","definitions":[{"definition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood; 2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDS, U","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-U","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome, Unclassifiable","termGroup":"AQ","termSource":"NCI"},{"termName":"Unclassifiable MDS","termGroup":"AQS","termSource":"NCI"},{"termName":"Unclassifiable Myelodysplastic Syndrome","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9989/3"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Syndrome_Unclassifiable"},{"name":"Maps_To","value":"Myelodysplastic syndrome, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0854809"}]}}{"C27780":{"preferredName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","code":"C27780","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"MDS/MPN, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/MPN, U","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/MPN-U","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Myeloproliferative_Disease_Unclassifiable"},{"name":"Maps_To","value":"Myelodysplastic and myeloproliferative disease, not elsewhere classified"},{"name":"Maps_To","value":"Myelodysplastic/myeloproliferative neoplasm, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1328061"}]}}{"C27701":{"preferredName":"Secondary Myelofibrosis","code":"C27701","definitions":[{"definition":"Myelofibrosis that develops in patients with a history of hematologic malignancies or toxic injury to the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Myelofibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secondary_Myelofibrosis"},{"name":"Maps_To","value":"Myelofibrosis as a result of myeloproliferative disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0242006"}]}}{"C191687":{"preferredName":"Invasive Nested Urothelial Carcinoma","code":"C191687","definitions":[{"definition":"Invasive urothelial carcinoma characterized by a nested growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Nested Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Nested Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nested urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1905262"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C155863":{"preferredName":"Poorly Differentiated Neuroendocrine Lesion","code":"C155863","definitions":[{"definition":"A neoplastic lesion with neuroendocrine differentiation and poorly differentiated histological features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Neuroendocrine Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, poorly differentiated"},{"name":"NCI_META_CUI","value":"CL562689"},{"name":"Semantic_Type","value":"Finding"}]}}{"C155861":{"preferredName":"Well Differentiated Neuroendocrine Lesion","code":"C155861","definitions":[{"definition":"A neoplastic lesion with neuroendocrine differentiation and well differentiated histological features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated Neuroendocrine Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neuroendocrine tumor, well differentiated"},{"name":"NCI_META_CUI","value":"CL562687"},{"name":"Semantic_Type","value":"Finding"}]}}{"C173720":{"preferredName":"Odontogenic Carcinoma","code":"C173720","definitions":[{"definition":"A carcinoma that arises from tooth-forming tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Odontogenic carcinoma"},{"name":"NCI_META_CUI","value":"CL1407572"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C173738":{"preferredName":"Odontogenic Sarcoma","code":"C173738","definitions":[{"definition":"A sarcoma that arises from tooth-forming tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Odontogenic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0542511"}]}}{"C129318":{"preferredName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","code":"C129318","definitions":[{"definition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted"},{"name":"NCI_META_CUI","value":"CL512489"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7072":{"preferredName":"Oncocytic Neoplasm","code":"C7072","definitions":[{"definition":"A benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm (oncocytes).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.  Representative examples include oncocytic neoplasms of the thyroid gland, and kidney. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Oncocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oncocytic_Neoplasm"},{"name":"Maps_To","value":"Oncocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378050"}]}}{"C121774":{"preferredName":"Malignant Ossifying Fibromyxoid Tumor","code":"C121774","definitions":[{"definition":"An ossifying fibromyxoid tumor characterized by the presence of high grade nuclear features or increased cellularity and more than two mitotic figures per 50 HPFs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ossifying Fibromyxoid Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ossifying fibromyxoid tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839955"}]}}{"C45837":{"preferredName":"Non-Functioning Pancreatic Neuroendocrine Tumor","code":"C45837","definitions":[{"definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the absence of a hormone-related clinical syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Functioning Pancreatic Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Inactive Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"NF-PanNET","termGroup":"AB","termSource":"NCI"},{"termName":"Non-Functional Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Functioning Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Functioning Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Functioning Well Differentiated Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Syndromic Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Syndromic Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonfunctional Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Nonfunctional Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonfunctioning Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonsyndromic Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonsyndromic Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/3"},{"name":"Legacy Concept Name","value":"Non-Functioning_Well_Differentiated_Pancreatic_Endocrine_Neoplasm"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, nonfunctioning"},{"name":"Maps_To","value":"Pancreatic neuroendocrine tumor, nonfunctioning"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839703"}]}}{"C45834":{"preferredName":"Pancreatic Neuroendocrine Microtumor","code":"C45834","definitions":[{"definition":"A non-functioning pancreatic neuroendocrine tumor measuring less than 0.5 cm in diameter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Microtumor","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Endocrine Microadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Neuroendocrine Microadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/0"},{"name":"Legacy Concept Name","value":"Pancreatic_Endocrine_Microadenoma"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, benign"},{"name":"Maps_To","value":"Pancreatic microadenoma"},{"name":"Maps_To","value":"Pancreatic neuroendocrine microadenoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709454"}]}}{"C4179":{"preferredName":"Papillary Cystic Neoplasm","code":"C4179","definitions":[{"definition":"A benign, malignant, or borderline epithelial neoplasm characterized by the presence of papillary mucinous, serous, or clear cell structures and cystic structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Cystic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Cystic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Cystic_Neoplasm"},{"name":"Maps_To","value":"Papillary cystic tumor"},{"name":"Maps_To","value":"Solid and cystic tumor"},{"name":"Maps_To","value":"Solid and papillary epithelial neoplasm"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334357"}]}}{"C173928":{"preferredName":"Periapical Cemento-Osseous Dysplasia","code":"C173928","definitions":[{"definition":"Cemento-osseous dysplasia affecting the apical areas of mandibular anterior teeth. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periapical Cemento-Osseous Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"PCOD","termGroup":"AB","termSource":"NCI"},{"termName":"Periapical COD","termGroup":"SY","termSource":"NCI"},{"termName":"Periapical Osseous Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Periapical cemental dysplasia"},{"name":"Maps_To","value":"Periapical cemento-osseous dysplasia"},{"name":"NCI_META_CUI","value":"CL1407696"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C121789":{"preferredName":"Malignant Phosphaturic Mesenchymal Tumor","code":"C121789","definitions":[{"definition":"A phosphaturic mesenchymal tumor characterized by the presence of nuclear atypia, high mitotic activity, increased cellularity, marked pleomorphism, and necrosis. It usually develops in lesions that have recurred locally and metastasizes to other sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Phosphaturic Mesenchymal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phosphaturic mesenchymal tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839061"}]}}{"C97051":{"preferredName":"Invasive Breast Lobular Carcinoma, Pleomorphic Variant","code":"C97051","definitions":[{"definition":"A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Pleomorphic Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Pleomorphic Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleomorphic lobular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273216"}]}}{"C45339":{"preferredName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","code":"C45339","definitions":[{"definition":"An aggressive, epidermotropic primary cutaneous T-cell lymphoma.  It is characterized by the presence of eruptive papules and nodules, or tumors, which may be localized or disseminated.  Morphologically, it is composed of small to medium-sized, or medium-sized to large, CD8-positive T-lymphocytes with pleomorphic or blastic nuclei.  Epidermotropism is often pronounced.  Angiocentricity and angioinvasion may be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9709/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_Aggressive_Epidermotropic_CD8-Positive_T-Cell_Lymphoma"},{"name":"Maps_To","value":"Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709653"}]}}{"C45194":{"preferredName":"Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","code":"C45194","definitions":[{"definition":"An aggressive primary cutaneous B-cell lymphoma, usually involving the lower leg.  It is composed of a generally monotonous proliferation of immunoblasts, or less frequently centroblasts, with few admixed reactive cells.  This type of lymphoma occurs most often in elderly women who present with rapidly growing tumors, usually on one or both legs.  Dissemination to extracutaneous sites is frequent.  Treatment with combination chemotherapy is usually required.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_Diffuse_Large_B-Cell_Lymphoma_Leg_Type"},{"name":"Maps_To","value":"Primary cutaneous DLBCL, leg type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709656"}]}}{"C71720":{"preferredName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","code":"C71720","definitions":[{"definition":"A diffuse large B-cell lymphoma arising from the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Diffuse Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Primary Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"CNS DLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"CNS Primary Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PCNS-LBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Diffuse Large B-Cell Lymphoma of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Primary DLBCL of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Large B-Cell Lymphoma of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Large B-Cell Lymphoma of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Diffuse_Large_B-Cell_Lymphoma"},{"name":"Maps_To","value":"Primary diffuse large B-cell lymphoma of the CNS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2026186"}]}}{"C142825":{"preferredName":"Pulmonary Artery Intimal Sarcoma","code":"C142825","definitions":[{"definition":"A sarcoma arising from the arterial intima of pulmonary arteries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Artery Intimal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Intimal Sarcoma of the Pulmonary Artery","termGroup":"SY","termSource":"NCI"},{"termName":"PAIS","termGroup":"AB","termSource":"NCI"},{"termName":"PAS","termGroup":"AB","termSource":"NCI"},{"termName":"PIS","termGroup":"AB","termSource":"NCI"},{"termName":"Pulmonary Artery Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Intimal Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary artery intimal sarcoma"},{"name":"NCI_META_CUI","value":"CL540697"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7168":{"preferredName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","code":"C7168","definitions":[{"definition":"A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"MDS with Increased Blasts-2","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-EB-2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-EB2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB-2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/AML","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Excess Blasts-2","termGroup":"SY","termSource":"NCI"},{"termName":"RAEB-2","termGroup":"AB","termSource":"NCI"},{"termName":"RAEB-II","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"RAEB-2"},{"name":"Maps_To","value":"RAEB II"},{"name":"Maps_To","value":"Refractory anemia with excess of blasts 2"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1318551"}]}}{"C9385":{"preferredName":"Renal Cell Carcinoma","code":"C9385","definitions":[{"definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from renal parenchyma.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from the renal parenchyma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"RCC","termGroup":"AB","termSource":"NCI"},{"termName":"Renal Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Stage Unspecified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8311/1"},{"name":"ICD-O-3_Code","value":"8312/3"},{"name":"Legacy Concept Name","value":"Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Renal cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1861854"}]}}{"C7572":{"preferredName":"Kidney Medullary Carcinoma","code":"C7572","definitions":[{"definition":"A type of renal carcinoma affecting mostly young African-Americans.  It is located in the medulla of the kidney, and follows an aggressive clinical course.  Most reported cases have shown metastatic disease at the time of diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kidney Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Renal Medullary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Medullary_Carcinoma"},{"name":"Maps_To","value":"Renal medullary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4049328"}]}}{"C5568":{"preferredName":"Skin Nodulo-Ulcerative Basal Cell Carcinoma","code":"C5568","definitions":[{"definition":"A type of basal cell carcinoma of the skin.  It appears as a flesh-colored papule with telangiectatic vessels on its surface.  It grows slowly; as it enlarges it becomes necrotic forming a central ulcer with raised borders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Nodulo-Ulcerative Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Nodulo-Ulcerative Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Rodent Ulcer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nodulo-Ulcerative_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"Rodent ulcer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862887"}]}}{"C5904":{"preferredName":"Salivary Duct Carcinoma","code":"C5904","definitions":[{"definition":"An aggressive, high grade adenocarcinoma that arises from the salivary glands. It usually affects elderly males and presents as a rapidly enlarging mass. It metastasizes to regional lymph nodes and distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Duct Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Salivary Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Salivary Duct","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Salivary Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SDC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salivary_Duct_Carcinoma"},{"name":"Maps_To","value":"Salivary duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301194"}]}}{"C49027":{"preferredName":"Sclerosing Epithelioid Fibrosarcoma","code":"C49027","definitions":[{"definition":"A well-circumscribed malignant fibroblastic neoplasm that usually arises from the soft tissue. It is characterized by the presence of nests of malignant epithelioid fibroblasts and sclerotic collagen stroma formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosing Epithelioid Fibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"SEF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sclerosing_Epithelioid_Fibrosarcoma"},{"name":"Maps_To","value":"Sclerosing epithelioid fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1710026"}]}}{"C121655":{"preferredName":"Sclerosing Rhabdomyosarcoma","code":"C121655","definitions":[{"definition":"An uncommon variant of rhabdomyosarcoma with sclerosing morphology.  It usually arises from the limbs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosing Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sclerosing rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4048700"}]}}{"C36310":{"preferredName":"Secondary Carcinoma","code":"C36310","definitions":[{"definition":"A carcinoma that arises from a pre-existing lower grade epithelial lesion, or as a result of a primary carcinoma that has spread to secondary sites, or due to a complication of a cancer treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secondary_Carcinoma"},{"name":"Maps_To","value":"Secondary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0085668"}]}}{"C40152":{"preferredName":"Serous Endometrial Intraepithelial Carcinoma","code":"C40152","definitions":[{"definition":"A precursor of endometrial serous adenocarcinoma characterized by the replacement of the normal endometrial cells by malignant glandular cells that resemble the malignant cells of invasive serous adenocarcinoma. The endometrial neoplastic process is non-invasive. It may coexist with invasive endometrial adenocarcinoma or can be associated with metastases outside the uterus, in the absence of invasive endometrial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Endometrial Intraepithelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"EIC","termGroup":"AB","termSource":"NCI"},{"termName":"Endometrial Intraepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Serous Carcinoma in Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Serous Intraepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Surface Serous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SEIC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Endometrial_Serous_Intraepithelial_Carcinoma"},{"name":"Maps_To","value":"Serous endometrial intraepithelial carcinoma"},{"name":"Maps_To","value":"Serous intraepithelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516857"}]}}{"C40440":{"preferredName":"Ovarian Small Cell Carcinoma, Pulmonary-Type","code":"C40440","definitions":[{"definition":"An aggressive small cell neuroendocrine carcinoma that arises from the ovary.  Morphologically, it resembles the small cell carcinoma that arises from the lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Small Cell Carcinoma, Pulmonary-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Small Cell NEC","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Small Cell Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Small_Cell_Carcinoma_Pulmonary_Type"},{"name":"Maps_To","value":"Small cell carcinoma pulmonary type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518737"}]}}{"C40439":{"preferredName":"Ovarian Small Cell Carcinoma, Hypercalcemic Type","code":"C40439","definitions":[{"definition":"An undifferentiated small cell carcinoma that arises from the ovary and is associated with hypercalcemia.  Electron microscopic studies show neurosecretory granules are either absent or, when present, are in small numbers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Small Cell Carcinoma, Hypercalcemic Type","termGroup":"PT","termSource":"NCI"},{"termName":"SCCOHT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Small_Cell_Carcinoma_Hypercalcemic_Type"},{"name":"Maps_To","value":"Small cell carcinoma, hypercalcemic type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518736"}]}}{"C3751":{"preferredName":"Smooth Muscle Neoplasm","code":"C3751","definitions":[{"definition":"A benign or malignant myomatous neoplasm arising from smooth muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smooth Muscle Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Smooth Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Smooth Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Smooth Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Smooth Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Smooth Muscle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Smooth_Muscle_Neoplasm"},{"name":"Maps_To","value":"Smooth muscle tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206658"}]}}{"C129530":{"preferredName":"Central Nervous System Solitary Fibrous Tumor, Grade 1","code":"C129530","definitions":[{"definition":"A solitary fibrous tumor that arises from the central nervous system. It corresponds most often to the collagenous and low cellularity spindle cell tumor which was diagnosed as central nervous system solitary fibrous tumor in the past.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Solitary Fibrous Tumor, Grade 1","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor, Grade 1","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)"},{"name":"Maps_To","value":"Solitary fibrous tumor/Hemangiopericytoma, grade 1"},{"name":"NCI_META_CUI","value":"CL512613"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129527":{"preferredName":"Central Nervous System Solitary Fibrous Tumor, Grade 3","code":"C129527","definitions":[{"definition":"A solitary fibrous tumor that arises from the central nervous system. It most often corresponds to the tumor previously diagnosed as anaplastic hemangiopericytoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Solitary Fibrous Tumor, Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Anaplastic Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Malignant Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor, Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)"},{"name":"NCI_META_CUI","value":"CL512610"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C94537":{"preferredName":"Spindle Cell Oncocytoma","code":"C94537","definitions":[{"definition":"A very rare, WHO grade 1 neoplasm of the posterior pituitary. It is characterized by the presence of spindle cells with eosinophilic, granular cytoplasm forming fascicles.  Electron microscopic studies demonstrate the accumulation of intracytoplasmic mitochondria and lack of secretory granules.  Immunohistochemical studies are negative for pituitary hormones.  Patients may present with pituitary hypofunction, visual disturbances, headache, nausea and vomiting.  The clinical course is usually benign.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Oncocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Folliculo-Stellate Cell Tumor of the Pituitary","termGroup":"AQS","termSource":"NCI"},{"termName":"SCO","termGroup":"AB","termSource":"NCI"},{"termName":"Spindle Cell Oncocytoma of the Adenohypophysis","termGroup":"AQS","termSource":"NCI"},{"termName":"Spindle Cell Oncocytoma of the Adenohypophysis (WHO Grade 1)","termGroup":"AQS","termSource":"NCI"},{"termName":"Spindle Cell Oncocytoma/Oncocytic Pituicytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8290/0"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Oncocytoma"},{"name":"Maps_To","value":"Spindle cell oncocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2986561"}]}}{"C40194":{"preferredName":"Cervical Squamotransitional Carcinoma","code":"C40194","definitions":[{"definition":"A human papillomavirus-related cervical squamous cell carcinoma characterized by the presence of papillary structures with fibrovascular cores. It is covered with multiple layers of atypical cells that resemble cervical intraepithelial neoplasia 3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Squamotransitional Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cervical_Squamotransitional_Carcinoma"},{"name":"Maps_To","value":"Squamotransitional cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516433"}]}}{"C176980":{"preferredName":"Superficial Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C176980","definitions":[{"definition":"An atypical lipomatous tumor/well differentiated liposarcoma that occurs in a superficial body structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Superficial ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Atypical Lipomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Well Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superficial well differentiated liposarcoma"},{"name":"Maps_To","value":"Well differentiated liposarcoma of superficial soft tissue"},{"name":"NCI_META_CUI","value":"CL1642763"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6900":{"preferredName":"Epithelioid Trophoblastic Tumor","code":"C6900","definitions":[{"definition":"A gestational trophoblastic tumor characterized by the presence of a monomorphous cellular population of intermediate trophoblastic cells infiltrating in a nodular pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Trophoblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"ETT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9105/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Trophoblastic_Tumor"},{"name":"Maps_To","value":"9105/3"},{"name":"Maps_To","value":"Trophoblastic tumor, epithelioid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266159"}]}}{"C35382":{"preferredName":"True Histiocytic Lymphoma","code":"C35382","definitions":[{"definition":"An antiquated term referring to large cell lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"An outdated term referring to non-Hodgkin lymphomas made up of large abnormal lymphoid cells. Histiocytic lymphomas include mature B-cell and T-cell non-Hodgkin lymphomas. Many tumors that were once called histiocytic lymphomas are now considered to be a type of large cell lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"True Histiocytic Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"True_Histiocytic_Lymphoma"},{"name":"Maps_To","value":"True histiocytic lymphoma"},{"name":"NCI_META_CUI","value":"CL414775"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C126303":{"preferredName":"Tubulocystic Renal Cell Carcinoma","code":"C126303","definitions":[{"definition":"A rare, cytologically high grade carcinoma that arises from the renal parenchyma. It is characterized by the presence of prominently dilated cystic spaces in a bland, fibrotic stroma. The lining cells have large irregular nuclei with prominent nucleoli and abundant eosinophilic cytoplasm. Necrosis and mitotic figures are not present. It rarely metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulocystic Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"TcRCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tubulocystic renal cell carcinoma"},{"name":"NCI_META_CUI","value":"CL504875"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C121802":{"preferredName":"Undifferentiated Epithelioid Sarcoma","code":"C121802","definitions":[{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a malignant cellular infiltrate with epithelioid morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Epithelioid Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Undifferentiated epithelioid sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4053898"}]}}{"C121799":{"preferredName":"Undifferentiated Round Cell Sarcoma","code":"C121799","definitions":[{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of uniform round or ovoid malignant cells with a high nuclear to cytoplasmic ratio.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Round Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Undifferentiated round cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4048304"}]}}{"C121797":{"preferredName":"Undifferentiated Spindle Cell Sarcoma","code":"C121797","definitions":[{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a malignant spindle cell infiltrate with amphophilic or palely eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Spindle Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Undifferentiated spindle cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4048234"}]}}{"C8972":{"preferredName":"Uterine Corpus Undifferentiated Sarcoma","code":"C8972","definitions":[{"definition":"A rare, high grade sarcoma that arises from the endometrial stroma or myometrium without a specific type of differentiation. It was previously also known as high grade endometrial stromal sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. Undifferentiated uterine sarcoma has a worse prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Undifferentiated Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Undifferentiated Uterine Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Undifferentiated Endometrial Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Undifferentiated_Uterine_Sarcoma"},{"name":"Maps_To","value":"Undifferentiated uterine sarcoma"},{"name":"NCI_META_CUI","value":"CL033042"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C39842":{"preferredName":"Urachal Carcinoma","code":"C39842","definitions":[{"definition":"A rare variant of carcinoma of the urachal remnant of bladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urachal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bladder Urachal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Urachal_Carcinoma"},{"name":"Maps_To","value":"Malignant neoplasm of urachus"},{"name":"Maps_To","value":"Urachal carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511205"}]}}{"C191681":{"preferredName":"Invasive Urothelial Carcinoma with Squamous Differentiation","code":"C191681","definitions":[{"definition":"An invasive urothelial carcinoma that exhibits squamous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Urothelial Carcinoma with Squamous Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Urothelial Carcinoma with Squamous Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urothelial carcinoma with squamous differentiation"},{"name":"NCI_META_CUI","value":"CL1905274"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C191682":{"preferredName":"Invasive Urothelial Carcinoma with Trophoblastic Differentiation","code":"C191682","definitions":[{"definition":"An invasive urothelial carcinoma characterized by the presence of trophoblastic differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Urothelial Carcinoma with Trophoblastic Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Urothelial Carcinoma with Trophoblastic Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urothelial carcinoma with trophoblastic differentiation"},{"name":"NCI_META_CUI","value":"CL1905273"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C89476":{"preferredName":"Stage 0 Vaginal Cancer AJCC v7","code":"C89476","definitions":[{"definition":"Abnormal cells are found in tissue lining the inside of the vagina (birth canal). These abnormal cells may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (preinvasive carcinoma). N0: No regional lymph node metastasis.  M0: No distant metastasis.  FIGO no longer includes stage 0. (AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Vaginal Cancer AJCC v7","termGroup":"PT","termSource":"NCI"},{"termName":"Grade III Vaginal Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Vaginal Intraepithelial Neoplasia AJCC v7","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vaginal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Intraepithelial Neoplasia Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Intraepithelial Neoplasia Grade 3 AJCC v7","termGroup":"SY","termSource":"NCI"},{"termName":"VAIN 3","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN 3 AJCC v7","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN III","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN III AJCC v7","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Maps_To","value":"VAIN III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3146269"}]}}{"C40208":{"preferredName":"Cervical Villoglandular Adenocarcinoma","code":"C40208","definitions":[{"definition":"A cervical adenocarcinoma characterized by the presence of a prominent villoglandular pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Villoglandular Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical Adenocarcinoma, Villoglandular Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Villoglandular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cervical_Mucinous_Adenocarcinoma_Villoglandular_Variant"},{"name":"Maps_To","value":"Villoglandular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516425"}]}}{"C7635":{"preferredName":"Well Differentiated Papillary Mesothelial Tumor","code":"C7635","definitions":[{"definition":"A localized or multifocal mesothelial neoplasm arising from the peritoneum and less often the pleura and paratesticular region. Cases arising from the peritoneum predominantly occur in women. It is characterized by the formation of papillae, covered by a single layer of blunt mesothelial cells. Mitotic figures are not present. There is no evidence of severe cytologic atypia. It has a relatively favorable clinical outcome, compared to malignant mesothelioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated Papillary Mesothelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"WDPMT","termGroup":"AB","termSource":"NCI"},{"termName":"Well-Differentiated Mesothelial Papillary Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Mesothelial Papillary Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Neoplasm of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Neoplasm of the Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Tumor of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Tumor of the Mesothelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"ICD-O-3_Code","value":"9052/1"},{"name":"Legacy Concept Name","value":"Well-Differentiated_Papillary_Mesothelioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1337012"}]}}{"C139012":{"preferredName":"Breast Implant-Associated Anaplastic Large Cell Lymphoma","code":"C139012","definitions":[{"definition":"A non-Hodgkin lymphoma which is associated with breast implants, and consists of large anaplastic cells. The WHO diagnostic criteria for BIA-ALCL includes positive expression of CD30 (CD30+) and negativity for anaplastic lymphoma kinase (ALK-).","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A rare anaplastic large cell lymphoma that develops in individuals with breast implants. It usually presents as an accumulation of seroma fluid between the implant and the surrounding fibrous capsule. The median interval from the time of the implant to the development of lymphoma is approximately 10 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Implant-Associated Anaplastic Large Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"BIA-ALCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast implant-associated anaplastic large cell lymphoma"},{"name":"NCI_META_CUI","value":"CL526545"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"xRef","value":"IMDRF:E180102"}]}}{"C139021":{"preferredName":"Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","code":"C139021","definitions":[{"definition":"A clonal T-cell lymphoproliferative disorder that can involve the mucosa in all sites of the gastrointestinal tract, but is most common in the small intestine and colon. The lymphoid cells infiltrate the lamina propria but usually do not show invasion of the epithelium. The clinical course is indolent, but most patients do not respond to conventional chemotherapy. A subset of cases progress to a higher-grade T-cell lymphoma with spread beyond the gastrointestinal tract. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","termGroup":"PT","termSource":"NCI"},{"termName":"Indolent T-Cell Lymphoma of the Gastrointestinal Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","termGroup":"SY","termSource":"NCI"},{"termName":"ITLPD-GI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indolent T-cell lymphoproliferative disorder of gastrointestinal tract"},{"name":"NCI_META_CUI","value":"CL526526"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C185467":{"preferredName":"Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype","code":"C185467","definitions":[{"definition":"An aggressive, WHO grade 4 diffuse brain glioma usually affecting children, adolescents, or young adults. It is characterized by the absence of histone H3, IDH1, and IDH2 mutations. It includes the following subtypes, based on DNA methylation profiles: diffuse pediatric-type high grade glioma RTK1, diffuse pediatric-type high grade glioma RTK2, and diffuse pediatric-type high grade glioma MYCN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse High Grade Glioma in Childhood, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse High-Grade Glioma in Childhood, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Glioblastoma, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric-Type Glioblastoma, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"pHGG, H3-Wildtype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse Pediatric-type High Grade Glioma"},{"name":"NCI_META_CUI","value":"CL1773755"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C28085":{"preferredName":"Gleason Pattern 1","code":"C28085","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of a well circumscribed nodule of separate glands which are closely packed. There is no infiltration of the surrounding parenchyma. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 1","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_1"},{"name":"Maps_To","value":"Pattern 1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276439"}]}}{"C28086":{"preferredName":"Gleason Pattern 2","code":"C28086","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of glands that are more loosely arranged and less uniform compared to Gleason pattern 1. Minimal invasion of the surrounding parenchyma may be present. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 2","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_2"},{"name":"Maps_To","value":"Pattern 2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276440"}]}}{"C28087":{"preferredName":"Gleason Pattern 3","code":"C28087","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of glands that are infiltrative and vary in size and shape. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 3","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_3"},{"name":"Maps_To","value":"Pattern 3"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276441"}]}}{"C139578":{"preferredName":"Stage R0","code":"C139578","definitions":[{"definition":"No detectable presence of residual tumor after treatment","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage R0","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage 0","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage R0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"R0"},{"name":"Maps_To","value":"Stage R0"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0475288"}]}}{"C139579":{"preferredName":"Stage R1","code":"C139579","definitions":[{"definition":"Presence of microscopic residual tumor after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage R1","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage 1","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage R1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"R1"},{"name":"Maps_To","value":"Stage R1"},{"name":"NCI_META_CUI","value":"CL526878"},{"name":"Semantic_Type","value":"Classification"}]}}{"C139580":{"preferredName":"Stage R2","code":"C139580","definitions":[{"definition":"Presence of macroscopic residual tumor after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage R2","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage 2","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage R2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"R2"},{"name":"Maps_To","value":"Stage R2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0475826"}]}}{"C139581":{"preferredName":"Stage RX","code":"C139581","definitions":[{"definition":"Presence of residual tumor after treatment cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage RX","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage RX","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage Unknown","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage X","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RX"},{"name":"Maps_To","value":"Stage RX"},{"name":"Maps_To","value":"Unknown"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0475287"}]}}{"C12252":{"preferredName":"Abdominal Esophagus","code":"C12252","definitions":[{"definition":"Clinical esophageal segment composed of smooth muscle. It corresponds to the inferior part of the lower third topographic segment of the esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"Clinical esophageal segment composed of smooth muscle. It corresponds to the inferior part of the lower third topographic segment of the esophagus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Abdominal Esophagus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Abdominal_Esophagus"},{"name":"Maps_To","value":"Abdominal esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227190"}]}}{"C12697":{"preferredName":"Cochlear Nerve","code":"C12697","definitions":[{"definition":"The cochlear portion of cranial nerve VIII (the vestibulocochlear nerve), which transmits auditory sensory impulses to the cochlear nucleus in the brainstem.","type":"DEFINITION","source":"NCI"},{"definition":"The cochlear portion of the vestibulocochlear nerve, which transmits auditory sensory impulses to the cochlear nucleus in the brainstem.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cochlear Nerve","termGroup":"PT","termSource":"NCI"},{"termName":"Cochlear Root of Acoustic Nerve","termGroup":"SY","termSource":"NCI"},{"termName":"Cochlear Root of Eighth Cranial Nerve","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cochlear_Nerve"},{"name":"Maps_To","value":"Acoustic nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009201"}]}}{"C13011":{"preferredName":"Ampulla of Vater","code":"C13011","definitions":[{"definition":"A dilation of the duodenal papilla that is the opening of the juncture of the common bile duct and the main pancreatic duct.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An enlargement of the ducts from the liver and pancreas at the point where they enter the small intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The junction of the common bile and main pancreatic ducts, which protrudes into the medial aspect of the descending duodenum at the major duodenal papilla.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The junction of the common bile and main pancreatic ducts, which protrudes into the medial aspect of the descending duodenum at the major duodenal papilla. The flow of bile and pancreatic juices into the duodenum through the Ampulla of Vater is controlled by the sphincter of Oddi.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampulla of Vater","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatopancreatic Ampulla","termGroup":"SY","termSource":"NCI"},{"termName":"Vater's Ampulla","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ampulla_of_Vater"},{"name":"Maps_To","value":"Ampulla of Vater"},{"name":"Maps_To","value":"Ampulla Of Vater"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042425"},{"name":"xRef","value":"UBERON:0004913"}]}}{"C12375":{"preferredName":"Anal Canal","code":"C12375","definitions":[{"definition":"The terminal section of the alimentary canal, which extends from the anorectal junction and ends at the anal opening.","type":"DEFINITION","source":"NCI"},{"definition":"The terminal section of the alimentary canal, which extends from the anorectal junction and ends at the anal opening. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"excludes skin of anus and perianal skin C44.5","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Anal Canal","termGroup":"PT","termSource":"NCI"},{"termName":"Functional Anal Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Surgical Anal Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Anal_Canal"},{"name":"Maps_To","value":"Anal canal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227411"}]}}{"C32098":{"preferredName":"Anterior Mediastinum","code":"C32098","definitions":[{"definition":"The area between the lungs; it contains the thymus, some lymph nodes, and vessels and branches of the internal thoracic artery.","type":"DEFINITION","source":"NCI"},{"definition":"The area between the lungs; it contains the thymus, some lymph nodes, and vessels and branches of the internal thoracic artery. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The area in the front part of the chest between the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anterior Mediastinum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Mediastinum"},{"name":"Maps_To","value":"Anterior mediastinum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230148"}]}}{"C12238":{"preferredName":"Anterior Surface of the Epiglottis","code":"C12238","definitions":[{"definition":"The lingual or upper surface of the epiglottis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anterior Surface of the Epiglottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Surface_of_the_Epiglottis"},{"name":"Maps_To","value":"Anterior surface of epiglottis"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227160"}]}}{"C12334":{"preferredName":"Anterior Wall of the Bladder","code":"C12334","definitions":[{"definition":"The anterior aspect of the bladder wall.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anterior Wall of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Anterior Wall of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Wall_of_the_Bladder"},{"name":"Maps_To","value":"Anterior wall of bladder"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0559280"}]}}{"C12245":{"preferredName":"Anterior Wall of the Nasopharynx","code":"C12245","definitions":[{"definition":"The anterior aspect of the nasopharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anterior Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Anterior Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Anterior wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225489"}]}}{"C43362":{"preferredName":"Anus","code":"C43362","definitions":[{"definition":"Orifice at the opposite end of an animal's digestive tract from the mouth. Its function is to expel feces, unwanted semi-solid matter produced during digestion, which, depending on the type of animal, may be one or more of: matter which the animal cannot digest, such as bones; food material after all the nutrients have been extracted, for example cellulose or lignin; ingested matter which would be toxic if it remained in the digestive tract; and dead or excess gut bacteria and other endosymbionts.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The distal orifice of the digestive tract located between the rectum and the external surface of the body, comprising glandular, transitional, and squamous epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.","type":"DEFINITION","source":"NCI"},{"definition":"The opening of the rectum to the outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Anus"},{"name":"Maps_To","value":"Anus"},{"name":"Maps_To","value":"Anus, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003461"},{"name":"xRef","value":"UBERON:0001245"}]}}{"C12380":{"preferredName":"Appendix","code":"C12380","definitions":[{"definition":"A blind-ended tube connected to the cecum, from which it develops embryologically.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A pouch-like tissue attached to the cecum, which may exist as a diverticulum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A small, fingerlike pouch that sticks out from the cecum (the first part of the large intestine near the end of the small intestine).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Appendix","termGroup":"PT","termSource":"NCI"},{"termName":"Vermiform Appendix","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vermiform_Appendix"},{"name":"Maps_To","value":"Appendix"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003617"},{"name":"xRef","value":"UBERON:0001154"}]}}{"C12265":{"preferredName":"Ascending Colon","code":"C12265","definitions":[{"definition":"Section of colon which is distal to the cecum and proximal to the transverse colon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ascending Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ascending_Colon"},{"name":"Maps_To","value":"Ascending Colon"},{"name":"Maps_To","value":"Ascending colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227375"},{"name":"xRef","value":"UBERON:0001156"}]}}{"C12673":{"preferredName":"Autonomic Nervous System","code":"C12673","definitions":[{"definition":"The autonomic nervous system is composed of neurons that are not under conscious control, and is comprised of two antagonistic components, the sympathetic and parasympathetic nervous systems. The autonomic nervous system regulates key functions including the activity of the cardiac (heart) muscle, smooth muscles (e.g. of the gut), and glands.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the nervous system of vertebrates that controls involuntary actions of the smooth muscles and heart and glands.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the nervous system that controls muscles of internal organs (such as the heart, blood vessels, lungs, stomach, and intestines) and glands (such as salivary glands and sweat glands). One part of the autonomic nervous system helps the body rest, relax, and digest food and another part helps a person fight or take flight in an emergency.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Autonomic Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"Autonomic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Autonomic_Nervous_System"},{"name":"Maps_To","value":"Autonomic Nervous System"},{"name":"Maps_To","value":"Autonomic nervous system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0004388"},{"name":"xRef","value":"UBERON:0002410"}]}}{"C12305":{"preferredName":"Axillary Tail of the Breast","code":"C12305","definitions":[{"definition":"The superolateral extension of the mammary gland into the axilla that consists of fibroadipose tissue, lymph nodes, and lymphatics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axillary Tail of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Axillary Process of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Axillary Tail of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Tail of Spence","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Axillary_Tail_of_the_Breast"},{"name":"Maps_To","value":"Axillary tail of breast"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0222611"}]}}{"C12678":{"preferredName":"Biliary Tract","code":"C12678","definitions":[{"definition":"The duct system that transports bile from its origination by hepatocytes in the liver to the small intestine. It is comprised of the common bile duct that connects the liver and gall bladder to the small intestine and the cystic duct that connects the gall bladder to the common bile duct. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organs and ducts that make and store bile (a fluid made by the liver that helps digest fat), and release it into the small intestine. The biliary tract includes the gallbladder and bile ducts inside and outside the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The system that transports bile from the hepatocytes in the liver to the small intestine. It is comprised of the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, and the gallbladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biliary Tract","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary System","termGroup":"SY","termSource":"NCI"},{"termName":"Tract, Biliary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Biliary_Tract"},{"name":"Maps_To","value":"Biliary tract, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005423"},{"name":"xRef","value":"IMDRF:E11"}]}}{"C12336":{"preferredName":"Bladder Neck","code":"C12336","definitions":[{"definition":"The inferior portion of the urinary bladder which is formed as the walls of the bladder converge and become contiguous with the proximal urethra.","type":"DEFINITION","source":"NCI"},{"definition":"The inferior portion of the urinary bladder which is formed as the walls of the bladder converge and become contiguous with the proximal urethra. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bladder Neck","termGroup":"PT","termSource":"NCI"},{"termName":"Cervix Vesicae","termGroup":"SY","termSource":"NCI"},{"termName":"Neck of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Neck"},{"name":"Maps_To","value":"Bladder neck"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227716"}]}}{"C12434":{"preferredName":"Blood","code":"C12434","definitions":[{"definition":"A fluid that is composed of blood plasma and erythrocytes.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A liquid tissue with the primary function of transporting oxygen and carbon dioxide. It supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","type":"DEFINITION","source":"NCI"},{"definition":"A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Blood","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Blood","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Blood"},{"name":"Maps_To","value":"Blood"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0005767"},{"name":"xRef","value":"UBERON:0000178"}]}}{"C12270":{"preferredName":"Body of the Pancreas","code":"C12270","definitions":[{"definition":"The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Body of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Body of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Body","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Body_of_the_Pancreas"},{"name":"Maps_To","value":"Body of pancreas"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227582"}]}}{"C12325":{"preferredName":"Body of the Penis","code":"C12325","definitions":[{"definition":"The portion of the penis between the glans penis and the radix penis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the penis that extends from the site of attachment to the glans, and which is covered by skin. It is formed by the joining of the two proximal free parts of the corpora cavernosa and the related free part of the corpus spongiosum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Body of the Penis","termGroup":"PT","termSource":"NCI"},{"termName":"Body of Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Body_of_the_Penis"},{"name":"Maps_To","value":"Body of penis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227936"}]}}{"C12258":{"preferredName":"Body of Stomach","code":"C12258","definitions":[{"definition":"The main section of the digestive tube that connects the esophagus to the small intestine. The body proper excludes the upper and lower sections of the fundus and pyloric portion respectively.","type":"DEFINITION","source":"NCI"},{"definition":"The main section of the digestive tube that connects the esophagus to the small intestine. The body proper excludes the upper and lower sections of the fundus and pyloric portion respectively. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Body of Stomach","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Body_of_Stomach"},{"name":"Maps_To","value":"Body of stomach"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227230"}]}}{"C32223":{"preferredName":"Bone of the Extremity","code":"C32223","definitions":[{"definition":"A bone within a limb of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone of the Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Bone of Extremity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bone_of_the_Extremity"},{"name":"Maps_To","value":"Bone of limb, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0582791"}]}}{"C12441":{"preferredName":"Brain Stem","code":"C12441","definitions":[{"definition":"Stalk-like part of the brain that includes amongst its parts the medulla oblongata of the hindbrain and the tegmentum of the midbrain.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the brain that connects the cerebral hemispheres with the spinal cord. It consists of the mesencephalon, pons, and medulla oblongata. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the brain that is connected to the spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Three sections, the midbrain, pons and medulla oblongata, that are located at the base of the brain. The brain stem regulates the central nervous system, and is vital as a conduit for motor and sensory innervations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brain Stem","termGroup":"PT","termSource":"NCI"},{"termName":"Brainstem","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Brain_Stem"},{"name":"Maps_To","value":"Brain stem"},{"name":"Maps_To","value":"Brain Stem"},{"name":"Maps_To","value":"Brain, Brain stem"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006121"},{"name":"xRef","value":"UBERON:0002298"}]}}{"C104813":{"preferredName":"Branchial Cleft Remnant","code":"C104813","definitions":[{"definition":"A congenital defect in the neck that occurs during early embryonic development.  It is caused by developmental abnormalities of the pharyngeal arches and results in the development of a cyst or a fissure in the side of the neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Branchial Cleft Remnant","termGroup":"PT","termSource":"NCI"},{"termName":"Branchial Cleft","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Branchial cleft"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"UMLS_CUI","value":"C0079037"}]}}{"C12318":{"preferredName":"Broad Ligament","code":"C12318","definitions":[{"definition":"A broad fold of peritoneum that extends from the side of the uterus to the wall of the pelvis.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A wide fold of peritoneum that connects the uterus to the lateral walls and floor of the pelvis, and also attaches to the ovaries, fallopian tubes, ovarian ligaments, round ligament of the uterus, and ovarian and uterine arteries.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A wide fold of peritoneum that connects the uterus to the lateral walls and floor of the pelvis, and contains the ovaries, fallopian tubes, ovarian ligaments, round ligament of the uterus, and ovarian and uterine arteries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broad Ligament","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Ligament","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Broad_Ligament"},{"name":"Maps_To","value":"Broad ligament"},{"name":"Maps_To","value":"Broad Ligament"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006205"},{"name":"xRef","value":"UBERON:0012332"}]}}{"C12256":{"preferredName":"Gastric Cardia","code":"C12256","definitions":[{"definition":"The area around the esophagogastric mucosal junction where the esophageal mucosa transitions into the gastric mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the stomach attached to the esophagus. The cardia begins immediately distal to the z-line of the gastroesophageal junction, where the squamous epithelium of the esophagus gives way to the columnar epithelium of the gastrointestinal tract.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region of the stomach adjacent to the esophogastric junction.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gastric Cardia","termGroup":"PT","termSource":"NCI"},{"termName":"Cardia","termGroup":"SY","termSource":"NCI"},{"termName":"Cardia of the Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cardia"},{"name":"Maps_To","value":"Cardia"},{"name":"Maps_To","value":"Cardia, NOS"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0007144"},{"name":"xRef","value":"UBERON:0001162"}]}}{"C66852":{"preferredName":"Carotid Body","code":"C66852","definitions":[{"definition":"A cluster of cells that function as chemo-receptors, located at the bifurcation of the carotid artery. Its main purpose is to detect changes in the composition of arterial blood.","type":"DEFINITION","source":"NCI"},{"definition":"A cluster of cells that function as chemo-receptors, located near the bifurcation of the carotid artery.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A small epithelioid structure consisting of a small cluster of chemoreceptive and supporting cells located near the bifurcation of the common carotid artery that serves as a chemoreceptive organ that senses the pH, carbon dioxide, and oxygen concentrations in the blood and plays a crucial role in their homeostatic control.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Carotid Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Carotid_Body"},{"name":"Maps_To","value":"Carotid body"},{"name":"Maps_To","value":"Carotid Body"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007277"},{"name":"xRef","value":"UBERON:0001629"}]}}{"C12689":{"preferredName":"Cauda Equina","code":"C12689","definitions":[{"definition":"The collection of spinal nerve roots, arising from lumbar pairs two through five, sacral pairs one through five, and the coccygeal nerve, that branch off the conus medularis at the termination of the spinal cord, and float freely within the lumbar cistern before exiting the spinal column at the appropriate vertebra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cauda Equina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cauda_Equina"},{"name":"Maps_To","value":"Cauda equina"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007458"}]}}{"C12381":{"preferredName":"Cecum","code":"C12381","definitions":[{"definition":"A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from On-line Medical Dictionary"}]},{"definition":"A pouch in the digestive tract that connects the ileum with the ascending colon of the large intestine. It is separated from the ileum by the ileocecal valve, and is the beginning of the large intestine. It is also separated from the colon by the cecocolic junction.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A pouch that forms the first part of the large intestine. It connects the small intestine to the colon, which is part of the large intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pouch-like portion of the proximal large intestine opening into the colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cecum","termGroup":"PT","termSource":"NCI"},{"termName":"Cecal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cecum"},{"name":"Maps_To","value":"Cecum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007531"},{"name":"xRef","value":"UBERON:0001153"}]}}{"C12300":{"preferredName":"Central Portion of the Breast","code":"C12300","definitions":[{"definition":"The part of the breast which is in the center.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Portion of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Central Portion of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Portion_of_the_Breast"},{"name":"Maps_To","value":"Central portion of breast"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0222595"}]}}{"C12445":{"preferredName":"Cerebellum","code":"C12445","definitions":[{"definition":"Brain structure derived from the anterior hindbrain, and perhaps including posterior midbrain. The cerebellum plays a role in somatic motor function, the control of muscle tone, and balance.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the brain in the back of the head between the cerebrum and the brain stem. The cerebellum controls balance for walking and standing, and other complex motor functions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the brain that extends from the brainstem through the cerebellar folia.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cerebellum","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebellar","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cerebellum"},{"name":"Maps_To","value":"Brain, Cerebellum, NOS"},{"name":"Maps_To","value":"Cerebellum"},{"name":"Maps_To","value":"Cerebellum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007765"},{"name":"xRef","value":"UBERON:0002037"}]}}{"C12349":{"preferredName":"Cerebral Meninges","code":"C12349","definitions":[{"definition":"The membranes that envelop and protect the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebral Meninges","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cerebral_Meninges"},{"name":"Maps_To","value":"Cerebral meninges"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228116"}]}}{"C12351":{"preferredName":"Cerebral Hemisphere","code":"C12351","definitions":[{"definition":"One of two bilateral, largely symmetrical organ subdivisions within the telencephalon which contain the cerebral cortex and cerebral white matter.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The largest part of the brain. It is divided into two hemispheres, or halves, called the cerebral hemispheres. Areas within the cerebrum control muscle functions and also control speech, thought, emotions, reading, writing, and learning.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the brain that controls muscle functions and also controls speech, thought, emotions, reading, writing, and learning. The right hemisphere controls the muscles on the left side of the body, and the left hemisphere controls the muscles on the right side of the body.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the brain comprising the frontal, parietal, temporal, and occipital lobes and extending through the thalamus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cerebral Hemisphere","termGroup":"PT","termSource":"NCI"},{"termName":"Brain Hemisphere","termGroup":"SY","termSource":"NCI"},{"termName":"Cerebral","termGroup":"AD","termSource":"NCI"},{"termName":"Cerebral Hemispheres","termGroup":"SY","termSource":"NCI"},{"termName":"Cerebrum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cerebral_Hemisphere"},{"name":"Maps_To","value":"Brain, Cerebrum"},{"name":"Maps_To","value":"Cerebrum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228174"},{"name":"xRef","value":"UBERON:0001869"}]}}{"C12250":{"preferredName":"Cervical Esophagus","code":"C12250","definitions":[{"definition":"Clinical esophageal segment composed of skeletal muscle. It corresponds to the superior part of the upper third topographic segment of the esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"Clinical esophageal segment composed of skeletal muscle. It corresponds to the superior part of the upper third topographic segment of the esophagus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cervical Esophagus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cervical_Esophagus"},{"name":"Maps_To","value":"Cervical esophagus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227186"}]}}{"C12505":{"preferredName":"Buccal Mucosa","code":"C12505","definitions":[{"definition":"The inner lining of the cheeks and lips.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The inner lining of the cheeks.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mucosal membranes located on the inside of the cheek, in the buccal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes located on the inside of the cheek, in the buccal cavity. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Buccal Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Buccal_Mucosa"},{"name":"Maps_To","value":"Buccal Mucosa"},{"name":"Maps_To","value":"Buccal mucosa"},{"name":"Maps_To","value":"Cheek mucosa"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C1578559"},{"name":"xRef","value":"UBERON:0006956"}]}}{"C12344":{"preferredName":"Choroid","code":"C12344","definitions":[{"definition":"A blood vessel-containing membrane of the eye that lies between the retina and the sclera.","type":"DEFINITION","source":"NCI"},{"definition":"A blood vessel-containing membrane of the eye that lies between the retina and the sclera. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thin layer of tissue that is part of the middle layer of the wall of the eye, between the sclera (white outer layer of the eye) and the retina (the inner layer of nerve tissue at the back of the eye). The choriod is filled with blood vessels that bring oxygen and nutrients to the eye.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Choroid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Choroid"},{"name":"Maps_To","value":"Choroid"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008520"}]}}{"C12345":{"preferredName":"Ciliary Body","code":"C12345","definitions":[{"definition":"A part of the middle layer of the wall of the eye. The ciliary body includes the ring-shaped muscle that changes the size of the pupil and the shape of the lens when the eye focuses. It also makes the fluid that fills the eye.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Circumferential tissue located behind the iris and composed of muscle and epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue located behind the iris and composed of muscle and epithelium. Its functions include the production of aqueous humor and changing the shape of the crystalline lens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ciliary_Body"},{"name":"Maps_To","value":"Ciliary body"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008779"}]}}{"C12308":{"preferredName":"Clitoris","code":"C12308","definitions":[{"definition":"The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.","type":"DEFINITION","source":"NCI"},{"definition":"The small, erectile body located at the anterior end of the vulva.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Clitoris","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Clitoris"},{"name":"Maps_To","value":"Clitoris"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008984"},{"name":"xRef","value":"UBERON:0002411"}]}}{"C32072":{"preferredName":"Anal Transitional Zone","code":"C32072","definitions":[{"definition":"The middle segment of the anal canal between the colorectal and squamous zones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Transitional Zone","termGroup":"PT","termSource":"NCI"},{"termName":"Cloacogenic Zone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anal_Transitional_Zone"},{"name":"Maps_To","value":"Cloacogenic zone"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0443181"}]}}{"C12227":{"preferredName":"Commissure of the Lip","code":"C12227","definitions":[{"definition":"The junction of the upper and lower lips at the corner of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The junction of the upper and lower lips at the corner of the mouth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Commissure of the Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Commissure of Lip","termGroup":"SY","termSource":"NCI"},{"termName":"Labial Commissure (Mouth)","termGroup":"SY","termSource":"NCI"},{"termName":"Labial Junction","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Commissure_of_the_Lip"},{"name":"Maps_To","value":"Commissure of lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226924"}]}}{"C12341":{"preferredName":"Conjunctiva","code":"C12341","definitions":[{"definition":"A thin tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thin, transparent tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball).","type":"DEFINITION","source":"NCI"},{"definition":"The mucous membrane that lines the inner surface of the eyelids and the front of the eyeball.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Conjunctiva","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Conjunctiva"},{"name":"Maps_To","value":"Conjunctiva"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009758"},{"name":"xRef","value":"UBERON:0001811"}]}}{"C12342":{"preferredName":"Cornea","code":"C12342","definitions":[{"definition":"A dome-shaped, transparent, avascular tissue covering the front of the eye. It is composed of five layers: squamous epithelium, Bowman's membrane, stroma, Descemet's membrane, and endothelium. Refraction of light contributing to eye's focusing ability is its characteristic function. It contains unmyelinated nerve endings which are responsible for the high sensitivity of the tissue.","type":"DEFINITION","source":"NCI"},{"definition":"The transparent part of the eye that covers the iris and the pupil and allows light to enter the inside.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The transparent, avascular tissue covering the front of the eye and is continuous with the sclera.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cornea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cornea"},{"name":"Maps_To","value":"Cornea, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0010031"}]}}{"C12396":{"preferredName":"Adrenal Cortex","code":"C12396","definitions":[{"definition":"The outer part of the adrenal gland (a small organ on top of each kidney). The adrenal cortex makes androgen and corticosteroid hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The outer region of the adrenal gland consisting of the zona glomerulosa, the zona fasciculata, and the zona reticularis. The adrenal cortex produces and secretes mineralocorticoids, glucocorticoids, and adrenal androgens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Cortex of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Cortical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex"},{"name":"Maps_To","value":"Cortex of adrenal gland"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0001613"}]}}{"C12700":{"preferredName":"Cranial Nerve","code":"C12700","definitions":[{"definition":"Any of the 12 paired nerves that originate in the brain stem.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the 12 paired nerves that originate in the brain stem. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cranial nerves are nerves that emerge directly from the brain, in contrast to spinal nerves, which emerge from segments of the spinal cord.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Cranial Nerve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cranial_Nerve"},{"name":"Maps_To","value":"Cranial nerve, NOS"},{"name":"Maps_To","value":"Nerve(s) Cranial"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0010268"},{"name":"xRef","value":"UBERON:0001785"}]}}{"C12357":{"preferredName":"Craniopharyngeal Duct","code":"C12357","definitions":[{"definition":"The slender tubular part of the hypophysial diverticulum; the stalk of Rathke's pocket.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Craniopharyngeal Duct","termGroup":"PT","termSource":"NCI"},{"termName":"Bucconeural Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Hypophysial Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Craniopharyngeal_Duct"},{"name":"Maps_To","value":"Craniopharyngeal duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229549"}]}}{"C12268":{"preferredName":"Descending Colon","code":"C12268","definitions":[{"definition":"The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the colon between the left colic flexure and the sigmoid colon at the pelvic brim; the portion of the descending colon lying in the left iliac fossa is sometimes called the iliac colon.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Descending Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Descending_Colon"},{"name":"Maps_To","value":"Descending Colon"},{"name":"Maps_To","value":"Descending colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227389"},{"name":"xRef","value":"UBERON:0001158"}]}}{"C12332":{"preferredName":"Dome of the Bladder","code":"C12332","definitions":[{"definition":"The upper, convex surface of the bladder.","type":"DEFINITION","source":"NCI"},{"definition":"The upper, convex surface of the bladder. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Dome of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Dome of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Surface of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Surface of the Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dome_of_the_Bladder"},{"name":"Maps_To","value":"Dome of bladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1288328"}]}}{"C12263":{"preferredName":"Duodenum","code":"C12263","definitions":[{"definition":"A jointed tube 25-30 cm long that connects the stomach to the jejunum.","type":"DEFINITION","source":"NCI"},{"definition":"The first part of the small intestine that connects to the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The first part of the small intestine. At the junction of the stomach and the duodenum the alimentary canal is inflected. The duodenum first goes anteriorly for a short distance, turns dorsally, and eventually caudally, thus it is a U-shaped structure with two horizontal sections (a ventral and a dorsal one).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the small intestine between the stomach and jejunum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Duodenum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Duodenum"},{"name":"Maps_To","value":"Duodenum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013303"},{"name":"xRef","value":"UBERON:0002114"}]}}{"C12309":{"preferredName":"Endocervix","code":"C12309","definitions":[{"definition":"The portion of the cervix which is lined by single columnar epithelium (mucosa).","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the cervix which is lined by single columnar epithelium (mucosa). (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endocervix","termGroup":"PT","termSource":"NCI"},{"termName":"Endocervical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endocervix"},{"name":"Maps_To","value":"Endocervix"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227837"}]}}{"C12704":{"preferredName":"Endocrine Gland","code":"C12704","definitions":[{"definition":"Ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.","type":"DEFINITION","source":"NCI"},{"definition":"Endocrine glands are glands of the endocrine system that secrete their products directly into the circulatory system rather than through a duct.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Endocrine Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Endocrine Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Endocrine_Gland"},{"name":"Maps_To","value":"Endocrine Gland"},{"name":"Maps_To","value":"Endocrine gland, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014133"},{"name":"xRef","value":"UBERON:0002368"}]}}{"C12313":{"preferredName":"Endometrium","code":"C12313","definitions":[{"definition":"The layer of tissue that lines the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mucous membrane comprising the inner layer of the uterine wall.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrium","termGroup":"PT","termSource":"NCI"},{"termName":"Tunica Mucosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrium"},{"name":"Maps_To","value":"Endometrium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014180"}]}}{"C12328":{"preferredName":"Epididymis","code":"C12328","definitions":[{"definition":"A crescent-like structure located adjacent to the testis. It consists of a single highly coiled duct and is divided into 3 regions: caput (head), corpus (body) and cauda (tail).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A crescent-like structure located in the upper and posterior surfaces of the testis. It consists of the efferent ductules and the duct of the epididymis. It facilitates the maturation of sperm that is produced in the testis.","type":"DEFINITION","source":"NCI"},{"definition":"A narrow, tightly-coiled tube that is attached to each of the testicles (the male sex glands that produce sperm). Sperm cells (male reproductive cells) move from the testicles into the epididymis, where they finish maturing and are stored.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The elongated structure connected to the posterior surface of the testis that transports, stores, and matures spermatozoa between testis and vas deferens.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Epididymis","termGroup":"PT","termSource":"NCI"},{"termName":"Epididymal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Epididymis"},{"name":"Maps_To","value":"Epididymis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014533"},{"name":"xRef","value":"UBERON:0001301"}]}}{"C12276":{"preferredName":"Ethmoid Sinus","code":"C12276","definitions":[{"definition":"A sinus of the meatuses of the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"A sinus of the meatuses of the nasal cavity. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). Ethmoid sinuses are found in the spongy ethmoid bone in the upper part of the nose between the eyes. They are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ethmoid Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Sinus, Ethmoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Ethmoid_Sinus"},{"name":"Maps_To","value":"Ethmoid sinus"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0015028"}]}}{"C12310":{"preferredName":"Ectocervix","code":"C12310","definitions":[{"definition":"Having to do with the part of the cervix that protrudes into the vagina and is lined with epithelial cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the cervix that extends into the vaginal vault, and is lined with stratified squamous epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ectocervix","termGroup":"PT","termSource":"NCI"},{"termName":"Exocervix","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ectocervix"},{"name":"Maps_To","value":"Exocervix"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227829"}]}}{"C12292":{"preferredName":"External Ear","code":"C12292","definitions":[{"definition":"The external part of the ear.","type":"DEFINITION","source":"NCI"},{"definition":"The external part of the ear. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Ear","termGroup":"PT","termSource":"NCI"},{"termName":"Auricle","termGroup":"SY","termSource":"NCI"},{"termName":"Ear, External","termGroup":"SY","termSource":"NCI"},{"termName":"Pinna","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"External_Ear"},{"name":"Maps_To","value":"Ear, Pinna (External)"},{"name":"Maps_To","value":"External ear"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013453"},{"name":"xRef","value":"UBERON:0001757"}]}}{"C12223":{"preferredName":"External Lip","code":"C12223","definitions":[{"definition":"One of two visible fleshy folds that surround the orifice of the mouth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"External Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"External_Lip"},{"name":"Maps_To","value":"External lip, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226926"}]}}{"C12222":{"preferredName":"External Lower Lip","code":"C12222","definitions":[{"definition":"The external surface of the lower lip.","type":"DEFINITION","source":"NCI"},{"definition":"The external surface of the lower lip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Lower Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"External_Lower_Lip"},{"name":"Maps_To","value":"External lower lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226942"}]}}{"C12221":{"preferredName":"External Upper Lip","code":"C12221","definitions":[{"definition":"The external surface of the upper lip.","type":"DEFINITION","source":"NCI"},{"definition":"The external surface of the upper lip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Upper Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"External_Upper_Lip"},{"name":"Maps_To","value":"External upper lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226936"}]}}{"C32573":{"preferredName":"Extrahepatic Bile Duct","code":"C32573","definitions":[{"definition":"The part of the common hepatic bile duct (tube that collects bile from the liver) that is outside the liver. This duct joins a duct from the gallbladder to form the common bile duct, which carries bile into the small intestine when food is being digested.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the biliary tract outside the liver; the common hepatic duct joins the cystic duct to form the common bile duct.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the biliary tract outside the liver; the common hepatic duct joins the cystic duct to form the common bile duct. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Extrahepatic Bile Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Extrahepatic_Bile_Duct"},{"name":"Maps_To","value":"Extrahepatic bile duct"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0206187"}]}}{"C12401":{"preferredName":"Eye","code":"C12401","definitions":[{"definition":"An organ that detects light.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Having to do with the eye.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The organ of sight or vision.","type":"DEFINITION","source":"NCI"},{"definition":"The sensory organ of vision.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Eye","termGroup":"PT","termSource":"NCI"},{"termName":"Eyeball","termGroup":"SY","termSource":"NCI"},{"termName":"Ocular","termGroup":"SY","termSource":"NCI"},{"termName":"Ophthalmic","termGroup":"AD","termSource":"NCI"},{"termName":"Optic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Eye"},{"name":"Maps_To","value":"Eye"},{"name":"Maps_To","value":"Eye, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015392"},{"name":"xRef","value":"IMDRF:E08"},{"name":"xRef","value":"UBERON:0000970"}]}}{"C12713":{"preferredName":"Eyelid","code":"C12713","definitions":[{"definition":"A thin membrane of skin with the purpose of covering and protecting an eye.","type":"DEFINITION","source":"NCI"},{"definition":"The section of skin, containing muscle and conjunctiva, that covers and protects the eye.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Eyelid","termGroup":"PT","termSource":"NCI"},{"termName":"Palpebra","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eyelid"},{"name":"Maps_To","value":"Eyelid"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015426"}]}}{"C12403":{"preferredName":"Fallopian Tube","code":"C12403","definitions":[{"definition":"A slender tube through which eggs pass from an ovary to the uterus. In the female reproductive tract, there is one ovary and one fallopian tube on each side of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Initial section of the oviduct through which the ova pass from the ovary to the uterus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.","type":"DEFINITION","source":"NCI"},{"definition":"The tube through which eggs pass from an ovary.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fallopian Tube","termGroup":"PT","termSource":"NCI"},{"termName":"Fallopian Tubes","termGroup":"SY","termSource":"NCI"},{"termName":"Oviduct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Fallopian_Tube"},{"name":"Maps_To","value":"Fallopian tube"},{"name":"Maps_To","value":"Fallopian Tube"},{"name":"Maps_To","value":"Fallopian Tube, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015560"},{"name":"xRef","value":"UBERON:0003889"}]}}{"C61600":{"preferredName":"Female Genitalia","code":"C61600","definitions":[{"definition":"Female internal and external organs of reproduction.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external female sexual organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Genitalia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Female_Genitalia"},{"name":"Maps_To","value":"Female genital tract, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017421"}]}}{"C12352":{"preferredName":"Frontal Lobe","code":"C12352","definitions":[{"definition":"Frontal lobe is the anterior-most of five lobes of the cerebral hemisphere. It is bounded by the central sulcus on its posterior border and by the longitudinal cerebral fissure on its medial border.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Frontal Lobe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Frontal_Lobe"},{"name":"Maps_To","value":"Brain, Frontal lobe"},{"name":"Maps_To","value":"Frontal lobe"},{"name":"Maps_To","value":"Frontal Lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016733"},{"name":"xRef","value":"UBERON:0016525"}]}}{"C12277":{"preferredName":"Frontal Sinus","code":"C12277","definitions":[{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). There are two, large frontal sinuses in the frontal bone, which forms the lower part of the forehead and reaches over the eye sockets and eyebrows. The frontal sinuses are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The paired, mucosal lined air spaces located above the orbit and communicating with the nasal passages.","type":"DEFINITION","source":"NCI"},{"definition":"The paired, mucosal lined air spaces located above the orbit and communicating with the nasal passages. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Frontal Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Sinus, Frontal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Frontal_Sinus"},{"name":"Maps_To","value":"Frontal sinus"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0016734"}]}}{"C12257":{"preferredName":"Fundus of the Stomach","code":"C12257","definitions":[{"definition":"The blind sac region of the glandular stomach.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fundus is the portion of the stomach that lies above the cardiac notch, and contains the fundic glands.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the stomach that lies above the cardiac notch. It allows for the accumulation of gases produced by chemical digestion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fundus of the Stomach","termGroup":"PT","termSource":"NCI"},{"termName":"Fundus of Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Fundus_of_the_Stomach"},{"name":"Maps_To","value":"Fundus of Stomach"},{"name":"Maps_To","value":"Fundus Of Stomach"},{"name":"Maps_To","value":"Fundus of stomach"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017129"},{"name":"xRef","value":"UBERON:0001160"}]}}{"C12315":{"preferredName":"Fundus Uteri","code":"C12315","definitions":[{"definition":"The upper, rounded portion of the uterus that is opposite from the cervix.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper, rounded portion of the uterus which is opposite from the cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fundus Uteri","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fundus_Uteri"},{"name":"Maps_To","value":"Fundus uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227817"}]}}{"C12259":{"preferredName":"Antrum Pylori","code":"C12259","definitions":[{"definition":"The initial part of the pyloric canal of the stomach. This site contains endocrine cells that produce gastrin and somatostatin.","type":"DEFINITION","source":"NCI"},{"definition":"The initial part of the pyloric canal of the stomach. This site contains endocrine cells that produce gastrin and somatostatin. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Antrum Pylori","termGroup":"PT","termSource":"NCI"},{"termName":"Gastric Antrum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antrum_Pylori"},{"name":"Maps_To","value":"Gastric antrum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0034193"}]}}{"C12324":{"preferredName":"Glans Penis","code":"C12324","definitions":[{"definition":"The most distal portion of the penis covered by the foreskin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The most distal portion of the penis covered by the foreskin.","type":"DEFINITION","source":"NCI"},{"definition":"The rounded, gland-like head of the penis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glans Penis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glans_Penis"},{"name":"Maps_To","value":"Glans penis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227948"}]}}{"C12724":{"preferredName":"Glottis","code":"C12724","definitions":[{"definition":"The middle part of the larynx; the area where the vocal cords are located.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The space in which the vocal cords are located.","type":"DEFINITION","source":"NCI"},{"definition":"The space in which the vocal cords are located. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The vocal apparatus of the larynx, which includes the vocal cords and the opening between them.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Glottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Glottis"},{"name":"Maps_To","value":"Glottis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017681"},{"name":"xRef","value":"UBERON:0002486"}]}}{"C12262":{"preferredName":"Greater Curvature of the Stomach","code":"C12262","definitions":[{"definition":"The lateral and inferior border of the stomach. Attached to it is the greater omentum.","type":"DEFINITION","source":"NCI"},{"definition":"The lateral and inferior border of the stomach. Attached to it is the greater omentum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"not classifiable to C16.0 to C16.4","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Greater Curvature of the Stomach","termGroup":"PT","termSource":"NCI"},{"termName":"Greater Curvature","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Greater_Curvature"},{"name":"Maps_To","value":"Greater curvature of stomach, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227223"}]}}{"C12230":{"preferredName":"Hard Palate","code":"C12230","definitions":[{"definition":"Anterior portion of the palate consisting of bone and mucous membranes [GO]. The hard palate is formed from bony processes of the maxilla, premaxilla and palatine bone.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bony anterior part of the roof of the mouth separating the nose from the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The front, bony part of the roof of the mouth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the roof of the mouth supported by bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hard Palate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hard_Palate"},{"name":"Maps_To","value":"Hard palate"},{"name":"Maps_To","value":"Hard Palate"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226901"},{"name":"xRef","value":"UBERON:0003216"}]}}{"C12269":{"preferredName":"Head of the Pancreas","code":"C12269","definitions":[{"definition":"That portion of the pancreas lying in the concavity of the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"That portion of the pancreas lying in the concavity of the duodenum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Head of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Head of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Head","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Head","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Head_of_the_Pancreas"},{"name":"Maps_To","value":"Head of pancreas"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227579"}]}}{"C12909":{"preferredName":"Hematopoietic System","code":"C12909","definitions":[{"definition":"The bodily system of organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes, involved in the production of blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic System","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Hematologic","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Hematologic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hematopoietic_System"},{"name":"Maps_To","value":"Hematopoietic system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0018957"},{"name":"xRef","value":"IMDRF:E03"}]}}{"C12266":{"preferredName":"Hepatic Flexure","code":"C12266","definitions":[{"definition":"Hepatic (or the right colic) flexure is the sharp bend between the ascending and the transverse colon. The right colic flexure is adjacent to the liver, and is therefore also known as the hepatic flexure. Thus, the left colic flexure is also known as the splenic flexure (as it is close to the spleen). The hepatic flexure lies in the right upper quadrant of the abdomen in humans.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bend at the junction of the ascending and transverse colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bend of the colon at the juncture of its ascending and transverse portions.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Hepatic Flexure","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatic Flexure of Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Flexure of the Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Right Colic Flexure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hepatic_Flexure"},{"name":"Maps_To","value":"Ascending Colon Hepatic Flexure"},{"name":"Maps_To","value":"Hepatic Flexure"},{"name":"Maps_To","value":"Hepatic flexure of colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227385"},{"name":"xRef","value":"UBERON:0022277"}]}}{"C12387":{"preferredName":"Ileum","code":"C12387","definitions":[{"definition":"The final section of the small intestine.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the small intestine between the jejunum and large intestine.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the small intestine that extends from the jejunum to the colon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"excludes ileocecal valve C18.0","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Ileum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ileum"},{"name":"Maps_To","value":"Ileum"},{"name":"Maps_To","value":"Iliac"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020885"},{"name":"xRef","value":"UBERON:0002116"}]}}{"C12736":{"preferredName":"Intestine","code":"C12736","definitions":[{"definition":"The long, tube-shaped organ in the abdomen that completes the process of digestion. The intestine has two parts, the small intestine and the large intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the gastrointestinal tract between the stomach and the anus. It includes the small intestine and large intestine.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the gastrointestinal tract that includes the small and large intestines.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intestine","termGroup":"PT","termSource":"NCI"},{"termName":"Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Intestines","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Intestine"},{"name":"Maps_To","value":"Bowel"},{"name":"Maps_To","value":"Intestinal tract, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0021853"}]}}{"C12360":{"preferredName":"Intra-Abdominal Lymph Node","code":"C12360","definitions":[{"definition":"Any lymph node within the abdomen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any lymph node within the abdomen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intra-Abdominal Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Intra-Abdominal Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intra-abdominal_Lymph_Node"},{"name":"Maps_To","value":"Intra-abdominal lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0588058"}]}}{"C12677":{"preferredName":"Intrahepatic Bile Duct","code":"C12677","definitions":[{"definition":"The bile ducts that pass through and drain bile from the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The bile ducts that pass through and drain bile from the liver. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bile ducts which are located within the liver. They include the small interlobular bile ducts, intrahepatic large bile ducts, and the intrahepatic portions of the left and right hepatic ducts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intrahepatic Bile Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intrahepatic_Bile_Duct"},{"name":"Maps_To","value":"Intrahepatic bile duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005401"}]}}{"C12359":{"preferredName":"Intrathoracic Lymph Node","code":"C12359","definitions":[{"definition":"Any lymph node within the thoracic cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Any lymph node within the thoracic cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intrathoracic Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Intra-Thoracic Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Intrathoracic Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intrathoracic_Lymph_Node"},{"name":"Maps_To","value":"Intrathoracic lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1517562"}]}}{"C12608":{"preferredName":"Islet of Langerhans","code":"C12608","definitions":[{"definition":"A specialized region of tissue located within the parenchyma of the pancreas that contains a mixed population of distinct endocrine cells, including beta, alpha, pancreatic polypeptide, delta, and epsilon cells, which respectively produce and secrete insulin, glucagon, pancreatic polypeptide, somatostatin, and ghrelin.","type":"DEFINITION","source":"NCI"},{"definition":"The pancreatic tissue that contains the islets of Langerhans. It is responsible for the production and secretions of the pancreatic hormones. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Islet of Langerhans","termGroup":"PT","termSource":"NCI"},{"termName":"Endocrine Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Islands of Langerhans","termGroup":"SY","termSource":"NCI"},{"termName":"Islet Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Islets of Langerhans","termGroup":"SY","termSource":"NCI"},{"termName":"Langerhans Islets","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Islets","termGroup":"SY","termSource":"NCI"},{"termName":"Pars Endocrina Pancreatis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Islet_of_Langerhans"},{"name":"Maps_To","value":"Islets of Langerhans"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0022131"}]}}{"C12312":{"preferredName":"Isthmus Uteri","code":"C12312","definitions":[{"definition":"An elongated constriction of the lower part of the uterus, located at the junction of the body of the uterus and the cervix, that is composed principally of smooth muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isthmus Uteri","termGroup":"PT","termSource":"NCI"},{"termName":"Isthmus of Uterus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isthmus_Uteri"},{"name":"Maps_To","value":"Isthmus uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1288329"}]}}{"C12388":{"preferredName":"Jejunum","code":"C12388","definitions":[{"definition":"The portion of the small intestine between the duodenum and ileum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the small intestine that extends from the duodenum to the ileum.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the small intestine that extends from the duodenum to the ileum.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Jejunum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Jejunum"},{"name":"Maps_To","value":"Jejunum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022378"},{"name":"xRef","value":"UBERON:0002115"}]}}{"C12306":{"preferredName":"Labium Majus","code":"C12306","definitions":[{"definition":"One of the two longitudinal folds of skin that form the lateral boundary of the vulva.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the two longitudinal folds of skin that form the lateral boundary of the vulva. It extends from the mons pubis to the perineum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Labium Majus","termGroup":"PT","termSource":"NCI"},{"termName":"Labia Majora","termGroup":"SY","termSource":"NCI"},{"termName":"Labia Majus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Labium_Majus"},{"name":"Maps_To","value":"Labium majus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227760"}]}}{"C12307":{"preferredName":"Labium Minus","code":"C12307","definitions":[{"definition":"One of the two longitudinal folds of skin located between the labia majora.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the two longitudinal folds of skin located between the labia majora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Labium Minus","termGroup":"PT","termSource":"NCI"},{"termName":"Labia Minora","termGroup":"SY","termSource":"NCI"},{"termName":"Labia Minus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Labium_Minus"},{"name":"Maps_To","value":"Labium minus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227766"}]}}{"C12346":{"preferredName":"Lacrimal Gland","code":"C12346","definitions":[{"definition":"A gland that secretes tears. The lacrimal glands are found in the upper, outer part of each eye socket.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Paired, almond-shaped exocrine glands situated superior and posterior to each orbit of the eye that produce and secrete the watery serous component of tears.","type":"DEFINITION","source":"NCI"},{"definition":"The exocrine glands that produce the watery serous component of tears.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lacrimal glands are paired almond-shaped glands, located in or near the orbital region, that secrete the aqueous layer of the tear film.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Lacrimal Gland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lacrimal_Gland"},{"name":"Maps_To","value":"Lacrimal gland"},{"name":"Maps_To","value":"Lacrimal Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022907"},{"name":"xRef","value":"UBERON:0001817"}]}}{"C12281":{"preferredName":"Laryngeal Cartilage","code":"C12281","definitions":[{"definition":"The nine cartilages that comprise the skeleton of the larynx, including the single thyroid, epiglottic, and cricoid cartilages, and the paired arytenoid, corniculate, and cuneiform cartilages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laryngeal Cartilage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laryngeal_Cartilage"},{"name":"Maps_To","value":"Laryngeal cartilage"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0023050"}]}}{"C12333":{"preferredName":"Lateral Wall of the Bladder","code":"C12333","definitions":[{"definition":"The aspect of the bladder wall that is located on the side.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lateral Wall of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Wall of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lateral_Wall_of_the_Bladder"},{"name":"Maps_To","value":"Lateral wall of bladder"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0447583"}]}}{"C12244":{"preferredName":"Lateral Wall of the Nasopharynx","code":"C12244","definitions":[{"definition":"The aspect of the nasopharyngeal wall that is located on the side.  It contains the pharyngeal opening of the auditory tube.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lateral Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lateral_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Lateral wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0225486"}]}}{"C12239":{"preferredName":"Lateral Wall of the Oropharynx","code":"C12239","definitions":[{"definition":"The aspect of the oropharyngeal wall that is located on the side.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lateral Wall of the Oropharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Wall of Oropharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lateral_Wall_of_the_Oropharynx"},{"name":"Maps_To","value":"Lateral wall of oropharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227156"}]}}{"C12261":{"preferredName":"Lesser Curvature of the Stomach","code":"C12261","definitions":[{"definition":"The medial border of the stomach. It is concave in shape and extends from the cardiac orifice to the pyloric orifice.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The right border of the stomach.  It is concave in shape and extends from the cardiac orifice to the pyloric orifice.","type":"DEFINITION","source":"NCI"},{"definition":"not classifiable to C16.1 to C16.4","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Lesser Curvature of the Stomach","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesser_Curvature"},{"name":"Maps_To","value":"Lesser curvature of stomach, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227221"}]}}{"C32988":{"preferredName":"Lingual Tonsil","code":"C32988","definitions":[{"definition":"A tonsil in the mucosa at the root of the tongue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymphoid follicles on the dorsal surface in the posterior region of the tongue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lingual Tonsil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lingual_Tonsil"},{"name":"Maps_To","value":"Lingual tonsil"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229871"}]}}{"C54204":{"preferredName":"Lower Gingiva","code":"C54204","definitions":[{"definition":"The gingiva covering the mandibular alveolar bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower Gingiva","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Gums","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower_Gingiva"},{"name":"Maps_To","value":"Lower gum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227123"}]}}{"C12742":{"preferredName":"Lower Extremity","code":"C12742","definitions":[{"definition":"The limb that is composed of the hip, thigh, leg and foot.","type":"DEFINITION","source":"NCI"},{"definition":"The limb that is composed of the hip, thigh, leg and foot. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lower Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lower_Extremity"},{"name":"Maps_To","value":"Lower limb, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0023216"}]}}{"C12287":{"preferredName":"Lower Lobe of the Lung","code":"C12287","definitions":[{"definition":"The bottom most subdivision of either the right or left lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower Lobe of the Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Lower Lobe, Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Lower Lobe","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Lower_Lobe"},{"name":"Maps_To","value":"Lower lobe, lung"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225758"}]}}{"C12255":{"preferredName":"Lower Third of the Esophagus","code":"C12255","definitions":[{"definition":"The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type.","type":"DEFINITION","source":"NCI"},{"definition":"The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lower Third of the Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Third of Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lower_Third_of_the_Esophagus"},{"name":"Maps_To","value":"Esophageal; Distal"},{"name":"Maps_To","value":"Lower third of esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227191"},{"name":"xRef","value":"UBERON:0013473"}]}}{"C12302":{"preferredName":"Lower-Inner Quadrant of the Breast","code":"C12302","definitions":[{"definition":"The quarter of the breast which is inferior and medial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower-Inner Quadrant of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Lower-Inner Quadrant of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower-inner_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Lower-inner quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222597"}]}}{"C12304":{"preferredName":"Lower-Outer Quadrant of the Breast","code":"C12304","definitions":[{"definition":"The quarter of the breast which is inferior and lateral.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower-Outer Quadrant of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Lower-Outer Quadrant of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower-outer_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Lower-outer quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222599"}]}}{"C12358":{"preferredName":"Head and Neck Lymph Node","code":"C12358","definitions":[{"definition":"Lymph nodes found within the head and neck region of the body, which drain into the deep cervical nodes, either directly or indirectly. These include the occipital, mastoid, parotid, facial, retropharyngeal, submandibular, submental, lingual and cervical lymph nodes. Any lymph node located in the head or neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Head and Neck Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Node of Head, Face and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Nodes of Head, Face and Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Head_and_Neck_Lymph_Node"},{"name":"Maps_To","value":"Lymph nodes of head, face and neck"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1185605"}]}}{"C12362":{"preferredName":"Lymph Node of Inguinal Region or Leg","code":"C12362","definitions":[{"definition":"Any lymph node that is located in the inguinal region or in either leg.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymph Node of Inguinal Region or Leg","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Nodes of Inguinal Region or Leg","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymph_Node_of_Inguinal_Region_or_Leg"},{"name":"Maps_To","value":"Lymph nodes of inguinal region or leg"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1518054"}]}}{"C12284":{"preferredName":"Main Bronchus","code":"C12284","definitions":[{"definition":"The left and right main bronchi considered as a group.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Main Bronchus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Main_Bronchus"},{"name":"Maps_To","value":"Main bronchus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024496"}]}}{"C12426":{"preferredName":"Salivary Gland","code":"C12426","definitions":[{"definition":"A gland in the mouth that produces saliva.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Any number of exocrine glands that secrete saliva into the oral cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Salivary Glands","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Glands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"ICDO3: excludes minor salivary gland, NOS C06.9"},{"name":"Legacy Concept Name","value":"Salivary_Gland"},{"name":"Maps_To","value":"Major salivary gland, NOS"},{"name":"Maps_To","value":"Salivary gland"},{"name":"Maps_To","value":"Salivary Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036098"}]}}{"C61599":{"preferredName":"Male Genitalia","code":"C61599","definitions":[{"definition":"Male internal and external organs of reproduction.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external male sexual organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Male Genitalia","termGroup":"PT","termSource":"NCI"},{"termName":"Male Genital Organ","termGroup":"SY","termSource":"NCI"},{"termName":"Male Genital Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Male_Genitalia"},{"name":"Maps_To","value":"Male genital organs, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017422"}]}}{"C12290":{"preferredName":"Mandible","code":"C12290","definitions":[{"definition":"A dentary bone that is the only bone in one of the lateral halves of the lower jaw skeleton.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower jaw bone holding the lower teeth.","type":"DEFINITION","source":"NCI"},{"definition":"The lower jaw bone holding the lower teeth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mandible","termGroup":"PT","termSource":"NCI"},{"termName":"Inferior Maxillary Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Lower Jaw","termGroup":"SY","termSource":"NCI"},{"termName":"Mandibular","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mandible"},{"name":"Maps_To","value":"Mandible"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024687"},{"name":"xRef","value":"UBERON:0001684"}]}}{"C12275":{"preferredName":"Maxillary Sinus","code":"C12275","definitions":[{"definition":"A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital.","type":"DEFINITION","source":"NCI"},{"definition":"A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). There are two large maxillary sinuses, one in each of the maxillary bones, which are in the cheek area next to the nose. The maxillary sinuses are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of the paired paranasal sinuses, located in the body of the maxilla, communicating with the middle meatus of the nasal cavity.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Maxillary Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Antrum Highmori","termGroup":"SY","termSource":"NCI"},{"termName":"Antrum of Highmore","termGroup":"SY","termSource":"NCI"},{"termName":"Antrum of Highmori","termGroup":"SY","termSource":"NCI"},{"termName":"Antrum, Maxillary","termGroup":"SY","termSource":"NCI"},{"termName":"Apertura Sinus Maxillaris","termGroup":"SY","termSource":"NCI"},{"termName":"Sinus, Maxillary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Maxillary_Sinus"},{"name":"Maps_To","value":"Maxillary sinus"},{"name":"Maps_To","value":"Sinus(es), Maxillary"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0024957"},{"name":"xRef","value":"UBERON:0001764"}]}}{"C12264":{"preferredName":"Meckel Diverticulum","code":"C12264","definitions":[{"definition":"A congenital pouch in the distal ileum. It may cause painless rectal bleeding and bowel obstruction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meckel Diverticulum","termGroup":"PT","termSource":"NCI"},{"termName":"Meckel's Diverticulum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Meckel_Diverticulum"},{"name":"Maps_To","value":"Meckel diverticulum"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0025037"}]}}{"C12397":{"preferredName":"Adrenal Medulla","code":"C12397","definitions":[{"definition":"The inner part of the adrenal gland (a small organ on top of each kidney). The adrenal medulla makes chemicals such as epinephrine (adrenaline) and norepinephrine (noradrenaline) which are involved in sending nerve signals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The inner region of the adrenal gland. The adrenal medulla produces, stores, and secretes epinephrine and norepinephrine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Medulla","termGroup":"PT","termSource":"NCI"},{"termName":"Medulla of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Medulla"},{"name":"Maps_To","value":"Medulla of adrenal gland"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0001629"}]}}{"C12274":{"preferredName":"Middle Ear","code":"C12274","definitions":[{"definition":"The part of the ear including the eardrum and ossicles.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the ear including the eardrum and ossicles. The middle ear leads to the inner ear.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Middle Ear","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Middle_Ear"},{"name":"Maps_To","value":"Middle ear"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013455"}]}}{"C12286":{"preferredName":"Middle Lobe of the Right Lung","code":"C12286","definitions":[{"definition":"The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure.","type":"DEFINITION","source":"NCI"},{"definition":"The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Middle Lobe of the Right Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Middle Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Middle Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Middle Lobe of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Right Middle Lobe, Lung","termGroup":"SY","termSource":"NCI"},{"termName":"RML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Only the right lung has a middle lobe."},{"name":"Legacy Concept Name","value":"Middle_Lobe_of_the_Right_Lung"},{"name":"Maps_To","value":"Middle lobe, lung"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225757"}]}}{"C12254":{"preferredName":"Middle Third of the Esophagus","code":"C12254","definitions":[{"definition":"The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Middle Third of the Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Middle Third of Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Middle_Third_of_the_Esophagus"},{"name":"Maps_To","value":"Esophageal; Mid"},{"name":"Maps_To","value":"Middle third of esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227189"},{"name":"xRef","value":"UBERON:0013474"}]}}{"C12421":{"preferredName":"Oral Cavity","code":"C12421","definitions":[{"definition":"Anatomical cavity at the start of the digestive tract that that is enclosed by the mouth. The boundaries and contents vary depending on the species. In vertebrates, the boundaries are the oral opening, the cheeks, the palate and (if present) the palatoglossal arch - if this is not present then the mouth and pharynx form the oropharyngeal cavity. The buccal cavity contains the teeth, tongue and palate (when present).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Refers to the mouth. It includes the lips, the lining inside the cheeks and lips, the front two thirds of the tongue, the upper and lower gums, the floor of the mouth under the tongue, the bony roof of the mouth, and the small area behind the wisdom teeth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Relating to the buccal cavity of the mouth (the pouch located between the cheek and the gum) as the intended site of administration, where the pharmaceutical product is intended for a systemic action after passing through the buccal mucosa.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.","type":"DEFINITION","source":"NCI"},{"definition":"The cavity of the mouth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The proximal portion of the digestive tract, containing the oral cavity and bounded by the oral opening. In vertebrates, this extends to the pharynx and includes gums, lips, tongue and parts of the palate. Typically also includes the teeth, except where these occur elsewhere (e.g. pharyngeal jaws) or protrude from the mouth (tusks).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Oral Cavity","termGroup":"PT","termSource":"NCI"},{"termName":"Buccal Cavity","termGroup":"SY","termSource":"NCI"},{"termName":"Mouth","termGroup":"SY","termSource":"NCI"},{"termName":"Oral","termGroup":"AD","termSource":"NCI"},{"termName":"Orally","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Oral_Cavity"},{"name":"Maps_To","value":"Buccal Cavity"},{"name":"Maps_To","value":"Mouth"},{"name":"Maps_To","value":"Mouth, NOS"},{"name":"Maps_To","value":"Oral Cavity"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226896"},{"name":"xRef","value":"UBERON:0000165"},{"name":"xRef","value":"UBERON:0000167"}]}}{"C12226":{"preferredName":"Mucosa of the Lip","code":"C12226","definitions":[{"definition":"The inner lining of the lips.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lining of the fleshy folds surrounding the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","type":"DEFINITION","source":"NCI"},{"definition":"The lining of the fleshy folds surrounding the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mucosa of the Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Labial Mucosa","termGroup":"SY","termSource":"NCI"},{"termName":"Mucosa of Lip","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Hair Bearing Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"ICD-O3: excludes skin of lip C44.0"},{"name":"Legacy Concept Name","value":"Labial_Mucosa"},{"name":"Legacy Concept Name","value":"Mucosa_of_the_Lip"},{"name":"Maps_To","value":"Mucosa of lip, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0226927"}]}}{"C12225":{"preferredName":"Mucosa of the Lower Lip","code":"C12225","definitions":[{"definition":"The lining of the inferior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucosa of the Lower Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Mucosa of Lower Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucosa_of_the_Lower_Lip"},{"name":"Maps_To","value":"Mucosa of lower lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226939"}]}}{"C12224":{"preferredName":"Mucosa of the Upper Lip","code":"C12224","definitions":[{"definition":"The lining of the superior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucosa of the Upper Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Mucosa of Upper Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucosa_of_the_Upper_Lip"},{"name":"Maps_To","value":"Mucosa of upper lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226933"}]}}{"C12314":{"preferredName":"Myometrium","code":"C12314","definitions":[{"definition":"The muscular outer layer of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The smooth muscle lining the uterus.","type":"DEFINITION","source":"NCI"},{"definition":"The smooth muscle lining the uterus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Myometrium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myometrium"},{"name":"Maps_To","value":"Myometrium"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0027088"}]}}{"C12424":{"preferredName":"Nasal Cavity","code":"C12424","definitions":[{"definition":"An anatomical cavity that is part of the olfactory apparatus. This includes the space bounded anteriorly by the nares and posteriorly by the choanae, when these structures are present.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The proximal portion of the respiratory passages on either side of the nasal septum lying between the floor of the cranium and the roof of the mouth and extending from the face to the pharynx. The nasal cavity is lined with ciliated mucosa, extending from the nares to the pharynx.","type":"DEFINITION","source":"NCI"},{"definition":"The upper respiratory tract extending from the nares to the pharynx.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nasal Cavity","termGroup":"PT","termSource":"NCI"},{"termName":"Nasal Fossa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Nasal_Cavity"},{"name":"Legacy Concept Name","value":"Nasal_Cavity_and_Paranasal_Sinus"},{"name":"Maps_To","value":"Nasal cavity"},{"name":"Maps_To","value":"Nasal Cavity"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0027423"},{"name":"xRef","value":"UBERON:0001707"}]}}{"C12755":{"preferredName":"Nervous System","code":"C12755","definitions":[{"definition":"The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.","type":"DEFINITION","source":"NCI"},{"definition":"The organized network of nerve tissue in the body. It includes the central nervous system (the brain and spinal cord), the peripheral nervous system (nerves that extend from the spinal cord to the rest of the body), and other nerve tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Neurologic","termGroup":"SY","termSource":"NCI"},{"termName":"Neurologic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Neurologic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Neurologic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Nervous_System"},{"name":"Maps_To","value":"Nervous system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0027763"},{"name":"xRef","value":"IMDRF:E01"}]}}{"C12299":{"preferredName":"Nipple","code":"C12299","definitions":[{"definition":"In anatomy, the small raised area in the center of the breast through which milk can flow to the outside.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pigmented protuberance on the surface of the breast through which milk is drawn from the breast.","type":"DEFINITION","source":"NCI"},{"definition":"The protuberance in the skin where the ducts of the mammary gland open.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nipple","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nipple"},{"name":"Maps_To","value":"Nipple"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0028109"}]}}{"C12355":{"preferredName":"Occipital Lobe","code":"C12355","definitions":[{"definition":"One of the four regions of cortex in each cerebral hemisphere, located posterior to the temporal lobe and inferior to the parietal lobe.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the four regions of cortex in each cerebral hemisphere. It is located posterior to the temporal lobe and inferior to the parietal lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occipital Lobe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Occipital_Lobe"},{"name":"Maps_To","value":"Brain, Occipital lobe"},{"name":"Maps_To","value":"Occipital lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0028785"}]}}{"C12759":{"preferredName":"Olfactory Nerve","code":"C12759","definitions":[{"definition":"The first cranial nerve.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The first cranial nerve. It is the shortest cranial nerve and of paramount importance in the sense of smell. Its neurons are in the olfactory mucosa in the nasal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Nerve","termGroup":"PT","termSource":"NCI"},{"termName":"Cranial Nerve I","termGroup":"SY","termSource":"NCI"},{"termName":"First Cranial Nerve","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Olfactory_Nerve"},{"name":"Maps_To","value":"Olfactory nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0028938"}]}}{"C12761":{"preferredName":"Optic Nerve","code":"C12761","definitions":[{"definition":"A cranial nerve extending between the retina and optic chiasma, which innervates the eye.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The nerve that carries messages from the retina to the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The second cranial nerve.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Optic Nerve","termGroup":"PT","termSource":"NCI"},{"termName":"Second Cranial Nerve","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Optic_Nerve"},{"name":"Maps_To","value":"Optic nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0029130"}]}}{"C12347":{"preferredName":"Orbit","code":"C12347","definitions":[{"definition":"The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.","type":"DEFINITION","source":"NCI"},{"definition":"The bony cavity that contains the eye and its associated structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Orbit","termGroup":"PT","termSource":"NCI"},{"termName":"Eye Socket","termGroup":"SY","termSource":"NCI"},{"termName":"Ocular Orbit","termGroup":"SY","termSource":"NCI"},{"termName":"Orbital Cavity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Orbit"},{"name":"Maps_To","value":"Ocular orbits"},{"name":"Maps_To","value":"Ocular Orbits"},{"name":"Maps_To","value":"Orbit, NOS"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0029180"},{"name":"xRef","value":"UBERON:0001697"}]}}{"C147919":{"preferredName":"Ill-Defined Anatomic Site","code":"C147919","definitions":[{"definition":"An anatomic site that is not specified or defined well enough to associate with a specific site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ill-Defined Anatomic Site","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other ill-defined sites"},{"name":"NCI_META_CUI","value":"CL545798"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C12273":{"preferredName":"Other Specified Parts of Pancreas","code":"C12273","definitions":[{"definition":"Any component associated with the pancreas that is different from the one(s) previously specified or mentioned.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Specified Parts of Pancreas","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Other_Specified_Parts_of_Pancreas"},{"name":"Maps_To","value":"Other specified parts of pancreas"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1518669"}]}}{"C12272":{"preferredName":"Pancreatic Duct","code":"C12272","definitions":[{"definition":"A duct joining the pancreas to the common bile duct to supply pancreatic juices.","type":"DEFINITION","source":"NCI"},{"definition":"A duct that conveys pancreatic secretions from the pancreas to the duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Part of a system of ducts in the pancreas. Pancreatic juices containing enzymes are released into these ducts and flow into the small intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatic Duct","termGroup":"PT","termSource":"NCI"},{"termName":"Canal of Wirsung","termGroup":"SY","termSource":"NCI"},{"termName":"Main Pancreatic Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Duct"},{"name":"Maps_To","value":"Pancreatic duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030288"}]}}{"C158551":{"preferredName":"Neck of the Pancreas","code":"C158551","definitions":[{"definition":"The portion of the pancreas that is the junction of the head and body of the pancreas, and lies anterior to the aorta.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the pancreas that is the junction of the head and body of the pancreas; the portion of the pancreas that lies anterior to the aorta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neck of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreas Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic neck"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0447556"}]}}{"C12320":{"preferredName":"Parametrium","code":"C12320","definitions":[{"definition":"The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament.","type":"DEFINITION","source":"NCI"},{"definition":"The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Parametrium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Parametrium"},{"name":"Maps_To","value":"Parametrium"},{"name":"Maps_To","value":"Parametrium, Left"},{"name":"Maps_To","value":"Parametrium, Right"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227822"}]}}{"C12765":{"preferredName":"Parathyroid Gland","code":"C12765","definitions":[{"definition":"Endocrine gland, usually in close proximity to the thyroid gland, that produces parathyroid hormone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parathyroid Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Parathyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Parathyroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"DesignNote","value":"Inadvertent removal of all parathyroid glands, as during thyroidectomy, produces tetany and death."},{"name":"Legacy Concept Name","value":"Parathyroid_Gland"},{"name":"Maps_To","value":"Parathyroid"},{"name":"Maps_To","value":"Parathyroid gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030518"},{"name":"xRef","value":"UBERON:0001132"}]}}{"C61122":{"preferredName":"Skene Gland","code":"C61122","definitions":[{"definition":"A gland located in the anterior wall of the vagina that drains into the urethra at the opening.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skene Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Paraurethral Skene Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Skene's Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skene_s_Gland"},{"name":"Maps_To","value":"Paraurethral gland"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227782"}]}}{"C12354":{"preferredName":"Parietal Lobe","code":"C12354","definitions":[{"definition":"One of the lobes of the cerebral hemisphere located superiorly to the occipital lobe and posteriorly to the frontal lobe. Cognition and visuospatial processing are its main function. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the lobes of the cerebral hemisphere located superiorly to the occipital lobe and posteriorly to the frontal lobe. Cognition and visuospatial processing are its main functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parietal Lobe","termGroup":"PT","termSource":"NCI"},{"termName":"Parietal Lobe of the Brain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Parietal_Lobe_of_the_Brain"},{"name":"Maps_To","value":"Brain, Parietal lobe"},{"name":"Maps_To","value":"Parietal lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030560"}]}}{"C12363":{"preferredName":"Pelvic Lymph Node","code":"C12363","definitions":[{"definition":"Any lymph node within the abdominal pelvic region.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Any lymph node within the abdominal pelvic region.","type":"DEFINITION","source":"NCI"},{"definition":"Any lymph node within the pelvic region. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pelvic Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Pelvic Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pelvic_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Pelvic"},{"name":"Maps_To","value":"Pelvic Lymph Node(s)"},{"name":"Maps_To","value":"Pelvic lymph nodes"},{"name":"Maps_To","value":"Pelvis, NOS"},{"name":"NCI_META_CUI","value":"CL455365"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"xRef","value":"UBERON:0015876"}]}}{"C12425":{"preferredName":"Pharynx","code":"C12425","definitions":[{"definition":"A hollow tube that starts posterior to the mouth and nasal cavity and ends superior to the trachea and esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"A passageway in the head and neck that includes the nasopharynx, oropharynx and laryngopharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The hollow tube inside the neck that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach). The pharynx is about 5 inches long, depending on body size.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pharynx is the part of the digestive system immediately posterior to the mouth.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pharynx","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pharynx"},{"name":"Maps_To","value":"Pharynx"},{"name":"Maps_To","value":"Pharynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0031354"},{"name":"xRef","value":"UBERON:0006562"}]}}{"C12398":{"preferredName":"Pineal Gland","code":"C12398","definitions":[{"definition":"A midline, cone like structure located in the dorso-caudal roof of the 3rd ventricle, attached by peduncles to the habenular and posterior commissures. The stalk contains nerve fibers, blood vessels, connective tissue and parenchymal cells (Paxinos, The Rat Central Nervous System, 2nd ed, pg 399).","type":"ALT_DEFINITION","source":"NCI"},{"definition":"A small endocrine gland in the brain, situated beneath the back part of the corpus callosum, that secretes melatonin.","type":"DEFINITION","source":"NCI"},{"definition":"A small endocrine gland that arises from the central posterior aspect of the diencephalon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tiny organ in the cerebrum that produces melatonin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pineal Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Pineal Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pineal_Gland"},{"name":"Maps_To","value":"Pineal"},{"name":"Maps_To","value":"Pineal Gland"},{"name":"Maps_To","value":"Pineal gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0031939"},{"name":"xRef","value":"UBERON:0001905"}]}}{"C12399":{"preferredName":"Pituitary Gland","code":"C12399","definitions":[{"definition":"A small endocrine gland extending from the hypothalamus at the base of the brain.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An endocrine gland located ventral to the diencephalon and derived from mixed neuroectodermal and non neuroectodermal origin.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Pea-sized endocrine gland located at the base of the brain in the pituitary fossa. It produces and secretes hormones such as oxytocin and vasopressin, to regulate the activities of the hypothalamus.","type":"DEFINITION","source":"NCI"},{"definition":"The main endocrine gland. It produces hormones that control other glands and many body functions, especially growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pituitary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Hypophysis","termGroup":"SY","termSource":"NCI"},{"termName":"Hypophysis Cerebri","termGroup":"SY","termSource":"NCI"},{"termName":"Nervous System, Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pituitary_Gland"},{"name":"Maps_To","value":"Pituitary gland"},{"name":"Maps_To","value":"Pituitary Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0032005"},{"name":"xRef","value":"UBERON:0000007"}]}}{"C54221":{"preferredName":"Postcricoid Region","code":"C54221","definitions":[{"definition":"The portion of the hypopharynx that is located posteriorly to the larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Postcricoid Region","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Hypopharyngeal Region","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower_Hypopharyngeal_Region"},{"name":"Maps_To","value":"Postcricoid region"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0225516"}]}}{"C33368":{"preferredName":"Posterior Mediastinum","code":"C33368","definitions":[{"definition":"The part of the lower portion of the mediastinum that is located behind the pericardium.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the lower portion of the mediastinum that is located behind the pericardium. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Posterior Mediastinum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Mediastinum"},{"name":"Maps_To","value":"Posterior mediastinum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230150"}]}}{"C12335":{"preferredName":"Posterior Wall of the Bladder","code":"C12335","definitions":[{"definition":"The posterior aspect of the bladder wall.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Bladder"},{"name":"Maps_To","value":"Posterior wall of bladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227701"}]}}{"C12249":{"preferredName":"Posterior Wall of the Hypopharynx","code":"C12249","definitions":[{"definition":"The region of the hypopharynx demarcated by a plane drawn at the level of the tip of the epiglottis to a plane at the inferior border of the cricoid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Hypopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Hypopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Hypopharynx"},{"name":"Maps_To","value":"Posterior wall of hypopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227174"}]}}{"C12243":{"preferredName":"Posterior Wall of the Nasopharynx","code":"C12243","definitions":[{"definition":"The dorsal portion of the nasopharyngeal cavity that contains the pharyngeal tonsil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Posterior wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0225484"}]}}{"C12240":{"preferredName":"Posterior Wall of the Oropharynx","code":"C12240","definitions":[{"definition":"The dorsal portion of the oropharyngeal cavity that is formed by the muscular pharyngeal wall comprising the superior and middle pharyngeal constrictor muscles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Oropharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Oropharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Oropharynx"},{"name":"Maps_To","value":"Posterior wall of oropharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227155"}]}}{"C12323":{"preferredName":"Prepuce","code":"C12323","definitions":[{"definition":"A covering fold of skin, often used alone to designate the preputium penis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"A fold of skin covering the end of the penis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Prepuce","termGroup":"PT","termSource":"NCI"},{"termName":"Preputium Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prepuce"},{"name":"Maps_To","value":"Prepuce"},{"name":"NCI_META_CUI","value":"CL415279"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C12260":{"preferredName":"Pylorus","code":"C12260","definitions":[{"definition":"The lower part of the stomach that connects to the duodenum.","type":"DEFINITION","source":"NCI"},{"definition":"The region of the stomach that connects to the duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The stomach tissue region surrounding and controlling the distal outlet of the stomach, which opens into the duodenum.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pylorus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pylorus"},{"name":"Maps_To","value":"Pylorus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0034196"},{"name":"xRef","value":"UBERON:0001166"}]}}{"C12780":{"preferredName":"Reticuloendothelial System","code":"C12780","definitions":[{"definition":"A widely distributed collection of both free and fixed macrophages derived from bone marrow precursor cells by way of monocytes; their substantial phagocytic activity is mediated by immunoglobulin and the serum complement system. In both connective and lymphoid tissue, they may occur as free and fixed macrophages; in the sinusoids of the liver, as Kupffer cells; in the lung, as alveolar macrophages; and in the nervous system, as microglia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reticuloendothelial System","termGroup":"PT","termSource":"NCI"},{"termName":"RE System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Reticuloendothelial_System"},{"name":"Maps_To","value":"Reticuloendothelial system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0035287"}]}}{"C12343":{"preferredName":"Retina","code":"C12343","definitions":[{"definition":"A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain.","type":"DEFINITION","source":"NCI"},{"definition":"A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The light-sensitive layers of nerve tissue at the back of the eye that receive images and sends them as electric signals through the optic nerve to the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The retina is the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Retina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Retina"},{"name":"Maps_To","value":"Retina"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0035298"},{"name":"xRef","value":"UBERON:0000966"}]}}{"C54223":{"preferredName":"Retromolar Trigone","code":"C54223","definitions":[{"definition":"A triangular-shaped area of mucosa located posterior the last mandibular molar tooth.","type":"DEFINITION","source":"NCI"},{"definition":"The small area behind the wisdom teeth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Retromolar Trigone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retromolar_Trigone"},{"name":"Maps_To","value":"Retromolar area"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0226920"}]}}{"C12319":{"preferredName":"Round Ligament","code":"C12319","definitions":[{"definition":"Any of the round ligaments including the round ligament of the liver and the round ligament of the uterus.","type":"DEFINITION","source":"NCI"},{"definition":"Band of fibrous tissue that anchors various organs in place.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Round Ligament","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Round_Ligament"},{"name":"Maps_To","value":"Round Ligament"},{"name":"Maps_To","value":"Round ligament"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3241921"}]}}{"C12785":{"preferredName":"Scrotum","code":"C12785","definitions":[{"definition":"In males, the external sac that contains the testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The external sac of skin that encloses the testes. It is an extension of the abdomen, and in placentals is located between the penis and anus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The musculocutaneous pouch that encloses the testicles.","type":"DEFINITION","source":"NCI"},{"definition":"The pouch that encloses the testicles.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Scrotum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Scrotum"},{"name":"Maps_To","value":"Scrotum"},{"name":"Maps_To","value":"Scrotum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036471"},{"name":"xRef","value":"UBERON:0001300"}]}}{"C12384":{"preferredName":"Sigmoid Colon","code":"C12384","definitions":[{"definition":"The S-shaped section of the colon that connects to the rectum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the large intestine that is closest to the rectum and anus. It forms a loop that averages about 40 cm. in length, and normally lies within the pelvis, but on account of its freedom of movement it is liable to be displaced into the abdominal cavity.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the colon that connects to the descending colon above and the rectum below.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The portion of the colon that connects to the descending colon above and the rectum below. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sigmoid Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sigmoid_Colon"},{"name":"Maps_To","value":"Sigmoid colon"},{"name":"Maps_To","value":"Sigmoid Colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227391"},{"name":"xRef","value":"UBERON:0001159"}]}}{"C12291":{"preferredName":"Skin of the Lip","code":"C12291","definitions":[{"definition":"The skin portion of the lip that contains hair.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The skin portion of the lip that contains hair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Hair Bearing Lip","termGroup":"SY","termSource":"NCI"},{"termName":"Skin of Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Lip"},{"name":"Maps_To","value":"Skin of lip, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222101"}]}}{"C12297":{"preferredName":"Skin of the Lower Limb and Hip","code":"C12297","definitions":[{"definition":"The integumentary covering of the lower limb and hip region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Lower Limb and Hip","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Lower Limb and Hip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Lower_Limb_and_Hip"},{"name":"Maps_To","value":"Skin of lower limb and hip"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222268"}]}}{"C33561":{"preferredName":"Skin of the Face","code":"C33561","definitions":[{"definition":"The integumentary covering of the face.","type":"DEFINITION","source":"NCI"},{"definition":"The skin or integument that covers the face.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Skin of the Face","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Face"},{"name":"Maps_To","value":"Skin of other and unspecified parts of face"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222084"}]}}{"C12294":{"preferredName":"Skin of the Scalp and Neck","code":"C12294","definitions":[{"definition":"The integumentary covering of the scalp and neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Scalp and Neck","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Scalp and Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Scalp_and_Neck"},{"name":"Maps_To","value":"Skin of scalp and neck"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1522650"}]}}{"C12295":{"preferredName":"Skin of the Trunk","code":"C12295","definitions":[{"definition":"The integument that covers the trunk of the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The skin or integument surrounding the trunk of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Trunk","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Trunk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Trunk"},{"name":"Maps_To","value":"Skin of trunk"},{"name":"Maps_To","value":"Skin, trunk, local"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0205031"}]}}{"C12296":{"preferredName":"Skin of the Upper Limb and Shoulder","code":"C12296","definitions":[{"definition":"The integumentary covering of the upper limb and shoulder region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Upper Limb and Shoulder","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Upper Limb and Shoulder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Upper_Limb_and_Shoulder"},{"name":"Maps_To","value":"Skin of upper limb and shoulder"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222212"}]}}{"C12231":{"preferredName":"Soft Palate","code":"C12231","definitions":[{"definition":"The back, muscular (not bony) part of the roof of the mouth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The muscular extension of the hard palate which comprises the posterior of the oral cavity and the floor of the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the roof of the mouth not supported by bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Soft Palate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Soft_Palate"},{"name":"Maps_To","value":"Soft palate, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030219"}]}}{"C12329":{"preferredName":"Spermatic Cord","code":"C12329","definitions":[{"definition":"A cord-like structure in the male reproductive system that contains nerves, blood and lymph vessels, and the vas deferens (a coiled tube that carries sperm out of the testicle). It runs from the abdomen to the testicle, and connects to the testicle in the scrotum (external sac).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tube-like structure composed of the vas deferens and surrounding tissue layers, that runs from the abdomen to each of the testicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spermatic Cord","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spermatic_Cord"},{"name":"Maps_To","value":"Spermatic cord"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037855"}]}}{"C12278":{"preferredName":"Sphenoid Sinus","code":"C12278","definitions":[{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). There are two large sphenoid sinuses in the sphenoid bone, which is behind the nose between the eyes. The sphenoid sinuses are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Either of the paired paranasal sinuses located in the anterior part of the body of the sphenoid bone, and communicating with the superior meatus of the nasal cavity on the same side.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of the paired paranasal sinuses, located in the anterior part of the body of the sphenoid bone and communicating with the superior meatus of the nasal cavity on the same side.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sphenoid Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Sinus, Sphenoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Sphenoid_Sinus"},{"name":"Maps_To","value":"Sphenoid sinus"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0037885"}]}}{"C12350":{"preferredName":"Spinal Meninges","code":"C12350","definitions":[{"definition":"Connective tissue membranes that surround and support the spinal cord and cauda equina. They are continuous with cranial meninges, which surround and support the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spinal Meninges","termGroup":"PT","termSource":"NCI"},{"termName":"Spinal Meninx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spinal_Meninges"},{"name":"Maps_To","value":"Spinal meninges"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037938"}]}}{"C12267":{"preferredName":"Splenic Flexure","code":"C12267","definitions":[{"definition":"The bend at the junction of the transverse and descending colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bend at the junction of the transverse and descending colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The splenic (or left colic) flexure is a sharp bend between the transverse and the descending colon in the left upper quadrant of humans. The left colic flexure is near the spleen, and hence called the splenic flexure. There are two colic flexures in the transverse colon; the other being the hepatic flexure in the right upper quadrant.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Splenic Flexure","termGroup":"PT","termSource":"NCI"},{"termName":"Left Colic Flexure","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Flexure of Colon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Splenic_Flexure"},{"name":"Maps_To","value":"Splenic Flexure"},{"name":"Maps_To","value":"Splenic flexure of colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227387"},{"name":"xRef","value":"UBERON:0022276"}]}}{"C12280":{"preferredName":"Subglottis","code":"C12280","definitions":[{"definition":"The area of the larynx below the vocal cords down to the trachea.","type":"DEFINITION","source":"NCI"},{"definition":"The area of the larynx below the vocal cords down to the trachea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lower portion of the larynx, extending from just beneath the vocal cords down to the top of the trachea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lowest part of the larynx; the area from just below the vocal cords down to the top of the trachea.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Subglottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Subglottis"},{"name":"Maps_To","value":"Subglottis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0456475"},{"name":"xRef","value":"UBERON:0036068"}]}}{"C12234":{"preferredName":"Sublingual Salivary Gland","code":"C12234","definitions":[{"definition":"A salivary gland located under the tongue in the floor of the oral cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The salivary gland located under the tongue in the floor of the oral cavity or adjacent to the submandibular salivary gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The small mucin-producing salivary glands in the floor of the mouth beneath the tongue, anterior to the submandibular gland.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Sublingual Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Sublingual Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sublingual_Salivary_Gland"},{"name":"Maps_To","value":"Sublingual gland"},{"name":"Maps_To","value":"Sublingual Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0038553"},{"name":"xRef","value":"UBERON:0001832"}]}}{"C12233":{"preferredName":"Submandibular Salivary Gland","code":"C12233","definitions":[{"definition":"Either of the paired compound tubuloalveolar (aka tubuloacinar) major salivary glands composed of both serous and mucous secretory cells and situated beneath the mandible.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of major salivary glands located below the floor of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The salivary gland located adjacent to the mandible.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Submandibular Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Submandibular Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Submaxillary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Submandibular_Gland"},{"name":"Maps_To","value":"Submandibular gland"},{"name":"Maps_To","value":"Submandibular Gland"},{"name":"NCI_META_CUI","value":"CL1773628"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"xRef","value":"UBERON:0001736"}]}}{"C12242":{"preferredName":"Superior Wall of the Nasopharynx","code":"C12242","definitions":[{"definition":"The roof of the nasopharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superior Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Nasopharyngeal Roof","termGroup":"SY","termSource":"NCI"},{"termName":"Roof of Nasopharynx","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Superior_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Superior wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225492"}]}}{"C12279":{"preferredName":"Supraglottis","code":"C12279","definitions":[{"definition":"The upper part of the larynx (voice box), including the epiglottis; the area above the vocal cords.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The upper part of the larynx, including the epiglottis; the area above the vocal cords.","type":"DEFINITION","source":"NCI"},{"definition":"The upper part of the larynx, including the epiglottis; the area above the vocal cords.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper part of the larynx, including the epiglottis; the area above the vocal cords.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Supraglottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Supraglottis"},{"name":"Maps_To","value":"Supraglottis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225574"},{"name":"xRef","value":"UBERON:0036263"}]}}{"C12271":{"preferredName":"Tail of the Pancreas","code":"C12271","definitions":[{"definition":"The left extremity of the pancreas within the lienorenal ligament.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The left extremity of the pancreas within the lienorenal ligament. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tail of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreas Tail","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Tail","termGroup":"SY","termSource":"NCI"},{"termName":"Tail of Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Tail_of_the_Pancreas"},{"name":"Maps_To","value":"Tail of pancreas"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227590"}]}}{"C12353":{"preferredName":"Temporal Lobe","code":"C12353","definitions":[{"definition":"One of the cerebral lobes. It is located inferior to the frontal and parietal lobes and anterior to the occipital lobe.","type":"DEFINITION","source":"NCI"},{"definition":"The second largest of the four cerebral lobes, the temporal lobe is approximately twenty two percent of the total neocortical volume. The temporal lobe can be divided into two main sections: first, the neocortex, comprising its lateral and inferolateral surfaces, and its standard cerebral cortex; and, second, the mesial temporal lobe, which is sometimes referred to as the limbic lobe, and includes the hippocampus, the amygdala, and the parahippocampal gyrus. Grossly, the lobe extends superiorly to the Sylvian fissure, and posteriorly to an imaginary line, the lateral parietotemporal line, which separates the temporal lobe from the inferior parietal lobule superiorly and the occipital lobe inferiorly. The middle cranial fossa forms its anterior and inferior boundaries.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Temporal Lobe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Temporal_Lobe"},{"name":"Maps_To","value":"Brain, Temporal lobe"},{"name":"Maps_To","value":"Temporal lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0039485"}]}}{"C12251":{"preferredName":"Thoracic Esophagus","code":"C12251","definitions":[{"definition":"Clinical esophageal segment composed of smooth muscle. It includes the middle third topographic segment, as well as parts of the upper and lower thirds.","type":"DEFINITION","source":"NCI"},{"definition":"Clinical esophageal segment composed of smooth muscle. It includes the middle third topographic segment, as well as parts of the upper and lower thirds. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thoracic Esophagus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thoracic_Esophagus"},{"name":"Maps_To","value":"Thoracic esophagus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227188"}]}}{"C12799":{"preferredName":"Thorax","code":"C12799","definitions":[{"definition":"Subdivision of trunk proper, which is demarcated from the neck by the plane of the superior thoracic aperture and from the abdomen internally by the inferior surface of the diaphragm and externally by the costal margin and associated with the thoracic vertebral column and ribcage and from the back of the thorax by the external surface of the posterolateral part of the rib cage, the anterior surface of the thoracic vertebral column and the posterior axillary lines; together with the abdomen and the perineum, it constitutes the trunk proper.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The division of the body lying between the neck and the abdomen.","type":"DEFINITION","source":"NCI"},{"definition":"The division of the body lying between the neck and the abdomen. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thorax","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thorax"},{"name":"Maps_To","value":"Thorax"},{"name":"Maps_To","value":"Thorax, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0817096"},{"name":"xRef","value":"UBERON:0001443"}]}}{"C12422":{"preferredName":"Tongue","code":"C12422","definitions":[{"definition":"A muscular organ in the floor of the mouth.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The muscular organ in the mouth used in taste perception and food ingestion.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tongue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tongue"},{"name":"Maps_To","value":"Tongue"},{"name":"Maps_To","value":"Tongue, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040408"},{"name":"xRef","value":"UBERON:0001723"}]}}{"C33250":{"preferredName":"Palatine Tonsil","code":"C33250","definitions":[{"definition":"A tonsil in the mucosa of the glossopalatine arch of the oropharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Two masses of lymphatic tissue located one on either side of the oropharynx in the oropharyngeal isthmus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palatine Tonsil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palatine_Tonsil"},{"name":"Maps_To","value":"Tonsil, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0040421"}]}}{"C12235":{"preferredName":"Tonsillar Fossa","code":"C12235","definitions":[{"definition":"A triangular shaped space that lies on each side of the oropharynx and houses the palatine tonsils.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillar Fossa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillar_Fossa"},{"name":"Maps_To","value":"Tonsillar fossa"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0229881"}]}}{"C12236":{"preferredName":"Tonsillar Pillar","code":"C12236","definitions":[{"definition":"The anterior and posterior borders of the tonsillar fossa.  They are composed of muscle tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillar Pillar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillar_Pillar"},{"name":"Maps_To","value":"Tonsillar pillar"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0229872"}]}}{"C12385":{"preferredName":"Transverse Colon","code":"C12385","definitions":[{"definition":"The proximal-distal subdivision of colon that runs transversely across the upper part of the abdomen, from the right to the left colic flexure. Continuous with the descending colon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Transverse Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Transverse_Colon"},{"name":"Maps_To","value":"Transverse colon"},{"name":"Maps_To","value":"Transverse Colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227386"},{"name":"xRef","value":"UBERON:0001157"}]}}{"C12331":{"preferredName":"Bladder Trigone","code":"C12331","definitions":[{"definition":"The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice.","type":"DEFINITION","source":"NCI"},{"definition":"The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bladder Trigone","termGroup":"PT","termSource":"NCI"},{"termName":"Trigone of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Bladder Trigone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Trigone"},{"name":"Maps_To","value":"Trigone of bladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0447586"}]}}{"C12326":{"preferredName":"Undescended Testes","code":"C12326","definitions":[{"definition":"A condition in which one or both testicles fail to move from the abdomen, where they develop before birth, into the scrotum. Undescended testicles may increase the risk for development of testicular cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The failure of one or both testes of a male fetus to descend from the abdomen into the scrotum during the late part of pregnancy. If not surgically corrected in early childhood, males may be at increased risk for testicular cancer later in life.","type":"DEFINITION","source":"NCI"},{"definition":"The persistent failure of one or both testes to descend into the scrotum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Undescended Testes","termGroup":"PT","termSource":"NCI"},{"termName":"Cryptorchidism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Undescended_Testis"},{"name":"Maps_To","value":"Undescended Testis"},{"name":"Maps_To","value":"Undescended testis"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3552639"}]}}{"C48322":{"preferredName":"Primary Site Unknown","code":"C48322","definitions":[{"definition":"Referring to the fact that the original site of growth of a metastatic cancer is unknown or uncertain.","type":"DEFINITION","source":"NCI"},{"definition":"Referring to the fact that the original site of growth of a metastatic cancer is unknown or uncertain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Primary Site Unknown","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Site_Unknown"},{"name":"Maps_To","value":"Unknown primary site"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709668"}]}}{"C54205":{"preferredName":"Upper Gingiva","code":"C54205","definitions":[{"definition":"The gingiva covering the maxillary alveolar bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper Gingiva","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Gums","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Upper_Gingiva"},{"name":"Maps_To","value":"Upper Gum"},{"name":"Maps_To","value":"Upper gum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227121"}]}}{"C12671":{"preferredName":"Upper Extremity","code":"C12671","definitions":[{"definition":"The part of the forelimb extending from the shoulder to the autopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region of the body that extends distal to the scapulohumeral joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The region of the body that includes the arm, the forearm, and hand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Upper_Extremity"},{"name":"Maps_To","value":"Upper limb, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C1140618"},{"name":"xRef","value":"UBERON:0001460"}]}}{"C12285":{"preferredName":"Upper Lobe of the Lung","code":"C12285","definitions":[{"definition":"The lobe of the right lung that lies above the oblique and horizontal fissures and includes the apical, posterior and anterior bronchopulmonary segments; in the left lung, the lobe lies above the oblique fissure and contains the apicoposterior, anterior, superior lingular and inferior lingular segments.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"Biology-online.org"}]}],"synonyms":[{"termName":"Upper Lobe of the Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Upper Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Lobe, Lung","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Upper_Lobe"},{"name":"Maps_To","value":"Upper lobe, lung"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225756"}]}}{"C33839":{"preferredName":"Upper Respiratory System","code":"C33839","definitions":[{"definition":"The sinuses and those parts of the respiratory system above the trachea. It includes the nares, nasopharynx, oropharynx, larynx, vocal cords, glottis and upper trachea.","type":"DEFINITION","source":"NCI"},{"definition":"The sinuses and those parts of the respiratory system above the trachea. It includes the nares, nasopharynx, oropharynx, larynx, vocal cords, glottis and upper trachea.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Upper Respiratory System","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Airway","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Upper_Respiratory_System"},{"name":"Maps_To","value":"Upper respiratory tract, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1519817"}]}}{"C12253":{"preferredName":"Upper Third of the Esophagus","code":"C12253","definitions":[{"definition":"The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type.","type":"DEFINITION","source":"NCI"},{"definition":"The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Upper Third of the Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Third of Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Upper_Third_of_the_Esophagus"},{"name":"Maps_To","value":"Esophageal; Proximal"},{"name":"Maps_To","value":"Upper third of esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227187"},{"name":"xRef","value":"UBERON:0013472"}]}}{"C12301":{"preferredName":"Upper-Inner Quadrant of the Breast","code":"C12301","definitions":[{"definition":"The quarter of the breast which is superior and medial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper-Inner Quadrant of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Upper-Inner Quadrant of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Upper-inner_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Upper-inner quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222596"}]}}{"C12303":{"preferredName":"Upper-Outer Quadrant of the Breast","code":"C12303","definitions":[{"definition":"The quarter of the breast which is superior and lateral.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper-Outer Quadrant of the Breast","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Upper-outer_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Upper-outer quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222598"}]}}{"C12338":{"preferredName":"Urachus","code":"C12338","definitions":[{"definition":"A cord of fibrous tissue that extends from the urinary bladder to the umbilicus. The urachus is a remnant of the fetal urinary canal.","type":"DEFINITION","source":"NCI"},{"definition":"A cord of fibrous tissue that extends from the urinary bladder to the umbilicus; the urachus is a remnant of the fetal urinary canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A fibrous cord that connects the urinary bladder to the umbilicus (navel).  The urachus is formed as the allantoic stalk during fetal development and lasts through life.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Urachus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urachus"},{"name":"Maps_To","value":"Urachus"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0041916"}]}}{"C12337":{"preferredName":"Ureteric Orifice","code":"C12337","definitions":[{"definition":"The opening of the ureter in the bladder that is situated at the lateral angle of the trigone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The opening of the ureter in the bladder that is situated at the lateral angle of the trigone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ureteric Orifice","termGroup":"PT","termSource":"NCI"},{"termName":"Orifice of the Ureter","termGroup":"SY","termSource":"NCI"},{"termName":"Ureteral Opening","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ureteric_Orifice"},{"name":"Maps_To","value":"Ureteric orifice"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0447577"}]}}{"C12413":{"preferredName":"Urinary System","code":"C12413","definitions":[{"definition":"The organs involved in the creation and excretion of urine.","type":"DEFINITION","source":"NCI"},{"definition":"The organs involved in the creation and excretion of urine. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organs that make urine and remove it from the body. The urinary tract is divided into two parts. The upper urinary tract includes the kidneys and ureters. The lower urinary tract includes the bladder and urethra. The kidneys remove waste and extra fluid from the blood to make urine. The urine flows from the kidneys through the ureters to the bladder. It is stored in the bladder until it leaves the body through the urethra.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Urinary System","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Renal/Urologic","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Renal/Urologic","termGroup":"SY","termSource":"NCI"},{"termName":"Renal/Urologic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Renal/Urologic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Urologic/Renal Body System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urinary_System"},{"name":"Maps_To","value":"Urinary system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C1508753"},{"name":"xRef","value":"IMDRF:E13"}]}}{"C12232":{"preferredName":"Uvula","code":"C12232","definitions":[{"definition":"Conic projection from the posterior edge of the middle of the soft palate, composed of connective tissue containing a number of racemose glands, and some muscular fibers.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fleshy lobe that hangs at the back of the soft palate.","type":"DEFINITION","source":"NCI"},{"definition":"The fleshy lobe that is suspended from the back of the soft palate in the oral cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The soft flap of tissue that hangs down at the back of the mouth (at the edge of the soft palate).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Uvula","termGroup":"PT","termSource":"NCI"},{"termName":"Palatine Uvula","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Uvula"},{"name":"Maps_To","value":"Uvula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042173"},{"name":"xRef","value":"UBERON:0001734"}]}}{"C12237":{"preferredName":"Vallecula","code":"C12237","definitions":[{"definition":"A groove between the base of the tongue and the epiglottis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vallecula","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vallecula"},{"name":"Maps_To","value":"Vallecula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227157"}]}}{"C12356":{"preferredName":"Brain Ventricle","code":"C12356","definitions":[{"definition":"The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Brain Ventricle","termGroup":"PT","termSource":"NCI"},{"termName":"Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Ventricle of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Ventricle, Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Ventricles, Brain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Ventricle_Brain"},{"name":"Maps_To","value":"Brain, Ventricle, NOS"},{"name":"Maps_To","value":"Ventricle, NOS"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0007799"}]}}{"C12998":{"preferredName":"Vertebral Column","code":"C12998","definitions":[{"definition":"A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"Subdivision of skeletal system that consists of all the vertebra and associated skeletal elements and joints in the body.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bones, muscles, tendons, and other tissues that reach from the base of the skull to the tailbone. The spinal column encloses the spinal cord and the fluid surrounding the spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The series of vertebrae and other tissues extending from the skull to the last tailbone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Vertebral Column","termGroup":"PT","termSource":"NCI"},{"termName":"Spinal Column","termGroup":"SY","termSource":"NCI"},{"termName":"Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vertebral_Column"},{"name":"Maps_To","value":"Spinal Column"},{"name":"Maps_To","value":"Spine"},{"name":"Maps_To","value":"Vertebral column"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037949"},{"name":"xRef","value":"UBERON:0001130"}]}}{"C165195":{"preferredName":"Vestibule of Mouth","code":"C165195","definitions":[{"definition":"The area inside the mouth between the cheek or lips, and the teeth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vestibule of Mouth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vestibule of mouth"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0226897"}]}}{"C73468":{"preferredName":"Waldeyer Ring","code":"C73468","definitions":[{"definition":"The ring of lymphoid tissue located in the pharynx, consisting of the pharyngeal, tubal, palatine, and lingual tonsils.","type":"DEFINITION","source":"NCI"},{"definition":"The ring of lymphoid tissue located in the pharynx, consisting of the pharyngeal, tubal, palatine, and lingual tonsils. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Waldeyer Ring","termGroup":"PT","termSource":"NCI"},{"termName":"Waldeyer Tonsillar Ring","termGroup":"SY","termSource":"NCI"},{"termName":"Waldeyer's Ring","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Waldeyers_Tonsillar_Ring"},{"name":"Maps_To","value":"Waldeyer ring"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0459892"}]}}{"C12443":{"preferredName":"Cerebral Cortex","code":"C12443","definitions":[{"definition":"The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers. It is responsible for memory, attention, consciousness and other higher levels of mental function.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers. It is responsible for memory, attention, consciousness and other higher levels of mental function.","type":"DEFINITION","source":"NCI"},{"definition":"The thin layer of gray matter on the surface of the cerebral hemisphere that develops from the telencephalon. It consists of the neocortex (6 layered cortex or isocortex), the hippocampal formation and the olfactory cortex.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Cerebral Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Cortical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cortex"},{"name":"Maps_To","value":"Cerebral Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007776"},{"name":"xRef","value":"UBERON:0000956"}]}}{"C158080":{"preferredName":"Deep Gray Matter","code":"C158080","definitions":[{"definition":"The gray matter that includes the basal ganglia and/or thalamus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Gray Matter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deep Gray (e.g. Basal Ganglia, Thalamus)"},{"name":"NCI_META_CUI","value":"CL937697"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C33892":{"preferredName":"White Matter","code":"C33892","definitions":[{"definition":"The nerve tissue forming the bulk of the deep parts of the brain and the superficial parts of the spinal cord. It is composed of nerve cell processes, i.e. extensions (axons), which connect various gray matter areas of the brain to each other and carry nerve impulses to and from the nerve cell bodies within the central nervous system (neurons). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The nerve tissue forming the bulk of the deep parts of the brain and the superficial parts of the spinal cord. It is composed of nerve cell processes, i.e. extensions (axons), which connect various grey matter areas of the brain to each other and carry nerve impulses to and from the nerve cell bodies within the central nervous system (neurons). Cerebral and spinal white matter does not contain dendrites. White matter is distinguished in that it is composed of axonal nerve fibers covered by a myelin sheath.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"White Matter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"White_Matter"},{"name":"Maps_To","value":"White Matter"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0682708"}]}}{"C38757":{"preferredName":"Negative Finding","code":"C38757","definitions":[{"definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","type":"DEFINITION","source":"NCI"},{"definition":"An indication of a negative finding for a test or assessment, such as for a disease, condition, analyte, or microorganism.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"COVID-19 test negative and no symptoms to suggest COVID-19","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]}],"synonyms":[{"termName":"Negative Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Negative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Negative_Finding"},{"name":"Maps_To","value":"Negative"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0205160"}]}}{"C160996":{"preferredName":"Transglottic Extension of Laryngeal Tumor","code":"C160996","definitions":[{"definition":"Extension of a laryngeal tumor beyond the glottic opening into the ventricles and vocal cords.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transglottic Extension of Laryngeal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"NCI_META_CUI","value":"CL970016"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25253":{"preferredName":"Multifocal","code":"C25253","definitions":[{"definition":"Arising from, pertaining to, or having many locations.","type":"DEFINITION","source":"NCI"},{"definition":"Arising from, pertaining to, or having many locations.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Multifocal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Multifocal"},{"name":"Maps_To","value":"Multifocal"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205292"}]}}{"C47862":{"preferredName":"Unifocal","code":"C47862","definitions":[{"definition":"Arising from, pertaining to, or having a single location.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unifocal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unifocal"},{"name":"Maps_To","value":"Unifocal"},{"name":"NCI_META_CUI","value":"CL448715"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C28077":{"preferredName":"Grade 1","code":"C28077","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is well differentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 1","termGroup":"PT","termSource":"NCI"},{"termName":"G1","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Grade_1"},{"name":"Maps_To","value":"G1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0687695"}]}}{"C28078":{"preferredName":"Grade 2","code":"C28078","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is moderately differentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"G2","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Grade_2"},{"name":"Maps_To","value":"G2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1522446"}]}}{"C28079":{"preferredName":"Grade 3","code":"C28079","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is poorly differentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"G3","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Grade_3"},{"name":"Maps_To","value":"G3"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0450094"}]}}{"C28082":{"preferredName":"Grade 4","code":"C28082","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is undifferentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is undifferentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 4","termGroup":"PT","termSource":"NCI"},{"termName":"G4","termGroup":"SY","termSource":"NCI"},{"termName":"Grade IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Grade_4"},{"name":"Maps_To","value":"G4"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0547054"}]}}{"C113730":{"preferredName":"Grade X","code":"C113730","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that the grade of a cancerous lesion cannot be assessed.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade X","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Cannot Be Assessed","termGroup":"SY","termSource":"NCI"},{"termName":"GX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GX"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3814800"}]}}{"C113729":{"preferredName":"Grade B","code":"C113729","definitions":[{"definition":"A morphologic qualifier indicating that a neoplasm is of borderline malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade B","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Grade","termGroup":"SY","termSource":"NCI"},{"termName":"GB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GB"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3714906"}]}}{"C14158":{"preferredName":"High Grade","code":"C14158","definitions":[{"definition":"A term used to describe cells that look abnormal under a microscope. These cells are more likely to grow and spread quickly than cells in low-grade cancer or in growths that may become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"High_Grade"},{"name":"Maps_To","value":"High Grade"},{"name":"NCI_META_CUI","value":"CL378245"},{"name":"Semantic_Type","value":"Classification"}]}}{"C28083":{"preferredName":"Intermediate Grade","code":"C28083","definitions":[{"definition":"A term referring to the degree of differentiation of a malignant neoplasm and indicating that it is moderately differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermediate Grade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Intermediate_Grade"},{"name":"Maps_To","value":"Intermediate Grade"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1512863"}]}}{"C14161":{"preferredName":"Low Grade","code":"C14161","definitions":[{"definition":"A term used to describe cells that look nearly normal under a microscope. These cells are less likely to grow and spread more quickly than cells in high-grade cancer or in growths that may become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Low_Grade"},{"name":"Maps_To","value":"Low Grade"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1282907"}]}}{"C155941":{"preferredName":"Tumor Regression Score 0","code":"C155941","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a complete response, defined as having no viable cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0"},{"name":"NCI_META_CUI","value":"CL562793"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C155942":{"preferredName":"Tumor Regression Score 1","code":"C155942","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a near complete response, defined as the presence of single cells or rare small groups of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1"},{"name":"NCI_META_CUI","value":"CL562794"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C155943":{"preferredName":"Tumor Regression Score 2","code":"C155943","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a partial response, defined as the presence of residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2"},{"name":"NCI_META_CUI","value":"CL562795"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C155944":{"preferredName":"Tumor Regression Score 3","code":"C155944","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates poor or no response, defined as extensive residual cancer with no evident tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3"},{"name":"NCI_META_CUI","value":"CL562817"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C44280":{"preferredName":"External","code":"C44280","definitions":[{"definition":"Happening or arising or located outside or beyond some limits, or especially, some surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"External","termGroup":"PT","termSource":"NCI"},{"termName":"Exogenous","termGroup":"AD","termSource":"NCI"},{"termName":"Externally","termGroup":"AD","termSource":"NCI"},{"termName":"Extramural","termGroup":"SY","termSource":"NCI"},{"termName":"Outside","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"External"},{"name":"Maps_To","value":"Extramural"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205101"}]}}{"C25234":{"preferredName":"Internal","code":"C25234","definitions":[{"definition":"Happening or arising or located within some limits, or especially, within some surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Internal","termGroup":"PT","termSource":"NCI"},{"termName":"Internally","termGroup":"AD","termSource":"NCI"},{"termName":"Intramural","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Internal"},{"name":"Maps_To","value":"Intramural"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205102"}]}}{"C43566":{"preferredName":"Gross","code":"C43566","definitions":[{"definition":"Visible to the naked eye.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gross","termGroup":"PT","termSource":"NCI"},{"termName":"Macroscopic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gross"},{"name":"Maps_To","value":"Macro"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0439806"}]}}{"C164046":{"preferredName":"Vascular Invasion Negative","code":"C164046","definitions":[{"definition":"An indication that signs of vascular invasion have not been found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Invasion Negative","termGroup":"PT","termSource":"NCI"},{"termName":"No Vascular Invasion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Vascular Invasion"},{"name":"NCI_META_CUI","value":"CL977185"},{"name":"Semantic_Type","value":"Finding"}]}}{"C62394":{"preferredName":"WHO Central Nervous System Grade 1","code":"C62394","definitions":[{"definition":"Describes central nervous system tumors that are generally low malignancy, non-infiltrative, and slow growing. Often they can be cured by surgery alone and there is a good chance of long term survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 1","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_I"},{"name":"Maps_To","value":"Grade I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883546"}]}}{"C62395":{"preferredName":"WHO Central Nervous System Grade 2","code":"C62395","definitions":[{"definition":"Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_II"},{"name":"Maps_To","value":"Grade II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883547"}]}}{"C62396":{"preferredName":"WHO Central Nervous System Grade 3","code":"C62396","definitions":[{"definition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_III"},{"name":"Maps_To","value":"Grade III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883548"}]}}{"C62397":{"preferredName":"WHO Central Nervous System Grade 4","code":"C62397","definitions":[{"definition":"Describes central nervous system tumors that are generally highly malignant, show rapid and aggressive growth, widely infiltrative, and prone to necrosis. They often recur rapidly after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 4","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_IV"},{"name":"Maps_To","value":"Grade IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883549"}]}}{"C165216":{"preferredName":"Experiment Metadata","code":"C165216","definitions":[{"definition":"Supporting information that describes the experimental design in a study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Experiment Metadata","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Experiment Metadata"},{"name":"NCI_META_CUI","value":"CL978398"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C126383":{"preferredName":"Drinker","code":"C126383","definitions":[{"definition":"An individual who drinks at least once per week with regularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Drinker","termGroup":"PT","termSource":"NCI"},{"termName":"Regular Drinker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Drinker"},{"name":"NCI_META_CUI","value":"CL504931"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C126384":{"preferredName":"Heavy Drinker","code":"C126384","definitions":[{"definition":"A man who drinks more than 14 standard drinks per week or a woman who drinks more than 7 standard drinks per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heavy Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heavy Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0337678"}]}}{"C126380":{"preferredName":"Lifelong Non-Drinker","code":"C126380","definitions":[{"definition":"An individual who does not drink at the present time and who claims that they have never been a drinker.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifelong Non-Drinker","termGroup":"PT","termSource":"NCI"},{"termName":"Teetotaller","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lifelong Non-Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0457801"}]}}{"C126379":{"preferredName":"Non-Drinker","code":"C126379","definitions":[{"definition":"An individual who does not drink at the present time. This is a heterogeneous group comprising both lifelong teetotallers and ex-drinkers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Drinker","termGroup":"PT","termSource":"NCI"},{"termName":"Abstainer","termGroup":"SY","termSource":"NCI"},{"termName":"Nondrinker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Drinker"},{"name":"NCI_META_CUI","value":"CL504930"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C126382":{"preferredName":"Occasional Drinker","code":"C126382","definitions":[{"definition":"An individual who drinks from time to time, but generally less than once per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occasional Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Occasional Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0556298"}]}}{"C156429":{"preferredName":"Social Drinker","code":"C156429","definitions":[{"definition":"An individual who generally only drinks at social events.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Social Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0337676"}]}}{"C66824":{"preferredName":"Beer","code":"C66824","definitions":[{"definition":"A carbonated alcoholic beverage made through the fermentation of sugars derived from malted grains; this beverage is usually flavored with hops but other herbs or fruit may be used to enhance its flavor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beer"},{"name":"Maps_To","value":"Beer"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C0004922"}]}}{"C66826":{"preferredName":"Liquor","code":"C66826","definitions":[{"definition":"An alcoholic beverage in which the initial fermentation mixture is distilled in order to concentrate the alcohol, generally resulting in a mixture that is at least 35% alcohol by volume.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liquor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liquor"},{"name":"Maps_To","value":"Liquor"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C0301611"}]}}{"C66822":{"preferredName":"Wine","code":"C66822","definitions":[{"definition":"An alcoholic beverage created from fermented juice of fresh grapes or of other fruit or plant products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"877011-55-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"13TE483N5I"},{"name":"Legacy Concept Name","value":"Wine"},{"name":"Maps_To","value":"Wine"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C0043188"}]}}{"C171137":{"preferredName":"Time of Exposure of Six Weeks or More","code":"C171137","definitions":[{"definition":"A response indicating that a subject was exposed to a potentially hazardous substance for six weeks or more.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time of Exposure of Six Weeks or More","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Six Weeks or More"},{"name":"NCI_META_CUI","value":"CL1405366"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C26659":{"preferredName":"Marijuana","code":"C26659","definitions":[{"definition":"Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The dried leaves and flowering tops of the Cannabis sativa plant, or an extract from the plant. Marijuana is being studied in the treatment of nausea and vomiting caused by chemotherapy or opiate drugs, such as morphine sulfate. Marijuana is also being studied in the treatment of pain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Marijuana","termGroup":"PT","termSource":"NCI"},{"termName":"Cannabis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FTS5RM302N"},{"name":"Legacy Concept Name","value":"Marijuana"},{"name":"Maps_To","value":"Marijuana"},{"name":"NCI_Drug_Dictionary_ID","value":"269131"},{"name":"NSC Number","value":"134452"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269131"},{"name":"PDQ_Open_Trial_Search_ID","value":"269131"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C0024808"}]}}{"C164057":{"preferredName":"Smoke Exposure","code":"C164057","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoke"},{"name":"Maps_To","value":"Smoke exposure, NOS"},{"name":"NCI_META_CUI","value":"CL977206"},{"name":"Semantic_Type","value":"Finding"}]}}{"C891":{"preferredName":"Tobacco","code":"C891","definitions":[{"definition":"A plant with leaves that have high levels of the addictive chemical nicotine. The leaves may be smoked (in cigarettes, cigars, and pipes), applied to the gums (as dipping and chewing tobacco), or inhaled (as snuff). Tobacco leaves also contain many cancer-causing chemicals, and tobacco use and exposure to secondhand tobacco smoke have been linked to many types of cancer and other diseases. The scientific name is Nicotiana tabacum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The dried cured leaves of the tobacco plant, Nicotiana tabacum, used for smoking, chewing, or snuff.  Tobacco contains nicotine, a stimulant, and other biologically active ingredients having carcinogenic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"8037-19-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YR2608RSU"},{"name":"Legacy Concept Name","value":"Tobacco"},{"name":"Maps_To","value":"Tobacco"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C0040329"}]}}{"C174115":{"preferredName":"Wood Dust Exposure","code":"C174115","definitions":[{"definition":"Environmental or occupational exposure to granular solids generated when timber is processed, such as when it is chipped, sawed, turned, drilled or sanded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wood Dust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood Dust"},{"name":"NCI_META_CUI","value":"CL1407785"},{"name":"Semantic_Type","value":"Finding"}]}}{"C61398":{"preferredName":"Radiation Exposure","code":"C61398","definitions":[{"definition":"Exposure to radioactive materials or ionizing radiation, whether by external irradiation, contact or contamination with radioactive material, or incorporation of radioactive materials, as in the case of certain diagnostic procedures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiation Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiation_Exposure"},{"name":"Maps_To","value":"Radiation"},{"name":"Semantic_Type","value":"Phenomenon or Process"},{"name":"UMLS_CUI","value":"C0015333"}]}}{"C55816":{"preferredName":"Asbestos Exposure","code":"C55816","definitions":[{"definition":"Inhalation of asbestos fibers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asbestos Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Asbestos_Exposure"},{"name":"Maps_To","value":"Asbestos"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0003948"}]}}{"C36290":{"preferredName":"Chemical Exposure","code":"C36290","definitions":[{"definition":"Contact with a chemical substance through touch, inhalation, or ingestion.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Contact with a chemical substance through touch, inhalation, or ingestion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chemical Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Chemical_Exposure"},{"name":"Maps_To","value":"Chemical"},{"name":"Maps_To","value":"Chemical Exposure, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0678803"},{"name":"Use_For","value":"Chemical Contamination"},{"name":"Use_For","value":"Contamination, Chemical"},{"name":"xRef","value":"IMDRF:E2003"}]}}{"C177573":{"preferredName":"Radon Exposure","code":"C177573","definitions":[{"definition":"Inhalation of radon gas which is found in rocks, soil and groundwater as a result of radioactive decay of uranium, thorium, or radium in the environment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radon Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radon"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0681792"}]}}{"C177575":{"preferredName":"Respirable Crystalline Silica Exposure","code":"C177575","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to respirable particles derived from industrial processing or breakdown of silica-containing materials such as sand, concrete, stone, mortar, bricks,  glass, pottery and ceramics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Respirable Crystalline Silica Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Respirable Crystalline Silica"},{"name":"NCI_META_CUI","value":"CL1643425"},{"name":"Semantic_Type","value":"Finding"}]}}{"C189768":{"preferredName":"Smokeless Tobacco Exposure","code":"C189768","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to any smokeless tobacco product.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokeless Tobacco Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smokeless Tobacco"},{"name":"NCI_META_CUI","value":"CL1798656"},{"name":"Semantic_Type","value":"Finding"}]}}{"C177574":{"preferredName":"Coal Dust Exposure","code":"C177574","definitions":[{"definition":"Environmental or occupational exposure to dust derived during the processing of coal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coal Dust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coal Dust"},{"name":"Maps_To","value":"Coal Gas, Coal Tar, Coal Tar Pitch, and Derivatives"},{"name":"NCI_META_CUI","value":"CL1643423"},{"name":"Semantic_Type","value":"Finding"}]}}{"C200417":{"preferredName":"Dust Exposure","code":"C200417","definitions":[{"definition":"Exposure to any type of airborne particulate matter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dust, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0239200"}]}}{"C67145":{"preferredName":"Current Every Day Smoker","code":"C67145","definitions":[{"definition":"Indicates a person who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes every day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Every Day Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Daily Smoker","termGroup":"SY","termSource":"NCI"},{"termName":"Every Day Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Current_Every_Day_Smoker"},{"name":"Maps_To","value":"Every day"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C3266136"}]}}{"C67146":{"preferredName":"Current Some Day Smoker","code":"C67146","definitions":[{"definition":"Indicates a person who has smoked at least 100 cigarettes in his or her lifetime, who smokes now, but does not smoke every day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Some Day Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Chipper","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Daily Smoker","termGroup":"SY","termSource":"NCI"},{"termName":"Occasional Smoker","termGroup":"SY","termSource":"NCI"},{"termName":"Some Day Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Current_Some_Day_Smoker"},{"name":"Maps_To","value":"Some days"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1880200"}]}}{"C164121":{"preferredName":"Time Between Waking and First Smoke - Within 5 Minutes","code":"C164121","definitions":[{"definition":"An indication that less than 5 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - Within 5 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Within 5 Minutes"},{"name":"NCI_META_CUI","value":"CL977379"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164124":{"preferredName":"Time Between Waking and First Smoke - Between 6 and 30 Minutes","code":"C164124","definitions":[{"definition":"An indication that between 6 and 30 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - Between 6 and 30 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6-30 Minutes"},{"name":"NCI_META_CUI","value":"CL977377"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164126":{"preferredName":"Time Between Waking and First Smoke - Between 31 and 60 Minutes","code":"C164126","definitions":[{"definition":"An indication that between 31 and 60 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - Between 31 and 60 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"31-60 Minutes"},{"name":"NCI_META_CUI","value":"CL977376"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164127":{"preferredName":"Time Between Waking and First Smoke - After 60 Minutes","code":"C164127","definitions":[{"definition":"An indication that more than 60 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - After 60 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"After 60 Minutes"},{"name":"NCI_META_CUI","value":"CL977375"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C65108":{"preferredName":"Never Smoker","code":"C65108","definitions":[{"definition":"A person who has never smoked at the time of the interview or has smoked less than 100 cigarettes in their life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Never Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Never Smoked","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Never_Smoker"},{"name":"Maps_To","value":"Lifelong Non-Smoker"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0425293"}]}}{"C67147":{"preferredName":"Current Smoker","code":"C67147","definitions":[{"definition":"An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes. Includes daily smokers and non-daily smokers (also known as occasional smokers).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Current_Smoker"},{"name":"Maps_To","value":"Current Smoker"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C3241966"}]}}{"C156828":{"preferredName":"Current Reformed Smoker, More than 15 Years","code":"C156828","definitions":[{"definition":"An individual who stopped smoking more than 15 years prior.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Reformed Smoker, More than 15 Years","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current Reformed Smoker for > 15 yrs"},{"name":"NCI_META_CUI","value":"CL935830"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C156829":{"preferredName":"Current Reformed Smoker Within Past 15 Years","code":"C156829","definitions":[{"definition":"An individual who stopped smoking within the past 15 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Reformed Smoker Within Past 15 Years","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current Reformed Smoker for < or = 15 yrs"},{"name":"NCI_META_CUI","value":"CL935827"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C156830":{"preferredName":"Current Reformed Smoker, Years Unknown","code":"C156830","definitions":[{"definition":"An individual who stopped smoking an unknown number of years prior.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Reformed Smoker, Years Unknown","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current Reformed Smoker, Duration Not Specified"},{"name":"NCI_META_CUI","value":"CL935828"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164079":{"preferredName":"Smoking at Diagnosis","code":"C164079","definitions":[{"definition":"An indication that a person was a smoker at the time they received a pathologic diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoking at Diagnosis","termGroup":"PT","termSource":"NCI"},{"termName":"Smoker at Diagnosis","termGroup":"SY","termSource":"NCI"},{"termName":"Smoker at Time of Diagnosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoker at Diagnosis"},{"name":"NCI_META_CUI","value":"CL979291"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C163971":{"preferredName":"Smoking Status Not Documented","code":"C163971","definitions":[{"definition":"Indicates that a person's smoking status has not been recorded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoking Status Not Documented","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoking history not documented"},{"name":"NCI_META_CUI","value":"CL979297"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C164066":{"preferredName":"Accidental Building Fire Smoke Exposure","code":"C164066","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a building fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Building Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental building fire smoke"},{"name":"NCI_META_CUI","value":"CL977400"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164067":{"preferredName":"Accidental Grass Fire Smoke Exposure","code":"C164067","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a grass fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Grass Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental fire smoke, grass"},{"name":"NCI_META_CUI","value":"CL977399"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164059":{"preferredName":"Accidental Fire Smoke Exposure","code":"C164059","definitions":[{"definition":"Environmental exposure to airborne gases and particulates produced during a fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental fire smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977204"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164068":{"preferredName":"Accidental Forest Fire Smoke Exposure","code":"C164068","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a forest fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Forest Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental forest fire smoke"},{"name":"NCI_META_CUI","value":"CL977398"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164069":{"preferredName":"Accidental Vehicle Fire Smoke Exposure","code":"C164069","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a vehicle fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Vehicle Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental vehicle fire smoke"},{"name":"NCI_META_CUI","value":"CL977397"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164072":{"preferredName":"Aircraft Smoke Exposure","code":"C164072","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when an aircraft is in operation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aircraft Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aircraft smoke"},{"name":"NCI_META_CUI","value":"CL977394"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164075":{"preferredName":"Burning Tree Smoke Exposure","code":"C164075","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when trees are undergoing combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Tree Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Burning tree smoke"},{"name":"NCI_META_CUI","value":"CL977392"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164060":{"preferredName":"Coal Smoke Exposure","code":"C164060","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when coal is rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coal Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coal smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977203"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164061":{"preferredName":"Cooking-Related Smoke Exposure","code":"C164061","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to vaporized materials produced when food products are being cooked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cooking-Related Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cooking-related smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977202"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164077":{"preferredName":"Electrical Fire Smoke Exposure","code":"C164077","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during an electrical fire.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electrical Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrical fire smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977390"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164062":{"preferredName":"Electronic Cigarette Smoke Exposure","code":"C164062","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of an electronic cigarette.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electronic Cigarette Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"e-Cigarette Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electronic cigarette smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977201"},{"name":"Semantic_Type","value":"Finding"}]}}{"C17140":{"preferredName":"Passive Smoke Exposure","code":"C17140","definitions":[{"definition":"Exposure to tobacco smoke products among individuals who do not smoke. This can result from sharing space with a smoker or from placental transfer from mother to fetus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Passive Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Passive Smoking","termGroup":"SY","termSource":"NCI"},{"termName":"Smoking, Passive","termGroup":"SY","termSource":"NCI"},{"termName":"Smoking, Tobacco and Cancer-Passive Smoking","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Passive_Smoke_Exposure"},{"name":"Maps_To","value":"Environmental tobacco smoke"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0037370"}]}}{"C164081":{"preferredName":"Factory Smokestack Smoke Exposure","code":"C164081","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates emitted by a factory smokestack.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Factory Smokestack Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Factory Smokestack Emission Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Factory smokestack smoke"},{"name":"NCI_META_CUI","value":"CL977387"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164082":{"preferredName":"Field Burning Smoke Exposure","code":"C164082","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when trees, brush and grass in a field are burning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Field Burning Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Field burning smoke"},{"name":"NCI_META_CUI","value":"CL977415"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164058":{"preferredName":"Fire Smoke Exposure","code":"C164058","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when materials are rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fire smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977205"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164083":{"preferredName":"Furnace or Boiler Smoke Exposure","code":"C164083","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates emitted by a boiler or furnace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Furnace or Boiler Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Furnace or boiler smoke"},{"name":"NCI_META_CUI","value":"CL977414"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164084":{"preferredName":"Propane Smoke Exposue","code":"C164084","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when propane is rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Propane Smoke Exposue","termGroup":"PT","termSource":"NCI"},{"termName":"Burning Propane Smoke Exposue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gas burning smoke, propane"},{"name":"NCI_META_CUI","value":"CL977413"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164085":{"preferredName":"Grease Fire Smoke Exposure","code":"C164085","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced during a grease fire.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grease Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grease fire smoke"},{"name":"NCI_META_CUI","value":"CL977412"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164086":{"preferredName":"Grilling Smoke Exposure","code":"C164086","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates emitted by an indoor or outdoor grill used for cooking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grilling Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grilling smoke"},{"name":"NCI_META_CUI","value":"CL977411"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164087":{"preferredName":"Hashish Smoke Exposure","code":"C164087","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted product made from cannabis plant resin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hashish Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hashish smoke"},{"name":"NCI_META_CUI","value":"CL979270"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164088":{"preferredName":"Coal-Burining Indoor Stove or Fireplace Smoke Exposure","code":"C164088","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when coal is subjected to combustion in an indoor stove or fireplace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coal-Burining Indoor Stove or Fireplace Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Indoor Coal-Burining Stove or Fireplace Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indoor stove or fireplace smoke, coal burning"},{"name":"NCI_META_CUI","value":"CL977410"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164064":{"preferredName":"Indoor Stove or Fireplace Smoke Exposure","code":"C164064","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when materials are subjected to combustion in an indoor stove or fireplace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indoor Stove or Fireplace Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indoor stove or fireplace smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977199"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164089":{"preferredName":"Wood-Burning Indoor Stove or Fireplace Smoke Exposure","code":"C164089","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when wood is subjected to combustion in an indoor stove or fireplace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wood-Burning Indoor Stove or Fireplace Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Indoor Wood-Burning Stove or Fireplace Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indoor stove or fireplace smoke, wood burning"},{"name":"NCI_META_CUI","value":"CL977409"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164090":{"preferredName":"Machine Smoke Exposure","code":"C164090","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates through the direct or nearby use of a machine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Machine Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Machine smoke"},{"name":"NCI_META_CUI","value":"CL977408"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164091":{"preferredName":"Marijuana Smoke Exposure","code":"C164091","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted product made from the leaves and flowers of the cannabis plant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marijuana Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Marijuana smoke"},{"name":"NCI_META_CUI","value":"CL979280"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164092":{"preferredName":"No Smoke Exposure","code":"C164092","definitions":[{"definition":"An indication that a subject has no history of smoke exposure from any source.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Smoke Exposure"},{"name":"NCI_META_CUI","value":"CL977407"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164093":{"preferredName":"Kerosene Smoke Exposure","code":"C164093","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when kerosene is rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kerosene Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Burning Kerosene Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oil burning smoke, Kerosene"},{"name":"NCI_META_CUI","value":"CL977406"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164063":{"preferredName":"Burning Oil Smoke Exposure","code":"C164063","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when oils are rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Oil Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Oil Burning Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oil burning smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977200"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164094":{"preferredName":"Recreational Fire Smoke Exposure","code":"C164094","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials (usually wood) are burned for recreational purposes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recreational Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recreational fire smoke"},{"name":"NCI_META_CUI","value":"CL977405"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164095":{"preferredName":"Smokehouse Smoke Exposure","code":"C164095","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced during indoor smoke curing of food products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokehouse Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smokehouse smoke"},{"name":"NCI_META_CUI","value":"CL977404"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164097":{"preferredName":"Cigar Smoke Exposure","code":"C164097","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a cigar.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigar Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco smoke, cigar"},{"name":"NCI_META_CUI","value":"CL977402"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164098":{"preferredName":"Cigarette Smoke Exposure","code":"C164098","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a cigarette.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigarette Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco smoke, cigarette"},{"name":"NCI_META_CUI","value":"CL977371"},{"name":"Semantic_Type","value":"Finding"}]}}{"C44456":{"preferredName":"Tobacco Smoke Related Exposure","code":"C44456","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted tobacco product.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Smoke Related Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Tobacco Related Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tobacco_Related_Exposure"},{"name":"Maps_To","value":"Tobacco smoke, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1710429"}]}}{"C164099":{"preferredName":"Tobacco Pipe Smoke Exposure","code":"C164099","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a tobacco pipe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Pipe Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Pipe Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco smoke, pipe"},{"name":"NCI_META_CUI","value":"CL977370"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164100":{"preferredName":"Volcanic Smoke Exposure","code":"C164100","definitions":[{"definition":"Environmental exposure to airborne gases and particulates produced by a volcanic event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Volcanic Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Volcanic smoke"},{"name":"NCI_META_CUI","value":"CL977369"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164101":{"preferredName":"Burning Waste Smoke Exposure","code":"C164101","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when trash or waste is burned.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Waste Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Waste burning smoke"},{"name":"NCI_META_CUI","value":"CL977368"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164102":{"preferredName":"Wood-Burning Factory Smoke Exposure","code":"C164102","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when wood is burned in a factory setting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wood-Burning Factory Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood burning smoke, factory"},{"name":"NCI_META_CUI","value":"CL977367"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164065":{"preferredName":"Burning Wood Smoke Exposure","code":"C164065","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when wood is subjected to combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Wood Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Wood Burning Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood burning smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977401"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164104":{"preferredName":"Occupational Artificial Smoke Machine Smoke Exposure","code":"C164104","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a machine that produces artificial smoke.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Artificial Smoke Machine Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, artificial smoke machines"},{"name":"NCI_META_CUI","value":"CL977365"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164105":{"preferredName":"Occupational Fire Fighting Smoke Exposure","code":"C164105","definitions":[{"definition":"Occupational exposure to airborne gases and particulates while preventing, controlling or extinguishing fires.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Fire Fighting Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, fire fighting"},{"name":"NCI_META_CUI","value":"CL977364"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164106":{"preferredName":"Occupational Foundry Smoke Exposure","code":"C164106","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a foundry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Foundry Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, foundry"},{"name":"NCI_META_CUI","value":"CL977363"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164107":{"preferredName":"Occupational Generator Smoke Exposure","code":"C164107","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a power generator.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Generator Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, generators"},{"name":"NCI_META_CUI","value":"CL977362"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164115":{"preferredName":"Occupational Military Smoke Exposure","code":"C164115","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during a military posting or deployment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Military Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, military"},{"name":"NCI_META_CUI","value":"CL977385"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164103":{"preferredName":"Work-Related Smoke Exposure","code":"C164103","definitions":[{"definition":"Occupational exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Work-Related Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977366"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164116":{"preferredName":"Occupational Paint Baking Smoke Exposure","code":"C164116","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a paint oven.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Paint Baking Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, paint baking"},{"name":"NCI_META_CUI","value":"CL977384"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164118":{"preferredName":"Occupational Plastics Factory Smoke Exposure","code":"C164118","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the manufacturing of plastics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Plastics Factory Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, plastics factory"},{"name":"NCI_META_CUI","value":"CL977382"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164119":{"preferredName":"Occupational Plumbing Smoke Exposure","code":"C164119","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the installation of plumbing pipes and fixtures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Plumbing Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, plumbing"},{"name":"NCI_META_CUI","value":"CL977381"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164120":{"preferredName":"Occupational Soldering/Welding Smoke Exposure","code":"C164120","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a soldering iron or welding machine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Soldering/Welding Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Occupational Soldering/Welding Smoke Exposure"},{"name":"Maps_To","value":"Work-related smoke, soldering/welding"},{"name":"NCI_META_CUI","value":"CL977380"},{"name":"Semantic_Type","value":"Finding"}]}}{"C1813":{"preferredName":"Cigar","code":"C1813","definitions":[{"definition":"A compact roll of tobacco leaves prepared for smoking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cigar"},{"name":"Maps_To","value":"Cigar"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C0678446"}]}}{"C1802":{"preferredName":"Cigarette","code":"C1802","definitions":[{"definition":"Finely cut tobacco encased in a wrapper of thin paper and rolled for smoking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigarette","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cigarette"},{"name":"Maps_To","value":"Cigarette"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C0677453"}]}}{"C120482":{"preferredName":"Electronic Cigarette","code":"C120482","definitions":[{"definition":"A battery-powered electronic device designed to atomize a nicotine-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electronic Cigarette","termGroup":"PT","termSource":"NCI"},{"termName":"Electronic Nicotine Delivery System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electronic Cigarette"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C3849993"}]}}{"C86044":{"preferredName":"Pipe","code":"C86044","definitions":[{"definition":"A tube with a small bowl at one end, especially one used for smoking tobacco.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pipe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pipe"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C2828033"}]}}{"C892":{"preferredName":"Smokeless Tobacco","code":"C892","definitions":[{"definition":"Tobacco that is not smoked but used in another form such as chewing tobacco or snuff.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokeless Tobacco","termGroup":"PT","termSource":"NCI"},{"termName":"Smoking, Tobacco and Cancer - Smokeless Tobacco","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Cancers of the oral cavity (mouth, lip, tongue) have been associated with the use of chewing tobacco as well as snuff. The tumors often arise at the site of placement of the tobacco. Smokeless tobacco was formally classified as a \"known human carcinogen\" by the US government in 2000. (MedicineNet.com)"},{"name":"Legacy Concept Name","value":"Smokeless_Tobacco"},{"name":"Maps_To","value":"Smokeless Tobacco"},{"name":"NCI_Drug_Dictionary_ID","value":"737707"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737707"},{"name":"PDQ_Open_Trial_Search_ID","value":"737707"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0040338"}]}}{"C166195":{"preferredName":"Adopted Brother","code":"C166195","definitions":[{"definition":"A male sibling who is legally adopted by one's biological parent or legal guardian.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Brother"},{"name":"NCI_META_CUI","value":"CL971457"},{"name":"Semantic_Type","value":"Human"}]}}{"C166131":{"preferredName":"Adopted Daughter","code":"C166131","definitions":[{"definition":"A female child in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Daughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Daughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337553"}]}}{"C166196":{"preferredName":"Adopted Sister","code":"C166196","definitions":[{"definition":"A female sibling who is legally adopted by one's biological parent or legal guardian.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Sister"},{"name":"NCI_META_CUI","value":"CL971456"},{"name":"Semantic_Type","value":"Human"}]}}{"C166132":{"preferredName":"Adopted Son","code":"C166132","definitions":[{"definition":"A male child in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337565"}]}}{"C166133":{"preferredName":"Adoptive Father","code":"C166133","definitions":[{"definition":"A male parent in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adoptive Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adoptive Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337495"}]}}{"C166134":{"preferredName":"Adoptive Mother","code":"C166134","definitions":[{"definition":"A female parent in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adoptive Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adoptive Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337487"}]}}{"C71405":{"preferredName":"Aunt","code":"C71405","definitions":[{"definition":"The sister of your father or mother; the wife of your uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aunt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aunt"},{"name":"Maps_To","value":"Aunt"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337576"}]}}{"C25289":{"preferredName":"Brother","code":"C25289","definitions":[{"definition":"A male sibling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brother"},{"name":"Maps_To","value":"Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337527"}]}}{"C71406":{"preferredName":"Brother-in-law","code":"C71406","definitions":[{"definition":"A brother by marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brother-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brother-in-law"},{"name":"Maps_To","value":"Brother-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C1553711"}]}}{"C150886":{"preferredName":"Child Relation","code":"C150886","definitions":[{"definition":"A biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An individual's biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child Relation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Child"},{"name":"NCI_META_CUI","value":"CL554545"},{"name":"Semantic_Type","value":"Human"}]}}{"C71410":{"preferredName":"Cousin","code":"C71410","definitions":[{"definition":"A child of your aunt or uncle or their descendents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cousin"},{"name":"Maps_To","value":"Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337580"}]}}{"C25165":{"preferredName":"Daughter","code":"C25165","definitions":[{"definition":"A female human offspring.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Daughter"},{"name":"Maps_To","value":"Daughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337552"}]}}{"C71401":{"preferredName":"Daughter-in-law","code":"C71401","definitions":[{"definition":"The wife of your son.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daughter-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Daughter-in-law"},{"name":"Maps_To","value":"Daughter-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C1553705"}]}}{"C53262":{"preferredName":"Domestic Partnership","code":"C53262","definitions":[{"definition":"Indicates a person who is a member of an unmarried couple, including same sex couples, living together in longstanding relationships, that are registered or unregistered.","type":"DEFINITION","source":"NCI"},{"definition":"Person declares that a domestic partnership relationship exists. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Domestic Partnership","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Domestic_Partnership"},{"name":"Maps_To","value":"Domestic Partner"},{"name":"Maps_To","value":"Domestic Partnership"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0683559"}]}}{"C25174":{"preferredName":"Father","code":"C25174","definitions":[{"definition":"A male parent.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A male parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Father"},{"name":"Maps_To","value":"Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0015671"}]}}{"C68640":{"preferredName":"Father-in-law","code":"C68640","definitions":[{"definition":"The father of your spouse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Father-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Father-in-law"},{"name":"Maps_To","value":"Father-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2349973"}]}}{"C165786":{"preferredName":"Female Cousin","code":"C165786","definitions":[{"definition":"A female child of one's aunt or uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Female Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337581"}]}}{"C166198":{"preferredName":"Female Sibling of Adopted Child","code":"C166198","definitions":[{"definition":"A female sibling of an adopted child. The said female is a biological or legal child of the parents who facilitated the adoption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Sibling of Adopted Child","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Female Sibling of Adopted Child"},{"name":"NCI_META_CUI","value":"CL971458"},{"name":"Semantic_Type","value":"Human"}]}}{"C71411":{"preferredName":"First Cousin","code":"C71411","definitions":[{"definition":"A child of your aunt or uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First_Cousin"},{"name":"Maps_To","value":"First Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337583"}]}}{"C71412":{"preferredName":"First Cousin Once Removed","code":"C71412","definitions":[{"definition":"A child of your first cousin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Cousin Once Removed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First_Cousin_Once_Removed"},{"name":"Maps_To","value":"First Cousin Once Removed"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2348676"}]}}{"C165788":{"preferredName":"Foster Brother","code":"C165788","definitions":[{"definition":"A male child being fostered by your parents or legal guardians.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337532"}]}}{"C165790":{"preferredName":"Foster Daughter","code":"C165790","definitions":[{"definition":"A female child you are fostering.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Daughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Daughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337556"}]}}{"C165792":{"preferredName":"Foster Father","code":"C165792","definitions":[{"definition":"A male foster parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337498"}]}}{"C165793":{"preferredName":"Foster Mother","code":"C165793","definitions":[{"definition":"A female foster parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337489"}]}}{"C165794":{"preferredName":"Foster Sister","code":"C165794","definitions":[{"definition":"A female child being fostered by your parents or legal guardians.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337519"}]}}{"C165795":{"preferredName":"Foster Son","code":"C165795","definitions":[{"definition":"A male child you are fostering.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337568"}]}}{"C165796":{"preferredName":"Fraternal Twin Brother","code":"C165796","definitions":[{"definition":"A male full sibling that developed from a separately fertilized ova during the same pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fraternal Twin Brother","termGroup":"PT","termSource":"NCI"},{"termName":"Dizygotic Twin Brother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fraternal Twin Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337536"}]}}{"C73428":{"preferredName":"Fraternal Twin","code":"C73428","definitions":[{"definition":"Either of the two offspring from separately fertilized ova during the same pregnancy.","type":"DEFINITION","source":"NCI"},{"definition":"Either of the two offspring resulting from two separately fertilized ovums during the same pregnancy.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fraternal Twin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fraternal_Twin"},{"name":"Maps_To","value":"Fraternal Twin Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0041429"}]}}{"C165797":{"preferredName":"Fraternal Twin Sister","code":"C165797","definitions":[{"definition":"A female full sibling that developed from a separately fertilized ova during the same pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fraternal Twin Sister","termGroup":"PT","termSource":"NCI"},{"termName":"Dizygotic Twin Sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fraternal Twin Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337523"}]}}{"C111201":{"preferredName":"Full Brother","code":"C111201","definitions":[{"definition":"A male who shares with his sibling the genetic makeup inherited from both of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A male who shares with his sibling the genetic makeup inherited from both of the biological parents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Full Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Full Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3830065"}]}}{"C111202":{"preferredName":"Full Sister","code":"C111202","definitions":[{"definition":"A female who shares with her sibling the genetic makeup inherited from both of the biological parents.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from both of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Full Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Full Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3827310"}]}}{"C165798":{"preferredName":"Great Nephew","code":"C165798","definitions":[{"definition":"A male child of one's niece or nephew.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Nephew","termGroup":"PT","termSource":"NCI"},{"termName":"Grand Nephew","termGroup":"SY","termSource":"NCI"},{"termName":"Grandnephew","termGroup":"SY","termSource":"NCI"},{"termName":"Great-Nephew","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grand Nephew"},{"name":"NCI_META_CUI","value":"CL979050"},{"name":"Semantic_Type","value":"Human"}]}}{"C165846":{"preferredName":"Great Niece","code":"C165846","definitions":[{"definition":"A female child of one's niece or nephew.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Niece","termGroup":"PT","termSource":"NCI"},{"termName":"Grand Niece","termGroup":"SY","termSource":"NCI"},{"termName":"Grandniece","termGroup":"SY","termSource":"NCI"},{"termName":"Great-Niece","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grand Niece"},{"name":"NCI_META_CUI","value":"CL979041"},{"name":"Semantic_Type","value":"Human"}]}}{"C71397":{"preferredName":"Grandchild","code":"C71397","definitions":[{"definition":"A child of your son or daughter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandchild","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandchild"},{"name":"Maps_To","value":"Grandchild"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337548"}]}}{"C71399":{"preferredName":"Granddaughter","code":"C71399","definitions":[{"definition":"A female grandchild.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granddaughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Granddaughter"},{"name":"Maps_To","value":"Granddaughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337561"}]}}{"C71387":{"preferredName":"Grandfather","code":"C71387","definitions":[{"definition":"The father of your father or mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandfather"},{"name":"Maps_To","value":"Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337475"}]}}{"C71386":{"preferredName":"Grandmother","code":"C71386","definitions":[{"definition":"The mother of your father or mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandmother"},{"name":"Maps_To","value":"Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337474"}]}}{"C71385":{"preferredName":"Grandparent","code":"C71385","definitions":[{"definition":"A parent of your father or mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandparent"},{"name":"Maps_To","value":"Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337471"}]}}{"C71398":{"preferredName":"Grandson","code":"C71398","definitions":[{"definition":"A male grandchild.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandson","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandson"},{"name":"Maps_To","value":"Grandson"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337573"}]}}{"C165847":{"preferredName":"Great Grandchild","code":"C165847","definitions":[{"definition":"A child of one's grandchild.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Grandchild","termGroup":"PT","termSource":"NCI"},{"termName":"Great-Grandchild","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Great Grandchild"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337549"}]}}{"C71402":{"preferredName":"Half Brother","code":"C71402","definitions":[{"definition":"A male sibling with whom you share a single parent.","type":"DEFINITION","source":"NCI"},{"definition":"A male who shares with his sibling the genetic makeup inherited from only one of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half Brother","termGroup":"PT","termSource":"NCI"},{"termName":"Half-brother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Half_Brother"},{"name":"Maps_To","value":"Half Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337531"}]}}{"C71391":{"preferredName":"Half Sibling","code":"C71391","definitions":[{"definition":"A person's brother or sister who has one parent in common.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A person's brother or sister with whom they share a genetic makeup inherited from one of their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sibling with whom you share a single parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Half Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Half Relation","termGroup":"SY","termSource":"NCI"},{"termName":"Half Relative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Half_Sibling"},{"name":"Maps_To","value":"Half Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337505"}]}}{"C71403":{"preferredName":"Half Sister","code":"C71403","definitions":[{"definition":"A female sibling with whom you share a single parent.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from only one of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half Sister","termGroup":"PT","termSource":"NCI"},{"termName":"Half-sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Half_Sister"},{"name":"Maps_To","value":"Half Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337518"}]}}{"C71588":{"preferredName":"Husband","code":"C71588","definitions":[{"definition":"A male partner in marriage.","type":"DEFINITION","source":"NCI"},{"definition":"A male partner in marriage. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Husband","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Husband"},{"name":"Maps_To","value":"Husband"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0242664"}]}}{"C165848":{"preferredName":"Identical Twin Brother","code":"C165848","definitions":[{"definition":"A male full sibling that developed from a shared ovum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Identical Twin Brother","termGroup":"PT","termSource":"NCI"},{"termName":"Monozygotic Twin Brother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Identical Twin Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337535"}]}}{"C73429":{"preferredName":"Identical Twin","code":"C73429","definitions":[{"definition":"Either of the two offspring resulting from a shared ovum.","type":"DEFINITION","source":"NCI"},{"definition":"Either of the two offspring resulting from a shared ovum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Identical Twin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Identical_Twin"},{"name":"Maps_To","value":"Identical Twin Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0041432"}]}}{"C165849":{"preferredName":"Identical Twin Sister","code":"C165849","definitions":[{"definition":"A female full sibling that developed from a shared ovum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Identical Twin Sister","termGroup":"PT","termSource":"NCI"},{"termName":"Monozygotic Twin Sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Identical Twin Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337522"}]}}{"C51828":{"preferredName":"Guardian","code":"C51828","definitions":[{"definition":"An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research.","type":"DEFINITION","source":"NCI"},{"definition":"An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guardian","termGroup":"PT","termSource":"NCI"},{"termName":"Legal Guardian","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guardian"},{"name":"Maps_To","value":"Legal Guardian"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C0023226"}]}}{"C165850":{"preferredName":"Male Cousin","code":"C165850","definitions":[{"definition":"A male child of one's aunt or uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Male Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Male Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337582"}]}}{"C166197":{"preferredName":"Male Sibling of Adopted Child","code":"C166197","definitions":[{"definition":"A male sibling of an adopted child. The said male is a biological or legal child of the parents who facilitated the adoption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Male Sibling of Adopted Child","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Male Sibling of Adopted Child"},{"name":"NCI_META_CUI","value":"CL971459"},{"name":"Semantic_Type","value":"Human"}]}}{"C96575":{"preferredName":"Biological Maternal Aunt","code":"C96575","definitions":[{"definition":"A female relative who is a sibling of the biological mother, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is a sibling of the biological mother, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Aunt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Aunt"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272872"}]}}{"C96576":{"preferredName":"Biological Maternal Cousin","code":"C96576","definitions":[{"definition":"A relative who is the offspring of a sibling of the biological mother and share a common ancestor.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A relative who is the offspring of a sibling of the biological mother and thus sharing a common ancestor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Maternal Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal First Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272873"}]}}{"C165851":{"preferredName":"Maternal First Cousin Once Removed","code":"C165851","definitions":[{"definition":"A child of one's first cousin who is related by lineage through the mother's side of the family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal First Cousin Once Removed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal First Cousin Once Removed"},{"name":"NCI_META_CUI","value":"CL979023"},{"name":"Semantic_Type","value":"Human"}]}}{"C96577":{"preferredName":"Biological Maternal Grandfather","code":"C96577","definitions":[{"definition":"A male relative who is the biological father of the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is the biological father of the biological mother. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272874"}]}}{"C96578":{"preferredName":"Biological Maternal Grandmother","code":"C96578","definitions":[{"definition":"A female relative who is the biological mother of the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is the biological mother of the biological mother. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272875"}]}}{"C111248":{"preferredName":"Maternal Biological Grandparent","code":"C111248","definitions":[{"definition":"A relative who is the biological parent of the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A relative who is the biological parent of the biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Maternal Biological Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3829175"}]}}{"C165853":{"preferredName":"Maternal Great Aunt","code":"C165853","definitions":[{"definition":"The aunt of one's mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Great Aunt","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Great-Aunt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Great Aunt"},{"name":"NCI_META_CUI","value":"CL979025"},{"name":"Semantic_Type","value":"Human"}]}}{"C166127":{"preferredName":"Maternal Great Grandparent","code":"C166127","definitions":[{"definition":"A parent of one's maternal grandparent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Great Grandparent","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Great-Grandparent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Great Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3242755"}]}}{"C165854":{"preferredName":"Maternal Great Uncle","code":"C165854","definitions":[{"definition":"The uncle of one's mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Great Uncle","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Great-Uncle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Great Uncle"},{"name":"NCI_META_CUI","value":"CL979020"},{"name":"Semantic_Type","value":"Human"}]}}{"C96656":{"preferredName":"Half-brother with Mother as Common Parent","code":"C96656","definitions":[{"definition":"A male sibling who shares the genetic makeup inherited from only the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A male who shares with his sibling the genetic makeup inherited from only the biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-brother with Mother as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Half Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272936"}]}}{"C166112":{"preferredName":"Maternal Half Sibling","code":"C166112","definitions":[{"definition":"A relative with whom you share a biological mother but you have different fathers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Half Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Half-Sibling","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Half Sibling"},{"name":"NCI_META_CUI","value":"CL979209"},{"name":"Semantic_Type","value":"Human"}]}}{"C96658":{"preferredName":"Half-sister with Mother as Common Parent","code":"C96658","definitions":[{"definition":"A female sibling who shares the genetic makeup inherited from only the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from only the biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-sister with Mother as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Half Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272938"}]}}{"C96579":{"preferredName":"Biological Maternal Uncle","code":"C96579","definitions":[{"definition":"A male relative who is a sibling of the biological mother, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is a sibling of the biological mother, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Uncle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Uncle"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272876"}]}}{"C25189":{"preferredName":"Mother","code":"C25189","definitions":[{"definition":"A female parent.","type":"DEFINITION","source":"NCI"},{"definition":"A female parent.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mother"},{"name":"Maps_To","value":"Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0026591"}]}}{"C68639":{"preferredName":"Mother-in-law","code":"C68639","definitions":[{"definition":"The mother of your spouse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mother-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mother-in-law"},{"name":"Maps_To","value":"Mother-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2349972"}]}}{"C96570":{"preferredName":"Biological Brother","code":"C96570","definitions":[{"definition":"A male who shares with his sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"DEFINITION","source":"NCI"},{"definition":"A male who shares with his sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337528"}]}}{"C42708":{"preferredName":"Offspring","code":"C42708","definitions":[{"definition":"A first-generation, biological descendant of any age.","type":"DEFINITION","source":"NCI"},{"definition":"A son or daughter with genetic makeup inherited from the parent.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Offspring; the product of reproduction or replication.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Offspring","termGroup":"PT","termSource":"NCI"},{"termName":"Biological Child","termGroup":"SY","termSource":"NCI"},{"termName":"Children","termGroup":"SY","termSource":"NCI"},{"termName":"Human, Child","termGroup":"SY","termSource":"NCI"},{"termName":"Progeny","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Child_Offspring"},{"name":"Maps_To","value":"Biological Child"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0680063"}]}}{"C96572":{"preferredName":"Biological Father","code":"C96572","definitions":[{"definition":"A male who contributes to the genetic makeup of his offspring through the fertilization of an ovum by his sperm.","type":"DEFINITION","source":"NCI"},{"definition":"A male who contributes to the genetic makeup of his offspring through the fertilization of an ovum by his sperm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337494"}]}}{"C100805":{"preferredName":"Biological Grandchild","code":"C100805","definitions":[{"definition":"A biological child of an individual's biological child.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A biological child of an individual's biological child.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Grandchild","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandchild"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3639748"}]}}{"C96573":{"preferredName":"Biological Grandfather","code":"C96573","definitions":[{"definition":"A male relative who is the biological father of either the biological mother or the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is the biological father of either the biological mother or the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337477"}]}}{"C96574":{"preferredName":"Biological Grandmother","code":"C96574","definitions":[{"definition":"A female relative who is the biological mother of either the biological mother or the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is the biological mother of either the biological mother or the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337476"}]}}{"C100806":{"preferredName":"Biological Grandparent","code":"C100806","definitions":[{"definition":"A biological parent of the biological father or biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A biological parent of the biological father or biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337472"}]}}{"C96580":{"preferredName":"Biological Mother","code":"C96580","definitions":[{"definition":"A female who contributes to the genetic makeup of her offspring from the fertilization of her ovum.","type":"DEFINITION","source":"NCI"},{"definition":"A female who contributes to the genetic makeup of her offspring from the fertilization of her ovum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337486"}]}}{"C166114":{"preferredName":"Biological Parent","code":"C166114","definitions":[{"definition":"The male who supplied the sperm or the female who supplied the egg which resulted in one's conception.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Parent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337465"}]}}{"C100809":{"preferredName":"Biological Sibling","code":"C100809","definitions":[{"definition":"A person's brother or sister with whom they share a genetic makeup inherited from one or both of their shared biological parents.","type":"DEFINITION","source":"NCI"},{"definition":"A person's brother or sister with whom they share a genetic makeup inherited from their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Sibling","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337502"}]}}{"C96586":{"preferredName":"Biological Sister","code":"C96586","definitions":[{"definition":"A female who shares with her sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337515"}]}}{"C150888":{"preferredName":"Biological Son","code":"C150888","definitions":[{"definition":"A male progeny with genetic makeup inherited from the parent.","type":"DEFINITION","source":"NCI"},{"definition":"A male progeny with genetic makeup inherited from the parent.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337564"}]}}{"C71409":{"preferredName":"Nephew","code":"C71409","definitions":[{"definition":"A son of your brother or sister.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nephew","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nephew"},{"name":"Maps_To","value":"Nephew"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337579"}]}}{"C71408":{"preferredName":"Niece","code":"C71408","definitions":[{"definition":"A daughter of your brother or sister.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niece","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Niece"},{"name":"Maps_To","value":"Niece"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337578"}]}}{"C166115":{"preferredName":"Biological Niece","code":"C166115","definitions":[{"definition":"A daughter of one's biological sibling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Niece","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Niece Second Degree Relative"},{"name":"NCI_META_CUI","value":"CL979211"},{"name":"Semantic_Type","value":"Human"}]}}{"C42709":{"preferredName":"Parent","code":"C42709","definitions":[{"definition":"A mother or a father.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A mother or a father; an immediate progenitor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parent","termGroup":"PT","termSource":"NCI"},{"termName":"Parental","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Parent"},{"name":"Maps_To","value":"Parent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0030551"}]}}{"C96581":{"preferredName":"Biological Paternal Aunt","code":"C96581","definitions":[{"definition":"A female relative who is a sibling of the biological father, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is a sibling of the biological father, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Aunt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Aunt"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272877"}]}}{"C96582":{"preferredName":"Biological Paternal Cousin","code":"C96582","definitions":[{"definition":"A relative who is the offspring of a sibling of the biological father and share a common ancestor.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A relative who is the offspring of a sibling of the biological father and thus sharing a common ancestor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Paternal Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal First Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272878"}]}}{"C165852":{"preferredName":"Paternal First Cousin Once Removed","code":"C165852","definitions":[{"definition":"A child of one's first cousin who is related by lineage through the father's side of the family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal First Cousin Once Removed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal First Cousin Once Removed"},{"name":"NCI_META_CUI","value":"CL979024"},{"name":"Semantic_Type","value":"Human"}]}}{"C96583":{"preferredName":"Biological Paternal Grandfather","code":"C96583","definitions":[{"definition":"A male relative who is the biological father of the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is the biological father of the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272879"}]}}{"C96584":{"preferredName":"Biological Paternal Grandmother","code":"C96584","definitions":[{"definition":"A female relative who is the biological mother of the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is the biological mother of the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272880"}]}}{"C111286":{"preferredName":"Paternal Biological Grandparent","code":"C111286","definitions":[{"definition":"A relative who is the biological parent of the biological father.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A relative who is the biological parent of the biological father.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Biological Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3828639"}]}}{"C165856":{"preferredName":"Paternal Great Aunt","code":"C165856","definitions":[{"definition":"The aunt of one's father.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Great Aunt","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Great-Aunt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Great Aunt"},{"name":"NCI_META_CUI","value":"CL979021"},{"name":"Semantic_Type","value":"Human"}]}}{"C166128":{"preferredName":"Paternal Great Grandparent","code":"C166128","definitions":[{"definition":"A parent of one's paternal grandparent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Great Grandparent","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Great-Grandparent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Great Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3242758"}]}}{"C165857":{"preferredName":"Paternal Great Uncle","code":"C165857","definitions":[{"definition":"The uncle of one's father.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Great Uncle","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Great-Uncle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Great Uncle"},{"name":"NCI_META_CUI","value":"CL979022"},{"name":"Semantic_Type","value":"Human"}]}}{"C96655":{"preferredName":"Half-brother with Father as Common Parent","code":"C96655","definitions":[{"definition":"A male sibling who shares the genetic makeup inherited from only the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A male who shares with his sibling the genetic makeup inherited from only the biological father.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-brother with Father as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Half Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272935"}]}}{"C166113":{"preferredName":"Paternal Half Sibling","code":"C166113","definitions":[{"definition":"A relative with whom you share a biological father but you have different mothers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Half Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Half-Sibling","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Half Sibling"},{"name":"NCI_META_CUI","value":"CL979210"},{"name":"Semantic_Type","value":"Human"}]}}{"C96657":{"preferredName":"Half-sister with Father as Common Parent","code":"C96657","definitions":[{"definition":"A female sibling who shares the genetic makeup inherited from only the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from only the biological father.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-sister with Father as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Half Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272937"}]}}{"C96585":{"preferredName":"Biological Paternal Uncle","code":"C96585","definitions":[{"definition":"A male relative who is a sibling of the biological father, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is a sibling of the biological father, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Uncle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Uncle"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272881"}]}}{"C25204":{"preferredName":"Sibling","code":"C25204","definitions":[{"definition":"A person's brother or sister who has the same parents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A person's brother or sister.","type":"DEFINITION","source":"NCI"},{"definition":"A person's brother or sister.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Sib","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sibling"},{"name":"Maps_To","value":"Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0037047"}]}}{"C25680":{"preferredName":"Sister","code":"C25680","definitions":[{"definition":"A female sibling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sister"},{"name":"Maps_To","value":"Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337514"}]}}{"C71407":{"preferredName":"Sister-in-law","code":"C71407","definitions":[{"definition":"A sister by marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sister-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sister-in-law"},{"name":"Maps_To","value":"Sister-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2350006"}]}}{"C25205":{"preferredName":"Son","code":"C25205","definitions":[{"definition":"A male human offspring.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Son"},{"name":"Maps_To","value":"Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0037683"}]}}{"C71400":{"preferredName":"Son-in-law","code":"C71400","definitions":[{"definition":"The husband of your daughter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Son-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Son-in-law"},{"name":"Maps_To","value":"Son-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2350007"}]}}{"C62649":{"preferredName":"Spouse","code":"C62649","definitions":[{"definition":"A person's partner in marriage.","type":"DEFINITION","source":"NCI"},{"definition":"A person's partner in marriage. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Spouse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spouse"},{"name":"Maps_To","value":"Spouse"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0162409"}]}}{"C166117":{"preferredName":"Step Child","code":"C166117","definitions":[{"definition":"A child of one's spouse, acquired through marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Step Child","termGroup":"PT","termSource":"NCI"},{"termName":"Stepchild","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Step Child"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337542"}]}}{"C166118":{"preferredName":"Step Sibling","code":"C166118","definitions":[{"definition":"A child of one's step parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Step Sibling","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Step Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337504"}]}}{"C166119":{"preferredName":"Stepbrother","code":"C166119","definitions":[{"definition":"A male child of one's step parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepbrother","termGroup":"PT","termSource":"NCI"},{"termName":"Stepbrother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepbrother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337530"}]}}{"C166123":{"preferredName":"Stepdaughter","code":"C166123","definitions":[{"definition":"A female child of one's spouse, acquired through marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepdaughter","termGroup":"PT","termSource":"NCI"},{"termName":"Step Daughter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepdaughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337554"}]}}{"C154851":{"preferredName":"Step Father","code":"C154851","definitions":[{"definition":"A male that is related to a child or children through marriage to their biological parent.","type":"DEFINITION","source":"NCI"},{"definition":"A male who has acquired children through marriage.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Step Father","termGroup":"PT","termSource":"NCI"},{"termName":"Stepfather","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337496"}]}}{"C132450":{"preferredName":"Stepmother","code":"C132450","definitions":[{"definition":"A female who has acquired children through marriage.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A female who is married to a spouse with children whom are not biologically related to her.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepmother","termGroup":"PT","termSource":"NCI"},{"termName":"Step Mother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337488"}]}}{"C166124":{"preferredName":"Stepsister","code":"C166124","definitions":[{"definition":"A female child of one's step parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepsister","termGroup":"PT","termSource":"NCI"},{"termName":"Step Sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepsister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337517"}]}}{"C166125":{"preferredName":"Stepson","code":"C166125","definitions":[{"definition":"A male child of one's spouse, acquired through marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepson","termGroup":"PT","termSource":"NCI"},{"termName":"Step Son","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepson"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337566"}]}}{"C73427":{"preferredName":"Twin","code":"C73427","definitions":[{"definition":"Either of two offspring born from the same pregnancy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from WordNet"}]},{"definition":"Either of two offspring born from the same pregnancy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Twin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Twin"},{"name":"Maps_To","value":"Twin Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0041427"}]}}{"C71404":{"preferredName":"Uncle","code":"C71404","definitions":[{"definition":"The brother of your father or mother; the husband of your aunt.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uncle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uncle"},{"name":"Maps_To","value":"Uncle"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337577"}]}}{"C25328":{"preferredName":"Unrelated","code":"C25328","definitions":[{"definition":"Not connected or associated e.g. by kinship.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unrelated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unrelated"},{"name":"Maps_To","value":"Unrelated"},{"name":"NCI_META_CUI","value":"CL448530"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C71413":{"preferredName":"Ward","code":"C71413","definitions":[{"definition":"A person who is under the protection or in the custody of another.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ward","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ward"},{"name":"Maps_To","value":"Ward"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2355574"}]}}{"C71587":{"preferredName":"Wife","code":"C71587","definitions":[{"definition":"A female partner in marriage.","type":"DEFINITION","source":"NCI"},{"definition":"A female partner in marriage.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Wife","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Wife"},{"name":"Maps_To","value":"Wife"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0242665"}]}}{"C21481":{"preferredName":"First Degree Relative","code":"C21481","definitions":[{"definition":"Any individual related biologically or legally to another individual and considered immediate family as in the case of a spouse, parent, sibling or child.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any relative who is one meiosis away from a particular individual in a family; a relative with whom one half of an individual's genes is shared (i.e., parent, sibling, offspring) (from Genetics Home Reference glossary)","type":"DEFINITION","source":"NCI"},{"definition":"The parents, siblings, or children of an individual.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"First Degree Relative","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First_Degree_Relative"},{"name":"Maps_To","value":"First Degree Relative, NOS"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C1517194"}]}}{"C9338":{"preferredName":"Malignant Adrenal Gland Neoplasm","code":"C9338","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the adrenal gland.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the adrenal glands (two glands located just above the kidneys). The adrenal glands make hormones that control heart rate, blood pressure, and other important body functions. Adrenal cancer that starts in the outside layer of the adrenal gland is called adrenocortical carcinoma. Adrenal cancer that starts in the center of the adrenal gland is called malignant pheochromocytoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Adrenal Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Adrenal Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Adrenal_Gland_Neoplasm"},{"name":"Maps_To","value":"Adrenal Gland Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified part of left adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified part of right adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified part of unspecified adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm: Adrenal gland, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0750887"}]}}{"C4912":{"preferredName":"Bladder Carcinoma","code":"C4912","definitions":[{"definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the bladder (the organ that stores urine). Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the bladder). Other types include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). The cells that form squamous cell carcinoma and adenocarcinoma develop in the inner lining of the bladder as a result of chronic irritation and inflammation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bladder Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bladder Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Bladder Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Bladder Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Carcinoma"},{"name":"Maps_To","value":"Bladder Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0699885"}]}}{"C116915":{"preferredName":"Liquid Tumor","code":"C116915","definitions":[{"definition":"A malignant tumor that originates from myeloid or lymphoid cells i.e., leukemias and lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liquid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3890429"}]}}{"C4016":{"preferredName":"Malignant Bone Neoplasm","code":"C4016","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","type":"DEFINITION","source":"NCI"},{"definition":"A solid malignant neoplasm that develops or arises in the bone.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Primary bone cancer is cancer that forms in cells of the bone. Some types of primary bone cancer are osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, and chondrosarcoma. Secondary bone cancer is cancer that spreads to the bone from another part of the body (such as the prostate, breast, or lung).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Bone Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Bone Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Osseous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Osseous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Malignant_Bone_Neoplasm"},{"name":"Maps_To","value":"Bone cancer"},{"name":"Maps_To","value":"Bone Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage of limbs"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage of other and unspecified sites"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage, site unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of bones of skull and face, except mandible"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of left lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of right lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of unspecified lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of pelvic bones, sacrum, and coccyx"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of left upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of right upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of unspecified upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of short bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of short bones of unspecified upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of short bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified bones and articular cartilage of right limb"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb"},{"name":"Maps_To","value":"Malignant neoplasm of vertebral column, excluding sacrum and coccyx"},{"name":"Maps_To","value":"Malignant neoplasm: Bone and articular cartilage, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Bones of skull and face"},{"name":"Maps_To","value":"Malignant neoplasm: Long bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm: Pelvic bones, sacrum and coccyx"},{"name":"Maps_To","value":"Malignant neoplasm: Scapula and long bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm: Short bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm: Short bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm: Vertebral column"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279530"}]}}{"C3568":{"preferredName":"Malignant Brain Neoplasm","code":"C3568","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the brain.","type":"DEFINITION","source":"NCI"},{"definition":"An abnormal solid mass arising within the brain with histologic features suggesting the potential to metastasize.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Malignant Brain Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Brain Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Brain Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brain Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Brain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Malignant_Brain_Neoplasm"},{"name":"Maps_To","value":"Brain Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of brain"},{"name":"Maps_To","value":"Malignant neoplasm of brain, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of other parts of brain"},{"name":"Maps_To","value":"Malignant neoplasm: Brain, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Cerebral ventricle"},{"name":"Maps_To","value":"Malignant neoplasm: Overlapping lesion of brain"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0153633"}]}}{"C4872":{"preferredName":"Breast Carcinoma","code":"C4872","definitions":[{"definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm that develops or arises in breast tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A malignant neoplasm that develops or arises in breast tissue.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mammary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Breast_Carcinoma"},{"name":"Maps_To","value":"Breast cancer"},{"name":"Maps_To","value":"Breast Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0678222"},{"name":"xRef","value":"IMDRF:E180101"}]}}{"C9039":{"preferredName":"Cervical Carcinoma","code":"C9039","definitions":[{"definition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the cervix (the organ connecting the uterus and vagina). It is usually a slow-growing cancer that may not have symptoms but can be found with regular Pap tests (a procedure in which cells are scraped from the cervix and looked at under a microscope). Cervical cancer is almost always caused by human papillomavirus (HPV) infection.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cervical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cervical_Carcinoma"},{"name":"Maps_To","value":"Cervical Cancer"},{"name":"Maps_To","value":"Cervical Cancer (all types)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302592"}]}}{"C4627":{"preferredName":"Malignant Central Nervous System Neoplasm","code":"C4627","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Central Nervous System Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Malignant Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Central Nervous System Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant CNS Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant CNS Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant CNS Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Central_Nervous_System_Neoplasm"},{"name":"Maps_To","value":"Brain and Nervous System"},{"name":"Maps_To","value":"CNS Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system"},{"name":"Maps_To","value":"Malignant neoplasm: Central nervous system, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0348374"}]}}{"C2955":{"preferredName":"Colorectal Carcinoma","code":"C2955","definitions":[{"definition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colorectal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Colorectal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"CRC","termGroup":"AB","termSource":"NCI"},{"termName":"Large Bowel Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Large Bowel Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Large Intestine Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Large Intestine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colorectal_Carcinoma"},{"name":"Maps_To","value":"Colorectal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0009402"}]}}{"C3513":{"preferredName":"Esophageal Carcinoma","code":"C3513","definitions":[{"definition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues lining the esophagus (the muscular tube through which food passes from the throat to the stomach). Two types of esophageal cancer are squamous cell carcinoma (cancer that begins in flat cells lining the esophagus) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Esophageal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"ESCA","termGroup":"AB","termSource":"NCI"},{"termName":"Esophageal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Esophagus Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Esophageal_Carcinoma"},{"name":"Maps_To","value":"Esophageal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152018"}]}}{"C3844":{"preferredName":"Gallbladder Carcinoma","code":"C3844","definitions":[{"definition":"A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the gallbladder. The gallbladder is a pear-shaped organ below the liver that collects and stores bile (a fluid made by the liver to digest fat). Gallbladder cancer begins in the innermost layer of tissue and spreads through the outer layers as it grows.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gallbladder Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gallbladder_Carcinoma"},{"name":"Maps_To","value":"Gallbladder Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0235782"}]}}{"C4911":{"preferredName":"Gastric Carcinoma","code":"C4911","definitions":[{"definition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues lining the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastric Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Gastric Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Stomach Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Stomach Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastric_Carcinoma"},{"name":"Maps_To","value":"Gastric Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0699791"}]}}{"C4913":{"preferredName":"Malignant Female Reproductive System Neoplasm","code":"C4913","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the female reproductive system.  Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer of the female reproductive tract, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Female Reproductive System Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Female Reproductive Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Gynecologic Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Female Reproductive System Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Gynecologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Gynecologic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Female Reproductive System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Female Reproductive System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Female Reproductive System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Female Reproductive System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Female_Reproductive_System_Neoplasm"},{"name":"Maps_To","value":"Gynecologic Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of female genital organ, site unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of other and unspecified female genital organs"},{"name":"Maps_To","value":"Malignant neoplasm of ovary and other uterine adnexa"},{"name":"Maps_To","value":"Malignant neoplasm of uterine adnexa, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Female genital organ, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Other specified female genital organs"},{"name":"Maps_To","value":"Malignant neoplasm: Uterine adnexa, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0699889"}]}}{"C4013":{"preferredName":"Malignant Head and Neck Neoplasm","code":"C4013","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that arises in the head or neck region (in the nasal cavity, sinuses, lip, mouth, salivary glands, throat, or larynx [voice box]).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Head and Neck Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Head and Neck Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Head and Neck Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Head and Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Head_and_Neck_Neoplasm"},{"name":"Maps_To","value":"Head and Neck Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of head, face, and neck"},{"name":"Maps_To","value":"Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses"},{"name":"Maps_To","value":"Malignant neoplasm of nasal cavity and middle ear"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites: Head, face and neck"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278996"}]}}{"C27134":{"preferredName":"Hematopoietic and Lymphoid Cell Neoplasm","code":"C27134","definitions":[{"definition":"A cancer of the blood or bone marrow, such as leukemia or lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm composed of hemolymphoreticular cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm that arises from hematopoietic and lymphoid cells. Representative examples include myeloproliferative neoplasms, myelodysplastic syndromes, leukemias, Hodgkin lymphomas, and non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic and Lymphoid Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Hematologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematological Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic and Lymphoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Neoplasms Including Lymphomas","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Hematologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Hematopoietic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Hematopoietic_Cell_Neoplasm"},{"name":"Maps_To","value":"Hematologic Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of lymphoid, haematopoietic and related tissue, unspecified"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue"},{"name":"Maps_To","value":"Other lymphatic and hematopoietic tissues"},{"name":"Maps_To","value":"Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0376545"}]}}{"C9384":{"preferredName":"Kidney Carcinoma","code":"C9384","definitions":[{"definition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the kidneys. Kidney cancer includes renal cell carcinoma (cancer that forms in the lining of very small tubes in the kidney that filter the blood and remove waste products) and renal pelvis carcinoma (cancer that forms in the center of the kidney where urine collects). It also includes Wilms tumor, which is a type of kidney cancer that usually develops in children under the age of 5.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Kidney Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Carcinoma"},{"name":"Maps_To","value":"Kidney Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378703"}]}}{"C4855":{"preferredName":"Laryngeal Carcinoma","code":"C4855","definitions":[{"definition":"Cancer that forms in tissues of the larynx (area of the throat that contains the vocal cords and is used for breathing, swallowing, and talking). Most laryngeal cancers are squamous cell carcinomas (cancer that begins in flat cells lining the larynx).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma that arises from the laryngeal epithelium. More than 90% of laryngeal carcinomas are squamous cell carcinomas. The remainder are adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas with neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laryngeal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Laryngeal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Larynx Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laryngeal_Carcinoma"},{"name":"Maps_To","value":"Laryngeal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0595989"}]}}{"C7927":{"preferredName":"Liver Carcinoma","code":"C7927","definitions":[{"definition":"A carcinoma that arises from the hepatocytes or intrahepatic bile ducts.  The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Primary liver cancer is cancer that forms in the tissues of the liver. Secondary liver cancer is cancer that spreads to the liver from another part of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Liver Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Bile Duct Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Bile Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Biliary Tract Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Biliary Tract Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Liver Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liver_and_Intrahepatic_Biliary_Tract_Carcinoma"},{"name":"Maps_To","value":"Liver Cancer"},{"name":"Maps_To","value":"Malignant neoplasm: Other specified carcinomas of liver"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279000"}]}}{"C4878":{"preferredName":"Lung Carcinoma","code":"C4878","definitions":[{"definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the lung, usually in the cells lining air passages. The two main types are small cell lung cancer and non-small cell lung cancer. These types are diagnosed based on how the cells look under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lung Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Carcinoma"},{"name":"Maps_To","value":"Lung Cancer"},{"name":"Maps_To","value":"Lung Cancer (all types)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0684249"}]}}{"C35812":{"preferredName":"Malignant Lymph Node Neoplasm","code":"C35812","definitions":[{"definition":"A primary or metastatic malignant tumor involving the lymph node.  Lymphomas and metastatic carcinomas are representative examples.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymph Node Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Node Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymph_Node_Neoplasm"},{"name":"Maps_To","value":"Lymph Node Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0948627"}]}}{"C7431":{"preferredName":"Malignant Ovarian Neoplasm","code":"C7431","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the ovary (one of a pair of female reproductive glands in which the ova, or eggs, are formed). Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Ovarian Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ovarian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm of left ovary"},{"name":"Maps_To","value":"Malignant neoplasm of ovary"},{"name":"Maps_To","value":"Malignant neoplasm of right ovary"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified ovary"},{"name":"Maps_To","value":"Ovarian Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3810371"}]}}{"C3850":{"preferredName":"Pancreatic Carcinoma","code":"C3850","definitions":[{"definition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"A disease in which malignant (cancer) cells are found in the tissues of the pancreas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Exocrine Pancreas Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Carcinoma"},{"name":"Maps_To","value":"Pancreas Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0235974"}]}}{"C7708":{"preferredName":"Childhood Malignant Liver Neoplasm","code":"C7708","definitions":[{"definition":"A malignant neoplasm that affects the liver and occurs during childhood.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant tumor of the liver occurring during childhood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood Malignant Liver Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Childhood Cancer of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Cancer of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Liver Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Malignant Liver Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Cancer of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Cancer of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Liver Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Malignant Liver Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Childhood_Liver_Cancer"},{"name":"Maps_To","value":"Pediatric Liver Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2945767"}]}}{"C4863":{"preferredName":"Prostate Carcinoma","code":"C4863","definitions":[{"definition":"Cancer that forms in tissues of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum). Prostate cancer usually occurs in older men.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Prostate_Carcinoma"},{"name":"Maps_To","value":"Prostate Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0600139"}]}}{"C9382":{"preferredName":"Rectal Carcinoma","code":"C9382","definitions":[{"definition":"A malignant epithelial neoplasm that arises from the rectum. The vast majority are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the rectum (the last several inches of the large intestine closest to the anus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rectal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Rectal Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rectal_Carcinoma"},{"name":"Maps_To","value":"Rectal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007113"}]}}{"C2920":{"preferredName":"Malignant Skin Neoplasm","code":"C2920","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the skin. There are several types of skin cancer. Skin cancer that forms in melanocytes (skin cells that make pigment) is called melanoma. Skin cancer that forms in the lower part of the epidermis (the outer layer of the skin) is called basal cell carcinoma. Skin cancer that forms in squamous cells (flat cells that form the surface of the skin) is called squamous cell carcinoma. Skin cancer that forms in neuroendocrine cells (cells that release hormones in response to signals from the nervous system) is called neuroendocrine carcinoma of the skin. Most skin cancers form in older people on parts of the body exposed to the sun or in people who have weakened immune systems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Skin Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma and Non-Melanoma Skin Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Cancer, Including Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Neoplasm, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Skin_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm: Malignant neoplasm of skin, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of ear and external auricular canal"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of eyelid, including canthus"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of other and unspecified parts of face"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of scalp and neck"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of trunk"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of upper limb, including shoulder"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of scalp and skin of neck"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of lower limb, including hip"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of other and unspecified parts of face"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of trunk, except scrotum"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of upper limb, including shoulder"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin, site unspecified"},{"name":"Maps_To","value":"Other malignant neoplasms of skin"},{"name":"Maps_To","value":"Other specified malignant neoplasm of overlapping sites of skin"},{"name":"Maps_To","value":"Other specified malignant neoplasm of scalp and skin of neck"},{"name":"Maps_To","value":"Other specified malignant neoplasm of skin, unspecified"},{"name":"Maps_To","value":"Skin Cancer"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of scalp and skin of neck"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of skin of unspecified part of face"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of skin, site unspecified"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of skin, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007114"}]}}{"C3539":{"preferredName":"Malignant Splenic Neoplasm","code":"C3539","definitions":[{"definition":"A malignant neoplasm affecting the spleen. Representative examples include leukemias, lymphomas, and sarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Splenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Splenic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Spleen Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Splenic_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm: Spleen"},{"name":"Maps_To","value":"Spleen Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0153470"}]}}{"C9063":{"preferredName":"Malignant Testicular Germ Cell Tumor","code":"C9063","definitions":[{"definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the testis (one of two egg-shaped glands inside the scrotum that make sperm and male hormones). Testicular cancer usually occurs in young or middle-aged men. Two main types of testicular cancer are seminomas (cancers that grow slowly and are sensitive to radiation therapy) and nonseminomas (different cell types that grow more quickly than seminomas).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Testicular Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Germ Cell Neoplasm of Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Germ Cell Neoplasm of the Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Germ Cell Tumor of Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Germ Cell Tumor of the Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Testicular Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Germ Cell Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Testicular_Germ_Cell_Tumor"},{"name":"Maps_To","value":"Testicular Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855197"}]}}{"C35506":{"preferredName":"Throat Carcinoma","code":"C35506","definitions":[{"definition":"Cancer that forms in tissues of the pharynx (the hollow tube inside the neck that starts behind the nose and ends at the top of the windpipe and esophagus). Throat cancer includes cancer of the nasopharynx (the upper part of the throat behind the nose), the oropharynx (the middle part of the pharynx), and the hypopharynx (the bottom part of the pharynx). Cancer of the larynx (voice box) may also be included as a type of throat cancer. Most throat cancers are squamous cell carcinomas (cancer that begins in thin, flat cells that look like fish scales).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma, predominantly squamous cell, arising from epithelial cells of the larynx or pharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Throat Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Throat Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Throat_Cancer"},{"name":"Maps_To","value":"Throat Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0740339"}]}}{"C4815":{"preferredName":"Thyroid Gland Carcinoma","code":"C4815","definitions":[{"definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant tumor arising from the epithelial cells of the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that forms in the thyroid gland (an organ at the base of the throat that makes hormones that help control heart rate, blood pressure, body temperature, and weight). Four main types of thyroid cancer are papillary, follicular, medullary, and anaplastic thyroid cancer. The four types are based on how the cancer cells look under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"THCA","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Thyroid_Carcinoma"},{"name":"Maps_To","value":"Thyroid cancer"},{"name":"Maps_To","value":"Thyroid Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0549473"}]}}{"C4824":{"preferredName":"Tongue Carcinoma","code":"C4824","definitions":[{"definition":"A malignant tumor arising from the epithelium that covers the tongue.  The vast majority of tongue carcinomas are moderately or poorly differentiated squamous cell carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that begins in the tongue. When the cancer begins in the front two-thirds of the tongue, it is considered to be a type of oral cavity cancer; when the cancer begins in the back third of the tongue, it is considered to be a type of oropharyngeal or throat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tongue Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Tongue Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tongue_Carcinoma"},{"name":"Maps_To","value":"Tongue Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0558353"}]}}{"C4825":{"preferredName":"Tonsillar Carcinoma","code":"C4825","definitions":[{"definition":"A carcinoma arising from the tonsilar epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillar Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Tonsil Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Tonsil Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tonsillar Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillar_Carcinoma"},{"name":"Maps_To","value":"Tonsillar Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0558355"}]}}{"C3552":{"preferredName":"Malignant Uterine Neoplasm","code":"C3552","definitions":[{"definition":"Cancer that forms in tissues of the uterus (the small, hollow, pear-shaped organ in a woman's pelvis in which a fetus develops). Two types of uterine cancer are endometrial cancer (cancer that begins in cells lining the uterus) and uterine sarcoma (a rare cancer that begins in muscle or other tissues in the uterus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Uterine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Uterine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Uterine_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm of isthmus"},{"name":"Maps_To","value":"Malignant neoplasm of uterus, part unspecified"},{"name":"Maps_To","value":"Uterine Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0153567"}]}}{"C143253":{"preferredName":"Abdominal Distension, CTCAE","code":"C143253","definitions":[{"definition":"A disorder characterized by swelling of the abdomen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling of the abdomen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Abdominal Distension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal Distension"},{"name":"Maps_To","value":"Abdominal distension"},{"name":"NCI_META_CUI","value":"CL541634"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143254":{"preferredName":"Abdominal Infection, CTCAE","code":"C143254","definitions":[{"definition":"A disorder characterized by an infectious process involving the abdominal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the abdominal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Abdominal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal Infection"},{"name":"Maps_To","value":"Abdominal infection"},{"name":"NCI_META_CUI","value":"CL541635"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143255":{"preferredName":"Abdominal Pain, CTCAE","code":"C143255","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the abdominal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the abdominal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Abdominal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal Pain"},{"name":"Maps_To","value":"Abdominal pain"},{"name":"NCI_META_CUI","value":"CL541636"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143256":{"preferredName":"Abdominal Soft Tissue Necrosis, CTCAE","code":"C143256","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Abdominal Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal Soft Tissue Necrosis"},{"name":"Maps_To","value":"Abdominal soft tissue necrosis"},{"name":"NCI_META_CUI","value":"CL541637"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143257":{"preferredName":"Abducens Nerve Disorder, CTCAE","code":"C143257","definitions":[{"definition":"A disorder characterized by dysfunction of the abducens nerve (sixth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the abducens nerve (sixth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Abducens Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abducens Nerve Disorder"},{"name":"Maps_To","value":"Abducens nerve disorder"},{"name":"NCI_META_CUI","value":"CL541638"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143258":{"preferredName":"Accessory Nerve Disorder, CTCAE","code":"C143258","definitions":[{"definition":"A disorder characterized by dysfunction of the accessory nerve (eleventh cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the accessory nerve (eleventh cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Accessory Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accessory Nerve Disorder"},{"name":"Maps_To","value":"Accessory nerve disorder"},{"name":"NCI_META_CUI","value":"CL541639"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143259":{"preferredName":"Acidosis, CTCAE","code":"C143259","definitions":[{"definition":"A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Acidosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acidosis"},{"name":"NCI_META_CUI","value":"CL541640"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143260":{"preferredName":"Acoustic Nerve Disorder NOS, CTCAE","code":"C143260","definitions":[{"definition":"A disorder characterized by dysfunction of the acoustic nerve (eighth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the acoustic nerve (eighth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Acoustic Nerve Disorder NOS, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acoustic Nerve Disorder NOS"},{"name":"Maps_To","value":"Acoustic nerve disorder NOS"},{"name":"NCI_META_CUI","value":"CL546042"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143261":{"preferredName":"Activated Partial Thromboplastin Time Prolonged, CTCAE","code":"C143261","definitions":[{"definition":"A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Activated Partial Thromboplastin Time Prolonged, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Activated Partial Thromboplastin Time Prolonged"},{"name":"Maps_To","value":"Activated partial thromboplastin time prolonged"},{"name":"NCI_META_CUI","value":"CL541628"},{"name":"Semantic_Type","value":"Finding"}]}}{"C53652":{"preferredName":"Acute Coronary Syndrome","code":"C53652","definitions":[{"definition":"A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Coronary Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Coronary_Syndrome"},{"name":"Maps_To","value":"Acute Coronary Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0948089"}]}}{"C143262":{"preferredName":"Acute Kidney Injury, CTCAE","code":"C143262","definitions":[{"definition":"A disorder characterized by the acute loss of renal function (within 2 weeks) and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the acute loss of renal function (within 2 weeks) and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Acute Kidney Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acute Kidney Injury"},{"name":"Maps_To","value":"Acute kidney injury"},{"name":"NCI_META_CUI","value":"CL545954"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55748":{"preferredName":"Adrenal Insufficiency, CTCAE","code":"C55748","definitions":[{"definition":"A disorder characterized by the adrenal cortex not producing enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the adrenal cortex not producing enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Adrenal Insufficiency, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Insufficiency_Adverse_Event"},{"name":"Maps_To","value":"Adrenal insufficiency"},{"name":"Maps_To","value":"Adrenal Insufficiency"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963059"}]}}{"C58020":{"preferredName":"Adult Respiratory Distress Syndrome, CTCAE","code":"C58020","definitions":[{"definition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Adult Respiratory Distress Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Respiratory_Distress_Syndrome_Adverse_Event"},{"name":"Maps_To","value":"Adult respiratory distress syndrome"},{"name":"Maps_To","value":"Adult Respiratory Distress Syndrome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963227"}]}}{"C146777":{"preferredName":"Agitation, CTCAE 5.0","code":"C146777","definitions":[{"definition":"A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Agitation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agitation"},{"name":"NCI_META_CUI","value":"CL544784"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143266":{"preferredName":"Akathisia, CTCAE","code":"C143266","definitions":[{"definition":"A disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Akathisia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Akathisia"},{"name":"NCI_META_CUI","value":"CL541629"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143267":{"preferredName":"Alanine Aminotransferase Increased, CTCAE","code":"C143267","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Alanine Aminotransferase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alanine Aminotransferase Increased"},{"name":"Maps_To","value":"Alanine aminotransferase increased"},{"name":"NCI_META_CUI","value":"CL541630"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143268":{"preferredName":"Alcohol Intolerance, CTCAE","code":"C143268","definitions":[{"definition":"A disorder characterized by an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Alcohol Intolerance, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alcohol Intolerance"},{"name":"Maps_To","value":"Alcohol intolerance"},{"name":"NCI_META_CUI","value":"CL541631"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143269":{"preferredName":"Alkaline Phosphatase Increased, CTCAE","code":"C143269","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Alkaline Phosphatase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alkaline Phosphatase Increased"},{"name":"Maps_To","value":"Alkaline phosphatase increased"},{"name":"NCI_META_CUI","value":"CL546025"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143270":{"preferredName":"Alkalosis, CTCAE","code":"C143270","definitions":[{"definition":"A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Alkalosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alkalosis"},{"name":"NCI_META_CUI","value":"CL541632"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143271":{"preferredName":"Allergic Reaction, CTCAE","code":"C143271","definitions":[{"definition":"A disorder characterized by an adverse local or general response from exposure to an allergen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an adverse local or general response from exposure to an allergen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Allergic Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergic Reaction"},{"name":"Maps_To","value":"Allergic reaction"},{"name":"NCI_META_CUI","value":"CL541633"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143272":{"preferredName":"Allergic Rhinitis, CTCAE","code":"C143272","definitions":[{"definition":"A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Allergic Rhinitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergic Rhinitis"},{"name":"Maps_To","value":"Allergic rhinitis"},{"name":"NCI_META_CUI","value":"CL541718"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57898":{"preferredName":"Alopecia, CTCAE","code":"C57898","definitions":[{"definition":"A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Alopecia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alopecia_Adverse_Event"},{"name":"Maps_To","value":"Alopecia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559115"}]}}{"C143274":{"preferredName":"Amnesia, CTCAE","code":"C143274","definitions":[{"definition":"A disorder characterized by systematic and extensive loss of memory.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by systematic and extensive loss of memory.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Amnesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amnesia"},{"name":"NCI_META_CUI","value":"CL541719"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143275":{"preferredName":"Anal Fistula, CTCAE","code":"C143275","definitions":[{"definition":"A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Fistula"},{"name":"Maps_To","value":"Anal fistula"},{"name":"NCI_META_CUI","value":"CL546016"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143276":{"preferredName":"Anal Hemorrhage, CTCAE","code":"C143276","definitions":[{"definition":"A disorder characterized by bleeding from the anal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the anal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Hemorrhage"},{"name":"Maps_To","value":"Anal hemorrhage"},{"name":"NCI_META_CUI","value":"CL541720"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143277":{"preferredName":"Anal Mucositis, CTCAE","code":"C143277","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the anus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the anus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Mucositis"},{"name":"Maps_To","value":"Anal mucositis"},{"name":"NCI_META_CUI","value":"CL541721"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143278":{"preferredName":"Anal Necrosis, CTCAE","code":"C143278","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the anal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the anal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Necrosis"},{"name":"Maps_To","value":"Anal necrosis"},{"name":"NCI_META_CUI","value":"CL541722"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143279":{"preferredName":"Anal Pain, CTCAE","code":"C143279","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the anal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the anal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Pain"},{"name":"Maps_To","value":"Anal pain"},{"name":"NCI_META_CUI","value":"CL541723"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143280":{"preferredName":"Anal Stenosis, CTCAE","code":"C143280","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the anal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the anal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Stenosis"},{"name":"Maps_To","value":"Anal stenosis"},{"name":"NCI_META_CUI","value":"CL541724"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143281":{"preferredName":"Anal Ulcer, CTCAE","code":"C143281","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the anal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the anal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Ulcer"},{"name":"Maps_To","value":"Anal ulcer"},{"name":"NCI_META_CUI","value":"CL541712"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143282":{"preferredName":"Anaphylaxis, CTCAE","code":"C143282","definitions":[{"definition":"A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anaphylaxis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaphylaxis"},{"name":"NCI_META_CUI","value":"CL546000"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143283":{"preferredName":"Anemia, CTCAE","code":"C143283","definitions":[{"definition":"A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anemia"},{"name":"NCI_META_CUI","value":"CL545972"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143284":{"preferredName":"Ankle Fracture, CTCAE","code":"C143284","definitions":[{"definition":"A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ankle Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ankle Fracture"},{"name":"Maps_To","value":"Ankle fracture"},{"name":"NCI_META_CUI","value":"CL541713"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143285":{"preferredName":"Anorectal Infection, CTCAE","code":"C143285","definitions":[{"definition":"A disorder characterized by an infectious process involving the anal area and the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the anal area and the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anorectal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anorectal Infection"},{"name":"Maps_To","value":"Anorectal infection"},{"name":"NCI_META_CUI","value":"CL541714"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57118":{"preferredName":"Anorexia, CTCAE","code":"C57118","definitions":[{"definition":"A disorder characterized by a loss of appetite.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a loss of appetite.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anorexia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anorexia_Adverse_Event"},{"name":"Maps_To","value":"Anorexia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963063"}]}}{"C143287":{"preferredName":"Anorgasmia, CTCAE","code":"C143287","definitions":[{"definition":"A disorder characterized by an inability to achieve orgasm.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inability to achieve orgasm.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anorgasmia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anorgasmia"},{"name":"NCI_META_CUI","value":"CL541715"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146778":{"preferredName":"Anxiety, CTCAE 5.0","code":"C146778","definitions":[{"definition":"A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anxiety, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anxiety"},{"name":"NCI_META_CUI","value":"CL544785"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143289":{"preferredName":"Aortic Injury, CTCAE","code":"C143289","definitions":[{"definition":"A finding of damage to the aorta.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the aorta.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Aortic Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aortic Injury"},{"name":"Maps_To","value":"Aortic injury"},{"name":"NCI_META_CUI","value":"CL541716"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143290":{"preferredName":"Aortic Valve Disease, CTCAE","code":"C143290","definitions":[{"definition":"A disorder characterized by a defect in aortic valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a defect in aortic valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Aortic Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aortic Valve Disease"},{"name":"Maps_To","value":"Aortic valve disease"},{"name":"NCI_META_CUI","value":"CL541717"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143291":{"preferredName":"Aphonia, CTCAE","code":"C143291","definitions":[{"definition":"A disorder characterized by the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Aphonia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aphonia"},{"name":"NCI_META_CUI","value":"CL541706"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55340":{"preferredName":"Apnea, CTCAE","code":"C55340","definitions":[{"definition":"A disorder characterized by cessation of breathing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by cessation of breathing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Apnea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Apnea_Adverse_Event"},{"name":"Maps_To","value":"Apnea"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963065"}]}}{"C143294":{"preferredName":"Appendicitis, CTCAE","code":"C143294","definitions":[{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Appendicitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Appendicitis"},{"name":"NCI_META_CUI","value":"CL545962"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143293":{"preferredName":"Appendicitis Perforated, CTCAE","code":"C143293","definitions":[{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Appendicitis Perforated, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Appendicitis Perforated"},{"name":"Maps_To","value":"Appendicitis perforated"},{"name":"NCI_META_CUI","value":"CL546033"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143295":{"preferredName":"Arachnoiditis, CTCAE","code":"C143295","definitions":[{"definition":"A disorder characterized by inflammation of the arachnoid membrane and adjacent subarachnoid space.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the arachnoid membrane and adjacent subarachnoid space.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Arachnoiditis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arachnoiditis"},{"name":"NCI_META_CUI","value":"CL541707"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143296":{"preferredName":"Arterial Injury, CTCAE","code":"C143296","definitions":[{"definition":"A finding of damage to an artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to an artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Arterial Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arterial Injury"},{"name":"Maps_To","value":"Arterial injury"},{"name":"NCI_META_CUI","value":"CL541708"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143297":{"preferredName":"Arteritis Infective, CTCAE","code":"C143297","definitions":[{"definition":"A disorder characterized by an infectious process involving an artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving an artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Arteritis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arteritis Infective"},{"name":"Maps_To","value":"Arteritis infective"},{"name":"NCI_META_CUI","value":"CL541709"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143298":{"preferredName":"Arthralgia, CTCAE","code":"C143298","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in a joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in a joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Arthralgia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arthralgia"},{"name":"NCI_META_CUI","value":"CL541710"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143299":{"preferredName":"Arthritis, CTCAE","code":"C143299","definitions":[{"definition":"A disorder characterized by inflammation involving a joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving a joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Arthritis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arthritis"},{"name":"NCI_META_CUI","value":"CL541711"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143300":{"preferredName":"Ascites, CTCAE","code":"C143300","definitions":[{"definition":"A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ascites, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ascites"},{"name":"NCI_META_CUI","value":"CL541698"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143301":{"preferredName":"Aspartate Aminotransferase Increased, CTCAE","code":"C143301","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Aspartate Aminotransferase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aspartate Aminotransferase Increased"},{"name":"Maps_To","value":"Aspartate aminotransferase increased"},{"name":"NCI_META_CUI","value":"CL541699"},{"name":"Semantic_Type","value":"Finding"}]}}{"C28245":{"preferredName":"Aspiration, CTCAE","code":"C28245","definitions":[{"definition":"A disorder characterized by inhalation of solids or liquids into the lungs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inhalation of solids or liquids into the lungs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"The entry of foreign material past the trachea, and into the lower respiratory tract.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Aspiration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Inhalation"},{"name":"Maps_To","value":"Aspiration"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963221"},{"name":"xRef","value":"IMDRF:E0704"}]}}{"C146731":{"preferredName":"Asystole, CTCAE 5.0","code":"C146731","definitions":[{"definition":"A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Asystole, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Asystole"},{"name":"NCI_META_CUI","value":"CL544694"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146737":{"preferredName":"Ataxia, CTCAE 5.0","code":"C146737","definitions":[{"definition":"A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ataxia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ataxia"},{"name":"NCI_META_CUI","value":"CL545970"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58022":{"preferredName":"Atelectasis, CTCAE","code":"C58022","definitions":[{"definition":"A disorder characterized by the collapse of part or the entire lung.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the collapse of part or the entire lung.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atelectasis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atelectasis_Adverse_Event"},{"name":"Maps_To","value":"Atelectasis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962948"}]}}{"C54767":{"preferredName":"Atrial Fibrillation, CTCAE","code":"C54767","definitions":[{"definition":"A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atrial Fibrillation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atrial_Fibrillation_Adverse_Event"},{"name":"Maps_To","value":"Atrial Fibrillation"},{"name":"Maps_To","value":"Atrial fibrillation"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963067"}]}}{"C54768":{"preferredName":"Atrial Flutter, CTCAE","code":"C54768","definitions":[{"definition":"A disorder characterized by a dysrhythmia with organized rhythmic atrial contractions with a rate of 200-300 beats per minute. The rhythm disturbance originates in the atria.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with organized rhythmic atrial contractions with a rate of 200-300 beats per minute. The rhythm disturbance originates in the atria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atrial Flutter, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atrial_Flutter_Adverse_Event"},{"name":"Maps_To","value":"Atrial flutter"},{"name":"Maps_To","value":"Atrial Flutter"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963068"}]}}{"C143308":{"preferredName":"Atrioventricular Block Complete, CTCAE","code":"C143308","definitions":[{"definition":"A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Atrioventricular Block Complete, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Atrioventricular block complete"},{"name":"Maps_To","value":"Atrioventricular Block Complete"},{"name":"NCI_META_CUI","value":"CL541700"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143309":{"preferredName":"Atrioventricular Block First Degree, CTCAE","code":"C143309","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval greater than 200 milliseconds.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval greater than 200 milliseconds.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Atrioventricular Block First Degree, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Atrioventricular block first degree"},{"name":"Maps_To","value":"Atrioventricular Block First Degree"},{"name":"NCI_META_CUI","value":"CL541701"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143310":{"preferredName":"Autoimmune Disorder, CTCAE","code":"C143310","definitions":[{"definition":"A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Autoimmune Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autoimmune Disorder"},{"name":"Maps_To","value":"Autoimmune disorder"},{"name":"NCI_META_CUI","value":"CL541702"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143311":{"preferredName":"Avascular Necrosis, CTCAE","code":"C143311","definitions":[{"definition":"A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Avascular Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Avascular necrosis"},{"name":"Maps_To","value":"Avascular Necrosis"},{"name":"NCI_META_CUI","value":"CL541703"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143312":{"preferredName":"Azoospermia, CTCAE","code":"C143312","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate complete absence of spermatozoa in the semen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate complete absence of spermatozoa in the semen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Azoospermia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Azoospermia"},{"name":"NCI_META_CUI","value":"CL541704"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146739":{"preferredName":"Back Pain, CTCAE 5.0","code":"C146739","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the back region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the back region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Back Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Back pain"},{"name":"Maps_To","value":"Back Pain"},{"name":"NCI_META_CUI","value":"CL544687"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143314":{"preferredName":"Bile Duct Stenosis, CTCAE","code":"C143314","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the bile duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the bile duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bile Duct Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bile Duct Stenosis"},{"name":"Maps_To","value":"Bile duct stenosis"},{"name":"NCI_META_CUI","value":"CL541705"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143315":{"preferredName":"Biliary Anastomotic Leak, CTCAE","code":"C143315","definitions":[{"definition":"A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Biliary Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary Anastomotic Leak"},{"name":"Maps_To","value":"Biliary anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541691"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143316":{"preferredName":"Biliary Fistula, CTCAE","code":"C143316","definitions":[{"definition":"A disorder characterized by an abnormal communication between the bile ducts and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the bile ducts and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Biliary Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary Fistula"},{"name":"Maps_To","value":"Biliary fistula"},{"name":"NCI_META_CUI","value":"CL541692"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143317":{"preferredName":"Biliary Tract Infection, CTCAE","code":"C143317","definitions":[{"definition":"A disorder characterized by an infectious process involving the biliary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the biliary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Biliary Tract Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary Tract Infection"},{"name":"Maps_To","value":"Biliary tract infection"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0920156"}]}}{"C143318":{"preferredName":"Bladder Anastomotic Leak, CTCAE","code":"C143318","definitions":[{"definition":"A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bladder Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bladder anastomotic leak"},{"name":"Maps_To","value":"Bladder Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL541693"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143319":{"preferredName":"Bladder Infection, CTCAE","code":"C143319","definitions":[{"definition":"A disorder characterized by an infectious process involving the bladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the bladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bladder Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bladder infection"},{"name":"Maps_To","value":"Bladder Infection"},{"name":"NCI_META_CUI","value":"CL541694"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146707":{"preferredName":"Bladder Perforation, CTCAE 5.0","code":"C146707","definitions":[{"definition":"A disorder characterized by a rupture in the bladder wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the bladder wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bladder Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bladder Perforation"},{"name":"Maps_To","value":"Bladder perforation"},{"name":"NCI_META_CUI","value":"CL544718"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146698":{"preferredName":"Bladder Spasm, CTCAE 5.0","code":"C146698","definitions":[{"definition":"A disorder characterized by a sudden and involuntary contraction of the bladder wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sudden and involuntary contraction of the bladder wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bladder Spasm, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Bladder Spasm"},{"name":"Maps_To","value":"Bladder spasm"},{"name":"NCI_META_CUI","value":"CL544725"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143322":{"preferredName":"Bloating, CTCAE","code":"C143322","definitions":[{"definition":"A disorder characterized by subject-reported feeling of uncomfortable fullness of the abdomen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by subject-reported feeling of uncomfortable fullness of the abdomen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bloating, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bloating"},{"name":"NCI_META_CUI","value":"CL541695"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143323":{"preferredName":"Blood and Lymphatic System Disorders - Other, Specify, CTCAE","code":"C143323","synonyms":[{"termName":"Blood and Lymphatic System Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood and Lymphatic System Disorders - Other"},{"name":"Maps_To","value":"Blood and lymphatic system disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541696"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143324":{"preferredName":"Blood Antidiuretic Hormone Abnormal, CTCAE","code":"C143324","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Blood Antidiuretic Hormone Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood antidiuretic hormone abnormal"},{"name":"Maps_To","value":"Blood Antidiuretic Hormone Abnormal"},{"name":"NCI_META_CUI","value":"CL541697"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143325":{"preferredName":"Blood Bilirubin Increased, CTCAE","code":"C143325","definitions":[{"definition":"A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Blood Bilirubin Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood bilirubin increased"},{"name":"Maps_To","value":"Blood Bilirubin Increased"},{"name":"NCI_META_CUI","value":"CL541683"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143326":{"preferredName":"Blood Corticotrophin Decreased, CTCAE","code":"C143326","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Blood Corticotrophin Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood corticotrophin decreased"},{"name":"Maps_To","value":"Blood Corticotrophin Decreased"},{"name":"NCI_META_CUI","value":"CL541684"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143327":{"preferredName":"Blood Gonadotrophin Abnormal, CTCAE","code":"C143327","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Blood Gonadotrophin Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood gonadotrophin abnormal"},{"name":"Maps_To","value":"Blood Gonadotrophin Abnormal"},{"name":"NCI_META_CUI","value":"CL541685"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143328":{"preferredName":"Blood Prolactin Abnormal, CTCAE","code":"C143328","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Blood Prolactin Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood prolactin abnormal"},{"name":"Maps_To","value":"Blood Prolactin Abnormal"},{"name":"NCI_META_CUI","value":"CL541686"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55906":{"preferredName":"Blurred Vision, CTCAE","code":"C55906","definitions":[{"definition":"A disorder characterized by visual perception of unclear or fuzzy images.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by visual perception of unclear or fuzzy images.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Blurred Vision, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blurred_Vision_Adverse_Event"},{"name":"Maps_To","value":"Blurred vision"},{"name":"Maps_To","value":"Blurred Vision"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1557375"}]}}{"C143330":{"preferredName":"Body Odor, CTCAE","code":"C143330","definitions":[{"definition":"A disorder characterized by an abnormal body smell resulting from the growth of bacteria on the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal body smell resulting from the growth of bacteria on the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Body Odor, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Body odor"},{"name":"Maps_To","value":"Body Odor"},{"name":"NCI_META_CUI","value":"CL541687"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143331":{"preferredName":"Bone Infection, CTCAE","code":"C143331","definitions":[{"definition":"A disorder characterized by an infectious process involving the bones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the bones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bone Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone infection"},{"name":"Maps_To","value":"Bone Infection"},{"name":"NCI_META_CUI","value":"CL541688"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143332":{"preferredName":"Bone Marrow Hypocellular, CTCAE","code":"C143332","definitions":[{"definition":"A disorder characterized by the inability of the bone marrow to produce hematopoietic elements.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the inability of the bone marrow to produce hematopoietic elements.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bone Marrow Hypocellular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone marrow hypocellular"},{"name":"Maps_To","value":"Bone Marrow Hypocellular"},{"name":"NCI_META_CUI","value":"CL541689"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146741":{"preferredName":"Bone Pain, CTCAE 5.0","code":"C146741","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the bones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the bones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bone Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone pain"},{"name":"Maps_To","value":"Bone Pain"},{"name":"NCI_META_CUI","value":"CL544689"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146754":{"preferredName":"Brachial Plexopathy, CTCAE 5.0","code":"C146754","definitions":[{"definition":"A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Brachial Plexopathy, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Brachial plexopathy"},{"name":"Maps_To","value":"Brachial Plexopathy"},{"name":"NCI_META_CUI","value":"CL544805"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143335":{"preferredName":"Breast Atrophy, CTCAE","code":"C143335","definitions":[{"definition":"A disorder characterized by underdevelopment of the breast.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by underdevelopment of the breast.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Breast Atrophy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast atrophy"},{"name":"Maps_To","value":"Breast Atrophy"},{"name":"NCI_META_CUI","value":"CL541690"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143336":{"preferredName":"Breast Infection, CTCAE","code":"C143336","definitions":[{"definition":"A disorder characterized by an infectious process involving the breast.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the breast.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Breast Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast infection"},{"name":"Maps_To","value":"Breast Infection"},{"name":"NCI_META_CUI","value":"CL552409"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146742":{"preferredName":"Breast Pain, CTCAE 5.0","code":"C146742","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the breast region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the breast region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Breast Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast pain"},{"name":"Maps_To","value":"Breast Pain"},{"name":"NCI_META_CUI","value":"CL545910"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143338":{"preferredName":"Bronchial Fistula, CTCAE","code":"C143338","definitions":[{"definition":"A disorder characterized by an abnormal communication between the bronchus and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the bronchus and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bronchial Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial fistula"},{"name":"Maps_To","value":"Bronchial Fistula"},{"name":"NCI_META_CUI","value":"CL541677"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143339":{"preferredName":"Bronchial Infection, CTCAE","code":"C143339","definitions":[{"definition":"A disorder characterized by an infectious process involving the bronchi.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the bronchi.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchial Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial infection"},{"name":"Maps_To","value":"Bronchial Infection"},{"name":"NCI_META_CUI","value":"CL546040"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143340":{"preferredName":"Bronchial Obstruction, CTCAE","code":"C143340","definitions":[{"definition":"A disorder characterized by blockage of a bronchus passage, most often by bronchial secretions and exudates.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of a bronchus passage, most often by bronchial secretions and exudates.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bronchial Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial obstruction"},{"name":"Maps_To","value":"Bronchial Obstruction"},{"name":"NCI_META_CUI","value":"CL541678"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143341":{"preferredName":"Bronchial Stricture, CTCAE","code":"C143341","definitions":[{"definition":"A disorder characterized by a narrowing of the bronchial tube.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the bronchial tube.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchial Stricture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial stricture"},{"name":"Maps_To","value":"Bronchial Stricture"},{"name":"NCI_META_CUI","value":"CL541679"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143342":{"preferredName":"Bronchopleural Fistula, CTCAE","code":"C143342","definitions":[{"definition":"A disorder characterized by an abnormal communication between a bronchus and the pleural cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between a bronchus and the pleural cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchopleural Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchopleural fistula"},{"name":"Maps_To","value":"Bronchopleural Fistula"},{"name":"NCI_META_CUI","value":"CL541680"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143343":{"preferredName":"Bronchopulmonary Hemorrhage, CTCAE","code":"C143343","definitions":[{"definition":"A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bronchopulmonary Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchopulmonary hemorrhage"},{"name":"Maps_To","value":"Bronchopulmonary Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541681"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143344":{"preferredName":"Bronchospasm, CTCAE","code":"C143344","definitions":[{"definition":"A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchospasm, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchospasm"},{"name":"NCI_META_CUI","value":"CL541682"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143345":{"preferredName":"Bruising, CTCAE","code":"C143345","definitions":[{"definition":"A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bruising, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bruising"},{"name":"NCI_META_CUI","value":"CL541669"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143346":{"preferredName":"Bullous Dermatitis, CTCAE","code":"C143346","definitions":[{"definition":"A disorder characterized by inflammation of the skin characterized by the presence of bullae which are filled with fluid.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the skin characterized by the presence of bullae which are filled with fluid.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bullous Dermatitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bullous dermatitis"},{"name":"Maps_To","value":"Bullous Dermatitis"},{"name":"NCI_META_CUI","value":"CL541670"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57900":{"preferredName":"Burn, CTCAE","code":"C57900","definitions":[{"definition":"A finding of impaired integrity to the anatomic site of an adverse thermal reaction. Burns can be caused by exposure to chemicals, direct heat, electricity, flames and radiation. The extent of damage depends on the length and intensity of exposure and time until provision of treatment.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of impaired integrity to the anatomic site of an adverse thermal reaction. Burns can be caused by exposure to chemicals, direct heat, electricity, flames and radiation. The extent of damage depends on the length and intensity of exposure and time until provision of treatment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Burn, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Burn_Adverse_Event"},{"name":"Maps_To","value":"Burn"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962979"}]}}{"C146744":{"preferredName":"Buttock Pain, CTCAE 5.0","code":"C146744","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the buttocks.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the buttocks.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Buttock Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buttock pain"},{"name":"Maps_To","value":"Buttock Pain"},{"name":"NCI_META_CUI","value":"CL544691"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143349":{"preferredName":"Capillary Leak Syndrome, CTCAE","code":"C143349","definitions":[{"definition":"A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Capillary Leak Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Capillary leak syndrome"},{"name":"Maps_To","value":"Capillary Leak Syndrome"},{"name":"NCI_META_CUI","value":"CL541671"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143350":{"preferredName":"Carbon Monoxide Diffusing Capacity Decreased, CTCAE","code":"C143350","definitions":[{"definition":"A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Carbon Monoxide Diffusing Capacity Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Carbon monoxide diffusing capacity decreased"},{"name":"Maps_To","value":"Carbon Monoxide Diffusing Capacity Decreased"},{"name":"NCI_META_CUI","value":"CL541672"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143351":{"preferredName":"Cardiac Arrest, CTCAE","code":"C143351","definitions":[{"definition":"A disorder characterized by cessation of the pumping function of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by cessation of the pumping function of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cardiac Arrest, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac arrest"},{"name":"Maps_To","value":"Cardiac Arrest"},{"name":"NCI_META_CUI","value":"CL541673"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143352":{"preferredName":"Cardiac Disorders - Other, Specify, CTCAE","code":"C143352","synonyms":[{"termName":"Cardiac Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac Disorders - Other"},{"name":"Maps_To","value":"Cardiac disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541674"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143353":{"preferredName":"Cardiac Troponin I Increased, CTCAE","code":"C143353","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin I in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin I in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cardiac Troponin I Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac troponin I increased"},{"name":"Maps_To","value":"Cardiac Troponin I Increased"},{"name":"NCI_META_CUI","value":"CL541675"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143354":{"preferredName":"Cardiac Troponin T Increased, CTCAE","code":"C143354","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin T in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin T in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cardiac Troponin T Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac troponin T increased"},{"name":"Maps_To","value":"Cardiac Troponin T Increased"},{"name":"NCI_META_CUI","value":"CL541676"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146674":{"preferredName":"Cataract, CTCAE 5.0","code":"C146674","definitions":[{"definition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cataract, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cataract"},{"name":"NCI_META_CUI","value":"CL545895"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143356":{"preferredName":"Catheter Related Infection, CTCAE","code":"C143356","definitions":[{"definition":"A disorder characterized by an infectious process that arises secondary to catheter use.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process that arises secondary to catheter use.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Catheter Related Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Catheter related infection"},{"name":"Maps_To","value":"Catheter Related Infection"},{"name":"NCI_META_CUI","value":"CL541776"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143357":{"preferredName":"CD4 Lymphocytes Decreased, CTCAE","code":"C143357","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"CD4 Lymphocytes Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD4 lymphocytes decreased"},{"name":"Maps_To","value":"CD4 Lymphocytes Decreased"},{"name":"NCI_META_CUI","value":"CL541777"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143358":{"preferredName":"Cecal Hemorrhage, CTCAE","code":"C143358","definitions":[{"definition":"A disorder characterized by bleeding from the cecum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the cecum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cecal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cecal hemorrhage"},{"name":"Maps_To","value":"Cecal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541778"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143359":{"preferredName":"Cecal Infection, CTCAE","code":"C143359","definitions":[{"definition":"A disorder characterized by an infectious process involving the cecum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the cecum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cecal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cecal infection"},{"name":"Maps_To","value":"Cecal Infection"},{"name":"NCI_META_CUI","value":"CL541779"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143360":{"preferredName":"Central Nervous System Necrosis, CTCAE","code":"C143360","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the brain and/or spinal cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the brain and/or spinal cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Central Nervous System Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Central nervous system necrosis"},{"name":"Maps_To","value":"Central Nervous System Necrosis"},{"name":"NCI_META_CUI","value":"CL541780"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143361":{"preferredName":"Cerebrospinal Fluid Leakage, CTCAE","code":"C143361","definitions":[{"definition":"A disorder characterized by loss of cerebrospinal fluid into the surrounding tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by loss of cerebrospinal fluid into the surrounding tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cerebrospinal Fluid Leakage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cerebrospinal fluid leakage"},{"name":"Maps_To","value":"Cerebrospinal Fluid Leakage"},{"name":"NCI_META_CUI","value":"CL541781"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143362":{"preferredName":"Cervicitis Infection, CTCAE","code":"C143362","definitions":[{"definition":"A disorder characterized by an infectious process involving the uterine cervix.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the uterine cervix.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cervicitis Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cervicitis infection"},{"name":"Maps_To","value":"Cervicitis Infection"},{"name":"NCI_META_CUI","value":"CL541782"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57901":{"preferredName":"Cheilitis, CTCAE","code":"C57901","definitions":[{"definition":"A disorder characterized by inflammation of the lip.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the lip.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cheilitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cheilitis_Adverse_Event"},{"name":"Maps_To","value":"Cheilitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962954"}]}}{"C143364":{"preferredName":"Chest Pain - Cardiac, CTCAE","code":"C143364","definitions":[{"definition":"A disorder characterized by substernal discomfort due to insufficient myocardial oxygenation e.g., angina pectoris.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by substernal discomfort due to insufficient myocardial oxygenation e.g., angina pectoris.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Chest Pain - Cardiac, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chest pain - cardiac"},{"name":"Maps_To","value":"Chest Pain - Cardiac"},{"name":"NCI_META_CUI","value":"CL545961"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146743":{"preferredName":"Chest Wall Pain, CTCAE 5.0","code":"C146743","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the chest wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the chest wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Chest Wall Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chest wall pain"},{"name":"Maps_To","value":"Chest Wall Pain"},{"name":"NCI_META_CUI","value":"CL544690"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143366":{"preferredName":"Chills, CTCAE","code":"C143366","definitions":[{"definition":"A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Chills, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chills"},{"name":"NCI_META_CUI","value":"CL541769"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146788":{"preferredName":"Cholecystitis, CTCAE 5.0","code":"C146788","definitions":[{"definition":"A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cholecystitis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cholecystitis"},{"name":"NCI_META_CUI","value":"CL544777"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143368":{"preferredName":"Cholesterol High, CTCAE","code":"C143368","definitions":[{"definition":"A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cholesterol High, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cholesterol high"},{"name":"Maps_To","value":"Cholesterol High"},{"name":"NCI_META_CUI","value":"CL545969"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143369":{"preferredName":"Chronic Kidney Disease, CTCAE","code":"C143369","definitions":[{"definition":"A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Chronic Kidney Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic kidney disease"},{"name":"Maps_To","value":"Chronic Kidney Disease"},{"name":"NCI_META_CUI","value":"CL541770"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58027":{"preferredName":"Chylothorax, CTCAE","code":"C58027","definitions":[{"definition":"A disorder characterized by milky pleural effusion (abnormal collection of fluid) resulting from accumulation of lymph fluid in the pleural cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by milky pleural effusion (abnormal collection of fluid) resulting from accumulation of lymph fluid in the pleural cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Chylothorax, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chylothorax_Adverse_Event"},{"name":"Maps_To","value":"Chylothorax"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962974"}]}}{"C146746":{"preferredName":"Cognitive Disturbance, CTCAE 5.0","code":"C146746","definitions":[{"definition":"A disorder characterized by a conspicuous change in cognitive function.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a conspicuous change in cognitive function.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cognitive Disturbance, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cognitive Disturbance"},{"name":"Maps_To","value":"Cognitive disturbance"},{"name":"NCI_META_CUI","value":"CL544693"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57134":{"preferredName":"Colitis, CTCAE","code":"C57134","definitions":[{"definition":"A disorder characterized by inflammation of the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Colitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colitis_Adverse_Event"},{"name":"Maps_To","value":"Colitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963084"}]}}{"C143373":{"preferredName":"Colonic Fistula, CTCAE","code":"C143373","definitions":[{"definition":"A disorder characterized by an abnormal communication between the large intestine and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the large intestine and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Colonic Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic fistula"},{"name":"Maps_To","value":"Colonic Fistula"},{"name":"NCI_META_CUI","value":"CL541771"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143374":{"preferredName":"Colonic Hemorrhage, CTCAE","code":"C143374","definitions":[{"definition":"A disorder characterized by bleeding from the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Colonic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic hemorrhage"},{"name":"Maps_To","value":"Colonic Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541772"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143375":{"preferredName":"Colonic Obstruction, CTCAE","code":"C143375","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Colonic Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic obstruction"},{"name":"Maps_To","value":"Colonic Obstruction"},{"name":"NCI_META_CUI","value":"CL541773"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143376":{"preferredName":"Colonic Perforation, CTCAE","code":"C143376","definitions":[{"definition":"A disorder characterized by a rupture in the colonic wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the colonic wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Colonic Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic perforation"},{"name":"Maps_To","value":"Colonic Perforation"},{"name":"NCI_META_CUI","value":"CL541774"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143377":{"preferredName":"Colonic Stenosis, CTCAE","code":"C143377","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Colonic Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic stenosis"},{"name":"Maps_To","value":"Colonic Stenosis"},{"name":"NCI_META_CUI","value":"CL541775"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143378":{"preferredName":"Colonic Ulcer, CTCAE","code":"C143378","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Colonic Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic ulcer"},{"name":"Maps_To","value":"Colonic Ulcer"},{"name":"NCI_META_CUI","value":"CL541761"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143379":{"preferredName":"Concentration Impairment, CTCAE","code":"C143379","definitions":[{"definition":"A disorder characterized by a deterioration in the ability to concentrate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a deterioration in the ability to concentrate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Concentration Impairment, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Concentration impairment"},{"name":"Maps_To","value":"Concentration Impairment"},{"name":"NCI_META_CUI","value":"CL541762"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143380":{"preferredName":"Conduction Disorder, CTCAE","code":"C143380","definitions":[{"definition":"A disorder characterized by pathological irregularities in the cardiac conduction system.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by pathological irregularities in the cardiac conduction system.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Conduction Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conduction disorder"},{"name":"Maps_To","value":"Conduction Disorder"},{"name":"NCI_META_CUI","value":"CL541763"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146785":{"preferredName":"Confusion, CTCAE 5.0","code":"C146785","definitions":[{"definition":"A disorder characterized by a lack of clear and orderly thought and behavior.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a lack of clear and orderly thought and behavior.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Confusion, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Confusion"},{"name":"NCI_META_CUI","value":"CL544775"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143382":{"preferredName":"Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","code":"C143382","synonyms":[{"termName":"Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Congenital, Familial and Genetic Disorders - Other"},{"name":"Maps_To","value":"Congenital, familial and genetic disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541764"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143384":{"preferredName":"Conjunctivitis, CTCAE","code":"C143384","definitions":[{"definition":"A disorder characterized by inflammation, swelling and redness to the conjunctiva of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation, swelling and redness to the conjunctiva of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Conjunctivitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conjunctivitis"},{"name":"NCI_META_CUI","value":"CL541766"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143383":{"preferredName":"Conjunctivitis Infective, CTCAE","code":"C143383","definitions":[{"definition":"A disorder characterized by an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Conjunctivitis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conjunctivitis infective"},{"name":"Maps_To","value":"Conjunctivitis Infective"},{"name":"NCI_META_CUI","value":"CL541765"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57141":{"preferredName":"Constipation, CTCAE","code":"C57141","definitions":[{"definition":"A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Constipation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Constipation_Adverse_Event"},{"name":"Maps_To","value":"Constipation"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963087"}]}}{"C78246":{"preferredName":"Constrictive Pericarditis","code":"C78246","definitions":[{"definition":"A disorder characterized by a thickened and fibrotic pericardial sac; these fibrotic changes impede normal myocardial function by restricting myocardial muscle action.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A heart disorder in which the pericardial sac becomes thickened and fibrotic, tightening the myocardium and impeding the normal myocardial function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Constrictive Pericarditis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Constrictive_Pericarditis"},{"name":"Maps_To","value":"Constrictive Pericarditis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0031048"}]}}{"C143386":{"preferredName":"Corneal Infection, CTCAE","code":"C143386","definitions":[{"definition":"A disorder characterized by an infectious process involving the cornea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the cornea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Corneal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Corneal infection"},{"name":"Maps_To","value":"Corneal Infection"},{"name":"NCI_META_CUI","value":"CL541767"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143387":{"preferredName":"Corneal Ulcer, CTCAE","code":"C143387","definitions":[{"definition":"A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Corneal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Corneal ulcer"},{"name":"Maps_To","value":"Corneal Ulcer"},{"name":"NCI_META_CUI","value":"CL541768"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58028":{"preferredName":"Cough, CTCAE","code":"C58028","definitions":[{"definition":"A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cough, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cough_Adverse_Event"},{"name":"Maps_To","value":"Cough"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1961131"}]}}{"C143389":{"preferredName":"CPK Increased, CTCAE","code":"C143389","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"CPK Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CPK increased"},{"name":"Maps_To","value":"CPK Increased"},{"name":"NCI_META_CUI","value":"CL541755"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143390":{"preferredName":"Cranial Nerve Infection, CTCAE","code":"C143390","definitions":[{"definition":"A disorder characterized by an infectious process involving a cranial nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a cranial nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cranial Nerve Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cranial nerve infection"},{"name":"Maps_To","value":"Cranial Nerve Infection"},{"name":"NCI_META_CUI","value":"CL541756"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143391":{"preferredName":"Creatinine Increased, CTCAE","code":"C143391","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Creatinine Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Creatinine increased"},{"name":"Maps_To","value":"Creatinine Increased"},{"name":"NCI_META_CUI","value":"CL546003"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143392":{"preferredName":"Cushingoid, CTCAE","code":"C143392","definitions":[{"definition":"A disorder characterized by signs and symptoms that resemble Cushing's disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by signs and symptoms that resemble Cushing's disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cushingoid, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cushingoid"},{"name":"NCI_META_CUI","value":"CL541757"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143393":{"preferredName":"Cystitis Noninfective, CTCAE","code":"C143393","definitions":[{"definition":"A disorder characterized by inflammation of the bladder which is not caused by an infection of the urinary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the bladder which is not caused by an infection of the urinary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cystitis Noninfective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Cystitis noninfective"},{"name":"Maps_To","value":"Cystitis Noninfective"},{"name":"NCI_META_CUI","value":"CL541758"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143394":{"preferredName":"Cytokine Release Syndrome, CTCAE","code":"C143394","definitions":[{"definition":"A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cytokine Release Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytokine release syndrome"},{"name":"Maps_To","value":"Cytokine Release Syndrome"},{"name":"NCI_META_CUI","value":"CL541759"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143395":{"preferredName":"Death Neonatal, CTCAE","code":"C143395","definitions":[{"definition":"Newborn death occurring during the first 28 days after birth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"Newborn death occurring during the first 28 days after birth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Death Neonatal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death neonatal"},{"name":"Maps_To","value":"Death Neonatal"},{"name":"NCI_META_CUI","value":"CL541760"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143396":{"preferredName":"Death NOS, CTCAE","code":"C143396","definitions":[{"definition":"Death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"Death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Death NOS, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death NOS"},{"name":"NCI_META_CUI","value":"CL550658"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57787":{"preferredName":"Dehydration, CTCAE","code":"C57787","definitions":[{"definition":"A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dehydration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dehydration_Adverse_Event"},{"name":"Maps_To","value":"Dehydration"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963090"}]}}{"C143398":{"preferredName":"Delayed Orgasm, CTCAE","code":"C143398","definitions":[{"definition":"A disorder characterized by sexual dysfunction characterized by a delay in climax.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by sexual dysfunction characterized by a delay in climax.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Delayed Orgasm, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Delayed orgasm"},{"name":"Maps_To","value":"Delayed Orgasm"},{"name":"NCI_META_CUI","value":"CL541748"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55742":{"preferredName":"Delayed Puberty, CTCAE","code":"C55742","definitions":[{"definition":"A disorder characterized by unusually late sexual maturity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by unusually late sexual maturity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Delayed Puberty, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Delayed_Puberty_Adverse_Event"},{"name":"Maps_To","value":"Delayed puberty"},{"name":"Maps_To","value":"Delayed Puberty"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1883716"}]}}{"C143400":{"preferredName":"Delirium, CTCAE","code":"C143400","definitions":[{"definition":"A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Delirium, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Delirium"},{"name":"NCI_META_CUI","value":"CL541749"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143401":{"preferredName":"Delusions, CTCAE","code":"C143401","definitions":[{"definition":"A disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Delusions, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Delusions"},{"name":"NCI_META_CUI","value":"CL541750"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143402":{"preferredName":"Dental Caries, CTCAE","code":"C143402","definitions":[{"definition":"A disorder characterized by the decay of a tooth, in which it becomes softened, discolored and/or porous.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the decay of a tooth, in which it becomes softened, discolored and/or porous.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dental Caries, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dental caries"},{"name":"Maps_To","value":"Dental Caries"},{"name":"NCI_META_CUI","value":"CL541751"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143403":{"preferredName":"Depressed Level of Consciousness, CTCAE","code":"C143403","definitions":[{"definition":"A disorder characterized by a decrease in ability to perceive and respond.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in ability to perceive and respond.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Depressed Level of Consciousness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Depressed level of consciousness"},{"name":"Maps_To","value":"Depressed Level of Consciousness"},{"name":"NCI_META_CUI","value":"CL541752"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55447":{"preferredName":"Depression, CTCAE","code":"C55447","definitions":[{"definition":"A disorder characterized by melancholic feelings of grief or unhappiness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by melancholic feelings of grief or unhappiness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Depression, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Depression_Adverse_Event"},{"name":"Maps_To","value":"Depression"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1999266"}]}}{"C143405":{"preferredName":"Dermatitis Radiation, CTCAE","code":"C143405","definitions":[{"definition":"A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dermatitis Radiation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dermatitis radiation"},{"name":"Maps_To","value":"Dermatitis Radiation"},{"name":"NCI_META_CUI","value":"CL541753"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143406":{"preferredName":"Device Related Infection, CTCAE","code":"C143406","definitions":[{"definition":"A disorder characterized by an infectious process involving the use of a medical device.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the use of a medical device.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Device Related Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Device related infection"},{"name":"Maps_To","value":"Device Related Infection"},{"name":"NCI_META_CUI","value":"CL541754"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57788":{"preferredName":"Diarrhea, CTCAE","code":"C57788","definitions":[{"definition":"A disorder characterized by an increase in frequency and/or loose or watery bowel movements.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in frequency and/or loose or watery bowel movements.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Diarrhea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Diarrhea_Adverse_Event"},{"name":"Maps_To","value":"Diarrhea"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963091"}]}}{"C55273":{"preferredName":"Disseminated Intravascular Coagulation, CTCAE","code":"C55273","definitions":[{"definition":"A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the risk of hemorrhage as the body is depleted of platelets and coagulation factors.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the risk of hemorrhage as the body is depleted of platelets and coagulation factors.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Disseminated Intravascular Coagulation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Disseminated_Intravascular_Coagulation_Adverse_Event"},{"name":"Maps_To","value":"Disseminated Intravascular Coagulation"},{"name":"Maps_To","value":"Disseminated intravascular coagulation"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963092"}]}}{"C146747":{"preferredName":"Dizziness, CTCAE 5.0","code":"C146747","definitions":[{"definition":"A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dizziness, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dizziness"},{"name":"NCI_META_CUI","value":"CL544801"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143410":{"preferredName":"Dry Eye, CTCAE","code":"C143410","definitions":[{"definition":"A disorder characterized by dryness of the cornea and conjunctiva.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dryness of the cornea and conjunctiva.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dry Eye, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dry eye"},{"name":"Maps_To","value":"Dry Eye"},{"name":"NCI_META_CUI","value":"CL545897"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143411":{"preferredName":"Dry Mouth, CTCAE","code":"C143411","definitions":[{"definition":"A disorder characterized by reduced salivary flow in the oral cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by reduced salivary flow in the oral cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dry Mouth, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dry Mouth"},{"name":"Maps_To","value":"Dry mouth"},{"name":"NCI_META_CUI","value":"CL541740"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57996":{"preferredName":"Dry Skin, CTCAE","code":"C57996","definitions":[{"definition":"A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dry Skin, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dry_Skin_Adverse_Event"},{"name":"Maps_To","value":"Dry Skin"},{"name":"Maps_To","value":"Dry skin"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963094"}]}}{"C57789":{"preferredName":"Duodenal Fistula, CTCAE","code":"C57789","definitions":[{"definition":"A disorder characterized by an abnormal communication between the duodenum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the duodenum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Duodenal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Duodenum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Duodenal Fistula"},{"name":"Maps_To","value":"Duodenal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962984"}]}}{"C143414":{"preferredName":"Duodenal Hemorrhage, CTCAE","code":"C143414","definitions":[{"definition":"A disorder characterized by bleeding from the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal hemorrhage"},{"name":"Maps_To","value":"Duodenal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541741"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143415":{"preferredName":"Duodenal Infection, CTCAE","code":"C143415","definitions":[{"definition":"A disorder characterized by an infectious process involving the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal infection"},{"name":"Maps_To","value":"Duodenal Infection"},{"name":"NCI_META_CUI","value":"CL541742"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143416":{"preferredName":"Duodenal Obstruction, CTCAE","code":"C143416","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of stomach contents through the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of stomach contents through the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Duodenal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal obstruction"},{"name":"Maps_To","value":"Duodenal Obstruction"},{"name":"NCI_META_CUI","value":"CL541743"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143417":{"preferredName":"Duodenal Perforation, CTCAE","code":"C143417","definitions":[{"definition":"A disorder characterized by a rupture in the duodenal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the duodenal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal perforation"},{"name":"Maps_To","value":"Duodenal Perforation"},{"name":"NCI_META_CUI","value":"CL541744"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143418":{"preferredName":"Duodenal Stenosis, CTCAE","code":"C143418","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Duodenal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal stenosis"},{"name":"Maps_To","value":"Duodenal Stenosis"},{"name":"NCI_META_CUI","value":"CL541745"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143419":{"preferredName":"Duodenal Ulcer, CTCAE","code":"C143419","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the duodenal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the duodenal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal ulcer"},{"name":"Maps_To","value":"Duodenal Ulcer"},{"name":"NCI_META_CUI","value":"CL541746"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143420":{"preferredName":"Dysarthria, CTCAE","code":"C143420","definitions":[{"definition":"A disorder characterized by slow and slurred speech resulting from an inability to coordinate the muscles used in speech.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by slow and slurred speech resulting from an inability to coordinate the muscles used in speech.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysarthria, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysarthria"},{"name":"NCI_META_CUI","value":"CL541747"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143421":{"preferredName":"Dysesthesia, CTCAE","code":"C143421","definitions":[{"definition":"A disorder characterized by distortion of sensory perception, resulting in an abnormal and unpleasant sensation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by distortion of sensory perception, resulting in an abnormal and unpleasant sensation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysesthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysesthesia"},{"name":"NCI_META_CUI","value":"CL541733"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143422":{"preferredName":"Dysgeusia, CTCAE","code":"C143422","definitions":[{"definition":"A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysgeusia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysgeusia"},{"name":"NCI_META_CUI","value":"CL541734"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143423":{"preferredName":"Dysmenorrhea, CTCAE","code":"C143423","definitions":[{"definition":"A disorder characterized by abnormally painful abdominal cramps during menses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by abnormally painful abdominal cramps during menses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dysmenorrhea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysmenorrhea"},{"name":"NCI_META_CUI","value":"CL541735"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143424":{"preferredName":"Dyspareunia, CTCAE","code":"C143424","definitions":[{"definition":"A disorder characterized by painful or difficult coitus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by painful or difficult coitus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dyspareunia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dyspareunia"},{"name":"NCI_META_CUI","value":"CL545960"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143425":{"preferredName":"Dyspepsia, CTCAE","code":"C143425","definitions":[{"definition":"A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dyspepsia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dyspepsia"},{"name":"NCI_META_CUI","value":"CL541736"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57795":{"preferredName":"Dysphagia, CTCAE","code":"C57795","definitions":[{"definition":"A disorder characterized by difficulty in swallowing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by difficulty in swallowing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysphagia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dysphagia_Adverse_Event"},{"name":"Maps_To","value":"Dysphagia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560331"}]}}{"C143427":{"preferredName":"Dysphasia, CTCAE","code":"C143427","definitions":[{"definition":"A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysphasia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysphasia"},{"name":"NCI_META_CUI","value":"CL541737"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58185":{"preferredName":"Dyspnea, CTCAE","code":"C58185","definitions":[{"definition":"A disorder characterized by an uncomfortable sensation of difficulty breathing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable sensation of difficulty breathing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dyspnea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dyspnea_Adverse_Event"},{"name":"Maps_To","value":"Dyspnea"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963100"}]}}{"C143429":{"preferredName":"Ear and Labyrinth Disorders - Other, Specify, CTCAE","code":"C143429","synonyms":[{"termName":"Ear and Labyrinth Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ear and Labyrinth Disorders - Other"},{"name":"Maps_To","value":"Ear and labyrinth disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541738"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143430":{"preferredName":"Ear Pain, CTCAE","code":"C143430","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the ear.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the ear.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ear Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ear pain"},{"name":"Maps_To","value":"Ear Pain"},{"name":"NCI_META_CUI","value":"CL541739"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143431":{"preferredName":"Edema Cerebral, CTCAE","code":"C143431","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Edema Cerebral, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema cerebral"},{"name":"Maps_To","value":"Edema Cerebral"},{"name":"NCI_META_CUI","value":"CL541725"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143432":{"preferredName":"Edema Face, CTCAE","code":"C143432","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Edema Face, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema Face"},{"name":"Maps_To","value":"Edema face"},{"name":"NCI_META_CUI","value":"CL541726"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143433":{"preferredName":"Edema Limbs, CTCAE","code":"C143433","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Edema Limbs, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema limbs"},{"name":"Maps_To","value":"Edema Limbs"},{"name":"NCI_META_CUI","value":"CL541727"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143434":{"preferredName":"Edema Trunk, CTCAE","code":"C143434","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Edema Trunk, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema trunk"},{"name":"Maps_To","value":"Edema Trunk"},{"name":"NCI_META_CUI","value":"CL541728"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143435":{"preferredName":"Ejaculation Disorder, CTCAE","code":"C143435","definitions":[{"definition":"A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ejaculation Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Ejaculation disorder"},{"name":"Maps_To","value":"Ejaculation Disorder"},{"name":"NCI_META_CUI","value":"CL541729"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143436":{"preferredName":"Ejection Fraction Decreased, CTCAE","code":"C143436","definitions":[{"definition":"The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ejection Fraction Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ejection fraction decreased"},{"name":"Maps_To","value":"Ejection Fraction Decreased"},{"name":"NCI_META_CUI","value":"CL541730"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143437":{"preferredName":"Electrocardiogram QT Corrected Interval Prolonged, CTCAE","code":"C143437","definitions":[{"definition":"A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Electrocardiogram QT Corrected Interval Prolonged, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrocardiogram QT corrected interval prolonged"},{"name":"Maps_To","value":"Electrocardiogram QT Corrected Interval Prolonged"},{"name":"NCI_META_CUI","value":"CL541731"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143438":{"preferredName":"Encephalitis Infection, CTCAE","code":"C143438","definitions":[{"definition":"A disorder characterized by an infectious process involving the brain tissue.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the brain tissue.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Encephalitis Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encephalitis infection"},{"name":"Maps_To","value":"Encephalitis Infection"},{"name":"NCI_META_CUI","value":"CL541732"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143439":{"preferredName":"Encephalomyelitis Infection, CTCAE","code":"C143439","definitions":[{"definition":"A disorder characterized by an infectious process involving the brain and spinal cord tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the brain and spinal cord tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Encephalomyelitis Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encephalomyelitis infection"},{"name":"Maps_To","value":"Encephalomyelitis Infection"},{"name":"NCI_META_CUI","value":"CL541836"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146699":{"preferredName":"Encephalopathy, CTCAE 5.0","code":"C146699","definitions":[{"definition":"A disorder characterized by a pathologic process involving the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a pathologic process involving the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Encephalopathy, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encephalopathy"},{"name":"NCI_META_CUI","value":"CL544726"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143441":{"preferredName":"Endocarditis Infective, CTCAE","code":"C143441","definitions":[{"definition":"A disorder characterized by an infectious process involving the endocardial layer of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the endocardial layer of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Endocarditis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endocarditis infective"},{"name":"Maps_To","value":"Endocarditis Infective"},{"name":"NCI_META_CUI","value":"CL541837"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143442":{"preferredName":"Endocrine Disorders - Other, Specify, CTCAE","code":"C143442","synonyms":[{"termName":"Endocrine Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endocrine Disorders - Other"},{"name":"Maps_To","value":"Endocrine disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL546037"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143443":{"preferredName":"Endophthalmitis, CTCAE","code":"C143443","definitions":[{"definition":"A disorder characterized by an infectious process involving the internal structures of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the internal structures of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Endophthalmitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endophthalmitis"},{"name":"NCI_META_CUI","value":"CL541838"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143445":{"preferredName":"Enterocolitis, CTCAE","code":"C143445","definitions":[{"definition":"A disorder characterized by inflammation of the small and large intestines.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the small and large intestines.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Enterocolitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterocolitis"},{"name":"NCI_META_CUI","value":"CL541840"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143444":{"preferredName":"Enterocolitis Infectious, CTCAE","code":"C143444","definitions":[{"definition":"A disorder characterized by an infectious process involving the small and large intestines.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the small and large intestines.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Enterocolitis Infectious, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterocolitis Infectious"},{"name":"Maps_To","value":"Enterocolitis infectious"},{"name":"NCI_META_CUI","value":"CL541839"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143446":{"preferredName":"Enterovesical Fistula, CTCAE","code":"C143446","definitions":[{"definition":"A disorder characterized by an abnormal communication between the urinary bladder and the intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the urinary bladder and the intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Enterovesical Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterovesical Fistula"},{"name":"Maps_To","value":"Enterovesical fistula"},{"name":"NCI_META_CUI","value":"CL541841"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143447":{"preferredName":"Epistaxis, CTCAE","code":"C143447","definitions":[{"definition":"A disorder characterized by bleeding from the nose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the nose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Epistaxis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epistaxis"},{"name":"NCI_META_CUI","value":"CL541842"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55615":{"preferredName":"Erectile Dysfunction, CTCAE","code":"C55615","definitions":[{"definition":"A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Erectile Dysfunction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Erectile_Dysfunction_Adverse_Event"},{"name":"Maps_To","value":"Erectile dysfunction"},{"name":"Maps_To","value":"Erectile Dysfunction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1961100"}]}}{"C143449":{"preferredName":"Erythema Multiforme, CTCAE","code":"C143449","definitions":[{"definition":"A disorder characterized by target lesions (a pink-red ring around a pale center).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by target lesions (a pink-red ring around a pale center).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Erythema Multiforme, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Erythema Multiforme"},{"name":"Maps_To","value":"Erythema multiforme"},{"name":"NCI_META_CUI","value":"CL541829"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143450":{"preferredName":"Erythroderma, CTCAE","code":"C143450","definitions":[{"definition":"A disorder characterized by generalized inflammatory erythema and exfoliation. The inflammatory process involves > 90% of the body surface area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by generalized inflammatory erythema and exfoliation. The inflammatory process involves > 90% of the body surface area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Erythroderma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Erythroderma"},{"name":"NCI_META_CUI","value":"CL540990"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143451":{"preferredName":"Esophageal Anastomotic Leak, CTCAE","code":"C143451","definitions":[{"definition":"A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Anastomotic Leak"},{"name":"Maps_To","value":"Esophageal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541830"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57798":{"preferredName":"Esophageal Fistula, CTCAE","code":"C57798","definitions":[{"definition":"A disorder characterized by an abnormal communication between the esophagus and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the esophagus and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Esophagus_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Esophageal fistula"},{"name":"Maps_To","value":"Esophageal Fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963104"}]}}{"C143453":{"preferredName":"Esophageal Hemorrhage, CTCAE","code":"C143453","definitions":[{"definition":"A disorder characterized by bleeding from the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Hemorrhage"},{"name":"Maps_To","value":"Esophageal hemorrhage"},{"name":"NCI_META_CUI","value":"CL541831"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143454":{"preferredName":"Esophageal Infection, CTCAE","code":"C143454","definitions":[{"definition":"A disorder characterized by an infectious process involving the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Infection"},{"name":"Maps_To","value":"Esophageal infection"},{"name":"NCI_META_CUI","value":"CL541832"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143455":{"preferredName":"Esophageal Necrosis, CTCAE","code":"C143455","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the esophageal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the esophageal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Necrosis"},{"name":"Maps_To","value":"Esophageal necrosis"},{"name":"NCI_META_CUI","value":"CL541833"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143456":{"preferredName":"Esophageal Obstruction, CTCAE","code":"C143456","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents in the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents in the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophageal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Obstruction"},{"name":"Maps_To","value":"Esophageal obstruction"},{"name":"NCI_META_CUI","value":"CL541834"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143457":{"preferredName":"Esophageal Pain, CTCAE","code":"C143457","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the esophageal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the esophageal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Pain"},{"name":"Maps_To","value":"Esophageal pain"},{"name":"NCI_META_CUI","value":"CL541835"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143458":{"preferredName":"Esophageal Perforation, CTCAE","code":"C143458","definitions":[{"definition":"A disorder characterized by a rupture in the wall of the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the wall of the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophageal Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Perforation"},{"name":"Maps_To","value":"Esophageal perforation"},{"name":"NCI_META_CUI","value":"CL541821"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143459":{"preferredName":"Esophageal Stenosis, CTCAE","code":"C143459","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophageal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Stenosis"},{"name":"Maps_To","value":"Esophageal stenosis"},{"name":"NCI_META_CUI","value":"CL541822"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143460":{"preferredName":"Esophageal Ulcer, CTCAE","code":"C143460","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the esophageal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the esophageal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophageal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Ulcer"},{"name":"Maps_To","value":"Esophageal ulcer"},{"name":"NCI_META_CUI","value":"CL541823"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146710":{"preferredName":"Esophageal Varices Hemorrhage, CTCAE 5.0","code":"C146710","definitions":[{"definition":"A disorder characterized by bleeding from esophageal varices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from esophageal varices.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Varices Hemorrhage, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Varices Hemorrhage"},{"name":"Maps_To","value":"Esophageal varices hemorrhage"},{"name":"NCI_META_CUI","value":"CL544721"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57797":{"preferredName":"Esophagitis, CTCAE","code":"C57797","definitions":[{"definition":"A disorder characterized by inflammation of the esophageal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the esophageal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophagitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Esophagitis_Adverse_Event"},{"name":"Maps_To","value":"Esophagitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963106"}]}}{"C146748":{"preferredName":"Euphoria, CTCAE 5.0","code":"C146748","definitions":[{"definition":"A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Euphoria, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Euphoria"},{"name":"NCI_META_CUI","value":"CL550637"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146749":{"preferredName":"Exostosis, CTCAE 5.0","code":"C146749","definitions":[{"definition":"A disorder characterized by non-neoplastic overgrowth of bone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by non-neoplastic overgrowth of bone.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Exostosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Exostosis"},{"name":"NCI_META_CUI","value":"CL544802"},{"name":"Semantic_Type","value":"Finding"}]}}{"C79601":{"preferredName":"Otitis Externa","code":"C79601","definitions":[{"definition":"A disorder characterized by inflammation, swelling and redness to the outer ear and ear canal.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the outer ear and/or ear canal.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Otitis Externa","termGroup":"PT","termSource":"NCI"},{"termName":"External Ear Inflammation","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammation of External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammation of the External Auditory Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"External_Ear_Inflammation"},{"name":"Maps_To","value":"External Ear Inflammation"},{"name":"Maps_To","value":"Otitis externa"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0029878"}]}}{"C146745":{"preferredName":"External Ear Pain, CTCAE 5.0","code":"C146745","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the external ear region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the external ear region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"External Ear Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"External ear pain"},{"name":"Maps_To","value":"External Ear Pain"},{"name":"NCI_META_CUI","value":"CL544692"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143466":{"preferredName":"Extraocular Muscle Paresis, CTCAE","code":"C143466","definitions":[{"definition":"A disorder characterized by incomplete paralysis of an extraocular muscle.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by incomplete paralysis of an extraocular muscle.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Extraocular Muscle Paresis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extraocular Muscle Paresis"},{"name":"Maps_To","value":"Extraocular muscle paresis"},{"name":"NCI_META_CUI","value":"CL541824"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143467":{"preferredName":"Extrapyramidal Disorder, CTCAE","code":"C143467","definitions":[{"definition":"A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Extrapyramidal Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extrapyramidal Disorder"},{"name":"Maps_To","value":"Extrapyramidal disorder"},{"name":"NCI_META_CUI","value":"CL541825"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143468":{"preferredName":"Eye Disorders - Other, Specify, CTCAE","code":"C143468","synonyms":[{"termName":"Eye Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eye Disorders - Other"},{"name":"Maps_To","value":"Eye disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541826"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143469":{"preferredName":"Eye Infection, CTCAE","code":"C143469","definitions":[{"definition":"A disorder characterized by an infectious process involving the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Eye Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eye Infection"},{"name":"Maps_To","value":"Eye infection"},{"name":"NCI_META_CUI","value":"CL541827"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146751":{"preferredName":"Eye Pain, CTCAE 5.0","code":"C146751","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Eye Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eye Pain"},{"name":"Maps_To","value":"Eye pain"},{"name":"NCI_META_CUI","value":"CL544803"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143471":{"preferredName":"Eyelid Function Disorder, CTCAE","code":"C143471","definitions":[{"definition":"A disorder characterized by impaired eyelid function.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by impaired eyelid function.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Eyelid Function Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eyelid Function Disorder"},{"name":"Maps_To","value":"Eyelid function disorder"},{"name":"NCI_META_CUI","value":"CL541828"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143472":{"preferredName":"Facial Muscle Weakness, CTCAE","code":"C143472","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the facial muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the facial muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Facial Muscle Weakness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Facial Muscle Weakness"},{"name":"Maps_To","value":"Facial muscle weakness"},{"name":"NCI_META_CUI","value":"CL541814"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143473":{"preferredName":"Facial Nerve Disorder, CTCAE","code":"C143473","definitions":[{"definition":"A disorder characterized by dysfunction of the facial nerve (seventh cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the facial nerve (seventh cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Facial Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Facial Nerve Disorder"},{"name":"Maps_To","value":"Facial nerve disorder"},{"name":"NCI_META_CUI","value":"CL541815"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143474":{"preferredName":"Facial Pain, CTCAE","code":"C143474","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the face.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the face.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Facial Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Facial Pain"},{"name":"Maps_To","value":"Facial pain"},{"name":"NCI_META_CUI","value":"CL541816"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143475":{"preferredName":"Fall, CTCAE","code":"C143475","definitions":[{"definition":"A finding of sudden movement downward, usually resulting in injury.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of sudden movement downward, usually resulting in injury.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fall, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fall"},{"name":"NCI_META_CUI","value":"CL546052"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143476":{"preferredName":"Fallopian Tube Anastomotic Leak, CTCAE","code":"C143476","definitions":[{"definition":"A finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fallopian Tube Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fallopian Tube Anastomotic Leak"},{"name":"Maps_To","value":"Fallopian tube anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541817"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146752":{"preferredName":"Fallopian Tube Obstruction, CTCAE 5.0","code":"C146752","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fallopian Tube Obstruction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fallopian Tube Obstruction"},{"name":"Maps_To","value":"Fallopian tube obstruction"},{"name":"NCI_META_CUI","value":"CL544804"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146714":{"preferredName":"Fallopian Tube Perforation, CTCAE 5.0","code":"C146714","definitions":[{"definition":"A disorder characterized by a rupture of the fallopian tube wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture of the fallopian tube wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fallopian Tube Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fallopian tube perforation"},{"name":"Maps_To","value":"Fallopian Tube Perforation"},{"name":"NCI_META_CUI","value":"CL544709"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78295":{"preferredName":"Fallopian Tube Stenosis","code":"C78295","definitions":[{"definition":"A disorder characterized by a narrowing of the fallopian tube lumen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Narrowing of the lumen of the fallopian tube.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fallopian Tube Stenosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fallopian_Tube_Stenosis"},{"name":"Maps_To","value":"Fallopian Tube Stenosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0459524"}]}}{"C143479":{"preferredName":"Fat Atrophy, CTCAE","code":"C143479","definitions":[{"definition":"A disorder characterized by shrinking of adipose tissue.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by shrinking of adipose tissue.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fat Atrophy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fat Atrophy"},{"name":"Maps_To","value":"Fat atrophy"},{"name":"NCI_META_CUI","value":"CL541818"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146753":{"preferredName":"Fatigue, CTCAE 5.0","code":"C146753","definitions":[{"definition":"A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fatigue, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Fatigue"},{"name":"NCI_META_CUI","value":"CL550640"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143481":{"preferredName":"Febrile Neutropenia, CTCAE","code":"C143481","definitions":[{"definition":"A disorder characterized by an ANC <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an ANC <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Febrile Neutropenia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Febrile Neutropenia"},{"name":"Maps_To","value":"Febrile neutropenia"},{"name":"NCI_META_CUI","value":"CL541819"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143482":{"preferredName":"Fecal Incontinence, CTCAE","code":"C143482","definitions":[{"definition":"A disorder characterized by inability to control the escape of stool from the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inability to control the escape of stool from the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fecal Incontinence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Fecal Incontinence"},{"name":"Maps_To","value":"Fecal incontinence"},{"name":"NCI_META_CUI","value":"CL541820"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78298":{"preferredName":"Female Genital Tract Fistula","code":"C78298","definitions":[{"definition":"A disorder characterized by an abnormal communication between a female reproductive system organ and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An abnormal communication between a female reproductive system organ and another organ or cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Genital Tract Fistula","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Female_Genital_Tract_Fistula"},{"name":"Maps_To","value":"Female Genital Tract Fistula"},{"name":"Semantic_Type","value":"Anatomical Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0269131"}]}}{"C143483":{"preferredName":"Feminization Acquired, CTCAE","code":"C143483","definitions":[{"definition":"A disorder characterized by the development of secondary female sex characteristics in males due to extrinsic factors.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the development of secondary female sex characteristics in males due to extrinsic factors.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Feminization Acquired, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Feminization Acquired"},{"name":"Maps_To","value":"Feminization acquired"},{"name":"NCI_META_CUI","value":"CL541807"},{"name":"Semantic_Type","value":"Finding"}]}}{"C50620":{"preferredName":"Intrauterine Fetal Death","code":"C50620","definitions":[{"definition":"A disorder characterized by death in utero; failure of the product of conception to show evidence of respiration, heartbeat, or definite movement of a voluntary muscle after expulsion from the uterus, without possibility of resuscitation.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Death in utero; failure of the product of conception to show evidence of respiration, heart beat, or definite movement of a voluntary muscle after expulsion from the uterus, with no possibility of resuscitation.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Death of a conceptus that occurred inside the uterus.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Death of a fetus after 10 weeks gestation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Death of a fetus after 10 weeks gestation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Intrauterine Fetal Death","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Death","termGroup":"SY","termSource":"NCI"},{"termName":"Fetal Demise","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Intrauterine_Fetal_Death"},{"name":"Maps_To","value":"Fetal death"},{"name":"Maps_To","value":"Fetal Death"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0015927"},{"name":"xRef","value":"IMDRF:F0201"}]}}{"C143484":{"preferredName":"Fetal Growth Retardation, CTCAE","code":"C143484","definitions":[{"definition":"A disorder characterized by inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fetal Growth Retardation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fetal Growth Retardation"},{"name":"Maps_To","value":"Fetal growth retardation"},{"name":"NCI_META_CUI","value":"CL546012"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143485":{"preferredName":"Fever, CTCAE","code":"C143485","definitions":[{"definition":"A disorder characterized by elevation of the body's temperature above the upper limit of normal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by elevation of the body's temperature above the upper limit of normal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fever, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fever"},{"name":"NCI_META_CUI","value":"CL541808"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143486":{"preferredName":"Fibrinogen Decreased, CTCAE","code":"C143486","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fibrinogen Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fibrinogen Decreased"},{"name":"Maps_To","value":"Fibrinogen decreased"},{"name":"NCI_META_CUI","value":"CL541809"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143487":{"preferredName":"Fibrosis Deep Connective Tissue, CTCAE","code":"C143487","definitions":[{"definition":"A disorder characterized by fibrotic degeneration of the deep connective tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by fibrotic degeneration of the deep connective tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fibrosis Deep Connective Tissue, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fibrosis Deep Connective Tissue"},{"name":"Maps_To","value":"Fibrosis deep connective tissue"},{"name":"NCI_META_CUI","value":"CL541810"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143488":{"preferredName":"Flank Pain, CTCAE","code":"C143488","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Flank Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flank Pain"},{"name":"Maps_To","value":"Flank pain"},{"name":"NCI_META_CUI","value":"CL541811"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143489":{"preferredName":"Flashing Lights, CTCAE","code":"C143489","definitions":[{"definition":"A disorder characterized by a sudden or brief burst of light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sudden or brief burst of light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Flashing Lights, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flashing Lights"},{"name":"Maps_To","value":"Flashing lights"},{"name":"NCI_META_CUI","value":"CL541812"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57807":{"preferredName":"Flatulence, CTCAE","code":"C57807","definitions":[{"definition":"A disorder characterized by a discharge of excessive gas from the lower GI tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a discharge of excessive gas from the lower GI tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Flatulence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Flatulence_Adverse_Event"},{"name":"Maps_To","value":"Flatulence"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962956"}]}}{"C143491":{"preferredName":"Floaters, CTCAE","code":"C143491","definitions":[{"definition":"A disorder characterized by an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Floaters, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Floaters"},{"name":"NCI_META_CUI","value":"CL541813"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143492":{"preferredName":"Flu Like Symptoms, CTCAE","code":"C143492","definitions":[{"definition":"A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry cough.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry cough.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Flu Like Symptoms, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flu Like Symptoms"},{"name":"Maps_To","value":"Flu like symptoms"},{"name":"NCI_META_CUI","value":"CL541799"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146643":{"preferredName":"Flushing, CTCAE 5.0","code":"C146643","definitions":[{"definition":"A disorder characterized by episodic reddening of the skin, especially face, neck, or chest.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by episodic reddening of the skin, especially face, neck, or chest.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Flushing, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flushing"},{"name":"NCI_META_CUI","value":"CL545971"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143494":{"preferredName":"Forced Expiratory Volume Decreased, CTCAE","code":"C143494","definitions":[{"definition":"A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Forced Expiratory Volume Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Forced Expiratory Volume Decreased"},{"name":"Maps_To","value":"Forced expiratory volume decreased"},{"name":"NCI_META_CUI","value":"CL541800"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58382":{"preferredName":"Fracture, CTCAE","code":"C58382","definitions":[{"definition":"A finding of traumatic injury to the bone in which the continuity of the bone is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of traumatic injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fracture_Adverse_Event"},{"name":"Maps_To","value":"Fracture"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963113"}]}}{"C143496":{"preferredName":"Gait Disturbance, CTCAE","code":"C143496","definitions":[{"definition":"A disorder characterized by walking difficulties.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by walking difficulties.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gait Disturbance, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gait Disturbance"},{"name":"Maps_To","value":"Gait disturbance"},{"name":"NCI_META_CUI","value":"CL541801"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57808":{"preferredName":"Gallbladder Fistula, CTCAE","code":"C57808","definitions":[{"definition":"A disorder characterized by an abnormal communication between the gallbladder and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the gallbladder and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gallbladder_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Gallbladder Fistula"},{"name":"Maps_To","value":"Gallbladder fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963110"}]}}{"C143497":{"preferredName":"Gallbladder Infection, CTCAE","code":"C143497","definitions":[{"definition":"A disorder characterized by an infectious process involving the gallbladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the gallbladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder Infection"},{"name":"Maps_To","value":"Gallbladder infection"},{"name":"NCI_META_CUI","value":"CL541802"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146735":{"preferredName":"Gallbladder Necrosis, CTCAE 5.0","code":"C146735","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the gallbladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the gallbladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Necrosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder Necrosis"},{"name":"Maps_To","value":"Gallbladder necrosis"},{"name":"NCI_META_CUI","value":"CL544698"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57810":{"preferredName":"Gallbladder Obstruction, CTCAE","code":"C57810","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents of the gallbladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents of the gallbladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gallbladder_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Gallbladder Obstruction"},{"name":"Maps_To","value":"Gallbladder obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1964021"}]}}{"C146755":{"preferredName":"Gallbladder Pain, CTCAE 5.0","code":"C146755","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the gallbladder region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the gallbladder region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder pain"},{"name":"Maps_To","value":"Gallbladder Pain"},{"name":"NCI_META_CUI","value":"CL544793"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146708":{"preferredName":"Gallbladder Perforation, CTCAE 5.0","code":"C146708","definitions":[{"definition":"A disorder characterized by a rupture in the gallbladder wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the gallbladder wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder Perforation"},{"name":"Maps_To","value":"Gallbladder perforation"},{"name":"NCI_META_CUI","value":"CL544719"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143498":{"preferredName":"Gastric Anastomotic Leak, CTCAE","code":"C143498","definitions":[{"definition":"A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Anastomotic Leak"},{"name":"Maps_To","value":"Gastric anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541803"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143499":{"preferredName":"Gastric Fistula, CTCAE","code":"C143499","definitions":[{"definition":"A disorder characterized by an abnormal communication between the stomach and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the stomach and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Fistula"},{"name":"Maps_To","value":"Gastric fistula"},{"name":"NCI_META_CUI","value":"CL541804"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143500":{"preferredName":"Gastric Hemorrhage, CTCAE","code":"C143500","definitions":[{"definition":"A disorder characterized by bleeding from the gastric wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the gastric wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Hemorrhage"},{"name":"Maps_To","value":"Gastric hemorrhage"},{"name":"NCI_META_CUI","value":"CL541805"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143501":{"preferredName":"Gastric Necrosis, CTCAE","code":"C143501","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the gastric wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the gastric wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Necrosis"},{"name":"Maps_To","value":"Gastric necrosis"},{"name":"NCI_META_CUI","value":"CL541806"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143502":{"preferredName":"Gastric Perforation, CTCAE","code":"C143502","definitions":[{"definition":"A disorder characterized by a rupture in the stomach wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the stomach wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastric Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Perforation"},{"name":"Maps_To","value":"Gastric perforation"},{"name":"NCI_META_CUI","value":"CL541791"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143503":{"preferredName":"Gastric Stenosis, CTCAE","code":"C143503","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Stenosis"},{"name":"Maps_To","value":"Gastric stenosis"},{"name":"NCI_META_CUI","value":"CL541792"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143504":{"preferredName":"Gastric Ulcer, CTCAE","code":"C143504","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Ulcer"},{"name":"Maps_To","value":"Gastric ulcer"},{"name":"NCI_META_CUI","value":"CL541793"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57812":{"preferredName":"Gastritis, CTCAE","code":"C57812","definitions":[{"definition":"A disorder characterized by inflammation of the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastritis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastritis_Adverse_Event"},{"name":"Maps_To","value":"Gastritis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560435"}]}}{"C143506":{"preferredName":"Gastroesophageal Reflux Disease, CTCAE","code":"C143506","definitions":[{"definition":"A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastroesophageal Reflux Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastroesophageal Reflux Disease"},{"name":"Maps_To","value":"Gastroesophageal reflux disease"},{"name":"NCI_META_CUI","value":"CL541794"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143507":{"preferredName":"Gastrointestinal Anastomotic Leak, CTCAE","code":"C143507","definitions":[{"definition":"A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastrointestinal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Anastomotic Leak"},{"name":"Maps_To","value":"Gastrointestinal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541795"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143508":{"preferredName":"Gastrointestinal Disorders - Other, Specify, CTCAE","code":"C143508","synonyms":[{"termName":"Gastrointestinal Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Disorders - Other"},{"name":"Maps_To","value":"Gastrointestinal disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541796"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146637":{"preferredName":"Gastrointestinal Fistula, CTCAE 5.0","code":"C146637","definitions":[{"definition":"A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastrointestinal Fistula, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Fistula"},{"name":"Maps_To","value":"Gastrointestinal fistula"},{"name":"NCI_META_CUI","value":"CL544669"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143510":{"preferredName":"Gastrointestinal Pain, CTCAE","code":"C143510","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastrointestinal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Pain"},{"name":"Maps_To","value":"Gastrointestinal pain"},{"name":"NCI_META_CUI","value":"CL541797"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143511":{"preferredName":"Gastrointestinal Stoma Necrosis, CTCAE","code":"C143511","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the gastrointestinal tract stoma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the gastrointestinal tract stoma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastrointestinal Stoma Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Stoma Necrosis"},{"name":"Maps_To","value":"Gastrointestinal stoma necrosis"},{"name":"NCI_META_CUI","value":"CL541798"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143512":{"preferredName":"Gastroparesis, CTCAE","code":"C143512","definitions":[{"definition":"A disorder characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastroparesis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastroparesis"},{"name":"NCI_META_CUI","value":"CL541783"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143513":{"preferredName":"General Disorders and Administration Site Conditions - Other, Specify, CTCAE","code":"C143513","synonyms":[{"termName":"General Disorders and Administration Site Conditions - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"General Disorders and Administration Site Conditions - Other"},{"name":"Maps_To","value":"General disorders and administration site conditions - Other, specify"},{"name":"NCI_META_CUI","value":"CL541784"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143514":{"preferredName":"Generalized Muscle Weakness, CTCAE","code":"C143514","definitions":[{"definition":"A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Generalized Muscle Weakness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Generalized Muscle Weakness"},{"name":"Maps_To","value":"Generalized muscle weakness"},{"name":"NCI_META_CUI","value":"CL541785"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143515":{"preferredName":"Genital Edema, CTCAE","code":"C143515","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the genitals.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the genitals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Genital Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genital Edema"},{"name":"Maps_To","value":"Genital edema"},{"name":"NCI_META_CUI","value":"CL541786"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143516":{"preferredName":"GGT Increased, CTCAE","code":"C143516","definitions":[{"definition":"A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"GGT Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GGT Increased"},{"name":"Maps_To","value":"GGT increased"},{"name":"NCI_META_CUI","value":"CL541787"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146626":{"preferredName":"Gingival Pain, CTCAE","code":"C146626","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the gingival region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the gingival region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gingival Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gingival Pain"},{"name":"Maps_To","value":"Gingival pain"},{"name":"NCI_META_CUI","value":"CL544673"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55842":{"preferredName":"Glaucoma, CTCAE","code":"C55842","definitions":[{"definition":"A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Glaucoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glaucoma_Adverse_Event"},{"name":"Maps_To","value":"Glaucoma"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962986"}]}}{"C143518":{"preferredName":"Glossopharyngeal Nerve Disorder, CTCAE","code":"C143518","definitions":[{"definition":"A disorder characterized by dysfunction of the glossopharyngeal nerve (ninth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the glossopharyngeal nerve (ninth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Glossopharyngeal Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glossopharyngeal Nerve Disorder"},{"name":"Maps_To","value":"Glossopharyngeal nerve disorder"},{"name":"NCI_META_CUI","value":"CL541788"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143519":{"preferredName":"Glucose Intolerance, CTCAE","code":"C143519","definitions":[{"definition":"A disorder characterized by an inability to properly metabolize glucose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inability to properly metabolize glucose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Glucose Intolerance, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glucose Intolerance"},{"name":"Maps_To","value":"Glucose intolerance"},{"name":"NCI_META_CUI","value":"CL541789"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143520":{"preferredName":"Growth Accelerated, CTCAE","code":"C143520","definitions":[{"definition":"A disorder characterized by greater growth than expected for age.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by greater growth than expected for age.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Growth Accelerated, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Growth Accelerated"},{"name":"Maps_To","value":"Growth accelerated"},{"name":"NCI_META_CUI","value":"CL541790"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143521":{"preferredName":"Growth Hormone Abnormal, CTCAE","code":"C143521","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Growth Hormone Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Growth Hormone Abnormal"},{"name":"Maps_To","value":"Growth hormone abnormal"},{"name":"NCI_META_CUI","value":"CL541895"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143522":{"preferredName":"Growth Suppression, CTCAE","code":"C143522","definitions":[{"definition":"A disorder characterized by stature that is smaller than normal as expected for age.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by stature that is smaller than normal as expected for age.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Growth Suppression, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Growth Suppression"},{"name":"Maps_To","value":"Growth suppression"},{"name":"NCI_META_CUI","value":"CL541896"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143523":{"preferredName":"Gum Infection, CTCAE","code":"C143523","definitions":[{"definition":"A disorder characterized by an infectious process involving the gums.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the gums.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gum Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gum Infection"},{"name":"Maps_To","value":"Gum infection"},{"name":"NCI_META_CUI","value":"CL541897"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146685":{"preferredName":"Gynecomastia, CTCAE 5.0","code":"C146685","definitions":[{"definition":"A disorder characterized by excessive development of the breasts in males.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive development of the breasts in males.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gynecomastia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Gynecomastia"},{"name":"NCI_META_CUI","value":"CL544743"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143525":{"preferredName":"Hallucinations, CTCAE","code":"C143525","definitions":[{"definition":"A disorder characterized by a false sensory perception in the absence of an external stimulus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a false sensory perception in the absence of an external stimulus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hallucinations, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hallucinations"},{"name":"NCI_META_CUI","value":"CL541898"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143526":{"preferredName":"Haptoglobin Decreased, CTCAE","code":"C143526","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Haptoglobin Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Haptoglobin Decreased"},{"name":"Maps_To","value":"Haptoglobin decreased"},{"name":"NCI_META_CUI","value":"CL541899"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58383":{"preferredName":"Head Soft Tissue Necrosis, CTCAE","code":"C58383","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the head.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the head.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Head Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Head_Soft_Tissue_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Head Soft Tissue Necrosis"},{"name":"Maps_To","value":"Head soft tissue necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963121"}]}}{"C143527":{"preferredName":"Headache, CTCAE","code":"C143527","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Headache, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Headache"},{"name":"NCI_META_CUI","value":"CL541900"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143528":{"preferredName":"Hearing Impaired, CTCAE","code":"C143528","definitions":[{"definition":"A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hearing Impaired, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hearing Impaired"},{"name":"Maps_To","value":"Hearing impaired"},{"name":"NCI_META_CUI","value":"CL545983"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143529":{"preferredName":"Heart Failure, CTCAE","code":"C143529","definitions":[{"definition":"A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Heart Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heart Failure"},{"name":"Maps_To","value":"Heart failure"},{"name":"NCI_META_CUI","value":"CL541901"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56539":{"preferredName":"Hematoma, CTCAE","code":"C56539","definitions":[{"definition":"A disorder characterized by a localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hematoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hematoma_Adverse_Event"},{"name":"Maps_To","value":"Hematoma"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962958"}]}}{"C143531":{"preferredName":"Hematosalpinx, CTCAE","code":"C143531","definitions":[{"definition":"A disorder characterized by the presence of blood in a fallopian tube.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the presence of blood in a fallopian tube.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hematosalpinx, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hematosalpinx"},{"name":"NCI_META_CUI","value":"CL541887"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143532":{"preferredName":"Hematuria, CTCAE","code":"C143532","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate blood in the urine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate blood in the urine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hematuria, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Hematuria"},{"name":"NCI_META_CUI","value":"CL541888"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143533":{"preferredName":"Hemoglobin Increased, CTCAE","code":"C143533","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of hemoglobin above normal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate increased levels of hemoglobin above normal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemoglobin Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemoglobin Increased"},{"name":"Maps_To","value":"Hemoglobin increased"},{"name":"NCI_META_CUI","value":"CL541889"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146768":{"preferredName":"Hemoglobinuria, CTCAE 5.0","code":"C146768","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemoglobinuria, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemoglobinuria"},{"name":"NCI_META_CUI","value":"CL544790"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55992":{"preferredName":"Hemolysis, CTCAE","code":"C55992","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate widespread erythrocyte cell membrane destruction.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate widespread erythrocyte cell membrane destruction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hemolysis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemolysis_Adverse_Event"},{"name":"Maps_To","value":"Hemolysis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560209"}]}}{"C143536":{"preferredName":"Hemolytic Uremic Syndrome, CTCAE","code":"C143536","definitions":[{"definition":"A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemolytic Uremic Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemolytic Uremic Syndrome"},{"name":"Maps_To","value":"Hemolytic uremic syndrome"},{"name":"NCI_META_CUI","value":"CL541890"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143537":{"preferredName":"Hemorrhoidal Hemorrhage, CTCAE","code":"C143537","definitions":[{"definition":"A disorder characterized by bleeding from the hemorrhoids.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the hemorrhoids.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemorrhoidal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemorrhoidal Hemorrhage"},{"name":"Maps_To","value":"Hemorrhoidal hemorrhage"},{"name":"NCI_META_CUI","value":"CL541891"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146738":{"preferredName":"Hemorrhoids, CTCAE 5.0","code":"C146738","definitions":[{"definition":"A disorder characterized by the presence of dilated veins in the rectum and surrounding area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the presence of dilated veins in the rectum and surrounding area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hemorrhoids, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Hemorrhoids"},{"name":"NCI_META_CUI","value":"CL544700"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143539":{"preferredName":"Hepatic Failure, CTCAE","code":"C143539","definitions":[{"definition":"A disorder characterized by the inability of the liver to metabolize chemicals in the body. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, alkaline phosphatase, aminotransferase, and/or prolongation of prothrombin time (INR.) Drug-induced liever injury (DILI) as defined by Hy's Law.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the inability of the liver to metabolize chemicals in the body. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, alkaline phosphatase, aminotransferase, and/or prolongation of prothrombin time (INR.) Drug-induced liever injury (DILI) as defined by Hy's Law.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hepatic Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic Failure"},{"name":"Maps_To","value":"Hepatic failure"},{"name":"NCI_META_CUI","value":"CL541892"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143540":{"preferredName":"Hepatic Hemorrhage, CTCAE","code":"C143540","definitions":[{"definition":"A disorder characterized by bleeding from the liver.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the liver.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hepatic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic hemorrhage"},{"name":"Maps_To","value":"Hepatic Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541893"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143541":{"preferredName":"Hepatic Infection, CTCAE","code":"C143541","definitions":[{"definition":"A disorder characterized by an infectious process involving the liver.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the liver.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hepatic Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic infection"},{"name":"Maps_To","value":"Hepatic Infection"},{"name":"NCI_META_CUI","value":"CL541894"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146736":{"preferredName":"Hepatic Necrosis, CTCAE 5.0","code":"C146736","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the hepatic parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the hepatic parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hepatic Necrosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic Necrosis"},{"name":"Maps_To","value":"Hepatic necrosis"},{"name":"NCI_META_CUI","value":"CL544699"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143542":{"preferredName":"Hepatic Pain, CTCAE","code":"C143542","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the liver region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the liver region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hepatic Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic pain"},{"name":"Maps_To","value":"Hepatic Pain"},{"name":"NCI_META_CUI","value":"CL541880"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143543":{"preferredName":"Hepatitis Viral, CTCAE","code":"C143543","definitions":[{"definition":"A disorder characterized by a viral pathologic process involving the liver parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a viral pathologic process involving the liver parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hepatitis Viral, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatitis viral"},{"name":"Maps_To","value":"Hepatitis Viral"},{"name":"NCI_META_CUI","value":"CL541881"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143544":{"preferredName":"Hepatobiliary Disorders - Other, Specify, CTCAE","code":"C143544","synonyms":[{"termName":"Hepatobiliary Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatobiliary Disorders - Other"},{"name":"Maps_To","value":"Hepatobiliary disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541882"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143545":{"preferredName":"Hiccups, CTCAE","code":"C143545","definitions":[{"definition":"A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hiccups, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hiccups"},{"name":"NCI_META_CUI","value":"CL541883"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143546":{"preferredName":"Hip Fracture, CTCAE","code":"C143546","definitions":[{"definition":"A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hip Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hip fracture"},{"name":"Maps_To","value":"Hip Fracture"},{"name":"NCI_META_CUI","value":"CL541884"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143547":{"preferredName":"Hirsutism, CTCAE","code":"C143547","definitions":[{"definition":"A disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hirsutism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hirsutism"},{"name":"NCI_META_CUI","value":"CL541885"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143548":{"preferredName":"Hoarseness, CTCAE","code":"C143548","definitions":[{"definition":"A disorder characterized by harsh and raspy voice arising from or spreading to the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by harsh and raspy voice arising from or spreading to the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hoarseness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hoarseness"},{"name":"NCI_META_CUI","value":"CL541886"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143549":{"preferredName":"Hot Flashes, CTCAE","code":"C143549","definitions":[{"definition":"A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hot Flashes, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Hot Flashes"},{"name":"Maps_To","value":"Hot flashes"},{"name":"NCI_META_CUI","value":"CL545907"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55401":{"preferredName":"Hydrocephalus, CTCAE","code":"C55401","definitions":[{"definition":"A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hydrocephalus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hydrocephalus_Adverse_Event"},{"name":"Maps_To","value":"Hydrocephalus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963137"}]}}{"C143551":{"preferredName":"Hypercalcemia, CTCAE","code":"C143551","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypercalcemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypercalcemia"},{"name":"NCI_META_CUI","value":"CL541874"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143552":{"preferredName":"Hyperglycemia, CTCAE","code":"C143552","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperglycemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperglycemia"},{"name":"NCI_META_CUI","value":"CL541875"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143553":{"preferredName":"Hyperhidrosis, CTCAE","code":"C143553","definitions":[{"definition":"A disorder characterized by excessive sweating.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive sweating.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hyperhidrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperhidrosis"},{"name":"NCI_META_CUI","value":"CL541876"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143554":{"preferredName":"Hyperkalemia, CTCAE","code":"C143554","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperkalemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperkalemia"},{"name":"NCI_META_CUI","value":"CL541877"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143555":{"preferredName":"Hypermagnesemia, CTCAE","code":"C143555","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypermagnesemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypermagnesemia"},{"name":"NCI_META_CUI","value":"CL546021"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143556":{"preferredName":"Hypernatremia, CTCAE","code":"C143556","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypernatremia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypernatremia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0020488"}]}}{"C143557":{"preferredName":"Hyperparathyroidism, CTCAE","code":"C143557","definitions":[{"definition":"A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hyperparathyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperparathyroidism"},{"name":"NCI_META_CUI","value":"CL541878"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143558":{"preferredName":"Hypersomnia, CTCAE","code":"C143558","definitions":[{"definition":"A disorder characterized by characterized by excessive sleepiness during the daytime.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by characterized by excessive sleepiness during the daytime.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypersomnia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypersomnia"},{"name":"NCI_META_CUI","value":"CL541879"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55060":{"preferredName":"Hypertension, CTCAE","code":"C55060","definitions":[{"definition":"A disorder characterized by a pathological increase in blood pressure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a pathological increase in blood pressure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypertension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypertension_Adverse_Event"},{"name":"Maps_To","value":"Hypertension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963138"}]}}{"C143560":{"preferredName":"Hyperthyroidism, CTCAE","code":"C143560","definitions":[{"definition":"A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperthyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperthyroidism"},{"name":"NCI_META_CUI","value":"CL541866"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143561":{"preferredName":"Hypertrichosis, CTCAE","code":"C143561","definitions":[{"definition":"A disorder characterized by hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypertrichosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypertrichosis"},{"name":"NCI_META_CUI","value":"CL541867"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143562":{"preferredName":"Hypertriglyceridemia, CTCAE","code":"C143562","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypertriglyceridemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypertriglyceridemia"},{"name":"NCI_META_CUI","value":"CL541868"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143563":{"preferredName":"Hyperuricemia, CTCAE","code":"C143563","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperuricemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperuricemia"},{"name":"NCI_META_CUI","value":"CL541869"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143564":{"preferredName":"Hypoalbuminemia, CTCAE","code":"C143564","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoalbuminemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoalbuminemia"},{"name":"NCI_META_CUI","value":"CL541870"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143565":{"preferredName":"Hypocalcemia, CTCAE","code":"C143565","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypocalcemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypocalcemia"},{"name":"NCI_META_CUI","value":"CL541871"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143566":{"preferredName":"Hypoglossal Nerve Disorder, CTCAE","code":"C143566","definitions":[{"definition":"A disorder characterized by dysfunction of the hypoglossal nerve (twelfth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the hypoglossal nerve (twelfth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoglossal Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoglossal Nerve Disorder"},{"name":"Maps_To","value":"Hypoglossal nerve disorder"},{"name":"NCI_META_CUI","value":"CL541872"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143567":{"preferredName":"Hypoglycemia, CTCAE","code":"C143567","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoglycemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoglycemia"},{"name":"NCI_META_CUI","value":"CL541873"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143568":{"preferredName":"Hypohidrosis, CTCAE","code":"C143568","definitions":[{"definition":"A disorder characterized by reduced sweating.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by reduced sweating.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypohidrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypohidrosis"},{"name":"NCI_META_CUI","value":"CL541859"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143569":{"preferredName":"Hypokalemia, CTCAE","code":"C143569","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypokalemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypokalemia"},{"name":"NCI_META_CUI","value":"CL541860"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143570":{"preferredName":"Hypomagnesemia, CTCAE","code":"C143570","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypomagnesemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypomagnesemia"},{"name":"NCI_META_CUI","value":"CL541861"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143571":{"preferredName":"Hyponatremia, CTCAE","code":"C143571","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hyponatremia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyponatremia"},{"name":"NCI_META_CUI","value":"CL541862"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143572":{"preferredName":"Hypoparathyroidism, CTCAE","code":"C143572","definitions":[{"definition":"A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoparathyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoparathyroidism"},{"name":"NCI_META_CUI","value":"CL541863"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143573":{"preferredName":"Hypophosphatemia, CTCAE","code":"C143573","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypophosphatemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypophosphatemia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0595888"}]}}{"C55061":{"preferredName":"Hypotension, CTCAE","code":"C55061","definitions":[{"definition":"A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypotension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypotension_Adverse_Event"},{"name":"Maps_To","value":"Hypotension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3163620"}]}}{"C55332":{"preferredName":"Hypothermia, CTCAE","code":"C55332","definitions":[{"definition":"A disorder characterized by an abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypothermia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypothermia_Adverse_Event"},{"name":"Maps_To","value":"Hypothermia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963170"}]}}{"C143576":{"preferredName":"Hypothyroidism, CTCAE","code":"C143576","definitions":[{"definition":"A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypothyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypothyroidism"},{"name":"NCI_META_CUI","value":"CL541864"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58188":{"preferredName":"Hypoxia, CTCAE","code":"C58188","definitions":[{"definition":"A disorder characterized by a decrease in the level of oxygen in the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in the level of oxygen in the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoxia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypoxia_Adverse_Event"},{"name":"Maps_To","value":"Hypoxia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963140"}]}}{"C57821":{"preferredName":"Ileal Fistula, CTCAE","code":"C57821","definitions":[{"definition":"A disorder characterized by an abnormal communication between the ileum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the ileum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Ileal Fistula"},{"name":"Maps_To","value":"Ileal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1397399"}]}}{"C56542":{"preferredName":"Ileal Hemorrhage, CTCAE","code":"C56542","definitions":[{"definition":"A disorder characterized by bleeding from the ileal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the ileal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Ileal Hemorrhage"},{"name":"Maps_To","value":"Ileal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963142"}]}}{"C57823":{"preferredName":"Ileal Obstruction, CTCAE","code":"C57823","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the ileum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the ileum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Ileal Obstruction"},{"name":"Maps_To","value":"Ileal obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1400387"}]}}{"C146633":{"preferredName":"Ileal Perforation, CTCAE 5.0","code":"C146633","definitions":[{"definition":"A disorder characterized by a rupture in the ileal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the ileal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ileal perforation"},{"name":"Maps_To","value":"Ileal Perforation"},{"name":"NCI_META_CUI","value":"CL544665"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143578":{"preferredName":"Ileal Stenosis, CTCAE","code":"C143578","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the ileum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the ileum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ileal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ileal stenosis"},{"name":"Maps_To","value":"Ileal Stenosis"},{"name":"NCI_META_CUI","value":"CL541865"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57826":{"preferredName":"Ileal Ulcer, CTCAE","code":"C57826","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the ileum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the ileum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Ulcer_Adverse_Event"},{"name":"Maps_To","value":"Ileal Ulcer"},{"name":"Maps_To","value":"Ileal ulcer"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963143"}]}}{"C57814":{"preferredName":"Ileus, CTCAE","code":"C57814","definitions":[{"definition":"A disorder characterized by failure of the ileum to transport intestinal contents.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by failure of the ileum to transport intestinal contents.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Ileus_Adverse_Event"},{"name":"Maps_To","value":"Ileus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560456"}]}}{"C143580":{"preferredName":"Immune System Disorders - Other, Specify, CTCAE","code":"C143580","synonyms":[{"termName":"Immune System Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immune System Disorders - Other"},{"name":"Maps_To","value":"Immune system disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541851"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143581":{"preferredName":"Infections and Infestations - Other, Specify, CTCAE","code":"C143581","synonyms":[{"termName":"Infections and Infestations - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infections and Infestations - Other"},{"name":"Maps_To","value":"Infections and infestations - Other, specify"},{"name":"NCI_META_CUI","value":"CL541852"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143582":{"preferredName":"Infective Myositis, CTCAE","code":"C143582","definitions":[{"definition":"A disorder characterized by an infectious process involving the skeletal muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the skeletal muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Infective Myositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infective myositis"},{"name":"Maps_To","value":"Infective Myositis"},{"name":"NCI_META_CUI","value":"CL541853"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143583":{"preferredName":"Infusion Related Reaction, CTCAE","code":"C143583","definitions":[{"definition":"A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Infusion Related Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infusion related reaction"},{"name":"Maps_To","value":"Infusion Related Reaction"},{"name":"NCI_META_CUI","value":"CL541854"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143584":{"preferredName":"Infusion Site Extravasation, CTCAE","code":"C143584","definitions":[{"definition":"A disorder characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms may include induration, erythema, swelling, burning sensation and marked discomfort at the infusion site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms may include induration, erythema, swelling, burning sensation and marked discomfort at the infusion site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Infusion Site Extravasation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infusion site extravasation"},{"name":"Maps_To","value":"Infusion Site Extravasation"},{"name":"NCI_META_CUI","value":"CL541855"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143585":{"preferredName":"Injection Site Reaction, CTCAE","code":"C143585","definitions":[{"definition":"A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Injection Site Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injection site reaction"},{"name":"Maps_To","value":"Injection Site Reaction"},{"name":"NCI_META_CUI","value":"CL541856"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143586":{"preferredName":"Injury To Carotid Artery, CTCAE","code":"C143586","definitions":[{"definition":"A finding of damage to the carotid artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the carotid artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Injury To Carotid Artery, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury to carotid artery"},{"name":"Maps_To","value":"Injury to Carotid Artery"},{"name":"NCI_META_CUI","value":"CL541857"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56735":{"preferredName":"Injury To Inferior Vena Cava, CTCAE","code":"C56735","definitions":[{"definition":"A finding of damage to the inferior vena cava.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the inferior vena cava.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Injury To Inferior Vena Cava, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inferior_Vena_Cava_Vein_Injury_Adverse_Event"},{"name":"Maps_To","value":"Injury to Inferior Vena Cava"},{"name":"Maps_To","value":"Injury to inferior vena cava"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559031"}]}}{"C143587":{"preferredName":"Injury To Jugular Vein, CTCAE","code":"C143587","definitions":[{"definition":"A finding of damage to the jugular vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the jugular vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Injury To Jugular Vein, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury to jugular vein"},{"name":"Maps_To","value":"Injury to Jugular Vein"},{"name":"NCI_META_CUI","value":"CL541858"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143588":{"preferredName":"Injury To Superior Vena Cava, CTCAE","code":"C143588","definitions":[{"definition":"A finding of damage to the superior vena cava.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the superior vena cava.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Injury To Superior Vena Cava, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury to superior vena cava"},{"name":"Maps_To","value":"Injury to Superior Vena Cava"},{"name":"NCI_META_CUI","value":"CL541843"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143589":{"preferredName":"Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","code":"C143589","synonyms":[{"termName":"Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury, Poisoning and Procedural Complications - Other"},{"name":"Maps_To","value":"Injury, poisoning and procedural complications - Other, specify"},{"name":"NCI_META_CUI","value":"CL541844"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143590":{"preferredName":"INR Increased, CTCAE","code":"C143590","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time to a control sample in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time to a control sample in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"INR Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"INR increased"},{"name":"Maps_To","value":"INR Increased"},{"name":"NCI_META_CUI","value":"CL541845"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146771":{"preferredName":"Insomnia, CTCAE 5.0","code":"C146771","definitions":[{"definition":"A disorder characterized by difficulty in falling asleep and/or remaining asleep.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by difficulty in falling asleep and/or remaining asleep.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Insomnia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Insomnia"},{"name":"NCI_META_CUI","value":"CL544779"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143592":{"preferredName":"Intestinal Stoma Leak, CTCAE","code":"C143592","definitions":[{"definition":"A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intestinal Stoma Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intestinal stoma leak"},{"name":"Maps_To","value":"Intestinal Stoma Leak"},{"name":"NCI_META_CUI","value":"CL541846"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143593":{"preferredName":"Intestinal Stoma Obstruction, CTCAE","code":"C143593","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents of the intestinal stoma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents of the intestinal stoma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intestinal Stoma Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intestinal stoma obstruction"},{"name":"Maps_To","value":"Intestinal Stoma Obstruction"},{"name":"NCI_META_CUI","value":"CL541847"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143594":{"preferredName":"Intestinal Stoma Site Bleeding, CTCAE","code":"C143594","definitions":[{"definition":"A disorder characterized by bleeding from the intestinal stoma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the intestinal stoma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intestinal Stoma Site Bleeding, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intestinal stoma site bleeding"},{"name":"Maps_To","value":"Intestinal Stoma Site Bleeding"},{"name":"NCI_META_CUI","value":"CL541848"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143595":{"preferredName":"Intra-Abdominal Hemorrhage, CTCAE","code":"C143595","definitions":[{"definition":"A disorder characterized by bleeding in the abdominal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding in the abdominal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intra-Abdominal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intra-abdominal hemorrhage"},{"name":"Maps_To","value":"Intra-Abdominal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541849"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143596":{"preferredName":"Intracranial Hemorrhage, CTCAE","code":"C143596","definitions":[{"definition":"A disorder characterized by bleeding from the cranium.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the cranium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intracranial Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intracranial hemorrhage"},{"name":"Maps_To","value":"Intracranial Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541850"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143597":{"preferredName":"Intraoperative Arterial Injury, CTCAE","code":"C143597","definitions":[{"definition":"A finding of damage to an artery during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to an artery during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Arterial Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative arterial injury"},{"name":"Maps_To","value":"Intraoperative Arterial Injury"},{"name":"NCI_META_CUI","value":"CL541956"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143598":{"preferredName":"Intraoperative Breast Injury, CTCAE","code":"C143598","definitions":[{"definition":"A finding of damage to the breast parenchyma during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the breast parenchyma during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Breast Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative breast injury"},{"name":"Maps_To","value":"Intraoperative Breast Injury"},{"name":"NCI_META_CUI","value":"CL541957"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143599":{"preferredName":"Intraoperative Cardiac Injury, CTCAE","code":"C143599","definitions":[{"definition":"A finding of damage to the heart during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the heart during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Cardiac Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative cardiac injury"},{"name":"Maps_To","value":"Intraoperative Cardiac Injury"},{"name":"NCI_META_CUI","value":"CL541958"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143600":{"preferredName":"Intraoperative Ear Injury, CTCAE","code":"C143600","definitions":[{"definition":"A finding of damage to the ear during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the ear during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Ear Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative ear injury"},{"name":"Maps_To","value":"Intraoperative Ear Injury"},{"name":"NCI_META_CUI","value":"CL541959"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143601":{"preferredName":"Intraoperative Endocrine Injury, CTCAE","code":"C143601","definitions":[{"definition":"A finding of damage to the endocrine gland during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the endocrine gland during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Endocrine Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative endocrine injury"},{"name":"Maps_To","value":"Intraoperative Endocrine Injury"},{"name":"NCI_META_CUI","value":"CL541960"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143602":{"preferredName":"Intraoperative Gastrointestinal Injury, CTCAE","code":"C143602","definitions":[{"definition":"A finding of damage to the gastrointestinal system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the gastrointestinal system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Gastrointestinal Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative gastrointestinal injury"},{"name":"Maps_To","value":"Intraoperative Gastrointestinal Injury"},{"name":"NCI_META_CUI","value":"CL541961"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143603":{"preferredName":"Intraoperative Head and Neck Injury, CTCAE","code":"C143603","definitions":[{"definition":"A finding of damage to the head and neck during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the head and neck during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Head and Neck Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative head and neck injury"},{"name":"Maps_To","value":"Intraoperative Head and Neck Injury"},{"name":"NCI_META_CUI","value":"CL541962"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143604":{"preferredName":"Intraoperative Hemorrhage, CTCAE","code":"C143604","definitions":[{"definition":"A finding of uncontrolled bleeding during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of uncontrolled bleeding during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative hemorrhage"},{"name":"Maps_To","value":"Intraoperative Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541963"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143605":{"preferredName":"Intraoperative Hepatobiliary Injury, CTCAE","code":"C143605","definitions":[{"definition":"A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Hepatobiliary Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative hepatobiliary injury"},{"name":"Maps_To","value":"Intraoperative Hepatobiliary Injury"},{"name":"NCI_META_CUI","value":"CL541948"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143606":{"preferredName":"Intraoperative Musculoskeletal Injury, CTCAE","code":"C143606","definitions":[{"definition":"A finding of damage to the musculoskeletal system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the musculoskeletal system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Musculoskeletal Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative musculoskeletal injury"},{"name":"Maps_To","value":"Intraoperative Musculoskeletal Injury"},{"name":"NCI_META_CUI","value":"CL541949"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143607":{"preferredName":"Intraoperative Neurological Injury, CTCAE","code":"C143607","definitions":[{"definition":"A finding of damage to the nervous system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the nervous system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Neurological Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative neurological injury"},{"name":"Maps_To","value":"Intraoperative Neurological Injury"},{"name":"NCI_META_CUI","value":"CL541950"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143608":{"preferredName":"Intraoperative Ocular Injury, CTCAE","code":"C143608","definitions":[{"definition":"A finding of damage to the eye during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the eye during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Ocular Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative ocular injury"},{"name":"Maps_To","value":"Intraoperative Ocular Injury"},{"name":"NCI_META_CUI","value":"CL541951"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143609":{"preferredName":"Intraoperative Renal Injury, CTCAE","code":"C143609","definitions":[{"definition":"A finding of damage to the kidney during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the kidney during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Renal Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative renal injury"},{"name":"Maps_To","value":"Intraoperative Renal Injury"},{"name":"NCI_META_CUI","value":"CL541952"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143610":{"preferredName":"Intraoperative Reproductive Tract Injury, CTCAE","code":"C143610","definitions":[{"definition":"A finding of damage to the reproductive organs during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the reproductive organs during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Reproductive Tract Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative reproductive tract injury"},{"name":"Maps_To","value":"Intraoperative Reproductive Tract Injury"},{"name":"NCI_META_CUI","value":"CL541953"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143611":{"preferredName":"Intraoperative Respiratory Injury, CTCAE","code":"C143611","definitions":[{"definition":"A finding of damage to the respiratory system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the respiratory system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Respiratory Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative respiratory injury"},{"name":"Maps_To","value":"Intraoperative Respiratory Injury"},{"name":"NCI_META_CUI","value":"CL541954"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78389":{"preferredName":"Intraoperative Skin Injury","code":"C78389","definitions":[{"definition":"A finding of damage to the skin during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Damage to the skin during a surgical procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraoperative Skin Injury","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraoperative_Skin_Injury"},{"name":"Maps_To","value":"Intraoperative Skin Injury"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1558746"}]}}{"C143612":{"preferredName":"Intraoperative Splenic Injury, CTCAE","code":"C143612","definitions":[{"definition":"A finding of damage to the spleen during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the spleen during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Splenic Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative splenic injury"},{"name":"Maps_To","value":"Intraoperative Splenic Injury"},{"name":"NCI_META_CUI","value":"CL541955"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143613":{"preferredName":"Intraoperative Urinary Injury, CTCAE","code":"C143613","definitions":[{"definition":"A finding of damage to the urinary system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the urinary system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Urinary Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative urinary injury"},{"name":"Maps_To","value":"Intraoperative Urinary Injury"},{"name":"NCI_META_CUI","value":"CL541940"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143614":{"preferredName":"Intraoperative Venous Injury, CTCAE","code":"C143614","definitions":[{"definition":"A finding of damage to a vein during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to a vein during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Venous Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative venous injury"},{"name":"Maps_To","value":"Intraoperative Venous Injury"},{"name":"NCI_META_CUI","value":"CL541941"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143615":{"preferredName":"Investigations - Other, Specify, CTCAE","code":"C143615","synonyms":[{"termName":"Investigations - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Investigations - Other"},{"name":"Maps_To","value":"Investigations - Other, specify"},{"name":"NCI_META_CUI","value":"CL541942"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55993":{"preferredName":"Iron Overload, CTCAE","code":"C55993","definitions":[{"definition":"A disorder characterized by accumulation of iron in the tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by accumulation of iron in the tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Iron Overload, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iron_Overload_Adverse_Event"},{"name":"Maps_To","value":"Iron overload"},{"name":"Maps_To","value":"Iron Overload"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963148"}]}}{"C143617":{"preferredName":"Irregular Menstruation, CTCAE","code":"C143617","definitions":[{"definition":"A disorder characterized by a change in cycle or duration of menses from baseline.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a change in cycle or duration of menses from baseline.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Irregular Menstruation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irregular menstruation"},{"name":"Maps_To","value":"Irregular Menstruation"},{"name":"NCI_META_CUI","value":"CL541943"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143618":{"preferredName":"Irritability, CTCAE","code":"C143618","definitions":[{"definition":"A disorder characterized by an abnormal responsiveness to stimuli or physiological arousal; may be in response to pain, fright, a drug, an emotional situation or a medical condition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal responsiveness to stimuli or physiological arousal; may be in response to pain, fright, a drug, an emotional situation or a medical condition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Irritability, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irritability"},{"name":"NCI_META_CUI","value":"CL541944"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143619":{"preferredName":"Ischemia Cerebrovascular, CTCAE","code":"C143619","definitions":[{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ischemia Cerebrovascular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ischemia cerebrovascular"},{"name":"Maps_To","value":"Ischemia Cerebrovascular"},{"name":"NCI_META_CUI","value":"CL541945"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143235":{"preferredName":"Trochlear Nerve Disorder, CTCAE","code":"C143235","definitions":[{"definition":"A disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Trochlear Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IVth Nerve Disorder"},{"name":"Maps_To","value":"Trochlear nerve disorder"},{"name":"NCI_META_CUI","value":"CL545921"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57827":{"preferredName":"Jejunal Fistula, CTCAE","code":"C57827","definitions":[{"definition":"A disorder characterized by an abnormal communication between the jejunum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the jejunum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Jejunal Fistula"},{"name":"Maps_To","value":"Jejunal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963149"}]}}{"C56543":{"preferredName":"Jejunal Hemorrhage, CTCAE","code":"C56543","definitions":[{"definition":"A disorder characterized by bleeding from the jejunal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the jejunal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Jejunal Hemorrhage"},{"name":"Maps_To","value":"Jejunal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963150"}]}}{"C57829":{"preferredName":"Jejunal Obstruction, CTCAE","code":"C57829","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the jejunum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the jejunum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Jejunal Obstruction"},{"name":"Maps_To","value":"Jejunal obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1401336"}]}}{"C143622":{"preferredName":"Jejunal Perforation, CTCAE","code":"C143622","definitions":[{"definition":"A disorder characterized by a rupture in the jejunal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the jejunal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Jejunal perforation"},{"name":"Maps_To","value":"Jejunal Perforation"},{"name":"NCI_META_CUI","value":"CL541946"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143623":{"preferredName":"Jejunal Stenosis, CTCAE","code":"C143623","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the jejunum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the jejunum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Jejunal stenosis"},{"name":"Maps_To","value":"Jejunal Stenosis"},{"name":"NCI_META_CUI","value":"CL541947"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57832":{"preferredName":"Jejunal Ulcer, CTCAE","code":"C57832","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the jejunum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the jejunum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Ulcer_Adverse_Event"},{"name":"Maps_To","value":"Jejunal Ulcer"},{"name":"Maps_To","value":"Jejunal ulcer"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963151"}]}}{"C146760":{"preferredName":"Joint Effusion, CTCAE 5.0","code":"C146760","definitions":[{"definition":"A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Joint Effusion, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint effusion"},{"name":"Maps_To","value":"Joint Effusion"},{"name":"NCI_META_CUI","value":"CL544798"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143626":{"preferredName":"Joint Infection, CTCAE","code":"C143626","definitions":[{"definition":"A disorder characterized by an infectious process involving a joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Joint Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint infection"},{"name":"Maps_To","value":"Joint Infection"},{"name":"NCI_META_CUI","value":"CL541933"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143629":{"preferredName":"Joint Range of Motion Decreased, CTCAE","code":"C143629","definitions":[{"definition":"A disorder characterized by a decrease in joint flexibility of any joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a decrease in joint flexibility of any joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Joint Range of Motion Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint range of motion decreased"},{"name":"Maps_To","value":"Joint Range of Motion Decreased"},{"name":"NCI_META_CUI","value":"CL541936"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143627":{"preferredName":"Joint Range of Motion Decreased Cervical Spine, CTCAE","code":"C143627","definitions":[{"definition":"A disorder characterized by a decrease in flexibility of a cervical spine joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in flexibility of a cervical spine joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Joint Range of Motion Decreased Cervical Spine, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint range of motion decreased cervical spine"},{"name":"Maps_To","value":"Joint Range of Motion Decreased Cervical Spine"},{"name":"NCI_META_CUI","value":"CL541934"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143628":{"preferredName":"Joint Range of Motion Decreased Lumbar Spine, CTCAE","code":"C143628","definitions":[{"definition":"A disorder characterized by a decrease in flexibility of a lumbar spine joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in flexibility of a lumbar spine joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Joint Range of Motion Decreased Lumbar Spine, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint range of motion decreased lumbar spine"},{"name":"Maps_To","value":"Joint Range of Motion Decreased Lumbar Spine"},{"name":"NCI_META_CUI","value":"CL541935"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55847":{"preferredName":"Keratitis, CTCAE","code":"C55847","definitions":[{"definition":"A disorder characterized by inflammation to the cornea of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation to the cornea of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Keratitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Keratitis_Adverse_Event"},{"name":"Maps_To","value":"Keratitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1557321"}]}}{"C143631":{"preferredName":"Kidney Anastomotic Leak, CTCAE","code":"C143631","definitions":[{"definition":"A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Kidney Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney anastomotic leak"},{"name":"Maps_To","value":"Kidney Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL541937"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143632":{"preferredName":"Kidney Infection, CTCAE","code":"C143632","definitions":[{"definition":"A disorder characterized by an infectious process involving the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the kidney.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Kidney Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney infection"},{"name":"Maps_To","value":"Kidney Infection"},{"name":"NCI_META_CUI","value":"CL546047"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143633":{"preferredName":"Kyphosis, CTCAE","code":"C143633","definitions":[{"definition":"A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Kyphosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kyphosis"},{"name":"NCI_META_CUI","value":"CL541938"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143634":{"preferredName":"Lactation Disorder, CTCAE","code":"C143634","definitions":[{"definition":"A disorder characterized by disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lactation Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lactation disorder"},{"name":"Maps_To","value":"Lactation Disorder"},{"name":"NCI_META_CUI","value":"CL541939"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143635":{"preferredName":"Large Intestinal Anastomotic Leak, CTCAE","code":"C143635","definitions":[{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Large Intestinal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Large intestinal anastomotic leak"},{"name":"Maps_To","value":"Large Intestinal Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL541925"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143636":{"preferredName":"Laryngeal Edema, CTCAE","code":"C143636","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal edema"},{"name":"Maps_To","value":"Laryngeal Edema"},{"name":"NCI_META_CUI","value":"CL541926"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58190":{"preferredName":"Laryngeal Fistula, CTCAE","code":"C58190","definitions":[{"definition":"A disorder characterized by an abnormal communication between the larynx and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the larynx and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Larynx_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Laryngeal Fistula"},{"name":"Maps_To","value":"Laryngeal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1397408"}]}}{"C56545":{"preferredName":"Laryngeal Hemorrhage, CTCAE","code":"C56545","definitions":[{"definition":"A disorder characterized by bleeding from the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Larynx_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Laryngeal hemorrhage"},{"name":"Maps_To","value":"Laryngeal Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1881362"}]}}{"C143637":{"preferredName":"Laryngeal Inflammation, CTCAE","code":"C143637","definitions":[{"definition":"A disorder characterized by an inflammation involving the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an inflammation involving the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Laryngeal Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal inflammation"},{"name":"Maps_To","value":"Laryngeal Inflammation"},{"name":"NCI_META_CUI","value":"CL541927"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143638":{"preferredName":"Laryngeal Mucositis, CTCAE","code":"C143638","definitions":[{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal mucositis"},{"name":"Maps_To","value":"Laryngeal Mucositis"},{"name":"NCI_META_CUI","value":"CL541928"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143639":{"preferredName":"Laryngeal Obstruction, CTCAE","code":"C143639","definitions":[{"definition":"A disorder characterized by blockage of the laryngeal airway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the laryngeal airway.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal obstruction"},{"name":"Maps_To","value":"Laryngeal Obstruction"},{"name":"NCI_META_CUI","value":"CL541929"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143640":{"preferredName":"Laryngeal Stenosis, CTCAE","code":"C143640","definitions":[{"definition":"A disorder characterized by a narrowing of the laryngeal airway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the laryngeal airway.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal stenosis"},{"name":"Maps_To","value":"Laryngeal Stenosis"},{"name":"NCI_META_CUI","value":"CL541930"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143641":{"preferredName":"Laryngitis, CTCAE","code":"C143641","definitions":[{"definition":"A disorder characterized by an inflammatory process involving the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inflammatory process involving the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngitis"},{"name":"NCI_META_CUI","value":"CL541931"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143642":{"preferredName":"Laryngopharyngeal Dysesthesia, CTCAE","code":"C143642","definitions":[{"definition":"A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Laryngopharyngeal Dysesthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngopharyngeal dysesthesia"},{"name":"Maps_To","value":"Laryngopharyngeal Dysesthesia"},{"name":"NCI_META_CUI","value":"CL541932"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143643":{"preferredName":"Laryngospasm, CTCAE","code":"C143643","definitions":[{"definition":"A disorder characterized by paroxysmal spasmodic muscular contraction of the vocal cords.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by paroxysmal spasmodic muscular contraction of the vocal cords.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Laryngospasm, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngospasm"},{"name":"NCI_META_CUI","value":"CL541917"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146719":{"preferredName":"Left Ventricular Systolic Dysfunction, CTCAE 5.0","code":"C146719","definitions":[{"definition":"A disorder characterized by failure of the left ventricle to produce adequate output.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by failure of the left ventricle to produce adequate output.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Left Ventricular Systolic Dysfunction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Left ventricular systolic dysfunction"},{"name":"Maps_To","value":"Left Ventricular Systolic Dysfunction"},{"name":"NCI_META_CUI","value":"CL544713"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143645":{"preferredName":"Lethargy, CTCAE","code":"C143645","definitions":[{"definition":"A disorder characterized by a decrease in consciousness characterized by mental and physical inertness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in consciousness characterized by mental and physical inertness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lethargy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lethargy"},{"name":"NCI_META_CUI","value":"CL541918"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143646":{"preferredName":"Leukemia Secondary To Oncology Chemotherapy, CTCAE","code":"C143646","definitions":[{"definition":"A disorder characterized by leukemia arising as a result of the mutagenic effect of chemotherapy agents.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by leukemia arising as a result of the mutagenic effect of chemotherapy agents.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Leukemia Secondary To Oncology Chemotherapy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leukemia secondary to oncology chemotherapy"},{"name":"Maps_To","value":"Leukemia Secondary to Oncology Chemotherapy"},{"name":"NCI_META_CUI","value":"CL541919"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143647":{"preferredName":"Leukocytosis, CTCAE","code":"C143647","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an increased number of white blood cells in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate an increased number of white blood cells in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Leukocytosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leukocytosis"},{"name":"NCI_META_CUI","value":"CL541920"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143648":{"preferredName":"Leukoencephalopathy, CTCAE","code":"C143648","definitions":[{"definition":"A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Leukoencephalopathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leukoencephalopathy"},{"name":"NCI_META_CUI","value":"CL541921"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143649":{"preferredName":"Libido Decreased, CTCAE","code":"C143649","definitions":[{"definition":"A disorder characterized by a decrease in sexual desire.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in sexual desire.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Libido Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Libido decreased"},{"name":"Maps_To","value":"Libido Decreased"},{"name":"NCI_META_CUI","value":"CL541922"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143650":{"preferredName":"Libido Increased, CTCAE","code":"C143650","definitions":[{"definition":"A disorder characterized by an increase in sexual desire.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in sexual desire.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Libido Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Libido increased"},{"name":"Maps_To","value":"Libido Increased"},{"name":"NCI_META_CUI","value":"CL541923"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143651":{"preferredName":"Lip Infection, CTCAE","code":"C143651","definitions":[{"definition":"A disorder characterized by an infectious process involving the lips.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the lips.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lip Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lip infection"},{"name":"Maps_To","value":"Lip Infection"},{"name":"NCI_META_CUI","value":"CL541924"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146761":{"preferredName":"Lip Pain, CTCAE 5.0","code":"C146761","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort of the lip.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort of the lip.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lip Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lip Pain"},{"name":"Maps_To","value":"Lip pain"},{"name":"NCI_META_CUI","value":"CL544799"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143652":{"preferredName":"Lipase Increased, CTCAE","code":"C143652","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lipase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipase increased"},{"name":"Maps_To","value":"Lipase Increased"},{"name":"NCI_META_CUI","value":"CL541910"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143653":{"preferredName":"Lipohypertrophy, CTCAE","code":"C143653","definitions":[{"definition":"A disorder characterized by hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lipohypertrophy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipohypertrophy"},{"name":"NCI_META_CUI","value":"CL541911"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143654":{"preferredName":"Localized Edema, CTCAE","code":"C143654","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Localized Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Localized edema"},{"name":"Maps_To","value":"Localized Edema"},{"name":"NCI_META_CUI","value":"CL541912"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143655":{"preferredName":"Lordosis, CTCAE","code":"C143655","definitions":[{"definition":"A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lordosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lordosis"},{"name":"NCI_META_CUI","value":"CL545982"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143656":{"preferredName":"Lower Gastrointestinal Hemorrhage, CTCAE","code":"C143656","definitions":[{"definition":"A disorder characterized by bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lower Gastrointestinal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lower gastrointestinal hemorrhage"},{"name":"Maps_To","value":"Lower Gastrointestinal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541913"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143657":{"preferredName":"Lung Infection, CTCAE","code":"C143657","definitions":[{"definition":"A disorder characterized by an infectious process involving the lungs, including pneumonia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the lungs, including pneumonia.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lung Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lung infection"},{"name":"Maps_To","value":"Lung Infection"},{"name":"NCI_META_CUI","value":"CL541914"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143658":{"preferredName":"Lymph Gland Infection, CTCAE","code":"C143658","definitions":[{"definition":"A disorder characterized by an infectious process involving the lymph nodes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the lymph nodes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lymph Gland Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph gland infection"},{"name":"Maps_To","value":"Lymph Gland Infection"},{"name":"NCI_META_CUI","value":"CL541915"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143659":{"preferredName":"Lymph Leakage, CTCAE","code":"C143659","definitions":[{"definition":"A disorder characterized by the loss of lymph fluid into the surrounding tissue or body cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the loss of lymph fluid into the surrounding tissue or body cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lymph Leakage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph leakage"},{"name":"Maps_To","value":"Lymph Leakage"},{"name":"NCI_META_CUI","value":"CL541916"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146773":{"preferredName":"Lymph Node Pain, CTCAE 5.0","code":"C146773","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in a lymph node.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in a lymph node.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lymph Node Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node Pain"},{"name":"Maps_To","value":"Lymph node pain"},{"name":"NCI_META_CUI","value":"CL544781"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143660":{"preferredName":"Lymphedema, CTCAE","code":"C143660","definitions":[{"definition":"A disorder characterized by excessive fluid collection in tissues that causes swelling.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive fluid collection in tissues that causes swelling.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lymphedema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphedema"},{"name":"NCI_META_CUI","value":"CL541902"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55705":{"preferredName":"Lymphocele, CTCAE","code":"C55705","definitions":[{"definition":"A disorder characterized by a cystic lesion containing lymph.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a cystic lesion containing lymph.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lymphocele, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocele_Adverse_Event"},{"name":"Maps_To","value":"Lymphocele"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963162"}]}}{"C143662":{"preferredName":"Lymphocyte Count Decreased, CTCAE","code":"C143662","definitions":[{"definition":"A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lymphocyte Count Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphocyte count decreased"},{"name":"Maps_To","value":"Lymphocyte Count Decreased"},{"name":"NCI_META_CUI","value":"CL541903"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143663":{"preferredName":"Lymphocyte Count Increased, CTCAE","code":"C143663","definitions":[{"definition":"A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lymphocyte Count Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphocyte count increased"},{"name":"Maps_To","value":"Lymphocyte Count Increased"},{"name":"NCI_META_CUI","value":"CL541904"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57838":{"preferredName":"Malabsorption, CTCAE","code":"C57838","definitions":[{"definition":"A disorder characterized by inadequate absorption of nutrients in the small intestine. Symptoms include abdominal marked discomfort, bloating and diarrhea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inadequate absorption of nutrients in the small intestine. Symptoms include abdominal marked discomfort, bloating and diarrhea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Malabsorption, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malabsorption_Adverse_Event"},{"name":"Maps_To","value":"Malabsorption"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963165"}]}}{"C143665":{"preferredName":"Malaise, CTCAE","code":"C143665","definitions":[{"definition":"A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Malaise, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Malaise"},{"name":"NCI_META_CUI","value":"CL541905"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143666":{"preferredName":"Mania, CTCAE","code":"C143666","definitions":[{"definition":"A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mania, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mania"},{"name":"NCI_META_CUI","value":"CL541906"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56549":{"preferredName":"Mediastinal Hemorrhage, CTCAE","code":"C56549","definitions":[{"definition":"A disorder characterized by bleeding from the mediastinum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the mediastinum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mediastinal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mediastinum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Mediastinal hemorrhage"},{"name":"Maps_To","value":"Mediastinal Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560796"}]}}{"C143667":{"preferredName":"Mediastinal Infection, CTCAE","code":"C143667","definitions":[{"definition":"A disorder characterized by an infectious process involving the mediastinum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the mediastinum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Mediastinal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mediastinal infection"},{"name":"Maps_To","value":"Mediastinal Infection"},{"name":"NCI_META_CUI","value":"CL541907"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146763":{"preferredName":"Memory Impairment, CTCAE 5.0","code":"C146763","definitions":[{"definition":"A disorder characterized by a deterioration in memory function.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a deterioration in memory function.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Memory Impairment, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Memory Impairment"},{"name":"Maps_To","value":"Memory impairment"},{"name":"NCI_META_CUI","value":"CL544787"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143669":{"preferredName":"Meningismus, CTCAE","code":"C143669","definitions":[{"definition":"A disorder characterized by neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Meningismus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Meningismus"},{"name":"NCI_META_CUI","value":"CL541908"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143670":{"preferredName":"Meningitis, CTCAE","code":"C143670","definitions":[{"definition":"A disorder characterized by acute inflammation of the meninges of the brain and/or spinal cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by acute inflammation of the meninges of the brain and/or spinal cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Meningitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Meningitis"},{"name":"NCI_META_CUI","value":"CL541909"},{"name":"Semantic_Type","value":"Finding"}]}}{"C3231":{"preferredName":"Menopause","code":"C3231","definitions":[{"definition":"A disorder characterized by the permanent cessation of menses, usually defined by 12 consecutive months of amenorrhea in a woman over 45 years of age.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"The permanent cessation of menses, usually defined by 6 to 12 months of amenorrhea in a woman over 45 years of age.","type":"DEFINITION","source":"NCI"},{"definition":"The time of life when a woman's ovaries stop producing hormones and menstrual periods stop. Natural menopause usually occurs around age 50. A woman is said to be in menopause when she hasn't had a period for 12 months in a row. Symptoms of menopause include hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Menopause","termGroup":"PT","termSource":"NCI"},{"termName":"Menopausal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Menopause"},{"name":"Maps_To","value":"Menopause"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0025320"}]}}{"C143671":{"preferredName":"Menorrhagia, CTCAE","code":"C143671","definitions":[{"definition":"A disorder characterized by abnormally heavy vaginal bleeding during menses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by abnormally heavy vaginal bleeding during menses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Menorrhagia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Menorrhagia"},{"name":"NCI_META_CUI","value":"CL542013"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143672":{"preferredName":"Metabolism and Nutrition Disorders - Other, Specify, CTCAE","code":"C143672","synonyms":[{"termName":"Metabolism and Nutrition Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metabolism and Nutrition Disorders - Other"},{"name":"Maps_To","value":"Metabolism and nutrition disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542014"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143673":{"preferredName":"Middle Ear Inflammation, CTCAE","code":"C143673","definitions":[{"definition":"A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Middle Ear Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Middle ear inflammation"},{"name":"Maps_To","value":"Middle Ear Inflammation"},{"name":"NCI_META_CUI","value":"CL542015"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143674":{"preferredName":"Mitral Valve Disease, CTCAE","code":"C143674","definitions":[{"definition":"A disorder characterized by a defect in mitral valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a defect in mitral valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mitral Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitral valve disease"},{"name":"Maps_To","value":"Mitral Valve Disease"},{"name":"NCI_META_CUI","value":"CL542016"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54772":{"preferredName":"Mobitz (Type) II Atrioventricular Block, CTCAE","code":"C54772","definitions":[{"definition":"A disorder characterized by a dysrhythmia with relatively constant PR interval prior to the block of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with relatively constant PR interval prior to the block of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mobitz (Type) II Atrioventricular Block, CTCAE","termGroup":"PT","termSource":"NCI"},{"termName":"AV Block Second Degree Mobitz Type II Adverse Event","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AV_Block_Second_Degree_Mobitz_Type_II_Adverse_Event"},{"name":"Maps_To","value":"Mobitz (type) II atrioventricular block"},{"name":"Maps_To","value":"Mobitz (Type) II Atrioventricular Block"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1964030"}]}}{"C54771":{"preferredName":"Mobitz Type I, CTCAE","code":"C54771","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a progressively lengthening PR interval prior to the blocking of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a progressively lengthening PR interval prior to the blocking of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mobitz Type I, CTCAE","termGroup":"PT","termSource":"NCI"},{"termName":"AV Block Second Degree Möbitz Type I Adverse Event","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AV_Block_Second_Degree_Mobitz_Type_I_Adverse_Event"},{"name":"Maps_To","value":"Mobitz type I"},{"name":"Maps_To","value":"Mobitz Type I"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560266"}]}}{"C143677":{"preferredName":"Movements Involuntary, CTCAE","code":"C143677","definitions":[{"definition":"A disorder characterized by uncontrolled and purposeless movements.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by uncontrolled and purposeless movements.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Movements Involuntary, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Movements involuntary"},{"name":"Maps_To","value":"Movements Involuntary"},{"name":"NCI_META_CUI","value":"CL545900"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143678":{"preferredName":"Mucosal Infection, CTCAE","code":"C143678","definitions":[{"definition":"A disorder characterized by an infectious process involving a mucosal surface.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a mucosal surface.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Mucosal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mucosal infection"},{"name":"Maps_To","value":"Mucosal Infection"},{"name":"NCI_META_CUI","value":"CL542017"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143679":{"preferredName":"Mucositis Oral, CTCAE","code":"C143679","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the oral mucosal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation of the oral mucosal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Mucositis Oral, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mucositis oral"},{"name":"Maps_To","value":"Mucositis Oral"},{"name":"NCI_META_CUI","value":"CL542018"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143680":{"preferredName":"Multi-Organ Failure, CTCAE","code":"C143680","definitions":[{"definition":"A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Multi-Organ Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-organ failure"},{"name":"Maps_To","value":"Multi-Organ Failure"},{"name":"NCI_META_CUI","value":"CL542019"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143681":{"preferredName":"Muscle Weakness Left-Sided, CTCAE","code":"C143681","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the muscles on the left side of the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a reduction in the strength of the muscles on the left side of the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Muscle Weakness Left-Sided, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle weakness left-sided"},{"name":"Maps_To","value":"Muscle Weakness Left-Sided"},{"name":"NCI_META_CUI","value":"CL542005"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143682":{"preferredName":"Muscle Weakness Lower Limb, CTCAE","code":"C143682","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the lower limb muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the lower limb muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Muscle Weakness Lower Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Lower Limb"},{"name":"Maps_To","value":"Muscle weakness lower limb"},{"name":"NCI_META_CUI","value":"CL542006"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143683":{"preferredName":"Muscle Weakness Right-Sided, CTCAE","code":"C143683","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the muscles on the right side of the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the muscles on the right side of the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Muscle Weakness Right-Sided, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Right-Sided"},{"name":"Maps_To","value":"Muscle weakness right-sided"},{"name":"NCI_META_CUI","value":"CL542007"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143684":{"preferredName":"Muscle Weakness Trunk, CTCAE","code":"C143684","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the trunk muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a reduction in the strength of the trunk muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Muscle Weakness Trunk, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Trunk"},{"name":"Maps_To","value":"Muscle weakness trunk"},{"name":"NCI_META_CUI","value":"CL542008"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143685":{"preferredName":"Muscle Weakness Upper Limb, CTCAE","code":"C143685","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the upper limb muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a reduction in the strength of the upper limb muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Muscle Weakness Upper Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Upper Limb"},{"name":"Maps_To","value":"Muscle weakness upper limb"},{"name":"NCI_META_CUI","value":"CL542009"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143686":{"preferredName":"Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","code":"C143686","synonyms":[{"termName":"Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Musculoskeletal and connective tissue disorder - Other, specify"},{"name":"Maps_To","value":"Musculoskeletal and Connective Tissue Disorders - Other"},{"name":"NCI_META_CUI","value":"CL542010"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143687":{"preferredName":"Musculoskeletal Deformity, CTCAE","code":"C143687","definitions":[{"definition":"A disorder characterized by a malformation of the musculoskeletal system.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a malformation of the musculoskeletal system.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Musculoskeletal Deformity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Musculoskeletal Deformity"},{"name":"Maps_To","value":"Musculoskeletal deformity"},{"name":"NCI_META_CUI","value":"CL542011"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143688":{"preferredName":"Myalgia, CTCAE","code":"C143688","definitions":[{"definition":"A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Myalgia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myalgia"},{"name":"NCI_META_CUI","value":"CL542012"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55459":{"preferredName":"Myelitis, CTCAE","code":"C55459","definitions":[{"definition":"A disorder characterized by inflammation involving the spinal cord. Symptoms include weakness, paresthesia, sensory loss, marked discomfort and incontinence.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation involving the spinal cord. Symptoms include weakness, paresthesia, sensory loss, marked discomfort and incontinence.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Myelitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myelitis_Adverse_Event"},{"name":"Maps_To","value":"Myelitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963178"}]}}{"C143690":{"preferredName":"Myelodysplastic Syndrome, CTCAE","code":"C143690","definitions":[{"definition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Myelodysplastic Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myelodysplastic Syndrome"},{"name":"Maps_To","value":"Myelodysplastic syndrome"},{"name":"NCI_META_CUI","value":"CL541998"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143691":{"preferredName":"Myocardial Infarction, CTCAE","code":"C143691","definitions":[{"definition":"A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Myocardial Infarction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myocardial Infarction"},{"name":"Maps_To","value":"Myocardial infarction"},{"name":"NCI_META_CUI","value":"CL546005"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146695":{"preferredName":"Myocarditis, CTCAE 5.0","code":"C146695","definitions":[{"definition":"A disorder characterized by inflammation of the muscle tissue of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the muscle tissue of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Myocarditis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myocarditis"},{"name":"NCI_META_CUI","value":"CL544737"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146787":{"preferredName":"Myositis, CTCAE 5.0","code":"C146787","definitions":[{"definition":"A disorder characterized by inflammation involving the skeletal muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving the skeletal muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Myositis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myositis"},{"name":"NCI_META_CUI","value":"CL544776"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143694":{"preferredName":"Nail Discoloration, CTCAE","code":"C143694","definitions":[{"definition":"A disorder characterized by a change in the color of the nail plate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a change in the color of the nail plate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nail Discoloration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Discoloration"},{"name":"Maps_To","value":"Nail discoloration"},{"name":"NCI_META_CUI","value":"CL541999"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143695":{"preferredName":"Nail Infection, CTCAE","code":"C143695","definitions":[{"definition":"A disorder characterized by an infectious process involving the nail.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the nail.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nail Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Infection"},{"name":"Maps_To","value":"Nail infection"},{"name":"NCI_META_CUI","value":"CL542000"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143696":{"preferredName":"Nail Loss, CTCAE","code":"C143696","definitions":[{"definition":"A disorder characterized by loss of all or a portion of the nail.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by loss of all or a portion of the nail.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nail Loss, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Loss"},{"name":"Maps_To","value":"Nail loss"},{"name":"NCI_META_CUI","value":"CL542001"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143697":{"preferredName":"Nail Ridging, CTCAE","code":"C143697","definitions":[{"definition":"A disorder characterized by vertical or horizontal ridges on the nails.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by vertical or horizontal ridges on the nails.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Nail Ridging, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Ridging"},{"name":"Maps_To","value":"Nail ridging"},{"name":"NCI_META_CUI","value":"CL542002"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143698":{"preferredName":"Nasal Congestion, CTCAE","code":"C143698","definitions":[{"definition":"A disorder characterized by obstruction of the nasal passage due to mucosal edema.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by obstruction of the nasal passage due to mucosal edema.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nasal Congestion, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nasal Congestion"},{"name":"Maps_To","value":"Nasal congestion"},{"name":"NCI_META_CUI","value":"CL542003"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146764":{"preferredName":"Nausea, CTCAE 5.0","code":"C146764","definitions":[{"definition":"A disorder characterized by a queasy sensation and/or the urge to vomit.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a queasy sensation and/or the urge to vomit.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nausea, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nausea"},{"name":"NCI_META_CUI","value":"CL550642"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143700":{"preferredName":"Neck Edema, CTCAE","code":"C143700","definitions":[{"definition":"A disorder characterized by swelling due to an accumulation of excessive fluid in the neck.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to an accumulation of excessive fluid in the neck.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Neck Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neck Edema"},{"name":"Maps_To","value":"Neck edema"},{"name":"NCI_META_CUI","value":"CL542004"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146766":{"preferredName":"Neck Pain, CTCAE 5.0","code":"C146766","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the neck area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the neck area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Neck Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neck pain"},{"name":"Maps_To","value":"Neck Pain"},{"name":"NCI_META_CUI","value":"CL544789"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58394":{"preferredName":"Neck Soft Tissue Necrosis, CTCAE","code":"C58394","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the neck.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the neck.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Neck Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neck_Soft_Tissue_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Neck soft tissue necrosis"},{"name":"Maps_To","value":"Neck Soft Tissue Necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963181"}]}}{"C143701":{"preferredName":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","code":"C143701","synonyms":[{"termName":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other"},{"name":"Maps_To","value":"Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify"},{"name":"NCI_META_CUI","value":"CL541991"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143702":{"preferredName":"Nervous System Disorders - Other, Specify, CTCAE","code":"C143702","synonyms":[{"termName":"Nervous System Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nervous System Disorders - Other"},{"name":"Maps_To","value":"Nervous system disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL546038"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143703":{"preferredName":"Neuralgia, CTCAE","code":"C143703","definitions":[{"definition":"A disorder characterized by intense painful sensation along a nerve or group of nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by intense painful sensation along a nerve or group of nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Neuralgia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neuralgia"},{"name":"NCI_META_CUI","value":"CL541992"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143704":{"preferredName":"Neutrophil Count Decreased, CTCAE","code":"C143704","definitions":[{"definition":"A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Neutrophil Count Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neutrophil Count Decreased"},{"name":"Maps_To","value":"Neutrophil count decreased"},{"name":"NCI_META_CUI","value":"CL541993"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143705":{"preferredName":"Night Blindness, CTCAE","code":"C143705","definitions":[{"definition":"A disorder characterized by an inability to see clearly in dim light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inability to see clearly in dim light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Night Blindness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Night Blindness"},{"name":"Maps_To","value":"Night blindness"},{"name":"NCI_META_CUI","value":"CL541994"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143706":{"preferredName":"Nipple Deformity, CTCAE","code":"C143706","definitions":[{"definition":"A disorder characterized by a malformation of the nipple.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a malformation of the nipple.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nipple Deformity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nipple Deformity"},{"name":"Maps_To","value":"Nipple deformity"},{"name":"NCI_META_CUI","value":"CL541995"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143707":{"preferredName":"Non-Cardiac Chest Pain, CTCAE","code":"C143707","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the chest unrelated to a heart disorder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the chest unrelated to a heart disorder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Non-Cardiac Chest Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Cardiac Chest Pain"},{"name":"Maps_To","value":"Non-cardiac chest pain"},{"name":"NCI_META_CUI","value":"CL541996"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146775":{"preferredName":"Nystagmus, CTCAE 5.0","code":"C146775","definitions":[{"definition":"A disorder characterized by involuntary movements of the eyeballs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by involuntary movements of the eyeballs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Nystagmus, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nystagmus"},{"name":"NCI_META_CUI","value":"CL544783"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55334":{"preferredName":"Obesity, CTCAE","code":"C55334","definitions":[{"definition":"A disorder characterized by having a high amount of body fat.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by having a high amount of body fat.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Obesity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Obesity_Adverse_Event"},{"name":"Maps_To","value":"Obesity"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963185"}]}}{"C143710":{"preferredName":"Obstruction Gastric, CTCAE","code":"C143710","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents in the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents in the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Obstruction Gastric, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Obstruction Gastric"},{"name":"Maps_To","value":"Obstruction gastric"},{"name":"NCI_META_CUI","value":"CL541997"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143711":{"preferredName":"Oculomotor Nerve Disorder, CTCAE","code":"C143711","definitions":[{"definition":"A disorder characterized by dysfunction of the oculomotor nerve (third cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the oculomotor nerve (third cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Oculomotor Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oculomotor Nerve Disorder"},{"name":"Maps_To","value":"Oculomotor nerve disorder"},{"name":"NCI_META_CUI","value":"CL541984"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143712":{"preferredName":"Olfactory Nerve Disorder, CTCAE","code":"C143712","definitions":[{"definition":"A disorder characterized by dysfunction of the olfactory nerve (first cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the olfactory nerve (first cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Olfactory Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Olfactory Nerve Disorder"},{"name":"Maps_To","value":"Olfactory nerve disorder"},{"name":"NCI_META_CUI","value":"CL541985"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143713":{"preferredName":"Oligospermia, CTCAE","code":"C143713","definitions":[{"definition":"A disorder characterized by a decrease in the number of spermatozoa in the semen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in the number of spermatozoa in the semen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Oligospermia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oligospermia"},{"name":"NCI_META_CUI","value":"CL541986"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143714":{"preferredName":"Optic Nerve Disorder, CTCAE","code":"C143714","definitions":[{"definition":"A disorder characterized by involvement of the optic nerve (second cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by involvement of the optic nerve (second cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Optic Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Optic Nerve Disorder"},{"name":"Maps_To","value":"Optic nerve disorder"},{"name":"NCI_META_CUI","value":"CL545955"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143715":{"preferredName":"Oral Cavity Fistula, CTCAE","code":"C143715","definitions":[{"definition":"A disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Oral Cavity Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Cavity Fistula"},{"name":"Maps_To","value":"Oral cavity fistula"},{"name":"NCI_META_CUI","value":"CL541987"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143716":{"preferredName":"Oral Dysesthesia, CTCAE","code":"C143716","definitions":[{"definition":"A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Oral Dysesthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Dysesthesia"},{"name":"Maps_To","value":"Oral dysesthesia"},{"name":"NCI_META_CUI","value":"CL541988"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56551":{"preferredName":"Oral Hemorrhage, CTCAE","code":"C56551","definitions":[{"definition":"A disorder characterized by bleeding from the mouth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the mouth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Oral Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Cavity_Adverse_Event_Hemorrhage"},{"name":"Maps_To","value":"Oral hemorrhage"},{"name":"Maps_To","value":"Oral Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560644"}]}}{"C146627":{"preferredName":"Oral Pain, CTCAE 5.0","code":"C146627","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Oral Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral pain"},{"name":"Maps_To","value":"Oral Pain"},{"name":"NCI_META_CUI","value":"CL544674"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143717":{"preferredName":"Osteonecrosis of Jaw, CTCAE","code":"C143717","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the bone of the mandible.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the bone of the mandible.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Osteonecrosis of Jaw, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Osteonecrosis of Jaw"},{"name":"Maps_To","value":"Osteonecrosis of jaw"},{"name":"NCI_META_CUI","value":"CL541989"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146767":{"preferredName":"Osteoporosis, CTCAE 5.0","code":"C146767","definitions":[{"definition":"A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Osteoporosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Osteoporosis"},{"name":"NCI_META_CUI","value":"CL545899"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143719":{"preferredName":"Otitis Externa, CTCAE","code":"C143719","definitions":[{"definition":"A disorder characterized by an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer's ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer's ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Otitis Externa, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Otitis Externa"},{"name":"Maps_To","value":"Otitis externa"},{"name":"NCI_META_CUI","value":"CL541990"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143720":{"preferredName":"Otitis Media, CTCAE","code":"C143720","definitions":[{"definition":"A disorder characterized by an infectious process involving the middle ear.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the middle ear.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Otitis Media, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Otitis Media"},{"name":"Maps_To","value":"Otitis media"},{"name":"NCI_META_CUI","value":"CL541977"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56553":{"preferredName":"Ovarian Hemorrhage, CTCAE","code":"C56553","definitions":[{"definition":"A disorder characterized by bleeding from the ovary.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the ovary.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ovarian Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovary_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Ovarian hemorrhage"},{"name":"Maps_To","value":"Ovarian Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963125"}]}}{"C143721":{"preferredName":"Ovarian Infection, CTCAE","code":"C143721","definitions":[{"definition":"A disorder characterized by an infectious process involving the ovary.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the ovary.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ovarian Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Infection"},{"name":"Maps_To","value":"Ovarian infection"},{"name":"NCI_META_CUI","value":"CL541978"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143722":{"preferredName":"Ovarian Rupture, CTCAE","code":"C143722","definitions":[{"definition":"A disorder characterized by tearing or disruption of the ovarian tissue.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by tearing or disruption of the ovarian tissue.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ovarian Rupture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Rupture"},{"name":"Maps_To","value":"Ovarian rupture"},{"name":"NCI_META_CUI","value":"CL541979"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146769":{"preferredName":"Ovulation Pain, CTCAE 5.0","code":"C146769","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ovulation Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovulation Pain"},{"name":"Maps_To","value":"Ovulation pain"},{"name":"NCI_META_CUI","value":"CL544791"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143725":{"preferredName":"Pain, CTCAE","code":"C143725","definitions":[{"definition":"A disorder characterized by the sensation of marked discomfort, distress or agony.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the sensation of marked discomfort, distress or agony.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pain"},{"name":"NCI_META_CUI","value":"CL550641"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143723":{"preferredName":"Pain In Extremity, CTCAE","code":"C143723","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pain In Extremity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pain in Extremity"},{"name":"Maps_To","value":"Pain in extremity"},{"name":"NCI_META_CUI","value":"CL541980"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143724":{"preferredName":"Pain of Skin, CTCAE","code":"C143724","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pain of Skin, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pain of Skin"},{"name":"Maps_To","value":"Pain of skin"},{"name":"NCI_META_CUI","value":"CL541981"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143726":{"preferredName":"Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE","code":"C143726","definitions":[{"definition":"A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Also known as Hand-Foot Syndrome.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Also known as Hand-Foot Syndrome.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Palmar-Plantar Erythrodysesthesia Syndrome"},{"name":"Maps_To","value":"Palmar-plantar erythrodysesthesia syndrome"},{"name":"NCI_META_CUI","value":"CL541982"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54935":{"preferredName":"Palpitations, CTCAE","code":"C54935","definitions":[{"definition":"A disorder characterized by an unpleasant sensation of irregular and/or forceful beating of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an unpleasant sensation of irregular and/or forceful beating of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Palpitations, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palpitations_Adverse_Event"},{"name":"Maps_To","value":"Palpitations"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3160712"}]}}{"C143728":{"preferredName":"Pancreas Infection, CTCAE","code":"C143728","definitions":[{"definition":"A disorder characterized by an infectious process involving the pancreas.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreas Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreas Infection"},{"name":"Maps_To","value":"Pancreas infection"},{"name":"NCI_META_CUI","value":"CL541983"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143729":{"preferredName":"Pancreatic Anastomotic Leak, CTCAE","code":"C143729","definitions":[{"definition":"A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pancreatic Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Anastomotic Leak"},{"name":"Maps_To","value":"Pancreatic anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541970"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143730":{"preferredName":"Pancreatic Duct Stenosis, CTCAE","code":"C143730","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the pancreatic duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the pancreatic duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Duct Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Duct Stenosis"},{"name":"Maps_To","value":"Pancreatic duct stenosis"},{"name":"NCI_META_CUI","value":"CL541971"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143731":{"preferredName":"Pancreatic Enzymes Decreased, CTCAE","code":"C143731","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pancreatic Enzymes Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Enzymes Decreased"},{"name":"Maps_To","value":"Pancreatic enzymes decreased"},{"name":"NCI_META_CUI","value":"CL541972"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57845":{"preferredName":"Pancreatic Fistula, CTCAE","code":"C57845","definitions":[{"definition":"A disorder characterized by an abnormal communication between the pancreas and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the pancreas and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreas_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Pancreatic Fistula"},{"name":"Maps_To","value":"Pancreatic fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963197"}]}}{"C56554":{"preferredName":"Pancreatic Hemorrhage, CTCAE","code":"C56554","definitions":[{"definition":"A disorder characterized by bleeding from the pancreas.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreas_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Pancreatic Hemorrhage"},{"name":"Maps_To","value":"Pancreatic hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963128"}]}}{"C143732":{"preferredName":"Pancreatic Necrosis, CTCAE","code":"C143732","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the pancreas.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pancreatic Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Necrosis"},{"name":"Maps_To","value":"Pancreatic necrosis"},{"name":"NCI_META_CUI","value":"CL541973"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146789":{"preferredName":"Pancreatitis, CTCAE 5.0","code":"C146789","definitions":[{"definition":"A disorder characterized by inflammation of the pancreas with no documented pancreas infection.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the pancreas with no documented pancreas infection.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pancreatitis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatitis"},{"name":"NCI_META_CUI","value":"CL544778"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143734":{"preferredName":"Papilledema, CTCAE","code":"C143734","definitions":[{"definition":"A disorder characterized by swelling around the optic disc.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling around the optic disc.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Papilledema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Papilledema"},{"name":"NCI_META_CUI","value":"CL541974"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143735":{"preferredName":"Papulopustular Rash, CTCAE","code":"C143735","definitions":[{"definition":"A disorder characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Papulopustular Rash, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Papulopustular Rash"},{"name":"Maps_To","value":"Papulopustular rash"},{"name":"NCI_META_CUI","value":"CL541975"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143736":{"preferredName":"Paresthesia, CTCAE","code":"C143736","definitions":[{"definition":"A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Paresthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paresthesia"},{"name":"NCI_META_CUI","value":"CL541976"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143737":{"preferredName":"Paronychia, CTCAE","code":"C143737","definitions":[{"definition":"A disorder characterized by an infectious process involving the soft tissues around the nail.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the soft tissues around the nail.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Paronychia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paronychia"},{"name":"NCI_META_CUI","value":"CL545950"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143738":{"preferredName":"Paroxysmal Atrial Tachycardia, CTCAE","code":"C143738","definitions":[{"definition":"A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Paroxysmal Atrial Tachycardia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paroxysmal Atrial Tachycardia"},{"name":"Maps_To","value":"Paroxysmal atrial tachycardia"},{"name":"NCI_META_CUI","value":"CL541964"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143739":{"preferredName":"Pelvic Floor Muscle Weakness, CTCAE","code":"C143739","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pelvic Floor Muscle Weakness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic Floor Muscle Weakness"},{"name":"Maps_To","value":"Pelvic floor muscle weakness"},{"name":"NCI_META_CUI","value":"CL541965"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143740":{"preferredName":"Pelvic Infection, CTCAE","code":"C143740","definitions":[{"definition":"A disorder characterized by an infectious process involving the pelvic cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the pelvic cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pelvic Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic Infection"},{"name":"Maps_To","value":"Pelvic infection"},{"name":"NCI_META_CUI","value":"CL546035"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146679":{"preferredName":"Pelvic Pain, CTCAE 5.0","code":"C146679","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the pelvis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the pelvis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pelvic Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic Pain"},{"name":"Maps_To","value":"Pelvic pain"},{"name":"NCI_META_CUI","value":"CL545999"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58399":{"preferredName":"Pelvic Soft Tissue Necrosis, CTCAE","code":"C58399","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pelvic Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pelvic_Soft_Tissue_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Pelvic soft tissue necrosis"},{"name":"Maps_To","value":"Pelvic Soft Tissue Necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962964"}]}}{"C143741":{"preferredName":"Penile Infection, CTCAE","code":"C143741","definitions":[{"definition":"A disorder characterized by an infectious process involving the penis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the penis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Penile Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Penile Infection"},{"name":"Maps_To","value":"Penile infection"},{"name":"NCI_META_CUI","value":"CL541966"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146680":{"preferredName":"Penile Pain, CTCAE 5.0","code":"C146680","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the penis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the penis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Penile Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Penile Pain"},{"name":"Maps_To","value":"Penile pain"},{"name":"NCI_META_CUI","value":"CL544633"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143742":{"preferredName":"Perforation Bile Duct, CTCAE","code":"C143742","definitions":[{"definition":"A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Perforation Bile Duct, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perforation Bile Duct"},{"name":"Maps_To","value":"Perforation bile duct"},{"name":"NCI_META_CUI","value":"CL541967"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143743":{"preferredName":"Pericardial Effusion, CTCAE","code":"C143743","definitions":[{"definition":"A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pericardial Effusion, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pericardial Effusion"},{"name":"Maps_To","value":"Pericardial effusion"},{"name":"NCI_META_CUI","value":"CL545996"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143744":{"preferredName":"Pericardial Tamponade, CTCAE","code":"C143744","definitions":[{"definition":"A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pericardial Tamponade, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pericardial Tamponade"},{"name":"Maps_To","value":"Pericardial tamponade"},{"name":"NCI_META_CUI","value":"CL541968"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55067":{"preferredName":"Pericarditis, CTCAE","code":"C55067","definitions":[{"definition":"A disorder characterized by irritation to the layers of the pericardium (the protective sac around the heart).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by irritation to the layers of the pericardium (the protective sac around the heart).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pericarditis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pericarditis_Adverse_Event"},{"name":"Maps_To","value":"Pericarditis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963211"}]}}{"C146681":{"preferredName":"Perineal Pain, CTCAE 5.0","code":"C146681","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Perineal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perineal Pain"},{"name":"Maps_To","value":"Perineal pain"},{"name":"NCI_META_CUI","value":"CL544634"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57849":{"preferredName":"Periodontal Disease, CTCAE","code":"C57849","definitions":[{"definition":"A disorder in the gingival tissue around the teeth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder in the gingival tissue around the teeth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Periodontal Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Periodontal_Disease_Adverse_Event"},{"name":"Maps_To","value":"Periodontal Disease"},{"name":"Maps_To","value":"Periodontal disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559300"}]}}{"C143747":{"preferredName":"Periorbital Edema, CTCAE","code":"C143747","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Periorbital Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Periorbital Edema"},{"name":"Maps_To","value":"Periorbital edema"},{"name":"NCI_META_CUI","value":"CL541969"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143748":{"preferredName":"Periorbital Infection, CTCAE","code":"C143748","definitions":[{"definition":"A disorder characterized by an infectious process involving the orbit of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the orbit of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Periorbital Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Periorbital Infection"},{"name":"Maps_To","value":"Periorbital infection"},{"name":"NCI_META_CUI","value":"CL542071"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143749":{"preferredName":"Peripheral Ischemia, CTCAE","code":"C143749","definitions":[{"definition":"A disorder characterized by impaired circulation to an extremity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by impaired circulation to an extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Peripheral Ischemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Ischemia"},{"name":"Maps_To","value":"Peripheral ischemia"},{"name":"NCI_META_CUI","value":"CL542072"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143750":{"preferredName":"Peripheral Motor Neuropathy, CTCAE","code":"C143750","definitions":[{"definition":"A disorder characterized by damage or dysfunction of the peripheral motor nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by damage or dysfunction of the peripheral motor nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Peripheral Motor Neuropathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Motor Neuropathy"},{"name":"Maps_To","value":"Peripheral motor neuropathy"},{"name":"NCI_META_CUI","value":"CL542073"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143751":{"preferredName":"Peripheral Nerve Infection, CTCAE","code":"C143751","definitions":[{"definition":"A disorder characterized by an infectious process involving the peripheral nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the peripheral nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Peripheral Nerve Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Nerve Infection"},{"name":"Maps_To","value":"Peripheral nerve infection"},{"name":"NCI_META_CUI","value":"CL542074"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143752":{"preferredName":"Peripheral Sensory Neuropathy, CTCAE","code":"C143752","definitions":[{"definition":"A disorder characterized by damage or dysfunction of the peripheral sensory nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by damage or dysfunction of the peripheral sensory nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Peripheral Sensory Neuropathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Sensory Neuropathy"},{"name":"Maps_To","value":"Peripheral sensory neuropathy"},{"name":"NCI_META_CUI","value":"CL542075"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143753":{"preferredName":"Peritoneal Infection, CTCAE","code":"C143753","definitions":[{"definition":"A disorder characterized by an infectious process involving the peritoneum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the peritoneum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Peritoneal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peritoneal Infection"},{"name":"Maps_To","value":"Peritoneal infection"},{"name":"NCI_META_CUI","value":"CL542076"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57850":{"preferredName":"Peritoneal Necrosis, CTCAE","code":"C57850","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the peritoneum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the peritoneum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Peritoneal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peritoneal_Cavity_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Peritoneal Necrosis"},{"name":"Maps_To","value":"Peritoneal necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556514"}]}}{"C143754":{"preferredName":"Personality Change, CTCAE","code":"C143754","definitions":[{"definition":"A disorder characterized by a conspicuous change in a person's behavior and thinking.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a conspicuous change in a person's behavior and thinking.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Personality Change, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personality Change"},{"name":"Maps_To","value":"Personality change"},{"name":"NCI_META_CUI","value":"CL542077"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146682":{"preferredName":"Phantom Pain, CTCAE 5.0","code":"C146682","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Phantom Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phantom pain"},{"name":"Maps_To","value":"Phantom Pain"},{"name":"NCI_META_CUI","value":"CL544740"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143755":{"preferredName":"Pharyngeal Anastomotic Leak, CTCAE","code":"C143755","definitions":[{"definition":"A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngeal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngeal Anastomotic Leak"},{"name":"Maps_To","value":"Pharyngeal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL542078"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57851":{"preferredName":"Pharyngeal Fistula, CTCAE","code":"C57851","definitions":[{"definition":"A disorder characterized by an abnormal communication between the pharynx and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the pharynx and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngeal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pharynx_GI_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Pharyngeal Fistula"},{"name":"Maps_To","value":"Pharyngeal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560407"}]}}{"C56557":{"preferredName":"Pharyngeal Hemorrhage, CTCAE","code":"C56557","definitions":[{"definition":"A disorder characterized by bleeding from the pharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the pharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngeal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pharynx_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Pharyngeal Hemorrhage"},{"name":"Maps_To","value":"Pharyngeal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560807"}]}}{"C143756":{"preferredName":"Pharyngeal Mucositis, CTCAE","code":"C143756","definitions":[{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the pharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the pharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngeal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngeal Mucositis"},{"name":"Maps_To","value":"Pharyngeal mucositis"},{"name":"NCI_META_CUI","value":"CL542065"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57855":{"preferredName":"Pharyngeal Necrosis, CTCAE","code":"C57855","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the pharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the pharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngeal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pharynx_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Pharyngeal Necrosis"},{"name":"Maps_To","value":"Pharyngeal necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1397204"}]}}{"C143757":{"preferredName":"Pharyngeal Stenosis, CTCAE","code":"C143757","definitions":[{"definition":"A disorder characterized by a narrowing of the pharyngeal airway.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the pharyngeal airway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngeal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngeal Stenosis"},{"name":"Maps_To","value":"Pharyngeal stenosis"},{"name":"NCI_META_CUI","value":"CL542066"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143758":{"preferredName":"Pharyngitis, CTCAE","code":"C143758","definitions":[{"definition":"A disorder characterized by inflammation of the throat.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the throat.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngitis"},{"name":"NCI_META_CUI","value":"CL542067"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143759":{"preferredName":"Pharyngolaryngeal Pain, CTCAE","code":"C143759","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the pharyngolaryngeal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the pharyngolaryngeal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngolaryngeal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngolaryngeal Pain"},{"name":"Maps_To","value":"Pharyngolaryngeal pain"},{"name":"NCI_META_CUI","value":"CL542068"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143761":{"preferredName":"Phlebitis, CTCAE","code":"C143761","definitions":[{"definition":"A disorder characterized by inflammation of the wall of a vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the wall of a vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Phlebitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phlebitis"},{"name":"NCI_META_CUI","value":"CL542070"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143760":{"preferredName":"Phlebitis Infective, CTCAE","code":"C143760","definitions":[{"definition":"A disorder characterized by an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Phlebitis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phlebitis Infective"},{"name":"Maps_To","value":"Phlebitis infective"},{"name":"NCI_META_CUI","value":"CL542069"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146770":{"preferredName":"Photophobia, CTCAE 5.0","code":"C146770","definitions":[{"definition":"A disorder characterized by fear and avoidance of light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by fear and avoidance of light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Photophobia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Photophobia"},{"name":"NCI_META_CUI","value":"CL544792"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58005":{"preferredName":"Photosensitivity, CTCAE","code":"C58005","definitions":[{"definition":"A disorder characterized by an increase in sensitivity of the skin to light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in sensitivity of the skin to light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Photosensitivity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Photosensitivity_Adverse_Event"},{"name":"Maps_To","value":"Photosensitivity"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2362621"}]}}{"C143764":{"preferredName":"Platelet Count Decreased, CTCAE","code":"C143764","definitions":[{"definition":"A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Platelet Count Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Platelet Count Decreased"},{"name":"Maps_To","value":"Platelet count decreased"},{"name":"NCI_META_CUI","value":"CL545991"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143765":{"preferredName":"Pleural Effusion, CTCAE","code":"C143765","definitions":[{"definition":"A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pleural Effusion, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleural Effusion"},{"name":"Maps_To","value":"Pleural effusion"},{"name":"NCI_META_CUI","value":"CL545973"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56558":{"preferredName":"Pleural Hemorrhage, CTCAE","code":"C56558","definitions":[{"definition":"A disorder characterized by bleeding from the pleural cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the pleural cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pleural Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleura_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Pleural Hemorrhage"},{"name":"Maps_To","value":"Pleural hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556619"}]}}{"C143766":{"preferredName":"Pleural Infection, CTCAE","code":"C143766","definitions":[{"definition":"A disorder characterized by an infectious process involving the pleura.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the pleura.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pleural Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleural Infection"},{"name":"Maps_To","value":"Pleural infection"},{"name":"NCI_META_CUI","value":"CL542057"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146663":{"preferredName":"Pleuritic Pain, CTCAE 5.0","code":"C146663","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the pleura.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the pleura.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pleuritic Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleuritic pain"},{"name":"Maps_To","value":"Pleuritic Pain"},{"name":"NCI_META_CUI","value":"CL544647"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143767":{"preferredName":"Pneumonitis, CTCAE","code":"C143767","definitions":[{"definition":"A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pneumonitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pneumonitis"},{"name":"NCI_META_CUI","value":"CL542058"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58201":{"preferredName":"Pneumothorax, CTCAE","code":"C58201","definitions":[{"definition":"A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the lung.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the lung.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pneumothorax, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pneumothorax_Adverse_Event"},{"name":"Maps_To","value":"Pneumothorax"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963215"}]}}{"C143769":{"preferredName":"Portal Hypertension, CTCAE","code":"C143769","definitions":[{"definition":"A disorder characterized by an increase in blood pressure in the portal venous system.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in blood pressure in the portal venous system.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Portal Hypertension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Portal Hypertension"},{"name":"Maps_To","value":"Portal hypertension"},{"name":"NCI_META_CUI","value":"CL542059"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143770":{"preferredName":"Portal Vein Thrombosis, CTCAE","code":"C143770","definitions":[{"definition":"A disorder characterized by the formation of a thrombus (blood clot) in the portal vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the formation of a thrombus (blood clot) in the portal vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Portal Vein Thrombosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Portal Vein Thrombosis"},{"name":"Maps_To","value":"Portal vein thrombosis"},{"name":"NCI_META_CUI","value":"CL542060"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143771":{"preferredName":"Postnasal Drip, CTCAE","code":"C143771","definitions":[{"definition":"A disorder characterized by excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Postnasal Drip, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Postnasal Drip"},{"name":"Maps_To","value":"Postnasal drip"},{"name":"NCI_META_CUI","value":"CL542061"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143772":{"preferredName":"Postoperative Hemorrhage, CTCAE","code":"C143772","definitions":[{"definition":"A disorder characterized by bleeding occurring after a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding occurring after a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Postoperative Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Postoperative Hemorrhage"},{"name":"Maps_To","value":"Postoperative hemorrhage"},{"name":"NCI_META_CUI","value":"CL542062"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143773":{"preferredName":"Postoperative Thoracic Procedure Complication, CTCAE","code":"C143773","definitions":[{"definition":"A finding of a previously undocumented problem that occurs after a thoracic procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of a previously undocumented problem that occurs after a thoracic procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Postoperative Thoracic Procedure Complication, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Postoperative Thoracic Procedure Complication"},{"name":"Maps_To","value":"Postoperative thoracic procedure complication"},{"name":"NCI_META_CUI","value":"CL542063"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146645":{"preferredName":"Precocious Puberty, CTCAE 5.0","code":"C146645","definitions":[{"definition":"A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Precocious Puberty, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Precocious puberty"},{"name":"Maps_To","value":"Precocious Puberty"},{"name":"NCI_META_CUI","value":"CL544661"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143775":{"preferredName":"Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","code":"C143775","synonyms":[{"termName":"Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pregnancy, Puerperium and Perinatal Conditions - Other"},{"name":"Maps_To","value":"Pregnancy, puerperium and perinatal conditions - Other, specify"},{"name":"NCI_META_CUI","value":"CL542064"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143776":{"preferredName":"Premature Delivery, CTCAE","code":"C143776","definitions":[{"definition":"A disorder characterized by delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Premature Delivery, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Premature Delivery"},{"name":"Maps_To","value":"Premature delivery"},{"name":"NCI_META_CUI","value":"CL542049"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143777":{"preferredName":"Premature Menopause, CTCAE","code":"C143777","definitions":[{"definition":"A disorder characterized by premature ovarian failure. Symptoms may include hot flashes, night sweats, mood swings, and a decrease in sex drive. Laboratory findings include elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH.)","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by premature ovarian failure. Symptoms may include hot flashes, night sweats, mood swings, and a decrease in sex drive. Laboratory findings include elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH.)","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Premature Menopause, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Premature Menopause"},{"name":"Maps_To","value":"Premature menopause"},{"name":"NCI_META_CUI","value":"CL542050"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143778":{"preferredName":"Presyncope, CTCAE","code":"C143778","definitions":[{"definition":"A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Presyncope, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Presyncope"},{"name":"NCI_META_CUI","value":"CL542051"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57857":{"preferredName":"Proctitis, CTCAE","code":"C57857","definitions":[{"definition":"A disorder characterized by inflammation of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Proctitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Proctitis_Adverse_Event"},{"name":"Maps_To","value":"Proctitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963216"}]}}{"C143780":{"preferredName":"Productive Cough, CTCAE","code":"C143780","definitions":[{"definition":"A disorder characterized by expectorated secretions upon coughing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by expectorated secretions upon coughing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Productive Cough, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Productive Cough"},{"name":"Maps_To","value":"Productive cough"},{"name":"NCI_META_CUI","value":"CL542052"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143781":{"preferredName":"Prolapse of Intestinal Stoma, CTCAE","code":"C143781","definitions":[{"definition":"A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Prolapse of Intestinal Stoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prolapse of Intestinal Stoma"},{"name":"Maps_To","value":"Prolapse of intestinal stoma"},{"name":"NCI_META_CUI","value":"CL542053"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143782":{"preferredName":"Prolapse of Urostomy, CTCAE","code":"C143782","definitions":[{"definition":"A finding of displacement of the urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of displacement of the urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Prolapse of Urostomy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prolapse of Urostomy"},{"name":"Maps_To","value":"Prolapse of urostomy"},{"name":"NCI_META_CUI","value":"CL542054"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143783":{"preferredName":"Prostate Infection, CTCAE","code":"C143783","definitions":[{"definition":"A disorder characterized by an infectious process involving the prostate gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the prostate gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Prostate Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostate Infection"},{"name":"Maps_To","value":"Prostate infection"},{"name":"NCI_META_CUI","value":"CL542055"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56552":{"preferredName":"Prostatic Hemorrhage, CTCAE","code":"C56552","definitions":[{"definition":"A disorder characterized by bleeding from the prostate gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the prostate gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Prostatic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prostate_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Prostatic hemorrhage"},{"name":"Maps_To","value":"Prostatic Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963129"}]}}{"C143784":{"preferredName":"Prostatic Obstruction, CTCAE","code":"C143784","definitions":[{"definition":"A disorder characterized by compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Prostatic Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostatic Obstruction"},{"name":"Maps_To","value":"Prostatic obstruction"},{"name":"NCI_META_CUI","value":"CL542056"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146664":{"preferredName":"Prostatic Pain, CTCAE 5.0","code":"C146664","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the prostate gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the prostate gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Prostatic Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostatic Pain"},{"name":"Maps_To","value":"Prostatic pain"},{"name":"NCI_META_CUI","value":"CL544648"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146758":{"preferredName":"Proteinuria, CTCAE 5.0","code":"C146758","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Proteinuria, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Proteinuria"},{"name":"NCI_META_CUI","value":"CL544796"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58006":{"preferredName":"Pruritus, CTCAE","code":"C58006","definitions":[{"definition":"A disorder characterized by an intense itching sensation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an intense itching sensation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pruritus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pruritus_Adverse_Event"},{"name":"Maps_To","value":"Pruritus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559138"}]}}{"C143787":{"preferredName":"Psychiatric Disorders - Other, Specify, CTCAE","code":"C143787","synonyms":[{"termName":"Psychiatric Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Psychiatric Disorders - Other"},{"name":"Maps_To","value":"Psychiatric disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542043"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143788":{"preferredName":"Psychosis, CTCAE","code":"C143788","definitions":[{"definition":"A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Psychosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Psychosis"},{"name":"NCI_META_CUI","value":"CL545977"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143789":{"preferredName":"Pulmonary Edema, CTCAE","code":"C143789","definitions":[{"definition":"A disorder characterized by accumulation of fluid in the lung tissues that causes a disturbance of the gas exchange that may lead to respiratory failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by accumulation of fluid in the lung tissues that causes a disturbance of the gas exchange that may lead to respiratory failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pulmonary Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Edema"},{"name":"Maps_To","value":"Pulmonary edema"},{"name":"NCI_META_CUI","value":"CL542044"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143790":{"preferredName":"Pulmonary Fibrosis, CTCAE","code":"C143790","definitions":[{"definition":"A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pulmonary Fibrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Fibrosis"},{"name":"Maps_To","value":"Pulmonary fibrosis"},{"name":"NCI_META_CUI","value":"CL542045"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143791":{"preferredName":"Pulmonary Fistula, CTCAE","code":"C143791","definitions":[{"definition":"A disorder characterized by an abnormal communication between the lung and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the lung and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pulmonary Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Fistula"},{"name":"Maps_To","value":"Pulmonary fistula"},{"name":"NCI_META_CUI","value":"CL542046"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55068":{"preferredName":"Pulmonary Hypertension, CTCAE","code":"C55068","definitions":[{"definition":"A disorder characterized by an increase in pressure within the pulmonary circulation due to lung or heart disorder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in pressure within the pulmonary circulation due to lung or heart disorder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pulmonary Hypertension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pulmonary_Hypertension_Adverse_Event"},{"name":"Maps_To","value":"Pulmonary hypertension"},{"name":"Maps_To","value":"Pulmonary Hypertension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963220"}]}}{"C143793":{"preferredName":"Pulmonary Valve Disease, CTCAE","code":"C143793","definitions":[{"definition":"A disorder characterized by a defect in pulmonary valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a defect in pulmonary valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pulmonary Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Valve Disease"},{"name":"Maps_To","value":"Pulmonary valve disease"},{"name":"NCI_META_CUI","value":"CL542047"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143794":{"preferredName":"Purpura, CTCAE","code":"C143794","definitions":[{"definition":"A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Purpura, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Purpura"},{"name":"NCI_META_CUI","value":"CL545981"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143795":{"preferredName":"Pyramidal Tract Syndrome, CTCAE","code":"C143795","definitions":[{"definition":"A disorder characterized by dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pyramidal Tract Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pyramidal Tract Syndrome"},{"name":"Maps_To","value":"Pyramidal tract syndrome"},{"name":"NCI_META_CUI","value":"CL542048"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143796":{"preferredName":"Radiation Recall Reaction (Dermatologic), CTCAE","code":"C143796","definitions":[{"definition":"A finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Radiation Recall Reaction (Dermatologic), CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation Recall Reaction (Dermatologic)"},{"name":"Maps_To","value":"Radiation recall reaction (dermatologic)"},{"name":"NCI_META_CUI","value":"CL542036"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143797":{"preferredName":"Radiculitis, CTCAE","code":"C143797","definitions":[{"definition":"A disorder characterized by inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Radiculitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiculitis"},{"name":"NCI_META_CUI","value":"CL542037"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143798":{"preferredName":"Rash Acneiform, CTCAE","code":"C143798","definitions":[{"definition":"A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rash Acneiform, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rash Acneiform"},{"name":"Maps_To","value":"Rash acneiform"},{"name":"NCI_META_CUI","value":"CL542038"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143799":{"preferredName":"Rash Maculo-Papular, CTCAE","code":"C143799","definitions":[{"definition":"A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rash Maculo-Papular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rash Maculo-Papular"},{"name":"Maps_To","value":"Rash maculo-papular"},{"name":"NCI_META_CUI","value":"CL542039"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143800":{"preferredName":"Rash Pustular, CTCAE","code":"C143800","definitions":[{"definition":"A disorder characterized by a circumscribed and elevated skin lesion filled with pus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed and elevated skin lesion filled with pus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rash Pustular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rash Pustular"},{"name":"Maps_To","value":"Rash pustular"},{"name":"NCI_META_CUI","value":"CL542040"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143801":{"preferredName":"Rectal Anastomotic Leak, CTCAE","code":"C143801","definitions":[{"definition":"A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rectal Anastomotic Leak"},{"name":"Maps_To","value":"Rectal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL546006"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57859":{"preferredName":"Rectal Fistula, CTCAE","code":"C57859","definitions":[{"definition":"A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Rectum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Rectal Fistula"},{"name":"Maps_To","value":"Rectal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963224"}]}}{"C56560":{"preferredName":"Rectal Hemorrhage, CTCAE","code":"C56560","definitions":[{"definition":"A disorder characterized by bleeding from the rectal wall and discharged from the anus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the rectal wall and discharged from the anus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Rectum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Rectal Hemorrhage"},{"name":"Maps_To","value":"Rectal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962965"}]}}{"C143802":{"preferredName":"Rectal Mucositis, CTCAE","code":"C143802","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal Mucositis"},{"name":"Maps_To","value":"Rectal mucositis"},{"name":"NCI_META_CUI","value":"CL542041"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57863":{"preferredName":"Rectal Necrosis, CTCAE","code":"C57863","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the rectal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the rectal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rectum_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Rectal Necrosis"},{"name":"Maps_To","value":"Rectal necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556521"}]}}{"C57864":{"preferredName":"Rectal Obstruction, CTCAE","code":"C57864","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rectum_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Rectal Obstruction"},{"name":"Maps_To","value":"Rectal obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1406054"}]}}{"C146631":{"preferredName":"Rectal Pain, CTCAE 5.0","code":"C146631","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the rectal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the rectal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal Pain"},{"name":"Maps_To","value":"Rectal pain"},{"name":"NCI_META_CUI","value":"CL544677"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146634":{"preferredName":"Rectal Perforation, CTCAE 5.0","code":"C146634","definitions":[{"definition":"A disorder characterized by a rupture in the rectal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the rectal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal perforation"},{"name":"Maps_To","value":"Rectal Perforation"},{"name":"NCI_META_CUI","value":"CL544666"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143803":{"preferredName":"Rectal Stenosis, CTCAE","code":"C143803","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal Stenosis"},{"name":"Maps_To","value":"Rectal stenosis"},{"name":"NCI_META_CUI","value":"CL542042"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57867":{"preferredName":"Rectal Ulcer, CTCAE","code":"C57867","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Rectum_Ulcer_Adverse_Event"},{"name":"Maps_To","value":"Rectal Ulcer"},{"name":"Maps_To","value":"Rectal ulcer"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963258"}]}}{"C143804":{"preferredName":"Recurrent Laryngeal Nerve Palsy, CTCAE","code":"C143804","definitions":[{"definition":"A disorder characterized by paralysis of the recurrent laryngeal nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by paralysis of the recurrent laryngeal nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Recurrent Laryngeal Nerve Palsy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrent Laryngeal Nerve Palsy"},{"name":"Maps_To","value":"Recurrent laryngeal nerve palsy"},{"name":"NCI_META_CUI","value":"CL542028"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143805":{"preferredName":"Renal and Urinary Disorders - Other, Specify, CTCAE","code":"C143805","synonyms":[{"termName":"Renal and Urinary Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal and Urinary Disorders - Other"},{"name":"Maps_To","value":"Renal and urinary disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542029"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143806":{"preferredName":"Renal Calculi, CTCAE","code":"C143806","definitions":[{"definition":"A disorder characterized by the formation of crystals/kidney stones in the pelvis of the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the formation of crystals/kidney stones in the pelvis of the kidney.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Renal Calculi, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Calculi"},{"name":"Maps_To","value":"Renal calculi"},{"name":"NCI_META_CUI","value":"CL542030"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143807":{"preferredName":"Renal Colic, CTCAE","code":"C143807","definitions":[{"definition":"A disorder characterized by paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of crystals/kidney stones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of crystals/kidney stones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Renal Colic, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Colic"},{"name":"Maps_To","value":"Renal colic"},{"name":"NCI_META_CUI","value":"CL542031"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56544":{"preferredName":"Renal Hemorrhage, CTCAE","code":"C56544","definitions":[{"definition":"A disorder characterized by bleeding from the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the kidney.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Renal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kidney_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Renal Hemorrhage"},{"name":"Maps_To","value":"Renal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963127"}]}}{"C143808":{"preferredName":"Reproductive System and Breast Disorders - Other, Specify, CTCAE","code":"C143808","synonyms":[{"termName":"Reproductive System and Breast Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Reproductive System and Breast Disorders - Other"},{"name":"Maps_To","value":"Reproductive system and breast disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542032"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143809":{"preferredName":"Respiratory Failure, CTCAE","code":"C143809","definitions":[{"definition":"A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of carbon dioxide.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of carbon dioxide.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Respiratory Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Respiratory Failure"},{"name":"Maps_To","value":"Respiratory failure"},{"name":"NCI_META_CUI","value":"CL542033"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143810":{"preferredName":"Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","code":"C143810","synonyms":[{"termName":"Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Respiratory, Thoracic and Mediastinal Disorders - Other"},{"name":"Maps_To","value":"Respiratory, thoracic and mediastinal disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542034"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143811":{"preferredName":"Restlessness, CTCAE","code":"C143811","definitions":[{"definition":"A disorder characterized by an inability to rest, relax or be still.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an inability to rest, relax or be still.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Restlessness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Restlessness"},{"name":"NCI_META_CUI","value":"CL542035"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55069":{"preferredName":"Restrictive Cardiomyopathy, CTCAE","code":"C55069","definitions":[{"definition":"A disorder characterized by an inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and loses its flexibility.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and loses its flexibility.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Restrictive Cardiomyopathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Restrictive_Cardiomyopathy_Adverse_Event"},{"name":"Maps_To","value":"Restrictive cardiomyopathy"},{"name":"Maps_To","value":"Restrictive Cardiomyopathy"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963079"}]}}{"C146729":{"preferredName":"Retinal Detachment, CTCAE 5.0","code":"C146729","definitions":[{"definition":"A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Retinal Detachment, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retinal Detachment"},{"name":"Maps_To","value":"Retinal detachment"},{"name":"NCI_META_CUI","value":"CL544707"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143814":{"preferredName":"Retinal Tear, CTCAE","code":"C143814","definitions":[{"definition":"A disorder characterized by a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Retinal Tear, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retinal Tear"},{"name":"Maps_To","value":"Retinal tear"},{"name":"NCI_META_CUI","value":"CL542020"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143815":{"preferredName":"Retinal Vascular Disorder, CTCAE","code":"C143815","definitions":[{"definition":"A disorder characterized by pathological retinal blood vessels that adversely affects vision.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by pathological retinal blood vessels that adversely affects vision.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Retinal Vascular Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retinal Vascular Disorder"},{"name":"Maps_To","value":"Retinal vascular disorder"},{"name":"NCI_META_CUI","value":"CL542021"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56635":{"preferredName":"Retinoic Acid Syndrome, CTCAE","code":"C56635","definitions":[{"definition":"A disorder characterized by weight gain, dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans retinoic acid.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by weight gain, dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans retinoic acid.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Retinoic Acid Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retinoic_Acid_Syndrome_Adverse_Event"},{"name":"Maps_To","value":"Retinoic Acid Syndrome"},{"name":"Maps_To","value":"Retinoic acid syndrome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962967"}]}}{"C55891":{"preferredName":"Retinopathy, CTCAE","code":"C55891","definitions":[{"definition":"A disorder involving the retina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder involving the retina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Retinopathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retinopathy_Adverse_Event"},{"name":"Maps_To","value":"Retinopathy"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962966"}]}}{"C146632":{"preferredName":"Retroperitoneal Hemorrhage, CTCAE 5.0","code":"C146632","definitions":[{"definition":"A disorder characterized by bleeding from the retroperitoneal area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the retroperitoneal area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Retroperitoneal Hemorrhage, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retroperitoneal hemorrhage"},{"name":"Maps_To","value":"Retroperitoneal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL544678"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143818":{"preferredName":"Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","code":"C143818","definitions":[{"definition":"A disorder characterized by headaches, mental status changes, visual disturbances, and/or seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition. Also known as posterior reversible encephalopathy syndrome (PRES).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by headaches, mental status changes, visual disturbances, and/or seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition. Also known as posterior reversible encephalopathy syndrome (PRES).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Reversible Posterior Leukoencephalopathy Syndrome"},{"name":"Maps_To","value":"Reversible posterior leukoencephalopathy syndrome"},{"name":"NCI_META_CUI","value":"CL542022"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143819":{"preferredName":"Rhinitis Infective, CTCAE","code":"C143819","definitions":[{"definition":"A disorder characterized by an infectious process involving the nasal mucosal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the nasal mucosal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rhinitis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rhinitis Infective"},{"name":"Maps_To","value":"Rhinitis infective"},{"name":"NCI_META_CUI","value":"CL542023"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55070":{"preferredName":"Right Ventricular Dysfunction, CTCAE","code":"C55070","definitions":[{"definition":"A disorder characterized by impairment of right ventricular function associated with low ejection fraction and a decrease in motility of the right ventricular wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by impairment of right ventricular function associated with low ejection fraction and a decrease in motility of the right ventricular wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Right Ventricular Dysfunction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Ventricular_Dysfunction_Adverse_Event"},{"name":"Maps_To","value":"Right Ventricular Dysfunction"},{"name":"Maps_To","value":"Right ventricular dysfunction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556315"}]}}{"C143821":{"preferredName":"Salivary Duct Inflammation, CTCAE","code":"C143821","definitions":[{"definition":"A disorder characterized by inflammation of the salivary duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the salivary duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Salivary Duct Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Salivary Duct Inflammation"},{"name":"Maps_To","value":"Salivary duct inflammation"},{"name":"NCI_META_CUI","value":"CL542024"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57868":{"preferredName":"Salivary Gland Fistula, CTCAE","code":"C57868","definitions":[{"definition":"A disorder characterized by an abnormal communication between a salivary gland and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between a salivary gland and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Salivary Gland Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Fistula"},{"name":"Maps_To","value":"Salivary Gland Fistula"},{"name":"Maps_To","value":"Salivary gland fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2700637"}]}}{"C143822":{"preferredName":"Salivary Gland Infection, CTCAE","code":"C143822","definitions":[{"definition":"A disorder characterized by an infectious process involving the salivary gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the salivary gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Salivary Gland Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Salivary Gland Infection"},{"name":"Maps_To","value":"Salivary gland infection"},{"name":"NCI_META_CUI","value":"CL542025"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146772":{"preferredName":"Scalp Pain, CTCAE 5.0","code":"C146772","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Scalp Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scalp pain"},{"name":"Maps_To","value":"Scalp Pain"},{"name":"NCI_META_CUI","value":"CL544780"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143823":{"preferredName":"Scleral Disorder, CTCAE","code":"C143823","definitions":[{"definition":"A disorder characterized by involvement of the sclera of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by involvement of the sclera of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Scleral Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scleral Disorder"},{"name":"Maps_To","value":"Scleral disorder"},{"name":"NCI_META_CUI","value":"CL542026"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143824":{"preferredName":"Scoliosis, CTCAE","code":"C143824","definitions":[{"definition":"A disorder characterized by a malformed, lateral curvature of the spine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a malformed, lateral curvature of the spine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Scoliosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scoliosis"},{"name":"NCI_META_CUI","value":"CL542027"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143825":{"preferredName":"Scrotal Infection, CTCAE","code":"C143825","definitions":[{"definition":"A disorder characterized by an infectious process involving the scrotum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the scrotum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Scrotal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scrotal Infection"},{"name":"Maps_To","value":"Scrotal infection"},{"name":"NCI_META_CUI","value":"CL542131"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146665":{"preferredName":"Scrotal Pain, CTCAE 5.0","code":"C146665","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the scrotal area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the scrotal area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Scrotal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scrotal Pain"},{"name":"Maps_To","value":"Scrotal pain"},{"name":"NCI_META_CUI","value":"CL544649"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146700":{"preferredName":"Seizure, CTCAE 5.0","code":"C146700","definitions":[{"definition":"A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Seizure, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Seizure"},{"name":"NCI_META_CUI","value":"CL544727"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143827":{"preferredName":"Sepsis, CTCAE","code":"C143827","definitions":[{"definition":"A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sepsis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sepsis"},{"name":"NCI_META_CUI","value":"CL545911"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58401":{"preferredName":"Seroma, CTCAE","code":"C58401","definitions":[{"definition":"A finding of tumor-like collection of serum in the tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of tumor-like collection of serum in the tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Seroma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Seroma_Adverse_Event"},{"name":"Maps_To","value":"Seroma"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963233"}]}}{"C143829":{"preferredName":"Serum Amylase Increased, CTCAE","code":"C143829","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Serum Amylase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Amylase Increased"},{"name":"Maps_To","value":"Serum amylase increased"},{"name":"NCI_META_CUI","value":"CL542132"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146642":{"preferredName":"Serum Sickness, CTCAE 5.0","code":"C146642","definitions":[{"definition":"A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Serum Sickness, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum sickness"},{"name":"Maps_To","value":"Serum Sickness"},{"name":"NCI_META_CUI","value":"CL544659"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54938":{"preferredName":"Sick Sinus Syndrome, CTCAE","code":"C54938","definitions":[{"definition":"A disorder characterized by a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by syncope, fatigue and dizziness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by syncope, fatigue and dizziness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sick Sinus Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sick_Sinus_Syndrome_Adverse_Event"},{"name":"Maps_To","value":"Sick Sinus Syndrome"},{"name":"Maps_To","value":"Sick sinus syndrome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963235"}]}}{"C54940":{"preferredName":"Sinus Bradycardia, CTCAE","code":"C54940","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sinus Bradycardia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sinus_Bradycardia_Adverse_Event"},{"name":"Maps_To","value":"Sinus Bradycardia"},{"name":"Maps_To","value":"Sinus bradycardia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963175"}]}}{"C143831":{"preferredName":"Sinus Disorder, CTCAE","code":"C143831","definitions":[{"definition":"A disorder characterized by involvement of the paranasal sinuses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by involvement of the paranasal sinuses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sinus Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinus Disorder"},{"name":"Maps_To","value":"Sinus disorder"},{"name":"NCI_META_CUI","value":"CL542133"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146783":{"preferredName":"Sinus Pain, CTCAE 5.0","code":"C146783","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sinus Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinus pain"},{"name":"Maps_To","value":"Sinus Pain"},{"name":"NCI_META_CUI","value":"CL544774"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146759":{"preferredName":"Sinus Tachycardia, CTCAE 5.0","code":"C146759","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sinus Tachycardia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinus Tachycardia"},{"name":"Maps_To","value":"Sinus tachycardia"},{"name":"NCI_META_CUI","value":"CL544797"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143832":{"preferredName":"Sinusitis, CTCAE","code":"C143832","definitions":[{"definition":"A disorder characterized by an infectious process involving the mucous membranes of the paranasal sinuses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the mucous membranes of the paranasal sinuses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sinusitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinusitis"},{"name":"NCI_META_CUI","value":"CL542134"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143833":{"preferredName":"Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","code":"C143833","synonyms":[{"termName":"Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin and Subcutaneous Tissue Disorders - Other"},{"name":"Maps_To","value":"Skin and subcutaneous tissue disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL546009"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146644":{"preferredName":"Skin Atrophy, CTCAE 5.0","code":"C146644","definitions":[{"definition":"A disorder characterized by the degeneration and thinning of the epidermis and dermis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the degeneration and thinning of the epidermis and dermis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Skin Atrophy, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin atrophy"},{"name":"Maps_To","value":"Skin Atrophy"},{"name":"NCI_META_CUI","value":"CL544660"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143835":{"preferredName":"Skin Hyperpigmentation, CTCAE","code":"C143835","definitions":[{"definition":"A disorder characterized by darkening of the skin due to excessive melanin deposition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by darkening of the skin due to excessive melanin deposition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Skin Hyperpigmentation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin Hyperpigmentation"},{"name":"Maps_To","value":"Skin hyperpigmentation"},{"name":"NCI_META_CUI","value":"CL542135"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143836":{"preferredName":"Skin Hypopigmentation, CTCAE","code":"C143836","definitions":[{"definition":"A disorder characterized by loss of skin pigment (e.g., vitiligo).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by loss of skin pigment (e.g., vitiligo).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Skin Hypopigmentation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin Hypopigmentation"},{"name":"Maps_To","value":"Skin hypopigmentation"},{"name":"NCI_META_CUI","value":"CL542136"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143837":{"preferredName":"Skin Induration, CTCAE","code":"C143837","definitions":[{"definition":"A disorder characterized by an area of hardness in the skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an area of hardness in the skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Skin Induration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin Induration"},{"name":"Maps_To","value":"Skin induration"},{"name":"NCI_META_CUI","value":"CL542125"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143838":{"preferredName":"Skin Infection, CTCAE","code":"C143838","definitions":[{"definition":"A disorder characterized by an infectious process involving the skin such as cellulitis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the skin such as cellulitis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Skin Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin infection"},{"name":"Maps_To","value":"Skin Infection"},{"name":"NCI_META_CUI","value":"CL545896"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143839":{"preferredName":"Skin Ulceration, CTCAE","code":"C143839","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Skin Ulceration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin ulceration"},{"name":"Maps_To","value":"Skin Ulceration"},{"name":"NCI_META_CUI","value":"CL542126"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143840":{"preferredName":"Sleep Apnea, CTCAE","code":"C143840","definitions":[{"definition":"A disorder characterized by cessation of breathing for short periods during sleep.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by cessation of breathing for short periods during sleep.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sleep Apnea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sleep apnea"},{"name":"Maps_To","value":"Sleep Apnea"},{"name":"NCI_META_CUI","value":"CL545901"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143841":{"preferredName":"Small Intestinal Anastomotic Leak, CTCAE","code":"C143841","definitions":[{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Small Intestinal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small intestinal anastomotic leak"},{"name":"Maps_To","value":"Small Intestinal Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542127"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143842":{"preferredName":"Small Intestinal Mucositis, CTCAE","code":"C143842","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Small Intestinal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small intestinal mucositis"},{"name":"Maps_To","value":"Small Intestinal Mucositis"},{"name":"NCI_META_CUI","value":"CL542128"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143843":{"preferredName":"Small Intestinal Obstruction, CTCAE","code":"C143843","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Small Intestinal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestinal Obstruction"},{"name":"Maps_To","value":"Small intestinal obstruction"},{"name":"NCI_META_CUI","value":"CL542129"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146635":{"preferredName":"Small Intestinal Perforation, CTCAE 5.0","code":"C146635","definitions":[{"definition":"A disorder characterized by a rupture in the small intestine wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the small intestine wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Small Intestinal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small intestinal perforation"},{"name":"Maps_To","value":"Small Intestinal Perforation"},{"name":"NCI_META_CUI","value":"CL544667"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143844":{"preferredName":"Small Intestinal Stenosis, CTCAE","code":"C143844","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Small Intestinal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestinal Stenosis"},{"name":"Maps_To","value":"Small intestinal stenosis"},{"name":"NCI_META_CUI","value":"CL542130"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143845":{"preferredName":"Small Intestine Infection, CTCAE","code":"C143845","definitions":[{"definition":"A disorder characterized by an infectious process involving the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Small Intestine Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestine Infection"},{"name":"Maps_To","value":"Small intestine infection"},{"name":"NCI_META_CUI","value":"CL542117"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143846":{"preferredName":"Small Intestine Ulcer, CTCAE","code":"C143846","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Small Intestine Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestine Ulcer"},{"name":"Maps_To","value":"Small intestine ulcer"},{"name":"NCI_META_CUI","value":"CL542118"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143847":{"preferredName":"Sneezing, CTCAE","code":"C143847","definitions":[{"definition":"A disorder characterized by the involuntary expulsion of air from the nose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the involuntary expulsion of air from the nose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sneezing, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sneezing"},{"name":"NCI_META_CUI","value":"CL542119"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143848":{"preferredName":"Social Circumstances - Other, Specify, CTCAE","code":"C143848","synonyms":[{"termName":"Social Circumstances - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social Circumstances - Other"},{"name":"Maps_To","value":"Social circumstances - Other, specify"},{"name":"NCI_META_CUI","value":"CL542120"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143849":{"preferredName":"Soft Tissue Infection, CTCAE","code":"C143849","definitions":[{"definition":"A disorder characterized by an infectious process involving soft tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving soft tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Soft Tissue Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Soft Tissue Infection"},{"name":"Maps_To","value":"Soft tissue infection"},{"name":"NCI_META_CUI","value":"CL542121"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143850":{"preferredName":"Soft Tissue Necrosis Lower Limb, CTCAE","code":"C143850","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Soft Tissue Necrosis Lower Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Soft Tissue Necrosis Lower Limb"},{"name":"Maps_To","value":"Soft tissue necrosis lower limb"},{"name":"NCI_META_CUI","value":"CL542122"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143851":{"preferredName":"Soft Tissue Necrosis Upper Limb, CTCAE","code":"C143851","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Soft Tissue Necrosis Upper Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Soft tissue necrosis upper limb"},{"name":"Maps_To","value":"Soft Tissue Necrosis Upper Limb"},{"name":"NCI_META_CUI","value":"CL542123"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143852":{"preferredName":"Somnolence, CTCAE","code":"C143852","definitions":[{"definition":"A disorder characterized by characterized by excessive sleepiness and drowsiness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by characterized by excessive sleepiness and drowsiness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Somnolence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Somnolence"},{"name":"NCI_META_CUI","value":"CL542124"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143853":{"preferredName":"Sore Throat, CTCAE","code":"C143853","definitions":[{"definition":"A disorder characterized by marked discomfort in the throat","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by marked discomfort in the throat","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sore Throat, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sore throat"},{"name":"Maps_To","value":"Sore Throat"},{"name":"NCI_META_CUI","value":"CL542109"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143854":{"preferredName":"Spasticity, CTCAE","code":"C143854","definitions":[{"definition":"A disorder characterized by increased involuntary muscle tone that affects the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by increased involuntary muscle tone that affects the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Spasticity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spasticity"},{"name":"NCI_META_CUI","value":"CL542110"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143855":{"preferredName":"Spermatic Cord Anastomotic Leak, CTCAE","code":"C143855","definitions":[{"definition":"A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Spermatic Cord Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spermatic cord anastomotic leak"},{"name":"Maps_To","value":"Spermatic Cord Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542111"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56563":{"preferredName":"Spermatic Cord Hemorrhage, CTCAE","code":"C56563","definitions":[{"definition":"A disorder characterized by bleeding from the spermatic cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the spermatic cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Spermatic Cord Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spermatic_Cord_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Spermatic cord hemorrhage"},{"name":"Maps_To","value":"Spermatic Cord Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963130"}]}}{"C146757":{"preferredName":"Spermatic Cord Obstruction, CTCAE 5.0","code":"C146757","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents of the spermatic cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the contents of the spermatic cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Spermatic Cord Obstruction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spermatic Cord Obstruction"},{"name":"Maps_To","value":"Spermatic cord obstruction"},{"name":"NCI_META_CUI","value":"CL544795"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143856":{"preferredName":"Spinal Fracture, CTCAE","code":"C143856","definitions":[{"definition":"A finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Spinal Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spinal fracture"},{"name":"Maps_To","value":"Spinal Fracture"},{"name":"NCI_META_CUI","value":"CL542112"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35823":{"preferredName":"Splenic Disorder","code":"C35823","definitions":[{"definition":"A disorder of the spleen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A non-neoplastic or neoplastic disorder affecting the spleen. Examples include infection, hemangioma, lymphoma, leukemia and angiosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Spleen Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Splenic_Disorder"},{"name":"Maps_To","value":"Other diseases of spleen"},{"name":"Maps_To","value":"Spleen Disorder"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0037997"}]}}{"C143857":{"preferredName":"Splenic Infection, CTCAE","code":"C143857","definitions":[{"definition":"A disorder characterized by an infectious process involving the spleen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the spleen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Splenic Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Splenic infection"},{"name":"Maps_To","value":"Splenic Infection"},{"name":"NCI_META_CUI","value":"CL542113"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143858":{"preferredName":"Stenosis of Gastrointestinal Stoma, CTCAE","code":"C143858","definitions":[{"definition":"A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Stenosis of Gastrointestinal Stoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stenosis of gastrointestinal stoma"},{"name":"Maps_To","value":"Stenosis of Gastrointestinal Stoma"},{"name":"NCI_META_CUI","value":"CL542114"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143859":{"preferredName":"Stevens-Johnson Syndrome, CTCAE","code":"C143859","definitions":[{"definition":"A disorder characterized by less than 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by less than 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stevens-Johnson Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stevens-Johnson syndrome"},{"name":"Maps_To","value":"Stevens-Johnson Syndrome"},{"name":"NCI_META_CUI","value":"CL542115"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143860":{"preferredName":"Stoma Site Infection, CTCAE","code":"C143860","definitions":[{"definition":"A disorder characterized by an infectious process involving a stoma (surgically created opening on the surface of the body).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a stoma (surgically created opening on the surface of the body).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stoma Site Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stoma site infection"},{"name":"Maps_To","value":"Stoma Site Infection"},{"name":"NCI_META_CUI","value":"CL542116"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146774":{"preferredName":"Stomach Pain, CTCAE 5.0","code":"C146774","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Stomach Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stomach Pain"},{"name":"Maps_To","value":"Stomach pain"},{"name":"NCI_META_CUI","value":"CL544782"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146694":{"preferredName":"Stomal Ulcer, CTCAE 5.0","code":"C146694","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stomal Ulcer, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stomal ulcer"},{"name":"Maps_To","value":"Stomal Ulcer"},{"name":"NCI_META_CUI","value":"CL544736"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143861":{"preferredName":"Stridor, CTCAE","code":"C143861","definitions":[{"definition":"A disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stridor, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stridor"},{"name":"NCI_META_CUI","value":"CL542102"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143862":{"preferredName":"Stroke, CTCAE","code":"C143862","definitions":[{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stroke, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stroke"},{"name":"NCI_META_CUI","value":"CL542103"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143863":{"preferredName":"Sudden Death NOS, CTCAE","code":"C143863","definitions":[{"definition":"An unexpected death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"An unexpected death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sudden Death NOS, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sudden death NOS"},{"name":"Maps_To","value":"Sudden Death NOS"},{"name":"NCI_META_CUI","value":"CL542104"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143864":{"preferredName":"Suicidal Ideation, CTCAE","code":"C143864","definitions":[{"definition":"A disorder characterized by thoughts of taking one's own life.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by thoughts of taking one's own life.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Suicidal Ideation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Suicidal ideation"},{"name":"Maps_To","value":"Suicidal Ideation"},{"name":"NCI_META_CUI","value":"CL545963"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143865":{"preferredName":"Suicide Attempt, CTCAE","code":"C143865","definitions":[{"definition":"A disorder characterized by self-inflicted harm in an attempt to end one's own life.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by self-inflicted harm in an attempt to end one's own life.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Suicide Attempt, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Suicide attempt"},{"name":"Maps_To","value":"Suicide Attempt"},{"name":"NCI_META_CUI","value":"CL542105"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143866":{"preferredName":"Superficial Soft Tissue Fibrosis, CTCAE","code":"C143866","definitions":[{"definition":"A disorder characterized by fibrotic degeneration of the superficial soft tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by fibrotic degeneration of the superficial soft tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Superficial Soft Tissue Fibrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superficial soft tissue fibrosis"},{"name":"Maps_To","value":"Superficial Soft Tissue Fibrosis"},{"name":"NCI_META_CUI","value":"CL542106"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143867":{"preferredName":"Superficial Thrombophlebitis, CTCAE","code":"C143867","definitions":[{"definition":"A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Superficial Thrombophlebitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superficial thrombophlebitis"},{"name":"Maps_To","value":"Superficial Thrombophlebitis"},{"name":"NCI_META_CUI","value":"CL542107"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143868":{"preferredName":"Superior Vena Cava Syndrome, CTCAE","code":"C143868","definitions":[{"definition":"A disorder characterized by obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Superior Vena Cava Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superior vena cava syndrome"},{"name":"Maps_To","value":"Superior Vena Cava Syndrome"},{"name":"NCI_META_CUI","value":"CL542108"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54945":{"preferredName":"Supraventricular Tachycardia, CTCAE","code":"C54945","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Supraventricular Tachycardia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supraventricular_Tachycardia_Adverse_Event"},{"name":"Maps_To","value":"Supraventricular Tachycardia"},{"name":"Maps_To","value":"Supraventricular tachycardia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963244"}]}}{"C143869":{"preferredName":"Surgical and Medical Procedures - Other, Specify, CTCAE","code":"C143869","synonyms":[{"termName":"Surgical and Medical Procedures - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgical and Medical Procedures - Other"},{"name":"Maps_To","value":"Surgical and medical procedures - Other, specify"},{"name":"NCI_META_CUI","value":"CL542094"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146750":{"preferredName":"Syncope, CTCAE 5.0","code":"C146750","definitions":[{"definition":"A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Syncope, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Syncope"},{"name":"NCI_META_CUI","value":"CL545953"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146740":{"preferredName":"Telangiectasia, CTCAE 5.0","code":"C146740","definitions":[{"definition":"A disorder characterized by local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Telangiectasia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Telangiectasia"},{"name":"NCI_META_CUI","value":"CL544688"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143872":{"preferredName":"Testicular Disorder, CTCAE","code":"C143872","definitions":[{"definition":"A disorder characterized by abnormal function or appearance of the testis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormal function or appearance of the testis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Testicular Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Testicular disorder"},{"name":"Maps_To","value":"Testicular Disorder"},{"name":"NCI_META_CUI","value":"CL542095"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56566":{"preferredName":"Testicular Hemorrhage, CTCAE","code":"C56566","definitions":[{"definition":"A disorder characterized by bleeding from the testis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the testis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Testicular Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Testes_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Testicular hemorrhage"},{"name":"Maps_To","value":"Testicular Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963131"}]}}{"C146666":{"preferredName":"Testicular Pain, CTCAE 5.0","code":"C146666","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the testis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the testis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Testicular Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Testicular pain"},{"name":"Maps_To","value":"Testicular Pain"},{"name":"NCI_META_CUI","value":"CL544635"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143873":{"preferredName":"Thromboembolic Event, CTCAE","code":"C143873","definitions":[{"definition":"A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Thromboembolic Event, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thromboembolic event"},{"name":"Maps_To","value":"Thromboembolic Event"},{"name":"NCI_META_CUI","value":"CL542096"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143874":{"preferredName":"Thrombotic Thrombocytopenic Purpura, CTCAE","code":"C143874","definitions":[{"definition":"A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Thrombotic Thrombocytopenic Purpura, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thrombotic thrombocytopenic purpura"},{"name":"Maps_To","value":"Thrombotic Thrombocytopenic Purpura"},{"name":"NCI_META_CUI","value":"CL542097"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146690":{"preferredName":"Tinnitus, CTCAE 5.0","code":"C146690","definitions":[{"definition":"A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tinnitus, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tinnitus"},{"name":"NCI_META_CUI","value":"CL545922"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143876":{"preferredName":"Tooth Development Disorder, CTCAE","code":"C143876","definitions":[{"definition":"A disorder characterized by a pathological process of the teeth occurring during tooth development.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a pathological process of the teeth occurring during tooth development.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tooth Development Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tooth development disorder"},{"name":"Maps_To","value":"Tooth Development Disorder"},{"name":"NCI_META_CUI","value":"CL542098"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143877":{"preferredName":"Tooth Discoloration, CTCAE","code":"C143877","definitions":[{"definition":"A disorder characterized by a change in tooth hue or tint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a change in tooth hue or tint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tooth Discoloration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tooth discoloration"},{"name":"Maps_To","value":"Tooth Discoloration"},{"name":"NCI_META_CUI","value":"CL542099"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143878":{"preferredName":"Tooth Infection, CTCAE","code":"C143878","definitions":[{"definition":"A disorder characterized by an infectious process involving a tooth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a tooth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tooth Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tooth infection"},{"name":"Maps_To","value":"Tooth Infection"},{"name":"NCI_META_CUI","value":"CL542100"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143879":{"preferredName":"Toothache, CTCAE","code":"C143879","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the tooth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the tooth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Toothache, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Toothache"},{"name":"NCI_META_CUI","value":"CL542101"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143880":{"preferredName":"Toxic Epidermal Necrolysis, CTCAE","code":"C143880","definitions":[{"definition":"A disorder characterized by greater than 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by greater than 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Toxic Epidermal Necrolysis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Toxic epidermal necrolysis"},{"name":"Maps_To","value":"Toxic Epidermal Necrolysis"},{"name":"NCI_META_CUI","value":"CL542087"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58205":{"preferredName":"Tracheal Fistula, CTCAE","code":"C58205","definitions":[{"definition":"A disorder characterized by an abnormal communication between the trachea and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the trachea and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tracheal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trachea_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Tracheal Fistula"},{"name":"Maps_To","value":"Tracheal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963251"}]}}{"C56567":{"preferredName":"Tracheal Hemorrhage, CTCAE","code":"C56567","definitions":[{"definition":"A disorder characterized by bleeding from the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tracheal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trachea_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Tracheal hemorrhage"},{"name":"Maps_To","value":"Tracheal Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556636"}]}}{"C143881":{"preferredName":"Tracheal Mucositis, CTCAE","code":"C143881","definitions":[{"definition":"A disorder characterized by an inflammation or ulceration involving the mucous membrane of the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inflammation or ulceration involving the mucous membrane of the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tracheal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheal mucositis"},{"name":"Maps_To","value":"Tracheal Mucositis"},{"name":"NCI_META_CUI","value":"CL542088"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143882":{"preferredName":"Tracheal Obstruction, CTCAE","code":"C143882","definitions":[{"definition":"A disorder characterized by blockage of the lumen of the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the lumen of the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tracheal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheal obstruction"},{"name":"Maps_To","value":"Tracheal Obstruction"},{"name":"NCI_META_CUI","value":"CL542089"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143883":{"preferredName":"Tracheal Stenosis, CTCAE","code":"C143883","definitions":[{"definition":"A disorder characterized by a narrowing of the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tracheal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheal stenosis"},{"name":"Maps_To","value":"Tracheal Stenosis"},{"name":"NCI_META_CUI","value":"CL542090"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143884":{"preferredName":"Tracheitis, CTCAE","code":"C143884","definitions":[{"definition":"A disorder characterized by an infectious process involving the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tracheitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheitis"},{"name":"NCI_META_CUI","value":"CL542091"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143885":{"preferredName":"Tracheostomy Site Bleeding, CTCAE","code":"C143885","definitions":[{"definition":"A disorder characterized by bleeding from the tracheostomy site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the tracheostomy site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tracheostomy Site Bleeding, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheostomy site bleeding"},{"name":"Maps_To","value":"Tracheostomy Site Bleeding"},{"name":"NCI_META_CUI","value":"CL542092"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143886":{"preferredName":"Transient Ischemic Attacks, CTCAE","code":"C143886","definitions":[{"definition":"A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Transient Ischemic Attacks, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transient ischemic attacks"},{"name":"Maps_To","value":"Transient Ischemic Attacks"},{"name":"NCI_META_CUI","value":"CL545979"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143887":{"preferredName":"Treatment Related Secondary Malignancy, CTCAE","code":"C143887","definitions":[{"definition":"A disorder characterized by development of a malignancy most probably as a result of treatment for a previously existing malignancy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by development of a malignancy most probably as a result of treatment for a previously existing malignancy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Treatment Related Secondary Malignancy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treatment related secondary malignancy"},{"name":"Maps_To","value":"Treatment Related Secondary Malignancy"},{"name":"NCI_META_CUI","value":"CL542093"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146780":{"preferredName":"Tremor, CTCAE 5.0","code":"C146780","definitions":[{"definition":"A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tremor, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tremor"},{"name":"NCI_META_CUI","value":"CL544772"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143889":{"preferredName":"Tricuspid Valve Disease, CTCAE","code":"C143889","definitions":[{"definition":"A disorder characterized by a defect in tricuspid valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a defect in tricuspid valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tricuspid Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tricuspid valve disease"},{"name":"Maps_To","value":"Tricuspid Valve Disease"},{"name":"NCI_META_CUI","value":"CL542079"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143890":{"preferredName":"Trigeminal Nerve Disorder, CTCAE","code":"C143890","definitions":[{"definition":"A disorder characterized by dysfunction of the trigeminal nerve (fifth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the trigeminal nerve (fifth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Trigeminal Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trigeminal nerve disorder"},{"name":"Maps_To","value":"Trigeminal Nerve Disorder"},{"name":"NCI_META_CUI","value":"CL542080"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58404":{"preferredName":"Trismus, CTCAE","code":"C58404","definitions":[{"definition":"A disorder characterized by lack of ability to open the mouth fully due to a decrease in the range of motion of the muscles of mastication.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by lack of ability to open the mouth fully due to a decrease in the range of motion of the muscles of mastication.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Trismus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trismus_Adverse_Event"},{"name":"Maps_To","value":"Trismus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1561266"}]}}{"C146688":{"preferredName":"Tumor Lysis Syndrome, CTCAE 5.0","code":"C146688","definitions":[{"definition":"A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tumor Lysis Syndrome, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor Lysis Syndrome"},{"name":"Maps_To","value":"Tumor lysis syndrome"},{"name":"NCI_META_CUI","value":"CL544746"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146782":{"preferredName":"Tumor Pain, CTCAE 5.0","code":"C146782","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tumor Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor pain"},{"name":"Maps_To","value":"Tumor Pain"},{"name":"NCI_META_CUI","value":"CL544773"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146730":{"preferredName":"Typhlitis, CTCAE 5.0","code":"C146730","definitions":[{"definition":"A disorder characterized by necrotizing enterocolitis in neutropenic patients.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by necrotizing enterocolitis in neutropenic patients.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Typhlitis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Typhlitis"},{"name":"NCI_META_CUI","value":"CL544708"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143894":{"preferredName":"Unequal Limb Length, CTCAE","code":"C143894","definitions":[{"definition":"A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Unequal Limb Length, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unequal limb length"},{"name":"Maps_To","value":"Unequal Limb Length"},{"name":"NCI_META_CUI","value":"CL542081"},{"name":"Semantic_Type","value":"Finding"}]}}{"C79801":{"preferredName":"Unintended Pregnancy","code":"C79801","definitions":[{"definition":"A disorder characterized by an unexpected pregnancy at the time of conception.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A pregnancy that was not desired or was timed incorrectly at the time that the conception occurred.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unintended Pregnancy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unintended_Pregnancy"},{"name":"Maps_To","value":"Unintended Pregnancy"},{"name":"Semantic_Type","value":"Organism Function"},{"name":"UMLS_CUI","value":"C0041747"}]}}{"C143895":{"preferredName":"Upper Gastrointestinal Hemorrhage, CTCAE","code":"C143895","definitions":[{"definition":"A disorder characterized by bleeding from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Upper Gastrointestinal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Upper gastrointestinal hemorrhage"},{"name":"Maps_To","value":"Upper Gastrointestinal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL542082"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143896":{"preferredName":"Upper Respiratory Infection, CTCAE","code":"C143896","definitions":[{"definition":"A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Upper Respiratory Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Upper respiratory infection"},{"name":"Maps_To","value":"Upper Respiratory Infection"},{"name":"NCI_META_CUI","value":"CL542083"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143897":{"preferredName":"Ureteric Anastomotic Leak, CTCAE","code":"C143897","definitions":[{"definition":"A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ureteric Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ureteric anastomotic leak"},{"name":"Maps_To","value":"Ureteric Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542084"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143898":{"preferredName":"Urethral Anastomotic Leak, CTCAE","code":"C143898","definitions":[{"definition":"A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urethral Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urethral anastomotic leak"},{"name":"Maps_To","value":"Urethral Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542085"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143899":{"preferredName":"Urethral Infection, CTCAE","code":"C143899","definitions":[{"definition":"A disorder characterized by an infectious process involving the urethra.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the urethra.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urethral Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urethral infection"},{"name":"Maps_To","value":"Urethral Infection"},{"name":"NCI_META_CUI","value":"CL542086"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143900":{"preferredName":"Urinary Fistula, CTCAE","code":"C143900","definitions":[{"definition":"A disorder characterized by an abnormal communication between any part of the urinary system and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between any part of the urinary system and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary fistula"},{"name":"Maps_To","value":"Urinary Fistula"},{"name":"NCI_META_CUI","value":"CL542190"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143901":{"preferredName":"Urinary Frequency, CTCAE","code":"C143901","definitions":[{"definition":"A disorder characterized by urination at short intervals.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by urination at short intervals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Frequency, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary frequency"},{"name":"Maps_To","value":"Urinary Frequency"},{"name":"NCI_META_CUI","value":"CL542191"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146786":{"preferredName":"Urinary Incontinence, CTCAE 5.0","code":"C146786","definitions":[{"definition":"A disorder characterized by inability to control the flow of urine from the bladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inability to control the flow of urine from the bladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Incontinence, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary incontinence"},{"name":"Maps_To","value":"Urinary Incontinence"},{"name":"NCI_META_CUI","value":"CL550644"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57097":{"preferredName":"Urinary Retention, CTCAE","code":"C57097","definitions":[{"definition":"A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Retention, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Urinary_Retention_Adverse_Event"},{"name":"Maps_To","value":"Urinary retention"},{"name":"Maps_To","value":"Urinary Retention"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1558141"}]}}{"C143904":{"preferredName":"Urinary Tract Infection, CTCAE","code":"C143904","definitions":[{"definition":"A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urinary Tract Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urinary tract infection"},{"name":"Maps_To","value":"Urinary Tract Infection"},{"name":"NCI_META_CUI","value":"CL545980"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143905":{"preferredName":"Urinary Tract Obstruction, CTCAE","code":"C143905","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of contents of the urinary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of contents of the urinary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Tract Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary tract obstruction"},{"name":"Maps_To","value":"Urinary Tract Obstruction"},{"name":"NCI_META_CUI","value":"CL542192"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143906":{"preferredName":"Urinary Tract Pain, CTCAE","code":"C143906","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the urinary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the urinary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urinary Tract Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary tract pain"},{"name":"Maps_To","value":"Urinary Tract Pain"},{"name":"NCI_META_CUI","value":"CL542193"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143907":{"preferredName":"Urinary Urgency, CTCAE","code":"C143907","definitions":[{"definition":"A disorder characterized by a sudden compelling urge to urinate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sudden compelling urge to urinate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Urgency, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary urgency"},{"name":"Maps_To","value":"Urinary Urgency"},{"name":"NCI_META_CUI","value":"CL542194"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143908":{"preferredName":"Urine Discoloration, CTCAE","code":"C143908","definitions":[{"definition":"A disorder characterized by a change in the color of the urine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a change in the color of the urine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urine Discoloration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urine discoloration"},{"name":"Maps_To","value":"Urine Discoloration"},{"name":"NCI_META_CUI","value":"CL542195"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143909":{"preferredName":"Urine Output Decreased, CTCAE","code":"C143909","definitions":[{"definition":"A finding based on test results that indicate urine production is less relative to previous output.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on test results that indicate urine production is less relative to previous output.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urine Output Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urine output decreased"},{"name":"Maps_To","value":"Urine Output Decreased"},{"name":"NCI_META_CUI","value":"CL542196"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143910":{"preferredName":"Urostomy Leak, CTCAE","code":"C143910","definitions":[{"definition":"A finding of leakage of contents from a urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of contents from a urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urostomy Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy leak"},{"name":"Maps_To","value":"Urostomy Leak"},{"name":"NCI_META_CUI","value":"CL542183"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143911":{"preferredName":"Urostomy Obstruction, CTCAE","code":"C143911","definitions":[{"definition":"A disorder characterized by blockage of the urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urostomy Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy obstruction"},{"name":"Maps_To","value":"Urostomy Obstruction"},{"name":"NCI_META_CUI","value":"CL542184"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143912":{"preferredName":"Urostomy Site Bleeding, CTCAE","code":"C143912","definitions":[{"definition":"A disorder characterized by bleeding from the urostomy site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the urostomy site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urostomy Site Bleeding, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy site bleeding"},{"name":"Maps_To","value":"Urostomy Site Bleeding"},{"name":"NCI_META_CUI","value":"CL542185"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143913":{"preferredName":"Urostomy Stenosis, CTCAE","code":"C143913","definitions":[{"definition":"A finding of narrowing of the opening of a urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of narrowing of the opening of a urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urostomy Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy stenosis"},{"name":"Maps_To","value":"Urostomy Stenosis"},{"name":"NCI_META_CUI","value":"CL542186"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58019":{"preferredName":"Urticaria, CTCAE","code":"C58019","definitions":[{"definition":"A disorder characterized by an itchy skin eruption characterized by wheals with pale interiors and well-defined red margins.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an itchy skin eruption characterized by wheals with pale interiors and well-defined red margins.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urticaria, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urticaria_Adverse_Reaction"},{"name":"Maps_To","value":"Urticaria"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559188"}]}}{"C143915":{"preferredName":"Uterine Anastomotic Leak, CTCAE","code":"C143915","definitions":[{"definition":"A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Uterine Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine anastomotic leak"},{"name":"Maps_To","value":"Uterine Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542187"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143916":{"preferredName":"Uterine Fistula, CTCAE","code":"C143916","definitions":[{"definition":"A disorder characterized by an abnormal communication between the uterus and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the uterus and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine fistula"},{"name":"Maps_To","value":"Uterine Fistula"},{"name":"NCI_META_CUI","value":"CL542188"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56572":{"preferredName":"Uterine Hemorrhage, CTCAE","code":"C56572","definitions":[{"definition":"A disorder characterized by bleeding from the uterus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the uterus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterus_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Uterine hemorrhage"},{"name":"Maps_To","value":"Uterine Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560757"}]}}{"C143917":{"preferredName":"Uterine Infection, CTCAE","code":"C143917","definitions":[{"definition":"A disorder characterized by an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine infection"},{"name":"Maps_To","value":"Uterine Infection"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0042136"}]}}{"C143918":{"preferredName":"Uterine Obstruction, CTCAE","code":"C143918","definitions":[{"definition":"A disorder characterized by blockage of the uterine outlet.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the uterine outlet.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Uterine Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine obstruction"},{"name":"Maps_To","value":"Uterine Obstruction"},{"name":"NCI_META_CUI","value":"CL542189"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146683":{"preferredName":"Uterine Pain, CTCAE 5.0","code":"C146683","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the uterus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the uterus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Uterine Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine Pain"},{"name":"Maps_To","value":"Uterine pain"},{"name":"NCI_META_CUI","value":"CL544741"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143919":{"preferredName":"Uterine Perforation, CTCAE","code":"C143919","definitions":[{"definition":"A disorder characterized by a rupture in the uterine wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the uterine wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Uterine Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine perforation"},{"name":"Maps_To","value":"Uterine Perforation"},{"name":"NCI_META_CUI","value":"CL542175"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55901":{"preferredName":"Uveitis, CTCAE","code":"C55901","definitions":[{"definition":"A disorder characterized by inflammation to the uvea of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation to the uvea of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uveitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uveitis_Adverse_Event"},{"name":"Maps_To","value":"Uveitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963266"}]}}{"C143921":{"preferredName":"Vaginal Anastomotic Leak, CTCAE","code":"C143921","definitions":[{"definition":"A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal anastomotic leak"},{"name":"Maps_To","value":"Vaginal Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542176"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143922":{"preferredName":"Vaginal Discharge, CTCAE","code":"C143922","definitions":[{"definition":"A disorder characterized by vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Discharge, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal discharge"},{"name":"Maps_To","value":"Vaginal Discharge"},{"name":"NCI_META_CUI","value":"CL542177"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146687":{"preferredName":"Vaginal Dryness, CTCAE 5.0","code":"C146687","definitions":[{"definition":"A disorder characterized by an uncomfortable feeling of itching and burning in the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable feeling of itching and burning in the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Dryness, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal Dryness"},{"name":"Maps_To","value":"Vaginal dryness"},{"name":"NCI_META_CUI","value":"CL544745"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57104":{"preferredName":"Vaginal Fistula, CTCAE","code":"C57104","definitions":[{"definition":"A disorder characterized by an abnormal communication between the vagina and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the vagina and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vagina_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Vaginal Fistula"},{"name":"Maps_To","value":"Vaginal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963267"}]}}{"C56573":{"preferredName":"Vaginal Hemorrhage, CTCAE","code":"C56573","definitions":[{"definition":"A disorder characterized by bleeding from the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vagina_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Vaginal Hemorrhage"},{"name":"Maps_To","value":"Vaginal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2911646"}]}}{"C143924":{"preferredName":"Vaginal Infection, CTCAE","code":"C143924","definitions":[{"definition":"A disorder characterized by an infectious process involving the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal infection"},{"name":"Maps_To","value":"Vaginal Infection"},{"name":"NCI_META_CUI","value":"CL542178"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143925":{"preferredName":"Vaginal Inflammation, CTCAE","code":"C143925","definitions":[{"definition":"A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal inflammation"},{"name":"Maps_To","value":"Vaginal Inflammation"},{"name":"NCI_META_CUI","value":"CL542179"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146696":{"preferredName":"Vaginal Obstruction, CTCAE 5.0","code":"C146696","definitions":[{"definition":"A disorder characterized by blockage of vaginal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of vaginal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Obstruction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal obstruction"},{"name":"Maps_To","value":"Vaginal Obstruction"},{"name":"NCI_META_CUI","value":"CL544738"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146684":{"preferredName":"Vaginal Pain, CTCAE 5.0","code":"C146684","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal Pain"},{"name":"Maps_To","value":"Vaginal pain"},{"name":"NCI_META_CUI","value":"CL544742"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146697":{"preferredName":"Vaginal Perforation, CTCAE 5.0","code":"C146697","definitions":[{"definition":"A disorder characterized by a rupture in the vaginal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the vaginal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal perforation"},{"name":"Maps_To","value":"Vaginal Perforation"},{"name":"NCI_META_CUI","value":"CL544739"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143926":{"preferredName":"Vaginal Stricture, CTCAE","code":"C143926","definitions":[{"definition":"A disorder characterized by a narrowing of the vaginal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the vaginal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Stricture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal stricture"},{"name":"Maps_To","value":"Vaginal Stricture"},{"name":"NCI_META_CUI","value":"CL542180"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78703":{"preferredName":"Vaginismus","code":"C78703","definitions":[{"definition":"A disorder characterized by involuntary spasms of the pelvic floor muscles, resulting in pathologic tightness of the vaginal wall during penetration such as during sexual intercourse.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Tightness of the vaginal wall during vaginal penetration including sexual intercourse. It is caused by involuntary spasm of the pelvic floor muscles, and results in painful intercourse or failure to have intercourse. It may due to psychological conditions, trauma in the vaginal area, or vaginal infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vaginismus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vaginismus"},{"name":"Maps_To","value":"Vaginismus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2004487"}]}}{"C143927":{"preferredName":"Vagus Nerve Disorder, CTCAE","code":"C143927","definitions":[{"definition":"A disorder characterized by dysfunction of the vagus nerve (tenth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the vagus nerve (tenth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vagus Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vagus nerve disorder"},{"name":"Maps_To","value":"Vagus Nerve Disorder"},{"name":"NCI_META_CUI","value":"CL542181"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143928":{"preferredName":"Vas Deferens Anastomotic Leak, CTCAE","code":"C143928","definitions":[{"definition":"A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vas Deferens Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vas deferens anastomotic leak"},{"name":"Maps_To","value":"Vas Deferens Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542182"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143929":{"preferredName":"Vascular Access Complication, CTCAE","code":"C143929","definitions":[{"definition":"A finding of a previously undocumented problem related to the vascular access site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of a previously undocumented problem related to the vascular access site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vascular Access Complication, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vascular access complication"},{"name":"Maps_To","value":"Vascular Access Complication"},{"name":"NCI_META_CUI","value":"CL542169"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143930":{"preferredName":"Vascular Disorders - Other, Specify, CTCAE","code":"C143930","synonyms":[{"termName":"Vascular Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vascular Disorders - Other"},{"name":"Maps_To","value":"Vascular disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542170"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54741":{"preferredName":"Vasculitis, CTCAE","code":"C54741","definitions":[{"definition":"A disorder characterized by inflammation involving the wall of a vessel.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving the wall of a vessel.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vasculitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vasculitis_Adverse_Event"},{"name":"Maps_To","value":"Vasculitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963274"}]}}{"C143932":{"preferredName":"Vasovagal Reaction, CTCAE","code":"C143932","definitions":[{"definition":"A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vasovagal Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vasovagal reaction"},{"name":"Maps_To","value":"Vasovagal Reaction"},{"name":"NCI_META_CUI","value":"CL542171"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143933":{"preferredName":"Venous Injury, CTCAE","code":"C143933","definitions":[{"definition":"A finding of damage to a vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to a vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Venous Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Venous injury"},{"name":"Maps_To","value":"Venous Injury"},{"name":"NCI_META_CUI","value":"CL542172"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146629":{"preferredName":"Ventricular Arrhythmia, CTCAE 5.0","code":"C146629","definitions":[{"definition":"A disorder characterized by a dysrhythmia that originates in the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia that originates in the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ventricular Arrhythmia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ventricular Arrhythmia"},{"name":"Maps_To","value":"Ventricular arrhythmia"},{"name":"NCI_META_CUI","value":"CL544675"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146732":{"preferredName":"Ventricular Fibrillation, CTCAE 5.0","code":"C146732","definitions":[{"definition":"A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ventricular Fibrillation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ventricular Fibrillation"},{"name":"Maps_To","value":"Ventricular fibrillation"},{"name":"NCI_META_CUI","value":"CL544695"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146733":{"preferredName":"Ventricular Tachycardia, CTCAE 5.0","code":"C146733","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ventricular Tachycardia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ventricular Tachycardia"},{"name":"Maps_To","value":"Ventricular tachycardia"},{"name":"NCI_META_CUI","value":"CL544696"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143935":{"preferredName":"Vertigo, CTCAE","code":"C143935","definitions":[{"definition":"A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vertigo, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vertigo"},{"name":"NCI_META_CUI","value":"CL546001"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143936":{"preferredName":"Vestibular Disorder, CTCAE","code":"C143936","definitions":[{"definition":"A disorder characterized by dizziness, imbalance, nausea, and vision problems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dizziness, imbalance, nausea, and vision problems.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vestibular Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vestibular disorder"},{"name":"Maps_To","value":"Vestibular Disorder"},{"name":"NCI_META_CUI","value":"CL545965"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143937":{"preferredName":"Virilization, CTCAE","code":"C143937","definitions":[{"definition":"A disorder characterized by inappropriate masculinization occurring in a female or prepubertal male.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inappropriate masculinization occurring in a female or prepubertal male.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Virilization, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Virilization"},{"name":"NCI_META_CUI","value":"CL542173"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143938":{"preferredName":"Visceral Arterial Ischemia, CTCAE","code":"C143938","definitions":[{"definition":"A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Visceral Arterial Ischemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Visceral arterial ischemia"},{"name":"Maps_To","value":"Visceral Arterial Ischemia"},{"name":"NCI_META_CUI","value":"CL542174"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143939":{"preferredName":"Vital Capacity Abnormal, CTCAE","code":"C143939","definitions":[{"definition":"A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vital Capacity Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vital capacity abnormal"},{"name":"Maps_To","value":"Vital Capacity Abnormal"},{"name":"NCI_META_CUI","value":"CL542161"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146677":{"preferredName":"Vitreous Hemorrhage, CTCAE 5.0","code":"C146677","definitions":[{"definition":"A disorder characterized by bleeding into the vitreous humor.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding into the vitreous humor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vitreous Hemorrhage, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vitreous hemorrhage"},{"name":"Maps_To","value":"Vitreous Hemorrhage"},{"name":"NCI_META_CUI","value":"CL544631"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143941":{"preferredName":"Voice Alteration, CTCAE","code":"C143941","definitions":[{"definition":"A disorder characterized by a change in the sound and/or speed of the voice.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a change in the sound and/or speed of the voice.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Voice Alteration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Voice alteration"},{"name":"Maps_To","value":"Voice Alteration"},{"name":"NCI_META_CUI","value":"CL542162"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57896":{"preferredName":"Vomiting, CTCAE","code":"C57896","definitions":[{"definition":"A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vomiting, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vomiting_Adverse_Event"},{"name":"Maps_To","value":"Vomiting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963281"}]}}{"C143943":{"preferredName":"Vulval Infection, CTCAE","code":"C143943","definitions":[{"definition":"A disorder characterized by an infectious process involving the vulva.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the vulva.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vulval Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vulval infection"},{"name":"Maps_To","value":"Vulval Infection"},{"name":"NCI_META_CUI","value":"CL542163"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143944":{"preferredName":"Watering Eyes, CTCAE","code":"C143944","definitions":[{"definition":"A disorder characterized by excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Watering Eyes, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Watering eyes"},{"name":"Maps_To","value":"Watering Eyes"},{"name":"NCI_META_CUI","value":"CL542164"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55338":{"preferredName":"Weight Gain, CTCAE","code":"C55338","definitions":[{"definition":"A finding characterized by an unexpected or abnormal increase in overall body weight; for pediatrics, greater than the baseline growth curve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding characterized by an unexpected or abnormal increase in overall body weight; for pediatrics, greater than the baseline growth curve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Weight Gain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Weight_Gain_Adverse_Event"},{"name":"Maps_To","value":"Weight gain"},{"name":"Maps_To","value":"Weight Gain"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2911647"}]}}{"C55339":{"preferredName":"Weight Loss, CTCAE","code":"C55339","definitions":[{"definition":"A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Weight Loss, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Weight_Loss_Adverse_Event"},{"name":"Maps_To","value":"Weight Loss"},{"name":"Maps_To","value":"Weight loss"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2911645"}]}}{"C143947":{"preferredName":"Wheezing, CTCAE","code":"C143947","definitions":[{"definition":"A disorder characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Wheezing, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wheezing"},{"name":"NCI_META_CUI","value":"CL542165"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143948":{"preferredName":"White Blood Cell Decreased, CTCAE","code":"C143948","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"White Blood Cell Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"White blood cell decreased"},{"name":"Maps_To","value":"White Blood Cell Decreased"},{"name":"NCI_META_CUI","value":"CL542166"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35132":{"preferredName":"Wolff-Parkinson-White Syndrome","code":"C35132","definitions":[{"definition":"A cardiac conduction disorder characterized by an electrocardiographic finding of ventricular pre-excitation, which is a short PR interval and a long QRS interval with a delta wave. Most individuals are asymptomatic; however they can experience periods of palpitations, shortness of breath or syncope during tachycardic episodes.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by the presence of an accessory conductive pathway between the atria and the ventricles that causes premature ventricular activation.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An electrocardiographic finding of ventricular pre-excitation. The syndrome is characterized by a short PR interval and a long QRS interval with a delta wave.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Wolff-Parkinson-White Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Wolff-Parkinson-White_Syndrome"},{"name":"Maps_To","value":"Wolff-Parkinson-White Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227386"}]}}{"C143949":{"preferredName":"Wound Complication, CTCAE","code":"C143949","definitions":[{"definition":"A finding of development of a new problem at the site of an existing wound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of development of a new problem at the site of an existing wound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Wound Complication, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wound complication"},{"name":"Maps_To","value":"Wound Complication"},{"name":"NCI_META_CUI","value":"CL542167"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143950":{"preferredName":"Wound Dehiscence, CTCAE","code":"C143950","definitions":[{"definition":"A finding of separation of the approximated margins of a surgical wound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of separation of the approximated margins of a surgical wound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Wound Dehiscence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wound dehiscence"},{"name":"Maps_To","value":"Wound Dehiscence"},{"name":"NCI_META_CUI","value":"CL542168"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143951":{"preferredName":"Wound Infection, CTCAE","code":"C143951","definitions":[{"definition":"A disorder characterized by an infectious process involving the wound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the wound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Wound Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wound infection"},{"name":"Maps_To","value":"Wound Infection"},{"name":"NCI_META_CUI","value":"CL542153"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143952":{"preferredName":"Wrist Fracture, CTCAE","code":"C143952","definitions":[{"definition":"A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Wrist Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wrist fracture"},{"name":"Maps_To","value":"Wrist Fracture"},{"name":"NCI_META_CUI","value":"CL542154"},{"name":"Semantic_Type","value":"Finding"}]}}{"C41338":{"preferredName":"Mild Adverse Event","code":"C41338","definitions":[{"definition":"A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mild Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Mild Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Mild_Adverse_Event"},{"name":"Maps_To","value":"Grade 1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1513302"}]}}{"C41339":{"preferredName":"Moderate Adverse Event","code":"C41339","definitions":[{"definition":"A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderate Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Moderate Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Moderate_Adverse_Event"},{"name":"Maps_To","value":"Grade 2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1513374"}]}}{"C41340":{"preferredName":"Severe Adverse Event","code":"C41340","definitions":[{"definition":"A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Severe Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 3 Severe Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Severe_Adverse_Event"},{"name":"Maps_To","value":"Grade 3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1519275"}]}}{"C84266":{"preferredName":"Life Threatening Adverse Event","code":"C84266","definitions":[{"definition":"An adverse event that has life-threatening consequences; for which urgent intervention is indicated; that puts the patient at risk of death at the time of the event if immediate intervention is not undertaken.","type":"DEFINITION","source":"NCI"},{"definition":"Any adverse drug experience that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred (i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death). [FDA 21 CFR 312.32; ICH-E2A]","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Life Threatening Adverse Event","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grade 4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1517874"}]}}{"C48275":{"preferredName":"Death Related to Adverse Event","code":"C48275","definitions":[{"definition":"The termination of life as a result of an adverse event. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The termination of life associated with an adverse event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Death Related to Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Fatal","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 5 Death Related to Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Death_Related_to_Adverse_Event"},{"name":"Maps_To","value":"Grade 5"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1705232"}]}}{"C26711":{"preferredName":"Candidiasis","code":"C26711","definitions":[{"definition":"A condition in which Candida albicans, a type of yeast, grows out of control in moist skin areas of the body. It is usually a result of a weakened immune system, but can be a side effect of chemotherapy or treatment with antibiotics. Thrush usually affects the mouth (oral thrush); however, rarely, it spreads throughout the entire body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An infection that is caused by one of many species of the genus Candida.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Infection with the organism Candida.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Candidiasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Candidiasis"},{"name":"Maps_To","value":"Candidiasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0006840"}]}}{"C84642":{"preferredName":"Coccidioidomycosis","code":"C84642","definitions":[{"definition":"A fungal infection caused by Coccidioides immitis. Affected individuals usually have mild flu-like symptoms. However, pneumonia and systemic involvement with the formation of abscesses may develop as complications of the disease.","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by Coccidioides immitis, which typically manifests as a flu-like illness, although pneumonia and systemic infection can occur.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Coccidioidomycosis","termGroup":"PT","termSource":"NCI"},{"termName":"Valley Fever","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Coccidioidomycosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009186"}]}}{"C2967":{"preferredName":"Cryptococcosis","code":"C2967","definitions":[{"definition":"An acute or chronic, localized or disseminated infection by Cryptococcus neoformans.  Sites of involvement include the lungs, central nervous system and meninges, skin, and visceral organs.--2004","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by Cryptococcus neoformans, and in some geographic areas by Cryptococcus gattii, which can be either acute or chronic, and either localized or disseminated; it typically involves the lungs, though disseminated disease can occur.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Cryptococcosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cryptococcosis"},{"name":"Maps_To","value":"Cryptococcosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0010414"}]}}{"C174107":{"preferredName":"Chronic Intestinal Cryptosporidiosis","code":"C174107","definitions":[{"definition":"A chronic infection caused by Cryptosporidium parvum or hominis that manifests as enteritis. It usually occurs in immunocompromised patients including persons with AIDS, transplant recipients, patients receiving cytotoxic chemotherapy, and patients with hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Intestinal Cryptosporidiosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cryptosporidiosis, Chronic Intestinal"},{"name":"NCI_META_CUI","value":"CL1407753"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C53649":{"preferredName":"Cytomegaloviral Infection","code":"C53649","definitions":[{"definition":"A herpesvirus infection caused by Cytomegalovirus. Healthy individuals generally do not produce symptoms. However, the infection may be life-threatening in affected immunocompromised patients. The virus may cause retinitis, esophagitis, gastritis, and colitis. Morphologically, it is characterized by the presence of intranuclear inclusion bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytomegaloviral Infection","termGroup":"PT","termSource":"NCI"},{"termName":"CMV Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Cytomegalovirus Infection","termGroup":"SY","termSource":"NCI"},{"termName":"HCMV Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cytomegaloviral_Infection"},{"name":"Maps_To","value":"Cytomegaloviral disease"},{"name":"Maps_To","value":"Cytomegaloviral disease, unspecified"},{"name":"Maps_To","value":"Cytomegalovirus"},{"name":"Maps_To","value":"Cytomegalovirus (CMV)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0010823"}]}}{"C26920":{"preferredName":"Encephalopathy","code":"C26920","definitions":[{"definition":"A disorder characterized by a pathologic process involving the brain.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A disorder of the brain that can be caused by disease, injury, drugs, or chemicals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A functional and/or structural disorder of the brain caused by diseases (e.g. liver disease, kidney disease), medications, chemicals, and injuries.","type":"DEFINITION","source":"NCI"},{"definition":"A functional and/or structural disorder of the brain that is acquired or congenital and characterised by mental and neurological symptoms.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Diffuse disease of the brain that alters function and/or structure of the brain and is characterized by an altered mental state.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Encephalopathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Encephalopathy"},{"name":"Maps_To","value":"Encephalopathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4013377"},{"name":"xRef","value":"IMDRF:E0115"}]}}{"C155871":{"preferredName":"Herpes Simplex Virus Infection","code":"C155871","definitions":[{"definition":"An infection that is caused by herpes simplex virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Herpes Simplex Virus Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HSV Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Herpes"},{"name":"Maps_To","value":"Herpes Simplex Virus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019340"}]}}{"C77201":{"preferredName":"Histoplasmosis","code":"C77201","definitions":[{"definition":"A disease caused by the fungus Histoplasma capsulatum. It primarily affects the lungs but can also occur as a disseminated disease that affects additional organs. The acute respiratory disease has symptoms similar to those of a cold or flu and it usually resolves without treatment in healthy individuals. The disseminated form is generally fatal if untreated.","type":"DEFINITION","source":"NCI"},{"definition":"An often self-limited infection that is caused by Histoplasma capsulatum, which typically manifests as a flu-like illness, but severe disseminated disease can occur.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Histoplasmosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Histoplasmosis"},{"name":"Maps_To","value":"Histoplasmosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0677640"}]}}{"C4076":{"preferredName":"Isosporiasis","code":"C4076","definitions":[{"definition":"A protozoan infection that is caused by Cystoisospora belli (formerly known as Isospora belli), which is most commonly acquired from contaminated food or water, and which is characterized by watery diarrhea and abdominal pain.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An intestinal infection with Isospora belli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isosporiasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Isosporiasis"},{"name":"Maps_To","value":"Isosporiasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0311386"}]}}{"C36197":{"preferredName":"Mycobacterium Avium Infection","code":"C36197","definitions":[{"definition":"An infection that is caused by Mycobacterium avium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium Avium Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mycobacterium_Avium_Infection"},{"name":"Maps_To","value":"Mycobacterium avium Complex"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026916"}]}}{"C128377":{"preferredName":"Tuberculosis Infection","code":"C128377","definitions":[{"definition":"The asymptomatic presence of Mycobacterium tuberculosis in the body, which is determined by a positive result to a tuberculin skin test or interferon-gamma release assay.","type":"DEFINITION","source":"NCI"},{"definition":"The asymptomatic presence of Mycobacterium tuberculosis in the body, which is determined by a positive result to a tuberculin skin test or interferon-gamma release assay.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Tuberculosis Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Mycobacterium tuberculosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1609538"}]}}{"C26831":{"preferredName":"Mycobacterial Infection","code":"C26831","definitions":[{"definition":"Infection due to organisms from the genus Mycobacteria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterial Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Mycobacterium Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mycobacterial_Infection"},{"name":"Maps_To","value":"Mycobacterium, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026918"}]}}{"C171147":{"preferredName":"Nocardiosis","code":"C171147","definitions":[{"definition":"A bacterial infection caused by members of the gram-positive bacilli genus Nocardia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nocardiosis","termGroup":"PT","termSource":"NCI"},{"termName":"Nocardial Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nocardiosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0028242"}]}}{"C3334":{"preferredName":"Pneumocystis Pneumonia","code":"C3334","definitions":[{"definition":"A severe, progressive pneumonia caused by Pneumocystis jirovecii, which is usually seen in immunologically compromised individuals.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months.  Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pneumocystis Pneumonia","termGroup":"PT","termSource":"NCI"},{"termName":"PCP","termGroup":"AB","termSource":"NCI"},{"termName":"PJP","termGroup":"AB","termSource":"NCI"},{"termName":"Pneumocystis","termGroup":"SY","termSource":"NCI"},{"termName":"Pneumocystis carinii Pneumonia","termGroup":"AQS","termSource":"NCI"},{"termName":"Pneumocystis jirovecii Pneumonia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pneumocystis_Carinii_Pneumonia"},{"name":"Maps_To","value":"Pneumocystis Pneumonia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1535939"}]}}{"C3333":{"preferredName":"Pneumonia","code":"C3333","definitions":[{"definition":"A condition resulting from infection in one or both lungs.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A severe inflammation of the lungs in which the alveoli (tiny air sacs) are filled with fluid. This may cause a decrease in the amount of oxygen that blood can absorb from air breathed into the lung. Pneumonia is usually caused by infection but may also be caused by radiation therapy, allergy, or irritation of lung tissue by inhaled substances. It may involve part or all of the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An acute and/or chronic inflammation focally or diffusely affecting the lung parenchyma.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pneumonia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pneumonia"},{"name":"Maps_To","value":"Pneumonia"},{"name":"Maps_To","value":"Pneumonia, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0032285"},{"name":"xRef","value":"IMDRF:E0733"}]}}{"C26815":{"preferredName":"Progressive Multifocal Leukoencephalopathy","code":"C26815","definitions":[{"definition":"A demyelinating central nervous system disease caused by reactivation of the polyomavirus JC, which results in a lytic infection of oligodendrocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A progressive demyelination within the central nervous system associated with reactivation of a latent JC virus infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progressive Multifocal Leukoencephalopathy","termGroup":"PT","termSource":"NCI"},{"termName":"PML","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Progressive_Multifocal_Leukoencephalopathy"},{"name":"Maps_To","value":"Progressive Multifocal Leukoencephalopathy"},{"name":"Maps_To","value":"Progressive multifocal leukoencephalopathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0023524"}]}}{"C171146":{"preferredName":"Salmonella Septicemia","code":"C171146","definitions":[{"definition":"Sepsis due to the presence of Salmonella bacteria in the bloodstream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salmonella Septicemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Salmonella Septicemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3163971"}]}}{"C3418":{"preferredName":"Toxoplasmosis","code":"C3418","definitions":[{"definition":"A parasitic disease contracted by the ingestion or fetal transmission of toxoplasma gondii.","type":"DEFINITION","source":"NCI"},{"definition":"A protozoan infection that is acquired by the ingestion or maternal-to-fetal transmission of Toxoplasma gondii.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Toxoplasmosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Toxoplasmosis"},{"name":"Maps_To","value":"Toxoplasmosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0040558"}]}}{"C171148":{"preferredName":"Wasting Syndrome","code":"C171148","definitions":[{"definition":"Pathologic loss of more than 10% of body weight concurrent with 30 or more days of either diarrhea or weakness and fever.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wasting Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wasting Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0043046"}]}}{"C3093":{"preferredName":"Hemophilia","code":"C3093","definitions":[{"definition":"A coagulation disorder characterized by the partial or complete absence of factor VIII or IX activity in the blood.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A deficiency or abnormality of a blood coagulation factor characterized by the tendency to hemorrhage. Hemophilia is typically a hereditary disorder but, rarely, may be acquired. Inherited coagulation factor-deficient hemophilias include hemophilia A or classic hemophilia (hereditary factor VIII deficiency) hemophilia B or Christmas disease (hereditary factor IX deficiency), and hemophilia C (hereditary factor XI deficiency). Factor VIII inhibitors may occur spontaneously as autoantibodies, resulting in acquired hemophilia known as acquired factor VIII deficiency. Approximately 10% of patients with acquired hemophilia have an underlying malignancy.","type":"DEFINITION","source":"NCI"},{"definition":"Group of hereditary disorders in which affected individuals fail to make enough of certain proteins needed to form blood clots.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hemophilia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hemophilia"},{"name":"Maps_To","value":"Hemophiliac"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0684275"}]}}{"C154862":{"preferredName":"Heterosexual Contact","code":"C154862","definitions":[{"definition":"Sexual contact with a member of the opposite sex.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Sexual contact with someone of the opposite sex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heterosexual Contact","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heterosexual Contact"},{"name":"NCI_META_CUI","value":"CL555675"},{"name":"Semantic_Type","value":"Individual Behavior"}]}}{"C154863":{"preferredName":"Homosexual Contact","code":"C154863","definitions":[{"definition":"Sexual contact with a member of the same sex.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Sexual contact with someone of the same sex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Homosexual Contact","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Homosexual Contact"},{"name":"NCI_META_CUI","value":"CL555676"},{"name":"Semantic_Type","value":"Individual Behavior"}]}}{"C84367":{"preferredName":"Intravenous Drug User","code":"C84367","definitions":[{"definition":"A person who injects recreational drugs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intravenous Drug User","termGroup":"PT","termSource":"NCI"},{"termName":"IDU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intravenous Drug User"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0242566"}]}}{"C159672":{"preferredName":"Risk Factor History Negative","code":"C159672","definitions":[{"definition":"The determination that an individual's risk factor history is negative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Risk Factor History Negative","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"None"},{"name":"NCI_META_CUI","value":"CL552484"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C171149":{"preferredName":"Transfusion Recipient","code":"C171149","definitions":[{"definition":"A person who receives a direct injection of whole blood or blood products derived from a blood donor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transfusion Recipient","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transfusion Recipient"},{"name":"NCI_META_CUI","value":"CL1405383"},{"name":"Semantic_Type","value":"Human"}]}}{"C26808":{"preferredName":"Acute Renal Failure","code":"C26808","definitions":[{"definition":"A disorder characterized by the acute loss of renal function and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Deterioration of renal function, occurring within a time frame of hours to weeks, that results in failure to maintain normal fluid, electrolyte, waste products, and/or acid-base balance.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Sudden and sustained deterioration of the kidney function characterized by decreased glomerular filtration rate, increased serum creatinine or oliguria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Renal Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Kidney Injury","termGroup":"SY","termSource":"NCI"},{"termName":"AKI","termGroup":"AB","termSource":"NCI"},{"termName":"ARF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Renal_Failure"},{"name":"Maps_To","value":"Acute kidney injury"},{"name":"Maps_To","value":"Acute Renal Failure"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0022660"}]}}{"C26691":{"preferredName":"Adrenocortical Insufficiency","code":"C26691","definitions":[{"definition":"A disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison's disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency).","type":"DEFINITION","source":"NCI"},{"definition":"Subnormal concentration of cortisol, with or without mineralocorticoid insufficiency.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Adrenocortical Insufficiency","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortical Insufficiency","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Insufficiency","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Insufficiency","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Adrenal_Gland_Insufficiency"},{"name":"Maps_To","value":"Adrenal insufficiency"},{"name":"Maps_To","value":"Adrenocortical Insufficiency"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4012286"}]}}{"C114476":{"preferredName":"Allergic Reaction","code":"C114476","definitions":[{"definition":"A disorder characterized by an adverse local or general response from exposure to an allergen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A hypersensitive immune reaction to a substance that normally is harmless or would not cause an immune response in most people. An allergic response may cause harmful symptoms such as itching or inflammation or tissue injury.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A hypersensitivity reaction triggered by exposure to a previously encountered foreign substance to which the individual has formed antibodies.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allergic Reaction","termGroup":"PT","termSource":"NCI"},{"termName":"Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Allergic reaction"},{"name":"Maps_To","value":"Allergies"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1527304"}]}}{"C84397":{"preferredName":"Alpha-1 Antitrypsin Deficiency","code":"C84397","definitions":[{"definition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-1 Antitrypsin Deficiency","termGroup":"PT","termSource":"NCI"},{"termName":"A-1ATD","termGroup":"AB","termSource":"NCI"},{"termName":"A1AD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Alpha-1 Antitrypsin"},{"name":"Maps_To","value":"Alpha-1 Antitrypsin Deficiency"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0221757"}]}}{"C2869":{"preferredName":"Anemia","code":"C2869","definitions":[{"definition":"A condition in which the number of red blood cells is below normal.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by an reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally low level of hemoglobin in the blood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Anemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Anemia"},{"name":"Maps_To","value":"Anemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229468"},{"name":"xRef","value":"IMDRF:E0301"}]}}{"C26696":{"preferredName":"Anxiety","code":"C26696","definitions":[{"definition":"An emotional state characterized by excessive worried thoughts that may be accompanied by restlessness, tension, tachycardia, increased blood pressure, and/or dyspnea.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","type":"DEFINITION","source":"NCI"},{"definition":"Apprehension or uneasiness which may be accompanied by restlessness, tension, tachycardia, and dyspnea.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Feelings of fear, dread, and uneasiness that may occur as a reaction to stress. A person with anxiety may sweat, feel restless and tense, and have a rapid heart beat. Extreme anxiety that happens often over time may be a sign of an anxiety disorder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anxiety","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Anxiety"},{"name":"Maps_To","value":"Anxiety"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C4228281"},{"name":"xRef","value":"IMDRF:E020201"}]}}{"C2881":{"preferredName":"Arrhythmia","code":"C2881","definitions":[{"definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","type":"DEFINITION","source":"NCI"},{"definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Arrhythmia","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiac Arrhythmia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Arrhythmia"},{"name":"Maps_To","value":"Arrhythmia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3275765"},{"name":"xRef","value":"IMDRF:E0601"}]}}{"C2883":{"preferredName":"Arthritis","code":"C2883","definitions":[{"definition":"A disease that causes inflammation and pain in the joints.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by inflammation involving a joint.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An inflammatory process affecting a joint.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the joint tissues of any etiology. Signs and symptoms may include pain, swelling, warmth, guarding, limited range of motion or overlying erythema.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Arthritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Arthritis"},{"name":"Maps_To","value":"Arthritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014799"},{"name":"xRef","value":"IMDRF:E1602"}]}}{"C28397":{"preferredName":"Asthma","code":"C28397","definitions":[{"definition":"A chronic disease in which the bronchial airways in the lungs become narrowed and swollen, making it difficult to breathe. Symptoms include wheezing, coughing, tightness in the chest, shortness of breath, and rapid breathing. An attack may be brought on by pet hair, dust, smoke, pollen, mold, exercise, cold air, or stress.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A chronic respiratory disease caused by obstruction of the bronchi and small airways, and characterized by wheezing and shortness of breath.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","type":"DEFINITION","source":"NCI"},{"definition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Asthma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Asthma"},{"name":"Maps_To","value":"Asthma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229310"},{"name":"xRef","value":"IMDRF:E0706"}]}}{"C2887":{"preferredName":"Ataxia Telangiectasia Syndrome","code":"C2887","definitions":[{"definition":"A rare, inherited, progressive, degenerative disease of childhood that causes loss of muscle control, a weakened immune system, and an increased risk of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ataxia Telangiectasia Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Ataxia Telangiectasia","termGroup":"SY","termSource":"NCI"},{"termName":"Ataxia-Telangiectasia Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Louis-Bar Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ataxia_Telangiectasia_Syndrome"},{"name":"Maps_To","value":"Ataxia-telangiectasia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004135"}]}}{"C50466":{"preferredName":"Atrial Fibrillation","code":"C50466","definitions":[{"definition":"A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A disorder characterized by an electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregular ventricular response. (CDISC)","type":"DEFINITION","source":"NCI"},{"definition":"An irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atrial.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Atrial Fibrillation","termGroup":"PT","termSource":"NCI"},{"termName":"AF","termGroup":"AB","termSource":"NCI"},{"termName":"AFib","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Atrial_Fibrillation"},{"name":"Maps_To","value":"Atrial Fibrillation"},{"name":"Maps_To","value":"Atrial fibrillation"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4015486"},{"name":"xRef","value":"IMDRF:E060102"}]}}{"C37864":{"preferredName":"Autoimmune Lymphoproliferative Syndrome","code":"C37864","definitions":[{"definition":"An autoimmune hematologic disorder characterized by autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatomegaly and splenomegaly. Patients are at an increased risk of developing Hodgkin and non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autoimmune Lymphoproliferative Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"ALPS","termGroup":"AB","termSource":"NCI"},{"termName":"Canale-Smith Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Autoimmune_Lymphoproliferative_Syndrome"},{"name":"Maps_To","value":"Autoimmune Lymphoproliferative Syndrome (ALPS)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1328840"}]}}{"C118385":{"preferredName":"Avascular Necrosis","code":"C118385","definitions":[{"definition":"Tissue death resulting from an interruption to the blood supply.","type":"DEFINITION","source":"NCI"},{"definition":"Tissue death resulting from an interruption to the blood supply.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Avascular Necrosis","termGroup":"PT","termSource":"NCI"},{"termName":"AVN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Avascular Necrosis"},{"name":"Maps_To","value":"Avascular necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3538978"}]}}{"C86172":{"preferredName":"Bacteroides fragilis","code":"C86172","definitions":[{"definition":"A species of obligately anaerobic, Gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is nonmotile, non-spore forming, indole positive, produces hydrogen sulfide, does not reduce nitrate, hydrolyzes esculin and starch, does not ferment trehalose, melezitose or arabinose, and is penicillin resistant. B. fragilis is commensal and part of the normal human gastrointestinal tract flora, but may become pathogenic in other body regions.","type":"DEFINITION","source":"NCI"},{"definition":"Any bacterial organism that can be assigned to the species Bacteroides fragilis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bacteroides fragilis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bacteroides fragilis"},{"name":"NCBI_Taxon_ID","value":"817"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"UMLS_CUI","value":"C0004663"}]}}{"C2891":{"preferredName":"Barrett Esophagus","code":"C2891","definitions":[{"definition":"A condition in which the cells lining the lower part of the esophagus have changed or been replaced with abnormal cells that could lead to cancer of the esophagus. The backing up of stomach contents (reflux) may irritate the esophagus and, over time, cause Barrett's esophagus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Esophageal lesion lined with columnar metaplastic epithelium which is flat or villiform. Barrett epithelium is characterized by two different types of cells: goblet cells and columnar cells. The symptomatology of Barrett esophagus is that of gastro-esophageal reflux. It is the precursor of most esophageal adenocarcinomas.  (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Barrett Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Barrett's Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"BE","termGroup":"AB","termSource":"NCI"},{"termName":"CELLO","termGroup":"AB","termSource":"NCI"},{"termName":"CLE","termGroup":"AB","termSource":"NCI"},{"termName":"Columnar Epithelial-Lined Lower Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Columnar-Lined Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Barrett_s_Esophagus"},{"name":"Maps_To","value":"Barrett oesophagus"},{"name":"Maps_To","value":"Barrett's Esophagus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004763"}]}}{"C34415":{"preferredName":"Beckwith-Wiedemann Syndrome","code":"C34415","definitions":[{"definition":"A complex syndrome resulting from various genetic and epigenetic anomalies of the 11p15.5 chromosomal region, leading to dysregulated expression of imprinted genes. Specific genes involved include CDKN1C, H19, IGF2, and KCNQ1OT1. One of the key genetic anomalies is an imbalance between the paternally expressed IGF2 growth enhancer gene and the maternally expressed H19 growth suppressor gene, leading to fetal and postnatal overgrowth. The condition is typically characterized by macrosomia, macroglossia, umbilical hernia or more severe abdominal wall anomalies such as omphalocele, ear lobe indentations, and hypoglycemia associated with hyperinsulinemia due to pancreatic islet cell hyperplasia. Patients with this syndrome have an increased risk for development of embryonal tumors (particularly Wilms tumor and hepatoblastoma) and adrenal cortex carcinoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A genetic syndrome caused by abnormalities in chromosome 11. It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia. Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, rhabdomyosarcoma) and adrenal cortex carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"A rare, overgrowth disorder in which babies are large at birth and may develop low blood sugar. Other common symptoms are a large tongue, large internal organs, and defects of the abdominal wall near the navel. Beckwith-Wiedemann syndrome increases the risk of developing certain cancers, especially Wilms tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Beckwith-Wiedemann Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Beckwith-Wiedemann_Syndrome"},{"name":"Maps_To","value":"Beckwith-Wiedemann"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004903"}]}}{"C34416":{"preferredName":"Behcet Syndrome","code":"C34416","definitions":[{"definition":"A rare chronic inflammatory disorder of unknown etiology. It is characterized by the development of ulcers in the mouth and genital region and uveitis. Other signs and symptoms include arthritis, deep vein thrombosis and superficial thrombophlebitis.","type":"DEFINITION","source":"NCI"},{"definition":"A systemic vasculitis affecting both arteries and veins which manifests primarily as recurrent oral and genital ulceration, uveitis, characteristic rash, and arthritis. It may also cause central nervous system disease, gastrointestinal inflammation or ulceration, or thrombophlebitis.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Behcet Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Behcet's Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Behçet Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Behcet_s_Syndrome"},{"name":"Maps_To","value":"Behcet's Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004943"}]}}{"C2899":{"preferredName":"Biliary System Disorder","code":"C2899","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biliary System Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Biliary Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Biliary_Tract_Disorder"},{"name":"Maps_To","value":"Biliary Disorder"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3275124"}]}}{"C27083":{"preferredName":"Blood Clot","code":"C27083","definitions":[{"definition":"A mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggregation of blood factors, primarily platelets and fibrin with entrapment of cellular elements, frequently causing vascular obstruction at the point of its formation.","type":"DEFINITION","source":"NCI"},{"definition":"An aggregation of platelets and fibrin within the cardiovascular system.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An intravascular aggregation of blood components, primarily platelets and fibrin with entrapment of cellular elements, which is attached to the vessel wall.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The formation of a blood clot in the lumen of a vessel or heart chamber","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The formation of a blood clot in the lumen of a vessel or heart chamber.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Blood Clot","termGroup":"PT","termSource":"NCI"},{"termName":"Thrombus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Blood_Clot"},{"name":"Maps_To","value":"Blood Clots"},{"name":"Maps_To","value":"Clot blood"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0087086"},{"name":"xRef","value":"IMDRF:E0514"}]}}{"C3046":{"preferredName":"Fracture","code":"C3046","definitions":[{"definition":"A finding of traumatic injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A traumatic injury to the bone in which the continuity of the bone is broken.","type":"DEFINITION","source":"NCI"},{"definition":"A traumatic injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A traumatic or pathological injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Localized disruption of bone or tooth structure resulting in partial or complete discontinuity. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fracture","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Fracture","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Fracture"},{"name":"Maps_To","value":"Bone Fracture(s)"},{"name":"Maps_To","value":"Fracture"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3808973"},{"name":"xRef","value":"IMDRF:E1603"}]}}{"C2911":{"preferredName":"Bronchitis","code":"C2911","definitions":[{"definition":"A disorder characterized by an infectious process involving the bronchi.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An acute or chronic inflammatory process affecting the bronchi.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An acute or chronic inflammatory process affecting the bronchi.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation (swelling and reddening) of the bronchi.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Inflammation of the bronchi.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Bronchitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Bronchitis"},{"name":"Maps_To","value":"Bronchitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0006277"},{"name":"xRef","value":"IMDRF:E0708"}]}}{"C333":{"preferredName":"Calcium Channel Blocker","code":"C333","definitions":[{"definition":"A pharmaceutical agent that inhibits the movement of calcium across through calcium channels in the cell membrane, preventing or decreasing the amount of calcium able to enter the cell. These drugs are used for their chronotropic, antihypertensive and vasodilatory effects.","type":"DEFINITION","source":"NCI"},{"definition":"A pharmaceutical agent that inhibits the movement of calcium across through calcium channels in the cell membrane, preventing or decreasing the amount of calcium able to enter the cell. These drugs are used for their chronotropic, antihypertensive and vasodilatory effects.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Calcium Channel Blocker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:38215"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Calcium_Channel_Blocker"},{"name":"Maps_To","value":"Calcium Channel Blockers"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0006684"}]}}{"C26713":{"preferredName":"Cataract","code":"C26713","definitions":[{"definition":"A condition in which the lens of the eye becomes cloudy. Symptoms include blurred, cloudy, or double vision; sensitivity to light; and difficulty seeing at night. Without treatment, cataracts can cause blindness. There are many different types and causes of cataracts. They may occur in people of all ages, but are most common in the elderly.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Opacity of the crystalline lens.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","type":"DEFINITION","source":"NCI"},{"definition":"Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Cataract","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Cataract"},{"name":"Maps_To","value":"Cataract"},{"name":"Maps_To","value":"Cataracts"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0086543"},{"name":"xRef","value":"IMDRF:E0802"}]}}{"C26714":{"preferredName":"Celiac Disease","code":"C26714","definitions":[{"definition":"A digestive disease that is caused by an immune response to a protein called gluten, which is found in wheat, rye, barley, and oats. Celiac disease damages the lining of the small intestine and interferes with the absorption of nutrients from food. A person with celiac disease may become malnourished no matter how much food is consumed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Celiac Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Celiac Sprue","termGroup":"SY","termSource":"NCI"},{"termName":"Gluten-Induced Enteropathy","termGroup":"SY","termSource":"NCI"},{"termName":"Non Tropical Sprue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Celiac_Disease"},{"name":"Maps_To","value":"Celiac Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007570"}]}}{"C2938":{"preferredName":"Cerebrovascular Disorder","code":"C2938","definitions":[{"definition":"A disorder resulting from inadequate blood flow in the vessels that supply the brain. Representative examples include cerebrovascular ischemia, cerebral embolism, and cerebral infarction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebrovascular Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebrovascular Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cerebrovascular_Disorder"},{"name":"Maps_To","value":"Cerebrovascular Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007820"}]}}{"C34463":{"preferredName":"Chlamydial Infection","code":"C34463","definitions":[{"definition":"An infection that is caused by Chlamydia trachomatis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlamydial Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chlamydial_Infection"},{"name":"Maps_To","value":"Chlamydia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0008149"}]}}{"C122822":{"preferredName":"Cholelithiasis","code":"C122822","definitions":[{"definition":"The presence of calculi in the gallbladder.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The presence of calculi in the gallbladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cholelithiasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Cholelithiasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3806112"}]}}{"C9438":{"preferredName":"Chronic Renal Failure","code":"C9438","definitions":[{"definition":"Impairment of the renal function due to chronic kidney damage.","type":"DEFINITION","source":"NCI"},{"definition":"Impairment of the renal function due to chronic kidney damage.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Chronic Renal Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"CRF - Chronic Renal Failure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Chronic_Renal_Failure"},{"name":"Maps_To","value":"Chronic renal failure"},{"name":"Maps_To","value":"Chronic Renal Failure"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3810486"}]}}{"C174112":{"preferredName":"Chronic Systemic Steroid Use","code":"C174112","definitions":[{"definition":"An indication that the subject has been using a systemic steroid at the prescribed dose for a long period of time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Systemic Steroid Use","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic Systemic Steroid Use"},{"name":"NCI_META_CUI","value":"CL1407748"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C2951":{"preferredName":"Cirrhosis","code":"C2951","definitions":[{"definition":"A chronic degenerative disease of the liver characterized by parenchymal nodularity and fibrosis.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","type":"DEFINITION","source":"NCI"},{"definition":"A type of chronic, progressive liver disease in which liver cells are replaced by scar tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cirrhosis","termGroup":"PT","termSource":"NCI"},{"termName":"Liver Cirrhosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cirrhosis"},{"name":"Maps_To","value":"Cirrhosis"},{"name":"Maps_To","value":"Cirrhosis of liver"},{"name":"Maps_To","value":"Cirrhosis, Unknown Etiology"},{"name":"Maps_To","value":"Liver Cirrhosis (Liver Disease)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4228437"}]}}{"C2954":{"preferredName":"Colon Polyp","code":"C2954","definitions":[{"definition":"A polypoid lesion that arises from the colon and protrudes into the lumen.  This group includes adenomatous polyps, serrated polyps, and hamartomatous polyps.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormal growths of tissue in the lining of the bowel.  Polyps are a risk factor for colon cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colon Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Colonic Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of the Colon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colon_Polyp"},{"name":"Maps_To","value":"Colon Polyps"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009376"}]}}{"C26725":{"preferredName":"Common Variable Immunodeficiency","code":"C26725","definitions":[{"definition":"A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally low level of functional immunoglobulins in the blood that is not associated with a primary immunodeficiency.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Common Variable Immunodeficiency","termGroup":"PT","termSource":"NCI"},{"termName":"Acquired Agammaglobulinemia","termGroup":"SY","termSource":"NCI"},{"termName":"Secondary Hypogammaglobulinemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Common_Variable_Immunodeficiency"},{"name":"Maps_To","value":"Common variable immune deficiency (CVID)"},{"name":"Maps_To","value":"Common Variable Immunodeficiency"},{"name":"Maps_To","value":"Secondary acquired hypogammaglobulinaemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009447"}]}}{"C3080":{"preferredName":"Congestive Heart Failure","code":"C3080","definitions":[{"definition":"Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.","type":"DEFINITION","source":"NCI"},{"definition":"Inability of the heart to pump blood adequately to fill tissue metabolic requirements or the ability to do so only at an elevated filling pressure.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Weakness of the heart muscle that leads to a buildup of fluid in body tissues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Congestive Heart Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiac Failure Congestive","termGroup":"SY","termSource":"NCI"},{"termName":"CHF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Congestive_Heart_Failure"},{"name":"Maps_To","value":"Congestive Heart Failure (CHF)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3551869"},{"name":"xRef","value":"IMDRF:E0611"}]}}{"C26729":{"preferredName":"Connective Tissue Disorder","code":"C26729","definitions":[{"definition":"A disorder characterized by abnormalities in one or more of the elements of the connective tissues, typically associated with genetic defects.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A non-neoplastic or neoplastic disorder that affects the connective tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A non-neoplastic or neoplastic disorder that affects the connective tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Connective Tissue Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Connective Tissue Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Connective Tissue Diseases","termGroup":"SY","termSource":"NCI"},{"termName":"Connective Tissue Disorders","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Connective_Tissue_Disorder"},{"name":"Maps_To","value":"Connective Tissue Disorder"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009782"},{"name":"xRef","value":"IMDRF:E1604"}]}}{"C3199":{"preferredName":"Chronic Obstructive Pulmonary Disease","code":"C3199","definitions":[{"definition":"A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","type":"DEFINITION","source":"NCI"},{"definition":"A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A type of lung disease marked by permanent damage to tissues in the lungs, making it hard to breathe. Chronic obstructive pulmonary disease includes chronic bronchitis, in which the bronchi (large air passages) are inflamed and scarred, and emphysema, in which the alveoli (tiny air sacs) are damaged. It develops over many years and is usually caused by cigarette smoking.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chronic Obstructive Pulmonary Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Obstructive Airways Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Obstructive Lung Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Obstructive Pulmonary Disease (COPD)","termGroup":"SY","termSource":"NCI"},{"termName":"COLD","termGroup":"AB","termSource":"NCI"},{"termName":"COPD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Chronic_Obstructive_Airways_Disease"},{"name":"Maps_To","value":"COPD"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0024117"},{"name":"xRef","value":"IMDRF:E0711"}]}}{"C26732":{"preferredName":"Coronary Artery Disease","code":"C26732","definitions":[{"definition":"Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coronary Artery Disease","termGroup":"PT","termSource":"NCI"},{"termName":"CAD","termGroup":"AB","termSource":"NCI"},{"termName":"Coronary Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Coronary_Disease"},{"name":"Maps_To","value":"Coronary Artery Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3549709"}]}}{"C2965":{"preferredName":"Crohn Disease","code":"C2965","definitions":[{"definition":"A chronic, transmural inflammation that can affect any location along the gastrointestinal tract.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A condition in which the gastrointestinal tract is inflamed over a long period of time. Crohn disease usually affects the small intestine and colon. Symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. Crohn disease increases the risk of colorectal cancer and small intestine cancer. It is a type of inflammatory bowel disease (IBD).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A condition in which the gastrointestinal tract is inflamed over a long period of time. Regional enteritis usually affects the small intestine and colon. Symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. Regional enteritis increases the risk of colorectal cancer and small intestine cancer. It is a type of inflammatory bowel disease (IBD).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crohn Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Crohn's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Regional Enteritis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Crohn_s_Disease"},{"name":"Maps_To","value":"Crohn's disease"},{"name":"Maps_To","value":"Crohn's Disease"},{"name":"Maps_To","value":"Other Crohn disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3553281"}]}}{"C62586":{"preferredName":"Cryptogenic Organizing Pneumonia","code":"C62586","definitions":[{"definition":"A form of organizing pneumonia with a non-infectious etiology. Excessive proliferation of granulation tissue occurs in alveolar ducts and alveoli and primarily causes injury to alveolar walls, but bronchioles may be affected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptogenic Organizing Pneumonia","termGroup":"PT","termSource":"NCI"},{"termName":"BOOP","termGroup":"AB","termSource":"NCI"},{"termName":"Bronchiolitis Obliterans Organizing Pneumonia","termGroup":"SY","termSource":"NCI"},{"termName":"COP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cryptogenic_Organizing_Pneumonia"},{"name":"Maps_To","value":"Cryptogenic Organizing Pneumonia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0242770"}]}}{"C174113":{"preferredName":"Cryptococcal Meningitis","code":"C174113","definitions":[{"definition":"A blood borne fungal infection of the membranes surrounding the brain and spinal column (meninges) caused by Cryptococcus, usually C. neoformans or C. gattii. It usually occurs in immunocompromised patients including persons with AIDS, transplant recipients, patients receiving cytotoxic chemotherapy, and patients with hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptococcal Meningitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cryptococcal Meningitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085436"}]}}{"C49343":{"preferredName":"Deep Vein Thrombosis","code":"C49343","definitions":[{"definition":"A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Formation of a blood clot within a deep vein.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The formation of a blood clot in a deep vein of the leg or lower pelvis. Symptoms may include pain, swelling, warmth, and redness in the affected area.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Thrombosis formation within deep veins during acute COVID-19","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]}],"synonyms":[{"termName":"Deep Vein Thrombosis","termGroup":"PT","termSource":"NCI"},{"termName":"DVT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Deep_Vein_Thrombosis"},{"name":"Maps_To","value":"Deep vein thrombosis"},{"name":"Maps_To","value":"Deep Vein Thrombosis / Thromboembolism"},{"name":"Maps_To","value":"DVT/PE"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0149871"}]}}{"C28195":{"preferredName":"Thromboembolism","code":"C28195","definitions":[{"definition":"A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"DEFINITION","source":"NCI"},{"definition":"Occlusion of the lumen of a vessel by a thrombus.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Thromboembolism","termGroup":"PT","termSource":"NCI"},{"termName":"Thromboembolic Event","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Thromboembolism"},{"name":"Maps_To","value":"Deep Vein Thrombosis / Thromboembolism"},{"name":"Maps_To","value":"Thromboembolism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3550383"},{"name":"xRef","value":"IMDRF:E050304"}]}}{"C84668":{"preferredName":"Denys-Drash Syndrome","code":"C84668","definitions":[{"definition":"A Wilms tumor 1 gene syndrome caused by various point mutation(s) affecting the zinc finger(s) of the Wilms tumor protein. This syndrome is characterized by congenital nephropathy (diffuse mesangial sclerosis), gonadal dysgenesis resulting in atypical genital and reproductive tract development in male infants, and high risk for development of Wilms tumor, an embryonal neoplasm defined by the presence of epithelial, mesenchymal, and blastema components.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare congenital syndrome caused by mutations in the WT1 gene. It is characterized by the presence of congenital nephropathy (diffuse mesangial sclerosis), Wilms tumor, and intersex disorders.","type":"DEFINITION","source":"NCI"},{"definition":"A rare disorder that causes kidney failure before age 3, abnormal development of the sexual organs, and, in most cases, Wilms tumor (a type of kidney cancer). Children with Denys-Drash syndrome are also at high risk of some other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Denys-Drash Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"DDS","termGroup":"AB","termSource":"NCI"},{"termName":"Denys Drash Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Denys-Drash Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0950121"}]}}{"C2982":{"preferredName":"Depression","code":"C2982","definitions":[{"definition":"A condition marked by ongoing feelings of sadness, despair, loss of energy, diminished interest/pleasure and difficulty dealing with normal daily life.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A disorder characterized by melancholic feelings of grief or unhappiness.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A melancholy feeling of sadness and despair.","type":"DEFINITION","source":"NCI"},{"definition":"A mental condition marked by ongoing feelings of sadness, despair, loss of energy, and difficulty dealing with normal daily life. Other symptoms of depression include feelings of worthlessness and hopelessness, loss of pleasure in activities, changes in eating or sleeping habits, and thoughts of death or suicide. Depression can affect anyone, and can be successfully treated. Depression affects 15-25% of cancer patients.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Depression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Depression"},{"name":"Maps_To","value":"Depression"},{"name":"Semantic_Type","value":"Mental or Behavioral Dysfunction"},{"name":"UMLS_CUI","value":"C3277399"},{"name":"xRef","value":"IMDRF:E020202"}]}}{"C2985":{"preferredName":"Diabetes Mellitus","code":"C2985","definitions":[{"definition":"A disease in which the body does not control the amount of glucose (a type of sugar) in the blood and the kidneys make a large amount of urine. This disease occurs when the body does not make enough insulin or does not use it the way it should.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A metabolic condition, characterized by hyperglycemia, caused by insufficient secretion of insulin by the pancreas and/or decreased insulin action in target tissues.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetes Mellitus","termGroup":"PT","termSource":"NCI"},{"termName":"Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"DM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Diabetes_Mellitus"},{"name":"Maps_To","value":"Diabetes"},{"name":"Maps_To","value":"Diabetes, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4013416"}]}}{"C26747":{"preferredName":"Type 2 Diabetes Mellitus","code":"C26747","definitions":[{"definition":"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.","type":"DEFINITION","source":"NCI"},{"definition":"Diabetes mellitus caused by decreased insulin action in target tissues and insufficient production of insulin by pancreatic beta cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Type 2 Diabetes Mellitus","termGroup":"PT","termSource":"NCI"},{"termName":"Adult-Onset Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Diabetes, Type 2","termGroup":"SY","termSource":"NCI"},{"termName":"NIDDM","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Insulin Dependent Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Insulin Dependent Diabetes Mellitus","termGroup":"SY","termSource":"NCI"},{"termName":"T2DM - Type 2 Diabetes mellitus","termGroup":"SY","termSource":"NCI"},{"termName":"Type 2 Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type 2 Diabetes Mellitus Non-Insulin Dependent","termGroup":"SY","termSource":"NCI"},{"termName":"Type II Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type II Diabetes Mellitus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Non-Insulin_Dependent_Diabetes_Mellitus"},{"name":"Maps_To","value":"Diabetes, Type II"},{"name":"Maps_To","value":"Type II diabetes mellitus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0011860"}]}}{"C26748":{"preferredName":"Diabetic Neuropathy","code":"C26748","definitions":[{"definition":"A chronic, pathological complication associated with diabetes mellitus, where nerve damages are incurred due to diabetic microvascular injury involving small blood vessels that supply these nerves, resulting in peripheral and/or autonomic nerve dysfunction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetic Neuropathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diabetic_Neuropathy"},{"name":"Maps_To","value":"Diabetic Neuropathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0011882"}]}}{"C184754":{"preferredName":"Diabetes Is Controlled by Diet","code":"C184754","definitions":[{"definition":"An indication that a subject with diabetes is able to control symptoms by modifying their diet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetes Is Controlled by Diet","termGroup":"PT","termSource":"NCI"},{"termName":"Diet Controlled Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Diet-Controlled Diabetes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diet Controlled Diabetes"},{"name":"NCI_META_CUI","value":"CL1773079"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C26752":{"preferredName":"Diverticulitis","code":"C26752","definitions":[{"definition":"An infection that develops in the diverticula of the intestinal tract. Signs and symptoms include abdominal pain, fever, and leukocytosis.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of one or more pouches or sacs that bulge out from the wall of a hollow organ, such as the colon. Symptoms include muscle spasms and cramps in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diverticulitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diverticulitis"},{"name":"Maps_To","value":"Diverticulitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0012813"}]}}{"C50713":{"preferredName":"Pulmonary Embolism","code":"C50713","definitions":[{"definition":"The obstruction of blood flow by an embolus within the pulmonary circulation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung, during acute COVID-19","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","type":"DEFINITION","source":"NCI"},{"definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Pulmonary Embolism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pulmonary_Embolism"},{"name":"Maps_To","value":"DVT/PE"},{"name":"Maps_To","value":"Pulmonary embolism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3552763"},{"name":"xRef","value":"IMDRF:E050303"}]}}{"C80385":{"preferredName":"Dyslipidemia","code":"C80385","definitions":[{"definition":"A lipoprotein metabolism disorder characterized by decreased levels of high-density lipoproteins, or elevated levels of plasma cholesterol, low-density lipoproteins and/or triglycerides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dyslipidemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dyslipidemia"},{"name":"Maps_To","value":"Dyslipidemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C4229397"}]}}{"C3001":{"preferredName":"Eczema","code":"C3001","definitions":[{"definition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A group of conditions in which the skin becomes inflamed, forms blisters, and becomes crusty, thick, and scaly. Eczema causes burning and itching, and may occur over a long period of time. Atopic dermatitis is the most common type of eczema.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Eczema","termGroup":"PT","termSource":"NCI"},{"termName":"Atopic Dermatitis","termGroup":"SY","termSource":"NCI"},{"termName":"Eczematous Dermatitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Eczema"},{"name":"Maps_To","value":"Eczema"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227545"},{"name":"xRef","value":"IMDRF:E172004"}]}}{"C3020":{"preferredName":"Seizure Disorder","code":"C3020","definitions":[{"definition":"A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.","type":"DEFINITION","source":"NCI"},{"definition":"A group of disorders marked by problems in the normal functioning of the brain.  These problems can produce seizures, unusual body movements, a loss of consciousness or changes in consciousness, as well as mental problems or problems with the senses.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neurological disorder characterized by recurring seizures.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Epilepsy caused or apparently caused by device. Do not use when epilepsy is a pre-existing condition.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Seizure Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Epilepsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Epilepsy"},{"name":"Maps_To","value":"Epilepsy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3810329"},{"name":"xRef","value":"IMDRF:E010903"}]}}{"C38759":{"preferredName":"EBV Infection","code":"C38759","definitions":[{"definition":"An infection that is caused by Epstein-Barr virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Epstein-Barr Virus Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epstein-Barr_Virus_Infection"},{"name":"Maps_To","value":"Epstein-Barr Virus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0149678"}]}}{"C62505":{"preferredName":"Fanconi Anemia","code":"C62505","definitions":[{"definition":"A chromosomal instability syndrome that is the most common form of inherited aplastic anemia. It is inherited as an autosomal recessive or X-linked disorder. In addition to bone marrow failure, it is associated with skeletal abnormalities and increased incidence of the development of malignancy. Multiple genes are responsible for Fanconi anemia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare inherited disorder in which the bone marrow does not make blood cells. It is usually diagnosed in children between 2 and 15 years old. Symptoms include frequent infections, easy bleeding, and extreme tiredness. People with Fanconi anemia may have a small skeleton and brown spots on the skin. They also have an increased risk of developing certain types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fanconi Anemia","termGroup":"PT","termSource":"NCI"},{"termName":"Fanconi's Anemia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancytopenia, Congenital","termGroup":"SY","termSource":"NCI"},{"termName":"Panmyelopathy, Fanconi","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Erythroid Hypoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Fanconi_Anemia"},{"name":"Maps_To","value":"Fanconi Anemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0015625"}]}}{"C3044":{"preferredName":"Fibrosis","code":"C3044","definitions":[{"definition":"Increase in collagen and low numbers of fibrocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The formation of fibrous tissue.","type":"DEFINITION","source":"NCI"},{"definition":"The formation of fibrous tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The growth of fibrous tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Fibrosis"},{"name":"Maps_To","value":"Fibrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3550476"},{"name":"xRef","value":"IMDRF:E2313"}]}}{"C26781":{"preferredName":"Gastroesophageal Reflux Disease","code":"C26781","definitions":[{"definition":"A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Reflux of stomach contents with symptoms and/or complications from the reflux act.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Gastroesophageal Reflux Disease","termGroup":"PT","termSource":"NCI"},{"termName":"GERD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Gastroesophageal_Reflux_Disease"},{"name":"Maps_To","value":"Gastro-oesophageal reflux disease with oesophagitis"},{"name":"Maps_To","value":"Gastroesophageal Reflux Disease"},{"name":"Maps_To","value":"Gastroesophageal reflux disease"},{"name":"Maps_To","value":"GERD"},{"name":"Maps_To","value":"Reflux Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229251"}]}}{"C26782":{"preferredName":"Glaucoma","code":"C26782","definitions":[{"definition":"A condition in which there is a build-up of fluid in the eye, which presses on the retina and the optic nerve. The retina is the layer of nerve tissue inside the eye that senses light and sends images along the optic nerve to the brain. Glaucoma can damage the optic nerve and cause loss of vision or blindness.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.","type":"DEFINITION","source":"NCI"},{"definition":"Optic nerve damage secondary to increased intraocular pressure.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Glaucoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Glaucoma"},{"name":"Maps_To","value":"Glaucoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4228099"},{"name":"xRef","value":"IMDRF:E0822"}]}}{"C61272":{"preferredName":"Glycogen Storage Disease","code":"C61272","definitions":[{"definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glycogen Storage Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Glycogen_Storage_Disease"},{"name":"Maps_To","value":"Glycogen Storage Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0017919"}]}}{"C26786":{"preferredName":"Gonadal Disorder","code":"C26786","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that affects the testis or the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadal Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Gonadal Disorders","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Gonadal_Disorder"},{"name":"Maps_To","value":"Gonadal Dysfunction"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018050"}]}}{"C2892":{"preferredName":"Nevoid Basal Cell Carcinoma Syndrome","code":"C2892","definitions":[{"definition":"A genetic condition that causes unusual facial features and disorders of the skin, bones, nervous system, eyes, and endocrine glands. People with this syndrome have a higher risk of basal cell carcinoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH and SUFU gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nevoid Basal Cell Carcinoma Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Nevus Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Gorlin Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Gorlin-Goltz Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Basal Cell Carcinomas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Basal_Cell_Nevus_Syndrome"},{"name":"Maps_To","value":"Gorlin Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004779"}]}}{"C34650":{"preferredName":"Gout","code":"C34650","definitions":[{"definition":"A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.","type":"DEFINITION","source":"NCI"},{"definition":"A condition marked by increased levels of uric acid in the blood, joints, and tissue. The buildup of uric acid in the joints and tissues causes arthritis and inflammation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gout","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gout"},{"name":"Maps_To","value":"Gout"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018099"}]}}{"C39293":{"preferredName":"Helicobacter Pylori Infection","code":"C39293","definitions":[{"definition":"A bacterial infection of the stomach, caused by Helicobacter pylori.  It is associated with the development of peptic ulcer and mucosa-associated lymphoid tissue lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Helicobacter Pylori Infection","termGroup":"PT","termSource":"NCI"},{"termName":"H. pylori Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Helicobacter_Pylori_Infection"},{"name":"Maps_To","value":"H. pylori Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0850666"}]}}{"C27191":{"preferredName":"Hashimoto Thyroiditis","code":"C27191","definitions":[{"definition":"An autoimmune condition of the thyroid gland (a gland located beneath the larynx). It is caused by the formation of antibodies that attack the thyroid gland and it usually causes hypothyroidism (too little thyroid hormone). Symptoms include fatigue, weight gain, constipation, dry skin, depression, and the inability to exercise. It is more common in females and can run in families.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.","type":"DEFINITION","source":"NCI"},{"definition":"An autoimmune disorder characterized by inflammation and lymphocytic infiltration of the thyroid gland, sometimes associated with reduced thyroid function.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hashimoto Thyroiditis","termGroup":"PT","termSource":"NCI"},{"termName":"Autoimmune Thyroiditis","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Lymphocytic Thyroiditis","termGroup":"SY","termSource":"NCI"},{"termName":"Hashimoto Thyroiditis","termGroup":"SY","termSource":"NCI"},{"termName":"Hashimoto's Thyroiditis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hashimoto_s_Thyroiditis"},{"name":"Maps_To","value":"Hashimoto's disease"},{"name":"Maps_To","value":"Hashimoto's Thyroiditis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0677607"}]}}{"C3079":{"preferredName":"Heart Disorder","code":"C3079","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.","type":"DEFINITION","source":"NCI"},{"definition":"The report describes a non-specific problem with the heart. Note: Please use \"Appropriate Term / Code Not Available\" if the report describes a specific problem but the relevant term does not exist.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Heart Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Heart Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Heart_Disease"},{"name":"Maps_To","value":"Heart Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018799"},{"name":"xRef","value":"IMDRF:E0623"}]}}{"C88541":{"preferredName":"Hemihypertrophy","code":"C88541","definitions":[{"definition":"A condition in which one side of the body or a part of one side is larger than the other. Children with hemihypertrophy have an increased risk of developing certain types of cancer, including Wilms tumor (a childhood kidney cancer) and liver cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A finding indicating the presence of greater than normal asymmetry between the right and left sides of the body. The asymmetry may be manifested in the entire side or part of it.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemihypertrophy","termGroup":"PT","termSource":"NCI"},{"termName":"Hemihyperplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Hemihypertrophy"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0332890"}]}}{"C114666":{"preferredName":"Hemorrhagic Cystitis","code":"C114666","definitions":[{"definition":"Inflammation of the bladder resulting in bloody urine.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammation of the bladder resulting in bloody urine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemorrhagic Cystitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Hemorrhagic Cystitis"},{"name":"Maps_To","value":"Hemorrhagic cystitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085692"}]}}{"C3095":{"preferredName":"Hepatitis","code":"C3095","definitions":[{"definition":"Disease of the liver causing inflammation. Symptoms include an enlarged liver, fever, nausea, vomiting, abdominal pain, and dark urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Inflammation of the liver.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Hepatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Hepatitis"},{"name":"Maps_To","value":"Hepatitis"},{"name":"Maps_To","value":"Hepatitis, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3806111"},{"name":"xRef","value":"IMDRF:E1102"}]}}{"C3096":{"preferredName":"Hepatitis A Infection","code":"C3096","definitions":[{"definition":"Acute inflammation of the liver caused by the hepatitis A virus. It is highly contagious and usually contracted through close contact with an infected individual or their feces, contaminated food or water.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis A Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Hepatitis A","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hepatitis_A"},{"name":"Maps_To","value":"Hepatitis A Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019159"}]}}{"C3097":{"preferredName":"Hepatitis B Infection","code":"C3097","definitions":[{"definition":"A viral infection caused by the hepatitis B virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatitis B","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis B Virus infection","termGroup":"SY","termSource":"NCI"},{"termName":"Viral Hepatitis B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hepatitis_B"},{"name":"Maps_To","value":"Hepatitis B Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019163"}]}}{"C3098":{"preferredName":"Hepatitis C Infection","code":"C3098","definitions":[{"definition":"A viral infection caused by the hepatitis C virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis C Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HCV Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C Virus Infection","termGroup":"SY","termSource":"NCI"},{"termName":"NANBH","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-A, Non-B Hepatitis","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatitis_C"},{"name":"Maps_To","value":"Hepatitis C Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019196"}]}}{"C82978":{"preferredName":"Chronic Hepatitis","code":"C82978","definitions":[{"definition":"An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Hepatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Chronic_Hepatitis"},{"name":"Maps_To","value":"Chronic Hepatitis"},{"name":"Maps_To","value":"Hepatitis, Chronic"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019189"}]}}{"C120083":{"preferredName":"Hereditary Nonpolyposis Colorectal Cancer Syndrome","code":"C120083","definitions":[{"definition":"An inherited disorder in which affected individuals have a higher-than-normal chance of developing colorectal cancer and certain other types of cancer, often before the age of 50.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inherited syndrome characterized by the development of several cancers, particularly colon and rectal cancers.  It includes Lynch syndrome which is associated with germline mutations in DNA mismatch-repair genes and familial colorectal cancer type X which is characterized by the absence of germline mutations in DNA mismatch-repair genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Nonpolyposis Colorectal Cancer Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Nonpolyposis Colorectal Cancer Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Nonpolyposis Colorectal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"HNPCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hereditary Non-polyposis Colon Cancer"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009405"}]}}{"C96768":{"preferredName":"High Grade Liver Dysplastic Nodule","code":"C96768","definitions":[{"definition":"A hepatic dysplastic nodule characterized by the presence of high grade atypical cellular changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Liver Dysplastic Nodule","termGroup":"PT","termSource":"NCI"},{"termName":"HGDN","termGroup":"AB","termSource":"NCI"},{"termName":"High Grade Hepatic Dysplastic Nodule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Grade Liver Dysplastic Nodule"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273016"}]}}{"C2851":{"preferredName":"Acquired Immunodeficiency Syndrome","code":"C2851","definitions":[{"definition":"A chronic, potentially life threatening condition that is caused by human immunodeficiency virus (HIV) infection, and is characterized by increased susceptibility to opportunistic infections, certain cancers and neurologic disorders.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disease caused by human immunodeficiency virus (HIV). People with acquired immunodeficiency syndrome are at an increased risk for developing certain cancers and for infections that usually occur only in individuals with a weak immune system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acquired Immunodeficiency Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Acquired Immune Deficiency","termGroup":"SY","termSource":"NCI"},{"termName":"AIDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"AIDS"},{"name":"Maps_To","value":"Acquired immune deficiency syndrome"},{"name":"Maps_To","value":"HIV / AIDS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0001175"}]}}{"C27851":{"preferredName":"Human Papillomavirus Infection","code":"C27851","definitions":[{"definition":"An infectious process caused by a human papillomavirus. This infection can cause abnormal tissue growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HPV","termGroup":"SY","termSource":"NCI"},{"termName":"HPV Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papilloma_Virus_Infection"},{"name":"Maps_To","value":"Human Papillomavirus Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0343641"}]}}{"C75545":{"preferredName":"Hemolytic Uremic Syndrome","code":"C75545","definitions":[{"definition":"A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.","type":"DEFINITION","source":"NCI"},{"definition":"Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hemolytic Uremic Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hemolytic_Uremic_Syndrome"},{"name":"Maps_To","value":"Hemolytic-uremic syndrome"},{"name":"Maps_To","value":"HUS/TTP"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3808621"}]}}{"C78797":{"preferredName":"Thrombotic Thrombocytopenic Purpura","code":"C78797","definitions":[{"definition":"A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.","type":"DEFINITION","source":"NCI"},{"definition":"A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.","type":"ALT_DEFINITION","source":"CTCAE"}],"synonyms":[{"termName":"Thrombotic Thrombocytopenic Purpura","termGroup":"PT","termSource":"NCI"},{"termName":"Moschowitz Disease","termGroup":"SY","termSource":"NCI"},{"termName":"TTP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Thrombotic_Thrombocytopenic_Purpura"},{"name":"Maps_To","value":"HUS/TTP"},{"name":"Maps_To","value":"Thrombotic thrombocytopenic purpura"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0034155"}]}}{"C3112":{"preferredName":"Hypercalcemia","code":"C3112","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium in blood.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high concentration of calcium in the peripheral blood.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally high level of calcium in the blood.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Higher than normal levels of calcium in the blood. Some types of cancer increase the risk of hypercalcemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Higher than normal levels of calcium in the circulating blood.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Hypercalcemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hypercalcemia"},{"name":"Maps_To","value":"Hypercalcemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0020437"},{"name":"xRef","value":"IMDRF:E120203"}]}}{"C37967":{"preferredName":"Hypercholesterolemia","code":"C37967","definitions":[{"definition":"A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A laboratory test result indicating an increased amount of cholesterol in the blood.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally high level of cholesterol in the blood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hypercholesterolemia","termGroup":"PT","termSource":"NCI"},{"termName":"High Cholesterol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hypercholesterolemia"},{"name":"Maps_To","value":"Hypercholesterolemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C1522133"}]}}{"C26797":{"preferredName":"Hyperglycemia","code":"C26797","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high level of glucose in the blood.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally high level of glucose in the blood.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Higher than normal amount of glucose (a type of sugar) in the blood. Hyperglycemia can be a sign of diabetes or other conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Plasma glucose concentration above the reference range.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hyperglycemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Hyperglycemia"},{"name":"Maps_To","value":"Hyperglycemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C4015534"},{"name":"xRef","value":"IMDRF:E1205"}]}}{"C34707":{"preferredName":"Hyperlipidemia","code":"C34707","definitions":[{"definition":"Elevated levels of lipids in the blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperlipidemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperlipidemia"},{"name":"Maps_To","value":"Hyperlipidemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0020473"}]}}{"C3117":{"preferredName":"Hypertension","code":"C3117","definitions":[{"definition":"A blood pressure of 140/90 or higher. High blood pressure usually has no symptoms. It can harm the arteries and cause an increase in the risk of stroke, heart attack, kidney failure, and blindness.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by a pathological increase in blood pressure; a repeatedly elevation in the blood pressure exceeding 140 over 90 mm Hg.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high blood pressure.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Blood pressure that is abnormally high.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Blood pressure that is abnormally high.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypertension","termGroup":"PT","termSource":"NCI"},{"termName":"High Blood Pressure","termGroup":"SY","termSource":"NCI"},{"termName":"HTN","termGroup":"AB","termSource":"NCI"},{"termName":"Vascular Hypertensive Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Hypertension"},{"name":"Maps_To","value":"Hypertension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4014808"},{"name":"xRef","value":"IMDRF:E2320"}]}}{"C40341":{"preferredName":"Hypospadias","code":"C40341","definitions":[{"definition":"A birth defect in which the opening of the urethra (the tube through which urine leaves the body) is not in its normal place. In males with hypospadias, the urethra opens on the underside of the penis or between the anus and the scrotum. In females with hypospadias, it opens into the vagina. Hypospadias is much more common in males than in females, and can be corrected by surgery. Children with hypospadias have an increased risk of developing Wilms tumor (a type of kidney cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A congenital abnormality in which the external urethral orifice is on the underside of the penis. In a minority of cases it is associated with other genitourinary abnormalities.","type":"DEFINITION","source":"NCI"},{"definition":"A congenital condition in which the urethra fails to develop properly, and the opening of the urethra is located on the ventrum of the penis, scrotum, or perineum.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Urethra opening on the underside of the penis or on the perineum. (Makris S, Solomon HM, Clark R, Shiota K, Barbellion S, Buschmann J, Ema M, Fujiwara M, Grote K, Hazelden KP, Hew KW, Horimoto M, Ooshima Y, Parkinson M, Wise LD. Terminology of developmental abnormalities in common laboratory mammals (Version 2). Part B. Birth Defects Res B Dev Reprod Toxicol. 2009 Aug;86(4):227-327.)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hypospadias","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hypospadias"},{"name":"Maps_To","value":"Hypospadias"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231490"}]}}{"C26800":{"preferredName":"Hypothyroidism","code":"C26800","definitions":[{"definition":"A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally low levels of thyroid hormone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Abnormally low levels of thyroid hormone.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Reduced secretion of thyroid hormone(s) by the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Too little thyroid hormone. Symptoms include weight gain, constipation, dry skin, and sensitivity to the cold.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hypothyroidism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hypothyroidism"},{"name":"Maps_To","value":"Hypothyroidism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229471"},{"name":"xRef","value":"IMDRF:E1212"}]}}{"C3138":{"preferredName":"Inflammatory Bowel Disease","code":"C3138","definitions":[{"definition":"A general term that refers to the inflammation of the colon and rectum. Inflammatory bowel disease includes ulcerative colitis and Crohn's disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.","type":"DEFINITION","source":"NCI"},{"definition":"Chronic inflammatory process affecting the gastrointestinal tract; primarily ulcerative colitis and Crohn's disease.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Inflammatory Bowel Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Autoimmune Bowel Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"IBD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Inflammatory_Bowel_Disease"},{"name":"Maps_To","value":"Inflammatory bowel disease"},{"name":"Maps_To","value":"Inflammatory Bowel Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227559"}]}}{"C184766":{"preferredName":"Diabetes Is Controlled by Insulin","code":"C184766","definitions":[{"definition":"An indication that a subject with diabetes is able to control symptoms using insulin-based therapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetes Is Controlled by Insulin","termGroup":"PT","termSource":"NCI"},{"termName":"Insulin Controlled Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin-Controlled Diabetes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Insulin Controlled Diabetes"},{"name":"NCI_META_CUI","value":"CL1773083"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C3353":{"preferredName":"Acute Respiratory Distress Syndrome","code":"C3353","definitions":[{"definition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.","type":"DEFINITION","source":"NCI"},{"definition":"Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Acute Respiratory Distress Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Adult RDS","termGroup":"SY","termSource":"NCI"},{"termName":"Adult Respiratory Distress Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"ARDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Adult_Respiratory_Distress_Syndrome"},{"name":"Maps_To","value":"Interstitial Pneumontis or ARDS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035222"},{"name":"xRef","value":"IMDRF:E0701"}]}}{"C27006":{"preferredName":"Interstitial Pneumonia","code":"C27006","definitions":[{"definition":"Inflammation of interstitial lung tissue, usually associated with infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interstitial Pneumonia","termGroup":"PT","termSource":"NCI"},{"termName":"Interstitial Pneumonitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Interstitial_Pneumonitis"},{"name":"Maps_To","value":"Interstitial Pneumontis or ARDS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014800"}]}}{"C38342":{"preferredName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm","code":"C38342","definitions":[{"definition":"A usually slow-growing epithelial neoplasm with ductal differentiation that arises from the exocrine pancreas and grows mostly within the pancreatic ducts. Grossly, it is characterized by the presence of intraductal masses. Morphologically, there is proliferation of mucin-producing cells within the pancreatic ducts, intraductal accumulation of mucin, and a papillary growth pattern. It may be associated with the presence of an invasive carcinoma. It usually occurs in older patients. Signs and symptoms include epigastric pain, weight loss, jaundice, chronic pancreatitis, and diabetes mellitus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary-Mucinous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic IPMN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Intraductal_Papillary-Mucinous_Neoplasm"},{"name":"Maps_To","value":"Intraductal Papillary Mucinous Neoplasm"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266071"}]}}{"C78393":{"preferredName":"Iron Overload","code":"C78393","definitions":[{"definition":"A condition in which the body takes up and stores more iron than it needs. The extra iron is stored in the liver, heart, and pancreas, which may cause liver disease, heart problems, organ failure, and cancer. It may also cause bronze skin, diabetes, pain in the joints and abdomen, tiredness, and impotence. Iron overload may be inherited, or it may be caused by blood transfusions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by accumulation of iron in the tissues.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high level of iron in the tissues.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Accumulation of iron in the tissues. It may be a manifestation of an inherited disorder (e.g., hemochromatosis) or acquired (in patients with repeated blood transfusions). Symptoms include hepatomegaly, arthritis, diabetes mellitus, and bronzed skin. If untreated it has a progressive course and may lead to death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iron Overload","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Iron_Overload"},{"name":"Maps_To","value":"Iron Overload"},{"name":"Maps_To","value":"Iron overload"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3806118"}]}}{"C50625":{"preferredName":"Ischemic Heart Disease","code":"C50625","definitions":[{"definition":"A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ischemic Heart Disease","termGroup":"PT","termSource":"NCI"},{"termName":"IHD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Ischemic_Heart_Disease"},{"name":"Maps_To","value":"Ischemic Heart Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0151744"},{"name":"xRef","value":"IMDRF:E0612"}]}}{"C3446":{"preferredName":"Primary Immune Thrombocytopenia","code":"C3446","definitions":[{"definition":"A condition in which platelets (blood cells that cause blood clots to form) are destroyed by the immune system. The low platelet count causes easy bruising and bleeding, which may be seen as purple areas in the skin, mucous membranes, and outer linings of organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).","type":"DEFINITION","source":"NCI"},{"definition":"Disorder characterized by abnormally low level of circulating platelets, usually with normal hemoglobin/red blood cell and white blood cell levels, and thought to be secondary to autoimmune destruction.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Primary Immune Thrombocytopenia","termGroup":"PT","termSource":"NCI"},{"termName":"Idiopathic Thrombocytopenia","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Thrombocytopenia Purpura","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Thrombocytopenic Purpura","termGroup":"SY","termSource":"NCI"},{"termName":"ITP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Idiopathic_Thrombocytopenic_Purpura"},{"name":"Maps_To","value":"Idiopathic thrombocytopenic purpura"},{"name":"Maps_To","value":"ITP"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0920163"}]}}{"C131579":{"preferredName":"Joint Replacement","code":"C131579","definitions":[{"definition":"A surgical procedure to replace part, or all structures, of a joint with an orthopedic prosthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Joint Replacement","termGroup":"PT","termSource":"NCI"},{"termName":"Joint Replacement Surgery","termGroup":"SY","termSource":"NCI"},{"termName":"Replacement Arthroplasty","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint Replacement"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0185317"}]}}{"C3476":{"preferredName":"Li-Fraumeni Syndrome","code":"C3476","definitions":[{"definition":"A rare, inherited predisposition to multiple cancers, caused by an alteration in the p53 tumor suppressor gene.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Li-Fraumeni Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Li-Fraumeni Familial Cancer Susceptibility Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Li-Fraumeni Syndrome, TP53-Associated","termGroup":"SY","termSource":"NCI"},{"termName":"TP53-Associated Li-Fraumeni Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Li-Fraumeni_Syndrome"},{"name":"Maps_To","value":"Li-Fraumeni Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085390"}]}}{"C184773":{"preferredName":"Personal History of Liver Toxicity due to Non-Infectious Cause","code":"C184773","definitions":[{"definition":"An indication that a subject a has a history that includes symptoms of liver toxicity that is not due to an infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Liver Toxicity due to Non-Infectious Cause","termGroup":"PT","termSource":"NCI"},{"termName":"History of Liver Toxicity due to Non-Infectious Cause","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liver Toxicity (Non-Infectious)"},{"name":"NCI_META_CUI","value":"CL1773090"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C96770":{"preferredName":"Low Grade Liver Dysplastic Nodule","code":"C96770","definitions":[{"definition":"A hepatic dysplastic nodule characterized by the presence of low grade atypical cellular changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Liver Dysplastic Nodule","termGroup":"PT","termSource":"NCI"},{"termName":"LGDN","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Hepatic Dysplastic Nodule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Grade Liver Dysplastic Nodule"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273018"}]}}{"C27153":{"preferredName":"Lupus Erythematosus","code":"C27153","definitions":[{"definition":"A chronic inflammatory connective tissue disease marked by skin rashes, joint pain and swelling, inflammation of the kidneys, inflammation of the fibrous tissue surrounding the heart (i.e., the pericardium), as well as other problems. Not all affected individuals display all of these problems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.","type":"DEFINITION","source":"NCI"},{"definition":"An umbrella term referring to disease entities such as cutaneous, subacute cutaneous, discoid and systemic lupus erythematosus.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Lupus Erythematosus","termGroup":"PT","termSource":"NCI"},{"termName":"Lupus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Lupus_Erythematosus"},{"name":"Maps_To","value":"Lupus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0409974"}]}}{"C174114":{"preferredName":"Lymphocytic Meningitis","code":"C174114","definitions":[{"definition":"Meningitis in which lymphocytes predominate in the cerebrospinal fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocytic Meningitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphocytic Meningitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0024266"}]}}{"C8494":{"preferredName":"Lynch Syndrome","code":"C8494","definitions":[{"definition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lynch Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Non-Polyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2)","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Colorectal Endometrial Cancer Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Defective Mismatch Repair Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Non-Polyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2)","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Nonpolyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hereditary_Non-Polyposis_Colon_Cancer"},{"name":"Maps_To","value":"Lynch Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1333990"}]}}{"C27314":{"preferredName":"Mycobacterium Avium Complex Lymphadenitis","code":"C27314","definitions":[{"definition":"Lymph node infection by Mycobacterium avium or Mycobacterium intracellulare. It most often affects children and usually presents with cervical lymph node enlargement. It generally follows a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium Avium Complex Lymphadenitis","termGroup":"PT","termSource":"NCI"},{"termName":"MAC Lymphadenitis","termGroup":"SY","termSource":"NCI"},{"termName":"MAI Lymphadenitis","termGroup":"SY","termSource":"NCI"},{"termName":"Mycobacterium Avium Intracellulare Lymphadenitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mycobacterium_Avium_Complex_Lymphadenitis"},{"name":"Maps_To","value":"MAI"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0858195"}]}}{"C34797":{"preferredName":"Malaria","code":"C34797","definitions":[{"definition":"A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.","type":"DEFINITION","source":"NCI"},{"definition":"Plasmodium parasite infection, characterized by fever, flu-like symptoms, anemia, and jaundice, that may be transmitted through infected mosquito bites, blood transfusion, organ transplant, contaminated needles or syringes, or before or during birth.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Malaria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Malaria"},{"name":"Maps_To","value":"Malaria"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0024530"}]}}{"C84442":{"preferredName":"Metabolic Syndrome","code":"C84442","definitions":[{"definition":"A combination of medical conditions that when present, increase the risk of heart attack, stroke, and diabetes mellitus. It includes the following medical conditions: increased blood pressure, central obesity, dyslipidemia, impaired glucose tolerance, and insulin resistance.","type":"DEFINITION","source":"NCI"},{"definition":"A condition is marked by extra fat around the abdomen, high levels of blood glucose (sugar) when not eating, high levels of triglycerides (a type of fat) in the blood, low levels of high-density lipoproteins (a type of protein that carries fats) in the blood, and high blood pressure. People with metabolic syndrome are at increased risk of diabetes mellitus and diseases of the heart and blood vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Metabolic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiometabolic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Metabolic Syndrome X","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metabolic Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0524620"}]}}{"C60989":{"preferredName":"Myasthenia Gravis","code":"C60989","definitions":[{"definition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","type":"DEFINITION","source":"NCI"},{"definition":"A disease in which antibodies made by a person's immune system prevent certain nerve-muscle interactions. It causes weakness in the arms and legs, vision problems, and drooping eyelids or head. It may also cause paralysis and problems with swallowing, talking, climbing stairs, lifting things, and getting up from a sitting position. The muscle weakness gets worse during activity, and improves after periods of rest.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Myasthenia Gravis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Myasthenia_Gravis"},{"name":"Maps_To","value":"Myasthenia Gravis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026896"}]}}{"C27996":{"preferredName":"Myocardial Infarction","code":"C27996","definitions":[{"definition":"A condition which occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","type":"DEFINITION","source":"NCI"},{"definition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Necrosis of the myocardium, as a result of interruption of the blood supply to the area.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Myocardial Infarction","termGroup":"PT","termSource":"NCI"},{"termName":"Heart Attack","termGroup":"SY","termSource":"NCI"},{"termName":"MI","termGroup":"SY","termSource":"NCI"},{"termName":"Myocardial Infarct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Myocardial_Infarction"},{"name":"Maps_To","value":"Myocardial Infarction"},{"name":"Maps_To","value":"Myocardial infarction"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3280935"},{"name":"xRef","value":"IMDRF:E061202"}]}}{"C3809":{"preferredName":"Neuroendocrine Neoplasm","code":"C3809","definitions":[{"definition":"A tumor that forms from cells that release hormones in response to a signal from the nervous system. Some examples of neuroendocrine tumors are carcinoid tumors, islet cell tumors, medullary thyroid carcinomas, pheochromocytomas, and neuroendocrine carcinomas of the skin (Merkel cell cancer). These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"NEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Neuroendocrine_Neoplasm"},{"name":"Maps_To","value":"Neuroendocrine Tumor"},{"name":"Maps_To","value":"Neuroendocrine tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206754"}]}}{"C84445":{"preferredName":"Nonalcoholic Steatohepatitis","code":"C84445","definitions":[{"definition":"Fatty replacement and damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonalcoholic Steatohepatitis","termGroup":"PT","termSource":"NCI"},{"termName":"NASH - Nonalcoholic Steatohepatitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Maps_To","value":"Nonalcoholic Steatohepatitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3241937"}]}}{"C3283":{"preferredName":"Obesity","code":"C3283","definitions":[{"definition":"A condition marked by an abnormally high, unhealthy amount of body fat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by having a high amount of body fat.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obesity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Obesity"},{"name":"Maps_To","value":"Obesity"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C3809449"}]}}{"C15289":{"preferredName":"Organ Transplantation","code":"C15289","definitions":[{"definition":"The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient's damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Organ Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical, Transplantation, Organ","termGroup":"SY","termSource":"NCI"},{"termName":"Organ Donation","termGroup":"SY","termSource":"NCI"},{"termName":"Organ Donation Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"organ grafting","termGroup":"SY","termSource":"NCI"},{"termName":"Organ Transplants","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Organ_Transplantation"},{"name":"Maps_To","value":"Organ transplant (site)"},{"name":"Maps_To","value":"Organ Transplantation"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0029216"}]}}{"C3293":{"preferredName":"Osteoarthritis","code":"C3293","definitions":[{"definition":"A disease process characterized by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A noninflammatory degenerative joint disease occurring chiefly in older persons, characterised by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. It is accompanied by pain and stiffness, particularly after prolonged activity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Osteoarthritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Osteoarthritis"},{"name":"Maps_To","value":"Osteoarthritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0029408"}]}}{"C3298":{"preferredName":"Osteoporosis","code":"C3298","definitions":[{"definition":"A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).","type":"DEFINITION","source":"NCI"},{"definition":"A condition that is marked by a decrease in bone mass and density, causing bones to become fragile.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Reduced bone mineral density due to decreased number and thickness of bone trabeculae and decreased cortical thickness, associated with increased risk of skeletal fractures. A clinical diagnosis of osteoporosis in childhood requires either a finding of one or more otherwise unexplained vertebral compression fractures, or the presence of bone mineral density Z-score less than or equal to 2.0 accompanied by one or more of the following: 1) at least two long bone fractures by age 10 years; 2) at least three long bone fractures up to age 19 years.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Osteoporosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Osteoporosis"},{"name":"Maps_To","value":"Osteoporosis or Osteopenia"},{"name":"Maps_To","value":"Osteoporosis, unspecified"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014080"}]}}{"C50910":{"preferredName":"Osteopenia","code":"C50910","definitions":[{"definition":"A condition in which there is a lower-than-normal bone mass or bone mineral density (the amount of bone mineral contained in a certain amount of bone). Osteopenia is a less severe form of bone loss than osteoporosis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Decreased calcification or density of bone tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Decreased calcification or density of bone tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteopenia","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Loss","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Osteopenia"},{"name":"Maps_To","value":"Osteoporosis or Osteopenia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4227764"},{"name":"xRef","value":"IMDRF:E1629"}]}}{"C184782":{"preferredName":"Personal History of Other Cancer Within 5 Years","code":"C184782","definitions":[{"definition":"An individual history of a cancer, other than those listed, within 5 years of the current cancer diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Cancer Within 5 Years","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Cancer Within 5 Years","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Cancer Within 5 Years"},{"name":"NCI_META_CUI","value":"CL1773099"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184785":{"preferredName":"Personal History of Other Nonmalignant Systemic Disease","code":"C184785","definitions":[{"definition":"An individual history of a nonmalignant systemic disease, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Nonmalignant Systemic Disease","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Nonmalignant Systemic Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Nonmalignant Systemic Disease"},{"name":"NCI_META_CUI","value":"CL1773108"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184786":{"preferredName":"Personal History of Other Pulmonary Complications","code":"C184786","definitions":[{"definition":"An individual history of a pulmonary complication, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Pulmonary Complications","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Pulmonary Complications","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Pulmonary Complications"},{"name":"NCI_META_CUI","value":"CL1773109"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C3303":{"preferredName":"Pain","code":"C3303","definitions":[{"definition":"A disorder characterized by the sensation of marked discomfort, distress or agony.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A feeling of distress, suffering, or agony, caused by stimulation of specialized nerve endings.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"An unpleasant sensation associated with real or perceived physical or mental trauma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An unpleasant sensory and emotional experience that is associated with actual or potential tissue damage or described in such terms.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pain"},{"name":"Maps_To","value":"Pain"},{"name":"Maps_To","value":"Pain (Various)"},{"name":"Maps_To","value":"Pain, not elsewhere classified"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C0030193"},{"name":"Use_For","value":"Soreness"},{"name":"xRef","value":"IMDRF:E2330"}]}}{"C3306":{"preferredName":"Pancreatitis","code":"C3306","definitions":[{"definition":"A disorder characterized by inflammation of the pancreas.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Inflammation of the pancreas.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the pancreas.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammation of the pancreas.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Inflammation of the pancreas. Chronic pancreatitis may cause diabetes and problems with digestion. Pain is the primary symptom.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pancreatitis"},{"name":"Maps_To","value":"Pancreatitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4011703"},{"name":"xRef","value":"IMDRF:E1021"}]}}{"C3318":{"preferredName":"Peptic Ulcer","code":"C3318","definitions":[{"definition":"A break in the lining of the lower part of the esophagus, the stomach, or the upper part of the small intestine. Peptic ulcers form when cells on the surface of the lining become inflamed and die. They are usually caused by Helicobacter pylori bacteria and by certain medicines, such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Peptic ulcers may be linked to cancer and other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.","type":"DEFINITION","source":"NCI"},{"definition":"A mucosal injury that occurs in the stomach or duodenum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Peptic Ulcer","termGroup":"PT","termSource":"NCI"},{"termName":"Peptic Ulcer Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Peptic_Ulcer"},{"name":"Maps_To","value":"Peptic ulcer"},{"name":"Maps_To","value":"Peptic Ulcer (Ulcer)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4012822"}]}}{"C119734":{"preferredName":"Peripheral Neuropathy","code":"C119734","definitions":[{"definition":"A disorder affecting one or more peripheral nerves. It is manifested with pain, tingling, numbness, and/ or muscle weakness. Causes may include physical injury, toxic substances, viral infection and systemic illness.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.","type":"DEFINITION","source":"NCI"},{"definition":"A nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Neuropathy may be caused by physical injury, infection, toxic substances, disease (such as cancer, diabetes, kidney failure, or malnutrition), or drugs, including anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peripheral Neuropathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Peripheral Neuropathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3277001"}]}}{"C35136":{"preferredName":"Peripheral Vascular Disorder","code":"C35136","definitions":[{"definition":"Any disorder affecting blood flow through the veins or arteries outside of the heart.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Vascular Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Peripheral Vascular Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Peripheral_Vascular_Disorder"},{"name":"Maps_To","value":"Peripheral Vascular Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085096"}]}}{"C3324":{"preferredName":"Peutz-Jeghers Syndrome","code":"C3324","definitions":[{"definition":"A genetic disorder in which polyps form in the intestine and dark spots appear on the mouth and fingers. Having Peutz-Jeghers syndrome increases the risk of developing gastrointestinal and many other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peutz-Jeghers Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Jeghers-Peutz Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Peutz's Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"PJS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peutz-Jeghers_Syndrome"},{"name":"Maps_To","value":"Peutz-Jeghers Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0031269"}]}}{"C26862":{"preferredName":"Polycystic Ovary Syndrome","code":"C26862","definitions":[{"definition":"A condition marked by infertility, enlarged ovaries, menstrual problems, high levels of male hormones, excess hair on the face and body, acne, and obesity. Women with PCOS have an increased risk of diabetes, high blood pressure, heart disease, and endometrial cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A condition of unknown or heterogenous genetic etiology that is characterized by hyperandrogenism and ovarian dysfunction, though the clinical features of the condition may differ between teenage girls and adult women. For teenage girls, the characteristic features generally manifest as persistent, otherwise unexplained hyperandrogenism and reduced or absent ovulation with associated menstrual irregularity, as determined by age- and pubertal stage-appropriate criteria. Additional clinical manifestations include some or all of the following: obesity, insulin resistance/hyperinsulinemia or frank type 2 diabetes mellitus, acanthosis nigricans, hirsutism, and polycystic ovary on ultrasound.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder that manifests as multiple cysts on the ovaries. It results in hormonal imbalances and leads to irregular and abnormal menstrual periods, excess growth of hair, acne eruptions and obesity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polycystic Ovary Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Polycystic Ovarian Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Stein-Leventhal Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Stein-Leventhal_Syndrome"},{"name":"Maps_To","value":"Polycystic Ovarian Syndrome (PCOS)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1835381"}]}}{"C124295":{"preferredName":"Pregnant","code":"C124295","definitions":[{"definition":"Observed to be or have been pregnant or positive for a pregnancy test.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Observed to be or have been pregnant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pregnant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pregnancy in Patient or Partner"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0549206"}]}}{"C4828":{"preferredName":"Primary Sclerosing Cholangitis","code":"C4828","definitions":[{"definition":"A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Sclerosing Cholangitis","termGroup":"PT","termSource":"NCI"},{"termName":"PSC","termGroup":"AB","termSource":"NCI"},{"termName":"Sclerosing Cholangitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Sclerosing_Cholangitis"},{"name":"Maps_To","value":"Primary Sclerosing Cholangitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0566602"}]}}{"C3346":{"preferredName":"Psoriasis","code":"C3346","definitions":[{"definition":"A chronic disease of the skin marked by red patches covered with white scales.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Psoriasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Psoriasis"},{"name":"Maps_To","value":"Psoriasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231128"}]}}{"C26869":{"preferredName":"Pulmonary Fibrosis","code":"C26869","definitions":[{"definition":"A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A interstitial lung disease characterized by the replacement of lung tissue with connective tissue.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Fibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Pulmonary_Fibrosis"},{"name":"Maps_To","value":"Pulmonary Fibrosis"},{"name":"Maps_To","value":"Pulmonary fibrosis"},{"name":"Maps_To","value":"Pulmonary interstitial fibrosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4013574"}]}}{"C78578":{"preferredName":"Pulmonary Hemorrhage","code":"C78578","definitions":[{"definition":"Bleeding from the lung parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Hemorrhage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pulmonary_Hemorrhage"},{"name":"Maps_To","value":"Pulmonary Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0151701"}]}}{"C15248":{"preferredName":"Hemodialysis","code":"C15248","definitions":[{"definition":"A therapeutic procedure involving the extracorporeal removal of harmful waste and fluids from the blood using a dialysis machine. Following dialysis, the blood is returned to the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A therapeutic procedure used in patients with kidney failure.  It involves the extracorporeal removal of harmful wastes and fluids from the blood using a dialysis machine.  Following the dialysis, the blood is returned to the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemodialysis","termGroup":"PT","termSource":"NCI"},{"termName":"Artificial Kidney Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Extracorporeal Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Dialysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemodialysis"},{"name":"Maps_To","value":"Renal Dialysis"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0019004"}]}}{"C184791":{"preferredName":"Personal History of Renal Failure Requiring Dialysis","code":"C184791","definitions":[{"definition":"An indication that a subject a history of renal failure that required treatment with dialysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Renal Failure Requiring Dialysis","termGroup":"PT","termSource":"NCI"},{"termName":"History of Renal Failure Requiring Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"History of Renal Failure that Required Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Personal History of Renal Failure that Required Dialysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Failure (Requiring Dialysis)"},{"name":"NCI_META_CUI","value":"CL1772993"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C4376":{"preferredName":"Renal Failure","code":"C4376","definitions":[{"definition":"A condition in which the kidneys stop working and are not able to remove waste and extra water from the blood or keep body chemicals in balance. Acute or severe renal failure happens suddenly (for example, after an injury) and may be treated and cured. Chronic renal failure develops over many years, may be caused by conditions like high blood pressure or diabetes, and cannot be cured. Chronic renal failure may lead to total and long-lasting renal failure, called end-stage renal disease (ESRD). A person in ESRD needs dialysis (the process of cleaning the blood by passing it through a membrane or filter) or a kidney transplant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood resulting in uremia and electrolyte imbalances.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Failure","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Insufficiency","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Renal_Failure"},{"name":"Maps_To","value":"Renal failure"},{"name":"Maps_To","value":"Renal Insufficiency"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1862666"},{"name":"xRef","value":"IMDRF:E130501"}]}}{"C2884":{"preferredName":"Rheumatoid Arthritis","code":"C2884","definitions":[{"definition":"A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A chronic, inflammatory condition manifesting primarily as a symmetric, erosive, polyarthritis that spares the axial skeleton and is typically associated with rheumatoid factor and anti-citrullinated protein antibodies.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.","type":"DEFINITION","source":"NCI"},{"definition":"An autoimmune disease that causes pain, swelling, and stiffness in the joints, and may cause severe joint damage, loss of function, and disability. The disease may last from months to a lifetime, and symptoms may improve and worsen over time.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rheumatoid Arthritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Rheumatoid_Arthritis"},{"name":"Maps_To","value":"Rheumatoid Arthritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0003873"},{"name":"xRef","value":"IMDRF:E160201"}]}}{"C27204":{"preferredName":"Rheumatologic Disorder","code":"C27204","definitions":[{"definition":"A group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A term previously used to describe chronic diseases of the connective tissue (e.g., rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis), but now is thought to be more appropriate for diseases associated with defects in collagen, which is a component of the connective tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An umbrella term used to encompass disorders characterized by autoimmunity, autoinflammatory processes, joint or connective tissue inflammation or degeneration.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rheumatologic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Collagen Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Musculoskeletal Pain Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Rheumatism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Rheumatologic_Disorder"},{"name":"Maps_To","value":"Rheumatologic Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035435"}]}}{"C75466":{"preferredName":"Rubinstein-Taybi Syndrome","code":"C75466","definitions":[{"definition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene. It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes. Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rubinstein-Taybi Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Rubinstein_Taybi_Syndrome"},{"name":"Maps_To","value":"Rubinstein-Taybi Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035934"}]}}{"C34995":{"preferredName":"Sarcoidosis","code":"C34995","definitions":[{"definition":"An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.","type":"DEFINITION","source":"NCI"},{"definition":"An inflammatory disease marked by the formation of granulomas (small nodules of immune cells) in the lungs, lymph nodes, and other organs. Sarcoidosis may be acute and go away by itself, or it may be chronic and progressive.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inflammatory disorder characterized by the formation of non-necrotizing granulomas often associated with multi-nucleated giant cells within affected organs. Virtually all organs may be affected; however, it often affects the lungs, lymph nodes, liver, synovium, skin, heart, and uveal tract.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sarcoidosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Sarcoidosis"},{"name":"Maps_To","value":"Sarcoidosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227551"}]}}{"C71079":{"preferredName":"Herpes Zoster","code":"C71079","definitions":[{"definition":"A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.","type":"DEFINITION","source":"NCI"},{"definition":"Varicella zoster virus infection that is caused by the reactivation of virus, which can be latent within dorsal root ganglia; zoster is characterized by vesicular lesions clustered unilaterally in a dermatomal distribution of one or more adjacent sensory nerves. Neuralgic pain can occur and can be severe.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Herpes Zoster","termGroup":"PT","termSource":"NCI"},{"termName":"Shingles","termGroup":"SY","termSource":"NCI"},{"termName":"Zoster","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Herpes_Zoster"},{"name":"Maps_To","value":"Herpes Zoster"},{"name":"Maps_To","value":"Shingles"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019360"}]}}{"C26883":{"preferredName":"Sjogren Syndrome","code":"C26883","definitions":[{"definition":"An autoimmune disease that affects the tear glands and salivary glands, and may affect glands in the stomach, pancreas, and intestines. The disease causes dry eyes and mouth, and may cause dryness in the nose, throat, air passages, skin, and vagina. It may also cause inflammation in the joints, muscles, and skin; pneumonia; tingling in the fingers and toes; and fatigue. It often occurs with rheumatoid arthritis or other connective tissue diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","type":"DEFINITION","source":"NCI"},{"definition":"Autoimmune epithelial inflammation often affecting the salivary and lacrimal glands (causing dry mouth and dry eyes) with potential extraglandular manifestations. In children, it most commonly presents with recurrent parotitis. It may occur alone (primary) or in association with another autoimmune disease (secondary).","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sjogren Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Sjogren's Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Sjögren Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Sjogren_s_Syndrome"},{"name":"Maps_To","value":"Sjogren's Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1527336"}]}}{"C26884":{"preferredName":"Sleep Apnea","code":"C26884","definitions":[{"definition":"A disorder characterized by cessation of breathing for short periods during sleep.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A sleep disorder that is marked by pauses in breathing of 10 seconds or more during sleep, and causes unrestful sleep. Symptoms include loud or abnormal snoring, daytime sleepiness, irritability, and depression.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Cessation of breathing for short periods during sleep. It is classified as obstructive, central, or mixed obstructive-central. It can occur at any age but it is more frequent in people over forty. Risk factors include male sex and obesity.","type":"DEFINITION","source":"NCI"},{"definition":"The cessation of breathing for periods of time during sleep.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sleep Apnea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Sleep_Apnea"},{"name":"Maps_To","value":"Sleep apnea"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C3279848"}]}}{"C17934":{"preferredName":"Tobacco Smoking","code":"C17934","definitions":[{"definition":"The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Smoking","termGroup":"PT","termSource":"NCI"},{"termName":"Smoking","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tobacco_Smoking"},{"name":"Maps_To","value":"Tobacco, Smoking"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0453996"}]}}{"C122576":{"preferredName":"Staphylococcus aureus Infection","code":"C122576","definitions":[{"definition":"An infectious process in which the bacteria Staphylococcus aureus is present.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An infectious process in which the bacteria Staphylococcus aureus is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staphylococcus aureus Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Staphylococcus aureus"},{"name":"Maps_To","value":"Staphylococcus aureus infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1318973"}]}}{"C36185":{"preferredName":"Steatosis","code":"C36185","definitions":[{"definition":"Acumulation of adipose tissue in intracytoplasmic or extracellular spaces.","type":"DEFINITION","source":"NCI"},{"definition":"Increased lipid within the cytoplasm of cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Steatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Fatty Change","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fatty_Change"},{"name":"Maps_To","value":"Steatosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1849982"}]}}{"C3390":{"preferredName":"Stroke","code":"C3390","definitions":[{"definition":"A disorder characterized by a sudden loss of sensory function due to an intracranial vascular event.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","type":"DEFINITION","source":"NCI"},{"definition":"An acute episode of focal or global neurological dysfunction caused by presumed brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction but with insufficient information to allow categorization as ischemic or hemorrhagic.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An episode of acute neurological dysfunction presumed to be caused by ischemia or hemorrhage, persisting greater than or equal to 24 h or until death but without sufficient evidence to be classified as one of the above","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Brain tissue necrosis due to a disturbance in the blood flow or hemorrhage.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"In medicine, a loss of blood flow to part of the brain, which damages brain tissue. Strokes are caused by blood clots and broken blood vessels in the brain. Symptoms include dizziness, numbness, weakness on one side of the body, and problems with talking, writing, or understanding language. The risk of stroke is increased by high blood pressure, older age, smoking, diabetes, high cholesterol, heart disease, atherosclerosis (a build-up of fatty material and plaque inside the coronary arteries), and a family history of stroke.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stroke","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebrovascular Accident","termGroup":"SY","termSource":"NCI"},{"termName":"CVA","termGroup":"AB","termSource":"NCI"},{"termName":"Stroke Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Cerebrovascular_Accident"},{"name":"Maps_To","value":"Cerebrovascular accident"},{"name":"Maps_To","value":"Stroke"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3554760"},{"name":"xRef","value":"IMDRF:E0133"}]}}{"C35055":{"preferredName":"Syphilis","code":"C35055","definitions":[{"definition":"A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by the spirochete Treponema pallidum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Syphilis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Syphilis"},{"name":"Maps_To","value":"Syphilis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0039128"}]}}{"C50781":{"preferredName":"Transient Ischemic Attack","code":"C50781","definitions":[{"definition":"A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"DEFINITION","source":"NCI"},{"definition":"A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A brief episode of neurological dysfunction, caused by focal brain or retinal ischemia without imaging evidence of acute infarction","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A transient episode of cerebral dysfunction of vascular origin with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Transient Ischemic Attack","termGroup":"PT","termSource":"NCI"},{"termName":"TIA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Transient_Ischemic_Attack"},{"name":"Maps_To","value":"Transient Ischemic Attack"},{"name":"Maps_To","value":"Transient ischemic attacks"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007787"},{"name":"xRef","value":"IMDRF:E0137"}]}}{"C85197":{"preferredName":"Treponemal Infection","code":"C85197","definitions":[{"definition":"A sexually transmitted infection caused by the Gram-negative spirochete Treponema pallidum. It is manifested as syphilis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treponemal Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treponema pallidum"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0040843"}]}}{"C3423":{"preferredName":"Tuberculosis","code":"C3423","definitions":[{"definition":"A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use.","type":"DEFINITION","source":"NCI"},{"definition":"A disease caused by Mycobacterium tuberculosis infection that is characterized by the growth of nodules in body tissues, most commonly the lungs, and may be transmitted through droplets from the throat or lungs of individuals with the active respiratory disease.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Tuberculosis","termGroup":"PT","termSource":"NCI"},{"termName":"TB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Tuberculosis"},{"name":"Maps_To","value":"Tuberculosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0041296"}]}}{"C3938":{"preferredName":"Turcot Syndrome","code":"C3938","definitions":[{"definition":"An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Turcot Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Turcot_Syndrome"},{"name":"Maps_To","value":"Turcot Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0265325"}]}}{"C98640":{"preferredName":"Tyrosinemia","code":"C98640","definitions":[{"definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tyrosinemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0268483"}]}}{"C2952":{"preferredName":"Ulcerative Colitis","code":"C2952","definitions":[{"definition":"A chronic inflammatory disease affecting the mucosal surface of the colon and rectum.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","type":"DEFINITION","source":"NCI"},{"definition":"Chronic inflammation of the colon that produces ulcers in its lining.  This condition is marked by abdominal pain, cramps, and loose discharges of pus, blood, and mucus from the bowel.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ulcerative Colitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Ulcerative_Colitis"},{"name":"Maps_To","value":"Ulcerative colitis"},{"name":"Maps_To","value":"Ulcerative Colitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3553962"}]}}{"C3718":{"preferredName":"WAGR Syndrome","code":"C3718","definitions":[{"definition":"A rare, genetic disorder that is present at birth and has two or more of the following symptoms: Wilms tumor (a type of kidney cancer); little or no iris (the colored part of the eye); defects in the sexual organs and urinary tract (the organs that make urine and pass it from the body); and below average mental ability. This syndrome occurs when part of chromosome 11 is missing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A syndrome characterized by a predisposition for Wilms tumor, aniridia, genitourinary anomalies, and developmental delay. This is a contiguous gene syndrome due to deletion in the vicinity of chromosome 11p13 in a region containing the WT1 and PAX6 genes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A very rare congenital condition involving the complex of Wilms tumor, aniridia, genitourinary abnormalities, and mental retardation. Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation (WAGR) syndrome involves deletions of several adjacent genes in chromosome region 11p13. Two or more of the four conditions must be present for an individual to be diagnosed with WAGR Syndrome. The clinical picture varies, depending upon the combination of abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WAGR Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Wilms_Tumor-Aniridia-Genitourinary_Anomalies-Mental_Retardation_Syndrome"},{"name":"Maps_To","value":"Wagr Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0206115"}]}}{"C3037":{"preferredName":"Chronic Fatigue Syndrome","code":"C3037","definitions":[{"definition":"A condition lasting for more than 6 months in which a person feels tired most of the time and may have trouble concentrating and carrying out daily activities. Other symptoms include sore throat, fever, muscle weakness, headache, and joint pain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A syndrome of unknown etiology. Chronic fatigue syndrome (CFS) is a clinical diagnosis characterized by an unexplained persistent or relapsing chronic fatigue that is of at least six months' duration, is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction of previous levels of occupational, educational, social, or personal activities. Common concurrent symptoms of at least six months duration include impairment of memory or concentration, diffuse pain, sore throat, tender lymph nodes, headaches of a new type, pattern, or severity, and nonrestorative sleep. The etiology of CFS may be viral or immunologic. Neurasthenia and fibromyalgia may represent related disorders. Also known as myalgic encephalomyelitis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Fatigue Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Myalgic Encephalomyelitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Chronic_Fatigue_Syndrome"},{"name":"Maps_To","value":"Chronic Fatigue Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0015674"}]}}{"C162188":{"preferredName":"Clonal Hematopoiesis","code":"C162188","definitions":[{"definition":"Cellular proliferation of hematopoietic cells where a substantial proportion of the cells is derived from a single hematopoietic stem cell lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clonal Hematopoiesis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clonal Hematopoiesis"},{"name":"NCI_META_CUI","value":"CL970785"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C87497":{"preferredName":"Fibromyalgia","code":"C87497","definitions":[{"definition":"A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.","type":"DEFINITION","source":"NCI"},{"definition":"Chronic, diffuse, non-inflammatory musculoskeletal pain disorder with characteristic tender points of neck, back, shoulders, hips, arms and legs, and associated with fatigue and sleep disturbance. Other symptoms may include headaches, abdominal discomfort, and depression/anxiety. It may also be associated with a primary rheumatic disorder.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Fibromyalgia","termGroup":"PT","termSource":"NCI"},{"termName":"Fibromyalgia Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Fibromyalgia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0016053"}]}}{"C26780":{"preferredName":"Gastritis","code":"C26780","definitions":[{"definition":"A disorder characterized by inflammation of the stomach.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Inflammation of the lining of the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Inflammation of the stomach.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the stomach.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Inflammation of the stomach.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Gastritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Gastritis"},{"name":"Maps_To","value":"Gastritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0017152"},{"name":"xRef","value":"IMDRF:E1012"}]}}{"C179424":{"preferredName":"Abnormal Glucose Level Finding","code":"C179424","definitions":[{"definition":"A finding that either fasting or postprandial blood glucose levels are above or below the normal thresholds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abnormal Glucose Level Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Abnormal Glucose Level","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abnormal Glucose Level"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0522083"}]}}{"C26744":{"preferredName":"Dermatomyositis","code":"C26744","definitions":[{"definition":"Inflammation of the skin and muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dermatomyositis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Dermatomyositis"},{"name":"Maps_To","value":"Dermatomyosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3278909"}]}}{"C96407":{"preferredName":"Varicella Zoster Infection","code":"C96407","definitions":[{"definition":"A highly contagious viral infection caused by the varicella zoster virus. Clinically, it may be manifested as shingles or chicken pox.","type":"DEFINITION","source":"NCI"},{"definition":"A highly contagious viral infection that is caused by the varicella zoster virus; it clinically manifests as either shingles or chicken pox.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Varicella Zoster Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Varicella Zoster Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0586989"}]}}{"C188353":{"preferredName":"Staphylococcal Osteomyelitis","code":"C188353","definitions":[{"definition":"Osteomyelitis resulting from an infection with Staphylococcus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staphylococcal Osteomyelitis","termGroup":"PT","termSource":"NCI"},{"termName":"Staph Osteomyelitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Infectious osteomyelitis usually results from an infection with Staphylococcus aureus."},{"name":"Maps_To","value":"Staph Osteomyelitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1535985"}]}}{"C27582":{"preferredName":"Central Nervous System Infectious Disorder","code":"C27582","definitions":[{"definition":"An infectious process that affects the brain and/or spinal cord. Representative examples include encephalitis, poliomyelitis, arachnoiditis, and meningitis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Infectious Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Infectious Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Infectious_Disorder"},{"name":"Maps_To","value":"CNS Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007684"}]}}{"C159717":{"preferredName":"EBV-Related Lymphoproliferative Disorder","code":"C159717","definitions":[{"definition":"A lymphoproliferative disorder associated with Epstein-Barr virus. This category includes, but is not limited to, Burkitt lymphoma, classic Hodgkin lymphoma, and lymphomas arising in immunocompromised individuals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV-Related Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Epstein-Barr Virus-Associated Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Epstein-Barr Virus-Related Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EBV Lymphoproliferation"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C2363744"}]}}{"C115248":{"preferredName":"Methicillin-Resistant Staphylococcus aureus Infection","code":"C115248","definitions":[{"definition":"A bacterial infection that is caused by Staphylococcus aureus and is resistant to methicillin treatment.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A bacterial infection that is caused by Staphylococcus aureus that is not susceptible to methicillin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methicillin-Resistant Staphylococcus aureus Infection","termGroup":"PT","termSource":"NCI"},{"termName":"MRSA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Methicillin-Resistant Staphylococcus aureus (MRSA)"},{"name":"Maps_To","value":"Methicillin-resistant Staphylococcus aureus infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0343401"}]}}{"C27566":{"preferredName":"Non-Neoplastic Thyroid Gland Disorder","code":"C27566","definitions":[{"definition":"A non-neoplastic disorder that affects the thyroid gland.  Representative examples include hyperthyroidism, hypothyroidism, thyroiditis, and thyroid gland abscess.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Neoplastic Thyroid Gland Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Non-Neoplastic_Thyroid_Gland_Disorder"},{"name":"Maps_To","value":"Thyroid Disease, Non-Cancer"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1335047"}]}}{"C50791":{"preferredName":"Urinary Tract Infection","code":"C50791","definitions":[{"definition":"A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An infection of the kidneys, ureters, bladder and/or urethra.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An inflammatory process affecting any part of the urinary tract, most commonly the bladder or the urethra.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Urinary Tract Infection","termGroup":"PT","termSource":"NCI"},{"termName":"UTI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Urinary_Tract_Infection"},{"name":"Maps_To","value":"Urinary tract infection"},{"name":"Maps_To","value":"Urinary Tract Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0042029"},{"name":"xRef","value":"IMDRF:E1310"}]}}{"C16681":{"preferredName":"Histology","code":"C16681","definitions":[{"definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","type":"DEFINITION","source":"NCI"},{"definition":"The study of tissues and cells under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Histology","termGroup":"PT","termSource":"NCI"},{"termName":"Microanatomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Histology"},{"name":"Maps_To","value":"Histology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0019638"}]}}{"C18189":{"preferredName":"Pathology","code":"C18189","definitions":[{"definition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pathology","termGroup":"PT","termSource":"NCI"},{"termName":"Pathological","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pathology"},{"name":"Maps_To","value":"Pathology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0030664"}]}}{"C19187":{"preferredName":"Diagnostic Radiology","code":"C19187","definitions":[{"definition":"The branch of radiology concerned with the use of ionizing or nonionizing radiation for diagnostic purposes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diagnostic Radiology","termGroup":"PT","termSource":"NCI"},{"termName":"Diagnostic Radiology (Ionizing and Nonionizing)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diagnostic_Radiology_Ionizing_and_Nonionizing"},{"name":"Maps_To","value":"Radiology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C1511880"}]}}{"C139651":{"preferredName":"Alpha-glucosidase Inhibitor","code":"C139651","definitions":[{"definition":"Any agent that inhibits the enzyme alpha-glucosidase located in the intestines. This prevents the breakdown of complex carbohydrates to glucose and other monosaccharides, which results in decreased intestinal absorption of monosaccharides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-glucosidase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"AGI","termGroup":"AB","termSource":"NCI"},{"termName":"AGIs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alpha-Glucosidase Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C2267008"}]}}{"C98234":{"preferredName":"Biguanide Antidiabetic Agent","code":"C98234","definitions":[{"definition":"Any antidiabetic agent with the biguanide base structure or phenformin derivatives with antihyperglycemic activity. Biguanide antidiabetic agents activate AMP-activated protein kinase (AMPK) resulting in decreased glucose production in the liver, increased peripheral glucose uptake and improved utilization of glucose. Biguanide-based antidiabetic agents do not cause hypoglycemia. In addition, biguanide antidiabetics decrease absorption of glucose from the gastrointestinal tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biguanide Antidiabetic Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biguanide"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273895"}]}}{"C15383":{"preferredName":"Special Diet Therapy","code":"C15383","definitions":[{"definition":"A form of therapy which includes dietary approaches and special diets that are applied as alternative therapies for risk factors or chronic disease in general.","type":"DEFINITION","source":"NCI"},{"definition":"A form of therapy which includes dietary approaches and special diets.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Special Diet Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Special Diet Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Special_Diet_Therapy"},{"name":"Maps_To","value":"Diet"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1519433"}]}}{"C179441":{"preferredName":"Injected Insulin Diabetes Therapy","code":"C179441","definitions":[{"definition":"The use of injected forms of insulin to treat diabetes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Injected Insulin Diabetes Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Injected Insulin","termGroup":"SY","termSource":"NCI"},{"termName":"Injected Insulin Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic Insulin Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injected Insulin"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0199782"}]}}{"C581":{"preferredName":"Therapeutic Insulin","code":"C581","definitions":[{"definition":"A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Insulin","termGroup":"PT","termSource":"NCI"},{"termName":"Insulin","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Insulin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11061-68-0"},{"name":"CAS_Registry","value":"9004-10-8"},{"name":"CHEBI_ID","value":"CHEBI:5931"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Insulin"},{"name":"Maps_To","value":"Insulin"},{"name":"NCI_Drug_Dictionary_ID","value":"43345"},{"name":"NSC Number","value":"88206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43345"},{"name":"PDQ_Open_Trial_Search_ID","value":"43345"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1579433"}]}}{"C179448":{"preferredName":"Oral Hypoglycemic Diabetes Therapy","code":"C179448","definitions":[{"definition":"The use of oral hypoglycemic agents to treat diabetes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Hypoglycemic Diabetes Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Oral Hypoglycemic Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic Oral Hypoglycemic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Hypoglycemic"},{"name":"NCI_META_CUI","value":"CL1662299"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C97936":{"preferredName":"Sulfonylurea Antidiabetic Agent","code":"C97936","definitions":[{"definition":"Sulfonamide urea derivatives with antihyperglycemic activity. Sulphonylurea antidiabetic agents bind to sulfonylurea receptor type 1 (SUR1), the subunit of ATP-sensitive inwardly-rectifier potassium (IKATP) channels on the membranes of pancreatic beta cells, thereby blocking the inward current flow (influx) of positively charged K+ ions into the cell. This results in tonic membrane depolarization, and induces a calcium ion influx through voltage-sensitive calcium channels; increased intracellular calcium ion levels trigger exocytosis of insulin-containing granules. This eventually induces secretion of insulin. The IKATP channels found in pancreatic islets are complexes of four IKATP 6.2 and four SUR1 subunits. In addition, some sulfonylureas of larger molecular size may increase the sensitivity of peripheral tissues to insulin mediated through peroxisome proliferator-activated receptor gamma (PPARgamma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulfonylurea Antidiabetic Agent","termGroup":"PT","termSource":"NCI"},{"termName":"Sulphonylurea Antidiabetic Agent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sulfonylurea"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273710"}]}}{"C98241":{"preferredName":"Thiazolidinedione Antidiabetic Agent","code":"C98241","definitions":[{"definition":"Any antidiabetic agent with the glitazone (thiazolidinedione) base structure with antihyperglycemic activity. Glitazone antidiabetic agents selectively bind to and stimulate the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma. This results in the selective transcription of a number of insulin-sensitive genes involved in glucose metabolism. This eventually enhances insulin sensitivity, reduces insulin resistance and decreases hepatic gluconeogenesis. PPARs function as transcription factors that regulate expressions of genes involved in cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), as well as tumorigenesis; PPARgamma is expressed at high levels in adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thiazolidinedione Antidiabetic Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thiazolidinedione"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273907"}]}}{"C83887":{"preferredName":"Linagliptin","code":"C83887","definitions":[{"definition":"A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linagliptin","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-8-(3-Amino-Piperidin-1-yl)-7-but-2-ynyl-3-Methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"8-((3R)-3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-3,7-Dihydro-1H-Purine-2,6-Dione","termGroup":"SN","termSource":"NCI"},{"termName":"BI 1356 BS","termGroup":"CN","termSource":"NCI"},{"termName":"BI-1356","termGroup":"CN","termSource":"NCI"},{"termName":"Tradjenta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diabetes Mellitus Type II"},{"name":"CAS_Registry","value":"668270-12-0"},{"name":"Chemical_Formula","value":"C25H28N8O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3X29ZEJ4R2"},{"name":"Maps_To","value":"Linagliptin"},{"name":"NCI_Drug_Dictionary_ID","value":"793591"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793591"},{"name":"PDQ_Open_Trial_Search_ID","value":"793591"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2746078"}]}}{"C165196":{"preferredName":"Biochemical Evidence of Disease","code":"C165196","definitions":[{"definition":"An indication that biochemical markers of a disease are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biochemical Evidence of Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BED-Biochemical Evidence of Disease"},{"name":"Maps_To","value":"Biochemical"},{"name":"NCI_META_CUI","value":"CL978408"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165205":{"preferredName":"Persistent Distant Metastasis","code":"C165205","definitions":[{"definition":"An indication that distant metastases have remained despite treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Persistent Distant Metastasis","termGroup":"PT","termSource":"NCI"},{"termName":"Persistent Distant Metastases","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PDM-Persistent Distant Metastasis"},{"name":"NCI_META_CUI","value":"CL978417"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188367":{"preferredName":"Persistent Locoregional Disease","code":"C188367","definitions":[{"definition":"A disease that persists locally and/or regionally in regards to the site of origin despite treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Persistent Locoregional Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Persistent Local and/or Regional Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Persistent Local-Regional Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PLD-Persistent Locoregional Disease"},{"name":"NCI_META_CUI","value":"CL1793605"},{"name":"Semantic_Type","value":"Finding"}]}}{"C105722":{"preferredName":"ECOG Performance Status 0","code":"C105722","definitions":[{"definition":"Fully active, able to carry on all pre-disease performance without restriction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 0","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"0"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830346"}]}}{"C105723":{"preferredName":"ECOG Performance Status 1","code":"C105723","definitions":[{"definition":"Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 1","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830345"}]}}{"C105725":{"preferredName":"ECOG Performance Status 2","code":"C105725","definitions":[{"definition":"Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 2","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830344"}]}}{"C105726":{"preferredName":"ECOG Performance Status 3","code":"C105726","definitions":[{"definition":"Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 3","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"3"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830343"}]}}{"C105727":{"preferredName":"ECOG Performance Status 4","code":"C105727","definitions":[{"definition":"Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 4","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"4"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830342"}]}}{"C105728":{"preferredName":"ECOG Performance Status 5","code":"C105728","definitions":[{"definition":"Dead.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 5","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"5"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830341"}]}}{"C158780":{"preferredName":"Biopsy with Histologic Confirmation","code":"C158780","definitions":[{"definition":"A biopsy with microscopic confirmation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biopsy with Histologic Confirmation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biopsy with Histologic Confirmation"},{"name":"Maps_To","value":"Histologic Confirmation"},{"name":"NCI_META_CUI","value":"CL950682"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C158782":{"preferredName":"Convincing Image Source","code":"C158782","definitions":[{"definition":"Radiologic evidence that supports a diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Convincing Image Source","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Convincing Image Source"},{"name":"NCI_META_CUI","value":"CL950684"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C83119":{"preferredName":"Physical Examination Finding","code":"C83119","definitions":[{"definition":"The result of an evaluation of the body and its functions using visual inspection, palpation, percussion, or auscultation that is performed to determine the presence, absence, or degree of a condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Physical Examination Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Physical Exam Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Exam Result","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Examination Result","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Physical_Exam_Result"},{"name":"Maps_To","value":"Physical Examination"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2826729"}]}}{"C150123":{"preferredName":"Biomarker Positive Malignant Neoplasm","code":"C150123","definitions":[{"definition":"A finding indicating the presence of a biomarker in a tumor sample from a patient with a malignant neoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biomarker Positive Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Biomarker Positive Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Positive Biomarker in Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Positive Biomarker in Malignant Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Positive Biomarker(s)"},{"name":"NCI_META_CUI","value":"CL551925"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C179455":{"preferredName":"Progestin Only Hormonal Contraception","code":"C179455","definitions":[{"definition":"A hormonal contraceptive that utilizes progestin (synthetic progesterone) to prevent implantation and pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progestin Only Hormonal Contraception","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progestin"},{"name":"NCI_META_CUI","value":"CL1662307"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C179456":{"preferredName":"Combination Estrogen/Progestin Hormonal Contraception","code":"C179456","definitions":[{"definition":"A hormonal contraceptive that utilizes a combination of estrogen and progestin (synthetic progesterone) to prevent ovulation and pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combination Estrogen/Progestin Hormonal Contraception","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progestin and Estrogen"},{"name":"NCI_META_CUI","value":"CL1662306"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C160671":{"preferredName":"Current Hormonal Contraceptive User","code":"C160671","definitions":[{"definition":"The individual is a current user of hormonal contraceptives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Hormonal Contraceptive User","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current User"},{"name":"NCI_META_CUI","value":"CL969602"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C160672":{"preferredName":"Former Hormonal Contraceptive User","code":"C160672","definitions":[{"definition":"The individual is a former user of hormonal contraceptives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Former Hormonal Contraceptive User","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Former User"},{"name":"NCI_META_CUI","value":"CL969601"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C160673":{"preferredName":"Never Used Hormonal Contraceptives","code":"C160673","definitions":[{"definition":"The individual has never used of hormonal contraceptives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Never Used Hormonal Contraceptives","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Never Used"},{"name":"NCI_META_CUI","value":"CL969600"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C179434":{"preferredName":"Estrogen Only Hormone Replacement Therapy","code":"C179434","definitions":[{"definition":"The use of estrogen in postmenopausal women or to women who have had their ovaries surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogen Only Hormone Replacement Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Estrogen only"},{"name":"NCI_META_CUI","value":"CL1662210"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C179452":{"preferredName":"Estrogen/Progesterone Hormone Replacement Therapy","code":"C179452","definitions":[{"definition":"A combination of estrogen and progesterone given to postmenopausal women or to women who have had their ovaries surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogen/Progesterone Hormone Replacement Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progesterone and Estrogen"},{"name":"NCI_META_CUI","value":"CL1662310"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C179453":{"preferredName":"Progesterone Only Hormone Replacement Therapy","code":"C179453","definitions":[{"definition":"Progesterone given to postmenopausal women or to women who have had their ovaries surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progesterone Only Hormone Replacement Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progesterone only"},{"name":"NCI_META_CUI","value":"CL1662305"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C14338":{"preferredName":"Human Papillomavirus-16","code":"C14338","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-16 (HPV16) has been directly linked to cervical cancer and is significantly associated with invasiveness. Progression from low- to high-grade neoplasia is often associated with the integration of the HPV16 genome into the host chromosome.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 16 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-16","termGroup":"PT","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus 16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus Subtype 16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus Subtype HPV16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus-16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Subtype HPV-16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Subtype HPV16","termGroup":"SY","termSource":"NCI"},{"termName":"HPV Genotype 16","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-16","termGroup":"AB","termSource":"NCI"},{"termName":"HPV16","termGroup":"AB","termSource":"NCI"},{"termName":"hrHPV-16","termGroup":"SY","termSource":"NCI"},{"termName":"hrHPV16","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 16","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Genotype 16","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 16","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus-16"},{"name":"Maps_To","value":"HPV16"},{"name":"NCBI_Taxon_ID","value":"333760"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0999806"}]}}{"C14377":{"preferredName":"Human Papillomavirus-18","code":"C14377","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-18 (HPV18) has been directly linked to cervical cancer and plays a role in the pathogenesis of the disease. The virus integrates its DNA at specific chromosomal locations, such as 8q24 and 12q15. The use of molecular markers for HPV18 infection may allow the identification of patients with early stage cervical cancer and those at high risk for disease recurrence.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 18 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-18","termGroup":"PT","termSource":"NCI"},{"termName":"HPV Genotype 18","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-18","termGroup":"AB","termSource":"NCI"},{"termName":"HPV18","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Genotype 18","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 18","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus-18"},{"name":"Maps_To","value":"HPV18"},{"name":"NCBI_Taxon_ID","value":"333761"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0999807"}]}}{"C102995":{"preferredName":"Human Papillomavirus-26","code":"C102995","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-26 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-26","termGroup":"PT","termSource":"NCI"},{"termName":"Alphapapillomavirus 5","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-26","termGroup":"SY","termSource":"NCI"},{"termName":"HPV26","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 26","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"26"},{"name":"NCBI_Taxon_ID","value":"333762"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1645198"}]}}{"C102904":{"preferredName":"Human Papillomavirus-31","code":"C102904","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-31 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 31 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-31","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-31","termGroup":"SY","termSource":"NCI"},{"termName":"HPV31","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 31","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV31"},{"name":"NCBI_Taxon_ID","value":"10585"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C2936597"}]}}{"C102996":{"preferredName":"Human Papillomavirus-33","code":"C102996","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-33 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 33 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-33","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-33","termGroup":"SY","termSource":"NCI"},{"termName":"HPV33","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV33"},{"name":"NCBI_Taxon_ID","value":"10586"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641011"}]}}{"C102997":{"preferredName":"Human Papillomavirus-35","code":"C102997","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-35 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 35 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-35","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-35","termGroup":"SY","termSource":"NCI"},{"termName":"HPV35","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 35","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV35"},{"name":"NCBI_Taxon_ID","value":"10587"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641012"}]}}{"C102998":{"preferredName":"Human Papillomavirus-39","code":"C102998","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-39 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 39 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-39","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-39","termGroup":"SY","termSource":"NCI"},{"termName":"HPV39","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 39","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV39"},{"name":"NCBI_Taxon_ID","value":"10588"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641013"}]}}{"C102999":{"preferredName":"Human Papillomavirus-45","code":"C102999","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-45 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 45 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-45","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-45","termGroup":"SY","termSource":"NCI"},{"termName":"HPV45","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 45","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV45"},{"name":"NCBI_Taxon_ID","value":"10593"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641014"}]}}{"C103000":{"preferredName":"Human Papillomavirus-51","code":"C103000","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-51 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 51 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-51","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-51","termGroup":"SY","termSource":"NCI"},{"termName":"HPV51","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 51","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV51"},{"name":"NCBI_Taxon_ID","value":"10595"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641015"}]}}{"C103001":{"preferredName":"Human Papillomavirus-52","code":"C103001","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-52 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 52 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-52","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-52","termGroup":"SY","termSource":"NCI"},{"termName":"HPV52","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 52","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV52"},{"name":"NCBI_Taxon_ID","value":"10618"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641016"}]}}{"C103002":{"preferredName":"Human Papillomavirus-53","code":"C103002","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-53 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 53 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-53","termGroup":"PT","termSource":"NCI"},{"termName":"Alphapapillomavirus 6","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-53","termGroup":"SY","termSource":"NCI"},{"termName":"HPV53","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 53","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"53"},{"name":"NCBI_Taxon_ID","value":"333765"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1629153"}]}}{"C103003":{"preferredName":"Human Papillomavirus-56","code":"C103003","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-56 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 56 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-56","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-56","termGroup":"SY","termSource":"NCI"},{"termName":"HPV56","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 56","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV56"},{"name":"NCBI_Taxon_ID","value":"10596"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641017"}]}}{"C103004":{"preferredName":"Human Papillomavirus-58","code":"C103004","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-58 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 58 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-58","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-58","termGroup":"SY","termSource":"NCI"},{"termName":"HPV58","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 58","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV58"},{"name":"NCBI_Taxon_ID","value":"10598"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641018"}]}}{"C103005":{"preferredName":"Human Papillomavirus-59","code":"C103005","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-59 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 59 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-59","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-59","termGroup":"SY","termSource":"NCI"},{"termName":"HPV59","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 59","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV59"},{"name":"NCBI_Taxon_ID","value":"37115"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641019"}]}}{"C156054":{"preferredName":"Human Papillomavirus-63","code":"C156054","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-63 may be associated with a risk for cervical cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-63","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-63","termGroup":"SY","termSource":"NCI"},{"termName":"HPV63","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus 63","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus-63","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 63","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"63"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1628029"}]}}{"C103006":{"preferredName":"Human Papillomavirus-66","code":"C103006","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-66 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 66 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-66","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-66","termGroup":"SY","termSource":"NCI"},{"termName":"HPV66","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 66","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV66"},{"name":"NCBI_Taxon_ID","value":"37119"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641020"}]}}{"C103007":{"preferredName":"Human Papillomavirus-68","code":"C103007","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-68 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 68 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-68","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-68","termGroup":"SY","termSource":"NCI"},{"termName":"HPV68","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 68","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV68"},{"name":"NCBI_Taxon_ID","value":"45240"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641021"}]}}{"C156055":{"preferredName":"Human Papillomavirus-70","code":"C156055","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-70 may be associated with a high risk for cervical cancer.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 70 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-70","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-70","termGroup":"SY","termSource":"NCI"},{"termName":"HPV70","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus 70","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus-70","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 70","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"70"},{"name":"NCBI_Taxon_ID","value":"39457"},{"name":"NCI_META_CUI","value":"CL562899"},{"name":"Semantic_Type","value":"Virus"}]}}{"C103008":{"preferredName":"Human Papillomavirus-73","code":"C103008","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-73 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-73","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-73","termGroup":"SY","termSource":"NCI"},{"termName":"HPV73","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 73","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV73"},{"name":"NCBI_Taxon_ID","value":"51033"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641022"}]}}{"C103009":{"preferredName":"Human Papillomavirus-82","code":"C103009","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-82 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-82","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-82","termGroup":"SY","termSource":"NCI"},{"termName":"HPV82","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 82","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"82"},{"name":"NCBI_Taxon_ID","value":"129724"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641023"}]}}{"C179443":{"preferredName":"Macroscopically Positive Parametrial Margin","code":"C179443","definitions":[{"definition":"The presence of macroscopically visible residual tumor in surgical margins in the parametrial region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macroscopically Positive Parametrial Margin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Macroscopic Parametrium"},{"name":"NCI_META_CUI","value":"CL1662302"},{"name":"Semantic_Type","value":"Finding"}]}}{"C179445":{"preferredName":"Microscopically Positive Parametrial Margin","code":"C179445","definitions":[{"definition":"The presence of microscopically visible residual tumor in surgical margins in the parametrial region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microscopically Positive Parametrial Margin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microscopic Parametrium"},{"name":"NCI_META_CUI","value":"CL1662298"},{"name":"Semantic_Type","value":"Finding"}]}}{"C48621":{"preferredName":"Negative Surgical Margin","code":"C48621","definitions":[{"definition":"Indicates the absence of tumor cells at the edge of a surgically excised specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Negative Surgical Margin","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Margin","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Surgical Margin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Negative_Surgical_Margin"},{"name":"Maps_To","value":"None"},{"name":"Maps_To","value":"Uninvolved"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709157"}]}}{"C15256":{"preferredName":"Hysterectomy","code":"C15256","definitions":[{"definition":"A surgical procedure to remove the uterine body (partial hysterectomy) or the uterine body and cervix (total hysterectomy).","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove the uterus and, sometimes, the cervix. When the uterus and the cervix are removed, it is called a total hysterectomy. When only the uterus is removed, it is called a partial hysterectomy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hysterectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hysterectomy"},{"name":"Maps_To","value":"Hysterectomy NOS"},{"name":"Maps_To","value":"Hysterectomy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0020699"}]}}{"C141477":{"preferredName":"Not Performed","code":"C141477","definitions":[{"definition":"An indicator that specifies that an activity did not occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Not Performed","termGroup":"PT","termSource":"NCI"},{"termName":"Not Performed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Not Performed"},{"name":"Maps_To","value":"Not performed"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0445106"}]}}{"C94470":{"preferredName":"Radical Hysterectomy","code":"C94470","definitions":[{"definition":"Surgery to remove the uterus, cervix, and part of the vagina. The ovaries, fallopian tubes, and nearby lymph nodes may also be removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of the uterus and surrounding structures, including bilateral pelvic lymph nodes, the parametrium, and the upper one-third to one-half of the vagina.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Hysterectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radical Hysterectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2987682"}]}}{"C15701":{"preferredName":"Total Hysterectomy","code":"C15701","definitions":[{"definition":"A surgical procedure to remove the uterine body and cervix. -- 2004","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove the entire uterus, including the cervix.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Total Hysterectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Hysterectomy"},{"name":"Maps_To","value":"Full Hysterectomy"},{"name":"Maps_To","value":"Simple Hysterectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0677962"}]}}{"C38758":{"preferredName":"Positive Finding","code":"C38758","definitions":[{"definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","type":"DEFINITION","source":"NCI"},{"definition":"A test result that shows a person has what was tested for. (https://mrctcenter.org/glossaryterm/positive-test-result/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"An indication of an affirmative finding for a test or assessment, such as for a disease, condition, analyte, or microorganism.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Positive Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Positive_Finding"},{"name":"Maps_To","value":"Positive"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1446409"}]}}{"C162575":{"preferredName":"99mTc Bone Scintography","code":"C162575","definitions":[{"definition":"An imaging modality that reflects alterations in the metabolic activity of bone through the use of radiopharmaceutical agents, commonly technetium-99m-labeled methylene diphosphonate (MDP).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"99mTc Bone Scintography","termGroup":"PT","termSource":"NCI"},{"termName":"99mTc Bone Scintiscan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"99mTc Bone Scintigraphy"},{"name":"NCI_META_CUI","value":"CL971093"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C17204":{"preferredName":"Computed Tomography","code":"C17204","definitions":[{"definition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","type":"DEFINITION","source":"NCI"},{"definition":"A series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A way to take pictures of the inside of a person's body using a type of radiation and a computer. (https://mrctcenter.org/glossaryterm/computerized-tomography-ct-scan/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"An imaging technique for examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Computed Tomography","termGroup":"PT","termSource":"NCI"},{"termName":"CAT","termGroup":"AB","termSource":"NCI"},{"termName":"CAT Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Computerized Axial Tomography","termGroup":"SY","termSource":"NCI"},{"termName":"Computerized Tomography","termGroup":"SY","termSource":"NCI"},{"termName":"CT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Computed_Tomography"},{"name":"Maps_To","value":"CT Scan"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0040405"}]}}{"C16809":{"preferredName":"Magnetic Resonance Imaging","code":"C16809","definitions":[{"definition":"A procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and diseased tissue. NMRI makes better images of organs and soft tissue than other scanning techniques, such as computed tomography (CT) or x-ray. NMRI is especially useful for imaging the brain, the spine, the soft tissue of joints, and the inside of bones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A way to take pictures of the inside of a person's body with a machine that uses strong magnets and radio waves. (https://mrctcenter.org/glossaryterm/magnetic-resonance-imaging-mri/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Magnetic Resonance Imaging","termGroup":"PT","termSource":"NCI"},{"termName":"Magnetic Resonance Imaging Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","termGroup":"SY","termSource":"NCI"},{"termName":"MR Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"MRI","termGroup":"AB","termSource":"NCI"},{"termName":"MRI Scan","termGroup":"SY","termSource":"NCI"},{"termName":"NMR Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"NMRI","termGroup":"AB","termSource":"NCI"},{"termName":"Nuclear Magnetic Resonance Imaging","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Magnetic_Resonance_Imaging"},{"name":"Maps_To","value":"MRI"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0024485"}]}}{"C17007":{"preferredName":"Positron Emission Tomography","code":"C17007","definitions":[{"definition":"A procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is used. Because cancer cells often use more glucose than normal cells, the pictures can be used to find cancer cells in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","type":"DEFINITION","source":"NCI"},{"definition":"An imaging technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance. A scanner reveals the tissue location of the metabolically-active substance administered.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Positron Emission Tomography","termGroup":"PT","termSource":"NCI"},{"termName":"Medical Imaging, Positron Emission Tomography","termGroup":"SY","termSource":"NCI"},{"termName":"PET","termGroup":"SY","termSource":"NCI"},{"termName":"PET Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Positron Emission Tomography Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Positron-Emission Tomography","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Positron_Emission_Tomography"},{"name":"Maps_To","value":"PET"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0032743"}]}}{"C17230":{"preferredName":"Ultrasound Imaging","code":"C17230","definitions":[{"definition":"A procedure in which high-energy sound waves are bounced off internal tissues or organs and make echoes. The echo patterns are shown on the screen of an ultrasound machine, forming a picture of body tissues called a sonogram.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The use of high-frequency sound waves to generate images of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ultrasound Imaging","termGroup":"PT","termSource":"NCI"},{"termName":"2-Dimensional Grayscale Ultrasound Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"2-Dimensional Ultrasound Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"2D-US","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasonography","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasound","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasound Test","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasound, Medical","termGroup":"SY","termSource":"NCI"},{"termName":"US","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Ultrasound_Imaging"},{"name":"Maps_To","value":"Ultrasound"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0041618"}]}}{"C15577":{"preferredName":"Anti-Tumor Necrosis Factor Therapy","code":"C15577","definitions":[{"definition":"Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Tumor Necrosis Factor Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"anti-TNF therapy","termGroup":"SY","termSource":"NCI"},{"termName":"anti-TNF-alpha therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-Tumor_Necrosis_Factor_Therapy"},{"name":"Maps_To","value":"Anti-TNF Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0281481"}]}}{"C290":{"preferredName":"Azathioprine","code":"C290","definitions":[{"definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azathioprine","termGroup":"PT","termSource":"NCI"},{"termName":"6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine","termGroup":"SN","termSource":"NCI"},{"termName":"AZA","termGroup":"AB","termSource":"NCI"},{"termName":"AZTP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"446-86-6"},{"name":"CHEBI_ID","value":"CHEBI:2948"},{"name":"Chemical_Formula","value":"C9H7N7O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MRK240IY2L"},{"name":"Legacy Concept Name","value":"Azathioprine"},{"name":"Maps_To","value":"Azathioprine"},{"name":"NSC Number","value":"39084"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004482"}]}}{"C405":{"preferredName":"Cyclophosphamide","code":"C405","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclophosphamide","termGroup":"PT","termSource":"NCI"},{"termName":"1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-[bis(b-chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane-2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-[di(chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane 2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Asta B 518","termGroup":"CN","termSource":"NCI"},{"termName":"B-518","termGroup":"CN","termSource":"NCI"},{"termName":"bis(2-chloroethyl)phosphamide cyclic propanolamide ester monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Carloxan","termGroup":"FB","termSource":"NCI"},{"termName":"Ciclofosfamida","termGroup":"SY","termSource":"NCI"},{"termName":"Ciclofosfamide","termGroup":"SY","termSource":"NCI"},{"termName":"Cicloxal","termGroup":"FB","termSource":"NCI"},{"termName":"Clafen","termGroup":"SY","termSource":"NCI"},{"termName":"Claphene","termGroup":"SY","termSource":"NCI"},{"termName":"CP monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"CTX","termGroup":"AB","termSource":"NCI"},{"termName":"CYCLO-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Cycloblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Cycloblastine","termGroup":"FB","termSource":"NCI"},{"termName":"Cyclophospham","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphamid monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphamide Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphamidum","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphan","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphanum","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclostin","termGroup":"FB","termSource":"NCI"},{"termName":"Cyclostine","termGroup":"FB","termSource":"NCI"},{"termName":"Cytophosphan","termGroup":"FB","termSource":"NCI"},{"termName":"Cytophosphane","termGroup":"SY","termSource":"NCI"},{"termName":"Fosfaseron","termGroup":"FB","termSource":"NCI"},{"termName":"Genoxal","termGroup":"FB","termSource":"NCI"},{"termName":"Genuxal","termGroup":"FB","termSource":"NCI"},{"termName":"Ledoxina","termGroup":"FB","termSource":"NCI"},{"termName":"Mitoxan","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)phosphorodiamidic acid intramolecular ester monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(b-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Neosar","termGroup":"AQS","termSource":"NCI"},{"termName":"Revimmune","termGroup":"SY","termSource":"NCI"},{"termName":"Syklofosfamid","termGroup":"SY","termSource":"NCI"},{"termName":"WR- 138719","termGroup":"CN","termSource":"NCI"},{"termName":"WR-138719","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Leukemias; Lupus nephritis; Lymphoma; Multiple myeloma; Neuroblastoma; Nephrotic syndrome; Ovarian cancer; Retinoblastoma; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia"},{"name":"CAS_Registry","value":"6055-19-2"},{"name":"CHEBI_ID","value":"CHEBI:4026"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O2P.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"8N3DW7272P"},{"name":"Legacy Concept Name","value":"Cyclophosphamide"},{"name":"Maps_To","value":"Cyclophosphamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39748"},{"name":"NSC Number","value":"26271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39748"},{"name":"PDQ_Open_Trial_Search_ID","value":"39748"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010583"}]}}{"C642":{"preferredName":"Methotrexate","code":"C642","definitions":[{"definition":"A drug used to treat some types of cancer, rheumatoid arthritis, and severe skin conditions, such as psoriasis. Amethopterin stops cells from making DNA and may kill cancer cells. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-10-methylfolic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Abitrexate","termGroup":"BR","termSource":"NCI"},{"termName":"Alpha-Methopterin","termGroup":"SY","termSource":"NCI"},{"termName":"Amethopterin","termGroup":"BR","termSource":"NCI"},{"termName":"Brimexate","termGroup":"FB","termSource":"NCI"},{"termName":"CL-14377","termGroup":"CN","termSource":"NCI"},{"termName":"Emtexate","termGroup":"FB","termSource":"NCI"},{"termName":"Emthexat","termGroup":"FB","termSource":"NCI"},{"termName":"Emthexate","termGroup":"FB","termSource":"NCI"},{"termName":"Farmitrexat","termGroup":"FB","termSource":"NCI"},{"termName":"Fauldexato","termGroup":"FB","termSource":"NCI"},{"termName":"Folex","termGroup":"BR","termSource":"NCI"},{"termName":"Folex PFS","termGroup":"BR","termSource":"NCI"},{"termName":"Lantarel","termGroup":"FB","termSource":"NCI"},{"termName":"Ledertrexate","termGroup":"FB","termSource":"NCI"},{"termName":"Lumexon","termGroup":"FB","termSource":"NCI"},{"termName":"Maxtrex","termGroup":"FB","termSource":"NCI"},{"termName":"Medsatrexate","termGroup":"FB","termSource":"NCI"},{"termName":"Metex","termGroup":"FB","termSource":"NCI"},{"termName":"Methoblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Methotrexate LPF","termGroup":"BR","termSource":"NCI"},{"termName":"Methotrexate Methylaminopterin","termGroup":"SY","termSource":"NCI"},{"termName":"Methotrexatum","termGroup":"SY","termSource":"NCI"},{"termName":"Metotrexato","termGroup":"SY","termSource":"NCI"},{"termName":"Metrotex","termGroup":"FB","termSource":"NCI"},{"termName":"Mexate","termGroup":"BR","termSource":"NCI"},{"termName":"Mexate-AQ","termGroup":"BR","termSource":"NCI"},{"termName":"MTX","termGroup":"AB","termSource":"NCI"},{"termName":"N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Novatrex","termGroup":"FB","termSource":"NCI"},{"termName":"Rheumatrex","termGroup":"BR","termSource":"NCI"},{"termName":"Texate","termGroup":"FB","termSource":"NCI"},{"termName":"Tremetex","termGroup":"FB","termSource":"NCI"},{"termName":"Trexeron","termGroup":"FB","termSource":"NCI"},{"termName":"Trixilem","termGroup":"FB","termSource":"NCI"},{"termName":"WR-19039","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Abortion; Bladder cancer; Breast cancer; Carcinomatous; meningitis; Chorioadenoma destruens; Crohn's disease; Ectopic pregnancy; Esophageal cancer; Gestational choriocarcinoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Graft versus host disease-prophylaxis; Head/neck cancer; Hydatidiform mole; Leukemia; meningeal; Lymphomas; Acute Lymphoblastic Leukemia; Burkitt's; Lung cancer; Mycosis fungoides; Osteosarcoma; Psoriasis; Rheumatoid arthritis; Wegener's granulomatosis"},{"name":"CAS_Registry","value":"59-05-2"},{"name":"CHEBI_ID","value":"CHEBI:44185"},{"name":"Chemical_Formula","value":"C20H22N8O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"YL5FZ2Y5U1"},{"name":"Legacy Concept Name","value":"Methotrexate"},{"name":"Maps_To","value":"Methotrexate"},{"name":"NCI_Drug_Dictionary_ID","value":"41719"},{"name":"NSC Number","value":"740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41719"},{"name":"PDQ_Open_Trial_Search_ID","value":"41719"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025677"}]}}{"C105720":{"preferredName":"Karnofsky Performance Status 0","code":"C105720","definitions":[{"definition":"Dead.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Equivalent to ECOG 5"},{"name":"Maps_To","value":"0"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829432"}]}}{"C105718":{"preferredName":"Karnofsky Performance Status 10","code":"C105718","definitions":[{"definition":"Moribund; fatal processes progressing rapidly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 10","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"10"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829430"}]}}{"C105716":{"preferredName":"Karnofsky Performance Status 20","code":"C105716","definitions":[{"definition":"Very sick; hospitalization necessary; active support treatment is necessary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 20","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 4"},{"name":"Maps_To","value":"20"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829429"}]}}{"C105715":{"preferredName":"Karnofsky Performance Status 30","code":"C105715","definitions":[{"definition":"Severely disabled; hospitalization is indicated, although death not imminent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 30","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 3"},{"name":"Maps_To","value":"30"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829428"}]}}{"C105714":{"preferredName":"Karnofsky Performance Status 40","code":"C105714","definitions":[{"definition":"Disabled; requires special care and assistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 40","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 3"},{"name":"Maps_To","value":"40"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829427"}]}}{"C105713":{"preferredName":"Karnofsky Performance Status 50","code":"C105713","definitions":[{"definition":"Requires considerable assistance and frequent medical care.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 50","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 2"},{"name":"Maps_To","value":"50"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829426"}]}}{"C105712":{"preferredName":"Karnofsky Performance Status 60","code":"C105712","definitions":[{"definition":"Requires occasional assistance, but is able to care for most personal needs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 60","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 2"},{"name":"Maps_To","value":"60"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829425"}]}}{"C105711":{"preferredName":"Karnofsky Performance Status 70","code":"C105711","definitions":[{"definition":"Cares for self; unable to carry on normal activity or do active work.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 70","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 1"},{"name":"Maps_To","value":"70"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829424"}]}}{"C105710":{"preferredName":"Karnofsky Performance Status 80","code":"C105710","definitions":[{"definition":"Normal activity with effort; some sign or symptoms of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 80","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 1"},{"name":"Maps_To","value":"80"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829423"}]}}{"C105709":{"preferredName":"Karnofsky Performance Status 90","code":"C105709","definitions":[{"definition":"Able to carry on normal activity; minor signs or symptoms of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 90","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 0"},{"name":"Maps_To","value":"90"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829422"}]}}{"C105707":{"preferredName":"Karnofsky Performance Status 100","code":"C105707","definitions":[{"definition":"Normal; no complaints; no evidence of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 100","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 0"},{"name":"Maps_To","value":"100"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829431"}]}}{"C15491":{"preferredName":"Premenopausal","code":"C15491","definitions":[{"definition":"Having to do with the time before menopause. Menopause (\"change of life\") is the time of life when a woman's menstrual periods stop permanently.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Prior to menopause.","type":"DEFINITION","source":"NCI"},{"definition":"The period of time before perimenopause.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Premenopausal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Premenopausal"},{"name":"Maps_To","value":"Premenopausal"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0279752"}]}}{"C15692":{"preferredName":"Perimenopausal","code":"C15692","definitions":[{"definition":"Describes the time in a woman's life as she approaches menopause. This is usually three to five years before menopause and is often marked by irregular menstrual periods and many of the symptoms of menopause, including hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.","type":"DEFINITION","source":"NCI"},{"definition":"Describes the time in a woman's life when menstrual periods become irregular as she approaches menopause. This is usually three to five years before menopause and is often marked by many of the symptoms of menopause, including hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The 10 or so years immediately prior to menopause when the subject experiences symptoms of menopause.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Perimenopausal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Perimenopausal"},{"name":"Maps_To","value":"Perimenopausal"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3839366"}]}}{"C15421":{"preferredName":"Postmenopausal","code":"C15421","definitions":[{"definition":"After menopause.","type":"DEFINITION","source":"NCI"},{"definition":"Having to do with the time after menopause. Menopause (\"change of life\") is the time in a woman's life when menstrual periods stop permanently.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The period of time after menopause.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Postmenopausal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Postmenopausal"},{"name":"Maps_To","value":"Postmenopausal"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0232970"}]}}{"C34945":{"preferredName":"Ectopic Pregnancy","code":"C34945","definitions":[{"definition":"A condition in which a fertilized egg grows outside of the uterus, usually in one of the fallopian tubes. Symptoms include sharp pain on one side of the abdomen and bleeding from the vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pregnancy that implants in a location other than the uterine endometrium.","type":"ALT_DEFINITION","source":"GAIA"},{"definition":"An abnormal pregnancy in which the conception is implanted outside the endometrial cavity.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An abnormal pregnancy in which the conception is implanted outside the endometrial cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Pregnancy condition that happens when there is a developing fetus or embryo outside the uterus.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Ectopic Pregnancy","termGroup":"PT","termSource":"NCI"},{"termName":"Extrauterine Pregnancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Ectopic_Pregnancy"},{"name":"Maps_To","value":"Ectopic Pregnancy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0032987"},{"name":"xRef","value":"IMDRF:E1506"}]}}{"C50613":{"preferredName":"Induced Abortion Finding","code":"C50613","definitions":[{"definition":"Abortion brought on intentionally.","type":"DEFINITION","source":"NCI"},{"definition":"Abortion brought on intentionally.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Induced Abortion Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Induced Abortion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Induced_Abortion"},{"name":"Maps_To","value":"Induced Abortion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1704300"},{"name":"xRef","value":"IMDRF:E150103"}]}}{"C114091":{"preferredName":"Live Birth","code":"C114091","definitions":[{"definition":"An infant delivered, that breathes/shows any evidence of life (e.g. beating heart, pulsation of umbilical cord) or definite movement of voluntary muscles.","type":"ALT_DEFINITION","source":"GAIA"},{"definition":"The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Live Birth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Live Birth"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0481667"}]}}{"C34336":{"preferredName":"Spontaneous Abortion","code":"C34336","definitions":[{"definition":"Early pregnancy loss.","type":"ALT_DEFINITION","source":"GAIA"},{"definition":"Fetal loss at less than 20 weeks of gestation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Fetal loss at less than 20 weeks of gestation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Spontaneous expulsion of a human fetus before it is viable.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Spontaneous Abortion","termGroup":"PT","termSource":"NCI"},{"termName":"Miscarriage","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Spontaneous_Abortion"},{"name":"Maps_To","value":"Miscarriage"},{"name":"Maps_To","value":"Spontaneous Abortion"},{"name":"Maps_To","value":"Spontaneous abortion"},{"name":"NCI_META_CUI","value":"CL793064"},{"name":"Semantic_Type","value":"Finding"},{"name":"xRef","value":"IMDRF:E150105"}]}}{"C49151":{"preferredName":"Stillbirth","code":"C49151","definitions":[{"definition":"A fetus of at least 20 weeks gestation, or of a birth weight of 350 grams or greater when the gestational age is not known, with no signs of life at the time of delivery, with Apgar scores of 0 at 1 and 5 minutes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A fetus of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, that is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Foetal death occurring before birth after a selected, pre-defined duration of gestation. The death of the foetus could have occurred before the onset of labor (antepartum) or at the time of delivery (intrapartum). For all levels of diagnostic certainty, the definition of stillbirth is defined by the two following criteria: First, determination of absence of signs of life in the foetus or newborn; Second, determination of foetal/newborn gestational age through maternal information or through foetal/newborn evaluation.","type":"ALT_DEFINITION","source":"GAIA"}],"synonyms":[{"termName":"Stillbirth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Stillbirth"},{"name":"Maps_To","value":"Stillbirth"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0595939"}]}}{"C16450":{"preferredName":"Colonoscopy","code":"C16450","definitions":[{"definition":"Endoscopic examination of the luminal surface of the colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Endoscopic examination of the luminal surface of the colon.","type":"DEFINITION","source":"NCI"},{"definition":"Examination of the inside of the colon using a colonoscope, inserted into the rectum. A colonoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colonoscopy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colonoscopy"},{"name":"Maps_To","value":"Colonoscopy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0009378"}]}}{"C16546":{"preferredName":"Endoscopic Procedure","code":"C16546","definitions":[{"definition":"A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A procedure that uses an endoscope to examine the inside of the body. An endoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An examination of the body using an endoscope.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endoscopic Procedure","termGroup":"PT","termSource":"NCI"},{"termName":"Endoscopic","termGroup":"AD","termSource":"NCI"},{"termName":"Endoscopic Examination","termGroup":"SY","termSource":"NCI"},{"termName":"Endoscopy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endoscopy"},{"name":"Maps_To","value":"Endoscopy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0014245"}]}}{"C55073":{"preferredName":"Recurrent Disease, Distant Site","code":"C55073","definitions":[{"definition":"Recurrence of symptoms of a disease, at a site different and away from the original site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recurrent Disease, Distant Site","termGroup":"PT","termSource":"NCI"},{"termName":"Relapse, Distant Site","termGroup":"SY","termSource":"NCI"},{"termName":"Relapsed Disease, Distant Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Recurrent_Disease_Distal_Site"},{"name":"Maps_To","value":"Distant"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1882917"}]}}{"C36162":{"preferredName":"Localized Disease","code":"C36162","definitions":[{"definition":"A disease that is confined to a specific organ or tissue and has not spread to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Localized Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Localized_Disease"},{"name":"Maps_To","value":"Local"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0277565"}]}}{"C41844":{"preferredName":"Regional Disease","code":"C41844","definitions":[{"definition":"A disease or condition that extends beyond the site and spreads into adjacent tissues and regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regional Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Regional_Disease"},{"name":"Maps_To","value":"Regional"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1514819"}]}}{"C25388":{"preferredName":"Local-Regional","code":"C25388","definitions":[{"definition":"Of or belonging to both a local and regional area of the body.","type":"DEFINITION","source":"NCI"},{"definition":"Of or belonging to either a local and/or regional area of the body in relation to a point of origin.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Local-Regional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Local-Regional"},{"name":"Maps_To","value":"Locoregional"},{"name":"Maps_To","value":"Locoregional Site"},{"name":"Semantic_Type","value":"Spatial Concept"},{"name":"UMLS_CUI","value":"C0205276"}]}}{"C29633":{"preferredName":"Antacid Preparation","code":"C29633","definitions":[{"definition":"Natural or synthetic compounds or mixtures, Antiacid Preparations such as sodium bicarbonate, sodium citrate, and phosphate salts act as proton acceptors, neutralizing the acidity of a biologic environment (skin, gastric content, urine, etc.) and raising the pH. These agents are used topically or systemically for management of metabolic acidosis, improved muscle contraction, and hyper-acidic conditions (preventing, counteracting, or neutralizing stomach acidity). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antacid Preparation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antacid_Preparation"},{"name":"Maps_To","value":"Antacids"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0003138"}]}}{"C29702":{"preferredName":"Histamine-2 Receptor Antagonist","code":"C29702","definitions":[{"definition":"A pharmaceutical agent that blocks the binding of histamine to the type II histamine receptor, and is often used to decrease gastric acid production and to treat urticaria.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any agent that competitively binds to and blocks the histamine H2 receptors found in the stomach, heart, uterus, on vascular smooth muscle and in the central nervous system (CNS). Of particular clinical relevance is the blockage of H2 receptors found on the parietal cells of the stomach, which prevents gastric acid secretion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histamine-2 Receptor Antagonist","termGroup":"PT","termSource":"NCI"},{"termName":"H2 Antagonist","termGroup":"SY","termSource":"NCI"},{"termName":"H2 Blocker","termGroup":"SY","termSource":"NCI"},{"termName":"H2 Receptor Antagonist","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:37961"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Histamine-2_Receptor_Antagonist"},{"name":"Maps_To","value":"H2 Blockers"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0019593"}]}}{"C165200":{"preferredName":"Medically Treated Reflux","code":"C165200","definitions":[{"definition":"An indication that a subject has used or is using medication to treat gastrointestinal reflux.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medically Treated Reflux","termGroup":"PT","termSource":"NCI"},{"termName":"Reflux Medically Treated","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medically Treated"},{"name":"NCI_META_CUI","value":"CL978412"},{"name":"Semantic_Type","value":"Finding"}]}}{"C29723":{"preferredName":"Proton Pump Inhibitor","code":"C29723","definitions":[{"definition":"A pharmaceutical agent that inhibits the transport of hydrogen ions, in exchange for potassium ions, into the gastric lumen and results in an inhibition of gastric acid secretion. These drugs are used for their anti-ulcer activity.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any one of the substituted benzimidazole compounds with anti-ulcer activity. A proton pump inhibitor is orally administered in the neutrally charged, inactive form and, upon entering the acidic environment of the parietal cell, gets protonated and converted into its active form. The active form will covalently and irreversibly bind to the proton pump, the H+/K+-ATPase, located on the surface of parietal cells. This leads to an inhibition of the transport of hydrogen ions, in exchange for potassium ions, into the gastric lumen and results in an inhibition of gastric acid secretion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proton Pump Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"PPI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:49200"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Proton_Pump_Inhibitor"},{"name":"Maps_To","value":"Proton Pump Inhibitors"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0358591"}]}}{"C15329":{"preferredName":"Surgical Procedure","code":"C15329","definitions":[{"definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","type":"DEFINITION","source":"NCI"},{"definition":"A procedure to remove or repair a part of the body or to find out whether disease is present. An operation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One or more surgical procedures, including percutaneous or minimally invasive procedures, were required, or an existing procedure changed.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Surgical Procedure","termGroup":"PT","termSource":"NCI"},{"termName":"Operation","termGroup":"SY","termSource":"NCI"},{"termName":"Surgery","termGroup":"SY","termSource":"NCI"},{"termName":"Surgical","termGroup":"AD","termSource":"NCI"},{"termName":"Surgical Interventions","termGroup":"SY","termSource":"NCI"},{"termName":"Surgical Procedures","termGroup":"SY","termSource":"NCI"},{"termName":"Surgically","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Surgical_Procedure"},{"name":"Maps_To","value":"Surgery, NOS"},{"name":"Maps_To","value":"Surgically Treated"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0543467"},{"name":"xRef","value":"IMDRF:F19"}]}}{"C120861":{"preferredName":"Adenosis","code":"C120861","definitions":[{"definition":"Any disease or disorder of a gland, characterized by abnormal development or enlargement of the gland.","type":"DEFINITION","source":"NCI"},{"definition":"The presence of small collections of epithelial cells with or without microlumens in the stroma adjacent to ducts or acini in glandular tissues.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adenosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosis (Atypical Adenomatous Hyperplasia)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334050"}]}}{"C5665":{"preferredName":"Atypical Adenomatous Lung Hyperplasia","code":"C5665","definitions":[{"definition":"A preinvasive lesion in the lung. It is characterized by the presence of a small, localized proliferation of mildly to moderately atypical type II pneumocytes and/or Clara cells lining alveolar walls and sometimes respiratory bronchioles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Adenomatous Lung Hyperplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Adenomatous Hyperplasia of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Adenomatous Hyperplasia of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Alveolar Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchioloalveolar Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Adenomatous_Lung_Hyperplasia"},{"name":"Maps_To","value":"Adenosis (Atypical Adenomatous Hyperplasia)"},{"name":"Maps_To","value":"Atypical adenomatous hyperplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332345"}]}}{"C16273":{"preferredName":"Alcohol Consumption","code":"C16273","definitions":[{"definition":"Consumption of liquids containing ethanol, including the behaviors associated with drinking the alcohol.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alcohol Consumption","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alcohol_Consumption"},{"name":"Maps_To","value":"Alcohol Consumption"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0001948"}]}}{"C34783":{"preferredName":"Alcoholic Liver Disease","code":"C34783","definitions":[{"definition":"A disorder caused by damage to the liver parenchyma due to alcohol consumption. It may present with an acute onset or follow a chronic course, leading to cirrhosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alcoholic Liver Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Alcoholic_Liver_Disease"},{"name":"Maps_To","value":"Alcoholic Liver Disease"},{"name":"Maps_To","value":"Alcoholic liver disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0023896"}]}}{"C172303":{"preferredName":"Animal Allergy","code":"C172303","definitions":[{"definition":"An allergic reaction triggered by exposure to animal-associated allergens, includes allergenic factors in venom, saliva and dander.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Animal Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Animal, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0700360"}]}}{"C172307":{"preferredName":"Venomous Ant Bite Allergy","code":"C172307","definitions":[{"definition":"An allergic reaction triggered by exposure to ant venom, usually as a result of being bitten by a fire ant (Solenopsis spp.).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venomous Ant Bite Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Ant Bite Allergy","termGroup":"SY","termSource":"NCI"},{"termName":"Ant Sting Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Ant"},{"name":"NCI_META_CUI","value":"CL1406169"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172308":{"preferredName":"Bee Venom Allergy","code":"C172308","definitions":[{"definition":"An allergic reaction triggered by being exposed to bee venom following a bee sting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bee Venom Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Bee Sting Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Bee"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1828283"}]}}{"C172310":{"preferredName":"Cat Allergy","code":"C172310","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens expressed by cats, includes allergenic factors found in feline saliva and dander.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cat Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Cat"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0339805"}]}}{"C175520":{"preferredName":"Dairy or Lactose Intolerance Allergy","code":"C175520","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in foods containing lactose or other dairy components.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dairy or Lactose Intolerance Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Dairy or Lactose"},{"name":"NCI_META_CUI","value":"CL1412861"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172311":{"preferredName":"Dog Allergy","code":"C172311","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens expressed by dogs, includes allergenic factors found in canine saliva and dander.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dog Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Dog"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0740913"}]}}{"C172313":{"preferredName":"Egg Allergy","code":"C172313","definitions":[{"definition":"An allergic reaction triggered by exposure to foodborne allergens found in eggs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Egg Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Egg"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0559469"}]}}{"C172304":{"preferredName":"Food Allergy","code":"C172304","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in food; exposure can occur through the skin, respiratory tract or digestive tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Food Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Foodborne Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Food, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3280920"}]}}{"C172316":{"preferredName":"Fruit Allergy","code":"C172316","definitions":[{"definition":"An allergic reaction triggered by exposure to foodborne allergens found in fruit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fruit Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Fruit"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0685901"}]}}{"C172317":{"preferredName":"Meat Allergy","code":"C172317","definitions":[{"definition":"An allergic reaction triggered by exposure to foodborne allergens found in meat.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meat Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Meat"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0859949"}]}}{"C172306":{"preferredName":"Mold or Dust Allergy","code":"C172306","definitions":[{"definition":"An allergic reaction triggered by exposure to airborne allergens expressed by dust mites or molds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mold or Dust Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Mold or Dust"},{"name":"NCI_META_CUI","value":"CL1406170"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C175521":{"preferredName":"Nut Allergy","code":"C175521","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in nuts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nut Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Nuts"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0577620"}]}}{"C175522":{"preferredName":"Processed Food Allergy","code":"C175522","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in processed foods.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Processed Food Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Processed Foods"},{"name":"NCI_META_CUI","value":"CL1412863"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172320":{"preferredName":"Shellfish Allergy","code":"C172320","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in foods containing molluscs, crustaceans or echinoderms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shellfish Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Seafood"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0577625"}]}}{"C172321":{"preferredName":"Wasp Venom Allergy","code":"C172321","definitions":[{"definition":"An allergic reaction triggered by being exposed to wasp venom following a wasp sting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wasp Venom Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Wasp Sting Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Wasp"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1827129"}]}}{"C156076":{"preferredName":"Autoimmune Atrophic Chronic Gastritis","code":"C156076","definitions":[{"definition":"Chronic atrophic gastritis that is caused by autoimmune destruction of parietal cells in the stomach resulting in hypochlorhydria and decreased production of intrinsic factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autoimmune Atrophic Chronic Gastritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autoimmune atrophic chronic gastritis"},{"name":"Maps_To","value":"Autoimmune Atrophic Chronic Gastritis"},{"name":"NCI_META_CUI","value":"CL562911"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172639":{"preferredName":"BAP1 Tumor Predisposition Syndrome","code":"C172639","definitions":[{"definition":"A syndrome caused by germline mutations in the BAP1 gene. It is inherited in an autosomal dominant pattern. Individuals carrying heterozygous BAP1 mutations have an increased risk of developing various tumor types, most commonly BAP1-inactivated nevi/melanocytomas of the skin, uveal and cutaneous melanomas, peritoneal and pleural mesotheliomas, clear cell renal cell carcinoma, and basal cell carcinoma. (WHO 2018)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BAP1 Tumor Predisposition Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"BAP1-TPDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BAP1 Tumor Predisposition Syndrome"},{"name":"NCI_META_CUI","value":"CL558268"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C2897":{"preferredName":"Benign Prostatic Hyperplasia","code":"C2897","definitions":[{"definition":"A benign (noncancerous) condition in which an overgrowth of prostate tissue pushes against the urethra and the bladder, blocking the flow of urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Prostatic Hyperplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Hyperplasia of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Hyperplasia of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Prostate Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Prostatic Hyperplasia - BPH","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Prostatic Hypertrophy","termGroup":"SY","termSource":"NCI"},{"termName":"BPH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Prostatic_Hyperplasia"},{"name":"Maps_To","value":"Benign Prostatic Hyperplasia"},{"name":"Maps_To","value":"Nodular Prostatic Hyperplasia"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0005001"}]}}{"C28244":{"preferredName":"Birt-Hogg-Dube Syndrome","code":"C28244","definitions":[{"definition":"A rare genetic syndrome with an autosomal dominant pattern of inheritance. It is caused by a mutation in the FLCN gene which encodes the protein folliculin. Clinical signs include multiple benign growths of the skin and lungs that begin to manifest in the second or third decade of life. The clinical course is characterized by the progressive growth of new and existing neoplasms. In those with mutations in both copies of FLCN, the kidneys may also be affected by the growth of benign or malignant neoplasms.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited condition in which benign tumors develop in hair follicles on the head, chest, back, and arms.  People who have this disorder may be at increased risk of developing colon or kidney cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Birt-Hogg-Dube Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Birt-Hogg-Dube_Syndrome"},{"name":"Maps_To","value":"Birt-Hogg-Dube Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0346010"}]}}{"C172230":{"preferredName":"Family History of BRCA Mutation","code":"C172230","definitions":[{"definition":"An indication that a variant in a BRCA family gene has been identified in a family member of a subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Family History of BRCA Mutation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRCA Family History"},{"name":"NCI_META_CUI","value":"CL1406124"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C171138":{"preferredName":"Bacterial Colonization","code":"C171138","definitions":[{"definition":"The detection of bacteria in or on an anatomic site, medical device or biospecimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bacterial Colonization","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonization, Bacterial"},{"name":"Maps_To","value":"Colonization; bacterial"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2747813"}]}}{"C82980":{"preferredName":"Fungal Colonization","code":"C82980","definitions":[{"definition":"Collection of fungal organisms in an anatomic site or medical device.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fungal Colonization","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fungal_Colonization"},{"name":"Maps_To","value":"Colonization, Fungal"},{"name":"Maps_To","value":"Colonization; fungal"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2826606"}]}}{"C3076":{"preferredName":"Cowden Syndrome","code":"C3076","definitions":[{"definition":"An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited disorder marked by the formation of many noncancerous growths called hamartomas. These growths occur in the skin, breast, thyroid, colon, intestines, and inside of the mouth. Patients with Cowden syndrome are at increased risk of certain types of cancer, including breast and thyroid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cowden Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Cowden Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Cowden's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Ruvalcaba-Myhre-Smith Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cowden_Syndrome"},{"name":"Maps_To","value":"Cowden Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018553"}]}}{"C2978":{"preferredName":"Cyst","code":"C2978","definitions":[{"definition":"A sac or capsule in the body. It may be filled with fluid or other material.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.","type":"DEFINITION","source":"NCI"},{"definition":"A sac-like closed pocket of tissue that may be empty or may be filled with fluid, gas, semisolid, or amorphous material. It typically has an outer epithelial-lined capsule.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cyst","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cyst"},{"name":"Maps_To","value":"Cyst(s)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0010709"}]}}{"C2986":{"preferredName":"Type 1 Diabetes Mellitus","code":"C2986","definitions":[{"definition":"A chronic condition characterized by minimal or absent production of insulin by the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Diabetes mellitus caused by cell-mediated autoimmune destruction of pancreatic beta cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Type 1 Diabetes Mellitus","termGroup":"PT","termSource":"NCI"},{"termName":"IDDM","termGroup":"AB","termSource":"NCI"},{"termName":"Insulin Dependent Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin Dependent Diabetes Mellitus","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type 1 Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type I Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type I Diabetes Mellitus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Insulin_Dependent_Diabetes_Mellitus"},{"name":"Maps_To","value":"Diabetes, Type I"},{"name":"Maps_To","value":"Type I diabetes mellitus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0011854"}]}}{"C15222":{"preferredName":"Diet","code":"C15222","definitions":[{"definition":"The customary allowance of food and drink taken by a person or an animal from day to day, particularly one especially planned to meet specific requirements of the individual, including or excluding certain items of food; a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health.","type":"DEFINITION","source":"NCI"},{"definition":"The things a person eats and drinks.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diet","termGroup":"PT","termSource":"NCI"},{"termName":"Dietary","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diet"},{"name":"Maps_To","value":"Diet"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0012155"}]}}{"C3014":{"preferredName":"Endometriosis","code":"C3014","definitions":[{"definition":"A benign condition in which tissue that looks like endometrial tissue grows in abnormal places in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Presence of endometrial tissue outside of endometrium and myometrium, consisting of both endometrial glands and stroma.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometriosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometriosis"},{"name":"Maps_To","value":"Endometriosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0014175"}]}}{"C179646":{"preferredName":"Endosalpingiosis","code":"C179646","definitions":[{"definition":"A rare condition characterized by the replacement of the epithelium of an organ which is not related to fallopian tube with ectopic fallopian tube-type ciliated epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endosalpingiosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endosalpingiosis"},{"name":"NCI_META_CUI","value":"CL1662418"},{"name":"Semantic_Type","value":"Finding"}]}}{"C8366":{"preferredName":"Intraepithelial Neoplasia","code":"C8366","definitions":[{"definition":"A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"Epithelial"},{"name":"Maps_To","value":"Epithelial Dysplasia"},{"name":"Maps_To","value":"Epithelial dysplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0878500"}]}}{"C3954":{"preferredName":"Gastric Polyp","code":"C3954","definitions":[{"definition":"A polyp that arises from the stomach.  This category includes neoplastic polyps (intestinal-type adenomatous polyps, gastric-type adenomas, and fundic gland polyps), and non-neoplastic polyps (hyperplastic polyps and hamartomatous polyps).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastric Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Gastric Polyposa","termGroup":"SY","termSource":"NCI"},{"termName":"Gastric Polyposis","termGroup":"SY","termSource":"NCI"},{"termName":"Polyps of Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Polyps of the Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastric_Polyp"},{"name":"Maps_To","value":"Gastric Polyp(s)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0236048"}]}}{"C84729":{"preferredName":"Gilbert Syndrome","code":"C84729","definitions":[{"definition":"An autosomal recessive inherited disorder characterized by unconjugated hyperbilirubinemia, resulting in harmless intermittent jaundice.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gilbert Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Gilbert Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gilbert's Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0017551"}]}}{"C35605":{"preferredName":"Glomerular Vascular Disorder","code":"C35605","definitions":[{"definition":"A disorder that is caused by pathologic changes in the glomerular vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomerular Vascular Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glomerular_Vascular_Disorder"},{"name":"Maps_To","value":"Glomerular Disease"},{"name":"Maps_To","value":"Glomerular disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0852683"}]}}{"C92188":{"preferredName":"Seasonal Allergic Rhinitis","code":"C92188","definitions":[{"definition":"Allergic rhinitis caused by outdoor allergens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seasonal Allergic Rhinitis","termGroup":"PT","termSource":"NCI"},{"termName":"Hay Fever","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hay Fever"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018621"}]}}{"C27121":{"preferredName":"Helicobacter Pylori-Associated Gastritis","code":"C27121","definitions":[{"definition":"Inflammation of the stomach that is associated with Helicobacter Pylori.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Helicobacter Pylori-Associated Gastritis","termGroup":"PT","termSource":"NCI"},{"termName":"Helicobacter Gastritis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Helicobacter_Pylori-Associated_Gastritis"},{"name":"Maps_To","value":"Helicobacter Pylori-Associated Gastritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0343378"}]}}{"C26323":{"preferredName":"Hematopoietic and Lymphoid Cell Disorder","code":"C26323","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that arises from the hematopoietic and lymphoid cells. Representative examples include disorders that affect the synthesis of hemoglobin, coagulation disorders, leukemias, and lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic and Lymphoid Cell Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic and Lymphocytic Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic and Lymphoid Cell Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematological Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hematologic_Disorder"},{"name":"Maps_To","value":"Disease of blood and blood-forming organs, unspecified"},{"name":"Maps_To","value":"Hematologic Disorder, NOS"},{"name":"Maps_To","value":"Other diseases of blood and blood-forming organs"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018939"}]}}{"C82892":{"preferredName":"Hemochromatosis","code":"C82892","definitions":[{"definition":"A condition in which the body takes up and stores more iron than it needs. The extra iron is stored in the liver, heart, and pancreas, which may cause liver disease, heart problems, organ failure, and cancer. It may also cause bronze skin, diabetes, pain in the joints and abdomen, tiredness, and impotence. Hemochromatosis may be inherited, or it may be caused by blood transfusions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Accumulation of iron in internal organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemochromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Hemosiderosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemosiderosis"},{"name":"Maps_To","value":"Hemochromatosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1849984"}]}}{"C79596":{"preferredName":"Hepatic Encephalopathy","code":"C79596","definitions":[{"definition":"A constellation of signs and symptoms characterized by changes in personality, consciousness, and reflexes, resulting from neuropsychiatric abnormalities secondary to liver failure without evidence of other brain disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatic Encephalopathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatic_Encephalopathy"},{"name":"Maps_To","value":"Hepatic Encephalopathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019151"}]}}{"C4503":{"preferredName":"Hereditary Breast Carcinoma","code":"C4503","definitions":[{"definition":"Breast carcinoma that has developed in relatives of patients with history of breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Breast Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Cancer of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Cancer of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Breast Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Breast_Carcinoma"},{"name":"Maps_To","value":"Hereditary Breast Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346153"}]}}{"C8960":{"preferredName":"Hereditary Kidney Oncocytoma","code":"C8960","definitions":[{"definition":"An inherited condition characterized by the development of kidney oncocytomas which are often bilateral and multifocal.  This condition may be connected to Birt-Hogg-Dube syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Kidney Oncocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Renal Oncocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Renal Oncocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Familial_Renal_Oncocytoma"},{"name":"Maps_To","value":"Hereditary Kidney Oncocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0879606"}]}}{"C36102":{"preferredName":"Hereditary Ovarian Carcinoma","code":"C36102","definitions":[{"definition":"Ovarian carcinoma that has developed in relatives of patients that have a history of ovarian carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Ovarian Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Ovarian Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Ovarian_Carcinoma"},{"name":"Maps_To","value":"Hereditary Ovarian Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333992"}]}}{"C9222":{"preferredName":"Hereditary Papillary Renal Cell Carcinoma","code":"C9222","definitions":[{"definition":"A familial carcinoma inherited in an autosomal dominant trait.  It is characterized by the development of multiple, bilateral papillary renal cell carcinomas.  The carcinomas range from microscopic lesions to clinically symptomatic tumors.  It is associated with activating mutations of the MET oncogene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Papillary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Renal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Kidney Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Papillary Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Papillary Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Papillary Renal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Renal_Papillary_Carcinoma"},{"name":"Maps_To","value":"Hereditary Papillary Renal Cell Carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0879257"}]}}{"C103817":{"preferredName":"Hereditary Prostate Carcinoma","code":"C103817","definitions":[{"definition":"Prostate carcinoma that has developed in relatives of patients with a history of prostate carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Prostate Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hereditary Prostate Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2931456"}]}}{"C39789":{"preferredName":"Hereditary Renal Cell Carcinoma","code":"C39789","definitions":[{"definition":"Renal cell carcinoma that has developed in relatives of patients with history of renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Renal Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Hereditary Renal Cell Carcinoma"},{"name":"NCI_META_CUI","value":"CL412456"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C5541":{"preferredName":"High Grade Prostatic Intraepithelial Neoplasia","code":"C5541","definitions":[{"definition":"Prostatic intraepithelial neoplasia characterized by the presence of morphologically malignant cells lining the acini and ducts.  The malignant cells are enlarged, contain prominent nucleoli, and have increased nuclear/cytoplasmic ratio.  The malignant cells may grow within the ducts and acini in four architectural patterns: flat, tufting, micropapillary, and cribriform.  The presence of high grade prostatic intraepithelial neoplasia in needle biopsy is a risk factor for the subsequent detection of carcinoma on repeat biopsy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Prostatic Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"HGPIN","termGroup":"AB","termSource":"NCI"},{"termName":"High-Grade Intraepithelial Neoplasia of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Intraepithelial Neoplasia of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade PIN","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Prostatic Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"High-Grade_Prostatic_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"High-grade Prostatic Intraepithelial Neoplasia (PIN)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1168327"}]}}{"C3108":{"preferredName":"HIV Infection","code":"C3108","definitions":[{"definition":"An infection caused by the human immunodeficiency virus.","type":"DEFINITION","source":"NCI"},{"definition":"Infection caused by the human immunodeficiency virus.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"HIV Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Human Immunodeficiency Virus Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"HIV_Infection"},{"name":"Maps_To","value":"HIV"},{"name":"Maps_To","value":"HIV infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019693"}]}}{"C3137":{"preferredName":"Inflammation","code":"C3137","definitions":[{"definition":"A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","type":"DEFINITION","source":"NCI"},{"definition":"A localized physical condition in which part of the body becomes reddened, swollen, or hot and often painful.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A response to an injury or abnormal stimuli characterized by inflammatory cell infiltration and varying degrees of vascular and tissue reactions (hyperemia, edema, fibrin, and/or fibrosis).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Redness, swelling, pain, and/or a feeling of heat in an area of the body. This is a protective reaction to injury, disease, or irritation of the tissues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Inflammation","termGroup":"PT","termSource":"NCI"},{"termName":"Inflammatory Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Inflammation"},{"name":"Maps_To","value":"Inflammation"},{"name":"Maps_To","value":"Inflammation, Hyperkeratosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0021368"},{"name":"xRef","value":"IMDRF:E2326"}]}}{"C35541":{"preferredName":"Hyperkeratosis","code":"C35541","definitions":[{"definition":"A condition marked by thickening of the outer layer of the skin, which is made of keratin (a tough, protective protein). It can result from normal use (corns, calluses), chronic inflammation (eczema), or genetic disorders (X-linked ichthyosis, ichthyosis vulgaris).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Hypertrophy of the outermost layer of the epidermis. It may be caused by physical or chemical irritants, irradiation, infection, or neoplastic processes.","type":"DEFINITION","source":"NCI"},{"definition":"Thickening of the outermost layer of stratified squamous epithelium.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hyperkeratosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperkeratosis"},{"name":"Maps_To","value":"Hyperkeratosis"},{"name":"Maps_To","value":"Inflammation, Hyperkeratosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3809745"}]}}{"C8360":{"preferredName":"Intestinal Metaplasia","code":"C8360","definitions":[{"definition":"A morphologic finding indicating the replacement of epithelial tissue outside the intestines by intestinal-type epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intestinal Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intestinal_Metaplasia"},{"name":"Maps_To","value":"Intestinal Metaplasia"},{"name":"Maps_To","value":"Intestinal metaplasia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334037"}]}}{"C38766":{"preferredName":"Lymphocytic Thyroiditis","code":"C38766","definitions":[{"definition":"An inflammatory disorder that affects the thyroid gland.  It is characterized by the infiltration of the thyroid parenchyma by lymphocytes.  It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocytic Thyroiditis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocytic_Thyroiditis"},{"name":"Maps_To","value":"Lymphocytic Thyroiditis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0920350"}]}}{"C84444":{"preferredName":"Nonalcoholic Fatty Liver Disease","code":"C84444","definitions":[{"definition":"A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonalcoholic Fatty Liver Disease","termGroup":"PT","termSource":"NCI"},{"termName":"NAFLD - Nonalcoholic Fatty Liver Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nonalcoholic Fatty Liver Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0400966"}]}}{"C389":{"preferredName":"Oral Contraceptive","code":"C389","definitions":[{"definition":"An agent taken orally to prevent conception.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Contraceptive","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:49325"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Contraceptive"},{"name":"Maps_To","value":"Oral Contraceptives"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0009905"}]}}{"C164213":{"preferredName":"Recurrent Pyogenic Cholangitis","code":"C164213","definitions":[{"definition":"A recurrent form of cholangitis that is characterized by intrabiliary pigment stone formation, biliary tree stricture and obstruction, and recurrent bouts of cholangitis. There is an association with biliary parasitosis, but evidence supporting these infections in the pathogenesis of recurrent pyogenic cholangitis is inconclusive. The most common causes of death are sepsis, liver failure, or complications from cirrhosis. Patients are also at increased risk of cholangiocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recurrent Pyogenic Cholangitis","termGroup":"PT","termSource":"NCI"},{"termName":"Cholangiohepatitis","termGroup":"SY","termSource":"NCI"},{"termName":"RPC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrent Pyogenic Cholangitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0267921"}]}}{"C26882":{"preferredName":"Sialadenitis","code":"C26882","definitions":[{"definition":"An acute or chronic inflammatory process affecting a salivary gland. Signs and symptoms include pain and tenderness in the affected area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialadenitis","termGroup":"PT","termSource":"NCI"},{"termName":"Sialoadenitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sialoadenitis"},{"name":"Maps_To","value":"Sialadenitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0037023"}]}}{"C3237":{"preferredName":"Squamous Metaplasia","code":"C3237","definitions":[{"definition":"A morphologic finding indicating the transformation of glandular or transitional epithelial cells to, usually, mature squamous epithelial cells.  Representative examples include squamous metaplasia of bronchial epithelium, cervix, urinary bladder, and prostate gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Squamous_Metaplasia"},{"name":"Maps_To","value":"Squamous Metaplasia"},{"name":"Maps_To","value":"Squamous metaplasia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0025570"}]}}{"C156464":{"preferredName":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","code":"C156464","definitions":[{"definition":"A very rare renal cell carcinoma that usually affects young adults. It is characterized by mutations in one of the four subunits of the SDH complex (SDHA, SDHB, SDHC, or SDHD gene). Most frequently, the mutations occur in the SDHB subunit. It has a relatively good prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"SDH Deficient Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SDH-Deficient Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SDH-RCC","termGroup":"AB","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma"},{"name":"NCI_META_CUI","value":"CL563184"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C113681":{"preferredName":"Skin Tattoo","code":"C113681","definitions":[{"definition":"A permanent mark created by the insertion of pigment below the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Tattoo","termGroup":"PT","termSource":"NCI"},{"termName":"Tattoo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tattoo"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1366940"}]}}{"C18059":{"preferredName":"Tobacco Use","code":"C18059","definitions":[{"definition":"Use of tobacco in any form, e.g., smoking, chewing or sniffing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Use","termGroup":"PT","termSource":"NCI"},{"termName":"Tobacco Consumption","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tobacco_Use"},{"name":"Maps_To","value":"Tobacco use"},{"name":"Maps_To","value":"Tobacco, NOS"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0543414"}]}}{"C137998":{"preferredName":"Smokeless Tobacco Use","code":"C137998","definitions":[{"definition":"Use of smokeless tobacco in any form, e.g., chewing or sniffing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokeless Tobacco Use","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco, Smokeless"},{"name":"NCI_META_CUI","value":"CL525032"},{"name":"Semantic_Type","value":"Individual Behavior"}]}}{"C3424":{"preferredName":"Tuberous Sclerosis","code":"C3424","definitions":[{"definition":"A genetic disorder in which benign (not cancer) tumors form in the kidneys, brain, eyes, heart, lungs, and skin. This disease can cause seizures, mental disabilities, and different types of skin lesions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Hereditary disease characterized by seizures, intracerebral tumors, cardiac tumors, developmental delay, and skin and ocular lesions.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuberous Sclerosis","termGroup":"PT","termSource":"NCI"},{"termName":"Bourneville's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"TSC","termGroup":"AB","termSource":"NCI"},{"termName":"Tuberous Sclerosis Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Tuberous_Sclerosis"},{"name":"Maps_To","value":"Tuberous Sclerosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0041341"}]}}{"C123036":{"preferredName":"Tubulointerstitial Disease","code":"C123036","definitions":[{"definition":"Disease affecting the renal tubules and interstitium of the kidney.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Disease affecting the renal tubules and interstitium of the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Tubulointerstitial Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Tubulointerstitial Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0041349"}]}}{"C171150":{"preferredName":"Tumor-Associated Lymphocytosis","code":"C171150","definitions":[{"definition":"Non-neoplastic lymphocytosis associated with the presence of a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor-Associated Lymphocytosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor-associated Lymphoid Proliferation"},{"name":"Maps_To","value":"Tumor-associated lymphoid proliferation"},{"name":"NCI_META_CUI","value":"CL1405382"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35117":{"preferredName":"Vascular Disorder","code":"C35117","definitions":[{"definition":"A non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels. Examples include vasculitis, thrombophlebitis, arteriosclerosis, lymphedema, hemangioma, and angiosarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"The report describes a non-specific problem with the vascular system. Note: Please use \"Appropriate Term / Code Not Available\" if the report describes a specific problem but the relevant term does not exist.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Vascular Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Vascular_Disorder"},{"name":"Maps_To","value":"Vascular Disease"},{"name":"Maps_To","value":"Vascular disorders of intestine"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0042373"},{"name":"xRef","value":"IMDRF:E0518"}]}}{"C3105":{"preferredName":"Von Hippel Lindau Syndrome","code":"C3105","definitions":[{"definition":"A rare inherited disorder in which blood vessels grow abnormally in the eyes, brain, spinal cord, adrenal glands, or other parts of the body. People with von Hippel-Lindau syndrome have a higher risk of developing some types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant multiple neoplasia syndrome caused by germline mutations of the VHL gene, encoding the protein von Hippel-Lindau tumor suppressor (pVHL). The condition is characterized by development of capillary hemangioblastomas of the central nervous system and retina, clear cell renal carcinoma, pheochromocytoma, pancreatic tumors, and inner ear tumors (endolymphatic sac tumors).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Von Hippel Lindau Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebroretinal Angiomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Syndrome (VHL)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Von_Hippel-Lindau_Syndrome"},{"name":"Maps_To","value":"Von Hippel-Lindau Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019562"}]}}{"C80078":{"preferredName":"Chronic Kidney Disease","code":"C80078","definitions":[{"definition":"A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Kidney Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"CKD - Chronic Kidney Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Chronic_Kidney_Disease"},{"name":"Maps_To","value":"Chronic kidney disease"},{"name":"Maps_To","value":"Chronic Kidney Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1561643"}]}}{"C34594":{"preferredName":"Escherichia coli Infection","code":"C34594","definitions":[{"definition":"Infection with the organism Escherichia Coli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Escherichia coli Infection","termGroup":"PT","termSource":"NCI"},{"termName":"E coli Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Escherichia_Coli_Infection"},{"name":"Maps_To","value":"Escherichia coli"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0014836"}]}}{"C39594":{"preferredName":"Skin Rash","code":"C39594","definitions":[{"definition":"An eruption in the skin which affects its appearance and/or texture.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An eruption in the skin which effects its appearance and/or texture.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Any change in the skin that affects its appearance or texture. A rash may be localized to one part of the body or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked, or blistered, swell, and may be painful.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.","type":"DEFINITION","source":"NCI"},{"definition":"Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked, or blistered, swell and may be painful.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Skin Rash","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Eruption","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Skin_Rash"},{"name":"Maps_To","value":"Rash"},{"name":"Maps_To","value":"Skin Rash"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4227880"},{"name":"xRef","value":"IMDRF:E1714"}]}}{"C6996":{"preferredName":"Uterine Corpus Adenomyosis","code":"C6996","definitions":[{"definition":"The growth of endometrial tissue inside the muscular wall of the uterine corpus. Clinical manifestations include pain, dysmenorrhea, and menorrhagia.","type":"DEFINITION","source":"NCI"},{"definition":"The growth of endometrial tissue inside the muscular wall of the uterus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Uterine Corpus Adenomyosis","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomyosis","termGroup":"SY","termSource":"NCI"},{"termName":"Adenomyosis of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Adenomyosis of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Adenomyosis","termGroup":"SY","termSource":"NCI"},{"termName":"Uterus Corpus Adenomyosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Adenomyosis"},{"name":"Maps_To","value":"Adenomyosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0341858"}]}}{"C128829":{"preferredName":"HHV6 Infection","code":"C128829","definitions":[{"definition":"An infection that is caused by human herpesvirus-6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HHV6 Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HHV-6 Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Human Herpes Virus-6 Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Human Herpesvirus-6 Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Human Herpesvirus-6 (HHV-6)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0854530"}]}}{"C39291":{"preferredName":"HHV8 Infection","code":"C39291","definitions":[{"definition":"An infectious process caused by the human herpesvirus 8. This infection is associated with Kaposi sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HHV8 Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Human Herpesvirus 8 Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Herpes_Virus_8_Infection"},{"name":"Maps_To","value":"Human Herpesvirus-8 (HHV-8)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1512508"}]}}{"C94719":{"preferredName":"Acetate","code":"C94719","definitions":[{"definition":"A form of acetic acid (an acid found in vinegar).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Salt or ester form of acetic acid. Acetate is the most common building block for biosynthesis, such as fatty acids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acetate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71-50-1"},{"name":"CHEBI_ID","value":"CHEBI:30089"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"569DQM74SC"},{"name":"Maps_To","value":"Acetate"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0000975"}]}}{"C74002":{"preferredName":"Fluciclovine F18","code":"C74002","definitions":[{"definition":"A radiotracer containing a synthetic amino acid analogue of L-leucine radiolabeled with fluorine F 18 with potential diagnostic imaging use. Similar to most amino acids, fluciclovine F18 appears to enter cells through the energy-independent L-type amino acid transporter (LAT) system. As an amino acid analogue, this agent is preferentially accumulated by tumor cells due to their increased metabolic needs; however, unlike naturally occurring amino acids, this non-natural amino acid-analogue radiotracer is not metabolized. Accordingly, fluciclovine F18 accumulates in tumor cells and can potentially be used to image tumors using positron emission tomography (PET).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluciclovine F18","termGroup":"PT","termSource":"NCI"},{"termName":"(18F)Fluciclovine","termGroup":"SY","termSource":"NCI"},{"termName":"(18F)GE-148","termGroup":"CN","termSource":"NCI"},{"termName":"(1R,3R)-1-Amino-3(18f)fluorocyclobutane-1-carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"18F-Fluciclovine","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]FACBC","termGroup":"AB","termSource":"NCI"},{"termName":"Anti-(18f)FABC","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-[18F] FACBC","termGroup":"AB","termSource":"NCI"},{"termName":"Axumin","termGroup":"BR","termSource":"NCI"},{"termName":"Fluciclovine (18F)","termGroup":"SY","termSource":"NCI"},{"termName":"GE-148 (18F)","termGroup":"CN","termSource":"NCI"},{"termName":"GE-148 F-18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222727-39-1"},{"name":"Chemical_Formula","value":"C5H8FNO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"38R1Q0L1ZE"},{"name":"Legacy Concept Name","value":"Anti-1-Amino-3-Fluorocyclobutane-1-Carboxylic_Acid"},{"name":"Maps_To","value":"Axumin"},{"name":"NCI_Drug_Dictionary_ID","value":"581382"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581382"},{"name":"PDQ_Open_Trial_Search_ID","value":"581382"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311253"}]}}{"C61674":{"preferredName":"Choline","code":"C61674","definitions":[{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Choline helps cells make membranes, make a neurotransmitter (a chemical that helps nerve cells communicate with other cells), and remove fat from the liver. It is found in whole milk, beef liver, eggs, soy foods, and peanuts. Choline is water-soluble (can dissolve in water) and must be taken in every day. Not enough choline can cause diseases of the heart and blood vessels and damage to the liver. A form of choline is being studied in the treatment of some types of cancer and to reduce pain and fever. Choline is also being studied together with vitamin B12 in the prevention and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Water-soluble vitamin that is a precursor for acetylcholine, phospholipids, and the methyl donor betaine. (DRI)","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Choline","termGroup":"PT","termSource":"NCI"},{"termName":"(2-Hydroxyethyl)trimethylammonium","termGroup":"SN","termSource":"NCI"},{"termName":"2-hydroxyethyl-trimethyl-ammonium","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin J","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62-49-7"},{"name":"CHEBI_ID","value":"CHEBI:15354"},{"name":"Chemical_Formula","value":"C5H14NO"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N91BDP6H0X"},{"name":"INFOODS","value":"CHOLN"},{"name":"Legacy Concept Name","value":"Choline"},{"name":"Maps_To","value":"Choline"},{"name":"Micronutrient","value":"Y"},{"name":"Nutrient","value":"Y"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"Tolerable_Level","value":"Y"},{"name":"UMLS_CUI","value":"C0008405"},{"name":"Unit","value":"mcg"},{"name":"US_Recommended_Intake","value":"Y"},{"name":"USDA_ID","value":"421"}]}}{"C17796":{"preferredName":"Glutamate Carboxypeptidase 2","code":"C17796","definitions":[{"definition":"Glutamate carboxypeptidase 2 (750 aa, ~84 kDa) is encoded by the human FOLH1 gene. This protein plays a role in the mediation of folate metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glutamate Carboxypeptidase 2","termGroup":"PT","termSource":"NCI"},{"termName":"Cell Growth-Inhibiting Gene 27 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.4.17.21","termGroup":"SY","termSource":"NCI"},{"termName":"FGCP","termGroup":"SY","termSource":"NCI"},{"termName":"Folate Hydrolase 1","termGroup":"SY","termSource":"NCI"},{"termName":"FOLH1","termGroup":"SY","termSource":"NCI"},{"termName":"Folylpoly-Gamma-Glutamate Carboxypeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"GCP2","termGroup":"SY","termSource":"NCI"},{"termName":"GCPII","termGroup":"SY","termSource":"NCI"},{"termName":"Glutamate Carboxypeptidase II","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane Glutamate Carboxypeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"mGCP","termGroup":"SY","termSource":"NCI"},{"termName":"N-Acetylated-Alpha-Linked Acidic Dipeptidase I","termGroup":"SY","termSource":"NCI"},{"termName":"NAALADase I","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate-Specific Membrane Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"PSM","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA","termGroup":"AB","termSource":"NCI"},{"termName":"Pteroylpoly-Gamma-Glutamate Carboxypeptidase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Folate_Hydrolase-1"},{"name":"Maps_To","value":"PSMA"},{"name":"OMIM_Number","value":"600934"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"Q04609"},{"name":"UMLS_CUI","value":"C1310550"}]}}{"C832":{"preferredName":"Sodium Fluoride","code":"C832","definitions":[{"definition":"An inorganic salt of fluoride used topically or in municipal water fluoridation systems to prevent dental caries.  Fluoride appears to bind to calcium ions in the hydroxyapatite of surface tooth enamel, preventing corrosion of tooth enamel by acids. This agent may also inhibit acid production by commensal oral bacteria. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Fluoride","termGroup":"PT","termSource":"NCI"},{"termName":"NaF","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7681-49-4"},{"name":"CHEBI_ID","value":"CHEBI:28741"},{"name":"Chemical_Formula","value":"F.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8ZYQ1474W7"},{"name":"Legacy Concept Name","value":"Sodium_Fluoride"},{"name":"Maps_To","value":"Sodium Fluoride"},{"name":"NCI_Drug_Dictionary_ID","value":"39598"},{"name":"NSC Number","value":"77385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39598"},{"name":"PDQ_Open_Trial_Search_ID","value":"39598"},{"name":"Semantic_Type","value":"Biomedical or Dental Material"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0037508"}]}}{"C96660":{"preferredName":"Hepatitis B Virus Core Antibody Measurement","code":"C96660","definitions":[{"definition":"The determination of the amount of Hepatitis B virus core antibody present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B Virus Core Antibody Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"HBV Core Antibody Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HBV Core Antibody"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3272940"}]}}{"C103404":{"preferredName":"Hepatitis B DNA Measurement","code":"C103404","definitions":[{"definition":"A measurement of the Hepatitis B virus DNA in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of hepatitis B virus DNA in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B DNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatitis B Virus DNA Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HBV DNA"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3641250"}]}}{"C117108":{"preferredName":"HBV Genotype Assay","code":"C117108","definitions":[{"definition":"An assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HBV Genotype Assay","termGroup":"PT","termSource":"NCI"},{"termName":"HBV Genotype Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"HBV Genotyping","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis B Virus Genotype Assay","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HBV Genotype"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3899000"}]}}{"C74711":{"preferredName":"Hepatitis B Surface Antibody Measurement","code":"C74711","definitions":[{"definition":"The determination of the surface antibody reaction of a sample to the Hepatitis B virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B Surface Antibody Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"HBV Surface Antibody Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatitis_B_Surface_Antibody_Measurement"},{"name":"Maps_To","value":"HBV Surface Antibody"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201478"}]}}{"C117109":{"preferredName":"HCV Genotype Assay","code":"C117109","definitions":[{"definition":"An assay for determining the genotype(s) of hepatitis C virus (HCV) in plasma or serum from HCV-infected individuals. Six major genotypes are recognized and they vary in their response to treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HCV Genotype Assay","termGroup":"PT","termSource":"NCI"},{"termName":"HCV Genotype Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"HCV Genotyping","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C Virus Genotype Assay","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HCV Genotype"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C1533728"}]}}{"C64850":{"preferredName":"Hepatitis B Virus Surface Antigen Measurement","code":"C64850","definitions":[{"definition":"A determination of the presence of hepatitis B virus surface antigen.","type":"DEFINITION","source":"NCI"},{"definition":"A measurement of the surface antigen reaction of a biological specimen to the Hepatitis B virus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hepatitis B Virus Surface Antigen Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatitis_B_Virus_Surface_Antigen_Measurement"},{"name":"Maps_To","value":"Hepatitis B Surface Antigen"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201477"}]}}{"C92535":{"preferredName":"Hepatitis C Antibody Measurement","code":"C92535","definitions":[{"definition":"A quantitative measurement of the antibody reaction of a biological specimen to the Hepatitis C virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis C Antibody Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatitis C Antibody"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201487"}]}}{"C142330":{"preferredName":"Hepatitis C Virus RNA Measurement","code":"C142330","definitions":[{"definition":"A measurement of the Hepatitis C virus RNA in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of hepatitis C virus RNA present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis C Virus RNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatitis C RNA","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C RNA Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatitis C Virus RNA"},{"name":"NCI_META_CUI","value":"CL540367"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C26149":{"preferredName":"B-Cell Lymphoma 6 Protein","code":"C26149","definitions":[{"definition":"B-cell lymphoma 6 protein (706 aa, ~79 kDa) is encoded by the human BCL6 gene. This protein is involved in transcriptional repression, apoptosis regulation and cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Lymphoma 6 Protein","termGroup":"PT","termSource":"NCI"},{"termName":"B-cell CLL/Lymphoma-6","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphoma 5 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-5","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-6","termGroup":"SY","termSource":"NCI"},{"termName":"BCL5","termGroup":"SY","termSource":"NCI"},{"termName":"BCL6","termGroup":"SY","termSource":"NCI"},{"termName":"BCL6 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Cys-His2 Zinc Finger Transcription Factor","termGroup":"SY","termSource":"NCI"},{"termName":"LAZ-3 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"LAZ3","termGroup":"SY","termSource":"NCI"},{"termName":"Protein LAZ-3","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger and BTB Domain-Containing Protein 27","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger Protein 51","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF51","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"B-Cell Lymphoma 6 Protein is a zinc finger transcription factor containing an N-terminal POZ domain. It acts as a sequence-specific repressor of transcription and its activity is dependent upon DNA-binding and on the N-terminal region containing the POZ motif. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. Target genes have roles in B-cell activation, B-cell differentiation, inflammation, and cell cycle control. Expression of BCL6 in some B-cells early in the antigen response may skew them toward a germinal center fate, away from a plasma cell fate. The BCL6 gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. (from OMIM, and LocusLink)"},{"name":"Legacy Concept Name","value":"B-Cell_Lymphoma-6_Protein"},{"name":"Maps_To","value":"BCL6"},{"name":"OMIM_Number","value":"109565"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P41182"},{"name":"UMLS_CUI","value":"C1448774"}]}}{"C325":{"preferredName":"CA-125 Antigen","code":"C325","definitions":[{"definition":"A substance that may be found in high amounts in the blood of patients with certain types of cancer, including ovarian cancer. CA-125 levels may also help monitor how well cancer treatments are working or if cancer has come back.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CA-125 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"CA-125","termGroup":"SY","termSource":"NCI"},{"termName":"CA125","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Antigen 125","termGroup":"SY","termSource":"NCI"},{"termName":"Carbohydrate Antigen 125","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Monitoring levels in patients with Ovarian Cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"45047SF2ZS"},{"name":"Legacy Concept Name","value":"CA-125_Antigen"},{"name":"Maps_To","value":"CA-125"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0006610"}]}}{"C327":{"preferredName":"CA19-9 Antigen","code":"C327","definitions":[{"definition":"CA 19-9 is a fucosylated glycosphingolipid carbohydrate antigen that is soluble and is adsorbed to erythrocytes and to many adenocarcinomas of the digestive tract, especially pancreatic tumors. By structure CA 19-9 is related to the Lewis blood group antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CA19-9 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"CA-19-9","termGroup":"SY","termSource":"NCI"},{"termName":"CA19-9","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Antigen 19-9","termGroup":"SY","termSource":"NCI"},{"termName":"Carbohydrate Antigen 19-9","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl Le(a) Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl LeA","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl LewisA","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl-Lewis A","termGroup":"SY","termSource":"NCI"},{"termName":"Sialylated Lewis (a) Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Sialylated Lewis a Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"SLeA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:61793"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZEJ6FM4UJK"},{"name":"Legacy Concept Name","value":"CA19-9_Antigen"},{"name":"Maps_To","value":"CA19-9"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0006613"}]}}{"C17988":{"preferredName":"G1/S-Specific Cyclin-D1","code":"C17988","definitions":[{"definition":"G1/S-specific cyclin-D1 (295 aa, ~34 kDa) is encoded by the human CCND1 gene. This protein is involved in the regulation of the G1/S transition of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"G1/S-Specific Cyclin-D1","termGroup":"PT","termSource":"NCI"},{"termName":"BCL-1 Oncogene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL1","termGroup":"SY","termSource":"NCI"},{"termName":"CCND1","termGroup":"SY","termSource":"NCI"},{"termName":"CCND1a","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D1a","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-D1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-D1a","termGroup":"SY","termSource":"NCI"},{"termName":"D11S287E","termGroup":"SY","termSource":"NCI"},{"termName":"G1/S-Specific Cyclin D1","termGroup":"SY","termSource":"NCI"},{"termName":"G1/S-Specific Cyclin D1a","termGroup":"SY","termSource":"NCI"},{"termName":"G1/S-Specific Cyclin-D1a","termGroup":"SY","termSource":"NCI"},{"termName":"PRAD1","termGroup":"SY","termSource":"NCI"},{"termName":"PRAD1 Oncogene","termGroup":"SY","termSource":"NCI"},{"termName":"U21B31","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Essential for control of the G1/S transition, cyclin D1 interacts with CDK4 and CDK6 to form a serine/threonine kinase holoenzyme and imparts substrate specificity to the complex.  RB regulates cyclin D1 gene expression.  Cyclin D1 expression may identify Barrett's esophagus patients at high risk for esophageal carcinoma; risk of progression to adenocarcinoma exhibits an odds ratio of 6.85.  The BCL1 and PRAD1 oncogenes involve cyclin D1 gene translocations.  (J Natl Cancer Inst 2000. 92:1282 & 1316, SWISS-PROT, OMIM)"},{"name":"Legacy Concept Name","value":"Cyclin-D1"},{"name":"Maps_To","value":"CCND1"},{"name":"OMIM_Number","value":"168461"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P24385"},{"name":"UMLS_CUI","value":"C1741716"}]}}{"C16836":{"preferredName":"Neprilysin","code":"C16836","definitions":[{"definition":"Neprilysin (750 aa, ~86 kDa) is encoded by the human MME gene. This protein is involved in the metabolism of biologically active peptides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neprilysin","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD10","termGroup":"SY","termSource":"NCI"},{"termName":"Atriopeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"CALLA","termGroup":"SY","termSource":"NCI"},{"termName":"CD10 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Common Acute Lymphoblastic Leukemia Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Common ALL Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.4.24.11","termGroup":"SY","termSource":"NCI"},{"termName":"Enkephalinase","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane Metalloendopeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"MME","termGroup":"SY","termSource":"NCI"},{"termName":"NEP","termGroup":"SY","termSource":"NCI"},{"termName":"Neutral Endopeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"SFE","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Fibroblast Elastase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Membrane Metalloendopeptidase is a zinc-binding type II transmembrane glycoprotein that preferentially cleaves Gly-Phe bonds of peptides at the N side of hydrophobic residues and inactivates several peptide hormones, including insulin, glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin, as well as casein, hemoglobin, and other proteins and polypeptides. An important cell surface marker of human acute lymphocytic leukemia, MME is present on pre-B leukemic cells, which represent 85% of cases of ALL."},{"name":"Legacy Concept Name","value":"Membrane_Metalloendopeptidase"},{"name":"Maps_To","value":"CD10"},{"name":"OMIM_Number","value":"120520"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P08473"},{"name":"UMLS_CUI","value":"C0025250"}]}}{"C17328":{"preferredName":"Mast/Stem Cell Growth Factor Receptor Kit","code":"C17328","definitions":[{"definition":"A protein on the surface of some cells that binds to biologic substance called stem cell factor (SCF). SCF causes certain types of blood cells to grow. The stem cell factor receptor is found at high levels or in a changed form on some types of cancer cells. This may cause these cells to grow rapidly when SCF is present. The stem cell factor receptor is a type of receptor tyrosine kinase.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Mast/stem cell growth factor receptor Kit (976 aa, ~110 kDa) is encoded by the human KIT gene. This protein is involved in cell survival, tyrosine phosphorylation and ligand-mediated signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast/Stem Cell Growth Factor Receptor Kit","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD117","termGroup":"SY","termSource":"NCI"},{"termName":"C-KIT","termGroup":"SY","termSource":"NCI"},{"termName":"CD117 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"EC 2.7.10.1","termGroup":"SY","termSource":"NCI"},{"termName":"KIT","termGroup":"SY","termSource":"NCI"},{"termName":"Mast Cell Growth Factor Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"p145 c-kit","termGroup":"SY","termSource":"NCI"},{"termName":"PBT","termGroup":"SY","termSource":"NCI"},{"termName":"Piebald Trait Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Proto-Oncogene c-Kit","termGroup":"SY","termSource":"NCI"},{"termName":"Proto-Oncogene Tyrosine-Protein Kinase Kit","termGroup":"SY","termSource":"NCI"},{"termName":"SCF Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"SCFR","termGroup":"AB","termSource":"NCI"},{"termName":"SCFR","termGroup":"SY","termSource":"NCI"},{"termName":"Stem Cell Factor Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Tyrosine-Protein Kinase Kit","termGroup":"SY","termSource":"NCI"},{"termName":"v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stem_Cell_Factor_Receptor"},{"name":"Maps_To","value":"CD117"},{"name":"NCI_META_CUI","value":"CL964236"},{"name":"OMIM_Number","value":"164920"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P10721"}]}}{"C96914":{"preferredName":"Syndecan-1","code":"C96914","definitions":[{"definition":"Syndecan-1 (310 aa, ~32 kDa) is encoded by the human SDC1 gene. This protein is involved in the mediation of cell adhesion, signaling and cytoskeletal organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syndecan-1","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD138","termGroup":"SY","termSource":"NCI"},{"termName":"CD138","termGroup":"SY","termSource":"NCI"},{"termName":"CD138 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"SDC1","termGroup":"SY","termSource":"NCI"},{"termName":"SYND1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD138"},{"name":"OMIM_Number","value":"186355"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P18827"},{"name":"UMLS_CUI","value":"C0753253"}]}}{"C17488":{"preferredName":"Monocyte Differentiation Antigen CD14","code":"C17488","definitions":[{"definition":"Monocyte differentiation antigen CD14 (375 aa, ~40 kDa) is encoded by the human CD14 gene. This protein plays a role in the innate immune response to lipopolysaccharide exposure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monocyte Differentiation Antigen CD14","termGroup":"PT","termSource":"NCI"},{"termName":"CD14","termGroup":"SY","termSource":"NCI"},{"termName":"CD14 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lipopolysaccharide Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Cell-Specific Leucine-Rich Glycoprotein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CD14_Antigen"},{"name":"Maps_To","value":"CD14"},{"name":"NCI_META_CUI","value":"CL1375183"},{"name":"OMIM_Number","value":"158120"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P08571"}]}}{"C96898":{"preferredName":"CD15 Antigen","code":"C96898","definitions":[{"definition":"A carbohydrate molecule found on the surface of neutrophils, eosinophils and monocytes. It is involved in neutrophil chemotaxis and phagocytosis. Expression of this antigen is associated with Hodgkin disease, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD15 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"3-Fucosyl-N-Acetyl-Lactosamine","termGroup":"SY","termSource":"NCI"},{"termName":"Lewis X","termGroup":"SY","termSource":"NCI"},{"termName":"LewisX Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"LeX","termGroup":"SY","termSource":"NCI"},{"termName":"SSEA-1","termGroup":"SY","termSource":"NCI"},{"termName":"Stage-Specific Embryonic Antigen 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD15"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0080188"}]}}{"C38894":{"preferredName":"B-Lymphocyte Antigen CD19","code":"C38894","definitions":[{"definition":"B-lymphocyte antigen CD19 (556 aa, ~61 kDa) is encoded by the human CD19 gene. This protein is involved in enhancing B-cell receptor-dependent signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Lymphocyte Antigen CD19","termGroup":"PT","termSource":"NCI"},{"termName":"B-Lymphocyte Surface Antigen B4","termGroup":"SY","termSource":"NCI"},{"termName":"B4","termGroup":"SY","termSource":"NCI"},{"termName":"CD19","termGroup":"SY","termSource":"NCI"},{"termName":"Differentiation Antigen CD19","termGroup":"SY","termSource":"NCI"},{"termName":"Leu-12","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Surface Antigen Leu-12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"When B-lymphocyte antigen CD19 complexes with the B-cell receptor, the threshold for antigen receptor-dependent stimulation of B lymphocyte proliferation is decreased. Additionally, CD19 functions as an adapter protein for Src family kinase amplification, which is crucial for antigen receptor-induced signal transduction."},{"name":"Legacy Concept Name","value":"CD19_Antigen"},{"name":"Maps_To","value":"CD19"},{"name":"NCI_META_CUI","value":"CL599759"},{"name":"OMIM_Number","value":"107265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P15391"}]}}{"C38896":{"preferredName":"B-Lymphocyte Antigen CD20","code":"C38896","definitions":[{"definition":"B-lymphocyte antigen CD20 (297 aa, ~33 kDa) is encoded by the human MS4A1 gene. This protein plays a role in both the activation and proliferation of B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Lymphocyte Antigen CD20","termGroup":"PT","termSource":"NCI"},{"termName":"B-Lymphocyte Surface Antigen B1","termGroup":"SY","termSource":"NCI"},{"termName":"B1","termGroup":"SY","termSource":"NCI"},{"termName":"Bp35","termGroup":"SY","termSource":"NCI"},{"termName":"CD20 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD20 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Leu-16","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane-Spanning 4-Domains Subfamily A Member 1","termGroup":"SY","termSource":"NCI"},{"termName":"MS4A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Expressed during B-cell ontogeny (early pre-B-cell to plasma cell) by human CD20 Gene (MS4A Family), 297-aa 33-kDa CD20 Antigen is a phosphorylated cell surface integral membrane protein shown to participate in B-cell proliferation, development, and differentiation into plasma cells. MS4A family proteins share structural similarity, sequence homology, and unique expression patterns among hematopoietic cells and nonlymphoid tissues. MS4A proteins contain 4 highly conserved transmembrane domains, flanked by N- and C-terminal cytoplasmic regions. CD20 may be involved in regulation of B-cell activation and may be regulated by protein kinases."},{"name":"Legacy Concept Name","value":"CD20_Antigen"},{"name":"Maps_To","value":"CD20"},{"name":"Maps_To","value":"FMC-7"},{"name":"OMIM_Number","value":"112210"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P11836"},{"name":"UMLS_CUI","value":"C0054946"}]}}{"C17279":{"preferredName":"B-Cell Receptor CD22","code":"C17279","definitions":[{"definition":"B-cell receptor CD22 (847 aa, ~95 kDa) is encoded by the human CD22 gene. This protein is involved in B-cell/B-cell interactions and downstream signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Receptor CD22","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Antigen CD22","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphocyte Cell Adhesion Molecule","termGroup":"SY","termSource":"NCI"},{"termName":"BL-CAM","termGroup":"SY","termSource":"NCI"},{"termName":"CD22 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lyb8","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Ig-Like Lectin 2","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Immunoglobulin-Like Lectin 2","termGroup":"SY","termSource":"NCI"},{"termName":"Siglec-2","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Surface Antigen Leu-14","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The CD22 gene is expressed in pro-B cells as a cytoplasmic protein and later as a cell surface protein, persisting until they differentiate into plasma cells. CD22 antigen is a glycoprotein heterodimer with two subunits from separate precursor molecules that arise by differential RNA processing of the same gene. The larger subunit is composed of an extracellular portion of seven Ig domains and a smaller subunit of five Ig domains. Structurally related to MAG, NCAM, and CEA, CD22 participates in adhesion between B-cells and other cell types. Conserved ITIM motifs in inhibitory receptors are sites for phosphorylation by a SRC kinase and dephosphorylation by tyrosine phosphatase SHP1 or inositol phosphatase SHIP, transducing signals to distinct pathways. CD22 ITIMs interact with SHP1 and oppose activation mediated by the B-cell receptor. CD22 is a negative regulator of antigen receptor signaling."},{"name":"Legacy Concept Name","value":"CD22_Antigen"},{"name":"Maps_To","value":"CD22"},{"name":"OMIM_Number","value":"107266"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P20273"},{"name":"UMLS_CUI","value":"C1505685"}]}}{"C96902":{"preferredName":"Low Affinity Immunoglobulin Epsilon Fc Receptor","code":"C96902","definitions":[{"definition":"Low affinity immunoglobulin epsilon Fc receptor (321 aa, ~36 kDa) is encoded by the human FCER2 gene. This protein is involved in B cell differentiation and IgE production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Affinity Immunoglobulin Epsilon Fc Receptor","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD23","termGroup":"SY","termSource":"NCI"},{"termName":"BLAST-2","termGroup":"SY","termSource":"NCI"},{"termName":"C-Type Lectin Domain Family 4 Member J","termGroup":"SY","termSource":"NCI"},{"termName":"CD23 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Fc-Epsilon-RII","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin E-Binding Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte IgE Receptor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD23"},{"name":"OMIM_Number","value":"151445"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P06734"},{"name":"UMLS_CUI","value":"C2744538"}]}}{"C17073":{"preferredName":"Interleukin-2 Receptor Subunit Alpha","code":"C17073","definitions":[{"definition":"Interleukin-2 receptor subunit alpha (272 aa, ~31 kDa) is encoded by the human IL2RA gene. This protein plays a role in interleukin-2-dependent signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-2 Receptor Subunit Alpha","termGroup":"PT","termSource":"NCI"},{"termName":"CD25","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2 Receptor Subunit Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2-RA","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2R","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2R Subunit Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"IL2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"IL2-RA","termGroup":"SY","termSource":"NCI"},{"termName":"IL2R","termGroup":"SY","termSource":"NCI"},{"termName":"IL2RA","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 2 Receptor, Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-2 Receptor Alpha Chain","termGroup":"SY","termSource":"NCI"},{"termName":"Low Affinity Interleukin 2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"p55","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Growth Factor Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"TAC Antigen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolysis. (LocusLink)"},{"name":"Legacy Concept Name","value":"Interleukin-2_Receptor_Alpha"},{"name":"Maps_To","value":"CD25"},{"name":"OMIM_Number","value":"147730"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P01589"},{"name":"UMLS_CUI","value":"C1700887"}]}}{"C38897":{"preferredName":"CD3 Complex","code":"C38897","definitions":[{"definition":"A protein complex comprised of one T-cell surface glycoprotein CD3 delta chain (CD3D), one T-cell surface glycoprotein CD3 gamma chain (CD3G) and two T-cell surface glycoprotein CD3 epsilon chains (CD3E). CD3D, CD3G and CD3E are transmembrane proteins with one extracellular immunoglobulin domain and one intracellular ITAM domain. The CD3 complex is a T-cell co-receptor that noncovalently associates with either the disulfide bound heterodimeric alpha/beta T-cell receptor (TCR) or gamma/delta TCR and two copies of the accessory protein, T-cell surface glycoprotein CD3 zeta chain (CD247), which is a transmembrane protein with three ITAM domains. The TCR moiety of the TCR-CD3 complex binds to MHC and processed antigens on antigen presenting cells, which triggers phosphorylation of and cellular propagation of the signal by CD247 and the CD3 complex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD3 Complex","termGroup":"PT","termSource":"NCI"},{"termName":"CD3","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Surface Glycoprotein CD3","termGroup":"SY","termSource":"NCI"},{"termName":"T3 Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CD3_Complex"},{"name":"Maps_To","value":"CD3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0108779"}]}}{"C38906":{"preferredName":"Tumor Necrosis Factor Receptor Superfamily Member 8","code":"C38906","definitions":[{"definition":"Tumor necrosis factor receptor superfamily member 8 (595 aa, ~ 64 kDa) is encoded by the human TNFRSF8 gene. This protein is involved in ligand-mediated signal transduction, the positive regulation of apoptosis and the inhibition of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Necrosis Factor Receptor Superfamily Member 8","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD30","termGroup":"SY","termSource":"NCI"},{"termName":"CD30 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD30L Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokine Receptor CD30","termGroup":"SY","termSource":"NCI"},{"termName":"Ki-1 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Activation Antigen CD30","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoid Activation Antigen CD30","termGroup":"SY","termSource":"NCI"},{"termName":"TNF Receptor 8","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Tumor necrosis factor receptor superfamily member 8 is a receptor for TNFSF8/CD30L and interacts with the TRAF1, TRAF2, TRAF3, and TRAF5. (UniProt)"},{"name":"Legacy Concept Name","value":"TNF_Receptor-8"},{"name":"Maps_To","value":"CD30"},{"name":"OMIM_Number","value":"153243"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P28908"},{"name":"UMLS_CUI","value":"C0054950"}]}}{"C97246":{"preferredName":"Myeloid Cell Surface Antigen CD33","code":"C97246","definitions":[{"definition":"Myeloid cell surface antigen CD33 (364 aa, ~40 kDa) is encoded by the human CD33 gene. This protein is involved in the mediation of cell adhesion and the regulation of cell-cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid Cell Surface Antigen CD33","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD33","termGroup":"SY","termSource":"NCI"},{"termName":"CD33 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"gp67","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Differentiation Antigen CD33","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Ig-Like Lectin 3","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Immunoglobulin-Like Lectin 3","termGroup":"SY","termSource":"NCI"},{"termName":"Siglec-3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD33"},{"name":"OMIM_Number","value":"159590"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P20138"},{"name":"UMLS_CUI","value":"C3491277"}]}}{"C17280":{"preferredName":"Hematopoietic Progenitor Cell Antigen CD34","code":"C17280","definitions":[{"definition":"Hematopoietic progenitor cell antigen CD34 (385 aa, ~41 kDa) is encoded by the human CD34 gene. This protein plays a role in cell-cell adhesion and may have a role in leukocyte migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic Progenitor Cell Antigen CD34","termGroup":"PT","termSource":"NCI"},{"termName":"CD34","termGroup":"SY","termSource":"NCI"},{"termName":"gp105-120","termGroup":"SY","termSource":"NCI"},{"termName":"HPCA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"A protein found on the surface of some bone marrow and blood cells. Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow."},{"name":"Legacy Concept Name","value":"CD34_Antigen"},{"name":"Maps_To","value":"CD34"},{"name":"OMIM_Number","value":"142230"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P28906"},{"name":"UMLS_CUI","value":"C0054953"}]}}{"C17282":{"preferredName":"Receptor-Type Tyrosine-Protein Phosphatase C","code":"C17282","definitions":[{"definition":"Receptor-type tyrosine-protein phosphatase C (1304 aa, ~147 kDa) is encoded by the human PTPRC gene. This protein plays a role in protein dephosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Receptor-Type Tyrosine-Protein Phosphatase C","termGroup":"PT","termSource":"NCI"},{"termName":"CD45 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD45RABC","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.1.3.48","termGroup":"SY","termSource":"NCI"},{"termName":"L-CA","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Common Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRC","termGroup":"SY","termSource":"NCI"},{"termName":"Receptor-Type Tyrosine-Protein Phosphatase C Isoform 1","termGroup":"SY","termSource":"NCI"},{"termName":"T200","termGroup":"SY","termSource":"NCI"},{"termName":"T200 Glycoprotein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Protein_Tyrosine_Phosphatase_Receptor_Type-C"},{"name":"Maps_To","value":"CD45"},{"name":"OMIM_Number","value":"151460"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P08575"},{"name":"UMLS_CUI","value":"C1870006"}]}}{"C73124":{"preferredName":"T-Cell Surface Glycoprotein CD5","code":"C73124","definitions":[{"definition":"T-cell surface glycoprotein CD5 (495 aa, ~54 kDa) is encoded by the human CD5 gene. This protein may be involved in regulating the proliferation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Surface Glycoprotein CD5","termGroup":"PT","termSource":"NCI"},{"termName":"CD5 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Antigen CD5","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Antigen T1/Leu-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"T-cell surface glycoprotein CD5 is a membrane bound glycoprotein expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies that specifically bind to CD5 can enhance T-cell receptor-mediated T-cell activation. This protein can bind to CD72 antigen. (Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)"},{"name":"Legacy Concept Name","value":"T-Cell_Surface_Glycoprotein_CD5"},{"name":"Maps_To","value":"CD5"},{"name":"OMIM_Number","value":"153340"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P06127"},{"name":"UMLS_CUI","value":"C0054964"}]}}{"C25276":{"preferredName":"Neural Cell Adhesion Molecule 1","code":"C25276","definitions":[{"definition":"Neural cell adhesion molecule 1 (761 aa, ~84 kDa) is encoded by the human NCAM1 gene. This protein is involved in the mediation of neuron-neuron adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neural Cell Adhesion Molecule 1","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen MSK39 Identified By Monoclonal Antibody 5.1H11","termGroup":"SY","termSource":"NCI"},{"termName":"CD56 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"N-CAM-1","termGroup":"SY","termSource":"NCI"},{"termName":"NCAM","termGroup":"AB","termSource":"NCI"},{"termName":"NCAM-1","termGroup":"SY","termSource":"NCI"},{"termName":"NCAM1","termGroup":"SY","termSource":"NCI"},{"termName":"Neural Cell Adhesion Molecule","termGroup":"SY","termSource":"NCI"},{"termName":"NKH-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Neural Cell Adhesion Molecule is a membrane-bound glycoprotein member of the Ig superfamily that binds to a variety of other cell adhesion proteins involved in diverse contact-mediated interactions.  NCAM appears on early embryonic cells and is important in the formation of cell collectives at sites of morphogenesis.  Later it is found on differentiated neurons, astrocytes, oligodendrocytes, and myotubes and mediates neuronal adhesion, guidance, and differentiation.  NCAM plays a role in cell-cell and cell-matrix adhesion through homophilic and heterophilic binding.  The invertebrate cell adhesion molecules fasciclin II (grasshoppers and Drosophila) and apCAM (Aplysia) are related to NCAM and can mediate homophilic cell aggregation.  Four main isoforms exist, including CD56, but many variants result from alternative splicing and post-translational modifications."},{"name":"Legacy Concept Name","value":"Neural_Cell_Adhesion_Molecule"},{"name":"Maps_To","value":"CD56"},{"name":"OMIM_Number","value":"116930"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P13591"},{"name":"UMLS_CUI","value":"C1999531"}]}}{"C38935":{"preferredName":"T-Cell Antigen CD7","code":"C38935","definitions":[{"definition":"T-cell antigen CD7 (240 aa, ~25 kDa) is encoded by the human CD7 gene. This protein plays a role in the development and function of lymphoid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Antigen CD7","termGroup":"PT","termSource":"NCI"},{"termName":"CD7 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"GP40","termGroup":"SY","termSource":"NCI"},{"termName":"Leu-9","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Leukemia Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"TP41","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Expressed in thymocytes and mature T cells by human CD7 Gene (Immunoglobulin Superfamily), 240-aa 25-kDa (precursor) T-Cell Antigen CD7 is a cell surface type I transmembrane glycoprotein that interacts with SECTM1, contains an Ig-like domain, and is essential in T-cell interactions and in T-cell/B-cell interaction during early lymphoid development. One of the earliest antigens on cells of the T-lymphocyte lineage, CD7 is the most reliable clinical marker of T-cell acute lymphocytic leukemia."},{"name":"Legacy Concept Name","value":"T-Cell_Antigen_CD7"},{"name":"Maps_To","value":"CD7"},{"name":"OMIM_Number","value":"186820"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P09564"},{"name":"UMLS_CUI","value":"C0054968"}]}}{"C97423":{"preferredName":"B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain","code":"C97423","definitions":[{"definition":"B-cell antigen receptor complex-associated protein alpha chain (226 aa, ~25 kDa) is encoded by the human CD79A gene. This protein is involved in the modulation of signaling in and proliferation of B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD79a","termGroup":"SY","termSource":"NCI"},{"termName":"CD79a","termGroup":"SY","termSource":"NCI"},{"termName":"CD79a Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Ig-Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"MB-1 Membrane Glycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane-Bound Immunoglobulin-Associated Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Surface IgM-Associated Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD79A"},{"name":"OMIM_Number","value":"112205"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P11912"},{"name":"UMLS_CUI","value":"C1506239"}]}}{"C16384":{"preferredName":"Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5","code":"C16384","definitions":[{"definition":"Carcinoembryonic antigen-related cell adhesion molecule 5 (702 aa, ~77 kDa) is encoded by the human CEACAM5 gene. This protein is involved in cell-cell adhesion, apotosis regulation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoembryonic Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD66e Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CEA","termGroup":"SY","termSource":"NCI"},{"termName":"CEACAM5","termGroup":"SY","termSource":"NCI"},{"termName":"Meconium Antigen 100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CD66E_Antigen"},{"name":"Maps_To","value":"CEA"},{"name":"OMIM_Number","value":"114890"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P06731"},{"name":"UMLS_CUI","value":"C2352715"}]}}{"C16692":{"preferredName":"HLA-DR Antigen","code":"C16692","definitions":[{"definition":"Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-DR Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-DR","termGroup":"SY","termSource":"NCI"},{"termName":"Human Leukocyte Antigen - DR Isotype","termGroup":"SY","termSource":"NCI"},{"termName":"Human Leukocyte Antigen-DR Isotype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HLA-DR_Antigen"},{"name":"Maps_To","value":"HLA-DR"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0019764"}]}}{"C20887":{"preferredName":"Mesothelin","code":"C20887","definitions":[{"definition":"A protein found on the surface of certain types of normal cells and cancer cells. Mesothelin may help these cells stick together and send signals. A higher-than-normal amount of mesothelin is found on some cancer cells, including mesothelioma, pancreatic cancer, and ovarian cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Mesothelin (630 aa, ~69 kDa) is encoded by the human MSLN gene. This protein may play a role in cellular adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesothelin","termGroup":"PT","termSource":"NCI"},{"termName":"CAK1 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"MSLN","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Pro-Megakaryocyte-Potentiating Factor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"An antibody that reacts with ovarian cancers and mesotheliomas was used to isolate a cell surface antigen named mesothelin. Although the function of mesothelin is unknown, it may play a role in cellular adhesion and is present on mesothelium, mesotheliomas, and ovarian cancers. Three transcript variants have been described for this gene and their protein products were initially named megakaryocyte potentiating factor (MPF), mesothelin, and the soluble member(s) of the mesothelin/MPF family. The protein isoform named MPF is a cytokine with megakaryocyte potentiating activity. The soluble member encoded by the third splice variant is detected in ovarian carcinoma; the full length sequence of the third variant has not been described. (LocusLink)"},{"name":"Legacy Concept Name","value":"Mesothelin"},{"name":"Maps_To","value":"Mesothelin"},{"name":"OMIM_Number","value":"601051"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q13421"},{"name":"UMLS_CUI","value":"C1429990"}]}}{"C62216":{"preferredName":"Gamma-Enolase","code":"C62216","definitions":[{"definition":"Gamma-enolase (434 aa, ~47 kDa) is encoded by the human ENO2 gene. This protein is involved in glycolysis, neurotrophy and neuroprotection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma-Enolase","termGroup":"PT","termSource":"NCI"},{"termName":"2-Phospho-D-Glycerate Hydro-Lyase","termGroup":"SY","termSource":"NCI"},{"termName":"EC 4.2.1.11","termGroup":"SY","termSource":"NCI"},{"termName":"ENO2","termGroup":"SY","termSource":"NCI"},{"termName":"Enolase 2","termGroup":"SY","termSource":"NCI"},{"termName":"Neural Enolase","termGroup":"SY","termSource":"NCI"},{"termName":"Neuron-Specific Enolase","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphopyruvate Hydratase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Gamma-enolase is expressed specifically in neurons."},{"name":"DesignNote","value":"Gamma-enolase protein levels are significantly elevated in brain tumors and Creutzfeld-Jacob disease. Cardiovascular accidents and cerebral trauma also cause dramatic increases in levels of this protein."},{"name":"Legacy Concept Name","value":"Gamma-Enolase"},{"name":"Maps_To","value":"NSE"},{"name":"OMIM_Number","value":"131360"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P09104"},{"name":"UMLS_CUI","value":"C1880904"}]}}{"C17525":{"preferredName":"Prostate-Specific Antigen","code":"C17525","definitions":[{"definition":"A protein made by the prostate gland and found in the blood. Prostate-specific antigen blood levels may be higher than normal in men who have prostate cancer, benign prostatic hyperplasia (BPH), or infection or inflammation of the prostate gland.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate-Specific Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen, Prostate-Specific","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.4.21.77","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-Seminoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Kallikrein-3","termGroup":"SY","termSource":"NCI"},{"termName":"KLK3","termGroup":"SY","termSource":"NCI"},{"termName":"P-30 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Specific Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Specific Antigen Preproprotein","termGroup":"SY","termSource":"NCI"},{"termName":"PSA","termGroup":"AB","termSource":"NCI"},{"termName":"Semenogelase","termGroup":"SY","termSource":"NCI"},{"termName":"Seminin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The serum level of PSA is used in diagnosis and monitoring of prostatic carcinoma, benign prostate hyperplasia, or infection or inflammation of the prostate."},{"name":"Legacy Concept Name","value":"Prostate-Specific_Antigen"},{"name":"Maps_To","value":"Prostate-Specific Antigen (PSA)"},{"name":"OMIM_Number","value":"176820"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P07288"},{"name":"UMLS_CUI","value":"C0138741"}]}}{"C120660":{"preferredName":"Squamous Cell Carcinoma Antigen Measurement","code":"C120660","definitions":[{"definition":"A measurement of the squamous cell carcinoma antigen in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the squamous cell carcinoma antigen present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma Antigen Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Serpin B3/B4 Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Squamous Cell Carcinoma Antigen (SCCA)"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C4049934"}]}}{"C17675":{"preferredName":"Antigen KI-67","code":"C17675","definitions":[{"definition":"Antigen KI-67 protein (3256 aa, ~359 kDa) is encoded by the human MKI67 gene. This protein is required for cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antigen KI-67","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen Identified by Monoclonal Antibody Ki-67","termGroup":"SY","termSource":"NCI"},{"termName":"Ki-67 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"KIA","termGroup":"SY","termSource":"NCI"},{"termName":"MIB-1","termGroup":"SY","termSource":"NCI"},{"termName":"MKI67","termGroup":"SY","termSource":"NCI"},{"termName":"MKI67 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferation-Related Ki-67 Antigen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Antigen KI-67 protein expression occurs during late G1, S, G2, and M phases of the cell cycle, while in cells in G0 phase the protein cannot be detected. The protein is located in the perinucleolar region during G1 phase. In the later phases it is detected throughout the nuclear interior, predominantly in the nuclear matrix. In mitosis, it is present on all chromosomes. (SwissProt)"},{"name":"DesignNote","value":"Detection of Antigen KI-67 is used to locate proliferating cells in neoplastic diseases. (OMIM)"},{"name":"Legacy Concept Name","value":"Proliferation-Related-Ki-67_Antigen"},{"name":"Maps_To","value":"Ki67"},{"name":"NCI_META_CUI","value":"CL963711"},{"name":"OMIM_Number","value":"176741"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P46013"}]}}{"C184770":{"preferredName":"Surface Immunoglobulin Light Chain Kappa","code":"C184770","definitions":[{"definition":"Immunoglobulin kappa proteins expressed on the extracellular surface of the plasma membrane","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surface Immunoglobulin Light Chain Kappa","termGroup":"PT","termSource":"NCI"},{"termName":"Surface Ig Kappa","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Kappa","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Kappa Light Chain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kappa, Surface"},{"name":"NCI_META_CUI","value":"CL1773095"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C184771":{"preferredName":"Surface Immunoglobulin Light Chain Lambda","code":"C184771","definitions":[{"definition":"Immunoglobulin lambda proteins expressed on the extracellular surface of the plasma membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surface Immunoglobulin Light Chain Lambda","termGroup":"PT","termSource":"NCI"},{"termName":"Surface Ig Lambda","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Lambda","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Lambda Light Chain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lambda, Surface"},{"name":"NCI_META_CUI","value":"CL1773092"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C1269":{"preferredName":"TAG-72 Antigen","code":"C1269","definitions":[{"definition":"A protein/sugar complex found on the surface of many cancer cells, including breast, colon, and pancreatic cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Tumor-associated oncofetal glycoprotein 72 (TAG-72) is a high molecular weight (220-400 kD) complex expressed by a wide variety of human adenocarcinomas. This antigen is expressed by a majority of invasive ductal breast carcinomas, and most colon, pancreatic, gastric, esophageal, lung (non-small cell), ovarian and endometrial adenocarcinomas, and on normal secretory endometrium, but not on other normal tissues. It is not expressed by leukemias, lymphomas, sarcomas, mesotheliomas, melanomas or benign tumors. The monoclonal antibodies against TAG-72 have been widely employed for the immunohistochemical analysis of adenocarcinomas as well as for radioimmunoscintigraphy and radioimmunoguided surgery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAG-72 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"Antitumor-Associated Glycoprotein 72","termGroup":"SY","termSource":"NCI"},{"termName":"CA 72-4","termGroup":"SY","termSource":"NCI"},{"termName":"CA-72-4","termGroup":"SY","termSource":"NCI"},{"termName":"CA72-4","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Antigen 72-4","termGroup":"SY","termSource":"NCI"},{"termName":"TAG-72","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TAG-72_Antigen"},{"name":"Maps_To","value":"TAG-72"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0077505"}]}}{"C172121":{"preferredName":"Cytoplasmic Immunoglobulin","code":"C172121","definitions":[{"definition":"Immunoglobulins found within intact cells. The proportion of cells expressing cytoplasmic immunoglobulin can be a diagnostic criterion in B-cell lymphoproliferative disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytoplasmic Immunoglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"cIg","termGroup":"SY","termSource":"NCI"},{"termName":"Cytoplasmic Ig","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunoglobulin, Cytoplasmic"},{"name":"NCI_META_CUI","value":"CL1406231"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C573":{"preferredName":"Surface Immunoglobulin","code":"C573","definitions":[{"definition":"Immunoglobulin containing a transmembrane region and expressed on the plasma membrane of a B cell.  Contrast with secreted Ig which has no transmembrane region but which can still be bound to the cell surface via Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surface Immunoglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"sIg","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Ig","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Surface_Immunoglobulin"},{"name":"Maps_To","value":"Immunoglobulin, Surface"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0034789"}]}}{"C101153":{"preferredName":"Leukosialin","code":"C101153","definitions":[{"definition":"Leukosialin (400 aa, ~40 kDa) is encoded by the human SPN gene. This protein is involved in immune cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leukosialin","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD43","termGroup":"SY","termSource":"NCI"},{"termName":"CD43","termGroup":"SY","termSource":"NCI"},{"termName":"CD43 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Galactoglycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"GALGP","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Large Sialoglycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Sialoglycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Sialophorin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD43"},{"name":"OMIM_Number","value":"182160"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P16150"},{"name":"UMLS_CUI","value":"C1434437"}]}}{"C84507":{"preferredName":"Buffy Coat","code":"C84507","definitions":[{"definition":"The middle fraction of an anticoagulated blood specimen following separation by centrifugation. It contains most of the white blood cells and platelets.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The middle layer of an anticoagulated blood specimen following separation by centrifugation. It contains most of the white blood cells and platelets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buffy Coat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buffy Coat"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0443089"}]}}{"C12374":{"preferredName":"Connective Tissue","code":"C12374","definitions":[{"definition":"Supporting tissue that surrounds other tissues and organs. Specialized connective tissue includes bone, cartilage, blood, and fat.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Supporting tissue that surrounds other tissues and organs. Specialized connective tissue includes bone, cartilage, blood, and fat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The supporting or framework tissue of the animal body, formed of fibrous and ground substance with more or less numerous cells of various kinds; it is derived from the mesenchyme, and this in turn from the mesoderm; the varieties of connective tissue are: areolar or loose; adipose; dense, regular or irregular, white fibrous; elastic; mucous; and lymphoid tissue; cartilage; and bone; the blood and lymph may be regarded as connective tissues the ground substance of which is a liquid.","type":"DEFINITION","source":"NCI"},{"definition":"The supporting or framework tissue of the body, formed of fibrous and ground substance with a variety of cell types. The varieties of connective tissue are: areolar or loose; adipose; dense, regular or irregular, white fibrous; elastic; mucous; lymphoid tissue; cartilage; bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Connective Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Connective_Tissue"},{"name":"Maps_To","value":"Connective Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0009780"},{"name":"xRef","value":"UBERON:0002384"}]}}{"C13398":{"preferredName":"Embryonic Fluid","code":"C13398","definitions":[{"definition":"Fluids surrounding or related to an embryo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonic Fluid","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonic Fluids","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonic Tissue, Fluids, Secretions","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Embryonic_Fluid"},{"name":"Maps_To","value":"Embryonic Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C1516820"}]}}{"C12950":{"preferredName":"Embryonic Tissue","code":"C12950","definitions":[{"definition":"Tissue that is formed during the embryonic stage of life of an organism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonic Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Embryonic_Tissue"},{"name":"Maps_To","value":"Embryonic Tissue"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0920502"}]}}{"C13234":{"preferredName":"Feces","code":"C13234","definitions":[{"definition":"The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.","type":"DEFINITION","source":"NCI"},{"definition":"The material discharged from the bowel during defecation. It consists of undigested food, intestinal mucus, epithelial cells, and bacteria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The material in a bowel movement. Feces is made up of undigested food, bacteria, mucus, and cells from the lining of the intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Feces","termGroup":"PT","termSource":"NCI"},{"termName":"Fecal","termGroup":"AD","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Feces","termGroup":"SY","termSource":"NCI"},{"termName":"Stool","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Feces"},{"name":"Maps_To","value":"Feces"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0015733"}]}}{"C12530":{"preferredName":"Granulocyte","code":"C12530","definitions":[{"definition":"A type of immune cell that has granules (small particles) with enzymes that are released during infections, allergic reactions, and asthma. Neutrophils, eosinophils, and basophils are granulocytes. A granulocyte is a type of white blood cell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of leukocyte containing a nucleus and cytoplasmic granules. Granulocytes are subdivided according to the staining properties of their granules into eosinophils, basophils, and neutrophils.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of leukocyte with a multilobed nucleus and cytoplasmic granules. The unique morphology of the nucleus has led to their also being known as polymorphonuclear leukocytes (PMLs or PMNs). Granulocytes are subdivided according to the staining properties of their granules into eosinophils (red with acidic dye), basophils (blue with basic dye), and neutrophils (not amenable to staining with either acidic or basic dyes).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granulocyte","termGroup":"PT","termSource":"NCI"},{"termName":"Granular Leukocyte","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Leukocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Granulocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Granulocytic","termGroup":"AD","termSource":"NCI"},{"termName":"Granulocytic Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphonuclear Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphonuclear Leukocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Granulocyte"},{"name":"Maps_To","value":"Granulocyte"},{"name":"Maps_To","value":"Granulocytes"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0018183"}]}}{"C18009":{"preferredName":"Tumor Tissue Sample","code":"C18009","definitions":[{"definition":"A tumor sample, or entire tumor that is removed for examination.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue sample that contains an abnormal cellular infiltrate forming a solid mass. The abnormal cellular component can be benign or malignant. Tumor samples are obtained for microscopic examination and/or molecular analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Tissue Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Tumor Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Tumor_Tissue"},{"name":"Maps_To","value":"Involved Tissue, NOS"},{"name":"Maps_To","value":"Tumor"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0475358"}]}}{"C12435":{"preferredName":"Muscle Tissue","code":"C12435","definitions":[{"definition":"Tissue responsible for body and internal organ movement. Muscle tissue is composed of specialized contractile cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue responsible for the body movements and the shape and size changes of internal organs.  Muscle tissue is composed of specialized contractile cells.  There are two types of muscle tissue recognized: striated and smooth muscle.  The striated muscle tissue is further subdivided into skeletal, visceral striated, and cardiac muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Muscle Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Muscle_Tissue"},{"name":"Maps_To","value":"Muscle Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C2328219"}]}}{"C13052":{"preferredName":"Nerve Tissue","code":"C13052","definitions":[{"definition":"The tissue that generates and conducts electrical signals in the body.  It contains the neurons.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Nervous Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nervous_Tissue"},{"name":"Maps_To","value":"Nerve Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0027757"}]}}{"C77612":{"preferredName":"Peritoneal Fluid","code":"C77612","definitions":[{"definition":"A liquid that is made in the abdominal cavity to lubricate the surface of the tissue that lines the abdominal wall and pelvic cavity and covers most of the organs in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid within the peritoneal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The small amount of fluid that is generated in the abdominal cavity to lubricate the peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneal Fluid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peritoneal_Fluid"},{"name":"Maps_To","value":"Peritoneal Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0003964"}]}}{"C13356":{"preferredName":"Plasma","code":"C13356","definitions":[{"definition":"Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.","type":"DEFINITION","source":"NCI"},{"definition":"The clear, yellowish, fluid part of the blood that carries the blood cells. The proteins that form blood clots are in plasma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid (acellular) portion of the circulating blood with retained clotting components.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Plasma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Plasma"},{"name":"Maps_To","value":"Plasma"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0032105"}]}}{"C77613":{"preferredName":"Pleural Fluid","code":"C77613","definitions":[{"definition":"The fluid that is ordinarily present in the pleural space. It allows for normal movement of the lungs during respiration.","type":"DEFINITION","source":"NCI"},{"definition":"The fluid within the pleural cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pleural Fluid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Pleural_Fluid"},{"name":"Maps_To","value":"Pleural Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0225778"}]}}{"C13275":{"preferredName":"Saliva","code":"C13275","definitions":[{"definition":"A clear liquid secreted by the salivary glands.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The watery fluid in the mouth made by the salivary glands. Saliva moistens food to help digestion and it helps protect the mouth against infections.","type":"DEFINITION","source":"NCI"},{"definition":"The watery fluid in the mouth made by the salivary glands. Saliva moistens food to help digestion and it helps protect the mouth against infections.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Saliva","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Saliva","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Saliva"},{"name":"Maps_To","value":"Saliva"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0036087"}]}}{"C13325":{"preferredName":"Serum","code":"C13325","definitions":[{"definition":"The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins.","type":"DEFINITION","source":"NCI"},{"definition":"The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Serum","termGroup":"PT","termSource":"NCI"},{"termName":"Sera","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Serum"},{"name":"Maps_To","value":"Serum"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0229671"}]}}{"C12801":{"preferredName":"Tissue","code":"C12801","definitions":[{"definition":"A group or layer of cells that work together to perform a specific function.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.","type":"DEFINITION","source":"NCI"},{"definition":"An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Normal Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tissues","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Tissue"},{"name":"Maps_To","value":"Tissue, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0040300"}]}}{"C162623":{"preferredName":"Normal Tissue Sample","code":"C162623","definitions":[{"definition":"Tissue sample with cellular composition and architectural patterns expected for the particular anatomic site in which it belongs. There is no evidence of abnormal cellular infiltrates or tumor mass formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Normal Tissue Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Normal Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Normal Tissue Segment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uninvolved Tissue, NOS"},{"name":"NCI_META_CUI","value":"CL971063"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C13283":{"preferredName":"Urine","code":"C13283","definitions":[{"definition":"Fluid containing water and waste products. Urine is made by the kidneys, stored in the bladder, and leaves the body through the urethra.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid produced by the kidneys.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fluid that is excreted by the kidneys.  It is stored in the bladder and discharged through the urethra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urine","termGroup":"PT","termSource":"NCI"},{"termName":"Urinary System, Urine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Urine"},{"name":"Maps_To","value":"Urine"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0042036"}]}}{"C13204":{"preferredName":"Human Chromosome 1","code":"C13204","definitions":[{"definition":"The designation for each member of the largest human autosomal chromosome pair. Chromosome 1 spans about 247 million nucleotide base pairs and represents about 8% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 1","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_1"},{"name":"Maps_To","value":"chr1"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008651"}]}}{"C13215":{"preferredName":"Human Chromosome 2","code":"C13215","definitions":[{"definition":"The designation for each member of the second largest human autosomal chromosome pair. Chromosome 2 spans more than 237 million base pairs and represents almost 8% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 2","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_2"},{"name":"Maps_To","value":"chr2"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008662"}]}}{"C13219":{"preferredName":"Human Chromosome 3","code":"C13219","definitions":[{"definition":"The designation for each member of the third largest human autosomal chromosome pair. Chromosome 3 spans almost 200 million base pairs and represents about 6.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 3","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_3"},{"name":"Maps_To","value":"chr3"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008666"}]}}{"C13220":{"preferredName":"Human Chromosome 4","code":"C13220","definitions":[{"definition":"The designation for each member of the fourth largest human autosomal chromosome pair. Chromosome 4 spans more than 186 million base pairs and represents between 6 and 6.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 4","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_4"},{"name":"Maps_To","value":"chr4"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008667"}]}}{"C13221":{"preferredName":"Human Chromosome 5","code":"C13221","definitions":[{"definition":"The designation for each member of the fifth largest human autosomal chromosome pair. Chromosome 5 spans about 181 million base pairs and represents almost 6% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 5","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_5"},{"name":"Maps_To","value":"chr5"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008668"}]}}{"C13222":{"preferredName":"Human Chromosome 6","code":"C13222","definitions":[{"definition":"The designation for each member of the sixth largest human autosomal chromosome pair. Chromosome 6 spans more than 170 million base pairs and represents between 5.5 and 6% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 6","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_6"},{"name":"Maps_To","value":"chr6"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008669"}]}}{"C13223":{"preferredName":"Human Chromosome 7","code":"C13223","definitions":[{"definition":"The designation for each member of the seventh largest human autosomal chromosome pair. Chromosome 7 spans more than 158 million base pairs and represents between 5 and 5.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 7","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_7"},{"name":"Maps_To","value":"chr7"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008670"}]}}{"C13224":{"preferredName":"Human Chromosome 8","code":"C13224","definitions":[{"definition":"The designation for each member of the eighth largest human autosomal chromosome pair. Chromosome 8 spans about 145 million base pairs and represents between 4.5 and 5.0% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 8","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_8"},{"name":"Maps_To","value":"chr8"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008671"}]}}{"C13225":{"preferredName":"Human Chromosome 9","code":"C13225","definitions":[{"definition":"The designation for each member of the ninth largest human autosomal chromosome pair. Chromosome 9 spans about 145 million base pairs of nucleic acids and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 9","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_9"},{"name":"Maps_To","value":"chr9"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008672"}]}}{"C13205":{"preferredName":"Human Chromosome 10","code":"C13205","definitions":[{"definition":"The designation for each member of the tenth largest human autosomal chromosome pair. Chromosome 10 spans about 135 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 10","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_10"},{"name":"Maps_To","value":"chr10"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008652"}]}}{"C13206":{"preferredName":"Human Chromosome 11","code":"C13206","definitions":[{"definition":"The designation for each member of the eleventh largest human autosomal chromosome pair. Chromosome 11 spans about 134.5 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 11","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_11"},{"name":"Maps_To","value":"chr11"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008653"}]}}{"C13207":{"preferredName":"Human Chromosome 12","code":"C13207","definitions":[{"definition":"The designation for each member of the twelfth largest human autosomal chromosome pair. Chromosome 12 spans about 143 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 12","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_12"},{"name":"Maps_To","value":"chr12"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008654"}]}}{"C13208":{"preferredName":"Human Chromosome 13","code":"C13208","definitions":[{"definition":"The designation for each member of the thirteenth largest human autosomal chromosome pair. Chromosome 13 spans about 113 million base pairs and represents between 3.5 and 4% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 13","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_13"},{"name":"Maps_To","value":"chr13"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008655"}]}}{"C13209":{"preferredName":"Human Chromosome 14","code":"C13209","definitions":[{"definition":"The designation for each member of the fourteenth largest human autosomal chromosome pair. Chromosome 14 spans about 105 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 14","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 14","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_14"},{"name":"Maps_To","value":"chr14"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008656"}]}}{"C13210":{"preferredName":"Human Chromosome 15","code":"C13210","definitions":[{"definition":"The designation for each member of the fifteenth largest human autosomal chromosome pair. Chromosome 15 spans about 106 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 15","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_15"},{"name":"Maps_To","value":"chr15"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008657"}]}}{"C13211":{"preferredName":"Human Chromosome 16","code":"C13211","definitions":[{"definition":"The designation for each member of the sixteenth largest human autosomal chromosome pair. Chromosome 16 spans about 90 million base pairs and represents just under 3% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 16","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 16","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_16"},{"name":"Maps_To","value":"chr16"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008658"}]}}{"C13212":{"preferredName":"Human Chromosome 17","code":"C13212","definitions":[{"definition":"The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 17","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 17","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_17"},{"name":"Maps_To","value":"chr17"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008659"}]}}{"C13213":{"preferredName":"Human Chromosome 18","code":"C13213","definitions":[{"definition":"The designation for each member of the eighteenth largest human autosomal chromosome pair. Chromosome 18 spans about 76 million base pairs and represents about 2.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 18","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 18","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_18"},{"name":"Maps_To","value":"chr18"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008660"}]}}{"C13214":{"preferredName":"Human Chromosome 19","code":"C13214","definitions":[{"definition":"The designation for each member of the nineteenth largest human autosomal chromosome pair. Chromosome 19 spans more than 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 19","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_19"},{"name":"Maps_To","value":"chr19"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008661"}]}}{"C13216":{"preferredName":"Human Chromosome 20","code":"C13216","definitions":[{"definition":"The designation for each member of the third smallest human autosomal chromosome pair. Chromosome 20 spans around 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 20","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_20"},{"name":"Maps_To","value":"chr20"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008663"}]}}{"C13217":{"preferredName":"Human Chromosome 21","code":"C13217","definitions":[{"definition":"The designation for each member of the second smallest human autosomal chromosome pair. Chromosome 21 spans around 47 million nucleotides and represents about 1.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 21","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 21","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_21"},{"name":"Maps_To","value":"chr21"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008664"}]}}{"C13218":{"preferredName":"Human Chromosome 22","code":"C13218","definitions":[{"definition":"The designation for each member of the smallest human autosomal chromosome pair. Chromosome 22 spans about 49 million base pairs and represents between 1.5 and 2% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 22","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 22","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_22"},{"name":"Maps_To","value":"chr22"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008665"}]}}{"C33542":{"preferredName":"Human Chromosome 23","code":"C33542","definitions":[{"definition":"The X or Y chromosome in human beings that determines the sex of an individual. Females have two X chromosomes in diploid cells; males have an X and a Y chromosome. The sex chromosomes comprise the 23rd chromosome pair in a human karyotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 23","termGroup":"PT","termSource":"NCI"},{"termName":"Chr23","termGroup":"SY","termSource":"NCI"},{"termName":"Human Sex Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Chromosome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sex_Chromosome"},{"name":"Maps_To","value":"chr23"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0036869"}]}}{"C28512":{"preferredName":"Mitochondrial DNA","code":"C28512","definitions":[{"definition":"Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitochondrial DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Mitochondrial Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"mtDNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mitochondrial_DNA"},{"name":"Maps_To","value":"chrM"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0012929"}]}}{"C13285":{"preferredName":"Human Chromosome X","code":"C13285","definitions":[{"definition":"The larger of the two human sex chromosomes. It is usually present singly in males and doubly in females.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome X","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome X","termGroup":"SY","termSource":"NCI"},{"termName":"Human X Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"X Chromosome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_X"},{"name":"Maps_To","value":"chrX"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0043292"}]}}{"C13286":{"preferredName":"Human Chromosome Y","code":"C13286","definitions":[{"definition":"The smaller of the two human sex chromosome. Its presence usually determines the development of a fetus as male, while its absence usually determines the development of a fetus as female.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome Y","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Y","termGroup":"SY","termSource":"NCI"},{"termName":"Human Y Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"Y Chromosome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_Y"},{"name":"Maps_To","value":"chrY"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0043381"}]}}{"C41179":{"preferredName":"Monoclonal Cellular Population Present","code":"C41179","definitions":[{"definition":"A finding indicating that a monoclonal population of cells were detected in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Cellular Population Present","termGroup":"PT","termSource":"NCI"},{"termName":"Clonal Cellular Population Present","termGroup":"SY","termSource":"NCI"},{"termName":"Monotypic Cell Population Present","termGroup":"SY","termSource":"NCI"},{"termName":"Monotypic Cells Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clonal_Cellular_Population_Present"},{"name":"Maps_To","value":"Clonal"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C1516667"}]}}{"C172229":{"preferredName":"Nonclonal Cellular Population Present","code":"C172229","definitions":[{"definition":"An indication that the cells in a sample did not arise from a single progenitor cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonclonal Cellular Population Present","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Clonal Cellular Population Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-clonal"},{"name":"NCI_META_CUI","value":"CL1406096"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C143031":{"preferredName":"A1CF Gene","code":"C143031","definitions":[{"definition":"This gene is involved in the deamination of APOB mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"A1CF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"A1CF","termGroup":"SY","termSource":"NCI"},{"termName":"APOBEC1 Complementation Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24086"},{"name":"Maps_To","value":"A1CF"},{"name":"NCI_META_CUI","value":"CL541489"},{"name":"OMIM_Number","value":"618199"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24824":{"preferredName":"ABI1 Gene","code":"C24824","definitions":[{"definition":"This gene plays a role in signal transduction and negative regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABI1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ABI1","termGroup":"SY","termSource":"NCI"},{"termName":"ABL Interactor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11320"},{"name":"Legacy Concept Name","value":"SSH3BP1_Gene"},{"name":"Maps_To","value":"ABI1"},{"name":"OMIM_Number","value":"603050"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335864"}]}}{"C17346":{"preferredName":"ABL1 Gene","code":"C17346","definitions":[{"definition":"This gene is involved in cell adhesion, differentiation, division and stress response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ABL","termGroup":"SY","termSource":"NCI"},{"termName":"ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:76"},{"name":"Legacy Concept Name","value":"ABL1_Gene"},{"name":"Maps_To","value":"ABL1"},{"name":"OMIM_Number","value":"189980"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412097"}]}}{"C18451":{"preferredName":"ABL2 Gene","code":"C18451","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ABL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:77"},{"name":"Legacy Concept Name","value":"ABL2_Gene"},{"name":"Maps_To","value":"ABL2"},{"name":"OMIM_Number","value":"164690"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812381"}]}}{"C91369":{"preferredName":"ACKR3 Gene","code":"C91369","definitions":[{"definition":"This gene is involved in the regulation of chemokine signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACKR3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACKR3","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Chemokine Receptor 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CXCR7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23692"},{"name":"Maps_To","value":"ACKR3"},{"name":"OMIM_Number","value":"610376"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1835886"}]}}{"C97365":{"preferredName":"ACSL3 Gene","code":"C97365","definitions":[{"definition":"This gene is involved in lipid biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACSL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACSL3","termGroup":"SY","termSource":"NCI"},{"termName":"Acyl-CoA Synthetase Long-Chain Family Member 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3570"},{"name":"Maps_To","value":"ACSL3"},{"name":"OMIM_Number","value":"602371"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414519"}]}}{"C97519":{"preferredName":"ACSL6 Gene","code":"C97519","definitions":[{"definition":"This gene is involved in the biosynthesis of lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACSL6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACSL6","termGroup":"SY","termSource":"NCI"},{"termName":"Acyl-CoA Synthetase Long-Chain Family Member 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16496"},{"name":"Maps_To","value":"ACSL6"},{"name":"OMIM_Number","value":"604443"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424328"}]}}{"C21267":{"preferredName":"ACVR1 Gene","code":"C21267","definitions":[{"definition":"This gene plays a role in the transforming growth factor-beta signal transduction pathway through serine/threonine specificity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACVR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Activin A Receptor Type 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ACVR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:171"},{"name":"Legacy Concept Name","value":"ACVR1_Gene"},{"name":"Maps_To","value":"ACVR1"},{"name":"OMIM_Number","value":"102576"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332012"}]}}{"C21271":{"preferredName":"ACVR2A Gene","code":"C21271","definitions":[{"definition":"This gene plays a role in the transforming growth factor-beta signal transduction pathway through constitutive kinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACVR2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Activin A Receptor, Type II Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ACVR2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:173"},{"name":"Legacy Concept Name","value":"ACVR2_Gene"},{"name":"Maps_To","value":"ACVR2A"},{"name":"OMIM_Number","value":"102581"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1706636"}]}}{"C24602":{"preferredName":"AFF1 Gene","code":"C24602","definitions":[{"definition":"This gene is involved in the regulation of transcription elongation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF4","termGroup":"SY","termSource":"NCI"},{"termName":"AF4/FMR2 Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFF1","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7135"},{"name":"Legacy Concept Name","value":"MLLT2_Gene"},{"name":"Maps_To","value":"AFF1"},{"name":"OMIM_Number","value":"159557"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826604"}]}}{"C24538":{"preferredName":"AFF3 Gene","code":"C24538","definitions":[{"definition":"This gene is involved in transcriptional activation and is purported to play roles in lymphoid development and oncogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF4/FMR2 Family, Member 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6473"},{"name":"Legacy Concept Name","value":"LAF4_Gene"},{"name":"Maps_To","value":"AFF3"},{"name":"OMIM_Number","value":"601464"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1708616"}]}}{"C21385":{"preferredName":"AFF4 Gene","code":"C21385","definitions":[{"definition":"This gene plays a regulatory role in transcription and is involved in male germ cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF4/FMR2 Family Member 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFF4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17869"},{"name":"Legacy Concept Name","value":"AF5Q31_Gene"},{"name":"Maps_To","value":"AFF4"},{"name":"OMIM_Number","value":"604417"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1706652"}]}}{"C21305":{"preferredName":"AKAP9 Gene","code":"C21305","definitions":[{"definition":"This gene plays a role in signal transduction and modulates synaptic transmission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKAP9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"A-Kinase Anchor Protein 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKAP9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:379"},{"name":"Legacy Concept Name","value":"AKAP9_Gene"},{"name":"Maps_To","value":"AKAP9"},{"name":"OMIM_Number","value":"604001"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332072"}]}}{"C18350":{"preferredName":"AKT1 Gene","code":"C18350","definitions":[{"definition":"This gene is involved in signal transduction and negative regulation of apoptosis. It also plays a role in glucose transport, glycogen synthesis, protein synthesis and neuronal survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Serine/Threonine Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:391"},{"name":"Legacy Concept Name","value":"AKT1_Gene"},{"name":"Maps_To","value":"AKT1"},{"name":"OMIM_Number","value":"164730"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812228"}]}}{"C18352":{"preferredName":"AKT2 Gene","code":"C18352","definitions":[{"definition":"This gene plays a role in glucose homeostasis and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Serine/Threonine Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKT2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:392"},{"name":"Legacy Concept Name","value":"AKT2_Gene"},{"name":"Maps_To","value":"AKT2"},{"name":"OMIM_Number","value":"164731"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812230"}]}}{"C20937":{"preferredName":"AKT3 Gene","code":"C20937","definitions":[{"definition":"This gene is involved in signal transduction and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Serine/Threonine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:393"},{"name":"Legacy Concept Name","value":"AKT3_Gene"},{"name":"Maps_To","value":"AKT3"},{"name":"OMIM_Number","value":"611223"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332074"}]}}{"C84921":{"preferredName":"ALDH2 Gene","code":"C84921","definitions":[{"definition":"This gene plays a role in intermediary metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALDH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Aldehyde Dehydrogenase 2 Family Member Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ALDH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:404"},{"name":"Maps_To","value":"ALDH2"},{"name":"OMIM_Number","value":"100650"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412335"}]}}{"C38184":{"preferredName":"ALK Gene","code":"C38184","definitions":[{"definition":"This gene is involved in brain development and neuronal specificity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ALK","termGroup":"SY","termSource":"NCI"},{"termName":"ALK Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:427"},{"name":"Legacy Concept Name","value":"ALK_Gene"},{"name":"Maps_To","value":"ALK"},{"name":"OMIM_Number","value":"105590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332080"}]}}{"C68718":{"preferredName":"AMER1 Gene","code":"C68718","definitions":[{"definition":"This gene may play a role in kidney development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AMER1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AMER1","termGroup":"SY","termSource":"NCI"},{"termName":"APC Membrane Recruitment Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAM123B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26837"},{"name":"Legacy Concept Name","value":"FAM123B_Gene"},{"name":"Maps_To","value":"AMER1"},{"name":"OMIM_Number","value":"300647"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825263"}]}}{"C84301":{"preferredName":"ANK1 Gene","code":"C84301","definitions":[{"definition":"This gene plays a role in red blood cell morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ANK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ANK1","termGroup":"SY","termSource":"NCI"},{"termName":"Ankyrin 1, Erythrocytic Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:492"},{"name":"Maps_To","value":"ANK1"},{"name":"OMIM_Number","value":"612641"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412402"}]}}{"C17567":{"preferredName":"APC Gene","code":"C17567","definitions":[{"definition":"This gene plays a role in signal transduction. It is involved in both adhesion and migration of cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"APC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"APC","termGroup":"SY","termSource":"NCI"},{"termName":"APC Regulator of WNT Signaling Pathway Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:583"},{"name":"Legacy Concept Name","value":"APC_Gene"},{"name":"Maps_To","value":"APC"},{"name":"OMIM_Number","value":"611731"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0162832"}]}}{"C117001":{"preferredName":"APOBEC3B Gene","code":"C117001","definitions":[{"definition":"This gene plays a role in viral DNA cytosine deamination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"APOBEC3B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"APOBEC3B","termGroup":"SY","termSource":"NCI"},{"termName":"Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17352"},{"name":"Maps_To","value":"APOBEC3B"},{"name":"OMIM_Number","value":"607110"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424925"}]}}{"C28539":{"preferredName":"AR Gene","code":"C28539","definitions":[{"definition":"This gene plays a role in the transcriptional activation of androgen responsive genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor (Dihydrotestosterone Receptor; Testicular Feminization; Spinal and Bulbar Muscular Atrophy; Kennedy Disease) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:644"},{"name":"Legacy Concept Name","value":"AR_Gene"},{"name":"Maps_To","value":"AR"},{"name":"OMIM_Number","value":"313700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367578"}]}}{"C18354":{"preferredName":"ARAF Gene","code":"C18354","definitions":[{"definition":"This gene plays a role in signal transduction and the cellular response to mitogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARAF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"A-Raf Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ARAF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:646"},{"name":"Legacy Concept Name","value":"ARAF1_Gene"},{"name":"Maps_To","value":"ARAF"},{"name":"OMIM_Number","value":"311010"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538917"}]}}{"C97504":{"preferredName":"ARHGAP26 Gene","code":"C97504","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARHGAP26 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARHGAP26","termGroup":"SY","termSource":"NCI"},{"termName":"Rho GTPase Activating Protein 26 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17073"},{"name":"Maps_To","value":"ARHGAP26"},{"name":"OMIM_Number","value":"605370"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538925"}]}}{"C97279":{"preferredName":"ARHGAP5 Gene","code":"C97279","definitions":[{"definition":"This gene is involved in the regulation of GTPase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARHGAP5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARHGAP5","termGroup":"SY","termSource":"NCI"},{"termName":"Rho GTPase Activating Protein 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:675"},{"name":"Maps_To","value":"ARHGAP5"},{"name":"OMIM_Number","value":"602680"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412522"}]}}{"C97436":{"preferredName":"ARHGEF12 Gene","code":"C97436","definitions":[{"definition":"This gene plays a role in both G-protein coupled receptor- and Rho-mediated signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARHGEF12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARHGEF12","termGroup":"SY","termSource":"NCI"},{"termName":"Rho Guanine Nucleotide Exchange Factor (GEF) 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14193"},{"name":"Maps_To","value":"ARHGEF12"},{"name":"OMIM_Number","value":"604763"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422475"}]}}{"C92530":{"preferredName":"ARID1A Gene","code":"C92530","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARID1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARID1A","termGroup":"SY","termSource":"NCI"},{"termName":"AT Rich Interactive Domain 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11110"},{"name":"Maps_To","value":"ARID1A"},{"name":"OMIM_Number","value":"603024"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420251"}]}}{"C102520":{"preferredName":"ARID1B Gene","code":"C102520","definitions":[{"definition":"This gene plays a role in both chromatin remodeling and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARID1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARID1B","termGroup":"SY","termSource":"NCI"},{"termName":"AT-Rich Interactive Domain 1B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18040"},{"name":"Maps_To","value":"ARID1B"},{"name":"OMIM_Number","value":"614556"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425260"}]}}{"C101088":{"preferredName":"ARID2 Gene","code":"C101088","definitions":[{"definition":"This gene is involved in both transcriptional regulation and chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARID2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARID2","termGroup":"SY","termSource":"NCI"},{"termName":"AT-Rich Interactive Domain 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18037"},{"name":"Maps_To","value":"ARID2"},{"name":"OMIM_Number","value":"609539"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425257"}]}}{"C26373":{"preferredName":"ARNT Gene","code":"C26373","definitions":[{"definition":"This gene is involved in xenobiotic metabolism and receptor-ligand mediated interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARNT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARNT","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Nuclear Translocator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:700"},{"name":"Legacy Concept Name","value":"ARNT_Gene"},{"name":"Maps_To","value":"ARNT"},{"name":"OMIM_Number","value":"126110"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332116"}]}}{"C70991":{"preferredName":"ASPSCR1 Gene","code":"C70991","definitions":[{"definition":"This gene is involved in the modulation of blood glucose levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASPSCR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ASPSCR1","termGroup":"SY","termSource":"NCI"},{"termName":"ASPSCR1 Tether for SLC2A4, UBX Domain Containing Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13825"},{"name":"Legacy Concept Name","value":"ASPSCR1_Gene"},{"name":"Maps_To","value":"ASPSCR1"},{"name":"OMIM_Number","value":"606236"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422219"}]}}{"C97320":{"preferredName":"ASXL1 Gene","code":"C97320","definitions":[{"definition":"This gene may be involved in both transcriptional regulation and chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASXL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ASXL Transcriptional Regulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ASXL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18318"},{"name":"Maps_To","value":"ASXL1"},{"name":"OMIM_Number","value":"612990"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425445"}]}}{"C116296":{"preferredName":"ASXL2 Gene","code":"C116296","definitions":[{"definition":"This gene plays a role in both chromatin modification and the positive regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASXL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Additional Sex Combs Like 2 (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ASXL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23805"},{"name":"Maps_To","value":"ASXL2"},{"name":"OMIM_Number","value":"612991"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428272"}]}}{"C92177":{"preferredName":"ATF1 Gene","code":"C92177","definitions":[{"definition":"This gene is involved in the modulation of transcription of genes with promoters containing a cAMP response element.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Activating Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ATF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:783"},{"name":"Maps_To","value":"ATF1"},{"name":"OMIM_Number","value":"123803"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412615"}]}}{"C97400":{"preferredName":"ATIC Gene","code":"C97400","definitions":[{"definition":"This gene plays a role in purine biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATIC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP Cyclohydrolase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ATIC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:794"},{"name":"Maps_To","value":"ATIC"},{"name":"OMIM_Number","value":"601731"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412625"}]}}{"C18583":{"preferredName":"ATM Gene","code":"C18583","definitions":[{"definition":"This gene is involved in apoptosis, DNA repair and cell cycle regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATM","termGroup":"SY","termSource":"NCI"},{"termName":"ATM Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:795"},{"name":"Legacy Concept Name","value":"ATM_Gene"},{"name":"Maps_To","value":"ATM"},{"name":"OMIM_Number","value":"607585"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919524"}]}}{"C113762":{"preferredName":"ATP1A1 Gene","code":"C113762","definitions":[{"definition":"This gene is involved in both ion transport and ATP metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATP1A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATP1A1","termGroup":"SY","termSource":"NCI"},{"termName":"ATPase Na+/K+ Transporting Subunit Alpha 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:799"},{"name":"Maps_To","value":"ATP1A1"},{"name":"OMIM_Number","value":"182310"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412628"}]}}{"C113765":{"preferredName":"ATP2B3 Gene","code":"C113765","definitions":[{"definition":"This gene plays a role in ATP-dependent calcium transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATP2B3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATP2B3","termGroup":"SY","termSource":"NCI"},{"termName":"ATPase Plasma Membrane Ca2+ Transporting 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:816"},{"name":"Maps_To","value":"ATP2B3"},{"name":"OMIM_Number","value":"300014"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412642"}]}}{"C20560":{"preferredName":"ATR Gene","code":"C20560","definitions":[{"definition":"This gene is involved in cell cycle checkpoints and DNA recombination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATR","termGroup":"SY","termSource":"NCI"},{"termName":"ATR Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:882"},{"name":"Legacy Concept Name","value":"ATR_Gene"},{"name":"Maps_To","value":"ATR"},{"name":"OMIM_Number","value":"601215"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332120"}]}}{"C74976":{"preferredName":"ATRX Gene","code":"C74976","definitions":[{"definition":"This gene plays a role in the regulation of both chromatin remodeling and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATRX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATRX","termGroup":"SY","termSource":"NCI"},{"termName":"ATRX, Chromatin Remodeler Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:886"},{"name":"Legacy Concept Name","value":"ATRX_Gene"},{"name":"Maps_To","value":"ATRX"},{"name":"OMIM_Number","value":"300032"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412697"}]}}{"C19969":{"preferredName":"AXIN1 Gene","code":"C19969","definitions":[{"definition":"This gene plays a role in signal transduction and is involved in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXIN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Axin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AXIN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:903"},{"name":"Legacy Concept Name","value":"AXIN1_Gene"},{"name":"Maps_To","value":"AXIN1"},{"name":"OMIM_Number","value":"603816"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332125"}]}}{"C20763":{"preferredName":"AXIN2 Gene","code":"C20763","definitions":[{"definition":"This gene is involved in signal transduction and plays a role in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXIN2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Axin 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AXIN2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:904"},{"name":"Legacy Concept Name","value":"AXIN2_Gene"},{"name":"Maps_To","value":"AXIN2"},{"name":"OMIM_Number","value":"604025"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332126"}]}}{"C62660":{"preferredName":"B2M Gene","code":"C62660","definitions":[{"definition":"This gene plays a role in immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B2M Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B2M","termGroup":"SY","termSource":"NCI"},{"termName":"Beta-2-Microglobulin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:914"},{"name":"Legacy Concept Name","value":"B2M_Gene"},{"name":"Maps_To","value":"B2M"},{"name":"OMIM_Number","value":"109700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412709"}]}}{"C20766":{"preferredName":"BAP1 Gene","code":"C20766","definitions":[{"definition":"This gene is involved in cellular growth regulation and is purported to have tumor suppression activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BAP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAP1","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA1 Associated Protein-1 (Ubiquitin Carboxy-Terminal Hydrolase) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:950"},{"name":"Legacy Concept Name","value":"BAP1_Gene"},{"name":"Maps_To","value":"BAP1"},{"name":"OMIM_Number","value":"603089"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332380"}]}}{"C20715":{"preferredName":"BARD1 Gene","code":"C20715","definitions":[{"definition":"This gene plays a role in cellular response and is susceptible to oncogenic mutations in breast and ovarian cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BARD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BARD1","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA1 Associated RING Domain 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:952"},{"name":"Legacy Concept Name","value":"BARD1_Gene"},{"name":"Maps_To","value":"BARD1"},{"name":"OMIM_Number","value":"601593"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332381"}]}}{"C24259":{"preferredName":"BCL10 Gene","code":"C24259","definitions":[{"definition":"This gene is involved in the promotion of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 10 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:989"},{"name":"Legacy Concept Name","value":"BCL10_Gene"},{"name":"Maps_To","value":"BCL10"},{"name":"OMIM_Number","value":"603517"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367449"}]}}{"C97394":{"preferredName":"BCL11A Gene","code":"C97394","definitions":[{"definition":"This gene is involved in both the modulation of cell shape and lymphopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL11A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAF Chromatin Remodeling Complex Subunit BCL11A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL11A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13221"},{"name":"Maps_To","value":"BCL11A"},{"name":"OMIM_Number","value":"606557"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421886"}]}}{"C91855":{"preferredName":"BCL11B Gene","code":"C91855","definitions":[{"definition":"This gene may play a role in tumor suppression, signaling and T cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL11B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAF Chromatin Remodeling Complex Subunit BCL11B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL11B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13222"},{"name":"Maps_To","value":"BCL11B"},{"name":"OMIM_Number","value":"606558"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421887"}]}}{"C17963":{"preferredName":"BCL2 Gene","code":"C17963","definitions":[{"definition":"A protein that helps control whether a cell lives or dies by blocking a type of cell death called apoptosis. The gene for BCL2 is found on chromosome 18, and transfer of the BCL2 gene to a different chromosome is seen in many B-cell leukemias and lymphomas. This causes the BCL2 protein to be made in larger amounts, which may keep cancer cells from dying.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in apoptotic regulation. Overexpression of this gene promotes the pathogenesis of B-Cell lymphomas, due to anti-apoptotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL2","termGroup":"SY","termSource":"NCI"},{"termName":"BCL2, Apoptosis Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:990"},{"name":"Legacy Concept Name","value":"BCL2_Gene"},{"name":"Maps_To","value":"BCL2"},{"name":"OMIM_Number","value":"151430"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0376515"}]}}{"C114743":{"preferredName":"BCL2L12 Gene","code":"C114743","definitions":[{"definition":"This gene is involved in the regulation of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL2L12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL2-Like 12 (Proline Rich) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL2L12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13787"},{"name":"Maps_To","value":"BCL2L12"},{"name":"OMIM_Number","value":"610837"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422195"}]}}{"C18360":{"preferredName":"BCL3 Gene","code":"C18360","definitions":[{"definition":"This gene is involved in transcriptional co-activation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL3","termGroup":"SY","termSource":"NCI"},{"termName":"BCL3 Transcription Coactivator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:998"},{"name":"Legacy Concept Name","value":"BCL3_Gene"},{"name":"Maps_To","value":"BCL3"},{"name":"OMIM_Number","value":"109560"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812238"}]}}{"C24260":{"preferredName":"BCL6 Gene","code":"C24260","definitions":[{"definition":"This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1001"},{"name":"Legacy Concept Name","value":"BCL6_Gene"},{"name":"Maps_To","value":"BCL6"},{"name":"OMIM_Number","value":"109565"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332399"}]}}{"C24261":{"preferredName":"BCL7A Gene","code":"C24261","definitions":[{"definition":"This gene may play a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL7A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAF Chromatin Remodeling Complex Subunit BCL7A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL7A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1004"},{"name":"Legacy Concept Name","value":"BCL7A_Gene"},{"name":"Maps_To","value":"BCL7A"},{"name":"OMIM_Number","value":"601406"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332400"}]}}{"C24262":{"preferredName":"BCL9 Gene","code":"C24262","definitions":[{"definition":"This gene plays a role in signal transduction and is involved in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL9","termGroup":"SY","termSource":"NCI"},{"termName":"BCL9 Transcription Coactivator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1008"},{"name":"Legacy Concept Name","value":"BCL9_Gene"},{"name":"Maps_To","value":"BCL9"},{"name":"OMIM_Number","value":"602597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332402"}]}}{"C132328":{"preferredName":"BCL9L Gene","code":"C132328","definitions":[{"definition":"This gene plays a role in the coactivation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL9L Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 9-Like Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL9L","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23688"},{"name":"Maps_To","value":"BCL9L"},{"name":"OMIM_Number","value":"609004"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428193"}]}}{"C115994":{"preferredName":"BCLAF1 Gene","code":"C115994","definitions":[{"definition":"Human BCLAF1 wild-type allele is located within 6q22-q23 and is approximately 33 kb in length. This allele, which encodes Bcl-2-associated transcription factor 1 protein, plays a role in both apoptosis promotion and the repression of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCLAF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL2-Associated Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCLAF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16863"},{"name":"Maps_To","value":"BCLAF1"},{"name":"OMIM_Number","value":"612588"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424602"}]}}{"C101091":{"preferredName":"BCOR Gene","code":"C101091","definitions":[{"definition":"This gene plays a role in the repression of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCOR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL6 Corepressor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCOR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20893"},{"name":"Maps_To","value":"BCOR"},{"name":"OMIM_Number","value":"300485"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427193"}]}}{"C131268":{"preferredName":"BCORL1 Gene","code":"C131268","definitions":[{"definition":"This gene plays a role in the inhibition of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCORL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL6 Corepressor-Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCORL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25657"},{"name":"Maps_To","value":"BCORL1"},{"name":"OMIM_Number","value":"300688"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538320"}]}}{"C18455":{"preferredName":"BCR Gene","code":"C18455","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCR","termGroup":"SY","termSource":"NCI"},{"termName":"BCR, RhoGEF and GTPase Activating Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1014"},{"name":"Legacy Concept Name","value":"BCR_Gene"},{"name":"Maps_To","value":"BCR"},{"name":"OMIM_Number","value":"151410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812385"}]}}{"C20356":{"preferredName":"BIRC3 Gene","code":"C20356","definitions":[{"definition":"This anti-apoptotic gene regulates apoptotic activity. BIRC3 gene promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BIRC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Baculoviral IAP Repeat Containing 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BIRC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:591"},{"name":"Legacy Concept Name","value":"BIRC3_Gene"},{"name":"Maps_To","value":"BIRC3"},{"name":"OMIM_Number","value":"601721"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332415"}]}}{"C20352":{"preferredName":"BIRC6 Gene","code":"C20352","definitions":[{"definition":"This gene regulates the apoptotic program via signal transduction in the ubiquitination pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BIRC6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Baculoviral IAP Repeat-Containing 6 (Apollon) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BIRC6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13516"},{"name":"Legacy Concept Name","value":"BIRC6_Gene"},{"name":"Maps_To","value":"BIRC6"},{"name":"OMIM_Number","value":"605638"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332417"}]}}{"C20805":{"preferredName":"BLM Gene","code":"C20805","definitions":[{"definition":"This gene plays a role in DNA unwinding and recombination-mediated telomere lengthening.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BLM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BLM","termGroup":"SY","termSource":"NCI"},{"termName":"Bloom Syndrome Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1058"},{"name":"Legacy Concept Name","value":"BLM_Gene"},{"name":"Maps_To","value":"BLM"},{"name":"OMIM_Number","value":"604610"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337098"}]}}{"C21353":{"preferredName":"BMP5 Gene","code":"C21353","definitions":[{"definition":"This gene plays a role in the regulation of mesenchymal differentiation. It is involved in cartilage and bone formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMP5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BMP5","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Morphogenetic Protein 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1072"},{"name":"Legacy Concept Name","value":"BMP5_Gene"},{"name":"Maps_To","value":"BMP5"},{"name":"OMIM_Number","value":"112265"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332426"}]}}{"C21366":{"preferredName":"BMPR1A Gene","code":"C21366","definitions":[{"definition":"This gene plays a role in the bone morphogenetic protein signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMPR1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BMPR1A","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Morphogenetic Protein Receptor Type 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1076"},{"name":"Legacy Concept Name","value":"BMPR1A_Gene"},{"name":"Maps_To","value":"BMPR1A"},{"name":"OMIM_Number","value":"601299"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332430"}]}}{"C18363":{"preferredName":"BRAF Gene","code":"C18363","definitions":[{"definition":"A gene that makes a protein called B-RAF, which is involved in sending signals in cells and in cell growth. This gene may be mutated (changed) in many types of cancer, which causes a change in the B-RAF protein. This can increase the growth and spread of cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in cell organization/biogenesis and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Raf Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BRAF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1097"},{"name":"Legacy Concept Name","value":"BRAF_Gene"},{"name":"Maps_To","value":"BRAF"},{"name":"OMIM_Number","value":"164757"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812241"}]}}{"C17965":{"preferredName":"BRCA1 Gene","code":"C17965","definitions":[{"definition":"This gene plays a role in cell cycle control, regulation of transcription and the maintenance of genomic stability. It is also involved in the inhibition of mammary cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRCA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRCA1","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA1, DNA Repair Associated Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer 1, Early Onset Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1100"},{"name":"Legacy Concept Name","value":"BRCA1_Gene"},{"name":"Maps_To","value":"BRCA1"},{"name":"OMIM_Number","value":"113705"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0376571"}]}}{"C18120":{"preferredName":"BRCA2 Gene","code":"C18120","definitions":[{"definition":"A gene on chromosome 13 that normally helps to suppress cell growth. A person who inherits an altered version of the BRCA2 gene has a higher risk of getting breast, ovarian, or prostate cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in cell cycle control, DNA repair and the maintenance of genomic stability. It also plays a role in the proliferation of embryonic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRCA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRCA2","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA2, DNA Repair Associated Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer 2, Early Onset Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1101"},{"name":"Legacy Concept Name","value":"BRCA2_Gene"},{"name":"Maps_To","value":"BRCA2"},{"name":"OMIM_Number","value":"600185"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0598034"}]}}{"C97397":{"preferredName":"BRD3 Gene","code":"C97397","definitions":[{"definition":"This gene may play a role in both histone acetylation and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRD3","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain Containing 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1104"},{"name":"Maps_To","value":"BRD3"},{"name":"OMIM_Number","value":"601541"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412821"}]}}{"C92702":{"preferredName":"BRD4 Gene","code":"C92702","definitions":[{"definition":"This gene plays a role in mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRD4","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain Containing 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13575"},{"name":"Maps_To","value":"BRD4"},{"name":"OMIM_Number","value":"608749"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422073"}]}}{"C63526":{"preferredName":"BRIP1 Gene","code":"C63526","definitions":[{"definition":"This gene is involved in DNA double-strand break repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRCA1 Interacting Protein C-Terminal Helicase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BRIP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20473"},{"name":"Legacy Concept Name","value":"BRIP1_Gene"},{"name":"Maps_To","value":"BRIP1"},{"name":"OMIM_Number","value":"605882"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426958"}]}}{"C80101":{"preferredName":"BTG1 Gene","code":"C80101","definitions":[{"definition":"This gene is involved in the regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BTG Anti-Proliferation Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BTG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1130"},{"name":"Legacy Concept Name","value":"BTG1_Gene"},{"name":"Maps_To","value":"BTG1"},{"name":"OMIM_Number","value":"109580"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1439347"}]}}{"C75013":{"preferredName":"BTK Gene","code":"C75013","definitions":[{"definition":"This gene is involved in both signaling and B-cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BTK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1133"},{"name":"Legacy Concept Name","value":"BTK_Gene"},{"name":"Maps_To","value":"BTK"},{"name":"OMIM_Number","value":"300300"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412841"}]}}{"C95592":{"preferredName":"BUB1B Gene","code":"C95592","definitions":[{"definition":"This gene is involved in mitotic progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BUB1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BUB1 Mitotic Checkpoint Serine/Threonine Kinase B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BUB1B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1149"},{"name":"Maps_To","value":"BUB1B"},{"name":"OMIM_Number","value":"602860"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412854"}]}}{"C98096":{"preferredName":"PIERCE2 Gene","code":"C98096","definitions":[{"definition":"This gene may play a role in microtubule structure and ciliary motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIERCE2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C15orf65","termGroup":"SY","termSource":"NCI"},{"termName":"FLJ27352","termGroup":"SY","termSource":"NCI"},{"termName":"PIERCE2","termGroup":"SY","termSource":"NCI"},{"termName":"Piercer of Microtubule Wall 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:44654"},{"name":"Maps_To","value":"C15orf65"},{"name":"OMIM_Number","value":"619669"},{"name":"PubMedID_Primary_Reference","value":"34715025"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C3273816"}]}}{"C113769":{"preferredName":"CACNA1D Gene","code":"C113769","definitions":[{"definition":"This gene is involved in voltage-dependent calcium transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CACNA1D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CACNA1D","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Voltage-Gated Channel Subunit Alpha1 D Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1391"},{"name":"Maps_To","value":"CACNA1D"},{"name":"OMIM_Number","value":"114206"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413058"}]}}{"C95313":{"preferredName":"CALR Gene","code":"C95313","definitions":[{"definition":"This gene plays a role in calcium binding and protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CALR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CALR","termGroup":"SY","termSource":"NCI"},{"termName":"Calreticulin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1455"},{"name":"Maps_To","value":"CALR"},{"name":"OMIM_Number","value":"109091"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413096"}]}}{"C101440":{"preferredName":"CAMTA1 Gene","code":"C101440","definitions":[{"definition":"This gene is involved in both DNA binding and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAMTA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Calmodulin Binding Transcription Activator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CAMTA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18806"},{"name":"Maps_To","value":"CAMTA1"},{"name":"OMIM_Number","value":"611501"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425790"}]}}{"C97375":{"preferredName":"CANT1 Gene","code":"C97375","definitions":[{"definition":"This gene plays a role in both nucleotide hydrolysis and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CANT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Calcium Activated Nucleotidase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CANT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19721"},{"name":"Maps_To","value":"CANT1"},{"name":"OMIM_Number","value":"613165"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538435"}]}}{"C60668":{"preferredName":"CARD11 Gene","code":"C60668","definitions":[{"definition":"This gene plays a role in apoptotic regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CARD11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CARD11","termGroup":"SY","termSource":"NCI"},{"termName":"Caspase Recruitment Domain Family Member 11 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16393"},{"name":"Legacy Concept Name","value":"CARD11_Gene"},{"name":"Maps_To","value":"CARD11"},{"name":"OMIM_Number","value":"607210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424244"}]}}{"C97369":{"preferredName":"CARS1 Gene","code":"C97369","definitions":[{"definition":"This gene is involved in transfer RNA metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CARS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CARS","termGroup":"SY","termSource":"NCI"},{"termName":"CARS1","termGroup":"SY","termSource":"NCI"},{"termName":"Cysteinyl-tRNA Synthetase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1493"},{"name":"Maps_To","value":"CARS"},{"name":"OMIM_Number","value":"123859"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413126"}]}}{"C26623":{"preferredName":"CASP8 Gene","code":"C26623","definitions":[{"definition":"This gene is involved in apoptosis, immune cell homeostasis, lymphocyte activation and immunoprotection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CASP8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CASP8","termGroup":"SY","termSource":"NCI"},{"termName":"Caspase 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1509"},{"name":"Legacy Concept Name","value":"CASP8_Gene"},{"name":"Maps_To","value":"CASP8"},{"name":"OMIM_Number","value":"601763"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332667"}]}}{"C97445":{"preferredName":"CBFA2T3 Gene","code":"C97445","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBFA2T3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CBFA2T3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1537"},{"name":"Maps_To","value":"CBFA2T3"},{"name":"OMIM_Number","value":"603870"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413149"}]}}{"C18584":{"preferredName":"CBFB Gene","code":"C18584","definitions":[{"definition":"This gene is involved in hematopoiesis and osteogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBFB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBFB","termGroup":"SY","termSource":"NCI"},{"termName":"Core-Binding Factor Subunit Beta Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1539"},{"name":"Legacy Concept Name","value":"CBFB_Gene"},{"name":"Maps_To","value":"CBFB"},{"name":"OMIM_Number","value":"121360"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332671"}]}}{"C18364":{"preferredName":"CBL Gene","code":"C18364","definitions":[{"definition":"This gene plays a role in signal transduction and the regulation of protein degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBL","termGroup":"SY","termSource":"NCI"},{"termName":"Cbl Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1541"},{"name":"Legacy Concept Name","value":"CBL_Gene"},{"name":"Maps_To","value":"CBL"},{"name":"OMIM_Number","value":"165360"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812242"}]}}{"C21589":{"preferredName":"CBLB Gene","code":"C21589","definitions":[{"definition":"This gene plays a role in the regulation of T cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBLB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cbl Proto-Oncogene B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CBLB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1542"},{"name":"Legacy Concept Name","value":"CBLB_Gene"},{"name":"Maps_To","value":"CBLB"},{"name":"OMIM_Number","value":"604491"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332672"}]}}{"C97439":{"preferredName":"CBLC Gene","code":"C97439","definitions":[{"definition":"This gene is involved in both ubiquitination and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBLC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cbl Proto-Oncogene C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CBLC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15961"},{"name":"Maps_To","value":"CBLC"},{"name":"OMIM_Number","value":"608453"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423865"}]}}{"C18376":{"preferredName":"CCDC6 Gene","code":"C18376","definitions":[{"definition":"This gene may play a role in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCDC6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCDC6","termGroup":"SY","termSource":"NCI"},{"termName":"Coiled-Coil Domain Containing 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18782"},{"name":"Legacy Concept Name","value":"D10S170"},{"name":"Maps_To","value":"CCDC6"},{"name":"OMIM_Number","value":"601985"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425774"}]}}{"C97372":{"preferredName":"CCNB1IP1 Gene","code":"C97372","definitions":[{"definition":"This gene plays a role in both ubiquitination and cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCNB1IP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCNB1IP1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin B1 Interacting Protein 1, E3 Ubiquitin Protein Ligase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19437"},{"name":"Maps_To","value":"CCNB1IP1"},{"name":"OMIM_Number","value":"608249"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426243"}]}}{"C105393":{"preferredName":"CCNC Gene","code":"C105393","definitions":[{"definition":"This gene plays a role in the modulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCNC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCNC","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1581"},{"name":"Maps_To","value":"CCNC"},{"name":"OMIM_Number","value":"123838"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413171"}]}}{"C18021":{"preferredName":"CCND1 Gene","code":"C18021","definitions":[{"definition":"This gene plays a role in the regulation of mitotic events.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCND1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCND1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1582"},{"name":"Legacy Concept Name","value":"CCND1_Gene"},{"name":"Maps_To","value":"CCND1"},{"name":"OMIM_Number","value":"168461"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413172"}]}}{"C39596":{"preferredName":"CCND2 Gene","code":"C39596","definitions":[{"definition":"This gene is involved in the regulation of the G1/S phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCND2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCND2","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Gene_Encodes_Product","value":"Cyclin-D2"},{"name":"HGNC_ID","value":"HGNC:1583"},{"name":"Legacy Concept Name","value":"CCND2_Gene"},{"name":"Maps_To","value":"CCND2"},{"name":"OMIM_Number","value":"123833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413173"}]}}{"C97381":{"preferredName":"CCND3 Gene","code":"C97381","definitions":[{"definition":"This gene is involved in cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCND3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCND3","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1585"},{"name":"Maps_To","value":"CCND3"},{"name":"OMIM_Number","value":"123834"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413175"}]}}{"C21412":{"preferredName":"CCNE1 Gene","code":"C21412","definitions":[{"definition":"This gene regulates the G1/S phase of the cell cycle by cyclin expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCNE1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCNE1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin E1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1589"},{"name":"Legacy Concept Name","value":"CCNE1_Gene"},{"name":"Maps_To","value":"CCNE1"},{"name":"OMIM_Number","value":"123837"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332697"}]}}{"C129065":{"preferredName":"CCR4 Gene","code":"C129065","definitions":[{"definition":"This gene is involved in chemokine-dependent G protein-coupled receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C-C Motif Chemokine Receptor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CCR4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1605"},{"name":"Maps_To","value":"CCR4"},{"name":"OMIM_Number","value":"604836"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413190"}]}}{"C104128":{"preferredName":"CCR7 Gene","code":"C104128","definitions":[{"definition":"This gene plays a role in immune function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCR7","termGroup":"SY","termSource":"NCI"},{"termName":"Chemokine (C-C motif) Receptor 7 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1608"},{"name":"Maps_To","value":"CCR7"},{"name":"OMIM_Number","value":"600242"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413191"}]}}{"C21568":{"preferredName":"CD209 Gene","code":"C21568","definitions":[{"definition":"This gene plays a role in the regulation of host defense responses and mediates pathogen-binding properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD209 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD209","termGroup":"SY","termSource":"NCI"},{"termName":"CD209 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1641"},{"name":"Legacy Concept Name","value":"CD209_Gene"},{"name":"Maps_To","value":"CD209"},{"name":"OMIM_Number","value":"604672"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332707"}]}}{"C96022":{"preferredName":"CD274 Gene","code":"C96022","definitions":[{"definition":"This gene is involved in T cell activation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD274 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD274","termGroup":"SY","termSource":"NCI"},{"termName":"CD274 Molecule Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PD-L1","termGroup":"SY","termSource":"NCI"},{"termName":"PDL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17635"},{"name":"Maps_To","value":"CD274"},{"name":"OMIM_Number","value":"605402"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1540292"}]}}{"C21291":{"preferredName":"CD28 Gene","code":"C21291","definitions":[{"definition":"This gene plays several roles in cellular functions specific to the T-cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD28 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD28","termGroup":"SY","termSource":"NCI"},{"termName":"CD28 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1653"},{"name":"Legacy Concept Name","value":"CD28_Gene"},{"name":"Maps_To","value":"CD28"},{"name":"OMIM_Number","value":"186760"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332709"}]}}{"C97418":{"preferredName":"CD74 Gene","code":"C97418","definitions":[{"definition":"This gene plays a role in antigen processing and presentation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD74 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD74","termGroup":"SY","termSource":"NCI"},{"termName":"CD74 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1697"},{"name":"Maps_To","value":"CD74"},{"name":"OMIM_Number","value":"142790"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413237"}]}}{"C97421":{"preferredName":"CD79A Gene","code":"C97421","definitions":[{"definition":"This gene is involved in B-cell signaling and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD79A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD79A","termGroup":"SY","termSource":"NCI"},{"termName":"CD79a Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1698"},{"name":"Maps_To","value":"CD79A"},{"name":"OMIM_Number","value":"112205"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413238"}]}}{"C97424":{"preferredName":"CD79B Gene","code":"C97424","definitions":[{"definition":"This gene plays a role in signaling in B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD79B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD79B","termGroup":"SY","termSource":"NCI"},{"termName":"CD79b Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1699"},{"name":"Maps_To","value":"CD79B"},{"name":"OMIM_Number","value":"147245"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413239"}]}}{"C102939":{"preferredName":"CD99 Gene","code":"C102939","definitions":[{"definition":"This gene plays a role in the cell adhesion process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD99 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD99","termGroup":"SY","termSource":"NCI"},{"termName":"CD99 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7082"},{"name":"Maps_To","value":"CD99"},{"name":"OMIM_Number","value":"313470"},{"name":"OMIM_Number","value":"450000"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417157"}]}}{"C43569":{"preferredName":"CDC73 Gene","code":"C43569","definitions":[{"definition":"This gene is involved in transcription and may play a role in cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC73 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDC73","termGroup":"SY","termSource":"NCI"},{"termName":"Cell Division Cycle 73 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16783"},{"name":"Legacy Concept Name","value":"HRPT2_Gene"},{"name":"Maps_To","value":"CDC73"},{"name":"OMIM_Number","value":"607393"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1708291"}]}}{"C18249":{"preferredName":"CDH1 Gene","code":"C18249","definitions":[{"definition":"This gene plays a role in cell-cell adhesion and loss of function contributes to the progression of many carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1748"},{"name":"Legacy Concept Name","value":"CDH1_Gene"},{"name":"Maps_To","value":"CDH1"},{"name":"OMIM_Number","value":"192090"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694872"}]}}{"C143093":{"preferredName":"CDH10 Gene","code":"C143093","definitions":[{"definition":"This gene plays a role in the modulation of neuronal cell shape and cell-cell adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 10 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1749"},{"name":"Maps_To","value":"CDH10"},{"name":"NCI_META_CUI","value":"CL541550"},{"name":"OMIM_Number","value":"604555"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97427":{"preferredName":"CDH11 Gene","code":"C97427","definitions":[{"definition":"This gene is involved in the adherens junction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1750"},{"name":"Maps_To","value":"CDH11"},{"name":"OMIM_Number","value":"600023"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413269"}]}}{"C143096":{"preferredName":"CDH17 Gene","code":"C143096","definitions":[{"definition":"This gene is involved in cell-cell adhesion and intestinal proton-dependent peptide transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH17 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 17 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH17","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1756"},{"name":"Maps_To","value":"CDH17"},{"name":"NCI_META_CUI","value":"CL541553"},{"name":"OMIM_Number","value":"603017"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C101095":{"preferredName":"CDK12 Gene","code":"C101095","definitions":[{"definition":"This gene is involved in protein phosphorylation, RNA splicing and transcription elongation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDK12","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24224"},{"name":"Maps_To","value":"CDK12"},{"name":"OMIM_Number","value":"615514"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824794"}]}}{"C18250":{"preferredName":"CDK4 Gene","code":"C18250","definitions":[{"definition":"This gene is involved in G1 stage cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDK4","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1773"},{"name":"Legacy Concept Name","value":"CDK4_Gene"},{"name":"Maps_To","value":"CDK4"},{"name":"OMIM_Number","value":"123829"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694873"}]}}{"C97384":{"preferredName":"CDK6 Gene","code":"C97384","definitions":[{"definition":"This gene plays a role in the progression of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDK6","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1777"},{"name":"Maps_To","value":"CDK6"},{"name":"OMIM_Number","value":"603368"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413287"}]}}{"C17782":{"preferredName":"CDKN1A Gene","code":"C17782","definitions":[{"definition":"This gene is a regulator of cell cycle progression at the G1 phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN1A","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1784"},{"name":"Legacy Concept Name","value":"CDKN1A_Gene"},{"name":"Maps_To","value":"CDKN1A"},{"name":"OMIM_Number","value":"116899"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0249197"}]}}{"C20060":{"preferredName":"CDKN1B Gene","code":"C20060","definitions":[{"definition":"This gene is involved in cell cycle regulation and cyclin regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN1B","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor 1B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1785"},{"name":"Legacy Concept Name","value":"CDKN1B_Gene"},{"name":"Maps_To","value":"CDKN1B"},{"name":"OMIM_Number","value":"600778"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332737"}]}}{"C18022":{"preferredName":"CDKN2A Gene","code":"C18022","definitions":[{"definition":"This gene functions as a tumor suppressor and transcriptional regulator.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN2A","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor 2A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1787"},{"name":"Legacy Concept Name","value":"CDKN2A_Gene"},{"name":"Maps_To","value":"CDKN2A"},{"name":"OMIM_Number","value":"600160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0525037"}]}}{"C24288":{"preferredName":"CDKN2C Gene","code":"C24288","definitions":[{"definition":"This gene is involved in cell cycle inhibition and regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN2C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN2C","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor 2C (p18, Inhibits CDK4) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1789"},{"name":"Legacy Concept Name","value":"CDKN2C_Gene"},{"name":"Maps_To","value":"CDKN2C"},{"name":"OMIM_Number","value":"603369"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332738"}]}}{"C24292":{"preferredName":"CDX2 Gene","code":"C24292","definitions":[{"definition":"This gene plays a role in transcriptional initiation, embryonic axial elongation and patterning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Caudal Type Homeobox 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDX2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1806"},{"name":"Legacy Concept Name","value":"CDX2_Gene"},{"name":"Maps_To","value":"CDX2"},{"name":"OMIM_Number","value":"600297"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332743"}]}}{"C39598":{"preferredName":"CEBPA Gene","code":"C39598","definitions":[{"definition":"This gene plays a role in body weight homeostasis and cellular proliferation. Mutations in the gene are associated with acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEBPA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCAAT Enhancer Binding Protein Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEBPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1833"},{"name":"Legacy Concept Name","value":"CEBPA_Gene"},{"name":"Maps_To","value":"CEBPA"},{"name":"OMIM_Number","value":"116897"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413322"}]}}{"C122887":{"preferredName":"CEP89 Gene","code":"C122887","definitions":[{"definition":"This gene is involved in cilia formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP89 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 89kDa Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP89","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25907"},{"name":"Maps_To","value":"CEP89"},{"name":"OMIM_Number","value":"615470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824650"}]}}{"C97403":{"preferredName":"CHCHD7 Gene","code":"C97403","definitions":[{"definition":"This gene may be involved in stature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHCHD7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHCHD7","termGroup":"SY","termSource":"NCI"},{"termName":"Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 7 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28314"},{"name":"Maps_To","value":"CHCHD7"},{"name":"OMIM_Number","value":"611238"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428688"}]}}{"C75307":{"preferredName":"CHD2 Gene","code":"C75307","definitions":[{"definition":"This gene may be involved in the regulation of both gene expression and chromatin modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHD2","termGroup":"SY","termSource":"NCI"},{"termName":"Chromodomain Helicase DNA Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1917"},{"name":"Legacy Concept Name","value":"CHD2_Gene"},{"name":"Maps_To","value":"CHD2"},{"name":"OMIM_Number","value":"602119"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413381"}]}}{"C128251":{"preferredName":"CHD4 Gene","code":"C128251","definitions":[{"definition":"This gene is involved in ATP-dependent chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHD4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHD4","termGroup":"SY","termSource":"NCI"},{"termName":"Chromodomain Helicase DNA Binding Protein 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1919"},{"name":"Maps_To","value":"CHD4"},{"name":"OMIM_Number","value":"603277"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413383"}]}}{"C40965":{"preferredName":"CHEK2 Gene","code":"C40965","definitions":[{"definition":"This gene plays a role in cell survival and the negative regulation of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHEK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Checkpoint Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CHEK2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16627"},{"name":"Legacy Concept Name","value":"CHEK2_Gene"},{"name":"Maps_To","value":"CHEK2"},{"name":"OMIM_Number","value":"604373"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424448"}]}}{"C97406":{"preferredName":"CHIC2 Gene","code":"C97406","definitions":[{"definition":"This gene may play a role in vesicular transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHIC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHIC2","termGroup":"SY","termSource":"NCI"},{"termName":"Cysteine Rich Hydrophobic Domain 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1935"},{"name":"Maps_To","value":"CHIC2"},{"name":"OMIM_Number","value":"604332"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413390"}]}}{"C143061":{"preferredName":"CHST11 Gene","code":"C143061","definitions":[{"definition":"This gene plays a role in the metabolism of chondroitin sulfate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHST11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Carbohydrate Sulfotransferase 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CHST11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17422"},{"name":"Maps_To","value":"CHST11"},{"name":"OMIM_Number","value":"610128"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424960"}]}}{"C97912":{"preferredName":"CIC Gene","code":"C97912","definitions":[{"definition":"This gene is involved in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CIC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Capicua Transcriptional Repressor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CIC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14214"},{"name":"Maps_To","value":"CIC"},{"name":"OMIM_Number","value":"612082"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422489"}]}}{"C96013":{"preferredName":"CIITA Gene","code":"C96013","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CIITA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CIITA","termGroup":"SY","termSource":"NCI"},{"termName":"Class II Major Histocompatibility Complex Transactivator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7067"},{"name":"Maps_To","value":"CIITA"},{"name":"OMIM_Number","value":"600005"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824738"}]}}{"C84464":{"preferredName":"CLIP1 Gene","code":"C84464","definitions":[{"definition":"This gene plays a role in both endocytosis and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CAP-GLY Domain Containing Linker Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLIP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10461"},{"name":"Maps_To","value":"CLIP1"},{"name":"OMIM_Number","value":"179838"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824746"}]}}{"C97528":{"preferredName":"CLP1 Gene","code":"C97528","definitions":[{"definition":"This gene plays a role in RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cleavage Factor Polyadenylation Kinase Subunit 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16999"},{"name":"Maps_To","value":"CLP1"},{"name":"OMIM_Number","value":"608757"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824753"}]}}{"C97412":{"preferredName":"CLTC Gene","code":"C97412","definitions":[{"definition":"This gene plays a role in both the formation of cellular vesicles and receptor-mediated endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLTC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Clathrin Heavy Chain Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLTC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2092"},{"name":"Maps_To","value":"CLTC"},{"name":"OMIM_Number","value":"118955"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413512"}]}}{"C97415":{"preferredName":"CLTCL1 Gene","code":"C97415","definitions":[{"definition":"This gene is involved in both receptor-mediated endocytosis and vesicle formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLTCL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Clathrin Heavy Chain Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLTCL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2093"},{"name":"Maps_To","value":"CLTCL1"},{"name":"OMIM_Number","value":"601273"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413513"}]}}{"C143056":{"preferredName":"CNBD1 Gene","code":"C143056","definitions":[{"definition":"This gene is involved in cyclic nucleotide binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNBD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CNBD1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclic Nucleotide Binding Domain Containing 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26663"},{"name":"Maps_To","value":"CNBD1"},{"name":"NCI_META_CUI","value":"CL541468"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97888":{"preferredName":"CNBP Gene","code":"C97888","definitions":[{"definition":"This gene is involved in sterol-mediated transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNBP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCHC-Type Zinc Finger, Nucleic Acid Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CNBP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13164"},{"name":"Maps_To","value":"CNBP"},{"name":"OMIM_Number","value":"116955"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824763"}]}}{"C107658":{"preferredName":"CNOT3 Gene","code":"C107658","definitions":[{"definition":"This gene is involved in mRNA degradation, miRNA-mediated repression, translational regulation and general transcription regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNOT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCR4-NOT Transcription Complex, Subunit 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CNOT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7879"},{"name":"Maps_To","value":"CNOT3"},{"name":"OMIM_Number","value":"604910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417765"}]}}{"C73461":{"preferredName":"CNTNAP2 Gene","code":"C73461","definitions":[{"definition":"This gene may be involved in axonal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNTNAP2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CNTNAP2","termGroup":"SY","termSource":"NCI"},{"termName":"Contactin Associated Protein-Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13830"},{"name":"Legacy Concept Name","value":"CNTNAP2_Gene"},{"name":"Maps_To","value":"CNTNAP2"},{"name":"OMIM_Number","value":"604569"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422223"}]}}{"C97891":{"preferredName":"CNTRL Gene","code":"C97891","definitions":[{"definition":"This gene plays a role in cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNTRL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centriolin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CNTRL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1858"},{"name":"Maps_To","value":"CNTRL"},{"name":"OMIM_Number","value":"605496"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824717"}]}}{"C29949":{"preferredName":"COL1A1 Gene","code":"C29949","definitions":[{"definition":"This gene plays an important structural role in cartilage and mutations in the gene are associated with osteogenesis imperfecta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COL1A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COL1A1","termGroup":"SY","termSource":"NCI"},{"termName":"Collagen Type I Alpha 1 Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2197"},{"name":"Legacy Concept Name","value":"COL1A1_Gene"},{"name":"Maps_To","value":"COL1A1"},{"name":"OMIM_Number","value":"120150"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332772"}]}}{"C75315":{"preferredName":"COL2A1 Gene","code":"C75315","definitions":[{"definition":"This gene plays a role in both skeletal development and cartilage structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COL2A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COL2A1","termGroup":"SY","termSource":"NCI"},{"termName":"Collagen, Type II, Alpha 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2200"},{"name":"Legacy Concept Name","value":"COL2A1_Gene"},{"name":"Maps_To","value":"COL2A1"},{"name":"OMIM_Number","value":"120140"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413580"}]}}{"C143052":{"preferredName":"COL3A1 Gene","code":"C143052","definitions":[{"definition":"This gene plays a role in collagen formation in connective tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COL3A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COL3A1","termGroup":"SY","termSource":"NCI"},{"termName":"Collagen Type III Alpha 1 Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2201"},{"name":"Maps_To","value":"COL3A1"},{"name":"OMIM_Number","value":"120180"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413581"}]}}{"C24308":{"preferredName":"COX6C Gene","code":"C24308","definitions":[{"definition":"This gene is involved in mitochondrial respiration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COX6C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COX6C","termGroup":"SY","termSource":"NCI"},{"termName":"Cytochrome C Oxidase Subunit VIC Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2285"},{"name":"Legacy Concept Name","value":"COX6C_Gene"},{"name":"Maps_To","value":"COX6C"},{"name":"OMIM_Number","value":"124090"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332776"}]}}{"C38536":{"preferredName":"CREB1 Gene","code":"C38536","definitions":[{"definition":"This gene is involved in transcriptional regulation and its activity is modulated in response to hormonal stimulation from the cAMP pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"cAMP Responsive Element Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2345"},{"name":"Legacy Concept Name","value":"CREB1_Gene"},{"name":"Maps_To","value":"CREB1"},{"name":"OMIM_Number","value":"123810"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413702"}]}}{"C95477":{"preferredName":"CREB3L1 Gene","code":"C95477","definitions":[{"definition":"This gene plays a role in transcriptional regulation in response to cellular stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREB3L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"cAMP Responsive Element Binding Protein 3-Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREB3L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18856"},{"name":"Maps_To","value":"CREB3L1"},{"name":"OMIM_Number","value":"616215"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425827"}]}}{"C95480":{"preferredName":"CREB3L2 Gene","code":"C95480","definitions":[{"definition":"This gene is involved in the response to cellular stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREB3L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"cAMP Responsive Element Binding Protein 3-Like 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREB3L2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23720"},{"name":"Maps_To","value":"CREB3L2"},{"name":"OMIM_Number","value":"608834"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428221"}]}}{"C26568":{"preferredName":"CREBBP Gene","code":"C26568","definitions":[{"definition":"This gene plays a role in transcriptional regulation and in NF-kappa B signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREBBP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CREB Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREBBP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2348"},{"name":"Legacy Concept Name","value":"CREBBP_Gene"},{"name":"Maps_To","value":"CREBBP"},{"name":"OMIM_Number","value":"600140"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337090"}]}}{"C97430":{"preferredName":"CRLF2 Gene","code":"C97430","definitions":[{"definition":"This gene is involved in cytokine binding and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRLF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CRLF2","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokine Receptor Like Factor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14281"},{"name":"Maps_To","value":"CRLF2"},{"name":"OMIM_Number","value":"300357"},{"name":"OMIM_Number","value":"400023"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422539"}]}}{"C143049":{"preferredName":"CRNKL1 Gene","code":"C143049","definitions":[{"definition":"This gene is involved in RNA binding and pre-mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRNKL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CRNKL1","termGroup":"SY","termSource":"NCI"},{"termName":"Crooked Neck Pre-mRNA Splicing Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15762"},{"name":"Maps_To","value":"CRNKL1"},{"name":"NCI_META_CUI","value":"CL541477"},{"name":"OMIM_Number","value":"610952"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C95449":{"preferredName":"CRTC1 Gene","code":"C95449","definitions":[{"definition":"This gene plays a role in the positive regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRTC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CREB Regulated Transcription Coactivator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CRTC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16062"},{"name":"Maps_To","value":"CRTC1"},{"name":"OMIM_Number","value":"607536"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824798"}]}}{"C95276":{"preferredName":"CRTC3 Gene","code":"C95276","definitions":[{"definition":"This gene is involved in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRTC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CREB Regulated Transcription Coactivator 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CRTC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26148"},{"name":"Maps_To","value":"CRTC3"},{"name":"OMIM_Number","value":"608986"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824800"}]}}{"C18516":{"preferredName":"CSF1R Gene","code":"C18516","definitions":[{"definition":"This gene is essential for the regulation of the production, differentiation, and function of macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSF1R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Colony Stimulating Factor 1 Receptor, Formerly McDonough Feline Sarcoma Viral (v-fms) Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CSF1R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2433"},{"name":"Legacy Concept Name","value":"CSF1R_Gene"},{"name":"Maps_To","value":"CSF1R"},{"name":"OMIM_Number","value":"164770"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879468"}]}}{"C24313":{"preferredName":"CSF3R Gene","code":"C24313","definitions":[{"definition":"This gene plays an inhibitory role in cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSF3R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Colony Stimulating Factor 3 Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CSF3R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2439"},{"name":"Legacy Concept Name","value":"CSF3R_Gene"},{"name":"Maps_To","value":"CSF3R"},{"name":"OMIM_Number","value":"138971"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332792"}]}}{"C143042":{"preferredName":"CSMD3 Gene","code":"C143042","definitions":[{"definition":"This gene plays a role in neuronal development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSMD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CSMD3","termGroup":"SY","termSource":"NCI"},{"termName":"CUB and Sushi Multiple Domains 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19291"},{"name":"Maps_To","value":"CSMD3"},{"name":"NCI_META_CUI","value":"CL541470"},{"name":"OMIM_Number","value":"608399"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C73679":{"preferredName":"CTCF Gene","code":"C73679","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTCF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCCTC-Binding Factor (Zinc Finger Protein) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTCF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13723"},{"name":"Legacy Concept Name","value":"CTCF_Gene"},{"name":"Maps_To","value":"CTCF"},{"name":"OMIM_Number","value":"604167"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422163"}]}}{"C143115":{"preferredName":"CTNNA2 Gene","code":"C143115","definitions":[{"definition":"This gene is involved in cell-cell adhesion and cellular differentiation in the nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNNA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin Alpha 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNNA2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2510"},{"name":"Maps_To","value":"CTNNA2"},{"name":"NCI_META_CUI","value":"CL541524"},{"name":"OMIM_Number","value":"114025"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C20987":{"preferredName":"CTNNB1 Gene","code":"C20987","definitions":[{"definition":"This gene is involved in signal transduction and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNNB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin Beta 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNNB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2514"},{"name":"Legacy Concept Name","value":"CTNNB1_Gene"},{"name":"Maps_To","value":"CTNNB1"},{"name":"OMIM_Number","value":"116806"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332803"}]}}{"C79770":{"preferredName":"CTNND1 Gene","code":"C79770","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNND1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin (Cadherin-Associated Protein), Delta 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNND1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2515"},{"name":"Legacy Concept Name","value":"CTNND1_Gene"},{"name":"Maps_To","value":"CTNND1"},{"name":"OMIM_Number","value":"601045"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413800"}]}}{"C82941":{"preferredName":"CTNND2 Gene","code":"C82941","definitions":[{"definition":"This gene is involved in the regulation of both transcription and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNND2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin (Cadherin-Associated Protein), Delta 2 (Neural Plakophilin-Related Arm-Repeat Protein) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNND2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2516"},{"name":"Legacy Concept Name","value":"CTNND2_Gene"},{"name":"Maps_To","value":"CTNND2"},{"name":"OMIM_Number","value":"604275"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413801"}]}}{"C24323":{"preferredName":"CUL3 Gene","code":"C24323","definitions":[{"definition":"This gene plays a role in protein degradation and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CUL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CUL3","termGroup":"SY","termSource":"NCI"},{"termName":"Cullin 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2553"},{"name":"Legacy Concept Name","value":"CUL3_Gene"},{"name":"Maps_To","value":"CUL3"},{"name":"OMIM_Number","value":"603136"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332811"}]}}{"C95578":{"preferredName":"CUX1 Gene","code":"C95578","definitions":[{"definition":"This gene is involved in both transcriptional regulation and Golgi vesicle transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CUX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cut-Like Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CUX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The CUX gene has two significantly different protein products with divergent molecular functions. The two proteins are the result of alternative splicing. (UniProt)"},{"name":"HGNC_ID","value":"HGNC:2557"},{"name":"Maps_To","value":"CUX1"},{"name":"OMIM_Number","value":"116896"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413827"}]}}{"C24327":{"preferredName":"CXCR4 Gene","code":"C24327","definitions":[{"definition":"This gene is involved in the mediation of viral entry into cells and cellular migration and chemotaxis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Chemokine (C-X-C Motif) Receptor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CXCR4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2561"},{"name":"Legacy Concept Name","value":"CXCR4_Gene"},{"name":"Maps_To","value":"CXCR4"},{"name":"OMIM_Number","value":"162643"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332823"}]}}{"C92678":{"preferredName":"CYLD Gene","code":"C92678","definitions":[{"definition":"This gene is involved in protein deubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYLD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CYLD","termGroup":"SY","termSource":"NCI"},{"termName":"CYLD Lysine 63 Deubiquitinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2584"},{"name":"Maps_To","value":"CYLD"},{"name":"OMIM_Number","value":"605018"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413850"}]}}{"C46071":{"preferredName":"CYP2C8 Gene","code":"C46071","definitions":[{"definition":"This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP2C8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CYP2C8","termGroup":"SY","termSource":"NCI"},{"termName":"Cytochrome P450, Family 2, Subfamily C, Polypeptide 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2622"},{"name":"Legacy Concept Name","value":"CYP2C8_Gene"},{"name":"Maps_To","value":"CYP2C8"},{"name":"OMIM_Number","value":"601129"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413873"}]}}{"C143039":{"preferredName":"CYSLTR2 Gene","code":"C143039","definitions":[{"definition":"This gene is involved in cysteinyl leukotriene binding and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYSLTR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CYSLTR2","termGroup":"SY","termSource":"NCI"},{"termName":"Cysteinyl Leukotriene Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18274"},{"name":"Maps_To","value":"CYSLTR2"},{"name":"NCI_META_CUI","value":"CL541483"},{"name":"OMIM_Number","value":"605666"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24330":{"preferredName":"DAXX Gene","code":"C24330","definitions":[{"definition":"This gene plays a role in signal transduction, regulation of transcription and enhancement of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DAXX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DAXX","termGroup":"SY","termSource":"NCI"},{"termName":"Death-Domain Associated Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2681"},{"name":"Legacy Concept Name","value":"DAXX_Gene"},{"name":"Maps_To","value":"DAXX"},{"name":"OMIM_Number","value":"603186"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333203"}]}}{"C143036":{"preferredName":"DCAF12L2 Gene","code":"C143036","definitions":[{"definition":"This gene may play a role in protein complex formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DCAF12L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DCAF12L2","termGroup":"SY","termSource":"NCI"},{"termName":"DDB1 and CUL4 Associated Factor 12 Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:32950"},{"name":"Maps_To","value":"DCAF12L2"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823822"}]}}{"C17358":{"preferredName":"DCC Gene","code":"C17358","definitions":[{"definition":"This gene plays a role in the regulation of several processes that determine neuronal cell morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DCC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DCC","termGroup":"SY","termSource":"NCI"},{"termName":"Deleted in Colorectal Carcinoma Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2701"},{"name":"Legacy Concept Name","value":"DCC_Gene"},{"name":"Maps_To","value":"DCC"},{"name":"OMIM_Number","value":"120470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0079414"}]}}{"C122875":{"preferredName":"DCTN1 Gene","code":"C122875","definitions":[{"definition":"This gene is involved in the modulation of retrograde transport of cytoplasmic organelles and vesicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DCTN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DCTN1","termGroup":"SY","termSource":"NCI"},{"termName":"Dynactin 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2711"},{"name":"Maps_To","value":"DCTN1"},{"name":"OMIM_Number","value":"601143"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413935"}]}}{"C93075":{"preferredName":"DDB2 Gene","code":"C93075","definitions":[{"definition":"This gene plays a role in DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Damage-Specific DNA Binding Protein 2, 48kDa Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DDB2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2718"},{"name":"Maps_To","value":"DDB2"},{"name":"OMIM_Number","value":"600811"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413942"}]}}{"C92539":{"preferredName":"DDIT3 Gene","code":"C92539","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDIT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHOP","termGroup":"SY","termSource":"NCI"},{"termName":"DDIT3","termGroup":"SY","termSource":"NCI"},{"termName":"DNA Damage Inducible Transcript 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2726"},{"name":"Maps_To","value":"DDIT3"},{"name":"OMIM_Number","value":"126337"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413947"}]}}{"C24333":{"preferredName":"DDR2 Gene","code":"C24333","definitions":[{"definition":"This gene plays a role in extracellular matrix communication processes and receptor-mediated signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDR2","termGroup":"SY","termSource":"NCI"},{"termName":"Discoidin Domain Receptor Family Member 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2731"},{"name":"Legacy Concept Name","value":"DDR2_Gene"},{"name":"Maps_To","value":"DDR2"},{"name":"OMIM_Number","value":"191311"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333207"}]}}{"C97457":{"preferredName":"DDX10 Gene","code":"C97457","definitions":[{"definition":"This gene plays a role in both RNA metabolism and ATP hydrolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX10","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 10 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2735"},{"name":"Maps_To","value":"DDX10"},{"name":"OMIM_Number","value":"601235"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413952"}]}}{"C101565":{"preferredName":"DDX3X Gene","code":"C101565","definitions":[{"definition":"This gene is involved in RNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX3X Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX3X","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 3 X-Linked Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2745"},{"name":"Maps_To","value":"DDX3X"},{"name":"OMIM_Number","value":"300160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413962"}]}}{"C97460":{"preferredName":"DDX5 Gene","code":"C97460","definitions":[{"definition":"This gene is involved in the mediation of RNA metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX5","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2746"},{"name":"Maps_To","value":"DDX5"},{"name":"OMIM_Number","value":"180630"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413963"}]}}{"C18378":{"preferredName":"DDX6 Gene","code":"C18378","definitions":[{"definition":"This gene plays a role in the translation of mRNA encoded by genes involved in cell proliferation and malignant transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX6","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2747"},{"name":"Legacy Concept Name","value":"DDX6_Gene"},{"name":"Maps_To","value":"DDX6"},{"name":"OMIM_Number","value":"600326"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812257"}]}}{"C24339":{"preferredName":"DEK Gene","code":"C24339","definitions":[{"definition":"This gene is involved in RNA processing and regulation of chromatin organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DEK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DEK","termGroup":"SY","termSource":"NCI"},{"termName":"DEK Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2768"},{"name":"Legacy Concept Name","value":"DEK_Gene"},{"name":"Maps_To","value":"DEK"},{"name":"OMIM_Number","value":"125264"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333214"}]}}{"C92663":{"preferredName":"DGCR8 Gene","code":"C92663","definitions":[{"definition":"This gene plays a role in microRNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DGCR8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DGCR8","termGroup":"SY","termSource":"NCI"},{"termName":"DGCR8 Microprocessor Complex Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2847"},{"name":"Maps_To","value":"DGCR8"},{"name":"OMIM_Number","value":"609030"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414028"}]}}{"C25956":{"preferredName":"DICER1 Gene","code":"C25956","definitions":[{"definition":"This gene is involved in the RNA interference pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DICER1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Dicer 1, Ribonuclease III Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DICER1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17098"},{"name":"Legacy Concept Name","value":"DICER1_Gene"},{"name":"Maps_To","value":"DICER1"},{"name":"OMIM_Number","value":"606241"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333218"}]}}{"C122560":{"preferredName":"DNAJB1 Gene","code":"C122560","definitions":[{"definition":"This gene plays a role in the regulation of protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNAJB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DnaJ (Hsp40) Homolog, Subfamily B, Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DNAJB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5270"},{"name":"Maps_To","value":"DNAJB1"},{"name":"OMIM_Number","value":"604572"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415791"}]}}{"C102796":{"preferredName":"DNM2 Gene","code":"C102796","definitions":[{"definition":"This gene plays a role in both GTP hydrolysis and microtubule organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNM2","termGroup":"SY","termSource":"NCI"},{"termName":"Dynamin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2974"},{"name":"Maps_To","value":"DNM2"},{"name":"OMIM_Number","value":"602378"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414120"}]}}{"C73652":{"preferredName":"DNMT3A Gene","code":"C73652","definitions":[{"definition":"This gene is involved in epigenetic modification of DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNMT3A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Methyltransferase 3 Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DNMT3A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2978"},{"name":"Legacy Concept Name","value":"DNMT3A_Gene"},{"name":"Maps_To","value":"DNMT3A"},{"name":"OMIM_Number","value":"602769"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414123"}]}}{"C25955":{"preferredName":"DROSHA Gene","code":"C25955","definitions":[{"definition":"This gene plays a role in the processing of microRNA in the nucleus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DROSHA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DROSHA","termGroup":"SY","termSource":"NCI"},{"termName":"Drosha Ribonuclease III Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RNASEN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17904"},{"name":"Legacy Concept Name","value":"Rnase-III_Gene"},{"name":"Maps_To","value":"DROSHA"},{"name":"OMIM_Number","value":"608828"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1709966"}]}}{"C124048":{"preferredName":"DUX4L1 Gene","code":"C124048","definitions":[{"definition":"Human DUX4L1 gene is located in the vicinity of 4q35 and is approximately 2 kb in length. The product is a processed pseudogene that produces an RNA transcript, but does not encode a protein product. This gene is within a D4Z4 repeat array; contraction of this macrosatellite repeat is associated with facioscapulohumeral muscular dystrophy (FSHD).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DUX4L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Double Homeobox 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Double Homeobox 4 Like 1 (Pseudogene) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Double Homeobox 4 Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DUX10","termGroup":"SY","termSource":"NCI"},{"termName":"DUX4L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The DUX4L1 gene is located within a D4Z4 repeat array in the subtelomeric region of chromosome 4q. (EntrezGene)"},{"name":"EntrezGene_ID","value":"22947"},{"name":"GenBank_Accession_Number","value":"D38024"},{"name":"HGNC_ID","value":"HGNC:3082"},{"name":"Maps_To","value":"DUX4L1"},{"name":"NCI_META_CUI","value":"CL498402"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C80023":{"preferredName":"EBF1 Gene","code":"C80023","definitions":[{"definition":"This gene plays a role in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Early B-Cell Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EBF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3126"},{"name":"Legacy Concept Name","value":"EBF1_Gene"},{"name":"Maps_To","value":"EBF1"},{"name":"OMIM_Number","value":"164343"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825022"}]}}{"C101452":{"preferredName":"ECT2L Gene","code":"C101452","definitions":[{"definition":"This gene may be involved in guanine nucleotide exchange.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECT2L Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ECT2L","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Cell Transforming Sequence 2 Oncogene-Like Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:21118"},{"name":"Maps_To","value":"ECT2L"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427334"}]}}{"C101721":{"preferredName":"EED Gene","code":"C101721","definitions":[{"definition":"This gene plays a role in the negative regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EED Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EED","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonic Ectoderm Development Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3188"},{"name":"Maps_To","value":"EED"},{"name":"OMIM_Number","value":"605984"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414269"}]}}{"C17757":{"preferredName":"EGFR Gene","code":"C17757","definitions":[{"definition":"This gene is involved in the epidermal growth factor signal transduction pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EGFR","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermal Growth Factor Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3236"},{"name":"Legacy Concept Name","value":"EGFR_Gene"},{"name":"Maps_To","value":"EGFR"},{"name":"OMIM_Number","value":"131550"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414313"}]}}{"C131315":{"preferredName":"EIF1AX Gene","code":"C131315","definitions":[{"definition":"This gene is involved in translation initiation and efficiency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EIF1AX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EIF1AX","termGroup":"SY","termSource":"NCI"},{"termName":"Eukaryotic Translation Initiation Factor 1A X-Linked Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3250"},{"name":"Maps_To","value":"EIF1AX"},{"name":"OMIM_Number","value":"300186"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539339"}]}}{"C18347":{"preferredName":"EIF3E Gene","code":"C18347","definitions":[{"definition":"This gene is involved in the initiation and regulation of protein translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EIF3E Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EIF3E","termGroup":"SY","termSource":"NCI"},{"termName":"Eukaryotic Translation Initiation Factor 3, Subunit E Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3277"},{"name":"Legacy Concept Name","value":"EIF3S6_Gene"},{"name":"Maps_To","value":"EIF3E"},{"name":"OMIM_Number","value":"602210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812224"}]}}{"C97467":{"preferredName":"EIF4A2 Gene","code":"C97467","definitions":[{"definition":"This gene is involved in translation initiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EIF4A2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EIF4A2","termGroup":"SY","termSource":"NCI"},{"termName":"Eukaryotic Translation Initiation Factor 4A2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3284"},{"name":"Maps_To","value":"EIF4A2"},{"name":"OMIM_Number","value":"601102"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414349"}]}}{"C20899":{"preferredName":"ELF3 Gene","code":"C20899","definitions":[{"definition":"This gene is involved in the regulation of both transcription and epithelial cell differentiation. It also plays a role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E74-Like Factor 3 (ETS Domain Transcription Factor, Epithelial-Specific) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ELF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3318"},{"name":"Legacy Concept Name","value":"ELF3_Gene"},{"name":"Maps_To","value":"ELF3"},{"name":"OMIM_Number","value":"602191"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366763"}]}}{"C97470":{"preferredName":"ELF4 Gene","code":"C97470","definitions":[{"definition":"This gene plays a role in both DNA binding and transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E74 Like ETS Transcription Factor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ELF4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3319"},{"name":"Maps_To","value":"ELF4"},{"name":"OMIM_Number","value":"300775"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414377"}]}}{"C97476":{"preferredName":"ELK4 Gene","code":"C97476","definitions":[{"definition":"This gene is involved in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELK4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ELK4","termGroup":"SY","termSource":"NCI"},{"termName":"ELK4, ETS-Domain Protein (SRF Accessory Protein 1) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3326"},{"name":"Maps_To","value":"ELK4"},{"name":"OMIM_Number","value":"600246"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414381"}]}}{"C97516":{"preferredName":"ELL Gene","code":"C97516","definitions":[{"definition":"This gene is involved in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ELL","termGroup":"SY","termSource":"NCI"},{"termName":"Elongation Factor RNA Polymerase II Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23114"},{"name":"Maps_To","value":"ELL"},{"name":"OMIM_Number","value":"600284"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427925"}]}}{"C75333":{"preferredName":"ELN Gene","code":"C75333","definitions":[{"definition":"This gene is involved in the structure of the extracellular matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Elastin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ELN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3327"},{"name":"Legacy Concept Name","value":"ELN_Gene"},{"name":"Maps_To","value":"ELN"},{"name":"OMIM_Number","value":"130160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414382"}]}}{"C71003":{"preferredName":"EML4 Gene","code":"C71003","definitions":[{"definition":"This gene may play a role in cytoskeletal assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EML4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Echinoderm Microtubule Associated Protein Like 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EML4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1316"},{"name":"Legacy Concept Name","value":"EML4_Gene"},{"name":"Maps_To","value":"EML4"},{"name":"OMIM_Number","value":"607442"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412993"}]}}{"C26569":{"preferredName":"EP300 Gene","code":"C26569","definitions":[{"definition":"This gene plays a role in DNA repair and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP300 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E1A Binding Protein p300 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EP300","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3373"},{"name":"Legacy Concept Name","value":"EP300_Gene"},{"name":"Maps_To","value":"EP300"},{"name":"OMIM_Number","value":"602700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333336"}]}}{"C104303":{"preferredName":"EPAS1 Gene","code":"C104303","definitions":[{"definition":"This gene plays a role in the cellular response to hypoxia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPAS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Endothelial PAS Domain Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPAS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3374"},{"name":"Maps_To","value":"EPAS1"},{"name":"OMIM_Number","value":"603349"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414421"}]}}{"C18384":{"preferredName":"EPHA3 Gene","code":"C18384","definitions":[{"definition":"This gene is involved in receptor tyrosine kinase signal transduction and plays a role in lymphoid function and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPHA3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EPH Receptor A3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPHA3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3387"},{"name":"Legacy Concept Name","value":"EPHA3_Gene"},{"name":"Maps_To","value":"EPHA3"},{"name":"OMIM_Number","value":"179611"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812263"}]}}{"C111841":{"preferredName":"EPHA7 Gene","code":"C111841","definitions":[{"definition":"This gene plays a role in mediation of developmental processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPHA7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EPH Receptor A7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPHA7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3390"},{"name":"Maps_To","value":"EPHA7"},{"name":"OMIM_Number","value":"602190"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414430"}]}}{"C24369":{"preferredName":"EPS15 Gene","code":"C24369","definitions":[{"definition":"This gene plays a role in signal transduction and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPS15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermal Growth Factor Receptor Pathway Substrate 15 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPS15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3419"},{"name":"Legacy Concept Name","value":"EPS15_Gene"},{"name":"Maps_To","value":"EPS15"},{"name":"OMIM_Number","value":"600051"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333343"}]}}{"C17756":{"preferredName":"ERBB2 Gene","code":"C17756","definitions":[{"definition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERBB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Erb-b2 Receptor Tyrosine Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERBB2","termGroup":"SY","termSource":"NCI"},{"termName":"HER2","termGroup":"SY","termSource":"NCI"},{"termName":"HER2/Neu","termGroup":"SY","termSource":"NCI"},{"termName":"NEU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3430"},{"name":"Legacy Concept Name","value":"ERBB2_Gene"},{"name":"Maps_To","value":"ERBB2"},{"name":"OMIM_Number","value":"164870"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0242957"}]}}{"C18386":{"preferredName":"ERBB3 Gene","code":"C18386","definitions":[{"definition":"This gene is involved in signal transduction pathways that result in cellular proliferation or differentiation. The gene has also been associated with numerous cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERBB3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Erb-B2 Receptor Tyrosine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERBB3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3431"},{"name":"Legacy Concept Name","value":"ERBB3_Gene"},{"name":"Maps_To","value":"ERBB3"},{"name":"OMIM_Number","value":"190151"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812265"}]}}{"C18388":{"preferredName":"ERBB4 Gene","code":"C18388","definitions":[{"definition":"This gene is involved in neuronal development and plays a role in receptor tyrosine kinase signal transduction that regulates cellular proliferation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERBB4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Erb-B2 Receptor Tyrosine Kinase 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERBB4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3432"},{"name":"Legacy Concept Name","value":"ERBB4_Gene"},{"name":"Maps_To","value":"ERBB4"},{"name":"OMIM_Number","value":"600543"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812267"}]}}{"C97499":{"preferredName":"ERC1 Gene","code":"C97499","definitions":[{"definition":"This gene plays a role in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ELKS/RAB6-Interacting/CAST Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17072"},{"name":"Maps_To","value":"ERC1"},{"name":"OMIM_Number","value":"607127"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825059"}]}}{"C20555":{"preferredName":"ERCC2 Gene","code":"C20555","definitions":[{"definition":"This gene is involved in nucleotide excision repair and corrects sensitivity to UV radiation and defective nucleotide excision repair in xeroderma pigmentosum cells of complementation group D.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3434"},{"name":"Legacy Concept Name","value":"ERCC2_Gene"},{"name":"Maps_To","value":"ERCC2"},{"name":"OMIM_Number","value":"126340"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333356"}]}}{"C20556":{"preferredName":"ERCC3 Gene","code":"C20556","definitions":[{"definition":"This gene is involved in DNA excision repair and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3435"},{"name":"Legacy Concept Name","value":"ERCC3_Gene"},{"name":"Maps_To","value":"ERCC3"},{"name":"OMIM_Number","value":"133510"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333357"}]}}{"C20558":{"preferredName":"ERCC4 Gene","code":"C20558","definitions":[{"definition":"This gene is involved in nucleotide excision repair and is involved in the correction of defective nucleotide excision repair in xeroderma pigmentosum cells of complementation group F.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 4, Endonuclease Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3436"},{"name":"Legacy Concept Name","value":"ERCC4_Gene"},{"name":"Maps_To","value":"ERCC4"},{"name":"OMIM_Number","value":"133520"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333358"}]}}{"C20557":{"preferredName":"ERCC5 Gene","code":"C20557","definitions":[{"definition":"This gene plays a role in the nucleotide base excision repair of UV-induced DNA damage and mutations of the gene cause Cockayne syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 5, Endonuclease Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3437"},{"name":"Legacy Concept Name","value":"ERCC5_Gene"},{"name":"Maps_To","value":"ERCC5"},{"name":"OMIM_Number","value":"133530"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333359"}]}}{"C18139":{"preferredName":"ERG Gene","code":"C18139","definitions":[{"definition":"This gene plays a regulatory role in transcription, cellular maintenance and hematopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERG","termGroup":"SY","termSource":"NCI"},{"termName":"ETS Transcription Factor ERG Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3446"},{"name":"Legacy Concept Name","value":"ERG_Gene"},{"name":"Maps_To","value":"ERG"},{"name":"OMIM_Number","value":"165080"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0599295"}]}}{"C38349":{"preferredName":"ESR1 Gene","code":"C38349","definitions":[{"definition":"This gene is involved in ligand-activated transcriptional activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ESR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ER","termGroup":"SY","termSource":"NCI"},{"termName":"ESR1","termGroup":"SY","termSource":"NCI"},{"termName":"Estrogen Receptor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3467"},{"name":"Legacy Concept Name","value":"ESR1_Gene"},{"name":"Maps_To","value":"ESR1"},{"name":"OMIM_Number","value":"133430"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414461"}]}}{"C122823":{"preferredName":"ETNK1 Gene","code":"C122823","definitions":[{"definition":"This gene plays a role in phospholipid biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETNK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ethanolamine Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETNK1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24649"},{"name":"Maps_To","value":"ETNK1"},{"name":"OMIM_Number","value":"609858"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539368"}]}}{"C24377":{"preferredName":"ETV1 Gene","code":"C24377","definitions":[{"definition":"This gene is involved in transcriptional activation and spinal cord development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ETS Variant Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3490"},{"name":"Legacy Concept Name","value":"ETV1_Gene"},{"name":"Maps_To","value":"ETV1"},{"name":"OMIM_Number","value":"600541"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333361"}]}}{"C24378":{"preferredName":"ETV4 Gene","code":"C24378","definitions":[{"definition":"This gene plays a regulatory role in transcription and in matrix metalloproteinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E1AF","termGroup":"SY","termSource":"NCI"},{"termName":"ETS Variant Transcription Factor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3493"},{"name":"Legacy Concept Name","value":"ETV4_Gene"},{"name":"Maps_To","value":"ETV4"},{"name":"OMIM_Number","value":"600711"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333362"}]}}{"C97479":{"preferredName":"ETV5 Gene","code":"C97479","definitions":[{"definition":"This gene plays a role in the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ets Variant Transcription Factor 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3494"},{"name":"Maps_To","value":"ETV5"},{"name":"OMIM_Number","value":"601600"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414477"}]}}{"C18312":{"preferredName":"ETV6 Gene","code":"C18312","definitions":[{"definition":"This gene plays a regulatory role in transcription and in matrix metalloproteinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ETS Variant Transcription Factor 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV6","termGroup":"SY","termSource":"NCI"},{"termName":"TEL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3495"},{"name":"Legacy Concept Name","value":"ETV6_Gene"},{"name":"Maps_To","value":"ETV6"},{"name":"OMIM_Number","value":"600618"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0796520"}]}}{"C18322":{"preferredName":"EWSR1 Gene","code":"C18322","definitions":[{"definition":"This gene may play a role in post-transcriptional regulation; however the function remains to be elucidated. Mutations in the gene result in Ewing sarcoma and other tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EWSR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ewing Sarcoma Breakpoint Region 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EWS RNA-Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EWSR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3508"},{"name":"Legacy Concept Name","value":"EWSR1_Gene"},{"name":"Maps_To","value":"EWSR1"},{"name":"OMIM_Number","value":"133450"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0808901"}]}}{"C18251":{"preferredName":"EXT1 Gene","code":"C18251","definitions":[{"definition":"This gene plays a role in heparin/heparin sulfate biosynthesis, axon guidance and biogenesis/cell organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EXT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Exostosin Glycosyltransferase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EXT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3512"},{"name":"Legacy Concept Name","value":"EXT1_Gene"},{"name":"Maps_To","value":"EXT1"},{"name":"OMIM_Number","value":"608177"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694878"}]}}{"C18252":{"preferredName":"EXT2 Gene","code":"C18252","definitions":[{"definition":"This gene is involved in the heparin/heparin sulfate biosynthesis, cell organization/biogenesis and development of the cytoskeleton in chondrocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EXT2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Exostosin Glycosyltransferase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EXT2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3513"},{"name":"Legacy Concept Name","value":"EXT2_Gene"},{"name":"Maps_To","value":"EXT2"},{"name":"OMIM_Number","value":"608210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694879"}]}}{"C21327":{"preferredName":"EZH2 Gene","code":"C21327","definitions":[{"definition":"This gene plays a role in chromatin remodeling and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EZH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3527"},{"name":"Legacy Concept Name","value":"EZH2_Gene"},{"name":"Maps_To","value":"EZH2"},{"name":"OMIM_Number","value":"601573"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333368"}]}}{"C68722":{"preferredName":"EZR Gene","code":"C68722","definitions":[{"definition":"This gene plays a role in cellular structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EZR","termGroup":"SY","termSource":"NCI"},{"termName":"Ezrin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12691"},{"name":"Legacy Concept Name","value":"VIL2_Gene"},{"name":"Maps_To","value":"EZR"},{"name":"OMIM_Number","value":"123900"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421450"}]}}{"C106340":{"preferredName":"FAM131B Gene","code":"C106340","definitions":[{"definition":"This gene has not been characterized.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAM131B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM131B","termGroup":"SY","termSource":"NCI"},{"termName":"Family with Sequence Similarity 131 Member B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22202"},{"name":"Maps_To","value":"FAM131B"},{"name":"OMIM_Number","value":"619282"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2239421"}]}}{"C143112":{"preferredName":"FAM135B Gene","code":"C143112","definitions":[{"definition":"This gene may play a role in the metabolism of lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAM135B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM135B","termGroup":"SY","termSource":"NCI"},{"termName":"Family with Sequence Similarity 135 Member B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28029"},{"name":"Maps_To","value":"FAM135B"},{"name":"NCI_META_CUI","value":"CL541537"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C96316":{"preferredName":"TENT5C Gene","code":"C96316","definitions":[{"definition":"This gene is involved in polyadenylation of RNA and mRNA stability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TENT5C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM46C","termGroup":"SY","termSource":"NCI"},{"termName":"TENT5C","termGroup":"SY","termSource":"NCI"},{"termName":"Terminal Nucleotidyltransferase 5C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24712"},{"name":"Maps_To","value":"FAM46C"},{"name":"OMIM_Number","value":"613952"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539445"}]}}{"C143109":{"preferredName":"FAM47C Gene","code":"C143109","definitions":[{"definition":"This gene has no known function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAM47C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM47C","termGroup":"SY","termSource":"NCI"},{"termName":"Family with Sequence Similarity 47 Member C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25301"},{"name":"Maps_To","value":"FAM47C"},{"name":"NCI_META_CUI","value":"CL541534"},{"name":"OMIM_Number","value":"301067"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C85995":{"preferredName":"FANCA Gene","code":"C85995","definitions":[{"definition":"This gene may be involved in the mediation of DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3582"},{"name":"Maps_To","value":"FANCA"},{"name":"OMIM_Number","value":"607139"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414527"}]}}{"C86025":{"preferredName":"FANCC Gene","code":"C86025","definitions":[{"definition":"This gene may play a role in DNA cross-link repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3584"},{"name":"Maps_To","value":"FANCC"},{"name":"OMIM_Number","value":"613899"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414529"}]}}{"C86549":{"preferredName":"FANCD2 Gene","code":"C86549","definitions":[{"definition":"This gene is involved in the regulation of meiosis, DNA repair and the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group D2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCD2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3585"},{"name":"Maps_To","value":"FANCD2"},{"name":"OMIM_Number","value":"613984"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414530"}]}}{"C86551":{"preferredName":"FANCE Gene","code":"C86551","definitions":[{"definition":"This gene plays a role in the regulation of both DNA repair and protein localization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group E Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3586"},{"name":"Maps_To","value":"FANCE"},{"name":"OMIM_Number","value":"613976"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414531"}]}}{"C86553":{"preferredName":"FANCF Gene","code":"C86553","definitions":[{"definition":"This gene may be involved in the regulation of DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group F Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3587"},{"name":"Maps_To","value":"FANCF"},{"name":"OMIM_Number","value":"613897"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414532"}]}}{"C24385":{"preferredName":"FANCG Gene","code":"C24385","definitions":[{"definition":"This gene is involved in the maintenance of genomic integrity and nuclear signal transduction. Allelic variants of the gene are involved in Fanconi syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group G Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3588"},{"name":"Legacy Concept Name","value":"FANCG_Gene"},{"name":"Maps_To","value":"FANCG"},{"name":"OMIM_Number","value":"602956"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333532"}]}}{"C21555":{"preferredName":"FAS Gene","code":"C21555","definitions":[{"definition":"This gene is involved in the mediation of cellular surface receptors and apoptotic signals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAS","termGroup":"SY","termSource":"NCI"},{"termName":"Fas Cell Surface Death Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11920"},{"name":"Legacy Concept Name","value":"TNFRSF6_Gene"},{"name":"Maps_To","value":"FAS"},{"name":"OMIM_Number","value":"134637"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539477"}]}}{"C18397":{"preferredName":"FAT1 Gene","code":"C18397","definitions":[{"definition":"This gene is involved in both cellular polarization and cell-cell adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAT","termGroup":"SY","termSource":"NCI"},{"termName":"FAT Atypical Cadherin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3595"},{"name":"Legacy Concept Name","value":"FAT_Gene"},{"name":"Maps_To","value":"FAT1"},{"name":"OMIM_Number","value":"600976"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812278"}]}}{"C143133":{"preferredName":"FAT3 Gene","code":"C143133","definitions":[{"definition":"This gene is involved in cell adhesion and neurite development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAT Atypical Cadherin 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23112"},{"name":"Maps_To","value":"FAT3"},{"name":"NCI_META_CUI","value":"CL541510"},{"name":"OMIM_Number","value":"612483"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C128254":{"preferredName":"FAT4 Gene","code":"C128254","definitions":[{"definition":"This gene plays a role in planar cell polarity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAT4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAT Atypical Cadherin 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAT4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23109"},{"name":"Maps_To","value":"FAT4"},{"name":"OMIM_Number","value":"612411"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427920"}]}}{"C143130":{"preferredName":"FBLN2 Gene","code":"C143130","definitions":[{"definition":"This gene plays a role in protein-protein interactions in the extracellular matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FBLN2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FBLN2","termGroup":"SY","termSource":"NCI"},{"termName":"Fibulin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3601"},{"name":"Maps_To","value":"FBLN2"},{"name":"NCI_META_CUI","value":"CL541507"},{"name":"OMIM_Number","value":"135821"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C101104":{"preferredName":"FBXO11 Gene","code":"C101104","definitions":[{"definition":"This gene plays a role in the recognition of proteins to be ubiquitinylated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FBXO11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"F-Box Protein 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FBXO11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13590"},{"name":"Maps_To","value":"FBXO11"},{"name":"OMIM_Number","value":"607871"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422085"}]}}{"C20786":{"preferredName":"FBXW7 Gene","code":"C20786","definitions":[{"definition":"This gene is involved in ubiquitin-dependent proteolysis and regulation of the G1-S cell cycle checkpoint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FBXW7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"F-Box and WD Repeat Domain Containing 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FBXW7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16712"},{"name":"Legacy Concept Name","value":"FBXW7_Gene"},{"name":"Maps_To","value":"FBXW7"},{"name":"OMIM_Number","value":"606278"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333533"}]}}{"C38554":{"preferredName":"FCGR2B Gene","code":"C38554","definitions":[{"definition":"This gene plays a role in the inhibition of immune functions and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FCGR2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Fc Gamma Receptor IIB Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FCGR2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3618"},{"name":"Legacy Concept Name","value":"FCGR2B_Gene"},{"name":"Maps_To","value":"FCGR2B"},{"name":"OMIM_Number","value":"604590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414554"}]}}{"C97592":{"preferredName":"FCRL4 Gene","code":"C97592","definitions":[{"definition":"This gene may be involved in B cell receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FCRL4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Fc Receptor-Like 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FCRL4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18507"},{"name":"Maps_To","value":"FCRL4"},{"name":"OMIM_Number","value":"605876"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539514"}]}}{"C98120":{"preferredName":"FEN1 Gene","code":"C98120","definitions":[{"definition":"This gene is involved in DNA replication and repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FEN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FEN1","termGroup":"SY","termSource":"NCI"},{"termName":"Flap Structure-Specific Endonuclease 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3650"},{"name":"Maps_To","value":"FEN1"},{"name":"OMIM_Number","value":"600393"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414583"}]}}{"C45497":{"preferredName":"FES Gene","code":"C45497","definitions":[{"definition":"This gene is involved in hematopoiesis and the maintenance of cellular transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FES Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Feline Sarcoma Oncogene Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FES","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3657"},{"name":"Legacy Concept Name","value":"FES_Gene"},{"name":"Maps_To","value":"FES"},{"name":"OMIM_Number","value":"190030"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414588"}]}}{"C97482":{"preferredName":"FEV Gene","code":"C97482","definitions":[{"definition":"This gene may play a role in transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FEV Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FEV","termGroup":"SY","termSource":"NCI"},{"termName":"FEV Transcription Factor, ETS Family Member Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18562"},{"name":"Maps_To","value":"FEV"},{"name":"OMIM_Number","value":"607150"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425602"}]}}{"C19929":{"preferredName":"FGFR1 Gene","code":"C19929","definitions":[{"definition":"This gene plays a role in mitogenesis and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR1","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 1 (FMS-Related Tyrosine Kinase 2, Pfeiffer Syndrome) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3688"},{"name":"Legacy Concept Name","value":"FGFR1_Gene"},{"name":"Maps_To","value":"FGFR1"},{"name":"OMIM_Number","value":"136350"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919509"}]}}{"C24401":{"preferredName":"CEP43 Gene","code":"C24401","definitions":[{"definition":"This gene is involved in the regulation of cell shape, polarity and motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP43 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 43 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP43","termGroup":"SY","termSource":"NCI"},{"termName":"FGFR1OP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17012"},{"name":"Legacy Concept Name","value":"FGFR1OP_Gene"},{"name":"Maps_To","value":"FGFR1OP"},{"name":"OMIM_Number","value":"605392"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333541"}]}}{"C19931":{"preferredName":"FGFR2 Gene","code":"C19931","definitions":[{"definition":"This gene plays a role in mitogenesis and differentiation and mutations in the gene are associated with craniosynostotic syndromes and bone malformations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR2","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3689"},{"name":"Legacy Concept Name","value":"FGFR2_Gene"},{"name":"Maps_To","value":"FGFR2"},{"name":"OMIM_Number","value":"176943"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333542"}]}}{"C24393":{"preferredName":"FGFR3 Gene","code":"C24393","definitions":[{"definition":"This gene plays a role in bone development and maintenance and mutations in the gene are associated with craniosynostosis and several types of skeletal dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR3","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3690"},{"name":"Legacy Concept Name","value":"FGFR3_Gene"},{"name":"Maps_To","value":"FGFR3"},{"name":"OMIM_Number","value":"134934"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333543"}]}}{"C20743":{"preferredName":"FGFR4 Gene","code":"C20743","definitions":[{"definition":"This gene plays a role in mitogenesis and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR4","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3691"},{"name":"Legacy Concept Name","value":"FGFR4_Gene"},{"name":"Maps_To","value":"FGFR4"},{"name":"OMIM_Number","value":"134935"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333544"}]}}{"C95268":{"preferredName":"FH Gene","code":"C95268","definitions":[{"definition":"This gene plays a role in the Krebs cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FH Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FH","termGroup":"SY","termSource":"NCI"},{"termName":"Fumarate Hydratase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3700"},{"name":"Maps_To","value":"FH"},{"name":"OMIM_Number","value":"136850"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366530"}]}}{"C18524":{"preferredName":"FHIT Gene","code":"C18524","definitions":[{"definition":"This gene is involved in nucleotide metabolism and cell cycle control.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FHIT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FHIT","termGroup":"SY","termSource":"NCI"},{"termName":"Fragile Histidine Triad Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3701"},{"name":"Legacy Concept Name","value":"FHIT_Gene"},{"name":"Maps_To","value":"FHIT"},{"name":"OMIM_Number","value":"601153"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919457"}]}}{"C97454":{"preferredName":"FIP1L1 Gene","code":"C97454","definitions":[{"definition":"This gene is involved in mRNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIP1L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FIP1 Like 1 (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FIP1L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19124"},{"name":"Maps_To","value":"FIP1L1"},{"name":"OMIM_Number","value":"607686"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426030"}]}}{"C143127":{"preferredName":"FKBP9 Gene","code":"C143127","definitions":[{"definition":"This gene is involved in chaperone-mediated protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FKBP9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FK506 Binding Protein 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FKBP9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3725"},{"name":"Maps_To","value":"FKBP9"},{"name":"NCI_META_CUI","value":"CL541520"},{"name":"OMIM_Number","value":"616257"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C63514":{"preferredName":"FLCN Gene","code":"C63514","definitions":[{"definition":"This gene may play a role in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLCN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLCN","termGroup":"SY","termSource":"NCI"},{"termName":"Folliculin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:27310"},{"name":"Legacy Concept Name","value":"FLCN_Gene"},{"name":"Maps_To","value":"FLCN"},{"name":"OMIM_Number","value":"607273"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539518"}]}}{"C18321":{"preferredName":"FLI1 Gene","code":"C18321","definitions":[{"definition":"This gene plays a role in transcriptional activation and has been implicated in the pathogenesis of neuroepithelioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLI1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLI1","termGroup":"SY","termSource":"NCI"},{"termName":"Friend Leukemia Virus Integration 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3749"},{"name":"Legacy Concept Name","value":"FLI1_Gene"},{"name":"Maps_To","value":"FLI1"},{"name":"OMIM_Number","value":"193067"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1860424"}]}}{"C113585":{"preferredName":"FLNA Gene","code":"C113585","definitions":[{"definition":"This gene is involved in remodeling of the cytoskeleton.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLNA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Filamin A, Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FLNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3754"},{"name":"Maps_To","value":"FLNA"},{"name":"OMIM_Number","value":"300017"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414635"}]}}{"C24399":{"preferredName":"FLT3 Gene","code":"C24399","definitions":[{"definition":"This gene plays a role in hematopoiesis and may function as a growth factor receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3","termGroup":"SY","termSource":"NCI"},{"termName":"FMS-Related Tyrosine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3765"},{"name":"Legacy Concept Name","value":"FLT3_Gene"},{"name":"Maps_To","value":"FLT3"},{"name":"OMIM_Number","value":"136351"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333568"}]}}{"C24400":{"preferredName":"FLT4 Gene","code":"C24400","definitions":[{"definition":"This gene plays an essential role in the development of embryonic cardiovasculature and lymphatic vessel formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLT4","termGroup":"SY","termSource":"NCI"},{"termName":"FMS Related Tyrosine Kinase 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3767"},{"name":"Legacy Concept Name","value":"FLT4_Gene"},{"name":"Maps_To","value":"FLT4"},{"name":"OMIM_Number","value":"136352"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333569"}]}}{"C97540":{"preferredName":"FNBP1 Gene","code":"C97540","definitions":[{"definition":"This gene plays a role in endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FNBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FNBP1","termGroup":"SY","termSource":"NCI"},{"termName":"Formin Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17069"},{"name":"Maps_To","value":"FNBP1"},{"name":"OMIM_Number","value":"606191"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424722"}]}}{"C101646":{"preferredName":"FOXA1 Gene","code":"C101646","definitions":[{"definition":"This gene plays a role in the modulation of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box A1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5021"},{"name":"Maps_To","value":"FOXA1"},{"name":"OMIM_Number","value":"602294"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415626"}]}}{"C75472":{"preferredName":"FOXL2 Gene","code":"C75472","definitions":[{"definition":"This gene plays a role in ovarian function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box L2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1092"},{"name":"Legacy Concept Name","value":"FOXL2_Gene"},{"name":"Maps_To","value":"FOXL2"},{"name":"OMIM_Number","value":"605597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412815"}]}}{"C24402":{"preferredName":"FOXO1 Gene","code":"C24402","definitions":[{"definition":"This gene is involved in transcriptional regulation and may play a role in myogenic growth and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXO1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box O1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXO1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3819"},{"name":"Legacy Concept Name","value":"FOXO1A_Gene"},{"name":"Maps_To","value":"FOXO1"},{"name":"OMIM_Number","value":"136533"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333572"}]}}{"C28519":{"preferredName":"FOXO3 Gene","code":"C28519","definitions":[{"definition":"This gene is involved in transcriptional regulation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXO3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box O3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXO3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3821"},{"name":"Legacy Concept Name","value":"FOXO3A_Gene"},{"name":"Maps_To","value":"FOXO3"},{"name":"OMIM_Number","value":"602681"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333573"}]}}{"C24606":{"preferredName":"FOXO4 Gene","code":"C24606","definitions":[{"definition":"This gene plays a role in smooth muscle cell differentiation, cellular growth, cell cycle regulation and tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXO4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box O4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXO4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7139"},{"name":"Legacy Concept Name","value":"MLLT7_Gene"},{"name":"Maps_To","value":"FOXO4"},{"name":"OMIM_Number","value":"300033"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334518"}]}}{"C97549":{"preferredName":"FOXP1 Gene","code":"C97549","definitions":[{"definition":"This gene is involved in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box P1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3823"},{"name":"Maps_To","value":"FOXP1"},{"name":"OMIM_Number","value":"605515"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414688"}]}}{"C143124":{"preferredName":"FOXR1 Gene","code":"C143124","definitions":[{"definition":"This gene plays a role in DNA binding and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box R1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29980"},{"name":"Maps_To","value":"FOXR1"},{"name":"NCI_META_CUI","value":"CL541517"},{"name":"OMIM_Number","value":"615755"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24408":{"preferredName":"FSTL3 Gene","code":"C24408","definitions":[{"definition":"This gene plays a role in a variety of processes including transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FSTL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Follistatin-Like 3 (Secreted Glycoprotein) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FSTL3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3973"},{"name":"Legacy Concept Name","value":"FSTL3_Gene"},{"name":"Maps_To","value":"FSTL3"},{"name":"OMIM_Number","value":"605343"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333581"}]}}{"C99614":{"preferredName":"FUBP1 Gene","code":"C99614","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FUBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Far Upstream Element (FUSE) Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FUBP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4004"},{"name":"Maps_To","value":"FUBP1"},{"name":"OMIM_Number","value":"603444"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414855"}]}}{"C91852":{"preferredName":"FUS Gene","code":"C91852","definitions":[{"definition":"This gene is involved in gene expression, genomic integrity and RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FUS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FUS","termGroup":"SY","termSource":"NCI"},{"termName":"FUS RNA Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TLS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4010"},{"name":"Maps_To","value":"FUS"},{"name":"OMIM_Number","value":"137070"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414860"}]}}{"C97562":{"preferredName":"GAS7 Gene","code":"C97562","definitions":[{"definition":"This gene may play a role in neuronal development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GAS7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GAS7","termGroup":"SY","termSource":"NCI"},{"termName":"Growth Arrest Specific 7 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4169"},{"name":"Maps_To","value":"GAS7"},{"name":"OMIM_Number","value":"603127"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414992"}]}}{"C28575":{"preferredName":"GATA1 Gene","code":"C28575","definitions":[{"definition":"This gene is involved in erythropoiesis and transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GATA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GATA Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GATA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4170"},{"name":"Legacy Concept Name","value":"GATA1_Gene"},{"name":"Maps_To","value":"GATA1"},{"name":"OMIM_Number","value":"305371"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333663"}]}}{"C97552":{"preferredName":"GATA2 Gene","code":"C97552","definitions":[{"definition":"This gene is involved in both DNA binding and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GATA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GATA Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GATA2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4171"},{"name":"Maps_To","value":"GATA2"},{"name":"OMIM_Number","value":"137295"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414993"}]}}{"C75492":{"preferredName":"GATA3 Gene","code":"C75492","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GATA3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GATA Binding Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GATA3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4172"},{"name":"Legacy Concept Name","value":"GATA3_Gene"},{"name":"Maps_To","value":"GATA3"},{"name":"OMIM_Number","value":"131320"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414994"}]}}{"C24432":{"preferredName":"GLI1 Gene","code":"C24432","definitions":[{"definition":"This gene plays a regulatory role in transcription and embryonic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GLI1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GLI Family Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GLI1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4317"},{"name":"Legacy Concept Name","value":"GLI_Gene"},{"name":"Maps_To","value":"GLI1"},{"name":"OMIM_Number","value":"165220"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812304"}]}}{"C97522":{"preferredName":"GMPS Gene","code":"C97522","definitions":[{"definition":"This gene plays a role in nucleotide biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GMPS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GMPS","termGroup":"SY","termSource":"NCI"},{"termName":"Guanine Monphosphate Synthetase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4378"},{"name":"Maps_To","value":"GMPS"},{"name":"OMIM_Number","value":"600358"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415137"}]}}{"C89717":{"preferredName":"GNA11 Gene","code":"C89717","definitions":[{"definition":"This gene is involved in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GNA11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"G Protein Subunit Alpha 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GNA11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4379"},{"name":"Maps_To","value":"GNA11"},{"name":"OMIM_Number","value":"139313"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415138"}]}}{"C38316":{"preferredName":"GNAQ Gene","code":"C38316","definitions":[{"definition":"This gene plays a role in signal transduction and is involved in calcium signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GNAQ Gene","termGroup":"PT","termSource":"NCI"},{"termName":"G Protein Subunit Alpha q Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GNAQ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4390"},{"name":"Legacy Concept Name","value":"GNAQ_Gene"},{"name":"Maps_To","value":"GNAQ"},{"name":"OMIM_Number","value":"600998"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333685"}]}}{"C38317":{"preferredName":"GNAS Gene","code":"C38317","definitions":[{"definition":"This gene plays a role in signal transduction and is associated with pituitary tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GNAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GNAS","termGroup":"SY","termSource":"NCI"},{"termName":"GNAS Complex Locus Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GNAS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4392"},{"name":"Legacy Concept Name","value":"GNAS_Gene"},{"name":"Maps_To","value":"GNAS"},{"name":"OMIM_Number","value":"139320"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366550"}]}}{"C97543":{"preferredName":"GOLGA5 Gene","code":"C97543","definitions":[{"definition":"This gene is involved in Golgi maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GOLGA5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GOLGA5","termGroup":"SY","termSource":"NCI"},{"termName":"Golgin A5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4428"},{"name":"Maps_To","value":"GOLGA5"},{"name":"OMIM_Number","value":"606918"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415177"}]}}{"C97546":{"preferredName":"GOPC Gene","code":"C97546","definitions":[{"definition":"This gene plays a role in protein transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GOPC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Golgi-Associated PDZ and Coiled-Coil Motif Containing Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GOPC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17643"},{"name":"Maps_To","value":"GOPC"},{"name":"OMIM_Number","value":"606845"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425021"}]}}{"C88173":{"preferredName":"GPC3 Gene","code":"C88173","definitions":[{"definition":"This gene is involved in heparin sulfate binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GPC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Glypican 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GPC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4451"},{"name":"Maps_To","value":"GPC3"},{"name":"OMIM_Number","value":"300037"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415195"}]}}{"C97525":{"preferredName":"GPHN Gene","code":"C97525","definitions":[{"definition":"This gene is involved in vitamin metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GPHN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Gephyrin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GPHN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15465"},{"name":"Maps_To","value":"GPHN"},{"name":"OMIM_Number","value":"603930"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423507"}]}}{"C98146":{"preferredName":"GRIN2A Gene","code":"C98146","definitions":[{"definition":"This gene is involved in the regulation of ion transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GRIN2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GRIN2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4585"},{"name":"Maps_To","value":"GRIN2A"},{"name":"OMIM_Number","value":"138253"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415299"}]}}{"C114529":{"preferredName":"GRM3 Gene","code":"C114529","definitions":[{"definition":"This gene is involved in ligand-depending signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GRM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Glutamate Receptor, Metabotropic 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GRM3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4595"},{"name":"Maps_To","value":"GRM3"},{"name":"OMIM_Number","value":"601115"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415307"}]}}{"C101443":{"preferredName":"H3-3A Gene","code":"C101443","definitions":[{"definition":"This gene is involved in chromatin structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H3-3A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H3-3A","termGroup":"SY","termSource":"NCI"},{"termName":"H3.3 Histone A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H3F3A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4764"},{"name":"Maps_To","value":"H3F3A"},{"name":"OMIM_Number","value":"601128"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415427"}]}}{"C113760":{"preferredName":"H3-3B Gene","code":"C113760","definitions":[{"definition":"This gene plays a role in nucleosome assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H3-3B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H3-3B","termGroup":"SY","termSource":"NCI"},{"termName":"H3.3 Histone B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H3F3B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4765"},{"name":"Maps_To","value":"H3F3B"},{"name":"OMIM_Number","value":"601058"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415428"}]}}{"C97534":{"preferredName":"HERPUD1 Gene","code":"C97534","definitions":[{"definition":"This gene is involved in the response to endoplasmic reticulum stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HERPUD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HERPUD1","termGroup":"SY","termSource":"NCI"},{"termName":"Homocysteine Inducible ER Protein with Ubiquitin Like Domain 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13744"},{"name":"Maps_To","value":"HERPUD1"},{"name":"OMIM_Number","value":"608070"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422179"}]}}{"C101107":{"preferredName":"HEY1 Gene","code":"C101107","definitions":[{"definition":"This gene is involved in both transcription factor binding and transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HEY1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Hes Related Family BHLH Transcription Factor With YRPW Motif 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HEY1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4880"},{"name":"Maps_To","value":"HEY1"},{"name":"OMIM_Number","value":"602953"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415524"}]}}{"C26372":{"preferredName":"HIF1A Gene","code":"C26372","definitions":[{"definition":"This gene plays a role in cardiovascular development and systemic oxygen homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIF1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HIF1A","termGroup":"SY","termSource":"NCI"},{"termName":"Hypoxia-Inducible Factor 1, Alpha Subunit (Basic Helix-Loop-Helix Transcription Factor) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4910"},{"name":"Legacy Concept Name","value":"HIF1A_Gene"},{"name":"Maps_To","value":"HIF1A"},{"name":"OMIM_Number","value":"603348"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333897"}]}}{"C97537":{"preferredName":"HIP1 Gene","code":"C97537","definitions":[{"definition":"This gene plays a role in both vesicle coat formation and endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HIP1","termGroup":"SY","termSource":"NCI"},{"termName":"Huntingtin Interacting Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4913"},{"name":"Maps_To","value":"HIP1"},{"name":"OMIM_Number","value":"601767"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415546"}]}}{"C101732":{"preferredName":"H3C2 Gene","code":"C101732","definitions":[{"definition":"This gene is involved in chromatin structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H3C2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H3 Clustered Histone 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H3C2","termGroup":"SY","termSource":"NCI"},{"termName":"HIST1H3B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4776"},{"name":"Maps_To","value":"HIST1H3B"},{"name":"OMIM_Number","value":"602819"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415439"}]}}{"C68734":{"preferredName":"H4C9 Gene","code":"C68734","definitions":[{"definition":"This gene plays a role in nucleosomal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H4C9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H4 Clustered Histone 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H4C9","termGroup":"SY","termSource":"NCI"},{"termName":"HIST1H4I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4793"},{"name":"Legacy Concept Name","value":"HIST1H4I_Gene"},{"name":"Maps_To","value":"HIST1H4I"},{"name":"OMIM_Number","value":"602833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415453"}]}}{"C28585":{"preferredName":"HLA-A Gene","code":"C28585","definitions":[{"definition":"This gene is involved in immune responses and histocompatibility processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-A","termGroup":"SY","termSource":"NCI"},{"termName":"Major Histocompatibility Complex, Class I, A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4931"},{"name":"Legacy Concept Name","value":"HLA-A_Gene"},{"name":"Maps_To","value":"HLA-A"},{"name":"OMIM_Number","value":"142800"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333899"}]}}{"C97556":{"preferredName":"HLF Gene","code":"C97556","definitions":[{"definition":"This gene is involved in both transcriptional regulation and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HLF","termGroup":"SY","termSource":"NCI"},{"termName":"HLF Transcription Factor, PAR BZIP Family Member Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4977"},{"name":"Maps_To","value":"HLF"},{"name":"OMIM_Number","value":"142385"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415594"}]}}{"C20576":{"preferredName":"HMGA1 Gene","code":"C20576","definitions":[{"definition":"This gene plays a role in a number of cellular processes including apoptosis, chromatin organization and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High Mobility Group AT-Hook 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5010"},{"name":"Legacy Concept Name","value":"HMGA1_Gene"},{"name":"Maps_To","value":"HMGA1"},{"name":"OMIM_Number","value":"600701"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333903"}]}}{"C20577":{"preferredName":"HMGA2 Gene","code":"C20577","definitions":[{"definition":"This gene is involved in chromatin organization and regulation of gene transcription. It also plays a role in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High Mobility Group AT-Hook 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGA2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5009"},{"name":"Legacy Concept Name","value":"HMGA2_Gene"},{"name":"Maps_To","value":"HMGA2"},{"name":"OMIM_Number","value":"600698"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333906"}]}}{"C98093":{"preferredName":"HMGN2P46 Gene","code":"C98093","definitions":[{"definition":"This gene may be involved in prostate functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGN2P46 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 46 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGN2P46","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26817"},{"name":"Maps_To","value":"HMGN2P46"},{"name":"OMIM_Number","value":"611314"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428626"}]}}{"C97825":{"preferredName":"HNF1A Gene","code":"C97825","definitions":[{"definition":"This gene plays a role in both DNA binding and transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HNF1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HNF1 Homeobox A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HNF1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11621"},{"name":"Maps_To","value":"HNF1A"},{"name":"OMIM_Number","value":"142410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420631"}]}}{"C97496":{"preferredName":"HNRNPA2B1 Gene","code":"C97496","definitions":[{"definition":"This gene is involved in RNA processing and transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HNRNPA2B1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heterogeneous Nuclear Ribonucleoprotein A2/B1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HNRNPA2B1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5033"},{"name":"Maps_To","value":"HNRNPA2B1"},{"name":"OMIM_Number","value":"600124"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415636"}]}}{"C97493":{"preferredName":"HOOK3 Gene","code":"C97493","definitions":[{"definition":"This gene plays a role in endocytosis and Golgi maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOOK3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Hook Homolog 3 (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOOK3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23576"},{"name":"Maps_To","value":"HOOK3"},{"name":"OMIM_Number","value":"607825"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428139"}]}}{"C97568":{"preferredName":"HOXA11 Gene","code":"C97568","definitions":[{"definition":"This gene is involved in embryologic pattern formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXA11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox A11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXA11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5101"},{"name":"Maps_To","value":"HOXA11"},{"name":"OMIM_Number","value":"142958"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415654"}]}}{"C97571":{"preferredName":"HOXA13 Gene","code":"C97571","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXA13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox A13 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXA13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5102"},{"name":"Maps_To","value":"HOXA13"},{"name":"OMIM_Number","value":"142959"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415655"}]}}{"C24474":{"preferredName":"HOXA9 Gene","code":"C24474","definitions":[{"definition":"This gene plays a role in transcriptional regulation, morphogenesis and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXA9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox A9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXA9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5109"},{"name":"Legacy Concept Name","value":"HOXA9_Gene"},{"name":"Maps_To","value":"HOXA9"},{"name":"OMIM_Number","value":"142956"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333922"}]}}{"C162630":{"preferredName":"HOXB1 Gene","code":"C162630","definitions":[{"definition":"This gene is involved in the development of anterior embryonic structures and facial nerves.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox B1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5111"},{"name":"Maps_To","value":"HOXB1"},{"name":"OMIM_Number","value":"142968"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415663"}]}}{"C97574":{"preferredName":"HOXC11 Gene","code":"C97574","definitions":[{"definition":"This gene is involved in embryological development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXC11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox C11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXC11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5123"},{"name":"Maps_To","value":"HOXC11"},{"name":"OMIM_Number","value":"605559"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415675"}]}}{"C97577":{"preferredName":"HOXC13 Gene","code":"C97577","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXC13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox C13 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXC13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5125"},{"name":"Maps_To","value":"HOXC13"},{"name":"OMIM_Number","value":"142976"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415677"}]}}{"C97580":{"preferredName":"HOXD11 Gene","code":"C97580","definitions":[{"definition":"This gene is involved in limb morphogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXD11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox D11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXD11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5134"},{"name":"Maps_To","value":"HOXD11"},{"name":"OMIM_Number","value":"142986"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415685"}]}}{"C97583":{"preferredName":"HOXD13 Gene","code":"C97583","definitions":[{"definition":"This gene plays a role in the development of limbs and appendages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXD13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox D13 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXD13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5136"},{"name":"Maps_To","value":"HOXD13"},{"name":"OMIM_Number","value":"142989"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415687"}]}}{"C17060":{"preferredName":"HRAS Gene","code":"C17060","definitions":[{"definition":"A gene that may cause cancer when it is mutated (changed). The Hras gene makes the HRAS protein, which is involved in cell signaling pathways, cell growth, and apoptosis (cell death). Agents that block the actions of the mutated Hras gene or its protein in cancer cells may stop the growth of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene plays a role in signal transduction and cellular communication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HRAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HRAS","termGroup":"SY","termSource":"NCI"},{"termName":"HRas Proto-Oncogene, GTPase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5173"},{"name":"Legacy Concept Name","value":"HRAS_Gene"},{"name":"Maps_To","value":"HRAS"},{"name":"OMIM_Number","value":"190020"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0079471"}]}}{"C97586":{"preferredName":"HSP90AA1 Gene","code":"C97586","definitions":[{"definition":"This gene is involved in both protein folding and nitric oxide metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HSP90AA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Alpha Family Class A Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90AA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5253"},{"name":"Maps_To","value":"HSP90AA1"},{"name":"OMIM_Number","value":"140571"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825534"}]}}{"C97589":{"preferredName":"HSP90AB1 Gene","code":"C97589","definitions":[{"definition":"This gene plays a role in both interferon signaling and protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HSP90AB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90kDa Alpha (Cytosolic), Class B Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90AB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5258"},{"name":"Maps_To","value":"HSP90AB1"},{"name":"OMIM_Number","value":"140572"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825540"}]}}{"C102968":{"preferredName":"ID3 Gene","code":"C102968","definitions":[{"definition":"This gene plays a role in transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ID3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ID3","termGroup":"SY","termSource":"NCI"},{"termName":"Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5362"},{"name":"Maps_To","value":"ID3"},{"name":"OMIM_Number","value":"600277"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415856"}]}}{"C77215":{"preferredName":"IDH1 Gene","code":"C77215","definitions":[{"definition":"This gene plays a role in carbohydrate metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IDH1","termGroup":"SY","termSource":"NCI"},{"termName":"Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5382"},{"name":"Legacy Concept Name","value":"IDH1_Gene"},{"name":"Maps_To","value":"IDH1"},{"name":"OMIM_Number","value":"147700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415876"}]}}{"C84948":{"preferredName":"IDH2 Gene","code":"C84948","definitions":[{"definition":"This gene plays a role in intermediary metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IDH2","termGroup":"SY","termSource":"NCI"},{"termName":"Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5383"},{"name":"Maps_To","value":"IDH2"},{"name":"OMIM_Number","value":"147650"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415877"}]}}{"C26422":{"preferredName":"Immunoglobulin Heavy Locus","code":"C26422","definitions":[{"definition":"This region represents the germline organization of the immunoglobulin heavy chain locus. The locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Heavy Locus","termGroup":"PT","termSource":"NCI"},{"termName":"IGH","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Heavy Chain Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Heavy Chain Locus","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Heavy Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"3492"},{"name":"GenBank_Accession_Number","value":"NG_001019"},{"name":"Gene_Encodes_Product","value":"Immunoglobulin Heavy Chain"},{"name":"HGNC_ID","value":"HGNC:5477"},{"name":"Legacy Concept Name","value":"Immunoglobulin_Heavy_Locus"},{"name":"Maps_To","value":"IGH"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0017351"}]}}{"C26425":{"preferredName":"Immunoglobulin Kappa Locus","code":"C26425","definitions":[{"definition":"This region represents the germline organization of the kappa light chain locus. The locus includes V (variable), J (joining), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a single V segment with a J segment; the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Kappa Locus","termGroup":"PT","termSource":"NCI"},{"termName":"IGK","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Kappa Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Kappa Light Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"50802"},{"name":"GenBank_Accession_Number","value":"NG_000833"},{"name":"Gene_Encodes_Product","value":"Immunoglobulin Light Chain, Kappa"},{"name":"HGNC_ID","value":"HGNC:5715"},{"name":"Legacy Concept Name","value":"Immunoglobulin_Kappa_Locus"},{"name":"Maps_To","value":"IGK"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366332"}]}}{"C171139":{"preferredName":"IGKC Gene","code":"C171139","definitions":[{"definition":"This gene plays a role in the structure of immunoglobulin light chains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGKC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IGKC","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Kappa Constant Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5716"},{"name":"Maps_To","value":"IGKC"},{"name":"OMIM_Number","value":"147200"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416163"}]}}{"C26423":{"preferredName":"Immunoglobulin Lambda Locus","code":"C26423","definitions":[{"definition":"This region represents the germline organization of the lambda light chain locus. The locus includes V (variable), J (joining), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a single V segment with a J segment; the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Lambda Locus","termGroup":"PT","termSource":"NCI"},{"termName":"IGL","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Lambda Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Lambda Light Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"3535"},{"name":"GenBank_Accession_Number","value":"NG_000002"},{"name":"Gene_Encodes_Product","value":"Immunoglobulin Light Chain, Lambda"},{"name":"HGNC_ID","value":"HGNC:5853"},{"name":"Legacy Concept Name","value":"Immunoglobulin_Lambda_Locus"},{"name":"Maps_To","value":"IGL"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0314619"}]}}{"C96383":{"preferredName":"IKBKB Gene","code":"C96383","definitions":[{"definition":"This gene is involved in protein phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IKBKB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IKBKB","termGroup":"SY","termSource":"NCI"},{"termName":"Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5960"},{"name":"Maps_To","value":"IKBKB"},{"name":"OMIM_Number","value":"603258"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1442489"}]}}{"C68730":{"preferredName":"IKZF1 Gene","code":"C68730","definitions":[{"definition":"This gene is involved in B-cell and T-cell maturation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IKZF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ikaros","termGroup":"SY","termSource":"NCI"},{"termName":"IKAROS Family Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"IKZF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13176"},{"name":"Legacy Concept Name","value":"IKZF1_Gene"},{"name":"Maps_To","value":"IKZF1"},{"name":"OMIM_Number","value":"603023"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825588"}]}}{"C24498":{"preferredName":"IL2 Gene","code":"C24498","definitions":[{"definition":"This gene is involved in growth and lymphokine regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL2","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6001"},{"name":"Legacy Concept Name","value":"IL2_Gene"},{"name":"Maps_To","value":"IL2"},{"name":"OMIM_Number","value":"147680"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879590"}]}}{"C68736":{"preferredName":"IL21R Gene","code":"C68736","definitions":[{"definition":"This gene is involved in cytokine recognition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL21R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL21R","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 21 Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6006"},{"name":"Legacy Concept Name","value":"IL21R_Gene"},{"name":"Maps_To","value":"IL21R"},{"name":"OMIM_Number","value":"605383"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416407"}]}}{"C24505":{"preferredName":"IL6ST Gene","code":"C24505","definitions":[{"definition":"This gene plays a role in signal transduction and is putatively involved in embryonic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL6ST Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL6ST","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 6 Signal Transducer Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6021"},{"name":"Legacy Concept Name","value":"IL6ST_Gene"},{"name":"Maps_To","value":"IL6ST"},{"name":"OMIM_Number","value":"600694"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1325331"}]}}{"C24506":{"preferredName":"IL7R Gene","code":"C24506","definitions":[{"definition":"This gene is involved in the regulation of lymphopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL7R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL7R","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 7 Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6024"},{"name":"Legacy Concept Name","value":"IL7R_Gene"},{"name":"Maps_To","value":"IL7R"},{"name":"OMIM_Number","value":"146661"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334123"}]}}{"C18430":{"preferredName":"IRF4 Gene","code":"C18430","definitions":[{"definition":"This gene is involved in the regulation of B-cell differentiation and proliferation. It also plays a role in mediating the proliferation of mitogen-stimulated T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IRF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Interferon Regulatory Factor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"IRF4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6119"},{"name":"Legacy Concept Name","value":"IRF4_Gene"},{"name":"Maps_To","value":"IRF4"},{"name":"OMIM_Number","value":"601900"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812314"}]}}{"C24524":{"preferredName":"IRS4 Gene","code":"C24524","definitions":[{"definition":"This gene plays a role in signal transduction and ligand binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IRS4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Insulin Receptor Substrate 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"IRS4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6128"},{"name":"Legacy Concept Name","value":"IRS4_Gene"},{"name":"Maps_To","value":"IRS4"},{"name":"OMIM_Number","value":"603510"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334142"}]}}{"C116411":{"preferredName":"ISX Gene","code":"C116411","definitions":[{"definition":"This gene is involved in gene expression regulation in the intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Intestine-Specific Homeobox Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ISX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28084"},{"name":"Maps_To","value":"ISX"},{"name":"OMIM_Number","value":"612019"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825625"}]}}{"C53661":{"preferredName":"ITGAV Gene","code":"C53661","definitions":[{"definition":"This gene plays a role in cell communication and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ITGAV Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Integrin, Alpha V Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ITGAV","termGroup":"SY","termSource":"NCI"},{"termName":"VTNR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6150"},{"name":"Legacy Concept Name","value":"ITGAV_Gene"},{"name":"Maps_To","value":"ITGAV"},{"name":"OMIM_Number","value":"193210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416494"}]}}{"C24526":{"preferredName":"ITK Gene","code":"C24526","definitions":[{"definition":"This gene is involved in the differentiation and proliferation of T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ITK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL2-Inducible T-Cell Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ITK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6171"},{"name":"Legacy Concept Name","value":"ITK_Gene"},{"name":"Maps_To","value":"ITK"},{"name":"OMIM_Number","value":"186973"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367389"}]}}{"C24528":{"preferredName":"JAK1 Gene","code":"C24528","definitions":[{"definition":"This gene plays a role in non-receptor tyrosine protein kinase-mediated signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAK1","termGroup":"SY","termSource":"NCI"},{"termName":"Janus Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6190"},{"name":"Legacy Concept Name","value":"JAK1_Gene"},{"name":"Maps_To","value":"JAK1"},{"name":"OMIM_Number","value":"147795"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334290"}]}}{"C24529":{"preferredName":"JAK2 Gene","code":"C24529","definitions":[{"definition":"This gene is involved in erythropoiesis and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAK2","termGroup":"SY","termSource":"NCI"},{"termName":"Janus Kinase 2 (A Protein Tyrosine Kinase) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6192"},{"name":"Legacy Concept Name","value":"JAK2_Gene"},{"name":"Maps_To","value":"JAK2"},{"name":"OMIM_Number","value":"147796"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334291"}]}}{"C24530":{"preferredName":"JAK3 Gene","code":"C24530","definitions":[{"definition":"This gene plays a role in signal transduction and non-receptor tyrosine protein kinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAK3","termGroup":"SY","termSource":"NCI"},{"termName":"Janus Kinase 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6193"},{"name":"Legacy Concept Name","value":"JAK3_Gene"},{"name":"Maps_To","value":"JAK3"},{"name":"OMIM_Number","value":"600173"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334292"}]}}{"C73542":{"preferredName":"JAZF1 Gene","code":"C73542","definitions":[{"definition":"This gene may be involved in transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAZF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAZF Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"JAZF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28917"},{"name":"Legacy Concept Name","value":"JAZF1_Gene"},{"name":"Maps_To","value":"JAZF1"},{"name":"OMIM_Number","value":"606246"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825635"}]}}{"C19531":{"preferredName":"JUN Gene","code":"C19531","definitions":[{"definition":"This gene plays a critical role in transcriptional regulation and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JUN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JUN","termGroup":"SY","termSource":"NCI"},{"termName":"v-JUN Sarcoma Virus 17 Oncogene Homolog (Avian) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6204"},{"name":"Legacy Concept Name","value":"JUN_Gene"},{"name":"Maps_To","value":"JUN"},{"name":"OMIM_Number","value":"165160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0162508"}]}}{"C71429":{"preferredName":"KAT6A Gene","code":"C71429","definitions":[{"definition":"This gene is involved in both histone acetylation and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KAT6A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KAT6A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Acetyltransferase 6A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MOZ","termGroup":"SY","termSource":"NCI"},{"termName":"MYST3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13013"},{"name":"Legacy Concept Name","value":"MYST3_Gene"},{"name":"Maps_To","value":"KAT6A"},{"name":"OMIM_Number","value":"601408"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421709"}]}}{"C71431":{"preferredName":"KAT6B Gene","code":"C71431","definitions":[{"definition":"This gene plays a role in both transcription and histone acetylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KAT6B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"K(Lysine) Acetyltransferase 6B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KAT6B","termGroup":"SY","termSource":"NCI"},{"termName":"MYST4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17582"},{"name":"Legacy Concept Name","value":"MYST4_Gene"},{"name":"Maps_To","value":"KAT6B"},{"name":"OMIM_Number","value":"605880"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425003"}]}}{"C73660":{"preferredName":"KAT7 Gene","code":"C73660","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression through histone acetylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KAT7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"K(Lysine) Acetyltransferase 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KAT7","termGroup":"SY","termSource":"NCI"},{"termName":"MYST2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17016"},{"name":"Legacy Concept Name","value":"MYST2_Gene"},{"name":"Maps_To","value":"KAT7"},{"name":"OMIM_Number","value":"609880"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424687"}]}}{"C95838":{"preferredName":"KCNJ5 Gene","code":"C95838","definitions":[{"definition":"This gene is involved in ion transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KCNJ5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KCNJ5","termGroup":"SY","termSource":"NCI"},{"termName":"Potassium Voltage-Gated Channel Subfamily J Member 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6266"},{"name":"Maps_To","value":"KCNJ5"},{"name":"OMIM_Number","value":"600734"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416587"}]}}{"C97595":{"preferredName":"KDM5A Gene","code":"C97595","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDM5A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JARID1A","termGroup":"SY","termSource":"NCI"},{"termName":"KDM5A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine (K)-Specific Demethylase 5A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9886"},{"name":"Maps_To","value":"KDM5A"},{"name":"OMIM_Number","value":"180202"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419288"}]}}{"C97598":{"preferredName":"KDM5C Gene","code":"C97598","definitions":[{"definition":"This gene is involved in histone modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDM5C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KDM5C","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine (K)-Specific Demethylase 5C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11114"},{"name":"Maps_To","value":"KDM5C"},{"name":"OMIM_Number","value":"314690"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539790"}]}}{"C96334":{"preferredName":"KDM6A Gene","code":"C96334","definitions":[{"definition":"This gene is involved in the modulation of histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDM6A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KDM6A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Demethylase 6A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12637"},{"name":"Maps_To","value":"KDM6A"},{"name":"OMIM_Number","value":"300128"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421414"}]}}{"C24532":{"preferredName":"KDR Gene","code":"C24532","definitions":[{"definition":"This gene plays a role in angiogenesis and vascular regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KDR","termGroup":"SY","termSource":"NCI"},{"termName":"Kinase Insert Domain Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6307"},{"name":"Legacy Concept Name","value":"KDR_Gene"},{"name":"Maps_To","value":"KDR"},{"name":"OMIM_Number","value":"191306"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334306"}]}}{"C24410":{"preferredName":"KDSR Gene","code":"C24410","definitions":[{"definition":"This gene plays a role in glycosphingolipid metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDSR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"3-Ketodihydrosphingosine Reductase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FVT1","termGroup":"SY","termSource":"NCI"},{"termName":"KDSR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4021"},{"name":"Legacy Concept Name","value":"FVT1_Gene"},{"name":"Maps_To","value":"KDSR"},{"name":"OMIM_Number","value":"136440"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333583"}]}}{"C112105":{"preferredName":"KEAP1 Gene","code":"C112105","definitions":[{"definition":"This gene is involved in ubiquitin-mediated protein degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KEAP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KEAP1","termGroup":"SY","termSource":"NCI"},{"termName":"Kelch-Like ECH-Associated Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23177"},{"name":"Maps_To","value":"KEAP1"},{"name":"OMIM_Number","value":"606016"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427969"}]}}{"C98017":{"preferredName":"KIAA1549 Gene","code":"C98017","definitions":[{"definition":"This gene may play a role in brain functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KIAA1549 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIAA1549","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22219"},{"name":"Maps_To","value":"KIAA1549"},{"name":"OMIM_Number","value":"613344"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2681629"}]}}{"C101425":{"preferredName":"KIF5B Gene","code":"C101425","definitions":[{"definition":"This gene is involved in the transport of vesicles along microtubules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KIF5B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIF5B","termGroup":"SY","termSource":"NCI"},{"termName":"Kinesin Family Member 5B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6324"},{"name":"Maps_To","value":"KIF5B"},{"name":"OMIM_Number","value":"602809"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416639"}]}}{"C18609":{"preferredName":"KIT Gene","code":"C18609","definitions":[{"definition":"This gene plays a role in cellular hematopoiesis and differentiations. Mutations in the gene are associated with several diseases, including acute myelogenous leukemia, gastrointestinal tumors, and mast cell disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KIT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIT","termGroup":"SY","termSource":"NCI"},{"termName":"V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6342"},{"name":"Legacy Concept Name","value":"C-KIT_Gene"},{"name":"Maps_To","value":"KIT"},{"name":"OMIM_Number","value":"164920"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416655"}]}}{"C73449":{"preferredName":"KLF4 Gene","code":"C73449","definitions":[{"definition":"This gene plays a role in gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KLF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KLF4","termGroup":"SY","termSource":"NCI"},{"termName":"Kruppel Like Factor 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6348"},{"name":"Legacy Concept Name","value":"KLF4_Gene"},{"name":"Maps_To","value":"KLF4"},{"name":"OMIM_Number","value":"602253"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416660"}]}}{"C97448":{"preferredName":"KLF6 Gene","code":"C97448","definitions":[{"definition":"This gene plays a role in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KLF6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KLF6","termGroup":"SY","termSource":"NCI"},{"termName":"Kruppel-Like Factor 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2235"},{"name":"Maps_To","value":"KLF6"},{"name":"OMIM_Number","value":"602053"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537486"}]}}{"C26584":{"preferredName":"KLK2 Gene","code":"C26584","definitions":[{"definition":"This gene plays a role in proteolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KLK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Kallikrein 2, Prostatic Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KLK2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6363"},{"name":"Legacy Concept Name","value":"KLK2_Gene"},{"name":"Maps_To","value":"KLK2"},{"name":"OMIM_Number","value":"147960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334308"}]}}{"C18585":{"preferredName":"KMT2A Gene","code":"C18585","definitions":[{"definition":"This gene is involved in transcriptional regulation and alterations in the gene are associated with acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KMT2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Methyltransferase 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MLL","termGroup":"SY","termSource":"NCI"},{"termName":"MLL Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7132"},{"name":"Legacy Concept Name","value":"MLL_Gene"},{"name":"Maps_To","value":"KMT2A"},{"name":"OMIM_Number","value":"159555"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919528"}]}}{"C93091":{"preferredName":"KMT2C Gene","code":"C93091","definitions":[{"definition":"This gene plays a role in both methylation and transcriptional regulation","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KMT2C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KMT2C","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Specific Methyltransferase 2C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MLL3","termGroup":"SY","termSource":"NCI"},{"termName":"MLL3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13726"},{"name":"Maps_To","value":"KMT2C"},{"name":"OMIM_Number","value":"606833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422165"}]}}{"C24600":{"preferredName":"KMT2D Gene","code":"C24600","definitions":[{"definition":"This gene plays a role in co-activation of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KMT2D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KMT2D","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Methyltransferase 2D Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MLL2","termGroup":"SY","termSource":"NCI"},{"termName":"MLL2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7133"},{"name":"Legacy Concept Name","value":"MLL2_Gene"},{"name":"Maps_To","value":"KMT2D"},{"name":"OMIM_Number","value":"602113"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334512"}]}}{"C97378":{"preferredName":"KNL1 Gene","code":"C97378","definitions":[{"definition":"This gene is involved in both signaling and chromosome alignment in mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KNL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CASC5","termGroup":"SY","termSource":"NCI"},{"termName":"Kinetochore Scaffold 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KNL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24054"},{"name":"Maps_To","value":"KNL1"},{"name":"OMIM_Number","value":"609173"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539063"}]}}{"C119652":{"preferredName":"KNSTRN Gene","code":"C119652","definitions":[{"definition":"This gene plays a role in both mitotic spindle formation and chromosome segregation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KNSTRN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Kinetochore-Localized Astrin/SPAG5 Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KNSTRN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30767"},{"name":"Maps_To","value":"KNSTRN"},{"name":"OMIM_Number","value":"614718"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539051"}]}}{"C25785":{"preferredName":"KRAS Gene","code":"C25785","definitions":[{"definition":"A gene that may cause cancer when it is mutated (changed). The Kras gene makes the KRAS protein, which is involved in cell signaling pathways, cell growth, and apoptosis (cell death). Agents that block the activity of the mutated Kras gene or its protein may stop the growth of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in signal transduction and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KRAS","termGroup":"SY","termSource":"NCI"},{"termName":"KRas Proto-Oncogene, GTPase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6407"},{"name":"Legacy Concept Name","value":"KRAS2_Gene"},{"name":"Maps_To","value":"KRAS"},{"name":"OMIM_Number","value":"190070"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537502"}]}}{"C96457":{"preferredName":"KRT20 Gene","code":"C96457","definitions":[{"definition":"This gene plays a role in the formation of intestinal epithelia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRT20 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Keratin 20 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KRT20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20412"},{"name":"Maps_To","value":"KRT20"},{"name":"OMIM_Number","value":"608218"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426926"}]}}{"C96444":{"preferredName":"KRT7 Gene","code":"C96444","definitions":[{"definition":"This gene plays a role in DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRT7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Keratin 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KRT7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6445"},{"name":"Maps_To","value":"KRT7"},{"name":"OMIM_Number","value":"148059"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416745"}]}}{"C97601":{"preferredName":"KTN1 Gene","code":"C97601","definitions":[{"definition":"This gene plays a role in kinesin function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KTN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Kinectin 1 (Kinesin Receptor) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KTN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6467"},{"name":"Maps_To","value":"KTN1"},{"name":"OMIM_Number","value":"600381"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416766"}]}}{"C143064":{"preferredName":"LARP4B Gene","code":"C143064","definitions":[{"definition":"This gene is involved in RNA metabolism and translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LARP4B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"La Ribonucleoprotein Domain Family Member 4B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LARP4B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28987"},{"name":"Maps_To","value":"LARP4B"},{"name":"NCI_META_CUI","value":"CL541460"},{"name":"OMIM_Number","value":"616513"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97604":{"preferredName":"LASP1 Gene","code":"C97604","definitions":[{"definition":"This gene is involved in actin-dependent ion transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LASP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LASP1","termGroup":"SY","termSource":"NCI"},{"termName":"LIM and SH3 Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6513"},{"name":"Maps_To","value":"LASP1"},{"name":"OMIM_Number","value":"602920"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416800"}]}}{"C18541":{"preferredName":"LCK Gene","code":"C18541","definitions":[{"definition":"This gene is involved in signal transduction and the development/function of T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LCK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LCK","termGroup":"SY","termSource":"NCI"},{"termName":"LCK Proto-Oncogene, Src Family Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6524"},{"name":"Legacy Concept Name","value":"LCK_Gene"},{"name":"Maps_To","value":"LCK"},{"name":"OMIM_Number","value":"153390"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919477"}]}}{"C21294":{"preferredName":"LCP1 Gene","code":"C21294","definitions":[{"definition":"This gene plays a role in cytoskeletal remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LCP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LCP1","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Cytosolic Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6528"},{"name":"Legacy Concept Name","value":"LCP1_Gene"},{"name":"Maps_To","value":"LCP1"},{"name":"OMIM_Number","value":"153430"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334332"}]}}{"C80032":{"preferredName":"LEF1 Gene","code":"C80032","definitions":[{"definition":"This gene plays a role in both signal transduction and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LEF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LEF1","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoid Enhancer-Binding Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6551"},{"name":"Legacy Concept Name","value":"LEF1_Gene"},{"name":"Maps_To","value":"LEF1"},{"name":"OMIM_Number","value":"153245"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1384617"}]}}{"C97607":{"preferredName":"LHFPL6 Gene","code":"C97607","definitions":[{"definition":"This gene may play a role in cell adhesion or cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LHFPL6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LHFP","termGroup":"SY","termSource":"NCI"},{"termName":"LHFPL Tetraspan Subfamily Member 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LHFPL6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6586"},{"name":"Maps_To","value":"LHFP"},{"name":"OMIM_Number","value":"606710"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416844"}]}}{"C24552":{"preferredName":"LIFR Gene","code":"C24552","definitions":[{"definition":"This gene plays a critical role in cell fate and proliferation in both embryonic and adult cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LIFR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Inhibitory Factor Receptor Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LIFR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6597"},{"name":"Legacy Concept Name","value":"LIFR_Gene"},{"name":"Maps_To","value":"LIFR"},{"name":"OMIM_Number","value":"151443"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334339"}]}}{"C61148":{"preferredName":"LMNA Gene","code":"C61148","definitions":[{"definition":"This gene is involved in the architecture of nuclear membrane construction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMNA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Lamin A/C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LMNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6636"},{"name":"Legacy Concept Name","value":"LMNA_Gene"},{"name":"Maps_To","value":"LMNA"},{"name":"OMIM_Number","value":"150330"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416877"}]}}{"C91263":{"preferredName":"LMO1 Gene","code":"C91263","definitions":[{"definition":"This gene is involved in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMO1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LIM Domain Only 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LMO1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6641"},{"name":"Maps_To","value":"LMO1"},{"name":"OMIM_Number","value":"186921"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416881"}]}}{"C17973":{"preferredName":"LMO2 Gene","code":"C17973","definitions":[{"definition":"This gene plays a crucial role in hematopoietic development and is involved in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMO2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LIM Domain Only 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LMO2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6642"},{"name":"Legacy Concept Name","value":"LMO2_Gene"},{"name":"Maps_To","value":"LMO2"},{"name":"OMIM_Number","value":"180385"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0380093"}]}}{"C97610":{"preferredName":"LPP Gene","code":"C97610","definitions":[{"definition":"This gene may be involved in cell shape and cell motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LPP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LIM Domain Containing Preferred Translocation Partner in Lipoma Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LPP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6679"},{"name":"Maps_To","value":"LPP"},{"name":"OMIM_Number","value":"600700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416904"}]}}{"C101446":{"preferredName":"LRIG3 Gene","code":"C101446","definitions":[{"definition":"This gene may be involved in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRIG3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Leucine-Rich Repeats and Immunoglobulin-Like Domains 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LRIG3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30991"},{"name":"Maps_To","value":"LRIG3"},{"name":"OMIM_Number","value":"608870"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537590"}]}}{"C111830":{"preferredName":"LRP1B Gene","code":"C111830","definitions":[{"definition":"This gene plays a role in low density lipoprotein metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRP1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Low Density Lipoprotein Receptor-Related Protein 1B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LRP1B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6693"},{"name":"Maps_To","value":"LRP1B"},{"name":"OMIM_Number","value":"608766"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416913"}]}}{"C122884":{"preferredName":"LSM14A Gene","code":"C122884","definitions":[{"definition":"This gene plays a role in the storage of mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LSM14A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LSM14A","termGroup":"SY","termSource":"NCI"},{"termName":"LSM14A, SCD6 Homolog A (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24489"},{"name":"Maps_To","value":"LSM14A"},{"name":"OMIM_Number","value":"610677"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825913"}]}}{"C24564":{"preferredName":"LYL1 Gene","code":"C24564","definitions":[{"definition":"This gene plays a role in transcriptional regulation and is involved in the pathogenesis of acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LYL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LYL1","termGroup":"SY","termSource":"NCI"},{"termName":"LYL1 Basic Helix-Loop-Helix Family Member Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6734"},{"name":"Legacy Concept Name","value":"LYL1_Gene"},{"name":"Maps_To","value":"LYL1"},{"name":"OMIM_Number","value":"151440"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334354"}]}}{"C128257":{"preferredName":"LZTR1 Gene","code":"C128257","definitions":[{"definition":"This gene may be involved in Golgi stabilization, embryogenesis or transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LZTR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Leucine Zipper Like Transcription Regulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LZTR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6742"},{"name":"Maps_To","value":"LZTR1"},{"name":"OMIM_Number","value":"600574"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416947"}]}}{"C18417":{"preferredName":"MAF Gene","code":"C18417","definitions":[{"definition":"This gene plays a role in transcriptional regulation and cellular differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAF","termGroup":"SY","termSource":"NCI"},{"termName":"MAF bZIP Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6776"},{"name":"Legacy Concept Name","value":"MAF_Gene"},{"name":"Maps_To","value":"MAF"},{"name":"OMIM_Number","value":"177075"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919481"}]}}{"C97671":{"preferredName":"MAFB Gene","code":"C97671","definitions":[{"definition":"This gene plays a role in both hematopoiesis and transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAFB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAF bZIP Transcription Factor B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MAFB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6408"},{"name":"Maps_To","value":"MAFB"},{"name":"OMIM_Number","value":"608968"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416710"}]}}{"C92696":{"preferredName":"MALAT1 Gene","code":"C92696","definitions":[{"definition":"This gene may play a role in carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MALAT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MALAT1","termGroup":"SY","termSource":"NCI"},{"termName":"Metastasis Associated Lung Adenocarcinoma Transcript 1 (Non-Protein Coding) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29665"},{"name":"Maps_To","value":"MALAT1"},{"name":"OMIM_Number","value":"607924"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537647"}]}}{"C60671":{"preferredName":"MALT1 Gene","code":"C60671","definitions":[{"definition":"This gene plays a role in signal transduction and in the pathology of mucosa-associated lymphoid tissue lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MALT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MALT1","termGroup":"SY","termSource":"NCI"},{"termName":"MALT1 Paracaspase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6819"},{"name":"Legacy Concept Name","value":"MALT1_Gene"},{"name":"Maps_To","value":"MALT1"},{"name":"OMIM_Number","value":"604860"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416991"}]}}{"C95456":{"preferredName":"MAML2 Gene","code":"C95456","definitions":[{"definition":"This gene plays a role in transcriptional regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAML2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAML2","termGroup":"SY","termSource":"NCI"},{"termName":"Mastermind Like Transcriptional Coactivator 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16259"},{"name":"Maps_To","value":"MAML2"},{"name":"OMIM_Number","value":"607537"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424132"}]}}{"C117094":{"preferredName":"MAML3 Gene","code":"C117094","definitions":[{"definition":"This gene plays a role in both transcriptional activation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAML3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAML3","termGroup":"SY","termSource":"NCI"},{"termName":"Mastermind Like Transcriptional Coactivator 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16272"},{"name":"Maps_To","value":"MAML3"},{"name":"OMIM_Number","value":"608991"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424142"}]}}{"C21222":{"preferredName":"MAP2K1 Gene","code":"C21222","definitions":[{"definition":"This gene plays a role in signal transduction and regulation of transcription. It is also involved in cell differentiation, growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP2K1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K1","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6840"},{"name":"Legacy Concept Name","value":"MAP2K1_Gene"},{"name":"Maps_To","value":"MAP2K1"},{"name":"OMIM_Number","value":"176872"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334474"}]}}{"C106606":{"preferredName":"MAP2K2 Gene","code":"C106606","definitions":[{"definition":"This gene plays a role in both protein phosphorylation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP2K2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K2","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6842"},{"name":"Maps_To","value":"MAP2K2"},{"name":"OMIM_Number","value":"601263"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1456385"}]}}{"C97674":{"preferredName":"MAP2K4 Gene","code":"C97674","definitions":[{"definition":"This gene is involved in MAPK signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP2K4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K4","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6844"},{"name":"Maps_To","value":"MAP2K4"},{"name":"OMIM_Number","value":"601335"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417008"}]}}{"C24572":{"preferredName":"MAP3K1 Gene","code":"C24572","definitions":[{"definition":"This gene plays a role in mediating cellular responses to growth factors, metabolic stimuli and mitogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP3K1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP3K1","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6848"},{"name":"Legacy Concept Name","value":"MAP3K1_Gene"},{"name":"Maps_To","value":"MAP3K1"},{"name":"OMIM_Number","value":"600982"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367675"}]}}{"C102523":{"preferredName":"MAP3K13 Gene","code":"C102523","definitions":[{"definition":"This gene is involved in both protein phosphorylation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP3K13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP3K13","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase Kinase 13 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6852"},{"name":"Maps_To","value":"MAP3K13"},{"name":"OMIM_Number","value":"604915"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417012"}]}}{"C21227":{"preferredName":"MAPK1 Gene","code":"C21227","definitions":[{"definition":"This gene plays a role in signal transduction and positive regulation of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAPK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAPK1","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6871"},{"name":"Legacy Concept Name","value":"MAPK1_Gene"},{"name":"Maps_To","value":"MAPK1"},{"name":"OMIM_Number","value":"176948"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366882"}]}}{"C18576":{"preferredName":"MAX Gene","code":"C18576","definitions":[{"definition":"This gene is involved in transcriptional regulation and plays a role in the mediation of DNA-protein interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAX","termGroup":"SY","termSource":"NCI"},{"termName":"MYC Associated Factor X Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6913"},{"name":"Legacy Concept Name","value":"MAX_Gene"},{"name":"Maps_To","value":"MAX"},{"name":"OMIM_Number","value":"154950"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919516"}]}}{"C132170":{"preferredName":"MB21D2 Gene","code":"C132170","definitions":[{"definition":"This gene plays a role in protein-protein interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MB21D2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mab-21 Domain Containing 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MB21D2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30438"},{"name":"Maps_To","value":"MB21D2"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C3147784"}]}}{"C18345":{"preferredName":"MDM2 Gene","code":"C18345","definitions":[{"definition":"This gene plays a role in several cellular processes related to cellular viability; including the cell cycle and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MDM2","termGroup":"SY","termSource":"NCI"},{"termName":"MDM2 Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6973"},{"name":"Legacy Concept Name","value":"MDM2_Gene"},{"name":"Maps_To","value":"MDM2"},{"name":"OMIM_Number","value":"164785"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812222"}]}}{"C88218":{"preferredName":"MDM4 Gene","code":"C88218","definitions":[{"definition":"This gene plays a role in both cell cycle arrest and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MDM4","termGroup":"SY","termSource":"NCI"},{"termName":"MDM4, p53 Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6974"},{"name":"Maps_To","value":"MDM4"},{"name":"OMIM_Number","value":"602704"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417089"}]}}{"C97615":{"preferredName":"MDS2 Gene","code":"C97615","definitions":[{"definition":"This gene plays a role in myelodysplastic syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MDS2","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome 2 Translocation Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29633"},{"name":"Maps_To","value":"MDS2"},{"name":"OMIM_Number","value":"607305"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825956"}]}}{"C18392":{"preferredName":"MECOM Gene","code":"C18392","definitions":[{"definition":"This gene plays a role in transcriptional regulation, histone methylation and leukemogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MECOM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EVI1","termGroup":"SY","termSource":"NCI"},{"termName":"MDS1 and EVI1 Complex Locus Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MECOM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3498"},{"name":"Legacy Concept Name","value":"EVI1_Gene"},{"name":"Maps_To","value":"MECOM"},{"name":"OMIM_Number","value":"165215"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812271"}]}}{"C98210":{"preferredName":"MED12 Gene","code":"C98210","definitions":[{"definition":"This gene plays a role in the regulation of RNA polymerase II-dependent transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MED12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MED12","termGroup":"SY","termSource":"NCI"},{"termName":"Mediator Complex Subunit 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11957"},{"name":"Maps_To","value":"MED12"},{"name":"OMIM_Number","value":"300188"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537677"}]}}{"C18254":{"preferredName":"MEN1 Gene","code":"C18254","definitions":[{"definition":"This gene is involved in transcriptional regulation and has tumor suppressor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MEN1","termGroup":"SY","termSource":"NCI"},{"termName":"Menin 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7010"},{"name":"Legacy Concept Name","value":"MEN1_Gene"},{"name":"Maps_To","value":"MEN1"},{"name":"OMIM_Number","value":"131100"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694884"}]}}{"C18325":{"preferredName":"MET Gene","code":"C18325","definitions":[{"definition":"This gene plays a regulatory role in the modulation of cell-surface receptors and hepatocyte growth factor interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MET","termGroup":"SY","termSource":"NCI"},{"termName":"MET Proto-Oncogene, Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7029"},{"name":"Legacy Concept Name","value":"C-MET_Gene"},{"name":"Maps_To","value":"MET"},{"name":"OMIM_Number","value":"164860"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417123"}]}}{"C21232":{"preferredName":"MGMT Gene","code":"C21232","definitions":[{"definition":"This gene is involved in DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MGMT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MGMT","termGroup":"SY","termSource":"NCI"},{"termName":"O-6-Methylguanine-DNA Methyltransferase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7059"},{"name":"Legacy Concept Name","value":"MGMT_Gene"},{"name":"Maps_To","value":"MGMT"},{"name":"OMIM_Number","value":"156569"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334505"}]}}{"C104651":{"preferredName":"MIB1 Gene","code":"C104651","definitions":[{"definition":"This gene is involved in both ubiquitination and cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MIB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MIB1","termGroup":"SY","termSource":"NCI"},{"termName":"Mindbomb E3 Ubiquitin Protein Ligase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:21086"},{"name":"Maps_To","value":"MIB1"},{"name":"OMIM_Number","value":"608677"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537692"}]}}{"C70584":{"preferredName":"MITF Gene","code":"C70584","definitions":[{"definition":"This gene is involved in transcriptional promotion in melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MITF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocyte Inducing Transcription Factor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MITF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7105"},{"name":"Legacy Concept Name","value":"MITF_Gene"},{"name":"Maps_To","value":"MITF"},{"name":"OMIM_Number","value":"156845"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417172"}]}}{"C97296":{"preferredName":"MRTFA Gene","code":"C97296","definitions":[{"definition":"This gene is involved in transcriptional modulation and muscle cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MRTFA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MKL1","termGroup":"SY","termSource":"NCI"},{"termName":"MRTFA","termGroup":"SY","termSource":"NCI"},{"termName":"Myocardin Related Transcription Factor A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14334"},{"name":"Maps_To","value":"MKL1"},{"name":"OMIM_Number","value":"606078"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422572"}]}}{"C97650":{"preferredName":"MLF1 Gene","code":"C97650","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MLF1","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Leukemia Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7125"},{"name":"Maps_To","value":"MLF1"},{"name":"OMIM_Number","value":"601402"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417188"}]}}{"C18482":{"preferredName":"MLH1 Gene","code":"C18482","definitions":[{"definition":"This gene plays a role in DNA mismatch repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MLH1","termGroup":"SY","termSource":"NCI"},{"termName":"MutL Homolog 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7127"},{"name":"Legacy Concept Name","value":"MLH1_Gene"},{"name":"Maps_To","value":"MLH1"},{"name":"OMIM_Number","value":"120436"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879389"}]}}{"C18590":{"preferredName":"PMS1 Gene","code":"C18590","definitions":[{"definition":"This gene is involved in mismatch repair and mutations in the gene result in hereditary non-polyposis colon cancer 3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PMS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MLH2","termGroup":"SY","termSource":"NCI"},{"termName":"PMS1","termGroup":"SY","termSource":"NCI"},{"termName":"PMS1 Postmeiotic Segregation Increased 1 (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9121"},{"name":"Legacy Concept Name","value":"PMS1_Gene"},{"name":"Maps_To","value":"MLH2"},{"name":"Maps_To","value":"PMS1"},{"name":"OMIM_Number","value":"600258"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879390"}]}}{"C24601":{"preferredName":"MLLT1 Gene","code":"C24601","definitions":[{"definition":"This gene is involved in transcriptional regulation as part of the transcription elongation factor complex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ENL","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT1","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT1, Super Elongation Complex Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7134"},{"name":"Legacy Concept Name","value":"MLLT1_Gene"},{"name":"Maps_To","value":"MLLT1"},{"name":"OMIM_Number","value":"159556"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334513"}]}}{"C84461":{"preferredName":"MLLT10 Gene","code":"C84461","definitions":[{"definition":"This gene may be involved in transcriptional regulation through the modulation of histone methyltransferase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF10","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT10","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16063"},{"name":"Maps_To","value":"MLLT10"},{"name":"OMIM_Number","value":"602409"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423947"}]}}{"C97387":{"preferredName":"MLLT11 Gene","code":"C97387","definitions":[{"definition":"This gene is involved in mitochondrial functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF1Q","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT11","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila); Translocated to, 11 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16997"},{"name":"Maps_To","value":"MLLT11"},{"name":"OMIM_Number","value":"604684"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826257"}]}}{"C24603":{"preferredName":"MLLT3 Gene","code":"C24603","definitions":[{"definition":"This gene plays a role in transcriptional regulation and translocations in the gene are associated with leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF9","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT3","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT3 Super Elongation Complex Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7136"},{"name":"Legacy Concept Name","value":"MLLT3_Gene"},{"name":"Maps_To","value":"MLLT3"},{"name":"OMIM_Number","value":"159558"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334515"}]}}{"C24604":{"preferredName":"AFDN Gene","code":"C24604","definitions":[{"definition":"This gene is involved in cell adhesion and cytoskeletal modeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFDN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF6","termGroup":"SY","termSource":"NCI"},{"termName":"Afadin, Adherens Junction Formation Factor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFDN","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7137"},{"name":"Legacy Concept Name","value":"MLLT4_Gene"},{"name":"Maps_To","value":"MLLT4"},{"name":"OMIM_Number","value":"159559"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334516"}]}}{"C24605":{"preferredName":"MLLT6 Gene","code":"C24605","definitions":[{"definition":"This gene is involved in transcriptional regulation and aberrations in the gene are associated with acute leukemias due to chromosomal translocations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF17","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT6","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT6, PHD Finger Containing Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7138"},{"name":"Legacy Concept Name","value":"MLLT6_Gene"},{"name":"Maps_To","value":"MLLT6"},{"name":"OMIM_Number","value":"600328"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334517"}]}}{"C97618":{"preferredName":"MN1 Gene","code":"C97618","definitions":[{"definition":"This gene is involved in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MN1","termGroup":"SY","termSource":"NCI"},{"termName":"MN1 Proto-Oncogene, Transcriptional Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7180"},{"name":"Maps_To","value":"MN1"},{"name":"OMIM_Number","value":"156100"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417217"}]}}{"C97559":{"preferredName":"MNX1 Gene","code":"C97559","definitions":[{"definition":"This gene plays a role in both the regulation of transcription and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MNX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HLXB9","termGroup":"SY","termSource":"NCI"},{"termName":"MNX1","termGroup":"SY","termSource":"NCI"},{"termName":"Motor Neuron and Pancreas Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4979"},{"name":"Maps_To","value":"MNX1"},{"name":"OMIM_Number","value":"142994"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415596"}]}}{"C18411":{"preferredName":"MPL Gene","code":"C18411","definitions":[{"definition":"This gene plays a regulatory role in megakaryocytopoiesis and platelet formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MPL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MPL","termGroup":"SY","termSource":"NCI"},{"termName":"MPL Proto-Oncogene, Thrombopoietin Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7217"},{"name":"Legacy Concept Name","value":"MPL_Gene"},{"name":"Maps_To","value":"MPL"},{"name":"OMIM_Number","value":"159530"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812295"}]}}{"C18481":{"preferredName":"MSH2 Gene","code":"C18481","definitions":[{"definition":"This gene plays a role in DNA mismatch repair mutations in the gene result in hereditary nonpolyposis colorectal cancer-1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MSH2","termGroup":"SY","termSource":"NCI"},{"termName":"MutS Homolog 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7325"},{"name":"Legacy Concept Name","value":"MSH2_Gene"},{"name":"Maps_To","value":"MSH2"},{"name":"OMIM_Number","value":"609309"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879290"}]}}{"C19195":{"preferredName":"MSH6 Gene","code":"C19195","definitions":[{"definition":"This gene is involved in mismatch repair and plays a role in several cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSH6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MSH6","termGroup":"SY","termSource":"NCI"},{"termName":"MutS Homolog 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7329"},{"name":"Legacy Concept Name","value":"MSH6_Gene"},{"name":"Maps_To","value":"MSH6"},{"name":"OMIM_Number","value":"600678"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879393"}]}}{"C91356":{"preferredName":"MSI2 Gene","code":"C91356","definitions":[{"definition":"This gene is involved in translational regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSI2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MSI2","termGroup":"SY","termSource":"NCI"},{"termName":"Musashi RNA Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18585"},{"name":"Maps_To","value":"MSI2"},{"name":"OMIM_Number","value":"607897"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425623"}]}}{"C97621":{"preferredName":"MSN Gene","code":"C97621","definitions":[{"definition":"This gene plays a role in both cell adhesion and cytoskeleton modeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Moesin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MSN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7373"},{"name":"Maps_To","value":"MSN"},{"name":"OMIM_Number","value":"309845"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417371"}]}}{"C24617":{"preferredName":"MTCP1 Gene","code":"C24617","definitions":[{"definition":"This gene plays a role in the proliferation of T cells and is involved in cell cycle regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MTCP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mature T-Cell Proliferation 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MTCP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7423"},{"name":"Legacy Concept Name","value":"MTCP1_Gene"},{"name":"Maps_To","value":"MTCP1"},{"name":"OMIM_Number","value":"300116"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334535"}]}}{"C38928":{"preferredName":"MTOR Gene","code":"C38928","definitions":[{"definition":"This gene plays a role in apoptosis, cell growth, differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MTOR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mechanistic Target of Rapamycin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MTOR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3942"},{"name":"Legacy Concept Name","value":"FRAP1_Gene"},{"name":"Maps_To","value":"MTOR"},{"name":"OMIM_Number","value":"601231"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414805"}]}}{"C38939":{"preferredName":"MUC1 Gene","code":"C38939","definitions":[{"definition":"This gene plays a role in cellular signal transduction and is used as a biomarker for breast cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MUC1","termGroup":"SY","termSource":"NCI"},{"termName":"Mucin 1, Cell Surface Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7508"},{"name":"Legacy Concept Name","value":"MUC1_Gene"},{"name":"Maps_To","value":"MUC1"},{"name":"OMIM_Number","value":"158340"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417490"}]}}{"C71018":{"preferredName":"MUC16 Gene","code":"C71018","definitions":[{"definition":"This gene is involved in both cellular adhesion and the maintenance of mucosal surfaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC16 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MUC16","termGroup":"SY","termSource":"NCI"},{"termName":"Mucin 16, Cell Surface Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15582"},{"name":"Legacy Concept Name","value":"MUC16_Gene"},{"name":"Maps_To","value":"MUC16"},{"name":"OMIM_Number","value":"606154"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423594"}]}}{"C128854":{"preferredName":"MUC4 Gene","code":"C128854","definitions":[{"definition":"This gene is involved in both cell adhesion and receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MUC4","termGroup":"SY","termSource":"NCI"},{"termName":"Mucin 4, Cell Surface Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7514"},{"name":"Maps_To","value":"MUC4"},{"name":"OMIM_Number","value":"158372"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417496"}]}}{"C61056":{"preferredName":"MUTYH Gene","code":"C61056","definitions":[{"definition":"This gene plays a role in the repair of oxidative DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUTYH Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MutY DNA Glycosylase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MUTYH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7527"},{"name":"Legacy Concept Name","value":"MUTYH_Gene"},{"name":"Maps_To","value":"MUTYH"},{"name":"OMIM_Number","value":"604933"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417505"}]}}{"C28569":{"preferredName":"MYB Gene","code":"C28569","definitions":[{"definition":"This gene plays a role in hematopoietic cell proliferation and development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYB","termGroup":"SY","termSource":"NCI"},{"termName":"MYB Proto-Oncogene, Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7545"},{"name":"Legacy Concept Name","value":"MYB_Gene"},{"name":"Maps_To","value":"MYB"},{"name":"OMIM_Number","value":"189990"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0751994"}]}}{"C16887":{"preferredName":"MYC Gene","code":"C16887","definitions":[{"definition":"This gene plays a role in cell cycle progression and apoptosis. Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYC","termGroup":"SY","termSource":"NCI"},{"termName":"v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7553"},{"name":"Legacy Concept Name","value":"MYC_Gene"},{"name":"Maps_To","value":"MYC"},{"name":"OMIM_Number","value":"190080"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0086661"}]}}{"C18407":{"preferredName":"MYCL Gene","code":"C18407","definitions":[{"definition":"This gene is involved in transcriptional regulation and is frequently amplified in small-cell lung cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYCL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LMYC","termGroup":"SY","termSource":"NCI"},{"termName":"MYCL","termGroup":"SY","termSource":"NCI"},{"termName":"MYCL Proto-Oncogene, bHLH Transcription Factor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MYCL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7555"},{"name":"Legacy Concept Name","value":"LMYC_Gene"},{"name":"Maps_To","value":"MYCL"},{"name":"OMIM_Number","value":"164850"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812289"}]}}{"C18405":{"preferredName":"MYCN Gene","code":"C18405","definitions":[{"definition":"This gene is involved in transcriptional regulation and amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYCN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYCN","termGroup":"SY","termSource":"NCI"},{"termName":"MYCN Proto-Oncogene, bHLH Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7559"},{"name":"Legacy Concept Name","value":"NMYC_Gene"},{"name":"Maps_To","value":"MYCN"},{"name":"NCI_META_CUI","value":"CL414356"},{"name":"OMIM_Number","value":"164840"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C90089":{"preferredName":"MYD88 Gene","code":"C90089","definitions":[{"definition":"This gene is involved in the modulation of proinflammatory gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYD88 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYD88","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Differentiation Primary Response 88 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7562"},{"name":"Maps_To","value":"MYD88"},{"name":"OMIM_Number","value":"602170"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417530"}]}}{"C29957":{"preferredName":"MYH11 Gene","code":"C29957","definitions":[{"definition":"This gene plays a regulatory role in muscle contraction and the required ATP hydrolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYH11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Myosin Heavy Chain 11 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7569"},{"name":"Legacy Concept Name","value":"MYH11_Gene"},{"name":"Maps_To","value":"MYH11"},{"name":"OMIM_Number","value":"160745"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334538"}]}}{"C97646":{"preferredName":"MYH9 Gene","code":"C97646","definitions":[{"definition":"This gene is involved in both cytoskeleton modeling and cytokinesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYH9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYH9","termGroup":"SY","termSource":"NCI"},{"termName":"Myosin Heavy Chain 9 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7579"},{"name":"Maps_To","value":"MYH9"},{"name":"OMIM_Number","value":"160775"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417544"}]}}{"C122881":{"preferredName":"MYO5A Gene","code":"C122881","definitions":[{"definition":"This gene is involved in vesicle transport along actin filaments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYO5A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYO5A","termGroup":"SY","termSource":"NCI"},{"termName":"Myosin VA (Heavy Chain 12, Myoxin) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7602"},{"name":"Maps_To","value":"MYO5A"},{"name":"OMIM_Number","value":"160777"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417565"}]}}{"C93113":{"preferredName":"MYOD1 Gene","code":"C93113","definitions":[{"definition":"This gene plays a role in DNA binding and myogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYOD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYOD1","termGroup":"SY","termSource":"NCI"},{"termName":"Myogenic Differentiation 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7611"},{"name":"Maps_To","value":"MYOD1"},{"name":"OMIM_Number","value":"159970"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417574"}]}}{"C122903":{"preferredName":"NAB2 Gene","code":"C122903","definitions":[{"definition":"This gene plays a role in the repression of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NAB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NAB2","termGroup":"SY","termSource":"NCI"},{"termName":"NGFI-A Binding Protein 2 (EGR1 Binding Protein 2) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7627"},{"name":"Maps_To","value":"NAB2"},{"name":"OMIM_Number","value":"602381"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417589"}]}}{"C97653":{"preferredName":"NACA Gene","code":"C97653","definitions":[{"definition":"This gene plays a role in protein sorting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NACA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NACA","termGroup":"SY","termSource":"NCI"},{"termName":"Nascent Polypeptide Associated Complex Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7629"},{"name":"Maps_To","value":"NACA"},{"name":"OMIM_Number","value":"601234"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417590"}]}}{"C143075":{"preferredName":"NBEA Gene","code":"C143075","definitions":[{"definition":"This gene plays a role in membrane-targeting of protein kinase A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NBEA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NBEA","termGroup":"SY","termSource":"NCI"},{"termName":"Neurobeachin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7648"},{"name":"Maps_To","value":"NBEA"},{"name":"NCI_META_CUI","value":"CL541563"},{"name":"OMIM_Number","value":"604889"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C21178":{"preferredName":"NBN Gene","code":"C21178","definitions":[{"definition":"This gene plays a role in DNA repair and cell cycle checkpoints.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NBN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NBN","termGroup":"SY","termSource":"NCI"},{"termName":"Nibrin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7652"},{"name":"Legacy Concept Name","value":"NBS1_Gene"},{"name":"Maps_To","value":"NBN"},{"name":"OMIM_Number","value":"602667"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334862"}]}}{"C97433":{"preferredName":"NCKIPSD Gene","code":"C97433","definitions":[{"definition":"This gene plays a role in stress fiber formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCKIPSD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCK Interacting Protein with SH3 Domain Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NCKIPSD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15486"},{"name":"Maps_To","value":"NCKIPSD"},{"name":"OMIM_Number","value":"606671"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423524"}]}}{"C20695":{"preferredName":"NCOA1 Gene","code":"C20695","definitions":[{"definition":"This gene plays a role in regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOA1","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Coactivator 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7668"},{"name":"Legacy Concept Name","value":"NCOA1_Gene"},{"name":"Maps_To","value":"NCOA1"},{"name":"OMIM_Number","value":"602691"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334866"}]}}{"C20697":{"preferredName":"NCOA2 Gene","code":"C20697","definitions":[{"definition":"This gene is involved in regulation of transcription. It also plays a role in myogenic differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOA2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Coactivator 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7669"},{"name":"Legacy Concept Name","value":"NCOA2_Gene"},{"name":"Maps_To","value":"NCOA2"},{"name":"OMIM_Number","value":"601993"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334867"}]}}{"C18381":{"preferredName":"NCOA4 Gene","code":"C18381","definitions":[{"definition":"This gene is involved in the transcriptional activation of target genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOA4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOA4","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Coactivator 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7671"},{"name":"Legacy Concept Name","value":"NCOA4_Gene"},{"name":"Maps_To","value":"NCOA4"},{"name":"OMIM_Number","value":"601984"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812260"}]}}{"C28640":{"preferredName":"NCOR1 Gene","code":"C28640","definitions":[{"definition":"This gene is involved in chromatin remodeling and repression of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOR1","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Co-Repressor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7672"},{"name":"Legacy Concept Name","value":"NCOR1_Gene"},{"name":"Maps_To","value":"NCOR1"},{"name":"OMIM_Number","value":"600849"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334870"}]}}{"C28633":{"preferredName":"NCOR2 Gene","code":"C28633","definitions":[{"definition":"This gene plays a role in repression of transcription. It is also involved in chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOR2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Co-Repressor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7673"},{"name":"Legacy Concept Name","value":"NCOR2_Gene"},{"name":"Maps_To","value":"NCOR2"},{"name":"OMIM_Number","value":"600848"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334871"}]}}{"C24625":{"preferredName":"NDRG1 Gene","code":"C24625","definitions":[{"definition":"This gene plays a role in cellular stress responses. It is also involved in both cell growth and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NDRG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"N-myc Downstream Regulated Gene 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NDRG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7679"},{"name":"Legacy Concept Name","value":"NDRG1_Gene"},{"name":"Maps_To","value":"NDRG1"},{"name":"OMIM_Number","value":"605262"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334873"}]}}{"C17424":{"preferredName":"NF1 Gene","code":"C17424","definitions":[{"definition":"This gene plays a role in signal transduction and cytoskeletal remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibromin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7765"},{"name":"Legacy Concept Name","value":"NF1_Gene"},{"name":"Maps_To","value":"NF1"},{"name":"OMIM_Number","value":"162200"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0085113"}]}}{"C17425":{"preferredName":"NF2 Gene","code":"C17425","definitions":[{"definition":"This gene plays a role in cell adhesion and cytoskeletal remodeling. It is also involved in suppression of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibromin 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NF2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7773"},{"name":"Legacy Concept Name","value":"NF2_Gene"},{"name":"Maps_To","value":"NF2"},{"name":"OMIM_Number","value":"607379"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0085114"}]}}{"C93138":{"preferredName":"NFATC2 Gene","code":"C93138","definitions":[{"definition":"This gene is involved in cytokine gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFATC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFATC2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor of Activated T Cells 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7776"},{"name":"Maps_To","value":"NFATC2"},{"name":"OMIM_Number","value":"600490"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417695"}]}}{"C54237":{"preferredName":"NFE2L2 Gene","code":"C54237","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFE2L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFE2L2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor (Erythroid-Derived 2)-Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7782"},{"name":"Legacy Concept Name","value":"NFE2L2_Gene"},{"name":"Maps_To","value":"NFE2L2"},{"name":"OMIM_Number","value":"600492"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417701"}]}}{"C38401":{"preferredName":"NFIB Gene","code":"C38401","definitions":[{"definition":"This gene plays a role in transcriptional regulation and mediates DNA-binding interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFIB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFIB","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor I/B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7785"},{"name":"Legacy Concept Name","value":"NFIB_Gene"},{"name":"Maps_To","value":"NFIB"},{"name":"OMIM_Number","value":"600728"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417704"}]}}{"C18404":{"preferredName":"NFKB2 Gene","code":"C18404","definitions":[{"definition":"This gene plays a role in transcriptional regulation, signal transduction and inflammatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFKB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFKB2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor Kappa B Subunit 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7795"},{"name":"Legacy Concept Name","value":"NFKB2_Gene"},{"name":"Maps_To","value":"NFKB2"},{"name":"OMIM_Number","value":"164012"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812286"}]}}{"C38396":{"preferredName":"NFKBIE Gene","code":"C38396","definitions":[{"definition":"This gene plays a role in signal transduction and regulation of transcription. It is involved in the immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFKBIE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFKB Inhibitor Epsilon Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NFKBIE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7799"},{"name":"Legacy Concept Name","value":"NFKBIE_Gene"},{"name":"Maps_To","value":"NFKBIE"},{"name":"OMIM_Number","value":"604548"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417710"}]}}{"C97668":{"preferredName":"NIN Gene","code":"C97668","definitions":[{"definition":"This gene is involved in the localization of the centrosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NIN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NIN","termGroup":"SY","termSource":"NCI"},{"termName":"Ninein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14906"},{"name":"Maps_To","value":"NIN"},{"name":"NCI_META_CUI","value":"CL505189"},{"name":"OMIM_Number","value":"608684"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C73443":{"preferredName":"NKX2-1 Gene","code":"C73443","definitions":[{"definition":"This gene plays a role in thyroid gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NKX2-1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NK2 Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NKX2-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11825"},{"name":"Legacy Concept Name","value":"NKX2-1_Gene"},{"name":"Maps_To","value":"NKX2-1"},{"name":"OMIM_Number","value":"600635"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1384616"}]}}{"C71419":{"preferredName":"NONO Gene","code":"C71419","definitions":[{"definition":"This gene may play a role in both transcriptional regulation and nuclear RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NONO Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Non-POU Domain Containing, Octamer-Binding Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NONO","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7871"},{"name":"Legacy Concept Name","value":"NONO_Gene"},{"name":"Maps_To","value":"NONO"},{"name":"OMIM_Number","value":"300084"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417758"}]}}{"C24636":{"preferredName":"NOTCH1 Gene","code":"C24636","definitions":[{"definition":"This gene is involved in intercellular signal transduction that plays a key role in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NOTCH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Notch 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NOTCH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7881"},{"name":"Legacy Concept Name","value":"NOTCH1_Gene"},{"name":"Maps_To","value":"NOTCH1"},{"name":"OMIM_Number","value":"190198"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334889"}]}}{"C97677":{"preferredName":"NOTCH2 Gene","code":"C97677","definitions":[{"definition":"This gene plays a role in cell-cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NOTCH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Notch 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NOTCH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7882"},{"name":"Maps_To","value":"NOTCH2"},{"name":"OMIM_Number","value":"600275"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417767"}]}}{"C21185":{"preferredName":"NPM1 Gene","code":"C21185","definitions":[{"definition":"This gene is involved in the regulation of ribosomal assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NPM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NPM1","termGroup":"SY","termSource":"NCI"},{"termName":"Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7910"},{"name":"Legacy Concept Name","value":"NPM1_Gene"},{"name":"Maps_To","value":"NPM1"},{"name":"OMIM_Number","value":"164040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334894"}]}}{"C96007":{"preferredName":"NR4A3 Gene","code":"C96007","definitions":[{"definition":"This gene is involved in nuclear receptor-dependent modulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NR4A3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NR4A3","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Subfamily 4 Group A Member 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7982"},{"name":"Maps_To","value":"NR4A3"},{"name":"OMIM_Number","value":"600542"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417837"}]}}{"C25786":{"preferredName":"NRAS Gene","code":"C25786","definitions":[{"definition":"This gene plays a role in signal transduction and cell cycle regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NRAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neuroblastoma RAS Viral Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NRAS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7989"},{"name":"Legacy Concept Name","value":"NRAS_Gene"},{"name":"Maps_To","value":"NRAS"},{"name":"OMIM_Number","value":"164790"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0809246"}]}}{"C20174":{"preferredName":"NRG1 Gene","code":"C20174","definitions":[{"definition":"This gene plays a role in cellular differentiation, growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NRG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neuregulin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NRG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7997"},{"name":"Legacy Concept Name","value":"NRG1_Gene"},{"name":"Maps_To","value":"NRG1"},{"name":"OMIM_Number","value":"142445"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367656"}]}}{"C75876":{"preferredName":"NSD1 Gene","code":"C75876","definitions":[{"definition":"This gene is involved in the mediation of histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NSD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NSD1","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Binding SET Domain Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14234"},{"name":"Legacy Concept Name","value":"NSD1_Gene"},{"name":"Maps_To","value":"NSD1"},{"name":"OMIM_Number","value":"606681"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422496"}]}}{"C21416":{"preferredName":"NSD2 Gene","code":"C21416","definitions":[{"definition":"This gene plays a role in histone-lysine methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NSD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NSD2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Binding SET Domain Protein 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WHSC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12766"},{"name":"Legacy Concept Name","value":"WHSC1_Gene"},{"name":"Maps_To","value":"NSD2"},{"name":"OMIM_Number","value":"602952"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421505"}]}}{"C96341":{"preferredName":"NSD3 Gene","code":"C96341","definitions":[{"definition":"This gene is involved in histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NSD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NSD3","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Binding SET Domain Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WHSC1L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12767"},{"name":"Maps_To","value":"NSD3"},{"name":"OMIM_Number","value":"607083"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421506"}]}}{"C104587":{"preferredName":"NT5C2 Gene","code":"C104587","definitions":[{"definition":"This gene plays a role in purine metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NT5C2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"5'-Nucleotidase, Cytosolic II Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NT5C2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8022"},{"name":"Maps_To","value":"NT5C2"},{"name":"OMIM_Number","value":"600417"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417862"}]}}{"C106190":{"preferredName":"NTHL1 Gene","code":"C106190","definitions":[{"definition":"This gene plays a role in nucleotide-excision DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NTHL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nth Like DNA Glycosylase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NTHL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8028"},{"name":"Maps_To","value":"NTHL1"},{"name":"OMIM_Number","value":"602656"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417867"}]}}{"C18551":{"preferredName":"NTRK1 Gene","code":"C18551","definitions":[{"definition":"This gene is involved in cellular differentiation and neurotrophic functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NTRK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurotrophic Receptor Tyrosine Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NTRK1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8031"},{"name":"Legacy Concept Name","value":"NTRK1_Gene"},{"name":"Maps_To","value":"NTRK1"},{"name":"OMIM_Number","value":"191315"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919487"}]}}{"C24647":{"preferredName":"NTRK3 Gene","code":"C24647","definitions":[{"definition":"This gene plays a role in neuronal development and cellular differentiation. Mutations in the gene are associated with medulloblastomas, secretory breast carcinomas and other cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NTRK3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurotrophic Receptor Tyrosine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NTRK3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8033"},{"name":"Legacy Concept Name","value":"NTRK3_Gene"},{"name":"Maps_To","value":"NTRK3"},{"name":"OMIM_Number","value":"191316"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334910"}]}}{"C24648":{"preferredName":"NUMA1 Gene","code":"C24648","definitions":[{"definition":"This gene plays an essential role in normal mitosis. It is also involved in cell organization/biogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUMA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nuclear Mitotic Apparatus Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUMA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8059"},{"name":"Legacy Concept Name","value":"NUMA1_Gene"},{"name":"Maps_To","value":"NUMA1"},{"name":"OMIM_Number","value":"164009"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334911"}]}}{"C24649":{"preferredName":"NUP214 Gene","code":"C24649","definitions":[{"definition":"This gene plays a critical role in nuclear transport and docking regulation. Alterations in the gene have been associated with several cancers and leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUP214 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleoporin 214 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUP214","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8064"},{"name":"Legacy Concept Name","value":"NUP214_Gene"},{"name":"Maps_To","value":"NUP214"},{"name":"OMIM_Number","value":"114350"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334912"}]}}{"C20820":{"preferredName":"NUP98 Gene","code":"C20820","definitions":[{"definition":"This gene plays a role in transport and is frequently overexpressed in prostate cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUP98 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleoporin 98 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUP98","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8068"},{"name":"Legacy Concept Name","value":"NUP98_Gene"},{"name":"Maps_To","value":"NUP98"},{"name":"OMIM_Number","value":"601021"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334913"}]}}{"C92705":{"preferredName":"NUTM1 Gene","code":"C92705","definitions":[{"definition":"This gene may be involved in testicular function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUTM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C15orf55","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Midline Carcinoma Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUTM1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29919"},{"name":"Maps_To","value":"NUTM1"},{"name":"OMIM_Number","value":"608963"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1837033"}]}}{"C101098":{"preferredName":"NUTM2A Gene","code":"C101098","definitions":[{"definition":"This gene has an unknown function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUTM2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM22A","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Family Member 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUTM2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23438"},{"name":"Maps_To","value":"NUTM2A"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C3541493"}]}}{"C101101":{"preferredName":"NUTM2B Gene","code":"C101101","definitions":[{"definition":"The function of this gene is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUTM2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM22B","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Family Member 2B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUTM2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23445"},{"name":"Maps_To","value":"NUTM2B"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539399"}]}}{"C68575":{"preferredName":"OLIG2 Gene","code":"C68575","definitions":[{"definition":"This gene is involved in transcriptional regulation and oligodendrocyte and motor neuron differentiation. This gene may play a role in the development of brain tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OLIG2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"OLIG2","termGroup":"SY","termSource":"NCI"},{"termName":"Oligodendrocyte Lineage Transcription Factor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9398"},{"name":"Legacy Concept Name","value":"OLIG2_Gene"},{"name":"Maps_To","value":"OLIG2"},{"name":"OMIM_Number","value":"606386"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418915"}]}}{"C97680":{"preferredName":"OMD Gene","code":"C97680","definitions":[{"definition":"This gene is involved in cell adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OMD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"OMD","termGroup":"SY","termSource":"NCI"},{"termName":"Osteomodulin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8134"},{"name":"Maps_To","value":"OMD"},{"name":"OMIM_Number","value":"618926"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417948"}]}}{"C97683":{"preferredName":"P2RY8 Gene","code":"C97683","definitions":[{"definition":"This gene plays a role in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P2RY8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"P2RY8","termGroup":"SY","termSource":"NCI"},{"termName":"P2Y Receptor Family Member 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15524"},{"name":"Maps_To","value":"P2RY8"},{"name":"OMIM_Number","value":"300525"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423554"}]}}{"C143072":{"preferredName":"PABPC1 Gene","code":"C143072","definitions":[{"definition":"This gene is involved in binding to poly(A)RNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PABPC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PABPC1","termGroup":"SY","termSource":"NCI"},{"termName":"Poly(A) Binding Protein Cytoplasmic 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8554"},{"name":"Maps_To","value":"PABPC1"},{"name":"NCI_META_CUI","value":"CL541452"},{"name":"OMIM_Number","value":"604679"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97894":{"preferredName":"PAFAH1B2 Gene","code":"C97894","definitions":[{"definition":"This gene is involved in lipid metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAFAH1B2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PAFAH1B2","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet Activating Factor Acetylhydrolase 1b Catalytic Subunit 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8575"},{"name":"Maps_To","value":"PAFAH1B2"},{"name":"OMIM_Number","value":"602508"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418246"}]}}{"C84945":{"preferredName":"PALB2 Gene","code":"C84945","definitions":[{"definition":"This gene may play a role in the repair of DNA damage that is resolved by recombination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PALB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PALB2","termGroup":"SY","termSource":"NCI"},{"termName":"Partner and Localizer of BRCA2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26144"},{"name":"Maps_To","value":"PALB2"},{"name":"OMIM_Number","value":"610355"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1835898"}]}}{"C97876":{"preferredName":"PATZ1 Gene","code":"C97876","definitions":[{"definition":"This gene is involved in both transcriptional regulation and the modulation of cellular tumor antigen p53-dependent cellular processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PATZ1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PATZ1","termGroup":"SY","termSource":"NCI"},{"termName":"POZ (BTB) and AT Hook Containing Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF278","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13071"},{"name":"Maps_To","value":"PATZ1"},{"name":"OMIM_Number","value":"605165"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826545"}]}}{"C24658":{"preferredName":"PAX3 Gene","code":"C24658","definitions":[{"definition":"This gene plays a role in the transcriptional activation of target genes. It is involved in melanogenesis, neurogenesis and skeletal muscle development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box Gene 3 (Waardenburg Syndrome 1) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8617"},{"name":"Legacy Concept Name","value":"PAX3_Gene"},{"name":"Maps_To","value":"PAX3"},{"name":"OMIM_Number","value":"606597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335192"}]}}{"C24659":{"preferredName":"PAX5 Gene","code":"C24659","definitions":[{"definition":"This gene is involved in the transcriptional regulation of target genes. It plays a role in B-cell differentiation, neural development and spermatogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8619"},{"name":"Legacy Concept Name","value":"PAX5_Gene"},{"name":"Maps_To","value":"PAX5"},{"name":"OMIM_Number","value":"167414"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335193"}]}}{"C24660":{"preferredName":"PAX7 Gene","code":"C24660","definitions":[{"definition":"This gene plays a role in the transcriptional regulation of target genes. It is involved in pattern formation during embryogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8621"},{"name":"Legacy Concept Name","value":"PAX7_Gene"},{"name":"Maps_To","value":"PAX7"},{"name":"OMIM_Number","value":"167410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335194"}]}}{"C97687":{"preferredName":"PAX8 Gene","code":"C97687","definitions":[{"definition":"This gene is involved in thyroid development and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box 8 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8622"},{"name":"Maps_To","value":"PAX8"},{"name":"OMIM_Number","value":"167415"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418277"}]}}{"C95438":{"preferredName":"PBRM1 Gene","code":"C95438","definitions":[{"definition":"This gene plays a role in chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PBRM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PBRM1","termGroup":"SY","termSource":"NCI"},{"termName":"Polybromo 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30064"},{"name":"Maps_To","value":"PBRM1"},{"name":"OMIM_Number","value":"606083"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1853685"}]}}{"C97317":{"preferredName":"PBX1 Gene","code":"C97317","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PBX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PBX1","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-B-Cell Leukemia Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8632"},{"name":"Maps_To","value":"PBX1"},{"name":"OMIM_Number","value":"176310"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418285"}]}}{"C95865":{"preferredName":"PCBP1 Gene","code":"C95865","definitions":[{"definition":"This gene plays a role in RNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PCBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PCBP1","termGroup":"SY","termSource":"NCI"},{"termName":"Poly(rC)-Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8647"},{"name":"Maps_To","value":"PCBP1"},{"name":"OMIM_Number","value":"601209"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418297"}]}}{"C97900":{"preferredName":"PCM1 Gene","code":"C97900","definitions":[{"definition":"This gene is involved in centrosome formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PCM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PCM1","termGroup":"SY","termSource":"NCI"},{"termName":"Pericentriolar Material 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8727"},{"name":"Maps_To","value":"PCM1"},{"name":"OMIM_Number","value":"600299"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418374"}]}}{"C45437":{"preferredName":"PDCD1LG2 Gene","code":"C45437","definitions":[{"definition":"This gene plays a role in the regulation of T-cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDCD1LG2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDCD1LG2","termGroup":"SY","termSource":"NCI"},{"termName":"Programmed Cell Death 1 Ligand 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18731"},{"name":"Legacy Concept Name","value":"PDCD1LG2_Gene"},{"name":"Maps_To","value":"PDCD1LG2"},{"name":"OMIM_Number","value":"605723"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425745"}]}}{"C97718":{"preferredName":"PDE4DIP Gene","code":"C97718","definitions":[{"definition":"This gene plays a role in protein complex localization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDE4DIP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDE4DIP","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphodiesterase 4D Interacting Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15580"},{"name":"Maps_To","value":"PDE4DIP"},{"name":"OMIM_Number","value":"608117"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423592"}]}}{"C18278":{"preferredName":"PDGFB Gene","code":"C18278","definitions":[{"definition":"This gene is involved in cellular growth and proliferation. It is also plays a role in intercellular signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDGFB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDGFB","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet Derived Growth Factor Subunit B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8800"},{"name":"Legacy Concept Name","value":"PDGFB_Gene"},{"name":"Maps_To","value":"PDGFB"},{"name":"OMIM_Number","value":"190040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0751995"}]}}{"C24666":{"preferredName":"PDGFRA Gene","code":"C24666","definitions":[{"definition":"This gene plays a role in mitogenic activities affecting mesenchymal cells and is involved in receptor tyrosine kinase signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDGFRA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDGFRA","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet-Derived Growth Factor Receptor, Alpha Polypeptide Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8803"},{"name":"Legacy Concept Name","value":"PDGFRA_Gene"},{"name":"Maps_To","value":"PDGFRA"},{"name":"OMIM_Number","value":"173490"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335201"}]}}{"C24667":{"preferredName":"PDGFRB Gene","code":"C24667","definitions":[{"definition":"This gene plays a role in mitogenic activities affecting mesenchymal cells and a translocation in the gene results in chronic myelomonocytic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDGFRB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDGFRB","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet-Derived Growth Factor Receptor, Beta Polypeptide Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8804"},{"name":"Legacy Concept Name","value":"PDGFRB_Gene"},{"name":"Maps_To","value":"PDGFRB"},{"name":"OMIM_Number","value":"173410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335202"}]}}{"C97721":{"preferredName":"PER1 Gene","code":"C97721","definitions":[{"definition":"This gene is involved in circadian rhythm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PER1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PER1","termGroup":"SY","termSource":"NCI"},{"termName":"Period Circadian Regulator 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8845"},{"name":"Maps_To","value":"PER1"},{"name":"OMIM_Number","value":"602260"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418464"}]}}{"C28656":{"preferredName":"PGR Gene","code":"C28656","definitions":[{"definition":"This gene plays a role in the signal transduction processes that are involved in pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PGR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PGR","termGroup":"SY","termSource":"NCI"},{"termName":"PR","termGroup":"SY","termSource":"NCI"},{"termName":"Progesterone Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8910"},{"name":"Legacy Concept Name","value":"PGR_Gene"},{"name":"Maps_To","value":"PGR"},{"name":"OMIM_Number","value":"607311"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366500"}]}}{"C101449":{"preferredName":"PHF6 Gene","code":"C101449","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PHF6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PHD Finger Protein 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PHF6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18145"},{"name":"Maps_To","value":"PHF6"},{"name":"OMIM_Number","value":"300414"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425343"}]}}{"C97724":{"preferredName":"PHOX2B Gene","code":"C97724","definitions":[{"definition":"This gene plays a role in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PHOX2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired-Like Homeobox 2b Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PHOX2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9143"},{"name":"Maps_To","value":"PHOX2B"},{"name":"OMIM_Number","value":"603851"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418697"}]}}{"C84434":{"preferredName":"PICALM Gene","code":"C84434","definitions":[{"definition":"This gene plays a role in receptor mediated endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PICALM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol Binding Clathrin Assembly Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PICALM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15514"},{"name":"Maps_To","value":"PICALM"},{"name":"OMIM_Number","value":"603025"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423544"}]}}{"C21220":{"preferredName":"PIK3CA Gene","code":"C21220","definitions":[{"definition":"This gene is involved in second messenger signaling, apoptosis, cell growth and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIK3CA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIK3CA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8975"},{"name":"Legacy Concept Name","value":"PIK3CA_Gene"},{"name":"Maps_To","value":"PIK3CA"},{"name":"OMIM_Number","value":"171834"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335212"}]}}{"C24672":{"preferredName":"PIK3CB Gene","code":"C24672","definitions":[{"definition":"This gene is involved in phosphorylation of phosphatidylinositol derivatives, apoptosis, cell growth and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIK3CB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIK3CB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8976"},{"name":"Legacy Concept Name","value":"PIK3CB_Gene"},{"name":"Maps_To","value":"PIK3CB"},{"name":"OMIM_Number","value":"602925"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335213"}]}}{"C97733":{"preferredName":"PIK3R1 Gene","code":"C97733","definitions":[{"definition":"This gene is involved in phosphoinositol signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIK3R1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIK3R1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8979"},{"name":"Maps_To","value":"PIK3R1"},{"name":"OMIM_Number","value":"171833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418576"}]}}{"C18337":{"preferredName":"PIM1 Gene","code":"C18337","definitions":[{"definition":"This gene is involved in apoptosis, cell cycle regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Pim-1 Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIM1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8986"},{"name":"Legacy Concept Name","value":"PIM1_Gene"},{"name":"Maps_To","value":"PIM1"},{"name":"OMIM_Number","value":"164960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812214"}]}}{"C71423":{"preferredName":"PLAG1 Gene","code":"C71423","definitions":[{"definition":"This gene is involved in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PLAG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PLAG1","termGroup":"SY","termSource":"NCI"},{"termName":"PLAG1 Zinc Finger Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9045"},{"name":"Legacy Concept Name","value":"PLAG1_Gene"},{"name":"Maps_To","value":"PLAG1"},{"name":"OMIM_Number","value":"603026"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418629"}]}}{"C104821":{"preferredName":"PLCG1 Gene","code":"C104821","definitions":[{"definition":"This gene is involved in both intracellular signaling and second messenger production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PLCG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phospholipase C, Gamma 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PLCG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9065"},{"name":"Maps_To","value":"PLCG1"},{"name":"OMIM_Number","value":"172420"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418640"}]}}{"C24686":{"preferredName":"PML Gene","code":"C24686","definitions":[{"definition":"This gene plays a role in tumor suppression and is involved in the regulation of p53 in response to oncogenic signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PML Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PML","termGroup":"SY","termSource":"NCI"},{"termName":"PML Nuclear Body Scaffold Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9113"},{"name":"Legacy Concept Name","value":"PML_Gene"},{"name":"Maps_To","value":"PML"},{"name":"OMIM_Number","value":"102578"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366903"}]}}{"C18591":{"preferredName":"PMS2 Gene","code":"C18591","definitions":[{"definition":"This gene is involved in mismatch repair and mutations in the gene result in hereditary non-polyposis colon cancer 4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PMS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PMS2","termGroup":"SY","termSource":"NCI"},{"termName":"PMS2 Postmeiotic Segregation Increased 2 (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9122"},{"name":"Legacy Concept Name","value":"PMS2_Gene"},{"name":"Maps_To","value":"PMS2"},{"name":"OMIM_Number","value":"600259"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879391"}]}}{"C106224":{"preferredName":"POLD1 Gene","code":"C106224","definitions":[{"definition":"This gene is involved in DNA replication and proofreading.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Delta 1, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLD1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9175"},{"name":"Maps_To","value":"POLD1"},{"name":"OMIM_Number","value":"174761"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418727"}]}}{"C106232":{"preferredName":"POLE Gene","code":"C106232","definitions":[{"definition":"This gene is involved in both DNA replication and DNA base-excision repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Epsilon, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9177"},{"name":"Maps_To","value":"POLE"},{"name":"OMIM_Number","value":"174761"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418729"}]}}{"C143069":{"preferredName":"POLG Gene","code":"C143069","definitions":[{"definition":"This gene plays a role in the replication of mitochondrial DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Gamma, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9179"},{"name":"Maps_To","value":"POLG"},{"name":"OMIM_Number","value":"174763"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418731"}]}}{"C131801":{"preferredName":"POLQ Gene","code":"C131801","definitions":[{"definition":"This gene is involved in DNA synthesis and repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLQ Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Theta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLQ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9186"},{"name":"Maps_To","value":"POLQ"},{"name":"OMIM_Number","value":"604419"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418738"}]}}{"C107655":{"preferredName":"POT1 Gene","code":"C107655","definitions":[{"definition":"This gene plays a role in the regulation of telomere length.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"POT1","termGroup":"SY","termSource":"NCI"},{"termName":"Protection of Telomeres Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17284"},{"name":"Maps_To","value":"POT1"},{"name":"OMIM_Number","value":"606478"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538704"}]}}{"C97730":{"preferredName":"POU2AF1 Gene","code":"C97730","definitions":[{"definition":"This gene is involved in both humoral immunity and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POU2AF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"POU Class 2 Associating Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POU2AF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9211"},{"name":"Maps_To","value":"POU2AF1"},{"name":"OMIM_Number","value":"601206"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418760"}]}}{"C61140":{"preferredName":"POU5F1 Gene","code":"C61140","definitions":[{"definition":"This gene plays a role in early mammalian development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POU5F1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"POU Class 5 Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POU5F1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9221"},{"name":"Legacy Concept Name","value":"POU5F1_Gene"},{"name":"Maps_To","value":"POU5F1"},{"name":"OMIM_Number","value":"164177"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418768"}]}}{"C24689":{"preferredName":"PPARG Gene","code":"C24689","definitions":[{"definition":"This gene plays a regulatory role in adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPARG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Peroxisome Proliferator-Activated Receptor Gamma Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PPARG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9236"},{"name":"Legacy Concept Name","value":"PPARG_Gene"},{"name":"Maps_To","value":"PPARG"},{"name":"OMIM_Number","value":"601487"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335238"}]}}{"C101494":{"preferredName":"PPFIBP1 Gene","code":"C101494","definitions":[{"definition":"This gene plays a role in protein-protein interactions and cell-matrix adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPFIBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPFIBP1","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9249"},{"name":"Maps_To","value":"PPFIBP1"},{"name":"OMIM_Number","value":"603141"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418789"}]}}{"C88179":{"preferredName":"PPM1D Gene","code":"C88179","definitions":[{"definition":"This gene plays a role in the modulation of cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPM1D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPM1D","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Phosphatase 1D Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9277"},{"name":"Maps_To","value":"PPM1D"},{"name":"OMIM_Number","value":"605100"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418816"}]}}{"C92536":{"preferredName":"PPP2R1A Gene","code":"C92536","definitions":[{"definition":"This gene plays a role in the regulation of cell growth and division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPP2R1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPP2R1A","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Phosphatase 2 Scaffold Subunit Aalpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9302"},{"name":"Maps_To","value":"PPP2R1A"},{"name":"OMIM_Number","value":"605983"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418837"}]}}{"C102901":{"preferredName":"PPP6C Gene","code":"C102901","definitions":[{"definition":"This gene plays a role in both protein dephosphorylation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPP6C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPP6C","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Phosphatase 6, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9323"},{"name":"Maps_To","value":"PPP6C"},{"name":"OMIM_Number","value":"612725"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418853"}]}}{"C70994":{"preferredName":"PRCC Gene","code":"C70994","definitions":[{"definition":"This gene may be involved in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRCC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Renal Cell Carcinoma (Translocation-Associated) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRCC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9343"},{"name":"Legacy Concept Name","value":"PRCC_Gene"},{"name":"Maps_To","value":"PRCC"},{"name":"OMIM_Number","value":"179755"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418872"}]}}{"C24692":{"preferredName":"PRDM1 Gene","code":"C24692","definitions":[{"definition":"This gene is involved in repression of transcription. It plays a role in the formation of pre-plasma memory B cells and immunoglobulin-secreting plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRDM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PR/SET Domain 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRDM1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9346"},{"name":"Legacy Concept Name","value":"PRDM1_Gene"},{"name":"Maps_To","value":"PRDM1"},{"name":"OMIM_Number","value":"603423"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335253"}]}}{"C97736":{"preferredName":"PRDM16 Gene","code":"C97736","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRDM16 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PR/SET Domain 16 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRDM16","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14000"},{"name":"Maps_To","value":"PRDM16"},{"name":"OMIM_Number","value":"605557"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422337"}]}}{"C143121":{"preferredName":"PRDM2 Gene","code":"C143121","definitions":[{"definition":"This gene is involved in both methylation of histone H3 and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRDM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PR/SET Domain 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRDM2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9347"},{"name":"Maps_To","value":"PRDM2"},{"name":"OMIM_Number","value":"601196"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418875"}]}}{"C102517":{"preferredName":"PREX2 Gene","code":"C102517","definitions":[{"definition":"This gene is involved in guanine nucleotide exchange activity that regulates the GTPase activity of Rac family proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PREX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac Exchange Factor 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PREX2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22950"},{"name":"Maps_To","value":"PREX2"},{"name":"OMIM_Number","value":"612139"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427805"}]}}{"C97739":{"preferredName":"PRF1 Gene","code":"C97739","definitions":[{"definition":"This gene is involved in cytolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Perforin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9360"},{"name":"Maps_To","value":"PRF1"},{"name":"OMIM_Number","value":"170280"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418887"}]}}{"C38409":{"preferredName":"PRKACA Gene","code":"C38409","definitions":[{"definition":"This gene is involved in the regulation of diverse cell processes including cell growth, proliferation, differentiation and motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRKACA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PRKACA","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase cAMP-Activated Catalytic Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9380"},{"name":"Legacy Concept Name","value":"PRKACA_Gene"},{"name":"Maps_To","value":"PRKACA"},{"name":"OMIM_Number","value":"601639"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418901"}]}}{"C97742":{"preferredName":"PRKAR1A Gene","code":"C97742","definitions":[{"definition":"This gene plays a role in the regulation of protein kinase A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRKAR1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PRKAR1A","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9388"},{"name":"Maps_To","value":"PRKAR1A"},{"name":"OMIM_Number","value":"188830"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418907"}]}}{"C39597":{"preferredName":"PRKCB Gene","code":"C39597","definitions":[{"definition":"This gene is involved in diverse cell processes such as apoptosis, B cell activation and endothelial cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRKCB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PRKCB","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase C, Beta Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9395"},{"name":"Legacy Concept Name","value":"PRKCB1_Gene"},{"name":"Maps_To","value":"PRKCB"},{"name":"OMIM_Number","value":"176970"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418913"}]}}{"C143090":{"preferredName":"PRPF40B Gene","code":"C143090","definitions":[{"definition":"This gene may be involved in mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRPF40B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Pre-mRNA Processing Factor 40 Homolog B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRPF40B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25031"},{"name":"Maps_To","value":"PRPF40B"},{"name":"NCI_META_CUI","value":"CL541547"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C98030":{"preferredName":"PRRX1 Gene","code":"C98030","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and muscle cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRRX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Related Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRRX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9142"},{"name":"Maps_To","value":"PRRX1"},{"name":"OMIM_Number","value":"167420"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418696"}]}}{"C20676":{"preferredName":"PSIP1 Gene","code":"C20676","definitions":[{"definition":"This gene is involved in regulation of transcription. It also plays a role in mediation of pre-mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PC4 and SFRS1 Interacting Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PSIP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9527"},{"name":"Legacy Concept Name","value":"PSIP1_Gene"},{"name":"Maps_To","value":"PSIP1"},{"name":"OMIM_Number","value":"603620"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335268"}]}}{"C18255":{"preferredName":"PTCH1 Gene","code":"C18255","definitions":[{"definition":"This gene is involved in tumor suppression and mutations in this gene have been associated with several cancers and cancer related diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTCH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Patched 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTCH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9585"},{"name":"Legacy Concept Name","value":"PTCH_Gene"},{"name":"Maps_To","value":"PTCH1"},{"name":"OMIM_Number","value":"601309"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826732"}]}}{"C18256":{"preferredName":"PTEN Gene","code":"C18256","definitions":[{"definition":"This gene plays a role in signal transduction and apoptosis. It is also involved in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTEN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatase and Tensin Homolog Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTEN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9588"},{"name":"Legacy Concept Name","value":"PTEN_Gene"},{"name":"Maps_To","value":"PTEN"},{"name":"OMIM_Number","value":"601728"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694888"}]}}{"C24701":{"preferredName":"PTK6 Gene","code":"C24701","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTK6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PTK6","termGroup":"SY","termSource":"NCI"},{"termName":"PTK6 Protein Tyrosine Kinase 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9617"},{"name":"Legacy Concept Name","value":"PTK6_Gene"},{"name":"Maps_To","value":"PTK6"},{"name":"OMIM_Number","value":"602004"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335274"}]}}{"C26337":{"preferredName":"PTPN11 Gene","code":"C26337","definitions":[{"definition":"This gene plays a role in the regulation of cell signaling. It is involved in cell migration, metabolic control, mitogenic activation and gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPN11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPN11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9644"},{"name":"Legacy Concept Name","value":"PTPN11_Gene"},{"name":"Maps_To","value":"PTPN11"},{"name":"OMIM_Number","value":"176876"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335280"}]}}{"C104212":{"preferredName":"PTPN13 Gene","code":"C104212","definitions":[{"definition":"This gene is involved in both protein dephosphorylation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPN13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Non-Receptor Type 13 (APO-1/CD95 (Fas)-Associated Phosphatase) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPN13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9646"},{"name":"Maps_To","value":"PTPN13"},{"name":"OMIM_Number","value":"600267"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419096"}]}}{"C24708":{"preferredName":"PTPN6 Gene","code":"C24708","definitions":[{"definition":"This gene plays a role in the regulation of multiple signaling pathways in hematopoietic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPN6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Non-Receptor Type 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPN6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9658"},{"name":"Legacy Concept Name","value":"PTPN6_Gene"},{"name":"Maps_To","value":"PTPN6"},{"name":"OMIM_Number","value":"176883"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335283"}]}}{"C122909":{"preferredName":"PTPRB Gene","code":"C122909","definitions":[{"definition":"This gene is involved in dephosphorylation of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type, B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9665"},{"name":"Maps_To","value":"PTPRB"},{"name":"OMIM_Number","value":"176882"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419112"}]}}{"C24711":{"preferredName":"PTPRC Gene","code":"C24711","definitions":[{"definition":"This gene plays a role in suppression of cytokine receptor signaling and the regulation of signal transduction in lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD45","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9666"},{"name":"Legacy Concept Name","value":"PTPRC_Gene"},{"name":"Maps_To","value":"PTPRC"},{"name":"OMIM_Number","value":"151460"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335285"}]}}{"C106113":{"preferredName":"PTPRK Gene","code":"C106113","definitions":[{"definition":"This gene is involved in receptor signaling, cell-cell contact and cell migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type, K Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9674"},{"name":"Maps_To","value":"PTPRK"},{"name":"OMIM_Number","value":"602545"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419117"}]}}{"C24716":{"preferredName":"PTPRT Gene","code":"C24716","definitions":[{"definition":"This gene plays a role in the control of motor axon guidance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type, T Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9682"},{"name":"Legacy Concept Name","value":"PTPRT_Gene"},{"name":"Maps_To","value":"PTPRT"},{"name":"OMIM_Number","value":"608712"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335289"}]}}{"C122890":{"preferredName":"PWWP2A Gene","code":"C122890","definitions":[{"definition":"This gene may play a role in protein-protein or protein-DNA interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PWWP2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PWWP Domain Containing 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PWWP2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29406"},{"name":"Maps_To","value":"PWWP2A"},{"name":"OMIM_Number","value":"617823"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2239866"}]}}{"C111937":{"preferredName":"QKI Gene","code":"C111937","definitions":[{"definition":"This gene is involved in both the biosynthesis and maintenance of mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"QKI Gene","termGroup":"PT","termSource":"NCI"},{"termName":"QKI","termGroup":"SY","termSource":"NCI"},{"termName":"QKI, KH Domain Containing, RNA Binding Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:21100"},{"name":"Maps_To","value":"QKI"},{"name":"OMIM_Number","value":"609590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427319"}]}}{"C97751":{"preferredName":"RABEP1 Gene","code":"C97751","definitions":[{"definition":"This gene is involved in the regulation of both GTPase activity and endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RABEP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Rabaptin, RAB GTPase Binding Effector Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RABEP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17677"},{"name":"Maps_To","value":"RABEP1"},{"name":"OMIM_Number","value":"603616"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425034"}]}}{"C99663":{"preferredName":"RAC1 Gene","code":"C99663","definitions":[{"definition":"This gene is involved in both cell motility and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAC1","termGroup":"SY","termSource":"NCI"},{"termName":"Ras-Related C3 Botulinum Toxin Substrate 1 (Rho Family, Small GTP Binding Protein Rac1) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9801"},{"name":"Maps_To","value":"RAC1"},{"name":"OMIM_Number","value":"602048"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419227"}]}}{"C93082":{"preferredName":"RAD21 Gene","code":"C93082","definitions":[{"definition":"This gene is involved in chromosomal cohesion, DNA repair and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAD21 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAD21","termGroup":"SY","termSource":"NCI"},{"termName":"RAD21 Cohesin Complex Component Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9811"},{"name":"Maps_To","value":"RAD21"},{"name":"OMIM_Number","value":"606462"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419235"}]}}{"C90145":{"preferredName":"RAD51B Gene","code":"C90145","definitions":[{"definition":"This gene plays a role in the mediation of homologous recombinational repair of DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAD51B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAD51 Paralog B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RAD51B","termGroup":"SY","termSource":"NCI"},{"termName":"RAD51L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9822"},{"name":"Maps_To","value":"RAD51B"},{"name":"OMIM_Number","value":"602948"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419241"}]}}{"C18338":{"preferredName":"RAF1 Gene","code":"C18338","definitions":[{"definition":"This gene is involved in cell growth, proliferation, differentiation and migration. It also plays a role in apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAF1","termGroup":"SY","termSource":"NCI"},{"termName":"v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9829"},{"name":"Legacy Concept Name","value":"RAF1_Gene"},{"name":"Maps_To","value":"RAF1"},{"name":"OMIM_Number","value":"164760"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812215"}]}}{"C24721":{"preferredName":"RALGDS Gene","code":"C24721","definitions":[{"definition":"This gene plays a role in signal transduction and cytoskeletal remodeling. It is also involved in regulation of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RALGDS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAL Guanine Nucleotide Dissociation Stimulator Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RALGDS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9842"},{"name":"Legacy Concept Name","value":"RALGDS_Gene"},{"name":"Maps_To","value":"RALGDS"},{"name":"OMIM_Number","value":"601619"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335588"}]}}{"C114452":{"preferredName":"RANBP2 Gene","code":"C114452","definitions":[{"definition":"This gene is involved in both SUMOylation and nuclear transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RANBP2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAN Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RANBP2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9848"},{"name":"Maps_To","value":"RANBP2"},{"name":"OMIM_Number","value":"601181"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419259"}]}}{"C97758":{"preferredName":"RAP1GDS1 Gene","code":"C97758","definitions":[{"definition":"This gene is involved in guanine nucleotide exchange.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAP1GDS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Rap1 GTPase-GDP Dissociation Stimulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RAP1GDS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9859"},{"name":"Maps_To","value":"RAP1GDS1"},{"name":"OMIM_Number","value":"179502"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419268"}]}}{"C21571":{"preferredName":"RARA Gene","code":"C21571","definitions":[{"definition":"This gene plays a role in transcription and retinoic acid receptor signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RARA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Retinoic Acid Receptor Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9864"},{"name":"Legacy Concept Name","value":"RARA_Gene"},{"name":"Maps_To","value":"RARA"},{"name":"OMIM_Number","value":"180240"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366536"}]}}{"C17360":{"preferredName":"RB1 Gene","code":"C17360","definitions":[{"definition":"This gene is involved in the regulation of cell differentiation, growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RB Transcriptional Corepressor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9884"},{"name":"Legacy Concept Name","value":"RB1_Gene"},{"name":"Maps_To","value":"RB1"},{"name":"OMIM_Number","value":"614041"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694889"}]}}{"C115382":{"preferredName":"RBM10 Gene","code":"C115382","definitions":[{"definition":"This gene is involved in RNA binding and processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RBM10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RBM10","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Binding Motif Protein 10 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9896"},{"name":"Maps_To","value":"RBM10"},{"name":"OMIM_Number","value":"300080"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419296"}]}}{"C97293":{"preferredName":"RBM15 Gene","code":"C97293","definitions":[{"definition":"This gene plays a role in RNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RBM15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RBM15","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Binding Motif Protein 15 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14959"},{"name":"Maps_To","value":"RBM15"},{"name":"OMIM_Number","value":"606077"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423088"}]}}{"C26492":{"preferredName":"RECQL4 Gene","code":"C26492","definitions":[{"definition":"This gene is involved in the initiation of DNA replication and sister-chromatid cohesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RECQL4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RecQ Like Helicase 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RECQL4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9949"},{"name":"Legacy Concept Name","value":"RECQL4_Gene"},{"name":"Maps_To","value":"RECQL4"},{"name":"OMIM_Number","value":"603780"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335607"}]}}{"C17084":{"preferredName":"REL Gene","code":"C17084","definitions":[{"definition":"This gene is involved in transcriptional regulation and signal transduction through the nuclear factor kappa B NFKB signal transduction pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"REL","termGroup":"SY","termSource":"NCI"},{"termName":"v-REL Avian Reticuloendotheliosis Viral Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9954"},{"name":"Legacy Concept Name","value":"REL_Gene"},{"name":"Maps_To","value":"REL"},{"name":"OMIM_Number","value":"164910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0035018"}]}}{"C18257":{"preferredName":"RET Gene","code":"C18257","definitions":[{"definition":"This gene plays an essential role in neural crest development, cellular growth and differentiation. Mutations in the gene are associated with a variety of neoplasias and carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RET Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RET","termGroup":"SY","termSource":"NCI"},{"termName":"RET Proto-Oncogene (Multiple Endocrine Neoplasia and Medullary Thyroid Carcinoma 1, Hirschsprung Disease) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9967"},{"name":"Legacy Concept Name","value":"RET_Gene"},{"name":"Maps_To","value":"RET"},{"name":"OMIM_Number","value":"164761"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694890"}]}}{"C143082":{"preferredName":"RGPD3 Gene","code":"C143082","definitions":[{"definition":"This gene may play a role in the localization of the GTPase Ran.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RGPD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RANBP2-Like and GRIP Domain Containing 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RGPD3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:32416"},{"name":"Maps_To","value":"RGPD3"},{"name":"NCI_META_CUI","value":"CL541555"},{"name":"OMIM_Number","value":"612706"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C143118":{"preferredName":"RGS7 Gene","code":"C143118","definitions":[{"definition":"This gene plays a role in the inhibition of both G protein-coupled receptor signaling and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RGS7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Regulator of G Protein Signaling 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RGS7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10003"},{"name":"Maps_To","value":"RGS7"},{"name":"OMIM_Number","value":"602517"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419377"}]}}{"C18356":{"preferredName":"RHOA Gene","code":"C18356","definitions":[{"definition":"This gene plays a role in signal transduction. It is involved in several cellular functions including cell differentiation and cytoskeletal remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RHOA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAS Homolog Family Member A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RHOA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:667"},{"name":"Legacy Concept Name","value":"ARHA_Gene"},{"name":"Maps_To","value":"RHOA"},{"name":"OMIM_Number","value":"165390"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812234"}]}}{"C21320":{"preferredName":"RHOH Gene","code":"C21320","definitions":[{"definition":"This gene plays a role in signal transduction in hematopoietic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RHOH Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAS Homolog Family Member H Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RHOH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:686"},{"name":"Legacy Concept Name","value":"ARHH_Gene"},{"name":"Maps_To","value":"RHOH"},{"name":"OMIM_Number","value":"602037"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332112"}]}}{"C96027":{"preferredName":"RMI2 Gene","code":"C96027","definitions":[{"definition":"This gene is involved in DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RMI2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RecQ Mediated Genome Instability 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RMI2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28349"},{"name":"Maps_To","value":"RMI2"},{"name":"OMIM_Number","value":"612426"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824428"}]}}{"C97390":{"preferredName":"RNF213 Gene","code":"C97390","definitions":[{"definition":"This gene may be involved in ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RNF213 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ring Finger Protein 213 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RNF213","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14539"},{"name":"Maps_To","value":"RNF213"},{"name":"OMIM_Number","value":"613768"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422738"}]}}{"C107649":{"preferredName":"RNF43 Gene","code":"C107649","definitions":[{"definition":"This gene is involved in both protein ubiquitination and the Wnt signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RNF43 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ring Finger Protein 43 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RNF43","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18505"},{"name":"Maps_To","value":"RNF43"},{"name":"OMIM_Number","value":"612482"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425565"}]}}{"C126774":{"preferredName":"ROBO2 Gene","code":"C126774","definitions":[{"definition":"This gene plays a role in ligand binding, axon guidance and cell migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ROBO2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ROBO2","termGroup":"SY","termSource":"NCI"},{"termName":"Roundabout Guidance Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10250"},{"name":"Maps_To","value":"ROBO2"},{"name":"OMIM_Number","value":"602431"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419597"}]}}{"C18399":{"preferredName":"ROS1 Gene","code":"C18399","definitions":[{"definition":"This gene plays a role in receptor tyrosine phosphorylation signal transduction, and is thought to play a role in cellular growth or differentiation, but an exact function has not been substantiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ROS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ROS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10261"},{"name":"Legacy Concept Name","value":"ROS1_Gene"},{"name":"Maps_To","value":"ROS1"},{"name":"NCI_META_CUI","value":"CL414355"},{"name":"OMIM_Number","value":"165020"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24748":{"preferredName":"RPL10 Gene","code":"C24748","definitions":[{"definition":"This gene plays a role in protein biosynthesis. It is also involved in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPL10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein L10 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPL10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10298"},{"name":"Legacy Concept Name","value":"RPL10_Gene"},{"name":"Maps_To","value":"RPL10"},{"name":"OMIM_Number","value":"312173"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335635"}]}}{"C97761":{"preferredName":"RPL22 Gene","code":"C97761","definitions":[{"definition":"This gene is involved in translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPL22 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein L22 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPL22","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10315"},{"name":"Maps_To","value":"RPL22"},{"name":"OMIM_Number","value":"180474"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419639"}]}}{"C107652":{"preferredName":"RPL5 Gene","code":"C107652","definitions":[{"definition":"This gene plays a role in ribosome assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPL5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein L5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPL5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10360"},{"name":"Maps_To","value":"RPL5"},{"name":"OMIM_Number","value":"603634"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419683"}]}}{"C97290":{"preferredName":"RPN1 Gene","code":"C97290","definitions":[{"definition":"This gene plays a role in post-translational protein modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribophorin I Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10381"},{"name":"Maps_To","value":"RPN1"},{"name":"OMIM_Number","value":"180470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419697"}]}}{"C106067":{"preferredName":"RSPO2 Gene","code":"C106067","definitions":[{"definition":"This gene plays a role in both Wnt signaling and embryonic morphogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RSPO2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"R-Spondin 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RSPO2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28583"},{"name":"Maps_To","value":"RSPO2"},{"name":"OMIM_Number","value":"610575"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826945"}]}}{"C24397":{"preferredName":"RSPO3 Gene","code":"C24397","definitions":[{"definition":"This gene is thought to be involved in transport; however, a function has yet to be elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RSPO3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"R-Spondin 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RSPO3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20866"},{"name":"Legacy Concept Name","value":"THSD2_Gene"},{"name":"Maps_To","value":"RSPO3"},{"name":"OMIM_Number","value":"610574"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1704989"}]}}{"C18579":{"preferredName":"RUNX1 Gene","code":"C18579","definitions":[{"definition":"This gene plays a role in transcriptional regulation and cytogenetic aberrations are associated with several leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RUNX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AML1","termGroup":"SY","termSource":"NCI"},{"termName":"Runt-Related Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RUNX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10471"},{"name":"Legacy Concept Name","value":"RUNX1_Gene"},{"name":"Maps_To","value":"RUNX1"},{"name":"OMIM_Number","value":"151385"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335654"}]}}{"C28570":{"preferredName":"RUNX1T1 Gene","code":"C28570","definitions":[{"definition":"This gene plays a role in transcriptional regulation and hematopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RUNX1T1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RUNX1 Partner Transcriptional Co-Repressor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RUNX1T1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1535"},{"name":"Legacy Concept Name","value":"CBFA2T1_Gene"},{"name":"Maps_To","value":"RUNX1T1"},{"name":"OMIM_Number","value":"133435"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539715"}]}}{"C143078":{"preferredName":"S100A7 Gene","code":"C143078","definitions":[{"definition":"This gene is involved in both calcium binding and antimicrobial activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"S100A7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"S100 Calcium Binding Protein A7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"S100A7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10497"},{"name":"Maps_To","value":"S100A7"},{"name":"NCI_META_CUI","value":"CL541566"},{"name":"OMIM_Number","value":"600353"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C112905":{"preferredName":"SALL4 Gene","code":"C112905","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and stem cell maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SALL4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SALL4","termGroup":"SY","termSource":"NCI"},{"termName":"Spalt Like Transcription Factor 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15924"},{"name":"Maps_To","value":"SALL4"},{"name":"OMIM_Number","value":"607343"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423836"}]}}{"C97767":{"preferredName":"SBDS Gene","code":"C97767","definitions":[{"definition":"This gene plays a role in ribosome formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SBDS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SBDS","termGroup":"SY","termSource":"NCI"},{"termName":"SBDS Ribosome Maturation Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19440"},{"name":"Maps_To","value":"SBDS"},{"name":"OMIM_Number","value":"607444"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426244"}]}}{"C101431":{"preferredName":"SDC4 Gene","code":"C101431","definitions":[{"definition":"This gene is involved in cell-matrix interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDC4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDC4","termGroup":"SY","termSource":"NCI"},{"termName":"Syndecan 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10661"},{"name":"Maps_To","value":"SDC4"},{"name":"OMIM_Number","value":"600017"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419894"}]}}{"C103873":{"preferredName":"SDHA Gene","code":"C103873","definitions":[{"definition":"This gene is involved in the mitochondrial respiratory chain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHA","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10680"},{"name":"Maps_To","value":"SDHA"},{"name":"OMIM_Number","value":"600857"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419906"}]}}{"C97770":{"preferredName":"SDHAF2 Gene","code":"C97770","definitions":[{"definition":"This gene is involved in the electron transport chain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHAF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHAF2","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Assembly Factor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26034"},{"name":"Maps_To","value":"SDHAF2"},{"name":"OMIM_Number","value":"613019"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2240298"}]}}{"C97773":{"preferredName":"SDHB Gene","code":"C97773","definitions":[{"definition":"This gene plays a role in electron transport in the mitochondria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHB","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Iron Sulfur Subunit B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10681"},{"name":"Maps_To","value":"SDHB"},{"name":"OMIM_Number","value":"185470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419907"}]}}{"C97776":{"preferredName":"SDHC Gene","code":"C97776","definitions":[{"definition":"This gene is involved in mitochondrial electron transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHC","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Subunit C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10682"},{"name":"Maps_To","value":"SDHC"},{"name":"OMIM_Number","value":"602413"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419908"}]}}{"C97779":{"preferredName":"SDHD Gene","code":"C97779","definitions":[{"definition":"This gene plays a role in the localization of succinate dehydrogenase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHD","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Subunit D Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10683"},{"name":"Maps_To","value":"SDHD"},{"name":"OMIM_Number","value":"602690"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419909"}]}}{"C97727":{"preferredName":"SEPTIN5 Gene","code":"C97727","definitions":[{"definition":"This gene plays a role in cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SEPTIN5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SEPT5","termGroup":"SY","termSource":"NCI"},{"termName":"Septin 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SEPTIN5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9164"},{"name":"Maps_To","value":"SEPT5"},{"name":"OMIM_Number","value":"602724"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539748"}]}}{"C97782":{"preferredName":"SEPTIN6 Gene","code":"C97782","definitions":[{"definition":"This gene is involved in both cytokinesis and the organization of the actin cytoskeleton.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SEPTIN6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SEPT6","termGroup":"SY","termSource":"NCI"},{"termName":"Septin 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SEPTIN6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15848"},{"name":"Maps_To","value":"SEPT6"},{"name":"OMIM_Number","value":"300683"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423771"}]}}{"C97897":{"preferredName":"SEPTIN9 Gene","code":"C97897","definitions":[{"definition":"This gene plays a role in actin filament dynamics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SEPTIN9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SEPT9","termGroup":"SY","termSource":"NCI"},{"termName":"Septin 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SEPTIN9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7323"},{"name":"Maps_To","value":"SEPT9"},{"name":"OMIM_Number","value":"604061"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539750"}]}}{"C24801":{"preferredName":"SET Gene","code":"C24801","definitions":[{"definition":"This gene is involved in apoptosis, biogenesis, DNA replication and nuclear organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SET Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET","termGroup":"SY","termSource":"NCI"},{"termName":"SET Nuclear Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10760"},{"name":"Legacy Concept Name","value":"SET_Gene"},{"name":"Maps_To","value":"SET"},{"name":"OMIM_Number","value":"600960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366517"}]}}{"C106635":{"preferredName":"SETBP1 Gene","code":"C106635","definitions":[{"definition":"This gene may be involved in the modulation of protein SET activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SETBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SETBP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15573"},{"name":"Maps_To","value":"SETBP1"},{"name":"OMIM_Number","value":"611060"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423585"}]}}{"C73662":{"preferredName":"SETD2 Gene","code":"C73662","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression through histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SETD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET Domain Containing 2, Histone Lysine Methyltransferase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SETD2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18420"},{"name":"Legacy Concept Name","value":"SETD2_Gene"},{"name":"Maps_To","value":"SETD2"},{"name":"OMIM_Number","value":"612778"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822686"}]}}{"C98284":{"preferredName":"SF3B1 Gene","code":"C98284","definitions":[{"definition":"This gene is involved in mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SF3B1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SF3B1","termGroup":"SY","termSource":"NCI"},{"termName":"Splicing Factor 3b Subunit 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10768"},{"name":"Maps_To","value":"SF3B1"},{"name":"OMIM_Number","value":"605590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419980"}]}}{"C71417":{"preferredName":"SFPQ Gene","code":"C71417","definitions":[{"definition":"This gene may be involved in both transcriptional regulation and nuclear RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SFPQ Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SFPQ","termGroup":"SY","termSource":"NCI"},{"termName":"Splicing Factor Proline/Glutamine-Rich (Polypyrimidine Tract Binding Protein Associated) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10774"},{"name":"Legacy Concept Name","value":"SFPQ_Gene"},{"name":"Maps_To","value":"SFPQ"},{"name":"OMIM_Number","value":"605199"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419984"}]}}{"C24804":{"preferredName":"SFRP4 Gene","code":"C24804","definitions":[{"definition":"This gene plays a role in signal transduction, apoptosis and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SFRP4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Secreted Frizzled Related Protein 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SFRP4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10778"},{"name":"Legacy Concept Name","value":"SFRP4_Gene"},{"name":"Maps_To","value":"SFRP4"},{"name":"OMIM_Number","value":"606570"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335814"}]}}{"C101559":{"preferredName":"SGK1 Gene","code":"C101559","definitions":[{"definition":"This gene plays a role in both protein phosphorylation and cellular stress response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SGK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serum/Glucocorticoid Regulated Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SGK1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10810"},{"name":"Maps_To","value":"SGK1"},{"name":"OMIM_Number","value":"602958"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420010"}]}}{"C102802":{"preferredName":"SH2B3 Gene","code":"C102802","definitions":[{"definition":"This gene plays a role in T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SH2B3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SH2B Adaptor Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SH2B3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29605"},{"name":"Maps_To","value":"SH2B3"},{"name":"OMIM_Number","value":"605093"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822705"}]}}{"C97788":{"preferredName":"SH3GL1 Gene","code":"C97788","definitions":[{"definition":"This gene may be involved in endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SH3GL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SH3-Domain GRB2-Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SH3GL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10830"},{"name":"Maps_To","value":"SH3GL1"},{"name":"OMIM_Number","value":"601768"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420025"}]}}{"C122906":{"preferredName":"SHTN1 Gene","code":"C122906","definitions":[{"definition":"This gene is involved in neuronal polarization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHTN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIAA1598","termGroup":"SY","termSource":"NCI"},{"termName":"Shootin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SHTN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29319"},{"name":"Maps_To","value":"SHTN1"},{"name":"OMIM_Number","value":"611171"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428834"}]}}{"C24710":{"preferredName":"SIRPA Gene","code":"C24710","definitions":[{"definition":"This gene is involved in cellular signal transduction and tyrosine kinase-coupled signaling processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIRPA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal-Regulatory Protein Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9662"},{"name":"Legacy Concept Name","value":"PTPNS1_Gene"},{"name":"Maps_To","value":"SIRPA"},{"name":"OMIM_Number","value":"602461"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822726"}]}}{"C69184":{"preferredName":"SKI Gene","code":"C69184","definitions":[{"definition":"This gene is involved in transcriptional regulation and is involved in cellular signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SKI Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SKI","termGroup":"SY","termSource":"NCI"},{"termName":"SKI Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10896"},{"name":"Legacy Concept Name","value":"SKI_Gene"},{"name":"Maps_To","value":"SKI"},{"name":"OMIM_Number","value":"164780"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812379"}]}}{"C101434":{"preferredName":"SLC34A2 Gene","code":"C101434","definitions":[{"definition":"This gene plays a role in phosphate transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SLC34A2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLC34A2","termGroup":"SY","termSource":"NCI"},{"termName":"Solute Carrier Family 34 Member 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11020"},{"name":"Maps_To","value":"SLC34A2"},{"name":"OMIM_Number","value":"604217"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420186"}]}}{"C97791":{"preferredName":"SLC45A3 Gene","code":"C97791","definitions":[{"definition":"This gene plays a role in transmembrane transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SLC45A3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLC45A3","termGroup":"SY","termSource":"NCI"},{"termName":"Solute Carrier Family 45, Member 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8642"},{"name":"Maps_To","value":"SLC45A3"},{"name":"OMIM_Number","value":"605097"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418294"}]}}{"C24566":{"preferredName":"SMAD2 Gene","code":"C24566","definitions":[{"definition":"This gene plays a role in signal transduction and repression of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMAD, Mothers Against DPP Homolog 2 (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SMAD2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6768"},{"name":"Legacy Concept Name","value":"MADH2_Gene"},{"name":"Maps_To","value":"SMAD2"},{"name":"OMIM_Number","value":"601366"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334468"}]}}{"C18504":{"preferredName":"SMAD3 Gene","code":"C18504","definitions":[{"definition":"This gene is involved in signal transduction and apoptosis. It also plays a role in the regulation of both steroid synthesis and T-cell response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mothers Against Decapentaplegic Homolog 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SMAD3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6769"},{"name":"Legacy Concept Name","value":"MADH3_Gene"},{"name":"Maps_To","value":"SMAD3"},{"name":"OMIM_Number","value":"603109"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919432"}]}}{"C18258":{"preferredName":"SMAD4 Gene","code":"C18258","definitions":[{"definition":"This gene plays a role in signal transduction and transcriptional activation. It is also involved in suppression of angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAD4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMAD Family Member 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SMAD4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6770"},{"name":"Legacy Concept Name","value":"MADH4_Gene"},{"name":"Maps_To","value":"SMAD4"},{"name":"OMIM_Number","value":"600993"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694891"}]}}{"C19878":{"preferredName":"SMARCA4 Gene","code":"C19878","definitions":[{"definition":"This gene plays a role in chromatin remodeling, cell cycle control and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCA4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCA4","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11100"},{"name":"Legacy Concept Name","value":"SMARCA4_Gene"},{"name":"Maps_To","value":"SMARCA4"},{"name":"OMIM_Number","value":"603254"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335843"}]}}{"C18394":{"preferredName":"SMARCB1 Gene","code":"C18394","definitions":[{"definition":"This gene plays a role in chromatin remodeling and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCB1","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11103"},{"name":"Legacy Concept Name","value":"SMARCB1_Gene"},{"name":"Maps_To","value":"SMARCB1"},{"name":"OMIM_Number","value":"601607"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812273"}]}}{"C19875":{"preferredName":"SMARCD1 Gene","code":"C19875","definitions":[{"definition":"This gene plays a role in chromatin remodeling and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCD1","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily D, Member 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11106"},{"name":"Legacy Concept Name","value":"SMARCD1_Gene"},{"name":"Maps_To","value":"SMARCD1"},{"name":"OMIM_Number","value":"601735"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335847"}]}}{"C19874":{"preferredName":"SMARCE1 Gene","code":"C19874","definitions":[{"definition":"This gene is involved in chromatin remodeling and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCE1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCE1","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily E, Member 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11109"},{"name":"Legacy Concept Name","value":"SMARCE1_Gene"},{"name":"Maps_To","value":"SMARCE1"},{"name":"OMIM_Number","value":"603111"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335850"}]}}{"C75406":{"preferredName":"SMC1A Gene","code":"C75406","definitions":[{"definition":"This gene is involved in maintenance of sister chromatid cohesion during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMC1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMC1A","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Maintenance of Chromosomes 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11111"},{"name":"Legacy Concept Name","value":"SMC1A_Gene"},{"name":"Maps_To","value":"SMC1A"},{"name":"OMIM_Number","value":"300040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822777"}]}}{"C24817":{"preferredName":"SMO Gene","code":"C24817","definitions":[{"definition":"This gene plays a role in G protein-coupled receptor signal transduction and sonic hedgehog pathway activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMO Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMO","termGroup":"SY","termSource":"NCI"},{"termName":"Smoothened, Frizzled Class Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11119"},{"name":"Legacy Concept Name","value":"SMO_Gene"},{"name":"Maps_To","value":"SMO"},{"name":"OMIM_Number","value":"601500"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1364142"}]}}{"C96331":{"preferredName":"SND1 Gene","code":"C96331","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and RNA interference.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SND1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SND1","termGroup":"SY","termSource":"NCI"},{"termName":"Staphylococcal Nuclease and Tudor Domain Containing 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30646"},{"name":"Maps_To","value":"SND1"},{"name":"OMIM_Number","value":"602181"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822796"}]}}{"C97764":{"preferredName":"SNX29 Gene","code":"C97764","definitions":[{"definition":"This gene may be involved in signal transduction or lipid binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SNX29 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RUNDC2A","termGroup":"SY","termSource":"NCI"},{"termName":"SNX29","termGroup":"SY","termSource":"NCI"},{"termName":"Sorting Nexin 29 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30542"},{"name":"Maps_To","value":"SNX29"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2680432"}]}}{"C97794":{"preferredName":"SOCS1 Gene","code":"C97794","definitions":[{"definition":"This gene is involved in the attenuation of cytokine signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SOCS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SOCS1","termGroup":"SY","termSource":"NCI"},{"termName":"Suppressor of Cytokine Signaling 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19383"},{"name":"Maps_To","value":"SOCS1"},{"name":"OMIM_Number","value":"603597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426208"}]}}{"C61136":{"preferredName":"SOX2 Gene","code":"C61136","definitions":[{"definition":"This gene is involved in embryonic development and in the determination of cell fate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SOX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SOX2","termGroup":"SY","termSource":"NCI"},{"termName":"SRY (Sex Determining Region Y)-Box 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11195"},{"name":"Legacy Concept Name","value":"SOX2_Gene"},{"name":"Maps_To","value":"SOX2"},{"name":"OMIM_Number","value":"184429"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420322"}]}}{"C97531":{"preferredName":"SPECC1 Gene","code":"C97531","definitions":[{"definition":"This gene may be involved in nuclear structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SPECC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SPECC1","termGroup":"SY","termSource":"NCI"},{"termName":"Sperm Antigen with Calponin Homology and Coiled-Coil Domains 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30615"},{"name":"Maps_To","value":"SPECC1"},{"name":"OMIM_Number","value":"608793"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823096"}]}}{"C115310":{"preferredName":"SPEN Gene","code":"C115310","definitions":[{"definition":"This gene plays a role in hormone-mediated transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SPEN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SPEN","termGroup":"SY","termSource":"NCI"},{"termName":"Spen Family Transcriptional Repressor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17575"},{"name":"Maps_To","value":"SPEN"},{"name":"OMIM_Number","value":"613484"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539835"}]}}{"C102534":{"preferredName":"SPOP Gene","code":"C102534","definitions":[{"definition":"This gene is involved in protein ubiquitination, which often leads to proteasomal degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SPOP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Speckle Type BTB/POZ Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SPOP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11254"},{"name":"Maps_To","value":"SPOP"},{"name":"OMIM_Number","value":"602650"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420368"}]}}{"C19917":{"preferredName":"SRC Gene","code":"C19917","definitions":[{"definition":"This gene is involved in apoptosis, hormonogenesis, focal adhesion and the formation of intercellular junctions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SRC","termGroup":"SY","termSource":"NCI"},{"termName":"SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11283"},{"name":"Legacy Concept Name","value":"SRC_Gene"},{"name":"Maps_To","value":"SRC"},{"name":"NCI_META_CUI","value":"CL448326"},{"name":"OMIM_Number","value":"190090"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97797":{"preferredName":"SRGAP3 Gene","code":"C97797","definitions":[{"definition":"This gene plays a role in GTPase-mediated signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRGAP3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLIT-ROBO Rho GTPase Activating Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SRGAP3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19744"},{"name":"Maps_To","value":"SRGAP3"},{"name":"OMIM_Number","value":"606525"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539848"}]}}{"C101110":{"preferredName":"SRSF2 Gene","code":"C101110","definitions":[{"definition":"This gene plays a role in RNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRSF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serine and Arginine Rich Splicing Factor 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SRSF2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10783"},{"name":"Maps_To","value":"SRSF2"},{"name":"OMIM_Number","value":"600813"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419992"}]}}{"C97785":{"preferredName":"SRSF3 Gene","code":"C97785","definitions":[{"definition":"This gene plays a role in RNA splicing and export.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRSF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serine/Arginine-Rich Splicing Factor 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SRSF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10785"},{"name":"Maps_To","value":"SRSF3"},{"name":"OMIM_Number","value":"603364"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419994"}]}}{"C97800":{"preferredName":"SS18 Gene","code":"C97800","definitions":[{"definition":"This gene is involved in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SS18 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SS18","termGroup":"SY","termSource":"NCI"},{"termName":"SS18 Subunit of BAF Chromatin Remodeling Complex Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11340"},{"name":"Maps_To","value":"SS18"},{"name":"OMIM_Number","value":"600192"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420439"}]}}{"C97803":{"preferredName":"SS18L1 Gene","code":"C97803","definitions":[{"definition":"This gene plays a role in the positive regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SS18L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SS18L1","termGroup":"SY","termSource":"NCI"},{"termName":"Synovial Sarcoma Translocation Gene on Chromosome 18-Like 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15592"},{"name":"Maps_To","value":"SS18L1"},{"name":"OMIM_Number","value":"606472"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423601"}]}}{"C97806":{"preferredName":"SSX1 Gene","code":"C97806","definitions":[{"definition":"This gene may be involved in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SSX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SSX Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SSX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11335"},{"name":"Maps_To","value":"SSX1"},{"name":"OMIM_Number","value":"312820"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420434"}]}}{"C97809":{"preferredName":"SSX2 Gene","code":"C97809","definitions":[{"definition":"This gene may play a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SSX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SSX Family Member 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SSX2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11336"},{"name":"Maps_To","value":"SSX2"},{"name":"OMIM_Number","value":"300192"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420435"}]}}{"C97814":{"preferredName":"SSX4 Gene","code":"C97814","definitions":[{"definition":"This gene may be involved in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SSX4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SSX Family Member 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SSX4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11338"},{"name":"Maps_To","value":"SSX4"},{"name":"OMIM_Number","value":"300326"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420437"}]}}{"C131224":{"preferredName":"STAG1 Gene","code":"C131224","definitions":[{"definition":"This gene plays a role in sister chromatid binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"STAG1","termGroup":"SY","termSource":"NCI"},{"termName":"Stromal Antigen 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11354"},{"name":"Maps_To","value":"STAG1"},{"name":"OMIM_Number","value":"604358"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420448"}]}}{"C101346":{"preferredName":"STAG2 Gene","code":"C101346","definitions":[{"definition":"This gene is involved in cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAG2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"STAG2","termGroup":"SY","termSource":"NCI"},{"termName":"STAG2 Cohesin Complex Component Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11355"},{"name":"Maps_To","value":"STAG2"},{"name":"OMIM_Number","value":"300826"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420449"}]}}{"C24833":{"preferredName":"STAT3 Gene","code":"C24833","definitions":[{"definition":"This gene plays a role in signal transduction and activation of transcription. It is involved in regulation of both apoptosis and cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal Transducer and Activator of Transcription 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STAT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11364"},{"name":"Legacy Concept Name","value":"STAT3_Gene"},{"name":"Maps_To","value":"STAT3"},{"name":"OMIM_Number","value":"102582"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367307"}]}}{"C28667":{"preferredName":"STAT5B Gene","code":"C28667","definitions":[{"definition":"This gene is involved in signal transduction and activation of transcription. It plays a role in the immune response via stimulation of T-cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT5B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal Transducer and Activator of Transcription 5B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STAT5B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11367"},{"name":"Legacy Concept Name","value":"STAT5B_Gene"},{"name":"Maps_To","value":"STAT5B"},{"name":"OMIM_Number","value":"604260"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335876"}]}}{"C24835":{"preferredName":"STAT6 Gene","code":"C24835","definitions":[{"definition":"This gene plays a role in signal transduction and activation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal Transducer and Activator of Transcription 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STAT6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11368"},{"name":"Legacy Concept Name","value":"STAT6_Gene"},{"name":"Maps_To","value":"STAT6"},{"name":"OMIM_Number","value":"601512"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1832224"}]}}{"C101126":{"preferredName":"STIL Gene","code":"C101126","definitions":[{"definition":"This gene plays a role in both cellular proliferation and embryonic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STIL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"STIL","termGroup":"SY","termSource":"NCI"},{"termName":"STIL Centriolar Assembly Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10879"},{"name":"Maps_To","value":"STIL"},{"name":"OMIM_Number","value":"181590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420065"}]}}{"C18253":{"preferredName":"STK11 Gene","code":"C18253","definitions":[{"definition":"This gene plays a role in cell cycle regulation. It is also putatively involved in glucose production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STK11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LKB1","termGroup":"SY","termSource":"NCI"},{"termName":"Serine/Threonine Kinase 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STK11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11389"},{"name":"Legacy Concept Name","value":"STK11_Gene"},{"name":"Maps_To","value":"STK11"},{"name":"OMIM_Number","value":"602216"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694883"}]}}{"C107661":{"preferredName":"STRN Gene","code":"C107661","definitions":[{"definition":"This gene may play a role in cell scaffolding or calcium signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STRN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Striatin, Calmodulin Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STRN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11424"},{"name":"Maps_To","value":"STRN"},{"name":"OMIM_Number","value":"614765"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420489"}]}}{"C97819":{"preferredName":"SUFU Gene","code":"C97819","definitions":[{"definition":"This gene plays a role in the regulation of both transcription and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SUFU Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SUFU","termGroup":"SY","termSource":"NCI"},{"termName":"SUFU Negative Regulator uf Hedgehog Signaling Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16466"},{"name":"Maps_To","value":"SUFU"},{"name":"OMIM_Number","value":"607035"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424302"}]}}{"C73545":{"preferredName":"SUZ12 Gene","code":"C73545","definitions":[{"definition":"This gene plays a role in embryonic development and histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SUZ12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Suppressor of Zeste 12 Homolog (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SUZ12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17101"},{"name":"Legacy Concept Name","value":"SUZ12_Gene"},{"name":"Maps_To","value":"SUZ12"},{"name":"OMIM_Number","value":"606245"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539902"}]}}{"C26536":{"preferredName":"SYK Gene","code":"C26536","definitions":[{"definition":"This gene plays a role in receptor tyrosine phosphorylation signal transduction, phagocytosis, endothelial cell growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SYK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Spleen Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SYK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11491"},{"name":"Legacy Concept Name","value":"SYK_Gene"},{"name":"Maps_To","value":"SYK"},{"name":"OMIM_Number","value":"600085"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335892"}]}}{"C95994":{"preferredName":"TAF15 Gene","code":"C95994","definitions":[{"definition":"This gene plays a role in transcriptional initiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAF15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TAF15","termGroup":"SY","termSource":"NCI"},{"termName":"TATA-Box Binding Protein Associated Factor 15 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11547"},{"name":"Maps_To","value":"TAF15"},{"name":"OMIM_Number","value":"601574"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420573"}]}}{"C18301":{"preferredName":"TAL1 Gene","code":"C18301","definitions":[{"definition":"This gene plays a role in regulation of transcription and cell organization. It is involved in both embryonic hematopoiesis and adult erythropoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TAL bHLH Transcription Factor 1, Erythroid Differentiation Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TAL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11556"},{"name":"Legacy Concept Name","value":"TAL1_Gene"},{"name":"Maps_To","value":"TAL1"},{"name":"OMIM_Number","value":"187040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0796355"}]}}{"C24843":{"preferredName":"TAL2 Gene","code":"C24843","definitions":[{"definition":"This gene is involved in transcriptional regulation. It plays a role in T-cell acute lymphocytic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TAL bHLH Transcription Factor 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TAL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11557"},{"name":"Legacy Concept Name","value":"TAL2_Gene"},{"name":"Maps_To","value":"TAL2"},{"name":"OMIM_Number","value":"186855"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336574"}]}}{"C80116":{"preferredName":"TBL1XR1 Gene","code":"C80116","definitions":[{"definition":"This gene is involved in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TBL1XR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TBL1X Receptor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TBL1XR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29529"},{"name":"Legacy Concept Name","value":"TBL1XR1_Gene"},{"name":"Maps_To","value":"TBL1XR1"},{"name":"OMIM_Number","value":"608628"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539940"}]}}{"C101638":{"preferredName":"TBX3 Gene","code":"C101638","definitions":[{"definition":"This gene is involved in both transcriptional repression and limb development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TBX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"T-Box 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TBX3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11602"},{"name":"Maps_To","value":"TBX3"},{"name":"OMIM_Number","value":"601621"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420613"}]}}{"C97822":{"preferredName":"TCEA1 Gene","code":"C97822","definitions":[{"definition":"This gene is involved in transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCEA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCEA1","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Elongation Factor A (SII), 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11612"},{"name":"Maps_To","value":"TCEA1"},{"name":"OMIM_Number","value":"601425"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420622"}]}}{"C97828":{"preferredName":"TCF12 Gene","code":"C97828","definitions":[{"definition":"This gene is involved in both transcriptional regulation and tissue differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCF12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCF12","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11623"},{"name":"Maps_To","value":"TCF12"},{"name":"OMIM_Number","value":"600480"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420632"}]}}{"C24846":{"preferredName":"TCF3 Gene","code":"C24846","definitions":[{"definition":"This gene plays a role in regulation of transcription. It is involved in the control of tissue-specific cell fate during embryogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E2A","termGroup":"SY","termSource":"NCI"},{"termName":"TCF3","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11633"},{"name":"Legacy Concept Name","value":"TCF3_Gene"},{"name":"Maps_To","value":"TCF3"},{"name":"OMIM_Number","value":"147141"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336596"}]}}{"C24847":{"preferredName":"TCF7L2 Gene","code":"C24847","definitions":[{"definition":"This gene plays a role in signal transduction and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCF7L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCF7L2","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor 7 Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11641"},{"name":"Legacy Concept Name","value":"TCF7L2_Gene"},{"name":"Maps_To","value":"TCF7L2"},{"name":"OMIM_Number","value":"602228"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420644"}]}}{"C92699":{"preferredName":"TCL1A Gene","code":"C92699","definitions":[{"definition":"This gene is involved in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCL1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCL1 Family AKT Coactivator A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCL1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11648"},{"name":"Maps_To","value":"TCL1A"},{"name":"OMIM_Number","value":"186960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420650"}]}}{"C24850":{"preferredName":"TEC Gene","code":"C24850","definitions":[{"definition":"This gene is involved in signal transduction and regulation of immune function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TEC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TEC","termGroup":"SY","termSource":"NCI"},{"termName":"Tec Protein Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11719"},{"name":"Legacy Concept Name","value":"TEC_Gene"},{"name":"Maps_To","value":"TEC"},{"name":"OMIM_Number","value":"600583"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336601"}]}}{"C18173":{"preferredName":"TERT Gene","code":"C18173","definitions":[{"definition":"This gene is involved in cell cycle regulation and telomere maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TERT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Telomerase Reverse Transcriptase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TERT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11730"},{"name":"Legacy Concept Name","value":"TERT_Gene"},{"name":"Maps_To","value":"TERT"},{"name":"OMIM_Number","value":"187270"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367342"}]}}{"C95423":{"preferredName":"TET1 Gene","code":"C95423","definitions":[{"definition":"This gene is involved in the regulation of DNA methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TET1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tet Methylcytosine Dioxygenase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TET1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29484"},{"name":"Maps_To","value":"TET1"},{"name":"OMIM_Number","value":"607790"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428863"}]}}{"C95252":{"preferredName":"TET2 Gene","code":"C95252","definitions":[{"definition":"This gene is involved in oxidation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TET2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tet Methylcytosine Dioxygenase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TET2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25941"},{"name":"Maps_To","value":"TET2"},{"name":"OMIM_Number","value":"612839"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825692"}]}}{"C24854":{"preferredName":"TFE3 Gene","code":"C24854","definitions":[{"definition":"This gene plays a role in transcriptional activation. It is involved in melanogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFE3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFE3","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor Binding to IGHM Enhancer 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11752"},{"name":"Legacy Concept Name","value":"TFE3_Gene"},{"name":"Maps_To","value":"TFE3"},{"name":"OMIM_Number","value":"314310"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336608"}]}}{"C94761":{"preferredName":"TFEB Gene","code":"C94761","definitions":[{"definition":"This gene plays a role in transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFEB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFEB","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor EB Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11753"},{"name":"Maps_To","value":"TFEB"},{"name":"OMIM_Number","value":"600744"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420699"}]}}{"C97834":{"preferredName":"TFG Gene","code":"C97834","definitions":[{"definition":"This gene is involved in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFG","termGroup":"SY","termSource":"NCI"},{"termName":"Trafficking from ER to Golgi Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11758"},{"name":"Maps_To","value":"TFG"},{"name":"OMIM_Number","value":"602498"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420703"}]}}{"C97837":{"preferredName":"TFPT Gene","code":"C97837","definitions":[{"definition":"This gene plays a role in the regulation of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFPT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCF3 Fusion Partner Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TFPT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13630"},{"name":"Maps_To","value":"TFPT"},{"name":"OMIM_Number","value":"609519"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422118"}]}}{"C38517":{"preferredName":"TFRC Gene","code":"C38517","definitions":[{"definition":"This gene plays a regulatory role in receptor-mediated endocytosis and iron metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFRC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFRC","termGroup":"SY","termSource":"NCI"},{"termName":"Transferrin Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11763"},{"name":"Legacy Concept Name","value":"TFRC_Gene"},{"name":"Maps_To","value":"TFRC"},{"name":"OMIM_Number","value":"190010"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420708"}]}}{"C18592":{"preferredName":"TGFBR2 Gene","code":"C18592","definitions":[{"definition":"This gene plays a role in cellular proliferation and mitogenic responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGFBR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TGFBR2","termGroup":"SY","termSource":"NCI"},{"termName":"Transforming Growth Factor, Beta Receptor II (70/80kDa) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11773"},{"name":"Legacy Concept Name","value":"TGFBR2_Gene"},{"name":"Maps_To","value":"TGFBR2"},{"name":"OMIM_Number","value":"190182"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919538"}]}}{"C97840":{"preferredName":"THRAP3 Gene","code":"C97840","definitions":[{"definition":"This gene is involved in the activation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"THRAP3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"THRAP3","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Hormone Receptor Associated Protein 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22964"},{"name":"Maps_To","value":"THRAP3"},{"name":"OMIM_Number","value":"603809"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427817"}]}}{"C18608":{"preferredName":"TLX1 Gene","code":"C18608","definitions":[{"definition":"This gene plays a role in transcriptional regulation and organogenesis. Translocations in the gene are associated with acute T-cell leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Leukemia Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TLX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5056"},{"name":"Legacy Concept Name","value":"HOX11_Gene"},{"name":"Maps_To","value":"TLX1"},{"name":"OMIM_Number","value":"186770"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0920270"}]}}{"C98099":{"preferredName":"TLX3 Gene","code":"C98099","definitions":[{"definition":"This gene may be involved in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Leukemia Homeobox 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TLX3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13532"},{"name":"Maps_To","value":"TLX3"},{"name":"OMIM_Number","value":"604640"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422043"}]}}{"C95303":{"preferredName":"TMEM127 Gene","code":"C95303","definitions":[{"definition":"This gene may play a role in signaling and protein trafficking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TMEM127 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TMEM127","termGroup":"SY","termSource":"NCI"},{"termName":"Transmembrane Protein 127 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26038"},{"name":"Maps_To","value":"TMEM127"},{"name":"OMIM_Number","value":"613403"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823386"}]}}{"C24871":{"preferredName":"TMPRSS2 Gene","code":"C24871","definitions":[{"definition":"This gene plays a role in the activation of pathway signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TMPRSS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TMPRSS2","termGroup":"SY","termSource":"NCI"},{"termName":"Transmembrane Serine Protease 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11876"},{"name":"Legacy Concept Name","value":"TMPRSS2_Gene"},{"name":"Maps_To","value":"TMPRSS2"},{"name":"OMIM_Number","value":"602060"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336641"}]}}{"C21091":{"preferredName":"TNC Gene","code":"C21091","definitions":[{"definition":"This gene is involved in cell adhesion, differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tenascin C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TNC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5318"},{"name":"Legacy Concept Name","value":"TNC_Gene"},{"name":"Maps_To","value":"TNC"},{"name":"OMIM_Number","value":"187380"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336642"}]}}{"C84928":{"preferredName":"TNFAIP3 Gene","code":"C84928","definitions":[{"definition":"This gene may play a role in the regulation of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNFAIP3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNF Alpha Induced Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TNFAIP3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11896"},{"name":"Maps_To","value":"TNFAIP3"},{"name":"OMIM_Number","value":"191163"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420799"}]}}{"C97843":{"preferredName":"TNFRSF14 Gene","code":"C97843","definitions":[{"definition":"This gene plays a role in receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNFRSF14 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNFRSF14","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Necrosis Factor Receptor Superfamily, Member 14 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11912"},{"name":"Maps_To","value":"TNFRSF14"},{"name":"OMIM_Number","value":"602746"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420808"}]}}{"C97846":{"preferredName":"TNFRSF17 Gene","code":"C97846","definitions":[{"definition":"This gene is involved in the modulation of cytokine signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNFRSF17 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNFRSF17","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Necrosis Factor Receptor Superfamily, Member 17 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11913"},{"name":"Maps_To","value":"TNFRSF17"},{"name":"OMIM_Number","value":"109545"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420809"}]}}{"C26591":{"preferredName":"TOP1 Gene","code":"C26591","definitions":[{"definition":"This gene is involved in the regulation of both DNA topology and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TOP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Topoisomerase I Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TOP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11986"},{"name":"Legacy Concept Name","value":"TOP1_Gene"},{"name":"Maps_To","value":"TOP1"},{"name":"OMIM_Number","value":"126420"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336656"}]}}{"C17359":{"preferredName":"TP53 Gene","code":"C17359","definitions":[{"definition":"This gene plays a critical role in cell cycle regulation and has tumor suppressor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TP53 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TP53","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Protein P53 (Li-Fraumeni Syndrome) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11998"},{"name":"Legacy Concept Name","value":"TP53_Gene"},{"name":"Maps_To","value":"TP53"},{"name":"OMIM_Number","value":"191170"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0079419"}]}}{"C91791":{"preferredName":"TP63 Gene","code":"C91791","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and limb development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TP63 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TP63","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Protein p63 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15979"},{"name":"Maps_To","value":"TP63"},{"name":"OMIM_Number","value":"603273"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422009"}]}}{"C97849":{"preferredName":"TPM3 Gene","code":"C97849","definitions":[{"definition":"This gene plays a role in muscle contraction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TPM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TPM3","termGroup":"SY","termSource":"NCI"},{"termName":"Tropomyosin 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12012"},{"name":"Maps_To","value":"TPM3"},{"name":"OMIM_Number","value":"191030"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420874"}]}}{"C97852":{"preferredName":"TPM4 Gene","code":"C97852","definitions":[{"definition":"This gene is involved in smooth muscle cell contraction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TPM4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TPM4","termGroup":"SY","termSource":"NCI"},{"termName":"Tropomyosin 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12013"},{"name":"Maps_To","value":"TPM4"},{"name":"OMIM_Number","value":"600317"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420875"}]}}{"C97855":{"preferredName":"TPR Gene","code":"C97855","definitions":[{"definition":"This gene plays a role in both nuclear transport and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TPR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TPR","termGroup":"SY","termSource":"NCI"},{"termName":"Translocated Promoter Region, Nuclear Basket Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12017"},{"name":"Maps_To","value":"TPR"},{"name":"OMIM_Number","value":"189940"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420877"}]}}{"C26419":{"preferredName":"T-Cell Receptor Alpha Locus","code":"C26419","definitions":[{"definition":"This region represents the germline organization of the T cell receptor alpha locus. The alpha locus includes V (variable), J (joining), and C (constant) segments. During T cell development, the alpha chain is synthesized by a recombination event at the DNA level joining a V segment with a J segment. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Receptor Alpha Locus","termGroup":"PT","termSource":"NCI"},{"termName":"T-Cell Receptor Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCRA","termGroup":"SY","termSource":"NCI"},{"termName":"TRA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"6955"},{"name":"GenBank_Accession_Number","value":"NG_001332"},{"name":"Gene_Encodes_Product","value":"T-Cell Receptor Alpha Chain"},{"name":"HGNC_ID","value":"HGNC:12027"},{"name":"Legacy Concept Name","value":"T-Cell_Receptor_Alpha_Locus"},{"name":"Maps_To","value":"TRA"},{"name":"OMIM_Number","value":"186880"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0524890"}]}}{"C107646":{"preferredName":"TRAF7 Gene","code":"C107646","definitions":[{"definition":"This gene is involved in both MAPK signaling and protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRAF7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNF Receptor-Associated Factor 7, E3 Ubiquitin Protein Ligase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TRAF7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20456"},{"name":"Maps_To","value":"TRAF7"},{"name":"OMIM_Number","value":"606692"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1540047"}]}}{"C26418":{"preferredName":"T-Cell Receptor Beta Locus","code":"C26418","definitions":[{"definition":"This region represents the germline organization of the T cell receptor beta locus. The beta locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During T cell development, the beta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase.  Chromosomal abnormalities involving the T-cell receptor beta locus have been associated with T-cell lymphomas. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Receptor Beta Locus","termGroup":"PT","termSource":"NCI"},{"termName":"T-Cell Receptor Beta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCRB","termGroup":"SY","termSource":"NCI"},{"termName":"TRB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"6957"},{"name":"GenBank_Accession_Number","value":"U66059"},{"name":"Gene_Encodes_Product","value":"T-Cell Receptor Beta Chain"},{"name":"HGNC_ID","value":"HGNC:12155"},{"name":"Legacy Concept Name","value":"T-Cell_Receptor_Beta_Locus"},{"name":"Maps_To","value":"TRB"},{"name":"OMIM_Number","value":"186930"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0524891"}]}}{"C26420":{"preferredName":"T-Cell Receptor Delta Locus","code":"C26420","definitions":[{"definition":"This region represents the germline organization of the T cell receptordelta locus. The delta locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During T cell development, the delta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Receptor Delta Locus","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Receptor Delta Locus","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Receptor Delta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCRD","termGroup":"SY","termSource":"NCI"},{"termName":"TRD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"6964"},{"name":"GenBank_Accession_Number","value":"M21624"},{"name":"Gene_Encodes_Product","value":"T-Cell Receptor Delta Chain"},{"name":"HGNC_ID","value":"HGNC:12252"},{"name":"Legacy Concept Name","value":"T-Cell_Receptor_Delta_Locus"},{"name":"Maps_To","value":"TRD"},{"name":"OMIM_Number","value":"186810"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0524893"}]}}{"C95280":{"preferredName":"TRIM24 Gene","code":"C95280","definitions":[{"definition":"This gene plays a role in hormone-dependent gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIM24 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TRIM24","termGroup":"SY","termSource":"NCI"},{"termName":"Tripartite Motif-Containing 24 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11812"},{"name":"Maps_To","value":"TRIM24"},{"name":"OMIM_Number","value":"603406"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823488"}]}}{"C24733":{"preferredName":"TRIM27 Gene","code":"C24733","definitions":[{"definition":"This gene is involved in the differentiation of male germ cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIM27 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TRIM27","termGroup":"SY","termSource":"NCI"},{"termName":"Tripartite Motif-Containing 27 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9975"},{"name":"Legacy Concept Name","value":"RFP_Gene"},{"name":"Maps_To","value":"TRIM27"},{"name":"OMIM_Number","value":"602165"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823489"}]}}{"C97858":{"preferredName":"TRIM33 Gene","code":"C97858","definitions":[{"definition":"This gene is involved in the mediation of protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIM33 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TRIM33","termGroup":"SY","termSource":"NCI"},{"termName":"Tripartite Motif Containing 33 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16290"},{"name":"Maps_To","value":"TRIM33"},{"name":"OMIM_Number","value":"605769"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424158"}]}}{"C97861":{"preferredName":"TRIP11 Gene","code":"C97861","definitions":[{"definition":"This gene plays a role in thyroid receptor binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIP11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Thyroid Hormone Receptor Interactor 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TRIP11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12305"},{"name":"Maps_To","value":"TRIP11"},{"name":"OMIM_Number","value":"604505"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421146"}]}}{"C24880":{"preferredName":"TRRAP Gene","code":"C24880","definitions":[{"definition":"This gene is involved in DNA repair and regulation of mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRRAP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Transformation/Transcription Domain-Associated Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TRRAP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12347"},{"name":"Legacy Concept Name","value":"TRRAP_Gene"},{"name":"Maps_To","value":"TRRAP"},{"name":"OMIM_Number","value":"603015"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336677"}]}}{"C18259":{"preferredName":"TSC1 Gene","code":"C18259","definitions":[{"definition":"This gene is involved in cell cycle regulation and the loss of cellular adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TSC1","termGroup":"SY","termSource":"NCI"},{"termName":"Tuberous Sclerosis 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12362"},{"name":"Legacy Concept Name","value":"TSC1_Gene"},{"name":"Maps_To","value":"TSC1"},{"name":"OMIM_Number","value":"605284"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694894"}]}}{"C18260":{"preferredName":"TSC2 Gene","code":"C18260","definitions":[{"definition":"This gene plays a role in signal transduction and cell cycle control. It is involved in cell adhesion, differentiation, growth and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TSC2","termGroup":"SY","termSource":"NCI"},{"termName":"Tuberous Sclerosis 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12363"},{"name":"Legacy Concept Name","value":"TSC2_Gene"},{"name":"Maps_To","value":"TSC2"},{"name":"OMIM_Number","value":"191092"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694895"}]}}{"C24881":{"preferredName":"TSHR Gene","code":"C24881","definitions":[{"definition":"This gene plays an important role in the regulation of thyroid cell metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSHR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Thyroid Stimulating Hormone Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TSHR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12373"},{"name":"Legacy Concept Name","value":"TSHR_Gene"},{"name":"Maps_To","value":"TSHR"},{"name":"OMIM_Number","value":"603372"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336679"}]}}{"C101113":{"preferredName":"U2AF1 Gene","code":"C101113","definitions":[{"definition":"This gene is involved in the splicing of mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"U2AF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"U2 Small Nuclear RNA Auxiliary Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"U2AF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12453"},{"name":"Maps_To","value":"U2AF1"},{"name":"OMIM_Number","value":"191317"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421254"}]}}{"C111928":{"preferredName":"UBR5 Gene","code":"C111928","definitions":[{"definition":"This gene plays a role in protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"UBR5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ubiquitin Protein Ligase E3 Component N-Recognin 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"UBR5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16806"},{"name":"Maps_To","value":"UBR5"},{"name":"OMIM_Number","value":"608413"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825027"}]}}{"C24892":{"preferredName":"USP6 Gene","code":"C24892","definitions":[{"definition":"This gene is involved in the regulation of cellular ubiquitination. It also plays a role in promoting the recycling of endocytic vesicles to the plasma membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"USP6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ubiquitin Specific Peptidase 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"USP6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12629"},{"name":"Legacy Concept Name","value":"USP6_Gene"},{"name":"Maps_To","value":"USP6"},{"name":"OMIM_Number","value":"604334"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421407"}]}}{"C24893":{"preferredName":"USP8 Gene","code":"C24893","definitions":[{"definition":"This gene plays a role in ubiquitin-dependent proteolysis and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"USP8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ubiquitin Specific Protease 8 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"USP8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12631"},{"name":"Legacy Concept Name","value":"USP8_Gene"},{"name":"Maps_To","value":"USP8"},{"name":"OMIM_Number","value":"603158"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336848"}]}}{"C18365":{"preferredName":"VAV1 Gene","code":"C18365","definitions":[{"definition":"This gene plays a role in signal transduction. It is involved in the development and activation of both B cells and T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VAV1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Vav Guanine Nucleotide Exchange Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"VAV1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12657"},{"name":"Legacy Concept Name","value":"VAV1_Gene"},{"name":"Maps_To","value":"VAV1"},{"name":"OMIM_Number","value":"164875"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336926"}]}}{"C18261":{"preferredName":"VHL Gene","code":"C18261","definitions":[{"definition":"This gene is involved in transcriptional repression and protein degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VHL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"VHL","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Tumor Suppressor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12687"},{"name":"Legacy Concept Name","value":"VHL_Gene"},{"name":"Maps_To","value":"VHL"},{"name":"OMIM_Number","value":"608537"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694897"}]}}{"C99462":{"preferredName":"VTI1A Gene","code":"C99462","definitions":[{"definition":"This gene is involved in vesicular transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VTI1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Vesicle Transport through Interaction with t-SNAREs Homolog 1A (Yeast) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"VTI1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17792"},{"name":"Maps_To","value":"VTI1A"},{"name":"OMIM_Number","value":"614316"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425079"}]}}{"C43236":{"preferredName":"WAS Gene","code":"C43236","definitions":[{"definition":"This gene is involved in signal transduction and plays a role in cell communication and organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WAS","termGroup":"SY","termSource":"NCI"},{"termName":"WASP Actin Nucleation Promoting Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12731"},{"name":"Legacy Concept Name","value":"WAS_Gene"},{"name":"Maps_To","value":"WAS"},{"name":"OMIM_Number","value":"300392"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421478"}]}}{"C101428":{"preferredName":"WDCP Gene","code":"C101428","definitions":[{"definition":"This gene plays a role in binding to tyrosine-protein kinase HCK.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WDCP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C2orf44","termGroup":"SY","termSource":"NCI"},{"termName":"WD Repeat and Coiled Coil Containing Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WDCP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26157"},{"name":"Maps_To","value":"WDCP"},{"name":"OMIM_Number","value":"616234"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824110"}]}}{"C97867":{"preferredName":"WIF1 Gene","code":"C97867","definitions":[{"definition":"This gene plays a role in Wnt protein-dependent signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WIF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WIF1","termGroup":"SY","termSource":"NCI"},{"termName":"WNT Inhibitory Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18081"},{"name":"Maps_To","value":"WIF1"},{"name":"OMIM_Number","value":"605186"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425289"}]}}{"C143106":{"preferredName":"WNK2 Gene","code":"C143106","definitions":[{"definition":"This gene plays a role in electrolyte homeostasis, cell signaling, cell survival, and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WNK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WNK Lysine Deficient Protein Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WNK2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14542"},{"name":"Maps_To","value":"WNK2"},{"name":"NCI_META_CUI","value":"CL541531"},{"name":"OMIM_Number","value":"606249"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C20070":{"preferredName":"WRN Gene","code":"C20070","definitions":[{"definition":"This gene is involved in DNA repair and the unwinding of DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WRN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Werner Syndrome Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WRN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12791"},{"name":"Legacy Concept Name","value":"WRN_Gene"},{"name":"Maps_To","value":"WRN"},{"name":"OMIM_Number","value":"604611"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337007"}]}}{"C18262":{"preferredName":"WT1 Gene","code":"C18262","definitions":[{"definition":"This gene plays a role in regulation of transcription. It is involved in the control of both cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WT1","termGroup":"SY","termSource":"NCI"},{"termName":"WT1 Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12796"},{"name":"Legacy Concept Name","value":"WT1_Gene"},{"name":"Maps_To","value":"WT1"},{"name":"OMIM_Number","value":"607102"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694898"}]}}{"C24844":{"preferredName":"WWTR1 Gene","code":"C24844","definitions":[{"definition":"This gene is involved in regulation of transcription. It is involved in fetal/neonatal cardiac and muscle development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WWTR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WW Domain Containing Transcription Regulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WWTR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24042"},{"name":"Legacy Concept Name","value":"TAZ_Gene"},{"name":"Maps_To","value":"WWTR1"},{"name":"OMIM_Number","value":"607392"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538117"}]}}{"C20361":{"preferredName":"XPA Gene","code":"C20361","definitions":[{"definition":"This gene facilitates DNA binding in repair processes and is associated with the disease xeroderma pigmentosum complementation group A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XPA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Xeroderma Pigmentosum, Complementation Group A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"XPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12814"},{"name":"Legacy Concept Name","value":"XPA_Gene"},{"name":"Maps_To","value":"XPA"},{"name":"OMIM_Number","value":"611153"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337030"}]}}{"C97870":{"preferredName":"XPC Gene","code":"C97870","definitions":[{"definition":"This gene is involved in nucleotide excision repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XPC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"XPC","termGroup":"SY","termSource":"NCI"},{"termName":"XPC Complex Subunit, DNA Damage Recognition and Repair Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12816"},{"name":"Maps_To","value":"XPC"},{"name":"OMIM_Number","value":"613208"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421540"}]}}{"C99484":{"preferredName":"XPO1 Gene","code":"C99484","definitions":[{"definition":"This gene plays a role in the regulation of nuclear export.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XPO1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Exportin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"XPO1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12825"},{"name":"Maps_To","value":"XPO1"},{"name":"OMIM_Number","value":"602559"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421544"}]}}{"C101116":{"preferredName":"YWHAE Gene","code":"C101116","definitions":[{"definition":"This gene plays a role in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"YWHAE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Epsilon Polypeptide Gene","termGroup":"SY","termSource":"NCI"},{"termName":"YWHAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12851"},{"name":"Maps_To","value":"YWHAE"},{"name":"OMIM_Number","value":"605066"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421560"}]}}{"C28635":{"preferredName":"ZBTB16 Gene","code":"C28635","definitions":[{"definition":"This gene plays a role in apoptosis and regulation of transcription. It is also involved in cell organization/biogenesis and megakaryocytic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZBTB16 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZBTB16","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger and BTB Domain Containing 16 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12930"},{"name":"Legacy Concept Name","value":"ZNF145_Gene"},{"name":"Maps_To","value":"ZBTB16"},{"name":"OMIM_Number","value":"176797"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538149"}]}}{"C122878":{"preferredName":"ZCCHC8 Gene","code":"C122878","definitions":[{"definition":"This gene plays a role in RNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZCCHC8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZCCHC8","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger CCHC-Type Containing 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25265"},{"name":"Maps_To","value":"ZCCHC8"},{"name":"OMIM_Number","value":"616381"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428463"}]}}{"C105605":{"preferredName":"ZEB1 Gene","code":"C105605","definitions":[{"definition":"This gene is involved in the transcriptional repression of interleukin 2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZEB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZEB1","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger E-Box Binding Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11642"},{"name":"Maps_To","value":"ZEB1"},{"name":"OMIM_Number","value":"189909"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420645"}]}}{"C115424":{"preferredName":"ZFHX3 Gene","code":"C115424","definitions":[{"definition":"This gene is involved in myoblast and neuronal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZFHX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZFHX3","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger Homeobox 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:777"},{"name":"Maps_To","value":"ZFHX3"},{"name":"OMIM_Number","value":"104155"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412611"}]}}{"C101617":{"preferredName":"ZMYM3 Gene","code":"C101617","definitions":[{"definition":"This gene is involved in chromatin modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZMYM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger, MYM-Type 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZMYM3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13054"},{"name":"Maps_To","value":"ZMYM3"},{"name":"OMIM_Number","value":"300061"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823959"}]}}{"C97873":{"preferredName":"ZMYM2 Gene","code":"C97873","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZMYM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger MYM-Type Containing 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZMYM2","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF198","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12989"},{"name":"Maps_To","value":"ZNF198"},{"name":"OMIM_Number","value":"602221"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823958"}]}}{"C97879":{"preferredName":"ZNF331 Gene","code":"C97879","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF331 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 331 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF331","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15489"},{"name":"Maps_To","value":"ZNF331"},{"name":"OMIM_Number","value":"606043"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423527"}]}}{"C97882":{"preferredName":"ZNF384 Gene","code":"C97882","definitions":[{"definition":"This gene is involved in both transcriptional regulation and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF384 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 384 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF384","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11955"},{"name":"Maps_To","value":"ZNF384"},{"name":"OMIM_Number","value":"609951"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420834"}]}}{"C143100":{"preferredName":"ZNF429 Gene","code":"C143100","definitions":[{"definition":"This gene may play a role in the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF429 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 429 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF429","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20817"},{"name":"Maps_To","value":"ZNF429"},{"name":"NCI_META_CUI","value":"CL541541"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C106358":{"preferredName":"ZNF444 Gene","code":"C106358","definitions":[{"definition":"This gene is involved in LDL metabolism, transcriptional regulation and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF444 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 444 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF444","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16052"},{"name":"Maps_To","value":"ZNF444"},{"name":"OMIM_Number","value":"607874"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423940"}]}}{"C143103":{"preferredName":"ZNF479 Gene","code":"C143103","definitions":[{"definition":"This gene may play a role in the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF479 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 479 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF479","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23258"},{"name":"Maps_To","value":"ZNF479"},{"name":"NCI_META_CUI","value":"CL541544"},{"name":"OMIM_Number","value":"617444"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97885":{"preferredName":"ZNF521 Gene","code":"C97885","definitions":[{"definition":"This gene plays a role in both the positive and negative regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF521 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 521 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF521","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24605"},{"name":"Maps_To","value":"ZNF521"},{"name":"OMIM_Number","value":"610974"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428393"}]}}{"C118319":{"preferredName":"ZNRF3 Gene","code":"C118319","definitions":[{"definition":"This gene is involved in protein ubiquitination and Wnt pathway inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNRF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc and Ring Finger 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNRF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18126"},{"name":"Maps_To","value":"ZNRF3"},{"name":"OMIM_Number","value":"612062"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538251"}]}}{"C101120":{"preferredName":"ZRSR2 Gene","code":"C101120","definitions":[{"definition":"This gene is involved in mRNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZRSR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZRSR2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23019"},{"name":"Maps_To","value":"ZRSR2"},{"name":"OMIM_Number","value":"300028"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824082"}]}}{"C21167":{"preferredName":"CHGA Gene","code":"C21167","definitions":[{"definition":"This gene plays a role in the modulation of the neuroendocrine system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHGA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHGA","termGroup":"SY","termSource":"NCI"},{"termName":"Chromogranin A (Parathyroid Secretory Protein 1) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1929"},{"name":"Legacy Concept Name","value":"CHGA_Gene"},{"name":"Maps_To","value":"CHGA"},{"name":"OMIM_Number","value":"118910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332754"}]}}{"C101144":{"preferredName":"SYP Gene","code":"C101144","definitions":[{"definition":"This gene is involved in vesicle targeting and synaptic plasticity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SYP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Synaptophysin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SYP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11506"},{"name":"Maps_To","value":"SYP"},{"name":"OMIM_Number","value":"313475"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420554"}]}}{"C181091":{"preferredName":"AQP1 Gene","code":"C181091","definitions":[{"definition":"This gene plays a role in transmembrane transport of water.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AQP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AQP1","termGroup":"SY","termSource":"NCI"},{"termName":"Aquaporin 1 (Colton Blood Group) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:633"},{"name":"Maps_To","value":"AQP1"},{"name":"OMIM_Number","value":"107776"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412491"}]}}{"C123856":{"preferredName":"CALB2 Gene","code":"C123856","definitions":[{"definition":"This gene is involved in calcium ion homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CALB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CALB2","termGroup":"SY","termSource":"NCI"},{"termName":"Calbindin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1435"},{"name":"Maps_To","value":"CALB2"},{"name":"OMIM_Number","value":"114051"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413081"}]}}{"C26556":{"preferredName":"DNTT Gene","code":"C26556","definitions":[{"definition":"This gene is involved in DNA synthesis. It also plays a role in the generation of antigen diversity in pre-B and pre-T lymphocytes during early differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNTT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Deoxynucleotidyltransferase, Terminal Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DNTT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2983"},{"name":"Legacy Concept Name","value":"DNTT_Gene"},{"name":"Maps_To","value":"DNTT"},{"name":"OMIM_Number","value":"187410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333243"}]}}{"C18421":{"preferredName":"EPCAM Gene","code":"C18421","definitions":[{"definition":"This gene is involved in calcium-independent cellular adhesion and in the regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPCAM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EPCAM","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Cell Adhesion Molecule Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TACSTD1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11529"},{"name":"Legacy Concept Name","value":"TACSTD1_Gene"},{"name":"Maps_To","value":"EPCAM"},{"name":"OMIM_Number","value":"185535"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812305"}]}}{"C106015":{"preferredName":"SERPINA9 Gene","code":"C106015","definitions":[{"definition":"This gene is involved in trypsin activity regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SERPINA9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serpin Family A Member 9","termGroup":"SY","termSource":"NCI"},{"termName":"SERPINA9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15995"},{"name":"Maps_To","value":"GCET1"},{"name":"OMIM_Number","value":"615677"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423895"}]}}{"C104785":{"preferredName":"PDPN Gene","code":"C104785","definitions":[{"definition":"This gene plays a role in cell shape.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDPN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDPN","termGroup":"SY","termSource":"NCI"},{"termName":"Podoplanin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29602"},{"name":"Maps_To","value":"PDPN"},{"name":"OMIM_Number","value":"608863"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826560"}]}}{"C26598":{"preferredName":"PTGS2 Gene","code":"C26598","definitions":[{"definition":"This gene is involved in mitogenesis, inflammation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTGS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COX2","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin-Endoperoxide Synthase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTGS2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9605"},{"name":"Legacy Concept Name","value":"PTGS2_Gene"},{"name":"Maps_To","value":"PTGS2"},{"name":"OMIM_Number","value":"600262"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367485"}]}}{"C24863":{"preferredName":"TLR2 Gene","code":"C24863","definitions":[{"definition":"This gene plays a role in pathogen recognition and mediates the host response to gram-positive bacteria and yeast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TLR2","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-Like Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11848"},{"name":"Legacy Concept Name","value":"TLR2_Gene"},{"name":"Maps_To","value":"TLR2"},{"name":"OMIM_Number","value":"603028"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336634"}]}}{"C103885":{"preferredName":"ACACA Gene","code":"C103885","definitions":[{"definition":"This gene plays a role in the synthesis of long-chain fatty acids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACACA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACACA","termGroup":"SY","termSource":"NCI"},{"termName":"Acetyl-CoA Carboxylase Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:84"},{"name":"Maps_To","value":"ACACA"},{"name":"OMIM_Number","value":"200350"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412104"}]}}{"C185736":{"preferredName":"BRD1 Gene","code":"C185736","definitions":[{"definition":"This gene is involved in the localization of histone acetyltransferase complexes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRD1","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain Containing 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1102"},{"name":"Maps_To","value":"BRD1"},{"name":"OMIM_Number","value":"604589"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412820"}]}}{"C126629":{"preferredName":"BTBD18 Gene","code":"C126629","definitions":[{"definition":"This gene may be involved in protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTBD18 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BTB Domain Containing 18 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BTBD18","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:37214"},{"name":"Maps_To","value":"BTBD18"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2828831"}]}}{"C104928":{"preferredName":"CBFA2T2 Gene","code":"C104928","definitions":[{"definition":"This gene may be involved in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBFA2T2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBFA2T2","termGroup":"SY","termSource":"NCI"},{"termName":"Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1536"},{"name":"Maps_To","value":"CBFA2T2"},{"name":"OMIM_Number","value":"603672"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413148"}]}}{"C200372":{"preferredName":"CEP164 Gene","code":"C200372","definitions":[{"definition":"This gene is involved in the formation of cilium basal bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP164 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 164 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP164","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29182"},{"name":"Maps_To","value":"CEP164"},{"name":"OMIM_Number","value":"614848"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824720"}]}}{"C126611":{"preferredName":"CEP170B Gene","code":"C126611","definitions":[{"definition":"This gene may be involved in microtubule organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP170B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 170B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP170B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20362"},{"name":"Maps_To","value":"CEP170B"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426896"}]}}{"C200378":{"preferredName":"CTDP1 Gene","code":"C200378","definitions":[{"definition":"This gene plays a role in the dephosphorylation of the C-terminal domain (CTD) of RNA polymerase II subunit A (POLR2A).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTDP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CTD Phosphatase Subunit 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTDP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2498"},{"name":"Maps_To","value":"CTDP1"},{"name":"OMIM_Number","value":"604927"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413790"}]}}{"C73677":{"preferredName":"DOT1L Gene","code":"C73677","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DOT1L Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DOT1-like, Histone H3 Methyltransferase (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DOT1L","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24948"},{"name":"Legacy Concept Name","value":"DOT1L_Gene"},{"name":"Maps_To","value":"DOT1L"},{"name":"OMIM_Number","value":"607375"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428431"}]}}{"C126623":{"preferredName":"FRYL Gene","code":"C126623","definitions":[{"definition":"This gene is involved in the regulation of cell shape and polarity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FRYL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FRY-Like Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FRYL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29127"},{"name":"Maps_To","value":"FRYL"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825320"}]}}{"C105900":{"preferredName":"GLIS2 Gene","code":"C105900","definitions":[{"definition":"This gene is involved in transcriptional regulation and signaling pathway modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GLIS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GLIS Family Zinc Finger 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GLIS2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29450"},{"name":"Maps_To","value":"GLIS2"},{"name":"OMIM_Number","value":"608539"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539573"}]}}{"C20580":{"preferredName":"HMGB3 Gene","code":"C20580","definitions":[{"definition":"This gene plays a role in development and the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGB3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High-Mobility Group Box 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGB3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5004"},{"name":"Legacy Concept Name","value":"HMGB3_Gene"},{"name":"Maps_To","value":"HMGB3"},{"name":"OMIM_Number","value":"300193"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333910"}]}}{"C200386":{"preferredName":"HNRNPH1 Gene","code":"C200386","definitions":[{"definition":"This gene is involved in the regulation of alternative pre-mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HNRNPH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heterogeneous Nuclear Ribonucleoprotein H1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HNRNPH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5041"},{"name":"Maps_To","value":"HNRNPH1"},{"name":"OMIM_Number","value":"601035"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415642"}]}}{"C125258":{"preferredName":"INO80D Gene","code":"C125258","definitions":[{"definition":"This gene plays a role in ATP-dependent chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INO80D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"INO80 Complex Subunit D Gene","termGroup":"SY","termSource":"NCI"},{"termName":"INO80D","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25997"},{"name":"Maps_To","value":"INO80D"},{"name":"OMIM_Number","value":"619207"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2681613"}]}}{"C200399":{"preferredName":"JARID2 Gene","code":"C200399","definitions":[{"definition":"This gene plays a role in transcriptional repression and the regulation of Polycomb repressive complex 2 (PRC2)-mediated histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JARID2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JARID2","termGroup":"SY","termSource":"NCI"},{"termName":"Jumonji and AT-Rich Interaction Domain Containing 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6196"},{"name":"Maps_To","value":"JARID2"},{"name":"OMIM_Number","value":"601594"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416528"}]}}{"C98035":{"preferredName":"PHF23 Gene","code":"C98035","definitions":[{"definition":"This gene may be involved in chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PHF23 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PHD Finger Protein 23 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PHF23","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28428"},{"name":"Maps_To","value":"PHF23"},{"name":"OMIM_Number","value":"612910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826581"}]}}{"C178143":{"preferredName":"PIM3 Gene","code":"C178143","definitions":[{"definition":"This gene is involved in serine/threonine kinase activity that inhibits apoptosis, promotes cell survival and regulates protein translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Pim-3 Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIM3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19310"},{"name":"Maps_To","value":"PIM3"},{"name":"OMIM_Number","value":"610580"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538648"}]}}{"C24704":{"preferredName":"PTP4A1 Gene","code":"C24704","definitions":[{"definition":"This gene is involved in liver cell growth and the cellular response to mitogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTP4A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase Type IVA, Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTP4A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9634"},{"name":"Legacy Concept Name","value":"PTP4A1_Gene"},{"name":"Maps_To","value":"PTP4A1"},{"name":"OMIM_Number","value":"601585"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335279"}]}}{"C200404":{"preferredName":"RPS15 Gene","code":"C200404","definitions":[{"definition":"This gene is involved in the maturation and nuclear export of the 40S ribosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPS15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein S15 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPS15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10388"},{"name":"Legacy Concept Name","value":"RPL10_Gene"},{"name":"Maps_To","value":"RPS15"},{"name":"OMIM_Number","value":"180535"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419704"}]}}{"C200408":{"preferredName":"SETD1A Gene","code":"C200408","definitions":[{"definition":"This gene plays a role in the transfer of one to three methyl groups to the lysine at amino acid residue 4 of histone H3 (H3K4).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SETD1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET Domain Containing 1A, Histone Lysine Methyltransferase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SETD1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29010"},{"name":"Legacy Concept Name","value":"SETD2_Gene"},{"name":"Maps_To","value":"SETD1A"},{"name":"OMIM_Number","value":"611052"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822684"}]}}{"C200414":{"preferredName":"SLC66A2 Gene","code":"C200414","definitions":[{"definition":"This gene may be involved in retrograde transport and phospholipid translocation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SLC66A2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLC66A2","termGroup":"SY","termSource":"NCI"},{"termName":"Solute Carrier Family 66 Member 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26188"},{"name":"Maps_To","value":"SLC66A2 (aka PQLC1)"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428559"}]}}{"C26593":{"preferredName":"TOP2B Gene","code":"C26593","definitions":[{"definition":"This gene is involved in chromosome recombination, DNA replication and the regulation of DNA topology during transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TOP2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Topoisomerase II Beta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TOP2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11990"},{"name":"Legacy Concept Name","value":"TOP2B_Gene"},{"name":"Maps_To","value":"TOP2B"},{"name":"OMIM_Number","value":"126431"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336658"}]}}{"C38431":{"preferredName":"UBB Gene","code":"C38431","definitions":[{"definition":"This gene is involved in ubiquitin-dependent proteolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"UBB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"UBB","termGroup":"SY","termSource":"NCI"},{"termName":"Ubiquitin B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12463"},{"name":"Legacy Concept Name","value":"UBB_Gene"},{"name":"Maps_To","value":"UBB"},{"name":"OMIM_Number","value":"191339"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421262"}]}}{"C75441":{"preferredName":"ZEB2 Gene","code":"C75441","definitions":[{"definition":"This gene is involved in regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZEB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZEB2","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger E-Box Binding Homeobox 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14881"},{"name":"Legacy Concept Name","value":"ZEB2_Gene"},{"name":"Maps_To","value":"ZEB2"},{"name":"OMIM_Number","value":"605802"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423021"}]}}{"C16683":{"preferredName":"Histone H1","code":"C16683","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H1. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. Histones are basic nuclear proteins responsible for the nucleosome structure of eukaryotic chromatin. Repeating nucleosome units contain two molecules each of core Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H1"},{"name":"Maps_To","value":"H1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0019644"}]}}{"C16684":{"preferredName":"Histone H2A","code":"C16684","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H2A. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Slightly lysine rich histone.  One of four histones assembled into a nucleosomal core octamer.  Various posttranslationally modified forms and variants exist.  Combines with histone H2B in a heterodimer; two H2A/H2B dimers are incorporated in the nucleosomal octamer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A","termGroup":"PT","termSource":"NCI"},{"termName":"H2A","termGroup":"SY","termSource":"NCI"},{"termName":"HIST1H2A","termGroup":"SY","termSource":"NCI"},{"termName":"Histone 2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H2A"},{"name":"Maps_To","value":"H2A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0019646"}]}}{"C17460":{"preferredName":"Histone H2B","code":"C17460","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H2B. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H2B is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H2B"},{"name":"Maps_To","value":"H2B"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0086411"}]}}{"C16685":{"preferredName":"Histone H3","code":"C16685","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H3. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H3 is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H3"},{"name":"Maps_To","value":"H3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0019647"}]}}{"C16686":{"preferredName":"Histone H4","code":"C16686","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H4. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H4 (103 aa, ~11 kDa) is encoded by the human H4C1, H4C2, H4C3, H4C4, H4C5, H4C6, H4C6, H4C8, H4C9, H4C11, H4C12, H4C13, H4C14, H4C15, H4-16 genes. This protein plays a role in nucleating the formation of high order chromatin structures as a part of nucleosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H4","termGroup":"PT","termSource":"NCI"},{"termName":"HIST1H4","termGroup":"SY","termSource":"NCI"},{"termName":"Histone 1, H4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Histone H4 is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. The nucleosome interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures."},{"name":"DesignNote","value":"Histone H4 is encoded for by a cluster of genes that are clustered in the vicinity of 6p21.33 and all have the same SwissProt identifier."},{"name":"Legacy Concept Name","value":"Histone-H4"},{"name":"Maps_To","value":"H4"},{"name":"OMIM_Number","value":"602830"},{"name":"OMIM_Number","value":"602833"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P62805"},{"name":"UMLS_CUI","value":"C0019648"}]}}{"C152974":{"preferredName":"Histone H3-Like Centromeric Protein A","code":"C152974","definitions":[{"definition":"An antigen of the centromere protein encoded by the CENPA gene, with a designation of A. It can be considered as an autoantigen and is commonly associated with the autoimmune disease CREST syndrome.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H3-like centromeric protein A (140 aa, ~16 kDa) is encoded by the human CENPA gene. This protein plays a role in cell cycle progression, cell division and centromeric nucleosome assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3-Like Centromeric Protein A","termGroup":"PT","termSource":"NCI"},{"termName":"CENP-A","termGroup":"SY","termSource":"NCI"},{"termName":"CENPA","termGroup":"SY","termSource":"NCI"},{"termName":"Centromere Autoantigen A","termGroup":"SY","termSource":"NCI"},{"termName":"Centromere Protein A","termGroup":"SY","termSource":"NCI"},{"termName":"Centromere-Specific Histone","termGroup":"SY","termSource":"NCI"},{"termName":"Centromeric Protein A","termGroup":"SY","termSource":"NCI"},{"termName":"Histone cenH3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CENP-A"},{"name":"NCI_META_CUI","value":"CL554177"},{"name":"OMIM_Number","value":"117139"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P49450"}]}}{"C154613":{"preferredName":"Histone H2A-Bbd","code":"C154613","definitions":[{"definition":"A variant form of histone H2A found in chromatin structures that are transcriptionally active.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A-Bbd","termGroup":"PT","termSource":"NCI"},{"termName":"H2A Barr Body Deficient","termGroup":"SY","termSource":"NCI"},{"termName":"H2A Barr Body-Deficient","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.B","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Bbd","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A-Bbd"},{"name":"NCI_META_CUI","value":"CL555506"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C19432":{"preferredName":"Histone H2AX","code":"C19432","definitions":[{"definition":"Histone H2AX (143 aa, ~15 kDa) is encoded by the human H2AX gene. This protein plays a role in nucleosome formation and V(D)J recombination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2AX","termGroup":"PT","termSource":"NCI"},{"termName":"H2A Histone Family, Member X","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.X","termGroup":"SY","termSource":"NCI"},{"termName":"H2A/X","termGroup":"SY","termSource":"NCI"},{"termName":"H2AFX","termGroup":"SY","termSource":"NCI"},{"termName":"H2AX","termGroup":"SY","termSource":"NCI"},{"termName":"H2AX Histone","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.X","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Histone H2AX is a variant histone H2A that replaces conventional H2A proteins."},{"name":"Legacy Concept Name","value":"Histone-H2AX"},{"name":"Maps_To","value":"H2A.X"},{"name":"OMIM_Number","value":"601772"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P16104"},{"name":"UMLS_CUI","value":"C1172465"}]}}{"C126766":{"preferredName":"Histone H2A.Z","code":"C126766","definitions":[{"definition":"Histone H2A.Z (128 aa, ~14 kDa) is encoded by the human H2AZ1 gene. This protein is involved in nucleosome and heterochromatin formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A.Z","termGroup":"PT","termSource":"NCI"},{"termName":"H2A.Z-1","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.1","termGroup":"SY","termSource":"NCI"},{"termName":"H2A/z","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ Histone","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A.Z"},{"name":"Maps_To","value":"H2A.Z.1"},{"name":"NCI_META_CUI","value":"CL507981"},{"name":"OMIM_Number","value":"142763"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P0C0S5"}]}}{"C162832":{"preferredName":"Histone H2A.V","code":"C162832","definitions":[{"definition":"Histone H2A.V (128 aa, ~14 kDa) is encoded by the human H2AZ2 gene. This protein is involved in nucleosome formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A.V","termGroup":"PT","termSource":"NCI"},{"termName":"H2A.F/Z","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z-2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z-2.1","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.2.1","termGroup":"SY","termSource":"NCI"},{"termName":"H2AFV","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.F/Z","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.V Isoform 1","termGroup":"SY","termSource":"NCI"},{"termName":"Purine-Rich Binding Element Protein B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A.Z.2"},{"name":"NCI_META_CUI","value":"CL973150"},{"name":"OMIM_Number","value":"620128"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q71UI9"}]}}{"C162834":{"preferredName":"Histone H2A.V Isoform 2","code":"C162834","definitions":[{"definition":"Histone H2A.V isoform 2 (114 aa, ~12 kDa) is encoded by the human H2AZ2 gene. This protein plays a role in nucleosome stability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A.V Isoform 2","termGroup":"PT","termSource":"NCI"},{"termName":"H2A.Z-2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ2","termGroup":"SY","termSource":"NCI"},{"termName":"Z.2.2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A.Z.2.2"},{"name":"NCI_META_CUI","value":"CL973148"},{"name":"OMIM_Number","value":"620128"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q71UI9"}]}}{"C101734":{"preferredName":"Histone H3.1","code":"C101734","definitions":[{"definition":"Histone H3.1 (136 aa, ~15 kDa) is encoded by the human H3C1, H3C2, H3C3, H3C4, H3C6, H3C7, H3C8, H3C10, H3C11 and H3C12 genes. This protein plays a role in the formation of chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.1","termGroup":"PT","termSource":"NCI"},{"termName":"Histone H3/a","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/b","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/c","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/d","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/f","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/h","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/i","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/j","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/k","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/l","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.1"},{"name":"OMIM_Number","value":"602810"},{"name":"OMIM_Number","value":"602811"},{"name":"OMIM_Number","value":"602812"},{"name":"OMIM_Number","value":"602813"},{"name":"OMIM_Number","value":"602814"},{"name":"OMIM_Number","value":"602815"},{"name":"OMIM_Number","value":"602816"},{"name":"OMIM_Number","value":"602817"},{"name":"OMIM_Number","value":"602818"},{"name":"OMIM_Number","value":"602819"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P68431"},{"name":"UMLS_CUI","value":"C3640207"}]}}{"C148067":{"preferredName":"Histone H3.2","code":"C148067","definitions":[{"definition":"Histone H3.2 (136 aa, ~15 kDa) is encoded by the human H3C13, H3C14 and H3C15 genes. This protein plays a role in nucleosome remodeling and chromosomal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.2","termGroup":"PT","termSource":"NCI"},{"termName":"Histone H3/m","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/o","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.2"},{"name":"NCI_META_CUI","value":"CL545807"},{"name":"OMIM_Number","value":"142780"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q71DI3"}]}}{"C101445":{"preferredName":"Histone H3.3","code":"C101445","definitions":[{"definition":"Histone H3.3 (136 aa, ~15 kDa) is encoded by both the human H3-3A and H3-3B genes. This protein plays a role in chromosomal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.3"},{"name":"OMIM_Number","value":"601058"},{"name":"OMIM_Number","value":"601128"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P84243"},{"name":"UMLS_CUI","value":"C0086412"}]}}{"C154668":{"preferredName":"Histone H3.3C","code":"C154668","definitions":[{"definition":"Histone H3.3C (135 aa, ~15 kDa) is encoded by the human H3-5 gene. This protein is involved in the modulation of DNA accessibility to the transcriptional machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.3C","termGroup":"PT","termSource":"NCI"},{"termName":"H3-5","termGroup":"SY","termSource":"NCI"},{"termName":"H3.3C","termGroup":"SY","termSource":"NCI"},{"termName":"H3.5","termGroup":"SY","termSource":"NCI"},{"termName":"H3F3C","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.5"},{"name":"NCI_META_CUI","value":"CL555444"},{"name":"OMIM_Number","value":"616134"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q6NXT2"}]}}{"C188199":{"preferredName":"Histone H3.X","code":"C188199","definitions":[{"definition":"Histone H3.X (147 aa, ~16 kDa) is encoded by the human H3Y2 gene. This protein may be involved in both transcriptional regulation and the formation of higher order chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.X","termGroup":"PT","termSource":"NCI"},{"termName":"H3.X","termGroup":"SY","termSource":"NCI"},{"termName":"H3.Y.2","termGroup":"SY","termSource":"NCI"},{"termName":"H3Y2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y.2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.X"},{"name":"NCI_META_CUI","value":"CL1793117"},{"name":"PubMedID_Primary_Reference","value":"20819935"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P0DPK5"}]}}{"C155738":{"preferredName":"Histone H3.Y","code":"C155738","definitions":[{"definition":"Histone H3.Y (136 aa, ~15 kDa) is encoded by the human H3Y1 gene. This protein may be involved in both the positive regulation of transcription and the formation of higher order chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.Y","termGroup":"PT","termSource":"NCI"},{"termName":"H3.Y","termGroup":"SY","termSource":"NCI"},{"termName":"H3.Y.1","termGroup":"SY","termSource":"NCI"},{"termName":"H3Y1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.y","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y.1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Histone H3.Y protein has been deposited in RefSeq with accession number NP_001342187."},{"name":"Maps_To","value":"H3.Y"},{"name":"NCI_META_CUI","value":"CL556224"},{"name":"PubMedID_Primary_Reference","value":"20819935"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P0DPK2"}]}}{"C154671":{"preferredName":"Histone H3.1t","code":"C154671","definitions":[{"definition":"Histone H3.1t (136 aa, ~16 kDa) is encoded by the human H3-4 gene. This protein is involved in formation of higher order chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.1t","termGroup":"PT","termSource":"NCI"},{"termName":"H3-4","termGroup":"SY","termSource":"NCI"},{"termName":"H3.4","termGroup":"SY","termSource":"NCI"},{"termName":"H3/g","termGroup":"SY","termSource":"NCI"},{"termName":"H3/t","termGroup":"SY","termSource":"NCI"},{"termName":"H3t","termGroup":"SY","termSource":"NCI"},{"termName":"HIST3H3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3t (H3.4)"},{"name":"NCI_META_CUI","value":"CL555447"},{"name":"OMIM_Number","value":"602820"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q16695"}]}}{"C95407":{"preferredName":"Core Histone Macro-H2A","code":"C95407","definitions":[{"definition":"A histone protein that is comprised of a histone H2A domain, which allows interaction with the nucleosome, and a macro domain, which may bind to ADP-ribose. This protein can substitute for histone H2A in the nucleosomal complex and plays a role in transcriptional repression and X chromosome inactivation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Core Histone Macro-H2A","termGroup":"PT","termSource":"NCI"},{"termName":"Histone MacroH2A","termGroup":"SY","termSource":"NCI"},{"termName":"MacroH2A","termGroup":"SY","termSource":"NCI"},{"termName":"mH2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mH2A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0908130"}]}}{"C113624":{"preferredName":"Core Histone Macro-H2A.1","code":"C113624","definitions":[{"definition":"Core histone macro-H2A.1 (372 aa, ~40 kDa) is encoded by the human MACROH2A1 gene. This protein plays a role in chromatin modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Core Histone Macro-H2A.1","termGroup":"PT","termSource":"NCI"},{"termName":"H2A/y","termGroup":"SY","termSource":"NCI"},{"termName":"H2A1.1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.Y","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A1.1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A1.2","termGroup":"SY","termSource":"NCI"},{"termName":"MACROH2A1","termGroup":"SY","termSource":"NCI"},{"termName":"MACROH2A1.1","termGroup":"SY","termSource":"NCI"},{"termName":"Medulloblastoma Antigen MU-MB-50.205","termGroup":"SY","termSource":"NCI"},{"termName":"mH2A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mH2A.1"},{"name":"OMIM_Number","value":"610054"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"O75367"},{"name":"UMLS_CUI","value":"C3814450"}]}}{"C154659":{"preferredName":"Core Histone Macro-H2A.2","code":"C154659","definitions":[{"definition":"Core histone macro-H2A.2 (372 aa, ~40 kDa) is encoded by the human MACROH2A2 gene. This protein plays a role in nucleosome formation and transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Core Histone Macro-H2A.2","termGroup":"PT","termSource":"NCI"},{"termName":"Core Histone MacroH2A2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2AFY2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A2","termGroup":"SY","termSource":"NCI"},{"termName":"MACROH2A2","termGroup":"SY","termSource":"NCI"},{"termName":"mH2A2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mH2A.2"},{"name":"NCI_META_CUI","value":"CL555437"},{"name":"OMIM_Number","value":"616141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q9P0M6"}]}}{"C112217":{"preferredName":"5-Hydroxyindoleacetic Acid Measurement","code":"C112217","definitions":[{"definition":"A measurement of 5-hydroxyindoleacetic acid in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of 5-hydroxyindoleacetic acid present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5-Hydroxyindoleacetic Acid Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5-Hydroxyindoleacetic Acid"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0523708"}]}}{"C63321":{"preferredName":"Absolute Neutrophil Count","code":"C63321","definitions":[{"definition":"A measurement of the neutrophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Absolute Neutrophil Count","termGroup":"PT","termSource":"NCI"},{"termName":"ANC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Absolute_Neutrophil_Count"},{"name":"Maps_To","value":"Absolute Neutrophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0948762"}]}}{"C64431":{"preferredName":"Albumin Measurement","code":"C64431","definitions":[{"definition":"A measurement of the albumin protein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of albumin present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Albumin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Albumin_Measurement"},{"name":"Maps_To","value":"Albumin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201838"}]}}{"C74732":{"preferredName":"Alpha-fetoprotein Measurement","code":"C74732","definitions":[{"definition":"A measurement of the alpha fetoprotein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of alpha-fetoprotein present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-fetoprotein Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Alpha-fetoprotein_Measurement"},{"name":"Maps_To","value":"Alpha Fetoprotein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201539"}]}}{"C171142":{"preferredName":"B-Cell Genotyping Assay","code":"C171142","definitions":[{"definition":"The determination of the genomic DNA sequences in a subject's B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Genotyping Assay","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Genotyping","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B-cell genotyping"},{"name":"NCI_META_CUI","value":"CL1405363"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C64470":{"preferredName":"Absolute Basophil Count","code":"C64470","definitions":[{"definition":"A measurement of the basophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Absolute Basophil Count","termGroup":"PT","termSource":"NCI"},{"termName":"Total Basophil Count","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Basophil_Count"},{"name":"Maps_To","value":"Basophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200641"}]}}{"C81980":{"preferredName":"Beta-2 Microglobulin Measurement","code":"C81980","definitions":[{"definition":"A measurement of the beta-2 microglobulin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of beta-2 microglobulin present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-2 Microglobulin Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Beta 2 Microglobulin Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beta-2_Microglobulin_Measurement"},{"name":"Maps_To","value":"Beta 2 Microglobulin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201910"}]}}{"C61019":{"preferredName":"Blood Urea Nitrogen Measurement","code":"C61019","definitions":[{"definition":"A quantitative measurement of the amount of urea nitrogen present in a serum sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Urea Nitrogen Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"BUN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blood_Urea_Nitrogen_Measurement"},{"name":"Maps_To","value":"Blood Urea Nitrogen"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0005845"}]}}{"C64548":{"preferredName":"C-Reactive Protein Measurement","code":"C64548","definitions":[{"definition":"A measurement of the C reactive protein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of C-reactive protein present in a sample.","type":"DEFINITION","source":"NCI"},{"definition":"A quantitative measurement of the amount of CRP, an inflammatory marker, in the blood, expressed as milligrams per liter.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"C-Reactive Protein Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"C-Reactive_Protein_Measurement"},{"name":"Maps_To","value":"C-Reactive Protein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201657"}]}}{"C64488":{"preferredName":"Calcium Measurement","code":"C64488","definitions":[{"definition":"A measurement of the calcium in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of calcium present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcium Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Calcium_Measurement"},{"name":"Maps_To","value":"Calcium"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201925"}]}}{"C111153":{"preferredName":"Cellularity Measurement","code":"C111153","definitions":[{"definition":"A measurement of the degree, quality or condition of cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of degree, quality or condition of cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellularity Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Cellularity Index","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cellularity"},{"name":"NCI_META_CUI","value":"CL453628"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C122108":{"preferredName":"Chromogranin A Measurement","code":"C122108","definitions":[{"definition":"A measurement of the chromogranin A in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of chromogranin A present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromogranin A Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"CgA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"CHGA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Chromogranin-A Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Parathyroid Secretory Protein 1 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Secretory Protein I Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"SP-I Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chromogranin A"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1295114"}]}}{"C174116":{"preferredName":"Chromogranin B Measurement","code":"C174116","definitions":[{"definition":"The determination of the amount of chromogranin B present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromogranin B Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"CgB Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"CHGB Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Chromogranin-B Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Secretogranin I Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Secretogranin-1 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"SgI Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chromogranin B"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1531661"}]}}{"C96593":{"preferredName":"Circulating Tumor Cell Count","code":"C96593","definitions":[{"definition":"A measurement of the circulating tumor cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of circulating tumor cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Circulating Tumor Cell Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Circulating Tumor Cells"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3272887"}]}}{"C64547":{"preferredName":"Creatinine Measurement","code":"C64547","definitions":[{"definition":"A measurement of the creatinine in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of creatinine present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Creatinine Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Cr","termGroup":"SY","termSource":"NCI"},{"termName":"Creatinine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Creatinine_Measurement"},{"name":"Maps_To","value":"Creatinine"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201975"}]}}{"C64550":{"preferredName":"Eosinophil Count","code":"C64550","definitions":[{"definition":"A measurement of the eosinophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of eosinophils in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eosinophil Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Eosinophil_Count"},{"name":"Maps_To","value":"Eosinophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200638"}]}}{"C171143":{"preferredName":"Epstein-Barr Virus Test","code":"C171143","definitions":[{"definition":"Any microbiologic test or molecular assay used to detect the presence of Epstein-Barr virus in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epstein-Barr Virus Test","termGroup":"PT","termSource":"NCI"},{"termName":"EBV Assay","termGroup":"SY","termSource":"NCI"},{"termName":"EBV Test","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epstein-Barr Virus"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0851107"}]}}{"C116205":{"preferredName":"Neuron Specific Enolase Measurement","code":"C116205","definitions":[{"definition":"A measurement of the neuron specific enolase in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of neuron specific enolase present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuron Specific Enolase Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"ENO2 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Enolase 2 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-Enolase Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Neuron-Specific Enolase Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"NSE Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gamma-Enolase"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202144"}]}}{"C105585":{"preferredName":"Glucose Measurement","code":"C105585","definitions":[{"definition":"A measurement of the glucose in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of glucose present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glucose Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Glucose"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0337438"}]}}{"C64796":{"preferredName":"Hematocrit Measurement","code":"C64796","definitions":[{"definition":"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.","type":"DEFINITION","source":"NCI"},{"definition":"The percentage of a whole blood specimen that is composed of red blood cells (erythrocytes).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hematocrit Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hematocrit"},{"name":"Maps_To","value":"Hematocrit"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0018935"}]}}{"C64848":{"preferredName":"Hemoglobin Measurement","code":"C64848","definitions":[{"definition":"A measurement of the total erythrocyte associated hemoglobin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of hemoglobin present in a biospecimen.","type":"DEFINITION","source":"NCI"},{"definition":"Concentration of hemoglobin in the peripheral blood stream, expressed as grams per deciliter.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Hemoglobin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hemoglobin_Measurement"},{"name":"Maps_To","value":"Hemoglobin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0518015"}]}}{"C171144":{"preferredName":"Human Papillomavirus E6/E7 Protein Measurement","code":"C171144","definitions":[{"definition":"The determination of the amount of the human papillomavirus transforming proteins E6 and E7 present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus E6/E7 Protein Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"E6/E7 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-E6/E7 Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV-E6/E7"},{"name":"NCI_META_CUI","value":"CL1405385"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C147128":{"preferredName":"Choriogonadotropin Measurement","code":"C147128","definitions":[{"definition":"A measurement of the total choriogonadotropin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of choriogonadotropin present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choriogonadotropin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Human Chorionic Gonadotropin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1295113"}]}}{"C171145":{"preferredName":"Human Papillomavirus Test","code":"C171145","definitions":[{"definition":"Any microbiologic test or molecular assay used to detect the presence of a human papillomavirus in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus Test","termGroup":"PT","termSource":"NCI"},{"termName":"HPV Assay","termGroup":"SY","termSource":"NCI"},{"termName":"HPV Test","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Human Papillomavirus"},{"name":"NCI_META_CUI","value":"CL1405384"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C81969":{"preferredName":"Immunoglobulin A Measurement","code":"C81969","definitions":[{"definition":"A measurement of the total immunoglobulin A in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin A present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin A Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Immunoglobulin_A_Measurement"},{"name":"Maps_To","value":"Immunoglobulin A"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202083"}]}}{"C81971":{"preferredName":"Immunoglobulin G Measurement","code":"C81971","definitions":[{"definition":"A measurement of the total immunoglobulin G in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin G present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin G Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Immunoglobulin_G_Measurement"},{"name":"Maps_To","value":"Immunoglobulin G"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202087"}]}}{"C81972":{"preferredName":"Immunoglobulin M Measurement","code":"C81972","definitions":[{"definition":"A measurement of the total immunoglobulin M in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin M present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin M Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Immunoglobulin_M_Measurement"},{"name":"Maps_To","value":"Immunoglobulin M"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202084"}]}}{"C64855":{"preferredName":"Lactate Dehydrogenase Measurement","code":"C64855","definitions":[{"definition":"A measurement of the lactate dehydrogenase in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of lactate dehydrogenase present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lactate Dehydrogenase Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"LDH Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lactate_Dehydrogenase_Measurement"},{"name":"Maps_To","value":"Lactate Dehydrogenase"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202113"}]}}{"C51948":{"preferredName":"Leukocyte Count","code":"C51948","definitions":[{"definition":"A measurement of the leukocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A test to determine the number of leukocytes in a biospecimen.","type":"DEFINITION","source":"NCI"},{"definition":"Concentration of leukocytes in the peripheral blood stream, expressed as WBCs per milliliter of whole blood.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Leukocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Leukocyte_Count"},{"name":"Maps_To","value":"Leukocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0023508"}]}}{"C74790":{"preferredName":"Luteinizing Hormone Measurement","code":"C74790","definitions":[{"definition":"A measurement of the luteinizing hormone in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of luteinizing hormone present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luteinizing Hormone Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Luteinizing_Hormone_Measurement"},{"name":"Maps_To","value":"Luteinizing Hormone"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202123"}]}}{"C102278":{"preferredName":"Lymphoblast Count","code":"C102278","definitions":[{"definition":"A measurement of the lymphoblasts (immature cells that differentiate to form lymphocytes) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of lymphoblasts (immature cells that differentiate to form lymphocytes) present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoblast Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphoblasts"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1167770"}]}}{"C51949":{"preferredName":"Lymphocyte Count","code":"C51949","definitions":[{"definition":"A measurement of the lymphocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of lymphocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lymphocyte_Count"},{"name":"Maps_To","value":"Lymphocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200635"}]}}{"C92291":{"preferredName":"Monoclonal Protein Measurement","code":"C92291","definitions":[{"definition":"A measurement of homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of monoclonal protein present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Protein Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"M Protein Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M Protein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0443737"}]}}{"C74615":{"preferredName":"Metamyelocyte Count","code":"C74615","definitions":[{"definition":"A measurement of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of metamyelocytes present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metamyelocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Metamyelocyte_Count"},{"name":"Maps_To","value":"Metamyelocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0455285"}]}}{"C74632":{"preferredName":"Myeloblast Count","code":"C74632","definitions":[{"definition":"A measurement of the myeloblast cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of myeloblast cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloblast Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myeloblast_Count"},{"name":"Maps_To","value":"Myeloblasts"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0580952"}]}}{"C74662":{"preferredName":"Myelocyte Count","code":"C74662","definitions":[{"definition":"A measurement of the myelocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of myelocyte cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myelocyte_Count"},{"name":"Maps_To","value":"Myelocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0455284"}]}}{"C64830":{"preferredName":"Neutrophil Band Form Count","code":"C64830","definitions":[{"definition":"A measurement of the banded neutrophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of band neutrophils in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neutrophil Band Form Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neutrophil_Band_Form_Count"},{"name":"Maps_To","value":"Neutrophil Bands"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0369738"}]}}{"C51951":{"preferredName":"Platelet Count","code":"C51951","definitions":[{"definition":"A measurement of the platelets (non-nucleated thrombocytes) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of platelets in a biospecimen.","type":"DEFINITION","source":"NCI"},{"definition":"The determination of the number of platelets in a blood sample, usually expressed as platelets per milliliter of whole blood.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Platelet Count","termGroup":"PT","termSource":"NCI"},{"termName":"Anucleated Thrombocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Platelet_Count"},{"name":"Maps_To","value":"Platelets"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0032181"}]}}{"C74620":{"preferredName":"Prolymphocyte Count","code":"C74620","definitions":[{"definition":"A measurement of the prolymphocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of prolymphocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prolymphocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prolymphocyte_Count"},{"name":"Maps_To","value":"Prolymphocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2698885"}]}}{"C74621":{"preferredName":"Promonocyte Count","code":"C74621","definitions":[{"definition":"A measurement of the promonocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of promonocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Promonocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Promonocyte_Count"},{"name":"Maps_To","value":"Promonocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2698887"}]}}{"C74622":{"preferredName":"Promyelocyte Count","code":"C74622","definitions":[{"definition":"A measurement of the promyelocytes (immature myelocytes) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of promyelocytes present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Promyelocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Promyelocyte_Count"},{"name":"Maps_To","value":"Promyelocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0455279"}]}}{"C81997":{"preferredName":"Segmented Neutrophil Count","code":"C81997","definitions":[{"definition":"A measurement of the segmented neutrophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of segmented neutrophils present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Segmented Neutrophil Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Segmented_Neutrophil_Count"},{"name":"Maps_To","value":"Segmented Neutrophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1168341"}]}}{"C98730":{"preferredName":"Free Kappa Light Chain Measurement","code":"C98730","definitions":[{"definition":"A measurement of the free kappa light chain in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of free kappa light chain present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Free Kappa Light Chain Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Free Immunoglobulin Light Chain, Kappa"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3274397"}]}}{"C98732":{"preferredName":"Free Lambda Light Chain Measurement","code":"C98732","definitions":[{"definition":"A measurement of the free lambda light chain in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of free lambda light chain present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Free Lambda Light Chain Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Free Immunoglobulin Light Chain, Lambda"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3274399"}]}}{"C147376":{"preferredName":"Immunoglobulin Light Chain Measurement","code":"C147376","definitions":[{"definition":"A measurement of the total immunoglobulin (kappa and lambda) light chains in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin light chain present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Light Chain Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Free Immunoglobulin Light Chain, NOS"},{"name":"NCI_META_CUI","value":"CL545281"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C74793":{"preferredName":"Total Testosterone Measurement","code":"C74793","definitions":[{"definition":"A measurement of the total (free and bound) testosterone in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of free and bound testosterone present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Testosterone Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Testosterone_Measurement"},{"name":"Maps_To","value":"Testosterone"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202227"}]}}{"C38037":{"preferredName":"Total Bilirubin Measurement","code":"C38037","definitions":[{"definition":"A measurement of the total bilirubin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Bilirubin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Total_Bilirubin"},{"name":"Maps_To","value":"Total Bilirubin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201913"}]}}{"C64858":{"preferredName":"Total Protein Measurement","code":"C64858","definitions":[{"definition":"A measurement of the total protein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of total protein present in a sample.","type":"DEFINITION","source":"NCI"},{"definition":"Test to determine total protein concentration in the product.","type":"ALT_DEFINITION","source":"PQCMC"}],"synonyms":[{"termName":"Total Protein Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Protein_Measurement"},{"name":"Maps_To","value":"Total Protein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0555903"}]}}{"C178240":{"preferredName":"BG8 IHC Staining Method","code":"C178240","definitions":[{"definition":"An immunohistochemical technique utilizing the mouse monoclonal antibody BG8, which is directed against the type 2 fucosylated antigen Lewis Y (LeY). BG8 specifically binds to LeY, a blood group Lewis carbohydrate determinant expressed on certain glycolipids and glycoproteins. In healthy subjects, LeY is expressed in low levels by a few types of epithelial cells; however, it is aberrantly expressed in high levels in many carcinomas. This method is use in the detection of certain tumors, such as carcinomas of the breast, lung, and colon. Additionally, it may distinguish neoplasms derived from mesothelium from other epithelial-derived neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BG8 IHC Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Anti-Lewis Y BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Anti-Lewis-Y BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LeY BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"BG-8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"BG8 Antibody Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"BG8 Staining Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BG8"},{"name":"NCI_META_CUI","value":"CL1647890"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C96592":{"preferredName":"Circulating Endothelial Cell Count","code":"C96592","definitions":[{"definition":"A measurement of the circulating endothelial cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of circulating endothelial cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Circulating Endothelial Cell Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Circulating Endothelial Cells"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3272886"}]}}{"C103871":{"preferredName":"Dopamine-Secreting","code":"C103871","definitions":[{"definition":"A finding indicating that an excess amount of dopamine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dopamine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Dopamine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dopamine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641670"}]}}{"C103869":{"preferredName":"Epinephrine-Secreting","code":"C103869","definitions":[{"definition":"A finding indicating that an excess amount of epinephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epinephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Epinephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epinephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641668"}]}}{"C103870":{"preferredName":"Metanephrine-Secreting","code":"C103870","definitions":[{"definition":"A finding indicating that an excess amount of metanephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metanephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Metanephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metanephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641669"}]}}{"C103872":{"preferredName":"Methoxytyramine-Secreting","code":"C103872","definitions":[{"definition":"A finding indicating that an excess amount of methoxytyramine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxytyramine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Methoxytyramine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methoxytyramine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641671"}]}}{"C36318":{"preferredName":"Microsatellite Instability","code":"C36318","definitions":[{"definition":"A change that occurs in the DNA of certain cells (such as tumor cells) in which the number of repeats of microsatellites (short, repeated sequences of DNA) is different than the number of repeats that was in the DNA when it was inherited. The cause of microsatellite instability may be a defect in the ability to repair mistakes made when DNA is copied in the cell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Genomic instability associated with the presence of hypermutability in specific genetic marker regions resulting from defective DNA mismatch repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microsatellite Instability","termGroup":"PT","termSource":"NCI"},{"termName":"Microsatellite Instability Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Microsatellite Instability Present","termGroup":"SY","termSource":"NCI"},{"termName":"MSI","termGroup":"AB","termSource":"NCI"},{"termName":"MSI Positive","termGroup":"SY","termSource":"NCI"},{"termName":"MSI Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Microsatellites are stretches of DNA in which a short motif (usually one to five nucleotides long) is repeated several times. Instability of these regions is initiated when mutations in genes that repair damaged DNA cause these regions to get longer or shorter. Hereditary colon cancer syndrome is associated with mutations in the DNA mismatch repair genes, which may result in alterations in the nucleotide sequence."},{"name":"Legacy Concept Name","value":"Microsatellite_Instability"},{"name":"Maps_To","value":"MSI"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0920269"}]}}{"C103867":{"preferredName":"Norepinephrine-Secreting","code":"C103867","definitions":[{"definition":"A finding indicating that an excess amount of norepinephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Norepinephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Norepinephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Norepinephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641666"}]}}{"C103868":{"preferredName":"Normetanephrine-Secreting","code":"C103868","definitions":[{"definition":"A finding indicating that an excess amount of normetanephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Normetanephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Normetanephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Normetanephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641667"}]}}{"C106505":{"preferredName":"Cancer Antigen 72-4 Measurement","code":"C106505","definitions":[{"definition":"A measurement of the cancer antigen 72-4 in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of the cancer antigen 72-4 present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Antigen 72-4 Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"TAG-72","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Associated Antigen 72 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor-Associated Antigen TAG-72 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor-Associated Glycoprotein 72 Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TAG-72"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2732693"}]}}{"C122859":{"preferredName":"Cytokeratin-5 Staining Method","code":"C122859","definitions":[{"definition":"An immunohistochemical technique used to detect the presence of cytokeratin-5 in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytokeratin-5 Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"CK5 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokeratin 5 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Keratin, Type II Cytoskeletal 5 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"KRT5 Staining Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytokeratin 5"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C4053759"}]}}{"C122858":{"preferredName":"Cytokeratin-6 Staining Method","code":"C122858","definitions":[{"definition":"An immunohistochemical technique used to detect the presence of cytokeratin-6 in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytokeratin-6 Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"CK6 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokeratin 6 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Keratin, Type II Cytoskeletal 6 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"KRT6 Staining Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytokeratin 6"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C4055167"}]}}{"C184798":{"preferredName":"Serum Mesothelin Measurement","code":"C184798","definitions":[{"definition":"A quantitative measurement of the amount of mesothelin present in a sample of serum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serum Mesothelin Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Serum MSLN Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Mesothelin"},{"name":"NCI_META_CUI","value":"CL1772988"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C74611":{"preferredName":"Erythrocyte Sedimentation Rate Measurement","code":"C74611","definitions":[{"definition":"A quantitative measurement of the distance that red blood cells settle in one hour in a sample of unclotted blood. Used in the evaluation of systemic inflammation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A quantitative measurement of the distance that red blood cells travel in 1 hour in a sample of unclotted blood.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"A quantitative measurement of the distance that red blood cells travel in one hour in a sample of unclotted blood.","type":"DEFINITION","source":"NCI"},{"definition":"The distance (e.g. millimeters) that red blood cells settle in unclotted blood over a specified unit of time (e.g. one hour).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The distance red blood cells travel in one hour in a sample of blood as they settle to the bottom of a test tube. The sedimentation rate is increased in inflammation, infection, cancer, rheumatic diseases, and diseases of the blood and bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Erythrocyte Sedimentation Rate Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Erythrocyte_Sedimentation_Rate_Measurement"},{"name":"Maps_To","value":"Erythrocyte Sedimentation Rate"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1176468"}]}}{"C62656":{"preferredName":"Prothrombin Time","code":"C62656","definitions":[{"definition":"A blood clotting measurement that evaluates the extrinsic pathway of coagulation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A measurement of the clotting time of plasma recalcified in the presence of excess tissue thromboplastin; it is a measure of the extrinsic pathway of coagulation. It is used to determine the clotting tendency of blood, in the measure of warfarin dosage, liver damage and vitamin K status. Factors measured are fibrinogen, prothrombin, and factors V, VII, and X.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prothrombin Time","termGroup":"PT","termSource":"NCI"},{"termName":"Prothrombin Time Test","termGroup":"SY","termSource":"NCI"},{"termName":"PT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Prothrombin_Time_Test"},{"name":"Maps_To","value":"Prothrombin Time"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0033707"}]}}{"C74605":{"preferredName":"Blast Count","code":"C74605","definitions":[{"definition":"A measurement of the blast cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of blast cells present in a biospecimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blast Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Blast_Count"},{"name":"Maps_To","value":"Blast Count"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0523113"}]}}{"C168918":{"preferredName":"Number of Cells in Metaphase during Karyotyping","code":"C168918","definitions":[{"definition":"The number of cells in metaphase during karyotype analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Number of Cells in Metaphase during Karyotyping","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Metaphase Nucleus Count"},{"name":"NCI_META_CUI","value":"CL1378987"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C185298":{"preferredName":"Measurable Residual Disease Assessment","code":"C185298","definitions":[{"definition":"An examination for minimal residual disease status.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Measurable Residual Disease Assessment","termGroup":"PT","termSource":"NCI"},{"termName":"Minimal Residual Disease Assessment","termGroup":"SY","termSource":"NCI"},{"termName":"MRD Assessment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Minimal Residual Disease"},{"name":"NCI_META_CUI","value":"CL1773389"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C64823":{"preferredName":"Monocyte Count","code":"C64823","definitions":[{"definition":"A measurement of the monocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of monocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Monocyte_Count"},{"name":"Maps_To","value":"Monocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200637"}]}}{"C18084":{"preferredName":"Comparative Genomic Hybridization","code":"C18084","definitions":[{"definition":"Comparative genomic hybridization (CGH) is a technique that allows the detection of losses and gains in DNA copy number across the entire genome without prior knowledge of specific chromosomal abnormalities.  Comparative genomic hybridization utilizes the hybridization of differentially labeled tumor and reference DNA to generate a map of DNA copy number changes in tumor genomes. Comparative genomic hybridization is an ideal tool for analyzing chromosomal imbalances in archived tumor material and for examining possible correlations between these findings and tumor phenotypes. (from Ried et al. J Mol Med 1997 75:801-14)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Comparative Genomic Hybridization","termGroup":"PT","termSource":"NCI"},{"termName":"CGH","termGroup":"AB","termSource":"NCI"},{"termName":"Comparative Genome Hybridization","termGroup":"SY","termSource":"NCI"},{"termName":"Comparative Genomic Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Comparative_Genomic_Analysis"},{"name":"Maps_To","value":"Comparative Genomic Hybridization"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0796358"}]}}{"C18280":{"preferredName":"Cytogenetic Analysis","code":"C18280","definitions":[{"definition":"An assessment by microscopic analysis of chromosomal and subchromosomal structure and function.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytogenetic Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Cytogenetic Techniques","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cytogenetic_Analysis"},{"name":"Maps_To","value":"Cytogenetics, NOS"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0752095"}]}}{"C17563":{"preferredName":"Fluorescence In Situ Hybridization","code":"C17563","definitions":[{"definition":"A laboratory technique used to look at genes or chromosomes in cells and tissues. Pieces of DNA that contain a fluorescent dye are made in the laboratory and added to cells or tissues on a glass slide. When these pieces of DNA bind to specific genes or areas of chromosomes on the slide, they light up when viewed under a microscope with a special light.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from Online Medical Dictionary and NHGRI Glossary"}]}],"synonyms":[{"termName":"Fluorescence In Situ Hybridization","termGroup":"PT","termSource":"NCI"},{"termName":"FISH","termGroup":"AB","termSource":"NCI"},{"termName":"Fluorescence in situ Hybridization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Fluorescence_in_situ_Hybridization"},{"name":"Maps_To","value":"FISH"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C0162789"}]}}{"C16585":{"preferredName":"Flow Cytometry","code":"C16585","definitions":[{"definition":"A method of measuring the number of cells in a sample, the percentage of live cells in a sample, and certain characteristics of cells, such as size, shape, and the presence of tumor markers on the cell surface. The cells are stained with a light-sensitive dye, placed in a fluid, and passed in a stream before a laser or other type of light. The measurements are based on how the light-sensitive dye reacts to the light.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.","type":"DEFINITION","source":"NCI"},{"definition":"A technique for counting, examining or sorting microscopic particles in which the particles are placed in a fluid (with or without light-sensitive dye) and passed through a beam of light.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Flow Cytometry","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Flow_Cytometry"},{"name":"Maps_To","value":"Flow Cytometry"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0016263"}]}}{"C23020":{"preferredName":"Immunohistochemistry Staining Method","code":"C23020","definitions":[{"definition":"A technique used to identify specific molecules in different kinds of tissue. The tissue is treated with antibodies that bind the specific molecule. These are made visible under a microscope by using a color reaction, a radioisotope, colloidal gold, or a fluorescent dye. Immunohistochemistry is used to help diagnose diseases, such as cancer, and to detect the presence of microorganisms. It is also used in basic research to understand how cells grow and differentiate (become more specialized).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","type":"DEFINITION","source":"NCI"},{"definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Immunohistochemistry Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"Cell/Tissue, Immunohistochemistry","termGroup":"SY","termSource":"NCI"},{"termName":"IHC","termGroup":"AB","termSource":"NCI"},{"termName":"Immunohistochemistry","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Immunohistochemistry_Staining_Method"},{"name":"Maps_To","value":"IHC"},{"name":"Maps_To","value":"Immunohistochemistry (IHC)"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0021044"}]}}{"C142337":{"preferredName":"Immunofluorescent Staining Method","code":"C142337","definitions":[{"definition":"A microscopy staining method that utilizes immunofluorescent markers for use with histological applications of preserved cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A microscopy staining method that utilizes immunofluorescent markers for use with histological applications of preserved cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunofluorescent Staining Method","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunofluorescence"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1318793"}]}}{"C17562":{"preferredName":"In Situ Hybridization","code":"C17562","definitions":[{"definition":"Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues.","type":"DEFINITION","source":"NCI"},{"definition":"Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"In Situ Hybridization","termGroup":"PT","termSource":"NCI"},{"termName":"Genetics, in situ Hybridization","termGroup":"SY","termSource":"NCI"},{"termName":"in situ Hybridization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"in_situ_Hybridization"},{"name":"Maps_To","value":"ISH"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C0162788"}]}}{"C16768":{"preferredName":"Karyotyping","code":"C16768","definitions":[{"definition":"The assessment of the chromosomal morphology and number in somatic cells of an individual.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]},{"definition":"The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell sample.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karyotyping","termGroup":"PT","termSource":"NCI"},{"termName":"Genetics, Karyotyping","termGroup":"SY","termSource":"NCI"},{"termName":"Karotype Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Karyotyping"},{"name":"Maps_To","value":"Karyotype"},{"name":"Semantic_Type","value":"Occupational Activity"},{"name":"UMLS_CUI","value":"C0022526"}]}}{"C18477":{"preferredName":"Microarray Analysis","code":"C18477","definitions":[{"definition":"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).","type":"DEFINITION","source":"NCI"},{"definition":"Information about all messenger RNAs that are made in various cell types. A gene expression profile may be used to find and diagnose a disease or condition and to see how well the body responds to treatment. Gene expression profiles may be used in personalized medicine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Microarray Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Expression Profiling","termGroup":"SY","termSource":"NCI"},{"termName":"Microarray Analysis","termGroup":"SY","termSource":"NCI"},{"termName":"Microarray Technology","termGroup":"SY","termSource":"NCI"},{"termName":"Microarray-Based Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microarray_Analysis"},{"name":"Maps_To","value":"Microarray"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1449575"}]}}{"C63331":{"preferredName":"Microsatellite Instability Analysis","code":"C63331","definitions":[{"definition":"A laboratory procedure to detect microsatellite instability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microsatellite Instability Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"MSI Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microsatellite_Instability_Analysis"},{"name":"Maps_To","value":"Microsatellite Analysis"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1881824"}]}}{"C165224":{"preferredName":"Nuclear Staining Method","code":"C165224","definitions":[{"definition":"A microscopy staining method that uses a dye or a contrast agent that specifically binds to chromosomal material and/or nucleoproteins, which permits visualization of a cellular nucleus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nuclear Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"Nuclear Staining","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nuclear Staining"},{"name":"NCI_META_CUI","value":"CL978405"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C17003":{"preferredName":"Polymerase Chain Reaction","code":"C17003","definitions":[{"definition":"A laboratory method used to make many copies of a specific DNA sequence.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.","type":"DEFINITION","source":"NCI"},{"definition":"A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase. This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Polymerase Chain Reaction","termGroup":"PT","termSource":"NCI"},{"termName":"PCR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Polymerase_Chain_Reaction"},{"name":"Maps_To","value":"PCR"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0032520"}]}}{"C124261":{"preferredName":"Whole Transcriptome Sequencing","code":"C124261","definitions":[{"definition":"A procedure that can determine the nucleotide sequence for all of the RNA transcripts in an individual.","type":"DEFINITION","source":"NCI"},{"definition":"An RNA sequencing technique in which all of the RNA transcripts of an individual's genome are sequenced.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Whole Transcriptome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"RNA Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"RNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Total RNA Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Total RNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Transcriptome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Whole-Transcriptome Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"RNA Sequencing"},{"name":"Maps_To","value":"RNA-Seq"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C4086963"}]}}{"C18136":{"preferredName":"Reverse Transcriptase-Polymerase Chain Reaction","code":"C18136","definitions":[{"definition":"A laboratory procedure in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase.","type":"DEFINITION","source":"NCI"},{"definition":"A molecular biology technique used to recreate and amplify complementary DNA (cDNA) from total RNA or messenger RNA (mRNA), using reverse transcriptase and DNA polymerase.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Reverse Transcriptase-Polymerase Chain Reaction","termGroup":"PT","termSource":"NCI"},{"termName":"RT-PCR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"RT-PCR"},{"name":"Maps_To","value":"RT-PCR"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C0599161"}]}}{"C17565":{"preferredName":"Sequence Analysis","code":"C17565","definitions":[{"definition":"The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sequence Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sequence_Analysis"},{"name":"Maps_To","value":"Sequencing, NOS"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0162801"}]}}{"C16356":{"preferredName":"Southern Blotting","code":"C16356","definitions":[{"definition":"A technique for the detection of specific DNA fragments that have been separated by polyacrylamide-gel electrophoresis, transferred to a nitrocellulose or other type of paper or nylon membrane, and detected by hybridization and visualization with a labeled probe.","type":"DEFINITION","source":"NCI"},{"definition":"Electrophoresis-based technique used in genetic testing to detect large deletions in DNA that can be missed by PCR-based genetic testing methods.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Southern Blotting","termGroup":"PT","termSource":"NCI"},{"termName":"Blotting, Southern","termGroup":"SY","termSource":"NCI"},{"termName":"Southern Blot","termGroup":"SY","termSource":"NCI"},{"termName":"Southern Blot Hybridization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blotting_Southern"},{"name":"Maps_To","value":"Southern Blotting"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0005862"}]}}{"C130177":{"preferredName":"Next Generation Targeted Sequencing","code":"C130177","definitions":[{"definition":"A technique that determines the nucleotide sequence of a pre-specified region of DNA or RNA by using primers that are specific for that region.","type":"DEFINITION","source":"NCI"},{"definition":"A type of next generation sequencing in which specific genes or portions of genes are targeted for sequencing using amplicon-based workflow.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Next Generation Targeted Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Targeted NGS","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Targeted Sequencing"},{"name":"NCI_META_CUI","value":"CL514064"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C101294":{"preferredName":"Whole Genome Sequencing","code":"C101294","definitions":[{"definition":"A DNA sequencing technique in which the entirety of the individual's genome is sequenced.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A procedure that can determine the DNA sequence for nearly the entire genome of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Whole Genome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"WGS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"WGS"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3640076"}]}}{"C101295":{"preferredName":"Whole Exome Sequencing","code":"C101295","definitions":[{"definition":"A DNA sequencing technique in which all of the exons of an individual's genome are sequenced.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A procedure that can determine the DNA sequence for all of the exons in an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Whole Exome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Exome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"WES","termGroup":"SY","termSource":"NCI"},{"termName":"Whole-Exome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"WXS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"WXS"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3640077"}]}}{"C16853":{"preferredName":"Microscopy","code":"C16853","definitions":[{"definition":"The application of microscope magnification to the study of materials that cannot be properly seen by the unaided eye. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The use of various technologies to resolve the structure or features of objects too small or fine to naturally be seen by eye.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microscopy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Microscopy"},{"name":"Maps_To","value":"Microscopy, NOS"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0026018"}]}}{"C63433":{"preferredName":"3' Untranslated Region Mutation","code":"C63433","definitions":[{"definition":"Any mutation in a gene occurring in the 3' end which contains sequences which may regulate the transcription or translation of the message. 3' UTR mutations are found only outside of open reading frames.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"3' Untranslated Region Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"3 Prime UTR Variant","termGroup":"SY","termSource":"NCI"},{"termName":"3' UTR Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_3_Untranslated_Region_Mutation"},{"name":"Maps_To","value":"3 Prime UTR Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883634"}]}}{"C63432":{"preferredName":"5' Untranslated Region Mutation","code":"C63432","definitions":[{"definition":"Any mutation in a gene occurring in the 5' end which contains sequences which may regulate the transcription or translation of the message. 5' UTR mutations are found only outside of open-reading frames.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5' Untranslated Region Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"5 Prime UTR Variant","termGroup":"SY","termSource":"NCI"},{"termName":"5' UTR Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_5_Untranslated_Region_Mutation"},{"name":"Maps_To","value":"5 Prime UTR Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883645"}]}}{"C148639":{"preferredName":"Exon Mutation","code":"C148639","definitions":[{"definition":"A change in the nucleotide sequence of an exon in a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exon Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Coding Region Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Coding Sequence Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coding Sequence Variant"},{"name":"Maps_To","value":"Exon Variant"},{"name":"NCI_META_CUI","value":"CL551156"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C63431":{"preferredName":"3' Flank Mutation","code":"C63431","definitions":[{"definition":"Any gene mutation that occurs in the sequences downstream from a coding region of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"3' Flank Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Downstream Gene Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"This term itself is applied primarily to polycistronic RNAs, in which any downstream mutation is considered a 3' flank mutation with respect to the upstream open reading frame."},{"name":"Legacy Concept Name","value":"_3_Flank_Mutation"},{"name":"Maps_To","value":"Downstream Gene Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883632"}]}}{"C148640":{"preferredName":"Elongation Mutation","code":"C148640","definitions":[{"definition":"The mutation of either a splice site or stop codon that leads to an extended transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elongation Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Feature Elongation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Feature Elongation"},{"name":"NCI_META_CUI","value":"CL551155"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148641":{"preferredName":"Truncation Mutation","code":"C148641","definitions":[{"definition":"The mutation of either a splice site or stop codon that leads to a truncated transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Truncation Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Feature Truncation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Feature Truncation"},{"name":"NCI_META_CUI","value":"CL551266"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C17354":{"preferredName":"Frameshift Mutation","code":"C17354","definitions":[{"definition":"A mutation occurring within the protein-coding region of a gene which results in a shift in the reading frame of the encoded protein. Frameshift mutations often result in the premature truncation of a gene product.","type":"DEFINITION","source":"NCI"},{"definition":"An insertion or deletion involving a number of base pairs that is not a multiple of three, which consequently disrupts the triplet reading frame of a DNA sequence. Such mutations usually lead to the creation of a premature termination (stop) codon, and result in a truncated (shorter-than-normal) protein product.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Frameshift Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Frameshift","termGroup":"SY","termSource":"NCI"},{"termName":"Frameshift Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Frameshift Variant","termGroup":"SY","termSource":"NCI"},{"termName":"fs","termGroup":"AB","termSource":"NCI"},{"termName":"Mutation, Frameshift","termGroup":"SY","termSource":"NCI"},{"termName":"Reading Frame Shift Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Frameshift_Mutation"},{"name":"Maps_To","value":"Frameshift Mutation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0079380"}]}}{"C179438":{"preferredName":"Incomplete Terminal Codon Variant","code":"C179438","definitions":[{"definition":"A change in the nucleotide sequence of at least one base of the final codon of a incompletely annotated transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Incomplete Terminal Codon Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Incomplete Terminal Codon Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Incomplete Terminal Codon Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Incomplete Terminal Codon Variant"},{"name":"NCI_META_CUI","value":"CL1662206"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C165225":{"preferredName":"Inframe Deletion","code":"C165225","definitions":[{"definition":"A loss of three consecutive nucleotides (one codon) or multiple codons in a gene that encodes for a protein where one or more canonical amino acids are deleted but does not result in a frameshift mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inframe Deletion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inframe Deletion"},{"name":"NCI_META_CUI","value":"CL978406"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C165226":{"preferredName":"Inframe Insertion","code":"C165226","definitions":[{"definition":"A gain of three consecutive nucleotides (one codon) or multiple codons in a gene that encodes for a protein where one or more non-wildtype amino acids are inserted but does not result in a frameshift mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inframe Insertion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inframe Insertion"},{"name":"NCI_META_CUI","value":"CL978407"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148642":{"preferredName":"Intergenic Mutation","code":"C148642","definitions":[{"definition":"A change in the nucleotide sequence of a region between gene loci.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergenic Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Intergenic Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intergenic Variant"},{"name":"NCI_META_CUI","value":"CL551265"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C63429":{"preferredName":"Intronic Mutation","code":"C63429","definitions":[{"definition":"Any mutation within an intron, including the sequences that comprise the intron boundary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intronic Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Intron Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Intron Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intronic_Mutation"},{"name":"Maps_To","value":"Intron Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1881250"}]}}{"C165227":{"preferredName":"Mature miRNA Variant","code":"C165227","definitions":[{"definition":"A ribonucleotide variation in the sequence of a fully processed microRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mature miRNA Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Mature MicroRNA Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mature miRNA Variant"},{"name":"NCI_META_CUI","value":"CL978379"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C18133":{"preferredName":"Missense Mutation","code":"C18133","definitions":[{"definition":"A point mutation occurring within the protein-coding region of a gene, and which codes for a different amino acid than expected.","type":"DEFINITION","source":"NCI"},{"definition":"A single base pair substitution that alters the genetic code in a way that produces an amino acid that is different from the usual amino acid at that position. Some missense mutations will alter the function of the protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Missense Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Exon Non-Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonic Non-Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Missense Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Missense Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Mutation, Missense","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Substitution Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Missense_Mutation"},{"name":"Legacy Concept Name","value":"Missense_Mutation_Abnormality"},{"name":"Maps_To","value":"Missense Variant"},{"name":"Maps_To","value":"Protein Altering Variant"},{"name":"Maps_To","value":"Substitution"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0599155"}]}}{"C148643":{"preferredName":"Non-Sense Mediated Decay Mutation","code":"C148643","definitions":[{"definition":"A mutation occurring in a sequence that regulates non-sense mediated mRNA decay.","type":"DEFINITION","source":"NCI"},{"definition":"A transcript with a premature stop codon considered likely to be subjected to targeted degradation. (Ensembl)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Non-Sense Mediated Decay Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"NMD Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"NMD Transcript Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NMD Transcript Variant"},{"name":"NCI_META_CUI","value":"CL551268"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148645":{"preferredName":"Non-Coding Gene Exon Mutation","code":"C148645","definitions":[{"definition":"A change in the nucleotide sequence of an exon in a non-coding gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Coding Gene Exon Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Coding Transcript Exon Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Noncoding Gene Exon Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Untranslated Gene Exon Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Coding Gene Exon Mutation"},{"name":"NCI_META_CUI","value":"CL551262"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148644":{"preferredName":"Non-Coding Gene Mutation","code":"C148644","definitions":[{"definition":"A change in the nucleotide sequence of a non-coding gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Coding Gene Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Coding Transcript Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Noncoding Gene Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Untranslated Gene Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Coding Gene Mutation"},{"name":"NCI_META_CUI","value":"CL551267"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C62198":{"preferredName":"Nonsense Mutation","code":"C62198","definitions":[{"definition":"A mutation that alters the genetic code in a way that causes the premature termination of a protein. The altered protein may be partially or completely inactivated, resulting in a change or loss of protein function.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A point mutation occurring within the protein-coding region of a gene, and which codes for a stop that can truncate the protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonsense Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Premature Termination Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Premature Termination Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Stop Gain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nonsense_Mutation"},{"name":"Maps_To","value":"Nonsense"},{"name":"Maps_To","value":"Stop Gain"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0544885"}]}}{"C148647":{"preferredName":"Regulatory Region Deletion","code":"C148647","definitions":[{"definition":"A deletion mutation where the deleted sequence includes a regulatory region for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regulatory Region Deletion","termGroup":"PT","termSource":"NCI"},{"termName":"Regulatory Region Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regulatory Region Ablation"},{"name":"NCI_META_CUI","value":"CL551264"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148648":{"preferredName":"Regulatory Region Amplification","code":"C148648","definitions":[{"definition":"An increase in the copy number of a region containing a regulatory sequence for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regulatory Region Amplification","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regulatory Region Amplification"},{"name":"NCI_META_CUI","value":"CL551263"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148646":{"preferredName":"Regulatory Region Mutation","code":"C148646","definitions":[{"definition":"A change in the nucleotide sequence of a regulatory region for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regulatory Region Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Regulatory Region Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regulatory Region Variant"},{"name":"NCI_META_CUI","value":"CL551261"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C45389":{"preferredName":"Acceptor Splice Site SNP","code":"C45389","definitions":[{"definition":"A heritable single nucleotide polymorphism located at the acceptor splice site in certain allelic variants of eukaryotic genes. These sites are located in genes at intron to exon junctions at the 3' end of the intron.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acceptor Splice Site SNP","termGroup":"PT","termSource":"NCI"},{"termName":"Intronic, Acceptor Splice Site SNP","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Acceptor Point Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Acceptor Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acceptor_Splice_Site_SNP"},{"name":"Maps_To","value":"Splice Acceptor Variant"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C1706692"}]}}{"C45390":{"preferredName":"Donor Splice Site SNP","code":"C45390","definitions":[{"definition":"An inherited single base change at a donor splice site in a genomic DNA sequence that results in an allelic variant of the wild-type gene. Donor splice sites are located at exon to intron junctions at the 5' end of the intron.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Donor Splice Site SNP","termGroup":"PT","termSource":"NCI"},{"termName":"Intronic, Donor Splice Site SNP","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Donor Point Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Donor Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Donor_Splice_Site_SNP"},{"name":"Maps_To","value":"Splice Donor Variant"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C1707808"}]}}{"C19798":{"preferredName":"Splice-Site Mutation","code":"C19798","definitions":[{"definition":"Any mutation that occurs within the discrete sequences comprising the 5' or 3' splice sites of a gene that has a spliced message. Splice-site mutation may result in a deletion or insertion of extraneous amino acids in the gene product or a change in the reading frame of the spliced message.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splice-Site Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Splice Region Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Splice-Juction Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Splice-Site Mutation Abnormality","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Splice-Site_Mutation"},{"name":"Maps_To","value":"Splice"},{"name":"Maps_To","value":"Splice Region Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1519478"}]}}{"C148649":{"preferredName":"Start Lost Mutation","code":"C148649","definitions":[{"definition":"A mutation occurring within the start codon of a gene that results in a sequence that no longer encodes a start codon. This can result in a gene deletion or gene transcription may start from an alternative start site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Start Lost Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Start Lost","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Start Lost"},{"name":"NCI_META_CUI","value":"CL551258"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148650":{"preferredName":"Nonstop Mutation","code":"C148650","definitions":[{"definition":"A mutation occurring within the stop codon of a gene that results in a sequence that no longer encodes a stop codon and results in the transcription of non-coding regions downstream of the gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonstop Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Read-Through Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Stop Lost","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extension"},{"name":"Maps_To","value":"Stop Lost"},{"name":"NCI_META_CUI","value":"CL551257"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148651":{"preferredName":"Silent Stop Codon Mutation","code":"C148651","definitions":[{"definition":"A mutation occurring within the stop codon of a gene, which still encodes a stop codon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silent Stop Codon Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Stop Retained Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stop Retained Variant"},{"name":"NCI_META_CUI","value":"CL551260"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C20629":{"preferredName":"Silent Mutation","code":"C20629","definitions":[{"definition":"A point mutation occurring within the protein-coding region of a gene, and which codes for the same amino acid as expected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silent Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Exon Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonic Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Mutation, Silent","termGroup":"SY","termSource":"NCI"},{"termName":"Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Synonymous Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Silent_Mutation"},{"name":"Maps_To","value":"Synonymous Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1519323"}]}}{"C148652":{"preferredName":"Transcription Factor Binding Site Mutation","code":"C148652","definitions":[{"definition":"A change in the nucleotide sequence of a transcription factor binding site for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcription Factor Binding Site Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"TF Binding Site Variant","termGroup":"SY","termSource":"NCI"},{"termName":"TFBS Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TF Binding Site Variant"},{"name":"NCI_META_CUI","value":"CL551259"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148653":{"preferredName":"Transcription Factor Binding Site Deletion Mutation","code":"C148653","definitions":[{"definition":"A deletion mutation where the deleted sequence includes a transcription factor binding site for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcription Factor Binding Site Deletion Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"TFBS Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TFBS Ablation"},{"name":"NCI_META_CUI","value":"CL551256"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148654":{"preferredName":"Transcription Factor Binding Site Amplification","code":"C148654","definitions":[{"definition":"An increase in the copy number of a region containing a transcription factor binding site for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcription Factor Binding Site Amplification","termGroup":"PT","termSource":"NCI"},{"termName":"TFBS Amplification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TFBS Amplification"},{"name":"NCI_META_CUI","value":"CL551255"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C16606":{"preferredName":"Gene Deletion","code":"C16606","definitions":[{"definition":"A deletion that results in the loss of a DNA segment encompassing an entire gene sequence.","type":"DEFINITION","source":"NCI"},{"definition":"The loss of all or a part of a gene. There may also be a change in the RNA and protein made from that gene. Certain gene deletions are found in cancer and in other genetic diseases and abnormalities.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gene Deletion","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Deletion Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Transcript Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Deletion"},{"name":"Maps_To","value":"Transcript Ablation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0017260"}]}}{"C45581":{"preferredName":"Gene Amplification Abnormality","code":"C45581","definitions":[{"definition":"An increase in the copy number of a particular gene. This type of abnormality can be either inherited or somatic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Amplification Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Amplification","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Amplification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Amplification_Abnormality"},{"name":"Maps_To","value":"Amplification"},{"name":"Maps_To","value":"Gene Amplification Abnormality"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705759"}]}}{"C63430":{"preferredName":"5' Flank Mutation","code":"C63430","definitions":[{"definition":"Any gene mutation that occurs in the sequences upstream from a coding region of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5' Flank Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Upstream Gene Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"This term is applied primarily to polycistronic RNAs, in which any upstream mutation is considered a 5' flank mutation with respect to the downstream open reading frame."},{"name":"Legacy Concept Name","value":"_5_Flank_Mutation"},{"name":"Maps_To","value":"Upstream Gene Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883643"}]}}{"C168802":{"preferredName":"Variant Benign","code":"C168802","definitions":[{"definition":"A genetic variant that is known to not contribute to the development of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Variant Benign","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Benign"},{"name":"NCI_META_CUI","value":"CL1378700"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C168801":{"preferredName":"Variant Likely Benign","code":"C168801","definitions":[{"definition":"A genetic variant that is not expected to contribute to the development of a disease, but the scientific evidence may be insufficient to prove this conclusively.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Variant Likely Benign","termGroup":"PT","termSource":"NCI"},{"termName":"Likely Benign Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Likely Benign"},{"name":"NCI_META_CUI","value":"CL1379136"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C168800":{"preferredName":"Likely Pathogenic Variant","code":"C168800","definitions":[{"definition":"A genetic variant that is known to have a high likelihood (greater than 90% certainty) to contribute to the development of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Likely Pathogenic Variant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Likely Pathogenic"},{"name":"NCI_META_CUI","value":"CL1379135"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C168799":{"preferredName":"Pathogenic Variant","code":"C168799","definitions":[{"definition":"A genetic variant that is known to directly contribute to the development of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pathogenic Variant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pathogenic"},{"name":"NCI_META_CUI","value":"CL1379138"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C94187":{"preferredName":"Variant of Unknown Significance","code":"C94187","definitions":[{"definition":"A variation in a genetic sequence whose association with disease risk is unknown.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Variant of Unknown Significance","termGroup":"PT","termSource":"NCI"},{"termName":"Uncertain Significance","termGroup":"SY","termSource":"NCI"},{"termName":"Variant of Undetermined Significance","termGroup":"SY","termSource":"NCI"},{"termName":"VUS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uncertain Significance"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C2986382"}]}}{"C2873":{"preferredName":"Aneuploidy","code":"C2873","definitions":[{"definition":"A chromosomal abnormality in which there is an addition or loss of chromosomes within a set (e.g., 23 + 22 or 23 + 24).","type":"DEFINITION","source":"NCI"},{"definition":"The occurrence of one or more extra or missing chromosomes leading to an unbalanced chromosome complement, or any chromosome number that is not an exact multiple of the haploid number (which is 46).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aneuploidy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aneuploidy"},{"name":"Maps_To","value":"Aneuploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0002938"}]}}{"C118941":{"preferredName":"Diploidy","code":"C118941","definitions":[{"definition":"Having two sets of homologous chromosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diploidy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diploid"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0012568"}]}}{"C80336":{"preferredName":"Hyperdiploidy","code":"C80336","definitions":[{"definition":"A chromosomal abnormality in which the chromosomal number is greater than the normal diploid number.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperdiploidy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperdiploidy"},{"name":"Maps_To","value":"Hyperdiploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1305143"}]}}{"C80337":{"preferredName":"Hypodiploidy","code":"C80337","definitions":[{"definition":"A chromosomal abnormality in which the chromosomal number is less than the normal diploid number.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypodiploidy","termGroup":"PT","termSource":"NCI"},{"termName":"Hypodiploid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypodiploidy"},{"name":"Maps_To","value":"Hypodiploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0333691"}]}}{"C165228":{"preferredName":"Near Diploidy","code":"C165228","definitions":[{"definition":"A chromosomal abnormality in which the total chromosome number is slightly more (hyperdiploid) or slightly less (hypodiploid) than the normal diploid number.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Near Diploidy","termGroup":"PT","termSource":"NCI"},{"termName":"Near Diploid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Near Diploid"},{"name":"NCI_META_CUI","value":"CL978380"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C28450":{"preferredName":"Tetraploidy","code":"C28450","definitions":[{"definition":"A numerical chromosomal abnormality characterized by the presence of four complete sets of chromosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetraploidy","termGroup":"PT","termSource":"NCI"},{"termName":"Tetraploid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tetraploidy"},{"name":"Maps_To","value":"Tetraploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0333694"}]}}{"C25966":{"preferredName":"MicroRNA","code":"C25966","definitions":[{"definition":"A sequence of single-stranded RNA which is typically 20-25 nucleotides in length and may regulate the expression of other genes. miRNAs are transcribed from DNA, but are not translated into proteins.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sequence of single-stranded RNA, that is 20-25 nucleotides in length, which is transcribed from DNA but is not translated into a protein. This nucleic acid may regulate the transcription or translation of other genes.","type":"DEFINITION","source":"NCI"},{"definition":"A type of RNA found in cells and in blood. MicroRNAs are smaller than many other types of RNA and can bind to messenger RNAs (mRNAs) to block them from making proteins. MicroRNAs are being studied in the diagnosis and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"MicroRNA","termGroup":"PT","termSource":"NCI"},{"termName":"Micro RNA","termGroup":"SY","termSource":"NCI"},{"termName":"micro-RNA","termGroup":"SY","termSource":"NCI"},{"termName":"MIR","termGroup":"SY","termSource":"NCI"},{"termName":"MIRN","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA","termGroup":"SY","termSource":"NCI"},{"termName":"Small Temporal RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MicroRNA"},{"name":"Maps_To","value":"miRNA"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C1101610"}]}}{"C813":{"preferredName":"Messenger RNA","code":"C813","definitions":[{"definition":"A class of RNA molecule containing protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A class of RNA molecule containing protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein.","type":"DEFINITION","source":"NCI"},{"definition":"A representation of a member of the class of RNA molecules that contains protein-coding information in its nucleotide sequence.   EXAMPLE(S): Homo sapiens BRCA1 transcript variant 1 mRNA, GenBank identifier NM_007294.3, is available at http://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3  OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"A type of RNA found in cells. Messenger RNA molecules carry the genetic information needed to make proteins. They carry the information from the DNA in the nucleus of the cell to the cytoplasm where the proteins are made.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Messenger RNA","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:33699"},{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail."},{"name":"Legacy Concept Name","value":"Messenger_RNA"},{"name":"Maps_To","value":"mRNA"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0035696"}]}}{"C17021":{"preferredName":"Protein","code":"C17021","definitions":[{"definition":"A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.","type":"DEFINITION","source":"NCI"},{"definition":"A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.","type":"ALT_DEFINITION","source":"PQCMC","qualifiers":[{"type":"attribution","value":"NCI"}]},{"definition":"A molecule made up of amino acids that are needed for the body to function properly. Proteins are the basis of body structures such as skin and hair and of substances such as enzymes, cytokines, and antibodies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A representation of an organic macromolecule in public resources (e.g., UniProt or NCBI RefSeq) composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons.  Comment Requested:  In interest of re-using existing standards, should the above definition of Protein be replaced by the following from the NLM -- :  A molecule made up of amino acids that are needed for the body to function properly. Proteins are the basis of body structures such as skin and hair and of substances such as enzymes, cytokines, and antibodies. [Source: http://ghr.nlm.nih.gov/glossary=protein]  EXAMPLE(S): A protein record from UniProt Knowledgebase: http://www.uniprot.org/uniprot/P38398   OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"}],"synonyms":[{"termName":"Protein","termGroup":"PT","termSource":"NCI"},{"termName":"Proteins","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:36080"},{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Protein"},{"name":"Maps_To","value":"Protein"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0033684"}]}}{"C26683":{"preferredName":"Abnormal Laboratory Test Result","code":"C26683","definitions":[{"definition":"A laboratory test result that falls outside of the normal, acceptable range.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abnormal Laboratory Test Result","termGroup":"PT","termSource":"NCI"},{"termName":"Abnormal Lab Test Result","termGroup":"SY","termSource":"NCI"},{"termName":"Abnormal Laboratory Test","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Abnormal_Laboratory_Test"},{"name":"Maps_To","value":"Abnormal, NOS"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0438215"}]}}{"C49142":{"preferredName":"Copy Number","code":"C49142","definitions":[{"definition":"The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Copy Number","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Copy_Number"},{"name":"Maps_To","value":"Copy Number Reported"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1707513"}]}}{"C165233":{"preferredName":"Expression Negative","code":"C165233","definitions":[{"definition":"An indication that expression of a gene, RNA species or protein is not detected in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Expression Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Absent","termGroup":"SY","termSource":"NCI"},{"termName":"Loss of Expression","termGroup":"SY","termSource":"NCI"},{"termName":"Negative","termGroup":"SY","termSource":"NCI"},{"termName":"Not Expressed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Loss of Expression"},{"name":"NCI_META_CUI","value":"CL978385"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C14165":{"preferredName":"Normal","code":"C14165","definitions":[{"definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","type":"DEFINITION","source":"NCI"},{"definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Normal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Normal"},{"name":"Maps_To","value":"Normal"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1550457"}]}}{"C177693":{"preferredName":"Elevated Expression","code":"C177693","definitions":[{"definition":"An indication that the expression of a gene, transcript or protein is higher than a previous value or a normal range of values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elevated Expression","termGroup":"PT","termSource":"NCI"},{"termName":"High Expression","termGroup":"SY","termSource":"NCI"},{"termName":"Overexpression","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Overexpressed"},{"name":"NCI_META_CUI","value":"CL930180"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C165229":{"preferredName":"Test Value Reported Indicator","code":"C165229","definitions":[{"definition":"An indication as to whether a test value has been reported or recorded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Test Value Reported Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Test Value Reported","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Test Value Reported"},{"name":"NCI_META_CUI","value":"CL978381"},{"name":"Semantic_Type","value":"Finding"}]}}{"C30103":{"preferredName":"Stable","code":"C30103","definitions":[{"definition":"Subject to little fluctuation; showing little if any change.","type":"DEFINITION","source":"NCI"},{"definition":"Subject to little fluctuation; showing little if any change. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Stable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stable"},{"name":"Maps_To","value":"Stable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205360"}]}}{"C177682":{"preferredName":"Gene Amplification Positive","code":"C177682","definitions":[{"definition":"An indication that amplification of one or more genes of interest was detected in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Amplification Positive","termGroup":"PT","termSource":"NCI"},{"termName":"Amplification Detected","termGroup":"SY","termSource":"NCI"},{"termName":"Amplification Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Amplified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amplified"},{"name":"NCI_META_CUI","value":"CL1643457"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C202274":{"preferredName":"Mitotic Count Reported Indicator","code":"C202274","definitions":[{"definition":"An indication that a mitotic count was reported for a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitotic Count Reported Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Mitotic Count Reported","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitotic Count Reported"},{"name":"NCI_META_CUI","value":"CL1921238"},{"name":"Semantic_Type","value":"Finding"}]}}{"C202275":{"preferredName":"Staining Intensity Value Reported Indicator","code":"C202275","definitions":[{"definition":"An indication that a staining intensity value was reported for a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity Value Reported Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Staining Intensity Value Reported","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Staining Intensity Value Reported"},{"name":"NCI_META_CUI","value":"CL1921239"},{"name":"Semantic_Type","value":"Finding"}]}}{"C17666":{"preferredName":"Germline Variation","code":"C17666","definitions":[{"definition":"A gene change in the body's reproductive cells (egg or sperm) that becomes incorporated into the DNA of every cell in the body of offspring; germline mutations are passed on from parents to offspring.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any inheritable variation in the DNA that is transmitted to the progeny with some frequency.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any mutation that appears in the gametes and which will therefore be transmitted to the progeny with some frequency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Germline Variation","termGroup":"PT","termSource":"NCI"},{"termName":"Germline Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Germline Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Germline Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Germline_Mutation"},{"name":"Maps_To","value":"Germline"},{"name":"Maps_To","value":"Simple Germline Variation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0206530"}]}}{"C18060":{"preferredName":"Somatic Variation","code":"C18060","definitions":[{"definition":"An alteration in DNA that occurs after conception. Somatic mutations can occur in any of the cells of the body except the germ cells (sperm and egg) and therefore are not passed on to children. These alterations can (but do not always) cause cancer or other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any mutation with an origin in cells that are not destined to become gametes. As a consequence, such mutations are not transmitted to progeny, though they will be transmitted during any mitosis within the individual. Somatic mutations may contribute to a broad variety of pathologies including cancer.","type":"DEFINITION","source":"NCI"},{"definition":"Any non-inheritable variation in the DNA that is not transmitted to the progeny but will be maintained during any mitosis within the individual.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Somatic Variation","termGroup":"PT","termSource":"NCI"},{"termName":"Somatic Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Somatic_Mutation"},{"name":"Maps_To","value":"Somatic"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0544886"}]}}{"C16277":{"preferredName":"Allele","code":"C16277","definitions":[{"definition":"Mutually exclusive alternative forms of the same gene occupying the same locus on homologous chromosomes, differing in nucleotide sequence and governing the same biochemical and developmental process.","type":"DEFINITION","source":"NCI"},{"definition":"One of two or more DNA sequences occurring at a particular gene locus. Typically one allele (normal DNA sequence) is common, and other alleles (mutations) are rare.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Allele","termGroup":"PT","termSource":"NCI"},{"termName":"Alleles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Two or more genes are said to be alleles if they occupy the same DNA sequence at a locus on homologous chromosomes."},{"name":"Legacy Concept Name","value":"Allele"},{"name":"Maps_To","value":"Alleles"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0002085"}]}}{"C62582":{"preferredName":"Chimerism","code":"C62582","definitions":[{"definition":"The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chimerism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chimerism"},{"name":"Maps_To","value":"Chimerism"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0333678"}]}}{"C165230":{"preferredName":"Conversion Mutation","code":"C165230","definitions":[{"definition":"A rearrangement where nonreciprocal transfer of genetic information between two sites in the genome lead to the deletion of one sequence and the duplication of the transferred sequence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conversion Mutation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conversion"},{"name":"NCI_META_CUI","value":"CL978382"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C19296":{"preferredName":"Deletion Mutation","code":"C19296","definitions":[{"definition":"Absence of a segment of DNA; may be as small as a single base or as large as a whole chromosome.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any rearrangement to the genomic content that results in the loss of one or more nucleotides of DNA. Deletions are generally irreversible rearrangements. They may alter the reading frame of a gene, or may result in loss of large chromosomal regions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deletion Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"del","termGroup":"AB","termSource":"NCI"},{"termName":"Deletion","termGroup":"SY","termSource":"NCI"},{"termName":"Deletion Abnormality","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Deletion_Mutation"},{"name":"Legacy Concept Name","value":"Gene_Deletion_Abnormality"},{"name":"Maps_To","value":"Deletion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1511760"}]}}{"C171175":{"preferredName":"Delins Mutation","code":"C171175","definitions":[{"definition":"A change in a nucleotide sequence where nucleotides in a reference sequence are replaced by other nucleotides and which is not a substitution, inversion or conversion.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution"}]}],"synonyms":[{"termName":"Delins Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Deletion-Insertion","termGroup":"SY","termSource":"NCI"},{"termName":"Deletion-Insertion Variant","termGroup":"SY","termSource":"NCI"},{"termName":"delins","termGroup":"SY","termSource":"NCI"},{"termName":"delins Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deletion-Insertion"},{"name":"NCI_META_CUI","value":"CL1405386"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C45582":{"preferredName":"Gene Duplication Abnormality","code":"C45582","definitions":[{"definition":"Generation of an extra copy of a particular gene in the genome. A gene duplication abnormality may occur by gene amplification, random breakage and reunion, retrotransposition or unequal crossing-over at meiosis. A gene duplication abnormality can be either heritable or somatic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Duplication Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Duplication","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Duplication","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Duplication_Abnormality"},{"name":"Maps_To","value":"Duplication"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705960"}]}}{"C37956":{"preferredName":"Gain","code":"C37956","definitions":[{"definition":"Gain; to increase or the amount of increase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gain"},{"name":"Maps_To","value":"Gain"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1517378"}]}}{"C20102":{"preferredName":"Hypermethylation","code":"C20102","definitions":[{"definition":"Hypermethylation appears to be a controlled, epigenetic, heritable, and aberrant DNA methylation reaction on gene promoter regions and CpG islands associated with loss of (e.g., tumor-suppressor) gene function in diverse cellular pathways through transcriptional silencing by the formation of transcriptionally repressive chromatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypermethylation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypermethylation"},{"name":"Maps_To","value":"Hypermethylation"},{"name":"Semantic_Type","value":"Phenomenon or Process"},{"name":"UMLS_CUI","value":"C1512554"}]}}{"C19295":{"preferredName":"Insertion Mutation","code":"C19295","definitions":[{"definition":"Any rearrangement to the genomic content that adds one or more extra nucleotides into the DNA. Insertions may be reversible, particulary if caused by transposable elements. They may alter the reading frame of a gene, or may cause large scale additions of genomic DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Insertion Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"ins","termGroup":"AB","termSource":"NCI"},{"termName":"Insertion","termGroup":"SY","termSource":"NCI"},{"termName":"Insertion Mutation Abnormality","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Insertion_Mutation"},{"name":"Maps_To","value":"Insertion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1512796"}]}}{"C45589":{"preferredName":"Inversion Mutation Abnormality","code":"C45589","definitions":[{"definition":"A structural change in genomic DNA where the 5' to 3' order of a nucleotide sequence is completely reversed to the 3' to 5' order relative to its adjacent sequences. This inversion is termed either pericentric, if it includes the centromere of a chromosome, or pancentric, if it excludes the centromere. An inversion mutation abnormality may be heritable or occur somatically.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inversion Mutation Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"inv","termGroup":"AB","termSource":"NCI"},{"termName":"Inversion","termGroup":"SY","termSource":"NCI"},{"termName":"Inversion Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Inversion_Mutation_Abnormality"},{"name":"Maps_To","value":"Inversion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705687"}]}}{"C25559":{"preferredName":"Loss","code":"C25559","definitions":[{"definition":"A gradual decline in amount or activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Loss","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Loss"},{"name":"Maps_To","value":"Loss"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1517945"}]}}{"C16848":{"preferredName":"Methylation","code":"C16848","definitions":[{"definition":"A chemical reaction in which a small molecule called a methyl group is added to other molecules. Methylation of proteins or nucleic acids may affect how they act in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The covalent chemical or biochemical addition of a methyl group(s) to a compound. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methylation"},{"name":"Maps_To","value":"Methylation"},{"name":"Semantic_Type","value":"Phenomenon or Process"},{"name":"UMLS_CUI","value":"C0025723"}]}}{"C92976":{"preferredName":"Mosaicism","code":"C92976","definitions":[{"definition":"The occurrence of 2 or more cell lines with different genetic or chromosomal make-up, within a single individual or tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The presence of more than one genetically distinct cell line in germ and/or somatic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mosaicism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mosaicism"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0026578"}]}}{"C165231":{"preferredName":"Partial DNA Methylation","code":"C165231","definitions":[{"definition":"An indication that 10-90% of the CpG islands in a gene or gene promoter have detectable methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial DNA Methylation","termGroup":"PT","termSource":"NCI"},{"termName":"Partial Methylation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Partial Methylation"},{"name":"NCI_META_CUI","value":"CL978383"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C36541":{"preferredName":"Chromosomal Rearrangement","code":"C36541","definitions":[{"definition":"Any change in the structure of one or more chromosomes.","type":"DEFINITION","source":"NCI"},{"definition":"Any process affecting a DNA sequence that results in the gain, loss or exchange of DNA between chromosomes and/or autonomous replicons.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]}],"synonyms":[{"termName":"Chromosomal Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosomal Rearrangements","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Chromosomal Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Chromosome Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Chromosome Anomalies","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Chromosomal_Rearrangement"},{"name":"Maps_To","value":"Rearrangement"},{"name":"Maps_To","value":"Structural Rearrangement"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515001"}]}}{"C13298":{"preferredName":"Repetitive Sequence","code":"C13298","definitions":[{"definition":"Nucleotide sequences present in multiple copies in the genome. There are several types of repeated sequences. Interspersed (or dispersed) DNA repeats (Interspersed Repetitive Sequences) are copies of transposable elements interspersed throughout the genome.  Flanking (or terminal) repeats (Terminal Repeat Sequences) are sequences that are repeated on both ends of a sequence, for example, the long terminal repeats (LTRs) on retroviruses. Direct terminal repeats are in the same direction and inverted terminal repeats are opposite to each other in direction. Tandem repeats (Tandem Repeat Sequences) are repeated copies which lie adjacent to each other. These can also be direct or inverted. The ribosomal RNA and transfer RNA genes belong to the class of middle repetitive DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Repetitive Sequence","termGroup":"PT","termSource":"NCI"},{"termName":"Repeated Sequence","termGroup":"SY","termSource":"NCI"},{"termName":"Repetitive Element","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Repetitive_Sequence"},{"name":"Maps_To","value":"Repeated Sequences"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C0086908"}]}}{"C3420":{"preferredName":"Chromosomal Translocation","code":"C3420","definitions":[{"definition":"A genetic exchange where a piece of one chromosome is transferred to another chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromosomal Translocation","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Translocation","termGroup":"SY","termSource":"NCI"},{"termName":"t","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Chromosomal_Translocation"},{"name":"Maps_To","value":"Translocation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0040715"}]}}{"C45584":{"preferredName":"Gene Fusion Abnormality","code":"C45584","definitions":[{"definition":"Fusion of two genes or segments of genes that were previously separated prior to a mutation abnormality such as translocation. A gene fusion abnormality results in the formation of a new genetic unit that typically exhibits altered functional characteristics. This type of mutation abnormality can be either heritable or occur somatically.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Fusion Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Fusion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Fusion_Abnormality"},{"name":"Maps_To","value":"Fusion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705736"}]}}{"C17004":{"preferredName":"Genetic Polymorphism","code":"C17004","definitions":[{"definition":"A common change in the genetic code in DNA. Polymorphisms can have a harmful effect, a good effect, or no effect. Some polymorphisms have been shown to increase the risk of certain types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The regular and simultaneous occurrence of alternative nucleotide sequences at equivalent locations of the genetic material among individuals of a single interbreeding population that are not maintained by recurrent mutation. Polymorphisms may range in size from single nucleotide to large nucleotide sequence variation visible at the chromosomal level.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genetic Polymorphism","termGroup":"PT","termSource":"NCI"},{"termName":"Polymorphism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Genetic_Polymorphism"},{"name":"Maps_To","value":"Genetic Polymorphism"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C0032529"}]}}{"C198980":{"preferredName":"Internal Tandem Duplication Mutation","code":"C198980","definitions":[{"definition":"The duplication of adjacent coding regions or whole exon sequences that are reinserted in-frame within the gene of origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Internal Tandem Duplication Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Internal Tandem Duplication","termGroup":"SY","termSource":"NCI"},{"termName":"ITD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Internal Tandem Duplication"},{"name":"NCI_META_CUI","value":"CL1907624"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C45576":{"preferredName":"Mutation Abnormality","code":"C45576","definitions":[{"definition":"Any change in the DNA of a cell. Mutations may be caused by mistakes during cell division, or they may be caused by exposure to DNA-damaging agents in the environment. Mutations can be harmful, beneficial, or have no effect. If they occur in cells that make eggs or sperm, they can be inherited; if mutations occur in other types of cells, they are not inherited. Certain mutations may lead to cancer or other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutation Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Genetic Alteration","termGroup":"SY","termSource":"NCI"},{"termName":"Genetic Change","termGroup":"SY","termSource":"NCI"},{"termName":"Mutated","termGroup":"AD","termSource":"NCI"},{"termName":"Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Mutation_Abnormality"},{"name":"Maps_To","value":"Mutation, NOS"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705285"}]}}{"C64346":{"preferredName":"Hemizygosity","code":"C64346","definitions":[{"definition":"Having only one copy of a particular gene or genetic region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemizygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Hemizygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemizygous"},{"name":"Maps_To","value":"Hemizygous"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1881036"}]}}{"C45825":{"preferredName":"Heterozygosity","code":"C45825","definitions":[{"definition":"Having two different allelic forms of a gene, one inherited from each parent, on each of the two homologous chromosomes.","type":"DEFINITION","source":"NCI"},{"definition":"Occurs when the two alleles at a particular gene locus are different. A heterozygous genotype may include one normal allele and one mutation, or two different mutations. The latter is called a compound heterozygote.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Heterozygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Heterozygote","termGroup":"SY","termSource":"NCI"},{"termName":"Heterozygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Heterozygous"},{"name":"Maps_To","value":"Heterozygous"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0019425"}]}}{"C45826":{"preferredName":"Homozygosity","code":"C45826","definitions":[{"definition":"Having two identical allelic forms of a gene, one inherited from each parent, on each of the two homologous chromosomes.","type":"DEFINITION","source":"NCI"},{"definition":"Occurs when both alleles at a particular gene locus are the same. A person may be homozygous for the normal allele or for a mutation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Homozygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Homozygote","termGroup":"SY","termSource":"NCI"},{"termName":"Homozygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Homozygous"},{"name":"Maps_To","value":"Homozygous"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0019904"}]}}{"C148063":{"preferredName":"Nullizygosity","code":"C148063","definitions":[{"definition":"Having no copies, or nonfunctional copies, of a particular gene or genetic region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nullizygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Homozygous Null","termGroup":"SY","termSource":"NCI"},{"termName":"Nullizygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nullizygous"},{"name":"NCI_META_CUI","value":"CL545804"},{"name":"Semantic_Type","value":"Functional Concept"}]}}{"C8362":{"preferredName":"Mild Dysplasia","code":"C8362","definitions":[{"definition":"A morphologic finding indicating the presence of mild cellular atypia associated with mild architectural changes in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mild Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mild_Dysplasia"},{"name":"Maps_To","value":"Mild"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334046"}]}}{"C8363":{"preferredName":"Moderate Dysplasia","code":"C8363","definitions":[{"definition":"A morphologic finding indicating the presence of moderate cellular atypia associated with moderate architectural changes in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderate Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Moderate_Dysplasia"},{"name":"Maps_To","value":"Moderate"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334047"}]}}{"C8364":{"preferredName":"Severe Dysplasia","code":"C8364","definitions":[{"definition":"A morphologic finding indicating the presence of severe cellular atypia associated with severe architectural changes in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Severe Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Severe_Dysplasia"},{"name":"Maps_To","value":"Severe"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334048"}]}}{"C174120":{"preferredName":"Esophageal Columnar Dysplasia","code":"C174120","definitions":[{"definition":"A morphologic finding the replacement of the normal lower esophagus squamous epithelium with columnar epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esophageal Columnar Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Columnar Epithelial Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"ECD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Columnar Dysplasia"},{"name":"Maps_To","value":"Esophageal Mucosa Columnar Dysplasia"},{"name":"NCI_META_CUI","value":"CL1407784"},{"name":"Semantic_Type","value":"Finding"}]}}{"C161017":{"preferredName":"Keratinizing Dysplasia","code":"C161017","definitions":[{"definition":"Epithelial dysplasia in which the dysplastic changes, although limited to the lower basal zone, are so severe, that there is a high probability of progression to invasive carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Keratinizing Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Keratinizing"},{"name":"NCI_META_CUI","value":"CL969991"},{"name":"Semantic_Type","value":"Finding"}]}}{"C161016":{"preferredName":"Non-Keratinizing Dysplasia","code":"C161016","definitions":[{"definition":"Intraepithelial proliferation of dysplastic epithelial cells not associated with keratin formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Keratinizing Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Nonkeratinizing Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nonkeratinizing"},{"name":"NCI_META_CUI","value":"CL969992"},{"name":"Semantic_Type","value":"Finding"}]}}{"C27296":{"preferredName":"Positive Lymph Node","code":"C27296","definitions":[{"definition":"Cancer that has spread to the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The presence of metastatic cancer cells in a lymph node.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Positive Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Positive_Lymph_Node"},{"name":"Maps_To","value":"Positive"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0746319"}]}}{"C36174":{"preferredName":"Negative Lymph Node","code":"C36174","definitions":[{"definition":"A clinical finding that a lymph node is free from cancer spread.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that has not spread to the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Negative Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Negative_Lymph_Node"},{"name":"Maps_To","value":"Negative"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0678034"}]}}{"C48620":{"preferredName":"Positive Surgical Margin","code":"C48620","definitions":[{"definition":"Indicates the presence of tumor cells at the edge of a surgically excised specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Positive Surgical Margin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Positive_Surgical_Margin"},{"name":"Maps_To","value":"Involved"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709603"}]}}{"C179432":{"preferredName":"Cohesive Pattern","code":"C179432","definitions":[{"definition":"A microscopic finding that the cells in the sample are tightly adhered to one another and distributed uniformly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cohesive Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Cohesive Architectural Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cohesive"},{"name":"NCI_META_CUI","value":"CL1662208"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35920":{"preferredName":"Cribriform Pattern","code":"C35920","definitions":[{"definition":"A morphologic finding indicating the presence of sheets of malignant epithelial cells punctuated by gland-like spaces in a tissue sample.","type":"DEFINITION","source":"NCI"},{"definition":"Formation of epithelial pseudoglandular structures with lumens.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cribriform Pattern","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cribriform_Pattern"},{"name":"Maps_To","value":"Cribiform"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1333163"}]}}{"C36181":{"preferredName":"Micropapillary Growth Pattern","code":"C36181","definitions":[{"definition":"A morphologic finding indicating the presence of a growth pattern dominated by the presence of small papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micropapillary Growth Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Micropapillary Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Micropapillary_Pattern"},{"name":"Maps_To","value":"Micropapillary"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1334756"}]}}{"C179447":{"preferredName":"Non-Cohesive Pattern","code":"C179447","definitions":[{"definition":"A microscopic finding where the cells in a sample are arranged, singly or in small clusters, demonstrate loose adhesion with one another and may not be distributed uniformly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Cohesive Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Cohesive Architectural Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-cohesive"},{"name":"NCI_META_CUI","value":"CL1662300"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35911":{"preferredName":"Papillary Growth Pattern","code":"C35911","definitions":[{"definition":"A morphologic finding indicating the presence of a cellular infiltrate with papillary growth in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Growth Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Pattern"},{"name":"Maps_To","value":"Papillary, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1335326"}]}}{"C36182":{"preferredName":"Solid Growth Pattern","code":"C36182","definitions":[{"definition":"A microscopic finding indicating that the neoplastic cells are arranged in solid sheets in a tumor sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Growth Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Pattern"},{"name":"Maps_To","value":"Solid"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1336028"}]}}{"C35925":{"preferredName":"Tubular Pattern","code":"C35925","definitions":[{"definition":"A morphological appearance characteristic of neoplasms which arise from the glandular or ductal (or both) epithelium, consisting of glandular or ductal neoplastic proliferations forming small tubules with a lumen lined by neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubular Pattern","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tubular_Pattern"},{"name":"Maps_To","value":"Tubular"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1336833"}]}}{"C28277":{"preferredName":"Pathology Report","code":"C28277","definitions":[{"definition":"A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.","type":"DEFINITION","source":"NCI"},{"definition":"The description of cells and tissues made by a pathologist based on microscopic evidence, and sometimes used to make a diagnosis of a disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pathology Report","termGroup":"PT","termSource":"NCI"},{"termName":"Histology Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Pathology_Report"},{"name":"Maps_To","value":"Pathology Report"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0807321"}]}}{"C63805":{"preferredName":"Portable Document Format","code":"C63805","definitions":[{"definition":"An open file format created and controlled by Adobe Systems, for representing two-dimensional documents in a device independent and resolution independent fixed-layout document format. Each PDF file encapsulates a complete description of a 2D document that includes the text, fonts, images, and 2D vector graphics that compose the document. PDF files do not encode information that is specific to the application software, hardware, or operating system used to create or view the document. This feature ensures that a valid PDF will render exactly the same regardless of its origin or destination (but depending on font availability when fonts are not encapsulated in the file).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Portable Document Format","termGroup":"PT","termSource":"NCI"},{"termName":"pdf","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Portable_Document_Format"},{"name":"Maps_To","value":"PDF"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1554990"}]}}{"C120024":{"preferredName":"Histone H3 Methyl Lys4","code":"C120024","definitions":[{"definition":"A form of histone H3 where the lysine residue at position 4 has been post-translationally modified with a single methyl group. This modification may be a marker for transcriptionally active genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Methyl Lys4","termGroup":"PT","termSource":"NCI"},{"termName":"H3K4me1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Methyl Lysine 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K4me1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C3896986"}]}}{"C107153":{"preferredName":"Histone H3 Trimethyl Lys4","code":"C107153","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 4 is trimethylated. This modification may be a marker for areas of active gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys4","termGroup":"PT","termSource":"NCI"},{"termName":"H3K4me3","termGroup":"SY","termSource":"NCI"},{"termName":"H3K4me3 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K4me3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C3829683"}]}}{"C174109":{"preferredName":"Histone H3 Trimethyl Lys9","code":"C174109","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 9 is trimethylated. This modification is associated with heterochromatin formation and plays a role in embryonic stem cell lineage commitment and maintenance of lineage fidelity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys9","termGroup":"PT","termSource":"NCI"},{"termName":"H3K9me3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K9me3"},{"name":"NCI_META_CUI","value":"CL1407747"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C174110":{"preferredName":"Histone H3 Trimethyl Lys28","code":"C174110","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 28 is trimethylated. This modification is associated with formation of heterochromatin and polycomb repressive complex 1 (PRC1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys28","termGroup":"PT","termSource":"NCI"},{"termName":"H3K27me3","termGroup":"SY","termSource":"NCI"},{"termName":"H3K28me3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 28","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Even though the literature refers to lysine 27 methylation or amino acid variation/mutation, RefSeq indicates that the lysine is located at amino acid position 28 in histone H3. (see https://link.springer.com/article/10.1007/s00401-018-1867-2)"},{"name":"Maps_To","value":"H3K27me3"},{"name":"NCI_META_CUI","value":"CL1407746"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C142872":{"preferredName":"Histone H3 Trimethyl Lys36","code":"C142872","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 36 is trimethylated. This modification may be involved in defining exon boundaries; it also may be a marker for genes targeted for transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys36","termGroup":"PT","termSource":"NCI"},{"termName":"H3K36me3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 36","termGroup":"SY","termSource":"NCI"},{"termName":"Trimethylated Histone H3 at Lysine 36","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K36me3"},{"name":"NCI_META_CUI","value":"CL540739"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C120023":{"preferredName":"Histone H3 Acetyl Lys28","code":"C120023","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 28 is acetylated. This modification may be a marker for transcriptional enhancement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Acetyl Lys28","termGroup":"PT","termSource":"NCI"},{"termName":"H3K27ac","termGroup":"SY","termSource":"NCI"},{"termName":"H3K28ac","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Acetyl Lys27","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Acetyl Lysine 28","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Even though the literature refers to lysine 27 methylation or amino acid variation/mutation, RefSeq indicates that the lysine is located at amino acid position 28 in histone H3. (see https://link.springer.com/article/10.1007/s00401-018-1867-2)"},{"name":"Maps_To","value":"H3K27ac"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C3898882"}]}}{"C156442":{"preferredName":"Control Analyte","code":"C156442","definitions":[{"definition":"A biospecimen that is used as a comparator for an experimental sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Control Analyte","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"00"},{"name":"Maps_To","value":"Control Analyte"},{"name":"Maps_To","value":"Input Control"},{"name":"NCI_META_CUI","value":"CL563180"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C163987":{"preferredName":"Affinity Enriched Genomic Library","code":"C163987","definitions":[{"definition":"A genomic library where the sample has been subjected to enrichment via binding to a target protein or oligonucleotide prior to molecular analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Affinity Enriched Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Affinity Enrichment"},{"name":"NCI_META_CUI","value":"CL977266"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163986":{"preferredName":"Hybrid Selected Genomic Library","code":"C163986","definitions":[{"definition":"A genomic library where the sample has been subjected to enrichment via nucleic acid hybridization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hybrid Selected Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hybrid Selection"},{"name":"NCI_META_CUI","value":"CL977267"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163991":{"preferredName":"miRNA Size Fractionated Genomic Library","code":"C163991","definitions":[{"definition":"A RNA library that has been fractionated by size exclusion methods to enrich for microRNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"miRNA Size Fractionated Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"miRNA Size Fractionation"},{"name":"NCI_META_CUI","value":"CL977262"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163988":{"preferredName":"Poly-A Enriched Genomic Library","code":"C163988","definitions":[{"definition":"A genomic library where the sample has been subjected to enrichment via binding to immobilized poly-T oligonucleotides, which will preferentially isolate polyadenylated (poly-A) RNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly-A Enriched Genomic Library","termGroup":"PT","termSource":"NCI"},{"termName":"Poly(A) Enriched Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"Poly(A) Selected Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-A Selected Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-T Enriched Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"PolyA Selected Genomic Library","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Poly-T Enrichment"},{"name":"NCI_META_CUI","value":"CL977265"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163989":{"preferredName":"Randomly Selected Genomic Library","code":"C163989","definitions":[{"definition":"A genomic library constructed to generate random DNA fragments by subjecting a genomic sample to either amplification using random primers or fragmentation via exposure to restriction enzymes or shear stress. The fragments can then be cloned or sequenced directly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Randomly Selected Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Random"},{"name":"NCI_META_CUI","value":"CL977264"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163990":{"preferredName":"rRNA Depleted Genomic Library","code":"C163990","definitions":[{"definition":"A genomic library where the sample has been subjected to a ribosomal RNA depletion step before it is amplified.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"rRNA Depleted Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"rRNA Depletion"},{"name":"NCI_META_CUI","value":"CL977263"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C150427":{"preferredName":"Unstranded Library Sequencing","code":"C150427","definitions":[{"definition":"Non-directional sequencing, where the reads can map from either the transcript strand or its complement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unstranded Library Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Unstranded","termGroup":"SY","termSource":"NCI"},{"termName":"Unstranded Library","termGroup":"SY","termSource":"NCI"},{"termName":"Unstranded Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unstranded"},{"name":"NCI_META_CUI","value":"CL552241"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C150428":{"preferredName":"First-strand Library Sequencing","code":"C150428","definitions":[{"definition":"Directional sequencing, where the first read (or the only read in case of single end reads) is from the complement strand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First-strand Library Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"First-strand","termGroup":"SY","termSource":"NCI"},{"termName":"First-strand Library","termGroup":"SY","termSource":"NCI"},{"termName":"First-strand Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First_Stranded"},{"name":"NCI_META_CUI","value":"CL552240"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C150426":{"preferredName":"Second-strand Library Sequencing","code":"C150426","definitions":[{"definition":"Directional sequencing, where the first read of the read pair (or in case of single end reads, the only read) is from the transcript strand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Second-strand Library Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Second-strand","termGroup":"SY","termSource":"NCI"},{"termName":"Second-strand Library","termGroup":"SY","termSource":"NCI"},{"termName":"Second-strand Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Second_Stranded"},{"name":"NCI_META_CUI","value":"CL552130"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C156056":{"preferredName":"ATAC-Seq","code":"C156056","definitions":[{"definition":"A molecular genetic technique that isolates and sequences chromosomal regions that are rich in open chromatin. First, nuclei are harvested from a cellular sample. Then a hyperactive Tn5 transposase is added to the nuclei where it excises non-nucleosomal DNA strands and ligates co-administered high-throughput sequencing adapters (tagmentation).  The tagged DNA fragments are isolated, amplified by PCR and sequenced. The number of reads for specific region of DNA correlate with increased chromatin accessibility and this method can identify regions of transcription factor and nucleosome binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATAC-Seq","termGroup":"PT","termSource":"NCI"},{"termName":"Assay for Transposase Accessible Chromatin with High-Throughput Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Assay for Transposase-Accessible Chromatin Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Assay for Transposase-Accessible Chromatin Using Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ATAC-Seq"},{"name":"NCI_META_CUI","value":"CL562893"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C106054":{"preferredName":"Bisulfite Sequencing","code":"C106054","definitions":[{"definition":"A DNA sequencing technique that can differentiate cytosine from 5-methylcytosine in a DNA sample. First, a denatured DNA sample is treated with bisulfite which converts non-methylated cytosine to uracil. Next, the sample is amplified using a PCR method that does not discriminate between non-methylated and methylated sequences. The amplified DNA is subjected to nucleotide sequencing. The resulting sequence is compared to an identical control sample of DNA that was not treated with bisulfite. Unmethylated cytosines will be displayed as cytosines in the control sample and as thymines in the bisulfite-treated sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisulfite Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Bisulfite-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Bisulphite Conversion Followed by Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"BS-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"DNA Methylation Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl-C-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Methylation Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"MethylC-Seq","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Bisulfite-Seq"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3829113"}]}}{"C106049":{"preferredName":"ChIP-Seq","code":"C106049","definitions":[{"definition":"A molecular genetic technique that combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing to map the binding sites of DNA-associated proteins in a sample of cells. First, crosslinked protein-DNA complexes are isolated using ChIP. Next, the crosslinks are broken, the proteins are removed and the purified DNA is modified with adaptor oligonucleotides to facilitate massively parallel DNA sequencing. Following sequencing, the DNA sequences that are obtained can be mapped to their genomic locations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ChIP-Seq","termGroup":"PT","termSource":"NCI"},{"termName":"ChIP-Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Chromatin Immunoprecipitation Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ChIP-Seq"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3831111"}]}}{"C156057":{"preferredName":"MicroRNA Sequencing","code":"C156057","definitions":[{"definition":"A next-generation or massively parallel high-throughput DNA sequencing-based procedure that can identify and quantify the microRNA sequences present in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MicroRNA Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"MicroRNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA-Seq","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"miRNA-Seq"},{"name":"NCI_META_CUI","value":"CL562894"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C171152":{"preferredName":"Single Cell RNA Sequencing","code":"C171152","definitions":[{"definition":"A procedure that can determine the nucleotide sequence for all of the RNA transcripts in an amplified nucleotide sample that was derived from a single cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Single Cell RNA Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"scRNA-Seq","termGroup":"AB","termSource":"NCI"},{"termName":"Single Cell RNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Single Cell Transcriptome Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"scRNA-Seq"},{"name":"NCI_META_CUI","value":"CL1405380"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179435":{"preferredName":"HiChIP","code":"C179435","definitions":[{"definition":"A method that combines chromosome conformation capture, proximity ligation and chromatin immunoprecipitation to isolate DNA from a biospecimen, create a genomic library and analyze 3D chromatin organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HiChIP","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HiChIP"},{"name":"NCI_META_CUI","value":"CL1662209"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179442":{"preferredName":"N6-Methyladenine RNA Analysis","code":"C179442","definitions":[{"definition":"An assay that quantitates the amount and identifies the location of N6-methyladenine modifications within an RNA sequence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N6-Methyladenine RNA Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"m6A RNA Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"m6A RNA Methylation"},{"name":"NCI_META_CUI","value":"CL1662303"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179458":{"preferredName":"Single Cell ATAC-Seq","code":"C179458","definitions":[{"definition":"A molecular genetic technique where DNA is isolated from single cell (sc) samples and amplified to create a genomic library. Then the library is subjected to ATAC-seq, which isolates and sequences regions rich in open chromatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Single Cell ATAC-Seq","termGroup":"PT","termSource":"NCI"},{"termName":"scATAC-Seq","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"scATAC-Seq"},{"name":"NCI_META_CUI","value":"CL1662285"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C188371":{"preferredName":"N6-Methyladenine RNA Immunoprecipitation-Sequencing","code":"C188371","definitions":[{"definition":"A method used to sequence N6-methyladenine (m6A)-modified RNA. Briefly, an RNA sample is subjected to immunoprecipitation using an antibody that specifically enriches m6A RNA, the m6A enriched RNA is reverse-transcribed to produce the complimentary DNA (cDNA) strand and the cDNA is subjected to sequencing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N6-Methyladenine RNA Immunoprecipitation-Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"m6A MeRIP-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"m6A-Methylated RNA Immunoprecipitation-Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"m6A-seq","termGroup":"SY","termSource":"NCI"},{"termName":"MeRIP-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Methylated RNA Immunoprecipitation-Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"m6A MeRIP-Seq"},{"name":"NCI_META_CUI","value":"CL1793642"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146815":{"preferredName":"Complete Genomics Sequencing","code":"C146815","definitions":[{"definition":"A next-generation DNA sequencing service offered by Complete Genomics. Unamplified human genomic DNA is sheared into 500bp fragments and then amplified to create DNA nano-balls (DNBs). The DNBs are arrayed on a substrate and their sequence is determined by Combinatorial Probe-Anchor Ligation (cPAL) sequencing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complete Genomics Sequencing","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Complete Genomics"},{"name":"NCI_META_CUI","value":"CL544862"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146817":{"preferredName":"Illumina Sequencing","code":"C146817","definitions":[{"definition":"A proprietary next-generation DNA sequencing system from Solexa that uses reversible terminator nucleotides. The genomic DNA to be sequenced is fragmented and ligated to adapter molecules on both ends to construct an Illumina-specific adapter library. PCR amplification of the DNA fragments is then performed using the adapter sequence as primer. Sequencing is carried out by repeated cycles of adding reversible fluorescent-labelled nucleotide and incorporation of the nucleotides to the complementary strand. The fluorescence of the incorporated nucleotides is detected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Illumina Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Illumina Sequencing Technology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Illumina"},{"name":"NCI_META_CUI","value":"CL544864"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C125894":{"preferredName":"Ion Semiconductor Sequencing","code":"C125894","definitions":[{"definition":"A method of DNA sequencing based on the detection of hydrogen ions that are released during synthesis of a complementary strand polymerized on a template strand. This technology differs from other sequencing technologies in that no modified nucleotides or optics are used. It claims to be simpler, faster, and more cost effective and scalable than any other technology available.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ion Semiconductor Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Ion Torrent Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Ion Torrent Sequencing Technology","termGroup":"SY","termSource":"NCI"},{"termName":"pH-Mediated Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Semiconductor Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Silicon Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ion Torrent"},{"name":"NCI_META_CUI","value":"CL504544"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146809":{"preferredName":"454 Sequencing","code":"C146809","definitions":[{"definition":"A proprietary next-generation DNA sequencing system from 454 Life Sciences that used large-scale parallel pyrosequencing. The system relied on fixing nebulized and adapter-ligated DNA fragments to small DNA-capture beads in a water-in-oil emulsion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"454 Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"454 Sequencing Technology","termGroup":"SY","termSource":"NCI"},{"termName":"LS 454 Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LS454"},{"name":"NCI_META_CUI","value":"CL544750"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146819":{"preferredName":"SMRT Sequencing","code":"C146819","definitions":[{"definition":"A proprietary third-generation DNA sequencing system from Pacific Biosciences that uses zero-mode waveguides (ZMWs) and phospholinked nucleotides. A single DNA polymerase enzyme is affixed at the bottom of a ZMW structure with a single molecule of DNA as a template. A fluorescent tag is cleaved off with each base addition and is detected to create the sequence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMRT Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Single Molecule, Real-Time Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"SMRT Sequencing Technology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PacBio"},{"name":"NCI_META_CUI","value":"CL544866"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146811":{"preferredName":"ABI SOLiD Sequencing","code":"C146811","definitions":[{"definition":"A proprietary next-generation DNA sequencing system from Applied Biosystems that utilizes DNA ligase. DNA fragments attached to beads are clonally amplified and ligated to fluorescently labeled \"interrogation probes\". Ligation frees the fluor, which is detected and identifies the specific probe. The marker of the attached probe is then removed and a 5'-phosphate group is regenerated. Multiple cycles of ligation, detection, and cleavage are performed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABI SOLiD Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Sequencing of Oligonucleotides by Ligation/Detection","termGroup":"SY","termSource":"NCI"},{"termName":"SOLiD Sequencing Technology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SOLiD"},{"name":"NCI_META_CUI","value":"CL544752"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C172256":{"preferredName":"Root Directory","code":"C172256","definitions":[{"definition":"The top-most directory in a hierarchical file system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Root Directory","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"root"},{"name":"NCI_META_CUI","value":"CL1406129"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C165214":{"preferredName":"Run Metadata","code":"C165214","definitions":[{"definition":"Supporting information that describes the nucleic acid sequencing run(s) in a study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Run Metadata","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Run Metadata"},{"name":"NCI_META_CUI","value":"CL978396"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C77608":{"preferredName":"Abdominal Wall","code":"C77608","definitions":[{"definition":"The tissue that surrounds the organs present in the abdominal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles.","type":"DEFINITION","source":"NCI"},{"definition":"The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Abdominal Wall","termGroup":"PT","termSource":"NCI"},{"termName":"wall of abdomen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Abdominal_Wall"},{"name":"Maps_To","value":"Abdominal Wall"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0836916"},{"name":"xRef","value":"UBERON:0003697"}]}}{"C32042":{"preferredName":"Acetabulum","code":"C32042","definitions":[{"definition":"The acetabulum is a concave surface of the pelvis. The head of the femur meets with the pelvis at the acetabulum, forming the hip joint. There are three bones of the os coxae (hip bone) that come together to form the acetabulum. Contributing a little more than two-fifths of the structure is the ischium, which provides lower and side boundaries to the acetabulum. The ilium forms the upper boundary, providing a little less than two-fifths of the structure of the acetabulum. The rest is formed by the pubis, near the midline. It is bounded by a prominent uneven rim, which is thick and strong above, and serves for the attachment of the acetabular labrum, which reduces its opening, and deepens the surface for formation of the hip joint. At the lower part of the acetabulum is the acetabular notch, which is continuous with a circular depression, the acetabular fossa, at the bottom of the cavity of the acetabulum. The rest of the acetabulum is formed by a curved, crescent-moon shaped surface, the lunate surface, where the joint is made with the head of the femur. Its counterpart in the pectoral girdle is the glenoid fossa.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Two cup shaped areas, one each on the lateral side of the lower pelvis that house the head of the femur to form the ball and socket joint of the hip.","type":"DEFINITION","source":"NCI"},{"definition":"Two cup shaped areas, one each on the lateral side of the lower pelvis that house the head of the femur to form the ball and socket joint of the hip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Acetabulum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Acetabulum"},{"name":"Maps_To","value":"Acetabulum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0000962"},{"name":"xRef","value":"UBERON:0001269"}]}}{"C33318":{"preferredName":"Pharyngeal Tonsil","code":"C33318","definitions":[{"definition":"A fold of lymphatic tissue covered by ciliated epithelium at the very back of the nose, in the roof of the nasopharynx.","type":"DEFINITION","source":"NCI"},{"definition":"A tonsil in the mucosa of the nasopharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymph tissue in the roof and posterior wall of the nasopharynx.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pharyngeal Tonsil","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pharyngeal_Tonsil"},{"name":"Maps_To","value":"Adenoid"},{"name":"Maps_To","value":"Tonsil (Pharyngeal)"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0001428"},{"name":"xRef","value":"UBERON:0001732"}]}}{"C12472":{"preferredName":"Adipose Tissue","code":"C12472","definitions":[{"definition":"A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers.","type":"DEFINITION","source":"NCI"},{"definition":"Connective tissue consisting primarily of adipocytes (fat cells) and supporting structural matrix.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Portion of connective tissue composed of adipocytes enmeshed in areolar tissue.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Adipose Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Body Fat","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Adipose_Tissue"},{"name":"Maps_To","value":"Adipose"},{"name":"NCI_META_CUI","value":"CL1773619"},{"name":"Semantic_Type","value":"Tissue"},{"name":"xRef","value":"UBERON:0001013"}]}}{"C89749":{"preferredName":"Alveolar Ridge","code":"C89749","definitions":[{"definition":"The thickened bony structures in the mandible and maxilla that contain the sockets of the teeth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The thickened bony structures in the mandible and maxilla that contain the sockets of the teeth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alveolar Ridge","termGroup":"PT","termSource":"NCI"},{"termName":"Alveolar Margin","termGroup":"SY","termSource":"NCI"},{"termName":"Alveolar Process","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Alveolar Ridge"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0447411"},{"name":"xRef","value":"UBERON:0004103"}]}}{"C13188":{"preferredName":"Amniotic Fluid","code":"C13188","definitions":[{"definition":"Amniotic fluid is a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. The composition of the fluid changes over the course of gestation. Initially, amniotic fluid is similar to maternal plasma, mainly water with electrolytes. As the fetus develops, proteins, carbohydrates, lipids, phospholipids originating from the lungs, fetal cells, and urea are deposited in the fluid.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fluid within the amniotic cavity which surrounds and protects the developing embryo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fluid within the amniotic cavity which surrounds and protects the developing embryo. It is initially produced by the amnion and then later by the lungs and kidneys. The amount at term normally varies from 500 to 2000 ml.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amniotic Fluid","termGroup":"PT","termSource":"NCI"},{"termName":"Aqua Amnii","termGroup":"SY","termSource":"NCI"},{"termName":"Liquor Amnii","termGroup":"SY","termSource":"NCI"},{"termName":"Waters (Amniotic Fluid)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Amniotic_Fluid"},{"name":"Maps_To","value":"Amniotic Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0002638"},{"name":"xRef","value":"UBERON:0000173"}]}}{"C165177":{"preferredName":"Anal Sphincter","code":"C165177","definitions":[{"definition":"A sphincter muscle that is part of the anal region.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The internal and external muscles surrounding the anus that maintain continence.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The internal and external muscles surrounding the anus that maintain continence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Sphincter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Anal Sphincter"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0002760"},{"name":"xRef","value":"UBERON:0004916"}]}}{"C32078":{"preferredName":"Ankle Joint","code":"C32078","definitions":[{"definition":"A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus.","type":"DEFINITION","source":"NCI"},{"definition":"A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A joint that connects the hindlimb autopod and zeugopod skeletons.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Ankle Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Ankle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ankle_Joint"},{"name":"Maps_To","value":"Ankle"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0003087"},{"name":"xRef","value":"UBERON:0001488"}]}}{"C129464":{"preferredName":"Anorectal","code":"C129464","definitions":[{"definition":"Pertaining to the anus and rectum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anorectal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anorectum"},{"name":"NCI_META_CUI","value":"CL018341"},{"name":"Semantic_Type","value":"Spatial Concept"}]}}{"C103238":{"preferredName":"Antecubital Fossa","code":"C103238","definitions":[{"definition":"A triangular space on the anterior side of the elbow joint. Three main veins of the arm, the brachial artery, the medial nerve and the tendon of the biceps muscle pass through this space.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A triangular space on the anterior side of the elbow joint. Three main veins of the arm, the brachial artery, the medial nerve and the tendon of the biceps pass through this space.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antecubital Fossa","termGroup":"PT","termSource":"NCI"},{"termName":"Cubital Fossa","termGroup":"SY","termSource":"NCI"},{"termName":"Elbow Pit","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antecubital Fossa"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0446523"}]}}{"C97102":{"preferredName":"Antrum","code":"C97102","definitions":[{"definition":"A chamber formation in an organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antrum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antrum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1549092"}]}}{"C12669":{"preferredName":"Aorta","code":"C12669","definitions":[{"definition":"The largest artery in the body. It carries oxygen-rich blood away from the heart to vessels that reach the rest of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The main trunk of the systemic arterial system that carries blood from the heart to all the organs and other structures of the body, bringing oxygenated blood to all parts of the body in the systemic circulation.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The major arterial trunk that carries oxygenated blood from the left ventricle into the ascending aorta behind the heart, the aortic arch, through the thorax as the descending aorta and through the abdomen as the abdominal aorta; it bifurcates into the left and right common iliac arteries.","type":"DEFINITION","source":"NCI"},{"definition":"The major artery of the body; it arises from the left ventricle of the heart and terminally bifurcates into the common iliac arteries.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Aorta","termGroup":"PT","termSource":"NCI"},{"termName":"Aortic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Aorta"},{"name":"Maps_To","value":"Aorta"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003483"},{"name":"xRef","value":"UBERON:0000947"}]}}{"C97112":{"preferredName":"Aortic Body","code":"C97112","definitions":[{"definition":"A small mass that is located in the inferior surface of the aortic arch. It functions as a peripheral chemoreceptor and is composed of glomus cells.","type":"DEFINITION","source":"NCI"},{"definition":"A small mass that is located on the inferior surface of the aortic arch. It functions as a peripheral chemoreceptor and is composed of glomus cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of several small clusters of chemoreceptors, baroreceptors, and supporting cells located along the aortic arch.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Aortic Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Aortic Body"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1510461"},{"name":"xRef","value":"UBERON:0034971"}]}}{"C13190":{"preferredName":"Aqueous Humor","code":"C13190","definitions":[{"definition":"A thick watery refractive medium that fills the space between the lens and the cornea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The watery fluid which is present in the anterior and posterior chambers of the eye.","type":"DEFINITION","source":"NCI"},{"definition":"The watery fluid which is present in the anterior and posterior chambers of the eye. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Aqueous Humor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Aqueous_Humor"},{"name":"Maps_To","value":"Aqueous Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0003662"},{"name":"xRef","value":"UBERON:0001796"}]}}{"C32141":{"preferredName":"Arm","code":"C32141","definitions":[{"definition":"The portion of the upper extremity between the shoulder and the elbow.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Arm"},{"name":"Maps_To","value":"Arm"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0446516"},{"name":"xRef","value":"UBERON:0004250"}]}}{"C12372":{"preferredName":"Artery","code":"C12372","definitions":[{"definition":"A blood vessel that carries blood away from the heart.","type":"DEFINITION","source":"NCI"},{"definition":"A blood vessel that carries blood away from the heart. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A blood vessel that carries blood from the heart to tissues and organs in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An epithelial tube or tree of tubes that transports blood away from the heart.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Artery","termGroup":"PT","termSource":"NCI"},{"termName":"Arterial","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Artery"},{"name":"Maps_To","value":"Artery"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003842"},{"name":"xRef","value":"UBERON:0001637"}]}}{"C12498":{"preferredName":"External Acoustic Meatus","code":"C12498","definitions":[{"definition":"A part of the ear canal that is external to the ear drum.","type":"DEFINITION","source":"NCI"},{"definition":"A tube running from the outer ear to the middle ear. The human ear canal extends from the pinna to the eardrum and is about 26 mm in length and 7 mm in diameter.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A tubular structure that runs from the outer ear to the tympanic membrane.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Acoustic Meatus","termGroup":"PT","termSource":"NCI"},{"termName":"External Auditory Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"External_Acoustic_Meatus"},{"name":"Maps_To","value":"Auditory Canal"},{"name":"Maps_To","value":"Ear Canal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013444"},{"name":"xRef","value":"UBERON:0001352"}]}}{"C12674":{"preferredName":"Axilla","code":"C12674","definitions":[{"definition":"The axilla is the area directly under the joint where the forelimb connects to the shoulder.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The underarm or armpit.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The underside concavity where the arm and the shoulder are joined.","type":"DEFINITION","source":"NCI"},{"definition":"The underside concavity where the arm and the shoulder are joined. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Axilla","termGroup":"PT","termSource":"NCI"},{"termName":"Armpit","termGroup":"SY","termSource":"NCI"},{"termName":"Underarm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Axilla"},{"name":"Maps_To","value":"Axilla"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C4018906"},{"name":"xRef","value":"UBERON:0009472"}]}}{"C13062":{"preferredName":"Back","code":"C13062","definitions":[{"definition":"A major subdivision of an organism that is the entire part of the organism dorsal to a horizontal plane and bounded on one side by the same transverse plane. In vertebrares this includes the vertebral column.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The dorsal area between the base of the neck and the sacrum.","type":"DEFINITION","source":"NCI"},{"definition":"The dorsal area between the base of the neck and the sacrum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Back","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Back"},{"name":"Maps_To","value":"Back"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0817745"},{"name":"xRef","value":"UBERON:0001137"}]}}{"C12376":{"preferredName":"Bile Duct","code":"C12376","definitions":[{"definition":"A tube through which bile passes in and out of the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any of the ducts conveying bile between the liver and the intestine, including hepatic, cystic, and common bile duct.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any of the ducts conveying bile between the liver and the intestine, including hepatic, cystic, and common bile duct.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the ducts that form the biliary tree, carrying bile from the liver to the small intestine.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Bile Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bile_Duct"},{"name":"Maps_To","value":"Bile Duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005400"},{"name":"xRef","value":"UBERON:0002394"}]}}{"C12679":{"preferredName":"Blood Vessel","code":"C12679","definitions":[{"definition":"A tube through which the blood circulates in the body.  Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tubular structure through which the blood circulates in the body. Blood vessels constitute a network composed of arteries, arterioles, capillaries, venules, and veins.","type":"DEFINITION","source":"NCI"},{"definition":"A tubular structure through which the blood circulates in the body. Blood vessels constitute a network composed of arteries, arterioles, capillaries, venules, and veins. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A vessel through which blood circulates in the body.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Blood Vessel","termGroup":"PT","termSource":"NCI"},{"termName":"Vessel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Blood_Vessel"},{"name":"Maps_To","value":"Blood Vessel"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005847"},{"name":"xRef","value":"UBERON:0001981"}]}}{"C12684":{"preferredName":"Bronchiole","code":"C12684","definitions":[{"definition":"A tiny branch of air tubes in the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The conducting airway of the lungs found terminal to the bronchi; these structures contain neither cartilage nor mucous-secreting glands; the epithelium of the bronchioles becomes thinner with each branching.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The smallest subdivisions of the bronchial tree, which are both acartilagenous and aglandular.","type":"DEFINITION","source":"NCI"},{"definition":"The smallest subdivisions of the bronchial tree, which are both acartilagenous and aglandular.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bronchiole","termGroup":"PT","termSource":"NCI"},{"termName":"Bronchioles","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchiolus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bronchiole"},{"name":"Maps_To","value":"Bronchiole"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006270"},{"name":"xRef","value":"UBERON:0002186"}]}}{"C32575":{"preferredName":"Eyebrow","code":"C32575","definitions":[{"definition":"The arched strip of hair on the bony ridge above each eye socket.","type":"DEFINITION","source":"NCI"},{"definition":"The arched strip of hairs (supercilia) on the brow ridge (supercilium) above each eye socket.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Eyebrow","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eyebrow"},{"name":"Maps_To","value":"Brow"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0015420"}]}}{"C89806":{"preferredName":"Buttock","code":"C89806","definitions":[{"definition":"A zone of soft tissue located on the posterior of the lateral side of the pelvic region corresponding to the gluteal muscles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Either of the fleshy mounds in the rear pelvic area of the human body formed by the gluteal muscles.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of the fleshy mounds in the rear pelvic area of the human body formed by the gluteal muscles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buttock","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Buttock"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0006497"},{"name":"xRef","value":"UBERON:0013691"}]}}{"C93027":{"preferredName":"Calf","code":"C93027","definitions":[{"definition":"The posterior aspect of the lower extremity that extends from the knee to the foot.","type":"DEFINITION","source":"NCI"},{"definition":"The posterior aspect of the lower extremity that extends from the knee to the foot. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Calf","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Calf"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0230445"}]}}{"C12685":{"preferredName":"Capillary","code":"C12685","definitions":[{"definition":"A tiny vessel that can be either a blood capillary or a lymphatic capillary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capillary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Capillary"},{"name":"Maps_To","value":"Capillary"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0935624"}]}}{"C25264":{"preferredName":"Carina","code":"C25264","definitions":[{"definition":"A cartilaginous ridge within the trachea that runs anteroposteriorly between the two primary bronchi at the site of the tracheal bifurcation at the lower end of the trachea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A ridge at the base of the trachea (windpipe) that separates the openings of the right and left main bronchi (the large air passages that lead from the trachea to the lungs)","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A ridge at the bifurcation of the trachea where the primary bronchi meet.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A ridge or ridge-like structure.  In humans it usually refers to the trachea.  The carina of trachea is part of the lowest tracheal cartilage which is placed between the orifices of the two bronchi.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Carina"},{"name":"Maps_To","value":"Carina"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225594"},{"name":"xRef","value":"UBERON:0006679"}]}}{"C12687":{"preferredName":"Common Carotid Artery","code":"C12687","definitions":[{"definition":"A major artery that carries blood from the heart to the head. There is a carotid artery on each side of the neck, and each one splits into two branches. The interior branch carries blood to the brain and eyes, and the exterior branch carries blood to the face, tongue, and outside parts of the head.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An artery of the mediastinum and neck; in general it arises as a primary or secondary branch of the aortic arch and branches into the internal and external carotid arteries.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of two arteries that supply oxygenated blood to the head and neck; the left common carotid branches from the aorta and the right common carotid from the innominate (brachiocephalic artery).","type":"DEFINITION","source":"NCI"},{"definition":"The artery of the neck that arises from the aortic arch and terminates in the external and internal carotid arteries whose pulse can be palpated just medial to the sternocleidomastoid muscle.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Common Carotid Artery","termGroup":"PT","termSource":"NCI"},{"termName":"Carotid Artery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Carotid_Artery"},{"name":"Legacy Concept Name","value":"Common_Carotid_Artery"},{"name":"Maps_To","value":"Carotid Artery"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007272"}]}}{"C12373":{"preferredName":"Cartilage","code":"C12373","definitions":[{"definition":"A tough, flexible tissue that lines joints and gives structure to the nose, ears, larynx, and other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of connective tissue composed of chondrocytes and an extracellular matrix composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cartilage","termGroup":"PT","termSource":"NCI"},{"termName":"Cartilagenous","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cartilage"},{"name":"Maps_To","value":"Cartilage"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0007301"}]}}{"C16403":{"preferredName":"Cell Line","code":"C16403","definitions":[{"definition":"A defined cell population established from serial passage of cells in culture.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"An established cell culture that has the potential to propagate indefinitely. [Source: <http://www.solvobiotech.com/support/glossary?/Literature/glossary.html>]  EXAMPLE(S): human HeLa cells, mouse fibroblast 3T3 cells  OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"Cells of a single type (human, animal, or plant) that have been adapted to grow continuously in the laboratory and are used in research.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cell Line","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Cell_Line"},{"name":"Maps_To","value":"Cell-Line"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0007600"}]}}{"C69313":{"preferredName":"Cervical Spine","code":"C69313","definitions":[{"definition":"The set of vertebrae immediately caudal to the skull.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The set of vertebrae immediately caudal to the skull.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Spine","termGroup":"PT","termSource":"NCI"},{"termName":"C Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Cervical_Spine"},{"name":"Maps_To","value":"Cervical Spine"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0728985"}]}}{"C25389":{"preferredName":"Chest","code":"C25389","definitions":[{"definition":"The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction.","type":"DEFINITION","source":"NCI"},{"definition":"The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Chest","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Chest"},{"name":"Maps_To","value":"Chest"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C1527391"}]}}{"C62484":{"preferredName":"Chest Wall","code":"C62484","definitions":[{"definition":"Subdivision of thorax which includes all structures from the skin to the costal pleura. Examples: There is only one chest wall.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The muscles, bones, and joints that make up the area of the body between the neck and the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.","type":"DEFINITION","source":"NCI"},{"definition":"The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Chest Wall","termGroup":"PT","termSource":"NCI"},{"termName":"Thoracic Wall","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Chest_Wall"},{"name":"Maps_To","value":"Chest wall"},{"name":"Maps_To","value":"Chest Wall"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0205076"},{"name":"xRef","value":"UBERON:0016435"}]}}{"C81169":{"preferredName":"Mentum","code":"C81169","definitions":[{"definition":"A subdivision of the face that is the anteriormost part of the lower jaw region.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the face below the lower lip and including the protruding part of the lower jaw.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the face below the lower lip and including the protruding part of the lower jaw.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mentum","termGroup":"PT","termSource":"NCI"},{"termName":"Chin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mentum"},{"name":"Maps_To","value":"Chin"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008114"},{"name":"xRef","value":"UBERON:0008199"}]}}{"C12695":{"preferredName":"Clavicle","code":"C12695","definitions":[{"definition":"One of a pair of bones at the base of the front of the neck. The clavicles connect the breastbone to the shoulder blades.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of a pair of bones linking the scapula and the sternum. The clavicle is part of the pectoral girdle.","type":"DEFINITION","source":"NCI"},{"definition":"The paired bone that is situated between the sternum and the shoulder.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Clavicle","termGroup":"PT","termSource":"NCI"},{"termName":"Collar Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Clavicle"},{"name":"Maps_To","value":"Clavicle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008913"},{"name":"xRef","value":"UBERON:0001105"}]}}{"C164003":{"preferredName":"Colonic Mucosa","code":"C164003","definitions":[{"definition":"Mucosa that is part of a colon. The mucosa of the colon is lined by a simple columnar epithelium with a thin brush border and numerous goblet cells.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The mucosal membranes that line the inner surface of the colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The mucus membrane lining the inner surface of the colon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colonic Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Colon - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227349"},{"name":"xRef","value":"UBERON:0000317"}]}}{"C12698":{"preferredName":"Common Bile Duct","code":"C12698","definitions":[{"definition":"A duct that conveys bile from the convergence of the cystic and hepatic duct to the duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tube that carries bile from the liver and the gallbladder through the pancreas and into the duodenum (the upper part of the small intestine). It is formed where the ducts from the liver and gallbladder are joined. It is part of the biliary duct system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Bile ducts are passageways that carry bile. Two major bile ducts come together into a \"trunk\"-the common bile duct which empties into the upper part of the small intestine (the part next to the stomach).","type":"DEFINITION","source":"NCI"},{"definition":"The part of the biliary tree formed by the union of the cystic duct and the common hepatic duct.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Common Bile Duct","termGroup":"PT","termSource":"NCI"},{"termName":"Ductus Communis Choledochus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Common_Bile_Duct"},{"name":"Maps_To","value":"Common Duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009437"},{"name":"xRef","value":"UBERON:0001174"}]}}{"C25478":{"preferredName":"Dermal","code":"C25478","definitions":[{"definition":"Of or relating to or located in the dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Of or relating to or located in the dermis. When used in the context of clinical observations, dermal may also include findings related to other components of the skin.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Dermal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dermal"},{"name":"Maps_To","value":"Dermal"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0221928"}]}}{"C12702":{"preferredName":"Diaphragm","code":"C12702","definitions":[{"definition":"A musculotendinous sheet separating the thoracic cavity from the abdominal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thin musculomembranous barrier that separates the abdominal and thoracic cavities. Often used for breathing control.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Fibromuscular tissue that separates the thoracic from the abdominal cavity. It increases the volume of the thoracic cavity through contractions, thus facilitating respiration.","type":"DEFINITION","source":"NCI"},{"definition":"The thin muscle below the lungs and heart that separates the chest from the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diaphragm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Diaphragm"},{"name":"Maps_To","value":"Diaphragm"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0011980"},{"name":"xRef","value":"UBERON:0001103"}]}}{"C12394":{"preferredName":"Ear","code":"C12394","definitions":[{"definition":"A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance.","type":"DEFINITION","source":"NCI"},{"definition":"A sensory organ that contains auditory and vestibular apparatuses.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Ear","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ear"},{"name":"Maps_To","value":"Ear"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013443"},{"name":"xRef","value":"IMDRF:E09"},{"name":"xRef","value":"UBERON:0001690"}]}}{"C3003":{"preferredName":"Effusion","code":"C3003","definitions":[{"definition":"A collection of fluid in a body cavity, which may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A collection of fluid in a body cavity, which may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung).","type":"DEFINITION","source":"NCI"},{"definition":"Abnormal collection of fluid in a body cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An abnormal collection of fluid in hollow spaces or between tissues of the body. For example, a pleural effusion is a collection of fluid between the two layers of membrane covering the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Effusion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Effusion"},{"name":"Maps_To","value":"Effusion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0013687"}]}}{"C32497":{"preferredName":"Elbow Joint","code":"C32497","definitions":[{"definition":"A joint involving the humerus, radius and ulna bones.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of hinge joint located between the forearm and upper arm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elbow Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Elbow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Elbow_Joint"},{"name":"Maps_To","value":"Elbow"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013770"},{"name":"xRef","value":"UBERON:0001461"}]}}{"C41449":{"preferredName":"Epidural Spinal Canal Space","code":"C41449","definitions":[{"definition":"Having to do with the space between the wall of the spinal canal and the covering of the spinal cord. An epidural injection is given into this space.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Space between the dura mater and the walls of the vertebral canal.","type":"DEFINITION","source":"NCI"},{"definition":"The body space between the dura mater and the walls of the vertebral canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The outermost part of the spinal canal. It is the space within the canal (formed by the surrounding vertebrae) lying outside the dura mater.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Epidural Spinal Canal Space","termGroup":"PT","termSource":"NCI"},{"termName":"Epidural Space","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Epidural_Spinal_Canal_Space"},{"name":"Maps_To","value":"Epidural Space"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0014537"},{"name":"xRef","value":"UBERON:0003691"}]}}{"C32668":{"preferredName":"Gastroesophageal Junction","code":"C32668","definitions":[{"definition":"The anatomical location where the esophagus joins to the stomach.","type":"DEFINITION","source":"NCI"},{"definition":"The anatomical location where the esophagus joins to the stomach. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The junction between the esophagus and the stomach epithelium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The place where the esophagus is connected to the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastroesophageal Junction","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gastroesophageal_Junction"},{"name":"Maps_To","value":"Esophagogastric Junction"},{"name":"Maps_To","value":"Gastroesophageal Junction"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0014871"},{"name":"xRef","value":"UBERON:0007650"}]}}{"C32538":{"preferredName":"Esophageal Mucosa","code":"C32538","definitions":[{"definition":"A mucosa that is part of a esophagus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lining of the esophagus. It is composed of non-keratinized stratified squamous epithelium, lamina propria, and muscularis mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes that line the inner surface of the esophagus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Esophageal Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Esophageal_Mucosa"},{"name":"Maps_To","value":"Esophagus - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227176"},{"name":"xRef","value":"UBERON:0002469"}]}}{"C12715":{"preferredName":"Femoral Artery","code":"C12715","definitions":[{"definition":"An artery of the thigh; in general it arises from the external iliac artery distal to the inguinal ligment and continues as the popliteal artery.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An artery that starts within the inguinal region and extends to the lower extremities.","type":"DEFINITION","source":"NCI"},{"definition":"The artery of the groin that supplies the lower extremity, including the anterior and anteromedial surfaces of the thigh, whose pulse is palpable below the inguinal ligament, midway between the anterior superior iliac spine and the symphysis pubis.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"The femoral artery is a large artery in the muscles of the thigh. It is a continuation of external iliac artery where it enters the femoral triangle at the mid inguinal point behind the inguinal ligament. It leaves femoral triangle through apex beneath the sartorius muscle. It enters the popliteal fossa by passing through the 5th osseo-aponeurotic (adductor hiatus) opening of adductor magnus where it becomes the Popliteal Artery.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Femoral Artery","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Femoral_Artery"},{"name":"Maps_To","value":"Femoral Artery"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015801"},{"name":"xRef","value":"UBERON:0002060"}]}}{"C12716":{"preferredName":"Femoral Vein","code":"C12716","definitions":[{"definition":"A vein of the thigh; in general it arises from the popliteal vein and drains into the external iliac vein.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A vein that starts within the inguinal region and extends to the lower extremities.","type":"DEFINITION","source":"NCI"},{"definition":"In the human body, the femoral vein is a blood vessel that accompanies the femoral artery in the femoral sheath. It begins at the adductor canal (also known as Hunter's canal) and is a continuation of the popliteal vein. It ends at the inferior margin of the inguinal ligament, where it becomes the external iliac vein.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Femoral Vein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Femoral_Vein"},{"name":"Maps_To","value":"Femoral Vein"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015809"},{"name":"xRef","value":"UBERON:0001361"}]}}{"C12717":{"preferredName":"Femur","code":"C12717","definitions":[{"definition":"Endochondral long bone connecting the pelvic girdle with posterior zeugopodium skeleton.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bone positioned between the pelvis and the femorotibial joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper leg bone positioned between the pelvis and the knee.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Femur","termGroup":"PT","termSource":"NCI"},{"termName":"Femoral","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Femur"},{"name":"Maps_To","value":"Femur"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015811"},{"name":"xRef","value":"UBERON:0000981"}]}}{"C12482":{"preferredName":"Fibroblast","code":"C12482","definitions":[{"definition":"A connective tissue cell that makes and secretes collagen proteins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A connective tissue cell that secretes collagen, a component of the extracellular matrix.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fibroblast","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblasts","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fibroblast"},{"name":"Maps_To","value":"Fibroblasts"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0016030"}]}}{"C12718":{"preferredName":"Fibula","code":"C12718","definitions":[{"definition":"The long bone that is lateral to the tibia.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The major postaxial endochondral bone in the posterior zeugopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The small, lateral calf bone extending from the knee to the ankle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibula","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Fibula"},{"name":"Maps_To","value":"Fibula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016068"},{"name":"xRef","value":"UBERON:0001446"}]}}{"C32608":{"preferredName":"Finger","code":"C32608","definitions":[{"definition":"A digit that is part of a manus (hand).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Any of the digits of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the digits of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Finger","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Finger"},{"name":"Maps_To","value":"Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0016129"},{"name":"xRef","value":"UBERON:0002389"}]}}{"C25278":{"preferredName":"Fluid","code":"C25278","definitions":[{"definition":"A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that flows smoothly and takes the shape of its container. Liquids and gases are fluids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fluid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fluid"},{"name":"Maps_To","value":"Fluid"},{"name":"Semantic_Type","value":"Substance"},{"name":"UMLS_CUI","value":"C1704353"}]}}{"C32622":{"preferredName":"Foot","code":"C32622","definitions":[{"definition":"Distal portion of the hind limb, including tarsal region, metatarsal region and digits.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The entire structure distal to the ankle joint/tarsus, which includes the metatarsus and digit(s).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The structure found below the ankle joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foot","termGroup":"PT","termSource":"NCI"},{"termName":"Pedal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Foot"},{"name":"Maps_To","value":"Foot"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0016504"},{"name":"xRef","value":"UBERON:0002387"}]}}{"C32628":{"preferredName":"Forearm","code":"C32628","definitions":[{"definition":"The structure on the upper limb, between the elbow and the wrist.","type":"DEFINITION","source":"NCI"},{"definition":"The structure on the upper limb, between the elbow and the wrist. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Forearm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Forearm"},{"name":"Maps_To","value":"Forearm"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0016536"}]}}{"C89803":{"preferredName":"Forehead","code":"C89803","definitions":[{"definition":"In human anatomy, the forehead is the fore part of the head. It is, formally, an area of the head bounded by three features, two of the skull and one of the scalp. The top of the forehead is marked by the hairline, the edge of the area where hair on the scalp grows. The bottom of the forehead is marked by the supraorbital ridge, the bone feature of the skull above the eyes. The two sides of the forehead are marked by the temporal ridge, a bone feature that links the supraorbital ridge to the coronal suture line and beyond.","type":"ALT_DEFINITION","source":"NCI"},{"definition":"The part of the face between the eyebrows and the normal hairline.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the face between the eyebrows and the normal hairline.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Forehead","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Forehead"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016540"},{"name":"xRef","value":"UBERON:0008200"}]}}{"C33049":{"preferredName":"Male Prepuce","code":"C33049","definitions":[{"definition":"A fold of skin covering the tip of the penis.","type":"DEFINITION","source":"NCI"},{"definition":"A fold of skin covering the tip of the penis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A retractable double-layered fold of skin and mucous membrane that covers the glans penis and protects the urinary meatus when the penis is not erect.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The loose skin that covers the head of the penis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Male Prepuce","termGroup":"PT","termSource":"NCI"},{"termName":"Foreskin","termGroup":"SY","termSource":"NCI"},{"termName":"Preputium Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Male_Prepuce"},{"name":"Maps_To","value":"Foreskin"},{"name":"Maps_To","value":"Prepuce"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227952"},{"name":"xRef","value":"UBERON:0001332"}]}}{"C177766":{"preferredName":"Frontal Lobe Cortex","code":"C177766","definitions":[{"definition":"Anterior portion of the neocortex, lying anterior to the central sulcus in humans. It is bounded by the parietal cortex posteriorly and the temporal cortex laterally.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The grey matter, or outermost layer of the frontal lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Frontal Lobe Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Frontal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Frontal Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228196"},{"name":"xRef","value":"UBERON:0001870"}]}}{"C12719":{"preferredName":"Ganglion","code":"C12719","definitions":[{"definition":"A biological tissue mass, most commonly a mass of nerve cell bodies.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS).","type":"DEFINITION","source":"NCI"},{"definition":"A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"is a macroscopic organ component of one or more nerves, which primarily consists of cell bodies of neurons located outside the central nervous system; together with nerve fibers, it constitutes a nerve or a nerve plexus. Example(s): spinal ganglion, trigeminal ganglion, superior cervical ganglion, celiac ganglion, inferior hypogastric (pelvic) ganglion.","type":"ALT_DEFINITION","source":"UWDA142"}],"synonyms":[{"termName":"Ganglion","termGroup":"PT","termSource":"NCI"},{"termName":"Ganglia","termGroup":"SY","termSource":"NCI"},{"termName":"Ganglionic","termGroup":"AD","termSource":"NCI"},{"termName":"Neural Ganglion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ganglion"},{"name":"Maps_To","value":"Ganglia"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017067"},{"name":"xRef","value":"UBERON:0000045"}]}}{"C32712":{"preferredName":"Hand","code":"C32712","definitions":[{"definition":"Distal segment of the fore limb, including carpal region, metacarpal region and digits.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits.","type":"DEFINITION","source":"NCI"},{"definition":"The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand"},{"name":"Maps_To","value":"Hand"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0018563"},{"name":"xRef","value":"UBERON:0002398"}]}}{"C12418":{"preferredName":"Head and Neck","code":"C12418","definitions":[{"definition":"For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.","type":"DEFINITION","source":"NCI"},{"definition":"The area of the body comprising the skull, facial bones and the cervical vertebrae, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature, soft tissue and lymph nodes draining these areas.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Head and Neck","termGroup":"PT","termSource":"NCI"},{"termName":"H and N","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Head_and_Neck"},{"name":"Maps_To","value":"Head & Neck"},{"name":"Maps_To","value":"Head and Neck"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0460004"},{"name":"xRef","value":"UBERON:0000033"},{"name":"xRef","value":"UBERON:0000974"}]}}{"C13308":{"preferredName":"Hepatic","code":"C13308","definitions":[{"definition":"Pertaining to, affecting, or associated with the liver.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hepatic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatic"},{"name":"Maps_To","value":"Hepatic"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205054"}]}}{"C32730":{"preferredName":"Hepatic Duct","code":"C32730","definitions":[{"definition":"Any of the three ducts associated with the liver including the right hepatic duct, left hepatic duct and common hepatic duct.","type":"DEFINITION","source":"NCI"},{"definition":"Any portion of the ducts that carry bile from the liver to the common bile duct. This may include both intrahepatic components (parts of left and right hepatic ducts) and extrahepatic components (common hepatic duct, plus hilar portion).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Hepatic Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hepatic_Duct"},{"name":"Maps_To","value":"Hepatic Duct"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0917710"},{"name":"xRef","value":"UBERON:0005171"}]}}{"C32736":{"preferredName":"Hepatic Vein","code":"C32736","definitions":[{"definition":"The blood vessels that drain blood from the central veins of the liver into the inferior vena cava.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The blood vessels that drain blood from the central veins of the liver into the inferior vena cava.","type":"DEFINITION","source":"NCI"},{"definition":"Vein that carries blood away from the liver.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Hepatic Vein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hepatic_Vein"},{"name":"Maps_To","value":"Hepatic Vein"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0019155"},{"name":"xRef","value":"UBERON:0001143"}]}}{"C64193":{"preferredName":"Hip","code":"C64193","definitions":[{"definition":"The hip region is located lateral to the gluteal region (i.e. the buttock), inferior to the iliac crest, and overlying the greater trochanter of the thigh bone. In adults, three of the bones of the pelvis have fused into the hip bone which forms part of the hip region. The hip joint, scientifically referred to as the acetabulofemoral joint (art. coxae), is the joint between the femur and acetabulum of the pelvis and its primary function is to support the weight of the body in both static (e.g. standing) and dynamic (e.g. walking or running) postures.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lateral prominence of the pelvis from the waist to the thigh.","type":"DEFINITION","source":"NCI"},{"definition":"The lateral prominence of the pelvis from the waist to the thigh. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hip"},{"name":"Maps_To","value":"Hip"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0019552"},{"name":"xRef","value":"UBERON:0001464"}]}}{"C12444":{"preferredName":"Hippocampus","code":"C12444","definitions":[{"definition":"A curved gray matter structure of the cerebrum that is part of the limbic system.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A curved gray matter structure of the temporal lobe lying on the floor of the lateral ventricle of the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hippocampus","termGroup":"PT","termSource":"NCI"},{"termName":"Hippocampal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Hippocampus"},{"name":"Maps_To","value":"Hippocampus"},{"name":"NCI_META_CUI","value":"CL554606"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"}]}}{"C12731":{"preferredName":"Humerus","code":"C12731","definitions":[{"definition":"Paired endochondral long bone that extends between the pectoral girdle and the skeletal parts of the forelimb.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bone between the scapulohumeral and humeroulnar joints.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper arm bone between the shoulder and elbow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Humerus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Humerus"},{"name":"Maps_To","value":"Humerus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020164"},{"name":"xRef","value":"UBERON:0000976"}]}}{"C32765":{"preferredName":"Ilium","code":"C32765","definitions":[{"definition":"Paired endochondral bone that is the dorsal-most of the pelvic bones, offering attachment areas for gluteal muscles on its main surface.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The broad, dorsal, upper, and widest of the three principal bones composing either half of the pelvis.","type":"DEFINITION","source":"NCI"},{"definition":"The broad, dorsal, upper, and widest of the three principal bones composing either half of the pelvis. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ilium","termGroup":"PT","termSource":"NCI"},{"termName":"Iliac","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ilium"},{"name":"Maps_To","value":"Ilium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020889"},{"name":"xRef","value":"UBERON:0001273"}]}}{"C52835":{"preferredName":"Hand Digit 2","code":"C52835","definitions":[{"definition":"2nd digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The second finger from the radial side of the hand, next to the thumb.","type":"DEFINITION","source":"NCI"},{"definition":"The second finger from the radial side of the hand, next to the thumb. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 2","termGroup":"PT","termSource":"NCI"},{"termName":"Index Finger","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_2"},{"name":"Maps_To","value":"Index Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230388"},{"name":"xRef","value":"UBERON:0003622"}]}}{"C32884":{"preferredName":"Ischium","code":"C32884","definitions":[{"definition":"Endochondral bone that is paired, forming the posterior part of the pelvis, articulating with the pubis and ilium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The most posterior and ventral bone making up the pelvis.","type":"DEFINITION","source":"NCI"},{"definition":"The most posterior and ventral bone making up the pelvis. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ischium","termGroup":"PT","termSource":"NCI"},{"termName":"Hip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ischium"},{"name":"Maps_To","value":"Ischium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022122"},{"name":"xRef","value":"UBERON:0001274"}]}}{"C32885":{"preferredName":"Islet Cell","code":"C32885","definitions":[{"definition":"A pancreatic cell that produces and secretes hormones such as insulin and glucagon.","type":"DEFINITION","source":"NCI"},{"definition":"A pancreatic cell that produces hormones (e.g., insulin and glucagon) that are secreted into the bloodstream. These hormones help control the level of glucose (sugar) in the blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Islet Cell","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Islet_Cell"},{"name":"Maps_To","value":"Islet Cells"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C1522529"}]}}{"C48821":{"preferredName":"Jaw Bone","code":"C48821","definitions":[{"definition":"Subdivision of skeleton which includes upper and lower jaw skeletons.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bones of the skull that frame the mouth and serve to open it; the bones that hold the teeth.","type":"DEFINITION","source":"NCI"},{"definition":"The structures of the skull that frame the mouth.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jaw Bone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Jaw"},{"name":"Maps_To","value":"Jaw"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0022359"},{"name":"xRef","value":"UBERON:0001708"}]}}{"C13044":{"preferredName":"Joint","code":"C13044","definitions":[{"definition":"Anatomical cluster that consists of two or more adjacent skeletal structures, which may be interconnected by various types of tissue.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"In medicine, the place where two or more bones are connected. Examples include the shoulder, elbow, knee, and jaw.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The connection point between two bones or skeletal elements. The joint may be fixed or movable.","type":"DEFINITION","source":"NCI"},{"definition":"The connection point between two bones or skeletal elements. The joint may be fixed or movable. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"is an organ that constitutes an anatomical junction; it consists of two or more adjacent bones, parts of which are interconnected by organ parts that consist of various types of connective tissue. Together with other joints and bones, a joint constitutes the skeletal system. Example(s): pubic symphysis, knee joint, temporomandibular joint.","type":"ALT_DEFINITION","source":"UWDA142"}],"synonyms":[{"termName":"Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Articular","termGroup":"AD","termSource":"NCI"},{"termName":"Articulation","termGroup":"SY","termSource":"NCI"},{"termName":"Joints","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Joint"},{"name":"Maps_To","value":"Joint"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0022417"},{"name":"xRef","value":"UBERON:0000982"}]}}{"C32898":{"preferredName":"Knee Joint","code":"C32898","definitions":[{"definition":"A joint connecting the lower part of the femur with the upper part of the tibia. The lower part of the femur and the upper part of the tibia are attached to each other by ligaments. Other structures of the knee joint include the upper part of the fibula, located below and parallel to the tibia, and the patella which moves as the knee bends.","type":"DEFINITION","source":"NCI"},{"definition":"A segment of the hindlimb that corresponds to the joint connecting a hindlimb stylopod and zeugopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The joint connecting the lower part of the femur with the upper part of the tibia.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Knee Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Knee","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Knee_Joint"},{"name":"Maps_To","value":"Knee"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022745"},{"name":"xRef","value":"UBERON:0001465"}]}}{"C12379":{"preferredName":"Large Intestine","code":"C12379","definitions":[{"definition":"A muscular tube that extends from the end of the small intestine to the anus.","type":"DEFINITION","source":"NCI"},{"definition":"A subdivision of the digestive tract that connects the small intestine to the cloaca or anus. Lacks or has few villi.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The avillous section of the intestine composed of crypts and extending from the terminal small intestine to the external orifice.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The long, tube-like organ that is connected to the small intestine at one end and the anus at the other. The large intestine has four parts: cecum, colon, rectum, and anal canal. Partly digested food moves through the cecum into the colon, where water and some nutrients and electrolytes are removed. The remaining material, solid waste called stool, moves through the colon, is stored in the rectum, and leaves the body through the anal canal and anus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Large Intestine","termGroup":"PT","termSource":"NCI"},{"termName":"Large Bowel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Large_Intestine"},{"name":"Maps_To","value":"Large Bowel"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0021851"},{"name":"xRef","value":"UBERON:0000059"}]}}{"C32974":{"preferredName":"Leg","code":"C32974","definitions":[{"definition":"The portion of the hindlimb that contains both the stylopod and zeugopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the lower extremity between the knee and the ankle.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the lower extremity between the knee and the ankle. For clinical purposes this term is also used to refer to the whole inferior limb.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leg","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Leg"},{"name":"Maps_To","value":"Leg"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1140621"},{"name":"xRef","value":"UBERON:0000978"}]}}{"C32979":{"preferredName":"Leptomeninges","code":"C32979","definitions":[{"definition":"Having to do with the two innermost meninges (thin layers of tissue that cover and protect the brain and spinal cord).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Pia mater or arachnoid mater.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater.","type":"DEFINITION","source":"NCI"},{"definition":"The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Leptomeninges","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Leptomeninges"},{"name":"Maps_To","value":"Leptomeninges"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0228126"},{"name":"xRef","value":"UBERON:0000391"}]}}{"C13046":{"preferredName":"Ligament","code":"C13046","definitions":[{"definition":"Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint.","type":"DEFINITION","source":"NCI"},{"definition":"Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Dense regular connective tissue connecting two or more adjacent skeletal elements or supporting an organ.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Ligament","termGroup":"PT","termSource":"NCI"},{"termName":"Ligaments","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ligament"},{"name":"Maps_To","value":"Ligament"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0023685"},{"name":"xRef","value":"UBERON:0000211"}]}}{"C69314":{"preferredName":"Lumbar Spine","code":"C69314","definitions":[{"definition":"The vertebrae located below the thoracic and above the sacral vertebrae.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Those vertebrae between the ribs and the pelvis, L1-L5 in man.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lumbar Spine","termGroup":"PT","termSource":"NCI"},{"termName":"L Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lumbar_Spine"},{"name":"Maps_To","value":"Lumbar Spine"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C3887615"}]}}{"C106042":{"preferredName":"Distant Lymph Node","code":"C106042","definitions":[{"definition":"A lymph node located distant to the anatomic site of interest.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) that is distant to the anatomic region of interest.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Distant Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Nodes"},{"name":"Maps_To","value":"Lymph Node(s) Distant"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3830456"}]}}{"C32853":{"preferredName":"Internal Mammary Lymph Node","code":"C32853","definitions":[{"definition":"Any of the lymph nodes of the breast located under the ribcage, near the sternum.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the lymph nodes of the breast located under the ribcage, near the sternum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Lymph node(s) in or adjacent to the mammary gland.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Internal Mammary Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Internal_Mammary_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Internal Mammary"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0444440"},{"name":"xRef","value":"UBERON:0035219"}]}}{"C137678":{"preferredName":"Intramammary Lymph Node","code":"C137678","definitions":[{"definition":"Any of the lymph nodes located within the breast parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramammary Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Intramammary Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node(s) Mammary"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2732830"}]}}{"C89780":{"preferredName":"Scalene Lymph Node","code":"C89780","definitions":[{"definition":"A lymph node located in proximity to any of the scalene muscles.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A lymph node located in proximity to any of the scalene muscles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scalene Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node(s) Scalene"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229744"}]}}{"C63705":{"preferredName":"Infraclavicular Lymph Node","code":"C63705","definitions":[{"definition":"A lymph node located in the area below the clavicle.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the area below the clavicle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located in the area below the clavicle. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Infraclavicular Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Deltopectoral Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Deltopectoral Node","termGroup":"SY","termSource":"NCI"},{"termName":"Infraclavicular Node","termGroup":"SY","termSource":"NCI"},{"termName":"Subclavicular Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Subclavicular Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Infraclavicular_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Subclavicular"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229743"},{"name":"xRef","value":"UBERON:0035162"}]}}{"C26470":{"preferredName":"Maxilla","code":"C26470","definitions":[{"definition":"The bone which normally forms the lateral upper jaw in osteichthyans, including tetrapods.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper jaw bone holding the upper teeth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper jawbone in vertebrates; it is fused to the cranium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maxilla","termGroup":"PT","termSource":"NCI"},{"termName":"Maxillary","termGroup":"AD","termSource":"NCI"},{"termName":"Upper Jaw","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Maxilla"},{"name":"Maps_To","value":"Maxilla"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024947"},{"name":"xRef","value":"UBERON:0002397"}]}}{"C164004":{"preferredName":"Mediastinal Soft Tissue","code":"C164004","definitions":[{"definition":"Any non-hardened or non-calcified tissue found in the mediastinum.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue of the mediastinum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mediastinal Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mediastinal Soft Tissue"},{"name":"Maps_To","value":"Mediastinal soft tissue"},{"name":"NCI_META_CUI","value":"CL977224"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C33103":{"preferredName":"Mesentery","code":"C33103","definitions":[{"definition":"A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines.","type":"DEFINITION","source":"NCI"},{"definition":"A double layer of peritoneum that attaches to the wall of the abdominal cavity and supports the small intestines.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Anatomical organ component composed of a double layer of serous membrane that suspends a viscus from the body wall or connects adjacent viscera and in doing so conveys blood vessels, lymphatics and nerves to and from the viscera. Examples: greater omentum, broad ligament of uterus, sigmoid mesocolon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The peritoneal membrane that attaches the intestines to the abdominal wall near the back.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mesentery","termGroup":"PT","termSource":"NCI"},{"termName":"Mesenteric Membrane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mesentery"},{"name":"Maps_To","value":"Mesentery"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0025474"},{"name":"xRef","value":"UBERON:0002095"}]}}{"C33105":{"preferredName":"Mesothelium","code":"C33105","definitions":[{"definition":"A simple layer of cells, derived from the mesoderm that lines the coelom or body cavity of the embryo. In the adult, it covers all true serous membranes (peritoneum, pericardium, pleura).","type":"DEFINITION","source":"NCI"},{"definition":"A simple layer of cells, derived from the mesoderm, that covers the serous membranes including the peritoneum, pericardium, and pleura.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Simple squamous epithelium of mesodermal origin which lines serous membranes. Examples: mesothelium of pleura, mesothelium of peritoneum[FMA]. Wikipedia: The mesothelium is a membrane that forms the lining of several body cavities: the pleura (thoracal cavity), peritoneum (abdominal cavity including the mesentery) and pericardium (heart sac). Mesothelial tissue also surrounds the male internal reproductive organs (the tunica vaginalis testis) and covers the internal reproductive organs of women (the tunica serosa uteri).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Mesothelium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mesothelium"},{"name":"Maps_To","value":"Mesothelium"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0086610"},{"name":"xRef","value":"UBERON:0001136"}]}}{"C52836":{"preferredName":"Hand Digit 3","code":"C52836","definitions":[{"definition":"The middle or third finger from the radial side of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"The middle or third finger from the radial side of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 3","termGroup":"PT","termSource":"NCI"},{"termName":"Middle Finger","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hand_Digit_3"},{"name":"Maps_To","value":"Middle Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230393"}]}}{"C13258":{"preferredName":"Mitochondrion","code":"C13258","definitions":[{"definition":"Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Mitochondria contain distinctive ribosomes, transfer RNAs, amino acyl t-RNA synthetases, and elongation and termination factors. Mitochondria depend upon genes within the nucleus for many essential messenger RNAs. Mitochondria consist of two sets of membranes, a smooth continuous outer coat and an inner membrane arranged in tubules or more often in folds that form platelike double membranes (cristae). Mitochondria are the principal energy source of the cell and contains the cytochrome enzymes of terminal electron transport and the enzymes of the citric acid cycle, fatty acid oxidation, and oxidative phosphorylation. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP.","type":"DEFINITION","source":"NCI"},{"definition":"Small structures in a cell that are found in the cytoplasm (fluid that surrounds the cell nucleus). Mitochondria make most of the energy for the cell and have their own genetic material that is different from the genetic material found in the nucleus. Many diseases are caused by mutations (changes) in the DNA of mitochondria. Mitochondria are cell organelles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mitochondrion","termGroup":"PT","termSource":"NCI"},{"termName":"Mitochondria","termGroup":"SY","termSource":"NCI"},{"termName":"Mitochondrial","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mitochondrion"},{"name":"Maps_To","value":"Mitochondria"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0026237"}]}}{"C13056":{"preferredName":"Muscle","code":"C13056","definitions":[{"definition":"A fibrous soft tissue with the ability to contract to produce force and motion.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the contractile organs of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Muscle","termGroup":"PT","termSource":"NCI"},{"termName":"Muscular","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Muscle"},{"name":"Maps_To","value":"Muscle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0026845"}]}}{"C33156":{"preferredName":"Nail","code":"C33156","definitions":[{"definition":"A horn-like keratin structure covering the dorsal aspect of the terminal phalanges of fingers and toes.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The cutaneous plate on the dorsal surface of the distal end of a finger or toe.","type":"DEFINITION","source":"NCI"},{"definition":"The cutaneous plate on the dorsal surface of the distal end of a finger or toe. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nail","termGroup":"PT","termSource":"NCI"},{"termName":"Nail Apparatus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Nail"},{"name":"Maps_To","value":"Nails"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0027342"},{"name":"xRef","value":"UBERON:0001705"}]}}{"C164006":{"preferredName":"Nasal Soft Tissue","code":"C164006","definitions":[{"definition":"Any non-hardened or non-calcified tissue found in the nose.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue of the nose.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nasal Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nasal Soft Tissue"},{"name":"Maps_To","value":"Nasal soft tissue"},{"name":"NCI_META_CUI","value":"CL977222"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C12466":{"preferredName":"Nerve","code":"C12466","definitions":[{"definition":"A bundle of fibers that receives and sends messages between the body and the brain. The messages are sent by chemical and electrical changes in the cells that make up the nerves.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A bundle of neuronal fibers that transmits electrochemical impulses encoding sensory and motor information from one body part to another.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Part of the peripheral nervous system composed of bundles of nerve fibers running to various organs and tissues of the body using chemical and electrical signals to transmit sensory and motor information from one body part to another.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nerve"},{"name":"Maps_To","value":"Nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0027740"}]}}{"C177767":{"preferredName":"Occipital Lobe Cortex","code":"C177767","definitions":[{"definition":"The grey matter, or outermost layer of the occipital lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occipital Lobe Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Occipital Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Occipital Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228221"},{"name":"xRef","value":"UBERON:0016540"}]}}{"C77637":{"preferredName":"Oral Mucosa","code":"C77637","definitions":[{"definition":"A mucous membrane that lines the mouth.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Moist tissue lining the oral cavity, containing mucous secreting glands.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes that line the oral cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Oral Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Oral_Mucosa"},{"name":"Maps_To","value":"Oral Cavity - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0026639"},{"name":"xRef","value":"UBERON:0003729"}]}}{"C97925":{"preferredName":"Para-Spinal Ganglion","code":"C97925","definitions":[{"definition":"A cluster of neuronal cell bodies and their dendrites located just ventral and lateral to the spinal cord that give rise to the sympathetic nervous system.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sympathetic ganglion located adjacent to the spinal column.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Para-Spinal Ganglion","termGroup":"PT","termSource":"NCI"},{"termName":"Bilaterally Symmetric Sympathetic Chain Ganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Paraspinal Ganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Paravertebral Ganglion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paraspinal Ganglion"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228973"}]}}{"C33282":{"preferredName":"Patella","code":"C33282","definitions":[{"definition":"A large sesamoid bone found in the distal femur/proximal tibial region of the hindlimb of tetrapods. The patella is the attachment site for proximal hindlimb tendons.","type":"ALT_DEFINITION","source":"NCI"},{"definition":"A small bone in front of the femorotibial joint that articulates with the femur.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A small flat triangular bone in front of the knee that articulates with the femur and protects the knee joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patella","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Patella"},{"name":"Maps_To","value":"Patella"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0030647"},{"name":"xRef","value":"UBERON:0002446"}]}}{"C13005":{"preferredName":"Pericardium","code":"C13005","definitions":[{"definition":"A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.","type":"DEFINITION","source":"NCI"},{"definition":"The combination of pericardial sac (a double-walled sac containing the heart and the roots of the great vessels) plus fibrous pericardium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The membrane surrounding the heart and roots of the vessels at the base of the heart.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pericardium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pericardium"},{"name":"Maps_To","value":"Pericardium"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0031050"},{"name":"xRef","value":"UBERON:0002407"}]}}{"C164007":{"preferredName":"Periorbital Soft Tissue","code":"C164007","definitions":[{"definition":"Any non-hardened or non-calcified tissue found in the periorbital area.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue of the peri-orbital region.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Periorbital Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peri-orbital soft tissue"},{"name":"Maps_To","value":"Periorbital Soft Tissue"},{"name":"NCI_META_CUI","value":"CL977221"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C103222":{"preferredName":"Popliteal Fossa","code":"C103222","definitions":[{"definition":"A depression on the ventral side of the femur, at the knee joint, between the condyles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A diamond-shaped depression located in the back of the knee joint bounded by the medial and lateral heads of the gastrocnemius muscle, the semimembranosus muscle, and the biceps femoris.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A diamond-shaped depression located in the back of the knee joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Popliteal Fossa","termGroup":"PT","termSource":"NCI"},{"termName":"Popliteal Fossa Structure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Popliteal Fossa"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230436"},{"name":"xRef","value":"UBERON:0013069"}]}}{"C54155":{"preferredName":"Retro-Orbital Region","code":"C54155","definitions":[{"definition":"The area behind the orbit of the eye.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The area of the body behind the orbit of the eye.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retro-Orbital Region","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retro-Orbital_Region"},{"name":"Maps_To","value":"Retro-Orbital Region"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0230065"}]}}{"C12782":{"preferredName":"Rib","code":"C12782","definitions":[{"definition":"An intersegmental rod-shaped bone that forms in the peritoneal membrane and attach to the vertebral parapophyses.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs.","type":"DEFINITION","source":"NCI"},{"definition":"Any one of the paired bones, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Rib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Rib"},{"name":"Maps_To","value":"Rib"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0035561"},{"name":"xRef","value":"UBERON:0002228"}]}}{"C52837":{"preferredName":"Hand Digit 4","code":"C52837","definitions":[{"definition":"4th digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fourth finger from the radial side of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"The fourth finger from the radial side of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 4","termGroup":"PT","termSource":"NCI"},{"termName":"Ring Finger","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_4"},{"name":"Maps_To","value":"Ring Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230398"},{"name":"xRef","value":"UBERON:0003624"}]}}{"C33508":{"preferredName":"Sacrum","code":"C33508","definitions":[{"definition":"A collection of sacral vertebrae in the sacral region that are fused and part of the bony pelvis.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The large, triangle-shaped bone in the lower spine that forms part of the pelvis. It is made of 5 fused bones of the spine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx.","type":"DEFINITION","source":"NCI"},{"definition":"The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sacrum","termGroup":"PT","termSource":"NCI"},{"termName":"Sacral","termGroup":"AD","termSource":"NCI"},{"termName":"Sacral Region","termGroup":"SY","termSource":"NCI"},{"termName":"Sacral Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sacrum"},{"name":"Maps_To","value":"Sacrum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C3669209"},{"name":"xRef","value":"UBERON:0005473"}]}}{"C12783":{"preferredName":"Scapula","code":"C12783","definitions":[{"definition":"A bone that articulates with the humerus and is part of the scapulohumeral joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Endochondral bone that is dorsoventrally compressed and provides attachment site for muscles of the pectoral appendage.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of triangular bones at the back of the shoulder. The scapula connects the collarbone with the upper arm bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The flat triangle-shaped bone that connects the humerus with the clavicle in the back of the shoulder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scapula","termGroup":"PT","termSource":"NCI"},{"termName":"Shoulder Blade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Scapula"},{"name":"Maps_To","value":"Scapula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036277"},{"name":"xRef","value":"UBERON:0006849"}]}}{"C52810":{"preferredName":"Sciatic Nerve","code":"C52810","definitions":[{"definition":"A large nerve that supplies nearly the whole of the skin of the leg, the muscles of the back of the thigh, and those of the leg and foot. It begins in the lower back and runs through the buttock and down the lower limb.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A nerve arising from the merge of the lumbar and sacral rami in the pelvis and dividing into the common peroneal and tibial nerves, and which innervates the muscles of the thigh.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The long nerve that is formed by the merging of the ventral rami of the L4, L5, and S1 in the pelvis and passes down the lower limb where it divides into the common peroneal and tibial nerves.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sciatic Nerve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sciatic_Nerve"},{"name":"Maps_To","value":"Sciatic Nerve"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0036394"},{"name":"xRef","value":"UBERON:0001322"}]}}{"C12787":{"preferredName":"Seminal Vesicle","code":"C12787","definitions":[{"definition":"A gland that helps produce semen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mammalian male reproductive accessory gland located adjacent to the urinary bladder and proximal to the prostate.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of a pair of glandular pouches that lie one on either side of the male reproductive tract posterolateral to the urinary bladder and in the human male secrete a sugar- and protein-containing fluid into the ejaculatory duct.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus deferens to form the ejaculatory duct.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seminal Vesicle","termGroup":"PT","termSource":"NCI"},{"termName":"Seminal Sacs","termGroup":"SY","termSource":"NCI"},{"termName":"Seminal Vesicles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Seminal_Vesicle"},{"name":"Maps_To","value":"Seminal Vesicle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036628"},{"name":"xRef","value":"UBERON:0000998"}]}}{"C25203":{"preferredName":"Shoulder","code":"C25203","definitions":[{"definition":"A subdivision of the pectoral complex consisting of the structures in the region of the shoulder joint (which connects the humerus, scapula and clavicle).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region of the body between the neck and the upper arm.","type":"DEFINITION","source":"NCI"},{"definition":"The region of the body between the neck and the upper arm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Shoulder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Shoulder"},{"name":"Maps_To","value":"Shoulder"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0037004"},{"name":"xRef","value":"UBERON:0001467"}]}}{"C33556":{"preferredName":"Sinus","code":"C33556","definitions":[{"definition":"A cavity, space, or channel in the body. Examples include hollow spaces in the bones at the front of the skull, and channels for blood and lymph. Sinuses may also be found in the heart, brain, and other organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recess, cavity, or channel.","type":"DEFINITION","source":"NCI"},{"definition":"A recess, cavity, or channel. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sinus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sinus"},{"name":"Maps_To","value":"Sinus"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1305231"}]}}{"C13050":{"preferredName":"Skeletal Muscle Tissue","code":"C13050","definitions":[{"definition":"Muscle tissue that consists primarily of skeletal muscle fibers.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Striated muscles that are under voluntary control of the organism.  They are connected at either or both ends to a bone and are utilized for locomotion and other movements.","type":"DEFINITION","source":"NCI"},{"definition":"Voluntary, striated muscle tissue predominantly associated with the skeleton.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Skeletal Muscle Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Skeletal Muscle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Skeletal_Muscle_Tissue"},{"name":"Maps_To","value":"Skeletal Muscle"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0242692"},{"name":"xRef","value":"UBERON:0001134"}]}}{"C12789":{"preferredName":"Skull","code":"C12789","definitions":[{"definition":"Anatomical structure that is part of the head consisting entirely of cranium and mandible.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bones that form the head, made up of the bones of the braincase and face.","type":"DEFINITION","source":"NCI"},{"definition":"The bones that form the head, made up of the bones of the braincase and face. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Skull","termGroup":"PT","termSource":"NCI"},{"termName":"Cranium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Skull"},{"name":"Maps_To","value":"Skull"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037303"},{"name":"xRef","value":"UBERON:0003128"}]}}{"C33568":{"preferredName":"Small Intestinal Mucosa","code":"C33568","definitions":[{"definition":"A mucosa that is part of a small intestine.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Mucosa arranged into two fundamental structures - villi and crypts of Lieberkuhn. Villi are projections into the lumen of the small intestine, covered with simple columnar epithelium. Crypts of Lieberkuhn are moat-like invaginations of the epithelium around the villi that extend through the lamina propria down to the muscularis mucosae. Lymphocytes often invade the epithelium or form solitary lymphoid nodules in the lamina propria. Lymph nodules may form longitudinal aggregations of 30-50 nodules in the lamina propria of the ileum. These large aggregations are called Peyer's patches. The muscularis mucosae has two layers and extends into the intestinal villi, where the smooth muscle cells form a longitudinal bundle in the centre of the villi. The small intestinal mucosa secretes gastrin, somatostatin, cholecystokinin and secretin.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes that line the inner surface of the small intestine.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Small Intestinal Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Small_Intestinal_Mucosa"},{"name":"Maps_To","value":"Small Bowel - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227261"},{"name":"xRef","value":"UBERON:0001204"}]}}{"C52838":{"preferredName":"Hand Digit 5","code":"C52838","definitions":[{"definition":"5th digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fifth and smallest finger from the radial side of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"The fifth and smallest finger from the radial side of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 5","termGroup":"PT","termSource":"NCI"},{"termName":"Little Finger","termGroup":"SY","termSource":"NCI"},{"termName":"Pinkie","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_5"},{"name":"Maps_To","value":"Small Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230403"},{"name":"xRef","value":"UBERON:0003625"}]}}{"C12793":{"preferredName":"Sternum","code":"C12793","definitions":[{"definition":"A midventral endochondral skeletal element which represents the origin site of the pectoral muscles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The long flat bone that forms the center front of the chest wall. The sternum is attached to the collarbone and the first seven ribs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The long, flat bone connecting with the cartilages of the first seven ribs and the clavicle.","type":"DEFINITION","source":"NCI"},{"definition":"The long, flat bone or sternebrae connecting with the cartilage of some ribs.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sternum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sternum"},{"name":"Maps_To","value":"Sternum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0038293"},{"name":"xRef","value":"UBERON:0000975"}]}}{"C32656":{"preferredName":"Gastric Mucosa","code":"C32656","definitions":[{"definition":"The mucosal layer that lines the stomach.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The mucosal membranes that line the inner surface of the stomach.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The mucus membrane lining the inner surface of the stomach.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastric Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gastric_Mucosa"},{"name":"Maps_To","value":"Stomach - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0017136"},{"name":"xRef","value":"UBERON:0001199"}]}}{"C33645":{"preferredName":"Subcutis","code":"C33645","definitions":[{"definition":"Adipose and connective tissue located deep to the dermis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subcutis","termGroup":"PT","termSource":"NCI"},{"termName":"Subcutaneous Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Subcutaneous Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Subcutis"},{"name":"Maps_To","value":"Subcutaneous Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0278403"}]}}{"C12473":{"preferredName":"Synovial Membrane","code":"C12473","definitions":[{"definition":"A layer of connective tissue that lines the cavities of joints, tendon sheaths, and bursae (fluid-filled sacs between tendons and bones). The synovial membrane makes synovial fluid, which has a lubricating function.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Soft tissue that lines the non-cartilaginous surfaces within joints with cavities (synovial joints).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The connective tissue and synoviocytes that line the inner surface of the joint capsule.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The inner layer of the connective tissue that seals the joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synovial Membrane","termGroup":"PT","termSource":"NCI"},{"termName":"Synovium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Synovial_Membrane"},{"name":"Maps_To","value":"Synovium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0039099"},{"name":"xRef","value":"UBERON:0002018"}]}}{"C177768":{"preferredName":"Temporal Lobe Cortex","code":"C177768","definitions":[{"definition":"Gray matter of the temporal region of the neocortex, located in the temporal lobe in gyrencephalic animals.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The grey matter, or outermost layer of the temporal lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temporal Lobe Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Temporal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Temporal Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228235"},{"name":"xRef","value":"UBERON:0016538"}]}}{"C13045":{"preferredName":"Tendon","code":"C13045","definitions":[{"definition":"A band of fibrous connective tissue that joins bone to muscle.","type":"DEFINITION","source":"NCI"},{"definition":"A band of fibrous connective tissue that joins bone to muscle. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Dense regular connective tissue that connects muscle to bone.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Tough, fibrous, cord-like tissue that connects muscle to bone or another structure, such as an eyeball. Tendons help the bone or structure to move.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tendon","termGroup":"PT","termSource":"NCI"},{"termName":"Tendons","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tendon"},{"name":"Maps_To","value":"Tendon"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0039508"},{"name":"xRef","value":"UBERON:0000043"}]}}{"C33763":{"preferredName":"Thigh","code":"C33763","definitions":[{"definition":"A part of the lower limb, located between hip and knee.","type":"DEFINITION","source":"NCI"},{"definition":"A part of the lower limb, located between hip and knee. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the hindlimb between pelvis and the knee, corresponding to the femur.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Thigh","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thigh"},{"name":"Maps_To","value":"Thigh"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0039866"},{"name":"xRef","value":"UBERON:0000376"}]}}{"C69315":{"preferredName":"Thoracic Spine","code":"C69315","definitions":[{"definition":"That part of the spine comprising the thoracic vertebrae.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The vertebrae of the thoracic spine, numbered one through twelve in humans.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The vertebrae of the thoracic spine, numbered one through twelve in man.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thoracic Spine","termGroup":"PT","termSource":"NCI"},{"termName":"T Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thoracic_Spine"},{"name":"Maps_To","value":"Thoracic Spine"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0581269"},{"name":"xRef","value":"UBERON:0006073"}]}}{"C54272":{"preferredName":"Throat","code":"C54272","definitions":[{"definition":"In anatomy, the throat is the anterior part of the neck, in front of the vertebral column. It consists of the pharynx and larynx. An important feature of the throat is the epiglottis, a flap which separates the esophagus from the trachea and prevents inhalation of food or drink. The throat contains various blood vessels, various pharyngeal muscles, the trachea (windpipe) and the esophagus. The hyoid bone and the clavicle are the only bones located in the throat of mammals. It is sometimes considered a synonym for fauces.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The hollow tube inside the neck that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach). The throat is about 5 inches long, depending on body size.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The narrow passage from the mouth to the cavity at the back of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The narrow passage from the mouth to the cavity at the back of the mouth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Throat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Throat"},{"name":"Maps_To","value":"Throat"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230069"},{"name":"xRef","value":"UBERON:0000341"}]}}{"C52834":{"preferredName":"Hand Digit 1","code":"C52834","definitions":[{"definition":"1st (preaxial) digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The thick and short hand digit which is next to the index finger in humans.","type":"DEFINITION","source":"NCI"},{"definition":"The thick and short hand digit which is next to the index finger in humans. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 1","termGroup":"PT","termSource":"NCI"},{"termName":"Thumb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_1"},{"name":"Maps_To","value":"Thumb"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0040067"},{"name":"xRef","value":"UBERON:0001463"}]}}{"C12800":{"preferredName":"Tibia","code":"C12800","definitions":[{"definition":"A bone located between the femur and the tarsus, being part of the lower leg.","type":"DEFINITION","source":"NCI"},{"definition":"The larger of two bones between the knee and ankle.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The long bone that is medial to the fibula.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The major preaxial endochondral bone in the posterior zeugopod.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Tibia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tibia"},{"name":"Maps_To","value":"Tibia"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040184"},{"name":"xRef","value":"UBERON:0000979"}]}}{"C12961":{"preferredName":"Trachea and Bronchus","code":"C12961","definitions":[{"definition":"Trachea -The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi. Bronchi-The larger air passages of the lungs arising from the terminal bifurcation of the trachea.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trachea and Bronchus","termGroup":"PT","termSource":"NCI"},{"termName":"Respiratory System, Trachea, Bronchus","termGroup":"SY","termSource":"NCI"},{"termName":"Trachea, Bronchus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trachea_and_Bronchus"},{"name":"Maps_To","value":"Trachea / Major Bronchi"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0302191"}]}}{"C33816":{"preferredName":"Trunk","code":"C33816","definitions":[{"definition":"Organism subdivision which is the part of the body posterior to the cervical region (or head, when cervical region not present) and anterior to the caudal region. Includes the sacrum when present.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The body excluding the head and neck and limbs.","type":"DEFINITION","source":"NCI"},{"definition":"The body excluding the head, neck and appendages.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Trunk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Trunk"},{"name":"Maps_To","value":"Trunk"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0460005"},{"name":"xRef","value":"UBERON:0002100"}]}}{"C34320":{"preferredName":"Umbilical Cord","code":"C34320","definitions":[{"definition":"Extraembryonic structure that connects the fetus to the placenta.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Extraembryonic structure that connects the fetus to the placenta. It contains two arteries and one vein.","type":"DEFINITION","source":"NCI"},{"definition":"The connecting cord from the developing embryo to the placenta.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Umbilical Cord","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Umbilical_Cord"},{"name":"Maps_To","value":"Umbilical Cord"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0041633"},{"name":"xRef","value":"UBERON:0002331"}]}}{"C191741":{"preferredName":"Urinary Tract","code":"C191741","definitions":[{"definition":"The parts of the urinary system that discharge urine. These include the renal pelvis, ureter, bladder, and urethra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urinary Tract","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urinary system, NOS"},{"name":"Maps_To","value":"Urinary Tract"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042027"}]}}{"C12813":{"preferredName":"Vas Deferens","code":"C12813","definitions":[{"definition":"A coiled tube that carries the sperm out of the testes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A duct carrying spermatozoa from the epididymides to the urethra.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A secretory duct that transports sperm from the testis. In mammals this is a continuation of the epididymis and ends in the prostatic urethra where it terminates to form ejaculatory duct.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Duct carrying spermatozoa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vas Deferens","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vas_Deferens"},{"name":"Maps_To","value":"Vas Deferens"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042360"},{"name":"xRef","value":"UBERON:0001000"}]}}{"C12814":{"preferredName":"Vein","code":"C12814","definitions":[{"definition":"A blood vessel that carries blood to the heart from tissues and organs in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A blood vessel that carries blood toward the heart.","type":"DEFINITION","source":"NCI"},{"definition":"A blood vessel that carries blood towards the heart.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any of the tubular branching vessels that carry blood from the capillaries toward the heart.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Vein","termGroup":"PT","termSource":"NCI"},{"termName":"Venous","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vein"},{"name":"Maps_To","value":"Vein"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042449"},{"name":"xRef","value":"UBERON:0001638"}]}}{"C25291":{"preferredName":"Venous","code":"C25291","definitions":[{"definition":"Of, or pertaining to, or contained in, or performing the function of the veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Venous"},{"name":"Maps_To","value":"Venous"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0348013"}]}}{"C12933":{"preferredName":"Vertebra","code":"C12933","definitions":[{"definition":"Any of thirty-three ring-shaped structures that form the vertebral column which surrounds and protects the spinal cord. Each vertebra consists of a bony body with its superior and inferior articular surfaces covered by hyaline cartilage. The body includes the centrum anteriorly and vertebral arch posteriorly. The articular surfaces of the vertebrae are connected by a fibrocartilaginous intervertebral disc.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vertebra","termGroup":"PT","termSource":"NCI"},{"termName":"Vertebrae","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vertebra"},{"name":"Maps_To","value":"Vertebra"},{"name":"Maps_To","value":"Vertebrae"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0549207"}]}}{"C12529":{"preferredName":"Leukocyte","code":"C12529","definitions":[{"definition":"A type of immune cell. Most leukocytes are made in the bone marrow and are found in the blood and lymph tissue. Leukocytes help the body fight infections and other diseases. Granulocytes, monocytes, and lymphocytes are leukocytes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Blood cells that are devoid of hemoglobin, capable of ameboid motion and phagocytosis, and act as the principal components of the immune system.","type":"DEFINITION","source":"NCI"},{"definition":"Blood cells that are devoid of hemoglobin, capable of amoeboid motion and phagocytosis, and act as the principal components of the immune system.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Leukocyte","termGroup":"PT","termSource":"NCI"},{"termName":"Leukocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Reticuloendothelial System, Leukocytes","termGroup":"SY","termSource":"NCI"},{"termName":"WBCs","termGroup":"SY","termSource":"NCI"},{"termName":"White Blood Cell","termGroup":"SY","termSource":"NCI"},{"termName":"White Blood Cells","termGroup":"SY","termSource":"NCI"},{"termName":"White Blood Corpuscle","termGroup":"AQS","termSource":"NCI"},{"termName":"White Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Leukocyte"},{"name":"Maps_To","value":"White Blood Cells"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0023516"}]}}{"C33894":{"preferredName":"Wrist Joint","code":"C33894","definitions":[{"definition":"A joint between the distal end of the radius and the proximal row of carpal bones.","type":"DEFINITION","source":"NCI"},{"definition":"A joint between the distal end of the radius and the proximal row of carpal bones. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A joint connecting the forelimb zeugopod skeleton with the carpal skeleton.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Wrist Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Carpal","termGroup":"AD","termSource":"NCI"},{"termName":"Radiocarpal Joint","termGroup":"SY","termSource":"NCI"},{"termName":"Wrist","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Wrist_Joint"},{"name":"Maps_To","value":"Wrist"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1322271"},{"name":"xRef","value":"UBERON:0001491"}]}}{"C172257":{"preferredName":"Conditionally Reprogrammed Cells","code":"C172257","definitions":[{"definition":"A cellular sample derived from epithelial cells isolated from a tissue sample that were rapidly expanded in a monolayer culture in the presence of irradiated mouse cells and a Rho kinase (ROCK) inhibitor. Under these conditions the cells are reprogrammed to be more stem-like but the reprogramming is conditional. When the cells are transferred to cultures that mimic in vivo environments they become differentiated and can form structures that resemble the tissue from which they were derived.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conditionally Reprogrammed Cells","termGroup":"PT","termSource":"NCI"},{"termName":"2D Classical Conditionally Reprogrammed Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Classical Conditionally Reprogrammed Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Classical CRC","termGroup":"SY","termSource":"NCI"},{"termName":"CRC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2D Classical Conditionally Reprogrammed Cells"},{"name":"NCI_META_CUI","value":"CL1406128"},{"name":"PubMedID_Primary_Reference","value":"23169653"},{"name":"Semantic_Type","value":"Cell"}]}}{"C172258":{"preferredName":"Modified Conditionally Reprogrammed Cells","code":"C172258","definitions":[{"definition":"A conditionally reprogrammed cell sample comprised of non-epithelial cells isolated from a tissue sample that were rapidly expanded in monolayer culture under various cell type-specific culture conditions to promote the rapid proliferation of the cell type of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Conditionally Reprogrammed Cells","termGroup":"PT","termSource":"NCI"},{"termName":"2D Modified Conditionally Reprogrammed Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Modified CRC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2D Modified Conditionally Reprogrammed Cells"},{"name":"NCI_META_CUI","value":"CL1406127"},{"name":"PubMedID_Primary_Reference","value":"26907527"},{"name":"Semantic_Type","value":"Cell"}]}}{"C172260":{"preferredName":"Air-Liquid Interface Organoid","code":"C172260","definitions":[{"definition":"An organoid grown in vitro where a portion of the cultured cells or tissue is in contact with the medium and another portion is exposed to air. This technique promotes the growth of three dimensional mass resembling a layered tissue or organ, such as the pseudostratified columnar epithelium normally found in the lung and other organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Air-Liquid Interface Organoid","termGroup":"PT","termSource":"NCI"},{"termName":"3D Air-Liquid Interface Organoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3D Air-Liquid Interface Organoid"},{"name":"NCI_META_CUI","value":"CL1406126"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172261":{"preferredName":"Neurosphere","code":"C172261","definitions":[{"definition":"A spherical organoid comprised of neural progenitor cells grown in suspension culture in the presence of a combination of growth factors that promote the proliferation neural stem cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurosphere","termGroup":"PT","termSource":"NCI"},{"termName":"3D Neurosphere","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3D Neurosphere"},{"name":"NCI_META_CUI","value":"CL1406125"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172259":{"preferredName":"Organoid","code":"C172259","definitions":[{"definition":"A three dimensional mass comprised of a cultured cell or tissue sample that resembles an in vivo tissue or organ. Organoids are grown in vitro from a combination of cells or tissue fragments cultured in medium containing a variety of biochemical factors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Organoid","termGroup":"PT","termSource":"NCI"},{"termName":"3D Organoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3D Organoid"},{"name":"PubMedID_Primary_Reference","value":"26907527"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0029250"}]}}{"C20216":{"preferredName":"Adherent Culture","code":"C20216","definitions":[{"definition":"A type of culture in which cells grow as a monolayer that is attached to the culture substrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adherent Culture","termGroup":"PT","termSource":"NCI"},{"termName":"Monolayer culture","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adherent_Culture"},{"name":"Maps_To","value":"Adherent Cell Line"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1510803"}]}}{"C164009":{"preferredName":"Bone Marrow Sample","code":"C164009","definitions":[{"definition":"A biological sample containing components collected from bone marrow of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Marrow Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Marrow Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Bone Marrow Components NOS"},{"name":"Maps_To","value":"Bone Marrow NOS"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0438737"},{"name":"xRef","value":"UBERON:0002371"}]}}{"C172264":{"preferredName":"Buccal Cell Sample","code":"C172264","definitions":[{"definition":"A sample comprised of cells collected from the inside of a subject's cheek.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buccal Cell Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buccal Cells"},{"name":"NCI_META_CUI","value":"CL365909"},{"name":"Semantic_Type","value":"Cell"}]}}{"C12508":{"preferredName":"Cell","code":"C12508","definitions":[{"definition":"The individual unit that makes up all of the tissues of the body. All living things are made up of one or more cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell","termGroup":"PT","termSource":"NCI"},{"termName":"Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cell Types","termGroup":"DN","termSource":"NCI"},{"termName":"Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Cellular","termGroup":"AD","termSource":"NCI"},{"termName":"Normal Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Cell"},{"name":"Maps_To","value":"Cell"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C3282337"}]}}{"C156445":{"preferredName":"Derived Cell Line","code":"C156445","definitions":[{"definition":"A biospecimen generated by in vitro culturing of a single cell isolated from a tissue of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Derived Cell Line","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Derived Cell Line"},{"name":"Maps_To","value":"Derived Cell Lines and Sorted Cells"},{"name":"NCI_META_CUI","value":"CL563176"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164010":{"preferredName":"Bone Marrow-Derived Fibroblasts","code":"C164010","definitions":[{"definition":"A biological sample containing fibroblasts isolated from the bone marrow of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Marrow-Derived Fibroblasts","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fibroblasts from Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977219"},{"name":"Semantic_Type","value":"Cell"}]}}{"C19315":{"preferredName":"Primary Cell Culture","code":"C19315","definitions":[{"definition":"The cells taken from a tissue source, and their progeny, grown in culture before subdivision and transfer to a sub culture.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Primary Cell Culture","termGroup":"PT","termSource":"NCI"},{"termName":"Culturing, in vitro Vertebrate, Primary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Cell_Culture"},{"name":"Maps_To","value":"Human Original Cells"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1449562"}]}}{"C20217":{"preferredName":"Suspension Culture","code":"C20217","definitions":[{"definition":"A type of culture in which cells, or aggregates of cells, multiply while suspended in liquid medium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suspension Culture","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Suspension_Culture"},{"name":"Maps_To","value":"Liquid Suspension Cell Line"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1515100"}]}}{"C12535":{"preferredName":"Lymphocyte","code":"C12535","definitions":[{"definition":"A type of immune cell that is made in the bone marrow and is found in the blood and in lymph tissue. The two main types of lymphocytes are B lymphocytes and T lymphocytes. B lymphocytes make antibodies, and T lymphocytes help kill tumor cells and help control immune responses. A lymphocyte is a type of white blood cell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocyte"},{"name":"Maps_To","value":"Lymphocytes"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0024264"}]}}{"C164011":{"preferredName":"Bone Marrow-Derived Mononuclear Cells","code":"C164011","definitions":[{"definition":"A biological sample containing mononuclear cells isolated from the bone marrow of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Marrow-Derived Mononuclear Cells","termGroup":"PT","termSource":"NCI"},{"termName":"BM-MNC","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Marrow-Derived Unselected Mononuclear Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Selected Mononuclear Cell","termGroup":"SY","termSource":"NCI"},{"termName":"tMNC","termGroup":"SY","termSource":"NCI"},{"termName":"Total Mononuclear Cell Population","termGroup":"SY","termSource":"NCI"},{"termName":"Unselected Mononuclear Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mononuclear Cells from Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977218"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"Semantic_Type","value":"Cell"}]}}{"C41067":{"preferredName":"Whole Blood","code":"C41067","definitions":[{"definition":"Blood that has not been separated into its various components; blood that has not been modified except for the addition of an anticoagulant.","type":"DEFINITION","source":"NCI"},{"definition":"Blood that has not been separated into its various components; blood that has not been modified except for the addition of an anticoagulant. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Whole Blood","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Whole_Blood"},{"name":"Maps_To","value":"Peripheral Whole Blood"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0370231"}]}}{"C3331":{"preferredName":"Pleural Effusion","code":"C3331","definitions":[{"definition":"A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An abnormal collection of fluid between the thin layers of tissue (pleura) lining the lung and the wall of the chest cavity.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An accumulation of fluid in the pleural cavity.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive HF, pleural and lung tumors, connective tissue disorders, and trauma","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive HF, pleural and lung tumors, connective tissue disorders, and trauma.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleural Effusion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pleural_Effusion"},{"name":"Maps_To","value":"Pleural effusion"},{"name":"Maps_To","value":"Pleural Effusion"},{"name":"Maps_To","value":"Unspecified pleural effusion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0032227"},{"name":"xRef","value":"IMDRF:E0731"}]}}{"C164014":{"preferredName":"Solid Tissue Specimen","code":"C164014","definitions":[{"definition":"A biological sample containing components collected from non-liquid tissue of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Tissue Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Tissue Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solid Tissue"},{"name":"NCI_META_CUI","value":"CL977215"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C126974":{"preferredName":"Sorted Cells","code":"C126974","definitions":[{"definition":"Cells separated and collected from a heterogeneous population based on physical, phenotypic, biochemical, and/or molecular properties, regardless of technique.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorted Cells","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Derived Cell Lines and Sorted Cells"},{"name":"Maps_To","value":"Sorted Cells"},{"name":"NCI_META_CUI","value":"CL508211"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C13278":{"preferredName":"Sputum","code":"C13278","definitions":[{"definition":"Material containing mucus, cellular debris, microorganisms and sometimes blood or pus.  It is ejected through the mouth from the lungs, bronchi, and trachea.","type":"DEFINITION","source":"NCI"},{"definition":"Material containing mucus, cellular debris, microorganisms and sometimes blood or pus. It is ejected through the mouth from the lungs, bronchi, and trachea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sputum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Sputum"},{"name":"Maps_To","value":"Sputum"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0038056"}]}}{"C84513":{"preferredName":"Whole Bone Marrow","code":"C84513","definitions":[{"definition":"Bone marrow sample containing a mixture of different types of stem cells, including hematopoietic stem cells, mesenchymal stem cells, and multipotent progenitor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Whole Bone Marrow","termGroup":"PT","termSource":"NCI"},{"termName":"WBM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Whole Bone Marrow"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C2827482"}]}}{"C174118":{"preferredName":"Mixed Adherent Cells in Suspension","code":"C174118","definitions":[{"definition":"A sample comprised of a mixture of cells or clumps of cells, which may have been isolated from normal or tumor tissues, that are maintained in a suspension culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Adherent Cells in Suspension","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed Adherent Suspension"},{"name":"NCI_META_CUI","value":"CL1407783"},{"name":"Semantic_Type","value":"Cell"}]}}{"C25408":{"preferredName":"Adjacent","code":"C25408","definitions":[{"definition":"Next to or adjoining.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adjacent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Adjacent"},{"name":"Maps_To","value":"Adjacent (< or = 2cm)"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205117"}]}}{"C25237":{"preferredName":"Distal","code":"C25237","definitions":[{"definition":"In medicine, refers to a part of the body that is farther away from the center of the body than another part. For example, the fingers are distal to the shoulder. The opposite is proximal.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline of the body.","type":"DEFINITION","source":"NCI"},{"definition":"Situated farthest from a point of reference.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Distal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Distal"},{"name":"Maps_To","value":"Distal (>2cm)"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205108"}]}}{"C91826":{"preferredName":"Abdominoperineal Resection","code":"C91826","definitions":[{"definition":"A therapeutic surgical procedure in which the anus, rectum, part of the sigmoid colon, and the regional lymph nodes are removed through abdominal and perineal incisions.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove the anus, the rectum, and part of the sigmoid colon through an incision made in the abdomen. The end of the intestine is attached to an opening in the surface of the abdomen and body waste is collected in a disposable bag outside of the body. This opening is called a colostomy. Lymph nodes that contain cancer may also be removed during this operation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Abdominoperineal Resection","termGroup":"PT","termSource":"NCI"},{"termName":"APR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdomino-perineal Resection of Rectum"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2004459"}]}}{"C113716":{"preferredName":"Low Anterior Resection","code":"C113716","definitions":[{"definition":"Resection of the rectum for cancer through an incision in the lower abdomen.","type":"DEFINITION","source":"NCI"},{"definition":"Resection of the rectum through an incision in the lower abdomen.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Low Anterior Resection","termGroup":"PT","termSource":"NCI"},{"termName":"LAR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anterior Resection of Rectum"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3814448"}]}}{"C159342":{"preferredName":"Ascites Drainage","code":"C159342","definitions":[{"definition":"The systematic withdrawal of ascitic fluid  from the abdominal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ascites Drainage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ascites Drainage"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0405789"}]}}{"C13347":{"preferredName":"Aspirate","code":"C13347","definitions":[{"definition":"Fluid withdrawn from a body cavity, cyst, or tumor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Fluid withdrawn from a body cavity, organ, cyst, or tumor.","type":"DEFINITION","source":"NCI"},{"definition":"Fluid withdrawn from a lump, often a cyst, or a nipple.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aspirate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aspirate"},{"name":"Maps_To","value":"Aspirate"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0370199"}]}}{"C172322":{"preferredName":"Buccal Mucosal Resection","code":"C172322","definitions":[{"definition":"Surgical removal of the mucosal lining of the inside of the cheek through the mouth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buccal Mucosal Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buccal Mucosal Resection"},{"name":"NCI_META_CUI","value":"CL1406180"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15217":{"preferredName":"Cystectomy","code":"C15217","definitions":[{"definition":"Surgery to remove all or part of the bladder (the organ that holds urine) or to remove a cyst (a sac or capsule in the body).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of the urinary bladder; or the surgical removal of a cyst..","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystectomy"},{"name":"Maps_To","value":"Cystectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0010651"}]}}{"C161002":{"preferredName":"Deep Parotidectomy","code":"C161002","definitions":[{"definition":"Surgical removal of part or all of the deep lobe of the parotid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Parotidectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deep Parotidectomy"},{"name":"NCI_META_CUI","value":"CL969979"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165178":{"preferredName":"Endorectal Tumor Resection","code":"C165178","definitions":[{"definition":"The use of an endoscope to guide the surgical removal of tumor and any surrounding tissue located inside the rectum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endorectal Tumor Resection","termGroup":"PT","termSource":"NCI"},{"termName":"Endorectal Endoscopic Tumor Resection","termGroup":"SY","termSource":"NCI"},{"termName":"Endorectal Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endo Rectal Tumor Resection"},{"name":"NCI_META_CUI","value":"CL978442"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C160999":{"preferredName":"Endolaryngeal Excision","code":"C160999","definitions":[{"definition":"Surgical excision performed through the mouth and glottic opening.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endolaryngeal Excision","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endolaryngeal Excision"},{"name":"NCI_META_CUI","value":"CL969981"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15389":{"preferredName":"Endoscopic Biopsy","code":"C15389","definitions":[{"definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis. In the case of an endoscopic biopsy, an endoscope is used to obtain the sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endoscopic Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Endoscopy and Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endoscopic_Biopsy"},{"name":"Maps_To","value":"Endoscopic Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0184980"}]}}{"C103242":{"preferredName":"Endoscopic Mucosal Resection","code":"C103242","definitions":[{"definition":"An endoscopic procedure that visualizes a part of the gastrointestinal tract to first identify and demarcate superficial mucosal lesions, then to guide a submucosal injection to the site to lift the lesion and finally to aid in the removal of the lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endoscopic Mucosal Resection","termGroup":"PT","termSource":"NCI"},{"termName":"EMR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endoscopic Mucosal Resection (EMR)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1700928"}]}}{"C51604":{"preferredName":"Glossectomy","code":"C51604","definitions":[{"definition":"Surgery involving partial or complete excision of the tongue.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of all or part of the tongue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glossectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Excision of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Resection of Tongue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glossectomy"},{"name":"Maps_To","value":"Glossectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0017673"}]}}{"C131672":{"preferredName":"Gross Total Resection","code":"C131672","definitions":[{"definition":"Surgical removal of an entire visible lesion, with no obvious lesion detected on post-operative evaluation; microscopic residual disease may be present.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of an entire visible lesion, with no obvious lesion detected on post-operative evaluation; microscopic residual disease may be present.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Gross Total Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Gross Total Resection"},{"name":"NCI_META_CUI","value":"CL514299"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165179":{"preferredName":"Hand Assisted Laparoscopic Radical Nephrectomy","code":"C165179","definitions":[{"definition":"A radical nephrectomy procedure performed using hand assisted laparoscopy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hand Assisted Laparoscopic Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hand Assisted Laparoscopic Radical Nephrectomy"},{"name":"NCI_META_CUI","value":"CL978423"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165180":{"preferredName":"Laparoscopic Biopsy","code":"C165180","definitions":[{"definition":"A biospy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0198536"}]}}{"C165181":{"preferredName":"Laparoscopic Partial Nephrectomy","code":"C165181","definitions":[{"definition":"A partial nephrectomy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Partial Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Partial Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1144661"}]}}{"C165182":{"preferredName":"Laparoscopic Radical Nephrectomy","code":"C165182","definitions":[{"definition":"A radical nephrectomy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Radical Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2584683"}]}}{"C165183":{"preferredName":"Laparoscopic Radical Prostatectomy with Robotics","code":"C165183","definitions":[{"definition":"A radical prostatectomy procedure performed with the aid of a robotic laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Radical Prostatectomy with Robotics","termGroup":"PT","termSource":"NCI"},{"termName":"RARP","termGroup":"SY","termSource":"NCI"},{"termName":"Robot-assisted Radical Prostatectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Radical Prostatectomy with Robotics"},{"name":"NCI_META_CUI","value":"CL978424"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165184":{"preferredName":"Laparoscopic Radical Prostatectomy","code":"C165184","definitions":[{"definition":"A radical prostatectomy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Radical Prostatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Radical Prostatectomy without Robotics"},{"name":"NCI_META_CUI","value":"CL978425"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C150660":{"preferredName":"Laryngopharyngectomy","code":"C150660","definitions":[{"definition":"Surgery involving the complete or partial excision of the larynx and pharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laryngopharyngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngopharyngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189242"}]}}{"C51624":{"preferredName":"Left Colectomy","code":"C51624","definitions":[{"definition":"Surgical removal of the left part of the colon.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the left portion of the colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Left Colectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Left Hemicolectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Left_Colectomy"},{"name":"Maps_To","value":"Left Hemicolectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192865"}]}}{"C135727":{"preferredName":"Liquid Biopsy","code":"C135727","definitions":[{"definition":"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liquid Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Liquid Biopsy","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Liquid Biopsy"},{"name":"NCI_META_CUI","value":"CL523042"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C15272":{"preferredName":"Lobectomy","code":"C15272","definitions":[{"definition":"Surgery to remove a whole lobe (section) of an organ (such as the lungs, liver, brain, or thyroid gland).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a lobe of an organ.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of a lobe of an organ.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lobectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lobectomy"},{"name":"Maps_To","value":"Lobectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0023928"}]}}{"C15755":{"preferredName":"Lumpectomy","code":"C15755","definitions":[{"definition":"Surgery to remove abnormal tissue or cancer from the breast and a small amount of normal tissue around it. It is a type of breast-sparing surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a discrete mass.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The surgical removal of a discrete mass.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lumpectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Lumpectomy of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Mastectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lumpectomy"},{"name":"Maps_To","value":"Lumpectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0851238"}]}}{"C15275":{"preferredName":"Lymphadenectomy","code":"C15275","definitions":[{"definition":"A surgical procedure in which the lymph nodes are removed and a sample of tissue is checked under a microscope for signs of cancer. For a regional lymphadenectomy, some of the lymph nodes in the tumor area are removed; for a radical lymphadenectomy, most or all of the lymph nodes in the tumor area are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of lymph nodes, usually done to assess the spread of cancer.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the lymph node(s).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymphadenectomy","termGroup":"PT","termSource":"NCI"},{"termName":"excision of the lymph node","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Node Dissection","termGroup":"SY","termSource":"NCI"},{"termName":"lymph node excision","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Lymphadenectomy"},{"name":"Maps_To","value":"Lymph Node Dissection"},{"name":"Maps_To","value":"Lymphadenectomy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0024203"}]}}{"C51664":{"preferredName":"Mandibulectomy","code":"C51664","definitions":[{"definition":"Surgery to remove part or all of the mandible.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mandibulectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Excision of Mandible","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mandibulectomy"},{"name":"Maps_To","value":"Mandibulectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0185566"}]}}{"C51656":{"preferredName":"Maxillectomy","code":"C51656","definitions":[{"definition":"Surgery to remove part or all of the maxilla.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maxillectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Maxillectomy"},{"name":"Maps_To","value":"Maxillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0407722"}]}}{"C94461":{"preferredName":"Metastasectomy","code":"C94461","definitions":[{"definition":"Surgery to remove one or more metastases (tumors formed from cells that have spread from the primary tumor). When all metastases are removed, it is called a complete metastasectomy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of metastases.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The surgical removal of metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Metastasectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2363923"}]}}{"C15278":{"preferredName":"Modified Radical Mastectomy","code":"C15278","definitions":[{"definition":"Surgery for breast cancer in which the breast, most or all of the lymph nodes under the arm, and the lining over the chest muscles are removed. Sometimes the surgeon also removes part of the chest wall muscles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of one or both breasts, including the areola, nipple, and the majority of the axillary lymph nodes, but sparing the pectoralis major muscle.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The surgical removal of one or both breasts, including the areola, nipple, and the majority of the axillary lymph nodes, but sparing the pectoralis major muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Radical Mastectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Mastectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Modified_Radical_Mastectomy"},{"name":"Maps_To","value":"Modified Radical Mastectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0024883"}]}}{"C15190":{"preferredName":"Needle Biopsy","code":"C15190","definitions":[{"definition":"The removal of a tissue sample using a needle, for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of tissue or fluid with a needle for examination under a microscope. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Needle Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Aspiration Biopsy","termGroup":"SY","termSource":"NCI"},{"termName":"Puncture Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Needle_Biopsy"},{"name":"Maps_To","value":"Needle Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0005560"}]}}{"C51787":{"preferredName":"Omentectomy","code":"C51787","definitions":[{"definition":"Partial or complete resection of the omentum.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove part or all of the omentum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Omentectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Epiploectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Resection of Omentum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Omentectomy"},{"name":"Maps_To","value":"Omentectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0812449"}]}}{"C15291":{"preferredName":"Oophorectomy","code":"C15291","definitions":[{"definition":"Partial or complete removal of one or both of the ovaries.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove one or both ovaries.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Oophorectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Female Castration","termGroup":"SY","termSource":"NCI"},{"termName":"Ovariectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oophorectomy"},{"name":"Maps_To","value":"Oophorectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0029936"}]}}{"C15214":{"preferredName":"Craniotomy","code":"C15214","definitions":[{"definition":"An operation in which an opening is made in the skull.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical creation of an opening of the skull.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Craniotomy","termGroup":"PT","termSource":"NCI"},{"termName":"incision of the skull","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Craniotomy"},{"name":"Maps_To","value":"Open Craniotomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0010280"}]}}{"C165186":{"preferredName":"Open Partial Nephrectomy","code":"C165186","definitions":[{"definition":"A partial nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Partial Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Open Partial Nephrectomy"},{"name":"NCI_META_CUI","value":"CL978427"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165187":{"preferredName":"Open Radical Nephrectomy","code":"C165187","definitions":[{"definition":"A radical nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Open Radical Nephrectomy"},{"name":"NCI_META_CUI","value":"CL978428"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165188":{"preferredName":"Open Radical Prostatectomy","code":"C165188","definitions":[{"definition":"A radical prostatectomy procedure performed using a long incision for visualization and the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Radical Prostatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Open Radical Prostatectomy"},{"name":"NCI_META_CUI","value":"CL978429"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15288":{"preferredName":"Orchiectomy","code":"C15288","definitions":[{"definition":"Surgery to remove one or both testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of one or both testicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orchiectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Castration","termGroup":"SY","termSource":"NCI"},{"termName":"Male Castration","termGroup":"SY","termSource":"NCI"},{"termName":"Male Gonadectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Orchiectomy"},{"name":"Maps_To","value":"Orchiectomy"},{"name":"Maps_To","value":"Testis Removed"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0029189"}]}}{"C184787":{"preferredName":"Biospecimen Collection by Other Surgical Resection Method","code":"C184787","definitions":[{"definition":"The use of an unspecified or other surgical resection procedure for biospecimen collection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biospecimen Collection by Other Surgical Resection Method","termGroup":"PT","termSource":"NCI"},{"termName":"Sample Collection by Other Surgical Resection Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Surgical Resection Method"},{"name":"NCI_META_CUI","value":"CL1773107"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C160997":{"preferredName":"Palatectomy","code":"C160997","definitions":[{"definition":"Surgical removal of part or all of the palate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Palatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1737220"}]}}{"C103239":{"preferredName":"Total Proctocolectomy","code":"C103239","definitions":[{"definition":"Surgical removal of the entire colon, anus, and rectum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Proctocolectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Pan-Procto Colectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-Proctocolectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Panproctocolectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-Procto Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0842176"}]}}{"C15294":{"preferredName":"Pancreatectomy","code":"C15294","definitions":[{"definition":"Surgery to remove all or part of the pancreas. In a total pancreatectomy, part of the stomach, part of the small intestine, the common bile duct, gallbladder, spleen, and nearby lymph nodes also are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of part or all of the pancreas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Excision of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Excision","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatectomy"},{"name":"Maps_To","value":"Pancreatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0030279"}]}}{"C15310":{"preferredName":"Paracentesis","code":"C15310","definitions":[{"definition":"A procedure in which a thin needle or tube is put into the abdomen to remove fluid from the peritoneal cavity (the space within the abdomen that contains the intestines, the stomach, and the liver).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of excess fluid via needle puncture from any body cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paracentesis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paracentesis"},{"name":"Maps_To","value":"Paracentesis"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0034115"}]}}{"C51490":{"preferredName":"Parotidectomy","code":"C51490","definitions":[{"definition":"Surgery involving complete or partial excision of the parotid gland.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove all or part of the parotid gland (a large salivary gland located in front of and just below the ear). In a radical parotidectomy, the entire gland is removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Parotidectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Parotidectomy"},{"name":"Maps_To","value":"Parotidectomy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193317"}]}}{"C15394":{"preferredName":"Partial Hepatectomy","code":"C15394","definitions":[{"definition":"Partial removal of the liver","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Hepatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"partial excision of liver","termGroup":"SY","termSource":"NCI"},{"termName":"subtotal hepatectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Partial_Hepatectomy"},{"name":"Maps_To","value":"Partial Hepatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193398"}]}}{"C94240":{"preferredName":"Partial Laryngectomy","code":"C94240","definitions":[{"definition":"An operation to remove part of the larynx (voice box).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Partial Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Partial Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189234"}]}}{"C51657":{"preferredName":"Partial Maxillectomy","code":"C51657","definitions":[{"definition":"Surgery to remove part of the maxilla.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Maxillectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Partial_Maxillectomy"},{"name":"Maps_To","value":"Partial Maxillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0407589"}]}}{"C51928":{"preferredName":"Partial Nephrectomy","code":"C51928","definitions":[{"definition":"Surgery to remove part of one kidney or a kidney tumor, but not an entire kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of a portion of a kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Nephrectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Nephron Sparing Surgery","termGroup":"SY","termSource":"NCI"},{"termName":"NSS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Partial_Nephrectomy"},{"name":"Maps_To","value":"Partial Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194086"}]}}{"C159340":{"preferredName":"Peritoneal Lavage","code":"C159340","definitions":[{"definition":"A minimally invasive procedure that permits sampling of peritoneal fluid for cytopathologic analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneal Lavage","termGroup":"PT","termSource":"NCI"},{"termName":"Peritoneal Washing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peritoneal Lavage"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0031148"}]}}{"C15305":{"preferredName":"Pneumonectomy","code":"C15305","definitions":[{"definition":"Surgery to remove all of one lung.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The excision of part or all of a lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pneumonectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pneumonectomy"},{"name":"Maps_To","value":"Pneumonectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0032284"}]}}{"C28743":{"preferredName":"Punch Biopsy","code":"C28743","definitions":[{"definition":"A type of biopsy in which a disk of tissue is removed using a punch device.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Removal of a disk of skin tissue, for microscopic examination, using a punch.","type":"DEFINITION","source":"NCI"},{"definition":"Removal of a small disk-shaped sample of tissue using a sharp, hollow device. The tissue is then examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Punch Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Punch Biopsy of Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Punch_Biopsy"},{"name":"Maps_To","value":"Punch Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0191321"}]}}{"C172324":{"preferredName":"Total Maxillectomy","code":"C172324","definitions":[{"definition":"Surgical removal of the entire maxilla, hard palate and orbital floor on one side of the face.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Maxillectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Radical Maxillectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radical Maxillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0407611"}]}}{"C51778":{"preferredName":"Radical Nephrectomy","code":"C51778","definitions":[{"definition":"Surgery to remove an entire kidney, nearby adrenal gland and lymph nodes, and other surrounding tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a kidney, the adrenal gland, adjacent lymph nodes, and other surrounding tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radical_Nephrectomy"},{"name":"Maps_To","value":"Radical Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0401181"}]}}{"C15399":{"preferredName":"Radical Prostatectomy","code":"C15399","definitions":[{"definition":"Surgery to remove the entire prostate. The two types of radical prostatectomy are retropubic prostatectomy (surgery through an incision in the wall of the abdomen) and perineal prostatectomy (surgery through an incision between the scrotum and the anus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of all of the prostate as well as some surrounding tissue, including lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Prostatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Prostatovesiculectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radical_Prostatectomy"},{"name":"Maps_To","value":"Radical Prostatectomy"},{"name":"Maps_To","value":"Radical prostatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194810"}]}}{"C51623":{"preferredName":"Right Colectomy","code":"C51623","definitions":[{"definition":"Surgical removal of the right part of the colon.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the right portion of the colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Right Colectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Right Hemicolectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Colectomy"},{"name":"Maps_To","value":"Right Hemicolectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192861"}]}}{"C51605":{"preferredName":"Salpingectomy","code":"C51605","definitions":[{"definition":"Surgery to remove part or all of the fallopian tube(s).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salpingectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Tubal Excision","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salpingectomy"},{"name":"Maps_To","value":"Salpingectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0041271"}]}}{"C15323":{"preferredName":"Salpingo-Oophorectomy","code":"C15323","definitions":[{"definition":"Surgical removal of the fallopian tube(s) and ovary(ies).","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the fallopian tubes and ovaries.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Salpingo-Oophorectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salpingo-Oophorectomy"},{"name":"Maps_To","value":"Salpingo-Oophorectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0036132"}]}}{"C91838":{"preferredName":"Sigmoidectomy","code":"C91838","definitions":[{"definition":"A surgical procedure involving the partial or complete resection of the sigmoid colon.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the sigmoid colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sigmoidectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Sigmoid Colectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sigmoid Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0810152"}]}}{"C15281":{"preferredName":"Total Mastectomy","code":"C15281","definitions":[{"definition":"A surgical procedure involving the removal of the entire breast tissue, nipple and a portion of the overlying skin, while leaving the axillary contents intact.","type":"DEFINITION","source":"NCI"},{"definition":"Removal of the breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Total Mastectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Simple Mastectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Mastectomy"},{"name":"Maps_To","value":"Simple Mastectomy"},{"name":"Maps_To","value":"Total Mastectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0024886"}]}}{"C172325":{"preferredName":"Subtotal Prostatectomy","code":"C172325","definitions":[{"definition":"Surgical removal of part of the prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subtotal Prostatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Simple Prostatectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subtotal Prostatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194809"}]}}{"C131680":{"preferredName":"Partial Resection","code":"C131680","definitions":[{"definition":"Surgical removal of a part of a lesion; some portion of the lesion is detectable on post-operative evaluation.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of a part of a lesion; some portion of the lesion is detectable on post-operative evaluation.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Partial Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Subtotal Resection"},{"name":"NCI_META_CUI","value":"CL514546"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C51910":{"preferredName":"Superficial Parotidectomy","code":"C51910","definitions":[{"definition":"Surgery involving excision of the superficial portion of the parotid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Parotidectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Superficial_Parotidectomy"},{"name":"Maps_To","value":"Superficial Parotidectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0554011"}]}}{"C126397":{"preferredName":"Supracervical Hysterectomy","code":"C126397","definitions":[{"definition":"A hysterectomy that removes the uterus and leaves the cervix in place.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supracervical Hysterectomy","termGroup":"PT","termSource":"NCI"},{"termName":"SCH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Supracervical Hysterectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1270948"}]}}{"C91839":{"preferredName":"Supracricoid Laryngectomy","code":"C91839","definitions":[{"definition":"A conservation laryngeal surgery involving the resection of the true and false vocal cords, both paraglottic spaces, and the thyroid cartilage. In some cases the preepiglottic space and the epiglottis are also removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supracricoid Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Supracricoid Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2984588"}]}}{"C51889":{"preferredName":"Supraglottic Laryngectomy","code":"C51889","definitions":[{"definition":"An operation to remove the supraglottis, which is part of the larynx (voice box) above the vocal cords.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of the portion of the larynx superior to the true vocal cords.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supraglottic Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supraglottic_Laryngectomy"},{"name":"Maps_To","value":"Supraglottic Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189240"}]}}{"C163997":{"preferredName":"Thoracoscopic Biopsy","code":"C163997","definitions":[{"definition":"The use of a thoracoscope to obtain a biopsy from the pleural cavity and/or thoracic cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thoracoscopic Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thoracoscopic Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0198373"}]}}{"C51679":{"preferredName":"Tonsillectomy","code":"C51679","definitions":[{"definition":"Surgical removal of the tonsils.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Surgical removal of the tonsils.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillectomy"},{"name":"Maps_To","value":"Tonsillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040423"}]}}{"C51924":{"preferredName":"Total Colectomy","code":"C51924","definitions":[{"definition":"Surgical removal of the entire colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Surgical removal of the entire colon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Colectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Complete Excisioin of Colon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Colectomy"},{"name":"Maps_To","value":"Total Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192871"}]}}{"C51781":{"preferredName":"Total Hepatectomy","code":"C51781","definitions":[{"definition":"Surgical removal of the entire liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Hepatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Hepatectomy"},{"name":"Maps_To","value":"Total Hepatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040507"}]}}{"C51771":{"preferredName":"Total Laryngectomy","code":"C51771","definitions":[{"definition":"An operation to remove all of the larynx (voice box).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgery to completely remove the larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Laryngectomy"},{"name":"Maps_To","value":"Total Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189231"}]}}{"C51632":{"preferredName":"Total Nephrectomy","code":"C51632","synonyms":[{"termName":"Total Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Nephrectomy"},{"name":"Maps_To","value":"Total Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0176996"}]}}{"C91840":{"preferredName":"Transoral Laser Microsurgery","code":"C91840","definitions":[{"definition":"A minimally invasive procedure in which a surgeon performs tumor resection through the mouth using a microscope for visualization and a CO2 laser for incisions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transoral Laser Microsurgery","termGroup":"PT","termSource":"NCI"},{"termName":"TLM","termGroup":"SY","termSource":"NCI"},{"termName":"Transoral Laser Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transoral Laser Excision"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2984589"}]}}{"C15342":{"preferredName":"Transplantation","code":"C15342","definitions":[{"definition":"A surgical procedure in which tissue or an organ is transferred from one area of a person's body to another area, or from one person (the donor) to another person (the recipient).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Grafting","termGroup":"SY","termSource":"NCI"},{"termName":"Grafting Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Surgery, Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"Transplant Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Transplantation Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transplantation"},{"name":"Maps_To","value":"Transplant"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040732"}]}}{"C116651":{"preferredName":"Transurethral Resection of Bladder Tumor","code":"C116651","definitions":[{"definition":"A surgical procedure in which a resectoscope is passed through the urethra into the bladder to diagnose and remove all or part of a bladder tumor.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A surgical procedure used to treat bladder tumors, during which a resectoscope is passed through the urethra and into the bladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transurethral Resection of Bladder Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"TURBT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transurethral resection (TURBT)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0401496"}]}}{"C15343":{"preferredName":"Transurethral Prostatic Resection","code":"C15343","definitions":[{"definition":"Prostate tissue removal via a cystoscope.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove tissue from the prostate using an instrument inserted through the urethra.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Transurethral Prostatic Resection","termGroup":"PT","termSource":"NCI"},{"termName":"Prostate Transurethral Resection","termGroup":"SY","termSource":"NCI"},{"termName":"Transurethral Prostatectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Transurethral Resection of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Transurethral Resection of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"TURP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Transurethral_Prostatic_Resection"},{"name":"Maps_To","value":"Transurethral Resection (TURP)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040771"}]}}{"C51612":{"preferredName":"Transverse Colectomy","code":"C51612","definitions":[{"definition":"Surgical removal of the transverse colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Surgical removal of the transverse colon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transverse Colectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transverse_Colectomy"},{"name":"Maps_To","value":"Transverse Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192863"}]}}{"C164212":{"preferredName":"Tumor Resection","code":"C164212","definitions":[{"definition":"A surgical procedure in which cancerous tissue is surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor Resection"},{"name":"NCI_META_CUI","value":"CL936686"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C51906":{"preferredName":"Hemilaryngectomy","code":"C51906","definitions":[{"definition":"An operation to remove one side of the larynx (voicebox).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgery to remove one half of the larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemilaryngectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Vertical Partial Laryngectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemilaryngectomy"},{"name":"Maps_To","value":"Vertical Hemilaryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189233"}]}}{"C51690":{"preferredName":"Wedge Excision","code":"C51690","definitions":[{"definition":"Surgery to remove a triangle-shaped slice of tissue. It may be used to remove a tumor and a small amount of normal tissue around it.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a triangular wedge shaped section of tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wedge Excision","termGroup":"PT","termSource":"NCI"},{"termName":"Wedge Resection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Wedge_Excision"},{"name":"Maps_To","value":"Wedge Resection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0184909"}]}}{"C15356":{"preferredName":"Whipple Procedure","code":"C15356","definitions":[{"definition":"A type of surgery used to treat pancreatic cancer. The head of the pancreas, the duodenum, a portion of the stomach, and other nearby tissues are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of part of the pancreas, duodenum, and distal part of the bile duct.  Sometimes, the lower portion of the stomach and the gallbladder are also removed.  This procedure is performed for pancreatic, ampullary, duodenal and distal bile duct cancers.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct. (Mayo Clinic)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Whipple Procedure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Whipple_procedure"},{"name":"Maps_To","value":"Whipple"},{"name":"Maps_To","value":"Whipple Procedure"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0085162"}]}}{"C16475":{"preferredName":"Cryopreservation","code":"C16475","definitions":[{"definition":"Preservation of cells, tissues, organs, or embryos by storage at low temperatures.","type":"DEFINITION","source":"NCI"},{"definition":"Storage at very low temperature, usually in liquid nitrogen or the vapor phase of liquid nitrogen.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"eManu"}]},{"definition":"The process of cooling and storing cells, tissues, or organs at very low or freezing temperatures to save them for future use.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cryopreservation","termGroup":"PT","termSource":"NCI"},{"termName":"Cryopreserved","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cryopreservation"},{"name":"Maps_To","value":"Cryopreserved"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0010405"}]}}{"C143028":{"preferredName":"Formalin-Fixed Paraffin-Embedded","code":"C143028","definitions":[{"definition":"Refers to a process where a sample is preserved with formalin and then embedded into a paraffin block for sectioning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"FFPE"},{"name":"NCI_META_CUI","value":"CL541488"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C84517":{"preferredName":"Fresh Specimen","code":"C84517","definitions":[{"definition":"A specimen that is analyzed in the state that it was collected.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue which has not been exposed to a fixative solution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fresh Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Fresh","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fresh"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C2827486"}]}}{"C70717":{"preferredName":"Frozen Specimen","code":"C70717","definitions":[{"definition":"A specimen that has been subjected to and immobilized by severe cold.","type":"DEFINITION","source":"NCI"},{"definition":"A specimen that has been subjected to and immobilized by severe cold. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Frozen Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Frozen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Frozen_Specimen"},{"name":"Maps_To","value":"Frozen"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1548793"}]}}{"C63523":{"preferredName":"Optimal Cutting Temperature Compound","code":"C63523","definitions":[{"definition":"A solution of water soluble glycols and resins that provide a specimen support matrix for cryostat sectioning at temperatures of -10 degrees C and below.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Optimal Cutting Temperature Compound","termGroup":"PT","termSource":"NCI"},{"termName":"OCT","termGroup":"AB","termSource":"NCI"},{"termName":"Tissue-Tek OCT","termGroup":"SY","termSource":"NCI"},{"termName":"Tissue-Tek Optimal Cutting Temperature Compound","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Optimal_Cutting_Temperature_Compound"},{"name":"Maps_To","value":"OCT"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C1882161"}]}}{"C63521":{"preferredName":"Quick Freeze","code":"C63521","definitions":[{"definition":"To freeze rapidly so as to preserve structure and prevent ice crystal formation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"To freeze rapidly so as to preserve structure and prevent ice crystal formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quick Freeze","termGroup":"PT","termSource":"NCI"},{"termName":"Flash Freeze","termGroup":"SY","termSource":"NCI"},{"termName":"Flash Frozen","termGroup":"AD","termSource":"NCI"},{"termName":"Quick Frozen","termGroup":"AD","termSource":"NCI"},{"termName":"Snap Freeze","termGroup":"SY","termSource":"NCI"},{"termName":"Snap Frozen","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Quick_Freeze"},{"name":"Maps_To","value":"Snap Frozen"},{"name":"Semantic_Type","value":"Activity"},{"name":"UMLS_CUI","value":"C1882516"}]}}{"C61742":{"preferredName":"Edetic Acid","code":"C61742","definitions":[{"definition":"The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"EDTA","termGroup":"AB","termSource":"NCI"},{"termName":"Ethylenediaminetetraacetic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60-00-4"},{"name":"CHEBI_ID","value":"CHEBI:4735"},{"name":"Chemical_Formula","value":"C10H16N2O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9G34HU7RV0"},{"name":"Legacy Concept Name","value":"Edetic_Acid"},{"name":"Maps_To","value":"EDTA"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0013618"}]}}{"C156441":{"preferredName":"Sample Derived from New Primary","code":"C156441","definitions":[{"definition":"A biospecimen derived from a new primary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sample Derived from New Primary","termGroup":"PT","termSource":"NCI"},{"termName":"New Primary Tumor Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Sample Derived from New Primary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"05"},{"name":"Maps_To","value":"Additional - New Primary"},{"name":"NCI_META_CUI","value":"CL563179"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C156440":{"preferredName":"Metastatic Tumor Sample","code":"C156440","definitions":[{"definition":"A biospecimen derived from a metastatic tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Tumor Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Metastatic Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"06"},{"name":"Maps_To","value":"07"},{"name":"Maps_To","value":"Additional Metastatic"},{"name":"Maps_To","value":"Metastatic"},{"name":"NCI_META_CUI","value":"CL563178"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C164015":{"preferredName":"Blood Cancer-Derived Bone Marrow Specimen","code":"C164015","definitions":[{"definition":"A bone marrow specimen collected from a subject that has been diagnosed with a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Bone Marrow Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Bone Marrow Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"09"},{"name":"Maps_To","value":"Blood Derived Cancer - Bone Marrow"},{"name":"Maps_To","value":"Primary Blood Derived Cancer - Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977214"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164017":{"preferredName":"Blood Cancer-Derived Bone Marrow Specimen, Post-Treatment","code":"C164017","definitions":[{"definition":"A bone marrow specimen collected from a subject after receiving treatment for a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Bone Marrow Specimen, Post-Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Bone Marrow Sample, Post-Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"04"},{"name":"Maps_To","value":"Blood Derived Cancer - Bone Marrow, Post-treatment"},{"name":"Maps_To","value":"Recurrent Blood Derived Cancer - Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977241"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164030":{"preferredName":"Blood Cancer-Derived Blood Specimen","code":"C164030","definitions":[{"definition":"A whole blood specimen collected from a subject that has been diagnosed with a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Blood Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Blood Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"03"},{"name":"Maps_To","value":"Blood Derived Cancer - Peripheral Blood"},{"name":"Maps_To","value":"Primary Blood Derived Cancer - Peripheral Blood"},{"name":"NCI_META_CUI","value":"CL977229"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164031":{"preferredName":"Blood Cancer-Derived Blood Specimen, Post-Treatment","code":"C164031","definitions":[{"definition":"A whole blood specimen collected from a subject after receiving treatment for a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Blood Specimen, Post-Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Blood Sample, Post-Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Sample, Post-Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Specimen, Post-Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"40"},{"name":"Maps_To","value":"Blood Derived Cancer - Peripheral Blood, Post-treatment"},{"name":"Maps_To","value":"Recurrent Blood Derived Cancer - Peripheral Blood, Post Treatment"},{"name":"NCI_META_CUI","value":"CL977228"},{"name":"Semantic_Type","value":"Cell"}]}}{"C156443":{"preferredName":"Cell Line-Derived Xenograft","code":"C156443","definitions":[{"definition":"A biospecimen derived from the culturing of a derived cell line in a non-human organism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell Line-Derived Xenograft","termGroup":"PT","termSource":"NCI"},{"termName":"CDX","termGroup":"AB","termSource":"NCI"},{"termName":"Cell Line Derived Xenograft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"61"},{"name":"Maps_To","value":"Cell Line Derived Xenograft Tissue"},{"name":"NCI_META_CUI","value":"CL563174"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C184757":{"preferredName":"Expanded Next Generation Cancer Model","code":"C184757","definitions":[{"definition":"A next generation cancer model that has been expanded using tissue culture or other methods.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Expanded Next Generation Cancer Model","termGroup":"PT","termSource":"NCI"},{"termName":"Expanded NGCM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Expanded Next Generation Cancer Model"},{"name":"NCI_META_CUI","value":"CL1773074"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C172267":{"preferredName":"Formalin-Fixed Paraffin-Embedded Tissue Sample from Recurrent Disease","code":"C172267","definitions":[{"definition":"A formalin-fixed, paraffin-embedded sample derived from tissue isolated from a subject with recurrent disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded Tissue Sample from Recurrent Disease","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE Recurrent Disease Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE Recurrent"},{"name":"NCI_META_CUI","value":"CL1406148"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172268":{"preferredName":"Formalin-Fixed Paraffin-Embedded Tissue Scroll","code":"C172268","definitions":[{"definition":"A formalin-fixed, paraffin-embedded tissue sample that has been cut on a microtome so that it rolls up on itself.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded Tissue Scroll","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE Scroll","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE Scroll"},{"name":"NCI_META_CUI","value":"CL1406147"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172293":{"preferredName":"Original Tumor Cell Sample","code":"C172293","definitions":[{"definition":"A sample comprised of cells that were isolated from a tumor and have not been cultured or expanded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Original Tumor Cell Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Original Tumor Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"08"},{"name":"Maps_To","value":"Human Tumor Original Cells"},{"name":"NCI_META_CUI","value":"CL1406152"},{"name":"Semantic_Type","value":"Cell"}]}}{"C36118":{"preferredName":"In Situ Lesion","code":"C36118","synonyms":[{"termName":"In Situ Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"In_Situ_Lesion"},{"name":"Maps_To","value":"In Situ Neoplasms"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1334167"}]}}{"C13049":{"preferredName":"Lymphoid Tissue","code":"C13049","definitions":[{"definition":"Tissue characterized by the presence of large numbers of lymphocytes in different stages of transformation. Connective tissue cells including fibroblasts and macrophages may be present. Lymphoid tissue is framed by a network of reticular fibers and may be diffuse, or densely aggregated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoid Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphoid_Tissue"},{"name":"Maps_To","value":"Lymphoid"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0024296"}]}}{"C172295":{"preferredName":"Next Generation Cancer Model","code":"C172295","definitions":[{"definition":"An approach to cancer modeling that utilizes clinical data as well as the genomic and transcriptomic profiles of the parent tumor, metastases, if present, and case-matched normal tissues from individual patients.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"RFA-CA-19-055"}]}],"synonyms":[{"termName":"Next Generation Cancer Model","termGroup":"PT","termSource":"NCI"},{"termName":"NGCM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Next Generation Cancer Model"},{"name":"NCI_META_CUI","value":"CL1406176"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C156444":{"preferredName":"Post Neoadjuvant Therapy Sample","code":"C156444","definitions":[{"definition":"A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post Neoadjuvant Therapy Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Post Neo-adjuvant Therapy Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post neo-adjuvant therapy"},{"name":"NCI_META_CUI","value":"CL563175"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C12932":{"preferredName":"Xenograft","code":"C12932","definitions":[{"definition":"Cells, tissues, or organs from a donor that are transplanted into a recipient of another species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xenograft","termGroup":"PT","termSource":"NCI"},{"termName":"Heterograft","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Xenograft"},{"name":"Maps_To","value":"Xenograft"},{"name":"Semantic_Type","value":"Biomedical or Dental Material"},{"name":"UMLS_CUI","value":"C0522537"}]}}{"C174119":{"preferredName":"Saliva Sample","code":"C174119","definitions":[{"definition":"A small volume of saliva removed for testing or storage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saliva Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Saliva"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C1608524"}]}}{"C172296":{"preferredName":"Biospecimen on a Slide","code":"C172296","definitions":[{"definition":"The deposition of a biospecimen onto a slide prior to analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biospecimen on a Slide","termGroup":"PT","termSource":"NCI"},{"termName":"Sample on a Slide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Slides"},{"name":"NCI_META_CUI","value":"CL1406175"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C164033":{"preferredName":"Tumor-Adjacent Normal Post Neoadjuvant Therapy Sample","code":"C164033","definitions":[{"definition":"A specimen derived from a tumor-adjacent normal tissue specimen that was collected from the subject after treatment with a neoadjuvant therapeutic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor-Adjacent Normal Post Neoadjuvant Therapy Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor Adjacent Normal - Post Neo-adjuvant Therapy"},{"name":"NCI_META_CUI","value":"CL977197"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C184781":{"preferredName":"Next Generation Cancer Model Expanded Under Non-Conforming Conditions","code":"C184781","definitions":[{"definition":"A next generation cancer model that has been expanded using unconventional culturing methods.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Next Generation Cancer Model Expanded Under Non-Conforming Conditions","termGroup":"PT","termSource":"NCI"},{"termName":"NGCM Expanded Under Non-Conforming Conditions","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Next Generation Cancer Model Expanded Under Non-Conforming Conditions"},{"name":"NCI_META_CUI","value":"CL1773098"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C172297":{"preferredName":"Prospective Tissue Collection","code":"C172297","definitions":[{"definition":"A process by which a tissue sample is collected from a subject prior to treatment or enrollment in a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prospective Tissue Collection","termGroup":"PT","termSource":"NCI"},{"termName":"Prospective Collection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prospective"},{"name":"NCI_META_CUI","value":"CL1406174"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C172298":{"preferredName":"Retrospective Tissue Collection","code":"C172298","definitions":[{"definition":"A process by which a tissue sample is collected from a subject following treatment or participation in a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retrospective Tissue Collection","termGroup":"PT","termSource":"NCI"},{"termName":"Retrospective Collection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retrospective"},{"name":"NCI_META_CUI","value":"CL1406173"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C25401":{"preferredName":"Abnormal","code":"C25401","definitions":[{"definition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.","type":"DEFINITION","source":"NCI"},{"definition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Not normal. An abnormal lesion or growth may be cancer, premalignant (likely to become cancer), or benign (not cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Abnormal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Abnormal"},{"name":"Maps_To","value":"Abnormal"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205161"}]}}{"C119010":{"preferredName":"Peritumoral","code":"C119010","definitions":[{"definition":"Located in tissues surrounding a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritumoral","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peritumoral"},{"name":"Semantic_Type","value":"Spatial Concept"},{"name":"UMLS_CUI","value":"C3897941"}]}}{"C7464":{"preferredName":"Acute Leukemia of Ambiguous Lineage","code":"C7464","definitions":[{"definition":"A rare subtype of acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid, or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. These subtypes account for less than 4% of cases of acute leukemia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Leukemia of Ambiguous Lineage","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Leukemia of Indeterminate Lineage","termGroup":"SY","termSource":"NCI"},{"termName":"ALAL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Leukemia_of_Ambiguous_Lineage"},{"name":"Maps_To","value":"Acute Leukemia of Ambiguous Lineage (ALAL)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301357"}]}}{"C9291":{"preferredName":"Anal Carcinoma","code":"C9291","definitions":[{"definition":"A carcinoma that arises from the anus. Anal carcinomas include the anal canal and perianal area (anal margin) carcinomas. Perianal carcinomas are staged separately as skin carcinomas in AJCC v6 and v7 editions. The AJCC v8 edition staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin).","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the anus. The anus is the opening of the rectum (last part of the large intestine) to the outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Anus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anal_Carcinoma"},{"name":"Maps_To","value":"Anal Cancer (all types)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279637"}]}}{"C132067":{"preferredName":"Low Grade Glioma","code":"C132067","definitions":[{"definition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"LGG","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS, low grade glioma (LGG)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1997217"}]}}{"C3222":{"preferredName":"Medulloblastoma","code":"C3222","definitions":[{"definition":"A malignant brain tumor that begins in the lower part of the brain and that can spread to the spine or to other parts of the body. Medulloblastomas are a type of primitive neuroectodermal tumor (PNET).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rapidly progressive cancer of the brain that originates in the cerebellum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9470/3"},{"name":"Legacy Concept Name","value":"Medulloblastoma"},{"name":"Maps_To","value":"CNS, medulloblastoma"},{"name":"Maps_To","value":"Medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025149"}]}}{"C184750":{"preferredName":"Personal History of Other Central Nervous System Tumor","code":"C184750","definitions":[{"definition":"An individual history of a cancer occurring in the central nervous system, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Central Nervous System Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Central Nervous System Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Other Central Nervous System Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS, other"},{"name":"NCI_META_CUI","value":"CL1773067"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184751":{"preferredName":"Personal History of Central Nervous System Rhabdoid Tumor","code":"C184751","definitions":[{"definition":"An individual history of a rhabdoid tumor occurring in the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Central Nervous System Rhabdoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"History of Central Nervous System Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS, rhabdoid tumor"},{"name":"NCI_META_CUI","value":"CL1773080"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184765":{"preferredName":"Personal History of Acute Myeloid Leukemia with Induction Failure","code":"C184765","definitions":[{"definition":"An individual history of acute myeloid leukemia and induction failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Acute Myeloid Leukemia with Induction Failure","termGroup":"PT","termSource":"NCI"},{"termName":"History of Acute Myeloid Leukemia with Induction Failure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Induction Failure AML (AML-IF)"},{"name":"NCI_META_CUI","value":"CL1773082"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C166238":{"preferredName":"Non-Tumor Tissue Area","code":"C166238","definitions":[{"definition":"The area within a sample that is represented by non-tumor tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Tumor Tissue Area","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"Non cancerous tissue"},{"name":"NCI_META_CUI","value":"CL971284"},{"name":"Semantic_Type","value":"Spatial Concept"}]}}{"C8715":{"preferredName":"Rhabdoid Tumor of the Kidney","code":"C8715","definitions":[{"definition":"A rhabdoid tumor that arises from the kidney.  It occurs in children and it is associated with abnormalities of chromosome 22. It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  The prognosis is poor.","type":"DEFINITION","source":"NCI"},{"definition":"A rhabdoid tumor that arises in the kidney.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Rhabdoid Tumor of the Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"MRTK","termGroup":"AB","termSource":"NCI"},{"termName":"Renal Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of the Kidney (RTK)","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumour of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumour of the Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Rhabdoid_Tumour_of_the_Kidney"},{"name":"Maps_To","value":"Rhabdoid tumor (kidney) (RT)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0854917"}]}}{"C7978":{"preferredName":"Ovarian Serous Cystadenocarcinoma","code":"C7978","definitions":[{"definition":"A malignant serous cystic epithelial neoplasm arising from the ovary.  It is characterized by the presence of glandular, papillary, or solid structures.  Psammoma bodies may be present.  In well differentiated cases the malignant epithelial cells resemble the cells of fallopian tube epithelium.  In poorly differentiated cases the malignant epithelial cells show anaplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Serous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Serous_Cystadenocarcinoma"},{"name":"Maps_To","value":"15"},{"name":"Maps_To","value":"21"},{"name":"Maps_To","value":"40"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279663"}]}}{"C4349":{"preferredName":"Colon Adenocarcinoma","code":"C4349","definitions":[{"definition":"An adenocarcinoma arising from the colon.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, colonic adenocarcinomas are divided into well, moderately, and poorly differentiated.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colon Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Colonic Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colon_Adenocarcinoma"},{"name":"Maps_To","value":"30"},{"name":"Maps_To","value":"41"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0338106"}]}}{"C3512":{"preferredName":"Lung Adenocarcinoma","code":"C3512","definitions":[{"definition":"A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"LUAD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Adenocarcinoma"},{"name":"Maps_To","value":"52"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152013"}]}}{"C3493":{"preferredName":"Lung Squamous Cell Carcinoma","code":"C3493","definitions":[{"definition":"A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LSCC","termGroup":"AB","termSource":"NCI"},{"termName":"LUSC","termGroup":"AB","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Lung_Carcinoma"},{"name":"Maps_To","value":"60"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0149782"}]}}{"C7558":{"preferredName":"Endometrial Carcinoma","code":"C7558","definitions":[{"definition":"A malignant epithelial neoplasm arising from the lining of the uterine body cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissue lining the uterus (the small, hollow, pear-shaped organ in a woman's pelvis in which a fetus develops). Most endometrial cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Endometrial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"UCEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrial_Carcinoma"},{"name":"Maps_To","value":"81"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0476089"}]}}{"C19594":{"preferredName":"Not Otherwise Specified","code":"C19594","definitions":[{"definition":"Not characterized in any other way.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Not Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Not_Otherwise_Specified"},{"name":"Maps_To","value":"NOS"},{"name":"Maps_To","value":"Not Otherwise Specified"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1518425"}]}}{"C165212":{"preferredName":"Cell Culture Image","code":"C165212","definitions":[{"definition":"Any image of cells grown or manipulated in a tissue culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell Culture Image","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cell Culture Image"},{"name":"NCI_META_CUI","value":"CL978394"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C165215":{"preferredName":"Slide Image","code":"C165215","definitions":[{"definition":"Any image of cells or tissue sections on a slide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Slide Image","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Slide Image"},{"name":"NCI_META_CUI","value":"CL978397"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C171154":{"preferredName":"Tissue Microarray Image","code":"C171154","definitions":[{"definition":"Any image of clinical tissue specimens within a tissue microarray.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tissue Microarray Image","termGroup":"PT","termSource":"NCI"},{"termName":"TMA Image","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tissue Microarray Image"},{"name":"NCI_META_CUI","value":"CL1405378"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C48230":{"preferredName":"JPEG","code":"C48230","definitions":[{"definition":"A file compression format mostly used for color and greyscale photographs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JPEG","termGroup":"PT","termSource":"NCI"},{"termName":"Joint Photographic Experts Group Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"JPEG"},{"name":"Maps_To","value":"JPEG"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1708584"}]}}{"C172214":{"preferredName":"Spectral View Settings Format","code":"C172214","definitions":[{"definition":"An electronic file format based on TIFF that is used for storing multiple high-resolution images in a single electronic file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spectral View Settings Format","termGroup":"PT","termSource":"NCI"},{"termName":"Spectral View Settings","termGroup":"SY","termSource":"NCI"},{"termName":"SVS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SVS"},{"name":"NCI_META_CUI","value":"CL1406108"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C70631":{"preferredName":"TIFF","code":"C70631","definitions":[{"definition":"A bitmap graphics file format utilizing tagged fields.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TIFF","termGroup":"PT","termSource":"NCI"},{"termName":"Tagged Image File Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TIFF"},{"name":"Maps_To","value":"TIFF"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2348636"}]}}{"C184768":{"preferredName":"JPEG 2000 Format","code":"C184768","definitions":[{"definition":"A discrete wavelet transform (DWT)-based compression standard electronic file format for storing video images.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JPEG 2000 Format","termGroup":"PT","termSource":"NCI"},{"termName":"Joint Photographic Experts Group 2000 Format","termGroup":"SY","termSource":"NCI"},{"termName":"JP2","termGroup":"SY","termSource":"NCI"},{"termName":"JPEG 2000","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JPEG 2000"},{"name":"NCI_META_CUI","value":"CL1773097"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C16396":{"preferredName":"Cell Culture","code":"C16396","definitions":[{"definition":"Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. [Source: Medical Subject Headings]  EXAMPLE(S):  OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"Controlled cell proliferation in flasks, fermentors or other devices under defined growth conditions.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"eManu"}]},{"definition":"General term referring to the maintenance of cell strains or lines in the laboratory.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Cell Culture","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cell_Culture"},{"name":"Maps_To","value":"Cell Culture"},{"name":"NCI_META_CUI","value":"CL473433"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C165218":{"preferredName":"Diagnostic Slide","code":"C165218","definitions":[{"definition":"A slide on which a biospecimen has been mounted in order to perform a microscopy-based diagnostic test.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diagnostic Slide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diagnostic Slide"},{"name":"NCI_META_CUI","value":"CL365977"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C165223":{"preferredName":"Tissue Slide","code":"C165223","definitions":[{"definition":"A slide on which a tissue section has been mounted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tissue Slide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tissue Slide"},{"name":"NCI_META_CUI","value":"CL978404"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C23011":{"preferredName":"Hematoxylin and Eosin Staining Method","code":"C23011","definitions":[{"definition":"A microscopy staining method that utilizes two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematoxylin and Eosin Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"H and E","termGroup":"SY","termSource":"NCI"},{"termName":"H and E Staining","termGroup":"SY","termSource":"NCI"},{"termName":"H and E Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"H&E","termGroup":"SY","termSource":"NCI"},{"termName":"H&E Staining","termGroup":"SY","termSource":"NCI"},{"termName":"H&E Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Hematoxylin and Eosin","termGroup":"SY","termSource":"NCI"},{"termName":"Hematoxylin and Eosin Staining","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hematoxylin_and_Eosin_Staining_Method"},{"name":"Maps_To","value":"Haemotoxylin and Eosin (H&E)"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0523207"}]}}{"C164052":{"preferredName":"Aligned Sequence Read","code":"C164052","definitions":[{"definition":"The determination of the order of a set of sequenced nucleic acid fragments via alignment to a reference genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Sequence Read","termGroup":"PT","termSource":"NCI"},{"termName":"Aligned Read","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aligned Reads"},{"name":"NCI_META_CUI","value":"CL977210"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C153249":{"preferredName":"Binary Alignment Map","code":"C153249","definitions":[{"definition":"A binary representation of a sequence alignment map (SAM), a compact and indexable representation of nucleotide sequence alignments, compressed by the BGZF (Blocked GNU Zip Format) library.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Binary Alignment Map","termGroup":"PT","termSource":"NCI"},{"termName":"BAM","termGroup":"SY","termSource":"NCI"},{"termName":"Binary Alignment/Map","termGroup":"SY","termSource":"NCI"},{"termName":"Binary Sequence Alignment Map","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BAM"},{"name":"NCI_META_CUI","value":"CL554575"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C165220":{"preferredName":"Low-Pass Whole Genome Sequencing","code":"C165220","definitions":[{"definition":"A form of whole genome sequencing where the sequencing read depth falls between 0.1 and 30 times.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low-Pass Whole Genome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Low Pass WGS","termGroup":"SY","termSource":"NCI"},{"termName":"Low Pass Whole Genome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Pass WGS","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Pass Whole-Genome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"LP WGS","termGroup":"AB","termSource":"NCI"},{"termName":"LP-WGS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Pass WGS"},{"name":"NCI_META_CUI","value":"CL978401"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C94411":{"preferredName":"Genomic Profile","code":"C94411","definitions":[{"definition":"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Genomic Profile","termGroup":"PT","termSource":"NCI"},{"termName":"Genome Profile","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Profiling","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Test","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Testing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genomic Profiling"},{"name":"Maps_To","value":"submitted_genomic_profile"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2986505"}]}}{"C171155":{"preferredName":"Combined Nucleotide Variation Profile","code":"C171155","definitions":[{"definition":"A genomic profile that includes all of the genome variants and/or polymorphisms detected during nucleotide sequencing of one or more samples derived from an individual subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Nucleotide Variation Profile","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Combined Nucleotide Variation"},{"name":"NCI_META_CUI","value":"CL1405377"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184758":{"preferredName":"FoundationOne Report","code":"C184758","definitions":[{"definition":"A document provided by FoundationOne listing the sequence variants, genetic aberrations and tumor biomarker-related findings detected in a solid or liquid tumor sample subjected to their proprietary companion diagnostic (CDx) testing. The report also may contain select clinical data related to the findings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FoundationOne Report","termGroup":"PT","termSource":"NCI"},{"termName":"FoundationOne CDx Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FoundationOne Report"},{"name":"NCI_META_CUI","value":"CL1773075"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184760":{"preferredName":"GENIE Report","code":"C184760","definitions":[{"definition":"A document that reports the sequence variants, genetic aberrations and tumor biomarker-related findings detected in a tumor sample and compares the findings to data stored the Genomics Evidence Neoplasia Information Exchange (GENIE) registry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GENIE Report","termGroup":"PT","termSource":"NCI"},{"termName":"Genomics Evidence Neoplasia Information Exchange Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GENIE Report"},{"name":"NCI_META_CUI","value":"CL1773089"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184794":{"preferredName":"Raw CpG Island Variation Data","code":"C184794","definitions":[{"definition":"CpG island sequence variation data that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw CpG Island Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw CGI Variant Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw CGI Variation Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw CpG Island Variant Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw CGI Variant"},{"name":"NCI_META_CUI","value":"CL1772992"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C172215":{"preferredName":"Mutation Annotation Format","code":"C172215","definitions":[{"definition":"A tab-delimited text file containing mutation information aggregated from variant call files (VCF) across a project, trial or study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutation Annotation Format","termGroup":"PT","termSource":"NCI"},{"termName":"MAF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"MAF"},{"name":"NCI_META_CUI","value":"CL1406107"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172216":{"preferredName":"Variant Call File Format","code":"C172216","definitions":[{"definition":"A text-based electronic file used for storing gene sequence variation data. The first text section is composed of a header containing the metadata and keywords used in the file. This is followed by the body of the file which is tab-separated into eight mandatory data columns for each sample. Additionally, the body of the file can include an unlimited number of optional columns to record other sample-related data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Variant Call File Format","termGroup":"PT","termSource":"NCI"},{"termName":"Variant Call File","termGroup":"SY","termSource":"NCI"},{"termName":"VCF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"VCF"},{"name":"NCI_META_CUI","value":"CL1406106"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C45967":{"preferredName":"Extensible Markup Language","code":"C45967","definitions":[{"definition":"A general-purpose markup language for creating special-purpose markup languages. It is capable of describing many different kinds of data. Its primary purpose is to facilitate the sharing of data across different systems, particularly systems connected via the Internet.","type":"DEFINITION","source":"NCI"},{"definition":"A set of rules for encoding documents and data in a format that is both human readable and machine readable. [After Study Data Technical Conformance Guide, Technical Specifications Document, March 2019; After W3C Extensible Markup Language (XML)] See also eXtensible markup language (XML) data element, Define-XML.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Extensible Markup Language","termGroup":"PT","termSource":"NCI"},{"termName":"XML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Extensible_Markup_Language"},{"name":"Maps_To","value":"XML"},{"name":"Semantic_Type","value":"Language"},{"name":"UMLS_CUI","value":"C1707981"}]}}{"C63328":{"preferredName":"DNA Methylation Analysis","code":"C63328","definitions":[{"definition":"The analysis of the methylated deoxyribonucleotides present in the genome in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Methylation Analysis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DNA_Methylation_Analysis"},{"name":"Maps_To","value":"DNA Methylation"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1880239"}]}}{"C164051":{"preferredName":"Methylation Beta Value","code":"C164051","definitions":[{"definition":"An estimate for the level of DNA methylation in a set of replicate samples that is calculated as the ratio of average signal intensities for methylated alleles divided by the average signal intensities of methylated alleles (M) plus unmethylated alleles (U) plus an offset factor (a), such that beta (b) equals M/(M+U+a). Beta values must fall between zero and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylation Beta Value","termGroup":"PT","termSource":"NCI"},{"termName":"Beta Value","termGroup":"SY","termSource":"NCI"},{"termName":"DNA Methylation Beta Value","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methylation Beta Value"},{"name":"NCI_META_CUI","value":"CL977211"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C85873":{"preferredName":"Plain Text Data Format","code":"C85873","definitions":[{"definition":"A data format consisting of readable textual material maintained as a sequential file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plain Text Data Format","termGroup":"PT","termSource":"NCI"},{"termName":"TXT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TXT"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2828004"}]}}{"C165222":{"preferredName":"DNA Methylation Array","code":"C165222","definitions":[{"definition":"The use of a high-throughput microarray where all of the known CpG islands either in a single specimen or all of the known promoter sequences of a specimen or a population group are coupled to beads or microwells to determine which are methylated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Methylation Array","termGroup":"PT","termSource":"NCI"},{"termName":"Methylation Array","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methylation Array"},{"name":"NCI_META_CUI","value":"CL978403"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C200431":{"preferredName":"Illumina Infinium Methylation BeadChip System","code":"C200431","definitions":[{"definition":"A platform that leverages bisulfite conversion with proprietary high-throughput silica beads on a chip microarray libraries, sequencing technology and sequence analysis tools developed by Illumina to analyze genome- and epigenome-wide DNA methylation at single nucleotide resolution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Illumina Infinium Methylation BeadChip System","termGroup":"PT","termSource":"NCI"},{"termName":"Illumina Infinium Methylation BeadChip Assay System","termGroup":"SY","termSource":"NCI"},{"termName":"Illumina Methylation","termGroup":"SY","termSource":"NCI"},{"termName":"Illumina Methylation Assay System","termGroup":"SY","termSource":"NCI"},{"termName":"Infinium Methylation BeadChip System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Illumina Human Methylation 27"},{"name":"Maps_To","value":"Illumina Human Methylation 450"},{"name":"Maps_To","value":"Illumina Methylation Epic"},{"name":"Maps_To","value":"Illumina Methylation Epic v2"},{"name":"NCI_META_CUI","value":"CL1907432"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C40207":{"preferredName":"Copy Number Polymorphism","code":"C40207","definitions":[{"definition":"Refers to the genetic trait involving the number of copies of a particular gene present in the genome of an individual. Genetic variants, including insertions, deletions, and duplications of segments of DNA, are also collectively referred to as copy number variants. Copy number variants account for a significant proportion of the genetic variation between individuals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Variation in the number of copies of a particular sequence within the genetic material of an individual. Large-scale copy number polymorphisms are common and widely distributed in the human genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copy Number Polymorphism","termGroup":"PT","termSource":"NCI"},{"termName":"CNA","termGroup":"AB","termSource":"NCI"},{"termName":"CNP","termGroup":"AB","termSource":"NCI"},{"termName":"CNV","termGroup":"AB","termSource":"NCI"},{"termName":"Copy Number Alteration","termGroup":"SY","termSource":"NCI"},{"termName":"Copy Number Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Copy_Number_Polymorphism"},{"name":"Maps_To","value":"Copy Number Variation"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C1511518"}]}}{"C165213":{"preferredName":"Copy Number Estimate","code":"C165213","definitions":[{"definition":"An estimation on the number of copies of a nucleic acid sequence of interest found in a sample using an algorithm that is based on the length and average mass of the sequence of interest and/or involves the normalization of a set of results gathered from similar samples or duplicate runs of a single sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copy Number Estimate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Copy Number Estimate"},{"name":"NCI_META_CUI","value":"CL978395"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C165219":{"preferredName":"Genotyping Array","code":"C165219","definitions":[{"definition":"The application of microarray technology to the determination of the nucleotide sequence of the genetic material of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genotyping Array","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genotyping Array"},{"name":"NCI_META_CUI","value":"CL978400"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C164053":{"preferredName":"Unaligned Sequence Read","code":"C164053","definitions":[{"definition":"A set of sequenced nucleic acid fragments that have not been aligned to each other or to a reference sequence or genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unaligned Sequence Read","termGroup":"PT","termSource":"NCI"},{"termName":"Unaligned Read","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unaligned Reads"},{"name":"NCI_META_CUI","value":"CL977209"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C153250":{"preferredName":"FASTQ Format","code":"C153250","definitions":[{"definition":"A text-based format for storing a biological sequence that encodes the nucleotide calls as well as their quality scores. It is an extension of the FASTA format.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FASTQ Format","termGroup":"PT","termSource":"NCI"},{"termName":"FASTQ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FASTQ"},{"name":"NCI_META_CUI","value":"CL554479"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172301":{"preferredName":"Read Pair 1","code":"C172301","definitions":[{"definition":"The read direction identified as number 1 in a paired-end nucleotide sequencing reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Read Pair 1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"R1"},{"name":"NCI_META_CUI","value":"CL1406307"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C172302":{"preferredName":"Read Pair 2","code":"C172302","definitions":[{"definition":"The read direction identified as number 2 in a paired-end nucleotide sequencing reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Read Pair 2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"R2"},{"name":"NCI_META_CUI","value":"CL1406328"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C156813":{"preferredName":"Initial Diagnosis","code":"C156813","definitions":[{"definition":"The first diagnosis of the disease.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The first diagnosis of the individual's condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Initial Diagnosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Adulthood"},{"name":"Maps_To","value":"Initial Diagnosis"},{"name":"NCI_META_CUI","value":"CL935841"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C35571":{"preferredName":"Progressive Disease","code":"C35571","definitions":[{"definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","type":"DEFINITION","source":"NCI"},{"definition":"A disease process that is increasing in extent or severity. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Progressive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Progressive_Disease"},{"name":"Maps_To","value":"PD-Progressive Disease"},{"name":"Maps_To","value":"Progressive Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1335499"}]}}{"C38155":{"preferredName":"Recurrent Disease","code":"C38155","definitions":[{"definition":"The return of a disease after a period of remission.","type":"DEFINITION","source":"NCI"},{"definition":"The return of a disease after a period of remission.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The return of a disease after a period of remission.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The return of a disease after a period of remission.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"The return of a disease or the signs and symptoms of a disease after a period of improvement.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recurrent Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Relapse","termGroup":"SY","termSource":"NCI"},{"termName":"Relapse, Site Not Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Relapsed Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Recurrent_Disease"},{"name":"Maps_To","value":"Recurrence"},{"name":"Maps_To","value":"Recurrent Disease"},{"name":"Maps_To","value":"Relapse"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0277556"}]}}{"C4809":{"preferredName":"Residual Disease","code":"C4809","definitions":[{"definition":"Cancer cells that remain after attempts to remove the cancer have been made.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Tumor cells that remain in the body following cancer treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Residual Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Residual_Disease"},{"name":"Maps_To","value":"Residual Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0543478"}]}}{"C90169":{"preferredName":"Persistent Disease","code":"C90169","definitions":[{"definition":"A disease that does not go to remission despite treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Persistent Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Persistent Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2983415"}]}}{"C39752":{"preferredName":"Refractory Disease","code":"C39752","definitions":[{"definition":"A disease that is not responsive to treatment.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disease that resists treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Refractory_Disease"},{"name":"Maps_To","value":"Refractory Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1514815"}]}}{"C41331":{"preferredName":"Adverse Event","code":"C41331","definitions":[{"definition":"An unexpected medical problem that happens during treatment with a drug or other therapy. Adverse effects do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any health problem that happens during the study. (https://mrctcenter.org/glossaryterm/adverse-event/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"Any unfavorable and unintended sign, symptom, disease, or other medical occurrence with a temporal association with the use of a medical product, procedure or other therapy, or in conjunction with a research study, regardless of causal relationship.   EXAMPLE(S): death, back pain, headache, pulmonary embolism, heart attack  OTHER NAME(S):  NOTE(S): The BRIDG SCC has a GForge Tracker Issue (#31893) indicating a need to validate the requirement that every AdverseEvent be described by a SafetyReportVersion.","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"Any unfavorable and unintended sign, symptom, disease, or other medical occurrence with a temporal association with the use of a medical product, procedure or other therapy, or in conjunction with a research study, regardless of causal relationship. EXAMPLE(S): death, back pain, headache, pulmonary embolism, heart attack","type":"ALT_DEFINITION","source":"BRIDG 3.0.3"},{"definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","type":"DEFINITION","source":"NCI"},{"definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. NOTE: For further information, see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. [Modified from ICH E2A] Synonyms: side effect, adverse experience. See also serious adverse event, serious adverse experience. (CDISC glossary)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. an adverse event (AE) can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. NOTE: For further information, see the ICH Guideline for Clinical safety Data Management: Definitions and standards for expedited Reporting. [After ICH E2A] See also serious adverse event, serious adverse experience.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Adverse Experience","termGroup":"SY","termSource":"NCI"},{"termName":"AE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Adverse_Event"},{"name":"Maps_To","value":"Adverse Event"},{"name":"Maps_To","value":"Adverse Event/Complications"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0877248"}]}}{"C82568":{"preferredName":"Study Medication Completed","code":"C82568","definitions":[{"definition":"An indication or description that the planned amount of medication was taken by the subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Study Medication Completed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Study_Medication_Completed"},{"name":"Maps_To","value":"Course of Therapy Completed"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2826299"}]}}{"C49634":{"preferredName":"Withdrawal by Subject","code":"C49634","definitions":[{"definition":"An indication that a study participant has removed themself from the study or from one or more segments of the study.","type":"DEFINITION","source":"NCI"},{"definition":"The subject-initiated act of discontinuing participation in a clinical study. NOTE: Withdrawal can range from the subject's complete withdrawal from study procedures and follow-up activities, to the subject's withdrawal from study-related interventions. [After Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues, September 21, 2010] See also discontinuation.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"The subject-initiated act of discontinuing participation in the study as a whole or one or more aspects of the study (e.g., a study period or use of biospecimens).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"To stop being a participant in a study. (https://mrctcenter.org/glossaryterm/withdraw/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Withdrawal by Subject","termGroup":"PT","termSource":"NCI"},{"termName":"Subject Dropped Out","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Withdrawal_by_Subject"},{"name":"Maps_To","value":"Withdrawal by Subject"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C1710677"}]}}{"C13041":{"preferredName":"Body","code":"C13041","definitions":[{"definition":"The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces.","type":"DEFINITION","source":"NCI"},{"definition":"The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Body"},{"name":"Maps_To","value":"Body, total"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1268086"}]}}{"C179433":{"preferredName":"Distant Site Receiving Treatment","code":"C179433","definitions":[{"definition":"The anatomic site that is located away from the primary disease site and is the target of a medical intervention.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Distant Site Receiving Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Treatment of Distant Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Site"},{"name":"NCI_META_CUI","value":"CL1662207"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C165193":{"preferredName":"Epitrochlear Region","code":"C165193","definitions":[{"definition":"The inner surface of the upper arm adjacent to the elbow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epitrochlear Region","termGroup":"PT","termSource":"NCI"},{"termName":"Epitrochlear","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epitrochlear"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0450279"}]}}{"C13359":{"preferredName":"Gastrointestinal","code":"C13359","definitions":[{"definition":"Pertaining to the stomach and intestines.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to the stomach and intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Relating to the stomach or duodenum as the intended site of administration, where direct administration is achieved using an appropriate device.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Gastrointestinal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal"},{"name":"Maps_To","value":"Gastrointestinal, Intestine"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0521362"}]}}{"C25350":{"preferredName":"Genitourinary","code":"C25350","definitions":[{"definition":"Of or related to the genital and urinary organs or their functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genitourinary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Genitourinary"},{"name":"Maps_To","value":"Genitourinary, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C3887515"}]}}{"C25724":{"preferredName":"Hilar","code":"C25724","definitions":[{"definition":"Refers to the area associated with the hilum.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to the area associated with the hilum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Refers to the area where nerves and blood vessels attach to an organ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hilar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hilar"},{"name":"Maps_To","value":"Hilar"},{"name":"NCI_META_CUI","value":"CL053209"},{"name":"Semantic_Type","value":"Spatial Concept"}]}}{"C13066":{"preferredName":"Ileocecal Valve","code":"C13066","definitions":[{"definition":"The valve between the ileum of the small intestine and the cecum of the large intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ileocecal Valve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileocecal_Valve"},{"name":"Maps_To","value":"Ileocecal Valve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020880"}]}}{"C12507":{"preferredName":"Mantle Field","code":"C12507","definitions":[{"definition":"A type of extended radiation field that includes lymph node areas in the neck, chest, and axilla.","type":"DEFINITION","source":"NCI"},{"definition":"The area of the neck, chest, and lymph nodes in the armpit that are exposed to radiation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mantle Field","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mantle_Field"},{"name":"Maps_To","value":"Mantle"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C1512986"}]}}{"C43200":{"preferredName":"Pouch","code":"C43200","definitions":[{"definition":"A flexible container used to protect or hold one or more doses of a drug product (e.g. a pouch into which oral contraceptive blister packs are inserted, and an overwrap pouch for large volume parenterals).","type":"ALT_DEFINITION","source":"PQCMC"},{"definition":"A flexible container used to protect or hold one or more doses of a drug product (e.g. a pouch into which oral contraceptive blister packs are inserted, and an overwrap pouch for large volume parenterals).","type":"DEFINITION","source":"NCI"},{"definition":"Item of packaging intended for use as an intermediate or outer container, intended to contain one or more medicinal product(s); it is made of a flexible material and may be for single use or be re-usable, and may be fitted with a closure system. Bags and sachets are excluded.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Pouch","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Package Type (C-DRG-00907)"},{"name":"Legacy Concept Name","value":"Drug_Pouch"},{"name":"Maps_To","value":"Pouch"},{"name":"NCI_META_CUI","value":"CL333395"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C179450":{"preferredName":"Primary Tumor Field","code":"C179450","definitions":[{"definition":"The anatomic site(s) surrounding and including a primary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Tumor Field","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Primary Tumor Field"},{"name":"NCI_META_CUI","value":"CL1662308"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C179451":{"preferredName":"Primary Tumor Site","code":"C179451","definitions":[{"definition":"The anatomic location of a primary tumor.","type":"DEFINITION","source":"NCI"},{"definition":"The anatomical location of the primary tumor site of disease.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Primary Tumor Site","termGroup":"PT","termSource":"NCI"},{"termName":"Anatomic Site of Primary Tumor Origin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Primary tumor site"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0475447"}]}}{"C90348":{"preferredName":"Prostate Bed","code":"C90348","definitions":[{"definition":"The anatomical space just below the bladder within which the prostate is situated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cavity just below the bladder where the prostate gland is located.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Bed","termGroup":"PT","termSource":"NCI"},{"termName":"Prostate Fossa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostate Bed"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2983573"}]}}{"C179457":{"preferredName":"Regional Site Receiving Treatment","code":"C179457","definitions":[{"definition":"The anatomic site that is located near the primary disease site and is targeted by a medical intervention.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regional Site Receiving Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Treatment of Regional Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regional Site"},{"name":"NCI_META_CUI","value":"CL1662286"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C164047":{"preferredName":"Skin of the Lower Extremity","code":"C164047","definitions":[{"definition":"The integument that covers the lower limb.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The integumentary covering of the lower extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Lower Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Extremity Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Skin of the Lower Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin, lower extremity, local"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1266887"}]}}{"C164048":{"preferredName":"Skin of the Upper Extremity","code":"C164048","definitions":[{"definition":"The integument that covers the upper limb.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The integumentary covering of the upper extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Upper Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of the Upper Limb","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Extremity Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin, upper extremity, local"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0205032"}]}}{"C64693":{"preferredName":"Centigray","code":"C64693","definitions":[{"definition":"The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Centigray","termGroup":"PT","termSource":"NCI"},{"termName":"cGy","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Centigray"},{"name":"Maps_To","value":"cGy"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0556645"}]}}{"C18063":{"preferredName":"Gray","code":"C18063","definitions":[{"definition":"A SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gray","termGroup":"PT","termSource":"NCI"},{"termName":"Gy","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gray"},{"name":"Maps_To","value":"Gy"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0556636"}]}}{"C28253":{"preferredName":"Milligram","code":"C28253","definitions":[{"definition":"A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass equal to one thousandth (1E-3) of a gram.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram","termGroup":"PT","termSource":"NCI"},{"termName":"mg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Milligram"},{"name":"Maps_To","value":"mg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439210"}]}}{"C64774":{"preferredName":"Area Under Curve","code":"C64774","definitions":[{"definition":"The area between the x-axis and the curve given by the integrand, equal to the definite integral of a function. For the purpose of pharmacokinetic measurements, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in tissue, blood, or other body fluid against time.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The area between the x-axis and the curve given by the integrand. It is equal to the definite integral of a function. In the field of pharmacokinetics, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in plasma against time. AUC is usually given for the time interval zero to infinity, and other time intervals are indicated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Area Under Curve","termGroup":"PT","termSource":"NCI"},{"termName":"AUC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Area_under_Curve"},{"name":"Maps_To","value":"AUC"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0376690"}]}}{"C67372":{"preferredName":"Gram per 24 Hours","code":"C67372","definitions":[{"definition":"A metric mass flow rate unit equal to the rate at which mass of matter of one gram crosses a given surface or/and is transferred over a period of twenty four hours.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass flow rate equal to one gram per day.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gram per 24 Hours","termGroup":"PT","termSource":"NCI"},{"termName":"g/24h","termGroup":"AB","termSource":"NCI"},{"termName":"g/d","termGroup":"AB","termSource":"NCI"},{"termName":"Gram/24 Hours","termGroup":"SY","termSource":"NCI"},{"termName":"gram/day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_24_Hours"},{"name":"Maps_To","value":"g/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439417"}]}}{"C67282":{"preferredName":"Gram per Square Meter","code":"C67282","definitions":[{"definition":"A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of area density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gram per Square Meter","termGroup":"PT","termSource":"NCI"},{"termName":"g/m2","termGroup":"AB","termSource":"NCI"},{"termName":"Gram per Meter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"Gram/Square Meter","termGroup":"SY","termSource":"NCI"},{"termName":"gsm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_Square_Meter"},{"name":"Maps_To","value":"g/m2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1300564"}]}}{"C67379":{"preferredName":"International Unit per Kilogram","code":"C67379","definitions":[{"definition":"A unit of measure of a quantity of substance per unit mass, expressed as the quantity of substance in International Units, divided by the mass of the substance in kilograms. It is also used as a dose calculation unit expressed in International Units of biological activity per one kilogram of body mass.","type":"DEFINITION","source":"NCI"},{"definition":"An arbitrary unit of substance content expressed in international units of biological activity per one kilogram of mass of the system. It is also used as a dose calculation unit expressed in international units of biological activity per one kilogram of body mass.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"International Unit per Kilogram","termGroup":"PT","termSource":"NCI"},{"termName":"[iU]/kg","termGroup":"AB","termSource":"NCI"},{"termName":"International Unit/Kilogram","termGroup":"SY","termSource":"NCI"},{"termName":"iU/kg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"International_Unit_per_Kilogram"},{"name":"Maps_To","value":"IU/kg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439463"}]}}{"C67380":{"preferredName":"International Unit per Milligram","code":"C67380","definitions":[{"definition":"A unit of measure of quantity of substance per unit mass, expressed in terms of International Units per milligram. (CDISC)","type":"DEFINITION","source":"NCI"},{"definition":"A unit of measure of quantity of substance per unit mass, expressed in terms of international units per milligram.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"International Unit per Milligram","termGroup":"PT","termSource":"NCI"},{"termName":"[iU]/mg","termGroup":"AB","termSource":"NCI"},{"termName":"International Unit/Milligram","termGroup":"SY","termSource":"NCI"},{"termName":"iU/mg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"International_Unit_per_Milligram"},{"name":"Maps_To","value":"IU/mg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1319632"}]}}{"C48511":{"preferredName":"Millicurie","code":"C48511","definitions":[{"definition":"A unit of radioactivity equal to one thousandth of a Curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.(NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of radioactivity equal to one thousandth of a curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Millicurie","termGroup":"PT","termSource":"NCI"},{"termName":"mCi","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Millicurie"},{"name":"Maps_To","value":"mCi"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0560005"}]}}{"C48512":{"preferredName":"Milliequivalent","code":"C48512","definitions":[{"definition":"A unit of relative amount of a substance equal to one thousandth of an equivalent weight.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of relative amount of a substance equal to one thousandth of an equivalent weight.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milliequivalent","termGroup":"PT","termSource":"NCI"},{"termName":"mEq","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Milliequivalent"},{"name":"Maps_To","value":"mEq"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439152"}]}}{"C67399":{"preferredName":"Milligram per 24 Hours","code":"C67399","definitions":[{"definition":"A unit of mass flow rate equal to one milligram per day.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milligram per 24 Hours","termGroup":"PT","termSource":"NCI"},{"termName":"mg/24h","termGroup":"AB","termSource":"NCI"},{"termName":"mg/d","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_24_Hours"},{"name":"Maps_To","value":"mg/24 hr"},{"name":"Maps_To","value":"mg/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439422"}]}}{"C67015":{"preferredName":"Milligram per Deciliter","code":"C67015","definitions":[{"definition":"A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Deciliter","termGroup":"PT","termSource":"NCI"},{"termName":"mg/dL","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram/Deciliter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Deciliter"},{"name":"Maps_To","value":"mg/dL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439269"}]}}{"C67401":{"preferredName":"Milligram per Kilogram","code":"C67401","definitions":[{"definition":"A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.","type":"DEFINITION","source":"NCI"},{"definition":"Milligrams (weight), divided by kilograms (weight) or nanograms (weight) per milligrams (weight).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Kilogram","termGroup":"PT","termSource":"NCI"},{"termName":"ag/pg","termGroup":"AB","termSource":"NCI"},{"termName":"Attogram per Picogram","termGroup":"SY","termSource":"NCI"},{"termName":"Femtogram per Nanogram","termGroup":"SY","termSource":"NCI"},{"termName":"fg/ng","termGroup":"AB","termSource":"NCI"},{"termName":"mcg/g","termGroup":"AB","termSource":"NCI"},{"termName":"mg/kg","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Gram","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/Kilogram","termGroup":"SY","termSource":"NCI"},{"termName":"Nanogram per Milligram","termGroup":"SY","termSource":"NCI"},{"termName":"ng/mg","termGroup":"AB","termSource":"NCI"},{"termName":"pg/mcg","termGroup":"AB","termSource":"NCI"},{"termName":"pg/ug","termGroup":"AB","termSource":"NCI"},{"termName":"Picogram per Microgram","termGroup":"SY","termSource":"NCI"},{"termName":"ug/g","termGroup":"AB","termSource":"NCI"},{"termName":"yg/ag","termGroup":"AB","termSource":"NCI"},{"termName":"Yoctogram per Attogram","termGroup":"SY","termSource":"NCI"},{"termName":"Zeptogram per Femtogram","termGroup":"SY","termSource":"NCI"},{"termName":"zg/fg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Kilogram"},{"name":"Maps_To","value":"mg/kg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439272"}]}}{"C66976":{"preferredName":"Milligram per Kilogram per Day","code":"C66976","definitions":[{"definition":"A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours.","type":"DEFINITION","source":"NCI"},{"definition":"A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Kilogram per Day","termGroup":"PT","termSource":"NCI"},{"termName":"mg/kg/d","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Kilogram per 24 Hours","termGroup":"SY","termSource":"NCI"},{"termName":"milligram/kilogram/day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Milligram_per_Kilogram_per_Day"},{"name":"Maps_To","value":"mg/kg/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C3665414"}]}}{"C67402":{"preferredName":"Milligram per Square Meter","code":"C67402","definitions":[{"definition":"A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of area density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Square Meter","termGroup":"PT","termSource":"NCI"},{"termName":"mg/m2","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Meter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/Square Meter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Square_Meter"},{"name":"Maps_To","value":"mg/m2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1319266"}]}}{"C66974":{"preferredName":"Milligram per Square Meter per Day","code":"C66974","definitions":[{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours.","type":"DEFINITION","source":"NCI"},{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Square Meter per Day","termGroup":"PT","termSource":"NCI"},{"termName":"mg/m2/d","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Square Meter per 24 Hours","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/meter2/day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Milligram_per_Square_Meter_per_Day"},{"name":"Maps_To","value":"mg/m2/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1532575"}]}}{"C88148":{"preferredName":"Milligram per Square Meter per Week","code":"C88148","definitions":[{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.","type":"DEFINITION","source":"NCI"},{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Square Meter per Week","termGroup":"PT","termSource":"NCI"},{"termName":"mg/m2/week","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/meter2/week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mg/m2/wk"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C2981713"}]}}{"C42576":{"preferredName":"Kilogram per Cubic Meter","code":"C42576","definitions":[{"definition":"A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of concentration or mass density equal to one milligram of substance per milliliter of solution or one gram of substance per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kilogram per Cubic Meter","termGroup":"PT","termSource":"NCI"},{"termName":"g/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"g/L","termGroup":"AB","termSource":"NCI"},{"termName":"Gram per Cubic Decimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Gram per Liter","termGroup":"SY","termSource":"NCI"},{"termName":"kg/m3","termGroup":"AB","termSource":"NCI"},{"termName":"Kilogram/Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"mg/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"ug/uL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Kilogram_per_Cubic_Meter"},{"name":"Maps_To","value":"g/L"},{"name":"Maps_To","value":"mg/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439294"}]}}{"C67404":{"preferredName":"Milligram per Week","code":"C67404","definitions":[{"definition":"A dose administration rate unit equal to the rate at which one thousandth of a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass flow rate equal to one milligram per week or a dose administration rate unit equal to the rate at which a milligram of a product is delivered or administered over the time period of one week.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Week","termGroup":"PT","termSource":"NCI"},{"termName":"mg/wk","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram/Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Week"},{"name":"Maps_To","value":"mg/wk"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1881833"}]}}{"C67316":{"preferredName":"Milliinternational Unit","code":"C67316","definitions":[{"definition":"A unit equal to one-thousandth of an international unit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milliinternational Unit","termGroup":"PT","termSource":"NCI"},{"termName":"m[iU]","termGroup":"AB","termSource":"NCI"},{"termName":"Milli-International Unit","termGroup":"SY","termSource":"NCI"},{"termName":"miU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milliinternational_Unit"},{"name":"Maps_To","value":"mIU"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439455"}]}}{"C28254":{"preferredName":"Milliliter","code":"C28254","definitions":[{"definition":"A measure of volume in the metric system. One thousand ccs equal one liter.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of volume equal to one thousandth (1E-3) of a liter.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"cc","termGroup":"AB","termSource":"NCI"},{"termName":"cm3","termGroup":"AB","termSource":"NCI"},{"termName":"cu cm","termGroup":"AB","termSource":"NCI"},{"termName":"Cubic Centimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"mL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Milliliter"},{"name":"Maps_To","value":"mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439242"}]}}{"C48152":{"preferredName":"Microgram","code":"C48152","definitions":[{"definition":"A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass equal to one millionth (1E-6) of a gram.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One millionth of a gram.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Microgram","termGroup":"PT","termSource":"NCI"},{"termName":"mcg","termGroup":"AB","termSource":"NCI"},{"termName":"ug","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Microgram"},{"name":"Maps_To","value":"ug"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439211"}]}}{"C67312":{"preferredName":"Microgram per Square Meter","code":"C67312","definitions":[{"definition":"A dose calculation unit expressed in microgram(s) per square meter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A metric unit of areal density equal to approximately 2.94935E-8 ounce per square yard. Also used as a dose calculation unit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microgram per Square Meter","termGroup":"PT","termSource":"NCI"},{"termName":"mcg/m2","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Meter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"Microgram/Square Meter","termGroup":"SY","termSource":"NCI"},{"termName":"ug/m2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Microgram_per_Square_Meter"},{"name":"Maps_To","value":"ug/m2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1319267"}]}}{"C48552":{"preferredName":"Wafer Dosing Unit","code":"C48552","definitions":[{"definition":"A dosing measurement based on the wafer unit.(NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A dosing unit equal to the amount of active ingredient(s) contained in a wafer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wafer Dosing Unit","termGroup":"PT","termSource":"NCI"},{"termName":"Wafer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Wafer_Dosing_Unit"},{"name":"Maps_To","value":"Wafer"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1706425"}]}}{"C156234":{"preferredName":"Complete Tumor Cell Necrosis","code":"C156234","definitions":[{"definition":"A morphologic finding indicating the presence of tumor cell necrosis involving the entire neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complete Tumor Cell Necrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Complete Necrosis (No Viable Tumor)"},{"name":"NCI_META_CUI","value":"CL562940"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156235":{"preferredName":"Incomplete Tumor Cell Necrosis","code":"C156235","definitions":[{"definition":"A morphologic finding indicating the presence of focal or diffuse tumor cell necrosis involving part of the neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are still present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Incomplete Tumor Cell Necrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Incomplete Necrosis (Viable Tumor Present)"},{"name":"NCI_META_CUI","value":"CL562941"},{"name":"Semantic_Type","value":"Finding"}]}}{"C168971":{"preferredName":"Necrosis Negative","code":"C168971","definitions":[{"definition":"An indication that signs of necrosis were not found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necrosis Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Negative for Necrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Necrosis"},{"name":"NCI_META_CUI","value":"CL1379139"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164134":{"preferredName":"No Effect","code":"C164134","definitions":[{"definition":"A subjective response indicating that something has or had no effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Effect","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Known Treatment Effect"},{"name":"NCI_META_CUI","value":"CL978353"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C64510":{"preferredName":"Every Hour","code":"C64510","definitions":[{"definition":"Every hour.","type":"DEFINITION","source":"NCI"},{"definition":"Every hour. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Every Hour","termGroup":"PT","termSource":"NCI"},{"termName":"Hourly","termGroup":"SY","termSource":"NCI"},{"termName":"QH","termGroup":"AB","termSource":"NCI"},{"termName":"quaque hora","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Every_Hour"},{"name":"Maps_To","value":"Every Hour"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0558292"}]}}{"C98849":{"preferredName":"Five Times Daily","code":"C98849","definitions":[{"definition":"Five times per day.","type":"DEFINITION","source":"NCI"},{"definition":"Five times per day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Five Times Daily","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Five Times Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0585292"}]}}{"C64530":{"preferredName":"Four Times Daily","code":"C64530","definitions":[{"definition":"Four times per day.","type":"DEFINITION","source":"NCI"},{"definition":"Four times per day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Four Times Daily","termGroup":"PT","termSource":"NCI"},{"termName":"Four times a day","termGroup":"SY","termSource":"NCI"},{"termName":"QID","termGroup":"AB","termSource":"NCI"},{"termName":"quarter in die","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Four_Times_Daily"},{"name":"Maps_To","value":"Four Times Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0585291"}]}}{"C64527":{"preferredName":"Three Times Daily","code":"C64527","definitions":[{"definition":"Three times per day.","type":"DEFINITION","source":"NCI"},{"definition":"Three times per day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Three Times Daily","termGroup":"PT","termSource":"NCI"},{"termName":"ter in die","termGroup":"SY","termSource":"NCI"},{"termName":"Three times a day","termGroup":"SY","termSource":"NCI"},{"termName":"TID","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Three_Times_Daily"},{"name":"Maps_To","value":"Three Times Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0556984"}]}}{"C64496":{"preferredName":"Twice Daily","code":"C64496","definitions":[{"definition":"Two times per day, at unspecified times.","type":"DEFINITION","source":"NCI"},{"definition":"Two times per day, at unspecified times. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Twice Daily","termGroup":"PT","termSource":"NCI"},{"termName":"BID","termGroup":"SY","termSource":"NCI"},{"termName":"bis in die","termGroup":"SY","termSource":"NCI"},{"termName":"Twice a day","termGroup":"SY","termSource":"NCI"},{"termName":"Two Times per Day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Twice_Daily"},{"name":"Maps_To","value":"Twice Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0585361"}]}}{"C64515":{"preferredName":"Every Twenty-Four Hours","code":"C64515","definitions":[{"definition":"Every twenty-four hours.","type":"DEFINITION","source":"NCI"},{"definition":"Every twenty-four hours. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Every Twenty-Four Hours","termGroup":"PT","termSource":"NCI"},{"termName":"Every 24 hours","termGroup":"SY","termSource":"NCI"},{"termName":"Q24H","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Every_Twenty-Four_Hours"},{"name":"Maps_To","value":"Every 24 Hours"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C1275548"}]}}{"C64525":{"preferredName":"Every Other Day","code":"C64525","definitions":[{"definition":"Every other day.","type":"DEFINITION","source":"NCI"},{"definition":"Every other day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Every Other Day","termGroup":"PT","termSource":"NCI"},{"termName":"Every Two Days","termGroup":"SY","termSource":"NCI"},{"termName":"q.a.d.","termGroup":"AB","termSource":"NCI"},{"termName":"Q2D","termGroup":"SY","termSource":"NCI"},{"termName":"QOD","termGroup":"AB","termSource":"NCI"},{"termName":"Quoque Alternis Die","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Every_Other_Day"},{"name":"Maps_To","value":"Every Other Day"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0558287"}]}}{"C64497":{"preferredName":"Twice Weekly","code":"C64497","definitions":[{"definition":"Two times per week.","type":"DEFINITION","source":"NCI"},{"definition":"Two times per week. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Twice Weekly","termGroup":"PT","termSource":"NCI"},{"termName":"BIS","termGroup":"SY","termSource":"NCI"},{"termName":"Twice a week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Twice_Weekly"},{"name":"Maps_To","value":"Twice Weekly"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0556985"}]}}{"C64526":{"preferredName":"Once Weekly","code":"C64526","definitions":[{"definition":"One time per week.","type":"DEFINITION","source":"NCI"},{"definition":"One time per week. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Once Weekly","termGroup":"PT","termSource":"NCI"},{"termName":"Once a week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Once_Weekly"},{"name":"Maps_To","value":"Once Weekly"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0558293"}]}}{"C25722":{"preferredName":"Adjuvant Generic","code":"C25722","definitions":[{"definition":"Serving to aid or contribute; auxiliary.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"Merriam-Webster OnLine"}]}],"synonyms":[{"termName":"Adjuvant Generic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adjuvant_CADSR"},{"name":"Maps_To","value":"Adjuvant"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1522673"}]}}{"C15481":{"preferredName":"Antiandrogen Therapy","code":"C15481","definitions":[{"definition":"A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment with drugs used to block production or interfere with the action of male sex hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Antiandrogen Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"ADT","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Deprivation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Deprivation Therapy (ADT)","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-androgen Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-androgen Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Antiandrogen Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Hormone Deprivation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Hormone-Deprivation Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antiandrogen_Therapy"},{"name":"Maps_To","value":"Androgen Deprivation Therapy (ADT)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0279492"}]}}{"C15971":{"preferredName":"Cancer Control","code":"C15971","definitions":[{"definition":"Integrated program having an objective of reducing risk, incidence, and mortality from cancer and to enhancing the quality of life for cancer survivors. Realized through an orderly sequence of measures from genetic, epidemiologic, behavioral, social, applied, and surveillance cancer research to the development and implementation of effective interventions, and monitor and analysis of cancer trends in all segments of the population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Control","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Control Science","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cancer_Control"},{"name":"Maps_To","value":"Cancer Control"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C1516188"}]}}{"C62220":{"preferredName":"Cure","code":"C62220","definitions":[{"definition":"Any action or response that serves to eliminate disease and prevent recurrence.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Serving or tending to restore health; a remedy.","type":"DEFINITION","source":"NCI"},{"definition":"To heal or restore health; a treatment to restore health.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cure","termGroup":"PT","termSource":"NCI"},{"termName":"Curative","termGroup":"AD","termSource":"NCI"},{"termName":"Cured","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cure"},{"name":"Maps_To","value":"Cure"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1880198"}]}}{"C15688":{"preferredName":"Maintenance Therapy","code":"C15688","definitions":[{"definition":"Continuation of treatment for an extended period of time to prevent relapse.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Maintenance Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Maintenance_Therapy"},{"name":"Maps_To","value":"Maintenance Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0677908"}]}}{"C15665":{"preferredName":"Neoadjuvant Therapy","code":"C15665","definitions":[{"definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Neoadjuvant Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Induction Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Neoadjuvant","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Adjuvant Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Preoperative Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Neoadjuvant_Therapy"},{"name":"Maps_To","value":"Neoadjuvant"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0600558"}]}}{"C15843":{"preferredName":"Preventive Intervention","code":"C15843","definitions":[{"definition":"Any action or response to modify or stop the development of a disease.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Practices or interventions used to help people stay healthy and avoid disease. NOTE: Involves limiting the chances of illness, injuries, or reduced health status from occurring (primary prevention) and, when diseases occur, supporting people to manage them as effectively as possible in order to prevent progression or recurrence (secondary prevention). Prevention is achieved by applying vaccines, behavioral changes, life style changes, improved nutrition, etc. [After Prevention is better than cure, UK Department of Health and Social Care, Nov 5th 2018. After Primary, secondary and tertiary prevention, Institute for Work & Health, Toronto April 2015]","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Preventive Intervention","termGroup":"PT","termSource":"NCI"},{"termName":"Prevention","termGroup":"SY","termSource":"NCI"},{"termName":"Prevention Measures","termGroup":"SY","termSource":"NCI"},{"termName":"Prophylaxis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Preventive_Intervention"},{"name":"Maps_To","value":"Prevention"},{"name":"NCI_META_CUI","value":"CL000755"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15679":{"preferredName":"Consolidation Therapy","code":"C15679","definitions":[{"definition":"Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Consolidation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Post Remission Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Postremission Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Consolidation_Therapy"},{"name":"Maps_To","value":"Consolidation Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1511484"}]}}{"C45792":{"preferredName":"First-Line Therapy","code":"C45792","definitions":[{"definition":"Initial treatment used to reduce a cancer. First-line therapy is followed by other treatments, such as chemotherapy, radiation therapy, and hormone therapy to get rid of cancer that remains.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The preferred standard treatment for a particular condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First-Line Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"First Line Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"First Line Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"First-Line Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First-Line_Therapy"},{"name":"Maps_To","value":"First-Line Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1708063"}]}}{"C158876":{"preferredName":"Induction Therapy","code":"C158876","definitions":[{"definition":"The first choice of treatment for a particular type of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Induction Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Induction"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0857127"}]}}{"C137812":{"preferredName":"Radiation Boost","code":"C137812","definitions":[{"definition":"One or more extra radiation treatments targeted at the tumor bed, given after the regular sessions of radiation are complete.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiation Boost","termGroup":"PT","termSource":"NCI"},{"termName":"Boost Radiation","termGroup":"SY","termSource":"NCI"},{"termName":"Boost Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Boost Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation Therapy Boost","termGroup":"SY","termSource":"NCI"},{"termName":"Radiotherapy Boost","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Radiation Boost"},{"name":"NCI_META_CUI","value":"CL524908"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C40413":{"preferredName":"No Evidence of Disease","code":"C40413","definitions":[{"definition":"An absence of detectable disease.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Diagnostic tests fail to detect presence of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Evidence of Disease","termGroup":"PT","termSource":"NCI"},{"termName":"NED","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"No_Evidence_of_Disease"},{"name":"Maps_To","value":"No Measurable Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1518340"}]}}{"C165209":{"preferredName":"Treatment Ongoing","code":"C165209","definitions":[{"definition":"An indication that a subject is still undergoing therapy to prevent, mitigate or cure a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treatment Ongoing","termGroup":"PT","termSource":"NCI"},{"termName":"Ongoing Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treatment Ongoing"},{"name":"NCI_META_CUI","value":"CL978421"},{"name":"Semantic_Type","value":"Finding"}]}}{"C105741":{"preferredName":"Treatment Terminated Due to Toxicity","code":"C105741","definitions":[{"definition":"Indicates that the patient terminated the treatment due to toxicity related to the treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treatment Terminated Due to Toxicity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treatment Stopped Due to Toxicity"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3827777"}]}}{"C198983":{"preferredName":"Tumor Markers Normalized","code":"C198983","definitions":[{"definition":"The levels of expression of tumor markers has decreased to non-disease levels due to therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Markers Normalized","termGroup":"PT","termSource":"NCI"},{"termName":"Normalization of Tumor Markers","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Marker Normalization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Normalization of Tumor Markers"},{"name":"NCI_META_CUI","value":"CL1906415"},{"name":"Semantic_Type","value":"Finding"}]}}{"C15215":{"preferredName":"Cryosurgery","code":"C15215","definitions":[{"definition":"A procedure in which tissue is frozen to destroy abnormal cells. Liquid nitrogen or liquid carbon dioxide is used to freeze the tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Removal, separation, detachment, extirpation or eradication of a body part, pathway or function by freezing. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The use of extreme cold to damage or destroy a body part, pathway, or function. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryosurgery","termGroup":"PT","termSource":"NCI"},{"termName":"Cryoablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cryosurgery"},{"name":"Maps_To","value":"Ablation, Cryo"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0010408"}]}}{"C67444":{"preferredName":"Ethanol Ablation Therapy","code":"C67444","definitions":[{"definition":"An injection of ethanol (alcohol) through the skin directly into a tumor to kill cancer cells. Ultrasound or a CT scan is used to guide the needle into the tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ethanol Ablation Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ethanol_Ablation_Therapy"},{"name":"Maps_To","value":"Ablation, Ethanol Injection"},{"name":"Maps_To","value":"Ethanol Injection Ablation"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1880568"}]}}{"C116643":{"preferredName":"Microwave Ablation","code":"C116643","definitions":[{"definition":"A treatment modality that uses directed electromagnetic waves within the microwave spectrum to heat the targeted tissue for the purpose of causing tissue necrosis within solid tissue tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microwave Ablation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ablation, Microwave"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3854551"}]}}{"C20985":{"preferredName":"Ablation Therapy","code":"C20985","definitions":[{"definition":"In medicine, the removal or destruction of a body part or tissue or its function. Ablation may be performed by surgery, hormones, drugs, radiofrequency, heat, or other methods.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Removal, separation, detachment, extirpation or eradication of a body part, pathway or function by surgery, chemical destruction, morbid process, or noxious substance. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by surgery, chemical destruction, morbid process, or noxious substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ablation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Ablation","termGroup":"SY","termSource":"NCI"},{"termName":"Local Ablation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Local Ablative Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ablation"},{"name":"Maps_To","value":"Ablation, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0547070"}]}}{"C15666":{"preferredName":"Radiofrequency Ablation","code":"C15666","definitions":[{"definition":"A procedure that uses radio waves to heat and destroy abnormal cells. The radio waves travel through electrodes (small devices that carry electricity). Radiofrequency ablation may be used to treat cancer and other conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A therapeutic procedure to kill tissue using radiowaves to generate heat. The procedure is performed by the insertion of an electrode into a target tissue. Electrical energy delivered to the electrode heats and destroys the tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiofrequency Ablation","termGroup":"PT","termSource":"NCI"},{"termName":"Radiofrequency Interstitial Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiofrequency_Interstitial_Ablation"},{"name":"Maps_To","value":"Ablation, Radiofrequency"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0850292"}]}}{"C15696":{"preferredName":"Radiosurgery","code":"C15696","definitions":[{"definition":"A surgical procedure to treat cancer cells that use high energy beams.","type":"DEFINITION","source":"NCI"},{"definition":"A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radiosurgery","termGroup":"PT","termSource":"NCI"},{"termName":"Radiation Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiation_Surgery"},{"name":"Maps_To","value":"Ablation, Radiosurgical"},{"name":"NCI_META_CUI","value":"CL031853"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15747":{"preferredName":"Supportive Care","code":"C15747","definitions":[{"definition":"Any action or process to maximize comfort, minimize side effects, or mitigate against a decline in the participant's health or function. (clinicaltrials.gov)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Supportive care is that which helps the patient and their family to cope with cancer and treatment of it from pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing illness or death and into bereavement. It helps the patient to maximize the benefits of treatment and to live as well as possible with the effects of the disease. Supportive therapy may provide a patient with friendship, encouragement, practical advice such as access to community resources or how to develop a more active social life, vocational counseling, suggestions for minimizing friction with family members, and, above all, hope that the life of the patient may be improved. In all situations, supportive therapy involves the teaching of such life skills as managing medication, learning to socialize, handling finances, and getting a job.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supportive Care","termGroup":"PT","termSource":"NCI"},{"termName":"Supportive Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Symptom Management","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy, Supportive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supportive_Care"},{"name":"Maps_To","value":"Ancillary Treatment"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0344211"}]}}{"C64172":{"preferredName":"Anticonvulsant Therapy","code":"C64172","definitions":[{"definition":"Drug treatment to prevent, stop, or reduce the severity of seizures or convulsions, commonly used in cases of epilepsy or other seizure disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anticonvulsant Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Antiseizure Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anticonvulsant_Therapy"},{"name":"Maps_To","value":"Antiseizure Treatment"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0521306"}]}}{"C443":{"preferredName":"Biphosphonate","code":"C443","definitions":[{"definition":"A drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Biphosphonate","termGroup":"PT","termSource":"NCI"},{"termName":"Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Diphosphonates","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Biphosphonate"},{"name":"Maps_To","value":"Bisphosphonate Therapy"},{"name":"Semantic_Type","value":"Chemical Viewed Structurally"},{"name":"UMLS_CUI","value":"C0012544"}]}}{"C70840":{"preferredName":"Blinded Clinical Study","code":"C70840","definitions":[{"definition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","type":"DEFINITION","source":"NCI"},{"definition":"A study in which the subject, the investigator, or anyone assessing the outcome is unaware of the treatment assignment(s). NOTE: Blinding is used to reduce the potential for bias. [Modified ICH E6 Glossary] See also blinding/masking, double-blind study, single-blind study, triple-blind study; contrast with open-label or unblinded study.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"A type of study in which the patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given. The opposite of a blinded study is an open label study.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Blinded Clinical Study","termGroup":"PT","termSource":"NCI"},{"termName":"Blind Clinical Study","termGroup":"SY","termSource":"NCI"},{"termName":"Blinded Clinical Trial","termGroup":"SY","termSource":"NCI"},{"termName":"Masked Clinical Study","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blinded_Clinical_Study"},{"name":"Maps_To","value":"Blinded Study, Treatment Unknown"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C2347038"}]}}{"C15651":{"preferredName":"High-Dose Rate Brachytherapy","code":"C15651","definitions":[{"definition":"A type of brachytherapy that targets a cancerous tissue with high doses of radiation through the use of inserted temporary implants.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Internal radiation treatment that targets a cancerous tissue with accurate, high doses of radiation through the use of inserted temporary implants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High-Dose Rate Brachytherapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"High-Dose_Rate_Brachytherapy"},{"name":"Maps_To","value":"Brachytherapy, High Dose"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0454270"}]}}{"C85254":{"preferredName":"Low-Dose Rate Brachytherapy","code":"C85254","definitions":[{"definition":"A type of brachytherapy that targets a cancerous tissue with low doses of radiation through the use of inserted temporary or permanent implants.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Internal radiation treatment that targets a cancerous tissue with low doses of radiation through the use of inserted temporary or permanent implants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low-Dose Rate Brachytherapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Brachytherapy, Low Dose"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0454271"}]}}{"C15195":{"preferredName":"Brachytherapy","code":"C15195","definitions":[{"definition":"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.","type":"DEFINITION","source":"NCI"},{"definition":"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brachytherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Internal Radiation","termGroup":"SY","termSource":"NCI"},{"termName":"Internal Radiation Brachytherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Internal Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation Brachytherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Radiation_Brachytherapy"},{"name":"Maps_To","value":"Brachytherapy, NOS"},{"name":"Maps_To","value":"Internal Radiation"},{"name":"Maps_To","value":"Radiation, Internal"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0006098"}]}}{"C15752":{"preferredName":"Chemoembolization","code":"C15752","definitions":[{"definition":"A procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This permits a higher concentration of drug to be in contact with the tumor for a longer period of time.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A procedure that introduces chemotherapy to blood vessels adjacent to a tumor, for the purpose of both treating the tumor and interrupt blood flow to the tumor, which serves both to trap the chemotherapeutic agent at the tumor and to decrease the amount of nutrients flowing to the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chemoembolization","termGroup":"PT","termSource":"NCI"},{"termName":"Chemotherapy Embolization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chemoembolization"},{"name":"Maps_To","value":"Chemoembolization"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0796679"}]}}{"C15533":{"preferredName":"Chemoprotection","code":"C15533","definitions":[{"definition":"The use of drugs to protect normal tissue from damage by cancer therapy agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chemoprotection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chemoprotection"},{"name":"Maps_To","value":"Chemoprotectant"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0280959"}]}}{"C15632":{"preferredName":"Chemotherapy","code":"C15632","definitions":[{"definition":"Non-systemic chemotherapy treatment (e.g., intra-peritoneal, intra-cavitary, intra-thecal), or chemotherapy not described by Chemotherapy Single Agent Systemic or Multi-Agent Systemic.","type":"ALT_DEFINITION","source":"CTEP"},{"definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","type":"DEFINITION","source":"NCI"},{"definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Treatment with anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chemotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Chemo","termGroup":"SY","termSource":"NCI"},{"termName":"Chemotherapy, Cancer, General","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity."},{"name":"Legacy Concept Name","value":"Chemotherapy"},{"name":"Maps_To","value":"Chemotherapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0392920"}]}}{"C141342":{"preferredName":"Concurrent Chemoradiation","code":"C141342","definitions":[{"definition":"Treatment in which radiation therapy is administered at the same time as chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Concurrent Chemoradiation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Maps_To","value":"Concurrent Chemoradiation"},{"name":"NCI_META_CUI","value":"CL539462"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15230":{"preferredName":"Embolization Therapy","code":"C15230","definitions":[{"definition":"A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells.","type":"DEFINITION","source":"NCI"},{"definition":"The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Embolization Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"therapy, embolization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Embolization_Therapy"},{"name":"Maps_To","value":"Embolization"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0013931"}]}}{"C15751":{"preferredName":"External Beam Radiation Therapy","code":"C15751","definitions":[{"definition":"A type of radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of radiation therapy that uses a machine to aim high-energy rays at the cancer from outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"External Beam Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Definitive Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"EBRT","termGroup":"SY","termSource":"NCI"},{"termName":"External Beam Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"External Beam RT","termGroup":"SY","termSource":"NCI"},{"termName":"External Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Teletherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Teletherapy Radiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"External_Beam_Radiation"},{"name":"Maps_To","value":"External Beam Radiation"},{"name":"Maps_To","value":"Radiation, External Beam"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0419095"}]}}{"C15445":{"preferredName":"Hormone Therapy","code":"C15445","definitions":[{"definition":"Cancer therapy, which incorporates hormonal manipulation (e.g., tamoxifen, androgen deprivation).","type":"ALT_DEFINITION","source":"CTEP"},{"definition":"Treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body's natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hormone Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Chemotherapy-Hormones/Steroids","termGroup":"SY","termSource":"NCI"},{"termName":"Hormonal Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"DesignNote","value":"The concept covers but is not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration."},{"name":"DesignNote","value":"The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy."},{"name":"Legacy Concept Name","value":"Hormone_Therapy"},{"name":"Maps_To","value":"Hormone Therapy"},{"name":"Maps_To","value":"Hormones"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0279025"}]}}{"C198584":{"preferredName":"Iodine I 131 Radiation Therapy","code":"C198584","definitions":[{"definition":"Radiation Therapy that uses iodine I-131. It is typically used to treat thyroid conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"I-131 Radiation Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"I-131 Radiation Therapy"},{"name":"NCI_META_CUI","value":"CL1905765"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15262":{"preferredName":"Immunotherapy","code":"C15262","definitions":[{"definition":"A therapy designed to induce changes in a patient's immune status.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Immunotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Immunologically Directed Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"The concept encompasses various treatment modalities including active and passive immunization, treatment with immunopotentiators, immunosuppressants and nonspecific systemic immunostimulators and adjuvants, desensitization to any allergens, bone marrow transplantation, thymus implantation."},{"name":"Legacy Concept Name","value":"Immunotherapy"},{"name":"Maps_To","value":"Immunotherapy (Including Vaccines)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0021083"}]}}{"C15393":{"preferredName":"Isolated Chemotherapeutic Limb Perfusion","code":"C15393","definitions":[{"definition":"A procedure used to deliver anticancer drugs directly to an arm or leg but not to the rest of the body. The flow of blood to and from the limb is temporarily stopped with a tourniquet (a tight band around the limb). Catheters (small, flexible tubes) attached to a pump are put into an artery and a vein in the limb so that blood can be circulated through the pump into the limb. Anticancer drugs are injected into the catheters. Wrapping the limb in a heated blanket or warming the drugs or blood may help the drugs work better.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Isolated Chemotherapeutic Limb Perfusion","termGroup":"PT","termSource":"NCI"},{"termName":"Limb Perfusion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Limb_Perfusion"},{"name":"Maps_To","value":"Isolated Limb Perfusion (ILP)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0396670"}]}}{"C15986":{"preferredName":"Pharmacotherapy","code":"C15986","definitions":[{"definition":"Treatment of disease through the use of drugs.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment with any substance, other than food, that is used to prevent, diagnose, treat, or relieve symptoms of a disease or abnormal condition.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pharmacotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Drug Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Pharmacological Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Pharmacological Treatments","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment With Medication","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pharmacological_Treatment"},{"name":"Maps_To","value":"Pharmaceutical Therapy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0013216"}]}}{"C66899":{"preferredName":"Pleurodesis","code":"C66899","definitions":[{"definition":"A medical procedure that uses chemicals or drugs to cause inflammation and adhesion between the layers of the pleura (a thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity). This prevents the buildup of fluid in the pleural cavity. It is used as a treatment for severe pleural effusion.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae.","type":"DEFINITION","source":"NCI"},{"definition":"A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pleurodesis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleurodesis"},{"name":"Maps_To","value":"Pleurodesis"},{"name":"Maps_To","value":"Pleurodesis, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189557"}]}}{"C15313":{"preferredName":"Radiation Therapy","code":"C15313","definitions":[{"definition":"Patient required additional radiation therapy.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that travels in the blood to tissues throughout the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","type":"DEFINITION","source":"NCI"},{"definition":"Use of targeted or whole body radiation to treat a disease.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Irradiate","termGroup":"SY","termSource":"NCI"},{"termName":"Irradiated","termGroup":"SY","termSource":"NCI"},{"termName":"Irradiation","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation","termGroup":"SY","termSource":"NCI"},{"termName":"Radiotherapeutics","termGroup":"SY","termSource":"NCI"},{"termName":"Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"RT","termGroup":"AB","termSource":"NCI"},{"termName":"Therapy, Radiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Radiation_Therapy"},{"name":"Maps_To","value":"Radiation Therapy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1522449"},{"name":"xRef","value":"IMDRF:F2305"}]}}{"C165189":{"preferredName":"Conventional Radiotherapy","code":"C165189","definitions":[{"definition":"A course of radiotherapy where minimal imaging support (i.e. X-rays films) is used to determine the positioning of radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conventional Radiotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"2-Dimensional Conventional Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"2D Conventional Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"2D Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"2D-RT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Radiation, 2D Conventional"},{"name":"NCI_META_CUI","value":"CL978430"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C16035":{"preferredName":"3-Dimensional Conformal Radiation Therapy","code":"C16035","definitions":[{"definition":"A procedure that uses a computer to create a 3-dimensional picture of the tumor. This allows doctors to give the highest possible dose of radiation to the tumor, while sparing the normal tissue as much as possible.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from Varian Oncology web site"}]},{"definition":"A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"3-Dimensional Conformal Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"3D-CRT","termGroup":"AB","termSource":"NCI"},{"termName":"Conformal Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation Conformal Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Three-Dimensional_Conformal_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, 3D Conformal"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0600521"}]}}{"C165192":{"preferredName":"Combination Radiotherapy","code":"C165192","definitions":[{"definition":"Simultaneous or consecutive use of radiotherapy and one or more non-radiation based treatment modalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combination Radiotherapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation, Combination"},{"name":"NCI_META_CUI","value":"CL978433"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C95484":{"preferredName":"CyberKnife","code":"C95484","definitions":[{"definition":"A proprietary, robotic radiosurgery system designed to deliver precise beams of high dose radiation to tumors with extreme accuracy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CyberKnife","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation, Cyberknife"},{"name":"NCI_META_CUI","value":"CL449164"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C66891":{"preferredName":"Interstitial Radiation Therapy","code":"C66891","definitions":[{"definition":"A type of brachytherapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue. (Cancer.gov)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interstitial Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Implant Radiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Interstitial_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, Implants"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1881237"}]}}{"C16135":{"preferredName":"Intensity-Modulated Radiation Therapy","code":"C16135","definitions":[{"definition":"A type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.","type":"DEFINITION","source":"NCI"},{"definition":"An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intensity-Modulated Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"IMRT","termGroup":"AB","termSource":"NCI"},{"termName":"Intensity Modulated RT","termGroup":"SY","termSource":"NCI"},{"termName":"Intensity-Modulated Radiotherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Intensity-Modulated_Radiotherapy"},{"name":"Maps_To","value":"Radiation, Intensity-Modulated Radiotherapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1512814"}]}}{"C66897":{"preferredName":"Proton Beam Radiation Therapy","code":"C66897","definitions":[{"definition":"A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A type of radiation therapy that uses streams of protons (tiny particles with a positive charge) that come from a special machine. This type of radiation kills tumor cells but does not damage nearby tissues. It is used to treat cancers in the head and neck and in organs such as the brain, eye, lung, spine, and prostate. Proton beam radiation is different from x-ray radiation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Proton Beam Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"PBRT","termGroup":"SY","termSource":"NCI"},{"termName":"Proton Radiation Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Proton_Beam_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, Proton Beam"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0436226"}]}}{"C15470":{"preferredName":"Isotope Therapy","code":"C15470","definitions":[{"definition":"Treatment of a disease by means of exposure of the target to radioisotopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isotope Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Radioactive Isotope Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radioisotope Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"therapy, isotope, radioactive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isotope_Therapy"},{"name":"Maps_To","value":"Radiation, Radioisotope"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0203608"}]}}{"C15382":{"preferredName":"Gamma Knife","code":"C15382","definitions":[{"definition":"A treatment using gamma rays, a type of high-energy radiation that can be tightly focused on small tumors or other lesions in the head or neck, so very little normal tissue receives radiation. The gamma rays are aimed at the tumor from many different angles at once, and deliver a large dose of radiation exactly to the tumor in one treatment session. This procedure is a type of stereotactic radiosurgery. Gamma Knife therapy is not a knife and is not surgery. Gamma Knife is a registered trademark of Elekta Instruments, Inc.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gamma Knife","termGroup":"PT","termSource":"NCI"},{"termName":"Gamma Knife Radiosurgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gamma_Knife"},{"name":"Maps_To","value":"Radiation, Stereotactic/Gamma Knife/SRS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0086330"}]}}{"C92991":{"preferredName":"Systemic Radiation Therapy","code":"C92991","definitions":[{"definition":"A type of radiation therapy in which a radioactive substance, such radioactive iodine or a radioactively labeled monoclonal antibody, is swallowed or injected into the body and travels through the blood, locating and killing tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation therapy in which radioactive drugs are administered orally or through an injection then circulate through the blood and collect in tumor sites where they kill cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Systemic Radiation Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation, Systemic"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2985381"}]}}{"C157968":{"preferredName":"Radioactive Iodine Therapy","code":"C157968","definitions":[{"definition":"The use of radioactive iodine to treat disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radioactive Iodine Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radioactive Iodine Therapy"},{"name":"NCI_META_CUI","value":"CL1407114"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C93340":{"preferredName":"Radioembolization","code":"C93340","definitions":[{"definition":"A combination therapy for cancer treatment that couples radiation therapy and embolization through the introduction of radioactive microspheres directly into vessels supplying the tumor, allowing for the delivery of high dose radiation without irradiating healthy tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A type of radiation therapy used to treat liver cancer that is advanced or has come back. Tiny beads that hold the radioisotope yttrium Y 90 are injected into the hepatic artery (the main blood vessel that carries blood to the liver). The beads collect in the tumor and the yttrium Y 90 gives off radiation. This destroys the blood vessels that the tumor needs to grow and kills the cancer cells. Radioembolization is a type of selective internal radiation therapy (SIRT).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radioembolization","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radioembolization"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2985560"}]}}{"C798":{"preferredName":"Radiosensitizing Agent","code":"C798","definitions":[{"definition":"An agent that makes tumor cells more sensitive to radiation therapy.","type":"DEFINITION","source":"NCI"},{"definition":"Drugs that make tumor cells more sensitive to radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radiosensitizing Agent","termGroup":"PT","termSource":"NCI"},{"termName":"Radiation Sensitizers","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation-Sensitizing Agents","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation-Sensitizing Drugs","termGroup":"SY","termSource":"NCI"},{"termName":"Radiosensitizers","termGroup":"SY","termSource":"NCI"},{"termName":"Radiosensitizing Drugs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiosensitizing_Agent"},{"name":"Maps_To","value":"Radiosensitizing Agent"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0034541"}]}}{"C46089":{"preferredName":"Allogeneic Hematopoietic Stem Cell Transplantation","code":"C46089","definitions":[{"definition":"A clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.","type":"DEFINITION","source":"NCI"},{"definition":"A procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. This is often a sister or brother, but could be an unrelated donor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Allogeneic Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Hematopoietic Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"HSC","termGroup":"AB","termSource":"NCI"},{"termName":"HSCT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Allogeneic_Hematopoietic_Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, Allogeneic"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2242529"}]}}{"C16039":{"preferredName":"Autologous Hematopoietic Stem Cell Transplantation","code":"C16039","definitions":[{"definition":"A procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stem cell transfer or transplantation in which the patient is their own donor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"AHSCT","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Hematopoietic Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Autologous_Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, Autologous"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1831743"}]}}{"C116466":{"preferredName":"Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation","code":"C116466","definitions":[{"definition":"Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from autologous hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"auto-auto HCT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Transplantation, Double Autologous"},{"name":"NCI_META_CUI","value":"CL388423"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C138187":{"preferredName":"Haploidentical Hematopoietic Cell Transplantation","code":"C138187","definitions":[{"definition":"A clinical treatment in which hematopoietic stem cells are transferred from a HLA half-matched donor to a recipient.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Haploidentical Hematopoietic Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Haploidentical Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-Haploidentical Hematopoietic Cell Transplantation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Transplantation, Haploidentical"},{"name":"Maps_To","value":"Transplant from live related donor"},{"name":"NCI_META_CUI","value":"CL525718"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C62714":{"preferredName":"Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","code":"C62714","definitions":[{"definition":"A modification of the standard method of allogeneic hematopoietic stem cell transplantation developed to allow for the therapy to be extended to a patient population that is unable to tolerate treatment with the conventional procedure due to its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Nonmyeloablative Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"NST","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Nonmyeloablative_Allogeneic_Hematopoietic_Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, Non-Myeloablative"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1831742"}]}}{"C15431":{"preferredName":"Hematopoietic Cell Transplantation","code":"C15431","definitions":[{"definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells from a donor to a recipient.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"HCT","termGroup":"AB","termSource":"NCI"},{"termName":"Hematopoietic Stem Cell Infusion","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"HSCT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0472699"}]}}{"C93196":{"preferredName":"Syngeneic Stem Cell Transplantation","code":"C93196","definitions":[{"definition":"A procedure in which a patient receives blood-forming stem cells (cells from which all blood cells develop) donated by his or her healthy identical twin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Syngeneic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Transplantation, Syngenic"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2985487"}]}}{"C165194":{"preferredName":"Stem Cell Therapy","code":"C165194","definitions":[{"definition":"A treatment modality that leverages stem cells to prevent or treat disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stem Cell Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Stem Cell Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Treatment"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0872278"}]}}{"C15358":{"preferredName":"Stereotactic Radiosurgery","code":"C15358","definitions":[{"definition":"A non-surgical procedure that was developed to deliver one or several maximum dose targeted radiation treatments for cancers in the brain or spine.","type":"DEFINITION","source":"NCI"},{"definition":"A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stereotactic Radiosurgery","termGroup":"PT","termSource":"NCI"},{"termName":"Stereotactic External Beam Irradiation","termGroup":"SY","termSource":"NCI"},{"termName":"Stereotactic Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Stereotactic Radiotherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Stereotaxic_Radiosurgery"},{"name":"Maps_To","value":"Stereotactic Radiosurgery"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0085203"}]}}{"C15370":{"preferredName":"Steroid Therapy","code":"C15370","definitions":[{"definition":"The use of exogenous steroids for the treatment of any disease or disorder.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Steroid Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Steroid_Therapy"},{"name":"Maps_To","value":"Steroid Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0149783"}]}}{"C76243":{"preferredName":"Targeted Molecular Therapy","code":"C76243","definitions":[{"definition":"Cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread.","type":"DEFINITION","source":"NCI"},{"definition":"In cancer treatment, substances that kill cancer cells by targeting key molecules involved in cancer cell growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Targeted Molecular Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Targeted_Molecular_Therapy"},{"name":"Maps_To","value":"Targeted Molecular Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2699893"}]}}{"C62726":{"preferredName":"Hypofractionated Radiation Therapy","code":"C62726","definitions":[{"definition":"Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypofractionated Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Hypofractionated Radiotherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Hypofractionated_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, Hypofractionated"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1831786"}]}}{"C152055":{"preferredName":"Direct Mixed Photon and Electron Field","code":"C152055","definitions":[{"definition":"A radiation therapy technique where external photon and electron beams are used to deliver treatment of superficial and deep-seated malignancies, respectively, while sparing underlying organs at risk.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Direct Mixed Photon and Electron Field","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Radiation, Mixed Photon Beam"},{"name":"NCI_META_CUI","value":"CL553390"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C104914":{"preferredName":"Photon Beam Radiation Therapy","code":"C104914","definitions":[{"definition":"A type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator (linac). The radiation dose is delivered at the surface of the body and goes into the tumor and through the body. Photon beam radiation therapy is different from proton beam therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation therapy using photon beam.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Photon Beam Radiation Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Radiation, Photon Beam"},{"name":"NCI_META_CUI","value":"CL445995"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C178422":{"preferredName":"Talc Poudrage","code":"C178422","definitions":[{"definition":"A surgical procedure in which talc is insufflated into the pleural space during thoracoscopy to promote the adhesion of the visceral and parietal layers of the pleura as a treatment for recurring pleural effusion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talc Poudrage","termGroup":"PT","termSource":"NCI"},{"termName":"Talc Pleurodesis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleurodesis, Talc"},{"name":"NCI_META_CUI","value":"CL1648595"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C162449":{"preferredName":"Peptide Receptor Radionuclide Therapy","code":"C162449","definitions":[{"definition":"Treatment with a radioactive substance that is linked to a peptide receptor so that it will attach to a specific cell type when injected into the body. It is currently being used to treat neuroendocrine tumors, using octreotide as the targeting peptide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptide Receptor Radionuclide Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"PRRT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peptide Receptor Radionuclide Therapy (PRRT)"},{"name":"NCI_META_CUI","value":"CL970990"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C51647":{"preferredName":"Distal Pancreatectomy","code":"C51647","definitions":[{"definition":"Removal of the body and tail of the pancreas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of the distal part of the pancreas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Distal Pancreatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Distal_Pancreatectomy"},{"name":"Maps_To","value":"Distal Pancreatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0176940"}]}}{"C172727":{"preferredName":"Minimally Invasive Surgery","code":"C172727","definitions":[{"definition":"Surgery that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. It also minimizes the risk of post-surgical complications, including less risk of infection, and is expected to reduce recovery time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Surgery","termGroup":"PT","termSource":"NCI"},{"termName":"Minimally-Invasive Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgery, Minimally Invasive"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0282624"}]}}{"C126391":{"preferredName":"Open Surgical Procedure","code":"C126391","definitions":[{"definition":"Traditional surgery using a long incision for visualization and for the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Surgical Procedure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgery, Open"},{"name":"NCI_META_CUI","value":"CL504936"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15340":{"preferredName":"Total Pancreatectomy","code":"C15340","definitions":[{"definition":"Surgery to remove the entire pancreas. Part of the stomach, part of the small intestine, the common bile duct, gallbladder, spleen, and nearby lymph nodes also are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of the entire pancreas.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Surgical removal of the entire pancreas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Pancreatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Total Excision of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Pancreatectomy"},{"name":"Maps_To","value":"Total Pancreatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040511"}]}}{"C957":{"preferredName":"10-Deacetyltaxol","code":"C957","definitions":[{"definition":"An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"10-Deacetyltaxol","termGroup":"PT","termSource":"NCI"},{"termName":"10-Deacetylpaclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"78432-77-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B77R96LJLK"},{"name":"Legacy Concept Name","value":"_10-Deacetyltaxol"},{"name":"Maps_To","value":"10-Deacetyltaxol"},{"name":"NSC Number","value":"656201"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044663"}]}}{"C49172":{"preferredName":"11C Topotecan","code":"C49172","definitions":[{"definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata radiolabeled with carbon 11 (11C) with antineoplastic and radiotracer properties. During the S phase of the cell cycle, topotecan inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Quantitation of 11C topotecan accumulated in tumor tissues by positron emission tomography (PET) may help predict responses to topotecan therapy.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of certain types of cancer, including ovarian cancer and lung cancer. 11C topotecan is a radioactive form of the anticancer drug topotecan. It builds up in tumor tissues and is detected by positron emission tomography (PET). It may be used to help determine whether treatment with topotecan will work. It is a type of topoisomerase I inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"11C Topotecan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_11C_Topotecan"},{"name":"Maps_To","value":"11C Topotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"454314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454314"},{"name":"PDQ_Open_Trial_Search_ID","value":"454314"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1711433"}]}}{"C28781":{"preferredName":"11D10 AluGel Anti-Idiotype Monoclonal Antibody","code":"C28781","definitions":[{"definition":"A monoclonal anti-idiotype antibody adsorbed to aluminum hydroxide gel (AluGel) with potential antineoplastic activity.  11D10 AluGel anti-idiotype monoclonal antibody mimics the human milk fat globule (HMFG) antigen found in breast and other cancers.  Vaccination with 11D10 AluGel anti-idiotype monoclonal antibody may induce a host antibody response against tumor cells positive for the HMFG antigen. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"11D10 AluGel Anti-Idiotype Monoclonal Antibody","termGroup":"PT","termSource":"NCI"},{"termName":"TriAb","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_11D10_AluGel_Anti-Idiotype_Monoclonal_Antibody"},{"name":"Maps_To","value":"11D10 AluGel Anti-Idiotype Monoclonal Antibody"},{"name":"NSC Number","value":"719681"},{"name":"NSC Number","value":"724593"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1520305"}]}}{"C41441":{"preferredName":"12-Allyldeoxoartemisinin","code":"C41441","definitions":[{"definition":"A semi-synthetic analogue of Artemisinin - a sesquiterpene lactone extracted from the dry leaves of Artemisia Annua (sweet wormwood) used as anti-malaria agent. Limited data is available on Artemisinin antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"12-Allyldeoxoartemisinin","termGroup":"PT","termSource":"NCI"},{"termName":"12-Allyldeoxoartemisinin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_12-Allyldeoxoartemisinin"},{"name":"Maps_To","value":"12-Allyldeoxoartemisinin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0294412"}]}}{"C2494":{"preferredName":"13-Deoxydoxorubicin","code":"C2494","definitions":[{"definition":"An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  13-Deoxydoxorubicin intercalates DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent was designed to be a non-cardiotoxic anthracycline antibiotic.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics. It is an anthracycline.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"13-Deoxydoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"GPX-100","termGroup":"CN","termSource":"NCI"},{"termName":"GPX100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"628290-43-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1S9VO1DQG5"},{"name":"Legacy Concept Name","value":"GPX-100"},{"name":"Maps_To","value":"13-Deoxydoxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"43222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43222"},{"name":"PDQ_Open_Trial_Search_ID","value":"43222"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796383"}]}}{"C62553":{"preferredName":"14C BMS-275183","code":"C62553","definitions":[{"definition":"An orally bioavailable taxane compound, a C-4 methyl carbonate analogue of paclitaxel, labeled with radioactive carbon 14, with potential antineoplastic and radioimaging activities. BMS-275183 binds to tubulin and as a result inhibits microtubule disassembly or assembly. This leads to cell cycle arrest at the G2/M phase, thereby resulting in an inhibition of cell division and ultimately cell death. BMS-275183 may be useful for treating multi-drug resistant tumors as it does not appear to be a substrate for P-glycoprotein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"14C BMS-275183","termGroup":"PT","termSource":"NCI"},{"termName":"[14C] BMS-275183","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_14C_BMS-275183"},{"name":"Maps_To","value":"14C BMS-275183"},{"name":"NCI_Drug_Dictionary_ID","value":"487486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487486"},{"name":"PDQ_Open_Trial_Search_ID","value":"487486"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831856"}]}}{"C133224":{"preferredName":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521","code":"C133224","definitions":[{"definition":"A selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17bHSD5, aldo-keto reductase 1C3; AKR1C3), with potential antineoplastic activity. Upon administration, ASP9521 selectively binds to and inhibits the activity of 17bHSD5. This prevents the conversion of the adrenal androgens dehydroepiandrosterone and androstenedione into 5-androstenediol and testosterone. By blocking testosterone production, ASP9521 may inhibit the growth of testosterone-dependent cancers such as castration-resistant prostate cancer (CRPC). 17bHSD5, expressed both in normal prostate tissue and in prostate cancer (PC), plays a crucial role in persistent production of androgens despite castration; its expression is associated with increased malignancy of PC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521","termGroup":"PT","termSource":"NCI"},{"termName":"(4-(2-Hydroxy-2-methylpropyl)piperidin-1-yl)(5-methoxy-1H-indol-2-yl)methanone","termGroup":"SN","termSource":"NCI"},{"termName":"17bHSD5 Inhibitor ASP9521","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 9521","termGroup":"CN","termSource":"NCI"},{"termName":"ASP9521","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1126084-37-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AA79G37CPR"},{"name":"Maps_To","value":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521"},{"name":"NCI_Drug_Dictionary_ID","value":"700558"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700558"},{"name":"PDQ_Open_Trial_Search_ID","value":"700558"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045761"}]}}{"C116618":{"preferredName":"2-Deoxy-D-glucose","code":"C116618","definitions":[{"definition":"A non-metabolizable glucose analog in which the hydroxyl group at position 2 of glucose is replaced by hydrogen, with potential glycolysis inhibiting and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration of 2-deoxy-D-glucose (2-DG), this agent competes with glucose for uptake by proliferating cells, such as tumor cells. 2-DG inhibits the first step of glycolysis and therefore prevents cellular energy production, which may result in decreased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Deoxy-D-glucose","termGroup":"PT","termSource":"NCI"},{"termName":"2-DG","termGroup":"AB","termSource":"NCI"},{"termName":"Deoxyglucose","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154-17-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9G2MP84A8W"},{"name":"Maps_To","value":"2-Deoxy-D-glucose"},{"name":"NCI_Drug_Dictionary_ID","value":"409701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"409701"},{"name":"PDQ_Open_Trial_Search_ID","value":"409701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011501"}]}}{"C1165":{"preferredName":"2-Ethylhydrazide","code":"C1165","definitions":[{"definition":"A podophyllic acid derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, 2-ethylhydrazide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Ethylhydrazide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_2-Ethylhydrazide"},{"name":"Maps_To","value":"2-Ethylhydrazide"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066615"}]}}{"C29794":{"preferredName":"2-Fluoroadenine","code":"C29794","definitions":[{"definition":"A fluorinated heterocyclic 2-ring compound. 2-fluoroadenine is the base moiety for many carbocyclic and acyclic nucleoside analogues, which may be used in antineoplastic studies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Fluoroadenine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Purin-6-amine, 2-fluoro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"2-Fad","termGroup":"AB","termSource":"NCI"},{"termName":"2-Fluoro-1H-purin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"Adenine, 2-fluoro-","termGroup":"SY","termSource":"NCI"},{"termName":"BRN 0610958","termGroup":"CN","termSource":"NCI"},{"termName":"Purine, 6-amino-2-fluoro-","termGroup":"SN","termSource":"NCI"},{"termName":"SRI 774","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"700-49-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2C8H3H4EBG"},{"name":"Legacy Concept Name","value":"_2-Fluoroadenine"},{"name":"Maps_To","value":"2-Fluoroadenine"},{"name":"NSC Number","value":"27364"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0046110"}]}}{"C131289":{"preferredName":"2-Fluorofucose","code":"C131289","definitions":[{"definition":"An orally bioavailable fluorinated analog of fucose that is a protein fucosylation inhibitor, with potential antineoplastic and immunomodulating activities. Upon administration, 2-fluorofucose (2-FF) mimics fucose and is converted to guanosine diphosphate (GDP)-2FF, which prevents the formation of the fucosylation substrate GDP-fucose, and the incorporation of fucose into glycoproteins by fucosyltransferase. As fucosylation of glycoproteins plays a key role in many biological processes, such as protein function, receptor binding, cell signaling and cellular adhesion, and is essential for tumor progression, blocking fucosylation decreases tumor cell growth. In addition, blocking fucosylation of monoclonal antibodies generates fucose-deficient antibodies that exert enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Fluorofucose","termGroup":"PT","termSource":"NCI"},{"termName":"2-FF Containing SGN-2FF","termGroup":"SY","termSource":"NCI"},{"termName":"2FF-containing SGN-2FF","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-2FF","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70763-62-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W39886N0ZG"},{"name":"Maps_To","value":"2-Fluorofucose-containing SGN-2FF"},{"name":"NCI_Drug_Dictionary_ID","value":"785540"},{"name":"NCI_META_CUI","value":"CL514470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785540"},{"name":"PDQ_Open_Trial_Search_ID","value":"785540"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120474":{"preferredName":"2-Hydroxyestradiol","code":"C120474","definitions":[{"definition":"A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 2 by the CYP450 enzymes 1A1/1A2. Theoretically, 2-hydroxyestradiol (2-OHE2) is able to undergo redox cycling, which generates active radicals and induces DNA damage; however, this estradiol metabolite is very unstable in vivo and is quickly inactivated by catechol-O-methyltransferase (COMT)-mediated O-methylation and converted to 2-methoxyestradiol (2-MeE2). 2-MeE2 exerts antineoplastic activities through its estrogen receptor antagonistic effect and the induction of apoptosis in susceptible cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Hydroxyestradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17beta)-Estra-1,3,5(10)-Triene-2,3,17-Triol","termGroup":"SY","termSource":"NCI"},{"termName":"2-Hydroxy-17beta-Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"2-Hydroxyestradiol-17beta","termGroup":"SY","termSource":"NCI"},{"termName":"2-OH-E2","termGroup":"AB","termSource":"NCI"},{"termName":"2-OH-Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"2-OHE2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-05-0"},{"name":"CHEBI_ID","value":"CHEBI:28744"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AYU2L67YUU"},{"name":"Maps_To","value":"2-Hydroxyestradiol"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046196"}]}}{"C63947":{"preferredName":"2-Hydroxyestrone","code":"C63947","definitions":[{"definition":"A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 2 by cytochrome P450 (CYP) enzymes, including CYP1A1 and 1A2, with potential anticarcinogenic activity. The mechanism of action for the antitumor activity of 2-hydroxyestrone is not known but this metabolic product has minimal estrogenic activity compared to the parent compound and other estrone metabolites. Additionally, O-methylation of this compound produces 2-methoxyestradiol (2-MeOE2), which is a potent inhibitor of both cell proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Hydroxyestrone","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5(10)-Estratrien-2,3-diol-17-one","termGroup":"SN","termSource":"NCI"},{"termName":"2-OHE(1)","termGroup":"SY","termSource":"NCI"},{"termName":"2-OHE1","termGroup":"SY","termSource":"NCI"},{"termName":"Catecholestrone","termGroup":"SY","termSource":"NCI"},{"termName":"Estra-1,3,5(1)-Trien-17-One, 2,3-Dihydroxy-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-06-1"},{"name":"CHEBI_ID","value":"CHEBI:1156"},{"name":"Chemical_Formula","value":"C18H22O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UQS3A06ILY"},{"name":"Legacy Concept Name","value":"_2-Hydroxyestrone"},{"name":"Maps_To","value":"2-Hydroxyestrone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046200"}]}}{"C85482":{"preferredName":"2-Hydroxyflutamide Depot","code":"C85482","definitions":[{"definition":"A depot formulation containing a bioresorbable, controlled-release, calcium sulphate-based paste of the nonsteroidal antiandrogen 2-hydroxyflutamide (2-HOF) with potential antineoplastic activity. Upon injection into the tumor site in the prostate, 2-hydroxyflutamide depot slowly releases 2-HOF, which competitively binds to androgen receptors (ARs), blocking the binding of dihydrotestosterone (DHT). This may inhibit androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest and decreased cellular proliferation. In addition, 2-HOF inhibits nuclear uptake of androgen in androgen-responsive tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Hydroxyflutamide Depot","termGroup":"PT","termSource":"NCI"},{"termName":"2-Hydroxyflutamide Controlled-Release Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"Liproca","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2-Hydroxyflutamide Depot"},{"name":"NCI_Drug_Dictionary_ID","value":"648122"},{"name":"NCI_META_CUI","value":"CL412370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648122"},{"name":"PDQ_Open_Trial_Search_ID","value":"648122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105401":{"preferredName":"Idroxioleic Acid","code":"C105401","definitions":[{"definition":"An orally bioavailable, synthetic analog of the fatty acid oleic acid, with potential antitumor activity. Upon administration,idroxioleic acid activates sphingomyelin synthase (SMS), thereby increasing the concentration of sphingomyelin (SM) and diacylglycerol (DAG) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signaling and the aberrant activity of signaling pathways in certain tumor cells, including the Ras/MAPK and PI3K/AKt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idroxioleic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2-Hydroxyoleic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"2-OHOA","termGroup":"CN","termSource":"NCI"},{"termName":"2OHOA","termGroup":"CN","termSource":"NCI"},{"termName":"LAM 561","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-561","termGroup":"CN","termSource":"NCI"},{"termName":"LAM561","termGroup":"CN","termSource":"NCI"},{"termName":"Minerval","termGroup":"FB","termSource":"NCI"},{"termName":"NFX88","termGroup":"CN","termSource":"NCI"},{"termName":"SML-0256","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56472-29-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OSV3KVO1BT"},{"name":"Maps_To","value":"2-Hydroxyoleic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"746793"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746793"},{"name":"PDQ_Open_Trial_Search_ID","value":"746793"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566317"}]}}{"C965":{"preferredName":"2-Methoxyestradiol","code":"C965","definitions":[{"definition":"2ME2. A drug derived from estrogen that belongs to the family of drugs called angiogenesis inhibitors.  It prevents the formation of new blood vessels that tumors need in order to grow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable estradiol metabolite with potential antineoplastic activity.  2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis.  This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Methoxyestradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol","termGroup":"SN","termSource":"NCI"},{"termName":"2-MeE2","termGroup":"AB","termSource":"NCI"},{"termName":"2-MeOE2","termGroup":"AB","termSource":"NCI"},{"termName":"2-Methoxy Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"2ME2","termGroup":"AB","termSource":"NCI"},{"termName":"Panzem","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-07-2"},{"name":"CHEBI_ID","value":"CHEBI:28955"},{"name":"Chemical_Formula","value":"C19H26O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6I2QW73SR5"},{"name":"Legacy Concept Name","value":"_2-Methoxyestradiol"},{"name":"Maps_To","value":"2-Methoxyestradiol"},{"name":"NCI_Drug_Dictionary_ID","value":"38472"},{"name":"NSC Number","value":"659853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38472"},{"name":"PDQ_Open_Trial_Search_ID","value":"38472"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046319"}]}}{"C62603":{"preferredName":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion","code":"C62603","definitions":[{"definition":"An orally bioavailable liquid formulation containing the small molecule 2-methoxyestradiol with potential antineoplastic activity. 2-Methoxyestradiol, a naturally occurring estradiol metabolite, exerts its antitumor effect by inhibiting endothelial cells as well as tumor cells through multiple mechanisms. This agent binds to tubulin and disrupts microtubule formation, thereby preventing mitosis and subsequent cellular proliferation. In addition, 2-methoxyestradiol induces caspase activation, resulting in cell cycle arrest in G2 phase and apoptosis in due course. This agent also down-regulates hypoxia inducible factor-one alpha (HIF-1a). The nanocrystal colloidal dispersion increases the absorption of 2-methoxyestradiol, thereby improving its bioavailability, which results in enhanced drug plasma levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion","termGroup":"PT","termSource":"NCI"},{"termName":"Panzem NCD","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_2-Methoxyestradiol_Nanocrystal_Colloidal_Dispersion"},{"name":"Maps_To","value":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion"},{"name":"NCI_Drug_Dictionary_ID","value":"488412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488412"},{"name":"PDQ_Open_Trial_Search_ID","value":"488412"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831865"}]}}{"C120472":{"preferredName":"2-Methoxyestrone","code":"C120472","definitions":[{"definition":"A metabolite formed during the methylation of 2-hydroxyestrone (2-OHE1) by catechol-O-methyltransferase (COMT), with potential anticarcinogenic and minimal estrogen activities. The mechanism of action for the antitumor activity of 2-methoxyestrone (2-OMeE1) is not known. A high 2-methoxyestrone (2-OMeE1)/2-OHE1 ratio indicates higher methylation efficiency and correlates with a lower cancer risk.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Methoxyestrone","termGroup":"PT","termSource":"NCI"},{"termName":"2-MeE1","termGroup":"AB","termSource":"NCI"},{"termName":"2-MeOE1","termGroup":"AB","termSource":"NCI"},{"termName":"2-OMeE1","termGroup":"AB","termSource":"NCI"},{"termName":"3-Hydroxy-2-Methoxyestra-1,3,5(10)-Trien-17-One","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-08-3"},{"name":"CHEBI_ID","value":"CHEBI:1189"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SJ5857RRL3"},{"name":"Maps_To","value":"2-Methoxyestrone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046322"}]}}{"C99130":{"preferredName":"Dociparstat sodium","code":"C99130","definitions":[{"definition":"A heparin derivative in which the 2-O and 3-O sulfate groups of heparin are removed and that lacks anticoagulant activity, with potential anti-inflammatory, immodulatory and antineoplastic activities. Upon administration, dociparstat sodium binds to both chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) and CXC chemokine receptor 4 (CXCR4). This prevents the interaction of CXCL12 with CXCR4, blocks CXCR4 activation, and may result in decreased proliferation and migration in CXCR4-overexpressing tumor cells. In addition, inhibition of CXCL12/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into the blood.  In addition, dociparstat sodium prevents the interaction of the receptor for advanced glycation end-products (RAGE) with its ligands, including advanced glycation end-products (AGEs), Mac-1(CD11b/CD18), the nuclear pro-inflammatory protein high mobility group box protein-1 (HMGB-1), carboxymethyl lysine-bovine serum albumin (CML-BSA) and members of the S100 calgranulin family. In addition, this agent inhibits the enzymes heparanase, cathepsin G, and human leukocyte elastase, which are involved in inflammation and metastasis. Altogether, this may inhibit tumor cell invasiveness and metastasis. Dociparstat sodium also binds to platelet factor 4 (PF4 or CXCL4) and may prevent PF4's inhibitory effect on platelet production. This may increase platelet production. Unlike heparin, this agent does not induce heparin-induced thrombocytopenia (HIT). RAGE, a receptor belonging to the immunoglobulin superfamily, plays a key role in inflammation and is overexpressed in a variety of cancers. CXCR4 is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family that plays an important role in chemotaxis, chemoresistance and angiogenesis, and is upregulated in several tumor cell types. The interaction between CXCL12/CXCR4 induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dociparstat sodium","termGroup":"PT","termSource":"NCI"},{"termName":"2,3-o-Desulfated Heparin (12000 da)","termGroup":"SN","termSource":"NCI"},{"termName":"CX 01","termGroup":"CN","termSource":"NCI"},{"termName":"CX-01","termGroup":"CN","termSource":"NCI"},{"termName":"CX01","termGroup":"CN","termSource":"NCI"},{"termName":"O-desulfated Heparin","termGroup":"SY","termSource":"NCI"},{"termName":"ODSH","termGroup":"AB","termSource":"NCI"},{"termName":"PGX-100","termGroup":"CN","termSource":"NCI"},{"termName":"PGX-ODSH","termGroup":"SY","termSource":"NCI"},{"termName":"PGX100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"177021-00-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O75889WF4"},{"name":"Maps_To","value":"2-O, 3-O Desulfated Heparin"},{"name":"Maps_To","value":"Dociparstat sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"715907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715907"},{"name":"PDQ_Open_Trial_Search_ID","value":"715907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0915548"}]}}{"C29796":{"preferredName":"2,6-Diaminopurine","code":"C29796","definitions":[{"definition":"One of a number of organic compounds that share a similar purine structure and possess antiviral and antitumor properties. 2,6-Diaminopurine nucleosides are versatile synthetic precursors for specific N-6 modifications of antiviral and antitumor agents. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2,6-Diaminopurine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Purine-2,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"9h-purine-2,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"DAP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1904-98-9"},{"name":"CHEBI_ID","value":"CHEBI:38001"},{"name":"Chemical_Formula","value":"C5H6N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49P95BAU4Z"},{"name":"Legacy Concept Name","value":"_2_6-Diaminopurine"},{"name":"Maps_To","value":"2,6-Diaminopurine"},{"name":"NSC Number","value":"743"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0045587"}]}}{"C126754":{"preferredName":"2,6-Dimethoxyquinone","code":"C126754","definitions":[{"definition":"A methoxy-substituted benzoquinone and bioactive compound found in fermented wheat germ extracts, with potential antineoplastic and immune-enhancing activity. 2,6-Dimethoxyquinone (2,6-DMBQ) inhibits anaerobic glycolysis thereby preventing cellular metabolism and inducing apoptosis. As cancer cells use the anaerobic glycolysis pathway to metabolize glucose and cancer cells proliferate at an increased rate as compared to normal, healthy cells, this agent is specifically cytotoxic towards cancer cells. In addition, 2,6-DMBQ exerts immune-enhancing effects by increasing natural killer (NK) cell and T-cell activity against cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2,6-Dimethoxyquinone","termGroup":"PT","termSource":"NCI"},{"termName":"2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy-","termGroup":"SY","termSource":"NCI"},{"termName":"2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Dimethoxy-1,4-Benzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-Dimethoxy-p-Benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Dimethoxy-p-Quinone","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-Dimethoxybenzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-Dimethoxycyclohexa-2,5-Diene-1,4-Dione","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-DMBQ","termGroup":"AB","termSource":"NCI"},{"termName":"p-Benzoquinone, 2,6-Dimethoxy-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"530-55-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z701W789S"},{"name":"Maps_To","value":"2,6-Dimethoxyquinone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0045611"}]}}{"C80036":{"preferredName":"2'-F-ara-deoxyuridine","code":"C80036","definitions":[{"definition":"A deoxyuridine prodrug with potential antineoplastic activity. Upon cellular uptake, 2'-F-ara-deoxyuridine (FAU) is phosphorylated by thymidine kinase to FAU monophosphate and subsequently methylated in the 5'-position by thymidylate synthase (TS) to its activated form, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) 5-methyluracil monophosphate (FMAUMP). FMAUMP is incorporated into DNA leading to an inhibition of DNA synthesis and so cell growth. The catalytic activity of TS is critical to activation of FAU and subsequent incorporation into DNA. FAU may be beneficial in the case of tumors with high TS activity that are resistant to TS inhibitors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of advanced solid tumors and lymphomas. It blocks the growth of cells and may cause cancer cells to die. It is a type of uracil analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"2'-F-ara-deoxyuridine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) Uracil","termGroup":"SN","termSource":"NCI"},{"termName":"FAU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69123-94-0"},{"name":"Chemical_Formula","value":"C9H11FN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K7386OMP29"},{"name":"Legacy Concept Name","value":"_2-F-ara-deoxyuridine"},{"name":"Maps_To","value":"2'-F-ara-deoxyuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"616102"},{"name":"NCI_META_CUI","value":"CL388502"},{"name":"PDQ_Closed_Trial_Search_ID","value":"616102"},{"name":"PDQ_Open_Trial_Search_ID","value":"616102"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29475":{"preferredName":"3'-C-ethynylcytidine","code":"C29475","definitions":[{"definition":"A synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"3'-C-ethynylcytidine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine","termGroup":"SN","termSource":"NCI"},{"termName":"3'-C-ethynylcytidine","termGroup":"SY","termSource":"NCI"},{"termName":"ECdy","termGroup":"AB","termSource":"NCI"},{"termName":"ECyd","termGroup":"AB","termSource":"NCI"},{"termName":"TAS-106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"180300-43-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y3O05I09ZK"},{"name":"Legacy Concept Name","value":"TAS-106"},{"name":"Maps_To","value":"3'-C-ethynylcytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"614024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614024"},{"name":"PDQ_Open_Trial_Search_ID","value":"614024"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0533115"}]}}{"C977":{"preferredName":"4-Nitroestrone 3-Methyl Ether","code":"C977","definitions":[{"definition":"A synthetic derivative of estradiol. 4-nitroestrone 3-methyl ether inhibits estrogen sulfotransferase (EST), a progesterone-induced secretory endometrial enzyme which affects estrogen receptor levels.  This agent has been shown to be an effective growth inhibitor of some chemically induced animal mammary tumors. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"4-Nitroestrone 3-Methyl Ether","termGroup":"PT","termSource":"NCI"},{"termName":"3-Methoxy-4-nitro-estra-1,3,5(10)-trien-17-one","termGroup":"SY","termSource":"NCI"},{"termName":"4-Nitroestrone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"14846-62-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G484L3U0O2"},{"name":"Legacy Concept Name","value":"_4-Nitroestrone_3-Methyl_Ether"},{"name":"Maps_To","value":"4-Nitroestrone 3-Methyl Ether"},{"name":"NCI_Drug_Dictionary_ID","value":"39339"},{"name":"NSC Number","value":"321803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39339"},{"name":"PDQ_Open_Trial_Search_ID","value":"39339"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048573"}]}}{"C121828":{"preferredName":"4-Thio-2-deoxycytidine","code":"C121828","definitions":[{"definition":"An orally bioavailable 4-thio modified 2-deoxycytidine analog, with potential antineoplastic activity. Upon administration of 4-thio-2-deoxycytidine (TdCyd), this cytidine analog gets incorporated into DNA during replication and inhibits the activity of DNA methyltransferase 1 (DNMT1), which blocks DNA hypermethylation. This results in DNMT1 depletion, hypomethylation of DNA, and the reactivation of tumor suppressor genes that were silenced by hypermethylation; this results in antitumor activity and an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"4-Thio-2-deoxycytidine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Thio-2'-deoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"T-dCyd","termGroup":"AB","termSource":"NCI"},{"termName":"TdCyd","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134111-30-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L76O0M313F"},{"name":"Maps_To","value":"4-Thio-2-deoxycytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"771603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771603"},{"name":"PDQ_Open_Trial_Search_ID","value":"771603"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0647434"}]}}{"C971":{"preferredName":"4'-Iodo-4'-Deoxydoxorubicin","code":"C971","definitions":[{"definition":"A substance that is being studied as a treatment for cancer, and for primary systemic amyloidosis (a disease in which proteins are deposited in specific organs). It belongs to the family of drugs called anthracycline analogues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An iodinated doxorubicin analogue with antiamyloid activity. 4'-Iodo-4'-deoxydoxorubicin (IDOX) binds with high affinity to five types of natural amyloid fibrils including immunoglobulin light chains, amyloid A, transthyretin (methionine-30 variant), beta-protein (Alzheimer), and beta2-microglobulin. This agent may inhibit fibril growth, increasing the solubility of amyloid tissue deposits and facilitating their clearance. IDOX has also been shown to insulin amyloid fibrillogenesis in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"4'-Iodo-4'-Deoxydoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxy-4'-Iododoxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"IDOX","termGroup":"AB","termSource":"NCI"},{"termName":"Iodo-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Iododoxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83997-75-5"},{"name":"CHEBI_ID","value":"CHEBI:47897"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65JH75I9JX"},{"name":"Legacy Concept Name","value":"_4_Iodo-4_Deoxydoxorubicin"},{"name":"Maps_To","value":"4'-Iodo-4'-Deoxydoxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"41162"},{"name":"NSC Number","value":"378901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41162"},{"name":"PDQ_Open_Trial_Search_ID","value":"41162"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0047758"}]}}{"C153479":{"preferredName":"5-Aza-4'-thio-2'-deoxycytidine","code":"C153479","definitions":[{"definition":"An orally bioavailable, nucleoside analog and DNA methyltransferase I (DNMT1) inhibitor, with potential DNA hypomethylating and antineoplastic activities. Upon administration, 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) gets incorporated into DNA, where it binds to the active site of DNMT1, a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. The formation of covalent DNMT1-DNA complexes inhibits DNMT1, prevents DNA methylation of CpG sites, causes CpG demethylation, and results in the re-expression and re-activation of silenced tumor suppressor genes. This inhibits tumor cell proliferation. DNMT1, overactivated in tumor cells, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5-Aza-4'-thio-2'-deoxycytidine","termGroup":"PT","termSource":"NCI"},{"termName":"5-Aza-4-thio-2-deoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"5-Aza-TdCyd","termGroup":"AB","termSource":"NCI"},{"termName":"Aza-TdC","termGroup":"AB","termSource":"NCI"},{"termName":"Aza-TdCyd","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"169514-76-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U2PTN0RZF6"},{"name":"Maps_To","value":"5-Aza-4'-thio-2'-deoxycytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"794175"},{"name":"NCI_META_CUI","value":"CL554978"},{"name":"NSC Number","value":"777586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794175"},{"name":"PDQ_Open_Trial_Search_ID","value":"794175"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62785":{"preferredName":"5-Fluoro-2-Deoxycytidine","code":"C62785","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It may prevent the growth of tumors by stopping cancer cells from dividing and by killing them. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5-Fluoro-2-Deoxycytidine","termGroup":"PT","termSource":"NCI"},{"termName":"Cytidine, 2'-deoxy-5-fluoro-","termGroup":"SN","termSource":"NCI"},{"termName":"FdCyd","termGroup":"AB","termSource":"NCI"},{"termName":"Ro 5-1090","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10356-76-0"},{"name":"Chemical_Formula","value":"C9H12FN3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KUA4693H5W"},{"name":"Legacy Concept Name","value":"_5-Fluoro-2-Deoxycytidine"},{"name":"Maps_To","value":"5-Fluoro-2-Deoxycytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"509184"},{"name":"NSC Number","value":"48006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"509184"},{"name":"PDQ_Open_Trial_Search_ID","value":"509184"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049174"}]}}{"C113787":{"preferredName":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158","code":"C113787","definitions":[{"definition":"An inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. PFKFB3, an enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, is highly expressed and active in human cancer cells; it plays a key role in increasing both glycolytic flux in and proliferation of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158","termGroup":"PT","termSource":"NCI"},{"termName":"ACT-PFK-158","termGroup":"CN","termSource":"NCI"},{"termName":"PFK-158","termGroup":"CN","termSource":"NCI"},{"termName":"PFKFB3 Inhibitor PFK-158","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158"},{"name":"NCI_Drug_Dictionary_ID","value":"757225"},{"name":"NCI_META_CUI","value":"CL471768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757225"},{"name":"PDQ_Open_Trial_Search_ID","value":"757225"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1611":{"preferredName":"7-Cyanoquinocarcinol","code":"C1611","definitions":[{"definition":"A semisynthetic analogue of the Streptomyces melanovinaceus-derived tetracyclic antitumor antibiotic quinocarmycin with potential antineoplastic activity. Quinocarmycin belongs to the naphthyridinomycin/saframycin class of antitumor antibiotics. These antibiotics appear to act through DNA alkylation.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics. It is an anthracycline.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"7-Cyanoquinocarcinol","termGroup":"PT","termSource":"NCI"},{"termName":"DX 52-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96251-59-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"64T9QZ8N2Y"},{"name":"Legacy Concept Name","value":"_7-Cyanoquinocarcinol"},{"name":"Maps_To","value":"7-Cyanoquinocarcinol"},{"name":"NCI_Drug_Dictionary_ID","value":"42444"},{"name":"NSC Number","value":"607097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42444"},{"name":"PDQ_Open_Trial_Search_ID","value":"42444"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0294165"}]}}{"C61618":{"preferredName":"7-Ethyl-10-Hydroxycamptothecin","code":"C61618","synonyms":[{"termName":"7-Ethyl-10-Hydroxycamptothecin","termGroup":"PT","termSource":"NCI"},{"termName":"7-Ethyl-10-hydroxy-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"SN 38","termGroup":"CN","termSource":"NCI"},{"termName":"SN-38","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86639-52-3"},{"name":"Chemical_Formula","value":"C22H20N2O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0H43101T0J"},{"name":"Legacy Concept Name","value":"_7-Ethyl-10-Hydroxycamptothecin"},{"name":"Maps_To","value":"7-Ethyl-10-Hydroxycamptothecin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0142710"}]}}{"C1271":{"preferredName":"7-Hydroxystaurosporine","code":"C1271","definitions":[{"definition":"A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called staurosporine analogues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"7-Hydroxystaurosporine","termGroup":"PT","termSource":"NCI"},{"termName":"7-Hydroxy-staurosporine","termGroup":"SN","termSource":"NCI"},{"termName":"8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo[a, g]cyclonona[cde] Trinden-1-one, 2,3,9,10,11, 12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)","termGroup":"SN","termSource":"NCI"},{"termName":"UCN-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112953-11-4"},{"name":"Chemical_Formula","value":"C28H26N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BU5H4V94A"},{"name":"Legacy Concept Name","value":"_7-Hydroxystaurosporine"},{"name":"Maps_To","value":"7-Hydroxystaurosporine"},{"name":"NCI_Drug_Dictionary_ID","value":"42305"},{"name":"NSC Number","value":"638850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42305"},{"name":"PDQ_Open_Trial_Search_ID","value":"42305"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077681"}]}}{"C28788":{"preferredName":"8-Azaguanine","code":"C28788","definitions":[{"definition":"A purine analogue with potential antineoplastic activity.  8-Azaguanine interferes with the modification of transfer ribonucleic acid (tRNA) by competing with guanine for incorporation into tRNA catalyzed by the enzyme tRNA-guanine ribosyltransferase (tRNA-guanine transglycosylase).  Altered guanine modification of tRNA has been implicated in cellular differentiation and neoplastic transformation.  8-Azaguanine also inhibits the formation of 43S and 80S initiation complexes, thereby interfering with initiation of translation and inhibiting protein synthesis.  This agent inhibits tumor cell growth and stimulates cell differentiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"8-Azaguanine","termGroup":"PT","termSource":"NCI"},{"termName":"5-Amino-1,4-dihydro-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-1H-v-triazolo(d)pyrimidin-7-ol","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-7-hydroxy-1H-v-triazolo(d)pyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"8 AG","termGroup":"AB","termSource":"NCI"},{"termName":"Guanazolo","termGroup":"SY","termSource":"NCI"},{"termName":"Pathocidin","termGroup":"SY","termSource":"NCI"},{"termName":"SF-337","termGroup":"CN","termSource":"NCI"},{"termName":"SK 1150","termGroup":"CN","termSource":"NCI"},{"termName":"Triazologuanine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134-58-7"},{"name":"CHEBI_ID","value":"CHEBI:63486"},{"name":"Chemical_Formula","value":"C4H4N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q150359I72"},{"name":"Legacy Concept Name","value":"_8-Azaguanine"},{"name":"Maps_To","value":"8-Azaguanine"},{"name":"NSC Number","value":"223526"},{"name":"NSC Number","value":"749"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004476"}]}}{"C28789":{"preferredName":"9-Ethyl 6-Mercaptopurine","code":"C28789","definitions":[{"definition":"A synthetic alkyl derivative prodrug of the antineoplastic agent 6-mercaptopurine (6-MP).  In vivo, 9-ethyl 6-mercaptopurine appears to be converted to 6-MP, which substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"9-Ethyl 6-Mercaptopurine","termGroup":"PT","termSource":"NCI"},{"termName":"9-Ethyl 6-MP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5427-20-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_9-Ethyl_6-Mercaptopurine"},{"name":"Maps_To","value":"9-Ethyl 6-Mercaptopurine"},{"name":"NSC Number","value":"14575"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0626019"}]}}{"C28793":{"preferredName":"9H-Purine-6Thio-98D","code":"C28793","definitions":[{"definition":"An antimetabolite analogue of purine with antineoplastic and immuno-suppressant properties.  9H-Purine-6Thio-98D substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. In vivo, this agent, also known as 6MP-arabinoside, may occur as a metabolite of the antineoplastic agent mercaptopurine. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"9H-Purine-6Thio-98D","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_9H-Purine-6Thio-98D"},{"name":"Maps_To","value":"9H-Purine-6Thio-98D"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515473"}]}}{"C26449":{"preferredName":"Abagovomab","code":"C26449","definitions":[{"definition":"A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abagovomab","termGroup":"PT","termSource":"NCI"},{"termName":"Monoclonal Antibody ACA125 Anti-Idiotype Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"VaccinOvar","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"792921-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3YK0326U7X"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_ACA125_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Abagovomab"},{"name":"NCI_Drug_Dictionary_ID","value":"299488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299488"},{"name":"PDQ_Open_Trial_Search_ID","value":"299488"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832044"}]}}{"C2015":{"preferredName":"Abarelix","code":"C2015","definitions":[{"definition":"A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone.  As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abarelix","termGroup":"PT","termSource":"NCI"},{"termName":"Plenaxis","termGroup":"SY","termSource":"NCI"},{"termName":"PPI-149","termGroup":"CN","termSource":"NCI"},{"termName":"R-3827","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prostate Cancer"},{"name":"CAS_Registry","value":"183552-38-7"},{"name":"CHEBI_ID","value":"CHEBI:337298"},{"name":"Chemical_Formula","value":"C72H95ClN14O14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"W486SJ5824"},{"name":"Legacy Concept Name","value":"Abarelix"},{"name":"Maps_To","value":"Abarelix"},{"name":"NCI_Drug_Dictionary_ID","value":"415570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415570"},{"name":"PDQ_Open_Trial_Search_ID","value":"415570"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1174732"}]}}{"C97660":{"preferredName":"Abemaciclib","code":"C97660","definitions":[{"definition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abemaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)","termGroup":"SN","termSource":"NCI"},{"termName":"LY-2835219","termGroup":"CN","termSource":"NCI"},{"termName":"LY2835219","termGroup":"CN","termSource":"NCI"},{"termName":"Verzenio","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer"},{"name":"CAS_Registry","value":"1231929-97-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"60UAB198HK"},{"name":"Maps_To","value":"Abemaciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"706364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706364"},{"name":"PDQ_Open_Trial_Search_ID","value":"706364"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852841"}]}}{"C162507":{"preferredName":"Abemaciclib Mesylate","code":"C162507","definitions":[{"definition":"The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abemaciclib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"LY-2835219 Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"LY-2835219 methanesulfonate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1231930-82-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KKT462Q807"},{"name":"Maps_To","value":"Abemaciclib Mesylate"},{"name":"NCI_META_CUI","value":"CL970947"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68920":{"preferredName":"Abexinostat","code":"C68920","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abexinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-benzofurancarboxamide, 3-((dimethylamino)methyl)-n-(2-(4-((hydroxyamino)carbonyl)phenoxy)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)-1-benzofuran-2-carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"CRA-024781","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC Inhibitor PCI-24781","termGroup":"SY","termSource":"NCI"},{"termName":"PCI-24781","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"783355-60-2"},{"name":"Chemical_Formula","value":"C21H23N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IYO470654U"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_CRA-024781"},{"name":"Maps_To","value":"Abexinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"553625"},{"name":"PDQ_Closed_Trial_Search_ID","value":"553625"},{"name":"PDQ_Open_Trial_Search_ID","value":"553625"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537177"}]}}{"C160889":{"preferredName":"Abexinostat Tosylate","code":"C160889","definitions":[{"definition":"The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abexinostat Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrolo(2,3-C)pyridine-2-carboxamide, N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl)-6,7-dihydro-6-methyl-7-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"PCI-24781 Tosylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138861-99-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AOH3JC92C0"},{"name":"Maps_To","value":"Abexinostat Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"553625"},{"name":"NCI_META_CUI","value":"CL969910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"553625"},{"name":"PDQ_Open_Trial_Search_ID","value":"553625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77333":{"preferredName":"Abiraterone","code":"C77333","definitions":[{"definition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abiraterone","termGroup":"PT","termSource":"NCI"},{"termName":"17-(3-Pyridyl)androsta-5,16-dien-3beta-ol","termGroup":"SN","termSource":"NCI"},{"termName":"CB 7598","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154229-19-3"},{"name":"Chemical_Formula","value":"C24H31NO"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"G819A456D0"},{"name":"Legacy Concept Name","value":"Abiraterone"},{"name":"Maps_To","value":"Abiraterone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0754011"}]}}{"C68845":{"preferredName":"Abiraterone Acetate","code":"C68845","definitions":[{"definition":"A substance being studied in the treatment of prostate cancer and breast cancer. It blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of cancer cells that need androgens to grow. It is a type of anti-androgen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abiraterone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"17-(3-Pyridyl)-5,16-androstadien-3beta-acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-","termGroup":"SN","termSource":"NCI"},{"termName":"BR9004","termGroup":"CN","termSource":"NCI"},{"termName":"BR9004-1","termGroup":"CN","termSource":"NCI"},{"termName":"CB7630","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-212082","termGroup":"CN","termSource":"NCI"},{"termName":"Yonsa","termGroup":"BR","termSource":"NCI"},{"termName":"Zytiga","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Castration-resistant prostate cancer"},{"name":"CAS_Registry","value":"154229-18-2"},{"name":"Chemical_Formula","value":"C26H33NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EM5OCB9YJ6"},{"name":"Legacy Concept Name","value":"Abiraterone_Acetate"},{"name":"Maps_To","value":"Abiraterone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"552704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"552704"},{"name":"PDQ_Open_Trial_Search_ID","value":"552704"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607886"}]}}{"C82422":{"preferredName":"Abituzumab","code":"C82422","definitions":[{"definition":"A humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities. Abituzumab, a chimeric antibody which includes the antigen binding sites of the anti-integrin mouse antibody 17E6, binds to and inhibits the activity of alphaVbeta3 integrin (vitronectin receptor); this may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alphavbeta3-expressing tumor cells. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is expressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 525797","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1105038-73-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"724QD330RD"},{"name":"Legacy Concept Name","value":"Anti-alphaVbeta3_Monoclonal_Antibody_EMD_525797"},{"name":"Maps_To","value":"Abituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"638087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638087"},{"name":"PDQ_Open_Trial_Search_ID","value":"638087"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830088"}]}}{"C99901":{"preferredName":"Acai Berry Juice","code":"C99901","definitions":[{"definition":"A juice product obtained from the fruit of the acai palm tree (Euterpe oleracea) with anti-inflammatory, antioxidant and potential chemopreventive activities. Besides high amounts of vitamins, minerals and fatty acids, acai berry is rich in phytonutrients such as anthocyanins and flavones which are potent scavengers of reactive oxygen species. The fruit also contains high amounts of the flavone velutin which exhibits potent anti-inflammatory properties. Velutin is able to inhibit the degradation of the inhibitor of nuclear factor kappa-B (NF-kB), thereby blocking the activation of NF-kB, as well as inhibiting phosphorylation of mitogen-activated protein kinase p38 and JNK. Inhibition of these processes results in suppression of the production of proinflammatory cytokines, such as tumor necrosis factor alpha and interleukin 6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acai Berry Juice","termGroup":"PT","termSource":"NCI"},{"termName":"Acai Juice","termGroup":"SY","termSource":"NCI"},{"termName":"Açai Berry Juice","termGroup":"SY","termSource":"NCI"},{"termName":"Açai Juice","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6JR5T80U0G"},{"name":"Maps_To","value":"Acai Berry Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"724700"},{"name":"NCI_META_CUI","value":"CL433602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724700"},{"name":"PDQ_Open_Trial_Search_ID","value":"724700"},{"name":"Semantic_Type","value":"Food"}]}}{"C113442":{"preferredName":"Acalabrutinib","code":"C113442","definitions":[{"definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acalabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"ACP-196","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-","termGroup":"SN","termSource":"NCI"},{"termName":"Bruton Tyrosine Kinase Inhibitor ACP-196","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy; with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"CAS_Registry","value":"1420477-60-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I42748ELQW"},{"name":"Maps_To","value":"Acalabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"756623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756623"},{"name":"PDQ_Open_Trial_Search_ID","value":"756623"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4078312"}]}}{"C103277":{"preferredName":"Acalisib","code":"C103277","definitions":[{"definition":"An inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. Acalisib inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acalisib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Fluoro-3-phenyl-2-((1S)-1-(7H-purin-6-ylamino)ethyl)quinazolin-4(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"CAL-120","termGroup":"CN","termSource":"NCI"},{"termName":"GS-9820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"870281-34-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OVW60IDW1D"},{"name":"Maps_To","value":"Acalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"741949"},{"name":"NCI_META_CUI","value":"CL438128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741949"},{"name":"PDQ_Open_Trial_Search_ID","value":"741949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C984":{"preferredName":"Aceglatone","code":"C984","definitions":[{"definition":"A derivative of D-glucaro-1, 4-lactone with chemopreventive and anti-tumor activities. One of the key processes in which human body eliminates toxic chemicals as well as hormones (such as estrogen) is by glucuronidation. When beta-glucuronidase deconjugates these glucuronides, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Thereby, aceglatone may suppress the developments of hormone-dependent cancers mediated through beta-glucuronidase inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aceglatone","termGroup":"PT","termSource":"NCI"},{"termName":"Glucaron","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"642-83-1"},{"name":"Chemical_Formula","value":"C10H10O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"347Q3OOJ13"},{"name":"Legacy Concept Name","value":"Aceglatone"},{"name":"Maps_To","value":"Aceglatone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050406"}]}}{"C200":{"preferredName":"Acetylcysteine","code":"C200","definitions":[{"definition":"A drug usually used to reduce the thickness of mucus and ease its removal. It is also used to reverse the toxicity of high doses of acetaminophen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acetylcysteine","termGroup":"PT","termSource":"NCI"},{"termName":"Acetadote","termGroup":"BR","termSource":"NCI"},{"termName":"Airbron","termGroup":"FB","termSource":"NCI"},{"termName":"Broncholysin","termGroup":"FB","termSource":"NCI"},{"termName":"Brunac","termGroup":"FB","termSource":"NCI"},{"termName":"Fabrol","termGroup":"FB","termSource":"NCI"},{"termName":"Fluatox","termGroup":"FB","termSource":"NCI"},{"termName":"Fluimucetin","termGroup":"FB","termSource":"NCI"},{"termName":"Fluimucil","termGroup":"FB","termSource":"NCI"},{"termName":"Fluprowit","termGroup":"FB","termSource":"NCI"},{"termName":"L-Alpha-acetamido-beta-mercaptopropionic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Muco Sanigen","termGroup":"FB","termSource":"NCI"},{"termName":"Mucocedyl","termGroup":"FB","termSource":"NCI"},{"termName":"Mucolator","termGroup":"FB","termSource":"NCI"},{"termName":"Mucolyticum","termGroup":"FB","termSource":"NCI"},{"termName":"Mucomyst","termGroup":"BR","termSource":"NCI"},{"termName":"Mucosolvin","termGroup":"FB","termSource":"NCI"},{"termName":"Mucret","termGroup":"FB","termSource":"NCI"},{"termName":"N-Acetyl Cysteine","termGroup":"SY","termSource":"NCI"},{"termName":"N-acetyl-3-mercaptoalanine","termGroup":"SY","termSource":"NCI"},{"termName":"N-acetyl-L-cysteine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Acetylcysteine","termGroup":"SY","termSource":"NCI"},{"termName":"NAC","termGroup":"AB","termSource":"NCI"},{"termName":"Neo-Fluimucil","termGroup":"FB","termSource":"NCI"},{"termName":"Parvolex","termGroup":"FB","termSource":"NCI"},{"termName":"Respaire","termGroup":"FB","termSource":"NCI"},{"termName":"Tixair","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acetaminophen Overdose"},{"name":"CAS_Registry","value":"616-91-1"},{"name":"CHEBI_ID","value":"CHEBI:28939"},{"name":"Chemical_Formula","value":"C5H9NO3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WYQ7N0BPYC"},{"name":"Legacy Concept Name","value":"Acetylcysteine"},{"name":"Maps_To","value":"Acetylcysteine"},{"name":"NCI_Drug_Dictionary_ID","value":"39130"},{"name":"NSC Number","value":"111180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39130"},{"name":"PDQ_Open_Trial_Search_ID","value":"39130"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001047"}]}}{"C985":{"preferredName":"Acitretin","code":"C985","definitions":[{"definition":"A substance that is used in the prevention of cancer and in the treatment of psoriasis. It belongs to the family of drugs called retinoids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acitretin","termGroup":"PT","termSource":"NCI"},{"termName":"(All-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Etretin","termGroup":"SY","termSource":"NCI"},{"termName":"Neotigason","termGroup":"FB","termSource":"NCI"},{"termName":"Ro 10-1670","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-10-1670","termGroup":"CN","termSource":"NCI"},{"termName":"Soriatane","termGroup":"BR","termSource":"NCI"},{"termName":"Trimethylmethoxyphenyl-retinoic acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Psoriasis; cutaneous T-cell lymphoma"},{"name":"CAS_Registry","value":"55079-83-9"},{"name":"CHEBI_ID","value":"CHEBI:50173"},{"name":"Chemical_Formula","value":"C21H26O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LCH760E9T7"},{"name":"Legacy Concept Name","value":"Acitretin"},{"name":"Maps_To","value":"Acitretin"},{"name":"NCI_Drug_Dictionary_ID","value":"43244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43244"},{"name":"PDQ_Open_Trial_Search_ID","value":"43244"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050559"}]}}{"C986":{"preferredName":"Acivicin","code":"C986","definitions":[{"definition":"A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acivicin","termGroup":"PT","termSource":"NCI"},{"termName":"(S-(R*,R*))-4,5-Dihydro-alpha-amino-3-chloro-5-isoxazoleacetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AT-125","termGroup":"CN","termSource":"NCI"},{"termName":"U-42126","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42228-92-2"},{"name":"Chemical_Formula","value":"C5H7ClN2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O0X60K76I6"},{"name":"Legacy Concept Name","value":"Acivicin"},{"name":"Maps_To","value":"Acivicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39132"},{"name":"NSC Number","value":"163501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39132"},{"name":"PDQ_Open_Trial_Search_ID","value":"39132"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050560"}]}}{"C1861":{"preferredName":"Aclacinomycin B","code":"C1861","definitions":[{"definition":"An antineoplastic oligosaccharide anthracycline antibiotic isolated from the bacterium Streptomyces galilaeus.  Aclacinomycin B intercalates into DNA and inhibits both the topoisomerase I and II enzymes, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aclacinomycin B","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexapyranosyl)oxy)-, methyl ester,(1R-(1-alpha,2-beta,4-beta))-","termGroup":"SN","termSource":"NCI"},{"termName":"Aclarubicin B","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic MA 144B1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57596-79-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P8EJD9HI5K"},{"name":"Legacy Concept Name","value":"Aclacinomycin_B"},{"name":"Maps_To","value":"Aclacinomycin B"},{"name":"NSC Number","value":"208735"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0889093"}]}}{"C202":{"preferredName":"Aclarubicin","code":"C202","definitions":[{"definition":"An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aclarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacenecarboxylic acid methyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1alpha,2beta,4beta))-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Aclacinomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Aclacinomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"Aclacinomycin-A","termGroup":"SY","termSource":"NCI"},{"termName":"ACM-A","termGroup":"AB","termSource":"NCI"},{"termName":"Antibiotic MA144-A1","termGroup":"SY","termSource":"NCI"},{"termName":"MA144-A1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57576-44-0"},{"name":"Chemical_Formula","value":"C42H53NO15"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"74KXF8I502"},{"name":"Legacy Concept Name","value":"Aclarubicin"},{"name":"Maps_To","value":"Aclarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39131"},{"name":"NSC Number","value":"208734"},{"name":"NSC Number","value":"240619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39131"},{"name":"PDQ_Open_Trial_Search_ID","value":"39131"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001143"}]}}{"C988":{"preferredName":"Acodazole","code":"C988","definitions":[{"definition":"A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acodazole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-imidazo[4,5-f]quinoline, acetamide deriv","termGroup":"SN","termSource":"NCI"},{"termName":"acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"79152-85-5"},{"name":"Chemical_Formula","value":"C20H19N5O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8M28A9O41G"},{"name":"Legacy Concept Name","value":"Acodazole"},{"name":"Maps_To","value":"Acodazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39786"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39786"},{"name":"PDQ_Open_Trial_Search_ID","value":"39786"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050565"}]}}{"C71627":{"preferredName":"Acodazole Hydrochloride","code":"C71627","definitions":[{"definition":"The hydrochloride salt of acodazole, a synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acodazole Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-, monohydrochloride (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55435-65-9"},{"name":"Chemical_Formula","value":"C20H19N5O.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6D7W9EAH22"},{"name":"Legacy Concept Name","value":"Acodazole_Hydrochloride"},{"name":"Maps_To","value":"Acodazole Hydrochloride"},{"name":"NSC Number","value":"305884"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0970589"}]}}{"C65213":{"preferredName":"Acolbifene Hydrochloride","code":"C65213","definitions":[{"definition":"A substance being studied in the prevention of breast cancer in women at high risk of breast cancer. Acolbifene hydrochloride binds to estrogen receptors in the body and blocks the effects of estrogen in the breast. It is a type of selective estrogen receptor modulator (SERM).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of acolbifene, a fourth-generation estrogen receptor modulator (SERM) with potential lipid lowering and antineoplastic activity. Acolbifene specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. Acolbifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the effects of estrogen in these tissues. This may inhibit tumor cell proliferation in ER-positive tumor cells. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acolbifene Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"252555-01-4"},{"name":"Chemical_Formula","value":"C29H31NO4.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KXC7811DBY"},{"name":"Legacy Concept Name","value":"Acolbifene_Hydrochloride"},{"name":"Maps_To","value":"Acolbifene Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"636416"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636416"},{"name":"PDQ_Open_Trial_Search_ID","value":"636416"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879543"}]}}{"C203":{"preferredName":"Acridine","code":"C203","definitions":[{"definition":"A polycyclic aromatic dye with antineoplastic, antimicrobial and imaging activities. Acridine and its derivatives intercalate within DNA and RNA by forming hydrogen-bonds and stacking between base pairs resulting in DNA crosslinks and strand breaks. In addition, acridine and its derivatives are a potent inhibitor of topoisomerase II enzyme. This results in the inhibition of DNA and RNA synthesis, predominantly occurring during S phase of the cell cycle and ultimately leads to cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acridine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"260-94-6"},{"name":"CHEBI_ID","value":"CHEBI:36420"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42NI1P5Q1X"},{"name":"Legacy Concept Name","value":"Acridine"},{"name":"Maps_To","value":"Acridine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001186"}]}}{"C2203":{"preferredName":"Acridine Carboxamide","code":"C2203","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tricyclic acridine-based (or carboxamide-based) drug with dual topoisomerase inhibitor and potential antineoplastic activities. Acridine carboxamide inhibits both topoisomerases I and II and intercalates into DNA, resulting in DNA damage, the disruption of DNA repair and replication, the inhibition of RNA and protein synthesis, and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acridine Carboxamide","termGroup":"PT","termSource":"NCI"},{"termName":"DACA","termGroup":"AB","termSource":"NCI"},{"termName":"N-(2-(Dimehtylamino)ethyl)acridine-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"SN 22995","termGroup":"CN","termSource":"NCI"},{"termName":"XR5000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89459-25-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0N3V8R4E13"},{"name":"Legacy Concept Name","value":"Acridine_Carboxamide"},{"name":"Maps_To","value":"Acridine Carboxamide"},{"name":"NCI_Drug_Dictionary_ID","value":"37776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37776"},{"name":"PDQ_Open_Trial_Search_ID","value":"37776"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919282"}]}}{"C75297":{"preferredName":"Acronine","code":"C75297","definitions":[{"definition":"A natural alkaloid with an acridine structure isolated from the bark of the plant Acronychia baueri (Australian scrub ash) with antineoplastic properties.  Acronycine appears to alkylate DNA and interfere with DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acronine","termGroup":"PT","termSource":"NCI"},{"termName":"Acronycine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7008-42-6"},{"name":"CHEBI_ID","value":"CHEBI:2437"},{"name":"Chemical_Formula","value":"C20H19NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QE0G097358"},{"name":"Legacy Concept Name","value":"Acronine"},{"name":"Maps_To","value":"Acronine"},{"name":"NSC Number","value":"403169"},{"name":"PubMedID_Primary_Reference","value":"11996885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001210"}]}}{"C82414":{"preferredName":"Actinium Ac 225 Lintuzumab","code":"C82414","definitions":[{"definition":"A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinium Ac 225 Lintuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"225Ac-HuM195","termGroup":"SY","termSource":"NCI"},{"termName":"Actimab-A","termGroup":"BR","termSource":"NCI"},{"termName":"Actinium (225Ac) Lintuzumab Satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-33 AC-225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2209911-94-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"V860J30J9N"},{"name":"Legacy Concept Name","value":"Actinium_Ac_225_Lintuzumab"},{"name":"Maps_To","value":"Actinium Ac 225 Lintuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"637163"},{"name":"NCI_META_CUI","value":"CL408677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637163"},{"name":"PDQ_Open_Trial_Search_ID","value":"637163"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158815":{"preferredName":"Actinium Ac 225-FPI-1434","code":"C158815","definitions":[{"definition":"A radioconjugate consisting of veligrotug, a humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-1R) linked, via a bifunctional chelate, to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-FPI-1434, the veligrotug moiety targets and binds to IGF-1R expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to IGF-1R-expressing tumor cells. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinium Ac 225-FPI-1434","termGroup":"PT","termSource":"NCI"},{"termName":"225Ac-FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"[225Ac]-FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"[Ac-225]-FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac 225-FPI-1397-FPI-1175","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac 225-labeled FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"FPI 1434","termGroup":"CN","termSource":"NCI"},{"termName":"FPI-1434","termGroup":"CN","termSource":"NCI"},{"termName":"FPI1434","termGroup":"CN","termSource":"NCI"},{"termName":"FPX 01","termGroup":"CN","termSource":"NCI"},{"termName":"FPX-01","termGroup":"CN","termSource":"NCI"},{"termName":"FPX01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Actinium_Ac_225_Lintuzumab"},{"name":"Maps_To","value":"Actinium Ac 225-FPI-1434"},{"name":"NCI_Drug_Dictionary_ID","value":"797340"},{"name":"NCI_META_CUI","value":"CL950887"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797340"},{"name":"PDQ_Open_Trial_Search_ID","value":"797340"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153159":{"preferredName":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","code":"C153159","definitions":[{"definition":"A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac-225 anti-PSMA monoclonal antibody J591 binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","termGroup":"PT","termSource":"NCI"},{"termName":"225Ac-J591","termGroup":"AB","termSource":"NCI"},{"termName":"Ac 225 MOAB J591","termGroup":"AB","termSource":"NCI"},{"termName":"Ac 225 Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac-225 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591"},{"name":"NCI_Drug_Dictionary_ID","value":"793676"},{"name":"NCI_META_CUI","value":"CL554298"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793676"},{"name":"PDQ_Open_Trial_Search_ID","value":"793676"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95198":{"preferredName":"Actinomycin C2","code":"C95198","definitions":[{"definition":"A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C2 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms including, intercalating into the minor groove of DNA and interfering with the function of topoisomerase II. In addition, actinomycin C2 appears to block the interaction between the SH2 domain of growth factor receptor-bound protein-2 (GRB2) and the Src homology 2 domain containing transforming protein 1 adaptor protein SHC, which plays a key role in the Ras signaling pathway thereby halting cellular differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinomycin C2","termGroup":"PT","termSource":"NCI"},{"termName":"Actinomycin D, 2a-D-Alloisoleucine-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2612-14-8"},{"name":"Chemical_Formula","value":"C63H88N12O16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"719U3YSA1F"},{"name":"Maps_To","value":"Actinomycin C2"},{"name":"NSC Number","value":"87221"},{"name":"PubMedID_Primary_Reference","value":"10888331"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762401"}]}}{"C99564":{"preferredName":"Actinomycin C3","code":"C99564","definitions":[{"definition":"A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C3 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms such as intercalating into the minor groove of DNA and interfering with the function of topoisomerase II.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinomycin C3","termGroup":"PT","termSource":"NCI"},{"termName":"2104-L-I","termGroup":"CN","termSource":"NCI"},{"termName":"Actinomycin AY1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin I3","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin VII","termGroup":"SY","termSource":"NCI"},{"termName":"Aurathin-A3","termGroup":"SY","termSource":"NCI"},{"termName":"AY 3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6156-47-4"},{"name":"Chemical_Formula","value":"C64H90N12O16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Z5DS38J6F"},{"name":"Maps_To","value":"Actinomycin C3"},{"name":"PubMedID_Primary_Reference","value":"10888331"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0604201"}]}}{"C2844":{"preferredName":"Actinomycin F1","code":"C2844","definitions":[{"definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Actinomycin F1 intercalates into the minor groove of DNA and binds to topoisomerase II, leading to the inhibition of DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinomycin F1","termGroup":"PT","termSource":"NCI"},{"termName":"Actinomycin KS4","termGroup":"SY","termSource":"NCI"},{"termName":"KS4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402-44-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D8HJS52NSZ"},{"name":"Legacy Concept Name","value":"Actinomycin_F1"},{"name":"Maps_To","value":"Actinomycin F1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515876"}]}}{"C118625":{"preferredName":"Activin Type 2B Receptor Fc Fusion Protein STM 434","code":"C118625","definitions":[{"definition":"A soluble fusion protein containing the extracellular domain of the activin receptor type 2B (ACVR2B or ActRIIB) fused to a human Fc domain, with potential antineoplastic activity. Upon intravenous administration, STM 434 selectively binds to the growth factor activin A, thereby preventing its binding to and the activation of endogenous ActRIIB. This prevents activin A/ActRIIB-mediated signaling and inhibits the proliferation of activin A-overexpressing tumor cells. Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, is overexpressed in a variety of cancers and plays a key role in promoting cancer cell proliferation, migration, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Activin Type 2B Receptor Fc Fusion Protein STM 434","termGroup":"PT","termSource":"NCI"},{"termName":"Activin Inhibitor STM 434","termGroup":"SY","termSource":"NCI"},{"termName":"STM 434","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2055761-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7G4D2B5AC8"},{"name":"Maps_To","value":"Activin Type 2B Receptor Fc Fusion Protein STM 434"},{"name":"NCI_Drug_Dictionary_ID","value":"765514"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765514"},{"name":"PDQ_Open_Trial_Search_ID","value":"765514"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896763"}]}}{"C151941":{"preferredName":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968","code":"C151941","definitions":[{"definition":"A prodrug of an acyclic nucleoside phosphonate, with potential anti-viral and antineoplastic activities. Upon administration, acyclic nucleoside phosphonate prodrug ABI-1968 is taken up by viral-infected cells and converted to its active metabolite. The metabolite is incorporated into DNA chains by DNA polymerases, which results in the termination of DNA synthesis, inhibits viral replication and induces apoptosis and inhibits the proliferation of susceptible virally-infected tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968","termGroup":"PT","termSource":"NCI"},{"termName":"ABI-1968","termGroup":"CN","termSource":"NCI"},{"termName":"ABI1968","termGroup":"CN","termSource":"NCI"},{"termName":"HTI 1968","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968"},{"name":"NCI_Drug_Dictionary_ID","value":"793142"},{"name":"NCI_META_CUI","value":"CL553169"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793142"},{"name":"PDQ_Open_Trial_Search_ID","value":"793142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143953":{"preferredName":"Ad-RTS-hIL-12","code":"C143953","definitions":[{"definition":"An inducible adenoviral vector encoding human pro-inflammatory cytokine interleukin-12 (IL-12; IL12), which is under the transcriptional control of the RheoSwitch Therapeutic System (RTS) (Ad-RTS-hIL-12), with potential immunomodulating and antineoplastic activities. RTS consists of two fusion proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). Upon intratumoral administration of Ad-RTS-hIL-12, given in combination with the proprietary, diacylhydrazine-based activator ligand veledimex (INXN-1001), veledimex binds specifically to the EcR part of the RTS and stabilizes heterodimerization between the two fusion proteins, forming an active transcription factor, which induces the transcription of IL-12 under the control of an inducible promoter containing Gal4-binding sites. The expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL)-mediated responses against tumor cells, which may result in immune-mediated tumor cell lysis and inhibition of tumor cell proliferation. In the presence of veledimex, the protein heterodimer changes to a stable conformation and can bind to the inducible promoter, while without veledimex the two fusion proteins form unstable heterodimers; this allows the controlled, regulated intratumoral expression of the IL-12 gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ad-RTS-hIL-12","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoviral- RheoSwitch Therapeutic System-Human Interleukin 12","termGroup":"SY","termSource":"NCI"},{"termName":"INXN 2001","termGroup":"CN","termSource":"NCI"},{"termName":"INXN-2001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ad-RTS-hIL-12"},{"name":"NCI_Drug_Dictionary_ID","value":"792151"},{"name":"NCI_META_CUI","value":"CL542155"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792151"},{"name":"PDQ_Open_Trial_Search_ID","value":"792151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99766":{"preferredName":"Adagloxad Simolenin","code":"C99766","definitions":[{"definition":"A carbohydrate-based immunostimulant comprised of the Globo H hexasaccharide 1 (Globo H) epitope linked to the immunostimulant carrier protein keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration of adagloxad simolenin, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. Globo H is a tumor associated antigen (TAA) commonly found on a variety of tumor cells including breast cancer cells. KLH improves antigenic immune recognition and T-cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adagloxad Simolenin","termGroup":"PT","termSource":"NCI"},{"termName":"OBI 822","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-822","termGroup":"CN","termSource":"NCI"},{"termName":"OBI822","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1458687-85-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UCG949AA7Z"},{"name":"Maps_To","value":"Adagloxad Simolenin"},{"name":"NCI_Drug_Dictionary_ID","value":"724401"},{"name":"NCI_META_CUI","value":"CL433491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724401"},{"name":"PDQ_Open_Trial_Search_ID","value":"724401"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91725":{"preferredName":"Adavosertib","code":"C91725","definitions":[{"definition":"A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adavosertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-1775","termGroup":"CN","termSource":"NCI"},{"termName":"AZD1775","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1775","termGroup":"CN","termSource":"NCI"},{"termName":"MK1775","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"955365-80-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K2T6HJX3I3"},{"name":"Maps_To","value":"Adavosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"594147"},{"name":"NCI_META_CUI","value":"CL791432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594147"},{"name":"PDQ_Open_Trial_Search_ID","value":"594147"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82358":{"preferredName":"Adecatumumab","code":"C82358","definitions":[{"definition":"A recombinant human IgG1 monoclonal antibody (MoAb) directed against the tumor associated antigen (TAA) epithelial cell adhesion molecule (EpCAM) with potential antitumor activity. Adecatumumab binds to EpCAM, which may result in antibody-dependent cellular cytotoxicity (ADCC) directed against EpCAM-expressing tumor cells. EpCAM (CD326), a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells; for some cancers, overexpression has been correlated with decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adecatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EpCAM Monoclonal Antibody MT201","termGroup":"SY","termSource":"NCI"},{"termName":"MT201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"503605-66-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"000705ZASD"},{"name":"Legacy Concept Name","value":"Adecatumumab"},{"name":"Maps_To","value":"Adecatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"640250"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640250"},{"name":"PDQ_Open_Trial_Search_ID","value":"640250"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1741817"}]}}{"C148039":{"preferredName":"Imaradenant","code":"C148039","definitions":[{"definition":"An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, imaradenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imaradenant","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR Antagonist AZD4635","termGroup":"SY","termSource":"NCI"},{"termName":"Adenosine A2A Receptor Antagonist AZD4635","termGroup":"SY","termSource":"NCI"},{"termName":"AZD-4635","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4635","termGroup":"CN","termSource":"NCI"},{"termName":"HTL-1071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1321514-06-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"770140J08A"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist AZD4635"},{"name":"Maps_To","value":"Imaradenant"},{"name":"NCI_Drug_Dictionary_ID","value":"794358"},{"name":"NCI_META_CUI","value":"CL545814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794358"},{"name":"PDQ_Open_Trial_Search_ID","value":"794358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142374":{"preferredName":"Adenosine A2A Receptor Antagonist NIR178","code":"C142374","definitions":[{"definition":"An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist NIR178 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2A Receptor Antagonist NIR178","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR Antagonist NIR178","termGroup":"SY","termSource":"NCI"},{"termName":"NIR 178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist NIR178"},{"name":"NCI_Drug_Dictionary_ID","value":"793151"},{"name":"NCI_META_CUI","value":"CL540321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793151"},{"name":"PDQ_Open_Trial_Search_ID","value":"793151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157489":{"preferredName":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999","code":"C157489","definitions":[{"definition":"An orally bioavailable inhibitor of both the adenosine A2A receptor (A2AR; ADORA2A) and phosphodiesterase 10A (PDE-10A), with potential immunomodulating and antineoplastic activities. Upon administration, A2A/PDE-10A inhibitor PBF-999 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression. In addition, PBF-999 binds to and inhibits the activity of PDE-10A, thereby preventing the degradation of cyclic guanosine monophosphate (cGMP) and activates cGMP/cGMP-dependent protein kinase G (PKG) signaling. This induces beta-catenin degradation and thereby prevents the translocation of beta-catenin into the nucleus, and the beta-catenin-mediated induction of transcription of survival proteins, such as cyclin D1 and survivin. It also suppresses RAS/RAF/mitogen-activated protein kinase (MAPK) signaling. This induces apoptosis and inhibits the growth of tumor cells in which PDE-10A is overexpressed. PDE-10A is a cGMP-degrading PDE isozyme that is highly expressed in the brain and overexpressed in certain types of tumor cells. Elevation of intracellular cGMP is known to inhibit tumor proliferation and induce apoptosis. cGMP levels are low in cancer cells resulting from the overexpression PDE-10A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999","termGroup":"PT","termSource":"NCI"},{"termName":"A2A/PDE-10A Inhibitor PBF-999","termGroup":"SY","termSource":"NCI"},{"termName":"PBF 999","termGroup":"CN","termSource":"NCI"},{"termName":"PBF-999","termGroup":"CN","termSource":"NCI"},{"termName":"PBF999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620909-95-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DY6W3NQA36"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999"},{"name":"NCI_Drug_Dictionary_ID","value":"796763"},{"name":"NCI_META_CUI","value":"CL937074"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796763"},{"name":"PDQ_Open_Trial_Search_ID","value":"796763"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159564":{"preferredName":"Etrumadenant","code":"C159564","definitions":[{"definition":"An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon administration, etrumadenant competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T-lymphocytes. The binding of AB928 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etrumadenant","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR/A2BR Antagonist AB928","termGroup":"SY","termSource":"NCI"},{"termName":"AB 928","termGroup":"CN","termSource":"NCI"},{"termName":"AB-928","termGroup":"CN","termSource":"NCI"},{"termName":"AB928","termGroup":"CN","termSource":"NCI"},{"termName":"Adenosine A2A/A2B Receptor Antagonist AB928","termGroup":"SY","termSource":"NCI"},{"termName":"Dual A2AR/A2BR Antagonist AB928","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2239273-34-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W0ZE0NT8IF"},{"name":"Maps_To","value":"Adenosine A2A/A2B Receptor Antagonist AB928"},{"name":"NCI_Drug_Dictionary_ID","value":"797798"},{"name":"NCI_META_CUI","value":"CL951401"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797798"},{"name":"PDQ_Open_Trial_Search_ID","value":"797798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148435":{"preferredName":"Adenosine A2B Receptor Antagonist PBF-1129","code":"C148435","definitions":[{"definition":"An orally bioavailable antagonist of the immunomodulatory checkpoint molecule adenosine A2B receptor (A2BR; ADORA2B), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, A2BR antagonist PBF-1129 competes with adenosine for binding to A2BR expressed on various cancer cell types and numerous immune cells, such as dendritic cells (DCs), mast cells, macrophages and lymphocytes. This inhibits A2BR activity and prevents adenosine/A2BR-mediated signaling. The inhibition of A2BR in cancer cells prevents activation of downstream oncogenic pathways, which leads to an inhibition of cell proliferation and metastasis. A2BR inhibition also prevents the release of various growth factors, cytokines and chemokines, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin-2 (Ang2) from immune cells, which may abrogate the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activate the immune system to exert anti-tumor immune responses against cancer cells leading to tumor cell killing. In addition, under non-cancerous inflammatory conditions, inhibition of A2BR leads to reduced activation and proliferation of various immune cells, which results in decreased pro-inflammatory cytokine production and may prevent inflammation. A2BR, a G protein-coupled signaling receptor, is expressed on the cell surfaces of numerous immune cells and is often overexpressed on a variety of cancer cell types; it plays a key role in their proliferation, progression and metastasis. Adenosine is overproduced under inflammatory conditions and plays a key role in pro-inflammatory actions. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation. The pro- and anti-inflammatory effects of adenosine and A2BR are cell type-specific and dependent on the extracellular microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2B Receptor Antagonist PBF-1129","termGroup":"PT","termSource":"NCI"},{"termName":"A2BR Antagonist PBF-1129","termGroup":"SY","termSource":"NCI"},{"termName":"PBF 1129","termGroup":"CN","termSource":"NCI"},{"termName":"PBF-1129","termGroup":"CN","termSource":"NCI"},{"termName":"PBF1129","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosine A2B Receptor Antagonist PBF-1129"},{"name":"NCI_Drug_Dictionary_ID","value":"793680"},{"name":"NCI_META_CUI","value":"CL550982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793680"},{"name":"PDQ_Open_Trial_Search_ID","value":"793680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106242":{"preferredName":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","code":"C106242","definitions":[{"definition":"A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","termGroup":"PT","termSource":"NCI"},{"termName":"Adenovector-transduced AP1903-inducible iMC-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","termGroup":"SY","termSource":"NCI"},{"termName":"BPX-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201"},{"name":"NCI_Drug_Dictionary_ID","value":"748904"},{"name":"NCI_META_CUI","value":"CL447413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748904"},{"name":"PDQ_Open_Trial_Search_ID","value":"748904"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143034":{"preferredName":"Adenoviral Brachyury Vaccine ETBX-051","code":"C143034","definitions":[{"definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Brachyury Vaccine ETBX-051","termGroup":"PT","termSource":"NCI"},{"termName":"ETBX 051","termGroup":"CN","termSource":"NCI"},{"termName":"ETBX-051","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2171537-82-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BPG11IF0HW"},{"name":"Maps_To","value":"Adenoviral Brachyury Vaccine ETBX-051"},{"name":"NCI_Drug_Dictionary_ID","value":"791863"},{"name":"NCI_META_CUI","value":"CL541478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791863"},{"name":"PDQ_Open_Trial_Search_ID","value":"791863"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156015":{"preferredName":"Adenoviral Cancer Vaccine PF-06936308","code":"C156015","definitions":[{"definition":"A cancer vaccine composed of a replication-defective E1-deleted adenovirus vector based on chimpanzee adenovirus serotype 68 (AdC68) expressing three not yet disclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral cancer vaccine PF-06936308, the adenovirus infects cells and expresses the TAAs. In turn, the TAAs activate the immune system to produce a cytotoxic T-lymphocyte (CTL) response against cells expressing the TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Cancer Vaccine PF-06936308","termGroup":"PT","termSource":"NCI"},{"termName":"PF 06936308","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06936308","termGroup":"CN","termSource":"NCI"},{"termName":"PF06936308","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Cancer Vaccine PF-06936308"},{"name":"NCI_Drug_Dictionary_ID","value":"795350"},{"name":"NCI_META_CUI","value":"CL562758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795350"},{"name":"PDQ_Open_Trial_Search_ID","value":"795350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143035":{"preferredName":"Adenoviral MUC1 Vaccine ETBX-061","code":"C143035","definitions":[{"definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral MUC1 Vaccine ETBX-061","termGroup":"PT","termSource":"NCI"},{"termName":"ETBX 061","termGroup":"CN","termSource":"NCI"},{"termName":"ETBX-061","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2171550-29-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"17K7SN702N"},{"name":"Maps_To","value":"Adenoviral MUC1 Vaccine ETBX-061"},{"name":"NCI_Drug_Dictionary_ID","value":"791864"},{"name":"NCI_META_CUI","value":"CL541479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791864"},{"name":"PDQ_Open_Trial_Search_ID","value":"791864"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148142":{"preferredName":"Adenoviral PSA Vaccine ETBX-071","code":"C148142","definitions":[{"definition":"A cancer vaccine composed of a genetically engineered, replication-deficient adenovirus carrying the gene encoding human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral-PSA vaccine ETBX-071, the adenovirus infects cells and expresses PSA. In turn, PSA activates the immune system and induces a cytotoxic T-lymphocyte (CTL) response against PSA-expressing tumor cells. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral PSA Vaccine ETBX-071","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoviral PSA Prostate Cancer Vaccine ETBX-071","termGroup":"SY","termSource":"NCI"},{"termName":"ETBX-071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68TF9SDE9N"},{"name":"Maps_To","value":"Adenoviral PSA Vaccine ETBX-071"},{"name":"NCI_Drug_Dictionary_ID","value":"795436"},{"name":"NCI_META_CUI","value":"CL550802"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795436"},{"name":"PDQ_Open_Trial_Search_ID","value":"795436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C101789":{"preferredName":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001","code":"C101789","definitions":[{"definition":"Autologous dendritic cells tranduced with a replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-3001) in combination with the proprietary orally bioavailable, small molecule activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer INXN-1001. Upon intratumoral injection of INXN-3001 and subsequent oral administration of activator ligand, INXN-1001 is able to induce expression of IL-12 in INXN-3001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells, inducing the secretion of interferon-gamma and inducing a cytotoxic T lymphocyte response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. As INXN-1001 regulates both the timing and the levels of IL-12 expression, IL-12 toxicity can be reduced.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001","termGroup":"PT","termSource":"NCI"},{"termName":"DC-RTS-IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"INXN-3001/1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"733561"},{"name":"NCI_META_CUI","value":"CL435907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733561"},{"name":"PDQ_Open_Trial_Search_ID","value":"733561"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162805":{"preferredName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","code":"C162805","definitions":[{"definition":"An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","termGroup":"PT","termSource":"NCI"},{"termName":"GAd-209-FSP","termGroup":"CN","termSource":"NCI"},{"termName":"GAd20-209-FSP","termGroup":"CN","termSource":"NCI"},{"termName":"Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP"},{"name":"NCI_Drug_Dictionary_ID","value":"799098"},{"name":"NCI_META_CUI","value":"CL973183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799098"},{"name":"PDQ_Open_Trial_Search_ID","value":"799098"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156925":{"preferredName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901","code":"C156925","definitions":[{"definition":"A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral-TSNA priming vaccine GRT-C901, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoviral TSNA Priming Vaccine GRT-C901","termGroup":"SY","termSource":"NCI"},{"termName":"GRT C901","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-C901","termGroup":"CN","termSource":"NCI"},{"termName":"GRTC901","termGroup":"CN","termSource":"NCI"},{"termName":"Priming Cancer Vaccine GRT-C901","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901"},{"name":"NCI_Drug_Dictionary_ID","value":"796478"},{"name":"NCI_META_CUI","value":"CL935908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796478"},{"name":"PDQ_Open_Trial_Search_ID","value":"796478"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131825":{"preferredName":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3","code":"C131825","definitions":[{"definition":"A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3","termGroup":"PT","termSource":"NCI"},{"termName":"M-VM3","termGroup":"CN","termSource":"NCI"},{"termName":"Mobilan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3"},{"name":"NCI_Drug_Dictionary_ID","value":"786108"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786108"},{"name":"PDQ_Open_Trial_Search_ID","value":"786108"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1177020"}]}}{"C97959":{"preferredName":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001","code":"C97959","definitions":[{"definition":"A replication incompetent adenovirus encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-2001) in combination with the proprietary activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer. Upon intratumoral administration of INXN-2001 and oral administration of INXN-1001, INXN-1001 is able to induce expression of IL-12 from INXN-2001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001","termGroup":"PT","termSource":"NCI"},{"termName":"Ad-RTS-IL-12 Plus AL","termGroup":"SY","termSource":"NCI"},{"termName":"INXN-2001/1001","termGroup":"CN","termSource":"NCI"},{"termName":"ZIN ATI-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"710508"},{"name":"NCI_META_CUI","value":"CL430563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710508"},{"name":"PDQ_Open_Trial_Search_ID","value":"710508"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C76115":{"preferredName":"Aderbasib","code":"C76115","definitions":[{"definition":"An orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase 'sheddase' activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. The metalloproteinase domains of ADAMs cleave cell surface proteins at extracellular sites proximal to the cell membrane, releasing or \"shedding\" soluble protein etcodomains from the cell surface; the disintegrin domains of these multifunctional proteins interact with various components of the extracellular matrix (ECM). ADAM10 processes particular epithelial growth factor receptor (EGFR) ligands and appears to regulate Notch signaling through the cleavage of Notch and its related ligand delta-like ligand-1 (Dll-1). ADAM17 (also known as Tumor necrosis factor-Converting Enzyme or TACE) is involved in processing tumor necrosis factor (TNF) from its membrane bound precursor to its soluble circulating form and in processing ligands for the epidermal growth factor receptor (EGFR) family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aderbasib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Azaspiro(2.5)octane-5-carboxylic Acid, 7-((Hydroxyamino)carbonyl)-6-((4-phenyl-1-piperazinyl)carbonyl)-, Methyl Ester, (6S,7S)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB007839","termGroup":"CN","termSource":"NCI"},{"termName":"INCB7839","termGroup":"CN","termSource":"NCI"},{"termName":"Methyl (6S,7S)-7-(Hhydroxyamino)carbonyl)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2.5)octane-5-carboxylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"791828-58-5"},{"name":"Chemical_Formula","value":"C21H28N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9YL6NEJ3G"},{"name":"Legacy Concept Name","value":"Aderbasib"},{"name":"Legacy Concept Name","value":"Sheddase_Inhibitor_INCB007839"},{"name":"Maps_To","value":"Aderbasib"},{"name":"NCI_Drug_Dictionary_ID","value":"633945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633945"},{"name":"PDQ_Open_Trial_Search_ID","value":"633945"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700364"}]}}{"C53399":{"preferredName":"ADH-1","code":"C53399","definitions":[{"definition":"A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ADH-1","termGroup":"PT","termSource":"NCI"},{"termName":"Exherin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"229971-81-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B058ME29VU"},{"name":"Legacy Concept Name","value":"ADH-1"},{"name":"Maps_To","value":"ADH-1"},{"name":"NCI_Drug_Dictionary_ID","value":"462569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462569"},{"name":"PDQ_Open_Trial_Search_ID","value":"462569"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706644"}]}}{"C91719":{"preferredName":"AE37 Peptide/GM-CSF Vaccine","code":"C91719","definitions":[{"definition":"A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AE37 Peptide/GM-CSF Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"AE-37 Peptide/GM-CSF Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AE37 Peptide/GM-CSF Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"564693"},{"name":"NCI_META_CUI","value":"CL376182"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564693"},{"name":"PDQ_Open_Trial_Search_ID","value":"564693"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48369":{"preferredName":"Multikinase Inhibitor AEE788","code":"C48369","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multikinase Inhibitor AEE788","termGroup":"PT","termSource":"NCI"},{"termName":"AEE-788","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"497839-62-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F9JLR95I3I"},{"name":"Legacy Concept Name","value":"AEE788"},{"name":"Maps_To","value":"AEE788"},{"name":"Maps_To","value":"Multikinase Inhibitor AEE788"},{"name":"NCI_Drug_Dictionary_ID","value":"371727"},{"name":"PDQ_Closed_Trial_Search_ID","value":"371727"},{"name":"PDQ_Open_Trial_Search_ID","value":"371727"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506057"}]}}{"C153133":{"preferredName":"Aerosol Gemcitabine","code":"C153133","definitions":[{"definition":"An aerosol inhalation formulation containing gemcitabine (GCB), a broad-spectrum antimetabolite and deoxycytidine analogue, with potential antineoplastic activity. Upon inhalation via a nebulizer, GCB is converted intracellularly by deoxycytidine kinase to its active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase (RNR), thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in DNA strand termination and the induction of apoptosis of lung tumor cells. GCB administration directly into the lungs via aerosol yields higher concentrations of GCB locally than can be achieved by systemic GCB administration, potentially reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aerosol Gemcitabine","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized GCB","termGroup":"SY","termSource":"NCI"},{"termName":"Aerosolized Gemcitabine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aerosol Gemcitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"793934"},{"name":"NCI_META_CUI","value":"CL554390"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793934"},{"name":"PDQ_Open_Trial_Search_ID","value":"793934"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101794":{"preferredName":"Aerosolized Aldesleukin","code":"C101794","definitions":[{"definition":"An aerosol formulation of aldesleukin, a recombinant form of interleukin-2 (IL-2), with potential immunostimulating activity. Upon IL-2 inhalation, this cytokine activates lymphokine-activated killer cells and natural killer cells, and induces expression of cytotoxic cytokines, such as interferon-gamma and transforming growth factor-beta. This may eventually halt tumor cell growth. Localized administration of IL-2 may decrease toxicity and increase efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aerosolized Aldesleukin","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized Recombinant IL-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aerosolized Aldesleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"733682"},{"name":"NCI_META_CUI","value":"CL435912"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733682"},{"name":"PDQ_Open_Trial_Search_ID","value":"733682"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C61071":{"preferredName":"Aerosolized Liposomal Rubitecan","code":"C61071","definitions":[{"definition":"An aerosolized liposomal preparation of rubitecan, a water-insoluble derivative of camptothecin with potential antineoplastic activity. Rubitecan (or 9-nitro-20 (S)-camptothecin) and its active metabolite 9-aminocamptothecin (9-AC) selectively stabilize topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. This agent is formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 micrometer mass median aerodynamic diameter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aerosolized Liposomal Rubitecan","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized liposomal 9-nitro-20(S)-camptothecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aerosolized_Liposomal_9-Nitrocamptothecin"},{"name":"Maps_To","value":"Aerosolized Liposomal Rubitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"473242"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473242"},{"name":"PDQ_Open_Trial_Search_ID","value":"473242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831773"}]}}{"C66940":{"preferredName":"Afatinib","code":"C66940","definitions":[{"definition":"An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afatinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide","termGroup":"SN","termSource":"NCI"},{"termName":"BIBW 2992","termGroup":"CN","termSource":"NCI"},{"termName":"BIBW-2992","termGroup":"CN","termSource":"NCI"},{"termName":"BIBW2992","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850140-72-6"},{"name":"CHEBI_ID","value":"CHEBI:61390"},{"name":"Chemical_Formula","value":"C24H25ClFN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"41UD74L59M"},{"name":"Legacy Concept Name","value":"BIBW_2992"},{"name":"Maps_To","value":"Afatinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987648"}]}}{"C97273":{"preferredName":"Afatinib Dimaleate","code":"C97273","definitions":[{"definition":"The dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afatinib Dimaleate","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate)","termGroup":"SY","termSource":"NCI"},{"termName":"2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2E)-, (2Z)-2-Butenedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"BIBW 2992MA2","termGroup":"CN","termSource":"NCI"},{"termName":"BIBW2992 MA2","termGroup":"CN","termSource":"NCI"},{"termName":"Gilotrif","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations"},{"name":"CAS_Registry","value":"850140-73-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V1T5K7RZ0B"},{"name":"Maps_To","value":"Afatinib Dimaleate"},{"name":"NCI_Drug_Dictionary_ID","value":"537572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537572"},{"name":"PDQ_Open_Trial_Search_ID","value":"537572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879772"}]}}{"C975":{"preferredName":"Afimoxifene","code":"C975","definitions":[{"definition":"A form of the drug tamoxifen that is made by the body after taking tamoxifen. It can also be made in the laboratory, and may help decrease breast density. A topical form of 4-hydroxytamoxifen is being studied in breast cancer screening.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afimoxifene","termGroup":"PT","termSource":"NCI"},{"termName":"4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hydroxy-Tamoxifen","termGroup":"SY","termSource":"NCI"},{"termName":"4-Hydroxytamoxifen","termGroup":"SY","termSource":"NCI"},{"termName":"4-OHT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68047-06-3"},{"name":"CAS_Registry","value":"68392-35-8"},{"name":"CHEBI_ID","value":"CHEBI:44616"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"17197F0KYM"},{"name":"Legacy Concept Name","value":"_4-Hydroxy-Tamoxifen"},{"name":"Maps_To","value":"Afimoxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"371709"},{"name":"PDQ_Closed_Trial_Search_ID","value":"371709"},{"name":"PDQ_Open_Trial_Search_ID","value":"371709"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347999"}]}}{"C82390":{"preferredName":"Afuresertib","code":"C82390","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afuresertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Thiophenecarboxamide, N-((1S)-2-amino-1-((3-fluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"GSK2110183","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1047644-62-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8739X25QI3"},{"name":"Legacy Concept Name","value":"Oral_Akt_Inhibitor_GSK2110183"},{"name":"Maps_To","value":"Afuresertib"},{"name":"NCI_Drug_Dictionary_ID","value":"642287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642287"},{"name":"PDQ_Open_Trial_Search_ID","value":"642287"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853882"}]}}{"C28580":{"preferredName":"Agatolimod Sodium","code":"C28580","definitions":[{"definition":"A substance that is being studied in the treatment of some types of cancer. It belongs to the family of drugs called biological response modifiers.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. Agatolimod selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agatolimod Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"(3'-5')d(P-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T) Tricosasodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"CpG 7909","termGroup":"CN","termSource":"NCI"},{"termName":"PF-3512676","termGroup":"CN","termSource":"NCI"},{"termName":"ProMune","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"541547-35-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I4Z5C8FM6H"},{"name":"Legacy Concept Name","value":"CpG_7909"},{"name":"Maps_To","value":"Agatolimod Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"38660"},{"name":"NSC Number","value":"731581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38660"},{"name":"PDQ_Open_Trial_Search_ID","value":"38660"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1436331"}]}}{"C107245":{"preferredName":"Agerafenib","code":"C107245","definitions":[{"definition":"An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agerafenib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"AC013773","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-32496","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188910-76-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78I4VEX88N"},{"name":"Maps_To","value":"Agerafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"750855"},{"name":"NCI_META_CUI","value":"CL550786"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750855"},{"name":"PDQ_Open_Trial_Search_ID","value":"750855"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73996":{"preferredName":"Aglatimagene Besadenovec","code":"C73996","definitions":[{"definition":"An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aglatimagene Besadenovec","termGroup":"PT","termSource":"NCI"},{"termName":"ADV-tk","termGroup":"AB","termSource":"NCI"},{"termName":"CAN 2409","termGroup":"CN","termSource":"NCI"},{"termName":"CAN-2409","termGroup":"CN","termSource":"NCI"},{"termName":"CAN2409","termGroup":"CN","termSource":"NCI"},{"termName":"GliAtak","termGroup":"BR","termSource":"NCI"},{"termName":"ProstAtak","termGroup":"BR","termSource":"NCI"},{"termName":"Virafir","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1621271-62-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Z72SSS34W"},{"name":"Legacy Concept Name","value":"Adenoviral_Vector_Encoding_HSV_Thymidine_Kinase"},{"name":"Maps_To","value":"Aglatimagene Besadenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"581584"},{"name":"NCI_META_CUI","value":"CL383459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581584"},{"name":"PDQ_Open_Trial_Search_ID","value":"581584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121538":{"preferredName":"Mitazalimab","code":"C121538","definitions":[{"definition":"A human immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, mitazalimab binds to CD40 on antigen-presenting dendritic cells, which leads to the activation and proliferation of effector and memory T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC). This eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitazalimab","termGroup":"PT","termSource":"NCI"},{"termName":"ADC 1013","termGroup":"CN","termSource":"NCI"},{"termName":"ADC-1013","termGroup":"CN","termSource":"NCI"},{"termName":"ADC1013","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ 7107","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64457107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2055640-86-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q9J81E7VFM"},{"name":"Maps_To","value":"Agonistic Anti-CD40 Monoclonal Antibody ADC-1013"},{"name":"Maps_To","value":"Mitazalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"770043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770043"},{"name":"PDQ_Open_Trial_Search_ID","value":"770043"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053684"}]}}{"C129967":{"preferredName":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949","code":"C129967","definitions":[{"definition":"An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, agonistic anti-OX40 monoclonal antibody INCAGN01949 selectively binds to and activates OX40 on activated T-cells, thereby potentiating T-cell receptor (TCR) signaling. OX40 activation inhibits regulatory T-cell (Treg)-mediated suppression of effector T-cells, induces the proliferation of memory and effector T-lymphocytes and modulates cytokine production. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. In addition, the IgG1 Fc region of INCAGN01949 binds to and co-engages with the IgG Fc-gamma receptor III (FcgammaRIII; CD16) expressed by immune effector cells; thus, binding activates FcgammaRIII-mediated signaling and facilitates the selective depletion of intratumoral Tregs, thereby further enhancing the cytotoxic T-lymphocyte (CTL)-mediated tumor cell response. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells; OX40 stimulation abrogates the immunosuppressive tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Agonist Antibody INCAGN01949","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-OX40 Monoclonal Antibody INCAGN0194","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 1949","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN-1949","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN1949","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody INCAGN01949","termGroup":"SY","termSource":"NCI"},{"termName":"NCAGN01949","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949"},{"name":"NCI_Drug_Dictionary_ID","value":"785256"},{"name":"NCI_META_CUI","value":"CL512862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785256"},{"name":"PDQ_Open_Trial_Search_ID","value":"785256"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C117293":{"preferredName":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469","code":"C117293","definitions":[{"definition":"An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-OX40 monoclonal antibody MEDI6469 selectively binds to and activates OX40. OX40 activation induces proliferation of effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469","termGroup":"PT","termSource":"NCI"},{"termName":"Agonistic Anti-CD134 Monoclonal Antibody MEDI6469","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI6469","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1715924-11-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AKV2GM43DD"},{"name":"Maps_To","value":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469"},{"name":"NCI_Drug_Dictionary_ID","value":"763664"},{"name":"NCI_META_CUI","value":"CL474118"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763664"},{"name":"PDQ_Open_Trial_Search_ID","value":"763664"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156414":{"preferredName":"AKR1C3-activated Prodrug AST-3424","code":"C156414","definitions":[{"definition":"A small-molecule nitro-benzene, aldo-keto reductase 1C3 (AKR1C3)-activated prodrug of N,N'-bisethylenephosphoramidate, a DNA bis-alkylating agent, with potential antineoplastic activity. Upon intravenous administration, AKR1C3-activated prodrug AST-3424 is converted to its active form by AKR1C3, which is upregulated in certain tumor cell types while not expressed in normal healthy cells. The active metabolite selectively binds to and alkylates DNA in AKR1C3-overexpressing tumor cells, resulting in DNA base pair mismatching, interstrand crosslinking and inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. As the expression of AKR1C3 is restricted to tumors, AST-3424 is selectively converted to its active metabolite in tumor cells only while its conversion in normal, healthy tissue is absent; this allows for an increased cytotoxic effect of the alkylating agent in tumor cells while decreasing its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKR1C3-activated Prodrug AST-3424","termGroup":"PT","termSource":"NCI"},{"termName":"AKR1C3-activated Prodrug OBI-3424","termGroup":"SY","termSource":"NCI"},{"termName":"AKR1C3-activated Prodrug TH-3424","termGroup":"SY","termSource":"NCI"},{"termName":"Aldo-keto Reductase 1c3-activated Prodrug OBI-3424","termGroup":"SY","termSource":"NCI"},{"termName":"OBI 3424","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-3424","termGroup":"CN","termSource":"NCI"},{"termName":"OBI3424","termGroup":"CN","termSource":"NCI"},{"termName":"TH 3424","termGroup":"CN","termSource":"NCI"},{"termName":"TH-3424","termGroup":"CN","termSource":"NCI"},{"termName":"TH3424","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097713-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X6SH5T8H76"},{"name":"Maps_To","value":"AKR1C3-activated Prodrug OBI-3424"},{"name":"NCI_Drug_Dictionary_ID","value":"795700"},{"name":"NCI_META_CUI","value":"CL563114"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795700"},{"name":"PDQ_Open_Trial_Search_ID","value":"795700"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111575":{"preferredName":"AKT 1/2 Inhibitor BAY1125976","code":"C111575","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) isoforms 1 and 2 (AKT1/2) with potential antineoplastic activity. AKT1/2 inhibitor BAY1125976 selectively binds to and inhibits the phosphorylation and activity of AKT1/2 in a non-ATP competitive manner, which may result in the inhibition of the phosphatidylinositol 3 (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. This may lead to both the reduction of cell proliferation and the induction of cell apoptosis in AKT-overexpressing tumor cells. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT 1/2 Inhibitor BAY1125976","termGroup":"PT","termSource":"NCI"},{"termName":"BAY1125976","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402608-02-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL7A1UM87X"},{"name":"Maps_To","value":"AKT 1/2 Inhibitor BAY1125976"},{"name":"NCI_Drug_Dictionary_ID","value":"752318"},{"name":"NCI_META_CUI","value":"CL453983"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752318"},{"name":"PDQ_Open_Trial_Search_ID","value":"752318"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99172":{"preferredName":"Miransertib","code":"C99172","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Miransertib binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. This may lead to the reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miransertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinamine, 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo(4,5-b)pyridin-2-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"ARQ 092","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10490","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313881-70-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T1DQI1B52Y"},{"name":"Maps_To","value":"AKT Inhibitor ARQ 092"},{"name":"Maps_To","value":"Miransertib"},{"name":"NCI_Drug_Dictionary_ID","value":"717768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717768"},{"name":"PDQ_Open_Trial_Search_ID","value":"717768"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274586"}]}}{"C95737":{"preferredName":"Akt Inhibitor LY2780301","code":"C95737","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor LY2780301 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway, thereby leading to inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Akt Inhibitor LY2780301","termGroup":"PT","termSource":"NCI"},{"termName":"LY2780301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Akt Inhibitor LY2780301"},{"name":"NCI_Drug_Dictionary_ID","value":"673505"},{"name":"NCI_META_CUI","value":"CL421578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673505"},{"name":"PDQ_Open_Trial_Search_ID","value":"673505"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90581":{"preferredName":"Akt Inhibitor MK2206","code":"C90581","definitions":[{"definition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Akt Inhibitor MK2206","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MK 2206","termGroup":"CN","termSource":"NCI"},{"termName":"MK-2206","termGroup":"CN","termSource":"NCI"},{"termName":"MK2206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032349-93-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"51HZG6MP1K"},{"name":"Maps_To","value":"Akt Inhibitor MK2206"},{"name":"NCI_Drug_Dictionary_ID","value":"596332"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596332"},{"name":"PDQ_Open_Trial_Search_ID","value":"596332"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933427"}]}}{"C85448":{"preferredName":"Akt Inhibitor SR13668","code":"C85448","definitions":[{"definition":"An orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities. Akt inhibitor SR13668 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation, and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Akt Inhibitor SR13668","termGroup":"PT","termSource":"NCI"},{"termName":"SRI13668","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Akt Inhibitor SR13668"},{"name":"NCI_Drug_Dictionary_ID","value":"642606"},{"name":"NCI_META_CUI","value":"CL412317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642606"},{"name":"PDQ_Open_Trial_Search_ID","value":"642606"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113792":{"preferredName":"Dordaviprone","code":"C113792","definitions":[{"definition":"A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dordaviprone","termGroup":"PT","termSource":"NCI"},{"termName":"Akt/ERK Inhibitor ONC201","termGroup":"SY","termSource":"NCI"},{"termName":"ONC201","termGroup":"CN","termSource":"NCI"},{"termName":"TIC10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616632-77-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9U35A31JAI"},{"name":"Maps_To","value":"Akt/ERK Inhibitor ONC201"},{"name":"NCI_Drug_Dictionary_ID","value":"757339"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757339"},{"name":"PDQ_Open_Trial_Search_ID","value":"757339"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3710983"}]}}{"C61438":{"preferredName":"Alacizumab Pegol","code":"C61438","definitions":[{"definition":"A pegylated, cross-linked, humanized divalent-Fab' antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab' antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alacizumab Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"CDP-791","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934216-54-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL9780F883"},{"name":"Legacy Concept Name","value":"Pegylated_Anti-GRF_Antibody_Fragment"},{"name":"Maps_To","value":"Alacizumab Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"472077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"472077"},{"name":"PDQ_Open_Trial_Search_ID","value":"472077"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831765"}]}}{"C994":{"preferredName":"Alanosine","code":"C994","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities. L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency. The clinical use of this agent may be limited by its toxicity profile. MTAP is a key enzyme in the adenine and methionine salvage pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alanosine","termGroup":"PT","termSource":"NCI"},{"termName":"3-(Hydroxynitrosoamino)-L-alanine","termGroup":"SN","termSource":"NCI"},{"termName":"Alanosine","termGroup":"SY","termSource":"NCI"},{"termName":"L-2-Amino-3-(hydroxynitrosoamino)propionic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"L-2-Amino-3-[(N-nitroso)hydroxylamino]propionic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"L-Alanosine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Alanosine Sodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5854-93-3"},{"name":"Chemical_Formula","value":"C3H7N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2CNI71214Y"},{"name":"Legacy Concept Name","value":"L-Alanosine"},{"name":"Maps_To","value":"Alanosine"},{"name":"NCI_Drug_Dictionary_ID","value":"39138"},{"name":"NSC Number","value":"529469"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39138"},{"name":"PDQ_Open_Trial_Search_ID","value":"39138"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051066"}]}}{"C131607":{"preferredName":"Albumin-binding Cisplatin Prodrug BTP-114","code":"C131607","definitions":[{"definition":"A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity.  Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Albumin-binding Cisplatin Prodrug BTP-114","termGroup":"PT","termSource":"NCI"},{"termName":"Albumin-conjugating Platinum-prodrug BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"BTP 114","termGroup":"CN","termSource":"NCI"},{"termName":"BTP-114","termGroup":"CN","termSource":"NCI"},{"termName":"Cisplatin Prodrug BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatin/Maleimide-based Complex BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum-Prodrug BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"Prodrug BTP 114","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Albumin-binding Cisplatin Prodrug BTP-114"},{"name":"NCI_Drug_Dictionary_ID","value":"786268"},{"name":"NCI_META_CUI","value":"CL514482"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786268"},{"name":"PDQ_Open_Trial_Search_ID","value":"786268"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1498":{"preferredName":"Aldesleukin","code":"C1498","definitions":[{"definition":"A drug used to treat some types of cancer. It is a form of interleukin-2, a cytokine made by leukocytes (white blood cells), that is made in the laboratory. Aldesleukin increases the activity and growth of white blood cells called T lymphocytes and B lymphocytes. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aldesleukin","termGroup":"PT","termSource":"NCI"},{"termName":"125-L-Serine-2-133-interleukin 2","termGroup":"SY","termSource":"NCI"},{"termName":"Proleukin","termGroup":"BR","termSource":"NCI"},{"termName":"r-serHuIL-2","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Human IL-2","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Interleukin-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110942-02-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M89N0Q7EQR"},{"name":"Legacy Concept Name","value":"Aldesleukin"},{"name":"Maps_To","value":"Aldesleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"39756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39756"},{"name":"PDQ_Open_Trial_Search_ID","value":"39756"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0218986"}]}}{"C68921":{"preferredName":"Aldoxorubicin","code":"C68921","definitions":[{"definition":"A 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, aldoxorubicin binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hypervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aldoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"DOXO-EMCH","termGroup":"AB","termSource":"NCI"},{"termName":"Doxorubicin-EMCH","termGroup":"SY","termSource":"NCI"},{"termName":"INNO-206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1361644-26-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C28MV4IM0B"},{"name":"Legacy Concept Name","value":"Doxorubicin_Prodrug_INNO-206"},{"name":"Maps_To","value":"Aldoxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"552648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"552648"},{"name":"PDQ_Open_Trial_Search_ID","value":"552648"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3495619"}]}}{"C101790":{"preferredName":"Alectinib","code":"C101790","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alectinib","termGroup":"PT","termSource":"NCI"},{"termName":"5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"AF-802","termGroup":"CN","termSource":"NCI"},{"termName":"AF802","termGroup":"CN","termSource":"NCI"},{"termName":"Alecensa","termGroup":"BR","termSource":"NCI"},{"termName":"Alecensa","termGroup":"FB","termSource":"NCI"},{"termName":"ALK Inhibitor RO5424802","termGroup":"SY","termSource":"NCI"},{"termName":"CH5424802","termGroup":"CN","termSource":"NCI"},{"termName":"RG7853","termGroup":"CN","termSource":"NCI"},{"termName":"RO5424802","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1256580-46-7"},{"name":"CHEBI_ID","value":"CHEBI:62268"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LIJ4CT1Z3Y"},{"name":"Maps_To","value":"Alectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"733572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733572"},{"name":"PDQ_Open_Trial_Search_ID","value":"733572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853921"}]}}{"C65220":{"preferredName":"Alefacept","code":"C65220","definitions":[{"definition":"A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Alefacept is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alefacept","termGroup":"PT","termSource":"NCI"},{"termName":"Amevive","termGroup":"BR","termSource":"NCI"},{"termName":"LFA3TIP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222535-22-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ELK3V90G6C"},{"name":"Legacy Concept Name","value":"Alefacept"},{"name":"Maps_To","value":"Alefacept"},{"name":"NCI_Drug_Dictionary_ID","value":"531798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531798"},{"name":"PDQ_Open_Trial_Search_ID","value":"531798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0962603"}]}}{"C1681":{"preferredName":"Alemtuzumab","code":"C1681","definitions":[{"definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alemtuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Campath","termGroup":"BR","termSource":"NCI"},{"termName":"Campath-1H","termGroup":"BR","termSource":"NCI"},{"termName":"LDP-03","termGroup":"CN","termSource":"NCI"},{"termName":"LDP03","termGroup":"CN","termSource":"NCI"},{"termName":"Lemtrada","termGroup":"BR","termSource":"NCI"},{"termName":"MabCampath","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Lymphocytic Leukemia (CLL)"},{"name":"CAS_Registry","value":"216503-57-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3A189DH42V"},{"name":"Legacy Concept Name","value":"Alemtuzumab"},{"name":"Maps_To","value":"Alemtuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"37783"},{"name":"NSC Number","value":"715969"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37783"},{"name":"PDQ_Open_Trial_Search_ID","value":"37783"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0383429"}]}}{"C77370":{"preferredName":"Alestramustine","code":"C77370","definitions":[{"definition":"The l-alanine ester form of estramustine, a combination of the nitrogen mustard normustine coupled via a carbamate to estradiol, with antineoplastic activity. Upon conversion of alestramustine to estramustine, estramustine binds to microtubule-associated proteins (MAPs) and beta tubulin, thereby interfering with microtubule dynamics and leading to microtubule disassembly and cell cycle arrest. Due to the estrogen moiety, this agent is able to selectively bind to and be taken up by estrogen receptor-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alestramustine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"139402-18-9"},{"name":"Chemical_Formula","value":"C26H36Cl2N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81U8A51CHK"},{"name":"Legacy Concept Name","value":"Alestramustine"},{"name":"Maps_To","value":"Alestramustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697985"}]}}{"C133719":{"preferredName":"Alflutinib Mesylate","code":"C133719","definitions":[{"definition":"The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alflutinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"ASK120067","termGroup":"CN","termSource":"NCI"},{"termName":"AST 2818 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"AST2818 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Furmonertinib Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Ivesa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2130958-55-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q09ZKD19V0"},{"name":"Maps_To","value":"Alflutinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"788215"},{"name":"NCI_META_CUI","value":"CL520357"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788215"},{"name":"PDQ_Open_Trial_Search_ID","value":"788215"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61082":{"preferredName":"Algenpantucel-L","code":"C61082","definitions":[{"definition":"A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Algenpantucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha (1,3) Galactosyltransferase Tumor Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Alpha-1,3-Galactosyltransferase-expressing Allogeneic Pancreatic Tumor Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HAPa","termGroup":"CN","termSource":"NCI"},{"termName":"Hyperacute Pancreatic Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HyperAcute-Pancreas Immunotherapy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I6HAD3HP89"},{"name":"Legacy Concept Name","value":"Alpha-Gal_Pancreatic_Cancer_Vaccine"},{"name":"Maps_To","value":"Algenpantucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"475734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"475734"},{"name":"PDQ_Open_Trial_Search_ID","value":"475734"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831790"}]}}{"C71717":{"preferredName":"Alisertib","code":"C71717","definitions":[{"definition":"A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alisertib","termGroup":"PT","termSource":"NCI"},{"termName":"Aurora A Kinase Inhibitor MLN8237","termGroup":"SY","termSource":"NCI"},{"termName":"Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"MLN-8237","termGroup":"CN","termSource":"NCI"},{"termName":"MLN8237","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1028486-01-2"},{"name":"Chemical_Formula","value":"C27H20ClFN4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T66ES73M18"},{"name":"Legacy Concept Name","value":"Aurora_A_Kinase_Inhibitor_MLN8237"},{"name":"Maps_To","value":"Alisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"561286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561286"},{"name":"PDQ_Open_Trial_Search_ID","value":"561286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346875"}]}}{"C1574":{"preferredName":"Alitretinoin","code":"C1574","definitions":[{"definition":"A drug being studied for cancer prevention.  It belongs to the family of drugs called retinoids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alitretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"9-cis Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"9-cis-RA","termGroup":"AB","termSource":"NCI"},{"termName":"9-cis-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"9-cRA","termGroup":"AB","termSource":"NCI"},{"termName":"ALRT1057","termGroup":"CN","termSource":"NCI"},{"termName":"LGD1057","termGroup":"CN","termSource":"NCI"},{"termName":"Panretin","termGroup":"BR","termSource":"NCI"},{"termName":"Panretyn","termGroup":"FB","termSource":"NCI"},{"termName":"Panrexin","termGroup":"FB","termSource":"NCI"},{"termName":"Retinoicacid-9-cis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi sarcoma"},{"name":"CAS_Registry","value":"5300-03-8"},{"name":"CHEBI_ID","value":"CHEBI:50648"},{"name":"Chemical_Formula","value":"C20H28O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1UA8E65KDZ"},{"name":"Legacy Concept Name","value":"Alitretinoin"},{"name":"Maps_To","value":"Alitretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"42147"},{"name":"NSC Number","value":"659772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42147"},{"name":"PDQ_Open_Trial_Search_ID","value":"42147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281666"}]}}{"C141136":{"preferredName":"ALK Inhibitor","code":"C141136","definitions":[{"definition":"Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Lymphoma Kinase Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK Inhibitor"},{"name":"NCI_META_CUI","value":"CL539186"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"}]}}{"C116727":{"preferredName":"ALK Inhibitor ASP3026","code":"C116727","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ASP3026 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor ASP3026","termGroup":"PT","termSource":"NCI"},{"termName":"ASP-3026","termGroup":"CN","termSource":"NCI"},{"termName":"ASP3026","termGroup":"CN","termSource":"NCI"},{"termName":"N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1097917-15-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HP4L6MXF10"},{"name":"Maps_To","value":"ALK Inhibitor ASP3026"},{"name":"NCI_Drug_Dictionary_ID","value":"694592"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694592"},{"name":"PDQ_Open_Trial_Search_ID","value":"694592"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896911"}]}}{"C148533":{"preferredName":"ALK Inhibitor PLB 1003","code":"C148533","definitions":[{"definition":"An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, PLB1003 selectively binds to and inhibits wild-type ALK, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor PLB 1003","termGroup":"PT","termSource":"NCI"},{"termName":"PLB 1003","termGroup":"CN","termSource":"NCI"},{"termName":"PLB-1003","termGroup":"CN","termSource":"NCI"},{"termName":"PLB1003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK Inhibitor PLB 1003"},{"name":"NCI_Drug_Dictionary_ID","value":"792707"},{"name":"NCI_META_CUI","value":"CL551132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792707"},{"name":"PDQ_Open_Trial_Search_ID","value":"792707"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154279":{"preferredName":"Iruplinalkib","code":"C154279","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, iruplinalkib binds to and inhibits ALK tyrosine kinase, ALK fusion proteins, ALK point mutation variants ALK L1196M, ALK C1156Y, and EGFR L858R/T790M. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iruplinalkib","termGroup":"PT","termSource":"NCI"},{"termName":"ALK Inhibitor WX-0593","termGroup":"SY","termSource":"NCI"},{"termName":"FL 006","termGroup":"CN","termSource":"NCI"},{"termName":"FL-006","termGroup":"CN","termSource":"NCI"},{"termName":"FL006","termGroup":"CN","termSource":"NCI"},{"termName":"WX 0593","termGroup":"CN","termSource":"NCI"},{"termName":"WX-0593","termGroup":"CN","termSource":"NCI"},{"termName":"WX0593","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1854943-32-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z5F65W1YAZ"},{"name":"Maps_To","value":"ALK Inhibitor WX-0593"},{"name":"NCI_Drug_Dictionary_ID","value":"794180"},{"name":"NCI_META_CUI","value":"CL555276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794180"},{"name":"PDQ_Open_Trial_Search_ID","value":"794180"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156729":{"preferredName":"Itacnosertib","code":"C156729","definitions":[{"definition":"An orally bioavailable inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2; ACRV1), with potential antineoplastic activity. Upon oral administration,itacnosertib targets, binds to and inhibits the activity of ALK-2. This prevents ALK-2-mediated signaling and inhibits cell growth in ALK-2-overexpressing tumor cells. In addition, in cancer and inflammatory conditions, ALK-2 is upregulated in response to increased signaling of pro-inflammatory cytokines, especially interleukin-6 (IL-6), and enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of iron homeostasis. Blocking ALK-2-mediated pathways in inflammation and cancer leads to a decrease of hepcidin expression and restores plasma iron levels, thereby preventing low serum iron levels and anemia of chronic disease (ACD). ALK-2, a serine/threonine receptor kinase, is constitutively activated due to activating mutations or upregulated upstream signaling pathways in inflammatory conditions and certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itacnosertib","termGroup":"PT","termSource":"NCI"},{"termName":"ACVR1 Inhibitor TP-0184","termGroup":"SY","termSource":"NCI"},{"termName":"ALK-2 Inhibitor TP-0184","termGroup":"SY","termSource":"NCI"},{"termName":"ALK2 Inhibitor TP-0184","termGroup":"SY","termSource":"NCI"},{"termName":"TP 0184","termGroup":"CN","termSource":"NCI"},{"termName":"TP-0184","termGroup":"CN","termSource":"NCI"},{"termName":"TP0184","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1628870-27-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22Z53X5LHF"},{"name":"Maps_To","value":"ALK-2 Inhibitor TP-0184"},{"name":"NCI_Drug_Dictionary_ID","value":"795585"},{"name":"NCI_META_CUI","value":"CL935854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795585"},{"name":"PDQ_Open_Trial_Search_ID","value":"795585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111685":{"preferredName":"ALK-FAK Inhibitor CEP-37440","code":"C111685","definitions":[{"definition":"An orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK-FAK Inhibitor CEP-37440","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-37440","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1391712-60-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3MNS8782H"},{"name":"Maps_To","value":"ALK-FAK Inhibitor CEP-37440"},{"name":"NCI_Drug_Dictionary_ID","value":"752740"},{"name":"NCI_META_CUI","value":"CL454076"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752740"},{"name":"PDQ_Open_Trial_Search_ID","value":"752740"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148513":{"preferredName":"ALK/c-Met Inhibitor TQ-B3139","code":"C148513","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK/c-Met Inhibitor TQ-B3139","termGroup":"PT","termSource":"NCI"},{"termName":"TQ B3139","termGroup":"CN","termSource":"NCI"},{"termName":"TQ-B3139","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK/c-Met Inhibitor TQ-B3139"},{"name":"NCI_Drug_Dictionary_ID","value":"792652"},{"name":"NCI_META_CUI","value":"CL551150"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792652"},{"name":"PDQ_Open_Trial_Search_ID","value":"792652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126648":{"preferredName":"ALK/FAK/Pyk2 Inhibitor CT-707","code":"C126648","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, ALK/FAK/Pyk2 inhibitor CT-707 selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK/FAK/Pyk2 Inhibitor CT-707","termGroup":"PT","termSource":"NCI"},{"termName":"CT 707","termGroup":"CN","termSource":"NCI"},{"termName":"CT-707","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK/FAK/Pyk2 Inhibitor CT-707"},{"name":"NCI_Drug_Dictionary_ID","value":"779790"},{"name":"NCI_META_CUI","value":"CL503764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779790"},{"name":"PDQ_Open_Trial_Search_ID","value":"779790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114287":{"preferredName":"ALK/TRK Inhibitor TSR-011","code":"C114287","definitions":[{"definition":"An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK/TRK Inhibitor TSR-011","termGroup":"PT","termSource":"NCI"},{"termName":"TSR-011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK/TRK Inhibitor TSR-011"},{"name":"NCI_Drug_Dictionary_ID","value":"757983"},{"name":"NCI_META_CUI","value":"CL471796"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757983"},{"name":"PDQ_Open_Trial_Search_ID","value":"757983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165556":{"preferredName":"Alkotinib","code":"C165556","definitions":[{"definition":"An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, alkotinib binds to and inhibits the wild-type, point mutations and fusion proteins of ALK and ROS1. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of proliferation in tumor cells which these kinases are overexpressed, rearranged or mutated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alkotinib","termGroup":"PT","termSource":"NCI"},{"termName":"ZG 0418","termGroup":"CN","termSource":"NCI"},{"termName":"ZG-0418","termGroup":"CN","termSource":"NCI"},{"termName":"ZG0418","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alkotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"799671"},{"name":"NCI_META_CUI","value":"CL978663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799671"},{"name":"PDQ_Open_Trial_Search_ID","value":"799671"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123911":{"preferredName":"Allodepleted T Cell Immunotherapeutic ATIR101","code":"C123911","definitions":[{"definition":"A cell-based immunotherapeutic product containing T-lymphocyte-enriched leukocytes that are devoid of alloreactive T-lymphocytes, that can potentially be used to restore lymphocyte levels after stem cell transplantations and are derived from partially matched (haploidentical) family donors for blood cancer patients who do not have a matching stem cell donor available. Host alloreactive T-cells, which can cause graft-versus-host disease (GVHD), are eliminated from the donor lymphocytes ex vivo using photodynamic therapy. After allogeneic hematopoietic stem cell transplantation (HSCT), allodepleted T cell immunotherapeutic ATIR101 is administered. This maintains a T-cell-mediated immune response against tumor cells and the donor T-cells can prevent opportunistic infections. ATIR101 does not cause severe, acute GVHD. In addition, administration of ATIR101 eliminates the need for immunosuppressants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allodepleted T Cell Immunotherapeutic ATIR101","termGroup":"PT","termSource":"NCI"},{"termName":"Allodepleted T-cell ImmunotheRapeutics","termGroup":"BR","termSource":"NCI"},{"termName":"ATIR101","termGroup":"CN","termSource":"NCI"},{"termName":"Theralux-ATIR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allodepleted T Cell Immunotherapeutic ATIR101"},{"name":"NCI_Drug_Dictionary_ID","value":"775836"},{"name":"NCI_META_CUI","value":"CL498275"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775836"},{"name":"PDQ_Open_Trial_Search_ID","value":"775836"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158558":{"preferredName":"Azercabtagene Zapreleucel","code":"C158558","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azercabtagene Zapreleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19-CAR T-cells PBCAR0191","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19-CAR T-lymphocytes PBCAR0191","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19-CAR Allogeneic T-cells PBCAR0191","termGroup":"SY","termSource":"NCI"},{"termName":"PBCAR0191","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PFZ3AP93TA"},{"name":"Maps_To","value":"Allogeneic Anti-CD19-CAR T-cells PBCAR0191"},{"name":"NCI_Drug_Dictionary_ID","value":"797475"},{"name":"NCI_META_CUI","value":"CL938005"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797475"},{"name":"PDQ_Open_Trial_Search_ID","value":"797475"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137863":{"preferredName":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100","code":"C137863","definitions":[{"definition":"A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells derived from a related but not completely matched human leukocyte antigen (HLA)-haploidentical donor that is seropositive for cytomegalovirus (CMV+), with potential cytolytic and antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+). The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15 (IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta) to generate the adaptive, CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100 ex vivo. Upon infusion of the allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100, these cells selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression of the memory-like activating receptor NKG2C and the maturation marker CD57 in the isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57 both enhances the effector function of NK cells and stimulates CD16-dependent signaling. Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor induces preferential expansion of CD57+ NK cells that exhibit enhanced interferon (IFN)-gamma production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100","termGroup":"PT","termSource":"NCI"},{"termName":"Adaptive Memory Natural Killer Cells FATE-NK100","termGroup":"SY","termSource":"NCI"},{"termName":"Adaptive Memory NKs Cells FATE-NK100","termGroup":"SY","termSource":"NCI"},{"termName":"Adaptive NKs Cells FATE-NK100","termGroup":"SY","termSource":"NCI"},{"termName":"FATE NK100","termGroup":"CN","termSource":"NCI"},{"termName":"FATE-NK100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100"},{"name":"NCI_Drug_Dictionary_ID","value":"790374"},{"name":"NCI_META_CUI","value":"CL524941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790374"},{"name":"PDQ_Open_Trial_Search_ID","value":"790374"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119759":{"preferredName":"Allogeneic Cellular Vaccine 1650-G","code":"C119759","definitions":[{"definition":"A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Cellular Vaccine 1650-G","termGroup":"PT","termSource":"NCI"},{"termName":"1650-G","termGroup":"CN","termSource":"NCI"},{"termName":"1650-G Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"1650G","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Cellular Vaccine 1650-G"},{"name":"NCI_Drug_Dictionary_ID","value":"810695"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896934"}]}}{"C146711":{"preferredName":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","code":"C146711","definitions":[{"definition":"A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Cancer Vaccine SV-BR-1-GM","termGroup":"SY","termSource":"NCI"},{"termName":"Bria-IMT","termGroup":"BR","termSource":"NCI"},{"termName":"GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM","termGroup":"SY","termSource":"NCI"},{"termName":"SV-BR-1 Breast Cancer Cell Line Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"SV-BR-1-GM","termGroup":"CN","termSource":"NCI"},{"termName":"SV-BR-1-GM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM"},{"name":"NCI_Drug_Dictionary_ID","value":"792158"},{"name":"NCI_META_CUI","value":"CL544722"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792158"},{"name":"PDQ_Open_Trial_Search_ID","value":"792158"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C2525":{"preferredName":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine","code":"C2525","definitions":[{"definition":"An allogeneic whole cell vaccine expressing human granulocyte macrophage-colony stimulating factor (GM-CSF) with potential antineoplastic activity. Tumor cells from prostate cancer patients are harvested and then genetically modified to secrete GM-CSF, an immune stimulatory growth factor that plays a key role in stimulating the body's immune responses against tumor cells. Because the vaccine is derived from allogenic cells, it has demonstrated a favorable side effect profile than other approaches of delivering long-lasting GM-CSF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic GM-CSF Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Prostate Cancer Vaccine, GM- CSF Gene Transduced","termGroup":"SY","termSource":"NCI"},{"termName":"Allogenic Prostate GVAX","termGroup":"SY","termSource":"NCI"},{"termName":"GM-CSF Gene Transduced Allogeneic Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Allogeneic Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Allogenic Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Cancer Vaccine, GM-CSF Gene Transduced","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Cancer Vaccine, GVAX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GVAX_Prostate_Cancer_Vaccine"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43459"},{"name":"PDQ_Open_Trial_Search_ID","value":"43459"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796615"}]}}{"C98282":{"preferredName":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine","code":"C98282","definitions":[{"definition":"An allogeneic cancer vaccine composed of lethally irradiated whole melanoma cancer cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the body's immune system against tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"GVAX Melanoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"712484"},{"name":"NCI_META_CUI","value":"CL432401"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712484"},{"name":"PDQ_Open_Trial_Search_ID","value":"712484"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101892":{"preferredName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo","code":"C101892","definitions":[{"definition":"An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo","termGroup":"PT","termSource":"NCI"},{"termName":"PANC 10.05 pcDNA-1/GM-Neo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo"},{"name":"NCI_Drug_Dictionary_ID","value":"734024"},{"name":"NCI_META_CUI","value":"CL436275"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734024"},{"name":"PDQ_Open_Trial_Search_ID","value":"734024"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101891":{"preferredName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo","code":"C101891","definitions":[{"definition":"An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo","termGroup":"PT","termSource":"NCI"},{"termName":"PANC 6.03 pcDNA-1/GM-Neo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo"},{"name":"NCI_Drug_Dictionary_ID","value":"734023"},{"name":"NCI_META_CUI","value":"CL436274"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734023"},{"name":"PDQ_Open_Trial_Search_ID","value":"734023"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90577":{"preferredName":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2","code":"C90577","definitions":[{"definition":"A preparation of glucocorticoid receptor (GR) negative, allogeneic cytotoxic T-lymphocytes (CTLs) expressing a membrane-tethered interleukin 13 (IL13) cytokine chimeric T-cell antigen receptor (zetakine), with potential antineoplastic activity. Upon transfection of donor T-lymphocytes with a plasmid encoding a fusion protein of the IL13-zetakine and the selection-suicide expression enzyme HyTK, these modified CTLs are expanded and introduced into a patient with glioblastoma multiforme (GBM). This agent specifically targets IL13 receptor alpha2, a glioma-restricted cell-surface epitope; the CTLs exert their cytolytic effect thereby killing IL13Ra2-expressing glioma cells. In addition, IL13-zetakine redirected CTLs induce production of certain cytokines. Furthermore, due to the fact that these CTLs are GR negative, they can be used concomitantly with glucocorticoid therapy. The IL13-zetakine consists of an extracellular IL-13 E13Y mutein-human IgG4 hinge-Fc chimera fused to human cytoplasmic CD3-zeta via the transmembrane domain of human CD4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2","termGroup":"PT","termSource":"NCI"},{"termName":"GRm13Z40-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2"},{"name":"NCI_Drug_Dictionary_ID","value":"668180"},{"name":"NCI_META_CUI","value":"CL416270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"668180"},{"name":"PDQ_Open_Trial_Search_ID","value":"668180"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103862":{"preferredName":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470","code":"C103862","definitions":[{"definition":"An allogeneic cancer vaccine composed of a mixture of lethally irradiated whole melanoma cancer cells obtained from four different melanoma cell lines, with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic irradiated melanoma cell vaccine may stimulate the body's immune system to exert a cytotoxic T-lymphocyte response and antibody-dependent cellular cytotoxicity (ADCC) against the melanoma cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470","termGroup":"PT","termSource":"NCI"},{"termName":"CSF 470 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CSF470 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470"},{"name":"NCI_Drug_Dictionary_ID","value":"743369"},{"name":"NCI_META_CUI","value":"CL438340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743369"},{"name":"PDQ_Open_Trial_Search_ID","value":"743369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78862":{"preferredName":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307","code":"C78862","definitions":[{"definition":"A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic LMI Melanoma Vaccine LP2307","termGroup":"SY","termSource":"NCI"},{"termName":"LP2307","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Allogeneic_Large_Multivalent_Immunogen_Melanoma_Vaccine_LP2307"},{"name":"Maps_To","value":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307"},{"name":"NCI_Drug_Dictionary_ID","value":"602166"},{"name":"NCI_META_CUI","value":"CL387595"},{"name":"PDQ_Closed_Trial_Search_ID","value":"602166"},{"name":"PDQ_Open_Trial_Search_ID","value":"602166"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78861":{"preferredName":"Allogeneic Melanoma Vaccine AGI-101H","code":"C78861","definitions":[{"definition":"A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Melanoma Vaccine AGI-101H","termGroup":"PT","termSource":"NCI"},{"termName":"AGI-101H","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Allogeneic_Melanoma_Vaccine_AGI-101H"},{"name":"Maps_To","value":"Allogeneic Melanoma Vaccine AGI-101H"},{"name":"NCI_Drug_Dictionary_ID","value":"601981"},{"name":"NCI_META_CUI","value":"CL387596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601981"},{"name":"PDQ_Open_Trial_Search_ID","value":"601981"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94209":{"preferredName":"Allogeneic Natural Killer Cell Line MG4101","code":"C94209","definitions":[{"definition":"A population of allogeneic, cytotoxic natural killer (NK) cells with potential antitumor activity. Allogeneic natural killer cell line MG4101 is derived from cells of a normal, healthy donor upon leukapheresis and activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Natural Killer Cell Line MG4101","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic NK Cell Line MG4101","termGroup":"SY","termSource":"NCI"},{"termName":"MG4101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WX2ZW10GHO"},{"name":"Maps_To","value":"Allogeneic Natural Killer Cell Line MG4101"},{"name":"NCI_Drug_Dictionary_ID","value":"686754"},{"name":"NCI_META_CUI","value":"CL426022"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686754"},{"name":"PDQ_Open_Trial_Search_ID","value":"686754"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117231":{"preferredName":"Allogeneic Natural Killer Cell Line NK-92","code":"C117231","definitions":[{"definition":"A proprietary, human cytotoxic cell line composed of allogeneic, activated, interleukin-2 (IL-2) dependent-natural killer cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma, with potential antineoplastic activity. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells. Upon infusion of the allogeneic NK cell line NK-92, the NKs recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in cancer cell lysis and apoptosis. In addition, NK-92 cells express high affinity Fc receptors, which bind to therapeutic antibodies; therefore, this agent can enhance antibody dependent cellular cytotoxicity (ADCC) of co-administered therapeutic antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Natural Killer Cell Line NK-92","termGroup":"PT","termSource":"NCI"},{"termName":"haNK","termGroup":"BR","termSource":"NCI"},{"termName":"NK-92","termGroup":"CN","termSource":"NCI"},{"termName":"NK-92 Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y0EW4890B4"},{"name":"Maps_To","value":"Allogeneic Natural Killer Cell Line NK-92"},{"name":"NCI_Drug_Dictionary_ID","value":"763083"},{"name":"NCI_META_CUI","value":"CL474099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763083"},{"name":"PDQ_Open_Trial_Search_ID","value":"763083"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95213":{"preferredName":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601","code":"C95213","definitions":[{"definition":"A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601","termGroup":"PT","termSource":"NCI"},{"termName":"IL-7/GM-CSF/CD80/CD154-encoding Synthetic dSLIM-30L1 Allogeneic Renal Cell Carcinoma Vaccine MGN1601","termGroup":"SY","termSource":"NCI"},{"termName":"MGN1601","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601"},{"name":"NCI_Drug_Dictionary_ID","value":"692088"},{"name":"NCI_META_CUI","value":"CL426701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"692088"},{"name":"PDQ_Open_Trial_Search_ID","value":"692088"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1649":{"preferredName":"Allovectin-7","code":"C1649","definitions":[{"definition":"A substance that is being studied as a gene therapy agent for the treatment of cancer.  It increases the ability of the immune system to recognize cancer cells and kill them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Allovectin-7","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2M DNA Lipid Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2M Plasmid DNA/DMRIE/DOPE Lipid Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2M Plasmid DNA/Lipid Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2Microglobulin DNA-Liposome Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Allovectin-7"},{"name":"Maps_To","value":"Allovectin-7"},{"name":"NCI_Drug_Dictionary_ID","value":"42356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42356"},{"name":"PDQ_Open_Trial_Search_ID","value":"42356"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338269"}]}}{"C81667":{"preferredName":"Almurtide","code":"C81667","definitions":[{"definition":"A synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Almurtide","termGroup":"PT","termSource":"NCI"},{"termName":"2-Acetamido-3-O-((((1S)-1-(((1R)-1-carbamoyl-3- carboxypropyl)carbamoyl)ethyl)carbamoyl)methyl)-2-deoxy-D- glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"Cgp-11637","termGroup":"CN","termSource":"NCI"},{"termName":"N-Acetyl-nor-muramyl-L-alanyl-D-isoglutamine","termGroup":"SY","termSource":"NCI"},{"termName":"nor-MDP","termGroup":"SY","termSource":"NCI"},{"termName":"norMDP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"61136-12-7"},{"name":"Chemical_Formula","value":"C18H30N4O11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1DCO35D4OR"},{"name":"Legacy Concept Name","value":"Almurtide"},{"name":"Maps_To","value":"Almurtide"},{"name":"NCI_Drug_Dictionary_ID","value":"702874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"702874"},{"name":"PDQ_Open_Trial_Search_ID","value":"702874"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0130664"}]}}{"C94214":{"preferredName":"Alpelisib","code":"C94214","definitions":[{"definition":"An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpelisib","termGroup":"PT","termSource":"NCI"},{"termName":"BYL719","termGroup":"CN","termSource":"NCI"},{"termName":"Phosphoinositide 3-kinase Inhibitor BYL719","termGroup":"SY","termSource":"NCI"},{"termName":"Piqray","termGroup":"BR","termSource":"NCI"},{"termName":"VIJOICE","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"f adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CARelated Overgrowth Spectrum (PROS) who require systemic therapy."},{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer"},{"name":"CAS_Registry","value":"1217486-61-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"08W5N2C97Q"},{"name":"Maps_To","value":"Alpelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"687431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687431"},{"name":"PDQ_Open_Trial_Search_ID","value":"687431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986399"}]}}{"C1720":{"preferredName":"Alpha Galactosylceramide","code":"C1720","definitions":[{"definition":"A drug being studied in the treatment of cancer. It is a biological response modifier that belongs to the family of drugs called glycosphingolipids or agelasphins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A potent alpha galactosylceramide modified from marine-sponge that stimulates the immune system to exhibit antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha Galactosylceramide","termGroup":"PT","termSource":"NCI"},{"termName":"a-GalCer","termGroup":"AB","termSource":"NCI"},{"termName":"KRN-7000","termGroup":"CN","termSource":"NCI"},{"termName":"KRN7000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"158021-47-7"},{"name":"CHEBI_ID","value":"CHEBI:466659"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WX671898JF"},{"name":"Legacy Concept Name","value":"KRN7000"},{"name":"Maps_To","value":"Alpha Galactosylceramide"},{"name":"NCI_Drug_Dictionary_ID","value":"43562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43562"},{"name":"PDQ_Open_Trial_Search_ID","value":"43562"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0534775"}]}}{"C52185":{"preferredName":"Alpha V Beta 1 Inhibitor ATN-161","code":"C52185","definitions":[{"definition":"A small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for integrin alpha5beta1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. Integrin alpha5beta1 is expressed on endothelial cells and plays a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. ATN-161 may prevent the spread of tumor cells and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alpha V Beta 1 Inhibitor ATN-161","termGroup":"PT","termSource":"NCI"},{"termName":"ATN-161","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"262438-43-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XW0H5LE42K"},{"name":"Legacy Concept Name","value":"ATN-161"},{"name":"Maps_To","value":"Alpha V Beta 1 Inhibitor ATN-161"},{"name":"NCI_Drug_Dictionary_ID","value":"459774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459774"},{"name":"PDQ_Open_Trial_Search_ID","value":"459774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706674"}]}}{"C120550":{"preferredName":"Idetrexed","code":"C120550","definitions":[{"definition":"An alpha-folate receptor (aFR)-mediated inhibitor of thymidylate synthase (TS), with potential antineoplastic activity. Upon intravenous infusion, idetrexed selectively targets and binds to aFR-expressing tumor cells. Upon uptake by aFR, this agent binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits both DNA synthesis and cell division, and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division. aFR, a cell-surface receptor glycoprotein, is overexpressed on various tumor cell types, but is minimally expressed by normal, healthy tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idetrexed","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801","termGroup":"SY","termSource":"NCI"},{"termName":"BGC 945","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-gamma-glutamyl-d-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ONX 0801","termGroup":"CN","termSource":"NCI"},{"termName":"ONX-0801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501332-69-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q718FS1C7X"},{"name":"Maps_To","value":"alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801"},{"name":"Maps_To","value":"Idetrexed"},{"name":"NCI_Drug_Dictionary_ID","value":"769152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769152"},{"name":"PDQ_Open_Trial_Search_ID","value":"769152"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1612758"}]}}{"C165548":{"preferredName":"Alpha-Gal AGI-134","code":"C165548","definitions":[{"definition":"A synthetic alpha Gal (aGal) molecule, with potential immunomodulating and antineoplastic activities. Upon intratumoral injection of aGal AGI-134, aGal coats the cancer cell membranes and triggers an anti-aGal antibody-mediated immune response leading to an initial complement-dependent and antibody-dependent cellular cytotoxicity (ADCC). This cytotoxicity causes release from tumor cells and subsequent uptake of released tumor-associated antigens (TAAs) by antigen-presenting cells (APCs). This may activate a systemic immune response against the TAAs and may eradicate cancer cells. aGal is a cell-surface carbohydrate antigen not expressed by humans while being expressed by all other mammals and bacteria. Anti-aGal antibodies are continuously and abundantly produced by humans due to exposure to aGal present on intestinal bacteria in the digestive system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-Gal AGI-134","termGroup":"PT","termSource":"NCI"},{"termName":"aGal AGI-134","termGroup":"SY","termSource":"NCI"},{"termName":"AGI 134","termGroup":"CN","termSource":"NCI"},{"termName":"AGI-134","termGroup":"CN","termSource":"NCI"},{"termName":"AGI134","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-alpha Gal Immunotherapeutic AGI-134","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1821461-84-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OE0L4ZX3I8"},{"name":"Maps_To","value":"Alpha-Gal AGI-134"},{"name":"NCI_Drug_Dictionary_ID","value":"799503"},{"name":"NCI_META_CUI","value":"CL978678"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799503"},{"name":"PDQ_Open_Trial_Search_ID","value":"799503"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159497":{"preferredName":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H","code":"C159497","definitions":[{"definition":"A synthetic proteolipid complex comprised of the alpha-1 domain of alpha-lactalbumin (lactose synthase B protein) and oleic acid, with potential antineoplastic activity. Upon intravesical instillation, alpha1H selectively accumulates in the nuclei of tumor cells and binds to histones H3, H4, and H2B. By binding to histones, alpha1H disrupts chromatin assembly and interferes with intact chromatin, thereby preventing tumor cell transcription and replication. Additionally, alpha1H inhibits the phosphorylation of multiple kinases involved in cancer-associated pathways including the Ras/Raf/ERK, PI3K/AKT, p38 MAPK and JNK signaling pathways. This may inhibit tumor cell proliferation and induce apoptosis in tumor cells that are driven by the dysregulation of certain kinases and oncogenic GTPases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha 1H","termGroup":"CN","termSource":"NCI"},{"termName":"Alpha-1H","termGroup":"CN","termSource":"NCI"},{"termName":"Alpha-lactalbumin-derived Synthetic Proteolipid Complex Alpha1H","termGroup":"SY","termSource":"NCI"},{"termName":"Alpha1H","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H"},{"name":"NCI_Drug_Dictionary_ID","value":"797495"},{"name":"NCI_META_CUI","value":"CL951455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797495"},{"name":"PDQ_Open_Trial_Search_ID","value":"797495"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28795":{"preferredName":"Alpha-Thioguanine Deoxyriboside","code":"C28795","definitions":[{"definition":"A purine analog with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-Thioguanine Deoxyriboside","termGroup":"PT","termSource":"NCI"},{"termName":"6H-Purine-6-thione, 2-amino-9-(2-deoxy-alpha-D-erythro-pentofuranosyl)-1,9-dihydro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"9H-Purine-6-thiol, 2-amino-9-(2-deoxy-alpha-D-erythro-pentofuranosyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"A-TGDR","termGroup":"AB","termSource":"NCI"},{"termName":"alpha-2'-Deoxy-6-thioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-2'-Deoxythioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-Thiodeoxyguanosine","termGroup":"SY","termSource":"NCI"},{"termName":"Thioguanine 9-alpha-D-2'-deoxyriboside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2133-81-5"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alpha-Thioguanine_Deoxyriboside"},{"name":"Maps_To","value":"Alpha-Thioguanine Deoxyriboside"},{"name":"NSC Number","value":"71851"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051299"}]}}{"C117234":{"preferredName":"Alpha-tocopheryloxyacetic Acid","code":"C117234","definitions":[{"definition":"An orally bioavailable vitamin E derivative with potential antineoplastic and immunostimulating activities. Upon administration, alpha-tocopheryloxyacetic acid (alpha-TEA) induces tumor autophagy; the autophagosomes formed, which carry tumor associated antigens (TAAs), allow for increased cross-presentation of TAAs by professional antigen-presenting cells (APCs). This activates a T cell-mediated T helper type 1 (TH1) response, generates a cytotoxic T-lymphocyte (CTL) response against cancer cells, and reduces the frequency of regulatory T-cell (Treg) differentiation. In addition, alpha-TEA modulates the release of various cytokines and chemokines and induces tumor cell apoptosis. Altogether, this results in decreased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-tocopheryloxyacetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2,5,7,8-Tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) Acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"a-TEA","termGroup":"AB","termSource":"NCI"},{"termName":"alpha-TEA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"261929-52-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JW7FJR3ZLY"},{"name":"Maps_To","value":"Alpha-tocopheryloxyacetic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"763148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763148"},{"name":"PDQ_Open_Trial_Search_ID","value":"763148"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1455006"}]}}{"C118290":{"preferredName":"Altiratinib","code":"C118290","definitions":[{"definition":"An orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Altiratinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"DCC-2701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1345847-93-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T678746713"},{"name":"Maps_To","value":"Altiratinib"},{"name":"NCI_Drug_Dictionary_ID","value":"764368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764368"},{"name":"PDQ_Open_Trial_Search_ID","value":"764368"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896881"}]}}{"C544":{"preferredName":"Altretamine","code":"C544","definitions":[{"definition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Altretamine","termGroup":"PT","termSource":"NCI"},{"termName":"2,4,6-tris(dimethylamino)-s-triazine","termGroup":"SN","termSource":"NCI"},{"termName":"ENT-50852","termGroup":"CN","termSource":"NCI"},{"termName":"Hemel","termGroup":"SY","termSource":"NCI"},{"termName":"Hexalen","termGroup":"BR","termSource":"NCI"},{"termName":"Hexaloids","termGroup":"SY","termSource":"NCI"},{"termName":"Hexamethylamine","termGroup":"SY","termSource":"NCI"},{"termName":"Hexamethylmelamine","termGroup":"SY","termSource":"NCI"},{"termName":"Hexastat","termGroup":"FB","termSource":"NCI"},{"termName":"Hexinawas","termGroup":"FB","termSource":"NCI"},{"termName":"HMM","termGroup":"AB","termSource":"NCI"},{"termName":"HXM","termGroup":"AB","termSource":"NCI"},{"termName":"N,n,n',N\"N\"-hexamethyl-1,3,5,-triazine-2,4,6,-triamine","termGroup":"SN","termSource":"NCI"},{"termName":"N,N,N',N',N\",N\"-hexamethyl-1,3,5-triazine-2,4,6-triamine","termGroup":"SN","termSource":"NCI"},{"termName":"RB-1515","termGroup":"CN","termSource":"NCI"},{"termName":"WR-95704","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"645-05-6"},{"name":"CHEBI_ID","value":"CHEBI:24564"},{"name":"Chemical_Formula","value":"C9H18N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q8BIH59O7H"},{"name":"Legacy Concept Name","value":"Altretamine"},{"name":"Maps_To","value":"Altretamine"},{"name":"NCI_Drug_Dictionary_ID","value":"39475"},{"name":"NSC Number","value":"13875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39475"},{"name":"PDQ_Open_Trial_Search_ID","value":"39475"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0019453"}]}}{"C38142":{"preferredName":"Alvespimycin","code":"C38142","definitions":[{"definition":"17-DMAG. A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called geldanamycin analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvespimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"17-DMAG","termGroup":"AB","termSource":"NCI"},{"termName":"Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"467214-20-6"},{"name":"Chemical_Formula","value":"C32H48N4O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"001L2FE0M3"},{"name":"Legacy Concept Name","value":"_17-Dimethylaminoethylamino_17-Demethoxygeldanamycin"},{"name":"Maps_To","value":"Alvespimycin"},{"name":"NSC Number","value":"707545"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527262"}]}}{"C76665":{"preferredName":"Alvespimycin Hydrochloride","code":"C76665","definitions":[{"definition":"The hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvespimycin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"17-DMAG HCl","termGroup":"AB","termSource":"NCI"},{"termName":"BMS-826476","termGroup":"CN","termSource":"NCI"},{"termName":"Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-, Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"KOS-1022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"467214-21-7"},{"name":"Chemical_Formula","value":"C32H48N4O8.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"612K359T69"},{"name":"Legacy Concept Name","value":"Alvespimycin_Hydrochloride"},{"name":"Maps_To","value":"Alvespimycin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"378203"},{"name":"PDQ_Closed_Trial_Search_ID","value":"378203"},{"name":"PDQ_Open_Trial_Search_ID","value":"378203"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350808"}]}}{"C74940":{"preferredName":"Alvocidib","code":"C74940","definitions":[{"definition":"The free base form of a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvocidib","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"Alvocidib Freebase","termGroup":"SY","termSource":"NCI"},{"termName":"Flavopiridol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"146426-40-6"},{"name":"Chemical_Formula","value":"C21H20ClNO5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"45AD6X575G"},{"name":"Legacy Concept Name","value":"Alvocidib_Freebase"},{"name":"Maps_To","value":"Alvocidib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0174903"}]}}{"C1571":{"preferredName":"Alvocidib Hydrochloride","code":"C1571","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It stops cells from dividing and may kill cancer cells. It is a type of cyclin-dependent kinase (CDK) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvocidib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Flavopiridol Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"HL-275","termGroup":"CN","termSource":"NCI"},{"termName":"HMR 1275","termGroup":"CN","termSource":"NCI"},{"termName":"L-86-8275","termGroup":"CN","termSource":"NCI"},{"termName":"L-868275","termGroup":"CN","termSource":"NCI"},{"termName":"MDL 107,826A","termGroup":"CN","termSource":"NCI"},{"termName":"MDL-107826A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"131740-09-5"},{"name":"Chemical_Formula","value":"C21H20ClNO5.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D48MS3A6N9"},{"name":"Legacy Concept Name","value":"Flavopiridol"},{"name":"Maps_To","value":"Alvocidib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42068"},{"name":"NSC Number","value":"649890"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42068"},{"name":"PDQ_Open_Trial_Search_ID","value":"42068"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281603"}]}}{"C165555":{"preferredName":"Alvocidib Prodrug TP-1287","code":"C165555","definitions":[{"definition":"An orally bioavailable, highly soluble phosphate prodrug of alvocidib, a potent inhibitor of cyclin-dependent kinase-9 (CDK9), with potential antineoplastic activity. Upon administration of the phosphate prodrug TP-1287, the prodrug is enzymatically cleaved at the tumor site and the active moiety alvocidib is released. Alvocidib targets and binds to CDK9, thereby reducing the expression of CDK9 target genes such as the anti-apoptotic protein MCL-1, and inducing G1 cell cycle arrest and apoptosis in CDK9-overexpressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvocidib Prodrug TP-1287","termGroup":"PT","termSource":"NCI"},{"termName":"Alvocidib Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Alvocidib Phosphate TP-1287","termGroup":"SY","termSource":"NCI"},{"termName":"TP 1287","termGroup":"CN","termSource":"NCI"},{"termName":"TP-1287","termGroup":"CN","termSource":"NCI"},{"termName":"TP1287","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2044686-42-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7MPP85IIJ3"},{"name":"Maps_To","value":"Alvocidib Prodrug TP-1287"},{"name":"NCI_Drug_Dictionary_ID","value":"799663"},{"name":"NCI_META_CUI","value":"CL978685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799663"},{"name":"PDQ_Open_Trial_Search_ID","value":"799663"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62483":{"preferredName":"Amatuximab","code":"C62483","definitions":[{"definition":"A chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed on many epithelial-derived cancer cells. Upon binding to the mesothelin antigen, amatuximab triggers an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing cells, resulting in cell lysis.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Amatuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Mesothelin Monoclonal Antibody MORAb-009","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(mesothelin) (Human-Mouse Monoclonal MORAb-009 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-009 Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb-009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"931402-35-6"},{"name":"Chemical_Formula","value":"C6394H9870N1694O2024S46"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6HP0354G04"},{"name":"Legacy Concept Name","value":"Anti-Mesothelin_Monoclonal_Antibody"},{"name":"Maps_To","value":"Amatuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"489384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489384"},{"name":"PDQ_Open_Trial_Search_ID","value":"489384"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3179481"}]}}{"C73320":{"preferredName":"Ambamustine","code":"C73320","definitions":[{"definition":"A tripeptidic nitrogen mustard compound and bifunctional alkylating agent with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ambamustine","termGroup":"PT","termSource":"NCI"},{"termName":"N-(3-(m-(Bis(2-chloroethyl)amino)phenyl)-N-(3-(p-fluorophenyl)-L-alanyl)-L-alanyl)-L-methionine, Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"PTT-119","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85754-59-2"},{"name":"Chemical_Formula","value":"C29H39Cl2FN4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IB1H345F24"},{"name":"Legacy Concept Name","value":"Ambamustine"},{"name":"Maps_To","value":"Ambamustine"},{"name":"PubMedID_Primary_Reference","value":"10683068"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244456"}]}}{"C72627":{"preferredName":"Ambazone","code":"C72627","definitions":[{"definition":"An antiseptic agent with potential antibacterial and antileukemic activity. Although the exact mechanism of action remains to be fully elucidated, ambazone appears to interfere with the membrane-bound nucleotide system by increasing the intracellular concentration of cAMP in leukemia cells and macrophages, which potentially contributes to this agent's antineoplastic activity. Furthermore, this agent's affinity for various cellular targets, i.e. membranes, nucleic acids and proteins, may contribute to the overall antibacterial effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ambazone","termGroup":"PT","termSource":"NCI"},{"termName":"Faringosept","termGroup":"BR","termSource":"NCI"},{"termName":"p-Benzoquinone Amidinohydrazone Thiosemicarbazone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6011-12-7"},{"name":"Chemical_Formula","value":"C8H11N7S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BYK4592A3Q"},{"name":"Legacy Concept Name","value":"Ambazone"},{"name":"Maps_To","value":"Ambazone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043983"}]}}{"C148521":{"preferredName":"Amblyomin-X","code":"C148521","definitions":[{"definition":"A recombinant form of a toxic protein derived from the salivary glands of the Amblyomma cajennense tick that inhibits Factor Xa and induces apoptosis, with potential antithrombotic and antineoplastic activities.  Upon administration, amblyomin-X promotes endoplasmic reticulum (ER) stress, mitochondrial dysfunction, cytochrome-c release, poly(ADP-ribose) polymerase (PARP) cleavage, and activation of caspase. Additionally, this agent selectively induces apoptosis in tumor cells. It also affects endothelial cell functions, such as adhesion, and may inhibit angiogenesis. Amblyomin-X targets and binds to factor Xa, inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. As cancer is associated with thrombosis, amblyomin-X could potentially exert its antineoplastic and antithrombotic effects in the cancer patient at the same time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amblyomin-X","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amblyomin-X"},{"name":"NCI_Drug_Dictionary_ID","value":"792680"},{"name":"NCI_META_CUI","value":"CL551143"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792680"},{"name":"PDQ_Open_Trial_Search_ID","value":"792680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104745":{"preferredName":"Amcasertib","code":"C104745","definitions":[{"definition":"An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, amcasertib targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amcasertib","termGroup":"PT","termSource":"NCI"},{"termName":"BBI503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1129403-56-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GLY8ABW25V"},{"name":"Maps_To","value":"Amcasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"746133"},{"name":"NCI_META_CUI","value":"CL445816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746133"},{"name":"PDQ_Open_Trial_Search_ID","value":"746133"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1342":{"preferredName":"Ametantrone","code":"C1342","definitions":[{"definition":"A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ametantrone","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-bis[[2-[(2-Hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64862-96-0"},{"name":"Chemical_Formula","value":"C22H28N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PNT6041ST1"},{"name":"Legacy Concept Name","value":"Ametantrone"},{"name":"Maps_To","value":"Ametantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"39147"},{"name":"NSC Number","value":"196473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39147"},{"name":"PDQ_Open_Trial_Search_ID","value":"39147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0102923"}]}}{"C488":{"preferredName":"Amifostine","code":"C488","definitions":[{"definition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amifostine","termGroup":"PT","termSource":"NCI"},{"termName":"2-[(3-Aminopropyl)amino]ethanethiol Dihydrogen Phosphate Ester Trihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Amifostine Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Aminopropylaminoethylthiophosphoric Acid Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"APAETP","termGroup":"AB","termSource":"NCI"},{"termName":"Cytofos","termGroup":"FB","termSource":"NCI"},{"termName":"Ethiofos","termGroup":"SY","termSource":"NCI"},{"termName":"Ethyol","termGroup":"BR","termSource":"NCI"},{"termName":"Gammaphos","termGroup":"SY","termSource":"NCI"},{"termName":"S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid Trihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"S-2-(3-Aminopropylamino)ethylphosphorothioic Acid Trihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"WR-2721","termGroup":"CN","termSource":"NCI"},{"termName":"WR2721","termGroup":"CN","termSource":"NCI"},{"termName":"YM-08310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cisplatin-induced nephrotoxicity; Radiation-induced mucositis and xerostomia"},{"name":"CAS_Registry","value":"112901-68-5"},{"name":"Chemical_Formula","value":"C5H15N2O3PS.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"M487QF2F4V"},{"name":"Legacy Concept Name","value":"Amifostine"},{"name":"Maps_To","value":"Amifostine"},{"name":"NCI_Drug_Dictionary_ID","value":"39741"},{"name":"NSC Number","value":"296961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39741"},{"name":"PDQ_Open_Trial_Search_ID","value":"39741"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015020"}]}}{"C15509":{"preferredName":"Amino Acid Injection","code":"C15509","definitions":[{"definition":"A concentrated dietary supplement for injection containing the essential amino acids leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine and tryptophan as well as the non-essential amino acids alanine, arginine, glycine, proline, serine and tyrosine, with potential anabolic and anti-catabolic activities. Upon dilution and intravenous infusion of the amino acid nutritional supplement, the amino acids serve as protein building blocks, promote protein synthesis in muscle cells and prevent protein breakdown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amino Acid Injection","termGroup":"PT","termSource":"NCI"},{"termName":"RenAmin","termGroup":"BR","termSource":"NCI"},{"termName":"Travasol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Amino_Acid_Injection"},{"name":"Maps_To","value":"Amino Acid Injection"},{"name":"NCI_Drug_Dictionary_ID","value":"757081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757081"},{"name":"PDQ_Open_Trial_Search_ID","value":"757081"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0076943"}]}}{"C1488":{"preferredName":"Aminocamptothecin","code":"C1488","definitions":[{"definition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aminocamptothecin","termGroup":"PT","termSource":"NCI"},{"termName":"9-AC","termGroup":"AB","termSource":"NCI"},{"termName":"9-amino-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"9-amino-20-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"9-amino-camptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"9-amino-CPT","termGroup":"SY","termSource":"NCI"},{"termName":"9-aminocamptothecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86639-63-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5MB77ICE2Q"},{"name":"Legacy Concept Name","value":"Aminocamptothecin"},{"name":"Maps_To","value":"Aminocamptothecin"},{"name":"NCI_Drug_Dictionary_ID","value":"41792"},{"name":"NSC Number","value":"603071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41792"},{"name":"PDQ_Open_Trial_Search_ID","value":"41792"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0214192"}]}}{"C2452":{"preferredName":"Aminocamptothecin Colloidal Dispersion","code":"C2452","definitions":[{"definition":"A colloidal dispersion formulation of 9-Aminocamptothecin, a water-insoluble camptothecin derivative. Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages. Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aminocamptothecin Colloidal Dispersion","termGroup":"PT","termSource":"NCI"},{"termName":"9-aminocamptothecin colloidal dispersion","termGroup":"SY","termSource":"NCI"},{"termName":"9AC colloidal dispersion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aminocamptothecin_Colloidal_Dispersion"},{"name":"Maps_To","value":"Aminocamptothecin Colloidal Dispersion"},{"name":"NCI_Drug_Dictionary_ID","value":"42874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42874"},{"name":"PDQ_Open_Trial_Search_ID","value":"42874"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677807"}]}}{"C48370":{"preferredName":"Aminoflavone Prodrug AFP464","code":"C48370","definitions":[{"definition":"A substance being studied in the treatment of cancer. AFP464 kills cancer cells or stops them from dividing. It is a type of aminoflavone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic lysyl prodrug of the amino-substituted flavone derivate aminoflavone with antiproliferative and antineoplastic activities. AFP464 is rapidly converted to aminoflavone in plasma. Aminoflavone activates the aryl hydrocarbon receptor (AhR) signaling pathway leading to an increase in cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1A2 (CYP1A2) expression and, to a lesser extent, an increase in cytochrome P450 1B1 (CYP1B1) expression. Subsequently, aminoflavone is metabolized to toxic metabolites by the cytochromome P450 enzymes that it induces; these toxic metabolites covalently bind to DNA, resulting in the phosphorylation of p53, the induction of the p53 downstream target p21Waf1/Cip1, and apoptosis. Pulmonary toxicity may be dose-limiting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aminoflavone Prodrug AFP464","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"468719-53-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"73JNH95XPX"},{"name":"Legacy Concept Name","value":"AFP464"},{"name":"Maps_To","value":"Aminoflavone Prodrug AFP464"},{"name":"NCI_Drug_Dictionary_ID","value":"453584"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453584"},{"name":"PDQ_Open_Trial_Search_ID","value":"453584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706653"}]}}{"C235":{"preferredName":"Aminopterin","code":"C235","definitions":[{"definition":"A synthetic derivative of pterins with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aminopterin","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-PGA","termGroup":"SY","termSource":"NCI"},{"termName":"4-Aminofolic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"4-Aminopteroyl-glutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"4-Aminopteroylglutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Aminopteroylglutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"APGA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54-62-6"},{"name":"CHEBI_ID","value":"CHEBI:22526"},{"name":"Chemical_Formula","value":"C19H20N8O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JYB41CTM2Q"},{"name":"Legacy Concept Name","value":"Aminopterin"},{"name":"Maps_To","value":"Aminopterin"},{"name":"NCI_Drug_Dictionary_ID","value":"39141"},{"name":"NSC Number","value":"739"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39141"},{"name":"PDQ_Open_Trial_Search_ID","value":"39141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002583"}]}}{"C74554":{"preferredName":"Aminopterin Sodium","code":"C74554","definitions":[{"definition":"The sodium salt of a pterin derivative with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aminopterin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Aminopterin Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Sodium Aminopterin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58602-66-7"},{"name":"Chemical_Formula","value":"C19H18N8O5.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FZU1QI13O9"},{"name":"Legacy Concept Name","value":"Aminopterin_Sodium"},{"name":"Maps_To","value":"Aminopterin Sodium"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282048"}]}}{"C90592":{"preferredName":"Amolimogene Bepiplasmid","code":"C90592","definitions":[{"definition":"A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amolimogene Bepiplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"Amolimogene","termGroup":"SY","termSource":"NCI"},{"termName":"Bacterially Derived DNA and Microparticles Made of Poly(D,L-lactide-co-glydolide)","termGroup":"SY","termSource":"NCI"},{"termName":"DNA (synthetic Plasmid p3kDRalphaHPV16-18)","termGroup":"SY","termSource":"NCI"},{"termName":"ZYC101a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"870524-46-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B5KCA0GAK"},{"name":"Maps_To","value":"Amolimogene Bepiplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"561721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561721"},{"name":"PDQ_Open_Trial_Search_ID","value":"561721"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1435422"}]}}{"C61306":{"preferredName":"Amonafide L-Malate","code":"C61306","definitions":[{"definition":"The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amonafide L-Malate","termGroup":"PT","termSource":"NCI"},{"termName":"5-amino-2-[2-(dimethylamino)ethyl]-1H-benz[de]isoquinoline-1,3(2H)-dione (2S)-2-ydroxybutanedioate","termGroup":"SN","termSource":"NCI"},{"termName":"AS1413","termGroup":"CN","termSource":"NCI"},{"termName":"Butanedioic Acid, 2-hydroxy-, (2S)-, compd. with 5-amino-2-(2-(dimethylamino)ethyl)-1h-benz[de]isoquinoline-1,3(2h)-dione (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"XAN-02","termGroup":"CN","termSource":"NCI"},{"termName":"Xanafide","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of secondary acute myeloid leukemia"},{"name":"CAS_Registry","value":"618863-54-0"},{"name":"Chemical_Formula","value":"C16H17N3O2.C4H6O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LI06Q37TEG"},{"name":"Legacy Concept Name","value":"Amonafide_L-Malate"},{"name":"Maps_To","value":"Amonafide L-Malate"},{"name":"NCI_Drug_Dictionary_ID","value":"485171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485171"},{"name":"PDQ_Open_Trial_Search_ID","value":"485171"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879697"}]}}{"C80089":{"preferredName":"Amrubicin","code":"C80089","definitions":[{"definition":"A substance being studied in the treatment of lung cancer. It is a type of anthracycline analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amrubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110267-81-7"},{"name":"Chemical_Formula","value":"C25H25NO9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"93N13LB4Z2"},{"name":"Legacy Concept Name","value":"Amrubicin"},{"name":"Maps_To","value":"Amrubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"813335"},{"name":"NCI_META_CUI","value":"CL405282"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C47948":{"preferredName":"Amrubicin Hydrochloride","code":"C47948","definitions":[{"definition":"The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amrubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Amrubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Calsed","termGroup":"FB","termSource":"NCI"},{"termName":"SM-5887","termGroup":"CN","termSource":"NCI"},{"termName":"SMP-5887","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110311-30-3"},{"name":"Chemical_Formula","value":"C25H25NO9.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EUL6MP8FZW"},{"name":"Legacy Concept Name","value":"Amrubicin_Hydrochloride"},{"name":"Maps_To","value":"Amrubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"443682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"443682"},{"name":"PDQ_Open_Trial_Search_ID","value":"443682"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762659"}]}}{"C240":{"preferredName":"Amsacrine","code":"C240","definitions":[{"definition":"An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amsacrine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-(9-Acridinylamino)methane-sulfon-m-anisidide","termGroup":"SN","termSource":"NCI"},{"termName":"Acridinyl Anisidide","termGroup":"SY","termSource":"NCI"},{"termName":"Amekrin","termGroup":"FB","termSource":"NCI"},{"termName":"AMSA","termGroup":"AB","termSource":"NCI"},{"termName":"Amsa P-D","termGroup":"BR","termSource":"NCI"},{"termName":"Amsidine","termGroup":"FB","termSource":"NCI"},{"termName":"Amsidyl","termGroup":"FB","termSource":"NCI"},{"termName":"Cain's Acridine","termGroup":"SY","termSource":"NCI"},{"termName":"CI-880","termGroup":"CN","termSource":"NCI"},{"termName":"Lamasine","termGroup":"FB","termSource":"NCI"},{"termName":"m-AMSA","termGroup":"AB","termSource":"NCI"},{"termName":"N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"SN-11841","termGroup":"CN","termSource":"NCI"},{"termName":"SN-21429","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51264-14-3"},{"name":"CHEBI_ID","value":"CHEBI:2687"},{"name":"Chemical_Formula","value":"C21H19N3O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"00DPD30SOY"},{"name":"Legacy Concept Name","value":"Amsacrine"},{"name":"Maps_To","value":"Amsacrine"},{"name":"NCI_Drug_Dictionary_ID","value":"39142"},{"name":"NSC Number","value":"249992"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39142"},{"name":"PDQ_Open_Trial_Search_ID","value":"39142"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0591085"}]}}{"C96771":{"preferredName":"Amsacrine Lactate","code":"C96771","definitions":[{"definition":"The lactate form of amsacrine, an aminoacridine analog and topoisomerase II inhibitor, with antineoplastic activity. Although the exact relationship between DNA binding and its activity has yet to be fully elucidated, amsacrine intercalates DNA through its acridine moiety, and its nonintercalative headgroup impedes topoisomerase II activity, augmenting enzyme-mediated DNA cleavage and resulting in DNA double-strand breaks. This ultimately induces programmed cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amsacrine Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"m-AMSA lactate","termGroup":"SY","termSource":"NCI"},{"termName":"Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-, compd. with Lactic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide compd. with Lactic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80277-11-8"},{"name":"Chemical_Formula","value":"C21H19N3O3S.C3H6O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"959PWE0Q2E"},{"name":"Maps_To","value":"Amsacrine Lactate"},{"name":"NSC Number","value":"141549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1271552"}]}}{"C38684":{"preferredName":"Amsilarotene","code":"C38684","definitions":[{"definition":"A retinobenzoic acid with potential antineoplastic activity. Amsilarotene inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest.  This agent also causes a cytotoxic decline in cyclin A and thymidylate synthase expression.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called synthetic retinoids and angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Amsilarotene","termGroup":"PT","termSource":"NCI"},{"termName":"TAC 101","termGroup":"CN","termSource":"NCI"},{"termName":"TAC-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125973-56-0"},{"name":"Chemical_Formula","value":"C20H27NO3Si2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1418F39MH"},{"name":"Legacy Concept Name","value":"TAC-101"},{"name":"Maps_To","value":"Amsilarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"350384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350384"},{"name":"PDQ_Open_Trial_Search_ID","value":"350384"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0675838"}]}}{"C75926":{"preferredName":"Amustaline","code":"C75926","definitions":[{"definition":"A quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amustaline","termGroup":"PT","termSource":"NCI"},{"termName":"(N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate","termGroup":"SN","termSource":"NCI"},{"termName":"S-303","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220180-88-1"},{"name":"Chemical_Formula","value":"C22H25Cl2N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25571657UW"},{"name":"Legacy Concept Name","value":"Amustaline"},{"name":"Maps_To","value":"Amustaline"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1667749"}]}}{"C75035":{"preferredName":"Amustaline Dihydrochloride","code":"C75035","definitions":[{"definition":"The hydrochloride salt form of amustaline, a quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amustaline Dihydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"210584-54-6"},{"name":"Chemical_Formula","value":"C22H25Cl2N3O2.2ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C5MKX7XOYA"},{"name":"Legacy Concept Name","value":"Amustaline_Dihydrochloride"},{"name":"Maps_To","value":"Amustaline Dihydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698106"}]}}{"C71750":{"preferredName":"Amuvatinib","code":"C71750","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks the action of certain enzymes involved in cell growth and the repair of DNA damaged by some anticancer drugs. It is a type of tyrosine kinase inhibitor and a type of recombinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amuvatinib","termGroup":"PT","termSource":"NCI"},{"termName":"HPK56","termGroup":"CN","termSource":"NCI"},{"termName":"MP470","termGroup":"CN","termSource":"NCI"},{"termName":"Receptor Tyrosine Kinase Inhibitor MP470","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850879-09-3"},{"name":"Chemical_Formula","value":"C23H21N5O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SO9S6QZB4R"},{"name":"Legacy Concept Name","value":"Receptor_Tyrosine_Kinase_Inhibitor_MP470"},{"name":"Maps_To","value":"Amuvatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"559320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"559320"},{"name":"PDQ_Open_Trial_Search_ID","value":"559320"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1958331"}]}}{"C95776":{"preferredName":"Amuvatinib Hydrochloride","code":"C95776","definitions":[{"definition":"The hydrochloride salt of an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amuvatinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazinecarbothioamide, N-(1,3-Benzodioxol-5-Ylmethyl)-4-Benzofuro(3,2-D)Pyrimidin-4-Yl-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"HPK56 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"MP-470 HCI","termGroup":"SY","termSource":"NCI"},{"termName":"MP470 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"N-(1,3-Benzodioxol-5-Ylmethyl)-4-(Benzofuro(3,2-D)Pyrimidin-4-Yl)Piperazine-1- Carbothioamide Monohydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1055986-67-8"},{"name":"Chemical_Formula","value":"C23H21N5O3S.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14L8O2K12B"},{"name":"Maps_To","value":"Amuvatinib Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987416"}]}}{"C38717":{"preferredName":"Anakinra","code":"C38717","definitions":[{"definition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is used to treat rheumatoid arthritis, and is being studied in the treatment of cancer. Anakinra blocks the action of interleukin 1 (IL-1). It is a type of interleukin receptor antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anakinra","termGroup":"PT","termSource":"NCI"},{"termName":"Kineret","termGroup":"BR","termSource":"NCI"},{"termName":"rIL-1ra","termGroup":"AB","termSource":"NCI"},{"termName":"rIL1RN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Rheumatoid arthritis"},{"name":"CAS_Registry","value":"143090-92-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9013DUQ28K"},{"name":"Legacy Concept Name","value":"Anakinra"},{"name":"Maps_To","value":"Anakinra"},{"name":"NCI_Drug_Dictionary_ID","value":"43007"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43007"},{"name":"PDQ_Open_Trial_Search_ID","value":"43007"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245109"}]}}{"C1607":{"preferredName":"Anastrozole","code":"C1607","definitions":[{"definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is used to decrease estrogen production and suppress the growth of tumors that need estrogen to grow. It is a type of nonsteroidal aromatase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anastrozole","termGroup":"PT","termSource":"NCI"},{"termName":"2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"Anastrazole","termGroup":"SY","termSource":"NCI"},{"termName":"Arimidex","termGroup":"BR","termSource":"NCI"},{"termName":"ICI-D1033","termGroup":"CN","termSource":"NCI"},{"termName":"ZD-1033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hormone Receptor-Positive Early Breast cancer"},{"name":"CAS_Registry","value":"120511-73-1"},{"name":"CHEBI_ID","value":"CHEBI:2704"},{"name":"Chemical_Formula","value":"C17H19N5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2Z07MYW1AZ"},{"name":"Legacy Concept Name","value":"Anastrozole"},{"name":"Maps_To","value":"Anastrozole"},{"name":"NCI_Drug_Dictionary_ID","value":"42540"},{"name":"NSC Number","value":"719344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42540"},{"name":"PDQ_Open_Trial_Search_ID","value":"42540"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0290883"}]}}{"C950":{"preferredName":"Anaxirone","code":"C950","definitions":[{"definition":"A synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaxirone","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-triglycidylurazol","termGroup":"SN","termSource":"NCI"},{"termName":"TGU","termGroup":"AB","termSource":"NCI"},{"termName":"Triglycidylurazol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"77658-97-0"},{"name":"Chemical_Formula","value":"C11H15N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"36R61Y789T"},{"name":"Legacy Concept Name","value":"Anaxirone"},{"name":"Maps_To","value":"Anaxirone"},{"name":"NCI_Drug_Dictionary_ID","value":"39194"},{"name":"NSC Number","value":"332488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39194"},{"name":"PDQ_Open_Trial_Search_ID","value":"39194"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043767"}]}}{"C80636":{"preferredName":"Ancitabine","code":"C80636","definitions":[{"definition":"A cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine, which is converted to the active triphosphate form and competes with deoxycytidine triphosphate for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA and RNA polymerases, resulting in a decrease in cell growth. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancitabine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31698-14-3"},{"name":"Chemical_Formula","value":"C9H11N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DO2D32W0VC"},{"name":"Legacy Concept Name","value":"Ancitabine"},{"name":"Maps_To","value":"Ancitabine"},{"name":"NCI_META_CUI","value":"CL406826"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C403":{"preferredName":"Ancitabine Hydrochloride","code":"C403","definitions":[{"definition":"The hydrochloride salt of a cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine. Subsequently, cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. Cytarabine agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancitabine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"6H-furo(2',3':4,5)oxazolo(3,2-a)pyrimidine-2-methanol,2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-,(2R(2alpha,3beta,3a beta,9a beta))","termGroup":"SN","termSource":"NCI"},{"termName":"Ancid","termGroup":"FB","termSource":"NCI"},{"termName":"Ancytabine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"CycloCMP Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclocytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclocytidine HCL","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclocytidine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"U-33, 624A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10212-25-6"},{"name":"Chemical_Formula","value":"C9H11N3O4.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3T6920M469"},{"name":"Legacy Concept Name","value":"Ancitabine_Hydrochloride"},{"name":"Maps_To","value":"Ancitabine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39199"},{"name":"NSC Number","value":"145668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39199"},{"name":"PDQ_Open_Trial_Search_ID","value":"39199"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010557"}]}}{"C98290":{"preferredName":"Androgen Antagonist APC-100","code":"C98290","definitions":[{"definition":"An orally available, vitamin E derivative and androgen receptor (AR) antagonist with potential anti-oxidant, chemopreventative and antineoplastic activity. APC-100 binds to ARs in target tissues thereby inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. By inhibiting the formation of the complex between androgen activated AR- and the AP1 transcription factor JunD, the expression of androgen-responsive genes are blocked. One of such gene is spermidine/spermine N1-acetyl transferase gene (SSAT) that is responsible for the breakdown of polyamines, which are produced in high levels by prostatic epithelial cells, into reactive oxygen species (ROS) that cause cellular damage. APC-100 may ultimately lead to an inhibition of growth in both AR-dependent and AR-independent prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Antagonist APC-100","termGroup":"PT","termSource":"NCI"},{"termName":"APC-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"950-99-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7G73627R36"},{"name":"Maps_To","value":"Androgen Antagonist APC-100"},{"name":"NCI_Drug_Dictionary_ID","value":"712831"},{"name":"NCI_META_CUI","value":"CL432408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712831"},{"name":"PDQ_Open_Trial_Search_ID","value":"712831"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148520":{"preferredName":"Androgen Receptor Antagonist BAY 1161116","code":"C148520","definitions":[{"definition":"An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist BAY 1161116 specifically binds to AR, inhibits AR activation, and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antagonist BAY 1161116","termGroup":"PT","termSource":"NCI"},{"termName":"AR Antagonist BAY 1161116","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1161116","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1161116","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1161116","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Antagonist BAY 1161116"},{"name":"NCI_Drug_Dictionary_ID","value":"792679"},{"name":"NCI_META_CUI","value":"CL551148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792679"},{"name":"PDQ_Open_Trial_Search_ID","value":"792679"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175852":{"preferredName":"Rezvilutamide","code":"C175852","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, rezvilutamide competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells. ARs are overexpressed in prostate cancer and play a key role in prostate cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rezvilutamide","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Antagonist SHR3680","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 3680","termGroup":"CN","termSource":"NCI"},{"termName":"SHR3680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1572045-62-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"70FJN2AW22"},{"name":"Maps_To","value":"Androgen Receptor Antagonist SHR3680"},{"name":"NCI_Drug_Dictionary_ID","value":"779621"},{"name":"NCI_META_CUI","value":"CL1413047"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137818":{"preferredName":"Androgen Receptor Antagonist TAS3681","code":"C137818","definitions":[{"definition":"An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antagonist TAS3681","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Inhibitor TAS3681","termGroup":"SY","termSource":"NCI"},{"termName":"AR Antagonist TAS3681","termGroup":"SY","termSource":"NCI"},{"termName":"TAS 3681","termGroup":"CN","termSource":"NCI"},{"termName":"TAS3681","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Antagonist TAS3681"},{"name":"NCI_Drug_Dictionary_ID","value":"789958"},{"name":"NCI_META_CUI","value":"CL524893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789958"},{"name":"PDQ_Open_Trial_Search_ID","value":"789958"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131874":{"preferredName":"Androgen Receptor Antagonist TRC253","code":"C131874","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antagonist TRC253","termGroup":"PT","termSource":"NCI"},{"termName":"AR Antagonist TRC253","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63576253","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63576253","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63576253","termGroup":"CN","termSource":"NCI"},{"termName":"TRC 253","termGroup":"CN","termSource":"NCI"},{"termName":"TRC-253","termGroup":"CN","termSource":"NCI"},{"termName":"TRC253","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GNG9GQ9Y27"},{"name":"Maps_To","value":"Androgen Receptor Antagonist TRC253"},{"name":"NCI_Drug_Dictionary_ID","value":"786539"},{"name":"NCI_META_CUI","value":"CL520350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786539"},{"name":"PDQ_Open_Trial_Search_ID","value":"786539"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116326":{"preferredName":"Androgen Receptor Antisense Oligonucleotide AZD5312","code":"C116326","definitions":[{"definition":"An antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon intravenous administration, AZD5312 hybridizes with AR mRNA, which blocks translation of the AR protein. This both inhibits AR-induced tumor cell growth and promotes apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antisense Oligonucleotide AZD5312","termGroup":"PT","termSource":"NCI"},{"termName":"AZD5312","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-ARRx","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-AZ1Rx","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S31QX1Q6J"},{"name":"Maps_To","value":"Androgen Receptor Antisense Oligonucleotide AZD5312"},{"name":"NCI_Drug_Dictionary_ID","value":"761561"},{"name":"NCI_META_CUI","value":"CL473660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761561"},{"name":"PDQ_Open_Trial_Search_ID","value":"761561"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96742":{"preferredName":"Androgen Receptor Antisense Oligonucleotide EZN-4176","code":"C96742","definitions":[{"definition":"A locked nucleic acid (LNA)-based antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon administration, EZN-4176 is hybridized and releases the complementary sequences of AR mRNA, thereby blocking translation of the AR protein and inhibiting AR-induced tumor cell growth and promoting tumor cell apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival. LNAs contain a methylene bridge linking 2'-oxygen and 4'-carbon of ribose sugar rings, thereby increasing their thermal stability and decreasing degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antisense Oligonucleotide EZN-4176","termGroup":"PT","termSource":"NCI"},{"termName":"EZN-4176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Antisense Oligonucleotide EZN-4176"},{"name":"NCI_Drug_Dictionary_ID","value":"699628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699628"},{"name":"PDQ_Open_Trial_Search_ID","value":"699628"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273001"}]}}{"C160788":{"preferredName":"Bavdegalutamide","code":"C160788","definitions":[{"definition":"An orally available selective androgen receptor (AR)-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Bavdegalutamide is composed of an AR ligand attached to an E3 ligase recognition moiety. Upon oral administration, bavdegalutamide targets and binds to the AR ligand binding domain. E3 ligase is recruited to the AR by the E3 ligase recognition moiety and the AR target protein is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome. This prevents the expression of AR target genes and halts AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. In addition, the degradation of the AR protein releases the ARV-110 is released and can bind to additional AR target proteins. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bavdegalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Degrader ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Receptor PROTAC Degrader ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"AR PROTAC ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"AR-targeted PROTAC Protein Degrader ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"ARV 110","termGroup":"CN","termSource":"NCI"},{"termName":"ARV-110","termGroup":"CN","termSource":"NCI"},{"termName":"ARV110","termGroup":"CN","termSource":"NCI"},{"termName":"PROTAC Degrader ARV-110","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222112-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H6NYM0V650"},{"name":"Maps_To","value":"Androgen Receptor Degrader ARV-110"},{"name":"NCI_Drug_Dictionary_ID","value":"798419"},{"name":"NCI_META_CUI","value":"CL969773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798419"},{"name":"PDQ_Open_Trial_Search_ID","value":"798419"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116726":{"preferredName":"Androgen Receptor Downregulator AZD3514","code":"C116726","definitions":[{"definition":"An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514 binds to the AR ligand binding domain and inhibits the binding of androgen, thereby preventing androgen-dependent AR signaling. AZD3514 also causes downregulation of AR expression, which further prevents AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. AR plays a key role in the proliferation of castration-resistant prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Downregulator AZD3514","termGroup":"PT","termSource":"NCI"},{"termName":"AZD3514","termGroup":"CN","termSource":"NCI"},{"termName":"SARD AZD3514","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Downregulator AZD3514"},{"name":"NCI_Drug_Dictionary_ID","value":"682100"},{"name":"NCI_Drug_Dictionary_ID","value":"810703"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682100"},{"name":"PDQ_Open_Trial_Search_ID","value":"682100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3712375"}]}}{"C121777":{"preferredName":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118","code":"C121777","definitions":[{"definition":"A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118","termGroup":"PT","termSource":"NCI"},{"termName":"AR LBD-encoding Plasmid DNA Vaccine MVI-118","termGroup":"SY","termSource":"NCI"},{"termName":"MVI-118","termGroup":"CN","termSource":"NCI"},{"termName":"pTVG-AR","termGroup":"AB","termSource":"NCI"},{"termName":"pTVG-AR Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118"},{"name":"NCI_Drug_Dictionary_ID","value":"771098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771098"},{"name":"PDQ_Open_Trial_Search_ID","value":"771098"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053487"}]}}{"C61637":{"preferredName":"Andrographolide","code":"C61637","definitions":[{"definition":"A labdane diterpenoid that is produced by the Andrographis paniculata plant, which has a broad range of therapeutic applications including anti-inflammatory and anti-platelet aggregation activities and potential antineoplastic properties. Since andrographolide has multiple therapeutic activities there are several proposed mechanisms of action for this agent. The anti-inflammatory effects of this agent appear to be related to the inhibition of nitric oxide (NO) production by macrophages. This agent may activate the NO/cyclic GMP pathway and inhibit both the phospholipase C gamma 2 (PLC gamma2)/protein kinase C (PKC) and PI3K/AKT-MAPK signaling pathways in activated platelets to inhibit platelet aggregation. In activated platelets, these three signaling pathways are downstream of integrin activation mediated by collagen binding and influence the association of fibrinogen with its receptors. Additionally, andrographolide may exert its anti-cancer activity through the induction of cell cycle arrest at G0/G1 phase and the stimulation of lymphocyte proliferation and activation. These processes could result in decreased proliferation of and increased immunocytotoxicity against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Andrographolide","termGroup":"PT","termSource":"NCI"},{"termName":"(1R-(1-alpha(E(S)),4a-beta,5alpha,6alpha,8a-alpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone","termGroup":"SY","termSource":"NCI"},{"termName":"(3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one","termGroup":"SY","termSource":"NCI"},{"termName":"(3E,4S)-4-hydroxy-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]ethylidene}dihydrofuran-2(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"2(3H)-Furanone, 3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-, (1R-(1-alpha(E(S*)),4a-beta,5-alpha,6-alpha,8a-alpha))-","termGroup":"SN","termSource":"NCI"},{"termName":"3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone","termGroup":"SY","termSource":"NCI"},{"termName":"Andrographis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5508-58-7"},{"name":"CHEBI_ID","value":"CHEBI:65408"},{"name":"Chemical_Formula","value":"C20H30O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"410105JHGR"},{"name":"Legacy Concept Name","value":"Andrographolide"},{"name":"Maps_To","value":"Andrographolide"},{"name":"NCI_Drug_Dictionary_ID","value":"755596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755596"},{"name":"PDQ_Open_Trial_Search_ID","value":"755596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051821"}]}}{"C78831":{"preferredName":"Androstane Steroid HE3235","code":"C78831","definitions":[{"definition":"An orally bioavailable adrenal steroid analogue with potential antineoplastic activity. Androstane steroid HE3235 appears to bind the androgen receptor (AR), down-regulating anti-apoptotic genes, such as Bcl-2, while increasing the expression of pro-apoptotic genes, such as caspases. In vitro and in vivo studies indicate that this agent inhibits androstenediol-dependent LNCaP cell tumor growth. In addition, HE3235 may potentiate chemotherapeutic agents by down-regulating ABCG2, the gene encoding the multi-drug resistant (MDR) protein MDR2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androstane Steroid HE3235","termGroup":"PT","termSource":"NCI"},{"termName":"17Alpha-ethynyl-5alpha-androstane-3alpha, 17Beta-diol","termGroup":"SN","termSource":"NCI"},{"termName":"APOPTONE","termGroup":"BR","termSource":"NCI"},{"termName":"HE3235","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183387-50-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"891O182ZP5"},{"name":"Legacy Concept Name","value":"Adrenal_Steroid_Analogue_HE3235"},{"name":"Maps_To","value":"Androstane Steroid HE3235"},{"name":"NCI_Drug_Dictionary_ID","value":"601983"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601983"},{"name":"PDQ_Open_Trial_Search_ID","value":"601983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2715313"}]}}{"C98293":{"preferredName":"Anetumab Ravtansine","code":"C98293","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of anetumab ravtansine targets and binds to the tumor associated antigen mesothelin; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anetumab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 94-9343","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1375258-01-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M170940PMI"},{"name":"Maps_To","value":"Anetumab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"712853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712853"},{"name":"PDQ_Open_Trial_Search_ID","value":"712853"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045305"}]}}{"C88301":{"preferredName":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241","code":"C88301","definitions":[{"definition":"A fusion protein containing angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF) derived peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic aldolase monoclonal antibody, with potential antiangiogenic and antineoplastic activities. The Ang2/VEGF peptide moieties of Ang2/VEGF-binding peptides-antibody fusion protein CVX-241 bind to Ang2 and VEGF receptors, which may inhibit tumor angiogenesis and tumor cell proliferation. The proprietary humanized catalytic IgG1 monoclonal aldolase antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the Ang2 and VEGFR peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. This agent possesses an enhanced half-life compared to the naked peptides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241","termGroup":"PT","termSource":"NCI"},{"termName":"CVX-241","termGroup":"CN","termSource":"NCI"},{"termName":"PF-05057459","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415642-63-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3RM68C5CTG"},{"name":"Maps_To","value":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241"},{"name":"NCI_Drug_Dictionary_ID","value":"659158"},{"name":"NCI_META_CUI","value":"CL413555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659158"},{"name":"PDQ_Open_Trial_Search_ID","value":"659158"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71539":{"preferredName":"Ofranergene Obadenovec","code":"C71539","definitions":[{"definition":"A non-replicating adenovirus 5 (Ad-5, El-deleted) encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin-1 (PPE-1) promoter, with potential anti-angiogenic activity. Upon the administration of ofranergene obadenovec, the modified murine PPE-1 promoter is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature.  Subsequently, the Fas-c pro-apoptotic transgene, containing the human tumor necrosis factor (TNF) receptor 1 (TNFR-1/p55) and the signaling domain of Fas, is expressed in angiogenic endothelial cells.  Fas-mediated apoptosis is activated via binding of the TNFR-1 receptor with TNF-alpha, which is more abundant in the tumor microenvironment (TME), enhancing specificity and limiting systemic toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ofranergene Obadenovec","termGroup":"PT","termSource":"NCI"},{"termName":"GT-111","termGroup":"CN","termSource":"NCI"},{"termName":"VB-111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1476737-24-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Q5PRH05GI"},{"name":"Legacy Concept Name","value":"GT-111"},{"name":"Maps_To","value":"Angiogenesis Inhibitor GT-111"},{"name":"Maps_To","value":"Ofranergene Obadenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"580988"},{"name":"NCI_META_CUI","value":"CL378317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580988"},{"name":"PDQ_Open_Trial_Search_ID","value":"580988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82413":{"preferredName":"Angiogenesis Inhibitor JI-101","code":"C82413","definitions":[{"definition":"An orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Angiogenesis inhibitor JI-101 binds to and inhibits VEGFR2, PDGFRb and EphB4, which may inhibit tumor angiogenesis and, so, cellular proliferation in tumor cells overexpressing VEGFR2, PDGFRb and EphB4. The receptor tyrosine kinases VEGFR2, PDGFRb and EphB4 may be overexpressed in a number of different cancer cell types and may play crucial roles in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiogenesis Inhibitor JI-101","termGroup":"PT","termSource":"NCI"},{"termName":"JI-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"900573-88-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"980M4N37DH"},{"name":"Legacy Concept Name","value":"Oral_Angiogenesis_Inhibitor_JI-101"},{"name":"Maps_To","value":"Angiogenesis Inhibitor JI-101"},{"name":"NCI_Drug_Dictionary_ID","value":"637113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637113"},{"name":"PDQ_Open_Trial_Search_ID","value":"637113"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830086"}]}}{"C95202":{"preferredName":"Pixatimod","code":"C95202","definitions":[{"definition":"A synthetic sugar modified heparan sulfate mimetic and agonist of toll-like receptor 9 (TLR9), with potential immunostimulating, antineoplastic and anti-viral activities. Upon administration, pixatimod binds to and activates TLR9 expressed by dendritic cells (DCs) and B-cells. This initiates cytokine release from DCs and activates innate immune signaling pathways, and leads to the activation of natural killer (NK) cells to destroy tumor cells. The combination of pixatimod with certain checkpoint inhibitors may enhance the activation of cytotoxic T-lymphocytes to further kill tumor cells. In addition, pixatimod inhibits the cleavage of heparan sulfate from cell surface proteoglycan by heparanase (HPSE) and inhibits the infiltration of tumor-associated macrophages (TAMs). TLR9, a member of the TLR family, plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pixatimod","termGroup":"PT","termSource":"NCI"},{"termName":"PG545","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1144617-49-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"66QR34C83N"},{"name":"Maps_To","value":"Angiogenesis/Heparanase Inhibitor PG545"},{"name":"Maps_To","value":"Pixatimod"},{"name":"NCI_Drug_Dictionary_ID","value":"690742"},{"name":"NCI_META_CUI","value":"CL426692"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690742"},{"name":"PDQ_Open_Trial_Search_ID","value":"690742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116625":{"preferredName":"Angiopoietin-2-specific Fusion Protein PF-04856884","code":"C116625","definitions":[{"definition":"A humanized monoclonal antibody fused to two peptides that bind to angiopoietin 2 (Ang2; ANGPT2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous administration, Ang2-targeting PF-04856884 CovX body specifically binds to Ang2 and prevents the binding of Ang2 to its receptor Tie2 expressed on endothelial cells. This inhibits Tie2-mediated signaling, prevents angiogenesis and inhibits tumor cell proliferation.  Ang2, a proangiogenic cytokine and ligand for the Tie2 receptor, plays a key role in the regulation of tumor angiogenesis and tumor cell proliferation; its expression is upregulated by tumor endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiopoietin-2-specific Fusion Protein PF-04856884","termGroup":"PT","termSource":"NCI"},{"termName":"CVX-060","termGroup":"CN","termSource":"NCI"},{"termName":"PF-04856884","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415649-10-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78LXD26OX3"},{"name":"Maps_To","value":"Angiopoietin-2-specific Fusion Protein PF-04856884"},{"name":"NCI_Drug_Dictionary_ID","value":"687982"},{"name":"NCI_META_CUI","value":"CL433732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687982"},{"name":"PDQ_Open_Trial_Search_ID","value":"687982"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2526":{"preferredName":"Anhydrovinblastine","code":"C2526","definitions":[{"definition":"A semisynthetic derivative of the vinca alkaloid vinblastine, with potential antineoplastic activity. Like vinblastine, anhydrovinblastine targets and binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and causing tumor cell cycle arrest in the M phase.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anhydrovinblastine","termGroup":"PT","termSource":"NCI"},{"termName":"AVLB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38390-45-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5B622U08B3"},{"name":"Legacy Concept Name","value":"Anhydrovinblastine"},{"name":"Maps_To","value":"Anhydrovinblastine"},{"name":"NCI_Drug_Dictionary_ID","value":"43460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43460"},{"name":"PDQ_Open_Trial_Search_ID","value":"43460"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796616"}]}}{"C249":{"preferredName":"Aniline Mustard","code":"C249","definitions":[{"definition":"An alkylating mustard with antineoplastic activity. Aniline mustard forms covalent linkages with nucleophilic centers, resulting in depurination, base miscoding and strand scission, and crosslinking of DNA strands, all of which contribute to its cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aniline Mustard","termGroup":"PT","termSource":"NCI"},{"termName":"A 14489","termGroup":"CN","termSource":"NCI"},{"termName":"Benzenamine, N, N-bis(2-chloroethyl)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"beta, beta'-dichlorodiethylaniline","termGroup":"SN","termSource":"NCI"},{"termName":"CB 1074","termGroup":"CN","termSource":"NCI"},{"termName":"Lymphochin","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocin","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoquin","termGroup":"SY","termSource":"NCI"},{"termName":"mesylerythrol","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)aniline","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)benzenamine","termGroup":"SN","termSource":"NCI"},{"termName":"phenylbis[2-chloroethylamine]","termGroup":"SN","termSource":"NCI"},{"termName":"SK 592","termGroup":"CN","termSource":"NCI"},{"termName":"TL 476","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"553-27-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CUJ6745Z9J"},{"name":"Legacy Concept Name","value":"Aniline_Mustard"},{"name":"Maps_To","value":"Aniline Mustard"},{"name":"NCI_Drug_Dictionary_ID","value":"39146"},{"name":"NSC Number","value":"18429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39146"},{"name":"PDQ_Open_Trial_Search_ID","value":"39146"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1142666"}]}}{"C106428":{"preferredName":"Catequentinib Hydrochloride","code":"C106428","definitions":[{"definition":"The hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Catequentinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"ALTN HCl","termGroup":"AB","termSource":"NCI"},{"termName":"Anlotinib Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1360460-82-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A3749M6582"},{"name":"Maps_To","value":"Anlotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"749736"},{"name":"NCI_META_CUI","value":"CL447782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749736"},{"name":"PDQ_Open_Trial_Search_ID","value":"749736"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2632":{"preferredName":"Annamycin","code":"C2632","definitions":[{"definition":"A lipophilic, anthracycline antineoplastic antibiotic. Annamycin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as inhibiting RNA and protein synthesis.  This agent appears to not be a substrate for the p-glycoprotein associated multidrug-resistance (MDR) transporter; therefore, overcoming the resistance pattern seen with other anthracycline compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annamycin","termGroup":"PT","termSource":"NCI"},{"termName":"2'-iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-l-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92689-49-1"},{"name":"Chemical_Formula","value":"C26H25IO11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SNU299M83Q"},{"name":"Legacy Concept Name","value":"Annamycin"},{"name":"Maps_To","value":"Annamycin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0214529"}]}}{"C25838":{"preferredName":"Annamycin Liposomal","code":"C25838","definitions":[{"definition":"A liposome-encapsulated form of the semi-synthetic doxorubicin analogue annamycin with antineoplastic activity. Annamycin intercalates into DNA and inhibits topoisomerase II, resulting in the inhibition of DNA replication and repair and RNA and protein synthesis. This agent circumvents multidrug-resistance (MDR) transporters, including P-glycoprotein (P-gp). Liposomal annamycin is less toxic and shows improved antitumor activity compared to annamycin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annamycin Liposomal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Annamycin_Liposomal"},{"name":"Maps_To","value":"Annamycin Liposomal"},{"name":"NCI_Drug_Dictionary_ID","value":"38230"},{"name":"NSC Number","value":"700363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38230"},{"name":"PDQ_Open_Trial_Search_ID","value":"38230"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0935796"}]}}{"C118972":{"preferredName":"Annonaceous Acetogenins","code":"C118972","definitions":[{"definition":"A family of naturally occurring polyketides that consist of C32 or C34 long chain fatty acids and combined with a propan-2-ol unit at C-2 to form a gamma-lactone, which are isolated from various species of the plant family Annonaceae, with potential antineoplastic and antimicrobial activity. Annonaceous acetogenins bind to the ubiquinone catalytic site(s) within the mitochondrial NADH:ubiquinone oxidoreductase (complex I), and block the electron transport chain in mitochondria. In addition, the acetogenins bind to and block the activity of ubiquinone-linked NADH oxidase, an enzyme overexpressed in the plasma membranes of cancer cells. This inhibits adenosine triphosphate (ATP) production, decreases intracellular ATP levels, and induces tumor cell apoptosis. Compared to normal cells, cancer cells have higher ATP demands. The Annonaceous acetogenins also inhibit microbial glucose dehydrogenase 6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annonaceous Acetogenins","termGroup":"PT","termSource":"NCI"},{"termName":"Acetogenins","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Annonaceous Acetogenins"},{"name":"NCI_Drug_Dictionary_ID","value":"766482"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766482"},{"name":"PDQ_Open_Trial_Search_ID","value":"766482"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1955902"}]}}{"C97710":{"preferredName":"Ansamitomicin P-3","code":"C97710","definitions":[{"definition":"An ansamacrolide and maytansine analogue originally isolated from the Ethiopian shrub Maytenus serrata with antineoplastic activity. Ansamitomicin P-3 binds to tubulin at the maytansine-binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ansamitomicin P-3","termGroup":"PT","termSource":"NCI"},{"termName":"Maytansine, 3-o-de(2-(acetylmethylamino)-1-oxopropyl)-3-o-(1-oxobutyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66547-09-9"},{"name":"Chemical_Formula","value":"C32H43ClN2O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7SUK7876BG"},{"name":"Maps_To","value":"Ansamitomicin P-3"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0952781"}]}}{"C252":{"preferredName":"Anthramycin","code":"C252","definitions":[{"definition":"A pyrrolo(1,4)benzodiazepine antineoplastic antibiotic isolated from the bacterium Streptomyces refuineus var. thermotolerans.  Anthramycin binds covalently to guanine in the minor groove of DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anthramycin","termGroup":"PT","termSource":"NCI"},{"termName":"3-(5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-1h-pyrrolo(2,1-c)(1,4)benzodiazepin-2-yl)-2-propenamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4803-27-4"},{"name":"Chemical_Formula","value":"C16H17N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0WZD9Y66WN"},{"name":"Legacy Concept Name","value":"Anthramycin"},{"name":"Maps_To","value":"Anthramycin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0003167"}]}}{"C2706":{"preferredName":"Anthrapyrazole","code":"C2706","definitions":[{"definition":"An antineoplastic antibiotic that intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Anthrapyrazoles may also block cell cycle division.  In the presence of electron donors, some anthrapyrazole antibiotics cause single-strand breaks in DNA via photosensitization by visible light.  These agents are less cardiotoxic than doxorubicin. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anthrapyrazole","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra[1, 9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-acetate (salt) hydrobromide(10:5:21)","termGroup":"SN","termSource":"NCI"},{"termName":"Anthra[1,9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-, acetate (salt) hydrobromide(10:5:21)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91440-30-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anthrapyrazole"},{"name":"Maps_To","value":"Anthrapyrazole"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051960"}]}}{"C117735":{"preferredName":"Anti c-KIT Antibody-drug Conjugate LOP628","code":"C117735","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) and conjugated, via a non-cleavable linker, to the cytotoxic agent maytansine, with potential antineoplastic activity. The monoclonal antibody moiety of anti c-KIT ADC LOP628 targets and binds to the cell surface antigen c-Kit. After antibody-antigen interaction followed by internalization, the maytansine moiety binds to tubulin, inhibits microtubule assembly, and induces microtubule disassembly. This leads to a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing c-Kit. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti c-KIT Antibody-drug Conjugate LOP628","termGroup":"PT","termSource":"NCI"},{"termName":"Anti c-KIT ADC LOP628","termGroup":"SY","termSource":"NCI"},{"termName":"LOP628","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti c-KIT Antibody-drug Conjugate LOP628"},{"name":"NCI_Drug_Dictionary_ID","value":"764075"},{"name":"NCI_META_CUI","value":"CL474131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764075"},{"name":"PDQ_Open_Trial_Search_ID","value":"764075"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107388":{"preferredName":"Anti-5T4 Antibody-Drug Conjugate PF-06263507","code":"C107388","definitions":[{"definition":"An antibody-drug conjugate composed of an antibody directed against 5T4 and conjugated, via the stable linker maleimidocaproyl (mc), to the microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration, the antibody moiety of PF-06263507 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-5T4 Antibody-Drug Conjugate PF-06263507","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06263507","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7U0JSO7FH"},{"name":"Maps_To","value":"Anti-5T4 Antibody-Drug Conjugate PF-06263507"},{"name":"NCI_Drug_Dictionary_ID","value":"751006"},{"name":"NCI_META_CUI","value":"CL449599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751006"},{"name":"PDQ_Open_Trial_Search_ID","value":"751006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90583":{"preferredName":"Anti-A33 Monoclonal Antibody KRN330","code":"C90583","definitions":[{"definition":"A recombinant fully human monoclonal antibody directed against the human A33 antigen, with potential immunomodulatory and antineoplastic activity. Anti-A33 monoclonal antibody KRN330 recognizes and binds to the human A33 antigen, which may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against A33-positive colorectal cancers. A33 antigen, a 43 kDa transmembrane glycoprotein of the immunoglobulin superfamily, is highly and homogenously expressed in 95% of colorectal cancer cancers with only restricted expression in normal colonic mucosa and small bowel epithelia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-A33 Monoclonal Antibody KRN330","termGroup":"PT","termSource":"NCI"},{"termName":"KRN330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A64J777I28"},{"name":"Maps_To","value":"Anti-A33 Monoclonal Antibody KRN330"},{"name":"NCI_Drug_Dictionary_ID","value":"584603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"584603"},{"name":"PDQ_Open_Trial_Search_ID","value":"584603"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983782"}]}}{"C85478":{"preferredName":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412","code":"C85478","definitions":[{"definition":"A monoclonal antibody directed against the human alpha5beta1 integrin with potential antiangiogenic and antineoplastic activities. Anti-alpha5beta1 integrin monoclonal antibody PF-04605412 selectively binds to alpha5beta1 integrin, preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alpha5beta1-expressing tumor cells. Alpha5beta1 integrin, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-alpha5beta1 Integrin Monoclonal Antibody PF-04605412","termGroup":"SY","termSource":"NCI"},{"termName":"PF-04605412","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CFN88ESH2J"},{"name":"Maps_To","value":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412"},{"name":"NCI_Drug_Dictionary_ID","value":"647821"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647821"},{"name":"PDQ_Open_Trial_Search_ID","value":"647821"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830142"}]}}{"C129715":{"preferredName":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087","code":"C129715","definitions":[{"definition":"Autologous T-lymphocytes that are genetically modified and transfected with a viral vector expressing the ACTR gene, a proprietary gene encoding for an antibody-coupled T-cell receptor (ATCR), with potential antineoplastic activity. The ACTR contains the extracellular Fc receptor CD16 domain, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-immunostimulatory signaling domain 4-1BB, normally expressed on T-cells, and linked to the intracellular CD3 zeta domain (CD3z), which is needed for TCR signaling. Upon reintroduction into the patient and co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, this induces the activation of the ACTR087 cells and destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; b) targeting and killing adjacent tumor cells that are not bound to the antibody; c) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it enhances the survival and persistence of T-lymphocytes. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087","termGroup":"PT","termSource":"NCI"},{"termName":"ACTR-087","termGroup":"CN","termSource":"NCI"},{"termName":"ACTR087","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-ACTR Viral Vector-transduced Autologous T-lymphocytes ACTR087","termGroup":"SY","termSource":"NCI"},{"termName":"CD16-41BB-CD3zeta ACTR Autologous T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Virally-delivered Antibody-coupled TCR ACTR087","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087"},{"name":"NCI_Drug_Dictionary_ID","value":"784523"},{"name":"NCI_META_CUI","value":"CL512898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784523"},{"name":"PDQ_Open_Trial_Search_ID","value":"784523"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133818":{"preferredName":"Anti-AG7 Antibody Drug Conjugate AbGn-107","code":"C133818","definitions":[{"definition":"An antibody drug conjugate (ADC) composed of a monoclonal antibody that targets the tumor-associated antigen (TAA) AG7 and is linked, through a hydrophilic, self-immolative linker, to a proprietary cytotoxic payload, with potential antineoplastic activity. Upon administration of AbGn-107 the antibody moiety targets and binds to the AG7 antigen expressed on a variety of cancer cells. Upon binding and internalization, the linker is cleaved and the payload is released, binds to tubulin, inhibits tubulin polymerization and kills the AG7-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AG7 Antibody Drug Conjugate AbGn-107","termGroup":"PT","termSource":"NCI"},{"termName":"Ab1-18Hr1","termGroup":"CN","termSource":"NCI"},{"termName":"AbGn-107","termGroup":"CN","termSource":"NCI"},{"termName":"AbGn107","termGroup":"CN","termSource":"NCI"},{"termName":"ADC AbGn-107","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-AG7 ADC AbGn-107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-AG7 Antibody Drug Conjugate AbGn-107"},{"name":"NCI_Drug_Dictionary_ID","value":"789018"},{"name":"NCI_META_CUI","value":"CL521740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789018"},{"name":"PDQ_Open_Trial_Search_ID","value":"789018"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82685":{"preferredName":"Anti-AGS-16 Monoclonal Antibody AGS-16M18","code":"C82685","definitions":[{"definition":"A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-16 with potential antineoplastic activity. Anti-AGS-16 monoclonal antibody AGS-16M18 selectively binds to AGS-16, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells expressing AGS-16. While normally expressed at low levels in the proximal tubules of the kidney, AGS-16 has been found to be overexpressed in more than 95% of kidney and 40% of liver neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AGS-16 Monoclonal Antibody AGS-16M18","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-16M18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-AGS-16_Monoclonal_Antibody_AGS-16M18"},{"name":"Maps_To","value":"Anti-AGS-16 Monoclonal Antibody AGS-16M18"},{"name":"NCI_Drug_Dictionary_ID","value":"633313"},{"name":"NCI_META_CUI","value":"CL388472"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633313"},{"name":"PDQ_Open_Trial_Search_ID","value":"633313"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C92590":{"preferredName":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME","code":"C92590","definitions":[{"definition":"An antibody drug conjugate (ADC) containing the fully human IgG2k monoclonal antibody targeting an epitope of SLC44A4 (AGS-5) linked, via a valine-citrulline (vc) maleimidocaproyl (mc) linker, to the antimicrotubulin drug monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of ASG-5ME selectively binds to AGS-5. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. SLC44A4, potentially a sodium-dependent transmembrane transport protein, is overexpressed on more than 80 percent of samples derived from patients with pancreatic, prostate and gastric cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME","termGroup":"PT","termSource":"NCI"},{"termName":"ASG-5ME","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME"},{"name":"NCI_Drug_Dictionary_ID","value":"682506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682506"},{"name":"PDQ_Open_Trial_Search_ID","value":"682506"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3696055"}]}}{"C82686":{"preferredName":"Anti-AGS-8 Monoclonal Antibody AGS-8M4","code":"C82686","definitions":[{"definition":"A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-8 with potential antineoplastic activity. Anti-AGS-8 monoclonal antibody AGS-8M4 selectively binds to AGS-8, triggering complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in tumor cells expressing AGS-8. While normally expressed at low levels in the heart in response to ischemia, AGS-8 has been found to be expressed in more than 70% of ovarian neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AGS-8 Monoclonal Antibody AGS-8M4","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-8M4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-AGS-8_Monoclonal_Antibody_AGS-8M4"},{"name":"Maps_To","value":"Anti-AGS-8 Monoclonal Antibody AGS-8M4"},{"name":"NCI_Drug_Dictionary_ID","value":"633505"},{"name":"NCI_META_CUI","value":"CL388473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633505"},{"name":"PDQ_Open_Trial_Search_ID","value":"633505"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C164668":{"preferredName":"Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383","code":"C164668","definitions":[{"definition":"A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities.  Upon administration, anti-BCMA/anti-CD3 T-cell engaging bispecific antibody ABBV-383 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to low-activating CD3 preferentially activates effector over regulatory T-cells and stimulates minimum cytokine release.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 383","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-383","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV383","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA x aCD3 T-BsAb TNB-383B","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA x aCD3 T-cell Engaging Bispecific Antibody TNB-383B","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA x CD3 T-cell Engaging Bispecific Antibody ABBV-383","termGroup":"SY","termSource":"NCI"},{"termName":"TNB 383B","termGroup":"CN","termSource":"NCI"},{"termName":"TNB-383B","termGroup":"CN","termSource":"NCI"},{"termName":"TNB383B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B"},{"name":"NCI_Drug_Dictionary_ID","value":"799707"},{"name":"NCI_META_CUI","value":"CL977826"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799707"},{"name":"PDQ_Open_Trial_Search_ID","value":"799707"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116865":{"preferredName":"Anti-alpha5beta1 Integrin Antibody MINT1526A","code":"C116865","definitions":[{"definition":"An antibody directed against the human alpha5beta1 integrin (a5b1) with potential antiangiogenic and antineoplastic activities. Anti-a5b1 antibody MINT1526A selectively binds to a5b1, thereby preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in a5b1-expressing tumor cells. a5b1, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in both endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-alpha5beta1 Integrin Antibody MINT1526A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-a5b1 Antibody MINT1526A","termGroup":"SY","termSource":"NCI"},{"termName":"MINT1526A","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7594","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H6BAM62K4Q"},{"name":"Maps_To","value":"Anti-alpha5beta1 Integrin Antibody MINT1526A"},{"name":"NCI_Drug_Dictionary_ID","value":"675425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675425"},{"name":"PDQ_Open_Trial_Search_ID","value":"675425"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053617"}]}}{"C95704":{"preferredName":"Anti-ANG2 Monoclonal Antibody MEDI-3617","code":"C95704","definitions":[{"definition":"A fully human IgG1 monoclonal antibody against angiopoietin 2 (ANG2), with potential antiangiogenic activity. Anti-ANG2 monoclonal antibody MEDI-3617 binds to Ang2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), thereby resulting in the disruption of vascular remodeling. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ANG2 Monoclonal Antibody MEDI-3617","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ANG2 MoAb MEDI-3617","termGroup":"AB","termSource":"NCI"},{"termName":"MEDI-3617","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415642-51-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6RH6DL8R4L"},{"name":"Maps_To","value":"Anti-ANG2 Monoclonal Antibody MEDI-3617"},{"name":"NCI_Drug_Dictionary_ID","value":"690474"},{"name":"NCI_META_CUI","value":"CL428170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690474"},{"name":"PDQ_Open_Trial_Search_ID","value":"690474"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116627":{"preferredName":"Anti-angiopoietin Monoclonal Antibody AMG 780","code":"C116627","definitions":[{"definition":"An immunoglobulin (Ig) G2 monoclonal antibody targeting the proangiogenic cytokines angiopoietin 1 (Ang1) and 2 (Ang2), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-angiopoietin monoclonal antibody AMG 780 binds to Ang1 and Ang2. This prevents the binding of the angiopoietin ligands to their receptor Tie2 (TEK), an endothelial cell-specific receptor tyrosine kinase. This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-angiopoietin Monoclonal Antibody AMG 780","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 780","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2473627-81-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C55H82K3JJ"},{"name":"Maps_To","value":"Anti-angiopoietin Monoclonal Antibody AMG 780"},{"name":"NCI_Drug_Dictionary_ID","value":"675243"},{"name":"NCI_META_CUI","value":"CL421599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675243"},{"name":"PDQ_Open_Trial_Search_ID","value":"675243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142822":{"preferredName":"Zigakibart","code":"C142822","definitions":[{"definition":"A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, zigakibart binds to APRIL and inhibits its binding to both of its receptors, B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and transmembrane activator and CAML Interactor (TACI; tumor necrosis factor receptor superfamily member 13B; TNFRSF13B). This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, zigakibart may reduce APRIL-induced drug resistance which occurs in some tumors. APRIL, an extracellular protein and member of the tumor necrosis factor ligand superfamily (TNFSF), is expressed by bone marrow plasma cells and myeloid cells, and overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and colorectal carcinoma. APRIL induces immune suppression and tumor progression through the activation of BCMA- and TACI-dependent signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zigakibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody BION-1301","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-APRIL Monoclonal Antibody BION-1301","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TNFSF13 Monoclonal Antibody BION-1301","termGroup":"SY","termSource":"NCI"},{"termName":"BION-1301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2642175-46-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WM18Z62RTI"},{"name":"Maps_To","value":"Anti-APRIL Monoclonal Antibody BION-1301"},{"name":"NCI_Drug_Dictionary_ID","value":"791698"},{"name":"NCI_META_CUI","value":"CL540711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791698"},{"name":"PDQ_Open_Trial_Search_ID","value":"791698"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156017":{"preferredName":"Batiraxcept","code":"C156017","definitions":[{"definition":"A soluble fusion protein comprised of the extracellular domain of the receptor tyrosine kinase (RTK) AXL (UFO) fused to a human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic activity. Upon administration, batiraxcept selectively binds to growth arrest-specific protein 6 (GAS6), the endogenous ligand for AXL. This may inhibit GAS6/AXL-mediated signaling, which plays a key role in tumor cell proliferation, survival, invasion and metastasis, as well as immune evasion and resistance to other anticancer agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of RTKs, is overexpressed by many tumor cell types and its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Batiraxcept","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-AXL Fusion Protein AVB-S6-500","termGroup":"SY","termSource":"NCI"},{"termName":"AVB S6 500","termGroup":"CN","termSource":"NCI"},{"termName":"AVB-500","termGroup":"CN","termSource":"NCI"},{"termName":"AVB-S6-500","termGroup":"CN","termSource":"NCI"},{"termName":"AVBS6500","termGroup":"CN","termSource":"NCI"},{"termName":"AXL Fc Fusion Protein AVB-S6-500","termGroup":"SY","termSource":"NCI"},{"termName":"RUGA-S6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2268717-61-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6840JH4EB"},{"name":"Maps_To","value":"Anti-AXL Fusion Protein AVB-S6-500"},{"name":"NCI_Drug_Dictionary_ID","value":"795349"},{"name":"NCI_META_CUI","value":"CL562760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795349"},{"name":"PDQ_Open_Trial_Search_ID","value":"795349"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160890":{"preferredName":"Anti-AXL/PBD Antibody-drug Conjugate ADCT-601","code":"C160890","synonyms":[{"termName":"Anti-AXL/PBD Antibody-drug Conjugate ADCT-601","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Jun 15 12:19:15 EDT 2022 - See 'Mipasetamab Uzoptirine(C175823)'"},{"name":"OLD_PARENT","value":"C129823"},{"name":"OLD_PARENT","value":"C1512"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122924":{"preferredName":"Anti-B7-H3 Antibody DS-5573a","code":"C122924","definitions":[{"definition":"An antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-B7-H3 antibody DS-5573a binds to the cell surface antigen B7-H3, thereby blocking B7-H3-mediated signaling. This abrogates the inhibitory effect on T-cell activation and may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-B7-H3 Antibody DS-5573a","termGroup":"PT","termSource":"NCI"},{"termName":"DS-5573a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-B7-H3 Antibody DS-5573a"},{"name":"NCI_Drug_Dictionary_ID","value":"763154"},{"name":"NCI_META_CUI","value":"CL474104"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763154"},{"name":"PDQ_Open_Trial_Search_ID","value":"763154"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155967":{"preferredName":"Alsevalimab","code":"C155967","definitions":[{"definition":"A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alsevalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B7-H4 Monoclonal Antibody FPA150","termGroup":"SY","termSource":"NCI"},{"termName":"FPA 150","termGroup":"CN","termSource":"NCI"},{"termName":"FPA-150","termGroup":"CN","termSource":"NCI"},{"termName":"FPA150","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254029-91-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U8LYN0Y118"},{"name":"Maps_To","value":"Alsevalimab"},{"name":"Maps_To","value":"Anti-B7-H4 Monoclonal Antibody FPA150"},{"name":"NCI_Drug_Dictionary_ID","value":"795105"},{"name":"NCI_META_CUI","value":"CL562720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795105"},{"name":"PDQ_Open_Trial_Search_ID","value":"795105"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159495":{"preferredName":"Vobramitamab Duocarmazine","code":"C159495","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of vobamitamab, an anti-B7-homolog 3 (B7-H3, CD276) humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody, conjugated to the cleavable linker-duocarmycin payload duocarmazine (valine-citrulline-seco duocarmycin hydroxybenzamide azaindole; vc-seco-DUBA), with potential antineoplastic activity. Upon administration of vobramitamab duocarmazine, vobramitamab specifically targets and binds to the cell surface antigen B7-H3, leading to internalization of the ADC by B7-H3-expressing tumor cells. The vc linker is cleaved inside the tumor cell by proteases, thereby releasing the duocarmycin payload. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vobramitamab Duocarmazine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B7H3 ADC","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-B7H3 Antibody-drug Conjugate MGC018","termGroup":"SY","termSource":"NCI"},{"termName":"MG-C018","termGroup":"CN","termSource":"NCI"},{"termName":"MGC 018","termGroup":"CN","termSource":"NCI"},{"termName":"MGC018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2490556-51-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ZK3D69DQJ"},{"name":"Maps_To","value":"Anti-B7H3 Antibody-drug Conjugate MGC018"},{"name":"NCI_Drug_Dictionary_ID","value":"797520"},{"name":"NCI_META_CUI","value":"CL951453"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797520"},{"name":"PDQ_Open_Trial_Search_ID","value":"797520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148176":{"preferredName":"Anti-BCMA Antibody SEA-BCMA","code":"C148176","definitions":[{"definition":"A humanized, afucosylated monoclonal antibody created using the proprietary, sugar-engineered antibody (SEA) platform and directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), with potential immunoadjuvant activity. Upon administration, the anti-BCMA antibody SEA-BCMA targets and binds to BCMA expressed on tumor cells.  When administered with antibody-coupled T-cell receptor (ACTR)-expressing T-cells, the ACTR-expressing T-cells bind, with high affinity, to the anti-BCMA antibody SEA-BCMA. This activates the ACTR T-cells and the T-cells induce specific cytotoxic T-lymphocyte (CTL)-mediated cytotoxicity toward BCMA-expressing tumor cells. BCMA, a cell surface protein and member of the tumor necrosis factor (TNF) receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA Antibody SEA-BCMA","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA Afucosylated Monoclonal Antibody SEA-BCMA","termGroup":"SY","termSource":"NCI"},{"termName":"SEA-BCMA","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2115084-53-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3C28VJ95EV"},{"name":"Maps_To","value":"Anti-BCMA Antibody SEA-BCMA"},{"name":"NCI_Drug_Dictionary_ID","value":"793894"},{"name":"NCI_META_CUI","value":"CL550772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793894"},{"name":"PDQ_Open_Trial_Search_ID","value":"793894"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162528":{"preferredName":"Anti-BCMA Antibody-drug Conjugate AMG 224","code":"C162528","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of an anti-human B-cell maturation antigen (BCMA) immunoglobulin G1 (IgG1) antibody conjugated via the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC), to the cytotoxic maytansine-derivative, DM1, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AMG 224 selectively binds to BCMA expressed on the surface of tumor cells. Upon internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of tumor cells that express BCMA. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF)and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA Antibody-drug Conjugate AMG 224","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 224","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-224","termGroup":"CN","termSource":"NCI"},{"termName":"AMG224","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y69B45U0TK"},{"name":"Maps_To","value":"Anti-BCMA Antibody-drug Conjugate AMG 224"},{"name":"NCI_META_CUI","value":"CL971104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114299":{"preferredName":"Belantamab Mafodotin","code":"C114299","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belantamab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"Belantamab Mafodotin-blmf","termGroup":"SY","termSource":"NCI"},{"termName":"Blenrep","termGroup":"BR","termSource":"NCI"},{"termName":"GSK2857916","termGroup":"CN","termSource":"NCI"},{"termName":"J6M0-mcMMAF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent."},{"name":"CAS_Registry","value":"2050232-20-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DB1041CXDG"},{"name":"Maps_To","value":"Anti-BCMA Antibody-drug Conjugate GSK2857916"},{"name":"Maps_To","value":"Belantamab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"758317"},{"name":"NCI_META_CUI","value":"CL471808"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758317"},{"name":"PDQ_Open_Trial_Search_ID","value":"758317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159652":{"preferredName":"Pacanalotamab","code":"C159652","definitions":[{"definition":"A short half-life bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pacanalotamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacanalotamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 420","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-420","termGroup":"CN","termSource":"NCI"},{"termName":"AMG420","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 BiTE AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 BiTE Antibody AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"BI 836909","termGroup":"CN","termSource":"NCI"},{"termName":"BI-836909","termGroup":"CN","termSource":"NCI"},{"termName":"BI836909","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 420","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2251756-52-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"102VUR9WQE"},{"name":"Maps_To","value":"Anti-BCMA/CD3 BiTE Antibody AMG 420"},{"name":"NCI_Drug_Dictionary_ID","value":"801291"},{"name":"NCI_META_CUI","value":"CL951538"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801291"},{"name":"PDQ_Open_Trial_Search_ID","value":"801291"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147028":{"preferredName":"Pavurutamab","code":"C147028","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pavurutamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pavurutamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 701","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-701","termGroup":"CN","termSource":"NCI"},{"termName":"AMG701","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 BiTE AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 BiTE Antibody AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 701","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2250292-39-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GLR3JG8TZU"},{"name":"Maps_To","value":"Anti-BCMA/CD3 BiTE Antibody AMG 701"},{"name":"NCI_Drug_Dictionary_ID","value":"792377"},{"name":"NCI_META_CUI","value":"CL545027"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792377"},{"name":"PDQ_Open_Trial_Search_ID","value":"792377"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158504":{"preferredName":"Linvoseltamab","code":"C158504","definitions":[{"definition":"A human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFvs): one directed again the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the CD3 antigen expressed on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linvoseltamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 BiTE REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 BiTE Antibody REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific BCMA x CD3 T-cell Engaging Antibody REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5458","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5458","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5458","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2408319-25-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M3CPC50MZS"},{"name":"Maps_To","value":"Anti-BCMA/CD3 BiTE Antibody REGN5458"},{"name":"NCI_Drug_Dictionary_ID","value":"797141"},{"name":"NCI_META_CUI","value":"CL938057"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797141"},{"name":"PDQ_Open_Trial_Search_ID","value":"797141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C150127":{"preferredName":"Anti-BCMA/PBD ADC MEDI2228","code":"C150127","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a fully human monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) that is site-specifically conjugated, via a protease-cleavable linker, to a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-BCMA/PBD ADC MEDI2228, the antibody moiety targets the cell surface antigen BCMA expressed on certain cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA/PBD ADC MEDI2228","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA ADC MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/PBD MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 2228","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-2228","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI2228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YQ4C0NDW44"},{"name":"Maps_To","value":"Anti-BCMA/PBD ADC MEDI2228"},{"name":"NCI_Drug_Dictionary_ID","value":"795378"},{"name":"NCI_META_CUI","value":"CL551921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795378"},{"name":"PDQ_Open_Trial_Search_ID","value":"795378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98295":{"preferredName":"Anti-c-fms Monoclonal Antibody AMG 820","code":"C98295","definitions":[{"definition":"A fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (or CSFR1), with potential antineoplastic activity. Upon administration, anti-c-fms monoclonal antibody AMG 820 binds to and blocks c-fms, thereby blocking CSF-1 binding to its receptor and suppressing CSF-1-induced c-fms signaling. This results in the suppression of recruitment and activation of tumor associated macrophages (TAM) within the tumor microenvironment. This eventually leads to a decrease in tumor growth. c-fms, a transmembrane protein belonging to the tyrosine kinase family, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation and regulation of cell proliferation. The presence of TAM is correlated with tumor proliferation, invasion and a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-fms Monoclonal Antibody AMG 820","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2243120-07-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SZ3778HS3S"},{"name":"Maps_To","value":"Anti-c-fms Monoclonal Antibody AMG 820"},{"name":"NCI_Drug_Dictionary_ID","value":"713961"},{"name":"NCI_META_CUI","value":"CL432413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713961"},{"name":"PDQ_Open_Trial_Search_ID","value":"713961"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125620":{"preferredName":"Anti-c-KIT Monoclonal Antibody CDX 0158","code":"C125620","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. Upon administration, the anti-c-KIT monoclonal antibody CDX 0158 binds to and inhibits the activation of the cell surface antigen c-Kit. This leads to an inhibition of the activation of c-KIT-mediated signal transduction pathways and inhibits cell proliferation in cancer cells expressing c-Kit. In mast cells, inhibition of c-KIT and c-KIT-mediated signaling prevents mast cell activation, degranulation and subsequent cytokine release. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in various cell types, including certain cancer cells and mast cells; it plays a key role in the regulation of cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-KIT Monoclonal Antibody CDX 0158","termGroup":"PT","termSource":"NCI"},{"termName":"CDX 0158","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-0158","termGroup":"CN","termSource":"NCI"},{"termName":"CDX0158","termGroup":"CN","termSource":"NCI"},{"termName":"KTN 0158","termGroup":"CN","termSource":"NCI"},{"termName":"KTN-0158","termGroup":"CN","termSource":"NCI"},{"termName":"KTN0158","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DF2O3JG5D2"},{"name":"Maps_To","value":"Anti-c-KIT Monoclonal Antibody CDX 0158"},{"name":"NCI_Drug_Dictionary_ID","value":"777970"},{"name":"NCI_META_CUI","value":"CL504322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777970"},{"name":"PDQ_Open_Trial_Search_ID","value":"777970"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146667":{"preferredName":"Anti-c-Met Antibody-drug Conjugate HTI-1066","code":"C146667","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of HTI-1066 targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the c-Met-expressing cancer cells, through an as of yet unknown mechanism of action. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Antibody-drug Conjugate HTI-1066","termGroup":"PT","termSource":"NCI"},{"termName":"ADC HTI-1066","termGroup":"SY","termSource":"NCI"},{"termName":"HTI 1066","termGroup":"CN","termSource":"NCI"},{"termName":"HTI-1066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Antibody-drug Conjugate HTI-1066"},{"name":"NCI_Drug_Dictionary_ID","value":"792156"},{"name":"NCI_META_CUI","value":"CL544636"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792156"},{"name":"PDQ_Open_Trial_Search_ID","value":"792156"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158513":{"preferredName":"Anti-c-Met Antibody-drug Conjugate TR1801","code":"C158513","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a non-agonizing anti-c-Met humanized monoclonal antibody that is linked in a site-specific manner to a pyrrolobenzodiazepine dimer (PBD) toxin, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety targets and binds to the c-Met protein, which is overexpressed in certain tumor types. Upon antibody/antigen binding and internalization, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of tumor cell DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of c-Met-expressing cells. c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Antibody-drug Conjugate TR1801","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-c-Met ADC TR1801","termGroup":"SY","termSource":"NCI"},{"termName":"MT 8633","termGroup":"CN","termSource":"NCI"},{"termName":"MT-8633","termGroup":"CN","termSource":"NCI"},{"termName":"TR 1801","termGroup":"CN","termSource":"NCI"},{"termName":"TR-1801","termGroup":"CN","termSource":"NCI"},{"termName":"TR1801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Antibody-drug Conjugate TR1801"},{"name":"NCI_Drug_Dictionary_ID","value":"797392"},{"name":"NCI_META_CUI","value":"CL938047"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797392"},{"name":"PDQ_Open_Trial_Search_ID","value":"797392"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C106262":{"preferredName":"Telisotuzumab","code":"C106262","definitions":[{"definition":"An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telisotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-700","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-c-Met Monoclonal Antibody ABT-700","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1781223-80-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R15ZW356HN"},{"name":"Maps_To","value":"Anti-c-Met Monoclonal Antibody ABT-700"},{"name":"Maps_To","value":"Telisotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"717765"},{"name":"NCI_META_CUI","value":"CL433934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717765"},{"name":"PDQ_Open_Trial_Search_ID","value":"717765"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113802":{"preferredName":"Anti-c-Met Monoclonal Antibody ARGX-111","code":"C113802","definitions":[{"definition":"A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and blocks both ligand-dependent and -independent activation of c-Met-mediated signaling pathways. In addition, this agent enhances antibody dependent cellular cytotoxicity (ADCC). This leads to a reduction in cell proliferation of c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors. Compared to other c-Met targeting monoclonal antibodies, ARGX-111 shows increased antibody circulation time, enhanced tissue distribution and increased efficacy. ARGX-111 is obtained through active immunization with C-met antigen in Camelids and utilizes the Camelid V-domains fused with human antibody backbones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Monoclonal Antibody ARGX-111","termGroup":"PT","termSource":"NCI"},{"termName":"ARGX-111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Monoclonal Antibody ARGX-111"},{"name":"NCI_Drug_Dictionary_ID","value":"757660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757660"},{"name":"PDQ_Open_Trial_Search_ID","value":"757660"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3827162"}]}}{"C95732":{"preferredName":"Emibetuzumab","code":"C95732","definitions":[{"definition":"A humanized IgG4 monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-MET) with potential antineoplastic activity. Emibetuzumab binds to c-MET, thereby preventing the binding of HGF to its receptor c-Met and subsequent activation of the HGF/c-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emibetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-c-MET Monoclonal Antibody LY2875358","termGroup":"SY","termSource":"NCI"},{"termName":"LA-480","termGroup":"CN","termSource":"NCI"},{"termName":"LY2875358","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1365287-97-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MO4K3GDN1I"},{"name":"Maps_To","value":"Anti-c-MET Monoclonal Antibody LY2875358"},{"name":"Maps_To","value":"Emibetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"694952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694952"},{"name":"PDQ_Open_Trial_Search_ID","value":"694952"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987383"}]}}{"C119619":{"preferredName":"Anti-C-met Monoclonal Antibody SAIT301","code":"C119619","definitions":[{"definition":"A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Anti-c-Met monoclonal antibody SAIT301 binds to c-Met, thereby preventing both binding of its ligand, HGF, and the subsequent activation of the HGF/c-Met signaling pathway. In addition, SAIT301 induces c-MET internalization and subsequent degradation, which further inhibits c-Met-mediated signaling. This leads to a reduction in the proliferation of c-Met-expressing cancer cells. c-Met, a proto-oncogene receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in various tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-C-met Monoclonal Antibody SAIT301","termGroup":"PT","termSource":"NCI"},{"termName":"SAIT301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-C-met Monoclonal Antibody SAIT301"},{"name":"NCI_Drug_Dictionary_ID","value":"766799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766799"},{"name":"PDQ_Open_Trial_Search_ID","value":"766799"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3896772"}]}}{"C116070":{"preferredName":"Lupartumab Amadotin","code":"C116070","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody against a structural homolog of the urokinase-type plasminogen activator receptor (uPAR) and tumor-associated antigen, C4.4a, and conjugated with a cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, lupartumab amadotin targets and binds to C4.4a-expressing tumor cells. Upon binding and cell entry, the cytotoxic agent kills the tumor cell. C4.4a, a glycolipid-anchored membrane protein and a member of the Ly-6 family, is overexpressed by a variety of cancer cell types whereas it is minimally expressed on healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lupartumab Amadotin","termGroup":"PT","termSource":"NCI"},{"termName":"BAY112-9980","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1129980","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1640972-00-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"21970JMA97"},{"name":"Maps_To","value":"Anti-C4.4a Antibody-Drug Conjugate BAY1129980"},{"name":"Maps_To","value":"Lupartumab Amadotin"},{"name":"NCI_Drug_Dictionary_ID","value":"761118"},{"name":"NCI_META_CUI","value":"CL473489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761118"},{"name":"PDQ_Open_Trial_Search_ID","value":"761118"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163020":{"preferredName":"Avdoralimab","code":"C163020","definitions":[{"definition":"A human monoclonal antibody targeting the C5a receptor (C5aR), with potential immunomodulating activity.  Upon administration, avdoralimab specifically targets, binds to and blocks C5aR expressed on subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils. This prevents the binding of its ligand C5a to C5aR and prevents the C5aR-mediated activation and accumulation of these cells in the tumor microenvironment (TME), and abrogates the secretion of inflammatory and angiogenic factors by these cells. This results in the activation of T- and natural killer (NK) cells, the induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSCs and neutrophils in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avdoralimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-C5aR-215","termGroup":"SY","termSource":"NCI"},{"termName":"IPH 5401","termGroup":"CN","termSource":"NCI"},{"termName":"IPH-5401","termGroup":"CN","termSource":"NCI"},{"termName":"IPH5401","termGroup":"CN","termSource":"NCI"},{"termName":"NN 8210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226393-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DW4CE8MKS9"},{"name":"Maps_To","value":"Anti-C5aR Monoclonal Antibody IPH5401"},{"name":"Maps_To","value":"Avdoralimab"},{"name":"NCI_Drug_Dictionary_ID","value":"798695"},{"name":"NCI_META_CUI","value":"CL973370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798695"},{"name":"PDQ_Open_Trial_Search_ID","value":"798695"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125900":{"preferredName":"Anti-CA19-9 Monoclonal Antibody 5B1","code":"C125900","definitions":[{"definition":"A human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, monoclonal antibody 5B1 binds to CA19-9 and kills CA19-9-expressing tumor cells, possibly through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CA19-9 Monoclonal Antibody 5B1","termGroup":"PT","termSource":"NCI"},{"termName":"5B1","termGroup":"CN","termSource":"NCI"},{"termName":"HuMab 5B1","termGroup":"SY","termSource":"NCI"},{"termName":"HuMab-5B1","termGroup":"SY","termSource":"NCI"},{"termName":"MVT-5873","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2101410-19-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KEX1QY18OH"},{"name":"Maps_To","value":"Anti-CA19-9 Monoclonal Antibody 5B1"},{"name":"NCI_Drug_Dictionary_ID","value":"778807"},{"name":"NCI_META_CUI","value":"CL504549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778807"},{"name":"PDQ_Open_Trial_Search_ID","value":"778807"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95764":{"preferredName":"Anti-CA6-DM4 Immunoconjugate SAR566658","code":"C95764","definitions":[{"definition":"An immunoconjugate consisting of a humanized monoclonal antibody against the tumor-associated sialoglycotope CA6 (huDS6) conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-CA6 monoclonal antibody moiety of SAR566658 targets and binds to the cell surface antigen CA6. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CA6-expressing tumor cells. The CA6 epitope is found on a variety of solid tumors, including breast, ovarian, cervical, lung and pancreatic tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CA6-DM4 Immunoconjugate SAR566658","termGroup":"PT","termSource":"NCI"},{"termName":"huDs6-DM4","termGroup":"AB","termSource":"NCI"},{"termName":"SAR-566658","termGroup":"CN","termSource":"NCI"},{"termName":"SAR566658","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UFB8CT84JS"},{"name":"Maps_To","value":"Anti-CA6-DM4 Immunoconjugate SAR566658"},{"name":"NCI_Drug_Dictionary_ID","value":"681584"},{"name":"NCI_META_CUI","value":"CL421654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681584"},{"name":"PDQ_Open_Trial_Search_ID","value":"681584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121231":{"preferredName":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1","code":"C121231","definitions":[{"definition":"A humanized version of the immunoglobulin (Ig) G1 monoclonal antibody Mik-Beta-1 (Hu-Mik-Beta-1) directed against CD122, the beta-subunit shared by the interleukin-2 (IL-2) and IL-15 receptor (IL-2/IL-15Rbeta). Upon intravenous infusion, Hu-Mik-Beta-1 binds to CD122 expressed on certain tumor cells. This blocks the binding of the inflammatory cytokines IL-2 and IL-15 to IL-2R and IL-15R, respectively, and prevents IL-2/IL-2R- and IL-15/IL-15R-mediated signaling. This may inhibit the proliferation of CD122-expressing tumor cells. In addition, blocking CD122 on T-lymphocytes prevents the over-activation of T-lymphocytes in various T-cell mediated autoimmune diseases, which is predominantly mediated by IL-15/IL-15R signaling. CD122, involved in both IL-2 and IL-15 signaling, is overexpressed on certain cancer cells, such as those found in T-cell large granular lymphocyte (T-LGL) leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1","termGroup":"PT","termSource":"NCI"},{"termName":"Hu-Mik-Beta-1","termGroup":"SY","termSource":"NCI"},{"termName":"Hu-Mik-beta1","termGroup":"SY","termSource":"NCI"},{"termName":"Hu-Mikb1","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Mik-beta-1","termGroup":"SY","termSource":"NCI"},{"termName":"HuMikBeta1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1"},{"name":"NCI_Drug_Dictionary_ID","value":"810708"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055462"}]}}{"C184834":{"preferredName":"Pivekimab Sunirine","code":"C184834","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pivekimab Sunirine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD123 ADC IMGN632","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate IMGN632","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-targeted ADC IMGN632","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN 632","termGroup":"CN","termSource":"NCI"},{"termName":"IMGN-632","termGroup":"CN","termSource":"NCI"},{"termName":"IMGN632","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417174-95-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L15LO3W1XX"},{"name":"Maps_To","value":"Anti-CD123 ADC IMGN632"},{"name":"NCI_Drug_Dictionary_ID","value":"792150"},{"name":"NCI_META_CUI","value":"CL541645"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91093":{"preferredName":"Anti-CD123 Monoclonal Antibody CSL360","code":"C91093","definitions":[{"definition":"A chimeric IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain) with potential antineoplastic activity. Derived from mouse monoclonal antibody 7G3, anti-CD123 monoclonal antibody CSL360 binds to and neutralizes CD123 which is upregulated on leukemic stem cells (LSC) in acute myeloid leukemia (AML). This may inhibit IL-3-dependent signalling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123 Monoclonal Antibody CSL360","termGroup":"PT","termSource":"NCI"},{"termName":"CSL360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123 Monoclonal Antibody CSL360"},{"name":"NCI_Drug_Dictionary_ID","value":"529287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529287"},{"name":"PDQ_Open_Trial_Search_ID","value":"529287"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832015"}]}}{"C123380":{"preferredName":"Anti-CD123 Monoclonal Antibody KHK2823","code":"C123380","definitions":[{"definition":"A fully human monoclonal antibody against CD123 (interleukin-3 receptor alpha chain) with potential antineoplastic activity. Anti-CD123 monoclonal antibody KHK2823 binds to and neutralizes CD123, which is upregulated on leukemic stem cells (LSC) found in myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This agent may inhibit IL-3-dependent signaling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123 Monoclonal Antibody KHK2823","termGroup":"PT","termSource":"NCI"},{"termName":"KHK2823","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123 Monoclonal Antibody KHK2823"},{"name":"NCI_Drug_Dictionary_ID","value":"762775"},{"name":"NCI_META_CUI","value":"CL474096"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762775"},{"name":"PDQ_Open_Trial_Search_ID","value":"762775"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127120":{"preferredName":"Vibecotamab","code":"C127120","definitions":[{"definition":"An anti-CD123/anti-CD3 bispecific monoclonal antibody, in which most of the naturally-occurring Fc domain is maintained, with potential immunostimulatory and antineoplastic activities. Vibecotamab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of vibecotamab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell mediated tumor cell killing through its binding to the Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vibecotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD123/Anti-CD3 Bispecific Antibody XmAb14045","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb14045","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138442-13-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JD56EJA59S"},{"name":"Maps_To","value":"Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404"},{"name":"Maps_To","value":"Vibecotamab"},{"name":"NCI_Drug_Dictionary_ID","value":"780966"},{"name":"NCI_META_CUI","value":"CL507910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780966"},{"name":"PDQ_Open_Trial_Search_ID","value":"780966"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129457":{"preferredName":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A","code":"C129457","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an anti-CD123 humanized monoclonal antibody conjugated, via a stable maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD123 ADC SGN-CD123A, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD123-overexpressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers, including myeloid leukemia, and increased expression of CD123 on leukemic stem cells is associated with poor prognosis. Cysteine engineering of the monoclonal antibody (EC-mAb) allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123 ADC SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123-PBD ADC SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD123A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD123A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"89ATB9I3D2"},{"name":"Maps_To","value":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A"},{"name":"NCI_Drug_Dictionary_ID","value":"784132"},{"name":"NCI_META_CUI","value":"CL512667"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784132"},{"name":"PDQ_Open_Trial_Search_ID","value":"784132"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157257":{"preferredName":"Anti-CD123/CD3 Bispecific Antibody APVO436","code":"C157257","definitions":[{"definition":"An immunoglobulin Fc-modified bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3 bispecific monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD123/CD3 monoclonal antibody APVO436 simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody. Compared to some other CD123 x CD3 targeting bispecific antibodies, APVO436 causes less cytokine release upon T-cell stimulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123/CD3 Bispecific Antibody APVO436","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD123 x Anti-CD3 Bispecific Antibody APVO436","termGroup":"SY","termSource":"NCI"},{"termName":"APVO 436","termGroup":"CN","termSource":"NCI"},{"termName":"APVO-436","termGroup":"CN","termSource":"NCI"},{"termName":"APVO436","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Anti-CD123 x Anti-CD3 Antibody APVO436","termGroup":"SY","termSource":"NCI"},{"termName":"CD123 x CD3 Targeting Bispecific Antibody APVO436","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DNP8BBW84R"},{"name":"Maps_To","value":"Anti-CD123/CD3 Bispecific Antibody APVO436"},{"name":"NCI_Drug_Dictionary_ID","value":"796808"},{"name":"NCI_META_CUI","value":"CL936868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796808"},{"name":"PDQ_Open_Trial_Search_ID","value":"796808"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128486":{"preferredName":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178","code":"C128486","definitions":[{"definition":"A humanized anti-CD123/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-CD123/CD3 bispecific antibody JNJ-63709178 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of JNJ-63709178, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of cancers; its expression is low or absent in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178","termGroup":"PT","termSource":"NCI"},{"termName":"Humanized CD123 x CD3 DuoBody JNJ-63709178","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ-63709178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178"},{"name":"NCI_Drug_Dictionary_ID","value":"782366"},{"name":"NCI_META_CUI","value":"CL507949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782366"},{"name":"PDQ_Open_Trial_Search_ID","value":"782366"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160348":{"preferredName":"Anti-CD123/CD3 BiTE Antibody SAR440234","code":"C160348","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody comprised of a humanized Fc-silenced immunoglobulin G1 (IgG1) backbone and two single-chain variable fragments (scFvs): one directed against the CD3 antigen expressed on T-lymphocytes and another directed against the alpha-chain of the interleukin-3 receptor (IL-3RA; CD123), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, anti-CD123/CD3 BiTE antibody SAR440234 binds to both CD3 expressed on T-cells and CD123 expressed on tumor cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CD123-expressing tumor cells, leading to enhanced CTL-mediated elimination of CD123-expressing tumor cells. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123/CD3 BiTE Antibody SAR440234","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody SAR440234","termGroup":"SY","termSource":"NCI"},{"termName":"CD123xCD3 Bispecific T-cell Engager SAR440234","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 440234","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-440234","termGroup":"CN","termSource":"NCI"},{"termName":"SAR440234","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123/CD3 BiTE Antibody SAR440234"},{"name":"NCI_Drug_Dictionary_ID","value":"798327"},{"name":"NCI_META_CUI","value":"CL969414"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798327"},{"name":"PDQ_Open_Trial_Search_ID","value":"798327"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C160715":{"preferredName":"Anti-CD137 Agonistic Monoclonal Antibody ADG106","code":"C160715","definitions":[{"definition":"A human agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating activity. Upon administration, anti-CD137 agonistic monoclonal antibody ADG106 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD137 Agonistic Monoclonal Antibody ADG106","termGroup":"PT","termSource":"NCI"},{"termName":"4-1BB-directed Agonistic Monoclonal Antibody ADG106","termGroup":"SY","termSource":"NCI"},{"termName":"ADG 106","termGroup":"SY","termSource":"NCI"},{"termName":"ADG-106","termGroup":"CN","termSource":"NCI"},{"termName":"ADG106","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody ADG106","termGroup":"SY","termSource":"NCI"},{"termName":"CD137-directed Agonistic Monoclonal Antibody ADG106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I4QM8E7Y2R"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody ADG106"},{"name":"NCI_Drug_Dictionary_ID","value":"797894"},{"name":"NCI_META_CUI","value":"CL969811"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797894"},{"name":"PDQ_Open_Trial_Search_ID","value":"797894"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162039":{"preferredName":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471","code":"C162039","definitions":[{"definition":"A fully human immunoglobulin G4 (IgG4) agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody CTX-471 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody CTX-471","termGroup":"SY","termSource":"NCI"},{"termName":"CTX 471","termGroup":"CN","termSource":"NCI"},{"termName":"CTX-471","termGroup":"CN","termSource":"NCI"},{"termName":"CTX471","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471"},{"name":"NCI_Drug_Dictionary_ID","value":"798594"},{"name":"NCI_META_CUI","value":"CL970637"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798594"},{"name":"PDQ_Open_Trial_Search_ID","value":"798594"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C120317":{"preferredName":"Anti-CD157 Monoclonal Antibody MEN1112","code":"C120317","definitions":[{"definition":"A humanized, Fc engineered, de-fucosylated monoclonal immunoglobulin G1 (IgG1) antibody directed against the bone marrow stromal cell antigen 1 (BST1/CD157), with potential antineoplastic activity. Upon intravenous infusion, anti-CD157 monoclonal antibody MEN1112 specifically binds to and induces an antibody dependent cell cytotoxic (ADCC) response against CD157-expressing tumor cells. CD157, also known as ADP-ribosyl cyclase 2, is a glycosyl-phosphatidylinositol (GPI)-anchored transmembrane protein belonging to the ADP-ribosyl-cyclase family and is overexpressed on certain cancer cell types. Fc-optimization of MEN1112, which involves the removal of fucose residues from its Fc domain, allows for enhanced Fc-gamma receptor binding on effector cells, such as natural killer (NK) cells, and further enhances tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD157 Monoclonal Antibody MEN1112","termGroup":"PT","termSource":"NCI"},{"termName":"MEN1112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD157 Monoclonal Antibody MEN1112"},{"name":"NCI_Drug_Dictionary_ID","value":"768862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768862"},{"name":"PDQ_Open_Trial_Search_ID","value":"768862"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3896815"}]}}{"C134697":{"preferredName":"Praluzatamab Ravtansine","code":"C134697","definitions":[{"definition":"A probody drug conjugate (PDC) composed of a recombinant antibody targeting the tumor-associated antigen (TAA) CD166, which is masked by a cleavable masking peptide, and conjugated to the cytotoxic agent maytansinoid DM4, with potential antineoplastic activity. Upon administration of praluzatamab ravtansine and migration to the tumor microenvironment (TME), the cleavable masking peptide, which prevent anti-CD166 antibody binding to the CD166 expressed on both normal cells and tumor cells, is proteolytically cleaved by tumor-associated proteases that are specifically present in the TME. This enables the anti-CD166 antibody moiety of CX-2009 to selectively bind to, be internalized by, and deliver DM4 into CD166-expressing tumor cells. Following internalization, DM4 is released, binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD166-expressing tumor cells. The masking peptide prevents binding of the anti-CD166 antibody to CD166 in normal tissues, thereby minimizing toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Praluzatamab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC CX-2009","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD166-DM4 CX-2009","termGroup":"SY","termSource":"NCI"},{"termName":"CX-2009","termGroup":"CN","termSource":"NCI"},{"termName":"PDC CX-2009","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2145115-85-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RD2I59M9FC"},{"name":"Maps_To","value":"Anti-CD166 Probody-drug Conjugate CX-2009"},{"name":"Maps_To","value":"Praluzatamab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"789027"},{"name":"NCI_META_CUI","value":"CL522231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789027"},{"name":"PDQ_Open_Trial_Search_ID","value":"789027"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126377":{"preferredName":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B","code":"C126377","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody (hBU12ec) with engineered cysteines (EC-mAb) conjugated, via a maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer (SGD-1882), with potential antineoplastic activity. Upon administration of anti-CD19 ADC SGN-CD19B, the antibody moiety targets the cell surface antigen CD19, which is found on B-cell-derived cancers. Upon antibody/antigen binding, internalization and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, is expressed on B-cell-derived cancers. The cysteine engineering of the EC-mAb allows for a site-specific and stable conjugation of PBD to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD19B","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD19B","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD19B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B"},{"name":"NCI_Drug_Dictionary_ID","value":"779706"},{"name":"NCI_META_CUI","value":"CL504928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779706"},{"name":"PDQ_Open_Trial_Search_ID","value":"779706"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105805":{"preferredName":"Anti-CD19 Monoclonal Antibody DI-B4","code":"C105805","definitions":[{"definition":"A low-fucosylated, humanized, IgG1 isotype, monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody DI-B4 binds to CD19, which may result in a strong antibody-dependent cellular cytotoxicity (ADCC) directed at CD19-expressing B-cells but with minimal complement dependent cytotoxicity. DI-B4 contains low levels of fucose, which contributes to its enhanced ADCC activity. CD19 is a B-cell specific membrane antigen that is widely expressed during B-cell development and in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Monoclonal Antibody DI-B4","termGroup":"PT","termSource":"NCI"},{"termName":"anti-CD19 MoAb DI-B4","termGroup":"SY","termSource":"NCI"},{"termName":"DI-B4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody DI-B4"},{"name":"NCI_Drug_Dictionary_ID","value":"747738"},{"name":"NCI_META_CUI","value":"CL447157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747738"},{"name":"PDQ_Open_Trial_Search_ID","value":"747738"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74003":{"preferredName":"Anti-CD19 Monoclonal Antibody MDX-1342","code":"C74003","definitions":[{"definition":"A fully human anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential antineoplastic activity. Anti-CD19 monoclonal antibody MDX-1342 binds to CD19, depleting and eliminating CD19-expressing B-cells. CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Monoclonal Antibody MDX-1342","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-1342","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD19_Monoclonal_Antibody_MDX-1342"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody MDX-1342"},{"name":"NCI_Drug_Dictionary_ID","value":"586439"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586439"},{"name":"PDQ_Open_Trial_Search_ID","value":"586439"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346795"}]}}{"C88283":{"preferredName":"Inebilizumab","code":"C88283","definitions":[{"definition":"A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inebilizumab","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI-551","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1299440-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"74T7185BMM"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody MEDI-551"},{"name":"Maps_To","value":"Inebilizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"656851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656851"},{"name":"PDQ_Open_Trial_Search_ID","value":"656851"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981806"}]}}{"C95768":{"preferredName":"Tafasitamab","code":"C95768","definitions":[{"definition":"An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tafasitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Monjuvi","termGroup":"BR","termSource":"NCI"},{"termName":"MOR-00208","termGroup":"CN","termSource":"NCI"},{"termName":"MOR00208","termGroup":"CN","termSource":"NCI"},{"termName":"MOR208","termGroup":"CN","termSource":"NCI"},{"termName":"Tafasitamab-cxix","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb5574","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"},{"name":"CAS_Registry","value":"1422527-84-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"QQA9MLH692"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody XmAb5574"},{"name":"Maps_To","value":"Tafasitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"682091"},{"name":"NCI_META_CUI","value":"CL421662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682091"},{"name":"PDQ_Open_Trial_Search_ID","value":"682091"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71009":{"preferredName":"Coltuximab Ravtansine","code":"C71009","definitions":[{"definition":"An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Coltuximab ravtansine targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coltuximab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19-DM4 Immunoconjugate SAR3419","termGroup":"SY","termSource":"NCI"},{"termName":"SAR3419","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1269764-99-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MRS84YT9L2"},{"name":"Legacy Concept Name","value":"Anti-CD19-DM4_Conjugate"},{"name":"Maps_To","value":"Anti-CD19-DM4 Immunoconjugate SAR3419"},{"name":"Maps_To","value":"Coltuximab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"574048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574048"},{"name":"PDQ_Open_Trial_Search_ID","value":"574048"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346794"}]}}{"C82375":{"preferredName":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL","code":"C82375","definitions":[{"definition":"A substance being studied in the treatment of some types of B-cell cancer. It contains an antibody linked to a toxic substance. The antibody binds to proteins called CD19 and CD22 on the surface of B cells, and the toxic substance kills the cells. It is a type of bispecific ligand-directed toxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunotoxin consisting of two scFv ligands recognizing human CD19 and CD22 linked to the first 389 amino acids of diphtheria toxin (DT), DT 390, with potential antineoplastic activity. The VH and VL regions of anti-CD22 (sFv) and anti-CD19 are reversed and linked by an aggregration stabilizing linker (ARL) consisting of a 20 amino acid segment of human muscle aldolase (hma) and an Xho1-compatible restriction site; the CDR3 region of the VH of anti-CD22 sFv is mutated to enhance its affinity. The anti-CD19 and anti CD-22 portions of the immunotoxin specifically bind to CD19 and CD22 receptors on tumor B cells. Upon internalization, DT catalyzes ADP ribosylation of elongation factor 2 (EF-2) which may result in the irreversible inhibition of protein synthesis and cell death in CD19- and CD22-expressing tumor cells. CD19 and CD22 are transmembrane proteins upregulated on malignant B cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/CD22 BLT DT2219ARL","termGroup":"SY","termSource":"NCI"},{"termName":"DT2219ARL","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD19_Anti-CD22_Bispecific_Immunotoxin_DT2219ARL"},{"name":"Maps_To","value":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL"},{"name":"NCI_Drug_Dictionary_ID","value":"641179"},{"name":"NCI_META_CUI","value":"CL408648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641179"},{"name":"PDQ_Open_Trial_Search_ID","value":"641179"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C153215":{"preferredName":"Anti-CD19/CD3 BiTE Antibody AMG 562","code":"C153215","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 BiTE antibody AMG 562 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/CD3 BiTE Antibody AMG 562","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 562","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-562","termGroup":"CN","termSource":"NCI"},{"termName":"AMG562","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 562","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 562","termGroup":"SY","termSource":"NCI"},{"termName":"CD19/CD3-directed Bispecific T-cell Engager Antibody AMG 562","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19/CD3 BiTE Antibody AMG 562"},{"name":"NCI_Drug_Dictionary_ID","value":"794049"},{"name":"NCI_META_CUI","value":"CL554338"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794049"},{"name":"PDQ_Open_Trial_Search_ID","value":"794049"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C115101":{"preferredName":"Anti-CD19/CD3 Tetravalent Antibody AFM11","code":"C115101","definitions":[{"definition":"An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/CD3 Tetravalent Antibody AFM11","termGroup":"PT","termSource":"NCI"},{"termName":"AFM11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"250245-29-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UGA95385P3"},{"name":"Maps_To","value":"Anti-CD19/CD3 Tetravalent Antibody AFM11"},{"name":"NCI_Drug_Dictionary_ID","value":"759829"},{"name":"NCI_META_CUI","value":"CL472632"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759829"},{"name":"PDQ_Open_Trial_Search_ID","value":"759829"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155899":{"preferredName":"Anti-CD20 Monoclonal Antibody B001","code":"C155899","definitions":[{"definition":"A recombinant humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Upon intravenous administration, anti-CD20 monoclonal antibody B001 specifically binds to CD20 on the surfaces of B-cells. Although the exact mechanisms through which B001 exert its effects have not been elucidated, B001 may induce a B-cell directed cell-mediated immune response against CD20-expressing B-cells and/or prevent CD20-medaited signaling. This induces tumor cell apoptosis and inhibits proliferation. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development and which is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody B001","termGroup":"PT","termSource":"NCI"},{"termName":"B 001","termGroup":"CN","termSource":"NCI"},{"termName":"B001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody B001"},{"name":"NCI_Drug_Dictionary_ID","value":"794877"},{"name":"NCI_META_CUI","value":"CL562774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794877"},{"name":"PDQ_Open_Trial_Search_ID","value":"794877"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90590":{"preferredName":"Anti-CD20 Monoclonal Antibody PRO131921","code":"C90590","definitions":[{"definition":"A third-generation, humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody PRO131921 specifically binds to the B cell-specific cell surface antigen CD20. This may result in the induction of a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B cells during most stages of B cell development and which is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody PRO131921","termGroup":"PT","termSource":"NCI"},{"termName":"PRO131921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody PRO131921"},{"name":"NCI_Drug_Dictionary_ID","value":"543157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543157"},{"name":"PDQ_Open_Trial_Search_ID","value":"543157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934873"}]}}{"C122680":{"preferredName":"Ripertamab","code":"C122680","definitions":[{"definition":"A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ripertamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody SCT400","termGroup":"SY","termSource":"NCI"},{"termName":"SCT400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249927-04-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"URS0374MIV"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody SCT400"},{"name":"NCI_Drug_Dictionary_ID","value":"772859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772859"},{"name":"PDQ_Open_Trial_Search_ID","value":"772859"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053591"}]}}{"C94206":{"preferredName":"Anti-CD20 Monoclonal Antibody TL011","code":"C94206","definitions":[{"definition":"A monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody TL011 specifically binds to the B cell-specific cell surface antigen CD20 antigen (MS4A1; membrane-spanning 4-domains, subfamily A, member 1), thereby potentially triggering an immune response against CD20-positive B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody TL011","termGroup":"PT","termSource":"NCI"},{"termName":"TL011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody TL011"},{"name":"NCI_Drug_Dictionary_ID","value":"686495"},{"name":"NCI_META_CUI","value":"CL426019"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686495"},{"name":"PDQ_Open_Trial_Search_ID","value":"686495"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123915":{"preferredName":"Eramkafusp Alfa","code":"C123915","definitions":[{"definition":"A humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20 and fused to the recombinant cytokine, interferon-alpha (IFN-a), with potential antineoplastic and immunomodulating activities. Upon administration of eramkafusp alfa, the antibody moiety specifically targets and binds to CD20. In turn, the IFN-a moiety binds to the IFN receptor, and activates IFN-mediated signal transduction, which induces the transcription and translation of genes whose protein products mediate anticancer effects. This results in the induction of both G2 cell cycle arrest and apoptosis in CD20-expressing tumor cells. In addition, IGN002 causes the induction of complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eramkafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody-IFN-a Fusion Protein IGN002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002","termGroup":"SY","termSource":"NCI"},{"termName":"IGN002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2388499-82-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N7FO1V18PR"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002"},{"name":"NCI_Drug_Dictionary_ID","value":"775840"},{"name":"NCI_META_CUI","value":"CL498279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775840"},{"name":"PDQ_Open_Trial_Search_ID","value":"775840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120546":{"preferredName":"Anti-CD20-engineered Toxin Body MT-3724","code":"C120546","definitions":[{"definition":"An engineered toxin body (ETB) composed of the single-chain variable fragment (ScFv) from an antibody targeting CD20 that is linked to a modified form of the ribosome-inactivating alpha subunit of Shiga-like toxin 1 (Shiga-like Toxin-1 A or SLT-1A), with antineoplastic activity. Upon administration, the ScFv moiety of anti-CD20-engineered toxin body MT-3724 targets and binds to the CD20 antigen expressed on tumor cells. Upon internalization, the SLT-1A moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and eventually leads to apoptosis of CD20-expressing tumor cells. CD20, a B-cell specific transmembrane protein and tumor-associated antigen (TAA), is expressed during most stages of B-cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20-engineered Toxin Body MT-3724","termGroup":"PT","termSource":"NCI"},{"termName":"MT-3724","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R23ZRN6GWR"},{"name":"Maps_To","value":"Anti-CD20-engineered Toxin Body MT-3724"},{"name":"NCI_Drug_Dictionary_ID","value":"769207"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769207"},{"name":"PDQ_Open_Trial_Search_ID","value":"769207"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053580"}]}}{"C165166":{"preferredName":"Imvotamab","code":"C165166","definitions":[{"definition":"An engineered immunoglobulin M (IgM) bispecific antibody, with potential antineoplastic activity. Imvotamab contains ten high affinity binding domains for the tumor-associated antigen (TAA) CD20, and one binding domain for CD3, a T-cell surface antigen. Upon administration, imvotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Additionally, imvotamab induces complement-dependent cytotoxicity (CDC) to a greater extent than anti-CD20/anti-CD3 IgG bispecific antibodies, thereby further enhancing the killing CD20-expressing tumor cells. The extra binding units of imvotamab may bind cancer cells that express relatively low amounts of CD20. Also, compared to IgG format bispecific T-cell engaging antibodies, imvotamab appears to induce less cytokine release, which may reduce the risk of cytokine release syndrome (CRS). CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imvotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific CD20xCD3 IgM Antibody IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific IgM Antibody IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"IGM 2323","termGroup":"CN","termSource":"NCI"},{"termName":"IgM Pentamer IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"IGM-2323","termGroup":"CN","termSource":"NCI"},{"termName":"IGM2323","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2573121-53-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3HG38I0T1"},{"name":"Maps_To","value":"Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323"},{"name":"NCI_Drug_Dictionary_ID","value":"799710"},{"name":"NCI_META_CUI","value":"CL978274"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799710"},{"name":"PDQ_Open_Trial_Search_ID","value":"799710"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119615":{"preferredName":"Odronextamab","code":"C119615","definitions":[{"definition":"A bispecific, human monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody REGN1979 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, odronextamab binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odronextamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979","termGroup":"SY","termSource":"NCI"},{"termName":"REGN1979","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11035","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801338-64-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8R5CM46UIO"},{"name":"Maps_To","value":"Anti-CD20/CD3 Monoclonal Antibody REGN1979"},{"name":"Maps_To","value":"Odronextamab"},{"name":"NCI_Drug_Dictionary_ID","value":"766653"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766653"},{"name":"PDQ_Open_Trial_Search_ID","value":"766653"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896743"}]}}{"C130050":{"preferredName":"Plamotamab","code":"C130050","definitions":[{"definition":"A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic activity. Plamotamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, plamotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell-mediated tumor cell killing because the agent is able to bind to Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plamotamab","termGroup":"PT","termSource":"NCI"},{"termName":"XmAb13676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138442-31-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5ENX424FNF"},{"name":"Maps_To","value":"Anti-CD20/CD3 Monoclonal Antibody XmAb13676"},{"name":"Maps_To","value":"Plamotamab"},{"name":"NCI_Drug_Dictionary_ID","value":"785610"},{"name":"NCI_META_CUI","value":"CL514016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785610"},{"name":"PDQ_Open_Trial_Search_ID","value":"785610"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156882":{"preferredName":"Anti-CD22 ADC TRPH-222","code":"C156882","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an anti-CD22 humanized monoclonal antibody site-specifically conjugated to, via formylglycine (FG) residues and a protease insensitive 4AP linker, a cytotoxic microtubule-targeting maytansinoid payload, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TRPH-222 binds to B-cell-specific CD22 receptors and is rapidly internalized, thereby delivering the payload intracellularly. Upon proteolytic cleavage, the maytansinoid payload binds to tubulin, disrupting microtubule assembly/disassembly dynamics, inhibiting both cell division and tumor cell proliferation. CD22, a cell surface sialoglycoprotein, is expressed on mature B-cells and on most malignant B-cells. The site specific and stable conjugation to the payload allows for a higher drug-to-antibody ratio (DAR) and an enhanced therapeutic index.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD22 ADC TRPH-222","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD22 Antibody-drug Conjugate TRPH-222","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD22-4AP ADC TRPH-222","termGroup":"SY","termSource":"NCI"},{"termName":"CAT-02-106","termGroup":"CN","termSource":"NCI"},{"termName":"TRPH 222","termGroup":"CN","termSource":"NCI"},{"termName":"TRPH-222","termGroup":"CN","termSource":"NCI"},{"termName":"TRPH222","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"00NT1ETN9K"},{"name":"Maps_To","value":"Anti-CD22 ADC TRPH-222"},{"name":"NCI_Drug_Dictionary_ID","value":"796465"},{"name":"NCI_META_CUI","value":"CL935995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796465"},{"name":"PDQ_Open_Trial_Search_ID","value":"796465"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104167":{"preferredName":"Pinatuzumab Vedotin","code":"C104167","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of MCDT2219A, a humanized IgG1 anti-CD22 monoclonal antibody covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of pinatuzumab vedotin binds to B cell-specific CD22 receptors and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pinatuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DCDT2980S","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate DCDT2980S","termGroup":"SY","termSource":"NCI"},{"termName":"DCDT2980S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313706-14-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6KA1906BLC"},{"name":"Maps_To","value":"Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S"},{"name":"Maps_To","value":"Pinatuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"686534"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686534"},{"name":"PDQ_Open_Trial_Search_ID","value":"686534"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641731"}]}}{"C121949":{"preferredName":"Camidanlumab Tesirine","code":"C121949","definitions":[{"definition":"An immunoconjugate consisting of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha or CD25) and conjugated, via a cleavable linker, to a synthetic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer that targets DNA minor grooves, with potential antineoplastic activity. The monoclonal antibody portion of the anti-CD25 antibody-drug conjugate (ADC) ADCT-301 specifically binds to the cell surface antigen CD25. This causes the internalization of ADCT-301 and the subsequent release of the cytotoxic PBD moiety. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD25-overexpressing tumor cells. CD25, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on certain cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camidanlumab Tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-301","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT-301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1853239-04-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LYJ1AEJ9YH"},{"name":"Maps_To","value":"Anti-CD25-PBD Antibody-drug Conjugate ADCT-301"},{"name":"Maps_To","value":"Camidanlumab Tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"771992"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771992"},{"name":"PDQ_Open_Trial_Search_ID","value":"771992"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053683"}]}}{"C150677":{"preferredName":"Anti-CD26 Monoclonal Antibody YS110","code":"C150677","definitions":[{"definition":"A humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells. YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD26 Monoclonal Antibody YS110","termGroup":"PT","termSource":"NCI"},{"termName":"YS110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD26 Monoclonal Antibody YS110"},{"name":"NCI_Drug_Dictionary_ID","value":"793089"},{"name":"NCI_META_CUI","value":"CL552568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793089"},{"name":"PDQ_Open_Trial_Search_ID","value":"793089"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C106266":{"preferredName":"Anti-CD27L Antibody-Drug Conjugate AMG 172","code":"C106266","definitions":[{"definition":"An immunoconjugate consisting of a human IgG1 monoclonal antibody directed against CD27L conjugated, via a non-cleavable linker, to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to CD27L on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of cancer cells that express CD27L. CD27L, a type II transmembrane protein and member of the tumor necrosis factor family, is a co-stimulatory molecule constitutively expressed on a subset of activated T-cells, B-cells, and dendritic cells, which is overexpressed in certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD27L Antibody-Drug Conjugate AMG 172","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 172","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-172","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6M586T6SD"},{"name":"Maps_To","value":"Anti-CD27L Antibody-Drug Conjugate AMG 172"},{"name":"NCI_Drug_Dictionary_ID","value":"721679"},{"name":"NCI_META_CUI","value":"CL433957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721679"},{"name":"PDQ_Open_Trial_Search_ID","value":"721679"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74004":{"preferredName":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)","code":"C74004","definitions":[{"definition":"A bivalent recombinant fusion protein immunotoxin derived from the anti-CD3 monoclonal antibody UCHT1 with potential antineoplastic activity. Anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1) consists of 1-390 amino acid residues of chain A diphtheria toxin (DT) joined via a spacer to the Fv fragment of UCHT1, which is connected to a second UCHT1 Fv fragment via a disulfide bond (hence the \"bisFv\" designation); the addition of the second Fv fragment overcomes the steric hindrance of immunotoxin binding due to the large N-terminal DT domain. Once inside target T cells, the DT moiety catalyzes the transfer of the ADP-ribose moiety of NAD to diphthamide, a posttranslationally modified histidine residue found in elongation factor 2 (EF-2); inactivation of EF-2, disruption of polypeptide chain elongation, and cell death ensue. CD3 is a complex of five cell-surface polypeptides associated with the T cell receptor (TCR) complex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)","termGroup":"PT","termSource":"NCI"},{"termName":"A-dmDT390-bisFv(UCHT1)","termGroup":"AB","termSource":"NCI"},{"termName":"Resimmune","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1470038-56-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P7MQ9ZOQ82"},{"name":"Legacy Concept Name","value":"Anti-CD3_Immunotoxin_A-dmDT390-bisFv_UCHT1"},{"name":"Maps_To","value":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)"},{"name":"NCI_Drug_Dictionary_ID","value":"588895"},{"name":"NCI_META_CUI","value":"CL383887"},{"name":"PDQ_Closed_Trial_Search_ID","value":"588895"},{"name":"PDQ_Open_Trial_Search_ID","value":"588895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136823":{"preferredName":"Teclistamab","code":"C136823","definitions":[{"definition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teclistamab","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 64007957","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64007957","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ64007957","termGroup":"CN","termSource":"NCI"},{"termName":"Teclistamab-cqyv","termGroup":"SY","termSource":"NCI"},{"termName":"Tecvayli","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2119595-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"54534MX6Z9"},{"name":"Maps_To","value":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957"},{"name":"Maps_To","value":"Teclistamab"},{"name":"NCI_Drug_Dictionary_ID","value":"789710"},{"name":"NCI_META_CUI","value":"CL524654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789710"},{"name":"PDQ_Open_Trial_Search_ID","value":"789710"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146860":{"preferredName":"Elranatamab","code":"C146860","definitions":[{"definition":"A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elranatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA x CD3 Bispecific Antibody PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-CD3 Bispecific Ab PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"Elranatamab-bcmm","termGroup":"SY","termSource":"NCI"},{"termName":"Elrexfio","termGroup":"BR","termSource":"NCI"},{"termName":"PF 06863135","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06863135","termGroup":"CN","termSource":"NCI"},{"termName":"PF06863135","termGroup":"CN","termSource":"NCI"},{"termName":"RN 613","termGroup":"CN","termSource":"NCI"},{"termName":"RN-613","termGroup":"CN","termSource":"NCI"},{"termName":"RN613","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adults with relapsed or refractory multiple myeloma."},{"name":"CAS_Registry","value":"2408850-14-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0HR9A577V"},{"name":"Maps_To","value":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135"},{"name":"NCI_Drug_Dictionary_ID","value":"792267"},{"name":"NCI_META_CUI","value":"CL544825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792267"},{"name":"PDQ_Open_Trial_Search_ID","value":"792267"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95760":{"preferredName":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05","code":"C95760","definitions":[{"definition":"A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. FBTA05 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human CD20, a tumor-associated antigen that is exclusively expressed on B cells during most stages of B cell development and often overexpressed in B-cell malignancies. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). FBTA05 brings T cells, CD20-expressing tumor B-cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells. Fc-mediated binding of APCs in the tricellular complex potentiates CD20 antigen presentation to T cells and the activation of anti-tumor cytotoxic T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05","termGroup":"PT","termSource":"NCI"},{"termName":"FBTA05","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05"},{"name":"NCI_Drug_Dictionary_ID","value":"675323"},{"name":"NCI_META_CUI","value":"CL421602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675323"},{"name":"PDQ_Open_Trial_Search_ID","value":"675323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171840":{"preferredName":"Talquetamab","code":"C171840","definitions":[{"definition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talquetamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"GPRC5D x CD3 Bispecific Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"GPRC5D x CD3 DuoBody Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"GPRC5D/CD3 DuoBody Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 64407564","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64407564","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ64407564","termGroup":"CN","termSource":"NCI"},{"termName":"Talquetamab-tgvs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226212-40-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4W3KFI3TN3"},{"name":"Maps_To","value":"Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564"},{"name":"NCI_Drug_Dictionary_ID","value":"792477"},{"name":"NCI_META_CUI","value":"CL545429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792477"},{"name":"PDQ_Open_Trial_Search_ID","value":"792477"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163022":{"preferredName":"Epcoritamab","code":"C163022","definitions":[{"definition":"A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epcoritamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20/CD3 Bispecific Antibody GEN3013","termGroup":"SY","termSource":"NCI"},{"termName":"DuoBody-CD3xCD20","termGroup":"SY","termSource":"NCI"},{"termName":"Epcoritamab-bysp","termGroup":"SY","termSource":"NCI"},{"termName":"Epkinly","termGroup":"BR","termSource":"NCI"},{"termName":"GEN 3013","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-3013","termGroup":"CN","termSource":"NCI"},{"termName":"GEN3013","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2134641-34-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D6OMY2L0WA"},{"name":"Maps_To","value":"Anti-CD3/CD20 Bispecific Antibody GEN3013"},{"name":"Maps_To","value":"Epcoritamab"},{"name":"NCI_Drug_Dictionary_ID","value":"798973"},{"name":"NCI_META_CUI","value":"CL973375"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798973"},{"name":"PDQ_Open_Trial_Search_ID","value":"798973"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153147":{"preferredName":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424","code":"C153147","definitions":[{"definition":"A humanized, bispecific monoclonal antibody (BsAb) targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody AMG 424 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 424","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-424","termGroup":"CN","termSource":"NCI"},{"termName":"AMG424","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD3 x Anti-CD38 Bispecific Monoclonal Antibody AMG 424","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD3/Anti-CD38 Bispecific Monoclonal Antibody AMG 424","termGroup":"SY","termSource":"NCI"},{"termName":"CD3xCD38 BsAb AMG 424","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424"},{"name":"NCI_Drug_Dictionary_ID","value":"793935"},{"name":"NCI_META_CUI","value":"CL554400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793935"},{"name":"PDQ_Open_Trial_Search_ID","value":"793935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77886":{"preferredName":"Anti-CD30 Monoclonal Antibody MDX-1401","code":"C77886","definitions":[{"definition":"A fully human, second-generation, nonfucosylated monoclonal antibody directed against the cell surface receptor CD30 with potential immunomodulating and antineoplastic activities. Anti-CD30 monoclonal antibody MDX-1401 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Compared to conventional antibodies, deletion of fucose molecules on the antibody backbone, as is done in MDX-1401, may result in an increased affinity for Fc receptors and an enhanced antibody-dependent cellular cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD30 Monoclonal Antibody MDX-1401","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-1401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD30_Monoclonal_Antibody_MDX-1401"},{"name":"Maps_To","value":"Anti-CD30 Monoclonal Antibody MDX-1401"},{"name":"NCI_Drug_Dictionary_ID","value":"592962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592962"},{"name":"PDQ_Open_Trial_Search_ID","value":"592962"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2703085"}]}}{"C74005":{"preferredName":"Anti-CD30 Monoclonal Antibody XmAb2513","code":"C74005","definitions":[{"definition":"A humanized monoclonal antibody directed against the cell surface receptor CD30 with potential immunotherapeutic activity. Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD30 Monoclonal Antibody XmAb2513","termGroup":"PT","termSource":"NCI"},{"termName":"XmAb2513","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33VWC847G8"},{"name":"Legacy Concept Name","value":"Anti-CD30_Monoclonal_Antibody_XmAb2513"},{"name":"Maps_To","value":"Anti-CD30 Monoclonal Antibody XmAb2513"},{"name":"NCI_Drug_Dictionary_ID","value":"589299"},{"name":"NCI_META_CUI","value":"CL383523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589299"},{"name":"PDQ_Open_Trial_Search_ID","value":"589299"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94219":{"preferredName":"Acimtamig","code":"C94219","definitions":[{"definition":"A tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, acimtamig binds to the CD16A expressed on natural killer (NK) cells with two of its binding sites and to CD30 on CD30-expressing tumor cells with the other two binding sites, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation, antibody-dependent cellular cytotoxicity (ADCC) and eventually tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is overexpressed in hematologic malignancies; CD16A is specifically expressed on the surface of NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acimtamig","termGroup":"PT","termSource":"NCI"},{"termName":"AFM13","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD30/CD16A Monoclonal Antibody AFM13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2738880-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ND470TT8Y3"},{"name":"Maps_To","value":"Anti-CD30/CD16A Monoclonal Antibody AFM13"},{"name":"NCI_Drug_Dictionary_ID","value":"687622"},{"name":"NCI_META_CUI","value":"CL426032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687622"},{"name":"PDQ_Open_Trial_Search_ID","value":"687622"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156458":{"preferredName":"Anti-CD32B Monoclonal Antibody BI-1206","code":"C156458","definitions":[{"definition":"A fully human monoclonal antibody targeting the Fc gamma receptor IIB (FcgRIIB; CD32B) with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, anti-CD32B monoclonal antibody BI-1206 selectively binds to CD32B, a receptor expressed on the surface of B-cells. This prevents CD32B-mediated internalization of anti-CD20 monoclonal antibodies, such as rituximab, which abrogates tumor cell resistance caused by CD32B-mediated monoclonal antibody internalization and degradation of CD32B-expressing B-cells. By blocking CD32B, BI-1206 may recover and enhance the activity of rituximab and other anti CD20 monoclonal antibodies. In addition, BI-1206 itself activates the immune system to exert an immune-mediated tumor cell death of B-cells. CD32B, an inhibitory member of the FcgammaR family, is implicated in immune cell desensitization and tumor cell resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD32B Monoclonal Antibody BI-1206","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-hFcgammaRIIB mAb BI-1206","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-hFcgRIIB Monoclonal Antibody BI-1206","termGroup":"SY","termSource":"NCI"},{"termName":"BI 1206","termGroup":"CN","termSource":"NCI"},{"termName":"BI-1206","termGroup":"CN","termSource":"NCI"},{"termName":"BI1206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"24S6PA0WXW"},{"name":"Maps_To","value":"Anti-CD32B Monoclonal Antibody BI-1206"},{"name":"NCI_Drug_Dictionary_ID","value":"795804"},{"name":"NCI_META_CUI","value":"CL563195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795804"},{"name":"PDQ_Open_Trial_Search_ID","value":"795804"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125717":{"preferredName":"Anti-CD33 Antibody-drug Conjugate IMGN779","code":"C125717","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody Z4681A conjugated, via a cleavable disulfide linker, to the cytotoxic DNA alkylating agent DGN462, which is an indolino-benzodiazepine dimer containing a mono-imine moiety, with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DGN462 conjugate IMGN779 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DGN462 moiety is released, and covalently binds to and alkylates DNA, thereby causing cell cycle arrest, apoptosis and inhibition of cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33 Antibody-drug Conjugate IMGN779","termGroup":"PT","termSource":"NCI"},{"termName":"ADC IMGN779","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33 ADC IMGN779","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN779","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YE6R3UY9IV"},{"name":"Maps_To","value":"Anti-CD33 Antibody-drug Conjugate IMGN779"},{"name":"NCI_Drug_Dictionary_ID","value":"778810"},{"name":"NCI_META_CUI","value":"CL504373"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778810"},{"name":"PDQ_Open_Trial_Search_ID","value":"778810"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135632":{"preferredName":"Vixtimotamab","code":"C135632","definitions":[{"definition":"An anti-CD33/anti-CD3 bispecific tetravalent antibody, with potential immunostimulatory and antineoplastic activities. Anti-CD33/CD3 tetravalent bispecific monoclonal antibody AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of a variety of tumor cell types. Upon infusion of vixtimotamab, this bispecific antibody binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed by a variety of cancers, including the majority of acute myeloid leukemias (AMLs), and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vixtimotamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMV 564","termGroup":"CN","termSource":"NCI"},{"termName":"AMV-564","termGroup":"CN","termSource":"NCI"},{"termName":"AMV564","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564","termGroup":"SY","termSource":"NCI"},{"termName":"CD33 x CD3 Tandem Diabody AMV-56","termGroup":"SY","termSource":"NCI"},{"termName":"CD33/CD3 TandAbs AMV564","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO-3953","termGroup":"CN","termSource":"NCI"},{"termName":"T652","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2243775-32-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56FUB33G5M"},{"name":"Maps_To","value":"Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564"},{"name":"NCI_Drug_Dictionary_ID","value":"789017"},{"name":"NCI_META_CUI","value":"CL522987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789017"},{"name":"PDQ_Open_Trial_Search_ID","value":"789017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116737":{"preferredName":"Anti-CD33 Monoclonal Antibody BI 836858","code":"C116737","definitions":[{"definition":"An engineered, fully human, immunoglobulin (Ig) G1 anti-CD33 monoclonal antibody, with potential antineoplastic activity. Upon administration, anti-CD33 monoclonal antibody BI 836858 induces an antibody-dependent cellular cytotoxicity (ADCC) against CD33-expressing tumor cells, leading to cell death. CD33, a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells, is overexpressed on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33 Monoclonal Antibody BI 836858","termGroup":"PT","termSource":"NCI"},{"termName":"BI 836858","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2206770-25-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JA7I0QFJ17"},{"name":"Maps_To","value":"Anti-CD33 Monoclonal Antibody BI 836858"},{"name":"NCI_Drug_Dictionary_ID","value":"737148"},{"name":"NCI_META_CUI","value":"CL446627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737148"},{"name":"PDQ_Open_Trial_Search_ID","value":"737148"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71523":{"preferredName":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633","code":"C71523","definitions":[{"definition":"An immunoconjugate consisting of the humanized monoclonal antibody huMy9-6 conjugated to the cytotoxic maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DM4 conjugate AVE9633 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DM4 moiety is released, binds tubulin, and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of cell division and cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells as well as on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD33-DM4_Conjugate"},{"name":"Maps_To","value":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633"},{"name":"NCI_Drug_Dictionary_ID","value":"575732"},{"name":"NCI_META_CUI","value":"CL378287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575732"},{"name":"PDQ_Open_Trial_Search_ID","value":"575732"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155970":{"preferredName":"Anti-CD33/CD3 Bispecific Antibody GEM 333","code":"C155970","definitions":[{"definition":"A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration of anti-CD33/CD3 bispecific antibody GEM 333, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33/CD3 Bispecific Antibody GEM 333","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD33 Bispecific Antibody GEM 333","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33/Anti-CD3 Bispecific Antibody GEM 333","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33/CD3 Antibody GEM 333","termGroup":"SY","termSource":"NCI"},{"termName":"GEM 333","termGroup":"CN","termSource":"NCI"},{"termName":"GEM-333","termGroup":"CN","termSource":"NCI"},{"termName":"GEM333","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD33/CD3 Bispecific Antibody GEM 333"},{"name":"NCI_Drug_Dictionary_ID","value":"795023"},{"name":"NCI_META_CUI","value":"CL562715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795023"},{"name":"PDQ_Open_Trial_Search_ID","value":"795023"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162296":{"preferredName":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244","code":"C162296","definitions":[{"definition":"A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD33/CD3 bispecific antibody JNJ-67571244 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen expressed on certain tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in CTL-mediated killing of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 67571244","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-67571244","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ67571244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244"},{"name":"NCI_Drug_Dictionary_ID","value":"798705"},{"name":"NCI_META_CUI","value":"CL970869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798705"},{"name":"PDQ_Open_Trial_Search_ID","value":"798705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123332":{"preferredName":"Eluvixtamab","code":"C123332","definitions":[{"definition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eluvixtamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 330","termGroup":"CN","termSource":"NCI"},{"termName":"AMG330","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD33/CD3 BiTE Antibody AMG 330","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 330","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 330","termGroup":"SY","termSource":"NCI"},{"termName":"CD33/CD3-directed Bispecific T-cell Engager Antibody AMG 330","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1679391-73-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6Z4B5PJ4OP"},{"name":"Maps_To","value":"Anti-CD33/CD3 BiTE Antibody AMG 330"},{"name":"NCI_Drug_Dictionary_ID","value":"775135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775135"},{"name":"PDQ_Open_Trial_Search_ID","value":"775135"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3851031"}]}}{"C175778":{"preferredName":"Emerfetamab","code":"C175778","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emerfetamab binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emerfetamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 673","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-673","termGroup":"CN","termSource":"NCI"},{"termName":"AMG673","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD33 x Anti-CD3 BiTE AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33/CD3 BiTE Antibody AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"CD33/CD3-directed Bispecific T-cell Engager Antibody AMG 673","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2250261-27-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HOG226RYH1"},{"name":"Maps_To","value":"Anti-CD33/CD3 BiTE Antibody AMG 673"},{"name":"NCI_Drug_Dictionary_ID","value":"792374"},{"name":"NCI_META_CUI","value":"CL545041"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131174":{"preferredName":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A","code":"C131174","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an engineered cysteine humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) that is conjugated to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD352 ADC SGN-CD352A, the antibody moiety targets the cell surface antigen CD352. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD352-overexpressing tumor cells. CD352, a tumor-associated antigen (TAA), is overexpressed on a variety of cancers. Cysteine engineering of the monoclonal antibody allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"PBD Dimer ADC SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"PBD-based Anti-CD352 ADC SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"PBD-based Anti-CD352 Antibody-drug Conjugate SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-CD352A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZX1I49XP7L"},{"name":"Maps_To","value":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A"},{"name":"NCI_Drug_Dictionary_ID","value":"785477"},{"name":"NCI_META_CUI","value":"CL513495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785477"},{"name":"PDQ_Open_Trial_Search_ID","value":"785477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C100101":{"preferredName":"Naratuximab Emtansine","code":"C100101","definitions":[{"definition":"An immunoconjugate that consists of a humanized IgG1 antibody K7153A against the cell-surface antigen CD37 and covalently linked via the uncleavable, maleimide-derived thioether-based linker SMCC to the maytansinoid DM1, with potential pro-apoptotic and cytotoxic activities. Upon administration of naratuximab emtansine, the antibody moiety of IMGN529 binds to CD37 on tumor B-cells and induces an antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and eventually causing cell death in CD37-positive B-cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies. Compared to reducible, cleavable linkers, the non-reducible SMCC linker shows increased stability in plasma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naratuximab Emtansine","termGroup":"PT","termSource":"NCI"},{"termName":"IMGN529","termGroup":"CN","termSource":"NCI"},{"termName":"MP 529","termGroup":"CN","termSource":"NCI"},{"termName":"MP-529","termGroup":"CN","termSource":"NCI"},{"termName":"MP529","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1607824-64-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WE1X5A83B9"},{"name":"Maps_To","value":"Anti-CD37 Antibody-Drug Conjugate IMGN529"},{"name":"Maps_To","value":"Naratuximab Emtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"727107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"727107"},{"name":"PDQ_Open_Trial_Search_ID","value":"727107"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3639093"}]}}{"C119700":{"preferredName":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E","code":"C119700","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of AGS67C, a human anti-CD37 monoclonal antibody covalently linked, via reduced cysteines and a protease cleavable linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AGS67E binds to CD37 antigens on tumor B-cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E","termGroup":"PT","termSource":"NCI"},{"termName":"AGS67E","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD37 MMAE ADC AGS67E","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E"},{"name":"NCI_Drug_Dictionary_ID","value":"762606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762606"},{"name":"PDQ_Open_Trial_Search_ID","value":"762606"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896733"}]}}{"C122833":{"preferredName":"Anti-CD37 Monoclonal Antibody BI 836826","code":"C122833","definitions":[{"definition":"An Fc-engineered, chimeric immunoglobulin (Ig) G1 monoclonal antibody against the tumor-associated antigen (TAA) CD37, with potential antineoplastic activity. Upon administration, the anti-CD37 monoclonal antibody BI 836826 both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. BI 836826 is Fc-engineered to improve ADCC activity and enhance affinity for the receptor Fc-gamma-RIIIa, which is expressed on human natural killer (NK) cells. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD37 Monoclonal Antibody BI 836826","termGroup":"PT","termSource":"NCI"},{"termName":"BI 836826","termGroup":"CN","termSource":"NCI"},{"termName":"MAb 37.1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LB090AB8DB"},{"name":"Maps_To","value":"Anti-CD37 Monoclonal Antibody BI 836826"},{"name":"NCI_Drug_Dictionary_ID","value":"695895"},{"name":"NCI_META_CUI","value":"CL433789"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695895"},{"name":"PDQ_Open_Trial_Search_ID","value":"695895"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97954":{"preferredName":"Felzartamab","code":"C97954","definitions":[{"definition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Felzartamab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Felzartamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38 Monoclonal Antibody MOR03087","termGroup":"SY","termSource":"NCI"},{"termName":"MOR03087","termGroup":"CN","termSource":"NCI"},{"termName":"MOR202","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2197112-39-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3O9FA4XC02"},{"name":"Maps_To","value":"Anti-CD38 Monoclonal Antibody MOR03087"},{"name":"Maps_To","value":"Felzartamab"},{"name":"NCI_Drug_Dictionary_ID","value":"710408"},{"name":"NCI_META_CUI","value":"CL430560"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710408"},{"name":"PDQ_Open_Trial_Search_ID","value":"710408"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148078":{"preferredName":"Mezagitamab","code":"C148078","definitions":[{"definition":"A human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. Mezagitamab specifically binds to CD38 that is expressed on human plasmablasts, plasma cells, NK cells and activated T- and B-cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), cell lysis and depletion of CD38-expressing cells. Additionally, TAK-079 does not induce CD38-dependent signaling and does not promote cytokine activation in peripheral blood mononuclear cells (PMBCs). CD38, a type II transmembrane glycoprotein, is overexpressed on cells associated with autoimmune diseases and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mezagitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38 MAb TAK-079","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 079","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-079","termGroup":"CN","termSource":"NCI"},{"termName":"TAK079","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2227490-52-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0XMR8L9LOL"},{"name":"Maps_To","value":"Anti-CD38 Monoclonal Antibody TAK-079"},{"name":"Maps_To","value":"Mezagitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"795705"},{"name":"NCI_META_CUI","value":"CL545882"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795705"},{"name":"PDQ_Open_Trial_Search_ID","value":"795705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C140427":{"preferredName":"Modakafusp Alfa","code":"C140427","definitions":[{"definition":"A proprietary preparation composed of an immunoglobulin G4 (IgG4) directed against the cell surface glycoprotein CD-38 (CD38) that is fused to an attenuated form of human interferon alpha (IFN alpha; IFNa), with potential immunomodulating and antineoplastic activities. Upon administration, modakafusp alfa specifically targets and binds to CD38 on CD38-positive tumor cells. In turn, the IFNa moiety binds to cell-surface IFN receptors, and activates IFN-mediated signal transduction pathways, which results in the transcription and translation of genes whose products may cause antiproliferative effects in CD38-positive tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modakafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38-targeted IgG4-attenuated IFNa TAK-573","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-targeted IgG4 Fused with Attenuated IFNa","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-573","termGroup":"CN","termSource":"NCI"},{"termName":"TEV-48573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254522-19-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TN8CEX4UT2"},{"name":"Maps_To","value":"Anti-CD38-targeted IgG4-attenuated IFNa TAK-573"},{"name":"Maps_To","value":"Modakafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"791259"},{"name":"NCI_META_CUI","value":"CL538488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791259"},{"name":"PDQ_Open_Trial_Search_ID","value":"791259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147563":{"preferredName":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342","code":"C147563","definitions":[{"definition":"A humanized, bispecific monoclonal antibody (BsAb) against human CD3, a T-cell surface antigen, and the human cell surface glycoprotein CD38, a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD38/anti-CD3 bispecific monoclonal antibody GBR 1342 binds to both CD3 on T-cells and CD38 expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis. GBR 1342 uses the proprietary bispecific engagement by antibodies based on the T-cell receptor (BEAT) platform.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38/Anti-CD3 Bispecific Monoclonal Antibody GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"BEAT GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"CD38xCD3 BsAb GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"GBR 1342","termGroup":"CN","termSource":"NCI"},{"termName":"GBR-1342","termGroup":"CN","termSource":"NCI"},{"termName":"GBR1342","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7H3Q0M9END"},{"name":"Maps_To","value":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342"},{"name":"NCI_Drug_Dictionary_ID","value":"792483"},{"name":"NCI_META_CUI","value":"CL545397"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792483"},{"name":"PDQ_Open_Trial_Search_ID","value":"792483"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162693":{"preferredName":"Anti-CD39 Monoclonal Antibody TTX-030","code":"C162693","definitions":[{"definition":"A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody TTX-030 specifically binds to the CD39 antigen, which may inhibit both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may promote the stimulation of dendritic and other myeloid-derived cells that are necessary for both innate and adaptive immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD39 Monoclonal Antibody TTX-030","termGroup":"PT","termSource":"NCI"},{"termName":"TTX 030","termGroup":"CN","termSource":"NCI"},{"termName":"TTX-030","termGroup":"CN","termSource":"NCI"},{"termName":"TTX030","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD39 Monoclonal Antibody TTX-030"},{"name":"NCI_Drug_Dictionary_ID","value":"798967"},{"name":"NCI_META_CUI","value":"CL973084"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798967"},{"name":"PDQ_Open_Trial_Search_ID","value":"798967"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139553":{"preferredName":"Giloralimab","code":"C139553","definitions":[{"definition":"An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, giloralimab binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giloralimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-927","termGroup":"CN","termSource":"NCI"},{"termName":"Agonistic Anti-CD40 Monoclonal Antibody ABBV-927","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Agonist Monoclonal Antibody ABBV-927","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Monoclonal Antibody ABBV-927","termGroup":"SY","termSource":"NCI"},{"termName":"PR-1614645","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226292-20-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6C58X3BFH"},{"name":"Maps_To","value":"Anti-CD40 Agonist Monoclonal Antibody ABBV-927"},{"name":"Maps_To","value":"Giloralimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791105"},{"name":"NCI_META_CUI","value":"CL526913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791105"},{"name":"PDQ_Open_Trial_Search_ID","value":"791105"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150558":{"preferredName":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","code":"C150558","definitions":[{"definition":"A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","termGroup":"PT","termSource":"NCI"},{"termName":"Agonist CD40 Antibody CDX-1140","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Agonistic Monoclonal Antibody CDX-1140","termGroup":"SY","termSource":"NCI"},{"termName":"CDX 1140","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-1140","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OWK8BG0FO6"},{"name":"Maps_To","value":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140"},{"name":"NCI_Drug_Dictionary_ID","value":"793440"},{"name":"NCI_META_CUI","value":"CL552359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793440"},{"name":"PDQ_Open_Trial_Search_ID","value":"793440"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101366":{"preferredName":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4","code":"C101366","definitions":[{"definition":"An IgG1 chimeric monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-CD40 monoclonal antibody Chi Lob 7/4 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent binds to the CD40 antigen present on the surfaces of some solid tumor cells, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) eventually resulting in decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and many solid tumors, mediating both indirect tumor cell death through the activation of the immune system and direct tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4","termGroup":"PT","termSource":"NCI"},{"termName":"Chi Lob 7/4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4"},{"name":"NCI_Drug_Dictionary_ID","value":"729807"},{"name":"NCI_META_CUI","value":"CL435546"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729807"},{"name":"PDQ_Open_Trial_Search_ID","value":"729807"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121217":{"preferredName":"Cifurtilimab","code":"C121217","definitions":[{"definition":"A proprietary, non-fucosylated monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, cifurtilimab binds to CD40 on a variety of immune cell types, triggering both cellular proliferation and activation of antigen-presenting cells (APCs), which activates B-cells and T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC), and eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system. The non-fucosylated antibody shows increased efficacy as compared to its fucosylated counterpart.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cifurtilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD40 Monoclonal Antibody SEA-CD40","termGroup":"SY","termSource":"NCI"},{"termName":"SEA CD40","termGroup":"CN","termSource":"NCI"},{"termName":"SEA-CD40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BY4DOG9SMH"},{"name":"Maps_To","value":"Anti-CD40 Monoclonal Antibody SEA-CD40"},{"name":"NCI_Drug_Dictionary_ID","value":"769820"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769820"},{"name":"PDQ_Open_Trial_Search_ID","value":"769820"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053590"}]}}{"C132681":{"preferredName":"Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428","code":"C132681","definitions":[{"definition":"A bispecific antibody directed against both the cell-surface receptor CD40 and the tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunostimulatory and antineoplastic activities. Upon administration of anti-CD40/anti-MSLN bispecific antibody ABBV-428, the anti-MSLN moiety targets and binds to MSLN expressed on tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells in the tumor microenvironment (TME) and induces CD40-dependent signaling pathways, which triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B-lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 428","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-428","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD40 x Anti-mesothelin Bispecific Antibody ABBV-428","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40/Anti-MSLN Bispecific Antibody ABBV-428","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428"},{"name":"NCI_Drug_Dictionary_ID","value":"787098"},{"name":"NCI_META_CUI","value":"CL520571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787098"},{"name":"PDQ_Open_Trial_Search_ID","value":"787098"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120140":{"preferredName":"Letolizumab","code":"C120140","definitions":[{"definition":"A dimeric fusion protein composed of the C-terminus of the domain antibody (dAb) BMS2h-572-633 targeting the CD40 ligand (CD40L or CD154) linked to a modified Fc fragment of immunoglobulin G1 (IgG1), with potential immunomodulatory activity. Upon intravenous administration, the peptide moiety of letolizumab specifically targets and binds to CD40L expressed on T-lymphocytes. This prevents the binding of CD40L to its cognate receptor CD40 expressed on B-lymphocytes, macrophages, and dendritic cells (DCs). This prevents T-cell mediated proliferation and differentiation of B-cells, and prevents the production of antibodies. By inhibiting both the production of anti-glycoprotein (GP) IIb/IIIa antibodies by B-cells and GPIIb/IIIa-dependent T-cell proliferation, letolizumab may prevent platelet destruction and may increase platelet counts in idiopathic thrombocytopenic purpura (ITP). The direct binding of letolizumab to CD40L on platelets further prevents CD40L/CD40-mediated destruction by macrophages and DCs in ITP. The modified Fc domain prevents the binding of letolizumab to the Fc receptor FcgammaRIIA on platelets, thereby preventing FcgammaRIIA-dependent platelet activation and anti-CD40L-induced thromboembolism. CD40L, a transmembrane protein of the tumor necrosis factor (TNF) superfamily, is primarily expressed on activated T-cells, but is also expressed on eosinophils, basophils, natural killer (NK) cells, mast cells, platelets and activated endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986004","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986004","termGroup":"CN","termSource":"NCI"},{"termName":"Fc-Fusion Protein BMS986004","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1450981-87-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"449MIE2SD6"},{"name":"Maps_To","value":"Anti-CD40L Fc-Fusion Protein BMS-986004"},{"name":"Maps_To","value":"Letolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"773819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"773819"},{"name":"PDQ_Open_Trial_Search_ID","value":"773819"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896896"}]}}{"C116881":{"preferredName":"Anti-CD44 Monoclonal Antibody RO5429083","code":"C116881","definitions":[{"definition":"A recombinant, humanized monoclonal antibody targeting the cancer stem cell (CSC) antigen CD44, with potential immunomodulating and antineoplastic activities. Upon administration, RO5429083 binds to the constant region of the extracellular domain of CD44, thereby preventing the activation of various CD44-mediated signal transduction pathways. This may lead to a reduction in the proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in tumor cell proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD44 Monoclonal Antibody RO5429083","termGroup":"PT","termSource":"NCI"},{"termName":"RG 7356","termGroup":"CN","termSource":"NCI"},{"termName":"RO5429083","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0T69CA5LQA"},{"name":"Maps_To","value":"Anti-CD44 Monoclonal Antibody RO5429083"},{"name":"NCI_Drug_Dictionary_ID","value":"701281"},{"name":"NCI_META_CUI","value":"CL433841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701281"},{"name":"PDQ_Open_Trial_Search_ID","value":"701281"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74009":{"preferredName":"Anti-CD45 Monoclonal Antibody AHN-12","code":"C74009","definitions":[{"definition":"A high affinity IgG1 monoclonal antibody with potential immunotherapeutic activity. Anti-CD45 monoclonal antibody AHN-12 recognizes CD45, a transmembrane protein tyrosine phosphatase that is expressed on the surface of normal and malignant hematopoietic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD45 Monoclonal Antibody AHN-12","termGroup":"PT","termSource":"NCI"},{"termName":"AHN-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD45_Monoclonal_Antibody_AHN-12"},{"name":"Maps_To","value":"Anti-CD45 Monoclonal Antibody AHN-12"},{"name":"NCI_Drug_Dictionary_ID","value":"587980"},{"name":"NCI_META_CUI","value":"CL383504"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587980"},{"name":"PDQ_Open_Trial_Search_ID","value":"587980"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156416":{"preferredName":"Anti-CD46 Antibody-drug Conjugate FOR46","code":"C156416","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and conjugated to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon administration, anti-CD46 ADC FOR46 specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. Upon binding and internalization, the cytotoxic payload kills the CD46-expressing tumor cells. The conformational epitope of CD46 is highly expressed in multiple tumor cell types while minimally expressed or absent in normal, healthy tissues.  FOR46 does not interfere with other CD46-mediated pathways that naturally occur in normal, healthy tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD46 Antibody-drug Conjugate FOR46","termGroup":"PT","termSource":"NCI"},{"termName":"ADC FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD46 ADC FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"CD46-ADC FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"FOR 46","termGroup":"CN","termSource":"NCI"},{"termName":"FOR-46","termGroup":"CN","termSource":"NCI"},{"termName":"FOR46","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD46 Antibody-drug Conjugate FOR46"},{"name":"NCI_Drug_Dictionary_ID","value":"795803"},{"name":"NCI_META_CUI","value":"CL563108"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795803"},{"name":"PDQ_Open_Trial_Search_ID","value":"795803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159600":{"preferredName":"Anti-CD47 Monoclonal Antibody AO-176","code":"C159600","definitions":[{"definition":"A humanized immunoglobulin G2 (IgG2) monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody AO-176 preferentially binds to CD47 on tumor cells because it exhibits enhanced binding at the acidic pH found in the tumor microenvironment (TME). This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. In addition, AO-176 induces immunogenic cell death (ICD) and releases damage-associated molecular patterns (DAMPs) from tumor cells, thereby further stimulating immune responses. AO-176 is also able to induce direct cytotoxic cell death by a cell autonomous mechanism. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody AO-176","termGroup":"PT","termSource":"NCI"},{"termName":"AO 176","termGroup":"CN","termSource":"NCI"},{"termName":"AO-176","termGroup":"CN","termSource":"NCI"},{"termName":"AO176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody AO-176"},{"name":"NCI_Drug_Dictionary_ID","value":"797803"},{"name":"NCI_META_CUI","value":"CL951599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797803"},{"name":"PDQ_Open_Trial_Search_ID","value":"797803"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C121211":{"preferredName":"Anti-CD47 Monoclonal Antibody CC-90002","code":"C121211","definitions":[{"definition":"A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody CC-90002","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Mab CC-90002","termGroup":"SY","termSource":"NCI"},{"termName":"CC 90002","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody CC-90002"},{"name":"NCI_Drug_Dictionary_ID","value":"769566"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769566"},{"name":"PDQ_Open_Trial_Search_ID","value":"769566"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053657"}]}}{"C117730":{"preferredName":"Magrolimab","code":"C117730","definitions":[{"definition":"A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, magrolimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Magrolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Hu5F9-G4","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-7913","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169232-81-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"90YIEHRFJ9"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody Hu5F9-G4"},{"name":"Maps_To","value":"Magrolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"763907"},{"name":"NCI_META_CUI","value":"CL474125"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763907"},{"name":"PDQ_Open_Trial_Search_ID","value":"763907"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157385":{"preferredName":"Letaplimab","code":"C157385","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, letaplimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letaplimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Monoclonal Antibody IBI188","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 188","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-188","termGroup":"CN","termSource":"NCI"},{"termName":"IBI188","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2283356-07-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BDN84I1TFE"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody IBI188"},{"name":"NCI_Drug_Dictionary_ID","value":"797112"},{"name":"NCI_META_CUI","value":"CL936985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797112"},{"name":"PDQ_Open_Trial_Search_ID","value":"797112"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160202":{"preferredName":"Anti-CD47 Monoclonal Antibody SHR-1603","code":"C160202","definitions":[{"definition":"A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SHR-1603 preferentially binds to CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody SHR-1603","termGroup":"PT","termSource":"NCI"},{"termName":"SHR 1603","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1603","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1603","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody SHR-1603"},{"name":"NCI_Drug_Dictionary_ID","value":"797797"},{"name":"NCI_META_CUI","value":"CL969337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797797"},{"name":"PDQ_Open_Trial_Search_ID","value":"797797"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C155976":{"preferredName":"Urabrelimab","code":"C155976","definitions":[{"definition":"A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, urabrelimab selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urabrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Monoclonal Antibody SRF231","termGroup":"SY","termSource":"NCI"},{"termName":"SRF 231","termGroup":"CN","termSource":"NCI"},{"termName":"SRF-231","termGroup":"CN","termSource":"NCI"},{"termName":"SRF231","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249722-58-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6284A5K8N"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody SRF231"},{"name":"Maps_To","value":"Urabrelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795110"},{"name":"NCI_META_CUI","value":"CL562712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795110"},{"name":"PDQ_Open_Trial_Search_ID","value":"795110"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163977":{"preferredName":"Lemzoparlimab","code":"C163977","definitions":[{"definition":"A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, lemzoparlimab preferentially binds to a unique epitope of CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. TJC4, compared to other anti-CD47 monoclonal antibodies, is designed to minimize inherent binding to normal red blood cells (RBCs), which may results in a more advantageous hematologic safety profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lemzoparlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Monoclonal Antibody TJC4","termGroup":"SY","termSource":"NCI"},{"termName":"TJ 011133","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-011133","termGroup":"CN","termSource":"NCI"},{"termName":"TJ011133","termGroup":"CN","termSource":"NCI"},{"termName":"TJC4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2377483-71-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0H2XLR2IKW"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody TJC4"},{"name":"NCI_Drug_Dictionary_ID","value":"801670"},{"name":"NCI_META_CUI","value":"CL977248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801670"},{"name":"PDQ_Open_Trial_Search_ID","value":"801670"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148103":{"preferredName":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A","code":"C148103","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody targeting the cell surface antigen CD48 that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary next-generation PEGylated glucuronide linker, with potential antineoplastic activity. Following intravenous administration, the antibody moiety of anti-CD48 ADC SGN-CD48A binds to CD48 on the surface of tumor cells. Following internalization of the ADC, the MMAE binds to tubulin and inhibits microtubule polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in CD48-expressing tumor cells. CD48, a member of the signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, is involved in T-cell activation and leukocyte trafficking. Additionally, CD48 is expressed on the surface of multiple myeloma cells at significantly higher levels than it is expressed on normal lymphocytes and monocytes. The linkage system in SGN-CD48A improves stability, reduces off-target uptake, and enables conjugation of larger numbers of MMAE/antibody than other systems, resulting in increased specificity against CD48-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD48 ADC SGN-CD48A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD48A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD48A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD48A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A"},{"name":"NCI_Drug_Dictionary_ID","value":"794392"},{"name":"NCI_META_CUI","value":"CL545862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794392"},{"name":"PDQ_Open_Trial_Search_ID","value":"794392"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160787":{"preferredName":"Anti-CD52 Monoclonal Antibody ALLO-647","code":"C160787","definitions":[{"definition":"A monoclonal antibody directed against the cell surface glycoprotein CD52 (CAMPATH-1 antigen; Cambridge pathology 1 antigen), with potential immunodepleting activity. Upon administration, anti-CD52 monoclonal antibody ALLO-647 selectively targets and binds to CD52, thereby triggering a host immune response that results in the lysis of CD52-positive lymphocytes. This leads to immunodepletion and may prevent graft-versus-host disease (GvHD). CD52 is a glycoprotein expressed on the surface of many immune cells, including essentially all B- and T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD52 Monoclonal Antibody ALLO-647","termGroup":"PT","termSource":"NCI"},{"termName":"ALLO 647","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-647","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO647","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD52 Monoclonal Antibody ALLO-647"},{"name":"NCI_Drug_Dictionary_ID","value":"798418"},{"name":"NCI_META_CUI","value":"CL969759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798418"},{"name":"PDQ_Open_Trial_Search_ID","value":"798418"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C84855":{"preferredName":"Anti-CD70 Antibody-Drug Conjugate MDX-1203","code":"C84855","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to a prodrug of a CC-1065 (rachelmycin) analogue via a stable peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate MDX-1203 selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the prodrug moiety is released and activated and binds to double-stranded B-DNA within the minor groove, thereby alkylating the -3 position of adenine, which may result in the inhibition of cellular proliferation of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The antitumor antibiotic CC-1065, a DNA minor-groove-binding alkylating agent, was originally isolated from the bacterium Streptomyces zelensis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 Antibody-Drug Conjugate MDX-1203","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 ADC MDX-1203","termGroup":"SY","termSource":"NCI"},{"termName":"MDX-1203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD70 Antibody-Drug Conjugate MDX-1203"},{"name":"NCI_Drug_Dictionary_ID","value":"651385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651385"},{"name":"PDQ_Open_Trial_Search_ID","value":"651385"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827532"}]}}{"C117732":{"preferredName":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A","code":"C117732","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing an engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70 molecule, conjugated to the synthetic, cytotoxic, DNA minor-groove crosslinking agent, pyrrolobenzodiazepine (PBD) dimer, via a stable, protease-cleavable, peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate SGN-CD70A selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the PBD dimer moiety is released and covalently binds, through its imine moieties, to the N2 positions of guanines on opposite strands of DNA. This induces DNA double strand breaks and inhibits DNA replication, which lead to the inhibition of cell growth of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The cysteine moiety of the EC-mAb allows for the stable conjugation of the PBD to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A","termGroup":"PT","termSource":"NCI"},{"termName":"SGN-CD70A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1447736-02-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YFZ7N482WG"},{"name":"Maps_To","value":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A"},{"name":"NCI_Drug_Dictionary_ID","value":"763909"},{"name":"NCI_META_CUI","value":"CL474127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763909"},{"name":"PDQ_Open_Trial_Search_ID","value":"763909"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162699":{"preferredName":"Anti-CD70 CAR-expressing T Lymphocytes","code":"C162699","definitions":[{"definition":"A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 CAR-expressing T Lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 CAR-expressing T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD70 CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD70 CAR T-lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD70 CAR-expressing T Lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"810124"},{"name":"NCI_META_CUI","value":"CL973102"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78187":{"preferredName":"Anti-CD70 Monoclonal Antibody MDX-1411","code":"C78187","definitions":[{"definition":"A glycoengineered, fully human IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Anti-CD70 fully human monoclonal antibody MDX-1411 selectivity binds to the extracellular domain of CD70, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on renal cell carcinoma (RCC) cells among other cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 Monoclonal Antibody MDX-1411","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-1411","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD70_Fully_Human_Monoclonal_Antibody_MDX-1411"},{"name":"Maps_To","value":"Anti-CD70 Monoclonal Antibody MDX-1411"},{"name":"NCI_Drug_Dictionary_ID","value":"594769"},{"name":"NCI_META_CUI","value":"CL383579"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594769"},{"name":"PDQ_Open_Trial_Search_ID","value":"594769"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153287":{"preferredName":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029","code":"C153287","definitions":[{"definition":"A probody-drug conjugate (PDC) composed of a monoclonal antibody directed against the transferrin receptor 1 (TFR1;TRP1; CD71), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, and conjugated, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of the anti-CD71/vcMMAE PDC CX-2029, the anti-CD71 moiety is unable to bind to CD71 antigen, which is highly expressed on both tumor and healthy dividing cells, until the masking peptide that is attached to the anti-CD71 probody is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Local protease-mediated removal of the linker and masking peptide enables specific binding of the unmasked anti-CD71 moiety to CD71 expressed on tumor cells. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of CD71-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. CD71, a transmembrane glycoprotein, is a highly expressed protein present in a number of solid and hematologic cancers, but is also expressed on normal, healthy tissues. The peptide masking of CX-2029 minimizes binding of the anti-CD71 antibody moiety to normal, healthy cells and may minimize systemic toxicity, when compared to other anti-CD71 antibody-drug conjugates (ADCs). Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD71 Probody/vcMMAE Drug Conjugate CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody Prodrug-drug Conjugate CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"CD71-directed PDC CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"CD71-Directed Probody Therapeutic CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"CX 2029","termGroup":"CN","termSource":"NCI"},{"termName":"CX-2029","termGroup":"CN","termSource":"NCI"},{"termName":"CX2029","termGroup":"CN","termSource":"NCI"},{"termName":"PBC CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"PDC-targeting CD71 CX-2029","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029"},{"name":"NCI_Drug_Dictionary_ID","value":"794073"},{"name":"NCI_META_CUI","value":"CL554515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794073"},{"name":"PDQ_Open_Trial_Search_ID","value":"794073"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132266":{"preferredName":"Anti-CD73 Monoclonal Antibody BMS-986179","code":"C132266","definitions":[{"definition":"A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody BMS-986179 targets and binds to CD73, leading to clustering and internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD73 Monoclonal Antibody BMS-986179","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986179","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7PO9B4VQ1U"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody BMS-986179"},{"name":"NCI_Drug_Dictionary_ID","value":"783651"},{"name":"NCI_META_CUI","value":"CL520363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783651"},{"name":"PDQ_Open_Trial_Search_ID","value":"783651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156061":{"preferredName":"Mupadolimab","code":"C156061","definitions":[{"definition":"A type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, mupadolimab targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mupadolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD73 Monoclonal Antibody CPI-006","termGroup":"SY","termSource":"NCI"},{"termName":"CPI 006","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-006","termGroup":"CN","termSource":"NCI"},{"termName":"CPI006","termGroup":"CN","termSource":"NCI"},{"termName":"CPX-006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2451856-97-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23ET6940RM"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody CPI-006"},{"name":"NCI_Drug_Dictionary_ID","value":"795397"},{"name":"NCI_META_CUI","value":"CL562920"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795397"},{"name":"PDQ_Open_Trial_Search_ID","value":"795397"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C158132":{"preferredName":"Anti-CD73 Monoclonal Antibody NZV930","code":"C158132","definitions":[{"definition":"A fully human monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-CD73 monoclonal antibody NZV930 targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated in many cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD73 Monoclonal Antibody NZV930","termGroup":"PT","termSource":"NCI"},{"termName":"NZV 930","termGroup":"CN","termSource":"NCI"},{"termName":"NZV-930","termGroup":"CN","termSource":"NCI"},{"termName":"NZV930","termGroup":"CN","termSource":"NCI"},{"termName":"SRF 373","termGroup":"CN","termSource":"NCI"},{"termName":"SRF-373","termGroup":"SY","termSource":"NCI"},{"termName":"SRF373","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2M0F9Q9SZ2"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody NZV930"},{"name":"NCI_Drug_Dictionary_ID","value":"797358"},{"name":"NCI_META_CUI","value":"CL937671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797358"},{"name":"PDQ_Open_Trial_Search_ID","value":"797358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159168":{"preferredName":"Uliledlimab","code":"C159168","definitions":[{"definition":"A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, uliledlimab targets and binds to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uliledlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD73 Monoclonal Antibody TJ4309","termGroup":"SY","termSource":"NCI"},{"termName":"TJ 004309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ 4309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-004309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-4309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ004309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ4309","termGroup":"CN","termSource":"NCI"},{"termName":"TJD5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2378407-27-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3OX1DBR75G"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody TJ4309"},{"name":"NCI_Drug_Dictionary_ID","value":"797647"},{"name":"NCI_META_CUI","value":"CL951040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797647"},{"name":"PDQ_Open_Trial_Search_ID","value":"797647"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148066":{"preferredName":"Anti-CD74 Antibody-drug Conjugate STRO-001","code":"C148066","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. The antibody moiety of anti-CD74 ADC STRO-001 targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD74 Antibody-drug Conjugate STRO-001","termGroup":"PT","termSource":"NCI"},{"termName":"ADC STRO-001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD74 ADC STRO-001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD74 Antibody-drug Conjugate BN301","termGroup":"SY","termSource":"NCI"},{"termName":"BN 301","termGroup":"CN","termSource":"NCI"},{"termName":"BN-301","termGroup":"CN","termSource":"NCI"},{"termName":"BN301","termGroup":"CN","termSource":"NCI"},{"termName":"SP7675","termGroup":"CN","termSource":"NCI"},{"termName":"STRO-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0D8BWL78LD"},{"name":"Maps_To","value":"Anti-CD74 Antibody-drug Conjugate STRO-001"},{"name":"NCI_Drug_Dictionary_ID","value":"795302"},{"name":"NCI_META_CUI","value":"CL545806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795302"},{"name":"PDQ_Open_Trial_Search_ID","value":"795302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113659":{"preferredName":"Anti-CD98 Monoclonal Antibody IGN523","code":"C113659","definitions":[{"definition":"A humanized, monoclonal antibody targeting the CD98 (gp125) antigen, with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, IGN523 binds to CD98 expressed on the tumor cell surface and elicits both natural killer (NK)-cell mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity towards CD98-expressing tumor cells. In addition, IGN523 inhibits essential amino acid uptake by rapidly proliferating tumor cells. CD98, a type II transmembrane glycoprotein, is involved in both integrin signaling and amino acid transport processes; it is overexpressed in certain cancer cells and plays a key role in the proliferation, survival and metastasis of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD98 Monoclonal Antibody IGN523","termGroup":"PT","termSource":"NCI"},{"termName":"IGN523","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2206820-08-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7OI79TB6KN"},{"name":"Maps_To","value":"Anti-CD98 Monoclonal Antibody IGN523"},{"name":"NCI_Drug_Dictionary_ID","value":"757070"},{"name":"NCI_META_CUI","value":"CL458372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757070"},{"name":"PDQ_Open_Trial_Search_ID","value":"757070"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131439":{"preferredName":"Anti-CDH6 Antibody-drug Conjugate HKT288","code":"C131439","definitions":[{"definition":"An immunoconjugate consisting of a human monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated to a maytansine-based cytotoxic agent, with potential antineoplastic activity. The monoclonal antibody moiety of HKT288 targets and binds to CDH6 located on tumor cell surfaces. After internalization, the maytansine moiety binds to tubulin, which disrupts microtubule assembly/disassembly dynamics and inhibits both division and proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CDH6 Antibody-drug Conjugate HKT288","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CDH6 ADC HKT288","termGroup":"SY","termSource":"NCI"},{"termName":"HKT 288","termGroup":"CN","termSource":"NCI"},{"termName":"HKT-288","termGroup":"CN","termSource":"NCI"},{"termName":"HKT288","termGroup":"CN","termSource":"NCI"},{"termName":"Maytansine-based ADC HKT-288","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"94ZE6ON35F"},{"name":"Maps_To","value":"Anti-CDH6 Antibody-drug Conjugate HKT288"},{"name":"NCI_Drug_Dictionary_ID","value":"786265"},{"name":"NCI_META_CUI","value":"CL514241"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786265"},{"name":"PDQ_Open_Trial_Search_ID","value":"786265"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95728":{"preferredName":"Anti-CEA BiTE Monoclonal Antibody AMG211","code":"C95728","definitions":[{"definition":"A recombinant, proprietary bispecific T-cell engagers (BiTE) antibody directed against human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Anti-CEA BiTE monoclonal antibody AMG211 possesses two antigen-recognition sites, one for CEA and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings CEA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CEA-expressing cells. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEA BiTE Monoclonal Antibody AMG211","termGroup":"PT","termSource":"NCI"},{"termName":"AMG211","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-565","termGroup":"CN","termSource":"NCI"},{"termName":"MT111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CEA BiTE Monoclonal Antibody AMG211"},{"name":"NCI_Drug_Dictionary_ID","value":"694640"},{"name":"NCI_META_CUI","value":"CL428189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694640"},{"name":"PDQ_Open_Trial_Search_ID","value":"694640"},{"name":"PubMedID_Primary_Reference","value":"19342971"},{"name":"PubMedID_Primary_Reference","value":"19953093"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68927":{"preferredName":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody","code":"C68927","definitions":[{"definition":"A bispecific monoclonal antibody (BsMAb) consisting of the Fab fragment of an anti-CEA monoclonal antibody (F6) coupled to the Fab fragment of an anti-DTPA-In monoclonal antibody (734) with potential radioimmunotherapeutic activity. In a two-step pretargeted radioimmunotherapeutic approach, this BsMAb, localizing to CEA-expressing tumor cells via the F6 Fab fragment, is introduced into patient first, followed by injection of indium 131-radiolabeled DTPA, which is recognized by the 734 Fab fragment of the BsMAb. Accordingly, a potentially lethal dose of indium 131 is delivered specifically to CEA-expressing tumor cells while minimizing radiotoxicity to normal tissues. CEA (carcinoembryonic antigen) is a tumor antigen overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. DTPA (diethylenetriaminepentaacetic acid) is a bivalent hapten.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody","termGroup":"PT","termSource":"NCI"},{"termName":"F6-734 BsMAb","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CEA_Anti-DTPA-In_F6-734_Bispecific_Antibody"},{"name":"Maps_To","value":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody"},{"name":"NCI_Drug_Dictionary_ID","value":"549681"},{"name":"NCI_META_CUI","value":"CL374415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"549681"},{"name":"PDQ_Open_Trial_Search_ID","value":"549681"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82355":{"preferredName":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2","code":"C82355","definitions":[{"definition":"A tri-Fab bispecific monoclonal antibody (BiMoAb) divalent for the carcinoembryonic antigen (CEA) and monovalent for histamine-succinyl-glycine (HSG) peptide-hapten. Anti-CEA/anti-HSG bispecific monoclonal antibody TF2 binds to the tumor associated antigen (TAA) CEA on CEA-expressing tumor cells. Subsequently, an HSG peptide-hapten carrying a radionuclide is administered, binding to the anti-HSG binding fragment on the BiMoAb. Depending on the characteristics of the radionuclide used, CEA-expressing tumor cells may then be radioimaged and/or treated radioimmunotherapeutically.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CEA x Anti-Histamine-Succinyl-Glycine Bispecific Monoclonal Antibody TF2","termGroup":"SY","termSource":"NCI"},{"termName":"TF2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CEA_Anti-HSG_Bispecific_Monoclonal_Antibody_TF2"},{"name":"Maps_To","value":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2"},{"name":"NCI_Drug_Dictionary_ID","value":"639754"},{"name":"NCI_META_CUI","value":"CL408839"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639754"},{"name":"PDQ_Open_Trial_Search_ID","value":"639754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C120305":{"preferredName":"Anti-CEACAM1 Monoclonal Antibody CM-24","code":"C120305","definitions":[{"definition":"A humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting the anti-carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1; CD66a), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CEACAM1 monoclonal antibody CM-24, this agent binds to CEACAM1 on cancer cells and certain immune cells. This blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. This enhances the activation of cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells and increases CTL- and NK-mediated killing of CEACAM1-overexpressing cancer cells. CEACAM1, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its overexpression is correlated with both immunosuppression and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEACAM1 Monoclonal Antibody CM-24","termGroup":"PT","termSource":"NCI"},{"termName":"CM-24","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1783801-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JTP97OR4LL"},{"name":"Maps_To","value":"Anti-CEACAM1 Monoclonal Antibody CM-24"},{"name":"NCI_Drug_Dictionary_ID","value":"768651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768651"},{"name":"PDQ_Open_Trial_Search_ID","value":"768651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896886"}]}}{"C117229":{"preferredName":"Tusamitamab Ravtansine","code":"C117229","definitions":[{"definition":"An immunoconjugate consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to a cytotoxic agent, with potential antineoplastic activity. Upon administration of tusamitamab ravtansine the antibody moiety targets CEACAM5 on tumor cells. Upon antibody/antigen binding and internalization, the immunoconjugate releases the cytotoxic agent, which results in tumor cell death. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tusamitamab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SAR408701","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CEACAM5 Antibody-Drug Conjugate SAR408701","termGroup":"SY","termSource":"NCI"},{"termName":"SAR408701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254086-60-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DSS3BE2ZXN"},{"name":"Maps_To","value":"Anti-CEACAM5 Antibody-Drug Conjugate SAR408701"},{"name":"NCI_Drug_Dictionary_ID","value":"762948"},{"name":"NCI_META_CUI","value":"CL474097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762948"},{"name":"PDQ_Open_Trial_Search_ID","value":"762948"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120068":{"preferredName":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47","code":"C120068","definitions":[{"definition":"A lyophilized formulation of DOS47, an immunoconjugate composed of AFAIKL2, a recombinant camelid single-domain antibody which recognizes carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), and the enzyme urease derived from the plant Canavalia ensiformis (Jack bean), with potential antineoplastic activity. Upon intravenous administration, the AFAIKL2 antibody fragment moiety of L-DOS47 specifically targets and binds to CEACAM6 expressed on certain tumor cells. In turn, the urease moiety of L-DOS47 catalyzes the hydrolysis of urea into ammonia, which is further hydrolyzed to produce hydroxyl ions, and causes a locally increased concentration of the toxic waste product ammonia, which under normal conditions is converted into the nontoxic substance urea via the urea cycle. This increases the pH of the tumor microenvironment and alkalinizes the highly acidic environment that is needed for cancer cell survival and proliferation. In addition, the ammonia diffuses into cancer cells and exerts a cytotoxic effect. Altogether, this leads to cell death of CEACAM6-expressing cancer cells. The naturally-occurring enzyme urease catalyzes the hydrolysis of urea into ammonia and carbon dioxide. CEACAM6, a tumor-associated antigen and CEA family member, is overexpressed in a variety of tumor cells and plays a key role in tumor initiation, progression, metastasis and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47","termGroup":"PT","termSource":"NCI"},{"termName":"L-DOS47","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"95E1ZQM329"},{"name":"Maps_To","value":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47"},{"name":"NCI_Drug_Dictionary_ID","value":"768359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768359"},{"name":"PDQ_Open_Trial_Search_ID","value":"768359"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896827"}]}}{"C171841":{"preferredName":"Tinurilimab","code":"C171841","definitions":[{"definition":"A humanized monoclonal antibody directed against the immune checkpoint regulator carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,tinurilimab targets, binds to and blocks the activity of CEACAM6 expressed on various tumor and immune cells, including T-cells. Blocking CEACAM6 signaling abrogates effector T-cell inhibition, activates antigen-specific T-lymphocytes, increases secretion of T-cell cytokines and effector molecules, and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated immune suppression. Elevated CEACAM6 expression is associated with advanced tumor stages and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinurilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CEACAM6 Antibody BAY1834942","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1834942","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1834942","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1834942","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226224-30-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"227KIR246G"},{"name":"Maps_To","value":"Anti-CEACAM6 Antibody BAY1834942"},{"name":"NCI_Drug_Dictionary_ID","value":"797774"},{"name":"NCI_META_CUI","value":"CL951555"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114286":{"preferredName":"Anti-CLDN6 Monoclonal Antibody ASP1650","code":"C114286","definitions":[{"definition":"A monoclonal antibody directed against the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN6 monoclonal antibody ASP1650 binds to CLDN-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (ADCC) and a complement-dependent cytotoxicity (CDC) mediated immune response against CLDN-6-expressing tumor cells. This may inhibit tumor cell growth. CLDN-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CLDN6 Monoclonal Antibody ASP1650","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Claudin 6 Monoclonal Antibody ASP1650","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 1650","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1650","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1650","termGroup":"CN","termSource":"NCI"},{"termName":"IMAB027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CLDN6 Monoclonal Antibody ASP1650"},{"name":"NCI_Drug_Dictionary_ID","value":"757981"},{"name":"NCI_META_CUI","value":"CL471794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757981"},{"name":"PDQ_Open_Trial_Search_ID","value":"757981"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148141":{"preferredName":"Tepoditamab","code":"C148141","definitions":[{"definition":"An immunoglobulin G1 (IgG1) bispecific human monoclonal antibody against human CD3, a T-cell surface antigen, and human C-type lectin domain family 12 member A (CLEC12A), a tumor-associated antigen (TAA) overexpressed on certain tumor cells, with potential antineoplastic activity. Upon administration, tepoditamab binds to both CD3 on T-cells and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor cells and leukemic stem cells (LSCs). This results in the cross-linking of T-cells with tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CLEC12A-expressing tumor cells. CLEC12A, a myeloid differentiation antigen and member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including hematopoietic stem cells (HSCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tepoditamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CLEC12A x CD3 Bispecific Antibody MCLA117","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CLEC12A/Anti-CD3 Bispecific Antibody MCLA117","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody MCLA-117","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Bispecific, Anti-(C-type lectin CLEC12A and CD3 Antigen) (Human Monoclonal MCLA-117 Gamma1-chain), Disulfide with Human Monoclonal MCLA-117 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MCLA 117","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA-117","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA117","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2044679-53-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LK0H7J2V3C"},{"name":"Maps_To","value":"Anti-CLEC12A/CD3 Bispecific Antibody MCLA117"},{"name":"Maps_To","value":"Tepoditamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792475"},{"name":"NCI_META_CUI","value":"CL550807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792475"},{"name":"PDQ_Open_Trial_Search_ID","value":"792475"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159536":{"preferredName":"Bexmarilimab","code":"C159536","definitions":[{"definition":"A monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1), with potential immunomodulatory and antineoplastic activities. Upon administration, bexmarilimab targets and binds to CLEVER-1 that is expressed on tumor endothelial cells. This prevents the recruitment, infiltration and attachment of tumor-associated macrophages (TAMs) at the tumor site. By preventing the binding of TAMs to tumor cells, the infiltration of activated T-regulatory cells (Tregs) to the tumor and the TAM-mediated immune suppression is abrogated, leading to the polarization of TAM from the immunosuppressive M2 macrophages to the anti-inflammatory and immunostimulatory M1 macrophages. This leads to the activation of the immune system, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response and inhibition of tumor cell growth and metastasis. CLEVER-1 is an endothelial cell surface molecule involved in immune suppression, cancer growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bexmarilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-stabilin-1 Monoclonal Antibody FP-1305","termGroup":"SY","termSource":"NCI"},{"termName":"Clevegen","termGroup":"FB","termSource":"NCI"},{"termName":"FP 1305","termGroup":"CN","termSource":"NCI"},{"termName":"FP-1305","termGroup":"CN","termSource":"NCI"},{"termName":"FP1305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2259301-27-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SA0O2AK3LA"},{"name":"Maps_To","value":"Anti-CLEVER-1 Monoclonal Antibody FP-1305"},{"name":"Maps_To","value":"Bexmarilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"797468"},{"name":"NCI_META_CUI","value":"CL951430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797468"},{"name":"PDQ_Open_Trial_Search_ID","value":"797468"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131301":{"preferredName":"Anti-CSF1 Monoclonal Antibody PD-0360324","code":"C131301","definitions":[{"definition":"A humanized immunoglobulin (Ig) G2 monoclonal antibody (mAb) directed against the cytokine colony stimulating factor 1 (CSF1; CSF-1; macrophage colony-stimulating factor; M-CSF), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CSF1 monoclonal antibody PD-0360324 targets, binds to and neutralizes CSF1. This prevents the binding of CSF1 to its receptor CSF1R (CD115; M-CSFR), which is expressed on various immune cells, such as monocytes and macrophages. This prevents CSF1R activation and CSF1R-mediated signaling in these cells; this inhibits monocyte differentiation, blocks the activity of macrophages, and reduces their production of inflammatory mediators, which reduces inflammation. By blocking the activity and proliferation of CSF1R-dependent tumor-associated macrophages (TAMs) in the tumor microenvironment, PD-0360324 reduces TAM-mediated immune suppression, decreases regulatory T-cells (Tregs), re-activates the immune system, and improves anti-tumor cell responses mediated by increasing infiltration by cytotoxic T-cells. TAMs play key roles in immune suppression, and tumor cell proliferation and survival. CSF-1 plays a key role in the regulation of the proliferation, differentiation and survival of monocytes and macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CSF1 Monoclonal Antibody PD-0360324","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-M-CSF mAb PD-0360324","termGroup":"SY","termSource":"NCI"},{"termName":"PD 0360324","termGroup":"CN","termSource":"NCI"},{"termName":"PD 360324","termGroup":"CN","termSource":"NCI"},{"termName":"PD-0360324","termGroup":"CN","termSource":"NCI"},{"termName":"PD-360,324","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1822383-05-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EF7PK2TQ0U"},{"name":"Maps_To","value":"Anti-CSF1 Monoclonal Antibody PD-0360324"},{"name":"NCI_Drug_Dictionary_ID","value":"785869"},{"name":"NCI_META_CUI","value":"CL514242"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785869"},{"name":"PDQ_Open_Trial_Search_ID","value":"785869"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96801":{"preferredName":"Anti-CSF1R Monoclonal Antibody IMC-CS4","code":"C96801","definitions":[{"definition":"A monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. CSF1R monoclonal antibody IMC-CS4 binds to CSF1R which may trigger antitumoral antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells overexpressing CSF1R. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (Cluster of Differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1); this receptor is overexpressed or mutated in certain tumor cell types and plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CSF1R Monoclonal Antibody IMC-CS4","termGroup":"PT","termSource":"NCI"},{"termName":"IMC-CS4","termGroup":"CN","termSource":"NCI"},{"termName":"LY3022855","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CSF1R Monoclonal Antibody IMC-CS4"},{"name":"NCI_Drug_Dictionary_ID","value":"710355"},{"name":"NCI_META_CUI","value":"CL429408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710355"},{"name":"PDQ_Open_Trial_Search_ID","value":"710355"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155813":{"preferredName":"Axatilimab","code":"C155813","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R), with potential antineoplastic activity. Upon intravenous administration, axatilimab binds to the ligand binding domain of CSF-1R, preventing binding and consequent activation by its natural ligands, IL-34 and colony-stimulating factor 1 (CSF-1). Inhibition of CSF-1R activation may disrupt the activity of tumor-associated macrophages (TAMs), which promote initiation and metastasis of tumor cells, inhibit T-cell responses, and stimulate tumor angiogenesis and disease progression. CSF-1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and cluster of differentiation 115 (CD115), is a tyrosine-protein kinase that plays an essential role in the regulation, proliferation, survival and differentiation of tissue macrophages as well as TAMs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axatilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-M-CSFR Monoclonal Antibody SNDX-6352","termGroup":"SY","termSource":"NCI"},{"termName":"SNDX 6352","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX-6352","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX6352","termGroup":"CN","termSource":"NCI"},{"termName":"UCB6352","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2155851-88-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R96Z451BMC"},{"name":"Maps_To","value":"Anti-CSF1R Monoclonal Antibody SNDX-6352"},{"name":"Maps_To","value":"Axatilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"794081"},{"name":"NCI_META_CUI","value":"CL556346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794081"},{"name":"PDQ_Open_Trial_Search_ID","value":"794081"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92577":{"preferredName":"Pamrevlumab","code":"C92577","definitions":[{"definition":"A human monoclonal antibody targeting connective tissue growth factor (CTGF) with potential anti-fibrotic and antineoplastic activities. Pamrevlumab binds to CTGF thereby preventing the binding of the ligand to the receptor and subsequent receptor activation. As CTGF enhances the production of collagen and fibronectin, FG-319 may prevent and reverse fibrosis. In addition, FG-3019 may prevent tumor cell proliferation in CTGF-expressing tumor cells. CTGF, a member of the CCN family (CTGF, CYR61/CEF and NOV), is expressed in a variety of tumor cell types and is involved in processes such as cell proliferation, cell migration, cell adhesion, differentiation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamrevlumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Connective Tissue Growth Factor Monoclonal Antibody FG-3019","termGroup":"SY","termSource":"NCI"},{"termName":"FG-3019","termGroup":"CN","termSource":"NCI"},{"termName":"FG3019","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946415-13-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QS5F6VTS0O"},{"name":"Maps_To","value":"Anti-CTGF Monoclonal Antibody FG-3019"},{"name":"Maps_To","value":"Pamrevlumab"},{"name":"NCI_Drug_Dictionary_ID","value":"683932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683932"},{"name":"PDQ_Open_Trial_Search_ID","value":"683932"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985186"}]}}{"C162505":{"preferredName":"Anti-CTLA-4 Monoclonal Antibody ADU-1604","code":"C162505","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADU-1604 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4 Monoclonal Antibody ADU-1604","termGroup":"PT","termSource":"NCI"},{"termName":"ADU 1604","termGroup":"CN","termSource":"NCI"},{"termName":"ADU-1604","termGroup":"CN","termSource":"NCI"},{"termName":"ADU1604","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody ADU-1604"},{"name":"NCI_Drug_Dictionary_ID","value":"798657"},{"name":"NCI_META_CUI","value":"CL970933"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798657"},{"name":"PDQ_Open_Trial_Search_ID","value":"798657"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158557":{"preferredName":"Botensilimab","code":"C158557","definitions":[{"definition":"An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody  botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botensilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 1181","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-1181","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1181","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody AGEN1181","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2408310-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z5YC3ME5N"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody AGEN1181"},{"name":"NCI_Drug_Dictionary_ID","value":"797474"},{"name":"NCI_META_CUI","value":"CL938004"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797474"},{"name":"PDQ_Open_Trial_Search_ID","value":"797474"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156734":{"preferredName":"Nurulimab","code":"C156734","definitions":[{"definition":"A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nurulimab targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nurulimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody BCD-145","termGroup":"SY","termSource":"NCI"},{"termName":"BCD 145","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-145","termGroup":"CN","termSource":"NCI"},{"termName":"BCD145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2168561-20-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"894KSI08XK"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody BCD-145"},{"name":"Maps_To","value":"Nurulimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795594"},{"name":"NCI_META_CUI","value":"CL935901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795594"},{"name":"PDQ_Open_Trial_Search_ID","value":"795594"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150679":{"preferredName":"Quavonlimab","code":"C150679","definitions":[{"definition":"A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, quavonlimab targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quavonlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody MK-1308","termGroup":"SY","termSource":"NCI"},{"termName":"MK 1308","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1308","termGroup":"CN","termSource":"NCI"},{"termName":"MK1308","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254059-25-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GG0AN49Y59"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody MK-1308"},{"name":"NCI_Drug_Dictionary_ID","value":"793094"},{"name":"NCI_META_CUI","value":"CL552570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793094"},{"name":"PDQ_Open_Trial_Search_ID","value":"793094"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159764":{"preferredName":"Anti-CTLA-4 Monoclonal Antibody REGN4659","code":"C159764","definitions":[{"definition":"A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4 Monoclonal Antibody REGN4659","termGroup":"PT","termSource":"NCI"},{"termName":"REGN 4659","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-4659","termGroup":"CN","termSource":"NCI"},{"termName":"REGN4659","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6CGQ1X5Y6V"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody REGN4659"},{"name":"NCI_Drug_Dictionary_ID","value":"797920"},{"name":"NCI_META_CUI","value":"CL951623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797920"},{"name":"PDQ_Open_Trial_Search_ID","value":"797920"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159530":{"preferredName":"Pavunalimab","code":"C159530","definitions":[{"definition":"An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pavunalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4/Anti-LAG-3 Bispecific Monoclonal Antibody XmAb22841","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841","termGroup":"SY","termSource":"NCI"},{"termName":"CTLA-4 x LAG-3 Bispecific Antibody XmAb22841","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb 22841","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb-22841","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb22841","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2329669-78-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3PT70X17VS"},{"name":"Maps_To","value":"Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841"},{"name":"NCI_Drug_Dictionary_ID","value":"797814"},{"name":"NCI_META_CUI","value":"CL951426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797814"},{"name":"PDQ_Open_Trial_Search_ID","value":"797814"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157494":{"preferredName":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","code":"C157494","definitions":[{"definition":"A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","termGroup":"PT","termSource":"NCI"},{"termName":"ADC 1015","termGroup":"SY","termSource":"NCI"},{"termName":"ADC-1015","termGroup":"CN","termSource":"NCI"},{"termName":"ADC1015","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR 1015","termGroup":"SY","termSource":"NCI"},{"termName":"ATOR-1015","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR1015","termGroup":"CN","termSource":"NCI"},{"termName":"CTLA-4 x OX40 Bispecific Antibody ATOR-1015","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015"},{"name":"NCI_Drug_Dictionary_ID","value":"796793"},{"name":"NCI_META_CUI","value":"CL937070"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796793"},{"name":"PDQ_Open_Trial_Search_ID","value":"796793"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135633":{"preferredName":"Anti-CTLA4 Monoclonal Antibody BMS-986218","code":"C135633","definitions":[{"definition":"A Fc-modified monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 monoclonal antibody BMS-986218 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. Removal of the fucose sugar units from the antibody's Fc region, enhances its activity and decreases the toxicity of BMS-986218.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA4 Monoclonal Antibody BMS-986218","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986218","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986218","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody BMS-986218","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA4 Monoclonal Antibody BMS-986218"},{"name":"NCI_Drug_Dictionary_ID","value":"789026"},{"name":"NCI_META_CUI","value":"CL522988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789026"},{"name":"PDQ_Open_Trial_Search_ID","value":"789026"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C131572":{"preferredName":"Anti-CXCR4 Monoclonal Antibody PF-06747143","code":"C131572","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) against C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, anti-CXCR4 mAb PF-06747143 binds to CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation. This results in decreased proliferation and migration of CXCR4-expressing tumor cells. In addition, PF-06747143 promotes cell death through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is upregulated in several tumor cell types and plays an important role in cancer cell proliferation, survival, and chemotaxis, and in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CXCR4 Monoclonal Antibody PF-06747143","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CXCR4 IgG1 Antibody PF-06747143","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06747143","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06747143","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7TS9C20ZWA"},{"name":"Maps_To","value":"Anti-CXCR4 Monoclonal Antibody PF-06747143"},{"name":"NCI_Drug_Dictionary_ID","value":"786269"},{"name":"NCI_META_CUI","value":"CL514243"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786269"},{"name":"PDQ_Open_Trial_Search_ID","value":"786269"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71749":{"preferredName":"Anti-Denatured Collagen Monoclonal Antibody TRC093","code":"C71749","definitions":[{"definition":"A humanized, affinity-matured IgG1k antibody directed against denatured collagens (I-IV) with potential antiangiogenic and antineoplastic activities. Anti-denatured collagen recombinant monoclonal antibody TRC093 binds to multiple epitopes on denatured collagens, inhibiting proteolytic collagen-mediated signaling in the extracellular matrix (ECM) that is important to tumor angiogenesis, tumor growth, and metastasis. The epitopes on denatured collagen bound by this antibody are considered cryptic because, in vivo, they are accessible only on the subendothelial basement membrane of tumors or in normal tissues undergoing neovascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Denatured Collagen Monoclonal Antibody TRC093","termGroup":"PT","termSource":"NCI"},{"termName":"D93","termGroup":"CN","termSource":"NCI"},{"termName":"MT293","termGroup":"CN","termSource":"NCI"},{"termName":"TRC093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Humanized_IgG1k_Monoclonal_Antibody_TRC093"},{"name":"Maps_To","value":"Anti-Denatured Collagen Monoclonal Antibody TRC093"},{"name":"NCI_Drug_Dictionary_ID","value":"560174"},{"name":"NCI_META_CUI","value":"CL376136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560174"},{"name":"PDQ_Open_Trial_Search_ID","value":"560174"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C99123":{"preferredName":"Sirexatamab","code":"C99123","definitions":[{"definition":"A humanized monoclonal antibody directed against the WNT antagonist dickkopf homolog 1 (DKK1), with potential anti-osteolytic activity. Upon administration, sirexatamab binds to and inhibits DKK1, thereby restoring signaling through the WNT pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1, overexpressed by certain cancer cells, is an inhibitor of the WNT signaling pathway and prevents the mediated formation of bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirexatamab","termGroup":"PT","termSource":"NCI"},{"termName":"DKK1-Neutralizing Monoclonal Antibody DKN-01","termGroup":"SY","termSource":"NCI"},{"termName":"DKN-01","termGroup":"CN","termSource":"NCI"},{"termName":"LY2812176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2414962-49-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RM898LZ4SI"},{"name":"Maps_To","value":"Anti-DKK-1 Monoclonal Antibody LY2812176"},{"name":"Maps_To","value":"DKK1-Neutralizing Monoclonal Antibody DKN-01"},{"name":"NCI_Drug_Dictionary_ID","value":"715663"},{"name":"NCI_META_CUI","value":"CL432944"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715663"},{"name":"PDQ_Open_Trial_Search_ID","value":"715663"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80040":{"preferredName":"Anti-DKK1 Monoclonal Antibody BHQ880","code":"C80040","definitions":[{"definition":"A humanized monoclonal antibody directed against Wnt antagonist Dickkopf-1 (DKK1) with potential anti-osteolytic activity. Anti-DKK1 monoclonal antibody BHQ880 binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1 is a potent Wnt signaling pathway antagonist.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DKK1 Monoclonal Antibody BHQ880","termGroup":"PT","termSource":"NCI"},{"termName":"BHQ-880","termGroup":"CN","termSource":"NCI"},{"termName":"BHQ880","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IS3ESI44W5"},{"name":"Legacy Concept Name","value":"Anti-DKK1_Monoclonal_Antibody_BHQ880"},{"name":"Maps_To","value":"Anti-DKK1 Monoclonal Antibody BHQ880"},{"name":"NCI_Drug_Dictionary_ID","value":"614254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614254"},{"name":"PDQ_Open_Trial_Search_ID","value":"614254"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703201"}]}}{"C147027":{"preferredName":"Anti-DLL3/CD3 BiTE Antibody AMG 757","code":"C147027","synonyms":[{"termName":"Anti-DLL3/CD3 BiTE Antibody AMG 757","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed May 04 11:36:45 EDT 2022 - See 'Tarlatamab(C175858)'"},{"name":"OLD_PARENT","value":"C20401"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C101521":{"preferredName":"Anti-DLL4 Monoclonal Antibody MEDI0639","code":"C101521","definitions":[{"definition":"An immunoglobulin G1 lambda monoclonal antibody directed against the Notch ligand delta-like 4 (DLL4) with potential antineoplastic activity. Anti-DLL4 monoclonal antibody MEDI0639 specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may block tumor angiogenesis and eventually the inhibition of tumor cell growth. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DLL4 Monoclonal Antibody MEDI0639","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI0639","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LPT9GX4OUB"},{"name":"Maps_To","value":"Anti-DLL4 Monoclonal Antibody MEDI0639"},{"name":"NCI_Drug_Dictionary_ID","value":"732226"},{"name":"NCI_META_CUI","value":"CL435778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732226"},{"name":"PDQ_Open_Trial_Search_ID","value":"732226"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119620":{"preferredName":"Navicixizumab","code":"C119620","definitions":[{"definition":"A bispecific monoclonal antibody directed against both the Notch ligand delta-like 4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors, and inhibits Notch-mediated signaling and gene transcription, which may both block tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling and further inhibits the growth and maintenance of tumor blood vessels. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navicixizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G2-kappa, Anti-(Homo sapiens DLL4(delta-like 4)) and Anti-(Homo sapiens VEGFA (Vascular Endothelial Growth Factor A,VEGF-a, VEGF)), Humanized and Chimeric Monoclonal Antibody, Bispecific","termGroup":"SN","termSource":"NCI"},{"termName":"OMP 305B83","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-305B83","termGroup":"CN","termSource":"NCI"},{"termName":"OMP305B83","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638338-43-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1W14T9L25W"},{"name":"Maps_To","value":"Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83"},{"name":"Maps_To","value":"Navicixizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"766887"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766887"},{"name":"PDQ_Open_Trial_Search_ID","value":"766887"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896797"}]}}{"C78826":{"preferredName":"Anti-DR5 Agonist Monoclonal Antibody TRA-8","code":"C78826","definitions":[{"definition":"An agonist mouse monoclonal antibody directed against TRAIL death receptor type 5 (DR5) with potential antineoplastic activity. Anti-DR5 agonist monoclonal antibody TRA-8 binds DR5, which may induce apoptosis in DR5-expressing tumor cells. DR5 is a tumor cell surface ligand that crosslinks with death receptor type 4 (DR4) when bound by TRAIL [Tumor necrosis (TNF)-related apoptosis-inducing ligand], triggering apoptosis via a death receptor signaling pathway. The apoptotic activity of this antibody may not require DR4/DR5 crosslinking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DR5 Agonist Monoclonal Antibody TRA-8","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-death Receptor 5 Agonist Monoclonal Antibody TRA-8","termGroup":"SY","termSource":"NCI"},{"termName":"TRA-8","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-DR5_Agonist_Monoclonal_Antibody_TRA-8"},{"name":"Maps_To","value":"Anti-DR5 Agonist Monoclonal Antibody TRA-8"},{"name":"NCI_Drug_Dictionary_ID","value":"601797"},{"name":"NCI_META_CUI","value":"CL387674"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601797"},{"name":"PDQ_Open_Trial_Search_ID","value":"601797"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121158":{"preferredName":"Anti-DR5 Agonistic Antibody DS-8273a","code":"C121158","definitions":[{"definition":"An agonistic monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2, with potential pro-apoptotic and antitumor activities. Upon administration, anti-DR5 agonistic antibody DS-8273a mimics the natural receptor ligand TRAIL and binds to DR5. This activates DR5 and leads to the activation of the death receptor signal pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily, is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DR5 Agonistic Antibody DS-8273a","termGroup":"PT","termSource":"NCI"},{"termName":"DS 8273","termGroup":"CN","termSource":"NCI"},{"termName":"DS-8273a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2107396-50-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G674PEN33T"},{"name":"Maps_To","value":"Anti-DR5 Agonistic Antibody DS-8273a"},{"name":"NCI_Drug_Dictionary_ID","value":"758683"},{"name":"NCI_META_CUI","value":"CL471819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758683"},{"name":"PDQ_Open_Trial_Search_ID","value":"758683"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157062":{"preferredName":"Anti-DR5 Agonistic Monoclonal Antibody INBRX-109","code":"C157062","definitions":[{"definition":"A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, INBRX-109 specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DR5 Agonistic Monoclonal Antibody INBRX-109","termGroup":"PT","termSource":"NCI"},{"termName":"INBRX 109","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX-109","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX109","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-DR5 Agonistic Monoclonal Antibody INBRX-109"},{"name":"NCI_Drug_Dictionary_ID","value":"796494"},{"name":"NCI_META_CUI","value":"CL936041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796494"},{"name":"PDQ_Open_Trial_Search_ID","value":"796494"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155876":{"preferredName":"Anti-EGFR Monoclonal Antibody CPGJ 602","code":"C155876","definitions":[{"definition":"A recombinant, human-mouse chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, anti-EGFR monoclonal antibody CPGJ 602 targets and binds to EGFR, which prevents receptor dimerization and activation. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody CPGJ 602","termGroup":"PT","termSource":"NCI"},{"termName":"CPGJ 602","termGroup":"CN","termSource":"NCI"},{"termName":"CPGJ-602","termGroup":"CN","termSource":"NCI"},{"termName":"CPGJ602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody CPGJ 602"},{"name":"NCI_Drug_Dictionary_ID","value":"794677"},{"name":"NCI_META_CUI","value":"CL562684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794677"},{"name":"PDQ_Open_Trial_Search_ID","value":"794677"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C2714":{"preferredName":"Anti-EGFR Monoclonal Antibody EMD 55900","code":"C2714","definitions":[{"definition":"A murine monoclonal antibody targeting the epidermal growth factor receptor (EGFR) exhibiting anti-tumor activity. EMD 55900 antibody binds to the extracellular domain of EGFR close to the EGF binding domain and does not induce any tyrosine kinase activity on its own. As a result, EMD 55900 binding inhibits receptor activation by natural ligands thereby interrupting activation of downstream signaling cascade, required for tumor cell growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody EMD 55900","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 55 900","termGroup":"CN","termSource":"NCI"},{"termName":"EMD 55900","termGroup":"CN","termSource":"NCI"},{"termName":"Mab 425","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody 425","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EMD_55900"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody EMD 55900"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1512123"}]}}{"C120316":{"preferredName":"Anti-EGFR Monoclonal Antibody GC1118","code":"C120316","definitions":[{"definition":"A recombinant, human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, GC1118 binds to and blocks the ligand binding site of EGFR, which prevents receptor dimerization and activation. This may lead to an inhibition of both EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody GC1118","termGroup":"PT","termSource":"NCI"},{"termName":"GC1118","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody GC1118"},{"name":"NCI_Drug_Dictionary_ID","value":"768860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768860"},{"name":"PDQ_Open_Trial_Search_ID","value":"768860"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3896855"}]}}{"C94221":{"preferredName":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX","code":"C94221","definitions":[{"definition":"A glycoengineered form of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Anti-EGFR monoclonal antibody GT-MAB 5.2-GEX specifically binds to the extracellular domain of EGFR, thereby potentially inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells, eventually leading to tumor cell apoptosis and an inhibition of tumor cell growth. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, is overexpressed on the cell surfaces of various solid tumors. This antibody has a specific glycosylation profile that may enhance its ADCC response against EGFR-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX","termGroup":"PT","termSource":"NCI"},{"termName":"CetuGEX","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX"},{"name":"NCI_Drug_Dictionary_ID","value":"687632"},{"name":"NCI_META_CUI","value":"CL426034"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687632"},{"name":"PDQ_Open_Trial_Search_ID","value":"687632"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163981":{"preferredName":"Pimurutamab","code":"C163981","definitions":[{"definition":"A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimurutamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR Monoclonal Antibody HLX-07","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab Biobetter HLX07","termGroup":"SY","termSource":"NCI"},{"termName":"HLX 07","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-07","termGroup":"CN","termSource":"NCI"},{"termName":"HLX07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2251771-76-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5V1Y8T4RB6"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody HLX-07"},{"name":"Maps_To","value":"Pimurutamab"},{"name":"NCI_Drug_Dictionary_ID","value":"799130"},{"name":"NCI_META_CUI","value":"CL977244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799130"},{"name":"PDQ_Open_Trial_Search_ID","value":"799130"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99899":{"preferredName":"Anti-EGFR Monoclonal Antibody Mixture MM-151","code":"C99899","definitions":[{"definition":"An oligoclonal therapeutic composed of three fully human monoclonal antibodies targeting epidermal growth factor receptor (EGFR or ErbB1), with potential antineoplastic activity. Upon administration of MM-151, the three antibodies bind to distinct, non-overlapping epitopes of EGFR, thereby preventing the binding of a full range of both high and low affinity EGFR ligands and inhibiting EGFR-ERK-mediated signaling. This eventually inhibits tumor cell proliferation in EGFR-overexpressing tumor cells. Furthermore, multi antibody-antigen bindings cause crosslinking of EGFR and downregulate receptor signalings that are mediated via heterodimerization of EGFR with other members of the EGFR family. EGFR, a receptor tyrosine kinase overexpressed in a variety of cancer cell types, is a key regulator of cancer cell proliferation, apoptosis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody Mixture MM-151","termGroup":"PT","termSource":"NCI"},{"termName":"MM-151","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody Mixture MM-151"},{"name":"NCI_Drug_Dictionary_ID","value":"724591"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724591"},{"name":"PDQ_Open_Trial_Search_ID","value":"724591"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3275035"}]}}{"C78838":{"preferredName":"Imgatuzumab","code":"C78838","definitions":[{"definition":"A glycoengineered monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Imgatuzumab binds to the extracellular domain of EGFR, preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition of downstream ERK and JNK signaling pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imgatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epidermal Growth Factor Receptor Monoclonal Antibody RO5083945","termGroup":"SY","termSource":"NCI"},{"termName":"GA-201","termGroup":"CN","termSource":"NCI"},{"termName":"GA201","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7160","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7160","termGroup":"CN","termSource":"NCI"},{"termName":"RG7160","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"959963-46-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V77J4WJF9Z"},{"name":"Legacy Concept Name","value":"Anti-EGFR_Monoclonal_Antibody_RO5083945"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody RO5083945"},{"name":"Maps_To","value":"Imgatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"609889"},{"name":"NCI_META_CUI","value":"CL387675"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609889"},{"name":"PDQ_Open_Trial_Search_ID","value":"609889"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117726":{"preferredName":"Anti-EGFR Monoclonal Antibody SCT200","code":"C117726","definitions":[{"definition":"A recombinant monoclonal antibody against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SCT200 targets EGFR, prevents the activation and subsequent dimerization of this receptor and inhibits both EGFR-mediated signal transduction and cellular proliferation of EGFR-expressing tumor cells. In addition, SCT200 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the cell surfaces of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody SCT200","termGroup":"PT","termSource":"NCI"},{"termName":"SCT200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody SCT200"},{"name":"NCI_Drug_Dictionary_ID","value":"763740"},{"name":"NCI_META_CUI","value":"CL474121"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763740"},{"name":"PDQ_Open_Trial_Search_ID","value":"763740"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C121550":{"preferredName":"Anti-EGFR Monoclonal Antibody SYN004","code":"C121550","definitions":[{"definition":"A glyco-engineered monoclonal antibody directed against the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SYN004 binds to the extracellular domain of EGFR, which prevents ligand binding and the subsequent activation and dimerization of the receptor. This inhibits the activation of EGFR-mediated signaling pathways and inhibits EGFR-dependent tumor cell proliferation. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody SYN004","termGroup":"PT","termSource":"NCI"},{"termName":"SYN004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody SYN004"},{"name":"NCI_Drug_Dictionary_ID","value":"770314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770314"},{"name":"PDQ_Open_Trial_Search_ID","value":"770314"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053588"}]}}{"C111906":{"preferredName":"Laprituximab Emtansine","code":"C111906","definitions":[{"definition":"A targeted antibody payload (TAP)-based immunoconjugate consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of laprituximab emtansine binds to and inhibits EGFR on tumor cell surfaces. Inhibition of EGFR prevents EGFR-mediated signaling and may inhibit tumor cell proliferation. After internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival. Linkage of the antibody and drug, through a nonreducible linker, appears to contribute to the improved efficacy and reduced toxicity of this antibody-drug conjugate (ADC) compared to similar ADCs constructed with reducible linkers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laprituximab Emtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR-SMCC-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN289","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622327-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7J0LQD86OG"},{"name":"Maps_To","value":"Anti-EGFR TAP Antibody-drug Conjugate IMGN289"},{"name":"Maps_To","value":"Laprituximab Emtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"753683"},{"name":"NCI_META_CUI","value":"CL454236"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753683"},{"name":"PDQ_Open_Trial_Search_ID","value":"753683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158085":{"preferredName":"Bafisontamab","code":"C158085","definitions":[{"definition":"A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR;; cMet; c-Met), with potential antineoplastic activity. Upon administration, bafisontamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In bafisontamab, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bafisontamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-cMET/EGFR Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/Anti-c-Met Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/c-Met Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"EMB 01","termGroup":"CN","termSource":"NCI"},{"termName":"EMB-01","termGroup":"CN","termSource":"NCI"},{"termName":"EMB01","termGroup":"CN","termSource":"NCI"},{"termName":"FIT-013a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2437210-79-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G86X5QQ7M5"},{"name":"Maps_To","value":"Anti-EGFR/c-Met Bispecific Antibody EMB-01"},{"name":"NCI_Drug_Dictionary_ID","value":"797352"},{"name":"NCI_META_CUI","value":"CL937694"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797352"},{"name":"PDQ_Open_Trial_Search_ID","value":"797352"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124993":{"preferredName":"Amivantamab","code":"C124993","definitions":[{"definition":"A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amivantamab","termGroup":"PT","termSource":"NCI"},{"termName":"Amivantamab-vmjw","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO-4424","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-611","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-61186372","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ61186372","termGroup":"CN","termSource":"NCI"},{"termName":"Rybrevant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations"},{"name":"CAS_Registry","value":"2171511-58-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0JSR7Z0NB6"},{"name":"Maps_To","value":"Amivantamab"},{"name":"Maps_To","value":"Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372"},{"name":"NCI_Drug_Dictionary_ID","value":"777269"},{"name":"NCI_META_CUI","value":"CL503840"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777269"},{"name":"PDQ_Open_Trial_Search_ID","value":"777269"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148507":{"preferredName":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100","code":"C148507","definitions":[{"definition":"A targeted antibody drug conjugate (ADC) consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AVID100 binds to  EGFR on tumor cell surfaces. Following receptor internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AVID100","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate AVID100","termGroup":"SY","termSource":"NCI"},{"termName":"AVID100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91PZ0ZWR8S"},{"name":"Maps_To","value":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100"},{"name":"NCI_Drug_Dictionary_ID","value":"792639"},{"name":"NCI_META_CUI","value":"CL551039"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792639"},{"name":"PDQ_Open_Trial_Search_ID","value":"792639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131175":{"preferredName":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013","code":"C131175","definitions":[{"definition":"An antibody mixture composed of six humanized, immunoglobulin G1 (IgG1) monoclonal antibodies directed against three members of the human epidermal growth factor receptor (EGFR; HER) family: EGFR (HER1; ErbB1), HER2 (ErbB2) and HER3 (ErbB3), with potential antineoplastic activity. Upon administration of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013, the six antibodies bind to non-overlapping epitopes on EGFR, HER2 and HER3, which prevents both ligand binding and receptor activation, and induce simultaneous down-modulation of EGFR, HER2 and HER3.  This inhibits the activation of HER-dependent signaling pathways and HER-dependent tumor cell proliferation. Overexpression of the HER family plays a key role in many cancers; targeting multiple HER family members simultaneously may increase therapeutic efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013","termGroup":"PT","termSource":"NCI"},{"termName":"pan-HER Antibody Mixture Sym013","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-HER mAb Mixture Sym013","termGroup":"SY","termSource":"NCI"},{"termName":"Sym-013","termGroup":"CN","termSource":"NCI"},{"termName":"Sym013","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013"},{"name":"NCI_Drug_Dictionary_ID","value":"785503"},{"name":"NCI_META_CUI","value":"CL513501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785503"},{"name":"PDQ_Open_Trial_Search_ID","value":"785503"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150590":{"preferredName":"Serclutamab Talirine","code":"C150590","definitions":[{"definition":"A antibody drug conjugate (ADC) consisting of serclutamab, an affinity-matured humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to a talirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration of serclutamab talirine, the serclutamab moiety targets and binds to EGFR on tumor cell surfaces. Following receptor internalization and lysosome-mediated cleavage, talirine is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase (RTK) that is overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serclutamab Talirine","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 321","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-321","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV321","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-321","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/PBD ADC ABBV-321","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2140174-56-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7W0O278T12"},{"name":"Maps_To","value":"Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321"},{"name":"Maps_To","value":"Serclutamab Talirine"},{"name":"NCI_Drug_Dictionary_ID","value":"793472"},{"name":"NCI_META_CUI","value":"CL552328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793472"},{"name":"PDQ_Open_Trial_Search_ID","value":"793472"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99222":{"preferredName":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595","code":"C99222","definitions":[{"definition":"An immunoconjugate consisting of a human monoclonal antibody directed against the deletion-mutant of epidermal growth factor receptor, EGFRvIII, conjugated via a non-cleavable linker to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to EGFRvIII on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that express the EGFRvIII mutant. EGFRvIII, a deletion mutation of exons 2-7 in the epidermal growth factor receptor gene, is overexpressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 595","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-EGFRvIII-DM1 Immunoconjugate AMG 595","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595"},{"name":"NCI_Drug_Dictionary_ID","value":"718917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"718917"},{"name":"PDQ_Open_Trial_Search_ID","value":"718917"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274618"}]}}{"C88307":{"preferredName":"Anti-EGFRvIII Immunotoxin MR1-1","code":"C88307","definitions":[{"definition":"A recombinant immunotoxin consisting of single-chain variable domain fragment antibody directed against the tumor-specific antigen EGFRvIII (MR1scFv) fused to domains II and III of the Pseudomonas exotoxin (PE38KDEL), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-EGFRvIII immunotoxin MR1-1 binds to EGFRvIII; upon internalization, the exotoxin portion inhibits protein synthesis, resulting in a reduction in tumor cell proliferation of EGFRvIII- expressing tumor cells. EGFRvIII, a type III in-frame deletion mutation of the epidermal growth factor receptor (EGFR) gene, is expressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma. Compared to intact IgG antibodies, single-chain antibodies such as MR1scFv are smaller and may penetrate tumors better. Pseudomonas exotoxin PE38KDEL was modified to remove the natural cell binding domain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFRvIII Immunotoxin MR1-1","termGroup":"PT","termSource":"NCI"},{"termName":"MR1-1","termGroup":"CN","termSource":"NCI"},{"termName":"MR1-1KDEL","termGroup":"SY","termSource":"NCI"},{"termName":"MR1scFvPE38KDEL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFRvIII Immunotoxin MR1-1"},{"name":"NCI_Drug_Dictionary_ID","value":"659598"},{"name":"NCI_META_CUI","value":"CL413562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659598"},{"name":"PDQ_Open_Trial_Search_ID","value":"659598"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146824":{"preferredName":"Etevritamab","code":"C146824","definitions":[{"definition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one that is directed against a tumor-associated antigen (TAA), the epidermal growth factor receptor (EGFR) deletion-mutant form, EGFR variant III (EGFRvIII), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of etevritamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and EGFRvIII found on EGFRvIII-expressing tumor cells. This activates and crosslinks CTLs with EGFRvIII-expressing tumor cells, which results in the CTL-mediated cell death of EGFRvIII-expressing tumor cells. EGFRvIII, a mutation in the EGFR gene where exons 2-7 have been deleted, is overexpressed by a variety of cancers, but is absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etevritamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 596","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-596","termGroup":"CN","termSource":"NCI"},{"termName":"AMG596","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-EGFRvIII x Anti-CD3 Bi-specific T-cell Engager AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFRvIII/CD3 BiTE Antibody AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific BITE Antibody AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"EGFRvIII specific BiTE Antibody AMG 596","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2329692-74-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WR4J8FV2SM"},{"name":"Maps_To","value":"Anti-EGFRvIII/CD3 BiTE Antibody AMG 596"},{"name":"NCI_Drug_Dictionary_ID","value":"792074"},{"name":"NCI_META_CUI","value":"CL544854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792074"},{"name":"PDQ_Open_Trial_Search_ID","value":"792074"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90551":{"preferredName":"Anti-EGP-2 Immunotoxin MOC31-PE","code":"C90551","definitions":[{"definition":"An immunotoxin consisting of a monoclonal antibody directed against epithelial glycoprotein-2 (EP-2, or epithelial cell adhesion molecule (EpCAM)) conjugated to the bacterial toxin Pseudomonas exotoxin A (PE) with potential antineoplastic activity. Upon administration of anti-EGP-2 immunotoxin MOC31-PE, the monoclonal antibody moiety targets and binds to EP-2. Upon internalization, the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in EP-2-expressing cells. EP-2, a tumor-associated antigen, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGP-2 Immunotoxin MOC31-PE","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epithelial Glycoprotein-2 Immunotoxin MOC31-PE","termGroup":"SY","termSource":"NCI"},{"termName":"MOC31-PE","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGP-2 Immunotoxin MOC31-PE"},{"name":"NCI_Drug_Dictionary_ID","value":"666058"},{"name":"NCI_META_CUI","value":"CL416235"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666058"},{"name":"PDQ_Open_Trial_Search_ID","value":"666058"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102980":{"preferredName":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F","code":"C102980","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity. Upon intravenous administration of ADC AGS-16C3F, the monoclonal antibody moiety of this conjugate selectively binds to ENPP3 then is internalized and undergoes proteolytic cleavage to release MMAF. MMAF binds to and inhibits tubulin polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 has been found to be overexpressed in renal neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AGS-16C3F","termGroup":"AB","termSource":"NCI"},{"termName":"AGS-16C3F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VC1D38AGN9"},{"name":"Maps_To","value":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F"},{"name":"NCI_Drug_Dictionary_ID","value":"739766"},{"name":"NCI_META_CUI","value":"CL437217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739766"},{"name":"PDQ_Open_Trial_Search_ID","value":"739766"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116626":{"preferredName":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F","code":"C116626","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a human immunoglobulin (Ig) G2k monoclonal antibody (AGS-16C) directed against the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3, NPP3, B10, PDNP3 CD203c, or PD-IBETA ), conjugated, via the non-cleavable maleimidocaproyl (mc) linker, to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-ENPP3/MMAF ADC AGS-16M8F, the monoclonal antibody moiety selectively binds to ENPP3 expressed on tumor cells; upon internalization, the ADC is degraded by lysosomal proteases and MMAF is released. In turn, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 is overexpressed in most renal neoplasms and some liver cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AGS-16M8F","termGroup":"SY","termSource":"NCI"},{"termName":"AGS 16M8F","termGroup":"CN","termSource":"NCI"},{"termName":"AGS-16M8F","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-ENPP3 ADC AGS-16M8F","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ENPP3/MMAF ADC AGS-16M8F","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F"},{"name":"NCI_Drug_Dictionary_ID","value":"673092"},{"name":"NCI_META_CUI","value":"CL421575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673092"},{"name":"PDQ_Open_Trial_Search_ID","value":"673092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133022":{"preferredName":"Anti-Ep-CAM Monoclonal Antibody ING-1","code":"C133022","definitions":[{"definition":"An engineered monoclonal antibody (MAb) directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326), with potential antitumor activity. Upon administration, anti-Ep-CAM monoclonal antibody ING-1 binds to Ep-CAM, which may result in a cytotoxic T-lymphocyte (CTL)-mediated immune response against Ep-CAM-expressing tumor cells. Ep-CAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Ep-CAM Monoclonal Antibody ING-1","termGroup":"PT","termSource":"NCI"},{"termName":"ING 1","termGroup":"CN","termSource":"NCI"},{"termName":"ING-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Ep-CAM Monoclonal Antibody ING-1"},{"name":"NCI_Drug_Dictionary_ID","value":"357603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357603"},{"name":"PDQ_Open_Trial_Search_ID","value":"357603"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328238"}]}}{"C136981":{"preferredName":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310","code":"C136981","definitions":[{"definition":"A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's efficacy while lowering its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EphA2 Antibody-targeted Nanoliposome MM-310","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EphA2 Docetaxel-based Nanoliposome MM-310","termGroup":"SY","termSource":"NCI"},{"termName":"EphA2-targeted Docetaxel Nanoliposome MM-310","termGroup":"SY","termSource":"NCI"},{"termName":"MM 310","termGroup":"CN","termSource":"NCI"},{"termName":"MM-310","termGroup":"CN","termSource":"NCI"},{"termName":"MM310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310"},{"name":"NCI_Drug_Dictionary_ID","value":"789748"},{"name":"NCI_META_CUI","value":"CL524774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789748"},{"name":"PDQ_Open_Trial_Search_ID","value":"789748"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118447":{"preferredName":"Anti-EphA2 Monoclonal Antibody DS-8895a","code":"C118447","definitions":[{"definition":"A monoclonal antibody directed against the ephrin receptor A2 (EphA2), with potential antineoplastic activity. Upon administration, anti-EphA2 monoclonal antibody DS-8895a selectively binds to cells expressing the EphA2 receptor. This blocks EphA2 activation and EphA2-mediated signaling. In addition, DS-8895a may activate an immune response against EphA2-expressing tumor cells. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EphA2 Monoclonal Antibody DS-8895a","termGroup":"PT","termSource":"NCI"},{"termName":"DS-8895a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EphA2 Monoclonal Antibody DS-8895a"},{"name":"NCI_Drug_Dictionary_ID","value":"756010"},{"name":"NCI_META_CUI","value":"CL471759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756010"},{"name":"PDQ_Open_Trial_Search_ID","value":"756010"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79836":{"preferredName":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","code":"C79836","definitions":[{"definition":"An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti-EphA2 monoclonal antibody-MMAF immunoconjugate MEDI-547 is generated by conjugating the fully human IgG1 anti-EphA2 monoclonal antibody (1C1) to the small-molecule microtubule inhibitor monomethyl auristatin phenylalanine (MMAF) via the stable linker maleimidocaproyl (mc) (1C1-mcMMAF). The monoclonal antibody moiety of this agent selectively binds to cells expressing the EphA2 receptor. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","termGroup":"PT","termSource":"NCI"},{"termName":"1C1-mcMMAF","termGroup":"AB","termSource":"NCI"},{"termName":"Medi-547","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D21E6RU881"},{"name":"Legacy Concept Name","value":"Anti-EphA2_Monoclonal_Antibody-MMAF_Immunoconjugate_MEDI-547"},{"name":"Maps_To","value":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547"},{"name":"NCI_Drug_Dictionary_ID","value":"629927"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629927"},{"name":"PDQ_Open_Trial_Search_ID","value":"629927"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703178"}]}}{"C85486":{"preferredName":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111","code":"C85486","definitions":[{"definition":"A bispecific monoclonal antibody directed against the human epidermal growth factor receptors ErbB2 (Her2) and ErbB3 (Her3) with potential antineoplastic activity. The anti-ErB2 targeting arm of anti-ErbB2/anti-ErbB3 bispecific monoclonal antibody MM-111 binds to ErbB2 on tumor cells with high affinity while the anti-Erb3 therapeutic arm binds to ErbB3, which may result in the inhibition of cellular proliferation and differentiation in ErbB2-overexpressing tumor cells via inhibition of ErbB3-dependent signal transduction pathways. ErbB2 and ErB3 are members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and are frequently overexpressed in solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111","termGroup":"PT","termSource":"NCI"},{"termName":"MM-111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1361108-53-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6IJ4CQY76O"},{"name":"Maps_To","value":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111"},{"name":"NCI_Drug_Dictionary_ID","value":"647542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647542"},{"name":"PDQ_Open_Trial_Search_ID","value":"647542"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830144"}]}}{"C158746":{"preferredName":"Barecetamab","code":"C158746","definitions":[{"definition":"A fully human antibody directed against the receptor tyrosine-protein kinase erbB-3 (ErbB3; HER3) with potential antineoplastic activity. Upon intravenous administration, barecetamab targets and binds to domain 3 and weakly interacts with domain 1 of ErbB3. This prevents heregulin (HRG) binding and blocks dimerization of ErbB3, thereby inactivating ErbB3 downstream signaling. ISU104 may also elicit the internalization of ErbB3 from the plasma membrane and downregulate ErbB3 expression. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Barecetamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ErbB3 Antibody ISU104","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER3 Antibody ISU104","termGroup":"SY","termSource":"NCI"},{"termName":"ISU 104","termGroup":"CN","termSource":"NCI"},{"termName":"ISU-104","termGroup":"SY","termSource":"NCI"},{"termName":"ISU104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2275727-74-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M9SE4M9U1V"},{"name":"Maps_To","value":"Anti-ErbB3 Antibody ISU104"},{"name":"NCI_Drug_Dictionary_ID","value":"797411"},{"name":"NCI_META_CUI","value":"CL950712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797411"},{"name":"PDQ_Open_Trial_Search_ID","value":"797411"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102535":{"preferredName":"Anti-ErbB3 Monoclonal Antibody AV-203","code":"C102535","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) directed against the human receptor tyrosine-protein kinase ErbB-3 (HER3) with potential antineoplastic activity. Anti-ErbB3 MoAb AV-203 binds to and inhibits both ligand neuregulin-1 (NRG-1)-dependent and ligand-independent ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and may lead to inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family, is frequently overexpressed in solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB3 Monoclonal Antibody AV-203","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ErbB3 MoAb AV-203","termGroup":"SY","termSource":"NCI"},{"termName":"AV 203","termGroup":"CN","termSource":"NCI"},{"termName":"AV-203","termGroup":"CN","termSource":"NCI"},{"termName":"AV203","termGroup":"CN","termSource":"NCI"},{"termName":"CAN-017","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353581-77-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"841P9W25WA"},{"name":"Maps_To","value":"Anti-ErbB3 Monoclonal Antibody AV-203"},{"name":"NCI_Drug_Dictionary_ID","value":"734410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734410"},{"name":"PDQ_Open_Trial_Search_ID","value":"734410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640798"}]}}{"C113333":{"preferredName":"Anti-ErbB3 Monoclonal Antibody CDX-3379","code":"C113333","definitions":[{"definition":"A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (HER3), with potential antineoplastic activity. Upon administration, the anti-ErbB3 monoclonal antibody CDX-3379 targets and binds to a unique epitope on ErbB3, thereby preventing ErbB3 phosphorylation and both ligand-dependent and ligand-independent ErbB3 signaling. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB3 Monoclonal Antibody CDX-3379","termGroup":"PT","termSource":"NCI"},{"termName":"CDX 3379","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-3379","termGroup":"CN","termSource":"NCI"},{"termName":"CDX3379","termGroup":"CN","termSource":"NCI"},{"termName":"KTN 3379","termGroup":"CN","termSource":"NCI"},{"termName":"KTN-3379","termGroup":"CN","termSource":"NCI"},{"termName":"KTN3379","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2070921-00-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"00X6I56YXR"},{"name":"Maps_To","value":"Anti-ErbB3 Monoclonal Antibody CDX-3379"},{"name":"NCI_Drug_Dictionary_ID","value":"756069"},{"name":"NCI_META_CUI","value":"CL458161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756069"},{"name":"PDQ_Open_Trial_Search_ID","value":"756069"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103859":{"preferredName":"Anti-ErbB3 Monoclonal Antibody REGN1400","code":"C103859","definitions":[{"definition":"A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Upon administration, anti-ErbB3 monoclonal antibody REGN1400 binds to ErbB3 and prevents neuregulin 1 ligand binding to ErbB3, which may result in an inhibition of ErbB3-dependent phosphatidylinositol-3 kinase (PI3K)/Akt signaling. This eventually leads to the inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB3 Monoclonal Antibody REGN1400","termGroup":"PT","termSource":"NCI"},{"termName":"REGN 1400","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-1400","termGroup":"CN","termSource":"NCI"},{"termName":"REGN1400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443016-81-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"93F274N35Z"},{"name":"Maps_To","value":"Anti-ErbB3 Monoclonal Antibody REGN1400"},{"name":"NCI_Drug_Dictionary_ID","value":"743118"},{"name":"NCI_META_CUI","value":"CL438337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743118"},{"name":"PDQ_Open_Trial_Search_ID","value":"743118"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103863":{"preferredName":"Istiratumab","code":"C103863","definitions":[{"definition":"A bispecific monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) and the human insulin-like growth factor-1 receptor (IGF-1R), with potential antineoplastic activity. The anti-IGF-1R targeting arm of Istiratumab binds to IGF-1R on tumor cells thereby preventing the binding of the natural ligands IGF-1, 2 and heregulin (HRG) to IGF-1R; the anti-ErbB3 therapeutic arm prevents the binding of neuregulin (NRG) to ErbB3. This prevents the activation of the PI3K/AKT signal transduction pathway and may result in both the induction of apoptosis and a decrease in cellular proliferation in IGF-1R and ErbB3-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, and ErB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Istiratumab","termGroup":"PT","termSource":"NCI"},{"termName":"MM-005","termGroup":"CN","termSource":"NCI"},{"termName":"MM-141","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1509928-04-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XLR461MD3M"},{"name":"Maps_To","value":"Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141"},{"name":"Maps_To","value":"Istiratumab"},{"name":"NCI_Drug_Dictionary_ID","value":"743370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743370"},{"name":"PDQ_Open_Trial_Search_ID","value":"743370"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641662"}]}}{"C116742":{"preferredName":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A","code":"C116742","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody against anti-endothelin B receptor (ETBR) and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DEDN6526A binds to ETBR-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. ETBR, a G-protein coupled receptor that can activate RAF/MEK signaling, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DEDN6526A","termGroup":"SY","termSource":"NCI"},{"termName":"DEDN6526A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A"},{"name":"NCI_Drug_Dictionary_ID","value":"724717"},{"name":"NCI_META_CUI","value":"CL433966"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724717"},{"name":"PDQ_Open_Trial_Search_ID","value":"724717"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129383":{"preferredName":"Simlukafusp Alfa","code":"C129383","definitions":[{"definition":"A recombinant fusion protein comprised of a human monoclonal antibody directed against fibroblast activation protein-alpha (FAP) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of simlukafusp alfa, the monoclonal antibody moiety recognizes and binds to FAP, thereby concentrating IL-2 in FAP-expressing tumor tissue. Subsequently, the IL-2 moiety of this fusion protein may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. FAP is a cell surface protein that is expressed on a wide variety of cancer cells. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simlukafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"aFAP-IL2v RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FAP/Interleukin-2 Fusion Protein RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"FAP-IL2v FP RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"FAP-IL2v RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"RG 7461","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7461","termGroup":"CN","termSource":"NCI"},{"termName":"RG7461","termGroup":"CN","termSource":"NCI"},{"termName":"RO 6874281","termGroup":"CN","termSource":"NCI"},{"termName":"RO-6874281","termGroup":"CN","termSource":"NCI"},{"termName":"RO6874281","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1776942-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FL08SGO9XA"},{"name":"Maps_To","value":"Anti-FAP/Interleukin-2 Fusion Protein RO6874281"},{"name":"Maps_To","value":"Simlukafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"783990"},{"name":"NCI_META_CUI","value":"CL512652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783990"},{"name":"PDQ_Open_Trial_Search_ID","value":"783990"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139549":{"preferredName":"Cevostamab","code":"C139549","definitions":[{"definition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevostamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FCRH5/CD3 BiTE Antibody BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FCRH5/CD3 TDB BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"BFCR4350A","termGroup":"CN","termSource":"NCI"},{"termName":"Cevostamab","termGroup":"SY","termSource":"NCI"},{"termName":"FCRH5/CD3 T Cell Dependent Bispecific Antibody BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"FCRH5/CD3 TDB Antibody BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"RO7187797","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249888-53-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P86BHN01VE"},{"name":"Maps_To","value":"Anti-FCRH5/CD3 BiTE Antibody BFCR4350A"},{"name":"Maps_To","value":"Cevostamab"},{"name":"NCI_Drug_Dictionary_ID","value":"791048"},{"name":"NCI_META_CUI","value":"CL526909"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791048"},{"name":"PDQ_Open_Trial_Search_ID","value":"791048"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107683":{"preferredName":"Aprutumab","code":"C107683","definitions":[{"definition":"An antibody against the fibroblast growth factor receptor type 2 (FGFR2), with potential antineoplastic activity. Upon administration, aprutumab binds to and inhibits FGFR2, which may result in the inhibition of both FGFR2 phosphorylation and FGFR2-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2, upregulated in many tumor cell types, is a receptor tyrosine kinase, which is essential to tumor cellular proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aprutumab","termGroup":"PT","termSource":"NCI"},{"termName":"AGC-2500","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1179470","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1179470","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1634620-63-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GK8781218Z"},{"name":"Maps_To","value":"Anti-FGFR2 Antibody BAY1179470"},{"name":"Maps_To","value":"Aprutumab"},{"name":"NCI_Drug_Dictionary_ID","value":"751593"},{"name":"NCI_META_CUI","value":"CL451871"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751593"},{"name":"PDQ_Open_Trial_Search_ID","value":"751593"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123829":{"preferredName":"Anti-FGFR3 Antibody-drug Conjugate LY3076226","code":"C123829","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody against the fibroblast growth factor receptor type 3 (FGFR3) that is conjugated to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the antibody moiety of anti-FGFR3 ADC LY3076226 binds to FGFR3. Upon internalization, the cytotoxic moiety causes cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FGFR3 Antibody-drug Conjugate LY3076226","termGroup":"PT","termSource":"NCI"},{"termName":"ADC LY3076226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FGFR3 ADC LY3076226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-fibroblast Growth Factor Receptor 3 Antibody-Drug Conjugate LY3076226","termGroup":"SY","termSource":"NCI"},{"termName":"LY3076226","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GP2L3N7FIM"},{"name":"Maps_To","value":"Anti-FGFR3 Antibody-drug Conjugate LY3076226"},{"name":"NCI_Drug_Dictionary_ID","value":"775899"},{"name":"NCI_META_CUI","value":"CL498222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775899"},{"name":"PDQ_Open_Trial_Search_ID","value":"775899"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126334":{"preferredName":"Anti-FGFR4 Monoclonal Antibody U3-1784","code":"C126334","definitions":[{"definition":"A human monoclonal antibody against human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, U3-1784 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FGFR4 Monoclonal Antibody U3-1784","termGroup":"PT","termSource":"NCI"},{"termName":"U3 1784","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1784","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-FGFR4 Monoclonal Antibody U3-1784"},{"name":"NCI_Drug_Dictionary_ID","value":"779617"},{"name":"NCI_META_CUI","value":"CL504900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779617"},{"name":"PDQ_Open_Trial_Search_ID","value":"779617"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129937":{"preferredName":"Anti-FLT3 Antibody-drug Conjugate AGS62P1","code":"C129937","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the extracellular domain of receptor-type tyrosine-protein kinase FLT3 (FLT-3; FMS-like tyrosine kinase 3; CD135; fetal-liver kinase 2; FLK2) and conjugated, via an oxime linker and the site-directed non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to a microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon administration of ADC AGS62P1, the antibody moiety targets and binds to FLT3. Upon antibody/antigen binding and internalization, the microtubule-targeting agent binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody, through pAcF, improves the biophysical properties of AGS62P1, increases payload distribution and stability, and optimizes its efficacy. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage, acute lymphoblastic leukemias and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FLT3 Antibody-drug Conjugate AGS62P1","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AGS62P1","termGroup":"SY","termSource":"NCI"},{"termName":"AGS62P1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37I4D4Q7S2"},{"name":"Maps_To","value":"Anti-FLT3 Antibody-drug Conjugate AGS62P1"},{"name":"NCI_Drug_Dictionary_ID","value":"785317"},{"name":"NCI_META_CUI","value":"CL513016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785317"},{"name":"PDQ_Open_Trial_Search_ID","value":"785317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129376":{"preferredName":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM","code":"C129376","definitions":[{"definition":"A human, Fc-optimized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135), with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody 4G8-SDIEM blocks FLT3 ligand binding to FLT3 and subsequent phosphorylation of FLT3, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may lead to the inhibition of cellular proliferation and decreased survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM","termGroup":"PT","termSource":"NCI"},{"termName":"4G8-SDIEM","termGroup":"CN","termSource":"NCI"},{"termName":"FLYSYN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM"},{"name":"NCI_Drug_Dictionary_ID","value":"783748"},{"name":"NCI_META_CUI","value":"CL512340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783748"},{"name":"PDQ_Open_Trial_Search_ID","value":"783748"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85453":{"preferredName":"Anti-FLT3 Monoclonal Antibody IMC-EB10","code":"C85453","definitions":[{"definition":"A fully human, IgG1 monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135) with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody IMC-EB10 blocks FLT3 ligand binding to FLT3 and subsequent FLT3 phosphorylation, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may result in the inhibition of cellular proliferation and survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FLT3 Monoclonal Antibody IMC-EB10","termGroup":"PT","termSource":"NCI"},{"termName":"IMC-EB10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-FLT3 Monoclonal Antibody IMC-EB10"},{"name":"NCI_Drug_Dictionary_ID","value":"642753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642753"},{"name":"PDQ_Open_Trial_Search_ID","value":"642753"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830134"}]}}{"C156399":{"preferredName":"Emirodatamab","code":"C156399","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emirodatamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emirodatamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 427","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-427","termGroup":"CN","termSource":"NCI"},{"termName":"AMG427","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-FLT3 x Anti-CD3 BiTE AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FLT3/CD3 BiTE Antibody AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"FLT3/CD3-directed Bispecific T-cell Engager Antibody AMG 427","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2449199-61-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P9I9Z3MF7Z"},{"name":"Maps_To","value":"Anti-FLT3/CD3 BiTE Antibody AMG 427"},{"name":"NCI_Drug_Dictionary_ID","value":"795695"},{"name":"NCI_META_CUI","value":"CL563094"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795695"},{"name":"PDQ_Open_Trial_Search_ID","value":"795695"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158067":{"preferredName":"Luveltamab Tazevibulin","code":"C158067","definitions":[{"definition":"An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luveltamab Tazevibulin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FolRa ADC STRO-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FolRalpha ADC STRO-002","termGroup":"SY","termSource":"NCI"},{"termName":"STRO 002","termGroup":"CN","termSource":"NCI"},{"termName":"STRO-002","termGroup":"CN","termSource":"NCI"},{"termName":"STRO002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2493327-62-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XDE2GOF1JT"},{"name":"Maps_To","value":"Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002"},{"name":"NCI_Drug_Dictionary_ID","value":"797174"},{"name":"NCI_META_CUI","value":"CL937710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797174"},{"name":"PDQ_Open_Trial_Search_ID","value":"797174"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118443":{"preferredName":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012","code":"C118443","definitions":[{"definition":"A monoclonal antibody directed against the ganglioside fucosyl-GM1, with potential antineoplastic and immunomodulating activities. Upon administration, anti-fucosyl-GM1 monoclonal antibody BMS-986012 binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1894272-37-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q8PK97HY9B"},{"name":"Maps_To","value":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012"},{"name":"NCI_Drug_Dictionary_ID","value":"764995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764995"},{"name":"PDQ_Open_Trial_Search_ID","value":"764995"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896899"}]}}{"C79795":{"preferredName":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962","code":"C79795","definitions":[{"definition":"A humanized anti-ganglioside GM2 (GM2) monoclonal antibody with potential antineoplastic and immunomodulating activities. Upon administration, anti-ganglioside GM2 monoclonal antibody BIW-8962 may activate an antibody dependent cellular cytotoxicity (ADCC) against GM2-expressing tumor cells. GM2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells, such as multiple myeloma (MM) cells and neuroblastoma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GM2 Monoclonal Antibody BIW-8962","termGroup":"SY","termSource":"NCI"},{"termName":"BIW-8962","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-Ganglioside_GM2_Monoclonal_Antibody_BIW-896"},{"name":"Maps_To","value":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962"},{"name":"NCI_Drug_Dictionary_ID","value":"618862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"618862"},{"name":"PDQ_Open_Trial_Search_ID","value":"618862"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2703163"}]}}{"C101524":{"preferredName":"Indusatumab Vedotin","code":"C101524","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a monoclonal antibody directed against guanylyl cyclase C (GCC or GUCY2C) conjugated to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. The monoclonal antibody moiety of indusatumab vedotin selectively binds to GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, but is also overexpressed on the surface of gastrointestinal cancers. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis in GCC-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indusatumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"MLN0264","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1514889-12-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3F0FR4W3H8"},{"name":"Maps_To","value":"Anti-GCC Antibody-Drug Conjugate MLN0264"},{"name":"Maps_To","value":"Indusatumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"732254"},{"name":"NCI_META_CUI","value":"CL435781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732254"},{"name":"PDQ_Open_Trial_Search_ID","value":"732254"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156707":{"preferredName":"Anti-GCC Antibody-Drug Conjugate TAK-164","code":"C156707","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of a full-length, fully-human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C), conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (IGN-P1), with potential antineoplastic activity. Upon intravenous administration of TAK-164, the antibody moiety selectively binds to GCC-expressing cells. Upon antibody/antigen binding and internalization, the cytotoxic DGN549 payload is released and binds to guanine residues on opposing strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of GCC-expressing cells. GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, is overexpressed on the surface of certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GCC Antibody-Drug Conjugate TAK-164","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GCC ADC TAK-164","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 164","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-164","termGroup":"CN","termSource":"NCI"},{"termName":"TAK164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QCA97P3GSS"},{"name":"Maps_To","value":"Anti-GCC Antibody-Drug Conjugate TAK-164"},{"name":"NCI_Drug_Dictionary_ID","value":"795729"},{"name":"NCI_META_CUI","value":"CL935871"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795729"},{"name":"PDQ_Open_Trial_Search_ID","value":"795729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158436":{"preferredName":"Nivatrotamab","code":"C158436","definitions":[{"definition":"A bispecific antibody comprised of a humanized anti-CD3 OKT3 (huOKT3) single chain variable fragment (scFv), linked to the carboxyl end of a humanized anti-GD2 3F8 (hu3F8) immunoglobulin G1 (IgG1) light chain, with potential antineoplastic activity. Upon intravenous administration, nivatrotamab binds to CD3 on T-cells and disialoganglioside GD2 expressed on certain tumor cells, thereby cross-linking T-cells with GD2-expressing tumor cells. This promotes a selective cytotoxic T-lymphocyte (CTL) response against GD2-expressing cells. The Fc region of the anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific antibody has two amino acid substitutions, N297A and K322A, which may prevent cytokine release syndrome and other unwanted side effects including complement-mediated pain. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells and is required for signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nivatrotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"hu3F8 x huOKT3 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"hu3F8-BsAb","termGroup":"AB","termSource":"NCI"},{"termName":"Humanized 3F8 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-GD2 x Anti-CD3 Bispecific Antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2278244-14-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8RV18E4A94"},{"name":"Maps_To","value":"Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody"},{"name":"NCI_Drug_Dictionary_ID","value":"804949"},{"name":"NCI_META_CUI","value":"CL937882"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80042":{"preferredName":"Anti-GD2 Monoclonal Antibody hu14.18K322A","code":"C80042","definitions":[{"definition":"A monoclonal antibody directed against human glycosphingolipid GD2 with potential antineoplastic activity. Upon binding to the GD2 antigen, anti-GD2 monoclonal antibody hu14.18K322A triggers a host immune response against GD2-expressing tumor cells, which may result in tumor cell death. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GD2 Monoclonal Antibody hu14.18K322A","termGroup":"PT","termSource":"NCI"},{"termName":"hu14.18K322A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-GD2_Monoclonal_Antibody_hu14_18K322A"},{"name":"Maps_To","value":"Anti-GD2 Monoclonal Antibody hu14.18K322A"},{"name":"NCI_Drug_Dictionary_ID","value":"614666"},{"name":"NCI_META_CUI","value":"CL388377"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614666"},{"name":"PDQ_Open_Trial_Search_ID","value":"614666"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C91383":{"preferredName":"Anti-GD2 Monoclonal Antibody MORAb-028","code":"C91383","definitions":[{"definition":"A human IgM monoclonal antibody directed against disialoganglioside GD2 with potential immunomodulating activity. Upon administration, anti-GD2 monoclonal antibody MORAb-028 may stimulate the immune system to exert a complement-mediated cytotoxic response against GD2-expressing tumor cells. The glycosphingolipid GD2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GD2 Monoclonal Antibody MORAb-028","termGroup":"PT","termSource":"NCI"},{"termName":"MORAb-028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GD2 Monoclonal Antibody MORAb-028"},{"name":"NCI_Drug_Dictionary_ID","value":"673996"},{"name":"NCI_META_CUI","value":"CL421587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673996"},{"name":"PDQ_Open_Trial_Search_ID","value":"673996"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136426":{"preferredName":"Anti-GD3 Antibody-drug Conjugate PF-06688992","code":"C136426","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells, and linked to an as of yet not fully elucidated chemotherapeutic agent, with potential antineoplastic activity. Upon administration of the ADC PF-06688992, the antibody moiety targets and binds to GD3 expressed on melanoma cells. Upon internalization, the chemotherapeutic agent specifically kills the GD3-positive cells. GD3 represents a major surface marker on most human melanoma cells and is not expressed on most other types of normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GD3 Antibody-drug Conjugate PF-06688992","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GD3 ADC PF-06688992","termGroup":"SY","termSource":"NCI"},{"termName":"GD3 ADC PF-06688992","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06688992","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06688992","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249791-21-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X6L6R3CFT8"},{"name":"Maps_To","value":"Anti-GD3 Antibody-drug Conjugate PF-06688992"},{"name":"NCI_Drug_Dictionary_ID","value":"789230"},{"name":"NCI_META_CUI","value":"CL523729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789230"},{"name":"PDQ_Open_Trial_Search_ID","value":"789230"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159411":{"preferredName":"Anti-GITR Agonistic Monoclonal Antibody ASP1951","code":"C159411","definitions":[{"definition":"A human, high-affinity, tetravalent monospecific agonistic monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357), with potential immune checkpoint modulating activity. Upon administration, anti-GITR agonistic monoclonal antibody ASP1951 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-lymphocytes. This induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs), which may promote the elimination of tumor cells. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Agonistic Monoclonal Antibody ASP1951","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GITR Agonistic Monoclonal Antibody PTZ-522","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 1951","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1951","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1951","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ 522","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ-522","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ522","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6WFM86G7J"},{"name":"Maps_To","value":"Anti-GITR Agonistic Monoclonal Antibody ASP1951"},{"name":"NCI_Drug_Dictionary_ID","value":"797644"},{"name":"NCI_META_CUI","value":"CL951269"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797644"},{"name":"PDQ_Open_Trial_Search_ID","value":"797644"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132267":{"preferredName":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156","code":"C132267","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody BMS-986156 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GITR MoAb BMS-986156","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986156","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986156","termGroup":"CN","termSource":"NCI"},{"termName":"GITR Agonist BMS-986156","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF18 Agonist BMS-986156","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V0XQ564M2L"},{"name":"Maps_To","value":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156"},{"name":"NCI_Drug_Dictionary_ID","value":"780443"},{"name":"NCI_META_CUI","value":"CL507899"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780443"},{"name":"PDQ_Open_Trial_Search_ID","value":"780443"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126643":{"preferredName":"Ragifilimab","code":"C126643","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody, with potential immune checkpoint modulating activity. Ragifilimab binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ragifilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GITR Agonistic Monoclonal Antibody INCAGN01876","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 01876","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN 1876","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN-1876","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN01876","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2207590-51-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O440IW9NHN"},{"name":"Maps_To","value":"Anti-GITR Agonistic Monoclonal Antibody INCAGN01876"},{"name":"Maps_To","value":"Ragifilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"779746"},{"name":"NCI_META_CUI","value":"CL503760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779746"},{"name":"PDQ_Open_Trial_Search_ID","value":"779746"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128028":{"preferredName":"Anti-GITR Monoclonal Antibody GWN 323","code":"C128028","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody GWN 323 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Monoclonal Antibody GWN 323","termGroup":"PT","termSource":"NCI"},{"termName":"GWN 323","termGroup":"CN","termSource":"NCI"},{"termName":"GWN323","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WYJ05POC5C"},{"name":"Maps_To","value":"Anti-GITR Monoclonal Antibody GWN 323"},{"name":"NCI_Drug_Dictionary_ID","value":"781243"},{"name":"NCI_META_CUI","value":"CL507922"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781243"},{"name":"PDQ_Open_Trial_Search_ID","value":"781243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116065":{"preferredName":"Anti-GITR Monoclonal Antibody MK-4166","code":"C116065","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody (MoAb) with potential immunomodulating activity. Anti-GITR monoclonal antibody MK-4166 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system and induces both the activation and proliferation of tumor-antigen-specific T effector cells, and suppresses the function of activated T regulatory cells. This leads to tumor cell eradication. Also, this agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including regulatory T-cells, effector T-cells, B-cells, and natural killer (NK) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Monoclonal Antibody MK-4166","termGroup":"PT","termSource":"NCI"},{"termName":"MK-4166","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GITR Monoclonal Antibody MK-4166"},{"name":"NCI_Drug_Dictionary_ID","value":"760889"},{"name":"NCI_META_CUI","value":"CL473484"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760889"},{"name":"PDQ_Open_Trial_Search_ID","value":"760889"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153261":{"preferredName":"Anti-Globo H Monoclonal Antibody OBI-888","code":"C153261","definitions":[{"definition":"A monoclonal antibody targeting the hexasaccharide glycosphingolipid antigen Globo H with potential immunostimulating, anti-angiogenic and antineoplastic activities. Upon infusion, anti-Globo H monoclonal antibody OBI-888 may induce tumor cell destruction via the activation of antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), and may reduce immunosuppression. Globo H is a tumor-associated antigen (TAA) expressed on the surface of various types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Globo H Monoclonal Antibody OBI-888","termGroup":"PT","termSource":"NCI"},{"termName":"OBI 888","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-888","termGroup":"CN","termSource":"NCI"},{"termName":"OBI888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2227156-40-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JI5TBH62QP"},{"name":"Maps_To","value":"Anti-Globo H Monoclonal Antibody OBI-888"},{"name":"NCI_Drug_Dictionary_ID","value":"794060"},{"name":"NCI_META_CUI","value":"CL554489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794060"},{"name":"PDQ_Open_Trial_Search_ID","value":"794060"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129936":{"preferredName":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974","code":"C129936","definitions":[{"definition":"An anti-glypican 3 (GPC3; GPC-3)/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-GPC3/CD3 bispecific antibody ERY974 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for GPC3, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of ERY974, this bispecific antibody simultaneously binds to both CD3-expressing and GPC3-expressing cells, thereby crosslinking GPC3-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and an oncofetal antigen protein, is overexpressed in a variety of cancers; it plays a role in cell division and growth regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GPC3/CD3 BiAb ERY974","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GPC3/CD3 Bispecific Antibody ERY974","termGroup":"SY","termSource":"NCI"},{"termName":"ERY974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PGF2HXQ0D3"},{"name":"Maps_To","value":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974"},{"name":"NCI_Drug_Dictionary_ID","value":"785257"},{"name":"NCI_META_CUI","value":"CL512901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785257"},{"name":"PDQ_Open_Trial_Search_ID","value":"785257"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85464":{"preferredName":"Anti-GnRH Vaccine PEP223","code":"C85464","definitions":[{"definition":"A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GnRH Vaccine PEP223","termGroup":"PT","termSource":"NCI"},{"termName":"PEP223","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GnRH Vaccine PEP223"},{"name":"NCI_Drug_Dictionary_ID","value":"643767"},{"name":"NCI_META_CUI","value":"CL412337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643767"},{"name":"PDQ_Open_Trial_Search_ID","value":"643767"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118442":{"preferredName":"Anti-gpA33/CD3 Monoclonal Antibody MGD007","code":"C118442","definitions":[{"definition":"An anti-glycoprotein A33 (gpA33)/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-gpA33/CD3 monoclonal antibody MGD007 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for gpA33, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of MGD007, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and gpA33-expressing cancer cells, thereby crosslinking cytotoxic T-lymphocytes (CTLs) to gpA33-expressing tumor cells. This may result in CTL-mediated cell lysis of the crosslinked tumor cells. The gpA33 antigen, a member of the immunoglobulin superfamily, is expressed in certain malignancies, including colon and gastrointestinal cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-gpA33/CD3 Monoclonal Antibody MGD007","termGroup":"PT","termSource":"NCI"},{"termName":"Humanized gpA33 x CD3 DART (TM) Protein MGD007","termGroup":"SY","termSource":"NCI"},{"termName":"MGD007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OZ8N9U6CEH"},{"name":"Maps_To","value":"Anti-gpA33/CD3 Monoclonal Antibody MGD007"},{"name":"NCI_Drug_Dictionary_ID","value":"764994"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764994"},{"name":"PDQ_Open_Trial_Search_ID","value":"764994"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896811"}]}}{"C103857":{"preferredName":"Anti-GRP78 Monoclonal Antibody PAT-SM6","code":"C103857","definitions":[{"definition":"A IgM monoclonal antibody (MoAb) against 78-kDa glucose-regulated protein (GRP78; also called BiP or HSPA5), with potential proapoptotic and antineoplastic activities. Upon intravenous administration of the anti-GRP78 monoclonal antibody PAT-SM6, the MoAb strongly binds to GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking the GRP78-induced suppression of apoptotic pathways. This eventually leads to the induction of tumor cell apoptosis and a reduction in tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types; its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GRP78 Monoclonal Antibody PAT-SM6","termGroup":"PT","termSource":"NCI"},{"termName":"PAT-SM6","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GRP78 Monoclonal Antibody PAT-SM6"},{"name":"NCI_Drug_Dictionary_ID","value":"743101"},{"name":"NCI_META_CUI","value":"CL438335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743101"},{"name":"PDQ_Open_Trial_Search_ID","value":"743101"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C131295":{"preferredName":"Anti-HA Epitope Monoclonal Antibody MEDI8852","code":"C131295","definitions":[{"definition":"A human immunoglobulin (Ig) G1 kappa monoclonal antibody (mAb) targeting a unique epitope in the stalk of the influenza A hemagglutinin (HA) protein, with broad influenza A virus neutralization activity. MEDI8852 was derived from an antibody isolated from human memory B-cells from patients previously infected with influenza caused by type A strains that was further optimized to increase neutralization potential. Upon infusion, MEDI8852 targets and binds to a region within the stalk of the HA protein that is highly conserved amongst all influenza A virus subtypes. This neutralizes and prevents essential steps of the viral lifecycle, thereby blocking infectivity of all influenza A virus subtypes. HA, a glycoprotein found on the surface of the influenza virus, plays a key role in viral attachment and cell entry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HA Epitope Monoclonal Antibody MEDI8852","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Influenza A Hemagglutinin Epitope mAb MEDI8852","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 8852","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-8852","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI8852","termGroup":"CN","termSource":"NCI"},{"termName":"pan-Influenza A mAb MEDI8852","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OZS4TXB9VO"},{"name":"Maps_To","value":"Anti-HA Epitope Monoclonal Antibody MEDI8852"},{"name":"NCI_Drug_Dictionary_ID","value":"785886"},{"name":"NCI_META_CUI","value":"CL514244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785886"},{"name":"PDQ_Open_Trial_Search_ID","value":"785886"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95721":{"preferredName":"Anti-HB-EGF Monoclonal Antibody KHK2866","code":"C95721","definitions":[{"definition":"A proprietary fucose-free monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HB-EGF Monoclonal Antibody KHK2866 binds to HBEGF, thereby blocking its binding to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation. The fucose-free monoclonal antibodies enhance antigen dependent cellular cytotoxicity (ADCC), and increase binding affinity to the Fc Receptor to overcome genetic polymorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HB-EGF Monoclonal Antibody KHK2866","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HB-EGF MoAb KHK2866","termGroup":"SY","termSource":"NCI"},{"termName":"KHK2866","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1832713-21-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"111EN0IJ7C"},{"name":"Maps_To","value":"Anti-HB-EGF Monoclonal Antibody KHK2866"},{"name":"NCI_Drug_Dictionary_ID","value":"694265"},{"name":"NCI_META_CUI","value":"CL428183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694265"},{"name":"PDQ_Open_Trial_Search_ID","value":"694265"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95736":{"preferredName":"Anti-HBEGF Monoclonal Antibody U3-1565","code":"C95736","definitions":[{"definition":"A humanized monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HBEGF monoclonal antibody U3-1565 binds to HBEGF and blocks the binding of HBEGF to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HBEGF Monoclonal Antibody U3-1565","termGroup":"PT","termSource":"NCI"},{"termName":"U3-1565","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HBEGF Monoclonal Antibody U3-1565"},{"name":"NCI_Drug_Dictionary_ID","value":"695315"},{"name":"NCI_META_CUI","value":"CL428196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695315"},{"name":"PDQ_Open_Trial_Search_ID","value":"695315"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116630":{"preferredName":"Anti-hepcidin Monoclonal Antibody LY2787106","code":"C116630","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) targeting the peptide hormone hepcidin, with potential anti-anemic activity. Upon intravenous administration, anti-hepcidin MoAb LY2787106 binds to hepcidin and prevents it from binding to the iron exporting protein ferroportin, which is expressed on both the basolateral surface of gastrointestinal (GI) enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export, thus increasing iron export from macrophages and iron absorption by enterocytes. This normalizes plasma iron levels, increases erythropoiesis and may inhibit anemia. Hepcidin, produced in hepatocytes, plays a key role in the homeostasis of systemic iron; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-hepcidin Monoclonal Antibody LY2787106","termGroup":"PT","termSource":"NCI"},{"termName":"LY2787106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q87RWM02HX"},{"name":"Maps_To","value":"Anti-hepcidin Monoclonal Antibody LY2787106"},{"name":"NCI_Drug_Dictionary_ID","value":"687185"},{"name":"NCI_META_CUI","value":"CL433725"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687185"},{"name":"PDQ_Open_Trial_Search_ID","value":"687185"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162577":{"preferredName":"Anbenitamab","code":"C162577","definitions":[{"definition":"An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anbenitamab simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2 heterodimerization and prevents the activation of HER-2 signaling pathways. By binding to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anbenitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER-2 Bispecific Antibody KN026","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Heterodimeric Antibody KN026","termGroup":"SY","termSource":"NCI"},{"termName":"HER2 Bispecific Antibody KN026","termGroup":"SY","termSource":"NCI"},{"termName":"KN 026","termGroup":"CN","termSource":"NCI"},{"termName":"KN-026","termGroup":"CN","termSource":"NCI"},{"termName":"KN026","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2367012-88-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RHS90QRF9E"},{"name":"Maps_To","value":"Anti-HER-2 Bispecific Antibody KN026"},{"name":"NCI_Drug_Dictionary_ID","value":"798820"},{"name":"NCI_META_CUI","value":"CL971091"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798820"},{"name":"PDQ_Open_Trial_Search_ID","value":"798820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128799":{"preferredName":"Trastuzumab Deruxtecan","code":"C128799","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"DS-8201","termGroup":"CN","termSource":"NCI"},{"termName":"DS-8201a","termGroup":"CN","termSource":"NCI"},{"termName":"Enhertu","termGroup":"BR","termSource":"NCI"},{"termName":"Fam-trastuzumab Deruxtecan-nxki","termGroup":"SY","termSource":"NCI"},{"termName":"WHO 10516","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH ) breast cancer; unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations."},{"name":"CAS_Registry","value":"1826843-81-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5384HK7574"},{"name":"Maps_To","value":"Anti-HER2 ADC DS-8201a"},{"name":"Maps_To","value":"Trastuzumab Deruxtecan"},{"name":"NCI_Drug_Dictionary_ID","value":"783025"},{"name":"NCI_META_CUI","value":"CL509598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783025"},{"name":"PDQ_Open_Trial_Search_ID","value":"783025"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156480":{"preferredName":"Trastuzumab Botidotin","code":"C156480","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated, via a cleavable linker, to the microtubule inhibitor and auristatin derivative duostatin-5 (Duo-5), with potential antineoplastic activity. Upon administration of trastuzumab botidotin, the trastuzumab moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, duo-5 binds to tubulin and inhibits its polymerization, which results in cell cycle arrest and induces tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Botidotin","termGroup":"PT","termSource":"NCI"},{"termName":"A 166","termGroup":"CN","termSource":"NCI"},{"termName":"A-166","termGroup":"CN","termSource":"NCI"},{"termName":"A166","termGroup":"CN","termSource":"NCI"},{"termName":"ADC A166","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC A166","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Antibody-drug Conjugate A166","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2699055-12-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6HUZ008AZX"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate A166"},{"name":"NCI_Drug_Dictionary_ID","value":"795827"},{"name":"NCI_META_CUI","value":"CL935677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795827"},{"name":"PDQ_Open_Trial_Search_ID","value":"795827"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123917":{"preferredName":"Anvatabart Opadotin","code":"C123917","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMAF) analog and potent microtubule inhibitor opadotin, with potential antineoplastic activity. Upon administration of anvatabart opadotin, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, opadotin binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of anvatabart opadotin, increases payload stability and optimizes its efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anvatabart Opadotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ARX788","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC ARX788","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Antibody-drug Conjugate ARX788","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788","termGroup":"SY","termSource":"NCI"},{"termName":"ARX788","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2636710-07-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B2KH16FA7H"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate ARX788"},{"name":"NCI_Drug_Dictionary_ID","value":"775851"},{"name":"NCI_META_CUI","value":"CL498281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775851"},{"name":"PDQ_Open_Trial_Search_ID","value":"775851"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126355":{"preferredName":"Anti-HER2 Antibody-drug Conjugate MEDI4276","code":"C126355","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a bispecific antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2; ERBB2) comprised of the single-chain variable fragment (scFv) of the anti- HER2 monoclonal antibody trastuzumab, which binds to domain IV of HER2, fused to the heavy chains of the anti-HER2 monoclonal antibody 39S, which binds to domain II of HER2, and conjugated, via a cleavable linker, to the cytotoxic anti-microtubule agent tubulysin, with potential antineoplastic activity. Upon administration of ADC MEDI4276, the anti-HER2 bispecific antibody specifically targets and binds to HER2 on the surface of certain cancer cells. Upon binding, crosslinking and internalization of antibody-HER2 complexes occurs and MEDI4276 is transported to the lysosome where the linker is cleaved, thereby delivering tubulysin inside HER2-expressing cancer cells. Tubulysin binds to tubulin and inhibits microtubule polymerization, which blocks cell division. This results in G2/M phase arrest, tumor cell apoptosis, and decreased proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Antibody-drug Conjugate MEDI4276","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MEDI4276","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-4276","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI4276","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAM3L34SEW"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate MEDI4276"},{"name":"NCI_Drug_Dictionary_ID","value":"780016"},{"name":"NCI_META_CUI","value":"CL504915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780016"},{"name":"PDQ_Open_Trial_Search_ID","value":"780016"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130011":{"preferredName":"Anti-HER2 Antibody-drug Conjugate RC48","code":"C130011","synonyms":[{"termName":"Anti-HER2 Antibody-drug Conjugate RC48","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Feb 02 11:54:11 EST 2022 - See 'Disitamab Vedotin(C169918)'"},{"name":"OLD_PARENT","value":"C155712"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130010":{"preferredName":"Zanidatamab","code":"C130010","definitions":[{"definition":"An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, with potential immunomodulating and antineoplastic activities. Upon administration, zanidatamab targets and binds to the two distinct HER2 domains on the tumor cell surface. This results in dual HER2 signal blockade, HER2 clustering, receptor internalization and downregulation. This also induces a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. Antibody-dependent cellular phagocytosis (ADCP) is also induced and further stimulates the immune system to kill HER2-overexpressing tumor cells. The HER2 receptor internalization also further inhibits HER2 activation, HER2-mediated signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanidatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2/HER2 Bispecific Antibody ZW25","termGroup":"SY","termSource":"NCI"},{"termName":"HER2 x HER2 Bispecific Antibody ZW25","termGroup":"SY","termSource":"NCI"},{"termName":"ZW-25","termGroup":"CN","termSource":"NCI"},{"termName":"ZW25","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169946-15-8"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z20OC92TDI"},{"name":"Maps_To","value":"Anti-HER2 Bi-specific Monoclonal Antibody ZW25"},{"name":"Maps_To","value":"Zanidatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"784826"},{"name":"NCI_META_CUI","value":"CL514017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784826"},{"name":"PDQ_Open_Trial_Search_ID","value":"784826"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162115":{"preferredName":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49","code":"C162115","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a bispecific monoclonal antibody (ZW25) directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2, receptor tyrosine-protein kinase erbB-2) linked to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon intravenous administration, anti-HER2 bispecific ADC ZW49 targets and binds to HER2 expressed on tumor cells. Following receptor internalization, the cytotoxic payload is released and induces tumor cell death through an as of yet unknown mechanism of action. Additionally, binding of HER2 may inhibit HER2 activation, HER2 signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ZW49","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Bispecific ADC ZW49","termGroup":"SY","termSource":"NCI"},{"termName":"ZW-49","termGroup":"CN","termSource":"NCI"},{"termName":"ZW49","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49"},{"name":"NCI_Drug_Dictionary_ID","value":"798595"},{"name":"NCI_META_CUI","value":"CL970593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798595"},{"name":"PDQ_Open_Trial_Search_ID","value":"798595"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160349":{"preferredName":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395","code":"C160349","definitions":[{"definition":"An immune stimulator-antibody conjugate (ISAC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a not yet disclosed immune stimulator, with potential antineoplastic and immunostimulating activities. Upon administration of the anti-HER2 immune stimulator-antibody conjugate NJH395, the antibody moiety targets and binds to HER2 expressed on tumor cells. Upon antibody/antigen binding, the immune-stimulating moiety may, through an as of yet undisclosed mechanism, enhance the immune-mediated killing of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed in many cancer types and plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 ISAC NJH395","termGroup":"SY","termSource":"NCI"},{"termName":"NJH 395","termGroup":"CN","termSource":"NCI"},{"termName":"NJH-395","termGroup":"CN","termSource":"NCI"},{"termName":"NJH395","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"301EY96MDU"},{"name":"Maps_To","value":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395"},{"name":"NCI_Drug_Dictionary_ID","value":"798283"},{"name":"NCI_META_CUI","value":"CL969413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798283"},{"name":"PDQ_Open_Trial_Search_ID","value":"798283"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1647":{"preferredName":"Trastuzumab","code":"C1647","definitions":[{"definition":"A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type of HER2 receptor antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 980","termGroup":"CN","termSource":"NCI"},{"termName":"ALT02","termGroup":"CN","termSource":"NCI"},{"termName":"Biceltis","termGroup":"FB","termSource":"NCI"},{"termName":"CANMab","termGroup":"FB","termSource":"NCI"},{"termName":"CT-P06","termGroup":"CN","termSource":"NCI"},{"termName":"CT-P6","termGroup":"CN","termSource":"NCI"},{"termName":"Herceptin","termGroup":"BR","termSource":"NCI"},{"termName":"Herceptin Biosimilar PF-05280014","termGroup":"SY","termSource":"NCI"},{"termName":"Herceptin Trastuzumab Biosimilar PF-05280014","termGroup":"SY","termSource":"NCI"},{"termName":"Herclon","termGroup":"FB","termSource":"NCI"},{"termName":"Hertraz","termGroup":"FB","termSource":"NCI"},{"termName":"Herzuma","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Kanjinti","termGroup":"BR","termSource":"NCI"},{"termName":"Ogivri","termGroup":"BR","termSource":"NCI"},{"termName":"Ontruzant","termGroup":"BR","termSource":"NCI"},{"termName":"PF-05280014","termGroup":"CN","termSource":"NCI"},{"termName":"QL 1701","termGroup":"CN","termSource":"NCI"},{"termName":"QL-1701","termGroup":"CN","termSource":"NCI"},{"termName":"QL1701","termGroup":"CN","termSource":"NCI"},{"termName":"rhuMAb HER2","termGroup":"AB","termSource":"NCI"},{"termName":"RO0452317","termGroup":"CN","termSource":"NCI"},{"termName":"SB3","termGroup":"CN","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar ABP 980","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar ALT02","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar CT-P6","termGroup":"SY","termSource":"NCI"},{"termName":"trastuzumab biosimilar EG12014","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar HLX02","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar PF-05280014","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar QL1701","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar SB3","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar SIBP-01","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-anns","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-dkst","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-dttb","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-pkrb","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-qyyp","termGroup":"SY","termSource":"NCI"},{"termName":"Trazimera","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer overexpressing HER2 protein; Pancreatic cancer overexpressing p185HER2"},{"name":"CAS_Registry","value":"180288-69-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"P188ANX8CK"},{"name":"Legacy Concept Name","value":"Trastuzumab"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody CT-P6"},{"name":"Maps_To","value":"Trastuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42265"},{"name":"NSC Number","value":"688097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42265"},{"name":"PDQ_Open_Trial_Search_ID","value":"42265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0728747"}]}}{"C142890":{"preferredName":"Cinrebafusp Alfa","code":"C142890","definitions":[{"definition":"A bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin with potential immunostimulatory and antineoplastic activities. Upon administration of cinrebafusp alfa, CD137 clustering is promoted by bridging CD137-positive T-cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. CD137 is a costimulatory immunoreceptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). Anticalins are synthetic antigen-binding proteins derived from lipocalins. Structurally dissimilar to antibodies, anticalins are able to bind to smaller antigens and exhibit improved tissue penetration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinrebafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 Monoclonal Antibody/Anti-CD137 Anticalin Bispecific Fusion Protein PRS-343","termGroup":"SY","termSource":"NCI"},{"termName":"PRS-343","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2218515-90-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"21Z359Z1CV"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody/Anti-CD137 Anticalin Bispecific Fusion Protein PRS-343"},{"name":"Maps_To","value":"Cinrebafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"791831"},{"name":"NCI_META_CUI","value":"CL541381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791831"},{"name":"PDQ_Open_Trial_Search_ID","value":"791831"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141420":{"preferredName":"Anti-HER2-vc0101 ADC PF-06804103","code":"C141420","definitions":[{"definition":"A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2-vc0101 ADC PF-06804103","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2-vcAur0101 ADC PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NG-HER2 ADC PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NG-Her2-vc0101 ADC PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06804103","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06804103","termGroup":"CN","termSource":"NCI"},{"termName":"PF06804103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2-vc0101 ADC PF-06804103"},{"name":"NCI_Drug_Dictionary_ID","value":"791410"},{"name":"NCI_META_CUI","value":"CL539508"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791410"},{"name":"PDQ_Open_Trial_Search_ID","value":"791410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156705":{"preferredName":"Runimotamab","code":"C156705","definitions":[{"definition":"An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Runimotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody RG 6194","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody 4017A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A","termGroup":"SY","termSource":"NCI"},{"termName":"BTRC 4017A","termGroup":"CN","termSource":"NCI"},{"termName":"BTRC-4017A","termGroup":"SY","termSource":"NCI"},{"termName":"BTRC4017A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 6194","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6194","termGroup":"CN","termSource":"NCI"},{"termName":"RG6194","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2361325-98-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F8Z9VSZ0K1"},{"name":"Maps_To","value":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A"},{"name":"NCI_Drug_Dictionary_ID","value":"795725"},{"name":"NCI_META_CUI","value":"CL935873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795725"},{"name":"PDQ_Open_Trial_Search_ID","value":"795725"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142889":{"preferredName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","code":"C142889","definitions":[{"definition":"An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 bispecific monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-HER2/Anti-CD3 bispecific monoclonal antibody GBR 1302 possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of GBR 1302, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","termGroup":"SY","termSource":"NCI"},{"termName":"GBR 1302","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HA8VPA83AE"},{"name":"Maps_To","value":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302"},{"name":"NCI_Drug_Dictionary_ID","value":"791830"},{"name":"NCI_META_CUI","value":"CL541380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791830"},{"name":"PDQ_Open_Trial_Search_ID","value":"791830"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C152948":{"preferredName":"Zenocutuzumab","code":"C152948","definitions":[{"definition":"A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zenocutuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-HER3 Bispecific Monoclonal Antibody MCLA-128","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128","termGroup":"SY","termSource":"NCI"},{"termName":"MCLA 128","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA-128","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA128","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1969309-56-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AE72RB1W1X"},{"name":"Maps_To","value":"Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128"},{"name":"NCI_Drug_Dictionary_ID","value":"794043"},{"name":"NCI_META_CUI","value":"CL554279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794043"},{"name":"PDQ_Open_Trial_Search_ID","value":"794043"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132112":{"preferredName":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522","code":"C132112","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed against the human epidermal growth factor receptor 2 (ERBB2; HER2), conjugated, via a proprietary biodegradable, hydrophilic polymer backbone and various linkers, to proprietary auristatin-derived payload molecules (about 15 per antibody), with potential antineoplastic activity. Upon administration of anti-HER2/auristatin payload ADC XMT-1522, the antibody moiety targets and binds to a unique epitope in the extracellular domain (ECD) of HER2. Upon internalization, cleavage and release of the cytotoxic molecules, the auristatin-derived molecules bind to tubulin and inhibit its polymerization, which results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells. The attachment of multiple auristatin molecules to the backbone enables XMT-1522 to effectively kill tumors that express relatively low amounts of the HER2 protein; therefore, this agent shows increased therapeutic potential in tumors with low HER2 expression compared to other anti-HER2 antibody-based therapies. The polymer-based proprietary platform optimizes delivery of the cytotoxic drug payload and improves drug solubility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522","termGroup":"PT","termSource":"NCI"},{"termName":"ADC XMT-1522","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC XMT-1522","termGroup":"SY","termSource":"NCI"},{"termName":"XMT-1522","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522"},{"name":"NCI_Drug_Dictionary_ID","value":"786937"},{"name":"NCI_META_CUI","value":"CL520319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786937"},{"name":"PDQ_Open_Trial_Search_ID","value":"786937"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155940":{"preferredName":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A","code":"C155940","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) linked to a DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA), with potential antineoplastic activity. Upon intravenous administration of ADC DHES0815A, the monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD-MA moiety is released. In turn, the imine groups of the PBD-MA moiety bind to and crosslink specific sites of DNA, resulting in DNA strand breaks, cell cycle arrest, and cell death in HER2 expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DHES0815A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/PBD-MA ADC DHES0815A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/PBD-Monoamide ADC DHES0815A","termGroup":"SY","termSource":"NCI"},{"termName":"DHES0815A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1E55T9OY5I"},{"name":"Maps_To","value":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A"},{"name":"NCI_Drug_Dictionary_ID","value":"795265"},{"name":"NCI_META_CUI","value":"CL562792"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795265"},{"name":"PDQ_Open_Trial_Search_ID","value":"795265"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136987":{"preferredName":"Patritumab Deruxtecan","code":"C136987","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patritumab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER3 Antibody-drug Conjugate U3 1402","termGroup":"SY","termSource":"NCI"},{"termName":"U3 1402","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1402","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1402a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2227102-46-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3XPI7EG4W8"},{"name":"Maps_To","value":"Anti-HER3 Antibody-drug Conjugate U3 1402"},{"name":"Maps_To","value":"Patritumab Deruxtecan"},{"name":"NCI_Drug_Dictionary_ID","value":"789807"},{"name":"NCI_META_CUI","value":"CL524745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789807"},{"name":"PDQ_Open_Trial_Search_ID","value":"789807"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111997":{"preferredName":"Anti-HER3 Monoclonal Antibody GSK2849330","code":"C111997","definitions":[{"definition":"A monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3) with potential antineoplastic activity. Anti-HER3 monoclonal antibody GSK2849330 binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER3 Monoclonal Antibody GSK2849330","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2849330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER3 Monoclonal Antibody GSK2849330"},{"name":"NCI_Drug_Dictionary_ID","value":"754219"},{"name":"NCI_META_CUI","value":"CL454286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754219"},{"name":"PDQ_Open_Trial_Search_ID","value":"754219"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C81939":{"preferredName":"Anti-HGF Monoclonal Antibody TAK-701","code":"C81939","definitions":[{"definition":"A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody TAK-701 binds to the soluble ligand HGF, preventing HGF binding to and activation of the HGF receptor c-Met and so the activation of the c-Met signaling pathway; this may result in the induction of cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HGF Monoclonal Antibody TAK-701","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HGF MoAb TAK-701","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-HGF_Monoclonal_Antibody_TAK-701"},{"name":"Maps_To","value":"Anti-HGF Monoclonal Antibody TAK-701"},{"name":"NCI_Drug_Dictionary_ID","value":"637760"},{"name":"NCI_META_CUI","value":"CL407463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637760"},{"name":"PDQ_Open_Trial_Search_ID","value":"637760"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68930":{"preferredName":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","code":"C68930","definitions":[{"definition":"A synthetic antisense oligodeoxynucleotide (AS ODN) targeting hypoxia-inducible factor-1alpha (HIF-1alpha) with potential antineoplastic activity. Anti-HIF-1alpha LNA antisense oligonucleotide EZN-2968 hybridizes with HIF-1alpha mRNA and blocks t HIF-1 alpha protein expression, which may result in the inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1alpha, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","termGroup":"PT","termSource":"NCI"},{"termName":"anti-HIF-1alpha LNA AS-ODN","termGroup":"SY","termSource":"NCI"},{"termName":"EZN-2968","termGroup":"CN","termSource":"NCI"},{"termName":"RO7070179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-HIF-1alpha_LNA_Antisense_Oligonucleotide_EZN-2968"},{"name":"Maps_To","value":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968"},{"name":"NCI_Drug_Dictionary_ID","value":"549337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"549337"},{"name":"PDQ_Open_Trial_Search_ID","value":"549337"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607869"}]}}{"C165547":{"preferredName":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1","code":"C165547","definitions":[{"definition":"A gene transfer construct composed of a self-inactivating (SIN) lentiviral vector (LV) expressing a short hairpin RNA (shRNA) that targets the human C-C chemokine receptor type 5 (CCR5) mRNA (sh5) and expressing the HIV entry inhibitor C46, with potential anti-human immunodeficiency virus (HIV) type 1 (HIV-1) activity. Upon transduction of the anti-HIV-1 LVsh5/C46 Cal-1 in specified blood cell populations, such as peripheral blood mononuclear cells (PBMCs), hematopoietic stem/progenitor cells (HSPCs) and CD4+ T-lymphocytes, the cells express shCCR5 and C46. shCCR5 targets and binds to CCR5 mRNA, which inhibits the expression of CCR5 and prevents binding of the virus to the cellular CCR5 co-receptor. The cell surface expression of the cell membrane-anchored C46  peptide blocks HIV-1 fusion to the cellular membrane. The removal of CCR5 from and the production of C46 in the bone marrow and white blood cells, make the transduced cells resistant to and protect them from HIV-1 entry, infection and replication. HIV-resistant HSPCs could provide long-term protection against latent HIV infection and against HIV-associated cancers. C46 is a membrane-anchored 46-amino acid sequence found in HIV-1 gp41. CCR5 is a HIV-1 co-receptor that mediates HIV attachment and cell entry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HIV-1 Lentiviral Vector sh5/C46","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HIV-1 LV-expressing sh5/C46 Cal-1","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HIV-1 LVsh5/C46","termGroup":"SY","termSource":"NCI"},{"termName":"Cal-1","termGroup":"CN","termSource":"NCI"},{"termName":"Cal-1 Vector","termGroup":"SY","termSource":"NCI"},{"termName":"LVsh5/C46","termGroup":"SY","termSource":"NCI"},{"termName":"LVsh5/C46 Vector","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1"},{"name":"NCI_Drug_Dictionary_ID","value":"799502"},{"name":"NCI_META_CUI","value":"CL978677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799502"},{"name":"PDQ_Open_Trial_Search_ID","value":"799502"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103860":{"preferredName":"Anti-HLA-DR Monoclonal Antibody IMMU-114","code":"C103860","definitions":[{"definition":"A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration, anti-HLA-DR monoclonal antibody IMMU-114 binds to HLA-DR on HLA-DR-expressing tumor cells and, although the exact mechanism has yet to be fully elucidated, appears to induce hyperactivation of ERK- and JNK-dependent mitogen activated protein kinase signaling pathways. This may lead to mitochondrial membrane depolarization and reactive oxygen species (ROS) generation. This eventually leads to an induction of tumor cell apoptosis and a reduction in tumor cell proliferation. IMMU-14 may be beneficial in the treatment of graft versus host disease (GVHD) as it appears to suppress T-lymphocyte proliferation and natural killer (NK) cell activation. As the Fc region of the orgnial IgG1 MoAb was replaced with the IgG4 isotype, IMMU-114 does not induce a complement cytotoxicity (CDC) or an antibody-dependent cell-mediated cytotoxicity (ADCC). HLA-DR, a MHC class II molecule, is found on various b-cell hematologic malignancies and in autoimmune diseases as well as on normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HLA-DR Monoclonal Antibody IMMU-114","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HLA-DR MoAb L243","termGroup":"SY","termSource":"NCI"},{"termName":"hL243gamma4P","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HLA-DR Monoclonal Antibody IMMU-114"},{"name":"NCI_Drug_Dictionary_ID","value":"743255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743255"},{"name":"PDQ_Open_Trial_Search_ID","value":"743255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3530137"}]}}{"C129694":{"preferredName":"Anti-human GITR Monoclonal Antibody AMG 228","code":"C129694","definitions":[{"definition":"An agonistic anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor receptor superfamily, member 18; TNFRSF18; GITR; CD357) humanized monoclonal antibody, with potential immune checkpoint modulating activity. Anti-human GITR monoclonal antibody AMG 228 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teffs), and suppresses the function of activated T regulatory cells (Tregs). This leads to immune-mediated tumor cell eradication though a cytotoxic T-lymphocyte (CTL) response. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-human GITR Monoclonal Antibody AMG 228","termGroup":"PT","termSource":"NCI"},{"termName":"Agonistic GITR Antibody AMG 228","termGroup":"SY","termSource":"NCI"},{"termName":"AMG 228","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-228","termGroup":"CN","termSource":"NCI"},{"termName":"AMG228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-human GITR Monoclonal Antibody AMG 228"},{"name":"NCI_META_CUI","value":"CL512894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95023":{"preferredName":"Anti-human GITR Monoclonal Antibody TRX518","code":"C95023","definitions":[{"definition":"A humanized, Fc disabled anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody (MoAb) with immunomodulating activity. Anti-human GITR MoAb TRX518 blocks the interaction of GITR, found on multiple types of T cells, with its ligand, thereby inducing both the activation of tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. This agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-human GITR Monoclonal Antibody TRX518","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-huGITR MoAb TRX518","termGroup":"SY","termSource":"NCI"},{"termName":"TRX518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-human GITR Monoclonal Antibody TRX518"},{"name":"NCI_Drug_Dictionary_ID","value":"689549"},{"name":"NCI_META_CUI","value":"CL426557"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689549"},{"name":"PDQ_Open_Trial_Search_ID","value":"689549"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88327":{"preferredName":"Bersanlimab","code":"C88327","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bersanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"BI-505","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1987854-08-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MP3N1L4OR6"},{"name":"Maps_To","value":"Anti-ICAM-1 Monoclonal Antibody BI-505"},{"name":"Maps_To","value":"Bersanlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"661398"},{"name":"NCI_META_CUI","value":"CL413589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661398"},{"name":"PDQ_Open_Trial_Search_ID","value":"661398"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126804":{"preferredName":"Feladilimab","code":"C126804","definitions":[{"definition":"An agonistic antibody for the inducible T-cell co-stimulator (ICOS; CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, feladilimab targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This stimulates ICOS-positive T-cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Feladilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS Agonist Antibody GSK3359609","termGroup":"SY","termSource":"NCI"},{"termName":"GSK3359609","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2252518-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OUP4QB2A3R"},{"name":"Maps_To","value":"Anti-ICOS Agonist Antibody GSK3359609"},{"name":"Maps_To","value":"Feladilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"780433"},{"name":"NCI_META_CUI","value":"CL507897"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780433"},{"name":"PDQ_Open_Trial_Search_ID","value":"780433"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146762":{"preferredName":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226","code":"C146762","definitions":[{"definition":"An agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS BMS-986226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-inducible T-cell Co-stimulator BMS-986226","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986226","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986226","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986226","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226"},{"name":"NCI_Drug_Dictionary_ID","value":"792161"},{"name":"NCI_META_CUI","value":"CL544800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792161"},{"name":"PDQ_Open_Trial_Search_ID","value":"792161"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C162521":{"preferredName":"Alomfilimab","code":"C162521","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, alomfilimab selectively binds to dimeric ICOS expressed on certain T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Additionally, KY1044 may eliminate ICOS-positive T-cells via antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alomfilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS Monoclonal Antibody KY1044","termGroup":"SY","termSource":"NCI"},{"termName":"KY 1044","termGroup":"CN","termSource":"NCI"},{"termName":"KY-1044","termGroup":"CN","termSource":"NCI"},{"termName":"KY1044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2378692-24-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D2OPG50FF7"},{"name":"Maps_To","value":"Anti-ICOS Monoclonal Antibody KY1044"},{"name":"NCI_Drug_Dictionary_ID","value":"798819"},{"name":"NCI_META_CUI","value":"CL970948"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798819"},{"name":"PDQ_Open_Trial_Search_ID","value":"798819"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123267":{"preferredName":"Anti-ICOS Monoclonal Antibody MEDI-570","code":"C123267","definitions":[{"definition":"An Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-ICOS MoAb MEDI-570 targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Fc optimization enhances antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ICOS Monoclonal Antibody MEDI-570","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI-570","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2179209-59-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G9F0G3YL28"},{"name":"Maps_To","value":"Anti-ICOS Monoclonal Antibody MEDI-570"},{"name":"NCI_Drug_Dictionary_ID","value":"774809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774809"},{"name":"PDQ_Open_Trial_Search_ID","value":"774809"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053619"}]}}{"C79798":{"preferredName":"Veligrotug","code":"C79798","definitions":[{"definition":"A humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) with potential antineoplastic activity. Veligrotug specifically binds to and blocks membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signal transduction, which may result in the induction of apoptosis and a decrease in cellular proliferation. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Veligrotug","termGroup":"PT","termSource":"NCI"},{"termName":"anti-CD122 monoclonal antibody AVE1642","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IGF-1R Monoclonal Antibody AVE1642","termGroup":"SY","termSource":"NCI"},{"termName":"AVE-1642","termGroup":"CN","termSource":"NCI"},{"termName":"AVE1642","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1242567-05-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z9U2SS9ZC8"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Monoclonal_Antibody_AVE1642"},{"name":"Maps_To","value":"Anti-IGF-1R Monoclonal Antibody AVE1642"},{"name":"NCI_Drug_Dictionary_ID","value":"619043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"619043"},{"name":"PDQ_Open_Trial_Search_ID","value":"619043"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703165"}]}}{"C71530":{"preferredName":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022","code":"C71530","definitions":[{"definition":"A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R recombinant monoclonal antibody BIIB022 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1242567-19-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y60655Y65T"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Recombinant_Monoclonal_Antibody_BIIB022"},{"name":"Maps_To","value":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022"},{"name":"NCI_Drug_Dictionary_ID","value":"579227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579227"},{"name":"PDQ_Open_Trial_Search_ID","value":"579227"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346816"}]}}{"C95708":{"preferredName":"Bermekimab","code":"C95708","definitions":[{"definition":"A human immunoglobulin (Ig) G1 monoclonal antibody directed against interleukin-1 alpha (IL-1a) and derived from human B-lymphocytes that were obtained from a natural human immune response against IL-1a, with potential antineoplastic, anti-inflammatory, anti-cachectic and anti-angiogenic activities. Upon administration, bermekimab targets, binds to and neutralizes IL-1a thereby preventing IL-1a activity. This prevents IL-1a-mediated inflammation, tumorigenesis and angiogenesis. In addition, bermekimab may abrogate IL-1a-mediated cachexia and stimulate metabolic activity in the central nervous system (CNS). IL-1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bermekimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-1 alpha Monoclonal Antibody MABp1","termGroup":"SY","termSource":"NCI"},{"termName":"CA-18C3","termGroup":"CN","termSource":"NCI"},{"termName":"CV 18C3","termGroup":"CN","termSource":"NCI"},{"termName":"CV-18C3","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-77474462","termGroup":"CN","termSource":"NCI"},{"termName":"MABp1","termGroup":"AB","termSource":"NCI"},{"termName":"MABp1","termGroup":"CN","termSource":"NCI"},{"termName":"RA 18C3","termGroup":"CN","termSource":"NCI"},{"termName":"RA-18C3","termGroup":"CN","termSource":"NCI"},{"termName":"Xilonix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401965-15-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N6SVN735GY"},{"name":"Maps_To","value":"Anti-IL-1 alpha Monoclonal Antibody MABp1"},{"name":"Maps_To","value":"Bermekimab"},{"name":"NCI_Drug_Dictionary_ID","value":"661044"},{"name":"NCI_Drug_Dictionary_ID","value":"691526"},{"name":"NCI_META_CUI","value":"CL428173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691526"},{"name":"PDQ_Open_Trial_Search_ID","value":"691526"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C87767":{"preferredName":"Lebrikizumab","code":"C87767","definitions":[{"definition":"A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lebrikizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-13 Humanized Monoclonal Antibody TNX-650","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Interleukin 13) (Human-Mouse Monoclonal MILR1444a Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal MILR1444a Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MILR1444A","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody TNX-650","termGroup":"SY","termSource":"NCI"},{"termName":"PRO301444","termGroup":"CN","termSource":"NCI"},{"termName":"TNX-650","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"953400-68-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U9JLP7V031"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_TNX-650"},{"name":"Maps_To","value":"Anti-IL-13 Humanized Monoclonal Antibody TNX-650"},{"name":"NCI_Drug_Dictionary_ID","value":"539362"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981360"}]}}{"C126841":{"preferredName":"Ordesekimab","code":"C126841","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human pro-inflammatory cytokine interleukin-15 (IL-15), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, ordesekimab binds to and neutralizes IL-15, thereby preventing IL-15-mediated pro-inflammatory signaling. By inhibiting IL-15-mediated immune responses, ordesekimab decreases natural killer (NK) cell activation and proliferation, reduces T-cell infiltration, increases T-cell apoptosis, and may prevent the growth of IL-15-driven cancer cells. IL-15 plays a key role in inflammation and is associated with a variety of autoimmune and inflammatory disorders as well as with cell proliferation in certain cancer types, such as T-cell lymphomas. IL-15 is required for the proliferation of certain T-cells and NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ordesekimab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 714","termGroup":"CN","termSource":"NCI"},{"termName":"AMG714","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-IL-15 Monoclonal Antibody AMG 714","termGroup":"SY","termSource":"NCI"},{"termName":"HuMab-IL15 AMG 714","termGroup":"SY","termSource":"NCI"},{"termName":"HUMAX-IL 15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2394931-19-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EJ48MR05C3"},{"name":"Maps_To","value":"Anti-IL-15 Monoclonal Antibody AMG 714"},{"name":"NCI_Drug_Dictionary_ID","value":"781143"},{"name":"NCI_META_CUI","value":"CL507916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781143"},{"name":"PDQ_Open_Trial_Search_ID","value":"781143"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124227":{"preferredName":"Adakitug","code":"C124227","definitions":[{"definition":"A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, adakitug directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, BMS-986253 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adakitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-8 Monoclonal Antibody BMS-986253","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986253","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986253","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986253","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-IL-8","termGroup":"SY","termSource":"NCI"},{"termName":"HuMax-IL8","termGroup":"SY","termSource":"NCI"},{"termName":"MDX 018","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231258-73-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N0YWS8X3S9"},{"name":"Maps_To","value":"Anti-IL-8 Monoclonal Antibody BMS-986253"},{"name":"Maps_To","value":"Anti-IL-8 Monoclonal Antibody HuMax-IL8"},{"name":"NCI_Drug_Dictionary_ID","value":"777250"},{"name":"NCI_META_CUI","value":"CL502607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777250"},{"name":"PDQ_Open_Trial_Search_ID","value":"777250"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156490":{"preferredName":"Bapotulimab","code":"C156490","definitions":[{"definition":"A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bapotulimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ILDR2 Inhibitor BAY1905254","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ILDR2 Monoclonal Antibody BAY 1905254","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-immunoglobulin-like Domain Containing Receptor 2 MoAb BAY1905254","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1905254","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1905254","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1905254","termGroup":"CN","termSource":"NCI"},{"termName":"ILDR2 Function-blocking Antibody BAY1905254","termGroup":"SY","termSource":"NCI"},{"termName":"Immune Checkpoint Inhibitor BAY1905254","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2359413-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I92BM16NTD"},{"name":"Maps_To","value":"Anti-ILDR2 Monoclonal Antibody BAY 1905254"},{"name":"NCI_Drug_Dictionary_ID","value":"795831"},{"name":"NCI_META_CUI","value":"CL935671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795831"},{"name":"PDQ_Open_Trial_Search_ID","value":"795831"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160204":{"preferredName":"Anti-ILT4 Monoclonal Antibody MK-4830","code":"C160204","definitions":[{"definition":"A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ILT4 Monoclonal Antibody MK-4830","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-leukocyte Immunoglobulin-like Receptor 2 Monoclonal Antibody MK-4830","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LIR2 Monoclonal Antibody MK-4830","termGroup":"SY","termSource":"NCI"},{"termName":"MK 4830","termGroup":"CN","termSource":"NCI"},{"termName":"MK-4830","termGroup":"CN","termSource":"NCI"},{"termName":"MK4830","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ILT4 Monoclonal Antibody MK-4830"},{"name":"NCI_Drug_Dictionary_ID","value":"797844"},{"name":"NCI_META_CUI","value":"CL969335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797844"},{"name":"PDQ_Open_Trial_Search_ID","value":"797844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78839":{"preferredName":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388","code":"C78839","definitions":[{"definition":"An immunoconjugate consisting of an anti-integrin monoclonal antibody covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Integrin-targeted immunoconjugate IMGN388 binds to tumor cell surface integrins; upon internalization, the DM4 moiety is released from the immunoconjugate, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in inhibition of cell division and cell growth of integrin-expressing tumor cells. Integrins, a class of transmembrane cell surface receptors, link the extracellular matrix (ECM) to intracellular signaling pathways that control cell proliferation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388","termGroup":"PT","termSource":"NCI"},{"termName":"IMGN388","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-Integrin_Immunotoxin_IMGN388"},{"name":"Maps_To","value":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388"},{"name":"NCI_Drug_Dictionary_ID","value":"609890"},{"name":"NCI_META_CUI","value":"CL387679"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609890"},{"name":"PDQ_Open_Trial_Search_ID","value":"609890"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78464":{"preferredName":"Anti-KIR Monoclonal Antibody IPH 2101","code":"C78464","definitions":[{"definition":"A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody IPH 2101 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-KIR Monoclonal Antibody IPH 2101","termGroup":"PT","termSource":"NCI"},{"termName":"1-7F9","termGroup":"CN","termSource":"NCI"},{"termName":"IPH 2101","termGroup":"CN","termSource":"NCI"},{"termName":"IPH-2101","termGroup":"CN","termSource":"NCI"},{"termName":"IPH2101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000676-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5Q686XLG8L"},{"name":"Legacy Concept Name","value":"Anti-KIR_Monoclonal_Antibody_1-7F9"},{"name":"Maps_To","value":"Anti-KIR Monoclonal Antibody IPH 2101"},{"name":"NCI_Drug_Dictionary_ID","value":"599832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599832"},{"name":"PDQ_Open_Trial_Search_ID","value":"599832"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703118"}]}}{"C82391":{"preferredName":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02","code":"C82391","definitions":[{"definition":"A lipid nanoparticle formulation containing two small interfering RNAs (siRNAs) for kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF) with potential antitumor activity. Upon intravenous administration, the siRNAs in KSP/VEGF siRNAs ALN-VSP02ALN bind to both KSP and VEGF messenger RNAs (mRNAs), preventing translation of KSP and VEGF proteins; this may result in growth inhibition of tumor cells that overexpress KSP and VEGF. VEGF and KSP are upregulated in many tumor cells and play an important role in tumor proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02","termGroup":"PT","termSource":"NCI"},{"termName":"ALN-VSP02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-KSP_Anti-VEGF_siRNAs_ALN-VSP02"},{"name":"Maps_To","value":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02"},{"name":"NCI_Drug_Dictionary_ID","value":"642288"},{"name":"NCI_META_CUI","value":"CL408662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642288"},{"name":"PDQ_Open_Trial_Search_ID","value":"642288"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157127":{"preferredName":"Tuparstobart","code":"C157127","definitions":[{"definition":"A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, tuparstobart targets and binds to human LAG-3 on tumor-infiltrating  lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both proliferation and activation of T-cells. Its expression on  TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuparstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody INCAGN02385","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody INCAGN02385","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 02385","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN 2385","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN02385","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN2385","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649466-03-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z0A08C63DF"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody INCAGN02385"},{"name":"NCI_Drug_Dictionary_ID","value":"796980"},{"name":"NCI_META_CUI","value":"CL936810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796980"},{"name":"PDQ_Open_Trial_Search_ID","value":"796980"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122683":{"preferredName":"Ieramilimab","code":"C122683","definitions":[{"definition":"A humanized monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, Ieramilimab binds to LAG-3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF) and expressed on various immune cells, negatively regulates cellular proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ieramilimab","termGroup":"PT","termSource":"NCI"},{"termName":"IMP-701","termGroup":"CN","termSource":"NCI"},{"termName":"LAG 525","termGroup":"CN","termSource":"NCI"},{"termName":"LAG525","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2137049-37-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OI8P0SFD4R"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody LAG525"},{"name":"Maps_To","value":"Ieramilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"772952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772952"},{"name":"PDQ_Open_Trial_Search_ID","value":"772952"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053626"}]}}{"C132339":{"preferredName":"Fianlimab","code":"C132339","definitions":[{"definition":"A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fianlimab binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks LAG-3 binding to tumor cells expressing major histocompatibility complex (MHC) class II molecules. This may activate antigen-specific T-lymphocytes and enhance cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells; its expression on TILs is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fianlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 MoAb REGN3767","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 3767","termGroup":"CN","termSource":"NCI"},{"termName":"REGN3767","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11182","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2126132-98-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OX5LRQ5H6K"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody REGN3767"},{"name":"Maps_To","value":"Fianlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"787595"},{"name":"NCI_META_CUI","value":"CL520574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787595"},{"name":"PDQ_Open_Trial_Search_ID","value":"787595"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150734":{"preferredName":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118","code":"C150734","definitions":[{"definition":"A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118","termGroup":"PT","termSource":"NCI"},{"termName":"FS118","termGroup":"CN","termSource":"NCI"},{"termName":"LAG-3/PD-L1 Bispecific Antibody FS118","termGroup":"SY","termSource":"NCI"},{"termName":"LAG-3/PD-L1 Mab2 FS118","termGroup":"SY","termSource":"NCI"},{"termName":"Mab2 FS118","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118"},{"name":"NCI_Drug_Dictionary_ID","value":"793522"},{"name":"NCI_META_CUI","value":"CL552521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793522"},{"name":"PDQ_Open_Trial_Search_ID","value":"793522"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150403":{"preferredName":"Miptenalimab","code":"C150403","definitions":[{"definition":"A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miptenalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody BI 754111","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody BI 754111","termGroup":"SY","termSource":"NCI"},{"termName":"BI 754111","termGroup":"CN","termSource":"NCI"},{"termName":"BI-754111","termGroup":"CN","termSource":"NCI"},{"termName":"BI754111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2245092-03-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NVCTROPV3P"},{"name":"Maps_To","value":"Anti-LAG3 Monoclonal Antibody BI 754111"},{"name":"Maps_To","value":"Miptenalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"792749"},{"name":"NCI_META_CUI","value":"CL552148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792749"},{"name":"PDQ_Open_Trial_Search_ID","value":"792749"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142077":{"preferredName":"Favezelimab","code":"C142077","definitions":[{"definition":"A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Favezelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody MK-4280","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody MK-4280","termGroup":"SY","termSource":"NCI"},{"termName":"MK 4280","termGroup":"CN","termSource":"NCI"},{"termName":"MK-4280","termGroup":"CN","termSource":"NCI"},{"termName":"MK4280","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231068-83-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H1396W7D1H"},{"name":"Maps_To","value":"Anti-LAG3 Monoclonal Antibody MK-4280"},{"name":"Maps_To","value":"Favezelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791433"},{"name":"NCI_META_CUI","value":"CL540133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791433"},{"name":"PDQ_Open_Trial_Search_ID","value":"791433"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142978":{"preferredName":"Encelimab","code":"C142978","definitions":[{"definition":"A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,encelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody TSR-033","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody TSR-033","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody TSR-033","termGroup":"SY","termSource":"NCI"},{"termName":"TSR 033","termGroup":"CN","termSource":"NCI"},{"termName":"TSR-033","termGroup":"CN","termSource":"NCI"},{"termName":"TSR033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2173096-82-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N151VZIIPD"},{"name":"Maps_To","value":"Anti-LAG3 Monoclonal Antibody TSR-033"},{"name":"Maps_To","value":"Encelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791832"},{"name":"NCI_META_CUI","value":"CL541410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791832"},{"name":"PDQ_Open_Trial_Search_ID","value":"791832"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126275":{"preferredName":"Anti-LAMP1 Antibody-drug Conjugate SAR428926","code":"C126275","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) conjugated, via the disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-LAMP1 ADC SAR428926, the anti-LAMP1 monoclonal antibody moiety targets and binds to the cell surface antigen LAMP1. After antibody-antigen interaction and internalization, the SPDB linker is selectively cleaved by proteases in the cytosol and the DM4 moiety is released. DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting both cell division and cell growth of LAMP1-expressing tumor cells. LAMP1, overexpressed on a variety of cancer cells, plays a key role in cell-cell adhesion and migration. The SPDB linker is resistant to cleavage in the bloodstream, which may increase stability and reduce toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LAMP1 Antibody-drug Conjugate SAR428926","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SAR428926","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAMP1 ADC SAR428926","termGroup":"SY","termSource":"NCI"},{"termName":"SAR428926","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LAMP1 Antibody-drug Conjugate SAR428926"},{"name":"NCI_Drug_Dictionary_ID","value":"779304"},{"name":"NCI_META_CUI","value":"CL504852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779304"},{"name":"PDQ_Open_Trial_Search_ID","value":"779304"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126794":{"preferredName":"Anti-LGR5 Monoclonal Antibody BNC101","code":"C126794","definitions":[{"definition":"A humanized monoclonal antibody targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, the anti-LGR5 humanized monoclonal antibody BNC101 targets and binds to LGR5, thereby inhibiting LRG5-mediated signal transduction pathways. This prevents proliferation of LRG5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LGR5 Monoclonal Antibody BNC101","termGroup":"PT","termSource":"NCI"},{"termName":"BNC-101","termGroup":"CN","termSource":"NCI"},{"termName":"BNC101","termGroup":"CN","termSource":"NCI"},{"termName":"ET-101","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LGR5 Monoclonal Antibody BNC101"},{"name":"NCI_Drug_Dictionary_ID","value":"780067"},{"name":"NCI_META_CUI","value":"CL507886"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780067"},{"name":"PDQ_Open_Trial_Search_ID","value":"780067"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156176":{"preferredName":"Falbikitug","code":"C156176","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, falbikitug binds to LIF and inhibits LIF signaling by blocking the recruitment of glycoprotein 130 (gp130) to the LIF-LIF receptor (LIFR)-gp130 signaling complex. This inhibits signal transducer and activator of transcription 3 (STAT3) signaling and inhibits tumor cell growth. In addition, the inhibition of LIF signaling abrogates the immunosuppressive tumor microenvironment (TME) by decreasing immunosuppressive M2 macrophages and allows for the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. LIF, a member of the interleukin-6 (IL-6) family of cytokines, is involved in many physiological and pathological processes and plays an important role in both creating the TME and promoting the activity of cancer-initiating cells (CICs). LIF is overexpressed in many tumor cell types and its expression correlates with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Falbikitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LIF Monoclonal Antibody MSC-1","termGroup":"SY","termSource":"NCI"},{"termName":"AZD 0171","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-0171","termGroup":"CN","termSource":"NCI"},{"termName":"AZD0171","termGroup":"CN","termSource":"NCI"},{"termName":"MSC 1","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-1","termGroup":"CN","termSource":"NCI"},{"termName":"MSC1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2740565-02-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E4JL3K3CI6"},{"name":"Maps_To","value":"Anti-LIF Monoclonal Antibody MSC-1"},{"name":"NCI_Drug_Dictionary_ID","value":"795377"},{"name":"NCI_META_CUI","value":"CL563028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795377"},{"name":"PDQ_Open_Trial_Search_ID","value":"795377"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C112001":{"preferredName":"Ladiratuzumab Vedotin","code":"C112001","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in ladiratuzumab vedotin is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ladiratuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"SGN-LIV1A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1629760-29-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VM4G5D1A60"},{"name":"Maps_To","value":"Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A"},{"name":"Maps_To","value":"Ladiratuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"754237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754237"},{"name":"PDQ_Open_Trial_Search_ID","value":"754237"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827076"}]}}{"C116745":{"preferredName":"Anti-Ly6E Antibody-Drug Conjugate RG 7841","code":"C116745","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) and linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of RG 7841 targets and binds to Ly6E expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills, through an as of yet unknown mechanism of action, the Ly6E-expressing cancer cells. Ly6E, an interferon (IFN)-inducible glycosylphosphatidylinositol (GPI)-linked cell membrane protein, is expressed on a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Ly6E Antibody-Drug Conjugate RG 7841","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DLYE5953A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LY6E-VCMMAE","termGroup":"SY","termSource":"NCI"},{"termName":"DLYE5953A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7841","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7841","termGroup":"CN","termSource":"NCI"},{"termName":"RG7841","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ONS92I2A7F"},{"name":"Maps_To","value":"Anti-Ly6E Antibody-Drug Conjugate RG 7841"},{"name":"NCI_Drug_Dictionary_ID","value":"759448"},{"name":"NCI_META_CUI","value":"CL473919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759448"},{"name":"PDQ_Open_Trial_Search_ID","value":"759448"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162462":{"preferredName":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C","code":"C162462","definitions":[{"definition":"A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon intravenous administration of IMC-C103C, the TCR moiety of this agent targets and binds to MAGE-A4 on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C","termGroup":"PT","termSource":"NCI"},{"termName":"IMC C103C","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-C103C","termGroup":"CN","termSource":"NCI"},{"termName":"IMCC103C","termGroup":"CN","termSource":"NCI"},{"termName":"ImmTAC IMC-C103C","termGroup":"SY","termSource":"NCI"},{"termName":"ImmTAC Molecule IMC-C103C","termGroup":"SY","termSource":"NCI"},{"termName":"Immune Mobilizing Monoclonal TCR Against Cancer IMC-C103C","termGroup":"SY","termSource":"NCI"},{"termName":"T-cell Redirecting Bi-specific Biologic IMC-C103C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C"},{"name":"NCI_Drug_Dictionary_ID","value":"801761"},{"name":"NCI_META_CUI","value":"CL970956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801761"},{"name":"PDQ_Open_Trial_Search_ID","value":"801761"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91092":{"preferredName":"Anti-Melanin Monoclonal Antibody PTI-6D2","code":"C91092","definitions":[{"definition":"A monoclonal antibody (MoAb) against extracellular melanin with tumor targeting activity. Anti-melanin monoclonal antibody PTI-6D2 binds to extracellular melanin, a melanocyte pigment which is released during tumor cell turnover from dead melanoma tumor cells, while avoiding the binding of melanin in normal, healthy tissue because of melanin's normal intracellular location. Upon labeling with the beta-emitting radioisotope rhenium Re 188 (PTI-188), this MoAb may target multiple melanoma (MM) cells, thereby delivering a cytotoxic dose of radiation specifically to the targeted tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Melanin Monoclonal Antibody PTI-6D2","termGroup":"PT","termSource":"NCI"},{"termName":"PTI-6D2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Melanin Monoclonal Antibody PTI-6D2"},{"name":"NCI_Drug_Dictionary_ID","value":"529286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529286"},{"name":"PDQ_Open_Trial_Search_ID","value":"529286"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832013"}]}}{"C120303":{"preferredName":"Anti-mesothelin Antibody-drug Conjugate BMS-986148","code":"C120303","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to an as of yet undisclosed cytotoxic drug, with potential antineoplastic activity. The monoclonal antibody moiety of anti-mesothelin ADC BMS-986148 targets and binds to the tumor associated antigen mesothelin. Upon internalization, the cytotoxic agent kills or prevents cellular proliferation of mesothelin-expressing tumor cells through an as of yet undescribed mechanism of action. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-mesothelin Antibody-drug Conjugate BMS-986148","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986148","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-mesothelin Antibody-drug Conjugate BMS-986148"},{"name":"NCI_Drug_Dictionary_ID","value":"768587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768587"},{"name":"PDQ_Open_Trial_Search_ID","value":"768587"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896897"}]}}{"C121653":{"preferredName":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100","code":"C121653","definitions":[{"definition":"An anti-mesothelin (MSLN) recombinant cytolytic fusion protein (cFP) composed of a humanized Fab fragment of anti-MSLN monoclonal antibody SS1 linked to a truncated and de-immunized 24 kDa fragment of the Pseudomonas exotoxin (PE) (PE24), with potential antineoplastic activity. Upon intravenous administration of anti-MSLN-PE24 cFP LMB-100, the anti-MSLN moiety targets and binds to MSLN-expressing tumor cells. Upon binding and internalization through endocytosis, the toxin moiety ADP-ribosylates and inactivates eukaryotic elongation factor 2 (eEF2), preventing the elongation step of protein synthesis and leading to both an inhibition of protein synthesis and an induction of MSLN-expressing tumor cell apoptosis. MSLN, a tumor-associated antigen overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation and migration. The engineered PE24 portion of LMB-100 does contain the targeting domain and furin cleavage site, which are needed for cytotoxicity, but most of the translocation domain II is deleted and the catalytic domain III contains point mutations, which result in the deletion and silencing of most T- and B-cell epitopes; therefore, the immunogenicity and toxicity is reduced compared to non-engineered PE toxin, which allows for the administration of larger doses of LMB-100.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-MSLN-PE24 cFP LMB-100","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-100","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7787","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7787","termGroup":"CN","termSource":"NCI"},{"termName":"RG7787","termGroup":"CN","termSource":"NCI"},{"termName":"RO 6927005","termGroup":"CN","termSource":"NCI"},{"termName":"RO6927005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1841500-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D6AT024T4P"},{"name":"Maps_To","value":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100"},{"name":"NCI_Drug_Dictionary_ID","value":"767396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767396"},{"name":"PDQ_Open_Trial_Search_ID","value":"767396"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4044528"}]}}{"C116746":{"preferredName":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A","code":"C116746","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of MMOT0530A, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface glycoprotein mesothelin (MSLN), and covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DMOT4039A binds to MSLN-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. MSLN, a tumor-associated antigen (TAA), is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A","termGroup":"PT","termSource":"NCI"},{"termName":"DMOT-4039A","termGroup":"CN","termSource":"NCI"},{"termName":"DMOT4039A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7600","termGroup":"CN","termSource":"NCI"},{"termName":"RG7600","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A"},{"name":"NCI_Drug_Dictionary_ID","value":"717527"},{"name":"NCI_META_CUI","value":"CL433928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717527"},{"name":"PDQ_Open_Trial_Search_ID","value":"717527"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127906":{"preferredName":"Anti-Met Monoclonal Antibody Mixture Sym015","code":"C127906","definitions":[{"definition":"A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the extracellular domain of the human hepatocyte growth factor receptor (MET; HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-MET monoclonal antibody mixture Sym015 targets and binds to the extracellular domain of MET, thereby preventing the binding of its ligand, hepatocyte growth factor (HGF). This may prevent activation of the receptor and MET-mediated signal transduction pathways. This inhibits MET-dependent tumor cell proliferation. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Met Monoclonal Antibody Mixture Sym015","termGroup":"PT","termSource":"NCI"},{"termName":"Hu9006-Hu9338","termGroup":"SY","termSource":"NCI"},{"termName":"Hu9006/Hu9338","termGroup":"SY","termSource":"NCI"},{"termName":"Sym 015","termGroup":"CN","termSource":"NCI"},{"termName":"Sym-015","termGroup":"CN","termSource":"NCI"},{"termName":"Sym015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Met Monoclonal Antibody Mixture Sym015"},{"name":"NCI_Drug_Dictionary_ID","value":"781406"},{"name":"NCI_META_CUI","value":"CL507929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781406"},{"name":"PDQ_Open_Trial_Search_ID","value":"781406"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118281":{"preferredName":"Anti-Met/EGFR Monoclonal Antibody LY3164530","code":"C118281","definitions":[{"definition":"A monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) and human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-Met/EGFR MoAb LY3164530 targets and prevents the activation of EGFR and c-Met. This leads to a downstream inhibition of EGFR/c-Met-mediated signal transduction pathways, and prevents cellular proliferation in tumor cells overexpressing EGFR and c-Met. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surface of various solid tumor cell types. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Met/EGFR Monoclonal Antibody LY3164530","termGroup":"PT","termSource":"NCI"},{"termName":"LY3164530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2069210-01-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K85WE44TZ7"},{"name":"Maps_To","value":"Anti-Met/EGFR Monoclonal Antibody LY3164530"},{"name":"NCI_Drug_Dictionary_ID","value":"764231"},{"name":"NCI_META_CUI","value":"CL474133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764231"},{"name":"PDQ_Open_Trial_Search_ID","value":"764231"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105803":{"preferredName":"Andecaliximab","code":"C105803","definitions":[{"definition":"A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential antineoplastic activity. Upon administration, andecaliximab binds to MMP-9 and inhibits its enzymatic activity. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in the degradation of collagens and proteoglycans; increased activity of MMP-9 has been associated with increased invasion and metastasis of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Andecaliximab","termGroup":"PT","termSource":"NCI"},{"termName":"GS-5745","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1518996-49-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"571045EIM4"},{"name":"Maps_To","value":"Andecaliximab"},{"name":"Maps_To","value":"Anti-MMP-9 Monoclonal Antibody GS-5745"},{"name":"NCI_Drug_Dictionary_ID","value":"747683"},{"name":"NCI_META_CUI","value":"CL447155"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747683"},{"name":"PDQ_Open_Trial_Search_ID","value":"747683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118362":{"preferredName":"Anti-MUC1 Monoclonal Antibody BTH1704","code":"C118362","definitions":[{"definition":"A monoclonal antibody against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, anti-MUC1 monoclonal antibody BTH1704 targets and binds to MUC1 expressed on the surface of tumor cells, which can potentially activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-MUC1 Monoclonal Antibody BTH1704","termGroup":"PT","termSource":"NCI"},{"termName":"BTH1704","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-MUC1 Monoclonal Antibody BTH1704"},{"name":"NCI_Drug_Dictionary_ID","value":"764610"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764610"},{"name":"PDQ_Open_Trial_Search_ID","value":"764610"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896895"}]}}{"C153129":{"preferredName":"Ubamatamab","code":"C153129","definitions":[{"definition":"A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen that is part of the T cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ubamatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-MUC16 x Anti-CD3 REGN4018","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-MUC16/CD3 Bispecific Antibody REGN4018","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 4018","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-4018","termGroup":"CN","termSource":"NCI"},{"termName":"REGN4018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305629-50-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6BUL1G4D60"},{"name":"Maps_To","value":"Anti-MUC16/CD3 Bispecific Antibody REGN4018"},{"name":"Maps_To","value":"Anti-MUC16/CD3 BiTE Antibody REGN4018"},{"name":"NCI_Drug_Dictionary_ID","value":"793937"},{"name":"NCI_META_CUI","value":"CL554386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793937"},{"name":"PDQ_Open_Trial_Search_ID","value":"793937"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147031":{"preferredName":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A","code":"C147031","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human mucin 16 (MUC16; cancer antigen 125; CA125; FLJ14303) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-MUC16/MMAE ADC DMUC4064A binds to MUC16 located on the tumor cell surface. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. MUC16, a member of the mucin family glycoproteins, is overexpressed in a variety of tumor cells and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DMUC4064A","termGroup":"SY","termSource":"NCI"},{"termName":"DMUC4064A","termGroup":"CN","termSource":"NCI"},{"termName":"RG7882","termGroup":"CN","termSource":"NCI"},{"termName":"THIOMAB-drug Conjugate DMUC4064A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D5STG0624V"},{"name":"Maps_To","value":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A"},{"name":"NCI_Drug_Dictionary_ID","value":"792380"},{"name":"NCI_META_CUI","value":"CL545030"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792380"},{"name":"PDQ_Open_Trial_Search_ID","value":"792380"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78840":{"preferredName":"Indatuximab Ravtansine","code":"C78840","definitions":[{"definition":"An immunoconjugate consisting of a monoclonal antibody directed against syndecan-1 (CD138) covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Upon administration, indatuximab ravtansine binds to syndecan-1-expressing tumor cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of syndecan-1-expressing tumor cells. Syndecan-1, a type 1 transmembrane proteoglycan and tumor-associated antigen (TAA), is overexpressed in a variety of cancer cells and plays a key role in the regulation of cell growth, differentiation, and adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indatuximab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","termGroup":"SY","termSource":"NCI"},{"termName":"BT-062","termGroup":"CN","termSource":"NCI"},{"termName":"BT062","termGroup":"CN","termSource":"NCI"},{"termName":"Maytansinoid-Conjugated Anti-Myeloma Monoclonal Antibody BT062","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1238517-16-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XGL4M23834"},{"name":"Legacy Concept Name","value":"Maytansinoid-Conjugated_Anti-Myeloma_Monoclonal_Antibody_BT062"},{"name":"Maps_To","value":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062"},{"name":"Maps_To","value":"Indatuximab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"609930"},{"name":"NCI_META_CUI","value":"CL387726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609930"},{"name":"PDQ_Open_Trial_Search_ID","value":"609930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99640":{"preferredName":"Landogrozumab","code":"C99640","definitions":[{"definition":"A monoclonal antibody against myostatin (MSTN) with potential anti-cachexia activity. Upon administration,  landogrozumab binds to and neutralizes the MSTN protein, thereby blocking the MSTN signalling pathway. This may help decrease muscle protein breakdown and muscle weakness and may attenuate cancer cachexia. MSTN, a member of the transforming growth factor-beta (TGF-beta) superfamily, is a negative regulator of muscle growth and development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Landogrozumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-myostatin Monoclonal Antibody LY2495655","termGroup":"SY","termSource":"NCI"},{"termName":"LY2495655","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1391726-30-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B1792M902R"},{"name":"Maps_To","value":"Anti-myostatin Monoclonal Antibody LY2495655"},{"name":"Maps_To","value":"Landogrozumab"},{"name":"NCI_Drug_Dictionary_ID","value":"722359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"722359"},{"name":"PDQ_Open_Trial_Search_ID","value":"722359"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274844"}]}}{"C147578":{"preferredName":"Upinitatug","code":"C147578","definitions":[{"definition":"A proprietary humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), with potential antineoplastic activity. Upon administration of upinitatug, the antibody targets and binds to NaPi2b expressed on tumor cells. Although the tumor cell killing effects of upinitatug are not established, this binding may induce an antibody-dependent cellular cytotoxicity (ADCC)-mediated immune response against NaPi2b-expressing tumor cells, and/or may inhibit NaPi2b-mediated sodium and phosphate ion cotransport activity and ion-dependent tumor cell signaling. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of tumor cells. It plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upinitatug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-NaPi2b MoAb XMT-1535","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b Monoclonal Antibody XMT-1535","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb XMT-1535","termGroup":"SY","termSource":"NCI"},{"termName":"Upifitamab","termGroup":"SY","termSource":"NCI"},{"termName":"XMT 1535","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1535","termGroup":"CN","termSource":"NCI"},{"termName":"XMT1535","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254118-43-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15OY7NA275"},{"name":"Maps_To","value":"Anti-NaPi2b Monoclonal Antibody XMT-1535"},{"name":"Maps_To","value":"Upifitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792494"},{"name":"NCI_META_CUI","value":"CL545380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792494"},{"name":"PDQ_Open_Trial_Search_ID","value":"792494"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114500":{"preferredName":"Enfortumab Vedotin","code":"C114500","definitions":[{"definition":"An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enfortumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"AGS 22ME","termGroup":"CN","termSource":"NCI"},{"termName":"AGS-22M6E","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-Nectin 4 ADC ASG-22CE","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E","termGroup":"SY","termSource":"NCI"},{"termName":"ASG-22CE","termGroup":"CN","termSource":"NCI"},{"termName":"Enfortumab Vedotin-ejfv","termGroup":"SY","termSource":"NCI"},{"termName":"Padcev","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting."},{"name":"CAS_Registry","value":"1346452-25-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DLE8519RWM"},{"name":"Maps_To","value":"Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E"},{"name":"Maps_To","value":"Enfortumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"759429"},{"name":"NCI_META_CUI","value":"CL472325"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759429"},{"name":"PDQ_Open_Trial_Search_ID","value":"759429"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91728":{"preferredName":"Vesencumab","code":"C91728","definitions":[{"definition":"A human IgG1 monoclonal antibody directed against neuropilin-1 (NRP1), with potential antiangiogenic and antineoplastic activities. Upon intravenous administration, vesencumab specifically targets and binds to NRP1; the antibody-NRP1 complex prevents the subsequent coupling of NRP1 to VEGFR2, thereby potentially inhibiting VEGF-mediated signaling and potentially preventing angiogenesis. In combination with other anti-VEGF therapies, vesencumab may enhance their anti-angiogenic effect. NRP1 is a membrane-bound co-receptor normally expressed by endothelial cells and overexpressed by certain tumor cells, and plays a role in angiogenesis, cell survival, migration, and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vesencumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin GL, Anti-(Human Neuropilin 1) (Human Monoclonal MNRP1685a Heavy Chain), Disulfide with Human Monoclonal MNRP1685a Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MNRP-1685A","termGroup":"CN","termSource":"NCI"},{"termName":"MNRP1685A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1205533-60-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7SF22186WT"},{"name":"Maps_To","value":"Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A"},{"name":"Maps_To","value":"Vesencumab"},{"name":"NCI_Drug_Dictionary_ID","value":"614996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614996"},{"name":"PDQ_Open_Trial_Search_ID","value":"614996"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984519"}]}}{"C124647":{"preferredName":"Anti-nf-P2X7 Antibody Ointment BIL-010t","code":"C124647","definitions":[{"definition":"An ointment formulation composed of a purified sheep immunoglobulin G (IgG) antibody against the non-functional form of the purinergic P2X7 receptor (nf-P2X7), with potential antineoplastic activity. Upon topical application of the anti-nf-P2X7 antibody ointment BIL-010t, the antibody binds to nf-P2X7 and inhibits its antiapoptotic activity. This may induce apoptosis and inhibit the growth of nf-P2X7-overexpressing cancer cells. P2X7, an ATP-gated cation-selective channel, plays a role in the induction of apoptosis; nf-P2X7, is upregulated in a variety of cancer cell types while not expressed on normal, healthy cells and is unable to form a large transmembrane, apoptotic pore upon exposure to ATP and prevents apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-nf-P2X7 Antibody Ointment BIL-010t","termGroup":"PT","termSource":"NCI"},{"termName":"BIL-010t","termGroup":"CN","termSource":"NCI"},{"termName":"BSCT 10 % Ointment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-nf-P2X7 Antibody Ointment BIL-010t"},{"name":"NCI_Drug_Dictionary_ID","value":"776771"},{"name":"NCI_META_CUI","value":"CL502879"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776771"},{"name":"PDQ_Open_Trial_Search_ID","value":"776771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91721":{"preferredName":"Anti-Nucleolin Aptamer AS1411","code":"C91721","definitions":[{"definition":"A 26-base guanine-rich oligodeoxynucleotide aptamer with potential apoptotic induction activity. Upon administration, anti-nucleolin aptamer AS1411 targets and binds to nucleolin, a nucleolar phosphoprotein which is overexpressed on the surface of certain cancer cells. Via binding to cell surface nucleolin, AS1411 is internalized and may prevent nucleolin from binding to and stabilizing mRNA of the anti-apoptotic BCL2, thereby destabilizing BCL2 mRNA, leading to a reduction in BCL2 protein synthesis. This may lead to the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Nucleolin Aptamer AS1411","termGroup":"PT","termSource":"NCI"},{"termName":"AS1411","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Nucleolin Aptamer AS1411"},{"name":"NCI_Drug_Dictionary_ID","value":"565948"},{"name":"PDQ_Closed_Trial_Search_ID","value":"565948"},{"name":"PDQ_Open_Trial_Search_ID","value":"565948"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1744513"}]}}{"C116847":{"preferredName":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A","code":"C116847","definitions":[{"definition":"An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A","termGroup":"PT","termSource":"NCI"},{"termName":"CTAG1A ASCI","termGroup":"SY","termSource":"NCI"},{"termName":"GSK-2241658A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2241658A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2241658A Antigen-Specific Cancer Immunotherapeutic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A"},{"name":"NCI_Drug_Dictionary_ID","value":"686918"},{"name":"NCI_META_CUI","value":"CL433722"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686918"},{"name":"PDQ_Open_Trial_Search_ID","value":"686918"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153130":{"preferredName":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso","code":"C153130","definitions":[{"definition":"A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and/or LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T-cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and/or LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific NY-ESO-1- and LAGE-1A-specific TCR/Anti-CD3","termGroup":"SY","termSource":"NCI"},{"termName":"HLA- A*0201-Restricted NY-ESO-1- and LAGE-1A-specific Soluble TCR/Anti-CD3 Bispecific Molecule","termGroup":"SY","termSource":"NCI"},{"termName":"IMCnyeso","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C416JC9CX0"},{"name":"Maps_To","value":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso"},{"name":"NCI_Drug_Dictionary_ID","value":"793936"},{"name":"NCI_META_CUI","value":"CL554387"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793936"},{"name":"PDQ_Open_Trial_Search_ID","value":"793936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118368":{"preferredName":"Anti-OFA Immunotherapeutic BB-MPI-03","code":"C118368","definitions":[{"definition":"A cancer vaccine composed of 3 different cytotoxic T-cell epitopes derived from the tumor-associated antigen oncofetal antigen (OFA), with potential immunostimulating and antineoplastic activities. Upon intradermal administration, anti-OFA immunotherapeutic vaccine BB-MPI-03 activates the immune system to elicit a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing OFA. OFA, also called immature laminin receptor protein (iLRP), is expressed in fetal tissues and is overexpressed in various cancers; its expression is correlated with cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OFA Immunotherapeutic BB-MPI-03","termGroup":"PT","termSource":"NCI"},{"termName":"BB-MPI-03","termGroup":"CN","termSource":"NCI"},{"termName":"BBMPI03","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-OFA Immunotherapeutic BB-MPI-03"},{"name":"NCI_Drug_Dictionary_ID","value":"764767"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764767"},{"name":"PDQ_Open_Trial_Search_ID","value":"764767"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896736"}]}}{"C161864":{"preferredName":"Revdofilimab","code":"C161864","definitions":[{"definition":"An agonistic humanized IgG1 monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, revdofilimab selectively binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Revdofilimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 368","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-368","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV368","termGroup":"CN","termSource":"NCI"},{"termName":"Agonistic Anti-OX40 Monoclonal Antibody ABBV-368","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-OX40 Agonist Monoclonal Antibody ABBV-368","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-OX40 Agonistic Monoclonal Antibody ABBV-368","termGroup":"SY","termSource":"NCI"},{"termName":"PR1628103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230138-89-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2Y83Y2ORD3"},{"name":"Maps_To","value":"Anti-OX40 Agonist Monoclonal Antibody ABBV-368"},{"name":"Maps_To","value":"Revdofilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"792559"},{"name":"NCI_META_CUI","value":"CL970355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792559"},{"name":"PDQ_Open_Trial_Search_ID","value":"792559"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121927":{"preferredName":"Ivuxolimab","code":"C121927","definitions":[{"definition":"An agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, ivuxolimab selectively binds to and activates OX40; which induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivuxolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Agonist Monoclonal Antibody PF-04518600","termGroup":"SY","termSource":"NCI"},{"termName":"PF-04518600","termGroup":"CN","termSource":"NCI"},{"termName":"PF-8600","termGroup":"CN","termSource":"NCI"},{"termName":"PF04518600","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2128729-41-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"APS3IS9D6W"},{"name":"Maps_To","value":"Anti-OX40 Agonist Monoclonal Antibody PF-04518600"},{"name":"Maps_To","value":"Ivuxolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"767326"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767326"},{"name":"PDQ_Open_Trial_Search_ID","value":"767326"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053606"}]}}{"C128026":{"preferredName":"Anti-OX40 Antibody BMS 986178","code":"C128026","definitions":[{"definition":"An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 monoclonal antibody BMS 986178 selectively binds to and activates the OX40 receptor, by mimicking the action of the endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor family (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OX40 Antibody BMS 986178","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986178","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P9XVH8H2HF"},{"name":"Maps_To","value":"Anti-OX40 Antibody BMS 986178"},{"name":"NCI_Drug_Dictionary_ID","value":"781172"},{"name":"NCI_META_CUI","value":"CL507919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781172"},{"name":"PDQ_Open_Trial_Search_ID","value":"781172"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124783":{"preferredName":"Anti-OX40 Monoclonal Antibody GSK3174998","code":"C124783","definitions":[{"definition":"An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-OX40 monoclonal antibody GSK3174998 selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OX40 Monoclonal Antibody GSK3174998","termGroup":"PT","termSource":"NCI"},{"termName":"GSK3174998","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2089398-68-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CT69TVL1KE"},{"name":"Maps_To","value":"Anti-OX40 Monoclonal Antibody GSK3174998"},{"name":"NCI_META_CUI","value":"CL503015"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158507":{"preferredName":"Cudarolimab","code":"C158507","definitions":[{"definition":"An agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4; TNFRSF4; CD134; OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cudarolimab selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cudarolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Monoclonal Antibody IBI101","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 101","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-101","termGroup":"CN","termSource":"NCI"},{"termName":"IBI101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2244739-29-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DT958C4NWR"},{"name":"Maps_To","value":"Anti-OX40 Monoclonal Antibody IBI101"},{"name":"NCI_Drug_Dictionary_ID","value":"797150"},{"name":"NCI_META_CUI","value":"CL938052"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797150"},{"name":"PDQ_Open_Trial_Search_ID","value":"797150"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124058":{"preferredName":"Sasanlimab","code":"C124058","definitions":[{"definition":"An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sasanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 PF-06801591","termGroup":"SY","termSource":"NCI"},{"termName":"PF-06801591","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11161","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2206792-50-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LZZ0IC2EWP"},{"name":"Maps_To","value":"Anti-PD-1 Checkpoint Inhibitor PF-06801591"},{"name":"Maps_To","value":"Sasanlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"776395"},{"name":"NCI_META_CUI","value":"CL502495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776395"},{"name":"PDQ_Open_Trial_Search_ID","value":"776395"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97039":{"preferredName":"Anti-PD-1 Fusion Protein AMP-224","code":"C97039","definitions":[{"definition":"A recombinant B7-DC Fc-fusion protein composed of the extracellular domain of the PD-1 ligand programmed cell death ligand 2 (PD-L2, B7-DC) and the Fc region of human immunoglobulin (Ig) G1, with potential immune checkpoint inhibitory and antineoplastic activities. Anti-PD-1 fusion protein AMP-224 specifically binds to PD-1 on chronically stimulated T-cells and reduces their proliferation. This may restore immune function and may result in the activation of cytotoxic T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein of Ig superfamily and inhibitor receptor expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. AMP-224 does not bind normal activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Fusion Protein AMP-224","termGroup":"PT","termSource":"NCI"},{"termName":"AMP-224","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422184-00-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SKF3JJJ5QA"},{"name":"Maps_To","value":"Anti-PD-1 Fusion Protein AMP-224"},{"name":"NCI_Drug_Dictionary_ID","value":"700595"},{"name":"NCI_META_CUI","value":"CL429646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700595"},{"name":"PDQ_Open_Trial_Search_ID","value":"700595"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155879":{"preferredName":"Penpulimab","code":"C155879","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, penpulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penpulimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 105","termGroup":"CN","termSource":"NCI"},{"termName":"AK-105","termGroup":"CN","termSource":"NCI"},{"termName":"AK105","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody AK105","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2350298-92-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IBS1BZ4E4I"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody AK105"},{"name":"NCI_Drug_Dictionary_ID","value":"794779"},{"name":"NCI_META_CUI","value":"CL562705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794779"},{"name":"PDQ_Open_Trial_Search_ID","value":"794779"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161597":{"preferredName":"Zeluvalimab","code":"C161597","definitions":[{"definition":"A human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zeluvalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zeluvalimab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 404","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-404","termGroup":"CN","termSource":"NCI"},{"termName":"AMG404","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody AMG 404","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2315361-37-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DX474PAV6P"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody AMG 404"},{"name":"NCI_Drug_Dictionary_ID","value":"798431"},{"name":"NCI_META_CUI","value":"CL970132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798431"},{"name":"PDQ_Open_Trial_Search_ID","value":"798431"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162871":{"preferredName":"Anti-PD-1 Monoclonal Antibody BAT1306","code":"C162871","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1306 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody BAT1306","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1 Monoclonal Antibody BAT1306","termGroup":"SY","termSource":"NCI"},{"termName":"BAT 1306","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-1306","termGroup":"CN","termSource":"NCI"},{"termName":"BAT1306","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody BAT1306"},{"name":"NCI_Drug_Dictionary_ID","value":"798913"},{"name":"NCI_META_CUI","value":"CL973356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798913"},{"name":"PDQ_Open_Trial_Search_ID","value":"798913"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148155":{"preferredName":"Prolgolimab","code":"C148155","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, prolgolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prolgolimab","termGroup":"PT","termSource":"NCI"},{"termName":"BCD 100","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-100","termGroup":"CN","termSource":"NCI"},{"termName":"BCD100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2093956-19-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W05CP6IT8R"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody BCD-100"},{"name":"Maps_To","value":"Prolgolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"792520"},{"name":"NCI_META_CUI","value":"CL1382578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792520"},{"name":"PDQ_Open_Trial_Search_ID","value":"792520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132252":{"preferredName":"Ezabenlimab","code":"C132252","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, ezabenlimab selectively binds to and blocks the activation of PD-1, an immunoglobulin (Ig) superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and T-cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ezabenlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody BI 754091","termGroup":"SY","termSource":"NCI"},{"termName":"BI 754091","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249882-54-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5V1UI86573"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody BI 754091"},{"name":"Maps_To","value":"Ezabenlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"787036"},{"name":"NCI_META_CUI","value":"CL520361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787036"},{"name":"PDQ_Open_Trial_Search_ID","value":"787036"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156726":{"preferredName":"Nofazinlimab","code":"C156726","definitions":[{"definition":"A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nofazinlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nofazinlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody CS1003","termGroup":"SY","termSource":"NCI"},{"termName":"CS 1003","termGroup":"CN","termSource":"NCI"},{"termName":"CS-1003","termGroup":"CN","termSource":"NCI"},{"termName":"CS1003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2377845-98-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42T48Q7A6O"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody CS1003"},{"name":"NCI_Drug_Dictionary_ID","value":"795581"},{"name":"NCI_META_CUI","value":"CL935855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795581"},{"name":"PDQ_Open_Trial_Search_ID","value":"795581"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162636":{"preferredName":"Rulonilimab","code":"C162636","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,rulonilimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rulonilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody F520","termGroup":"SY","termSource":"NCI"},{"termName":"F 520","termGroup":"CN","termSource":"NCI"},{"termName":"F520","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417124-95-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KQA6N2NT4Z"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody F520"},{"name":"NCI_Drug_Dictionary_ID","value":"798724"},{"name":"NCI_META_CUI","value":"CL971026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798724"},{"name":"PDQ_Open_Trial_Search_ID","value":"798724"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159549":{"preferredName":"Zimberelimab","code":"C159549","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zimberelimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zimberelimab","termGroup":"PT","termSource":"NCI"},{"termName":"AB 122","termGroup":"CN","termSource":"NCI"},{"termName":"AB-122","termGroup":"CN","termSource":"NCI"},{"termName":"AB122","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody GLS-010","termGroup":"SY","termSource":"NCI"},{"termName":"GLS 010","termGroup":"CN","termSource":"NCI"},{"termName":"GLS-010","termGroup":"CN","termSource":"NCI"},{"termName":"GLS010","termGroup":"CN","termSource":"NCI"},{"termName":"WBP-3055","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2259860-24-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ZBL7O904IL"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody GLS-010"},{"name":"NCI_Drug_Dictionary_ID","value":"797805"},{"name":"NCI_META_CUI","value":"CL951387"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797805"},{"name":"PDQ_Open_Trial_Search_ID","value":"797805"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156738":{"preferredName":"Serplulimab","code":"C156738","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serplulimab","termGroup":"PT","termSource":"NCI"},{"termName":"HLX 10","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-10","termGroup":"CN","termSource":"NCI"},{"termName":"HLX10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231029-82-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"S3GQZ2K36V"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody HLX10"},{"name":"Maps_To","value":"Serplulimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795682"},{"name":"NCI_META_CUI","value":"CL935905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795682"},{"name":"PDQ_Open_Trial_Search_ID","value":"795682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160717":{"preferredName":"Pucotenlimab","code":"C160717","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pucotenlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pucotenlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody HX008","termGroup":"SY","termSource":"NCI"},{"termName":"HX 008","termGroup":"CN","termSource":"NCI"},{"termName":"HX-008","termGroup":"CN","termSource":"NCI"},{"termName":"HX008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2403647-03-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CGA81G3KR5"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody HX008"},{"name":"NCI_Drug_Dictionary_ID","value":"797959"},{"name":"NCI_META_CUI","value":"CL969824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797959"},{"name":"PDQ_Open_Trial_Search_ID","value":"797959"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157485":{"preferredName":"Pimivalimab","code":"C157485","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pimivalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimivalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody JTX-4014","termGroup":"SY","termSource":"NCI"},{"termName":"JTX 4014","termGroup":"CN","termSource":"NCI"},{"termName":"JTX-4014","termGroup":"CN","termSource":"NCI"},{"termName":"JTX4014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2293951-22-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MA05AF40UO"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody JTX-4014"},{"name":"NCI_Drug_Dictionary_ID","value":"796722"},{"name":"NCI_META_CUI","value":"CL937077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796722"},{"name":"PDQ_Open_Trial_Search_ID","value":"796722"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153149":{"preferredName":"Lipustobart","code":"C153149","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, lipustobart binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways, leading to the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells that negatively regulates T-cell activation and effector function when activated by its ligands. PD-1 plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipustobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody LZM009","termGroup":"SY","termSource":"NCI"},{"termName":"LZM 009","termGroup":"CN","termSource":"NCI"},{"termName":"LZM-009","termGroup":"CN","termSource":"NCI"},{"termName":"LZM009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2639481-06-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H6KN31H3XF"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody LZM009"},{"name":"NCI_Drug_Dictionary_ID","value":"793463"},{"name":"NCI_META_CUI","value":"CL554402"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793463"},{"name":"PDQ_Open_Trial_Search_ID","value":"793463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113332":{"preferredName":"Anti-PD-1 Monoclonal Antibody MEDI0680","code":"C113332","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MEDI0680 binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody MEDI0680","termGroup":"PT","termSource":"NCI"},{"termName":"AMP-514","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI0680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody MEDI0680"},{"name":"NCI_Drug_Dictionary_ID","value":"756047"},{"name":"NCI_META_CUI","value":"CL458160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756047"},{"name":"PDQ_Open_Trial_Search_ID","value":"756047"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C142168":{"preferredName":"Retifanlimab","code":"C142168","definitions":[{"definition":"A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retifanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"INCMGA 0012","termGroup":"CN","termSource":"NCI"},{"termName":"INCMGA-0012","termGroup":"CN","termSource":"NCI"},{"termName":"INCMGA00012","termGroup":"CN","termSource":"NCI"},{"termName":"INCMGA0012","termGroup":"CN","termSource":"NCI"},{"termName":"MGA 012","termGroup":"CN","termSource":"NCI"},{"termName":"MGA-012","termGroup":"CN","termSource":"NCI"},{"termName":"MGA012","termGroup":"CN","termSource":"NCI"},{"termName":"Retifanlimab-dlwr","termGroup":"SY","termSource":"NCI"},{"termName":"Zynyz","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)."},{"name":"CAS_Registry","value":"2226345-85-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2Y3T5IF01Z"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody MGA012"},{"name":"Maps_To","value":"Retifanlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791453"},{"name":"NCI_META_CUI","value":"CL540160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791453"},{"name":"PDQ_Open_Trial_Search_ID","value":"791453"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142865":{"preferredName":"Anti-PD-1 Monoclonal Antibody Sym021","code":"C142865","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 , PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody Sym021 binds to and inhibits PD-1 activation and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF), is expressed on T-cells and functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2). Activated PD-1 plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody Sym021","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1 Monoclonal Antibody Sym021","termGroup":"SY","termSource":"NCI"},{"termName":"Sym021","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2233593-42-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K45ZNW8WU9"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody Sym021"},{"name":"NCI_Drug_Dictionary_ID","value":"791807"},{"name":"NCI_META_CUI","value":"CL540754"},{"name":"PDQ_Open_Trial_Search_ID","value":"791807"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126799":{"preferredName":"Dostarlimab","code":"C126799","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dostarlimab","termGroup":"PT","termSource":"NCI"},{"termName":"ANB011","termGroup":"CN","termSource":"NCI"},{"termName":"Dostarlimab-gxly","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Jemperli","termGroup":"BR","termSource":"NCI"},{"termName":"TSR 042","termGroup":"CN","termSource":"NCI"},{"termName":"TSR-042","termGroup":"CN","termSource":"NCI"},{"termName":"TSR042","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer"},{"name":"CAS_Registry","value":"2022215-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"P0GVQ9A4S5"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody TSR-042"},{"name":"Maps_To","value":"Dostarlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"780223"},{"name":"NCI_META_CUI","value":"CL1676862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780223"},{"name":"PDQ_Open_Trial_Search_ID","value":"780223"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158505":{"preferredName":"Lorigerlimab","code":"C158505","definitions":[{"definition":"A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lorigerlimab","termGroup":"PT","termSource":"NCI"},{"termName":"AEX-1344","termGroup":"CN","termSource":"NCI"},{"termName":"AEX1344","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-CTLA4 DART Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific DART Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"D-1 x CTLA4 DART Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"Dual-affinity Retargeting Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"MGD 019","termGroup":"CN","termSource":"NCI"},{"termName":"MGD-019","termGroup":"SY","termSource":"NCI"},{"termName":"MGD019","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 x CTLA4 Bispecific DART Molecule MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA4 DART Protein MGD019","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416595-46-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JM802R57SA"},{"name":"Maps_To","value":"Anti-PD-1/Anti-CTLA4 DART Protein MGD019"},{"name":"NCI_Drug_Dictionary_ID","value":"797142"},{"name":"NCI_META_CUI","value":"CL938054"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797142"},{"name":"PDQ_Open_Trial_Search_ID","value":"797142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143957":{"preferredName":"Tebotelimab","code":"C143957","definitions":[{"definition":"An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T-cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tebotelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-LAG-3 DART Protein MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific DART Protein MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"Dual-affinity Retargeting Protein MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"MGD 013","termGroup":"CN","termSource":"NCI"},{"termName":"MGD-013","termGroup":"CN","termSource":"NCI"},{"termName":"MGD013","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 x LAG-3 Bispecific DART Molecule MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x LAG-3 DART Molecule MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x LAG-3 DART Protein MGD013","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2245725-04-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L62556GPXB"},{"name":"Maps_To","value":"Anti-PD-1/Anti-LAG-3 DART Protein MGD013"},{"name":"NCI_Drug_Dictionary_ID","value":"792154"},{"name":"NCI_META_CUI","value":"CL542159"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792154"},{"name":"PDQ_Open_Trial_Search_ID","value":"792154"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160605":{"preferredName":"Reozalimab","code":"C160605","definitions":[{"definition":"A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reozalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/PD-L1 Bispecific Antibody LY3434172","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody LY3434172","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3434172","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3434172","termGroup":"CN","termSource":"NCI"},{"termName":"LY3434172","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1LO2LQW7QG"},{"name":"Maps_To","value":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172"},{"name":"NCI_Drug_Dictionary_ID","value":"801671"},{"name":"NCI_META_CUI","value":"CL969662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801671"},{"name":"PDQ_Open_Trial_Search_ID","value":"801671"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C153379":{"preferredName":"Cadonilimab","code":"C153379","definitions":[{"definition":"A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cadonilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 104","termGroup":"CN","termSource":"NCI"},{"termName":"AK-104","termGroup":"CN","termSource":"NCI"},{"termName":"AK104","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 x CTLA-4 Bispecific Antibody AK104","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/CTLA-4 Bispecific Antibody AK104","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD1/Anti-CTLA4 Bispecific Antibody AK104","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA-4 Dual Checkpoint Inhibitor AK104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2394841-59-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6FYG1DS4NW"},{"name":"Maps_To","value":"Anti-PD-1/CTLA-4 Bispecific Antibody AK104"},{"name":"NCI_Drug_Dictionary_ID","value":"793930"},{"name":"NCI_META_CUI","value":"CL554535"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793930"},{"name":"PDQ_Open_Trial_Search_ID","value":"793930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160714":{"preferredName":"Lomvastomig","code":"C160714","definitions":[{"definition":"A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lomvastomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 x TIM-3 Bispecific Antibody RO7121661","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-TIM-3 Bispecific Antibody RO7121661","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/TIM-3 Bispecific Antibody RO7121661","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7121661","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7121661","termGroup":"SY","termSource":"NCI"},{"termName":"RO7121661","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9GAH9VG7IP"},{"name":"Maps_To","value":"Anti-PD-1/TIM-3 Bispecific Antibody RO7121661"},{"name":"NCI_Drug_Dictionary_ID","value":"797892"},{"name":"NCI_META_CUI","value":"CL969812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797892"},{"name":"PDQ_Open_Trial_Search_ID","value":"797892"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163992":{"preferredName":"Tagitanlimab","code":"C163992","definitions":[{"definition":"A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tagitanlimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tagitanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"A 167","termGroup":"CN","termSource":"NCI"},{"termName":"A-167","termGroup":"CN","termSource":"NCI"},{"termName":"A167","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody A167","termGroup":"SY","termSource":"NCI"},{"termName":"KL A167","termGroup":"CN","termSource":"NCI"},{"termName":"KL-A167","termGroup":"CN","termSource":"NCI"},{"termName":"KLA167","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417649-97-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GUY458P83P"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody A167"},{"name":"NCI_Drug_Dictionary_ID","value":"799136"},{"name":"NCI_META_CUI","value":"CL977261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799136"},{"name":"PDQ_Open_Trial_Search_ID","value":"799136"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156741":{"preferredName":"Manelimab","code":"C156741","definitions":[{"definition":"A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, manelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Manelimab","termGroup":"PT","termSource":"NCI"},{"termName":"BCD 135","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-135","termGroup":"CN","termSource":"NCI"},{"termName":"BCD135","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2168561-26-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U3OZ7HX207"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody BCD-135"},{"name":"Maps_To","value":"Manelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795701"},{"name":"NCI_META_CUI","value":"CL935904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795701"},{"name":"PDQ_Open_Trial_Search_ID","value":"795701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155654":{"preferredName":"Garivulimab","code":"C155654","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, garivulimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333 blocks the interaction between PD-L1 and its other receptor, the immunostimulatory molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling and inhibits the induction of PD-L1-induced apoptosis of activated CD8+ T-cells and increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Garivulimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody BGB-A333","termGroup":"SY","termSource":"NCI"},{"termName":"BGB A333","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A333","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA333","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2342597-81-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CSJ7UEQ4D9"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody BGB-A333"},{"name":"NCI_Drug_Dictionary_ID","value":"794412"},{"name":"NCI_META_CUI","value":"CL556266"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794412"},{"name":"PDQ_Open_Trial_Search_ID","value":"794412"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156692":{"preferredName":"Benmelstobart","code":"C156692","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, benmelstobart specifically targets and binds to PD-L1, preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benmelstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody CBT-502","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody TQB2450","termGroup":"SY","termSource":"NCI"},{"termName":"APL502","termGroup":"CN","termSource":"NCI"},{"termName":"CBT 502","termGroup":"CN","termSource":"NCI"},{"termName":"CBT-502","termGroup":"CN","termSource":"NCI"},{"termName":"CBT502","termGroup":"CN","termSource":"NCI"},{"termName":"TQB 2450","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-2450","termGroup":"CN","termSource":"NCI"},{"termName":"TQB2450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2303884-58-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B25CF42QKP"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody CBT-502"},{"name":"NCI_Drug_Dictionary_ID","value":"795708"},{"name":"NCI_META_CUI","value":"CL935711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795708"},{"name":"PDQ_Open_Trial_Search_ID","value":"795708"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151947":{"preferredName":"Cosibelimab","code":"C151947","definitions":[{"definition":"An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cosibelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody TG-1501","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDL1 Monoclonal Antibody TG-1501","termGroup":"SY","termSource":"NCI"},{"termName":"CK 301","termGroup":"CN","termSource":"NCI"},{"termName":"CK-301","termGroup":"CN","termSource":"NCI"},{"termName":"TG 1501","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1501","termGroup":"CN","termSource":"NCI"},{"termName":"TG1501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2216751-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PNW7GBB44P"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody CK-301"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody TG-1501"},{"name":"Maps_To","value":"Cosibelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"793157"},{"name":"NCI_META_CUI","value":"CL937684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793157"},{"name":"PDQ_Open_Trial_Search_ID","value":"793157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154550":{"preferredName":"Sugemalimab","code":"C154550","definitions":[{"definition":"A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sugemalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody CS1001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody WBP 3155","termGroup":"SY","termSource":"NCI"},{"termName":"Cejemly","termGroup":"FB","termSource":"NCI"},{"termName":"CS 1001","termGroup":"SY","termSource":"NCI"},{"termName":"CS-1001","termGroup":"CN","termSource":"NCI"},{"termName":"CS1001","termGroup":"CN","termSource":"NCI"},{"termName":"WBP 315","termGroup":"CN","termSource":"NCI"},{"termName":"WBP-315","termGroup":"CN","termSource":"NCI"},{"termName":"WBP315","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2256084-03-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"90IQR2I6TR"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody CS1001"},{"name":"Maps_To","value":"Sugemalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"794350"},{"name":"NCI_META_CUI","value":"CL555350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794350"},{"name":"PDQ_Open_Trial_Search_ID","value":"794350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131537":{"preferredName":"Anti-PD-L1 Monoclonal Antibody FAZ053","code":"C131537","definitions":[{"definition":"A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1), with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody FAZ053 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated anti-tumor immune response and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody FAZ053","termGroup":"PT","termSource":"NCI"},{"termName":"FAZ 053","termGroup":"CN","termSource":"NCI"},{"termName":"FAZ-053","termGroup":"CN","termSource":"NCI"},{"termName":"FAZ053","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V6W1OW12H2"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody FAZ053"},{"name":"NCI_Drug_Dictionary_ID","value":"786263"},{"name":"NCI_META_CUI","value":"CL514246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786263"},{"name":"PDQ_Open_Trial_Search_ID","value":"786263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159538":{"preferredName":"Anti-PD-L1 Monoclonal Antibody GR1405","code":"C159538","definitions":[{"definition":"A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody GR1405 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody GR1405","termGroup":"PT","termSource":"NCI"},{"termName":"GR 1405","termGroup":"CN","termSource":"NCI"},{"termName":"GR-1405","termGroup":"CN","termSource":"NCI"},{"termName":"GR1405","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody GR1405"},{"name":"NCI_Drug_Dictionary_ID","value":"797479"},{"name":"NCI_META_CUI","value":"CL951376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797479"},{"name":"PDQ_Open_Trial_Search_ID","value":"797479"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165270":{"preferredName":"Opucolimab","code":"C165270","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, opucolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opucolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody HLX20","termGroup":"SY","termSource":"NCI"},{"termName":"HLX 20","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-20","termGroup":"CN","termSource":"NCI"},{"termName":"HLX20","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1-targeting Monoclonal Antibody HLX20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2251771-79-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"20ZE3P16HV"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody HLX20"},{"name":"Maps_To","value":"Opucolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"799415"},{"name":"NCI_META_CUI","value":"CL978537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799415"},{"name":"PDQ_Open_Trial_Search_ID","value":"799415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128138":{"preferredName":"Lodapolimab","code":"C128138","definitions":[{"definition":"A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lodapolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Checkpoint Antibody LY3300054","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody LY3300054","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Programmed Cell Death Ligand 1 Checkpoint Antibody LY3300054","termGroup":"SY","termSource":"NCI"},{"termName":"LY3300054","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11185","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2118349-31-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NR4MAD6PPB"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody LY3300054"},{"name":"Maps_To","value":"Lodapolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"782062"},{"name":"NCI_META_CUI","value":"CL507936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782062"},{"name":"PDQ_Open_Trial_Search_ID","value":"782062"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78852":{"preferredName":"Anti-PD-L1 Monoclonal Antibody MDX-1105","code":"C78852","definitions":[{"definition":"A fully human monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody MDX-1105","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 936559","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-1105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TLZ6R6973Z"},{"name":"Legacy Concept Name","value":"Anti-PD-L1_Monoclonal_Antibody_MDX-1105"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody MDX-1105"},{"name":"NCI_Drug_Dictionary_ID","value":"612730"},{"name":"NCI_META_CUI","value":"CL387680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612730"},{"name":"PDQ_Open_Trial_Search_ID","value":"612730"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155931":{"preferredName":"Betifisolimab","code":"C155931","definitions":[{"definition":"A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Betifisolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody MSB2311","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDL1 Monoclonal Antibody MSB2311","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-PD-L1 Monoclonal Antibody MSB2311","termGroup":"SY","termSource":"NCI"},{"termName":"MSB 2311","termGroup":"CN","termSource":"NCI"},{"termName":"MSB-2311","termGroup":"CN","termSource":"NCI"},{"termName":"MSB2311","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460539-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7XRB4BO26"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody MSB2311"},{"name":"NCI_Drug_Dictionary_ID","value":"795264"},{"name":"NCI_META_CUI","value":"CL562806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795264"},{"name":"PDQ_Open_Trial_Search_ID","value":"795264"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148535":{"preferredName":"Adebrelimab","code":"C148535","definitions":[{"definition":"An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adebrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"HTI-1088","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1316","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2247114-85-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1XBY50W1OX"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody SHR-1316"},{"name":"NCI_Drug_Dictionary_ID","value":"792709"},{"name":"NCI_META_CUI","value":"CL551134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792709"},{"name":"PDQ_Open_Trial_Search_ID","value":"792709"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162504":{"preferredName":"Socazolimab","code":"C162504","definitions":[{"definition":"A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, socazolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Socazolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody ZKAB001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDL1 Monoclonal Antibody ZKAB001","termGroup":"SY","termSource":"NCI"},{"termName":"STI A1014","termGroup":"CN","termSource":"NCI"},{"termName":"STI-A1014","termGroup":"CN","termSource":"NCI"},{"termName":"STIA1014","termGroup":"CN","termSource":"NCI"},{"termName":"ZKAB 001","termGroup":"CN","termSource":"NCI"},{"termName":"ZKAB-001","termGroup":"CN","termSource":"NCI"},{"termName":"ZKAB001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305043-30-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82P4S8Q3FB"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody ZKAB001"},{"name":"NCI_Drug_Dictionary_ID","value":"798649"},{"name":"NCI_META_CUI","value":"CL970934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798649"},{"name":"PDQ_Open_Trial_Search_ID","value":"798649"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C159978":{"preferredName":"Enristomig","code":"C159978","definitions":[{"definition":"A recombinant, humanized, bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, enristomig simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, enristomig acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, Ienristomig prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enristomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1/CD137 Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"},{"termName":"ES 101","termGroup":"CN","termSource":"NCI"},{"termName":"ES-101","termGroup":"CN","termSource":"NCI"},{"termName":"ES101","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX 105","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX-105","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX105","termGroup":"CN","termSource":"NCI"},{"termName":"PDL1 x 4-1BB Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"},{"termName":"PDL1 x CD137 Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2539845-73-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3CX9U8V1CV"},{"name":"Maps_To","value":"Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105"},{"name":"NCI_Drug_Dictionary_ID","value":"797967"},{"name":"NCI_META_CUI","value":"CL969077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797967"},{"name":"PDQ_Open_Trial_Search_ID","value":"797967"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160772":{"preferredName":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","code":"C160772","definitions":[{"definition":"A full-length, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/CD137 bispecific antibody MCLA-145 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, MCLA-145 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, MCLA-145 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1/4-1BB Bispecific Antibody MCLA-145","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1/Anti-CD137 Bispecific Antibody MCLA-145","termGroup":"SY","termSource":"NCI"},{"termName":"MCLA 145","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA-145","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145"},{"name":"NCI_Drug_Dictionary_ID","value":"798414"},{"name":"NCI_META_CUI","value":"CL969758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798414"},{"name":"PDQ_Open_Trial_Search_ID","value":"798414"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157058":{"preferredName":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","code":"C157058","definitions":[{"definition":"A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3415244","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3415244","termGroup":"SY","termSource":"NCI"},{"termName":"LY3415244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"603H2FWG4N"},{"name":"Maps_To","value":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244"},{"name":"NCI_Drug_Dictionary_ID","value":"796576"},{"name":"NCI_META_CUI","value":"CL936018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796576"},{"name":"PDQ_Open_Trial_Search_ID","value":"796576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136465":{"preferredName":"Balstilimab","code":"C136465","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balstilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 2034","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-2034","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN2034","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230167-06-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Q2QT5M7EO"},{"name":"Maps_To","value":"Anti-PD1 Monoclonal Antibody AGEN2034"},{"name":"Maps_To","value":"Balstilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"789509"},{"name":"NCI_META_CUI","value":"CL523768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789509"},{"name":"PDQ_Open_Trial_Search_ID","value":"789509"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150463":{"preferredName":"Vudalimab","code":"C150463","definitions":[{"definition":"A Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vudalimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T-lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with XmAb20717 may enhance T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vudalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-CTLA-4 XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD1/CTLA4 Bispecific Antibody XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA-4 Bispecific Antibody XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA-4 Dual Checkpoint Inhibitor XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb 20717","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb20717","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2329669-72-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4I9I5X3Z6N"},{"name":"Maps_To","value":"Anti-PD1/CTLA4 Bispecific Antibody XmAb20717"},{"name":"NCI_Drug_Dictionary_ID","value":"793410"},{"name":"NCI_META_CUI","value":"CL552206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793410"},{"name":"PDQ_Open_Trial_Search_ID","value":"793410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78486":{"preferredName":"Anti-PLGF Monoclonal Antibody TB-403","code":"C78486","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the placenta growth factor (PGF), with potential anti-angiogenic and antineoplastic activities. Anti-PGF monoclonal antibody TB-403 binds to both PGF-1 and -2, thereby inhibiting the binding of PGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and subsequent VEGFR-1 phosphorylation. This may result in the inhibition of tumor angiogenesis and tumor cell proliferation. PGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PLGF Monoclonal Antibody TB-403","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PGF Monoclonal Antibody RO5323441","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Placental Growth Factor Monoclonal Antibody TB-403","termGroup":"SY","termSource":"NCI"},{"termName":"RG7334","termGroup":"CN","termSource":"NCI"},{"termName":"RO5323441","termGroup":"CN","termSource":"NCI"},{"termName":"TB-403","termGroup":"CN","termSource":"NCI"},{"termName":"THR 317","termGroup":"CN","termSource":"NCI"},{"termName":"THR-317","termGroup":"CN","termSource":"NCI"},{"termName":"THR317","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46MVG4H2LF"},{"name":"Legacy Concept Name","value":"Anti-PLGF_Monoclonal_Antibody_TB-403"},{"name":"Maps_To","value":"Anti-PGF Monoclonal Antibody RO5323441"},{"name":"Maps_To","value":"Anti-PLGF Monoclonal Antibody TB-403"},{"name":"NCI_Drug_Dictionary_ID","value":"601058"},{"name":"NCI_META_CUI","value":"CL387523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601058"},{"name":"PDQ_Open_Trial_Search_ID","value":"601058"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84847":{"preferredName":"Anti-PKN3 siRNA Atu027","code":"C84847","definitions":[{"definition":"A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and fusiogenic lipids with potential antineoplastic activity. Upon administration, catiogenic and fusiogenic lipids promote anti-PKN3 siRNA Atu02 uptake by tumor cells; the siRNAs moieties are subsequently released once inside the cell. The siRNAs bind to PKN3 mRNAs, which may result in the inhibition of translation and expression of the PKN3 protein and, so, growth inhibition of tumor cells that overexpress PKN3. The protein kinase C-related molecule PKN3, downstream in the phosphoinositide-3-kinase (PI3K) signaling pathway, is upregulated in many tumor cells and plays an important role in invasive cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PKN3 siRNA Atu027","termGroup":"PT","termSource":"NCI"},{"termName":"Atu027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415935-22-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IFJ2SAK127"},{"name":"Maps_To","value":"Anti-PKN3 siRNA Atu027"},{"name":"NCI_Drug_Dictionary_ID","value":"650831"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650831"},{"name":"PDQ_Open_Trial_Search_ID","value":"650831"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827525"}]}}{"C123924":{"preferredName":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4","code":"C123924","definitions":[{"definition":"A T-cell receptor (TCR)-like monoclonal antibody against PR1, a 9 amino-acid (VLQELNVTV) human leukocyte antigen (HLA)-A2-restricted leukemia-associated antigen (LAA) derived from the myeloid leukemia-associated antigens proteinase 3 (P3) and neutrophil elastase (NE), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PR1/HLA-A2 monoclonal antibody Hu8F4 selectively binds to a combined epitope of the PR1/HLA-A2 complex expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSC), and prevents PR1/HLA-A2-mediated signaling. This induces complement-dependent cytotoxicity (CDC), to a lesser extent, antibody-dependent cell-mediated cytotoxicity (ADCC), and CDC/ADCC-independent cytolysis of myeloid leukemia cells. This results in a reduction of cellular proliferation in PR1/HLA-A2-overexpressing leukemic cells. PR1 in combination with the HLA-A2 molecule is highly expressed on AML blasts and LSCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4","termGroup":"PT","termSource":"NCI"},{"termName":"Hu8F4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NL06848HBQ"},{"name":"Maps_To","value":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4"},{"name":"NCI_Drug_Dictionary_ID","value":"775929"},{"name":"NCI_META_CUI","value":"CL498288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775929"},{"name":"PDQ_Open_Trial_Search_ID","value":"775929"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116848":{"preferredName":"Anti-PRAME Immunotherapeutic GSK2302032A","code":"C116848","definitions":[{"definition":"An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PRAME Immunotherapeutic GSK2302032A","termGroup":"PT","termSource":"NCI"},{"termName":"GSK-2302032A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2302032A","termGroup":"CN","termSource":"NCI"},{"termName":"PRAME ASCI","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PRAME Immunotherapeutic GSK2302032A"},{"name":"NCI_Drug_Dictionary_ID","value":"681985"},{"name":"NCI_META_CUI","value":"CL421661"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681985"},{"name":"PDQ_Open_Trial_Search_ID","value":"681985"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151931":{"preferredName":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab","code":"C151931","definitions":[{"definition":"A humanized monoclonal antibody against  phosphatase of regenerating liver 3 (PRL-3; PTP4A3), with potential immunomodulating and antineoplastic activities. Upon administration, anti-PRL-3 monoclonal antibody PRL3-zumab targets, binds to and blocks PRL-3 expressed on tumor cells. Although the exact mechanism of action through which this antibody kills tumor cells has yet to be fully elucidated, PRL3-zumab binds to PRL-3. This prevents PRL-3-mediated signaling in, inhibits the proliferation of and induces apoptosis in PRL-3-expressing tumor cells. PRL-3, a member of the PRL family of protein tyrosine kinases, is upregulated in a variety of tumor cells. Its expression is associated with increased invasiveness, higher metastatic potential, increased tumor cell survival and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab","termGroup":"PT","termSource":"NCI"},{"termName":"PRL3 Zumab","termGroup":"SY","termSource":"NCI"},{"termName":"PRL3-zumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab"},{"name":"NCI_Drug_Dictionary_ID","value":"793124"},{"name":"NCI_META_CUI","value":"CL553270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793124"},{"name":"PDQ_Open_Trial_Search_ID","value":"793124"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C96744":{"preferredName":"Anti-prolactin Receptor Antibody LFA102","code":"C96744","definitions":[{"definition":"A neutralizing antibody against the prolactin receptor (PRLR) with potential antineoplastic activity. Upon administration, anti-prolactin receptor antibody LFA102 binds to PRLR and prevents the binding of the peptide hormone prolactin (PRL) to its receptor. This binding induces an antibody-dependent cellular cytotoxicity (ADCC) and may eventually prevent tumor cell proliferation in PRLR-positive cancer cells. PRLR/PRL signaling pathway is frequently overexpressed in breast and prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-prolactin Receptor Antibody LFA102","termGroup":"PT","termSource":"NCI"},{"termName":"LFA102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-prolactin Receptor Antibody LFA102"},{"name":"NCI_Drug_Dictionary_ID","value":"699731"},{"name":"NCI_META_CUI","value":"CL429368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699731"},{"name":"PDQ_Open_Trial_Search_ID","value":"699731"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71157":{"preferredName":"Anti-PSCA Monoclonal Antibody AGS-1C4D4","code":"C71157","definitions":[{"definition":"An IgG1k fully human monoclonal antibody directed against the human prostate stem cell antigen (PSCA) with potential antineoplastic activity. Anti-PSCA fully human monoclonal antibody MK4721 selectively targets and binds to PSCA, triggering complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in tumor cells expressing PSCA. PSCA is a glycosyl-phosphatidylinositol (GPI)-linked cell surface antigen found in cancers of the bladder, pancreas, and prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSCA Monoclonal Antibody AGS-1C4D4","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-1C4D4","termGroup":"CN","termSource":"NCI"},{"termName":"MK4721","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0505LPC7O"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_MK4721"},{"name":"Maps_To","value":"Anti-PSCA Monoclonal Antibody AGS-1C4D4"},{"name":"NCI_Drug_Dictionary_ID","value":"570981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570981"},{"name":"PDQ_Open_Trial_Search_ID","value":"570981"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347292"}]}}{"C113439":{"preferredName":"PSMA-targeting Fluorescent Imaging Agent MDX1201-A488","code":"C113439","definitions":[{"definition":"A recombinant, human monoclonal antibody targeting an extracellular epitope of human prostate specific membrane antigen (PSMA) that is conjugated with A488, a photostable fluorescent dye with a high quantum yield, with potential imaging activity. Upon intravenous administration of PSMA-targeting fluorescent imaging agent MDX1201-A488, the MDX1201 moiety targets PSMA expressed on cancer cells. Subsequently, the A488 moiety can then be visualized by fluorescence-based imaging and the amount of PSMA-expressing tumor cells can be assessed. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA-targeting Fluorescent Imaging Agent MDX1201-A488","termGroup":"PT","termSource":"NCI"},{"termName":"MDX1201-A488","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA Monoclonal Antibody MDX1201-A488"},{"name":"NCI_Drug_Dictionary_ID","value":"756416"},{"name":"NCI_META_CUI","value":"CL458233"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756416"},{"name":"PDQ_Open_Trial_Search_ID","value":"756416"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26660":{"preferredName":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704","code":"C26660","definitions":[{"definition":"A substance that is being studied in the treatment of prostate cancer. It belongs to the family of drugs called antibody drug conjugates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate that consists of a humanized monoclonal antibody (MLN591), directed against prostate-specific membrane antigen linked to a maytansinoid (DM1). The monoclonal antibody moiety of MLN2704 binds to tumor cells expressing prostate-specific membrane antigen; MLN274 is then internalized into the tumor cell where the DM1 maytansinoid moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704","termGroup":"PT","termSource":"NCI"},{"termName":"MLN591DM1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MLN2704"},{"name":"Maps_To","value":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704"},{"name":"NCI_Drug_Dictionary_ID","value":"299464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299464"},{"name":"PDQ_Open_Trial_Search_ID","value":"299464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327945"}]}}{"C95707":{"preferredName":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate","code":"C95707","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody directed against prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  The monoclonal antibody moiety of this conjugate selectively binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA Monoclonal Antibody-Monomethylauristatin E Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PSMA-MMAE-ADC","termGroup":"AB","termSource":"NCI"},{"termName":"Prostate-specific Membrane Antigen Antibody-Drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA ADC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"709281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709281"},{"name":"PDQ_Open_Trial_Search_ID","value":"709281"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987347"}]}}{"C162936":{"preferredName":"Nezastomig","code":"C162936","definitions":[{"definition":"A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of nezastomig this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nezastomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA/Anti-CD28 Bispecific Antibody REGN5678","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PSMA/CD28 Bispecific Antibody REGN5678","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PSMAxCD28 Antibody REGN5678","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5678","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5678","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5678","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2657613-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M355PGI1TG"},{"name":"Maps_To","value":"Anti-PSMA/CD28 Bispecific Antibody REGN5678"},{"name":"NCI_Drug_Dictionary_ID","value":"799093"},{"name":"NCI_META_CUI","value":"CL973295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799093"},{"name":"PDQ_Open_Trial_Search_ID","value":"799093"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163976":{"preferredName":"Voxalatamab","code":"C163976","definitions":[{"definition":"An immunoglobulin G4 (IgG4) bispecific antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, voxalatamab simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Voxalatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63898081","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63898081","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-8081","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63898081","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2411871-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O257GFG7G0"},{"name":"Maps_To","value":"Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081"},{"name":"NCI_Drug_Dictionary_ID","value":"801628"},{"name":"NCI_META_CUI","value":"CL977249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801628"},{"name":"PDQ_Open_Trial_Search_ID","value":"801628"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118626":{"preferredName":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414","code":"C118626","definitions":[{"definition":"An anti-prostate specific membrane antigen (PSMA)/anti-CD3 bispecific humanized monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Anti-PSMA/CD3 monoclonal antibody MOR209/ES414 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for PSMA, a tumor-associated antigen (TAA) overexpressed on the surface of prostate tumor cells. Upon intravenous administration of MOR209/ES414, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and PSMA-expressing cancer cells, thereby crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in CTL-mediated cancer cell lysis of prostate cancer cells expressing PSMA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414","termGroup":"PT","termSource":"NCI"},{"termName":"MOR209/ES414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414"},{"name":"NCI_Drug_Dictionary_ID","value":"765517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765517"},{"name":"PDQ_Open_Trial_Search_ID","value":"765517"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896808"}]}}{"C140552":{"preferredName":"Anti-PSMA/PBD ADC MEDI3726","code":"C140552","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an engineered version of anti-human prostate-specific membrane antigen (PSMA) monoclonal antibody J591 conjugated, via a valine-alanine dipeptide linker, to tesirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-PSMA/PBD ADC MEDI3726, the antibody moiety targets the cell surface antigen PSMA, which is found on prostate cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage of the dipeptide linker, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of PSMA-overexpressing tumor cells. PSMA is overexpressed by prostate cancers; its expression is associated with poor prognosis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA/PBD ADC MEDI3726","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MEDI3726","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT 401","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT-401","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT401","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI 3726","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-3726","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI3726","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SA4H7K0SW2"},{"name":"Maps_To","value":"Anti-PSMA/PBD ADC MEDI3726"},{"name":"NCI_Drug_Dictionary_ID","value":"791113"},{"name":"NCI_META_CUI","value":"CL538618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791113"},{"name":"PDQ_Open_Trial_Search_ID","value":"791113"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123828":{"preferredName":"Cofetuzumab Pelidotin","code":"C123828","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cofetuzumab Pelidotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC PF-06647020","termGroup":"SY","termSource":"NCI"},{"termName":"ADC PF-7020","termGroup":"SY","termSource":"NCI"},{"termName":"h6M24-vc0101","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human protein tyrosine kinase 7) (humanized Mus musculus clone hu24 gamma-chain), Disulfide with humanized Mus musculus clone hu24 kappa-chain, Dimer, Thioether with N-(((4-((N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl)amino)phenyl)methoxy)carbonyl)-2-methylalanyl-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(2-thiazolyl)ethyl)amino)propyl)-1-pyrrolidinyl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide","termGroup":"SN","termSource":"NCI"},{"termName":"PF 06647020","termGroup":"CN","termSource":"NCI"},{"termName":"PF 7020","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06647020","termGroup":"CN","termSource":"NCI"},{"termName":"PF-7020","termGroup":"CN","termSource":"NCI"},{"termName":"PF06647020","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1869937-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"249EAP69MT"},{"name":"Maps_To","value":"Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020"},{"name":"Maps_To","value":"Cofetuzumab Pelidotin"},{"name":"NCI_Drug_Dictionary_ID","value":"764236"},{"name":"NCI_META_CUI","value":"CL474137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764236"},{"name":"PDQ_Open_Trial_Search_ID","value":"764236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156791":{"preferredName":"Anti-PVRIG Monoclonal Antibody COM701","code":"C156791","definitions":[{"definition":"A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody COM701 targets and binds to PVRIG expressed on cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG, abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PVRIG Monoclonal Antibody COM701","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-poliovirus Receptor-related Immunoglobulin COM701","termGroup":"SY","termSource":"NCI"},{"termName":"COM 701","termGroup":"CN","termSource":"NCI"},{"termName":"COM-701","termGroup":"CN","termSource":"NCI"},{"termName":"COM701","termGroup":"CN","termSource":"NCI"},{"termName":"PVRIG Inhibitor COM701","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253186-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IAY02XUV7L"},{"name":"Maps_To","value":"Anti-PVRIG Monoclonal Antibody COM701"},{"name":"NCI_Drug_Dictionary_ID","value":"796463"},{"name":"NCI_META_CUI","value":"CL935797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796463"},{"name":"PDQ_Open_Trial_Search_ID","value":"796463"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157772":{"preferredName":"Zilovertamab Vedotin","code":"C157772","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zilovertamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ROR1 ADC VLS-101","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate VLS-101","termGroup":"SY","termSource":"NCI"},{"termName":"MK-2140","termGroup":"CN","termSource":"NCI"},{"termName":"VLS 101","termGroup":"CN","termSource":"NCI"},{"termName":"VLS-101","termGroup":"CN","termSource":"NCI"},{"termName":"VLS101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2376463-48-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IZY9ZSI6FI"},{"name":"Maps_To","value":"Anti-ROR1 ADC VLS-101"},{"name":"NCI_Drug_Dictionary_ID","value":"797160"},{"name":"NCI_META_CUI","value":"CL937381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797160"},{"name":"PDQ_Open_Trial_Search_ID","value":"797160"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157061":{"preferredName":"Anti-S15 Monoclonal Antibody NC318","code":"C157061","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting sialic acid binding Ig-like lectin 15 (Siglec-15; SIGLEC15; S15), a member of the sialic acid-binding immunoglobulin type lectins, with potential antineoplastic and immunomodulatory activities. Upon administration, anti-S15 monoclonal antibody NC318 targets and binds to S15 on the surface of tumor-associated macrophages (TAMs) and certain tumor cells. Binding to S15 may disrupt TAM-mediated activities such as promotion of tumor initiation and metastasis of tumor cells, inhibition of T-cell responses, and stimulation of tumor angiogenesis and disease progression. S15, a highly conserved type 1 cell surface protein, normally involved in osteoclast differentiation and bone remodeling, may play a role in the survival and differentiation of TAMs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-S15 Monoclonal Antibody NC318","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-S15 mAb NC318","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Siglec-15 Monoclonal Antibody NC318","termGroup":"SY","termSource":"NCI"},{"termName":"NC 318","termGroup":"CN","termSource":"NCI"},{"termName":"NC-318","termGroup":"CN","termSource":"NCI"},{"termName":"NC318","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-S15 Monoclonal Antibody NC318"},{"name":"NCI_Drug_Dictionary_ID","value":"796496"},{"name":"NCI_META_CUI","value":"CL936043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796496"},{"name":"PDQ_Open_Trial_Search_ID","value":"796496"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121778":{"preferredName":"Sotevtamab","code":"C121778","definitions":[{"definition":"A humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential antineoplastic and anti-metastatic activities. Upon administration, sotevtamab specifically binds to tumor-associated sCLU and inhibits its activity. This inhibits both the sCLU-mediated signal transduction pathways and epithelial-to-mesenchymal transition (EMT), which leads to the inhibition of tumor cell migration and invasion. In addition, sotevtamab enhances chemo-sensitivity. sCLU, a heterodimeric disulfide-linked glycoprotein overexpressed by various types of cancer cells, contributes to proliferation and survival of cancer cells, and stimulates tumor cell EMT.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotevtamab","termGroup":"PT","termSource":"NCI"},{"termName":"AB-16B5","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-sCLU Monoclonal Antibody AB-16B5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2411526-47-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YQ3YJK67AF"},{"name":"Maps_To","value":"Anti-sCLU Monoclonal Antibody AB-16B5"},{"name":"NCI_Drug_Dictionary_ID","value":"771181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771181"},{"name":"PDQ_Open_Trial_Search_ID","value":"771181"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053577"}]}}{"C157501":{"preferredName":"Anzurstobart","code":"C157501","definitions":[{"definition":"An immunoglobulin G1 (IgG1) monoclonal antibody targeting signal-regulatory protein alpha (SIRPa; CD172a) with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anzurstobart targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47/SIRPa-mediated signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anzurstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-SIRPa Monoclonal Antibody CC-95251","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986351","termGroup":"CN","termSource":"NCI"},{"termName":"CC 95251","termGroup":"CN","termSource":"NCI"},{"termName":"CC-95251","termGroup":"CN","termSource":"NCI"},{"termName":"CC95251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2543693-10-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"61FKP5V847"},{"name":"Maps_To","value":"Anti-SIRPa Monoclonal Antibody CC-95251"},{"name":"NCI_Drug_Dictionary_ID","value":"796792"},{"name":"NCI_META_CUI","value":"CL937061"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796792"},{"name":"PDQ_Open_Trial_Search_ID","value":"796792"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C152370":{"preferredName":"Sirtratumab Vedotin","code":"C152370","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of sirtratumab, a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of sirtratumab vedotin binds to SLITRK6 expressed on tumor cells, which facilitates both the internalization of the ADC and the intracellular delivery of MMAE. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.  SLITRK6, a member of the Slitrk family of leucine-rich repeat (LRR) neuronal transmembrane proteins, is minimally expressed in normal tissue but overexpressed in a variety of cancers, including bladder cancer, some forms of lung cancer, breast cancer and glioblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirtratumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-15E","termGroup":"CN","termSource":"NCI"},{"termName":"AGS15E","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-SLITRK6 ADC AGS15E","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-SLITRK6 Antibody-drug Conjugate AGS15E","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E","termGroup":"SY","termSource":"NCI"},{"termName":"ASG-15ME","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1824663-83-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E58B6OP5QG"},{"name":"Maps_To","value":"Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E"},{"name":"NCI_Drug_Dictionary_ID","value":"754120"},{"name":"NCI_META_CUI","value":"CL553574"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28880":{"preferredName":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218","code":"C28880","definitions":[{"definition":"An immunoglobulin derived from the single-chain antigen-binding domain (sFv) of the monoclonal antibody CC-49 with potential antineoplastic activity.  The parent monoclonal antibody CC-49 binds to the tumor-associated glycoprotein TAG-72 with high affinity, recognizing many tumor cell types that express TAG-72. Because of its single-chain structure, CC-49/218 sFv may exhibit a longer half-life than the parent monoclonal antibody CC-49; 218 represents the linker sequence that helps reduce aggregation and proteolysis of this agent.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Single-chain Fv construct of CC49 monoclonal antibody containing a linker sequence 218 that targets tumor-associated glycoprotein (TAG)-72"},{"name":"Legacy Concept Name","value":"CC49-218_sFv"},{"name":"Maps_To","value":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1511412"}]}}{"C96430":{"preferredName":"Anti-TF Monoclonal Antibody ALT-836","code":"C96430","definitions":[{"definition":"A recombinant human-mouse chimeric monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody ALT-836 binds to TF or the TF-Factor VIIa (FVIIa) complex preventing binding and activation of Factor X (FX) and Factor IX (FIX). This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and procoagulant, is overexpressed in many tumor cell types, and is correlated with metastasis, angiogenesis, tumor growth and tumor-associated thrombosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TF Monoclonal Antibody ALT-836","termGroup":"PT","termSource":"NCI"},{"termName":"ALT-836","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-TF MoAb ALT-836","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TF Monoclonal Antibody ALT-836"},{"name":"NCI_Drug_Dictionary_ID","value":"698353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698353"},{"name":"PDQ_Open_Trial_Search_ID","value":"698353"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272773"}]}}{"C132250":{"preferredName":"Nisevokitug","code":"C132250","definitions":[{"definition":"A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Upon administration, nisevokitug targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nisevokitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TGF-beta Monoclonal Antibody NIS793","termGroup":"SY","termSource":"NCI"},{"termName":"NIS793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649854-92-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W2OR26S7UE"},{"name":"Maps_To","value":"Anti-TGF-beta Monoclonal Antibody NIS793"},{"name":"NCI_Drug_Dictionary_ID","value":"786999"},{"name":"NCI_META_CUI","value":"CL520460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786999"},{"name":"PDQ_Open_Trial_Search_ID","value":"786999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146862":{"preferredName":"Anti-TGF-beta Monoclonal Antibody SAR-439459","code":"C146862","definitions":[{"definition":"A monoclonal antibody (mAb) directed against human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-TGF-beta monoclonal antibody SAR-439459 specifically targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGF-beta is overactivated. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a variety of cancer cell types, is involved in cancer cell proliferation and migration, and in tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TGF-beta Monoclonal Antibody SAR-439459","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TGFb SAR-439459","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-transforming Growth Factor-beta mAb SAR439459","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 439459","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-439459","termGroup":"CN","termSource":"NCI"},{"termName":"SAR439459","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7EFI23P78R"},{"name":"Maps_To","value":"Anti-TGF-beta Monoclonal Antibody SAR-439459"},{"name":"NCI_Drug_Dictionary_ID","value":"792270"},{"name":"NCI_META_CUI","value":"CL544827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792270"},{"name":"PDQ_Open_Trial_Search_ID","value":"792270"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102853":{"preferredName":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1","code":"C102853","definitions":[{"definition":"A monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. Anti-TGF-beta RII monoclonal antibody IMC-TR1 specifically targets and binds to TGF-beta R11, thereby preventing the activation of TGF-beta RII-mediated signaling pathways. TGF-beta RII is mutated in a number of cancer cell types and is involved in cancer cell proliferation and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1","termGroup":"PT","termSource":"NCI"},{"termName":"IMC-TR1","termGroup":"CN","termSource":"NCI"},{"termName":"LY3022859","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1"},{"name":"NCI_Drug_Dictionary_ID","value":"737617"},{"name":"NCI_META_CUI","value":"CL437134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737617"},{"name":"PDQ_Open_Trial_Search_ID","value":"737617"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162875":{"preferredName":"Domvanalimab","code":"C162875","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, domvanalimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Domvanalimab","termGroup":"PT","termSource":"NCI"},{"termName":"AB 154","termGroup":"CN","termSource":"NCI"},{"termName":"AB-154","termGroup":"CN","termSource":"NCI"},{"termName":"AB154","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-TIGIT Monoclonal Antibody AB154","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2368219-35-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"45X7OU8C4J"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody AB154"},{"name":"NCI_Drug_Dictionary_ID","value":"798948"},{"name":"NCI_META_CUI","value":"CL973360"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798948"},{"name":"PDQ_Open_Trial_Search_ID","value":"798948"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131907":{"preferredName":"Renvistobart","code":"C131907","definitions":[{"definition":"A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, renvistobart binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renvistobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIGIT Monoclonal Antibody BMS-986207","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2725062-35-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81J55YFQ16"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody BMS-986207"},{"name":"NCI_Drug_Dictionary_ID","value":"786363"},{"name":"NCI_META_CUI","value":"CL520364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786363"},{"name":"PDQ_Open_Trial_Search_ID","value":"786363"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142821":{"preferredName":"Etigilimab","code":"C142821","definitions":[{"definition":"A monoclonal antibody targeting the human co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, etigilimab binds to TIGIT expressed on various immune cells, including T-cells, and prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8-positive T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etigilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIGIT OMP-313M32","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Receptor TIGIT(T-cell Immunoreceptor with Ig and iTIM Domains)) (Humanized Mouse Monoclonal OMP-313M32 Gamma1-chain), Disulfide with Humanized Mouse Monoclonal OMP-313M32 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"OMP 313M32","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-313M32","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10742","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2044984-83-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FC1ZF28VIT"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody OMP-313M32"},{"name":"Maps_To","value":"Etigilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791697"},{"name":"NCI_META_CUI","value":"CL540712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791697"},{"name":"PDQ_Open_Trial_Search_ID","value":"791697"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148042":{"preferredName":"Anti-TIM-3 Antibody BMS-986258","code":"C148042","definitions":[{"definition":"An antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Following administration, anti-TIM-3 antibody BMS-986258 binds to TIM-3 that is expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which together result in decreased tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM-3 Antibody BMS-986258","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM3 Antibody BMS-986258","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986258","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P339Q7RL7K"},{"name":"Maps_To","value":"Anti-TIM-3 Antibody BMS-986258"},{"name":"NCI_Drug_Dictionary_ID","value":"795721"},{"name":"NCI_META_CUI","value":"CL545803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795721"},{"name":"PDQ_Open_Trial_Search_ID","value":"795721"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157242":{"preferredName":"Surzebiclimab","code":"C157242","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, surzebiclimab binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surzebiclimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM-3 Monoclonal Antibody BGB-A425","termGroup":"SY","termSource":"NCI"},{"termName":"BGB A425","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A425","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA425","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2342597-90-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53YMC3A1CU"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody BGB-A425"},{"name":"NCI_Drug_Dictionary_ID","value":"796770"},{"name":"NCI_META_CUI","value":"CL936885"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796770"},{"name":"PDQ_Open_Trial_Search_ID","value":"796770"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162625":{"preferredName":"Verzistobart","code":"C162625","definitions":[{"definition":"A fully human Fc-engineered immunoglobulin G1 kappa (IgG1kappa) antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, verzistobart forms a high-affinity interaction with TIM-3 expressed on certain T-cells, thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. Additionally, INCAGN02390 elicits TIM-3 receptor internalization, potentially preventing interactions with other ligands.TIM-3, a transmembrane protein and immune checkpoint receptor expressed on certain lymphocytes, including tumor infiltrating lymphocytes (TILs), is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verzistobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM-3 Monoclonal Antibody INCAGN02390","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 02390","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN-02390","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN02390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649466-18-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KAC8QY6TMN"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody INCAGN02390"},{"name":"NCI_Drug_Dictionary_ID","value":"798754"},{"name":"NCI_META_CUI","value":"CL971021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798754"},{"name":"PDQ_Open_Trial_Search_ID","value":"798754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124850":{"preferredName":"Sabatolimab","code":"C124850","definitions":[{"definition":"An inhibitor of the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sabatolimab binds to TIM-3 expressed on certain immune cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis resulting in a reduction in tumor growth. TIM-3, a transmembrane protein expressed on certain T-cells, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sabatolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM-3 Monoclonal Antibody MBG453","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TIM3 Checkpoint Inhibitor MBG453","termGroup":"SY","termSource":"NCI"},{"termName":"MBG 453","termGroup":"CN","termSource":"NCI"},{"termName":"MBG453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2252262-24-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3L7R886Y06"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody MBG453"},{"name":"Maps_To","value":"Sabatolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"777759"},{"name":"NCI_META_CUI","value":"CL503065"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777759"},{"name":"PDQ_Open_Trial_Search_ID","value":"777759"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150560":{"preferredName":"Anti-TIM-3 Monoclonal Antibody Sym023","code":"C150560","definitions":[{"definition":"A recombinant, fully human monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody Sym023 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM-3 Monoclonal Antibody Sym023","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM3 Monoclonal Antibody Sym023","termGroup":"SY","termSource":"NCI"},{"termName":"Sym 023","termGroup":"CN","termSource":"NCI"},{"termName":"Sym-023","termGroup":"CN","termSource":"NCI"},{"termName":"Sym023","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9GEU9XHE20"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody Sym023"},{"name":"NCI_Drug_Dictionary_ID","value":"793443"},{"name":"NCI_META_CUI","value":"CL552361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793443"},{"name":"PDQ_Open_Trial_Search_ID","value":"793443"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128627":{"preferredName":"Cobolimab","code":"C128627","definitions":[{"definition":"A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cobolimab binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cobolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM3 Checkpoint Inhibitor TSR-022","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TIM3 Monoclonal Antibody TSR-022","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Hepatitis A Virus Cellular Receptor 2 (havcr2)) (Humanized Clone ABT2 Gamma4-chain), Disulfide with Humanized Clone ABT2 Kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"TSR-022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2022215-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3K5H4TX2KP"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody TSR-022"},{"name":"Maps_To","value":"Cobolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"782940"},{"name":"NCI_META_CUI","value":"CL509686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782940"},{"name":"PDQ_Open_Trial_Search_ID","value":"782940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137820":{"preferredName":"Anti-TIM3 Monoclonal Antibody LY3321367","code":"C137820","definitions":[{"definition":"A monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody LY3321367 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM3 Monoclonal Antibody LY3321367","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3321367","termGroup":"CN","termSource":"NCI"},{"termName":"LY3321367","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2U7U2OB839"},{"name":"Maps_To","value":"Anti-TIM3 Monoclonal Antibody LY3321367"},{"name":"NCI_Drug_Dictionary_ID","value":"789989"},{"name":"NCI_META_CUI","value":"CL524891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789989"},{"name":"PDQ_Open_Trial_Search_ID","value":"789989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104291":{"preferredName":"Anti-Tissue Factor Monoclonal Antibody MORAb-066","code":"C104291","definitions":[{"definition":"A humanized monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody MORAb-066 binds to TF and prevents Factor VIIa (FVIIa) from binding, thereby interfering with the activation of Factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor endothelial cells; its expression is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Tissue Factor Monoclonal Antibody MORAb-066","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TF Monoclonal Antibody MORAb-066","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb-066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Tissue Factor Monoclonal Antibody MORAb-066"},{"name":"NCI_Drug_Dictionary_ID","value":"745031"},{"name":"NCI_META_CUI","value":"CL445626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745031"},{"name":"PDQ_Open_Trial_Search_ID","value":"745031"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C151967":{"preferredName":"Datopotamab Deruxtecan","code":"C151967","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) conjugated, via an enzymatically cleavable tetrapeptide-based  linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the datopotamab deruxtecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Datopotamab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DS-1062a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a","termGroup":"SY","termSource":"NCI"},{"termName":"Dato-DXd","termGroup":"SY","termSource":"NCI"},{"termName":"DS-1062","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1062a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2238831-60-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GD2OWY1DTK"},{"name":"Maps_To","value":"Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a"},{"name":"NCI_Drug_Dictionary_ID","value":"793720"},{"name":"NCI_META_CUI","value":"CL553190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793720"},{"name":"PDQ_Open_Trial_Search_ID","value":"793720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97337":{"preferredName":"Anti-TWEAK Monoclonal Antibody RG7212","code":"C97337","definitions":[{"definition":"A humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. Anti-TWEAK monoclonal antibody RG7212 binds to TWEAK and prevents the binding of TWEAK to its receptor, FGF-inducible molecule 14 (Fn14), thereby blocking the TWEAK/Fn14 signaling. This may prevent tumor cell proliferation, invasion, migration and angiogenesis. TWEAK has pleiotropic effects, mediating proinflammatory and pro-angiogenic activity as well as stimulation of invasion, migration, and survival mediated via its receptor Fn14; Fn14 is expressed at relatively low levels in normal tissues, but is elevated in tumor cells and locally in injured and diseased tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TWEAK Monoclonal Antibody RG7212","termGroup":"PT","termSource":"NCI"},{"termName":"RG 7212","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7212","termGroup":"CN","termSource":"NCI"},{"termName":"RG7212","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5458640","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5458640","termGroup":"CN","termSource":"NCI"},{"termName":"RO5458640","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TWEAK Monoclonal Antibody RG7212"},{"name":"NCI_Drug_Dictionary_ID","value":"703243"},{"name":"NCI_META_CUI","value":"CL429827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703243"},{"name":"PDQ_Open_Trial_Search_ID","value":"703243"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91376":{"preferredName":"Anti-VEGF Anticalin PRS-050-PEG40","code":"C91376","definitions":[{"definition":"A pegylated, proprietary lipocalin that targets human vascular endothelial growth factor (VEGF), with potential antineoplastic activity. Pegylated anti-VEGF anticalin PRS-050 specifically targets and binds to VEGF receptor 2 (VEGFR2 or KDR), thereby preventing its activity. This may inhibit angiogenesis and eventually reduce tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF Anticalin PRS-050-PEG40","termGroup":"PT","termSource":"NCI"},{"termName":"PRS-050-PEG40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGF Anticalin PRS-050-PEG40"},{"name":"NCI_Drug_Dictionary_ID","value":"675538"},{"name":"NCI_META_CUI","value":"CL421607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675538"},{"name":"PDQ_Open_Trial_Search_ID","value":"675538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156139":{"preferredName":"Anti-VEGF Monoclonal Antibody hPV19","code":"C156139","definitions":[{"definition":"A humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-VEGF monoclonal antibody hPV19 targets and binds to VEGFR at a unique binding site and inhibits VEGF binding to its receptors, VEGFR1 and VEGFR2, thereby preventing VEGF/VEGFR-mediated signaling. This prevents the growth and maintenance of tumor blood vessels. This decreases nutrient supply to tumor cells, resulting in tumor cell death. Increased VEGF/VEGFR signaling is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF Monoclonal Antibody hPV19","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGF MAb hPV19","termGroup":"SY","termSource":"NCI"},{"termName":"hPV 19","termGroup":"CN","termSource":"NCI"},{"termName":"hPV-19","termGroup":"CN","termSource":"NCI"},{"termName":"hPV19","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb hPV19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGF Monoclonal Antibody hPV19"},{"name":"NCI_Drug_Dictionary_ID","value":"795278"},{"name":"NCI_META_CUI","value":"CL562852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795278"},{"name":"PDQ_Open_Trial_Search_ID","value":"795278"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126644":{"preferredName":"Anti-VEGF/ANG2 Nanobody BI 836880","code":"C126644","definitions":[{"definition":"A nanobody directed against angiopoietin-2 (Ang2; ANGPT2)- and vascular endothelial growth factor (VEGF)-derived peptides, with potential antiangiogenic and antineoplastic activities. Anti-VEGF/ANG2 nanobody BI 836880 binds to Ang2 and VEGF and inhibits receptor binding; this prevents Ang2- and VEGF-mediated signaling and inhibits both tumor angiogenesis and tumor cell proliferation. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. The nanobody is based on functional fragments of single-chain antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF/ANG2 Nanobody BI 836880","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGF/ANG2 BI 836880","termGroup":"SY","termSource":"NCI"},{"termName":"BI 836880","termGroup":"CN","termSource":"NCI"},{"termName":"Bi-specific Anti-VEGF/Ang2 Nanobody BI 836880","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254603-60-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IS7N1X9TSW"},{"name":"Maps_To","value":"Anti-VEGF/ANG2 Nanobody BI 836880"},{"name":"NCI_Drug_Dictionary_ID","value":"779752"},{"name":"NCI_META_CUI","value":"CL503761"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779752"},{"name":"PDQ_Open_Trial_Search_ID","value":"779752"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162872":{"preferredName":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T","code":"C162872","definitions":[{"definition":"A recombinant, human immunoglobulin Fc fusion protein targeting both the transforming growth factor (TGF) beta 1 (TGF-beta 1; TGFb1) and the vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration of anti-VEGF/TGF-beta 1 fusion protein HB-002T, the fusion protein specifically and selectively targets, binds to and neutralizes both TGF-beta 1 and VEGF. This prevents TGFb1- and VEGF-mediated signaling and abrogates VEGF/VEGFR-induced angiogenesis and TGFb1-mediated induction of VEGF, which further inhibits angiogenesis. It also inhibits TGFb1-mediated immunosuppression, thereby enhancing anti-tumor immunity in the tumor microenvironment (TME) and promoting a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T","termGroup":"PT","termSource":"NCI"},{"termName":"HB 002T","termGroup":"CN","termSource":"NCI"},{"termName":"HB-002T","termGroup":"CN","termSource":"NCI"},{"termName":"HB002.1T","termGroup":"CN","termSource":"NCI"},{"termName":"HB002T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T"},{"name":"NCI_Drug_Dictionary_ID","value":"798914"},{"name":"NCI_META_CUI","value":"CL973357"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798914"},{"name":"PDQ_Open_Trial_Search_ID","value":"798914"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99765":{"preferredName":"Anti-VEGFC Monoclonal Antibody VGX-100","code":"C99765","definitions":[{"definition":"A fully human monoclonal antibody directed against the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity. Anti-VEGFC monoclonal antibody VGX-100 specifically binds to and inhibits VEGFC protein, thereby preventing its binding to VEGFR3 (FLT4) or VEGFR2 (KDR or FLK1). This may prevent VEGFC-mediated signaling and may lead to the inhibition of vascular and lymphatic endothelial cell proliferation. The inhibition of tumor angiogenesis and lymphangiogenesis may eventually decrease tumor cell proliferation and prevent metastasis. VEGFC is overexpressed in a variety of cancer cells, and is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGFC Monoclonal Antibody VGX-100","termGroup":"PT","termSource":"NCI"},{"termName":"VEGF-C mAb VGX-100","termGroup":"SY","termSource":"NCI"},{"termName":"VGX-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RJ12A315RN"},{"name":"Maps_To","value":"Anti-VEGFC Monoclonal Antibody VGX-100"},{"name":"NCI_Drug_Dictionary_ID","value":"724066"},{"name":"NCI_META_CUI","value":"CL433490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724066"},{"name":"PDQ_Open_Trial_Search_ID","value":"724066"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156172":{"preferredName":"Vulinacimab","code":"C156172","definitions":[{"definition":"A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vulinacimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR2 Monoclonal Antibody HLX06","termGroup":"SY","termSource":"NCI"},{"termName":"HLX 06","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-06","termGroup":"CN","termSource":"NCI"},{"termName":"HLX06","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2250342-36-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SA09JNQ24D"},{"name":"Maps_To","value":"Anti-VEGFR2 Monoclonal Antibody HLX06"},{"name":"Maps_To","value":"Vulinacimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795367"},{"name":"NCI_META_CUI","value":"CL563001"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795367"},{"name":"PDQ_Open_Trial_Search_ID","value":"795367"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95734":{"preferredName":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5","code":"C95734","definitions":[{"definition":"A fully-human monoclonal antibody directed against human vascular endothelial growth factor receptor 3 (VEGFR-3; Flt-4) with antiangiogenic activity. Anti-VEGFR-3 monoclonal antibody IMC-3C5 specifically binds to and inhibits VEGFR-3, which may result in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-3 plays a critical role in the embryonic vascular system development but is restricted postnatally to endothelial cells of lymphatic vessels and found to be expressed in many solid and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR3 MoAb IMC-3C5","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-3C5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5"},{"name":"NCI_Drug_Dictionary_ID","value":"695064"},{"name":"NCI_META_CUI","value":"CL428195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695064"},{"name":"PDQ_Open_Trial_Search_ID","value":"695064"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127124":{"preferredName":"Onvatilimab","code":"C127124","definitions":[{"definition":"A human monoclonal antibody against the protein V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative checkpoint regulatory and antineoplastic activities. Upon administration, onvatilimab targets and binds to VISTA. This inhibits VISTA signaling, abrogates the VISTA-induced suppression of T-lymphocyte-mediated immune responses, enhances cytotoxic T-cell responses against tumor cells and inhibits tumor cell growth. VISTA, mainly expressed on hematopoietic cells, plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onvatilimab","termGroup":"PT","termSource":"NCI"},{"termName":"CI 8993","termGroup":"CN","termSource":"NCI"},{"termName":"CI-8993","termGroup":"CN","termSource":"NCI"},{"termName":"CI8993","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Protein Vista (v-domain Immunoglobulin Suppressor of T Cell Activation)) (Human Clone JNJ 61610588 gamma1-chain), Disulfide with Human Clone JNJ","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 61610588","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-61610588","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10758","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1969313-51-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1UI8F5IIZ4"},{"name":"Maps_To","value":"Anti-VISTA Monoclonal Antibody JNJ 61610588"},{"name":"Maps_To","value":"Onvatilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"780996"},{"name":"NCI_META_CUI","value":"CL507914"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99761":{"preferredName":"Antiangiogenic Drug Combination TL-118","code":"C99761","definitions":[{"definition":"A proprietary, oral suspension containing a combination of agents comprised of a nonsteroidal anti-inflammatory agent, an alkylating agent, a histamine H2 antagonist and a sulfonamide with potential anti-angiogenic and antineoplastic activities. Antiangiogenic drug combination TL-118 is administrated as a specific dosing regimen and may result in a synergistic effect and reduce angiogenesis and inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antiangiogenic Drug Combination TL-118","termGroup":"PT","termSource":"NCI"},{"termName":"Hamsa-1","termGroup":"FB","termSource":"NCI"},{"termName":"TL-118","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antiangiogenic Drug Combination TL-118"},{"name":"NCI_Drug_Dictionary_ID","value":"723650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"723650"},{"name":"PDQ_Open_Trial_Search_ID","value":"723650"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274907"}]}}{"C161599":{"preferredName":"Anti-SEZ6 Antibody-drug Conjugate ABBV-011","code":"C161599","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against seizure protein 6 homolog (SEZ6) linked to the cytotoxic antitumor antibiotic calicheamicin, with potential antineoplastic activity. Upon administration of anti-SEZ6 ADC ABBV-011, the monoclonal antibody moiety targets and binds to SEZ6 expressed on tumor cells. Upon binding and internalization, calicheamicin is released. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in apoptosis of SEZ6-expressing tumor cells. SEZ6, overexpressed in certain cancers while minimally expressed in normal tissues, plays a role in cell-cell recognition and in neuronal membrane signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-SEZ6 Antibody-drug Conjugate ABBV-011","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 011","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-011","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV011","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-SEZ6 ADC ABBV-011","termGroup":"SY","termSource":"NCI"},{"termName":"SC 011","termGroup":"CN","termSource":"NCI"},{"termName":"SC-011","termGroup":"CN","termSource":"NCI"},{"termName":"SC011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-011"},{"name":"NCI_Drug_Dictionary_ID","value":"798433"},{"name":"NCI_META_CUI","value":"CL970130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798433"},{"name":"PDQ_Open_Trial_Search_ID","value":"798433"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124134":{"preferredName":"Samrotamab Vedotin","code":"C124134","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of samrotamab vedotin, the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts (CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily, is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor stroma and on tumor cells in certain tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samrotamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-085","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-085","termGroup":"SY","termSource":"NCI"},{"termName":"PR-1498487 PAB-MMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2052649-42-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SY5HF6N5MB"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-085"},{"name":"Maps_To","value":"Samrotamab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"776647"},{"name":"NCI_META_CUI","value":"CL502530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776647"},{"name":"PDQ_Open_Trial_Search_ID","value":"776647"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157279":{"preferredName":"Mirzotamab Clezutoclax","code":"C157279","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity. Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirzotamab Clezutoclax","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 155","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-155","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV155","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-155","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate ABBV-155","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2229859-12-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TY49T0B03B"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-155"},{"name":"Maps_To","value":"Mirzotamab Clezutoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"796806"},{"name":"NCI_META_CUI","value":"CL937020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796806"},{"name":"PDQ_Open_Trial_Search_ID","value":"796806"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137991":{"preferredName":"Rolinsatamab Talirine","code":"C137991","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against the prolactin receptor (PRLR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration of rolinsatamab talirine, rolinsatamab targets and binds to PRLR expressed on tumor cells. Upon binding and internalization, talirine is released and kills the PRLR-expressing tumor cells, through an as of yet unknown mechanism of action. PRLR, a tumor-associated antigen (TAA), is overexpressed by a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rolinsatamab Talirine","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 176","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-176","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV176","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-176","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095467-44-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25TA76U16O"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-176"},{"name":"Maps_To","value":"Rolinsatamab Talirine"},{"name":"NCI_Drug_Dictionary_ID","value":"790299"},{"name":"NCI_META_CUI","value":"CL525031"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790299"},{"name":"PDQ_Open_Trial_Search_ID","value":"790299"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122816":{"preferredName":"Azintuxizumab Vedotin","code":"C122816","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody targeting CS1 (SLAMF7/CD319) that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a cathepsin-cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of azintuxizumab vedotin binds to CS1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CS1-expressing tumor cells.  CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is expressed with high levels and prevalence on multiple myeloma (MM) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azintuxizumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-838","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-838","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1826819-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6XQ9TM3U2G"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-838"},{"name":"Maps_To","value":"Azintuxizumab Vedotin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053688"}]}}{"C147577":{"preferredName":"Upinitatug Rilsodotin","code":"C147577","definitions":[{"definition":"A proprietary antibody-drug conjugate (ADC) composed of upinitatug , a proprietary, humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), site-specifically linked, via a protease cleavable linker, to the proprietary cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upinitatug rilsodotin is produced via the proprietary dolaflexin ADC conjugation platform, which promotes the conjugation of between 10 and 15 AF-HPA payload molecules to each XMT-1535 antibody. Upon administration of upinitatug rilsodotin, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Upon binding, internalization by endosomes/lysosomes, and enzymatic cleavage, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upinitatug Rilsodotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC XMT-1536","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b ADC XMT-1536","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b/Auristatin F-HPA ADC XMT-1536","termGroup":"SY","termSource":"NCI"},{"termName":"Upifitamab Rilsodotin","termGroup":"SY","termSource":"NCI"},{"termName":"XMT 1536","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1536","termGroup":"CN","termSource":"NCI"},{"termName":"XMT1536","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254119-00-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E8US1SQ3B5"},{"name":"Maps_To","value":"Antibody-drug Conjugate ADC XMT-1536"},{"name":"NCI_Drug_Dictionary_ID","value":"792493"},{"name":"NCI_META_CUI","value":"CL545394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792493"},{"name":"PDQ_Open_Trial_Search_ID","value":"792493"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129401":{"preferredName":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014","code":"C129401","definitions":[{"definition":"A monoclonal antibody-drug conjugate (ADC) comprised of human immunoglobulin G1 (IgG1) clone CR014, which targets the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1; HAVCR1), that is linked, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of ADC anti-TIM-1-vcMMAE CDX-014, the monoclonal antibody moiety targets and binds to TIM-1. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of TIM-1-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. TIM-1 is upregulated in a variety of cancer cell types while only minimally expressed in healthy tissue. The linkage system in CDX-014 is highly stable in plasma, resulting in increased specificity and cytotoxic efficacy towards TIM-1-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014","termGroup":"PT","termSource":"NCI"},{"termName":"ADC Anti-TIM-1-vcMMAE CDX-014","termGroup":"SY","termSource":"NCI"},{"termName":"ADC CDX-014","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate CDX-014","termGroup":"SY","termSource":"NCI"},{"termName":"CDX-014","termGroup":"CN","termSource":"NCI"},{"termName":"CR014-vc-MMAE","termGroup":"SY","termSource":"NCI"},{"termName":"CR014-vcMMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GJV1PP34M2"},{"name":"Maps_To","value":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014"},{"name":"NCI_Drug_Dictionary_ID","value":"783989"},{"name":"NCI_META_CUI","value":"CL512670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783989"},{"name":"PDQ_Open_Trial_Search_ID","value":"783989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106256":{"preferredName":"Antibody-Drug Conjugate DFRF4539A","code":"C106256","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against a specific myeloma antigen and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DFRF4539A selectively binds to a specific protein expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-Drug Conjugate DFRF4539A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DFRF4539A","termGroup":"SY","termSource":"NCI"},{"termName":"DFRF4539A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-Drug Conjugate DFRF4539A"},{"name":"NCI_Drug_Dictionary_ID","value":"710969"},{"name":"NCI_META_CUI","value":"CL433882"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710969"},{"name":"PDQ_Open_Trial_Search_ID","value":"710969"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137821":{"preferredName":"Anti-ASCT2 Antibody-drug Conjugate MEDI7247","code":"C137821","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody against neutral amino acid transporter B(0) (ASCT2; SLC1A5) that is site-specifically conjugated, via a protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-ASCT2 ADC MEDI7247, the antibody moiety targets and binds to ASCT2 expressed on cancer cells. Upon antibody/antigen binding, internalization and linker cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of ASCT2-overexpressing tumor cells. ASCT2, a neutral amino acid transporter that mediates the uptake of glutamine, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ASCT2 Antibody-drug Conjugate MEDI7247","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ASCT2 ADC MEDI7247","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ASCT2/PBD ADC MEDI7247","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 7247","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI7247","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XZ66R08EI3"},{"name":"Maps_To","value":"Antibody-drug Conjugate MEDI7247"},{"name":"NCI_Drug_Dictionary_ID","value":"789996"},{"name":"NCI_META_CUI","value":"CL524897"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789996"},{"name":"PDQ_Open_Trial_Search_ID","value":"789996"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118572":{"preferredName":"Antibody-drug Conjugate PF-06647263","code":"C118572","synonyms":[{"termName":"Antibody-drug Conjugate PF-06647263","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06647263","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate PF-06647263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896742"}]}}{"C118570":{"preferredName":"Antibody-drug Conjugate PF-06664178","code":"C118570","synonyms":[{"termName":"Antibody-drug Conjugate PF-06664178","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06664178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate PF-06664178"},{"name":"NCI_META_CUI","value":"CL474086"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123284":{"preferredName":"Antibody-drug Conjugate SC-002","code":"C123284","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an as of yet publicly unknown monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-002 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-002","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-002","termGroup":"SY","termSource":"NCI"},{"termName":"SC-002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-002"},{"name":"NCI_Drug_Dictionary_ID","value":"774849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774849"},{"name":"PDQ_Open_Trial_Search_ID","value":"774849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0967624"}]}}{"C124133":{"preferredName":"Tamrintamab Pamozirine","code":"C124133","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against dipeptidase 3 (DPEP3) conjugated, via a plasma-stable valine-alanine dipeptide linker, to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of tamrintamab pamozirine targets DPEP3 expressed on tumor cells. Upon binding and internalization, the cytotoxic, DNA cross-linking PBD moiety is released. This inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DPEP3-expressing tumor cells. DPEP3, a membrane-bound glycoprotein, is overexpressed in some ovarian cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamrintamab Pamozirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-003","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1(226-serine), Anti-(Human Dipeptidase 3)(Human-mus musculus Monoclonal sc34.28SS1 Gamma1-chain), Compd. with Human-mus musculus Monoclonal sc34.28SS1 Kappa-chain, Dimer, Bis(thioether) with N-(6-(3-mercapto-2, 5-dioxo-1-pyrrolidinyl)-1","termGroup":"SY","termSource":"NCI"},{"termName":"SC 003","termGroup":"CN","termSource":"NCI"},{"termName":"SC-003","termGroup":"CN","termSource":"NCI"},{"termName":"SC003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2148334-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GM0RU5SU0E"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-003"},{"name":"Maps_To","value":"Tamrintamab Pamozirine"},{"name":"NCI_Drug_Dictionary_ID","value":"776646"},{"name":"NCI_META_CUI","value":"CL502529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776646"},{"name":"PDQ_Open_Trial_Search_ID","value":"776646"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136807":{"preferredName":"Antibody-drug Conjugate SC-004","code":"C136807","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-004 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-004","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-004","termGroup":"SY","termSource":"NCI"},{"termName":"SC 004","termGroup":"CN","termSource":"NCI"},{"termName":"SC-004","termGroup":"CN","termSource":"NCI"},{"termName":"SC004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EBA1W201ZY"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-004"},{"name":"NCI_Drug_Dictionary_ID","value":"789553"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789553"},{"name":"PDQ_Open_Trial_Search_ID","value":"789553"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0967625"}]}}{"C154558":{"preferredName":"Antibody-drug Conjugate SC-005","code":"C154558","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-005 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-005","termGroup":"PT","termSource":"NCI"},{"termName":"SC 005","termGroup":"CN","termSource":"NCI"},{"termName":"SC 005","termGroup":"SY","termSource":"NCI"},{"termName":"SC-005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BT8F8AD6WO"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-005"},{"name":"NCI_Drug_Dictionary_ID","value":"794353"},{"name":"NCI_META_CUI","value":"CL555355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794353"},{"name":"PDQ_Open_Trial_Search_ID","value":"794353"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136779":{"preferredName":"Antibody-drug Conjugate SC-006","code":"C136779","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-006 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-006","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-006","termGroup":"SY","termSource":"NCI"},{"termName":"SC 006","termGroup":"CN","termSource":"NCI"},{"termName":"SC-006","termGroup":"CN","termSource":"NCI"},{"termName":"SC006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"293BGU7HL8"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-006"},{"name":"NCI_Drug_Dictionary_ID","value":"789538"},{"name":"NCI_META_CUI","value":"CL524579"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789538"},{"name":"PDQ_Open_Trial_Search_ID","value":"789538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147029":{"preferredName":"Antibody-drug Conjugate SC-007","code":"C147029","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an undisclosed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-007 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-007","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-007","termGroup":"SY","termSource":"NCI"},{"termName":"SC-007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4NP0CFH7QL"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-007"},{"name":"NCI_Drug_Dictionary_ID","value":"792378"},{"name":"NCI_META_CUI","value":"CL545028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792378"},{"name":"PDQ_Open_Trial_Search_ID","value":"792378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90562":{"preferredName":"Asunercept","code":"C90562","definitions":[{"definition":"A human, soluble fusion protein consisting of the extracellular domain of the CD95 receptor fused to the Fc-domain of the human IgG antibody, with potential antineoplastic activity. Upon administration, asunercept binds to the CD95 ligand (CD95L) and blocks the binding of CD95L to the CD95 receptor. In tumor cells, blockage of CD95L-mediated signaling pathways may prevent cell migration and invasive cell growth; in healthy cells, blockage of CD95L-mediated signaling pathways may prevent apoptosis and may protect cell damage. Activation of the CD95 receptor plays an important role in the initiation of apoptosis in healthy cells or the invasive growth of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asunercept","termGroup":"PT","termSource":"NCI"},{"termName":"APG-101","termGroup":"CN","termSource":"NCI"},{"termName":"APG101","termGroup":"CN","termSource":"NCI"},{"termName":"Apocept","termGroup":"BR","termSource":"NCI"},{"termName":"CAN-008","termGroup":"CN","termSource":"NCI"},{"termName":"CAN008","termGroup":"CN","termSource":"NCI"},{"termName":"CD95-Fc Fusion Protein CAN008","termGroup":"SY","termSource":"NCI"},{"termName":"Fas-Fc Fusion Protein CAN008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1450882-18-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F333OQQ9UV"},{"name":"Maps_To","value":"Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008"},{"name":"Maps_To","value":"Asunercept"},{"name":"NCI_Drug_Dictionary_ID","value":"666905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666905"},{"name":"PDQ_Open_Trial_Search_ID","value":"666905"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983762"}]}}{"C165256":{"preferredName":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV","code":"C165256","definitions":[{"definition":"A preparation of antigen presenting cells (APCs) specific for human papillomavirus (HPV) type 16 E6 and E7 proteins, with potential immunomodulating and antineoplastic activities. Autologous peripheral blood mononuclear cells (PBMCs) were ex vivo manipulated, using a technique involving membrane disruption to get the HPV16 E6 and E7 proteins into the cells; the resulting APCs present the antigens in a major histocompatibility type I (MHC-I) manner.  Upon administration of the APCs-expressing HPV16 E6/E7 SQZ-PBMC-HPV, these cells activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing HPV16 E6 and E7.  HPV16 E6 and E7 play an important role in the development of certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV","termGroup":"PT","termSource":"NCI"},{"termName":"APCs Expressing HPV16 E6/E7 SQZ-PBMC-HPV","termGroup":"SY","termSource":"NCI"},{"termName":"SQZ PBMC HPV","termGroup":"CN","termSource":"NCI"},{"termName":"SQZ-PBMC-HPV","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV"},{"name":"NCI_Drug_Dictionary_ID","value":"799743"},{"name":"NCI_META_CUI","value":"CL978557"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799743"},{"name":"PDQ_Open_Trial_Search_ID","value":"799743"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125690":{"preferredName":"Antimetabolite FF-10502","code":"C125690","definitions":[{"definition":"An antimetabolite with potential antineoplastic activity. Upon administration, FF-10502 is able to enter the nucleus where it inhibits DNA polymerases, thereby preventing DNA synthesis and halting tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antimetabolite FF-10502","termGroup":"PT","termSource":"NCI"},{"termName":"FF-10502","termGroup":"CN","termSource":"NCI"},{"termName":"FF-10502-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antimetabolite FF-10502"},{"name":"NCI_Drug_Dictionary_ID","value":"778592"},{"name":"NCI_META_CUI","value":"CL504366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778592"},{"name":"PDQ_Open_Trial_Search_ID","value":"778592"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124051":{"preferredName":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus","code":"C124051","definitions":[{"definition":"A combination agent containing racemetyrosine, methoxsalen, phenytoin and sirolimus, with potential antineoplastic activity. Upon administration of racemetyrosine/methoxsalen/phenytoin/sirolimus SM-88, racemetyrosine, being a dysfunctional and modified form of the non-essential amino acid tyrosine, is specifically taken up by cancer cells through the transporter L-amino acid transferase-1 (LAT1; CD98). As a tyrosine derivative and faulty amino acid protein building block, racemetyrosine prevents protein synthesis in cancer cells. Specifically, this prevents mucin-1 (MUC1) protein synthesis. MUC1 is highly overexpressed by most cancer cells and regulates the increased reactive oxygen species (ROS) in cancer cells created from the altered metabolism that cancer cells utilize, by upregulating key antioxidant defenses and preventing ROS-mediated apoptosis. In the absence of MUC1, ROS levels are increased, leading to an increase in oxidative stress, and induction of apoptosis. Also, being a protective transmembrane protein, MUC1 is part of the protective layer on the outside of cancer cells and plays a key role in shielding the cancer cell from the immune system. The loss of MUC1 compromises the cell membrane, thereby making the cancer cell more vulnerable to be recognized and attacked by the immune system. Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, increases the cancer cells' need for tyrosine uptake and increases the uptake of racemetyrosine by LAT1. Phenytoin stimulates the release of reactive lipid species by the liver which accumulate in the tumor microenvironment (TME) and are taken up by cancer cells, thereby further increasing ROS within the cancer cell and increasing oxidative-related apoptosis. Mehoxsalen promotes toxic electron transfer and increases melanin, increases oxidative reactions and production of ROS. This further stimulates oxidative stress-mediated apoptosis. Normal cells do not regularly take up certain non-essential amino acids, such as tyrosine, but readily convert phenylalanine to tyrosine, so normal healthy cells are not expected to consume racemetyrosine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus","termGroup":"PT","termSource":"NCI"},{"termName":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus Combination","termGroup":"SY","termSource":"NCI"},{"termName":"SM-88 Used with Methoxsalen/Phenytoin/Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"SM-88 Used with MPS","termGroup":"SY","termSource":"NCI"},{"termName":"SM-88/Methoxsalen/Phenytoin/Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Tyrosine Isomers/Phenytoin/Methoxsalen/Sirolimus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antineoplastic Agent Combination SM-88"},{"name":"Maps_To","value":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88"},{"name":"NCI_Drug_Dictionary_ID","value":"776184"},{"name":"NCI_META_CUI","value":"CL498405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776184"},{"name":"PDQ_Open_Trial_Search_ID","value":"776184"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1663":{"preferredName":"Antineoplastic Vaccine","code":"C1663","definitions":[{"definition":"A type of vaccine that is usually made from a patient's own tumor cells or from substances taken from tumor cells. A cancer vaccine may help the immune system kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of vaccine that prevents or treats cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplastic Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antineoplastic_Vaccine"},{"name":"Maps_To","value":"Antineoplastic Vaccine"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0376659"}]}}{"C2100":{"preferredName":"Antineoplastic Vaccine GV-1301","code":"C2100","definitions":[{"definition":"Antineoplastic vaccine being developed against liver cancer. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplastic Vaccine GV-1301","termGroup":"PT","termSource":"NCI"},{"termName":"GV-1301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GV-1301"},{"name":"Maps_To","value":"Antineoplastic Vaccine GV-1301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517372"}]}}{"C1004":{"preferredName":"Antineoplaston A10","code":"C1004","definitions":[{"definition":"A piperidinedione antineoplaston with potential antineoplastic activity.  Antineoplaston A10 was originally isolated from human urine but is now synthetically derived.  This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis.  Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplaston A10","termGroup":"PT","termSource":"NCI"},{"termName":"3-Phenylacetylamino-2, 6-piperidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"A10","termGroup":"AB","termSource":"NCI"},{"termName":"Atengenal","termGroup":"SY","termSource":"NCI"},{"termName":"Benzeneacetamide, N-(2,6-dioxo-3-piperidinyl)-, (S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91531-30-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16VY3TM7ZO"},{"name":"Legacy Concept Name","value":"Antineoplaston_A10"},{"name":"Maps_To","value":"Antineoplaston A10"},{"name":"NCI_Drug_Dictionary_ID","value":"41984"},{"name":"NSC Number","value":"377381"},{"name":"NSC Number","value":"619130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41984"},{"name":"PDQ_Open_Trial_Search_ID","value":"41984"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052080"}]}}{"C1613":{"preferredName":"Antineoplaston AS2-1","code":"C1613","definitions":[{"definition":"A 4:1 mixture of phenylacetate and phenylacetylgluatmine, degradation products of the antineoplaston agent A10.  Antineoplaston AS2-1 inhibits the incorporation of L-glutamine into tumor-cell proteins, leading to cell cycle arrest in the G1 phase and inhibition of mitosis.  This agent may also inhibit RAS oncogene expression and activate tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplaston AS2-1","termGroup":"PT","termSource":"NCI"},{"termName":"AS2-1","termGroup":"AB","termSource":"NCI"},{"termName":"Astugenal","termGroup":"SY","termSource":"NCI"},{"termName":"L-Glutamine, N2-(phenylacetyl)-, Monosodium Salt, Mixture with Sodium Benzeneacetate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"104624-98-8"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antineoplaston_AS2-1"},{"name":"Maps_To","value":"Antineoplaston AS2-1"},{"name":"NCI_Drug_Dictionary_ID","value":"41985"},{"name":"NSC Number","value":"620261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41985"},{"name":"PDQ_Open_Trial_Search_ID","value":"41985"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0294295"}]}}{"C26652":{"preferredName":"Antisense Oligonucleotide GTI-2040","code":"C26652","definitions":[{"definition":"A 20-mer antisense oligonucleotide complementary to a coding region in the mRNA of the R2 small subunit component of human ribonucleotide reductase.  GTI-2040 decreases mRNA and protein levels of R2 in vitro and may inhibit tumor cell proliferation in human tumors in vivo. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It blocks the production of a protein called ribonucleotide reductase, which helps cells make DNA. This may kill cancer cells that need ribonucleotide reductase to grow. It may also make cells more sensitive to anticancer drugs. It is a type of antisense oligonucleotide, and a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Antisense Oligonucleotide GTI-2040","termGroup":"PT","termSource":"NCI"},{"termName":"GTI-2040","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"236391-66-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5WY0FWR2CF"},{"name":"Legacy Concept Name","value":"GTI-2040"},{"name":"Maps_To","value":"Antisense Oligonucleotide GTI-2040"},{"name":"NCI_Drug_Dictionary_ID","value":"301635"},{"name":"NSC Number","value":"722929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301635"},{"name":"PDQ_Open_Trial_Search_ID","value":"301635"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1142995"}]}}{"C156694":{"preferredName":"Antitumor B Key Active Component-alpha","code":"C156694","definitions":[{"definition":"An orally available concentrated preparation of antitumor B (ATB, Zeng Sheng Ping), a Chinese herbal formula comprised of Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera, with potential antineoplastic activity. Upon administration, antitumor B key active component-alpha (ATB-KAC-alpha) may, through a not yet fully elucidated mechanism, inhibit tumorigenesis and prevent the development of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antitumor B Key Active Component-alpha","termGroup":"PT","termSource":"NCI"},{"termName":"Antitumor B KAC-a","termGroup":"SY","termSource":"NCI"},{"termName":"C156694","termGroup":"SY","termSource":"NCI"},{"termName":"Chinese Herbal Mixture Antitumor B KAC-a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antitumor B Key Active Component-alpha"},{"name":"NCI_Drug_Dictionary_ID","value":"795710"},{"name":"NCI_META_CUI","value":"CL935709"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795710"},{"name":"PDQ_Open_Trial_Search_ID","value":"795710"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95731":{"preferredName":"Antrodia cinnamomea Supplement","code":"C95731","definitions":[{"definition":"A dietary supplement containing extract from the medicinal fungus Antrodia cinnamomea with potential antiangiogenic, hepatoprotective and antioxidant activities. The components in Antrodia cinnamomea supplement are rather complex, however, rich in triterpenoids, polysaccharides, nucleosides (adenosine) nucleic acids, superoxide dismutase, other small molecular weight proteins and steroid like compounds. Neutral sugars in this supplement show inhibitory activity on endothelial tube formation, while maleimide and maleic anhydride derivative components in the extract, such as antrodin B and antrodin C and their metabolites, exhibit significant cytotoxic effects on tumor cells and hepatitis C virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antrodia cinnamomea Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antrodia cinnamomea Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"694951"},{"name":"NCI_META_CUI","value":"CL428192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694951"},{"name":"PDQ_Open_Trial_Search_ID","value":"694951"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119701":{"preferredName":"Antroquinonol Capsule","code":"C119701","definitions":[{"definition":"An orally available capsule containing antroquinonol, a farnesylated quinone derivative isolated from the mycelium of Antrodia camphorata, with potential antineoplastic activity. Upon oral administration, antroquinonol binds to and inhibits protein prenylation mediated by the enzymes farnesyltransferase (FTase) and geranylgeranyltransferase 1 (GGTase-1). This prevents both post-translational prenylation and signaling activity of a number of Ras superfamily proteins, such as Ras and Rho. This results in the inhibition of downstream signaling, such as the PI3K/mTOR signaling pathway, and induces apoptosis in susceptible tumor cells. Ras superfamily proteins are overexpressed in numerous cancer cell types, and play a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antroquinonol Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Hocena","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1010081-09-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AX9P92T7JZ"},{"name":"Maps_To","value":"Antroquinonol Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"674922"},{"name":"NCI_META_CUI","value":"CL421596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674922"},{"name":"PDQ_Open_Trial_Search_ID","value":"674922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92574":{"preferredName":"Apalutamide","code":"C92574","definitions":[{"definition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"ARN 509","termGroup":"CN","termSource":"NCI"},{"termName":"ARN-509","termGroup":"CN","termSource":"NCI"},{"termName":"ARN509","termGroup":"CN","termSource":"NCI"},{"termName":"Erleada","termGroup":"BR","termSource":"NCI"},{"termName":"JNJ 56021927","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-56021927","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-metastatic castration-resistant prostate cancer"},{"name":"CAS_Registry","value":"956104-40-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"4T36H88UA7"},{"name":"Maps_To","value":"Apalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"683082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683082"},{"name":"PDQ_Open_Trial_Search_ID","value":"683082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985183"}]}}{"C71740":{"preferredName":"Apatorsen","code":"C71740","definitions":[{"definition":"A second-generation antisense oligonucleotide targeting heat shock protein 27 (Hsp27) with potential antitumor and chemosensitizing activities. Apatorsen suppresses tumor cell expression of Hsp27, which may induce tumor cell apoptosis and enhance tumor cell sensitivity to cytotoxic agents. Hsp27, a chaperone belonging to the small heat shock protein (sHsp) group of proteins, is a cytoprotective protein that supports cell survival under conditions of stress; it has been found to be over-expressed in a variety of human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apatorsen","termGroup":"PT","termSource":"NCI"},{"termName":"ISIS 306053","termGroup":"CN","termSource":"NCI"},{"termName":"OGX-427","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1002331-21-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IFJ6X26JW6"},{"name":"Legacy Concept Name","value":"Hsp27_Antisense_Oligonucleotide_OGX-427"},{"name":"Maps_To","value":"Apatorsen"},{"name":"NCI_Drug_Dictionary_ID","value":"559200"},{"name":"PDQ_Closed_Trial_Search_ID","value":"559200"},{"name":"PDQ_Open_Trial_Search_ID","value":"559200"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348994"}]}}{"C1087":{"preferredName":"Apaziquone","code":"C1087","definitions":[{"definition":"An indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is converted to active metabolites in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. The active metabolites alkylate DNA, resulting in apoptotic cell death. This agent displays selectivity activity towards both hypoxic solid tumors, which exhibits higher expression of cytochrome P450 reductase, and well-oxygenated malignant cells that overexpress the bioreductive enzyme NQO1 (NAD(P)H: quinone oxidoreductase). Apaziquone may selectively sensitize hypoxic tumor cells to radiocytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apaziquone","termGroup":"PT","termSource":"NCI"},{"termName":"3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-en-alpha-ol","termGroup":"SN","termSource":"NCI"},{"termName":"E O9","termGroup":"SY","termSource":"NCI"},{"termName":"EO9","termGroup":"CN","termSource":"NCI"},{"termName":"Eoquin","termGroup":"BR","termSource":"NCI"},{"termName":"Neoquin","termGroup":"BR","termSource":"NCI"},{"termName":"Qapzola","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114560-48-4"},{"name":"Chemical_Formula","value":"C15H16N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H464ZO600O"},{"name":"Legacy Concept Name","value":"EO9"},{"name":"Maps_To","value":"Apaziquone"},{"name":"NCI_Drug_Dictionary_ID","value":"42095"},{"name":"NSC Number","value":"382456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42095"},{"name":"PDQ_Open_Trial_Search_ID","value":"42095"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0095568"}]}}{"C48640":{"preferredName":"APC8015F","code":"C48640","definitions":[{"definition":"A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.","type":"DEFINITION","source":"NCI"},{"definition":"A vaccine made from immune system cells taken from a patient with prostate cancer and frozen for future use. The cells are treated in the laboratory with a growth factor attached to a protein called prostatic-acid phosphatase (PAP), which is found on prostate cancer cells. When APC8015F is injected into the patient, it may cause T cells (a type of white blood cell) to kill tumor cells that have PAP on them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"APC8015F","termGroup":"PT","termSource":"NCI"},{"termName":"APC 8015F","termGroup":"CN","termSource":"NCI"},{"termName":"APC8015F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"APC8015F"},{"name":"Maps_To","value":"APC8015F"},{"name":"NCI_Drug_Dictionary_ID","value":"385490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385490"},{"name":"PDQ_Open_Trial_Search_ID","value":"385490"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541593"}]}}{"C150216":{"preferredName":"APE1/Ref-1 Redox Inhibitor APX3330","code":"C150216","definitions":[{"definition":"An orally bioavailable inhibitor of apurinic/apyrimidinic endonuclease 1/reduction-oxidation (redox) effector factor-1 (APE1/Ref-1; APEX1), with potential anti-angiogenic and antineoplastic activities. Upon administration, the APE1/Ref-1 Inhibitor APX3330 selectively targets and binds to APE1/Ref-1. This inhibits the redox-dependent signaling activity of APE1/Ref-1, by preventing the reduction and activation of numerous APE1/Ref-1-dependent oncogenic transcription factors (TFs), such as nuclear factor kappa B (NF-kB), AP-1, STAT3, p53, NRF2 and HIF-1alpha, that are involved in signaling, cell proliferation, tumor progression and survival of cancer cells. Therefore, this agent inhibits the activation of multiple TF-mediated signaling pathways and inhibits tumor cell proliferation and survival.  APE1/Ref-1, a multifunctional protein overexpressed in many cancer cell types, plays a key role as a redox regulator of transcription factor activation and in base excision repair upon DNA damage. It drives cancer cell proliferation, migration, drug resistance, angiogenesis and inflammation and its expression level correlates with increased tumor aggressiveness and decreased patient survival. APX3330 specifically blocks the redox activity of APE1/Ref-1 and does not affect its ability to act as a DNA repair endonuclease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"APE1/Ref-1 Redox Inhibitor APX3330","termGroup":"PT","termSource":"NCI"},{"termName":"[(2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-undecanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"APE1/Ref-1 Inhibitor APX3330","termGroup":"SY","termSource":"NCI"},{"termName":"APX 3330","termGroup":"CN","termSource":"NCI"},{"termName":"APX-3330","termGroup":"CN","termSource":"NCI"},{"termName":"APX3330","termGroup":"CN","termSource":"NCI"},{"termName":"E 3330","termGroup":"CN","termSource":"NCI"},{"termName":"E3330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"136164-66-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"11267UI968"},{"name":"Maps_To","value":"APE1/Ref-1 Redox Inhibitor APX3330"},{"name":"NCI_Drug_Dictionary_ID","value":"794415"},{"name":"NCI_META_CUI","value":"CL551955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794415"},{"name":"PDQ_Open_Trial_Search_ID","value":"794415"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28802":{"preferredName":"Aphidicoline Glycinate","code":"C28802","definitions":[{"definition":"A tetracyclic diterpene antibiotic isolated from the fungus Cephalosporium aphidicola and other fungal species with potential antineoplastic activity.  Aphidicoline glycinate blocks the cell cycle at early S-phase by specifically inhibiting DNA polymerases in eukaryotic cells, induces apoptosis, and stops the growth of eukaryotic cells and certain viruses by selectively inhibiting DNA polymerase II or viral-induced DNA polymerases. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aphidicoline Glycinate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aphidicoline_Glycinate"},{"name":"Maps_To","value":"Aphidicoline Glycinate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516035"}]}}{"C126661":{"preferredName":"Apilimod Dimesylate Capsule","code":"C126661","definitions":[{"definition":"A capsule containing the dimesylate salt form of apilimod, an inhibitor of the class III PI kinase phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), with potential antineoplastic and immunomodulatory activities. Upon oral administration of apilimod dimesylate capsule, apilimod selectively binds to and inhibits PIKfyve. The inhibition leads to disruption of PIKfyve-mediated signal transduction pathways and eventually inhibits tumor cell growth in PIKfyve-overexpressing tumor cells. Also, PIKfyve inhibition by apilimod inhibits the toll-like receptor (TLR)-induced production of various cytokines, including interleukin-12 (IL-12) and IL-23, thereby preventing IL-12/IL-23-mediated immune responses. PIKfyve, a lipid kinase dysregulated in various tumor types, plays a key role in TLR signaling and tumor cell migration, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apilimod Dimesylate Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"LAM 002A","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-002A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Apilimod Dimesylate Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"780441"},{"name":"NCI_META_CUI","value":"CL503772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780441"},{"name":"PDQ_Open_Trial_Search_ID","value":"780441"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91731":{"preferredName":"Apitolisib","code":"C91731","definitions":[{"definition":"An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Apitolisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apitolisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 0980","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0980","termGroup":"CN","termSource":"NCI"},{"termName":"GNE 390","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7422","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032754-93-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1C854K1MIJ"},{"name":"Maps_To","value":"Apitolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"639518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639518"},{"name":"PDQ_Open_Trial_Search_ID","value":"639518"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984520"}]}}{"C2228":{"preferredName":"Apolizumab","code":"C2228","definitions":[{"definition":"A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of hematologic (blood) cancers. Apolizumab binds to a protein called ID10, which is found on the surface of some types of immune cells and cancer cells. It may help the immune system kill cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Apolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"1D10 Anti-lymphoma Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MAbHu1D10","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Hu1D10","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal antibody 1D10","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody Hu1D10","termGroup":"SY","termSource":"NCI"},{"termName":"Remitogen","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"267227-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G88KCP51RE"},{"name":"Legacy Concept Name","value":"Apolizumab"},{"name":"Maps_To","value":"Apolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38451"},{"name":"NSC Number","value":"704867"},{"name":"NSC Number","value":"710066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38451"},{"name":"PDQ_Open_Trial_Search_ID","value":"38451"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122758"}]}}{"C71693":{"preferredName":"Apomab","code":"C71693","definitions":[{"definition":"A fully human monoclonal antibody directed against human death receptor 5 (DR5; TRAIL-R2; TNFRSF10B) with potential pro-apoptotic and antineoplastic activities. Mimicking the natural ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand), apomab binds to DR5, which may directly activate the extrinsic apoptosis pathway and indirectly induce the intrinsic apoptosis pathway in tumor cells. DR5 is a cell surface receptor of the TNF-receptor superfamily and is expressed in a broad range of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apomab","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1108170-71-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"703KLX5LXZ"},{"name":"Legacy Concept Name","value":"Apomab"},{"name":"Maps_To","value":"Apomab"},{"name":"NCI_Drug_Dictionary_ID","value":"555507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"555507"},{"name":"PDQ_Open_Trial_Search_ID","value":"555507"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346838"}]}}{"C1873":{"preferredName":"Apomine","code":"C1873","definitions":[{"definition":"A 1,1-bisphosphonate ester with potential antineoplastic and hypocholesterolemic activities. SR-45023A binds to hydroxyapatite crystals in the bone matrix where it inhibits enzymatic activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for the formation of mevalonate, the precursor of cholesterol. Consequently, shortage of mevalonate impedes the synthesis of downstream isoprenoids that are essential for protein prenylation. This leads to the loss of activity of proteins involved in osteoclast function and cellular proliferation, such as Ras and Rho, leading to an inhibition of cellular proliferation, and induction of osteoclasts apoptosis. In addition, SR-45023A activates the farnesoid X activated receptor (FXR), a member of the nuclear hormone superfamily implicated in cholesterol metabolism and bile acid transport and may play a role in this agent's antineoplastic effect.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called bisphosphonates. It affects cancer cell receptors governing cell growth and cell death.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Apomine","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl) Ester","termGroup":"SN","termSource":"NCI"},{"termName":"SKF 99085","termGroup":"CN","termSource":"NCI"},{"termName":"SR-45023A","termGroup":"CN","termSource":"NCI"},{"termName":"Tetraisopropyl-2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethylidene-1,1-diphosphonate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"126411-13-0"},{"name":"Chemical_Formula","value":"C28H52O7P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JQ95208805"},{"name":"Legacy Concept Name","value":"SR-45023A"},{"name":"Maps_To","value":"Apomine"},{"name":"NCI_Drug_Dictionary_ID","value":"43447"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43447"},{"name":"PDQ_Open_Trial_Search_ID","value":"43447"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0766100"}]}}{"C69134":{"preferredName":"Apoptosis Inducer BZL101","code":"C69134","definitions":[{"definition":"An orally active aqueous extract derived from the plant Scutellaria barbata with potential antineoplastic activity. Sparing normal cells, apoptosis inducer BZL101 specifically facilitates translocation of the protein apoptosis-inducing factor (AIF) from the mitochondrial membrane into the nucleus in tumor cells, thereby causing tumor cell-specific chromatin condensation and DNA degradation followed by the induction of caspase-independent apoptosis. AIF is both a mitochondrial intermembrane flavoprotein with oxidoreductase activity and a caspase-independent death effector that, similar to cytochrome c, is released from mitochondria early in the apoptotic process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apoptosis Inducer BZL101","termGroup":"PT","termSource":"NCI"},{"termName":"BZL101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J52LXC6DTW"},{"name":"Legacy Concept Name","value":"Apoptosis_Inducer_BZL101"},{"name":"Maps_To","value":"Apoptosis Inducer BZL101"},{"name":"NCI_Drug_Dictionary_ID","value":"543519"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543519"},{"name":"PDQ_Open_Trial_Search_ID","value":"543519"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1999759"}]}}{"C70984":{"preferredName":"Apoptosis Inducer GCS-100","code":"C70984","definitions":[{"definition":"A galectin-binding polysaccharide derived from citrus pectin with potential antineoplastic activity. Apoptosis inducer GCS-100 binds to the carbohydrate-binding domain of the lectin galectin-3, which may result in apoptosis mediated through mitochondria/caspase activation cascades; this agent may overcome tumor growth mediated through anti-apoptotic protein Bcl-2, heat-shock protein 27 (Hsp27), and nuclear factor-kappa B (NF-kB). Galectin-3, a chimeric molecule consisting of both carbohydrate recognition and collagen-like domains, interacts with a variety of carbohydrate and protein ligands to form pentamers with unique crosslinking abilities; this lectin also exhibits anti-apoptotic properties, perhaps, in part, through the regulation of intracellular signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apoptosis Inducer GCS-100","termGroup":"PT","termSource":"NCI"},{"termName":"GCS-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3HO3IZ2ILX"},{"name":"Legacy Concept Name","value":"Apoptosis_Inducer_GCS-100"},{"name":"Maps_To","value":"Apoptosis Inducer GCS-100"},{"name":"NCI_Drug_Dictionary_ID","value":"567705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"567705"},{"name":"PDQ_Open_Trial_Search_ID","value":"567705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1690444"}]}}{"C64781":{"preferredName":"Apoptosis Inducer MPC-2130","code":"C64781","definitions":[{"definition":"A broad-acting, apoptosis-inducing, small molecule with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, apoptosis inducer MPC-2130 exhibits proapoptotic activities in tumor cells, including membrane phosphatidylserine externalization, release of cytochrome C from mitochondria, caspase activation, cell condensation, and DNA fragmentation. In addition, because this agent is not a substrate for several types of multidrug resistance (MDR) ABC superfamily transporters, such as P-glycoprotein 1 (MDR-1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1/ABCG2), it may be useful in treating MDR tumors that express these particular MDR efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apoptosis Inducer MPC-2130","termGroup":"PT","termSource":"NCI"},{"termName":"MPC-2130","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MPC-2130"},{"name":"Maps_To","value":"Apoptosis Inducer MPC-2130"},{"name":"NCI_Drug_Dictionary_ID","value":"526178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526178"},{"name":"PDQ_Open_Trial_Search_ID","value":"526178"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881499"}]}}{"C74021":{"preferredName":"Apricoxib","code":"C74021","definitions":[{"definition":"An orally bioavailable nonsteroidal anti-inflammatory agent (NSAID) with potential antiangiogenic and antineoplastic activities. Apricoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. Apricoxib-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apricoxib","termGroup":"PT","termSource":"NCI"},{"termName":"COX-2 Inhibitor TG01","termGroup":"SY","termSource":"NCI"},{"termName":"CS-706","termGroup":"CN","termSource":"NCI"},{"termName":"R-109339","termGroup":"CN","termSource":"NCI"},{"termName":"TG01","termGroup":"CN","termSource":"NCI"},{"termName":"TP2001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197904-84-0"},{"name":"Chemical_Formula","value":"C19H20N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5X5HB3VZ3Z"},{"name":"Legacy Concept Name","value":"COX-2_Inhibitor_TG01"},{"name":"Maps_To","value":"Apricoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"594363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594363"},{"name":"PDQ_Open_Trial_Search_ID","value":"594363"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1737955"}]}}{"C121212":{"preferredName":"Aprutumab Ixadotin","code":"C121212","definitions":[{"definition":"An antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated to an as of yet unidentified toxin, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2. Upon binding, the toxin selectively induces cell death, through an as of yet undisclosed mechanism of action, in FGFR2-expressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays an essential role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aprutumab Ixadotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BAY1187982","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1187982","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1187982","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1708947-48-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DDD2AB5TWK"},{"name":"Maps_To","value":"Aprutumab Ixadotin"},{"name":"NCI_Drug_Dictionary_ID","value":"769589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769589"},{"name":"PDQ_Open_Trial_Search_ID","value":"769589"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053667"}]}}{"C62522":{"preferredName":"AR Antagonist BMS-641988","code":"C62522","definitions":[{"definition":"An androgen receptor (AR) antagonist with potential antineoplastic and anti-androgenic activities. BMS-641988 binds to the androgen receptor in target tissues, thereby preventing androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This may inhibit androgen-dependent gene expression, subsequently leading to an inhibition of cell growth and apoptosis in AR-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AR Antagonist BMS-641988","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-641988","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1093276-09-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W17M53Y8IM"},{"name":"Legacy Concept Name","value":"BMS-641988"},{"name":"Maps_To","value":"AR Antagonist BMS-641988"},{"name":"NCI_Drug_Dictionary_ID","value":"489385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489385"},{"name":"PDQ_Open_Trial_Search_ID","value":"489385"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831892"}]}}{"C1879":{"preferredName":"Arabinoxylan Compound MGN3","code":"C1879","definitions":[{"definition":"An arabinoxylane polysaccharide composed of the hemicellulose-Beta extract of rice bran, treated with enzymes from Shiitake mushrooms, that exerts antitumor and antiviral activity by increasing the level of natural killer cells activation. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arabinoxylan Compound MGN3","termGroup":"PT","termSource":"NCI"},{"termName":"Arabinoxylan Compound","termGroup":"SY","termSource":"NCI"},{"termName":"Biobran","termGroup":"FB","termSource":"NCI"},{"termName":"MGN3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"204866-62-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MGN3"},{"name":"Maps_To","value":"Arabinoxylan Compound MGN3"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0963824"}]}}{"C162540":{"preferredName":"Aranose","code":"C162540","definitions":[{"definition":"A nitrosourea derivative with potential antineoplastic activity. Upon administration, aranose alkylates and crosslinks DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aranose","termGroup":"PT","termSource":"NCI"},{"termName":"3-(alpha-L-Arabinopyranosyl)-1-methyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Aranoza","termGroup":"SY","termSource":"NCI"},{"termName":"CRC 0510375","termGroup":"CN","termSource":"NCI"},{"termName":"CRC-0510375","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"167396-23-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7149VX7891"},{"name":"Maps_To","value":"Aranose"},{"name":"NCI_META_CUI","value":"CL971124"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161803":{"preferredName":"ARC Fusion Protein SL-279252","code":"C161803","definitions":[{"definition":"An agonist redirected checkpoint (ARC) fusion protein consisting of the extracellular domains of human programmed cell death 1 (PD-1; PDCD1; CD279) and tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 ligand; OX40L; CD252), linked by a central Fc domain (PD1-Fc-OX40L), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, ARC fusion protein SL-279252 simultaneously binds to both tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40) and PD-1 expressed on T-lymphocytes. Stimulation of OX40 may promote cytokine production and induce proliferation of memory and effector T-lymphocytes against tumor cells, while PD-1 binding disrupts PD-1 signaling and may restore immune function through the activation of T-cells. This may enhance the immune-mediated elimination of tumor cells more effectively than PD-1 blockade or OX40-agonism alone. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARC Fusion Protein SL-279252","termGroup":"PT","termSource":"NCI"},{"termName":"Agonist Redirected Checkpoint Fusion Protein SL-279252","termGroup":"SY","termSource":"NCI"},{"termName":"PD1-Fc-OX40L ARC Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"SL 279252","termGroup":"CN","termSource":"NCI"},{"termName":"SL-279252","termGroup":"CN","termSource":"NCI"},{"termName":"SL279252","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ARC Fusion Protein SL-279252"},{"name":"NCI_Drug_Dictionary_ID","value":"798455"},{"name":"NCI_META_CUI","value":"CL970428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798455"},{"name":"PDQ_Open_Trial_Search_ID","value":"798455"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88335":{"preferredName":"Archexin","code":"C88335","definitions":[{"definition":"A 20-mer antisense oligodeoxynucleotide (ODN) against the proto-oncogene Akt with potential antineoplastic activity. Akt-1 antisense oligonucleotide RX-0201 binds to Akt-1 mRNA, inhibiting translation of the transcript; suppression of Akt-1 expression may result in the inhibition of cellular proliferation and the induction of apoptosis in tumor cells that overexpress Akt-1. Akt-1 is a serine-threonine protein kinase that stimulates proliferation and inhibits apoptosis of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Archexin","termGroup":"PT","termSource":"NCI"},{"termName":"Akt-1 Antisense Oligonucleotide RX-0201","termGroup":"SY","termSource":"NCI"},{"termName":"RX-0201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Chemical_Formula","value":"C194H228N70O103P19S19"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4TEW51C830"},{"name":"Maps_To","value":"Archexin"},{"name":"NCI_Drug_Dictionary_ID","value":"662321"},{"name":"NCI_META_CUI","value":"CL413599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662321"},{"name":"PDQ_Open_Trial_Search_ID","value":"662321"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1494":{"preferredName":"Arcitumomab","code":"C1494","definitions":[{"definition":"A murine IgG monoclonal Fab' fragment antibody directed against carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cell types. For tumors that overexpress CEA, technetium-99m labeled arcitumomab may be used as an adjunct diagnostic imaging tool to obtain prognostic information following resection and to monitor for recurrent disease. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arcitumomab","termGroup":"PT","termSource":"NCI"},{"termName":"CEA-Scan","termGroup":"BR","termSource":"NCI"},{"termName":"IMMU-4","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G 1 (mouse monoclonal IMMU-4 Fab' fragment gamma-chain anti-human antigen CEA), disulfide with mouse Monoclonal IMMU-4 Light Chain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colorectal carcinoma and medullary thyroid carcinoma detection"},{"name":"CAS_Registry","value":"154361-48-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"79T6JRG308"},{"name":"Legacy Concept Name","value":"Arcitumomab"},{"name":"Maps_To","value":"Arcitumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"42612"},{"name":"NCI_META_CUI","value":"CL938206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42612"},{"name":"PDQ_Open_Trial_Search_ID","value":"42612"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157079":{"preferredName":"Arfolitixorin","code":"C157079","definitions":[{"definition":"The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect against certain antimetabolite-associated adverse effects, such as those seen with high-dose (HD) methotrexate. Upon administration of arfolitixorin, 5,10-methylenetetrahydrofolate (MTHF) is a reduced folate substrate for the enzyme thymidylate synthase (TS) and stabilizes, upon co-administration of 5-FU, the covalent binding of the 5-FU metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), instead of deoxyuridine monophosphate (dUMP), to its target enzyme TS, which results in an inhibition of TS. This inhibits the synthesis of deoxythymidine monophosphate (dTMP) and leads to the depletion of thymidine triphosphate (TTP), which is a necessary constituent of DNA. This inhibits DNA synthesis, which leads to an inhibition of cellular proliferation and induces tumor cell death. As MTHF is able to stabilize and strengthen the ternary complex, co-administration of arfolitixorin enhances the inhibition of DNA synthesis and increases the cytotoxic effect of 5-FU. As MTHF is the active form of folate and the active metabolite of LV and l-LV, arfolitixorin does not need to be converted to an active metabolite to become activated. In DNA synthesis, a ternary complex is formed between the reduced folate substrate MTHF, the TS enzyme and dUMP in order to convert dUMP to the DNA building block dTMP, which is necessary for DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arfolitixorin","termGroup":"PT","termSource":"NCI"},{"termName":"(6R)-5,10-Methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"6R-5,10-methyleneTHF","termGroup":"SY","termSource":"NCI"},{"termName":"6R-5-10-Methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"6R-methylene THF","termGroup":"SY","termSource":"NCI"},{"termName":"6R-MTHF","termGroup":"AB","termSource":"NCI"},{"termName":"[6R] 5,10-methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"[6R]-5,10-methylene-tetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"Methylenetetrahydrofolic Acid, L-(+)-","termGroup":"SY","termSource":"NCI"},{"termName":"Modufolin","termGroup":"BR","termSource":"NCI"},{"termName":"Rescufolin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31690-11-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z8R4A37V9Q"},{"name":"Maps_To","value":"Arfolitixorin"},{"name":"NCI_Drug_Dictionary_ID","value":"796585"},{"name":"NCI_META_CUI","value":"CL936794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796585"},{"name":"PDQ_Open_Trial_Search_ID","value":"796585"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142866":{"preferredName":"Numidargistat","code":"C142866","definitions":[{"definition":"An orally available inhibitor of arginase, a manganese-dependent enzyme that hydrolyzes the amino acid arginine to form ornithine and urea, with potential immunomodulating and antineoplastic activities. Upon administration, numidargistat inhibits the breakdown of arginine by arginase, which is produced by myeloid cells, and restores arginine levels. This allows arginine to stimulate the synthesis of nitric oxide and the secretion of pro-inflammatory cytokines and chemokines, which induces the proliferation and activation of T-cells. Therefore, this agent may prevent the immunosuppressive effects of tumor-infiltrating myeloid cells and promote lymphocyte-mediated immune responses against tumor cells. Arginase is produced by neutrophils, macrophages and myeloid-derived suppressor cells (MDSC) and plays a role in inflammation-associated immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Numidargistat","termGroup":"PT","termSource":"NCI"},{"termName":"Arginase Inhibitor INCB001158","termGroup":"SY","termSource":"NCI"},{"termName":"CB-1158","termGroup":"CN","termSource":"NCI"},{"termName":"CB1158","termGroup":"CN","termSource":"NCI"},{"termName":"INCB001158","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095732-06-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IFD73D535A"},{"name":"Maps_To","value":"Arginase Inhibitor INCB001158"},{"name":"Maps_To","value":"Numidargistat"},{"name":"NCI_Drug_Dictionary_ID","value":"791808"},{"name":"NCI_META_CUI","value":"CL540753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791808"},{"name":"PDQ_Open_Trial_Search_ID","value":"791808"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2570":{"preferredName":"Arginine Butyrate","code":"C2570","definitions":[{"definition":"A compound composed of the short chain fatty acid (SCFA) butyrate combined with the amino acid arginine, with potential Epstein-Barr virus thymidine kinase gene (EBV-TK)-inducing activity. Upon administration, arginine butyrate induces the expression of thymidine kinase (TK). This activates a co-administered antiviral, such as ganciclovir, and results in the destruction of EBV-infected cancer cells. In addition, butyrate inhibits histone deacetylase (HDAC), which results in hyperacetylation of histones H3 and H4. Acetylated histones have a reduced affinity for chromatin; this reduced histone-chromatin affinity may allow chromosomal unfolding, potentially enhancing the expression of genes related to tumor cell growth arrest and apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Arginine Butyrate","termGroup":"PT","termSource":"NCI"},{"termName":"HQK-1004","termGroup":"CN","termSource":"NCI"},{"termName":"L-Arginine, Butanoate (3:4)","termGroup":"SY","termSource":"NCI"},{"termName":"SCFA HQK-1004","termGroup":"AB","termSource":"NCI"},{"termName":"Short Chain Fatty Acid HQK-1004","termGroup":"SY","termSource":"NCI"},{"termName":"VX-105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80407-72-3"},{"name":"Chemical_Formula","value":"3C6H14N4O2.4C4H8O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IK8S1P79MU"},{"name":"Legacy Concept Name","value":"Arginine_Butyrate"},{"name":"Maps_To","value":"Arginine Butyrate"},{"name":"Maps_To","value":"Short Chain Fatty Acid HQK-1004"},{"name":"NCI_Drug_Dictionary_ID","value":"42492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42492"},{"name":"PDQ_Open_Trial_Search_ID","value":"42492"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052329"}]}}{"C74013":{"preferredName":"Arnebia Indigo Jade Pearl Topical Cream","code":"C74013","definitions":[{"definition":"A proprietary multiherbal topical cream based on Chinese herbal medicine with potential antineoplastic, antiviral, antibacterial and immunostimulatory activities. Arnebia Indigo Jade Pearl topical cream contains 12 ingredients including 9 herbs infused in sesame oil, with an additional three powdered ingredients and beeswax added to the infused oil to create the salve. The purported mechanism(s) of action is unclear due to the complexity of the herbal mixture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arnebia Indigo Jade Pearl Topical Cream","termGroup":"PT","termSource":"NCI"},{"termName":"AIJP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Arnebia_Indigo_Jade_Pearl_Topical_Cream"},{"name":"Maps_To","value":"Arnebia Indigo Jade Pearl Topical Cream"},{"name":"NCI_Drug_Dictionary_ID","value":"589518"},{"name":"NCI_META_CUI","value":"CL383530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589518"},{"name":"PDQ_Open_Trial_Search_ID","value":"589518"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1005":{"preferredName":"Arsenic Trioxide","code":"C1005","definitions":[{"definition":"A drug used to treat acute promyelocytic leukemia (APL) that has not gotten better or that has come back after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arsenic Trioxide","termGroup":"PT","termSource":"NCI"},{"termName":"Arsenic (III) Oxide","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenic Sesquioxide","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenous Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenous Acid Anhydride","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenous Oxide","termGroup":"SY","termSource":"NCI"},{"termName":"ATO","termGroup":"AB","termSource":"NCI"},{"termName":"Trisenox","termGroup":"BR","termSource":"NCI"},{"termName":"White Arsenic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Myelodysplastic syndrome; multiple myeloma; chronic myeloid leukemia; acute myelocytic leukemia"},{"name":"CAS_Registry","value":"1327-53-3"},{"name":"CHEBI_ID","value":"CHEBI:30621"},{"name":"Chemical_Formula","value":"As2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"S7V92P67HO"},{"name":"Legacy Concept Name","value":"Arsenic_Trioxide"},{"name":"Maps_To","value":"Arsenic Trioxide"},{"name":"NCI_Drug_Dictionary_ID","value":"43067"},{"name":"NSC Number","value":"706363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43067"},{"name":"PDQ_Open_Trial_Search_ID","value":"43067"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052416"}]}}{"C133720":{"preferredName":"Arsenic Trioxide Capsule Formulation ORH 2014","code":"C133720","definitions":[{"definition":"An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells, including tumor cells. In addition, As2O3 causes damage to and induces degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein, and inhibits the activity of the enzyme thioredoxin reductase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arsenic Trioxide Capsule Formulation ORH 2014","termGroup":"PT","termSource":"NCI"},{"termName":"Arsenic Trioxide Formulation ORH 2014","termGroup":"SY","termSource":"NCI"},{"termName":"As2O3 Formulation ORH 2014","termGroup":"SY","termSource":"NCI"},{"termName":"Oral Arsenic Trioxide Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"ORH 2014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arsenic Trioxide Capsule Formulation ORH 2014"},{"name":"NCI_Drug_Dictionary_ID","value":"788312"},{"name":"NCI_META_CUI","value":"CL520496"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788312"},{"name":"PDQ_Open_Trial_Search_ID","value":"788312"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118504":{"preferredName":"Artemether Sublingual Spray","code":"C118504","definitions":[{"definition":"A sublingual spray containing artemether, a semisynthetic derivative of artemisinin, an endoperoxide extracted from the Chinese herb qinghaosu (Artemisia annua or annual wormwood), with antiparasitic and potential antineoplastic activity. Upon sublingual application of the spray, artemether exerts its antineoplastic activity through as of yet not fully elucidated mechanism(s) of action. This agent binds to heme molecules inside cells, thereby inducing reactive oxygen species (ROS)-mediated damage which selectively kills cancer cells. In addition, artemether appears to target and modulate the expression of various proteins involved in cancer cell proliferation, angiogenesis, invasion and metastasis. Also, this agent depletes T regulatory cells, and modulates the production of inflammatory cytokines, such as interleukin-4 and interferon-gamma. Altogether, this inhibits tumor cell proliferation. The sublingual spray allows faster absorption of a higher percentage of the artemether dose, when compared to the oral form, as it avoids first pass metabolism; this results in an increased efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artemether Sublingual Spray","termGroup":"PT","termSource":"NCI"},{"termName":"LON002","termGroup":"CN","termSource":"NCI"},{"termName":"Sublingual Artemether Spray","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Artemether Sublingual Spray"},{"name":"NCI_Drug_Dictionary_ID","value":"765719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765719"},{"name":"PDQ_Open_Trial_Search_ID","value":"765719"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3900015"}]}}{"C60769":{"preferredName":"Artemisinin Dimer","code":"C60769","definitions":[{"definition":"A sesquiterpene lactone peroxide and dimerized plant product derived from Artemisia annua L with anti-malarial, anti-proliferative and anti-angiogenic effects. Artemisinin contains an endoperoxide moiety which forms free radicals when it reacts with iron. The resultant carbon-based radical can lead to cellular damage and cell death by reacting with cellular macromolecules such as proteins and membrane lipids. Malaria parasites contain large amounts of heme-iron, a product from the digestion of hemoglobin. However, recently it has been suggested that activation of artemisinin inside the parasite is by ferrous iron. Furthermore, due to their rapid rate of division, cancer cells require and uptake a large amount of iron to proliferate, therefore they are more susceptible to the cytotoxic effect of artemisinin than non-cancerous cells. The dimer configuration has been shown to increase compound stability and reduce general toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artemisinin Dimer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Artemisinin_Dimer"},{"name":"Maps_To","value":"Artemisinin Dimer"},{"name":"NSC Number","value":"724910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879739"}]}}{"C73005":{"preferredName":"Artesunate","code":"C73005","definitions":[{"definition":"A water-soluble, semi-synthetic derivative of the sesquiterpine lactone artemisinin with anti-malarial, anti-schistosomiasis, antiviral, and potential anti-neoplastic activities. Upon hydrolysis of artesunate's active endoperoxide bridge moiety by liberated heme in parasite-infected red blood cells, reactive oxygen species and carbon-centered radicals form, which have been shown to damage and kill parasitic organisms. Additionally, in vitro studies demonstrate that this agent induces DNA breakage in a dose-dependent manner. Artesunate has also been shown to stimulate cell differentiation, arrest the cell cycle in the G1 and G2/M phases, inhibit cell proliferation, and induce apoptosis through mitochondrial and caspase signaling pathways. Artemisinin is isolated from the plant Artemisia annua.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artesunate","termGroup":"PT","termSource":"NCI"},{"termName":"4-oxo-4-{[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy}butanoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"WR 256283","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88495-63-0"},{"name":"CHEBI_ID","value":"CHEBI:63918"},{"name":"Chemical_Formula","value":"C19H28O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"60W3249T9M"},{"name":"Legacy Concept Name","value":"Artesunate"},{"name":"Maps_To","value":"Artesunate"},{"name":"NCI_Drug_Dictionary_ID","value":"617258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617258"},{"name":"PDQ_Open_Trial_Search_ID","value":"617258"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052432"}]}}{"C131020":{"preferredName":"Arugula Seed Powder","code":"C131020","definitions":[{"definition":"A dietary supplement containing an extract powder derived from the seeds of the cruciferous vegetable arugula (Eruca sativa), with potential chemopreventive and antioxidant activities. Arugula seed powder contains numerous vitamins and minerals, and is rich in phytonutrients, such as sulforaphane and indole-3-carbinol. Although the exact mechanism of action through which arugula seed powder may exert its anti-tumor effect has yet to be fully elucidated, the effects of this powder on cancer cells may be attributable to the antioxidant and pro-apoptotic activities of the phytonutrients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arugula Seed Powder","termGroup":"PT","termSource":"NCI"},{"termName":"Eruca sativa Seed Powder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arugula Seed Powder"},{"name":"NCI_Drug_Dictionary_ID","value":"785258"},{"name":"NCI_META_CUI","value":"CL513823"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785258"},{"name":"PDQ_Open_Trial_Search_ID","value":"785258"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164317":{"preferredName":"Aryl Hydrocarbon Receptor Antagonist BAY2416964","code":"C164317","definitions":[{"definition":"An orally available formulation containing a small molecule antagonist of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76) with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR antagonist BAY2416964 specifically binds to AhR, inhibits AhR activation, and prevents AhR-mediated signaling. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, has important roles in regulating immunity and cellular differentiation. AhR can exhibit both pro-oncogenic and tumor suppressor-like functions depending on the tumor type; therefore, its expression may serve as a negative or positive prognostic factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aryl Hydrocarbon Receptor Antagonist BAY2416964","termGroup":"PT","termSource":"NCI"},{"termName":"AhR Antagonist BAY2416964","termGroup":"SY","termSource":"NCI"},{"termName":"AhR Inhibitor BAY2416964","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Inhibitor BAY2416964","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2416964","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2416964","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2416964","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aryl Hydrocarbon Receptor Antagonist BAY2416964"},{"name":"NCI_Drug_Dictionary_ID","value":"799706"},{"name":"NCI_META_CUI","value":"CL977437"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799706"},{"name":"PDQ_Open_Trial_Search_ID","value":"799706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1346":{"preferredName":"Asaley","code":"C1346","definitions":[{"definition":"An L-leucine derivative of melphalan with antineoplastic activity. Asaley alkylates and crosslinks DNA, resulting in disruption of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asaley","termGroup":"PT","termSource":"NCI"},{"termName":"Asalex","termGroup":"SY","termSource":"NCI"},{"termName":"ethyl ester of N-acetyl-DL-sarcolysyl-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"L-leucine, N-[N-acetyl-4-[bis(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"L-leucine, N-[N-acetyl-4-[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethylester","termGroup":"SN","termSource":"NCI"},{"termName":"leucine, N-[N-acetyl-3-[p-[bis(2-chloroethyl)amino]phenyl]-DL-alanyl]-, ethyl ester, L- (8CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Asaley"},{"name":"Maps_To","value":"Asaley"},{"name":"NCI_Drug_Dictionary_ID","value":"39151"},{"name":"NSC Number","value":"167780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39151"},{"name":"PDQ_Open_Trial_Search_ID","value":"39151"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064791"}]}}{"C114494":{"preferredName":"Asciminib","code":"C114494","definitions":[{"definition":"An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asciminib","termGroup":"PT","termSource":"NCI"},{"termName":"ABL 001","termGroup":"CN","termSource":"NCI"},{"termName":"ABL-001","termGroup":"CN","termSource":"NCI"},{"termName":"ABL001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1492952-76-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"L1F3R18W77"},{"name":"Maps_To","value":"Asciminib"},{"name":"NCI_META_CUI","value":"CL472320"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91073":{"preferredName":"Ascrinvacumab","code":"C91073","definitions":[{"definition":"A fully human, IgG2 monoclonal antibody directed against activin-like receptor kinase 1 (ALK-1) with potential antineoplastic activity. Ascrinvacumab binds to and neutralizes ALK-1. This may disrupt tumor endothelial cell function and inhibit tumor angiogenesis, eventually leading to an inhibition of tumor cell proliferation. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ascrinvacumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Activin Receptor-like Kinase 1 Monoclonal Antibody PF-03446962","termGroup":"SY","termSource":"NCI"},{"termName":"PF-03446962","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1463459-96-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"716FQ5REVO"},{"name":"Maps_To","value":"Ascrinvacumab"},{"name":"NCI_Drug_Dictionary_ID","value":"580797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580797"},{"name":"PDQ_Open_Trial_Search_ID","value":"580797"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984015"}]}}{"C77883":{"preferredName":"Ashwagandha Root Powder Extract","code":"C77883","definitions":[{"definition":"A dietary supplement containing an extract powder derived from the root of the ashwagandha shrub with potential antineoplastic, antioxidant, immunostimulating and anti-angiogenic activities. Ashwagandha root powder extract contains numerous alkaloids, including withanine as the primary alkaloid, and steroidal lactone withanolides. The withanolides in this agent may suppress nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene expression, potentiating apoptosis and inhibiting tumor cell invasion. Cultivated in India and North America, ashwagandha (Withania somnifera Dunal or Indian ginseng) belongs to the Solanaceae (nightshade) family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ashwagandha Root Powder Extract","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ashwagandha_Root_Powder_Extract"},{"name":"Maps_To","value":"Ashwagandha Root Powder Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"598859"},{"name":"NCI_META_CUI","value":"CL387179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598859"},{"name":"PDQ_Open_Trial_Search_ID","value":"598859"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122720":{"preferredName":"ASP4132","code":"C122720","definitions":[{"definition":"A molecule with potential antineoplastic activity. Upon oral administration, ASP4132 affects oxidative phosphorylation in mitochondria of metabolically-active tumor cells, which reduces both energy production and tumor cell proliferation. Mitochondrial oxidative phosphorylation is hyperactivated in tumor cells and plays a key role in the promotion of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASP4132","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ASP4132"},{"name":"NCI_Drug_Dictionary_ID","value":"770100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770100"},{"name":"PDQ_Open_Trial_Search_ID","value":"770100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055601"}]}}{"C286":{"preferredName":"Asparaginase","code":"C286","definitions":[{"definition":"A drug that is used to treat acute lymphoblastic leukemia (ALL) and is being studied in the treatment of some other types of cancer. It is an enzyme taken from the bacterium Escherichia coli (E. coli). It breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asparaginase","termGroup":"PT","termSource":"NCI"},{"termName":"ASP-1","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase II","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase-E.Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Colaspase","termGroup":"SY","termSource":"NCI"},{"termName":"Elspar","termGroup":"BR","termSource":"NCI"},{"termName":"Kidrolase","termGroup":"FB","termSource":"NCI"},{"termName":"L-Asnase","termGroup":"BR","termSource":"NCI"},{"termName":"L-ASP","termGroup":"AB","termSource":"NCI"},{"termName":"L-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"L-Asparagine Amidohydrolase","termGroup":"SY","termSource":"NCI"},{"termName":"Laspar","termGroup":"FB","termSource":"NCI"},{"termName":"Lcf-ASP","termGroup":"AB","termSource":"NCI"},{"termName":"Leucogen","termGroup":"FB","termSource":"NCI"},{"termName":"Leunase","termGroup":"FB","termSource":"NCI"},{"termName":"MK-965","termGroup":"CN","termSource":"NCI"},{"termName":"Paronal","termGroup":"FB","termSource":"NCI"},{"termName":"Re-82-TAD-15","termGroup":"CN","termSource":"NCI"},{"termName":"Serasa","termGroup":"FB","termSource":"NCI"},{"termName":"Spectrila","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute non-lymphocytic leukemia"},{"name":"CAS_Registry","value":"9015-68-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G4FQ3CKY5R"},{"name":"Legacy Concept Name","value":"Asparaginase"},{"name":"Maps_To","value":"Asparaginase"},{"name":"NCI_Drug_Dictionary_ID","value":"41146"},{"name":"NSC Number","value":"109229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41146"},{"name":"PDQ_Open_Trial_Search_ID","value":"41146"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0003993"}]}}{"C64260":{"preferredName":"Asparaginase Erwinia chrysanthemi","code":"C64260","definitions":[{"definition":"A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asparaginase Erwinia chrysanthemi","termGroup":"PT","termSource":"NCI"},{"termName":"Asparaginase Erwinia chrysanthemi (Recombinant)-rywn","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase Erwinia chrysanthemi, Recombinant-rywn","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase Erwinia chrysanthemi-rywn","termGroup":"SY","termSource":"NCI"},{"termName":"Crisantaspase","termGroup":"SY","termSource":"NCI"},{"termName":"Crisantaspase Biobetter JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Crisantaspasum","termGroup":"SY","termSource":"NCI"},{"termName":"Erwinase","termGroup":"FB","termSource":"NCI"},{"termName":"Erwinaze","termGroup":"BR","termSource":"NCI"},{"termName":"JZP 458","termGroup":"CN","termSource":"NCI"},{"termName":"JZP-458","termGroup":"CN","termSource":"NCI"},{"termName":"JZP458","termGroup":"CN","termSource":"NCI"},{"termName":"PF743","termGroup":"CN","termSource":"NCI"},{"termName":"RC-P JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Asparaginase erwinia chrysanthemi JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Crisantaspase JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Erwinia asparaginase JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Rylaze","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute non-lymphocytic leukemia"},{"name":"CAS_Registry","value":"9015-68-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D733ET3F9O"},{"name":"Legacy Concept Name","value":"Asparaginase-Erwinia"},{"name":"Maps_To","value":"Asparaginase Erwinia chrysanthemi"},{"name":"Maps_To","value":"Recombinant Erwinia asparaginase JZP-458"},{"name":"NCI_Drug_Dictionary_ID","value":"601044"},{"name":"NSC Number","value":"106977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601044"},{"name":"PDQ_Open_Trial_Search_ID","value":"601044"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771210"}]}}{"C165280":{"preferredName":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10","code":"C165280","definitions":[{"definition":"A radioimmunoconjugate composed of the anti-CD38 monoclonal antibody (MoAb) OKT10-B10 labeled with the alpha-emitting radionuclide astatine (At) 211 (211At), with potential antineoplastic activity. Upon administration of astatine At 211 anti-CD38 MoAb OKT10-B10, the MoAb moiety targets and binds to CD38-expressing tumor cells, thereby delivering a cytotoxic dose of alpha radiation directly to the CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein and tumor-associated antigen (TAA), is present on various immune cells and in hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10","termGroup":"PT","termSource":"NCI"},{"termName":"211At-OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"[211At]OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 Anti-CD38 MoAb OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine-211-OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"At211-OKT10-B10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10"},{"name":"NCI_Drug_Dictionary_ID","value":"799762"},{"name":"NCI_META_CUI","value":"CL978515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799762"},{"name":"PDQ_Open_Trial_Search_ID","value":"799762"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133190":{"preferredName":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","code":"C133190","definitions":[{"definition":"A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MAb) BC8 where the lysine side groups have been conjugated with decaborate (closo-decaborate; B10) and labeled with astatine (At) 211, with potential immunotherapeutic activity. Astatine At 211 anti-CD45 monoclonal antibody BC8-B10 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of alpha radiation. Additionally, the radiolabel can be leveraged to assay the biodistribution and/or pharmacokinetics (absorption, distribution, metabolism and excretion) for this agent. The use of B10 rather than other labeling methods increases the therapeutic efficacy while decreasing the toxicity of the radioconjugate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","termGroup":"PT","termSource":"NCI"},{"termName":"Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 MAb BC8-B10","termGroup":"SY","termSource":"NCI"},{"termName":"At 211 Anti-CD45 Monoclonal Antibody BC8-B10","termGroup":"SY","termSource":"NCI"},{"termName":"At 211 MAb BC8-B10","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3BVH1ZF9JX"},{"name":"Maps_To","value":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10"},{"name":"NCI_Drug_Dictionary_ID","value":"789457"},{"name":"NCI_META_CUI","value":"CL520581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789457"},{"name":"PDQ_Open_Trial_Search_ID","value":"789457"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78478":{"preferredName":"Astuprotimut-R","code":"C78478","definitions":[{"definition":"A cancer vaccine consisting of a recombinant form of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with potential immunostimulatory and antineoplastic activities. Upon administration, astuprotimut-R may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen (TAA) originally discovered in melanoma cells, is expressed by various tumor types. The proprietary immunostimulating adjuvant in this agent is composed of a specific combination of immunostimulating compounds selected to increase the anti-tumor immune response to MAGE-A3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astuprotimut-R","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1203486A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK1572932A","termGroup":"CN","termSource":"NCI"},{"termName":"Immunotherapeutic GSK1572932A","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant MAGE-A3 ASCI GSK1203486A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"949885-73-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"50I23C5UOR"},{"name":"Legacy Concept Name","value":"Recombinant_MAGE-A3_Antigen-Specific_Cancer_Immunotherapeutic_GSK1203486A"},{"name":"Maps_To","value":"Astuprotimut-R"},{"name":"Maps_To","value":"Immunotherapeutic GSK1572932A"},{"name":"NCI_Drug_Dictionary_ID","value":"600553"},{"name":"NCI_META_CUI","value":"CL414862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600553"},{"name":"PDQ_Open_Trial_Search_ID","value":"600553"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91758":{"preferredName":"Asulacrine","code":"C91758","definitions":[{"definition":"An amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asulacrine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Acridinecarboxamide,9-((2-methoxy-4-((methylsulfonyl)amino)phenyl)amino)-N,5-dimethyl","termGroup":"SN","termSource":"NCI"},{"termName":"Amsalog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80841-47-0"},{"name":"Chemical_Formula","value":"C24H24N4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S8P50T62B6"},{"name":"Legacy Concept Name","value":"CI-921"},{"name":"Maps_To","value":"Asulacrine"},{"name":"NSC Number","value":"343499"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1765331"}]}}{"C1050":{"preferredName":"Asulacrine Isethionate","code":"C1050","definitions":[{"definition":"The isethionate salt of an amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asulacrine Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"9-(2-Methoxy-4-(methylsulfonylamino)phenylamino)-N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"CI-921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80841-48-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"649R3P169I"},{"name":"Legacy Concept Name","value":"CI-921"},{"name":"Maps_To","value":"Asulacrine Isethionate"},{"name":"NCI_Drug_Dictionary_ID","value":"38943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38943"},{"name":"PDQ_Open_Trial_Search_ID","value":"38943"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0130561"}]}}{"C2490":{"preferredName":"At 211 Monoclonal Antibody 81C6","code":"C2490","definitions":[{"definition":"A radioimmunoconjugate of a human-murine chimeric IgG2 monoclonal antibody (MoAb) 81C6 labeled with an alpha-emitting radionuclide Astatine 211 (At-211), with imaging and radioimmunotherapeutic properties. MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), which is up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for At-211 results in the targeted imaging and/or destruction of cells expressing tenascin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"At 211 Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"Astatine 211 Conjugated 81C6 Anti-Tenascin Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 MOAB 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine-211 Labelled Anti-Tenascin Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"At_211_Monoclonal_Antibody_81C6"},{"name":"Maps_To","value":"At 211 Monoclonal Antibody 81C6"},{"name":"NCI_Drug_Dictionary_ID","value":"43148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43148"},{"name":"PDQ_Open_Trial_Search_ID","value":"43148"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796331"}]}}{"C1224":{"preferredName":"Atamestane","code":"C1224","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. Atamestane blocks the production of the hormone estrogen in the body. It belongs to the family of drugs called antiestrogens.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic steroidal substance with antineoplastic activity.  Atamestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atamestane","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96301-34-7"},{"name":"Chemical_Formula","value":"C20H26O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"62GA3K28B6"},{"name":"Legacy Concept Name","value":"Atamestane"},{"name":"Maps_To","value":"Atamestane"},{"name":"NCI_Drug_Dictionary_ID","value":"38195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38195"},{"name":"PDQ_Open_Trial_Search_ID","value":"38195"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074442"}]}}{"C106250":{"preferredName":"Atezolizumab","code":"C106250","definitions":[{"definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atezolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"MPDL 3280A","termGroup":"CN","termSource":"NCI"},{"termName":"MPDL 328OA","termGroup":"SY","termSource":"NCI"},{"termName":"MPDL-3280A","termGroup":"CN","termSource":"NCI"},{"termName":"MPDL3280A","termGroup":"CN","termSource":"NCI"},{"termName":"MPDL328OA","termGroup":"SY","termSource":"NCI"},{"termName":"RG7446","termGroup":"CN","termSource":"NCI"},{"termName":"RO5541267","termGroup":"CN","termSource":"NCI"},{"termName":"Tecentriq","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC); locally advanced or metastatic urothelial carcinoma; extensive-stage small cell lung cancer (ES-SCLC)"},{"name":"Accepted_Therapeutic_Use_For","value":"the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%]), with no EGFR or ALK genomic tumor aberrations."},{"name":"CAS_Registry","value":"1380723-44-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"52CMI0WC3Y"},{"name":"Maps_To","value":"Atezolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"702758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"702758"},{"name":"PDQ_Open_Trial_Search_ID","value":"702758"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827082"}]}}{"C52184":{"preferredName":"Atiprimod","code":"C52184","definitions":[{"definition":"A substance being studied in the treatment of certain multiple myelomas and other advanced cancers. SK&F106615 may block the growth of tumors and may prevent the growth of new blood vessels that tumors need to grow. SK&F106615 is a type of signal transduction inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic properties. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atiprimod","termGroup":"PT","termSource":"NCI"},{"termName":"Azaspirane SK&F106615","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine","termGroup":"SN","termSource":"NCI"},{"termName":"SK&F106615","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123018-47-3"},{"name":"Chemical_Formula","value":"C22H44N2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MG7D3QD743"},{"name":"Legacy Concept Name","value":"Atiprimod"},{"name":"Maps_To","value":"Atiprimod"},{"name":"NCI_Drug_Dictionary_ID","value":"382134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"382134"},{"name":"PDQ_Open_Trial_Search_ID","value":"382134"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1579206"}]}}{"C76969":{"preferredName":"Atiprimod Dihydrochloride","code":"C76969","definitions":[{"definition":"The dihydrochloride salt form of atiprimod, an orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and anti-angiogenic activities. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and AKT, blocking the signaling pathways of interleukin-6, vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. This results in the inhibition of cell proliferation, induction of cell cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atiprimod Dihydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130065-61-1"},{"name":"Chemical_Formula","value":"C22H44N2.2ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O12I24570R"},{"name":"Legacy Concept Name","value":"Atiprimod_Dihydrochloride"},{"name":"Maps_To","value":"Atiprimod Dihydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698190"}]}}{"C76970":{"preferredName":"Atiprimod Dimaleate","code":"C76970","definitions":[{"definition":"The dimaleate salt form of atiprimod, an orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic activities. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and AKT, blocking the signaling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. This results in the inhibition of cell proliferation, induction of cell cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atiprimod Dimaleate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183063-72-1"},{"name":"Chemical_Formula","value":"C22H44N2.2C4H4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YNU265SSR3"},{"name":"Legacy Concept Name","value":"Atiprimod_Dimaleate"},{"name":"Maps_To","value":"Atiprimod Dimaleate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698191"}]}}{"C138076":{"preferredName":"ATM Inhibitor M 3541","code":"C138076","definitions":[{"definition":"An orally bioavailable inhibitor of ataxia telangiectasia mutated kinase (ATM), with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, M 3541 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, M 3541 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Inhibitor M 3541","termGroup":"PT","termSource":"NCI"},{"termName":"Ataxia Telangiectasia Mutated Kinase Inhibitor M 3541","termGroup":"SY","termSource":"NCI"},{"termName":"M 3541","termGroup":"CN","termSource":"NCI"},{"termName":"M3541","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ATM Inhibitor M 3541"},{"name":"NCI_Drug_Dictionary_ID","value":"790665"},{"name":"NCI_META_CUI","value":"CL525064"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790665"},{"name":"PDQ_Open_Trial_Search_ID","value":"790665"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124648":{"preferredName":"ATM Kinase Inhibitor AZD0156","code":"C124648","definitions":[{"definition":"An orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, AZD0156 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, AZD0156 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Kinase Inhibitor AZD0156","termGroup":"PT","termSource":"NCI"},{"termName":"AZD0156","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1821428-35-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P5T0XWC07Z"},{"name":"Maps_To","value":"ATM Kinase Inhibitor AZD0156"},{"name":"NCI_Drug_Dictionary_ID","value":"776772"},{"name":"NCI_META_CUI","value":"CL502880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776772"},{"name":"PDQ_Open_Trial_Search_ID","value":"776772"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150167":{"preferredName":"ATM Kinase Inhibitor AZD1390","code":"C150167","definitions":[{"definition":"An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death in ATM-overexpressing tumor cells. AZD1390 hypersensitizes tumors to chemo/radiotherapy. In addition, AZD1390 is able to cross the blood-brain barrier (BBB). ATM, a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family of protein kinases, is upregulated in a variety of cancer cell types. It is activated in response to DNA double-strand breaks (DSB) and plays a key role in DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Kinase Inhibitor AZD1390","termGroup":"PT","termSource":"NCI"},{"termName":"7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-1390","termGroup":"CN","termSource":"NCI"},{"termName":"AZD1390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2089288-03-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CI43QFE22O"},{"name":"Maps_To","value":"ATM Kinase Inhibitor AZD1390"},{"name":"NCI_Drug_Dictionary_ID","value":"804166"},{"name":"NCI_META_CUI","value":"CL552001"},{"name":"PDQ_Closed_Trial_Search_ID","value":"804166"},{"name":"PDQ_Open_Trial_Search_ID","value":"804166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28837":{"preferredName":"Atorvastatin Calcium","code":"C28837","definitions":[{"definition":"A drug used to lower the amount of cholesterol in the blood and to prevent stroke, heart attack, and angina (chest pain). It is also being studied in the prevention and treatment of some types of cancer and other conditions. Atorvastatin calcium blocks an enzyme that helps make cholesterol in the body. It also causes an increase in the breakdown of cholesterol. It is a type of HMG-CoA reductase inhibitor and a type of statin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atorvastatin Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"CI-981","termGroup":"CN","termSource":"NCI"},{"termName":"Lipitor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134523-03-8"},{"name":"CAS_Registry","value":"344423-98-9"},{"name":"CHEBI_ID","value":"CHEBI:2911"},{"name":"Chemical_Formula","value":"2C33H34FN2O5.Ca.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48A5M73Z4Q"},{"name":"Legacy Concept Name","value":"Atorvastatin"},{"name":"Maps_To","value":"Atorvastatin Calcium"},{"name":"NCI_Drug_Dictionary_ID","value":"460239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"460239"},{"name":"PDQ_Open_Trial_Search_ID","value":"460239"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286650"}]}}{"C78676":{"preferredName":"Atorvastatin Sodium","code":"C78676","definitions":[{"definition":"The sodium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atorvastatin Sodium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134523-01-6"},{"name":"Chemical_Formula","value":"C33H34FN2O5.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DN43058TIV"},{"name":"Legacy Concept Name","value":"Atorvastatin_Sodium"},{"name":"Maps_To","value":"Atorvastatin Sodium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698196"}]}}{"C146807":{"preferredName":"Elimusertib","code":"C146807","definitions":[{"definition":"An orally available ataxia telangiectasia and Rad3-related (ATR)-specific kinase inhibitor, with potential antineoplastic activity. Upon oral administration, elimusertib selectively binds to and inhibits the activity of ATR, which prevents ATR-mediated signaling. This inhibits DNA damage checkpoint activation, disrupts DNA damage repair and induces apoptosis in ATR-overexpressing tumor cells. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elimusertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATR Inhibitor BAY1895344","termGroup":"SY","termSource":"NCI"},{"termName":"ATR Kinase Inhibitor BAY1895344","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1895344","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1895344","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1895344","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1876467-74-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7N13IK9LNH"},{"name":"Maps_To","value":"ATR Kinase Inhibitor BAY1895344"},{"name":"NCI_Drug_Dictionary_ID","value":"792166"},{"name":"NCI_META_CUI","value":"CL544748"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792166"},{"name":"PDQ_Open_Trial_Search_ID","value":"792166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116355":{"preferredName":"Berzosertib","code":"C116355","definitions":[{"definition":"An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. Upon administration, berzosertib selectively binds to and inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Berzosertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"M 6620","termGroup":"CN","termSource":"NCI"},{"termName":"M6620","termGroup":"CN","termSource":"NCI"},{"termName":"VX 970","termGroup":"CN","termSource":"NCI"},{"termName":"VX-970","termGroup":"CN","termSource":"NCI"},{"termName":"VX970","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1232416-25-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L423PRV3V3"},{"name":"Maps_To","value":"ATR Kinase Inhibitor M6620"},{"name":"Maps_To","value":"Berzosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"761970"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761970"},{"name":"PDQ_Open_Trial_Search_ID","value":"761970"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896746"}]}}{"C129693":{"preferredName":"Gartisertib","code":"C129693","definitions":[{"definition":"An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration,gartisertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gartisertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATR Kinase Inhibitor VX-803","termGroup":"SY","termSource":"NCI"},{"termName":"M 4344","termGroup":"CN","termSource":"NCI"},{"termName":"M-4344","termGroup":"CN","termSource":"NCI"},{"termName":"M4344","termGroup":"CN","termSource":"NCI"},{"termName":"VX 803","termGroup":"CN","termSource":"NCI"},{"termName":"VX-803","termGroup":"CN","termSource":"NCI"},{"termName":"VX803","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1613191-99-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7OM98IUD1O"},{"name":"Maps_To","value":"ATR Kinase Inhibitor VX-803"},{"name":"NCI_Drug_Dictionary_ID","value":"802157"},{"name":"NCI_META_CUI","value":"CL507788"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802157"},{"name":"PDQ_Open_Trial_Search_ID","value":"802157"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1779":{"preferredName":"Atrasentan Hydrochloride","code":"C1779","definitions":[{"definition":"The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity.  As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atrasentan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-A 127722","termGroup":"CN","termSource":"NCI"},{"termName":"(2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ABT-627","termGroup":"CN","termSource":"NCI"},{"termName":"Xinlay","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195733-43-8"},{"name":"Chemical_Formula","value":"C29H38N2O6.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E4G31X93ZA"},{"name":"Legacy Concept Name","value":"Atrasentan"},{"name":"Maps_To","value":"Atrasentan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38333"},{"name":"NSC Number","value":"720763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38333"},{"name":"PDQ_Open_Trial_Search_ID","value":"38333"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0387926"}]}}{"C62409":{"preferredName":"Attenuated Listeria monocytogenes ANZ-100","code":"C62409","definitions":[{"definition":"A live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, attenuated Listeria monocytogenes ANZ-100 may accumulate in and infect liver cells where it may activate a potent innate immune response and an adaptive immune response involving the by recruitment and activation of T lymphocytes. This agent may potentiate the immune response to vaccines against various liver neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Attenuated Listeria monocytogenes ANZ-100","termGroup":"PT","termSource":"NCI"},{"termName":"ANZ 100","termGroup":"CN","termSource":"NCI"},{"termName":"ANZ-100","termGroup":"CN","termSource":"NCI"},{"termName":"ANZ100","termGroup":"CN","termSource":"NCI"},{"termName":"CRS-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7UKM1TA46L"},{"name":"Legacy Concept Name","value":"CRS-100"},{"name":"Maps_To","value":"Attenuated Listeria monocytogenes CRS-100"},{"name":"NCI_Drug_Dictionary_ID","value":"487160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487160"},{"name":"PDQ_Open_Trial_Search_ID","value":"487160"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"UMLS_CUI","value":"C1831855"}]}}{"C74595":{"preferredName":"Axalimogene Filolisbac","code":"C74595","definitions":[{"definition":"A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axalimogene Filolisbac","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS11-001","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS11-001 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Attenuated Live Listeria Encoding HPV 16 E7 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Attenuated Live Listeria Encoding Human Papilloma Virus 16 E7 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Lm-LLO-E7","termGroup":"SY","termSource":"NCI"},{"termName":"Lovaxin-C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1587258-09-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NY7PTD1862"},{"name":"Legacy Concept Name","value":"Attenuated_Live_Listeria_Encoding_HPV_16_E7_Vaccine"},{"name":"Maps_To","value":"Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001"},{"name":"Maps_To","value":"Axalimogene Filolisbac"},{"name":"NCI_Drug_Dictionary_ID","value":"673240"},{"name":"NCI_META_CUI","value":"CL384120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673240"},{"name":"PDQ_Open_Trial_Search_ID","value":"673240"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C65242":{"preferredName":"Auranofin","code":"C65242","definitions":[{"definition":"An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Auranofin","termGroup":"PT","termSource":"NCI"},{"termName":"Ridaura","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"34031-32-8"},{"name":"CHEBI_ID","value":"CHEBI:2922"},{"name":"Chemical_Formula","value":"C20H34AuO9PS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3H04W2810V"},{"name":"Legacy Concept Name","value":"Auranofin"},{"name":"Maps_To","value":"Auranofin"},{"name":"NCI_Drug_Dictionary_ID","value":"710355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710355"},{"name":"PDQ_Open_Trial_Search_ID","value":"710355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699923"}]}}{"C148501":{"preferredName":"Aurora A Kinase Inhibitor LY3295668","code":"C148501","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor LY3295668","termGroup":"PT","termSource":"NCI"},{"termName":"AK 01","termGroup":"CN","termSource":"NCI"},{"termName":"AK-01","termGroup":"CN","termSource":"NCI"},{"termName":"LY 3295668","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3295668","termGroup":"CN","termSource":"NCI"},{"termName":"LY3295668","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1919888-06-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1WX8O5XV4R"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor LY3295668"},{"name":"NCI_Drug_Dictionary_ID","value":"792635"},{"name":"NCI_META_CUI","value":"CL551041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792635"},{"name":"PDQ_Open_Trial_Search_ID","value":"792635"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165238":{"preferredName":"Aurora A Kinase Inhibitor LY3295668 Erbumine","code":"C165238","definitions":[{"definition":"The tert-butylamine salt form of LY3295668, an orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor LY3295668 Erbumine","termGroup":"PT","termSource":"NCI"},{"termName":"AK-01 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"Aurora Kinase A Inhibitor LY3295668 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3295668 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"LY-3295668 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"LY3295668 Erbumine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor LY3295668 Erbumine"},{"name":"NCI_Drug_Dictionary_ID","value":"792635"},{"name":"NCI_META_CUI","value":"CL978388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792635"},{"name":"PDQ_Open_Trial_Search_ID","value":"792635"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90585":{"preferredName":"Aurora A Kinase Inhibitor MK5108","code":"C90585","definitions":[{"definition":"An orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A, with potential antimitotic and antineoplastic activity. Aurora A kinase inhibitor MK5108 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and eventually inhibition of cell division, proliferation and an induction of apoptosis in cells overexpressing Aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aurora kinases are overexpressed in a wide variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor MK5108","termGroup":"PT","termSource":"NCI"},{"termName":"MK 5108","termGroup":"CN","termSource":"NCI"},{"termName":"MK-5108","termGroup":"CN","termSource":"NCI"},{"termName":"MK5108","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1010085-13-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H8J407531S"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor MK5108"},{"name":"NCI_Drug_Dictionary_ID","value":"575529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575529"},{"name":"PDQ_Open_Trial_Search_ID","value":"575529"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2932550"}]}}{"C116068":{"preferredName":"Aurora A Kinase Inhibitor VIC-1911","code":"C116068","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon intravenous administration, aurora A kinase inhibitor VIC-1911 binds to and inhibits aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis; it plays an essential role in the regulation of spindle assembly. Aurora kinase A is overexpressed in a wide variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor VIC-1911","termGroup":"PT","termSource":"NCI"},{"termName":"Aurora A Kinase Inhibitor TAS-119","termGroup":"SY","termSource":"NCI"},{"termName":"TAS-119","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-2104","termGroup":"CN","termSource":"NCI"},{"termName":"VIC 1911","termGroup":"CN","termSource":"NCI"},{"termName":"VIC-1911","termGroup":"CN","termSource":"NCI"},{"termName":"VIC1911","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor TAS-119"},{"name":"NCI_Drug_Dictionary_ID","value":"760907"},{"name":"NCI_META_CUI","value":"CL473487"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760907"},{"name":"PDQ_Open_Trial_Search_ID","value":"760907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78190":{"preferredName":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076","code":"C78190","definitions":[{"definition":"An orally bioavailable synthetic small molecule with potential antiangiogenic and antineoplastic activities. Aurora A kinase/tyrosine kinase inhibitor ENMD-2076 selectively binds to and inhibits non-specified tyrosine kinases and Aurora kinases (AKs). The inhibition of AKs may result in the inhibition of cell division and proliferation and may induce apoptosis in tumor cells that overexpress AKs; antiangiogenic activity is related to the inhibition of angiogenic tyrosine kinases. AKs are serine-threonine kinases that play an essential role in mitotic checkpoint control during mitosis and are important regulators of cell division and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076","termGroup":"PT","termSource":"NCI"},{"termName":"ENMD-2076","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453868-32-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KXQ762CQTH"},{"name":"Legacy Concept Name","value":"Aurora_A_Kinase_Tyrosine_Kinase_Inhibitor_ENMD-2076"},{"name":"Maps_To","value":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076"},{"name":"NCI_Drug_Dictionary_ID","value":"594863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594863"},{"name":"PDQ_Open_Trial_Search_ID","value":"594863"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703108"}]}}{"C82674":{"preferredName":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901","code":"C82674","definitions":[{"definition":"A small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B kinase inhibitor TAK-901 binds to and inhibits the activity of Aurora B, which may result in a decrease in the proliferation of tumor cells that overexpress Aurora B. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere; the segregation of sister chromatids to each daughter cell; and the separation of daughter cells during cytokinesis. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901","termGroup":"PT","termSource":"NCI"},{"termName":"TAK-901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934541-31-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DM9UIR23R7"},{"name":"Legacy Concept Name","value":"Aurora_B_Serine_Threonine_Kinase_Inhibitor_TAK-901"},{"name":"Maps_To","value":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901"},{"name":"NCI_Drug_Dictionary_ID","value":"632219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632219"},{"name":"PDQ_Open_Trial_Search_ID","value":"632219"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2826371"}]}}{"C91081":{"preferredName":"Aurora B/C Kinase Inhibitor GSK1070916A","code":"C91081","definitions":[{"definition":"An ATP-competitive inhibitor of the serine/threonine kinases Aurora B and C with potential antineoplastic activity. Aurora B/C kinase inhibitor GSK1070916A binds to and inhibits the activity of Aurora B and C, which may result in inhibition of cellular division and a decrease in the proliferation of tumor cells that overexpress the Aurora kinases B and C. Aurora kinases play essential roles in mitotic checkpoint control during mitosis, and are overexpressed by a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora B/C Kinase Inhibitor GSK1070916A","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1070916A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora B/C Kinase Inhibitor GSK1070916A"},{"name":"NCI_Drug_Dictionary_ID","value":"670668"},{"name":"NCI_META_CUI","value":"CL416287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670668"},{"name":"PDQ_Open_Trial_Search_ID","value":"670668"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162532":{"preferredName":"Tinengotinib","code":"C162532","definitions":[{"definition":"An orally available small molecule inhibitor of Aurora kinases (AKs) A and B, Janus kinases (JAKs), fibroblast growth factor receptors (FGFRs) and vascular endothelial growth factor receptors (VEGFRs), with potential antineoplastic and immunomodulatory activities. Upon oral administration, tinengotinib selectively binds to and inhibits AKs A and B, which inhibit cell division in tumor cells that overexpress AKs. Tinengotinib also targets JAKs that are involved in cytokine signaling and inflammation, and FGFRs and VEGFRs, which  are overexpressed in the microenvironment (TME) and contribute to neovascularization, tumor growth and metastasis.  These kinases are overexpressed by a wide variety of cancer cell types and drive tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinengotinib","termGroup":"PT","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor TT-00420","termGroup":"SY","termSource":"NCI"},{"termName":"Multi-target Kinase Inhibitor TT-00420","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Kinase Inhibitor TT-00420","termGroup":"SY","termSource":"NCI"},{"termName":"TT 00420","termGroup":"CN","termSource":"NCI"},{"termName":"TT-00420","termGroup":"CN","termSource":"NCI"},{"termName":"TT00420","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230490-29-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WZ9TJ0L9Y8"},{"name":"Maps_To","value":"Aurora kinase A/B inhibitor TT-00420"},{"name":"NCI_Drug_Dictionary_ID","value":"798739"},{"name":"NCI_META_CUI","value":"CL971116"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798739"},{"name":"PDQ_Open_Trial_Search_ID","value":"798739"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82349":{"preferredName":"Aurora Kinase Inhibitor AMG 900","code":"C82349","definitions":[{"definition":"A small-molecule inhibitor of Aurora kinases A, B and C with potential antineoplastic activity. Aurora kinase inhibitor AMG 900 selectively binds to and inhibits the activities of Aurora kinases A, B and C, which may result in inhibition of cellular division and proliferation in tumor cells that overexpress these kinases. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis and are overexpressed by a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor AMG 900","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 900","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945595-80-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9R2G075611"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_Inhibitor_AMG_900"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor AMG 900"},{"name":"NCI_Drug_Dictionary_ID","value":"639524"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639524"},{"name":"PDQ_Open_Trial_Search_ID","value":"639524"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830045"}]}}{"C74014":{"preferredName":"Aurora Kinase Inhibitor BI 811283","code":"C74014","definitions":[{"definition":"A small molecule inhibitor of the serine/threonine protein kinase Aurora kinase with potential antineoplastic activity. Aurora kinase inhibitor BI 811283 binds to and inhibits Aurora kinases, resulting in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor BI 811283","termGroup":"PT","termSource":"NCI"},{"termName":"BI 811283","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_Inhibitor_BI_811283"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor BI 811283"},{"name":"NCI_Drug_Dictionary_ID","value":"590640"},{"name":"NCI_META_CUI","value":"CL383543"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590640"},{"name":"PDQ_Open_Trial_Search_ID","value":"590640"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61075":{"preferredName":"Aurora Kinase Inhibitor MLN8054","code":"C61075","definitions":[{"definition":"An orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Auora kinase inhibitor MLN8054 binds to and inhibits Aurora kinase A, resulting in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A localizes in mitosis to the spindle poles and to spindle microtubules and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor MLN8054","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic Acid, 4-((9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"MLN 8054","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-8054","termGroup":"CN","termSource":"NCI"},{"termName":"MLN8054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"869363-13-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BX854EHD63"},{"name":"Legacy Concept Name","value":"MLN8054"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor MLN8054"},{"name":"NCI_Drug_Dictionary_ID","value":"473901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473901"},{"name":"PDQ_Open_Trial_Search_ID","value":"473901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831780"}]}}{"C66946":{"preferredName":"Aurora Kinase Inhibitor PF-03814735","code":"C66946","definitions":[{"definition":"An aurora kinase inhibitor with potential antineoplastic activity. PF-03814735 binds to and inhibits aurora kinases, serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of aurora kinases may result in an inhibition of cellular division and proliferation in tumor cells that overexpress aurora kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor PF-03814735","termGroup":"PT","termSource":"NCI"},{"termName":"PF-03814735","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"942487-16-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6V5T4O5758"},{"name":"Legacy Concept Name","value":"PF-03814735"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor PF-03814735"},{"name":"NCI_Drug_Dictionary_ID","value":"536035"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536035"},{"name":"PDQ_Open_Trial_Search_ID","value":"536035"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882256"}]}}{"C70655":{"preferredName":"Aurora Kinase Inhibitor SNS-314","code":"C70655","definitions":[{"definition":"A synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively binds to and inhibits AKs A and B, which may result in the inhibition of cellular division and proliferation in tumor cells that overexpress AKs. AKs are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor SNS-314","termGroup":"PT","termSource":"NCI"},{"termName":"SNS-314","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1057249-41-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"802IFJ0Z8X"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_Inhibitor_SNS-314"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor SNS-314"},{"name":"NCI_Drug_Dictionary_ID","value":"570599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570599"},{"name":"PDQ_Open_Trial_Search_ID","value":"570599"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346877"}]}}{"C84846":{"preferredName":"Aurora Kinase Inhibitor TTP607","code":"C84846","definitions":[{"definition":"A small-molecule pan-Aurora kinase inhibitor with potential antineoplastic activity. Aurora kinase inhibitor TTP607 selectively binds to and inhibits Aurora kinases A, B and C, which may result in the disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cellular division and proliferation in Aurora kinase-overexpressing tumor cells. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor TTP607","termGroup":"PT","termSource":"NCI"},{"termName":"TTP607","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor TTP607"},{"name":"NCI_Drug_Dictionary_ID","value":"650689"},{"name":"NCI_META_CUI","value":"CL412399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650689"},{"name":"PDQ_Open_Trial_Search_ID","value":"650689"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70983":{"preferredName":"Aurora Kinase/VEGFR2 Inhibitor CYC116","code":"C70983","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It blocks certain enzymes involved in cell division and may kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of protein kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule multi-kinase inhibitor with antineoplastic activity. Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis. Aurora kinases are serine/threonine protein kinases that are only expressed in actively dividing cells and are critical in division or mitosis. VEGFR2 is a receptor tyrosine kinase that appears to account for most of the mitogenic and chemotactic effects of vascular endothelial growth factor (VEGF) on adult endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase/VEGFR2 Inhibitor CYC116","termGroup":"PT","termSource":"NCI"},{"termName":"CYC116","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_VEGFR2_Inhibitor_CYC116"},{"name":"Maps_To","value":"Aurora Kinase/VEGFR2 Inhibitor CYC116"},{"name":"NCI_Drug_Dictionary_ID","value":"566443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"566443"},{"name":"PDQ_Open_Trial_Search_ID","value":"566443"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346878"}]}}{"C139730":{"preferredName":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707","code":"C139730","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified, using proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, to express a chimeric protein containing, at least, the extracellular Fc receptor domain of CD16, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-stimulatory signaling domain of CD28, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient with co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, the autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707 bind to the antibody, become activated and induce the destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; c) targeting and killing adjacent tumor cells that are not bound to the antibody; d) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. Compared to other T-cell products, ACTR-based products do not target a specific TAA and can potentially be used in a variety of tumors because targeting is based on the specificity of the co-administered antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707","termGroup":"PT","termSource":"NCI"},{"termName":"ACTR707","termGroup":"AB","termSource":"NCI"},{"termName":"ACTR707 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ACTR707 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707"},{"name":"NCI_Drug_Dictionary_ID","value":"791109"},{"name":"NCI_META_CUI","value":"CL537915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791109"},{"name":"PDQ_Open_Trial_Search_ID","value":"791109"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155883":{"preferredName":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585","code":"C155883","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused, via an as of yet unknown linker, to the co-stimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA CAR transduced T-cells KITE-585 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. The CD28 co-stimulatory domain optimizes T-cell expansion and function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Genetically Modified Anti-BCMA CAR-T Cells KITE-585","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified Anti-BCMA CAR-transduced T-cells KITE-585","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cells KITE-585","termGroup":"SY","termSource":"NCI"},{"termName":"KITE 585","termGroup":"CN","termSource":"NCI"},{"termName":"KITE-585","termGroup":"CN","termSource":"NCI"},{"termName":"KITE585","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585"},{"name":"NCI_Drug_Dictionary_ID","value":"794792"},{"name":"NCI_META_CUI","value":"CL562701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794792"},{"name":"PDQ_Open_Trial_Search_ID","value":"794792"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142864":{"preferredName":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101","code":"C142864","definitions":[{"definition":"A preparation consisting of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac) containing an undisclosed selection gene and encoding both an unidentified human-derived safety switch and a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing Tscm P-BCMA-101 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than agents based on antibody-derived single chain variable fragments (scFv), and this agent may exhibit increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can induce the rapid attenuation or elimination of P-BCMA-101. BCMA, a tumor-specific antigen and a member of the tumor necrosis factor receptor superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13) and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA Centyrin-based Chimeric Antigen Receptor-expressing Tscm","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous P-BCMA-101 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous P-BCMA-101 CAR-T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous P-BCMA-101 CARTyrin-T cells","termGroup":"SY","termSource":"NCI"},{"termName":"P-BCMA-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101"},{"name":"NCI_Drug_Dictionary_ID","value":"791806"},{"name":"NCI_META_CUI","value":"CL540755"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791806"},{"name":"PDQ_Open_Trial_Search_ID","value":"791806"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147523":{"preferredName":"Orvacabtagene Autoleucel","code":"C147523","definitions":[{"definition":"A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orvacabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA CAR-T Cells JCARH 125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA 41BBz CAR-T Cell JCARH-125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA-specific CAR-T Cells JCARH125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA-specific CAR4-1BB-CD3zeta-expressing CD4+/CD8+ T Lymphocytes JCARH 125","termGroup":"SY","termSource":"NCI"},{"termName":"JCARH 125","termGroup":"CN","termSource":"NCI"},{"termName":"JCARH-125","termGroup":"CN","termSource":"NCI"},{"termName":"JCARH125","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K8RW1TW3EM"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125"},{"name":"Maps_To","value":"Orvacabtagene Autoleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"792482"},{"name":"NCI_META_CUI","value":"CL545333"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792482"},{"name":"PDQ_Open_Trial_Search_ID","value":"792482"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C140310":{"preferredName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217","code":"C140310","definitions":[{"definition":"A preparation of autologous memory T-lymphocytes transduced, ex vivo, with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-B-cell maturation antigen (BCMA) single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137) and a CD3-zeta T-cell activation domain, with potential immunostimulating and antineoplastic activities. Upon intravenous administration back into the patient, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing memory T-lymphocytes bb21217 are directed to, and induce selective toxicity in, BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival. BCMA is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-Cells bb21217","termGroup":"SY","termSource":"NCI"},{"termName":"BB 21217","termGroup":"CN","termSource":"NCI"},{"termName":"bb-21217","termGroup":"CN","termSource":"NCI"},{"termName":"bb21217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217"},{"name":"NCI_Drug_Dictionary_ID","value":"791258"},{"name":"NCI_META_CUI","value":"CL538477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791258"},{"name":"PDQ_Open_Trial_Search_ID","value":"791258"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165507":{"preferredName":"Zevorcabtagene Autoleucel","code":"C165507","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a humanized single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, zevorcabtagene autoleucel specifically recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zevorcabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA-CAR-41BB-CD3zeta-expressing T-cells CT053","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA Car-T (CT053)","termGroup":"SY","termSource":"NCI"},{"termName":"CAR-BCMA T-cells CT053","termGroup":"SY","termSource":"NCI"},{"termName":"CT 053","termGroup":"CN","termSource":"NCI"},{"termName":"CT-053","termGroup":"CN","termSource":"NCI"},{"termName":"CT053","termGroup":"CN","termSource":"NCI"},{"termName":"CT053 CAR-BCMA T","termGroup":"SY","termSource":"NCI"},{"termName":"CT053 CAR-BCMA T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GMV2GFP3G2"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053"},{"name":"NCI_Drug_Dictionary_ID","value":"799961"},{"name":"NCI_META_CUI","value":"CL978697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799961"},{"name":"PDQ_Open_Trial_Search_ID","value":"799961"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142807":{"preferredName":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143","code":"C142807","definitions":[{"definition":"A preparation of ex vivo expanded autologous CD8+ and CD4+ T-cells that have been genetically modified to express a chimeric antigen receptor (CAR) specific for human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR CD4+/CD8+ Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-expressing CD8+ and CD4+ T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA CAR-CD4+/CD8+ T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-specific CAR-expressing CD4+/CD8+ T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"FCARH143","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143"},{"name":"NCI_Drug_Dictionary_ID","value":"794992"},{"name":"NCI_META_CUI","value":"CL540710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794992"},{"name":"PDQ_Open_Trial_Search_ID","value":"794992"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155888":{"preferredName":"Autologous Anti-CD19 CAR T-cells IM19","code":"C155888","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells IM19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR T-cells IM19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells IM19","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-specific CAR-T Cells IM19","termGroup":"SY","termSource":"NCI"},{"termName":"IM19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR T-cells IM19"},{"name":"NCI_Drug_Dictionary_ID","value":"794869"},{"name":"NCI_META_CUI","value":"CL562698"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794869"},{"name":"PDQ_Open_Trial_Search_ID","value":"794869"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156271":{"preferredName":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19","code":"C156271","definitions":[{"definition":"Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a humanized single chain variable fragment (scFv) of anti-CD19 coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta) and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon re-introduction into the patient, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, resulting in tumor cell lysis. CD19 (cluster of differentiation 19) is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the co-stimulatory signaling domains increases human T-cell function, expansion, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 CAR-T Cells huCART19","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 Humanized scFv TCRz-41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells huCART19","termGroup":"SY","termSource":"NCI"},{"termName":"CTL119","termGroup":"CN","termSource":"NCI"},{"termName":"CTL119 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"huCART19 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"huCART19 T-lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19"},{"name":"NCI_Drug_Dictionary_ID","value":"795543"},{"name":"NCI_META_CUI","value":"CL562996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795543"},{"name":"PDQ_Open_Trial_Search_ID","value":"795543"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162856":{"preferredName":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002","code":"C162856","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD28 T-cells ET019002 target, bind to, and induce selective toxicity in CD19-expressing B-cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 Autologous CAR T-cells ET019002","termGroup":"SY","termSource":"NCI"},{"termName":"ET019002-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002"},{"name":"NCI_Drug_Dictionary_ID","value":"798902"},{"name":"NCI_Drug_Dictionary_ID","value":"813320"},{"name":"NCI_META_CUI","value":"CL973342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798902"},{"name":"PDQ_Open_Trial_Search_ID","value":"798902"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153118":{"preferredName":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01","code":"C153118","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domains of 4-1BB (CD137) and the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01 target, bind to, and induce selective toxicity in CD19-expressing B cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD19-specific CAR-T cells PZ01","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PZ01 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"PZ01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01"},{"name":"NCI_Drug_Dictionary_ID","value":"793588"},{"name":"NCI_META_CUI","value":"CL554376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793588"},{"name":"PDQ_Open_Trial_Search_ID","value":"793588"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158604":{"preferredName":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901","code":"C158604","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T-lymphocytes CLIC-1901 bind to and induce selective toxicity against CD19-expressing tumor cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CLIC-1901 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CLIC 1901","termGroup":"CN","termSource":"NCI"},{"termName":"CLIC-1901","termGroup":"CN","termSource":"NCI"},{"termName":"CLIC1901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901"},{"name":"NCI_Drug_Dictionary_ID","value":"797095"},{"name":"NCI_META_CUI","value":"CL938077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797095"},{"name":"PDQ_Open_Trial_Search_ID","value":"797095"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142887":{"preferredName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19","code":"C142887","definitions":[{"definition":"A proprietary preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells SJCAR19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells SJCAR19","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CART Cells SJCAR19","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-specific CAR-T Cells SJCAR19","termGroup":"SY","termSource":"NCI"},{"termName":"SJCAR19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19"},{"name":"NCI_Drug_Dictionary_ID","value":"791828"},{"name":"NCI_META_CUI","value":"CL541378"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791828"},{"name":"PDQ_Open_Trial_Search_ID","value":"791828"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148030":{"preferredName":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1","code":"C148030","definitions":[{"definition":"Autologous human peripheral blood T-lymphocytes transduced with a lentivirus encoding a proprietary expression construct composed of a T-cell receptor (TCR)-like human antibody, which is synthesized by a proprietary phage display platform, targeting peptides derived from the tumor-associated antigen (TAA) CD19 that are presented in the context of major histocompatibility complex (MHC) molecules, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the autologous anti-CD19 TCR T-cells ET190L1 target and bind to tumor cells expressing CD19 peptide/MHC complexes. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. CD19, cluster of differentiation antigen 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. ET190L1 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells; however, ET190L1 is less likely to stimulate cytokine release syndrome (CRS) and does not cause CAR T-cell-triggered neurotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1","termGroup":"PT","termSource":"NCI"},{"termName":"ET 190","termGroup":"CN","termSource":"NCI"},{"termName":"ET190","termGroup":"CN","termSource":"NCI"},{"termName":"ET190L1","termGroup":"CN","termSource":"NCI"},{"termName":"ET190L1-ARTEMIS (TM)","termGroup":"SY","termSource":"NCI"},{"termName":"ET190L1-ARTEMIS (TM) T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1"},{"name":"NCI_Drug_Dictionary_ID","value":"794393"},{"name":"NCI_META_CUI","value":"CL545822"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794393"},{"name":"PDQ_Open_Trial_Search_ID","value":"794393"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162620":{"preferredName":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3","code":"C162620","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a bicistronic retroviral vector encoding both an anti-CD19 chimeric antigen receptor (CAR) fused to OX40 co-stimulatory domain and an anti-CD22 CAR linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), optimized with a novel pentameric spacer derived from the collagen oligomeric matrix protein (COMP), with potential antineoplastic activity. Upon administration, the autologous anti-CD19/CD22 CAR T-cells AUTO3 bind to and induce selective toxicity in tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/CD22 CAR Autologous T-lymphocytes AUTO3","termGroup":"SY","termSource":"NCI"},{"termName":"AUTO 3","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO-3","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3"},{"name":"NCI_Drug_Dictionary_ID","value":"798924"},{"name":"NCI_META_CUI","value":"CL971066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798924"},{"name":"PDQ_Open_Trial_Search_ID","value":"798924"},{"name":"Semantic_Type","value":"Cell"}]}}{"C126639":{"preferredName":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014","code":"C126639","definitions":[{"definition":"A defined preparation of CD4+ and CD8+ central memory (CM) autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domains of CD28, 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+CM T-lymphocytes JCAR014 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ CM T-lymphocytes JCAR014","termGroup":"SY","termSource":"NCI"},{"termName":"JCAR014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014"},{"name":"NCI_Drug_Dictionary_ID","value":"780444"},{"name":"NCI_META_CUI","value":"CL505072"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780444"},{"name":"PDQ_Open_Trial_Search_ID","value":"780444"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156251":{"preferredName":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s","code":"C156251","definitions":[{"definition":"Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD22 human single chain variable fragment (scFv) and linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD22 CAR-4-1BB-TCRz -transduced T-lymphocytes CART22-65s express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD22 CAR T-Cells CART22-65s","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD22 scFv CAR 4-1BB-TCRz-expressing T-lymphocytes CART22-65s","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CART22-65s Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CART22-65s T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CART22-65s-expressing T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CART22-65s","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s"},{"name":"NCI_Drug_Dictionary_ID","value":"795556"},{"name":"NCI_META_CUI","value":"CL562955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795556"},{"name":"PDQ_Open_Trial_Search_ID","value":"795556"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162260":{"preferredName":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202","code":"C162260","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) antibody synthesized by a proprietary phage display platform, targeting the immunogenetic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) complexed with human leukocyte antigen (HLA)-A*02 (HLA-A*02/AFP), with potential antineoplastic and immunomodulatory activities. Upon administration, the autologous anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202 specifically recognize and selectively bind to AFP peptides presented by HLA-A*02. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of AFP-expressing tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202","termGroup":"PT","termSource":"NCI"},{"termName":"ET 140202","termGroup":"CN","termSource":"NCI"},{"termName":"ET-140202","termGroup":"CN","termSource":"NCI"},{"termName":"ET140202","termGroup":"CN","termSource":"NCI"},{"termName":"ET140202 Autologous T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202"},{"name":"NCI_Drug_Dictionary_ID","value":"798638"},{"name":"NCI_META_CUI","value":"CL970721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798638"},{"name":"PDQ_Open_Trial_Search_ID","value":"798638"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155884":{"preferredName":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1","code":"C155884","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for an immunogenic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) epitope, AFP158-166, complexed with human leukocyte antigen (HLA)-A*02:01 (HLA-A*0201/AFP), fused to the co-stimulatory domains of CD28 and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-HLA-A*0201/AFP CAR T-cells ET1402L1 specifically recognize and selectively bind to the AFP158-166 peptide presented by HLA-A*0201. Upon binding to the AFP-MHC complex, the T-cells release cytokines and induce selective toxicity in HLA-A*0201/AFP-positive tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous AFP-CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous AFP-CAR-transduced T-cells ET1402L1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ET1402L1-CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ET1402L1-CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cells Transduced with ET1402L1-CAR","termGroup":"SY","termSource":"NCI"},{"termName":"ET1402L1-CAR T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1"},{"name":"NCI_Drug_Dictionary_ID","value":"794793"},{"name":"NCI_META_CUI","value":"CL562702"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794793"},{"name":"PDQ_Open_Trial_Search_ID","value":"794793"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121379":{"preferredName":"Letetresgene Autoleucel","code":"C121379","definitions":[{"definition":"Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letetresgene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1a GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"NY-ESO-1c259 T Cells GSK3377794","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B5ME4ZU4BS"},{"name":"Maps_To","value":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794"},{"name":"Maps_To","value":"Letetresgene Autoleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"786186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786186"},{"name":"PDQ_Open_Trial_Search_ID","value":"786186"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055426"}]}}{"C154276":{"preferredName":"Autologous AXL-targeted CAR T-cells CCT301-38","code":"C154276","definitions":[{"definition":"A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous AXL-targeted CAR T-cells CCT301-38","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-AXL CAR T Cells CCT30138","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR T-cells Targeting AXL CCT301-38","termGroup":"SY","termSource":"NCI"},{"termName":"CCT301 38","termGroup":"CN","termSource":"NCI"},{"termName":"CCT301-38","termGroup":"CN","termSource":"NCI"},{"termName":"CCT30138 CAR T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous AXL-targeted CAR T-cells CCT301-38"},{"name":"NCI_Drug_Dictionary_ID","value":"794160"},{"name":"NCI_META_CUI","value":"CL555277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794160"},{"name":"PDQ_Open_Trial_Search_ID","value":"794160"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156153":{"preferredName":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B","code":"C156153","definitions":[{"definition":"An autologous vaccine composed of the antigen presenting cells (APCs) B-lymphocytes and monocytes presenting the tumor-associated antigen (TAA) human epidermal growth factor receptor type 2 (HER2/neu; HER-2; EGFR2; ErbB2). Upon administration of the autologous B-cell- and monocyte-presenting HER2/neu antigen vaccine BVAC-B, the APCs may stimulate the immune system to mount a HER2/neu-specific cytotoxic T-lymphocyte (CTL) immune response as well as a natural killer (NK) cell, and antibody-mediated immune response against HER-2/neu-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed by a variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B","termGroup":"PT","termSource":"NCI"},{"termName":"BVAC B","termGroup":"CN","termSource":"NCI"},{"termName":"BVAC-B","termGroup":"CN","termSource":"NCI"},{"termName":"BVACB","termGroup":"CN","termSource":"NCI"},{"termName":"HER2/neu-specific Autologous B-cell/Monocyte Vaccine BVAC-B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B"},{"name":"NCI_Drug_Dictionary_ID","value":"795331"},{"name":"NCI_META_CUI","value":"CL562872"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795331"},{"name":"PDQ_Open_Trial_Search_ID","value":"795331"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162506":{"preferredName":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M","code":"C162506","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T-cells LCAR-B4822M specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous LCAR-B4822M CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-specific CAR-expressing T-lymphocytes LCAR-B4822M","termGroup":"SY","termSource":"NCI"},{"termName":"LCAR B4822M","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B4822M","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B4822M CAR-T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"LCAR-B4822M-02 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"LCARB4822M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M"},{"name":"NCI_Drug_Dictionary_ID","value":"798658"},{"name":"NCI_META_CUI","value":"CL970932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798658"},{"name":"PDQ_Open_Trial_Search_ID","value":"798658"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148498":{"preferredName":"Ciltacabtagene Autoleucel","code":"C148498","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciltacabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA CAR-T Cells JNJ-68284528","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Bi-epitope CAR T-cells JNJ-68284528","termGroup":"SY","termSource":"NCI"},{"termName":"CARVYKTI","termGroup":"BR","termSource":"NCI"},{"termName":"Cilta-cel","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ-68284528","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B38M","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B38M-transduced Car-T Cells JNJ-68284528","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"the treatment of adult patients with relapsed or refractory multiple myeloma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0L1F17908Q"},{"name":"Maps_To","value":"Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528"},{"name":"Maps_To","value":"Ciltacabtagene Autoleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"792630"},{"name":"NCI_META_CUI","value":"CL551044"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792630"},{"name":"PDQ_Open_Trial_Search_ID","value":"792630"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103865":{"preferredName":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001","code":"C103865","definitions":[{"definition":"A cell-based product containing autologous bone marrow derived CD34 positive and C-X-C chemokine receptor type 4 (CXCR4) positive stem cells with potential antiapoptotic and proangiogenic activities. Upon intracoronary infusion after a myocardial infarction (MI), autologous bone marrow-derived CD34/CXCR4-positive stem cells may preserve cardiac muscle cells and prevent apoptosis; thus improving myocardial perfusion. CD34/CXCR4-positive stem cells are naturally mobilized upon cell injury through signaling by hypoxia inducing factor (HIF), which is secreted in response to hypoxia. In turn, HIF induces the synthesis of stromal-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) which mobilize CD34/CXCR4 positive stem cells; CXCR4 is the receptor for stromal-derived factor 1 (SDF-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001","termGroup":"PT","termSource":"NCI"},{"termName":"AMR-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001"},{"name":"NCI_Drug_Dictionary_ID","value":"743421"},{"name":"NCI_META_CUI","value":"CL438343"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743421"},{"name":"PDQ_Open_Trial_Search_ID","value":"743421"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158533":{"preferredName":"Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005","code":"C158533","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the unshed portion of the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-MUC16 CAR-mbIL15-safety switch T-cells PRGN-3005 into the patient, the T-cells target and bind to MUC16-expressing tumor cells, thereby inducing selective toxicity in MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed on a variety of cancer cell types. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-MUC16 CAR-T Cells PRGN-3005","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T Cells PRGN 3005","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PRGN-3005 UltraCAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"PRGN 3005","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN-3005","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN-3005 UltraCAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"PRGN3005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005"},{"name":"NCI_Drug_Dictionary_ID","value":"798316"},{"name":"NCI_META_CUI","value":"CL937966"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798316"},{"name":"PDQ_Open_Trial_Search_ID","value":"798316"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160847":{"preferredName":"Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006","code":"C160847","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD33, a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-CD33 CAR-mbIL15-safety switch T-cells PRGN-3006 into the patient, the T-cells target and bind to CD33-expressing tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD33 CAR-T Cells PRGN-3006","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T Cells PRGN 3006","termGroup":"SY","termSource":"NCI"},{"termName":"PRGN 3006","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN-3006","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN3006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006"},{"name":"NCI_Drug_Dictionary_ID","value":"798420"},{"name":"NCI_META_CUI","value":"CL969928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798420"},{"name":"PDQ_Open_Trial_Search_ID","value":"798420"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148526":{"preferredName":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123","code":"C148526","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD123 (interleukin-3 receptor alpha chain or IL3RA) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD123-4SCAR-expressing T-cells 4SCAR123 are directed to and induce selective toxicity in CD123-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD123-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR123","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR123 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123 CAR-T Cells 4SCAR123","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR123","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123"},{"name":"NCI_Drug_Dictionary_ID","value":"792687"},{"name":"NCI_META_CUI","value":"CL551139"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792687"},{"name":"PDQ_Open_Trial_Search_ID","value":"792687"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155878":{"preferredName":"Relmacabtagene Autoleucel","code":"C155878","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relmacabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR T-cells JWCAR029","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-targeted CAR T Cells JWCAR029","termGroup":"SY","termSource":"NCI"},{"termName":"JWCAR 029","termGroup":"CN","termSource":"NCI"},{"termName":"JWCAR-029","termGroup":"CN","termSource":"NCI"},{"termName":"JWCAR029","termGroup":"CN","termSource":"NCI"},{"termName":"Relma-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K5CXA4X5U8"},{"name":"Maps_To","value":"Autologous CD19-targeted CAR T Cells JWCAR029"},{"name":"NCI_Drug_Dictionary_ID","value":"794777"},{"name":"NCI_META_CUI","value":"CL562704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794777"},{"name":"PDQ_Open_Trial_Search_ID","value":"794777"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148525":{"preferredName":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20","code":"C148525","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD20 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD20-4SCAR-expressing T-cells 4SCAR20 are directed to and induce selective toxicity in CD20-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD20-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR20","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR20 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20 CAR-T Cells 4SCAR20","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR20","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20"},{"name":"NCI_Drug_Dictionary_ID","value":"792686"},{"name":"NCI_META_CUI","value":"CL551140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792686"},{"name":"PDQ_Open_Trial_Search_ID","value":"792686"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148524":{"preferredName":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22","code":"C148524","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD22 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD22-4SCAR-expressing T-cells 4SCAR22 are directed to and induce selective toxicity in CD22-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD22-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR22","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR22 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD22 CAR-T Cells 4SCAR22","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD22-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR22","termGroup":"SY","termSource":"NCI"},{"termName":"CD22-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD22-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD22-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22"},{"name":"NCI_Drug_Dictionary_ID","value":"792685"},{"name":"NCI_META_CUI","value":"CL551144"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792685"},{"name":"PDQ_Open_Trial_Search_ID","value":"792685"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148523":{"preferredName":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38","code":"C148523","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD38 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD38-4SCAR-expressing T-cells 4SCAR38 are directed to and induce selective toxicity in CD38-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD38-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR38","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR38 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38 CAR-T Cells 4SCAR38","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR38","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38"},{"name":"NCI_Drug_Dictionary_ID","value":"792684"},{"name":"NCI_META_CUI","value":"CL551145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792684"},{"name":"PDQ_Open_Trial_Search_ID","value":"792684"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158091":{"preferredName":"Autologous Deep IL-15 Primed T-cells TRQ15-01","code":"C158091","definitions":[{"definition":"A preparation of genetically modified, multi-antigen-directed autologous T-lymphocytes, that have particles, consisting of multiple chemically crosslinked human cytokine interleukin-15 (IL-15)/IL-15 receptor alpha (IL-15Ra)/Fc heterodimers, attached to their surface, with potential immunostimulating and antineoplastic activities. TRQ15-01 is made from monocyte-derived dendritic cells (moDCs) that are pulsed with peptides from multiple tumor-associated antigens (TAAs) to expand cytotoxic T-lymphocytes (CTLs) that are subsequently loaded with IL-15 particles. Upon administration of the autologous deep IL-15 primed T-cells, the IL-15/IL-15Ra fusion proteins are slowly released in vivo from the T-cells in a controlled manner and induce autocrine cytokine stimulation of the administered T-cells, thereby increasing T-cell division of the administered T-cells. The expanded T-cells target, bind to and kill tumor cells. This increases tumor cell growth inhibition by T-cells. IL-15 is a pro-survival, inflammatory cytokine and causes sustained T-cell expansion and enhanced anti-tumor activity. Compared to systemically delivered IL-15, IL-15 attached to the T-cells greatly increases target CD8 T-cell concentrations in the tumor, without significant systemic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Deep IL-15 Primed T-cells TRQ15-01","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15 Loaded Autologous T-lymphocytes TRQ15-01","termGroup":"SY","termSource":"NCI"},{"termName":"TRQ15-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Deep IL-15 Primed T-cells TRQ15-01"},{"name":"NCI_Drug_Dictionary_ID","value":"797353"},{"name":"NCI_META_CUI","value":"CL937688"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797353"},{"name":"PDQ_Open_Trial_Search_ID","value":"797353"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121856":{"preferredName":"Autologous Dendritic Cell Vaccine ACT2001","code":"C121856","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Dendritic Cell Vaccine ACT2001","termGroup":"PT","termSource":"NCI"},{"termName":"ACT2001","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous DC Vaccine ACT2001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Dendritic Cell Vaccine ACT2001"},{"name":"NCI_Drug_Dictionary_ID","value":"771721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771721"},{"name":"PDQ_Open_Trial_Search_ID","value":"771721"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053686"}]}}{"C123928":{"preferredName":"Audencel","code":"C123928","definitions":[{"definition":"A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of audencel, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Audencel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous DC-based Immunotherapeutic AV0113","termGroup":"SY","termSource":"NCI"},{"termName":"AV0113","termGroup":"CN","termSource":"NCI"},{"termName":"AV0113 DC-CIT","termGroup":"SY","termSource":"NCI"},{"termName":"AV0113 Dendritic Cell Cancer Immunotherapeutic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H2CDQ1PWN7"},{"name":"Maps_To","value":"Audencel"},{"name":"Maps_To","value":"Autologous Dendritic Cell-based Immunotherapeutic AV0113"},{"name":"NCI_Drug_Dictionary_ID","value":"775935"},{"name":"NCI_META_CUI","value":"CL498291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775935"},{"name":"PDQ_Open_Trial_Search_ID","value":"775935"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150698":{"preferredName":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa","code":"C150698","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-folate receptor alpha (FRa; folate receptor 1; FOLR1) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa are directed to and induce selective toxicity in FRa-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. FRa is overexpressed in various tumor cell types, and is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa","termGroup":"PT","termSource":"NCI"},{"termName":"4SCAR-FRa","termGroup":"AB","termSource":"NCI"},{"termName":"Autologous 4S-FRa-CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-FRa-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR-FRa","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric Antigen Receptor T Cells 4SCAR-FRa","termGroup":"SY","termSource":"NCI"},{"termName":"FRa-specific 4th Generation CART Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa"},{"name":"NCI_Drug_Dictionary_ID","value":"793118"},{"name":"NCI_META_CUI","value":"CL552500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793118"},{"name":"PDQ_Open_Trial_Search_ID","value":"793118"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162804":{"preferredName":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells","code":"C162804","definitions":[{"definition":"Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous genetically-modified MAGE-A4 C1032 CD8alpha T-cells bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T-cells into CD8+ cytotoxic T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"ADP-A2M4CD8","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified Melanoma Antigen A4 CD8alpha T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous MAGE-A4 C1032 TCR-modified CD8alpha T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TCR-transduced MAGE-A4 C1032 CD8alpha T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4 SPEAR CD8alpha T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4-specific TCR gene-transduced C1032 CD8alpha T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"SPEAR T-cell ADP-A2M4CD8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"799099"},{"name":"NCI_META_CUI","value":"CL973182"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799099"},{"name":"PDQ_Open_Trial_Search_ID","value":"799099"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175738":{"preferredName":"Afamitresgene Autoleucel","code":"C175738","definitions":[{"definition":"A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afamitresgene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"ADP-A2M4","termGroup":"CN","termSource":"NCI"},{"termName":"Afami-cel","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified MAGE-A4 C1032 T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified MAGE-A4 C1032 T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4 SPEAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4C1032T","termGroup":"SY","termSource":"NCI"},{"termName":"SPEAR T-cell ADP-A2M4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CUY18BJ7BP"},{"name":"Maps_To","value":"Autologous Genetically-modified MAGE-A4 C1032 T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"790617"},{"name":"NCI_META_CUI","value":"CL1413156"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C37448":{"preferredName":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858","code":"C37448","definitions":[{"definition":"A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes.  HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858","termGroup":"PT","termSource":"NCI"},{"termName":"AG-858","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Autologous_Heat-Shock_Protein_70_Peptide_Vaccine"},{"name":"Maps_To","value":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858"},{"name":"NCI_Drug_Dictionary_ID","value":"334949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"334949"},{"name":"PDQ_Open_Trial_Search_ID","value":"334949"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328058"}]}}{"C159977":{"preferredName":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439","code":"C159977","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted human papillomavirus type 16 isoform E7 protein (HPV16 E7) with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous HPV16 E7-specific HLA-A*02:01-restricted T-lymphocytes KITE-439 target and bind HPV16 E7-expressing tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 E7 antigen. HPV16 E7, a cell surface glycoprotein and tumor-associated antigen (TAA), is overexpressed in various HPV-mediated cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E7 T-cell Receptor Engineered T-cells KITE-439","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Autologous T-lymphocytes KITE-439","termGroup":"SY","termSource":"NCI"},{"termName":"KITE 439","termGroup":"CN","termSource":"NCI"},{"termName":"KITE-439","termGroup":"CN","termSource":"NCI"},{"termName":"KITE439","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439"},{"name":"NCI_Drug_Dictionary_ID","value":"797966"},{"name":"NCI_META_CUI","value":"CL969078"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797966"},{"name":"PDQ_Open_Trial_Search_ID","value":"797966"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162627":{"preferredName":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001","code":"C162627","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A02:01/24:02/11:01-restricted Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Upon administration, the autologous LMP1/LMP2/EBNA1-specific, HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001 recognize and bind to HLA-presented EBV peptides, which may promote cell death and inhibit the growth of tumor cells expressing LMP1, LMP2 or EBNA1. LMP1, LMP2, and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous EBV-specific TCR T-cells YT-E001","termGroup":"SY","termSource":"NCI"},{"termName":"YT E001","termGroup":"CN","termSource":"NCI"},{"termName":"YT-E001","termGroup":"CN","termSource":"NCI"},{"termName":"YTE001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001"},{"name":"NCI_Drug_Dictionary_ID","value":"798763"},{"name":"NCI_META_CUI","value":"CL971019"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798763"},{"name":"PDQ_Open_Trial_Search_ID","value":"798763"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135534":{"preferredName":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718","code":"C135534","definitions":[{"definition":"Human autologous T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-MAGE-A3/A6 TCR-transduced T Cells KITE-718","termGroup":"SY","termSource":"NCI"},{"termName":"KITE 718","termGroup":"CN","termSource":"NCI"},{"termName":"KITE-718","termGroup":"CN","termSource":"NCI"},{"termName":"MAGE-A3/A6 T Cell Receptor Engineered T-Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3/A6 T-Cell Receptor Engineered T-Cells KITE-718","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3/A6 TCR Engineered T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"MAGEA3/A6-targeted TCR-transduced T-Cells KITE-718","termGroup":"SY","termSource":"NCI"},{"termName":"TCR-transduced Autologous T-Cells KITE-718","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718"},{"name":"NCI_Drug_Dictionary_ID","value":"788966"},{"name":"NCI_META_CUI","value":"CL522896"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788966"},{"name":"PDQ_Open_Trial_Search_ID","value":"788966"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156382":{"preferredName":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","code":"C156382","definitions":[{"definition":"A preparation of autologous CD4+ and CD62L-expressing CD8+ T-cells transduced with a third generation lentiviral vector (LV) to express the high affinity T-cell receptor (TCR) A2 -MCC1, specific for the human leukocyte antigen (HLA)-A02-restricted Merkel cell polyomavirus (MCPyV; MCV) viral oncoprotein, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD8+ and CD4+ T-cells FH-MCVA2TCR selectively bind to the KLLEIAPNC epitope (KLL epitope) within the MCPyV viral oncoprotein. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the MCPyV viral oncoprotein. Additionally, tumor-specific HLA-A02-restricted CD4+ cells promote class I-restricted CD8+ proliferation, survival and effector functions by producing interleukin (IL)-2 and facilitating the activation of dendritic cells (DCs). MCPyV viral oncoprotein is highly expressed in Merkel cell carcinoma (MCC) caused by MCPyV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1","termGroup":"SY","termSource":"NCI"},{"termName":"FH-MCVA2TCR","termGroup":"CN","termSource":"NCI"},{"termName":"FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR"},{"name":"NCI_Drug_Dictionary_ID","value":"795693"},{"name":"NCI_META_CUI","value":"CL563078"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795693"},{"name":"PDQ_Open_Trial_Search_ID","value":"795693"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113803":{"preferredName":"Autologous Mesenchymal Stem Cells Apceth_101","code":"C113803","definitions":[{"definition":"Human autologous mesenchymal stem cells (MSCs) harvested from the bone marrow of a patient and genetically modified with a self-inactivating retroviral vector expressing the suicide gene herpes simplex virus thymidine kinase (HSV-TK), that can be used to activate synthetic acyclic guanosine analogues when co-administered. Upon intravenous administration of autologous mesenchymal stem cells apceth_101, the cells are actively recruited to the tumor stroma, differentiate into more mature mesenchymal cells, and become part of the tumor microenvironment. When a synthetic acyclic guanosine analogue, such as ganciclovir, is co-administered, the HSV-TK within the HSV-TK-transduced MSCs will monophosphorylate this prodrug. Subsequently the monophosphate form is further converted to the diphosphate form and then to its active triphosphate form by cellular kinases. The active form of ganciclovir kills the HSV-TK-transduced MSCs and leads to a bystander effect, which eliminates neighboring cancer cells. Therefore, synthetic acyclic guanosine analogues are activated only at the tumor site, which increases their local efficacy and reduces systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Mesenchymal Stem Cells Apceth_101","termGroup":"PT","termSource":"NCI"},{"termName":"Agenmestencel-T","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous MSC_Apceth_101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Mesenchymal Stem Cells Apceth_101"},{"name":"NCI_Drug_Dictionary_ID","value":"757685"},{"name":"NCI_META_CUI","value":"CL471784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757685"},{"name":"PDQ_Open_Trial_Search_ID","value":"757685"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155775":{"preferredName":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","code":"C155775","definitions":[{"definition":"Autologous peripheral blood mononuclear cells (PBMCs) transfected with anti-mesothelin chimeric antigen receptor (CAR) mRNA, with potential antineoplastic activity. Upon intraperitoneal (IP) administration, the autologous mesothelin-specific human mRNA CAR-transfected PBMCs MCY-M11 recognize, bind to, phagocytose and directly kill cancer cells expressing mesothelin. In addition, MCY-M11 stimulates the immune system to induce a cytotoxic T-lymphocyte response against the mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-mesothelin mRNA-transfected Autologous PBMCs MCY-M11","termGroup":"SY","termSource":"NCI"},{"termName":"MCY-M11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ER09HM7LIR"},{"name":"Maps_To","value":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11"},{"name":"NCI_Drug_Dictionary_ID","value":"794988"},{"name":"NCI_META_CUI","value":"CL556250"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794988"},{"name":"PDQ_Open_Trial_Search_ID","value":"794988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121536":{"preferredName":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01","code":"C121536","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified and transduced with a retroviral vector to express a chimeric antigen receptor (CAR) encoding full-length human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) fused to the CD3zeta cytoplasmic signaling domain and containing the naturally-expressed adaptor molecule DNAX-activating protein of 10 kDa (DAP10), with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR-CD3zeta-DAP10-expressing T-lymphocytes CYAD-01 specifically recognize and bind to tumor cells expressing NKG2D ligands. This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-01 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The CD3zeta signaling domain and DAP10 provide co-stimulatory signaling upon ligand binding, enhance the secretion of pro-inflammatory cytokines in response to binding to NKG2D ligand-expressing tumor cells and enhances T-cell cytotoxicity. DAP10 also associates with and stabilizes NKG2D, which facilitates expression of the NKG2D-CAR-CD3zeta construct at the cell surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CAR NKG2D","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T NKG2D","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T NKR-2","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CM-CS1 T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-cells CYAD-01","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKR 2 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKR-2 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CM CS-1","termGroup":"CN","termSource":"NCI"},{"termName":"CM-CS-1","termGroup":"CN","termSource":"NCI"},{"termName":"CM-CS1","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD-01","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD-101","termGroup":"CN","termSource":"NCI"},{"termName":"NKR 2","termGroup":"CN","termSource":"NCI"},{"termName":"NKR-2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01"},{"name":"NCI_Drug_Dictionary_ID","value":"788734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788734"},{"name":"PDQ_Open_Trial_Search_ID","value":"788734"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055424"}]}}{"C82361":{"preferredName":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101","code":"C82361","definitions":[{"definition":"A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered; AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA.  This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101","termGroup":"PT","termSource":"NCI"},{"termName":"BP-GMAX-CD1","termGroup":"SY","termSource":"NCI"},{"termName":"BPX-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"iCD40_Receptor_Pulsed_Autologous_Dendritic_Cell_Vaccine_BP-GMAX-CD1"},{"name":"Maps_To","value":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101"},{"name":"NCI_Drug_Dictionary_ID","value":"640422"},{"name":"NCI_META_CUI","value":"CL408640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640422"},{"name":"PDQ_Open_Trial_Search_ID","value":"640422"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128031":{"preferredName":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601","code":"C128031","definitions":[{"definition":"A preparation of autologous T-lymphocytes expressing a chimeric antigen receptor (CAR) consisting of an anti-human prostate stem cell antigen (PSCA) scFv (single chain variable fragment) coupled to the zeta chain of the T-cell receptor (TCRzeta) and a drug-induced co-stimulatory molecule, composed of an inducible, chimeric MyD88/CD40 (inducible MC; iMC) co-stimulatory domain, in which both the MyD88 and CD40 lack their extracellular domains, with potential antineoplastic activity. Upon administration of BPX-601, the T-cells target and bind to PSCA-expressing cancer cells. Upon subsequent administration of the chemical inducer of dimerization (CID) agent rimiducid, this agent targets and binds to the drug binding domain, which leads to iMC expression, activation of both CD40- and MyD88-mediated signal transduction pathways, and an induction of selective cytotoxicity in, and eradication of PSCA-expressing cancer cells. iMC activation by rimiducid increases T-cell survival and anti-tumor activity of the administered T-cells, compared to T-cells without the drug iMC activation-switch. As these T-cells are engineered to only be fully activated by binding to both antigen and rimiducid, T-cell proliferation, activity and toxicity can be controlled by adjusting the dose of rimiducid, thereby preventing uncontrolled T-cell activation which increases the safety of the administered T-cells. PSCA is a glycosylphosphatidylinositol (GPI)-anchored cell surface antigen overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous PSCA-specific CAR T Cells BPX-601","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PSCA-Specific Chimeric Antigen Receptor Engineered T Cells BPX-601","termGroup":"SY","termSource":"NCI"},{"termName":"BPX-601","termGroup":"CN","termSource":"NCI"},{"termName":"GoCART BPX-601","termGroup":"SY","termSource":"NCI"},{"termName":"iMC/PSCA-zeta CAR BPX-601","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601"},{"name":"NCI_Drug_Dictionary_ID","value":"781278"},{"name":"NCI_META_CUI","value":"CL507925"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781278"},{"name":"PDQ_Open_Trial_Search_ID","value":"781278"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154277":{"preferredName":"Autologous ROR2-targeted CAR T-cells CCT301-59","code":"C154277","definitions":[{"definition":"A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, CCT301-59 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of ROR2-expressing tumor cells. ROR2 is involved in Wnt signal transduction and is involved in tumorigenesis and progression. ROR2 expression is upregulated in certain tumor types and high levels of ROR2 expression often correlates with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous ROR2-targeted CAR T-cells CCT301-59","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-ROR2 CAR T Cells CCT301-59","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR T-cells Targeting ROR2 CCT301-59","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CCT301-59 CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CCT301 59","termGroup":"CN","termSource":"NCI"},{"termName":"CCT301-59","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous ROR2-targeted CAR T-cells CCT301-59"},{"name":"NCI_Drug_Dictionary_ID","value":"794161"},{"name":"NCI_META_CUI","value":"CL555278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794161"},{"name":"PDQ_Open_Trial_Search_ID","value":"794161"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154285":{"preferredName":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1","code":"C154285","definitions":[{"definition":"A preparation of autologous dendritic cells (DCs) loaded with immunogenic tumor-associated antigens (TAAs) derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TAAs-loaded Autologous DCs AV-GBM-1","termGroup":"SY","termSource":"NCI"},{"termName":"AV GBM 1","termGroup":"CN","termSource":"NCI"},{"termName":"AV-GBM-1","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen-loaded Autologous Dendritic Cells AV-GBM-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1"},{"name":"NCI_Drug_Dictionary_ID","value":"794138"},{"name":"NCI_META_CUI","value":"CL555286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794138"},{"name":"PDQ_Open_Trial_Search_ID","value":"794138"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146779":{"preferredName":"Autologous TCR-engineered T-cells IMA201","code":"C146779","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for an as of yet not identified tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA201 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TCR-engineered T-cells IMA201","termGroup":"PT","termSource":"NCI"},{"termName":"ACTengine IMA201","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cell Receptor-engineered T-cells IMA201","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TCR-engineered T-cells IMA201","termGroup":"SY","termSource":"NCI"},{"termName":"IMA 201","termGroup":"CN","termSource":"NCI"},{"termName":"IMA-201","termGroup":"CN","termSource":"NCI"},{"termName":"IMA201","termGroup":"CN","termSource":"NCI"},{"termName":"IMA201 Autologous T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"IMA201 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCR-engineered T-cells IMA201"},{"name":"NCI_Drug_Dictionary_ID","value":"792163"},{"name":"NCI_META_CUI","value":"CL544786"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792163"},{"name":"PDQ_Open_Trial_Search_ID","value":"792163"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153218":{"preferredName":"Autologous TCR-engineered T-cells IMA202","code":"C153218","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) targeting patient-specific tumor associated antigens (TAAs), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA202 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TCR-engineered T-cells IMA202","termGroup":"PT","termSource":"NCI"},{"termName":"ACTengine IMA202","termGroup":"SY","termSource":"NCI"},{"termName":"IMA 202","termGroup":"CN","termSource":"NCI"},{"termName":"IMA-202","termGroup":"CN","termSource":"NCI"},{"termName":"IMA202","termGroup":"CN","termSource":"NCI"},{"termName":"IMA202 T-cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"IMA202 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCR-engineered T-cells IMA202"},{"name":"NCI_Drug_Dictionary_ID","value":"794052"},{"name":"NCI_META_CUI","value":"CL554340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794052"},{"name":"PDQ_Open_Trial_Search_ID","value":"794052"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161831":{"preferredName":"Autologous PRAME-targeting TCR-engineered T-cells IMA203","code":"C161831","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous PRAME-targeting TCR-engineered T-cells IMA203 specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous PRAME-targeting TCR-engineered T-cells IMA203","termGroup":"PT","termSource":"NCI"},{"termName":"ACTengine IMA203","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cell Receptor-engineered T-cells IMA203","termGroup":"SY","termSource":"NCI"},{"termName":"IMA 203","termGroup":"CN","termSource":"NCI"},{"termName":"IMA-203","termGroup":"CN","termSource":"NCI"},{"termName":"IMA203","termGroup":"CN","termSource":"NCI"},{"termName":"IMA203 Autologous T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"IMA203 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCR-engineered T-cells IMA203"},{"name":"NCI_Drug_Dictionary_ID","value":"798429"},{"name":"NCI_META_CUI","value":"CL970385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798429"},{"name":"PDQ_Open_Trial_Search_ID","value":"798429"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120552":{"preferredName":"Lifileucel","code":"C120552","definitions":[{"definition":"A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifileucel","termGroup":"PT","termSource":"NCI"},{"termName":"Amtagvi","termGroup":"BR","termSource":"NCI"},{"termName":"Autologous TIL LN-144","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tumor Infiltrating Lymphocytes LN-144","termGroup":"SY","termSource":"NCI"},{"termName":"Contego","termGroup":"AQS","termSource":"NCI"},{"termName":"LN-144","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2306267-74-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R0835E18NH"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes LN-144"},{"name":"Maps_To","value":"Lifileucel"},{"name":"NCI_Drug_Dictionary_ID","value":"769186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769186"},{"name":"PDQ_Open_Trial_Search_ID","value":"769186"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053624"}]}}{"C135634":{"preferredName":"Autologous Tumor Infiltrating Lymphocytes LN-145","code":"C135634","definitions":[{"definition":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tumor Infiltrating Lymphocytes LN-145","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous TILs LN-145","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tumor-infiltrating Lymphocytes LN-145","termGroup":"SY","termSource":"NCI"},{"termName":"LN-145","termGroup":"CN","termSource":"NCI"},{"termName":"LN145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes LN-145"},{"name":"NCI_Drug_Dictionary_ID","value":"789043"},{"name":"NCI_META_CUI","value":"CL522989"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789043"},{"name":"PDQ_Open_Trial_Search_ID","value":"789043"},{"name":"Semantic_Type","value":"Cell"}]}}{"C153312":{"preferredName":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL","code":"C153312","definitions":[{"definition":"A preparation of autologous tumor infiltrating lymphocytes (TILs) with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, then cultured and expanded in vitro in the presence of interleukin-2 (IL-2) and an agonistic anti-4-1BB (CD137) antibody. Upon infusion of the autologous expanded TILs back into the patient, the cells specifically recognize, target, and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL","termGroup":"PT","termSource":"NCI"},{"termName":"MDA Autologous TILs","termGroup":"SY","termSource":"NCI"},{"termName":"MDA Autologous Tumor Infiltrating Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"MDA-TILs","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL"},{"name":"NCI_Drug_Dictionary_ID","value":"794072"},{"name":"NCI_META_CUI","value":"CL554425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794072"},{"name":"PDQ_Open_Trial_Search_ID","value":"794072"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160786":{"preferredName":"Avadomide","code":"C160786","definitions":[{"definition":"A novel, small molecule cereblon-modulating agent with potential antineoplastic, antiangiogenic and immunomodulatory activities. Upon oral administration, avadomide binds to and modulates cereblon to promote recruitment of the hematopoietic transcription factors Aiolos and Ikaros to the Cullin-4 RING E3 ubiquitin ligase complex. This binding results in the ubiquitination and rapid proteasomal degradation of Aiolos and Ikaros and the derepression of interferon (IFN)-stimulated genes, including DDX58 and IRF7, leading to apoptosis of certain tumor cells. Additionally, Aiolos degredation leads to derepression of the IL2 gene, thereby enhancing interleukin-2 production, costimulation of T-lymphocytes and IL-2-induced T-cell proliferation. Avadomide may also promote the activation of natural killer (NK) cells, potentially enhancing tumor cell killing. Aiolos and Ikaros are transcriptional repressors known to play an important role in normal B- and T-cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avadomide","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CC 122","termGroup":"CN","termSource":"NCI"},{"termName":"CC-122","termGroup":"CN","termSource":"NCI"},{"termName":"CC122","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1015474-32-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"28DZS29F59"},{"name":"Maps_To","value":"Avadomide"},{"name":"NCI_Drug_Dictionary_ID","value":"798417"},{"name":"NCI_META_CUI","value":"CL969760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798417"},{"name":"PDQ_Open_Trial_Search_ID","value":"798417"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97956":{"preferredName":"Avadomide Hydrochloride","code":"C97956","definitions":[{"definition":"The hydrochloride salt form of avadomide, a novel, small molecule, cereblon-modulating agent with potential antineoplastic, antiangiogenic and immunomodulatory activities. Upon oral administration, avadomide binds to and modulates cereblon to promote recruitment of the hematopoietic transcription factors Aiolos and Ikaros to the Cullin-4 RING E3 ubiquitin ligase complex. This binding results in the ubiquitination and rapid proteasomal degradation of Aiolos and Ikaros and the derepression of interferon (IFN)-stimulated genes, including DDX58 and IRF7, leading to apoptosis of certain tumor cells. Additionally, Aiolos degredation leads to derepression of the IL2 gene, thereby enhancing interleukin-2 production, costimulation of T-lymphocytes and IL-2-induced T-cell proliferation. Avadomide may also promote the activation of natural killer (NK) cells, potentially enhancing tumor cell killing. Aiolos and Ikaros are transcriptional repressors known to play an important role in normal B- and T-cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avadomide Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Piperidinedione, 3-(5-Amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CC-122 Hydrochloride","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1398053-45-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6CX4AEX3KR"},{"name":"Maps_To","value":"Avadomide Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"710428"},{"name":"NCI_META_CUI","value":"CL430562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710428"},{"name":"PDQ_Open_Trial_Search_ID","value":"710428"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123827":{"preferredName":"Avapritinib","code":"C123827","definitions":[{"definition":"An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avapritinib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine","termGroup":"SY","termSource":"NCI"},{"termName":"AYVAKIT","termGroup":"BR","termSource":"NCI"},{"termName":"Ayvakyt","termGroup":"FB","termSource":"NCI"},{"termName":"BLU-285","termGroup":"CN","termSource":"NCI"},{"termName":"CS3007","termGroup":"CN","termSource":"NCI"},{"termName":"PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of Adults with Unresectable or Metastatic Gastrointestinal Stromal Tumor Harboring a Platelet-derived Growth Factor Receptor Alpha Exon 18 Mutation"},{"name":"CAS_Registry","value":"1703793-34-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"513P80B4YJ"},{"name":"Maps_To","value":"Avapritinib"},{"name":"NCI_Drug_Dictionary_ID","value":"775630"},{"name":"NCI_META_CUI","value":"CL498221"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775630"},{"name":"PDQ_Open_Trial_Search_ID","value":"775630"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116870":{"preferredName":"Avelumab","code":"C116870","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avelumab","termGroup":"PT","termSource":"NCI"},{"termName":"Bavencio","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"MSB-0010718C","termGroup":"CN","termSource":"NCI"},{"termName":"MSB0010718C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma (MCC); advanced renal cell carcinoma (RCC)."},{"name":"CAS_Registry","value":"1537032-82-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"KXG2PJ551I"},{"name":"Maps_To","value":"Avelumab"},{"name":"NCI_Drug_Dictionary_ID","value":"745752"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745752"},{"name":"PDQ_Open_Trial_Search_ID","value":"745752"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055417"}]}}{"C118671":{"preferredName":"Abivertinib Maleate Anhydrous","code":"C118671","definitions":[{"definition":"The maleate salt form of abivertinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abivertinib Maleate Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"AC0010 Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"AC0010 Maleate Dihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"AC0010MA","termGroup":"CN","termSource":"NCI"},{"termName":"Avitinib Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"STI-5656","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1557268-88-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0447KM2XTD"},{"name":"Maps_To","value":"Avitinib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"765931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765931"},{"name":"PDQ_Open_Trial_Search_ID","value":"765931"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053687"}]}}{"C120309":{"preferredName":"Axicabtagene Ciloleucel","code":"C120309","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axicabtagene Ciloleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Axi-cel","termGroup":"SY","termSource":"NCI"},{"termName":"Axicel","termGroup":"SY","termSource":"NCI"},{"termName":"KTE C19","termGroup":"CN","termSource":"NCI"},{"termName":"KTE-C19","termGroup":"CN","termSource":"NCI"},{"termName":"KTE-C19 CAR","termGroup":"SY","termSource":"NCI"},{"termName":"Yescarta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy; for adult patients with large B-cell lymphoma (LBCL)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U2I8T43Y7R"},{"name":"Maps_To","value":"Axicabtagene Ciloleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"768723"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768723"},{"name":"PDQ_Open_Trial_Search_ID","value":"768723"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896829"}]}}{"C38718":{"preferredName":"Axitinib","code":"C38718","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and protein tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axitinib","termGroup":"PT","termSource":"NCI"},{"termName":"AG-013736","termGroup":"CN","termSource":"NCI"},{"termName":"AG013736","termGroup":"CN","termSource":"NCI"},{"termName":"Inlyta","termGroup":"BR","termSource":"NCI"},{"termName":"N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"319460-85-0"},{"name":"Chemical_Formula","value":"C22H18N4OS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"C9LVQ0YUXG"},{"name":"Legacy Concept Name","value":"AG-013736"},{"name":"Maps_To","value":"Axitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"352181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352181"},{"name":"PDQ_Open_Trial_Search_ID","value":"352181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1700874"}]}}{"C152976":{"preferredName":"AXL Inhibitor DS-1205c","code":"C152976","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, DS-1205c targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways and inhibits tumor cell proliferation and migration. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types. It plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL Inhibitor DS-1205c","termGroup":"PT","termSource":"NCI"},{"termName":"DS 1205c","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1205c","termGroup":"CN","termSource":"NCI"},{"termName":"DS1205c","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL Inhibitor DS-1205c"},{"name":"NCI_Drug_Dictionary_ID","value":"793863"},{"name":"NCI_META_CUI","value":"CL554179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793863"},{"name":"PDQ_Open_Trial_Search_ID","value":"793863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132025":{"preferredName":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M","code":"C132025","definitions":[{"definition":"An orally available inhibitor of the AXL receptor tyrosine kinase (AXL; UFO) and the receptor tyrosine kinase c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Upon administration, AXL receptor tyrosine kinase/cMET inhibitor BPI-9016M, binds to both AXL and cMet, thereby disrupting both AXL- and c-Met-mediated signaling pathways. Altogether, this agent inhibits growth in AXL and cMet-overexpressing tumor cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, and cMet, both overexpressed by many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M","termGroup":"PT","termSource":"NCI"},{"termName":"AXL/cMET Inhibitor BPI-9016M","termGroup":"SY","termSource":"NCI"},{"termName":"BPI 9016","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-9016","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-9016M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M"},{"name":"NCI_Drug_Dictionary_ID","value":"786576"},{"name":"NCI_META_CUI","value":"CL520367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786576"},{"name":"PDQ_Open_Trial_Search_ID","value":"786576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153122":{"preferredName":"Axl/Mer Inhibitor INCB081776","code":"C153122","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, INCB081776 targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axl/Mer Inhibitor INCB081776","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 081776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 81776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-081776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-81776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB081776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB81776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Axl/Mer Inhibitor INCB081776"},{"name":"Maps_To","value":"Axl/Mer Inhibitor INCB081776"},{"name":"NCI_Drug_Dictionary_ID","value":"793938"},{"name":"NCI_META_CUI","value":"CL554380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793938"},{"name":"PDQ_Open_Trial_Search_ID","value":"793938"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C288":{"preferredName":"Azacitidine","code":"C288","definitions":[{"definition":"A drug that is used to treat myelodysplastic syndromes and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azacitidine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-AC","termGroup":"AB","termSource":"NCI"},{"termName":"5-Aza-cytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Azacitidine","termGroup":"SY","termSource":"NCI"},{"termName":"5-Azacytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-AZC","termGroup":"AB","termSource":"NCI"},{"termName":"Azacytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Ladakamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Mylosar","termGroup":"SY","termSource":"NCI"},{"termName":"U-18496","termGroup":"CN","termSource":"NCI"},{"termName":"Vidaza","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Myelodysplastic Syndrome; acute myeloid leukemia"},{"name":"CAS_Registry","value":"320-67-2"},{"name":"CHEBI_ID","value":"CHEBI:2038"},{"name":"Chemical_Formula","value":"C8H12N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M801H13NRU"},{"name":"Legacy Concept Name","value":"Azacitidine"},{"name":"Maps_To","value":"Azacitidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39153"},{"name":"NSC Number","value":"102816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39153"},{"name":"PDQ_Open_Trial_Search_ID","value":"39153"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004475"}]}}{"C1007":{"preferredName":"Azapicyl","code":"C1007","definitions":[{"definition":"A hydrazine compound that has been investigated for antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azapicyl","termGroup":"PT","termSource":"NCI"},{"termName":"1-acetyl-2-picolinoylhydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"2-acetylhydrazide-2-pyridinecarboxylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"P-2292","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17433-31-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"186TH42ZNH"},{"name":"Legacy Concept Name","value":"Azapicyl"},{"name":"Maps_To","value":"Azapicyl"},{"name":"NCI_Drug_Dictionary_ID","value":"39154"},{"name":"NSC Number","value":"68626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39154"},{"name":"PDQ_Open_Trial_Search_ID","value":"39154"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052754"}]}}{"C1008":{"preferredName":"Azaribine","code":"C1008","definitions":[{"definition":"The triacetate salt of azauridine, a synthetic triazine nucleoside derivative possessing antineoplastic and anti-psoriatic activity. After metabolism to 6-azauridine-5-prime monophosphate, 6-Azauridine inhibits de novo pyrimidine biosynthesis and its 5-prime triphosphate metabolite gets incorporated into RNA, thereby preventing RNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azaribine","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-Triazine-3,5(2H,4H)-dione, 2-Beta-D-ribofuranosyl-","termGroup":"SN","termSource":"NCI"},{"termName":"2',3',4'-azauridine triacetate","termGroup":"SN","termSource":"NCI"},{"termName":"2-(2,3,5-Tri-O-acetyl-beta-D-ribofuranosyl)-as-triazine-3,5(2H,4H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"6-Azauridine Triacetate","termGroup":"SY","termSource":"NCI"},{"termName":"Azauridine Triacetate","termGroup":"SY","termSource":"NCI"},{"termName":"Triacetyl 6-azuridine","termGroup":"SN","termSource":"NCI"},{"termName":"Triazure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169-64-4"},{"name":"Chemical_Formula","value":"C14H17N3O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K1U80DO9EB"},{"name":"Legacy Concept Name","value":"Azauridine_Triacetate"},{"name":"Maps_To","value":"Azaribine"},{"name":"NCI_Drug_Dictionary_ID","value":"39155"},{"name":"NSC Number","value":"67239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39155"},{"name":"PDQ_Open_Trial_Search_ID","value":"39155"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052757"}]}}{"C289":{"preferredName":"Azaserine","code":"C289","definitions":[{"definition":"A naturally occurring serine derivative diazo compound with antineoplastic properties, Azaserine functions as a purine antagonist and glutamine analogue (glutamine amidotransferase inhibitor) that competitively inhibits pathways in which glutamine is metabolized. An antibiotic and antitumor agent, Azaserine is used in clinical studies as a potential antineoplastic agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azaserine","termGroup":"PT","termSource":"NCI"},{"termName":"AZS","termGroup":"AB","termSource":"NCI"},{"termName":"CL-337","termGroup":"CN","termSource":"NCI"},{"termName":"CN-15757","termGroup":"CN","termSource":"NCI"},{"termName":"Diazoacetate (Ester) L-Serine","termGroup":"SY","termSource":"NCI"},{"termName":"Diazoacetic Acid Ester with Serine","termGroup":"SY","termSource":"NCI"},{"termName":"Diazoacetylserine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Azaserine","termGroup":"SN","termSource":"NCI"},{"termName":"L-diazoacetate (ester) serine","termGroup":"SN","termSource":"NCI"},{"termName":"L-serine diazoacetate (ester)","termGroup":"SN","termSource":"NCI"},{"termName":"O-diazoacetyl-L-serine","termGroup":"SN","termSource":"NCI"},{"termName":"P-165","termGroup":"CN","termSource":"NCI"},{"termName":"Serine Diazoacetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"115-02-6"},{"name":"Chemical_Formula","value":"C5H7N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"87299V3Q9W"},{"name":"Legacy Concept Name","value":"Azaserine"},{"name":"Maps_To","value":"Azaserine"},{"name":"NCI_Drug_Dictionary_ID","value":"39156"},{"name":"NSC Number","value":"742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39156"},{"name":"PDQ_Open_Trial_Search_ID","value":"39156"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004480"}]}}{"C1347":{"preferredName":"Azimexon","code":"C1347","definitions":[{"definition":"Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azimexon","termGroup":"PT","termSource":"NCI"},{"termName":"2-Aziridinecarboxamide, 1-[1-(2-cyano-1-aziridinyl)-1-methylethyl]","termGroup":"SN","termSource":"NCI"},{"termName":"2-Cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane","termGroup":"SN","termSource":"NCI"},{"termName":"AZ","termGroup":"AB","termSource":"NCI"},{"termName":"Azimexone","termGroup":"SY","termSource":"NCI"},{"termName":"BM 12.531","termGroup":"CN","termSource":"NCI"},{"termName":"BM12531","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64118-86-1"},{"name":"Chemical_Formula","value":"C9H14N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4NJ842U6BZ"},{"name":"Legacy Concept Name","value":"Azimexon"},{"name":"Maps_To","value":"Azimexon"},{"name":"NCI_Drug_Dictionary_ID","value":"39159"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39159"},{"name":"PDQ_Open_Trial_Search_ID","value":"39159"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0104835"}]}}{"C29404":{"preferredName":"Aziridinylbenzoquinone RH1","code":"C29404","definitions":[{"definition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aziridinylbenzoquinone RH1","termGroup":"PT","termSource":"NCI"},{"termName":"2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"RH1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"RH1"},{"name":"Maps_To","value":"Aziridinylbenzoquinone RH1"},{"name":"NCI_Drug_Dictionary_ID","value":"580840"},{"name":"NSC Number","value":"697726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580840"},{"name":"PDQ_Open_Trial_Search_ID","value":"580840"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0764431"}]}}{"C28803":{"preferredName":"Azotomycin","code":"C28803","definitions":[{"definition":"An antineoplastic-antibiotic diazo analog of L-glutamine isolated from the bacterium Streptomyces ambofaciens.  Azotomycin inhibits glutamine-dependent enzymes involved in purine and pyrimidine biosynthesis, resulting in inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azotomycin","termGroup":"PT","termSource":"NCI"},{"termName":"A 10270B","termGroup":"CN","termSource":"NCI"},{"termName":"Diazomycin B","termGroup":"SY","termSource":"NCI"},{"termName":"Duazomycin B","termGroup":"SY","termSource":"NCI"},{"termName":"L-Norleucine, 6-diazo-N-(6-diazo-N-L-gamma-glutamyl-5-oxo-L-norleucyl)-5-oxo- (8CI 9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7644-67-9"},{"name":"Chemical_Formula","value":"C17H23N7O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6TQY580E8M"},{"name":"Legacy Concept Name","value":"Azotomycin"},{"name":"Maps_To","value":"Azotomycin"},{"name":"NSC Number","value":"56654"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052821"}]}}{"C85480":{"preferredName":"Azurin:50-77 Cell Penetrating Peptide p28","code":"C85480","definitions":[{"definition":"A water-soluble, amphipathic, 28 amino acid (amino acids 50-77), 2.9 kD fragment peptide (p28) derived from the protein azurin with potential antineoplastic and antiangiogenic activities. Although the mechanism has yet to be fully elucidated, the preferential cellular uptake of azurin-derived cell-penetrating peptide p28 by tumor cells and endothelial cells is likely via caveolae-mediated endocytosis; the C-terminal 18 amino acid residues (50-67) appear to be responsible for this preferential uptake. After cell entry, the first 12 amino acid residues interact with tumor suppressor p53 and form a p28:p53 complex, which may result in a reduction of proteasomal degradation of p53, increased p53 levels, and p53-mediated cell cycle inhibition and apoptosis. Azurin is a cupredoxin secreted by the bacterium Pseudomonas aeruginosa. Cell penetrating peptides (CPPs) are cationic and/or amphipathic peptides, typically less than 30 amino acids in length, that can penetrate cell membranes easily and may transport molecular cargo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azurin:50-77 Cell Penetrating Peptide p28","termGroup":"PT","termSource":"NCI"},{"termName":"Azurin-Derived Cell Penetrating Peptide p28","termGroup":"SY","termSource":"NCI"},{"termName":"Azurin:50-77 CPP p28","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897026-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H4QZU9L323"},{"name":"Maps_To","value":"Azurin:50-77 Cell Penetrating Peptide p28"},{"name":"NCI_Drug_Dictionary_ID","value":"647827"},{"name":"NCI_META_CUI","value":"CL412365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647827"},{"name":"PDQ_Open_Trial_Search_ID","value":"647827"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61311":{"preferredName":"B-Raf/VEGFR-2 Inhibitor RAF265","code":"C61311","definitions":[{"definition":"A substance being studied in the treatment of melanoma. CHIR-265 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It is a type of Raf kinase inhibitor and angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Raf/VEGFR-2 Inhibitor RAF265","termGroup":"PT","termSource":"NCI"},{"termName":"CHIR-265","termGroup":"CN","termSource":"NCI"},{"termName":"RAF 265","termGroup":"CN","termSource":"NCI"},{"termName":"RAF-265","termGroup":"CN","termSource":"NCI"},{"termName":"RAF265","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"927880-90-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8O434L3768"},{"name":"Legacy Concept Name","value":"CHIR-265"},{"name":"Maps_To","value":"B-Raf/VEGFR-2 Inhibitor RAF265"},{"name":"NCI_Drug_Dictionary_ID","value":"484456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"484456"},{"name":"PDQ_Open_Trial_Search_ID","value":"484456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831810"}]}}{"C155974":{"preferredName":"Babaodan Capsule","code":"C155974","definitions":[{"definition":"An orally available mixed powder of traditional Chinese medicine containing eight constituents including natural calculus bovis, snake gall, antelope horn, pearl, musk, radix notoginseng, and other as of yet not disclosed ingredients, with potential antifibrotic, immunomodulatory, and antineoplastic activities. Upon oral administration, babaodan may ameliorate substance-induced liver injury and fibrosis, and inhibit lipopolysaccharide (LPS)-induced hepatic stellate cell (HSC) activation and proliferation through toll-like receptor 4 (TLR4)/nuclear factor-kappa B and TLR4/extracellular-signal-regulated kinase (ERK) pathways. Babaodan may, through an as of yet not elucidated mechanism, enhance the efficacy of chemotherapeutic drugs and may inhibit the occurrence and development of certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Babaodan Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Babao Dan","termGroup":"SY","termSource":"NCI"},{"termName":"BBD","termGroup":"AB","termSource":"NCI"},{"termName":"BD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Babaodan Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"795030"},{"name":"NCI_META_CUI","value":"CL562711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795030"},{"name":"PDQ_Open_Trial_Search_ID","value":"795030"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77694":{"preferredName":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen","code":"C77694","synonyms":[{"termName":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin Live Antigen, B","termGroup":"SY","termSource":"NCI"},{"termName":"Immucyst","termGroup":"BR","termSource":"NCI"},{"termName":"Mycobacterium bovis BCG Substrain Connaught","termGroup":"SY","termSource":"NCI"},{"termName":"Mycobax","termGroup":"BR","termSource":"NCI"},{"termName":"TheraCys","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5H5854UBMZ"},{"name":"Legacy Concept Name","value":"Bacillus_Calmette-Guerin_Live_Antigen_B"},{"name":"Maps_To","value":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0255289"}]}}{"C28850":{"preferredName":"Bactobolin","code":"C28850","definitions":[{"definition":"A 3-dichloromethylactinobolin antineoplastic antibiotic isolated from various Pseudomonas bacterial species.  BN-183 induces apoptosis via a caspase-dependent pathway.  This agent also has immunomodulatory properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bactobolin","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Bactobolin","termGroup":"SY","termSource":"NCI"},{"termName":"2-Amino-N-[3-(dichloromethyl)-3,4,4a,5,6,7- hexahydro-5,6,8-trihydroxy-3-methyl-1-oxo-1H-2- benzopyran-4-yl], Propanamide","termGroup":"SN","termSource":"NCI"},{"termName":"Antibiotic BN 183B","termGroup":"SY","termSource":"NCI"},{"termName":"BN 183B","termGroup":"CN","termSource":"NCI"},{"termName":"Y 12278","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72615-20-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EOF7S67HS2"},{"name":"Legacy Concept Name","value":"Bactobolin"},{"name":"Maps_To","value":"Bactobolin"},{"name":"NSC Number","value":"325014"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052913"}]}}{"C62516":{"preferredName":"Bafetinib","code":"C62516","definitions":[{"definition":"An orally active 2-phenylaminopyrimidine derivative with potential antineoplastic activity. INNO-406 specifically binds to and inhibits the Bcr/Abl fusion protein tyrosine kinase, an abnormal enzyme produced by Philadelphia chromosomal translocation associated with chronic myeloid leukemia (CML). Furthermore, this agent also inhibits the Src-family member Lyn tyrosine kinase, upregulated in imatinib-resistant CML cells and in a variety of solid cancer cell types. The inhibitory effect of INNO-406 on these specific tyrosine kinases decreases cellular proliferation and induces apoptosis. A high percentage of CML patients are refractory to imatinib, which sometimes results from point mutations occurring in the kinase domain of the Bcr/Abl fusion product. Due to its dual inhibitory activity, INNO-406 has been shown to overcome this particular drug resistance and to be a potent and effective agent in the treatment of imatinib-resistant CML.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bafetinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CNS-9","termGroup":"CN","termSource":"NCI"},{"termName":"Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406","termGroup":"SY","termSource":"NCI"},{"termName":"INNO-406","termGroup":"CN","termSource":"NCI"},{"termName":"NS-187","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"859212-16-1"},{"name":"Chemical_Formula","value":"C30H31F3N8O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NVW4Z03I9B"},{"name":"Legacy Concept Name","value":"INNO-406"},{"name":"Maps_To","value":"Bafetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"500041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500041"},{"name":"PDQ_Open_Trial_Search_ID","value":"500041"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607225"}]}}{"C91094":{"preferredName":"Balixafortide","code":"C91094","definitions":[{"definition":"An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Balixafortide binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balixafortide","termGroup":"PT","termSource":"NCI"},{"termName":"Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his Cyclic (2->9)-disulfide","termGroup":"SY","termSource":"NCI"},{"termName":"POL6326","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1051366-32-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PRC974M49B"},{"name":"Maps_To","value":"Balixafortide"},{"name":"NCI_Drug_Dictionary_ID","value":"672350"},{"name":"NCI_META_CUI","value":"CL421480"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672350"},{"name":"PDQ_Open_Trial_Search_ID","value":"672350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129374":{"preferredName":"Baltaleucel-T","code":"C129374","definitions":[{"definition":"A preparation of autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (CTLs), which have specific reactivity to the EBV antigens, latent membrane proteins (LMP) 1 (LMP1) and 2 (LMP2), EBV nuclear antigen (EBNA) and BamHI-A rightward frame-1 (BARF1), with potential immunomodulating and antineoplastic activities. Upon administration, baltaleucel-T targets and binds to EBV-expressing cancer cells specifically expressing the targeted antigens. This may kill LMP1/LMP2/EBNA/BARF1-expressing EBV-associated cancer cells. LMP1, LMP2, EBNA and BARF1 are tumor-associated antigens (TAAs) that are specifically associated with EBV infection, and play key roles in the proliferation of a variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Baltaleucel-T","termGroup":"PT","termSource":"NCI"},{"termName":"Baltaleucel T","termGroup":"SY","termSource":"NCI"},{"termName":"CMD-003","termGroup":"CN","termSource":"NCI"},{"termName":"Epstein Barr Virus-specific LMP1/LMP2/EBNABARF1-targeting Autologous Cytotoxic T-lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F9670LP52I"},{"name":"Maps_To","value":"Baltaleucel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"783439"},{"name":"NCI_META_CUI","value":"CL512344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783439"},{"name":"PDQ_Open_Trial_Search_ID","value":"783439"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79528":{"preferredName":"Banoxantrone","code":"C79528","definitions":[{"definition":"A bioreductive, alkylaminoanthraquinone prodrug with antineoplastic activity. Under hypoxic conditions, often seen in solid tumors, banoxantrone (AQ4N) is converted and activated by cytochrome P450 enzymes, which are upregulated in certain tumors, to the cytotoxic DNA-binding agent AQ4. Banoxantrone intercalates into and crosslinks DNA, and inhibits topoisomerase II. This results in an inhibition of DNA replication and repair in tumor cells. Combined with conventional therapeutic agents, both oxygenic and hypoxic regions of tumors can be targeted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Banoxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Anthracenedione, 1,4-bis((2-(dimethylamino)ethyl)amino)-5,8-dihydroxy-, N,N'-dioxide","termGroup":"SN","termSource":"NCI"},{"termName":"AQ 4N","termGroup":"CN","termSource":"NCI"},{"termName":"Aq4N","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"136470-65-0"},{"name":"Chemical_Formula","value":"C22H28N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W5H7E45YT3"},{"name":"Legacy Concept Name","value":"Banoxantrone"},{"name":"Maps_To","value":"Banoxantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"393464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"393464"},{"name":"PDQ_Open_Trial_Search_ID","value":"393464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299316"}]}}{"C62502":{"preferredName":"Barasertib","code":"C62502","definitions":[{"definition":"An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity. Upon administration and rapid conversion from the prodrug form in plasma, AZD1152-HQPA specifically binds to and inhibits Aurora kinase B, which results in the disruption of spindle checkpoint functions and chromosome alignment and, so, the disruption of chromosome segregation and cytokinesis. Consequently, cell division and cell proliferation are inhibited and apoptosis is induced in Aurora kinase B-overexpressing tumor cells. Aurora kinase B, a serine/threonine protein kinase that functions in the attachment of the mitotic spindle to the centromere, is overexpressed in a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Barasertib","termGroup":"PT","termSource":"NCI"},{"termName":"1h-pyrazole-3-acetamide, 5-((7-(3-(ethyl(2-(phosphonooxy)ethyl)amino)propoxy)-4-quinazolinyl)amino)-n-(3-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Aurora Kinase Inhibitor AZD1152","termGroup":"SY","termSource":"NCI"},{"termName":"AZD-1152","termGroup":"CN","termSource":"NCI"},{"termName":"AZD1152","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"722543-31-9"},{"name":"Chemical_Formula","value":"C26H31FN7O6P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"16XC2U7W8N"},{"name":"Legacy Concept Name","value":"AZD1152"},{"name":"Maps_To","value":"Barasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"496937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496937"},{"name":"PDQ_Open_Trial_Search_ID","value":"496937"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831923"}]}}{"C48382":{"preferredName":"Bardoxolone","code":"C48382","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. CDDO may block enzymes involved in inflammation and cancer growth. It is a type of antineoplastic plant product.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bardoxolone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"CDDO","termGroup":"AB","termSource":"NCI"},{"termName":"Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-","termGroup":"SN","termSource":"NCI"},{"termName":"RTA 401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Antineoplastic and anti-inflammatory"},{"name":"CAS_Registry","value":"218600-44-3"},{"name":"Chemical_Formula","value":"C31H41NO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7HT68L8941"},{"name":"Legacy Concept Name","value":"CDDO"},{"name":"Maps_To","value":"Bardoxolone"},{"name":"NCI_Drug_Dictionary_ID","value":"453589"},{"name":"NSC Number","value":"711193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453589"},{"name":"PDQ_Open_Trial_Search_ID","value":"453589"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762434"}]}}{"C98250":{"preferredName":"Bardoxolone Methyl","code":"C98250","definitions":[{"definition":"The methyl ester form of bardoxolone, a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bardoxolone Methyl","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate","termGroup":"SN","termSource":"NCI"},{"termName":"2-cyano-3,12-dioxoolean-1,9-dien-28-oic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"CDDO Methyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"CDDO-Me","termGroup":"AB","termSource":"NCI"},{"termName":"RTA 402","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"218600-53-4"},{"name":"Chemical_Formula","value":"C32H43NO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CEG1Q6OGU1"},{"name":"Maps_To","value":"Bardoxolone Methyl"},{"name":"NSC Number","value":"713200"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1100924"}]}}{"C127012":{"preferredName":"Baricitinib","code":"C127012","definitions":[{"definition":"An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Baricitinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 028050","termGroup":"CN","termSource":"NCI"},{"termName":"INCB028050","termGroup":"CN","termSource":"NCI"},{"termName":"LY 3009104","termGroup":"CN","termSource":"NCI"},{"termName":"LY3009104","termGroup":"CN","termSource":"NCI"},{"termName":"Olumiant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Emergency Use Authorization (EUA): for the treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)."},{"name":"CAS_Registry","value":"1187594-09-7"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ISP4442I3Y"},{"name":"Maps_To","value":"Baricitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"781527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781527"},{"name":"PDQ_Open_Trial_Search_ID","value":"781527"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4044947"}]}}{"C72716":{"preferredName":"Batabulin","code":"C72716","definitions":[{"definition":"A synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to beta tubulin, resulting in a disruption of microtubule polymerization, collapse of the cytoskeleton, cell cycle arrest, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called mitotic inhibitors. It inhibits the growth of cancer cells by preventing cell division.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Batabulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195533-53-0"},{"name":"Chemical_Formula","value":"C13H7F6NO3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T4NP8G3K6Q"},{"name":"Legacy Concept Name","value":"Batabulin"},{"name":"Maps_To","value":"Batabulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0767920"}]}}{"C1835":{"preferredName":"Batabulin Sodium","code":"C1835","definitions":[{"definition":"The sodium salt form of batabulin, a synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Batabulin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-1-methoxy-4-(pentafluorophenyl-sulfonamido)benzene, Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"T138067 Sodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195533-98-3"},{"name":"Chemical_Formula","value":"C13H6F6NO3S.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G04B77F772"},{"name":"Legacy Concept Name","value":"T138067"},{"name":"Maps_To","value":"Batabulin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43107"},{"name":"PDQ_Open_Trial_Search_ID","value":"43107"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0767921"}]}}{"C1529":{"preferredName":"Batimastat","code":"C1529","definitions":[{"definition":"A synthetic hydroxamate with potential antineoplastic activity.  Batimastat binds covalently to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Batimastat is a matrix metalloproteinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Batimastat","termGroup":"PT","termSource":"NCI"},{"termName":"(2R,3S)-N{4}-Hydroxy-N{1}-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide","termGroup":"SN","termSource":"NCI"},{"termName":"[4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide","termGroup":"SN","termSource":"NCI"},{"termName":"[4-(N-Hydroxyamino)-2R-isobutyl-3S-(thiophen-2-ylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide","termGroup":"SN","termSource":"NCI"},{"termName":"BB-94","termGroup":"CN","termSource":"NCI"},{"termName":"BB94","termGroup":"CN","termSource":"NCI"},{"termName":"Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130370-60-4"},{"name":"Chemical_Formula","value":"C23H31N3O4S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK349F52C9"},{"name":"Legacy Concept Name","value":"Batimastat"},{"name":"Maps_To","value":"Batimastat"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0215791"}]}}{"C49088":{"preferredName":"Bavituximab","code":"C49088","definitions":[{"definition":"A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bavituximab","termGroup":"PT","termSource":"NCI"},{"termName":"Chimeric Anti-Phosphotidylserine Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"PGN401","termGroup":"CN","termSource":"NCI"},{"termName":"Tarvacin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"648904-28-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q16CT95N25"},{"name":"Legacy Concept Name","value":"Chimeric_Anti-Phosphotidylserine_Monoclonal_Antibody"},{"name":"Maps_To","value":"Bavituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"450954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"450954"},{"name":"PDQ_Open_Trial_Search_ID","value":"450954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707382"}]}}{"C73598":{"preferredName":"Bazedoxifene","code":"C73598","definitions":[{"definition":"An indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration, bazedoxifene specifically binds to estrogen receptors in responsive tissues, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it either promotes or suppresses the transcription of estrogen-regulated genes. Bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues. Bazedoxifene functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bazedoxifene","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"TSE-424","termGroup":"SY","termSource":"NCI"},{"termName":"WAY 140424","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198481-32-2"},{"name":"Chemical_Formula","value":"C30H34N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q16TT9C5BK"},{"name":"Legacy Concept Name","value":"Bazedoxifene"},{"name":"Maps_To","value":"Bazedoxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"772911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772911"},{"name":"PDQ_Open_Trial_Search_ID","value":"772911"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346970"}]}}{"C107685":{"preferredName":"BC-819 Plasmid/Polyethylenimine Complex","code":"C107685","definitions":[{"definition":"A plasmid DNA encoding for the A fragment of Diphtheria Toxin (DTA) under the control of the H19 gene promoter (BC-819 or DTA-H19) and mixed with the transfectant polyethylenimine (PEI), with potential antineoplastic activity. Upon administration, the PEI moiety enhances the entry of the agent into rapidly dividing cells. Upon cell entry, activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells. H19, an oncofetal, regulatory RNA, is overexpressed in certain cancer cells while its expression in normal cells is minimal or absent; it plays a key role in cancer progression, angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BC-819 Plasmid/Polyethylenimine Complex","termGroup":"PT","termSource":"NCI"},{"termName":"BC-819/PEI","termGroup":"AB","termSource":"NCI"},{"termName":"DTA-H19/PEI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BC-819 Plasmid/Polyethylenimine Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"751613"},{"name":"NCI_META_CUI","value":"CL451873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751613"},{"name":"PDQ_Open_Trial_Search_ID","value":"751613"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83496":{"preferredName":"BCG Solution","code":"C83496","definitions":[{"definition":"A form of biological therapy for superficial (not invasive) bladder cancer. The solution is made from a weakened form of the bacterium Mycobacterium bovis (bacillus Calmette-Guerin) that does not cause disease but stimulates the body's immune system. A catheter is used to place the BCG solution into the bladder where it is held for about two hours.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A solution containing an attenuated, live culture preparation of the Bacillus Calmette Guerin (BCG) strain of Mycobacterium bovis with potential immunostimulating activity. Although the precise mechanism of action is unknown, upon intravesical administration, attenuated, live BCG bacteria in the solution come into direct contact with the bladder wall, inciting an antitumor granulomatous inflammatory reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCG Solution","termGroup":"PT","termSource":"NCI"},{"termName":"Bacillus Calmette Guerin Solution","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin Solution","termGroup":"SY","termSource":"NCI"},{"termName":"TICE BCG Solution","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BCG Solution"},{"name":"NCI_Drug_Dictionary_ID","value":"632465"},{"name":"NCI_META_CUI","value":"CL388460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632465"},{"name":"PDQ_Open_Trial_Search_ID","value":"632465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126694":{"preferredName":"BCG Tokyo-172 Strain Solution","code":"C126694","definitions":[{"definition":"A solution containing an attenuated, live culture preparation of the bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis obtained from the Pasteur Institute in 1924, with potential immunostimulating and antineoplastic activities. Although the precise mechanism of action is unknown, upon intravesical instillation through a catheter, the attenuated, live BCG bacteria in the BCG Tokyo-172 strain solution come into direct contact with the bladder wall and elicits a local, multifaceted immune response against the BCG antigens, which kills the bladder cancer cells. Previous vaccination with a systemic BCG vaccine may enhance the immune system's response against the BCG antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCG Tokyo-172 Strain Solution","termGroup":"PT","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin Tokyo-172 Strain Solution","termGroup":"SY","termSource":"NCI"},{"termName":"Immunobladder","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"267H8I71ZT"},{"name":"Maps_To","value":"BCG Tokyo-172 Strain Solution"},{"name":"NCI_Drug_Dictionary_ID","value":"788251"},{"name":"NCI_META_CUI","value":"CL508158"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788251"},{"name":"PDQ_Open_Trial_Search_ID","value":"788251"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C298":{"preferredName":"BCG Vaccine","code":"C298","definitions":[{"definition":"A tuberculosis vaccine containing bacillus Calmette-Guérin, a live attenuated strain of Mycobacterium bovis. There are many different strains of BCG vaccine, all of which were originally derived from one strain, but which now have very different properties.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","type":"DEFINITION","source":"NCI"},{"definition":"A weakened form of the bacterium Mycobacterium bovis (bacillus Calmette-Guerin) that does not cause disease. BCG is used in a solution to stimulate the immune system in the treatment of bladder cancer and as a vaccine to prevent tuberculosis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"BCG Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Bacille Calmette Guerin","termGroup":"SY","termSource":"NCI"},{"termName":"Bacille Calmette-Guerin Live","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillius Calmette-Guerin Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillus Calmette Guerin Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin","termGroup":"SY","termSource":"NCI"},{"termName":"BCG","termGroup":"SY","termSource":"NCI"},{"termName":"BCG (Pasteur)","termGroup":"SY","termSource":"NCI"},{"termName":"BCG Tice","termGroup":"SY","termSource":"NCI"},{"termName":"Cultivo BCG","termGroup":"FB","termSource":"NCI"},{"termName":"ImmuCyst","termGroup":"BR","termSource":"NCI"},{"termName":"Imovax BCG","termGroup":"FB","termSource":"NCI"},{"termName":"Live Intravesical BCG","termGroup":"SY","termSource":"NCI"},{"termName":"Monovax","termGroup":"FB","termSource":"NCI"},{"termName":"Mycobacterium bovis (Strain BCG)","termGroup":"SY","termSource":"NCI"},{"termName":"Oncotice","termGroup":"FB","termSource":"NCI"},{"termName":"Pacis","termGroup":"FB","termSource":"NCI"},{"termName":"Pastimmun","termGroup":"FB","termSource":"NCI"},{"termName":"TICE BCG","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Tuberculosis, immunization"},{"name":"Accepted_Therapeutic_Use_For","value":"Immunoadjuvant in Vaccine Therapy"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"BCG_Vaccine"},{"name":"Maps_To","value":"BCG Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43028"},{"name":"NSC Number","value":"116328"},{"name":"NSC Number","value":"116341"},{"name":"NSC Number","value":"614389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43028"},{"name":"PDQ_Open_Trial_Search_ID","value":"43028"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3257574"}]}}{"C156249":{"preferredName":"Lisaftoclax","code":"C156249","definitions":[{"definition":"An orally bioavailable and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lisaftoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lisaftoclax","termGroup":"PT","termSource":"NCI"},{"termName":"APG 2575","termGroup":"CN","termSource":"NCI"},{"termName":"APG-2575","termGroup":"CN","termSource":"NCI"},{"termName":"APG2575","termGroup":"CN","termSource":"NCI"},{"termName":"Bcl-2 Inhibitor APG 2575","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2180923-05-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OSL3FEZ1IF"},{"name":"Maps_To","value":"Bcl-2 Inhibitor APG 2575"},{"name":"NCI_Drug_Dictionary_ID","value":"795558"},{"name":"NCI_META_CUI","value":"CL562961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795558"},{"name":"PDQ_Open_Trial_Search_ID","value":"795558"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125603":{"preferredName":"Bcl-2 Inhibitor BCL201","code":"C125603","definitions":[{"definition":"A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bcl-2 Inhibitor BCL201","termGroup":"PT","termSource":"NCI"},{"termName":"BCL-201","termGroup":"CN","termSource":"NCI"},{"termName":"BCL201","termGroup":"CN","termSource":"NCI"},{"termName":"S-55746","termGroup":"CN","termSource":"NCI"},{"termName":"S55746","termGroup":"CN","termSource":"NCI"},{"termName":"Servier 1","termGroup":"CN","termSource":"NCI"},{"termName":"Servier-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448584-12-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W93257I68I"},{"name":"Maps_To","value":"Bcl-2 Inhibitor BCL201"},{"name":"NCI_Drug_Dictionary_ID","value":"778922"},{"name":"NCI_META_CUI","value":"CL504308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778922"},{"name":"PDQ_Open_Trial_Search_ID","value":"778922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158510":{"preferredName":"BCL2 Inhibitor VOB560","code":"C158510","definitions":[{"definition":"An inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon intravenous administration, Bcl-2 inhibitor VOB560 binds to and inhibits the activity of Bcl-2, thereby restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancer types and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL2 Inhibitor VOB560","termGroup":"PT","termSource":"NCI"},{"termName":"Bcl-2 Inhibitor S65487","termGroup":"SY","termSource":"NCI"},{"termName":"S 65487","termGroup":"CN","termSource":"NCI"},{"termName":"S-65487","termGroup":"CN","termSource":"NCI"},{"termName":"S65487","termGroup":"CN","termSource":"NCI"},{"termName":"VOB 560","termGroup":"CN","termSource":"NCI"},{"termName":"VOB-560","termGroup":"CN","termSource":"NCI"},{"termName":"VOB560","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bcl-2 Inhibitor S65487"},{"name":"NCI_Drug_Dictionary_ID","value":"797175"},{"name":"NCI_META_CUI","value":"CL938051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797175"},{"name":"PDQ_Open_Trial_Search_ID","value":"797175"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28860":{"preferredName":"Bcl-Xs Adenovirus Vaccine","code":"C28860","definitions":[{"definition":"A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity.  Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected.  Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bcl-Xs Adenovirus Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bcl-Xs_Adenovirus_Vaccine"},{"name":"Maps_To","value":"Bcl-Xs Adenovirus Vaccine"},{"name":"NSC Number","value":"689513"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1511078"}]}}{"C156052":{"preferredName":"BCMA x CD3 T-cell Engaging Antibody CC-93269","code":"C156052","synonyms":[{"termName":"BCMA x CD3 T-cell Engaging Antibody CC-93269","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Feb 07 10:05:59 EST 2024 - See 'Alnuctamab(C175740)'"},{"name":"NCI_META_CUI","value":"CL562897"},{"name":"OLD_PARENT","value":"C181114"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174748":{"preferredName":"Vodobatinib","code":"C174748","definitions":[{"definition":"An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vodobatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Methyl-3-quinolin-3-ylethynylbenzoic Acid N'-(2-chloro-6-methylbenzoyl) Hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"Bcr-Abl Kinase Inhibitor K0706","termGroup":"SY","termSource":"NCI"},{"termName":"K-0706","termGroup":"CN","termSource":"NCI"},{"termName":"K0706","termGroup":"CN","termSource":"NCI"},{"termName":"SCO-088","termGroup":"CN","termSource":"NCI"},{"termName":"SUN K706","termGroup":"CN","termSource":"NCI"},{"termName":"SUN-K0706","termGroup":"CN","termSource":"NCI"},{"termName":"SUN-K706","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11506","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1388803-90-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N8Q12KU2SW"},{"name":"Maps_To","value":"Bcr-Abl Kinase Inhibitor K0706"},{"name":"NCI_Drug_Dictionary_ID","value":"787015"},{"name":"NCI_META_CUI","value":"CL520597"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787015"},{"name":"PDQ_Open_Trial_Search_ID","value":"787015"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130033":{"preferredName":"Vamotinib","code":"C130033","definitions":[{"definition":"An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor, with potential antineoplastic activity. Designed to overcome resistance of tumor cells to second generation Bcr-Abl inhibitors, vamotinib targets and binds to the Bcr-Abl fusion oncoprotein, including those fusion proteins with the 'gatekeeper' resistance mutation T315I, an amino acid substitution at position 315 in Bcr-Abl from a threonine (T) to an isoleucine (I). This inhibits Bcr-Abl-mediated proliferation of, and enhances apoptosis in, Philadelphia chromosome-positive (Ph+) hematologic malignancies. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by leukemia cells that contain the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vamotinib","termGroup":"PT","termSource":"NCI"},{"termName":"Bcr-Abl Inhibitor PF-114","termGroup":"SY","termSource":"NCI"},{"termName":"Bcr-Abl Kinase Inhibitor PF-114","termGroup":"SY","termSource":"NCI"},{"termName":"PF-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1416241-23-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I8C3R768IZ"},{"name":"Maps_To","value":"Bcr-Abl Kinase Inhibitor PF-114"},{"name":"NCI_Drug_Dictionary_ID","value":"784962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784962"},{"name":"PDQ_Open_Trial_Search_ID","value":"784962"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4043268"}]}}{"C165549":{"preferredName":"Olverembatinib","code":"C165549","definitions":[{"definition":"An orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity. Upon administration,olverembatinib targets, binds to and inhibits the kinase activities of Bcr-Abl, AKT, c-Kit and ERK. This inhibits their mediated signaling pathways and inhibits proliferation of tumor cells in which these kinases are overexpressed and/or mutated. Bcr-Abl, c-Kit, AKT and ERK play key roles in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olverembatinib","termGroup":"PT","termSource":"NCI"},{"termName":"BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351","termGroup":"SY","termSource":"NCI"},{"termName":"GZD-824","termGroup":"CN","termSource":"NCI"},{"termName":"HQP 1351","termGroup":"CN","termSource":"NCI"},{"termName":"HQP-1351","termGroup":"CN","termSource":"NCI"},{"termName":"HQP1351","termGroup":"CN","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor HQP1351","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1257628-77-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KV1M7Q3CBP"},{"name":"Maps_To","value":"BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351"},{"name":"NCI_Drug_Dictionary_ID","value":"799639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799639"},{"name":"PDQ_Open_Trial_Search_ID","value":"799639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659765"}]}}{"C1011":{"preferredName":"Beauvericin","code":"C1011","definitions":[{"definition":"A cyclic hexadepsipeptide antibiotic and mycotoxin isolated from the fungus Beauveria bassiana and various Fusarium fungal species.  As a potassium-specific ionophore, beauvericin A increases intracellular calcium concentrations and triggers DNA fragmentation and apoptosis through a calcium dependent caspase 3-sensitive pathway.  This agent has been studied as a potential antineoplastic agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beauvericin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26048-05-5"},{"name":"CHEBI_ID","value":"CHEBI:3000"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"26S048LS2R"},{"name":"Legacy Concept Name","value":"Beauvericin"},{"name":"Maps_To","value":"Beauvericin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053065"}]}}{"C1620":{"preferredName":"Becatecarin","code":"C1620","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called antitumor antibiotics and topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic diethylaminoethyl analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin.  Becatecarin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Becatecarin","termGroup":"PT","termSource":"NCI"},{"termName":"5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-181176","termGroup":"CN","termSource":"NCI"},{"termName":"BMY-27557-14","termGroup":"CN","termSource":"NCI"},{"termName":"DEAE-Rebeccamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Rebeccamycin Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"Rebeccamycin Analogue, Tartrate Salt","termGroup":"SY","termSource":"NCI"},{"termName":"XL119","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"119673-08-4"},{"name":"Chemical_Formula","value":"C33H34Cl2N4O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A60X6MBU6G"},{"name":"Legacy Concept Name","value":"Rebeccamycin_Analogue"},{"name":"Maps_To","value":"Becatecarin"},{"name":"NCI_Drug_Dictionary_ID","value":"42257"},{"name":"NSC Number","value":"655649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42257"},{"name":"PDQ_Open_Trial_Search_ID","value":"42257"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0936065"}]}}{"C73438":{"preferredName":"Belagenpumatucel-L","code":"C73438","definitions":[{"definition":"A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belagenpumatucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Lucanix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Belagenpumatucel-L"},{"name":"Maps_To","value":"Belagenpumatucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"590662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590662"},{"name":"PDQ_Open_Trial_Search_ID","value":"590662"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1739687"}]}}{"C91385":{"preferredName":"Belimumab","code":"C91385","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Benlysta","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(Human Cytokine BAFF) (Human Monoclonal LymphoStat-B Heavy Chain), Disulfide with Human Monoclonal LymphoStat-B lambda-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"LymphoStat-B","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Systemic Lupus Erythematosus"},{"name":"CAS_Registry","value":"356547-88-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"73B0K5S26A"},{"name":"Maps_To","value":"Belimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"680522"},{"name":"PDQ_Closed_Trial_Search_ID","value":"680522"},{"name":"PDQ_Open_Trial_Search_ID","value":"680522"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723401"}]}}{"C48812":{"preferredName":"Belinostat","code":"C48812","definitions":[{"definition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Belinostat blocks enzymes needed for cell division and may kill cancer cells. It also prevents the growth of blood vessels needed for tumors to grow and may make tumor cells more sensitive to other anticancer drugs. It is a type of histone deacetylase (HDAC) inhibitor, a type of angiogenesis inhibitor, and a type of chemosensitizer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Belinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Beleodaq","termGroup":"BR","termSource":"NCI"},{"termName":"PXD 101","termGroup":"CN","termSource":"NCI"},{"termName":"PXD101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory peripheral T-cell lymphoma (PTCL)"},{"name":"CAS_Registry","value":"414864-00-9"},{"name":"CHEBI_ID","value":"CHEBI:61076"},{"name":"Chemical_Formula","value":"C15H14N2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F4H96P17NZ"},{"name":"Legacy Concept Name","value":"PXD101"},{"name":"Maps_To","value":"Belinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"454583"},{"name":"NSC Number","value":"726630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454583"},{"name":"PDQ_Open_Trial_Search_ID","value":"454583"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1948068"}]}}{"C66954":{"preferredName":"Belotecan Hydrochloride","code":"C66954","definitions":[{"definition":"A substance being studied in the treatment of small cell lung cancer and other types of cancer. It blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of camptothecin analog and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the semi-synthetic camptothecin analogue belotecan with potential antitumor activity. Belotecan binds to and inhibits the activity of topoisomerase I, stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Topoisomerase I is an enzyme that mediates reversible single-strand breaks in DNA during DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"CKD602 HCl","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"213819-48-8"},{"name":"Chemical_Formula","value":"C25H27N3O4.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01DZ4127G7"},{"name":"Legacy Concept Name","value":"Belotecan_Hydrochloride"},{"name":"Maps_To","value":"Belotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"537355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537355"},{"name":"PDQ_Open_Trial_Search_ID","value":"537355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762739"}]}}{"C120040":{"preferredName":"Bemarituzumab","code":"C120040","definitions":[{"definition":"A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration, bemarituzumab specifically binds to and inhibits FGFR2b on tumor cell surfaces, which prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing tumor cells. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bemarituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"FPA144","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1952272-74-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RJW23BQ0KW"},{"name":"Maps_To","value":"Bemarituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"767461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767461"},{"name":"PDQ_Open_Trial_Search_ID","value":"767461"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896858"}]}}{"C121854":{"preferredName":"Bemcentinib","code":"C121854","definitions":[{"definition":"An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration, bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, bemcentinib enhances chemo-sensitivity. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bemcentinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-Dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"AXL Inhibitor BGB324","termGroup":"SY","termSource":"NCI"},{"termName":"BGB 324","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-324","termGroup":"CN","termSource":"NCI"},{"termName":"BGB324","termGroup":"CN","termSource":"NCI"},{"termName":"R-428","termGroup":"CN","termSource":"NCI"},{"termName":"R428","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10631","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1037624-75-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0ICW2LX8AS"},{"name":"Maps_To","value":"Bemcentinib"},{"name":"NCI_Drug_Dictionary_ID","value":"771720"},{"name":"NCI_META_CUI","value":"CL777354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771720"},{"name":"PDQ_Open_Trial_Search_ID","value":"771720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131019":{"preferredName":"Bempegaldesleukin","code":"C131019","definitions":[{"definition":"A recombinant form of the endogenous cytokine interleukin-2 (IL-2) conjugated to six releasable polyethylene glycol (PEG) chains, with potential immunostimulating activity. Upon administration of bempegaldesleukin, the IL-2 moiety binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells primarily causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells. PEG conjugation prevents IL-2 binding to the IL2Ralpha subunit (IL2Ra) because signaling through IL2Ra activates CD4-positive regulatory, immunosuppressive T-cells (Tregs), which would suppress tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bempegaldesleukin","termGroup":"PT","termSource":"NCI"},{"termName":"Aldesleukin Prodrug NKTR-214","termGroup":"SY","termSource":"NCI"},{"termName":"NKTR-214","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1939126-74-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BNO1JG5MZC"},{"name":"Maps_To","value":"Bempegaldesleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"785056"},{"name":"NCI_META_CUI","value":"CL513468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785056"},{"name":"PDQ_Open_Trial_Search_ID","value":"785056"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73231":{"preferredName":"Benaxibine","code":"C73231","definitions":[{"definition":"A cyclophosphamide synergizer with antineoplastic, antidiabetic, antihypertensive and immunopotentiating activity. Benaxibine is active against integrin alph-4 precursor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benaxibine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Aminobenzoic acid-N-xyloside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"27661-27-4"},{"name":"Chemical_Formula","value":"C12H15NO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6EEL176LGY"},{"name":"Legacy Concept Name","value":"Benaxibine"},{"name":"Maps_To","value":"Benaxibine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048028"}]}}{"C73261":{"preferredName":"Bendamustine","code":"C73261","definitions":[{"definition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat chronic lymphocytic leukemia (CLL), to treat slow-growing B-cell non-Hodgkin lymphoma (NHL) that has gotten worse within 6 months of treatment with other anticancer drugs, and is being studied in the treatment of other types of cancer. Bendamustine may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bendamustine","termGroup":"PT","termSource":"NCI"},{"termName":"5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"SDX-105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Lymphocytic Leukemia, Indolent B-cell non-Hodgkin Lymphoma"},{"name":"CAS_Registry","value":"16506-27-7"},{"name":"Chemical_Formula","value":"C16H21Cl2N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"9266D9P3PQ"},{"name":"Legacy Concept Name","value":"Bendamustine"},{"name":"Maps_To","value":"Bendamustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0525079"}]}}{"C61565":{"preferredName":"Bendamustine Hydrochloride","code":"C61565","definitions":[{"definition":"A drug used to treat chronic lymphocytic leukemia (CLL). It is also used to treat slow-growing B-cell non-Hodgkin lymphoma (NHL) that has gotten worse within 6 months of treatment with other anticancer drugs.It is being studied in the treatment of other types of cancer. Bendamustine hydrochloride may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bendamustine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-Benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Belrapzo","termGroup":"BR","termSource":"NCI"},{"termName":"Bendamustin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Bendeka","termGroup":"BR","termSource":"NCI"},{"termName":"CEP-18083","termGroup":"CN","termSource":"NCI"},{"termName":"Cytostasan Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Levact","termGroup":"FB","termSource":"NCI"},{"termName":"Ribomustin","termGroup":"FB","termSource":"NCI"},{"termName":"SyB L-0501","termGroup":"CN","termSource":"NCI"},{"termName":"Treakisym","termGroup":"FB","termSource":"NCI"},{"termName":"Treanda","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia"},{"name":"CAS_Registry","value":"3543-75-7"},{"name":"Chemical_Formula","value":"C16H21Cl2N3O2.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"981Y8SX18M"},{"name":"Legacy Concept Name","value":"Bendamustine_Hydrochloride"},{"name":"Maps_To","value":"Bendamustine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"350251"},{"name":"NSC Number","value":"138783"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350251"},{"name":"PDQ_Open_Trial_Search_ID","value":"350251"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0772139"}]}}{"C124053":{"preferredName":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107","code":"C124053","definitions":[{"definition":"A nanoparticle-based formulation containing the alkyl ester of bendamustine, a bifunctional mechlorethamine derivative, encapsulated in human serum albumin (HSA), with potential alkylating and antineoplastic activities. Upon administration of the alkyl ester bendamustine-containing nanoparticle formulation RXDX-107, the nanoparticle formulation permits high concentrations of the alkyl ester of bendamustine be localized at the tumor site. The modified bendamustine alkylates and crosslinks macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-40125","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX 107","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1456608-94-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22C7JIO84O"},{"name":"Maps_To","value":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107"},{"name":"NCI_Drug_Dictionary_ID","value":"776266"},{"name":"NCI_META_CUI","value":"CL498407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776266"},{"name":"PDQ_Open_Trial_Search_ID","value":"776266"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107164":{"preferredName":"Benzaldehyde Dimethane Sulfonate","code":"C107164","definitions":[{"definition":"A dimethane sulfonate derivative and alkylating agent with a structure similar to other alkylating agents such as chlorambucil, busulfan and melphalan, with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, benzaldehyde dimethane sulfonate alkylates DNA, which results in DNA double strand breaks, inhibition of DNA replication, cell cycle arrest and cell death. In addition, this agent is metabolized by the enzyme aldehyde dehydrogenase (ALDH) into the active carboxylic acid metabolite benzoic acid dimethane sulfonate (BA), which further contributes to its alkylating activity. Unlike other alkylating agents, benzaldehyde dimethane sulfonate has demonstrated antitumor activity in renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benzaldehyde Dimethane Sulfonate","termGroup":"PT","termSource":"NCI"},{"termName":"BEN","termGroup":"AB","termSource":"NCI"},{"termName":"DMS612","termGroup":"CN","termSource":"NCI"},{"termName":"NSC 281612","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56967-08-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96B0BRI1JU"},{"name":"Maps_To","value":"Benzaldehyde Dimethane Sulfonate"},{"name":"NCI_Drug_Dictionary_ID","value":"750365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750365"},{"name":"PDQ_Open_Trial_Search_ID","value":"750365"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661349"}]}}{"C2618":{"preferredName":"Benzoylphenylurea","code":"C2618","definitions":[{"definition":"A low molecular weight agent with antineoplastic activity. Benzoylphenylurea binds to the colchicine binding site on tubulin, thereby blocking tubulin polymerization and disrupting mitotic function.  This agent also inhibits DNA polymerase, and has been shown to arrest leukemia cells in the G1-S transition phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of antitubulin agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Benzoylphenylurea","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-(aminocarbonyl)-N-phenyl-","termGroup":"SY","termSource":"NCI"},{"termName":"BPU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1195179-46-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M10I9SO6RR"},{"name":"Legacy Concept Name","value":"Benzoylphenylurea"},{"name":"Maps_To","value":"Benzoylphenylurea"},{"name":"NCI_Drug_Dictionary_ID","value":"38213"},{"name":"NSC Number","value":"639829"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38213"},{"name":"PDQ_Open_Trial_Search_ID","value":"38213"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935907"}]}}{"C87331":{"preferredName":"Berberine Chloride","code":"C87331","definitions":[{"definition":"The orally bioavailable, hydrochloride salt form of berberine, a quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation.  In addition, berberine modulates lipid and glucose metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Berberine Chloride","termGroup":"PT","termSource":"NCI"},{"termName":"5,6-Dihydro-9,10-Dimethoxybenzo(G)-1,3-Benzodioxolo(5,6-A)Quinolizinium Chloride","termGroup":"SN","termSource":"NCI"},{"termName":"Berberine Chloride Dihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Berberine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Berberinum Chloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"633-65-8"},{"name":"Chemical_Formula","value":"C20H18NO4.Cl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UOT4O1BYV8"},{"name":"Maps_To","value":"Berberine Chloride"},{"name":"NCI_Drug_Dictionary_ID","value":"764359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764359"},{"name":"PDQ_Open_Trial_Search_ID","value":"764359"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0873019"}]}}{"C61568":{"preferredName":"Berubicin Hydrochloride","code":"C61568","definitions":[{"definition":"A substance being studied in the treatment of adult brain tumors. RTA 744 crosses the blood-brain barrier and blocks an enzyme needed for cancer growth. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the anthracycline derivative berubicin with potential antineoplastic activity. Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. Unlike other anthracycline derivatives, this agent crosses the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Berubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,10S)-10-((3-amino-4-O-benzyl-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)- 6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"RTA 744","termGroup":"CN","termSource":"NCI"},{"termName":"WP744","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"293736-67-1"},{"name":"Chemical_Formula","value":"C34H35NO11.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BA3X03948"},{"name":"Legacy Concept Name","value":"RTA_744"},{"name":"Maps_To","value":"Berubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"491929"},{"name":"NCI_META_CUI","value":"CL364772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"491929"},{"name":"PDQ_Open_Trial_Search_ID","value":"491929"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126805":{"preferredName":"BET Bromodomain Inhibitor ZEN-3694","code":"C126805","definitions":[{"definition":"An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ZEN-3694 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Bromodomain Inhibitor ZEN-3694","termGroup":"PT","termSource":"NCI"},{"termName":"BETi ZEN-3694","termGroup":"SY","termSource":"NCI"},{"termName":"ZEN 3694","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN-3694","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN003694","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET Bromodomain Inhibitor ZEN-3694"},{"name":"NCI_Drug_Dictionary_ID","value":"780442"},{"name":"NCI_META_CUI","value":"CL507898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780442"},{"name":"PDQ_Open_Trial_Search_ID","value":"780442"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148415":{"preferredName":"BET Inhibitor ABBV-744","code":"C148415","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ABBV-744 preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor ABBV-744","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 744","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-744","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV744","termGroup":"CN","termSource":"NCI"},{"termName":"BD2-selective BET Inhibitor ABBV-744","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138861-99-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9MX546E2SF"},{"name":"Maps_To","value":"BET Inhibitor ABBV-744"},{"name":"NCI_Drug_Dictionary_ID","value":"794664"},{"name":"NCI_META_CUI","value":"CL550999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794664"},{"name":"PDQ_Open_Trial_Search_ID","value":"794664"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121213":{"preferredName":"BET Inhibitor BAY1238097","code":"C121213","definitions":[{"definition":"An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BAY1238097 binds to the acetylated lysine recognition motifs on the BRD of BET proteins, thereby preventing the interaction between BET proteins and histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes. This leads to an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor BAY1238097","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1238097","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1238097","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1238097","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1564268-08-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M9ALI41OQR"},{"name":"Maps_To","value":"BET Inhibitor BAY1238097"},{"name":"NCI_Drug_Dictionary_ID","value":"769590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769590"},{"name":"PDQ_Open_Trial_Search_ID","value":"769590"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053666"}]}}{"C160257":{"preferredName":"Amredobresib","code":"C160257","definitions":[{"definition":"An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity. Upon oral administration, amredobresib binds to bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) as well as bromodomain testis-specific protein (BRDT), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, including Myc and other transcriptional regulators. Preventing the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amredobresib","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-Triazolo(4,3-a)pyrazin-8-amine, N,3-dimethyl-6-(6-(4-methyl-1-piperazinyl)-1-(phenylmethyl)-1hbenzimidazol-2-yl)","termGroup":"SN","termSource":"NCI"},{"termName":"6-(1-Benzyl-6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl)-N,3-dimethyl-(1,2,4)triazolo(4,3-a)pyrazin-8-amine","termGroup":"SN","termSource":"NCI"},{"termName":"BET inhibitor BI 894999","termGroup":"SY","termSource":"NCI"},{"termName":"BI 894999","termGroup":"CN","termSource":"NCI"},{"termName":"BI-894999","termGroup":"CN","termSource":"NCI"},{"termName":"BI894999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610044-98-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6XR3O34V2"},{"name":"Maps_To","value":"BET inhibitor BI 894999"},{"name":"NCI_META_CUI","value":"CL969271"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121849":{"preferredName":"Ezobresib","code":"C121849","definitions":[{"definition":"An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, ezobresib binds to the acetyl-lysine binding site in the BRD of BET proteins, thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes, resulting in an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ezobresib","termGroup":"PT","termSource":"NCI"},{"termName":"BET Inhibitor BMS-986158","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986158","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1800340-40-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X8BW0MQ5PI"},{"name":"Maps_To","value":"BET Inhibitor BMS-986158"},{"name":"NCI_Drug_Dictionary_ID","value":"771520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771520"},{"name":"PDQ_Open_Trial_Search_ID","value":"771520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053659"}]}}{"C151951":{"preferredName":"Trotabresib","code":"C151951","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trotabresib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl)-2-methylisoquinolin-1-one","termGroup":"SY","termSource":"NCI"},{"termName":"BET Inhibitor CC-90010","termGroup":"SY","termSource":"NCI"},{"termName":"CC 90010","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90010","termGroup":"CN","termSource":"NCI"},{"termName":"CC90010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1706738-98-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K424WH3WU0"},{"name":"Maps_To","value":"BET Inhibitor CC-90010"},{"name":"NCI_Drug_Dictionary_ID","value":"793170"},{"name":"NCI_META_CUI","value":"CL553179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793170"},{"name":"PDQ_Open_Trial_Search_ID","value":"793170"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111901":{"preferredName":"Pelabresib Anhydrous","code":"C111901","definitions":[{"definition":"The anhydrous form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of two bromodomains at the N-terminus, the BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelabresib Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"BET Inhibitor CPI-0610","termGroup":"SY","termSource":"NCI"},{"termName":"CPI-0610 Anhydrous","termGroup":"SY","termSource":"NCI"},{"termName":"CPI-232","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-267232","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1380087-89-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U4017GUQ06"},{"name":"Maps_To","value":"BET Inhibitor CPI-0610"},{"name":"Maps_To","value":"Pelabresib"},{"name":"NCI_Drug_Dictionary_ID","value":"753680"},{"name":"NCI_META_CUI","value":"CL454233"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753680"},{"name":"PDQ_Open_Trial_Search_ID","value":"753680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123733":{"preferredName":"BET Inhibitor FT-1101","code":"C123733","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor FT-1101","termGroup":"PT","termSource":"NCI"},{"termName":"CC 95775","termGroup":"CN","termSource":"NCI"},{"termName":"CC-95775","termGroup":"CN","termSource":"NCI"},{"termName":"CC95775","termGroup":"CN","termSource":"NCI"},{"termName":"FT-1101","termGroup":"CN","termSource":"NCI"},{"termName":"FT1101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET Inhibitor FT-1101"},{"name":"NCI_Drug_Dictionary_ID","value":"775905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775905"},{"name":"PDQ_Open_Trial_Search_ID","value":"775905"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053643"}]}}{"C126640":{"preferredName":"Alobresib","code":"C126640","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, alobresib binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alobresib","termGroup":"PT","termSource":"NCI"},{"termName":"(2-Cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1hbenzimidazol-4-yl)(dipyridin-2-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"GS 5829","termGroup":"CN","termSource":"NCI"},{"termName":"GS-5829","termGroup":"CN","termSource":"NCI"},{"termName":"GS5829","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637771-14-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3QBL0BLP3D"},{"name":"Maps_To","value":"Alobresib"},{"name":"Maps_To","value":"BET Inhibitor GS-5829"},{"name":"NCI_Drug_Dictionary_ID","value":"770347"},{"name":"NCI_META_CUI","value":"CL505073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770347"},{"name":"PDQ_Open_Trial_Search_ID","value":"770347"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125391":{"preferredName":"BET Inhibitor GSK2820151","code":"C125391","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor GSK2820151 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor GSK2820151","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 2820151","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2820151","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET Inhibitor GSK2820151"},{"name":"NCI_Drug_Dictionary_ID","value":"778693"},{"name":"NCI_META_CUI","value":"CL504160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778693"},{"name":"PDQ_Open_Trial_Search_ID","value":"778693"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121948":{"preferredName":"BET Inhibitor INCB054329","code":"C121948","definitions":[{"definition":"An inhibitor of the Bromodomain and Extra-Terminal (BET) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor INCB054329 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor INCB054329","termGroup":"PT","termSource":"NCI"},{"termName":"INCB054329","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET Inhibitor INCB054329"},{"name":"NCI_Drug_Dictionary_ID","value":"771984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771984"},{"name":"PDQ_Open_Trial_Search_ID","value":"771984"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053634"}]}}{"C128622":{"preferredName":"BET Inhibitor INCB057643","code":"C128622","definitions":[{"definition":"An inhibitor of the Bromodomain (BRD) and Extra-Terminal (BET) family of BRD-containing proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor INCB057643 binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, such as c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. BET proteins are transcriptional regulators that are overexpressed in certain tumor cells and play an important role in cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor INCB057643","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 057643","termGroup":"CN","termSource":"NCI"},{"termName":"INCB057643","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1820889-23-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"87TZD0JEBS"},{"name":"Maps_To","value":"BET Inhibitor INCB057643"},{"name":"NCI_Drug_Dictionary_ID","value":"780220"},{"name":"NCI_META_CUI","value":"CL507893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780220"},{"name":"PDQ_Open_Trial_Search_ID","value":"780220"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C112500":{"preferredName":"BET Inhibitor RO6870810","code":"C112500","definitions":[{"definition":"A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor RO6870810 binds to the acetylated lysine recognition motifs found in the bromodomain of BET proteins, which prevents the interaction between BET proteins and acetylated histones. This interaction disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor RO6870810","termGroup":"PT","termSource":"NCI"},{"termName":"Bromodomain and Extra-Terminal Protein Inhibitor RO6870810","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6146","termGroup":"CN","termSource":"NCI"},{"termName":"RG6146","termGroup":"CN","termSource":"NCI"},{"termName":"RO6870810","termGroup":"CN","termSource":"NCI"},{"termName":"TEN 010","termGroup":"CN","termSource":"NCI"},{"termName":"TEN-010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1349719-98-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TA3QN7788D"},{"name":"Maps_To","value":"BET Inhibitor RO6870810"},{"name":"NCI_Drug_Dictionary_ID","value":"755021"},{"name":"NCI_META_CUI","value":"CL454674"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755021"},{"name":"PDQ_Open_Trial_Search_ID","value":"755021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148138":{"preferredName":"BET-bromodomain Inhibitor ODM-207","code":"C148138","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ODM-207 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression of oncogenic drivers that are important for cell proliferation and survival. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that bind to acetylated lysine residues in histones and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET-bromodomain Inhibitor ODM-207","termGroup":"PT","termSource":"NCI"},{"termName":"BET Inhibitor ODM-207","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain and Extraterminal Domain Protein Inhibitor ODM-207","termGroup":"SY","termSource":"NCI"},{"termName":"ODM 207","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-207","termGroup":"CN","termSource":"NCI"},{"termName":"ODM207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET-bromodomain Inhibitor ODM-207"},{"name":"NCI_Drug_Dictionary_ID","value":"792467"},{"name":"NCI_META_CUI","value":"CL550806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792467"},{"name":"PDQ_Open_Trial_Search_ID","value":"792467"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2605":{"preferredName":"Beta Alethine","code":"C2605","definitions":[{"definition":"A disulfide agent that stimulates T and B-cell functions and exhibits anti-tumor and immunostimulant activity. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to a family of chemicals called disulfides.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Beta Alethine","termGroup":"PT","termSource":"NCI"},{"termName":"Alethine","termGroup":"SY","termSource":"NCI"},{"termName":"Beta-alanyl-cysteamine Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"BetaLT","termGroup":"BR","termSource":"NCI"},{"termName":"Betathine","termGroup":"BR","termSource":"NCI"},{"termName":"N,N'-(Dithiodiethylene)bis(3-aminopropionamide)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"646-08-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LY583605Y8"},{"name":"Legacy Concept Name","value":"Beta_Alethine"},{"name":"Maps_To","value":"Beta Alethine"},{"name":"NCI_Drug_Dictionary_ID","value":"38126"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38126"},{"name":"PDQ_Open_Trial_Search_ID","value":"38126"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0290021"}]}}{"C1016":{"preferredName":"Beta-Carotene","code":"C1016","definitions":[{"definition":"A naturally-occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities.  As an anti-oxidant, beta carotene inhibits free-radical damage to DNA.  This agent also induces cell differentiation and apoptosis of some tumor cell types, particularly in early stages of tumorigenesis, and enhances immune system activity by stimulating the release of natural killer cells, lymphocytes, and monocytes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance found in yellow and orange fruits and vegetables and in dark green, leafy vegetables. The body can make vitamin A from beta carotene. Beta carotene is being studied in the prevention of some types of cancer. It is a type of antioxidant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carotenoid consisting of a cyclic structure on each end with additional double bonds at the number 5 and 5' carbon atoms of the cyclic structures.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Beta-Carotene","termGroup":"PT","termSource":"NCI"},{"termName":"Beta Carotene","termGroup":"SY","termSource":"NCI"},{"termName":"Beta-carotene","termGroup":"SY","termSource":"NCI"},{"termName":"Lumitene","termGroup":"BR","termSource":"NCI"},{"termName":"Solatene","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dietary supplement; prevention of photosensitivity reactions in patients with erythropoietic protoporphyria; polymorphous light eruption; chemoprevention for cardiovascular disease and cancer"},{"name":"CAS_Registry","value":"7235-40-7"},{"name":"CHEBI_ID","value":"CHEBI:17579"},{"name":"Chemical_Formula","value":"C40H56"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01YAE03M7J"},{"name":"INFOODS","value":"CARTB"},{"name":"Legacy Concept Name","value":"Beta_Carotene"},{"name":"Maps_To","value":"Beta-Carotene"},{"name":"NCI_Drug_Dictionary_ID","value":"40992"},{"name":"NSC Number","value":"62794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40992"},{"name":"PDQ_Open_Trial_Search_ID","value":"40992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"UMLS_CUI","value":"C0053396"},{"name":"Unit","value":"mcg"},{"name":"USDA_ID","value":"321"}]}}{"C103177":{"preferredName":"Beta-elemene","code":"C103177","definitions":[{"definition":"One of the isomers of elemene, a lipid soluble sesquiterpene and the active component isolated from the Chinese medicinal herb Rhizoma zedoariae with potential antineoplastic and chemopreventive activities. Although the exact mechanism of action through which beta-elemene exerts its effect has yet to be fully elucidated, this agent appears to induce apoptosis through different mechanisms of action and induces cell cycle arrest at different stages based on the tumor cell type involved. Beta-elemene may sensitize cancer cells to other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-elemene","termGroup":"PT","termSource":"NCI"},{"termName":"(1alpha,2beta,4beta)-1-Methyl-2,4-bis(methylvinyl)-1- vinylcyclohexane","termGroup":"SN","termSource":"NCI"},{"termName":"(1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Beta-elemene"},{"name":"NCI_Drug_Dictionary_ID","value":"740161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740161"},{"name":"PDQ_Open_Trial_Search_ID","value":"740161"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1101268"}]}}{"C2678":{"preferredName":"Beta-Glucan","code":"C2678","definitions":[{"definition":"A polysaccharide isolated from the cell walls of bacteria, plants, and fungi with immunostimulant and antineoplastic activities. In a solubilized form, beta-glucan binds to a lectin site within complement receptor 3 (CR3) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to complement 3 (iC3b)-coated tumors. Thus, the attachment of beta-glucan to CR3 of circulating leukocytes simulates leukocytes to kill iC3b-coated tumor cells in the same way as they kill iC3b-coated yeast. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance found in bacteria, plants, and certain foods, such as baker's yeast, cereal grains, and mushrooms. It is a type of polysaccharide that is made of a string of glucose (sugar) molecules joined together. Beta-glucan may stimulate the immune system and help kill cancer cells. It is being studied in the treatment of cancer. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Beta-Glucan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:28793"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beta-Glucan"},{"name":"Maps_To","value":"Beta-Glucan"},{"name":"NCI_Drug_Dictionary_ID","value":"38642"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38642"},{"name":"PDQ_Open_Trial_Search_ID","value":"38642"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134651"}]}}{"C82657":{"preferredName":"Beta-Glucan MM-10-001","code":"C82657","definitions":[{"definition":"A powder formulation containing a triple helix beta-glucan, isolated from the cell walls of the shiitake mushroom (Lentinula edodes), with potential immunostimulating activity. The beta-glucan in beta-glucan MM-10-001 binds to a lectin site within the complement receptor 3 (CR3 or iC3b receptor) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to iC3b-opsonized tumor cells. iC3b is the proteolyticly inactive product of the complement cleavage fragment C3b.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-Glucan MM-10-001","termGroup":"PT","termSource":"NCI"},{"termName":"MM-10-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beta-Glucan_MM-10-001"},{"name":"Maps_To","value":"Beta-Glucan MM-10-001"},{"name":"NCI_Drug_Dictionary_ID","value":"636186"},{"name":"NCI_META_CUI","value":"CL388490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636186"},{"name":"PDQ_Open_Trial_Search_ID","value":"636186"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99146":{"preferredName":"Beta-lapachone Prodrug ARQ 761","code":"C99146","definitions":[{"definition":"A synthetic, soluble prodrug of beta-lapachone, a poorly soluble, ortho-naphthoquinone with potential antineoplastic and radiosensitizing activity. ARQ 761 is converted to beta-lapachone (b-lap) in vivo. When b-lap is activated by NAD(P)H:quinone oxidoreductase-1 (NQO1) this agent creates a futile oxidoreduction, generating highly reactive oxygen species (ROS) that results in DNA damage. The activation of b-lap also causes hyperactivation of poly (ADP-ribose) polymerase-1 (PARP-1), an enzyme that facilitates DNA repair, accompanied by rapid depletion of NAD+/ATP nucleotide levels. As a result, a caspase-independent and endoplasmic reticulum (ER) stress-induced mu-calpain-mediated cell death occurs in NQO1-overexpressing tumor cells. In addition, b-lap induces expression of the checkpoints activator E2F transcription factor 1 (E2F1) and thereby activates the E2F1-mediated checkpoint pathway that directly triggers apoptosis. As ARQ 761 is soluble and requires less solvent, this formulation may cause less hemolytic anemia associated with administration of the synthetic b-lap ARQ 501.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-lapachone Prodrug ARQ 761","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 761","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Beta-lapachone Prodrug ARQ 761"},{"name":"NCI_Drug_Dictionary_ID","value":"715599"},{"name":"NCI_META_CUI","value":"CL432960"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715599"},{"name":"PDQ_Open_Trial_Search_ID","value":"715599"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1350":{"preferredName":"Beta-Thioguanine Deoxyriboside","code":"C1350","definitions":[{"definition":"A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication.  This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo.  Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-Thioguanine Deoxyriboside","termGroup":"PT","termSource":"NCI"},{"termName":"1,9-dihydro-6H-purine-6-thione, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"2'-deoxythioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"2'-desoxy-6-thioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"6-Mercaptoguaninedeoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"9H-purine-6-thiol, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl) monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"B-TGDR","termGroup":"AB","termSource":"NCI"},{"termName":"Beta Thioguanine Deoxyriboside","termGroup":"SY","termSource":"NCI"},{"termName":"beta-2'-deoxy-6-thioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"beta-2'-deoxythioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"beta-2'-deoxythiol guanosine","termGroup":"SN","termSource":"NCI"},{"termName":"BTG","termGroup":"AB","termSource":"NCI"},{"termName":"thioguanine 9-beta-D-2'-deoxyriboside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64039-27-6"},{"name":"CAS_Registry","value":"789-61-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KR0RFB46DF"},{"name":"Legacy Concept Name","value":"Beta-Thioguanine_Deoxyriboside"},{"name":"Maps_To","value":"Beta-Thioguanine Deoxyriboside"},{"name":"NCI_Drug_Dictionary_ID","value":"39711"},{"name":"NSC Number","value":"71261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39711"},{"name":"PDQ_Open_Trial_Search_ID","value":"39711"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053376"}]}}{"C38126":{"preferredName":"Betulinic Acid","code":"C38126","definitions":[{"definition":"A pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial apogenic factors, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Betulinic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(3beta)-3-Hydroxy-lup-20(29)-en-28-oic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ALS-357","termGroup":"CN","termSource":"NCI"},{"termName":"Mairin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"472-15-1"},{"name":"Chemical_Formula","value":"C30H48O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4G6A18707N"},{"name":"Legacy Concept Name","value":"Betulinic_Acid"},{"name":"Maps_To","value":"Betulinic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"496932"},{"name":"NSC Number","value":"113090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496932"},{"name":"PDQ_Open_Trial_Search_ID","value":"496932"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053530"}]}}{"C2039":{"preferredName":"Bevacizumab","code":"C2039","definitions":[{"definition":"A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bevacizumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 215","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-VEGF Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VEGF Monoclonal Antibody SIBP04","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VEGF rhuMAb","termGroup":"SY","termSource":"NCI"},{"termName":"Avastin","termGroup":"BR","termSource":"NCI"},{"termName":"BAT 1706","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-1706","termGroup":"CN","termSource":"NCI"},{"termName":"BAT1706","termGroup":"CN","termSource":"NCI"},{"termName":"BAT1706 Biosimilar","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab awwb","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar ABP 215","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar BAT1706","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar BEVZ92","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar BI 695502","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar CBT 124","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar CT-P16","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar FKB238","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar GB-222","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar HD204","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar HLX04","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar IBI305","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar LY01008","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar MIL60","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar Mvasi","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar MYL-1402O","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar QL 1101","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar QL1101","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar RPH-001","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar SCT501","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar Zirabev","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab-adcd","termGroup":"SY","termSource":"NCI"},{"termName":"BP102","termGroup":"CN","termSource":"NCI"},{"termName":"BP102 Biosimilar","termGroup":"SY","termSource":"NCI"},{"termName":"CT-P16","termGroup":"CN","termSource":"NCI"},{"termName":"HD204","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Mvasi","termGroup":"BR","termSource":"NCI"},{"termName":"MYL-1402O","termGroup":"CN","termSource":"NCI"},{"termName":"QL1101","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Humanized Anti-VEGF Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"rhuMab-VEGF","termGroup":"AB","termSource":"NCI"},{"termName":"SCT501","termGroup":"CN","termSource":"NCI"},{"termName":"SIBP 04","termGroup":"CN","termSource":"NCI"},{"termName":"SIBP-04","termGroup":"CN","termSource":"NCI"},{"termName":"SIBP04","termGroup":"CN","termSource":"NCI"},{"termName":"Vegzelma","termGroup":"BR","termSource":"NCI"},{"termName":"Zirabev","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic Colorectal Cancer, Non-small Cell Lung Cancer, glioblastoma; Metastatic Renal Cell Carcinoma; persistent, recurrent or metastatic cervical cancer; epithelial ovarian, fallopian tube, or primary peritoneal cancer"},{"name":"CAS_Registry","value":"216974-75-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2S9ZZM9Q9V"},{"name":"Legacy Concept Name","value":"Bevacizumab"},{"name":"Maps_To","value":"Bevacizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"43234"},{"name":"NSC Number","value":"704865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43234"},{"name":"PDQ_Open_Trial_Search_ID","value":"43234"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796392"}]}}{"C1635":{"preferredName":"Bexarotene","code":"C1635","definitions":[{"definition":"A drug used to treat skin problems caused by cutaneous T-cell lymphoma that have not gotten better after other treatment. It is also being studied in the treatment of other types of cancer. Bexarotene is a type of retinoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bexarotene","termGroup":"PT","termSource":"NCI"},{"termName":"3-methyl TTNEB","termGroup":"SY","termSource":"NCI"},{"termName":"4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LGD1069","termGroup":"CN","termSource":"NCI"},{"termName":"Targretin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Oral or topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)."},{"name":"CAS_Registry","value":"153559-49-0"},{"name":"CHEBI_ID","value":"CHEBI:50859"},{"name":"Chemical_Formula","value":"C24H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A61RXM4375"},{"name":"Legacy Concept Name","value":"Bexarotene"},{"name":"Maps_To","value":"Bexarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"42117"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42117"},{"name":"PDQ_Open_Trial_Search_ID","value":"42117"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0765273"}]}}{"C131905":{"preferredName":"BF-200 Gel Formulation","code":"C131905","definitions":[{"definition":"A topical nanoemulsion-based gel formulation containing 5-aminolevulinic acid (ALA), a metabolic precursor of the photosensitizer protoporphyrin IX, with a potential application for enhanced photodynamic therapy (PDT) for various precancerous and malignant skin lesions. After topical administration of a thick layer of the ALA-based BF-200 gel formulation to the affected area, ALA penetrates the skin and is intracellularly converted to protoporphyrin IX (PpIX). Exposure of PpIX to the proper excitation wavelength of light generates singlet oxygen molecules, resulting in a local cytotoxic effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BF-200 Gel Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"BF-200","termGroup":"CN","termSource":"NCI"},{"termName":"BF-200 ALA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BF-200 Gel Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"786308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786308"},{"name":"PDQ_Open_Trial_Search_ID","value":"786308"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490787"}]}}{"C114384":{"preferredName":"BH3 Mimetic ABT-737","code":"C114384","definitions":[{"definition":"An orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic activities. ABT-737 binds to the hydrophobic groove of multiple members of the anti-apoptotic Bcl-2 protein family, including Bcl-2, Bcl-xl and Bcl-w. This inhibits the activity of these pro-survival proteins and restores apoptotic processes in tumor cells, via activation of Bak/Bax-mediated apoptosis. The pro-survival Bcl-2 proteins are overexpressed in many cancers and play important roles in the regulation of apoptosis. Their expression is associated with increased drug resistance and tumor cell survival. ABT-737 does not inhibit the pro-survival proteins Mcl-1, Bcl-B, Bfl-1 (A1); therefore, tumors that overexpress these Bcl-2 family proteins are resistant to ABT-737.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BH3 Mimetic ABT-737","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-737","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 4-(4-((4'-Chloro(1,1'-biphenyl)-2-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"852808-04-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z5NFR173NV"},{"name":"Maps_To","value":"BH3 Mimetic ABT-737"},{"name":"NCI_Drug_Dictionary_ID","value":"758552"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758552"},{"name":"PDQ_Open_Trial_Search_ID","value":"758552"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1570187"}]}}{"C425":{"preferredName":"Dianhydrogalactitol","code":"C425","definitions":[{"definition":"A bifunctional hexitol derivative with potential antineoplastic activity. Dianhydrogalactitol alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in disruption of DNA function and cell cycle arrest. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dianhydrogalactitol","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,5,6 dianhydrogalactitol","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:5, 6-diepoxydulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:5,6 dianhydrogalactitol","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:5,6-dianhydrodulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"Bi-functional Alkylating Agent VAL-083","termGroup":"SY","termSource":"NCI"},{"termName":"DAG","termGroup":"AB","termSource":"NCI"},{"termName":"dianhydrodulcitol","termGroup":"SY","termSource":"NCI"},{"termName":"diepoxydulcitol","termGroup":"SY","termSource":"NCI"},{"termName":"diepoxygalactitol","termGroup":"SY","termSource":"NCI"},{"termName":"dulcitol diepoxide","termGroup":"SY","termSource":"NCI"},{"termName":"Galactitol","termGroup":"SY","termSource":"NCI"},{"termName":"galactitol, 1,2:5,6-dianhydro- (8CI 9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"VAL-083","termGroup":"CN","termSource":"NCI"},{"termName":"VAL083","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23261-20-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4S465RYF7M"},{"name":"Legacy Concept Name","value":"Dianhydrogalactitol"},{"name":"Maps_To","value":"Bi-functional Alkylating Agent VAL-083"},{"name":"Maps_To","value":"Dianhydrogalactitol"},{"name":"NCI_Drug_Dictionary_ID","value":"39215"},{"name":"NSC Number","value":"132313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39215"},{"name":"PDQ_Open_Trial_Search_ID","value":"39215"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011967"}]}}{"C1599":{"preferredName":"Bicalutamide","code":"C1599","definitions":[{"definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antiandrogens.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bicalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline","termGroup":"SN","termSource":"NCI"},{"termName":"Casodex","termGroup":"BR","termSource":"NCI"},{"termName":"Cosudex","termGroup":"FB","termSource":"NCI"},{"termName":"ICI 176,334","termGroup":"CN","termSource":"NCI"},{"termName":"ICI 176334","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic prostate cancer"},{"name":"CAS_Registry","value":"90357-06-5"},{"name":"CHEBI_ID","value":"CHEBI:3090"},{"name":"Chemical_Formula","value":"C18H14F4N2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"A0Z3NAU9DP"},{"name":"Legacy Concept Name","value":"Bicalutamide"},{"name":"Maps_To","value":"Bicalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"41298"},{"name":"NSC Number","value":"722665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41298"},{"name":"PDQ_Open_Trial_Search_ID","value":"41298"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0285590"}]}}{"C111898":{"preferredName":"Bimiralisib","code":"C111898","definitions":[{"definition":"An orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Bimiralisib inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy. As mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase. By inhibiting mTOR to a lesser extent than PI3K, PQR309 does not interfere with the mTOR-mediated negative feedback loop on PI3K signaling. Blocking the negative feedback loop would potentially increase PI3K signaling and decrease therapeutic efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bimiralisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinamine, 5-(4,6-Di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"PQR-309","termGroup":"CN","termSource":"NCI"},{"termName":"PQR309","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1225037-39-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Z3QHB00LB"},{"name":"Maps_To","value":"Bimiralisib"},{"name":"NCI_Drug_Dictionary_ID","value":"753407"},{"name":"NCI_META_CUI","value":"CL454230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753407"},{"name":"PDQ_Open_Trial_Search_ID","value":"753407"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C589":{"preferredName":"Binetrakin","code":"C589","definitions":[{"definition":"A recombinant agent chemically identical to or similar to the endogenous cytokine interleukin-4 (IL-4). Produced primarily by activated T-cells, IL-4 binds to and activates its cell-surface receptor, stimulating the proliferation and differentiation of activated B-cells and enhancing their ability to present antigens to T-cells. As a potential immunotherapeutic agent, binetrakin also augments the effects of other cytokines on dendritic cells (DC), cytotoxic T lymphocytes (CTL), and tumor-infiltrating lymphocytes (TIL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Binetrakin","termGroup":"PT","termSource":"NCI"},{"termName":"B Cell Proliferating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Stimulatory Factor 1","termGroup":"SY","termSource":"NCI"},{"termName":"BCGF","termGroup":"AB","termSource":"NCI"},{"termName":"BCSF 1","termGroup":"AB","termSource":"NCI"},{"termName":"IL-4","termGroup":"AB","termSource":"NCI"},{"termName":"Interleukin 4 (Human) 129","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4","termGroup":"SY","termSource":"NCI"},{"termName":"Mast Cell Growth Factor-2","termGroup":"SY","termSource":"NCI"},{"termName":"MCGF 2","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Human IL-4","termGroup":"SY","termSource":"NCI"},{"termName":"RHIL-4","termGroup":"AB","termSource":"NCI"},{"termName":"SCH 93400","termGroup":"CN","termSource":"NCI"},{"termName":"T-Cell Growth Factor 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"207137-56-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"751635Z921"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-4"},{"name":"Maps_To","value":"Binetrakin"},{"name":"NCI_Drug_Dictionary_ID","value":"39324"},{"name":"NSC Number","value":"618085"},{"name":"NSC Number","value":"620211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39324"},{"name":"PDQ_Open_Trial_Search_ID","value":"39324"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522540"}]}}{"C84865":{"preferredName":"Binimetinib","code":"C84865","definitions":[{"definition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Binimetinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-162","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-438162","termGroup":"CN","termSource":"NCI"},{"termName":"MEK162","termGroup":"CN","termSource":"NCI"},{"termName":"Mektovi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation"},{"name":"CAS_Registry","value":"606143-89-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"181R97MR71"},{"name":"Maps_To","value":"Binimetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"653635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653635"},{"name":"PDQ_Open_Trial_Search_ID","value":"653635"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830125"}]}}{"C124229":{"preferredName":"Bintrafusp Alfa","code":"C124229","definitions":[{"definition":"A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bintrafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PDL1/TGFb Trap MSB0011359C","termGroup":"SY","termSource":"NCI"},{"termName":"M7824","termGroup":"SY","termSource":"NCI"},{"termName":"MSB0011359C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1918149-01-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NW9K8C1JN3"},{"name":"Maps_To","value":"Bintrafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"795582"},{"name":"NCI_META_CUI","value":"CL502609"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795582"},{"name":"PDQ_Open_Trial_Search_ID","value":"795582"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103298":{"preferredName":"Birabresib","code":"C103298","definitions":[{"definition":"A synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity. Upon administration, birabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, including c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, the BET proteins BRD2, BRD3, BRD4 are transcriptional regulators that play an important role in cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Birabresib","termGroup":"PT","termSource":"NCI"},{"termName":"6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6S)-","termGroup":"SN","termSource":"NCI"},{"termName":"BRD 2/3/4 Inhibitor OTX015","termGroup":"SY","termSource":"NCI"},{"termName":"MK-8628","termGroup":"CN","termSource":"NCI"},{"termName":"OTX015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"202590-98-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X40LKS49S3"},{"name":"Maps_To","value":"Birabresib"},{"name":"NCI_Drug_Dictionary_ID","value":"742152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742152"},{"name":"PDQ_Open_Trial_Search_ID","value":"742152"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641185"}]}}{"C88295":{"preferredName":"Birinapant","code":"C88295","definitions":[{"definition":"A synthetic small molecule that is both a peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity. As a SMAC mimetic and IAP antagonist, birinapant selectively binds to and inhibits the activity of IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 (cIAP1) and 2 (cIAP2), with a greater effect on cIAP1 than cIAP2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells and inactivate the nuclear factor-kappa B (NF-kB)-mediated survival pathway. IAPs are overexpressed by many cancer cell types. They are able to suppress apoptosis by binding to, via their baculoviral lAP repeat (BIR) domains, and inhibiting active caspases-3, -7 and -9. IAP overexpression promotes both cancer cell survival and chemotherapy resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Birinapant","termGroup":"PT","termSource":"NCI"},{"termName":"Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-,(2S,2'S)-","termGroup":"SN","termSource":"NCI"},{"termName":"TL32711","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260251-31-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6O4Z07B57R"},{"name":"Maps_To","value":"Birinapant"},{"name":"NCI_Drug_Dictionary_ID","value":"657946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"657946"},{"name":"PDQ_Open_Trial_Search_ID","value":"657946"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658709"}]}}{"C62514":{"preferredName":"Tiomolibdate Choline","code":"C62514","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may prevent the growth of new blood vessels that tumors need to grow. ATN-224 also blocks enzymes that cells need to divide and grow, and it may kill cancer cells. It is a type of antiangiogenesis agent and a type of superoxide dismutase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active second generation tetrathiomolybdate analog with anti-angiogenic and antineoplastic activities. Tiomolibdate choline selectively chelates the copper ion in superoxide dismutase 1 (SOD1) in endothelial cells, thereby depleting SOD1 of copper and inhibiting its activity. Inhibition of SOD1 interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis, including those mediated by ERK1/2 and FAK and Src kinases. This results in an inhibition of cell proliferation and angiogenesis as well as induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tiomolibdate Choline","termGroup":"PT","termSource":"NCI"},{"termName":"ALXN-1840","termGroup":"CN","termSource":"NCI"},{"termName":"ATN 224","termGroup":"CN","termSource":"NCI"},{"termName":"ATN-224","termGroup":"CN","termSource":"NCI"},{"termName":"Bis(choline)tetrathiomolybdate","termGroup":"SY","termSource":"NCI"},{"termName":"Ethanaminium, 2-Hydroxy-N,N,N-Trimethyl-, (T-4)-Tetrathioxomolybdate(2-) (2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"SOD1 Inhibitor ATN-224","termGroup":"SY","termSource":"NCI"},{"termName":"WTX-101","termGroup":"CN","termSource":"NCI"},{"termName":"WTX101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"649749-10-0"},{"name":"Chemical_Formula","value":"2C5H14NO.MoS4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FD57A79R4P"},{"name":"Legacy Concept Name","value":"ATN-224"},{"name":"Maps_To","value":"Bis(choline)tetrathiomolybdate"},{"name":"Maps_To","value":"Tiomolibdate Choline"},{"name":"NCI_Drug_Dictionary_ID","value":"500040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500040"},{"name":"PDQ_Open_Trial_Search_ID","value":"500040"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831930"}]}}{"C1019":{"preferredName":"Bisantrene","code":"C1019","definitions":[{"definition":"An anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication.  This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisantrene","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxakdehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]","termGroup":"SN","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxaldehyde Bis(2-imidazolin-2-yl)hydrazone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"78186-34-2"},{"name":"Chemical_Formula","value":"C22H22N8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39C34M111K"},{"name":"Legacy Concept Name","value":"Bisantrene"},{"name":"Maps_To","value":"Bisantrene"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053776"}]}}{"C77218":{"preferredName":"Bisantrene Hydrochloride","code":"C77218","definitions":[{"definition":"The hydrochloride salt of an anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the helical structure of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisantrene Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"9,10,Anthracenedicarboxaldehyde Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxakdehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxaldehyde Bis(2-imidazolin-2-yl)hydrazone Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Bisantrene Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"CL-216942","termGroup":"CN","termSource":"NCI"},{"termName":"Orange Crush","termGroup":"SY","termSource":"NCI"},{"termName":"Zantrene","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71439-68-4"},{"name":"Chemical_Formula","value":"C22H22N8.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"74GNV897RO"},{"name":"Legacy Concept Name","value":"Bisantrene_Hydrochloride"},{"name":"Maps_To","value":"Bisantrene Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39136"},{"name":"PDQ_Open_Trial_Search_ID","value":"39136"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0955176"}]}}{"C73611":{"preferredName":"Bisnafide","code":"C73611","definitions":[{"definition":"A bis-naphthalimide compound with anticancer activity. Bisnafide selectively intercalates guanine-cytosine (GC) rich regions of DNA, thereby interfering with DNA replication machinery and activity of topoisomerase II. As a result, this agent causes potent cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisnafide","termGroup":"PT","termSource":"NCI"},{"termName":"DMP 840","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144849-63-8"},{"name":"Chemical_Formula","value":"C32H28N6O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"62H4W26906"},{"name":"Legacy Concept Name","value":"Bisnafide"},{"name":"Maps_To","value":"Bisnafide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0250021"}]}}{"C73307":{"preferredName":"Bisnafide Dimesylate","code":"C73307","definitions":[{"definition":"The dimesylate salt form of bisnafide, a bis-naphthalimide compound with anticancer activity. Bisnafide selectively intercalates guanine-cytosine (GC) rich regions of DNA, thereby interfering with DNA replication machinery and activity of topoisomerase II. As a result, this agent causes potent cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisnafide Dimesylate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145124-30-7"},{"name":"Chemical_Formula","value":"C32H28N6O8.2CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J30IBO0LMA"},{"name":"Legacy Concept Name","value":"Bisnafide_Dimesylate"},{"name":"Maps_To","value":"Bisnafide Dimesylate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347031"}]}}{"C2399":{"preferredName":"Bispecific Antibody 2B1","code":"C2399","definitions":[{"definition":"A monoclonal antibody with potential antineoplastic activity.  Specific for both the immunoglobulin G (IgG) receptor CD16 and c-erbB-2, bispecific antibody 2B1 may enhance cellular immune responses against c-erbB-2-positive cells, resulting in increased tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody 2B1","termGroup":"PT","termSource":"NCI"},{"termName":"2B1","termGroup":"SY","termSource":"NCI"},{"termName":"2B1 Antibody, Bispecific","termGroup":"SY","termSource":"NCI"},{"termName":"2B1 Bispecific MAb","termGroup":"SY","termSource":"NCI"},{"termName":"2B1 Bispecific Murine MAb","termGroup":"SY","termSource":"NCI"},{"termName":"bsAb 2B1","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb 2B1 Bispecific","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bispecific_Antibody_2B1"},{"name":"Maps_To","value":"Bispecific Antibody 2B1"},{"name":"NCI_Drug_Dictionary_ID","value":"42286"},{"name":"NSC Number","value":"673928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42286"},{"name":"PDQ_Open_Trial_Search_ID","value":"42286"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338223"}]}}{"C1578":{"preferredName":"Bispecific Antibody MDX-H210","code":"C1578","definitions":[{"definition":"A humanized bivalent antibody directed against both cytotoxic effector cells expressing Fc gamma receptor type I (Fc gammaRI, or CD64) and HER2/neu-overexpressing tumor cells with potential antineoplastic activity. Bispecific antibody MDX-H210 was constructed by chemically linking Fab' fragments of the anti-HER2/neu-specific monoclonal antibody 520C9 and the Fab' fragments of the anti-Fc gammaRI-specific monoclonal antibody H22. This agent selectively binds to both HER2/neu-expressing tumor cells and Fc gammaRI-expressing cytotoxic effector cells, which may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis of HER2/neu-expressing tumor cells. While HER2/neu is overexpressed in a variety of epithelial malignancies, expression of Fc gammaRI is primarily found in cytotoxic immune cells, including monocytes, macrophages, and cytokine-activated polymorphonuclear (PMN) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody MDX-H210","termGroup":"PT","termSource":"NCI"},{"termName":"520C9x22 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"520C9xH22 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody, Bispecific 520C9xH22","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody 520C9 x H22","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody MDXH210","termGroup":"SY","termSource":"NCI"},{"termName":"BsAb 520C9x22","termGroup":"SY","termSource":"NCI"},{"termName":"BsAb 520C9xH22","termGroup":"SY","termSource":"NCI"},{"termName":"MDX-210","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-H210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bispecific_Antibody_520C9XH22"},{"name":"Maps_To","value":"Bispecific Antibody MDX-H210"},{"name":"NCI_Drug_Dictionary_ID","value":"42227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42227"},{"name":"PDQ_Open_Trial_Search_ID","value":"42227"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281736"}]}}{"C2207":{"preferredName":"Bispecific Antibody MDX447","code":"C2207","definitions":[{"definition":"An antibody with potential antineoplastic activity. Specific for both the high-affinity immunoglobulin G (IgG) receptor CD64 and epidermal growth factor receptor (EGFR), bispecific antibody MDX447 may enhance cellular immune responses against EGFR positive cells, resulting in increased tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody MDX447","termGroup":"PT","termSource":"NCI"},{"termName":"BsAb MDX447","termGroup":"SY","termSource":"NCI"},{"termName":"EMD 82633","termGroup":"CN","termSource":"NCI"},{"termName":"MDX 447","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-447","termGroup":"CN","termSource":"NCI"},{"termName":"MDX447","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bispecific_Antibody_MDX447"},{"name":"Maps_To","value":"Bispecific Antibody MDX447"},{"name":"NCI_Drug_Dictionary_ID","value":"37952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37952"},{"name":"PDQ_Open_Trial_Search_ID","value":"37952"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879492"}]}}{"C163996":{"preferredName":"Bisthianostat","code":"C163996","definitions":[{"definition":"An orally bioavailable pan-inhibitor of human histone deacetylase (HDAC), with potential antineoplastic activity. Upon administration, bisthianostat selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes. This prevents cell division, induces cell cycle arrest and apoptosis. This may inhibit the proliferation of susceptible tumor cells. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisthianostat","termGroup":"PT","termSource":"NCI"},{"termName":"CF367","termGroup":"CN","termSource":"NCI"},{"termName":"CFH367 C","termGroup":"CN","termSource":"NCI"},{"termName":"CFH367-C","termGroup":"CN","termSource":"NCI"},{"termName":"CFH367C","termGroup":"CN","termSource":"NCI"},{"termName":"PY-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bisthianostat"},{"name":"NCI_Drug_Dictionary_ID","value":"799197"},{"name":"NCI_META_CUI","value":"CL977258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799197"},{"name":"PDQ_Open_Trial_Search_ID","value":"799197"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151943":{"preferredName":"Bivalent BRD4 Inhibitor AZD5153","code":"C151943","definitions":[{"definition":"An orally bioavailable bivalent inhibitor of  bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor AZD5153 selectively binds to the acetylated lysine recognition motifs in two bromodomains in the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dysregulates expression of target genes, which leads to the downregulation of the expression of certain growth-promoting genes, induces apoptosis and inhibits the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bivalent BRD4 Inhibitor AZD5153","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-4-(2-(4-(1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 5153","termGroup":"CN","termSource":"NCI"},{"termName":"AZD5153","termGroup":"CN","termSource":"NCI"},{"termName":"BET Inhibitor AZD5153","termGroup":"SY","termSource":"NCI"},{"termName":"Bivalent BET Bromodomain Inhibitor AZD5153","termGroup":"SY","termSource":"NCI"},{"termName":"BRD4/BET Bromodomain Antagonist AZD5153","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1869912-39-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C7C7U6YEAO"},{"name":"Maps_To","value":"Bivalent BRD4 Inhibitor AZD5153"},{"name":"NCI_Drug_Dictionary_ID","value":"793144"},{"name":"NCI_META_CUI","value":"CL553171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793144"},{"name":"PDQ_Open_Trial_Search_ID","value":"793144"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1472":{"preferredName":"Bizelesin","code":"C1472","definitions":[{"definition":"A synthetic cyclopropylpyrroloindole antineoplastic antibiotic.  Bizelesin binds to the minor groove of DNA and induces interstrand cross-linking of DNA, thereby inhibiting DNA replication and RNA synthesis.  Bizelesin also enhances p53 and p21 induction and triggers G2/M cell-cycle arrest, resulting in cell senescence without apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents. It is also an antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bizelesin","termGroup":"PT","termSource":"NCI"},{"termName":"Benzo(1,2-b:4,3-b')dipyrrol-4-ol, 6,6'-(carbonylbis(imino-1H-indole-5,2-diylcarbonyl))bis(8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (S-(R*,R*)))-","termGroup":"SN","termSource":"NCI"},{"termName":"U-77779","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129655-21-6"},{"name":"Chemical_Formula","value":"C43H36Cl2N8O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0O9OBI87E"},{"name":"Legacy Concept Name","value":"Bizelesin"},{"name":"Maps_To","value":"Bizelesin"},{"name":"NCI_Drug_Dictionary_ID","value":"42688"},{"name":"NSC Number","value":"615291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42688"},{"name":"PDQ_Open_Trial_Search_ID","value":"42688"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0209891"}]}}{"C1842":{"preferredName":"BL22 Immunotoxin","code":"C1842","definitions":[{"definition":"A bacterial toxic substance linked to an antibody that attaches to cancer cells and kills them. It belongs to the family of drugs called bacterial immunotoxins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity.  BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells.  The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BL22 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD22 Recombinant Immunotoxin BL22","termGroup":"SY","termSource":"NCI"},{"termName":"BL22","termGroup":"SY","termSource":"NCI"},{"termName":"BL22 Immunotoxin [RFB4(dsFv)-PE38]","termGroup":"SY","termSource":"NCI"},{"termName":"CAT 3888","termGroup":"CN","termSource":"NCI"},{"termName":"CAT-3888","termGroup":"CN","termSource":"NCI"},{"termName":"CAT3888","termGroup":"CN","termSource":"NCI"},{"termName":"GCR-3888","termGroup":"CN","termSource":"NCI"},{"termName":"Immunotoxin BL22","termGroup":"SY","termSource":"NCI"},{"termName":"RFB4(dsFv)-PE38 Immunotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"BL22_Immunotoxin"},{"name":"Maps_To","value":"BL22 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43322"},{"name":"NSC Number","value":"691237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43322"},{"name":"PDQ_Open_Trial_Search_ID","value":"43322"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796473"}]}}{"C26647":{"preferredName":"Black Cohosh","code":"C26647","definitions":[{"definition":"A triterpene-containing herb isolated from the roots and rhizomes of the plant Cimicifuga racemosa (also known as Actaea racemosa). While the mechanism of action of black cohosh is not completely understood, it appears to act as a selective estrogen receptor modulator.  In vitro, this preparation has been shown to induce cell cycle arrest and caspase-dependent apoptosis of estrogen-sensitive breast cancer cells. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An eastern North American perennial herb. A substance obtained from the root of the plant has been used in some cultures to treat a number of medical problems. It is being studied in the treatment of hot flashes and other symptoms of menopause. The scientific name is Cimicifuga racemosa.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Black Cohosh","termGroup":"PT","termSource":"NCI"},{"termName":"Actaea racemosa Root","termGroup":"SY","termSource":"NCI"},{"termName":"Cimicifuga racemosa Root","termGroup":"SY","termSource":"NCI"},{"termName":"Cimicifugae racemosae Rhizoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fariy Candle Root","termGroup":"SY","termSource":"NCI"},{"termName":"Remifemin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K73E24S6X9"},{"name":"Legacy Concept Name","value":"Black_Cohosh"},{"name":"Maps_To","value":"Black Cohosh"},{"name":"NCI_Drug_Dictionary_ID","value":"302635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"302635"},{"name":"PDQ_Open_Trial_Search_ID","value":"302635"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C0771967"}]}}{"C122398":{"preferredName":"Black Raspberry Nectar","code":"C122398","definitions":[{"definition":"A concentrated fruit juice containing black raspberries, with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, anthocyanidins, and flavonoids. Upon oral administration, the phytochemicals in the black raspberry nectar inhibit the activation of several signal transduction pathways involved in carcinogenesis and the expression of downstream target genes that are upregulated in a variety of cancer cell types. In addition, the phytochemicals in black raspberry may protect the oral microbiome and may enhance the bacterial defense against pathogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Black Raspberry Nectar","termGroup":"PT","termSource":"NCI"},{"termName":"BRB Nectar","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Black Raspberry Nectar"},{"name":"NCI_Drug_Dictionary_ID","value":"772463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772463"},{"name":"PDQ_Open_Trial_Search_ID","value":"772463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055378"}]}}{"C313":{"preferredName":"Bleomycin","code":"C313","definitions":[{"definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It comes from the bacterium Streptomyces verticillus. Bleomycin damages DNA and may kill rapidly growing cancer cells. It is a type of antineoplastic antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bleomycin","termGroup":"PT","termSource":"NCI"},{"termName":"BLEO","termGroup":"AB","termSource":"NCI"},{"termName":"BLM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11056-06-7"},{"name":"CHEBI_ID","value":"CHEBI:3139"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"40S1VHN69B"},{"name":"Legacy Concept Name","value":"Bleomycin"},{"name":"Maps_To","value":"Bleomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"813324"},{"name":"NSC Number","value":"125066"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005740"}]}}{"C311":{"preferredName":"Bleomycin A2","code":"C311","definitions":[{"definition":"The primary bleomycin species in bleomycin sulfate, a mixture of the sulfate salts of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Bleomycin A2 forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bleomycin A2","termGroup":"PT","termSource":"NCI"},{"termName":"N1-(3-(Dimethylsulfonio)propyl)bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"Pingyangmycin A2","termGroup":"SY","termSource":"NCI"},{"termName":"Zhengguangmycin A2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11116-31-7"},{"name":"CHEBI_ID","value":"CHEBI:3139"},{"name":"Chemical_Formula","value":"C55H84N17O21S3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"13M89UEA7W"},{"name":"Legacy Concept Name","value":"Bleomycin_A2"},{"name":"Maps_To","value":"Bleomycin A2"},{"name":"NSC Number","value":"146842"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005736"}]}}{"C81672":{"preferredName":"Bleomycin B2","code":"C81672","definitions":[{"definition":"One of the primary bleomycin species in bleomycin sulfate, a mixture of the sulfate salts of glycopeptide bleomycin A2 and B2 isolated from Streptomyces verticillus with potential antineoplastic activity. Bleomycin B2 forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bleomycin B2","termGroup":"PT","termSource":"NCI"},{"termName":"Bleomycinamide, N1-(4-((aminoiminomethyl)amino)butyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Dehydrophleomycin D1","termGroup":"SY","termSource":"NCI"},{"termName":"N1-(4-((Aminoiminomethyl)amino)butyl)bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"Phleomycin D2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9060-10-0"},{"name":"CHEBI_ID","value":"CHEBI:28641"},{"name":"Chemical_Formula","value":"C55H84N20O21S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M62KK37O40"},{"name":"Legacy Concept Name","value":"Bleomycin_B2"},{"name":"Maps_To","value":"Bleomycin B2"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005738"}]}}{"C312":{"preferredName":"Bleomycin Sulfate","code":"C312","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It comes from the bacterium Streptomyces verticillus. Blenoxane that damages DNA and may kill cancer cells. It is a type of antineoplastic antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin sulfate forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bleomycin Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"Blanoxan","termGroup":"FB","termSource":"NCI"},{"termName":"BleMomycine","termGroup":"BR","termSource":"NCI"},{"termName":"Blenoxane","termGroup":"AQS","termSource":"NCI"},{"termName":"Bleo-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Bleo-S","termGroup":"FB","termSource":"NCI"},{"termName":"Bleocin","termGroup":"FB","termSource":"NCI"},{"termName":"Bleolem","termGroup":"FB","termSource":"NCI"},{"termName":"Bleomycin Sulfas","termGroup":"SY","termSource":"NCI"},{"termName":"Bleomycin Sulphate","termGroup":"SY","termSource":"NCI"},{"termName":"Bleomycini Sulfas","termGroup":"SY","termSource":"NCI"},{"termName":"Blexane","termGroup":"SY","termSource":"NCI"},{"termName":"Oil Bleo","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Squamous cell carcinomas of the head and neck; penis; cervix and vulva; Hodgkins and; non-Hodgkins lymphoma; testicular embryonal cell and ovarian carcinoma; chorio- and teratocarcinoma; malignant pleural effusion; melanoma; sarcoma; ovary germ cell tumor"},{"name":"CAS_Registry","value":"9041-93-4"},{"name":"CHEBI_ID","value":"CHEBI:34582"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7DP3NTV15T"},{"name":"Legacy Concept Name","value":"Bleomycin_Sulphate"},{"name":"Maps_To","value":"Bleomycin Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"39139"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39139"},{"name":"PDQ_Open_Trial_Search_ID","value":"39139"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005739"}]}}{"C62528":{"preferredName":"Blinatumomab","code":"C62528","definitions":[{"definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blinatumomab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 103","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103","termGroup":"SY","termSource":"NCI"},{"termName":"Blincyto","termGroup":"BR","termSource":"NCI"},{"termName":"MEDI-538","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI538","termGroup":"CN","termSource":"NCI"},{"termName":"MT-103","termGroup":"CN","termSource":"NCI"},{"termName":"MT103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)"},{"name":"CAS_Registry","value":"853426-35-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4FR53SIF3A"},{"name":"Legacy Concept Name","value":"Anti-CD19_Anti-CD3_Bispecific_Monoclonal_Antibody"},{"name":"Maps_To","value":"Blinatumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"487684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487684"},{"name":"PDQ_Open_Trial_Search_ID","value":"487684"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853839"}]}}{"C98108":{"preferredName":"Blueberry Powder Supplement","code":"C98108","definitions":[{"definition":"An orally available, dietary supplement consisting of lyophilized blueberry powder, with antioxidant and potential chemopreventive and chemosensitizing activity. In addition to vitamins and minerals, blueberries are rich in phytonutrients, such as proanthocyanidins, anthocyanins (e.g. malvidin, delphinidin, pelargonidin, cyanidin, petunidin, and peonidin), hydroxycinnamic acids, hydroxybenzoic acids, pterostilbene, resveratrol, and flavonols (e.g. kaempferol, quercetin and myricetin). Although the exact mechanism of action through which blueberries may exert their anti-tumor effect has yet to be fully elucidated, the effects of blueberry powder on cancer cells may be attributable to the phytonutrient's antioxidant and pro-apoptotic activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blueberry Powder Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blueberry Powder Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"710970"},{"name":"NCI_META_CUI","value":"CL430627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710970"},{"name":"PDQ_Open_Trial_Search_ID","value":"710970"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121645":{"preferredName":"Unesbulin","code":"C121645","definitions":[{"definition":"An orally active inhibitor of the polycomb ring finger oncogene BMI1 (B-cell-specific Moloney murine leukemia virus integration site 1), with potential antineoplastic activity. Upon oral administration, unesbulin targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1 leading to its degradation. This inhibits BMI1-mediated signal transduction pathways and results in a reduction of proliferation of BMI1-expressing tumor cells.  BMI1, a key protein in the polycomb repressive complex 1 (PRC1), is overexpressed in certain tumor cell types, and plays a key role in CSC survival, proliferation and resistance to chemotherapeutics; its expression is associated with increased tumor aggressiveness and a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unesbulin","termGroup":"PT","termSource":"NCI"},{"termName":"Polycomb Ring Finger Oncogene Inhibitor PTC596","termGroup":"SY","termSource":"NCI"},{"termName":"PTC596","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610964-64-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z4HZ70S62Q"},{"name":"Maps_To","value":"BMI1 Inhibitor PTC596"},{"name":"NCI_Drug_Dictionary_ID","value":"770799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770799"},{"name":"PDQ_Open_Trial_Search_ID","value":"770799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053603"}]}}{"C1843":{"preferredName":"BMS-184476","code":"C1843","definitions":[{"definition":"A 7-methylthiomethyl ether derivative of paclitaxel with antineoplastic activity.  BMS-184476 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"BMS-184476","termGroup":"PT","termSource":"NCI"},{"termName":"7-O-[(Methylthio)methyl]paclitaxel","termGroup":"SN","termSource":"NCI"},{"termName":"beta-(Benzoylamino)-a-hydroxybenzenepropanoic Acid (aR,bS)-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-[(methylthio)methoxy]-5-oxo-7,11-methano-1H","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-184476","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160237-25-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3811W2NBZ8"},{"name":"Legacy Concept Name","value":"BMS-184476"},{"name":"Maps_To","value":"BMS-184476"},{"name":"NCI_Drug_Dictionary_ID","value":"43331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43331"},{"name":"PDQ_Open_Trial_Search_ID","value":"43331"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796479"}]}}{"C1859":{"preferredName":"BMS-188797","code":"C1859","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called taxane analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analog of paclitaxel with antineoplastic activity.  BMS-188797 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMS-188797","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-188797","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"427896-23-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0HG7S0S581"},{"name":"Legacy Concept Name","value":"BMS-188797"},{"name":"Maps_To","value":"BMS-188797"},{"name":"NCI_Drug_Dictionary_ID","value":"37942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37942"},{"name":"PDQ_Open_Trial_Search_ID","value":"37942"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879485"}]}}{"C1856":{"preferredName":"BMS-214662","code":"C1856","definitions":[{"definition":"A nonsedating benzodiazepine derivative with potential antineoplastic activity. Farnesyltransferase inhibitor BMS-214662 inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. This agent may reverse the malignant phenotype of H-Ras-transformed cells and has been shown to be active against tumor cells with and without Ras mutations.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"BMS-214662","termGroup":"PT","termSource":"NCI"},{"termName":"7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-Benzodiazepine","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-214662","termGroup":"CN","termSource":"NCI"},{"termName":"FTI BMS 214662","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195987-41-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L2U9GFD244"},{"name":"Legacy Concept Name","value":"BMS214662"},{"name":"Maps_To","value":"BMS-214662"},{"name":"NCI_Drug_Dictionary_ID","value":"37852"},{"name":"NSC Number","value":"710086"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37852"},{"name":"PDQ_Open_Trial_Search_ID","value":"37852"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1306120"}]}}{"C62639":{"preferredName":"BMS-275183","code":"C62639","definitions":[{"definition":"An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin and stabilizes microtubules, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and an induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMS-275183","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"355113-98-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UQC681JJIV"},{"name":"Legacy Concept Name","value":"BMS-275183"},{"name":"Maps_To","value":"BMS-275183"},{"name":"NCI_Drug_Dictionary_ID","value":"415311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415311"},{"name":"PDQ_Open_Trial_Search_ID","value":"415311"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1098058"}]}}{"C102878":{"preferredName":"Boanmycin Hydrochloride","code":"C102878","definitions":[{"definition":"The hydrochloride salt form of boanmycin (aka bleomycin A6), a component of the antibiotic bleomycin produced by Streptomyces species, with potential antineoplastic activity. Upon administration, boanmycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals. This causes single- and double-stranded DNA breaks which eventually leads to cell death. Compared to bleomycin, boanmycin appears to have a more favorable toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Boanmycin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BAM HCl","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K4QGS58U92"},{"name":"Maps_To","value":"Boanmycin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"738501"},{"name":"NCI_META_CUI","value":"CL437181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738501"},{"name":"PDQ_Open_Trial_Search_ID","value":"738501"},{"name":"Semantic_Type","value":"Antibiotic"}]}}{"C2405":{"preferredName":"Boronophenylalanine-Fructose Complex","code":"C2405","definitions":[{"definition":"A boronated phenylalanine complexed with fructose to increase its solubility. When exposed to neutron irradiation, boronophenylalanine absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A substance used in a type of radiation therapy called boron neutron capture therapy. BPA-F is injected into a vein, and becomes concentrated in tumor cells. The patient then receives radiation treatment with atomic particles called neutrons. The neutrons react with the boron in BPA-F, producing radioactive particles that kill the tumor cells without harming normal cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Boronophenylalanine-Fructose Complex","termGroup":"PT","termSource":"NCI"},{"termName":"p-Boronophenylalanine-Fructose Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Boronophenylalanine-Fructose_Complex"},{"name":"Maps_To","value":"Boronophenylalanine-Fructose Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"42404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42404"},{"name":"PDQ_Open_Trial_Search_ID","value":"42404"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0289335"}]}}{"C1851":{"preferredName":"Bortezomib","code":"C1851","definitions":[{"definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bortezomib","termGroup":"PT","termSource":"NCI"},{"termName":"[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LDP 341","termGroup":"CN","termSource":"NCI"},{"termName":"MLN341","termGroup":"CN","termSource":"NCI"},{"termName":"PS-341","termGroup":"CN","termSource":"NCI"},{"termName":"PS341","termGroup":"CN","termSource":"NCI"},{"termName":"Velcade","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Multiple Myeloma; Advanced Thyroid Cancer"},{"name":"CAS_Registry","value":"179324-69-7"},{"name":"CHEBI_ID","value":"CHEBI:52717"},{"name":"Chemical_Formula","value":"C19H25BN4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"69G8BD63PP"},{"name":"Legacy Concept Name","value":"Bortezomib"},{"name":"Maps_To","value":"Bortezomib"},{"name":"NCI_Drug_Dictionary_ID","value":"43560"},{"name":"NSC Number","value":"681239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43560"},{"name":"PDQ_Open_Trial_Search_ID","value":"43560"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1176309"}]}}{"C60809":{"preferredName":"Bosutinib","code":"C60809","definitions":[{"definition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bosutinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"4-Anilino-3-quinolinecarbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"4-Anilinobenzo(g)quinoline-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"SKI 606","termGroup":"CN","termSource":"NCI"},{"termName":"SKI-606","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"380843-75-4"},{"name":"CHEBI_ID","value":"CHEBI:39112"},{"name":"Chemical_Formula","value":"C26H29Cl2N5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5018V4AEZ0"},{"name":"Legacy Concept Name","value":"Bosutinib"},{"name":"Maps_To","value":"Bosutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"467222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467222"},{"name":"PDQ_Open_Trial_Search_ID","value":"467222"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831731"}]}}{"C154440":{"preferredName":"Bosutinib Monohydrate","code":"C154440","definitions":[{"definition":"The monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bosutinib Monohydrate","termGroup":"PT","termSource":"NCI"},{"termName":"3-Quinolinecarbonitrile, 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, Hydrate (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"Bosulif","termGroup":"SY","termSource":"NCI"},{"termName":"SKI-606 Monohydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"918639-08-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"844ZJE6I55"},{"name":"Maps_To","value":"Bosutinib Monohydrate"},{"name":"NCI_META_CUI","value":"CL555365"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153419":{"preferredName":"Botanical Agent BEL-X-HG","code":"C153419","definitions":[{"definition":"An orally available botanically-based agent with potential antineoplastic activity. Upon oral administration, the components in BEL-X-HG may exert cytotoxic effects against cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botanical Agent BEL-X-HG","termGroup":"PT","termSource":"NCI"},{"termName":"BEL X HG","termGroup":"CN","termSource":"NCI"},{"termName":"BEL-X-HG","termGroup":"CN","termSource":"NCI"},{"termName":"BELXHG","termGroup":"CN","termSource":"NCI"},{"termName":"Botanical Agent BEL X HG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Botanical Agent BEL-X-HG"},{"name":"NCI_Drug_Dictionary_ID","value":"793949"},{"name":"NCI_META_CUI","value":"CL554859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793949"},{"name":"PDQ_Open_Trial_Search_ID","value":"793949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129711":{"preferredName":"Botanical Agent LEAC-102","code":"C129711","definitions":[{"definition":"A botanical-based formulation derived from the Taiwanese mushroom Antrodia cinnamomea, with potential antineoplastic activity, Upon administration, the components in LEAC-102 may exert cytotoxic effects against cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botanical Agent LEAC-102","termGroup":"PT","termSource":"NCI"},{"termName":"LEAC 102","termGroup":"CN","termSource":"NCI"},{"termName":"LEAC-102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3796H63LII"},{"name":"Maps_To","value":"Botanical Agent LEAC-102"},{"name":"NCI_Drug_Dictionary_ID","value":"784382"},{"name":"NCI_META_CUI","value":"CL512955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784382"},{"name":"PDQ_Open_Trial_Search_ID","value":"784382"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2418":{"preferredName":"Bovine Cartilage","code":"C2418","definitions":[{"definition":"Cartilage extracted from various parts of a cow and is proposed to stimulate the immune system and inhibit tumor cell growth.  It was used in the 1950s and 60s to enhance wound healing. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bovine Cartilage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bovine_Cartilage"},{"name":"Maps_To","value":"Bovine Cartilage"},{"name":"NCI_Drug_Dictionary_ID","value":"42603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42603"},{"name":"PDQ_Open_Trial_Search_ID","value":"42603"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0106940"}]}}{"C129717":{"preferredName":"Vebreltinib","code":"C129717","definitions":[{"definition":"An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vebreltinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(1-Cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine","termGroup":"SY","termSource":"NCI"},{"termName":"APL-101","termGroup":"CN","termSource":"NCI"},{"termName":"APL101","termGroup":"CN","termSource":"NCI"},{"termName":"Bozitinib","termGroup":"SY","termSource":"NCI"},{"termName":"CBI-3103","termGroup":"CN","termSource":"NCI"},{"termName":"CBT-101","termGroup":"CN","termSource":"NCI"},{"termName":"PLB-1001","termGroup":"CN","termSource":"NCI"},{"termName":"PLB1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1440964-89-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2WZP8A9VFN"},{"name":"Maps_To","value":"Bozitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"784709"},{"name":"NCI_META_CUI","value":"CL512997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784709"},{"name":"PDQ_Open_Trial_Search_ID","value":"784709"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107387":{"preferredName":"BP-Cx1-Platinum Complex BP-C1","code":"C107387","definitions":[{"definition":"A combination agent composed of the benzo-poly-carbonic-acid polymer BP-Cx1 chelated to platinum with potential antineoplastic activity. Upon intramuscular injection, the polymer moiety of BP-Cx1-Platinum Complex BP-C1 (BP-C1) alters the permeability of the cell membranes, which allows for increased penetration of platinum into tumor cells. In turn, platinum binds to nucleophilic groups such as GC-rich sites in DNA and induces intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. In addition, the BP-Cx1 ligand is able to stimulate the innate immune system and upregulates a variety of cytokines including interferon, tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), and various interleukins (ILs) such as IL-6 and IL-25. In comparison to cisplatin and other platinum-based compounds, treatment with BP-C1 allows for less platinum administration, which reduces platinum-associated systemic toxicity and side effects, and enhances the safety profile while maintaining or improving its efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BP-Cx1-Platinum Complex BP-C1","termGroup":"PT","termSource":"NCI"},{"termName":"BP-C1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BP-Cx1-Platinum Complex BP-C1"},{"name":"NCI_Drug_Dictionary_ID","value":"751002"},{"name":"NCI_META_CUI","value":"CL449598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751002"},{"name":"PDQ_Open_Trial_Search_ID","value":"751002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1617":{"preferredName":"BR96-Doxorubicin Immunoconjugate","code":"C1617","definitions":[{"definition":"An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin.  The antibody moiety of BMS-182248-1 binds to Lewis Y, a cell surface antigen expressed on many solid tumor types.  Thus, the doxorubicin conjugate is targeted specifically to Lewis Y-expressing tumor cells, where it intercalates with DNA, thereby inhibiting DNA replication and repair, RNA synthesis and protein synthesis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BR96-Doxorubicin Immunoconjugate","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-182248-01","termGroup":"CN","termSource":"NCI"},{"termName":"BR96-DOX","termGroup":"AB","termSource":"NCI"},{"termName":"BR96-DOX immunoconjugate","termGroup":"SY","termSource":"NCI"},{"termName":"BR96-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"BR96-Doxorubicin Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"cBR96-Doxorubicin Immunoconjugate","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-15","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"BR96-Doxorubicin_Immunoconjugate"},{"name":"Maps_To","value":"BR96-Doxorubicin Immunoconjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"38477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38477"},{"name":"PDQ_Open_Trial_Search_ID","value":"38477"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0295525"}]}}{"C106267":{"preferredName":"Brachyury-expressing Yeast Vaccine GI-6301","code":"C106267","definitions":[{"definition":"A cancer vaccine composed of a heat-killed, recombinant form of the yeast Saccharomyces cerevisiae that is genetically modified to express the transcription factor brachyury protein, with potential antineoplastic activity. Upon subcutaneous administration, the brachyury-expressing yeast vaccine GI-6301 is recognized by dendritic cells, processed, and presented by Class I and II MHC molecules on the dendritic cell surface. This elicits a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response. This process kills brachyury-expressing tumor cells. Brachyury is overexpressed in a variety of tumor types and plays an important role in cancer progression and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brachyury-expressing Yeast Vaccine GI-6301","termGroup":"PT","termSource":"NCI"},{"termName":"GI-6301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B0L24T8TB7"},{"name":"Maps_To","value":"Brachyury-expressing Yeast Vaccine GI-6301"},{"name":"NCI_Drug_Dictionary_ID","value":"724520"},{"name":"NCI_META_CUI","value":"CL433965"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724520"},{"name":"PDQ_Open_Trial_Search_ID","value":"724520"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155322":{"preferredName":"BRAF Inhibitor","code":"C155322","definitions":[{"definition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"B-RAF Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF Inhibitor"},{"name":"NCI_META_CUI","value":"CL556869"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94224":{"preferredName":"BRAF Inhibitor ARQ 736","code":"C94224","definitions":[{"definition":"An orally bioavailable, highly soluble phosphate prodrug of B-raf (BRAF) protein kinase with potential antineoplastic activity. BRAF inhibitor ARQ 736 is converted into its active form ARQ 680 in the presence of phosphatases. In turn, ARQ 680 selectively binds to and inhibits the activity of oncogenic B-raf, which may inhibit the proliferation of tumor cells expressing mutated B-raf gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. The valine to glutamic acid substitution at residue 600 (V600E) accounts for about 90% of BRAF gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF Inhibitor ARQ 736","termGroup":"PT","termSource":"NCI"},{"termName":"AQ 736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228237-57-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2H4S74Y8U"},{"name":"Maps_To","value":"BRAF Inhibitor ARQ 736"},{"name":"NCI_Drug_Dictionary_ID","value":"688029"},{"name":"NCI_META_CUI","value":"CL433988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688029"},{"name":"PDQ_Open_Trial_Search_ID","value":"688029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113330":{"preferredName":"Plixorafenib","code":"C113330","definitions":[{"definition":"An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, plixorafenib selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plixorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"BRAF Inhibitor FORE8394","termGroup":"SY","termSource":"NCI"},{"termName":"BRAF Inhibitor PLX8394","termGroup":"SY","termSource":"NCI"},{"termName":"FORE 8394","termGroup":"CN","termSource":"NCI"},{"termName":"FORE-8394","termGroup":"CN","termSource":"NCI"},{"termName":"FORE8394","termGroup":"CN","termSource":"NCI"},{"termName":"PL -8394","termGroup":"CN","termSource":"NCI"},{"termName":"PLX8394","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1393466-87-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J2L7Z273SG"},{"name":"Maps_To","value":"BRAF Inhibitor PLX8394"},{"name":"NCI_Drug_Dictionary_ID","value":"756043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756043"},{"name":"PDQ_Open_Trial_Search_ID","value":"756043"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827086"}]}}{"C92591":{"preferredName":"BRAF(V600E) Kinase Inhibitor RO5212054","code":"C92591","definitions":[{"definition":"An orally available small-molecule inhibitor of mutant (V600E) v-raf murine sarcoma viral oncogene homolog B1 (BRAF) with potential antineoplastic activity. BRAF(V600E) kinase inhibitor RO5212054 selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. The valine to glutamic acid substitution at residue 600 accounts for about 90% of BRAF gene mutations; the oncogenic product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF(V600E) Kinase Inhibitor RO5212054","termGroup":"PT","termSource":"NCI"},{"termName":"B-Raf Inhibitor RO5212054","termGroup":"SY","termSource":"NCI"},{"termName":"PLX3603","termGroup":"CN","termSource":"NCI"},{"termName":"RO5212054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF(V600E) Kinase Inhibitor RO5212054"},{"name":"NCI_Drug_Dictionary_ID","value":"680347"},{"name":"NCI_META_CUI","value":"CL421616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"680347"},{"name":"PDQ_Open_Trial_Search_ID","value":"680347"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124995":{"preferredName":"Lifirafenib","code":"C124995","definitions":[{"definition":"An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifirafenib","termGroup":"PT","termSource":"NCI"},{"termName":"Begeine-283","termGroup":"SY","termSource":"NCI"},{"termName":"BGB 283","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-283","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446090-79-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8762XZS5ZF"},{"name":"Maps_To","value":"BRAF/EGFR Inhibitor BGB-283"},{"name":"Maps_To","value":"Lifirafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"777271"},{"name":"NCI_META_CUI","value":"CL503841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777271"},{"name":"PDQ_Open_Trial_Search_ID","value":"777271"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C134967":{"preferredName":"BRAFV600/PI3K Inhibitor ASN003","code":"C134967","definitions":[{"definition":"A selective inhibitor of mutated forms of B-RAF kinase at amino acid position 600 (BRAFV600), including BRAFV600E, the alpha, delta and, to a lesser extent, beta isoforms of phosphatidylinositide 3-kinase (PI3K), including mutated forms of PI3KCA, which encodes the p110-alpha catalytic subunit of the class I PI3K, and the phosphatase and tensin homologs (PTEN) with loss-of-function mutation, with potential antineoplastic activity. Upon administration of ASN003, this agent selectively targets, binds to and inhibits the activity of BRAFV600 mutants as well as mutated isoforms of PI3K. This inhibits signaling through B-RAF- and PI3K/mechanistic target of rapamycin (mTOR)-mediated pathways and inhibits cellular proliferation in tumor cells with BRAFV600 mutations, those expressing PI3K and/or those driven by PTEN. Dysregulation of the B-RAF- and PI3K-mediated pathways is frequently seen in a variety of tumors and results in increased tumor cell growth and survival. Dual targeting of both pathways may increase efficacy and anti-tumor potential compared to the targeting of just one pathway by a selective B-RAF inhibitor or selective PI3K pathway inhibitor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAFV600/PI3K Inhibitor ASN003","termGroup":"PT","termSource":"NCI"},{"termName":"ASN 003","termGroup":"CN","termSource":"NCI"},{"termName":"ASN-003","termGroup":"CN","termSource":"NCI"},{"termName":"ASN003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAFV600/PI3K Inhibitor ASN003"},{"name":"NCI_Drug_Dictionary_ID","value":"789080"},{"name":"NCI_META_CUI","value":"CL522477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789080"},{"name":"PDQ_Open_Trial_Search_ID","value":"789080"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146825":{"preferredName":"BRD4 Inhibitor PLX2853","code":"C146825","definitions":[{"definition":"An orally bioavailable inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor PLX2853 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dyregulates gene expression. This may lead to the downregulation of the expression of certain growth-promoting genes, which may induce apoptosis and inhibit the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD4 Inhibitor PLX2853","termGroup":"PT","termSource":"NCI"},{"termName":"PLX 2853","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-2853","termGroup":"CN","termSource":"NCI"},{"termName":"PLX2853","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRD4 Inhibitor PLX2853"},{"name":"NCI_Drug_Dictionary_ID","value":"792077"},{"name":"NCI_META_CUI","value":"CL544855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792077"},{"name":"PDQ_Open_Trial_Search_ID","value":"792077"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125739":{"preferredName":"BRD4 Inhibitor PLX51107","code":"C125739","definitions":[{"definition":"An inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon administration, the BRD4 inhibitor PLX51107 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD4 Inhibitor PLX51107","termGroup":"PT","termSource":"NCI"},{"termName":"PLX 51107","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-51107","termGroup":"CN","termSource":"NCI"},{"termName":"PLX51107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1627929-55-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W758F1L9ND"},{"name":"Maps_To","value":"BRD4 Inhibitor PLX51107"},{"name":"NCI_Drug_Dictionary_ID","value":"779000"},{"name":"NCI_META_CUI","value":"CL504394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779000"},{"name":"PDQ_Open_Trial_Search_ID","value":"779000"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28855":{"preferredName":"Breflate","code":"C28855","definitions":[{"definition":"A water soluble analogue of the antineoplastic agent brefeldin A (BFA). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breflate","termGroup":"PT","termSource":"NCI"},{"termName":"13-(N,N-Dimethylglycyl)brefeldin A","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"174305-65-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Y1QP4AO5M"},{"name":"Legacy Concept Name","value":"Breflate"},{"name":"Maps_To","value":"Breflate"},{"name":"NSC Number","value":"656202"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0760968"}]}}{"C2007":{"preferredName":"Brentuximab","code":"C2007","definitions":[{"definition":"A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brentuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD30 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"CAC-10","termGroup":"CN","termSource":"NCI"},{"termName":"CAC10","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody SGN-30","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-30","termGroup":"CN","termSource":"NCI"},{"termName":"SGN30","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"775303-41-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C67ORA155P"},{"name":"Legacy Concept Name","value":"SGN-30"},{"name":"Maps_To","value":"Brentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"357600"},{"name":"NSC Number","value":"731636"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357600"},{"name":"PDQ_Open_Trial_Search_ID","value":"357600"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328236"}]}}{"C66944":{"preferredName":"Brentuximab Vedotin","code":"C66944","definitions":[{"definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brentuximab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-35","termGroup":"CN","termSource":"NCI"},{"termName":"Adcetris","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-CD30 Antibody-Drug Conjugate SGN-35","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD30 Monoclonal Antibody-MMAE SGN-35","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35","termGroup":"SY","termSource":"NCI"},{"termName":"cAC10-vcMMAE","termGroup":"AB","termSource":"NCI"},{"termName":"SGN-35","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hodgkin lymphoma (HL); anaplastic large cell lymphoma (ALCL); other CD30-expressing peripheral T-cell lymphomas"},{"name":"CAS_Registry","value":"914088-09-8"},{"name":"Chemical_Formula","value":"C68H106N11O15S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7XL5ISS668"},{"name":"Legacy Concept Name","value":"SGN-35"},{"name":"Maps_To","value":"Brentuximab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"530758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530758"},{"name":"PDQ_Open_Trial_Search_ID","value":"530758"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2932409"}]}}{"C1560":{"preferredName":"Brequinar","code":"C1560","definitions":[{"definition":"A synthetic quinolinecarboxylic acid analogue with antineoplastic properties.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brequinar","termGroup":"PT","termSource":"NCI"},{"termName":"6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Bipenquinate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96187-53-0"},{"name":"Chemical_Formula","value":"C23H15F2NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5XL19F49H6"},{"name":"Legacy Concept Name","value":"Brequinar"},{"name":"Maps_To","value":"Brequinar"},{"name":"NCI_Drug_Dictionary_ID","value":"40886"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40886"},{"name":"PDQ_Open_Trial_Search_ID","value":"40886"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280509"}]}}{"C1078":{"preferredName":"Brequinar Sodium","code":"C1078","definitions":[{"definition":"The sodium salt form of Brequinar.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brequinar Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"DUP-785","termGroup":"CN","termSource":"NCI"},{"termName":"DUP785","termGroup":"CN","termSource":"NCI"},{"termName":"Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96201-88-6"},{"name":"Chemical_Formula","value":"C23H14F2NO2.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49EEF6HRUS"},{"name":"Legacy Concept Name","value":"Brequinar_Sodium"},{"name":"Maps_To","value":"Brequinar Sodium"},{"name":"NSC Number","value":"368390"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058809"}]}}{"C90541":{"preferredName":"Briciclib Sodium","code":"C90541","definitions":[{"definition":"A benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, briciclib is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Briciclib Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methoxy-5-(((2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)phenyl Disodium Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"ON 013105","termGroup":"CN","termSource":"NCI"},{"termName":"Phenol, 2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)-, 1-(Dihydrogen Phosphate), Sodium Salt (1:2)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"865784-01-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7C9N0VM8NR"},{"name":"Maps_To","value":"Briciclib Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"664346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"664346"},{"name":"PDQ_Open_Trial_Search_ID","value":"664346"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983737"}]}}{"C98831":{"preferredName":"Brigatinib","code":"C98831","definitions":[{"definition":"An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brigatinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone","termGroup":"SN","termSource":"NCI"},{"termName":"5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"Alunbrig","termGroup":"BR","termSource":"NCI"},{"termName":"AP 26113","termGroup":"CN","termSource":"NCI"},{"termName":"AP-26113","termGroup":"CN","termSource":"NCI"},{"termName":"AP26113","termGroup":"CN","termSource":"NCI"},{"termName":"Biganib","termGroup":"FB","termSource":"NCI"},{"termName":"Briganix","termGroup":"FB","termSource":"NCI"},{"termName":"Trepmac","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1197953-54-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HYW8DB273J"},{"name":"Maps_To","value":"Brigatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"714373"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714373"},{"name":"PDQ_Open_Trial_Search_ID","value":"714373"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274459"}]}}{"C106235":{"preferredName":"Brilanestrant","code":"C106235","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brilanestrant","termGroup":"PT","termSource":"NCI"},{"termName":"ARN-810","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0810","termGroup":"CN","termSource":"NCI"},{"termName":"RO7056118","termGroup":"CN","termSource":"NCI"},{"termName":"SERD ARN-810","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1365888-06-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9MM2R1A06R"},{"name":"Maps_To","value":"Brilanestrant"},{"name":"NCI_Drug_Dictionary_ID","value":"748900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748900"},{"name":"PDQ_Open_Trial_Search_ID","value":"748900"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827161"}]}}{"C158723":{"preferredName":"Brimonidine Tartrate Nanoemulsion OCU-300","code":"C158723","definitions":[{"definition":"An ophthalmic nanoemulsion consisting of the tartrate salt form of brimonidine, an imidazole derivative and selective alpha-2 adrenergic receptor agonist, with potential anti-inflammatory and vasoconstrictive activities. Upon ophthalmic instillation, brimonidine tartrate nanoemulsion OCU-300 reduces intraocular pressure by promoting the outflow and decreasing the production of aqueous humor and may reduce ocular erythema through direct vasoconstriction. Additionally, brimonidine may disrupt leukocyte extravasation into the ocular tissue, inhibit nociception and reduce inflammation associated with ocular graft-versus-host disease (oGvHD). The nanoemulsion formulation may enhance distribution of brimonidine to target tissues, thereby allowing more of the active drug to reach underlying ocular tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brimonidine Tartrate Nanoemulsion OCU-300","termGroup":"PT","termSource":"NCI"},{"termName":"OCU 300","termGroup":"CN","termSource":"NCI"},{"termName":"OCU-300","termGroup":"CN","termSource":"NCI"},{"termName":"OCU300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Brimonidine Tartrate Nanoemulsion OCU-300"},{"name":"NCI_Drug_Dictionary_ID","value":"797485"},{"name":"NCI_META_CUI","value":"CL950750"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797485"},{"name":"PDQ_Open_Trial_Search_ID","value":"797485"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67040":{"preferredName":"Brivanib","code":"C67040","definitions":[{"definition":"A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. BMS-540215 specifically targets and binds strongly to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Brivanib may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brivanib","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-540215","termGroup":"CN","termSource":"NCI"},{"termName":"VEGFR2 Inhibitor BMS-540215","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"649735-46-6"},{"name":"Chemical_Formula","value":"C19H19FN4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DDU33B674I"},{"name":"Legacy Concept Name","value":"BMS-540215"},{"name":"Maps_To","value":"Brivanib"},{"name":"NCI_Drug_Dictionary_ID","value":"539377"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539377"},{"name":"PDQ_Open_Trial_Search_ID","value":"539377"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700604"}]}}{"C53397":{"preferredName":"Brivanib Alaninate","code":"C53397","definitions":[{"definition":"A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brivanib Alaninate","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 582664","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-582664","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"649735-63-7"},{"name":"Chemical_Formula","value":"C22H24FN5O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U2Y5OFN795"},{"name":"Legacy Concept Name","value":"BMS-582664"},{"name":"Maps_To","value":"Brivanib Alaninate"},{"name":"NCI_Drug_Dictionary_ID","value":"462556"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462556"},{"name":"PDQ_Open_Trial_Search_ID","value":"462556"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1701190"}]}}{"C67088":{"preferredName":"Brivudine","code":"C67088","definitions":[{"definition":"A substance that is being studied in the treatment of infections caused by herpesvirus, including herpes-zoster (shingles). It belongs to the family of drugs called antivirals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A uridine derivative and nucleoside analog with pro-apoptotic and chemosensitizing properties. In vitro, bromovinyl-deoxyuridine (BVDU) has been shown to downregulate the multifunctional DNA repair enzyme APEX nuclease 1, resulting in the inhibition of DNA repair and the induction of apoptosis. In addition, this agent may inhibit the expression of STAT3 (signal transducer and activator of transcription 3), which may result in the downregulation of vascular endothelial growth factor (VEGF). BVDU has also been found to inhibit the upregulation of chemoresistance genes (Mdr1 and DHFR) during chemotherapy. Overall, the gene expression changes associated with BVDU treatment result in the decrease or prevention of chemoresistance. In addition, this agent has been shown to enhance the cytolytic activity of NK-92 natural killer cells towards a pancreatic cancer cell line in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brivudine","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-5-(2-Bromovinyl)-deoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"Bromovinyl-Deoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"BVDU","termGroup":"AB","termSource":"NCI"},{"termName":"Helpin","termGroup":"BR","termSource":"NCI"},{"termName":"RP101","termGroup":"CN","termSource":"NCI"},{"termName":"Trans-5-(2-Bromovinyl)-2'-deoxyuridine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69304-47-8"},{"name":"Chemical_Formula","value":"C11H13BrN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2M3055079H"},{"name":"Legacy Concept Name","value":"Brivudine"},{"name":"Maps_To","value":"Brivudine"},{"name":"NCI_Drug_Dictionary_ID","value":"577369"},{"name":"NSC Number","value":"633770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577369"},{"name":"PDQ_Open_Trial_Search_ID","value":"577369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0163272"}]}}{"C1882":{"preferredName":"Brivudine Phosphoramidate","code":"C1882","definitions":[{"definition":"A small molecule phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) with potential antineoplastic activity. Selectively active against tumor cells expressing high levels of thymidylate synthase (TS), brivudine is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites. As key enzyme in the de novo synthesis of dTMP, TS is an enzyme critical to DNA biosynthesis and is overexpressed in many solid tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied for its ability to make cancer cells respond to drugs to which they have become resistant. It is a type of nucleoside analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brivudine Phosphoramidate","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-5-(2-Bromovinyl)-2'-deoxy-5'-uridyl Phenyl L-methoxyalaninylphosphoramidate","termGroup":"SN","termSource":"NCI"},{"termName":"BVdU Phosphoramidate","termGroup":"SY","termSource":"NCI"},{"termName":"BVDU Prodrug","termGroup":"SY","termSource":"NCI"},{"termName":"NB101.1","termGroup":"CN","termSource":"NCI"},{"termName":"NB1011","termGroup":"CN","termSource":"NCI"},{"termName":"Thymectacin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"232925-18-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ZRZ4TSW3F"},{"name":"Legacy Concept Name","value":"NB1011"},{"name":"Maps_To","value":"Brivudine Phosphoramidate"},{"name":"NCI_Drug_Dictionary_ID","value":"38549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38549"},{"name":"PDQ_Open_Trial_Search_ID","value":"38549"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0964443"}]}}{"C70598":{"preferredName":"Broad-Spectrum Human Papillomavirus Vaccine V505","code":"C70598","definitions":[{"definition":"A non-infectious recombinant cancer vaccine prepared from the human papillomavirus (HPV) with potential immunoprophylactic activity. Vaccination with broad-spectrum human papillomavirus vaccine V505 may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte (CTL) responses against HPV-infected cells. HPV infection, the cause of genital warts, is a risk factor for the development of cancers of the cervix, vagina, vulva, anus, and penis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broad-Spectrum Human Papillomavirus Vaccine V505","termGroup":"PT","termSource":"NCI"},{"termName":"V505","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Broad-Spectrum_Human_Papillomavirus_Vaccine_V505"},{"name":"Maps_To","value":"Broad-Spectrum Human Papillomavirus Vaccine V505"},{"name":"NCI_Drug_Dictionary_ID","value":"570766"},{"name":"NCI_META_CUI","value":"CL375942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570766"},{"name":"PDQ_Open_Trial_Search_ID","value":"570766"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C128293":{"preferredName":"Broccoli Sprout/Broccoli Seed Extract Supplement","code":"C128293","definitions":[{"definition":"A tablet-based nutritional supplement composed of a mixture of sprout and seed extracts of the cruciferous vegetable broccoli, with potential chemopreventive and antioxidant activities. Broccoli sprout/broccoli seed extract contains a high amount of both the glycosinolate glucoraphanin and the enzyme myrosinase, which catalyzes the production of glucoraphanin to sulforaphane. Upon administration of the broccoli sprout/broccoli seed extract, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs promote the transcription of antioxidant and detoxifying enzymes, particularly glutathione-S-transferase and NAD(P)H dehydrogenase [quinone] 1 (NAD(P)H:quinone oxidoreductase; NQO1), resulting in the detoxification of highly reactive carcinogens. This accelerates the elimination of carcinogens, may protect against cellular damage, and prevents cancer formation. AREs are cis-acting regulatory enhancer elements found in the 5' flanking region of many phase II detoxification enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broccoli Sprout/Broccoli Seed Extract Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Avmacol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Broccoli Sprout/Broccoli Seed Extract Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"782181"},{"name":"NCI_META_CUI","value":"CL507940"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782181"},{"name":"PDQ_Open_Trial_Search_ID","value":"782181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73259":{"preferredName":"Bromacrylide","code":"C73259","definitions":[{"definition":"A propenamide-based agent with antineoplastic activity. Bromacrylide has been shown to decrease tumor growth in animal models, but is accompanied with severe toxicity, including severe bone marrow suppression and weight loss.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bromacrylide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4213-51-8"},{"name":"Chemical_Formula","value":"C7H11BrN2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"173648DEO8"},{"name":"Legacy Concept Name","value":"Bromacrylide"},{"name":"Maps_To","value":"Bromacrylide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347213"}]}}{"C72089":{"preferredName":"Bromebric Acid","code":"C72089","definitions":[{"definition":"A derivative of bromoacrylic acid with cytostatic and antineoplastic activity. Bromebric acid appears to inhibit purine synthesis, oxidative phosphorylation and DNA synthesis. This agent inhibits tumor cell growth and causes cell cycle arrest. This agent may also have some use in the phrophylaxis of migraine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bromebric Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-3-p-Anisoyl-3-bromoacrylic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5711-40-0"},{"name":"Chemical_Formula","value":"C11H9BrO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FGE8818GWA"},{"name":"Legacy Concept Name","value":"Bromebric_Acid"},{"name":"Maps_To","value":"Bromebric Acid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054091"}]}}{"C317":{"preferredName":"Bromocriptine Mesylate","code":"C317","definitions":[{"definition":"The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine selectively binds to and activates postsynaptic dopamine D2 receptors in the corpus striatum of the central nervous system (CNS). Activation of these D2 receptors activate inhibitory G-proteins, which inhibit adenylyl cyclase, preventing signal transduction mediated via cAMP and resulting in the inhibition of neurotransmission and an antidyskinetic effect. This agent also stimulates dopamine D2 receptors in the anterior pituitary gland, which results in the inhibition of prolactin secretion and lactation and may inhibit the proliferation of prolactin-dependent breast cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bromocriptine Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-","termGroup":"SN","termSource":"NCI"},{"termName":"Parlodel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Parlodel treatment is indicated in patients with prolactin-secreting adenomas."},{"name":"CAS_Registry","value":"22260-51-1"},{"name":"CHEBI_ID","value":"CHEBI:3182"},{"name":"Chemical_Formula","value":"C32H40BrN5O5.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FFP983J3OD"},{"name":"Legacy Concept Name","value":"Bromocriptine"},{"name":"Maps_To","value":"Bromocriptine Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"39165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39165"},{"name":"PDQ_Open_Trial_Search_ID","value":"39165"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546852"}]}}{"C103274":{"preferredName":"Brontictuzumab","code":"C103274","definitions":[{"definition":"A humanized monoclonal antibody directed against the Notch-1 receptor with potential antineoplastic activity. Upon administration, brontictuzumab binds to Notch-1 on the cell surface, thereby inhibiting Notch-mediated signaling and tumor cell proliferation. Notch 1, a type 1 transmembrane protein belonging to the Notch family, functions as a receptor for membrane bound ligands and has various roles during development; dysregulated Notch signaling is associated with increased cell growth and chemoresistance in cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brontictuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G2-lambda, Anti-(homo Sapiens Notch1 (Notch 1, Translocation-associated Notch-1, TAN-1,Tan1)), Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"OMP-52M51","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1447814-75-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UNY2TQA40E"},{"name":"Maps_To","value":"Brontictuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"741867"},{"name":"NCI_META_CUI","value":"CL438125"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741867"},{"name":"PDQ_Open_Trial_Search_ID","value":"741867"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128040":{"preferredName":"Brostacillin Hydrochloride","code":"C128040","definitions":[{"definition":"A substance being studied in the treatment of cancer. Brostallicin hydrochloride binds to DNA and may kill cancer cells. It may also help other drugs kill cancer cells. It is a type of DNA minor groove binding agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of brostacillin, a synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brostacillin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide) Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"PNU-166196 Hydrochloride","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203258-38-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1DKC476797"},{"name":"Maps_To","value":"Brostacillin Hydrochloride"},{"name":"NCI_META_CUI","value":"CL509004"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1889":{"preferredName":"Brostallicin","code":"C1889","definitions":[{"definition":"A synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brostallicin","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide)","termGroup":"SN","termSource":"NCI"},{"termName":"PNU-166196","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203258-60-0"},{"name":"Chemical_Formula","value":"C30H35BrN12O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RPC6R41K4I"},{"name":"Legacy Concept Name","value":"Brostallicin"},{"name":"Maps_To","value":"Brostallicin"},{"name":"NCI_Drug_Dictionary_ID","value":"590644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590644"},{"name":"PDQ_Open_Trial_Search_ID","value":"590644"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122890"}]}}{"C318":{"preferredName":"Broxuridine","code":"C318","definitions":[{"definition":"A drug that makes cancer cells more sensitive to radiation and is also used as a diagnostic agent to determine how fast cancer cells grow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A halogenated thymidine analogue with potential antineoplastic and radiosensitizing activities. Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and the inhibition of cell proliferation. As a radiosensitizer, this agent is associated with the inhibition of repair of radiation-induced DNA double-strand breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broxuridine","termGroup":"PT","termSource":"NCI"},{"termName":"5-BrdU","termGroup":"AB","termSource":"NCI"},{"termName":"5-Bromo-2'-deoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Bromodeoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Bromouracil Deoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"5-Bromouracil-2-deoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"BrdU","termGroup":"AB","termSource":"NCI"},{"termName":"Bromo Deoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodeoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Bromouracil Deoxyriboside","termGroup":"SY","termSource":"NCI"},{"termName":"Bromouridine","termGroup":"SY","termSource":"NCI"},{"termName":"Broxine","termGroup":"BR","termSource":"NCI"},{"termName":"Neomark","termGroup":"BR","termSource":"NCI"},{"termName":"Neomark-BU","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59-14-3"},{"name":"CHEBI_ID","value":"CHEBI:472552"},{"name":"Chemical_Formula","value":"C9H11BrN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G34N38R2N1"},{"name":"Legacy Concept Name","value":"Bromodeoxyuridine"},{"name":"Maps_To","value":"Broxuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39168"},{"name":"NSC Number","value":"38297"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39168"},{"name":"PDQ_Open_Trial_Search_ID","value":"39168"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006233"}]}}{"C1765":{"preferredName":"Bruceanol A","code":"C1765","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol A","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-(benzoyloxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101391-06-4"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_A"},{"name":"Maps_To","value":"Bruceanol A"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0626930"}]}}{"C1764":{"preferredName":"Bruceanol B","code":"C1764","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol B","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-15-((1-oxopentyl)oxy)-, Methyl Ester, (1beta,11beta,12alpha,15beta)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101391-05-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_B"},{"name":"Maps_To","value":"Bruceanol B"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0626928"}]}}{"C1768":{"preferredName":"Bruceanol C","code":"C1768","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol C","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-((4-(acetyloxy)-3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114586-21-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_C"},{"name":"Maps_To","value":"Bruceanol C"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0634036"}]}}{"C1535":{"preferredName":"Bruceanol D","code":"C1535","definitions":[{"definition":"A quassinoid phytochemical isolated form the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol D","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152645-84-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_D"},{"name":"Maps_To","value":"Bruceanol D"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0252924"}]}}{"C1536":{"preferredName":"Bruceanol E","code":"C1536","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol E","termGroup":"PT","termSource":"NCI"},{"termName":"Picrasan-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152645-85-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_E"},{"name":"Maps_To","value":"Bruceanol E"},{"name":"NSC Number","value":"368672"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0252925"}]}}{"C1537":{"preferredName":"Bruceanol F","code":"C1537","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol F","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-2-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-2,11,12-trihydroxy-1,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101910-72-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_F"},{"name":"Maps_To","value":"Bruceanol F"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0252926"}]}}{"C1694":{"preferredName":"Bruceanol G","code":"C1694","definitions":[{"definition":"A natural quassinoid agent extracted from Brucea antidysenterica with potential antineoplastic activity that is cytotoxic to certain cancer cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol G","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"168301-20-0"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_G"},{"name":"Maps_To","value":"Bruceanol G"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391118"}]}}{"C1695":{"preferredName":"Bruceanol H","code":"C1695","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol H","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"168569-27-5"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_H"},{"name":"Maps_To","value":"Bruceanol H"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391119"}]}}{"C1025":{"preferredName":"Bruceantin","code":"C1025","definitions":[{"definition":"A triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica.  Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis.  Bruceantin also has antiamoebic and antimalarial activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceantin","termGroup":"PT","termSource":"NCI"},{"termName":"2H-3, 11c-(Epoxymethano)phenanthro[10,1-bc]pyran, Picras-3-en-21-oic Acid Derivative","termGroup":"SN","termSource":"NCI"},{"termName":"[11Beta,12alpha,15beta(E)]-15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxopicras-3-en-21-oic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11, 12-trihydroxy-2,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E))","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41451-75-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3NW88DI4T"},{"name":"Legacy Concept Name","value":"Bruceantin"},{"name":"Maps_To","value":"Bruceantin"},{"name":"NCI_Drug_Dictionary_ID","value":"39169"},{"name":"NSC Number","value":"165563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39169"},{"name":"PDQ_Open_Trial_Search_ID","value":"39169"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0054160"}]}}{"C1026":{"preferredName":"Bryostatin 1","code":"C1026","definitions":[{"definition":"A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity.  Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer and certain brain conditions such as Alzheimer disease and stroke. It binds to an enzyme involved in cell growth and it may help anticancer drugs work better. Bryostatin 1 comes from a marine organism. It is a type of protein kinase C modulator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bryostatin 1","termGroup":"PT","termSource":"NCI"},{"termName":"B705008K112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83314-01-6"},{"name":"Chemical_Formula","value":"C47H68O17"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37O2X55Y9E"},{"name":"Legacy Concept Name","value":"Bryostatin-1"},{"name":"Maps_To","value":"Bryostatin 1"},{"name":"NCI_Drug_Dictionary_ID","value":"41959"},{"name":"NSC Number","value":"339555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41959"},{"name":"PDQ_Open_Trial_Search_ID","value":"41959"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054173"}]}}{"C138066":{"preferredName":"Nemtabrutinib","code":"C138066","definitions":[{"definition":"An orally available reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, nemtabrutinib non-covalently binds to and inhibits the activity of both the wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, nemtabrutinib does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemtabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 531","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ-531","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ531","termGroup":"CN","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor ARQ 531","termGroup":"SY","termSource":"NCI"},{"termName":"BTK Inhibitor ARQ 531","termGroup":"SY","termSource":"NCI"},{"termName":"MK-1026","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095393-15-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JTZ51LIXN4"},{"name":"Maps_To","value":"BTK Inhibitor ARQ 531"},{"name":"NCI_Drug_Dictionary_ID","value":"790667"},{"name":"NCI_META_CUI","value":"CL525087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790667"},{"name":"PDQ_Open_Trial_Search_ID","value":"790667"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C138164":{"preferredName":"BTK Inhibitor CT-1530","code":"C138164","definitions":[{"definition":"An inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, CT-1530 binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor CT-1530","termGroup":"PT","termSource":"NCI"},{"termName":"CT 1530","termGroup":"CN","termSource":"NCI"},{"termName":"CT-1530","termGroup":"CN","termSource":"NCI"},{"termName":"CT1530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor CT-1530"},{"name":"NCI_Drug_Dictionary_ID","value":"790538"},{"name":"NCI_META_CUI","value":"CL525731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790538"},{"name":"PDQ_Open_Trial_Search_ID","value":"790538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130001":{"preferredName":"BTK Inhibitor DTRMWXHS-12","code":"C130001","definitions":[{"definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, DTRMWXHS-12 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor DTRMWXHS-12","termGroup":"PT","termSource":"NCI"},{"termName":"DTRMWXHS 12","termGroup":"CN","termSource":"NCI"},{"termName":"DTRMWXHS-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor DTRMWXHS-12"},{"name":"NCI_Drug_Dictionary_ID","value":"784823"},{"name":"NCI_META_CUI","value":"CL513821"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784823"},{"name":"PDQ_Open_Trial_Search_ID","value":"784823"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156173":{"preferredName":"Orelabrutinib","code":"C156173","definitions":[{"definition":"A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orelabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"BTK Inhibitor ICP-022","termGroup":"SY","termSource":"NCI"},{"termName":"ICP 022","termGroup":"CN","termSource":"NCI"},{"termName":"ICP-022","termGroup":"CN","termSource":"NCI"},{"termName":"ICP022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1655504-04-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WJA5UO9E10"},{"name":"Maps_To","value":"BTK Inhibitor ICP-022"},{"name":"Maps_To","value":"Orelabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"795368"},{"name":"NCI_META_CUI","value":"CL563002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795368"},{"name":"PDQ_Open_Trial_Search_ID","value":"795368"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158617":{"preferredName":"Pirtobrutinib","code":"C158617","definitions":[{"definition":"An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirtobrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"BTK Inhibitor LOXO-305","termGroup":"SY","termSource":"NCI"},{"termName":"Jaypirca","termGroup":"BR","termSource":"NCI"},{"termName":"LOXO 305","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO-305","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO305","termGroup":"CN","termSource":"NCI"},{"termName":"LY3527727","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory mantle cell lymphoma (MCL)"},{"name":"CAS_Registry","value":"2101700-15-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JNA39I7ZVB"},{"name":"Maps_To","value":"BTK Inhibitor LOXO-305"},{"name":"NCI_Drug_Dictionary_ID","value":"797383"},{"name":"NCI_META_CUI","value":"CL950650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797383"},{"name":"PDQ_Open_Trial_Search_ID","value":"797383"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129710":{"preferredName":"BTK Inhibitor TL-895","code":"C129710","definitions":[{"definition":"An orally bioavailable, selective inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor TL-895 targets and covalently binds to BTK, thereby preventing its activity. This leads to an inhibition of B cell receptor (BCR) signaling and inhibits cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor TL-895","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor M7583","termGroup":"SY","termSource":"NCI"},{"termName":"M 7583","termGroup":"CN","termSource":"NCI"},{"termName":"M-7583","termGroup":"CN","termSource":"NCI"},{"termName":"M7583","termGroup":"CN","termSource":"NCI"},{"termName":"TL 895","termGroup":"CN","termSource":"NCI"},{"termName":"TL-895","termGroup":"CN","termSource":"NCI"},{"termName":"TL895","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor M7583"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor TL-895"},{"name":"NCI_Drug_Dictionary_ID","value":"784381"},{"name":"NCI_META_CUI","value":"CL512935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175775":{"preferredName":"Edralbrutinib","code":"C175775","definitions":[{"definition":"An orally available irreversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, edralbrutinib covalently binds to and irreversibly inhibits BTK activity, thereby preventing the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This may inhibit the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edralbrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"BTK inhibitor TG-1701","termGroup":"SY","termSource":"NCI"},{"termName":"EBI 1459","termGroup":"CN","termSource":"NCI"},{"termName":"EBI-1459","termGroup":"CN","termSource":"NCI"},{"termName":"EBI1459","termGroup":"CN","termSource":"NCI"},{"termName":"SHR 1459","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1459","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1459","termGroup":"CN","termSource":"NCI"},{"termName":"TG 1701","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1701","termGroup":"CN","termSource":"NCI"},{"termName":"TG1701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858206-58-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SG5I5QTR4E"},{"name":"Maps_To","value":"BTK inhibitor TG-1701"},{"name":"NCI_Drug_Dictionary_ID","value":"798666"},{"name":"NCI_META_CUI","value":"CL970969"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137682":{"preferredName":"Budigalimab","code":"C137682","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody ABBV-181 targets and binds to PD-1, thereby blocking its binding to the PD-1 ligand, programmed cell death-1 ligand 1 (PD-L1), and preventing the activation of PD-1/PD-L1 downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs). PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Budigalimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 181","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-181","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV181","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098225-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6VDO4TY3OO"},{"name":"Maps_To","value":"Budigalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"790298"},{"name":"NCI_META_CUI","value":"CL524834"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790298"},{"name":"PDQ_Open_Trial_Search_ID","value":"790298"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C81555":{"preferredName":"Budotitane","code":"C81555","definitions":[{"definition":"A titanium metal complex, coordinated with asymmetric beta-diketonate ligands, with antineoplastic activity. Although the exact mechanism of action remains to be elucidated, budotitane potentially binds either to macromolecules via coordinative covalent bonds, or via intercalation between nucleic acids strands by the aromatic ring of the beta-diketonate. In addition, this agent appears to cause cardiac arrhythmias and is toxic to the liver and kidneys at higher doses. The development of budotitane was halted due to the rapid loss of its labile groups under physiological conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Budotitane","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85969-07-9"},{"name":"Chemical_Formula","value":"2C10H9O2.2C2H5O.Ti"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DV05VZD83V"},{"name":"Legacy Concept Name","value":"Budotitane"},{"name":"Maps_To","value":"Budotitane"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057922"}]}}{"C107555":{"preferredName":"Bufalin","code":"C107555","definitions":[{"definition":"An active ingredient and one of the glycosides in the traditional Chinese medicine ChanSu; it is also a bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans, with potential cardiotonic and antineoplastic activity. Although the mechanism of action of bufalin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and can induce apoptosis in cancer cell lines through the activation of the transcription factor AP-1 via a mitogen activated protein kinase (MAPK) pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bufalin","termGroup":"PT","termSource":"NCI"},{"termName":"3,14-Dihydroxy-Bufa-20,22-Dienolide","termGroup":"SN","termSource":"NCI"},{"termName":"3-Beta,14-Dihydroxy-5-Beta-Bufa-20,22-Dienolide","termGroup":"SY","termSource":"NCI"},{"termName":"3beta,14beta-Dihydroxy-5beta-Bufa-20,22-Dienolide","termGroup":"SY","termSource":"NCI"},{"termName":"5-Beta-Bufa-20,22-Dienolide, 3-Beta,14-Dihydroxy-","termGroup":"SN","termSource":"NCI"},{"termName":"5beta-Bufa-20,22-Dienolide, 3beta,14-Dihydroxy- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3-Beta,5-Beta)- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3beta,5beta)- (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"465-21-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U549S98QLW"},{"name":"Maps_To","value":"Bufalin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054205"}]}}{"C90565":{"preferredName":"Buparlisib","code":"C90565","definitions":[{"definition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buparlisib","termGroup":"PT","termSource":"NCI"},{"termName":"AN2025","termGroup":"CN","termSource":"NCI"},{"termName":"BKM120","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor BKM120","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"944396-07-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0ZM2Z182GD"},{"name":"Maps_To","value":"Buparlisib"},{"name":"NCI_Drug_Dictionary_ID","value":"667281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"667281"},{"name":"PDQ_Open_Trial_Search_ID","value":"667281"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3886769"}]}}{"C88323":{"preferredName":"Burixafor","code":"C88323","definitions":[{"definition":"An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation; this may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burixafor","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphonic Acid, p-(2-(4-(6-Amino-2-(((trans-4-(((3-(cyclohexylamino)propyl)amino)methyl)cyclohexyl)methyl)amino)-4-pyrimidinyl)-1-piperazinyl)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"TG-0054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1191448-17-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2G17Y0Q20G"},{"name":"Maps_To","value":"Burixafor"},{"name":"NCI_Drug_Dictionary_ID","value":"813325"},{"name":"NCI_META_CUI","value":"CL413584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130049":{"preferredName":"Burixafor Hydrobromide","code":"C130049","definitions":[{"definition":"The hydrobromide salt form of burixafor, an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with hematopoietic stem cell (HSC)-mobilization and chemosensitizing activities. Upon administration, burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into the peripheral circulation. Additionally, burixafor-mediated mobilization of disseminated tumor cells (DTCs) from the bone marrow into the blood may make these metastatic tumor cells more susceptible to the actions of chemotherapeutic agents. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burixafor Hydrobromide","termGroup":"PT","termSource":"NCI"},{"termName":"Burixafor HBr","termGroup":"SY","termSource":"NCI"},{"termName":"TG-0054 HBr","termGroup":"SY","termSource":"NCI"},{"termName":"TG-0054 Hydrobromide","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Burixafor Hydrobromide"},{"name":"NCI_Drug_Dictionary_ID","value":"661023"},{"name":"NCI_META_CUI","value":"CL513400"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119744":{"preferredName":"Burosumab","code":"C119744","definitions":[{"definition":"An orally bioavailable recombinant human immunoglobulin G1 monoclonal antibody directed against human fibroblast growth factor 23 (FGF23), that can be used to increase serum phosphate levels. Upon subcutaneous administration, burosumab binds to and inhibits FGF23, thereby interfering with FGF23 signaling. This increases tubular phosphate reabsorption, decreases excretion of phosphate, and increases serum phosphate levels, resulting in enhanced bone mineralization. FGF23, a member of the fibroblast growth factor (FGF) family produced by osteocytes, plays a key role in hypophosphatemic rickets/osteomalacia, such as X-linked hypophosphatemia (XLH) and tumor-induced rickets/osteomalacia. Increased FGF23 levels lead to decreased expression of the sodium-phosphate co-transporters in the proximal tubules, reduced renal phosphate reabsorption, increased excretion by the kidneys, and low serum phosphate concentration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burosumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-FGF23 IgG1 Monoclonal Antibody KRN23","termGroup":"SY","termSource":"NCI"},{"termName":"Burosumab-TWZA","termGroup":"SY","termSource":"NCI"},{"termName":"Crysvita","termGroup":"BR","termSource":"NCI"},{"termName":"KRN23","termGroup":"CN","termSource":"NCI"},{"termName":"UX023","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610833-03-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G9WJT6RD29"},{"name":"Maps_To","value":"Burosumab"},{"name":"NCI_Drug_Dictionary_ID","value":"767123"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767123"},{"name":"PDQ_Open_Trial_Search_ID","value":"767123"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896830"}]}}{"C320":{"preferredName":"Buserelin","code":"C320","definitions":[{"definition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called gonadotropin-releasing hormones. In prostate cancer therapy, buserelin blocks the production of testosterone in the testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Buserelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)","termGroup":"SN","termSource":"NCI"},{"termName":"BSRL","termGroup":"AB","termSource":"NCI"},{"termName":"Busereline","termGroup":"SY","termSource":"NCI"},{"termName":"Etilamide","termGroup":"BR","termSource":"NCI"},{"termName":"HOE 766","termGroup":"CN","termSource":"NCI"},{"termName":"ICI 123215","termGroup":"CN","termSource":"NCI"},{"termName":"S74-6766","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Contraception, female; Endometriosis; Infertility; in vitro fertilization; Polycystic ovary syndrome; Prostate cancer; Uterine leiomyoma"},{"name":"CAS_Registry","value":"57982-77-1"},{"name":"Chemical_Formula","value":"C60H86N16O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PXW8U3YXDV"},{"name":"Legacy Concept Name","value":"Buserelin"},{"name":"Maps_To","value":"Buserelin"},{"name":"NCI_Drug_Dictionary_ID","value":"39170"},{"name":"NSC Number","value":"725176"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39170"},{"name":"PDQ_Open_Trial_Search_ID","value":"39170"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006456"}]}}{"C160712":{"preferredName":"Bushen Culuan Decoction","code":"C160712","definitions":[{"definition":"A traditional Chinese medicine (TCM) decoction containing a mixture of ten Chinese herbs including Tusizi, Yinyanghuo, Xianmao, Xuduan, Gouqizi, Nvzhenzi, Zelan, Shengpuhuang, Xiangfu and Chuanshanlong, with potential to induce ovulation. Upon oral administration, Bushen Culuan decoction may, through a not yet fully elucidated mechanism, depress follicle-stimulating hormone (FSH) levels, elevate anti-Mullerian hormone (AMH) levels, and increase the number of antral follicle counts (AFCs), thereby promoting ovulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bushen Culuan Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"Bushen Culuan TCM Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"Bushen Culuan Traditional Chinese Medicine Decoction","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bushen Culuan Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"797882"},{"name":"NCI_META_CUI","value":"CL969814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797882"},{"name":"PDQ_Open_Trial_Search_ID","value":"797882"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151930":{"preferredName":"Bushen-Jianpi Decoction","code":"C151930","definitions":[{"definition":"A traditional Chinese medicine (TCM) that is used for Yin deficiency of the liver, kidney and spleen, with potential immunomodulating and antineoplastic activities. Bushen-Jianpi decoction (BSJPD; BJD) consists of various herbs, including, but not limited to, Radix Codonopsis (Dang Shen), Fructus Lycii (the fruit of Chinese wolfberry), Rhizoma Atractylodis Macrocephalae (Baishu; Bai Zhu), Fructus Ligustri Lucidi, Cuscuta chinensis (Chinese dodder) seed, and Psoralea corylifolia Linn. As a TCM, Bushen-Jianpi is used as an antineoplastic agent as it is thought to invigorate the spleen and tonify the kidney, which presumably prevents or treats a variety of cancers. Upon administration of Bushen-Jianpi decoction, the ingredients in the decoction may affect signaling pathways involved in carcinogenesis and enhance the immune system by increasing the levels of numerous cytokines and a variety of immune cells, such as cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs) and macrophages. It may also reduce the expression of various proteins involved in tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bushen-Jianpi Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"BJD","termGroup":"AB","termSource":"NCI"},{"termName":"BJHD","termGroup":"AB","termSource":"NCI"},{"termName":"BSJPD","termGroup":"AB","termSource":"NCI"},{"termName":"Jianpi Bushen","termGroup":"SY","termSource":"NCI"},{"termName":"Jianpi Bushen Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"JPBS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bushen-Jianpi Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"793123"},{"name":"NCI_META_CUI","value":"CL553269"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793123"},{"name":"PDQ_Open_Trial_Search_ID","value":"793123"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C321":{"preferredName":"Busulfan","code":"C321","definitions":[{"definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Busulfan","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-Bis(methanesulfonoxy)butane","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Bitanediol Dimethanesulfonate Esters","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Butanediol Dimethylsulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Di(methanesulfonyloxy)butane","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Di(methylsulfonyloxy)butane","termGroup":"SN","termSource":"NCI"},{"termName":"BUS","termGroup":"AB","termSource":"NCI"},{"termName":"Busilvex","termGroup":"FB","termSource":"NCI"},{"termName":"Bussulfam","termGroup":"SY","termSource":"NCI"},{"termName":"Busulfanum","termGroup":"SY","termSource":"NCI"},{"termName":"Busulfex","termGroup":"BR","termSource":"NCI"},{"termName":"Busulphan","termGroup":"SY","termSource":"NCI"},{"termName":"CB-2041","termGroup":"CN","termSource":"NCI"},{"termName":"Glyzophrol","termGroup":"SY","termSource":"NCI"},{"termName":"GT-41","termGroup":"CN","termSource":"NCI"},{"termName":"Joacamine","termGroup":"SY","termSource":"NCI"},{"termName":"Methanesulfonic Acid Tetramethylene Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Mielucin","termGroup":"FB","termSource":"NCI"},{"termName":"Misulban","termGroup":"FB","termSource":"NCI"},{"termName":"Misulfan","termGroup":"SY","termSource":"NCI"},{"termName":"Mitosan","termGroup":"FB","termSource":"NCI"},{"termName":"Myeleukon","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloleukon","termGroup":"SY","termSource":"NCI"},{"termName":"Myelosan","termGroup":"SY","termSource":"NCI"},{"termName":"Mylecytan","termGroup":"SY","termSource":"NCI"},{"termName":"Myleran","termGroup":"BR","termSource":"NCI"},{"termName":"Sulfabutin","termGroup":"SY","termSource":"NCI"},{"termName":"Tetramethylene Bis(methanesulfonate)","termGroup":"SY","termSource":"NCI"},{"termName":"WR-19508","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bone marrow disorders; chronic myelogenous leukemia; palliative; neoadjuvant to allogeneic hematopoietic progenitor cell transplantation; neoplastic meningitis; primary brain malignancies"},{"name":"CAS_Registry","value":"55-98-1"},{"name":"CHEBI_ID","value":"CHEBI:28901"},{"name":"Chemical_Formula","value":"C6H14O6S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"G1LN9045DK"},{"name":"Legacy Concept Name","value":"Busulfan"},{"name":"Maps_To","value":"Busulfan"},{"name":"NCI_Drug_Dictionary_ID","value":"41947"},{"name":"NSC Number","value":"750"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41947"},{"name":"PDQ_Open_Trial_Search_ID","value":"41947"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006463"}]}}{"C1029":{"preferredName":"Buthionine Sulfoximine","code":"C1029","definitions":[{"definition":"A drug that may help prevent resistance to some anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buthionine Sulfoximine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino-4-(S-butylsulfonimidoyl) Butanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BSO","termGroup":"AB","termSource":"NCI"},{"termName":"Butanoic Acid, 2-Amino-4-(S-butylsulfonimidoyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Buthionine Sulphoximine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Buthionine Sulfoximine","termGroup":"SY","termSource":"NCI"},{"termName":"S-(3-Amino-3-carboxypropyl)-S-butylsulfoximine","termGroup":"SN","termSource":"NCI"},{"termName":"S-(n-Butyl)homocysteine Sulfoximine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83730-53-4"},{"name":"Chemical_Formula","value":"C8H18N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EEY8DZS103"},{"name":"Legacy Concept Name","value":"Buthionine_Sulfoximine"},{"name":"Maps_To","value":"Buthionine Sulfoximine"},{"name":"NCI_Drug_Dictionary_ID","value":"39123"},{"name":"NSC Number","value":"326231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39123"},{"name":"PDQ_Open_Trial_Search_ID","value":"39123"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054252"}]}}{"C131491":{"preferredName":"BXQ-350 Nanovesicle Formulation","code":"C131491","definitions":[{"definition":"A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BXQ-350 Nanovesicle Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"BXQ-350","termGroup":"CN","termSource":"NCI"},{"termName":"SapC-DOPS Nanovesicles","termGroup":"SY","termSource":"NCI"},{"termName":"Saposin C-Dioleoylphosphatidylserine Complexes","termGroup":"SY","termSource":"NCI"},{"termName":"Saposin C-Dioleoylphosphatidylserine Nanovesicles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2N62LTC861"},{"name":"Maps_To","value":"BXQ-350 Nanovesicle Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"785725"},{"name":"NCI_META_CUI","value":"CL514261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785725"},{"name":"PDQ_Open_Trial_Search_ID","value":"785725"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121647":{"preferredName":"Bezuclastinib","code":"C121647","definitions":[{"definition":"An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bezuclastinib","termGroup":"PT","termSource":"NCI"},{"termName":"c-Kit Inhibitor PLX9486","termGroup":"SY","termSource":"NCI"},{"termName":"CGT 9486","termGroup":"CN","termSource":"NCI"},{"termName":"CGT-9486","termGroup":"CN","termSource":"NCI"},{"termName":"CGT9486","termGroup":"CN","termSource":"NCI"},{"termName":"PLX9486","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616385-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ROQ545LAG"},{"name":"Maps_To","value":"c-Kit Inhibitor PLX9486"},{"name":"NCI_Drug_Dictionary_ID","value":"770823"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770823"},{"name":"PDQ_Open_Trial_Search_ID","value":"770823"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053605"}]}}{"C129314":{"preferredName":"c-Met Inhibitor AL2846","code":"C129314","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration AL2846 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor AL2846","termGroup":"PT","termSource":"NCI"},{"termName":"AL 2846","termGroup":"CN","termSource":"NCI"},{"termName":"AL-2846","termGroup":"CN","termSource":"NCI"},{"termName":"AL2846","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor AL2846"},{"name":"NCI_Drug_Dictionary_ID","value":"783249"},{"name":"NCI_META_CUI","value":"CL512253"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783249"},{"name":"PDQ_Open_Trial_Search_ID","value":"783249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82677":{"preferredName":"c-Met Inhibitor AMG 208","code":"C82677","definitions":[{"definition":"A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity, which may result in cell growth inhibition in tumors that overexpress c-Met. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase, plays an important role in epithelial cell proliferation and has been shown to be overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor AMG 208","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1002304-34-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2SR66P7VM"},{"name":"Legacy Concept Name","value":"c-Met_Inhibitor_AMG_208"},{"name":"Maps_To","value":"c-Met Inhibitor AMG 208"},{"name":"NCI_Drug_Dictionary_ID","value":"632625"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632625"},{"name":"PDQ_Open_Trial_Search_ID","value":"632625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830208"}]}}{"C95203":{"preferredName":"c-Met Inhibitor AMG 337","code":"C95203","definitions":[{"definition":"An orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-Met, thereby disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor AMG 337","termGroup":"PT","termSource":"NCI"},{"termName":"1,6-Naphthyridin-5(6H)-one, 6-((1R)-1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo(4,3-a)pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"AMG 337","termGroup":"CN","termSource":"NCI"},{"termName":"AMG337","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1173699-31-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"08WG8S0L8D"},{"name":"Maps_To","value":"c-Met Inhibitor AMG 337"},{"name":"NCI_Drug_Dictionary_ID","value":"690935"},{"name":"NCI_META_CUI","value":"CL426693"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690935"},{"name":"PDQ_Open_Trial_Search_ID","value":"690935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128895":{"preferredName":"c-Met Inhibitor HS-10241","code":"C128895","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor HS-10241","termGroup":"PT","termSource":"NCI"},{"termName":"HS-10241","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor HS-10241"},{"name":"NCI_Drug_Dictionary_ID","value":"782607"},{"name":"NCI_META_CUI","value":"CL512254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782607"},{"name":"PDQ_Open_Trial_Search_ID","value":"782607"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77893":{"preferredName":"c-Met Inhibitor JNJ-38877605","code":"C77893","definitions":[{"definition":"An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor JNJ-38877605","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-38877605","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943540-75-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15UDG410PN"},{"name":"Legacy Concept Name","value":"c-Met_Inhibitor_JNJ-38877605"},{"name":"Maps_To","value":"c-Met Inhibitor JNJ-38877605"},{"name":"NCI_Drug_Dictionary_ID","value":"594157"},{"name":"NCI_META_CUI","value":"CL383572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594157"},{"name":"PDQ_Open_Trial_Search_ID","value":"594157"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90591":{"preferredName":"c-Met Inhibitor MK2461","code":"C90591","definitions":[{"definition":"A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor MK2461 preferentially inhibits activated c-Met in an ATP-competitive manner, thereby inhibiting its tyrosine kinase activity, which may inhibit c-Met signaling and result in cell growth inhibition in tumors that overexpress c-Met. c-Met, encoding the hepatocyte growth factor receptor (HGFR) tyrosine kinase, plays an important role in tumor cell proliferation and has been shown to be overexpressed or mutated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor MK2461","termGroup":"PT","termSource":"NCI"},{"termName":"MK2461","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor MK2461"},{"name":"NCI_Drug_Dictionary_ID","value":"560555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560555"},{"name":"PDQ_Open_Trial_Search_ID","value":"560555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983789"}]}}{"C116866":{"preferredName":"c-Met Inhibitor MK8033","code":"C116866","definitions":[{"definition":"An orally bioavailable inhibitor of c-Met, with potential antineoplastic activity. Upon administration, c-Met inhibitor MK8033 binds to and inhibits the autophosphorylation of the c-Met protein, which disrupts c-Met signal transduction pathways and may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. In addition, MK8033 inhibits Ron (receptor originated from nantes, MST1R). c-Met protein, which is encoded by the proto-oncogene MET, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis. Ron, a member of the Met family of cell surface receptor tyrosine kinases, is also overexpressed on certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor MK8033","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"MK 8033","termGroup":"CN","termSource":"NCI"},{"termName":"MK-8033","termGroup":"CN","termSource":"NCI"},{"termName":"MK8033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1196681-38-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"350H6PBQ5Q"},{"name":"Maps_To","value":"c-Met Inhibitor MK8033"},{"name":"NCI_Drug_Dictionary_ID","value":"580991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580991"},{"name":"PDQ_Open_Trial_Search_ID","value":"580991"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659325"}]}}{"C88314":{"preferredName":"Tepotinib","code":"C88314","definitions":[{"definition":"An orally bioavailable inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR), is the product of the proto-oncogene c-Met and is overexpressed or mutated in many tumor cell types; this protein plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tepotinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzonitrile, 3-(1,6-Dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"c-Met Inhibitor MSC2156119J","termGroup":"SY","termSource":"NCI"},{"termName":"EMD 1214063","termGroup":"CN","termSource":"NCI"},{"termName":"EMD-1214063","termGroup":"CN","termSource":"NCI"},{"termName":"EMD1214063","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-2156119","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-2156119J","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2156119J","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1100598-32-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1IJV77EI07"},{"name":"Maps_To","value":"c-Met Inhibitor MSC2156119J"},{"name":"Maps_To","value":"Tepotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"749525"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658472"}]}}{"C1541":{"preferredName":"C-myb Antisense Oligonucleotide G4460","code":"C1541","definitions":[{"definition":"A 24-base phosphorothiolate antisense oligodeoxynucleotide (ODN) for the proto-oncogene c-myb with potential antineoplastic activity. C-myb antisense oligonucleotide G4460 binds to codon sequences 2 to 9 of c-myb mRNA, inhibiting translation of the transcript. Suppression of c-myb expression with this agent may result in the restoration of normal differentiation pathways, increased antiproliferative effects, and the induction of apoptosis in early progenitor hematopoietic cells and in tumor cells that overexpress c-myb. Tumor-cell overexpression of c-myb blocks differentiation, promotes proliferation, and inhibits apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"C-myb Antisense Oligonucleotide G4460","termGroup":"PT","termSource":"NCI"},{"termName":"c-MYB Antisense","termGroup":"SY","termSource":"NCI"},{"termName":"c-MYB Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"c-Myb Antisense OND","termGroup":"SY","termSource":"NCI"},{"termName":"c-Myb LR-3001","termGroup":"SY","termSource":"NCI"},{"termName":"G4460","termGroup":"CN","termSource":"NCI"},{"termName":"INX-3001","termGroup":"CN","termSource":"NCI"},{"termName":"LR-3001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LR-3001"},{"name":"Maps_To","value":"C-myb Antisense Oligonucleotide G4460"},{"name":"NCI_Drug_Dictionary_ID","value":"43388"},{"name":"NSC Number","value":"710296"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43388"},{"name":"PDQ_Open_Trial_Search_ID","value":"43388"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253788"}]}}{"C2721":{"preferredName":"c-raf Antisense Oligonucleotide ISIS 5132","code":"C2721","definitions":[{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA.  ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo.  Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-raf Antisense Oligonucleotide ISIS 5132","termGroup":"PT","termSource":"NCI"},{"termName":"c-RAF Antisense","termGroup":"SY","termSource":"NCI"},{"termName":"CGP 69846A","termGroup":"CN","termSource":"NCI"},{"termName":"CGP69846A","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS 5132","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS 5132/CGP69846A","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS-5132","termGroup":"CN","termSource":"NCI"},{"termName":"RAF-IK Antisense ODN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"177075-18-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48IAF3FDP3"},{"name":"Legacy Concept Name","value":"ISIS_5132"},{"name":"Maps_To","value":"c-raf Antisense Oligonucleotide ISIS 5132"},{"name":"NCI_Drug_Dictionary_ID","value":"42994"},{"name":"NSC Number","value":"719336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42994"},{"name":"PDQ_Open_Trial_Search_ID","value":"42994"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0389883"}]}}{"C88264":{"preferredName":"C-VISA BikDD:Liposome","code":"C88264","definitions":[{"definition":"A formulation composed of DOTAP:cholesterol liposome nanoparticles complexed with the plasmid C-VISA BiKDD, with potential antineoplastic activity. C-VISA BikDD: liposome consists of a pancreatic-cancer-specific expression vector VISA (VP16-GAL4-WPRE integrated systemic amplifier) and a pancreatic-cancer-specific promoter CCKAR (cholecystokinin type A receptor) (CCKAR-VISA or C-VISA) which drives expression of the gene BikDD, a mutant form of the potent proapoptotic gene Bik (Bcl-2 interacting killer). Upon administration and transduction into pancreatic tumor cells, expression of BikDD by C-VISA BikDD:liposome may induce pancreatic tumor cell apoptosis and suppress pancreatic tumor cell proliferation. BikDD binds with greater affinity to anti-apoptotic proteins bcl-2, bcl-xl, bcl-w and Mcl-1 and is more potent than wild-type Bik. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at molar ratio of 1:1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"C-VISA BikDD:Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"C-VISA BikDD Plasmid: DOTAP:Cholesterol Liposome-Based Nanoparticle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C-VISA BikDD:Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"654631"},{"name":"NCI_META_CUI","value":"CL412442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654631"},{"name":"PDQ_Open_Trial_Search_ID","value":"654631"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155812":{"preferredName":"Ozuriftamab Vedotin","code":"C155812","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Upon administration of ozuriftamab vedotin, the anti-ROR2 antibody becomes activated through an as of yet not fully elucidated process, only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells and not in the microenvironment of normal, healthy tissues. Upon binding to ROR2-expressing cancer cells and internalization, the cytotoxic agent kills the cancer cells. ROR2, highly expressed during embryonic development while only minimally expressed on certain normal, healthy cells, is involved in Wnt signal transduction and is overexpressed on certain cancer cells. It plays a key role in cancer cell proliferation, migration and invasion. High levels of ROR2 expression often correlates with poor prognosis. The CAB antibody allows for efficient binding to ROR2-expressing cancer cells only, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy ROR2-expressing cells under normal conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ozuriftamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ROR2 CAB ADC","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"BA 3021","termGroup":"CN","termSource":"NCI"},{"termName":"BA3021","termGroup":"CN","termSource":"NCI"},{"termName":"CAB Anti-ROR2 ADC BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"CAB-ROR2-ADC","termGroup":"SY","termSource":"NCI"},{"termName":"CAB-ROR2-ADC BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"Conditionally Active Biologic Anti-ROR2 Antibody-drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"ROR2-targeted ADC BA3021","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460400-11-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BPM6YN0KLI"},{"name":"Maps_To","value":"CAB-ROR2-ADC BA3021"},{"name":"NCI_Drug_Dictionary_ID","value":"794991"},{"name":"NCI_META_CUI","value":"CL556342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794991"},{"name":"PDQ_Open_Trial_Search_ID","value":"794991"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66937":{"preferredName":"Cabazitaxel","code":"C66937","definitions":[{"definition":"A drug used with prednisone to treat hormone-resistant prostate cancer that has spread and that had been treated with docetaxel. It is also being studied in the treatment of other types of cancer. Cabazitaxel blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabazitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]","termGroup":"SN","termSource":"NCI"},{"termName":"Jevtana","termGroup":"BR","termSource":"NCI"},{"termName":"RPR-116258A","termGroup":"CN","termSource":"NCI"},{"termName":"RPR116258A","termGroup":"CN","termSource":"NCI"},{"termName":"Taxoid XRP6258","termGroup":"SY","termSource":"NCI"},{"termName":"TXD258","termGroup":"CN","termSource":"NCI"},{"termName":"XRP-6258","termGroup":"CN","termSource":"NCI"},{"termName":"XRP6258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic hormone-refractory prostate cancer"},{"name":"CAS_Registry","value":"183133-96-2"},{"name":"CHEBI_ID","value":"CHEBI:63584"},{"name":"Chemical_Formula","value":"C45H57NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"51F690397J"},{"name":"Legacy Concept Name","value":"XRP6258"},{"name":"Maps_To","value":"Cabazitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"534131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"534131"},{"name":"PDQ_Open_Trial_Search_ID","value":"534131"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830183"}]}}{"C123831":{"preferredName":"Cabiralizumab","code":"C123831","definitions":[{"definition":"A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks bone destruction. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabiralizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CSF1R FPA008","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986227","termGroup":"CN","termSource":"NCI"},{"termName":"FPA 008","termGroup":"CN","termSource":"NCI"},{"termName":"FPA-008","termGroup":"CN","termSource":"NCI"},{"termName":"FPA008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1613144-80-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5FJL6W0640"},{"name":"Maps_To","value":"Cabiralizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"775874"},{"name":"NCI_META_CUI","value":"CL498224"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775874"},{"name":"PDQ_Open_Trial_Search_ID","value":"775874"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52200":{"preferredName":"Cabozantinib","code":"C52200","definitions":[{"definition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabozantinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849217-68-1"},{"name":"Chemical_Formula","value":"C28H24FN3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"1C39JW444G"},{"name":"Legacy Concept Name","value":"XL184"},{"name":"Maps_To","value":"Cabozantinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3181682"}]}}{"C97938":{"preferredName":"Cabozantinib S-malate","code":"C97938","definitions":[{"definition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabozantinib S-malate","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-907351","termGroup":"CN","termSource":"NCI"},{"termName":"Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Cabometyx","termGroup":"BR","termSource":"NCI"},{"termName":"Cometriq","termGroup":"BR","termSource":"NCI"},{"termName":"XL-184","termGroup":"CN","termSource":"NCI"},{"termName":"XL184","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced renal cell carcinoma (RCC); hepatocellular carcinoma (HCC)"},{"name":"CAS_Registry","value":"1140909-48-3"},{"name":"Chemical_Formula","value":"C28H24FN3O5.C4H6O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DR7ST46X58"},{"name":"Maps_To","value":"Cabozantinib S-malate"},{"name":"NCI_Drug_Dictionary_ID","value":"461103"},{"name":"PDQ_Closed_Trial_Search_ID","value":"461103"},{"name":"PDQ_Open_Trial_Search_ID","value":"461103"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3468008"}]}}{"C1032":{"preferredName":"Cactinomycin","code":"C1032","definitions":[{"definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Cactinomycin binds to DNA by intercalating between guanine and cytosine, forming stable antibiotic-DNA complexes that inhibit RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cactinomycin","termGroup":"PT","termSource":"NCI"},{"termName":"Actinomycin C","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"8052-16-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0OCC969V50"},{"name":"Legacy Concept Name","value":"Cactinomycin"},{"name":"Maps_To","value":"Cactinomycin"},{"name":"NSC Number","value":"18268"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054404"}]}}{"C63756":{"preferredName":"Caffeic Acid Phenethyl Ester","code":"C63756","definitions":[{"definition":"The phenethyl alcohol ester of caffeic acid and a bioactive component of honeybee hive propolis, with antineoplastic, cytoprotective and immunomodulating activities. Upon administration, caffeic acid phenethyl ester (CAPE) inhibits the activation of nuclear transcription factor NF-kappa B and may suppress p70S6K and Akt-driven signaling pathways. In addition, CAPE inhibits PDGF-induced proliferation of vascular smooth muscle cells through the activation of p38 mitogen-activated protein kinase (MAPK) and hypoxia-inducible factor (HIF)-1alpha and subsequent induction of heme oxygenase-1 (HO-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Caffeic Acid Phenethyl Ester","termGroup":"PT","termSource":"NCI"},{"termName":"2-Phenylethyl 3-(3,4-dihydroxyphenyl)-2-propenoate","termGroup":"SN","termSource":"NCI"},{"termName":"3-(3,4-Dihydroxyphenyl)-2-propenoic Acid, 2-Phenylethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"CAPE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"104594-70-9"},{"name":"Chemical_Formula","value":"C17H16O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G960R9S5SK"},{"name":"Legacy Concept Name","value":"Caffeic_Acid_Phenethyl_Ester"},{"name":"Maps_To","value":"Caffeic Acid Phenethyl Ester"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054434"}]}}{"C117731":{"preferredName":"CAIX Inhibitor DTP348","code":"C117731","definitions":[{"definition":"An orally bioavailable, nitroimidazole-based sulfamide, carbonic anhydrase IX (CAIX) inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor DTP348 inhibits tumor-associated CAIX, a hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents the acidification of the tumor's extracellular microenvironment and decreases the intracellular pH. This results in increased cell death in CAIX-expressing, hypoxic tumors. In addition, DTP348, through its nitroimidazole moiety, is able to sensitize hypoxic tumor cells to irradiation. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAIX Inhibitor DTP348","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide","termGroup":"SN","termSource":"NCI"},{"termName":"DTP348","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1383370-92-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2HB46A9CNM"},{"name":"Maps_To","value":"CAIX Inhibitor DTP348"},{"name":"NCI_Drug_Dictionary_ID","value":"763908"},{"name":"NCI_META_CUI","value":"CL474126"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763908"},{"name":"PDQ_Open_Trial_Search_ID","value":"763908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117728":{"preferredName":"CAIX Inhibitor SLC-0111","code":"C117728","definitions":[{"definition":"A sulfonamide carbonic anhydrase inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor SLC-0111 inhibits tumor-associated carbonic anhydrase IX (CAIX), an hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents both the acidification of the tumor's extracellular microenvironment and cytoplasmic alkalization. This increases cell death in CAIX-expressing, hypoxic tumors. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion; it is also involved in resistance to both chemo- and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAIX Inhibitor SLC-0111","termGroup":"PT","termSource":"NCI"},{"termName":"SLC-0111","termGroup":"CN","termSource":"NCI"},{"termName":"U-104","termGroup":"CN","termSource":"NCI"},{"termName":"U104","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"178606-66-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ANM9DBL9JT"},{"name":"Maps_To","value":"CAIX Inhibitor SLC-0111"},{"name":"NCI_Drug_Dictionary_ID","value":"763832"},{"name":"NCI_META_CUI","value":"CL474123"},{"name":"NSC Number","value":"213841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763832"},{"name":"PDQ_Open_Trial_Search_ID","value":"763832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78198":{"preferredName":"Calaspargase Pegol","code":"C78198","definitions":[{"definition":"A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the anticancer drug PEG-asparaginase that stays in the body longer. EZN-2285 is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol, L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calaspargase Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl)","termGroup":"SY","termSource":"NCI"},{"termName":"Asparlas","termGroup":"BR","termSource":"NCI"},{"termName":"Calaspargase Pegol","termGroup":"SY","termSource":"NCI"},{"termName":"Calaspargase Pegol-mknl","termGroup":"SY","termSource":"NCI"},{"termName":"EZN-2285","termGroup":"CN","termSource":"NCI"},{"termName":"SC-PEG E. Coli L-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute lymphoblastic leukemia (ALL)"},{"name":"CAS_Registry","value":"941577-06-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T9FVH03HMZ"},{"name":"Legacy Concept Name","value":"Succinimidyl_Carbonate_Monomethoxypolyethylene_Glycol_E_Coli_L-Asparaginase"},{"name":"Maps_To","value":"Calaspargase Pegol-mknl"},{"name":"NCI_Drug_Dictionary_ID","value":"595298"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595298"},{"name":"PDQ_Open_Trial_Search_ID","value":"595298"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699709"}]}}{"C330":{"preferredName":"Calcitriol","code":"C330","definitions":[{"definition":"A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active form of vitamin D. Calcitriol is formed in the kidneys or made in the laboratory. It is used as a drug to increase calcium levels in the body in order to treat skeletal and tissue-related calcium deficiencies caused by kidney or thyroid disorders.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Calcitriol","termGroup":"PT","termSource":"NCI"},{"termName":"(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol","termGroup":"SN","termSource":"NCI"},{"termName":"1,25(OH)2-D3","termGroup":"AB","termSource":"NCI"},{"termName":"1,25-DHCC","termGroup":"SY","termSource":"NCI"},{"termName":"1,25-Dihydroxycholecalciferol","termGroup":"SY","termSource":"NCI"},{"termName":"1,25-Dihydroxycholecaliferol","termGroup":"SY","termSource":"NCI"},{"termName":"Calcijex","termGroup":"BR","termSource":"NCI"},{"termName":"Rocaltrol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hyperparathyroidism; Hypocalcemia"},{"name":"CAS_Registry","value":"32222-06-3"},{"name":"CHEBI_ID","value":"CHEBI:17823"},{"name":"Chemical_Formula","value":"C27H44O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FXC9231JVH"},{"name":"Legacy Concept Name","value":"Calcitriol"},{"name":"Maps_To","value":"Calcitriol"},{"name":"NCI_Drug_Dictionary_ID","value":"41919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41919"},{"name":"PDQ_Open_Trial_Search_ID","value":"41919"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006674"}]}}{"C136828":{"preferredName":"Calcium Release-activated Channels Inhibitor RP4010","code":"C136828","definitions":[{"definition":"A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential antineoplastic activity. Upon administration, RP4010 binds to and inhibits CRACs, thereby preventing the transport of extracellular Ca2+ into the cell and inhibiting the subsequent activation of Ca2+-mediated signaling and transcription of target genes. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), play key roles in calcium homeostasis and are over-activated in a number of cancer cell types. Aberrant activation of CRACs leads to increased cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcium Release-activated Channels Inhibitor RP4010","termGroup":"PT","termSource":"NCI"},{"termName":"CRAC Inhibitor RP4010","termGroup":"SY","termSource":"NCI"},{"termName":"RP 4010","termGroup":"CN","termSource":"NCI"},{"termName":"RP-4010","termGroup":"CN","termSource":"NCI"},{"termName":"RP4010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Calcium Release-activated Channels Inhibitor RP4010"},{"name":"NCI_Drug_Dictionary_ID","value":"790238"},{"name":"NCI_META_CUI","value":"CL524660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790238"},{"name":"PDQ_Open_Trial_Search_ID","value":"790238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C335":{"preferredName":"Calcium Saccharate","code":"C335","definitions":[{"definition":"The calcium salt form of glucaric acid, a natural substance found in many fruits and vegetables, with potential anti-cancer property. One of the key processes in which the human body eliminates toxic chemicals as well as hormones (such as estrogen) is by attaching glucuronic acid to them in the liver and then excreting the complex in the bile. When beta-glucuronidase breaks the bond, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Therefore, supplementing calcium glucarate may suppress the developments of hormone-dependent cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcium Saccharate","termGroup":"PT","termSource":"NCI"},{"termName":"2,3,4,5-tetrahydroxy-1,6- dioxido-hexane-1,6-dione, Calcium","termGroup":"SN","termSource":"NCI"},{"termName":"Antacidin","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium D-Glucarate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium D-Saccharate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Glucarate","termGroup":"SY","termSource":"NCI"},{"termName":"CGT","termGroup":"AB","termSource":"NCI"},{"termName":"Saccharated Lime","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5793-89-5"},{"name":"Chemical_Formula","value":"C6H8O8.Ca.4H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6AP9J91K4V"},{"name":"Legacy Concept Name","value":"Calcium_Glucarate"},{"name":"Maps_To","value":"Calcium Saccharate"},{"name":"NCI_Drug_Dictionary_ID","value":"41803"},{"name":"NSC Number","value":"122011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41803"},{"name":"PDQ_Open_Trial_Search_ID","value":"41803"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771997"}]}}{"C121642":{"preferredName":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule","code":"C121642","definitions":[{"definition":"An orally available traditional Chinese medicine (TCM)-based capsule formulation containing Calculus bovis, the dried gallstones of cattle, Moschus, also referred to as deer musk, the resin Olibanum and the resin Myrrha, with potential antineoplastic and chemopreventive activities. Although the exact mechanisms of action through which the active ingredients in the Calculus bovis/Moschus/Olibanum/Myrrha capsule elicit their effects have yet to be fully elucidated, they may, upon intake, exert their antineoplastic activity through modulation of the immune system, inhibition of tumor cell proliferation and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Wangbang Pharmaceutical Xihuang Capsule","termGroup":"SY","termSource":"NCI"},{"termName":"XHP","termGroup":"AB","termSource":"NCI"},{"termName":"Xihuang Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"770710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770710"},{"name":"PDQ_Open_Trial_Search_ID","value":"770710"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053490"}]}}{"C1035":{"preferredName":"Calicheamicin Gamma 1I","code":"C1035","definitions":[{"definition":"An oligosaccharide enediyne antitumor antibiotic isolated from Micromonospora echinospora ssp. Calichensis.  Calicheamicin Gamma 1I binds to the minor groove of DNA, resulting in site-specific double-strand breaks and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calicheamicin Gamma 1I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Calicheamicin_Gamma_1I"},{"name":"Maps_To","value":"Calicheamicin Gamma 1I"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0054506"}]}}{"C338":{"preferredName":"Camptothecin","code":"C338","definitions":[{"definition":"An alkaloid isolated from the Chinese tree Camptotheca acuminata, with antineoplastic activity.  During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Camptothecin","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-Camptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"(S)-4-ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolozino[1,2-b]quinoline-3,14(4H,12H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Pyrano[3',3'.6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4hydroxy-(S)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"20-(S)-camptothecine","termGroup":"SY","termSource":"NCI"},{"termName":"21, 22-secocamptothecin-21-oic acid lactone","termGroup":"SN","termSource":"NCI"},{"termName":"camptothecine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7689-03-4"},{"name":"CHEBI_ID","value":"CHEBI:27656"},{"name":"Chemical_Formula","value":"C20H16N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XT3Z54Z28A"},{"name":"Legacy Concept Name","value":"Camptothecin"},{"name":"Maps_To","value":"Camptothecin"},{"name":"NCI_Drug_Dictionary_ID","value":"39173"},{"name":"NSC Number","value":"94600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39173"},{"name":"PDQ_Open_Trial_Search_ID","value":"39173"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006812"}]}}{"C80047":{"preferredName":"Camptothecin Analogue TLC388","code":"C80047","definitions":[{"definition":"A synthetic analogue of camptothecin with potential antineoplastic and radio-sensitizing activities. Camptothecin analogue TLC388 selectively stabilizes topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Topoisomerase I relaxes negative super-coiled DNA during replication and transcription. This agent has been chemically modified to enhance the potency and stability of camptothecin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camptothecin Analogue TLC388","termGroup":"PT","termSource":"NCI"},{"termName":"Lipotecan","termGroup":"BR","termSource":"NCI"},{"termName":"TLC388","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1432468-79-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D47234N30N"},{"name":"Legacy Concept Name","value":"Camptothecin_Analogue_TLC388"},{"name":"Maps_To","value":"Camptothecin Analogue TLC388"},{"name":"NCI_Drug_Dictionary_ID","value":"615096"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615096"},{"name":"PDQ_Open_Trial_Search_ID","value":"615096"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703206"}]}}{"C1886":{"preferredName":"Afeletecan Hydrochloride","code":"C1886","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called camptothecins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of afeletecan, a water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. Afeletecan stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afeletecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 38-3441","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 56-3722","termGroup":"CN","termSource":"NCI"},{"termName":"BAY56-3722","termGroup":"CN","termSource":"NCI"},{"termName":"Camptothecin Glycoconjugate BAY 38-3441","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"215604-74-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DTJ7VPW43J"},{"name":"Legacy Concept Name","value":"BAY_56-3722"},{"name":"Maps_To","value":"Camptothecin Glycoconjugate BAY 38-3441"},{"name":"NCI_Drug_Dictionary_ID","value":"38705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38705"},{"name":"PDQ_Open_Trial_Search_ID","value":"38705"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1101785"}]}}{"C2344":{"preferredName":"Camptothecin Sodium","code":"C2344","definitions":[{"definition":"The sodium salt of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, with antineoplastic activity.  During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The sodium salt of camptothecin is more water-soluble than the parent molecule. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camptothecin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Camptothecin Sodium Salt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"25387-67-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3L6CT9UWOM"},{"name":"Legacy Concept Name","value":"Camptothecin_Sodium"},{"name":"Maps_To","value":"Camptothecin Sodium"},{"name":"NSC Number","value":"100880"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516156"}]}}{"C84857":{"preferredName":"Camptothecin-20(S)-O-Propionate Hydrate","code":"C84857","definitions":[{"definition":"The hydrated, crystalline propionate ester (attached in position C-20) prodrug of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, with potential antineoplastic activity. Upon entry into cells, camptothecin-20(S)-O-propionate is hydrolyzed by esterases into the active form camptothecin. Camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery, thus inhibiting DNA replication and triggering apoptotic cell death. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active, S-configured lactone structure to an inactive carboxylate form. The ester chain in the vicinity of the S-configured lactone moiety, a key determinant for the chemotherapeutic efficacy of the camptothecins, inhibits protein binding, rendering this agent resistant to hydrolysis and prolonging its half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camptothecin-20(S)-O-Propionate Hydrate","termGroup":"PT","termSource":"NCI"},{"termName":"CZ48","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Camptothecin-20(S)-O-Propionate Hydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"651549"},{"name":"NCI_META_CUI","value":"CL412415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651549"},{"name":"PDQ_Open_Trial_Search_ID","value":"651549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123816":{"preferredName":"Camrelizumab","code":"C123816","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camrelizumab","termGroup":"PT","termSource":"NCI"},{"termName":"AiRuiKa","termGroup":"FB","termSource":"NCI"},{"termName":"AiRuiKa (TM)","termGroup":"SY","termSource":"NCI"},{"termName":"Carrizumab","termGroup":"SY","termSource":"NCI"},{"termName":"HR-301210","termGroup":"CN","termSource":"NCI"},{"termName":"SHR 1210","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1210","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1798286-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"73096E137E"},{"name":"Maps_To","value":"Camrelizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"775449"},{"name":"NCI_META_CUI","value":"CL498210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775449"},{"name":"PDQ_Open_Trial_Search_ID","value":"775449"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78863":{"preferredName":"Camsirubicin","code":"C78863","definitions":[{"definition":"A synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Camsirubicin intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camsirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"5-Imino-13-deoxydoxoubicin","termGroup":"SN","termSource":"NCI"},{"termName":"GPX-150","termGroup":"CN","termSource":"NCI"},{"termName":"GPX150","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"236095-26-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VI79RD8VNN"},{"name":"Legacy Concept Name","value":"Anthracycline_Analogue_GPX-150"},{"name":"Maps_To","value":"Camsirubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"601485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601485"},{"name":"PDQ_Open_Trial_Search_ID","value":"601485"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698125"}]}}{"C1775":{"preferredName":"Cancell","code":"C1775","definitions":[{"definition":"A liquid that has been promoted as a treatment for a wide range of diseases, including cancer. The ingredients thought to be in Cancell have been tested, and none of them has been shown to be effective in treating any form of cancer. Cancell is not available in the United States.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Cancell (Entelev or Cantron), is a liquid that has been produced in various forms, principally by two manufacturers, since the late 1930s.  The exact composition of Cancell/Entelev is unknown, but the U.S. Food and Drug Administration (FDA) has listed the components as inositol, nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, and catechol.  NCI studies determined that the mixture lacked substantial antitumor activity. (from CancerNet)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancell","termGroup":"PT","termSource":"NCI"},{"termName":"Entelev","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cancell"},{"name":"Maps_To","value":"Cancell"},{"name":"NCI_Drug_Dictionary_ID","value":"257610"},{"name":"NSC Number","value":"637907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257610"},{"name":"PDQ_Open_Trial_Search_ID","value":"257610"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0656937"}]}}{"C121776":{"preferredName":"Cancer Peptide Vaccine S-588410","code":"C121776","definitions":[{"definition":"A cancer peptide vaccine containing five human leukocyte antigen (HLA)-A*2402-restricted epitope peptides derived from as of yet not disclosed oncoantigens, with potential immunostimulating and antineoplastic activities. Upon administration of the cancer peptide vaccine S-588410, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Peptide Vaccine S-588410","termGroup":"PT","termSource":"NCI"},{"termName":"S-588410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cancer Peptide Vaccine S-588410"},{"name":"NCI_Drug_Dictionary_ID","value":"770997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770997"},{"name":"PDQ_Open_Trial_Search_ID","value":"770997"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053593"}]}}{"C88318":{"preferredName":"Canerpaturev","code":"C88318","definitions":[{"definition":"A non-engineered, naturally oncolytic, replication-competent spontaneous herpes simplex virus (HSV) type I mutant variant. Upon intratumoral injection, canerpaturev transfects, replicates in, and lyses rapidly dividing cells such as tumor cells. In addition, this agent may increase host immune responses that may kill non-infected tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canerpaturev","termGroup":"PT","termSource":"NCI"},{"termName":"Herpes Simplex Virus Type 1 HF10","termGroup":"SY","termSource":"NCI"},{"termName":"HF10","termGroup":"CN","termSource":"NCI"},{"termName":"HSV1 HF10","termGroup":"SY","termSource":"NCI"},{"termName":"Msc 2","termGroup":"SY","termSource":"NCI"},{"termName":"TBI-1401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1662666-66-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3F5D10T4M"},{"name":"Maps_To","value":"Canerpaturev"},{"name":"NCI_Drug_Dictionary_ID","value":"660850"},{"name":"NCI_META_CUI","value":"CL413628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660850"},{"name":"PDQ_Open_Trial_Search_ID","value":"660850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1880":{"preferredName":"Canertinib Dihydrochloride","code":"C1880","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. Canertinib blocks the action of proteins called epidermal growth factor receptors, and may cause cancer cells to die. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canertinib Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"CI-1033","termGroup":"CN","termSource":"NCI"},{"termName":"N-[-4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"PD-0183805-002B","termGroup":"CN","termSource":"NCI"},{"termName":"PD183805","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"289499-45-2"},{"name":"Chemical_Formula","value":"C24H25ClFN5O3.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ICJ93X8X90"},{"name":"Legacy Concept Name","value":"CI-1033"},{"name":"Maps_To","value":"Canertinib Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38403"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38403"},{"name":"PDQ_Open_Trial_Search_ID","value":"38403"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707132"}]}}{"C83581":{"preferredName":"Canfosfamide","code":"C83581","definitions":[{"definition":"A modified glutathione analogue and nitrogen mustard prodrug, with potential antineoplastic activity. Canfosfamide is selectively activated by glutathione S-transferase P1-1 into an alkylating metabolite that forms covalent linkages with nucleophilic centers in tumor cell DNA, which may induce a cellular stress response and cytotoxicity, and decrease tumor cell proliferation. Glutathione S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canfosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-L-gamma-Glutamyl-3-((2-((bis(bis(2-chloroethyl)amino)phosphinyl)oxy)ethyl)sulfonyl)-L-alanyl-2-phenylglycine","termGroup":"SN","termSource":"NCI"},{"termName":"Ter 286","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"158382-37-7"},{"name":"Chemical_Formula","value":"C26H40Cl4N5O10PS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1RS284BFUI"},{"name":"Maps_To","value":"Canfosfamide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664315"}]}}{"C2641":{"preferredName":"Canfosfamide Hydrochloride","code":"C2641","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called glutathione analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a modified glutathione analogue with potential antineoplastic activity. Canfosfamide is selectively activated by glutathione S-transferase P1-1 into an alkylating metabolite that forms covalent linkages with nucleophilic centers in tumor cell DNA, which may induce a cellular stress response and cytotoxicity, and decrease tumor proliferation. S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canfosfamide Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Telcyta","termGroup":"BR","termSource":"NCI"},{"termName":"TLK286","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"439943-59-6"},{"name":"Chemical_Formula","value":"C26H40Cl4N5O10PS.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1LI341K7NQ"},{"name":"Legacy Concept Name","value":"TLK286"},{"name":"Maps_To","value":"Canfosfamide Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38367"},{"name":"PDQ_Open_Trial_Search_ID","value":"38367"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1258106"}]}}{"C118452":{"preferredName":"Cannabidiol","code":"C118452","definitions":[{"definition":"A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor 1. CBD stimulates endoplasmic reticulum (ER) stress and inhibits AKT/mTOR signaling, thereby activating autophagy and promoting apoptosis. In addition, CBD enhances the generation of reactive oxygen species (ROS), which further enhances apoptosis. This agent also upregulates the expression of intercellular adhesion molecule 1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) and decreases the expression of inhibitor of DNA binding 1 (ID-1). This inhibits cancer cell invasiveness and metastasis. CBD may also activate the transient receptor potential vanilloid type 2 (TRPV2), which may increase the uptake of various cytotoxic agents in cancer cells. The analgesic effect of CBD is mediated through the binding of this agent to and activation of CB1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cannabidiol","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-","termGroup":"SN","termSource":"NCI"},{"termName":"CBD","termGroup":"AB","termSource":"NCI"},{"termName":"CBD Oil","termGroup":"SY","termSource":"NCI"},{"termName":"Epidiolex","termGroup":"BR","termSource":"NCI"},{"termName":"GWP42003-P","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13956-29-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19GBJ60SN5"},{"name":"Maps_To","value":"Cannabidiol"},{"name":"NCI_Drug_Dictionary_ID","value":"765192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765192"},{"name":"PDQ_Open_Trial_Search_ID","value":"765192"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006863"}]}}{"C159719":{"preferredName":"Cantrixil","code":"C159719","definitions":[{"definition":"A cyclodextrin-encapsulated, third generation super-benzopyran (SBP) compound with potential antineoplastic activity. Upon intraperitoneal (IP) administration, cantrixil enhances the activation and expression of c-Jun, downregulates phosphorylated extracellular signal-regulated kinase (p-ERK) and induces activation of caspase-3, -7 and -9, thereby inducing tumor cell apoptosis. c-Jun, an activator protein-1 (AP-1) transcription factor component, is involved in a wide range of cellular processes including cell cycle progression, differentiation, cell transformation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cantrixil","termGroup":"PT","termSource":"NCI"},{"termName":"cis-4-(para-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan","termGroup":"SN","termSource":"NCI"},{"termName":"TRX E 002 1","termGroup":"CN","termSource":"NCI"},{"termName":"TRX-E-002-1","termGroup":"CN","termSource":"NCI"},{"termName":"TRXE0021","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1803036-93-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5DVS457HEG"},{"name":"Maps_To","value":"Cantrixil"},{"name":"NCI_Drug_Dictionary_ID","value":"797919"},{"name":"NCI_META_CUI","value":"CL951687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797919"},{"name":"PDQ_Open_Trial_Search_ID","value":"797919"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61576":{"preferredName":"Cantuzumab Ravtansine","code":"C61576","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It is made by linking the monoclonal antibody huC242 to a toxic substance called maytansinoid DM4. The monoclonal antibody binds to the surfaces of cancer cells and the maytansinoid DM4 enters the cells and blocks their growth. It is a type of immunotoxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated to a derivative of the cytotoxic agent maytansine, DM4, with potential antitumor activity. Cantuzumab ravtansine is generated from MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. As a result, this agent prevents cell division and reduces cell growth of cancer cells that express CA242.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cantuzumab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"HuC242-DM4","termGroup":"AB","termSource":"NCI"},{"termName":"IMGN242","termGroup":"CN","termSource":"NCI"},{"termName":"Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"868747-45-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RNQ8JQ4R9P"},{"name":"Legacy Concept Name","value":"HuC242-DM4"},{"name":"Maps_To","value":"Cantuzumab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"492706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492706"},{"name":"PDQ_Open_Trial_Search_ID","value":"492706"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831909"}]}}{"C1794":{"preferredName":"Capecitabine","code":"C1794","definitions":[{"definition":"A drug used to treat stage III colon cancer in patients who had surgery to remove the cancer. It is also used to treat metastatic breast cancer that has not improved after treatment with certain other anticancer drugs. Xeloda is being studied in the treatment of other types of cancer. It is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills tumor cells. Xeloda is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capecitabine","termGroup":"PT","termSource":"NCI"},{"termName":"5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine","termGroup":"SN","termSource":"NCI"},{"termName":"Ro 09-1978/000","termGroup":"CN","termSource":"NCI"},{"termName":"Xeloda","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Colorectal cancer, Stage III colon cancer"},{"name":"CAS_Registry","value":"154361-50-9"},{"name":"CHEBI_ID","value":"CHEBI:31348"},{"name":"Chemical_Formula","value":"C15H22FN3O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6804DJ8Z9U"},{"name":"Legacy Concept Name","value":"Capecitabine"},{"name":"Maps_To","value":"Capecitabine"},{"name":"Maps_To","value":"Xeloda"},{"name":"NCI_Drug_Dictionary_ID","value":"42852"},{"name":"NSC Number","value":"712807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42852"},{"name":"PDQ_Open_Trial_Search_ID","value":"42852"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0671970"}]}}{"C99629":{"preferredName":"Capecitabine Rapidly Disintegrating Tablet","code":"C99629","definitions":[{"definition":"A rapidly disintegrating film-coated tablet composed of the fluoropyrimidine carbamate antimetabolite capecitabine with antineoplastic activity. As a prodrug, capecitabine is converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by hepatic carboxylesterase and then to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase and is eventually activated by thymidine phosphorylase to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine triphosphate production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Capecitabine rapidly disintegrating tablet (RDT) contains the water insoluble, disintegrating agent crospovidone which very rapidly disperses and swells in water making this RDT easier to swallow than the traditional capecitabine tablet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capecitabine Rapidly Disintegrating Tablet","termGroup":"PT","termSource":"NCI"},{"termName":"Capecitabine RDT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Capecitabine Rapidly Disintegrating Tablet"},{"name":"NCI_Drug_Dictionary_ID","value":"721986"},{"name":"NCI_META_CUI","value":"CL433297"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721986"},{"name":"PDQ_Open_Trial_Search_ID","value":"721986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102564":{"preferredName":"Capivasertib","code":"C102564","definitions":[{"definition":"A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capivasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD5363","termGroup":"CN","termSource":"NCI"},{"termName":"Truqap","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations"},{"name":"CAS_Registry","value":"1143532-39-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WFR23M21IE"},{"name":"Maps_To","value":"Capivasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"688304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688304"},{"name":"PDQ_Open_Trial_Search_ID","value":"688304"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3502775"}]}}{"C90564":{"preferredName":"Capmatinib","code":"C90564","definitions":[{"definition":"An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capmatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"INC-280","termGroup":"CN","termSource":"NCI"},{"termName":"INC280","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 28060","termGroup":"CN","termSource":"NCI"},{"termName":"INCB028060","termGroup":"CN","termSource":"NCI"},{"termName":"INCB28060","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1029712-80-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"TY34L4F9OZ"},{"name":"Maps_To","value":"Capmatinib"},{"name":"NCI_META_CUI","value":"CL416248"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C340":{"preferredName":"Captopril","code":"C340","definitions":[{"definition":"A drug used to treat high blood pressure that is also being studied in the prevention of side effects caused by radiation therapy used in the treatment of cancer. It belongs to the family of drugs called ACE inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity. Captopril competitively inhibits angiotensin converting enzyme (ACE), thereby decreasing levels of angiotensin II, increasing plasma renin activity, and decreasing aldosterone secretion.  This agent may also inhibit tumor angiogenesis by inhibiting endothelial cell matrix metalloproteinases (MMPs) and endothelial cell migration. Captopril may also exhibit antineoplastic activity independent of effects on tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Captopril","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline","termGroup":"SN","termSource":"NCI"},{"termName":"Capoten","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypertension; Heart failure; Left ventricular dysfunction; Diabetic nephropathy"},{"name":"CAS_Registry","value":"62571-86-2"},{"name":"CHEBI_ID","value":"CHEBI:3380"},{"name":"Chemical_Formula","value":"C9H15NO3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9G64RSX1XD"},{"name":"Legacy Concept Name","value":"Captopril"},{"name":"Maps_To","value":"Captopril"},{"name":"NCI_Drug_Dictionary_ID","value":"37824"},{"name":"NSC Number","value":"719847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37824"},{"name":"PDQ_Open_Trial_Search_ID","value":"37824"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006938"}]}}{"C150586":{"preferredName":"CAR T-Cells AMG 119","code":"C150586","definitions":[{"definition":"A preparation of T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of the CAR T-cells AMG 119, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAR T-Cells AMG 119","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 119","termGroup":"CN","termSource":"NCI"},{"termName":"AMG 119 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"AMG-119","termGroup":"CN","termSource":"NCI"},{"termName":"AMG119","termGroup":"CN","termSource":"NCI"},{"termName":"CAR-T Cells AMG 119","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CAR T-Cells AMG 119"},{"name":"NCI_Drug_Dictionary_ID","value":"793448"},{"name":"NCI_META_CUI","value":"CL552332"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793448"},{"name":"PDQ_Open_Trial_Search_ID","value":"793448"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1037":{"preferredName":"Caracemide","code":"C1037","definitions":[{"definition":"An agent derived from acetohydroxamic acid with potential antineoplastic activity.  Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase.  In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Caracemide","termGroup":"PT","termSource":"NCI"},{"termName":"Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81424-67-1"},{"name":"Chemical_Formula","value":"C6H11N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H74F6J185A"},{"name":"Legacy Concept Name","value":"Caracemide"},{"name":"Maps_To","value":"Caracemide"},{"name":"NCI_Drug_Dictionary_ID","value":"39751"},{"name":"NSC Number","value":"253272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39751"},{"name":"PDQ_Open_Trial_Search_ID","value":"39751"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054633"}]}}{"C1154":{"preferredName":"Carbendazim","code":"C1154","definitions":[{"definition":"A broad-spectrum benzimidazole antifungal with potential antimitotic and antineoplastic activities. Although the exact mechanism of action is unclear, carbendazim appears to binds to an unspecified site on tubulin and suppresses microtubule assembly dynamic. This results in cell cycle arrest at the G2/M phase and an induction of apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antifungal agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carbendazim","termGroup":"PT","termSource":"NCI"},{"termName":"1H-benzimidazol-2-ylcarbamic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"2-(Methoxycarbonylamino)benzimidazole","termGroup":"SN","termSource":"NCI"},{"termName":"2-Benzimidazolecarcamic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"BAS-3460","termGroup":"CN","termSource":"NCI"},{"termName":"BAS-67054","termGroup":"CN","termSource":"NCI"},{"termName":"Bavistin","termGroup":"FB","termSource":"NCI"},{"termName":"BCM","termGroup":"AB","termSource":"NCI"},{"termName":"BMC","termGroup":"AB","termSource":"NCI"},{"termName":"Carbendazole","termGroup":"SY","termSource":"NCI"},{"termName":"CTR-6669","termGroup":"CN","termSource":"NCI"},{"termName":"Derosal","termGroup":"FB","termSource":"NCI"},{"termName":"FB642","termGroup":"CN","termSource":"NCI"},{"termName":"HOE-17411","termGroup":"CN","termSource":"NCI"},{"termName":"MBC","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl 2-Benzimidazolecarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl Benzimidazol-2-ylcarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-1H-benzimidazol-2-yl Carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-2-benzimidazole Carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-2-benzimidazolecarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-alpha-benzimidazole Carbamate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10605-21-7"},{"name":"Chemical_Formula","value":"C9H9N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H75J14AA89"},{"name":"Legacy Concept Name","value":"Carbendazim"},{"name":"Maps_To","value":"Carbendazim"},{"name":"NCI_Drug_Dictionary_ID","value":"43319"},{"name":"NSC Number","value":"109874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43319"},{"name":"PDQ_Open_Trial_Search_ID","value":"43319"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065839"}]}}{"C1356":{"preferredName":"Carbetimer","code":"C1356","definitions":[{"definition":"Carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride.  It has demonstrated antitumor activity against several animal models.  It has calcium chelation activity but seems to inhibit growth of sensitive cells by disrupting nucleoside uptake and metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carbetimer","termGroup":"PT","termSource":"NCI"},{"termName":"carbethimer","termGroup":"SY","termSource":"NCI"},{"termName":"carboxyaminidate","termGroup":"SY","termSource":"NCI"},{"termName":"N-137","termGroup":"CN","termSource":"NCI"},{"termName":"NED-137","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"82230-03-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A678KM0M0N"},{"name":"Legacy Concept Name","value":"Carbetimer"},{"name":"Maps_To","value":"Carbetimer"},{"name":"NCI_Drug_Dictionary_ID","value":"40089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40089"},{"name":"PDQ_Open_Trial_Search_ID","value":"40089"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0108454"}]}}{"C1038":{"preferredName":"Carbogen","code":"C1038","definitions":[{"definition":"An inhalant consisting of hyperoxic gas (95%-98% oxygen and 2%-5% carbon dioxide) with radiosensitizing properties.  Inhaled carbogen reduces diffusion-limited tumor hypoxia, increasing tumor radiosensitivity due to the increased availability of molecular oxygen for cytotoxic radiation-induced oxygen free radical production. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An inhalant of oxygen and carbon dioxide that increases the sensitivity of tumor cells to the effects of radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carbogen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"inhalation therapy to produce vasodilation."},{"name":"CAS_Registry","value":"8063-77-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FJQ44KPA4J"},{"name":"Legacy Concept Name","value":"Carbogen"},{"name":"Maps_To","value":"Carbogen"},{"name":"NCI_Drug_Dictionary_ID","value":"42043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42043"},{"name":"PDQ_Open_Trial_Search_ID","value":"42043"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054692"}]}}{"C1282":{"preferredName":"Carboplatin","code":"C1282","definitions":[{"definition":"A drug that is used to treat advanced ovarian cancer that has never been treated or symptoms of ovarian cancer that has come back after treatment with other anticancer drugs. It is also used with other drugs to treat advanced, metastatic, or recurrent non-small cell lung cancer and is being studied in the treatment of other types of cancer. Paraplatin is a form of the anticancer drug cisplatin and causes fewer side effects in patients. It attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum","termGroup":"SN","termSource":"NCI"},{"termName":"1,1-cyclobutanedicarboxylic acid platinum complex","termGroup":"SN","termSource":"NCI"},{"termName":"Blastocarb","termGroup":"FB","termSource":"NCI"},{"termName":"Carboplat","termGroup":"FB","termSource":"NCI"},{"termName":"Carboplatin Hexal","termGroup":"SY","termSource":"NCI"},{"termName":"Carboplatino","termGroup":"SY","termSource":"NCI"},{"termName":"Carboplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Carbosin","termGroup":"FB","termSource":"NCI"},{"termName":"Carbosol","termGroup":"FB","termSource":"NCI"},{"termName":"Carbotec","termGroup":"FB","termSource":"NCI"},{"termName":"CBDCA","termGroup":"AB","termSource":"NCI"},{"termName":"cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"cis-diammine(cyclobutanedicarboxylato)platinum II","termGroup":"SN","termSource":"NCI"},{"termName":"Displata","termGroup":"FB","termSource":"NCI"},{"termName":"Ercar","termGroup":"FB","termSource":"NCI"},{"termName":"JM-8","termGroup":"CN","termSource":"NCI"},{"termName":"JM8","termGroup":"CN","termSource":"NCI"},{"termName":"Nealorin","termGroup":"FB","termSource":"NCI"},{"termName":"Novoplatinum","termGroup":"FB","termSource":"NCI"},{"termName":"Paraplat","termGroup":"AQS","termSource":"NCI"},{"termName":"Paraplatin","termGroup":"AQS","termSource":"NCI"},{"termName":"Paraplatin AQ","termGroup":"FB","termSource":"NCI"},{"termName":"Paraplatine","termGroup":"FB","termSource":"NCI"},{"termName":"platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)","termGroup":"SN","termSource":"NCI"},{"termName":"Platinwas","termGroup":"FB","termSource":"NCI"},{"termName":"Ribocarbo","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Osteogenic sarcoma; CNS and germ cell tumors; ovarian; lung; head and neck; endometrial; esophageal; bladder; breast; cervical cancer."},{"name":"CAS_Registry","value":"41575-94-4"},{"name":"CHEBI_ID","value":"CHEBI:31355"},{"name":"Chemical_Formula","value":"C6H6O4.Pt.2H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"BG3F62OND5"},{"name":"Legacy Concept Name","value":"Carboplatin"},{"name":"Maps_To","value":"Carboplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39176"},{"name":"NSC Number","value":"201345"},{"name":"NSC Number","value":"241240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39176"},{"name":"PDQ_Open_Trial_Search_ID","value":"39176"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079083"}]}}{"C342":{"preferredName":"Carboquone","code":"C342","definitions":[{"definition":"An aziridinylbenzoquinone-based alkylating agent with potential antineoplastic activity. The alkylating group in carboquone becomes activated upon reduction of quinone to the hydroquinone form. This eventually results in the alkylation and crosslinking of DNA, thereby inhibiting DNA replication followed by an induction of apoptosis. In addition, reactive oxygen species may form during redox cycling which may contribute to this agent's cytotoxic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboquone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"24279-91-2"},{"name":"Chemical_Formula","value":"C15H19N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1CB0HBT12C"},{"name":"Legacy Concept Name","value":"Carboquone"},{"name":"Maps_To","value":"Carboquone"},{"name":"NSC Number","value":"662"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006971"}]}}{"C1141":{"preferredName":"Carboxyamidotriazole","code":"C1141","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active agent with potential antineoplastic activity.  Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis.  This agent may also inhibit tumor cell growth, invasion and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyamidotriazole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4(4-chlorobenzoyl)phenyl)methyl)","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1H-1,2,3-triazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CAI","termGroup":"AB","termSource":"NCI"},{"termName":"Carboxyamido-triazole","termGroup":"SY","termSource":"NCI"},{"termName":"Carboxyaminoimidazole","termGroup":"SY","termSource":"NCI"},{"termName":"L651582","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99519-84-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6ST3ZF52WB"},{"name":"Legacy Concept Name","value":"Carboxyamidotriazole"},{"name":"Maps_To","value":"Carboxyamidotriazole"},{"name":"NCI_Drug_Dictionary_ID","value":"41613"},{"name":"NSC Number","value":"609974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41613"},{"name":"PDQ_Open_Trial_Search_ID","value":"41613"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064494"}]}}{"C91090":{"preferredName":"Carboxyamidotriazole Orotate","code":"C91090","definitions":[{"definition":"The orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable small molecule with potential antiangiogenic and antiproliferative activities. Carboxyamidotriazole binds to and inhibits non-voltage-operated calcium channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores, resulting in the disruption of calcium channel-mediated signal transduction. CAI inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling. This may inhibit endothelial proliferation, tumor cell growth, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyamidotriazole Orotate","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3-Carboxyamido-triazole Orotate","termGroup":"SN","termSource":"NCI"},{"termName":"CTO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"187739-60-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"776C212QQH"},{"name":"Maps_To","value":"Carboxyamidotriazole Orotate"},{"name":"NCI_Drug_Dictionary_ID","value":"671851"},{"name":"NCI_META_CUI","value":"CL421478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671851"},{"name":"PDQ_Open_Trial_Search_ID","value":"671851"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1169":{"preferredName":"Carboxyphenyl Retinamide","code":"C1169","definitions":[{"definition":"A synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Carboxyphenyl retinamide induces cell differentiation and inhibits tumor cell growth and carcinogenesis.  This agent may also induce cell cycle arrest in the G1 phase in some cancer cell types. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyphenyl Retinamide","termGroup":"PT","termSource":"NCI"},{"termName":"4-carboxyphenyl retinamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-(4-carboxyphenyl)retinamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74193-17-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carboxyphenyl_Retinamide"},{"name":"Maps_To","value":"Carboxyphenyl Retinamide"},{"name":"NCI_Drug_Dictionary_ID","value":"42559"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42559"},{"name":"PDQ_Open_Trial_Search_ID","value":"42559"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0067533"}]}}{"C52196":{"preferredName":"Carfilzomib","code":"C52196","definitions":[{"definition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carfilzomib","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide","termGroup":"SN","termSource":"NCI"},{"termName":"Carfilnat","termGroup":"FB","termSource":"NCI"},{"termName":"CFZ","termGroup":"AB","termSource":"NCI"},{"termName":"Kyprolis","termGroup":"BR","termSource":"NCI"},{"termName":"PR-171","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed multiple myeloma (MM)"},{"name":"CAS_Registry","value":"868540-17-4"},{"name":"Chemical_Formula","value":"C40H57N5O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"72X6E3J5AR"},{"name":"Legacy Concept Name","value":"PR-171"},{"name":"Maps_To","value":"Carfilzomib"},{"name":"NCI_Drug_Dictionary_ID","value":"459751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459751"},{"name":"PDQ_Open_Trial_Search_ID","value":"459751"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709429"}]}}{"C80048":{"preferredName":"Caricotamide/Tretazicar","code":"C80048","definitions":[{"definition":"A combination therapy consisting of the prodrug tretazicar and the enzyme co-substrate caricotamide with potential antineoplastic activity. In the presence of separately and simultaneously administered caricotamide, tretazicar is converted to the short-lived cytotoxic DNA cross-linking agent dinitrobenzamide by NAD(P)H quinine oxidoreductase 2 (NQO2), resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be elevated in certain cancers such as hepatocellular carcinoma (HCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Caricotamide/Tretazicar","termGroup":"PT","termSource":"NCI"},{"termName":"EP-0152R/CB1954","termGroup":"CN","termSource":"NCI"},{"termName":"Prolarix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Caricotamide_Tretazicar"},{"name":"Maps_To","value":"Caricotamide/Tretazicar"},{"name":"NCI_Drug_Dictionary_ID","value":"615142"},{"name":"NCI_META_CUI","value":"CL388385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615142"},{"name":"PDQ_Open_Trial_Search_ID","value":"615142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71010":{"preferredName":"Carlumab","code":"C71010","definitions":[{"definition":"A human IgG1 kappa monoclonal antibody directed against human CC chemokine ligand 2 (CCL2) with potential antineoplastic activity. Carlumab binds to and inhibits CLL2, which may result in inhibition of angiogenesis and, so, tumor cell proliferation. Endothelium-derived CLL2 (monocyte chemoattractant protein; MCP1) is a member of the beta-chemokine family, can stimulate monocyte/macrophage migration and smooth muscle cell (SMC) proliferation, and plays a role in angiogenesis and tumor cell migration; CCL2 induction of angiogenesis may involve the upregulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression which, in turn, induces vascular endothelial growth factor-A (VEGF-A) gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carlumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-human Small-inducible Cytokine A2 Monoclonal Antibody CNTO 888","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO 888","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human monocyte chemoattractant protein-1) (human monoclonal CNTO888 gamma 1-chain), disulfide with human monoclonal CNTO888 kappa-chain, dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915404-94-3"},{"name":"Chemical_Formula","value":"C6442H9966N1706O2018S40"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6TC1BB2EV9"},{"name":"Legacy Concept Name","value":"Anti-CCL2_Human_Monoclonal_Antibody_CNTO_888"},{"name":"Maps_To","value":"Carlumab"},{"name":"NCI_Drug_Dictionary_ID","value":"573742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573742"},{"name":"PDQ_Open_Trial_Search_ID","value":"573742"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537194"}]}}{"C955":{"preferredName":"Carmofur","code":"C955","definitions":[{"definition":"An antimetabolite (pyrimidine analogue) antineoplastic derivative of 5-fluorouracil. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmofur","termGroup":"PT","termSource":"NCI"},{"termName":"1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo-","termGroup":"SN","termSource":"NCI"},{"termName":"1-Hexylcarbamoyl-5-Fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"HCFU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"61422-45-5"},{"name":"Chemical_Formula","value":"C11H16FN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HA82M3RAB2"},{"name":"Legacy Concept Name","value":"Carmofur"},{"name":"Maps_To","value":"Carmofur"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044401"}]}}{"C349":{"preferredName":"Carmustine","code":"C349","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Bis(2-chloroethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"1,3-Bis(beta-chloroethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"BCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Becenum","termGroup":"BR","termSource":"NCI"},{"termName":"Becenun","termGroup":"FB","termSource":"NCI"},{"termName":"BiCNU","termGroup":"BR","termSource":"NCI"},{"termName":"Bis(chloroethyl) Nitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"Bis-Chloronitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"Carmubris","termGroup":"BR","termSource":"NCI"},{"termName":"Carmustin","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustinum","termGroup":"FB","termSource":"NCI"},{"termName":"FDA 0345","termGroup":"CN","termSource":"NCI"},{"termName":"N,N'-bis(2-chloroethyl)-N-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Nitrourean","termGroup":"FB","termSource":"NCI"},{"termName":"Nitrumon","termGroup":"FB","termSource":"NCI"},{"termName":"SK 27702","termGroup":"CN","termSource":"NCI"},{"termName":"SRI 1720","termGroup":"CN","termSource":"NCI"},{"termName":"WR-139021","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Brain tumors; colon cancer; lung cancer; lymphomas; Hodgkins and Non-Hodgkins; melanoma; multiple myeloma; mycosis fungoides"},{"name":"CAS_Registry","value":"154-93-8"},{"name":"CHEBI_ID","value":"CHEBI:3423"},{"name":"Chemical_Formula","value":"C5H9Cl2N3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"U68WG3173Y"},{"name":"Legacy Concept Name","value":"Carmustine"},{"name":"Maps_To","value":"Carmustine"},{"name":"NCI_Drug_Dictionary_ID","value":"43027"},{"name":"NSC Number","value":"409962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43027"},{"name":"PDQ_Open_Trial_Search_ID","value":"43027"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0007257"}]}}{"C2487":{"preferredName":"Carmustine Implant","code":"C2487","definitions":[{"definition":"A biodegradable wafer that is used to deliver the anticancer drug carmustine directly into a brain tumor site after the tumor has been removed by surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine Implant","termGroup":"PT","termSource":"NCI"},{"termName":"BCNU Wafer","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustine Copolymer","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustine Wafer","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustine Wafers","termGroup":"SY","termSource":"NCI"},{"termName":"Gliadel","termGroup":"BR","termSource":"NCI"},{"termName":"Gliadel Wafer","termGroup":"BR","termSource":"NCI"},{"termName":"Gliadel Wafer","termGroup":"SY","termSource":"NCI"},{"termName":"Gliadel Wafers","termGroup":"BR","termSource":"NCI"},{"termName":"Polifeprosan 20 with Carmustine Implant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant glioma, adjuvant to surgery and radiation; Recurrent glioblastoma multiforme, adjuvant to surgery"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polifeprosan_20_with_Carmustine_Implant"},{"name":"Maps_To","value":"Carmustine Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"43142"},{"name":"NCI_META_CUI","value":"CL381677"},{"name":"NSC Number","value":"714372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43142"},{"name":"PDQ_Open_Trial_Search_ID","value":"43142"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2602":{"preferredName":"Carmustine in Ethanol","code":"C2602","definitions":[{"definition":"A formulation containing carmustine dissolved in ethanol for intra-tumoral administration that allows carmustine to enter both aqueous and lipid compartments of the target tissue. As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect. Carmustine is highly lipophilic and crosses the blood-brain barrier readily.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine in Ethanol","termGroup":"PT","termSource":"NCI"},{"termName":"DTI-015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carmustine_in_Ethanol"},{"name":"Maps_To","value":"Carmustine in Ethanol"},{"name":"NCI_Drug_Dictionary_ID","value":"38104"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38104"},{"name":"PDQ_Open_Trial_Search_ID","value":"38104"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935694"}]}}{"C102847":{"preferredName":"Carmustine Sustained-Release Implant Wafer","code":"C102847","definitions":[{"definition":"A sustained release (SR) implant wafer containing the lipophilic nitrosourea carmustine (BCNU) with antineoplastic activity. Upon intracranial administration of the implant wafer and subsequent release of BCNU from the wafer, this agent alkylates and cross-links DNA during all phases of the cell cycle, resulting in the disruption of DNA function, cell cycle arrest, and apoptosis. This wafer contains the biodegradable copolymer PLGA (poly(lactide-co-glycolide) as the major drug delivery vehicle which is slowly degraded into water and carbon dioxide thereby continously releasing BCNU over approximately 3-4 weeks. Compared to systemic administration of BCNU alone, this local SR formulation is able to maintain higher drug concentrations locally over a longer period of time while minimizing exposure to other tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine Sustained-Release Implant Wafer","termGroup":"PT","termSource":"NCI"},{"termName":"CASANT Wafer","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Carmustine Sustained-Release Implant Wafer"},{"name":"NCI_Drug_Dictionary_ID","value":"737196"},{"name":"NCI_META_CUI","value":"CL437131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737196"},{"name":"PDQ_Open_Trial_Search_ID","value":"737196"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74010":{"preferredName":"Carotuximab","code":"C74010","definitions":[{"definition":"A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Carotuximab binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carotuximab","termGroup":"PT","termSource":"NCI"},{"termName":"TRC 105","termGroup":"CN","termSource":"NCI"},{"termName":"TRC-105","termGroup":"CN","termSource":"NCI"},{"termName":"TRC105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268714-50-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YB2EWE6139"},{"name":"Legacy Concept Name","value":"Anti-Endoglin_Chimeric_Monoclonal_Antibody_TRC105"},{"name":"Maps_To","value":"Carotuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"584952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"584952"},{"name":"PDQ_Open_Trial_Search_ID","value":"584952"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346810"}]}}{"C352":{"preferredName":"Carubicin","code":"C352","definitions":[{"definition":"An anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata. Carubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S,3S)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,10,12-tetrahydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"(8S-cis)-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"4-O-demethyldaunorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetra-hydroxy-(8S-cis)-(8CI 9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetra-hydroxy-,(8S-cis)-(8CI)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Carminomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Carminomycin I","termGroup":"SY","termSource":"NCI"},{"termName":"CMM","termGroup":"AB","termSource":"NCI"},{"termName":"Demethyldaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Karminomitsin","termGroup":"SY","termSource":"NCI"},{"termName":"Karminomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50935-04-1"},{"name":"Chemical_Formula","value":"C26H27NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E7437K3983"},{"name":"Legacy Concept Name","value":"Carubicin"},{"name":"Maps_To","value":"Carubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39175"},{"name":"NSC Number","value":"180024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39175"},{"name":"PDQ_Open_Trial_Search_ID","value":"39175"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0007308"}]}}{"C1582":{"preferredName":"Carubicin Hydrochloride","code":"C1582","definitions":[{"definition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic carubicin.  Carubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carubicin Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52794-97-5"},{"name":"Chemical_Formula","value":"C26H27NO10.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4V3R166MB3"},{"name":"Legacy Concept Name","value":"Carubicin_Hydrochloride"},{"name":"Maps_To","value":"Carubicin Hydrochloride"},{"name":"NSC Number","value":"275649"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282089"}]}}{"C1441":{"preferredName":"Carzelesin","code":"C1441","definitions":[{"definition":"A cyclopropylpyrroloindole prodrug analogue and DNA minor groove binding agent, with antineoplastic activity.  After hydrolysis, the cyclopropyl group of carzelesin alkylates N3-adenine in a sequence-selective fashion. This results in tumor growth inhibition.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carzelesin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Benzofurancarboxamide, N-(2-((1-(chloromethyl)-1,6-dihydro-8-methyl-5-(((phenylamino)carbonyl)oxy)benzo(1,2-b:4,3-b')dipyrrol-3(2H)-yl)carbonyl)-1H-indol-5-yl)-6-(diethylamino)-, (S)-","termGroup":"SN","termSource":"NCI"},{"termName":"U-80244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"119813-10-4"},{"name":"Chemical_Formula","value":"C41H37ClN6O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"668UF07O1P"},{"name":"Legacy Concept Name","value":"Carzelesin"},{"name":"Maps_To","value":"Carzelesin"},{"name":"NCI_Drug_Dictionary_ID","value":"42571"},{"name":"NSC Number","value":"619029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42571"},{"name":"PDQ_Open_Trial_Search_ID","value":"42571"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0172048"}]}}{"C1040":{"preferredName":"Carzinophilin","code":"C1040","definitions":[{"definition":"An ethylenimine antineoplastic antibiotic isolated from the bacterium Streptomyces sahachiroi.  Carzinophilin forms interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carzinophilin","termGroup":"PT","termSource":"NCI"},{"termName":"Cardinophillin","termGroup":"SY","termSource":"NCI"},{"termName":"Cardinophyllin","termGroup":"SY","termSource":"NCI"},{"termName":"Carzinophyllin","termGroup":"SY","termSource":"NCI"},{"termName":"CZP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1403-28-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"051R55X44C"},{"name":"Legacy Concept Name","value":"Carzinophilin"},{"name":"Maps_To","value":"Carzinophilin"},{"name":"NSC Number","value":"20088"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054841"}]}}{"C118292":{"preferredName":"Ropocamptide","code":"C118292","definitions":[{"definition":"A synthetic form of a human antimicrobial peptide (37 amino acids), belonging to the cathelicidin family, with antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities. Upon intratumoral injection of the ropocamptide, this peptide increases p53 expression, and induces phosphatidylserine externalization, DNA fragmentation, cell cycle arrest and caspase-independent apoptosis-inducing factor (AIF)/ endonuclease G (EndoG)-mediated apoptotic cell death in susceptible cancer cells. This suppresses tumor cell proliferation.  LL-37, a protein secreted by bone marrow cells, circulating leukocytes, and various epithelial tissues, plays a crucial role in the innate host immune defense via the regulation of leukocyte chemotaxis and cytokine production; it also promotes wound healing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ropocamptide","termGroup":"PT","termSource":"NCI"},{"termName":"Antimicrobial Peptide, Human LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES","termGroup":"SY","termSource":"NCI"},{"termName":"Cathelicidin LL-37","termGroup":"SY","termSource":"NCI"},{"termName":"LL-37","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154947-66-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3DD771JO2H"},{"name":"Maps_To","value":"Cathelicidin LL-37"},{"name":"Maps_To","value":"Ropocamptide"},{"name":"NCI_Drug_Dictionary_ID","value":"764409"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764409"},{"name":"PDQ_Open_Trial_Search_ID","value":"764409"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391752"}]}}{"C69130":{"preferredName":"Cationic Liposome-Encapsulated Paclitaxel","code":"C69130","definitions":[{"definition":"A cationic liposome preparation of paclitaxel with antineoplastic activity. Paclitaxel, the active ingredient in cationic liposome-encapsulated paclitaxel, binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis and cellular proliferation, and apoptosis. Cationic liposome encapsulation of paclitaxel allows the delivery of high doses of paclitaxel to target tissues while minimizing systemic toxicity. Tumor endothelial cells may preferentially bind and internalize cationic liposomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cationic Liposome-Encapsulated Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"EndoTAG-1","termGroup":"FB","termSource":"NCI"},{"termName":"LipoPac","termGroup":"FB","termSource":"NCI"},{"termName":"MBT-0206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cationic_Liposome-Encapsulated_Paclitaxel"},{"name":"Maps_To","value":"Cationic Liposome-Encapsulated Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"543136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543136"},{"name":"PDQ_Open_Trial_Search_ID","value":"543136"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1722887"}]}}{"C62445":{"preferredName":"Catumaxomab","code":"C62445","definitions":[{"definition":"A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Catumaxomab","termGroup":"PT","termSource":"NCI"},{"termName":"Removab","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"509077-98-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M2HPV837HO"},{"name":"Legacy Concept Name","value":"Catumaxomab"},{"name":"Maps_To","value":"Catumaxomab"},{"name":"NCI_Drug_Dictionary_ID","value":"487002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487002"},{"name":"PDQ_Open_Trial_Search_ID","value":"487002"},{"name":"PubMedID_Primary_Reference","value":"17622246"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831854"}]}}{"C95894":{"preferredName":"Foscenvivint","code":"C95894","definitions":[{"definition":"A potent, specific inhibitor of the canonical Wnt signaling pathway in cancer stem cells with potential antineoplastic activity. Foscenvivint specifically inhibits the recruiting of beta-catenin with its coactivator CBP (the binding protein of the cAMP response element-binding protein CREB); together with other transcription factors beta-catenin/CBP binds to WRE (Wnt-responsive element) and activates transcription of a wide range of target genes of Wnt/beta-catenin signaling. Blocking the interaction of CBP and beta-catenin by this agent prevents gene expression of many proteins necessary for growth, thereby potentially suppressing cancer cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foscenvivint","termGroup":"PT","termSource":"NCI"},{"termName":"CBP/beta-catenin Antagonist PRI-724","termGroup":"SY","termSource":"NCI"},{"termName":"PRI-724","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422253-38-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43Y934BBZ6"},{"name":"Maps_To","value":"CBP/beta-catenin Antagonist PRI-724"},{"name":"NCI_Drug_Dictionary_ID","value":"696436"},{"name":"NCI_META_CUI","value":"CL428291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696436"},{"name":"PDQ_Open_Trial_Search_ID","value":"696436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153376":{"preferredName":"CBP/beta-catenin Modulator E7386","code":"C153376","definitions":[{"definition":"An orally bioavailable, specific inhibitor of the canonical Wnt/beta-catenin signaling pathway, with potential antineoplastic activity. Upon oral administration, CBP/beta-catenin modulator E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBP/beta-catenin Modulator E7386","termGroup":"PT","termSource":"NCI"},{"termName":"E 7386","termGroup":"CN","termSource":"NCI"},{"termName":"E-7386","termGroup":"CN","termSource":"NCI"},{"termName":"E7386","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1799824-08-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I0DX1FG55Y"},{"name":"Maps_To","value":"CBP/beta-catenin Modulator E7386"},{"name":"NCI_Drug_Dictionary_ID","value":"793902"},{"name":"NCI_META_CUI","value":"CL554532"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793902"},{"name":"PDQ_Open_Trial_Search_ID","value":"793902"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120302":{"preferredName":"CCR2 Antagonist CCX872-B","code":"C120302","definitions":[{"definition":"An orally available human C-C chemokine receptor type 2 (CCR2) antagonist, with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist CCX872-B specifically binds to CCR2 and prevents the binding its cognate endothelium-derived chemokine ligand CCL2 (monocyte chemoattractant protein-1 or MCP1). This may result in the inhibition of both CCR2 activation and CCR2-mediated signal transduction, which may inhibit inflammatory processes, angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, and stimulates their migration and infiltration; it plays a key role in inflammation. CCR2 is overexpressed in certain cancer cell types, where it is involved in angiogenesis, tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR2 Antagonist CCX872-B","termGroup":"PT","termSource":"NCI"},{"termName":"CCX872-B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CCR2 Antagonist CCX872-B"},{"name":"NCI_Drug_Dictionary_ID","value":"768571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768571"},{"name":"PDQ_Open_Trial_Search_ID","value":"768571"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896888"}]}}{"C97507":{"preferredName":"CCR2 Antagonist PF-04136309","code":"C97507","definitions":[{"definition":"An orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR2 Antagonist PF-04136309","termGroup":"PT","termSource":"NCI"},{"termName":"PF-04136309","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1341224-83-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3M2595V4KT"},{"name":"Maps_To","value":"CCR2 Antagonist PF-04136309"},{"name":"NCI_Drug_Dictionary_ID","value":"703421"},{"name":"NCI_META_CUI","value":"CL430252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703421"},{"name":"PDQ_Open_Trial_Search_ID","value":"703421"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139550":{"preferredName":"CCR2/CCR5 Antagonist BMS-813160","code":"C139550","definitions":[{"definition":"An antagonist of both human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating and antineoplastic activities. Upon administration, CCR2/CCR5 antagonist BMS-813160 specifically binds and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages, and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune disease. CCR2 and CCR5 are overexpressed in certain cancer cell types, and are also involved in angiogenesis, and in tumor cell migration, proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR2/CCR5 Antagonist BMS-813160","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-[(1S,2R,4R)-4-isopropyl(methyl)amino)-2-propylcyclohexyl]-3-(6(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-813160","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1286279-29-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"83U7957287"},{"name":"Maps_To","value":"CCR2/CCR5 Antagonist BMS-813160"},{"name":"NCI_Drug_Dictionary_ID","value":"791102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791102"},{"name":"PDQ_Open_Trial_Search_ID","value":"791102"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490973"}]}}{"C157240":{"preferredName":"Tivumecirnon","code":"C157240","definitions":[{"definition":"An orally available, small molecule antagonist of C-C chemokine receptor type 4 (CCR4) with potential immunomodulatory and antineoplastic activities. Upon oral administration, tivumecirnon inhibits the binding of CCR4 to its signaling molecules, thereby blocking the recruitment of regulatory T-cells (Tregs) to the tumor microenvironment (TME). This may abrogate the immunosuppressive effects of Tregs and promote an effective anti-tumor immune response. CCR4, a chemokine receptor normally expressed on circulating and tissue-resident T-cells, is highly expressed on circulating Tregs and is associated with poor prognosis in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tivumecirnon","termGroup":"PT","termSource":"NCI"},{"termName":"CCR4 Inhibitor FLX475","termGroup":"SY","termSource":"NCI"},{"termName":"FLX 475","termGroup":"CN","termSource":"NCI"},{"termName":"FLX-475","termGroup":"CN","termSource":"NCI"},{"termName":"FLX475","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2174938-78-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1T69T65FJ"},{"name":"Maps_To","value":"CCR4 Inhibitor FLX475"},{"name":"NCI_Drug_Dictionary_ID","value":"796771"},{"name":"NCI_META_CUI","value":"CL936884"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796771"},{"name":"PDQ_Open_Trial_Search_ID","value":"796771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129596":{"preferredName":"CD4-specific Telomerase Peptide Vaccine UCPVax","code":"C129596","definitions":[{"definition":"A therapeutic peptide vaccine containing the human telomerase reverse transcriptase catalytic subunit (hTERT)-derived universal cancer peptides 2 (UCP2) and 4 (UCP4), and combined with the immunoadjuvant Montanide ISA 51 VG, with potential immunostimulating and antineoplastic activities. Vaccination with the CD4-specific telomerase peptide vaccine UCPVax activates the immune system to mount a T-helper 1 (TH1) CD4-positive T-lymphocyte immune response against and ultimately killing telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD4-specific Telomerase Peptide Vaccine UCPVax","termGroup":"PT","termSource":"NCI"},{"termName":"UCP2/UCP4 CD4-specific Telomerase Peptide Vaccine UCPVax","termGroup":"SY","termSource":"NCI"},{"termName":"UCPVax","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD4-specific Telomerase Peptide Vaccine UCPVax"},{"name":"NCI_Drug_Dictionary_ID","value":"783988"},{"name":"NCI_META_CUI","value":"CL512660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783988"},{"name":"PDQ_Open_Trial_Search_ID","value":"783988"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119740":{"preferredName":"Selicrelumab","code":"C119740","definitions":[{"definition":"A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selicrelumab","termGroup":"PT","termSource":"NCI"},{"termName":"CD40 Agonist Monoclonal Antibody CP-870,893","termGroup":"SY","termSource":"NCI"},{"termName":"CP-870,893","termGroup":"CN","termSource":"NCI"},{"termName":"RO7009789","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622140-49-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0O39RGI33V"},{"name":"Legacy Concept Name","value":"Anti-CD40_Monoclonal_Antibody_CP-870_893"},{"name":"Maps_To","value":"CD40 Agonist Monoclonal Antibody CP-870,893"},{"name":"Maps_To","value":"Selicrelumab"},{"name":"NCI_Drug_Dictionary_ID","value":"588974"},{"name":"NCI_Drug_Dictionary_ID","value":"767014"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767014"},{"name":"PDQ_Open_Trial_Search_ID","value":"767014"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896775"}]}}{"C123734":{"preferredName":"Sotigalimab","code":"C123734","definitions":[{"definition":"A humanized monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Similar to the endogenous CD40 ligand (CD40L or CD154), sotigalimab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Sotigalimab also binds to and activates CD40 present on the surfaces of some solid tumor cells, leading to apoptosis and decreased tumor growth. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it mediates both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotigalimab","termGroup":"PT","termSource":"NCI"},{"termName":"APX 005","termGroup":"CN","termSource":"NCI"},{"termName":"APX 005M","termGroup":"CN","termSource":"NCI"},{"termName":"APX-005M","termGroup":"CN","termSource":"NCI"},{"termName":"APX005M","termGroup":"CN","termSource":"NCI"},{"termName":"CD40 Agonistic Monoclonal Antibody APX005M","termGroup":"SY","termSource":"NCI"},{"termName":"EPI-0050","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305607-45-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JEA93WJ5DG"},{"name":"Maps_To","value":"CD40 Agonistic Monoclonal Antibody APX005M"},{"name":"Maps_To","value":"Sotigalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"775520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775520"},{"name":"PDQ_Open_Trial_Search_ID","value":"775520"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053581"}]}}{"C142813":{"preferredName":"CD44 Targeted Agent SPL-108","code":"C142813","definitions":[{"definition":"A proprietary agent that targets the cancer stem cell (CSC) antigen CD44, with potential antineoplastic activity. Although the mechanism of action has not been elucidated, following subcutaneous administration, CD44 targeted agent SPL-108 binds to CD44 and prevents the activation of various CD44-mediated signal transduction pathways, which may lead to reduced proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in the proliferation, migration and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD44 Targeted Agent SPL-108","termGroup":"PT","termSource":"NCI"},{"termName":"SPL 108","termGroup":"CN","termSource":"NCI"},{"termName":"SPL-108","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD44 Targeted Agent SPL-108"},{"name":"NCI_Drug_Dictionary_ID","value":"789749"},{"name":"NCI_META_CUI","value":"CL540705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789749"},{"name":"PDQ_Open_Trial_Search_ID","value":"789749"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132851":{"preferredName":"Evorpacept","code":"C132851","definitions":[{"definition":"A variant of signal regulatory protein alpha (SIRPa) that antagonizes the human cell surface antigen CD47, with potential phagocytosis-inducing, immunostimulating and antineoplastic activities. Upon administration, evorpacept binds to CD47 expressed on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of the pro-phagocytic signal calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evorpacept","termGroup":"PT","termSource":"NCI"},{"termName":"ALX 148","termGroup":"CN","termSource":"NCI"},{"termName":"ALX-148","termGroup":"CN","termSource":"NCI"},{"termName":"ALX148","termGroup":"CN","termSource":"NCI"},{"termName":"CD47 Antagonist ALX148","termGroup":"SY","termSource":"NCI"},{"termName":"CD47/SIRPa-blocking Agent ALX148","termGroup":"SY","termSource":"NCI"},{"termName":"LGGL-ALX-148","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa Variant ALX148","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2484949-51-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X7K762X1IJ"},{"name":"Maps_To","value":"CD47 Antagonist ALX148"},{"name":"NCI_Drug_Dictionary_ID","value":"787529"},{"name":"NCI_META_CUI","value":"CL519706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787529"},{"name":"PDQ_Open_Trial_Search_ID","value":"787529"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126641":{"preferredName":"Simurosertib","code":"C126641","definitions":[{"definition":"An orally bioavailable inhibitor of cell division cycle 7 (cell division cycle 7-related protein kinase; CDC7), with potential antineoplastic activity. Upon administration, simurosertib binds to and inhibits CDC7; this prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis. This inhibits cell growth in CDC7-overexpressing tumor cells. CDC7, a serine/threonine kinase and cell division cycle protein, is overexpressed in a variety of cancers and plays a key role in the activation of DNA replication and the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simurosertib","termGroup":"PT","termSource":"NCI"},{"termName":"Cell Division Cycle 7 Inhibitor TAK-931","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 931","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-931","termGroup":"CN","termSource":"NCI"},{"termName":"Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-Azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1330782-76-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LST350G3XU"},{"name":"Maps_To","value":"CDC7 Inhibitor TAK-931"},{"name":"Maps_To","value":"Simurosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"779700"},{"name":"NCI_META_CUI","value":"CL505074"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779700"},{"name":"PDQ_Open_Trial_Search_ID","value":"779700"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82418":{"preferredName":"CDC7 Kinase Inhibitor BMS-863233","code":"C82418","definitions":[{"definition":"An orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC7 Kinase Inhibitor BMS-863233","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-863233","termGroup":"CN","termSource":"NCI"},{"termName":"Cell Division Cycle 7 Homolog Kinase Inhibitor BMS-863233","termGroup":"SY","termSource":"NCI"},{"termName":"XL-413","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1169558-38-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8QK62S7492"},{"name":"Legacy Concept Name","value":"CDC7_Kinase_Inhibitor_BMS-863233"},{"name":"Maps_To","value":"CDC7 Kinase Inhibitor BMS-863233"},{"name":"NCI_Drug_Dictionary_ID","value":"637599"},{"name":"NCI_META_CUI","value":"CL408681"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637599"},{"name":"PDQ_Open_Trial_Search_ID","value":"637599"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148509":{"preferredName":"CDC7 Kinase Inhibitor LY3143921 Hydrate","code":"C148509","definitions":[{"definition":"The hydrated form of an orally bioavailable inhibitor of cell division cycle 7 (CDC7) kinase, with potential antineoplastic activity. Upon administration of CDC7 kinase inhibitor LY3143921 hydrate, LY3143921 targets, binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 plays a key role in DNA replication by binding to and  phosphorylating serine (Ser)-40 and 53 of MCM2 (minichromosome maintenance complex component 2), which is required for the initiation of DNA replication. Although expressed at low levels in healthy, normal cells, CDC7 is expressed at much higher levels in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC7 Kinase Inhibitor LY3143921 Hydrate","termGroup":"PT","termSource":"NCI"},{"termName":"LY-3143921 Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"LY3143921 Hydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDC7 Kinase Inhibitor LY3143921 Hydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"792646"},{"name":"NCI_META_CUI","value":"CL551033"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792646"},{"name":"PDQ_Open_Trial_Search_ID","value":"792646"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88316":{"preferredName":"CDC7 Kinase Inhibitor NMS-1116354","code":"C88316","definitions":[{"definition":"An orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor NMS-1116354 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 initiates DNA replication by phosphorylating MCM2 (minichromosome maintenance complex component 2) at Ser40 and Ser53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC7 Kinase Inhibitor NMS-1116354","termGroup":"PT","termSource":"NCI"},{"termName":"NMS-1116354","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDC7 Kinase Inhibitor NMS-1116354"},{"name":"NCI_Drug_Dictionary_ID","value":"660731"},{"name":"NCI_META_CUI","value":"CL413571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660731"},{"name":"PDQ_Open_Trial_Search_ID","value":"660731"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64761":{"preferredName":"CDK Inhibitor AT7519","code":"C64761","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. AT7519M blocks enzymes needed for cells to divide. It is a type of cyclin-dependent kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK Inhibitor AT7519","termGroup":"PT","termSource":"NCI"},{"termName":"AT7519","termGroup":"CN","termSource":"NCI"},{"termName":"AT7519M","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor AT7519M","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"844442-38-2"},{"name":"Chemical_Formula","value":"C16H17Cl2N5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X1BF92PW9T"},{"name":"Legacy Concept Name","value":"AT7519M"},{"name":"Maps_To","value":"CDK Inhibitor AT7519"},{"name":"NCI_Drug_Dictionary_ID","value":"513177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513177"},{"name":"PDQ_Open_Trial_Search_ID","value":"513177"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879520"}]}}{"C64544":{"preferredName":"CDK Inhibitor R547","code":"C64544","definitions":[{"definition":"An orally bioavailable diaminopyrimidine compound and a cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and are frequently overexpressed in cancerous cells. R547 selectively binds to and inhibits CDKs, especially CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1. The inhibition of CDKs results in cell cycle arrest, inhibition of tumor cell proliferation, and induction of apoptosis. By inhibiting CDK activity, R547 also reduces phosphorylation of the retinoblastoma (Rb) protein, thereby preventing activation of transcription factor E2F and leading to further suppression of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK Inhibitor R547","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor R547","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor R547","termGroup":"SY","termSource":"NCI"},{"termName":"R 547","termGroup":"CN","termSource":"NCI"},{"termName":"R547","termGroup":"CN","termSource":"NCI"},{"termName":"RO 4584820","termGroup":"CN","termSource":"NCI"},{"termName":"RO-4584820","termGroup":"CN","termSource":"NCI"},{"termName":"RO4584820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"741713-40-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T61871RKRI"},{"name":"Legacy Concept Name","value":"R547"},{"name":"Maps_To","value":"CDK Inhibitor R547"},{"name":"NCI_Drug_Dictionary_ID","value":"529189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529189"},{"name":"PDQ_Open_Trial_Search_ID","value":"529189"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832011"}]}}{"C62523":{"preferredName":"CDK Inhibitor SNS-032","code":"C62523","definitions":[{"definition":"A small aminothiazole molecule and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. SNS-032 binds to and prevents the phosphorylation of cyclin-dependent kinases, especially CDK2, 7, and 9 that regulate cell cycle progression. Inhibition of CDKs leads to cell cycle arrest and induces apoptosis. As a result, this agent causes cytotoxicity and prevents further tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK Inhibitor SNS-032","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-387032","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-032","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"345627-80-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9979I93686"},{"name":"Legacy Concept Name","value":"SNS-032"},{"name":"Maps_To","value":"CDK Inhibitor SNS-032"},{"name":"NCI_Drug_Dictionary_ID","value":"488948"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488948"},{"name":"PDQ_Open_Trial_Search_ID","value":"488948"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451099"}]}}{"C105851":{"preferredName":"Zotiraciclib Citrate","code":"C105851","definitions":[{"definition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zotiraciclib Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"20-Oxa-5,7,14,27-tetraazatetracyclo(19.3.1.12,6.18,12)heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-Methyl-, 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"SB1317 Citrate","termGroup":"SY","termSource":"NCI"},{"termName":"TG02 Citrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204918-73-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3VF50SU4RZ"},{"name":"Maps_To","value":"CDK/JAK2/FLT3 Inhibitor TG02 Citrate"},{"name":"Maps_To","value":"Zotiraciclib Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"686272"},{"name":"NCI_META_CUI","value":"CL447179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686272"},{"name":"PDQ_Open_Trial_Search_ID","value":"686272"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163985":{"preferredName":"Avotaciclib","code":"C163985","definitions":[{"definition":"An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avotaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"BEY 1107","termGroup":"CN","termSource":"NCI"},{"termName":"BEY-1107","termGroup":"CN","termSource":"NCI"},{"termName":"BEY-A","termGroup":"CN","termSource":"NCI"},{"termName":"BEY1107","termGroup":"CN","termSource":"NCI"},{"termName":"BEY1107G","termGroup":"CN","termSource":"NCI"},{"termName":"BEY1107P","termGroup":"CN","termSource":"NCI"},{"termName":"CDK1 Inhibitor BEY1107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1983983-41-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z6BYC0F36E"},{"name":"Maps_To","value":"CDK1 Inhibitor BEY1107"},{"name":"NCI_Drug_Dictionary_ID","value":"799135"},{"name":"NCI_META_CUI","value":"CL977268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799135"},{"name":"PDQ_Open_Trial_Search_ID","value":"799135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52182":{"preferredName":"CDK1/2/4 Inhibitor AG-024322","code":"C52182","definitions":[{"definition":"A cyclin-dependent kinase (CDK) inhibitor with antineoplastic activity. AG-024322 selectively inhibits cyclin-dependent kinases (particularly CDK1,2 and 4), enzymes that regulate cell cycle progression. Inhibition of CDK may result in cell cycle arrest, induction of apoptosis, and inhibition of DNA replication and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK1/2/4 Inhibitor AG-024322","termGroup":"PT","termSource":"NCI"},{"termName":"AG-024322","termGroup":"CN","termSource":"NCI"},{"termName":"AG-24322","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"837364-57-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"926F8X7TNO"},{"name":"Legacy Concept Name","value":"AG-024322"},{"name":"Maps_To","value":"CDK1/2/4 Inhibitor AG-024322"},{"name":"NCI_Drug_Dictionary_ID","value":"459491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459491"},{"name":"PDQ_Open_Trial_Search_ID","value":"459491"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706655"}]}}{"C155956":{"preferredName":"CDK2/4/6/FLT3 Inhibitor FN-1501","code":"C155956","definitions":[{"definition":"A small molecule multi-kinase inhibitor of cyclin-dependent kinase (CDK) subtypes 2 (CDK2), 4 (CDK4), and 6 (CDK6) and FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon intravenous administration, CDK2/4/6/FLT3 inhibitor FN-1501 binds to and inhibits CDK2, CDK4, and CDK6, as well as FLT3. This may induce apoptosis and inhibit tumor cell proliferation in cancer cells that overexpress these kinases. CDKs are serine/threonine kinases that assist in cell cycle regulation and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in many cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK2/4/6/FLT3 Inhibitor FN-1501","termGroup":"PT","termSource":"NCI"},{"termName":"4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CDK/FLT3 Inhibitor FN-1501","termGroup":"SY","termSource":"NCI"},{"termName":"FN 1501","termGroup":"CN","termSource":"NCI"},{"termName":"FN-1501","termGroup":"CN","termSource":"NCI"},{"termName":"FN1501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429515-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6MC966B505"},{"name":"Maps_To","value":"CDK2/4/6/FLT3 Inhibitor FN-1501"},{"name":"NCI_Drug_Dictionary_ID","value":"795267"},{"name":"NCI_META_CUI","value":"CL562813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795267"},{"name":"PDQ_Open_Trial_Search_ID","value":"795267"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123902":{"preferredName":"Fadraciclib","code":"C123902","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fadraciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CYC065","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1070790-89-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YET2XNU791"},{"name":"Maps_To","value":"CDK2/5/9 Inhibitor CYC065"},{"name":"Maps_To","value":"Fadraciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"775991"},{"name":"NCI_META_CUI","value":"CL498266"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775991"},{"name":"PDQ_Open_Trial_Search_ID","value":"775991"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80049":{"preferredName":"CDK4 Inhibitor P1446A-05","code":"C80049","definitions":[{"definition":"A protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with potential antineoplastic activity. CDK4 inhibitor P1446A-05 specifically inhibits CDK4-mediated G1-S phase transition, arresting cell cycling and inhibiting cancer cell growth. The serine/threonine kinase CDK4 is found in a complex with D-type G1 cyclins and is the first kinase to become activated upon mitogenic stimulation, releasing cells from a quiescent stage into the G1/S growth cycling stage; CDK-cyclin complexes have been shown to phosphorylate the retinoblastoma (Rb) transcription factor in early G1, displacing histone deacetylase (HDAC) and blocking transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4 Inhibitor P1446A-05","termGroup":"PT","termSource":"NCI"},{"termName":"P1446A-05","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CDK4_Serine_Threonine_Kinase_Inhibitor_P1446A-05"},{"name":"Maps_To","value":"CDK4 Inhibitor P1446A-05"},{"name":"NCI_Drug_Dictionary_ID","value":"618682"},{"name":"NCI_META_CUI","value":"CL388407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"618682"},{"name":"PDQ_Open_Trial_Search_ID","value":"618682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116938":{"preferredName":"CDK4/6 Inhibition","code":"C116938","definitions":[{"definition":"Inhibition of cyclin-dependent kinases 4 and 6 pathway activity to prevent proliferation of cancer cells and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibition","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinases 4 and 6 Inhibition","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3899807"}]}}{"C157481":{"preferredName":"CDK4/6 Inhibitor BPI-16350","code":"C157481","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor BPI-16350 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor BPI-16350","termGroup":"PT","termSource":"NCI"},{"termName":"BPI 16350","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-16350","termGroup":"CN","termSource":"NCI"},{"termName":"BPI16350","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor BPI-16350"},{"name":"NCI_Drug_Dictionary_ID","value":"796716"},{"name":"NCI_META_CUI","value":"CL937081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796716"},{"name":"PDQ_Open_Trial_Search_ID","value":"796716"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165199":{"preferredName":"CDK4/6 Inhibitor FCN-437","code":"C165199","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor FCN-437 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1/S transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play key roles in the regulation of both cell cycle progression from the G1-phase into the S-phase and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor FCN-437","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin-dependent Kinase 4/6 Inhibitor FCN-437","termGroup":"SY","termSource":"NCI"},{"termName":"FCN 437","termGroup":"CN","termSource":"NCI"},{"termName":"FCN-437","termGroup":"CN","termSource":"NCI"},{"termName":"FCN-437c","termGroup":"SY","termSource":"NCI"},{"termName":"FCN437","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor FCN-437"},{"name":"NCI_Drug_Dictionary_ID","value":"799711"},{"name":"NCI_META_CUI","value":"CL978411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799711"},{"name":"PDQ_Open_Trial_Search_ID","value":"799711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C138165":{"preferredName":"Lerociclib","code":"C138165","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lerociclib","termGroup":"PT","termSource":"NCI"},{"termName":"7',8'-Dihydro-2'-((5-(4-(1-methylethyl)-1-piperazinyl)-2-pyridinyl)amino)spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one","termGroup":"SY","termSource":"NCI"},{"termName":"CDK4/6 Inhibitor G1T38","termGroup":"SY","termSource":"NCI"},{"termName":"G1T38","termGroup":"CN","termSource":"NCI"},{"termName":"G1T38 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"GB 491","termGroup":"CN","termSource":"NCI"},{"termName":"GB-491","termGroup":"CN","termSource":"NCI"},{"termName":"GB491","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1628256-23-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WBH8AY6ENB"},{"name":"Maps_To","value":"CDK4/6 Inhibitor G1T38"},{"name":"Maps_To","value":"Lerociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"790539"},{"name":"NCI_META_CUI","value":"CL525730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790539"},{"name":"PDQ_Open_Trial_Search_ID","value":"790539"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125899":{"preferredName":"Dalpiciclib","code":"C125899","definitions":[{"definition":"A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dalpiciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK4/6 Inhibitor SHR6390","termGroup":"SY","termSource":"NCI"},{"termName":"SHR-6390","termGroup":"CN","termSource":"NCI"},{"termName":"SHR6390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637781-04-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5ZHA5P4PFX"},{"name":"Maps_To","value":"CDK4/6 Inhibitor SHR6390"},{"name":"NCI_Drug_Dictionary_ID","value":"778742"},{"name":"NCI_META_CUI","value":"CL504548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778742"},{"name":"PDQ_Open_Trial_Search_ID","value":"778742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155652":{"preferredName":"Samuraciclib","code":"C155652","definitions":[{"definition":"An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samuraciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK7 Inhibitor CT7001","termGroup":"SY","termSource":"NCI"},{"termName":"CT 7001","termGroup":"CN","termSource":"NCI"},{"termName":"CT-7001","termGroup":"CN","termSource":"NCI"},{"termName":"CT7001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1805833-75-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46D4HS9ODA"},{"name":"Maps_To","value":"CDK7 Inhibitor CT7001"},{"name":"Maps_To","value":"Samuraciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"794642"},{"name":"NCI_META_CUI","value":"CL556268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794642"},{"name":"PDQ_Open_Trial_Search_ID","value":"794642"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139552":{"preferredName":"Mevociclib","code":"C139552","definitions":[{"definition":"A selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon administration, SY-1365 binds to and inhibits CDK7, thereby inhibiting CDK7-mediated signal transduction pathways. This inhibits cell growth of CDK7-overexpressing tumor cells. CDK7, a serine/threonine kinase, plays a key role in cell proliferation; CDK7 is overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mevociclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK7 Inhibitor SY-1365","termGroup":"SY","termSource":"NCI"},{"termName":"SY-1365","termGroup":"CN","termSource":"NCI"},{"termName":"SY1365","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1816989-16-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"704LW082GI"},{"name":"Maps_To","value":"CDK7 Inhibitor SY-1365"},{"name":"Maps_To","value":"Mevociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"791104"},{"name":"NCI_META_CUI","value":"CL526907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791104"},{"name":"PDQ_Open_Trial_Search_ID","value":"791104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153377":{"preferredName":"CDK9 Inhibitor AZD4573","code":"C153377","definitions":[{"definition":"A selective, short-acting inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon intravenous administration, AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. This induces cell cycle arrest and apoptosis, and leads to a reduction in tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA polymerase II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK9 Inhibitor AZD4573","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 4573","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-4573","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2057509-72-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E5XSP3X68B"},{"name":"Maps_To","value":"CDK9 Inhibitor AZD4573"},{"name":"NCI_Drug_Dictionary_ID","value":"793903"},{"name":"NCI_META_CUI","value":"CL554533"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793903"},{"name":"PDQ_Open_Trial_Search_ID","value":"793903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131129":{"preferredName":"CEA-MUC-1-TRICOM Vaccine CV301","code":"C131129","definitions":[{"definition":"A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEA-MUC-1-TRICOM Vaccine CV301","termGroup":"PT","termSource":"NCI"},{"termName":"CV-301","termGroup":"CN","termSource":"NCI"},{"termName":"CV301","termGroup":"CN","termSource":"NCI"},{"termName":"CV301-V/F","termGroup":"CN","termSource":"NCI"},{"termName":"CVAC-301","termGroup":"CN","termSource":"NCI"},{"termName":"MVA-BN/Fowlpox-CEA-MUC-1-TRICOM Vaccine CV301","termGroup":"SY","termSource":"NCI"},{"termName":"PANVAC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEA-MUC-1-TRICOM Vaccine CV301"},{"name":"NCI_Drug_Dictionary_ID","value":"787798"},{"name":"NCI_META_CUI","value":"CL513447"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787798"},{"name":"PDQ_Open_Trial_Search_ID","value":"787798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159892":{"preferredName":"CEA-targeting Agent RG6123","code":"C159892","definitions":[{"definition":"An agent targeting the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, CEA-targeting agent RG6123 targets and binds to human CEA that is specifically expressed on certain tumor cells. This may, through an as of yet not elucidated mechanism of action, kill CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEA-targeting Agent RG6123","termGroup":"PT","termSource":"NCI"},{"termName":"RG 6123","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6123","termGroup":"CN","termSource":"NCI"},{"termName":"RG6123","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7172508","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7172508","termGroup":"CN","termSource":"NCI"},{"termName":"RO7172508","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEA-targeting Agent RG6123"},{"name":"NCI_Drug_Dictionary_ID","value":"797964"},{"name":"NCI_META_CUI","value":"CL968916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797964"},{"name":"PDQ_Open_Trial_Search_ID","value":"797964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126800":{"preferredName":"CEBPA-targeting saRNA MTL-CEBPA Liposome","code":"C126800","definitions":[{"definition":"A lipid-based nanoparticle formulation composed of liposomes encapsulating a small oligonucleotide encoding a small activating RNA (saRNA) targeting the CCAAT enhancer binding protein alpha (CEBPA; C/EBP-a) gene, with potential antineoplastic activity. Although the exact mechanism of action through which saRNAs exert their effect(s) is still largely being investigated, it appears that, upon administration, the CEBPA-targeting saRNA MTL-CEBPA liposome targets and binds to a specific DNA regulatory target region, most likely the promoter region, for the CEBPA gene. This restores CEBPA gene transcription, and increases both CEBPA mRNA levels and protein expression. This in turn activates the expression of tumor suppressor genes and may halt proliferation of susceptible tumor cells. Specifically, upregulation of CEBPA in liver cells abrogates liver cancer cell proliferation, thereby prevents liver failure and normalizes liver function. CEBPA, a transcription factor that plays a key role in the regulation of the expression of genes with many functions, including those involved in cellular proliferation, metastasis and normal hepatocyte function, is found in many tissues, including liver cells, adipose tissue and myeloid cells. CEBPA is downregulated in certain types of cancer cells, such as liver cancer cells. saRNA is a short, double-stranded RNA that is structurally related to siRNAs; saRNA is most likely to bind to a target site on the promoter of the CEBPA gene and upregulates its gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEBPA-targeting saRNA MTL-CEBPA Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"MTL-501","termGroup":"CN","termSource":"NCI"},{"termName":"MTL-CEBPA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEBPA-targeting saRNA MTL-CEBPA Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"780224"},{"name":"NCI_META_CUI","value":"CL507895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780224"},{"name":"PDQ_Open_Trial_Search_ID","value":"780224"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164146":{"preferredName":"Cedazuridine","code":"C164146","definitions":[{"definition":"An orally available synthetic nucleoside analog derived from tetrahydrouridine (THU) and cytidine deaminase inhibitor (CDAi), that can potentially be used to prevent the breakdown of cytidines. Upon oral administration, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. Given in combination with a cytidine, such as the antineoplastic hypomethylating agent decitabine, it specifically prevents its breakdown and increases its bioavailability and efficacy. In addition, this allows for lower doses of decitabine to be administered, which results in decreased decitabine-associated GI toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cedazuridine","termGroup":"PT","termSource":"NCI"},{"termName":"(4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine","termGroup":"SY","termSource":"NCI"},{"termName":"CDA Inhibitor E7727","termGroup":"SY","termSource":"NCI"},{"termName":"E7727","termGroup":"CN","termSource":"NCI"},{"termName":"Uridine, 2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydro-, (4R)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1141397-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39IS23Q1EW"},{"name":"Maps_To","value":"Cedazuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"799445"},{"name":"NCI_META_CUI","value":"CL977331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799445"},{"name":"PDQ_Open_Trial_Search_ID","value":"799445"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C115102":{"preferredName":"Decitabine and Cedazuridine","code":"C115102","definitions":[{"definition":"An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Decitabine and Cedazuridine","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX727","termGroup":"CN","termSource":"NCI"},{"termName":"C-DEC","termGroup":"SY","termSource":"NCI"},{"termName":"CDA Inhibitor E7727/Decitabine Combination Agent ASTX727","termGroup":"SY","termSource":"NCI"},{"termName":"Cedazuridine/Decitabine Combination Agent ASTX727","termGroup":"SY","termSource":"NCI"},{"termName":"Cedazuridine/Decitabine Tablet","termGroup":"SY","termSource":"NCI"},{"termName":"DEC-C","termGroup":"SY","termSource":"NCI"},{"termName":"Inqovi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with myelodysplastic syndromes (MDS)"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Cedazuridine/Decitabine Combination Agent ASTX727"},{"name":"Maps_To","value":"Decitabine and Cedazuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"759831"},{"name":"NCI_META_CUI","value":"CL472633"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759831"},{"name":"PDQ_Open_Trial_Search_ID","value":"759831"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78081":{"preferredName":"Cedefingol","code":"C78081","definitions":[{"definition":"A derivative of sphingosine, with potential antineoplastic activity. As a sphingosine derivative, cedefingol appears to inhibit protein kinase C (PKC), a kinase that plays an important role in tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cedefingol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"35301-24-7"},{"name":"Chemical_Formula","value":"C20H41NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81HH79X39W"},{"name":"Legacy Concept Name","value":"Cedefingol"},{"name":"Maps_To","value":"Cedefingol"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699130"}]}}{"C80867":{"preferredName":"Cediranib","code":"C80867","definitions":[{"definition":"An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cediranib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline","termGroup":"SN","termSource":"NCI"},{"termName":"AZ-D2171","termGroup":"CN","termSource":"NCI"},{"termName":"AZD2171","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"288383-20-0"},{"name":"Chemical_Formula","value":"C25H27FN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NQU9IPY4K9"},{"name":"Legacy Concept Name","value":"Cediranib"},{"name":"Maps_To","value":"Cediranib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1698364"}]}}{"C48379":{"preferredName":"Cediranib Maleate","code":"C48379","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. Cediranib maleate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cediranib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"AZD2171 Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"Recentin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857036-77-2"},{"name":"Chemical_Formula","value":"C25H27FN4O3.C4H4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68AYS9A614"},{"name":"Legacy Concept Name","value":"AZD2171"},{"name":"Maps_To","value":"Cediranib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"425596"},{"name":"NSC Number","value":"732208"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425596"},{"name":"PDQ_Open_Trial_Search_ID","value":"425596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541530"}]}}{"C1728":{"preferredName":"Celecoxib","code":"C1728","definitions":[{"definition":"A drug that reduces pain. Celecoxib belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is being studied in the prevention of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Celecoxib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"Celebrex","termGroup":"BR","termSource":"NCI"},{"termName":"SC-58635","termGroup":"CN","termSource":"NCI"},{"termName":"YM 177","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute pain; Familial adenomatous polyposis; Primary dysmenorrhea; Osteoarthritis; Rheumatoid arthritis"},{"name":"CAS_Registry","value":"169590-42-5"},{"name":"CHEBI_ID","value":"CHEBI:41423"},{"name":"Chemical_Formula","value":"C17H14F3N3O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JCX84Q7J1L"},{"name":"Legacy Concept Name","value":"Celecoxib"},{"name":"Maps_To","value":"Celecoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"43023"},{"name":"NSC Number","value":"719627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43023"},{"name":"PDQ_Open_Trial_Search_ID","value":"43023"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0538927"}]}}{"C67075":{"preferredName":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83","code":"C67075","definitions":[{"definition":"A proprietary agent with potential antineoplastic activity. IC83 appears to target cell cycle checkpoint/DNA repair enzymes, which are involved in the recognition and repair of damaged DNA and are overexpressed in many types of cancer cells. Inhibition of cell cycle checkpoint/DNA repair enzymes may enhance the cytotoxicity of DNA damaging agents and dissipate tumor cell resistance to chemotherapy and radiation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83","termGroup":"PT","termSource":"NCI"},{"termName":"IC83","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"IC83"},{"name":"Maps_To","value":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83"},{"name":"NCI_Drug_Dictionary_ID","value":"536220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536220"},{"name":"PDQ_Open_Trial_Search_ID","value":"536220"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881108"}]}}{"C75875":{"preferredName":"Cemadotin","code":"C75875","definitions":[{"definition":"A synthetic dolastatin 15 analogue with potential antineoplastic activity.  Cemadotin suppresses spindle microtubule dynamics by binding to tubulin, thereby blocking mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemadotin","termGroup":"PT","termSource":"NCI"},{"termName":"LU-103793","termGroup":"CN","termSource":"NCI"},{"termName":"LU103793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"159776-69-9"},{"name":"Chemical_Formula","value":"C35H56N6O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SQ8M7ZSFV"},{"name":"Legacy Concept Name","value":"Cemadotin_Base"},{"name":"Maps_To","value":"Cemadotin"},{"name":"NSC Number","value":"D-669356"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0754175"}]}}{"C1634":{"preferredName":"Cemadotin Hydrochloride","code":"C1634","definitions":[{"definition":"An anticancer drug that reduces the risk of tumor cell growth and reproduction.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of cemadotin, a synthetic dolastatin 15 analogue with potential antineoplastic activity.  Cemadotin suppresses spindle microtubule dynamics by binding to tubulin, thereby blocking mitosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemadotin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Cemadotin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"LU-103793","termGroup":"CN","termSource":"NCI"},{"termName":"LU103793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"172837-41-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"CCR recorded NSC-D-669356"},{"name":"FDA_UNII_Code","value":"4LJQ1IXS6C"},{"name":"Legacy Concept Name","value":"Cemadotin"},{"name":"Maps_To","value":"Cemadotin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42651"},{"name":"NSC Number","value":"D-669356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42651"},{"name":"PDQ_Open_Trial_Search_ID","value":"42651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299746"}]}}{"C121540":{"preferredName":"Cemiplimab","code":"C121540","definitions":[{"definition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemiplimab","termGroup":"PT","termSource":"NCI"},{"termName":"Cemiplimab RWLC","termGroup":"SY","termSource":"NCI"},{"termName":"Cemiplimab-rwlc","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Libtayo","termGroup":"BR","termSource":"NCI"},{"termName":"REGN2810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC"},{"name":"CAS_Registry","value":"1801342-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6QVL057INT"},{"name":"Maps_To","value":"Cemiplimab"},{"name":"NCI_Drug_Dictionary_ID","value":"770083"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770083"},{"name":"PDQ_Open_Trial_Search_ID","value":"770083"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053601"}]}}{"C37454":{"preferredName":"Cenersen","code":"C37454","definitions":[{"definition":"A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cenersen","termGroup":"PT","termSource":"NCI"},{"termName":"Aezea","termGroup":"BR","termSource":"NCI"},{"termName":"EL625","termGroup":"CN","termSource":"NCI"},{"termName":"OL(1)p53","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"415168-49-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K6KJ8AZ05F"},{"name":"Legacy Concept Name","value":"EL625"},{"name":"Maps_To","value":"Cenersen"},{"name":"NCI_Drug_Dictionary_ID","value":"354249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354249"},{"name":"PDQ_Open_Trial_Search_ID","value":"354249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700610"}]}}{"C64540":{"preferredName":"Cenisertib","code":"C64540","definitions":[{"definition":"A water-soluble, synthetic small molecule with potential antineoplastic activity. Cenisertib selectively binds to and inhibits aurora kinases (AKs), a family of serine-threonine kinases which are important regulators of cell division and proliferation, and which are overexpressed in certain types of cancer. Inhibition of aurora kinases inhibits cell division and proliferation and induces apoptosis in tumor cells overexpressing AKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cenisertib","termGroup":"PT","termSource":"NCI"},{"termName":"AS703569","termGroup":"CN","termSource":"NCI"},{"termName":"Aurora Kinase Inhibitor AS703569","termGroup":"SY","termSource":"NCI"},{"termName":"R763","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871357-89-0"},{"name":"Chemical_Formula","value":"C24H30FN7O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5277GPA358"},{"name":"Legacy Concept Name","value":"R763"},{"name":"Maps_To","value":"Cenisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"522734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"522734"},{"name":"PDQ_Open_Trial_Search_ID","value":"522734"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853900"}]}}{"C91080":{"preferredName":"CENP-E Inhibitor GSK-923295A","code":"C91080","definitions":[{"definition":"A small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), with potential antineoplastic activity. Upon administration, GSK-923295A binds to and inhibits CENP-E, thereby preventing cell division, inducing cell cycle arrest, and ultimately leading to an inhibition of cell proliferation. CENP-E, a kinetochore-associated mitotic kinesin, plays an essential role in chromosome movement during mitosis and regulates cell-cycle transition from metaphase to anaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CENP-E Inhibitor GSK-923295A","termGroup":"PT","termSource":"NCI"},{"termName":"Centromere-Associated Protein E Inhibitor GSK-923295","termGroup":"SY","termSource":"NCI"},{"termName":"GSK 923295","termGroup":"CN","termSource":"NCI"},{"termName":"GSK 923295A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-923295","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-923295A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK923295","termGroup":"CN","termSource":"NCI"},{"termName":"GSK923295A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1088965-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"072702W9QD"},{"name":"Maps_To","value":"CENP-E Inhibitor GSK-923295"},{"name":"NCI_Drug_Dictionary_ID","value":"562003"},{"name":"NCI_META_CUI","value":"CL376164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"562003"},{"name":"PDQ_Open_Trial_Search_ID","value":"562003"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111993":{"preferredName":"Ceralasertib","code":"C111993","definitions":[{"definition":"An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceralasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD6738","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1352226-88-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"85RE35306Z"},{"name":"Maps_To","value":"Ceralasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"754022"},{"name":"NCI_META_CUI","value":"CL454282"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754022"},{"name":"PDQ_Open_Trial_Search_ID","value":"754022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131434":{"preferredName":"Ceramide Nanoliposome","code":"C131434","definitions":[{"definition":"A lipid-based nanoparticle formulation composed of the apoptosis-inducing sphingolipid ceramide encapsulated within nanoliposomes, with potential apoptotic and antineoplastic activities. Upon administration, ceramide nanoliposomes accumulate in the tumor environment, due to the unique properties of the tumor vasculature, and easily enter tumor cells. This delivers ceramide inside the tumor cells, where ceramide induces apoptosis. Although the process is not completely understood, ceramide-dependent apoptosis most likely results from the downregulation of nutrient transporter proteins, which prevents cellular access to extracellular nutrients and causes tumor cell starvation. This selectively destroys tumor cells. Ceramide alone is insoluble and has a very short half-life; therefore, the nanoliposome formulation increases its solubility and half-life. Ceramide plays a key role in the regulation of autophagy, apoptosis, survival and proliferation. Serving as a tumor suppressor lipid, the expression of ceramide is inversely correlated with tumor cell growth, survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceramide Nanoliposome","termGroup":"PT","termSource":"NCI"},{"termName":"CNL","termGroup":"AB","termSource":"NCI"},{"termName":"KN 001","termGroup":"CN","termSource":"NCI"},{"termName":"KN-001","termGroup":"CN","termSource":"NCI"},{"termName":"KN-01","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoliposomal Ceramide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ceramide Nanoliposome"},{"name":"NCI_Drug_Dictionary_ID","value":"786010"},{"name":"NCI_META_CUI","value":"CL514701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786010"},{"name":"PDQ_Open_Trial_Search_ID","value":"786010"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113173":{"preferredName":"Cerdulatinib","code":"C113173","definitions":[{"definition":"An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerdulatinib","termGroup":"PT","termSource":"NCI"},{"termName":"PRT-062070","termGroup":"CN","termSource":"NCI"},{"termName":"PRT062070","termGroup":"CN","termSource":"NCI"},{"termName":"Syk/JAK Inhibitor PRT062070","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1198300-79-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D1LXQ45S1O"},{"name":"Maps_To","value":"Cerdulatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"755483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755483"},{"name":"PDQ_Open_Trial_Search_ID","value":"755483"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827083"}]}}{"C146660":{"preferredName":"Mezigdomide","code":"C146660","definitions":[{"definition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mezigdomide","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986348","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986348","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986348","termGroup":"CN","termSource":"NCI"},{"termName":"CC 92480","termGroup":"CN","termSource":"NCI"},{"termName":"CC-92480","termGroup":"CN","termSource":"NCI"},{"termName":"CELMoD CC-92480","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ligase Modulation Drug CC-92480","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon Modulator CC-92480","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2259648-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LA88IH4O02"},{"name":"Maps_To","value":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480"},{"name":"NCI_Drug_Dictionary_ID","value":"792155"},{"name":"NCI_META_CUI","value":"CL544644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792155"},{"name":"PDQ_Open_Trial_Search_ID","value":"792155"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131177":{"preferredName":"Eragidomide","code":"C131177","definitions":[{"definition":"A modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, eragidomide specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex. This leads to the ubiquitination of certain substrate proteins and induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcriptional repressors in T-cells. This reduces the levels of these transcription factors, and modulates the activity of the immune system, which may include the activation of T-lymphocytes. In addition, this downregulates the expression of other proteins, including interferon regulatory factor 4 (IRF4) and c-myc, which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eragidomide","termGroup":"PT","termSource":"NCI"},{"termName":"CC 90009","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90009","termGroup":"CN","termSource":"NCI"},{"termName":"Cereblon Modulator CC-90009","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1860875-51-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R76M2Z6366"},{"name":"Maps_To","value":"Cereblon Modulator CC-90009"},{"name":"NCI_Drug_Dictionary_ID","value":"785499"},{"name":"NCI_META_CUI","value":"CL514037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785499"},{"name":"PDQ_Open_Trial_Search_ID","value":"785499"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141459":{"preferredName":"Cergutuzumab Amunaleukin","code":"C141459","definitions":[{"definition":"A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of cergutuzumab amunaleukin, the cergutuzumab moiety recognizes and binds to CEA, thereby specifically targeting IL-2v to CEA-expressing tumor tissue. Subsequently, the IL-2v moiety stimulates a local immune response, which activates both natural killer (NK) cells and cytotoxic T-cells, and eventually leads to tumor cell killing. CEA is a cell surface protein that is expressed on a wide variety of cancer cells. The mutations found in IL-2v inhibit its binding to IL-2 receptor-alpha (CD25, IL2Ra), which prevents the activation of regulatory T-cells (Tregs); however, IL-2v is able to bind to and induce signaling through IL-2Rbetagamma, which allows the preferential expansion of NK cells and CD8-positive T-cells. The Fc domain of cergutuzumab is modified to prevent Fc-gamma binding and downstream effector functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cergutuzumab Amunaleukin","termGroup":"PT","termSource":"NCI"},{"termName":"CEA-IL-2variant","termGroup":"SY","termSource":"NCI"},{"termName":"CEA-IL2v","termGroup":"SY","termSource":"NCI"},{"termName":"RG-7813","termGroup":"CN","termSource":"NCI"},{"termName":"RG7813","termGroup":"CN","termSource":"NCI"},{"termName":"RO-6895882","termGroup":"CN","termSource":"NCI"},{"termName":"RO6895882","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1509916-03-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48FCG62C25"},{"name":"Maps_To","value":"Cergutuzumab Amunaleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"791420"},{"name":"NCI_META_CUI","value":"CL539489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791420"},{"name":"PDQ_Open_Trial_Search_ID","value":"791420"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C115112":{"preferredName":"Ceritinib","code":"C115112","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceritinib","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"LDK 378","termGroup":"CN","termSource":"NCI"},{"termName":"LDK378","termGroup":"CN","termSource":"NCI"},{"termName":"Zykadia","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive"},{"name":"CAS_Registry","value":"1032900-25-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K418KG2GET"},{"name":"Maps_To","value":"Ceritinib"},{"name":"NCI_Drug_Dictionary_ID","value":"694589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694589"},{"name":"PDQ_Open_Trial_Search_ID","value":"694589"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3818721"}]}}{"C28882":{"preferredName":"Cesalin","code":"C28882","definitions":[{"definition":"An antineoplastic protein isolated from the seeds of the plant Caesalpinia gilliesii with antineoplastic activity.  Cesalin intercalates into and crosslinks DNA and inhibits the incorporation of the nucleotides uridine and thymidine into DNA, thereby inhibiting DNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cesalin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cesalin"},{"name":"Maps_To","value":"Cesalin"},{"name":"NSC Number","value":"110435"},{"name":"NSC Number","value":"264879"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055132"}]}}{"C147521":{"preferredName":"cEt KRAS Antisense Oligonucleotide AZD4785","code":"C147521","definitions":[{"definition":"A proprietary formulation composed of a high affinity antisense oligonucleotide (ASO) that contains 2'-4' constrained ethyl residues (cEt) and targets KRAS (K-RAS) transcripts, with potential antineoplastic activity. Upon intravenous administration, cEt KRAS antisense oligonucleotide AZD4785 targets and binds, with high affinity, to a unique genetic sequence within KRAS messenger RNA (mRNA), thereby inhibiting translation of KRAS protein, including forms containing activating mutations. Inhibition of KRAS protein synthesis prevents KRAS-dependent signaling and inhibits the proliferation of KRAS-driven tumor cells. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cEt KRAS Antisense Oligonucleotide AZD4785","termGroup":"PT","termSource":"NCI"},{"termName":"ASO AZD4785","termGroup":"SY","termSource":"NCI"},{"termName":"AZD 4785","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-4785","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4785","termGroup":"CN","termSource":"NCI"},{"termName":"cEt KRAS ASO AZD4785","termGroup":"SY","termSource":"NCI"},{"termName":"Generation 2.5 Drug AZD4785","termGroup":"SY","termSource":"NCI"},{"termName":"IONIS-KRAS-2.5Rx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D43WWD6RDZ"},{"name":"Maps_To","value":"cEt KRAS Antisense Oligonucleotide AZD4785"},{"name":"NCI_Drug_Dictionary_ID","value":"792660"},{"name":"NCI_META_CUI","value":"CL545331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792660"},{"name":"PDQ_Open_Trial_Search_ID","value":"792660"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129448":{"preferredName":"Cetrelimab","code":"C129448","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 protein (PD-1, PCDC-1), with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 63723283","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63723283","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63723283","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10757","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2050478-92-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LYK98WP91F"},{"name":"Maps_To","value":"Cetrelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"784126"},{"name":"NCI_META_CUI","value":"CL512668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784126"},{"name":"PDQ_Open_Trial_Search_ID","value":"784126"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1723":{"preferredName":"Cetuximab","code":"C1723","definitions":[{"definition":"A monoclonal antibody used to treat certain types of head and neck cancer, and colorectal cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Erbitux binds to the epidermal growth factor receptor (EGFR), which is found on the surface of some types of cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetuximab","termGroup":"PT","termSource":"NCI"},{"termName":"C225","termGroup":"CN","termSource":"NCI"},{"termName":"Cetuximab Biosimilar CDP-1","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab Biosimilar CMAB009","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab Biosimilar KL 140","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric Anti-EGFR Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric MoAb C225","termGroup":"AB","termSource":"NCI"},{"termName":"Chimeric Monoclonal Antibody C225","termGroup":"SY","termSource":"NCI"},{"termName":"Erbitux","termGroup":"BR","termSource":"NCI"},{"termName":"IMC-C225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced colorectal cancer; Head and neck cancer"},{"name":"CAS_Registry","value":"205923-56-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PQX0D8J21J"},{"name":"Legacy Concept Name","value":"Cetuximab"},{"name":"Maps_To","value":"Cetuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"42384"},{"name":"NSC Number","value":"714692"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42384"},{"name":"PDQ_Open_Trial_Search_ID","value":"42384"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0995188"}]}}{"C121850":{"preferredName":"Cetuximab Sarotalocan Sodium","code":"C121850","definitions":[{"definition":"The sodium salt form of cetuximab sarotalocan, which consists of a chemical conjugate composed of the dye IR700 linked to cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon injection of cetuximab sarotalocan sodium, the cetuximab moiety targets and binds to EGFR-expressing tumor cells, resulting in the internalization of the conjugate. Upon localized application of near-infrared (NIR) light, the IR700 dye becomes activated, disrupts the cell membrane and selectively kills the EGFR-expressing tumor cells. EGFR, a tyrosine kinase receptor, is overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetuximab Sarotalocan Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"ASP 1929","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1929","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1929","termGroup":"CN","termSource":"NCI"},{"termName":"Cet-IR700","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab-IR700 Conjugate RM-1929","termGroup":"SY","termSource":"NCI"},{"termName":"RM-1929","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2166339-33-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MG94W1I5XW"},{"name":"Maps_To","value":"Cetuximab Sarotalocan"},{"name":"Maps_To","value":"Cetuximab-IR700 Conjugate RM-1929"},{"name":"NCI_Drug_Dictionary_ID","value":"771602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771602"},{"name":"PDQ_Open_Trial_Search_ID","value":"771602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053596"}]}}{"C158083":{"preferredName":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)","code":"C158083","definitions":[{"definition":"A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)","termGroup":"PT","termSource":"NCI"},{"termName":"Cetuximab-loaded Polymeric Nanoparticles Decorated With Octreotide","termGroup":"SY","termSource":"NCI"},{"termName":"Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Octreotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)"},{"name":"NCI_Drug_Dictionary_ID","value":"797050"},{"name":"NCI_META_CUI","value":"CL937696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797050"},{"name":"PDQ_Open_Trial_Search_ID","value":"797050"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C77064":{"preferredName":"Cevipabulin","code":"C77064","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevipabulin","termGroup":"PT","termSource":"NCI"},{"termName":"Cevipabulinum","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 237","termGroup":"SY","termSource":"NCI"},{"termName":"Tubulin Binding Agent TTI-237","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849550-05-6"},{"name":"Chemical_Formula","value":"C18H18ClF5N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P14M0DWS2J"},{"name":"Legacy Concept Name","value":"Cevipabulin"},{"name":"Legacy Concept Name","value":"TTI-237"},{"name":"Maps_To","value":"Cevipabulin"},{"name":"Maps_To","value":"Tubulin Binding Agent TTI-237"},{"name":"NCI_Drug_Dictionary_ID","value":"432958"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699167"}]}}{"C73815":{"preferredName":"Cevipabulin Fumarate","code":"C73815","definitions":[{"definition":"The fumarate salt of cevipabulin, a synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth., a small, water soluble, synthetic tubulin-binding agent with potential antineoplastic activity.  Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and may reduce cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevipabulin Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, (2E)-2-butenedioate (1:1), dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"TTI-237","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849550-69-2"},{"name":"Chemical_Formula","value":"C18H18ClF5N6O.C4H4O4.2H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q380BYV049"},{"name":"Legacy Concept Name","value":"Cevipabulin_Fumarate"},{"name":"Maps_To","value":"Cevipabulin Fumarate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347606"}]}}{"C96746":{"preferredName":"Cevipabulin Succinate","code":"C96746","definitions":[{"definition":"The succinate salt form of cevipabulin, a synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin binds at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. This stabilizes tubulin and prevents microtubule disassembly. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevipabulin Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"5-chloro-6-(2,6-difluoro-4-(3-(methylamino)propoxy)phenyl)-N-((1S)-2,2,2-trifluoro-1-methylethyl)(1,2,4)triazolo(1,5-a)pyrimidin-7-amine succinate dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"TTI-237 Succinate Dihydrate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"852954-81-5"},{"name":"Chemical_Formula","value":"C18H18ClF5N6O.C4H6O4.2H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8XI0CX98LY"},{"name":"Maps_To","value":"Cevipabulin Succinate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273003"}]}}{"C96227":{"preferredName":"cFMS Tyrosine Kinase Inhibitor ARRY-382","code":"C96227","definitions":[{"definition":"A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; cFMS) with potential antineoplastic activity. cFMS tyrosine kinase inhibitor ARRY-382 binds to and inhibits the activity of cFMS. By preventing colony-stimulating factor-1 (CSF-1)-cFMS signaling, this agent may inhibit tumor cell proliferation in cFMS-overexpressing tumor cells. cFMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation and regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cFMS Tyrosine Kinase Inhibitor ARRY-382","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-382","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"cFMS Tyrosine Kinase Inhibitor ARRY-382"},{"name":"NCI_Drug_Dictionary_ID","value":"697525"},{"name":"NCI_META_CUI","value":"CL429011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697525"},{"name":"PDQ_Open_Trial_Search_ID","value":"697525"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1767":{"preferredName":"Chaparrin","code":"C1767","definitions":[{"definition":"A quassinoid phytochemical isolated from Simaba cedron and other plant species with potential antineoplastic activity.  Chaparrin is a mixture of compounds that includes flavonoids, antioxidants, and nordihydroguaiaretic acid (NDGA).  NDGA is an antioxidant and lipoxygenase inhibitor that promotes cell differentiation, induces G1 phase cell-cycle arrest, and causes apoptosis in certain cancer cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chaparrin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4616-50-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YX31WC5SRV"},{"name":"Legacy Concept Name","value":"Chaparrin"},{"name":"Maps_To","value":"Chaparrin"},{"name":"NSC Number","value":"132794"},{"name":"NSC Number","value":"79404"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0630780"}]}}{"C1046":{"preferredName":"Chaparrinone","code":"C1046","definitions":[{"definition":"A quassinoid phytochemical isolated from Ailanthus integrifolia sp. calycina and other plant species with potential antineoplastic activity.  Chaparrinone inhibits protein synthesis, has antimalarial properties, and is cytotoxic to some tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chaparrinone","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-ene-2,16-dione, 11,20-epoxy-1,11,12-trihydroxy-, (1beta,11beta,12alpha)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"22611-34-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chaparrinone"},{"name":"Maps_To","value":"Chaparrinone"},{"name":"NSC Number","value":"288754"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055268"}]}}{"C66961":{"preferredName":"Checkpoint Kinase Inhibitor AZD7762","code":"C66961","definitions":[{"definition":"A synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis. This agent may enhance the cytotoxicity of DNA-damaging agents. Chks are protein kinases that regulate either G1/S or G2/M transitions in the cell cycle. In the presence of DNA damage or incomplete DNA replication, Chks become activated and initiate cell cycle arrest to allow DNA repair or the completion of DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Checkpoint Kinase Inhibitor AZD7762","termGroup":"PT","termSource":"NCI"},{"termName":"AZD7762","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"860352-01-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5D822Y3L1H"},{"name":"Legacy Concept Name","value":"AZD7762"},{"name":"Maps_To","value":"Checkpoint Kinase Inhibitor AZD7762"},{"name":"NCI_Drug_Dictionary_ID","value":"530784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530784"},{"name":"PDQ_Open_Trial_Search_ID","value":"530784"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832037"}]}}{"C61102":{"preferredName":"Checkpoint Kinase Inhibitor XL844","code":"C61102","definitions":[{"definition":"A synthetic small-molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antineoplastic activity. XL844 binds to and inhibits Chks 1 and 2, resulting in inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumor cell apoptosis. This agent also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), important mediators of tumor angiogenesis and lymphogenesis, respectively. In the presence of extensive damage or absence of timely repair, these checkpoint-signaling pathways may also trigger a pathway that effects apoptosis. Normal functions of Chks involve the initiation of cell-cycle arrest and the up-regulation of transcription genes involved with DNA excision repair and dNTP synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Checkpoint Kinase Inhibitor XL844","termGroup":"PT","termSource":"NCI"},{"termName":"Chk Inhibitor XL844","termGroup":"SY","termSource":"NCI"},{"termName":"XL844","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XL844"},{"name":"Maps_To","value":"Checkpoint Kinase Inhibitor XL844"},{"name":"NCI_Drug_Dictionary_ID","value":"469731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"469731"},{"name":"PDQ_Open_Trial_Search_ID","value":"469731"},{"name":"PubMedID_Primary_Reference","value":"20024691"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831757"}]}}{"C115970":{"preferredName":"Ibcasertib","code":"C115970","definitions":[{"definition":"An orally available, small molecule inhibitor of select serine-threonine kinases, including aurora kinase B (aurora B), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-KIT), and platelet-derived growth factor receptors (PDGFRs), with potential antineoplastic activity. Upon oral administration, ibcasertib binds to and inhibits the activity of aurora B, VEGFRs, c-kit and PDGFRs, which may result in a decrease in the proliferation of tumor cells that overexpress these kinases. These kinases are overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibcasertib","termGroup":"PT","termSource":"NCI"},{"termName":"Chiauranib","termGroup":"SY","termSource":"NCI"},{"termName":"CS2164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256349-48-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F40IRN5981"},{"name":"Maps_To","value":"Chiauranib"},{"name":"NCI_Drug_Dictionary_ID","value":"760526"},{"name":"NCI_META_CUI","value":"CL473304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760526"},{"name":"PDQ_Open_Trial_Search_ID","value":"760526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156351":{"preferredName":"Chimeric Monoclonal Antibody 81C6","code":"C156351","definitions":[{"definition":"A chimeric, murine-human monoclonal antibody directed against the tumor-associated antigen (TAA) tenascin (hexabrachion) that may, when conjugated with a radioisotope, be useful in radiotherapy or radioimaging. Tenascin, an extracellular matrix glycoprotein is upregulated in certain pathological conditions such as infection, inflammation and tumor growth, and is highly expressed in the tumor microenvironment in some malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chimeric Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"ch81c6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chimeric Monoclonal Antibody 81C6"},{"name":"NCI_META_CUI","value":"CL563141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C119741":{"preferredName":"ChiNing Decoction","code":"C119741","definitions":[{"definition":"A decoction of Liang Ge San, a traditional Chinese herbal medicine, with potential anti-inflammatory and anti-stomatitis activities. Although the complete mechanism of action through which the ChiNing decoction works has yet to be fully elucidated, upon oral administration, the active ingredients may inhibit the inflammatory response, possibly by reducing the levels of pro-inflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNFa), in the saliva. This may protect the oral mucosa against these inflammatory mediators, and may reduce and relieve radiation-induced stomatitis and the associated pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ChiNing Decoction","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ChiNing Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"767025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767025"},{"name":"PDQ_Open_Trial_Search_ID","value":"767025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899687"}]}}{"C129580":{"preferredName":"Chk1 Inhibitor SRA737","code":"C129580","definitions":[{"definition":"An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor SRA737 selectively binds to chk1, thereby preventing chk1 activity and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. SRA737 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an adenosine triphosphate (ATP)-dependent serine/threonine kinase overexpressed in a variety of cancer cell types, mediates cell cycle checkpoint control and is essential for DNA repair; it plays a key role in resistance to chemotherapeutic agents by repairing DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chk1 Inhibitor SRA737","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"CCT245737","termGroup":"CN","termSource":"NCI"},{"termName":"Checkpoint Kinase 1 Inhibitor CCT245737","termGroup":"SY","termSource":"NCI"},{"termName":"Chk1 Inhibitor CCT245737","termGroup":"SY","termSource":"NCI"},{"termName":"PNT-737","termGroup":"CN","termSource":"NCI"},{"termName":"SRA 737","termGroup":"CN","termSource":"NCI"},{"termName":"SRA-737","termGroup":"CN","termSource":"NCI"},{"termName":"SRA737","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1489389-18-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QB6LNL4NF6"},{"name":"Maps_To","value":"Chk1 Inhibitor CCT245737"},{"name":"NCI_Drug_Dictionary_ID","value":"783792"},{"name":"NCI_META_CUI","value":"CL512598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783792"},{"name":"PDQ_Open_Trial_Search_ID","value":"783792"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116756":{"preferredName":"Chk1 Inhibitor GDC-0425","code":"C116756","definitions":[{"definition":"An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor GDC-0425 selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. GDC-0425 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an ATP-dependent serine/threonine kinase, mediates cell cycle checkpoint control, is essential for DNA repair, and plays a key role in resistance to chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chk1 Inhibitor GDC-0425","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0425","termGroup":"CN","termSource":"NCI"},{"termName":"RG7602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1627539-18-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4N173XZ7SX"},{"name":"Maps_To","value":"Chk1 Inhibitor GDC-0425"},{"name":"NCI_Drug_Dictionary_ID","value":"701310"},{"name":"NCI_META_CUI","value":"CL433842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701310"},{"name":"PDQ_Open_Trial_Search_ID","value":"701310"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116845":{"preferredName":"Chk1 Inhibitor GDC-0575","code":"C116845","definitions":[{"definition":"A small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity. Chk1 inhibitor GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis. Therefore, Chk1 inhibition may sensitize tumor cells to the DNA-damaging effects of certain chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that phosphorylates cdc25 phosphatases in response to DNA damage. This results in both inhibitory tyrosine phosphorylation of cyclin-dependent kinase (CDK)-cyclin complexes and cell cycle arrest, which facilitates DNA damage repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chk1 Inhibitor GDC-0575","termGroup":"PT","termSource":"NCI"},{"termName":"Checkpoint Kinase 1 Inhibitor GDC-0575","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0575","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chk1 Inhibitor GDC-0575"},{"name":"NCI_Drug_Dictionary_ID","value":"730054"},{"name":"NCI_META_CUI","value":"CL446611"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730054"},{"name":"PDQ_Open_Trial_Search_ID","value":"730054"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79867":{"preferredName":"CHK1 Inhibitor MK-8776","code":"C79867","definitions":[{"definition":"An agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities. Chk1 inhibitor MK-8776 specifically binds to and inhibits Chk1, which may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases to undergo DNA repair prior to entry into mitosis; tumor cells may thus be sensitized to the DNA-damaging effects of ionizing radiation and alkylating chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that in response to DNA damage phosphorylates cdc25 phosphatases, resulting in inhibitory tyrosine phosphorylation of CDK-cyclin complexes and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHK1 Inhibitor MK-8776","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-6-Bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine","termGroup":"SN","termSource":"NCI"},{"termName":"MK8776","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900776","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-900776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"891494-63-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K2ZSF0992C"},{"name":"Legacy Concept Name","value":"CHK1_Inhibitor_SCH_900776"},{"name":"Maps_To","value":"CHK1 Inhibitor MK-8776"},{"name":"NCI_Drug_Dictionary_ID","value":"624396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"624396"},{"name":"PDQ_Open_Trial_Search_ID","value":"624396"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703183"}]}}{"C68820":{"preferredName":"CHK1 Inhibitor PF-477736","code":"C68820","definitions":[{"definition":"A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHK1 Inhibitor PF-477736","termGroup":"PT","termSource":"NCI"},{"termName":"PF-00477736","termGroup":"CN","termSource":"NCI"},{"termName":"PF-477736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"952021-60-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XO23PGZ0SM"},{"name":"Legacy Concept Name","value":"CHK1_Inhibitor_PF-477736"},{"name":"Maps_To","value":"CHK1 Inhibitor PF-477736"},{"name":"NCI_Drug_Dictionary_ID","value":"539740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539740"},{"name":"PDQ_Open_Trial_Search_ID","value":"539740"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4049082"}]}}{"C362":{"preferredName":"Chlorambucil","code":"C362","definitions":[{"definition":"A drug used to treat several types of leukemias and lymphomas. It blocks cell growth by damaging the cell's DNA and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorambucil","termGroup":"PT","termSource":"NCI"},{"termName":"4-[bis(2-chloroethyl)amino]benzenebutanoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"Alti-chlorambucil","termGroup":"FB","termSource":"NCI"},{"termName":"Ambochlorin","termGroup":"SY","termSource":"NCI"},{"termName":"Amboclorin","termGroup":"SY","termSource":"NCI"},{"termName":"aminochlorambucil","termGroup":"SY","termSource":"NCI"},{"termName":"benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)","termGroup":"SN","termSource":"NCI"},{"termName":"CB-1348","termGroup":"CN","termSource":"NCI"},{"termName":"CHL","termGroup":"AB","termSource":"NCI"},{"termName":"Chlorambucilum","termGroup":"SY","termSource":"NCI"},{"termName":"Chloraminophen","termGroup":"SY","termSource":"NCI"},{"termName":"Chloraminophene","termGroup":"FB","termSource":"NCI"},{"termName":"Chlorbutin","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorbutine","termGroup":"SY","termSource":"NCI"},{"termName":"chlorbutinum","termGroup":"SY","termSource":"NCI"},{"termName":"chloroambucil","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorobutin","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorobutine","termGroup":"SY","termSource":"NCI"},{"termName":"Ecloril","termGroup":"SY","termSource":"NCI"},{"termName":"Elcoril","termGroup":"SY","termSource":"NCI"},{"termName":"gamma-(p-bis(2-chloroethyl)aminophenyl)butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"Leukeran","termGroup":"BR","termSource":"NCI"},{"termName":"Leukersan","termGroup":"SY","termSource":"NCI"},{"termName":"Leukoran","termGroup":"SY","termSource":"NCI"},{"termName":"Linfolizin","termGroup":"SY","termSource":"NCI"},{"termName":"Lympholysin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"p-(N, N-di-2-chloroethyl)aminophenyl butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"p-N, N-di-(beta-chloroethyl)aminophenyl butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"phenylbutyric acid nitrogen mustard","termGroup":"SY","termSource":"NCI"},{"termName":"WR-139013","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia, Hodgkin lymphoma, and certain types of non-Hodgkin lymphoma."},{"name":"CAS_Registry","value":"305-03-3"},{"name":"CHEBI_ID","value":"CHEBI:28830"},{"name":"Chemical_Formula","value":"C14H19Cl2NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"18D0SL7309"},{"name":"Legacy Concept Name","value":"Chlorambucil"},{"name":"Maps_To","value":"Chlorambucil"},{"name":"NCI_Drug_Dictionary_ID","value":"43113"},{"name":"NSC Number","value":"3088"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43113"},{"name":"PDQ_Open_Trial_Search_ID","value":"43113"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008163"}]}}{"C2085":{"preferredName":"Chlorodihydropyrimidine","code":"C2085","definitions":[{"definition":"A pyrimidine derivative with antitumor activity. Chlorodihydropyrimidine competitively and reversibly inhibits dihydropyrimidine dehydrogenase, a rate-limiting enzyme in the catabolism of fluoropyrimidines thereby blocking the degradation of the fluoropyrimidines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorodihydropyrimidine","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chlorodihydropyrimidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chlorodihydropyrimidine"},{"name":"Maps_To","value":"Chlorodihydropyrimidine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516486"}]}}{"C61671":{"preferredName":"Chloroquine","code":"C61671","definitions":[{"definition":"A 4-aminoquinoline with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the mechanism is not well understood, chloroquine is shown to inhibit the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. This agent may also interfere with the biosynthesis of nucleic acids. Chloroquine's potential chemosensitizing and radiosensitizing activities in cancer may be related to its inhibition of autophagy, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chloroquine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54-05-7"},{"name":"CHEBI_ID","value":"CHEBI:3638"},{"name":"Chemical_Formula","value":"C18H26ClN3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"886U3H6UFF"},{"name":"Legacy Concept Name","value":"Chloroquine"},{"name":"Maps_To","value":"Chloroquine"},{"name":"NCI_Drug_Dictionary_ID","value":"654729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654729"},{"name":"PDQ_Open_Trial_Search_ID","value":"654729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008269"}]}}{"C982":{"preferredName":"Chloroquinoxaline Sulfonamide","code":"C982","definitions":[{"definition":"A chlorinated heterocyclic sulfanilamide with potential antineoplastic activity and potential immunosuppressive activity.  Chloroquinoxaline sulfonamide poisons topoisomerase II alpha and topoisomerase II beta, thereby causing double-stranded breaks in DNA, accumulation of unrepaired DNA, and apoptosis.  This agent also exhibits lymphotoxicity by inhibiting lymphocyte activation in a cell cycle-specific manner. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chloroquinoxaline Sulfonamide","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, 4-amino-N-(5-chloro-2-quinoxalinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"chlorosulfaquinoxaline","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorsulfaquinoxaline","termGroup":"SY","termSource":"NCI"},{"termName":"CQS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97919-22-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O0408QB48D"},{"name":"Legacy Concept Name","value":"Chloroquinoxaline_Sulfonamide"},{"name":"Maps_To","value":"Chloroquinoxaline Sulfonamide"},{"name":"NCI_Drug_Dictionary_ID","value":"41055"},{"name":"NSC Number","value":"339004"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41055"},{"name":"PDQ_Open_Trial_Search_ID","value":"41055"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049111"}]}}{"C94723":{"preferredName":"Chlorotoxin","code":"C94723","definitions":[{"definition":"A neurotoxin with potential anticancer property. Chlorotoxin (CTX) is a 36-amino acid peptide found in the venom of the deathstalker scorpion, and a chloride channel blocker. This toxin binds preferentially to glioma cells via the transmembrane endopeptidase matrix metalloproteinase-2 (MMP-2), and thereby prevents the spread of tumor cells. MMP-2 is specifically up-regulated in gliomas and related cancers, but is not normally expressed in brain.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the diagnosis and treatment of glioma (a type of brain cancer) and other types of cancer. It binds to cancer cells in the brain and peripheral nervous system and may keep them from spreading. Chlorotoxin comes from the venom of a type of scorpion. A form of chlorotoxin made in the laboratory is called TM-601. Chlorotoxin is a type of neurotoxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chlorotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"TM-601","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"163515-35-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"06UV5RFW57"},{"name":"Maps_To","value":"Chlorotoxin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Biologically Active Substance"},{"name":"UMLS_CUI","value":"C0293227"}]}}{"C1049":{"preferredName":"Chlorozotocin","code":"C1049","definitions":[{"definition":"A glucose-linked chloroethylnitrosourea with potential antineoplastic activity.  Chlorozotocin alkylates DNA and proteins, induces the formation of interstrand DNA and DNA-protein crosslinks, and causes DNA strand breakage, thereby damaging DNA and resulting in cell death.  This agent has been shown to exhibit antitumor and immunomodulatory effects in cell lines and animal models.  Chlorozotocin is a mutagen and is less myelotoxic than other nitrosoureas. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorozotocin","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-chloroethyl)-1-nitroso-3-(D-glucos-2-yl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"2-[3-(2-chloroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"2-[[[(2-chloroethyl)nitrosamino]carbonyl]amino]-2-deoxy-D-glucose","termGroup":"SN","termSource":"NCI"},{"termName":"Chlorozotocyna","termGroup":"SY","termSource":"NCI"},{"termName":"CHLZ","termGroup":"AB","termSource":"NCI"},{"termName":"CZT","termGroup":"AB","termSource":"NCI"},{"termName":"D-glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy","termGroup":"SN","termSource":"NCI"},{"termName":"D-glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"DCNU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54749-90-5"},{"name":"Chemical_Formula","value":"C9H16ClN3O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3053LTY75Z"},{"name":"Legacy Concept Name","value":"Chlorozotocin"},{"name":"Maps_To","value":"Chlorozotocin"},{"name":"NCI_Drug_Dictionary_ID","value":"39182"},{"name":"NSC Number","value":"178248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39182"},{"name":"PDQ_Open_Trial_Search_ID","value":"39182"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055465"}]}}{"C94213":{"preferredName":"Choline Kinase Alpha Inhibitor TCD-717","code":"C94213","definitions":[{"definition":"A small-molecule inhibitor of choline kinase alpha (CHKA), with potential antineoplastic activity. TCD-717 targets and binds to CHKA, an enzyme that plays a key role in the synthesis of phosphatidylcholine, the major phospholipid in eukaryotic cell membranes. Blockade of this enzyme induces cells to activate a different route for phospholipid production which causes a toxic effect and eventually leads to cell destruction. CHKA, overexpressed in human cancer cells while only minimally expressed in normal cells, appears to play a significant role in cellular proliferation, evasion of apoptosis, increased cell motility and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choline Kinase Alpha Inhibitor TCD-717","termGroup":"PT","termSource":"NCI"},{"termName":"CHKA Inhibitor TCD-717","termGroup":"SY","termSource":"NCI"},{"termName":"RSM-932A","termGroup":"CN","termSource":"NCI"},{"termName":"TCD-717","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850993-73-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KC1UXA6R4Z"},{"name":"Maps_To","value":"Choline Kinase Alpha Inhibitor TCD-717"},{"name":"NCI_Drug_Dictionary_ID","value":"687183"},{"name":"NCI_META_CUI","value":"CL426026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687183"},{"name":"PDQ_Open_Trial_Search_ID","value":"687183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62598":{"preferredName":"CHP-NY-ESO-1 Peptide Vaccine IMF-001","code":"C62598","definitions":[{"definition":"A peptide cancer vaccine containing nanoparticles of cholesteryl hydrophobized pullulan (CHP) complexed with the cancer-testis antigen NY-ESO-1 protein, with potential immunostimulating and antineoplastic activities.  Upon administration, CHP-NY-ESO-1 peptide vaccine IMF-001 may stimulate the host immune system to mount a humoral and cytotoxic T-cell response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water. NY-ESO-1, an antigen found in normal testis, is upregulated in various cancers, including bladder, breast, hepatocellular, melanoma, and prostate cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHP-NY-ESO-1 Peptide Vaccine IMF-001","termGroup":"PT","termSource":"NCI"},{"termName":"Cholesteryl Pullulan-NY-ESO-1 Vaccine IMF-001","termGroup":"SY","termSource":"NCI"},{"termName":"IMF-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CHP-NY-ESO-1_Peptide_Vaccine"},{"name":"Maps_To","value":"CHP-NY-ESO-1 Peptide Vaccine IMF-001"},{"name":"NCI_Drug_Dictionary_ID","value":"489132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489132"},{"name":"PDQ_Open_Trial_Search_ID","value":"489132"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831881"}]}}{"C895":{"preferredName":"Chromomycin A3","code":"C895","definitions":[{"definition":"A glycosidic antineoplastic antibiotic isolated from the bacterium Streptomyces griseus.  Chromomycin A3 reversibly binds to guanine-cytosine (G-C) base pairs in the minor groove of DNA, thereby inhibiting RNA synthesis.  This agent is used as a fluorescent chromosome dye. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromomycin A3","termGroup":"PT","termSource":"NCI"},{"termName":"3B-O-(4-O-Acetyl-2,6-dideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-7-methylolivomycin D","termGroup":"SN","termSource":"NCI"},{"termName":"Antibiotic 69895 A","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic B 599","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic from Streptomyces griseus","termGroup":"SY","termSource":"NCI"},{"termName":"Olivomycin D, 3B-O-(4-O-Acetyl-2, 6-dideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-7-methyl- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Toyomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7059-24-7"},{"name":"CHEBI_ID","value":"CHEBI:34638"},{"name":"Chemical_Formula","value":"C57H82O26"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DVW027E7NL"},{"name":"Legacy Concept Name","value":"Chromomycin_A3"},{"name":"Maps_To","value":"Chromomycin A3"},{"name":"NCI_Drug_Dictionary_ID","value":"39184"},{"name":"NSC Number","value":"58514"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39184"},{"name":"PDQ_Open_Trial_Search_ID","value":"39184"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040563"}]}}{"C1828":{"preferredName":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement","code":"C1828","definitions":[{"definition":"A mixture of eight herbs that has been sold as a dietary supplement and promoted as a way to keep the prostate healthy and to treat prostate cancer. PC-SPES has been studied in the treatment of prostate cancer, but has been taken off the market in the U.S. because of safety concerns.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An herbal mixture with potential antineoplastic effects. PC-SPES, an herbal supplement containing extracts from 8 herbs including Chrysanthemum morifolium, Ganoderma lucidum (a root fungus), Glycyrrhiza glabra (Spanish liquorice), Isatis indigotica, Panax pseudoginseng, Rabdosia rubescens, Scutellaria baicalensis, and Serona repens (saw palmetto), with potential antineoplastic and antiproliferative effects, specifically in prostate cancer cells. Its exact pharmacology is not fully understood due to the complexity of the herbal mixture and may involve multiple metabolic pathways. Exposure to PC-SPES in vitro has resulted in a decreased expression of genes encoding cell cycle regulatory proteins as well as an upregulation of genes that modulate apoptosis in both androgen-dependent and androgen-independent cells. The PC in the acronym PC-SPES stands for Prostate Cancer, while SPES is the Latin word for hope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"374933-93-4"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PC-SPES"},{"name":"Maps_To","value":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"404383"},{"name":"PDQ_Closed_Trial_Search_ID","value":"404383"},{"name":"PDQ_Open_Trial_Search_ID","value":"404383"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0756934"}]}}{"C120097":{"preferredName":"Cibisatamab","code":"C120097","definitions":[{"definition":"An anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific monoclonal antibody with potential antineoplastic activity. Cibisatamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CEA, a tumor-associated antigen that is specifically expressed on certain tumor cells. Upon intravenous administration, cibisatamab binds to both T-cells and CEA-expressing tumor cells, which cross-links the T-cells with the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cibisatamab","termGroup":"PT","termSource":"NCI"},{"termName":"RG-7802","termGroup":"CN","termSource":"NCI"},{"termName":"RG7802","termGroup":"CN","termSource":"NCI"},{"termName":"RO6958688","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10636","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1855925-27-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAM5J1ATF2"},{"name":"Maps_To","value":"Cibisatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"767685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767685"},{"name":"PDQ_Open_Trial_Search_ID","value":"767685"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896776"}]}}{"C175786":{"preferredName":"Fosciclopirox","code":"C175786","definitions":[{"definition":"A phosphoryloxymethyl (POM) ester-based prodrug of ciclopirox (CPX), a synthetic, broad-spectrum antifungal agent with antibacterial, anti-inflammatory and potential antineoplastic activities. Upon intravenous administration of fosciclopirox, the POM moiety is cleaved off by phosphatases and the active metabolite CPX is released. Although its exact anticancer mechanism is not yet fully elucidated, CPX has been shown to inhibit tumor cell proliferation, induce apoptosis, and reduce tumor cell mobility in certain cancer types. CPX inhibits Notch1 activation and inhibits the Notch1-mediated signaling pathway, which is upregulated in many cancer cell types. This inhibits Notch downstream target proteins, inhibits the expression of gamma-secretase complex proteins, and prevents proliferation in susceptible cancer cells. CPX inhibits the iron-containing enzymes, catalase and peroxidase, which facilitate the decomposition of hydrogen peroxide, a reactive oxygen species (ROS) involved in oxidative stress. CPX also inhibits the iron-dependent enzyme ribonucleotide reductase, which is essential in DNA synthesis. CPX downregulates protein expression of cyclin D1 and cyclin E1, as well as their enzymatic counterparts cyclin-dependent kinases 4 and 2 (CDK4 and CDK2), which may inhibit tumor cell proliferation by slowing cell cycle progression from G1/G0 to S phase. Further, CPX may induce apoptosis by downregulating the expression of anti-apoptotic proteins, Bcl-xL and survivin, and increasing cleavage of Bcl-2. Additionally, CPX may inhibit tumor cell proliferation, survival and motility by inhibiting the phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), two downstream effector molecules of the mammalian target of rapamycin complex 1 (mTORC1). The CPX-POM prodrug improves the solubility of CPX and increases systemic efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosciclopirox","termGroup":"PT","termSource":"NCI"},{"termName":"Ciclopirox Prodrug","termGroup":"SY","termSource":"NCI"},{"termName":"Ciclopirox Prodrug CPX-POM","termGroup":"SY","termSource":"NCI"},{"termName":"Ciclopirox-POM","termGroup":"SY","termSource":"NCI"},{"termName":"CPX POM","termGroup":"CN","termSource":"NCI"},{"termName":"CPX-POM","termGroup":"CN","termSource":"NCI"},{"termName":"CPXPOM","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1380539-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G8FR269QPQ"},{"name":"Maps_To","value":"Ciclopirox Prodrug CPX-POM"},{"name":"NCI_Drug_Dictionary_ID","value":"794795"},{"name":"NCI_META_CUI","value":"CL562696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794795"},{"name":"PDQ_Open_Trial_Search_ID","value":"794795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118451":{"preferredName":"Cidan Herbal Capsule","code":"C118451","definitions":[{"definition":"A capsule-based formulation containing artificial bezoar, Strychni pulveratum (strychnos powder), camphol alcohol (borneol or borneo camphor) and extracts from Zedoary rhizome (Rhizoma curcumae), Pseudobulbus cremastrae seu pleiones (dried pseudobulb of Cremastra appendiculata), Yatantzu (seed of Brucca javanica), beehive, Bombyx mori (Bombyx batryticatus or silkworm), Danshen (dried root of Salvia miltiorrhiza or red sage root), Radix astragali, and Angelica, with potential antineoplastic activity. Upon oral administration of the cidan herbal capsule, the active ingredients in the plant extracts may induce tumor cell apoptosis and reduce tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cidan Herbal Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Zedoary rhizome/Pseudobulbus cremastrae seu pleiones/Yatantzu/Strychni pulveratum/Beehive/Artificial Bezoar/Bombyx mori/Danshen Root/Radix astragali/Angelica/Camphol Alcohol Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cidan Herbal Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"765191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765191"},{"name":"PDQ_Open_Trial_Search_ID","value":"765191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899625"}]}}{"C125659":{"preferredName":"Ciforadenant","code":"C125659","definitions":[{"definition":"A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration, ciforadenant binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor-released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine-induced immunosuppression in the tumor microenvironment. This may stimulate anti-tumor immune responses, resulting in tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciforadenant","termGroup":"PT","termSource":"NCI"},{"termName":"3H-1,2,3-Triazolo(4,5-d)pyrimidin-5-amine, 7-(5-Methyl-2-furanyl)-3-((6-((((3S)-tetrahydro-3-furanyl)oxy)methyl)-2-pyridinyl)methyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Adenosine-A2A Receptor-Targeting Agent CPI-444","termGroup":"SY","termSource":"NCI"},{"termName":"CPI-444","termGroup":"CN","termSource":"NCI"},{"termName":"V81444","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1202402-40-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8KFO2187CP"},{"name":"Maps_To","value":"Ciforadenant"},{"name":"NCI_Drug_Dictionary_ID","value":"778585"},{"name":"NCI_META_CUI","value":"CL504345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778585"},{"name":"PDQ_Open_Trial_Search_ID","value":"778585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1834":{"preferredName":"Cilengitide","code":"C1834","definitions":[{"definition":"A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity.  Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as an anticancer and antiangiogenesis drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cilengitide","termGroup":"PT","termSource":"NCI"},{"termName":"cyclo(L-arginylglycyl-L-a-aspartyl-D-phenylalanyl-N-methyl-L-valyl)","termGroup":"SN","termSource":"NCI"},{"termName":"EMD 121974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"188968-51-6"},{"name":"Chemical_Formula","value":"C27H40N8O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4EDF46E4GI"},{"name":"Legacy Concept Name","value":"Cilengitide"},{"name":"Maps_To","value":"Cilengitide"},{"name":"NCI_Drug_Dictionary_ID","value":"37844"},{"name":"NSC Number","value":"707544"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37844"},{"name":"PDQ_Open_Trial_Search_ID","value":"37844"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0971473"}]}}{"C374":{"preferredName":"Cimetidine","code":"C374","definitions":[{"definition":"A drug usually used to treat stomach ulcers and heartburn. It is also commonly used in a regimen to prevent allergic reactions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cimetidine","termGroup":"PT","termSource":"NCI"},{"termName":"Guanidine, N''-Cyano-N-Methyl-N'-(2-(((5-Methyl-1H-Imidazol-4-yl)Methyl)Thio)Ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-Cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine","termGroup":"SN","termSource":"NCI"},{"termName":"Tagamet","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastrointestinal conditions; allergic reaction prevention; immune modulation"},{"name":"CAS_Registry","value":"51481-61-9"},{"name":"CHEBI_ID","value":"CHEBI:3699"},{"name":"Chemical_Formula","value":"C10H16N6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"80061L1WGD"},{"name":"Legacy Concept Name","value":"Cimetidine"},{"name":"Maps_To","value":"Cimetidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39185"},{"name":"NSC Number","value":"335308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39185"},{"name":"PDQ_Open_Trial_Search_ID","value":"39185"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008783"}]}}{"C47450":{"preferredName":"Cinacalcet Hydrochloride","code":"C47450","definitions":[{"definition":"The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels; PTH appears to raise PSA levels and may increase prostate cancer cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinacalcet Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthalenemethanamine, a-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-,(aR)-, Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Mimpara","termGroup":"FB","termSource":"NCI"},{"termName":"Sensipar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"364782-34-3"},{"name":"CHEBI_ID","value":"CHEBI:48391"},{"name":"Chemical_Formula","value":"C22H22F3N.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1K860WSG25"},{"name":"Legacy Concept Name","value":"Cinacalcet_Hydrochloride"},{"name":"Maps_To","value":"Cinacalcet Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"662071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662071"},{"name":"PDQ_Open_Trial_Search_ID","value":"662071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1260199"}]}}{"C95021":{"preferredName":"Cinobufagin","code":"C95021","definitions":[{"definition":"A bufadienolide compound extracted from the dried venom secreted by the parotid glands of toads and one of the glycosides in the traditional Chinese medicine ChanSu, with potential antineoplastic activity. Although the mechanism of action of cinobufagin is still under investigation, it has been found to suppress cancer cell proliferation and cause apoptosis in cancer cells via a sequence of apoptotic modulators that include mitochondrial Bax and cytosolic chromosome c, and caspases 3, 8, and 9. Possible upstream mediators of cinobufagin-induced apoptosis include Fas and p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinobufagin","termGroup":"PT","termSource":"NCI"},{"termName":"Cinobufacini","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"470-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T9PSN4R8IR"},{"name":"Maps_To","value":"Cinobufagin"},{"name":"NCI_Drug_Dictionary_ID","value":"689412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689412"},{"name":"PDQ_Open_Trial_Search_ID","value":"689412"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055767"}]}}{"C151929":{"preferredName":"Cinobufotalin","code":"C151929","definitions":[{"definition":"A bufadienolide isolated from toad venom and utilized in traditional Chinese medicine (TCM) for its cardiotonic, diuretic and hemostatic effects, with potential cytotoxic and antineoplastic activities. Upon administration and although the exact mechanism of action(s) (MoAs) through which this agent exerts its effects have yet to be fully discovered, cinobufotalin causes DNA fragmentation, decreases mitochondrial membrane potential (MMP), increases intracellular calcium (Ca2+) ion concentrations and reactive oxygen species (ROS) production, upregulates Fas protein and activates cytochrome C, various caspases, Bid and Bax. This causes cell cycle arrest, induces apoptosis and inhibits tumor cell growth and survival. In addition, cinobufotalin inhibits the activity of sphingosine kinase 1 (SphK1) and induces pro-apoptotic ceramide production, which further promotes tumor cell apoptosis. Cinobufotalin also induces mitochondrial protein cyclophilin D (Cyp-D)-dependent opening of the mitochondrial permeability transition pore (mPTP), which may contribute to cinobufotalin-induced non-apoptotic death of certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinobufotalin","termGroup":"PT","termSource":"NCI"},{"termName":"14,15b-Epoxy-3b,5a,16b-trihydroxy-5b,20(22)-bufadienolide 16-Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"5-Beta-bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-, 16-Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"5b,20(22)-Bufadienolide-14,15b-epoxy-3b,5a,16b-triol 16-Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"CB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1108-68-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0QBZ37386"},{"name":"Maps_To","value":"Cinobufotalin"},{"name":"NCI_Drug_Dictionary_ID","value":"793122"},{"name":"NCI_META_CUI","value":"CL553268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793122"},{"name":"PDQ_Open_Trial_Search_ID","value":"793122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2599":{"preferredName":"Cintredekin Besudotox","code":"C2599","definitions":[{"definition":"A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R).The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is made by combining interleukin-13 with a toxin from Pseudomonas bacteria. It is a type of recombinant chimeric protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cintredekin Besudotox","termGroup":"PT","termSource":"NCI"},{"termName":"hIL13-PE38QQR","termGroup":"SY","termSource":"NCI"},{"termName":"IL 13-PE38QQR","termGroup":"AB","termSource":"NCI"},{"termName":"IL-13 Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"IL-13-PE38QQR Cytotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"IL-13PE","termGroup":"SY","termSource":"NCI"},{"termName":"IL13-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-13 PE38QQR Immunotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"372075-36-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL04JX89M7"},{"name":"Legacy Concept Name","value":"Interleukin-13_PE38QQR_Immunotoxin"},{"name":"Maps_To","value":"Cintredekin Besudotox"},{"name":"NCI_Drug_Dictionary_ID","value":"38095"},{"name":"NSC Number","value":"722759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38095"},{"name":"PDQ_Open_Trial_Search_ID","value":"38095"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1434448"}]}}{"C118284":{"preferredName":"Zilovertamab","code":"C118284","definitions":[{"definition":"A humanized monoclonal antibody against the extracellular domain of the human receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential antineoplastic activity. Upon administration, zilovertamab binds to ROR1 and blocks ROR1-mediated signaling. This prevents tumor cell proliferation in cancer cells overexpressing ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is normally expressed during embryogenesis.  It is overexpressed in certain leukemias and solid tumors, but minimally expressed in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zilovertamab","termGroup":"PT","termSource":"NCI"},{"termName":"Cirmtuzumab","termGroup":"SY","termSource":"NCI"},{"termName":"UC-961","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2485779-13-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FEH7RQ7B3J"},{"name":"Maps_To","value":"Cirmtuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"764235"},{"name":"NCI_META_CUI","value":"CL474136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764235"},{"name":"PDQ_Open_Trial_Search_ID","value":"764235"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99125":{"preferredName":"cis-Urocanic Acid","code":"C99125","definitions":[{"definition":"A derivative of the amino acid histidine, formed in the mammalian skin from trans-urocanic acid upon ultraviolet radiation, and protodynamic agent, with potential anti-inflammatory and antiproliferative activity. Upon intravesical instillation of cis-urocanic acid (cis-UCA), this agent is protonated at the imidazolyl moiety in the mildly acidic extracellular tumor environment and penetrates into the cancer cell. Once inside the cell and due to the slightly alkaline pH inside the tumor cell, cis-UCA is deprotonated, i.e. the imidazolyl proton is released into the cytosol which eventually raises the intracellular acidity. This acidification impairs many cellular processes, such as metabolic activity, and may lead to cell cycle arrest, an induction of cellular apoptosis and necrotic cell death. In addition, cis-UCA enhances ERK and JNK signaling pathways by inhibiting the activity of serine/threonine and tyrosine phosphatases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cis-Urocanic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"cis-UCA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7699-35-6"},{"name":"CHEBI_ID","value":"CHEBI:30818"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5LM7WD7VIC"},{"name":"Maps_To","value":"cis-Urocanic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"715688"},{"name":"NCI_META_CUI","value":"CL432945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715688"},{"name":"PDQ_Open_Trial_Search_ID","value":"715688"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C376":{"preferredName":"Cisplatin","code":"C376","definitions":[{"definition":"A drug used to treat many types of cancer. Cisplatin contains the metal platinum. It kills cancer cells by damaging their DNA and stopping them from dividing. Cisplatin is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(SP-4-2)-Diamminedichloroplatinum","termGroup":"SN","termSource":"NCI"},{"termName":"Abiplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Blastolem","termGroup":"FB","termSource":"NCI"},{"termName":"Briplatin","termGroup":"FB","termSource":"NCI"},{"termName":"CDDP","termGroup":"AB","termSource":"NCI"},{"termName":"Cis-diammine-dichloroplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-diamminedichloridoplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-diamminedichloro Platinum (II)","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-diamminedichloroplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-dichloroammine Platinum (II)","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinous Diamine Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinum II","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinum II Diamine Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cismaplat","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatina","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatyl","termGroup":"FB","termSource":"NCI"},{"termName":"Citoplatino","termGroup":"FB","termSource":"NCI"},{"termName":"Citosin","termGroup":"FB","termSource":"NCI"},{"termName":"Cysplatyna","termGroup":"SY","termSource":"NCI"},{"termName":"DDP","termGroup":"AB","termSource":"NCI"},{"termName":"Lederplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Metaplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Neoplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Peyrone's Chloride","termGroup":"SY","termSource":"NCI"},{"termName":"Peyrone's Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Placis","termGroup":"FB","termSource":"NCI"},{"termName":"Plastistil","termGroup":"FB","termSource":"NCI"},{"termName":"Platamine","termGroup":"FB","termSource":"NCI"},{"termName":"Platiblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Platiblastin-S","termGroup":"FB","termSource":"NCI"},{"termName":"Platinex","termGroup":"FB","termSource":"NCI"},{"termName":"Platinol","termGroup":"BR","termSource":"NCI"},{"termName":"Platinol- AQ","termGroup":"FB","termSource":"NCI"},{"termName":"Platinol-AQ","termGroup":"BR","termSource":"NCI"},{"termName":"Platinol-AQ VHA Plus","termGroup":"FB","termSource":"NCI"},{"termName":"Platinoxan","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum Diamminodichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum, Diaminedichloro-, cis- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Platiran","termGroup":"FB","termSource":"NCI"},{"termName":"Platistin","termGroup":"FB","termSource":"NCI"},{"termName":"Platosin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic testicular cancer; ovarian cancer; head and neck cancer; breast cancer; Hodgkin's and non-Hodgkin's lymphoma; myeloma and melanoma"},{"name":"CAS_Registry","value":"15663-27-1"},{"name":"CHEBI_ID","value":"CHEBI:27899"},{"name":"Chemical_Formula","value":"2Cl.Pt.2H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"Q20Q21Q62J"},{"name":"Legacy Concept Name","value":"Cisplatin"},{"name":"Maps_To","value":"Cisplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39515"},{"name":"NSC Number","value":"119875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39515"},{"name":"PDQ_Open_Trial_Search_ID","value":"39515"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008838"}]}}{"C2502":{"preferredName":"Cisplatin Liposomal","code":"C2502","definitions":[{"definition":"A synthetic formulation in which the antineoplastic agent cisplatin is encapsulated in lipids.  Cisplatin liposomal consists of small aggregates of cisplatin covered by a single lipid bilayer. Encasement in liposomes improves cisplatin's tumor bioavailability and toxicity profile. Liposomal encapsulation does not affect the pharmacological properties of cisplatin directly.  Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin Liposomal","termGroup":"PT","termSource":"NCI"},{"termName":"Cisplatin, Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"SPI-077","termGroup":"CN","termSource":"NCI"},{"termName":"SPI-77","termGroup":"CN","termSource":"NCI"},{"termName":"STEALTH Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"STEALTH Liposomal Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"STEALTH Liposomal Encapsulated Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"STEALTH Liposome Cisplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cisplatin_Liposomal"},{"name":"Maps_To","value":"Cisplatin Liposomal"},{"name":"NCI_Drug_Dictionary_ID","value":"43292"},{"name":"NSC Number","value":"719334"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43292"},{"name":"PDQ_Open_Trial_Search_ID","value":"43292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0964924"}]}}{"C17879":{"preferredName":"Cisplatin-E Therapeutic Implant","code":"C17879","definitions":[{"definition":"An injectable gel comprised of a collagen matrix containing the inorganic platinum (Pt) agent cisplatin and the sympathomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, cisplatin forms highly reactive, positively charged, platinum complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. This induces both intra- and inter-strand DNA cross-links. In addition, cisplatin forms DNA-Pt-protein cross-links. Cross-link formation results in both the induction of apoptosis and cell growth inhibition. Epinephrine, a potent vasoconstrictor, is added to the gel to both enhance the penetration of cisplatin into tumor tissue and reduce its dispersion into the surrounding tissues. Intratumoral injection of cisplatin-E therapeutic implant may increase local chemotherapeutic efficacy, as compared to the systemic administration of cisplatin, while reducing its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin-E Therapeutic Implant","termGroup":"PT","termSource":"NCI"},{"termName":"CDDP-e therapeutic implant","termGroup":"SY","termSource":"NCI"},{"termName":"CDDP/epi","termGroup":"SY","termSource":"NCI"},{"termName":"CDDP/epi gel","termGroup":"SY","termSource":"NCI"},{"termName":"CEG","termGroup":"AB","termSource":"NCI"},{"termName":"Cisplatin-Epinephrine","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatin/Epinephrine Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Intradose","termGroup":"SY","termSource":"NCI"},{"termName":"Intradose MPI-5010","termGroup":"SY","termSource":"NCI"},{"termName":"MP 5010 Therapeutic Implant","termGroup":"SY","termSource":"NCI"},{"termName":"MP 5010 TI","termGroup":"SY","termSource":"NCI"},{"termName":"MPI 5010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cisplatin-E_Therapeutic_Implant"},{"name":"Maps_To","value":"Cisplatin-E Therapeutic Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"42697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42697"},{"name":"PDQ_Open_Trial_Search_ID","value":"42697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677669"}]}}{"C136428":{"preferredName":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","code":"C136428","definitions":[{"definition":"A formulation composed of three agents in a fixed ratio: two chemotherapeutic agents, the platinum compound cisplatin and the vinca alkaloid vinblastine, and a proprietary amphiphilic excipient that acts as a penetration enhancer, with potential antineoplastic activity. Upon intra-tumoral (IT) injection of INT230-6, the dispersion/cell penetration enhancer excipient of INT230-6 facilitates dispersion of the two drugs throughout the tumor tissue and enables increased cellular uptake of these agents into tumor cells. Once inside the cell, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, which results in apoptosis and cell growth inhibition. Vinblastine kills the tumor cells through binding to tubulin and thereby inhibits microtubule formation, resulting in disruption of the mitotic spindle assembly and cell cycle arrest of tumor. In addition, the tumor cell killing leads to recruitment of dendritic cells (DCs) and induces a tumor-specific T-cell-mediated immune response that attacks both the injected tumor and distant tumor lesions. Local administration of both cisplatin and vinblastine, without the diffusion/penetration enhancer, results in to poor diffusion and a lack of cellular uptake of the agents; INT230-6 increases the intracellular concentration of cisplatin and vinblastine, thereby improving efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","termGroup":"PT","termSource":"NCI"},{"termName":"Cisplatin/Vinblastine Formulation with Cell Penetration Enhancer INT230-6","termGroup":"SY","termSource":"NCI"},{"termName":"INT 230-6","termGroup":"CN","termSource":"NCI"},{"termName":"INT230-6","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6"},{"name":"NCI_Drug_Dictionary_ID","value":"789458"},{"name":"NCI_META_CUI","value":"CL523731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789458"},{"name":"PDQ_Open_Trial_Search_ID","value":"789458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121641":{"preferredName":"Citarinostat","code":"C121641","definitions":[{"definition":"An orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, citarinostat inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Citarinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"5-Pyrimidinecarboxamide, 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"ACY-241","termGroup":"CN","termSource":"NCI"},{"termName":"CC-96241","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC-IN-2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor ACY-241","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1316215-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"441P620G3P"},{"name":"Maps_To","value":"Citarinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"770662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770662"},{"name":"PDQ_Open_Trial_Search_ID","value":"770662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053685"}]}}{"C71694":{"preferredName":"Citatuzumab Bogatox","code":"C71694","definitions":[{"definition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody Fab fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a modified bouganin cytotoxin with potential antineoplastic activity. Citatuzumab bogatox binds to EpCAM, delivering modified bouganin cytotoxin directly to EpCam-positive tumor cells, which may result in the inhibition of tumor cell protein synthesis and tumor cell death. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers. Bouganin is a plant-derived ribosome-inactivating protein (RIP), a toxic plant N-glycosidase that depurinates the universally conserved alpha-sarcin loop of ribosomal rRNA, inactivating the ribosome and preventing protein synthesis. Compared to unmodified bouganins, modified bouganins may have a reduced propensity to activate human T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Citatuzumab Bogatox","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EpCAM Antibody Fragment-Bouganin Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"VB6-845","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945228-49-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23J303Z5CA"},{"name":"Legacy Concept Name","value":"Anti-EpCAM-Bouganin_Fusion_Protein"},{"name":"Maps_To","value":"Citatuzumab Bogatox"},{"name":"NCI_Drug_Dictionary_ID","value":"555692"},{"name":"NCI_META_CUI","value":"CL376117"},{"name":"PDQ_Closed_Trial_Search_ID","value":"555692"},{"name":"PDQ_Open_Trial_Search_ID","value":"555692"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79828":{"preferredName":"Cixutumumab","code":"C79828","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It is a monoclonal antibody that is made in the laboratory and can bind to substances in the body. Cixutumumab blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cixutumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-A12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"947687-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2285XW22DR"},{"name":"Legacy Concept Name","value":"Cixutumumab"},{"name":"Maps_To","value":"Cixutumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"561575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561575"},{"name":"PDQ_Open_Trial_Search_ID","value":"561575"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703174"}]}}{"C102849":{"preferredName":"CK2-targeting Synthetic Peptide CIGB-300","code":"C102849","definitions":[{"definition":"A synthetic peptide targeting the substrates of casein kinase 2 (CK2), with potential antineoplastic activity. Upon administration and nucleolar localization, CK2-targeting synthetic peptide CIGB-300 binds to phosphoacceptor sites on the CK2 substrates, in particular the oncoprotein nucleophosmin (B23 or NPM1). This blocks the activation of B23 and induces apoptosis, thereby inhibiting tumor cell growth in susceptible tumor cells. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. Overexpression of B23 has been correlated with increased cellular growth and proliferation as well as inhibition of differentiation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CK2-targeting Synthetic Peptide CIGB-300","termGroup":"PT","termSource":"NCI"},{"termName":"CIGB-300","termGroup":"CN","termSource":"NCI"},{"termName":"CIGB-325","termGroup":"CN","termSource":"NCI"},{"termName":"P15-tat","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1072877-99-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X6HMT2EDH9"},{"name":"Maps_To","value":"CK2-targeting Synthetic Peptide CIGB-300"},{"name":"NCI_Drug_Dictionary_ID","value":"737263"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737263"},{"name":"PDQ_Open_Trial_Search_ID","value":"737263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2605865"}]}}{"C1052":{"preferredName":"CL 246738","code":"C1052","definitions":[{"definition":"An immunomodulator, 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride, used in a phase I study for possible immunostimulatory effects in colorectal cancer. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CL 246738","termGroup":"PT","termSource":"NCI"},{"termName":"3,6-bis-(2-piperidinoethoxyl)acridine trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CL 246,738","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CL_246738"},{"name":"Maps_To","value":"CL 246738"},{"name":"NCI_Drug_Dictionary_ID","value":"40443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40443"},{"name":"PDQ_Open_Trial_Search_ID","value":"40443"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055843"}]}}{"C1336":{"preferredName":"Cladribine","code":"C1336","definitions":[{"definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cladribine","termGroup":"PT","termSource":"NCI"},{"termName":"2-CdA","termGroup":"AB","termSource":"NCI"},{"termName":"2-Chloro-2-Deoxyadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Chlorodeoxyadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"2CDA","termGroup":"AB","termSource":"NCI"},{"termName":"CdA","termGroup":"AB","termSource":"NCI"},{"termName":"Cladribina","termGroup":"SY","termSource":"NCI"},{"termName":"Leustat","termGroup":"FB","termSource":"NCI"},{"termName":"Leustatin","termGroup":"BR","termSource":"NCI"},{"termName":"Leustatine","termGroup":"FB","termSource":"NCI"},{"termName":"RWJ-26251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute myeloid leukemia; Chronic lymphocytic leukemia; Cutaneous T-cell lymphoma; Hairy cell leukemia; Langerhans cell histiocytosis; Non-Hodgkins lymphoma; Waldenstroms macroglobulinemia"},{"name":"CAS_Registry","value":"4291-63-8"},{"name":"CHEBI_ID","value":"CHEBI:567361"},{"name":"Chemical_Formula","value":"C10H12ClN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"http://www.cancercare.on.ca/pdfdrugs/Cladribi.pdf"},{"name":"FDA_UNII_Code","value":"47M74X9YT5"},{"name":"Legacy Concept Name","value":"Cladribine"},{"name":"Maps_To","value":"Cladribine"},{"name":"NCI_Drug_Dictionary_ID","value":"41184"},{"name":"NSC Number","value":"105014"},{"name":"NSC Number","value":"105014-F"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41184"},{"name":"PDQ_Open_Trial_Search_ID","value":"41184"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0092801"}]}}{"C78082":{"preferredName":"Clanfenur","code":"C78082","definitions":[{"definition":"A substituted benzoylphenylurea and an analogue of the pesticide diflubenzuron with potential antineoplastic activity. Upon administration, clanfenur binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clanfenur","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51213-99-1"},{"name":"Chemical_Formula","value":"C16H15ClFN3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KAM54NKT1Q"},{"name":"Legacy Concept Name","value":"Clanfenur"},{"name":"Maps_To","value":"Clanfenur"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253858"}]}}{"C1054":{"preferredName":"Clarithromycin","code":"C1054","definitions":[{"definition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An antibiotic drug used to treat infection. It belongs to the family of drugs called macrolides.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clarithromycin","termGroup":"PT","termSource":"NCI"},{"termName":"6-O-Methylerythromycin","termGroup":"SN","termSource":"NCI"},{"termName":"Abbott-56268","termGroup":"SY","termSource":"NCI"},{"termName":"Biaxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"H. pylori infection; Various bacterial infections"},{"name":"CAS_Registry","value":"81103-11-9"},{"name":"CHEBI_ID","value":"CHEBI:3732"},{"name":"Chemical_Formula","value":"C38H69NO13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"H1250JIK0A"},{"name":"Legacy Concept Name","value":"Clarithromycin"},{"name":"Maps_To","value":"Clarithromycin"},{"name":"NCI_Drug_Dictionary_ID","value":"42308"},{"name":"NSC Number","value":"643733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42308"},{"name":"PDQ_Open_Trial_Search_ID","value":"42308"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055856"}]}}{"C160606":{"preferredName":"Bocodepsin Besylate","code":"C160606","definitions":[{"definition":"The besylate form of bocodepsin, an orally bioavailable inhibitor of the histone deacetylase (HDAC) subtypes 1 and 4, with potential antineoplastic activity. Upon administration,bocodepsin targets, binds to and inhibits the activity of HDAC1/4. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This consequently results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC1/4. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins and plays a key role in transcriptional regulation and cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bocodepsin Besylate","termGroup":"PT","termSource":"NCI"},{"termName":"Class 1/4 Histone Deacetylase Inhibitor OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"Class-1/4 HDACi OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDAC Inhibitor OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDAC1/4i OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDACi 1/4 OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDACi OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"OKI 179","termGroup":"CN","termSource":"NCI"},{"termName":"OKI-179","termGroup":"CN","termSource":"NCI"},{"termName":"OKI179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1834513-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LVM50TS2UO"},{"name":"Maps_To","value":"Class 1/4 Histone Deacetylase Inhibitor OKI-179"},{"name":"NCI_Drug_Dictionary_ID","value":"801634"},{"name":"NCI_META_CUI","value":"CL969661"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801634"},{"name":"PDQ_Open_Trial_Search_ID","value":"801634"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71104":{"preferredName":"Clinical Trial","code":"C71104","definitions":[{"definition":"A research investigation involving human subjects that is designed to answer specific questions about the safety and efficacy of a biomedical intervention (drug, treatment, device) or new ways of using a known drug, treatment, or device). NOTE: NIH Office of Science Policy further specifies that a clinical trial is a type of research study that prospectively assigns subjects to interventions, and the EU clinical trial regulations set forth 3 specific conditions, any one of which qualifies a study as a clinical trial. These conditions include applying diagnostic or monitoring procedures not used in normal clinical practice to subjects. [After ICH E6 [R2], EU CTR 2014] (CDISC Glossary)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A research investigation involving human subjects that is designed to answer specific questions about the safety and efficacy of a biomedical intervention (drug, treatment, device) or new ways of using a known drug, treatment, or device). NOTE: NIH Office of Science Policy further specifies that a clinical trial is a type of research study that prospectively assigns subjects to interventions, and the EU clinical trial regulations set forth 3 specific conditions, any one of which qualifies a study as a clinical trial. These conditions include applying diagnostic or monitoring procedures not used in normal clinical practice to subjects. [After ICH E6 [R2], EU CTR 2014] See also clinical study, clinical investigation, randomized controlled trial (RCT).","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"A research investigation involving human subjects that is designed to answer specific questions about the safety and efficacy of a biomedical intervention (drug, treatment, device) or new ways of using a known drug, treatment, or device). NOTE: NIH Office of Science Policy further specifies that a clinical trial is a type of research study that prospectively assigns subjects to interventions. The EU clinical trial regulations include applying diagnostic or monitoring procedures not used in normal clinical practice to subjects in its criterion. [after ICH E6 [R2]; EU CTR 2014] See also clinical study, clinical investigation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.","type":"DEFINITION","source":"NCI"},{"definition":"A research study that tests drugs, devices and treatments to see if they are safe and work in people. (https://mrctcenter.org/glossaryterm/clinical-trial/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Clinical Trial","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical Trials","termGroup":"SY","termSource":"NCI"},{"termName":"Clinical Trials, Unspecified","termGroup":"SY","termSource":"NCI"},{"termName":"Trial","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Clinical_Trial_Generic"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C0008976"}]}}{"C90373":{"preferredName":"Clinical Trial Agent","code":"C90373","definitions":[{"definition":"The pharmacological substance that is being administered in the study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical Trial Agent","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical Trial-Study Agent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clinical Trial"},{"name":"Maps_To","value":"Clinical Trial Agent"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C2983596"}]}}{"C65337":{"preferredName":"Clioquinol","code":"C65337","definitions":[{"definition":"An orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. Clioquinol forms a stable chelate with copper (copper (II) ions), which inhibits the chymotrypsin-like activity of the proteasome; consequently, ubiquitinated proteins may accumulate in tumor cells, followed by tumor cell apoptosis and the inhibition of tumor angiogenesis. In addition, the clioquinol-copper complex appears to decrease the expression of androgen receptors (AR) in human copper-enriched prostate cancer cells. Serum levels of copper are often elevated in patients with cancer; copper chelation may inhibit copper-dependent endothelial cell proliferation and tumor secretion of angiogenic factors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clioquinol","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-7-iodo-8-hydroxyquinoline","termGroup":"SN","termSource":"NCI"},{"termName":"5-Chloro-7-iodo-quinolin-8-ol","termGroup":"SN","termSource":"NCI"},{"termName":"AI3-16451","termGroup":"CN","termSource":"NCI"},{"termName":"Iodochlorohydroxyquinoline","termGroup":"SY","termSource":"NCI"},{"termName":"Mycoquin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130-26-7"},{"name":"Chemical_Formula","value":"C9H5ClINO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BHQ856EJ5"},{"name":"Legacy Concept Name","value":"Clioquinol"},{"name":"Maps_To","value":"Clioquinol"},{"name":"NCI_Drug_Dictionary_ID","value":"653982"},{"name":"NSC Number","value":"3531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653982"},{"name":"PDQ_Open_Trial_Search_ID","value":"653982"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021978"}]}}{"C88638":{"preferredName":"Clivatuzumab","code":"C88638","definitions":[{"definition":"A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1, with potential antineoplastic activity. Clivatuzumab binds to tumor cells expressing the MUC1 antigen and prevents MUC1-mediated signaling. MUC1, a mucin antigen, is overexpressed in pancreatic cancer but not in normal, healthy pancreatic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clivatuzumab","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622075-09-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RGU8A332UL"},{"name":"Maps_To","value":"Clivatuzumab"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2982120"}]}}{"C1418":{"preferredName":"Clodronate Disodium","code":"C1418","definitions":[{"definition":"A drug used as treatment for hypercalcemia (abnormally high levels of calcium in the blood) and for cancer that has spread to the bone (bone metastases). It may decrease pain, the risk of fractures, and the development of new bone metastases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clodronate Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Bonefos","termGroup":"FB","termSource":"NCI"},{"termName":"CL2MDP","termGroup":"CN","termSource":"NCI"},{"termName":"Clasteon","termGroup":"FB","termSource":"NCI"},{"termName":"Clodronate","termGroup":"SY","termSource":"NCI"},{"termName":"Clodronic Acid Disodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Dichloromethylene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Difosfonal","termGroup":"FB","termSource":"NCI"},{"termName":"Loron","termGroup":"FB","termSource":"NCI"},{"termName":"Mebonat","termGroup":"FB","termSource":"NCI"},{"termName":"Ossiten","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adjuvant usage in bone metastasis of Breast cancer"},{"name":"CAS_Registry","value":"88416-50-6"},{"name":"CHEBI_ID","value":"CHEBI:59587"},{"name":"Chemical_Formula","value":"CH2Cl2O6P2.2Na.4H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N030400H8J"},{"name":"Legacy Concept Name","value":"Clodronate_Disodium"},{"name":"Maps_To","value":"Clodronate Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"41862"},{"name":"NSC Number","value":"713466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41862"},{"name":"PDQ_Open_Trial_Search_ID","value":"41862"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008994"}]}}{"C61685":{"preferredName":"Clodronic Acid","code":"C61685","definitions":[{"definition":"A first-generation bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Clodronic acid adsorbs onto the surface of the hydroxyapatite crystals in bone matrix. Although the exact mechanism through which clodronic acid exerts its cytotoxic effect on osteoclasts has yet to be fully elucidated, this agent is metabolized intracellularly to a toxic beta-gamma-methylene analog of adenosine triphosphate (ATP), AppCCl2p. The ATP analog AppCCl2p competitively inhibits ADP/ATP translocase, thereby interfering with mitochondrial membrane potential and cellular energy metabolism. This may cause osteoclast apoptosis and, eventually, inhibiting osteoclast-mediated bone resorption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clodronic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(Dichloromethylene)bisphosphonic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Clodronate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10596-23-3"},{"name":"CHEBI_ID","value":"CHEBI:110423"},{"name":"Chemical_Formula","value":"CH4Cl2O6P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0813BZ6866"},{"name":"Legacy Concept Name","value":"Clodronic_Acid"},{"name":"Maps_To","value":"Clodronic Acid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012081"}]}}{"C26638":{"preferredName":"Clofarabine","code":"C26638","definitions":[{"definition":"A drug used to treat certain types of acute lymphoblastic leukemia in children. It is also being studied in the treatment of other types of cancer. Clolar is a type of nucleoside analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clofarabine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine","termGroup":"SN","termSource":"NCI"},{"termName":"Clofarex","termGroup":"FB","termSource":"NCI"},{"termName":"Clolar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphoblastic leukemia, pediatric"},{"name":"CAS_Registry","value":"123318-82-1"},{"name":"CHEBI_ID","value":"CHEBI:47311"},{"name":"CHEBI_ID","value":"CHEBI:681569"},{"name":"Chemical_Formula","value":"C10H11ClFN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"762RDY0Y2H"},{"name":"Legacy Concept Name","value":"Clofarabine"},{"name":"Maps_To","value":"Clofarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"257309"},{"name":"NSC Number","value":"606869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257309"},{"name":"PDQ_Open_Trial_Search_ID","value":"257309"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0092777"}]}}{"C28888":{"preferredName":"Clomesone","code":"C28888","definitions":[{"definition":"The 2-chloroethyl ester of (methylsulfonyl) methanesulfonic acid with potential antineoplastic effects.  Acting as a chloroethylating agent, clomesone induces the formation of DNA interstrand crosslinks in some cell lines, and exhibits antitumor activity in some animal models.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clomesone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloroethyl (methylsulfonyl)methanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Chlorethyl SOSO","termGroup":"SY","termSource":"NCI"},{"termName":"SRI 6155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88343-72-0"},{"name":"Chemical_Formula","value":"C4H9ClO5S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2J031W0YZI"},{"name":"Legacy Concept Name","value":"Clomesone"},{"name":"Maps_To","value":"Clomesone"},{"name":"NSC Number","value":"338947"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055920"}]}}{"C61607":{"preferredName":"Clomiphene","code":"C61607","definitions":[{"definition":"A triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer.  Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clomiphene","termGroup":"PT","termSource":"NCI"},{"termName":"2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911-45-5"},{"name":"CHEBI_ID","value":"CHEBI:3752"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1HRS458QU2"},{"name":"Legacy Concept Name","value":"Clomiphene_Base"},{"name":"Maps_To","value":"Clomiphene"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0009008"}]}}{"C379":{"preferredName":"Clomiphene Citrate","code":"C379","definitions":[{"definition":"The citrate salt form of clomiphene, a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clomiphene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine Citrate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Clomid","termGroup":"BR","termSource":"NCI"},{"termName":"Serophene","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-41-9"},{"name":"CHEBI_ID","value":"CHEBI:3753"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1B8447E7YI"},{"name":"Legacy Concept Name","value":"Clomiphene"},{"name":"Maps_To","value":"Clomiphene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"39542"},{"name":"NSC Number","value":"35770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39542"},{"name":"PDQ_Open_Trial_Search_ID","value":"39542"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546859"}]}}{"C62762":{"preferredName":"Clostridium Novyi-NT Spores","code":"C62762","definitions":[{"definition":"Spores of the bacterial strain Clostridium novyi-NT, the attenuated obligate anaerobic C. novyi, with potential immunostimulating, bacteriolytic, and antineoplastic activities. Upon intravenous administration, Clostridium novyi-NT spores germinate exclusively in hypoxic tissue, such as avascular regions of tumors. Germination results in lysis and destruction of surrounding viable tumor cells. Due to their anaerobic nature, C. novyi-NT spores do not proliferate in oxygenated tumor regions. However, this agent may stimulate the immune system to exert a cellular immune response, resulting in additional killing of tumor cells not lysed by the bacteria, including those in the well-oxygenated tumor area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clostridium Novyi-NT Spores","termGroup":"PT","termSource":"NCI"},{"termName":"C. novyi-NT Spores","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clostridium_Novyi-NT_Spores"},{"name":"Maps_To","value":"Clostridium Novyi-NT Spores"},{"name":"NCI_Drug_Dictionary_ID","value":"502157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"502157"},{"name":"PDQ_Open_Trial_Search_ID","value":"502157"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831945"}]}}{"C68923":{"preferredName":"Cobimetinib","code":"C68923","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cobimetinib","termGroup":"PT","termSource":"NCI"},{"termName":"Cotellic","termGroup":"BR","termSource":"NCI"},{"termName":"GDC-0973","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor GDC-0973","termGroup":"SY","termSource":"NCI"},{"termName":"XL518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable or metastatic melanoma with BRAF V600E or V600K mutation"},{"name":"CAS_Registry","value":"934660-93-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ER29L26N1X"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_XL518"},{"name":"Maps_To","value":"Cobimetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"551654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551654"},{"name":"PDQ_Open_Trial_Search_ID","value":"551654"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346910"}]}}{"C124225":{"preferredName":"Cobomarsen","code":"C124225","definitions":[{"definition":"A locked nucleic acid (LNA)-based oligonucleotide inhibitor of microRNA (miRNA) 155 (miR-155), with potential antineoplastic activity. Upon administration, cobomarsen targets, binds to and inhibits miR-155. This silences miR-155 and prevents the translation of certain tumor promoting genes, which leads to the induction of cancer cell apoptosis and the inhibition of tumor cell growth. miR-155, an oncogenic single-stranded, non-coding RNA that is critical to the regulation of gene expression, is overexpressed in certain tumor cell types. Up-regulation of miR-155 plays a key role in increased tumor cell proliferation and survival. The LNA is an RNA analog in which the ribose ring is locked in a particular confirmation that increases stability. Compared to the unmodified oligonucleotide, the LNA-modified oligonucleotide shows increased affinity for its target miR-155.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cobomarsen","termGroup":"PT","termSource":"NCI"},{"termName":"MRG-106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1848257-52-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3JKW7CI9IU"},{"name":"Maps_To","value":"Cobomarsen"},{"name":"NCI_Drug_Dictionary_ID","value":"776775"},{"name":"NCI_META_CUI","value":"CL502605"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776775"},{"name":"PDQ_Open_Trial_Search_ID","value":"776775"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80043":{"preferredName":"Codrituzumab","code":"C80043","definitions":[{"definition":"A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Codrituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Glypican 3 Monoclonal Antibody GC33","termGroup":"SY","termSource":"NCI"},{"termName":"GC-33","termGroup":"CN","termSource":"NCI"},{"termName":"GC33","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7686","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5137382","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5137382","termGroup":"CN","termSource":"NCI"},{"termName":"RO5137382","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1365267-33-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U9I0PLD4HT"},{"name":"Legacy Concept Name","value":"Codrituzumab"},{"name":"Maps_To","value":"Codrituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"614683"},{"name":"NCI_META_CUI","value":"CL388379"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614683"},{"name":"PDQ_Open_Trial_Search_ID","value":"614683"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C916":{"preferredName":"Coenzyme Q10","code":"C916","definitions":[{"definition":"A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme Q10 functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme Q10 may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient that the body needs in small amounts to function and stay healthy. Coenzyme Q10 helps mitochondria (small structures in the cell) make energy. It is an antioxidant that helps prevent cell damage caused by free radicals (highly reactive chemicals). Coenzyme Q10 is fat-soluble (can dissolve in fats and oils) and is found in fatty fish, beef, soybeans, peanuts, and spinach. It is being studied in the prevention and treatment of some types of cancer and heart disease and in the relief of side effects caused by some cancer treatments.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Coenzyme Q10","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecanyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Co-Q10","termGroup":"AB","termSource":"NCI"},{"termName":"Ubidecarenone","termGroup":"SY","termSource":"NCI"},{"termName":"Ubiquinone 10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic heart failure; mitochondrial cytopathies"},{"name":"CAS_Registry","value":"303-98-0"},{"name":"CHEBI_ID","value":"CHEBI:46245"},{"name":"Chemical_Formula","value":"C59H90O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EJ27X76M46"},{"name":"Legacy Concept Name","value":"Coenzyme-Q"},{"name":"Maps_To","value":"Coenzyme Q10"},{"name":"NCI_Drug_Dictionary_ID","value":"39187"},{"name":"NSC Number","value":"140865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39187"},{"name":"PDQ_Open_Trial_Search_ID","value":"39187"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056077"}]}}{"C2679":{"preferredName":"Colchicine-Site Binding Agent ABT-751","code":"C2679","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called sulfonamides.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable antimitotic sulfonamide. ABT- 751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colchicine-Site Binding Agent ABT-751","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-751","termGroup":"CN","termSource":"NCI"},{"termName":"E 7010","termGroup":"CN","termSource":"NCI"},{"termName":"E-7010","termGroup":"CN","termSource":"NCI"},{"termName":"E7010","termGroup":"CN","termSource":"NCI"},{"termName":"N-[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"141430-65-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WDT5V5OB9F"},{"name":"Legacy Concept Name","value":"ABT-751"},{"name":"Maps_To","value":"Colchicine-Site Binding Agent ABT-751"},{"name":"NCI_Drug_Dictionary_ID","value":"38646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38646"},{"name":"PDQ_Open_Trial_Search_ID","value":"38646"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134654"}]}}{"C82344":{"preferredName":"Cold Contaminant-free Iobenguane I-131","code":"C82344","definitions":[{"definition":"An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine, manufactured with a proprietary process, with radioisotopic and potential antineoplastic activities. Cold contaminant-free iobenguane I 131 (MIBG) localizes to adrenergic tissue and may be used to image or eradicate tumor cells that accumulate and metabolize norepinephrine. This agent is manufactured using a technology that avoids the production of unwanted \"cold contaminants\" (i.e., carrier molecules), which may cause undesirable side effects and compete with MIBG for binding on target receptor sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cold Contaminant-free Iobenguane I-131","termGroup":"PT","termSource":"NCI"},{"termName":"Azedra","termGroup":"BR","termSource":"NCI"},{"termName":"Cold Contaminant-free I 131-MIBG","termGroup":"SY","termSource":"NCI"},{"termName":"Cold Contaminant-free Iobenguane I 131","termGroup":"SY","termSource":"NCI"},{"termName":"Ultratrace Iodine I 131 Metaiodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"Ultratrace MIBG","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL)"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cold_Contaminant-free_Iobenguane_I_131"},{"name":"Maps_To","value":"Cold Contaminant-free Iobenguane I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"629499"},{"name":"NCI_META_CUI","value":"CL388440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629499"},{"name":"PDQ_Open_Trial_Search_ID","value":"629499"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62538":{"preferredName":"Colloidal Gold-Bound Tumor Necrosis Factor","code":"C62538","definitions":[{"definition":"A nanoparticle delivery system for recombinant human tumor necrosis factor (TNF) consisting of recombinant TNF bound to pegylated colloidal gold nanoparticles with potential antineoplastic activity. Upon intravenous administration, colloidal gold-bound recombinant human TNF travels through the bloodstream, avoiding immune detection and uptake by the reticuloendothelial system because of nanoparticle pegylation. Due to their size, the colloidal gold nanoparticles exit the circulatory system only at hyperpermeable tumor neovasculature sites; TNF then binds to and activates tumor cell TNF receptors, which may result in an increase in tumor cell apoptosis and a reduction in tumor cell proliferation. Compared to the administration of unbound TNF, colloidal gold-bound TNF may improve the efficacy and safety of TNF administration by delivering TNF specifically to tumor tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. Aurimmune is made in the laboratory by binding a cancer-killing protein called tumor necrosis factor (TNF) to the surface of very tiny particles of gold. These TNF-gold particles may kill cancer cells without harming healthy tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colloidal Gold-Bound Tumor Necrosis Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Aurimmune","termGroup":"BR","termSource":"NCI"},{"termName":"Colloidal Gold-Bound Recombinant Human Tumor Necrosis Factor","termGroup":"SY","termSource":"NCI"},{"termName":"colloidal gold-bound rhTNF","termGroup":"SY","termSource":"NCI"},{"termName":"colloidal gold-bound TNF","termGroup":"SY","termSource":"NCI"},{"termName":"CYT-6091","termGroup":"CN","termSource":"NCI"},{"termName":"TNF-bound colloidal gold","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colloidal_Gold-Bound_Tumor_Necrosis_Factor"},{"name":"Maps_To","value":"Colloidal Gold-Bound Tumor Necrosis Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"492715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492715"},{"name":"PDQ_Open_Trial_Search_ID","value":"492715"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831911"}]}}{"C154278":{"preferredName":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","code":"C154278","definitions":[{"definition":"A peptide cancer vaccine consisting of a combination of six synthetic polypeptides directed against cancer testis antigens (CTAs) frequently expressed in colorectal cancers, with potential antineoplastic and immunostimulatory activities. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","termGroup":"PT","termSource":"NCI"},{"termName":"PolyPEPI 1018","termGroup":"CN","termSource":"NCI"},{"termName":"PolyPEPI-1018","termGroup":"CN","termSource":"NCI"},{"termName":"PolyPEPI1018","termGroup":"CN","termSource":"NCI"},{"termName":"PolyPEPI1018 CRC Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"PolyPEPI1018 CRC Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colorectal Cancer Peptide Vaccine PolyPEPI1018"},{"name":"NCI_Drug_Dictionary_ID","value":"794166"},{"name":"NCI_META_CUI","value":"CL555275"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794166"},{"name":"PDQ_Open_Trial_Search_ID","value":"794166"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79806":{"preferredName":"Colorectal Tumor-Associated Peptides Vaccine IMA910","code":"C79806","definitions":[{"definition":"A synthetic tumor-associated peptide (TUMAP)-based cancer vaccine directed against colorectal cancer with potential immunostimulatory and antineoplastic activities. Synthetic colorectal tumor-associated peptides vaccine IMA910 contains 13 different synthetic TUMAPs, each of which represents a tumor associated antigen (TAA) specific for colorectal cancer. Upon administration, this agent may elicit a cytotoxic T-lymphocyte (CTL) response against colorectal tumors expressing these TAAs, which may result in a reduction in colorectal tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colorectal Tumor-Associated Peptides Vaccine IMA910","termGroup":"PT","termSource":"NCI"},{"termName":"IMA910","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colorectal_Tumor-Associated_Peptides_Vaccine_IMA910"},{"name":"Maps_To","value":"Colorectal Tumor-Associated Peptides Vaccine IMA910"},{"name":"NCI_Drug_Dictionary_ID","value":"626093"},{"name":"NCI_META_CUI","value":"CL388427"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626093"},{"name":"PDQ_Open_Trial_Search_ID","value":"626093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80014":{"preferredName":"Combretastatin","code":"C80014","definitions":[{"definition":"A stilbenoid phenol, originally isolated from the bark of the African bush willow tree Combretum caffrum, with vascular disrupting and antineoplastic activities. Combretastatin targets and binds to the colchicine-binding site of tubulin, thereby impairs the polymerization of tubulin dimers and prevents the formation of microtubules in the endothelial cells of tumor. As a result, this may eventually lead to a destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combretastatin","termGroup":"PT","termSource":"NCI"},{"termName":"3-Hydroxy-4-methoxy-alpha-(3,4,5-trimethoxyphenyl)benzeneethanol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"82855-09-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7O62J06F18"},{"name":"Legacy Concept Name","value":"Combretastatin"},{"name":"Maps_To","value":"Combretastatin"},{"name":"NSC Number","value":"348103"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056152"}]}}{"C162344":{"preferredName":"Combretastatin A-1","code":"C162344","definitions":[{"definition":"A stilbenoid originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 (CA1) promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis; destruction of the tumor vasculature; disruption of tumor blood flow; and tumor cell necrosis. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combretastatin A-1","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Benzenediol, 3-Methoxy-6-(2-(3,4,5-trimethoxyphenyl)ethenyl)-, (Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"CA1","termGroup":"AB","termSource":"NCI"},{"termName":"Combretastatin A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"109971-63-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2222ATS339"},{"name":"Maps_To","value":"Combretastatin A-1"},{"name":"NCI_META_CUI","value":"CL970855"},{"name":"NSC Number","value":"600032"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84867":{"preferredName":"Combretastatin A1 Diphosphate","code":"C84867","definitions":[{"definition":"The diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 diphosphate (CA1P) is dephosphorylated to the active metabolite combretastatin A1 (CA1), which promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis, destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis may ensue. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production. CA1 binds to tubulin at the same site as colchicine but with higher affinity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combretastatin A1 Diphosphate","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, 1,2-bis(dihydrogen Phosphate)","termGroup":"SN","termSource":"NCI"},{"termName":"CA1P","termGroup":"SY","termSource":"NCI"},{"termName":"Combretastatin A-1 bis(phosphate)","termGroup":"SY","termSource":"NCI"},{"termName":"OXI 4503","termGroup":"CN","termSource":"NCI"},{"termName":"OXi4503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"288847-35-8"},{"name":"Chemical_Formula","value":"C18H22O12P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JH6Z94GLUD"},{"name":"Maps_To","value":"Combretastatin A1 Diphosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"653978"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653978"},{"name":"PDQ_Open_Trial_Search_ID","value":"653978"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1143252"}]}}{"C120314":{"preferredName":"Compound Kushen Injection","code":"C120314","definitions":[{"definition":"A traditional Chinese medicine (TCM) formulation composed of compound Kushen injection (CKI) containing aqueous extracts from the roots of Kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma smilacis Glabrae), with potential antineoplastic and immunomodulating activities. CKI contains numerous chemicals including alkaloids, such as matrine and oxymatrine, flavonoids, alkylxanthones, quinones, triterpene glycosides, fatty acids, and essential oils. Although the exact mechanism(s) of action through which CKI exerts its effects has yet to be fully elucidated, CKI is able to interfere with the activation of various signal transduction pathways, such as the Wnt/beta-catenin signaling pathway, inhibit nuclear factor-kappa B (NF-KB) activation, and block the activity of multiple receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). CKI induces apoptosis in and inhibits proliferation, migration, invasion and adhesion of tumor cells. CKI also modulates the production of inflammatory mediators.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Compound Kushen Injection","termGroup":"PT","termSource":"NCI"},{"termName":"CKI","termGroup":"AB","termSource":"NCI"},{"termName":"Yanshu Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Compound Kushen Injection"},{"name":"NCI_Drug_Dictionary_ID","value":"768804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768804"},{"name":"PDQ_Open_Trial_Search_ID","value":"768804"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3890596"}]}}{"C71015":{"preferredName":"Conatumumab","code":"C71015","definitions":[{"definition":"A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 655","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-TRAIL Receptor 2 Monoclonal Antibody AMG 655","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Receptor Superfamily Member 10b (Death Receptor 5, Trail-R2, CD262 Antigen))","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))Gamma-1 Heavy Chain (225-215')-Disulphide With Kappa Light Chain (231-231'':234-234'')-Bisdisulphide Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"896731-82-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1P48L61KM0"},{"name":"Legacy Concept Name","value":"Anti-TRAIL_Receptor_2_Monoclonal_Antibody_AMG_655"},{"name":"Maps_To","value":"Conatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"573083"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573083"},{"name":"PDQ_Open_Trial_Search_ID","value":"573083"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346822"}]}}{"C162879":{"preferredName":"Conbercept","code":"C162879","definitions":[{"definition":"A recombinant, soluble, vascular endothelial growth factor receptor (VEGFR) protein composed of the second immunoglobulin (Ig) domain of VEGFR-1, the third and fourth Ig domains of VEGFR-2, and the constant region (Fc) of human immunoglobulin G1 (IgG1) with potential anti-angiogenic activities. Upon intravitreal injection, conbercept, functioning as a soluble decoy receptor, binds with high affinity to all VEGF-A isoforms, VEGF-B, as well as placenta growth factor (PlGF)-1 and PlGF-2. This prevents the binding of these growth factors to their endogenous receptors, potentially inhibiting angiogenesis and tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conbercept","termGroup":"PT","termSource":"NCI"},{"termName":"FP 3","termGroup":"CN","termSource":"NCI"},{"termName":"FP-3","termGroup":"CN","termSource":"NCI"},{"termName":"FP3","termGroup":"CN","termSource":"NCI"},{"termName":"KH 902","termGroup":"CN","termSource":"NCI"},{"termName":"KH 903","termGroup":"CN","termSource":"NCI"},{"termName":"KH-902","termGroup":"CN","termSource":"NCI"},{"termName":"KH-903","termGroup":"CN","termSource":"NCI"},{"termName":"KH902","termGroup":"CN","termSource":"NCI"},{"termName":"KH903","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227158-72-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1P05PW62F3"},{"name":"Maps_To","value":"Conbercept"},{"name":"NCI_Drug_Dictionary_ID","value":"798956"},{"name":"NCI_META_CUI","value":"CL973317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798956"},{"name":"PDQ_Open_Trial_Search_ID","value":"798956"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165273":{"preferredName":"Concentrated Lingzhi Mushroom Extract","code":"C165273","definitions":[{"definition":"A nutritional supplement and traditional Chinese medicine (TCM) composed of a highly concentrated extract of the fruiting body of the red reishi mushroom Ganoderma lucidum  (G. lucidum; lingzhi), with potential immunomodulating activities. Upon administration, the concentrated lingzhi mushroom extract may support the body's immune function and may support the immune system to eliminate tumor cells. The lingzhi mushroom extract contains high amounts of G. lucidum polysaccharides and G. lucidum triterpenoids (GLTs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Concentrated Lingzhi Mushroom Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Concentrated Ganoderma lucidum Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Concentrated Red Reishi Mushroom Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Mikei Red Reishi Essence EX","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Concentrated Lingzhi Mushroom Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"799459"},{"name":"NCI_META_CUI","value":"CL978540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799459"},{"name":"PDQ_Open_Trial_Search_ID","value":"799459"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156141":{"preferredName":"Mecbotamab Vedotin","code":"C156141","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a conditionally active biologic (CAB) antibody against AXL receptor tyrosine kinase (AXL; UFO) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of mecbotamab vedotin, the anti-AXL antibody becomes activated through an as of yet not fully elucidated process only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells, and not in the microenvironment of normal, healthy tissues. Upon selective binding to AXL-expressing tumor cells and internalization, the cytotoxic agent kills the tumor cells through an as of yet undisclosed mechanism of action (MoA). AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases normally expressed on many normal, healthy cells and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis. The CAB antibody allows for efficient and reversible binding to AXL-expressing tumor cells under conditions that are present only in the TME, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy AXL-expressing cells under normal conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mecbotamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BA3011","termGroup":"SY","termSource":"NCI"},{"termName":"BA 3011","termGroup":"CN","termSource":"NCI"},{"termName":"BA-3011","termGroup":"CN","termSource":"NCI"},{"termName":"BA3011","termGroup":"CN","termSource":"NCI"},{"termName":"CAB Anti-AXL ADC BA3011","termGroup":"SY","termSource":"NCI"},{"termName":"CAB-AXL-ADC BA3011","termGroup":"SY","termSource":"NCI"},{"termName":"Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460400-64-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VF40YVX65F"},{"name":"Maps_To","value":"Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011"},{"name":"NCI_Drug_Dictionary_ID","value":"795303"},{"name":"NCI_META_CUI","value":"CL562853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795303"},{"name":"PDQ_Open_Trial_Search_ID","value":"795303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96796":{"preferredName":"Copanlisib","code":"C96796","definitions":[{"definition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copanlisib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 80-6946","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor BAY 80-6946","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032568-63-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WI6V529FZ9"},{"name":"Maps_To","value":"Copanlisib"},{"name":"NCI_Drug_Dictionary_ID","value":"653981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653981"},{"name":"PDQ_Open_Trial_Search_ID","value":"653981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852004"}]}}{"C138994":{"preferredName":"Copanlisib Hydrochloride","code":"C138994","definitions":[{"definition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copanlisib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)","termGroup":"SY","termSource":"NCI"},{"termName":"Aliqopa","termGroup":"BR","termSource":"NCI"},{"termName":"BAY 80-6946 Dihydrochloride","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-80-6946 Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Copanlisib Dihydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402152-13-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"03ZI7RZ52O"},{"name":"Maps_To","value":"Copanlisib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"653981"},{"name":"NCI_META_CUI","value":"CL526449"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653981"},{"name":"PDQ_Open_Trial_Search_ID","value":"653981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79824":{"preferredName":"Copper Cu 64-ATSM","code":"C79824","definitions":[{"definition":"A radioconjugate consisting of a lipophilic copper(II)bis(thiosemicarbazone) labeled with the positron- and beta-emitting isotope (64)Cu with hypoxia-selective and antineoplastic activities. With a high membrane permeability and redox potential, copper Cu 64-ATSM is preferentially taken up by hypoxic cells compared to normoxic cells; the extent of retention in tissue is inversely related to the state of tissue oxygenation allowing the quantitation of tissue hypoxia by positron emission tomography (PET). In addition, the radioactive copper moiety of this agent may deliver a selective cytotoxic dose of beta radiation to hypoxic tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in PET imaging to detect certain types of tumors. Copper Cu 64 is a radioactive substance. It is linked to ATSM, which is taken up by tissues that have low levels of oxygen, such as some tumor tissues. A PET scanner is used to detect which cells in the body have taken up copper Cu 64-ATSM. It is a type of radioimaging agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Copper Cu 64-ATSM","termGroup":"PT","termSource":"NCI"},{"termName":"(64)Cu-ATSM","termGroup":"SY","termSource":"NCI"},{"termName":"Copper-64-diacetyl-bis(N4-methylthiosemicarbazone)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Copper_Cu_64-ATSM"},{"name":"Maps_To","value":"Copper Cu 64-ATSM"},{"name":"NCI_Drug_Dictionary_ID","value":"626166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626166"},{"name":"PDQ_Open_Trial_Search_ID","value":"626166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1828021"}]}}{"C80050":{"preferredName":"Copper Gluconate","code":"C80050","definitions":[{"definition":"The orally bioavailable copper salt of D-gluconic acid. In addition to its roles as an enzyme cofactor for cytochrome C oxidase and superoxide dismutase, copper forms complexes with the thiocarbamate disulfiram (DSF) forming DSF-copper complexes, which enhances the DSF-mediated inhibition of the 26S proteasome; proteasome inhibition may result in inhibition of cellular protein degradation, cessation of cell cycle progression, inhibition of cellular proliferation, and the induction of apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copper Gluconate","termGroup":"PT","termSource":"NCI"},{"termName":"Cupric Gluconate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"527-09-3"},{"name":"Chemical_Formula","value":"2C6H11O7.Cu"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RV823G6G67"},{"name":"Legacy Concept Name","value":"Copper_Gluconate"},{"name":"Maps_To","value":"Copper Gluconate"},{"name":"NCI_Drug_Dictionary_ID","value":"614606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614606"},{"name":"PDQ_Open_Trial_Search_ID","value":"614606"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0982097"}]}}{"C128560":{"preferredName":"Cord Blood-derived Expanded Natural Killer Cells PNK-007","code":"C128560","definitions":[{"definition":"A population of allogeneic lytic natural killer (NK) cells derived from human umbilical cord blood (UCB), with potential cytotoxic activity. Hematopoietic stem cells (HSC) are isolated from human UCB; this is followed by ex vivo differentiation into mature, highly lytic, NK cells, and expansion. Upon administration, the CB-derived expanded NK cells PNK-007 may lyse cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cord Blood-derived Expanded Natural Killer Cells PNK-007","termGroup":"PT","termSource":"NCI"},{"termName":"Cord Blood-derived Expanded NK Cells PNK-007","termGroup":"SY","termSource":"NCI"},{"termName":"Human CB-derived Natural Killer Cells PNK-007","termGroup":"SY","termSource":"NCI"},{"termName":"PNK 007","termGroup":"CN","termSource":"NCI"},{"termName":"PNK-007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cord Blood-derived Expanded Natural Killer Cells PNK-007"},{"name":"NCI_Drug_Dictionary_ID","value":"782352"},{"name":"NCI_META_CUI","value":"CL509621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782352"},{"name":"PDQ_Open_Trial_Search_ID","value":"782352"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1057":{"preferredName":"Cordycepin","code":"C1057","definitions":[{"definition":"A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to a family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cordycepin","termGroup":"PT","termSource":"NCI"},{"termName":"3'-dA-CE Phosphoramidite","termGroup":"SN","termSource":"NCI"},{"termName":"3'-Deoxyadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"3-dAdenosine","termGroup":"SN","termSource":"NCI"},{"termName":"9-Cordyceposidoadenine","termGroup":"SN","termSource":"NCI"},{"termName":"COR","termGroup":"AB","termSource":"NCI"},{"termName":"Cordycepine","termGroup":"SY","termSource":"NCI"},{"termName":"Kordicepin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"TdT-positive acute lymphocytic leukemia."},{"name":"CAS_Registry","value":"73-03-0"},{"name":"CHEBI_ID","value":"CHEBI:29014"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GZ8VF4M2J8"},{"name":"Legacy Concept Name","value":"Cordycepin"},{"name":"Maps_To","value":"Cordycepin"},{"name":"NCI_Drug_Dictionary_ID","value":"42667"},{"name":"NSC Number","value":"401022"},{"name":"NSC Number","value":"627047"},{"name":"NSC Number","value":"63984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42667"},{"name":"PDQ_Open_Trial_Search_ID","value":"42667"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056331"}]}}{"C967":{"preferredName":"Cordycepin Triphosphate","code":"C967","definitions":[{"definition":"The triphosphate salt of cordycepin, a purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK), and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cordycepin Triphosphate","termGroup":"PT","termSource":"NCI"},{"termName":"3'-Deoxyadenosine-5'-(tetrahydrogen triphosphate)","termGroup":"SN","termSource":"NCI"},{"termName":"Cordycepin-5'-triphosphate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73-04-1"},{"name":"CHEBI_ID","value":"CHEBI:52316"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"59P84ZU54H"},{"name":"Legacy Concept Name","value":"Cordycepin_Triphosphate"},{"name":"Maps_To","value":"Cordycepin Triphosphate"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046803"}]}}{"C78184":{"preferredName":"Coriolus Versicolor Extract","code":"C78184","definitions":[{"definition":"A substance being studied in the treatment of breast cancer and other types of cancer. Coriolus versicolor is a type of mushroom. Its extract is used with other treatments in some cultures to treat cancer and other conditions. The extract may boost the immune system, slow the growth of some tumor cells, and lessen the side effects of chemotherapy and radiation therapy. It is a type of biological response modifier (BRM) and a type of dietary supplement.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An extract derived from the mushroom Coriolus versicolor, containing polysaccharide K (PSK) and polysaccharide-peptide (PSP), with potential immunomodulating and antineoplastic activities. Coriolus versicolor extract has been shown to stimulate the production of lymphocytes and cytokines, such as interferons and interleukins, and may exhibit antioxidant activities. However, the precise mechanism of action(s) of this agent is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coriolus Versicolor Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Yunzhi Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Coriolus_Versicolor_Extract"},{"name":"Maps_To","value":"Coriolus Versicolor Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"594403"},{"name":"NCI_META_CUI","value":"CL383577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594403"},{"name":"PDQ_Open_Trial_Search_ID","value":"594403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C76112":{"preferredName":"Corticorelin Acetate","code":"C76112","definitions":[{"definition":"A substance being studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt form of coticorelin, a synthetic peptide of neurohormone corticotropin-releasing factor (CRF), with potential antitumor and antiangiogenesis activities. Upon administration, corticorelin stimulates adrenocorticotropic hormone (ACTH) secretion from the anterior pituitary gland. In turn, ACTH stimulates cortisol production from the adrenal cortex and is regulated by a negative feedback mechanism. Corticorelin appears to inhibit swelling around brain tumors through reduction in vascular leakage and maintenance of endothelial cell integrity. This agent potentially suppresses vascularization and tumor cell growth through reduction of vascular endothelial growth factor (VEGF) that appears to be via activation of corticotrophin-releasing factor receptor 2 (CRFR2), a G protein-coupled receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Corticorelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"hCRF","termGroup":"AB","termSource":"NCI"},{"termName":"Human Corticotropin-Releasing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Xerecept","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86784-80-7"},{"name":"Chemical_Formula","value":"C208H344N60O63S2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2YF82QN5RY"},{"name":"Legacy Concept Name","value":"Corticorelin_Acetate"},{"name":"Maps_To","value":"Corticorelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"385686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385686"},{"name":"PDQ_Open_Trial_Search_ID","value":"385686"},{"name":"PubMedID_Primary_Reference","value":"19437022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515366"}]}}{"C1058":{"preferredName":"Cortisone Acetate","code":"C1058","definitions":[{"definition":"The acetate salt form of cortisone, a synthetic or semisynthetic analog of the naturally occurring cortisone hormone produced by the adrenal glands with anti-inflammatory and immunomodulating properties. Cortisone acetate diffuses through the cell membrane and binds to nuclear glucocorticoid receptors. The receptor-ligand complex binds to promotor regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cortisone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"21-(Acetyloxy)-17-hydroxypregn-4-ene-3,11,20-trione","termGroup":"SN","termSource":"NCI"},{"termName":"6alpha,9Difluoro-11beta,17,21-trihydroxypregna-1,4- diene-3,20-dione 21-acetate 17- Butyrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cortogen","termGroup":"BR","termSource":"NCI"},{"termName":"Cortone","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-04-4"},{"name":"Chemical_Formula","value":"C23H30O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"883WKN7W8X"},{"name":"Legacy Concept Name","value":"Cortisone_Acetate"},{"name":"Maps_To","value":"Cortisone Acetate"},{"name":"NSC Number","value":"49420"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056391"}]}}{"C1877":{"preferredName":"Cositecan","code":"C1877","definitions":[{"definition":"A drug being studied in the treatment of cancer.  It belongs to a family of drugs called topoisomerase inhibitors. It is related to the anticancer drug camptothecin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic silicon-containing agent related to camptothecin with antineoplastic properties.  Cositecan stabilizes the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks and consequently triggering apoptosis.  Because it is lipophilic, cositecan exhibits enhanced tissue penetration and bio-availability compared to water-soluble camptothecins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cositecan","termGroup":"PT","termSource":"NCI"},{"termName":"(4S)-4-Ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"BNP1350","termGroup":"CN","termSource":"NCI"},{"termName":"DB 172","termGroup":"CN","termSource":"NCI"},{"termName":"Karenitecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203923-89-1"},{"name":"Chemical_Formula","value":"C25H28N2O4Si"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"24R60NVC41"},{"name":"Legacy Concept Name","value":"Karenitecin"},{"name":"Maps_To","value":"Cositecan"},{"name":"NCI_Drug_Dictionary_ID","value":"38211"},{"name":"NSC Number","value":"710270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38211"},{"name":"PDQ_Open_Trial_Search_ID","value":"38211"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935985"}]}}{"C61493":{"preferredName":"Gebasaxturev","code":"C61493","definitions":[{"definition":"A preparation of naturally occurring, oncolytic enterovirus, with potential antineoplastic activity. Upon administration, gebasaxturev targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are overexpressed on certain malignant cells. After entering the cells, gebasaxturev replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gebasaxturev","termGroup":"PT","termSource":"NCI"},{"termName":"CAVATAK","termGroup":"BR","termSource":"NCI"},{"termName":"Coxsackievirus A21","termGroup":"SY","termSource":"NCI"},{"termName":"Coxsackievirus V937","termGroup":"SY","termSource":"NCI"},{"termName":"CVA21","termGroup":"AB","termSource":"NCI"},{"termName":"V 937","termGroup":"CN","termSource":"NCI"},{"termName":"V-937","termGroup":"CN","termSource":"NCI"},{"termName":"V937","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802360-06-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4B57CWT710"},{"name":"Legacy Concept Name","value":"Coxsackievirus_A21"},{"name":"Maps_To","value":"Coxsackievirus A21"},{"name":"Maps_To","value":"Coxsackievirus V937"},{"name":"NCI_Drug_Dictionary_ID","value":"486330"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486330"},{"name":"PDQ_Open_Trial_Search_ID","value":"486330"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1440507"}]}}{"C88342":{"preferredName":"CpG Oligodeoxynucleotide GNKG168","code":"C88342","definitions":[{"definition":"A synthetic, 21-mer, unmethylated CpG motif-based oligodeoxynucleotide (ODN), with immunostimulatory activity. CpG oligodeoxynucleotide GNKG168 binds to and activates Toll-like receptor 9 (TLR9) and is taken up into cells by endocytosis; once internalized, it may activate numerous signaling transduction pathways resulting in the release of multiple cytokines, such as immunoglobulins (Igs), interferons (IFNs), interleukins (ILs) and tumor necrosis factor (TNF). Through activation of TLR9, this ODN can directly stimulate B-lymphocytes, dendritic and natural killer (NK) cells, resulting in an increase in innate immunity and antibody-dependent cellular cytotoxicity (ADCC). In addition, through the release of IL-12 and IFN, this agent may induce a preferential shift to the T-helper 1(Th1) phenotype resulting in enhanced CD8+ T cell-mediated antitumor cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CpG Oligodeoxynucleotide GNKG168","termGroup":"PT","termSource":"NCI"},{"termName":"CpG ODN GNKG168","termGroup":"AB","termSource":"NCI"},{"termName":"GNKG-168","termGroup":"CN","termSource":"NCI"},{"termName":"GNKG168","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JK03C8HWHK"},{"name":"Maps_To","value":"CpG Oligodeoxynucleotide GNKG168"},{"name":"NCI_Drug_Dictionary_ID","value":"662816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662816"},{"name":"PDQ_Open_Trial_Search_ID","value":"662816"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981861"}]}}{"C64639":{"preferredName":"Crenolanib","code":"C64639","definitions":[{"definition":"An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crenolanib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine","termGroup":"SN","termSource":"NCI"},{"termName":"CP-868,596","termGroup":"CN","termSource":"NCI"},{"termName":"CP-868596","termGroup":"CN","termSource":"NCI"},{"termName":"PDGFR Inhibitor CP-868596","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"670220-88-9"},{"name":"Chemical_Formula","value":"C26H29N5O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LQF7I567TQ"},{"name":"Legacy Concept Name","value":"CP-868_596"},{"name":"Maps_To","value":"Crenolanib"},{"name":"NCI_Drug_Dictionary_ID","value":"518325"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518325"},{"name":"PDQ_Open_Trial_Search_ID","value":"518325"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831982"}]}}{"C106204":{"preferredName":"Crenolanib Besylate","code":"C106204","definitions":[{"definition":"The besylate salt form of crenolanib, an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crenolanib Besylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-, Benzenesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine Monobenzenesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"CP-868,596-26","termGroup":"CN","termSource":"NCI"},{"termName":"CP-86859626","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"670220-93-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MC4B01024K"},{"name":"Maps_To","value":"Crenolanib Besylate"},{"name":"NCI_Drug_Dictionary_ID","value":"779361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779361"},{"name":"PDQ_Open_Trial_Search_ID","value":"779361"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827141"}]}}{"C74061":{"preferredName":"Crizotinib","code":"C74061","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It blocks enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crizotinib","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"MET Tyrosine Kinase Inhibitor PF-02341066","termGroup":"SY","termSource":"NCI"},{"termName":"PF-2341066","termGroup":"CN","termSource":"NCI"},{"termName":"PF02341066","termGroup":"CN","termSource":"NCI"},{"termName":"Xalkori","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Small Cell Lung Cancer; inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT)."},{"name":"CAS_Registry","value":"877399-52-5"},{"name":"CHEBI_ID","value":"CHEBI:64310"},{"name":"Chemical_Formula","value":"C21H22Cl2FN5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"53AH36668S"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_PF-02341066"},{"name":"Maps_To","value":"Crizotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"586080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586080"},{"name":"PDQ_Open_Trial_Search_ID","value":"586080"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2974289"}]}}{"C66938":{"preferredName":"Crolibulin","code":"C66938","definitions":[{"definition":"A small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Microtubulin inhibitor EPC2407 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of tubulin into microtubules, which may result in cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. As a vascular disruption agent (VDA), this agent also disrupts tumor neovascularization, which may result in a reduction in tumor blood flow and tumor hypoxia and ischemic necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crolibulin","termGroup":"PT","termSource":"NCI"},{"termName":"EPC2407","termGroup":"CN","termSource":"NCI"},{"termName":"Microtubule Inhibitor EPC2407","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000852-17-4"},{"name":"Chemical_Formula","value":"C18H17BrN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9ENT43KY91"},{"name":"Legacy Concept Name","value":"EPC2407"},{"name":"Maps_To","value":"Crolibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"536028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536028"},{"name":"PDQ_Open_Trial_Search_ID","value":"536028"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880474"}]}}{"C1546":{"preferredName":"Cryptophycin","code":"C1546","definitions":[{"definition":"The cryptophycins are a family of 16-membered macrolide antimitotic agents isolated from the cyanobacteria Nostoc sp. The mechanism of anticancer activity of the cryptophycins has been associated with their destabilization of microtubules and induction of bcl-2 phosphorylation leading to apoptosis. Cryptophycins demonstrated activity against the wide spectrum of solid tumors including those that overexpress the multidrug resistance efflux pump P-glycoprotein. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptophycin","termGroup":"PT","termSource":"NCI"},{"termName":"10-((3-Chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone","termGroup":"SN","termSource":"NCI"},{"termName":"Cryptophycin 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124689-65-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XO974V2M5T"},{"name":"Legacy Concept Name","value":"Cryptophycin"},{"name":"Maps_To","value":"Cryptophycin"},{"name":"NSC Number","value":"667642"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0257217"}]}}{"C1826":{"preferredName":"Cryptophycin 52","code":"C1826","definitions":[{"definition":"A member of the cryptophycin family of antitumor agents that binds to microtubules, inducing growth arrest and apoptosis in solid tumors. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptophycin 52","termGroup":"PT","termSource":"NCI"},{"termName":"C-52","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclo[2,2-dimethyl-beta-alanyl-(2S)-2-hydroxy-4-methylpentanoyl-(2E,5S,6S)-5-hydroxy-6-[(2R,3R)-3-phenyloxiranyl]-2-heptenoyl-3-chloro-O-methyl-D-tyrosyl]","termGroup":"SN","termSource":"NCI"},{"termName":"LY 355703","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186256-67-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I7FQ5A183L"},{"name":"Legacy Concept Name","value":"Cryptophycin_52"},{"name":"Maps_To","value":"Cryptophycin 52"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0756544"}]}}{"C95769":{"preferredName":"Crystalline Genistein Formulation AXP107-11","code":"C95769","definitions":[{"definition":"The sodium salt dihydrate form of crystalline genistein, a soy-derived isoflavone and phytoestrogen, with potential antineoplastic, chemosensitizing, and antioxidant activities. Upon administration, crystalline genistein formulation AXP107-11 binds to and modulates the activities of the nuclear estrogen receptors ERalpha (ESR1) and ERbeta (ESR2), and activates the G-coupled estrogen receptor 1 (GPER1). In addition, this agent increases the expression of phosphatase and tensin homolog (PTEN), which deactivates protein kinase Akt and mitogen-activated protein kinases (MAPK1 and 3; ERK2 and 1), thereby disrupting PI3K/Akt signal transduction and inducing apoptosis. AXP107-11 also induces antioxidant enzymes through AMP-activated protein kinase (AMPK) activation, inhibits nuclear factor kappa-B (NF-kB) activation and decreases inflammation response, thereby sensitizing tumors to chemotherapy. Compared to genistein itself, which has poor oral availability, this crystalline formulation shows improved solubility and bioavailability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crystalline Genistein Formulation AXP107-11","termGroup":"PT","termSource":"NCI"},{"termName":"AXP107-11","termGroup":"CN","termSource":"NCI"},{"termName":"Crystalline Genistein Sodium Dihydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Crystalline Genistein Formulation AXP107-11"},{"name":"NCI_Drug_Dictionary_ID","value":"683963"},{"name":"NCI_META_CUI","value":"CL428211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683963"},{"name":"PDQ_Open_Trial_Search_ID","value":"683963"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C129653":{"preferredName":"Sotuletinib","code":"C129653","definitions":[{"definition":"An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF-1R; CSF1R), with potential antineoplastic activity. CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. This inhibits the activity and proliferation of TAMs, and reprograms the immunosuppressive nature of existing TAMs. Altogether, this reduces TAM-mediated immune suppression in the tumor microenvironment, re-activates the immune system, and improves anti-tumor cell responses mediated by T-cells.  CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand, colony stimulating factor 1 (CSF1); this receptor is overexpressed by TAMs in the tumor microenvironment, and plays a major role in both immune suppression and the induction of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotuletinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-((2-(((1R,2R)-2-hydroxycyclohexyl)amino)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-[2((1R,2R)-2-Hydroxycyclohexylamino)-benzothiazol-6-yloxyl]-pyridine- 2-carboxylic Acid Methylamide","termGroup":"SN","termSource":"NCI"},{"termName":"BLZ 945","termGroup":"CN","termSource":"NCI"},{"termName":"BLZ-945","termGroup":"CN","termSource":"NCI"},{"termName":"BLZ945","termGroup":"CN","termSource":"NCI"},{"termName":"CSF-1R Inhibitor BLZ945","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"953769-46-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7W3V82OQ0P"},{"name":"Maps_To","value":"CSF-1R Inhibitor BLZ945"},{"name":"NCI_Drug_Dictionary_ID","value":"784318"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784318"},{"name":"PDQ_Open_Trial_Search_ID","value":"784318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3252423"}]}}{"C136424":{"preferredName":"CSF1R Inhibitor DCC-3014","code":"C136424","synonyms":[{"termName":"CSF1R Inhibitor DCC-3014","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Dec 08 11:10:29 EST 2021 - See 'Vimseltinib(C175876)'"},{"name":"OLD_PARENT","value":"C129825"},{"name":"OLD_PARENT","value":"C1967"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129688":{"preferredName":"CSF1R Inhibitor PLX73086","code":"C129688","definitions":[{"definition":"An inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antineoplastic activity. Upon administration, CSF1R inhibitor PLX73086 targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activity of tumor-associated macrophages (TAMs) in the tumor tissue and prevents TAM-related tumor cell growth. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSF1R Inhibitor PLX73086","termGroup":"PT","termSource":"NCI"},{"termName":"AC-708","termGroup":"CN","termSource":"NCI"},{"termName":"AC708","termGroup":"CN","termSource":"NCI"},{"termName":"PLX7 3086","termGroup":"CN","termSource":"NCI"},{"termName":"PLX73086","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CSF1R Inhibitor PLX73086"},{"name":"NCI_META_CUI","value":"CL507868"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1729 ":{"preferredName":"CT2584","code":"C1729","definitions":[{"definition":"A lipid metabolism and phosphatidic acid modulator, with potential antineoplastic activity. Upon administration, CT-2584 inhibits phospholipid signaling which may inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It may prevent the growth of blood vessels from surrounding tissue into a solid tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"CT2584","termGroup":"PT","termSource":"NCI"},{"termName":"1-(11-(dodecylamino)-10-hydroxyundecyl)-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1-(11-Dodecylamino-10-Hydroxyundecyl)-3,7-Dimethylxanthine","termGroup":"SN","termSource":"NCI"},{"termName":"Apra","termGroup":"BR","termSource":"NCI"},{"termName":"CT-2584","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"166981-13-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67E5N3R22H"},{"name":"Legacy Concept Name","value":"CT2584_HMS"},{"name":"Maps_To","value":"CT2584"},{"name":"NCI_Drug_Dictionary_ID","value":"42509"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0539091"}]}}{"C146765":{"preferredName":"Sovipostobart","code":"C146765","definitions":[{"definition":"A probody composed of ipilimumab, a recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of sovipostobart, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986249 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sovipostobart","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986249","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986249","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986249","termGroup":"CN","termSource":"NCI"},{"termName":"CTLA-4 Probody BMS-986249","termGroup":"SY","termSource":"NCI"},{"termName":"CTLA-4-directed Probody BMS-986249","termGroup":"SY","termSource":"NCI"},{"termName":"Protease-activated Anti-CTLA-4 Antibody Prodrug BMS-986249","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649371-19-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U1OMP6W1PM"},{"name":"Maps_To","value":"CTLA-4-directed Probody BMS-986249"},{"name":"NCI_Drug_Dictionary_ID","value":"792162"},{"name":"NCI_META_CUI","value":"CL544788"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792162"},{"name":"PDQ_Open_Trial_Search_ID","value":"792162"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C401":{"preferredName":"Curcumin","code":"C401","definitions":[{"definition":"A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties.  Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C.  These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A yellow pigment of the spice turmeric that is being studied in cancer prevention.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Curcumin","termGroup":"PT","termSource":"NCI"},{"termName":"(E,E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"C.I. 75300","termGroup":"CN","termSource":"NCI"},{"termName":"C.I. Natural Yellow 3","termGroup":"SY","termSource":"NCI"},{"termName":"Diferuloylmethane","termGroup":"SY","termSource":"NCI"},{"termName":"Turmeric Yellow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"458-37-7"},{"name":"CHEBI_ID","value":"CHEBI:3962"},{"name":"Chemical_Formula","value":"C21H20O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IT942ZTH98"},{"name":"Legacy Concept Name","value":"Curcumin"},{"name":"Maps_To","value":"Curcumin"},{"name":"NCI_Drug_Dictionary_ID","value":"43115"},{"name":"NSC Number","value":"32982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43115"},{"name":"PDQ_Open_Trial_Search_ID","value":"43115"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010467"}]}}{"C154569":{"preferredName":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110","code":"C154569","definitions":[{"definition":"A water-soluble, nano-sized formulation composed of nanoparticles encapsulating the poorly water-soluble curcumin, a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI), and the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of the curcumin/doxorubicin-encapsulating nanoparticle IMX-110, the curcumin moiety targets and inhibits the activation of STAT3 and NF-kB and prevents STAT3- and NF-kB-mediated signaling pathways, both of which are activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, tumor resistance to apoptosis, metastasis and immune evasion. The doxorubicin moiety intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and curcumin, by inhibiting NFkB and STAT3 activity, may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells. Chemotherapeutic agents, such as doxorubicin, upregulate the expression of NF-kB in tumor cells which generates chemotherapy-resistant tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110","termGroup":"PT","termSource":"NCI"},{"termName":"IMX 110","termGroup":"CN","termSource":"NCI"},{"termName":"IMX-110","termGroup":"CN","termSource":"NCI"},{"termName":"IMX110","termGroup":"CN","termSource":"NCI"},{"termName":"Stat3/NF-kB/poly-tyrosine Kinase Inhibitor/Doxorubicin-encapsulating Nanoparticle IMX-110","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110"},{"name":"NCI_Drug_Dictionary_ID","value":"794327"},{"name":"NCI_META_CUI","value":"CL555361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794327"},{"name":"PDQ_Open_Trial_Search_ID","value":"794327"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106116":{"preferredName":"Cusatuzumab","code":"C106116","definitions":[{"definition":"A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cusatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 Monoclonal Antibody ARGX-110","termGroup":"SY","termSource":"NCI"},{"termName":"ARGX-110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1864871-20-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RR5U4UFJ8L"},{"name":"Maps_To","value":"Cusatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"748589"},{"name":"NCI_META_CUI","value":"CL447355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748589"},{"name":"PDQ_Open_Trial_Search_ID","value":"748589"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1055":{"preferredName":"Custirsen Sodium","code":"C1055","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks the production of a protein called clusterin, which helps cells live longer. This may kill cancer cells that need clusterin to grow. It may also make cells more sensitive to anticancer drugs. It is a type of antisense oligonucleotide, and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Custirsen Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"(3'-5')d(P-thio)([2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m5rC-A-G-C-A-G-A-G-T-C-T-T-C-A-[2'-O-(2- methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]m5rU), Eicosasodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Antisense Testosterone-Repressed Prostate Message 2","termGroup":"SY","termSource":"NCI"},{"termName":"Antisense TRPM-2","termGroup":"SY","termSource":"NCI"},{"termName":"Clusterin Antisense Oligonucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 112989","termGroup":"CN","termSource":"NCI"},{"termName":"OGX-011","termGroup":"CN","termSource":"NCI"},{"termName":"TRPM-2 Antisense","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685922-56-9"},{"name":"Chemical_Formula","value":"C231H292N78O119P20S20.20Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ILE26V76EB"},{"name":"Legacy Concept Name","value":"OGX-011"},{"name":"Maps_To","value":"Custirsen Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"271195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"271195"},{"name":"PDQ_Open_Trial_Search_ID","value":"271195"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328699"}]}}{"C123383":{"preferredName":"CXC Chemokine Receptor 2 Antagonist AZD5069","code":"C123383","definitions":[{"definition":"An orally bioavailable, selective and reversible antagonist of CXC chemokine receptor 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells. In addition, AZD5069 reduces both neutrophil recruitment and migration from the systemic circulation into sites of inflammation, including the lung mucosa; it may also prevent neutrophil migration from the bone marrow. This results in the reduction of inflammation, mucus production, and neutrophil proteinase-mediated tissue destruction in the lung. CXCR2, a G protein-coupled receptor protein also known as IL-8 receptor B (IL-8RB), is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation and progression; it is known to be elevated in several inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXC Chemokine Receptor 2 Antagonist AZD5069","termGroup":"PT","termSource":"NCI"},{"termName":"AZD5069","termGroup":"CN","termSource":"NCI"},{"termName":"CXCR2 Antagonist AZD5069","termGroup":"SY","termSource":"NCI"},{"termName":"N-(2-(((2,3-difluorophenyl)methyl)thio)-6-(((1R,2S)-2,3-dihydroxy-1-methylpropyl)oxy)-4-pyrimidinyl)-1-azetidinesulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"878385-84-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4ADT8JXB9S"},{"name":"Maps_To","value":"CXC Chemokine Receptor 2 Antagonist AZD5069"},{"name":"NCI_Drug_Dictionary_ID","value":"774892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774892"},{"name":"PDQ_Open_Trial_Search_ID","value":"774892"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045791"}]}}{"C150389":{"preferredName":"CXCR1/2 Inhibitor SX-682","code":"C150389","definitions":[{"definition":"An orally bioavailable, selective and reversible antagonist of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration CXCR1/2 inhibitor SX-682 selectively and allosterically binds to CXCR 1 and 2 and inhibits their activation by tumor-secreted chemokines. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance and myeloid cell suppression. They play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR1/2 Inhibitor SX-682","termGroup":"PT","termSource":"NCI"},{"termName":"(2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"SX 682","termGroup":"CN","termSource":"NCI"},{"termName":"SX-682","termGroup":"CN","termSource":"NCI"},{"termName":"SX682","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1648843-04-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H5212R2DPM"},{"name":"Maps_To","value":"CXCR1/2 Inhibitor SX-682"},{"name":"NCI_Drug_Dictionary_ID","value":"792795"},{"name":"NCI_META_CUI","value":"CL552163"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792795"},{"name":"PDQ_Open_Trial_Search_ID","value":"792795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153151":{"preferredName":"CXCR2 Antagonist QBM076","code":"C153151","definitions":[{"definition":"An orally available small molecule antagonist of the G protein-coupled receptor, C-X-C motif chemokine receptor 2 (CXCR2), with potential immunomodulating and antineoplastic activities. Upon administration, QBM076 binds to and inhibits the activation of CXCR2, resulting in reduced neutrophil recruitment, myeloid-derived suppressor cell (MDSC) accumulation, and may potentially slow tumorigenesis and metastatic processes. CXCR2 is upregulated in a variety of cancer types, predominately in neutrophils/MDSCs rather than tumor cells, and is thought to contribute to tumor cell proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR2 Antagonist QBM076","termGroup":"PT","termSource":"NCI"},{"termName":"QBM 076","termGroup":"CN","termSource":"NCI"},{"termName":"QBM-076","termGroup":"CN","termSource":"NCI"},{"termName":"QBM076","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CXCR2 Antagonist QBM076"},{"name":"NCI_Drug_Dictionary_ID","value":"793940"},{"name":"NCI_META_CUI","value":"CL554404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793940"},{"name":"PDQ_Open_Trial_Search_ID","value":"793940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88309":{"preferredName":"Motixafortide","code":"C88309","definitions":[{"definition":"An orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. CXCR4 antagonist BL-8040 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor 1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood. The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; SDF-1/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motixafortide","termGroup":"PT","termSource":"NCI"},{"termName":"4F-Benzoyl-TN14003","termGroup":"SY","termSource":"NCI"},{"termName":"BKT140","termGroup":"CN","termSource":"NCI"},{"termName":"BL-8040","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-fluoro-benzoyl)-l-arginyl-l-arginyl-(l-3-(naphthyl)alanyl)-l-cysteinyl-l-tyrosyl-l-citrullinyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-l-arginyl-l-citrullinyl-l-cysteinyl-l-arginine Amide,Cyclic (4-13)-disulfide","termGroup":"SY","termSource":"NCI"},{"termName":"TF 14016","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"664334-36-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DA9G065962"},{"name":"Maps_To","value":"CXCR4 Antagonist BL-8040"},{"name":"Maps_To","value":"Motixafortide"},{"name":"NCI_Drug_Dictionary_ID","value":"659935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659935"},{"name":"PDQ_Open_Trial_Search_ID","value":"659935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981825"}]}}{"C131534":{"preferredName":"CXCR4 Antagonist USL311","code":"C131534","definitions":[{"definition":"An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, USL311 binds to CXCR4, thereby preventing the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Antagonist USL311","termGroup":"PT","termSource":"NCI"},{"termName":"CXCR4 Inhibitor USL311","termGroup":"SY","termSource":"NCI"},{"termName":"USL 311","termGroup":"CN","termSource":"NCI"},{"termName":"USL311","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1373268-67-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BTG5MX2Q2"},{"name":"Maps_To","value":"CXCR4 Antagonist USL311"},{"name":"NCI_Drug_Dictionary_ID","value":"786185"},{"name":"NCI_META_CUI","value":"CL514455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786185"},{"name":"PDQ_Open_Trial_Search_ID","value":"786185"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74022":{"preferredName":"CXCR4 Inhibitor Q-122","code":"C74022","definitions":[{"definition":"An orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Inhibitor Q-122","termGroup":"PT","termSource":"NCI"},{"termName":"MSX-122","termGroup":"CN","termSource":"NCI"},{"termName":"Q 122","termGroup":"CN","termSource":"NCI"},{"termName":"Q-122","termGroup":"CN","termSource":"NCI"},{"termName":"Q122","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897657-95-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69D634Q702"},{"name":"Maps_To","value":"CXCR4 Inhibitor Q-122"},{"name":"NCI_Drug_Dictionary_ID","value":"586491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586491"},{"name":"PDQ_Open_Trial_Search_ID","value":"586491"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347544"}]}}{"C106253":{"preferredName":"CXCR4 Peptide Antagonist LY2510924","code":"C106253","definitions":[{"definition":"An inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Peptide Antagonist LY2510924","termGroup":"PT","termSource":"NCI"},{"termName":"LY2510924","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CXCR4 Peptide Antagonist LY2510924"},{"name":"NCI_Drug_Dictionary_ID","value":"703819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703819"},{"name":"PDQ_Open_Trial_Search_ID","value":"703819"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827103"}]}}{"C148166":{"preferredName":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115","code":"C148166","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor BCD 115 binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of certain tumor promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. CDK8 plays a key role in transcription regulation and is an important oncogenic driver in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115","termGroup":"PT","termSource":"NCI"},{"termName":"BCD 115","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-115","termGroup":"CN","termSource":"NCI"},{"termName":"BCD115","termGroup":"CN","termSource":"NCI"},{"termName":"CDK 8/19 Inhibitor BCD 115","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1449228-40-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E2X758P2BZ"},{"name":"Maps_To","value":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115"},{"name":"NCI_Drug_Dictionary_ID","value":"792544"},{"name":"NCI_META_CUI","value":"CL550778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792544"},{"name":"PDQ_Open_Trial_Search_ID","value":"792544"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151988":{"preferredName":"Ebvaciclib","code":"C151988","definitions":[{"definition":"An orally bioavailable, cyclin dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, ebvaciclib selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and proliferation and are frequently overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ebvaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK Inhibitor PF-06873600","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06873600","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06873600","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2185857-97-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3B512HJD65"},{"name":"Maps_To","value":"Cyclin-dependent Kinase Inhibitor PF-06873600"},{"name":"NCI_Drug_Dictionary_ID","value":"793673"},{"name":"NCI_META_CUI","value":"CL553210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793673"},{"name":"PDQ_Open_Trial_Search_ID","value":"793673"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62600":{"preferredName":"Davamotecan Pegadexamer","code":"C62600","definitions":[{"definition":"A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration of davamotecan pegadexamer, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Davamotecan Pegadexamer","termGroup":"PT","termSource":"NCI"},{"termName":"Camptothecin-Polymer Conjugate IT-101","termGroup":"SY","termSource":"NCI"},{"termName":"CRLX101","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclodextrin-Based Polymer-Camptothecin CRLX101","termGroup":"SY","termSource":"NCI"},{"termName":"EP0057","termGroup":"CN","termSource":"NCI"},{"termName":"IT-101","termGroup":"CN","termSource":"NCI"},{"termName":"Linear Cyclodextrin-cysteine-PEG Based Polymer Conjugate of Camptothecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1883668-61-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NFH8D7ZGF5"},{"name":"Legacy Concept Name","value":"Cyclodextrin-Based_Polymer-Camptothecin"},{"name":"Maps_To","value":"Cyclodextrin-Based Polymer-Camptothecin CRLX101"},{"name":"NCI_Drug_Dictionary_ID","value":"489507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489507"},{"name":"PDQ_Open_Trial_Search_ID","value":"489507"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831896"}]}}{"C28899":{"preferredName":"Cyclodisone","code":"C28899","definitions":[{"definition":"A cyclic sulfonate ester with potential antineoplastic activity.  As an alkylating agent, clyclodisone induces the formation of DNA interstrand crosslinks, DNA strand breaks, and alkali-labile lesions in the DNA of some tumor cell lines.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclodisone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99591-73-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7YFV4WN79I"},{"name":"Legacy Concept Name","value":"Cyclodisone"},{"name":"Maps_To","value":"Cyclodisone"},{"name":"NSC Number","value":"348948"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056746"}]}}{"C404":{"preferredName":"Cycloleucine","code":"C404","definitions":[{"definition":"A non-metabolizable synthetic amino acid, formed through the cyclization of the amino acid leucine, with immunosuppressive, antineoplastic, and cytostatic activities. Cycloleucine competitively inhibits the enzyme methionine adenosyltransferase, resulting in the inhibition of S-adenosylmethionine (SAM) synthesis from methionine and ATP, and subsequent nucleic acid methylation and polyamine production; RNA, and perhaps to a lesser extent, DNA biosyntheses and cell cycle progression are finally disrupted. This agent is also a competitive inhibitor at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cycloleucine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Aminocyclopentane","termGroup":"SY","termSource":"NCI"},{"termName":"1-aminocyclopentanecarboxylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"ACP","termGroup":"AB","termSource":"NCI"},{"termName":"ACPC","termGroup":"AB","termSource":"NCI"},{"termName":"CB-1639","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52-52-8"},{"name":"Chemical_Formula","value":"C6H11NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0TQU7668EI"},{"name":"Legacy Concept Name","value":"Cycloleucine"},{"name":"Maps_To","value":"Cycloleucine"},{"name":"NCI_Drug_Dictionary_ID","value":"39200"},{"name":"NSC Number","value":"1026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39200"},{"name":"PDQ_Open_Trial_Search_ID","value":"39200"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010575"}]}}{"C1359":{"preferredName":"Cyclopentenyl Cytosine","code":"C1359","definitions":[{"definition":"A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5'-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclopentenyl Cytosine","termGroup":"PT","termSource":"NCI"},{"termName":"CPE-C","termGroup":"AB","termSource":"NCI"},{"termName":"Cyclopentenylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclopentenylcytosine Triphosphate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"90597-22-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69MO0NDN8K"},{"name":"Legacy Concept Name","value":"Cyclopentenyl_Cytosine"},{"name":"Maps_To","value":"Cyclopentenyl Cytosine"},{"name":"NCI_Drug_Dictionary_ID","value":"41433"},{"name":"NSC Number","value":"375575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41433"},{"name":"PDQ_Open_Trial_Search_ID","value":"41433"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0111606"}]}}{"C61694":{"preferredName":"Cyclophosphamide Anhydrous","code":"C61694","definitions":[{"definition":"The anhydrous form of cyclophosphamide, a synthetic nitrogen mustard alkylating agent, with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to active metabolites including phosphoramide mustard, which binds to and crosslinks DNA and RNA, thereby inhibiting DNA replication and protein synthesis. This agent, at low doses, is also a potent immunosuppressant primarily by depleting T-regulatory cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclophosphamide Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-Oxide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-18-0"},{"name":"CHEBI_ID","value":"CHEBI:4027"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O2P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6UXW23996M"},{"name":"Legacy Concept Name","value":"Cyclophosphamide_Anhydrous"},{"name":"Maps_To","value":"Cyclophosphamide Anhydrous"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880207"}]}}{"C406":{"preferredName":"Cyclosporine","code":"C406","definitions":[{"definition":"A drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclosporine","termGroup":"PT","termSource":"NCI"},{"termName":"27-400","termGroup":"CN","termSource":"NCI"},{"termName":"Ciclosporin","termGroup":"SY","termSource":"NCI"},{"termName":"CsA","termGroup":"AB","termSource":"NCI"},{"termName":"CyA","termGroup":"AB","termSource":"NCI"},{"termName":"Cyclosporin","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclosporin A","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclosporine Modified","termGroup":"SY","termSource":"NCI"},{"termName":"Gengraf","termGroup":"BR","termSource":"NCI"},{"termName":"Neoral","termGroup":"BR","termSource":"NCI"},{"termName":"OL 27-400","termGroup":"CN","termSource":"NCI"},{"termName":"Sandimmune","termGroup":"BR","termSource":"NCI"},{"termName":"SangCya","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Allogenic transplants; prophylaxis of organ rejection in bone marrow; kidney; liver and heart transplants; psoriasis; rheumatoid arthritis; various diseases that involve autoimmune response"},{"name":"CAS_Registry","value":"59865-13-3"},{"name":"CHEBI_ID","value":"CHEBI:4031"},{"name":"Chemical_Formula","value":"C62H111N11O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"83HN0GTJ6D"},{"name":"Legacy Concept Name","value":"Cyclosporine"},{"name":"Maps_To","value":"Cyclosporine"},{"name":"NCI_Drug_Dictionary_ID","value":"39201"},{"name":"NSC Number","value":"290193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39201"},{"name":"PDQ_Open_Trial_Search_ID","value":"39201"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010592"}]}}{"C95716":{"preferredName":"CYL-02 Plasmid DNA","code":"C95716","definitions":[{"definition":"A gene transfer preparation of a plasmid DNA encoding mouse somatostatin receptor subtype 2 (sst2) and a fusion protein of human deoxycytidine kinase (DCK) and uridine monophosphate kinase (UMK), complexed to a synthetic polycationic carrier, polyethylenimine, with antineoplastic adjuvant application. Upon administration, CYL-02 plasmid DNA expresses DCK::UMK fusion protein that converts gemcitabine into its toxic phosphorylated metabolite. Expression of sst2 protein by this agent could induce both antioncogenic and local antitumor bystander effects. A loss of sst2 gene expression often is found in pancreatic and colorectal cancers, and is the receptor for somatostatin which negatively regulates a number of processes such as epithelial cell proliferation. Combination effects of these gene products allows for less chemotherapy to cause tumor cell lysis in not only the original tumor, but in distant tumors as well.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYL-02 Plasmid DNA","termGroup":"PT","termSource":"NCI"},{"termName":"CYL-02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CYL-02 Plasmid DNA"},{"name":"NCI_Drug_Dictionary_ID","value":"693517"},{"name":"NCI_META_CUI","value":"CL428180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693517"},{"name":"PDQ_Open_Trial_Search_ID","value":"693517"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156744":{"preferredName":"Opevesostat","code":"C156744","definitions":[{"definition":"An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-liming step in steroid hormone biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opevesostat","termGroup":"PT","termSource":"NCI"},{"termName":"CYP11A1 inhibitor ODM-208","termGroup":"SY","termSource":"NCI"},{"termName":"MK 5684","termGroup":"CN","termSource":"NCI"},{"termName":"MK-5684","termGroup":"CN","termSource":"NCI"},{"termName":"MK5684","termGroup":"CN","termSource":"NCI"},{"termName":"ODM 208","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-208","termGroup":"CN","termSource":"NCI"},{"termName":"ODM208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231294-96-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z7MAV4KQC"},{"name":"Maps_To","value":"CYP11A1 inhibitor ODM-208"},{"name":"NCI_Drug_Dictionary_ID","value":"795704"},{"name":"NCI_META_CUI","value":"CL935891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795704"},{"name":"PDQ_Open_Trial_Search_ID","value":"795704"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102855":{"preferredName":"CYP17/CYP11B2 Inhibitor LAE001","code":"C102855","definitions":[{"definition":"An orally bioavailable, non-steroidal, potent, reversible, dual inhibitor of cytochrome P450 17 (CYP17 or CYP17A1) and CYP11B2, with potential antiandrogen and antineoplastic activities. Upon oral administration, LAE001 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. LAE001 also inhibits the enzymatic activity of CYP11B2, thereby inhibiting aldosterone production. This may reduce the elevated aldosterone levels resulting from CYP17 inhibition and androgen deprivation, leading to a reduction in mineralocorticoid side effects including cardiovascular complications. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones. The cytochrome P450 enzyme CYP11B2, aldosterone synthase, is an enzyme that plays a key role in aldosterone biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP17/CYP11B2 Inhibitor LAE001","termGroup":"PT","termSource":"NCI"},{"termName":"CFG 920","termGroup":"CN","termSource":"NCI"},{"termName":"CFG-920","termGroup":"CN","termSource":"NCI"},{"termName":"CFG920","termGroup":"CN","termSource":"NCI"},{"termName":"LAE 001","termGroup":"CN","termSource":"NCI"},{"termName":"LAE-001","termGroup":"CN","termSource":"NCI"},{"termName":"LAE001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260006-20-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UP0K5026VB"},{"name":"Maps_To","value":"CYP17 Inhibitor CFG920"},{"name":"Maps_To","value":"CYP17/CYP11B2 Inhibitor LAE001"},{"name":"NCI_Drug_Dictionary_ID","value":"737730"},{"name":"NCI_META_CUI","value":"CL437136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737730"},{"name":"PDQ_Open_Trial_Search_ID","value":"737730"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120310":{"preferredName":"CYP17 Lyase Inhibitor ASN001","code":"C120310","definitions":[{"definition":"An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, CYP17 lyase inhibitor ASN001 selectively binds to and inhibits the lyase activity of CYP17A1 in both the testes and adrenal glands, resulting in a significant reduction in androgen production to castrate-range levels. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The selective inhibition of CYP17A1 lyase activity by ASN001 prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP17 Lyase Inhibitor ASN001","termGroup":"PT","termSource":"NCI"},{"termName":"ASN001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429329-63-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J03L4XRQ2R"},{"name":"Maps_To","value":"CYP17 Lyase Inhibitor ASN001"},{"name":"NCI_Drug_Dictionary_ID","value":"768724"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768724"},{"name":"PDQ_Open_Trial_Search_ID","value":"768724"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896913"}]}}{"C120304":{"preferredName":"CYP17/Androgen Receptor Inhibitor ODM 204","code":"C120304","definitions":[{"definition":"An orally available inhibitor of both the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17) and androgen receptor (AR), with potential anti-androgen and antineoplastic activities. Upon oral administration, CYP17/AR inhibitor ODM 204 selectively inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. In addition, ODM 204 binds to ARs in target tissues and inhibits androgen-induced receptor activation and AR nuclear translocation, which prevents the binding to and transcription of AR-responsive genes. This leads to an inhibition of growth in AR-expressing prostate cancer cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP17/Androgen Receptor Inhibitor ODM 204","termGroup":"PT","termSource":"NCI"},{"termName":"ODM 204","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-204","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CYP17/Androgen Receptor Inhibitor ODM 204"},{"name":"NCI_Drug_Dictionary_ID","value":"768588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768588"},{"name":"PDQ_Open_Trial_Search_ID","value":"768588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896798"}]}}{"C407":{"preferredName":"Cyproterone","code":"C407","definitions":[{"definition":"A synthetic steroidal anti-androgen with antineoplastic activity. Cyproterone, in its acetate form, binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation and inhibiting the growth of testosterone-sensitive tumor cells.  This agent also exerts progesterogenic activity, resulting in a reduction in testicular androgen secretion and total androgen blockade. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyproterone","termGroup":"PT","termSource":"NCI"},{"termName":"Med Cyproterone","termGroup":"BR","termSource":"NCI"},{"termName":"SH-881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098-66-0"},{"name":"CHEBI_ID","value":"CHEBI:50742"},{"name":"Chemical_Formula","value":"C22H27ClO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E61Q31EK2F"},{"name":"Legacy Concept Name","value":"Cyproterone"},{"name":"Maps_To","value":"Cyproterone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010621"}]}}{"C1059":{"preferredName":"Cyproterone Acetate","code":"C1059","definitions":[{"definition":"A synthetic hormone being studied for treatment of hot flashes in men with prostate cancer who have had both testicles removed by surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyproterone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(Acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-","termGroup":"SN","termSource":"NCI"},{"termName":"6-Chloro-1b,2b-dihydro-17a-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Andro-Diane","termGroup":"FB","termSource":"NCI"},{"termName":"Androcur","termGroup":"FB","termSource":"NCI"},{"termName":"Chloro-6-hydroxy-17 Alpha Methylene-1 Alpha, 2 Alpha Pregnadiene-4,6 Dione-3, 20 Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"CyPat","termGroup":"AB","termSource":"NCI"},{"termName":"Cyprone","termGroup":"FB","termSource":"NCI"},{"termName":"Cyprostat","termGroup":"FB","termSource":"NCI"},{"termName":"Cyproteronazetat","termGroup":"SY","termSource":"NCI"},{"termName":"Cyproteroni Acetas","termGroup":"SY","termSource":"NCI"},{"termName":"Diane","termGroup":"FB","termSource":"NCI"},{"termName":"Dianette","termGroup":"FB","termSource":"NCI"},{"termName":"SH-714","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"427-51-0"},{"name":"CHEBI_ID","value":"CHEBI:50743"},{"name":"Chemical_Formula","value":"C24H29ClO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4KM2BN5JHF"},{"name":"Legacy Concept Name","value":"Cyproterone_Acetate"},{"name":"Maps_To","value":"Cyproterone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"39203"},{"name":"NSC Number","value":"81430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39203"},{"name":"PDQ_Open_Trial_Search_ID","value":"39203"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056855"}]}}{"C408":{"preferredName":"Cytarabine","code":"C408","definitions":[{"definition":"A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","termGroup":"SY","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosylcytosine","termGroup":"SN","termSource":"NCI"},{"termName":"2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","termGroup":"SY","termSource":"NCI"},{"termName":"4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone","termGroup":"SN","termSource":"NCI"},{"termName":"Alexan","termGroup":"FB","termSource":"NCI"},{"termName":"Ara-C","termGroup":"AB","termSource":"NCI"},{"termName":"ARA-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Arabine","termGroup":"FB","termSource":"NCI"},{"termName":"Arabinofuranosylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Arabinosylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Aracytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Aracytin","termGroup":"FB","termSource":"NCI"},{"termName":"Aracytine","termGroup":"FB","termSource":"NCI"},{"termName":"Beta-cytosine Arabinoside","termGroup":"SY","termSource":"NCI"},{"termName":"CHX-3311","termGroup":"CN","termSource":"NCI"},{"termName":"Cytarabinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cytarbel","termGroup":"FB","termSource":"NCI"},{"termName":"Cytosar","termGroup":"FB","termSource":"NCI"},{"termName":"Cytosar-U","termGroup":"AQS","termSource":"NCI"},{"termName":"Cytosine-beta-arabinoside","termGroup":"SY","termSource":"NCI"},{"termName":"Erpalfa","termGroup":"FB","termSource":"NCI"},{"termName":"Starasid","termGroup":"FB","termSource":"NCI"},{"termName":"Tarabine PFS","termGroup":"SY","termSource":"NCI"},{"termName":"U 19920","termGroup":"CN","termSource":"NCI"},{"termName":"U-19920","termGroup":"CN","termSource":"NCI"},{"termName":"Udicil","termGroup":"FB","termSource":"NCI"},{"termName":"WR-28453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute Nonlymphocytic leukemia; Bone marrow transplantation; Carcinomatous meningitis; Chronic myelogenous leukemia; Hogkins disease;"},{"name":"Accepted_Therapeutic_Use_For","value":"Meningeal leukemia; Acute Myeloid Leukemia; Meningitis lymphomatous; Myelodysplasic syndrome; Non-Hodgkins lymphoma; Ovarian cancer, intraperitoneal treatment; Retinoblastoma"},{"name":"CAS_Registry","value":"147-94-4"},{"name":"CHEBI_ID","value":"CHEBI:28680"},{"name":"Chemical_Formula","value":"C9H13N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"04079A1RDZ"},{"name":"Legacy Concept Name","value":"Cytosine_Arabinoside"},{"name":"Maps_To","value":"Cytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"39015"},{"name":"NSC Number","value":"287459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39015"},{"name":"PDQ_Open_Trial_Search_ID","value":"39015"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010711"}]}}{"C128888":{"preferredName":"Cytarabine Monophosphate Prodrug MB07133","code":"C128888","definitions":[{"definition":"A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytarabine Monophosphate Prodrug MB07133","termGroup":"PT","termSource":"NCI"},{"termName":"(2R,4S)-4-amino-1-[5-O-[2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl]-beta-d-arabinofuranosyl]-2(1H)-pyrimidinone","termGroup":"SN","termSource":"NCI"},{"termName":"Cytarabine Prodrug MB07133","termGroup":"SY","termSource":"NCI"},{"termName":"MB07133","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytarabine Monophosphate Prodrug MB07133"},{"name":"NCI_Drug_Dictionary_ID","value":"352009"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352009"},{"name":"PDQ_Open_Trial_Search_ID","value":"352009"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328712"}]}}{"C153327":{"preferredName":"Aspacytarabine","code":"C153327","definitions":[{"definition":"A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aspacytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"Ara-C Asparagine Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Asparagine Ara-C Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Asparagine Cytarabine Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Astarabine","termGroup":"SY","termSource":"NCI"},{"termName":"BST 236","termGroup":"CN","termSource":"NCI"},{"termName":"BST-236","termGroup":"CN","termSource":"NCI"},{"termName":"BST236","termGroup":"CN","termSource":"NCI"},{"termName":"Cytarabine Asparagine Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098942-53-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JL7V54Z2BR"},{"name":"Maps_To","value":"Aspacytarabine"},{"name":"Maps_To","value":"Cytarabine-asparagine Prodrug BST-236"},{"name":"NCI_Drug_Dictionary_ID","value":"795601"},{"name":"NCI_META_CUI","value":"CL554435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795601"},{"name":"PDQ_Open_Trial_Search_ID","value":"795601"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113444":{"preferredName":"Roducitabine","code":"C113444","definitions":[{"definition":"An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, tRoducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roducitabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl)pyrimidin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"Cytidine Analog RX-3117","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorocyclopentenylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"RX-3117","termGroup":"CN","termSource":"NCI"},{"termName":"TV-1360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"865838-26-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0Z4A82I0JO"},{"name":"Maps_To","value":"Cytidine Analog RX-3117"},{"name":"Maps_To","value":"Roducitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"756625"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756625"},{"name":"PDQ_Open_Trial_Search_ID","value":"756625"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3834251"}]}}{"C28950":{"preferredName":"Cytochlor","code":"C28950","definitions":[{"definition":"A radio-sensitizing pyrimidine nucleoside with potential antineoplastic activity.  Cytochlor is metabolized first to a phosphate derivative, CldCMP, by the enzyme deoxycytidine kinase and then to the active uracyl derivative, CldUMP, by the enzyme dCMP deaminase; deoxycytidine kinase and dCMP deaminase have been found in abnormally high concentrations in most cancers. CldUMP, the active metabolite, incorporates into DNA and, upon exposure to radiation, induces the formation of uracil radicals and double-strand DNA breaks. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of radiosensitizer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cytochlor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"32387-56-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J14D49ZN55"},{"name":"Legacy Concept Name","value":"Cytochlor"},{"name":"Maps_To","value":"Cytochlor"},{"name":"NCI_Drug_Dictionary_ID","value":"353478"},{"name":"NSC Number","value":"371331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"353478"},{"name":"PDQ_Open_Trial_Search_ID","value":"353478"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328172"}]}}{"C53396":{"preferredName":"Cytokine-based Biologic Agent IRX-2","code":"C53396","definitions":[{"definition":"A cell-free mixture comprised of a variety of naturally-derived cytokines obtained from normal, unrelated donor lymphocytes with potential immunostimulatory activity. The cytokines in IRX-2, including interleukin (IL)-1, -2, -6, -8, -10, -12, tumor necrosis factor alpha (TNF-a), interferon-gamma (IFN-g) and colony stimulating factors (CSFs), play vital roles in regulating cellular immunity and may synergistically stimulate a cellular immune response against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytokine-based Biologic Agent IRX-2","termGroup":"PT","termSource":"NCI"},{"termName":"IRX-2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"951209-71-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZDR4QSJ43F"},{"name":"Legacy Concept Name","value":"IRX-2"},{"name":"Maps_To","value":"Cytokine-based Biologic Agent IRX-2"},{"name":"NCI_Drug_Dictionary_ID","value":"462160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462160"},{"name":"PDQ_Open_Trial_Search_ID","value":"462160"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0758290"}]}}{"C69140":{"preferredName":"D-methionine Formulation MRX-1024","code":"C69140","definitions":[{"definition":"A proprietary oral formulation of D-methionine with antioxidant and antimucositis activities. D-methionine formulation MRX-1024 may selectively protect the oral mucosa from the toxic effects of chemotherapy and radiation therapy without compromising antitumor activity. D-methionine may be converted into the L- isomer in vivo, particularly in instances of L-methionine deprivation; both isomers have antioxidant activity which may be due, in part, to their sulfur moieties and chelating properties. L-methionine, an essential amino acid, also may help to maintain the ratio of reduced glutathione to oxidized glutathione in cells undergoing oxidative stress and may provide a source of L-cysteine for glutathione synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"D-methionine Formulation MRX-1024","termGroup":"PT","termSource":"NCI"},{"termName":"MRX-1024","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"348-67-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"868496F25R"},{"name":"Legacy Concept Name","value":"D-methionine_Formulation_MRX-1024"},{"name":"Maps_To","value":"D-methionine Formulation MRX-1024"},{"name":"NCI_Drug_Dictionary_ID","value":"540244"},{"name":"NCI_META_CUI","value":"CL371849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"540244"},{"name":"PDQ_Open_Trial_Search_ID","value":"540244"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2383":{"preferredName":"DAB389 Epidermal Growth Factor","code":"C2383","definitions":[{"definition":"A recombinant fusion protein composed of the diphtheria toxin with the receptor-binding domain replaced by human epidermal growth factor (EGF).  When administered, EGF binds to the endothelial cell growth factor receptor, EGFR, which is upregulated in many solid tumors.  After binding to the EGF receptor, the agent is internalized by the cell, where the diphtheria toxin moiety exerts its cytotoxic effect, inhibiting protein synthesis through ADP-ribosylation of elongation factor 2. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DAB389 Epidermal Growth Factor","termGroup":"PT","termSource":"NCI"},{"termName":"DAB389 EGF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DAB389_Epidermal_Growth_Factor"},{"name":"Maps_To","value":"DAB389 Epidermal Growth Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"42032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42032"},{"name":"PDQ_Open_Trial_Search_ID","value":"42032"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281573"}]}}{"C82386":{"preferredName":"Dabrafenib","code":"C82386","definitions":[{"definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dabrafenib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-","termGroup":"SN","termSource":"NCI"},{"termName":"BRAF Inhibitor GSK2118436","termGroup":"SY","termSource":"NCI"},{"termName":"GSK-2118436","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-2118436A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2118436","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation"},{"name":"CAS_Registry","value":"1195765-45-7"},{"name":"Chemical_Formula","value":"C23H20F3N5O2S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"QGP4HA4G1B"},{"name":"Legacy Concept Name","value":"BRAF_Inhibitor_GSK2118436"},{"name":"Maps_To","value":"Dabrafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"641977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641977"},{"name":"PDQ_Open_Trial_Search_ID","value":"641977"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467876"}]}}{"C128059":{"preferredName":"Dabrafenib Mesylate","code":"C128059","definitions":[{"definition":"The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dabrafenib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Dabrafenib Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2118436 Methane Sulfonate Salt","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2118436B","termGroup":"CN","termSource":"NCI"},{"termName":"Tafinlar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation"},{"name":"CAS_Registry","value":"1195768-06-9"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6DC89I63E"},{"name":"Maps_To","value":"Dabrafenib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"641977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641977"},{"name":"PDQ_Open_Trial_Search_ID","value":"641977"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3644554"}]}}{"C411":{"preferredName":"Dacarbazine","code":"C411","definitions":[{"definition":"A drug that is used to treat Hodgkin lymphoma and malignant melanoma and is being studied in the treatment of other types of cancer. It attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dacarbazine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"5-(3-3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"5-(dimethyltriazeno)imidazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Asercit","termGroup":"FB","termSource":"NCI"},{"termName":"Biocarbazine","termGroup":"SY","termSource":"NCI"},{"termName":"Dacarbazina","termGroup":"SY","termSource":"NCI"},{"termName":"Dacarbazina Almirall","termGroup":"SY","termSource":"NCI"},{"termName":"Dacarbazine - DTIC","termGroup":"SY","termSource":"NCI"},{"termName":"Dacatic","termGroup":"FB","termSource":"NCI"},{"termName":"Dakarbazin","termGroup":"SY","termSource":"NCI"},{"termName":"Deticene","termGroup":"FB","termSource":"NCI"},{"termName":"Detimedac","termGroup":"FB","termSource":"NCI"},{"termName":"DIC","termGroup":"AB","termSource":"NCI"},{"termName":"Dimethyl (triazeno) imidazolecarboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyl Triazeno Imidazol Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyl Triazeno Imidazole Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"dimethyl-triazeno-imidazole carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyl-triazeno-imidazole-carboximide","termGroup":"SY","termSource":"NCI"},{"termName":"DTIC","termGroup":"AB","termSource":"NCI"},{"termName":"DTIC-Dome","termGroup":"AQS","termSource":"NCI"},{"termName":"Fauldetic","termGroup":"FB","termSource":"NCI"},{"termName":"Imidazole Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Imidazole Carboxamide Dimethyltriazeno","termGroup":"SY","termSource":"NCI"},{"termName":"WR-139007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Carcinoid cancer; Hodgkins disease; Islet cell carcinoma; Melanoma; Neuroblastoma; Soft tissue sarcoma"},{"name":"CAS_Registry","value":"4342-03-4"},{"name":"CHEBI_ID","value":"CHEBI:4305"},{"name":"Chemical_Formula","value":"C6H10N6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7GR28W0FJI"},{"name":"Legacy Concept Name","value":"Dacarbazine"},{"name":"Maps_To","value":"Dacarbazine"},{"name":"NCI_Drug_Dictionary_ID","value":"39768"},{"name":"NSC Number","value":"45388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39768"},{"name":"PDQ_Open_Trial_Search_ID","value":"39768"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010927"}]}}{"C62179":{"preferredName":"Dacetuzumab","code":"C62179","definitions":[{"definition":"A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that binds to cells that have the CD40 antigen on their surface, including cells from multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. SGN-40 is being studied in the treatment of cancer. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dacetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-huCD40 mAb","termGroup":"SY","termSource":"NCI"},{"termName":"huS2C6","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody SGN-40","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"880486-59-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UT59FF4T5X"},{"name":"Legacy Concept Name","value":"SGN-40"},{"name":"Maps_To","value":"Dacetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"365545"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365545"},{"name":"PDQ_Open_Trial_Search_ID","value":"365545"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742509"}]}}{"C64784":{"preferredName":"DACH Polymer Platinate AP5346","code":"C64784","definitions":[{"definition":"A low molecular weight polymer-conjugated platinum complex with potential antineoplastic activity. This polymer drug delivery system consists of cytotoxic diaminocyclohexane (DACH)-platinum (Pt) coupled to a water-soluble biocompatible hydroxypropylmethacrylamide (HPMA) copolymer via a pH sensitive linker. Due to decreased pH at the tumor site, the linker is cleaved and the chelated active moiety DACH-Pt is released in tumor cells. DACH-Pt alkylates macromolecules and causes both inter- and intra-strand platinum-DNA crosslinks, which impede DNA replication and transcription, thereby resulting in cell-cycle independent cytotoxicity. The HPMA-based drug delivery system enhances the concentration of DACH-Pt at the tumor site and prolongs the half life of the agent, thereby increasing exposure and efficacy at the target tumor sites while minimizing side effects in normal tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of head and neck cancer. It may kill cancer cells by carrying an anticancer drug into the tumor. It is a type of platinum compound.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DACH Polymer Platinate AP5346","termGroup":"PT","termSource":"NCI"},{"termName":"AP5346","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DACH_Polymer_Platinate_AP5346"},{"name":"Maps_To","value":"DACH Polymer Platinate AP5346"},{"name":"NCI_Drug_Dictionary_ID","value":"526175"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526175"},{"name":"PDQ_Open_Trial_Search_ID","value":"526175"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723251"}]}}{"C113175":{"preferredName":"DACH-Platin Micelle NC-4016","code":"C113175","definitions":[{"definition":"Polymeric micellar nanoparticles containing diaminocyclohexane platinum (DACH-platin or DACH-Pt) with potential antineoplastic activity. DACH-platin micelle NC-4016 is prepared through the formation of a polymer-metal complex between DACH-platin and the polyethylene glycol-poly (glutamic acid) block copolymer, PEG-P(Glu). DACH-platin, an active metabolite of the platinum-based antineoplastic agent oxaliplatin, is highly hydrophobic and toxic when administered systemically. The use of polymeric micelles incorporating DACH-platin may both increase cell permeability and enhance the retention of the agent. This allows an extended half-life in the blood circulation and a selective and high accumulation of DACH-platin at tumor sites. This results in increased anticancer efficacy while reducing side effects due to DACH-platin toxicity. Upon intravenous administration and internalization by tumor cells, DACH-platin binds to and causes both inter- and intra-strand cross-links in DNA, forming platinum adducts and triggering tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DACH-Platin Micelle NC-4016","termGroup":"PT","termSource":"NCI"},{"termName":"Dach-Platin Micelle NC-4016","termGroup":"SY","termSource":"NCI"},{"termName":"DACH-Pt/m NC-4016","termGroup":"SY","termSource":"NCI"},{"termName":"Diaminocyclohexane Platinum Micelle NC-4016","termGroup":"SY","termSource":"NCI"},{"termName":"NC-4016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DACH-Platin Micelle NC-4016"},{"name":"NCI_Drug_Dictionary_ID","value":"755556"},{"name":"NCI_META_CUI","value":"CL455246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755556"},{"name":"PDQ_Open_Trial_Search_ID","value":"755556"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1569":{"preferredName":"Daclizumab","code":"C1569","definitions":[{"definition":"A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daclizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Tac","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Tac Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Tac Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Dacliximab","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-Tac Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-Tac","termGroup":"SY","termSource":"NCI"},{"termName":"Zenapax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Kidney transplant rejection, prevention"},{"name":"CAS_Registry","value":"152923-56-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CUJ2MVI71Y"},{"name":"Legacy Concept Name","value":"Daclizumab"},{"name":"Maps_To","value":"Daclizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42006"},{"name":"NSC Number","value":"725173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42006"},{"name":"PDQ_Open_Trial_Search_ID","value":"42006"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0663182"}]}}{"C53398":{"preferredName":"Dacomitinib","code":"C53398","definitions":[{"definition":"A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dacomitinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide","termGroup":"SN","termSource":"NCI"},{"termName":"EGFR Inhibitor PF-00299804","termGroup":"SY","termSource":"NCI"},{"termName":"PF-00299804","termGroup":"CN","termSource":"NCI"},{"termName":"PF-00299804-03","termGroup":"CN","termSource":"NCI"},{"termName":"PF-299804","termGroup":"CN","termSource":"NCI"},{"termName":"Vizimpro","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations"},{"name":"CAS_Registry","value":"1042385-75-0"},{"name":"Chemical_Formula","value":"C24H25ClFN5O2.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5092U85G58"},{"name":"Legacy Concept Name","value":"PF-00299804"},{"name":"Maps_To","value":"Dacomitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"462567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462567"},{"name":"PDQ_Open_Trial_Search_ID","value":"462567"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709400"}]}}{"C28955":{"preferredName":"Carboxyphthalato-1,2-diaminocyclohexaneplatinum","code":"C28955","definitions":[{"definition":"A second-generation platinum analog with potential antineoplastic activity.  Carboxyphthalato-1,2-diaminocyclohexaneplatinum alkylates DNA at the N-7 position of guanine, thereby producing DNA interstrand crosslinks and DNA strand breaks, and inhibiting DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyphthalato-1,2-diaminocyclohexaneplatinum","termGroup":"PT","termSource":"NCI"},{"termName":"(4-carboxyphthalato)(1,2-diaminocyclohexane)-platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"(SP-4-3)-Hydrogen (1,2,4-benzenetricarboxylato(3-)-O(1),O(2))(1,2-cyclohexanediamine-N,N') platinate(1-)","termGroup":"SY","termSource":"NCI"},{"termName":"DAC Platinum","termGroup":"SY","termSource":"NCI"},{"termName":"DACCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65296-81-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"918CG3EO0F"},{"name":"Legacy Concept Name","value":"Dacplatinum"},{"name":"Maps_To","value":"Dacplatinum"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054768"}]}}{"C412":{"preferredName":"Dactinomycin","code":"C412","definitions":[{"definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dactinomycin","termGroup":"PT","termSource":"NCI"},{"termName":"2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3","termGroup":"SN","termSource":"NCI"},{"termName":"Actinomycin A IV","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin C1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin D","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin I1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin IV","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin X 1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin-[thr-val-pro-sar-meval]","termGroup":"SY","termSource":"NCI"},{"termName":"Cosmegen","termGroup":"BR","termSource":"NCI"},{"termName":"DACT","termGroup":"AB","termSource":"NCI"},{"termName":"Dactinomycine","termGroup":"SY","termSource":"NCI"},{"termName":"Lyovac Cosmegen","termGroup":"FB","termSource":"NCI"},{"termName":"Meractinomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Wilms' tumor; rhabdomyosarcoma; Ewing's sarcoma; testicular cancer; gestational trophoblastic neoplasia; choriocarcinoma; melanoma; neuroblastoma; retinoblastoma; uterine sarcomas; Kaposi's sarcoma; sarcoma botryoides; soft tissue sarcoma."},{"name":"CAS_Registry","value":"50-76-0"},{"name":"CHEBI_ID","value":"CHEBI:27666"},{"name":"Chemical_Formula","value":"C62H86N12O16"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"1CC1JFE158"},{"name":"Legacy Concept Name","value":"Dactinomycin"},{"name":"Maps_To","value":"Dactinomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39675"},{"name":"NSC Number","value":"3053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39675"},{"name":"PDQ_Open_Trial_Search_ID","value":"39675"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010934"}]}}{"C74072":{"preferredName":"Dactolisib","code":"C74072","definitions":[{"definition":"An orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dactolisib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-","termGroup":"SN","termSource":"NCI"},{"termName":"BEZ235","termGroup":"CN","termSource":"NCI"},{"termName":"NVPBEZ235","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915019-65-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RUJ6Z9Y0DT"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_BEZ235"},{"name":"Maps_To","value":"Dactolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"589292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589292"},{"name":"PDQ_Open_Trial_Search_ID","value":"589292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2604817"}]}}{"C162346":{"preferredName":"Dactolisib Tosylate","code":"C162346","definitions":[{"definition":"The tosylate salt form of dactolisib, an orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Upon administration, dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dactolisib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile 4-Methylbenzenesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-, 4-Methylbenzenesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"NVP-BEZ235-ANA","termGroup":"SY","termSource":"NCI"},{"termName":"NVP-BEZ235-NX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1028385-32-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U54GT9151S"},{"name":"Maps_To","value":"Dactolisib Tosylate"},{"name":"NCI_META_CUI","value":"CL970853"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88296":{"preferredName":"Dalantercept","code":"C88296","definitions":[{"definition":"A soluble fusion protein containing the extracellular domain of activin receptor-like kinase-1 (ALK1) fused to a human Fc domain (ALK1-Fc fusion protein), with potential antiangiogenic and antineoplastic activities. Upon administration, dalantercept binds to various ALK1 ligands, preventing activation of tumor cell ALK1 receptors and so inhibiting the ALK1 signaling pathway; growth factor-induced angiogenesis is thus inhibited, which may result in the inhibition of tumor cell proliferation and tumor cell death. ALK1 is a type I cell surface receptor with serine/threonine kinase activity that mediates signaling by members of the transforming growth factor-beta (TGFbeta) superfamily and plays a key role in angiogenesis; ligands for this receptor include TGFbeta1 and TGFbeta2. The Fc moiety of this fusion protein mediates clearance of ligand-fusion protein complexes by the reticuloendothelial system (RES).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dalantercept","termGroup":"PT","termSource":"NCI"},{"termName":"ACE-041","termGroup":"CN","termSource":"NCI"},{"termName":"Activin Receptor-like Kinase 1 Inhibitor ACE-041","termGroup":"SY","termSource":"NCI"},{"termName":"ALK1-Fc Fusion Protein ACE-041","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1186210-24-1"},{"name":"Chemical_Formula","value":"C3206H4960N904O976S38"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EGC16R10V0"},{"name":"Maps_To","value":"Dalantercept"},{"name":"NCI_Drug_Dictionary_ID","value":"658276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658276"},{"name":"PDQ_Open_Trial_Search_ID","value":"658276"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537264"}]}}{"C74011":{"preferredName":"Dalotuzumab","code":"C74011","definitions":[{"definition":"A recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Dalotuzumab binds to membrane-bound IGF1R, preventing binding of the ligand IGF1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of many types of cancer. MK-0646 binds to a protein called insulin-like growth factor receptor (IGFR) on the surface of cells. This may prevent the cells from growing when IGF is present. It may also kill cancer cells. MK-0646 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dalotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody MK-0646","termGroup":"SY","termSource":"NCI"},{"termName":"MK-0646","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005389-60-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YI1L648RH"},{"name":"Legacy Concept Name","value":"Anti-IGF1R_Recombinant_Monoclonal_Antibody_MK-0646"},{"name":"Maps_To","value":"Dalotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"489297"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489297"},{"name":"PDQ_Open_Trial_Search_ID","value":"489297"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987605"}]}}{"C66984":{"preferredName":"Daniquidone","code":"C66984","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may kill cancer cells by causing damage to the DNA. Batracylin is a type of heterocyclic aryl amine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A water-insoluble heterocyclic amide with potential antineoplastic activity. Daniquidone inhibits topoisomerases I and II, thereby inhibiting DNA replication and repair, and RNA and protein synthesis. The acetylated form of daniquidone is highly toxic and is capable of inducing unscheduled DNA synthesis; rapid acetylators are more likely to experience toxicity with this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daniquidone","termGroup":"PT","termSource":"NCI"},{"termName":"8-Aminoisoindolo(1,2-b)quinazolin-12(10H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"Batracylin","termGroup":"SY","termSource":"NCI"},{"termName":"Bay H 2049","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67199-66-0"},{"name":"Chemical_Formula","value":"C15H11N3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E780TX33D2"},{"name":"Legacy Concept Name","value":"Daniquidone"},{"name":"Maps_To","value":"Daniquidone"},{"name":"NCI_Drug_Dictionary_ID","value":"539029"},{"name":"NSC Number","value":"320846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539029"},{"name":"PDQ_Open_Trial_Search_ID","value":"539029"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053006"}]}}{"C61587":{"preferredName":"Danusertib","code":"C61587","definitions":[{"definition":"A small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed. This agent may preferentially bind to and inhibit Aurora B kinase. Aurora kinases, a family of serine-threonine kinases, are important regulators of cellular proliferation and division.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of chronic myelogenous leukemia. PHA-739358 may stop tumor growth by blocking certain enzymes needed for cancer cells to divide and causing them to die. It is a type of kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Danusertib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)- methoxyphenylacetyl)pyrrolo(3,4-c)pyrazol-3-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"PHA-739358","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"827318-97-8"},{"name":"Chemical_Formula","value":"C26H30N6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M3X659D0FY"},{"name":"Legacy Concept Name","value":"PHA-739358"},{"name":"Maps_To","value":"Danusertib"},{"name":"NCI_Drug_Dictionary_ID","value":"489092"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489092"},{"name":"PDQ_Open_Trial_Search_ID","value":"489092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700603"}]}}{"C101368":{"preferredName":"Danvatirsen","code":"C101368","definitions":[{"definition":"An antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3) with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. STAT3, a protein overexpressed in a variety of human cancers, plays a critical role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Danvatirsen","termGroup":"PT","termSource":"NCI"},{"termName":"AZD9150","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS 481464","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-STAT3rx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402357-06-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31N550RD05"},{"name":"Maps_To","value":"Danvatirsen"},{"name":"NCI_Drug_Dictionary_ID","value":"729992"},{"name":"NCI_META_CUI","value":"CL435548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729992"},{"name":"PDQ_Open_Trial_Search_ID","value":"729992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67043":{"preferredName":"Daporinad","code":"C67043","definitions":[{"definition":"A small molecule with potential antineoplastic and antiangiogenic activities. Daporinad binds to and inhibits nicotinamide phosphoribosyltransferase (NMPRTase), inhibiting the biosynthesis of nicotinamide adenine dinucleotide (NAD+) from niacinamide (vitamin B3), which may deplete energy reserves in metabolically active tumor cells and induce tumor cell apoptosis. In addition, this agent may inhibit tumor cell production of vascular endothelial growth factor (VEGF), resulting in the inhibition of tumor angiogenesis. The coenzyme NAD+ plays an essential role in cellular redox reactions, including the redox reaction linking the citric acid cycle and oxidative phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daporinad","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-(1-Benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"APO866","termGroup":"AB","termSource":"NCI"},{"termName":"FK-866","termGroup":"CN","termSource":"NCI"},{"termName":"K 22.175","termGroup":"CN","termSource":"NCI"},{"termName":"NMPRTase Inhibitor APO866","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"658084-64-1"},{"name":"Chemical_Formula","value":"C24H29N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V71TF6V9M7"},{"name":"Legacy Concept Name","value":"APO866"},{"name":"Maps_To","value":"Daporinad"},{"name":"NCI_Drug_Dictionary_ID","value":"537396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537396"},{"name":"PDQ_Open_Trial_Search_ID","value":"537396"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879518"}]}}{"C74007":{"preferredName":"Daratumumab","code":"C74007","definitions":[{"definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daratumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Daratumumab Biosimilar HLX15","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab-fihj","termGroup":"SY","termSource":"NCI"},{"termName":"Darzalex","termGroup":"BR","termSource":"NCI"},{"termName":"HLX15","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-CD38","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ-54767414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma"},{"name":"CAS_Registry","value":"945721-28-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4Z63YK6E0E"},{"name":"Legacy Concept Name","value":"Anti-CD38_Monoclonal_Antibody"},{"name":"Maps_To","value":"Daratumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"583564"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583564"},{"name":"PDQ_Open_Trial_Search_ID","value":"583564"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346802"}]}}{"C156401":{"preferredName":"Daratumumab and Hyaluronidase-fihj","code":"C156401","definitions":[{"definition":"A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daratumumab and Hyaluronidase-fihj","termGroup":"PT","termSource":"NCI"},{"termName":"DARA Co-formulated with rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"DARA/rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab + rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab and Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab and Hyaluronidase-fihj","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab with rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab-rHuPH20","termGroup":"CN","termSource":"NCI"},{"termName":"Daratumumab/Hyaluronidase-fihj","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab/rHuPH20 Co-formulation","termGroup":"SY","termSource":"NCI"},{"termName":"Darzalex Faspro","termGroup":"BR","termSource":"NCI"},{"termName":"Darzalex/rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"HuMax-CD38-rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Hyaluronidase Mixed with Daratumumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with newly diagnosed or relapsed/refractory multiple myeloma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Daratumumab and Hyaluronidase-fihj"},{"name":"Maps_To","value":"Daratumumab/rHuPH20"},{"name":"NCI_Drug_Dictionary_ID","value":"795698"},{"name":"NCI_META_CUI","value":"CL563089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795698"},{"name":"PDQ_Open_Trial_Search_ID","value":"795698"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61490":{"preferredName":"Darinaparsin","code":"C61490","definitions":[{"definition":"A small-molecule organic arsenical with potential antineoplastic activity. Although the exact mechanism of action is unclear, darinaparsin, a highly toxic metabolic intermediate of inorganic arsenicals (iAs) that occurs in vivo, appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low. The arsenic compounds generated from darinaparsin disrupt mitochondrial bioenergetics, producing reactive oxygen species (ROS) and inducing ROS-mediated tumor cell apoptosis; in addition, this agent or its byproducts may initiate cell death by interrupting the G2/M phase of the cell cycle and may exhibit antiangiogenic effects. Compared to inorganic arsenic compounds such as arsenic trioxide (As2O3), darinaparsin appears to exhibit a wide therapeutic window.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darinaparsin","termGroup":"PT","termSource":"NCI"},{"termName":"DMAIII(SG)","termGroup":"AB","termSource":"NCI"},{"termName":"S-Dimethylarsino-Glutathione","termGroup":"SY","termSource":"NCI"},{"termName":"ZIO-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69819-86-9"},{"name":"Chemical_Formula","value":"C12H22AsN3O6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9XX54M675G"},{"name":"Legacy Concept Name","value":"S-Dimethylarsino-Glutathione"},{"name":"Maps_To","value":"Darinaparsin"},{"name":"NCI_Drug_Dictionary_ID","value":"486305"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486305"},{"name":"PDQ_Open_Trial_Search_ID","value":"486305"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872686"}]}}{"C90546":{"preferredName":"Darleukin","code":"C90546","definitions":[{"definition":"An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. The L19 moiety of L19-IL2 monoclonal antibody-cytokine fusion protein binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 moiety may locally activate natural killer (NK) cells and macrophages, and may induce T cell cytotoxic immune responses against ED-B fibronectin-expressing tumor cells. This may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darleukin","termGroup":"PT","termSource":"NCI"},{"termName":"L19-IL2","termGroup":"AB","termSource":"NCI"},{"termName":"L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2OQ3OPV2F8"},{"name":"Maps_To","value":"Darleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"665656"},{"name":"NCI_META_CUI","value":"CL416230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665656"},{"name":"PDQ_Open_Trial_Search_ID","value":"665656"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104748":{"preferredName":"Darolutamide","code":"C104748","definitions":[{"definition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darolutamide","termGroup":"PT","termSource":"NCI"},{"termName":"Antiandrogen ODM-201","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1841788","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1841788","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1841788","termGroup":"CN","termSource":"NCI"},{"termName":"Nubeqa","termGroup":"BR","termSource":"NCI"},{"termName":"ODM 201","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-metastatic castration-resistant prostate cancer"},{"name":"CAS_Registry","value":"1297538-32-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"X05U0N2RCO"},{"name":"Maps_To","value":"Darolutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"746231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746231"},{"name":"PDQ_Open_Trial_Search_ID","value":"746231"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641866"}]}}{"C154627":{"preferredName":"Daromun","code":"C154627","definitions":[{"definition":"A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), and fibromun (L19-TNFalpha), an immunocytokine consisting of human tumor necrosis factor alpha (TNFalpha) fused to a human scFv antibody fragment directed against the ED-B of L19, with potential antineoplastic and immunostimulating activities. Upon administration, the L-19 moieties of each immunocytokine bind to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 and TNF-alpha moieties of darleukin and fibromun, respectively, may locally induce an immune response against ED-B fibronectin-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daromun","termGroup":"PT","termSource":"NCI"},{"termName":"Darleukin and Fibromun","termGroup":"SY","termSource":"NCI"},{"termName":"Darleukin/Fibromun","termGroup":"SY","termSource":"NCI"},{"termName":"L19-IL2 and L19-TNF-alpha","termGroup":"SY","termSource":"NCI"},{"termName":"L19-IL2/L19-TNF-alpha","termGroup":"SY","termSource":"NCI"},{"termName":"L19IL2/L19TNF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Daromun"},{"name":"NCI_Drug_Dictionary_ID","value":"794649"},{"name":"NCI_META_CUI","value":"CL555512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794649"},{"name":"PDQ_Open_Trial_Search_ID","value":"794649"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38713":{"preferredName":"Dasatinib","code":"C38713","definitions":[{"definition":"A drug used to treat certain types of chronic myeloid leukemia and acute lymphoblastic leukemia. BMS-354825 is also being studied in the treatment of certain other blood diseases and types of cancer. BMS-354825 binds to and blocks BCR-ABL and other proteins that help cancer cells grow. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dasatinib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-354825","termGroup":"CN","termSource":"NCI"},{"termName":"Dasatinib Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Dasatinib Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Sprycel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"863127-77-9"},{"name":"Chemical_Formula","value":"C22H26ClN7O2S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RBZ1571X5H"},{"name":"Legacy Concept Name","value":"BMS-354825"},{"name":"Maps_To","value":"Dasatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"315885"},{"name":"NSC Number","value":"732517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"315885"},{"name":"PDQ_Open_Trial_Search_ID","value":"315885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1455147"}]}}{"C62091":{"preferredName":"Daunorubicin","code":"C62091","definitions":[{"definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat acute leukemias and some other types of cancer. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. It is a type of anthracycline antibiotic and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Daunorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-","termGroup":"SN","termSource":"NCI"},{"termName":"Daunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorrubicina","termGroup":"SY","termSource":"NCI"},{"termName":"DNR","termGroup":"AB","termSource":"NCI"},{"termName":"L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-","termGroup":"SN","termSource":"NCI"},{"termName":"Leukaemomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Rubidomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Rubomycin C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"20830-81-3"},{"name":"CHEBI_ID","value":"CHEBI:41977"},{"name":"Chemical_Formula","value":"C27H29NO10"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"ZS7284E0ZP"},{"name":"Legacy Concept Name","value":"Daunorubicin"},{"name":"Maps_To","value":"Daunorubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011015"}]}}{"C47471":{"preferredName":"Daunorubicin Citrate","code":"C47471","definitions":[{"definition":"A semi-synthetic anthracycline glycoside antibiotic obtained from Streptomyces with antineoplastic activity. Daunorubicin citrate intercalates DNA, which leads to inhibition of DNA and RNA synthesis, and consequently blocks cell division and results in apoptosis. This anti-tumor antibiotic is most active in the S phase of cell division. Daunorubicin is indicated in the treatment of a wide variety of cancers including acute non-lymphocytic leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor, and chronic myelocytic leukemia. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daunorubicin Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"371770-68-2"},{"name":"Chemical_Formula","value":"C27H29NO10.C6H8O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5L84T2Z6NP"},{"name":"Legacy Concept Name","value":"Daunorubicin_Citrate"},{"name":"Maps_To","value":"Daunorubicin Citrate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1289972"}]}}{"C1583":{"preferredName":"Daunorubicin Hydrochloride","code":"C1583","definitions":[{"definition":"A drug used to treat acute leukemias and some other types of cancer. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Cerubidine is a type of anthracycline antibiotic and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daunorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S-cis)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Cerubidin","termGroup":"FB","termSource":"NCI"},{"termName":"Cerubidine","termGroup":"BR","termSource":"NCI"},{"termName":"Cloridrato de Daunorubicina","termGroup":"SY","termSource":"NCI"},{"termName":"Daunoblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Daunoblastina","termGroup":"FB","termSource":"NCI"},{"termName":"Daunoblastine","termGroup":"SY","termSource":"NCI"},{"termName":"Daunomycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicini Hydrochloridum","termGroup":"SY","termSource":"NCI"},{"termName":"FI-6339","termGroup":"CN","termSource":"NCI"},{"termName":"L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-,hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Ondena","termGroup":"FB","termSource":"NCI"},{"termName":"RP-13057","termGroup":"CN","termSource":"NCI"},{"termName":"Rubidomycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Rubilem","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia"},{"name":"CAS_Registry","value":"23541-50-6"},{"name":"Chemical_Formula","value":"C27H29NO10.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UD984I04LZ"},{"name":"Legacy Concept Name","value":"Daunomycin"},{"name":"Maps_To","value":"Daunorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39779"},{"name":"NSC Number","value":"82151"},{"name":"NSC Number","value":"83142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39779"},{"name":"PDQ_Open_Trial_Search_ID","value":"39779"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282123"}]}}{"C170362":{"preferredName":"Rasdegafusp Alfa","code":"C170362","definitions":[{"definition":"A fusion protein consisting of a fully human monoclonal antibody directed against the endocytic dendritic cell (DC) receptor, DEC-205, linked to the tumor-associated antigen (TAA) NY-ESO-1 with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of rasdegafusp alfa1 binds to the endocytic DC receptor, which may result in DC endocytic internalization of this agent, specifically delivering the NY-ESO-1 moiety. DC processing of NY-ESO-1 may boost the immune system to mount a cytotoxic T-lymphocyte response (CTL) against cancer cells expressing NY-ESO-1. NY-ESO-1, a cell surface protein expressed in normal fetal and adult testes, is upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rasdegafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"CDX-1401","termGroup":"CN","termSource":"NCI"},{"termName":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1587257-96-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SU9AMV39DB"},{"name":"Maps_To","value":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401"},{"name":"NCI_Drug_Dictionary_ID","value":"651880"},{"name":"NCI_META_CUI","value":"CL1382603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651880"},{"name":"PDQ_Open_Trial_Search_ID","value":"651880"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C981":{"preferredName":"Decitabine","code":"C981","definitions":[{"definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that is used to treat myelodysplastic syndromes and is being studied in the treatment of other types of cancer. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Decitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-5-azacytidine","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-Aza-2'-deoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Aza-2'-deoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"5-Aza-2'deoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Aza-2-deoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Azadeoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"Dacogen","termGroup":"BR","termSource":"NCI"},{"termName":"Decitabine for Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxyazacytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Dezocitidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Myelodysplastic Syndrome"},{"name":"CAS_Registry","value":"2353-33-5"},{"name":"CHEBI_ID","value":"CHEBI:50131"},{"name":"Chemical_Formula","value":"C8H12N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"776B62CQ27"},{"name":"Legacy Concept Name","value":"Decitabine"},{"name":"Maps_To","value":"Decitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"39299"},{"name":"NSC Number","value":"127716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39299"},{"name":"PDQ_Open_Trial_Search_ID","value":"39299"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049065"}]}}{"C79809":{"preferredName":"Defactinib","code":"C79809","definitions":[{"definition":"An orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Defactinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"PF-04554878","termGroup":"CN","termSource":"NCI"},{"termName":"VS-6063","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1073154-85-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53O87HA2QU"},{"name":"Legacy Concept Name","value":"FAK_Inhibitor_PF-04554878"},{"name":"Maps_To","value":"Defactinib"},{"name":"NCI_Drug_Dictionary_ID","value":"746096"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746096"},{"name":"PDQ_Open_Trial_Search_ID","value":"746096"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703169"}]}}{"C128039":{"preferredName":"Defactinib Hydrochloride","code":"C128039","definitions":[{"definition":"The hydrochloride salt form of defactinib, an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Defactinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1073160-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L2S469LM49"},{"name":"Maps_To","value":"Defactinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"812840"},{"name":"NCI_META_CUI","value":"CL512846"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C416":{"preferredName":"Deferoxamine","code":"C416","definitions":[{"definition":"An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death. It is used in conjunction with other anticancer agents in pediatric neuroblastoma therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Deferoxamine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane","termGroup":"SN","termSource":"NCI"},{"termName":"Desferoxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"Desferrioxamine","termGroup":"SY","termSource":"NCI"},{"termName":"Desferrioxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"DFO-B","termGroup":"AB","termSource":"NCI"},{"termName":"N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxybutanediamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70-51-9"},{"name":"CHEBI_ID","value":"CHEBI:4356"},{"name":"Chemical_Formula","value":"C25H48N6O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"J06Y7MXW4D"},{"name":"Legacy Concept Name","value":"Deferoxamine"},{"name":"Maps_To","value":"Deferoxamine"},{"name":"NSC Number","value":"527604"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011145"}]}}{"C417":{"preferredName":"Deferoxamine Mesylate","code":"C417","definitions":[{"definition":"The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deferoxamine Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Deferoxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"Deferoxamine Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Deferrioxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"Desferal","termGroup":"BR","termSource":"NCI"},{"termName":"Desferrioxamine Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"DFM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"138-14-7"},{"name":"CHEBI_ID","value":"CHEBI:31460"},{"name":"Chemical_Formula","value":"C25H48N6O8.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9TKO7EO6K"},{"name":"Legacy Concept Name","value":"Deferoxamine_Mesylate"},{"name":"Maps_To","value":"Deferoxamine Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"41696"},{"name":"NSC Number","value":"644468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41696"},{"name":"PDQ_Open_Trial_Search_ID","value":"41696"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011148"}]}}{"C48385":{"preferredName":"Degarelix","code":"C48385","definitions":[{"definition":"A drug that is used to treat advanced prostate cancer and is also being studied in the treatment of benign prostatic hyperplasia. Degarelix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This causes the body to stop making testosterone, which prostate cancer needs to grow. Degarelix is a type of GnRH antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Degarelix","termGroup":"PT","termSource":"NCI"},{"termName":"ASP3550","termGroup":"CN","termSource":"NCI"},{"termName":"FE200486","termGroup":"CN","termSource":"NCI"},{"termName":"Firmagon","termGroup":"FB","termSource":"NCI"},{"termName":"Firmagon","termGroup":"BR","termSource":"NCI"},{"termName":"N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced prostate cancer"},{"name":"CAS_Registry","value":"214766-78-6"},{"name":"Chemical_Formula","value":"C82H103ClN18O16"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"SX0XJI3A11"},{"name":"Legacy Concept Name","value":"Degarelix"},{"name":"Maps_To","value":"Degarelix"},{"name":"NCI_Drug_Dictionary_ID","value":"441235"},{"name":"PDQ_Closed_Trial_Search_ID","value":"441235"},{"name":"PDQ_Open_Trial_Search_ID","value":"441235"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0971731"}]}}{"C80443":{"preferredName":"Degarelix Acetate","code":"C80443","definitions":[{"definition":"The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Degarelix Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3- pyridinyl)-D-alanyl-L- seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]- L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L- lysyl-L-prolyl, Acetate, Hydrate","termGroup":"SN","termSource":"NCI"},{"termName":"FE200486 Acetate Hydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced prostate cancer"},{"name":"CAS_Registry","value":"934246-14-7"},{"name":"Chemical_Formula","value":"C82H103ClN18O16.C2H4O2.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I18S89P20R"},{"name":"Legacy Concept Name","value":"Degarelix_Acetate"},{"name":"Maps_To","value":"Degarelix Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"813358"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2718533"}]}}{"C74075":{"preferredName":"Delanzomib","code":"C74075","definitions":[{"definition":"An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Delanzomib represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Delanzomib","termGroup":"PT","termSource":"NCI"},{"termName":"((1R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpyridine-2-carboxamido)butanamido)-3-methylbutyl)boronic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"CEP 18770","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-18770","termGroup":"CN","termSource":"NCI"},{"termName":"CT-47098","termGroup":"CN","termSource":"NCI"},{"termName":"NPH-007098","termGroup":"CN","termSource":"NCI"},{"termName":"NPH007098","termGroup":"CN","termSource":"NCI"},{"termName":"Proteasome Inhibitor CEP 18770","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"847499-27-8"},{"name":"Chemical_Formula","value":"C21H28BN3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6IF28942WO"},{"name":"Legacy Concept Name","value":"Proteasome_Inhibitor_CEP_18770"},{"name":"Maps_To","value":"Delanzomib"},{"name":"NCI_Drug_Dictionary_ID","value":"583540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583540"},{"name":"PDQ_Open_Trial_Search_ID","value":"583540"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467895"}]}}{"C80041":{"preferredName":"Demcizumab","code":"C80041","definitions":[{"definition":"A humanized monoclonal antibody directed against the N-terminal epitope of Notch ligand DLL4 (delta-like 4) with potential antineoplastic activity. Demcizumab binds to the membrane-binding portion of DLL4 and prevents its interaction with Notch-1 and Notch-4 receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated into the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Demcizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Delta-like 4 Monoclonal Antibody OMP-21M18","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-DLL4 Monoclonal Antibody OMP-21M18","termGroup":"SY","termSource":"NCI"},{"termName":"OMP-21M18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1243262-17-0"},{"name":"Chemical_Formula","value":"1243262-17-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SF168W7FW0"},{"name":"Legacy Concept Name","value":"Anti-DLL4_Monoclonal_Antibody_OMP-21M18"},{"name":"Maps_To","value":"Demcizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"614677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614677"},{"name":"PDQ_Open_Trial_Search_ID","value":"614677"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698134"}]}}{"C419":{"preferredName":"Demecolcine","code":"C419","definitions":[{"definition":"A colchicine analog with potential antimitotic and antineoplastic activities. Demecolcine acid binds to the colchicine-binding site of tubulin, inhibiting its polymerization into microtubules, causing cell cycle arrest at metaphase and preventing cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Demecolcine","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Colchamine","termGroup":"SY","termSource":"NCI"},{"termName":"Methylcolchicine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Methyl-N-desacetylcolchicine","termGroup":"SN","termSource":"NCI"},{"termName":"Santavy's Substance F","termGroup":"SY","termSource":"NCI"},{"termName":"X 153","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"477-30-5"},{"name":"CHEBI_ID","value":"CHEBI:4393"},{"name":"Chemical_Formula","value":"C21H25NO5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z01IVE25KI"},{"name":"Legacy Concept Name","value":"Demecolcine"},{"name":"Maps_To","value":"Demecolcine"},{"name":"NSC Number","value":"3096"},{"name":"NSC Number","value":"403147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011259"}]}}{"C85476":{"preferredName":"Demplatin Pegraglumer","code":"C85476","definitions":[{"definition":"A nanoparticle-based prodrug formulation consisting of polymeric micelles incorporating the inorganic platinum agent cisplatin with potential antineoplastic activity. In demplatin pegraglumer, cisplatin forms a polymer-metal complex with hydrophilic polyethylene glycol poly(glutamic acid) block copolymers by attaching to the micelle inner core consisting of the hydrophobic polyamino acids. Upon cell entry and release from the polymer-metal complex, cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-linking, DNA-protein cross-linking and, subsequently, tumor cell apoptosis and growth inhibition. Due to the hydrophilic nature of polyethylene glycol, this formulation increases the water-solubility of cisplatin and decreases the nephrotoxicity and neurotoxicity associated with the administration of cisplatin alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Demplatin Pegraglumer","termGroup":"PT","termSource":"NCI"},{"termName":"Nanoplatin","termGroup":"FB","termSource":"NCI"},{"termName":"NC-6004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1009838-50-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9DMG482P0R"},{"name":"Maps_To","value":"Demplatin Pegraglumer"},{"name":"NCI_Drug_Dictionary_ID","value":"647541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647541"},{"name":"PDQ_Open_Trial_Search_ID","value":"647541"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830141"}]}}{"C28310":{"preferredName":"Dendritic Cell Vaccine","code":"C28310","definitions":[{"definition":"A vaccine made of antigens and dendritic antigen-presenting cells (APCs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dendritic Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Dendritic Cell-based Cancer Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dendritic_Cell_Vaccine"},{"name":"Maps_To","value":"Dendritic Cell Vaccine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1511767"}]}}{"C26446":{"preferredName":"Dendritic Cell-Autologous Lung Tumor Vaccine","code":"C26446","definitions":[{"definition":"A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells.  The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient.  In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen.  Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendritic Cell-Autologous Lung Tumor Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"DCVax-L","termGroup":"SY","termSource":"NCI"},{"termName":"DCVax-Lung","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dendritic_Cell-Autologous_Lung_Tumor_Vaccine"},{"name":"Maps_To","value":"Dendritic Cell-Autologous Lung Tumor Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"256453"},{"name":"PDQ_Closed_Trial_Search_ID","value":"256453"},{"name":"PDQ_Open_Trial_Search_ID","value":"256453"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327750"}]}}{"C115976":{"preferredName":"Dendritic Cell-targeting Lentiviral Vector ID-LV305","code":"C115976","definitions":[{"definition":"An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendritic Cell-targeting Lentiviral Vector ID-LV305","termGroup":"PT","termSource":"NCI"},{"termName":"DCvex-NY-ESO-1","termGroup":"SY","termSource":"NCI"},{"termName":"ID-LV305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dendritic Cell-targeting Lentiviral Vector ID-LV305"},{"name":"NCI_Drug_Dictionary_ID","value":"760531"},{"name":"NCI_META_CUI","value":"CL473308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760531"},{"name":"PDQ_Open_Trial_Search_ID","value":"760531"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62492":{"preferredName":"Denenicokin","code":"C62492","definitions":[{"definition":"A recombinant peptide similar to or identical to endogenous human cytokine interleukin-21 (IL-21) with potential antineoplastic activity. Denenicokin binds to and activates IL-21 receptors, expressed on T-cells, B-cells, dendritic cells (DC), and natural killer (NK) cells, modulating the proliferation and/or differentiation of T and B cells, promoting T cell survival, and increasing the cytolytic activity of cytotoxic T lymphocytes (CTLs) and NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denenicokin","termGroup":"PT","termSource":"NCI"},{"termName":"IL-21","termGroup":"AB","termSource":"NCI"},{"termName":"L-methionyl(Human Interleukin-21)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Interleukin-21","termGroup":"SY","termSource":"NCI"},{"termName":"rhIL-21","termGroup":"AB","termSource":"NCI"},{"termName":"rIL-21","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"716840-32-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A4LY1V9F0H"},{"name":"Legacy Concept Name","value":"Recombinant_Human_Interleukin-21"},{"name":"Maps_To","value":"Denenicokin"},{"name":"NCI_Drug_Dictionary_ID","value":"409696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"409696"},{"name":"PDQ_Open_Trial_Search_ID","value":"409696"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831593"}]}}{"C77065":{"preferredName":"Denibulin","code":"C77065","definitions":[{"definition":"A small molecular vascular disrupting agent (VDA), with potential antimitotic and antineoplastic activities. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denibulin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"284019-34-7"},{"name":"Chemical_Formula","value":"C18H19N5O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K7037M241U"},{"name":"Legacy Concept Name","value":"Denibulin"},{"name":"Maps_To","value":"Denibulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699587"}]}}{"C72736":{"preferredName":"Denibulin Hydrochloride","code":"C72736","definitions":[{"definition":"The hydrochloride salt of denibulin, a small molecular vascular disrupting agent, with potential antimitotic and antineoplastic activities. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation., a small molecule vascular disrupting agent (VDA), with potential antimitotic and antineoplastic activity. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells (EC), ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denibulin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"MN-029","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"779356-64-8"},{"name":"Chemical_Formula","value":"C18H19N5O3S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0U575HR16Q"},{"name":"Legacy Concept Name","value":"Denibulin_Hydrochloride"},{"name":"Maps_To","value":"Denibulin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"746028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746028"},{"name":"PDQ_Open_Trial_Search_ID","value":"746028"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1679364"}]}}{"C1476":{"preferredName":"Denileukin Diftitox","code":"C1476","definitions":[{"definition":"A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat cutaneous T-cell lymphoma that can bind the cytokine IL-2 and that has not responded to other treatment. It is also being studied in the treatment of other types of cancer. Ontak is made by combining a part of IL-2 with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and then the toxin kills the cells. Ontak is a type of immunotoxin and a type of fusion toxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Denileukin Diftitox","termGroup":"PT","termSource":"NCI"},{"termName":"DAB(389)-Interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"DAB(389)IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"DAB389 Interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"DAB389 Interleukin-2 Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"DAB389IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"DAB389IL2","termGroup":"AB","termSource":"NCI"},{"termName":"DABIL2","termGroup":"SY","termSource":"NCI"},{"termName":"Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777","termGroup":"SY","termSource":"NCI"},{"termName":"E7777","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-2 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-2 Fusion Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"LY335348","termGroup":"CN","termSource":"NCI"},{"termName":"Ontak","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cutaneous T-cell lymphoma"},{"name":"CAS_Registry","value":"173146-27-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"25E79B5CTM"},{"name":"Legacy Concept Name","value":"Denileukin_Diftitox"},{"name":"Maps_To","value":"Denileukin Diftitox"},{"name":"Maps_To","value":"Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777"},{"name":"NCI_Drug_Dictionary_ID","value":"42325"},{"name":"NSC Number","value":"714744"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42325"},{"name":"PDQ_Open_Trial_Search_ID","value":"42325"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0717670"}]}}{"C105150":{"preferredName":"Denintuzumab Mafodotin","code":"C105150","definitions":[{"definition":"An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases MMAF, which binds to tubulin and inhibits its polymerization. Inhibition of tubulin polymerization may result in G2/M phase arrest and tumor cell apoptosis. This causes inhibition of cell growth of CD19-expressing tumor cells. CD19, a B-cell antigen, is overexpressed by a variety of different cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denintuzumab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-19A","termGroup":"AB","termSource":"NCI"},{"termName":"Immunoglobulin G1-kappa Auristatin F Conjugate, Anti-(homosapiens CD19 (B Lymphocyte Surface Antigen B4, leu-12)), Humanized Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"SGN-19A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD19A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1399672-02-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"H5324S1M7H"},{"name":"Maps_To","value":"Denintuzumab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"746594"},{"name":"NCI_META_CUI","value":"CL446112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746594"},{"name":"PDQ_Open_Trial_Search_ID","value":"746594"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61313":{"preferredName":"Denosumab","code":"C61313","definitions":[{"definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody being studied in the treatment of multiple myeloma (a cancer that forms in bones) and in the prevention and treatment of bone metastases (cancer that has spread to bone from another organ). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. AMG 162 binds to the protein RANKL and helps keep bone from breaking down.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Denosumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 162","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-162","termGroup":"CN","termSource":"NCI"},{"termName":"Denosumab Biosimilar MW032","termGroup":"SY","termSource":"NCI"},{"termName":"Denosumab Biosimilar QL1206","termGroup":"SY","termSource":"NCI"},{"termName":"Denosumab Biosimilar TK-006","termGroup":"SY","termSource":"NCI"},{"termName":"Prolia","termGroup":"BR","termSource":"NCI"},{"termName":"TK-006","termGroup":"CN","termSource":"NCI"},{"termName":"Xgeva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Osteolytic Bone Metastases of Solid Tumors"},{"name":"CAS_Registry","value":"615258-40-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"4EQZ6YO2HI"},{"name":"Legacy Concept Name","value":"Densosumab"},{"name":"Maps_To","value":"Denosumab"},{"name":"NCI_Drug_Dictionary_ID","value":"481348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481348"},{"name":"PDQ_Open_Trial_Search_ID","value":"481348"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1690432"}]}}{"C82697":{"preferredName":"Radgocitabine","code":"C82697","definitions":[{"definition":"An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radgocitabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-L-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)- 2(1H)-pyrimidinone","termGroup":"SY","termSource":"NCI"},{"termName":"CNDAC","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxycytidine Analogue TAS-109","termGroup":"SY","termSource":"NCI"},{"termName":"TAS-109","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135598-68-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"00M634HD2V"},{"name":"Legacy Concept Name","value":"Deoxycytidine_Analogue_TAS-109"},{"name":"Maps_To","value":"Deoxycytidine Analogue TAS-109"},{"name":"Maps_To","value":"Radgocitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"633936"},{"name":"NCI_META_CUI","value":"CL388479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633936"},{"name":"PDQ_Open_Trial_Search_ID","value":"633936"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150430":{"preferredName":"Radgocitabine Hydrochloride","code":"C150430","definitions":[{"definition":"The hydrochloride salt form of radgocitabine, an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radgocitabine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CNDAC Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxycytidine Analogue TAS-109 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134665-72-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VSS4ZDZ2IE"},{"name":"Maps_To","value":"Deoxycytidine Analogue TAS-109 Hydrochloride"},{"name":"Maps_To","value":"Radgocitabine Hydrochloride"},{"name":"NCI_META_CUI","value":"CL552242"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95206":{"preferredName":"Depatuxizumab","code":"C95206","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) with antineoplastic activity. Depatuxizumab targets the EGFR deletion variant, de2-7 EGFR as well as wild-type EGFR expressed in cells overexpressing the receptor, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization result in an inhibition in signal transduction and anti-proliferative effects. This MoAb targets cells expressing aberrant EGFR, hence making it an ideal candidate for generation of radioisotope or toxin conjugates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Depatuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-806","termGroup":"CN","termSource":"NCI"},{"termName":"anti-EGFR mAb ABT-806","termGroup":"SY","termSource":"NCI"},{"termName":"anti-EGFR MoAb ABT-806","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor) (Human-mus musculus Monoclonal ABT-806 Heavy Chain), Disulfide with Human-mus musculus Monoclonal ABT-806 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"mAb-806","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1471999-69-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W984C353CG"},{"name":"Maps_To","value":"Depatuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"691187"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691187"},{"name":"PDQ_Open_Trial_Search_ID","value":"691187"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048804"}]}}{"C105612":{"preferredName":"Depatuxizumab Mafodotin","code":"C105612","definitions":[{"definition":"An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Depatuxizumab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1585973-65-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3R7A4P04N"},{"name":"Maps_To","value":"Depatuxizumab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"747249"},{"name":"NCI_META_CUI","value":"CL446449"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747249"},{"name":"PDQ_Open_Trial_Search_ID","value":"747249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104267":{"preferredName":"Derazantinib","code":"C104267","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Derazantinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 087","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ-087","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1234356-69-4"},{"name":"CHEBI_ID","value":"CHEBI:63453"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N9B0H171MJ"},{"name":"Maps_To","value":"Derazantinib"},{"name":"NCI_Drug_Dictionary_ID","value":"744652"},{"name":"NCI_META_CUI","value":"CL445613"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744652"},{"name":"PDQ_Open_Trial_Search_ID","value":"744652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38709":{"preferredName":"Deslorelin","code":"C38709","definitions":[{"definition":"A substance being studied in the treatment of cancer as a way to block sex hormones made by the ovaries or testicles. It is a type of gonadotropin-releasing hormone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deslorelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Tryptophan-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Swine)","termGroup":"SN","termSource":"NCI"},{"termName":"Ovuplant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Central precocious puberty"},{"name":"CAS_Registry","value":"57773-65-6"},{"name":"Chemical_Formula","value":"C64H83N17O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TKG3I66TVE"},{"name":"Legacy Concept Name","value":"Deslorelin"},{"name":"Maps_To","value":"Deslorelin"},{"name":"NCI_Drug_Dictionary_ID","value":"357620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357620"},{"name":"PDQ_Open_Trial_Search_ID","value":"357620"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0083220"}]}}{"C82600":{"preferredName":"Deslorelin Acetate","code":"C82600","definitions":[{"definition":"A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deslorelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"5-Oxo-L-Prolyl-L-Histidyl-L-Tryptophyl-L-Seryl-L-Tyrosyl-D-Tryptophyl-L-Leucyl-L-Arginyl-N-Ethyl-L-Prolinamide Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"6-D-Tryptophan-9-(N-Ethyl-L-Prolinamide)-1-9-Luteinizing Hormone-Releasing Factor (Swine) Acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"82318-06-7"},{"name":"Chemical_Formula","value":"C64H83N17O12.C2H4O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"679007NR5C"},{"name":"Legacy Concept Name","value":"Deslorelin_Acetate"},{"name":"Maps_To","value":"Deslorelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"357620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357620"},{"name":"PDQ_Open_Trial_Search_ID","value":"357620"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0378714"}]}}{"C132693":{"preferredName":"Detirelix","code":"C132693","synonyms":[{"termName":"Detirelix","termGroup":"PT","termSource":"NCI"},{"termName":"BRN 6564671","termGroup":"CN","termSource":"NCI"},{"termName":"D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N(sup 6)-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-L-arginyl-L-prolyl-","termGroup":"SN","termSource":"NCI"},{"termName":"N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,D-Ala(10)-GnRH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89662-30-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05ME7P8ZBJ"},{"name":"Maps_To","value":"Detirelix"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057576"}]}}{"C1066":{"preferredName":"Detorubicin","code":"C1066","definitions":[{"definition":"A semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Detorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"14-Diethoxyacetoxydaunorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"Diethoxy-,2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester,(2S-cis) Acetic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66211-92-5"},{"name":"Chemical_Formula","value":"C33H39NO14"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"822EC3XEJZ"},{"name":"Legacy Concept Name","value":"Detorubicin"},{"name":"Maps_To","value":"Detorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39213"},{"name":"NSC Number","value":"292652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39213"},{"name":"PDQ_Open_Trial_Search_ID","value":"39213"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057578"}]}}{"C132685":{"preferredName":"Deuteporfin","code":"C132685","definitions":[{"definition":"A photosensitizing agent composed of four sub-porphyrin derivatives, methoxyethy-hydroxyethyl-dipropionic, di-methoxyethyl-dipropionic, hydroxyethy-vinyl-dipropionic and methoxyethy-vinyl-dipropionic, with potential photosensitizing activity upon photodynamic therapy (PDT) and potential diagnostic imaging activity. Upon intravenous administration, deuteporfin preferentially targets and accumulates in cancer cells, especially those in the lymphatic system. Following photoactivation with an appropriate wavelength, deuteporfin generates highly cytotoxic singlet oxygen species, and induces oxidative stress that results in the damage and death of cancer cells. In addition, deuteporfin could be used as a tracer in near-infrared (NIR) fluorescence lymph node mapping.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deuteporfin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deuteporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"787101"},{"name":"NCI_META_CUI","value":"CL519824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787101"},{"name":"PDQ_Open_Trial_Search_ID","value":"787101"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158096":{"preferredName":"Deutenzalutamide","code":"C158096","definitions":[{"definition":"A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Upon administration, deutenzalutamide competitively binds to and inhibits the activity of ARs expressed on prostate cancer cells, which impairs nuclear translocation and DNA binding, resulting in apoptosis of prostate cancer cells. This results in a reduction in prostate cancer cell growth. AR overexpression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. Deuterium incorporation, by replacing the hydrogen atoms of the N-CH3 moiety with deuterium atoms, decreases enzalutamide's metabolism and allows for an increased pharmacokinetic profile, thereby enhancing its anti-tumor efficacy compared to non-deuterated enzalutamide. As the deuterated form can't cross the blood-brain barrier (BBB), the deutenzalutamide form also reduces the unwanted brain-related side effects of enzalutamide and improves its safety profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deutenzalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"D3-ENT","termGroup":"SY","termSource":"NCI"},{"termName":"Deuterated Enzalutamide","termGroup":"SY","termSource":"NCI"},{"termName":"Enzalutamide Deuterated","termGroup":"SY","termSource":"NCI"},{"termName":"HC 1119","termGroup":"CN","termSource":"NCI"},{"termName":"HC-1119","termGroup":"CN","termSource":"NCI"},{"termName":"HC1119","termGroup":"CN","termSource":"NCI"},{"termName":"N-trideuteromethyl Enzalutamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443331-82-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3OKI556HC2"},{"name":"Maps_To","value":"Deuterated Enzalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"797006"},{"name":"NCI_META_CUI","value":"CL937681"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797006"},{"name":"PDQ_Open_Trial_Search_ID","value":"797006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80039":{"preferredName":"Devimistat","code":"C80039","definitions":[{"definition":"A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Devimistat","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha-Lipoic Acid Analogue CPI-613","termGroup":"SY","termSource":"NCI"},{"termName":"CPI 613","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-613","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95809-78-2"},{"name":"Chemical_Formula","value":"C22H28O2S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E76113IR49"},{"name":"Legacy Concept Name","value":"Alpha-Lipoic_Acid_Analogue_CPI-613"},{"name":"Maps_To","value":"Devimistat"},{"name":"NCI_Drug_Dictionary_ID","value":"614265"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614265"},{"name":"PDQ_Open_Trial_Search_ID","value":"614265"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703200"}]}}{"C422":{"preferredName":"Dexamethasone","code":"C422","definitions":[{"definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland). Dexamethasone is used to treat leukemia and lymphoma and may be used to treat some of the problems caused by other cancers and their treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dexamethasone","termGroup":"PT","termSource":"NCI"},{"termName":"(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"16Alpha-methyl-9alpha-fluoroprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"9alpha-Fluoro-16alpha- methylprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"9Alpha-fluoro-16alpha-methylprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"Aacidexam","termGroup":"FB","termSource":"NCI"},{"termName":"Adexone","termGroup":"FB","termSource":"NCI"},{"termName":"Aknichthol Dexa","termGroup":"FB","termSource":"NCI"},{"termName":"Alba-Dex","termGroup":"BR","termSource":"NCI"},{"termName":"Alin","termGroup":"FB","termSource":"NCI"},{"termName":"Alin Depot","termGroup":"FB","termSource":"NCI"},{"termName":"Alin Oftalmico","termGroup":"FB","termSource":"NCI"},{"termName":"Amplidermis","termGroup":"FB","termSource":"NCI"},{"termName":"Anemul mono","termGroup":"FB","termSource":"NCI"},{"termName":"Auricularum","termGroup":"FB","termSource":"NCI"},{"termName":"Auxiloson","termGroup":"FB","termSource":"NCI"},{"termName":"Baycadron","termGroup":"BR","termSource":"NCI"},{"termName":"Baycuten","termGroup":"FB","termSource":"NCI"},{"termName":"Baycuten N","termGroup":"FB","termSource":"NCI"},{"termName":"Cortidexason","termGroup":"FB","termSource":"NCI"},{"termName":"Cortisumman","termGroup":"FB","termSource":"NCI"},{"termName":"Decacort","termGroup":"FB","termSource":"NCI"},{"termName":"Decadrol","termGroup":"BR","termSource":"NCI"},{"termName":"Decadron","termGroup":"BR","termSource":"NCI"},{"termName":"Decadron DP","termGroup":"BR","termSource":"NCI"},{"termName":"Decalix","termGroup":"FB","termSource":"NCI"},{"termName":"Decameth","termGroup":"FB","termSource":"NCI"},{"termName":"Decasone R.p.","termGroup":"BR","termSource":"NCI"},{"termName":"Dectancyl","termGroup":"FB","termSource":"NCI"},{"termName":"Dekacort","termGroup":"FB","termSource":"NCI"},{"termName":"Deltafluorene","termGroup":"FB","termSource":"NCI"},{"termName":"Deronil","termGroup":"BR","termSource":"NCI"},{"termName":"Desamethasone","termGroup":"SY","termSource":"NCI"},{"termName":"Desameton","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-Mamallet","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-Rhinosan","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-Scheroson","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-sine","termGroup":"FB","termSource":"NCI"},{"termName":"Dexacortal","termGroup":"FB","termSource":"NCI"},{"termName":"Dexacortin","termGroup":"FB","termSource":"NCI"},{"termName":"Dexafarma","termGroup":"FB","termSource":"NCI"},{"termName":"Dexafluorene","termGroup":"FB","termSource":"NCI"},{"termName":"Dexalocal","termGroup":"FB","termSource":"NCI"},{"termName":"Dexamecortin","termGroup":"FB","termSource":"NCI"},{"termName":"Dexameth","termGroup":"BR","termSource":"NCI"},{"termName":"Dexamethasone Intensol","termGroup":"SY","termSource":"NCI"},{"termName":"Dexamethasone Intensol","termGroup":"BR","termSource":"NCI"},{"termName":"Dexamethasonum","termGroup":"SY","termSource":"NCI"},{"termName":"Dexamonozon","termGroup":"FB","termSource":"NCI"},{"termName":"Dexapos","termGroup":"FB","termSource":"NCI"},{"termName":"Dexinoral","termGroup":"FB","termSource":"NCI"},{"termName":"Dexone","termGroup":"FB","termSource":"NCI"},{"termName":"Dinormon","termGroup":"FB","termSource":"NCI"},{"termName":"Dxevo","termGroup":"BR","termSource":"NCI"},{"termName":"Fluoro-9alpha Methyl-16alpha Prednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"Fluorodelta","termGroup":"FB","termSource":"NCI"},{"termName":"Fortecortin","termGroup":"FB","termSource":"NCI"},{"termName":"Gammacorten","termGroup":"BR","termSource":"NCI"},{"termName":"Hemady","termGroup":"BR","termSource":"NCI"},{"termName":"Hexadecadrol","termGroup":"SY","termSource":"NCI"},{"termName":"Hexadrol","termGroup":"BR","termSource":"NCI"},{"termName":"Lokalison-F","termGroup":"FB","termSource":"NCI"},{"termName":"Loverine","termGroup":"FB","termSource":"NCI"},{"termName":"Methylfluorprednisolone","termGroup":"SY","termSource":"NCI"},{"termName":"Millicorten","termGroup":"FB","termSource":"NCI"},{"termName":"Mymethasone","termGroup":"FB","termSource":"NCI"},{"termName":"Orgadrone","termGroup":"FB","termSource":"NCI"},{"termName":"Spersadex","termGroup":"FB","termSource":"NCI"},{"termName":"TaperDex","termGroup":"BR","termSource":"NCI"},{"termName":"Visumetazone","termGroup":"FB","termSource":"NCI"},{"termName":"ZoDex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Allergic disorders; antiemetic; corneal injury; inflammatory conditions"},{"name":"CAS_Registry","value":"50-02-2"},{"name":"CHEBI_ID","value":"CHEBI:41879"},{"name":"Chemical_Formula","value":"C22H29FO5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7S5I7G3JQL"},{"name":"Legacy Concept Name","value":"Dexamethasone"},{"name":"Maps_To","value":"Dexamethasone"},{"name":"NCI_Drug_Dictionary_ID","value":"39789"},{"name":"NSC Number","value":"34521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39789"},{"name":"PDQ_Open_Trial_Search_ID","value":"39789"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011777"}]}}{"C77001":{"preferredName":"Dexamethasone Phosphate","code":"C77001","synonyms":[{"termName":"Dexamethasone Phosphate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"312-93-6"},{"name":"Chemical_Formula","value":"C22H30FO8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BP70L44PR"},{"name":"Legacy Concept Name","value":"Dexamethasone_Phosphate"},{"name":"Maps_To","value":"Dexamethasone Phosphate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770565"}]}}{"C1362":{"preferredName":"Dexamethasone Sodium Phosphate","code":"C1362","definitions":[{"definition":"A sodium phosphate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dexamethasone Sodium Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Cebedex","termGroup":"FB","termSource":"NCI"},{"termName":"Corson","termGroup":"FB","termSource":"NCI"},{"termName":"Dalalone","termGroup":"BR","termSource":"NCI"},{"termName":"Decaject","termGroup":"FB","termSource":"NCI"},{"termName":"Dekasol LA","termGroup":"FB","termSource":"NCI"},{"termName":"Dexacen","termGroup":"FB","termSource":"NCI"},{"termName":"Dexamethasone Sodium Phosphates","termGroup":"SY","termSource":"NCI"},{"termName":"Dexasone","termGroup":"BR","termSource":"NCI"},{"termName":"Dezone","termGroup":"FB","termSource":"NCI"},{"termName":"ReadySharp Dexamethasone","termGroup":"BR","termSource":"NCI"},{"termName":"Soludecadron","termGroup":"FB","termSource":"NCI"},{"termName":"Solurex","termGroup":"BR","termSource":"NCI"},{"termName":"Topidex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2392-39-4"},{"name":"CHEBI_ID","value":"CHEBI:4462"},{"name":"Chemical_Formula","value":"C22H28FO8P.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AI9376Y64P"},{"name":"Legacy Concept Name","value":"Dexamethasone_Sodium_Phosphate"},{"name":"Maps_To","value":"Dexamethasone Sodium Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"813361"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0113286"}]}}{"C99381":{"preferredName":"Dexanabinol","code":"C99381","definitions":[{"definition":"A synthetic, terpene-based cannabinoid derivative devoid of cannabinoid receptors 1 and 2 agonist activity and with potential neuroprotective, antiinflammatory and antineoplastic activities. Functioning as an N-Methyl-D-aspartate (NMDA) receptor antagonist, dexanabinol protects neuronal cells against NMDA and glutamate neurotoxicity. This agent also scavenges peroxy radicals and protects neurons from the damages of reactive oxygen species. Furthermore, dexanabinol inhibits the activity of nuclear factor kappa B (NF-kB), thereby preventing the expression of NF-kB target genes, such as tumor necrosis factor alpha, cytokines and inducible nitric oxide synthase. As a result, this agent may restore apoptotic processes in cancerous cells. NF-kB is activated in a variety of cancer cells and plays a key role in the regulation of apoptosis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dexanabinol","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol","termGroup":"SN","termSource":"NCI"},{"termName":"7-Hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl","termGroup":"SN","termSource":"NCI"},{"termName":"HU-211","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112924-45-5"},{"name":"Chemical_Formula","value":"C25H38O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6VT8U5372"},{"name":"Maps_To","value":"Dexanabinol"},{"name":"NCI_Drug_Dictionary_ID","value":"720043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"720043"},{"name":"PDQ_Open_Trial_Search_ID","value":"720043"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0526471"}]}}{"C1333":{"preferredName":"Dexrazoxane","code":"C1333","definitions":[{"definition":"A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat severe side effects caused by certain anticancer drugs. Under the brand name Totect it is used to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. Under the brand name Zinecard it is used to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dexrazoxane","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione)","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ADR-529","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF-187","termGroup":"CN","termSource":"NCI"},{"termName":"Razoxane (+)-form","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chemotherapy-induced cardiomyopathy"},{"name":"CAS_Registry","value":"24584-09-6"},{"name":"CHEBI_ID","value":"CHEBI:50223"},{"name":"Chemical_Formula","value":"C11H16N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"048L81261F"},{"name":"Legacy Concept Name","value":"Dexrazoxane"},{"name":"Maps_To","value":"Dexrazoxane"},{"name":"NSC Number","value":"169780"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086444"}]}}{"C66945":{"preferredName":"Dexrazoxane Hydrochloride","code":"C66945","definitions":[{"definition":"A drug used to treat severe side effects caused by certain anticancer drugs. It is used under the brand name Totect to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. It is also used under the brand name Zinecard to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane hydrochloride is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues.  This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dexrazoxane Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Cardioxane","termGroup":"BR","termSource":"NCI"},{"termName":"Totect","termGroup":"BR","termSource":"NCI"},{"termName":"Zinecard","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"severe side effects caused by certain types of chemotherapy including extravasation, cardiac side effects by doxorubicin."},{"name":"CAS_Registry","value":"149003-01-0"},{"name":"CHEBI_ID","value":"CHEBI:50224"},{"name":"Chemical_Formula","value":"C11H16N4O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5346058Q7S"},{"name":"Legacy Concept Name","value":"Dexrazoxane_Hydrochloride"},{"name":"Maps_To","value":"Dexrazoxane Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39485"},{"name":"PDQ_Open_Trial_Search_ID","value":"39485"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0982118"}]}}{"C968":{"preferredName":"Dezaguanine","code":"C968","definitions":[{"definition":"A purine nucleoside analogue with antineoplastic and antiviral activities.  By replacing guanine, dezaguanine incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dezaguanine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Deazaguanine","termGroup":"SY","termSource":"NCI"},{"termName":"CI-908","termGroup":"CN","termSource":"NCI"},{"termName":"Deazaguanine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41729-52-6"},{"name":"Chemical_Formula","value":"C6H6N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9DRB973HUI"},{"name":"Legacy Concept Name","value":"Dezaguanine"},{"name":"Maps_To","value":"Dezaguanine"},{"name":"NCI_Drug_Dictionary_ID","value":"40086"},{"name":"NSC Number","value":"261726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40086"},{"name":"PDQ_Open_Trial_Search_ID","value":"40086"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0047332"}]}}{"C80635":{"preferredName":"Dezaguanine Mesylate","code":"C80635","definitions":[{"definition":"The mesylate salt form of dezaguanine, a purine nucleoside analogue with antineoplastic and antiviral activities.  By competing with guanine, dezaguanine gets incorporated into DNA and inhibits DNA synthesis, thereby inducing cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dezaguanine Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"3-Deazaguanine Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87434-82-0"},{"name":"Chemical_Formula","value":"C6H6N4O.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H56TJ4554M"},{"name":"Legacy Concept Name","value":"Dezaguanine_Mesylate"},{"name":"Maps_To","value":"Dezaguanine Mesylate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825284"}]}}{"C107686":{"preferredName":"Dezapelisib","code":"C107686","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity. Dezapelisib specifically inhibits PI3Kdelta, which prevents both the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in PI3K-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is often overexpressed in tumor cells, especially those of hematologic origin, and plays a crucial role in tumor cell regulation and survival. The targeted inhibition of PI3Kdelta allows for PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dezapelisib","termGroup":"PT","termSource":"NCI"},{"termName":"5H-Thiazolo(3,2-a)pyrimidin-5-one, 6-(3-Fluorophenyl)-3-methyl-7-((1S)-1-(9H-purin-6-ylamino)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB040093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1262440-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2K59L7G59M"},{"name":"Maps_To","value":"Dezapelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"751623"},{"name":"NCI_META_CUI","value":"CL451874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751623"},{"name":"PDQ_Open_Trial_Search_ID","value":"751623"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2649":{"preferredName":"DHA-Paclitaxel","code":"C2649","definitions":[{"definition":"A combination of DHA (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel.  Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).  DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DHA-Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"Docosahexaenoic Acid-Paclitaxel conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Taxoprexin","termGroup":"BR","termSource":"NCI"},{"termName":"TXP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73-67-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OJE5810C4F"},{"name":"Legacy Concept Name","value":"DHA-Paclitaxel"},{"name":"Maps_To","value":"DHA-Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"38414"},{"name":"NSC Number","value":"28247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38414"},{"name":"PDQ_Open_Trial_Search_ID","value":"38414"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134470"}]}}{"C2707":{"preferredName":"DHEA Mustard","code":"C2707","definitions":[{"definition":"A steroidal alkylating agent with potential antineoplastic activity.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DHEA Mustard","termGroup":"PT","termSource":"NCI"},{"termName":"dehydroepiandrosterone mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DHEA_Mustard"},{"name":"Maps_To","value":"DHEA Mustard"},{"name":"NCI_Drug_Dictionary_ID","value":"39214"},{"name":"NSC Number","value":"121210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39214"},{"name":"PDQ_Open_Trial_Search_ID","value":"39214"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0279151"}]}}{"C78451":{"preferredName":"DI-Leu16-IL2 Immunocytokine","code":"C78451","definitions":[{"definition":"A recombinant fusion protein consisting of de-immunized and humanized anti-CD20 monoclonal antibody Leu16 fused to human cytokine interleukin-2 (IL2) with potential antineoplastic activity. The antibody moiety of DI-Leu16-IL2 immunocytokine binds to tumor cells expressing the CD20 antigen, which may result in an antibody-dependent cell-mediated cytotoxicity (ADCC) towards CD20-expressing tumor cells; the localized IL2 moiety of this fusion protein may stimulate natural killer (NK) and T-lymphocyte mediated immune responses, enhancing the ADCC response. De-immunization involves the modification of potential helper T cell epitopes that bind to MHC class II molecules; humanization involves combining recombinant murine variable (V) regions with human immunoglobulin light and heavy chain constant regions. CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes, is overexpressed by various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DI-Leu16-IL2 Immunocytokine","termGroup":"PT","termSource":"NCI"},{"termName":"De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2","termGroup":"SY","termSource":"NCI"},{"termName":"DI-Leu16-IL-2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8PQK3QPW4P"},{"name":"Legacy Concept Name","value":"De-Immunized_DI-Leu16-IL2_Immunocytokine"},{"name":"Maps_To","value":"DI-Leu16-IL2 Immunocytokine"},{"name":"NCI_Drug_Dictionary_ID","value":"599668"},{"name":"NCI_META_CUI","value":"CL387463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599668"},{"name":"PDQ_Open_Trial_Search_ID","value":"599668"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1632":{"preferredName":"Diarylsulfonylurea Compound ILX-295501","code":"C1632","definitions":[{"definition":"A substance that is being studied as an anticancer drug.  It belongs to the family of drugs called diarylsulfonylureas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"ILX-295501 is a novel sulfonylurea compound that has demonstrated in-vivo antitumor activity against a broad spectrum of solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diarylsulfonylurea Compound ILX-295501","termGroup":"PT","termSource":"NCI"},{"termName":"ILX 295501","termGroup":"CN","termSource":"NCI"},{"termName":"ILX295501","termGroup":"CN","termSource":"NCI"},{"termName":"LY-295501","termGroup":"CN","termSource":"NCI"},{"termName":"LY295501","termGroup":"CN","termSource":"NCI"},{"termName":"N-(((3,4-Dichlorophenyl)amino)carbonyl)-2,3-dihydro-5-benzofuransulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-(5-(2,3-Dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"150869-74-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"240Y4YO0TN"},{"name":"Legacy Concept Name","value":"ILX-295501"},{"name":"Maps_To","value":"Diarylsulfonylurea Compound ILX-295501"},{"name":"NCI_Drug_Dictionary_ID","value":"37917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37917"},{"name":"PDQ_Open_Trial_Search_ID","value":"37917"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299218"}]}}{"C62508":{"preferredName":"Diazepinomicin","code":"C62508","definitions":[{"definition":"A potent inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity. Diazepinomicin binds to and inhibits Ras kinase, thereby preventing the phosphorylation and activation of proteins downstream of the Ras signal transduction pathway, including serine/threonine kinase RAF (BRAF) and extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK-2), that play a crucial role in regulating cell growth and survival. Diazepinomicin also selectively binds to the peripheral benzodiazepine receptor (BZRP), a receptor highly expressed in certain cancer cells, thus inducing cell cycle arrest and apoptosis in BZRP-expressing cells. In addition, diazepinomicin is able to cross the blood-brain barrier, thereby reaching therapeutic concentrations in the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diazepinomicin","termGroup":"PT","termSource":"NCI"},{"termName":"11h-dibenzo(B,E)(1,4)diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BU-4664L","termGroup":"CN","termSource":"NCI"},{"termName":"ECO-4601","termGroup":"CN","termSource":"NCI"},{"termName":"TLN-4601","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"733035-26-2"},{"name":"Chemical_Formula","value":"C28H34N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YPH994Y0RF"},{"name":"Legacy Concept Name","value":"ECO-4601"},{"name":"Maps_To","value":"Diazepinomicin"},{"name":"NCI_Drug_Dictionary_ID","value":"496938"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496938"},{"name":"PDQ_Open_Trial_Search_ID","value":"496938"},{"name":"PubMedID_Primary_Reference","value":"20655882"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048794"}]}}{"C1363":{"preferredName":"Diaziquone","code":"C1363","definitions":[{"definition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is able to cross the blood-brain barrier and kill cancer cells in the central nervous system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diaziquone","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-cyclohexadiene-1,4-dicarbamic acid, 2, 5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-cyclohexadiene-1,4-dicarbamic acid,2,5-bis(1-aziridinyl)-3,6-dioxo,-diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-bis(1-aciridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-bis(1-aziridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-diaziridinyl-3,6-bis(ethoxycarbonyl-amino)-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"[2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]biscarbamic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"Aziridinyl Benzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"Aziridinylbenzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"Aziridinylbenzoquinone carbamic acid","termGroup":"SY","termSource":"NCI"},{"termName":"AZQ","termGroup":"AB","termSource":"NCI"},{"termName":"carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1, 4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"CI-904","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57998-68-2"},{"name":"Chemical_Formula","value":"C16H20N4O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FQL5EUP13W"},{"name":"Legacy Concept Name","value":"Diaziquone"},{"name":"Maps_To","value":"Diaziquone"},{"name":"NCI_Drug_Dictionary_ID","value":"39161"},{"name":"NSC Number","value":"182986"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39161"},{"name":"PDQ_Open_Trial_Search_ID","value":"39161"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0113600"}]}}{"C427":{"preferredName":"Diazooxonorleucine","code":"C427","definitions":[{"definition":"An L-glutamine diazo analogue amino acid antibiotic isolated from a species of the bacterial genus Streptomyces with potential antineoplastic activity. Diazooxonorleucine inhibits several glutamine-dependent biosynthetic pathways involved in the syntheses of D-glucosamine phosphate, purines and pyrimidines. This agent inhibits phosphate-activated glutaminase, a key enzyme for the synthesis of releasable glutamine, depleting cells of this essential amino acid and reducing their capacity to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diazooxonorleucine","termGroup":"PT","termSource":"NCI"},{"termName":"6-diazo-5-oxo-L-norleucine","termGroup":"SN","termSource":"NCI"},{"termName":"6-diazo-5-oxo-norleucine","termGroup":"SN","termSource":"NCI"},{"termName":"DON","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157-03-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"03J0H273KZ"},{"name":"Legacy Concept Name","value":"Diazooxonorleucine"},{"name":"Maps_To","value":"Diazooxonorleucine"},{"name":"NCI_Drug_Dictionary_ID","value":"39224"},{"name":"NSC Number","value":"7365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39224"},{"name":"PDQ_Open_Trial_Search_ID","value":"39224"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0012020"}]}}{"C81362":{"preferredName":"Dibrospidium Chloride","code":"C81362","definitions":[{"definition":"A dispirotripiperazine derivative and alkylating agent with potential antineoplastic and anti-inflammatory activities. Dibrospidium chloride has been examined for the treatment of bone cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dibrospidium Chloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86641-76-1"},{"name":"Chemical_Formula","value":"C18H32Br2N4O2.2Cl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GRX5L9Y3Z3"},{"name":"Legacy Concept Name","value":"Dibrospidium_Chloride"},{"name":"Maps_To","value":"Dibrospidium Chloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825594"}]}}{"C28959":{"preferredName":"Dichloroallyl Lawsone","code":"C28959","definitions":[{"definition":"A triazine derivative with antineoplastic activity.  Dichloroallyl lawsone inhibits mitochondrial dihydroorotate dehydrogenase (DHOD), an enzyme that catalyzes the only redox step in de novo pyrimidine biosynthesis, and nucleotide (RNA and DNA) biosynthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dichloroallyl Lawsone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"36417-16-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZE2BI297KA"},{"name":"Legacy Concept Name","value":"Dichloroallyl_Lawsone"},{"name":"Maps_To","value":"Dichloroallyl Lawsone"},{"name":"NSC Number","value":"126771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057845"}]}}{"C107676":{"preferredName":"Dicycloplatin","code":"C107676","definitions":[{"definition":"A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks. This mechanism results in the induction of apoptosis and cell growth inhibition. Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dicycloplatin","termGroup":"PT","termSource":"NCI"},{"termName":"DCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"287402-09-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0KC57I4UNB"},{"name":"Maps_To","value":"Dicycloplatin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3815135"}]}}{"C1338":{"preferredName":"Didox","code":"C1338","definitions":[{"definition":"A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides obligatory for synthesis of the proviral DNA intermediate of retrovirus replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Didox","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydroxybenzohydroxamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69839-83-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L106XFV0RQ"},{"name":"Legacy Concept Name","value":"Didox"},{"name":"Maps_To","value":"Didox"},{"name":"NCI_Drug_Dictionary_ID","value":"40191"},{"name":"NSC Number","value":"324360"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40191"},{"name":"PDQ_Open_Trial_Search_ID","value":"40191"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0094556"}]}}{"C87238":{"preferredName":"Dienogest","code":"C87238","definitions":[{"definition":"An orally-active, semisynthetic, fourth generation, nonethinylated progestogen with antiproliferative, antiandrogenic, anti-inflammatory and antiangiogenic activities that is used in hormone therapy and as a female contraceptive. Upon oral administration, dienogest binds intracellular progesterone receptors which then translocate to the nucleus where the drug-receptor complex interacts with progesterone response elements, thus altering the expression of target genes. Dienogest reduces the production of estradiol, prevents ovulation and alters the cervical mucus and endometrium. In addition, dienogest appears to suppress the expression of cell cycle regulator cyclin D1. Altogether, this may prevent the growth of endometrial epithelial cells and may reduce symptoms associated with leiomyoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dienogest","termGroup":"PT","termSource":"NCI"},{"termName":"17-Hydroxy-3-Oxo-19-Nor-17Alpha-Pregna-4,9-Diene-21-Nitrile","termGroup":"SN","termSource":"NCI"},{"termName":"19-Norpregna-4,9-Diene-21-Nitrile, 17-Hydroxy-3-Oxo-, (17Alpha)-","termGroup":"SN","termSource":"NCI"},{"termName":"M 18575","termGroup":"CN","termSource":"NCI"},{"termName":"MJR-35","termGroup":"CN","termSource":"NCI"},{"termName":"STS 557","termGroup":"CN","termSource":"NCI"},{"termName":"ZK 37659","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65928-58-7"},{"name":"Chemical_Formula","value":"C20H25NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46M3EV8HHE"},{"name":"Maps_To","value":"Dienogest"},{"name":"NCI_Drug_Dictionary_ID","value":"743773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743773"},{"name":"PDQ_Open_Trial_Search_ID","value":"743773"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057916"}]}}{"C1168":{"preferredName":"Diethylnorspermine","code":"C1168","definitions":[{"definition":"A synthetic bis-ethyl analogue of spermine with potential antineoplastic activity. N(1),N(11)-bis(ethyl)norspermine (DENSPM), a N-terminally alkylated tetraamine and polyamine mimetics, disrupts polyamine pool homeostasis by modulating the activities of the biosynthetic enzymes, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC). This agent also reduces polyamine concentrations through the induction of the catabolic enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT). Polyamines, an integral part of the DNA helix structure, play a critical role in cell division, differentiation and membrane function. Disruption of normal polyamine concentrations by DENSPM may lead to cell growth inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diethylnorspermine","termGroup":"PT","termSource":"NCI"},{"termName":"CI-1006","termGroup":"CN","termSource":"NCI"},{"termName":"DENSPM","termGroup":"AB","termSource":"NCI"},{"termName":"N(1),N(11)-diethylnorspermine","termGroup":"SN","termSource":"NCI"},{"termName":"N1,N11-bis(ethyl)norspermine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"121749-39-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HLI827Z1ST"},{"name":"Legacy Concept Name","value":"N_1_N_11_bis_ethyl_norspermine"},{"name":"Maps_To","value":"Diethylnorspermine"},{"name":"NCI_Drug_Dictionary_ID","value":"375649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"375649"},{"name":"PDQ_Open_Trial_Search_ID","value":"375649"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0067116"}]}}{"C2634":{"preferredName":"Digitoxin","code":"C2634","definitions":[{"definition":"A lipid soluble cardiac glycoside that inhibits the plasma membrane sodium potassium ATPase, leading to increased intracellular sodium and calcium levels and decreased intracellular potassium levels.  In studies increased intracellular calcium precedes cell death and decreased intracellular potassium increase caspase activation and DNA fragmentation, causing apoptosis and inhibition of cancer cell growth. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Digitoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Cardidigin","termGroup":"SY","termSource":"NCI"},{"termName":"CP4071","termGroup":"CN","termSource":"NCI"},{"termName":"Crystalline Digitalin","termGroup":"SY","termSource":"NCI"},{"termName":"Crystodigin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Atrial Fibrillation; Atrial Flutter; Congestive Heart Failure; Supraventricular Tachyarrhythmias."},{"name":"CAS_Registry","value":"71-63-6"},{"name":"CHEBI_ID","value":"CHEBI:28544"},{"name":"Chemical_Formula","value":"C41H64O13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E90NZP2L9U"},{"name":"Legacy Concept Name","value":"Digitoxin"},{"name":"Maps_To","value":"Digitoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"38332"},{"name":"NSC Number","value":"7529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38332"},{"name":"PDQ_Open_Trial_Search_ID","value":"38332"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012258"}]}}{"C28990":{"preferredName":"Digoxin","code":"C28990","definitions":[{"definition":"A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility.  This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity.  Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat irregular heartbeat and some types of heart failure. It is also being studied in the treatment of some types of cancer. Digoxin helps the heart work normally by controlling the amount of calcium that goes into the heart muscle. It also may kill cancer cells and make them more sensitive to anticancer drugs. It is a type of cardiac glycoside.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Digoxin","termGroup":"PT","termSource":"NCI"},{"termName":"12beta-Hydroxydigitoxin","termGroup":"SY","termSource":"NCI"},{"termName":"3beta,12beta,14-Trihydroxy-5beta,14beta-card-20(22)-enolid-3-tridigitoxosid","termGroup":"SN","termSource":"NCI"},{"termName":"Cardiogoxin","termGroup":"BR","termSource":"NCI"},{"termName":"Digoxigenin-tridigitoxosid","termGroup":"SY","termSource":"NCI"},{"termName":"Lanoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"20830-75-5"},{"name":"CHEBI_ID","value":"CHEBI:4551"},{"name":"Chemical_Formula","value":"C41H64O14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"73K4184T59"},{"name":"Legacy Concept Name","value":"Digoxin"},{"name":"Maps_To","value":"Digoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"485249"},{"name":"NSC Number","value":"95100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485249"},{"name":"PDQ_Open_Trial_Search_ID","value":"485249"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012265"}]}}{"C980":{"preferredName":"Dihydro-5-Azacytidine","code":"C980","definitions":[{"definition":"A synthetic nucleoside analogue of deoxycytidine. Dihydro-5-azacytidine inhibits DNA methyltransferase, thereby interfering with abnormal DNA methylation patterns that are associated with genetic instability in some tumor cells. Inhibition of this enzyme may restore expression of tumor-suppressor genes and result in antitumor activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dihydro-5-Azacytidine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5-triazin-2(1H)-one, 4-amino-3, 6-dihydro-1-beta-D-ribofuranosyl monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"5,6-dihydro-5-azacytidine HCl","termGroup":"SN","termSource":"NCI"},{"termName":"5,6-dihydro-5-azacytidine hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"DHAC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62488-57-7"},{"name":"Chemical_Formula","value":"C8H14N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0627D8VG1C"},{"name":"Legacy Concept Name","value":"Dihydro-5-Azacytidine"},{"name":"Maps_To","value":"Dihydro-5-Azacytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39220"},{"name":"NSC Number","value":"264880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39220"},{"name":"PDQ_Open_Trial_Search_ID","value":"39220"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048906"}]}}{"C1463":{"preferredName":"Dihydrolenperone","code":"C1463","definitions":[{"definition":"A butyrophenone that has been investigated for antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dihydrolenperone","termGroup":"PT","termSource":"NCI"},{"termName":"1-Butanone, 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydro-lenperone","termGroup":"SY","termSource":"NCI"},{"termName":"RMI 11974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38077-12-2"},{"name":"Chemical_Formula","value":"C22H25F2NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RJ5N8VE7Z"},{"name":"Legacy Concept Name","value":"Dihydrolenperone"},{"name":"Maps_To","value":"Dihydrolenperone"},{"name":"NCI_Drug_Dictionary_ID","value":"40107"},{"name":"NSC Number","value":"343513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40107"},{"name":"PDQ_Open_Trial_Search_ID","value":"40107"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0208317"}]}}{"C158103":{"preferredName":"Dihydroorotate Dehydrogenase Inhibitor AG-636","code":"C158103","definitions":[{"definition":"An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, AG-636 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dihydroorotate Dehydrogenase Inhibitor AG-636","termGroup":"PT","termSource":"NCI"},{"termName":"AG 636","termGroup":"CN","termSource":"NCI"},{"termName":"AG-636","termGroup":"CN","termSource":"NCI"},{"termName":"AG636","termGroup":"CN","termSource":"NCI"},{"termName":"DHODH Inhibitor AG-636","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dihydroorotate Dehydrogenase Inhibitor AG-636"},{"name":"NCI_Drug_Dictionary_ID","value":"797356"},{"name":"NCI_META_CUI","value":"CL937737"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797356"},{"name":"PDQ_Open_Trial_Search_ID","value":"797356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153137":{"preferredName":"Orludodstat","code":"C153137","definitions":[{"definition":"An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, orludodstat specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) production, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orludodstat","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 2402234","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2402234","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2402234","termGroup":"CN","termSource":"NCI"},{"termName":"DHODH Inhibitor BAY2402234","termGroup":"SY","termSource":"NCI"},{"termName":"Dihydroorotate Dehydrogenase Inhibitor BAY2402234","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2225819-06-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X8GF945GMK"},{"name":"Maps_To","value":"Dihydroorotate Dehydrogenase Inhibitor BAY2402234"},{"name":"NCI_Drug_Dictionary_ID","value":"793941"},{"name":"NCI_META_CUI","value":"CL554394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793941"},{"name":"PDQ_Open_Trial_Search_ID","value":"793941"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C53434":{"preferredName":"Diindolylmethane","code":"C53434","definitions":[{"definition":"A phytonutrient and plant indole found in cruciferous vegetables including broccoli, Brussels sprouts, cabbage, cauliflower and kale, with potential anti-androgenic and antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) promotes beneficial estrogen metabolism in both sexes by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of 2-hydroxy estrogen metabolites, resulting in increased antioxidant activity. Although this agent induces apoptosis in tumor cells in vitro, the exact mechanism by which DIM exhibits its antineoplastic activity in vivo is unknown.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of prostate cancer and in the prevention of cervical cancer. Diindolylmethane is found in cruciferous vegetables like broccoli, brussels sprouts, cauliflower, cabbage, and kale. It is a type of plant indole.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diindolylmethane","termGroup":"PT","termSource":"NCI"},{"termName":"3,3'-Diindolymethane","termGroup":"SN","termSource":"NCI"},{"termName":"3,3'-Methylenebis-1H-indole","termGroup":"SN","termSource":"NCI"},{"termName":"CCRIS 5806","termGroup":"CN","termSource":"NCI"},{"termName":"Di-Indoly Methane","termGroup":"SY","termSource":"NCI"},{"termName":"DIM-Plus","termGroup":"BR","termSource":"NCI"},{"termName":"DIMPRO","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1968-05-4"},{"name":"CHEBI_ID","value":"CHEBI:50182"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SSZ9HQT61Z"},{"name":"Legacy Concept Name","value":"Diindolylmethane"},{"name":"Maps_To","value":"Diindolylmethane"},{"name":"NCI_Drug_Dictionary_ID","value":"462587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462587"},{"name":"PDQ_Open_Trial_Search_ID","value":"462587"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1100708"}]}}{"C1073":{"preferredName":"Dimethylmyleran","code":"C1073","definitions":[{"definition":"An aliphatic analogue of busulfan with potential antineoplastic activity.  As an alkylating agent, dimethylbusulfan induces neutropenia and has been shown to exhibit antitumor effects in some animal models.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dimethylmyleran","termGroup":"PT","termSource":"NCI"},{"termName":"2,5-Dimethanesulfonoxyhexane","termGroup":"SN","termSource":"NCI"},{"termName":"Dimethyl-Myleran","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylbusulfan","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylmyleran","termGroup":"SY","termSource":"NCI"},{"termName":"DMB","termGroup":"AB","termSource":"NCI"},{"termName":"DMM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55-93-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dimethylbusulfan"},{"name":"Maps_To","value":"Dimethylmyleran"},{"name":"NCI_Drug_Dictionary_ID","value":"39221"},{"name":"NSC Number","value":"180541"},{"name":"NSC Number","value":"180542"},{"name":"NSC Number","value":"180543"},{"name":"NSC Number","value":"23890"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39221"},{"name":"PDQ_Open_Trial_Search_ID","value":"39221"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058272"}]}}{"C78854":{"preferredName":"Dinaciclib","code":"C78854","definitions":[{"definition":"A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of advanced melanoma (a type of skin cancer) and other types of cancer. It blocks cell division and may cause cancer cells to die. It is a type of cyclin-dependent kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dinaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- a]pyrimidin-5-yl]-, (2S)-","termGroup":"SN","termSource":"NCI"},{"termName":"CDK Inhibitor SCH 727965","termGroup":"SY","termSource":"NCI"},{"termName":"MK-7965","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 727965","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"779353-01-4"},{"name":"Chemical_Formula","value":"C21H28N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4V8ECV0NBQ"},{"name":"Legacy Concept Name","value":"CDK_Inhibitor_SCH_727965"},{"name":"Maps_To","value":"Dinaciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"612855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612855"},{"name":"PDQ_Open_Trial_Search_ID","value":"612855"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698720"}]}}{"C1570":{"preferredName":"Dinutuximab","code":"C1570","definitions":[{"definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dinutuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Ch 14.18UTC","termGroup":"SY","termSource":"NCI"},{"termName":"Ch14.18","termGroup":"CN","termSource":"NCI"},{"termName":"Dinutuximab Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Qarziba","termGroup":"FB","termSource":"NCI"},{"termName":"Unituxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"childhood neuroblastoma"},{"name":"CAS_Registry","value":"1363687-32-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7SQY4ZUD30"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Ch14_18"},{"name":"Maps_To","value":"Dinutuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"42042"},{"name":"NSC Number","value":"623408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42042"},{"name":"PDQ_Open_Trial_Search_ID","value":"42042"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3871452"}]}}{"C115103":{"preferredName":"Dioscorea nipponica Makino Extract DNE3","code":"C115103","definitions":[{"definition":"An extract of the plant Dioscorea nipponica Makino and inhibitor of both the serine/threonine protein kinase Akt (protein kinase B) and members of the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases, with potential antineoplastic and anti-metastatic activities. Dioscorea nipponica Makino extracted with ethyl acetate (DNE3) binds to and inhibits PI3K and Akt. This inhibits PI3K/Akt-mediated signaling and prevents both growth and survival of PI3K/Akt-overexpressing tumor cells. In addition, DNE3 increases the expression of tissue inhibitor of metalloproteinase-2 (TIMP-2), inhibits the secretion of matrix metalloproteinases (MMPs), primarily MMP-2 and MMP-9, and inhibits the serine protease urokinase (urokinase-type plasminogen activator; u-PA). This inhibits tumor cell invasion, migration, motility, and adhesion. This agent also inhibits the activation of both cAMP response element-binding (CREB) and activating protein-1 (AP-1), and increases the expression of IkappaB (IkB), which inhibits the activation of nuclear factor-kappa B (NF-kB). These processes further contribute to this agent's anti-tumor potential in susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dioscorea nipponica Makino Extract DNE3","termGroup":"PT","termSource":"NCI"},{"termName":"Dioscorea nipponica Extract with Ethyl Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"DNE3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dioscorea nipponica Makino Extract DNE3"},{"name":"NCI_Drug_Dictionary_ID","value":"759832"},{"name":"NCI_META_CUI","value":"CL472634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759832"},{"name":"PDQ_Open_Trial_Search_ID","value":"759832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28994":{"preferredName":"Diphencyprone","code":"C28994","definitions":[{"definition":"A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diphencyprone","termGroup":"PT","termSource":"NCI"},{"termName":"Diphenylcyclopropenone","termGroup":"SY","termSource":"NCI"},{"termName":"DPCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"886-38-4"},{"name":"CHEBI_ID","value":"CHEBI:53074"},{"name":"Chemical_Formula","value":"C15H10O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I7G14NW5EC"},{"name":"Legacy Concept Name","value":"Diphencyprone"},{"name":"Maps_To","value":"Diphencyprone"},{"name":"NCI_Drug_Dictionary_ID","value":"742143"},{"name":"NSC Number","value":"57541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742143"},{"name":"PDQ_Open_Trial_Search_ID","value":"742143"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058379"}]}}{"C432":{"preferredName":"Ditiocarb","code":"C432","definitions":[{"definition":"A sulfhydryl-containing carbamate that is the primary in vivo metabolite of disulfiram. Diethyldithiocarbamate chelates zinc, thereby inhibiting metalloproteinases, thereby preventing the degradation of the extracellular matrix and inhibiting an initial step in cancer metastasis and angiogenesis. A known inhibitor of superoxide dismutase, this agent can either potentiate or protect against cell oxidative damage caused by ionizing radiation, depending on the time of administration. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ditiocarb","termGroup":"PT","termSource":"NCI"},{"termName":"DDTC","termGroup":"AB","termSource":"NCI"},{"termName":"DIECA","termGroup":"AB","termSource":"NCI"},{"termName":"Diethylcarbamodithioic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldione","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithiocarbamate","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithiocarbamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithiocarbaminic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithione","termGroup":"SY","termSource":"NCI"},{"termName":"DTC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"147-84-2"},{"name":"Chemical_Formula","value":"C5H11NS2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"99Z2744345"},{"name":"Legacy Concept Name","value":"Diethyldithiocarbamate"},{"name":"Maps_To","value":"Ditiocarb"},{"name":"NCI_Drug_Dictionary_ID","value":"40247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40247"},{"name":"PDQ_Open_Trial_Search_ID","value":"40247"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012194"}]}}{"C90539":{"preferredName":"Mipicoledine","code":"C90539","definitions":[{"definition":"A cholesterol carbonate derivative of 4-demethylpenclomedine (DM-PEN) with potential antineoplastic alkylating activity. Upon intravenous administration of mipicoledine, the carbonium moiety binds to and alkylates DNA at the N7 guanine position, thereby causing DNA crosslinks. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. In addition, due to its lipophilic cholesteryl moiety this agent is able to cross the blood brain barrier (BBB) and therefore can be given intravenously compared to other alkylating agents that need to be given intra-cranially.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mipicoledine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Demethylcholesteryloxycarbonylpenclomedine","termGroup":"SN","termSource":"NCI"},{"termName":"DM-CHOC-PEN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"942149-56-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1S83F4T2WE"},{"name":"Maps_To","value":"DM-CHOC-PEN"},{"name":"NCI_Drug_Dictionary_ID","value":"664344"},{"name":"NCI_META_CUI","value":"CL416220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"664344"},{"name":"PDQ_Open_Trial_Search_ID","value":"664344"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77864":{"preferredName":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015","code":"C77864","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against the cell surface-associated protein Cripto and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of DM4-conjugated anti-Cripto monoclonal antibody BIIB015 binds to the tumor associated antigen (TAA) Cripto; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of Cripto-expressing tumor cells. Constitutively expressed during embryogenesis, Cripto belongs to the EGF-CFC family of growth factor-like molecules and plays a key role in signaling pathways of certain transforming growth factor-beta superfamily members; as a TAA, Cripto is overexpressed in carcinomas such as those of the breast, ovary, stomach, lung, and pancreas while its expression is absent in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DM4-Conjugated_Anti-Cripto_Monoclonal_Antibody_BIIB015"},{"name":"Maps_To","value":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015"},{"name":"NCI_Drug_Dictionary_ID","value":"596550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596550"},{"name":"PDQ_Open_Trial_Search_ID","value":"596550"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2713087"}]}}{"C92588":{"preferredName":"DNA Interference Oligonucleotide PNT2258","code":"C92588","definitions":[{"definition":"A liposomal formulation of the 24-mer oligonucleotide PNT100, with potential antineoplastic activity. PNT2258 targets and complements to untranscribed DNA sequence upstream of BCL2 promoters, thereby interfering with DNA replication and transcription of the BCL2 gene. This may promote and restore the apoptotic pathway in BCL2-overexpressing tumor cells. BCL2, an anti-apoptotic protein, is overexpressed in a wide variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Interference Oligonucleotide PNT2258","termGroup":"PT","termSource":"NCI"},{"termName":"DNAi Drug PNT2258","termGroup":"BR","termSource":"NCI"},{"termName":"PNT2258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Interference Oligonucleotide PNT2258"},{"name":"NCI_Drug_Dictionary_ID","value":"685213"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685213"},{"name":"PDQ_Open_Trial_Search_ID","value":"685213"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985197"}]}}{"C29435":{"preferredName":"DNA Minor Groove Binding Agent SG2000","code":"C29435","definitions":[{"definition":"A sequence-selective pyrrolobenzodiazepine (PBD) dimer with potential antineoplastic activity. Following intravenous administration, DNA minor groove binding agent SG2000 preferentially and covalently binds to purine-GATC-pyrimidine sequences, with the imine/carbinolamine moieties of SG2000 binding to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links and inhibits both DNA replication and gene transcription, which lead to the inhibition of cell growth. With a preference for binding to purine-GATC-pyrimidine sequences, SG2000 adducts do not appear to be susceptible to p53-mediated DNA excision repair.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called DNA cross-linking agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DNA Minor Groove Binding Agent SG2000","termGroup":"PT","termSource":"NCI"},{"termName":"(11aS,11a'S)-8,8'-(propane-1,3-diylbis(oxy))bis(7-methoxy-2-methylene-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one)","termGroup":"SN","termSource":"NCI"},{"termName":"BN2629","termGroup":"CN","termSource":"NCI"},{"termName":"NSC 694501","termGroup":"CN","termSource":"NCI"},{"termName":"Pyrrolobenzodiazepine Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"SG2000","termGroup":"CN","termSource":"NCI"},{"termName":"SJG136","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"232931-57-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KT0ZQ64X1A"},{"name":"Legacy Concept Name","value":"SJG-136"},{"name":"Maps_To","value":"DNA Minor Groove Binding Agent SG2000"},{"name":"NCI_Drug_Dictionary_ID","value":"415963"},{"name":"NSC Number","value":"694501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415963"},{"name":"PDQ_Open_Trial_Search_ID","value":"415963"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519143"}]}}{"C116709":{"preferredName":"Rocakinogene Sifuplasmid","code":"C116709","definitions":[{"definition":"A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of rocakinogene sifuplasmid, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rocakinogene Sifuplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Plasmid Encoding Interleukin-12 INO-9012","termGroup":"SY","termSource":"NCI"},{"termName":"INO-9012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253753-17-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91JHE0ANN8"},{"name":"Maps_To","value":"DNA Plasmid Encoding Interleukin-12 INO-9012"},{"name":"Maps_To","value":"Rocakinogene Sifuplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"762182"},{"name":"NCI_META_CUI","value":"CL473906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762182"},{"name":"PDQ_Open_Trial_Search_ID","value":"762182"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163978":{"preferredName":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151","code":"C163978","definitions":[{"definition":"A DNA-based combined formulation composed of INO-5150, DNA plasmids encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), and INO-9012, a plasmid DNA vaccine encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery of INO-5151 and electroporation of the PSA/PSMA DNA plasmid INO-5150, PSA and PSMA are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing PSA and PSMA, resulting in tumor cell lysis. Upon electroporation of the DNA plasmid encoding IL-12 INO-9012, IL-12 is translated in cells and the expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of INO-5150 alone. PSA and PSMA are overexpressed on a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151","termGroup":"PT","termSource":"NCI"},{"termName":"Formulation INO-5150 with INO-9012","termGroup":"SY","termSource":"NCI"},{"termName":"INO 5151","termGroup":"CN","termSource":"NCI"},{"termName":"INO-5150 with INO-9012","termGroup":"SY","termSource":"NCI"},{"termName":"INO-5150/INO-9012 Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"INO-5151","termGroup":"CN","termSource":"NCI"},{"termName":"INO5151","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151"},{"name":"NCI_META_CUI","value":"CL977247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123919":{"preferredName":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457","code":"C123919","definitions":[{"definition":"A DNA-based combination immunotherapeutic, MEDI0457, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457","termGroup":"PT","termSource":"NCI"},{"termName":"INO 3112","termGroup":"CN","termSource":"NCI"},{"termName":"INO-3112","termGroup":"CN","termSource":"NCI"},{"termName":"INO-3112 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 0457","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-0457","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI0457","termGroup":"CN","termSource":"NCI"},{"termName":"VGX-3100 Plus INO-9012","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457"},{"name":"NCI_Drug_Dictionary_ID","value":"775854"},{"name":"NCI_META_CUI","value":"CL498283"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775854"},{"name":"PDQ_Open_Trial_Search_ID","value":"775854"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123923":{"preferredName":"DNA Vaccine VB10.16","code":"C123923","definitions":[{"definition":"A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Vaccine VB10.16","termGroup":"PT","termSource":"NCI"},{"termName":"VB10.16","termGroup":"CN","termSource":"NCI"},{"termName":"VB10.16 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Vaccine VB10.16"},{"name":"NCI_Drug_Dictionary_ID","value":"775928"},{"name":"NCI_META_CUI","value":"CL498287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775928"},{"name":"PDQ_Open_Trial_Search_ID","value":"775928"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129061":{"preferredName":"DNA-dependent Protein Kinase Inhibitor VX-984","code":"C129061","definitions":[{"definition":"An ATP-competitive inhibitor of the catalytic subunit of DNA-dependent protein kinase (DNA-PK), with potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, DNA-PK inhibitor VX-984 binds to and inhibits the catalytic subunit of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-dependent Protein Kinase Inhibitor VX-984","termGroup":"PT","termSource":"NCI"},{"termName":"DNA-PK Inhibitor VX-984","termGroup":"SY","termSource":"NCI"},{"termName":"VX-984","termGroup":"CN","termSource":"NCI"},{"termName":"VX984","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1476074-39-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0C33IBK195"},{"name":"Maps_To","value":"DNA-dependent Protein Kinase Inhibitor VX-984"},{"name":"NCI_Drug_Dictionary_ID","value":"783593"},{"name":"NCI_META_CUI","value":"CL512131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783593"},{"name":"PDQ_Open_Trial_Search_ID","value":"783593"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97040":{"preferredName":"DNA-PK/TOR Kinase Inhibitor CC-115","code":"C97040","definitions":[{"definition":"A dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. CC-115 binds to and inhibits the activity of DNA-PK and both raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2), which may lead to a reduction in cellular proliferation of cancer cells expressing DNA-PK and TOR. DNA-PK, a serine/threonine kinase and a member of the PI3K-related kinase subfamily of protein kinases, is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks via the DNA nonhomologous end joining (NHEJ) pathway; mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-PK/TOR Kinase Inhibitor CC-115","termGroup":"PT","termSource":"NCI"},{"termName":"CC-115","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228013-15-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FII75TFH5L"},{"name":"Maps_To","value":"DNA-PK/TOR Kinase Inhibitor CC-115"},{"name":"NCI_Drug_Dictionary_ID","value":"700650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700650"},{"name":"PDQ_Open_Trial_Search_ID","value":"700650"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273208"}]}}{"C2530":{"preferredName":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98","code":"C2530","definitions":[{"definition":"A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3' un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It blocks the production of a protein called DNA methyltransferase, which helps control gene expression. This may kill cancer cells that need DNA methyltransferase to grow. It is a type of antisense oligonucleotide.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98","termGroup":"PT","termSource":"NCI"},{"termName":"MG 98","termGroup":"CN","termSource":"NCI"},{"termName":"MG-98","termGroup":"CN","termSource":"NCI"},{"termName":"MG-98 oligonucleotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MG_98"},{"name":"Maps_To","value":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98"},{"name":"NCI_Drug_Dictionary_ID","value":"43475"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43475"},{"name":"PDQ_Open_Trial_Search_ID","value":"43475"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796640"}]}}{"C1526":{"preferredName":"Docetaxel","code":"C1526","definitions":[{"definition":"A drug used together with other drugs to treat certain types of breast cancer, stomach cancer, prostate cancer, and certain types of head and neck cancer. It is also being studied in the treatment of other types of cancer. Docetaxel is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"[2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Docecad","termGroup":"FB","termSource":"NCI"},{"termName":"N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol","termGroup":"SN","termSource":"NCI"},{"termName":"RP 56976","termGroup":"CN","termSource":"NCI"},{"termName":"RP56976","termGroup":"CN","termSource":"NCI"},{"termName":"Taxotere","termGroup":"BR","termSource":"NCI"},{"termName":"Taxotere Injection Concentrate","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Esophageal cancer; Gastric cancer; Head/Neck cancers; Locally Advanced or Metastatic Non small-cell lung cancer; Ovarian cancer; Metastatic Prostate cancer"},{"name":"CAS_Registry","value":"148408-66-6"},{"name":"CHEBI_ID","value":"CHEBI:59809"},{"name":"Chemical_Formula","value":"C43H53NO14.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"15H5577CQD"},{"name":"Legacy Concept Name","value":"Docetaxel"},{"name":"Maps_To","value":"Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"41657"},{"name":"NSC Number","value":"628503"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41657"},{"name":"PDQ_Open_Trial_Search_ID","value":"41657"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0246415"}]}}{"C61734":{"preferredName":"Docetaxel Anhydrous","code":"C61734","definitions":[{"definition":"The anhydrous form of docetaxel, a semisynthetic side-chain analogue of paclitaxel with antineoplastic property. Docetaxel binds specifically to the beta-tubulin subunit of microtubules and thereby antagonizes the disassembly of the microtubule proteins. This results in the persistence of aberrant microtubule structures and results in cell-cycle arrest and subsequent cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"DOCEFREZ","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114977-28-5"},{"name":"CHEBI_ID","value":"CHEBI:4672"},{"name":"Chemical_Formula","value":"C43H53NO14"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"699121PHCA"},{"name":"Legacy Concept Name","value":"Docetaxel_Anhydrous"},{"name":"Maps_To","value":"Docetaxel Anhydrous"},{"name":"NSC Number","value":"628503"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771375"}]}}{"C78196":{"preferredName":"Docetaxel Emulsion ANX-514","code":"C78196","definitions":[{"definition":"An injectable emulsion formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Docetaxel emulsion ANX-514 is formulated without polysorbate 80 or other detergents in order to reduce the incidence and severity of hypersensitivity reactions. In addition, the exclusion of polysorbate 80 in this formulation precludes foaming during the preparation process, thus facilitating preparation and administration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Emulsion ANX-514","termGroup":"PT","termSource":"NCI"},{"termName":"ANX-514","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Docetaxel_Emulsion_ANX-514"},{"name":"Maps_To","value":"Docetaxel Emulsion ANX-514"},{"name":"NCI_Drug_Dictionary_ID","value":"595290"},{"name":"NCI_META_CUI","value":"CL383589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595290"},{"name":"PDQ_Open_Trial_Search_ID","value":"595290"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88322":{"preferredName":"Docetaxel Formulation CKD-810","code":"C88322","definitions":[{"definition":"An injectable formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Formulation CKD-810","termGroup":"PT","termSource":"NCI"},{"termName":"CKD-810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Formulation CKD-810"},{"name":"NCI_Drug_Dictionary_ID","value":"661020"},{"name":"NCI_META_CUI","value":"CL413582"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661020"},{"name":"PDQ_Open_Trial_Search_ID","value":"661020"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102568":{"preferredName":"Docetaxel Lipid Microspheres","code":"C102568","definitions":[{"definition":"A lipid microsphere (LM)-based formulation containing the poorly water soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which causes cell cycle arrest at the G2/M phase and leads to cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the LM formulation may enhance stability, improve efficacy and may reduce toxicity; this formulation does not contain toxic detergents needed to solubilize docetaxel which further improves its side effect profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Lipid Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"DLE","termGroup":"AB","termSource":"NCI"},{"termName":"Docetaxel Lipid Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"DT-LM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Lipid Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"735255"},{"name":"NCI_META_CUI","value":"CL436875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735255"},{"name":"PDQ_Open_Trial_Search_ID","value":"735255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121961":{"preferredName":"Docetaxel Nanoparticle CPC634","code":"C121961","definitions":[{"definition":"A polymeric nanoparticle (PNP) formulation containing the poorly water-soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel nanoparticle CPC634, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site, binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Nanoparticle CPC634","termGroup":"PT","termSource":"NCI"},{"termName":"CPC 634","termGroup":"CN","termSource":"NCI"},{"termName":"CPC-634","termGroup":"CN","termSource":"NCI"},{"termName":"CPC634","termGroup":"CN","termSource":"NCI"},{"termName":"CriPec (R) Docetaxel","termGroup":"FB","termSource":"NCI"},{"termName":"Docetaxel containing CriPec (R) Nanoparticles","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-containing CriPec (R) Nanoparticles CPC634","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle-encapsulated Docetaxel CPC634","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Nanoparticle CPC634"},{"name":"NCI_Drug_Dictionary_ID","value":"772251"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772251"},{"name":"PDQ_Open_Trial_Search_ID","value":"772251"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054421"}]}}{"C165263":{"preferredName":"Docetaxel Polymeric Micelles","code":"C165263","definitions":[{"definition":"A nanoparticle-based formulation consisting of polymeric micelles (PMs), made with poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) block polymers, encapsulating the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with potential antineoplastic activity. Upon intravenous administration of the docetaxel PMs, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site where it binds specifically to the beta-tubulin subunit of the microtubule, thereby stabilizing tubulin and inhibiting microtubule disassembly. This results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Polymeric Micelles","termGroup":"PT","termSource":"NCI"},{"termName":"Docetaxel Lipid Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-loaded PM","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-loaded PMs","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-loaded Polymeric Micelles","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-PM","termGroup":"SY","termSource":"NCI"},{"termName":"NANOXEL-M","termGroup":"FB","termSource":"NCI"},{"termName":"NanoxelM","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Polymeric Micelles"},{"name":"NCI_Drug_Dictionary_ID","value":"799405"},{"name":"NCI_META_CUI","value":"CL978531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799405"},{"name":"PDQ_Open_Trial_Search_ID","value":"799405"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121539":{"preferredName":"Docetaxel-loaded Nanopharmaceutical CRLX301","code":"C121539","definitions":[{"definition":"A nanoparticle-based formulation containing the poorly water-soluble, second-generation taxane analog docetaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel-loaded nanopharmaceutical CRLX301, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, CRLX301 is taken up by the tumor cell via macropinocytosis. Subsequently, docetaxel is slowly released into the cytoplasm where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This prevents mitosis and results in cell death. Compared to the administration of docetaxel alone, this formulation is able to increase docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel-loaded Nanopharmaceutical CRLX301","termGroup":"PT","termSource":"NCI"},{"termName":"CRLX301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel-loaded Nanopharmaceutical CRLX301"},{"name":"NCI_Drug_Dictionary_ID","value":"770081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770081"},{"name":"PDQ_Open_Trial_Search_ID","value":"770081"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053653"}]}}{"C91087":{"preferredName":"Docetaxel-PNP","code":"C91087","definitions":[{"definition":"A polymeric nanoparticle (PNP) formulation containing the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the PNP formulation may enhance stability and improve delivery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel-PNP","termGroup":"PT","termSource":"NCI"},{"termName":"PNP-DTX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel-PNP"},{"name":"NCI_Drug_Dictionary_ID","value":"671819"},{"name":"NCI_META_CUI","value":"CL421475"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671819"},{"name":"PDQ_Open_Trial_Search_ID","value":"671819"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162784":{"preferredName":"Docetaxel/Ritonavir","code":"C162784","definitions":[{"definition":"An orally bioavailable combination agent containing docetaxel, a second generation taxane, and ritonavir, a cytochrome P450 (CYP) 3A4 inhibitor, with potential enhanced antineoplastic activity. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death.  Docetaxel is metabolized by CYP3A4  enzymes which is inhibited by the presence of ritonavir. This increases the plasma concentration of docetaxel and may increase docetaxel's efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel/Ritonavir","termGroup":"PT","termSource":"NCI"},{"termName":"ModraDoc006/r","termGroup":"FB","termSource":"NCI"},{"termName":"Oral Docetaxel/Ritonavir","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel/Ritonavir"},{"name":"NCI_Drug_Dictionary_ID","value":"798993"},{"name":"NCI_META_CUI","value":"CL973164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798993"},{"name":"PDQ_Open_Trial_Search_ID","value":"798993"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1300":{"preferredName":"Dolastatin 10","code":"C1300","definitions":[{"definition":"A pentapeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Binding to tubulin, Dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis.  This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It binds to a protein that cells need to divide and it may kill cancer cells. Dolastatin 10 comes from a marine organism. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dolastatin 10","termGroup":"PT","termSource":"NCI"},{"termName":"B720389K560","termGroup":"CN","termSource":"NCI"},{"termName":"Dolastatin-10","termGroup":"SY","termSource":"NCI"},{"termName":"L-Valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1- methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*[1S*,2S*,3(R*)]]]","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110417-88-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EI946JT51X"},{"name":"Legacy Concept Name","value":"Dolastatin_10"},{"name":"Maps_To","value":"Dolastatin 10"},{"name":"NCI_Drug_Dictionary_ID","value":"42316"},{"name":"NSC Number","value":"376128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42316"},{"name":"PDQ_Open_Trial_Search_ID","value":"42316"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0082338"}]}}{"C1439":{"preferredName":"Dolastatin 15","code":"C1439","definitions":[{"definition":"A depsipeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Less potent than the structurally-related compound dolastatin 10, dolastatin 15 binds weakly to tubulin and blocks microtubule assembly, thereby inhibiting mitosis.  Dolastatin 15 also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dolastatin 15","termGroup":"PT","termSource":"NCI"},{"termName":"L-Proline, 1-(1-(N-(N-(N,N-dimethyl-L-valyl)-L-valyl)-N-methyl-L-valyl)-L-prolyl)-, 1-((2,5-dihydro-3-methoxy-5-oxo-2-(phenylmethyl)-1H-pyrrol-1-yl)carbonyl)-2-methylpropyl ester, (S-(R*,R*))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123884-00-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J9ZKS885H5"},{"name":"Legacy Concept Name","value":"Dolastatin_15"},{"name":"Maps_To","value":"Dolastatin 15"},{"name":"NSC Number","value":"617668"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0170214"}]}}{"C96797":{"preferredName":"Domatinostat","code":"C96797","definitions":[{"definition":"An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity. Domatinostat selectively binds to and inhibits class I HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the selective transcription of tumor suppressor genes, and the tumor suppressor protein-mediated inhibition of tumor cell division and eventually the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Domatinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(2-aminophenyl)-3-(1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"4SC-202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"910462-43-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"264ARM7UXX"},{"name":"Maps_To","value":"Domatinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"700110"},{"name":"NCI_META_CUI","value":"CL429405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700110"},{"name":"PDQ_Open_Trial_Search_ID","value":"700110"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118294":{"preferredName":"Donafenib","code":"C118294","definitions":[{"definition":"An orally available multikinase inhibitor that targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, donafenib binds to and blocks the activity of Raf kinase, and inhibits Raf-mediated signal transduction pathways. This inhibits cell proliferation in Raf-expressing tumor cells. In addition, this agent may inhibit unidentified RTKs, and thus may further block tumor cell proliferation in susceptible tumor cells. Raf, a serine/threonine protein kinase, plays a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway. Deregulation of this pathway often results in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Donafenib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinecarboxamide, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-(4-((4-Chloro-3-(trifluoromethyl)phenyl)carbamoylamino)phenoxy)-N-(trideuteriomethyl)pyridine-2-carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"CM-4307","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1130115-44-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"41XGO0VS1U"},{"name":"Maps_To","value":"Donafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"764413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764413"},{"name":"PDQ_Open_Trial_Search_ID","value":"764413"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899341"}]}}{"C88345":{"preferredName":"Onzigolide","code":"C88345","definitions":[{"definition":"A chimeric dopamine (DA)-somatostatin (SST) compound, with potential antineoplastic activity. Upon administration, onzigolide binds with high affinity to dopamine D2 receptor (D2R) and somatostatin receptor subtype 2 (SSTR2), and to a lesser extent to somatostatin receptor subtype 5 (SSTR5). This agent appears to exert its effect mainly by binding to D2R to activate the ERK1/2 and p38 MAPK pathways, thus inducing apoptosis and inhibiting cellular proliferation in non-functioning pituitary adenoma (NFPA) and neuroendocrine tumors. By binding to SSTR2, this agent may inhibit the secretion of growth hormone (GH) by the pituitary gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onzigolide","termGroup":"PT","termSource":"NCI"},{"termName":"BIM-23A760","termGroup":"CN","termSource":"NCI"},{"termName":"Dopamine-Somatostatin Chimeric Molecule TBR-760","termGroup":"SY","termSource":"NCI"},{"termName":"TBR 760","termGroup":"CN","termSource":"NCI"},{"termName":"TBR-760","termGroup":"CN","termSource":"NCI"},{"termName":"TBR760","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"868562-36-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L32IM11DV4"},{"name":"Maps_To","value":"Dopamine-Somatostatin Chimeric Molecule BIM-23A760"},{"name":"NCI_Drug_Dictionary_ID","value":"661022"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661022"},{"name":"PDQ_Open_Trial_Search_ID","value":"661022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2604387"}]}}{"C148462":{"preferredName":"Delolimogene Mupadenorepvec","code":"C148462","definitions":[{"definition":"A double-armed oncolytic adenovirus composed of a recombinant genetically modified E1/E3-deleted, adenoviral serotype 5 (Ad5) vector, with the L5 segment of the Ad5 fiber replaced by the shaft and knob from the Ad35 serotype (Ad5/35), which expresses a trimerized (TMZ) form of the membrane-bound immunostimulator CD40 ligand (CD40L; TNFSF5) and the ligand for the signaling domain 4-1BB (4-1BBL; CD137L; TNFSF9), under the control of a CMV promoter, with potential immunostimulating and antineoplastic activities. Upon intratumoral administration of delolimogene mupadenorepvec, the virus infects and selectively replicates in tumor cells. This causes direct oncolysis and the release of a plethora of tumor-associated antigens (TAAs) from the tumor cells. The released TAAs stimulate the immune system and activate anti-tumor cytotoxic T-lymphocytes (CTLs), thereby further killing tumor cells. In addition, infected tumor cells and tumor stroma cells, including stellate cells and infiltrating immune cells, express the immunostimulants CD40L and 4-1BBL. The expressed CD40L and 4-1BBL proteins activate the CD40L- and 4-1BBL-mediated signaling pathways, respectively. This activates antigen-presenting cells (APCs), such as dendritic cells (DCs) and M1 macrophages. The DCs produce various cytokines, including interleukin-12 (IL12), IL21, tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFNg), which leads to the activation and expansion of both T-cells and natural killer (NK) cells. Altogether, this modulates immune suppression in the tumor microenvironment (TME), disrupts tumor stroma, and causes additional immune stimulation against tumor cells, thereby inducing further tumor cell lysis. In addition, CD40L reduces myeloid suppressor cells in the TME. Inclusion of the chimeric Ad5/35 fiber targets CD46 and increases viral uptake in cells. Transgene expression is driven by a separate promoter to allow for efficient expression in both tumor cells and tumor stroma. Replication is restricted to tumor cells by the presence of the delta24 mutation in the E1A gene, which deletes the retinoplastoma protein (pRb)-binding domain and forces viral replication to be conditional on hyperphosphorylated pRb and a dysfunctional Rb pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Delolimogene Mupadenorepvec","termGroup":"PT","termSource":"NCI"},{"termName":"LOAd 703","termGroup":"CN","termSource":"NCI"},{"termName":"LOAd-703","termGroup":"CN","termSource":"NCI"},{"termName":"LOAd703","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenovirus LOAd703","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2061938-98-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3ZQ57V6YWZ"},{"name":"Maps_To","value":"Delolimogene Mupadenorepvec"},{"name":"Maps_To","value":"Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703"},{"name":"NCI_Drug_Dictionary_ID","value":"802087"},{"name":"NCI_META_CUI","value":"CL551080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802087"},{"name":"PDQ_Open_Trial_Search_ID","value":"802087"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C76199":{"preferredName":"Dovitinib","code":"C76199","definitions":[{"definition":"A benzimidazole-quinolinone compound and receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. In addition, this agent also inhibits other members of the RTK superfamily, including fibroblast growth factor receptor 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1. This may further lead to a reduction of cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dovitinib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"405169-16-6"},{"name":"Chemical_Formula","value":"C21H21FN6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I35H55G906"},{"name":"Legacy Concept Name","value":"Dovitinib"},{"name":"Maps_To","value":"Dovitinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699806"}]}}{"C62435":{"preferredName":"Dovitinib Lactate","code":"C62435","definitions":[{"definition":"The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dovitinib Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one mono 2-hydroxypropanoate Hydrate","termGroup":"SN","termSource":"NCI"},{"termName":"CHIR-258","termGroup":"CN","termSource":"NCI"},{"termName":"RTK Inhibitor TKI258","termGroup":"SY","termSource":"NCI"},{"termName":"TKI-258","termGroup":"CN","termSource":"NCI"},{"termName":"TKI258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915769-50-5"},{"name":"Chemical_Formula","value":"C21H21FN6O.C3H6O3.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69VKY8P7EA"},{"name":"Legacy Concept Name","value":"CHIR-258"},{"name":"Maps_To","value":"Dovitinib Lactate"},{"name":"NCI_Drug_Dictionary_ID","value":"488976"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488976"},{"name":"PDQ_Open_Trial_Search_ID","value":"488976"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1568328"}]}}{"C61737":{"preferredName":"Doxazosin","code":"C61737","definitions":[{"definition":"A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxazosin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74191-85-8"},{"name":"CHEBI_ID","value":"CHEBI:4708"},{"name":"Chemical_Formula","value":"C23H25N5O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NW1291F1W8"},{"name":"Legacy Concept Name","value":"Doxazosin"},{"name":"Maps_To","value":"Doxazosin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0114873"}]}}{"C2645":{"preferredName":"Doxercalciferol","code":"C2645","definitions":[{"definition":"A substance being studied in the prevention of recurrent prostate cancer. It is a type of vitamin D analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analog of vitamin D with potential antineoplastic activity. In the liver, doxercalciferol is converted to its biologically active vitamin D metabolites, which control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. Through interaction with specific receptor proteins in target tissues, these vitamin D metabolites act directly on osteoblasts to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion. This agent has also been shown to inhibit the growth of retinoblastomas, and may exhibit some antiproliferative activity against prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxercalciferol","termGroup":"PT","termSource":"NCI"},{"termName":"(1alpha,3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol","termGroup":"SN","termSource":"NCI"},{"termName":"1-Alpha-Hydroxyvitamin D2","termGroup":"SN","termSource":"NCI"},{"termName":"Hectorol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Secondary hyperparathyroidism in end stage renal disease in patients on hemodialysis."},{"name":"CAS_Registry","value":"54573-75-0"},{"name":"Chemical_Formula","value":"C28H44O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3DIZ9LF5Y9"},{"name":"Legacy Concept Name","value":"Doxercalciferol"},{"name":"Maps_To","value":"Doxercalciferol"},{"name":"NCI_Drug_Dictionary_ID","value":"38406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38406"},{"name":"PDQ_Open_Trial_Search_ID","value":"38406"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043668"}]}}{"C978":{"preferredName":"Doxifluridine","code":"C978","definitions":[{"definition":"A fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxifluridine","termGroup":"PT","termSource":"NCI"},{"termName":"5'-Deoxy-5-fluorouridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-DFUR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3094-09-5"},{"name":"Chemical_Formula","value":"C9H11FN2O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"V1JK16Y2JP"},{"name":"Legacy Concept Name","value":"Doxifluridine"},{"name":"Maps_To","value":"Doxifluridine"},{"name":"NCI_Drug_Dictionary_ID","value":"481255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481255"},{"name":"PDQ_Open_Trial_Search_ID","value":"481255"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048808"}]}}{"C456":{"preferredName":"Doxorubicin","code":"C456","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. Doxorubicin comes from the bacterium Streptomyces peucetius. It damages DNA and may kill cancer cells. It is a type of anthracycline antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"14-Hydroxydaunomycin","termGroup":"SN","termSource":"NCI"},{"termName":"Adriablastin","termGroup":"SY","termSource":"NCI"},{"termName":"Hydroxydaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Hydroxyl Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Hydroxyldaunorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23214-92-8"},{"name":"CHEBI_ID","value":"CHEBI:28748"},{"name":"Chemical_Formula","value":"C27H29NO11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"80168379AG"},{"name":"Legacy Concept Name","value":"Doxorubicin"},{"name":"Maps_To","value":"Doxorubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0013089"}]}}{"C1326":{"preferredName":"Doxorubicin Hydrochloride","code":"C1326","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. Adriamycin PFS comes from the bacterium Streptomyces peucetius. It damages DNA and may kill cancer cells. It is a type of anthracycline antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"14-Hydroxydaunorubicin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"3-Hydroxyacetyldaunorubicin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ADM","termGroup":"AB","termSource":"NCI"},{"termName":"Adriacin","termGroup":"FB","termSource":"NCI"},{"termName":"Adriamycin","termGroup":"BR","termSource":"NCI"},{"termName":"Adriamycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Adriamycin PFS","termGroup":"AQS","termSource":"NCI"},{"termName":"Adriamycin RDF","termGroup":"AQS","termSource":"NCI"},{"termName":"Adriamycine","termGroup":"SY","termSource":"NCI"},{"termName":"Adriblastina","termGroup":"FB","termSource":"NCI"},{"termName":"Adriblastine","termGroup":"FB","termSource":"NCI"},{"termName":"Adrimedac","termGroup":"FB","termSource":"NCI"},{"termName":"Chloridrato de Doxorrubicina","termGroup":"SY","termSource":"NCI"},{"termName":"DOX","termGroup":"AB","termSource":"NCI"},{"termName":"DOXO-CELL","termGroup":"FB","termSource":"NCI"},{"termName":"Doxolem","termGroup":"FB","termSource":"NCI"},{"termName":"Doxorubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubin","termGroup":"FB","termSource":"NCI"},{"termName":"Farmiblastina","termGroup":"FB","termSource":"NCI"},{"termName":"FI-106","termGroup":"CN","termSource":"NCI"},{"termName":"L-Lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Rubex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Wilms' tumor; neuroblastoma; soft tissue and bone sarcomas; small cell carcinoma of the lung; lymphomas; multiple myeloma; mesotheliomas; germ cell tumors of the ovary or testis."},{"name":"Accepted_Therapeutic_Use_For","value":"Carcinomas of breast, thyroid, gastric, ovarian, bronchogenic, head and neck, prostate, cervical, pancreatic, uterine, hepatic, and transitional cell bladder carcinomas."},{"name":"CAS_Registry","value":"25316-40-9"},{"name":"Chemical_Formula","value":"C27H29NO11.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"82F2G7BL4E"},{"name":"Legacy Concept Name","value":"Doxorubicin_Hydrochloride"},{"name":"Maps_To","value":"Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38860"},{"name":"NSC Number","value":"123127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38860"},{"name":"PDQ_Open_Trial_Search_ID","value":"38860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546861"}]}}{"C1853":{"preferredName":"Doxorubicin Prodrug L-377,202","code":"C1853","definitions":[{"definition":"A prodrug in which a peptide is covalently conjugated with the anthracycline antineoplastic antibiotic doxorubicin.  This complex is hydrolyzed by the enzyme prostate-specific antigen (PSA), resulting in the formation of doxorubicin and leucine-doxorubicin.  Selective targeting of these drugs to prostate tumor cells occurs because the hydrolyzing PSA enzyme is localized to the prostate gland.  Doxorubicin and leucine-doxorubicin intercalate into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  These agents also produce toxic free-radical intermediates and interact with cell membrane lipids causing lipid peroxidation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Doxorubicin Prodrug L-377,202","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 10-((3-(((4R)-1-(4-carboxy-1-oxobutyl)-4-hydroxy-L-prolyl-L-alanyl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl)amino)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-","termGroup":"SN","termSource":"NCI"},{"termName":"L-377202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"207395-85-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VDXVABRQTV"},{"name":"Legacy Concept Name","value":"L-377_202"},{"name":"Maps_To","value":"Doxorubicin Prodrug L-377,202"},{"name":"NCI_Drug_Dictionary_ID","value":"37792"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37792"},{"name":"PDQ_Open_Trial_Search_ID","value":"37792"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0879383"}]}}{"C82419":{"preferredName":"Doxorubicin-Eluting Beads","code":"C82419","definitions":[{"definition":"A drug-device combination product consisting of small polymeric beads impregnated with the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with doxorubicin. During transarterial chemoembolization (TACE), doxorubicin-eluting beads embolize to the tumor vasculature and release cytotoxic doxorubicin, which may result in both ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature and doxorubicin-mediated inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-Eluting Beads","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Doxorubicin-Eluting_Beads"},{"name":"Maps_To","value":"Doxorubicin-Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"637761"},{"name":"NCI_META_CUI","value":"CL413528"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637761"},{"name":"PDQ_Open_Trial_Search_ID","value":"637761"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1366":{"preferredName":"Doxorubicin-HPMA Conjugate","code":"C1366","definitions":[{"definition":"A copolymer conjugate of the antineoplastic anthracycline doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipid. HPMA conjugation enhances the permeability and retention of this agent within the tumor vasculature. Poorly cleared by the lymphatic system, this formulation undergoes increased cleavage by tumor cell lysosomal proteinases, resulting in increased, sustained intracellular concentrations of free doxorubicin. Compared to other doxorubicin-containing formulations, this formulation may exhibit an improved toxicity profile due to the lower concentrations of free doxorubicin to which non-malignant tissues are exposed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-HPMA Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"Doxorubicin-HPMA","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin-HPMA Copolymer Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"HPMA-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"P(GFLG)-ADR","termGroup":"AB","termSource":"NCI"},{"termName":"PK1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Doxorubicin-HPMA_Conjugate"},{"name":"Maps_To","value":"Doxorubicin-HPMA Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"42904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42904"},{"name":"PDQ_Open_Trial_Search_ID","value":"42904"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0114882"}]}}{"C128897":{"preferredName":"Doxorubicin-loaded EGFR-targeting Nanocells","code":"C128897","definitions":[{"definition":"A nanocell formulation targeting the epidermal growth factor receptor (EGFR) using bispecific antibodies (bsAb) against EGFR and containing the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of doxorubicin-loaded EGFR-targeting nanocells, the nanocells are stable in the bloodstream and the anti-EGFR bsAb moiety targets and binds to EGFR-expressing tumor cells. Upon binding, the nanocell allows for specific delivery of doxorubicin to tumor cells overexpressing EGFR. Upon endocytosis by the tumor cells, the nanocell is broken down and releases doxorubicin, which intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted delivery of doxorubicin improves efficacy while lowering the toxicity profile. EGFR, a tyrosine kinase receptor, is overexpressed in many cancer cell types. The nanocell is a bacterially derived nanosphere; the bacterial components are unlikely to induce an immune response in the immunosuppressed tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-loaded EGFR-targeting Nanocells","termGroup":"PT","termSource":"NCI"},{"termName":"Doxorubicin-loaded EGFR-targeting Nanocell","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR (Vectibix Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR(V)-EDV-Dox","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR-targeted EnGeneIC Dream Vectors Containing Doxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Doxorubicin-loaded EGFR-targeting Nanocells"},{"name":"NCI_Drug_Dictionary_ID","value":"782631"},{"name":"NCI_META_CUI","value":"CL512145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782631"},{"name":"PDQ_Open_Trial_Search_ID","value":"782631"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2644":{"preferredName":"Doxorubicin-Magnetic Targeted Carrier Complex","code":"C2644","definitions":[{"definition":"A formulation of the anthracycline antibiotic doxorubicin in which doxorubicin is bound to microscopic beads of activated carbon and iron as a magnetic-targeted carrier (MTC). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipids. Guided by the placement of a magnet on the body surface overlying a tumor site, the doxorubicin-MTC complex delivers doxorubicin directly to the tumor site, thereby targeting and prolonging the duration of doxorubicin-mediated cytotoxicity to the tumor bed while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-Magnetic Targeted Carrier Complex","termGroup":"PT","termSource":"NCI"},{"termName":"DOX-MTC","termGroup":"AB","termSource":"NCI"},{"termName":"MTC-DOX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Doxorubicin-Magnetic_Targeted_Carrier_Complex"},{"name":"Maps_To","value":"Doxorubicin-Magnetic Targeted Carrier Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"38388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38388"},{"name":"PDQ_Open_Trial_Search_ID","value":"38388"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134452"}]}}{"C120213":{"preferredName":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine","code":"C120213","definitions":[{"definition":"A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"G250 Peptide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"768355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768355"},{"name":"PDQ_Open_Trial_Search_ID","value":"768355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3890943"}]}}{"C120214":{"preferredName":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine","code":"C120214","definitions":[{"definition":"A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), typhoid, Staphylococcus aureus, paratyphoid A and paratyphoid B, with potential immunostimulating activity. Subcutaneous administration of the DPT/typhoid/Staphylococcus aureus/paratyphoid A/paratyphoid B vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"768356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768356"},{"name":"PDQ_Open_Trial_Search_ID","value":"768356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899464"}]}}{"C131494":{"preferredName":"DPX-E7 HPV Vaccine","code":"C131494","definitions":[{"definition":"A therapeutic vaccine composed of a synthetic peptide consisting of amino acids 11 through 19 of the viral oncoprotein human papillomavirus (HPV) subtype 16 E7 (HPV16-E7 11-19), with potential antineoplastic and immunostimulating activities. Immunization with the DPX-E7 HPV vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the HPV16-E7 protein. HPV type 16 plays a key role in the carcinogenesis of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DPX-E7 HPV Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"DPX E7","termGroup":"CN","termSource":"NCI"},{"termName":"DPX-E7","termGroup":"CN","termSource":"NCI"},{"termName":"DPX-E7 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16-E7 11-19 Nanomer Vaccine DPX-E7","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16-E7 11-19 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DPX-E7 HPV Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"785825"},{"name":"NCI_META_CUI","value":"CL514623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785825"},{"name":"PDQ_Open_Trial_Search_ID","value":"785825"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153259":{"preferredName":"Tilogotamab","code":"C153259","definitions":[{"definition":"An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic activity. Upon administration, tilogotamab specifically binds to and activates DR5. This results in the activation of caspase cascades and the induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029 (DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced formation of antibody hexamers and receptor clusters at the cell surface due to E430G mutations in the Fc domains of both antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tilogotamab","termGroup":"PT","termSource":"NCI"},{"termName":"DR5 HexaBody Agonist GEN1029","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1029","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1029","termGroup":"CN","termSource":"NCI"},{"termName":"HexaBody-DR5-01/DR5-05","termGroup":"SY","termSource":"NCI"},{"termName":"HexaBody-DR5/DR5","termGroup":"SY","termSource":"NCI"},{"termName":"Hx-DR5-01/05","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2109731-10-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1BU5EGF80S"},{"name":"Maps_To","value":"DR5 HexaBody Agonist GEN1029"},{"name":"Maps_To","value":"Tilogotamab"},{"name":"NCI_Drug_Dictionary_ID","value":"794053"},{"name":"NCI_META_CUI","value":"CL554487"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794053"},{"name":"PDQ_Open_Trial_Search_ID","value":"794053"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116886":{"preferredName":"DR5-targeting Tetrameric Nanobody Agonist TAS266","code":"C116886","definitions":[{"definition":"An agonistic tetravalent nanobody, in which the four single, high affinity heavy chain variable domain (VHH) antibodies are separated by a peptide linker, targeting death receptor type 5 (DR5), with potential antineoplastic activity. Upon administration, DR5-targeting tetrameric nanobody agonist TAS266, with its four DR5-specific single-chain antibodies, specifically binds to and activates DR5 receptors. This results in the activation of caspase cascades and induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor (TNF)-receptor superfamily, triggers apoptosis. Compared to certain anti-DR5 antibody agonists, TAS266 shows increased receptor activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DR5-targeting Tetrameric Nanobody Agonist TAS266","termGroup":"PT","termSource":"NCI"},{"termName":"TAS266","termGroup":"CN","termSource":"NCI"},{"termName":"Tetrameric Nanobody Agonist-targeting death receptor 5 TAS266","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ND8DG76YE"},{"name":"Maps_To","value":"DR5-targeting Tetrameric Nanobody Agonist TAS266"},{"name":"NCI_Drug_Dictionary_ID","value":"725486"},{"name":"NCI_META_CUI","value":"CL433974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"725486"},{"name":"PDQ_Open_Trial_Search_ID","value":"725486"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1077":{"preferredName":"Dromostanolone Propionate","code":"C1077","definitions":[{"definition":"The propionate salt form of dromostanolone, a synthetic anabolic steroid related to dihydrotestosterone that has antiestrogenic effects.  Dromostanolone inhibits the growth of estrogen receptor-presenting breast cancers; its virilizing effects limit its clinical usefulness. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dromostanolone Propionate","termGroup":"PT","termSource":"NCI"},{"termName":"2 Alpha-Methyldihydrotestosterone Propionate","termGroup":"SN","termSource":"NCI"},{"termName":"2-Alpha-Methyldihydrotestosterone Propionate","termGroup":"SN","termSource":"NCI"},{"termName":"Compound 32379","termGroup":"SY","termSource":"NCI"},{"termName":"Drolban","termGroup":"BR","termSource":"NCI"},{"termName":"Drostanolone Propionate","termGroup":"SY","termSource":"NCI"},{"termName":"Emdisterone","termGroup":"SY","termSource":"NCI"},{"termName":"Masterid","termGroup":"FB","termSource":"NCI"},{"termName":"Masteril","termGroup":"FB","termSource":"NCI"},{"termName":"Masteron","termGroup":"FB","termSource":"NCI"},{"termName":"Masterone","termGroup":"FB","termSource":"NCI"},{"termName":"Permastril","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"521-12-0"},{"name":"CHEBI_ID","value":"CHEBI:31523"},{"name":"Chemical_Formula","value":"C23H36O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X20UZ57G4O"},{"name":"Legacy Concept Name","value":"Dromostanolone_Propionate"},{"name":"Maps_To","value":"Dromostanolone Propionate"},{"name":"NCI_Drug_Dictionary_ID","value":"39226"},{"name":"NSC Number","value":"12198"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39226"},{"name":"PDQ_Open_Trial_Search_ID","value":"39226"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058758"}]}}{"C95784":{"preferredName":"Drozitumab","code":"C95784","synonyms":[{"termName":"Drozitumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-DR5 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10B (death receptor 5, TRAIL-R2, CD262 antigen)); [113-lysine,116-threonine,360-glutamic acid,362-methionine]human monoclonal gamma-1 heavy chain (224-212')-disulfide with human monoclonal lambda-3 light chain (230-230'':233-233'')-bisdisulfide dimer","termGroup":"SY","termSource":"NCI"},{"termName":"PRO95780","termGroup":"CN","termSource":"NCI"},{"termName":"rhuMAb DR5","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"912628-39-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SQ67484MA7"},{"name":"Maps_To","value":"Drozitumab"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987421"}]}}{"C74043":{"preferredName":"Dual IGF-1R/InsR Inhibitor BMS-754807","code":"C74043","definitions":[{"definition":"An oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases with potential antineoplastic activity. Dual IGF-IR/InsR inhibitor BMS-754807 binds reversibly to and inhibits the activities of IGF-1R and InsR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R and InsR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in mitogenesis, angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dual IGF-1R/InsR Inhibitor BMS-754807","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-754807","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1001350-96-4"},{"name":"Chemical_Formula","value":"C23H26FN9O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W9E3353E8J"},{"name":"Legacy Concept Name","value":"IGF1R_Antagonist_BMS-754807"},{"name":"Maps_To","value":"Dual IGF-1R/InsR Inhibitor BMS-754807"},{"name":"NCI_Drug_Dictionary_ID","value":"583260"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583260"},{"name":"PDQ_Open_Trial_Search_ID","value":"583260"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346450"}]}}{"C116750":{"preferredName":"Dilpacimab","code":"C116750","definitions":[{"definition":"A bispecific, tetravalent immunoglobulin (Ig) G-like molecule containing the target-binding variable domains of two monoclonal antibodies, one targeting the Notch ligand delta-like 4 (DLL4) and the other one targeting the human tyrosine kinase vascular endothelial growth factor (VEGF), combined via linkers, with potential anti-angiogenic and antineoplastic activities. Upon administration, dilpacimab targets and binds to both DLL4 and VEGF. This prevents the activation of DLL-4/Notch- and VEGF/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dilpacimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-165","termGroup":"CN","termSource":"NCI"},{"termName":"DVD-Ig ABT-165","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin, Anti-(Notch Ligand DLL4/Vascular Endothelial Growth Factor) (Synthetic Human PR-1283233 Heavy Chain), Disulfide with Synthetic Human PR-1283233 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"PR-1283233","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10863","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1791420-09-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F27LAH6D5O"},{"name":"Maps_To","value":"Dilpacimab"},{"name":"Maps_To","value":"Dual Variable Domain Immunoglobulin ABT-165"},{"name":"NCI_Drug_Dictionary_ID","value":"753544"},{"name":"NCI_META_CUI","value":"CL471747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753544"},{"name":"PDQ_Open_Trial_Search_ID","value":"753544"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136983":{"preferredName":"Obrindatamab","code":"C136983","definitions":[{"definition":"An Fc-bearing humanized bispecific dual-affinity re-targeting (DART) protein composed of Fv regions derived from monoclonal antibodies against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration of obrindatamab, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3. This cross-links the T-cells to B7-H3-expressing tumor cells, activates and redirects endogenous T-cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obrindatamab","termGroup":"PT","termSource":"NCI"},{"termName":"B7-H3 x CD3 DART Protein","termGroup":"SY","termSource":"NCI"},{"termName":"B7-H3 x CD3 Dual-affinity Re-targeting Protein MGD009","termGroup":"SY","termSource":"NCI"},{"termName":"DART Protein MGD009","termGroup":"SY","termSource":"NCI"},{"termName":"Dual-affinity B7-H3/CD3-targeted Protein MGD009","termGroup":"SY","termSource":"NCI"},{"termName":"MGD 009","termGroup":"CN","termSource":"NCI"},{"termName":"MGD-009","termGroup":"CN","termSource":"NCI"},{"termName":"MGD009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2069959-72-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YE8XXF1SDZ"},{"name":"Maps_To","value":"Dual-affinity B7-H3/CD3-targeted Protein MGD009"},{"name":"NCI_Drug_Dictionary_ID","value":"789782"},{"name":"NCI_META_CUI","value":"CL524772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789782"},{"name":"PDQ_Open_Trial_Search_ID","value":"789782"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127116":{"preferredName":"Dubermatinib","code":"C127116","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, dubermatinib targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dubermatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-((5-Chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"TP 0903","termGroup":"CN","termSource":"NCI"},{"termName":"TP-0903","termGroup":"CN","termSource":"NCI"},{"termName":"TP0903","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1341200-45-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14D65TV20J"},{"name":"Maps_To","value":"Dubermatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"780923"},{"name":"NCI_META_CUI","value":"CL507906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780923"},{"name":"PDQ_Open_Trial_Search_ID","value":"780923"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1062":{"preferredName":"Duborimycin","code":"C1062","definitions":[{"definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Duborimycin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duborimycin","termGroup":"PT","termSource":"NCI"},{"termName":"13-Hydroxydaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-, (8S-cis)-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Daunomycinol","termGroup":"SY","termSource":"NCI"},{"termName":"Daunomycinol HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicineal","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicinol","termGroup":"SY","termSource":"NCI"},{"termName":"Duborimycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Duborimycine","termGroup":"SY","termSource":"NCI"},{"termName":"Duborimycine, Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"28008-55-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YDU8YIP30L"},{"name":"Legacy Concept Name","value":"Duborimycin"},{"name":"Maps_To","value":"Duborimycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39228"},{"name":"NSC Number","value":"180510"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39228"},{"name":"PDQ_Open_Trial_Search_ID","value":"39228"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057159"}]}}{"C1685":{"preferredName":"Dulanermin","code":"C1685","definitions":[{"definition":"A recombinant human soluble protein corresponding to amino acids 114-281 of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (RhApo2L/TRAIL) with potential antineoplastic activity. Dulanermin binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, also known as DR4 (death receptor 4) and DR5 (death receptor 5), are members of the TNF receptor family and are overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dulanermin","termGroup":"PT","termSource":"NCI"},{"termName":"114-281-protein TRAIL","termGroup":"SY","termSource":"NCI"},{"termName":"AMG 951","termGroup":"CN","termSource":"NCI"},{"termName":"APO2L/TRAIL","termGroup":"SY","termSource":"NCI"},{"termName":"RG3639","termGroup":"CN","termSource":"NCI"},{"termName":"rTRAIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer"},{"name":"CAS_Registry","value":"867153-61-5"},{"name":"Chemical_Formula","value":"C871H1329N243O260S4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L65E7T81M5"},{"name":"Legacy Concept Name","value":"Therapeutic_TNF-Related_Apoptosis-Inducing_Ligand"},{"name":"Maps_To","value":"Dulanermin"},{"name":"NCI_Drug_Dictionary_ID","value":"564398"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564398"},{"name":"PDQ_Open_Trial_Search_ID","value":"564398"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385242"}]}}{"C116628":{"preferredName":"Duligotuzumab","code":"C116628","definitions":[{"definition":"An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Duligotuzumab binds to both EGFR and HER3 and inhibits their activation. This may prevent EGFR/HER3-mediated signaling and inhibit EGFR/HER3-dependent tumor cell proliferation. In addition, MEHD7945A induces antibody-dependent cell-mediated cytotoxicity (ADCC) against EGR/HER3-expressing tumor cells. EGFR and HER3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in tumors; their expression is associated with both poor prognosis and drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duligotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Duligotumab","termGroup":"SY","termSource":"NCI"},{"termName":"MEHD 7945A","termGroup":"CN","termSource":"NCI"},{"termName":"MEHD-7945A","termGroup":"CN","termSource":"NCI"},{"termName":"MEHD7945A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7597","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312797-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8PMF8YQX2T"},{"name":"Maps_To","value":"Duligotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"686389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686389"},{"name":"PDQ_Open_Trial_Search_ID","value":"686389"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490133"}]}}{"C162455":{"preferredName":"Dupilumab","code":"C162455","definitions":[{"definition":"A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dupilumab","termGroup":"PT","termSource":"NCI"},{"termName":"Dupixent","termGroup":"BR","termSource":"NCI"},{"termName":"REGN 668","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-668","termGroup":"CN","termSource":"NCI"},{"termName":"REGN668","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 231893","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-231893","termGroup":"CN","termSource":"NCI"},{"termName":"SAR231893","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1190264-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"420K487FSG"},{"name":"Maps_To","value":"Dupilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"798743"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798743"},{"name":"PDQ_Open_Trial_Search_ID","value":"798743"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660996"}]}}{"C103194":{"preferredName":"Durvalumab","code":"C103194","definitions":[{"definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Durvalumab","termGroup":"PT","termSource":"NCI"},{"termName":"Imfinzi","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-4736","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI4736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma; unresectable stage III non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1428935-60-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"28X28X9OKV"},{"name":"Maps_To","value":"Durvalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"740856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740856"},{"name":"PDQ_Open_Trial_Search_ID","value":"740856"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641122"}]}}{"C82683":{"preferredName":"Dusigitumab","code":"C82683","definitions":[{"definition":"A humanized monoclonal antibody directed against insulin-like growth factors 1 and 2 (IGF-1/2) with potential antineoplastic activity. Dusigitumab inhibits IGF1- and IGF2-stimulated activation of membrane-bound IGF receptors and the subsequent triggering of proliferation and survival signaling pathways. This may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF1/2 ligands stimulate cell proliferation, enable oncogenic transformation, and suppress apoptosis; IGF1/2 signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dusigitumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Insulin-Like Growth Factor 1/2 Monoclonal Antibody MEDI-573","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G2, Anti-(Human Insulin-like Growth Factor I/Insulin-like Growth Factor II); Human Monoclonal MEDI-573 gamma Heavy Chain (134-216')-Disulfide with Human Monoclonal MEDI-573 lambda Light Chain Dimer (222-222'':223-223'':226-226'':229-229'')-Tetrakisdisulfide","termGroup":"SN","termSource":"NCI"},{"termName":"MEDI-573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204390-13-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0Z70DT5PRX"},{"name":"Legacy Concept Name","value":"Anti-IGF_1_2_Monoclonal_Antibody_MEDI-573"},{"name":"Maps_To","value":"Dusigitumab"},{"name":"NCI_Drug_Dictionary_ID","value":"633311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633311"},{"name":"PDQ_Open_Trial_Search_ID","value":"633311"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830209"}]}}{"C116885":{"preferredName":"dUTPase/DPD Inhibitor TAS-114","code":"C116885","definitions":[{"definition":"An orally bioavailable inhibitor of both deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD), with potential antineoplastic adjuvant activity. Upon oral administration in combination with a prodrug of the pyrimidine antagonist 5-fluorouracil (5-FU), TAS-114 inhibits (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. This prevents first-pass metabolism of 5-FU, allowing oral administration of the 5-FU prodrug and increasing the efficacy of 5-FU. In addition, as a dUTPase inhibitor, TAS-114 enhances the antitumor activity of 5-FU by preventing the hydrolysis and breakdown of 5-fluoro-deoxyuridine triphosphate (FdUTP) and deoxyuridine triphosphate (dUTP), which are active metabolites of 5-FU. This promotes DNA polymerase-dependent incorporation of these antimetabolites into DNA and leads to DNA damage and tumor cell death. Co-administration with TAS-114 allows lower dosing of 5-FU prodrugs, which decreases 5-FU-related toxicity, while maintaining therapeutic levels of 5-FU at the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"dUTPase/DPD Inhibitor TAS-114","termGroup":"PT","termSource":"NCI"},{"termName":"TAS-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"dUTPase/DPD Inhibitor TAS-114"},{"name":"NCI_Drug_Dictionary_ID","value":"735151"},{"name":"NCI_META_CUI","value":"CL446618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735151"},{"name":"PDQ_Open_Trial_Search_ID","value":"735151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99225":{"preferredName":"Duvelisib","code":"C99225","definitions":[{"definition":"An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, duvelisib prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duvelisib","termGroup":"PT","termSource":"NCI"},{"termName":"1(2H)-Isoquinolinone, 8-Chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one","termGroup":"SY","termSource":"NCI"},{"termName":"Copiktra","termGroup":"BR","termSource":"NCI"},{"termName":"INK-1197","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL)"},{"name":"CAS_Registry","value":"1201438-56-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"610V23S0JI"},{"name":"Maps_To","value":"Duvelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"718963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"718963"},{"name":"PDQ_Open_Trial_Search_ID","value":"718963"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274621"}]}}{"C122406":{"preferredName":"Duvortuxizumab","code":"C122406","definitions":[{"definition":"An anti-CD19/anti-CD3 bispecific, humanized antibody-like protein, with potential immunostimulatory and antineoplastic activities. Duvortuxizumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon administration, duvortuxizumab binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during normal B-cell development and on B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duvortuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"CD19 x CD3 DART Protein JNJ-64052781","termGroup":"SY","termSource":"NCI"},{"termName":"hBU12(2.4)-hXR32-MP3 M1.2","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ-64052781","termGroup":"CN","termSource":"NCI"},{"termName":"MGD011","termGroup":"CN","termSource":"NCI"},{"termName":"RES192M1.2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1831098-91-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J545GSE96Y"},{"name":"Maps_To","value":"Duvortuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"772810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772810"},{"name":"PDQ_Open_Trial_Search_ID","value":"772810"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053583"}]}}{"C1928":{"preferredName":"Dynemicin","code":"C1928","definitions":[{"definition":"An antitumor antibiotic of the enediyne class. It has demonstrated high DNA cleavage activity in the presence of NADPH, antimicrobial and tumor growth-inhibiting properties. Dynemicin recognizes and cleaves conformationally flexible regions of DNA. It attacks bases at 3'-side of purine residues such as 5'-AG, 5'-AT, and 5'-GC sequences. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dynemicin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dynemicin"},{"name":"Maps_To","value":"Dynemicin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C1512097"}]}}{"C1079":{"preferredName":"Dynemicin A","code":"C1079","definitions":[{"definition":"An enediyne antineoplastic antibiotic hybrid containing an anthraquinone moiety isolated from the bacterium Micromonospora chersina.  The anthraquinone moiety intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in double-strand breaks in DNA, inhibition of DNA replication and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dynemicin A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124412-57-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D3G8N2863A"},{"name":"Legacy Concept Name","value":"Dynemicin_A"},{"name":"Maps_To","value":"Dynemicin A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058837"}]}}{"C64767":{"preferredName":"E2F1 Pathway Activator ARQ 171","code":"C64767","definitions":[{"definition":"A second-generation E2F1 pathway activator with potential antineoplastic activity. ARQ 171 induces the expression of E2F transcription factor 1, thereby activating the E2F1-mediated checkpoint process. E2F1, down-regulated in cancer cells, regulates expression of genes involved in the cell cycle progression from G1 into S phase. The G1/S checkpoint process selectively induces cell cycle arrest in cancer cells with irreparable DNA damages and triggers subsequent apoptosis, while allowing cell division to proceed in cells without or with minor reparable DNA damage. As a result, this agent exerts anti-tumor activity through checkpoint activation independent of p53 mediated tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"E2F1 Pathway Activator ARQ 171","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 171","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ARQ_171"},{"name":"Maps_To","value":"E2F1 Pathway Activator ARQ 171"},{"name":"NCI_Drug_Dictionary_ID","value":"529342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529342"},{"name":"PDQ_Open_Trial_Search_ID","value":"529342"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832018"}]}}{"C159410":{"preferredName":"EBNA-1 inhibitor VK-2019","code":"C159410","definitions":[{"definition":"An orally available, small molecule inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1) with potential antineoplastic activity. Upon administration, EBNA-1 inhibitor VK-2019 binds to EBNA-1 and inhibits EBNA-1 DNA binding activity. This disrupts the replication, maintenance and segregation of the Epstein-Barr virus (EBV) genome, which may lead to tumor cell death in EBV-associated malignancies. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBNA-1 inhibitor VK-2019","termGroup":"PT","termSource":"NCI"},{"termName":"Epstein-Barr Nuclear Antigen 1 Inhibitor VK-2019","termGroup":"SY","termSource":"NCI"},{"termName":"VK 2019","termGroup":"CN","termSource":"NCI"},{"termName":"VK-2019","termGroup":"CN","termSource":"NCI"},{"termName":"VK2019","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EBNA-1 inhibitor VK-2019"},{"name":"NCI_Drug_Dictionary_ID","value":"797645"},{"name":"NCI_META_CUI","value":"CL951268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797645"},{"name":"PDQ_Open_Trial_Search_ID","value":"797645"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C462":{"preferredName":"Echinomycin","code":"C462","definitions":[{"definition":"A polypeptide quinoxaline antineoplastic antibiotic isolated from the bacterium Streptomyces echinatus.  Echinomycin intercalates into DNA at two locations simultaneously in a sequence-specific fashion, thereby inhibiting DNA replication and RNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Echinomycin","termGroup":"PT","termSource":"NCI"},{"termName":"Bis-Quinoline Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"BRN 0078671","termGroup":"CN","termSource":"NCI"},{"termName":"Echinomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"Levomycin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N'-(2,4,12,15,17,25-hexamethyl-11,24-bis(1-methylethyl)-27-(methylthio)-3,6,10,13,16,19,23,26-octaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo(12.12.3)nonacosane-7,20-diyl)bis(2-quinoxalinecarboxamide)","termGroup":"SN","termSource":"NCI"},{"termName":"Quinomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"SK 302B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"512-64-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TG824J6RQT"},{"name":"Legacy Concept Name","value":"Echinomycin"},{"name":"Maps_To","value":"Echinomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39587"},{"name":"NSC Number","value":"526417"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39587"},{"name":"PDQ_Open_Trial_Search_ID","value":"39587"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0013508"}]}}{"C61095":{"preferredName":"Ecromeximab","code":"C61095","definitions":[{"definition":"A low-fucose, human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity targeting at the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. Monoclonal antibody KW-2871 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. This agent is prepared by fusing murine immunoglobulin (Ig) light and heavy variable regions derived from the murine IgG3 antibody KM-641 to a human constant (Fc) region. The low fucose content of the oligosaccharide side chains of this antibody may enhance binding of the antibody Fc region to lymphocyte Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ecromeximab","termGroup":"PT","termSource":"NCI"},{"termName":"Chimeric Monoclonal Antibody KW-2871","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Gd3 Ganglioside) (Human-Mouse Monoclonal Km871 Gamma-1-Chain), Disulfide with Human-Mouse Monoclonal KM871 Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"KM871","termGroup":"CN","termSource":"NCI"},{"termName":"KW-2871","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody KW-2871","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"292819-64-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M76FX2JZRM"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_KW-2871"},{"name":"Maps_To","value":"Ecromeximab"},{"name":"NCI_Drug_Dictionary_ID","value":"467926"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467926"},{"name":"PDQ_Open_Trial_Search_ID","value":"467926"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1669509"}]}}{"C958":{"preferredName":"Edatrexate","code":"C958","definitions":[{"definition":"A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to a family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Edatrexate","termGroup":"PT","termSource":"NCI"},{"termName":"10-EDAM","termGroup":"AB","termSource":"NCI"},{"termName":"10-Ethyl-10-deaza-aminopterin","termGroup":"SN","termSource":"NCI"},{"termName":"CGP-30694","termGroup":"CN","termSource":"NCI"},{"termName":"EDAM","termGroup":"AB","termSource":"NCI"},{"termName":"N-[4-[1-[(2,4-Diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80576-83-6"},{"name":"Chemical_Formula","value":"C22H25N7O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JT4X6Z1HRR"},{"name":"Legacy Concept Name","value":"Edatrexate"},{"name":"Maps_To","value":"Edatrexate"},{"name":"NCI_Drug_Dictionary_ID","value":"40887"},{"name":"NSC Number","value":"626715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40887"},{"name":"PDQ_Open_Trial_Search_ID","value":"40887"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044667"}]}}{"C956":{"preferredName":"Edelfosine","code":"C956","definitions":[{"definition":"A synthetic analog of lysophosphatidylcholine, an ether lipid, possessing anti-leishmanial and antineoplastic activity.  The mechanism of action for edelfosine has not been fully elucidated.  Targeting cellular membranes, edelfosine modulates membrane permeability, membrane lipid composition, and phospholipid metabolism.  Edelfosine also inhibits the phosphatidylinositol 3 kinase (PI3K)-AKT/PKB survival pathway, possibly activating the pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  In addition, this agent inhibits protein kinase C, intracellular activation of the Fas/CD95 receptor, and intracellular acidification.  Anti-leishmanial activity may be due to inhibition of a glycosomal alkyl-specific-acylCoA acyltransferase. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edelfosine","termGroup":"PT","termSource":"NCI"},{"termName":"1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocholine","termGroup":"SN","termSource":"NCI"},{"termName":"Edelfosinum","termGroup":"SY","termSource":"NCI"},{"termName":"ET-18-OCH3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70641-51-9"},{"name":"Chemical_Formula","value":"C27H58NO6P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Y6SNA8L5S"},{"name":"Legacy Concept Name","value":"Edelfosine"},{"name":"Maps_To","value":"Edelfosine"},{"name":"NCI_Drug_Dictionary_ID","value":"41814"},{"name":"NSC Number","value":"324368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41814"},{"name":"PDQ_Open_Trial_Search_ID","value":"41814"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044549"}]}}{"C2665":{"preferredName":"Edotecarin","code":"C2665","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of topoisomerase I inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic indolocarbazole with antineoplastic activity. Edotecarin inhibits the enzyme topoisomerase I through stabilization of the DNA-enzyme complex and enhanced single-strand DNA cleavage, resulting in inhibition of DNA replication and decreased tumor cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edotecarin","termGroup":"PT","termSource":"NCI"},{"termName":"6-N-(1-hydroxymethyla-2-hydroxy)ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolol[3,4-c]-carbazole-5,7(6H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"J-107088","termGroup":"CN","termSource":"NCI"},{"termName":"J107088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"174402-32-5"},{"name":"Chemical_Formula","value":"C29H28N4O11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1V8X590XDP"},{"name":"Legacy Concept Name","value":"Edotecarin"},{"name":"Maps_To","value":"Edotecarin"},{"name":"NCI_Drug_Dictionary_ID","value":"38537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38537"},{"name":"PDQ_Open_Trial_Search_ID","value":"38537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328673"}]}}{"C1554":{"preferredName":"Edrecolomab","code":"C1554","definitions":[{"definition":"A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Edrecolomab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G2A (Mouse Monoclonal 17-1A Gamma-Chain Anti-Human Colon Cancer Tumor-Associated Antigen), Disulfide With Mouse Monoclonal 17-1A Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB 17-1A","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody 17-1A","termGroup":"SY","termSource":"NCI"},{"termName":"Panorex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156586-89-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0KYI9U9FSJ"},{"name":"Legacy Concept Name","value":"Edrecolomab"},{"name":"Maps_To","value":"Edrecolomab"},{"name":"NCI_Drug_Dictionary_ID","value":"39352"},{"name":"NSC Number","value":"377963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39352"},{"name":"PDQ_Open_Trial_Search_ID","value":"39352"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0279218"}]}}{"C133819":{"preferredName":"EED Inhibitor MAK683","code":"C133819","definitions":[{"definition":"An inhibitor of embryonic ectoderm development protein (EED) and allosteric inhibitor of polycomb repressive complex 2 (PRC2), with potential antineoplastic activity. Upon administration, MAK683 selectively binds to the domain of EED that interacts with trimethylated lysine 27 on histone 3 (H3K27me3), which leads to a conformational change in the EED H3K27me3-binding pocket and prevents the interaction of EED with the histone methyltransferase enhancer zeste homolog 2 (EZH2). Disruption of the EED-EZH2 protein-protein interaction (PPI) results in a loss of H3K27me3-stimulated PRC2 activity and prevents H3K27 trimethylation. This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2-mutated and PRC2-dependent cancer cells. PRC2, a histone H3 lysine 27 methyltransferase and multi-protein complex comprised of EZH2, EED and suppressor of zeste 12 (SUZ12), plays a key role in gene regulation, especially during embryonic development. EZH2, the catalytic subunit of PRC2, is overexpressed or mutated in a variety of cancer cells. EED is essential for the histone methyltransferase activity of PRC2 because EED directly binds to H3K27me3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EED Inhibitor MAK683","termGroup":"PT","termSource":"NCI"},{"termName":"Ectodermal Embryonic Development Inhibitor MAK683","termGroup":"SY","termSource":"NCI"},{"termName":"EED PPI Inhibitor MAK683","termGroup":"SY","termSource":"NCI"},{"termName":"EED Protein-protein Interaction Inhibitor MAK683","termGroup":"SY","termSource":"NCI"},{"termName":"MAK 683","termGroup":"CN","termSource":"NCI"},{"termName":"MAK683","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1951408-58-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4K446Z8N51"},{"name":"Maps_To","value":"EED Inhibitor MAK683"},{"name":"NCI_Drug_Dictionary_ID","value":"788547"},{"name":"NCI_META_CUI","value":"CL521741"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788547"},{"name":"PDQ_Open_Trial_Search_ID","value":"788547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83819":{"preferredName":"Efatutazone","code":"C83819","definitions":[{"definition":"An orally bioavailable thiazolidinedione and an agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity. Efatutazone binds to and activates PPAR-gamma thus inducing cell differentiation and apoptosis, leading to a reduction in cellular proliferation. PPAR-gamma is a nuclear hormone receptor and a ligand-activated transcription factor that controls the expression of genes involved in macromolecule metabolism and cell differentiation, specifically adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efatutazone","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Thiazolidinedione, 5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Inolitazone","termGroup":"SY","termSource":"NCI"},{"termName":"Rac-5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-1,3-Thiazolidine-2,4-Dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"223132-37-4"},{"name":"Chemical_Formula","value":"C27H26N4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M17ILL71MC"},{"name":"Maps_To","value":"Efatutazone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827204"}]}}{"C64764":{"preferredName":"Efatutazone Dihydrochloride","code":"C64764","definitions":[{"definition":"The dihydrochloride salt of efatutazone, an orally bioavailable agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity. Efatutazone binds to and activates PPAR-gamma, a nuclear hormone receptor and a ligand-activated transcription factor controling gene expression involved in macromolecule metabolism and cell differentiation, specifically adipocyte differentiation. Mediated through activation of PPAR-gamma, this agent is capable of inducing cell differentiation and apoptosis, thereby leading to a reduction in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efatutazone Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-thiazolidinedione, 5-((4-((6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)-, Hydrochloride (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"CS-7017","termGroup":"CN","termSource":"NCI"},{"termName":"Inolitazone Dihydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"223132-38-5"},{"name":"Chemical_Formula","value":"C27H26N4O4S.2ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"76B44WEA8O"},{"name":"Legacy Concept Name","value":"CS-7017"},{"name":"Maps_To","value":"Efatutazone Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"529846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529846"},{"name":"PDQ_Open_Trial_Search_ID","value":"529846"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721778"}]}}{"C118282":{"preferredName":"Efizonerimod","code":"C118282","definitions":[{"definition":"An agonistic monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, efizonerimod selectively binds to and activates the OX40 receptor, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efizonerimod","termGroup":"PT","termSource":"NCI"},{"termName":"Efizonerimod Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4 (10-proline) (Human Heavy Chain Fc Fragment) Fusion Protein with Tumor Necrosis Factor Receptor-associated Factor TRAF2 (Human C-C Domain Fragment) Fusion Protein with CD252 Antigen (Human Extracellular Domain Fragment), Hexamer","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI6383","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1635395-27-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1MH7C2X8KE"},{"name":"Maps_To","value":"Efizonerimod"},{"name":"NCI_Drug_Dictionary_ID","value":"764233"},{"name":"NCI_META_CUI","value":"CL474134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764233"},{"name":"PDQ_Open_Trial_Search_ID","value":"764233"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C226":{"preferredName":"Eflornithine","code":"C226","definitions":[{"definition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cancer. It belongs to the family of drugs called antiprotozoals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Eflornithine","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Difluoromethyl)-DL-ornithine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Difluoromethylornithine","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-Difluoromethylornithine","termGroup":"SY","termSource":"NCI"},{"termName":"D,L-alpha-Difluoromethylornithine","termGroup":"SN","termSource":"NCI"},{"termName":"DFMO","termGroup":"AB","termSource":"NCI"},{"termName":"Difluoromethylornithine","termGroup":"SY","termSource":"NCI"},{"termName":"Difluromethylornithine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hirsutism, facial; Trypanosoma brucei gambiense (sleeping sickness) infection"},{"name":"CAS_Registry","value":"67037-37-0"},{"name":"CAS_Registry","value":"70052-12-9"},{"name":"CHEBI_ID","value":"CHEBI:41948"},{"name":"Chemical_Formula","value":"C6H12F2N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZQN1G5V6SR"},{"name":"Legacy Concept Name","value":"Eflornithine"},{"name":"Maps_To","value":"Eflornithine"},{"name":"NCI_Drug_Dictionary_ID","value":"39754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39754"},{"name":"PDQ_Open_Trial_Search_ID","value":"39754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002260"}]}}{"C1579":{"preferredName":"Eflornithine Hydrochloride","code":"C1579","definitions":[{"definition":"The hydrochloride form of eflornithine, a difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eflornithine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Difluoromethyl)-dl-ornithine Hydrochloride, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-Difluoromethyl-dl-ornithine, Monohydrochloride, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-Difluoromethylornithine hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Iwilfin","termGroup":"BR","termSource":"NCI"},{"termName":"MDL 71782","termGroup":"CN","termSource":"NCI"},{"termName":"Ornidyl","termGroup":"BR","termSource":"NCI"},{"termName":"RMI-71782","termGroup":"CN","termSource":"NCI"},{"termName":"Vaniqa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB)."},{"name":"CAS_Registry","value":"96020-91-6"},{"name":"Chemical_Formula","value":"C6H12F2N2O2.HCl.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4NH22NDW9H"},{"name":"Legacy Concept Name","value":"Eflornithine_Hydrochloride"},{"name":"Maps_To","value":"Eflornithine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39754"},{"name":"NSC Number","value":"270295"},{"name":"NSC Number","value":"337250"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39754"},{"name":"PDQ_Open_Trial_Search_ID","value":"39754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282042"}]}}{"C62509":{"preferredName":"Eftilagimod Alpha","code":"C62509","definitions":[{"definition":"A T-cell immunostimulatory factor, derived from the soluble form of the lymphocyte-activation gene 3 (LAG-3) protein, with potential antineoplastic activity. Upon administration, alone or in combination with tumor antigens, eftilagimod alpha binds with high affinity to MHC class II molecules expressed by dendritic cells (DC), potentially resulting in DC maturation, DC migration to lymph nodes, enhanced DC cross-presentation of antigens to T cells, and antitumor cytotoxic T cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eftilagimod Alpha","termGroup":"PT","termSource":"NCI"},{"termName":"Immufact","termGroup":"FB","termSource":"NCI"},{"termName":"IMP321","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1800476-36-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SJ82PK3HWA"},{"name":"Legacy Concept Name","value":"IMP321"},{"name":"Maps_To","value":"Eftilagimod Alpha"},{"name":"NCI_Drug_Dictionary_ID","value":"496939"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496939"},{"name":"PDQ_Open_Trial_Search_ID","value":"496939"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1739076"}]}}{"C90557":{"preferredName":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205","code":"C90557","definitions":[{"definition":"A small-molecule inhibitor of the human kinesin-related motor protein Eg5 with potential antineoplastic activity. Eg5 kinesin-related motor protein inhibitor 4SC-205 selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and cell death. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein essential for the regulation of spindle dynamics, including assembly and maintenance, during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205","termGroup":"PT","termSource":"NCI"},{"termName":"4SC 205","termGroup":"CN","termSource":"NCI"},{"termName":"4SC-205","termGroup":"CN","termSource":"NCI"},{"termName":"4SC205","termGroup":"CN","termSource":"NCI"},{"termName":"Eg5 Kinesin Inhibitor 4SC-205","termGroup":"SY","termSource":"NCI"},{"termName":"SC-205","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205"},{"name":"NCI_Drug_Dictionary_ID","value":"666188"},{"name":"NCI_META_CUI","value":"CL416241"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666188"},{"name":"PDQ_Open_Trial_Search_ID","value":"666188"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82694":{"preferredName":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621","code":"C82694","definitions":[{"definition":"A small-molecule inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Eg5 kinesin-related motor protein inhibitor ARQ 621 selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and cell death. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein involved in the regulation of spindle dynamics, including assembly and maintenance, during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 621","termGroup":"CN","termSource":"NCI"},{"termName":"Eg5 inhibitor ARQ 621","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UU55190C8S"},{"name":"Legacy Concept Name","value":"Eg5_Kinesin-Related_Motor_Protein_Inhibitor_ARQ_621"},{"name":"Maps_To","value":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621"},{"name":"NCI_Drug_Dictionary_ID","value":"634612"},{"name":"NCI_META_CUI","value":"CL388484"},{"name":"PDQ_Closed_Trial_Search_ID","value":"634612"},{"name":"PDQ_Open_Trial_Search_ID","value":"634612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26646":{"preferredName":"EGb761","code":"C26646","definitions":[{"definition":"A standardized ginkgo biloba extract with antioxidant and neuroprotective activities.  EGb761 has been shown to inhibit the proliferation of certain tumor cells in vitro. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cognitive dysfunction (slowed ability to think, reason, concentrate, or remember) in patients receiving chemotherapy. It comes from ginkgo biloba leaves.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"EGb761","termGroup":"PT","termSource":"NCI"},{"termName":"EGb761","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EGb761"},{"name":"Maps_To","value":"EGb761"},{"name":"NCI_Drug_Dictionary_ID","value":"257914"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257914"},{"name":"PDQ_Open_Trial_Search_ID","value":"257914"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1095795"}]}}{"C123722":{"preferredName":"EGFR Antagonist Hemay022","code":"C123722","definitions":[{"definition":"An orally available, irreversible inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, Hemay022 covalently binds to and inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Antagonist Hemay022","termGroup":"PT","termSource":"NCI"},{"termName":"EGFR Inhibitor Hemay022","termGroup":"SY","termSource":"NCI"},{"termName":"Hemay022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Antagonist Hemay022"},{"name":"NCI_Drug_Dictionary_ID","value":"775380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775380"},{"name":"PDQ_Open_Trial_Search_ID","value":"775380"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053636"}]}}{"C156732":{"preferredName":"EGFR Antisense DNA BB-401","code":"C156732","definitions":[{"definition":"A recombinant, plasmid DNA expression vector encoding a 39 nucleotide (nt) short hairpin RNA (shRNA) specific for the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon intratumoral administration, the EGFR antisense DNA BB-401 is taken up by tumor cells and shRNA is transcribed. The shRNA is converted into small interfering RNA (siRNA) via the RNA interference (RNAi) pathway. The siRNA targets and binds to EGFR RNA expressed by tumor cells. This blocks EGFR mRNA translation and prevents EGFR protein expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Antisense DNA BB-401","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR ddRNAi BB-401","termGroup":"SY","termSource":"NCI"},{"termName":"BB 401","termGroup":"CN","termSource":"NCI"},{"termName":"BB-401","termGroup":"CN","termSource":"NCI"},{"termName":"BB401","termGroup":"CN","termSource":"NCI"},{"termName":"ddRNAi BB-401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Antisense DNA BB-401"},{"name":"NCI_Drug_Dictionary_ID","value":"795589"},{"name":"NCI_META_CUI","value":"CL935856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795589"},{"name":"PDQ_Open_Trial_Search_ID","value":"795589"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118289":{"preferredName":"Zorifertinib","code":"C118289","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration,  zorifertinib binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zorifertinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD3759","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1626387-80-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67SX9H68W2"},{"name":"Maps_To","value":"EGFR Inhibitor AZD3759"},{"name":"Maps_To","value":"Zorifertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"764365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764365"},{"name":"PDQ_Open_Trial_Search_ID","value":"764365"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896908"}]}}{"C80868":{"preferredName":"Falnidamol","code":"C80868","definitions":[{"definition":"A drug that may inhibit tumor cells from multiplying. It is being studied for its ability to treat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Falnidamol","termGroup":"PT","termSource":"NCI"},{"termName":"BIBX-1382","termGroup":"CN","termSource":"NCI"},{"termName":"BIBX1382","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR Inhibitor BIBX 1382","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"196612-93-8"},{"name":"Chemical_Formula","value":"C18H19ClFN7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0MU316797D"},{"name":"Legacy Concept Name","value":"BIBX_1382"},{"name":"Legacy Concept Name","value":"Falnidamol"},{"name":"Maps_To","value":"EGFR Inhibitor BIBX 1382"},{"name":"NCI_Drug_Dictionary_ID","value":"43568"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825367"}]}}{"C153427":{"preferredName":"EGFR/HER2 Inhibitor ABT-101","code":"C153427","definitions":[{"definition":"An orally bioavailable dual kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), including EGFR L858R, EGFR T790M and HER2 exon 20 insertion (Ex20ins) mutations, with potential antineoplastic activity. Upon oral administration, EGFR/HER2 inhibitor ABT-101 targets, binds to and inhibits the activity of EGFR or HER2 insertions or mutations. This prevents EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 alterations constitutively upregulate kinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER2 Inhibitor ABT-101","termGroup":"PT","termSource":"NCI"},{"termName":"ABT 101","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-101","termGroup":"CN","termSource":"NCI"},{"termName":"ABT101","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR 112","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR-112","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Inhibitor DBPR112"},{"name":"NCI_Drug_Dictionary_ID","value":"794067"},{"name":"NCI_META_CUI","value":"CL554867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794067"},{"name":"PDQ_Open_Trial_Search_ID","value":"794067"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2727":{"preferredName":"EGFR Inhibitor PD-168393","code":"C2727","definitions":[{"definition":"A quinazolone compound with anti-tumor activity. PD-168393 is a cell-permeable, irreversible, and selective inhibitor of ligand-dependent epidermal growth factor (EGF) receptor (EGFR). This agent binds to the catalytic domain of EGFR with a 1:1 stoichiometry and inactivates the EGFR tyrosine kinase activity through alkylation of a cystine residue (Cys-773) within the ATP-binding pocket, thereby inhibiting proliferation of EGFR-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Inhibitor PD-168393","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(3-Bromophenyl)amino]-6-Acrylamidoquinazoline","termGroup":"SN","termSource":"NCI"},{"termName":"PD 168 393","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194423-15-9"},{"name":"Chemical_Formula","value":"C17H13BrN4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3R996Y9T0I"},{"name":"Legacy Concept Name","value":"PD-168393"},{"name":"Maps_To","value":"EGFR Inhibitor PD-168393"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518781"}]}}{"C154286":{"preferredName":"Rezivertinib","code":"C154286","definitions":[{"definition":"An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutations T790M and L858R, as well as exon 19 deletion, with potential antineoplastic activity. Upon administration, rezivertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, BPI-7711 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rezivertinib","termGroup":"PT","termSource":"NCI"},{"termName":"BPI 7711","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-7711","termGroup":"CN","termSource":"NCI"},{"termName":"BPI7711","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR Mutant-specific Inhibitor BPI-7711","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1835667-12-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U65F5M6BD5"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor BPI-7711"},{"name":"Maps_To","value":"Rezivertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"794290"},{"name":"NCI_META_CUI","value":"CL555283"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794290"},{"name":"PDQ_Open_Trial_Search_ID","value":"794290"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132023":{"preferredName":"EGFR Mutant-specific Inhibitor CK-101","code":"C132023","definitions":[{"definition":"An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and del 19 mutations, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor CK-101 specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CK-101 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Mutant-specific Inhibitor CK-101","termGroup":"PT","termSource":"NCI"},{"termName":"CK 101","termGroup":"CN","termSource":"NCI"},{"termName":"CK-101","termGroup":"CN","termSource":"NCI"},{"termName":"CK101","termGroup":"CN","termSource":"NCI"},{"termName":"RX-518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1660963-42-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"708TLB8J3Y"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor CK-101"},{"name":"NCI_Drug_Dictionary_ID","value":"786517"},{"name":"NCI_META_CUI","value":"CL521020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786517"},{"name":"PDQ_Open_Trial_Search_ID","value":"786517"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175747":{"preferredName":"Befotertinib","code":"C175747","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, befotertinib specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. Compared to some other EGFR inhibitors, befotertinib may have therapeutic benefits in tumors with T790M-mediated drug resistance. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Befotertinib","termGroup":"PT","termSource":"NCI"},{"termName":"D 0316","termGroup":"CN","termSource":"NCI"},{"termName":"D-0316","termGroup":"CN","termSource":"NCI"},{"termName":"D0316","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1835667-63-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0XT2CPR891"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor D-0316"},{"name":"NCI_Drug_Dictionary_ID","value":"795785"},{"name":"NCI_META_CUI","value":"CL935820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153173":{"preferredName":"EGFR Mutant-specific Inhibitor ZN-e4","code":"C153173","definitions":[{"definition":"An orally available selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor ZN-e4 specifically binds to and inhibits selective EGFR mutations, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors, ZN-e4 may offer therapeutic benefits in tumors with T790M-mediated drug resistance and may limit toxicities associated with non-selective EGFR inhibitors. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Mutant-specific Inhibitor ZN-e4","termGroup":"PT","termSource":"NCI"},{"termName":"KP-673","termGroup":"CN","termSource":"NCI"},{"termName":"ZN e4","termGroup":"CN","termSource":"NCI"},{"termName":"ZN-e4","termGroup":"CN","termSource":"NCI"},{"termName":"ZNe4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor ZN-e4"},{"name":"NCI_Drug_Dictionary_ID","value":"793946"},{"name":"NCI_META_CUI","value":"CL554308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793946"},{"name":"PDQ_Open_Trial_Search_ID","value":"793946"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131909":{"preferredName":"EGFR T790M Antagonist BPI-15086","code":"C131909","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M antagonist BPI-15086 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR T790M Antagonist BPI-15086","termGroup":"PT","termSource":"NCI"},{"termName":"BPI 15086","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-15086","termGroup":"CN","termSource":"NCI"},{"termName":"BPI15086","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR T790M Inhibitor BPI-15086","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR T790M Antagonist BPI-15086"},{"name":"NCI_Drug_Dictionary_ID","value":"786371"},{"name":"NCI_META_CUI","value":"CL520366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786371"},{"name":"PDQ_Open_Trial_Search_ID","value":"786371"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133691":{"preferredName":"Aumolertinib","code":"C133691","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, aumolertinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aumolertinib","termGroup":"PT","termSource":"NCI"},{"termName":"Almonertinib","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR Tyrosine Kinase Inhibitor HS-10296","termGroup":"SY","termSource":"NCI"},{"termName":"EQ143","termGroup":"CN","termSource":"NCI"},{"termName":"HS-10296","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1899921-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T4RS462G19"},{"name":"Maps_To","value":"EGFR T790M Inhibitor HS-10296"},{"name":"NCI_Drug_Dictionary_ID","value":"788548"},{"name":"NCI_META_CUI","value":"CL521177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788548"},{"name":"PDQ_Open_Trial_Search_ID","value":"788548"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131492":{"preferredName":"Ruserontinib","code":"C131492","definitions":[{"definition":"An orally available inhibitor of epidermal growth factor receptor (EGFR), FMS-related tyrosine kinase 3 (FLT3, STK1, CD135 or FLK2), and the non-receptor tyrosine kinase ABL (Abl), with potential antineoplastic activity. Upon administration, ruserontinib specifically binds to and inhibits EGFR, FLT3 and Abl, which interferes with the activation of EGFR-, FLT3- and Abl-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress EGFR, FLT3 and/or Abl. EGFR, EGFR and Abl are all overexpressed in a variety of cancers and play key roles in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruserontinib","termGroup":"PT","termSource":"NCI"},{"termName":"9-Isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"9H-Purine-2,8-diamine, 9-(1-Methylethyl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-3-pyridinyl-","termGroup":"SN","termSource":"NCI"},{"termName":"EGFR/FLT3/Abl Inhibitor SKLB1028","termGroup":"SY","termSource":"NCI"},{"termName":"Multikinase Inhibitor SKLB1028","termGroup":"SY","termSource":"NCI"},{"termName":"SKLB 1028","termGroup":"CN","termSource":"NCI"},{"termName":"SKLB-1028","termGroup":"CN","termSource":"NCI"},{"termName":"SKLB1028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1350544-93-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AQ3TTU8UM7"},{"name":"Maps_To","value":"EGFR/FLT3/Abl Inhibitor SKLB1028"},{"name":"NCI_Drug_Dictionary_ID","value":"785726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785726"},{"name":"PDQ_Open_Trial_Search_ID","value":"785726"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3501119"}]}}{"C1871":{"preferredName":"EGFR/HER1/HER2 Inhibitor PKI166","code":"C1871","definitions":[{"definition":"A pyrrolo-pyrimidine epidermal growth factor receptor (EGFR) protein kinase inhibitor with anti-tumor activity. PKI-166 reversibly inhibits HER1 and HER2 tyrosine kinases, belong to the epidermal growth factor receptor family, thereby inhibiting tumor growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER1/HER2 Inhibitor PKI166","termGroup":"PT","termSource":"NCI"},{"termName":"CGP 75166","termGroup":"CN","termSource":"NCI"},{"termName":"CGP 75166/PKI166","termGroup":"SY","termSource":"NCI"},{"termName":"CGP75166]","termGroup":"CN","termSource":"NCI"},{"termName":"PKI-166","termGroup":"CN","termSource":"NCI"},{"termName":"PKI166","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"187724-61-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RIE5HW38P"},{"name":"Legacy Concept Name","value":"PKI166"},{"name":"Maps_To","value":"EGFR/HER1/HER2 Inhibitor PKI166"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0915195"}]}}{"C126752":{"preferredName":"Mobocertinib","code":"C126752","definitions":[{"definition":"An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mobocertinib","termGroup":"PT","termSource":"NCI"},{"termName":"AP 32788","termGroup":"CN","termSource":"NCI"},{"termName":"AP-32788","termGroup":"CN","termSource":"NCI"},{"termName":"AP32788","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/HER2 Inhibitor TAK-788","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 788","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-788","termGroup":"CN","termSource":"NCI"},{"termName":"TAK788","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1847461-43-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"39HBQ4A67L"},{"name":"Maps_To","value":"EGFR/HER2 Inhibitor AP32788"},{"name":"Maps_To","value":"Mobocertinib"},{"name":"NCI_META_CUI","value":"CL507888"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64627":{"preferredName":"EGFR/HER2 Inhibitor AV-412","code":"C64627","definitions":[{"definition":"A second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to first-generation kinase inhibitors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER2 Inhibitor AV-412","termGroup":"PT","termSource":"NCI"},{"termName":"AV 412","termGroup":"CN","termSource":"NCI"},{"termName":"AV-412","termGroup":"CN","termSource":"NCI"},{"termName":"AV412","termGroup":"CN","termSource":"NCI"},{"termName":"MP 412","termGroup":"CN","termSource":"NCI"},{"termName":"MP-412","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"451493-31-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z541VW0W40"},{"name":"Legacy Concept Name","value":"AV-412"},{"name":"Maps_To","value":"EGFR/HER2 Inhibitor AV-412"},{"name":"NCI_Drug_Dictionary_ID","value":"513167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513167"},{"name":"PDQ_Open_Trial_Search_ID","value":"513167"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831968"}]}}{"C90589":{"preferredName":"EGFR/HER2 Kinase Inhibitor TAK-285","code":"C90589","definitions":[{"definition":"An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with potential antineoplastic activity. EGFR/HER2 kinase inhibitor TAK-285 binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to trastuzumab. EGFR and HER2, receptor tyrosine kinases overexpressed in a variety of tumor cell types, play major roles in tumor cell proliferation and tumor vascularization. In addition, TAK-285 appears to pass the blood brain barrier (BBB) and does not appear to be a substrate for efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER2 Kinase Inhibitor TAK-285","termGroup":"PT","termSource":"NCI"},{"termName":"TAK-285","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871026-44-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"70CCB438L6"},{"name":"Maps_To","value":"EGFR/HER2 Kinase Inhibitor TAK-285"},{"name":"NCI_Drug_Dictionary_ID","value":"573406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573406"},{"name":"PDQ_Open_Trial_Search_ID","value":"573406"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983788"}]}}{"C67080":{"preferredName":"Eicosapentaenoic Acid","code":"C67080","definitions":[{"definition":"A class of polyunsaturated fatty acids with 20 carbons and 5 double bonds.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"An essential, polyunsaturated, 20-carbon omega-3 fatty acid with anti-inflammatory and potential antineoplastic and chemopreventive activities. Eicosapentaenoic acid (EPA) may activate caspase 3, resulting in apoptosis in susceptible tumor cell populations. In addition, this agent may inhibit cyclooxygenase-2 (COX-2), resulting in inhibition of prostaglandin synthesis and prostaglandin-mediated inflammatory processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eicosapentaenoic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"All cis-5,8,11,14,17-Eicosapentaenoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"EPA","termGroup":"AB","termSource":"NCI"},{"termName":"Icosapentaenoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"IPA","termGroup":"AB","termSource":"NCI"},{"termName":"Timnodonic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"25378-27-2"},{"name":"CHEBI_ID","value":"CHEBI:36006"},{"name":"Chemical_Formula","value":"C20H30O2"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Essential_Fatty_Acid","value":"Y"},{"name":"INFOODS","value":"F20D5"},{"name":"Legacy Concept Name","value":"Eicosapentaenoic_Acid"},{"name":"Macronutrient","value":"Y"},{"name":"Maps_To","value":"Eicosapentaenoic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"537376"},{"name":"Nutrient","value":"Y"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537376"},{"name":"PDQ_Open_Trial_Search_ID","value":"537376"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0000545"},{"name":"Unit","value":"g"}]}}{"C95740":{"preferredName":"eIF4E Antisense Oligonucleotide ISIS 183750","code":"C95740","definitions":[{"definition":"A second-generation antisense oligonucleotide targeting the eukaryotic translation initiation factor 4E (eIF4E) with potential antitumor activity. Antisense oligonucleotide ISIS EIF4ERx suppresses the expression of eIF4E in fast dividing tumor cells. Blocking the expression of eIF4E results in inhibition of the synthesis of tumor angiogenic factors, thereby leading to the inhibition of cellular proliferation and apoptosis in tumor cells. eIF4E is overexpressed in a variety of cancers, is involved in the mRNA-ribosome binding step of eukaryotic protein synthesis and is the rate-limiting component of the eukaryotic translation apparatus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"eIF4E Antisense Oligonucleotide ISIS 183750","termGroup":"PT","termSource":"NCI"},{"termName":"eIF4E Inhibitor ISIS 183750","termGroup":"SY","termSource":"NCI"},{"termName":"eIF4E Modulator ISIS 183750","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 183750","termGroup":"CN","termSource":"NCI"},{"termName":"LY2275796","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"eIF4E Antisense Oligonucleotide ISIS 183750"},{"name":"NCI_Drug_Dictionary_ID","value":"680421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"680421"},{"name":"PDQ_Open_Trial_Search_ID","value":"680421"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987390"}]}}{"C120211":{"preferredName":"Elacestrant","code":"C120211","definitions":[{"definition":"An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. This prevents ER-mediated signaling and inhibits proliferation of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elacestrant","termGroup":"PT","termSource":"NCI"},{"termName":"(6R)-6-(2-(Ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol","termGroup":"SY","termSource":"NCI"},{"termName":"ER-306323","termGroup":"CN","termSource":"NCI"},{"termName":"RAD1901","termGroup":"CN","termSource":"NCI"},{"termName":"SERD/SERM RAD1901","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"722533-56-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"FM6A2627A8"},{"name":"Maps_To","value":"Elacestrant"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896781"}]}}{"C53401":{"preferredName":"Elacytarabine","code":"C53401","definitions":[{"definition":"The lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As a prodrug, elacytarabine is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, elacytarabine shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elacytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-amino-1-[5-O-[(9E)-octadec-9-enoyl]-beta-D-arabinofuranosyl]pyrimidin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"CP-4055","termGroup":"CN","termSource":"NCI"},{"termName":"Elacyt","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"188181-42-2"},{"name":"CAS_Registry","value":"675837-43-1"},{"name":"Chemical_Formula","value":"C27H45N3O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TA7WJG93AR"},{"name":"Legacy Concept Name","value":"CP-4055"},{"name":"Maps_To","value":"Elacytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"463939"},{"name":"PDQ_Closed_Trial_Search_ID","value":"463939"},{"name":"PDQ_Open_Trial_Search_ID","value":"463939"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707141"}]}}{"C153373":{"preferredName":"Elagolix","code":"C153373","definitions":[{"definition":"An orally bioavailable, second-generation, non-peptide based, small molecule compound and selective gonadotropin-releasing hormone (GnRH; LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, elagolix competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland. This inhibits the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. In women, inhibition of FSH and LH prevents the production of estrogen by the ovaries. Inhibition of GnRH signaling may treat or prevent symptoms of sex hormone-dependent disease states.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elagolix","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-620","termGroup":"CN","termSource":"NCI"},{"termName":"Butanoic Acid, 4-(((1R)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl)-1-phenylethyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"NBI 56418","termGroup":"CN","termSource":"NCI"},{"termName":"NBI-56418","termGroup":"CN","termSource":"NCI"},{"termName":"Orilissa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"pain associated with endometriosis in women"},{"name":"CAS_Registry","value":"834153-87-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5B2546MB5Z"},{"name":"Legacy Concept Name","value":"Degarelix_Acetate"},{"name":"Maps_To","value":"Elagolix"},{"name":"NCI_Drug_Dictionary_ID","value":"793786"},{"name":"NCI_META_CUI","value":"CL554529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793786"},{"name":"PDQ_Open_Trial_Search_ID","value":"793786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159973":{"preferredName":"Elbasvir/Grazoprevir","code":"C159973","definitions":[{"definition":"A fixed dose combination of elbasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A), and grazoprevir, a second-generation inhibitor of the HCV NS3/4A serine protease, with activity against certain HCV genotypes. Upon oral administration of elbasvir/grazoprevir, elbasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. Grazoprevir inhibits the NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elbasvir/Grazoprevir","termGroup":"PT","termSource":"NCI"},{"termName":"Elbasvir-Grazoprevir","termGroup":"SY","termSource":"NCI"},{"termName":"Grazoprevir-Elbasvir","termGroup":"SY","termSource":"NCI"},{"termName":"Grazoprevir/Elbasvir","termGroup":"SY","termSource":"NCI"},{"termName":"MK-8742/ MK-5172","termGroup":"CN","termSource":"NCI"},{"termName":"Zepatier","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Elbasvir/Grazoprevir"},{"name":"NCI_Drug_Dictionary_ID","value":"797922"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797922"},{"name":"PDQ_Open_Trial_Search_ID","value":"797922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4080453"}]}}{"C75291":{"preferredName":"Elesclomol","code":"C75291","definitions":[{"definition":"A small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol induces oxidative stress, creating high levels of reactive oxygen species (ROS), such as hydrogen peroxide, in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared to normal cells, the increase in oxidative stress beyond baseline levels elevates ROS beyond sustainable levels, exhausting tumor cell antioxidant capacity, which may result in the induction of the mitochondrial apoptosis pathway. Normal cells are spared because the increase in the level of oxidative stress induced by this agent is below the threshold at which apoptosis is induced.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elesclomol","termGroup":"PT","termSource":"NCI"},{"termName":"1-N'-benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl- oxopropanehydrazidide","termGroup":"SN","termSource":"NCI"},{"termName":"Propanedioic Acid, Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"488832-69-5"},{"name":"Chemical_Formula","value":"C19H20N4O2S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6UK191M53P"},{"name":"Legacy Concept Name","value":"Elesclomol"},{"name":"Maps_To","value":"Elesclomol"},{"name":"NCI_Drug_Dictionary_ID","value":"377539"},{"name":"PDQ_Closed_Trial_Search_ID","value":"377539"},{"name":"PDQ_Open_Trial_Search_ID","value":"377539"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2608060"}]}}{"C79840":{"preferredName":"Elesclomol Sodium","code":"C79840","definitions":[{"definition":"A drug used in the treatment of skin cancer that has spread. It is also being studied in the treatment of other types of cancer. It increases the amount of harmful oxygen molecules in cells and may kill cancer cells. It may also help other drugs kill cancer cells. It is a type of oxidative stress inducer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The water soluble sodium salt of a small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol induces oxidative stress, creating high levels of reactive oxygen species (ROS), such as hydrogen peroxide, in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared to normal cells, the increase in oxidative stress beyond baseline levels elevates ROS beyond sustainable levels, exhausting tumor cell antioxidant capacity, which may result in the induction of the mitochondrial apoptosis pathway. Normal cells are spared because the increase in the level of oxidative stress induced by this agent is below the threshold at which apoptosis is induced.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elesclomol Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"1-N'-benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl- oxopropanehydrazidide Sodium","termGroup":"SN","termSource":"NCI"},{"termName":"Propanedioic Acid, Bis[2-methyl-2-(phenylthioxomethyl)hydrazide], Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"STA-4783","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"874477-51-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L219C7807V"},{"name":"Legacy Concept Name","value":"Elesclomol_Sodium"},{"name":"Maps_To","value":"Elesclomol Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"631615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"631615"},{"name":"PDQ_Open_Trial_Search_ID","value":"631615"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541326"}]}}{"C101895":{"preferredName":"Elgemtumab","code":"C101895","definitions":[{"definition":"A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Elgemtumab binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elgemtumab","termGroup":"PT","termSource":"NCI"},{"termName":"LJM-716","termGroup":"CN","termSource":"NCI"},{"termName":"LJM716","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1512559-37-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5F1CN52GFM"},{"name":"Maps_To","value":"Elgemtumab"},{"name":"NCI_Drug_Dictionary_ID","value":"734177"},{"name":"NCI_META_CUI","value":"CL436278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734177"},{"name":"PDQ_Open_Trial_Search_ID","value":"734177"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1615":{"preferredName":"Elinafide","code":"C1615","definitions":[{"definition":"A symmetrical dimeric bis-naphthalimide compound and a topoisomerase II inhibitor with antineoplastic activity. Elinafide contains two neutral chromophores joined by a cationic linker and is capable of bis-intercalation at the TpG and CpA steps of the DNA hexanucleotide. Intercalation inhibits topoisomerase II activity and causing DNA stand breakage, thereby leads to inhibition of DNA, RNA, and protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that kills cancer cells by affecting DNA synthesis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Elinafide","termGroup":"PT","termSource":"NCI"},{"termName":"LU 79553","termGroup":"CN","termSource":"NCI"},{"termName":"LU-79553","termGroup":"CN","termSource":"NCI"},{"termName":"N,N'-(Trimethylenebis(iminoethylene))dinaphthalimide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"162706-37-8"},{"name":"Chemical_Formula","value":"C31H28N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HL580335SI"},{"name":"Legacy Concept Name","value":"LU_79553"},{"name":"Maps_To","value":"Elinafide"},{"name":"NCI_Drug_Dictionary_ID","value":"42578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42578"},{"name":"PDQ_Open_Trial_Search_ID","value":"42578"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1433453"}]}}{"C66949":{"preferredName":"Elisidepsin","code":"C66949","definitions":[{"definition":"A synthetic cyclic depsipeptide of the kahalalides family with potential antineoplastic activity. PM02734 is a derivative of a natural marine compound extracted from the sacoglossan sea slug, Elysia rufescens. Although the exact mechanism of action has yet to be elucidated, elisidepsin exhibits anti-proliferative activity in a wide variety of cancer types, such as breast, colon, pancreas, lung, and prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elisidepsin","termGroup":"PT","termSource":"NCI"},{"termName":"Depsipeptide PM02734","termGroup":"SY","termSource":"NCI"},{"termName":"L-Valine, N-((4S)-4-methyl-1-oxohexyl)-D-valyl-L-threonyl-L-valyl-D-valyl-D-prolyl-L-ornithyl-D-alloisoleucyl-D-allothreonyl-D-alloisoleucyl-D-valyl-L-phenylalanyl-(2Z)-2-amino-2-butenoyl-, (13-8)-lactone, 2,2,2-trifluoroacetate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"PM02734","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"681272-30-0"},{"name":"CAS_Registry","value":"915713-02-9"},{"name":"Chemical_Formula","value":"C57H87N7O15"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0FWR494EC9"},{"name":"Legacy Concept Name","value":"Depsipeptide_PM02734"},{"name":"Maps_To","value":"Elisidepsin"},{"name":"NCI_Drug_Dictionary_ID","value":"530791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530791"},{"name":"PDQ_Open_Trial_Search_ID","value":"530791"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467776"}]}}{"C90495":{"preferredName":"Elliptinium","code":"C90495","definitions":[{"definition":"A derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elliptinium","termGroup":"PT","termSource":"NCI"},{"termName":"9-Hydroxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazolium","termGroup":"SN","termSource":"NCI"},{"termName":"9-Hydroxy-2-methylellipticinium","termGroup":"SN","termSource":"NCI"},{"termName":"N-2-Methyl-9-hydroxyellipticinium","termGroup":"SN","termSource":"NCI"},{"termName":"NMHE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58337-34-1"},{"name":"Chemical_Formula","value":"C18H17N2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1F1959S062"},{"name":"Legacy Concept Name","value":"Elliptinium"},{"name":"Maps_To","value":"Elliptinium"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0115685"}]}}{"C1367":{"preferredName":"Elliptinium Acetate","code":"C1367","definitions":[{"definition":"Acetate salt of elliptinium, a derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elliptinium Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"9-Hydroxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazolium Acetate (Salt)","termGroup":"SN","termSource":"NCI"},{"termName":"9-Hydroxy-2-methylellipticinium Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Celiptium","termGroup":"BR","termSource":"NCI"},{"termName":"N-2-Methyl-9-hydroxyellipticinium Acetate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58337-35-2"},{"name":"Chemical_Formula","value":"C18H17N2O.C2H3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H9B41234P4"},{"name":"Legacy Concept Name","value":"Elliptinium"},{"name":"Maps_To","value":"Elliptinium Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"39231"},{"name":"NSC Number","value":"264137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39231"},{"name":"PDQ_Open_Trial_Search_ID","value":"39231"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0100593"}]}}{"C73262":{"preferredName":"Elmustine","code":"C73262","definitions":[{"definition":"A (2-chloroethy1)nitrosourea derivative related to carmustine, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elmustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"1-Nitroso-1-chloroethyl-3-hydroxyethylurea","termGroup":"SN","termSource":"NCI"},{"termName":"HeCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Hydroxyethyl CNU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60784-46-5"},{"name":"Chemical_Formula","value":"C5H10ClN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NAT2FD82D7"},{"name":"Legacy Concept Name","value":"Elmustine"},{"name":"Maps_To","value":"Elmustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059035"}]}}{"C66982":{"preferredName":"Elotuzumab","code":"C66982","definitions":[{"definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of advanced multiple myeloma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuLuc63 binds to CS1, a protein that is found mainly on the surface of multiple myeloma cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Elotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-901608","termGroup":"CN","termSource":"NCI"},{"termName":"Empliciti","termGroup":"BR","termSource":"NCI"},{"termName":"HuLuc-63","termGroup":"CN","termSource":"NCI"},{"termName":"HuLuc63","termGroup":"AB","termSource":"NCI"},{"termName":"PDL-063","termGroup":"CN","termSource":"NCI"},{"termName":"PDL063","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma (MM)"},{"name":"CAS_Registry","value":"915296-00-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1351PE5UGS"},{"name":"Legacy Concept Name","value":"Anti-CS1_Monoclonal_Antibody_HuLuc63"},{"name":"Maps_To","value":"Elotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"532249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"532249"},{"name":"PDQ_Open_Trial_Search_ID","value":"532249"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832049"}]}}{"C74090":{"preferredName":"Elpamotide","code":"C74090","definitions":[{"definition":"A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elpamotide","termGroup":"PT","termSource":"NCI"},{"termName":"L-Arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-alpha-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine Human Soluble (Vascular Endothelial Growth Factor Receptor) VEGFR2-(169-177)-peptide","termGroup":"SY","termSource":"NCI"},{"termName":"VEGFR2-169","termGroup":"SY","termSource":"NCI"},{"termName":"VEGFR2-169 Peptide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"673478-49-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S68632MB2G"},{"name":"Legacy Concept Name","value":"VEGFR2-169_Peptide_Vaccine"},{"name":"Maps_To","value":"Elpamotide"},{"name":"NCI_Drug_Dictionary_ID","value":"589327"},{"name":"NCI_META_CUI","value":"CL383528"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589327"},{"name":"PDQ_Open_Trial_Search_ID","value":"589327"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1080":{"preferredName":"Elsamitrucin","code":"C1080","definitions":[{"definition":"An heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21.  Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elsamitrucin","termGroup":"PT","termSource":"NCI"},{"termName":"10-O-Elsaminosylelsarosylchartarin","termGroup":"SN","termSource":"NCI"},{"termName":"BBM 2478A","termGroup":"CN","termSource":"NCI"},{"termName":"Benzo(h)(1)benzopyrano(5,4,3-cde)(1)ebnzopyran-5,12-dione,10((2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl)oxy)-6-hydroxy-1-methyl","termGroup":"SN","termSource":"NCI"},{"termName":"BMY-28090","termGroup":"CN","termSource":"NCI"},{"termName":"BRN 5214813","termGroup":"CN","termSource":"NCI"},{"termName":"Elsamicin A","termGroup":"SY","termSource":"NCI"},{"termName":"Elsamitrucina","termGroup":"SY","termSource":"NCI"},{"termName":"Elsamitrucine","termGroup":"SY","termSource":"NCI"},{"termName":"Elsamitrucinum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97068-30-9"},{"name":"Chemical_Formula","value":"C33H35NO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZTV0FOB6NU"},{"name":"Legacy Concept Name","value":"Elsamitrucin"},{"name":"Maps_To","value":"Elsamitrucin"},{"name":"NCI_Drug_Dictionary_ID","value":"41409"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41409"},{"name":"PDQ_Open_Trial_Search_ID","value":"41409"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059041"}]}}{"C125193":{"preferredName":"Eltanexor","code":"C125193","definitions":[{"definition":"An orally bioavailable inhibitor of exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic activity. Upon administration, eltanexor binds to the XPO1 cargo binding site, which prevents the XPO1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p73, BRCA1/2, pRB, FOXO, and other growth regulatory proteins and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), KPT-8602 restores the nuclear localization and function of tumor suppressing proteins which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The export of tumor suppressor proteins into the cytoplasm prevents them from initiating apoptosis and leads to uncontrolled tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eltanexor","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide","termGroup":"SY","termSource":"NCI"},{"termName":"ATG 016","termGroup":"CN","termSource":"NCI"},{"termName":"ATG-016","termGroup":"CN","termSource":"NCI"},{"termName":"ATG016","termGroup":"CN","termSource":"NCI"},{"termName":"Exportin 1 Inhibitor KPT-8602","termGroup":"SY","termSource":"NCI"},{"termName":"KPT-8602","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Inhibitor of Nuclear Export KPT-8602","termGroup":"SY","termSource":"NCI"},{"termName":"XPO1-inhibiting SINE Compound KPT-8602","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1642300-52-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q59IQJ9NTK"},{"name":"Maps_To","value":"Eltanexor"},{"name":"NCI_Drug_Dictionary_ID","value":"778691"},{"name":"NCI_META_CUI","value":"CL504007"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778691"},{"name":"PDQ_Open_Trial_Search_ID","value":"778691"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125548":{"preferredName":"Emactuzumab","code":"C125548","definitions":[{"definition":"A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities. Upon administration, emactuzumab binds to CSF1R expressed on macrophages and inhibits the binding of colony-stimulating factor-1 (CSF-1) to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells, which blocks the production of inflammatory mediators by macrophages and reduces inflammation. By blocking both the activity of CSF1R-dependent tumor-associated macrophages (TAMs) and the recruitment of TAMs to the tumor microenvironment, emactuzumab enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emactuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"RG-7155","termGroup":"CN","termSource":"NCI"},{"termName":"RG7155","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5509554","termGroup":"CN","termSource":"NCI"},{"termName":"RO5509554","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448221-67-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6FY6EI1X8R"},{"name":"Maps_To","value":"Emactuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"721542"},{"name":"NCI_META_CUI","value":"CL433956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721542"},{"name":"PDQ_Open_Trial_Search_ID","value":"721542"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127123":{"preferredName":"Emapalumab","code":"C127123","definitions":[{"definition":"A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emapalumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IFN gamma Monoclonal Antibody NI-0501","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IFNg mAb NI-0501","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-interferon gamma Monoclonal Antibody NI-0501","termGroup":"SY","termSource":"NCI"},{"termName":"Emapalumab-lzsg","termGroup":"SY","termSource":"NCI"},{"termName":"Gamifant","termGroup":"BR","termSource":"NCI"},{"termName":"NI-0501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"primary hemophagocytic lymphohistiocytosis (HLH)"},{"name":"CAS_Registry","value":"1709815-23-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3S252O2Z4X"},{"name":"Maps_To","value":"Emapalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"780986"},{"name":"NCI_META_CUI","value":"CL507913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780986"},{"name":"PDQ_Open_Trial_Search_ID","value":"780986"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2195":{"preferredName":"Emepepimut-S","code":"C2195","definitions":[{"definition":"A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emepepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"BLP 25","termGroup":"CN","termSource":"NCI"},{"termName":"BLP-25","termGroup":"CN","termSource":"NCI"},{"termName":"BLP-25 Liposomal Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"BLP25","termGroup":"CN","termSource":"NCI"},{"termName":"BLP25 Liposome Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"BP1-7-KLH","termGroup":"AB","termSource":"NCI"},{"termName":"EMD 531444","termGroup":"CN","termSource":"NCI"},{"termName":"Glycine, L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-L-alanyl-L-histidylglycyl-L-valyl-L-threonyl-L-seryl-L-alanyl-L-prolyl-L-alpha-aspartyl-L-threonyl-L-arginyl-L-prolyl-L-alanyl-L-prolylglycyl-L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-N6-(1-oxohexadecyl)-L-lysyl-","termGroup":"SN","termSource":"NCI"},{"termName":"L-BLP25","termGroup":"AB","termSource":"NCI"},{"termName":"Stimuvax","termGroup":"BR","termSource":"NCI"},{"termName":"Tecemotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"221214-84-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q7Y026G2CX"},{"name":"Legacy Concept Name","value":"BLP25"},{"name":"Maps_To","value":"Emepepimut-S"},{"name":"NCI_Drug_Dictionary_ID","value":"529341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529341"},{"name":"PDQ_Open_Trial_Search_ID","value":"529341"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832016"}]}}{"C1022":{"preferredName":"Emitefur","code":"C1022","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD) inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar ratio, with antineoplastic activity.  Upon administration, the prodrug emitefur is converted into 5-FU, while CNDP prevents the degradation of 5-FU by inhibiting DPYD and thereby prolonging the half-life of 5-FU. This increases 5-FU's concentration and thus its antitumor activity through inhibition of DNA and RNA synthesis, as well as inhibition of thymidylate synthase activity. In addition, by inhibiting the formation of 5-FU metabolites, some toxic effects associated with these metabolites may be reduced. DPYD is the rate-limiting enzyme in the catabolism of 5-FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emitefur","termGroup":"PT","termSource":"NCI"},{"termName":"(2) m-[[3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 2-Ester with 2,6-Dihydroxynicotinonitrile Benzoate (Ester)","termGroup":"SN","termSource":"NCI"},{"termName":"3-((3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"3-[3-(6-Benzoyloxy-3-cyrano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"[[Ethoxymethyl-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 6-(Benzoyloxy)-3-cyano-2-pyridinyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"BOF-A2","termGroup":"CN","termSource":"NCI"},{"termName":"Last-F","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110690-43-2"},{"name":"Chemical_Formula","value":"C28H19FN4O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9I50NF4AQ2"},{"name":"Legacy Concept Name","value":"Emitefur"},{"name":"Maps_To","value":"Emitefur"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053902"}]}}{"C29019":{"preferredName":"Emofolin Sodium","code":"C29019","definitions":[{"definition":"The sodium salt of a synthetic antimetabolite analogue of folate with antineoplastic activity.  Emfolin sodium competes for the folate binding site of the enzyme dihydrofolate reductase, resulting in inhibition of tetrahydrofolate synthesis, depletion of nucleotide pools, and inhibition of DNA, RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emofolin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"MeTHHF Disodium","termGroup":"AB","termSource":"NCI"},{"termName":"Methyltetrahydrohomofolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52386-42-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Emfolin_Sodium"},{"name":"Maps_To","value":"Emofolin Sodium"},{"name":"NSC Number","value":"139490"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0098575"}]}}{"C116074":{"preferredName":"Empesertib","code":"C116074","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase, with potential antineoplastic activity. Upon administration, empesertib binds to and inhibits the activity of Mps1. This causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy. This leads to the induction of cell death in cancer cells overexpressing Mps1. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for SAC functioning and controls chromosome alignment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Empesertib","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-2-(4-Fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide","termGroup":"SY","termSource":"NCI"},{"termName":"BAY116-1909","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1161909","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443763-60-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"02Y3Z2756M"},{"name":"Maps_To","value":"Empesertib"},{"name":"NCI_Drug_Dictionary_ID","value":"761238"},{"name":"NCI_META_CUI","value":"CL473492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761238"},{"name":"PDQ_Open_Trial_Search_ID","value":"761238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113786":{"preferredName":"Enadenotucirev","code":"C113786","definitions":[{"definition":"A complex, replication-selective, chimeric adenovirus type 11p (Ad11p)/Ad3 oncolytic virus vaccine, with potential antineoplastic and immunomodulating activities. Enadenotucirev has the Ad11p backbone with a large deletion in the E3-region and a small E4-domain (E4orf4) deleted, in addition to a partial E2B substitution by the Ad3 E2B genes. Upon intravenous administration of enadenotucirev, the adenovirus selectively reaches the tumor cells due to the leaky tumor vasculature and replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune response. This further kills tumor cells. This may also stimulate long-term anti-tumor immunity. Although the cancer-selectivity of enadenotucirev is not entirely understood, the virus does not efficiently infect normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enadenotucirev","termGroup":"PT","termSource":"NCI"},{"termName":"Chimeric Oncolytic Adenovirus Ad3/Ad11p Containing Two Deletions in the Viral Genome in the E3 Region (2444 bp) and in the E4 Region (24 bp) and 197 Non-homologous Nucleotides in the E2B Region","termGroup":"SY","termSource":"NCI"},{"termName":"ColoAd-1","termGroup":"CN","termSource":"NCI"},{"termName":"ColoAd1","termGroup":"CN","termSource":"NCI"},{"termName":"ColoAd1 Oncolytic Virus","termGroup":"SY","termSource":"NCI"},{"termName":"EnAd","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402042-02-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KX7ZYR6OQW"},{"name":"Maps_To","value":"Enadenotucirev"},{"name":"NCI_Drug_Dictionary_ID","value":"757141"},{"name":"NCI_META_CUI","value":"CL471767"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757141"},{"name":"PDQ_Open_Trial_Search_ID","value":"757141"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159599":{"preferredName":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A","code":"C159599","definitions":[{"definition":"An oncolytic adenoviral vector, enadenotucirev (EnAd), that expresses a full-length agonistic anti-CD40 monoclonal antibody, with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of NG-350A, enadenotucirev specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses the agonistic anti-CD40 antibody. The locally expressed anti-CD40 antibody targets and binds to CD40 on a variety of immune cells, including B-cells, T-cells and dendritic cells (DCs) in the tumor microenvironment (TME). This induces CD40-dependent signaling pathways, which activates these immune cells and induces a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response and leads to tumor cell death. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A","termGroup":"PT","termSource":"NCI"},{"termName":"NG 350A","termGroup":"CN","termSource":"NCI"},{"termName":"NG-350A","termGroup":"CN","termSource":"NCI"},{"termName":"NG350A","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector Expressing Anti-CD40 Antibody NG-350A","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector-expressing Anti-CD40 Agonistic Antibody NG-350A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A"},{"name":"NCI_Drug_Dictionary_ID","value":"797804"},{"name":"NCI_META_CUI","value":"CL951598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797804"},{"name":"PDQ_Open_Trial_Search_ID","value":"797804"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111573":{"preferredName":"Enasidenib","code":"C111573","definitions":[{"definition":"An orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enasidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AG-221","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90007 Free Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446502-11-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3T1SS4E7AG"},{"name":"Maps_To","value":"Enasidenib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827168"}]}}{"C137825":{"preferredName":"Enasidenib Mesylate","code":"C137825","definitions":[{"definition":"The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enasidenib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"AG-221 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"CC-90007","termGroup":"CN","termSource":"NCI"},{"termName":"Enasidenib Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Idhifa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation"},{"name":"CAS_Registry","value":"1650550-25-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UF6PC17XAV"},{"name":"Maps_To","value":"Enasidenib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"752247"},{"name":"NCI_META_CUI","value":"CL524900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752247"},{"name":"PDQ_Open_Trial_Search_ID","value":"752247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80045":{"preferredName":"Enavatuzumab","code":"C80045","definitions":[{"definition":"A humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. Enavatuzumab binds to TWEAKR and inhibits TWEAK ligand binding and activation of NF-kappaB-mediated cytokine release, which may result in tumor cell apoptosis. TWEAKR is a cell-surface receptor with homology to tumor necrosis factor receptors. Upon binding with its ligand, TWEAKR has been shown to stimulate cytokine release and cell proliferation, migration, and survival; it may also promote apoptosis under some conditions. This receptor may be overexpressed in a variety of tumors including those of the pancreas, colon, lung, kidney, and breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enavatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-tumor Necrosis Factor-like Weak Inducer of Apoptosis Monoclonal Antibody PDL192","termGroup":"SY","termSource":"NCI"},{"termName":"PDL 192","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1062149-33-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"914910XFBB"},{"name":"Legacy Concept Name","value":"Anti-TWEAKR_Monoclonal_Antibody_PDL192"},{"name":"Maps_To","value":"Enavatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"613893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613893"},{"name":"PDQ_Open_Trial_Search_ID","value":"613893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698154"}]}}{"C28211":{"preferredName":"Enclomiphene","code":"C28211","definitions":[{"definition":"The trans-isomer of clomiphene citrate (CC).  Enclomiphene has a higher rate of clearance and is less active than the cis-isomer, cis-clomiphene.  Clomiphene citrate has been evaluated for antineoplastic activity against breast cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enclomiphene","termGroup":"PT","termSource":"NCI"},{"termName":"Enclomifene","termGroup":"SY","termSource":"NCI"},{"termName":"ICI 46476","termGroup":"CN","termSource":"NCI"},{"termName":"RMI 16,289","termGroup":"CN","termSource":"NCI"},{"termName":"trans Clomiphene","termGroup":"SY","termSource":"NCI"},{"termName":"trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15690-57-0"},{"name":"Chemical_Formula","value":"C26H28ClNO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6D2UI4FLS"},{"name":"Legacy Concept Name","value":"Enclomiphene"},{"name":"Maps_To","value":"Enclomiphene"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086213"}]}}{"C61745":{"preferredName":"Enclomiphene Citrate","code":"C61745","definitions":[{"definition":"The orally bioavailable citrate salt of enclomiphene, the trans-isomer of the nonsteroidal triphenylethylene compound clomiphene, with tissue-selective estrogenic and antiestrogenic activities. As a selective estrogen receptor modulator (SERM), enclomiphene binds to hypothalamic estrogen receptors, blocking the negative feedback of endogenous estrogens and stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus; released GnRH subsequently stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary, resulting in ovulation. In addition, this agent may bind to estrogen receptors on breast cancer cells, resulting in the inhibition of estrogen-stimulated proliferation in susceptible cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enclomiphene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Androxal","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7599-79-3"},{"name":"Chemical_Formula","value":"C26H28ClNO.C6H8O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J303A6U9Y6"},{"name":"Legacy Concept Name","value":"Enclomiphene_Citrate"},{"name":"Maps_To","value":"Enclomiphene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"39307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39307"},{"name":"PDQ_Open_Trial_Search_ID","value":"39307"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086214"}]}}{"C98283":{"preferredName":"Encorafenib","code":"C98283","definitions":[{"definition":"An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"Braftovi","termGroup":"BR","termSource":"NCI"},{"termName":"LGX 818","termGroup":"CN","termSource":"NCI"},{"termName":"LGX-818","termGroup":"CN","termSource":"NCI"},{"termName":"LGX818","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation"},{"name":"CAS_Registry","value":"1269440-17-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8L7891MRB6"},{"name":"Maps_To","value":"Encorafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"712549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712549"},{"name":"PDQ_Open_Trial_Search_ID","value":"712549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4079208"}]}}{"C26678":{"preferredName":"Endothelin Receptor Type A Antagonist YM598","code":"C26678","definitions":[{"definition":"A substance that is being studied as a treatment for advanced prostate cancer and for pain caused by prostate cancer that has spread to the bone. It belongs to the family of drugs called endothelin ETA receptor antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endothelin Receptor Type A Antagonist YM598","termGroup":"PT","termSource":"NCI"},{"termName":"Potassium (E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylenthene Sulfonamidate","termGroup":"SN","termSource":"NCI"},{"termName":"YM598","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"342005-82-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OK6K3MDZ98"},{"name":"Legacy Concept Name","value":"YM598"},{"name":"Maps_To","value":"Endothelin Receptor Type A Antagonist YM598"},{"name":"NCI_Drug_Dictionary_ID","value":"270682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"270682"},{"name":"PDQ_Open_Trial_Search_ID","value":"270682"},{"name":"PubMedID_Primary_Reference","value":"16843458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1175067"}]}}{"C162248":{"preferredName":"Engineered Human Umbilical Vein Endothelial Cells AB-205","code":"C162248","definitions":[{"definition":"A population of ex vivo expanded, genetically engineered CD31 (platelet endothelial cell adhesion molecule; PECAM-1)-positive human umbilical vein endothelial cells (HUVECs) derived from human umbilical vein tissue, that can be used to enhance the hematopoietic stem and progenitor cells (HSPCs) transplantation potential and improve blood cell recovery. Following autologous stem cell transplantation (ASCT) and upon the administration of the engineered HUVEC AB-205, the endothelial cells secrete angiocrine growth factors and interact with the HSPCs, thereby forming endothelial cell network structures and improving engraftment potential. AB-205 also interacts with injured or damaged vascular niche cells, thereby promoting blood cell recovery and improving tissue regeneration. This enhances recovery from toxicities related to chemo/radiation regimens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Human Umbilical Vein Endothelial Cells AB-205","termGroup":"PT","termSource":"NCI"},{"termName":"AB 205","termGroup":"CN","termSource":"NCI"},{"termName":"AB-205","termGroup":"CN","termSource":"NCI"},{"termName":"AB-205 Cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"AB205","termGroup":"CN","termSource":"NCI"},{"termName":"Engineered HUVEC AB-205","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Human Umbilical Vein Endothelial Cells AB-205"},{"name":"NCI_Drug_Dictionary_ID","value":"798637"},{"name":"NCI_META_CUI","value":"CL970717"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798637"},{"name":"PDQ_Open_Trial_Search_ID","value":"798637"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162649":{"preferredName":"Engineered Toxin Body Targeting HER2 MT-5111","code":"C162649","definitions":[{"definition":"An engineered toxin body (ETB) composed of a single chain variable fragment (scFv) from an antibody targeting the human epidermal growth factor receptor 2 (HER2; HER-2), fused to the enzymatically active de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration, the scFv moiety of MT-5111 specifically targets and binds to a distinct epitope on HER2-expressing cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and leads to apoptosis in HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Toxin Body Targeting HER2 MT-5111","termGroup":"PT","termSource":"NCI"},{"termName":"ETB Targeting HER2 MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"HER2-targeted ETB MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"MT 5111","termGroup":"CN","termSource":"NCI"},{"termName":"MT-5111","termGroup":"CN","termSource":"NCI"},{"termName":"MT5111","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Fusion Protein MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted Engineered Toxin Body MT-5111","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Toxin Body Targeting HER2 MT-5111"},{"name":"NCI_Drug_Dictionary_ID","value":"798930"},{"name":"NCI_META_CUI","value":"CL971043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798930"},{"name":"PDQ_Open_Trial_Search_ID","value":"798930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C11252":{"preferredName":"Eniluracil/5-FU Combination Tablet","code":"C11252","definitions":[{"definition":"A combination tablet of ethynyluracil and fluorouracil. Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Ethynyluracil is an orally-active fluoropyrimidine analog that inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil in the liver. This may lead to an increase in the bioavailability and, effectiveness of fluorouracil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eniluracil/5-FU Combination Tablet","termGroup":"PT","termSource":"NCI"},{"termName":"776C85/5-FU","termGroup":"SY","termSource":"NCI"},{"termName":"Ethynyluracil/Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"GW776/5-Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"GW776/5-FU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ethynyluracil_Fluorouracil"},{"name":"Maps_To","value":"Eniluracil/5-FU Combination Tablet"},{"name":"NCI_Drug_Dictionary_ID","value":"42618"},{"name":"NSC Number","value":"710026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42618"},{"name":"PDQ_Open_Trial_Search_ID","value":"42618"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393027"}]}}{"C95323":{"preferredName":"Enloplatin","code":"C95323","definitions":[{"definition":"A platinum-based alkylating agent with antineoplastic activity. Although its pharmacokinetic properties are similar to that of carboplatin, enloplatin appears to be non-cross resistant with other platinum-based agents, such as cisplatin and carboplatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enloplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-(1,1-Cyclobutanedicarboxylato)(Tetrahydro-4H-Pyran-4,4-Bis(Methylamine))Platinum","termGroup":"SN","termSource":"NCI"},{"termName":"CL 287,110","termGroup":"CN","termSource":"NCI"},{"termName":"CL-287110","termGroup":"CN","termSource":"NCI"},{"termName":"Platinum, (1,1-Cyclobutanedicarboxylato(2-))(Tetrahydro-4h-Pyran-4,4-Dimethanamine-N,N')-, (Sp-4-2)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111523-41-2"},{"name":"Chemical_Formula","value":"C7H16N2O.C6H6O4.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C7HT2IO79H"},{"name":"Maps_To","value":"Enloplatin"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165431"}]}}{"C97510":{"preferredName":"Enoblituzumab","code":"C97510","definitions":[{"definition":"An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enoblituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"MGA271","termGroup":"CN","termSource":"NCI"},{"termName":"TJ 271","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-271","termGroup":"CN","termSource":"NCI"},{"termName":"TJ271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353485-38-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M6030H73N9"},{"name":"Maps_To","value":"Enoblituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"703720"},{"name":"NCI_META_CUI","value":"CL430254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703720"},{"name":"PDQ_Open_Trial_Search_ID","value":"703720"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C69161":{"preferredName":"Enobosarm","code":"C69161","definitions":[{"definition":"A non-steroidal agent with anabolic activity. Selective androgen receptor modulator (SARM) GTx-024 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone's action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enobosarm","termGroup":"PT","termSource":"NCI"},{"termName":"Gtx-024","termGroup":"CN","termSource":"NCI"},{"termName":"Ostarine","termGroup":"BR","termSource":"NCI"},{"termName":"Propanamide, 3-(4-cyanophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-, (2S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"841205-47-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3571H3R8N"},{"name":"Legacy Concept Name","value":"Selective_Androgen_Receptor_Modulator_Gtx-024"},{"name":"Maps_To","value":"Enobosarm"},{"name":"NCI_Drug_Dictionary_ID","value":"551564"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551564"},{"name":"PDQ_Open_Trial_Search_ID","value":"551564"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742262"}]}}{"C82367":{"preferredName":"Enoticumab","code":"C82367","definitions":[{"definition":"A human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity. Enoticumab specifically binds to human DLL4, preventing its binding to Notch receptors and inhibiting Notch signaling, which may result in defective tumor vascularization and, so, the inhibition of tumor cell growth. DLL4 is the only Notch ligand selectively expressed on endothelial cells; DLL4/Notch signaling is required for the development of functional tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enoticumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Delta-Like 4 Monoclonal Antibody REGN421","termGroup":"SY","termSource":"NCI"},{"termName":"REGN421","termGroup":"CN","termSource":"NCI"},{"termName":"SAR153192","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1192578-27-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B59DCD0F7D"},{"name":"Legacy Concept Name","value":"Anti-Dll4_Monoclonal_Antibody_REGN421"},{"name":"Maps_To","value":"Enoticumab"},{"name":"NCI_Drug_Dictionary_ID","value":"640973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640973"},{"name":"PDQ_Open_Trial_Search_ID","value":"640973"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830058"}]}}{"C83689":{"preferredName":"Enpromate","code":"C83689","definitions":[{"definition":"A synthetic acetylenic carbamate, an alkylating agent, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enpromate","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Diphenyl-2-propynyl-N-cyclohexylcarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Acetylenic Carbamate","termGroup":"SY","termSource":"NCI"},{"termName":"Lilly 59156","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10087-89-5"},{"name":"Chemical_Formula","value":"C22H23NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HBS2850E4H"},{"name":"Maps_To","value":"Enpromate"},{"name":"NSC Number","value":"112682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050514"}]}}{"C102754":{"preferredName":"Ensartinib","code":"C102754","definitions":[{"definition":"An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ensartinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- N-{4-[(3R,5S)-3,5-dimethylpiperazine- 1-carbonyl]phenyl}pyridazine-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"X-396","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1370651-20-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"SMA5ZS5B22"},{"name":"Maps_To","value":"Ensartinib"},{"name":"NCI_Drug_Dictionary_ID","value":"735953"},{"name":"NCI_META_CUI","value":"CL437011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735953"},{"name":"PDQ_Open_Trial_Search_ID","value":"735953"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90532":{"preferredName":"Ensituximab","code":"C90532","definitions":[{"definition":"A chimeric monoclonal antibody against human colorectal and pancreatic carcinoma-associated antigens (CPAAs) with potential immunomodulating and anti-tumor activities. Anti-CPAA monoclonal antibody NPC-1C binds to CPAAs, which may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cellular cytotoxicity (ADCC) response against CPAA-expressing tumor cells. CPAAs, cell surface proteins, are upregulated on colon and pancreatic tumor cells. NPC-1C contains the variable region of the heavy and light chain of murine NPC-1 and linked in-frame to constant regions of a human IgG1 isotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ensituximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Colorectal and Pancreatic Carcinoma-Associated Antigen Monoclonal Antibody NPC-1C","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CPAA Monoclonal Antibody NPC-1C","termGroup":"SY","termSource":"NCI"},{"termName":"NPC-1C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092658-06-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F988K568V2"},{"name":"Maps_To","value":"Ensituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"663436"},{"name":"NCI_META_CUI","value":"CL413613"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663436"},{"name":"PDQ_Open_Trial_Search_ID","value":"663436"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82660":{"preferredName":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride","code":"C82660","definitions":[{"definition":"An enteric-coated orally bioavailable formulation of the hydrochloride salt of a small-molecule agonist for transient receptor potential melastatin member 8 (TRPM8 or Trp-p8) with potential antineoplastic activity. The active ingredient in enteric-coated TRPM8 agonist D-3263 hydrochloride binds to and activates TRPM8, which may result in an increase in calcium and sodium entry; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. This agent may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and BPH. TRPM8 is a transmembrane calcium channel protein that is normally expressed in prostate cells and appears to be overexpressed in benign prostatic hyperplasia (BPH) and in prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"EC D-3263 HCl","termGroup":"SY","termSource":"NCI"},{"termName":"EC D-3263 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1008763-54-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R82GTC01OB"},{"name":"Legacy Concept Name","value":"Enteric-Coated_TRPM8_Agonist_D-3263_Hydrochloride"},{"name":"Maps_To","value":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"636649"},{"name":"NCI_META_CUI","value":"CL411370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636649"},{"name":"PDQ_Open_Trial_Search_ID","value":"636649"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160293":{"preferredName":"Enterococcus gallinarum Strain MRx0518","code":"C160293","definitions":[{"definition":"A live strain of the flagellin-producing Gram-positive bacterium Enterococcus (E.) gallinarum that is isolated from a healthy human gut, with potential immunomodulating and antineoplastic activities. Upon oral administration, MRx0518 modulates the intestinal microbiota and targets both intestinal epithelial cells (IECs), and various immune cells, such as macrophages and dendritic cells (DCs)  and is able to induce the production of both pro- and anti-inflammatory mediators, such as interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-a), IL-1beta, IL-6, IL-23, in these cells and activates the innate immune system. The flagellin produced by MRx0518 interacts with and activates toll-like receptor 5 (TLR5), thereby activating the adaptive immune system and modulating the tumor microenvironment (TME). This activates the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enterococcus gallinarum Strain MRx0518","termGroup":"PT","termSource":"NCI"},{"termName":"E. gallinarum MRx0518","termGroup":"SY","termSource":"NCI"},{"termName":"Gut Microbiota-derived Strain MRx0518","termGroup":"SY","termSource":"NCI"},{"termName":"MRx 0518","termGroup":"CN","termSource":"NCI"},{"termName":"MRx-0518","termGroup":"CN","termSource":"NCI"},{"termName":"MRx0518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterococcus gallinarum Strain MRx0518"},{"name":"NCI_Drug_Dictionary_ID","value":"798317"},{"name":"NCI_META_CUI","value":"CL969238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798317"},{"name":"PDQ_Open_Trial_Search_ID","value":"798317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1863":{"preferredName":"Entinostat","code":"C1863","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Carbamic Acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3- pyridinylmethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"MS 27-275","termGroup":"CN","termSource":"NCI"},{"termName":"MS-275","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]b enzamide","termGroup":"SN","termSource":"NCI"},{"termName":"SNDX-275","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"209783-80-2"},{"name":"Chemical_Formula","value":"C21H20N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1ZNY4FKK9H"},{"name":"Legacy Concept Name","value":"MS-27-275"},{"name":"Maps_To","value":"Entinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"38294"},{"name":"NSC Number","value":"706995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38294"},{"name":"PDQ_Open_Trial_Search_ID","value":"38294"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048552"}]}}{"C99166":{"preferredName":"Entolimod","code":"C99166","definitions":[{"definition":"A polypeptide derived from the Salmonella filament protein flagellin with potential radioprotective and anticancer activities. As a toll-like receptor 5 (TLR5) agonist, entolimod binds to and activates TLR5 thereby stimulating tumor necrosis factor production and activating nuclear factor kappa B (NF-kB). This induces NF-kB-mediated signaling pathways and inhibits the induction of apoptosis. This may prevent apoptosis in normal, healthy cells during radiotherapy of cancerous cells and may allow for increased doses of ionizing radiation. In addition, entolimod may inhibit radiation-independent proliferation in TLR5-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entolimod","termGroup":"PT","termSource":"NCI"},{"termName":"CBLB502","termGroup":"CN","termSource":"NCI"},{"termName":"TLR5 Agonist CBLB502","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"951628-22-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1UQ6D1ECM"},{"name":"Maps_To","value":"Entolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"717513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717513"},{"name":"PDQ_Open_Trial_Search_ID","value":"717513"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2353146"}]}}{"C105402":{"preferredName":"Entospletinib","code":"C105402","definitions":[{"definition":"An orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entospletinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine","termGroup":"SN","termSource":"NCI"},{"termName":"ENTO","termGroup":"AB","termSource":"NCI"},{"termName":"GS 9973","termGroup":"CN","termSource":"NCI"},{"termName":"GS-9973","termGroup":"CN","termSource":"NCI"},{"termName":"Imidazo(1,2-a)pyrazin-8-amine, 6-(1H-indazol-6-yl)-N-(4-(4-morpholinyl)phenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229208-44-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6I3O3W6O3B"},{"name":"Maps_To","value":"Entospletinib"},{"name":"NCI_Drug_Dictionary_ID","value":"746910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746910"},{"name":"PDQ_Open_Trial_Search_ID","value":"746910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642151"}]}}{"C114984":{"preferredName":"Entrectinib","code":"C114984","definitions":[{"definition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Rozlytrek","termGroup":"BR","termSource":"NCI"},{"termName":"RXDX 101","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-101","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion"},{"name":"CAS_Registry","value":"1108743-60-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"L5ORF0AN1I"},{"name":"Maps_To","value":"Entrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"759586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759586"},{"name":"PDQ_Open_Trial_Search_ID","value":"759586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896774"}]}}{"C129714":{"preferredName":"Envafolimab","code":"C129714","definitions":[{"definition":"An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Envafolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 MoAb KN035","termGroup":"SY","termSource":"NCI"},{"termName":"KN 035","termGroup":"CN","termSource":"NCI"},{"termName":"KN035","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2102192-68-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ES1M06M6QH"},{"name":"Maps_To","value":"Envafolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"784496"},{"name":"NCI_META_CUI","value":"CL512904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784496"},{"name":"PDQ_Open_Trial_Search_ID","value":"784496"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71744":{"preferredName":"Enzalutamide","code":"C71744","definitions":[{"definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enzalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"ASP9785","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MDV3100","termGroup":"CN","termSource":"NCI"},{"termName":"Xtandi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"castration-resistant prostate cancer (CRPC)"},{"name":"CAS_Registry","value":"915087-33-1"},{"name":"Chemical_Formula","value":"C21H16F4N4O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"93T0T9GKNU"},{"name":"Legacy Concept Name","value":"Selective_Androgen_Receptor_Modulator_MDV3100"},{"name":"Maps_To","value":"Enzalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"560774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560774"},{"name":"PDQ_Open_Trial_Search_ID","value":"560774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348174"}]}}{"C77392":{"preferredName":"Enzastaurin","code":"C77392","definitions":[{"definition":"A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Enzastaurin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"170364-57-5"},{"name":"Chemical_Formula","value":"C32H29N5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UC96G28EQF"},{"name":"Legacy Concept Name","value":"Enzastaurin"},{"name":"Maps_To","value":"Enzastaurin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327830"}]}}{"C26658":{"preferredName":"Enzastaurin Hydrochloride","code":"C26658","definitions":[{"definition":"A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin hydrochloride blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity.  Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enzastaurin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrole-2,5-dione, 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-, Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"3-(1-Methyl-1H-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Enzastaurin Monohydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"LY317615","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"359017-79-1"},{"name":"Chemical_Formula","value":"C32H29N5O2.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KX7K68Z2UH"},{"name":"Legacy Concept Name","value":"LY317615"},{"name":"Maps_To","value":"Enzastaurin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"269069"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269069"},{"name":"PDQ_Open_Trial_Search_ID","value":"269069"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1615613"}]}}{"C150376":{"preferredName":"EP4 Antagonist ONO-4578","code":"C150376","definitions":[{"definition":"An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist ONO-4578 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP4 Antagonist ONO-4578","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986310","termGroup":"CN","termSource":"NCI"},{"termName":"ONO 4578","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-4578","termGroup":"CN","termSource":"NCI"},{"termName":"ONO4578","termGroup":"CN","termSource":"NCI"},{"termName":"PGE2 Receptor Antagonist ONO-4578","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 Receptor Antagonist ONO-4578","termGroup":"SY","termSource":"NCI"},{"termName":"Selective PGE2 Receptor 4 Antagonist ONO-4578","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EP4 Antagonist ONO-4578"},{"name":"NCI_Drug_Dictionary_ID","value":"792745"},{"name":"NCI_META_CUI","value":"CL552175"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792745"},{"name":"PDQ_Open_Trial_Search_ID","value":"792745"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C92582":{"preferredName":"Epacadostat","code":"C92582","definitions":[{"definition":"An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. Epacadostat targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, INCB024360 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), NK cells, and T-lymphocytes, as well as interferon (IFN) production, and a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and DCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epacadostat","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,5-Oxadiazole-3-carboximidamide, 4-((2-((Aminosulfonyl)amino)ethyl)amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-, (C(Z))-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 024360","termGroup":"CN","termSource":"NCI"},{"termName":"INCB024360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204669-58-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71596A9R13"},{"name":"Maps_To","value":"Epacadostat"},{"name":"NCI_Drug_Dictionary_ID","value":"685310"},{"name":"NCI_META_CUI","value":"CL423831"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685310"},{"name":"PDQ_Open_Trial_Search_ID","value":"685310"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1866":{"preferredName":"Epipodophyllotoxin Analog GL331","code":"C1866","definitions":[{"definition":"An epipodophyllotoxin analogue possessing antineoplastic properties.  GL331 binds to and inhibits topoisomerase II, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epipodophyllotoxin Analog GL331","termGroup":"PT","termSource":"NCI"},{"termName":"GL331","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GL331"},{"name":"Maps_To","value":"Epipodophyllotoxin Analog GL331"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0908996"}]}}{"C78083":{"preferredName":"Epipropidine","code":"C78083","definitions":[{"definition":"An epoxide and alkylating agent with antineoplastic activity. Epipropidone is not used clinically due to its unstable nature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epipropidine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5696-17-3"},{"name":"Chemical_Formula","value":"C16H28N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T3RCY5OD7A"},{"name":"Legacy Concept Name","value":"Epipropidine"},{"name":"Maps_To","value":"Epipropidine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700003"}]}}{"C62028":{"preferredName":"Epirubicin","code":"C62028","definitions":[{"definition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used together with other drugs to treat early breast cancer that has spread to lymph nodes. It is also being studied in the treatment of other types of cancer. Epirubicin is a type of anthracycline antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Epirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"4'-epi DX","termGroup":"AB","termSource":"NCI"},{"termName":"4'-Epiadriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"4'-Epidoxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Epi DX","termGroup":"AB","termSource":"NCI"},{"termName":"Epidoxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Pidorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56420-45-2"},{"name":"CHEBI_ID","value":"CHEBI:47898"},{"name":"Chemical_Formula","value":"C27H29NO11"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3Z8479ZZ5X"},{"name":"Legacy Concept Name","value":"Epirubicin_Base"},{"name":"Maps_To","value":"Epirubicin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014582"}]}}{"C474":{"preferredName":"Epirubicin Hydrochloride","code":"C474","definitions":[{"definition":"A drug used together with other drugs to treat early breast cancer that has spread to lymph nodes. It is also being studied in the treatment of other types of cancer. Ellence is a type of anthracycline antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epirubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Ellence","termGroup":"BR","termSource":"NCI"},{"termName":"IMI-28","termGroup":"CN","termSource":"NCI"},{"termName":"Pharmorubicin PFS","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer"},{"name":"CAS_Registry","value":"56390-09-1"},{"name":"Chemical_Formula","value":"C27H29NO11.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22966TX7J5"},{"name":"Legacy Concept Name","value":"Epirubicin"},{"name":"Maps_To","value":"Epirubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39232"},{"name":"NSC Number","value":"256942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39232"},{"name":"PDQ_Open_Trial_Search_ID","value":"39232"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700582"}]}}{"C153095":{"preferredName":"Epitinib Succinate","code":"C153095","definitions":[{"definition":"The succinate salt form of epitinib, an orally available epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon administration, epitinib inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may lead to induction of cell death and inhibition of tumor growth in EGFR-overexpressing tumor cells. EGFR is a receptor tyrosine kinase (RTK) that is overexpressed in certain tumor types and plays a key role in tumor cell proliferation and vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epitinib Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL 813","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-813","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL813","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2252334-12-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2138WW3F3R"},{"name":"Maps_To","value":"Epitinib Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"793471"},{"name":"NCI_META_CUI","value":"CL554354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793471"},{"name":"PDQ_Open_Trial_Search_ID","value":"793471"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1089":{"preferredName":"Epitiostanol","code":"C1089","definitions":[{"definition":"An androgenic anabolic steroid having potent anti-estrogenic effect, which inhibits the progression of estrogen-stimulated cancers such as breast cancer. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epitiostanol","termGroup":"PT","termSource":"NCI"},{"termName":"10275-S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2363-58-8"},{"name":"Chemical_Formula","value":"C19H30OS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YE7586973L"},{"name":"Legacy Concept Name","value":"Epitiostanol"},{"name":"Maps_To","value":"Epitiostanol"},{"name":"NCI_Drug_Dictionary_ID","value":"39595"},{"name":"NSC Number","value":"194684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39595"},{"name":"PDQ_Open_Trial_Search_ID","value":"39595"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059457"}]}}{"C118450":{"preferredName":"Utidelone","code":"C118450","definitions":[{"definition":"A genetically engineered epothilone analog with potential antineoplastic activity. Upon administration, utidelone binds to tubulin, induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and enhanced activity against certain multidrug-resistant (MDR) tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Utidelone","termGroup":"PT","termSource":"NCI"},{"termName":"Epothilone Analog UTD1","termGroup":"SY","termSource":"NCI"},{"termName":"UTD1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epothilone Analog UTD1"},{"name":"NCI_Drug_Dictionary_ID","value":"765129"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765129"},{"name":"PDQ_Open_Trial_Search_ID","value":"765129"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896752"}]}}{"C77892":{"preferredName":"Epothilone KOS-1584","code":"C77892","definitions":[{"definition":"A second-generation epothilone with potential antineoplastic activity. Epothilone KOS-1584 binds to tubulin and induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and efficacy with an enhanced pharmaceutical profile, including enhanced water solubility and tumor penetration, and reduced CNS exposure. In addition, epothilone KOS-1584 is a poor substrate for the P-glycoprotein (P-gp) drug efflux pump.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epothilone KOS-1584","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Didehydroepothilone D","termGroup":"SN","termSource":"NCI"},{"termName":"KOS-1584","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"350493-61-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82481G197K"},{"name":"Legacy Concept Name","value":"Epothilone_KOS-1584"},{"name":"Maps_To","value":"Epothilone KOS-1584"},{"name":"NCI_Drug_Dictionary_ID","value":"594152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594152"},{"name":"PDQ_Open_Trial_Search_ID","value":"594152"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099968"}]}}{"C1887":{"preferredName":"Epratuzumab","code":"C1887","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epratuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 412","termGroup":"CN","termSource":"NCI"},{"termName":"hLL2","termGroup":"AB","termSource":"NCI"},{"termName":"IMMU-HLL2","termGroup":"SY","termSource":"NCI"},{"termName":"LymphoCide","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Systemic lupus erythematosus"},{"name":"CAS_Registry","value":"205923-57-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3062P60MH9"},{"name":"Legacy Concept Name","value":"Epratuzumab"},{"name":"Maps_To","value":"Epratuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42234"},{"name":"NSC Number","value":"716711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42234"},{"name":"PDQ_Open_Trial_Search_ID","value":"42234"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1120776"}]}}{"C155794":{"preferredName":"Epratuzumab-cys-tesirine","code":"C155794","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a cysteine-engineered version of epratuzumab (hLL2), a humanized anti-CD22 monoclonal antibody derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2), site-specifically conjugated to the cross-linking cytotoxic agent tesirine (SG3249), a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine dimer (PBD), with potential antineoplastic activity. Upon administration of epratuzumab-cys-tesirine, the epratuzumab moiety targets and binds to the B cell-specific CD22 receptor and is rapidly internalized. Upon cleavage, the imine groups of tesirine target and bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD22-overexpressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epratuzumab-cys-tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-602","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT-602","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT602","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD22/PBD ADC ADCT-602","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate ADCT-602","termGroup":"SY","termSource":"NCI"},{"termName":"Epratuzumab-cys-SG3249","termGroup":"SY","termSource":"NCI"},{"termName":"hLL2-cys-PBD","termGroup":"SY","termSource":"NCI"},{"termName":"hLL2-cys-SG3249","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7X6143A60Y"},{"name":"Maps_To","value":"Epratuzumab-cys-tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"794990"},{"name":"NCI_META_CUI","value":"CL556329"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794990"},{"name":"PDQ_Open_Trial_Search_ID","value":"794990"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C165420":{"preferredName":"Vepdegestrant","code":"C165420","definitions":[{"definition":"An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vepdegestrant","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Piperidinedione, 3-(1,3-dihydro-1-oxo-5-(4-((1-(4-((1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenyl)-4-piperidinyl)methyl)-1-piperazinyl)-2H-isoindol-2-yl)-, (3S)-","termGroup":"SN","termSource":"NCI"},{"termName":"ARV 471","termGroup":"CN","termSource":"NCI"},{"termName":"ARV-471","termGroup":"CN","termSource":"NCI"},{"termName":"ARV471","termGroup":"CN","termSource":"NCI"},{"termName":"ER alpha PROTAC Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"},{"termName":"ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"},{"termName":"Estrogen Receptor alpha PROTAC Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"},{"termName":"PF 07850327","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07850327","termGroup":"CN","termSource":"NCI"},{"termName":"PF07850327","termGroup":"CN","termSource":"NCI"},{"termName":"PROTAC Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2229711-68-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WC1U3R1YMI"},{"name":"Maps_To","value":"ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471"},{"name":"NCI_Drug_Dictionary_ID","value":"799764"},{"name":"NCI_META_CUI","value":"CL978634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799764"},{"name":"PDQ_Open_Trial_Search_ID","value":"799764"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95720":{"preferredName":"ERa36 Modulator Icaritin","code":"C95720","definitions":[{"definition":"A metabolite of icariin, a principal flavonoid glycoside in Herba Epimedii (a traditional Chinese medicine herb used in treating osteoporosis) with potential antineoplastic activity. ERa36 modulator icaritin selectively binds to a novel variant of estrogen receptor alpha, a36, and mediates a membrane-initiated \"nongenomic\" signaling pathway, which is linked to activate signaling pathways like the MAPK/ERK and the PI3K/Akt pathways. This agent induces cell cycle arrest at G1, or G2/M arrest depending upon the dose. Consistently with G1 arrest, icaritin increases protein expressions of pRb, p27(Kip1) and p16(Ink4a), while decreasing phosphorylated pRb, Cyclin D1 and CDK4. 40% of ER-negative breast cancer tumors express high levels of ERa36, and this subset of patients is less likely to benefit from tamoxifen treatment compared with those with ERa66-positive/ERa36-negative tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERa36 Modulator Icaritin","termGroup":"PT","termSource":"NCI"},{"termName":"4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118525-40-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERa36 Modulator Icaritin"},{"name":"NCI_Drug_Dictionary_ID","value":"694226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694226"},{"name":"PDQ_Open_Trial_Search_ID","value":"694226"},{"name":"PubMedID_Primary_Reference","value":"17382317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567768"}]}}{"C70625":{"preferredName":"Erastin Analogue PRLX 93936","code":"C70625","definitions":[{"definition":"A structural analogue of erastin with potential antineoplastic activity. Erastin analogue PRLX 93936 appears to inhibit mitochondrial outer membrane protein VDACs (voltage-dependent anion channels) 2 and 3, resulting in an oxidative, non-apoptotic cell death. Erastin analogue PRLX 93936 exhibits greater lethality in cell lines harboring mutations in the GTPase protein oncogenes HRAS and KRAS or the serine-threonine protein kinase oncogene BRAF than in non-tumorigenic cell lines. VDACs 2 and 3 are up-regulated in a wide variety of tumor cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erastin Analogue PRLX 93936","termGroup":"PT","termSource":"NCI"},{"termName":"PRLX 93936","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Erastin_Analogue_PRLX93936"},{"name":"Maps_To","value":"Erastin Analogue PRLX 93936"},{"name":"NCI_Drug_Dictionary_ID","value":"570728"},{"name":"NCI_META_CUI","value":"CL375988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570728"},{"name":"PDQ_Open_Trial_Search_ID","value":"570728"},{"name":"PubMedID_Primary_Reference","value":"17568748"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73258":{"preferredName":"Erbulozole","code":"C73258","definitions":[{"definition":"A water soluble congener of tubulozole and a tubulin binding agent with potential antimitotic and antineoplastic activities. Erbulozole targets and binds to tubulin, thereby preventing the polymerization of tubulin. This may lead to an inhibition of cell division and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erbulozole","termGroup":"PT","termSource":"NCI"},{"termName":"Carbamic acid, (4-(((2-(1H-imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl)methyl)thio)phenyl)-,ethyl ester, cis-(+-)-","termGroup":"SN","termSource":"NCI"},{"termName":"R55104","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124784-31-2"},{"name":"Chemical_Formula","value":"C24H27N3O5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78XGN2K5RX"},{"name":"Legacy Concept Name","value":"Erbulozole"},{"name":"Maps_To","value":"Erbulozole"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059504"}]}}{"C103273":{"preferredName":"Erdafitinib","code":"C103273","definitions":[{"definition":"An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erdafitinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Balversa","termGroup":"BR","termSource":"NCI"},{"termName":"JNJ-42756493","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma"},{"name":"CAS_Registry","value":"1346242-81-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"890E37NHMV"},{"name":"Maps_To","value":"Erdafitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"741845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741845"},{"name":"PDQ_Open_Trial_Search_ID","value":"741845"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641169"}]}}{"C96748":{"preferredName":"Eribulin","code":"C96748","definitions":[{"definition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eribulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"ER-086526","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast Cancer"},{"name":"CAS_Registry","value":"253128-41-5"},{"name":"CHEBI_ID","value":"CHEBI:63587"},{"name":"Chemical_Formula","value":"C40H59NO11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LR24G6354G"},{"name":"Maps_To","value":"Eribulin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350866"}]}}{"C26644":{"preferredName":"Eribulin Mesylate","code":"C26644","definitions":[{"definition":"A drug used to treat metastatic breast cancer in patients who have already been treated with other chemotherapy. It is also being studied in the treatment of other types of cancer. Halaven may block cancer cell growth by stopping cell division. It belongs to the family of drugs called antitubulin agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eribulin Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"B1939 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"E7389","termGroup":"CN","termSource":"NCI"},{"termName":"ER-086526 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Halaven","termGroup":"BR","termSource":"NCI"},{"termName":"Halichondrin B Analog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable or metastatic liposarcoma; breast cancer"},{"name":"CAS_Registry","value":"253128-41-5"},{"name":"Chemical_Formula","value":"C40H59NO11.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AV9U0660CW"},{"name":"Legacy Concept Name","value":"E7389"},{"name":"Maps_To","value":"Eribulin Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"257773"},{"name":"NSC Number","value":"707389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257773"},{"name":"PDQ_Open_Trial_Search_ID","value":"257773"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2608038"}]}}{"C155785":{"preferredName":"ERK 1/2 Inhibitor ASTX029","code":"C155785","definitions":[{"definition":"An orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, ASTX029 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK 1/2 Inhibitor ASTX029","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 029","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX-029","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX029","termGroup":"CN","termSource":"NCI"},{"termName":"ERK Inhibitor ASTX029","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor ASTX029","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase Inhibitor ASTX029","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095719-92-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14FDK6ISC9"},{"name":"Maps_To","value":"ERK 1/2 Inhibitor ASTX029"},{"name":"NCI_Drug_Dictionary_ID","value":"794989"},{"name":"NCI_META_CUI","value":"CL556263"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794989"},{"name":"PDQ_Open_Trial_Search_ID","value":"794989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119747":{"preferredName":"ERK Inhibitor CC-90003","code":"C119747","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, CC-90003 inhibits ERK activity, and prevents the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK Inhibitor CC-90003","termGroup":"PT","termSource":"NCI"},{"termName":"CC-90003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK Inhibitor CC-90003"},{"name":"NCI_Drug_Dictionary_ID","value":"767257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767257"},{"name":"PDQ_Open_Trial_Search_ID","value":"767257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896889"}]}}{"C170364":{"preferredName":"Ravoxertinib","code":"C170364","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, ravoxertinib inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ravoxertinib","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor GDC-0994","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0994","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453848-26-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6AXV96CRH"},{"name":"Maps_To","value":"ERK Inhibitor GDC-0994"},{"name":"NCI_Drug_Dictionary_ID","value":"750790"},{"name":"NCI_META_CUI","value":"CL1382601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750790"},{"name":"PDQ_Open_Trial_Search_ID","value":"750790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126687":{"preferredName":"Rineterkib","code":"C126687","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, rineterkib binds to and inhibits ERK, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in numerous tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rineterkib","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor LTT462","termGroup":"SY","termSource":"NCI"},{"termName":"LTT 462","termGroup":"CN","termSource":"NCI"},{"termName":"LTT462","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1715025-32-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15KFN616FK"},{"name":"Maps_To","value":"ERK Inhibitor LTT462"},{"name":"NCI_Drug_Dictionary_ID","value":"780511"},{"name":"NCI_META_CUI","value":"CL507900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780511"},{"name":"PDQ_Open_Trial_Search_ID","value":"780511"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104045":{"preferredName":"ERK Inhibitor MK-8353","code":"C104045","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, MK-8353 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways; thereby, preventing ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK Inhibitor MK-8353","termGroup":"PT","termSource":"NCI"},{"termName":"MK-8353","termGroup":"CN","termSource":"NCI"},{"termName":"MK-8353-001","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900353","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK Inhibitor MK-8353"},{"name":"NCI_Drug_Dictionary_ID","value":"701114"},{"name":"NCI_META_CUI","value":"CL433840"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701114"},{"name":"PDQ_Open_Trial_Search_ID","value":"701114"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150248":{"preferredName":"ERK1/2 Inhibitor ERAS-007","code":"C150248","definitions":[{"definition":"An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERAS-007 specifically binds to and inhibits the serine/threonine-protein kinase activities of both ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor ERAS-007","termGroup":"PT","termSource":"NCI"},{"termName":"ASN 007","termGroup":"CN","termSource":"NCI"},{"termName":"ASN-007","termGroup":"CN","termSource":"NCI"},{"termName":"ASN007","termGroup":"CN","termSource":"NCI"},{"termName":"ERAS 007","termGroup":"CN","termSource":"NCI"},{"termName":"ERAS-007","termGroup":"CN","termSource":"NCI"},{"termName":"ERAS007","termGroup":"CN","termSource":"NCI"},{"termName":"ERK Inhibitor ASN007","termGroup":"SY","termSource":"NCI"},{"termName":"ERK Inhibitor ERAS-007","termGroup":"SY","termSource":"NCI"},{"termName":"ERK1/2 Inhibitor ASN007","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor ASN007"},{"name":"NCI_Drug_Dictionary_ID","value":"805553"},{"name":"NCI_META_CUI","value":"CL552048"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141074":{"preferredName":"ERK1/2 Inhibitor KO-947","code":"C141074","definitions":[{"definition":"An inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon intravenous administration, KO-947 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor KO-947","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor KO-947","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor KO-947","termGroup":"SY","termSource":"NCI"},{"termName":"KO 947","termGroup":"CN","termSource":"NCI"},{"termName":"KO-947","termGroup":"CN","termSource":"NCI"},{"termName":"KO947","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor KO-947"},{"name":"NCI_Drug_Dictionary_ID","value":"791296"},{"name":"NCI_META_CUI","value":"CL539120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791296"},{"name":"PDQ_Open_Trial_Search_ID","value":"791296"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131335":{"preferredName":"Temuterkib","code":"C131335","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, temuterkib inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temuterkib","termGroup":"PT","termSource":"NCI"},{"termName":"ERK1/2 Inhibitor LY3214996","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3214996","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3214996","termGroup":"CN","termSource":"NCI"},{"termName":"LY3214996","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1951483-29-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V0Q46LFE6F"},{"name":"Maps_To","value":"ERK1/2 Inhibitor LY3214996"},{"name":"NCI_Drug_Dictionary_ID","value":"785705"},{"name":"NCI_META_CUI","value":"CL514490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785705"},{"name":"PDQ_Open_Trial_Search_ID","value":"785705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C65530":{"preferredName":"Erlotinib","code":"C65530","definitions":[{"definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erlotinib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183321-74-6"},{"name":"CHEBI_ID","value":"CHEBI:114785"},{"name":"Chemical_Formula","value":"C22H23N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"J4T82NDH7E"},{"name":"Legacy Concept Name","value":"Erlotinib_Base"},{"name":"Maps_To","value":"Erlotinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1135135"}]}}{"C2693":{"preferredName":"Erlotinib Hydrochloride","code":"C2693","definitions":[{"definition":"A drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib hydrochloride is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erlotinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"CP-358","termGroup":"CN","termSource":"NCI"},{"termName":"Cp-358,774","termGroup":"CN","termSource":"NCI"},{"termName":"Erlotinib Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"OSI-774","termGroup":"CN","termSource":"NCI"},{"termName":"Tarceva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant glioma; Locally advanced or metastic non-small cell lung carcinoma; Locally advanced, unresectable or metastatic pancreatic carcinoma"},{"name":"CAS_Registry","value":"183319-69-9"},{"name":"CHEBI_ID","value":"CHEBI:53509"},{"name":"Chemical_Formula","value":"C22H23N3O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DA87705X9K"},{"name":"Legacy Concept Name","value":"Erlotinib"},{"name":"Maps_To","value":"Erlotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38428"},{"name":"NSC Number","value":"718781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38428"},{"name":"PDQ_Open_Trial_Search_ID","value":"38428"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1533491"}]}}{"C2658":{"preferredName":"Ertumaxomab","code":"C2658","definitions":[{"definition":"A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth.  Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ertumaxomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3 x anti-HER-2-neu Bispecific Monoclonal Antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"509077-99-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L5L45YGP1O"},{"name":"Legacy Concept Name","value":"Anti-CD3_x_anti-HER-2-neu_Bispecific_Monoclonal_Antibody"},{"name":"Maps_To","value":"Ertumaxomab"},{"name":"NCI_Drug_Dictionary_ID","value":"38498"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38498"},{"name":"PDQ_Open_Trial_Search_ID","value":"38498"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723386"}]}}{"C99767":{"preferredName":"Eryaspase","code":"C99767","definitions":[{"definition":"A suspension of erythrocytes encapsulating L-asparaginase with potential antineoplastic activity. Upon administration of eryaspase, L-asparagine is hydrolyzed to L-aspartic acid and ammonia in plasma, thereby depleting tumor cells of asparagine. Due to low asparagine synthetase activity in tumor cells, de novo synthesis of asparagine is suppressed within tumor cells. Shortage of asparagine prevents synthesis of important proteins necessary for tumor cell growth. Encapsulation of asparaginase in erythrocytes decreases the immunogenicity of exogenous protein, enhances its circulation time and may limit toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eryaspase","termGroup":"PT","termSource":"NCI"},{"termName":"ERY001","termGroup":"CN","termSource":"NCI"},{"termName":"Erythrocyte-encapsulated L-asparaginase Suspension","termGroup":"SY","termSource":"NCI"},{"termName":"GRASPA","termGroup":"FB","termSource":"NCI"},{"termName":"L-asparaginase Encapsulated in RBCs","termGroup":"SY","termSource":"NCI"},{"termName":"L-asparaginase Encapsulated in Red Blood Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Erythrocyte-encapsulated L-asparaginase Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"724517"},{"name":"NCI_META_CUI","value":"CL433492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724517"},{"name":"PDQ_Open_Trial_Search_ID","value":"724517"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C972":{"preferredName":"Esorubicin","code":"C972","definitions":[{"definition":"A synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxyadriamycin","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Deoxydoxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"Deoxyadriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxydoxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Esorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"IMI-58","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63521-85-7"},{"name":"Chemical_Formula","value":"C27H29NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RMC41L2WQ3"},{"name":"Legacy Concept Name","value":"Deoxydoxorubicin"},{"name":"Maps_To","value":"Esorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39211"},{"name":"NSC Number","value":"267469"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39211"},{"name":"PDQ_Open_Trial_Search_ID","value":"39211"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0047760"}]}}{"C74943":{"preferredName":"Esorubicin Hydrochloride","code":"C74943","definitions":[{"definition":"A hydrochloride salt of esorubicin, a derivative of the anthracycline antineoplastic antibiotic doxorubicin, with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(2S-(2alpha(8R*,10R*),4beta,6beta))-10-((4-Aminotetrahydro-6-methyl-2H-pyran-2-yl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Deoxyadriamycin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"4'-Deoxydoxorubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxydoxorubicin HCI","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63950-06-1"},{"name":"Chemical_Formula","value":"C27H29NO10.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2UB1JJT82D"},{"name":"Legacy Concept Name","value":"Esorubicin_Hydrochloride"},{"name":"Maps_To","value":"Esorubicin Hydrochloride"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700018"}]}}{"C1301":{"preferredName":"Esperamicin A1","code":"C1301","definitions":[{"definition":"An enediyne antineoplastic antibiotic hybrid containing an anthranilate moiety.  Esperamicin A1 is isolated from the bacterium Actinomadura verrucosospora.  The anthranilate component of esperamicin A1 intercalates DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-stranded breaks in DNA and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esperamicin A1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99674-26-7"},{"name":"CHEBI_ID","value":"CHEBI:53273"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PLX8T21X8G"},{"name":"Legacy Concept Name","value":"Esperamicin_A1"},{"name":"Maps_To","value":"Esperamicin A1"},{"name":"NSC Number","value":"372668"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0082481"}]}}{"C26649":{"preferredName":"Essiac","code":"C26649","definitions":[{"definition":"An herbal formula containing burdock root (Arctium lappa), Turkey rhubarb root (Rheum palmatum), sheep sorrel (Rumex acetosella), and slippery elm bark (Ulmus fulva) with potential immunostimulating, anti-inflammatory and anti-tumor activities. The extract's chemical profile, their respective concentrations and the mechanism of action of Essiac are largely unknown due to the proprietary nature of the formula and product inconsistency. Several chemical classes in Essiac are consistently represented and may attribute to its therapeutic effect, including anthraquinone derivatives such as rhein and emodin, high molecular polysaccharides, and lignans such as arctigenin. However, all these chemicals are unlikely to occur in high concentrations in Essiac, and its potential therapeutic effect may be attributed to a potential synergistic effect of these various compounds.","type":"DEFINITION","source":"NCI"},{"definition":"An herbal tea mixture that contains burdock root, Indian rhubarb root, sheep sorrel, and slippery elm bark. It has been claimed to remove toxins from the body, make the immune system stronger, relieve pain, control diabetes, treat AIDS, reduce tumor size, increase cancer survival, and improve quality of life. No clinical trial using Essiac in humans has been reported in a peer-reviewed, scientific journal, and the FDA has not approved the use of Essiac for the treatment of any medical conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Essiac","termGroup":"PT","termSource":"NCI"},{"termName":"Esiak","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Essiac"},{"name":"Maps_To","value":"Essiac"},{"name":"NCI_Drug_Dictionary_ID","value":"304440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304440"},{"name":"PDQ_Open_Trial_Search_ID","value":"304440"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0673827"}]}}{"C154677":{"preferredName":"Esterified Estrogens","code":"C154677","definitions":[{"definition":"A mixture of the sodium salts of the sulfate esters of estrogen including sodium estrone sulfate, sodium equilin sulfate and the concomitant component, 17 alpha-estradiol, that is used for estrogen replacement. Estrogens bind to nuclear receptors in estrogen-responsive tissues and modulate the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), stimulate skeletal growth, and have a widespread effect on metabolic processes including protein transport and electrolyte balance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esterified Estrogens","termGroup":"PT","termSource":"NCI"},{"termName":"Estrogens, Esterified","termGroup":"SY","termSource":"NCI"},{"termName":"Menest (BR)","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3ASP8Q3768"},{"name":"Maps_To","value":"Esterified Estrogens"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0717752"}]}}{"C1090":{"preferredName":"Estradiol Valerate","code":"C1090","definitions":[{"definition":"The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estradiol Valerate","termGroup":"PT","termSource":"NCI"},{"termName":"Delestrogen","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"979-32-8"},{"name":"Chemical_Formula","value":"C23H32O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OKG364O896"},{"name":"Legacy Concept Name","value":"Estradiol_Valerate"},{"name":"Maps_To","value":"Estradiol Valerate"},{"name":"NCI_Drug_Dictionary_ID","value":"39270"},{"name":"NSC Number","value":"17590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39270"},{"name":"PDQ_Open_Trial_Search_ID","value":"39270"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059623"}]}}{"C479":{"preferredName":"Estramustine","code":"C479","definitions":[{"definition":"A combination of the hormone estradiol (an estrogen) and nitrogen mustard (an anticancer drug). Used in the palliative therapy of prostate cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estramustine","termGroup":"PT","termSource":"NCI"},{"termName":"17beta-(estra-1,3,5(10)-triene-3,17-diol 3-(bis(2-chloroethyl)carbamate))","termGroup":"SN","termSource":"NCI"},{"termName":"estra-1,3,5(10)triene-317beta-diol 3-[N,N-bis-(2-chloroethyl)carbamate]","termGroup":"SN","termSource":"NCI"},{"termName":"estradiol 3-bis(2-chloroethyl)carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Leo 275","termGroup":"CN","termSource":"NCI"},{"termName":"RO 21-8837","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prostate Neoplasm"},{"name":"CAS_Registry","value":"2998-57-4"},{"name":"CHEBI_ID","value":"CHEBI:4868"},{"name":"Chemical_Formula","value":"C23H31Cl2NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"35LT29625A"},{"name":"Legacy Concept Name","value":"Estramustine"},{"name":"Maps_To","value":"Estramustine"},{"name":"NSC Number","value":"89201"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014921"}]}}{"C480":{"preferredName":"Estramustine Phosphate Sodium","code":"C480","definitions":[{"definition":"The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estramustine Phosphate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Emcyt","termGroup":"BR","termSource":"NCI"},{"termName":"Estracyt","termGroup":"FB","termSource":"NCI"},{"termName":"Estramustine 17-(Dihydrogenphosphate) Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Estramustine Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Estramustine Sodium Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Leo-299","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-21-8837/001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52205-73-9"},{"name":"CHEBI_ID","value":"CHEBI:31562"},{"name":"Chemical_Formula","value":"C23H30Cl2NO6P.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"75F375MT2N"},{"name":"Legacy Concept Name","value":"Estramustine_Phosphate_Sodium"},{"name":"Maps_To","value":"Estramustine Phosphate Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39235"},{"name":"NSC Number","value":"89199"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39235"},{"name":"PDQ_Open_Trial_Search_ID","value":"39235"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014922"}]}}{"C96432":{"preferredName":"Estrogen Receptor Agonist GTx-758","code":"C96432","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor (ER) alpha agonist with potential antineoplastic activity. Upon administration of GTx-758, this agent suppresses the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the pituitary gland through feedback inhibition. In males, the inhibition of LH secretion prevents the synthesis of androgens, including testosterone, by the testes. This may result in suppressed total serum testosterone to the levels observed in castration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogen Receptor Agonist GTx-758","termGroup":"PT","termSource":"NCI"},{"termName":"Capesaris","termGroup":"BR","termSource":"NCI"},{"termName":"GTx-758","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"938067-78-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"406GR1485Z"},{"name":"Maps_To","value":"Estrogen Receptor Agonist GTx-758"},{"name":"NCI_Drug_Dictionary_ID","value":"698431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698431"},{"name":"PDQ_Open_Trial_Search_ID","value":"698431"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272775"}]}}{"C482":{"preferredName":"Estrogens, Conjugated","code":"C482","definitions":[{"definition":"Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogens, Conjugated","termGroup":"PT","termSource":"NCI"},{"termName":"ATC:G03CA57","termGroup":"CN","termSource":"NCI"},{"termName":"Conestron","termGroup":"FB","termSource":"NCI"},{"termName":"Conjugated Estrogens","termGroup":"SY","termSource":"NCI"},{"termName":"Femest","termGroup":"BR","termSource":"NCI"},{"termName":"Premarin","termGroup":"BR","termSource":"NCI"},{"termName":"Sodestrin","termGroup":"FB","termSource":"NCI"},{"termName":"Tag-39","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced androgen-dependent prostate cancer, palliative; Breast cancer, palliative; Estrogen replacement; Menopausal symptoms; Postmenopausal osteoporosis"},{"name":"CAS_Registry","value":"12126-59-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IU5QR144QX"},{"name":"Legacy Concept Name","value":"Conjugated_Estrogens"},{"name":"Maps_To","value":"Estrogens, Conjugated"},{"name":"NCI_Drug_Dictionary_ID","value":"39237"},{"name":"NSC Number","value":"18313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39237"},{"name":"PDQ_Open_Trial_Search_ID","value":"39237"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014938"}]}}{"C1626":{"preferredName":"Etalocib","code":"C1626","definitions":[{"definition":"A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called leukotriene B4 receptor antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Etalocib","termGroup":"PT","termSource":"NCI"},{"termName":"2-[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"2-[3-[3-[(5-Ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LY293111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"161172-51-6"},{"name":"Chemical_Formula","value":"C33H33FO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"THY6RIW44R"},{"name":"Legacy Concept Name","value":"LY293111"},{"name":"Maps_To","value":"Etalocib"},{"name":"NCI_Drug_Dictionary_ID","value":"38111"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38111"},{"name":"PDQ_Open_Trial_Search_ID","value":"38111"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0298619"}]}}{"C2381":{"preferredName":"Etanercept","code":"C2381","definitions":[{"definition":"A drug that is commonly used to treat arthritis. It is also being studied in the treatment of cancer, and as a treatment for loss of appetite and weight loss in cancer patients. It belongs to the family of drugs called tumor necrosis factor (TNF) antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etanercept","termGroup":"PT","termSource":"NCI"},{"termName":"Enbrel","termGroup":"BR","termSource":"NCI"},{"termName":"TNFR:Fc","termGroup":"AB","termSource":"NCI"},{"termName":"Tumor Necrosis Factor Receptor IgG Chimera","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"juvenile arthritis; psoriatic arthritis; rheumatoid arthritis."},{"name":"CAS_Registry","value":"185243-69-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OP401G7OJC"},{"name":"Legacy Concept Name","value":"Etanercept"},{"name":"Maps_To","value":"Etanercept"},{"name":"NCI_Drug_Dictionary_ID","value":"257809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257809"},{"name":"PDQ_Open_Trial_Search_ID","value":"257809"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0717758"}]}}{"C1092":{"preferredName":"Etanidazole","code":"C1092","definitions":[{"definition":"A 2-nitroimidazole with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the cytotoxicity of ionizing radiation. This agent may also be useful as an imaging agent for identifying hypoxic, drug-resistant regions of primary tumors or metastases.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that increases the effectiveness of radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Etanidazole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Imidazole-1-acetamide, N-(2-hydroxyethyl)-2-nitro-","termGroup":"SN","termSource":"NCI"},{"termName":"2-Nitroimidazole-1-acetamide, N-(2-hydroxyethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"SR-2508","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"22668-01-5"},{"name":"Chemical_Formula","value":"C7H10N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"30DKA3Q1HL"},{"name":"Legacy Concept Name","value":"Etanidazole"},{"name":"Maps_To","value":"Etanidazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39446"},{"name":"NSC Number","value":"301467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39446"},{"name":"PDQ_Open_Trial_Search_ID","value":"39446"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059682"}]}}{"C1800":{"preferredName":"Etaracizumab","code":"C1800","definitions":[{"definition":"A humanized monoclonal IgG1 antibody directed against the vitronectin receptor alpha v beta 3 integrin. Etaracizumab blocks the binding of ligands, such as vitronectin, to alpha v beta 3 integrin, resulting in inhibition of angiogenesis and metastasis. Alpha v beta 3 integrin is a cell adhesion and signaling receptor that is expressed on the surface of tumor vessel endothelial cells, some tumor cells, and a number of other cell types.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer and other conditions. Abegrin binds to a protein on the surface of blood vessels and may prevent the growth of new blood vessels that tumors need to grow. It may also prevent the spread of cancer. It is a type of antiangiogenesis agent, a type of metastasis inhibitor, and a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Etaracizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Abegrin","termGroup":"BR","termSource":"NCI"},{"termName":"Humanized Monoclonal Antibody LM609","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-522","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-alpha V Beta 3 Integrin MEDI-522","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-Avb3 Integrin Medi-522","termGroup":"SY","termSource":"NCI"},{"termName":"Vitaxin","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"892553-42-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"41W9MFI160"},{"name":"Legacy Concept Name","value":"Vitaxin"},{"name":"Maps_To","value":"Etaracizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38491"},{"name":"NSC Number","value":"719850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38491"},{"name":"PDQ_Open_Trial_Search_ID","value":"38491"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350723"}]}}{"C96705":{"preferredName":"Etarotene","code":"C96705","definitions":[{"definition":"An ethylsulfonyl derivative of arotinoic acid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, etarotene binds to and activates retinoic acid receptors (RARs), thereby inducing changes in the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etarotene","termGroup":"PT","termSource":"NCI"},{"termName":"6-((E)-p-(Ethylsulfonyl)-alpha-methylstyryl)-1,2,3,4-tetrahydronaphthalene","termGroup":"SN","termSource":"NCI"},{"termName":"Arotinoid Ethyl Sulfone","termGroup":"SY","termSource":"NCI"},{"termName":"Arotinoid Ethyl Sulphone","termGroup":"SY","termSource":"NCI"},{"termName":"Naphthalene, 6-(2-(4-(ethylsulfonyl)phenyl)-1-methylethenyl)-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ro 15-1570/000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87719-32-2"},{"name":"Chemical_Formula","value":"C25H32O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PD3817FE9N"},{"name":"Maps_To","value":"Etarotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272976"}]}}{"C116713":{"preferredName":"Ethaselen","code":"C116713","definitions":[{"definition":"An orally bioavailable organoselenium inhibitor of thioredoxin reductase 1 (TrxR1), with potential antineoplastic activity. Upon oral administration, ethaselen specifically binds to the selenocysteine-cysteine redox pair in the C-terminal active site of TrxR1 and inhibits its activity, which may result in growth inhibition and the induction of apoptosis in TrxR1 overexpressing tumor cells. TrxR1, upregulated in many cancer cell types, plays a key role in various redox-dependent cellular pathways, regulates transcription factor activity, inhibits apoptosis, and promotes cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethaselen","termGroup":"PT","termSource":"NCI"},{"termName":"1, 2-[Bis (1, 2-Benzisoselenazolone-3 (2H) -Ketone)] Ethane","termGroup":"SN","termSource":"NCI"},{"termName":"BBSKE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"217798-39-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4Q2EZS1IWG"},{"name":"Maps_To","value":"Ethaselen"},{"name":"NCI_Drug_Dictionary_ID","value":"762438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762438"},{"name":"PDQ_Open_Trial_Search_ID","value":"762438"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1312515"}]}}{"C486":{"preferredName":"Ethinyl Estradiol","code":"C486","definitions":[{"definition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethinyl Estradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol","termGroup":"SN","termSource":"NCI"},{"termName":"Diogyn E","termGroup":"FB","termSource":"NCI"},{"termName":"Estinyl","termGroup":"BR","termSource":"NCI"},{"termName":"Ethinoral","termGroup":"BR","termSource":"NCI"},{"termName":"Ethinylestradiol","termGroup":"SY","termSource":"NCI"},{"termName":"Eticylol","termGroup":"FB","termSource":"NCI"},{"termName":"Feminone","termGroup":"BR","termSource":"NCI"},{"termName":"Inestra","termGroup":"FB","termSource":"NCI"},{"termName":"Lynoral","termGroup":"FB","termSource":"NCI"},{"termName":"Orestralyn","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced androgen-dependent prostate cancer, palliative; Breast cancer, palliative; Estrogen replacement; Menopausal symptoms; Postmenopausal osteoporosis"},{"name":"CAS_Registry","value":"57-63-6"},{"name":"CHEBI_ID","value":"CHEBI:4903"},{"name":"Chemical_Formula","value":"C20H24O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"423D2T571U"},{"name":"Legacy Concept Name","value":"Ethinyl_Estradiol"},{"name":"Maps_To","value":"Ethinyl Estradiol"},{"name":"NCI_Drug_Dictionary_ID","value":"39238"},{"name":"NSC Number","value":"10973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39238"},{"name":"PDQ_Open_Trial_Search_ID","value":"39238"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015011"}]}}{"C1009":{"preferredName":"Ethyleneimine","code":"C1009","definitions":[{"definition":"A monofunctional alkylating agent with potential antineoplastic activity.  Reacting with DNA mainly at guanine and adenine residues, ethylenimine alkylates DNA, thereby producing DNA interstrand crosslinks and DNA breaks, and interfering with DNA replication and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethyleneimine","termGroup":"PT","termSource":"NCI"},{"termName":"Aminoethylene","termGroup":"SY","termSource":"NCI"},{"termName":"Azacyclopropane","termGroup":"SY","termSource":"NCI"},{"termName":"Azirane","termGroup":"SY","termSource":"NCI"},{"termName":"Aziridine","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyleneimine","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylenimine","termGroup":"SY","termSource":"NCI"},{"termName":"Ethylenimine","termGroup":"SY","termSource":"NCI"},{"termName":"Ethylimine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151-56-4"},{"name":"CHEBI_ID","value":"CHEBI:30969"},{"name":"Chemical_Formula","value":"C2H5N"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54P5FEX9FH"},{"name":"Legacy Concept Name","value":"Ethylenimine"},{"name":"Maps_To","value":"Ethyleneimine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052794"}]}}{"C26563":{"preferredName":"Ethylnitrosourea","code":"C26563","definitions":[{"definition":"A nitrosourea with potential antineoplastic activity.  Used experimentally as a mutagen and carcinogen, ethylnitrosourea alkylates DNA and proteins, thereby damaging DNA and inducing point mutations. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethylnitrosourea","termGroup":"PT","termSource":"NCI"},{"termName":"1-Ethyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"ENU","termGroup":"AB","termSource":"NCI"},{"termName":"N-Ethyl-N-nitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"N-Nitroso-N-Ethylurea","termGroup":"SY","termSource":"NCI"},{"termName":"Nitrosoethylurea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"759-73-9"},{"name":"CHEBI_ID","value":"CHEBI:23995"},{"name":"Chemical_Formula","value":"C3H7N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P8M1T4190R"},{"name":"Legacy Concept Name","value":"Ethylnitrosourea"},{"name":"Maps_To","value":"Ethylnitrosourea"},{"name":"NSC Number","value":"45403"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0015111"}]}}{"C125901":{"preferredName":"Etidronate-Cytarabine Conjugate MBC-11","code":"C125901","definitions":[{"definition":"A synthetic conjugate composed of the bisphosphonate etidronate linked to the cytostatic agent and antimetabolite cytarabine, with potential antineoplastic and antiresorptive activities. Upon intravenous administration of the etidronate-cytarabine conjugate MBC-11, the etidronate moiety targets bone and the two moieties are released upon hydrolysis. Etidronate binds to hydroxyapatite crystals in bone tissues and prevents its resorption. This prevents bone destruction and induces bone cell mineralization. In addition, the bone-targeting nature of this agent allows for the accumulation of cytarabine in bone tissue, where it is able to exert its antitumor effect locally by competing with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis, while reducing systemic exposure. This leads to a destruction of bone-associated tumor cells, an inhibition of tumor cell proliferation and bone metastasis, and prevents tumor-mediated bone destruction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etidronate-Cytarabine Conjugate MBC-11","termGroup":"PT","termSource":"NCI"},{"termName":"Etidronate-ara-C Conjugate MBC-11","termGroup":"SY","termSource":"NCI"},{"termName":"MBC-11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"332863-86-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4M53T688S5"},{"name":"Maps_To","value":"Etidronate-Cytarabine Conjugate MBC-11"},{"name":"NCI_Drug_Dictionary_ID","value":"778808"},{"name":"NCI_META_CUI","value":"CL504550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778808"},{"name":"PDQ_Open_Trial_Search_ID","value":"778808"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74069":{"preferredName":"Etirinotecan Pegol","code":"C74069","definitions":[{"definition":"An extended-release (ER) formulation composed of irinotecan, which is a semisynthetic derivative of camptothecin and a topoisomerase I-inhibitor prodrug, that is conjugated, via a proprietary biodegradable ester-based linker, to polyethylene glycol (PEG), with antineoplastic activity. Upon administration of etirinotecan pegol (EP), the agent penetrates into the leaky tumor vasculature and accumulates in the tumor. The linker slowly hydrolyzes and releases irinotecan, which leads to sustained exposure of the tumor to irinotecan. In turn, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN38) by a carboxylesterase. SN38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA; this results in DNA breaks that inhibit DNA replication and trigger apoptosis. Pegylation provides improved systemic exposure, increases drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etirinotecan Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"NKTR 102","termGroup":"CN","termSource":"NCI"},{"termName":"NKTR-102","termGroup":"CN","termSource":"NCI"},{"termName":"Onzeald","termGroup":"BR","termSource":"NCI"},{"termName":"PEG-Irinotecan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848779-32-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LJ16641SFT"},{"name":"Legacy Concept Name","value":"Pegylated_Irinotecan_NKTR_102"},{"name":"Maps_To","value":"Etirinotecan Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"586949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586949"},{"name":"PDQ_Open_Trial_Search_ID","value":"586949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659087"}]}}{"C489":{"preferredName":"Etoglucid","code":"C489","definitions":[{"definition":"An epoxide compound with potential antineoplastic alkylating activity. Etoglucid is able to crosslink DNA via its epoxide group, resulting in disruption of DNA function and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoglucid","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-bis[2-(2,3-epoxypropoxy)ethoxy]ethane","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:15,16-diepoxy-4,7,10,13-tetraoxahexadecane","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bisoxirane","termGroup":"SN","termSource":"NCI"},{"termName":"Epodyl","termGroup":"BR","termSource":"NCI"},{"termName":"Ethoglucid","termGroup":"SY","termSource":"NCI"},{"termName":"ICI-32865","termGroup":"CN","termSource":"NCI"},{"termName":"Triethylene Glycol Diglycidyl Ether","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1954-28-5"},{"name":"Chemical_Formula","value":"C12H22O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4F9KUA0T4D"},{"name":"Legacy Concept Name","value":"Etoglucid"},{"name":"Maps_To","value":"Etoglucid"},{"name":"NCI_Drug_Dictionary_ID","value":"39233"},{"name":"NSC Number","value":"80439"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39233"},{"name":"PDQ_Open_Trial_Search_ID","value":"39233"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015039"}]}}{"C491":{"preferredName":"Etoposide","code":"C491","definitions":[{"definition":"A drug used to treat testicular and small cell lung cancers. It is also being studied in the treatment of several other types of cancer. Vepesid blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of podophyllotoxin derivative and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoposide","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]","termGroup":"SN","termSource":"NCI"},{"termName":"9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one","termGroup":"SN","termSource":"NCI"},{"termName":"Demethyl Epipodophyllotoxin Ethylidine Glucoside","termGroup":"SY","termSource":"NCI"},{"termName":"EPEG","termGroup":"AB","termSource":"NCI"},{"termName":"Lastet","termGroup":"BR","termSource":"NCI"},{"termName":"Vepesid","termGroup":"AQS","termSource":"NCI"},{"termName":"VP 16","termGroup":"CN","termSource":"NCI"},{"termName":"VP 16213","termGroup":"CN","termSource":"NCI"},{"termName":"VP-16","termGroup":"CN","termSource":"NCI"},{"termName":"VP-16-213","termGroup":"CN","termSource":"NCI"},{"termName":"VP16","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute leukemia; Adrenal cortical cancer; Brain cancer; Chronic Lymphocytic leukemia; Choriocarcinoma; Esophageal cancer; Ewing's sarcoma; Gastric cancer; Germ Cell cancer; Gestational trophoblastic neoplasms; Hepatocellular cancer; Hodgkin's disease"},{"name":"Accepted_Therapeutic_Use_For","value":"Hypereosinophilic syndrome; Kaposi's sarcoma; Langerhans cell histiocytosis; Mobilization of peripheral-blood progenitor cells; Multiple myeloma; Neuroblastoma; Non-small lung cancer; Osteogenic sarcoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Ovarian cancer; Retinoblastoma; Small cell lung cancer; Soft tissue sarcomas; Testicular cancer; Thymoma; Thyroid cancer; Uterine cancer; Wilms' tumor"},{"name":"CAS_Registry","value":"33419-42-0"},{"name":"CHEBI_ID","value":"CHEBI:4911"},{"name":"Chemical_Formula","value":"C29H32O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"6PLQ3CP4P3"},{"name":"Legacy Concept Name","value":"Etoposide"},{"name":"Maps_To","value":"Etoposide"},{"name":"NCI_Drug_Dictionary_ID","value":"39207"},{"name":"NSC Number","value":"141540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39207"},{"name":"PDQ_Open_Trial_Search_ID","value":"39207"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015133"}]}}{"C1093":{"preferredName":"Etoposide Phosphate","code":"C1093","definitions":[{"definition":"A drug used to treat testicular and small cell lung cancers. It is also being studied in the treatment of several other types of cancer. Etopophos blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of podophyllotoxin derivative and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoposide Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Etopophos","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute leukemia; Adrenal cortical cancer; Brain cancer; Chronic lymphocytic leukemia; Choriocarcinoma; Esophageal cancer; Ewings sarcoma; Gastric cancer; Germ cell cancer; Gestational trophoblastic neoplasms"},{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular cancer; Hodgkins disease; Hypereosinophilic syndrome; Kaposis sarcoma; Testicular cancer; Thymoma; Thyroid cancer; Uterine cancer; Wilms tumor"},{"name":"Accepted_Therapeutic_Use_For","value":"Langerhans cell histiocytosis; Mobilization of peripheral-blood progenitor cells; Multiple myeloma; Neuroblastoma; Non-small lung cancer; Osteogenic sarcoma; Ovarian cancer; Retinoblastoma; Small cell lung cancer; Soft tissue sarcomas"},{"name":"CAS_Registry","value":"117091-64-2"},{"name":"Chemical_Formula","value":"C29H33O16P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"528XYJ8L1N"},{"name":"Legacy Concept Name","value":"Etoposide_Phosphate"},{"name":"Maps_To","value":"Etoposide Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"42801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42801"},{"name":"PDQ_Open_Trial_Search_ID","value":"42801"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059874"}]}}{"C114977":{"preferredName":"Etoposide Toniribate","code":"C114977","definitions":[{"definition":"A prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of etoposide toniribate, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoposide Toniribate","termGroup":"PT","termSource":"NCI"},{"termName":"CAP7.1","termGroup":"CN","termSource":"NCI"},{"termName":"EDO-S7.1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"433304-61-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A59HL2Q48U"},{"name":"Maps_To","value":"Etoposide Toniribate"},{"name":"NCI_Drug_Dictionary_ID","value":"759515"},{"name":"NCI_META_CUI","value":"CL472574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759515"},{"name":"PDQ_Open_Trial_Search_ID","value":"759515"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73236":{"preferredName":"Etoprine","code":"C73236","definitions":[{"definition":"A lipophilic, diaminopyrimidine folate antagonist with potential antineoplastic activity. Etoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism. This may eventually result in a reduction of cellular growth and the induction of apoptosis. In addition, this agent inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble etoprine is capable of crossing the blood-brain barrier.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoprine","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-5-(3,4-dichlorophenyl)-6-ethylpyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"AI3-25008","termGroup":"CN","termSource":"NCI"},{"termName":"DDEP","termGroup":"AB","termSource":"NCI"},{"termName":"Ethodichlorophen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18588-57-3"},{"name":"Chemical_Formula","value":"C12H12Cl2N4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"406PGU9KGI"},{"name":"Legacy Concept Name","value":"Etoprine"},{"name":"Maps_To","value":"Etoprine"},{"name":"NSC Number","value":"3062"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059875"}]}}{"C52188":{"preferredName":"Etoricoxib","code":"C52188","definitions":[{"definition":"A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoricoxib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine","termGroup":"SN","termSource":"NCI"},{"termName":"Arcoxia","termGroup":"BR","termSource":"NCI"},{"termName":"L-791456","termGroup":"CN","termSource":"NCI"},{"termName":"MK-0663","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"202409-33-4"},{"name":"CHEBI_ID","value":"CHEBI:6339"},{"name":"Chemical_Formula","value":"C18H15ClN2O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WRX4NFY03R"},{"name":"Legacy Concept Name","value":"Etoricoxib"},{"name":"Maps_To","value":"Etoricoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"462092"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462092"},{"name":"PDQ_Open_Trial_Search_ID","value":"462092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0972314"}]}}{"C125657":{"preferredName":"Ets-family Transcription Factor Inhibitor TK216","code":"C125657","definitions":[{"definition":"A proprietary biologic that inhibits the transcriptional-promoting activity of E26 transformation-specific (Ets, E-twenty-six) family transcription factors, with potential antineoplastic activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration, Ets-family transcription factor inhibitor TK216 inhibits transcriptional activation mediated by Ets family proteins, including the oncogenic Ewing sarcoma breakpoint region 1/Friend leukemia virus integration 1 (EWSR1/FLI1; EWS/FLI1) fusion protein. This agent may both inhibit the malignant downstream effects mediated by genomic rearrangements that result in the overexpression of Ets family transcription factors and decrease tumor cell growth and proliferation. A chromosomal translocation t(11;22)(q24;q12) fuses the EWSR1 gene and the FLI1 gene and encodes the EWSR1/FLI1 fusion protein, which is an oncoprotein expressed by peripheral primitive neuroectodermal (pPNET) tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ets-family Transcription Factor Inhibitor TK216","termGroup":"PT","termSource":"NCI"},{"termName":"TK-216","termGroup":"CN","termSource":"NCI"},{"termName":"TK216","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ets-family Transcription Factor Inhibitor TK216"},{"name":"NCI_Drug_Dictionary_ID","value":"778521"},{"name":"NCI_META_CUI","value":"CL504343"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778521"},{"name":"PDQ_Open_Trial_Search_ID","value":"778521"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48387":{"preferredName":"Everolimus","code":"C48387","definitions":[{"definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat advanced kidney cancer that did not respond to treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Afinitor stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. It also decreases the body's immune responses. It is a type of immunosuppressant and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Everolimus","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone","termGroup":"SN","termSource":"NCI"},{"termName":"42-O-(2-Hydroxy)ethyl Rapamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Afinitor","termGroup":"BR","termSource":"NCI"},{"termName":"Certican","termGroup":"BR","termSource":"NCI"},{"termName":"RAD 001","termGroup":"CN","termSource":"NCI"},{"termName":"RAD-001","termGroup":"CN","termSource":"NCI"},{"termName":"RAD001","termGroup":"CN","termSource":"NCI"},{"termName":"Votubia","termGroup":"BR","termSource":"NCI"},{"termName":"Zortress","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"neuroendocrine tumors (NET) of gastrointestinal (GI), lung or pancreatic origin"},{"name":"CAS_Registry","value":"159351-69-6"},{"name":"Chemical_Formula","value":"C53H83NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9HW64Q8G6G"},{"name":"Legacy Concept Name","value":"Everolimus"},{"name":"Maps_To","value":"Everolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"372905"},{"name":"NSC Number","value":"733504"},{"name":"PDQ_Closed_Trial_Search_ID","value":"372905"},{"name":"PDQ_Open_Trial_Search_ID","value":"372905"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0541315"}]}}{"C102880":{"preferredName":"Everolimus Tablets for Oral Suspension","code":"C102880","definitions":[{"definition":"Tablets for oral suspension containing everolimus, a derivative of the natural macrocyclic lactone sirolimus, with immunosuppressive and antineoplastic activities. After suspension of the everolimus tablets in water and oral administration, this agent inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR) by binding to mTOR's cytosolic receptor immunophilin FK Binding Protein-12 (FKBP-12). Inhibition of the mTOR complex may result in the inhibition of the phosphatidylinositol 3 kinase/Akt/mTOR pathway and an inhibition in the expression of vascular endothelial cell growth factor (VEGF) and hypoxia-inducible factor. Ultimately, this may result in decreased tumor cell proliferation and tumor angiogenesis. This pediatric formulation can dissolve easily in a small volume of water making it easier to swallow and is available in smaller dose increments thereby allowing for greater dosing flexibility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Everolimus Tablets for Oral Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"Afinitor Disperz","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"tuberous sclerosis complex (TSC)-associated partial-onset seizures; TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Everolimus Tablets for Oral Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"739586"},{"name":"NCI_META_CUI","value":"CL437183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739586"},{"name":"PDQ_Open_Trial_Search_ID","value":"739586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71722":{"preferredName":"Evofosfamide","code":"C71722","definitions":[{"definition":"A hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division, and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evofosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"HAP TH-302","termGroup":"AB","termSource":"NCI"},{"termName":"Hypoxia-Activated Prodrug TH-302","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphorodiamidic Acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"TH-302","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"918633-87-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8A9RZ3HN8W"},{"name":"Legacy Concept Name","value":"HAP_TH-302"},{"name":"Maps_To","value":"Evofosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"560194"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560194"},{"name":"PDQ_Open_Trial_Search_ID","value":"560194"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348906"}]}}{"C131305":{"preferredName":"Ex Vivo-expanded Autologous T Cells IMA101","code":"C131305","definitions":[{"definition":"A preparation of autologous cytotoxic T-lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T-cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T-cells IMA101 target and kill tumor cells. The T-cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ex Vivo-expanded Autologous T Cells IMA101","termGroup":"PT","termSource":"NCI"},{"termName":"ACTolog IMA101","termGroup":"SY","termSource":"NCI"},{"termName":"IMA101","termGroup":"CN","termSource":"NCI"},{"termName":"IMA101 T-cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"IMA101 T-Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ex Vivo-expanded Autologous T Cells IMA101"},{"name":"NCI_Drug_Dictionary_ID","value":"785549"},{"name":"NCI_META_CUI","value":"CL514353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785549"},{"name":"PDQ_Open_Trial_Search_ID","value":"785549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1679":{"preferredName":"Exatecan Mesylate","code":"C1679","definitions":[{"definition":"A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogues. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Exatecan Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"10H,13H-Benzo(de)pyrano(3'm4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S-trans)-, Methanesulfonate (1:1) (Salt), Dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"DX-8951f","termGroup":"CN","termSource":"NCI"},{"termName":"Exatecan Mesylate Dihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Exatecan Mesylate Hydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197720-53-9"},{"name":"Chemical_Formula","value":"C24H22FN3O4.CH4O3S.2H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D2VJ1CC26Q"},{"name":"Legacy Concept Name","value":"Exatecan_Mesylate"},{"name":"Maps_To","value":"Exatecan Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"43386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43386"},{"name":"PDQ_Open_Trial_Search_ID","value":"43386"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935945"}]}}{"C162348":{"preferredName":"Exatecan Mesylate Anhydrous","code":"C162348","definitions":[{"definition":"The anhydrous, mesylate salt form of exatecan, a semisynthetic, water-soluble derivative of camptothecin, with antineoplastic activity. Upon administration, exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting re-ligation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exatecan Mesylate Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"10H,13H-Benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-Amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, Methanesulfonate (1:1)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"169869-90-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y76278R9RJ"},{"name":"Maps_To","value":"Exatecan Mesylate Anhydrous"},{"name":"NCI_META_CUI","value":"CL970851"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1097":{"preferredName":"Exemestane","code":"C1097","definitions":[{"definition":"A drug used to treat advanced breast cancer and to prevent recurrent breast cancer in postmenopausal women who have already been treated with tamoxifen. It is also being studied in the treatment of other types of cancer. Aromasin causes a decrease in the amount of estrogen made by the body. It is a type of aromatase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exemestane","termGroup":"PT","termSource":"NCI"},{"termName":"6-Methyleneandrosta-1,4-diene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Aromasin","termGroup":"BR","termSource":"NCI"},{"termName":"FCE-24304","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Estrogen Receptor-Positive Early Breast Cancer; early and advanced-stage breast cancer"},{"name":"CAS_Registry","value":"107868-30-4"},{"name":"CHEBI_ID","value":"CHEBI:4953"},{"name":"Chemical_Formula","value":"C20H24O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NY22HMQ4BX"},{"name":"Legacy Concept Name","value":"Exemestane"},{"name":"Maps_To","value":"Exemestane"},{"name":"NCI_Drug_Dictionary_ID","value":"42297"},{"name":"NSC Number","value":"713563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42297"},{"name":"PDQ_Open_Trial_Search_ID","value":"42297"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0851344"}]}}{"C1239":{"preferredName":"Exisulind","code":"C1239","definitions":[{"definition":"A drug being studied in the treatment and prevention of cancer. It has been shown to cause apoptosis (cell death) in cells that are malignant (cancer) and in cells that may become cancer. It acts through a group of cellular enzymes called cGMP phosphodiesterases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac.  After oral administration, sulindac undergoes extensive biotransformation including irreversible oxidation to sulindac sulfone.  Approximately, one half of an administered dose of sulindac is eliminated through the urine, mostly as the conjugated sulfone metabolite. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exisulind","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Indene-3-acetic Acid, 5-Fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene), (Z)","termGroup":"SN","termSource":"NCI"},{"termName":"Aptosyn","termGroup":"BR","termSource":"NCI"},{"termName":"FGN-1","termGroup":"CN","termSource":"NCI"},{"termName":"Sulindac Sulfone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colonic adenomatous polyps in the inherited disease adenomatous polyposis coli, control and suppression"},{"name":"CAS_Registry","value":"59973-80-7"},{"name":"CHEBI_ID","value":"CHEBI:64212"},{"name":"Chemical_Formula","value":"C20H17FO4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K619IIG2R9"},{"name":"Legacy Concept Name","value":"Sulindac_Sulfone"},{"name":"Maps_To","value":"Exisulind"},{"name":"NCI_Drug_Dictionary_ID","value":"43057"},{"name":"NSC Number","value":"719619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43057"},{"name":"PDQ_Open_Trial_Search_ID","value":"43057"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075616"}]}}{"C112498":{"preferredName":"Extended Release Flucytosine","code":"C112498","definitions":[{"definition":"An extended release (ER) oral tablet that contains flucytosine (5-FC), a fluorinated cytosine analog, with antifungal activity and potential anti-cancer activity. Following oral administration of ER 5-FC, the 5-FC is deaminated to its active metabolite 5-fluorouracil (5-FU). 5-FU replaces uracil during RNA synthesis, which consequently inhibits downstream protein synthesis. In addition, 5-FU is metabolized further to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase. Inhibition of this enzyme interrupts nucleotide synthesis, DNA replication and cell proliferation. Negative regulation of protein synthesis, DNA replication and cell proliferation can lead to cell death. Following ingestion of ER 5-FC, intravenous injection of a retroviral vector encoding cytosine deaminase (TC 511) at a tumor site may result in higher local concentrations of 5-FU and its metabolites, and increased tumor cell death than other 5-FU treatment regimens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extended Release Flucytosine","termGroup":"PT","termSource":"NCI"},{"termName":"Extended Release 5-FC","termGroup":"SY","termSource":"NCI"},{"termName":"Extended Release 5-Fluorocytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-Release 5-FC","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-Release 5-Fluorocytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-Release Flucytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Toca FC","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extended Release Flucytosine"},{"name":"NCI_Drug_Dictionary_ID","value":"755027"},{"name":"NCI_META_CUI","value":"CL454672"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755027"},{"name":"PDQ_Open_Trial_Search_ID","value":"755027"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113797":{"preferredName":"Extended-release Onapristone","code":"C113797","definitions":[{"definition":"An extended-release (ER) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extended-release Onapristone","termGroup":"PT","termSource":"NCI"},{"termName":"ER Onapristone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extended-release Onapristone"},{"name":"NCI_Drug_Dictionary_ID","value":"757592"},{"name":"NCI_META_CUI","value":"CL471779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757592"},{"name":"PDQ_Open_Trial_Search_ID","value":"757592"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127114":{"preferredName":"Valemetostat","code":"C127114","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valemetostat","termGroup":"PT","termSource":"NCI"},{"termName":"DS 3201","termGroup":"CN","termSource":"NCI"},{"termName":"DS-3201","termGroup":"CN","termSource":"NCI"},{"termName":"DS3201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1809336-39-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"60RD0234VE"},{"name":"Maps_To","value":"EZH1/2 Inhibitor DS-3201"},{"name":"Maps_To","value":"Valemetostat"},{"name":"NCI_Drug_Dictionary_ID","value":"780797"},{"name":"NCI_META_CUI","value":"CL507903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780797"},{"name":"PDQ_Open_Trial_Search_ID","value":"780797"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121639":{"preferredName":"Lirametostat","code":"C121639","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, lirametostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, a histone lysine methyltransferase (HMT) class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirametostat","termGroup":"PT","termSource":"NCI"},{"termName":"CPI-1205","termGroup":"CN","termSource":"NCI"},{"termName":"EZH2 Inhibitor CPI-1205","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1621862-70-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"455J2479FY"},{"name":"Maps_To","value":"EZH2 Inhibitor CPI-1205"},{"name":"NCI_Drug_Dictionary_ID","value":"770459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770459"},{"name":"PDQ_Open_Trial_Search_ID","value":"770459"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053654"}]}}{"C156743":{"preferredName":"EZH2 Inhibitor PF-06821497","code":"C156743","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH2 inhibitor PF-06821497 selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH2 Inhibitor PF-06821497","termGroup":"PT","termSource":"NCI"},{"termName":"1(2H)-Isoquinolinone, 5,8-Dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"PF 06821497","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06821497","termGroup":"CN","termSource":"NCI"},{"termName":"PF06821497","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1844849-10-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S4L4MM20B6"},{"name":"Maps_To","value":"EZH2 Inhibitor PF-06821497"},{"name":"NCI_Drug_Dictionary_ID","value":"795703"},{"name":"NCI_META_CUI","value":"CL935894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795703"},{"name":"PDQ_Open_Trial_Search_ID","value":"795703"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158742":{"preferredName":"EZH2 Inhibitor SHR2554","code":"C158742","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH2 inhibitor SHR2554 selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH2 Inhibitor SHR2554","termGroup":"PT","termSource":"NCI"},{"termName":"Enhancer of Zeste Homolog 2 Inhibitor SHR2554","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 2554","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-2554","termGroup":"CN","termSource":"NCI"},{"termName":"SHR2554","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EZH2 Inhibitor SHR2554"},{"name":"NCI_Drug_Dictionary_ID","value":"797374"},{"name":"NCI_META_CUI","value":"CL950708"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797374"},{"name":"PDQ_Open_Trial_Search_ID","value":"797374"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91395":{"preferredName":"F16-IL2 Fusion Protein","code":"C91395","definitions":[{"definition":"An immunocytokine of the human monoclonal antibody fragment F16 (scFv) against the extra-domain A1 of tenascin-C fused, via a short 5-amino acid linker, to a recombinant form of the human cytokine interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. The monoclonal antibody portion of the F16-IL2 fusion protein binds to tumor cells expressing the tumor associated antigen (TAA) tenascin-C. In turn, the IL-2 moiety of the fusion protein stimulates natural killer (NK) cells, macrophages and neutrophils and induces T-cell antitumor cellular immune responses thereby selectively killing tenascin-C-expressing tumor cells. In addition, F16-IL2 may potentiate the cytotoxicity of other chemotherapeutic agents. Tenascin-C, a glycoprotein of the extracellular matrix, is expressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"F16-IL2 Fusion Protein","termGroup":"PT","termSource":"NCI"},{"termName":"Teleukin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"F16-IL2 Fusion Protein"},{"name":"NCI_Drug_Dictionary_ID","value":"674718"},{"name":"NCI_META_CUI","value":"CL421592"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674718"},{"name":"PDQ_Open_Trial_Search_ID","value":"674718"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107239":{"preferredName":"FACT Complex-targeting Curaxin CBL0137","code":"C107239","definitions":[{"definition":"An orally available curaxin-based agent targeting the Facilitates Chromatin Transcription (FACT) complex, with potential antineoplastic activity. Upon administration, CBL0137 binds to FACT and sequesters the FACT complex on chromatin, which inhibits its activity. This prevents transcription of certain genes involved in cancer-associated signaling pathways; it specifically inhibits the transcription of both NF-kappa B and heat shock transcription factor 1 (HSF1) and simultaneously activates p53. This causes an increase in tumor cell apoptosis and a decrease in tumor cell proliferation, in FACT-positive cancers. In addition, this agent is able to sensitize FACT-positive tumor cells to the cytotoxic effects of other chemotherapeutic agents. FACT, a transcription and replication factor composed of the Structure Specific Recognition Protein (SSRP1) and suppressor of Ty 16 (Spt16) proteins, is expressed in a variety of tumor cells while almost absent in normal cells; its expression is associated with increased tumor aggressiveness and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FACT Complex-targeting Curaxin CBL0137","termGroup":"PT","termSource":"NCI"},{"termName":"CBL0137","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FACT Complex-targeting Curaxin CBL0137"},{"name":"NCI_Drug_Dictionary_ID","value":"750614"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750614"},{"name":"PDQ_Open_Trial_Search_ID","value":"750614"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827145"}]}}{"C129313":{"preferredName":"Factor VII-targeting Immunoconjugate Protein ICON-1","code":"C129313","definitions":[{"definition":"A human immunoconjugate (ICON) fusion protein composed of a modified version of human factor VII (FVII) which targets tissue factor (TF) that is fused to the Fc domain of the human immunoglobulin G1, with potential anti-thrombotic and antineoplastic activities. Acting in a similar manner as plasma FVII, the natural ligand of TF, ICON-1 targets and binds to TF expressed on neovascular endothelia, thereby preventing TF-mediated signaling pathways, and leading to the initiation of an immune response and the destruction of neovascular tissue. This prevents angiogenesis, inflammation and blood coagulation. Upon intravitreal administration, ICON-1 may block TF-induced angiogenesis and treat wet age-related macular degeneration (AMD) and ocular melanoma. TF, a naturally occurring glycoprotein in humans, regulates blood clotting, angiogenesis, and inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Factor VII-targeting Immunoconjugate Protein ICON-1","termGroup":"PT","termSource":"NCI"},{"termName":"FVII Modified Conjugate ICON-1","termGroup":"SY","termSource":"NCI"},{"termName":"FVII-targeting Immunoconjugate Protein ICON-1","termGroup":"SY","termSource":"NCI"},{"termName":"Human Immuno-conjugate 1","termGroup":"SY","termSource":"NCI"},{"termName":"ICON-1","termGroup":"CN","termSource":"NCI"},{"termName":"VII-Fc Fusion Protein ICON-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Factor VII-targeting Immunoconjugate Protein ICON-1"},{"name":"NCI_Drug_Dictionary_ID","value":"783145"},{"name":"NCI_META_CUI","value":"CL512298"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783145"},{"name":"PDQ_Open_Trial_Search_ID","value":"783145"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88324":{"preferredName":"Factor VIIa Inhibitor PCI-27483","code":"C88324","definitions":[{"definition":"A reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential antineoplastic and antithrombotic activities.  FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, factor VIIa inhibitor PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells. In addition, this agent inhibits both the extrinsic and intrinsic coagulation cascades, preventing blood clot formation. TF, a blood protein overexpressed on the cell surface of a variety of tumor cell types, may correlate with poor prognosis; PAR-2 (also known as thrombin receptor-like 1) is a G protein-coupled receptor (GPCR) and a protease-activated receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Factor VIIa Inhibitor PCI-27483","termGroup":"PT","termSource":"NCI"},{"termName":"PCI-27483","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871266-63-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6073LCU8U9"},{"name":"Maps_To","value":"Factor VIIa Inhibitor PCI-27483"},{"name":"NCI_Drug_Dictionary_ID","value":"661024"},{"name":"NCI_META_CUI","value":"CL413585"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661024"},{"name":"PDQ_Open_Trial_Search_ID","value":"661024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1044":{"preferredName":"Fadrozole Hydrochloride","code":"C1044","definitions":[{"definition":"The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers. Aromatase, a member of the cytochrome P-450 superfamily, is found in many tissues; overexpression has been linked to the development of preneoplastic and neoplastic changes in breast tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fadrozole Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Afema","termGroup":"FB","termSource":"NCI"},{"termName":"Arensin","termGroup":"FB","termSource":"NCI"},{"termName":"CGS-16949A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"102676-31-3"},{"name":"CAS_Registry","value":"102676-96-0"},{"name":"Chemical_Formula","value":"C14H13N3.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H0Q44H4ECQ"},{"name":"Legacy Concept Name","value":"Fadrozole_Hydrochloride"},{"name":"Maps_To","value":"Fadrozole Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41025"},{"name":"PDQ_Open_Trial_Search_ID","value":"41025"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0917743"}]}}{"C88346":{"preferredName":"FAK Inhibitor GSK2256098","code":"C88346","definitions":[{"definition":"A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt, thereby inhibiting tumor cell migration, proliferation and survival, and tumor angiogenesis. The tyrosine kinase FAK is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK Inhibitor GSK2256098","termGroup":"PT","termSource":"NCI"},{"termName":"Focal Adhesion Kinase Inhibitor GSK2256098","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2256098","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1224887-10-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R7O0O4110G"},{"name":"Maps_To","value":"FAK Inhibitor GSK2256098"},{"name":"NCI_Drug_Dictionary_ID","value":"658411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658411"},{"name":"PDQ_Open_Trial_Search_ID","value":"658411"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981865"}]}}{"C78199":{"preferredName":"FAK Inhibitor PF-00562271","code":"C78199","definitions":[{"definition":"An orally bioavailable small molecule and ATP-competitive focal adhesion kinase (FAK) inhibitor with potential antineoplastic and antiangiogenic activities. FAK inhibitor PF-00562271 inhibits the tyrosine kinase FAK, and to a lesser extent, proline-rich tyrosine kinase (PYK2), which may inhibit tumor cell migration, proliferation, and survival. As FAK is a signal transducer for integrins, inhibition of FAK by this agent may prevent integrin-mediated activation of several downstream signals including ERK, JNK/MAPK and PI3K/Akt. FAK and PYK2, upregulated in many tumor cell types, are involved in tumor cell invasion, migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK Inhibitor PF-00562271","termGroup":"PT","termSource":"NCI"},{"termName":"Focal Adhesion Kinase Inhibitor PF-00562271","termGroup":"SY","termSource":"NCI"},{"termName":"PF-00562271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"939791-38-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FK2M84H8UI"},{"name":"Legacy Concept Name","value":"FAK_Inhibitor_PF-00562271"},{"name":"Maps_To","value":"FAK Inhibitor PF-00562271"},{"name":"NCI_Drug_Dictionary_ID","value":"595536"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595536"},{"name":"PDQ_Open_Trial_Search_ID","value":"595536"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703113"}]}}{"C107238":{"preferredName":"FAK Inhibitor VS-4718","code":"C107238","definitions":[{"definition":"An orally bioavailable focal adhesion kinase (FAK) inhibitor with potential antineoplastic activity. Upon administration, VS-4718 inhibits FAK, blocks fibronectin-stimulated FAK autophosphorylation of Tyr397, and may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt. This results in the reduction of the number of cancer stem cells (CSCs) and inhibits tumor cell migration, proliferation and survival. The cytoplasmic tyrosine kinase FAK is a signal transducer for integrins and is constitutively activated in various tumor cell types; it is involved in tumor cell invasion, migration and proliferation and plays a key role in the development, function and survival of CSCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK Inhibitor VS-4718","termGroup":"PT","termSource":"NCI"},{"termName":"VS-4718","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1061353-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L2BD0MW4OL"},{"name":"Maps_To","value":"FAK Inhibitor VS-4718"},{"name":"NCI_Drug_Dictionary_ID","value":"750562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750562"},{"name":"PDQ_Open_Trial_Search_ID","value":"750562"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3177516"}]}}{"C29316":{"preferredName":"Falimarev","code":"C29316","definitions":[{"definition":"A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A cancer vaccine made with a form of a chicken virus that does not cause disease in humans. It is being studied in the treatment of some types of cancer. The virus is changed in the laboratory to make human proteins that may help immune cells in the body kill tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Falimarev","termGroup":"PT","termSource":"NCI"},{"termName":"fCEA-MUC-1-TRI","termGroup":"AB","termSource":"NCI"},{"termName":"Fowlpox-CEA(D609)-MUC1(L93)-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Fowlpox-CEA-MUC-1-TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"PANVAC-F","termGroup":"BR","termSource":"NCI"},{"termName":"rFowlpox-CEA(D609)/MUC1(L93)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685563-14-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"rFowlpox-CEA_D609_MUC1_L93_TRICOM"},{"name":"Maps_To","value":"Falimarev"},{"name":"NCI_Drug_Dictionary_ID","value":"385667"},{"name":"NSC Number","value":"727027"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385667"},{"name":"PDQ_Open_Trial_Search_ID","value":"385667"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1541350"}]}}{"C97512":{"preferredName":"Famitinib","code":"C97512","definitions":[{"definition":"An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs, dysregulated in a variety of tumors, including stem cell factor receptor (c-Kit; SCFR), vascular endothelial growth factor receptor (VEGFR) 2 and 3, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinases Flt1 and Flt3. Inhibition of these RTKs may result in an inhibition of tumor growth and angiogenesis, and eventually tumor regression in tumor cells overexpressing these RTKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Famitinib","termGroup":"PT","termSource":"NCI"},{"termName":"4H-pyrrolo(3,2-c)pyridin-4-one, 5-(2-(diethylamino)ethyl)-2-((5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-1,5,6,7-tetrahydro-3-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"SHR-1020","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1020","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1044040-56-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"768FW21J3L"},{"name":"Maps_To","value":"Famitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"703815"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703815"},{"name":"PDQ_Open_Trial_Search_ID","value":"703815"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273460"}]}}{"C61503":{"preferredName":"Farletuzumab","code":"C61503","definitions":[{"definition":"A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Farletuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"MORAb-003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"896723-44-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2O09BG0OWA"},{"name":"Legacy Concept Name","value":"Anti-GP-3_Monoclonal_Antibody"},{"name":"Maps_To","value":"Farletuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"486728"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486728"},{"name":"PDQ_Open_Trial_Search_ID","value":"486728"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700602"}]}}{"C1840":{"preferredName":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123","code":"C1840","definitions":[{"definition":"A benzonitrile derivative capable of inhibiting some prenyltransferases. L-778,123 is a dual inhibitor of farnesyl:protein and geranylgeranyl:protein transferases; both enzymes catalyze prenylation of oncoprotein KRAS, a prerequisite step in activation of KRAS in signal transduction pathway of apoptosis. Although this agent was developed in part as an anti-KRAS agent, L-778,123 failed in a Phase I trial to inhibit KRAS, which is associated with many types of solid tumors.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called enzyme inhibitors. It may inhibit the transformation of normal cells into cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123","termGroup":"PT","termSource":"NCI"},{"termName":"4-[[5-[[4-(3-Chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]benzonitrile Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"L 778123","termGroup":"CN","termSource":"NCI"},{"termName":"L-778123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"253863-00-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2A2059P49U"},{"name":"Legacy Concept Name","value":"L-778_123"},{"name":"Maps_To","value":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123"},{"name":"NCI_Drug_Dictionary_ID","value":"43144"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43144"},{"name":"PDQ_Open_Trial_Search_ID","value":"43144"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796327"}]}}{"C67041":{"preferredName":"Fas Receptor Agonist APO010","code":"C67041","definitions":[{"definition":"A recombinant, soluble, hexameric fusion protein consisting of three human Fas ligand (FasL) extracellular domains fused to the dimer-forming collagen domain of human adiponectin with potential pro-apoptotic and antineoplastic activities. Assembled into a soluble hexameric structure mimicking the ligand clustering of endogenous active FasL, Fas receptor agonist APO010 activates the Fas receptor, resulting in caspase-dependent apoptosis in susceptible tumor cell populations. FasL is a transmembrane protein of the tumor necrosis factor (TNF) superfamily and a pro-apoptotic ligand for the death receptor Fas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fas Receptor Agonist APO010","termGroup":"PT","termSource":"NCI"},{"termName":"APO010","termGroup":"AB","termSource":"NCI"},{"termName":"Mega-FasLigand","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"APO010"},{"name":"Maps_To","value":"Fas Receptor Agonist APO010"},{"name":"NCI_Drug_Dictionary_ID","value":"539307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539307"},{"name":"PDQ_Open_Trial_Search_ID","value":"539307"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879517"}]}}{"C142086":{"preferredName":"Fascin Inhibitor NP-G2-044","code":"C142086","definitions":[{"definition":"An orally available inhibitor of the protein fascin, with potential antineoplastic activity. Upon oral administration, NP-G2-044 targets and binds to fascin, thereby preventing the interaction of fascin with actin filaments, thereby preventing actin bundling and filopodia formation. By preventing actin cytoskeletal reorganization, the dynamic changes in cell shape that are necessary for tumor cell migration and invasion to occur are impaired, and tumor cell migration and metastasis are inhibited. Fascin, the main actin cross-linker protein in filopodia, is upregulated in many types of metastatic tumor cells while its expression is low or absent in normal adult epithelial cells; its expression is correlated with aggressive phenotypes, poor prognosis, and shorter survival. Filopodia, finger-like plasma membrane protrusions that are formed upon remodeling of the actin cytoskeleton, are found at a high frequency in metastatic tumor cells and their presence is correlated with tumor cell invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fascin Inhibitor NP-G2-044","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"NP G2 044","termGroup":"CN","termSource":"NCI"},{"termName":"NP-G2-044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1807454-59-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1ER2O3UZ4W"},{"name":"Maps_To","value":"Fascin Inhibitor NP-G2-044"},{"name":"NCI_Drug_Dictionary_ID","value":"793138"},{"name":"NCI_META_CUI","value":"CL540124"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793138"},{"name":"PDQ_Open_Trial_Search_ID","value":"793138"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118285":{"preferredName":"Denifanstat","code":"C118285","definitions":[{"definition":"An orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, denifanstat binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denifanstat","termGroup":"PT","termSource":"NCI"},{"termName":"ASC 40","termGroup":"CN","termSource":"NCI"},{"termName":"ASC-40","termGroup":"CN","termSource":"NCI"},{"termName":"ASC40","termGroup":"CN","termSource":"NCI"},{"termName":"FASN Inhibitor TVB-2640","termGroup":"SY","termSource":"NCI"},{"termName":"TVB 2640","termGroup":"CN","termSource":"NCI"},{"termName":"TVB-2640","termGroup":"CN","termSource":"NCI"},{"termName":"TVB2640","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1399177-37-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4GF95B2LZA"},{"name":"Maps_To","value":"FASN Inhibitor TVB-2640"},{"name":"NCI_Drug_Dictionary_ID","value":"764237"},{"name":"NCI_META_CUI","value":"CL474138"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764237"},{"name":"PDQ_Open_Trial_Search_ID","value":"764237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1096":{"preferredName":"Fazarabine","code":"C1096","definitions":[{"definition":"An anticancer drug that is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fazarabine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3, 5-Triazin-2(1H)-one, 4-Amino-1-beta-D- arabinofuranosyl- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosyl-5-azacytosine","termGroup":"SN","termSource":"NCI"},{"termName":"Ara AC","termGroup":"AB","termSource":"NCI"},{"termName":"ara-AC","termGroup":"AB","termSource":"NCI"},{"termName":"Kymarabine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65886-71-7"},{"name":"Chemical_Formula","value":"C8H12N4O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5V71D8JOKK"},{"name":"Legacy Concept Name","value":"Fazarabine"},{"name":"Maps_To","value":"Fazarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"40564"},{"name":"NSC Number","value":"281272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40564"},{"name":"PDQ_Open_Trial_Search_ID","value":"40564"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060103"}]}}{"C65629":{"preferredName":"Febuxostat","code":"C65629","definitions":[{"definition":"An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Febuxostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Adenuric","termGroup":"FB","termSource":"NCI"},{"termName":"TMX 67","termGroup":"CN","termSource":"NCI"},{"termName":"Uloric","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144060-53-7"},{"name":"CHEBI_ID","value":"CHEBI:31596"},{"name":"Chemical_Formula","value":"C16H16N2O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"101V0R1N2E"},{"name":"Legacy Concept Name","value":"Febuxostat"},{"name":"Maps_To","value":"Febuxostat"},{"name":"NCI_Drug_Dictionary_ID","value":"743107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743107"},{"name":"PDQ_Open_Trial_Search_ID","value":"743107"},{"name":"PubMedID_Primary_Reference","value":"16339094"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0249529"}]}}{"C88293":{"preferredName":"Fedratinib","code":"C88293","definitions":[{"definition":"An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fedratinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-","termGroup":"SY","termSource":"NCI"},{"termName":"SAR302503","termGroup":"CN","termSource":"NCI"},{"termName":"TG101348","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936091-26-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6L1XP550I6"},{"name":"Maps_To","value":"Fedratinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2353170"}]}}{"C162995":{"preferredName":"Fedratinib Hydrochloride","code":"C162995","definitions":[{"definition":"The monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fedratinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, N-(1,1-Dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Fedratinib Dihydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Inrebic","termGroup":"BR","termSource":"NCI"},{"termName":"N-tert-butyl-3-((5-methyl-2-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)pyrimidin-4-yl)amino) Benzenesulfonamide Dihydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"SAR302503a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)."},{"name":"CAS_Registry","value":"1374744-69-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UH9J2HBQWJ"},{"name":"Maps_To","value":"Fedratinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"657793"},{"name":"NCI_META_CUI","value":"CL973405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"657793"},{"name":"PDQ_Open_Trial_Search_ID","value":"657793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116844":{"preferredName":"Fenebrutinib","code":"C116844","definitions":[{"definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenebrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton Tyrosine Kinase Inhibitor GDC-0853","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0853","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1434048-34-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E9L2885WUL"},{"name":"Maps_To","value":"Fenebrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"755178"},{"name":"NCI_META_CUI","value":"CL774945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755178"},{"name":"PDQ_Open_Trial_Search_ID","value":"755178"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1098":{"preferredName":"Fenretinide","code":"C1098","definitions":[{"definition":"A substance being studied in the treatment and prevention of some types of cancer. Fenretinide may cause ceramide (a wax-like substance) to build up in tumor cells and kill them. It is a type of retinoid, which are substances related to vitamin A.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenretinide","termGroup":"PT","termSource":"NCI"},{"termName":"4-(all-trans-retino-yl)aminophenol","termGroup":"SN","termSource":"NCI"},{"termName":"4-HPR","termGroup":"AB","termSource":"NCI"},{"termName":"4-Hydroxyphenylretinamide","termGroup":"SN","termSource":"NCI"},{"termName":"All-trans-4'-Hydroxyretinanilide","termGroup":"SN","termSource":"NCI"},{"termName":"all-trans-N-(4-Hydroxyphenyl)retinamide","termGroup":"SN","termSource":"NCI"},{"termName":"all-trans-N-4'-hydroxyretinanilide","termGroup":"SN","termSource":"NCI"},{"termName":"Fenretinimide","termGroup":"SY","termSource":"NCI"},{"termName":"HPR-4","termGroup":"AB","termSource":"NCI"},{"termName":"McN-R-1967","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-hydroxyphenyl)retinamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65646-68-6"},{"name":"CHEBI_ID","value":"CHEBI:42588"},{"name":"Chemical_Formula","value":"C26H33NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"187EJ7QEXL"},{"name":"Legacy Concept Name","value":"Fenretinide"},{"name":"Maps_To","value":"Fenretinide"},{"name":"NCI_Drug_Dictionary_ID","value":"39582"},{"name":"NSC Number","value":"374551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39582"},{"name":"PDQ_Open_Trial_Search_ID","value":"39582"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060197"}]}}{"C63482":{"preferredName":"Fenretinide Lipid Matrix","code":"C63482","definitions":[{"definition":"A powdered form of fenretinide that is being studied in the treatment of neuroblastoma. It may be used by the body more easily than the pill form. Fenretinide may cause ceramide (a wax-like substance) to build up in tumor cells and kill them. It is a type of retinoid, which are substances related to vitamin A.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable powder formulation of a synthetic phenylretinamide analogue of retinol with potential chemopreventive and antineoplastic activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types, including those of the colon, breast, prostate, and neuroblastoma. Independent of RAR activation, this agent also modulates gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS). Compared to the capsule form, the powder contains a mixture of wheat flour, fats, and sugar that may contribute to the enhanced bioavailability of fenretinide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenretinide Lipid Matrix","termGroup":"PT","termSource":"NCI"},{"termName":"Fenretinide LXS","termGroup":"BR","termSource":"NCI"},{"termName":"Fenretinide Lym-X-Sorb","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fenretinide_Lipid_Matrix"},{"name":"Maps_To","value":"Fenretinide Lipid Matrix"},{"name":"NCI_Drug_Dictionary_ID","value":"468556"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468556"},{"name":"PDQ_Open_Trial_Search_ID","value":"468556"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831747"}]}}{"C77970":{"preferredName":"FGF Receptor Antagonist HGS1036","code":"C77970","definitions":[{"definition":"A soluble fusion protein consisting of the extracellular domain of human fibroblast growth factor receptor 1 (FGFR1) fused to the Fc portion of human immunoglobulin G1 (IgG1) with potential antineoplastic and anti-angiogenic activities. FGFR1 receptor antagonist FP-1039 prevents FGFR ligands, such as FGF1, FGF2, FGF4, from binding to their cognate receptors, thereby inhibiting the activation of the related FGFR tyrosine kinases. Inhibition of FGFR1 by this agent may retard tumor cell proliferation and induce tumor cell death. FP-1039 may also inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis. FGFR1 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cellular proliferation, differentiation, angiogenesis, and survival; most ligands that bind to FGFR1 also bind to the related receptors FGFR3 and FGFR4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGF Receptor Antagonist HGS1036","termGroup":"PT","termSource":"NCI"},{"termName":"FP-1039","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3052230","termGroup":"CN","termSource":"NCI"},{"termName":"HGS1036","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1631072-93-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CTG26PRE5S"},{"name":"Legacy Concept Name","value":"FGF_Receptor_Antagonist_FP-1039"},{"name":"Maps_To","value":"FGF Receptor Antagonist HGS1036"},{"name":"NCI_Drug_Dictionary_ID","value":"599037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599037"},{"name":"PDQ_Open_Trial_Search_ID","value":"599037"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703098"}]}}{"C118672":{"preferredName":"Tasurgratinib","code":"C118672","definitions":[{"definition":"An inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, tasurgratinib selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasurgratinib","termGroup":"PT","termSource":"NCI"},{"termName":"E-7090","termGroup":"CN","termSource":"NCI"},{"termName":"E7090","termGroup":"CN","termSource":"NCI"},{"termName":"FGF/FGFR Pathway Inhibitor E7090","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622204-21-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TN7CUD1NGA"},{"name":"Maps_To","value":"FGF/FGFR Pathway Inhibitor E7090"},{"name":"NCI_Drug_Dictionary_ID","value":"766006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766006"},{"name":"PDQ_Open_Trial_Search_ID","value":"766006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896866"}]}}{"C122719":{"preferredName":"FGFR Inhibitor ASP5878","code":"C122719","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor ASP5878 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR Inhibitor ASP5878","termGroup":"PT","termSource":"NCI"},{"termName":"ASP5878","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453208-66-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C0Z095LL72"},{"name":"Maps_To","value":"FGFR Inhibitor ASP5878"},{"name":"NCI_Drug_Dictionary_ID","value":"756907"},{"name":"NCI_META_CUI","value":"CL471763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756907"},{"name":"PDQ_Open_Trial_Search_ID","value":"756907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88272":{"preferredName":"Fexagratinib","code":"C88272","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fexagratinib","termGroup":"PT","termSource":"NCI"},{"termName":"ABSK-091","termGroup":"CN","termSource":"NCI"},{"termName":"ABSK091","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4547","termGroup":"CN","termSource":"NCI"},{"termName":"FGFR Inhibitor AZD4547","termGroup":"SY","termSource":"NCI"},{"termName":"KB-74810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1035270-39-3"},{"name":"CHEBI_ID","value":"CHEBI:63453"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2167OG1EKJ"},{"name":"Maps_To","value":"FGFR Inhibitor AZD4547"},{"name":"NCI_Drug_Dictionary_ID","value":"655951"},{"name":"NCI_META_CUI","value":"CL412460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655951"},{"name":"PDQ_Open_Trial_Search_ID","value":"655951"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174762":{"preferredName":"Zoligratinib","code":"C174762","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. Zoligratinib binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, is essential for tumor cellular proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zoligratinib","termGroup":"PT","termSource":"NCI"},{"termName":"CH5183284","termGroup":"CN","termSource":"NCI"},{"termName":"debio 1347","termGroup":"CN","termSource":"NCI"},{"termName":"debio 1347-101","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-1347","termGroup":"CN","termSource":"NCI"},{"termName":"Debio1347","termGroup":"CN","termSource":"NCI"},{"termName":"Debiopharm 1347","termGroup":"SY","termSource":"NCI"},{"termName":"FF284","termGroup":"CN","termSource":"NCI"},{"termName":"FGFR Inhibitor Debio 1347","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1265229-25-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NR9ZYH80Z8"},{"name":"Maps_To","value":"FGFR Inhibitor Debio 1347"},{"name":"NCI_Drug_Dictionary_ID","value":"808368"},{"name":"NCI_META_CUI","value":"CL1412276"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114283":{"preferredName":"Futibatinib","code":"C114283","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Futibatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propen-1-one, 1-((3S)-3-(4-Amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Lytgobi","termGroup":"BR","termSource":"NCI"},{"termName":"TAS-120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements."},{"name":"CAS_Registry","value":"1448169-71-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4B93MGE4AL"},{"name":"Maps_To","value":"FGFR Inhibitor TAS-120"},{"name":"Maps_To","value":"Futibatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"757896"},{"name":"NCI_META_CUI","value":"CL471791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757896"},{"name":"PDQ_Open_Trial_Search_ID","value":"757896"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116894":{"preferredName":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","code":"C116894","definitions":[{"definition":"A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FMS-related tyrosine kinase 3 (FLT3), and SRC, with potential antineoplastic activity. Upon administration, XL999 binds to and inhibits the activity of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR, PDGFR, FLT-3, and SRC are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","termGroup":"PT","termSource":"NCI"},{"termName":"Spectrum Selective Kinase Inhibitor XL999","termGroup":"SY","termSource":"NCI"},{"termName":"SSKI XL999","termGroup":"SY","termSource":"NCI"},{"termName":"XL-999","termGroup":"CN","termSource":"NCI"},{"termName":"XL999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"705946-27-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6I7PLF6N8L"},{"name":"Maps_To","value":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999"},{"name":"NCI_Drug_Dictionary_ID","value":"425377"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425377"},{"name":"PDQ_Open_Trial_Search_ID","value":"425377"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541529"}]}}{"C150383":{"preferredName":"FGFR1/2/3 Inhibitor HMPL-453","code":"C150383","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Upon administration, FGFR inhibitor HMPL-453 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR1/2/3 Inhibitor HMPL-453","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR Inhibitor HMPL-453","termGroup":"SY","termSource":"NCI"},{"termName":"HMPL 453","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-453","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR1/2/3 Inhibitor HMPL-453"},{"name":"NCI_Drug_Dictionary_ID","value":"792789"},{"name":"NCI_META_CUI","value":"CL552165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792789"},{"name":"PDQ_Open_Trial_Search_ID","value":"792789"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143067":{"preferredName":"FGFR4 Antagonist INCB062079","code":"C143067","definitions":[{"definition":"An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist INCB062079 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Antagonist INCB062079","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR4 Inhibitor INCB062079","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Antagonist INCB062079","termGroup":"SY","termSource":"NCI"},{"termName":"INCB 062079","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-062079","termGroup":"CN","termSource":"NCI"},{"termName":"INCB062079","termGroup":"CN","termSource":"NCI"},{"termName":"INCB62079","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR4 Antagonist INCB062079"},{"name":"NCI_Drug_Dictionary_ID","value":"791889"},{"name":"NCI_META_CUI","value":"CL541447"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791889"},{"name":"PDQ_Open_Trial_Search_ID","value":"791889"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162342":{"preferredName":"FGFR4 Inhibitor BLU 9931","code":"C162342","definitions":[{"definition":"An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist BLU 9931 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand, fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Inhibitor BLU 9931","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(2-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)-3-methylphenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"BLU 9931","termGroup":"CN","termSource":"NCI"},{"termName":"BLU-9931","termGroup":"CN","termSource":"NCI"},{"termName":"BLU9931","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)-3-methylphenyl)-2-propenamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1538604-68-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FQK825B5DX"},{"name":"Maps_To","value":"FGFR4 Inhibitor BLU 9931"},{"name":"NCI_META_CUI","value":"CL970841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120102":{"preferredName":"Roblitinib","code":"C120102","definitions":[{"definition":"An inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, roblitinib binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roblitinib","termGroup":"PT","termSource":"NCI"},{"termName":"FGF401","termGroup":"CN","termSource":"NCI"},{"termName":"FGFR4 Inhibitor FGF401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1708971-55-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M64JF6WMSA"},{"name":"Maps_To","value":"FGFR4 Inhibitor FGF401"},{"name":"Maps_To","value":"Roblitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"767955"},{"name":"NCI_META_CUI","value":"CL507817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767955"},{"name":"PDQ_Open_Trial_Search_ID","value":"767955"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128862":{"preferredName":"FGFR4 Inhibitor H3B-6527","code":"C128862","definitions":[{"definition":"An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival; FGFR4 expression is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Inhibitor H3B-6527","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Inhibitor H3B-6527","termGroup":"SY","termSource":"NCI"},{"termName":"H3B 6527","termGroup":"CN","termSource":"NCI"},{"termName":"H3B-6527","termGroup":"CN","termSource":"NCI"},{"termName":"H3B6527","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1702259-66-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4HTE364XIK"},{"name":"Maps_To","value":"FGFR4 Inhibitor H3B-6527"},{"name":"NCI_Drug_Dictionary_ID","value":"783108"},{"name":"NCI_META_CUI","value":"CL512384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783108"},{"name":"PDQ_Open_Trial_Search_ID","value":"783108"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162852":{"preferredName":"FGFR4 Inhibitor ICP-105","code":"C162852","definitions":[{"definition":"An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, ICP-105 specifically targets, binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase overexpressed on a variety of cancer cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Inhibitor ICP-105","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR4 Antagonist ICP-105","termGroup":"SY","termSource":"NCI"},{"termName":"ICP 105","termGroup":"CN","termSource":"NCI"},{"termName":"ICP-105","termGroup":"CN","termSource":"NCI"},{"termName":"ICP105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR4 Inhibitor ICP-105"},{"name":"NCI_Drug_Dictionary_ID","value":"798826"},{"name":"NCI_META_CUI","value":"CL973353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798826"},{"name":"PDQ_Open_Trial_Search_ID","value":"798826"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166939":{"preferredName":"Onfekafusp Alfa","code":"C166939","definitions":[{"definition":"An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onfekafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Fibromun","termGroup":"SY","termSource":"NCI"},{"termName":"L19-TNF-alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Fusion Protein L19TNFalpha","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1957239-88-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6HXC0O6JMV"},{"name":"Maps_To","value":"Fibromun"},{"name":"NCI_Drug_Dictionary_ID","value":"686947"},{"name":"NCI_META_CUI","value":"CL972185"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78844":{"preferredName":"Ficlatuzumab","code":"C78844","definitions":[{"definition":"A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Ficlatuzumab binds to the soluble ligand HGF, preventing the binding of HGF to its receptor c-Met and activation of the HGF/c-Met signaling pathway, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ficlatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HGF Monoclonal Antibody SCH900105","termGroup":"SY","termSource":"NCI"},{"termName":"AV-299","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1174900-84-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"77E89833TG"},{"name":"Legacy Concept Name","value":"Anti-HGF_Monoclonal_Antibody_SCH900105"},{"name":"Maps_To","value":"Ficlatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"610133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610133"},{"name":"PDQ_Open_Trial_Search_ID","value":"610133"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703138"}]}}{"C52187":{"preferredName":"Figitumumab","code":"C52187","definitions":[{"definition":"A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Figitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"CP-751,871","termGroup":"CN","termSource":"NCI"},{"termName":"CP-751871","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943453-46-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"VE267FC2UB"},{"name":"Legacy Concept Name","value":"CP-751871"},{"name":"Maps_To","value":"Figitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"456793"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456793"},{"name":"PDQ_Open_Trial_Search_ID","value":"456793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713009"}]}}{"C68937":{"preferredName":"Filanesib","code":"C68937","definitions":[{"definition":"A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. Filanesib specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, this agent does not cause the peripheral neuropathy that is often associated with tubulin-targeting agents. KSP is an ATP-dependent microtubule motor protein that is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Filanesib","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,4-Thiadiazole-3(2H)-carboxamide, 2-(3-Aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-, (2S)-","termGroup":"SN","termSource":"NCI"},{"termName":"ARRY-520","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY520","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"885060-09-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8A49OSO368"},{"name":"Legacy Concept Name","value":"KSP_Inhibitor_ARRY-520"},{"name":"Maps_To","value":"Filanesib"},{"name":"NCI_Drug_Dictionary_ID","value":"546990"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546990"},{"name":"PDQ_Open_Trial_Search_ID","value":"546990"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346611"}]}}{"C155799":{"preferredName":"Filgotinib","code":"C155799","definitions":[{"definition":"An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Filgotinib","termGroup":"PT","termSource":"NCI"},{"termName":"GLPG 0634","termGroup":"CN","termSource":"NCI"},{"termName":"GLPG0634","termGroup":"CN","termSource":"NCI"},{"termName":"GS-6034","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1206161-97-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3XVL385Q0M"},{"name":"Maps_To","value":"Filgotinib"},{"name":"NCI_META_CUI","value":"CL556330"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1474":{"preferredName":"Filgrastim","code":"C1474","definitions":[{"definition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that is a type of hematopoietic (blood-forming) agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Filgrastim","termGroup":"PT","termSource":"NCI"},{"termName":"Filgrastim Biosimilar Filgrastim-sndz","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim Biosimilar Tbo-filgrastim","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim XM02","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim-aafi","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim-ayow","termGroup":"SY","termSource":"NCI"},{"termName":"G-CSF","termGroup":"AB","termSource":"NCI"},{"termName":"Granix","termGroup":"BR","termSource":"NCI"},{"termName":"Neupogen","termGroup":"BR","termSource":"NCI"},{"termName":"Neutroval","termGroup":"BR","termSource":"NCI"},{"termName":"Nivestym","termGroup":"BR","termSource":"NCI"},{"termName":"r-metHuG-CSF","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Releuko","termGroup":"BR","termSource":"NCI"},{"termName":"rG-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Tevagrastim","termGroup":"BR","termSource":"NCI"},{"termName":"XM02","termGroup":"CN","termSource":"NCI"},{"termName":"Zarxio","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Aplastic neutropenia; Bone marrow transplantation; Cancer patients receiving myelosuppressive chemotherapy; Congenital neutropenia; Idiopathic or cyclic neutropenia; Peripheral blood progenitor cell mobilization"},{"name":"CAS_Registry","value":"121181-53-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"PVI5M0M1GW"},{"name":"Legacy Concept Name","value":"Filgrastim"},{"name":"Maps_To","value":"Filgrastim"},{"name":"NCI_Drug_Dictionary_ID","value":"41057"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41057"},{"name":"PDQ_Open_Trial_Search_ID","value":"41057"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0210630"}]}}{"C104008":{"preferredName":"Fimepinostat","code":"C104008","definitions":[{"definition":"An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, fimepinostat inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fimepinostat","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC-907","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1339928-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S9RX35S5X"},{"name":"Maps_To","value":"Fimepinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"743908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743908"},{"name":"PDQ_Open_Trial_Search_ID","value":"743908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3530053"}]}}{"C70651":{"preferredName":"Firtecan Pegol","code":"C70651","definitions":[{"definition":"A polyethylene glycol (PEG) conjugate of 7-ethyl-10-hydroxycamptothecin with potential antineoplastic activity. After hydrolysis in vivo, 7-ethyl-10-hydroxycamptothecin (SN38), an active metabolite of irinotecan, is released from firtecan pegol; 7-ethyl-10-hydroxycamptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to unPEGylated 7-ethyl-10-hydroxycamptothecin, PEGylation improves solubility and allows for parental delivery, and may result in a longer half-life and higher exposure for tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Firtecan Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"EZN-2208","termGroup":"CN","termSource":"NCI"},{"termName":"PEG-SN38","termGroup":"AB","termSource":"NCI"},{"termName":"Poly(oxy-1,2-ethanediyl), alpha,alpha',alpha'',alpha'''-(oxydi-3,1,2-propanetriyl)tetrakis(omega-(2-((2-(((4S)- 4,11-diethyl-9-hydroxy-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano(3',4':6,7) indolizino(1,2-b)quinolin-4-yl)oxy)-2-oxoethyl)amino)-2-oxoethoxy)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946062-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WC4978T687"},{"name":"Legacy Concept Name","value":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin"},{"name":"Maps_To","value":"Firtecan Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"570645"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570645"},{"name":"PDQ_Open_Trial_Search_ID","value":"570645"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347621"}]}}{"C123826":{"preferredName":"Fisogatinib","code":"C123826","definitions":[{"definition":"An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fisogatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-","termGroup":"SY","termSource":"NCI"},{"termName":"BLU 554","termGroup":"CN","termSource":"NCI"},{"termName":"BLU-554","termGroup":"CN","termSource":"NCI"},{"termName":"BLU554","termGroup":"CN","termSource":"NCI"},{"termName":"CS 3008","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3008","termGroup":"CN","termSource":"NCI"},{"termName":"CS3008","termGroup":"CN","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Inhibitor BLU-554","termGroup":"SY","termSource":"NCI"},{"termName":"N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1707289-21-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Q7R99CKV2"},{"name":"Maps_To","value":"Fisogatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"775629"},{"name":"NCI_META_CUI","value":"CL498220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775629"},{"name":"PDQ_Open_Trial_Search_ID","value":"775629"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91384":{"preferredName":"Flanvotumab","code":"C91384","definitions":[{"definition":"A monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. Anti-gp75 monoclonal antibody IMC-20D7S targets and binds to gp75. This may lead to the induction of cytotoxic T cell immune and antibody-mediated immune responses against melanoma cells expressing gp75. gp75, a pigmentation-associated antigen, is expressed in melanosomes of human melanocytes and melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flanvotumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-gp75 Monoclonal Antibody IMC-20D7S","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-20D7S","termGroup":"CN","termSource":"NCI"},{"termName":"IMC20D7S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188277-05-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZNV4738BS6"},{"name":"Maps_To","value":"Flanvotumab"},{"name":"NCI_Drug_Dictionary_ID","value":"675217"},{"name":"NCI_META_CUI","value":"CL421598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675217"},{"name":"PDQ_Open_Trial_Search_ID","value":"675217"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117238":{"preferredName":"Flotetuzumab","code":"C117238","definitions":[{"definition":"An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flotetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"CD123 x CD3 DART Bi-Specific Antibody MGD006","termGroup":"SY","termSource":"NCI"},{"termName":"CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006","termGroup":"SY","termSource":"NCI"},{"termName":"MGD006","termGroup":"CN","termSource":"NCI"},{"termName":"RES234","termGroup":"CN","termSource":"NCI"},{"termName":"S80880","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1664355-28-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0AHT0IC02G"},{"name":"Maps_To","value":"Flotetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"763236"},{"name":"NCI_META_CUI","value":"CL474112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763236"},{"name":"PDQ_Open_Trial_Search_ID","value":"763236"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C504":{"preferredName":"Floxuridine","code":"C504","definitions":[{"definition":"A drug used in the treatment of cancer. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Floxuridine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"2'-Deoxy-5-fluorouridine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Deoxy-5-fluorouridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-2'-deoxy-beta-uridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-2'-deoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorodeoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorouracil Deoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorouridine Deoxyribose","termGroup":"SN","termSource":"NCI"},{"termName":"5-FUdR","termGroup":"AB","termSource":"NCI"},{"termName":"FDUR","termGroup":"AB","termSource":"NCI"},{"termName":"Floxuridin","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorodeoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouridine Deoxyribose","termGroup":"SY","termSource":"NCI"},{"termName":"Fluoruridine Deoxyribose","termGroup":"SY","termSource":"NCI"},{"termName":"FUdR","termGroup":"AB","termSource":"NCI"},{"termName":"WR-138720","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastrointestinal adenocarcinoma metastatic to the liver"},{"name":"CAS_Registry","value":"50-91-9"},{"name":"CHEBI_ID","value":"CHEBI:60761"},{"name":"Chemical_Formula","value":"C9H11FN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"039LU44I5M"},{"name":"Legacy Concept Name","value":"Floxuridine"},{"name":"Maps_To","value":"Floxuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39242"},{"name":"NSC Number","value":"27640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39242"},{"name":"PDQ_Open_Trial_Search_ID","value":"39242"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016343"}]}}{"C137988":{"preferredName":"FLT3 Inhibitor FF-10101 Succinate","code":"C137988","definitions":[{"definition":"The succinate salt form of FF-10101, a FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) inhibitor, with potential antineoplastic activity. Upon administration of FLT3 inhibitor FF-10101 succinate (FF-10101-01), FF-10101 irreversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3 Inhibitor FF-10101 Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"FF-10101 Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"FF-10101-01","termGroup":"CN","termSource":"NCI"},{"termName":"FF10101 Succinate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3 Inhibitor FF-10101 Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"790705"},{"name":"NCI_META_CUI","value":"CL524957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790705"},{"name":"PDQ_Open_Trial_Search_ID","value":"790705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165254":{"preferredName":"Tuspetinib","code":"C165254","definitions":[{"definition":"A selective, reversible type I inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) with potential antineoplastic activity. Upon administration, tuspetinib reversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuspetinib","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3 Inhibitor HM43239","termGroup":"SY","termSource":"NCI"},{"termName":"FMS-like Tyrosine Kinase 3 Inhibitor HM43239","termGroup":"SY","termSource":"NCI"},{"termName":"HM 43239","termGroup":"CN","termSource":"NCI"},{"termName":"HM-43239","termGroup":"CN","termSource":"NCI"},{"termName":"HM43239","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2294874-49-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C0WUS7XXE9"},{"name":"Maps_To","value":"FLT3 Inhibitor HM43239"},{"name":"NCI_Drug_Dictionary_ID","value":"799742"},{"name":"NCI_META_CUI","value":"CL978555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799742"},{"name":"PDQ_Open_Trial_Search_ID","value":"799742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155773":{"preferredName":"Denfivontinib Hydrochloride","code":"C155773","definitions":[{"definition":"The hydrochloride salt form of denfivontinib, an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, denfivontinib binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, denfivontinib also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denfivontinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3 Inhibitor SKI-G-801","termGroup":"SY","termSource":"NCI"},{"termName":"FLT3 Kinase Inhibitor SKI-G-801","termGroup":"SY","termSource":"NCI"},{"termName":"FLT3 Tyrosine Kinase Inhibitor SKI-G-801","termGroup":"SY","termSource":"NCI"},{"termName":"G-749 HCl Salt","termGroup":"SY","termSource":"NCI"},{"termName":"G-749 Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"G-801","termGroup":"CN","termSource":"NCI"},{"termName":"SKI-G-801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1457983-33-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01ZQ25VJAL"},{"name":"Maps_To","value":"FLT3 Inhibitor SKI-G-801"},{"name":"NCI_Drug_Dictionary_ID","value":"794986"},{"name":"NCI_META_CUI","value":"CL556252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794986"},{"name":"PDQ_Open_Trial_Search_ID","value":"794986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123362":{"preferredName":"FLT3 Tyrosine Kinase Inhibitor TTT-3002","code":"C123362","definitions":[{"definition":"An orally bioavailable indolocarbazole derivative and inhibitor of constitutively active mutant forms of FMS-like tyrosine kinase 3 (FLT3) with potential antineoplastic activity. Following administration, FLT3 tyrosine kinase inhibitor TTT-3002 binds to and inhibits ligand-dependent dimerization and autophosphorylation of mutant forms of FLT3 with constitutively activating mutations, including FLT3 internal tandem duplication (FLT3/ITD) and the activating point mutation D835Y. Prevention of autophosphorylation inhibits uncontrolled FLT3 signaling and may result in the inhibition of proliferation in tumor cells expressing constitutively active mutant forms of FLT3. The ability of TTT-3002 to inhibit FLT3 proteins with activating point mutations may result in increased efficacy because the activity of these mutants are resistant to other FLT3 kinase inhibitors. FLT3, a tyrosine kinase receptor, plays a role in the regulation of hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. Constitutively activating mutations of FLT3 are the most frequent genetic alterations in acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3 Tyrosine Kinase Inhibitor TTT-3002","termGroup":"PT","termSource":"NCI"},{"termName":"TTT-3002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3 Tyrosine Kinase Inhibitor TTT-3002"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3850293"}]}}{"C116858":{"preferredName":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449","code":"C116858","definitions":[{"definition":"An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential antineoplastic activity. Upon administration, FLT3/ABL/Aurora kinase inhibitor KW-2449 specifically binds to and inhibits both wild-type and mutated forms of FLT3, ABL and aurora kinases, which both interferes with the activation of signal transduction pathways mediated by these kinases and reduces the proliferation of susceptible cancer cells. FLT3 and ABL kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis. Aurora kinases, serine-threonine kinases overexpressed by a wide variety of cancer cell types, play essential roles in mitotic checkpoint control.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449","termGroup":"PT","termSource":"NCI"},{"termName":"KW-2449","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"841258-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2D9N67F58G"},{"name":"Maps_To","value":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449"},{"name":"NCI_Drug_Dictionary_ID","value":"496931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496931"},{"name":"PDQ_Open_Trial_Search_ID","value":"496931"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831922"}]}}{"C120209":{"preferredName":"FLT3/CDK4/6 Inhibitor FLX925","code":"C120209","definitions":[{"definition":"An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2) and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, FLT3/CDK4/6 inhibitor FLX925 specifically binds to and inhibits FLT3, which interferes with the activation of FLT3-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress FLT3. In addition FLX925 inhibits CDK4 and 6 and prevents the phosphorylation of retinoblastoma (Rb) protein in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, which causes G1 phase cell cycle arrest, suppresses DNA synthesis and inhibits cancer cell growth. FLT3, a class III tyrosine kinase receptor, is overexpressed in a variety of cancers. Overexpression of CDK4/6, which is seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/CDK4/6 Inhibitor FLX925","termGroup":"PT","termSource":"NCI"},{"termName":"FLX925","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3/CDK4/6 Inhibitor FLX925"},{"name":"NCI_Drug_Dictionary_ID","value":"768269"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768269"},{"name":"PDQ_Open_Trial_Search_ID","value":"768269"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896859"}]}}{"C101520":{"preferredName":"FLT3/KIT Kinase Inhibitor AKN-028","code":"C101520","definitions":[{"definition":"An orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/KIT Kinase Inhibitor AKN-028","termGroup":"PT","termSource":"NCI"},{"termName":"AKN-028","termGroup":"CN","termSource":"NCI"},{"termName":"BVT-II","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1175017-90-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y66IS3CS0R"},{"name":"Maps_To","value":"FLT3/KIT Kinase Inhibitor AKN-028"},{"name":"NCI_Drug_Dictionary_ID","value":"731885"},{"name":"PDQ_Closed_Trial_Search_ID","value":"731885"},{"name":"PDQ_Open_Trial_Search_ID","value":"731885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852612"}]}}{"C151407":{"preferredName":"Flt3/MerTK Inhibitor MRX-2843","code":"C151407","definitions":[{"definition":"An orally bioavailable inhibitor of two receptor tyrosine kinases (RTKs), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2) and tyrosine-protein kinase Mer (MerTK; proto-oncogene c-Mer; Mer), with potential antineoplastic activity. Upon administration, MRX-2843 targets and binds to both Flt3 and MerTK. This prevents ligand-dependent phosphorylation and activation of Flt3 and MerTK, which inhibits the activation of their downstream signaling pathways. This induces apoptosis and inhibits proliferation of Flt3- and/or MerTK-overexpressing tumor cells. Flt3 and MerTK, are overexpressed in certain tumor cell types and play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flt3/MerTK Inhibitor MRX-2843","termGroup":"PT","termSource":"NCI"},{"termName":"MRX 2843","termGroup":"SY","termSource":"NCI"},{"termName":"MRX-2843","termGroup":"CN","termSource":"NCI"},{"termName":"MRX2843","termGroup":"CN","termSource":"NCI"},{"termName":"UNC-2371A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429882-07-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2MT30EHI63"},{"name":"Maps_To","value":"Flt3/MerTK Inhibitor MRX-2843"},{"name":"NCI_Drug_Dictionary_ID","value":"793562"},{"name":"NCI_META_CUI","value":"CL553239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793562"},{"name":"PDQ_Open_Trial_Search_ID","value":"793562"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1094":{"preferredName":"Fludarabine","code":"C1094","definitions":[{"definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat B-cell chronic lymphocytic leukemia (CLL) that has not responded to treatment with other anticancer drugs or that has gotten worse. Fludarabine blocks cells from making DNA and may kill cancer cells. It is a type of purine antagonist and a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fludarabine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-9-beta-arabinofuranosyladenine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Fluorovidarabine","termGroup":"SN","termSource":"NCI"},{"termName":"9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"9-Beta-D-arabinofuranosyl-2-fluoroadenine","termGroup":"SN","termSource":"NCI"},{"termName":"Fluradosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute nonlymphocytic leukemia; Chronic lymphocytic leukemia; Indolent Non - Hodkins Lymphoma"},{"name":"CAS_Registry","value":"21679-14-1"},{"name":"Chemical_Formula","value":"C10H12FN5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"P2K93U8740"},{"name":"Legacy Concept Name","value":"Fludarabine"},{"name":"Maps_To","value":"Fludarabine"},{"name":"NSC Number","value":"118218"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059985"}]}}{"C1102":{"preferredName":"Fludarabine Phosphate","code":"C1102","definitions":[{"definition":"A drug used to treat B-cell chronic lymphocytic leukemia (CLL) that has not responded to treatment with other anticancer drugs or that has gotten worse. It is also being studied in the treatment of other types of cancer. Fludara blocks cells from making DNA and may kill cancer cells. It is a type of purine antagonist and a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fludarabine Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"2-F-ara-AMP","termGroup":"AB","termSource":"NCI"},{"termName":"9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Beneflur","termGroup":"FB","termSource":"NCI"},{"termName":"Fludara","termGroup":"AQS","termSource":"NCI"},{"termName":"Fludarabine-5'-Monophosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Oforta","termGroup":"AQS","termSource":"NCI"},{"termName":"SH T 586","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Lymphocytic Leukemia"},{"name":"CAS_Registry","value":"75607-67-9"},{"name":"CHEBI_ID","value":"CHEBI:63599"},{"name":"Chemical_Formula","value":"C10H13FN5O7P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1X9VK9O1SC"},{"name":"Legacy Concept Name","value":"Fludarabine_Phosphate"},{"name":"Maps_To","value":"Fludarabine Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"486428"},{"name":"NSC Number","value":"312887"},{"name":"NSC Number","value":"328002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486428"},{"name":"PDQ_Open_Trial_Search_ID","value":"486428"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060483"}]}}{"C138991":{"preferredName":"Flumbatinib","code":"C138991","definitions":[{"definition":"An orally bioavailable tyrosine kinase inhibitor, with potential antineoplastic activity. Upon administration, flumbatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flumbatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Flumatinib","termGroup":"SY","termSource":"NCI"},{"termName":"HH-GV-678","termGroup":"CN","termSource":"NCI"},{"termName":"HH-GV678","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"895519-90-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R4009Y24AI"},{"name":"Maps_To","value":"Flumatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"763682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763682"},{"name":"PDQ_Open_Trial_Search_ID","value":"763682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3888332"}]}}{"C117723":{"preferredName":"Flumatinib Mesylate","code":"C117723","definitions":[{"definition":"The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flumatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide Mesylate","termGroup":"SN","termSource":"NCI"},{"termName":"HH-GV-678 Mesylate","termGroup":"CN","termSource":"NCI"},{"termName":"HH-GV678 Mesylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"895519-91-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"95Y8L63NBC"},{"name":"Maps_To","value":"Flumatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"763682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763682"},{"name":"PDQ_Open_Trial_Search_ID","value":"763682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2973571"}]}}{"C29042":{"preferredName":"Fluorodopan","code":"C29042","definitions":[{"definition":"An alkylating agent with potential antineoplastic activity.  Fluorodopan alkylates DNA at the N7 position of guanine.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorodopan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"834-91-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O1EXJ975PT"},{"name":"Legacy Concept Name","value":"Fluorodopan"},{"name":"Maps_To","value":"Fluorodopan"},{"name":"NSC Number","value":"73754"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060560"}]}}{"C505":{"preferredName":"Fluorouracil","code":"C505","definitions":[{"definition":"A drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorouracil","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Dioxo-5-fluoropyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"5 Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"5 Fluorouracilum","termGroup":"SY","termSource":"NCI"},{"termName":"5 FU","termGroup":"AB","termSource":"NCI"},{"termName":"5-Fluoro-2,4(1H,3H)-pyrimidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"5-Fluracil","termGroup":"SY","termSource":"NCI"},{"termName":"5-FU","termGroup":"AB","termSource":"NCI"},{"termName":"5FU","termGroup":"AB","termSource":"NCI"},{"termName":"AccuSite","termGroup":"FB","termSource":"NCI"},{"termName":"Adrucil","termGroup":"AQS","termSource":"NCI"},{"termName":"Carac","termGroup":"BR","termSource":"NCI"},{"termName":"Fluoro Uracil","termGroup":"SY","termSource":"NCI"},{"termName":"Fluouracil","termGroup":"SY","termSource":"NCI"},{"termName":"Flurablastin","termGroup":"FB","termSource":"NCI"},{"termName":"Fluracedyl","termGroup":"FB","termSource":"NCI"},{"termName":"Fluracil","termGroup":"FB","termSource":"NCI"},{"termName":"Fluril","termGroup":"FB","termSource":"NCI"},{"termName":"Fluroblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Ribofluor","termGroup":"FB","termSource":"NCI"},{"termName":"Ro-2-9757","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Palliative treatment: Colorectal cancer, Breast cancer, Stomach cancer, Pancreatic cancer. Topical treatment for the following: Superficial basal cell carcinoma that cannot be treated with surgery, and Actinic keratosis."},{"name":"CAS_Registry","value":"51-21-8"},{"name":"CHEBI_ID","value":"CHEBI:46345"},{"name":"Chemical_Formula","value":"C4H3FN2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U3P01618RT"},{"name":"Legacy Concept Name","value":"Fluorouracil"},{"name":"Maps_To","value":"Fluorouracil"},{"name":"NCI_Drug_Dictionary_ID","value":"43130"},{"name":"NSC Number","value":"19893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43130"},{"name":"PDQ_Open_Trial_Search_ID","value":"43130"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016360"}]}}{"C90544":{"preferredName":"Fluorouracil Implant","code":"C90544","definitions":[{"definition":"An implant containing a sustained release particle of fluorouracil, an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine, with antineoplastic activity. Upon implantation and subsequent release, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with the pyrimidine uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and thus DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorouracil Implant","termGroup":"PT","termSource":"NCI"},{"termName":"Sinofuan","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fluorouracil Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"665364"},{"name":"NCI_META_CUI","value":"CL416225"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665364"},{"name":"PDQ_Open_Trial_Search_ID","value":"665364"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C17877":{"preferredName":"Fluorouracil-E Therapeutic Implant","code":"C17877","definitions":[{"definition":"An injectable collagen matrix gel containing the antimetabolite fluorouracil and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and, so, DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into tumor tissue and reduce dispersion to surrounding tissues, thus enhancing the local concentration of fluorouracil. Compared to systemic administration, the intratumoral injection of fluorouracil combined with epinephrine may increase fluorouracil's chemotherapeutic efficacy while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorouracil-E Therapeutic Implant","termGroup":"PT","termSource":"NCI"},{"termName":"5-Fluorouracil/epi","termGroup":"SY","termSource":"NCI"},{"termName":"5-FU-e TI","termGroup":"SY","termSource":"NCI"},{"termName":"5-FU/epi gel","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouracil-E Therapeutic Implant","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouracil-epinephrine therapeutic implant","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouracil/epi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fluorouracil-E_Therapeutic_Implant"},{"name":"Maps_To","value":"Fluorouracil-E Therapeutic Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"41859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41859"},{"name":"PDQ_Open_Trial_Search_ID","value":"41859"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281426"}]}}{"C507":{"preferredName":"Fluoxymesterone","code":"C507","definitions":[{"definition":"A halogenated derivative of 17-alpha-methyltestosterone.  Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus.  This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluoxymesterone","termGroup":"PT","termSource":"NCI"},{"termName":"(11Beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"11Beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"9Alpha-fluoro-11beta-hydroxy-17alpha-methyltestosterone","termGroup":"SN","termSource":"NCI"},{"termName":"Androfluorene","termGroup":"SY","termSource":"NCI"},{"termName":"Android-F","termGroup":"BR","termSource":"NCI"},{"termName":"Androsterolo","termGroup":"SY","termSource":"NCI"},{"termName":"Androxy","termGroup":"BR","termSource":"NCI"},{"termName":"FXM","termGroup":"AB","termSource":"NCI"},{"termName":"Halodrin","termGroup":"BR","termSource":"NCI"},{"termName":"Halotestin","termGroup":"BR","termSource":"NCI"},{"termName":"Ora-Testryl","termGroup":"BR","termSource":"NCI"},{"termName":"Oratestin","termGroup":"FB","termSource":"NCI"},{"termName":"Stenox","termGroup":"FB","termSource":"NCI"},{"termName":"Testoral","termGroup":"FB","termSource":"NCI"},{"termName":"Ultandren","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"76-43-7"},{"name":"CHEBI_ID","value":"CHEBI:5120"},{"name":"Chemical_Formula","value":"C20H29FO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9JU12S4YFY"},{"name":"Legacy Concept Name","value":"Fluoxymesterone"},{"name":"Maps_To","value":"Fluoxymesterone"},{"name":"NCI_Drug_Dictionary_ID","value":"494707"},{"name":"NSC Number","value":"12165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"494707"},{"name":"PDQ_Open_Trial_Search_ID","value":"494707"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016366"}]}}{"C509":{"preferredName":"Flutamide","code":"C509","definitions":[{"definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of antiandrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Flutamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Nitro-3'-trifluoromethylisobutyranilide","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha,alpha,alpha-trifluoro-2-methy-4'-nitro-m-propionotoluidide","termGroup":"SN","termSource":"NCI"},{"termName":"Apimid","termGroup":"FB","termSource":"NCI"},{"termName":"Cebatrol","termGroup":"FB","termSource":"NCI"},{"termName":"Chimax","termGroup":"FB","termSource":"NCI"},{"termName":"Cytomid","termGroup":"FB","termSource":"NCI"},{"termName":"Drogenil","termGroup":"FB","termSource":"NCI"},{"termName":"Euflex","termGroup":"FB","termSource":"NCI"},{"termName":"Eulexin","termGroup":"AQS","termSource":"NCI"},{"termName":"Eulexine","termGroup":"FB","termSource":"NCI"},{"termName":"Flucinom","termGroup":"SY","termSource":"NCI"},{"termName":"Flucinome","termGroup":"FB","termSource":"NCI"},{"termName":"Flugerel","termGroup":"SY","termSource":"NCI"},{"termName":"Fluken","termGroup":"FB","termSource":"NCI"},{"termName":"Flulem","termGroup":"FB","termSource":"NCI"},{"termName":"FLUT","termGroup":"AB","termSource":"NCI"},{"termName":"Fluta-Gry","termGroup":"FB","termSource":"NCI"},{"termName":"Flutabene","termGroup":"FB","termSource":"NCI"},{"termName":"Flutacan","termGroup":"FB","termSource":"NCI"},{"termName":"Flutamex","termGroup":"FB","termSource":"NCI"},{"termName":"Flutamin","termGroup":"FB","termSource":"NCI"},{"termName":"Flutan","termGroup":"FB","termSource":"NCI"},{"termName":"Flutaplex","termGroup":"FB","termSource":"NCI"},{"termName":"Fugerel","termGroup":"FB","termSource":"NCI"},{"termName":"Grisetin","termGroup":"FB","termSource":"NCI"},{"termName":"Niftolide","termGroup":"SY","termSource":"NCI"},{"termName":"Oncosal","termGroup":"FB","termSource":"NCI"},{"termName":"Profamid","termGroup":"FB","termSource":"NCI"},{"termName":"Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"Prostacur","termGroup":"FB","termSource":"NCI"},{"termName":"Prostadirex","termGroup":"FB","termSource":"NCI"},{"termName":"Prostica","termGroup":"FB","termSource":"NCI"},{"termName":"Prostogenat","termGroup":"FB","termSource":"NCI"},{"termName":"SCH 13521","termGroup":"CN","termSource":"NCI"},{"termName":"Tafenil","termGroup":"FB","termSource":"NCI"},{"termName":"Tecnoflut","termGroup":"FB","termSource":"NCI"},{"termName":"Testotard","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hirsutism; Prostate carcinoma"},{"name":"CAS_Registry","value":"13311-84-7"},{"name":"CHEBI_ID","value":"CHEBI:5132"},{"name":"Chemical_Formula","value":"C11H11F3N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"76W6J0943E"},{"name":"Legacy Concept Name","value":"Flutamide"},{"name":"Maps_To","value":"Flutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39811"},{"name":"NSC Number","value":"147834"},{"name":"NSC Number","value":"215876"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39811"},{"name":"PDQ_Open_Trial_Search_ID","value":"39811"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016384"}]}}{"C61768":{"preferredName":"Fluvastatin","code":"C61768","definitions":[{"definition":"A synthetic lipid-lowering agent with antilipidemic and potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated antigen-presenting cells such as human vascular endothelial cells. Due to its anti-inflammatory effects mediated by alterations of lipid metabolism, fluvastatin may possess chemopreventive and therapeutic antineoplastic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluvastatin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93957-54-1"},{"name":"CHEBI_ID","value":"CHEBI:38561"},{"name":"CHEBI_ID","value":"CHEBI:5136"},{"name":"Chemical_Formula","value":"C24H26FNO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4L066368AS"},{"name":"Legacy Concept Name","value":"Fluvastatin"},{"name":"Maps_To","value":"Fluvastatin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0082608"}]}}{"C29062":{"preferredName":"Fluvastatin Sodium","code":"C29062","definitions":[{"definition":"The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic activity. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Through the inhibition of mevalonate synthesis, statins, like fluvastatin, have been shown to inhibit the production of dolichol, geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP) and the isoprenylation of the intracellular G-proteins Ras and Rho, which may result in antiangiogenic, apoptotic, and antimetastatic effects in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluvastatin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,5S,6E)-(+/-)-7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Lescol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93957-55-2"},{"name":"Chemical_Formula","value":"C24H25FNO4.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PYF7O1FV7F"},{"name":"Legacy Concept Name","value":"Fluvastatin_Sodium"},{"name":"Maps_To","value":"Fluvastatin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"487588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487588"},{"name":"PDQ_Open_Trial_Search_ID","value":"487588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0246203"}]}}{"C126274":{"preferredName":"Fuzuloparib","code":"C126274","definitions":[{"definition":"An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration, fuzuloparib inhibits PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks, promotes genomic instability, and leads to an induction of apoptosis. The PARP family of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fuzuloparib","termGroup":"PT","termSource":"NCI"},{"termName":"4-((3-((5,6-Dihydro-2-(trifluoromethyl)(1,2,4)triazolo(1,5-a)pyrazin-7(8H)-yl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinone","termGroup":"SY","termSource":"NCI"},{"termName":"AiRuiYi","termGroup":"BR","termSource":"NCI"},{"termName":"Fluzoparib","termGroup":"SY","termSource":"NCI"},{"termName":"SHR-3162","termGroup":"CN","termSource":"NCI"},{"termName":"SHR3162","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1358715-18-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TWF0ML1CK8"},{"name":"Maps_To","value":"Fluzoparib"},{"name":"NCI_Drug_Dictionary_ID","value":"779303"},{"name":"NCI_META_CUI","value":"CL504851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779303"},{"name":"PDQ_Open_Trial_Search_ID","value":"779303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101519":{"preferredName":"Edicotinib","code":"C101519","definitions":[{"definition":"A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. Edicotinib blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS can not activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells. FMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation, recruitment, and activation as well as the regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edicotinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Imidazole-2-carboxamide, 5-Cyano-N-(2-(4,4-dimethyl-1-cyclohexen-1-yl)-6-(tetrahydro-2,2,6,6-tetramethyl-2H-pyran-4-yl)-3-pyridinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyl-tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"JNJ-40346527","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1142363-52-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3NU609VYNF"},{"name":"Maps_To","value":"Edicotinib"},{"name":"Maps_To","value":"FMS Inhibitor JNJ-40346527"},{"name":"NCI_Drug_Dictionary_ID","value":"730665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730665"},{"name":"PDQ_Open_Trial_Search_ID","value":"730665"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640124"}]}}{"C105804":{"preferredName":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate","code":"C105804","definitions":[{"definition":"The tosylate salt form of PLX7486, a selective inhibitor of the receptor tyrosine kinases colony-stimulating factor-1 receptor (CSF1R; fms) and neurotrophic tyrosine kinase receptor types 1, 2 and 3 (TrkA, TrkB, and TrkC, respectively) with potential antineoplastic activity. Upon administration, PLX7486 binds to and inhibits the activity of these tyrosine kinases. This inhibits Fms and Trk-mediated signaling transduction pathways that are upregulated in certain cancer cell types. This may eventually halt tumor cell proliferation in Fms and TrkA, TrkB, and/or TrkC-overexpressing tumor cells. Fms and TrkA, TrkB, and TrkC are receptor tyrosine kinases that are upregulated or mutated in a variety of tumors and promote tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"PLX7486-TsOH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"747694"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747694"},{"name":"PDQ_Open_Trial_Search_ID","value":"747694"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3830093"}]}}{"C71524":{"preferredName":"Folate Receptor Targeted Epothilone BMS753493","code":"C71524","definitions":[{"definition":"A folate receptor-targeting antimitotic agent with potential antineoplastic activity. Folate receptor-targeted epothilone BMS753493 contains an epothilone moiety linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the antimitotic epothilone component into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the epothilone moiety induces microtubule polymerization and stabilizes microtubules against depolymerization, resulting in the inhibition of mitosis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor Targeted Epothilone BMS753493","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Folate_Receptor-Targeted_Epothilone_BMS753493"},{"name":"Maps_To","value":"Folate Receptor Targeted Epothilone BMS753493"},{"name":"NCI_Drug_Dictionary_ID","value":"575735"},{"name":"NCI_META_CUI","value":"CL376231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575735"},{"name":"PDQ_Open_Trial_Search_ID","value":"575735"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113176":{"preferredName":"Folate Receptor-Targeted Tubulysin Conjugate EC1456","code":"C113176","definitions":[{"definition":"An injectable targeted small molecule drug conjugate (SMDC) consisting of folate (vitamin B9) covalently linked to the potent mitotic poison and cytotoxic agent, tubulysin B hydrazide (Tub-B-H) with potential antineoplastic activity. Upon administration, the folate moiety of folate receptor-targeted tubulysin conjugate EC1456 preferentially binds to tumor cells expressing folate receptors (FR). After binding to FR, the agent is internalized by tumor cells and the Tub-B-H moiety inhibits the polymerization of tubulin into microtubules. This may lead to both cell cycle arrest and tumor cell apoptosis. FR, the membrane-bound, high-affinity receptor for folate, is overexpressed on a wide range of primary and metastatic human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor-Targeted Tubulysin Conjugate EC1456","termGroup":"PT","termSource":"NCI"},{"termName":"EC1456","termGroup":"CN","termSource":"NCI"},{"termName":"Folate Receptor-Targeting Folate-Tubulysin Conjugate EC1456","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Folate Receptor-Targeted Tubulysin Conjugate EC1456"},{"name":"NCI_Drug_Dictionary_ID","value":"755557"},{"name":"NCI_META_CUI","value":"CL455247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755557"},{"name":"PDQ_Open_Trial_Search_ID","value":"755557"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C81935":{"preferredName":"Folate Receptor-Targeted Vinca Alkaloid EC0489","code":"C81935","definitions":[{"definition":"A folate receptor-targeting cytotoxic drug conjugate consisting of a folate vitamin analogue linked to a vinca alkaloid microtubule destabilizing agent with potential antineoplastic activity. Mediated through its folate moiety, folate receptor-targeted vinca alkaloid EC0489 delivers the cytotoxic vinca alkaloid moiety directly to cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. The relative tumor cell specificity of this agent reduces the toxicity profile of its vinca alkaloid moiety.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor-Targeted Vinca Alkaloid EC0489","termGroup":"PT","termSource":"NCI"},{"termName":"EC0489","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Folate_Receptor_Targeted-Microtubule_Destabilizing_Agent_EC0489"},{"name":"Maps_To","value":"Folate Receptor-Targeted Vinca Alkaloid EC0489"},{"name":"NCI_Drug_Dictionary_ID","value":"638649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638649"},{"name":"PDQ_Open_Trial_Search_ID","value":"638649"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830054"}]}}{"C66987":{"preferredName":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225","code":"C66987","definitions":[{"definition":"A folate receptor-targeting cytotoxic agent with potential antineoplastic activity. Folate receptor-targeted vinca alkaloid/mitomycin C EC0225 contains two potent cytotoxic agents, a vinca alkaloid and mitomycin C, linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the cytotoxic agents directly into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. Mitomycin C alkylates DNA, producing DNA cross-links and inhibiting DNA replication. The relative tumor cell specificity of EC0225 reduces the toxicity profiles of its cytotoxic agent moieties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225","termGroup":"PT","termSource":"NCI"},{"termName":"EC0225","termGroup":"CN","termSource":"NCI"},{"termName":"Folate Linked Vinca Alkaloid/Mitomycin C EC0225","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EC0225"},{"name":"Maps_To","value":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225"},{"name":"NCI_Drug_Dictionary_ID","value":"539691"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539691"},{"name":"PDQ_Open_Trial_Search_ID","value":"539691"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880433"}]}}{"C62479":{"preferredName":"Folate-FITC","code":"C62479","definitions":[{"definition":"A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate-FITC","termGroup":"PT","termSource":"NCI"},{"termName":"EC-17","termGroup":"CN","termSource":"NCI"},{"termName":"EC17","termGroup":"AB","termSource":"NCI"},{"termName":"Folate Fluorescein Isothiocyanate Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"L-glutamine, N2-(4-(((2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-n-(2-((((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3h),9'-(9h)xanthen)-5-yl)amino)thioxomethyl)amino)ethyl)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"583037-91-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7YQ6134AE"},{"name":"Legacy Concept Name","value":"EC17"},{"name":"Maps_To","value":"Folate-FITC"},{"name":"NCI_Drug_Dictionary_ID","value":"489286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489286"},{"name":"PDQ_Open_Trial_Search_ID","value":"489286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831885"}]}}{"C510":{"preferredName":"Folic Acid","code":"C510","definitions":[{"definition":"A collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. As a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Folate helps to make red blood cells. It is found in whole-grain breads and cereals, liver, green vegetables, orange juice, lentils, beans, and yeast. Folate is water-soluble (can dissolve in water) and must be taken in every day. Not enough folate can cause anemia (a condition in which the number of red blood cells is below normal), diseases of the heart and blood vessels, and defects in the brain and spinal cord in a fetus. Folate is being studied with vitamin B12 in the prevention and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Synthetic folate in fortified foods and supplements containing a single glutamate molecule.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Folic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid","termGroup":"SY","termSource":"NCI"},{"termName":"FA","termGroup":"AB","termSource":"NCI"},{"termName":"Ffolate","termGroup":"SY","termSource":"NCI"},{"termName":"Folacin","termGroup":"SY","termSource":"NCI"},{"termName":"N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid","termGroup":"SN","termSource":"NCI"},{"termName":"N-[4-[[(2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Vitamin B9","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin Bc","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59-30-3"},{"name":"CHEBI_ID","value":"CHEBI:27470"},{"name":"Chemical_Formula","value":"C19H19N7O6"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"935E97BOY8"},{"name":"INFOODS","value":"FOLAC"},{"name":"Legacy Concept Name","value":"Folic_Acid"},{"name":"Maps_To","value":"Folic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"39641"},{"name":"NSC Number","value":"3073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39641"},{"name":"PDQ_Open_Trial_Search_ID","value":"39641"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"Tolerable_Level","value":"Y"},{"name":"UMLS_CUI","value":"C0016410"},{"name":"Unit","value":"mcg"},{"name":"US_Recommended_Intake","value":"Y* (*for women of childbearing age)"},{"name":"USDA_ID","value":"431"}]}}{"C61304":{"preferredName":"Folitixorin","code":"C61304","definitions":[{"definition":"A folate-based biomodulator with potential antineoplastic activity. 5,10-methylenetetrahydrofolate (MTHF) stabilizes the covalent binding of the fluorouracil metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP) to its target enzyme, thymidylate synthase, which results in inhibition of thymidylate synthase, depletion of thymidine triphosphate (TTP), a necessary constituent of DNA, and tumor cell death. Unlike leucovorin, MTHF, as the active form of folate, does not require metabolic activation and may increase the chemotherapeutic effects of fluorouracil with lower toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folitixorin","termGroup":"PT","termSource":"NCI"},{"termName":"5,10-methylene-5,6,7,8-tetrahydrofolic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5,10-Methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"CoFactor","termGroup":"BR","termSource":"NCI"},{"termName":"N-(4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Tetrahydromethylenefolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3432-99-3"},{"name":"CHEBI_ID","value":"CHEBI:1989"},{"name":"Chemical_Formula","value":"C20H23N7O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0SXY5ET48B"},{"name":"Legacy Concept Name","value":"_5_10-Methylenetetrahydrofolate"},{"name":"Maps_To","value":"Folitixorin"},{"name":"NCI_Drug_Dictionary_ID","value":"405875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"405875"},{"name":"PDQ_Open_Trial_Search_ID","value":"405875"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048858"}]}}{"C80058":{"preferredName":"Foretinib","code":"C80058","definitions":[{"definition":"A substance being studied in the treatment of cancer. Foretinib blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foretinib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1363089","termGroup":"CN","termSource":"NCI"},{"termName":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","termGroup":"SY","termSource":"NCI"},{"termName":"N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"XL880","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849217-64-7"},{"name":"Chemical_Formula","value":"C34H34F2N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81FH7VK1C4"},{"name":"Legacy Concept Name","value":"Multitargeted_Tyrosine_Kinase_Inhibitor_GSK1363089"},{"name":"Maps_To","value":"Foretinib"},{"name":"NCI_Drug_Dictionary_ID","value":"428188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"428188"},{"name":"PDQ_Open_Trial_Search_ID","value":"428188"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698272"}]}}{"C974":{"preferredName":"Formestane","code":"C974","definitions":[{"definition":"A synthetic steroidal substance with antineoplastic activity.  Formestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formestane","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hydroxyandrost-4-ene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hydroxyandrostenedione","termGroup":"SY","termSource":"NCI"},{"termName":"4-OHA","termGroup":"AB","termSource":"NCI"},{"termName":"4-OHAD","termGroup":"AB","termSource":"NCI"},{"termName":"CGP-32349","termGroup":"CN","termSource":"NCI"},{"termName":"Lentaron","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"566-48-3"},{"name":"Chemical_Formula","value":"C19H26O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PUB9T8T355"},{"name":"Legacy Concept Name","value":"Formestane"},{"name":"Maps_To","value":"Formestane"},{"name":"NCI_Drug_Dictionary_ID","value":"41766"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41766"},{"name":"PDQ_Open_Trial_Search_ID","value":"41766"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048306"}]}}{"C26655":{"preferredName":"Forodesine Hydrochloride","code":"C26655","definitions":[{"definition":"A substance being studied in the treatment of some types of leukemia and lymphoma. It is a type of purine nucleoside phosphorylase (PNP) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the synthetic high-affinity transition-state analogue forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes. A transition state analogue is a substrate designed to mimic the properties or the geometry of the transition state of reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Forodesine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BCX-1777","termGroup":"CN","termSource":"NCI"},{"termName":"Fodosine","termGroup":"FB","termSource":"NCI"},{"termName":"Immucillin-H","termGroup":"SY","termSource":"NCI"},{"termName":"Mundesine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"284490-13-7"},{"name":"Chemical_Formula","value":"C11H14N4O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SN82Y9U73"},{"name":"Legacy Concept Name","value":"Immucillin-H"},{"name":"Maps_To","value":"Forodesine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"301648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301648"},{"name":"PDQ_Open_Trial_Search_ID","value":"301648"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1175653"}]}}{"C72787":{"preferredName":"Fosaprepitant","code":"C72787","definitions":[{"definition":"A water-soluble, N-phosphorylated prodrug of the substance P (SP; neurokinin 1 (NK1)) antagonist aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent selectively binds to and blocks the human substance P receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosaprepitant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"172673-20-0"},{"name":"CHEBI_ID","value":"CHEBI:64321"},{"name":"Chemical_Formula","value":"C23H22F7N4O6P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6L8OF9XRDC"},{"name":"Legacy Concept Name","value":"Fosaprepitant"},{"name":"Maps_To","value":"Fosaprepitant"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2349941"}]}}{"C82378":{"preferredName":"Fosbretabulin","code":"C82378","definitions":[{"definition":"A water-soluble prodrug derived from the African bush willow (Combretum caffrum) with antineoplastic activity. Fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which binds to tubulin and inhibits microtubule polymerization, resulting in mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosbretabulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Combretastatin A-4 Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, Dihydrogen Phosphate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222030-63-9"},{"name":"Chemical_Formula","value":"C18H21O8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I5590ES2QZ"},{"name":"Legacy Concept Name","value":"Fosbretabulin"},{"name":"Maps_To","value":"Fosbretabulin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796467"}]}}{"C2503":{"preferredName":"Fosbretabulin Disodium","code":"C2503","definitions":[{"definition":"The disodium salt of a water-soluble phosphate derivative of a natural stilbenoid phenol derived from the African bush willow (Combretum caffrum) with potential vascular disrupting and antineoplastic activities. Upon administration, the prodrug fosbretabulin is dephosphorylated to its active metabolite, the microtubule-depolymerizing agent combretastatin A4, which binds to tubulin dimers and prevents microtubule polymerization, resulting in mitotic arrest and apoptosis in endothelial cells. In addition, this agent disrupts the engagement of the endothelial cell-specific junctional molecule vascular endothelial-cadherin (VE-cadherin) and so the activity of the VE-cadherin/beta-catenin/Akt signaling pathway, which may result in the inhibition of endothelial cell migration and capillary tube formation. As a result of fosbretabulin's dual mechanism of action, the tumor vasculature collapses, resulting in reduced tumor blood flow and ischemic necrosis of tumor tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosbretabulin Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl Disodium Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"CA4DP","termGroup":"CN","termSource":"NCI"},{"termName":"Combretastatin A4 Disodium Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, Dihydrogen Phosphate, Disodium Salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222030-63-9"},{"name":"Chemical_Formula","value":"C18H19O8P.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"702RHR475O"},{"name":"Legacy Concept Name","value":"Combretastatin_A4_Phosphate"},{"name":"Maps_To","value":"Fosbretabulin Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43316"},{"name":"PDQ_Open_Trial_Search_ID","value":"43316"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0962508"}]}}{"C83721":{"preferredName":"Fosbretabulin Tromethamine","code":"C83721","definitions":[{"definition":"The tromethamine salt form of prodrug fosbretabulin, a water-soluble phosphate derivative of a stilbenoid phenol derived from the African bush willow (Combretum caffrum) with antineoplastic activities. Upon administration, fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which targets and binds to tubulin dimers and prevents microtubule polymerization, thereby resulting in mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosbretabulin Tromethamine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Dihydroxy-2-(Hydroxymethyl)Propan-2-Aminium 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Hydrogen Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"1,3-Propanediol, 2-Amino-2-(Hydroxymethyl)-, Compd. With 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Dihydrogen Phosphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CA4P","termGroup":"AB","termSource":"NCI"},{"termName":"Zybrestat","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"404886-32-4"},{"name":"Chemical_Formula","value":"C18H21O8P.C4H11NO3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GBW044919E"},{"name":"Maps_To","value":"Fosbretabulin Tromethamine"},{"name":"NCI_Drug_Dictionary_ID","value":"696306"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696306"},{"name":"PDQ_Open_Trial_Search_ID","value":"696306"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827157"}]}}{"C123824":{"preferredName":"Foslinanib","code":"C123824","definitions":[{"definition":"An orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foslinanib","termGroup":"PT","termSource":"NCI"},{"termName":"4(1H)-Quinolinone, 2-(3-Fluorophenyl)-6-methoxy-5-(phosphonooxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"CVM 1118","termGroup":"CN","termSource":"NCI"},{"termName":"CVM-1118","termGroup":"CN","termSource":"NCI"},{"termName":"CVM1118","termGroup":"CN","termSource":"NCI"},{"termName":"TRX 818","termGroup":"CN","termSource":"NCI"},{"termName":"TRX-818","termGroup":"CN","termSource":"NCI"},{"termName":"TRX818","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10721","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256037-60-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2X2DNM7NGX"},{"name":"Maps_To","value":"Foslinanib"},{"name":"NCI_Drug_Dictionary_ID","value":"775625"},{"name":"NCI_META_CUI","value":"CL498218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775625"},{"name":"PDQ_Open_Trial_Search_ID","value":"775625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163994":{"preferredName":"Foslinanib Disodium","code":"C163994","definitions":[{"definition":"The disodium salt form of foslinanib, an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foslinanib Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"4(1H)-Quinolinone, 2-(3-Fluorophenyl)-6-methoxy-5-(phosphonooxy)-, Sodium Salt (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"CVM-1118 Disodium","termGroup":"SY","termSource":"NCI"},{"termName":"TRX-818","termGroup":"CN","termSource":"NCI"},{"termName":"TRX818 Disodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256037-62-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8X5F5LAF7B"},{"name":"Maps_To","value":"Foslinanib Disodium"},{"name":"NCI_META_CUI","value":"CL977259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1371":{"preferredName":"Fosquidone","code":"C1371","definitions":[{"definition":"A water-soluble pentacyclic pyrolloquinone analogue of mitoquidone with potential antineoplastic activity. Currently, the mechanism of action of fosquidone is unknown. In vitro studies indicate that this agent does not bind to DNA or inhibit topoisomerases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosquidone","termGroup":"PT","termSource":"NCI"},{"termName":"GR 63178A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114517-02-1"},{"name":"Chemical_Formula","value":"C28H22NO6P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"NSC D611615 from CCR."},{"name":"FDA_UNII_Code","value":"FD6QP9BP8U"},{"name":"Legacy Concept Name","value":"Fosquidone"},{"name":"Maps_To","value":"Fosquidone"},{"name":"NCI_Drug_Dictionary_ID","value":"41153"},{"name":"NSC Number","value":"611615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41153"},{"name":"PDQ_Open_Trial_Search_ID","value":"41153"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0118171"}]}}{"C1372":{"preferredName":"Fostriecin","code":"C1372","definitions":[{"definition":"An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fostriecin","termGroup":"PT","termSource":"NCI"},{"termName":"2H-pyran-2-one,5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11,-tridecatetraenyl)-,trans","termGroup":"SN","termSource":"NCI"},{"termName":"FST","termGroup":"AB","termSource":"NCI"},{"termName":"Phosphotrienin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87810-56-8"},{"name":"Chemical_Formula","value":"C19H27O9P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZO1648L551"},{"name":"Legacy Concept Name","value":"Fostriecin"},{"name":"Maps_To","value":"Fostriecin"},{"name":"NCI_Drug_Dictionary_ID","value":"41703"},{"name":"NSC Number","value":"339638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41703"},{"name":"PDQ_Open_Trial_Search_ID","value":"41703"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0118175"}]}}{"C1106":{"preferredName":"Fotemustine","code":"C1106","definitions":[{"definition":"A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of brain tumors and metastatic melanoma of the eye. It is a type of nitrosourea.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fotemustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-[N-(2-chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"[1-[[[(2-chloroethyl)nitrosamino]-carbonyl]amino]ethyl]phosphonic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"diethyl[1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate","termGroup":"SN","termSource":"NCI"},{"termName":"Muphoran","termGroup":"FB","termSource":"NCI"},{"termName":"S 10036","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92118-27-9"},{"name":"Chemical_Formula","value":"C9H19ClN3O5P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"GQ7JL9P5I2"},{"name":"Legacy Concept Name","value":"Fotemustine"},{"name":"Maps_To","value":"Fotemustine"},{"name":"NCI_Drug_Dictionary_ID","value":"38865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38865"},{"name":"PDQ_Open_Trial_Search_ID","value":"38865"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060696"}]}}{"C65767":{"preferredName":"Fotretamine","code":"C65767","definitions":[{"definition":"A pentaethyleneimine derivative with antineoplastic alkylating activity. Fotretamine causes chromosomal breaks in lymphocytes which contributes to its immunosuppressive activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fotretamine","termGroup":"PT","termSource":"NCI"},{"termName":"2,2,4,4,6-Pentaethylenimino-6-morpholino-cyclotriphosphazatrien","termGroup":"SN","termSource":"NCI"},{"termName":"Fotrin","termGroup":"SY","termSource":"NCI"},{"termName":"Photrin","termGroup":"SY","termSource":"NCI"},{"termName":"Photrine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37132-72-2"},{"name":"Chemical_Formula","value":"C14H28N9OP3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7Z7670589C"},{"name":"Legacy Concept Name","value":"Fotretamine"},{"name":"Maps_To","value":"Fotretamine"},{"name":"NSC Number","value":"216135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060698"}]}}{"C141298":{"preferredName":"FPV Vaccine CV301","code":"C141298","definitions":[{"definition":"A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration following the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine MVA-BN-CV301, the FPV vaccine CV301, which is used as a booster vaccine, activates a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when FPV-CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. The TAAs CEA and MUC-1 are overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FPV Vaccine CV301","termGroup":"PT","termSource":"NCI"},{"termName":"Boost Vaccine FPV-CV301","termGroup":"SY","termSource":"NCI"},{"termName":"Fowlpox-based FPV-CV301","termGroup":"SY","termSource":"NCI"},{"termName":"FPV-CV-301","termGroup":"SY","termSource":"NCI"},{"termName":"FPV-CV301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FPV Vaccine CV301"},{"name":"NCI_Drug_Dictionary_ID","value":"797362"},{"name":"NCI_META_CUI","value":"CL539397"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797362"},{"name":"PDQ_Open_Trial_Search_ID","value":"797362"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148402":{"preferredName":"FPV-Brachyury-TRICOM Vaccine","code":"C148402","definitions":[{"definition":"A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FPV-Brachyury-TRICOM Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"FPV-Brachyury","termGroup":"SY","termSource":"NCI"},{"termName":"FPV-Brachyury Boost Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FPV-Brachyury-TRICOM Vaccine"},{"name":"NCI_META_CUI","value":"CL551011"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C63546":{"preferredName":"Fresolimumab","code":"C63546","definitions":[{"definition":"A monoclonal antibody being studied in the treatment of kidney cancer, melanoma, and pulmonary fibrosis. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-TGF-beta monoclonal antibody GC1008 binds to the protein transforming growth factor-beta (TGF?) and may block the growth of cancer cells that make it.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fresolimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TGF-Beta Monoclonal Antibody GC1008","termGroup":"SY","termSource":"NCI"},{"termName":"GC1008","termGroup":"CN","termSource":"NCI"},{"termName":"Human Anti-TGF-Beta Monoclonal Antibody GC1008","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, anti-(transforming growth factor beta) (human monoclonal GC-1008 heavy chain), disulfide with human monoclonal GC-1008 light chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, and cancer"},{"name":"CAS_Registry","value":"948564-73-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"375142VBIA"},{"name":"Legacy Concept Name","value":"Anti-TGF-Beta_Monoclonal_Antibody_GC1008"},{"name":"Maps_To","value":"Fresolimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"530302"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530302"},{"name":"PDQ_Open_Trial_Search_ID","value":"530302"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987643"}]}}{"C102852":{"preferredName":"Fruquintinib","code":"C102852","definitions":[{"definition":"An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fruquintinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(6,7-Dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Elunate","termGroup":"FB","termSource":"NCI"},{"termName":"Fruzaqla","termGroup":"BR","termSource":"NCI"},{"termName":"HMPL-013","termGroup":"CN","termSource":"NCI"},{"termName":"VEGFR-1/2/3 Inhibitor HMPL-013","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with metastatic colorectal cancer (mCRC)."},{"name":"CAS_Registry","value":"1194506-26-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"49DXG3M5ZW"},{"name":"Maps_To","value":"Fruquintinib"},{"name":"NCI_Drug_Dictionary_ID","value":"737616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737616"},{"name":"PDQ_Open_Trial_Search_ID","value":"737616"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640967"}]}}{"C1379":{"preferredName":"Fulvestrant","code":"C1379","definitions":[{"definition":"A drug used to treat certain types of breast cancer in postmenopausal women. It is also being studied in the treatment of other types of cancer. Faslodex blocks estrogen activity in the body and is a type of antiestrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fulvestrant","termGroup":"PT","termSource":"NCI"},{"termName":"7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol","termGroup":"SN","termSource":"NCI"},{"termName":"Faslodex","termGroup":"BR","termSource":"NCI"},{"termName":"ICI 182,780","termGroup":"CN","termSource":"NCI"},{"termName":"ZD9238","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hormone receptor-positive metastatic breast cancer"},{"name":"CAS_Registry","value":"129453-61-8"},{"name":"CHEBI_ID","value":"CHEBI:31638"},{"name":"Chemical_Formula","value":"C32H47F5O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"22X328QOC4"},{"name":"Legacy Concept Name","value":"Fulvestrant"},{"name":"Maps_To","value":"Fulvestrant"},{"name":"NCI_Drug_Dictionary_ID","value":"43053"},{"name":"NSC Number","value":"719276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43053"},{"name":"PDQ_Open_Trial_Search_ID","value":"43053"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935916"}]}}{"C88321":{"preferredName":"Fumagillin-Derived Polymer Conjugate XMT-1107","code":"C88321","definitions":[{"definition":"A polymeric prodrug consisting of the fumagillol-derived small molecule XMT-1191 tethered to the hydrophilic, biodegradable70 kDa polymer poly[1-hydroxymethylethylene hydroxymethylformal] (PHF) with potential antiangiogenic and antineoplastic activities. Upon administration, fumagillin-derived polymer conjugate XMT-1107 releases XMT-1191, which may inhibit angiogenesis through the irreversible inhibition of the methionine aminopeptidase 2 (METAP2); although the exact mechanism of action has yet to be fully elucidated, this agent appears to induce cell cycle arrest in endothelial cells, inhibiting their proliferation and migration. Compared to an unconjugated fumagillin analog, XMT-1107 exhibits improved solubility and an extended half life due to its PHF backbone. METAP2, a member of the methionyl aminopeptidase family, binds two cobalt or manganese ions and protects the alpha subunit of eukaryotic initiation factor 2 (EIF2) from inhibitory phosphorylation by removing the amino-terminal methionine residue from nascent protein; this aminopeptidase may be overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fumagillin-Derived Polymer Conjugate XMT-1107","termGroup":"PT","termSource":"NCI"},{"termName":"XMT-1107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fumagillin-Derived Polymer Conjugate XMT-1107"},{"name":"NCI_Drug_Dictionary_ID","value":"660895"},{"name":"NCI_META_CUI","value":"CL413581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660895"},{"name":"PDQ_Open_Trial_Search_ID","value":"660895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121852":{"preferredName":"Fursultiamine","code":"C121852","definitions":[{"definition":"A nutritional supplement and vitamin B1 derivative, with potential antineoplastic activity. Upon oral administration, fursultiamine inhibits the expressions of octamer-binding transcription factor 4 (OCT-4), SRY (sex determining region Y)-box 2 (SOX-2), and Nanog homeobox (NANOG) in cancer stem cells (CSCs). This may inhibit the proliferation of CSCs thereby preventing tumor cell growth. In addition, fursultiamine inhibits the expression of ATP-binding cassette (ABC) transporters subfamily B member 1 (ABCB1) and subfamily G member 2 (ABCG2) in cancer CSCs, which may abrogate resistance to chemo- and radiotherapy in CSCs. CSCs promote tumor initiation, progression and metastasis; they play a key role in cancer recurrence and resistance to chemotherapy and radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fursultiamine","termGroup":"PT","termSource":"NCI"},{"termName":"Formamide, N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-1-methyl-2-(((tetrahydro-2-furanyl)methyl)dithio)-1-butenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Thiamine Tetrahydrofurfuryl Disulfide","termGroup":"SY","termSource":"NCI"},{"termName":"TTFD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"804-30-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05J61265PX"},{"name":"Maps_To","value":"Fursultiamine"},{"name":"NCI_Drug_Dictionary_ID","value":"771695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771695"},{"name":"PDQ_Open_Trial_Search_ID","value":"771695"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016865"}]}}{"C152971":{"preferredName":"Futuximab","code":"C152971","definitions":[{"definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR; ErbB1; HER1), with potential antineoplastic activity. Upon administration, futuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Futuximab","termGroup":"PT","termSource":"NCI"},{"termName":"992 DS","termGroup":"CN","termSource":"NCI"},{"termName":"992-DS","termGroup":"CN","termSource":"NCI"},{"termName":"992DS","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Extracellular Domain III) (Human-Mus Musculus Monoclonal 992 DS Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal 992 DS Light Chain, Dimer","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1310460-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B37J680LX0"},{"name":"Maps_To","value":"Futuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"793850"},{"name":"NCI_META_CUI","value":"CL554174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793850"},{"name":"PDQ_Open_Trial_Search_ID","value":"793850"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91381":{"preferredName":"Futuximab/Modotuximab Mixture","code":"C91381","definitions":[{"definition":"A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain III, with potential antineoplastic activity. Anti-EGFR monoclonal antibody mixture Sym004 binds to the extracellular domain of EGFR, thereby preventing ligand binding. This may prevent activation and subsequent dimerization of the receptor; the decrease in receptor activation may result in an inhibition of downstream ERK and JNK signaling pathways and thus inhibition of EGFR-dependent tumor cell proliferation and metastasis. In addition, binding of Sym004 to EGFRs causes EGFR internalization and degradation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Futuximab/Modotuximab Mixture","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR Monoclonal Antibody Mixture Sym004","termGroup":"SY","termSource":"NCI"},{"termName":"Futuximab/Modotuximab","termGroup":"SY","termSource":"NCI"},{"termName":"Futuximab/Zatuximab","termGroup":"SY","termSource":"NCI"},{"termName":"Sym004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Futuximab/Modotuximab Mixture"},{"name":"NCI_Drug_Dictionary_ID","value":"673604"},{"name":"NCI_META_CUI","value":"CL421582"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673604"},{"name":"PDQ_Open_Trial_Search_ID","value":"673604"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95893":{"preferredName":"G-Quadruplex Stabilizer BMVC","code":"C95893","definitions":[{"definition":"A carbazole derivative (3,6-bis[2-(1-methylpyridinium)vinyl]carbazole diiodide) that selectively targets to the G-quadruplex DNA structure, used as a fluorescent probe for cancer cytological diagnosis and with potential antitumor activity. G-quadruplex stabilizer BMVC, preferentially uptaken by cancer cells, binds to and stabilize the telomeric G-quadruplex structure at the end of DNA; when visualized with fluorescent imaging device, BMVC emits bright fluorescent light and can be used to differentiate tumor cells from normal cells. The BMVC/G-quadruplex complexes also interfere with the activity of telomerase, which is highly active in tumor cells and plays a key role in tumorigenesis while expressed at very low levels in most somatic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"G-Quadruplex Stabilizer BMVC","termGroup":"PT","termSource":"NCI"},{"termName":"3,6-bis (1-methyl-4-vinylpyridinium) Carbazole Diiodide","termGroup":"SN","termSource":"NCI"},{"termName":"3,6-bis[2-(1-methylpyridinium)vinyl]carbazole Diiodide","termGroup":"SN","termSource":"NCI"},{"termName":"BMVC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"G-Quadruplex Stabilizer BMVC"},{"name":"NCI_Drug_Dictionary_ID","value":"696431"},{"name":"NCI_META_CUI","value":"CL428290"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696431"},{"name":"PDQ_Open_Trial_Search_ID","value":"696431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C76791":{"preferredName":"Galamustine","code":"C76791","definitions":[{"definition":"A galactose mustard compound, an alkylating agent, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galamustine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"105618-02-8"},{"name":"Chemical_Formula","value":"C10H19Cl2NO5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P771FDQ1WJ"},{"name":"Legacy Concept Name","value":"Galamustine"},{"name":"Maps_To","value":"Galamustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700228"}]}}{"C81422":{"preferredName":"Galarubicin","code":"C81422","definitions":[{"definition":"An anthracycline derivative with antineoplastic activity developed to circumvent doxorubicin resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,10S)-10-((2.6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 8(sup 2)-ester with Beta-alanine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"140637-86-1"},{"name":"Chemical_Formula","value":"C30H32FNO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6F39648E92"},{"name":"Legacy Concept Name","value":"Galarubicin"},{"name":"Maps_To","value":"Galarubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825624"}]}}{"C115111":{"preferredName":"Belapectin","code":"C115111","definitions":[{"definition":"A carbohydrate-based galectin inhibitor, with potential antineoplastic activity. Belapectin binds to the carbohydrate-binding domain of galectins, especially galectin-3, and may result in an induction of apoptosis mediated through activation of both mitochondria and caspases. This may reduce tumor growth in galectin-overexpressing tumor cells. Galectins, often overexpressed on tumor cells, play a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belapectin","termGroup":"PT","termSource":"NCI"},{"termName":"Galactoarabino-rhamnogalacturonate","termGroup":"SY","termSource":"NCI"},{"termName":"GR-MD-02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1980787-47-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K7ODU55HT6"},{"name":"Maps_To","value":"Belapectin"},{"name":"Maps_To","value":"Galectin Inhibitor GR-MD-02"},{"name":"NCI_Drug_Dictionary_ID","value":"760131"},{"name":"NCI_META_CUI","value":"CL472642"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760131"},{"name":"PDQ_Open_Trial_Search_ID","value":"760131"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103828":{"preferredName":"Galectin-1 Inhibitor OTX008","code":"C103828","definitions":[{"definition":"A calixarene-based compound and galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. Upon subcutaneous administration, galectin-1 inhibitor OTX008 binds Gal-1 which leads to Gal-1 oxidation and proteasomal degradation, through an as of yet not fully elucidated mechanism, and eventually downregulation of Gal-1. This decreases tumor cell growth and inhibits angiogenesis. Gal-1, a multifunctional carbohydrate-binding protein, is often overexpressed on tumor cells and plays a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galectin-1 Inhibitor OTX008","termGroup":"PT","termSource":"NCI"},{"termName":"Gal-1 Inhibitor OTX008","termGroup":"SY","termSource":"NCI"},{"termName":"KM-0118","termGroup":"CN","termSource":"NCI"},{"termName":"OTX008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"286936-40-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8JI63CFH5V"},{"name":"Maps_To","value":"Galectin-1 Inhibitor OTX008"},{"name":"NCI_Drug_Dictionary_ID","value":"742751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742751"},{"name":"PDQ_Open_Trial_Search_ID","value":"742751"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641630"}]}}{"C84866":{"preferredName":"Galeterone","code":"C84866","definitions":[{"definition":"An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galeterone","termGroup":"PT","termSource":"NCI"},{"termName":"Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-","termGroup":"SN","termSource":"NCI"},{"termName":"Specific Androgen Receptor Modulator/CYP17 Lyase Inhibitor TOK-001","termGroup":"SY","termSource":"NCI"},{"termName":"TOK-001","termGroup":"CN","termSource":"NCI"},{"termName":"VN/124","termGroup":"CN","termSource":"NCI"},{"termName":"VN/124-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"851983-85-2"},{"name":"Chemical_Formula","value":"C26H32N2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WA33E149SW"},{"name":"Maps_To","value":"Galeterone"},{"name":"NCI_Drug_Dictionary_ID","value":"653977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653977"},{"name":"PDQ_Open_Trial_Search_ID","value":"653977"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490719"}]}}{"C26447":{"preferredName":"Galiximab","code":"C26447","definitions":[{"definition":"A chimeric IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of follicular non-Hodgkin lymphoma. It binds to the protein CD80, which is found on certain normal white blood cells and on white blood cells that are cancer. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Galiximab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-B7-1","termGroup":"SY","termSource":"NCI"},{"termName":"anti-CD80 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"IDEC-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"357613-77-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9OX9692ZB"},{"name":"Legacy Concept Name","value":"IDEC-114_Monoclonal_Antibody"},{"name":"Maps_To","value":"Galiximab"},{"name":"NCI_Drug_Dictionary_ID","value":"285686"},{"name":"NSC Number","value":"734532"},{"name":"PDQ_Closed_Trial_Search_ID","value":"285686"},{"name":"PDQ_Open_Trial_Search_ID","value":"285686"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1098262"}]}}{"C73254":{"preferredName":"Galocitabine","code":"C73254","definitions":[{"definition":"An orally available 5-fluorouracil (5-FU) prodrug with potential antineoplastic activity. Upon administration, galocitabine is converted into 5'-deoxy-5-fluorocytidine, 5'-deoxy-fluorouridine, and 5-FU. 5-FU is further metabolized into other cytotoxic metabolites that interfere with RNA and DNA synthesis via inhibition of thymidylate synthase. As a result, this agent eventually inhibits tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galocitabine","termGroup":"PT","termSource":"NCI"},{"termName":"Ro 09-1390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124012-42-6"},{"name":"Chemical_Formula","value":"C19H22FN3O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X9788XI79O"},{"name":"Legacy Concept Name","value":"Galocitabine"},{"name":"Maps_To","value":"Galocitabine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084382"}]}}{"C116891":{"preferredName":"Galunisertib","code":"C116891","definitions":[{"definition":"An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), with potential antineoplastic activity. Upon administration, galunisertib specifically targets and binds to the kinase domain of TGFBR1, thereby preventing the activation of TGF-b-mediated signaling pathways. This may inhibit the proliferation of TGF-b-overexpressing tumor cells. Dysregulation of the TGF-b signaling pathway is seen in a number of cancers and is associated with increased cancer cell proliferation, migration, invasion and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galunisertib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"LY-2157299","termGroup":"CN","termSource":"NCI"},{"termName":"LY2157299","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"700874-72-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3OKH1W5LZE"},{"name":"Maps_To","value":"Galunisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"687583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687583"},{"name":"PDQ_Open_Trial_Search_ID","value":"687583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3180910"}]}}{"C118444":{"preferredName":"Gamboge Resin Extract TSB-9-W1","code":"C118444","definitions":[{"definition":"An orally bioavailable extract from the yellow to brown gum-resin of the gamboge tree (genus Garcinia) belonging to the Clusiaceae (or Guttiferae) family, with potential anti-inflammatory and antineoplastic activities. Gamboge resin extract TSB-9-W1 contains various active ingredients, including gambogic acid, formoxanthone A, betulin, betulinic acid, morellic acid, isomorellic acid, isogambogic acid, isomorellinol and desoxymorellin. Upon oral administration, the various active components of the gamboge resin extract TSB-9-W1 may bind to and inhibit the activity of a variety of cancer-related proteins, may induce apoptosis, and may exert cytotoxic activity on tumor cells, thereby inhibiting tumor cell proliferation. TSB-9 is derived from TSB-14, which is the acetone-extract of gamboge resin, and pulverized into powder form; TSB-9 is 90% extract and 10% brown sugar. TSB-9-W1 is a milled form of TSB-9 with a particle size of 5 micrometers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamboge Resin Extract TSB-9-W1","termGroup":"PT","termSource":"NCI"},{"termName":"Garcinia Hanburyi Rhizome Resin","termGroup":"SY","termSource":"NCI"},{"termName":"Garcinia Hanburyi Root Resin","termGroup":"SY","termSource":"NCI"},{"termName":"TSB-9-W1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KQR4YN4C28"},{"name":"Maps_To","value":"Gamboge Resin Extract TSB-9-W1"},{"name":"NCI_Drug_Dictionary_ID","value":"764996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764996"},{"name":"PDQ_Open_Trial_Search_ID","value":"764996"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896755"}]}}{"C101517":{"preferredName":"Gamma-delta Tocotrienol","code":"C101517","definitions":[{"definition":"An orally available nutritional supplement containing the gamma and delta forms of the vitamin E family member tocotrienol, with hypocholesterolemic, antithrombotic, antioxidant, and potential antineoplastic activity. Upon oral administration, gamma-delta tocotrienol accumulates in cancer cells and may exert their anti-cancer activity in part through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase downregulation and/or degradation, cell cycle arrest, and induction of caspase-mediated apoptosis. In addition, this agent may inhibit angiogenesis partially through the blockage of vascular endothelial growth factor receptor (VEGFR) and the inhibition of tumor cell-induced vessel formation. Altogether, this may result in the inhibition of tumor cell growth. Further, this agent prevents free radical formation and inhibits lipid peroxidation. Tocotrienols contain 3 double bonds, absent in tocopherols, on its farnesyl isoprenoid side chain that likely contribute to its anti-cancer activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma-delta Tocotrienol","termGroup":"PT","termSource":"NCI"},{"termName":"GDT","termGroup":"AB","termSource":"NCI"},{"termName":"gdT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gamma-delta Tocotrienol"},{"name":"NCI_Drug_Dictionary_ID","value":"730661"},{"name":"NCI_META_CUI","value":"CL435774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730661"},{"name":"PDQ_Open_Trial_Search_ID","value":"730661"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121535":{"preferredName":"Gamma-Secretase Inhibitor LY3039478","code":"C121535","synonyms":[{"termName":"Gamma-Secretase Inhibitor LY3039478","termGroup":"PT","termSource":"NCI"},{"termName":"4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide","termGroup":"SN","termSource":"NCI"},{"termName":"JSMD194","termGroup":"CN","termSource":"NCI"},{"termName":"LY 3039478","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3039478","termGroup":"CN","termSource":"NCI"},{"termName":"LY3039478","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1421438-81-4"},{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Jul 07 17:27:51 EDT 2021 - See 'Crenigacestat(C171871)'"},{"name":"OLD_PARENT","value":"C471"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88333":{"preferredName":"Gamma-Secretase Inhibitor RO4929097","code":"C88333","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain enzymes that are needed for cell growth. This may slow the growth of cancer cells. It may also decrease the growth of new blood vessels that tumors need to grow. It is a type of gamma-secretase inhibitor and a type of Notch signaling inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, small-molecule gamma secretase (GS) inhibitor with potential antitumor activity. Gamma secretase inhibitor RO4929097 binds to GS and blocks activation of Notch receptors, which may inhibit tumor cell proliferation. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma-Secretase Inhibitor RO4929097","termGroup":"PT","termSource":"NCI"},{"termName":"R04929097","termGroup":"SY","termSource":"NCI"},{"termName":"RO4929097","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"847925-91-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KK8645V7LE"},{"name":"Maps_To","value":"Gamma-Secretase Inhibitor RO4929097"},{"name":"NCI_Drug_Dictionary_ID","value":"662240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662240"},{"name":"PDQ_Open_Trial_Search_ID","value":"662240"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742210"}]}}{"C116857":{"preferredName":"Gandotinib","code":"C116857","definitions":[{"definition":"An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. JAK2V617F has a substitution of phenylalanine for valine at amino acid position 617 and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gandotinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(Morpholinomethyl)imidazo(1,2-b)pyridazin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"LY 2784544","termGroup":"CN","termSource":"NCI"},{"termName":"LY2784544","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229236-86-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ANC71R916O"},{"name":"Maps_To","value":"Gandotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"682801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682801"},{"name":"PDQ_Open_Trial_Search_ID","value":"682801"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659426"}]}}{"C77872":{"preferredName":"Ganetespib","code":"C77872","definitions":[{"definition":"A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganetespib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole 3h-1,2,4-triazol-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Hsp90 Inhibitor STA-9090","termGroup":"SY","termSource":"NCI"},{"termName":"STA-9090","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1143571-94-1"},{"name":"Chemical_Formula","value":"C20H20N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2E8412Y946"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_STA-9090"},{"name":"Maps_To","value":"Ganetespib"},{"name":"NCI_Drug_Dictionary_ID","value":"598379"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598379"},{"name":"PDQ_Open_Trial_Search_ID","value":"598379"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607234"}]}}{"C1110":{"preferredName":"Ganglioside GD2","code":"C1110","definitions":[{"definition":"A cell surface antigen expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastomas, sarcoma, astrocytomas, and small cell lung cancer. GD2, an O-acetylated disialoganglioside, belongs to the group of glycosphingolipids that are widely expressed in many tissues and organs in vertebrates and have been suggested to be involved in the regulation of development and differentiation as recognition molecules or signal modulators. Due to its high level of expression in neuroblastoma, GD2 has the potential to be used as a component of anti-neuroblastoma vaccines, in addition to being used in polyvalent anti-melanoma vaccines.","type":"DEFINITION","source":"NCI"},{"definition":"A sialic acid-containing glycosphingolipid antigen and a component of the cell plasma membrane that modulates cell signal transduction, with a designation of GD2. It can be considered as an autoantigen and is commonly associated with autoimmune neuropathies such as Guillain-Barre syndrome and multiple sclerosis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ganglioside GD2","termGroup":"PT","termSource":"NCI"},{"termName":"Disialoganglioside GD-2","termGroup":"SY","termSource":"NCI"},{"termName":"GalNAc(beta 1->4)-[NeuAc(alpha 2->8)NeuAc(alpha 2->3)]Gal(beta 1->4)GlcCer","termGroup":"SN","termSource":"NCI"},{"termName":"Ganglioside, GD2","termGroup":"SY","termSource":"NCI"},{"termName":"GD2","termGroup":"SY","termSource":"NCI"},{"termName":"GD2 Ganglioside","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65988-71-8"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FUI2V09E1C"},{"name":"Legacy Concept Name","value":"Ganglioside_GD2"},{"name":"Maps_To","value":"Ganglioside GD2"},{"name":"NCI_Drug_Dictionary_ID","value":"42295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42295"},{"name":"PDQ_Open_Trial_Search_ID","value":"42295"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061104"}]}}{"C516":{"preferredName":"Ganglioside GM2","code":"C516","definitions":[{"definition":"A glycosphingolipid antigen expressed by a variety of human cancer cells. GM2 containing vaccines have been shown to elicit antibodies production in melanoma patients without deleterious effects associated with an immune response to GM2. Mutations in at least 1 of 3 recessive genes: HEXA, HEXB, and GM2A cause defects in GM2 catabolism, leading to lysosomal lipid storage disorders that manifest primarily as neurodegenerative diseases, including Tay-Sachs and Sandhoff Disease.","type":"DEFINITION","source":"NCI"},{"definition":"A sialic acid-containing glycosphingolipid antigen and a component of the cell plasma membrane that modulates cell signal transduction, with a designation of GM2. It can be considered as an autoantigen and is commonly associated with autoimmune neuropathies such as Guillain-Barre syndrome and multiple sclerosis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ganglioside GM2","termGroup":"PT","termSource":"NCI"},{"termName":"GM2 ganglioside","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"19600-01-2"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ganglioside_GM2"},{"name":"Maps_To","value":"Ganglioside GM2"},{"name":"NCI_Drug_Dictionary_ID","value":"40785"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40785"},{"name":"PDQ_Open_Trial_Search_ID","value":"40785"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0016896"}]}}{"C71531":{"preferredName":"Ganitumab","code":"C71531","definitions":[{"definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganitumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 479","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-IGF-1R Human Monoclonal Antibody AMG-479","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"905703-97-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CK1441RCZ8"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Human_Monoclonal_Antibody_AMG-479"},{"name":"Maps_To","value":"Ganitumab"},{"name":"NCI_Drug_Dictionary_ID","value":"578040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"578040"},{"name":"PDQ_Open_Trial_Search_ID","value":"578040"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2744646"}]}}{"C118365":{"preferredName":"Ganoderma lucidum Spores Powder Capsule","code":"C118365","definitions":[{"definition":"An orally available powder-based nutritional supplement containing the spores of the mushroom Ganoderma lucidum (Ganoderma l.), a traditional Chinese medicine, with potential protective, sedative, anti-oxidant, immunomodulating, and antineoplastic activities. The spores contain various bioactive components including polysaccharides, triterpenoids, peptidoglycans, amino acids, fatty acids, vitamins, and minerals. Upon oral administration of the Ganoderma lucidum spores powder capsule, the active ingredients may modulate the immune system, may activate dendritic cells, natural killer cells, and macrophages and may modulate the production of certain cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin (IL) 1-beta (IL-1b), IL-2, IL-6 and IL-8. This supplement may improve cancer-related fatigue and may be used as a sleep aid; it may also have a beneficial effect on the heart, lung, liver, pancreas, kidney, and the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganoderma lucidum Spores Powder Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Ganoderma l. Spores Powder Capsule","termGroup":"SY","termSource":"NCI"},{"termName":"Lingzhi Spores Powder Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ganoderma lucidum Spores Powder Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"764697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764697"},{"name":"PDQ_Open_Trial_Search_ID","value":"764697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899040"}]}}{"C38706":{"preferredName":"Garlic","code":"C38706","definitions":[{"definition":"A European plant that has a bulb used to flavor food. It has also been used in some cultures to treat certain medical conditions including high cholesterol, high blood pressure, infections, and cancer. The scientific name is Allium sativum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A bulbous herb isolated from the plant Allium sativum with potential antineoplastic activity. Garlic contains a number of different organosulfur compounds, some of which have displayed antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Garlic","termGroup":"PT","termSource":"NCI"},{"termName":"Ajo","termGroup":"SY","termSource":"NCI"},{"termName":"Allium Sativum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V1V998DC17"},{"name":"Legacy Concept Name","value":"Garlic"},{"name":"Maps_To","value":"Garlic"},{"name":"NCI_Drug_Dictionary_ID","value":"357490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357490"},{"name":"PDQ_Open_Trial_Search_ID","value":"357490"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0993630"}]}}{"C1692":{"preferredName":"Gastrin Immunotoxin","code":"C1692","definitions":[{"definition":"An immunotoxin containing an epitope of human gastrin conjugated to diphtheria toxin, with antineoplastic activity. The gastrin epitope in this vaccine is chemically identical or similar to the endogenous gastrin-17 (G-17), a 17-amino acid peptide hormone that stimulates secretion of gastric acid by the stomach. Diphtheria toxin inhibits protein synthesis via modifying translation elongation factor 2 (EF-2). Vaccination with this immunotoxin may elicit production of antibodies against gastrinoma cells overexpressing gastrin, in addition to the toxic effects on protein synthesis exerted by the diphtheria toxin moiety.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrin Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-gastrin 17","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Gastrin Therapeutic Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"G17DT","termGroup":"AB","termSource":"NCI"},{"termName":"G17DT Immunogen","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrimmune","termGroup":"BR","termSource":"NCI"},{"termName":"Neutralize Hormone G17","termGroup":"SY","termSource":"NCI"},{"termName":"Neutralizing G17 Hormone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J9W34L3K8B"},{"name":"Legacy Concept Name","value":"Gastrin_Immunotoxin"},{"name":"Maps_To","value":"Gastrin Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"38352"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38352"},{"name":"PDQ_Open_Trial_Search_ID","value":"38352"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935889"}]}}{"C61329":{"preferredName":"Nastorazepide Calcium","code":"C61329","definitions":[{"definition":"A selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nastorazepide Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360","termGroup":"SY","termSource":"NCI"},{"termName":"Z-360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"343326-69-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GZ3I1DMI8Q"},{"name":"Legacy Concept Name","value":"Z-360"},{"name":"Maps_To","value":"Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360"},{"name":"NCI_Drug_Dictionary_ID","value":"485295"},{"name":"NCI_META_CUI","value":"CL937292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485295"},{"name":"PDQ_Open_Trial_Search_ID","value":"485295"},{"name":"PubMedID_Primary_Reference","value":"17961733"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66935":{"preferredName":"Gataparsen Sodium","code":"C66935","definitions":[{"definition":"A second-generation antisense oligonucleotide against survivin mRNA with potential antitumor activity. Gataparsen hybridizes to survivin mRNA, thereby blocking translation of survivin protein, a member of the inhibitor of apoptosis (IAP) family. Survivin, expressed during embryonal development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy. Silencing expression of survivin potentially leads to restoration of the apoptotic process in cancer cells, thereby facilitating chemotherapeutic treatments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gataparsen Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Antisurvivin Antisense Oligonucleotide LY2181308","termGroup":"SY","termSource":"NCI"},{"termName":"LY 2181308","termGroup":"CN","termSource":"NCI"},{"termName":"LY-2181308","termGroup":"CN","termSource":"NCI"},{"termName":"LY2181308","termGroup":"CN","termSource":"NCI"},{"termName":"LY2181308 Heptadecasodium Salt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"928768-71-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3KY0EUQ36S"},{"name":"Legacy Concept Name","value":"LY2181308"},{"name":"Maps_To","value":"Gataparsen Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"532253"},{"name":"PDQ_Closed_Trial_Search_ID","value":"532253"},{"name":"PDQ_Open_Trial_Search_ID","value":"532253"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832051"}]}}{"C94220":{"preferredName":"Gatipotuzumab","code":"C94220","definitions":[{"definition":"A humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), with potential antineoplastic activity. Gatipotuzumab targets and binds to the TA-MUC1 epitopes expressed on the cell surface of tumor cells, thereby potentially activating the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against the TA-MUC1-expressing tumor cells. TA-MUC1 is designated to MUC1 epitopes with O-glycosylated carbohydrate-induced conformational structures that are tumor-specific, thereby enabling gatipotuzumab to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gatipotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"PankoMab","termGroup":"CN","termSource":"NCI"},{"termName":"PankoMab-GEX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1264737-26-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"85V55ZLV2Z"},{"name":"Maps_To","value":"Gatipotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"687630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687630"},{"name":"PDQ_Open_Trial_Search_ID","value":"687630"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986405"}]}}{"C91732":{"preferredName":"Gedatolisib","code":"C91732","definitions":[{"definition":"An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, gedatolisib inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gedatolisib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(4-[[4-(dimethylamino)piperidin-1-yl]carbonyl]phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea","termGroup":"SN","termSource":"NCI"},{"termName":"PF 05212384","termGroup":"CN","termSource":"NCI"},{"termName":"PF-05212384","termGroup":"CN","termSource":"NCI"},{"termName":"PKI 587","termGroup":"CN","termSource":"NCI"},{"termName":"PKI-587","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1197160-78-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96265TNH2R"},{"name":"Maps_To","value":"Gedatolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"651189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651189"},{"name":"PDQ_Open_Trial_Search_ID","value":"651189"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933603"}]}}{"C1855":{"preferredName":"Gefitinib","code":"C1855","definitions":[{"definition":"A drug that is used to treat certain types of non-small cell lung cancer and is being studied in the treatment of other types of cancer. It is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gefitinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","termGroup":"SN","termSource":"NCI"},{"termName":"Iressa","termGroup":"BR","termSource":"NCI"},{"termName":"N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","termGroup":"SN","termSource":"NCI"},{"termName":"ZD 1839","termGroup":"CN","termSource":"NCI"},{"termName":"ZD1839","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Small Cell Lung Carcinoma"},{"name":"CAS_Registry","value":"184475-35-2"},{"name":"CHEBI_ID","value":"CHEBI:49668"},{"name":"Chemical_Formula","value":"C22H24ClFN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"S65743JHBS"},{"name":"Legacy Concept Name","value":"Gefitinib"},{"name":"Maps_To","value":"Gefitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"43649"},{"name":"NSC Number","value":"715055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43649"},{"name":"PDQ_Open_Trial_Search_ID","value":"43649"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122962"}]}}{"C1112":{"preferredName":"Geldanamycin","code":"C1112","definitions":[{"definition":"A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Geldanamycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Geldanamycin","termGroup":"PT","termSource":"NCI"},{"termName":"Antibiotic U 29135","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"30562-34-6"},{"name":"CHEBI_ID","value":"CHEBI:5292"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z3K3VJ16KU"},{"name":"Legacy Concept Name","value":"Geldanamycin"},{"name":"Maps_To","value":"Geldanamycin"},{"name":"NSC Number","value":"122750"},{"name":"NSC Number","value":"212518"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061179"}]}}{"C133021":{"preferredName":"Gelonin","code":"C133021","definitions":[{"definition":"A class I ribosome-inactivating protein (RIP) and toxin derived from the seeds of the plant Gelonium multiflorum. Gelonin (rGel) exerts N-glycosidase activity on the 28S ribosomal RNA (rRNA) unit of eukaryotic ribosomes by cleaving out adenine at the 4324 site, which depurinates rRNA, inactivates ribosomes, inhibits protein synthesis, and results in cell death. Used as the toxin moiety of certain immunotoxins and linked to antibodies specific for a tumor-associated antigen (TAA), gelonin can be targeted to and induce specific cytotoxicity in tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gelonin","termGroup":"PT","termSource":"NCI"},{"termName":"GEL Protein, Gelonium multiflorum","termGroup":"SY","termSource":"NCI"},{"termName":"LGK974","termGroup":"CN","termSource":"NCI"},{"termName":"rGel","termGroup":"SY","termSource":"NCI"},{"termName":"Ribosome-inactivating Protein Gelonin, Gelonium multiflorum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75037-46-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gelonin"},{"name":"NCI_Drug_Dictionary_ID","value":"357568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357568"},{"name":"PDQ_Open_Trial_Search_ID","value":"357568"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061184"}]}}{"C66876":{"preferredName":"Gemcitabine","code":"C66876","definitions":[{"definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gemcitabine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose","termGroup":"SN","termSource":"NCI"},{"termName":"2'Deoxy-2',2'-Difluorocytidine","termGroup":"SN","termSource":"NCI"},{"termName":"dFdC","termGroup":"AB","termSource":"NCI"},{"termName":"dFdCyd","termGroup":"AB","termSource":"NCI"},{"termName":"Difluorodeoxycytidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95058-81-4"},{"name":"CHEBI_ID","value":"CHEBI:175901"},{"name":"Chemical_Formula","value":"C9H11F2N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"B76N6SBZ8R"},{"name":"Legacy Concept Name","value":"Gemcitabine_Base"},{"name":"Maps_To","value":"Gemcitabine"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045093"}]}}{"C79803":{"preferredName":"Gemcitabine Elaidate","code":"C79803","definitions":[{"definition":"A lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Elaidate","termGroup":"PT","termSource":"NCI"},{"termName":"CP-4126","termGroup":"CN","termSource":"NCI"},{"termName":"Gemcitabine 5'-Elaidic Acid Ester","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"210829-30-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"231C73W7LG"},{"name":"Legacy Concept Name","value":"Gemcitabine_5-Elaidic_Acid_Ester"},{"name":"Maps_To","value":"Gemcitabine Elaidate"},{"name":"NCI_Drug_Dictionary_ID","value":"624375"},{"name":"PDQ_Closed_Trial_Search_ID","value":"624375"},{"name":"PDQ_Open_Trial_Search_ID","value":"624375"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703166"}]}}{"C961":{"preferredName":"Gemcitabine Hydrochloride","code":"C961","definitions":[{"definition":"A drug used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine hydrochloride blocks the cell from making DNA and may kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"2'Deoxy-2',2'-Difluorocytidine, Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"dFdCyd","termGroup":"SY","termSource":"NCI"},{"termName":"Difluorodeoxycytidine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Gemcitabine HCI","termGroup":"SY","termSource":"NCI"},{"termName":"Gemzar","termGroup":"BR","termSource":"NCI"},{"termName":"LY-188011","termGroup":"CN","termSource":"NCI"},{"termName":"LY188011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Breast cancer; Carcinoma of unknown primary origin; Lung cancer; including non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma"},{"name":"CAS_Registry","value":"122111-03-9"},{"name":"CHEBI_ID","value":"CHEBI:31647"},{"name":"Chemical_Formula","value":"C9H11F2N3O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U347PV74IL"},{"name":"Legacy Concept Name","value":"Gemcitabine"},{"name":"Maps_To","value":"Gemcitabine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41213"},{"name":"NSC Number","value":"613327"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41213"},{"name":"PDQ_Open_Trial_Search_ID","value":"41213"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771488"}]}}{"C105613":{"preferredName":"Gemcitabine Hydrochloride Emulsion","code":"C105613","definitions":[{"definition":"An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Hydrochloride Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"D07001-F4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gemcitabine Hydrochloride Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"747250"},{"name":"NCI_META_CUI","value":"CL446450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747250"},{"name":"PDQ_Open_Trial_Search_ID","value":"747250"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102856":{"preferredName":"Gemcitabine Prodrug LY2334737","code":"C102856","definitions":[{"definition":"An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine prodrug LY2334737 is hydrolyzed by carboxylesterase 2 (CES2) and releases gemcitabine systemically over a period of time consistent with formation rate-limited kinetics. In turn, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis. Compared to gemcitabine, this prodrug is able to avoid hydrolysis in enterocytes and the portal circulation thus avoiding first pass metabolism and increasing systemic gemcitabine availability. In addition, the slow release of gemcitabine may enhance efficacy while lowering toxicity. CES2, a serine ester hydrolase, is expressed in certain tumors which may allow for increased conversion of gemcitabine at the tumor site thus increases cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Prodrug LY2334737","termGroup":"PT","termSource":"NCI"},{"termName":"LY-2334737","termGroup":"CN","termSource":"NCI"},{"termName":"LY2334737","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"892128-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YLR364XYSA"},{"name":"Maps_To","value":"Gemcitabine Prodrug LY2334737"},{"name":"NCI_Drug_Dictionary_ID","value":"737787"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737787"},{"name":"PDQ_Open_Trial_Search_ID","value":"737787"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3252354"}]}}{"C102752":{"preferredName":"Fosgemcitabine Palabenamide","code":"C102752","definitions":[{"definition":"A pyrimidine analogue and a proprietary prodrug based on an aryloxy phosphoramidate derivative of gemcitabine with potential antineoplastic activity. Upon intravenous administration and cellular uptake, fosgemcitabine palabenamide is converted into the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually induction of apoptosis. With the phosphoramidate moiety on the gemcitabine monophosphate group, NUC-1031 has improved properties over its parent molecule: 1) is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, 2) as the agent is delivered in the monophosphate form, the first phosphorylation step by deoxycytidine kinase is not required, 3) this agent is not susceptible to deactivation by cytidine deaminase cleavage of the monophosphorylated form. Altogether, this may help overcome resistance to gemcitabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosgemcitabine Palabenamide","termGroup":"PT","termSource":"NCI"},{"termName":"Acelarin","termGroup":"BR","termSource":"NCI"},{"termName":"Gemictabine ProTide","termGroup":"SY","termSource":"NCI"},{"termName":"NUC 1031","termGroup":"CN","termSource":"NCI"},{"termName":"NUC-1031","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1562406-27-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I17GWP65CE"},{"name":"Maps_To","value":"Fosgemcitabine Palabenamide"},{"name":"Maps_To","value":"Gemcitabine-Phosphoramidate Hydrochloride NUC-1031"},{"name":"NCI_Drug_Dictionary_ID","value":"735822"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735822"},{"name":"PDQ_Open_Trial_Search_ID","value":"735822"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640933"}]}}{"C150807":{"preferredName":"Gemcitabine-Releasing Intravesical System","code":"C150807","definitions":[{"definition":"A controlled-release intravesical system consisting of a small flexible tube-like device with a solid core composed of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. Upon placement of the gemcitabine-releasing intravesical system (GemRIS) into the bladder, gemcitabine is gradually and continuously released from the system over an extended period of time before being removed from the bladder. Upon release, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis of bladder tumor cells. In addition, dFdCDP inhibits ribonucleotide reductase (RNR) and reduces the deoxynucleotide pool available for DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine-Releasing Intravesical System","termGroup":"PT","termSource":"NCI"},{"termName":"GemRIS","termGroup":"BR","termSource":"NCI"},{"termName":"TAR 200","termGroup":"CN","termSource":"NCI"},{"termName":"TAR-200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gemcitabine-Releasing Intravesical System"},{"name":"NCI_Drug_Dictionary_ID","value":"793540"},{"name":"NCI_META_CUI","value":"CL552666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793540"},{"name":"PDQ_Open_Trial_Search_ID","value":"793540"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1806":{"preferredName":"Gemtuzumab Ozogamicin","code":"C1806","definitions":[{"definition":"A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemtuzumab Ozogamicin","termGroup":"PT","termSource":"NCI"},{"termName":"Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"CDP-771","termGroup":"CN","termSource":"NCI"},{"termName":"CMA-676","termGroup":"CN","termSource":"NCI"},{"termName":"hP67.6-Calicheamicin","termGroup":"SY","termSource":"NCI"},{"termName":"Mylotarg","termGroup":"BR","termSource":"NCI"},{"termName":"WAY-CMA-676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Myeloid Leukemia."},{"name":"CAS_Registry","value":"220578-59-6"},{"name":"Chemical_Formula","value":"C73H96IN6O25S3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"8GZG754X6M"},{"name":"Legacy Concept Name","value":"Gemtuzumab_Ozogamicin"},{"name":"Maps_To","value":"Gemtuzumab Ozogamicin"},{"name":"NCI_Drug_Dictionary_ID","value":"42868"},{"name":"NSC Number","value":"720568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42868"},{"name":"PDQ_Open_Trial_Search_ID","value":"42868"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1533699"}]}}{"C1113":{"preferredName":"Genistein","code":"C1113","definitions":[{"definition":"A soy-derived isoflavone and phytoestrogen with antineoplastic activity. Genistein binds to and inhibits protein-tyrosine kinase, thereby disrupting signal transduction and inducing cell differentiation.  This agent also inhibits topoisomerase-II, leading to DNA fragmentation and apoptosis, and induces G2/M cell cycle arrest.  Genistein exhibits antioxidant, antiangiogenic, and immunosuppressive activities. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An isoflavone found in soy products. Soy isoflavones are being studied to see if they help prevent cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An isoflavone with a hydroxyl group on the B-ring and a second hydroxyl group on the A-ring.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Genistein","termGroup":"PT","termSource":"NCI"},{"termName":"4',5,7-Trihydroxyisoflavone","termGroup":"SN","termSource":"NCI"},{"termName":"5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"Genestein","termGroup":"SY","termSource":"NCI"},{"termName":"Genisteol","termGroup":"SY","termSource":"NCI"},{"termName":"Prunetol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"446-72-0"},{"name":"CHEBI_ID","value":"CHEBI:28088"},{"name":"Chemical_Formula","value":"C15H10O5"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DH2M523P0H"},{"name":"INFOODS","value":"GNSTEIN"},{"name":"Legacy Concept Name","value":"Genistein"},{"name":"Maps_To","value":"Genistein"},{"name":"NCI_Drug_Dictionary_ID","value":"43214"},{"name":"NSC Number","value":"36586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43214"},{"name":"PDQ_Open_Trial_Search_ID","value":"43214"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061202"},{"name":"Unit","value":"mcg"}]}}{"C154552":{"preferredName":"Gentuximab","code":"C154552","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gentuximab","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"794351"},{"name":"NCI_META_CUI","value":"CL555348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794351"},{"name":"PDQ_Open_Trial_Search_ID","value":"794351"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104414":{"preferredName":"Geranylgeranyltransferase I Inhibitor","code":"C104414","definitions":[{"definition":"A substance that inhibits protein geranylgeranyltransferase type 1 (GGTase-I), with potential antineoplastic activity. GGTase-I is involved in the posttranslational modification of a number of oncogenic GTPases, including K-Ras, N-Ras, RhoA, RhoC, Cdc42, RalA, RalB and Rac1. Inhibition of the prenylation of these oncogenic proteins inhibits both their oncogenic activity and membrane localization. This may result in cell cycle arrest and apoptosis. Protein geranylgeranylation, catayzed by GGTase-I, plays a critical role in malignant transformation and cancer cell proliferation, migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Geranylgeranyltransferase I Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"GGTase-I Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"GGTI-I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Geranylgeranyltransferase I Inhibitor"},{"name":"NCI_Drug_Dictionary_ID","value":"745403"},{"name":"NCI_META_CUI","value":"CL445681"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745403"},{"name":"PDQ_Open_Trial_Search_ID","value":"745403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61489":{"preferredName":"GI-4000 Vaccine","code":"C61489","definitions":[{"definition":"A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity. Upon administration, GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras. This may lead to a destruction of cancer cells expressing a Ras mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GI-4000 Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GI-4000_Vaccine"},{"name":"Maps_To","value":"GI-4000 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"486259"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486259"},{"name":"PDQ_Open_Trial_Search_ID","value":"486259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831831"}]}}{"C116722":{"preferredName":"Gilteritinib","code":"C116722","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gilteritinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ASP-2215","termGroup":"CN","termSource":"NCI"},{"termName":"ASP2215","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory acute myeloid leukemia (AML)"},{"name":"CAS_Registry","value":"1254053-43-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"66D92MGC8M"},{"name":"Maps_To","value":"Gilteritinib"},{"name":"NCI_Drug_Dictionary_ID","value":"752319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752319"},{"name":"PDQ_Open_Trial_Search_ID","value":"752319"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896738"}]}}{"C119665":{"preferredName":"Gilteritinib Fumarate","code":"C119665","definitions":[{"definition":"The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gilteritinib Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-, (2E)-2-Butenedioate (2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"ASP-2215 Hemifumarate","termGroup":"CN","termSource":"NCI"},{"termName":"ASP2215 Hemifumarate","termGroup":"CN","termSource":"NCI"},{"termName":"Gilteritinib Hemifumarate","termGroup":"SY","termSource":"NCI"},{"termName":"Xospata","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment(s)."},{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation"},{"name":"CAS_Registry","value":"1254053-84-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5RZZ0Z1GJT"},{"name":"Maps_To","value":"Gilteritinib Fumarate"},{"name":"NCI_Drug_Dictionary_ID","value":"792549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792549"},{"name":"PDQ_Open_Trial_Search_ID","value":"792549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896946"}]}}{"C65804":{"preferredName":"Gimatecan","code":"C65804","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, semi-synthetic lipophilic analogue of camptothecin, a quinoline alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic and antiangiogenic activities. Gimatecan binds to and inhibits the activity of topoisomerase I, stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Although the mechanism of its antiangiogenic activity has yet to be full elucidated, this agent may inhibit endothelial cell migration, tumor neovascularization, and the expression of proangiogenic basic fibroblast growth factor (bFGF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gimatecan","termGroup":"PT","termSource":"NCI"},{"termName":"7-t-Butoxyiminomethylcamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"LBQ707","termGroup":"CN","termSource":"NCI"},{"termName":"STI481","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"292618-32-7"},{"name":"Chemical_Formula","value":"C25H25N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7KKS9R192F"},{"name":"Legacy Concept Name","value":"Gimatecan"},{"name":"Maps_To","value":"Gimatecan"},{"name":"NCI_Drug_Dictionary_ID","value":"537638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537638"},{"name":"PDQ_Open_Trial_Search_ID","value":"537638"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0969276"}]}}{"C2416":{"preferredName":"Gimeracil","code":"C2416","definitions":[{"definition":"A pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly inhibiting the enzyme dihydropyrimidine dehydrogenase causing decreased degradation of the fluoropyrimidines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gimeracil","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-2,4-pyridinediol","termGroup":"SN","termSource":"NCI"},{"termName":"CDHP","termGroup":"AB","termSource":"NCI"},{"termName":"Chlorodihydroxypyridine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103766-25-2"},{"name":"Chemical_Formula","value":"C5H4ClNO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UA8SE1325T"},{"name":"Legacy Concept Name","value":"Chlorodihydroxypyridine"},{"name":"Maps_To","value":"Gimeracil"},{"name":"NCI_Drug_Dictionary_ID","value":"42587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42587"},{"name":"PDQ_Open_Trial_Search_ID","value":"42587"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0535459"}]}}{"C103300":{"preferredName":"Ginsenoside Rg3 Capsule","code":"C103300","definitions":[{"definition":"A capsule containing the steroidal saponin ginsenoside Rg3 isolated from the root of Panax ginseng, with potential cancer preventive and anti-angiogenic activities. Upon oral administration, ginsenoside Rg3 appears to inhibit endothelial cell proliferation, migration and tubular formation, and promotes cancer cell apoptosis. This agent also modulates the activities of certain growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinases (MMPs), on tumor angiogenesis. In addition, ginsenoside Rg3 may be able to sensitize cancer cells to some chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ginsenoside Rg3 Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Shen Yi Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ginsenoside Rg3 Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"742493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742493"},{"name":"PDQ_Open_Trial_Search_ID","value":"742493"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385181"}]}}{"C1960":{"preferredName":"Girentuximab","code":"C1960","definitions":[{"definition":"A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, monoclonal antibody G250 (mAb G250) may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Girentuximab","termGroup":"PT","termSource":"NCI"},{"termName":"cG250","termGroup":"AB","termSource":"NCI"},{"termName":"Chimeric Monoclonal Antibody cG250","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb G250","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody G250","termGroup":"SY","termSource":"NCI"},{"termName":"Rencarex","termGroup":"BR","termSource":"NCI"},{"termName":"WX-G250","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"916138-87-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"539B57DFJF"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_G-250"},{"name":"Maps_To","value":"Girentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"373829"},{"name":"PDQ_Closed_Trial_Search_ID","value":"373829"},{"name":"PDQ_Open_Trial_Search_ID","value":"373829"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0540128"}]}}{"C1373":{"preferredName":"Girodazole","code":"C1373","definitions":[{"definition":"A compound isolated from the marine sponge Pseudaxinyssa cantharella exhibiting anti-tumor activity.  Studies indicate girodazole acts during the elongation/termination steps of protein synthesis, resulting in protein synthesis inhibition. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Girodazole","termGroup":"PT","termSource":"NCI"},{"termName":"3-Amino-1-[4-(2 amino-1H-imidazolyl)]-propanol, 2HCl","termGroup":"SN","termSource":"NCI"},{"termName":"Giroline","termGroup":"SY","termSource":"NCI"},{"termName":"RP 49532A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135824-74-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Girodazole"},{"name":"Maps_To","value":"Girodazole"},{"name":"NSC Number","value":"627434"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0119196"}]}}{"C169931":{"preferredName":"Efgivanermin Alfa","code":"C169931","definitions":[{"definition":"A homogenous hexameric agonist fusion protein composed of the extracellular domain (ECD) of the T-cell costimulatory receptor human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR) ligand (GITRL) and an immunoglobulin (Ig) G1 Fc domain, with potential immunomodulating and antineoplastic activities. Upon administration, efgivanermin alfa binds to and activates GITR found on multiple types of T-cells, thereby inducing both the activation and proliferation of tumor antigen-specific T effector cells. This abrogates the suppression of T effector cells which is induced by inappropriately activated T regulatory cells (Tregs), suppresses Tregs and decreases Treg tumor infiltration, and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including Tregs, effector T-cells, B-cells, dendritic cells (DCs) and natural killer (NK) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efgivanermin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"GITR Agonist MEDI1873","termGroup":"SY","termSource":"NCI"},{"termName":"GITR Stimulant MEDI1873","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 1873","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI1873","termGroup":"CN","termSource":"NCI"},{"termName":"TNFRSF18 Agonist MEDI1873","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF18 Protein Stimulant MEDI1873","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1807864-13-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2R45V0JU8"},{"name":"Maps_To","value":"GITR Agonist MEDI1873"},{"name":"NCI_Drug_Dictionary_ID","value":"776837"},{"name":"NCI_META_CUI","value":"CL1382432"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71716":{"preferredName":"Givinostat","code":"C71716","definitions":[{"definition":"An orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. Givinostat inhibits class I and class II HDACs, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. At low, nonapoptotic concentrations, this agent inhibits the production of pro-inflammatory cytokines such as tumor necrosis factor- (TNF-), interleukin-1 (IL-1), IL-6 and interferon-gamma. Givinostat has also been shown to activate the intrinsic apoptotic pathway, inducing apoptosis in hepatoma cells and leukemic cells. This agent may also exhibit anti-angiogenic activity, inhibiting the production of angiogenic factors such as IL-6 and vascular endothelial cell growth factor (VEGF) by bone marrow stromal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Givinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Gavinostat","termGroup":"SY","termSource":"NCI"},{"termName":"ITF2357","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"497833-27-9"},{"name":"Chemical_Formula","value":"C24H27N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5P60F84FBH"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_ITF2357"},{"name":"Maps_To","value":"Givinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"560751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560751"},{"name":"PDQ_Open_Trial_Search_ID","value":"560751"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987670"}]}}{"C84862":{"preferredName":"Glasdegib","code":"C84862","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glasdegib","termGroup":"PT","termSource":"NCI"},{"termName":"PF 04449913","termGroup":"CN","termSource":"NCI"},{"termName":"PF-04449913","termGroup":"CN","termSource":"NCI"},{"termName":"PF04449913","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1095173-27-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K673DMO5H9"},{"name":"Maps_To","value":"Glasdegib"},{"name":"NCI_META_CUI","value":"CL412426"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156894":{"preferredName":"Glasdegib Maleate","code":"C156894","definitions":[{"definition":"The maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets, binds to and inhibits the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glasdegib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"1-((2R,4R)-2-(1H-Benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate","termGroup":"SN","termSource":"NCI"},{"termName":"Daurismo","termGroup":"BR","termSource":"NCI"},{"termName":"PF 04449913 Maleate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute myeloid leukemia (AML)"},{"name":"CAS_Registry","value":"2030410-25-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TH2EV99S4Z"},{"name":"Maps_To","value":"Glasdegib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"652940"},{"name":"NCI_META_CUI","value":"CL935991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"652940"},{"name":"PDQ_Open_Trial_Search_ID","value":"652940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1114":{"preferredName":"Glaucarubolone","code":"C1114","definitions":[{"definition":"A polycyclic lactone quassinoid phytochemical isolated from the seeds of Hannoa undulata and other plant species with potential antineoplastic activity.  This agent also has antiviral and antitumor properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glaucarubolone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1990-01-8"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glaucarubolone"},{"name":"Maps_To","value":"Glaucarubolone"},{"name":"NSC Number","value":"126764"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061299"}]}}{"C160484":{"preferredName":"Glecaprevir/Pibrentasvir","code":"C160484","definitions":[{"definition":"A fixed dose combination of glecaprevir, an inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease, and pibrentasvir, an inhibitor of the HCV non-structural protein 5A (NS5A), with activity against HCV genotypes 1-6. Upon oral administration of glecaprevir/pibrentasvir, glecaprevir inhibits the HCV NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. Pibrentasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glecaprevir/Pibrentasvir","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-493/ABT-530","termGroup":"CN","termSource":"NCI"},{"termName":"GLE/PIB","termGroup":"BR","termSource":"NCI"},{"termName":"Glecaprevir and Pibrentasvir","termGroup":"SY","termSource":"NCI"},{"termName":"Glecaprevir-Pibrentasvir","termGroup":"SY","termSource":"NCI"},{"termName":"Mavyret","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glecaprevir/Pibrentasvir"},{"name":"NCI_Drug_Dictionary_ID","value":"798328"},{"name":"NCI_META_CUI","value":"CL777819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798328"},{"name":"PDQ_Open_Trial_Search_ID","value":"798328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78449":{"preferredName":"Glembatumumab Vedotin","code":"C78449","definitions":[{"definition":"An antibody-drug conjugate, consisting of the fully human monoclonal antibody CR011 directed against glycoprotein NMB (GPNMB) and conjugated via a cathepsin B-sensitive valine-citrulline (vc) linkage to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody CR011 moiety binds to glycoprotein nmb (GPNMB), expressed on the surfaces of a variety of cancer cell types; upon endocytosis, the synthetic dolastin analogue MMAE is released via enzymatic cleavage into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and apoptosis. The vc linkage system is highly stable in serum, rendering the cytotoxicity of glembatumumab vedotin specific for GPNMB-positive cells. GPNMB is a transmembrane protein overexpressed on the surfaces of various cancer cell types, including melanoma, breast, and prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glembatumumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate CR011-vcMMAE","termGroup":"SY","termSource":"NCI"},{"termName":"CDX-011","termGroup":"CN","termSource":"NCI"},{"termName":"CR011-vcMMAE","termGroup":"CN","termSource":"NCI"},{"termName":"CR011-vcMMAE Immunotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1182215-65-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1568H6A58U"},{"name":"Legacy Concept Name","value":"Antibody-Drug_Conjugate_CR011-vcMMAE"},{"name":"Maps_To","value":"Glembatumumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"599456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599456"},{"name":"PDQ_Open_Trial_Search_ID","value":"599456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698156"}]}}{"C77876":{"preferredName":"Glesatinib","code":"C77876","definitions":[{"definition":"An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Glesatinib binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glesatinib","termGroup":"PT","termSource":"NCI"},{"termName":"MG90265","termGroup":"CN","termSource":"NCI"},{"termName":"MG90265X","termGroup":"CN","termSource":"NCI"},{"termName":"MGCD265","termGroup":"CN","termSource":"NCI"},{"termName":"TKI MGCD265","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936694-12-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7Q29OXD98N"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor_MGCD265"},{"name":"Maps_To","value":"Glesatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"597305"},{"name":"NCI_META_CUI","value":"CL383618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"597305"},{"name":"PDQ_Open_Trial_Search_ID","value":"597305"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107502":{"preferredName":"Glioblastoma Cancer Vaccine ERC1671","code":"C107502","definitions":[{"definition":"A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma Cancer Vaccine ERC1671","termGroup":"PT","termSource":"NCI"},{"termName":"ERC-1671","termGroup":"CN","termSource":"NCI"},{"termName":"ERC1671","termGroup":"CN","termSource":"NCI"},{"termName":"Gliovac","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioblastoma Cancer Vaccine ERC1671"},{"name":"NCI_Drug_Dictionary_ID","value":"751319"},{"name":"NCI_META_CUI","value":"CL451748"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751319"},{"name":"PDQ_Open_Trial_Search_ID","value":"751319"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94211":{"preferredName":"Glioblastoma Multiforme Multipeptide Vaccine IMA950","code":"C94211","definitions":[{"definition":"A cancer vaccine comprised of 11 peptides associated with glioblastoma multiforme (GBM), with potential immunomodulating and antineoplastic activities. Vaccination with glioblastoma multiforme multi-antigen vaccine IMA950 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response as well as a T-helper (Th) immune response against tumor cells expressing these peptides, potentially resulting in decreased tumor growth of GBM. Peptides in IMA950 consist of the following: brevican (BCAN); chondroitin sulfate proteoglycan 4 (CSPG4); fatty acid binding protein 7, brain (FABP7); insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3); neuroligin 4, X-linked (NLGN4X); neuronal cell adhesion molecule (NRCAM); protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1); tenascin C (TNC); Met proto-oncogene (MET); baculoviral IAP repeat-containing 5 (BIRC5); and hepatitis B virus core antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma Multiforme Multipeptide Vaccine IMA950","termGroup":"PT","termSource":"NCI"},{"termName":"IMA950","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioblastoma Multiforme Multipeptide Vaccine IMA950"},{"name":"NCI_Drug_Dictionary_ID","value":"687015"},{"name":"NCI_META_CUI","value":"CL426024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687015"},{"name":"PDQ_Open_Trial_Search_ID","value":"687015"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139000":{"preferredName":"Glioma Lysate Vaccine GBM6-AD","code":"C139000","definitions":[{"definition":"An allogeneic cell lysate-based vaccine derived from the glioma stem cell line GBM6-AD, which was isolated from the brain tumor of a patient diagnosed with glioblastoma multiforme (GBM), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, the glioma lysate vaccine GBM6-AD exposes the immune system to an undefined amount of glioma-associated antigens (GAAs), and stimulates the immune system to mount a specific anti-tumoral, cytotoxic T-lymphocyte (CTL)-mediated response against the GAA-expressing cells, resulting in glioma cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioma Lysate Vaccine GBM6-AD","termGroup":"PT","termSource":"NCI"},{"termName":"GBM6-AD","termGroup":"CN","termSource":"NCI"},{"termName":"GBM6-AD Lysate Protein Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Glioma Cell Lysate Vaccine GBM6-AD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioma Lysate Vaccine GBM6-AD"},{"name":"NCI_Drug_Dictionary_ID","value":"790956"},{"name":"NCI_META_CUI","value":"CL526538"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790956"},{"name":"PDQ_Open_Trial_Search_ID","value":"790956"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114496":{"preferredName":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701","code":"C114496","definitions":[{"definition":"A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701","termGroup":"PT","termSource":"NCI"},{"termName":"SL-701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701"},{"name":"NCI_Drug_Dictionary_ID","value":"759093"},{"name":"NCI_META_CUI","value":"CL472322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759093"},{"name":"PDQ_Open_Trial_Search_ID","value":"759093"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119745":{"preferredName":"Globo H-DT Vaccine OBI-833","code":"C119745","definitions":[{"definition":"A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Globo H-DT Vaccine OBI-833","termGroup":"PT","termSource":"NCI"},{"termName":"Globo H-CRM197 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"OBI-833","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2142641-90-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NC1XBS5AET"},{"name":"Maps_To","value":"Globo H-DT Vaccine OBI-833"},{"name":"NCI_Drug_Dictionary_ID","value":"767196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767196"},{"name":"PDQ_Open_Trial_Search_ID","value":"767196"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896801"}]}}{"C346":{"preferredName":"Glucarpidase","code":"C346","definitions":[{"definition":"A bacterial enzyme that breaks down proteins and other substances, including methotrexate. It is being studied in the treatment of toxic effects caused by methotrexate. It may also help activate certain drugs to kill cancer cells. It is a type of chemoprotective agent and a type of prodrug activator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A zinc-dependent enzyme isolated from a strain of the bacterium Pseudomonas. Because glucarpidase rapidly hydrolyzes methotrexate into inactive metabolites, it may be useful as a rescue agent for methotrexate-induced nephrotoxicity. In antibody-directed enzyme prodrug therapy (ADEPT), this agent is conjugated with an antibody that binds to a specific tumor cell type, allowing for glucarpidase-catalyzed activation of a co-administered prodrug at the site of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glucarpidase","termGroup":"PT","termSource":"NCI"},{"termName":"Acetylaspartylglutamate Dipeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"Carboxypeptidase G2","termGroup":"SY","termSource":"NCI"},{"termName":"CPDG2","termGroup":"AB","termSource":"NCI"},{"termName":"CPG2","termGroup":"AB","termSource":"NCI"},{"termName":"Poly(gamma-glutamic Acid) Endohydrolase","termGroup":"SY","termSource":"NCI"},{"termName":"Pteroylpolygammaglutamyl Hydrolase","termGroup":"SY","termSource":"NCI"},{"termName":"Voraxaze","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9074-87-7"},{"name":"Chemical_Formula","value":"C20H20O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2GFP9BJD79"},{"name":"Legacy Concept Name","value":"Carboxypeptidase-G2"},{"name":"Maps_To","value":"Glucarpidase"},{"name":"NCI_Drug_Dictionary_ID","value":"41665"},{"name":"NSC Number","value":"641273"},{"name":"NSC Number","value":"732443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41665"},{"name":"PDQ_Open_Trial_Search_ID","value":"41665"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0007072"}]}}{"C162509":{"preferredName":"Glucocorticoid Receptor Antagonist ORIC-101","code":"C162509","definitions":[{"definition":"A mifepristone-based steroidal glucocorticoid receptor (GR) antagonist with potential antineoplastic activity. Upon oral administration, ORIC-101 selectively binds to GRs, thereby inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers. Due to its reduced androgen receptor (AR) agonistic activity and improved cytochrome P450 2C8 (CYP2C8) and 2C9 (CYP2C9) inhibition profile, ORIC-101 may be useful in the treatment of AR-positive tumors with reduced potential for drug-drug interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glucocorticoid Receptor Antagonist ORIC-101","termGroup":"PT","termSource":"NCI"},{"termName":"19,21-Dinorchol-4-en-20(22)-yn-3-one, 17-Hydroxy-23,23-dimethyl-11-(4-(methyl(1-methylethyl)amino)phenyl)-, (11.Beta.,17.Alpha.)-","termGroup":"SN","termSource":"NCI"},{"termName":"GR Antagonist ORIC-101","termGroup":"SY","termSource":"NCI"},{"termName":"ORIC 101","termGroup":"CN","termSource":"NCI"},{"termName":"ORIC-101","termGroup":"CN","termSource":"NCI"},{"termName":"ORIC101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222344-98-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VI6E2D3CYP"},{"name":"Maps_To","value":"Glucocorticoid Receptor Antagonist ORIC-101"},{"name":"NCI_Drug_Dictionary_ID","value":"798818"},{"name":"NCI_META_CUI","value":"CL970945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798818"},{"name":"PDQ_Open_Trial_Search_ID","value":"798818"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1612":{"preferredName":"Glufosfamide","code":"C1612","definitions":[{"definition":"A compound consisting of the mustard agent ifosforamide conjugated to glucose, with potential alkylating activity. Glufosfamide is cleaved by glucosidases in tumor cells and forms ifosforamide. In turn, ifosforamide alkylates and forms DNA crosslinks, thereby inhibiting DNA replication and subsequent cell growth. The glucose moiety may enhance this agent's uptake by tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glufosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"Beta-D-Glucosyl-Ifosfamide Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"D-19575","termGroup":"CN","termSource":"NCI"},{"termName":"glc-IPM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"132682-98-5"},{"name":"Chemical_Formula","value":"C10H21Cl2N2O7P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1W5N8SZD9A"},{"name":"Legacy Concept Name","value":"Glufosfamide"},{"name":"Maps_To","value":"Glufosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"42676"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42676"},{"name":"PDQ_Open_Trial_Search_ID","value":"42676"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0380377"}]}}{"C156700":{"preferredName":"Gumarontinib","code":"C156700","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, gumarontinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gumarontinib","termGroup":"PT","termSource":"NCI"},{"termName":"Glumetinib","termGroup":"SY","termSource":"NCI"},{"termName":"SCC 244","termGroup":"CN","termSource":"NCI"},{"termName":"SCC-244","termGroup":"CN","termSource":"NCI"},{"termName":"SCC244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1642581-63-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7JTT036WGX"},{"name":"Maps_To","value":"Glumetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"795718"},{"name":"NCI_META_CUI","value":"CL935869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795718"},{"name":"PDQ_Open_Trial_Search_ID","value":"795718"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114381":{"preferredName":"Telaglenastat","code":"C114381","definitions":[{"definition":"An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telaglenastat","termGroup":"PT","termSource":"NCI"},{"termName":"CB-839","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10815","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1439399-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U6CL98GLP4"},{"name":"Maps_To","value":"Glutaminase Inhibitor CB-839"},{"name":"Maps_To","value":"Telaglenastat"},{"name":"NCI_Drug_Dictionary_ID","value":"758477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758477"},{"name":"PDQ_Open_Trial_Search_ID","value":"758477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827146"}]}}{"C150413":{"preferredName":"Telaglenastat Hydrochloride","code":"C150413","definitions":[{"definition":"The hydrochloride salt form of CB-839, an orally bioavailable inhibitor of glutaminase, with potential antineoplastic and immunostimulating activities. Upon oral administration, CB-839 selectively and reversibly binds to and inhibits human glutaminase, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, CB-839 causes accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon cell death. As glutamine is essential for T-cell generation, CB-839 may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telaglenastat Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CB-839 HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Glutaminase Inhibitor CB-839 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1874231-60-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B33561JJ61"},{"name":"Maps_To","value":"Glutaminase Inhibitor CB-839 Hydrochloride"},{"name":"Maps_To","value":"Telaglenastat Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"801359"},{"name":"NCI_META_CUI","value":"CL552142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801359"},{"name":"PDQ_Open_Trial_Search_ID","value":"801359"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106121":{"preferredName":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101","code":"C106121","definitions":[{"definition":"A glutathione (GSH) pegylated, liposome-encapsulated preparation of the hydrochloride salt form of the anthracycline antineoplastic antibiotic doxorubicin, with potential anetineoplastic activity. Upon administration, the glutathione pegylated liposomal formulation 2B3-101 specifically delivers doxorubicin into the brain. Doxorubicin intercalates between DNA base pairs and interferes with topoisomerase II activity, which inhibits both DNA replication and RNA synthesis, resulting in cancer cell death and tumor regression. Doxorubicin also generates reactive oxygen species, which causes cell membrane lipid peroxidation leading to cytotoxicity. The pegylated liposomal delivery of doxorubicin improves drug penetration into tumors and prolongs circulation time, thereby increasing doxorubicin's efficacy and decreasing its toxicity. Conjugation of GSH to the PEG molecules directs the liposomes to the GSH transporters on the blood brain barrier (BBB) and improves the delivery of doxorubicin into the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101","termGroup":"PT","termSource":"NCI"},{"termName":"2B3-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101"},{"name":"NCI_Drug_Dictionary_ID","value":"748730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748730"},{"name":"PDQ_Open_Trial_Search_ID","value":"748730"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827174"}]}}{"C151952":{"preferredName":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01","code":"C151952","definitions":[{"definition":"A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01","termGroup":"PT","termSource":"NCI"},{"termName":"CHO H01","termGroup":"CN","termSource":"NCI"},{"termName":"CHO-H01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OJ72N0B4UC"},{"name":"Maps_To","value":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01"},{"name":"NCI_Drug_Dictionary_ID","value":"793171"},{"name":"NCI_META_CUI","value":"CL553180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793171"},{"name":"PDQ_Open_Trial_Search_ID","value":"793171"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97917":{"preferredName":"Glycooptimized Trastuzumab-GEX","code":"C97917","definitions":[{"definition":"A glycoengineered form of a monoclonal antibody directed against the human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. Glycooptimized trastuzumab-GEX specifically binds to the extracellular domain of HER2, thereby inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. This eventually results in apoptosis and growth inhibition of tumor cells. HER2, a member of the receptor tyrosine kinase EGFR superfamily, is overexpressed on the cell surfaces of various solid tumors. This agent has a specific glycosylation profile that may enhance its ADCC response against HER2-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glycooptimized Trastuzumab-GEX","termGroup":"PT","termSource":"NCI"},{"termName":"Ant-HER2 Monoclonal Antibody GT-Mab 7.3-GEX","termGroup":"SY","termSource":"NCI"},{"termName":"GT-Mab 7.3-GEX","termGroup":"SY","termSource":"NCI"},{"termName":"TrasGEX","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glycooptimized Trastuzumab-GEX"},{"name":"NCI_Drug_Dictionary_ID","value":"708211"},{"name":"NCI_META_CUI","value":"CL430400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"708211"},{"name":"PDQ_Open_Trial_Search_ID","value":"708211"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98287":{"preferredName":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102","code":"C98287","definitions":[{"definition":"A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102","termGroup":"PT","termSource":"NCI"},{"termName":"CGTG-102","termGroup":"CN","termSource":"NCI"},{"termName":"ONCOS-102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102"},{"name":"NCI_Drug_Dictionary_ID","value":"712555"},{"name":"NCI_META_CUI","value":"CL432405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712555"},{"name":"PDQ_Open_Trial_Search_ID","value":"712555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74037":{"preferredName":"Gold Sodium Thiomalate","code":"C74037","definitions":[{"definition":"The sodium salt of gold thiomalic acid, an organogold compound with antirheumatic and potential antineoplastic activities. Gold sodium thiomalate (GST) appears to inhibit the activity of atypical protein kinase C iota (PKCiota) by forming a cysteinyl-aurothiomalate adduct with the cysteine residue Cys-69 within the PB1 binding domain of PKCiota. This prevents the binding of Par6 (Partitioning defective protein 6) to PKCiota, thereby inhibiting PKCiota-mediated oncogenic signaling, which may result in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. Atypical PKCiota, a serine/threonine kinase overexpressed in numerous cancer cell types, plays an important role in cancer proliferation, invasion, and survival; Par6 is a scaffold protein that facilitates atypical PKC-mediated phosphorylation of cytoplasmic proteins involved in epithelial and neuronal cell polarization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gold Sodium Thiomalate","termGroup":"PT","termSource":"NCI"},{"termName":"Aurolate","termGroup":"BR","termSource":"NCI"},{"termName":"Aurothiomalate Disodium","termGroup":"SY","termSource":"NCI"},{"termName":"Myochrysine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12244-57-4"},{"name":"CHEBI_ID","value":"CHEBI:5516"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E4768ZY6GM"},{"name":"Legacy Concept Name","value":"Gold_Sodium_Thiomalate"},{"name":"Maps_To","value":"Gold Sodium Thiomalate"},{"name":"NCI_Drug_Dictionary_ID","value":"581226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581226"},{"name":"PDQ_Open_Trial_Search_ID","value":"581226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0018034"}]}}{"C26444":{"preferredName":"Golnerminogene Pradenovec","code":"C26444","definitions":[{"definition":"A gene therapy product that is being studied in combination with radiation therapy in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golnerminogene Pradenovec","termGroup":"PT","termSource":"NCI"},{"termName":"Ad 5-TNF Alpha","termGroup":"AB","termSource":"NCI"},{"termName":"Adenovirus 5-Tumor Necrosis Factor Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"ADgv EGR.TNF.11D","termGroup":"CN","termSource":"NCI"},{"termName":"TNFerade","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of solid tumors including pancreatic cancer"},{"name":"CAS_Registry","value":"957472-14-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenovirus_5-Tumor_Necrosis_Factor_Alpha"},{"name":"Maps_To","value":"Golnerminogene Pradenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"258431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"258431"},{"name":"PDQ_Open_Trial_Search_ID","value":"258431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327819"}]}}{"C76497":{"preferredName":"Golotimod","code":"C76497","definitions":[{"definition":"An orally bioavailable synthetic peptide containing the amino acids D-glutamine and L-tryptophan connected by a gamma-glutamyl linkage with potential immunostimulating, antimicrobial and antineoplastic activities. Although the exact mechanism of action is unknown, golotimod appears to inhibit the expression of STAT-3, reversing immunosuppression and stimulating an anti-tumor immune response. This agent may stimulate the production of T-lymphocytes, in particular the helper T (Th1) cells, activate macrophages, and increase levels of interleukin 2 and interferon gamma. STAT-3, a transcription factor upregulated in many cancer cell types, is involved in tumor cell growth and survival and immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golotimod","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"gamma-D-Glu-L-trp","termGroup":"AB","termSource":"NCI"},{"termName":"Gamma-D-Glutamyl-L-Tryptophan","termGroup":"SY","termSource":"NCI"},{"termName":"SCV 07","termGroup":"CN","termSource":"NCI"},{"termName":"SCV-07","termGroup":"CN","termSource":"NCI"},{"termName":"SCV07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"229305-39-9"},{"name":"Chemical_Formula","value":"C16H19N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"637C487Y09"},{"name":"Legacy Concept Name","value":"Golotimod"},{"name":"Maps_To","value":"Golotimod"},{"name":"NCI_Drug_Dictionary_ID","value":"617379"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617379"},{"name":"PDQ_Open_Trial_Search_ID","value":"617379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1173247"}]}}{"C82363":{"preferredName":"Golvatinib","code":"C82363","definitions":[{"definition":"An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golvatinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-cyclopropanedicarboxamide, N-(2-fluoro-4-((2-(((4-(4-methyl-1-piperazinyl)-1-piperidinyl)carbonyl)amino)-4-pyridinyl)oxy)phenyl)-N'-(4-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"c-Met/VEGFR-2 Kinase Inhibitor E7050","termGroup":"SY","termSource":"NCI"},{"termName":"E7050","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"928037-13-2"},{"name":"Chemical_Formula","value":"C33H37F2N7O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"516Z3YP58E"},{"name":"Legacy Concept Name","value":"c-Met_VEGFR_Kinase_Inhibitor_E7050"},{"name":"Maps_To","value":"Golvatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"640626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640626"},{"name":"PDQ_Open_Trial_Search_ID","value":"640626"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642430"}]}}{"C1910":{"preferredName":"Gonadotropin-releasing Hormone Analog","code":"C1910","definitions":[{"definition":"A substance that keeps the testicles and ovaries from making sex hormones by blocking other hormones that are needed to make them. In men, gonadotropin-releasing hormone agonists cause the testicles to stop making testosterone. In women, they cause the ovaries to stop making estrogen and progesterone. Some gonadotropin-releasing hormone agonists are used to treat prostate cancer. Also called GnRH agonist, LH-RH agonist, and luteinizing hormone-releasing hormone agonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadotropin-releasing Hormone Analog","termGroup":"PT","termSource":"NCI"},{"termName":"GnRH Agonist","termGroup":"SY","termSource":"NCI"},{"termName":"GnRH Analog","termGroup":"SY","termSource":"NCI"},{"termName":"Gonadotropin-Releasing Hormone Agonist","termGroup":"SY","termSource":"NCI"},{"termName":"Gonadotropin-Releasing Hormone Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"LH-RH Analogs","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinizing Hormone-Releasing Hormone Analog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Luteinizing_Hormone-releasing_Hormone_Agonist"},{"name":"Maps_To","value":"Gonadotropin-releasing Hormone Analog"},{"name":"NCI_Drug_Dictionary_ID","value":"42628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42628"},{"name":"PDQ_Open_Trial_Search_ID","value":"42628"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1268900"}]}}{"C1374":{"preferredName":"Goserelin","code":"C1374","definitions":[{"definition":"A drug that belongs to the family of drugs called gonadotropin-releasing hormone analogues. Goserelin is used to block hormone production in the ovaries or testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goserelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"ICI-118630","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Endometrial-thinning; Endometriosis; In vitro fertilization; Prostate cancer"},{"name":"CAS_Registry","value":"65807-02-5"},{"name":"Chemical_Formula","value":"C59H84N18O14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"0F65R8P09N"},{"name":"Legacy Concept Name","value":"Goserelin"},{"name":"Maps_To","value":"Goserelin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0120107"}]}}{"C1417":{"preferredName":"Goserelin Acetate","code":"C1417","definitions":[{"definition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goserelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"D-Ser(bu(t))(6)azgly(10)-LHRH Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"ZDX","termGroup":"AB","termSource":"NCI"},{"termName":"Zoladex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast Carcinoma; Prostate Carcinoma; Endometriosis"},{"name":"CAS_Registry","value":"65807-02-5"},{"name":"Chemical_Formula","value":"C59H84N18O14.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YUU2PV0U8"},{"name":"Legacy Concept Name","value":"Goserelin_Acetate"},{"name":"Maps_To","value":"Goserelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"40224"},{"name":"NSC Number","value":"606864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40224"},{"name":"PDQ_Open_Trial_Search_ID","value":"40224"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700476"}]}}{"C156710":{"preferredName":"Goserelin Acetate Extended-release Microspheres LY01005","code":"C156710","definitions":[{"definition":"A long-acting, extended-release microsphere formulation of the acetate form of goserelin, a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH), with potential antineoplastic activity. Upon administration, goserelin binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in an extended-release formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goserelin Acetate Extended-release Microspheres LY01005","termGroup":"PT","termSource":"NCI"},{"termName":"Goserelin Acetate Extended-release Microspheres","termGroup":"SY","termSource":"NCI"},{"termName":"LY 01005","termGroup":"CN","termSource":"NCI"},{"termName":"LY-01005","termGroup":"SY","termSource":"NCI"},{"termName":"LY01005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Goserelin Acetate Extended-release Microspheres LY01005"},{"name":"NCI_Drug_Dictionary_ID","value":"795737"},{"name":"NCI_META_CUI","value":"CL935864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795737"},{"name":"PDQ_Open_Trial_Search_ID","value":"795737"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C529":{"preferredName":"Gossypol","code":"C529","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It comes from the seed of the cotton plant (Gossypium). It blocks the growth of cells and may kill cancer cells. Cottonseed meal toxin may also act as a male contraceptive (a type of birth control).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active polyphenolic aldehyde with potential antineoplastic activity. Derived primarily from unrefined cottonseed oil, gossypol induces cell cycle arrest at the G0/G1 phase, thereby inhibiting DNA replication and inducing apoptosis. This agent also inhibits cell-signaling enzymes, resulting in inhibition of cell growth, and may act as a male contraceptive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gossypol","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-Gossypol","termGroup":"SY","termSource":"NCI"},{"termName":"1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde","termGroup":"SN","termSource":"NCI"},{"termName":"1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3-3'-dimethyl[2,2'-binaphthalene]-8,8'-dicarboxaldehyde","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-bis(1,6,7-trihydroxy-4-methyl-5-isopropyl-8-aldehydonaphthalene)","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-bis[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]","termGroup":"SN","termSource":"NCI"},{"termName":"BL-193","termGroup":"CN","termSource":"NCI"},{"termName":"Cottonseed Meal Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"No Fertil","termGroup":"BR","termSource":"NCI"},{"termName":"Pogosin","termGroup":"SY","termSource":"NCI"},{"termName":"Tash 1","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"303-45-7"},{"name":"CHEBI_ID","value":"CHEBI:28584"},{"name":"Chemical_Formula","value":"C30H30O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KAV15B369O"},{"name":"Legacy Concept Name","value":"Gossypol"},{"name":"Maps_To","value":"Gossypol"},{"name":"NCI_Drug_Dictionary_ID","value":"505287"},{"name":"NSC Number","value":"56817"},{"name":"NSC Number","value":"624336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"505287"},{"name":"PDQ_Open_Trial_Search_ID","value":"505287"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0018096"}]}}{"C1118":{"preferredName":"Gossypol Acetic Acid","code":"C1118","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It is a form of a chemical taken from the seed of the cotton plant (Gossypium). It blocks the growth of cells and may kill cancer cells. Gossypol acetic acid may also act as a male contraceptive (form of birth control).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The naturally occurring acetic acid form of gossypol, and an orally available polyphenolic aldehyde derived mostly from cottonseed with potential antineoplastic activity.  The biologic activities of gossypol acetic acid are similar to those of gossypol and include suppression of DNA replication, inhibition of tumor cell proliferation, and male contraceptive effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gossypol Acetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Gossypol Acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12542-36-8"},{"name":"Chemical_Formula","value":"C30H30O8.C2H4O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S7RL72610R"},{"name":"Legacy Concept Name","value":"Gossypol_Acetic_Acid"},{"name":"Maps_To","value":"Gossypol Acetic Acid"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061824"}]}}{"C124131":{"preferredName":"Grapiprant","code":"C124131","definitions":[{"definition":"An orally bioavailable antagonist of the prostaglandin E receptor subtype 4 (EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration of grapiprant, this agent selectively binds to and inhibits the binding of prostaglandin E2 (PGE2) and prevents the activation of the EP4 receptor. This inhibits PGE2-EP4 receptor-mediated signaling and prevents proliferation in tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 receptor inhibition modulates the immune system by preventing both interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. As EP4 is expressed by peripheral sensory neurons, blockade of EP4-mediated signaling may induce an analgesic effect. EP4, a prostanoid receptor subtype, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grapiprant","termGroup":"PT","termSource":"NCI"},{"termName":"AAT-007","termGroup":"CN","termSource":"NCI"},{"termName":"AT-001","termGroup":"CN","termSource":"NCI"},{"termName":"CJ 023,423","termGroup":"CN","termSource":"NCI"},{"termName":"CJ-023,423","termGroup":"CN","termSource":"NCI"},{"termName":"CJ023,423","termGroup":"CN","termSource":"NCI"},{"termName":"N-[[2,4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenylethylamino]carbonyl]-4-methyl-benzenesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"RQ-00000007","termGroup":"CN","termSource":"NCI"},{"termName":"RQ-07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"415903-37-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J9F5ZPH7NB"},{"name":"Maps_To","value":"Grapiprant"},{"name":"NCI_Drug_Dictionary_ID","value":"776626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776626"},{"name":"PDQ_Open_Trial_Search_ID","value":"776626"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4279768"}]}}{"C97514":{"preferredName":"Green Tea Extract-based Antioxidant Supplement","code":"C97514","definitions":[{"definition":"A dietary supplement containing a green tea extract including the catechin epigallocatechin gallate and other vitamins and antioxidants, with potential antineoplastic and chemopreventive activities. The polyphenols in green tea act as antioxidants and scavenge free radicals which may inhibit cellular oxidation and prevent free radical damage to cells. In addition, polyphenols may affect enzymes involved in cellular reproduction and tumor angiogenesis by modulating angiogenic factors. Other ingredients in green tea extract-based antioxidant supplement include dry cinnamon extract, germanium, zinc sulfate, manganese sulfate, arginine, cysteine, malic acid, ascorbic acid (vitamin c), glycyrrhizinic acid, glycine, glucosamine, pyridoxal (vitamin B6), calcium pantothenate (vitamin B5), folic acid, cyanocobalamin (vitamin B12).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Green Tea Extract-based Antioxidant Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Oncoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Green Tea Extract-based Antioxidant Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"703891"},{"name":"NCI_META_CUI","value":"CL430258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703891"},{"name":"PDQ_Open_Trial_Search_ID","value":"703891"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116872":{"preferredName":"Osugacestat","code":"C116872","definitions":[{"definition":"A small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon intravenous administration, osugacestat binds to GS and blocks activation of Notch receptors, which may inhibit the proliferation of tumor cells with an overly-active Notch pathway. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains that lead to their activation. Overactivation of the Notch signaling pathway, often triggered by activating mutations, has been correlated with increased cellular proliferation and poor prognosis in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osugacestat","termGroup":"PT","termSource":"NCI"},{"termName":"AL 101","termGroup":"CN","termSource":"NCI"},{"termName":"AL-101","termGroup":"CN","termSource":"NCI"},{"termName":"AL101","termGroup":"CN","termSource":"NCI"},{"termName":"BM-0018","termGroup":"CN","termSource":"NCI"},{"termName":"BM0018","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-906024","termGroup":"CN","termSource":"NCI"},{"termName":"GS/pan-Notch Inhibitor AL101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401066-79-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DRL23N424R"},{"name":"Maps_To","value":"GS/pan-Notch Inhibitor AL101"},{"name":"NCI_Drug_Dictionary_ID","value":"695660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695660"},{"name":"PDQ_Open_Trial_Search_ID","value":"695660"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896900"}]}}{"C118573":{"preferredName":"GS/pan-Notch Inhibitor AL102","code":"C118573","definitions":[{"definition":"An orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, GS/pan-Notch inhibitor AL102 binds to GS and blocks the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth of tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains and leads to their activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GS/pan-Notch Inhibitor AL102","termGroup":"PT","termSource":"NCI"},{"termName":"AL 102","termGroup":"CN","termSource":"NCI"},{"termName":"AL-102","termGroup":"CN","termSource":"NCI"},{"termName":"AL102","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986115","termGroup":"CN","termSource":"NCI"},{"termName":"WHG 626","termGroup":"CN","termSource":"NCI"},{"termName":"WHG-626","termGroup":"CN","termSource":"NCI"},{"termName":"WHG626","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1584647-27-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LSK1L593UU"},{"name":"Maps_To","value":"GS/pan-Notch Inhibitor BMS-986115"},{"name":"NCI_Drug_Dictionary_ID","value":"754986"},{"name":"NCI_META_CUI","value":"CL471756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754986"},{"name":"PDQ_Open_Trial_Search_ID","value":"754986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156792":{"preferredName":"Elraglusib","code":"C156792","definitions":[{"definition":"A maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3; serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Upon intravenous administration, elraglusib binds to and competitively inhibits GSK-3, which may lead to downregulation of nuclear factor kappa B (NF-kappaB) and decreased expression of NF-kappaB target genes including cyclin D1, B-cell lymphoma 2 (Bcl-2), anti-apoptotic protein XIAP, and B-cell lymphoma extra-large (Bcl-XL). This may inhibit NF-kappaB-mediated survival and chemoresistance in certain tumor types. GSK-3, a constitutively active serine/threonine kinase that plays a role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and metabolism, is aberrantly overexpressed in certain tumor types and may promote tumor cell survival and resistance to chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elraglusib","termGroup":"PT","termSource":"NCI"},{"termName":"9 ING 41","termGroup":"CN","termSource":"NCI"},{"termName":"9-ING-41","termGroup":"CN","termSource":"NCI"},{"termName":"Glycogen Synthase Kinase-3 Inhibitor 9-ING-41","termGroup":"SY","termSource":"NCI"},{"termName":"GSK-3 Inhibitor 9-ING-41","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1034895-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ND1SOF0DLU"},{"name":"Maps_To","value":"GSK-3 Inhibitor 9-ING-41"},{"name":"NCI_Drug_Dictionary_ID","value":"796464"},{"name":"NCI_META_CUI","value":"CL935798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796464"},{"name":"PDQ_Open_Trial_Search_ID","value":"796464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116849":{"preferredName":"GSK-3 Inhibitor LY2090314","code":"C116849","definitions":[{"definition":"An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK-3 in an ATP-competitive manner. This prevents GSK-3-mediated phosphorylation of beta-catenin, which inhibits the subsequent ubiquitination and proteasomal degradation of beta-catenin. This leads to the activation of the Wnt/beta-catenin pathway and the induction of apoptosis in susceptible tumor cells. GSK-3, a serine/threonine kinase, plays a key role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and apoptosis. The Wnt/beta-catenin signaling pathway plays key roles in both cellular proliferation and differentiation. The increased expression of beta-catenin, a transcriptional activator, correlates with decreased cellular proliferation and improved prognosis in select cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GSK-3 Inhibitor LY2090314","termGroup":"PT","termSource":"NCI"},{"termName":"3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"LY 2090314","termGroup":"CN","termSource":"NCI"},{"termName":"LY-2090314","termGroup":"CN","termSource":"NCI"},{"termName":"LY2090314","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"603288-22-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"822M3GYM67"},{"name":"Maps_To","value":"GSK-3 Inhibitor LY2090314"},{"name":"NCI_Drug_Dictionary_ID","value":"686910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686910"},{"name":"PDQ_Open_Trial_Search_ID","value":"686910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3713994"}]}}{"C95209":{"preferredName":"Guadecitabine","code":"C95209","definitions":[{"definition":"A dinucleotide antimetabolite composed of a decitabine linked via phosphodiester bond to a deoxyguanosine, with potential antineoplastic activity. Following metabolic activation via cleavage of the phosphodiester bond and incorporation of the decitabine moiety into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing non-specific, genome-wide hypomethylation, and induction of cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, which may result in gradual release of decitabine both extra- and intra-cellularly, leading to prolonged exposure to decitabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guadecitabine","termGroup":"PT","termSource":"NCI"},{"termName":"DNMT inhibitor SGI-110","termGroup":"AB","termSource":"NCI"},{"termName":"S110","termGroup":"CN","termSource":"NCI"},{"termName":"SGI-110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"929901-49-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2KT4YN1DP7"},{"name":"Maps_To","value":"Guadecitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"691684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691684"},{"name":"PDQ_Open_Trial_Search_ID","value":"691684"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986994"}]}}{"C65826":{"preferredName":"Guanabenz Acetate","code":"C65826","definitions":[{"definition":"The orally bioavailable, acetate salt form of guanabenz, a centrally-acting alpha-2 adrenergic receptor agonist, with anti-hypertensive and potential antineoplastic, cytoprotective and bone resorption inhibitory activities. Upon oral administration, guanabenz suppresses endoplasmic reticulum (ER) stress by inhibiting the stress-induced dephosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2a), thereby enhancing the phosphorylation level of eIF2a. This causes elF2a-mediated downregulation of the Rac1 pathway, upregulates the expression of activating transcription factor 4 (ATF4), which plays a key role in osteoblastogenesis, and downregulates the expression of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), which is a transcription factor that plays a key role in osteoclastogenesis. This enhances osteoblastogenesis and suppresses osteoclastogenesis. Altogether, this promotes new bone formation and prevents bone degradation. In addition, guanabenz blocks the proliferation, survival, motility and invasiveness of tumor cells through the eIF2a-mediated downregulation of Rac1 signaling. Rac1, a Ras-related small GTPase belonging to the Rho family, plays a key role in tumor cell proliferation, survival and motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guanabenz Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"3-((2,6-Dichlorophenyl)methylene)carbazamidine Monoacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Wytensin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23256-50-0"},{"name":"Chemical_Formula","value":"C8H8Cl2N4.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"443O19GK1A"},{"name":"Legacy Concept Name","value":"Guanabenz_Acetate"},{"name":"Maps_To","value":"Guanabenz Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"772252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772252"},{"name":"PDQ_Open_Trial_Search_ID","value":"772252"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0018313"}]}}{"C150390":{"preferredName":"Guselkumab","code":"C150390","definitions":[{"definition":"An orally available, human, immunoglobulin G1 (IgG1) kappa, monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon administration, guselkumab binds to the p19 subunit of IL-23, thereby blocking the binding of IL-23 to the IL-23 receptor. This inhibits IL-23-mediated signaling and the differentiation of CD4-positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated immune responses and inhibits the production of pro-inflammatory cytokines. This may prevent or reduce symptoms and severity of immune-mediated inflammatory disorders. IL-23 plays a key role in the regulation of inflammation and the immune system, and modulates the release of various pro-inflammatory cytokines and chemokines. It is upregulated in various immune-mediated inflammatory disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guselkumab","termGroup":"PT","termSource":"NCI"},{"termName":"CNTO 1959","termGroup":"CN","termSource":"NCI"},{"termName":"Tremfya","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1350289-85-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"089658A12D"},{"name":"Maps_To","value":"Guselkumab"},{"name":"NCI_Drug_Dictionary_ID","value":"792847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792847"},{"name":"PDQ_Open_Trial_Search_ID","value":"792847"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852217"}]}}{"C1598":{"preferredName":"Gusperimus Trihydrochloride","code":"C1598","definitions":[{"definition":"A derivative of the antitumor antibiotic spergualin with immunosuppressant activity.  Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gusperimus Trihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-Amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione","termGroup":"SN","termSource":"NCI"},{"termName":"15-Deoxyspergualin","termGroup":"SN","termSource":"NCI"},{"termName":"15-Deoxyspergualin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"7-[(Aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amnio]-1-hydroxy-2-oxoethyl]heptanamide","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-181173","termGroup":"CN","termSource":"NCI"},{"termName":"BMY-42215-1","termGroup":"CN","termSource":"NCI"},{"termName":"Deoxyspergualin","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxyspergualin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"DSG","termGroup":"AB","termSource":"NCI"},{"termName":"N-[[[4-[(3-Aminopropyl)amino]-butyl]carbamoyl]hydroxymethyl]-7-guanidinoheptanamide","termGroup":"SN","termSource":"NCI"},{"termName":"NKT-01","termGroup":"CN","termSource":"NCI"},{"termName":"Spanidin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84937-45-1"},{"name":"Chemical_Formula","value":"C17H37N7O3.3HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QZS4144IO0"},{"name":"Legacy Concept Name","value":"Gusperimus"},{"name":"Maps_To","value":"Gusperimus Trihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"40369"},{"name":"NSC Number","value":"356894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40369"},{"name":"PDQ_Open_Trial_Search_ID","value":"40369"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0284559"}]}}{"C1532":{"preferredName":"Gutolactone","code":"C1532","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Simaba guianensis with potential antineoplastic and antimalarial activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gutolactone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152369-48-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gutolactone"},{"name":"Maps_To","value":"Gutolactone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0250977"}]}}{"C2024":{"preferredName":"H-ras Antisense Oligodeoxynucleotide ISIS 2503","code":"C2024","definitions":[{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic oligodeoxynucleotide.  Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the oncogene H-Ras.  ISIS 2503 selectively inhibits the expression of H-Ras, and may inhibit the growth of some Ras-dependent tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H-ras Antisense Oligodeoxynucleotide ISIS 2503","termGroup":"PT","termSource":"NCI"},{"termName":"H-RAS Antisense","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 2503","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-2503","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS2503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149957-14-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I444I66XWH"},{"name":"Legacy Concept Name","value":"ISIS_2503"},{"name":"Maps_To","value":"H-ras Antisense Oligodeoxynucleotide ISIS 2503"},{"name":"NCI_Drug_Dictionary_ID","value":"37795"},{"name":"NSC Number","value":"718878"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37795"},{"name":"PDQ_Open_Trial_Search_ID","value":"37795"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879385"}]}}{"C114284":{"preferredName":"H1299 Tumor Cell Lysate Vaccine","code":"C114284","definitions":[{"definition":"A cell lysate derived from a lung cancer cell line, H1299, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, the H1299 tumor cell lysate exposes the immune system to an undefined amount of tumor associated antigens (TAA), particularly cancer testis antigens (CTAs), which may result in the induction of both anti-tumoral cytotoxic T-lymphocytes (CTL) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. CTAs, such as MAGE, are selectively expressed in a variety of cancers but are not expressed in normal, healthy cells outside the testis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H1299 Tumor Cell Lysate Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"H1299 Lysate Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H1299 Tumor Cell Lysate Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"757927"},{"name":"NCI_META_CUI","value":"CL471792"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757927"},{"name":"PDQ_Open_Trial_Search_ID","value":"757927"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148522":{"preferredName":"HAAH Lambda phage Vaccine SNS-301","code":"C148522","definitions":[{"definition":"A nanoparticle-based cancer vaccine composed of a neutralized bacteriophage Lambda construct that is genetically engineered to contain peptide fragments of human aspartyl/asparaginyl beta-hydroxylase (HAAH; ASPH) on its surface and are fused to the C-terminus of the head protein of phage lambda gpD, with potential immunostimulating and antineoplastic activities. HAAH lambda phage vaccine SNS-301 also contains DNA fragments representing the phage CpG motif that activate the MHC class II pathway. Upon intradermal administration of the HAAH lambda phage vaccine SNS-301, the bacteriophage exposes the immune system to HAAH, producing a HAAH-specific antibody response, and may activate the immune system to induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against HAAH-expressing tumor cells. HAAH is a transmembrane protein and highly conserved enzyme that catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of substrate proteins. HAAH is normally expressed in fetal development and is upregulated in a variety of cancer cell types, while its expression is nearly absent in healthy, normal cells. HAAH plays a key role in cancer cell growth, cell motility and invasiveness. Its expression is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HAAH Lambda phage Vaccine SNS-301","termGroup":"PT","termSource":"NCI"},{"termName":"Bacteriophage Cancer Vaccine SNS-301","termGroup":"SY","termSource":"NCI"},{"termName":"HAAH-1/2/3 Lambda Phage Vaccine SNS-301","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle HAAH Vaccine SNS-301","termGroup":"SY","termSource":"NCI"},{"termName":"PAN 301-1","termGroup":"CN","termSource":"NCI"},{"termName":"PAN-301-1","termGroup":"CN","termSource":"NCI"},{"termName":"SNS 301","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-301","termGroup":"CN","termSource":"NCI"},{"termName":"SNS301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HAAH Lambda phage Vaccine SNS-301"},{"name":"NCI_Drug_Dictionary_ID","value":"792681"},{"name":"NCI_META_CUI","value":"CL551142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792681"},{"name":"PDQ_Open_Trial_Search_ID","value":"792681"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98280":{"preferredName":"Hafnium Oxide-containing Nanoparticles NBTXR3","code":"C98280","definitions":[{"definition":"A suspension of nanoparticles containing inert inorganic hafnium oxide (HfO2) crystals with potential antineoplastic activity. Upon injection of NBTXR3 in the tumor, the hafnium oxide-containing nanoparticles accumulate into the tumor cells. Subsequent application of radiation beams to the tumor tissue causes HfO2 particles to emit huge amounts of electrons. This results in the formation of free radicals within the tumor cells, which in turn causes targeted destruction of the cancer cells. Compared to standard radiotherapy, because of the inert nature of NBTXR3, this agent emits electrons only during its exposure to radiation which improves radiotherapy efficiency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hafnium Oxide-containing Nanoparticles NBTXR3","termGroup":"PT","termSource":"NCI"},{"termName":"NBTXR3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12055-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3C4Z4KG52T"},{"name":"Maps_To","value":"Hafnium Oxide-containing Nanoparticles NBTXR3"},{"name":"NCI_Drug_Dictionary_ID","value":"712103"},{"name":"NCI_META_CUI","value":"CL432399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712103"},{"name":"PDQ_Open_Trial_Search_ID","value":"712103"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156697":{"preferredName":"Halichondrin Analogue E7130","code":"C156697","definitions":[{"definition":"A halichondrin analogue derived from a marine sponge with potential antineoplastic activity. Upon intravenous infusion, halichondrin analogue E7130 may bind to the vinca domain of tubulin and inhibit the polymerization of tubulin and the assembly of microtubules, thereby inhibiting mitotic spindle assembly and inducing cell cycle arrest at the G2/M phase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halichondrin Analogue E7130","termGroup":"PT","termSource":"NCI"},{"termName":"E 7130","termGroup":"CN","termSource":"NCI"},{"termName":"E-7130","termGroup":"CN","termSource":"NCI"},{"termName":"E7130","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6WE4X56YH"},{"name":"Maps_To","value":"Halichondrin Analogue E7130"},{"name":"NCI_Drug_Dictionary_ID","value":"795713"},{"name":"NCI_META_CUI","value":"CL935716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795713"},{"name":"PDQ_Open_Trial_Search_ID","value":"795713"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1376":{"preferredName":"Halichondrin B","code":"C1376","definitions":[{"definition":"A complex macrolide polyether from marine sponge genera, such as Halichondria, Axinella, Phakellia, and Lissodendoryx that binds to tubulin, thereby inhibiting mitosis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halichondrin B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103614-76-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"269R6PFM59"},{"name":"Legacy Concept Name","value":"Halichondrin_B"},{"name":"Maps_To","value":"Halichondrin B"},{"name":"NSC Number","value":"609395"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0120715"}]}}{"C1120":{"preferredName":"Halofuginone","code":"C1120","definitions":[{"definition":"An orally-active quinazolinone alkaloid with potential antineoplastic activity. Halofuginone interferes with the signaling pathway of transforming growth factor beta (TGF beta) and inhibits expression of matrix metalloproteinase 2, thereby inhibiting collagen type I synthesis and inducing extracellular matrix degradation, resulting in inhibition of angiogenesis, tumor growth, or metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halofuginone","termGroup":"PT","termSource":"NCI"},{"termName":"trans-(+/-)-7-Bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55837-20-2"},{"name":"Chemical_Formula","value":"C16H17BrClN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L31MM1385E"},{"name":"Legacy Concept Name","value":"Halofuginone"},{"name":"Maps_To","value":"Halofuginone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062095"}]}}{"C2656":{"preferredName":"Halofuginone Hydrobromide","code":"C2656","definitions":[{"definition":"A substance that is being studied for its ability to slow the growth of connective tissue and to prevent the growth of new blood vessels that tumors need to grow. It is a type of quinazolinone alkaloid and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halofuginone Hydrobromide","termGroup":"PT","termSource":"NCI"},{"termName":"Halofuginone IV (intravenous)","termGroup":"SY","termSource":"NCI"},{"termName":"RU 19110","termGroup":"CN","termSource":"NCI"},{"termName":"Tempostatin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Scleroderma and Antiprotozoal; Coccidiosis (Vet)."},{"name":"CAS_Registry","value":"17395-31-2"},{"name":"CAS_Registry","value":"64924-67-0"},{"name":"Chemical_Formula","value":"C16H17BrClN3O3.BrH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PTC2969MV1"},{"name":"Legacy Concept Name","value":"Halofuginone_Hydrobromide"},{"name":"Maps_To","value":"Halofuginone Hydrobromide"},{"name":"NCI_Drug_Dictionary_ID","value":"38485"},{"name":"NSC Number","value":"713205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38485"},{"name":"PDQ_Open_Trial_Search_ID","value":"38485"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0521922"}]}}{"C121570":{"preferredName":"HCV DNA Vaccine INO-8000","code":"C121570","definitions":[{"definition":"A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HCV DNA Vaccine INO-8000","termGroup":"PT","termSource":"NCI"},{"termName":"INO-8000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HCV DNA Vaccine INO-8000"},{"name":"NCI_Drug_Dictionary_ID","value":"771488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771488"},{"name":"PDQ_Open_Trial_Search_ID","value":"771488"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053630"}]}}{"C160706":{"preferredName":"HDAC Class I/IIb Inhibitor HG146","code":"C160706","definitions":[{"definition":"An orally available inhibitor of histone deacetylase (HDAC) classes I and IIb with potential antineoplastic activities. Upon oral administration, HDAC I/IIb inhibitor HG146 selectively inhibits the catalytic activity of class I and IIb HDACs, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Class I HDACs are located in the nucleus and include HDACs 1, 2, 3, and 8; class IIb HDACs include HDAC 6 and 10 and are located in both the nucleus and the cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Class I/IIb Inhibitor HG146","termGroup":"PT","termSource":"NCI"},{"termName":"Class I/IIb HDACi HG146","termGroup":"SY","termSource":"NCI"},{"termName":"HDAC I/IIb Selective Inhibitor HG146","termGroup":"SY","termSource":"NCI"},{"termName":"HG 146","termGroup":"CN","termSource":"NCI"},{"termName":"HG-146","termGroup":"SY","termSource":"NCI"},{"termName":"HG0146","termGroup":"CN","termSource":"NCI"},{"termName":"HG146","termGroup":"CN","termSource":"NCI"},{"termName":"HG280146","termGroup":"CN","termSource":"NCI"},{"termName":"HG280146-P1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC Class I/IIb Inhibitor HG146"},{"name":"NCI_Drug_Dictionary_ID","value":"797880"},{"name":"NCI_META_CUI","value":"CL969804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797880"},{"name":"PDQ_Open_Trial_Search_ID","value":"797880"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116850":{"preferredName":"HDAC Inhibitor REC-2282","code":"C116850","definitions":[{"definition":"An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, REC-2282 inhibits the catalytic activity of HDAC, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor REC-2282","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"AR-42","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC-42","termGroup":"CN","termSource":"NCI"},{"termName":"OSU-HDAC42","termGroup":"CN","termSource":"NCI"},{"termName":"REC-2282","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"935881-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E0GG29V0AQ"},{"name":"Maps_To","value":"HDAC Inhibitor AR-42"},{"name":"NCI_Drug_Dictionary_ID","value":"673209"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673209"},{"name":"PDQ_Open_Trial_Search_ID","value":"673209"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2001522"}]}}{"C94225":{"preferredName":"Ivaltinostat","code":"C94225","definitions":[{"definition":"A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Ivaltinosta tinhibits the catalytic activity of HDAC, resulting in an accumulation of highly acetylated chromatin histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. In particular, this agent enhances the histone acetylation of the tumor suppressor gene p53. This results in an accumulation of p53, p53-dependent transactivation and apoptosis in tumor cells. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivaltinostat","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-N(1)-(3-(dimethylamino)propyl)-N(8)-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide","termGroup":"SN","termSource":"NCI"},{"termName":"CG200745","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC inhibitor CG200745","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936221-33-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4I8MLM7L2H"},{"name":"Maps_To","value":"HDAC inhibitor CG200745"},{"name":"Maps_To","value":"Ivaltinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"688308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688308"},{"name":"PDQ_Open_Trial_Search_ID","value":"688308"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3492625"}]}}{"C152539":{"preferredName":"Tefinostat","code":"C152539","definitions":[{"definition":"A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Tefinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tefinostat","termGroup":"PT","termSource":"NCI"},{"termName":"CHR 2845","termGroup":"CN","termSource":"NCI"},{"termName":"CHR-2845","termGroup":"CN","termSource":"NCI"},{"termName":"CHR2845","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"914382-60-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAU91150SB"},{"name":"Maps_To","value":"HDAC Inhibitor CHR-2845"},{"name":"Maps_To","value":"Tefinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"633696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633696"},{"name":"PDQ_Open_Trial_Search_ID","value":"633696"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830214"}]}}{"C148157":{"preferredName":"HDAC Inhibitor CKD-581","code":"C148157","definitions":[{"definition":"A highly water-soluble, pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, HDAC inhibitor CKD-581 targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor CKD-581","termGroup":"PT","termSource":"NCI"},{"termName":"CKD 581","termGroup":"CN","termSource":"NCI"},{"termName":"CKD-581","termGroup":"CN","termSource":"NCI"},{"termName":"CKD581","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC Inhibitor CKD-581"},{"name":"NCI_Drug_Dictionary_ID","value":"792522"},{"name":"NCI_META_CUI","value":"CL550791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792522"},{"name":"PDQ_Open_Trial_Search_ID","value":"792522"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C112177":{"preferredName":"Zabadinostat","code":"C112177","definitions":[{"definition":"A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zabadinostat","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 9468","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9468","termGroup":"CN","termSource":"NCI"},{"termName":"CXD101","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC Inhibitor CXD101","termGroup":"SY","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor CXD101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934828-12-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5TNV87ICD2"},{"name":"Maps_To","value":"HDAC Inhibitor CXD101"},{"name":"NCI_Drug_Dictionary_ID","value":"754547"},{"name":"NCI_META_CUI","value":"CL454389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754547"},{"name":"PDQ_Open_Trial_Search_ID","value":"754547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120312":{"preferredName":"HDAC Inhibitor MPT0E028","code":"C120312","definitions":[{"definition":"An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon administration, HDAC inhibitor MPT0E028 selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in both an induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. This prevents cell division and induces both cell cycle arrest and apoptosis, which may inhibit the proliferation of susceptible tumor cells. In addition, MPT0E028 inhibits the phosphorylation and activation of Akt, which prevents the activation of downstream signaling pathways, independent of its HDAC inhibitory activity. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins. Akt, overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor MPT0E028","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide","termGroup":"SN","termSource":"NCI"},{"termName":"3-(1-Benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxy-acrylamide","termGroup":"SN","termSource":"NCI"},{"termName":"MPT 0E028","termGroup":"CN","termSource":"NCI"},{"termName":"MPT-0E028","termGroup":"CN","termSource":"NCI"},{"termName":"MPT0E028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1338320-94-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC Inhibitor MPT0E028"},{"name":"NCI_Drug_Dictionary_ID","value":"768773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768773"},{"name":"PDQ_Open_Trial_Search_ID","value":"768773"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661262"}]}}{"C121665":{"preferredName":"HDAC Inhibitor OBP-801","code":"C121665","definitions":[{"definition":"An inhibitor of histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon administration, OBP-801 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. This may inhibit proliferation of susceptible tumor cells. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor OBP-801","termGroup":"PT","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor OBP-801","termGroup":"SY","termSource":"NCI"},{"termName":"OBP-801","termGroup":"CN","termSource":"NCI"},{"termName":"YM753","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"328548-11-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"30Q3VS5HZ4"},{"name":"Maps_To","value":"HDAC Inhibitor OBP-801"},{"name":"NCI_Drug_Dictionary_ID","value":"771191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771191"},{"name":"PDQ_Open_Trial_Search_ID","value":"771191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661318"}]}}{"C78850":{"preferredName":"HDAC/EGFR/HER2 Inhibitor CUDC-101","code":"C78850","definitions":[{"definition":"A multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential antineoplastic activity. HDAC/EGFR/HER2 inhibitor CUDC-101 inhibits the activity of these three enzymes but the exact mechanism of action is presently unknown. This agent may help overcome resistance to inhibition of EGFR and Her2 through a simultaneous, synergistic inhibition of EGFR, Her2, and HDAC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC/EGFR/HER2 Inhibitor CUDC-101","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1012054-59-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1A7Y9MP123"},{"name":"Legacy Concept Name","value":"HDAC_EGFR_HER2_Inhibitor_CUDC-101"},{"name":"Maps_To","value":"HDAC/EGFR/HER2 Inhibitor CUDC-101"},{"name":"NCI_Drug_Dictionary_ID","value":"612729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612729"},{"name":"PDQ_Open_Trial_Search_ID","value":"612729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703140"}]}}{"C135629":{"preferredName":"HDAC6 Inhibitor KA2507","code":"C135629","definitions":[{"definition":"An orally bioavailable inhibitor of histone deacetylase (HDAC) type 6 (HDAC6; HDAC-6), with potential antineoplastic activity. Upon administration, KA2507 targets, binds to and inhibits the activity of HDAC6. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. Specifically, inhibition of HDAC6 prevents STAT3 activity, which leads to a reduction in programmed death-1 (PD-1) expression. Eventually, this results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC6. HDAC6, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC6 Inhibitor KA2507","termGroup":"PT","termSource":"NCI"},{"termName":"HDAC6i KA2507","termGroup":"SY","termSource":"NCI"},{"termName":"KA2507","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VQ7NU11KRM"},{"name":"Maps_To","value":"HDAC6 Inhibitor KA2507"},{"name":"NCI_Drug_Dictionary_ID","value":"788956"},{"name":"NCI_META_CUI","value":"CL522984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788956"},{"name":"PDQ_Open_Trial_Search_ID","value":"788956"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159496":{"preferredName":"HDAC8 Inhibitor NBM-BMX","code":"C159496","definitions":[{"definition":"An orally bioavailable inhibitor of histone deacetylase (HDAC) type 8 (HDAC8; HDAC-8), with potential antineoplastic activity. Upon administration, NBM-BMX targets and inhibits the activity of HDAC8. This results in an accumulation of highly acetylated chromatin histones, chromatin remodeling, and selective transcription of tumor suppressor genes, ultimately promoting cell-cycle arrest and induction of tumor cell apoptosis. HDAC8, a class 1 histone deacetylase, plays a key role in transcriptional regulation and cell cycle progression. Aberrant expression of HDAC8 or deregulated interactions with transcription factors may contribute to tumorigenesis. Isotype-selective HDAC inhibitors may be associated with fewer adverse effects compared to pan-HDAC inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC8 Inhibitor NBM-BMX","termGroup":"PT","termSource":"NCI"},{"termName":"HDAC8i NBM-BMX","termGroup":"SY","termSource":"NCI"},{"termName":"NBM BMX","termGroup":"CN","termSource":"NCI"},{"termName":"NBM-BMX","termGroup":"CN","termSource":"NCI"},{"termName":"NBMBMX","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC8 Inhibitor NBM-BMX"},{"name":"NCI_Drug_Dictionary_ID","value":"797563"},{"name":"NCI_META_CUI","value":"CL951454"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797563"},{"name":"PDQ_Open_Trial_Search_ID","value":"797563"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116325":{"preferredName":"Siremadlin","code":"C116325","definitions":[{"definition":"An orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity. Siremadlin inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of both p53 signaling and p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Siremadlin","termGroup":"PT","termSource":"NCI"},{"termName":"HDM201","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-HDM 201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448867-41-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0282IF4JC8"},{"name":"Maps_To","value":"HDM2 Inhibitor HDM201"},{"name":"Maps_To","value":"Siremadlin"},{"name":"NCI_Drug_Dictionary_ID","value":"761551"},{"name":"NCI_META_CUI","value":"CL473659"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761551"},{"name":"PDQ_Open_Trial_Search_ID","value":"761551"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116867":{"preferredName":"HDM2 Inhibitor MK-8242","code":"C116867","definitions":[{"definition":"An orally bioavailable inhibitor of human homolog of double minute 2 (HDM2), with potential antineoplastic activity. Upon oral administration, HDM2 inhibitor MK-8242 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the degradation of p53 is inhibited, which may result in the restoration of p53 signaling. This induces p53-mediated tumor cell apoptosis. HDM2 is a member of the RING finger-type family of E3 ubiquitin protein ligases and targets p53 for degradation; it is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDM2 Inhibitor MK-8242","termGroup":"PT","termSource":"NCI"},{"termName":"MK-8242","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900242","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDM2 Inhibitor MK-8242"},{"name":"NCI_Drug_Dictionary_ID","value":"714504"},{"name":"NCI_META_CUI","value":"CL433891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714504"},{"name":"PDQ_Open_Trial_Search_ID","value":"714504"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60772":{"preferredName":"Smoothened Antagonist IPI-609","code":"C60772","definitions":[{"definition":"A semi-synthetic cyclopamine analogue and an inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon administration, smoothened antagonist IPI-609 targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist IPI-609","termGroup":"PT","termSource":"NCI"},{"termName":"IPI 269609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI 609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-269609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI269609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI609","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"878204-96-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0E0K1H745W"},{"name":"Legacy Concept Name","value":"IPI-609"},{"name":"Maps_To","value":"Hedgehog Inhibitor IPI-609"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881124"}]}}{"C1071":{"preferredName":"Porfimer Sodium","code":"C1071","definitions":[{"definition":"A drug used to treat some types of cancer. When absorbed by cancer cells and exposed to light, porfimer sodium becomes active and kills the cancer cells. It is a type of photodynamic therapy agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm wavelength laser light, resulting in tumor cell cytotoxicity. In addition, tumor cell death may occur due to ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by the release of thromboxane A2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porfimer Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"CL-184116","termGroup":"CN","termSource":"NCI"},{"termName":"DHE","termGroup":"AB","termSource":"NCI"},{"termName":"Dihematoporphyrin Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Dihematoporphyrin Ether","termGroup":"SY","termSource":"NCI"},{"termName":"Hematoporphyrin Derivative","termGroup":"SY","termSource":"NCI"},{"termName":"HPD","termGroup":"AB","termSource":"NCI"},{"termName":"Photobarr","termGroup":"FB","termSource":"NCI"},{"termName":"Photofrin II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Photosensitizer, bladder, esophagel, gastric, lung and rectal cancer"},{"name":"CAS_Registry","value":"87806-31-3"},{"name":"CHEBI_ID","value":"CHEBI:60773"},{"name":"Chemical_Formula","value":"(C34H35N4NaO5)n.(C34H33N4NaO4)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y3834SIK5F"},{"name":"Legacy Concept Name","value":"Porfimer_Sodium"},{"name":"Maps_To","value":"Hematoporphyrin Derivative"},{"name":"Maps_To","value":"Porfimer Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"40294"},{"name":"NCI_META_CUI","value":"CL524033"},{"name":"NSC Number","value":"603062"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49083":{"preferredName":"Hemiasterlin Analog E7974","code":"C49083","definitions":[{"definition":"An analog of the sponge-derived anti-microtubule tripeptide hemiasterlin with antimitotic and potential antineoplastic activities. Hemiasterlin analog E7974 binds to the Vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly; depolymerization of existing microtubules; inhibition of mitosis; and inhibition of cellular proliferation. This agent may have more affinity for the beta-3 tubulin isotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemiasterlin Analog E7974","termGroup":"PT","termSource":"NCI"},{"termName":"E7974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"610787-07-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1BO0C11BSH"},{"name":"Legacy Concept Name","value":"Hemiasterlin_Analog_7974"},{"name":"Maps_To","value":"Hemiasterlin Analog E7974"},{"name":"NCI_Drug_Dictionary_ID","value":"447049"},{"name":"PDQ_Closed_Trial_Search_ID","value":"447049"},{"name":"PDQ_Open_Trial_Search_ID","value":"447049"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708344"}]}}{"C97949":{"preferredName":"Henatinib Maleate","code":"C97949","definitions":[{"definition":"The maleate salt form of henatinib, an orally bioavalable, multitargeted tyrosine kinase inhibitor with potential antitumor and antiangiogenic activities. Henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Henatinib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"(R,Z)-2-[(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c] azepin-4-ketone Maleate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Henatinib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"709376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709376"},{"name":"PDQ_Open_Trial_Search_ID","value":"709376"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2935073"}]}}{"C170206":{"preferredName":"Necuparanib","code":"C170206","definitions":[{"definition":"A low molecular weight heparin derivative and heparan sulfate proteoglycan (HSPG) mimetic with no or minimal anticoagulant activity and potential antineoplastic activities. Upon administration, necuparanib mimics HSPGs by binding to and inhibiting various heparin-binding growth factors, chemokines, and cytokines such as VEGF, HGF, FGF2, SDF-1a, heparanase and P-selectin all of which are essential for tumor angiogenesis and metastasis to occur. This inhibits heparin binding growth factor-mediated signaling and disrupts tumor-stromal interactions eventually leading to an inhibition of angiogenesis and tumor cell progression. In addition, M402 may enhance the cytotoxic effect of other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necuparanib","termGroup":"PT","termSource":"NCI"},{"termName":"Heparan Sulfate Glycosaminoglycan Mimetic M402","termGroup":"SY","termSource":"NCI"},{"termName":"HSGAG Mimetic M402","termGroup":"SY","termSource":"NCI"},{"termName":"M402","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415139-34-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ULS0NT2D68"},{"name":"Maps_To","value":"Heparan Sulfate Glycosaminoglycan Mimetic M402"},{"name":"NCI_Drug_Dictionary_ID","value":"735811"},{"name":"NCI_META_CUI","value":"CL1382683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104412":{"preferredName":"Roneparstat","code":"C104412","definitions":[{"definition":"An N-acetylated, glycol-split form of heparin that is devoid of anticoagulant activity and is an inhibitor of heparanase with antineoplastic and antiangiogenic activities. Upon subcutaneous administration, roneparstat inhibits the activity of heparanase. This prevents the heparanase-mediated cleavage of heparan sulfate (HS) proteoglycans on cell surfaces and within the extracellular matrix. In addition, this agent prevents the heparanase-induced production of a number of angiogenic growth factors, including matrix metalloproteinase-9, hepatocyte growth factor and vascular endothelial growth factor. Altogether, this leads to an inhibition of both tumor cell growth and angiogenesis. Heparanase, an enzyme that is responsible for the proteolytic cleavage of proteoglycans, is upregulated in a variety of tumor cell types and promotes tumor cell growth; it plays a key role in tumor cell invasion, metastasis and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roneparstat","termGroup":"PT","termSource":"NCI"},{"termName":"100NA,RO-H","termGroup":"SY","termSource":"NCI"},{"termName":"SST0001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1407492-04-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1J0593208B"},{"name":"Maps_To","value":"Heparin Derivative SST0001"},{"name":"Maps_To","value":"Roneparstat"},{"name":"NCI_Drug_Dictionary_ID","value":"745171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745171"},{"name":"PDQ_Open_Trial_Search_ID","value":"745171"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3177718"}]}}{"C128283":{"preferredName":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131","code":"C128283","definitions":[{"definition":"A cancer vaccine consisting of a fusion peptide, composed of three peptides derived from the extracellular domain (ECD) of the HER2 peptide antigen found on B-cells (P4, P6 and P7; P467), conjugated to the carrier protein DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), and combined with the immunoadjuvant montanide ISA 51, with potential immunostimulatory and antineoplastic activities. Upon administration, IMU-131 vaccine induces the production of polyclonal antibodies against the HER2 protein. In turn, the antibodies bind to three separate binding sites on HER2 expressed on tumor cells and inhibit HER2 dimerization and activity, which leads to the inhibition of HER2-mediated signal transduction pathways. This induces apoptosis in and reduces cellular proliferation of HER2-overexpressing tumor cells. In addition, IMU-131 induces a cytotoxic T-lymphocyte (CTL) response against the HER2-expressing tumor cells. The tumor-associated antigen (TAA) HER2, also called Neu or ErbB2, is a tyrosine kinase receptor for epidermal growth factor (EGF) and is often overexpressed by a variety of tumor cell types. Montanide ISA 51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. DT-CRM197 is used to increase the immunogenicity of the HER2/neu peptide antigen. In P467, the three B-cell epitopes were combined in a specific order into a single 49 amino acid peptide antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131","termGroup":"PT","termSource":"NCI"},{"termName":"HER-Vaxx","termGroup":"SY","termSource":"NCI"},{"termName":"HER-Vaxx Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"IMU-131","termGroup":"CN","termSource":"NCI"},{"termName":"IMU-131 HER2/Neu Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"IMU-131 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"P467-CRM197/Montanide Vaccine IMU-131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131"},{"name":"NCI_Drug_Dictionary_ID","value":"782063"},{"name":"NCI_META_CUI","value":"CL507937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782063"},{"name":"PDQ_Open_Trial_Search_ID","value":"782063"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99903":{"preferredName":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901","code":"C99903","definitions":[{"definition":"A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901","termGroup":"PT","termSource":"NCI"},{"termName":"Alphavirus-like Replicon Particles-containing Self Amplifying Replicon RNA for HER2 AVX901","termGroup":"SY","termSource":"NCI"},{"termName":"AVX 901","termGroup":"CN","termSource":"NCI"},{"termName":"AVX-901","termGroup":"CN","termSource":"NCI"},{"termName":"AVX901","termGroup":"CN","termSource":"NCI"},{"termName":"HER2 ECDTM VRP","termGroup":"SY","termSource":"NCI"},{"termName":"VRP-HER2 AVX901","termGroup":"SY","termSource":"NCI"},{"termName":"VRP-HER2 ECDTM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901"},{"name":"NCI_Drug_Dictionary_ID","value":"725234"},{"name":"NCI_META_CUI","value":"CL433604"},{"name":"PDQ_Closed_Trial_Search_ID","value":"725234"},{"name":"PDQ_Open_Trial_Search_ID","value":"725234"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26648":{"preferredName":"HER2 Inhibitor CP-724,714","code":"C26648","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called ErbB receptor tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable quinazoline with potential antineoplastic activity.  CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth.  HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Inhibitor CP-724,714","termGroup":"PT","termSource":"NCI"},{"termName":"CP 724714","termGroup":"CN","termSource":"NCI"},{"termName":"CP-724,714","termGroup":"CN","termSource":"NCI"},{"termName":"CP-724-714","termGroup":"CN","termSource":"NCI"},{"termName":"CP724714","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"383432-38-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I05QZ0S4V3"},{"name":"Legacy Concept Name","value":"CP-724_714"},{"name":"Maps_To","value":"HER2 Inhibitor CP-724,714"},{"name":"NCI_Drug_Dictionary_ID","value":"285619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"285619"},{"name":"PDQ_Open_Trial_Search_ID","value":"285619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327906"}]}}{"C146810":{"preferredName":"HER2 Inhibitor TAS0728","code":"C146810","definitions":[{"definition":"An orally available covalent inhibitor of human epidermal growth factor receptor 2 (HER2; ERBB2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor TAS0728 specifically and irreversibly binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2- and HER3 (ErbB3)-expressing tumor cells. HER2, a receptor tyrosine kinase mutated or overexpressed in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization. HER3 has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Inhibitor TAS0728","termGroup":"PT","termSource":"NCI"},{"termName":"TAS 0728","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-0728","termGroup":"CN","termSource":"NCI"},{"termName":"TAS0728","termGroup":"CN","termSource":"NCI"},{"termName":"TPC-107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2 Inhibitor TAS0728"},{"name":"NCI_Drug_Dictionary_ID","value":"792168"},{"name":"NCI_META_CUI","value":"CL544751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792168"},{"name":"PDQ_Open_Trial_Search_ID","value":"792168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148491":{"preferredName":"HER2-targeted DARPin MP0274","code":"C148491","definitions":[{"definition":"A proprietary, designed ankyrin repeat proteins (DARPin)-based agent targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential antineoplastic activity. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the HER2-targeted DARPin MP0274 binds to two distinct non-overlapping epitopes on HER2, thereby inhibiting the activity of HER2 and promoting HER2 internalization. This prevents HER2-mediated signaling, induces apoptosis and inhibits the growth of HER2-overexpressing tumor cells. DARPin also binds to human serum albumin, which extends the half-life of MP0274. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2-targeted DARPin MP0274","termGroup":"PT","termSource":"NCI"},{"termName":"DARPin MP0274","termGroup":"SY","termSource":"NCI"},{"termName":"HER-2-targeting DARPin MP0274","termGroup":"SY","termSource":"NCI"},{"termName":"HER2-targeting DARPin Drug MP0274","termGroup":"SY","termSource":"NCI"},{"termName":"MP 0274","termGroup":"CN","termSource":"NCI"},{"termName":"MP0274","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2-targeted DARPin MP0274"},{"name":"NCI_Drug_Dictionary_ID","value":"792625"},{"name":"NCI_META_CUI","value":"CL551054"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792625"},{"name":"PDQ_Open_Trial_Search_ID","value":"792625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96038":{"preferredName":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302","code":"C96038","definitions":[{"definition":"An antibody-targeted lipidic nano-carrier containing the antineoplastic anthracycline antibiotic doxorubicin encapsulated within liposomes, and conjugated to a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), with potential antitumor activity. Upon administration of HER2-targeted liposomal doxorubicin hydrochloride MM-302, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the HER2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted liposomal delivery of doxorubicin improves efficacy while lowering the toxicity profile. HER2, a tyrosine kinase receptor, is overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302","termGroup":"PT","termSource":"NCI"},{"termName":"MM-302","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302"},{"name":"NCI_Drug_Dictionary_ID","value":"696572"},{"name":"NCI_META_CUI","value":"CL428372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696572"},{"name":"PDQ_Open_Trial_Search_ID","value":"696572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118953":{"preferredName":"HER2-targeting Antibody Fc Fragment FS102","code":"C118953","definitions":[{"definition":"A proprietary, antibody fragment composed of a constant (Fc) region that is engineered to bind to the tumor-associated antigen human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. HER2-targeted antibody Fc fragment FS102 specifically binds to its HER2 epitope, and causes downregulation of HER2-mediated signaling. This leads to tumor cell apoptosis. HER2, a member of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) superfamily, is overexpressed on the cell surface of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2-targeting Antibody Fc Fragment FS102","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 FCAB FS102","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986186","termGroup":"CN","termSource":"NCI"},{"termName":"Fcab FS102","termGroup":"SY","termSource":"NCI"},{"termName":"FS102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z27ZI1MZY9"},{"name":"Maps_To","value":"HER2-targeting Antibody Fc Fragment FS102"},{"name":"NCI_Drug_Dictionary_ID","value":"766415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766415"},{"name":"PDQ_Open_Trial_Search_ID","value":"766415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896857"}]}}{"C2661":{"preferredName":"Herba Scutellaria Barbata","code":"C2661","definitions":[{"definition":"A Chinese herb isolated from the plant Scutellaria barbata D. Don (Lamiaceae) with potential antineoplastic activity. Containing the antioxidant flavone scutellarin, herba Scutellaria barbata has been shown to induce apoptosis of ovarian and breast tumor cells in vitro.","type":"DEFINITION","source":"NCI"},{"definition":"An herb that belongs to a group of herbs named the Scutellaria species or scullcap. Both the root and the above-ground part have been used to make herbal medicines. The root has been used in traditional Chinese medicine to treat lung cancer and other medical problems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Herba Scutellaria Barbata","termGroup":"PT","termSource":"NCI"},{"termName":"Ban Zhi Lian","termGroup":"SY","termSource":"NCI"},{"termName":"Barbed Skullcap Herb","termGroup":"SY","termSource":"NCI"},{"termName":"Herba Scutellariae Barbatae","termGroup":"SY","termSource":"NCI"},{"termName":"HSB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DPR4R122E7"},{"name":"Legacy Concept Name","value":"Herba_Scutellariae_Barbatae"},{"name":"Maps_To","value":"Herba Scutellaria Barbata"},{"name":"NCI_Drug_Dictionary_ID","value":"467184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467184"},{"name":"PDQ_Open_Trial_Search_ID","value":"467184"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134548"}]}}{"C1124":{"preferredName":"Herbimycin","code":"C1124","definitions":[{"definition":"A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Herbimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Herbimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-Demethoxy-15-methoxy-11-O-methylgeldanamycin, (15R)-","termGroup":"SN","termSource":"NCI"},{"termName":"Herbimycin A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70563-58-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"815WDV2HST"},{"name":"Legacy Concept Name","value":"Herbimycin"},{"name":"Maps_To","value":"Herbimycin"},{"name":"NSC Number","value":"305978"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062565"}]}}{"C122401":{"preferredName":"Heterodimeric Interleukin-15","code":"C122401","definitions":[{"definition":"A fusion protein complex composed of heterodimeric IL-15 (hetIL-15), which consists of a synthetic form of the endogenous cytokine interleukin-15 chain (IL-15) complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL-15Ra) (IL15:sIL-15Ra), with potential immunomodulatory, anti-infective and antineoplastic activities. Upon administration, hetIL-15 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbeta-gamma) receptor on natural killer (NK) and T-lymphocytes, which activates and increases the levels of NK cells and CD8+ and CD4+ T-cells. The T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. Altogether, this enhances tumor cell killing and decreases tumor cell proliferation. By coupling IL-15 to IL15Ra, this agent has an improved pharmacokinetic profile, shows an increased ability to bind IL-2Rbeta-gamma, and shows increased immunostimulatory activity as compared to IL-15 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heterodimeric Interleukin-15","termGroup":"PT","termSource":"NCI"},{"termName":"hetIL-15","termGroup":"AB","termSource":"NCI"},{"termName":"IL-15/sIL-15Ra","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heterodimeric Interleukin-15"},{"name":"NCI_Drug_Dictionary_ID","value":"772563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772563"},{"name":"PDQ_Open_Trial_Search_ID","value":"772563"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053488"}]}}{"C1125":{"preferredName":"Hexamethylene Bisacetamide","code":"C1125","definitions":[{"definition":"A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines.  Its precise mechanism of action is unknown. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hexamethylene Bisacetamide","termGroup":"PT","termSource":"NCI"},{"termName":"Acetamide, N,N'-1, 6-hexanediylbis-","termGroup":"SN","termSource":"NCI"},{"termName":"Acetamide, N,N'-hexamethylenebis-","termGroup":"SN","termSource":"NCI"},{"termName":"Hexamethylenebisacetamide","termGroup":"SY","termSource":"NCI"},{"termName":"Hexamethylenediacetamide","termGroup":"SY","termSource":"NCI"},{"termName":"HMBA","termGroup":"AB","termSource":"NCI"},{"termName":"N, N'-Diacetylhexamethylenediamine","termGroup":"SN","termSource":"NCI"},{"termName":"N,N'-1,6-Hexanediylbisacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N'-Hexamethylenebisacetamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3073-59-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LA133J59VU"},{"name":"Legacy Concept Name","value":"Hexamethylene_Bisacetamide"},{"name":"Maps_To","value":"Hexamethylene Bisacetamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39990"},{"name":"NSC Number","value":"95580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39990"},{"name":"PDQ_Open_Trial_Search_ID","value":"39990"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062641"}]}}{"C26654":{"preferredName":"Hexaminolevulinate","code":"C26654","definitions":[{"definition":"A substance that is used to find and kill tumor cells. It enters tumor cells and becomes activated when exposed to a special type of light. A chemical reaction causes the cells to produce fluorescent light and die.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hexyl ester of 5-aminolevulinic acid (ALA) with photodynamic properties. As a precursor of photoactive porphorins, hexyl 5-aminolevulinate induces the endogenous production of the photosensitizer protoporphyrin IX (PPIX) which accumulates selectively in tumor tissue. When exposed to specific wavelengths of light, PPIX is activated and, depending on the wavelength and/or intensity of light, either fluoresces, thereby allowing tumor imaging, or induces tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hexaminolevulinate","termGroup":"PT","termSource":"NCI"},{"termName":"HAL","termGroup":"AB","termSource":"NCI"},{"termName":"HexvixR","termGroup":"BR","termSource":"NCI"},{"termName":"Hexyl 5-Aminolevulinate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"140898-97-1"},{"name":"Chemical_Formula","value":"C11H21NO3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G7H20TKI67"},{"name":"Legacy Concept Name","value":"Hexyl_5-Aminolevulinate"},{"name":"Maps_To","value":"Hexaminolevulinate"},{"name":"NCI_Drug_Dictionary_ID","value":"269130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269130"},{"name":"PDQ_Open_Trial_Search_ID","value":"269130"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327841"}]}}{"C29092":{"preferredName":"Hexylresorcinol","code":"C29092","definitions":[{"definition":"A substituted phenol with bactericidal, antihelminthic and potential antineoplastic activities. Hexylresorcinol is used as an antiseptic in mouthwashes and skin wound cleansers. Hexylresorcinol may also inhibit oxidative DNA damage by enhancing the activity of antioxidant enzymes, including glutathione peroxidase and glutathione reductase, which facilitate scavenging reactive oxygen molecules by glutathione (GSH).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hexylresorcinol","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hexylresorcinol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"136-77-6"},{"name":"Chemical_Formula","value":"C12H18O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R9QTB5E82N"},{"name":"Legacy Concept Name","value":"Hexylresorcinol"},{"name":"Maps_To","value":"Hexylresorcinol"},{"name":"NSC Number","value":"1570"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0019497"}]}}{"C70953":{"preferredName":"HIF-1alpha Inhibitor PX-478","code":"C70953","definitions":[{"definition":"An orally active small molecule with potential antineoplastic activity. Although its mechanism of action has yet to be fully elucidated, HIF1-alpha inhibitor PX-478 appears to inhibit hypoxia-inducible factor 1-alpha (HIF1A) expression, which may result in decreased expression of HIF1A downstream target genes important to tumor growth and survival, a reduction in tumor cell proliferation, and the induction of tumor cell apoptosis. The inhibitory effect of this agent is independent of the tumor suppressor genes VHL and p53 and may be related to derangements in glucose uptake and metabolism due to inhibition of glucose transporter-1 (Glut-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIF-1alpha Inhibitor PX-478","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-4-(2-Amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline Oxide Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Hypoxia Inducible Factor 1-Alpha PX-478","termGroup":"SY","termSource":"NCI"},{"termName":"L-Phenylalanine, 4-[Bis(2-chloroethyl)oxidoamino]-, Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"L-Phenylalanine, 4-[Bis(2-chloroethyl)oxidoamino]-, Hydrochloride (1:2)","termGroup":"SY","termSource":"NCI"},{"termName":"PX-478","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685898-44-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T23U22X160"},{"name":"Legacy Concept Name","value":"Hypoxia_Inducible_Factor_1-Alpha_PX-478"},{"name":"Maps_To","value":"HIF-1alpha Inhibitor PX-478"},{"name":"NCI_Drug_Dictionary_ID","value":"570895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570895"},{"name":"PDQ_Open_Trial_Search_ID","value":"570895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1528551"}]}}{"C119618":{"preferredName":"HIF-2alpha Inhibitor PT2385","code":"C119618","definitions":[{"definition":"An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor PT2385 allosterically binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed in many cancers, promotes tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIF-2alpha Inhibitor PT2385","termGroup":"PT","termSource":"NCI"},{"termName":"PT2385","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HIF-2alpha Inhibitor PT2385"},{"name":"NCI_Drug_Dictionary_ID","value":"766768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766768"},{"name":"PDQ_Open_Trial_Search_ID","value":"766768"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896783"}]}}{"C135627":{"preferredName":"Belzutifan","code":"C135627","definitions":[{"definition":"An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belzutifan","termGroup":"PT","termSource":"NCI"},{"termName":"HIF-2alpha Inhibitor PT2977","termGroup":"SY","termSource":"NCI"},{"termName":"MK 6482","termGroup":"CN","termSource":"NCI"},{"termName":"MK-6482","termGroup":"CN","termSource":"NCI"},{"termName":"MK6482","termGroup":"CN","termSource":"NCI"},{"termName":"PT2977","termGroup":"CN","termSource":"NCI"},{"termName":"Welireg","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET)"},{"name":"CAS_Registry","value":"1672668-24-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7K28NB895L"},{"name":"Maps_To","value":"Belzutifan"},{"name":"Maps_To","value":"HIF-2alpha Inhibitor PT2977"},{"name":"NCI_Drug_Dictionary_ID","value":"788947"},{"name":"NCI_META_CUI","value":"CL522982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788947"},{"name":"PDQ_Open_Trial_Search_ID","value":"788947"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113334":{"preferredName":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126","code":"C113334","definitions":[{"definition":"A small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone-lysine N-methyltransferase EZH2, with potential antineoplastic activity. Upon administration, histone-lysine N-methyltransferase EZH2 inhibitor GSK2816126 inhibits the activity of EZH2 and specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in cancer cells that overexpress this enzyme. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancers and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126","termGroup":"PT","termSource":"NCI"},{"termName":"EZH2 Inhibitor GSK2816126","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2816126","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126"},{"name":"NCI_Drug_Dictionary_ID","value":"756211"},{"name":"NCI_META_CUI","value":"CL458162"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756211"},{"name":"PDQ_Open_Trial_Search_ID","value":"756211"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77424":{"preferredName":"Histrelin Acetate","code":"C77424","definitions":[{"definition":"The acetate salt form of histrelin, a long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histrelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Supprelin","termGroup":"BR","termSource":"NCI"},{"termName":"Vantas","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"76712-82-8"},{"name":"Chemical_Formula","value":"C66H86N18O12.C2H4O2.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QMG7HLD1ZE"},{"name":"Legacy Concept Name","value":"Histrelin_Acetate"},{"name":"Maps_To","value":"Histrelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"732255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732255"},{"name":"PDQ_Open_Trial_Search_ID","value":"732255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0724597"}]}}{"C111689":{"preferredName":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001","code":"C111689","definitions":[{"definition":"A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT), TERT 572Y (YLFFYRKSV; TYR-Vx001) and TERT 572 (RLFFYRKSV; ARG-Vx001), with potential immunostimulating and antineoplastic activities. Subcutaneous injection of TERT(572Y) peptide followed by subcutaneous administration of the TERT(572) peptide may elicit a specific and possibly optimal cytotoxic T cell (CTL) response against hTERT-expressing tumor cells. hTERT, the catalytic subunit of human telomerase, is an human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase. TERT is expressed in the majority of human cancer cells, is not expressed or is expressed at very low levels in normal cells and plays a key role in tumorigenesis. TERT572Y is the optimized variant of the native cryptic peptide TERT572 in which tyrosine has been substituted for an arginine at position 1; TERT572Y shows increased HLA-A*0201 binding affinity compared to TERT572.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-A*0201 Restricted Telomerase-specific Vaccine Vx-001","termGroup":"SY","termSource":"NCI"},{"termName":"Vx-001","termGroup":"CN","termSource":"NCI"},{"termName":"Vx001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001"},{"name":"NCI_Drug_Dictionary_ID","value":"752897"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752897"},{"name":"PDQ_Open_Trial_Search_ID","value":"752897"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1958472"}]}}{"C101893":{"preferredName":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410","code":"C101893","definitions":[{"definition":"A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410","termGroup":"PT","termSource":"NCI"},{"termName":"S-488410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410"},{"name":"NCI_Drug_Dictionary_ID","value":"733798"},{"name":"NCI_META_CUI","value":"CL436276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733798"},{"name":"PDQ_Open_Trial_Search_ID","value":"733798"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128489":{"preferredName":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201","code":"C128489","definitions":[{"definition":"A cancer peptide vaccine composed of four human leukocyte antigen (HLA)-A2 (HLA-A*02)-restricted peptides derived from four specific and separate tumor-associated antigens (TAAs) expressed by melanoma cells, with potential antineoplastic activity. Upon administration of the HLA-A2-restricted melanoma-specific peptides vaccine, the melanoma specific antigens in the vaccine activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the HLA-A2-positive melanoma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine GRN-1201","termGroup":"SY","termSource":"NCI"},{"termName":"GRN-1201","termGroup":"CN","termSource":"NCI"},{"termName":"Peptide Cancer Vaccine GRN-1201","termGroup":"SY","termSource":"NCI"},{"termName":"Peptide Vaccine GRN-1201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201"},{"name":"NCI_Drug_Dictionary_ID","value":"782566"},{"name":"NCI_META_CUI","value":"CL509065"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782566"},{"name":"PDQ_Open_Trial_Search_ID","value":"782566"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153102":{"preferredName":"HM2/MMAE Antibody-Drug Conjugate ALT-P7","code":"C153102","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of the trastuzumab biobetter HM2 conjugated, in a site-specific manner, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of ALT-P7, the antibody moiety targets and binds to human epidermal growth factor receptor 2 (HER2) on tumor cells. Upon antibody/antigen binding and internalization, the MMAE moiety is released, binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. HER2 is a receptor tyrosine kinase (RTK) that is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HM2/MMAE Antibody-Drug Conjugate ALT-P7","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ALT-P7","termGroup":"SY","termSource":"NCI"},{"termName":"ALT-P7","termGroup":"SY","termSource":"NCI"},{"termName":"HER2ALT-P7","termGroup":"CN","termSource":"NCI"},{"termName":"HM2-MMAE","termGroup":"SY","termSource":"NCI"},{"termName":"HM2/MMAE ADC ALT-P7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HM2/MMAE Antibody-Drug Conjugate ALT-P7"},{"name":"NCI_Drug_Dictionary_ID","value":"793586"},{"name":"NCI_META_CUI","value":"CL554360"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793586"},{"name":"PDQ_Open_Trial_Search_ID","value":"793586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61592":{"preferredName":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine","code":"C61592","definitions":[{"definition":"An allogeneic vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. In addition, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"KGEL Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Antigens-GM-CSF-Expressing_Cell_Vaccine"},{"name":"Maps_To","value":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"445421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"445421"},{"name":"PDQ_Open_Trial_Search_ID","value":"445421"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831712"}]}}{"C88336":{"preferredName":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres","code":"C88336","definitions":[{"definition":"Holmium Ho166 containing poly l-lactic acid (PLA) microspheres with potential antineoplastic actvity. Upon intra-arterial hepatic administration of holmium 166 microspheres, this agent is able to emit both beta particles direct killing cells and gamma photons for nuclear imaging. In addition, since holmium 166 is paramagnetic, this agent can be used for magnetic resonance imaging (MRI).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"Holmium-166 PLA Microspheres","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"735181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735181"},{"name":"PDQ_Open_Trial_Search_ID","value":"735181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981854"}]}}{"C2636":{"preferredName":"HPPH","code":"C2636","definitions":[{"definition":"A drug that is used in photodynamic therapy that is absorbed by tumor cells; when exposed to light, it becomes active and kills the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lipophilic, second-generation, chlorin-based photosensitizer. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When laser light is applied, a photodynamic reaction between HPPH and oxygen occurs, resulting in the production of cytotoxic free radicals and singlet oxygen and free radical-mediated cell death. Compared to the first-generation photosensitizer porfimer sodium, HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity which declines rapidly within a few days after administration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPPH","termGroup":"PT","termSource":"NCI"},{"termName":"2-(1-Hexyloxyethyl)-2-Devinyl Pyropheophorbide-a","termGroup":"SN","termSource":"NCI"},{"termName":"2-[1-Hexyloxyethyl]-2-devinyl Pyropheophorbide-alpha","termGroup":"SN","termSource":"NCI"},{"termName":"Photochlor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149402-51-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DOB7Y3RSX0"},{"name":"Legacy Concept Name","value":"HPPH"},{"name":"Maps_To","value":"HPPH"},{"name":"NCI_Drug_Dictionary_ID","value":"38335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38335"},{"name":"PDQ_Open_Trial_Search_ID","value":"38335"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0248392"}]}}{"C117240":{"preferredName":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c","code":"C117240","definitions":[{"definition":"An orally available Lactobacillis casei (L. casei)-based vaccine expressing the human papillomavirus (HPV) type 16 isoform E7 protein linked to the poly-gamma-glutamate synthetase complex gene pgsA, with potential immunostimulating activity. Upon oral administration, the expressed HPV 16 E7 may stimulate the immune system to mount a mucosal cytotoxic T-lymphocyte (CTL) response against HPV 16 E7-expressing tumor cells. The poly-glutamic acid synthetase PgsA from Bacillus subtilis acts as an anchoring motif that facilitates the expression of the HPV antigen protein on the surface of the bacteria. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in various viral-related cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c","termGroup":"PT","termSource":"NCI"},{"termName":"BLS-ILB-E710c","termGroup":"CN","termSource":"NCI"},{"termName":"BLS-ILS-E710c","termGroup":"CN","termSource":"NCI"},{"termName":"L. casei-E7 BLS_ILB_E710c","termGroup":"SY","termSource":"NCI"},{"termName":"L.casei-PgsA-E7","termGroup":"SY","termSource":"NCI"},{"termName":"LacE7 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c"},{"name":"NCI_Drug_Dictionary_ID","value":"763356"},{"name":"NCI_META_CUI","value":"CL474114"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763356"},{"name":"PDQ_Open_Trial_Search_ID","value":"763356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77909":{"preferredName":"Bizalimogene Ralaplasmid","code":"C77909","definitions":[{"definition":"A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, bizalimogene ralaplasmid expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bizalimogene Ralaplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"HPV DNA Plasmids Therapeutic Vaccine VGX-3100","termGroup":"SY","termSource":"NCI"},{"termName":"pGX3002","termGroup":"CN","termSource":"NCI"},{"termName":"VGX-3100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1977488-08-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D8W2DVO5ZJ"},{"name":"Legacy Concept Name","value":"HPV_DNA_Plasmids_Therapeutic_Vaccine_VGX-3100"},{"name":"Maps_To","value":"Bizalimogene Ralaplasmid"},{"name":"Maps_To","value":"HPV DNA Plasmids Therapeutic Vaccine VGX-3100"},{"name":"NCI_Drug_Dictionary_ID","value":"599041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599041"},{"name":"PDQ_Open_Trial_Search_ID","value":"599041"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703096"}]}}{"C102787":{"preferredName":"HPV E6/E7 DNA Vaccine GX-188E","code":"C102787","definitions":[{"definition":"A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV E6/E7 DNA Vaccine GX-188E","termGroup":"PT","termSource":"NCI"},{"termName":"GX-188E","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV E6/E7 DNA Vaccine GX-188E"},{"name":"NCI_Drug_Dictionary_ID","value":"736688"},{"name":"NCI_META_CUI","value":"CL437024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736688"},{"name":"PDQ_Open_Trial_Search_ID","value":"736688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131495":{"preferredName":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C","code":"C131495","definitions":[{"definition":"An immunotherapeutic vaccine composed of the immunoadjuvant alpha-galactosylceramide (a-GC) and autologous antigen presenting cells (APCs), specifically B-lymphocytes and monocytes transfected with an adenoviral vector that expresses the tumor-associated antigens (TAAs) E6 and E7 derived from human papillomavirus (HPV) types 16 and 18 (HPV-16/18 E6/E7), with potential immunostimulating and antineoplastic activities. Upon administration of BVAC-C, the APCs stimulate the immune system to mount a TAA-specific cytotoxic T-lymphocyte (CTL) response, as well as natural killer (NK) cell, NK T-cell (NKT), helper T-cell and antibody-mediated immune responses, against the tumor cells. This directly or indirectly kills the TAA-expressing tumor cells. HPV-16/18 E6/E7 are overexpressed on certain tumor cell types and play key roles in tumor cell proliferation. a-GC, an NKT cell ligand, is used to specifically stimulate NKT cells and to further stimulate an anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Lymphocyte/Tumor Antigen Gene Vaccine BVAC-C","termGroup":"SY","termSource":"NCI"},{"termName":"BVAC-C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C"},{"name":"NCI_Drug_Dictionary_ID","value":"785876"},{"name":"NCI_META_CUI","value":"CL514359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785876"},{"name":"PDQ_Open_Trial_Search_ID","value":"785876"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102874":{"preferredName":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract","code":"C102874","definitions":[{"definition":"A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with an extract of Candida albicans, with potential immunomodulating and antineoplastic activities. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the Candida albicans may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions, and HPV may be a cause of some head and neck squamous cell carcinomas (HNSCCs). Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-16 E6 Peptides Vaccine/Candin","termGroup":"SY","termSource":"NCI"},{"termName":"PepCan","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"738026"},{"name":"NCI_META_CUI","value":"CL437177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738026"},{"name":"PDQ_Open_Trial_Search_ID","value":"738026"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123378":{"preferredName":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106","code":"C123378","definitions":[{"definition":"A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-6 E6/E7 DNA Vaccine INO-3106","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-6-targeting Immunotherapeutic INO-3106","termGroup":"SY","termSource":"NCI"},{"termName":"INO-3106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106"},{"name":"NCI_Drug_Dictionary_ID","value":"764841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764841"},{"name":"PDQ_Open_Trial_Search_ID","value":"764841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053632"}]}}{"C162459":{"preferredName":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101","code":"C162459","definitions":[{"definition":"A fusion protein composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, with a peptide epitope derived from the human papillomavirus type 16 (HPV16) E7 protein (amino acid residues 11-20), a reduced affinity human interleukin-2 (IL-2) variant, and an effector attenuated human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic and immunostimulatory activities. Upon administration, CUE-101 targets and selectively binds to E7-specific CD8-positive T-cells present in patients with HPV16-driven malignancies. This may induce the secretion of inflammatory cytokines such as interferon gamma (IFN gamma) and promote the activation and expansion of tumor-specific CD8-positive cells, which may lead to T-cell-mediated elimination of tumor cells expressing the HPV16 E7 antigen. The HPV16 E7 oncoprotein is a cell surface glycoprotein and tumor-associated antigen (TAA) that is overexpressed in various HPV-associated cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HPV16 E7 Fusion Protein CUE-101","termGroup":"SY","termSource":"NCI"},{"termName":"CUE 101","termGroup":"CN","termSource":"NCI"},{"termName":"CUE-101","termGroup":"CN","termSource":"NCI"},{"termName":"CUE101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101"},{"name":"NCI_Drug_Dictionary_ID","value":"798742"},{"name":"NCI_META_CUI","value":"CL970959"},{"name":"PDQ_Open_Trial_Search_ID","value":"798742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121648":{"preferredName":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN","code":"C121648","definitions":[{"definition":"A recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\\E6\\E7), with potential immunoprotective and antineoplastic properties. Upon administration, HPV16 L2\\E6\\E7 fusion protein vaccine TA-CIN may stimulate the immune system to generate HPV16 E6\\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN","termGroup":"PT","termSource":"NCI"},{"termName":"TA-CIN","termGroup":"CN","termSource":"NCI"},{"termName":"Tissue Antigen-Cervical Intraepithelial Neoplasia Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN"},{"name":"NCI_Drug_Dictionary_ID","value":"770825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770825"},{"name":"PDQ_Open_Trial_Search_ID","value":"770825"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053587"}]}}{"C69139":{"preferredName":"Hsp90 Antagonist KW-2478","code":"C69139","definitions":[{"definition":"An agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 antagonist KW-2478 appears to inhibit Hsp90, resulting in impaired signal transduction, inhibition of cell proliferation, and the induction of apoptosis in tumor cells. HSP90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Antagonist KW-2478","termGroup":"PT","termSource":"NCI"},{"termName":"KW-2478","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"819812-18-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E628ZH6U2C"},{"name":"Legacy Concept Name","value":"Hsp90_Antagonist_KW-2478"},{"name":"Maps_To","value":"Hsp90 Antagonist KW-2478"},{"name":"NCI_Drug_Dictionary_ID","value":"548017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"548017"},{"name":"PDQ_Open_Trial_Search_ID","value":"548017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348995"}]}}{"C82691":{"preferredName":"Hsp90 Inhibitor AB-010","code":"C82691","definitions":[{"definition":"An orally bioavailable nanoparticle albumin-bound inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AB-010 selectively binds to Hsp90, inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This agent may inhibit the growth of a wide variety of cancer cell types; the incorporation of albumin into its formulation may facilitate its endothelial transcytosis through the gp60-regulated albumin transport pathway. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor AB-010","termGroup":"PT","termSource":"NCI"},{"termName":"AB-010","termGroup":"CN","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor AB-010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_AB-010"},{"name":"Maps_To","value":"Hsp90 Inhibitor AB-010"},{"name":"NCI_Drug_Dictionary_ID","value":"633820"},{"name":"NCI_META_CUI","value":"CL388478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633820"},{"name":"PDQ_Open_Trial_Search_ID","value":"633820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62517":{"preferredName":"Hsp90 Inhibitor BIIB021","code":"C62517","definitions":[{"definition":"An orally active inhibitor of heat shock protein 90 (HSP90) with potential antineoplastic activity. HSP90, a chaperon protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins. HSP90 inhibitor BIIB021 specifically blocks active HSP90, thereby inhibiting its chaperon function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. As a result, CNF2024 has the potential to inhibit the growth of a wide range of cancer cells in both solid tumors and blood-based cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor BIIB021","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB-021","termGroup":"CN","termSource":"NCI"},{"termName":"BIIB021","termGroup":"CN","termSource":"NCI"},{"termName":"CNF2024","termGroup":"CN","termSource":"NCI"},{"termName":"Hsp90 Antagonist CNF2024","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848695-25-0"},{"name":"Chemical_Formula","value":"C14H15ClN6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"851B9FQ7Q0"},{"name":"Legacy Concept Name","value":"CNF2024"},{"name":"Maps_To","value":"Hsp90 Inhibitor BIIB021"},{"name":"NCI_Drug_Dictionary_ID","value":"497050"},{"name":"PDQ_Closed_Trial_Search_ID","value":"497050"},{"name":"PDQ_Open_Trial_Search_ID","value":"497050"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831929"}]}}{"C78846":{"preferredName":"Hsp90 Inhibitor BIIB028","code":"C78846","definitions":[{"definition":"A small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2/Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to other molecules involved in cell cycle regulation and immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor BIIB028","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911398-13-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KD4GWWK597"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_BIIB02"},{"name":"Maps_To","value":"Hsp90 Inhibitor BIIB028"},{"name":"NCI_Drug_Dictionary_ID","value":"612037"},{"name":"NCI_META_CUI","value":"CL387614"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612037"},{"name":"PDQ_Open_Trial_Search_ID","value":"612037"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92572":{"preferredName":"Hsp90 Inhibitor Debio 0932","code":"C92572","definitions":[{"definition":"An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Debio 0932 specifically blocks Hsp90, thereby inhibiting its chaperone function and promoting the degradation of its client proteins, many of which are oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stabilization and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor Debio 0932","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC-305","termGroup":"CN","termSource":"NCI"},{"termName":"Debio 0932","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-0932","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1061318-81-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0V278OKN9G"},{"name":"Maps_To","value":"Hsp90 Inhibitor Debio 0932"},{"name":"NCI_Drug_Dictionary_ID","value":"682685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682685"},{"name":"PDQ_Open_Trial_Search_ID","value":"682685"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742735"}]}}{"C116851":{"preferredName":"Hsp90 Inhibitor DS-2248","code":"C116851","definitions":[{"definition":"An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor DS-2248","termGroup":"PT","termSource":"NCI"},{"termName":"DS-2248","termGroup":"CN","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor DS-2248","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1015051-35-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3HJ2545H66"},{"name":"Maps_To","value":"Hsp90 Inhibitor DS-2248"},{"name":"NCI_Drug_Dictionary_ID","value":"694996"},{"name":"NCI_META_CUI","value":"CL433776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694996"},{"name":"PDQ_Open_Trial_Search_ID","value":"694996"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82387":{"preferredName":"Hsp90 Inhibitor HSP990","code":"C82387","definitions":[{"definition":"An orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Hsp990 binds to and inhibits the activity of Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90, upregulated in a variety of tumor cells, is a molecular chaperone that plays a key role in the conformational maturation, stability and function of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation and/or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor HSP990","termGroup":"PT","termSource":"NCI"},{"termName":"HSP990","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Hsp90_Inhibitor_HSP990"},{"name":"Maps_To","value":"Hsp90 Inhibitor HSP990"},{"name":"NCI_Drug_Dictionary_ID","value":"641983"},{"name":"NCI_META_CUI","value":"CL408658"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641983"},{"name":"PDQ_Open_Trial_Search_ID","value":"641983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84836":{"preferredName":"Hsp90 Inhibitor LAM-003A","code":"C84836","definitions":[{"definition":"An orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor LAM-003A selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; this agent may inhibit the growth and survival of a wide variety of cancer cell types. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability, and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor LAM-003A","termGroup":"PT","termSource":"NCI"},{"termName":"LAM 003A","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-003A","termGroup":"CN","termSource":"NCI"},{"termName":"LAM003A","termGroup":"CN","termSource":"NCI"},{"termName":"MPC-3100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"958025-66-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9UMA2EEO9Q"},{"name":"Maps_To","value":"Hsp90 Inhibitor MPC-3100"},{"name":"NCI_Drug_Dictionary_ID","value":"649142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649142"},{"name":"PDQ_Open_Trial_Search_ID","value":"649142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830123"}]}}{"C101227":{"preferredName":"Zelavespib","code":"C101227","definitions":[{"definition":"A purine-based heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Zelavespib specifically inhibits active Hsp90, thereby inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may result in the inhibition of cellular proliferation in susceptible tumor cell populations. Hsp90, a molecular chaperone protein, is upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zelavespib","termGroup":"PT","termSource":"NCI"},{"termName":"9H-Purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Hsp90 Inhibitor PU-H71","termGroup":"SY","termSource":"NCI"},{"termName":"PU-H-71","termGroup":"CN","termSource":"NCI"},{"termName":"PU-H71","termGroup":"CN","termSource":"NCI"},{"termName":"PUH71","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"873436-91-0"},{"name":"Chemical_Formula","value":"C18H21IN6O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"06IVK87M04"},{"name":"Maps_To","value":"Hsp90 Inhibitor PU-H71"},{"name":"Maps_To","value":"Zelavespib"},{"name":"NCI_Drug_Dictionary_ID","value":"732547"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732547"},{"name":"PDQ_Open_Trial_Search_ID","value":"732547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3502086"}]}}{"C91068":{"preferredName":"Hsp90 Inhibitor SNX-5422 Mesylate","code":"C91068","definitions":[{"definition":"A substance being studied in the treatment of cancer. SNX-5422 mesylate blocks a protein needed for cells to grow and may kill cancer cells. It is a type of heat shock protein 90 inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor SNX-5422 Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"SNX-5422 Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1173111-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K3BO8V06RM"},{"name":"Maps_To","value":"Hsp90 Inhibitor SNX-5422 Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"590712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590712"},{"name":"PDQ_Open_Trial_Search_ID","value":"590712"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3253587"}]}}{"C74040":{"preferredName":"Hsp90 Inhibitor SNX-5542 Mesylate","code":"C74040","definitions":[{"definition":"The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5542 is rapidly converted to SNX-2112, which accumulates in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor SNX-5542 Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"SNX-5542 Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_SNX-5542_Mesylate"},{"name":"Maps_To","value":"Hsp90 Inhibitor SNX-5542 Mesylate"},{"name":"NCI_META_CUI","value":"CL383549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79835":{"preferredName":"Hsp90 Inhibitor XL888","code":"C79835","definitions":[{"definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor XL888 specifically binds to Hsp90, inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; inhibition of tumor cell proliferation may result. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins, including Her-2 and Met.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor XL888","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor XL888","termGroup":"SY","termSource":"NCI"},{"termName":"XL-888","termGroup":"CN","termSource":"NCI"},{"termName":"XL888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1149705-71-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7M346920EV"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_XL888"},{"name":"Maps_To","value":"Hsp90 Inhibitor XL888"},{"name":"NCI_Drug_Dictionary_ID","value":"629922"},{"name":"NCI_META_CUI","value":"CL388445"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629922"},{"name":"PDQ_Open_Trial_Search_ID","value":"629922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151953":{"preferredName":"Locnartecan","code":"C151953","definitions":[{"definition":"A miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates  and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Locnartecan","termGroup":"PT","termSource":"NCI"},{"termName":"HDC SN-38","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90-targeted SN-38 Conjugate PEN-866","termGroup":"SY","termSource":"NCI"},{"termName":"PEN 866","termGroup":"CN","termSource":"NCI"},{"termName":"PEN-866","termGroup":"CN","termSource":"NCI"},{"termName":"PEN866","termGroup":"CN","termSource":"NCI"},{"termName":"STA-12-8666","termGroup":"CN","termSource":"NCI"},{"termName":"STA-8666","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1472614-83-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56DL1J49LR"},{"name":"Maps_To","value":"HSP90-targeted SN-38 Conjugate PEN-866"},{"name":"NCI_Drug_Dictionary_ID","value":"793183"},{"name":"NCI_META_CUI","value":"CL601355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793183"},{"name":"PDQ_Open_Trial_Search_ID","value":"793183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C134448":{"preferredName":"Pimitespib","code":"C134448","definitions":[{"definition":"A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, pimitespib specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. Hsp90, a family of molecular chaperone proteins that are upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability, and function of \"client\" proteins within the cell,; many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, cell-cycle regulators, transcription factors and hormone receptors. As TAS-116 selectively inhibits cytosolic HSP90alpha and beta only and does not inhibit HSP90 paralogs, such as endoplasmic reticulum GRP94 or mitochondrial TRAP1, this agent may have less off-target toxicity as compared to non-selective HSP90 inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimitespib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)benzamide","termGroup":"SY","termSource":"NCI"},{"termName":"Heat Shock Protein 90 alpha/beta Inhibitor TAS-116","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90alpha/beta Inhibitor TAS-116","termGroup":"SY","termSource":"NCI"},{"termName":"TAS-116","termGroup":"CN","termSource":"NCI"},{"termName":"TAS116","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260533-36-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PLO044MUDZ"},{"name":"Maps_To","value":"HSP90alpha/beta Inhibitor TAS-116"},{"name":"Maps_To","value":"Pimitespib"},{"name":"NCI_Drug_Dictionary_ID","value":"788861"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788861"},{"name":"PDQ_Open_Trial_Search_ID","value":"788861"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4044757"}]}}{"C119616":{"preferredName":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301","code":"C119616","definitions":[{"definition":"A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301","termGroup":"PT","termSource":"NCI"},{"termName":"GX 301","termGroup":"CN","termSource":"NCI"},{"termName":"GX301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301"},{"name":"NCI_Drug_Dictionary_ID","value":"766744"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766744"},{"name":"PDQ_Open_Trial_Search_ID","value":"766744"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896843"}]}}{"C80055":{"preferredName":"hTERT Vaccine V934/V935","code":"C80055","definitions":[{"definition":"A cancer vaccine directed against human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. Upon administration, hTERT vaccine V934/V935 may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase is involved in the restoration and maintenance of telomere length and so the functional lifespan of cells. Abnormally reactivated in tumorigenesis, telomerase is expressed in the majority of human cancer cells but is not expressed or is expressed at very low levels in normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"hTERT Vaccine V934/V935","termGroup":"PT","termSource":"NCI"},{"termName":"V934/V935","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"hTERT_Vaccine_V934_V935"},{"name":"Maps_To","value":"hTERT Vaccine V934/V935"},{"name":"NCI_Drug_Dictionary_ID","value":"615723"},{"name":"NCI_META_CUI","value":"CL388391"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615723"},{"name":"PDQ_Open_Trial_Search_ID","value":"615723"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119737":{"preferredName":"hTERT-encoding DNA Vaccine INVAC-1","code":"C119737","definitions":[{"definition":"A DNA vaccine consisting of a plasmid encoding a modified, inactive form of the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase which synthesizes telomeric DNA at the chromosome ends, fused to ubiquitin, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INVAC-1 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. hTERT conjugation to ubiquitin, a 76 amino-acid peptide involved in the regulation of normal protein intracellular turnover in the cytoplasm, enhances proteasome-dependent degradation of the hTERT protein, increases hTERT presentation by major histocompatibility complex (MHC) class I molecules and results in an increased immune response against hTERT.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"hTERT-encoding DNA Vaccine INVAC-1","termGroup":"PT","termSource":"NCI"},{"termName":"INVAC-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1708137-44-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S8GQZ8LF0D"},{"name":"Maps_To","value":"hTERT-encoding DNA Vaccine INVAC-1"},{"name":"NCI_Drug_Dictionary_ID","value":"766989"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766989"},{"name":"PDQ_Open_Trial_Search_ID","value":"766989"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896833"}]}}{"C162537":{"preferredName":"Lorukafusp alfa","code":"C162537","definitions":[{"definition":"A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1) chimeric monoclonal antibody directed against the surface disialoganglioside GD2, fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, the antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed on certain tumor cells. This may stimulate the activation of immune effector cells including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME), IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed on the surface of many tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lorukafusp alfa","termGroup":"PT","termSource":"NCI"},{"termName":"APN 301","termGroup":"CN","termSource":"NCI"},{"termName":"APN-301","termGroup":"CN","termSource":"NCI"},{"termName":"APN301","termGroup":"CN","termSource":"NCI"},{"termName":"EMD 273063","termGroup":"CN","termSource":"NCI"},{"termName":"EMD-273063","termGroup":"CN","termSource":"NCI"},{"termName":"Hu 14.18/IL - 2 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Hu14.18-IL2","termGroup":"SY","termSource":"NCI"},{"termName":"Hu14.18-IL2","termGroup":"AB","termSource":"NCI"},{"termName":"Hu14.18-IL2 Fusion Protein EMD 273063","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2131168-99-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PL21OR4LXE"},{"name":"Maps_To","value":"Hu14.18-IL2 Fusion Protein EMD 273063"},{"name":"NCI_Drug_Dictionary_ID","value":"43349"},{"name":"NCI_META_CUI","value":"CL971111"},{"name":"NSC Number","value":"721298"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82415":{"preferredName":"HuaChanSu","code":"C82415","definitions":[{"definition":"A traditional Chinese medicine (TCM) containing a water soluble Bufo toad skin extract that includes the cardiac glycosides bufalin, cinobufagin and resibufogenin with potential antineoplastic and antiangiogenic activities. Although the exact mechanism of action of this TCM has yet to be fully elucidated, huachansu, which may be administered in an injectable form, may induce cell cycle arrest and apoptosis by suppressing the expression of anti-apoptotic proteins, such as Bcl-2, while inducing the expression of pro-apoptotic proteins, such as BAX.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HuaChanSu","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HuaChanSu"},{"name":"Maps_To","value":"HuaChanSu"},{"name":"NCI_Drug_Dictionary_ID","value":"637352"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637352"},{"name":"PDQ_Open_Trial_Search_ID","value":"637352"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2745673"}]}}{"C125001":{"preferredName":"Huaier Extract Granule","code":"C125001","definitions":[{"definition":"An orally bioavailable traditional Chinese medicine (TCM) composed of a granule containing an aqueous extract of Trametes robiniophila murr (Huaier), a mushroom found on hardwood tree trunks, with potential antineoplastic and anti-angiogenic activities. Although the exact mechanism of action through which Huaier exerts its effects is largely unknown, upon administration, this agent induces cell cycle arrest and apoptosis, and inhibits proliferation and migration of susceptible cancer cells through the modulation of various signal transduction pathways involved in carcinogenesis and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Huaier Extract Granule","termGroup":"PT","termSource":"NCI"},{"termName":"Huaier Granule","termGroup":"SY","termSource":"NCI"},{"termName":"Trametes robiniophila murr Extract Granule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Huaier Extract Granule"},{"name":"NCI_Drug_Dictionary_ID","value":"777301"},{"name":"NCI_META_CUI","value":"CL503847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777301"},{"name":"PDQ_Open_Trial_Search_ID","value":"777301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2626":{"preferredName":"Huang Lian","code":"C2626","definitions":[{"definition":"A Chinese herb of a desiccated root from the plant Coptis chinensis. Although the mechanism of action remains to be fully elucidated, Huang Lian has antibacterial, antifungal, and antiprotozoal activities. In addition, this herb exhibits antioxidant property that influences positively on lipid metabolism, cause dilation of blood vessels, and may slow the growth of tumor cells. This herb contains rich amount of phytogens, such as berberine, palmatine, jatrorrhizine, columbamine, geniposide, and anti-HIV compound baicalin, which might explain the broad effects of this herb. Huang Lian is commonly used to treat diarrhea or dysentery in Chinese medicine.","type":"DEFINITION","source":"NCI"},{"definition":"A Chinese herb that has been used as a treatment for a variety of medical problems.  It is being studied as an anticancer drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Huang Lian","termGroup":"PT","termSource":"NCI"},{"termName":"Rhizoma Coptidis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Huang_Lian"},{"name":"Maps_To","value":"Huang Lian"},{"name":"NCI_Drug_Dictionary_ID","value":"38268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38268"},{"name":"PDQ_Open_Trial_Search_ID","value":"38268"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0696725"}]}}{"C74041":{"preferredName":"huBC1-huIL12 Fusion Protein AS1409","code":"C74041","definitions":[{"definition":"An immunoconjugate consisting of the anti-tumor cytokine interleukin-12 (IL-12) fused to the tumor-targeting antibody BC1 with potential immunostimulatory and antineoplastic activities. The antibody moiety of huBC1-huIL12 fusion protein AS1409 binds to the human fibronectin splice variant ED-B, delivering IL-12 directly to the tumor vasculature; tumor vasculature-targeted IL-12 initiates localized immune cascade responses and exhibits cytotoxic and anti-angiogenic activity while minimizing the systemic side effects of IL-12. The human fibronectin splice variant ED-B is over-expressed in the extracellular matrix and blood vessels of tumor tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"huBC1-huIL12 Fusion Protein AS1409","termGroup":"PT","termSource":"NCI"},{"termName":"AS1409","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"huBC1-huIL12_Fusion_Protein_AS1409"},{"name":"Maps_To","value":"huBC1-huIL12 Fusion Protein AS1409"},{"name":"NCI_Drug_Dictionary_ID","value":"590612"},{"name":"NCI_META_CUI","value":"CL383540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590612"},{"name":"PDQ_Open_Trial_Search_ID","value":"590612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116788":{"preferredName":"Ianalumab","code":"C116788","definitions":[{"definition":"A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ianalumab","termGroup":"PT","termSource":"NCI"},{"termName":"HuCAL-based Antibody VAY736","termGroup":"SY","termSource":"NCI"},{"termName":"Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736","termGroup":"SY","termSource":"NCI"},{"termName":"VAY 736","termGroup":"CN","termSource":"NCI"},{"termName":"VAY736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1929549-92-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZN2GQ3II96"},{"name":"Maps_To","value":"Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736"},{"name":"Maps_To","value":"Ianalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"762784"},{"name":"NCI_META_CUI","value":"CL473936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762784"},{"name":"PDQ_Open_Trial_Search_ID","value":"762784"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66980":{"preferredName":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104","code":"C66980","definitions":[{"definition":"An allogeneic human cytotoxic T-lymphocyte cell line (TALL-104) with potential antineoplastic activity. TALL-104 is an IL-2-dependent human leukemic T cell line, expressing CD8 and T-cell receptor CD3, but not CD16. Because these cells are endowed with MHC-non-restricted killer activity, TALL-104 has destructive potential against a broad range of tumors, while sparing normal cells. Upon administration, TALL-104 targets and interacts with tumor cells and activates apoptotic and necrotic pathways, eventually leading to lysis of tumor cells. In addition, TALL-104 may induce secretion of various cytokines, such as interferon-gamma, thereby potentially enhancing the cytotoxic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104","termGroup":"PT","termSource":"NCI"},{"termName":"TALL-104","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_MHC_Non-Restricted_Cytotoxic_T-Cell_Line_TALL-104"},{"name":"Maps_To","value":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104"},{"name":"NCI_Drug_Dictionary_ID","value":"531055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531055"},{"name":"PDQ_Open_Trial_Search_ID","value":"531055"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832042"}]}}{"C29089":{"preferredName":"Human MOAB LICO 28a32","code":"C29089","definitions":[{"definition":"A human monoclonal immunoglobulin M (IgM) antibody with potential antineoplastic activity.  Human MOAB LICO 28a32 binds to the colon tumor-associated antigen 28A32 (CTAA 28A32) found on the cell surface and in the cytoplasm of colon carcinoma cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human MOAB LICO 28a32","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_MOAB_LICO_28a32"},{"name":"Maps_To","value":"Human MOAB LICO 28a32"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1512509"}]}}{"C62532":{"preferredName":"Human Monoclonal Antibody 216","code":"C62532","definitions":[{"definition":"A naturally-occurring human IgM monoclonal antibody with potential antineoplastic activity. Human monoclonal antibody 216, derived from the gene VH4-34, binds to the glycosylated epitope CDIM on the surface of both malignant and normal B cells. Upon binding to B cells, this antibody may crosslink two or more CDIM molecules, resulting in the formation of cell membrane pores, the disruption of cell membrane integrity, and B cell lysis; this mechanism of antibody-mediated cell death is direct and does not involve mechanisms of complement-mediated cytotoxicity or antibody-dependent cell-mediated cytotoxicity (ADCC). CDIM is the glyco-moiety of a 75kD B-cell cell surface glycoprotein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Monoclonal Antibody 216","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb 216","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Monoclonal_Antibody_216"},{"name":"Maps_To","value":"Human Monoclonal Antibody 216"},{"name":"NCI_Drug_Dictionary_ID","value":"488467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488467"},{"name":"PDQ_Open_Trial_Search_ID","value":"488467"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C1831869"}]}}{"C77858":{"preferredName":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307","code":"C77858","definitions":[{"definition":"A human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. Upon internalization and processing, APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells. The tumor-associated antigen (TAA) hCG beta is selectively overexpressed by a number of tumors including breast, colorectal, pancreatic, bladder and ovarian tumors; its expression may correlate with the stage of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307","termGroup":"PT","termSource":"NCI"},{"termName":"CDX-1307","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Monoclonal_Antibody_B11-hCG_Beta_Fusion_Protein_CDX-1307"},{"name":"Maps_To","value":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307"},{"name":"NCI_Drug_Dictionary_ID","value":"593942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593942"},{"name":"PDQ_Open_Trial_Search_ID","value":"593942"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2713084"}]}}{"C2569":{"preferredName":"Human Papillomavirus 16 E7 Peptide/Padre 965.10","code":"C2569","definitions":[{"definition":"A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms.  HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator.  This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas.  PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus 16 E7 Peptide/Padre 965.10","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E7/PADRE 965.10","termGroup":"SY","termSource":"NCI"},{"termName":"Lipidated HPV-16 E7/Padre-965.10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus_16_E7_Peptide-Padre_965_10"},{"name":"Maps_To","value":"Human Papillomavirus 16 E7 Peptide/Padre 965.10"},{"name":"NCI_Drug_Dictionary_ID","value":"42276"},{"name":"NSC Number","value":"679904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42276"},{"name":"PDQ_Open_Trial_Search_ID","value":"42276"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338214"}]}}{"C550":{"preferredName":"Hycanthone","code":"C550","definitions":[{"definition":"A thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. Hycanthone interferes with parasite nerve function, resulting in parasite paralysis and death.  This agent also intercalates into DNA and inhibits RNA synthesis in vitro. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hycanthone","termGroup":"PT","termSource":"NCI"},{"termName":"Etrenol","termGroup":"BR","termSource":"NCI"},{"termName":"HYC","termGroup":"AB","termSource":"NCI"},{"termName":"Hycanthone Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3105-97-3"},{"name":"CHEBI_ID","value":"CHEBI:52768"},{"name":"Chemical_Formula","value":"C20H24N2O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BXX5EVN2A"},{"name":"Legacy Concept Name","value":"Hycanthone"},{"name":"Maps_To","value":"Hycanthone"},{"name":"NCI_Drug_Dictionary_ID","value":"39477"},{"name":"NSC Number","value":"134434"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39477"},{"name":"PDQ_Open_Trial_Search_ID","value":"39477"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020207"}]}}{"C551":{"preferredName":"Hydralazine Hydrochloride","code":"C551","definitions":[{"definition":"The hydrochloride salt of hydralazine, a phthalazine derivative with antihypertensive and potential antineoplastic activities. Hydralazine alters intracellular calcium release and interferes with smooth muscle cell calcium influx, resulting in arterial vasodilatation. This agent also inhibits the phosphorylation of myosin protein and chelation of trace metals required for smooth muscle contraction, resulting in an increase in heart rate, stroke volume and cardiac output. In addition to its cardiovascular effects, hydralazine inhibits DNA methyltransferase, which may result in inhibition of DNA methylation in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydralazine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Apresoline","termGroup":"BR","termSource":"NCI"},{"termName":"Apressin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"304-20-1"},{"name":"CHEBI_ID","value":"CHEBI:31672"},{"name":"Chemical_Formula","value":"C8H8N4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FD171B778Y"},{"name":"Legacy Concept Name","value":"Hydralazine"},{"name":"Maps_To","value":"Hydralazine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41835"},{"name":"NSC Number","value":"89394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41835"},{"name":"PDQ_Open_Trial_Search_ID","value":"41835"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699178"}]}}{"C1819":{"preferredName":"Hydrocortisone Sodium Succinate","code":"C1819","definitions":[{"definition":"The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydrocortisone Sodium Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"A-Hydrocort","termGroup":"BR","termSource":"NCI"},{"termName":"Buccalsone","termGroup":"FB","termSource":"NCI"},{"termName":"Corlan","termGroup":"FB","termSource":"NCI"},{"termName":"Cortisol Sodium Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"Cortop","termGroup":"FB","termSource":"NCI"},{"termName":"Efcortelan","termGroup":"FB","termSource":"NCI"},{"termName":"Emergent-EZ","termGroup":"BR","termSource":"NCI"},{"termName":"Flebocortid","termGroup":"FB","termSource":"NCI"},{"termName":"Hidroc Clora","termGroup":"FB","termSource":"NCI"},{"termName":"Hycorace","termGroup":"SY","termSource":"NCI"},{"termName":"Hydro-Adreson","termGroup":"FB","termSource":"NCI"},{"termName":"Hydrocort","termGroup":"FB","termSource":"NCI"},{"termName":"Hydrocortisone 21-Sodium Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"Hydrocortisone Na Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"Kinogen","termGroup":"FB","termSource":"NCI"},{"termName":"Nordicort","termGroup":"FB","termSource":"NCI"},{"termName":"Nositrol","termGroup":"FB","termSource":"NCI"},{"termName":"Sinsurrene","termGroup":"FB","termSource":"NCI"},{"termName":"Solu-Cortef","termGroup":"BR","termSource":"NCI"},{"termName":"Solu-Glyc","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125-04-2"},{"name":"Chemical_Formula","value":"C25H33O8.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"50LQB69S1Z"},{"name":"Legacy Concept Name","value":"Hydrocortisone_Sodium_Succinate"},{"name":"Maps_To","value":"Hydrocortisone Sodium Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"39861"},{"name":"NSC Number","value":"9152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39861"},{"name":"PDQ_Open_Trial_Search_ID","value":"39861"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770560"}]}}{"C557":{"preferredName":"Hydroxychloroquine","code":"C557","definitions":[{"definition":"A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that decreases immune responses in the body.  It is used to treat some autoimmune diseases, and is being studied as a treatment for graft-versus-host disease. Hydroxychloroquine belongs to the family of drugs called antiprotozoals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hydroxychloroquine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malaria; Rheumatoid arthritis"},{"name":"CAS_Registry","value":"118-42-3"},{"name":"Chemical_Formula","value":"C18H26ClN3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4QWG6N8QKH"},{"name":"Legacy Concept Name","value":"Hydroxychloroquine"},{"name":"Maps_To","value":"Hydroxychloroquine"},{"name":"NCI_Drug_Dictionary_ID","value":"38571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38571"},{"name":"PDQ_Open_Trial_Search_ID","value":"38571"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020336"}]}}{"C960":{"preferredName":"Hydroxyprogesterone Caproate","code":"C960","definitions":[{"definition":"A synthetic progestational agent similar to the endogenous progesterone used in hormone therapy or as a female contraceptive. Mimicking the action of progesterone, hydroxyprogesterone caporate binds to and activates nuclear progesterone receptors in the reproductive system and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. Due to the negative feedback mechanism seen with progesterone, this agent also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impeding the growth of estrogen-sensitive tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydroxyprogesterone Caproate","termGroup":"PT","termSource":"NCI"},{"termName":"17-[(1-Oxohexyl)oxy]pregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17alpha-Hydroxyprogesterone Caproate","termGroup":"SY","termSource":"NCI"},{"termName":"Delalutin","termGroup":"BR","termSource":"NCI"},{"termName":"Makena","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Endometrial cancer; amenorrhea"},{"name":"CAS_Registry","value":"630-56-8"},{"name":"Chemical_Formula","value":"C27H40O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"276F2O42F5"},{"name":"Legacy Concept Name","value":"Hydroxyprogesterone_Caproate"},{"name":"Maps_To","value":"Hydroxyprogesterone Caproate"},{"name":"NCI_Drug_Dictionary_ID","value":"39803"},{"name":"NSC Number","value":"17592"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39803"},{"name":"PDQ_Open_Trial_Search_ID","value":"39803"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044971"}]}}{"C63690":{"preferredName":"Hydroxytyrosol","code":"C63690","definitions":[{"definition":"A phenolic phytochemical naturally occurring in extra virgin olive oil, with potential antioxidant, anti-inflammatory and cancer preventive activities. Although the mechanisms of action through which hydroxytyrosol exerts its effects have yet to be fully determined, this agent affects the expression of various components of the inflammatory response, possibly through the modulation of the nuclear factor-kappa B (NF-kB) pathway. The effects include the modulation of pro-inflammatory cytokines, such as the inhibition of interleukin-1alpha (IL-1a), IL-1beta, IL-6, IL-12, and tumor necrosis factor-alpha (TNF-a); increased secretion of the anti-inflammatory cytokine IL-10; inhibition of the production of certain chemokines, such as C-X-C motif chemokine ligand 10 (CXCL10/IP-10), C-C motif chemokine ligand 2 (CCL2/MCP-1), and macrophage inflammatory protein-1beta (CCL4/MIP-1b); and inhibition of the expression of the enzymes inducible nitric oxide synthase (iNOS/NOS2) and prostaglandin E2 synthase (PGES), which prevent the production of nitric oxide (NO) and prostaglandin E (PGE2), respectively. In addition, hydroxytyrosol is able to regulate the expression of other genes involved in the regulation of tumor cell proliferation, such as extracellular signal-regulated and cyclin-dependent kinases. Also, hydroxytyrosol scavenges free radicals and prevents oxidative DNA damage. This induces apoptosis and inhibits proliferation in susceptible cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydroxytyrosol","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3,4-Dihydroxyphenyl)ethanol","termGroup":"SY","termSource":"NCI"},{"termName":"3,4-DHPEA","termGroup":"AB","termSource":"NCI"},{"termName":"3,4-Dihydroxyphenylethanol","termGroup":"SN","termSource":"NCI"},{"termName":"4-(2-Hydroxyethyl)-1,2-benzenediol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10597-60-1"},{"name":"Chemical_Formula","value":"C8H10O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QEU0NE4O90"},{"name":"Legacy Concept Name","value":"_3_4-Dihydroxyphenylethanol"},{"name":"Maps_To","value":"Hydroxytyrosol"},{"name":"NCI_Drug_Dictionary_ID","value":"758473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758473"},{"name":"PDQ_Open_Trial_Search_ID","value":"758473"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046981"}]}}{"C560":{"preferredName":"Hydroxyurea","code":"C560","definitions":[{"definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hydroxyurea","termGroup":"PT","termSource":"NCI"},{"termName":"Droxia","termGroup":"BR","termSource":"NCI"},{"termName":"Hydrea","termGroup":"BR","termSource":"NCI"},{"termName":"Hydroxycarbamide","termGroup":"SY","termSource":"NCI"},{"termName":"Litalir","termGroup":"FB","termSource":"NCI"},{"termName":"Onco-Carbide","termGroup":"FB","termSource":"NCI"},{"termName":"Oncocarbide","termGroup":"FB","termSource":"NCI"},{"termName":"Oxeron","termGroup":"FB","termSource":"NCI"},{"termName":"SQ-1089","termGroup":"CN","termSource":"NCI"},{"termName":"Syrea","termGroup":"FB","termSource":"NCI"},{"termName":"WR 83799","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Myelogenous Leukemia; Head and Neck Cancer; Malignant Melanoma; Ovarian Carcinoma; Sickle Cell Anemia; Adjuvant in Retroviral Therapy."},{"name":"CAS_Registry","value":"127-07-1"},{"name":"CHEBI_ID","value":"CHEBI:44423"},{"name":"Chemical_Formula","value":"CH4N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"X6Q56QN5QC"},{"name":"Legacy Concept Name","value":"Hydroxyurea"},{"name":"Maps_To","value":"Hydroxyurea"},{"name":"NCI_Drug_Dictionary_ID","value":"40685"},{"name":"NSC Number","value":"32065"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40685"},{"name":"PDQ_Open_Trial_Search_ID","value":"40685"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020402"}]}}{"C37456":{"preferredName":"Hypericin","code":"C37456","definitions":[{"definition":"An anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John's wort) with antidepressant, potential antiviral, antineoplastic and immunostimulating activities. Hypericin appears to inhibit the neuronal uptake of serotonin, norepinephrine, dopamine, gamma-amino butyric acid (GABA) and L-glutamate, which may contribute to its antidepressant effect. Hypericin may also prevent the replication of encapsulated viruses probably due to inhibition of the assembly and shedding of virus particles in infected cells. This agent also exerts potent phototoxic effects by triggering apoptotic signaling that results in formation of reactive oxygen species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypericin","termGroup":"PT","termSource":"NCI"},{"termName":"4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethyl-mesonapthtodianthron","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"548-04-9"},{"name":"CHEBI_ID","value":"CHEBI:5835"},{"name":"Chemical_Formula","value":"C30H16O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7V2F1075HD"},{"name":"Legacy Concept Name","value":"Hypericin"},{"name":"Maps_To","value":"Hypericin"},{"name":"NSC Number","value":"407313"},{"name":"NSC Number","value":"622946"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063220"}]}}{"C101523":{"preferredName":"Hypoxia-activated Prodrug TH-4000","code":"C101523","definitions":[{"definition":"A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug TH-4000 is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypoxia-activated Prodrug TH-4000","termGroup":"PT","termSource":"NCI"},{"termName":"Hypoxin","termGroup":"BR","termSource":"NCI"},{"termName":"PR610","termGroup":"CN","termSource":"NCI"},{"termName":"TH-4000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoxia-activated Prodrug TH-4000"},{"name":"NCI_Drug_Dictionary_ID","value":"732241"},{"name":"NCI_META_CUI","value":"CL435780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732241"},{"name":"PDQ_Open_Trial_Search_ID","value":"732241"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2357":{"preferredName":"I 131 Antiferritin Immunoglobulin","code":"C2357","definitions":[{"definition":"A radioimmunoconjugate of a rabbit antihuman ferritin IgG labeled with iodine 131 (I-131). Using anti-ferritin IgG as a carrier for I-131 may result in the targeted imaging and/or destruction of cells expressing ferritin. Observed in 35% to 100% of patients with hepatocellular carcinoma, high serum ferritin levels may be due to ferritin production by the tumor cells, or related to the associated iron overload and/or cirrhosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Antiferritin Immunoglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"I 131-AFI","termGroup":"AB","termSource":"NCI"},{"termName":"I 131-antiferritin IgG","termGroup":"SY","termSource":"NCI"},{"termName":"immunoglobulin, iodine I 131 antiferritin","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Antiferritin Immunoglobulin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Antiferritin_Immunoglobulin"},{"name":"Maps_To","value":"I 131 Antiferritin Immunoglobulin"},{"name":"NCI_Drug_Dictionary_ID","value":"40362"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40362"},{"name":"PDQ_Open_Trial_Search_ID","value":"40362"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280029"}]}}{"C2477":{"preferredName":"I 131 Monoclonal Antibody A33","code":"C2477","definitions":[{"definition":"A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 131 (I-131). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancers, with only restricted expression in normal colonic mucosa. Using MoAb A33 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressed A33 antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody A33","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody A33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_A33"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody A33"},{"name":"NCI_Drug_Dictionary_ID","value":"43095"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43095"},{"name":"PDQ_Open_Trial_Search_ID","value":"43095"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678093"}]}}{"C26442":{"preferredName":"I 131 Monoclonal Antibody CC49","code":"C26442","definitions":[{"definition":"A radioimmunoconjugate of the humanized monoclonal antibody CC49 labeled with iodine I 131. Iodine I 131 monoclonal antibody CC49 delivers beta and gamma radiation-emitting I 131 radionuclide specifically to tumor cells that express tumor-associated glycoprotein (TAG)-72, allowing localization of TAG-72-expressing tumor cells with radioimaging devices in diagnostic applications or resulting in specific TAG-72-expressing tumor cell radiocytotoxicity in therapeutic applications. Monoclonal antibody CC49 binds to TAG-72, a pancarcinoma antigen, with high affinity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody CC49","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody CC49"},{"name":"NCI_Drug_Dictionary_ID","value":"269166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269166"},{"name":"PDQ_Open_Trial_Search_ID","value":"269166"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327845"}]}}{"C2515":{"preferredName":"I 131 Monoclonal Antibody F19","code":"C2515","definitions":[{"definition":"A radioimmunoconjugate of a murine monoclonal antibody (MoAb) F19 labelled with Iodine 131 (I-131). MoAb F19 was raised against fibroblast activation protein (FAP), which is highly expressed by tumor stromal cells. Using MoAb F19 as a carrier for I-131 results in the targeted imaging and/or destruction of cells overexpressed FAP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody F19","termGroup":"PT","termSource":"NCI"},{"termName":"131I-mAbF19","termGroup":"AB","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody F19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_F19"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody F19"},{"name":"NCI_Drug_Dictionary_ID","value":"43385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43385"},{"name":"PDQ_Open_Trial_Search_ID","value":"43385"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796525"}]}}{"C2103":{"preferredName":"I 131 Monoclonal Antibody Lym-1","code":"C2103","definitions":[{"definition":"A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with iodine 131 (I-131). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. I-131 MoAb Lym-1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express HLA-DR, thereby allowing imaging and/or treatment of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody Lym-1","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolym","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_Lym-1"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody Lym-1"},{"name":"NCI_Drug_Dictionary_ID","value":"38533"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38533"},{"name":"PDQ_Open_Trial_Search_ID","value":"38533"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134561"}]}}{"C162535":{"preferredName":"Dasminapant","code":"C162535","definitions":[{"definition":"A small molecule, second mitochondria-derived activator of caspases (SMAC)-mimetic targeting inhibitor of apoptosis proteins (IAPs) with potential apoptosis-inducing and antineoplastic activities. Upon administration, dasminapant selectively binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, dasminapant may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dasminapant","termGroup":"PT","termSource":"NCI"},{"termName":"APG 1387","termGroup":"CN","termSource":"NCI"},{"termName":"APG-1387","termGroup":"CN","termSource":"NCI"},{"termName":"APG1387","termGroup":"CN","termSource":"NCI"},{"termName":"IAP Antagonist APG-1387","termGroup":"SY","termSource":"NCI"},{"termName":"IAP Inhibitor APG-1387","termGroup":"SY","termSource":"NCI"},{"termName":"Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, 3,3'-(1,3-phenylenebis(sulfonyl))bis(N-(diphenylmethyl)decahydro-5-(((2S)-2-(methylamino)-1-oxopropyl)amino)-6-oxo-, (5S,5'S,8S,8'S,10aR,10'ar)-","termGroup":"SN","termSource":"NCI"},{"termName":"SM-1387","termGroup":"CN","termSource":"NCI"},{"termName":"SMAC-mimetic APG-1387","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1570231-89-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E53VN70K2X"},{"name":"Maps_To","value":"IAP Inhibitor APG-1387"},{"name":"NCI_Drug_Dictionary_ID","value":"794301"},{"name":"NCI_META_CUI","value":"CL971113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794301"},{"name":"PDQ_Open_Trial_Search_ID","value":"794301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90574":{"preferredName":"Xevinapant","code":"C90574","definitions":[{"definition":"An orally available mimetic of the natural second mitochondrial-derived activator of caspases (Smac) and inhibitor of Inhibitor of Apoptosis Proteins (IAPs), with potential immunomodulating, apoptotic-inducing, chemo-radio-sensitizing and antineoplastic activities. Upon oral administration,xevinapant targets and binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP), and the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This inhibits the activities of these IAPs and promotes the induction of apoptosis. Additionally, as xevinapant inhibits the activity of IAPs, it may work synergistically with cytotoxic drugs and/or radiation to overcome tumor cell resistance to apoptosis. As IAPs regulate nuclear factor-kappa B (NFkB) signaling pathways, which drives the expression of genes involved in immune and inflammatory responses, xevinapant may enhance anti-tumor immune responses when administered with certain immunomodulating agents, such as immune checkpoint inhibitors. IAPs are overexpressed by many cancer cell types and suppress both intrinsic and extrinsic apoptosis by binding to and inhibiting active caspases via their baculoviral lAP repeat (BIR) domains. They contribute to chemo-radio-resistance of cancer cells to certain cytotoxic agents and radiation, promote tumor cell survival and are associated with poor prognosis in certain types of cancer. SMAC, a pro-apoptotic mitochondrial protein, is an endogenous inhibitor of the IAPs family of cellular proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xevinapant","termGroup":"PT","termSource":"NCI"},{"termName":"AT-406","termGroup":"CN","termSource":"NCI"},{"termName":"D1143","termGroup":"CN","termSource":"NCI"},{"termName":"Debio 1143","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-1143","termGroup":"CN","termSource":"NCI"},{"termName":"Debio1143","termGroup":"CN","termSource":"NCI"},{"termName":"IAPs Antagonist Debio 1143","termGroup":"SY","termSource":"NCI"},{"termName":"IAPs Inhibitor Debio 1143","termGroup":"SY","termSource":"NCI"},{"termName":"Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, n-((1,1'-biphenyl)-2-ylmethyl)decahydro-5-(((2s)-2-(methylamino)-1-oxopropyl)amino)-3-(3-methyl-1-oxobutyl)-6-oxo-, (5s,8s,10ar)","termGroup":"SY","termSource":"NCI"},{"termName":"Second Mitochondrial-derived Activator of Caspases Mimetic Debio 1143","termGroup":"SY","termSource":"NCI"},{"termName":"SM-406","termGroup":"CN","termSource":"NCI"},{"termName":"SMAC Mimetic Debio 1143","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1071992-81-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N65WC8PXDD"},{"name":"Maps_To","value":"IAP Inhibitor AT-406"},{"name":"Maps_To","value":"Xevinapant"},{"name":"NCI_Drug_Dictionary_ID","value":"667935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"667935"},{"name":"PDQ_Open_Trial_Search_ID","value":"667935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3177416"}]}}{"C78484":{"preferredName":"IAP Inhibitor HGS1029","code":"C78484","definitions":[{"definition":"The hydrochloride salt of a small-molecule inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins with potential antineoplastic activity. IAP inhibitor HGS1029 selectively inhibits the biological activity of IAP proteins, which may restore apoptotic signaling pathways; this agent may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IAP Inhibitor HGS1029","termGroup":"PT","termSource":"NCI"},{"termName":"AEG40826-2HCl","termGroup":"CN","termSource":"NCI"},{"termName":"HGS1029","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"IAP_Inhibitor_HGS1029"},{"name":"Maps_To","value":"IAP Inhibitor HGS1029"},{"name":"NCI_Drug_Dictionary_ID","value":"601033"},{"name":"NCI_META_CUI","value":"CL387473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601033"},{"name":"PDQ_Open_Trial_Search_ID","value":"601033"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1670":{"preferredName":"Ibandronate Sodium","code":"C1670","definitions":[{"definition":"A drug that is used to prevent and treat osteoporosis, and is being studied in the treatment of cancer that has spread to the bones. It belongs to the family of drugs called bisphosphonates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibandronate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Bondronate","termGroup":"FB","termSource":"NCI"},{"termName":"Boniva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Osteoporosis, treatment and prevention"},{"name":"CAS_Registry","value":"138926-19-9"},{"name":"Chemical_Formula","value":"C9H22NO7P2.Na.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J12U072QL0"},{"name":"Legacy Concept Name","value":"Ibandronate"},{"name":"Maps_To","value":"Ibandronate Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"365963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365963"},{"name":"PDQ_Open_Trial_Search_ID","value":"365963"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0772244"}]}}{"C129048":{"preferredName":"Iberdomide","code":"C129048","definitions":[{"definition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iberdomide","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"CC 220","termGroup":"CN","termSource":"NCI"},{"termName":"CC-220","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1323403-33-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8V66F27X44"},{"name":"Maps_To","value":"Iberdomide"},{"name":"NCI_Drug_Dictionary_ID","value":"783168"},{"name":"NCI_META_CUI","value":"CL512126"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783168"},{"name":"PDQ_Open_Trial_Search_ID","value":"783168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1680":{"preferredName":"Iboctadekin","code":"C1680","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, iboctadekin displays antitumor effects in vitro and in animal models. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iboctadekin","termGroup":"PT","termSource":"NCI"},{"termName":"Human Interleukin-18 (Recombinant, Expressed in Escherichia coli)","termGroup":"SN","termSource":"NCI"},{"termName":"Human Recombinant Interleukin-18","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-Gamma-Inducing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"IL-18","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon-Gamma-Inducing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-18","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Interleukin-18","termGroup":"SY","termSource":"NCI"},{"termName":"SB 485232","termGroup":"CN","termSource":"NCI"},{"termName":"SB-485232","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"479198-61-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X08H9UZ7TO"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-18"},{"name":"Maps_To","value":"Iboctadekin"},{"name":"Maps_To","value":"Recombinant Interleukin-18"},{"name":"NCI_Drug_Dictionary_ID","value":"386168"},{"name":"PDQ_Closed_Trial_Search_ID","value":"386168"},{"name":"PDQ_Open_Trial_Search_ID","value":"386168"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527127"}]}}{"C29981":{"preferredName":"Ibritumomab Tiuxetan","code":"C29981","definitions":[{"definition":"A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other types of B-cell tumors. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Ibritumomab binds to the protein called CD20, which is found on B cells. It is linked to the compound tiuxetan. This allows certain radioisotopes to be attached before it is given to a patient. It is a type of monoclonal antibody-chelator conjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibritumomab Tiuxetan","termGroup":"PT","termSource":"NCI"},{"termName":"IDEC-129","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-2B8","termGroup":"CN","termSource":"NCI"},{"termName":"Zevalin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"206181-63-7"},{"name":"Chemical_Formula","value":"C23H32N5O10S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4Q52C550XK"},{"name":"Legacy Concept Name","value":"Ibritumomab_Tiuxetan"},{"name":"Maps_To","value":"Ibritumomab Tiuxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"43080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43080"},{"name":"PDQ_Open_Trial_Search_ID","value":"43080"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0877880"}]}}{"C81934":{"preferredName":"Ibrutinib","code":"C81934","definitions":[{"definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BTK Inhibitor PCI-32765","termGroup":"SY","termSource":"NCI"},{"termName":"CRA-032765","termGroup":"CN","termSource":"NCI"},{"termName":"Imbruvica","termGroup":"BR","termSource":"NCI"},{"termName":"PCI-32765","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Waldenstrom's macroglobulinemia (WM); mantle cell lymphoma (MCL); chronic lymphocytic leukemia (CLL)"},{"name":"CAS_Registry","value":"936563-96-1"},{"name":"Chemical_Formula","value":"C25H24N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1X70OSD4VX"},{"name":"Legacy Concept Name","value":"BTK_Inhibitor_PCI-32765"},{"name":"Maps_To","value":"Ibrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"638648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638648"},{"name":"PDQ_Open_Trial_Search_ID","value":"638648"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830052"}]}}{"C99160":{"preferredName":"Icotinib Hydrochloride","code":"C99160","definitions":[{"definition":"The hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Icotinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"BPI-2009H","termGroup":"CN","termSource":"NCI"},{"termName":"Conmana","termGroup":"FB","termSource":"NCI"},{"termName":"Icotinib HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204313-51-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JTD32I0J83"},{"name":"Maps_To","value":"Icotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"717145"},{"name":"NCI_META_CUI","value":"CL524350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717145"},{"name":"PDQ_Open_Trial_Search_ID","value":"717145"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79808":{"preferredName":"Icrucumab","code":"C79808","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Icrucumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody IMC-18F1","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VEGFR-1 Monoclonal Antibody IMC-18F1","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-18F1","termGroup":"CN","termSource":"NCI"},{"termName":"IMC18F1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1024603-92-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T7H0B1R64U"},{"name":"Legacy Concept Name","value":"Anti-VEGFR-1_Monoclonal_Antibody_IMC-18F1"},{"name":"Maps_To","value":"Icrucumab"},{"name":"NCI_Drug_Dictionary_ID","value":"625428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"625428"},{"name":"PDQ_Open_Trial_Search_ID","value":"625428"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703168"}]}}{"C124652":{"preferredName":"ICT-121 Dendritic Cell Vaccine","code":"C124652","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ICT-121 Dendritic Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"CD133 Peptides-pulsed Autologous DC Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CD133 Peptides-pulsed Autologous Dendritic Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"ICT-121","termGroup":"CN","termSource":"NCI"},{"termName":"ICT-121 DC Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ICT-121 Dendritic Cell Vaccine"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4086505"}]}}{"C562":{"preferredName":"Idarubicin","code":"C562","definitions":[{"definition":"A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Idarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Demethoxydaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"4-Demethoxydaunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"4-DMDR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute myeloid leukemia; acute nonlymphocytic leukemia"},{"name":"CAS_Registry","value":"58957-92-9"},{"name":"CHEBI_ID","value":"CHEBI:42068"},{"name":"Chemical_Formula","value":"C26H27NO9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"ZRP63D75JW"},{"name":"Legacy Concept Name","value":"Idarubicin"},{"name":"Maps_To","value":"Idarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39753"},{"name":"PDQ_Open_Trial_Search_ID","value":"39753"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020789"}]}}{"C1587":{"preferredName":"Idarubicin Hydrochloride","code":"C1587","definitions":[{"definition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idarubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Idamycin","termGroup":"BR","termSource":"NCI"},{"termName":"Idamycin PFS","termGroup":"BR","termSource":"NCI"},{"termName":"Idarubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"IMI-30","termGroup":"CN","termSource":"NCI"},{"termName":"SC-33428","termGroup":"CN","termSource":"NCI"},{"termName":"Zavedos","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"In combination therapies for acute myelogenous leukemia and pediatric acute lymphocytic leukemia."},{"name":"CAS_Registry","value":"57852-57-0"},{"name":"Chemical_Formula","value":"C26H27NO9.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5VV3MDU5IE"},{"name":"Legacy Concept Name","value":"Idarubicin_Hydrochloride"},{"name":"Maps_To","value":"Idarubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39753"},{"name":"NSC Number","value":"256439"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39753"},{"name":"PDQ_Open_Trial_Search_ID","value":"39753"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0939353"}]}}{"C90593":{"preferredName":"Idarubicin-Eluting Beads","code":"C90593","definitions":[{"definition":"A sustained-release drug delivery embolization system containing small polymeric beads impregnated with the anthracycline antibiotic idarubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with idarubicin. During transarterial chemoembolization (TACE) in the hepatic artery, idarubicin-eluting beads embolize to the tumor vasculature, occlude tumor blood vessels and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. Simultaneously, idarubicin-eluting beads release cytotoxic idarubicin locally and in a sustained manner. This may result in idarubicin-mediated inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idarubicin-Eluting Beads","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Idarubicin-Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"663437"},{"name":"NCI_META_CUI","value":"CL413614"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663437"},{"name":"PDQ_Open_Trial_Search_ID","value":"663437"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99131":{"preferredName":"Idasanutlin","code":"C99131","definitions":[{"definition":"An orally available, small molecule, antagonist of MDM2 (mouse double minute 2; Mdm2 p53 binding protein homolog), with potential antineoplastic activity. Idasanutlin binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idasanutlin","termGroup":"PT","termSource":"NCI"},{"termName":"RG-7388","termGroup":"CN","termSource":"NCI"},{"termName":"RG7388","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5503781","termGroup":"CN","termSource":"NCI"},{"termName":"RO5503781","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229705-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QSQ883V35U"},{"name":"Maps_To","value":"Idasanutlin"},{"name":"NCI_Drug_Dictionary_ID","value":"715916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715916"},{"name":"PDQ_Open_Trial_Search_ID","value":"715916"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3851180"}]}}{"C117729":{"preferredName":"Idecabtagene Vicleucel","code":"C117729","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idecabtagene Vicleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Abecma","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-BCMA CAR T Cells BB2121","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA-CAR-transduced T Cells BB2121","termGroup":"SY","termSource":"NCI"},{"termName":"BB2121","termGroup":"CN","termSource":"NCI"},{"termName":"BCMA-specific CAR-expressing T Lymphocytes BB2121","termGroup":"SY","termSource":"NCI"},{"termName":"Ide-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with multiple myeloma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8PX1X7UG4D"},{"name":"Maps_To","value":"Idecabtagene Vicleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"763837"},{"name":"NCI_META_CUI","value":"CL474124"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763837"},{"name":"PDQ_Open_Trial_Search_ID","value":"763837"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78825":{"preferredName":"Idelalisib","code":"C78825","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idelalisib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"CAL-101","termGroup":"CN","termSource":"NCI"},{"termName":"GS 1101","termGroup":"CN","termSource":"NCI"},{"termName":"GS-1101","termGroup":"CN","termSource":"NCI"},{"termName":"Phosphoinositide-3 Kinase Delta Inhibitor CAL-101","termGroup":"SY","termSource":"NCI"},{"termName":"Zydelig","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed chronic lymphocytic leukemia (CLL)"},{"name":"CAS_Registry","value":"870281-82-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YG57I8T5M0"},{"name":"Legacy Concept Name","value":"PI3K-delta_Inhibitor_CAL-101"},{"name":"Maps_To","value":"Idelalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"601486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601486"},{"name":"PDQ_Open_Trial_Search_ID","value":"601486"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698692"}]}}{"C121457":{"preferredName":"IDH1(R132) Inhibitor IDH305","code":"C121457","definitions":[{"definition":"An inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, IDH305 specifically inhibits IDH1(R132) mutant forms in the cytoplasm, which inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1(R132)-expressing tumor cells. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH1(R132) Inhibitor IDH305","termGroup":"PT","termSource":"NCI"},{"termName":"IDH305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDH1(R132) Inhibitor IDH305"},{"name":"NCI_Drug_Dictionary_ID","value":"770082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770082"},{"name":"PDQ_Open_Trial_Search_ID","value":"770082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053635"}]}}{"C117235":{"preferredName":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M","code":"C117235","definitions":[{"definition":"A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M","termGroup":"PT","termSource":"NCI"},{"termName":"PEPIDH1M","termGroup":"CN","termSource":"NCI"},{"termName":"PEPIDH1M Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M"},{"name":"NCI_Drug_Dictionary_ID","value":"763159"},{"name":"NCI_META_CUI","value":"CL474105"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763159"},{"name":"PDQ_Open_Trial_Search_ID","value":"763159"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74042":{"preferredName":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020","code":"C74042","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020","termGroup":"PT","termSource":"NCI"},{"termName":"APC8020","termGroup":"CN","termSource":"NCI"},{"termName":"Mylovenge","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Idiotype-Pulsed_Autologous_Dendritic_Cell_Vaccine_APC8020"},{"name":"Maps_To","value":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020"},{"name":"NCI_Drug_Dictionary_ID","value":"584999"},{"name":"NCI_META_CUI","value":"CL383479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"584999"},{"name":"PDQ_Open_Trial_Search_ID","value":"584999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159498":{"preferredName":"IDO Peptide Vaccine IO102","code":"C159498","definitions":[{"definition":"A second-generation peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. Vaccination with IDO peptide vaccine IO102 may activate the immune system to induce an immune response against IDO-expressing tumor cells. This may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO Peptide Vaccine IO102","termGroup":"PT","termSource":"NCI"},{"termName":"IDO-derived Vaccine IO102","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine 2,3-dioxygenase-derived Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"IO 102","termGroup":"CN","termSource":"NCI"},{"termName":"IO-102","termGroup":"SY","termSource":"NCI"},{"termName":"IO102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO Peptide Vaccine IO102"},{"name":"NCI_Drug_Dictionary_ID","value":"797514"},{"name":"NCI_META_CUI","value":"CL951456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797514"},{"name":"PDQ_Open_Trial_Search_ID","value":"797514"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143068":{"preferredName":"IDO-1 Inhibitor LY3381916","code":"C143068","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor LY3381916 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, LY3381916 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO-1 Inhibitor LY3381916","termGroup":"PT","termSource":"NCI"},{"termName":"IDO1 Inhibitor LY3381916","termGroup":"SY","termSource":"NCI"},{"termName":"LY-3381916","termGroup":"CN","termSource":"NCI"},{"termName":"LY3381916","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO-1 Inhibitor LY3381916"},{"name":"NCI_Drug_Dictionary_ID","value":"794987"},{"name":"NCI_META_CUI","value":"CL541448"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794987"},{"name":"PDQ_Open_Trial_Search_ID","value":"794987"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151945":{"preferredName":"IDO/TDO Inhibitor HTI-1090","code":"C151945","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor HTI-1090 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, HTI-1090 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO/TDO Inhibitor HTI-1090","termGroup":"PT","termSource":"NCI"},{"termName":"HTI 1090","termGroup":"CN","termSource":"NCI"},{"termName":"HTI-1090","termGroup":"CN","termSource":"NCI"},{"termName":"SHR9146","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO/TDO Inhibitor HTI-1090"},{"name":"NCI_Drug_Dictionary_ID","value":"793153"},{"name":"NCI_META_CUI","value":"CL553173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793153"},{"name":"PDQ_Open_Trial_Search_ID","value":"793153"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129790":{"preferredName":"IDO1 Inhibitor KHK2455","code":"C129790","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor KHK2455 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, KHK2455 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes. KHK2455 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1 Inhibitor KHK2455","termGroup":"PT","termSource":"NCI"},{"termName":"IDO-1 Inhibitor KHK2455","termGroup":"SY","termSource":"NCI"},{"termName":"KHK 2455","termGroup":"CN","termSource":"NCI"},{"termName":"KHK2455","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1 Inhibitor KHK2455"},{"name":"NCI_Drug_Dictionary_ID","value":"784565"},{"name":"NCI_META_CUI","value":"CL512931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784565"},{"name":"PDQ_Open_Trial_Search_ID","value":"784565"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148235":{"preferredName":"IDO1 Inhibitor MK-7162","code":"C148235","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor MK-7162 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, MK-7162 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This agent may also induce increased interferon (IFN) production, which may lead to a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against and inhibit the growth of the IDO1-expressing tumor cells. IDO1, an enzyme overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1 Inhibitor MK-7162","termGroup":"PT","termSource":"NCI"},{"termName":"Indoleamine-2,3-dioxygenase-1 Inhibitor MK-7162","termGroup":"SY","termSource":"NCI"},{"termName":"MK 7162","termGroup":"CN","termSource":"NCI"},{"termName":"MK-7162","termGroup":"CN","termSource":"NCI"},{"termName":"MK7162","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1 Inhibitor MK-7162"},{"name":"NCI_META_CUI","value":"CL550836"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129375":{"preferredName":"IDO1 Inhibitor PF-06840003","code":"C129375","definitions":[{"definition":"An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor PF-06840003 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, PF-06840003 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes; PF-06840003 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1 Inhibitor PF-06840003","termGroup":"PT","termSource":"NCI"},{"termName":"IDO-1 Inhibitor PF-06840003","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase Inhibitor PF-06840003","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06840003","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06840003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198474-05-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5K1FUI0T2C"},{"name":"Maps_To","value":"IDO1 Inhibitor PF-06840003"},{"name":"NCI_Drug_Dictionary_ID","value":"783440"},{"name":"NCI_META_CUI","value":"CL512154"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783440"},{"name":"PDQ_Open_Trial_Search_ID","value":"783440"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162858":{"preferredName":"IDO1/TDO2 Inhibitor DN1406131","code":"C162858","definitions":[{"definition":"An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor DN1406131 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (KYN). This inhibits the IDO1/TDO2-KYN-AhR pathway. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types, plays a key role in immunosuppression and its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1/TDO2 Inhibitor DN1406131","termGroup":"PT","termSource":"NCI"},{"termName":"DN 1406131","termGroup":"CN","termSource":"NCI"},{"termName":"DN-1406131","termGroup":"CN","termSource":"NCI"},{"termName":"DN131","termGroup":"CN","termSource":"NCI"},{"termName":"DN1406131","termGroup":"CN","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase 2 Inhibitor DN1406131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1/TDO2 Inhibitor DN1406131"},{"name":"NCI_Drug_Dictionary_ID","value":"798903"},{"name":"NCI_META_CUI","value":"CL973340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798903"},{"name":"PDQ_Open_Trial_Search_ID","value":"798903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2642":{"preferredName":"Idronoxil","code":"C2642","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idronoxil","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol","termGroup":"SN","termSource":"NCI"},{"termName":"NOX66","termGroup":"CN","termSource":"NCI"},{"termName":"NV-06","termGroup":"CN","termSource":"NCI"},{"termName":"Phenoxodiol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81267-65-4"},{"name":"Chemical_Formula","value":"C15H12O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"995FT1W541"},{"name":"Legacy Concept Name","value":"Phenoxodiol"},{"name":"Maps_To","value":"Idronoxil"},{"name":"NCI_Drug_Dictionary_ID","value":"38371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38371"},{"name":"PDQ_Open_Trial_Search_ID","value":"38371"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134444"}]}}{"C132257":{"preferredName":"Idronoxil Suppository NOX66","code":"C132257","definitions":[{"definition":"A proprietary, suppository-based formulation composed of idronoxil, a synthetic flavonoid derivative, surrounded by a proprietary lipid that protects idronoxil from phase 2 degradation, with potential chemo- and radio-sensitizing activities. Upon administration, idronoxil blocks the activity of ecto-NOX disulfide-thiol exchanger 2 (ENOX2; tNOX), a tumor-specific external NADH oxidase that maintains the transmembrane electron potential across the plasma membrane and is overexpressed in certain cancer cell types while absent in normal, healthy cells. Loss of this potential directly inhibits certain pro-survival signal transduction pathways, such as the PARP1/PI3 kinase/Akt signaling pathway. The inhibition of these pathways prevents resistance to standard chemo- and radio-therapy and makes tumor cells more susceptible to the anti-tumor activity of conventional chemotherapeutic agents and radiotherapy. The formulation prevents detoxification of idronoxil to an inactive form by bypassing phase 2 metabolism; this increases idronoxil's bioavailability as compared to idronoxil alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idronoxil Suppository NOX66","termGroup":"PT","termSource":"NCI"},{"termName":"NOX66","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Idronoxil Suppository NOX66"},{"name":"NCI_Drug_Dictionary_ID","value":"787307"},{"name":"NCI_META_CUI","value":"CL520045"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787307"},{"name":"PDQ_Open_Trial_Search_ID","value":"787307"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116629":{"preferredName":"Ifabotuzumab","code":"C116629","definitions":[{"definition":"A non-fucosylated monoclonal antibody directed against the ephrin receptor A3 (EphA3), with potential antineoplastic activity. Upon administration, ifabotuzumab selectively binds to tumor cells expressing EphA3. This blocks both EphA3 activation and EphA3-mediated signaling, and induces apoptosis in EphA3-expressing tumor cells. In addition, ifabotuzumab can stimulate antibody dependent cell-mediated cytotoxicity (ADCC) against EphA3-expressing tumor cells. This agent also prevents tumor cell proliferation by inhibiting both EphA3 signaling and proliferation of endothelial cells in the tumor vasculature. The cell-surface receptor EphA3, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of tumor types but is not expressed in normal healthy adult tissues. It plays an important role in tumor cell proliferation. Non-fucosylation of the antibody enhances its ADCC activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifabotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Fibatuzumab","termGroup":"SY","termSource":"NCI"},{"termName":"KB 004","termGroup":"CN","termSource":"NCI"},{"termName":"KB-004","termGroup":"CN","termSource":"NCI"},{"termName":"KB004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1234137-51-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BN89552WP"},{"name":"Maps_To","value":"Ifabotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"686621"},{"name":"NCI_META_CUI","value":"CL433718"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686621"},{"name":"PDQ_Open_Trial_Search_ID","value":"686621"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C81570":{"preferredName":"Ifetroban","code":"C81570","definitions":[{"definition":"An orally bioavailable thromboxane (TxA2) and prostaglandin H2 (PGH2) (TP) receptor antagonist, with anti-thrombotic, anti-hypertensive, anti-asthmatic and potential anti-metastatic activities. Upon administration, ifetroban targets and binds to TxA2 and PGH2 receptors, thereby preventing the activity of both TxA2 and PGH2 and disrupting their downstream signaling pathways. This prevents platelet activation, aggregation and thrombosis. It also prevents vascular constriction and causes vasodilation. In addition, as cancer cells use platelets to metastasize to different parts of the body, ifetroban can reduce the stickiness of the platelets and prevent metastasis. TxA2 causes vascular contraction and platelet activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifetroban","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"143443-90-7"},{"name":"Chemical_Formula","value":"C25H32N2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E833KT807K"},{"name":"Legacy Concept Name","value":"Ifetroban"},{"name":"Maps_To","value":"Ifetroban"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0287939"}]}}{"C564":{"preferredName":"Ifosfamide","code":"C564","definitions":[{"definition":"A drug that is used with other drugs to treat germ cell testicular cancer that did not respond to previous treatment with other drugs. It is also being studied in the treatment of other types of cancer. Ifex attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent and a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-oxo-N,3-bis-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin- 2-amine","termGroup":"SN","termSource":"NCI"},{"termName":"3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"Asta Z-4942","termGroup":"CN","termSource":"NCI"},{"termName":"Cyfos","termGroup":"SY","termSource":"NCI"},{"termName":"Holoxan","termGroup":"FB","termSource":"NCI"},{"termName":"Holoxane","termGroup":"FB","termSource":"NCI"},{"termName":"Ifex","termGroup":"BR","termSource":"NCI"},{"termName":"IFO","termGroup":"AB","termSource":"NCI"},{"termName":"IFO-Cell","termGroup":"FB","termSource":"NCI"},{"termName":"Ifolem","termGroup":"FB","termSource":"NCI"},{"termName":"Ifomida","termGroup":"FB","termSource":"NCI"},{"termName":"Ifomide","termGroup":"SY","termSource":"NCI"},{"termName":"Ifosfamidum","termGroup":"SY","termSource":"NCI"},{"termName":"Ifoxan","termGroup":"FB","termSource":"NCI"},{"termName":"IFX","termGroup":"AB","termSource":"NCI"},{"termName":"Iphosphamid","termGroup":"SY","termSource":"NCI"},{"termName":"Iphosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Iso-Endoxan","termGroup":"SY","termSource":"NCI"},{"termName":"Isoendoxan","termGroup":"SY","termSource":"NCI"},{"termName":"Isophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Mitoxana","termGroup":"FB","termSource":"NCI"},{"termName":"MJF-9325","termGroup":"CN","termSource":"NCI"},{"termName":"N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"Naxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Seromida","termGroup":"FB","termSource":"NCI"},{"termName":"Tronoxal","termGroup":"FB","termSource":"NCI"},{"termName":"Z-4942","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; gastric carcinoma; lung cancer; lymphocytic leukemias; lymphoma; Hodgkins and Non-Hodgkins; ovarian cancer; pancreatic carcinoma; sarcomas; testicular cancer"},{"name":"CAS_Registry","value":"3778-73-2"},{"name":"CHEBI_ID","value":"CHEBI:5864"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O2P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"UM20QQM95Y"},{"name":"Legacy Concept Name","value":"Ifosfamide"},{"name":"Maps_To","value":"Ifosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"40024"},{"name":"NSC Number","value":"109724"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40024"},{"name":"PDQ_Open_Trial_Search_ID","value":"40024"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020823"}]}}{"C184764":{"preferredName":"IGF-1R Inhibition","code":"C184764","definitions":[{"definition":"Inhibition of insulin-like growth factor 1 receptor activity to prevent proliferation of cancer cells and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-1R Inhibition","termGroup":"PT","termSource":"NCI"},{"termName":"CD221 Inhibition","termGroup":"SY","termSource":"NCI"},{"termName":"IGF1R Inhibition","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin-Like Growth Factor 1 Receptor Inhibition","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IGF-1R Inhibitor"},{"name":"NCI_META_CUI","value":"CL1773085"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C104746":{"preferredName":"IGF-1R Inhibitor PL225B","code":"C104746","definitions":[{"definition":"An orally bioavailable inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor PL225B selectively binds to and inhibits the activities of IGF-1R, which may result in both the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis in IGF-1R-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a significant role in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-1R Inhibitor PL225B","termGroup":"PT","termSource":"NCI"},{"termName":"PL225B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IGF-1R Inhibitor PL225B"},{"name":"NCI_Drug_Dictionary_ID","value":"746194"},{"name":"NCI_META_CUI","value":"CL445817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746194"},{"name":"PDQ_Open_Trial_Search_ID","value":"746194"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84871":{"preferredName":"IGF-1R/IR Inhibitor KW-2450","code":"C84871","definitions":[{"definition":"An orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential antineoplastic activity. IGF-1R/IR inhibitor KW-2450 selectively binds to and inhibits the activities of IGF-1R and IR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-R1 and IR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-1R/IR Inhibitor KW-2450","termGroup":"PT","termSource":"NCI"},{"termName":"KW-2450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1360433-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2TRH1EX32K"},{"name":"Maps_To","value":"IGF-1R/IR Inhibitor KW-2450"},{"name":"NCI_Drug_Dictionary_ID","value":"648543"},{"name":"NCI_META_CUI","value":"CL412997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648543"},{"name":"PDQ_Open_Trial_Search_ID","value":"648543"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113789":{"preferredName":"IGF-methotrexate Conjugate","code":"C113789","definitions":[{"definition":"A conjugate containing the antimetabolite and antifolate agent methotrexate conjugated to insulin-like growth factor (IGF), with potential antineoplastic activity. After intravenous administration, the IGF moiety of the IGF-methotrexate conjugate binds to and is internalized by IGF receptors (IGFR) on the surface of tumor cells. Following cell entry, the methotrexate then binds to and inhibits the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. This results in both the inhibition of DNA and RNA synthesis and the induction of death in rapidly dividing cells. Binding to IGFR can localize the cytotoxic effect of methotrexate in tumor cells. This may increase its efficacy while decreasing its toxicity to normal, healthy cells. IGFR is overexpressed on many types of cancer cells and has been implicated in metastasis and resistance to apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-methotrexate Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"765IGF-MTX","termGroup":"AB","termSource":"NCI"},{"termName":"IGF/MTX","termGroup":"CN","termSource":"NCI"},{"termName":"IGF/MTX Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IGF-methotrexate Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"757276"},{"name":"NCI_META_CUI","value":"CL471770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757276"},{"name":"PDQ_Open_Trial_Search_ID","value":"757276"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126840":{"preferredName":"IL-10 Immunomodulator MK-1966","code":"C126840","definitions":[{"definition":"An agent that downregulates the activity of the anti-inflammatory cytokine human interleukin-10 (IL-10), with potential immunomodulating and antineoplastic activities. Upon administration, IL-10 immunomodulator MK-1966 blocks the activity of IL-10 and may abrogate the IL-10-induced immunosuppressive tumor microenvironment. This activates cell-mediated immunity against cancer cells, increases cytokine production, including interferon-gamma (IFN-g), decreases T regulatory cell (Treg) activity, and induces a tumor-specific cytotoxic CD8+ T-cell-mediated immune response, which enhances tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-10 Immunomodulator MK-1966","termGroup":"PT","termSource":"NCI"},{"termName":"MK 1966","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1966","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-10 Immunomodulator MK-1966"},{"name":"NCI_Drug_Dictionary_ID","value":"780778"},{"name":"NCI_META_CUI","value":"CL507902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780778"},{"name":"PDQ_Open_Trial_Search_ID","value":"780778"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114294":{"preferredName":"IL-12-expressing HSV-1 NSC 733972","code":"C114294","definitions":[{"definition":"A genetically engineered, replication selective, infected cell protein (ICP) 34.5 gene-deleted, oncolytic human simplex virus type 1 (HSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12), with potential antineoplastic activity. Upon intratumoral administration of HSV-1 expressing IL-12 NSC 733972, the IL-12-expressing HSV-1 preferentially infects and replicates in tumor cells of neuronal origin causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. In addition, the IL-12-expressing HSV-1 promotes the secretion of IL-12 by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-12-expressing HSV-1 NSC 733972","termGroup":"PT","termSource":"NCI"},{"termName":"M032","termGroup":"CN","termSource":"NCI"},{"termName":"NSC 733972","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-12-expressing HSV-1 NSC 733972"},{"name":"NCI_Drug_Dictionary_ID","value":"758218"},{"name":"NCI_META_CUI","value":"CL471805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758218"},{"name":"PDQ_Open_Trial_Search_ID","value":"758218"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C114385":{"preferredName":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051","code":"C114385","definitions":[{"definition":"Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051","termGroup":"PT","termSource":"NCI"},{"termName":"GX-051","termGroup":"CN","termSource":"NCI"},{"termName":"MSCs/IL-12M","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051"},{"name":"NCI_Drug_Dictionary_ID","value":"758797"},{"name":"NCI_META_CUI","value":"CL471821"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758797"},{"name":"PDQ_Open_Trial_Search_ID","value":"758797"},{"name":"Semantic_Type","value":"Cell"}]}}{"C71743":{"preferredName":"IL-2 Recombinant Fusion Protein ALT-801","code":"C71743","definitions":[{"definition":"A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor suppressor p53-derived antigen with potential immunopotentiating and antineoplastic activities. The TCR moiety of IL-2 recombinant fusion protein ALT-801 binds to tumor cells displaying p53 epitope/MHC complexes; subsequently, the tumor cell-localized IL-2 moiety may stimulate natural killer (NK) cell and T cell cytotoxic immune responses against p53-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-2 Recombinant Fusion Protein ALT-801","termGroup":"PT","termSource":"NCI"},{"termName":"ALT-801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188450-53-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QWZ40O5W6K"},{"name":"Legacy Concept Name","value":"IL-2_Recombinant_Fusion_Protein_ALT-801"},{"name":"Maps_To","value":"IL-2 Recombinant Fusion Protein ALT-801"},{"name":"NCI_Drug_Dictionary_ID","value":"560749"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560749"},{"name":"PDQ_Open_Trial_Search_ID","value":"560749"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346454"}]}}{"C146636":{"preferredName":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1","code":"C146636","definitions":[{"definition":"A pegylated peptide antagonist that binds to the common gamma chain (gc; IL2RG; CD132) of the signaling receptor for the pro-inflammatory cytokines interleukin (IL)-2, IL-9, and IL-15, with potential immunomodulating and antineoplastic activities. Upon administration, IL-2/9/15 gc receptor inhibitor BNZ-1 specifically targets and binds to the IL binding site on the gc receptor and blocks IL-2, IL-9 and IL-15 binding, thereby inhibiting IL-2-, IL-9-, and IL-15-mediated signaling and downstream pathways. This may inhibit proliferation of tumor cells that are dependent on IL-2/9/15 signaling for their growth. IL-2/9/15 are upregulated in certain tumor cell types and play a key role in tumor progression and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1","termGroup":"PT","termSource":"NCI"},{"termName":"BNZ-1","termGroup":"CN","termSource":"NCI"},{"termName":"BNZ132-1-40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1"},{"name":"NCI_Drug_Dictionary_ID","value":"792153"},{"name":"NCI_META_CUI","value":"CL544668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792153"},{"name":"PDQ_Open_Trial_Search_ID","value":"792153"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79843":{"preferredName":"Bizaxofusp","code":"C79843","definitions":[{"definition":"A fusion protein consisting of the cytokine interleukin-4 (IL-4) linked to a truncated form of Pseudomonas exotoxin with potential antineoplastic activity. Upon specific, high-affinity binding to IL-4 receptors located on the tumor cell surface., bizaxofusp is internalized; the exotoxin moiety then binds to translation elongation factor 2 (EF-2), which may result in ADP ribosylation, deactivation of EF-2, inhibition of protein synthesis, and tumor cell apoptosis. The Pseudomonas exotoxin moiety of this agent has been engineered to reduce non-specific binding to cells expressing its receptor, the multiligand cell surface receptor alpha 2-macroglobulin receptor/low-density lipoprotein receptor-related protein (alpha 2MR/LRP). IL-4R is a type I transmembrane protein that binds IL-4 and IL-13 and may be overexpressed by cancers such as renal cell carcinoma and glioma.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is made by combining interleukin-4 with a bacterial toxin. Interleukin-4 PE38KDEL immunotoxin is a type of recombinant chimeric protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bizaxofusp","termGroup":"PT","termSource":"NCI"},{"termName":"IL-4 Fusion Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"IL-4 PE38KDEL Immunotoxin","termGroup":"SN","termSource":"NCI"},{"termName":"IL4-PE","termGroup":"AB","termSource":"NCI"},{"termName":"IL4-Pseudomonas Exotoxin Fusion Protein MDNA55","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4 Fusion Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4 PE38kdel Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4 Pseudomonas Exotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"INxin","termGroup":"BR","termSource":"NCI"},{"termName":"MDNA55","termGroup":"CN","termSource":"NCI"},{"termName":"NBI-3001","termGroup":"CN","termSource":"NCI"},{"termName":"PRX-321","termGroup":"CN","termSource":"NCI"},{"termName":"PRX321","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1236019-35-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FRY3MOL2QU"},{"name":"Maps_To","value":"IL4-Pseudomonas Exotoxin Fusion Protein MDNA55"},{"name":"NCI_Drug_Dictionary_ID","value":"630680"},{"name":"NCI_META_CUI","value":"CL388450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"630680"},{"name":"PDQ_Open_Trial_Search_ID","value":"630680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99902":{"preferredName":"Ilixadencel","code":"C99902","definitions":[{"definition":"An off-the-shelf immune primer consisting of allogeneic monocyte-derived dendritic cells (MoDCs) that have been stimulated with a combination of activating factors to produce pro-inflammatory factors including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-12, p70 (IL-12 p70), C-C motif chemokine 4 (CCL4; macrophage inflammatory protein 1-beta; MIP-1-beta), C-C motif chemokine 5 (CCL5; RANTES), and C-X-C motif chemokine 10 (CXCL10), with potential immunostimulating and antineoplastic activities. Upon intratumoral injection of ilixadencel, the dendritic cells (DCs) release type 1 T-helper cell (Th1)-associated chemokines, including CCL4, CCL5 and CXCL10, that may recruit natural killer (NK)-cells and pre-DCs into the tumor microenvironment (TME). The interaction between NK cells and ilixadencel DCs may induce NK-cell-mediated killing of tumor cells, resulting in release of tumor-associated-antigens (TAAs). The production of interferon-gamma (IFN-gamma) by activated NK-cells and TNF-alpha/beta released by ilixadencel DCs will induce maturation and promote cross-presentation of TAAs by recruited endogenous \"bystander\" DCs. Migration of these antigen-loaded and matured \"bystander\" DCs to the tumor-draining lymph node will lead to a Th1-polarized activation of tumor-specific T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ilixadencel","termGroup":"PT","termSource":"NCI"},{"termName":"COMBIG-DC","termGroup":"SY","termSource":"NCI"},{"termName":"Intuvax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PY29292DVJ"},{"name":"Maps_To","value":"Ilixadencel"},{"name":"NCI_Drug_Dictionary_ID","value":"797415"},{"name":"NCI_META_CUI","value":"CL433603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797415"},{"name":"PDQ_Open_Trial_Search_ID","value":"797415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48397":{"preferredName":"Iloprost","code":"C48397","definitions":[{"definition":"A prostacyclin analogue with potential chemopreventive activity. Iloprost binds to the prostacyclin receptor in various target cells, thereby causing vasodilation, inhibition of platelet aggregation, and decreased tumor cell adhesion to endothelium among other effects. Prostacyclin is a naturally occurring eicosanoid with anti-inflammatory, antineoplastic, and anti-metastatic properties. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of lung cancer. It belongs to the family of drugs called prostaglandin analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iloprost","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Ciloprost","termGroup":"SY","termSource":"NCI"},{"termName":"Iloprost Clathrate","termGroup":"SY","termSource":"NCI"},{"termName":"Pentanoic Acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ventavis","termGroup":"SY","termSource":"NCI"},{"termName":"ZK 36374","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"78919-13-8"},{"name":"CHEBI_ID","value":"CHEBI:63916"},{"name":"Chemical_Formula","value":"C22H32O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JED5K35YGL"},{"name":"Legacy Concept Name","value":"Iloprost"},{"name":"Maps_To","value":"Iloprost"},{"name":"NCI_Drug_Dictionary_ID","value":"365679"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365679"},{"name":"PDQ_Open_Trial_Search_ID","value":"365679"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079594"}]}}{"C116729":{"preferredName":"Ilorasertib","code":"C116729","definitions":[{"definition":"An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ilorasertib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(4-(4-Amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"A-968660.0","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-348","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227939-82-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6L5D03D975"},{"name":"Maps_To","value":"Ilorasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"672556"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672556"},{"name":"PDQ_Open_Trial_Search_ID","value":"672556"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660880"}]}}{"C104260":{"preferredName":"Imalumab","code":"C104260","definitions":[{"definition":"A human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, imalumab binds to MIF, blocking its activity and preventing the MIF-mediated secretion of certain cytokines, including interleukin-1 beta and tumor necrosis factor-alpha. This may lead to an inhibition of cancer cell proliferation in MIF-overexpressing tumor cells. MIF, a pro-inflammatory cytokine overexpressed in some cancers, plays a key role in inflammation, immune responses and cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imalumab","termGroup":"PT","termSource":"NCI"},{"termName":"BAX-69","termGroup":"CN","termSource":"NCI"},{"termName":"BAX069","termGroup":"CN","termSource":"NCI"},{"termName":"BAX69","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1-kappa, Anti-(Homo sapiens MIF (Macrophage Migration Inhibitory Factor, Glycosylation-inhibiting Factor, GlIF, GIF)), Homo sapiens Monoclonal Antibody","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1430205-07-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22F97PC79G"},{"name":"Maps_To","value":"Imalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"740468"},{"name":"NCI_META_CUI","value":"CL446652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740468"},{"name":"PDQ_Open_Trial_Search_ID","value":"740468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62035":{"preferredName":"Imatinib","code":"C62035","definitions":[{"definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152459-95-5"},{"name":"CHEBI_ID","value":"CHEBI:45783"},{"name":"Chemical_Formula","value":"C29H31N7O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"BKJ8M8G5HI"},{"name":"Legacy Concept Name","value":"Imatinib_Base"},{"name":"Maps_To","value":"Imatinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935989"}]}}{"C1687":{"preferredName":"Imatinib Mesylate","code":"C1687","definitions":[{"definition":"A drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Imatinib mesylate blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"CGP 57148","termGroup":"CN","termSource":"NCI"},{"termName":"CGP57148B","termGroup":"CN","termSource":"NCI"},{"termName":"Gleevec","termGroup":"BR","termSource":"NCI"},{"termName":"Glivec","termGroup":"FB","termSource":"NCI"},{"termName":"STI-571","termGroup":"CN","termSource":"NCI"},{"termName":"STI571","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia, gastrointestinal stromal tumor, hypereosinophillic syndrome, dermatofibrosarcoma protuberans, mutated-PDGFR myelodysplastic/myeloproliferative diseases."},{"name":"CAS_Registry","value":"220127-57-1"},{"name":"CHEBI_ID","value":"CHEBI:31690"},{"name":"Chemical_Formula","value":"C29H31N7O.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8A1O1M485B"},{"name":"Legacy Concept Name","value":"Imatinib"},{"name":"Maps_To","value":"Imatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"37862"},{"name":"NSC Number","value":"716051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37862"},{"name":"PDQ_Open_Trial_Search_ID","value":"37862"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0939537"}]}}{"C49084":{"preferredName":"Imetelstat","code":"C49084","definitions":[{"definition":"A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imetelstat","termGroup":"PT","termSource":"NCI"},{"termName":"DNA, d(3'-amino-3'-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3- [(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate]","termGroup":"SN","termSource":"NCI"},{"termName":"GRN 163L","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"868169-64-6"},{"name":"Chemical_Formula","value":"C148H211N68O53P13S13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F60NE4XB53"},{"name":"Legacy Concept Name","value":"GRN163L"},{"name":"Maps_To","value":"Imetelstat"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2746063"}]}}{"C84511":{"preferredName":"Imetelstat Sodium","code":"C84511","definitions":[{"definition":"The sodium salt of imetelstat, a synthetic lipid-conjugated, 13-mer oligonucleotide N3' P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase RNA (hTR), imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a \"telomerase template antagonist\"), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imetelstat Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"DNA, d(3'-amino-3'-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3- [(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate], Sodium Salt (1:13)","termGroup":"SN","termSource":"NCI"},{"termName":"GRN163L","termGroup":"CN","termSource":"NCI"},{"termName":"GRN163L, Sodium Salt","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1007380-31-5"},{"name":"Chemical_Formula","value":"C148H198N68O53P13S13.13Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2AW48LAZ4I"},{"name":"Maps_To","value":"Imetelstat Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"447136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"447136"},{"name":"PDQ_Open_Trial_Search_ID","value":"447136"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708156"}]}}{"C29115":{"preferredName":"Imexon","code":"C29115","definitions":[{"definition":"A 2-cyanoaziridine derivative with antitumor activity in multiple myeloma.  Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8.  Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It belongs to the family of drugs called cyanoaziridine derivatives.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Imexon","termGroup":"PT","termSource":"NCI"},{"termName":"4-imino-1,3-diazabicyclo[3,1,0]-hexan-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"Amplimexon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59643-91-3"},{"name":"Chemical_Formula","value":"C4H5N3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8F63U28T2V"},{"name":"Legacy Concept Name","value":"Imexon"},{"name":"Maps_To","value":"Imexon"},{"name":"NCI_Drug_Dictionary_ID","value":"468469"},{"name":"NSC Number","value":"714597"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468469"},{"name":"PDQ_Open_Trial_Search_ID","value":"468469"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0097147"}]}}{"C2216":{"preferredName":"Imidazole Mustard","code":"C2216","definitions":[{"definition":"A synthetic derivative of imidazole with potent antineoplastic properties.  Imidazole mustard alkylates DNA, preferentially at guanine residues, resulting in DNA interstrand crosslinks and inhibition of DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imidazole Mustard","termGroup":"PT","termSource":"NCI"},{"termName":"5-[3,3-Bis(2-Chloroethyl)-1-Triazeno]Imidazole-4-Carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BIC","termGroup":"AB","termSource":"NCI"},{"termName":"TIC Mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5034-77-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OY338X4M2P"},{"name":"Legacy Concept Name","value":"Imidazole_Mustard"},{"name":"Maps_To","value":"Imidazole Mustard"},{"name":"NCI_Drug_Dictionary_ID","value":"39483"},{"name":"NSC Number","value":"82196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39483"},{"name":"PDQ_Open_Trial_Search_ID","value":"39483"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063382"}]}}{"C29344":{"preferredName":"Imidazole-Pyrazole","code":"C29344","definitions":[{"definition":"A synthetic agent, also known as IMPY, with antineoplastic properties.  IMPY inhibits ribonucleotide reductase, an enzyme that converts ribonucleotides to deoxyribonucleotides during DNA synthesis; this agent specifically binds the smaller, nonheme-iron subunit of the enzyme. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imidazole-Pyrazole","termGroup":"PT","termSource":"NCI"},{"termName":"2,3-Dihydro-1H-imidazo(1,2-b)pyrazole","termGroup":"SN","termSource":"NCI"},{"termName":"BRN 0742753","termGroup":"CN","termSource":"NCI"},{"termName":"Imidazolepyrazole","termGroup":"SY","termSource":"NCI"},{"termName":"IMPY","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6714-29-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Inhibits the nonheme-iron subunit of ribonucleotide reductase"},{"name":"FDA_UNII_Code","value":"MX6Z942BKY"},{"name":"Legacy Concept Name","value":"Pyrazole_Imidazole"},{"name":"Maps_To","value":"Imidazole-Pyrazole"},{"name":"NSC Number","value":"51143"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045368"}]}}{"C126638":{"preferredName":"Imipramine Blue","code":"C126638","definitions":[{"definition":"A triphenylmethane-based dye and an inhibitor of nicotinamide adenine dinucleotide phosphate (NADP+) oxidase 4 (NOX4), with potential anti-invasive and anti-oxidative activities. Upon administration, imipramine blue (IB) inhibits the activity of NOX4 and prevents NOX4-mediated cell signaling. This prevents the formation of NOX4-mediated reactive oxygen species (ROS), abrogates the ROS-induced inhibition of protein tyrosine phosphatase (PTP) activation, and induces both G2/M cell cycle arrest and apoptosis. NOX4, an enzyme belonging to the NOX family of proteins, promotes the production of ROS and plays a key role in the suppression of PTP activation; it is upregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imipramine Blue","termGroup":"PT","termSource":"NCI"},{"termName":"IB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Imipramine Blue"},{"name":"NCI_META_CUI","value":"CL505071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1431":{"preferredName":"Imiquimod","code":"C1431","definitions":[{"definition":"A drug used to treat early basal cell skin cancer and certain other skin conditions. It is being studied in the treatment of other types of cancer. Imiquimod is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imiquimod","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline","termGroup":"SN","termSource":"NCI"},{"termName":"Aldara","termGroup":"BR","termSource":"NCI"},{"termName":"R 837","termGroup":"CN","termSource":"NCI"},{"termName":"S 26308","termGroup":"CN","termSource":"NCI"},{"termName":"Zyclara","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Condyloma; Superficial Basal Cell Carcinoma; Actinic Keratosis"},{"name":"CAS_Registry","value":"99011-02-6"},{"name":"CHEBI_ID","value":"CHEBI:36704"},{"name":"Chemical_Formula","value":"C14H16N4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P1QW714R7M"},{"name":"Legacy Concept Name","value":"Imiquimod"},{"name":"Maps_To","value":"Imiquimod"},{"name":"NCI_Drug_Dictionary_ID","value":"38558"},{"name":"NSC Number","value":"369100"},{"name":"NSC Number","value":"741062"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38558"},{"name":"PDQ_Open_Trial_Search_ID","value":"38558"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0718327"}]}}{"C113795":{"preferredName":"Immediate-release Onapristone","code":"C113795","definitions":[{"definition":"An immediate-release (IR) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immediate-release Onapristone","termGroup":"PT","termSource":"NCI"},{"termName":"IR Onapristone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immediate-release Onapristone"},{"name":"NCI_Drug_Dictionary_ID","value":"757590"},{"name":"NCI_META_CUI","value":"CL471777"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757590"},{"name":"PDQ_Open_Trial_Search_ID","value":"757590"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113658":{"preferredName":"Immediate-release Tablet Afuresertib","code":"C113658","definitions":[{"definition":"An immediate-release (IR) tablet formulation containing afuresertib, an inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Upon oral administration of the IR formulation, afuresertib binds to and inhibits the activity of Akt, which may result in the inhibition of PI3K/Akt signaling pathway, decreased tumor cell proliferation and the induction of tumor cell apoptosis in Akt-expressing tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immediate-release Tablet Afuresertib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2110183 IR Tablet","termGroup":"SY","termSource":"NCI"},{"termName":"IR Afuresertib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immediate-release Tablet Afuresertib"},{"name":"NCI_Drug_Dictionary_ID","value":"757069"},{"name":"NCI_META_CUI","value":"CL458371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757069"},{"name":"PDQ_Open_Trial_Search_ID","value":"757069"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141421":{"preferredName":"Anti-TIGIT Monoclonal Antibody ASP8374","code":"C141421","definitions":[{"definition":"A fully human, immunoglobulin G4 (IgG4) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody ASP8374 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIGIT Monoclonal Antibody ASP8374","termGroup":"PT","termSource":"NCI"},{"termName":"ASP 8374","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-8374","termGroup":"CN","termSource":"NCI"},{"termName":"ASP8374","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TB50XV90MW"},{"name":"Maps_To","value":"Immune Checkpoint Inhibitor ASP8374"},{"name":"NCI_Drug_Dictionary_ID","value":"791403"},{"name":"NCI_META_CUI","value":"CL539507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791403"},{"name":"PDQ_Open_Trial_Search_ID","value":"791403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104058":{"preferredName":"Lumretuzumab","code":"C104058","definitions":[{"definition":"An immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3), with potential antineoplastic activity. Upon administration,  lumretuzumab binds to the extracellular domain of HER3 and inhibits HER3 dimerization; thereby, preventing EGFR-dependent signaling. In addition, RO5479599 stimulates the immune system to exert antibody-dependent cellular cytotoxicity (ADCC). This may decrease proliferation of HER3-overexpressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lumretuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"RO5479599","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448327-63-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y6M3205516"},{"name":"Maps_To","value":"Immunoconjugate RO5479599"},{"name":"Maps_To","value":"Lumretuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"744816"},{"name":"NCI_META_CUI","value":"CL433954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744816"},{"name":"PDQ_Open_Trial_Search_ID","value":"744816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97961":{"preferredName":"Immunocytokine NHS-IL12","code":"C97961","definitions":[{"definition":"A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunocytokine NHS-IL12","termGroup":"PT","termSource":"NCI"},{"termName":"M-9241","termGroup":"CN","termSource":"NCI"},{"termName":"M9241","termGroup":"CN","termSource":"NCI"},{"termName":"NHS-IL-12","termGroup":"CN","termSource":"NCI"},{"termName":"NHS-IL12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1807503-77-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KF6D9Z1MER"},{"name":"Maps_To","value":"Immunocytokine NHS-IL12"},{"name":"NCI_Drug_Dictionary_ID","value":"710539"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710539"},{"name":"PDQ_Open_Trial_Search_ID","value":"710539"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273725"}]}}{"C82411":{"preferredName":"Immunocytokine NHS-IL2-LT","code":"C82411","definitions":[{"definition":"A fusion protein consisting of a mouse-human chimeric antibody directed against DNA released by necrotic tumor cells fused to two molecules of a genetically modified human interleukin-2 (IL-2) with potential antineoplastic activity. Upon administration, the antibody moiety of immunocytokine NHS-IL2-LT binds to DNA released by necrotic tumor cells located primarily at the core of necrotic solid tumors, delivering the IL-2 moiety. In turn, the IL-2 moiety of this agent activates the immune system to mount a cytotoxic T lymphocyte response against nearby tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunocytokine NHS-IL2-LT","termGroup":"PT","termSource":"NCI"},{"termName":"Ch.14.18-IL2","termGroup":"AB","termSource":"NCI"},{"termName":"EMD 521873","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-2 Fusion Protein MSB0010445","termGroup":"SY","termSource":"NCI"},{"termName":"MSB0010445","termGroup":"CN","termSource":"NCI"},{"termName":"NHS-IL2","termGroup":"CN","termSource":"NCI"},{"termName":"Selectikine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1223034-72-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EI74F49ZLJ"},{"name":"Legacy Concept Name","value":"Selectikine"},{"name":"Maps_To","value":"Immunocytokine NHS-IL2-LT"},{"name":"NCI_Drug_Dictionary_ID","value":"641919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641919"},{"name":"PDQ_Open_Trial_Search_ID","value":"641919"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830085"}]}}{"C152979":{"preferredName":"Hsp90 Inhibitor LAM-003","code":"C152979","definitions":[{"definition":"An L-alanine ester prodrug of LAM-003A, an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, LAM-003 is converted to LAM-003A. LAM-003A selectively targets and binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may inhibit the growth and survival of a wide variety of cancer cell types. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability, and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor LAM-003","termGroup":"PT","termSource":"NCI"},{"termName":"LAM 003","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-003","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-003A Prodrug LAM-003","termGroup":"SY","termSource":"NCI"},{"termName":"LAM003","termGroup":"CN","termSource":"NCI"},{"termName":"Prodrug LAM-003","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunomodulator LAM-003"},{"name":"NCI_Drug_Dictionary_ID","value":"793859"},{"name":"NCI_META_CUI","value":"CL554182"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793859"},{"name":"PDQ_Open_Trial_Search_ID","value":"793859"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49092":{"preferredName":"Immunomodulator OHR/AVR118","code":"C49092","definitions":[{"definition":"A broad-spectrum peptide nucleic acid formulation comprised of breakdown products of casein, peptone, RNA and serum albumin, with potential anti-inflammatory, immunomodulatory, anti-anorectic and anti-cachexia activities. AVR118 mainly contains two peptides, peptide A and peptide B, in approximately a 1:1 ratio: peptide A (31 a. a.) is derived from bovine casein; peptide B (21 a. a.) is covalently linked via phosphodiester bond to a diadenosine unit. In addition, AVR118 contains nucleosides, nucleoside diphosphates and nucleoside monophosphates. Upon subcutaneous injection of AVR118, this agent affects the synthesis of many pro-inflammatory chemokines and cytokines, especially monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-8, IL-1 beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha). In particular, AVR118 stimulates macrophages to produce these mediators while in highly activated macrophages this agent inhibits their synthesis. This way, AVR118 may prevent the excessive release of cytokines seen during chemotherapy. Controlling the release of pro-inflammatory mediators may ultimately improve appetite and mood, increase strength and weight gain, and decrease fatigue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunomodulator OHR/AVR118","termGroup":"PT","termSource":"NCI"},{"termName":"AVR118","termGroup":"CN","termSource":"NCI"},{"termName":"Product R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AVR118"},{"name":"Maps_To","value":"Immunomodulator OHR/AVR118"},{"name":"NCI_Drug_Dictionary_ID","value":"453546"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453546"},{"name":"PDQ_Open_Trial_Search_ID","value":"453546"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1172837"}]}}{"C101370":{"preferredName":"Immunomodulatory Agent CC-11006","code":"C101370","definitions":[{"definition":"A proprietary, orally available, small molecule and thalidomide analog, with potential immunomodulating and antineoplastic activity. CC-11006 appears to have a similar mechanism to thalidomide and may modulate the expression of proinflammatory and regulatory cytokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunomodulatory Agent CC-11006","termGroup":"PT","termSource":"NCI"},{"termName":"CC-11006","termGroup":"CN","termSource":"NCI"},{"termName":"CC-11006-MDS-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444287-44-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6DC9826KIM"},{"name":"Maps_To","value":"Immunomodulatory Agent CC-11006"},{"name":"NCI_Drug_Dictionary_ID","value":"730575"},{"name":"NCI_META_CUI","value":"CL435550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730575"},{"name":"PDQ_Open_Trial_Search_ID","value":"730575"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49182":{"preferredName":"Immunomodulatory Oligonucleotide HYB2055","code":"C49182","definitions":[{"definition":"A second generation synthetic oligonucleotide with immunomodulatory and potential antineoplastic activities. HYB2055 consists of unmethylated CpG dinucleotide motifs that are present abundantly in bacterial and parasitic DNA, and a novel DNA structure, called an immunomer that contributes to metabolic stability of the agent. Upon infections, CpG-containing DNA released from pathogenic organisms triggers host immune responses, which are mediated by the action of intracellular toll-like receptor 9 (TLR9), a pattern recognition receptor. This agent mimics bacterial DNA and selectively activates TLR9, thereby initiating immune signaling pathways, and leading to activation of B-cells and dendritic cells and induction of Th1-type cytokine production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunomodulatory Oligonucleotide HYB2055","termGroup":"PT","termSource":"NCI"},{"termName":"Amplivax","termGroup":"BR","termSource":"NCI"},{"termName":"IMO-2055","termGroup":"SY","termSource":"NCI"},{"termName":"Imoxine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HYB2055"},{"name":"Maps_To","value":"Immunomodulatory Oligonucleotide HYB2055"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708303"}]}}{"C122922":{"preferredName":"Immunotherapeutic Combination Product CMB305","code":"C122922","definitions":[{"definition":"An immunotherapeutic combination product composed of LV305, an engineered lentiviral vector that both targets dendritic cells (DCs) and contains nucleic acids encoding the human tumor-associated cancer-testis antigen NY-ESO-1 (CTAG1), and G305, a cancer vaccine comprised of an NY-ESO-1 recombinant protein and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential synergistic immunostimulatory and antineoplastic activities. Upon intradermal administration of LV305, the DC-targeting lentiviral vector targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, which stimulates DC maturation, and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells; this may result in tumor cell lysis. Upon the sequential intramuscular injection of G305, the adjuvant portion of G305 binds to toll-like receptor 4 (TLR-4) expressed on various immune cells, including DCs, monocytes, macrophages and B-cells. The activated DCs present the NY-ESO-1 antigen to CD4-positive Th1 T-lymphocytes. The induction of antigen-specific CD4-positive T-lymphocytes further induces a CTL response against NY-ESO-1-expressing tumor cells. In addition, G305 induces an NY-ESO-1-specific antibody response. NY-ESO-1, expressed in normal testes and on the surfaces of various tumor cells, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunotherapeutic Combination Product CMB305","termGroup":"PT","termSource":"NCI"},{"termName":"CMB 305","termGroup":"CN","termSource":"NCI"},{"termName":"CMB305","termGroup":"CN","termSource":"NCI"},{"termName":"ID-CMB305","termGroup":"CN","termSource":"NCI"},{"termName":"ID-LV305 Plus ID G305","termGroup":"SY","termSource":"NCI"},{"termName":"LV 305 Plus G 305","termGroup":"SY","termSource":"NCI"},{"termName":"LV305 Plus G305","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunotherapeutic Combination Product CMB305"},{"name":"NCI_Drug_Dictionary_ID","value":"777295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777295"},{"name":"PDQ_Open_Trial_Search_ID","value":"777295"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053576"}]}}{"C77971":{"preferredName":"Immunotherapy Regimen MKC-1106-MT","code":"C77971","definitions":[{"definition":"A regimen containing three components: a plasmid encoding portions of the two melanoma-associated antigens Melan A (also called MART-1) and tyrosinase and two synthetic analogs of Melan-A and tyrosinase antigen epitopes with potential immunostimulating and antitumor activities. First, the plasmid is injected directly into lymph nodes in order to sensitize or prime antigen-presenting cells (APCs) and central memory T cells in lymph nodes to plasmid-expressed Melan A and tyrosinase.  After several priming injections with plasmids, the Melan A and tyrosinase synthetic epitope analogs are injected directly into lymph nodes; upon binding to major histocompatibility complex (MHC) molecules on APC cell surfaces, these synthetic epitope analogs may stimulate a \"primed\" cytotoxic T lymphocyte (CTL) response against melanoma tumor cells, resulting in tumor cell lysis. Melan-A and tyrosinase are overexpressed by melanoma tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"An immunotherapy regimen containing three components: a plasmid encoding portions of the two melanoma-associated antigens Melan A (also called MART-1) and tyrosinase and two synthetic analogs of Melan-A and tyrosinase antigen epitopes with potential immunostimulating and antitumor activities. First, the plasmid is injected directly into lymph nodes in order to sensitize or prime antigen-presenting cells (APCs) and central memory T cells in lymph nodes to plasmid-expressed Melan A and tyrosinase.  After several priming injections with plasmids, the Melan A and tyrosinase synthetic epitope analogs are injected directly into lymph nodes; upon binding to major histocompatibility complex (MHC) molecules on APC cell surfaces, these synthetic epitope analogs may stimulate a \"primed\" cytotoxic T lymphocyte (CTL) response against melanoma tumor cells, resulting in tumor cell lysis. Melan-A and tyrosinase are overexpressed by melanoma tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunotherapy Regimen MKC-1106-MT","termGroup":"PT","termSource":"NCI"},{"termName":"MKC-1106-MT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MKC-1106-MT"},{"name":"Maps_To","value":"Immunotherapy Regimen MKC-1106-MT"},{"name":"NCI_Drug_Dictionary_ID","value":"598417"},{"name":"NCI_META_CUI","value":"CL386958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598417"},{"name":"PDQ_Open_Trial_Search_ID","value":"598417"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62480":{"preferredName":"Immunotoxin CMD-193","code":"C62480","definitions":[{"definition":"A humanized immunotoxin directed against the Lewis Y antigen conjugated with calicheamicin, a hydrophobic enediyne antibiotic, with potential antineoplastic activity. CMD193 binds to the Lewis Y antigen, a tetrasaccharide expressed on the cell surfaces of many tumor cell types. Upon binding, CMD-193 is internalized, thereby delivering the attached calicheamicin to Lewis Y antigen-expressing tumor cells. Calicheamicin binds non-covalently to the minor groove of DNA and prompts conformational changes and DNA oxidation, thereby inhibiting DNA synthesis and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunotoxin CMD-193","termGroup":"PT","termSource":"NCI"},{"termName":"CMD 193","termGroup":"CN","termSource":"NCI"},{"termName":"CMD-193","termGroup":"CN","termSource":"NCI"},{"termName":"CMD193","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1080645-97-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CMD-193"},{"name":"Maps_To","value":"Immunotoxin CMD-193"},{"name":"NCI_Drug_Dictionary_ID","value":"489295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489295"},{"name":"PDQ_Open_Trial_Search_ID","value":"489295"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879965"}]}}{"C77863":{"preferredName":"IMT-1012 Immunotherapeutic Vaccine","code":"C77863","definitions":[{"definition":"A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IMT-1012 Immunotherapeutic Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"IMT-1012","termGroup":"CN","termSource":"NCI"},{"termName":"OCPM Immunotherapeutic Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"IMT-1012_Immunotherapeutic_Vaccine"},{"name":"Maps_To","value":"IMT-1012 Immunotherapeutic Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"596541"},{"name":"NCI_META_CUI","value":"CL383604"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596541"},{"name":"PDQ_Open_Trial_Search_ID","value":"596541"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C29317":{"preferredName":"Inalimarev","code":"C29317","definitions":[{"definition":"A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A cancer vaccine made with a form of vaccinia virus that does not cause disease in humans. It is being studied in the treatment of some types of cancer. The virus is changed in the laboratory to make human proteins, including the tumor markers called CEA and MUC-1, that may help immune cells in the body kill tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Inalimarev","termGroup":"PT","termSource":"NCI"},{"termName":"PANVAC-V","termGroup":"BR","termSource":"NCI"},{"termName":"rVaccinia-CEA(D609)/MUC1(L93)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Vaccinia-CEA-MUC1-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685563-13-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"rVaccinia-CEA_D609_MUC1_L93_TRICOM"},{"name":"Maps_To","value":"Inalimarev"},{"name":"NCI_Drug_Dictionary_ID","value":"385666"},{"name":"NSC Number","value":"727026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385666"},{"name":"PDQ_Open_Trial_Search_ID","value":"385666"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1541349"}]}}{"C2454":{"preferredName":"Incyclinide","code":"C2454","definitions":[{"definition":"A chemically-modified tetracycline with potential antineoplastic activity. Incyclinide inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent also causes mitochondrial depolarization in tumor cells and induces both cellular apoptosis and tissue necrosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. COL-3 may block the growth of new blood vessels that tumors need to grow. It is a type of matrix metalloproteinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Incyclinide","termGroup":"PT","termSource":"NCI"},{"termName":"4-dedimethylamino sancycline","termGroup":"SN","termSource":"NCI"},{"termName":"4-Dimethlyamino Sancycline","termGroup":"SN","termSource":"NCI"},{"termName":"4-Dimethlyaminosancycline","termGroup":"SN","termSource":"NCI"},{"termName":"6-deoxy, 6-demethyl, 4-de-dimethylamino tetracycline","termGroup":"SN","termSource":"NCI"},{"termName":"6-deoxy-6-demethyl-4-dedimethylaminotetracycline","termGroup":"SN","termSource":"NCI"},{"termName":"CMT-3","termGroup":"CN","termSource":"NCI"},{"termName":"COL 3","termGroup":"CN","termSource":"NCI"},{"termName":"COL-3","termGroup":"CN","termSource":"NCI"},{"termName":"Metastat","termGroup":"BR","termSource":"NCI"},{"termName":"Tetracycline CMT-3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15866-90-7"},{"name":"Chemical_Formula","value":"C19H17NO7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"21G64WZQ4I"},{"name":"Legacy Concept Name","value":"COL-3"},{"name":"Maps_To","value":"Incyclinide"},{"name":"NCI_Drug_Dictionary_ID","value":"42884"},{"name":"NSC Number","value":"683551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42884"},{"name":"PDQ_Open_Trial_Search_ID","value":"42884"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0763138"}]}}{"C2049":{"preferredName":"Indibulin","code":"C2049","definitions":[{"definition":"A synthetic small molecule with antimitotic and potential antineoplastic activities. Indibulin binds to a site on tubulin that is different from taxane- or Vinca alkaloid-binding sites, destabilizing tubulin polymerization and inducing tumor cell cycle arrest and apoptosis. This agent has been shown to be active against multidrug-resistant (MDR) and taxane- resistant tumor cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indibulin","termGroup":"PT","termSource":"NCI"},{"termName":"D 24851","termGroup":"CN","termSource":"NCI"},{"termName":"D-24851","termGroup":"CN","termSource":"NCI"},{"termName":"N-(Pyridin-4-yl)-(1-(4-chlorobenzyl)indol-3-yl)glycoxylamide","termGroup":"SN","termSource":"NCI"},{"termName":"ZIO-301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"204205-90-3"},{"name":"Chemical_Formula","value":"C22H16ClN3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"80K4H2RB8P"},{"name":"Legacy Concept Name","value":"D_24851"},{"name":"Maps_To","value":"Indibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"587341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587341"},{"name":"PDQ_Open_Trial_Search_ID","value":"587341"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1956330"}]}}{"C1134":{"preferredName":"Indicine-N-Oxide","code":"C1134","definitions":[{"definition":"A natural pyrrolizidine alkaloid with antineoplastic properties.  Indicine-N-oxide alkylates and crosslinks DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indicine-N-Oxide","termGroup":"PT","termSource":"NCI"},{"termName":"2,3-Dihydroxy-2-(1-methylethyl)butanoic Acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl Ester N-Oxide","termGroup":"SN","termSource":"NCI"},{"termName":"Butanoic Acid, 2,3-Dihydroxy-2-(1-methylethyl)- (2,3,5, 7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) Methyl Ester, N-Oxide,(1R-(1alpha,7(2R*,3S*),7a-beta))-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Indicine N-Oxide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41708-76-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69L6IW0Y7P"},{"name":"Legacy Concept Name","value":"Indicine-N-Oxide"},{"name":"Maps_To","value":"Indicine-N-Oxide"},{"name":"NCI_Drug_Dictionary_ID","value":"39482"},{"name":"NSC Number","value":"132319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39482"},{"name":"PDQ_Open_Trial_Search_ID","value":"39482"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063465"}]}}{"C25797":{"preferredName":"Indisulam","code":"C25797","definitions":[{"definition":"A drug that belongs to the family of drugs called sulfonamides.  It is being studied for its ability to treat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A novel sulfonamide compound with potential antineoplastic activity. Indisulam inhibits cyclin-dependent kinases (CDK), which regulate cell cycle progression and are usually over-expressed in cancerous cells. Inhibition of CDK results in G1/S phase arrest of the cell cycle, and may lead to induction of apoptosis and inhibition of tumor cell proliferation. In addition, indisulam also inhibits carbonic anhydrases (CA), especially isoforms IX and XII that are involved in aqueous humor production and are highly overexpressed in some types of cancers. Inhibition of CA IX and XII results in interference with ion exchange and pH in hypoxic tumor tissue and preventing chemoresistance to weakly basic antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indisulam","termGroup":"PT","termSource":"NCI"},{"termName":"E7070","termGroup":"CN","termSource":"NCI"},{"termName":"N-(3-Chloro-7-indoyl)-1,4-Benzenedisulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"165668-41-7"},{"name":"Chemical_Formula","value":"C14H12ClN3O4S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WJ98J3NM90"},{"name":"Legacy Concept Name","value":"E7070"},{"name":"Maps_To","value":"Indisulam"},{"name":"NCI_Drug_Dictionary_ID","value":"43559"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43559"},{"name":"PDQ_Open_Trial_Search_ID","value":"43559"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099211"}]}}{"C158750":{"preferredName":"Pegsitacianine","code":"C158750","definitions":[{"definition":"A micellar polymer tracer labeled with the near-infrared (NIR) fluorescent imaging dye indocyanine green (ICG), with potential fluorescent imaging activity. Upon administration, pegsitacianine accumulates in tumor tissue. The micelles dissociate and subsequently fluoresce upon exposure to the acidic conditions of the tumor microenvironment (TME), allowing the visualization of tumors using infrared-based cameras.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegsitacianine","termGroup":"PT","termSource":"NCI"},{"termName":"Indocyanine Green-labeled Polymeric Micelles ONM-100","termGroup":"SY","termSource":"NCI"},{"termName":"ONM 100","termGroup":"CN","termSource":"NCI"},{"termName":"ONM-100","termGroup":"CN","termSource":"NCI"},{"termName":"ONM100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2396651-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49X2Q41T99"},{"name":"Maps_To","value":"Indocyanine Green-labeled Polymeric Micelles ONM-100"},{"name":"NCI_Drug_Dictionary_ID","value":"797414"},{"name":"NCI_META_CUI","value":"CL950716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797414"},{"name":"PDQ_Open_Trial_Search_ID","value":"797414"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"}]}}{"C1135":{"preferredName":"Indole-3-Carbinol","code":"C1135","definitions":[{"definition":"A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a cancer prevention drug.  It is found in cruciferous vegetables.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indole with a carbinol group (-C2OH) attached at the 3 position of the pyrrole ring. The chemical structure is C1=CC=C2C(=C1)C(=CN2)CO.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Indole-3-Carbinol","termGroup":"PT","termSource":"NCI"},{"termName":"1H-indole-3-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"I3C","termGroup":"AB","termSource":"NCI"},{"termName":"Indole-3-carbinol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"700-06-1"},{"name":"CHEBI_ID","value":"CHEBI:24814"},{"name":"Chemical_Formula","value":"C9H9NO"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C11E72455F"},{"name":"Legacy Concept Name","value":"Indole-3-Carbinol"},{"name":"Maps_To","value":"Indole-3-Carbinol"},{"name":"NCI_Drug_Dictionary_ID","value":"38058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38058"},{"name":"PDQ_Open_Trial_Search_ID","value":"38058"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063491"}]}}{"C576":{"preferredName":"Indomethacin","code":"C576","definitions":[{"definition":"A drug that reduces pain, fever, swelling, and redness. It is also being used to reduce tumor-induced suppression of the immune system and to increase the effectiveness of anticancer drugs. It is a type of nonsteroidal anti-inflammatory drug (NSAID).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indomethacin","termGroup":"PT","termSource":"NCI"},{"termName":"1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1-H-indole-3-acetic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Indocin","termGroup":"BR","termSource":"NCI"},{"termName":"Indometacin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dysmennorhea; Inflammatory disorders; Pain"},{"name":"CAS_Registry","value":"53-86-1"},{"name":"CHEBI_ID","value":"CHEBI:49662"},{"name":"Chemical_Formula","value":"C19H16ClNO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"XXE1CET956"},{"name":"Legacy Concept Name","value":"Indomethacin"},{"name":"Maps_To","value":"Indomethacin"},{"name":"NCI_Drug_Dictionary_ID","value":"39489"},{"name":"NSC Number","value":"77541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39489"},{"name":"PDQ_Open_Trial_Search_ID","value":"39489"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021246"}]}}{"C71535":{"preferredName":"Indoximod","code":"C71535","definitions":[{"definition":"A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of melanoma and many other types of cancer. 1-methyl-d-tryptophan blocks the breakdown of the amino acid tryptophan, which is needed for T cells (a type of immune system cell) to kill tumor cells. Giving 1-methyl-d-tryptophan to patients who have received chemotherapy for cancer may help kill more tumor cells. It is a type of enzyme inhibitor and immunosuppressant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Indoximod","termGroup":"PT","termSource":"NCI"},{"termName":"1-Methyl-D-tryptophan","termGroup":"SY","termSource":"NCI"},{"termName":"1-MT","termGroup":"AB","termSource":"NCI"},{"termName":"D-(+)-1-Methyltryptophan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110117-83-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TX5CYN1KMZ"},{"name":"Legacy Concept Name","value":"_1-Methyl-d-Tryptophan"},{"name":"Maps_To","value":"Indoximod"},{"name":"NCI_Drug_Dictionary_ID","value":"579646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579646"},{"name":"PDQ_Open_Trial_Search_ID","value":"579646"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045546"}]}}{"C150393":{"preferredName":"Indoximod Prodrug NLG802","code":"C150393","definitions":[{"definition":"An orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against IDO1-expressing tumor cells, thereby inhibiting their growth. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system. NLG802 elicits increased plasma concentrations of indoximod and improves its efficacy, compared to the direct administration of indoximod.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indoximod Prodrug NLG802","termGroup":"PT","termSource":"NCI"},{"termName":"IDO1 Inhibitor NLG802","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase (IDO) Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"NLG 802","termGroup":"CN","termSource":"NCI"},{"termName":"NLG-1564","termGroup":"CN","termSource":"NCI"},{"termName":"NLG-802","termGroup":"CN","termSource":"NCI"},{"termName":"NLG802","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2071683-98-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NVJ85QZ036"},{"name":"Maps_To","value":"Indoximod Prodrug NLG802"},{"name":"NCI_Drug_Dictionary_ID","value":"792849"},{"name":"NCI_META_CUI","value":"CL552162"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792849"},{"name":"PDQ_Open_Trial_Search_ID","value":"792849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83818":{"preferredName":"Inecalcitol","code":"C83818","definitions":[{"definition":"An analog of calcitriol and a vitamin D3 receptor (VDR) agonist, with potential antineoplastic activity. Upon administration, inecalcitol targets and binds to VDR. This activates VDR and VDR-mediated signal transduction pathways. This modulates the VDR-mediated expression of certain genes, including the expression of anti-cancer genes, enhances cellular differentiation, induces tumor cell apoptosis and inhibits tumor cell growth. VDR plays a central role in calcium homeostasis and in the growth of certain cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inecalcitol","termGroup":"PT","termSource":"NCI"},{"termName":"(7E)-19-Nor-9,10-seco-14beta-cholesta-5,7-dien-23-yne-1alpha,3beta,25-triol","termGroup":"SN","termSource":"NCI"},{"termName":"ICC","termGroup":"AB","termSource":"NCI"},{"termName":"TX 522","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"163217-09-2"},{"name":"Chemical_Formula","value":"C26H40O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05FZV98342"},{"name":"Maps_To","value":"Inecalcitol"},{"name":"NCI_Drug_Dictionary_ID","value":"782341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782341"},{"name":"PDQ_Open_Trial_Search_ID","value":"782341"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827203"}]}}{"C88302":{"preferredName":"Infigratinib","code":"C88302","definitions":[{"definition":"An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infigratinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea","termGroup":"SY","termSource":"NCI"},{"termName":"BGJ-398","termGroup":"CN","termSource":"NCI"},{"termName":"BGJ398","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"872511-34-7"},{"name":"CHEBI_ID","value":"CHEBI:63451"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A4055ME1VK"},{"name":"Maps_To","value":"Infigratinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981819"}]}}{"C162568":{"preferredName":"Infigratinib Mesylate","code":"C162568","definitions":[{"definition":"The mesylate salt of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infigratinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"BGJ 398 Mesylate","termGroup":"CN","termSource":"NCI"},{"termName":"BGJ-398 Mesylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1310746-12-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E223Z0KWCC"},{"name":"Maps_To","value":"Infigratinib Mesylate"},{"name":"NCI_META_CUI","value":"CL971083"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1789":{"preferredName":"Infliximab","code":"C1789","definitions":[{"definition":"A monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infliximab","termGroup":"PT","termSource":"NCI"},{"termName":"Avakine","termGroup":"SY","termSource":"NCI"},{"termName":"cA2","termGroup":"CN","termSource":"NCI"},{"termName":"Remicade","termGroup":"BR","termSource":"NCI"},{"termName":"Remsima","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Ankylosis spondylitis; Crohns disease; Plaque psoriasis; Rheumatoid arthritis; Sarcoidosis"},{"name":"CAS_Registry","value":"170277-31-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B72HH48FLU"},{"name":"Legacy Concept Name","value":"Infliximab"},{"name":"Maps_To","value":"Infliximab"},{"name":"NCI_Drug_Dictionary_ID","value":"38698"},{"name":"NSC Number","value":"728729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38698"},{"name":"PDQ_Open_Trial_Search_ID","value":"38698"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0666743"}]}}{"C48398":{"preferredName":"Ingenol Mebutate","code":"C48398","definitions":[{"definition":"A selective small-molecule activator of protein kinase C (PKC) isolated from the plant Euphorbia peplus with potential antineoplastic activity. Ingenol mebutate activates various protein kinase C (PKC) isoforms, thereby inducing apoptosis in some tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes including proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ingenol Mebutate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Butenoic acid, 2-methyl-, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-1a,2,5,5a,6,9,10,10a- octahydro-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1H-2,8a- methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl ester, (2Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"I3A","termGroup":"AB","termSource":"NCI"},{"termName":"Ingenol-3-angelate","termGroup":"SY","termSource":"NCI"},{"termName":"PEP-005","termGroup":"CN","termSource":"NCI"},{"termName":"PEP005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75567-37-2"},{"name":"Chemical_Formula","value":"C25H34O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7686S50JAH"},{"name":"Legacy Concept Name","value":"Ingenol_3-Angelate"},{"name":"Maps_To","value":"Ingenol Mebutate"},{"name":"NCI_Drug_Dictionary_ID","value":"432941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"432941"},{"name":"PDQ_Open_Trial_Search_ID","value":"432941"},{"name":"PubMedID_Primary_Reference","value":"19178487"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1452152"}]}}{"C118776":{"preferredName":"Ingenol Mebutate Gel","code":"C118776","definitions":[{"definition":"A topical, aqueous gel formulation containing the mebutate salt form of ingenol, a selective small-molecule activator of protein kinase C (PKC) that is isolated from the sap of Euphorbia species, with potential antineoplastic activity. Upon topical application of the ingenol mebutate gel, ingenol activates various PKC isoforms, which induces apoptosis in certain tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes, including proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ingenol Mebutate Gel","termGroup":"PT","termSource":"NCI"},{"termName":"Ingenol-3-angelate Gel","termGroup":"SY","termSource":"NCI"},{"termName":"PEP-005 Topical Gel","termGroup":"CN","termSource":"NCI"},{"termName":"PEP005 Gel","termGroup":"CN","termSource":"NCI"},{"termName":"Picato","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ingenol Mebutate Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"766480"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766480"},{"name":"PDQ_Open_Trial_Search_ID","value":"766480"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3257744"}]}}{"C62526":{"preferredName":"Iniparib","code":"C62526","definitions":[{"definition":"A small molecule iodobenzamide with potential cytotoxic and antineoplastic activities. Although the mechanism of action is unknown, iniparib appears to be cytotoxic in cells with DNA alterations or DNA damage, like that found in tumor cells with mutations in the ataxia telangiectasia mutated (ATM) gene. ATM encodes a serine/threonine protein kinase and mutations of the gene are associated with ataxia telangiectasia and contribute to certain cancers such as T-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia and B-cell non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. BSI-201 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iniparib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Iodo-3-Nitrobenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"BSI-201","termGroup":"CN","termSource":"NCI"},{"termName":"PARP-1 Inhibitor BSI-201","termGroup":"SY","termSource":"NCI"},{"termName":"SAR240550","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160003-66-7"},{"name":"CAS_Registry","value":"937799-96-7"},{"name":"Chemical_Formula","value":"C7H5IN2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ZWI7KHK8F"},{"name":"Legacy Concept Name","value":"BSI-201"},{"name":"Maps_To","value":"Iniparib"},{"name":"NCI_Drug_Dictionary_ID","value":"488465"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488465"},{"name":"PDQ_Open_Trial_Search_ID","value":"488465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0291482"}]}}{"C82362":{"preferredName":"Innate Immunostimulator rBBX-01","code":"C82362","definitions":[{"definition":"A recombinant 19 kDa protein derived from the Apicomplexa protozoan Eimeria with potential immunostimulating and antitumor activities. Upon administration, innate immunostimulator rBBX-01 activates dendritic cells (DCs), stimulates the Toll-like receptor 11 (TLR-11)-mediated release of interleukin-12 (Il-12) from DCs, and induces a T-helper 1 (Th1) type immune response, which may induce an immune response against tumor cells. Infection with Eimeria, a coccidian commonly infecting the intestine, may be negatively correlated with tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Innate Immunostimulator rBBX-01","termGroup":"PT","termSource":"NCI"},{"termName":"rBBX-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Innate_Immunostimulator_rBBX-01"},{"name":"Maps_To","value":"Innate Immunostimulator rBBX-01"},{"name":"NCI_Drug_Dictionary_ID","value":"640624"},{"name":"NCI_META_CUI","value":"CL408641"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640624"},{"name":"PDQ_Open_Trial_Search_ID","value":"640624"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61315":{"preferredName":"INO-1001","code":"C61315","definitions":[{"definition":"A isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INO-1001","termGroup":"PT","termSource":"NCI"},{"termName":"INO 1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"624747-02-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"55E08EN074"},{"name":"Legacy Concept Name","value":"INO-1001"},{"name":"Maps_To","value":"INO-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"485165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485165"},{"name":"PDQ_Open_Trial_Search_ID","value":"485165"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1504945"}]}}{"C157333":{"preferredName":"Inodiftagene Vixteplasmid","code":"C157333","definitions":[{"definition":"A recombinant DNA plasmid carrying the gene for diphtheria toxin-A (dT-A) chain under the regulation of the H19 promoter, with potential antineoplastic activity. Upon intravesical administration, dT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The dT-A chain binds to nicotinamide adenine dinucleotide (NAD) and inactivates the ADP-ribosylation of elongation factor 2 (EF2), resulting in the inhibition of protein synthesis and cell death leading to tumor cell destruction. Inodiftagene Vixteplasmid does not carry the gene for the diphtheria toxin-B (dT-B) chain, thereby preventing the transfer of the toxic dT-A chain between cells. H19, a paternally imprinted, oncofetal gene, is highly expressed in embryonic and certain malignant tissues, but minimally expressed in normal, adult tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inodiftagene Vixteplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"BC 819","termGroup":"CN","termSource":"NCI"},{"termName":"BC-819","termGroup":"CN","termSource":"NCI"},{"termName":"BC819","termGroup":"CN","termSource":"NCI"},{"termName":"Diphtheria-toxin-A-H19","termGroup":"SY","termSource":"NCI"},{"termName":"dT-A-H19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2166100-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98YK326XZ6"},{"name":"Maps_To","value":"Inodiftagene Vixteplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"796809"},{"name":"NCI_META_CUI","value":"CL937035"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796809"},{"name":"PDQ_Open_Trial_Search_ID","value":"796809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116728":{"preferredName":"iNOS Dimerization Inhibitor FK-330","code":"C116728","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of inducible nitric oxide synthase (iNOS) with potential antineoplastic activity. Upon administration, iNOS Dimerization Inhibitor FK-330 inhibits iNOS dimerization, which results in decreased nitric oxide (NO) production. iNOS expression is upregulated in certain cancers and may invoke a chronic inflammatory state in tumor cells that promotes metastatic growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iNOS Dimerization Inhibitor FK-330","termGroup":"PT","termSource":"NCI"},{"termName":"FK-330","termGroup":"CN","termSource":"NCI"},{"termName":"FR-260330","termGroup":"CN","termSource":"NCI"},{"termName":"iNOS Dimerization Inhibitor ASP9853","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"442198-67-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K47C68D94B"},{"name":"Maps_To","value":"iNOS Dimerization Inhibitor ASP9853"},{"name":"NCI_Drug_Dictionary_ID","value":"741936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741936"},{"name":"PDQ_Open_Trial_Search_ID","value":"741936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3900153"}]}}{"C122835":{"preferredName":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01","code":"C122835","definitions":[{"definition":"An orally bioavailable inhibitor of inosine 5'- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration, IMPDH inhibitor FF-10501-01 competitively inhibits the enzyme IMPDH, thereby preventing the conversion of inosine monophosphate to xanthosine monophosphate. This inhibits the synthesis of guanine nucleotides, deprives cancer cells of guanosine triphosphate (GTP), disrupts DNA and RNA synthesis, and decreases tumor cell proliferation. Tumor cells are highly susceptible to IMPDH inhibition because they are rapidly dividing cells that are dependent on rapid DNA synthesis, which requires a high concentration of nucleotides. IMPDH, an enzyme that catalyzes the rate-limiting step in the synthesis of guanosine triphosphate (GTP), is overexpressed in numerous tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01","termGroup":"PT","termSource":"NCI"},{"termName":"FF-10501","termGroup":"CN","termSource":"NCI"},{"termName":"FF-10501-01","termGroup":"CN","termSource":"NCI"},{"termName":"IMPDH Inhibitor FF-10501","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01"},{"name":"NCI_Drug_Dictionary_ID","value":"763219"},{"name":"NCI_META_CUI","value":"CL474107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763219"},{"name":"PDQ_Open_Trial_Search_ID","value":"763219"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49181":{"preferredName":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944","code":"C49181","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks cells from making DNA and RNA and may kill cancer cells. It is a type of inosine monophosphate dehydrogenase (IMPDH) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine triphosphate (GTP), a purine molecule required for DNA and RNA synthesis.  Inhibition of IMPDH deprives cancer cells of GTP, resulting in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 appears to have a selective effect on cancer cells in that deprivation of GTP in normal cells results in a temporary slowing of cell growth only. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944","termGroup":"PT","termSource":"NCI"},{"termName":"AVN944","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"297730-17-7"},{"name":"Chemical_Formula","value":"C25H27N5O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I3NPL1V48Q"},{"name":"Legacy Concept Name","value":"AVN944"},{"name":"Maps_To","value":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944"},{"name":"NCI_Drug_Dictionary_ID","value":"486333"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486333"},{"name":"PDQ_Open_Trial_Search_ID","value":"486333"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706677"}]}}{"C28163":{"preferredName":"Inositol","code":"C28163","definitions":[{"definition":"A natural sugar found in cell membrane phospholipids, plasma lipoproteins, and (as the phosphate form) in the nucleus with potential chemopreventive properties. As one of a number of intracellular phosphate compounds, inositol is involved in cell signaling and may stimulate tumor cell differentiation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Myoinositol helps cells make membranes and respond to messages from their environment. It has the same chemical formula as glucose (the chief source of energy for living organisms) but has a different arrangement of atoms. It is found in beans, peas, brown rice, wheat bran and nuts. It is water-soluble (can dissolve in water) and must be taken in every day. Myoinositol is being studied in the prevention of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Inositol","termGroup":"PT","termSource":"NCI"},{"termName":"cis-1,2,3,5-trans-4,6-Cyclohexanehexol","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclohexanehexol","termGroup":"SN","termSource":"NCI"},{"termName":"myo-Inositol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87-89-8"},{"name":"CHEBI_ID","value":"CHEBI:17268"},{"name":"Chemical_Formula","value":"C6H12O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4L6452S749"},{"name":"Legacy Concept Name","value":"Inositol"},{"name":"Maps_To","value":"Inositol"},{"name":"NCI_Drug_Dictionary_ID","value":"305828"},{"name":"NSC Number","value":"55552"},{"name":"NSC Number","value":"8101"},{"name":"PDQ_Closed_Trial_Search_ID","value":"305828"},{"name":"PDQ_Open_Trial_Search_ID","value":"305828"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021547"}]}}{"C71542":{"preferredName":"Inotuzumab Ozogamicin","code":"C71542","definitions":[{"definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inotuzumab Ozogamicin","termGroup":"PT","termSource":"NCI"},{"termName":"Besponsa","termGroup":"BR","termSource":"NCI"},{"termName":"CMC-544","termGroup":"CN","termSource":"NCI"},{"termName":"Way 207294","termGroup":"CN","termSource":"NCI"},{"termName":"WAY-207294","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)."},{"name":"CAS_Registry","value":"635715-01-4"},{"name":"Chemical_Formula","value":"C73H96IN6O25S3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"P93RUU11P7"},{"name":"Legacy Concept Name","value":"Anti-CD22-CalichDMH_Conjugate"},{"name":"Maps_To","value":"Inotuzumab Ozogamicin"},{"name":"NCI_Drug_Dictionary_ID","value":"352004"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352004"},{"name":"PDQ_Open_Trial_Search_ID","value":"352004"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567130"}]}}{"C65919":{"preferredName":"Inproquone","code":"C65919","definitions":[{"definition":"A benzoquinone-based antineoplastic agent. Inproquone was never marketed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inproquone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"436-40-8"},{"name":"Chemical_Formula","value":"C16H22N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C6Y700V0M4"},{"name":"Legacy Concept Name","value":"Inproquone"},{"name":"Maps_To","value":"Inproquone"},{"name":"NSC Number","value":"17261"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063600"}]}}{"C61501":{"preferredName":"Integrin alpha-2 Inhibitor E7820","code":"C61501","definitions":[{"definition":"A small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Integrin alpha-2 Inhibitor E7820","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"289483-69-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TVH5K7949N"},{"name":"Legacy Concept Name","value":"E7820"},{"name":"Maps_To","value":"Integrin alpha-2 Inhibitor E7820"},{"name":"NCI_Drug_Dictionary_ID","value":"363619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"363619"},{"name":"PDQ_Open_Trial_Search_ID","value":"363619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1172515"}]}}{"C96223":{"preferredName":"Integrin Receptor Antagonist GLPG0187","code":"C96223","definitions":[{"definition":"A small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity. Upon administration, GLPG0187 binds to and blocks the activity of 5 RGD-integrin receptor subtypes, including alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6 and alpha5beta1. This may result in the inhibition of endothelial cell-cell interactions and endothelial cell-matrix interactions, and the prevention of angiogenesis and metastasis in tumor cells expressing these integrin receptors. Integrin receptors are transmembrane glycoproteins expressed on the surface of tumor vessel endothelial cells and some types of cancer cells, and play a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Integrin Receptor Antagonist GLPG0187","termGroup":"PT","termSource":"NCI"},{"termName":"GLPG0187","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1320346-97-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43A5P87Z4T"},{"name":"Maps_To","value":"Integrin Receptor Antagonist GLPG0187"},{"name":"NCI_Drug_Dictionary_ID","value":"697397"},{"name":"NCI_META_CUI","value":"CL429007"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697397"},{"name":"PDQ_Open_Trial_Search_ID","value":"697397"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C20493":{"preferredName":"Interferon","code":"C20493","definitions":[{"definition":"A biological response modifier (a substance that can improve the body's natural response to infection and disease). Interferons interfere with the division of cancer cells and can slow tumor growth. There are several types of interferons, including interferon-alpha, -beta, and -gamma. These substances are normally produced by the body. They are also made in the laboratory for use in treating cancer and other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon","termGroup":"PT","termSource":"NCI"},{"termName":"Human Fibroblast Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Human Leukocyte Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Human Lymphoblastoid Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Interferon"},{"name":"Maps_To","value":"Interferon"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0021747"}]}}{"C2220":{"preferredName":"Interferon Alfa-N1","code":"C2220","definitions":[{"definition":"A highly purified alpha interferon produced by a human lymphoid cell line.  Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.  In contrast, recombinant alpha interferons are individual non-glycosylated proteins produced from individual alpha interferon genes.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose proteins have antiviral, antiproliferative, anticancer, and immune-modulating effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Alfa-N1","termGroup":"PT","termSource":"NCI"},{"termName":"Humoferon","termGroup":"FB","termSource":"NCI"},{"termName":"Interferon Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"Wellferon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Hepatitis C"},{"name":"CAS_Registry","value":"308067-63-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"41697D4Z5C"},{"name":"Legacy Concept Name","value":"Interferon_Alfa-N1"},{"name":"Maps_To","value":"Interferon Alfa-N1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699817"}]}}{"C30136":{"preferredName":"Interferon Alfa-N3","code":"C30136","definitions":[{"definition":"A formulated therapeutic analog of the endogenous alpha interferon containing multiple interferon species with antiviral and antitumor properties.  Interferons bind to specific cell-surface receptors, leading to the transcription and translation of genes with an interferon-specific response element, thereby inducing: antiviral effects (the most important being inhibition of viral protein synthesis); antiproliferative effects (including inhibition of cellular growth and alteration of cellular differentiation); anticancer effects (including interference with oncogene expression); and immune-modulating effects (including activation of natural killer cells, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Alfa-N3","termGroup":"PT","termSource":"NCI"},{"termName":"Alfa-N3 Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Alferon N","termGroup":"BR","termSource":"NCI"},{"termName":"Altemol","termGroup":"FB","termSource":"NCI"},{"termName":"Interferon Alfa-3N, Human Leukocyte Derived","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9008-11-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"47BPR3V3MP"},{"name":"Legacy Concept Name","value":"Interferon_Alfa-N3"},{"name":"Maps_To","value":"Interferon Alfa-N3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1621234"}]}}{"C1766":{"preferredName":"Interferon Alfacon-1","code":"C1766","definitions":[{"definition":"An analogue of consensus interferon which contains an additional methionyl amino acid residue.  Consensus interferon (also known as interferon alfacon-1, rCon-IFN, and CIFN) is a genetically engineered synthetic interferon created from the most common amino acid sequences from the naturally occurring alpha interferons.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Alfacon-1","termGroup":"PT","termSource":"NCI"},{"termName":"Advaferon","termGroup":"FB","termSource":"NCI"},{"termName":"CIFN","termGroup":"AB","termSource":"NCI"},{"termName":"Consensus Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN Alfacon-1","termGroup":"SY","termSource":"NCI"},{"termName":"Infergen","termGroup":"BR","termSource":"NCI"},{"termName":"Interferon Consensus, Methionyl","termGroup":"SY","termSource":"NCI"},{"termName":"Methionyl Interferon Consensus","termGroup":"SY","termSource":"NCI"},{"termName":"Methionyl-Interferon-Consensus","termGroup":"SY","termSource":"NCI"},{"termName":"r-metHuIFN-Con1","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Consensus Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant methionyl human consensus interferon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118390-30-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56588OP40D"},{"name":"Legacy Concept Name","value":"Interferon_Alfacon-1"},{"name":"Maps_To","value":"Interferon Alfacon-1"},{"name":"NCI_Drug_Dictionary_ID","value":"42870"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42870"},{"name":"PDQ_Open_Trial_Search_ID","value":"42870"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0164613"}]}}{"C1823":{"preferredName":"Interferon Beta-1A","code":"C1823","definitions":[{"definition":"A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities. Upon administration, interferon beta-1a targets and binds to specific type I IFN receptors, which eventually results in the transcription and translation of genes containing an interferon-specific response element and leads to the production of various anti-viral proteins and modulates the production of various immune-modulating proteins. This reduces the production of certain pro-inflammatory cytokines while upregulating the anti-inflammatory cytokine interleukin 10 (IL-10), upregulates the expression of major histocompatibility (MHC) I proteins which allows for increased presentation of peptides derived from viral antigens, and activates CD8+ T cells as well as other immune cells. Endogenous IFN-beta-1a is produced following viral infection and it plays a key role in innate immune response against viral pathogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Beta-1A","termGroup":"PT","termSource":"NCI"},{"termName":"Avonex","termGroup":"BR","termSource":"NCI"},{"termName":"BG9418","termGroup":"CN","termSource":"NCI"},{"termName":"Rebif","termGroup":"BR","termSource":"NCI"},{"termName":"Recombinant interferon beta-1a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Multiple sclerosis"},{"name":"CAS_Registry","value":"145258-61-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XRO4566Q4R"},{"name":"Legacy Concept Name","value":"Interferon_Beta-1A"},{"name":"Maps_To","value":"Interferon Beta-1A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0982234"}]}}{"C100089":{"preferredName":"Interferon Gamma-1b","code":"C100089","definitions":[{"definition":"A recombinant form of the endogenous cytokine human interferon (IFN) gamma-1b, with immunomodulating activity. Upon administration, IFN gamma-1b targets, binds to, and activates the cell-surface IFN-gamma receptor, stimulating antibody dependent cellular cytotoxicity (ADCC), activating natural killer (NK) cells, and enhancing the oxidative metabolism of macrophages. IFN-gamma plays important roles in the innate and adaptive immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Gamma-1b","termGroup":"PT","termSource":"NCI"},{"termName":"Actimmune","termGroup":"BR","termSource":"NCI"},{"termName":"gamma Interferon 1B","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-g-1b","termGroup":"AB","termSource":"NCI"},{"termName":"IFN-gamma 1b","termGroup":"SY","termSource":"NCI"},{"termName":"IFNg-1b","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon gamma-1b, Recombinant","termGroup":"SY","termSource":"NCI"},{"termName":"N(Sup 2)-L-Methionyl-1-139-Interferon G","termGroup":"SY","termSource":"NCI"},{"termName":"N(sup 2)-L-Methionyl-1-139-interferon gamma (Human Lymphocyte Protein Moiety Reduced)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Interferon Gamma-1b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98059-61-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"21K6M2I7AG"},{"name":"Maps_To","value":"Interferon Gamma-1b"},{"name":"NCI_Drug_Dictionary_ID","value":"784898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784898"},{"name":"PDQ_Open_Trial_Search_ID","value":"784898"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1579322"}]}}{"C66972":{"preferredName":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002","code":"C66972","definitions":[{"definition":"A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002","termGroup":"PT","termSource":"NCI"},{"termName":"Ad-IFNg","termGroup":"AB","termSource":"NCI"},{"termName":"ASN-002","termGroup":"CN","termSource":"NCI"},{"termName":"INFg-expressing Ad Vaccine ASN-002","termGroup":"SY","termSource":"NCI"},{"termName":"TG1042","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002"},{"name":"NCI_Drug_Dictionary_ID","value":"530060"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530060"},{"name":"PDQ_Open_Trial_Search_ID","value":"530060"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832028"}]}}{"C15543":{"preferredName":"Interleukin Therapy","code":"C15543","definitions":[{"definition":"The use of interleukin in the treatment of any disease or disorder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Interleukin_Therapy"},{"name":"Maps_To","value":"Interleukin Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0281177"}]}}{"C2373":{"preferredName":"Interleukin-2 Liposome","code":"C2373","definitions":[{"definition":"A formulation in which liposomes are loaded with the cytokine interleukin-2 (IL-2). By activating cytotoxic T-lymphocytes, such as lymphokine-activated killer cells, and increasing levels of the cytotoxic cytokines interferon-gamma (IFN-gamma) and transforming growth factor-beta (TGF-beta), IL-2 may exhibit antitumoral activity.  Liposomal formulations of IL-2 may promote entry of the cytokine into target tumor cells and may be used as an immunoadjuvant in cancer vaccine therapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-2 Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"Liposome encapsulated interleukin-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Interleukin-2_Liposome"},{"name":"Maps_To","value":"Interleukin-2 Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"41486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41486"},{"name":"PDQ_Open_Trial_Search_ID","value":"41486"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0281031"}]}}{"C128107":{"preferredName":"Nemvaleukin Alfa","code":"C128107","definitions":[{"definition":"A selective effector cell activator protein and agonist of the intermediate-affinity interleukin-2 (IL-2) receptor with potential immunostimulating and antineoplastic activity. Upon administration, nemvaleukin alfa binds to and signals through the intermediate-affinity IL-2 receptor complex; this may selectively stimulate and activate natural killer (NK) cells and memory CD8 T-cells, leading to tumor cell elimination, while circumventing the activation of immunosuppressive cells that may prevent the anti-tumor response. IL-2 is a cytokine signaling molecule that plays a critical role in the immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemvaleukin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"ALKS 4230","termGroup":"CN","termSource":"NCI"},{"termName":"Intermediate-affinity IL-2R Agonist ALKS 4230","termGroup":"SY","termSource":"NCI"},{"termName":"Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230","termGroup":"SY","termSource":"NCI"},{"termName":"RDB 1450","termGroup":"CN","termSource":"NCI"},{"termName":"RDB-1450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2315268-27-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7ZX1Q9SJ1F"},{"name":"Maps_To","value":"Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230"},{"name":"NCI_Drug_Dictionary_ID","value":"782089"},{"name":"NCI_META_CUI","value":"CL507938"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782089"},{"name":"PDQ_Open_Trial_Search_ID","value":"782089"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61070":{"preferredName":"Intetumumab","code":"C61070","definitions":[{"definition":"A pan alpha-v human monoclonal antibody that recognizes alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, and alpha-v beta-6 integrins with antiangiogenic and antitumor activities. Intetumumab competitively binds to and blocks both alpha-v beta-3 and alpha-v beta-5 integrins, resulting in inhibition of integrin-mediated tumor angiogenesis and tumor growth. Integrins facilitate the adhesion of stimulated endothelial cells to the extracellular matrix (ECM); trigger the secretion of ECM-rearranging proteases; and propagate signaling events that promote the survival and differentiation of cells in newly formed vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intetumumab","termGroup":"PT","termSource":"NCI"},{"termName":"CNTO 095","termGroup":"CN","termSource":"NCI"},{"termName":"CNTO-95","termGroup":"CN","termSource":"NCI"},{"termName":"Human Anti-Alpha-5 Integrin Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Human Monoclonal CNTO 95 gamma1 heavy chain (222-215')-disulfide with Human Monoclonal CNTO 95 kappa light chain dimer (228-228'':231-231'')-bisdisulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human integrin alpha-V (vitronectin receptor subunit alpha or CD51))","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"725735-28-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GQE1BJE2NI"},{"name":"Legacy Concept Name","value":"Human_Anti-Alpha-5_Integrin_Monoclonal_Antibody"},{"name":"Maps_To","value":"Intetumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"473196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473196"},{"name":"PDQ_Open_Trial_Search_ID","value":"473196"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881068"}]}}{"C83820":{"preferredName":"Intiquinatine","code":"C83820","definitions":[{"definition":"An antineoplastic agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intiquinatine","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-2-(4-((7-Bromoquinolin-2-yl)Oxy)Phenoxy)Propanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Tiliquinatine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"445041-75-8"},{"name":"Chemical_Formula","value":"C18H14BrNO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G5067X5156"},{"name":"Maps_To","value":"Intiquinatine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827205"}]}}{"C1495":{"preferredName":"Intoplicine","code":"C1495","definitions":[{"definition":"A benzopyridoindole derivative with antineoplastic property. Intoplicine inhibits activities of both topoisomerase I and II via intercalating DNA helix, thereby hindering the movements of enzymes along DNA molecules during DNA transcription and replication, respectively. Furthermore, this agent stabilizes DNA-enzyme complexes during unwinding processes by both topoisomerases, leading to double- and single-stranded DNA breaks. Consequently, these effects bring about cell growth inhibition and apoptosis of tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that has been studied in the treatment of some types of cancer. Intoplicine blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Intoplicine","termGroup":"PT","termSource":"NCI"},{"termName":"7H-benzo(e)pyrido(4,3-b)indol-3-ol, 11-((3-(dimethylamino)propyl)amino)-8-methyl","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125974-72-3"},{"name":"Chemical_Formula","value":"C21H24N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FB2CIN6HMI"},{"name":"Legacy Concept Name","value":"Intoplicine"},{"name":"Maps_To","value":"Intoplicine"},{"name":"NCI_Drug_Dictionary_ID","value":"43318"},{"name":"NSC Number","value":"645008"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43318"},{"name":"PDQ_Open_Trial_Search_ID","value":"43318"},{"name":"PubMedID_Primary_Reference","value":"12570767"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0217476"}]}}{"C61506":{"preferredName":"Inulin","code":"C61506","definitions":[{"definition":"A naturally occurring, indigestible and non-absorbable oligosaccharide produced by certain plants with prebiotic and potential anticancer activity. Inulin stimulates the growth of beneficial bacteria in the colon, including Bifidobacteria and Lactobacilli, thereby modulating the composition of microflora. This creates an environment that protects against pathogens, toxins and carcinogens, which can cause inflammation and cancer. In addition, fermentation of inulin leads to an increase in short-chain fatty acids and lactic acid production, thereby reducing colonic pH, which may further control pathogenic bacteria growth and may contribute to inulin's cancer protective properties.","type":"DEFINITION","source":"NCI"},{"definition":"Class of oligosaccharides produced by plants that are polymers mainly comprised of fructose (generally 2 to 140) units usually with a glucose end. These units are joined by beta-(2-1) glycosidic links.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Inulin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9005-80-5"},{"name":"CHEBI_ID","value":"CHEBI:15443"},{"name":"Chemical_Formula","value":"C18H32O16(C6H10O5)n"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JOS53KRJ01"},{"name":"INFOODS","value":"INULN"},{"name":"Legacy Concept Name","value":"Inulin"},{"name":"Maps_To","value":"Inulin"},{"name":"NCI_Drug_Dictionary_ID","value":"486745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486745"},{"name":"PDQ_Open_Trial_Search_ID","value":"486745"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021936"}]}}{"C970":{"preferredName":"Iobenguane I-131","code":"C970","definitions":[{"definition":"A radioactive substance that is used in imaging tests, and is being studied in the treatment of cancer. It is a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Iobenguane localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iobenguane I-131","termGroup":"PT","termSource":"NCI"},{"termName":"(131)I-MIBG","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 Meta-iodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 Metaiodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"Iobenguane (131I)","termGroup":"SY","termSource":"NCI"},{"termName":"Iobenguane I 131","termGroup":"SY","termSource":"NCI"},{"termName":"Iobenguane I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Metaiodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"MIBG I-131","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diagnostic imaging; Neuroendocrine tumors."},{"name":"CAS_Registry","value":"77679-27-7"},{"name":"Chemical_Formula","value":"C8H10IN3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q461L7AK4R"},{"name":"Legacy Concept Name","value":"Meta-Iodobenzylguanidine"},{"name":"Maps_To","value":"Iobenguane I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"38020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38020"},{"name":"PDQ_Open_Trial_Search_ID","value":"38020"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879568"}]}}{"C2440":{"preferredName":"Iodine I 124 Monoclonal Antibody A33","code":"C2440","definitions":[{"definition":"A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 124 (I-124). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancer metastases, with only restricted expression in normal colonic mucosa. I-124 MoAb A33 delivers beta particle emitting I-124 nuclide directly to metastatic colorectal tissues, thereby this agent could be used in kinetics studies or radioimmunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 124 Monoclonal Antibody A33","termGroup":"PT","termSource":"NCI"},{"termName":"I 124 Monoclonal Antibody A33","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 124 MOAB A33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_124_Monoclonal_Antibody_A33"},{"name":"Maps_To","value":"Iodine I 124 Monoclonal Antibody A33"},{"name":"NCI_Drug_Dictionary_ID","value":"42707"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42707"},{"name":"PDQ_Open_Trial_Search_ID","value":"42707"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C0677678"}]}}{"C158629":{"preferredName":"Iodine I 124 Monoclonal Antibody M5A","code":"C158629","definitions":[{"definition":"A radioimmunoconjugate comprised of M5A, a humanized monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), labeled with iodine I 124 (I-124) with potential radiolocalization applications. Upon administration, the antibody moiety of iodine I 124 monoclonal antibody M5A specifically binds to cells expressing CEA. Upon binding, the radioisotope moiety can be detected using positron-emission tomography (PET), thereby allowing the imaging and quantification of CEA-expressing tumor cells. CEA, a tumor associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 124 Monoclonal Antibody M5A","termGroup":"PT","termSource":"NCI"},{"termName":"124I-hT84.66-M5A","termGroup":"SY","termSource":"NCI"},{"termName":"124I-M5A","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 124 Anti-CEA Monoclonal Antibody hT84.66-M5A","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 124 Anti-CEA Monoclonal Antibody M5A","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 124 Monoclonal Antibody hT84.66-M5A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 124 Monoclonal Antibody M5A"},{"name":"NCI_Drug_Dictionary_ID","value":"797482"},{"name":"NCI_META_CUI","value":"CL950662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797482"},{"name":"PDQ_Open_Trial_Search_ID","value":"797482"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74051":{"preferredName":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody","code":"C74051","definitions":[{"definition":"A radioimmunoconjugate consisting of a murine IgG2a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR) labeled with iodine I 125 with potential antineoplastic activity. Iodine I 125 anti-EGFR-425 monoclonal antibody binds specifically to the epidermal growth factor receptor (EGFR). Upon binding to EGFR-expressing tumor cells, this agent is internalized, selectively delivering a potentially cytotoxic dose of gamma radiation. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iodine_I_125-Anti-EGFR-425_Monoclonal_Antibody"},{"name":"Maps_To","value":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody"},{"name":"NCI_Drug_Dictionary_ID","value":"586304"},{"name":"NCI_META_CUI","value":"CL383810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586304"},{"name":"PDQ_Open_Trial_Search_ID","value":"586304"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91389":{"preferredName":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP","code":"C91389","definitions":[{"definition":"An iodine 131 radioimmunoconjugate of a small immunoprotein (SIP), derived from the variable region fragment of human monoclonal antibody L19, that is directed against the extra-domain B (ED-B) of fibronectin, with potential radioimmunotherapeutic activity. The SIP moiety of iodine I 131 anti-fibronectin antibody fragment L19-SIP binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. Upon internalization, the I 131 radionuclide may selectively detect or deliver cytotoxic radiation to fibronectin-expressing tumor cells. ED-B of fibronectin, a naturally occurring marker of tissue remodeling and angiogenesis, is expressed in the majority of aggressive solid human tumors, whereas it is not detectable in normal vessels and tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP","termGroup":"PT","termSource":"NCI"},{"termName":"L19-SIP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP"},{"name":"NCI_Drug_Dictionary_ID","value":"674133"},{"name":"NCI_META_CUI","value":"CL421588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674133"},{"name":"PDQ_Open_Trial_Search_ID","value":"674133"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2223":{"preferredName":"Iodine I 131 Derlotuximab Biotin","code":"C2223","definitions":[{"definition":"An iodine 131 labeled radioimmunoconjugate of monoclonal antibody (MOAB) TNT-1/B with radioimaging and antineoplastic properties. MOAB TNT-1/B was developed for radioimmunotherapy of solid tumors, designated as Tumor Necrosis Treatment (TNT). TNT exploits the presence of degenerating and necrotic cells within tumors by utilizing MOAbs directed against universal, intracellular nucleosomal determinants consisting of histone H1 and DNA. This MOAB was conjugated with biotin (B) molecules, which increase pharmacokinetic performance of the monoclonal antibody. Upon administration, iodine I 131 derlotuximab biotin delivers I 131 to tumor cells and results in the targeted imaging and/or destruction of cells with exposed necrotic antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Derlotuximab Biotin","termGroup":"PT","termSource":"NCI"},{"termName":"Cotara","termGroup":"BR","termSource":"NCI"},{"termName":"I 131 MOAB TNT-1/B","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody TNT-1/B","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB TNT-1/B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"340013-96-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1724UJB90B"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_TNT-1_B"},{"name":"Maps_To","value":"Iodine I 131 Derlotuximab Biotin"},{"name":"NCI_Drug_Dictionary_ID","value":"43561"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43561"},{"name":"PDQ_Open_Trial_Search_ID","value":"43561"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879273"}]}}{"C2696":{"preferredName":"Iodine I 131 Ethiodized Oil","code":"C2696","definitions":[{"definition":"A cytotoxic radioconjugate consisting of lipiodol, an iodinated ethyl ester derived from poppy seed oil, labeled with iodine 131 (I-131).  I-131 Lipiodol accumulates in hepatocellular carcinoma and hepatoblastoma tumor cells, resulting in targeted cytotoxicity to tumor cells while sparing surrounding normal cells and tissues. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A radioactive substance being studied in the treatment of liver cancer. It is a form of poppy seed oil that contains iodine, some of which is the radioactive substance iodine I 131. It builds up in the blood and lymph vessels in the liver and may kill cancer cells. It is a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iodine I 131 Ethiodized Oil","termGroup":"PT","termSource":"NCI"},{"termName":"131 I-Ethiodized Oil","termGroup":"SY","termSource":"NCI"},{"termName":"I 131 Lipiodol","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Lipiodol","termGroup":"SY","termSource":"NCI"},{"termName":"Lipiocis","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Lipiodol"},{"name":"Maps_To","value":"Iodine I 131 Ethiodized Oil"},{"name":"NCI_Drug_Dictionary_ID","value":"38497"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38497"},{"name":"PDQ_Open_Trial_Search_ID","value":"38497"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527224"}]}}{"C131821":{"preferredName":"Iodine I 131 MIP-1095","code":"C131821","definitions":[{"definition":"A radioconjugate composed of MIP-1095, a urea-based ligand for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) radiolabeled with iodine I 131 (I131), with potential antineoplastic activity. Upon administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells. PSMA is a transmembrane glycoprotein that is highly expressed by malignant prostate epithelial cells and certain other tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 MIP-1095","termGroup":"PT","termSource":"NCI"},{"termName":"((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(131)I]iodophenyl)ureido)pentyl)ureido)pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"(131) I-MIP-1095","termGroup":"SY","termSource":"NCI"},{"termName":"131I-MIP-1095","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 MIP-1095","termGroup":"SY","termSource":"NCI"},{"termName":"MIP-1095 I-131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1258980-67-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7DM27RQ9V0"},{"name":"Maps_To","value":"Iodine I 131 MIP-1095"},{"name":"NCI_Drug_Dictionary_ID","value":"786538"},{"name":"NCI_META_CUI","value":"CL514422"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786538"},{"name":"PDQ_Open_Trial_Search_ID","value":"786538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2488":{"preferredName":"Iodine I 131 Monoclonal Antibody 81C6","code":"C2488","definitions":[{"definition":"A radioimmunoconjugate consisting of 81C6, a murine IgG2 anti-tenascin monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic activities. Using monoclonal antibody 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"81C6-I-131","termGroup":"SY","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Neuradiab","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000874-23-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D4E1UP3RMV"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_81C6"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody 81C6"},{"name":"NCI_Drug_Dictionary_ID","value":"43146"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43146"},{"name":"PDQ_Open_Trial_Search_ID","value":"43146"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796329"}]}}{"C2527":{"preferredName":"Iodine I 131 Apamistamab","code":"C2527","definitions":[{"definition":"A monoclonal antibody that contains the radioactive substance iodine I131. It is being studied in the treatment of acute myeloid leukemia. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Iodine I 131 monoclonal antibody BC8 binds to the protein CD45, which is found on most white blood cells and myeloid and lymphoid leukemia cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45. CD45 is tyrosine phosphatase expressed on virtually all leukocytes, including myeloid and lymphoid precursors in bone marrow and mature lymphocytes in lymph nodes; it is also expressed on most myeloid and lymphoid leukemic cells, but not on mature erythrocytes or platelets. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Apamistamab","termGroup":"PT","termSource":"NCI"},{"termName":"I 131 MOAB BC8","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody BC8","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine (131I) Apamistamab","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB BC8","termGroup":"SY","termSource":"NCI"},{"termName":"Iomab-B","termGroup":"BR","termSource":"NCI"},{"termName":"MOAB BC8, iodine I 131","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody BC8, iodine I 131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097132-02-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71RR81V666"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_BC8"},{"name":"Maps_To","value":"Iodine I 131 Apamistamab"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody BC8"},{"name":"NCI_Drug_Dictionary_ID","value":"43463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43463"},{"name":"PDQ_Open_Trial_Search_ID","value":"43463"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796627"}]}}{"C2697":{"preferredName":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2","code":"C2697","definitions":[{"definition":"A radioimmunoconjugate consisting of the humanized CH2 domain-deleted monoclonal antibody CC49 and iodine I 131 with antineoplastic activity. Monoclonal antibody CC49-deltaCH2 targets the tumor-associated glycoprotein 72 (TAG-72) that is expressed by a wide range of human neoplasms including colorectal, gastric, pancreatic, ovarian, endometrial, breast, non-small cell lung, and prostate cancers. Iodine I 131 monoclonal antibody CC49-deltaCH2 binds to tumor cells expressing TAG-72, selectively delivering a cytotoxic dose of beta and gamma radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2","termGroup":"PT","termSource":"NCI"},{"termName":"131I-HuCC49-deltaCH2","termGroup":"AB","termSource":"NCI"},{"termName":"131I-MOAB CC49-deltaCH2","termGroup":"AB","termSource":"NCI"},{"termName":"I131 MOAB CC49-deltaCH2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iodine_I_131_Monoclonal_Antibody_CC49-deltaCH2"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2"},{"name":"NCI_Drug_Dictionary_ID","value":"453590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453590"},{"name":"PDQ_Open_Trial_Search_ID","value":"453590"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134477"}]}}{"C95025":{"preferredName":"Iodine I 131 Monoclonal Antibody F16SIP","code":"C95025","definitions":[{"definition":"A fully human monoclonal antibody (MoAb) against human A1 domain of tenascin-C, in small immunoprotein (SIP) format conjugated with iodine 131 with potential antineoplastic activity. Iodine I 131 MoAb F16SIP binds to tenascin-C on the vascular tissues and delivers cytotoxic radiation to the tumors, thereby minimizing systemic radiotoxicity. Tenascin-C is a glycoprotein of the extracellular matrix, and the large isoform of this matrix protein is expressed and restricted around vascular structures in the tumor stroma of a variety of different tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody F16SIP","termGroup":"PT","termSource":"NCI"},{"termName":"(131I) Monoclonal Antibody F16SIP","termGroup":"SY","termSource":"NCI"},{"termName":"131I-F16SIP","termGroup":"AB","termSource":"NCI"},{"termName":"F16-131I","termGroup":"AB","termSource":"NCI"},{"termName":"Tenarad","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody F16SIP"},{"name":"NCI_Drug_Dictionary_ID","value":"689747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689747"},{"name":"PDQ_Open_Trial_Search_ID","value":"689747"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986856"}]}}{"C2449":{"preferredName":"Iodine I 131 Monoclonal Antibody G-250","code":"C2449","definitions":[{"definition":"A radioimmunoconjugate comprised of the chimeric monoclonal antibody G-250 conjugated with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 chimeric monoclonal antibody G-250 binds to G-250, a renal-cell carcinoma-associated antigen, delivering cytotoxic iodine I 131 specifically to renal carcinoma cells that express G-250.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody G-250","termGroup":"PT","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody G-250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB G 250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB G-250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB G250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 monoclonal antibody G250","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_G-250"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody G-250"},{"name":"NCI_Drug_Dictionary_ID","value":"42854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42854"},{"name":"PDQ_Open_Trial_Search_ID","value":"42854"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677789"}]}}{"C2604":{"preferredName":"Iodine I 131 Monoclonal Antibody muJ591","code":"C2604","definitions":[{"definition":"A radioimmunoconjugate of a mouse monoclonal antibody (MoAb) J591 labeled with Iodine 131 (I-131). MoAb muJ591 recognizes the extracellular domain of the prostate-specific membrane antigen (PSMA) and reacts with tumor vascular endothelium. Using MoAb muJ591 as a carrier for I-131 results in the targeted imaging and/or destruction of cells overexpressed PSM.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody muJ591","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iodine_I_131_Monoclonal_Antibody_muJ591"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody muJ591"},{"name":"NCI_Drug_Dictionary_ID","value":"38113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38113"},{"name":"PDQ_Open_Trial_Search_ID","value":"38113"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935700"}]}}{"C48400":{"preferredName":"Iodine I 131 Omburtamab","code":"C48400","definitions":[{"definition":"A radioimmunoconjugate consisting of the iodine 131-radiolabeled murine IgG1 monoclonal antibody 8H9 directed against the surface immunomodulatory glycoprotein 4Ig-B7-H3 with potential radioimaging and radioimmunotherapeutic uses. Iodine I 131 monoclonal antibody 8H9 binds to 4Ig-B7-H3 (human B7-H3 with 4 Ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4Ig-B7-H3 inhibits T-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mdDCs). In vitro, it has been shown that monoclonal antibody-mediated masking of 4Ig-B7-H3 on neuroblastoma cells resulted in the enhancement of natural killer (NK)-mediated lysis of target cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Omburtamab","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 MOAB 8H9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6PMV8U3C4"},{"name":"Legacy Concept Name","value":"Iodine_I_131_Monoclonal_Antibody_8H9"},{"name":"Maps_To","value":"Iodine I 131 Omburtamab"},{"name":"NCI_Drug_Dictionary_ID","value":"380753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"380753"},{"name":"PDQ_Open_Trial_Search_ID","value":"380753"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541591"}]}}{"C102981":{"preferredName":"Iodine I 131 Rituximab","code":"C102981","definitions":[{"definition":"A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Rituximab","termGroup":"PT","termSource":"NCI"},{"termName":"(131)I-Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"131I-Rituxan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K2I4B6I9L1"},{"name":"Maps_To","value":"Iodine I 131 Rituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"739942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739942"},{"name":"PDQ_Open_Trial_Search_ID","value":"739942"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1676077"}]}}{"C124996":{"preferredName":"Iodine I 131 Tenatumomab","code":"C124996","definitions":[{"definition":"A radioimmunoconjugate of tenatumomab, a murine monoclonal antibody targeting the tumor-associated antigen (TAA) tenascin-C (TNC), labeled with iodine I 131, with potential antineoplastic activity. The antibody moiety of iodine I 131 tenatumomab binds to TNC, thereby delivering a cytotoxic dose of iodine I 131 specifically to tumors expressing TNC. TNC, an extracellular matrix protein, is upregulated in a variety of tumor cell types; it plays a key role in invasion, tumor cell proliferation and immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Tenatumomab","termGroup":"PT","termSource":"NCI"},{"termName":"131I-Tenatumomab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 Tenatumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"777273"},{"name":"NCI_META_CUI","value":"CL503842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777273"},{"name":"PDQ_Open_Trial_Search_ID","value":"777273"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48263":{"preferredName":"Iodine I 131 TM-601","code":"C48263","definitions":[{"definition":"An iodine 131 (I 131) radioconjugate of the synthetic chlorotoxin (CTX) TM-601 with potential antiangiogenic and antineoplastic activities. CTX is a 36 amino acid neurotoxin found in the venom of the giant yellow scorpion Leiurus quinquestriatus that preferentially binds malignant cells of neuroectodermal origin. The recombinant version of this peptide, TM-601, is expressed in and purified from E. coli and then covalently linked to I 131 to produce 131I-TM-601. 131I-TM-601 binds to tumor cells of neuroectodermal origin and is internalized; administered once, it may be used as a radioimaging agent; repeated administration may result in a tumor-specific, cumulative radiocytotoxic dose of I 131. In addition, TM-601 alone, similar to native CTX, may inhibit angiogenesis due to its ability to bind to and inhibit matrix metalloproteinase 2 (MMP-2), an endopeptidase involved in tissue remodeling processes such as angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 TM-601","termGroup":"PT","termSource":"NCI"},{"termName":"131I-Chlorotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"131I-TM-601","termGroup":"SY","termSource":"NCI"},{"termName":"131I-TM601","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 TM-601","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_TM-601"},{"name":"Maps_To","value":"Iodine I 131 TM-601"},{"name":"NCI_Drug_Dictionary_ID","value":"440314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"440314"},{"name":"PDQ_Open_Trial_Search_ID","value":"440314"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2316450"}]}}{"C2444":{"preferredName":"Iodine I 131 Tositumomab","code":"C2444","definitions":[{"definition":"A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types of non-Hodgkin lymphoma. It belongs to the family of drugs called radioconjugated monoclonal antibodies. When iodine I 131 tositumomab and tositumomab are given together, the combination is called the Bexxar regimen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Tositumomab","termGroup":"PT","termSource":"NCI"},{"termName":"131-I-Anti-B1 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Bexxar","termGroup":"BR","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody Anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"I 131 Tositumomab","termGroup":"SY","termSource":"NCI"},{"termName":"I131-MOAB-B1","termGroup":"AB","termSource":"NCI"},{"termName":"Iodine I 131 MOAB Anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody Anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 Anti-B1 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 Anti-CD20 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 Tositumomab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"CD-20-antigen-expressing, relapsed or refractory, low-grade, follicular, or transformed Non-Hodgkins lymphoma"},{"name":"CAS_Registry","value":"192391-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K1KT5M40JC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_Anti-B1"},{"name":"Maps_To","value":"Iodine I 131 Tositumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"42806"},{"name":"NSC Number","value":"715813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42806"},{"name":"PDQ_Open_Trial_Search_ID","value":"42806"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0768182"}]}}{"C1639":{"preferredName":"Iodine I-131","code":"C1639","definitions":[{"definition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I-131","termGroup":"PT","termSource":"NCI"},{"termName":"131-Iodine","termGroup":"SY","termSource":"NCI"},{"termName":"Bound Iodide I-131","termGroup":"SY","termSource":"NCI"},{"termName":"I 131","termGroup":"AB","termSource":"NCI"},{"termName":"I-131","termGroup":"AB","termSource":"NCI"},{"termName":"Iodide I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodide, I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine 131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodotope","termGroup":"BR","termSource":"NCI"},{"termName":"Iodotrope","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hyperthyroidism"},{"name":"CAS_Registry","value":"10043-66-0"},{"name":"Chemical_Formula","value":"I"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I5X6L61HUT"},{"name":"Legacy Concept Name","value":"Iodine_131"},{"name":"Maps_To","value":"Iodine I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"43630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43630"},{"name":"PDQ_Open_Trial_Search_ID","value":"43630"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0303029"}]}}{"C80056":{"preferredName":"Ioflubenzamide I-131","code":"C80056","definitions":[{"definition":"An iodine 131-radiolabeled small-molecule benzamide compound with potential antineoplastic activity. The benzamide moiety of 131-I-MIP-1145 binds to melanin, selectively delivering a cyotoxic dose of gamma and beta radiation to melanin-expressing tumor cells. Melanin pigments, polymer derivatives of the amino acid tyrosine, are over-expressed in approximately 40% of melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ioflubenzamide I-131","termGroup":"PT","termSource":"NCI"},{"termName":"Ioflubenzamide (131I)","termGroup":"SY","termSource":"NCI"},{"termName":"MIP-1145","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-((sup 131)I)iodo-2-methoxybenzamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1214283-52-9"},{"name":"Chemical_Formula","value":"C21H25FIN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65O1D58Z6V"},{"name":"Legacy Concept Name","value":"Iodine_I_131_MIP-1145"},{"name":"Maps_To","value":"Ioflubenzamide I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"615097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615097"},{"name":"PDQ_Open_Trial_Search_ID","value":"615097"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934646"}]}}{"C596":{"preferredName":"Ionomycin","code":"C596","definitions":[{"definition":"A polyether antibiotic isolated from Streptomyces conglobatus sp. nov. Trejo with antineoplastic activity.  Ionomycin is a calcium ionophore that increases intracellular Ca++ levels, possibly relating to endonuclease activation of lymphocytes and decreased ratio of Bcl-2 to Bax and ultimately apoptosis.  In addition, this agent is used to investigate the role of intracellular calcium in cellular processes. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ionomycin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56092-81-0"},{"name":"CHEBI_ID","value":"CHEBI:63954"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54V905V6AT"},{"name":"Legacy Concept Name","value":"Ionomycin"},{"name":"Maps_To","value":"Ionomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"43046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43046"},{"name":"PDQ_Open_Trial_Search_ID","value":"43046"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0022020"}]}}{"C102565":{"preferredName":"Ipafricept","code":"C102565","definitions":[{"definition":"A proprietary fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with potential antineoplastic activity. Upon intravenous administration, ipafricept competes with the membrane-bound Fzd8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling. This may result in the inhibition of Wnt-driven tumor growth. Fzd8, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipafricept","termGroup":"PT","termSource":"NCI"},{"termName":"Fusion Protein For Immune Applications (fpia) Comprising Homo Sapiens FZD8 (Frizzled Family Receptor 8, Frizzled-8) Extracellular Domain, Fused With Homo Sapiens Immunoglobulin G1 Fc Fragment","termGroup":"SY","termSource":"NCI"},{"termName":"Fzd8-Fc","termGroup":"CN","termSource":"NCI"},{"termName":"OMP 54F28","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-54F28","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1391727-24-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2N71QUE3NL"},{"name":"Maps_To","value":"Ipafricept"},{"name":"NCI_Drug_Dictionary_ID","value":"734935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734935"},{"name":"PDQ_Open_Trial_Search_ID","value":"734935"},{"name":"PubMedID_Primary_Reference","value":"17545618"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4049114"}]}}{"C91072":{"preferredName":"Ipatasertib","code":"C91072","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipatasertib","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one","termGroup":"SN","termSource":"NCI"},{"termName":"GDC-0068","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7440","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1001264-89-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"524Y3IB4HQ"},{"name":"Maps_To","value":"Ipatasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"669600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"669600"},{"name":"PDQ_Open_Trial_Search_ID","value":"669600"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984014"}]}}{"C2654":{"preferredName":"Ipilimumab","code":"C2654","definitions":[{"definition":"A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipilimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-734016","termGroup":"CN","termSource":"NCI"},{"termName":"Ipilimumab Biosimilar CS1002","termGroup":"SY","termSource":"NCI"},{"termName":"MDX-010","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-CTLA4","termGroup":"AB","termSource":"NCI"},{"termName":"Yervoy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Unresectable or Metastatic Melanoma"},{"name":"CAS_Registry","value":"477202-00-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6T8C155666"},{"name":"Legacy Concept Name","value":"Anti-Cytotoxic_T-Lymphocyte-Associated_Antigen-4_Monoclonal_Antibody"},{"name":"Maps_To","value":"Ipilimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38447"},{"name":"NSC Number","value":"720801"},{"name":"NSC Number","value":"732442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38447"},{"name":"PDQ_Open_Trial_Search_ID","value":"38447"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1367202"}]}}{"C976":{"preferredName":"Ipomeanol","code":"C976","definitions":[{"definition":"A natural toxic furan isolated from a fungus-infected sweet potato (Ipomoea batatas) with potential antineoplastic activity.  Ipomeanol is activated by mixed function oxidases in vivo to its epoxide form, an alkylating agent that covalently binds cell macromolecules. This agent causes cell death by a p53-independent mechanism. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipomeanol","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-furanyl)-4-hydroxy-1-pentanone","termGroup":"SN","termSource":"NCI"},{"termName":"4-ipomeanol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"32954-58-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"URT1FLO407"},{"name":"Legacy Concept Name","value":"Ipomeanol"},{"name":"Maps_To","value":"Ipomeanol"},{"name":"NCI_Drug_Dictionary_ID","value":"38852"},{"name":"NSC Number","value":"349438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38852"},{"name":"PDQ_Open_Trial_Search_ID","value":"38852"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048420"}]}}{"C1070":{"preferredName":"Iproplatin","code":"C1070","definitions":[{"definition":"A synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death.  Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iproplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(OC-6-33)-dichlorodihydroxybis(2-propanamine)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"CHIP","termGroup":"AB","termSource":"NCI"},{"termName":"Diisopropylammine-trans-dihydroxymalonatoplatinum(IV)","termGroup":"SN","termSource":"NCI"},{"termName":"JM-9","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62928-11-4"},{"name":"CAS_Registry","value":"83291-20-7"},{"name":"Chemical_Formula","value":"2C3H9N.2Cl.Pt.2HO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5R9F9NE9Z2"},{"name":"Legacy Concept Name","value":"Iproplatin"},{"name":"Maps_To","value":"Iproplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39183"},{"name":"NSC Number","value":"256927"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39183"},{"name":"PDQ_Open_Trial_Search_ID","value":"39183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057856"}]}}{"C164140":{"preferredName":"iPSC-derived CD16-expressing Natural Killer Cells FT516","code":"C164140","definitions":[{"definition":"An allogeneic, off-the-shelf, natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived CD16-expressing NK cells FT516 bind to the Fc portion of tumor cell-bound monoclonal antibodies and activate NK cell activation, cytokine secretion and antibody-dependent cellular cytotoxicity (ADCC). CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response. FT516 NK cells' hnCD16 Fc receptor prevents downregulation and optimizes binding to tumor-targeting antibodies for enhanced ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iPSC-derived CD16-expressing Natural Killer Cells FT516","termGroup":"PT","termSource":"NCI"},{"termName":"FT 516","termGroup":"CN","termSource":"NCI"},{"termName":"FT-516","termGroup":"CN","termSource":"NCI"},{"termName":"FT516","termGroup":"CN","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived CD16-expressing Natural Killer Cells FT516","termGroup":"SY","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived CD16-expressing NK Cells FT516","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3NBZ936ONT"},{"name":"Maps_To","value":"iPSC-derived CD16-expressing Natural Killer Cells FT516"},{"name":"NCI_Drug_Dictionary_ID","value":"799446"},{"name":"NCI_META_CUI","value":"CL977336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799446"},{"name":"PDQ_Open_Trial_Search_ID","value":"799446"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158438":{"preferredName":"iPSC-derived Natural Killer Cells FT500","code":"C158438","definitions":[{"definition":"A preparation of off-the-shelf, natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived natural killer cells FT500 bind to stress-induced ligands on tumor cells, leading to tumor cell lysis and release of tumor neoantigens. Additionally, iPSC-NK cells secrete inflammatory cytokines and chemokines including interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokines 3, 4, and 22 (CCL3, CCL4, and CCL22), and C-X-C motif chemokine 10 (CXCL10), thereby enhancing T-cell activity and recruitment to the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iPSC-derived Natural Killer Cells FT500","termGroup":"PT","termSource":"NCI"},{"termName":"FT 500","termGroup":"CN","termSource":"NCI"},{"termName":"FT-500","termGroup":"CN","termSource":"NCI"},{"termName":"FT500","termGroup":"CN","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived Natural Killer Cells FT500","termGroup":"SY","termSource":"NCI"},{"termName":"iPSC-derived NK Cells FT500","termGroup":"SY","termSource":"NCI"},{"termName":"iPSC-NK Cells FT500","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"iPSC-derived Natural Killer Cells FT500"},{"name":"NCI_Drug_Dictionary_ID","value":"801298"},{"name":"NCI_META_CUI","value":"CL937880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801298"},{"name":"PDQ_Open_Trial_Search_ID","value":"801298"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148455":{"preferredName":"Emavusertib","code":"C148455","definitions":[{"definition":"An orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential antineoplastic, immunomodulating and anti-inflammatory activities. Upon oral administration, emavusertib targets, binds to, and blocks the kinase activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. In addition, CA-4948 may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emavusertib","termGroup":"PT","termSource":"NCI"},{"termName":"AU 4948","termGroup":"CN","termSource":"NCI"},{"termName":"AU-4948","termGroup":"CN","termSource":"NCI"},{"termName":"CA 4948","termGroup":"CN","termSource":"NCI"},{"termName":"CA-4948","termGroup":"CN","termSource":"NCI"},{"termName":"CA4948","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948","termGroup":"SY","termSource":"NCI"},{"termName":"IRAK4 Inhibitor CA-4948","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801343-74-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MH5DMF9JKY"},{"name":"Maps_To","value":"IRAK4 Inhibitor CA-4948"},{"name":"NCI_Drug_Dictionary_ID","value":"794871"},{"name":"NCI_META_CUI","value":"CL551081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794871"},{"name":"PDQ_Open_Trial_Search_ID","value":"794871"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26441":{"preferredName":"Iratumumab","code":"C26441","definitions":[{"definition":"A fully human monoclonal antibody with potential antineoplastic activity.  MDX-060 is a fully humanized antibody that targets CD30, a member of the tumor necrosis factor receptor superfamily found on activated lymphocytes.  CD30 is over-expressed in various lymphoproliferative disorders, Hodgkin disease and other lymphomas, and other cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some lymphomas. Monoclonal antibodies are produced in the laboratory and can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iratumumab","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-060","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody MDX-060","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"640735-09-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AYH22O1B1U"},{"name":"Legacy Concept Name","value":"MDX-060_Monoclonal_Antibody"},{"name":"Maps_To","value":"Iratumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"301900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301900"},{"name":"PDQ_Open_Trial_Search_ID","value":"301900"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327954"}]}}{"C104270":{"preferredName":"Iridium Ir 192","code":"C104270","definitions":[{"definition":"A radioactive isotope of iridium. Iridium-192 emits gamma rays and has a half-life of 74 days. A high dose rate of this radioisotope can be used in brachytherapy to treat tumors by selectively delivering a cytotoxic dose of radiation to the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iridium Ir 192","termGroup":"PT","termSource":"NCI"},{"termName":"Ir-192","termGroup":"AB","termSource":"NCI"},{"termName":"Iridium-192","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"14694-69-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"064LI0IBFL"},{"name":"Maps_To","value":"Iridium Ir 192"},{"name":"NCI_Drug_Dictionary_ID","value":"744818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744818"},{"name":"PDQ_Open_Trial_Search_ID","value":"744818"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C0303472"}]}}{"C62040":{"preferredName":"Irinotecan","code":"C62040","definitions":[{"definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Irinotecan","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"[1,4'-bipiperidine]-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97682-44-5"},{"name":"Chemical_Formula","value":"C33H38N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7673326042"},{"name":"Legacy Concept Name","value":"Irinotecan_Base"},{"name":"Maps_To","value":"Irinotecan"},{"name":"NSC Number","value":"616348"},{"name":"NSC Number","value":"728073"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0123931"}]}}{"C1381":{"preferredName":"Irinotecan Hydrochloride","code":"C1381","definitions":[{"definition":"A drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Camptosar blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Campto","termGroup":"FB","termSource":"NCI"},{"termName":"Camptosar","termGroup":"BR","termSource":"NCI"},{"termName":"Camptothecin-11","termGroup":"SY","termSource":"NCI"},{"termName":"CPT-11","termGroup":"CN","termSource":"NCI"},{"termName":"Irinomedac","termGroup":"FB","termSource":"NCI"},{"termName":"Irinotecan Hydrochloride Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Monohydrochloride Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"U-101440E","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"State IVB Cervical cancer; Colorectal cancer; Esophageal cancer; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer"},{"name":"CAS_Registry","value":"136572-09-3"},{"name":"Chemical_Formula","value":"C33H38N4O6.HCl.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"042LAQ1IIS"},{"name":"Legacy Concept Name","value":"Irinotecan"},{"name":"Maps_To","value":"Irinotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41714"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41714"},{"name":"PDQ_Open_Trial_Search_ID","value":"41714"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0594375"}]}}{"C82682":{"preferredName":"Irinotecan-Eluting Beads","code":"C82682","definitions":[{"definition":"Microporous hydrospheres of polyvinylalcohol (PVA) impregnated with irinotecan with potential antineoplastic activity. In transarterial chemoembolization (TACE), irinotecan-eluting beads are administered into blood vessels that feed the tumor, occluding tumor blood vessels and inducing ischemic tumor necrosis while simultaneously delivering high-dose chemotherapy locally. Irinotecan, a semisynthetic derivative of camptothecin, inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan-Eluting Beads","termGroup":"PT","termSource":"NCI"},{"termName":"CM-BC2","termGroup":"CN","termSource":"NCI"},{"termName":"Irinotecan Hydrochloride Drug-eluting Beads","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Irinotecan-Eluting_Beads"},{"name":"Maps_To","value":"Irinotecan-Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"632992"},{"name":"NCI_META_CUI","value":"CL388467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632992"},{"name":"PDQ_Open_Trial_Search_ID","value":"632992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88280":{"preferredName":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet","code":"C88280","definitions":[{"definition":"An orally bioavailable combination tablet containing the semisynthetic camptothecin derivative irinotecan and the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181AK, with potential antineoplastic activity. HM30181A binds to P-gp and prevents the P-gp-mediated efflux of irinotecan from tumor cells, which may result in greater intracellular concentrations of irinotecan and enhanced cytotoxicity. Retained intracellularly, the prodrug irinotecan is converted, by a carboxylesterase-converting enzyme, to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38). SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters and is overexpressed by some MDR tumors, preventing the intracellular accumulation of various cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet","termGroup":"PT","termSource":"NCI"},{"termName":"Oratecan","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet"},{"name":"NCI_Drug_Dictionary_ID","value":"656527"},{"name":"NCI_META_CUI","value":"CL412470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656527"},{"name":"PDQ_Open_Trial_Search_ID","value":"656527"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1717":{"preferredName":"Irofulven","code":"C1717","definitions":[{"definition":"A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. Irofulven attaches to the cell's DNA and may block cancer cell growth. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Irofulven","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"6-Hydroxymethylacylfulvene","termGroup":"SY","termSource":"NCI"},{"termName":"HMAF","termGroup":"AB","termSource":"NCI"},{"termName":"Hydroxymethylacylfulvene","termGroup":"SY","termSource":"NCI"},{"termName":"MGI 114","termGroup":"CN","termSource":"NCI"},{"termName":"MGI-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"158440-71-2"},{"name":"Chemical_Formula","value":"C15H18O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6B799IH05A"},{"name":"Legacy Concept Name","value":"Irofulven"},{"name":"Maps_To","value":"Irofulven"},{"name":"NCI_Drug_Dictionary_ID","value":"43097"},{"name":"NSC Number","value":"683863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43097"},{"name":"PDQ_Open_Trial_Search_ID","value":"43097"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0532362"}]}}{"C79827":{"preferredName":"Irosustat","code":"C79827","definitions":[{"definition":"Steroid sulfatase inhibitor BN 83495 selectively binds to and inhibits steroid sulfatase (STS), which may inhibit the production of locally active estrogens and so inhibit estrogen-dependent cell growth in tumor cells, such as those of the breast, ovary, and endometrium. STS is a cytoplasmic enzyme responsible for the conversion of circulating inactive estrone sulfate and estradiol sulfate to biologically active unconjugated estrone and estradiol, respectively.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irosustat","termGroup":"PT","termSource":"NCI"},{"termName":"667 Coumate","termGroup":"SY","termSource":"NCI"},{"termName":"BN83495","termGroup":"CN","termSource":"NCI"},{"termName":"Steroid Sulfatase Inhibitor BN 83495","termGroup":"SY","termSource":"NCI"},{"termName":"STX 64","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"288628-05-7"},{"name":"Chemical_Formula","value":"C14H15NO5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"366037O6O7"},{"name":"Legacy Concept Name","value":"Steroid_Sulfatase_Inhibitor_BN_83495"},{"name":"Maps_To","value":"Irosustat"},{"name":"NCI_Drug_Dictionary_ID","value":"626715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626715"},{"name":"PDQ_Open_Trial_Search_ID","value":"626715"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853843"}]}}{"C90578":{"preferredName":"Isatuximab","code":"C90578","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isatuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Hu 38SB19","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human CD38 Antigen) (Human-mus musculus Monoclonal HU38SB19 Heavy Chain), Disulfide with Human-mus musculus Monoclonal HU38SB19 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Isatuximab-irfc","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 650984","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-650984","termGroup":"CN","termSource":"NCI"},{"termName":"SAR650984","termGroup":"CN","termSource":"NCI"},{"termName":"Sarclisa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1461640-62-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R30772KCU0"},{"name":"Maps_To","value":"Isatuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"668181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"668181"},{"name":"PDQ_Open_Trial_Search_ID","value":"668181"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983777"}]}}{"C97332":{"preferredName":"Iso-fludelone","code":"C97332","definitions":[{"definition":"A third-generation epothilone B analogue with potential anti-mitotic and antineoplastic activites. Iso-fludelone binds to tubulin and induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to other generations of epothilones, iso-fludelone exhibits increased stability, water solubility, potency, duration of action, tumor penetration as well as reduced toxicity. In addition, this agent is a not a substrate of the P-glycoprotein (P-gp), a multidrug resistance pump often overexpressed in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iso-fludelone","termGroup":"PT","termSource":"NCI"},{"termName":"17-Iso-oxazole-26-F3-9,10-dehydro-12,13-desoxy-epothilone B","termGroup":"SN","termSource":"NCI"},{"termName":"17-Iso-oxazole-fludelone","termGroup":"SY","termSource":"NCI"},{"termName":"KOS-1803","termGroup":"CN","termSource":"NCI"},{"termName":"KOSN-1724","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"693272-98-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6MUO20693U"},{"name":"Maps_To","value":"Iso-fludelone"},{"name":"NCI_Drug_Dictionary_ID","value":"703135"},{"name":"NCI_META_CUI","value":"CL429824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703135"},{"name":"PDQ_Open_Trial_Search_ID","value":"703135"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1774":{"preferredName":"Isobrucein B","code":"C1774","definitions":[{"definition":"A quassinoid phytochemical isolated from the tropical plant Cedronia granatensis with potential antineoplastic and chemopreventive activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isobrucein B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53663-03-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isobrucein_B"},{"name":"Maps_To","value":"Isobrucein B"},{"name":"NSC Number","value":"238181"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0653458"}]}}{"C1888":{"preferredName":"Isocoumarin NM-3","code":"C1888","definitions":[{"definition":"An orally bioavailable antiangiogenic isocoumarin with potential antineoplastic activity.  NM-3 inhibits vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor, thereby inhibiting endothelial cell proliferation.  This agent also induces apoptosis by a mechanism involving reactive oxygen species. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isocoumarin NM-3","termGroup":"PT","termSource":"NCI"},{"termName":"NM-3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"181427-78-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5797K23F95"},{"name":"Legacy Concept Name","value":"NM-3"},{"name":"Maps_To","value":"Isocoumarin NM-3"},{"name":"NCI_Drug_Dictionary_ID","value":"355804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355804"},{"name":"PDQ_Open_Trial_Search_ID","value":"355804"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122058"}]}}{"C603":{"preferredName":"Isotretinoin","code":"C603","definitions":[{"definition":"A drug that is used in the treatment of acne and psoriasis and is being studied in cancer prevention. It is a type of retinoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isotretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"13-cis-Retinoate","termGroup":"SY","termSource":"NCI"},{"termName":"13-cis-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"13-cis-Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"13-cRA","termGroup":"AB","termSource":"NCI"},{"termName":"3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Absorica","termGroup":"BR","termSource":"NCI"},{"termName":"Accure","termGroup":"FB","termSource":"NCI"},{"termName":"Accutane","termGroup":"BR","termSource":"NCI"},{"termName":"Amnesteem","termGroup":"BR","termSource":"NCI"},{"termName":"cis-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Cistane","termGroup":"BR","termSource":"NCI"},{"termName":"Claravis","termGroup":"BR","termSource":"NCI"},{"termName":"Isotretinoinum","termGroup":"SY","termSource":"NCI"},{"termName":"Isotrex","termGroup":"FB","termSource":"NCI"},{"termName":"Isotrexin","termGroup":"FB","termSource":"NCI"},{"termName":"Myorisan","termGroup":"BR","termSource":"NCI"},{"termName":"Neovitamin A","termGroup":"SY","termSource":"NCI"},{"termName":"Neovitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Oratane","termGroup":"FB","termSource":"NCI"},{"termName":"Retinoicacid-13-cis","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 4-3780","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-4-3780","termGroup":"CN","termSource":"NCI"},{"termName":"Roaccutan","termGroup":"FB","termSource":"NCI"},{"termName":"Roaccutane","termGroup":"FB","termSource":"NCI"},{"termName":"Roacutan","termGroup":"FB","termSource":"NCI"},{"termName":"Sotret","termGroup":"BR","termSource":"NCI"},{"termName":"ZENATANE","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Severe recalcitrant nodular acne; psoriasis; cornification disorders; cutaneous T-cell lymphoma; juvenile metastatic neuroblastoma and leukemia"},{"name":"CAS_Registry","value":"4759-48-2"},{"name":"CHEBI_ID","value":"CHEBI:6067"},{"name":"Chemical_Formula","value":"C20H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"EH28UP18IF"},{"name":"Legacy Concept Name","value":"Isotretinoin"},{"name":"Maps_To","value":"Isotretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"42657"},{"name":"NSC Number","value":"329481"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42657"},{"name":"PDQ_Open_Trial_Search_ID","value":"42657"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0022265"}]}}{"C38131":{"preferredName":"Ispinesib","code":"C38131","definitions":[{"definition":"A substance being studied in the treatment of cancer. Ispinesib blocks a protein that tumor cells need to divide. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ispinesib","termGroup":"PT","termSource":"NCI"},{"termName":"CK0238273","termGroup":"CN","termSource":"NCI"},{"termName":"SB-715992","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"336113-53-2"},{"name":"Chemical_Formula","value":"C30H33ClN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BKT5F9C2NI"},{"name":"Legacy Concept Name","value":"SB-715992"},{"name":"Maps_To","value":"Ispinesib"},{"name":"NCI_Drug_Dictionary_ID","value":"391236"},{"name":"NSC Number","value":"727990"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391236"},{"name":"PDQ_Open_Trial_Search_ID","value":"391236"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527260"}]}}{"C77518":{"preferredName":"Ispinesib Mesylate","code":"C77518","definitions":[{"definition":"The mesylate salt form of ispinesib, a synthetic small molecule, derived from quinazolinone, and kinesin spindle protein (KSP) inhibitor, with antineoplastic activity. Ispinesib selectively inhibits KSP and prevents its binding to microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the M-phase, and cell death in tumor cells that are actively dividing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ispinesib Mesylate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"514820-03-2"},{"name":"Chemical_Formula","value":"C30H33ClN4O2.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6ZMD4UH3D"},{"name":"Legacy Concept Name","value":"Ispinesib_Mesylate"},{"name":"Maps_To","value":"Ispinesib Mesylate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697824"}]}}{"C61080":{"preferredName":"ISS 1018 CpG Oligodeoxynucleotide","code":"C61080","definitions":[{"definition":"A short, synthetic, unmethylated CpG motif-based oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. As an immunostimulatory sequence (ISS) that signals through Toll-like receptor 9 (TLR9), ISS 1018 CpG ODN induces the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin (IL) -12, and tumor necrosis factor (TNF) -alpha by plasmacytoid dendritic cells (pDC). pDC, through cell-cell contact, and IFN-alpha and -beta, in turn, induce natural killer (NK) cell proliferation, NK cell production of IFN-gamma, and NK cell-mediated cytotoxicity; secreted IFNs also stimulate bystander T cell activation and differentiation of naive CD4+ T cells into T-helper 1 cells on specific antigen challenge. In addition, ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS 1018 CpG Oligodeoxynucleotide","termGroup":"PT","termSource":"NCI"},{"termName":"1018 ISS","termGroup":"SY","termSource":"NCI"},{"termName":"CPG 1018","termGroup":"CN","termSource":"NCI"},{"termName":"DNA, D(P-THIO)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"937402-51-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25DT549L0G"},{"name":"Legacy Concept Name","value":"ISS1018_Oligodeoxynucleotide"},{"name":"Maps_To","value":"ISS 1018 CpG Oligodeoxynucleotide"},{"name":"NCI_Drug_Dictionary_ID","value":"474964"},{"name":"PDQ_Closed_Trial_Search_ID","value":"474964"},{"name":"PDQ_Open_Trial_Search_ID","value":"474964"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506199"}]}}{"C116855":{"preferredName":"Itacitinib","code":"C116855","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itacitinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Azetidineacetonitrile, 1-(1-((3-Fluoro-2-(trifluoromethyl)-4-pyridinyl)carbonyl)-4-piperidinyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 039110","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-039110","termGroup":"CN","termSource":"NCI"},{"termName":"INCB039110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1334298-90-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19J3781LPM"},{"name":"Maps_To","value":"Itacitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"740328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740328"},{"name":"PDQ_Open_Trial_Search_ID","value":"740328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896836"}]}}{"C158906":{"preferredName":"Itacitinib Adipate","code":"C158906","definitions":[{"definition":"The adipate salt form of itacitinib, an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itacitinib Adipate","termGroup":"PT","termSource":"NCI"},{"termName":"INCB-039110 Adipate","termGroup":"SY","termSource":"NCI"},{"termName":"INCB039110 Adipate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1334302-63-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XZG407XE0Y"},{"name":"Maps_To","value":"Itacitinib Adipate"},{"name":"NCI_Drug_Dictionary_ID","value":"740328"},{"name":"NCI_META_CUI","value":"CL950797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740328"},{"name":"PDQ_Open_Trial_Search_ID","value":"740328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162010":{"preferredName":"Soquelitinib","code":"C162010","definitions":[{"definition":"An orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) with potential immunomodulatory and antineoplastic activities. Upon oral administration, soquelitinib selectively and covalently binds to the cysteine residue at position 442 (CYS-442) of ITK, thereby disrupting ITK-mediated signal transduction, while sparing tyrosine-protein kinase TXK (resting lymphocyte kinase, RLK) activity. This may abrogate T-cell receptor (TCR) signaling through ITK and inhibit TCR-induced proliferation of malignant T-cells. Additionally, inhibiting ITK activation may prevent the upregulation of GATA-3, a transcription factor that drives T-helper 2 (Th2) cell differentiation and is overexpressed in certain T-cell lymphomas. Thus, selective inhibition of ITK may inhibit Th2 responses without affecting T-helper 1 (Th1)-dependent immunity. ITK, a member of the Tec family of non-receptor protein tyrosine kinases plays a significant role in the T-cell development, differentiation and production of pro-inflammatory cytokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soquelitinib","termGroup":"PT","termSource":"NCI"},{"termName":"CPI 818","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-818","termGroup":"CN","termSource":"NCI"},{"termName":"CPI818","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-2 Inducible T-cell Kinase Inhibitor CPI-818","termGroup":"SY","termSource":"NCI"},{"termName":"ITK Inhibitor CPI-818","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226636-04-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6I5H17AN3I"},{"name":"Maps_To","value":"ITK Inhibitor CPI-818"},{"name":"NCI_Drug_Dictionary_ID","value":"798593"},{"name":"NCI_META_CUI","value":"CL970662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798593"},{"name":"PDQ_Open_Trial_Search_ID","value":"798593"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1138":{"preferredName":"Itraconazole","code":"C1138","definitions":[{"definition":"A drug used to prevent or treat fungal infections.  It belongs to the family of drugs called antifungal agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itraconazole","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one","termGroup":"SN","termSource":"NCI"},{"termName":"Lozanoc","termGroup":"FB","termSource":"NCI"},{"termName":"Oriconazole","termGroup":"SY","termSource":"NCI"},{"termName":"R 51,211","termGroup":"CN","termSource":"NCI"},{"termName":"Sporanox","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Fungal Infections"},{"name":"CAS_Registry","value":"84625-61-6"},{"name":"CHEBI_ID","value":"CHEBI:6076"},{"name":"Chemical_Formula","value":"C35H38Cl2N8O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"304NUG5GF4"},{"name":"Legacy Concept Name","value":"Itraconazole"},{"name":"Maps_To","value":"Itraconazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39106"},{"name":"PDQ_Open_Trial_Search_ID","value":"39106"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064113"}]}}{"C104048":{"preferredName":"Itraconazole Dispersion In Polymer Matrix","code":"C104048","definitions":[{"definition":"A proprietary oral formulation composed of the poorly soluble, synthetic triazole agent, itraconazole, dispersed in a polymer matrix, with antifungal and potential anti-angiogenic activities. Upon oral administration, itraconazole inhibits the enzyme cytochrome P450 lanosterol 14 alpha-demethylase, resulting in a decrease in fungal ergosterol synthesis. Although the exact mechanism through which itraconazole inhibits angiogenesis has yet to be fully elucidated, this agent appears to inhibit the Hedgehog (Hh) signaling pathway, cholesterol synthesis and mammalian target of rapamycin (mTOR) signaling in endothelial cells. This agent may also prevent the activation of and signaling by various angiogenic growth factors. By decreasing the tumor vasculature and nutrient supply, itraconazole ultimately inhibits tumor cell growth. The solid dispersion of itraconazole in the polymer matrix enhances dissolution of itraconazole in the gastrointestinal tract and increases its bioavailability; this allows for the administration of a much lower dose compared to itraconazole alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itraconazole Dispersion In Polymer Matrix","termGroup":"PT","termSource":"NCI"},{"termName":"SUBA-Itraconazole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Itraconazole Dispersion In Polymer Matrix"},{"name":"NCI_Drug_Dictionary_ID","value":"744267"},{"name":"NCI_META_CUI","value":"CL439067"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744267"},{"name":"PDQ_Open_Trial_Search_ID","value":"744267"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114383":{"preferredName":"Ivosidenib","code":"C114383","definitions":[{"definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivosidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AG-120","termGroup":"CN","termSource":"NCI"},{"termName":"Tibsovo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation"},{"name":"CAS_Registry","value":"1448347-49-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q2PCN8MAM6"},{"name":"Maps_To","value":"Ivosidenib"},{"name":"NCI_Drug_Dictionary_ID","value":"758551"},{"name":"NCI_META_CUI","value":"CL471818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758551"},{"name":"PDQ_Open_Trial_Search_ID","value":"758551"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C37452":{"preferredName":"Ixabepilone","code":"C37452","definitions":[{"definition":"A drug used to treat metastatic or locally advanced breast cancer that has not improved after treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Ixempra stops the growth of tumor cells by blocking cell division. It is a type of epothilone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ixabepilone","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Azaepothilone B","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 247550","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-247550","termGroup":"CN","termSource":"NCI"},{"termName":"BMS247550","termGroup":"CN","termSource":"NCI"},{"termName":"Epothilone","termGroup":"SY","termSource":"NCI"},{"termName":"Epothilone-B BMS 247550","termGroup":"SY","termSource":"NCI"},{"termName":"Ixempra","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic or locally advanced breast cancer."},{"name":"CAS_Registry","value":"219989-84-1"},{"name":"CHEBI_ID","value":"CHEBI:63605"},{"name":"Chemical_Formula","value":"C27H42N2O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K27005NP0A"},{"name":"Legacy Concept Name","value":"Ixabepilone"},{"name":"Maps_To","value":"Ixabepilone"},{"name":"NCI_Drug_Dictionary_ID","value":"37860"},{"name":"NSC Number","value":"710428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37860"},{"name":"PDQ_Open_Trial_Search_ID","value":"37860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1135132"}]}}{"C97940":{"preferredName":"Ixazomib","code":"C97940","definitions":[{"definition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ixazomib","termGroup":"PT","termSource":"NCI"},{"termName":"MLN-2238","termGroup":"CN","termSource":"NCI"},{"termName":"MLN2238","termGroup":"CN","termSource":"NCI"},{"termName":"{(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1072833-77-2"},{"name":"Chemical_Formula","value":"C14H19BCl2N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"71050168A2"},{"name":"Maps_To","value":"Ixazomib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467949"}]}}{"C82653":{"preferredName":"Ixazomib Citrate","code":"C82653","definitions":[{"definition":"The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ixazomib Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,2-dioxaborinane-4-acetic acid, 4-carboxy-2-((1r)-1-((2-((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl)-6-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"MLN-9708","termGroup":"CN","termSource":"NCI"},{"termName":"MLN9708","termGroup":"CN","termSource":"NCI"},{"termName":"Ninlaro","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma (MM)"},{"name":"CAS_Registry","value":"1239908-20-3"},{"name":"Chemical_Formula","value":"C20H23BCl2N2O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46CWK97Z3K"},{"name":"Legacy Concept Name","value":"Proteasome_Inhibitor_MLN9708"},{"name":"Maps_To","value":"Ixazomib Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"635527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"635527"},{"name":"PDQ_Open_Trial_Search_ID","value":"635527"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830202"}]}}{"C111761":{"preferredName":"JAK Inhibitor INCB047986","code":"C111761","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinases (JAK), with potential antineoplastic activity. Upon oral administration, INCB047986 specifically binds to and inhibits the phosphorylation of JAK, which affects JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK Inhibitor INCB047986","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 047986","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-047986","termGroup":"CN","termSource":"NCI"},{"termName":"INCB047986","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JAK Inhibitor INCB047986"},{"name":"NCI_Drug_Dictionary_ID","value":"753081"},{"name":"NCI_META_CUI","value":"CL454148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753081"},{"name":"PDQ_Open_Trial_Search_ID","value":"753081"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156774":{"preferredName":"Golidocitinib","code":"C156774","definitions":[{"definition":"An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golidocitinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 4205","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-4205","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4205","termGroup":"CN","termSource":"NCI"},{"termName":"JAK1 Inhibitor AZD4205","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2091134-68-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3BY9Z3M34G"},{"name":"Maps_To","value":"JAK1 Inhibitor AZD4205"},{"name":"NCI_Drug_Dictionary_ID","value":"795786"},{"name":"NCI_META_CUI","value":"CL935810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795786"},{"name":"PDQ_Open_Trial_Search_ID","value":"795786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118629":{"preferredName":"JAK1 Inhibitor INCB052793","code":"C118629","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, INCB052793 specifically binds to and inhibits the phosphorylation of JAK1, which interferes with JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK1 Inhibitor INCB052793","termGroup":"PT","termSource":"NCI"},{"termName":"INCB052793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JAK1 Inhibitor INCB052793"},{"name":"NCI_Drug_Dictionary_ID","value":"765639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765639"},{"name":"PDQ_Open_Trial_Search_ID","value":"765639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896740"}]}}{"C91394":{"preferredName":"JAK2 Inhibitor AZD1480","code":"C91394","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Inhibitor AZD1480","termGroup":"PT","termSource":"NCI"},{"termName":"AZD1480","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"935666-88-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KL2Z2TLF01"},{"name":"Maps_To","value":"JAK2 Inhibitor AZD1480"},{"name":"NCI_Drug_Dictionary_ID","value":"672901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672901"},{"name":"PDQ_Open_Trial_Search_ID","value":"672901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2745423"}]}}{"C95702":{"preferredName":"JAK2 Inhibitor BMS-911543","code":"C95702","definitions":[{"definition":"An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS-911543 selectively inhibits JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Inhibitor BMS-911543","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 911543","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-911543","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1271022-90-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7N03P021J8"},{"name":"Maps_To","value":"JAK2 Inhibitor BMS-911543"},{"name":"NCI_Drug_Dictionary_ID","value":"689517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689517"},{"name":"PDQ_Open_Trial_Search_ID","value":"689517"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987343"}]}}{"C90573":{"preferredName":"JAK2 Inhibitor XL019","code":"C90573","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. XL019 inhibits the activation of JAK2 as well as the mutated form JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and may induce apoptosis. The JAK2 mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Inhibitor XL019","termGroup":"PT","termSource":"NCI"},{"termName":"XL019","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945755-56-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4L1AM42NVA"},{"name":"Maps_To","value":"JAK2 Inhibitor XL019"},{"name":"NCI_Drug_Dictionary_ID","value":"667451"},{"name":"NCI_META_CUI","value":"CL416257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"667451"},{"name":"PDQ_Open_Trial_Search_ID","value":"667451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98109":{"preferredName":"Ilginatinib","code":"C98109","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. Ilginatinib competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, ilginatinib inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs); JAK2V617F is a constitutively activated kinase that activates the JAK/STAT signaling pathway and dysregulates cell growth and function, and its expression transforms hematopoietic cells to cytokine-independent growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ilginatinib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-","termGroup":"SN","termSource":"NCI"},{"termName":"NS-018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1239358-86-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56R994WX4L"},{"name":"Maps_To","value":"Ilginatinib"},{"name":"Maps_To","value":"JAK2/Src Inhibitor NS-018"},{"name":"NCI_Drug_Dictionary_ID","value":"710644"},{"name":"NCI_META_CUI","value":"CL430628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710644"},{"name":"PDQ_Open_Trial_Search_ID","value":"710644"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61316":{"preferredName":"Jin Fu Kang","code":"C61316","definitions":[{"definition":"A traditional Chinese herbal medicine derived from the plant Astragalus membranaceus with potential immunopotentiation activity. Jin Fu Kang may stimulate anti-tumor macrophage and natural killer cell activity and may enhance immune recognition of tumor cells by inhibiting the production of T-helper cell type 2 (Th2) cytokines such as interleukin-4 (IL-4) and interleukin-10 (IL-10).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Jin Fu Kang","termGroup":"PT","termSource":"NCI"},{"termName":"Jinfukang","termGroup":"SY","termSource":"NCI"},{"termName":"Jinfukang Koufuye","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jin_Fu_Kang"},{"name":"Maps_To","value":"Jin Fu Kang"},{"name":"NCI_Drug_Dictionary_ID","value":"484642"},{"name":"PDQ_Closed_Trial_Search_ID","value":"484642"},{"name":"PDQ_Open_Trial_Search_ID","value":"484642"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831812"}]}}{"C49095":{"preferredName":"JNK Inhibitor CC-401","code":"C49095","definitions":[{"definition":"A second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. Based on the chemistry of SP600125, another anthrapyrazolone inhibitor of JNK, CC-401 competitively binds the ATP binding site of JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of transcription factor c-Jun; decreased transcription activity of c-Jun; and a variety of cellular effects including decreased cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JNK Inhibitor CC-401","termGroup":"PT","termSource":"NCI"},{"termName":"CC-401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"395104-30-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NOE38VQA1W"},{"name":"Legacy Concept Name","value":"CC-401"},{"name":"Maps_To","value":"JNK Inhibitor CC-401"},{"name":"NCI_Drug_Dictionary_ID","value":"453550"},{"name":"NCI_META_CUI","value":"CL937289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453550"},{"name":"PDQ_Open_Trial_Search_ID","value":"453550"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91705":{"preferredName":"Kanglaite","code":"C91705","definitions":[{"definition":"An injectable microemulsion of a purified oil extracted from the seeds of the traditional Chinese medicinal herb Coix lacryma-jobi (Job's tears), with potential antineoplastic activity. Although the exact mechanism of action is unknown, kanglaite exhibits an antineoplastic effect, potentially via interfering with the cell cycle and halting tumor cells in the G2/M phase, which may eventually inhibit mitosis and proliferation of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kanglaite","termGroup":"PT","termSource":"NCI"},{"termName":"Coicis Semen Oil","termGroup":"SY","termSource":"NCI"},{"termName":"KLT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YCB6D9ELEQ"},{"name":"Maps_To","value":"Kanglaite"},{"name":"NCI_Drug_Dictionary_ID","value":"361791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"361791"},{"name":"PDQ_Open_Trial_Search_ID","value":"361791"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1568044"}]}}{"C605":{"preferredName":"Ketoconazole","code":"C605","definitions":[{"definition":"A drug that treats infection caused by a fungus. It is also used as a treatment for prostate cancer because it can block the production of male sex hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ketoconazole","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine","termGroup":"SN","termSource":"NCI"},{"termName":"Fungarest","termGroup":"FB","termSource":"NCI"},{"termName":"Fungoral","termGroup":"FB","termSource":"NCI"},{"termName":"Ketoderm","termGroup":"FB","termSource":"NCI"},{"termName":"Ketoisdin","termGroup":"FB","termSource":"NCI"},{"termName":"Nizoral","termGroup":"BR","termSource":"NCI"},{"termName":"Orifungal M","termGroup":"FB","termSource":"NCI"},{"termName":"Panfungol","termGroup":"FB","termSource":"NCI"},{"termName":"R-41400","termGroup":"CN","termSource":"NCI"},{"termName":"Xolegel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Seborrheic Dermatitis; Prostate cancer"},{"name":"CAS_Registry","value":"65277-42-1"},{"name":"CHEBI_ID","value":"CHEBI:47519"},{"name":"Chemical_Formula","value":"C26H28Cl2N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"R9400W927I"},{"name":"Legacy Concept Name","value":"Ketoconazole"},{"name":"Maps_To","value":"Ketoconazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39488"},{"name":"NSC Number","value":"317629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39488"},{"name":"PDQ_Open_Trial_Search_ID","value":"39488"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0022625"}]}}{"C77403":{"preferredName":"Ketotrexate","code":"C77403","definitions":[{"definition":"A folic acid antagonist and mammalian dihydrofolate reductase inhibitor with antineoplastic activity. Ketotrexate inhibits dihydrofolate reductase, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid which is essential for the synthesis of purine nucleotides and thymidylate. By depleting tetrahydrofolic acid availability, DNA synthesis is halted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ketotrexate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"877017-93-1"},{"name":"Chemical_Formula","value":"C21H27N7O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"504RN634MM"},{"name":"Legacy Concept Name","value":"Ketotrexate"},{"name":"Maps_To","value":"Ketotrexate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697842"}]}}{"C157493":{"preferredName":"Adagrasib","code":"C157493","definitions":[{"definition":"An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adagrasib","termGroup":"PT","termSource":"NCI"},{"termName":"KRAS G12C Inhibitor MRTX849","termGroup":"SY","termSource":"NCI"},{"termName":"Krazati","termGroup":"BR","termSource":"NCI"},{"termName":"MRTX 849","termGroup":"CN","termSource":"NCI"},{"termName":"MRTX-849","termGroup":"CN","termSource":"NCI"},{"termName":"MRTX849","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)."},{"name":"CAS_Registry","value":"2326521-71-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8EOO6HQF8Y"},{"name":"Maps_To","value":"KRAS G12C Inhibitor MRTX849"},{"name":"NCI_Drug_Dictionary_ID","value":"796791"},{"name":"NCI_META_CUI","value":"CL937069"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796791"},{"name":"PDQ_Open_Trial_Search_ID","value":"796791"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154287":{"preferredName":"Sotorasib","code":"C154287","definitions":[{"definition":"An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotorasib","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 510","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-510","termGroup":"CN","termSource":"NCI"},{"termName":"AMG510","termGroup":"CN","termSource":"NCI"},{"termName":"Lumakras","termGroup":"BR","termSource":"NCI"},{"termName":"Lumykras","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"2296729-00-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2B2VM6UC8G"},{"name":"Maps_To","value":"KRAS Mutant-targeting AMG 510"},{"name":"Maps_To","value":"Sotorasib"},{"name":"NCI_Drug_Dictionary_ID","value":"794411"},{"name":"NCI_META_CUI","value":"CL555284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794411"},{"name":"PDQ_Open_Trial_Search_ID","value":"794411"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164218":{"preferredName":"SHP2 Inhibitor JAB-3312","code":"C164218","definitions":[{"definition":"An orally bioavailable allosteric inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3312 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements, which are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP2 Inhibitor JAB-3312","termGroup":"PT","termSource":"NCI"},{"termName":"JAB 3312","termGroup":"CN","termSource":"NCI"},{"termName":"JAB-3312","termGroup":"CN","termSource":"NCI"},{"termName":"JAB3312","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"KRAS-MAPK Signaling Pathway Inhibitor JAB-3312"},{"name":"NCI_Drug_Dictionary_ID","value":"799443"},{"name":"NCI_META_CUI","value":"CL977520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799443"},{"name":"PDQ_Open_Trial_Search_ID","value":"799443"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1614":{"preferredName":"KRN5500","code":"C1614","definitions":[{"definition":"A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces alanosinicus.  KRN 5500 inhibits protein synthesis by interfering with endoplasmic reticulum and Golgi apparatus functions.  This agent also induces cell differentiation and caspase-dependent apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to a family of drugs called antitumor antibiotics. It is an anthracycline.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"KRN5500","termGroup":"PT","termSource":"NCI"},{"termName":"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-beta-L-mannohepto-pyranosyl]amino-9H-purine","termGroup":"SN","termSource":"NCI"},{"termName":"KRN5500","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151276-95-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8VH13L5K20"},{"name":"Legacy Concept Name","value":"KRN5500"},{"name":"Maps_To","value":"KRN5500"},{"name":"NCI_Drug_Dictionary_ID","value":"42581"},{"name":"NSC Number","value":"650426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42581"},{"name":"PDQ_Open_Trial_Search_ID","value":"42581"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0294829"}]}}{"C64522":{"preferredName":"KSP Inhibitor AZD4877","code":"C64522","definitions":[{"definition":"A synthetic kinesin spindle protein (KSP) inhibitor with potential antineoplastic activity. AZD4877 selectively inhibits microtubule motor protein KSP (also called kinesin-5 or Eg5), which is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis. Inhibition of KSP results in an inhibition of mitotic spindle assembly, activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, thereby causing cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, AZD4877 may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KSP Inhibitor AZD4877","termGroup":"PT","termSource":"NCI"},{"termName":"AZD4877","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1176760-49-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19ORU63E06"},{"name":"Legacy Concept Name","value":"AZD4877"},{"name":"Maps_To","value":"KSP Inhibitor AZD4877"},{"name":"NCI_Drug_Dictionary_ID","value":"522717"},{"name":"PDQ_Closed_Trial_Search_ID","value":"522717"},{"name":"PDQ_Open_Trial_Search_ID","value":"522717"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879525"}]}}{"C52199":{"preferredName":"KSP Inhibitor SB-743921","code":"C52199","definitions":[{"definition":"A synthetic small molecule with potential antineoplastic properties. SB-743921 selectively inhibits kinesin spindle protein (KSP), an important protein involved in the early stages of mitosis that is expressed in proliferating cells. Inhibition of KSP results in inhibition of mitotic spindle assembly and interrupts cell division, thereby causing cell cycle arrest and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KSP Inhibitor SB-743921","termGroup":"PT","termSource":"NCI"},{"termName":"SB 743921","termGroup":"CN","termSource":"NCI"},{"termName":"SB-743921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"618430-39-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"24DSZ1VN92"},{"name":"Legacy Concept Name","value":"SB-743921"},{"name":"Maps_To","value":"KSP Inhibitor SB-743921"},{"name":"NCI_Drug_Dictionary_ID","value":"456262"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456262"},{"name":"PDQ_Open_Trial_Search_ID","value":"456262"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709979"}]}}{"C67049":{"preferredName":"Kunecatechins Ointment","code":"C67049","definitions":[{"definition":"A topical ointment containing a green tea polyphenol mixture (kunecatechins) with potential antiviral, antibacterial, antioxidant, and chemopreventive activities. Kunecatechins is a partially purified fraction of the aqueous extract of green tea leaves from Camellia sinensis and contains catechins and other green tea components. Catechins, polyphenolic antioxidant plant metabolites or flavonoids, comprise most of the drug substance in kunecatechins with epigallocatechin gallate (EGCG) present as the primary catechin. Catechins may inhibit basic functions of human papillomavirus (HPV), counteract specific changes in tumor cells, affect cell signaling, and stimulate the immune system. Topical application of kunecatechins ointment has been reported to reduce HPV-induced genital and anal warts through a not yet fully understood mechanism, which may involve anti-oxidative activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kunecatechins Ointment","termGroup":"PT","termSource":"NCI"},{"termName":"Defined Green Tea Catechin Extract OIntment","termGroup":"SY","termSource":"NCI"},{"termName":"Polyphenon E Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Polyphenon E Topical Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Veregen","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Genital and Perianal Warts"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kunecatechin_Ointment"},{"name":"Maps_To","value":"Kunecatechins Ointment"},{"name":"NCI_Drug_Dictionary_ID","value":"533915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"533915"},{"name":"PDQ_Open_Trial_Search_ID","value":"533915"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1816306"}]}}{"C62178":{"preferredName":"L-Gossypol","code":"C62178","definitions":[{"definition":"The levo-enantiomer of an orally bioavailable polyphenolic aldehyde, derived primarily from unrefined cottonseed oil, with potential antineoplastic activity. Mimicking the inhibitory BH3 (Bcl-2 homology 3) domain of endogenous antagonists of Bcl-2, L-gossypol binds to and inhibits various anti-apoptotic Bcl-2 proteins, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. This agent has greater affinity for Bcl-2 proteins than racemic gossypol.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"L-Gossypol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"90141-22-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"L-Gossypol"},{"name":"Maps_To","value":"L-Gossypol"},{"name":"NCI_Drug_Dictionary_ID","value":"570759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570759"},{"name":"PDQ_Open_Trial_Search_ID","value":"570759"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831823"}]}}{"C107240":{"preferredName":"L-methylfolate","code":"C107240","definitions":[{"definition":"A nutritional supplement containing the biologically active form of the B9 vitamin folate, 5-methyltetrahydrofolate (L-methylfolate), with potential antineoplastic activity. Upon administration, L-methylfolate is able to provide methyl groups allowing an increase in the level of DNA methylation in the promoter regions of certain tumor-promoting genes, thereby reversing the DNA hypomethylation of these genes and inactivating them. This may result in a decrease of both tumor cell proliferation and tumor progression. In addition, administration of L-methylfolate may sensitize tumor cells to the cytotoxic effects of other chemotherapeutic agents. Unlike folic acid, L-methylfolate is able to cross the blood brain barrier and could be beneficial in the treatment of brain tumors. DNA hypomethylation of certain genes leads to chromosome instability and contributes to tumor development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"L-methylfolate","termGroup":"PT","termSource":"NCI"},{"termName":"5-Methyl terahydrofolic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"5-Methyltetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"5-MTHF","termGroup":"AB","termSource":"NCI"},{"termName":"Deplin","termGroup":"BR","termSource":"NCI"},{"termName":"L-Glutamic Acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5- methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"L-methyltetrahydrofolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"L-methylfolate"},{"name":"NCI_Drug_Dictionary_ID","value":"750726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750726"},{"name":"PDQ_Open_Trial_Search_ID","value":"750726"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049315"}]}}{"C95710":{"preferredName":"Labetuzumab Govitecan","code":"C95710","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent topoisomerase I inhibitor SN-38, with antineoplastic activity.  The monoclonal antibody moiety of labetuzumab govitecan selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5), which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication and transcription and leading to tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Labetuzumab Govitecan","termGroup":"PT","termSource":"NCI"},{"termName":"ADC IMMU-130","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate IMMU-130","termGroup":"SY","termSource":"NCI"},{"termName":"hMN14-SN38","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1469876-18-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8E3HI6QQ9J"},{"name":"Maps_To","value":"Labetuzumab Govitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"692828"},{"name":"NCI_META_CUI","value":"CL428175"},{"name":"PDQ_Closed_Trial_Search_ID","value":"692828"},{"name":"PDQ_Open_Trial_Search_ID","value":"692828"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90547":{"preferredName":"Ruxotemitide","code":"C90547","definitions":[{"definition":"A peptide derived from human lactoferrin, with potential lytic and immunostimulating activities. Upon transdermal injection directly into the tumor, ruxotemitide may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis. In turn, presentation of the tumor antigens to the immune system may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells. This may trigger an immune response against tumor associated antigens on tumors distant from the primary tumor. Human lactoferrin, a 692 amino acid glycoprotein, belongs to the transferrin family of metal-binding proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruxotemitide","termGroup":"PT","termSource":"NCI"},{"termName":"LTX-315","termGroup":"CN","termSource":"NCI"},{"termName":"Oncopore","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1345407-05-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"75FBL12IZ7"},{"name":"Maps_To","value":"Lactoferrin-derived Lytic Peptide LTX-315"},{"name":"Maps_To","value":"Ruxotemitide"},{"name":"NCI_Drug_Dictionary_ID","value":"665662"},{"name":"NCI_META_CUI","value":"CL416231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665662"},{"name":"PDQ_Open_Trial_Search_ID","value":"665662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124999":{"preferredName":"Lacutamab","code":"C124999","definitions":[{"definition":"A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. Upon administration, lacutamab binds to KIR3DL2 expressed on certain tumor cells. This recruits natural killer (NK) cells and leads to lysis of KIR3DL2-expressing tumor cells. In addition, IPH4102 induces antibody-dependent cellular cytotoxicity (ADCC), thereby further eliminating tumor cells. KIR3DL2, a tumor-associated antigen (TAA) and inhibitory receptor of the KIR family, is specifically expressed in most subtypes of cutaneous T-cell lymphomas (CTCL) and expressed only on a fraction of normal NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lacutamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-KIR3DL2 mAb IPH4102","termGroup":"SY","termSource":"NCI"},{"termName":"IPH-4102","termGroup":"CN","termSource":"NCI"},{"termName":"IPH4102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2187368-16-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N8O7MY0VNS"},{"name":"Maps_To","value":"Lacutamab"},{"name":"NCI_Drug_Dictionary_ID","value":"777272"},{"name":"NCI_META_CUI","value":"CL503845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777272"},{"name":"PDQ_Open_Trial_Search_ID","value":"777272"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83861":{"preferredName":"Ladirubicin","code":"C83861","definitions":[{"definition":"A 4-demethoxydaunorubicin (idarubicin) analog with an aziridinyl group in position C-3' and a methylsulphonyl on position C-4', with potential antineoplastic activity. Upon intravenous administration, ladirubicin alkylates guanine residues at the N7 position in the DNA major groove, resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ladirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"FCE 28729","termGroup":"CN","termSource":"NCI"},{"termName":"Idarubicin Analog PNU-159548","termGroup":"SY","termSource":"NCI"},{"termName":"PNU 159548","termGroup":"CN","termSource":"NCI"},{"termName":"PNU-159548","termGroup":"CN","termSource":"NCI"},{"termName":"PNU159548","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"171047-47-5"},{"name":"Chemical_Formula","value":"C29H31NO11S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U395ERO49H"},{"name":"Maps_To","value":"Ladirubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827222"}]}}{"C29149":{"preferredName":"Laetrile","code":"C29149","definitions":[{"definition":"A substance found in the pits of many fruits such as apricots and papayas, and in other foods. It has been tried in some countries as a treatment for cancer, but it has not been shown to work in clinical studies. Laetrile is not approved for use in the United States.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laetrile","termGroup":"PT","termSource":"NCI"},{"termName":"Beta-D-Glucopyranosiduronic acid, alpha-cyanobenzyl","termGroup":"SN","termSource":"NCI"},{"termName":"Cyanophenylmethyl-beta-D-glucopyranosiduronic acid","termGroup":"SN","termSource":"NCI"},{"termName":"L-Mandelonitrile-beta-glucuronoside","termGroup":"SN","termSource":"NCI"},{"termName":"Laetrille","termGroup":"SY","termSource":"NCI"},{"termName":"Mandelonitrile-beta-glucuronide","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin B17","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Chemical_Formula","value":"C14-H15-N-O7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laetrille"},{"name":"Maps_To","value":"Laetrile"},{"name":"NCI_Drug_Dictionary_ID","value":"257611"},{"name":"NSC Number","value":"103055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257611"},{"name":"PDQ_Open_Trial_Search_ID","value":"257611"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0878244"}]}}{"C28698":{"preferredName":"Laniquidar","code":"C28698","definitions":[{"definition":"A stereoisomer of verapamil and third-generation P-glycoprotein inhibitor. Laniquidar inhibits the drug efflux pump P-glycoprotein, resulting in higher concentrations of antineoplastic agents in tumor cells that are multi-drug resistant due to the overexpression of P-glycoprotein. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied for its ability to make cancer cells respond to drugs to which they have become resistant. It belongs to the family of drugs called multidrug resistance inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Laniquidar","termGroup":"PT","termSource":"NCI"},{"termName":"R101933","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197509-46-9"},{"name":"Chemical_Formula","value":"C37H36N4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K3FRN4DDOY"},{"name":"Legacy Concept Name","value":"Laniquidar"},{"name":"Maps_To","value":"Laniquidar"},{"name":"NCI_Drug_Dictionary_ID","value":"38526"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38526"},{"name":"PDQ_Open_Trial_Search_ID","value":"38526"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0916124"}]}}{"C74584":{"preferredName":"Lanreotide Acetate","code":"C74584","definitions":[{"definition":"The acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lanreotide Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"AT-1001","termGroup":"CN","termSource":"NCI"},{"termName":"L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide, acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Somatuline Depot","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"127984-74-1"},{"name":"Chemical_Formula","value":"C54H69N11O10S2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IEU56G3J9C"},{"name":"Legacy Concept Name","value":"Lanreotide_Acetate"},{"name":"Maps_To","value":"Lanreotide Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"750171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750171"},{"name":"PDQ_Open_Trial_Search_ID","value":"750171"},{"name":"PubMedID_Primary_Reference","value":"9641549"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771414"}]}}{"C28694":{"preferredName":"Lapachone","code":"C28694","definitions":[{"definition":"A poorly soluble, ortho-naphthoquinone with potential antineoplastic and radiosensitizing activity. Beta-lapachone (b-lap) is bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), creating a futile oxidoreduction that generates high levels of superoxide. In turn, the highly reactive oxygen species (ROS) interact with DNA, thereby causing single-strand DNA breaks and calcium release from endoplasmic reticulum (ER) stores. Eventually, the extensive DNA damage causes hyperactivation of poly(ADP-ribose) polymerase-1 (PARP-1), an enzyme facilitating DNA repair, accompanied by rapid depletion of NAD+/ATP nucleotide levels. As a result, a caspase-independent and ER-stress induced mu-calpain-mediated cell death occurs in NQO1-overexpressing tumor cells. NQO1, a flavoprotein and two-electron oxidoreductase, is overexpressed in a variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapachone","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"ARQ 501","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ501","termGroup":"CN","termSource":"NCI"},{"termName":"Beta-Lap-WJ","termGroup":"BR","termSource":"NCI"},{"termName":"Beta-Lapachone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4707-32-8"},{"name":"Chemical_Formula","value":"C15H14O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6N4FA2QQ6A"},{"name":"Legacy Concept Name","value":"beta-Lapachone"},{"name":"Maps_To","value":"Lapachone"},{"name":"NCI_Drug_Dictionary_ID","value":"357565"},{"name":"NSC Number","value":"26326"},{"name":"NSC Number","value":"629749"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357565"},{"name":"PDQ_Open_Trial_Search_ID","value":"357565"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053471"}]}}{"C26653":{"preferredName":"Lapatinib","code":"C26653","definitions":[{"definition":"A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapatinib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK572016","termGroup":"CN","termSource":"NCI"},{"termName":"GW2016","termGroup":"CN","termSource":"NCI"},{"termName":"GW572016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"231277-92-2"},{"name":"CHEBI_ID","value":"CHEBI:49603"},{"name":"Chemical_Formula","value":"C29H26ClFN4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0VUA21238F"},{"name":"Legacy Concept Name","value":"GW572016"},{"name":"Maps_To","value":"Lapatinib"},{"name":"NSC Number","value":"727989"},{"name":"PubMedID_Primary_Reference","value":"12214266"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506770"}]}}{"C66878":{"preferredName":"Lapatinib Ditosylate","code":"C66878","definitions":[{"definition":"A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib ditosylate is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapatinib Ditosylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl), bis(4-methylbenzenesulfonate), Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Tykerb","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2 positive metastatic breast cancer"},{"name":"CAS_Registry","value":"388082-78-8"},{"name":"Chemical_Formula","value":"C29H26ClFN4O4S.2C7H8O3S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G873GX646R"},{"name":"Legacy Concept Name","value":"Lapatinib_Ditosylate"},{"name":"Maps_To","value":"Lapatinib Ditosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"269659"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269659"},{"name":"PDQ_Open_Trial_Search_ID","value":"269659"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1504917"}]}}{"C2057":{"preferredName":"Lapuleucel-T","code":"C2057","definitions":[{"definition":"A cell-based vaccine targets tumors expressing the HER2/neu marker.  HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers.  APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient.  These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapuleucel-T","termGroup":"PT","termSource":"NCI"},{"termName":"APC 8024","termGroup":"CN","termSource":"NCI"},{"termName":"APC8024","termGroup":"CN","termSource":"NCI"},{"termName":"DN24-02","termGroup":"CN","termSource":"NCI"},{"termName":"Neuvenge","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845680-07-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"J5Z87L8ROA"},{"name":"Legacy Concept Name","value":"APC_8024"},{"name":"Maps_To","value":"Lapuleucel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"735849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735849"},{"name":"PDQ_Open_Trial_Search_ID","value":"735849"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515856"}]}}{"C2653":{"preferredName":"Laromustine","code":"C2653","definitions":[{"definition":"A drug used to treat acute myelogenous leukemia (AML). It is also being studied in the treatment of several other types of cancer. It blocks cell growth by damaging the cell's DNA and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfonyl hydrazine prodrug with antineoplastic activity. Laromustine releases the DNA chloroethylating agent 90CE after entering the blood stream; 90CE chloroethylates alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. Intracellular metabolism of this agent also releases methyl isocyanate which inhibits O6-alkyl-guanine transferase, an enzyme involved with DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laromustine","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"101M","termGroup":"CN","termSource":"NCI"},{"termName":"Cloretazine","termGroup":"SY","termSource":"NCI"},{"termName":"Onrigin","termGroup":"BR","termSource":"NCI"},{"termName":"VNP40101M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"173424-77-6"},{"name":"Chemical_Formula","value":"C6H14ClN3O5S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14J2G0U3NQ"},{"name":"Legacy Concept Name","value":"VNP40101M"},{"name":"Maps_To","value":"Laromustine"},{"name":"NCI_Drug_Dictionary_ID","value":"38440"},{"name":"NSC Number","value":"734246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38440"},{"name":"PDQ_Open_Trial_Search_ID","value":"38440"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713559"}]}}{"C48427":{"preferredName":"Larotaxel","code":"C48427","definitions":[{"definition":"A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of breast cancer. It belongs to the family of drugs called taxane derivatives.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Larotaxel","termGroup":"PT","termSource":"NCI"},{"termName":"RPR 109881A","termGroup":"CN","termSource":"NCI"},{"termName":"RPR-109881","termGroup":"CN","termSource":"NCI"},{"termName":"Taxoid-109881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156294-36-9"},{"name":"Chemical_Formula","value":"C45H53NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TWQ8K8A81Y"},{"name":"Legacy Concept Name","value":"XRP9881"},{"name":"Maps_To","value":"Larotaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"42554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42554"},{"name":"PDQ_Open_Trial_Search_ID","value":"42554"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0392979"}]}}{"C115977":{"preferredName":"Larotrectinib","code":"C115977","definitions":[{"definition":"An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larotrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-","termGroup":"SN","termSource":"NCI"},{"termName":"3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ARRY 470","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO 101","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1223403-58-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PF9462I9HX"},{"name":"Maps_To","value":"Larotrectinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4278057"}]}}{"C156895":{"preferredName":"Larotrectinib Sulfate","code":"C156895","definitions":[{"definition":"The sulfate salt form of larotrectinib, an orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larotrectinib Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide;sulfuric acid","termGroup":"SN","termSource":"NCI"},{"termName":"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, Sulfate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"ARRY 470 Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"LOXO 101 Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"LOXO-101 Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"Vitrakvi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation"},{"name":"CAS_Registry","value":"1223405-08-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RDF76R62ID"},{"name":"Maps_To","value":"Larotrectinib Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"760532"},{"name":"NCI_META_CUI","value":"CL935988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760532"},{"name":"PDQ_Open_Trial_Search_ID","value":"760532"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1142":{"preferredName":"Lavendustin A","code":"C1142","definitions":[{"definition":"A compound isolated from strains of Streptomyces griseolavendus that may exert antitumor activity by inhibition of protein tyrosine kinase and tubulin polymerization. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lavendustin A","termGroup":"PT","termSource":"NCI"},{"termName":"5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy Benzoic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125697-92-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3Y0G32G2RV"},{"name":"Legacy Concept Name","value":"Lavendustin_A"},{"name":"Maps_To","value":"Lavendustin A"},{"name":"NSC Number","value":"678027"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064695"}]}}{"C148147":{"preferredName":"Lazertinib","code":"C148147","definitions":[{"definition":"An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lazertinib","termGroup":"PT","termSource":"NCI"},{"termName":"GNS-1480","termGroup":"CN","termSource":"NCI"},{"termName":"N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"YH 25448","termGroup":"CN","termSource":"NCI"},{"termName":"YH-25448","termGroup":"CN","termSource":"NCI"},{"termName":"YH25448","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1903008-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4A2Y23XK11"},{"name":"Maps_To","value":"Lazertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"792503"},{"name":"NCI_META_CUI","value":"CL550797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792503"},{"name":"PDQ_Open_Trial_Search_ID","value":"792503"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97500":{"preferredName":"Lead Pb 212 TCMC-trastuzumab","code":"C97500","definitions":[{"definition":"A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional chelating agent TCMC ((1,4,7,10-Tetra-(2-Carbamoyl Methyl)-Cyclododecane), and radiolabeled with the alpha-emitting isotope lead Pb 212, with potential anti-tumor activity. Upon administration, the antibody moiety of lead Pb 212 TCMC-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2); after internalization, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed on the cell surface of a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lead Pb 212 TCMC-trastuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"[212]Pb TCMC-Herceptin","termGroup":"SY","termSource":"NCI"},{"termName":"[212]Pb TCMC-trastuzumab","termGroup":"SY","termSource":"NCI"},{"termName":"Lead Pb 212 TCMC-Herceptin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lead Pb 212 TCMC-trastuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"703322"},{"name":"NCI_META_CUI","value":"CL430248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703322"},{"name":"PDQ_Open_Trial_Search_ID","value":"703322"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94207":{"preferredName":"Lefitolimod","code":"C94207","definitions":[{"definition":"A synthetic oligonucleotide based on a proprietary double stem-loop immunomodulator design with potential immunostimulating activity. Lefitolimod binds to and activates intracellular Toll-like receptor 9 (TLR9) in monocytes/macrophages, plasmacytoidal and myeloid dendritic cells (DCs), and natural killer (NK) cells, initiating immune signaling pathways and inducing T-helper 1 cell (Th1) production leading to the production of memory T cells and a Th1-mediated immune response. By activating the immune system, MGN1703 may attack tumor associated antigen (TAAs). TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lefitolimod","termGroup":"PT","termSource":"NCI"},{"termName":"dSLIM-30L1","termGroup":"SY","termSource":"NCI"},{"termName":"MGN-1703","termGroup":"CN","termSource":"NCI"},{"termName":"MGN1703","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1548439-51-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SO72A12FN"},{"name":"Maps_To","value":"Lefitolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"686500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686500"},{"name":"PDQ_Open_Trial_Search_ID","value":"686500"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986392"}]}}{"C1128":{"preferredName":"Leflunomide","code":"C1128","definitions":[{"definition":"A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties.  As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes.  This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that works by inhibiting a cancer cell growth factor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leflunomide","termGroup":"PT","termSource":"NCI"},{"termName":"4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Arava","termGroup":"BR","termSource":"NCI"},{"termName":"SU101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75706-12-6"},{"name":"CHEBI_ID","value":"CHEBI:6402"},{"name":"Chemical_Formula","value":"C12H9F3N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G162GK9U4W"},{"name":"Legacy Concept Name","value":"Leflunomide"},{"name":"Maps_To","value":"Leflunomide"},{"name":"NCI_Drug_Dictionary_ID","value":"42253"},{"name":"NSC Number","value":"677411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42253"},{"name":"PDQ_Open_Trial_Search_ID","value":"42253"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063041"}]}}{"C2668":{"preferredName":"Lenalidomide","code":"C2668","definitions":[{"definition":"A drug that is similar to thalidomide, and is used to treat multiple myeloma and certain types of anemia. It is also being studied in the treatment of other types of cancer. Lenalidomide belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenalidomide","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"CC-5013","termGroup":"CN","termSource":"NCI"},{"termName":"CC5013","termGroup":"CN","termSource":"NCI"},{"termName":"CDC 501","termGroup":"CN","termSource":"NCI"},{"termName":"Revlimid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndrome; multiple myeloma, lymphoma"},{"name":"CAS_Registry","value":"191732-72-6"},{"name":"CHEBI_ID","value":"CHEBI:63791"},{"name":"Chemical_Formula","value":"C13H13N3O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F0P408N6V4"},{"name":"Legacy Concept Name","value":"CC-5013"},{"name":"Maps_To","value":"Lenalidomide"},{"name":"NCI_Drug_Dictionary_ID","value":"38564"},{"name":"NSC Number","value":"703813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38564"},{"name":"PDQ_Open_Trial_Search_ID","value":"38564"},{"name":"PubMedID_Primary_Reference","value":"16085014"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1144149"}]}}{"C162878":{"preferredName":"Lenalidomide Analog KPG-121","code":"C162878","definitions":[{"definition":"A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenalidomide Analog KPG-121","termGroup":"PT","termSource":"NCI"},{"termName":"KPG 121","termGroup":"CN","termSource":"NCI"},{"termName":"KPG-121","termGroup":"CN","termSource":"NCI"},{"termName":"KPG121","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lenalidomide Analog KPG-121"},{"name":"NCI_Drug_Dictionary_ID","value":"798954"},{"name":"NCI_META_CUI","value":"CL973359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798954"},{"name":"PDQ_Open_Trial_Search_ID","value":"798954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28168":{"preferredName":"Lentinan","code":"C28168","definitions":[{"definition":"A beta-glucan (a type of polysaccharide) from the mushroom Lentinus edodes (shiitake mushroom).  It has been studied in Japan as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lentinan","termGroup":"PT","termSource":"NCI"},{"termName":"LC-33","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37339-90-5"},{"name":"Chemical_Formula","value":"(C12H20O10)n.HO(C6H10O5)n"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6751655D1D"},{"name":"Legacy Concept Name","value":"Lentinan"},{"name":"Maps_To","value":"Lentinan"},{"name":"NSC Number","value":"130122"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0023324"}]}}{"C95124":{"preferredName":"Lenvatinib","code":"C95124","definitions":[{"definition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenvatinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"E7080","termGroup":"CN","termSource":"NCI"},{"termName":"ER-203492-00","termGroup":"CN","termSource":"NCI"},{"termName":"Multi-Kinase Inhibitor E7080","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable hepatocellular carcinoma (HCC)"},{"name":"CAS_Registry","value":"417716-92-8"},{"name":"Chemical_Formula","value":"C21H19ClN4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"EE083865G2"},{"name":"Maps_To","value":"Lenvatinib"},{"name":"PubMedID_Primary_Reference","value":"18765537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986924"}]}}{"C48636":{"preferredName":"Lenvatinib Mesylate","code":"C48636","definitions":[{"definition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenvatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, methanesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"E7080 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Lenvima","termGroup":"BR","termSource":"NCI"},{"termName":"Multi-Kinase Inhibitor E7080 Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer; advanced renal cell carcinoma (RCC); first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)."},{"name":"CAS_Registry","value":"857890-39-2"},{"name":"Chemical_Formula","value":"C21H19ClN4O4.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3J78384F61"},{"name":"Legacy Concept Name","value":"E7080"},{"name":"Maps_To","value":"Lenvatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"445461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"445461"},{"name":"PDQ_Open_Trial_Search_ID","value":"445461"},{"name":"PubMedID_Primary_Reference","value":"18765537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4018332"}]}}{"C125081":{"preferredName":"Lenzilumab","code":"C125081","definitions":[{"definition":"A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenzilumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1-kappa, Anti-(Homo sapiens CSF2 (Colony Stimulating Factor 2 (Granulocyte-Macrophage), Granulocyte Macrophage Colony Stimulating Factor, GM-CSF)), Homo sapiens Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"KB 003","termGroup":"CN","termSource":"NCI"},{"termName":"KB003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229575-09-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IE4X6497XK"},{"name":"Maps_To","value":"Lenzilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"778430"},{"name":"NCI_META_CUI","value":"CL503921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778430"},{"name":"PDQ_Open_Trial_Search_ID","value":"778430"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48402":{"preferredName":"Lestaurtinib","code":"C48402","definitions":[{"definition":"A drug being studied in the treatment of acute leukemias and some other types of cancer. It binds to a protein that is present on the surface of some types of cancer cells and stops them from dividing. CEP-701 is a type of receptor tyrosine kinase inhibitor and a type of indolocarbazole alkaloid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lestaurtinib","termGroup":"PT","termSource":"NCI"},{"termName":"9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-","termGroup":"SN","termSource":"NCI"},{"termName":"CEP-701","termGroup":"CN","termSource":"NCI"},{"termName":"KT-5555","termGroup":"CN","termSource":"NCI"},{"termName":"SPM-924","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111358-88-4"},{"name":"Chemical_Formula","value":"C26H21N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DO989GC5D1"},{"name":"Legacy Concept Name","value":"Lestaurtinib"},{"name":"Maps_To","value":"Lestaurtinib"},{"name":"NCI_Drug_Dictionary_ID","value":"367053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"367053"},{"name":"PDQ_Open_Trial_Search_ID","value":"367053"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541677"}]}}{"C1527":{"preferredName":"Letrozole","code":"C1527","definitions":[{"definition":"A drug used to treat advanced breast cancer in postmenopausal women. Letrozole causes a decrease in the amount of estrogen made by the body. It is a type of aromatase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letrozole","termGroup":"PT","termSource":"NCI"},{"termName":"4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"CGS 20267","termGroup":"CN","termSource":"NCI"},{"termName":"Femara","termGroup":"BR","termSource":"NCI"},{"termName":"Fempro","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hormone receptor-positive early breast cancer; Delayed puberty; Endometrial cancer; Ovulatory induction"},{"name":"CAS_Registry","value":"112809-51-5"},{"name":"CHEBI_ID","value":"CHEBI:6413"},{"name":"Chemical_Formula","value":"C17H11N5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7LKK855W8I"},{"name":"Legacy Concept Name","value":"Letrozole"},{"name":"Maps_To","value":"Letrozole"},{"name":"NCI_Drug_Dictionary_ID","value":"42086"},{"name":"NSC Number","value":"719345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42086"},{"name":"PDQ_Open_Trial_Search_ID","value":"42086"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0246421"}]}}{"C71631":{"preferredName":"Leucovorin","code":"C71631","definitions":[{"definition":"A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil's converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to lessen the toxic effects of substances that block the action of folic acid, especially the anticancer drug methotrexate. Folinic acid is used to treat some types of anemia and is also used with fluorouracil to treat colorectal cancer. It is also being studied in the treatment of other types of cancer and other conditions. Folinic acid is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leucovorin","termGroup":"PT","termSource":"NCI"},{"termName":"5-Formyltetrahydrofolate","termGroup":"SN","termSource":"NCI"},{"termName":"Folinic acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58-05-9"},{"name":"CHEBI_ID","value":"CHEBI:15640"},{"name":"Chemical_Formula","value":"C20H23N7O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q573I9DVLP"},{"name":"Legacy Concept Name","value":"Leucovorin"},{"name":"Maps_To","value":"Leucovorin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0023413"}]}}{"C607":{"preferredName":"Leucovorin Calcium","code":"C607","definitions":[{"definition":"A drug used to lessen the toxic effects of substances that block the action of folic acid, especially the anticancer drug methotrexate. Leucovorin calcium is used to treat some types of anemia and is also used with fluorouracil to treat colorectal cancer. It is also being studied in the treatment of other types of cancer and other conditions. Leucovorin calcium is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leucovorin Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"5-Formyl Tetrahydrofolate","termGroup":"SN","termSource":"NCI"},{"termName":"5-Formyl-5,6,7,8-tetrahydrofolic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Adinepar","termGroup":"FB","termSource":"NCI"},{"termName":"Calcifolin","termGroup":"FB","termSource":"NCI"},{"termName":"Calcium (6S)-Folinate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Folinate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Leucovorin","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium N-(p-((((6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Calfolex","termGroup":"FB","termSource":"NCI"},{"termName":"Calinat","termGroup":"FB","termSource":"NCI"},{"termName":"Cehafolin","termGroup":"FB","termSource":"NCI"},{"termName":"Citofolin","termGroup":"FB","termSource":"NCI"},{"termName":"Citrec","termGroup":"FB","termSource":"NCI"},{"termName":"Citrovorum Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Cromatonbic Folinico","termGroup":"FB","termSource":"NCI"},{"termName":"Dalisol","termGroup":"FB","termSource":"NCI"},{"termName":"Disintox","termGroup":"FB","termSource":"NCI"},{"termName":"Divical","termGroup":"FB","termSource":"NCI"},{"termName":"Ecofol","termGroup":"FB","termSource":"NCI"},{"termName":"Emovis","termGroup":"FB","termSource":"NCI"},{"termName":"Factor, Citrovorum","termGroup":"SY","termSource":"NCI"},{"termName":"Flynoken A","termGroup":"FB","termSource":"NCI"},{"termName":"Folaren","termGroup":"FB","termSource":"NCI"},{"termName":"Folaxin","termGroup":"FB","termSource":"NCI"},{"termName":"FOLI-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Foliben","termGroup":"FB","termSource":"NCI"},{"termName":"Folidan","termGroup":"FB","termSource":"NCI"},{"termName":"Folidar","termGroup":"FB","termSource":"NCI"},{"termName":"Folinac","termGroup":"FB","termSource":"NCI"},{"termName":"Folinate Calcium","termGroup":"SY","termSource":"NCI"},{"termName":"Folinic Acid Calcium Salt Pentahydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Folinoral","termGroup":"FB","termSource":"NCI"},{"termName":"Folinvit","termGroup":"FB","termSource":"NCI"},{"termName":"Foliplus","termGroup":"FB","termSource":"NCI"},{"termName":"Folix","termGroup":"FB","termSource":"NCI"},{"termName":"Imo","termGroup":"FB","termSource":"NCI"},{"termName":"Lederfolat","termGroup":"FB","termSource":"NCI"},{"termName":"Lederfolin","termGroup":"FB","termSource":"NCI"},{"termName":"Leucosar","termGroup":"FB","termSource":"NCI"},{"termName":"N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid, Calcium Salt (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Rescufolin","termGroup":"FB","termSource":"NCI"},{"termName":"Rescuvolin","termGroup":"FB","termSource":"NCI"},{"termName":"Tonofolin","termGroup":"FB","termSource":"NCI"},{"termName":"Wellcovorin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Megaloblastic anemia due to folate deficiency; Enhanced fluorouracil inhibition of thymidylate synthase; Reverse dihydrofolate reductase inhibition by methotrexate; Folic acid antagonist overdose; Nitrous Oxide toxicity"},{"name":"CAS_Registry","value":"1492-18-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RPR1R4C0P4"},{"name":"Legacy Concept Name","value":"Leucovorin_Calcium"},{"name":"Maps_To","value":"Leucovorin Calcium"},{"name":"NCI_Drug_Dictionary_ID","value":"42584"},{"name":"NSC Number","value":"3590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42584"},{"name":"PDQ_Open_Trial_Search_ID","value":"42584"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0731033"}]}}{"C62042":{"preferredName":"Leuprolide","code":"C62042","definitions":[{"definition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat symptoms of advanced prostate cancer. It is also used to treat early puberty in children and certain gynecologic conditions. It is being studied in the treatment of other conditions and types of cancer. Leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of gonadotropin-releasing hormone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leuprolide","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig)","termGroup":"SN","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)","termGroup":"SN","termSource":"NCI"},{"termName":"Leuprorelin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53714-56-0"},{"name":"CHEBI_ID","value":"CHEBI:6427"},{"name":"Chemical_Formula","value":"C59H84N16O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"EFY6W0M8TG"},{"name":"Legacy Concept Name","value":"Leuprolide_Base"},{"name":"Maps_To","value":"Leuprolide"},{"name":"NSC Number","value":"377526"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0085272"}]}}{"C1319":{"preferredName":"Leuprolide Acetate","code":"C1319","definitions":[{"definition":"A drug used to treat symptoms of advanced prostate cancer. It is also being studied in the treatment of other conditions and types of cancer. The active ingredient leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. Some brands of leuprolide are also used to treat early puberty in children and certain gynecologic conditions. Leuprolide acetate is a type of gonadotropin-releasing hormone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leuprolide Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate","termGroup":"SN","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate","termGroup":"SN","termSource":"NCI"},{"termName":"A-43818","termGroup":"CN","termSource":"NCI"},{"termName":"Abbott 43818","termGroup":"CN","termSource":"NCI"},{"termName":"Abbott-43818","termGroup":"CN","termSource":"NCI"},{"termName":"Carcinil","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Eligard","termGroup":"FB","termSource":"NCI"},{"termName":"Enanton","termGroup":"FB","termSource":"NCI"},{"termName":"Enantone","termGroup":"FB","termSource":"NCI"},{"termName":"Enantone-Gyn","termGroup":"FB","termSource":"NCI"},{"termName":"Ginecrin","termGroup":"FB","termSource":"NCI"},{"termName":"LEUP","termGroup":"AB","termSource":"NCI"},{"termName":"Leuplin","termGroup":"FB","termSource":"NCI"},{"termName":"Leuprorelin Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"Lucrin","termGroup":"FB","termSource":"NCI"},{"termName":"Lucrin Depot","termGroup":"FB","termSource":"NCI"},{"termName":"Luprodex Depot","termGroup":"FB","termSource":"NCI"},{"termName":"Lupron","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot-3 Month","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot-4 Month","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot-Ped","termGroup":"BR","termSource":"NCI"},{"termName":"Lutrate","termGroup":"FB","termSource":"NCI"},{"termName":"Procren","termGroup":"FB","termSource":"NCI"},{"termName":"Procrin","termGroup":"FB","termSource":"NCI"},{"termName":"Prostap","termGroup":"FB","termSource":"NCI"},{"termName":"TAP-144","termGroup":"CN","termSource":"NCI"},{"termName":"Trenantone","termGroup":"FB","termSource":"NCI"},{"termName":"Uno-Enantone","termGroup":"FB","termSource":"NCI"},{"termName":"Viadur","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Endometriosis; In-vitro fertilization; Precocious puberty; Premenstrual syndrome; Prostate cancer; Uterine fibroid tumors"},{"name":"CAS_Registry","value":"74381-53-6"},{"name":"CHEBI_ID","value":"CHEBI:63597"},{"name":"Chemical_Formula","value":"C59H84N16O12.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37JNS02E7V"},{"name":"Legacy Concept Name","value":"Leuprolide"},{"name":"Maps_To","value":"Leuprolide Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"40058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40058"},{"name":"PDQ_Open_Trial_Search_ID","value":"40058"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700596"}]}}{"C118363":{"preferredName":"Leuprolide Mesylate Injectable Suspension","code":"C118363","definitions":[{"definition":"A depot suspension for injection composed of the mesylate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous injection of the depot suspension, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leuprolide Mesylate Injectable Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"LMIS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leuprolide Mesylate Injectable Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"764623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764623"},{"name":"PDQ_Open_Trial_Search_ID","value":"764623"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896651"}]}}{"C81421":{"preferredName":"Leurubicin","code":"C81421","definitions":[{"definition":"An N-L-leucyl prodrug of the anthracycline doxorubicin, with antineoplastic activity. Leurubicin is converted to its active form doxorubicin in or on tumor cells by hydrolytic enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leurubicin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70774-25-3"},{"name":"Chemical_Formula","value":"C33H40N2O12"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z20MGK851"},{"name":"Legacy Concept Name","value":"Leurubicin"},{"name":"Maps_To","value":"Leurubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825623"}]}}{"C47581":{"preferredName":"Levetiracetam","code":"C47581","definitions":[{"definition":"A drug used to treat seizures (involuntary muscle movements) caused by epilepsy (a group of brain disorders). Keppra is being studied in the treatment of seizures in patients with cancer that has spread to the brain. It is a type of anticonvulsant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levetiracetam","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-,(S)-","termGroup":"SN","termSource":"NCI"},{"termName":"Keppra","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treating partial-onset seizures in patients with epilepsy."},{"name":"CAS_Registry","value":"102767-28-2"},{"name":"CHEBI_ID","value":"CHEBI:6437"},{"name":"Chemical_Formula","value":"C8H14N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44YRR34555"},{"name":"Legacy Concept Name","value":"Levetiracetam"},{"name":"Maps_To","value":"Levetiracetam"},{"name":"NCI_Drug_Dictionary_ID","value":"526173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526173"},{"name":"PDQ_Open_Trial_Search_ID","value":"526173"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0377265"}]}}{"C62080":{"preferredName":"Levothyroxine","code":"C62080","definitions":[{"definition":"A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levothyroxine","termGroup":"PT","termSource":"NCI"},{"termName":"L-Thyroxine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51-48-9"},{"name":"CHEBI_ID","value":"CHEBI:18332"},{"name":"Chemical_Formula","value":"C15H11I4NO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q51BO43MG4"},{"name":"Legacy Concept Name","value":"Levothyroxine"},{"name":"Maps_To","value":"Levothyroxine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881373"}]}}{"C888":{"preferredName":"Levothyroxine Sodium","code":"C888","definitions":[{"definition":"The sodium salt of levothyroxine, a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levothyroxine Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Levothroid","termGroup":"BR","termSource":"NCI"},{"termName":"Synthroid","termGroup":"BR","termSource":"NCI"},{"termName":"Therapeutic Levothyroxine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"25416-65-3"},{"name":"Chemical_Formula","value":"C15H10I4NO4.Na.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"9J765S329G"},{"name":"Legacy Concept Name","value":"Therapeutic_Levothyroxine"},{"name":"Maps_To","value":"Levothyroxine Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39298"},{"name":"NSC Number","value":"36397"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39298"},{"name":"PDQ_Open_Trial_Search_ID","value":"39298"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079691"}]}}{"C64621":{"preferredName":"Lexatumumab","code":"C64621","definitions":[{"definition":"A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. HGS-ETR2 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lexatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2","termGroup":"SY","termSource":"NCI"},{"termName":"HGS-ETR2","termGroup":"SY","termSource":"NCI"},{"termName":"HGS-ETR2","termGroup":"CN","termSource":"NCI"},{"termName":"HGS1018","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody HGS-ETR2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845816-02-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"967Q0SJD77"},{"name":"Legacy Concept Name","value":"Lexatumumab"},{"name":"Maps_To","value":"Lexatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"528015"},{"name":"PDQ_Closed_Trial_Search_ID","value":"528015"},{"name":"PDQ_Open_Trial_Search_ID","value":"528015"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721684"}]}}{"C77882":{"preferredName":"Lexibulin","code":"C77882","definitions":[{"definition":"An orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. Lexibulin inhibits tubulin polymerization in tumor blood vessel endothelial cells and tumor cells, blocking the formation of the mitotic spindle and leading to cell cycle arrest at the G2/M phase; this may result in disruption of the tumor vasculature and tumor blood flow, and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lexibulin","termGroup":"PT","termSource":"NCI"},{"termName":"1-ethyl-3-(2-methoxy-4-(5-methyl-4-(((1s)-1-(pyridin-3-yl)butyl)amino)pyrimidin-2-yl)phenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"CYT997","termGroup":"CN","termSource":"NCI"},{"termName":"Tubulin Inhibitor CYT997","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917111-44-5"},{"name":"Chemical_Formula","value":"C24H30N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2GTU230HA1"},{"name":"Legacy Concept Name","value":"Tubulin_Inhibitor_CYT997"},{"name":"Maps_To","value":"Lexibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"598799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598799"},{"name":"PDQ_Open_Trial_Search_ID","value":"598799"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703082"}]}}{"C1433":{"preferredName":"Liarozole","code":"C1433","definitions":[{"definition":"An anticancer drug that promotes differentiation by increasing the levels of retinoic acid within the tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liarozole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Liazal","termGroup":"BR","termSource":"NCI"},{"termName":"R 75251","termGroup":"CN","termSource":"NCI"},{"termName":"R-61405","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"115575-11-6"},{"name":"Chemical_Formula","value":"C17H13ClN4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K0Q29TGV9Y"},{"name":"Legacy Concept Name","value":"Liarozole"},{"name":"Maps_To","value":"Liarozole"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165479"}]}}{"C1524":{"preferredName":"Liarozole Fumarate","code":"C1524","definitions":[{"definition":"The orally active fumarate salt of the benzimidazole derivative liarozole with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liarozole Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-5-(m-Chloro-alpha-imidazol-1-ylbenzyl)benzimidazole Fumarate (2:3)","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-, (+-)-, (E)-2-butenedioate (2:3)","termGroup":"SN","termSource":"NCI"},{"termName":"R85246","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145858-52-2"},{"name":"Chemical_Formula","value":"2C17H13ClN4.3C4H4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91W7VLK7J3"},{"name":"Legacy Concept Name","value":"Liarozole_Fumarate"},{"name":"Maps_To","value":"Liarozole Fumarate"},{"name":"NCI_Drug_Dictionary_ID","value":"41252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41252"},{"name":"PDQ_Open_Trial_Search_ID","value":"41252"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245820"}]}}{"C80333":{"preferredName":"Liarozole Hydrochloride","code":"C80333","definitions":[{"definition":"The fumarate salt of an orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liarozole Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-5-(m-Chloro-alpha-imidazol-1-ylbenzyl)benzimidazole Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-, Monohydrochloride, (+-)-","termGroup":"SN","termSource":"NCI"},{"termName":"Liarozole HCl","termGroup":"SY","termSource":"NCI"},{"termName":"R 75251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145858-50-0"},{"name":"Chemical_Formula","value":"C17H13ClN4.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29T7S2IB97"},{"name":"Legacy Concept Name","value":"Liarozole_Hydrochloride"},{"name":"Maps_To","value":"Liarozole Hydrochloride"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697919"}]}}{"C104275":{"preferredName":"Licartin","code":"C104275","definitions":[{"definition":"An immunoradioconjugate containing metuximab, an antibody fragment targeting the hepatocellular cancer (HCC)-associated antigen HAb18G/CD147, that is conjugated to the radioisotope iodine I 131, with potential antineoplastic activity. Upon administration, the metuximab moiety of licartin targets and binds to HAb18G/CD147 on HCC cells; upon internalization, the radioisotope I 131 delivers a cytotoxic dose of gamma radiation, thereby causing selective destruction of HAb18G/CD147-expressing cells. HAb18G/CD147, a member of CD147 family, is overexpressed in HCC and fibroblasts and its expression is associated with cancer cell progression and increased adhesion, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Licartin","termGroup":"PT","termSource":"NCI"},{"termName":"(131)I-labeled HAb18 F(ab')(2)","termGroup":"SY","termSource":"NCI"},{"termName":"[131I] mAb HAb18G/CD147","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Metuximab","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine[131I] Metuximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Licartin"},{"name":"NCI_Drug_Dictionary_ID","value":"744892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744892"},{"name":"PDQ_Open_Trial_Search_ID","value":"744892"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1722701"}]}}{"C61436":{"preferredName":"Licorice","code":"C61436","definitions":[{"definition":"A substance prepared from dried roots of the plant Glycyrrhiza glabra. It is used as a flavoring in medicines, drinks, and sweets, and it is being studied in the treatment of cancer. Licorice root extract contains several compounds that reduce inflammation, kill certain bacteria and viruses, act like estrogen and other hormones, and may cause cancer cells to die. It is a type of antioxidant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An herbal extract derived from the root of the plant Glycyrrhiza glabra with potential anti-inflammatory, antioxidant, and antineoplastic activities. Licorice root extract contains glycoside glycyrrhizinic acid and numerous flavonoids. Glycyrrhizinic acid in licorice root extract is hydrolyzed to glycyrrhetic acid (GA); GA inhibits 11 beta-hydroxysteroid dehydrogenase, resulting in inhibition of the conversion of cortisol to the inactive steroid cortisone and elevated cortisol levels. In addition, GA inhibits 17,20-lyase and 17 beta-hydroxysteroid dehydrogenase, resulting in decreased conversions of 17-hydroxyprogesterone to androstenedione and androstenedione to testosterone. The primary antioxidant found in licorice root, the flavonoid glabridin, may inactivate or inhibit the activities of some cytochrome P450 enzymes. In tumor cells, beta-hydroxy-DHP, another flavonoid, may induce Bcl-2 phosphorylation, apoptosis, and G2/M cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Licorice","termGroup":"PT","termSource":"NCI"},{"termName":"Glycyrrhiza","termGroup":"SY","termSource":"NCI"},{"termName":"Glycyrrhizae Radix","termGroup":"SY","termSource":"NCI"},{"termName":"Licorice Root Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"61ZBX54883"},{"name":"Legacy Concept Name","value":"Licorice_Root_Extract"},{"name":"Maps_To","value":"Licorice"},{"name":"NCI_Drug_Dictionary_ID","value":"471833"},{"name":"PDQ_Closed_Trial_Search_ID","value":"471833"},{"name":"PDQ_Open_Trial_Search_ID","value":"471833"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086555"}]}}{"C116747":{"preferredName":"Lifastuzumab Vedotin","code":"C116747","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the sodium-dependent phosphate transport protein 2B (NaPi2b), and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DNIB0600A binds to NaPi2b-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. NaPi2b, a tumor-associated antigen (TAA), overexpressed in a variety of cancer cell types, plays a key role in transport of inorganic phosphate and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifastuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DNIB0600A","termGroup":"SY","termSource":"NCI"},{"termName":"DNIB0600A","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7599","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401812-88-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7IUT83FK6S"},{"name":"Maps_To","value":"Lifastuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"701789"},{"name":"NCI_META_CUI","value":"CL433844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701789"},{"name":"PDQ_Open_Trial_Search_ID","value":"701789"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137951":{"preferredName":"Belzupacap Sarotalocan","code":"C137951","definitions":[{"definition":"A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belzupacap Sarotalocan","termGroup":"PT","termSource":"NCI"},{"termName":"AU-011","termGroup":"CN","termSource":"NCI"},{"termName":"HPV-NP AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Virus-like Particles Conjugated with IR700 Dye AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"Light-activated AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"Viral Nanoparticle Conjugates AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"VNC AU-011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2390462-37-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DK0ZGA5Y2R"},{"name":"Maps_To","value":"Light-activated AU-011"},{"name":"NCI_Drug_Dictionary_ID","value":"790618"},{"name":"NCI_META_CUI","value":"CL524973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790618"},{"name":"PDQ_Open_Trial_Search_ID","value":"790618"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79833":{"preferredName":"Olvimulogene Nanivacirepvec","code":"C79833","definitions":[{"definition":"An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olvimulogene Nanivacirepvec","termGroup":"PT","termSource":"NCI"},{"termName":"GL-ONC1","termGroup":"CN","termSource":"NCI"},{"termName":"GLV-1h68","termGroup":"CN","termSource":"NCI"},{"termName":"Olvi-Vec","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1473430-36-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CF19SF72O5"},{"name":"Legacy Concept Name","value":"Light-Emitting_Oncolytic_Vaccinia_Virus_GL-ONC1"},{"name":"Maps_To","value":"Light-Emitting Oncolytic Vaccinia Virus GL-ONC1"},{"name":"Maps_To","value":"Olvimulogene Nanivacirepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"629379"},{"name":"NCI_META_CUI","value":"CL388438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629379"},{"name":"PDQ_Open_Trial_Search_ID","value":"629379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61714":{"preferredName":"Limonene, (+)-","code":"C61714","definitions":[{"definition":"A terpene with two isoprene units forming a ring. The chemical structure is CC1=CCC(CC1)C(=C)C.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"An oral dietary supplement containing a natural cyclic monoterpene, and a major component of the oil extracted from citrus peels, with potential chemopreventive and antineoplastic activities. Upon oral administration, D-limonene activates aldehyde dehydrogenase 3A1 (ALDH3A1), thereby decreasing aldehyde level. This may protect salivary stem/progenitor cells (SSPCs) from toxic aldehydes and prevent or improve radiation-induced xerostomia. Limonene and its metabolites perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol may also inhibit tumor growth through inhibition of p21-dependent signaling and may induce apoptosis via the induction of the transforming growth factor beta-signaling pathway. In addition, they inhibit post-translational modification of signal transduction proteins, resulting in G1 cell cycle arrest as well as differential expression of cell cycle- and apoptosis-related genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Limonene, (+)-","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(R)-4-isopropenyl-1-methylcyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"(+)-alpha-Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"(+)-limonene","termGroup":"SY","termSource":"NCI"},{"termName":"(4R)-1-methyl-4-(1-methylethenyl)cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"(R)-(+)-limonene","termGroup":"SY","termSource":"NCI"},{"termName":"(R)-4-isopropenyl-1-methylcyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"1-methyl-4-isopropenyl-1-cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"Alda 341","termGroup":"CN","termSource":"NCI"},{"termName":"Alda-341","termGroup":"CN","termSource":"NCI"},{"termName":"Alda341","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclohexene, 1-methyl-4-(1-methylethenyl)-, (4R)-","termGroup":"SN","termSource":"NCI"},{"termName":"D-Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"Limonene, D-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5989-27-5"},{"name":"CAS_Registry","value":"7705-13-7"},{"name":"CHEBI_ID","value":"CHEBI:15382"},{"name":"Chemical_Formula","value":"C10H16"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GFD7C86Q1W"},{"name":"Legacy Concept Name","value":"D-Limonene"},{"name":"Maps_To","value":"Limonene, (+)-"},{"name":"NCI_Drug_Dictionary_ID","value":"664042"},{"name":"PDQ_Closed_Trial_Search_ID","value":"664042"},{"name":"PDQ_Open_Trial_Search_ID","value":"664042"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0950252"}]}}{"C61709":{"preferredName":"Limonene, (+/-)-","code":"C61709","definitions":[{"definition":"A racemic mixture of limonene, a natural cyclic monoterpene and major component of the oil extracted from citrus rind with chemo-preventive and antitumor activities. The metabolites of DL-limonene, perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol are suggested to inhibit tumor growth through inhibition of p21-dependent signaling, induce apoptosis via the induction of the transforming growth factor beta-signaling pathway, inhibit post-translational modification of signal transduction proteins, result in G1 cell cycle arrest as well as cause differential expression of cell cycle- and apoptosis-related genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Limonene, (+/-)-","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-1-methyl-4-(1-methylethenyl)cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"1-methyl-4-(1-methylethenyl)cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"1-methyl-4-prop-1-en-2-yl-cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"Cajeputene","termGroup":"SY","termSource":"NCI"},{"termName":"Cinene","termGroup":"SY","termSource":"NCI"},{"termName":"Dipentene","termGroup":"SY","termSource":"NCI"},{"termName":"DL-Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"Eulimen","termGroup":"SY","termSource":"NCI"},{"termName":"Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"Nesol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"138-86-3"},{"name":"CHEBI_ID","value":"CHEBI:15384"},{"name":"Chemical_Formula","value":"C10H16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9MC3I34447"},{"name":"Legacy Concept Name","value":"DL-Limonene"},{"name":"Maps_To","value":"Limonene, (+/-)-"},{"name":"NSC Number","value":"21446"},{"name":"NSC Number","value":"844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880232"}]}}{"C71759":{"preferredName":"Linifanib","code":"C71759","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. ABT-869 blocks the action of several growth factors. It may also block the growth of new blood vessels that tumors need to grow and may cause cancer cells to die. It is a type of receptor tyrosine kinase inhibitor and a type of angiogensis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linifanib","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-869","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"796967-16-3"},{"name":"Chemical_Formula","value":"C21H18FN5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CO93X137CW"},{"name":"Legacy Concept Name","value":"Receptor_Tyrosine_Kinase_Inhibitor_ABT-869"},{"name":"Maps_To","value":"Linifanib"},{"name":"NCI_Drug_Dictionary_ID","value":"558913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558913"},{"name":"PDQ_Open_Trial_Search_ID","value":"558913"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048786"}]}}{"C101792":{"preferredName":"Linoleyl Carbonate-Paclitaxel","code":"C101792","definitions":[{"definition":"A formulation of the 6-omega fatty acid derivative 2'-linoleyl carbonate (LOC) conjugated to paclitaxel, a taxane compound extracted from the Pacific yew tree Taxus brevifolia, with potential antineoplastic activity. Paclitaxel binds to and stabilizes tubulin, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. LOC enhances the uptake of paclitaxel by tumor cells, thereby concentrating this agent in tumor cells compared to normal cells, and may decrease its toxicity profile; fatty acids serve as energy sources and biochemical precursors for the fast growing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linoleyl Carbonate-Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"2-Linoleyl Carbonate-paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"LOC-paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Linoleyl Carbonate-Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"733643"},{"name":"NCI_META_CUI","value":"CL435910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733643"},{"name":"PDQ_Open_Trial_Search_ID","value":"733643"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141135":{"preferredName":"Linrodostat","code":"C141135","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, linrodostat specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, BMS-986205 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linrodostat","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide","termGroup":"SN","termSource":"NCI"},{"termName":"BMS 986205","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986205","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986205","termGroup":"CN","termSource":"NCI"},{"termName":"IDO-1 Inhibitor BMS-986205","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205","termGroup":"SY","termSource":"NCI"},{"termName":"ONO-7701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1923833-60-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0A7729F42K"},{"name":"Maps_To","value":"Linrodostat"},{"name":"NCI_Drug_Dictionary_ID","value":"791293"},{"name":"NCI_META_CUI","value":"CL539187"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791293"},{"name":"PDQ_Open_Trial_Search_ID","value":"791293"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70982":{"preferredName":"Linsitinib","code":"C70982","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks a protein called IGF-1R, which is found at high levels in some types of tumors. IGF-1R is needed for cell growth and blocking it may cause tumor cells to die. IGF-1R inhibitor OSI-906 is a type of IGF-1R inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linsitinib","termGroup":"PT","termSource":"NCI"},{"termName":"cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, cis-","termGroup":"SN","termSource":"NCI"},{"termName":"OSI-906","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-906AA","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"867160-71-2"},{"name":"Chemical_Formula","value":"C26H23N5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15A52GPT8T"},{"name":"Legacy Concept Name","value":"IGF-1R_Inhibitor_OSI-906"},{"name":"Maps_To","value":"Linsitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"566191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"566191"},{"name":"PDQ_Open_Trial_Search_ID","value":"566191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346449"}]}}{"C1716":{"preferredName":"Lintuzumab","code":"C1716","definitions":[{"definition":"A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of myelodysplastic syndromes and some types of leukemia. It binds to CD33, a protein on the surface of certain normal blood stem cells and some abnormal blood cells. It causes the immune system to kill these cells. Lintuzumab is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lintuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Hu-M195 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"HuG1-M195 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized M195","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb HuG1-M195","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb HuM195","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody HuG1-M195","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody HuM195","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody HuM195 HuG1-M195","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-33","termGroup":"CN","termSource":"NCI"},{"termName":"SMART M195","termGroup":"SY","termSource":"NCI"},{"termName":"Zamyl","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"166089-32-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V00Y10W60W"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuG1-M195"},{"name":"Maps_To","value":"Lintuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42049"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42049"},{"name":"PDQ_Open_Trial_Search_ID","value":"42049"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0530093"}]}}{"C2396":{"preferredName":"Liothyronine I-131","code":"C2396","definitions":[{"definition":"A radioconjugate of synthetic active thyroid hormone, liothyronine (T3), labeled with Iodine 131. Liothyronine involves many important metabolic functions and is essential to the proper development and differentiation of all cells. I131 liothyronine may be used in radiotherapy in thyroid cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liothyronine I-131","termGroup":"PT","termSource":"NCI"},{"termName":"I 131 Liothyronine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"20196-64-9"},{"name":"Chemical_Formula","value":"C15H12I3NO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"86AZ0G22V2"},{"name":"Legacy Concept Name","value":"I_131_Liothyronine"},{"name":"Maps_To","value":"Liothyronine I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"39721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39721"},{"name":"PDQ_Open_Trial_Search_ID","value":"39721"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338103"}]}}{"C2581":{"preferredName":"Liothyronine Sodium","code":"C2581","definitions":[{"definition":"A drug that is used to treat certain thyroid (a gland located near the voice box) conditions. It is also being studied in the treatment of thyroid cancer. Cytomel is made in the laboratory and is a form of the thyroid hormone triiodthyronine (T3).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liothyronine Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Cytomel","termGroup":"BR","termSource":"NCI"},{"termName":"Triostat","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55-06-1"},{"name":"CHEBI_ID","value":"CHEBI:6484"},{"name":"Chemical_Formula","value":"C15H11I3NO4.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GCA9VV7D2N"},{"name":"Legacy Concept Name","value":"Liothyronine_Sodium"},{"name":"Maps_To","value":"Liothyronine Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43629"},{"name":"PDQ_Open_Trial_Search_ID","value":"43629"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546882"}]}}{"C116889":{"preferredName":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1","code":"C116889","definitions":[{"definition":"short interfering RNAs (siRNAs) directed against polo-like kinase 1 (PLK1, STPK13), with potential antineoplastic activity. Upon administration of lipid-encapsulated anti-PLK1 siRNA TKM-PLK1, siRNA binds to PLK1 mRNA, which results in the inhibition of both the translation and expression of the PLK1 protein. Blockage of PLK1 expression prevents proper tumor cell mitosis, causes cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis; its expression is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation. The pegylated lipid bilayer of SNALP provides stability and protects siRNA degradation; it facilitates uptake into the cell and release from endosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1","termGroup":"PT","termSource":"NCI"},{"termName":"PLK1 SNALP","termGroup":"SY","termSource":"NCI"},{"termName":"PLK1424","termGroup":"CN","termSource":"NCI"},{"termName":"TKM-080301","termGroup":"CN","termSource":"NCI"},{"termName":"TKM-PLK1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1"},{"name":"NCI_Drug_Dictionary_ID","value":"691765"},{"name":"NCI_META_CUI","value":"CL433763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691765"},{"name":"PDQ_Open_Trial_Search_ID","value":"691765"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160867":{"preferredName":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191","code":"C160867","definitions":[{"definition":"A formulation consisting of lipid nanoparticle encapsulated messenger RNA (mRNA) encoding human interleukin-12 subunit beta (IL-12B; IL-12 subunit p40) and interleukin-12 subunit alpha (IL-12A; IL-12 subunit p35) with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon intratumoral injection, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the IL-12A and IL-12B mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce a single-chain fusion protein of IL-12B and IL-12A subunits, which is secreted into the local tumor microenvironment (TME). Secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191","termGroup":"PT","termSource":"NCI"},{"termName":"LNP Encapsulated Human IL-12A/IL-12B mRNAs MEDI-1191","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-1191","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI1191","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191"},{"name":"NCI_Drug_Dictionary_ID","value":"798427"},{"name":"NCI_META_CUI","value":"CL969889"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798427"},{"name":"PDQ_Open_Trial_Search_ID","value":"798427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142137":{"preferredName":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416","code":"C142137","definitions":[{"definition":"A proprietary formulation consisting of a lipid nanoparticle encapsulating a synthetic messenger RNA (mRNA) encoding the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), with potential immunomodulatory and antitumor activities. Although the mechanism of action has not been completely characterized, following intratumoral injection of lipid nanoparticle encapsulated OX40L mRNA-2416, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the OX40L mRNA into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes. Altogether, this may enhance an immune response that promotes the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L","termGroup":"SY","termSource":"NCI"},{"termName":"mRNA 2416","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-2416","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416"},{"name":"NCI_Drug_Dictionary_ID","value":"791451"},{"name":"NCI_META_CUI","value":"CL540181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791451"},{"name":"PDQ_Open_Trial_Search_ID","value":"791451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157247":{"preferredName":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","code":"C157247","definitions":[{"definition":"A lipid nanoparticle encapsulating mRNAs encoding for the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), the pro-inflammatory cytokines interleukin-23 (IL-23) and interleukin-36gamma (IL-36gamma), with potential immunomodulatory and anti-tumor activities. Upon intratumoral (IT) injection of the lipid nanoparticle encapsulated mRNAs encoding human OX40L/IL-23/IL-36gamma mRNA-2752, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNAs into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes against the nearby tumor cells. The co-administration of IL-23 and IL-36gamma further stimulates anti-tumor immune responses. Altogether, this may enhance T-cell mediated anti-tumor immune responses thereby killing of the tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. IL-36gamma activates innate immune cells and promotes T-helper 1 (Th1) responses, whereas IL-23 has been implicated in Th1/Th17 immunity as well as in the modulation of antigen-presenting cells (APCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulated OX40L/IL-23/IL-36gamma mRNAs mRNA-2752","termGroup":"SY","termSource":"NCI"},{"termName":"mRNA 2752","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-2752","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA2752","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752"},{"name":"NCI_Drug_Dictionary_ID","value":"796816"},{"name":"NCI_META_CUI","value":"CL936882"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796816"},{"name":"PDQ_Open_Trial_Search_ID","value":"796816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95718":{"preferredName":"Liposomal c-raf Antisense Oligonucleotide","code":"C95718","definitions":[{"definition":"The liposomal formulation of a c-raf-1 antisense oligonucleotide, with potential antineoplastic activity. Liposomal c-raf antisense oligonucleotide targets the translation initiation site of human c-raf-1 mRNA, thereby blocking the expression and production of Raf-1 protein and thus inhibit tumor cell growth and development. Raf-1 plays a key role in the RAF/MEK/ERK signaling pathway, which regulates mammalian cell proliferation and growth. The liposomal formulation increases the solubility of the c-raf antisense oligonucleotide, thus improving its pharmacodynamic profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal c-raf Antisense Oligonucleotide","termGroup":"PT","termSource":"NCI"},{"termName":"c-raf Antisense Oligodeoxynucleotide Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"LErafAON","termGroup":"AB","termSource":"NCI"},{"termName":"liposome-encapsulated c-raf Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal c-raf Antisense Oligonucleotide"},{"name":"NCI_Drug_Dictionary_ID","value":"419645"},{"name":"PDQ_Closed_Trial_Search_ID","value":"419645"},{"name":"PDQ_Open_Trial_Search_ID","value":"419645"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1436330"}]}}{"C116322":{"preferredName":"Liposomal Curcumin","code":"C116322","definitions":[{"definition":"A liposomal formulation containing curcumin, a poorly water-soluble polylphenol pigment isolated from the plant Curcuma longa, with potential antineoplastic, chemopreventive, antioxidant, anti-angiogenic and anti-inflammatory activities. Upon intravenous administration of liposomal curcumin, this agent blocks the formation of reactive-oxygen species, neutralizes free radicals, and exhibits anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation. In addition, curcumin disrupts various cell signal transduction pathways involved in carcinogenesis, inhibits the activity of nuclear factor-kappa B (NF-kB), SRC, and annexin A2 (ANXA2), and reduces the expression of both matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor receptor 2 (VEGFR2). This prevents and/or inhibits tumor cell formation and proliferation. Liposome encapsulation of curcumin improves its efficacy, when compared to the administration of unencapsulated curcumin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Curcumin","termGroup":"PT","termSource":"NCI"},{"termName":"Curcumin Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Curcumin"},{"name":"NCI_Drug_Dictionary_ID","value":"761276"},{"name":"NCI_META_CUI","value":"CL473656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761276"},{"name":"PDQ_Open_Trial_Search_ID","value":"761276"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2388":{"preferredName":"Liposomal Cytarabine","code":"C2388","definitions":[{"definition":"A form of the anticancer drug cytarabine that is contained inside very tiny, fat-like particles. It may have fewer side effects and work better than cytarabine. It is used to treat lymphoma that has spread to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Cytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"Cytarabine Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Cytarabine Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"DepoCyt","termGroup":"BR","termSource":"NCI"},{"termName":"DepoCyte","termGroup":"FB","termSource":"NCI"},{"termName":"DepoFoam Encapsulated Cytarabine","termGroup":"SY","termSource":"NCI"},{"termName":"DTC 101","termGroup":"CN","termSource":"NCI"},{"termName":"Encapsulated Cytarabine","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Ara-C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Lymphomatous meningitis"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Liposomal_Cytarabine"},{"name":"Maps_To","value":"Liposomal Cytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"42260"},{"name":"NSC Number","value":"715320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42260"},{"name":"PDQ_Open_Trial_Search_ID","value":"42260"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0795597"}]}}{"C2213":{"preferredName":"Liposomal Daunorubicin Citrate","code":"C2213","definitions":[{"definition":"A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Daunorubicin Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Daunorubicin Citrate Liposome Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicin Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"DaunoXome","termGroup":"BR","termSource":"NCI"},{"termName":"Liposomal Daunorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Nonlymphocytic Leukemia; Acute Lymphocytic Leukemia; Advanced HIV-associated Karposi Sarcoma."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Liposomal_Daunorubicin_Citrate"},{"name":"Maps_To","value":"Liposomal Daunorubicin Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"37796"},{"name":"NSC Number","value":"697732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37796"},{"name":"PDQ_Open_Trial_Search_ID","value":"37796"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0717668"}]}}{"C92581":{"preferredName":"Liposomal Docetaxel","code":"C92581","definitions":[{"definition":"A formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel encapsulated within liposomes, with antineoplastic activity.  Upon intravenous administration, docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death.  This liposomal formulation solubilizes docetaxel without the use of toxic solvents such as Tween 80, permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity, including hypersensitivity reactions. In addition, liposomal delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"LE-DT","termGroup":"AB","termSource":"NCI"},{"termName":"Liposome Entrapped Docetaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"684963"},{"name":"NCI_META_CUI","value":"CL423830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684963"},{"name":"PDQ_Open_Trial_Search_ID","value":"684963"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111899":{"preferredName":"Liposomal Eribulin Mesylate","code":"C111899","definitions":[{"definition":"A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance derived from the marine sponge genus Halichondria, with potential antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits both the polymerization of tubulin and the assembly of microtubules. This results in the inhibition of mitotic spindle assembly, the induction of cell cycle arrest at G2/M phase, as well as tumor cell apoptosis. Compared to the administration of eribulin alone, liposomal delivery of eribulin allows for a longer half-life, which allows increased drug concentration in target tissues while decreasing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Eribulin Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"E7389 Liposomal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"E7389-LF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Eribulin Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"753504"},{"name":"NCI_META_CUI","value":"CL454231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753504"},{"name":"PDQ_Open_Trial_Search_ID","value":"753504"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111688":{"preferredName":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","code":"C111688","definitions":[{"definition":"A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","termGroup":"PT","termSource":"NCI"},{"termName":"mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"PDS0101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101"},{"name":"NCI_Drug_Dictionary_ID","value":"752827"},{"name":"NCI_META_CUI","value":"CL454078"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752827"},{"name":"PDQ_Open_Trial_Search_ID","value":"752827"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82676":{"preferredName":"Irinotecan Sucrosofate","code":"C82676","definitions":[{"definition":"A liposomal dispersion formulated with the semisynthetic camptothecin analogue irinotecan, provided as the hydrochloride trihydrate form, which is encapsulated and entrapped within liposomes in a gelated or precipitated state as the irinotecan sucrose octasulfate (sucrosulfate) salt form, with potential antineoplastic activity. Upon administration of the liposomes containing irinotecan sucrosulfate, irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. During the S-phase, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell, extends the circulation of irinotecan, and prolongs the duration of active therapy at the site of tumor to inhibit tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan Sucrosofate","termGroup":"PT","termSource":"NCI"},{"termName":"inotecan Hydrochloride as Sucrosulfate Salt Form Liposomal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Sucrosofate Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Sucrosofate-containing Pegylated Liposomal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"MM 398","termGroup":"CN","termSource":"NCI"},{"termName":"MM-398","termGroup":"CN","termSource":"NCI"},{"termName":"MM398","termGroup":"CN","termSource":"NCI"},{"termName":"nal-IRI","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoliposomal Irinotecan","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoliposomal Irinotecan as Sucrosofate","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Liposome Formulation of Irinotecan","termGroup":"SY","termSource":"NCI"},{"termName":"Onivyde","termGroup":"BR","termSource":"NCI"},{"termName":"PEP-02","termGroup":"CN","termSource":"NCI"},{"termName":"PEP02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic adenocarcinoma of the pancreas"},{"name":"CAS_Registry","value":"1361317-83-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OL741S3N8B"},{"name":"Legacy Concept Name","value":"Liposome-Encapsulated_Irinotecan_Hydrochloride_PEP02"},{"name":"Maps_To","value":"Irinotecan Sucrosofate"},{"name":"Maps_To","value":"Liposomal Irinotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"632436"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632436"},{"name":"PDQ_Open_Trial_Search_ID","value":"632436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4057931"}]}}{"C116064":{"preferredName":"Liposomal Mitoxantrone Hydrochloride","code":"C116064","definitions":[{"definition":"A formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in the rapidly dividing cancer cells. The liposomal delivery of mitoxantrone improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering the toxic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Mitoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Mitoxantrone Hydrochloride Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Mitoxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"760808"},{"name":"NCI_META_CUI","value":"CL473483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760808"},{"name":"PDQ_Open_Trial_Search_ID","value":"760808"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101262":{"preferredName":"Liposomal MUC1/PET-lipid A Vaccine ONT-10","code":"C101262","definitions":[{"definition":"A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine ONT-10 results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal MUC1/PET-lipid A Vaccine ONT-10","termGroup":"PT","termSource":"NCI"},{"termName":"ONT-10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal MUC1/PET-lipid A Vaccine ONT-10"},{"name":"NCI_Drug_Dictionary_ID","value":"729635"},{"name":"NCI_META_CUI","value":"CL435510"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729635"},{"name":"PDQ_Open_Trial_Search_ID","value":"729635"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1383":{"preferredName":"Liposomal NDDP","code":"C1383","definitions":[{"definition":"A synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement of the 2 long-chain aliphatic leaving groups (neodecanoic acid), platinum diaminocyclohexane (DACH) complexes become highly reactive and alkylate macromolecules, forming both inter- and intra-stranded DNA cross-linkings and inhibiting DNA synthesis, which results in tumor cell cytotoxicity. Because DNA mismatch-repair (MMR) complexes do not recognize DACH-platinum adducts, DNA repair mechanisms are inhibited, overcoming limitations observed with other platinum-based agents. In addition, the liposomal encapsulation improves the bioavailability of NDDP and reduces its toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal NDDP","termGroup":"PT","termSource":"NCI"},{"termName":"Aroplatin","termGroup":"BR","termSource":"NCI"},{"termName":"L-NDDP","termGroup":"AB","termSource":"NCI"},{"termName":"Liposomal Neodecanoic Acid Platinum Complex","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal-Cisplatin Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal-Entrapped Cis-Bis-Neodecanoate-trans-R,R-1,2-Diaminocyclohexane Platinum (II)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114488-24-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J7M4Z2D183"},{"name":"Legacy Concept Name","value":"Liposomal-Cisplatin_Analogue"},{"name":"Maps_To","value":"Liposomal NDDP"},{"name":"NCI_Drug_Dictionary_ID","value":"43010"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43010"},{"name":"PDQ_Open_Trial_Search_ID","value":"43010"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0125061"}]}}{"C107679":{"preferredName":"Liposomal Rhenium Re 186","code":"C107679","definitions":[{"definition":"A therapeutic preparation consisting of the beta-emitting radioisotope rhenium Re 186 encapsulated in a nanoliposome, with potential antineoplastic activity. Upon intratumoral infusion of liposomal rhenium Re 186, the radioisotope releases radiation, which directly kills the tumor cells. The nanoliposomes facilitate the retention of the radioisotope by the tumor cells and localize the radiocytotoxicity to the tumor while sparing surrounding normal, healthy cells. Re-186 has a short half-life and a short path length, which contributes further to limiting the radiotoxicity to the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Rhenium Re 186","termGroup":"PT","termSource":"NCI"},{"termName":"(186)Re-Liposomes","termGroup":"SY","termSource":"NCI"},{"termName":"186RNL","termGroup":"AB","termSource":"NCI"},{"termName":"Liposomal Rhenium-186","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-186 Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Rhenium Re 186"},{"name":"NCI_Drug_Dictionary_ID","value":"751420"},{"name":"NCI_META_CUI","value":"CL451869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751420"},{"name":"PDQ_Open_Trial_Search_ID","value":"751420"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95717":{"preferredName":"Liposomal SN-38","code":"C95717","definitions":[{"definition":"The liposomal formulation of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. SN-38 has been reported to exhibit up to 1,000-fold more cytotoxic activity against various cancer cells in vitro than irinotecan. The liposomal formulation of SN-38 increases the solubility of SN-38, which is a relatively insoluble compound, and improves the pharmacodynamic profile as compared to SN-38 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal SN-38","termGroup":"PT","termSource":"NCI"},{"termName":"7-Ethyl-10-hydroxycamptothecin Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"LE-SN38","termGroup":"AB","termSource":"NCI"},{"termName":"SN-38 Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal SN-38"},{"name":"NCI_Drug_Dictionary_ID","value":"355805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355805"},{"name":"PDQ_Open_Trial_Search_ID","value":"355805"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328201"}]}}{"C165505":{"preferredName":"Liposomal Topotecan FF-10850","code":"C165505","definitions":[{"definition":"A liposome encapsulated formulation of the semisynthetic camptothecin analogue topotecan with potential antineoplastic activity. Upon administration, liposomal topotecan FF-10850 preferentially releases topotecan, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminate, into the tumor environment. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The novel liposome used in this agent prolongs its serum half-life while promoting efficient drug delivery into the cytosol from the endosome compartment of the tumor cell, which may minimize the adverse effect of bone marrow suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Topotecan FF-10850","termGroup":"PT","termSource":"NCI"},{"termName":"FF 10850","termGroup":"CN","termSource":"NCI"},{"termName":"FF-10850","termGroup":"CN","termSource":"NCI"},{"termName":"FF10850","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Topotecan FF-10850"},{"name":"NCI_Drug_Dictionary_ID","value":"799933"},{"name":"NCI_META_CUI","value":"CL978696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799933"},{"name":"PDQ_Open_Trial_Search_ID","value":"799933"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62790":{"preferredName":"Liposomal Vinorelbine","code":"C62790","definitions":[{"definition":"A formulation of the semisynthetic vinca alkaloid, vinorelbine, encapsulated within liposomes, with antineoplastic activity. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in cell cycle arrest in metaphase. Like other vinca alkaloids, vinorelbine may also interfere with the metabolism of nucleic acids, lipids, amino acids, cAMP, and glutathione, as well as other biological processes including calmodulin-dependent Ca2+-transport, ATPase activity, or cellular respiration. Liposomal delivery of vinorelbine improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Vinorelbine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liposomal_Vinorelbine"},{"name":"Maps_To","value":"Liposomal Vinorelbine"},{"name":"NCI_Drug_Dictionary_ID","value":"507579"},{"name":"PDQ_Closed_Trial_Search_ID","value":"507579"},{"name":"PDQ_Open_Trial_Search_ID","value":"507579"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831959"}]}}{"C135619":{"preferredName":"Liposomal Vinorelbine Tartrate","code":"C135619","definitions":[{"definition":"A formulation of the tartrate salt form of vinorelbine, a semisynthetic vinca alkaloid, encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, vinorelbine binds to tubulin within tumor cells and prevents the formation of the mitotic spindle, resulting in cell cycle arrest, induction of apoptosis and an inhibition of tumor cell growth. Compared to the administration of vinorelbine alone, the liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing vinorelbine's efficacy while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Vinorelbine Tartrate","termGroup":"PT","termSource":"NCI"},{"termName":"TLC-178","termGroup":"CN","termSource":"NCI"},{"termName":"TLC178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Vinorelbine Tartrate"},{"name":"NCI_Drug_Dictionary_ID","value":"789502"},{"name":"NCI_META_CUI","value":"CL522975"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789502"},{"name":"PDQ_Open_Trial_Search_ID","value":"789502"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C18208":{"preferredName":"Liposome","code":"C18208","definitions":[{"definition":"A very tiny, fat-like particle that is made in the laboratory. In medicine, liposomes containing drugs or other substances are used in the treatment of cancer and other diseases. Drugs given in liposomes may have fewer side effects and work better than the same drugs given alone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Substances composed of layers of lipid that form hollow microscopic spheres within which drugs or agents could be contained for enhanced safety and efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liposome"},{"name":"Maps_To","value":"Liposome"},{"name":"Semantic_Type","value":"Drug Delivery Device"},{"name":"UMLS_CUI","value":"C0023828"}]}}{"C67504":{"preferredName":"Liposome-encapsulated Daunorubicin-Cytarabine","code":"C67504","definitions":[{"definition":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated Daunorubicin-Cytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"CPX-351","termGroup":"CN","termSource":"NCI"},{"termName":"Cytarabine and Daunorubicin Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Cytarabine-Daunorubicin Liposome for Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal AraC-Daunorubicin CPX-351","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Cytarabine-Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Liposome-encapsulated Combination of Daunorubicin and Cytarabine","termGroup":"SY","termSource":"NCI"},{"termName":"Vyxeos","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Liposomal_Cytarabine-Daunorubicin_CPX-351"},{"name":"Maps_To","value":"Liposome-encapsulated Daunorubicin-Cytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"554979"},{"name":"NCI_META_CUI","value":"CL372099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"554979"},{"name":"PDQ_Open_Trial_Search_ID","value":"554979"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61317":{"preferredName":"Liposome-Encapsulated Doxorubicin Citrate","code":"C61317","definitions":[{"definition":"A form of the anticancer drug doxorubicin citrate that is contained inside very tiny, fat-like particles. It is being studied in the treatment of breast cancer that has spread and in the treatment of other types of cancer. Doxorubicin citrate damages DNA and may kill cancer cells. Liposomal-encapsulated doxorubicin citrate may have fewer side effects and may work better than doxorubicin citrate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-Encapsulated Doxorubicin Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Myocet","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111266-55-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AJQ2ZNG2WL"},{"name":"Legacy Concept Name","value":"Liposome-Encapsulated_Doxorubicin_Citrate"},{"name":"Maps_To","value":"Liposome-Encapsulated Doxorubicin Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"481301"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481301"},{"name":"PDQ_Open_Trial_Search_ID","value":"481301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1512062"}]}}{"C105802":{"preferredName":"Liposome-encapsulated miR-34 Mimic MRX34","code":"C105802","definitions":[{"definition":"A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated miR-34 Mimic MRX34","termGroup":"PT","termSource":"NCI"},{"termName":"MRX34","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposome-encapsulated miR-34 Mimic MRX34"},{"name":"NCI_Drug_Dictionary_ID","value":"747643"},{"name":"NCI_META_CUI","value":"CL447293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747643"},{"name":"PDQ_Open_Trial_Search_ID","value":"747643"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38694":{"preferredName":"Liposome-encapsulated OSI-7904","code":"C38694","definitions":[{"definition":"A liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called thymidylate synthase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Liposome-encapsulated OSI-7904","termGroup":"PT","termSource":"NCI"},{"termName":"GS7904L","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-7904L","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"139987-54-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ON177ZCE7M"},{"name":"Legacy Concept Name","value":"OSI-7904L"},{"name":"Maps_To","value":"Liposome-encapsulated OSI-7904"},{"name":"NCI_Drug_Dictionary_ID","value":"352016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352016"},{"name":"PDQ_Open_Trial_Search_ID","value":"352016"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328144"}]}}{"C106271":{"preferredName":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94","code":"C106271","definitions":[{"definition":"A systemic gene therapy anti-cancer agent composed of cationic liposomes, which encapsulates plasmid DNA encoding for the tumor suppressor gene RB94 and is complexed with anti-transferrin receptor single chain antibody fragment (TfRscFv), with potential antineoplastic activity. Upon systemic administration of liposome-encapsulated RB94 plasmid DNA gene therapy agent SGT-94, the TfRscFv portion of this agent selectively targets the tumor cells expressing transferrin receptors. TfRscFv binding to the transferrin receptor allows receptor-mediated endocytosis and transfection, followed by the expression of RB94 gene. This induces tumor cell apoptosis through an as of yet unknown pathway. RB94 is a modified, N-terminal truncated form of the full-length protein retinoblastoma gene RB110, and exerts enhanced antitumor activity. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin, and is overexpressed in a variety of tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94","termGroup":"PT","termSource":"NCI"},{"termName":"SGT-94","termGroup":"CN","termSource":"NCI"},{"termName":"TfRscFv/Lip/RB94","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94"},{"name":"NCI_Drug_Dictionary_ID","value":"724243"},{"name":"NCI_META_CUI","value":"CL433963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724243"},{"name":"PDQ_Open_Trial_Search_ID","value":"724243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103820":{"preferredName":"Lirilumab","code":"C103820","definitions":[{"definition":"A fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon administration, lirilumab binds to KIR, thereby preventing the binding of KIR ligands to KIR on natural killer (NK) cells. By blocking these inhibitory receptors, NK cells become activated and attack cancer cells leading to tumor cell death. KIR, a member of the immunoglobulin superfamily, is expressed on the surface of NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirilumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986015","termGroup":"CN","termSource":"NCI"},{"termName":"IPH2102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000676-41-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9XDI9W918"},{"name":"Maps_To","value":"Lirilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"742530"},{"name":"NCI_META_CUI","value":"CL438303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742530"},{"name":"PDQ_Open_Trial_Search_ID","value":"742530"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97664":{"preferredName":"Lisavanbulin","code":"C97664","definitions":[{"definition":"An orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL27862 with potential antitumor activity. Upon administration of lisavanbulin and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lisavanbulin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2,6-Diamino-N-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1H-benzimidazol-1-yl)acetyl)phenyl)hexanamide","termGroup":"SN","termSource":"NCI"},{"termName":"BAL-101553","termGroup":"CN","termSource":"NCI"},{"termName":"BAL101553","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1263384-43-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5PT0QP06X5"},{"name":"Maps_To","value":"Lisavanbulin"},{"name":"NCI_Drug_Dictionary_ID","value":"706747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706747"},{"name":"PDQ_Open_Trial_Search_ID","value":"706747"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273554"}]}}{"C125192":{"preferredName":"Lisocabtagene Maraleucel","code":"C125192","definitions":[{"definition":"A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lisocabtagene Maraleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017","termGroup":"SY","termSource":"NCI"},{"termName":"Breyanzi","termGroup":"BR","termSource":"NCI"},{"termName":"JCAR 017","termGroup":"CN","termSource":"NCI"},{"termName":"JCAR017","termGroup":"CN","termSource":"NCI"},{"termName":"Liso-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with certain types of large B-cell lymphoma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7K2YOJ14X0"},{"name":"Maps_To","value":"Lisocabtagene Maraleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"778386"},{"name":"NCI_META_CUI","value":"CL504006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778386"},{"name":"PDQ_Open_Trial_Search_ID","value":"778386"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120103":{"preferredName":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142","code":"C120103","definitions":[{"definition":"A cancer vaccine containing a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a fusion protein composed of the tumor-associated antigen (TAA) human prostate-specific antigen (PSA) fused to a fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-LLO-PSA vaccine ADXS31-142, the expressed LLO-PSA is processed by antigen presenting cells (APCs), presented to the immune system by both major histocompatibility complex (MHC) I and II molecules, and activates the immune system to exert both an innate and adaptive immune response involving the recruitment and activation of T-lymphocytes against PSA-expressing tumor cells as well as the inhibition of tumor-infiltrating T regulatory cells (T regs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS-PSA","termGroup":"SY","termSource":"NCI"},{"termName":"ADXS31-142","termGroup":"CN","termSource":"NCI"},{"termName":"Lm-LLO-PSA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142"},{"name":"NCI_Drug_Dictionary_ID","value":"767990"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767990"},{"name":"PDQ_Open_Trial_Search_ID","value":"767990"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896925"}]}}{"C88328":{"preferredName":"Litronesib","code":"C88328","definitions":[{"definition":"An inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein that plays an essential role during mitosis, particularly in the regulation of spindle dynamics, including assembly and maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Litronesib","termGroup":"PT","termSource":"NCI"},{"termName":"KF89617","termGroup":"CN","termSource":"NCI"},{"termName":"LY2523355","termGroup":"CN","termSource":"NCI"},{"termName":"Propanamide, N-[4-(2,2-dimethyl-1-oxopropyl)-5-[[[[2-(ethylamino)ethyl]sulfonyl] amino]methyl]-4,5-dihydro-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethyl-, (-)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"910634-41-2"},{"name":"Chemical_Formula","value":"C23H37N5O4S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6611F8KYCV"},{"name":"Maps_To","value":"Litronesib"},{"name":"NCI_Drug_Dictionary_ID","value":"661443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661443"},{"name":"PDQ_Open_Trial_Search_ID","value":"661443"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981845"}]}}{"C125631":{"preferredName":"Opolimogene Capmilisbac","code":"C125631","definitions":[{"definition":"A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, opolimogene capmilisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opolimogene Capmilisbac","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-741","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64041809","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-809","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2O95SM11L5"},{"name":"Maps_To","value":"Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809"},{"name":"Maps_To","value":"Opolimogene Capmilisbac"},{"name":"NCI_Drug_Dictionary_ID","value":"778079"},{"name":"NCI_META_CUI","value":"CL504330"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778079"},{"name":"PDQ_Open_Trial_Search_ID","value":"778079"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74055":{"preferredName":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","code":"C74055","definitions":[{"definition":"A recombinant Listeria-based cancer vaccine containing a live-attenuated strain of the facultative intracellular bacterium Listeria monocytogenes (Lm) expressing human mesothelin with potential immunostimulatory and antineoplastic activities. Upon administration of this vaccine, Listeria invade professional phagocytes within the immune system and express mesothelin, which may activate a cytotoxic T-lymphocyte (CTL) response against mesothelin-expressing tumor cells, resulting in tumor cell lysis. In addition, the Listeria vector itself may induce a potent innate and adaptive immunity unrelated to mesothelin expression. Mesothelin is a cell surface glycoprotein involved in cell adhesion and is overexpressed in many epithelial-derived cancers, including pancreatic, ovarian and lung cancers, and malignant mesotheliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","termGroup":"PT","termSource":"NCI"},{"termName":"CRS-207","termGroup":"CN","termSource":"NCI"},{"termName":"LADD Listeria monocytogenes CRS-207","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JJX4JHS4PO"},{"name":"Legacy Concept Name","value":"Live-Attenuated_Listeria_Encoding_Human_Mesothelin_Vaccine_CRS-207"},{"name":"Maps_To","value":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207"},{"name":"NCI_Drug_Dictionary_ID","value":"586104"},{"name":"NCI_META_CUI","value":"CL383482"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586104"},{"name":"PDQ_Open_Trial_Search_ID","value":"586104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111998":{"preferredName":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623","code":"C111998","definitions":[{"definition":"A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-623","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623"},{"name":"NCI_Drug_Dictionary_ID","value":"754227"},{"name":"NCI_META_CUI","value":"CL454287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754227"},{"name":"PDQ_Open_Trial_Search_ID","value":"754227"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131910":{"preferredName":"Abequolixron","code":"C131910","definitions":[{"definition":"An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abequolixron","termGroup":"PT","termSource":"NCI"},{"termName":"Liver X Receptor beta Agonist RGX-104","termGroup":"SY","termSource":"NCI"},{"termName":"LXR-b Agonist RGX-104","termGroup":"SY","termSource":"NCI"},{"termName":"RGX 104","termGroup":"CN","termSource":"NCI"},{"termName":"RGX-104","termGroup":"CN","termSource":"NCI"},{"termName":"RGX104","termGroup":"CN","termSource":"NCI"},{"termName":"SB-742881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"610318-54-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q26B92650V"},{"name":"Maps_To","value":"Liver X Receptor beta Agonist RGX-104"},{"name":"NCI_Drug_Dictionary_ID","value":"786379"},{"name":"NCI_META_CUI","value":"CL520758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786379"},{"name":"PDQ_Open_Trial_Search_ID","value":"786379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148380":{"preferredName":"Lm-tLLO-neoantigens Vaccine ADXS-NEO","code":"C148380","definitions":[{"definition":"A proprietary, personalized plasmid DNA-based cancer vaccine composed of a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a proprietary plasmid vector encoding multiple, patient-specific, immunogenic neoepitopes fused to a truncated form of the immunostimulant listeriolysin O (tLLO), with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-tLLO-neoantigens vaccine ADXS-NEO, the ADXS-NEO is taken up by antigen presenting cells (APCs), such as dendritic cells (DCs), and the expressed tLLO-neoantigens fusion protein is processed and presented to the immune system by both major histocompatibility complex (MHC) I and II molecules. This activates the immune system to exert both innate and adaptive immune responses involving the recruitment and activation of T-lymphocytes against the tumor-associated antigens (TAAs) specifically expressed by the patient's tumor cells, and inhibits the immunosuppressive tumor-infiltrating T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME). This results in tumor cell lysis. The various unique mutation-derived TAAs that are used in ADXS-NEO are identified from a biopsy of the patient's tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lm-tLLO-neoantigens Vaccine ADXS-NEO","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS NEO","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS-NEO","termGroup":"CN","termSource":"NCI"},{"termName":"Neoepitope-based Immunotherapeutic ADXS-NEO","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lm-tLLO-neoantigens Vaccine ADXS-NEO"},{"name":"NCI_Drug_Dictionary_ID","value":"793901"},{"name":"NCI_META_CUI","value":"CL551029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793901"},{"name":"PDQ_Open_Trial_Search_ID","value":"793901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2499":{"preferredName":"LMB-1 Immunotoxin","code":"C2499","definitions":[{"definition":"A chimeric protein consisting of the Fv portion of a monoclonal antibody attached to a fragment of Pseudomonas exotoxin A without its cell-binding region.  LMB-1 immunotoxin targets B3, a Lewis Y-related carbohydrate epitope found on some solid tumors.  The antibody attaches to the tumor cell and the exotoxin stops protein synthesis by inactivating elongation factor 2. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-1 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"B3-NLysPE38","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-1","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-1_Immunotoxin"},{"name":"Maps_To","value":"LMB-1 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43265"},{"name":"NSC Number","value":"651311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43265"},{"name":"PDQ_Open_Trial_Search_ID","value":"43265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796420"}]}}{"C2513":{"preferredName":"LMB-2 Immunotoxin","code":"C2513","definitions":[{"definition":"A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-2 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Tac(Fv)-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized AntiTac Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-2","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-2","termGroup":"AB","termSource":"NCI"},{"termName":"LMB-2 (Anti-TAC(FV)-PE-38)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-2_Immunotoxin"},{"name":"Maps_To","value":"LMB-2 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43377"},{"name":"NSC Number","value":"676422"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43377"},{"name":"PDQ_Open_Trial_Search_ID","value":"43377"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0655013"}]}}{"C1619":{"preferredName":"LMB-7 Immunotoxin","code":"C1619","definitions":[{"definition":"A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells.  The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-7 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"B3(Fv)-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"B3(Fv)-PE38 Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"HB21(Fv)PE40","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-7","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-7 (Single-Chain Immunotoxin)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-7_Immunotoxin"},{"name":"Maps_To","value":"LMB-7 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"42683"},{"name":"NSC Number","value":"658931"},{"name":"NSC Number","value":"659639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42683"},{"name":"PDQ_Open_Trial_Search_ID","value":"42683"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0296314"}]}}{"C2472":{"preferredName":"LMB-9 Immunotoxin","code":"C2472","definitions":[{"definition":"A recombinant disulfide stabilized anti-Lewis Y IgG immunotoxin containing a 38 KD toxic element derived from the Pseudomonas aeruginosa exotoxin A and a monoclonal antibody fragment, designed to target adenocarcinomas expressing Lewis Y. LMB-9 immunotoxin attaches to tumor cells, facilitating he entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-9 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"B3 (dsFv)-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-9","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-9_Immunotoxin"},{"name":"Maps_To","value":"LMB-9 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43018"},{"name":"NSC Number","value":"691236"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43018"},{"name":"PDQ_Open_Trial_Search_ID","value":"43018"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678023"}]}}{"C121541":{"preferredName":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164","code":"C121541","definitions":[{"definition":"A cancer vaccine containing a live, highly attenuated strain of the Gram-positive bacterium Listeria monocytogenes (LmddA) encoding a fusion protein composed of a chimeric peptide comprised of three highly immunogenic epitopes of the human tumor-associated antigen (TAA) HER2/neu (chHER2) fused to a non-hemolytic fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the LmddA-LLO-chHER2 vaccine OST31-164, the LmddA is taken up by phagocytic cells; then the listeriolysin portion of the expressed LLO-chHER2 can form pores in the phagolysosomes and the fusion protein can escape into the cytosol. In turn, the LLO-chHER2 is processed and presented to the immune system by major histocompatibility complex (MHC) I on the phagocytic cells. Antigen presentation activates the immune system to exert an immune response involving the recruitment and activation of T-lymphocytes against HER2-expressing tumor cells, and inhibits tumor-infiltrating T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis. HER2/neu, a tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, is overexpressed in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS 31164","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS-HER2","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS31-164","termGroup":"CN","termSource":"NCI"},{"termName":"OST-HER2","termGroup":"CN","termSource":"NCI"},{"termName":"OST31 164","termGroup":"CN","termSource":"NCI"},{"termName":"OST31164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164"},{"name":"NCI_Drug_Dictionary_ID","value":"770190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770190"},{"name":"PDQ_Open_Trial_Search_ID","value":"770190"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053682"}]}}{"C62767":{"preferredName":"LMP-2:340-349 Peptide Vaccine","code":"C62767","definitions":[{"definition":"A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP-2:340-349 Peptide Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMP-2_340-349_Peptide_Vaccine"},{"name":"Maps_To","value":"LMP-2:340-349 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"504594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504594"},{"name":"PDQ_Open_Trial_Search_ID","value":"504594"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831952"}]}}{"C62768":{"preferredName":"LMP-2:419-427 Peptide Vaccine","code":"C62768","definitions":[{"definition":"A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP-2:419-427 Peptide Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMP-2_419-427_Peptide_Vaccine"},{"name":"Maps_To","value":"LMP-2:419-427 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"504596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504596"},{"name":"PDQ_Open_Trial_Search_ID","value":"504596"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831953"}]}}{"C1434":{"preferredName":"Lobaplatin","code":"C1434","definitions":[{"definition":"A substance that contains the metal platinum and may kill cancer cells by damaging their DNA and stopping them from dividing. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A third-generation, water-soluble platinum compound with potential antineoplastic activity. Lobaplatin forms highly reactive, charged, platinum complexes that bind to nucleophilic groups such as GC- and AG-rich sites in DNA, inducing intrastrand DNA cross-links. These cross-links will ultimately result in induction of apoptosis and cell growth inhibition. Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lobaplatin","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-diammino-methy lcyclobutane-platinum (II) lactate","termGroup":"SN","termSource":"NCI"},{"termName":"D-19466","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135558-11-1"},{"name":"Chemical_Formula","value":"C6H14N2.C3H4O3.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OX5XK1JD8C"},{"name":"Legacy Concept Name","value":"Lobaplatin"},{"name":"Maps_To","value":"Lobaplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"41669"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41669"},{"name":"PDQ_Open_Trial_Search_ID","value":"41669"},{"name":"PubMedID_Primary_Reference","value":"21034513"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165747"}]}}{"C979":{"preferredName":"Lometrexol","code":"C979","definitions":[{"definition":"A folate analog antimetabolite with antineoplastic activity. As the 6R diastereomer of 5,10-dideazatetrahydrofolate, lometrexol inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis, arresting cells in the S phase of the cell cycle, and inhibiting tumor cell proliferation.  The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called antifolates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lometrexol","termGroup":"PT","termSource":"NCI"},{"termName":"(6R)-DDATHF","termGroup":"AB","termSource":"NCI"},{"termName":"6R-5,10-Dideazatetrahydrofolate","termGroup":"SN","termSource":"NCI"},{"termName":"L-Glutamic acid, N-(4-(2-((6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"L-Glutamic acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (R)-","termGroup":"SN","termSource":"NCI"},{"termName":"Pyrido[2,3-d]pyrimidine, L-glutamic acid derivative (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"106400-81-1"},{"name":"Chemical_Formula","value":"C21H25N5O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6P3AVY8A7Q"},{"name":"Legacy Concept Name","value":"Lometrexol"},{"name":"Maps_To","value":"Lometrexol"},{"name":"NCI_Drug_Dictionary_ID","value":"41670"},{"name":"NSC Number","value":"660025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41670"},{"name":"PDQ_Open_Trial_Search_ID","value":"41670"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048852"}]}}{"C90623":{"preferredName":"Lometrexol Sodium","code":"C90623","definitions":[{"definition":"The sodium salt form of lometrexol, a folate analogue antimetabolite with antineoplastic activity. As the stereoisomer of 5,10-dideazatetrahydrofolate, lometrexol selectively inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis and leading to an inhibition of tumor cell proliferation.  The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate, but causes severe, dose-limiting toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lometrexol Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"LY264618 Disodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"120408-07-3"},{"name":"Chemical_Formula","value":"C21H23N5O6.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"US81N1145T"},{"name":"Maps_To","value":"Lometrexol Sodium"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983806"}]}}{"C617":{"preferredName":"Lomustine","code":"C617","definitions":[{"definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lomustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Belustin","termGroup":"FB","termSource":"NCI"},{"termName":"Belustine","termGroup":"FB","termSource":"NCI"},{"termName":"CCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Cecenu","termGroup":"FB","termSource":"NCI"},{"termName":"CeeNU","termGroup":"BR","termSource":"NCI"},{"termName":"Chloroethylcyclo- hexylnitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Chloroethylcyclohexylnitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"Citostal","termGroup":"FB","termSource":"NCI"},{"termName":"Gleostine","termGroup":"BR","termSource":"NCI"},{"termName":"Lomeblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Lomustinum","termGroup":"SY","termSource":"NCI"},{"termName":"Lucostin","termGroup":"FB","termSource":"NCI"},{"termName":"Lucostine","termGroup":"FB","termSource":"NCI"},{"termName":"N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Prava","termGroup":"FB","termSource":"NCI"},{"termName":"RB-1509","termGroup":"CN","termSource":"NCI"},{"termName":"WR-139017","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Brain tumors; Hodgkins disease"},{"name":"CAS_Registry","value":"13010-47-4"},{"name":"Chemical_Formula","value":"C9H16ClN3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7BRF0Z81KG"},{"name":"Legacy Concept Name","value":"Lomustine"},{"name":"Maps_To","value":"Lomustine"},{"name":"NCI_Drug_Dictionary_ID","value":"43065"},{"name":"NSC Number","value":"79037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43065"},{"name":"PDQ_Open_Trial_Search_ID","value":"43065"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0023972"}]}}{"C1829":{"preferredName":"Lonafarnib","code":"C1829","definitions":[{"definition":"A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called enzyme inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lonafarnib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[2-[4-(3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Sarasar","termGroup":"BR","termSource":"NCI"},{"termName":"SCH 66336","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-66336","termGroup":"CN","termSource":"NCI"},{"termName":"SCH66336","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"193275-84-2"},{"name":"Chemical_Formula","value":"C27H31Br2ClN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IOW153004F"},{"name":"Legacy Concept Name","value":"Lonafarnib"},{"name":"Maps_To","value":"Lonafarnib"},{"name":"NCI_Drug_Dictionary_ID","value":"43503"},{"name":"NSC Number","value":"719467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43503"},{"name":"PDQ_Open_Trial_Search_ID","value":"43503"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1257385"}]}}{"C125549":{"preferredName":"Loncastuximab Tesirine","code":"C125549","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Loncastuximab Tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-402","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT-402","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD19 PBD-conjugate ADCT-402","termGroup":"SY","termSource":"NCI"},{"termName":"Loncastuximab Tesirine-lpyl","termGroup":"SY","termSource":"NCI"},{"termName":"MT 2111","termGroup":"CN","termSource":"NCI"},{"termName":"MT-2111","termGroup":"CN","termSource":"NCI"},{"termName":"MT2111","termGroup":"CN","termSource":"NCI"},{"termName":"Zynlonta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory large B-cell lymphoma"},{"name":"CAS_Registry","value":"1879918-31-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7K5O7P6QIU"},{"name":"Maps_To","value":"Loncastuximab Tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"778954"},{"name":"NCI_META_CUI","value":"CL504277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778954"},{"name":"PDQ_Open_Trial_Search_ID","value":"778954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116067":{"preferredName":"Long Peptide Vaccine 7","code":"C116067","definitions":[{"definition":"A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Long Peptide Vaccine 7","termGroup":"PT","termSource":"NCI"},{"termName":"LPV7","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Long Peptide Vaccine 7"},{"name":"NCI_Drug_Dictionary_ID","value":"760895"},{"name":"NCI_META_CUI","value":"CL473486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760895"},{"name":"PDQ_Open_Trial_Search_ID","value":"760895"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113656":{"preferredName":"Long-acting Release Pasireotide","code":"C113656","definitions":[{"definition":"A long-acting release (LAR) formulation containing pasireotide, a synthetic long-acting cyclohexapeptide, with somatostatin-like activity. Upon intramuscular administration of the LAR formulation of pasireotide, this somatostatin analog strongly binds to and activates somatostatin receptor (SSTR) subtypes 1, 2, 3, and 5. This leads to an inhibition in the secretion of human growth hormone (hGH) and results in decreased production of insulin-like growth factor (IGF-1), which may inhibit IGF-1-mediated cell signaling pathways. This may lead to an inhibition in tumor cell growth and an increase in apoptosis in IGF-1-overexpressing tumor cells. In addition, this agent causes a reduction in adrenocorticotropic hormone (ACTH), which leads to an inhibition of cortisol secretion. ACTH-producing tumors cause hypersecretion of cortisol which results in many unwanted symptoms. This agent may also block other key survival pathways such as the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) signaling pathways. Pasireotide also inhibits vascular endothelial growth factor (VEGF) secretion, thereby decreasing angiogenesis and tumor cell growth in VEGF-overexpressing tumor cells. The long-acting form of pasireotide allows for less frequent administration as compared to the original form of this agent. SSTRs are overexpressed by some neuroendocrine and non-neuroendocrine tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Long-acting Release Pasireotide","termGroup":"PT","termSource":"NCI"},{"termName":"LAR Pasireotide","termGroup":"SY","termSource":"NCI"},{"termName":"SOM230 LAR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Long-acting Release Pasireotide"},{"name":"NCI_Drug_Dictionary_ID","value":"756940"},{"name":"NCI_META_CUI","value":"CL458369"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756940"},{"name":"PDQ_Open_Trial_Search_ID","value":"756940"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2830":{"preferredName":"Lontucirev","code":"C2830","definitions":[{"definition":"A modified cold virus that selectively grows in and destroys certain types of cancer cells and leaves normal cells undamaged.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of lontucirev-mediated tumor cell cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lontucirev","termGroup":"PT","termSource":"NCI"},{"termName":"CI 1042","termGroup":"CN","termSource":"NCI"},{"termName":"CI-1042","termGroup":"CN","termSource":"NCI"},{"termName":"E1B 55kDa mutant adenovirus dl1520","termGroup":"SY","termSource":"NCI"},{"termName":"E1B-Attenuated Adenovirus","termGroup":"SY","termSource":"NCI"},{"termName":"Lontucirev (Replicating Adenovirus)","termGroup":"SY","termSource":"NCI"},{"termName":"ONYX-015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"437981-77-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F1F4B2ILM1"},{"name":"Legacy Concept Name","value":"ONYX-015"},{"name":"Maps_To","value":"Lontucirev"},{"name":"NCI_Drug_Dictionary_ID","value":"43035"},{"name":"NSC Number","value":"688653"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43035"},{"name":"PDQ_Open_Trial_Search_ID","value":"43035"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678040"}]}}{"C113655":{"preferredName":"Lorlatinib","code":"C113655","definitions":[{"definition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lorlatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-","termGroup":"SY","termSource":"NCI"},{"termName":"7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"Lorbrena","termGroup":"BR","termSource":"NCI"},{"termName":"Lorviqua","termGroup":"FB","termSource":"NCI"},{"termName":"PF-06463922","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1454846-35-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OSP71S83EU"},{"name":"Maps_To","value":"Lorlatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"756930"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756930"},{"name":"PDQ_Open_Trial_Search_ID","value":"756930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3884739"}]}}{"C38714":{"preferredName":"Lorvotuzumab Mertansine","code":"C38714","definitions":[{"definition":"A substance that combines a monoclonal antibody (huN901) with an anticancer drug (DM1), and is being studied in the treatment of certain cancers, including non-small cell lung cancer. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lorvotuzumab Mertansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Human NCAM-1 Monoclonal Antibody N901","termGroup":"SY","termSource":"NCI"},{"termName":"BB-10901","termGroup":"CN","termSource":"NCI"},{"termName":"huN901-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1008106-64-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0IVD6ASY0W"},{"name":"Legacy Concept Name","value":"BB-10901"},{"name":"Maps_To","value":"Lorvotuzumab Mertansine"},{"name":"NCI_Drug_Dictionary_ID","value":"346110"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346110"},{"name":"PDQ_Open_Trial_Search_ID","value":"346110"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987530"}]}}{"C120556":{"preferredName":"Losatuxizumab Vedotin","code":"C120556","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of losatuxizumab vedotin selectively targets and binds to EGFR. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Losatuxizumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-221","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1685249-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"17C83BVV62"},{"name":"Maps_To","value":"Losatuxizumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"769542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769542"},{"name":"PDQ_Open_Trial_Search_ID","value":"769542"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055621"}]}}{"C1521":{"preferredName":"Losoxantrone","code":"C1521","definitions":[{"definition":"An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antipyrazoles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Losoxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"Biantrazole","termGroup":"SY","termSource":"NCI"},{"termName":"CI-941","termGroup":"CN","termSource":"NCI"},{"termName":"DuP 941","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88303-60-0"},{"name":"Chemical_Formula","value":"C22H27N5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"47KPH00809"},{"name":"Legacy Concept Name","value":"Losoxantrone"},{"name":"Maps_To","value":"Losoxantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"41809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41809"},{"name":"PDQ_Open_Trial_Search_ID","value":"41809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245032"}]}}{"C72077":{"preferredName":"Losoxantrone Hydrochloride","code":"C72077","definitions":[{"definition":"The hydrochloride salt form of losoxantrone, an anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Losoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Losoxantrone HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Losoxantrone Hydrochloride Hydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"132937-89-4"},{"name":"Chemical_Formula","value":"2C22H27N5O4.4ClH.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6E275IURX"},{"name":"Legacy Concept Name","value":"Losoxantrone_Hydrochloride"},{"name":"Maps_To","value":"Losoxantrone Hydrochloride"},{"name":"NSC Number","value":"357885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346902"}]}}{"C620":{"preferredName":"Lovastatin","code":"C620","definitions":[{"definition":"A drug used to lower the amount of cholesterol in the blood. It is also being studied in the prevention and treatment of some types of cancer. Lovastatin is a type of HMG-CoA reductase inhibitor (statin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering and potential antineoplastic activities. Lovastatin is hydrolyzed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in cholesterol biosynthesis. In addition, this agent may induce tumor cell apoptosis and inhibit tumor cell invasiveness, possibly by inhibiting protein farnesylation and protein geranylgeranylation, and may arrest cells in the G1 phase of the cell cycle. The latter effect sensitizes tumor cells to the cytotoxic effects of ionizing radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lovastatin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-Methylbutanoic Acid, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Lovastatin Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Mevacor","termGroup":"BR","termSource":"NCI"},{"termName":"Mevinolin","termGroup":"SY","termSource":"NCI"},{"termName":"Monacolin K","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Atherosclerosis; Coronary heart disease, prevention; Hypercholesterolemia"},{"name":"CAS_Registry","value":"75330-75-5"},{"name":"CHEBI_ID","value":"CHEBI:40303"},{"name":"Chemical_Formula","value":"C24H36O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9LHU78OQFD"},{"name":"Legacy Concept Name","value":"Lovastatin"},{"name":"Maps_To","value":"Lovastatin"},{"name":"NCI_Drug_Dictionary_ID","value":"41658"},{"name":"NSC Number","value":"633781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41658"},{"name":"PDQ_Open_Trial_Search_ID","value":"41658"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0024027"}]}}{"C160691":{"preferredName":"Lenumlostat","code":"C160691","definitions":[{"definition":"An orally available, small-molecule, irreversible inhibitor of lysyl oxidase homolog 2 (lysyl oxidase-like protein 2; LOXL2) with potential antifibrotic activity. Upon oral administration, the aminomethyl pyridine moiety of lenumlostat interacts with the active site of LOXL2 to form a pseudo-irreversible inhibitory complex, thereby inhibiting the catalytic activity of LOXL2. LOXL2, a secreted glycoprotein, catalyzes the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, leading to the formation of deaminated lysine (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages that impact remodeling of the extracellular matrix (ECM), potentially leading to fibrosis. Inhibition of LOXL2, which is often upregulated in fibrotic tissue, may reduce fibrosis in certain chronic fibrotic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenumlostat","termGroup":"PT","termSource":"NCI"},{"termName":"GB 2064","termGroup":"CN","termSource":"NCI"},{"termName":"GB-2064","termGroup":"CN","termSource":"NCI"},{"termName":"GB2064","termGroup":"CN","termSource":"NCI"},{"termName":"LOXL2 Inhibitor GB2064","termGroup":"SY","termSource":"NCI"},{"termName":"Lysyl Oxidase-like Protein 2 Inhibitor PAT-1251","termGroup":"SY","termSource":"NCI"},{"termName":"PAT 1251","termGroup":"CN","termSource":"NCI"},{"termName":"PAT-1251","termGroup":"CN","termSource":"NCI"},{"termName":"PAT1251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098884-52-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y3HMF6G24B"},{"name":"Maps_To","value":"LOXL2 Inhibitor PAT-1251"},{"name":"NCI_Drug_Dictionary_ID","value":"800789"},{"name":"NCI_META_CUI","value":"CL969613"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800789"},{"name":"PDQ_Open_Trial_Search_ID","value":"800789"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165553":{"preferredName":"LRP5/6 Antagonist BI 905677","code":"C165553","definitions":[{"definition":"A humanized biparatopic nanobody composed of two blocking domains for the Wnt ligand co-receptors lipoprotein receptor-related proteins (LRP) 5 and 6, with potential antineoplastic and immunomodulating activities. Upon administration, BI 905677 targets and binds to LRP5 and LRP6, thereby blocking the binding of Wnt ligands to LRP5/6. This prevents the activation of the Frizzled (FZD)-Wnt-LRP5/6 trimeric complex and prevents the inactivation of the beta-catenin degradation complex, which leads to beta-catenin degradation. This inhibits the Wnt/beta-catenin signaling pathway, prevents the beta-catenin-mediated activation of Wnt target genes, and inhibits the proliferation and survival of Wnt-driven tumor cells. In addition, inhibition of Wnt signaling by BI 905677 prevents Wnt-mediated immune escape, thereby re-activating the immune system, specifically inducing the activation of dendritic cells (DCs) and activation as well as infiltration of cytotoxic T-cells into the tumor tissue. The FZD-Wnt-LRP5/6 trimeric complex induces phosphorylation of LRP5 or LRP6 intracellular domains leading to inactivation of the beta-catenin degradation complex, allowing beta-catenin accumulation; stabilized beta-catenin enters the nucleus and acts as a transcriptional activator of Wnt target genes. Wnt/beta-catenin signaling plays a key role in tumorigenesis and resistance to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRP5/6 Antagonist BI 905677","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LRP5/6 Nanobody BI 905677","termGroup":"SY","termSource":"NCI"},{"termName":"BI 905677","termGroup":"CN","termSource":"NCI"},{"termName":"BI-905677","termGroup":"CN","termSource":"NCI"},{"termName":"BI905677","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LRP5/6 Antagonist BI 905677"},{"name":"NCI_Drug_Dictionary_ID","value":"799658"},{"name":"NCI_META_CUI","value":"CL978683"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799658"},{"name":"PDQ_Open_Trial_Search_ID","value":"799658"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131303":{"preferredName":"Pulrodemstat","code":"C131303","definitions":[{"definition":"An orally available inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, pulrodemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor (remove hyphen) suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family that is overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulrodemstat","termGroup":"PT","termSource":"NCI"},{"termName":"CC 90011","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90011","termGroup":"CN","termSource":"NCI"},{"termName":"CC90011","termGroup":"CN","termSource":"NCI"},{"termName":"LSD1 Inhibitor CC-90011","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine-specific Demethylase 1 Inhibitor CC-90011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1821307-10-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6F4FRQ5QC"},{"name":"Maps_To","value":"LSD1 Inhibitor CC-90011"},{"name":"NCI_Drug_Dictionary_ID","value":"785511"},{"name":"NCI_META_CUI","value":"CL514523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785511"},{"name":"PDQ_Open_Trial_Search_ID","value":"785511"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113646":{"preferredName":"LSD1 Inhibitor GSK2879552","code":"C113646","definitions":[{"definition":"An orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LSD1 Inhibitor GSK2879552","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2879552","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LSD1 Inhibitor GSK2879552"},{"name":"NCI_Drug_Dictionary_ID","value":"756742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756742"},{"name":"PDQ_Open_Trial_Search_ID","value":"756742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827120"}]}}{"C131827":{"preferredName":"Bomedemstat","code":"C131827","definitions":[{"definition":"An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; thus, inhibition of LSD1 also promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression, tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bomedemstat","termGroup":"PT","termSource":"NCI"},{"termName":"IMG 7289","termGroup":"CN","termSource":"NCI"},{"termName":"IMG-7289","termGroup":"CN","termSource":"NCI"},{"termName":"LSD-1 Inhibitor IMG-7289","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine-specific Demethylase 1 Inhibitor IMG-7289","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1990504-34-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2T4ALDEAT"},{"name":"Maps_To","value":"Bomedemstat"},{"name":"Maps_To","value":"LSD1 Inhibitor IMG-7289"},{"name":"NCI_Drug_Dictionary_ID","value":"786176"},{"name":"NCI_META_CUI","value":"CL514400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786176"},{"name":"PDQ_Open_Trial_Search_ID","value":"786176"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131908":{"preferredName":"Iadademstat","code":"C131908","definitions":[{"definition":"An orally available inhibitor of lysine specific histone demethylase 1 (KDM1A; LSD1), with potential antineoplastic activity. Upon administration, iadademstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9, which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in in the regulation of gene expression, tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iadademstat","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-Cyclohexanediamine, N1-((1R,2S)-2-Phenylcyclopropyl)-, trans-","termGroup":"SN","termSource":"NCI"},{"termName":"ORY 1001","termGroup":"CN","termSource":"NCI"},{"termName":"ORY-1001","termGroup":"CN","termSource":"NCI"},{"termName":"RG 6016","termGroup":"CN","termSource":"NCI"},{"termName":"RG6016","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7051790","termGroup":"CN","termSource":"NCI"},{"termName":"RO7051790","termGroup":"CN","termSource":"NCI"},{"termName":"trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1431304-21-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54T74394F8"},{"name":"Maps_To","value":"Iadademstat"},{"name":"Maps_To","value":"LSD1 Inhibitor RO7051790"},{"name":"NCI_Drug_Dictionary_ID","value":"786364"},{"name":"NCI_META_CUI","value":"CL521133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786364"},{"name":"PDQ_Open_Trial_Search_ID","value":"786364"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83925":{"preferredName":"Lucanthone","code":"C83925","definitions":[{"definition":"An orally available thioxanthone-based DNA intercalator and inhibitor of the DNA repair enzyme apurinic-apyrimidinic endonuclease 1 (APEX1 or APE1), with anti-schistosomal and potential antineoplastic activity. Lucanthone intercalates DNA and interferes with the activity of topoisomerases I and II during replication and transcription, thereby inhibiting the synthesis of macromolecules. In addition, this agent specifically inhibits the endonuclease activity of APE1, without affecting its redox activity, resulting in un-repaired DNA strand breaks which may induce apoptosis. Therefore, lucanthone may sensitize tumor cells to radiation and chemotherapy. Furthermore, lucanthone inhibits autophagy through the disruption of lysosomal function. The multifunctional nuclease APE1 is a key component for DNA repair; its expression is often correlated with tumor cell resistance to radio- and chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucanthone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"479-50-5"},{"name":"CHEBI_ID","value":"CHEBI:51052"},{"name":"Chemical_Formula","value":"C20H24N2OS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FC6D57000M"},{"name":"Maps_To","value":"Lucanthone"},{"name":"NCI_Drug_Dictionary_ID","value":"733534"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733534"},{"name":"PDQ_Open_Trial_Search_ID","value":"733534"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0024071"}]}}{"C48405":{"preferredName":"Lucatumumab","code":"C48405","definitions":[{"definition":"A fully human monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. Lucatumumab binds to and inhibits CD40, thereby inhibiting CD40 ligand-induced cell proliferation and triggering cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells overexpressing CD40. CD40, an integral membrane protein found on the surface of B lymphocytes, is a member of the tumor necrosis factor receptor superfamily and is highly expressed in a number of B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD40 Monoclonal Antibody CHIR-12.12","termGroup":"SY","termSource":"NCI"},{"termName":"CHIR-12.12","termGroup":"CN","termSource":"NCI"},{"termName":"HCD-122","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody CHIR-12.12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"903512-50-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P0EP9VFC4R"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CHIR-12_12"},{"name":"Maps_To","value":"Lucatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"432936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"432936"},{"name":"PDQ_Open_Trial_Search_ID","value":"432936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2980061"}]}}{"C95726":{"preferredName":"Lucitanib","code":"C95726","definitions":[{"definition":"A novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. Lucitanib inhibits VEGFR-1, -2, -3 and FGFR-1, -2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and FGFRs belong to the family of receptor tyrosine kinases that may be upregulated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucitanib","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"AL3810","termGroup":"CN","termSource":"NCI"},{"termName":"E-3810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1058137-23-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PP449XA4BH"},{"name":"Maps_To","value":"Lucitanib"},{"name":"NCI_Drug_Dictionary_ID","value":"694590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694590"},{"name":"PDQ_Open_Trial_Search_ID","value":"694590"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3887575"}]}}{"C71467":{"preferredName":"Luminespib","code":"C71467","definitions":[{"definition":"A derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Luminespib has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luminespib","termGroup":"PT","termSource":"NCI"},{"termName":"AUY922","termGroup":"CN","termSource":"NCI"},{"termName":"NVP AUY 922","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-AUY 922","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"747412-64-2"},{"name":"Chemical_Formula","value":"C27H33N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C6V1DAR5EB"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_AUY922"},{"name":"Maps_To","value":"Luminespib"},{"name":"NCI_Drug_Dictionary_ID","value":"570982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570982"},{"name":"PDQ_Open_Trial_Search_ID","value":"570982"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348996"}]}}{"C162567":{"preferredName":"Luminespib Mesylate","code":"C162567","definitions":[{"definition":"The mesylate salt of luminespib, a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Upon administration, luminespib binds with high affinity to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luminespib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Luminespib Mesilate","termGroup":"SY","termSource":"NCI"},{"termName":"Luminespib Mesylate Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"NVP-AUY922-AGB","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1051919-26-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6R0MAC137G"},{"name":"Maps_To","value":"Luminespib Mesylate"},{"name":"NCI_META_CUI","value":"CL971084"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118623":{"preferredName":"Lung-targeted Immunomodulator QBKPN","code":"C118623","definitions":[{"definition":"A proprietary, lung-targeted, site specific immunomodulator (SSI), with potential immunostimulating and antineoplastic activities. Although the exact type and composition of the lung-targeted immunomodulator QBKPN has yet to be fully disclosed, upon subcutaneous administration, this agent is able to activate a local innate immune response in the lung tissue. This results in an increased number of M1 macrophages, which induces a shift from M2 to M1 macrophage dominance in the tumor microenvironment, and stimulates the recruitment of other immune cells. The M1 macrophages exert antitumor activity and eradicate lung cancer cells through phagocytosis. QBKPN does not induce a systemic immune response or affect other organs or tissues. Altogether, this SSI may decrease tumor cell growth in the lungs. SSIs contain specific, inactivated components of pathogens, such as bacteria and/or viruses, which normally cause an acute infection in the specific organ or tissue of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung-targeted Immunomodulator QBKPN","termGroup":"PT","termSource":"NCI"},{"termName":"QBKPN","termGroup":"CN","termSource":"NCI"},{"termName":"Site Specific Immunomodulator QBKPN","termGroup":"SY","termSource":"NCI"},{"termName":"SSI QBKPN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lung-targeted Immunomodulator QBKPN"},{"name":"NCI_Drug_Dictionary_ID","value":"765293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765293"},{"name":"PDQ_Open_Trial_Search_ID","value":"765293"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896726"}]}}{"C82382":{"preferredName":"Lurbinectedin","code":"C82382","definitions":[{"definition":"A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lurbinectedin","termGroup":"PT","termSource":"NCI"},{"termName":"PM-01183","termGroup":"CN","termSource":"NCI"},{"termName":"PM01183","termGroup":"CN","termSource":"NCI"},{"termName":"Zepzelca","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy"},{"name":"CAS_Registry","value":"497871-47-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2CN60TN6ZS"},{"name":"Legacy Concept Name","value":"DNA_Minor_Groove_Binding_Agent_PM01183"},{"name":"Maps_To","value":"Lurbinectedin"},{"name":"NCI_Drug_Dictionary_ID","value":"641468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641468"},{"name":"PDQ_Open_Trial_Search_ID","value":"641468"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830066"}]}}{"C1610":{"preferredName":"Lurtotecan","code":"C1610","definitions":[{"definition":"A semisynthetic analogue of camptothecin with antineoplastic activity. Lurtotecan selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. Independent from DNA replication inhibition, lurtotecan also inhibits RNA synthesis, multi-ubiquitination and degradation of topoisomerase I and chromatin reorganization.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lurtotecan","termGroup":"PT","termSource":"NCI"},{"termName":"7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"GG 211","termGroup":"CN","termSource":"NCI"},{"termName":"GI147211","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149882-10-0"},{"name":"Chemical_Formula","value":"C28H30N4O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4J1L80T08I"},{"name":"Legacy Concept Name","value":"Lurtotecan"},{"name":"Maps_To","value":"Lurtotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"42331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42331"},{"name":"PDQ_Open_Trial_Search_ID","value":"42331"},{"name":"PubMedID_Primary_Reference","value":"15571957"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0293658"}]}}{"C1876":{"preferredName":"Lurtotecan Liposome","code":"C1876","definitions":[{"definition":"A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lurtotecan Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"liposomal lurtotecan","termGroup":"SY","termSource":"NCI"},{"termName":"liposome, lurtotecan","termGroup":"SY","termSource":"NCI"},{"termName":"NX211","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-211","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lurtotecan_Liposome"},{"name":"Maps_To","value":"Lurtotecan Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"43473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43473"},{"name":"PDQ_Open_Trial_Search_ID","value":"43473"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935959"}]}}{"C142176":{"preferredName":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","code":"C142176","definitions":[{"definition":"A radioimmunoconjugate comprised of a human monoclonal antibody (huMAb-5B1) against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9) that is conjugated to the chelator 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A''-DTPA) and labeled with the beta-emitting radioisotope lutetium Lu 177 (Lu 177), with radioisotopic activity and potential use as an antineoplastic radiotherapeutic and an imaging agent in both planar imaging and single-photon emission computed tomography (SPECT). The antibody moiety of Lu 177 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9-expressing tumor cells. This may promote killing of CA19-9-expressing tumor cells through the local induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Additionally, upon binding and internalization, the Lu 177 moiety can deliver a cytotoxic dose of beta radiation to the CA19-9-expressing tumor cells. Furthermore, the radioisotope moiety may be imaged using planar imaging and SPECT, thus allowing evaluation of the pharmacokinetic profile of the agent, and the imaging and quantification of CA19-9-expressing tumor cells, respectively. CA19-9, a Lewis-type carbohydrate antigen overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu Human Monoclonal Antibody 5B1","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-CHX-A''-DTPA-HuMab-5B1","termGroup":"SY","termSource":"NCI"},{"termName":"Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","termGroup":"SY","termSource":"NCI"},{"termName":"MVT-1075","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"473BOU89F3"},{"name":"Maps_To","value":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1"},{"name":"NCI_Drug_Dictionary_ID","value":"791457"},{"name":"NCI_META_CUI","value":"CL540167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791457"},{"name":"PDQ_Open_Trial_Search_ID","value":"791457"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113801":{"preferredName":"Lutetium Lu 177 DOTA-biotin","code":"C113801","definitions":[{"definition":"A radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 DOTA-biotin","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-ST2210","termGroup":"SY","termSource":"NCI"},{"termName":"[177Lu]DOTA-biotin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5U8L0A8I80"},{"name":"Maps_To","value":"Lutetium Lu 177 DOTA-biotin"},{"name":"NCI_Drug_Dictionary_ID","value":"757658"},{"name":"NCI_META_CUI","value":"CL471782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757658"},{"name":"PDQ_Open_Trial_Search_ID","value":"757658"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158044":{"preferredName":"Lutetium Lu 177 DOTA-N3-CTT1403","code":"C158044","definitions":[{"definition":"A radioconjucate consisting of CTT1403, a phosphoramidate-based irreversible inhibitor of human prostate-specific membrane antigen with an albumin binding moiety, connected via click chemistry to lutetium Lu 177-dodecanetetraacetic acid-azide (177Lu-DOTA-N3), with potential antineoplastic activity. Upon administration, lutetium Lu 177-DOTA-N3-CTT1403 targets and binds to PSMA expressed on tumor cells via its CTT1403 moiety, and upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on most prostate tumor cells. The albumin binding motif extends circulation half-life thereby improving tumor cell uptake of the radioconjugate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 DOTA-N3-CTT1403","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-azide-CTT1403","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA-N3-CTT1403","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA-azide-CTT1403","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177 DOTA-N3-CTT1403"},{"name":"NCI_Drug_Dictionary_ID","value":"797172"},{"name":"NCI_META_CUI","value":"CL937593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797172"},{"name":"PDQ_Open_Trial_Search_ID","value":"797172"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105403":{"preferredName":"Lutetium Lu 177 DOTA-Tetulomab","code":"C105403","definitions":[{"definition":"A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 DOTA-Tetulomab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-HH1","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Dota-Tetulomab","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-HH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CPW7BR9UY7"},{"name":"Maps_To","value":"Lutetium Lu 177 DOTA-Tetulomab"},{"name":"NCI_Drug_Dictionary_ID","value":"746917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746917"},{"name":"PDQ_Open_Trial_Search_ID","value":"746917"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659253"}]}}{"C95020":{"preferredName":"Lutetium Lu 177 Dotatate","code":"C95020","definitions":[{"definition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Dotatate","termGroup":"PT","termSource":"NCI"},{"termName":"177 Lu-DOTA-TATE","termGroup":"AB","termSource":"NCI"},{"termName":"177 Lu-DOTA-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA0-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutathera","termGroup":"BR","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 Dotatate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"lutetium Lu 177-DOTATATE","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Oxodotreotide Lu-177","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"omatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"},{"name":"CAS_Registry","value":"437608-50-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"AE221IM3BB"},{"name":"Maps_To","value":"Lutetium Lu 177 Dotatate"},{"name":"NCI_Drug_Dictionary_ID","value":"715523"},{"name":"NCI_META_CUI","value":"CL433757"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715523"},{"name":"PDQ_Open_Trial_Search_ID","value":"715523"},{"name":"PubMedID_Primary_Reference","value":"18649310"},{"name":"PubMedID_Primary_Reference","value":"20168290"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162565":{"preferredName":"Lutetium Lu 177 Lilotomab-satetraxetan","code":"C162565","definitions":[{"definition":"A radioconjugate consisting of lilotomab, a murine immunoglobulin G1 (IgG1) antibody directed against the CD37 antigen, conjugated via the chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA) with potential antineoplastic activities. Upon administration of lutetium Lu 177 lilotomab-satetraxetan, the lilotomab moiety binds to CD37 expressed on certain tumor cells. Upon binding, lutetium Lu 177 lilotomab-satetraxetan delivers a cytotoxic dose of beta radiation to CD37-expressing cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Lilotomab-satetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu Lilotomab Satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Lilotomab-satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Betalutin","termGroup":"BR","termSource":"NCI"},{"termName":"Lutetium Lu-177 Lilotomab Satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu-177 Lilotomab-satetraxetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453362-90-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"054ZP16K2Q"},{"name":"Maps_To","value":"Lutetium Lu 177 Lilotomab-satetraxetan"},{"name":"NCI_META_CUI","value":"CL446324"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2598":{"preferredName":"Lutetium Lu 177 Monoclonal Antibody CC49","code":"C2598","definitions":[{"definition":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Monoclonal Antibody CC49","termGroup":"PT","termSource":"NCI"},{"termName":"177 Lu-CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177_Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"Lutetium Lu 177 Monoclonal Antibody CC49"},{"name":"NCI_Drug_Dictionary_ID","value":"38083"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38083"},{"name":"PDQ_Open_Trial_Search_ID","value":"38083"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935675"}]}}{"C38701":{"preferredName":"Lutetium Lu 177 Rosopatamab Tetraxetan","code":"C38701","definitions":[{"definition":"A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Rosopatamab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-TLX591","termGroup":"SY","termSource":"NCI"},{"termName":"DOTA-HUJ-591 LU-177","termGroup":"SY","termSource":"NCI"},{"termName":"Lu 177 MOAB J591","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium Lu 177 Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 Rosopatamab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-Rosopatamab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-TLX591","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JB9647672Z"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177_Monoclonal_Antibody_J591"},{"name":"Maps_To","value":"Lutetium Lu 177 Monoclonal Antibody J591"},{"name":"NCI_Drug_Dictionary_ID","value":"361550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"361550"},{"name":"PDQ_Open_Trial_Search_ID","value":"361550"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518042"}]}}{"C114499":{"preferredName":"Lutetium Lu 177 PP-F11N","code":"C114499","definitions":[{"definition":"A radioconjugate composed of PP-F11N, a gastrin analog, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and potential use as an imaging agent for scintigraphy. Following intravenous administration, the PP-F11N moiety binds to the cholecystokinin-2 (CCK-2) receptor. Subsequently, the CCK-2 receptor-expressing tumor cells can be visualized scintigraphically. In addition, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CCK-2 receptor-expressing tumor cells. CCK-2 receptors are expressed on a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 PP-F11N","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-PP-F11N","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1771736-69-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"639NVQ0SXF"},{"name":"Maps_To","value":"Lutetium Lu 177 PP-F11N"},{"name":"NCI_Drug_Dictionary_ID","value":"759373"},{"name":"NCI_META_CUI","value":"CL472324"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759373"},{"name":"PDQ_Open_Trial_Search_ID","value":"759373"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124929":{"preferredName":"Lutetium Lu 177 Satoreotide Tetraxetan","code":"C124929","definitions":[{"definition":"A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-JR11 binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Satoreotide Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA-JR11","termGroup":"SY","termSource":"NCI"},{"termName":"Lu-177 OPS-201","termGroup":"SY","termSource":"NCI"},{"termName":"Satoreotide Tetraxetan Lutetium-177","termGroup":"SY","termSource":"NCI"},{"termName":"SOMther","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1934243-21-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CAX3X53UL6"},{"name":"Maps_To","value":"Lutetium Lu 177 Satoreotide Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"777267"},{"name":"NCI_META_CUI","value":"CL503798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777267"},{"name":"PDQ_Open_Trial_Search_ID","value":"777267"},{"name":"PubMedID_Primary_Reference","value":"24963127"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154549":{"preferredName":"Lutetium Lu 177-DOTA-EB-TATE","code":"C154549","definitions":[{"definition":"A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intravenous administration, lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), specifically with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-DOTA-EB-TATE","termGroup":"PT","termSource":"NCI"},{"termName":"(177)Lu-DOTA-EB-TATE","termGroup":"SY","termSource":"NCI"},{"termName":"177 Lu-DOTA-EB-TATE","termGroup":"AB","termSource":"NCI"},{"termName":"177Lu-DOTA-EB-TATE","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA0-EB-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA(0)-EB-Tyr(3)-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-EB-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans blue-octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177-DOTA-EB-TATE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177-DOTA-EB-TATE"},{"name":"NCI_Drug_Dictionary_ID","value":"794348"},{"name":"NCI_META_CUI","value":"CL555349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794348"},{"name":"PDQ_Open_Trial_Search_ID","value":"794348"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88277":{"preferredName":"Lutetium Lu 177-Edotreotide","code":"C88277","definitions":[{"definition":"A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-Edotreotide","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTATOC","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Edo","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Edotreotide","termGroup":"SY","termSource":"NCI"},{"termName":"[177LuDOTA]-TOC","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium 177Lu-Edotreotide","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA-Tyr3-octreotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"321835-55-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RGO812Q0C8"},{"name":"Maps_To","value":"Lutetium Lu 177-Edotreotide"},{"name":"NCI_Drug_Dictionary_ID","value":"656307"},{"name":"NCI_META_CUI","value":"CL412466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656307"},{"name":"PDQ_Open_Trial_Search_ID","value":"656307"},{"name":"PubMedID_Primary_Reference","value":"18448552"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158734":{"preferredName":"Lutetium Lu 177-NeoB","code":"C158734","definitions":[{"definition":"A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-NeoB","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-NeoB","termGroup":"SY","termSource":"NCI"},{"termName":"[177Lu]-NeoB","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium 177-NeoB","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA-NeoBOMB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177-NeoB"},{"name":"NCI_Drug_Dictionary_ID","value":"797487"},{"name":"NCI_META_CUI","value":"CL950703"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797487"},{"name":"PDQ_Open_Trial_Search_ID","value":"797487"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148145":{"preferredName":"Lutetium Lu 177 Vipivotide Tetraxetan","code":"C148145","definitions":[{"definition":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Vipivotide Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-labeled PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"AAA 617","termGroup":"CN","termSource":"NCI"},{"termName":"AAA-617","termGroup":"CN","termSource":"NCI"},{"termName":"AAA617","termGroup":"CN","termSource":"NCI"},{"termName":"Lu177-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"Pluvicto","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."},{"name":"CAS_Registry","value":"1703749-62-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G6UF363ECX"},{"name":"Maps_To","value":"Lutetium Lu 177-PSMA-617"},{"name":"NCI_Drug_Dictionary_ID","value":"792497"},{"name":"NCI_META_CUI","value":"CL550803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792497"},{"name":"PDQ_Open_Trial_Search_ID","value":"792497"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67039":{"preferredName":"Lutetium Lu-177 Capromab","code":"C67039","definitions":[{"definition":"A radioimmunoconjugate consisting of capromab linked to lutetium Lu 177 via the bifunctional macrocyclic chelator methoxy-tetraazacyclododecane-tetraacetic acid (MeO-DOTA) with potential antineoplastic activity. Lutetium Lu 177-capromab binds to human prostate specific membrane antigen (PSMA) expressed on tumor cell surfaces via its capromab moiety and, upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA is a cell surface glycoprotein abundantly expressed by prostate epithelium and is typically overexpressed by prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 Capromab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-meO-DOTA-7E11","termGroup":"AB","termSource":"NCI"},{"termName":"CYT-500","termGroup":"CN","termSource":"NCI"},{"termName":"Lutetium Lu 177-Labeled Capromab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177_Monoclonal_Antibody_7E11"},{"name":"Maps_To","value":"Lutetium Lu-177 Capromab"},{"name":"NCI_Drug_Dictionary_ID","value":"539702"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539702"},{"name":"PDQ_Open_Trial_Search_ID","value":"539702"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881486"}]}}{"C66978":{"preferredName":"Lutetium Lu-177 Girentuximab","code":"C66978","definitions":[{"definition":"A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 Girentuximab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-cG250","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium Lu-177-DOTA-Chimeric Monoclonal Antibody cG250","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177 Labeled cG250","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177-DOTA-Chimeric_Monoclonal_Antibody_cG250"},{"name":"Maps_To","value":"Lutetium Lu-177 Girentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"531051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531051"},{"name":"PDQ_Open_Trial_Search_ID","value":"531051"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881485"}]}}{"C150467":{"preferredName":"Lutetium Lu-177 PSMA-R2","code":"C150467","definitions":[{"definition":"A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 177Lu-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 PSMA-R2","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-PSMA-R2","termGroup":"SY","termSource":"NCI"},{"termName":"177LuPSMA-R2","termGroup":"SY","termSource":"NCI"},{"termName":"Lu177-PSMA-R2","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177 PSMA-R2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu-177 PSMA-R2"},{"name":"NCI_Drug_Dictionary_ID","value":"793409"},{"name":"NCI_META_CUI","value":"CL552202"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793409"},{"name":"PDQ_Open_Trial_Search_ID","value":"793409"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162563":{"preferredName":"Lutetium Lu-177 Rituximab","code":"C162563","definitions":[{"definition":"A radioconjugate composed of rituximab, a recombinant chimeric murine/human immunoglobulin G1 (IgG1) antibody directed against the CD20 antigen, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, the rituximab moiety targets and binds to CD20 expressed on tumor cells and delivers a cytotoxic dose of beta radiation to CD20-expressing cells. CD20 is expressed on the surface of pre-B and mature B-lymphocytes and is overexpressed in a variety of B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 Rituximab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu-177 Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177 Labeled Rituximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu-177 Rituximab"},{"name":"NCI_META_CUI","value":"CL971073"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78832":{"preferredName":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1","code":"C78832","definitions":[{"definition":"A whole-cell cancer vaccine, containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein encoded by a self-inactivating lentiviral vector (LV), with potential antineoplastic and immunomodulating activities. Upon administration, LV.IL-2/B7.1-transduced AML blast vaccine RFUSIN2-AML1 may stimulate a host cytotoxic T lymphocyte (CTL) response against AML cells.  The single fusion protein encoded by the LV is postsynthetically cleaved to produce biologically active membrane-anchored B7.1 and secreted IL-2 in AML blasts; combined expression of IL-2 and the co-stimulatory molecule B7.1 by AML blasts may increase stimulation of both allogeneic and autologous cytotoxic T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1","termGroup":"PT","termSource":"NCI"},{"termName":"Lentivirus-transduced AML Blasts Expressing B7.1 and IL-2","termGroup":"SY","termSource":"NCI"},{"termName":"RFUSIN2-AML1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LV_IL-2_B7_1-Transduced_AML_Blast_Vaccine"},{"name":"Maps_To","value":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1"},{"name":"NCI_Drug_Dictionary_ID","value":"609860"},{"name":"NCI_META_CUI","value":"CL387720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609860"},{"name":"PDQ_Open_Trial_Search_ID","value":"609860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99163":{"preferredName":"Lyophilized Black Raspberry Lozenge","code":"C99163","definitions":[{"definition":"A lozenge containing lyophilized black raspberry with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, proanthocyanidins, and flavonoids. The anthocyanins appear to contribute significantly to this agent's effects. Anthocyanins inhibit both the activation of several signal transduction pathways, including the mitogen-activated protein kinase-mediated pathways, and certain transcription factors, such as nuclear factor kappa B (NF-kB), activator protein-1 (AP-1) complex, and nuclear factor in activated T-cells (NFAT). This inhibitory activity modulates the expression of downstream target genes that are upregulated in a variety of cancer cell types, including inducible nitric oxide synthase, cyclooxygenase-2, vascular endothelial growth factor and the anti-apoptotic protein survivin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lyophilized Black Raspberry Lozenge","termGroup":"PT","termSource":"NCI"},{"termName":"Black Raspberry Confection","termGroup":"SY","termSource":"NCI"},{"termName":"BRB Confection","termGroup":"SY","termSource":"NCI"},{"termName":"LBR Lozenge","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lyophilized Black Raspberry Lozenge"},{"name":"NCI_Drug_Dictionary_ID","value":"717458"},{"name":"NCI_META_CUI","value":"CL433013"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717458"},{"name":"PDQ_Open_Trial_Search_ID","value":"717458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99164":{"preferredName":"Lyophilized Black Raspberry Saliva Substitute","code":"C99164","definitions":[{"definition":"A saliva substitute (or artificial saliva) containing lyophilized black raspberry with potential antioxidant, pro-apoptotic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in flavonols of which the anthocyanins appear to contribute significantly to this agent's chemopreventive effects. Anthocyanins inhibit the activation of several signal transduction pathways, including the mitogen-activated protein kinase-mediated pathways, and certain transcription factors, such as nuclear factor kappa B (NF-kB), activator protein-1 (AP-1) complex, and nuclear factor in activated T-cells (NFAT). This in turn modulates the expression of downstream target genes that are upregulated in a variety of cancer cell types, including inducible nitric oxide synthase, cyclooxygenase-2, vascular endothelial growth factor and the anti-apoptotic protein survivin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lyophilized Black Raspberry Saliva Substitute","termGroup":"PT","termSource":"NCI"},{"termName":"LBR Saliva Substitute","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lyophilized Black Raspberry Saliva Substitute"},{"name":"NCI_Drug_Dictionary_ID","value":"717459"},{"name":"NCI_META_CUI","value":"CL433014"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717459"},{"name":"PDQ_Open_Trial_Search_ID","value":"717459"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126421":{"preferredName":"Lysine-specific Demethylase 1 Inhibitor INCB059872","code":"C126421","definitions":[{"definition":"An orally available inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, INCB059872 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively, through amine oxidation. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression and in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lysine-specific Demethylase 1 Inhibitor INCB059872","termGroup":"PT","termSource":"NCI"},{"termName":"INCB059872","termGroup":"CN","termSource":"NCI"},{"termName":"LSD1 Inhibitor INCB059872","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802909-49-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"12XU6D9FLM"},{"name":"Maps_To","value":"Lysine-specific Demethylase 1 Inhibitor INCB059872"},{"name":"NCI_Drug_Dictionary_ID","value":"780284"},{"name":"NCI_META_CUI","value":"CL504960"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780284"},{"name":"PDQ_Open_Trial_Search_ID","value":"780284"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61571":{"preferredName":"Lyso-Thermosensitive Liposome Doxorubicin","code":"C61571","definitions":[{"definition":"A temperature-sensitive liposomal formulation of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Upon intravenous administration, circulating thermosensitive liposomes are activated locally by increasing the tumor temperature to 40-41 degrees Celsius using an external heat source. The elevated temperature causes compositional changes in the liposomes, creating openings that allow for the release of encapsulated doxorubicin. Compared to non-thermosensitive liposomes, lyso-thermosensitive liposomes deliver higher concentrations of a cytotoxic agent to a heat-treated tumor site while sparing normal tissues unexposed to heat treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lyso-Thermosensitive Liposome Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"Heat-Activated Liposomal Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Temperature Sensitive Liposome Encapsulated Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"ThermoDox","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lyso-Thermosensitive_Liposome_Doxorubicin"},{"name":"Maps_To","value":"Lyso-Thermosensitive Liposome Doxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"491935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"491935"},{"name":"PDQ_Open_Trial_Search_ID","value":"491935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831903"}]}}{"C95123":{"preferredName":"Macimorelin","code":"C95123","definitions":[{"definition":"An orally available synthetic mimetic of the growth hormone (GH) secretagogue ghrelin with potential anti-cachexia activity. Upon oral administration, macimorelin mimics endogenous ghrelin by stimulating appetite and binds to the growth hormone secretagogue receptor GHSR in the central nervous system, thereby mimicking the GH-releasing effects of ghrelin from the pituitary gland. Stimulation of GH secretion increases insulin-like growth factor-I (IGF-I) levels which may further stimulate protein synthesis. In addition, ghrelin reduces the production of pro-inflammatory cytokines, which may play a direct role in cancer-related loss of appetite.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macimorelin","termGroup":"PT","termSource":"NCI"},{"termName":"AEZS-130","termGroup":"CN","termSource":"NCI"},{"termName":"D-Tryptophanamide,2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"EP 1572","termGroup":"CN","termSource":"NCI"},{"termName":"JMV 1843","termGroup":"CN","termSource":"NCI"},{"termName":"Solorel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"381231-18-1"},{"name":"Chemical_Formula","value":"C26H30N6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8680B21W73"},{"name":"Maps_To","value":"Macimorelin"},{"name":"NCI_Drug_Dictionary_ID","value":"735530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735530"},{"name":"PDQ_Open_Trial_Search_ID","value":"735530"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986922"}]}}{"C87728":{"preferredName":"Macitentan","code":"C87728","definitions":[{"definition":"An orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macitentan","termGroup":"PT","termSource":"NCI"},{"termName":"ACT-064992","termGroup":"CN","termSource":"NCI"},{"termName":"Actelion-1","termGroup":"SY","termSource":"NCI"},{"termName":"N-(5-(4-Bromophenyl)-6-(2-((5-Bromopyrimidin-2-Yl)Oxi)Ethoxy)Pyrimidin-4-Yl)-N'-Propylsulfuric Diamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Pulmonary arterial hypertension, idiopathic pulmonary fibrosis, oncology"},{"name":"CAS_Registry","value":"441798-33-0"},{"name":"Chemical_Formula","value":"C19H20Br2N6O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z9K9Y9WMVL"},{"name":"Maps_To","value":"Macitentan"},{"name":"NCI_Drug_Dictionary_ID","value":"721764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721764"},{"name":"PDQ_Open_Trial_Search_ID","value":"721764"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2606556"}]}}{"C154567":{"preferredName":"Maekmoondong-tang","code":"C154567","definitions":[{"definition":"A traditional East Asian herbal medicine composed of six herbs, including Ophiopogonis tuber, Pinelliae tuber, Glycyrrhizae radix, Zizyphi fructus, Ginseng radix, and Oryzae semen, with potential anti-tussive activity. Maekmoondong-tang is traditionally prescribed for respiratory symptoms to direct the qi downwards and compensate for lung-yin deficiency or dry lung by tonifying yin and moistening the lung. Although the exact mechanisms through which Maekmoondong-tang exerts its effects have yet to be fully elucidated, this agent may, upon administration, improve the severity of chronic cough, reduce airway hyper-responsiveness possibly by reducing the cough reflex and bronchodilation, and airway inflammation possibly through anti-inflammatory and immunomodulatory effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maekmoondong-tang","termGroup":"PT","termSource":"NCI"},{"termName":"Bakumondo-to","termGroup":"SY","termSource":"NCI"},{"termName":"Maekgeuron Granules","termGroup":"SY","termSource":"NCI"},{"termName":"Mai-men-dong-tang","termGroup":"SY","termSource":"NCI"},{"termName":"MMDT","termGroup":"AB","termSource":"NCI"},{"termName":"Ophiopogonis tuber/Pinelliae tuber/Glycyrrhizae radix/Zizyphi fructus/Ginseng radix/Oryzae semen Herbal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"TJ-29","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maekmoondong-tang"},{"name":"NCI_Drug_Dictionary_ID","value":"794323"},{"name":"NCI_META_CUI","value":"CL555363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794323"},{"name":"PDQ_Open_Trial_Search_ID","value":"794323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1150":{"preferredName":"Mafosfamide","code":"C1150","definitions":[{"definition":"A form of cyclophosphamide that can be administered as an intrathecal infusion.  Mafosfamide is being studied as an anticancer drug.  It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic oxazaphosphorine derivative with antineoplastic properties.  Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis.  Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mafosfamide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88859-04-5"},{"name":"Chemical_Formula","value":"C9H19Cl2N2O5PS2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5970HH9923"},{"name":"Legacy Concept Name","value":"Mafosfamide"},{"name":"Maps_To","value":"Mafosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"41254"},{"name":"NSC Number","value":"345842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41254"},{"name":"PDQ_Open_Trial_Search_ID","value":"41254"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065506"}]}}{"C2681":{"preferredName":"MAGE-10.A2","code":"C2681","definitions":[{"definition":"A synthetic nonapeptide derived from a melanoma-associated antigen. Vaccination with MAGE-10.A2 may stimulate a host cytotoxic T-cell response against tumor cells that express the melanoma-associated antigen, resulting in tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-10.A2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MAGE-10_A2"},{"name":"Maps_To","value":"MAGE-10.A2"},{"name":"NCI_Drug_Dictionary_ID","value":"38649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38649"},{"name":"PDQ_Open_Trial_Search_ID","value":"38649"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134715"}]}}{"C166968":{"preferredName":"Biropepimut-S","code":"C166968","definitions":[{"definition":"A proprietary, peptide cancer vaccine comprised of multiple peptides derived from human melanoma antigen A3 (MAGE-A3; MAGEA3), with potential immunostimulating and antineoplastic activities. Upon administration, biropepimut-S may stimulate the immune system to mount specific responses from B-cells, and CD4-positive and CD8-positive cells against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biropepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"GL-0817","termGroup":"CN","termSource":"NCI"},{"termName":"GL-0817 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GL0817","termGroup":"CN","termSource":"NCI"},{"termName":"MAGE-A3 Multipeptide Vaccine GL-0817","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3 Peptide Vaccine GL-0817","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911338-45-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6XJF4EZC5Z"},{"name":"Maps_To","value":"MAGE-A3 Multipeptide Vaccine GL-0817"},{"name":"NCI_Drug_Dictionary_ID","value":"391278"},{"name":"NCI_META_CUI","value":"CL512878"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91710":{"preferredName":"MAGE-A3 Peptide Vaccine","code":"C91710","definitions":[{"definition":"A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A3 Peptide Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A3 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"391278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391278"},{"name":"PDQ_Open_Trial_Search_ID","value":"391278"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541478"}]}}{"C123649":{"preferredName":"MAGE-A3-specific Immunotherapeutic GSK 2132231A","code":"C123649","definitions":[{"definition":"An immunotherapeutic agent composed of a fusion protein containing the human melanoma-associated antigen MAGE-A3 fused to a lipidated protein D derived from Haemophilus influenzae and combined with the immunoadjuvant AS15, with potential immunostimulating and antineoplastic activities. Upon intramuscular (IM) administration, GSK 2132231A may stimulate a specific cytotoxic T-lymphocyte (CTL) response against MAGE-A3-expressing tumor cells, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen, is upregulated in a variety of cancer cell types. This fusion protein may boost antitumoral immune responses. AS15, a liposomal formulation containing the immunostimulating compounds CpG 7909, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and QS-21, increases the immune response against MAGE-A3-expressing tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A3-specific Immunotherapeutic GSK 2132231A","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen Specific Cancer Immunotherapeutic GSK 2132231A","termGroup":"SY","termSource":"NCI"},{"termName":"ASCI GSK 2132231A","termGroup":"SY","termSource":"NCI"},{"termName":"GSK 2132231A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2132231A","termGroup":"CN","termSource":"NCI"},{"termName":"MAGE-A3 ASCI GSK 2132231A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A3-specific Immunotherapeutic GSK 2132231A"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053638"}]}}{"C114978":{"preferredName":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201","code":"C114978","definitions":[{"definition":"Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T-lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201","termGroup":"PT","termSource":"NCI"},{"termName":"TBI-1201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201"},{"name":"NCI_Drug_Dictionary_ID","value":"759543"},{"name":"NCI_META_CUI","value":"CL472575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759543"},{"name":"PDQ_Open_Trial_Search_ID","value":"759543"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71156":{"preferredName":"Magnesium Valproate","code":"C71156","definitions":[{"definition":"The magnesium salt of valproic acid (2-propylpentanoic acid) with antiepileptic and potential antineoplastic activities. Magnesium valproate dissociates in the gastrointestinal tract and is absorbed into the circulation as magnesium ions and valproic acid ions; valproic acid may inhibit histone deacetylases, inducing tumor cell differentiation, apoptosis, and growth arrest. In addition, valproic acid exerts an antiepileptic effect, likely by inhibiting enzymes that catabolize the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) catabolism and so increasing concentrations of GABA in the central nervous system (CNS). The presence of the magnesium in this agent may contribute to its anticonvulsant activity and sedative properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Magnesium Valproate","termGroup":"PT","termSource":"NCI"},{"termName":"Magnesium Dipropylacetate","termGroup":"SY","termSource":"NCI"},{"termName":"Pentanoic acid, 2-propyl-, Magnesium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Valproate Magnesium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62959-43-7"},{"name":"Chemical_Formula","value":"2C8H15O2.Mg"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q400352CM2"},{"name":"Legacy Concept Name","value":"Magnesium_Valproate"},{"name":"Maps_To","value":"Magnesium Valproate"},{"name":"NCI_Drug_Dictionary_ID","value":"573418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573418"},{"name":"PDQ_Open_Trial_Search_ID","value":"573418"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0524735"}]}}{"C160147":{"preferredName":"Safimaltib","code":"C160147","definitions":[{"definition":"An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, safimaltib targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor-kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Safimaltib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(1-Oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"JNJ 67856633","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-67856633","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ67856633","termGroup":"CN","termSource":"NCI"},{"termName":"MALT1 Inhibitor JNJ-67856633","termGroup":"SY","termSource":"NCI"},{"termName":"Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor JNJ-67856633","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230273-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L9790S42AI"},{"name":"Maps_To","value":"MALT1 Inhibitor JNJ-67856633"},{"name":"NCI_Drug_Dictionary_ID","value":"798315"},{"name":"NCI_META_CUI","value":"CL969161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798315"},{"name":"PDQ_Open_Trial_Search_ID","value":"798315"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83904":{"preferredName":"Mannosulfan","code":"C83904","definitions":[{"definition":"An alkyl sulfonate with potential antineoplastic activity. Mannosulfan alkylates DNA, thereby producing DNA intra- or interstrand crosslinks, and ultimately results in inhibiting DNA replication and cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mannosulfan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7518-35-6"},{"name":"Chemical_Formula","value":"C10H22O14S4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"135FQ40L36"},{"name":"Maps_To","value":"Mannosulfan"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065696"}]}}{"C1990":{"preferredName":"Mannosylerythritol Lipid","code":"C1990","definitions":[{"definition":"A yeast glycolipid biosurfactant with potential antineoplastic activity.  Mannosylerythritol lipid activates protein kinase signal cascades, resulting in cell differentiation, condensation of chromatin, DNA fragmentation, G1 phase cell-cycle arrest, and apoptosis of tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mannosylerythritol Lipid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mannosylerythritol_Lipid"},{"name":"Maps_To","value":"Mannosylerythritol Lipid"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099170"}]}}{"C61502":{"preferredName":"Mapatumumab","code":"C61502","definitions":[{"definition":"A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL R1 on the surface of some tumor cells. This may kill the tumor cells. Anti-TRAIL R1-mAb is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mapatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TRAIL R1-mAb","termGroup":"SY","termSource":"NCI"},{"termName":"HGS-ETR1","termGroup":"CN","termSource":"NCI"},{"termName":"TRM-1 mAb","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"658052-09-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WZ1025JPGR"},{"name":"Legacy Concept Name","value":"Mapatumumab"},{"name":"Maps_To","value":"Mapatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"486626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486626"},{"name":"PDQ_Open_Trial_Search_ID","value":"486626"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1665688"}]}}{"C157776":{"preferredName":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7","code":"C157776","definitions":[{"definition":"A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7","termGroup":"PT","termSource":"NCI"},{"termName":"MG1-E6/E7","termGroup":"SY","termSource":"NCI"},{"termName":"MG1-E6E7","termGroup":"SY","termSource":"NCI"},{"termName":"MG1-expressing Mutant HPV E6/E7","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic MG1 Virus-encoding E6E7","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Virus MG1-E6E7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7"},{"name":"NCI_Drug_Dictionary_ID","value":"797163"},{"name":"NCI_META_CUI","value":"CL937424"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797163"},{"name":"PDQ_Open_Trial_Search_ID","value":"797163"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1152":{"preferredName":"Marcellomycin","code":"C1152","definitions":[{"definition":"An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum.  Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marcellomycin","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthacenecarboxylic acid, 4-[[O-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-O-2, 6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-2,3, 6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-2-e thyl-1,2,3,4,6,11-hexahydro-2,5,7,10-tetrahydroxy-6,11-dioxo-, methyl ester, (1R-(1alpha,2beta,4beta))- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Rhodirubin E","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63710-10-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3296X8L13E"},{"name":"Legacy Concept Name","value":"Marcellomycin"},{"name":"Maps_To","value":"Marcellomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39758"},{"name":"NSC Number","value":"265211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39758"},{"name":"PDQ_Open_Trial_Search_ID","value":"39758"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065718"}]}}{"C156733":{"preferredName":"MARCKS Protein Inhibitor BIO-11006","code":"C156733","definitions":[{"definition":"An aerosolized 10-amino acid peptide that inhibits the myristoylated alanine rich protein kinase C substrate (MARCKS) protein, with potential immunomodulating and antineoplastic activities. Upon inhalation, the MARCKS protein inhibitor BIO-11006 targets, binds to and inhibits the phosphorylation of MARCKS (P-MARCKS). This prevents MARCKS-mediated signaling, thereby preventing the release of phosphatidylinositol 4,5-bisphosphate (PIP2) from the cell membrane upon MARCKS binding. This prevents the PIP2-mediated activation of focal adhesion kinase (FAK) and the FAK-mediated activation of the PI3K/AKT pathway and the activation of integrins, talin, vinculin and paxillin. This leads to an inhibition of tumor cell proliferation, migration, metastasis and survival. In addition, inhibition of MARCKS prevents mucin granule release and reduces the overproduction of mucus in the lungs. This may abrogate airway obstruction, impaired lung function, airway inflammation and bacterial infections associated with overproduction of mucus in the lungs. The MARCKS protein, a filamentous actin crosslinking protein and substrate for protein kinase C (PKC) is localized on the plasma membrane. Upon phosphorylation by PKC or binding to the calcium-calmodulin complex, the association of MARCKS with actin and with the plasma membrane is blocked, leading to its presence in the cytoplasm. The MARCKS protein plays a key role in the exocytosis of a number of vesicles and granules, cell movement, mitogenesis and membrane trafficking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MARCKS Protein Inhibitor BIO-11006","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized BIO-11006","termGroup":"SY","termSource":"NCI"},{"termName":"BIO 11006","termGroup":"CN","termSource":"NCI"},{"termName":"BIO-11006","termGroup":"CN","termSource":"NCI"},{"termName":"BIO-11006 Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"BIO11006","termGroup":"CN","termSource":"NCI"},{"termName":"Myristoylated Alanine Rich C Kinase Substrate Inhibitor BIO-11006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"901117-03-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"609AWV0US2"},{"name":"Maps_To","value":"MARCKS Protein Inhibitor BIO-11006"},{"name":"NCI_Drug_Dictionary_ID","value":"795591"},{"name":"NCI_META_CUI","value":"CL935857"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795591"},{"name":"PDQ_Open_Trial_Search_ID","value":"795591"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91733":{"preferredName":"Margetuximab","code":"C91733","definitions":[{"definition":"A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Margetuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human Neu (Receptor)) (Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Heavy Chain), Disulfide with Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Margenza","termGroup":"BR","termSource":"NCI"},{"termName":"Margetuximab-cmkb","termGroup":"SY","termSource":"NCI"},{"termName":"MGAH-22","termGroup":"CN","termSource":"NCI"},{"termName":"MGAH22","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic HER2-positive breast cancer"},{"name":"CAS_Registry","value":"1350624-75-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K911R84KEW"},{"name":"Maps_To","value":"Margetuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"681010"},{"name":"NCI_META_CUI","value":"CL421637"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681010"},{"name":"PDQ_Open_Trial_Search_ID","value":"681010"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1652":{"preferredName":"Marimastat","code":"C1652","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Marimastat is a matrix metalloproteinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marimastat","termGroup":"PT","termSource":"NCI"},{"termName":"(2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"(2S,3R)-3-{(S)-[2,2-Dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BB-2516","termGroup":"CN","termSource":"NCI"},{"termName":"Marimistat","termGroup":"AQS","termSource":"NCI"},{"termName":"TA-2516","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154039-60-8"},{"name":"CHEBI_ID","value":"CHEBI:50662"},{"name":"Chemical_Formula","value":"C15H29N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D5EQV23TDS"},{"name":"Legacy Concept Name","value":"Marimastat"},{"name":"Maps_To","value":"Marimastat"},{"name":"NCI_Drug_Dictionary_ID","value":"42443"},{"name":"NSC Number","value":"689451"},{"name":"NSC Number","value":"719333"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42443"},{"name":"PDQ_Open_Trial_Search_ID","value":"42443"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338344"}]}}{"C64634":{"preferredName":"Marizomib","code":"C64634","definitions":[{"definition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marizomib","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,4R,5S)-4-(2-chloroethyl)-1-{(S)-[(1S)-cyclohex-2-en-1-yl]hydroxymethyl}-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Marizomib","termGroup":"SY","termSource":"NCI"},{"termName":"ML 858","termGroup":"CN","termSource":"NCI"},{"termName":"NPI-0052","termGroup":"CN","termSource":"NCI"},{"termName":"Salinosporamide A","termGroup":"SY","termSource":"NCI"},{"termName":"Salinosporin A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"437742-34-2"},{"name":"CHEBI_ID","value":"CHEBI:48045"},{"name":"Chemical_Formula","value":"C15H20ClNO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"703P9YDP7F"},{"name":"Legacy Concept Name","value":"NPI-0052"},{"name":"Maps_To","value":"Marizomib"},{"name":"NCI_Drug_Dictionary_ID","value":"518316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518316"},{"name":"PDQ_Open_Trial_Search_ID","value":"518316"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1259854"}]}}{"C79831":{"preferredName":"Masitinib Mesylate","code":"C79831","definitions":[{"definition":"The orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masitinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide Mesylate","termGroup":"SN","termSource":"NCI"},{"termName":"AB1010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1048007-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZK89EG3A18"},{"name":"Legacy Concept Name","value":"Masitinib_Mesylate"},{"name":"Maps_To","value":"Masitinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"629109"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629109"},{"name":"PDQ_Open_Trial_Search_ID","value":"629109"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351399"}]}}{"C701":{"preferredName":"Masoprocol","code":"C701","definitions":[{"definition":"A drug put on the skin to treat growths caused by sun exposure. A form of Masoprocol that is taken by mouth is being studied in the treatment of prostate cancer. Masoprocol is an antioxidant, and it may block certain enzymes needed for tumor growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally occurring antioxidant dicatechol originally derived from the creosote bush Larrea divaricatta with antipromoter, anti-inflammatory, and antineoplastic activities. Masoprocol directly inhibits activation of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu receptor, resulting in decreased proliferation of susceptible tumor cell populations. This agent may induce apoptosis in susceptible tumor cell populations as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases (SAPKs). In addition, masoprocol inhibits arachidonic acid 5-lipoxygenase (5LOX), resulting in diminished synthesis of inflammatory mediators such as prostaglandins and leukotrienes. It may prevent leukocyte infiltration into tissues and the release of reactive oxygen species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masoprocol","termGroup":"PT","termSource":"NCI"},{"termName":"4,4'-(2,3-Dimethyl-1,4-butanediyl)bis[1,2-benzenediol]","termGroup":"SN","termSource":"NCI"},{"termName":"Actinex","termGroup":"BR","termSource":"NCI"},{"termName":"NDGA","termGroup":"AB","termSource":"NCI"},{"termName":"NDHGA","termGroup":"AB","termSource":"NCI"},{"termName":"Nordihydroguaiaretic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"27686-84-6"},{"name":"Chemical_Formula","value":"C18H22O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BO8G1BYQU"},{"name":"Legacy Concept Name","value":"Nordihydroguaiaretic_Acid"},{"name":"Maps_To","value":"Masoprocol"},{"name":"NCI_Drug_Dictionary_ID","value":"479648"},{"name":"NSC Number","value":"4291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"479648"},{"name":"PDQ_Open_Trial_Search_ID","value":"479648"},{"name":"PubMedID_Primary_Reference","value":"8450672"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0733397"}]}}{"C153180":{"preferredName":"MAT2A Inhibitor AG-270","code":"C153180","definitions":[{"definition":"An orally available small molecule inhibitor of methionine adenosyltransferase II alpha (MAT2A) with potential antineoplastic activity. Upon administration, AG-270 inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-Adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in methylthioadenosine phosphorylase (MTAP), a critical enzyme in the methionine salvage pathway, that is deleted in some human cancers. Inhibition of MAT2A may potentially inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAT2A Inhibitor AG-270","termGroup":"PT","termSource":"NCI"},{"termName":"AG 270","termGroup":"CN","termSource":"NCI"},{"termName":"AG-270","termGroup":"CN","termSource":"NCI"},{"termName":"AG270","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2201056-66-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E1P2TDU69L"},{"name":"Maps_To","value":"MAT2A Inhibitor AG-270"},{"name":"NCI_Drug_Dictionary_ID","value":"793947"},{"name":"NCI_META_CUI","value":"CL554312"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793947"},{"name":"PDQ_Open_Trial_Search_ID","value":"793947"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2045":{"preferredName":"Matrix Metalloproteinase Inhibitor MMI270","code":"C2045","definitions":[{"definition":"An orally-active synthetic hydroxamic acid derivative with potential antineoplastic activity.  MMI270 inhibits a broad spectrum of matrix metalloproteinases (MMPs) (specifically MMP-1, 2, 3, 9, and 13), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also downregulate lymphangiogenesis, resulting in decreased lymphatic system-related metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Matrix Metalloproteinase Inhibitor MMI270","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-N-Hydroxy-2-[[(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methylbutanamide Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CGS27023","termGroup":"CN","termSource":"NCI"},{"termName":"CGS27023A","termGroup":"CN","termSource":"NCI"},{"termName":"MMI 270B CGS27023A","termGroup":"SY","termSource":"NCI"},{"termName":"N-hydroxy-2(R)-[(4-methoxysulfony) (3-picolyl)-amino]-3-metylbutaneamide hydrochloride monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N-hydroxy-2(R)-[[4- methoxysulfonyl](3-picolyl)amino]-3-methylbutaneamide hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MMI270"},{"name":"Maps_To","value":"Matrix Metalloproteinase Inhibitor MMI270"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385829"}]}}{"C2012":{"preferredName":"Matuzumab","code":"C2012","definitions":[{"definition":"A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and inhibiting receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. EMD 72000 binds to the epithelial growth factor receptor (EGFR) on tumor cells and blocks growth signals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Matuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 72000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"339186-68-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MG4M3QB242"},{"name":"Legacy Concept Name","value":"EMD_72000"},{"name":"Maps_To","value":"Matuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"350433"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350433"},{"name":"PDQ_Open_Trial_Search_ID","value":"350433"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328134"}]}}{"C120307":{"preferredName":"Mavelertinib","code":"C120307","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mavelertinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)-3-pyrrolidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"PF-06747775","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1776112-90-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YXX2180047"},{"name":"Maps_To","value":"Mavelertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"768709"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768709"},{"name":"PDQ_Open_Trial_Search_ID","value":"768709"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896785"}]}}{"C126660":{"preferredName":"Mavorixafor","code":"C126660","definitions":[{"definition":"An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T-cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mavorixafor","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"AMD-070","termGroup":"CN","termSource":"NCI"},{"termName":"AMD-11070","termGroup":"CN","termSource":"NCI"},{"termName":"AMD11070","termGroup":"CN","termSource":"NCI"},{"termName":"X4P 001","termGroup":"CN","termSource":"NCI"},{"termName":"X4P-001","termGroup":"CN","termSource":"NCI"},{"termName":"X4P001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"558447-26-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0G9LGB5O2W"},{"name":"Maps_To","value":"Mavorixafor"},{"name":"NCI_Drug_Dictionary_ID","value":"780512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780512"},{"name":"PDQ_Open_Trial_Search_ID","value":"780512"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2930725"}]}}{"C626":{"preferredName":"Maytansine","code":"C626","definitions":[{"definition":"An ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata. Maytansine binds to tubulin at the rhizoxin binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.  Maytansine exhibits cytotoxicity against many tumor cell lines and may inhibit tumor growth in vivo. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maytansine","termGroup":"PT","termSource":"NCI"},{"termName":"alanine, N-acetyl-N-methyl-, 6-ester with 11-chloro-6, 21-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1(10,24).0(3,5)]hexacosa-10,12,14[26], 16,18-pentaene-8,23-dione","termGroup":"SN","termSource":"NCI"},{"termName":"L-alanine, N-acetyl-N-methyl-, 11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03, 5]hexacosa-10,12,14(26),16,18-pentaen-6-yl ester, [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]","termGroup":"SN","termSource":"NCI"},{"termName":"Maitansine","termGroup":"SY","termSource":"NCI"},{"termName":"Maysanine","termGroup":"SY","termSource":"NCI"},{"termName":"Maytansin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"35846-53-8"},{"name":"Chemical_Formula","value":"C34H46ClN3O10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14083FR882"},{"name":"Legacy Concept Name","value":"Maytansine"},{"name":"Maps_To","value":"Maytansine"},{"name":"NCI_Drug_Dictionary_ID","value":"39492"},{"name":"NSC Number","value":"153858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39492"},{"name":"PDQ_Open_Trial_Search_ID","value":"39492"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0024975"}]}}{"C127817":{"preferredName":"Tapotoclax","code":"C127817","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tapotoclax","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1883727-34-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"97W7N9T08G"},{"name":"Maps_To","value":"MCL-1 Inhibitor AMG 176"},{"name":"Maps_To","value":"Tapotoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"781850"},{"name":"NCI_META_CUI","value":"CL507931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781850"},{"name":"PDQ_Open_Trial_Search_ID","value":"781850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156740":{"preferredName":"Murizatoclax","code":"C156740","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor AMG 397 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Murizatoclax","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 397","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-397","termGroup":"CN","termSource":"NCI"},{"termName":"AMG397","termGroup":"CN","termSource":"NCI"},{"termName":"MCL-1 inhibitor AMG 397","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Cell Leukemia 1 Inhibitor AMG 397","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2245848-05-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BO0V7196L2"},{"name":"Maps_To","value":"MCL-1 inhibitor AMG 397"},{"name":"Maps_To","value":"Murizatoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"795697"},{"name":"NCI_META_CUI","value":"CL935903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795697"},{"name":"PDQ_Open_Trial_Search_ID","value":"795697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137989":{"preferredName":"Mcl-1 Inhibitor AZD5991","code":"C137989","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, AZD5991 binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins, and promoting apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mcl-1 Inhibitor AZD5991","termGroup":"PT","termSource":"NCI"},{"termName":"AZD-5991","termGroup":"CN","termSource":"NCI"},{"termName":"AZD5991","termGroup":"CN","termSource":"NCI"},{"termName":"MCL1 Inhibitor AZD5991","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2143010-83-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E3T5XXY9HX"},{"name":"Maps_To","value":"Mcl-1 Inhibitor AZD5991"},{"name":"NCI_Drug_Dictionary_ID","value":"790242"},{"name":"NCI_META_CUI","value":"CL524956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790242"},{"name":"PDQ_Open_Trial_Search_ID","value":"790242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133174":{"preferredName":"Mcl-1 Inhibitor MIK665","code":"C133174","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mcl-1 Inhibitor MIK665","termGroup":"PT","termSource":"NCI"},{"termName":"MIK 665","termGroup":"CN","termSource":"NCI"},{"termName":"MIK-665","termGroup":"CN","termSource":"NCI"},{"termName":"MIK665","termGroup":"CN","termSource":"NCI"},{"termName":"S 64315","termGroup":"CN","termSource":"NCI"},{"termName":"S-64315","termGroup":"CN","termSource":"NCI"},{"termName":"S64315","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1799638-19-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"801XYWHNOS"},{"name":"Maps_To","value":"Mcl-1 Inhibitor MIK665"},{"name":"NCI_Drug_Dictionary_ID","value":"788002"},{"name":"NCI_META_CUI","value":"CL520448"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788002"},{"name":"PDQ_Open_Trial_Search_ID","value":"788002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162749":{"preferredName":"MDM2 Antagonist ASTX295","code":"C162749","definitions":[{"definition":"An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Antagonist ASTX295","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 295","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX-295","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX295","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2 Inhibitor ASTX295","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MDM2 Antagonist ASTX295"},{"name":"NCI_Drug_Dictionary_ID","value":"798989"},{"name":"NCI_META_CUI","value":"CL973194"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798989"},{"name":"PDQ_Open_Trial_Search_ID","value":"798989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91724":{"preferredName":"MDM2 Antagonist RO5045337","code":"C91724","definitions":[{"definition":"An MDM2 (human homolog of double minutes-2; HDM2) antagonist with potential antineoplastic activity. RO5045337 binds to MDM2, thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Antagonist RO5045337","termGroup":"PT","termSource":"NCI"},{"termName":"R7112","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5045337","termGroup":"CN","termSource":"NCI"},{"termName":"RO5045337","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"939981-39-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q8MI0X869M"},{"name":"Maps_To","value":"MDM2 Antagonist RO5045337"},{"name":"NCI_Drug_Dictionary_ID","value":"581121"},{"name":"NCI_META_CUI","value":"CL421615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581121"},{"name":"PDQ_Open_Trial_Search_ID","value":"581121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114980":{"preferredName":"MDM2 Antagonist RO6839921","code":"C114980","definitions":[{"definition":"An MDM2 (human homolog of murine double minute-2; HDM2) antagonist with potential antineoplastic activity. Upon intravenous administration, RO6839921 binds to MDM2 and prevents the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling, followed by p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway and is often overexpressed in cancer cells; p53 inhibition has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Antagonist RO6839921","termGroup":"PT","termSource":"NCI"},{"termName":"RO6839921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MDM2 Antagonist RO6839921"},{"name":"NCI_Drug_Dictionary_ID","value":"759578"},{"name":"NCI_META_CUI","value":"CL472577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759578"},{"name":"PDQ_Open_Trial_Search_ID","value":"759578"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116624":{"preferredName":"Navtemadlin","code":"C116624","definitions":[{"definition":"An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration,navtemadlin binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navtemadlin","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"AMG 232","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-232","termGroup":"CN","termSource":"NCI"},{"termName":"KRT 232","termGroup":"CN","termSource":"NCI"},{"termName":"KRT-232","termGroup":"CN","termSource":"NCI"},{"termName":"KRT232","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2 Inhibitor KRT-232","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1352066-68-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7R7G6EH5UL"},{"name":"Maps_To","value":"MDM2 Inhibitor AMG-232"},{"name":"Maps_To","value":"MDM2 Inhibitor KRT-232"},{"name":"NCI_Drug_Dictionary_ID","value":"742695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742695"},{"name":"PDQ_Open_Trial_Search_ID","value":"742695"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852521"}]}}{"C156709":{"preferredName":"Brigimadlin","code":"C156709","definitions":[{"definition":"An orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, brigimadlin binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. Compared to currently available MDM2 inhibitors, the pharmacokinetic properties of BI 907828 allow for more optimal dosing and dose schedules that may reduce myelosuppression, an on-target, dose-limiting toxicity for this class of inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brigimadlin","termGroup":"PT","termSource":"NCI"},{"termName":"BI 907828","termGroup":"CN","termSource":"NCI"},{"termName":"BI-907828","termGroup":"CN","termSource":"NCI"},{"termName":"BI907828","termGroup":"SY","termSource":"NCI"},{"termName":"MDM2 Inhibitor BI 907828","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095116-40-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9A934ZAN94"},{"name":"Maps_To","value":"MDM2 Inhibitor BI 907828"},{"name":"NCI_Drug_Dictionary_ID","value":"795735"},{"name":"NCI_META_CUI","value":"CL935863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795735"},{"name":"PDQ_Open_Trial_Search_ID","value":"795735"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118669":{"preferredName":"Sulanemadlin","code":"C118669","definitions":[{"definition":"An orally available peptide inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, sulanemadlin binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulanemadlin","termGroup":"PT","termSource":"NCI"},{"termName":"ALRN-6924","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2/MDMX Inhibitor ALRN-6924","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1451199-98-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6BGF28R54M"},{"name":"Maps_To","value":"MDM2/MDMX Inhibitor ALRN-6924"},{"name":"NCI_Drug_Dictionary_ID","value":"765720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765720"},{"name":"PDQ_Open_Trial_Search_ID","value":"765720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896920"}]}}{"C67042":{"preferredName":"MDR Modulator CBT-1","code":"C67042","definitions":[{"definition":"A naturally-occurring, orally bioavailable bisbenzylisoquinoline plant alkaloid with potential chemosensitization activity. MDR modulator CBT-1 binds to and inhibits the MDR efflux pump P-glycoprotein (P-gp), which may inhibit the efflux of various chemotherapeutic agents from tumor cells and reverse P-gp-mediated tumor cell MDR. P-gp is a transmembrane ATP-binding cassette (ABC) transporter and is overexpressed by some multidrug resistant tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance taken from plants that is being studied in the treatment of cancer. It may help drugs kill tumor cells that have become resistant to drugs. It is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"MDR Modulator CBT-1","termGroup":"PT","termSource":"NCI"},{"termName":"CBT-1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CBT-1"},{"name":"Maps_To","value":"MDR Modulator CBT-1"},{"name":"NCI_Drug_Dictionary_ID","value":"538747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"538747"},{"name":"PDQ_Open_Trial_Search_ID","value":"538747"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0916470"}]}}{"C62056":{"preferredName":"Mechlorethamine","code":"C62056","definitions":[{"definition":"A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The nitrogen mustard vesicant HN-2.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mechlorethamine","termGroup":"PT","termSource":"NCI"},{"termName":"Bis(2-chloroethyl)methylamine","termGroup":"SN","termSource":"NCI"},{"termName":"chlorethazine","termGroup":"SY","termSource":"NCI"},{"termName":"Chlormethine","termGroup":"SY","termSource":"NCI"},{"termName":"chloromethine","termGroup":"SY","termSource":"NCI"},{"termName":"ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl","termGroup":"SN","termSource":"NCI"},{"termName":"HN 2","termGroup":"AB","termSource":"NCI"},{"termName":"Methylbis(beta-chloroethyl)amine","termGroup":"SN","termSource":"NCI"},{"termName":"methylchlorethamine","termGroup":"SY","termSource":"NCI"},{"termName":"Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"Mustine","termGroup":"SY","termSource":"NCI"},{"termName":"Nitrogen Mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51-75-2"},{"name":"CHEBI_ID","value":"CHEBI:28925"},{"name":"Chemical_Formula","value":"C5H11Cl2N"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"50D9XSG0VR"},{"name":"Legacy Concept Name","value":"Mechlorethamine"},{"name":"Maps_To","value":"Mechlorethamine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025033"}]}}{"C627":{"preferredName":"Mechlorethamine Hydrochloride","code":"C627","definitions":[{"definition":"A drug used to treat some types of cancer and some skin conditions that may become cancer. It attaches to the cell's DNA and may kill cancer cells. Mechlorethamine hydrochloride is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of mechlorethamine, a nitrogen mustard and an analogue of sulfur mustard, with antineoplastic and immunosuppressive activities. Mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that alkylates DNA, particularly the 7 nitrogen of guanine residues, resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. This agent also exhibits lympholytic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mechlorethamine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Bis(2-chloroethyl)methylamine Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Caryolysine","termGroup":"FB","termSource":"NCI"},{"termName":"Chlorethamine HCl","termGroup":"SY","termSource":"NCI"},{"termName":"chlorethamine hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorethazine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Chlormethine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Chloromethine HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Chloromethine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cloramin","termGroup":"FB","termSource":"NCI"},{"termName":"Erasol","termGroup":"FB","termSource":"NCI"},{"termName":"ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"HN 2 Hydrochloride","termGroup":"AB","termSource":"NCI"},{"termName":"mechlorethamine HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Methylbis(beta-chloroethyl)amine Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Methylchlorethamine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mustargen","termGroup":"BR","termSource":"NCI"},{"termName":"Mustargen HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Mustargen Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mustine Hydrochloride","termGroup":"FB","termSource":"NCI"},{"termName":"N-Lost","termGroup":"SY","termSource":"NCI"},{"termName":"Onco-Cloramin","termGroup":"FB","termSource":"NCI"},{"termName":"WR-147650","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bronchogenic carcinoma; chronic lymphocytic and myelcytic leukemia; Hodgkins dieseas, palliative; lymphosarcoma; mycosis fungoides; polycythemia vera"},{"name":"CAS_Registry","value":"55-86-7"},{"name":"CHEBI_ID","value":"CHEBI:55368"},{"name":"Chemical_Formula","value":"C5H11Cl2N.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0MR697HHI"},{"name":"Legacy Concept Name","value":"Nitrogen_Mustard"},{"name":"Maps_To","value":"Mechlorethamine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"43434"},{"name":"NSC Number","value":"762"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43434"},{"name":"PDQ_Open_Trial_Search_ID","value":"43434"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0600266"}]}}{"C119736":{"preferredName":"Mechlorethamine Hydrochloride Gel","code":"C119736","definitions":[{"definition":"A gel formulation composed of the hydrochloride salt form of mechlorethamine, which is a nitrogen mustard alkylating agent and an analog of sulfur mustard, with antineoplastic and immunosuppressive activities. Upon topical application, mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that binds to and alkylates DNA, with a high affinity to the N7 nitrogen of guanine residues. This results in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mechlorethamine Hydrochloride Gel","termGroup":"PT","termSource":"NCI"},{"termName":"Mechlorethamine HCl Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Valchlor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mechlorethamine Hydrochloride Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"766986"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766986"},{"name":"PDQ_Open_Trial_Search_ID","value":"766986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3666714"}]}}{"C87599":{"preferredName":"Medorubicin","code":"C87599","definitions":[{"definition":"A demethoxy derivative of doxorubicin with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S)-3-Glycoloyl-1,2,3,4,6,11-Hexahydro-3,5,12-Trihydroxy-6,11-Dioxo-1-Naphthacenyl 3-Amino-2,3,6-Trideoxy-Alpha-L-Lyxo-Hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"4-Demethoxydoxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64314-52-9"},{"name":"Chemical_Formula","value":"C26H27NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NU158DGH9E"},{"name":"Maps_To","value":"Medorubicin"},{"name":"NSC Number","value":"256438"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048224"}]}}{"C629":{"preferredName":"Medroxyprogesterone","code":"C629","definitions":[{"definition":"A hormonal anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called progestins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medroxyprogesterone","termGroup":"PT","termSource":"NCI"},{"termName":"(6Alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17Alpha-hydroxy-6alpha-methylprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6Alpha-methyl-17alpha-hydroxyprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6Alpha-methyl-4-pregnen-17alpha-ol-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Curretab","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast carcinoma; Contraception; Endometrial carcinoma; Renal cell carcinoma"},{"name":"CAS_Registry","value":"520-85-4"},{"name":"CHEBI_ID","value":"CHEBI:6715"},{"name":"Chemical_Formula","value":"C22H32O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HSU1C9YRES"},{"name":"Legacy Concept Name","value":"Medroxyprogesterone"},{"name":"Maps_To","value":"Medroxyprogesterone"},{"name":"NCI_Drug_Dictionary_ID","value":"39813"},{"name":"NSC Number","value":"27408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39813"},{"name":"PDQ_Open_Trial_Search_ID","value":"39813"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025147"}]}}{"C1155":{"preferredName":"Medroxyprogesterone Acetate","code":"C1155","definitions":[{"definition":"A drug used to prevent endometrial cancer. It is also used to treat menstrual disorders and as a form of birth control. It is a form of the female hormone progesterone and belongs to the family of drugs called progestins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medroxyprogesterone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"(6alpha)-17-(Acetyloxy)-6-methylpregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17-(Acetyloxy)-6alpha-methylpregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"17Alpha-acetoxy-6alpha-methylprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6-Alpha-methyl-17alpha-acetoxyprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"Amen","termGroup":"BR","termSource":"NCI"},{"termName":"Aragest","termGroup":"FB","termSource":"NCI"},{"termName":"Ciclotal","termGroup":"FB","termSource":"NCI"},{"termName":"Clinofem","termGroup":"FB","termSource":"NCI"},{"termName":"Clinovir","termGroup":"FB","termSource":"NCI"},{"termName":"Cycrin","termGroup":"BR","termSource":"NCI"},{"termName":"Depo-Clinovir","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Provera","termGroup":"BR","termSource":"NCI"},{"termName":"Depot-Medroxyprogestereone Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"Farlutal","termGroup":"FB","termSource":"NCI"},{"termName":"G-Farlutal","termGroup":"FB","termSource":"NCI"},{"termName":"Gestapuran","termGroup":"FB","termSource":"NCI"},{"termName":"Hysron","termGroup":"FB","termSource":"NCI"},{"termName":"Lutoral","termGroup":"FB","termSource":"NCI"},{"termName":"Medroxyprogesterone 17-Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"Medroxyprogesteroni Acetas","termGroup":"SY","termSource":"NCI"},{"termName":"Methylacetoxyprogesterone","termGroup":"SY","termSource":"NCI"},{"termName":"Metipregnone","termGroup":"SY","termSource":"NCI"},{"termName":"MPA","termGroup":"AB","termSource":"NCI"},{"termName":"Nadigest (vet)","termGroup":"FB","termSource":"NCI"},{"termName":"Nidaxin (vet)","termGroup":"FB","termSource":"NCI"},{"termName":"Oragest","termGroup":"BR","termSource":"NCI"},{"termName":"Perlutex","termGroup":"FB","termSource":"NCI"},{"termName":"Prodasone","termGroup":"FB","termSource":"NCI"},{"termName":"Provera","termGroup":"BR","termSource":"NCI"},{"termName":"Sodelut G","termGroup":"FB","termSource":"NCI"},{"termName":"Veramix","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71-58-9"},{"name":"CHEBI_ID","value":"CHEBI:6716"},{"name":"Chemical_Formula","value":"C24H34O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C2QI4IOI2G"},{"name":"Legacy Concept Name","value":"Medroxyprogesterone_17-Acetate"},{"name":"Maps_To","value":"Medroxyprogesterone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"39813"},{"name":"NSC Number","value":"21171"},{"name":"NSC Number","value":"26386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39813"},{"name":"PDQ_Open_Trial_Search_ID","value":"39813"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065864"}]}}{"C1156":{"preferredName":"Megestrol Acetate","code":"C1156","definitions":[{"definition":"A drug used to block estrogen and suppress the effects of estrogen and androgens. It is used to treat breast and endometrial cancer, and is being studied in the treatment of other types of cancer. It is also used to improve appetite in patients with cancer. Megace belongs to the group of hormones called progestins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Megestrol Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"(9beta,10alpha)-17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17 Alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"6-Dehydro-6-methyl-17 alpha-acetoxyprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6-Methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"BDH-1298","termGroup":"CN","termSource":"NCI"},{"termName":"Maygace","termGroup":"FB","termSource":"NCI"},{"termName":"Megace","termGroup":"BR","termSource":"NCI"},{"termName":"Megestat","termGroup":"FB","termSource":"NCI"},{"termName":"Megestil","termGroup":"FB","termSource":"NCI"},{"termName":"Niagestin","termGroup":"FB","termSource":"NCI"},{"termName":"Ovaban","termGroup":"SY","termSource":"NCI"},{"termName":"Pallace","termGroup":"SY","termSource":"NCI"},{"termName":"SC-10363","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Appetite enhancement, AIDS patients; Breast cancer, palliative treatment; Endometrial carcinoma, palliative treatment"},{"name":"CAS_Registry","value":"595-33-5"},{"name":"CHEBI_ID","value":"CHEBI:6723"},{"name":"Chemical_Formula","value":"C24H32O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TJ2M0FR8ES"},{"name":"Legacy Concept Name","value":"Megestrol_Acetate"},{"name":"Maps_To","value":"Megestrol Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"43435"},{"name":"NSC Number","value":"71423"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43435"},{"name":"PDQ_Open_Trial_Search_ID","value":"43435"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065879"}]}}{"C98832":{"preferredName":"MEK 1/2 Inhibitor AS703988/MSC2015103B","code":"C98832","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2 with potential antineoplastic activity. MEK1/2 inhibitor AS703988/MSC2015103B selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK 1/2 Inhibitor AS703988/MSC2015103B","termGroup":"PT","termSource":"NCI"},{"termName":"AS703988","termGroup":"CN","termSource":"NCI"},{"termName":"AS703988/MSC2015103B","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2015103B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK 1/2 Inhibitor AS703988/MSC2015103B"},{"name":"NCI_Drug_Dictionary_ID","value":"714900"},{"name":"NCI_META_CUI","value":"CL432851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714900"},{"name":"PDQ_Open_Trial_Search_ID","value":"714900"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C69143":{"preferredName":"MEK Inhibitor AZD8330","code":"C69143","definitions":[{"definition":"An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor AZD8330","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-424704","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-704","termGroup":"CN","termSource":"NCI"},{"termName":"AZD8330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"869357-68-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G4990BOZ66"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_AZD8330"},{"name":"Maps_To","value":"MEK Inhibitor AZD8330"},{"name":"NCI_Drug_Dictionary_ID","value":"543526"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543526"},{"name":"PDQ_Open_Trial_Search_ID","value":"543526"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346908"}]}}{"C2670":{"preferredName":"MEK Inhibitor CI-1040","code":"C2670","definitions":[{"definition":"An agent that inhibits both mitogen-activated protein kinase kinases 1 and 2 (MEK1 and MEK2), substrates of Raf and phosphorylates extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2), preventing phosphorylation and activation of the Mitogen-Activated Protein Kinase (MAPK) pathways, involved with signal transduction pathways and tumor proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor CI-1040","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"CI-1040","termGroup":"CN","termSource":"NCI"},{"termName":"PD 184352/CI-1040","termGroup":"SY","termSource":"NCI"},{"termName":"PD-184352","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"212631-79-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R3K9Y00J04"},{"name":"Legacy Concept Name","value":"CI-1040"},{"name":"Maps_To","value":"MEK Inhibitor CI-1040"},{"name":"NCI_Drug_Dictionary_ID","value":"38593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38593"},{"name":"PDQ_Open_Trial_Search_ID","value":"38593"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0769765"}]}}{"C155971":{"preferredName":"MEK inhibitor CS3006","code":"C155971","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, MEK inhibitor CS3006 specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins including extracellular signal-regulated kinase (ERK) and inhibits the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the  RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in a variety of tumor cell types. The RAS/RAF/MEK/ERK pathway regulates key cellular activities including cell growth, proliferation, survival, differentiation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK inhibitor CS3006","termGroup":"PT","termSource":"NCI"},{"termName":"CS 3006","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3006","termGroup":"CN","termSource":"NCI"},{"termName":"CS3006","termGroup":"CN","termSource":"NCI"},{"termName":"MAPK Kinase Inhibitor CS3006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK inhibitor CS3006"},{"name":"NCI_Drug_Dictionary_ID","value":"795024"},{"name":"NCI_META_CUI","value":"CL562716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795024"},{"name":"PDQ_Open_Trial_Search_ID","value":"795024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95738":{"preferredName":"MEK Inhibitor GDC-0623","code":"C95738","definitions":[{"definition":"An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor GDC-0623","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0623","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1168091-68-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HW67545I4Q"},{"name":"Maps_To","value":"MEK Inhibitor GDC-0623"},{"name":"NCI_Drug_Dictionary_ID","value":"673612"},{"name":"NCI_META_CUI","value":"CL421583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673612"},{"name":"PDQ_Open_Trial_Search_ID","value":"673612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52195":{"preferredName":"Mirdametinib","code":"C52195","definitions":[{"definition":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirdametinib","termGroup":"PT","termSource":"NCI"},{"termName":"MEK Inhibitor PD0325901","termGroup":"SY","termSource":"NCI"},{"termName":"PD 901","termGroup":"CN","termSource":"NCI"},{"termName":"PD-0325901","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"391210-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"86K0J5AK6M"},{"name":"Legacy Concept Name","value":"PD-0325901"},{"name":"Maps_To","value":"MEK Inhibitor PD0325901"},{"name":"Maps_To","value":"Mirdametinib"},{"name":"NCI_Drug_Dictionary_ID","value":"456780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456780"},{"name":"PDQ_Open_Trial_Search_ID","value":"456780"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1675748"}]}}{"C82696":{"preferredName":"MEK Inhibitor RO4987655","code":"C82696","definitions":[{"definition":"An orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor RO4987655 binds to and inhibits MEK, which may result in the inhibition of MEK-dependent cell signaling and the inhibition of tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor RO4987655","termGroup":"PT","termSource":"NCI"},{"termName":"RO4987655","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"874101-00-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I3733P75ML"},{"name":"Legacy Concept Name","value":"MEK_Serine_Threonine_Kinase_Inhibitor_RO4987655"},{"name":"Maps_To","value":"MEK Inhibitor RO4987655"},{"name":"NCI_Drug_Dictionary_ID","value":"633506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633506"},{"name":"PDQ_Open_Trial_Search_ID","value":"633506"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830219"}]}}{"C150680":{"preferredName":"MEK Inhibitor SHR 7390","code":"C150680","definitions":[{"definition":"An orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor SHR 7390 selectively binds to and inhibits the activity of MEK. This prevents the activation of MEK-dependent effector proteins, which results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase family that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor SHR 7390","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K Inhibitor SHR 7390","termGroup":"SY","termSource":"NCI"},{"termName":"MAPK Kinase Inhibitor SHR 7390","termGroup":"SY","termSource":"NCI"},{"termName":"MEKi SHR 7390","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 7390","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-7390","termGroup":"CN","termSource":"NCI"},{"termName":"SHR7390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK Inhibitor SHR 7390"},{"name":"NCI_Drug_Dictionary_ID","value":"793097"},{"name":"NCI_META_CUI","value":"CL552486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793097"},{"name":"PDQ_Open_Trial_Search_ID","value":"793097"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84858":{"preferredName":"MEK Inhibitor REC-4881","code":"C84858","definitions":[{"definition":"An orally bioavailable, non-ATP-competitive, allosteric, small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and MEK2, with potential antineoplastic activity. Upon oral administration, MEK inhibitor REC-4881 selectively binds to and inhibits the activity of MEK1/2. This prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor REC-4881","termGroup":"PT","termSource":"NCI"},{"termName":"REC 4881","termGroup":"CN","termSource":"NCI"},{"termName":"REC-4881","termGroup":"CN","termSource":"NCI"},{"termName":"REC4881","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-733","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1035555-63-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5J61HSP0QJ"},{"name":"Maps_To","value":"MEK Inhibitor TAK-733"},{"name":"NCI_Drug_Dictionary_ID","value":"651550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651550"},{"name":"PDQ_Open_Trial_Search_ID","value":"651550"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827535"}]}}{"C101532":{"preferredName":"MEK Inhibitor WX-554","code":"C101532","definitions":[{"definition":"An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic activity. MEK inhibitor WX-554 selectively binds to and inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins including some transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor WX-554","termGroup":"PT","termSource":"NCI"},{"termName":"WX-554","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK Inhibitor WX-554"},{"name":"NCI_Drug_Dictionary_ID","value":"732484"},{"name":"NCI_META_CUI","value":"CL435784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732484"},{"name":"PDQ_Open_Trial_Search_ID","value":"732484"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79848":{"preferredName":"MEK-1/MEKK-1 Inhibitor E6201","code":"C79848","definitions":[{"definition":"A synthetic, fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK-1/MEKK-1 Inhibitor E6201","termGroup":"PT","termSource":"NCI"},{"termName":"E6201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"603987-35-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CZP9GB25HO"},{"name":"Legacy Concept Name","value":"MEK-1_MEKK-1_Tyrosine_Kinase_Inhibitor_E6201"},{"name":"Maps_To","value":"MEK-1/MEKK-1 Inhibitor E6201"},{"name":"NCI_Drug_Dictionary_ID","value":"629676"},{"name":"NCI_META_CUI","value":"CL388442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629676"},{"name":"PDQ_Open_Trial_Search_ID","value":"629676"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106126":{"preferredName":"MEK/Aurora Kinase Inhibitor BI 847325","code":"C106126","definitions":[{"definition":"An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells.  Altogether, this leads to the inhibition of cell proliferation and tumor growth as well as the induction of tumor regression. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK/Aurora Kinase Inhibitor BI 847325","termGroup":"PT","termSource":"NCI"},{"termName":"BI 847325","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK/Aurora Kinase Inhibitor BI 847325"},{"name":"NCI_Drug_Dictionary_ID","value":"698315"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698315"},{"name":"PDQ_Open_Trial_Search_ID","value":"698315"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827151"}]}}{"C29178":{"preferredName":"Melanoma Monoclonal Antibody hIgG2A","code":"C29178","definitions":[{"definition":"One of a number human monoclonal antibodies of the immunoglobulin subclass IgG2a directed against melanoma antigens with potential antineoplastic activity.  A melanoma monoclonal antibody, subclass IgG2A, may have potential use as a diagnostic agent and, therapeutically, may induce macrophage-mediated cytotoxicity against antibody-bound melanoma cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma Monoclonal Antibody hIgG2A","termGroup":"PT","termSource":"NCI"},{"termName":"M A IG2A Human Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanoma_Monoclonal_Antibody_hIgG2A"},{"name":"Maps_To","value":"Melanoma Monoclonal Antibody hIgG2A"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513096"}]}}{"C91380":{"preferredName":"Melanoma TRP2 CTL Epitope Vaccine SCIB1","code":"C91380","definitions":[{"definition":"A proprietary DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. Upon intramuscular injection and electroporation, melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma TRP2 CTL Epitope Vaccine SCIB1","termGroup":"PT","termSource":"NCI"},{"termName":"SCIB1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Melanoma TRP2 CTL Epitope Vaccine SCIB1"},{"name":"NCI_Drug_Dictionary_ID","value":"675320"},{"name":"NCI_META_CUI","value":"CL421601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675320"},{"name":"PDQ_Open_Trial_Search_ID","value":"675320"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120183":{"preferredName":"Eltrapuldencel-T","code":"C120183","definitions":[{"definition":"A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, eltrapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eltrapuldencel-T","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous DCs Loaded with Irradiated Autologous Tumor Cells in GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Dendritic Cells Loaded with Irradiated Autologous Tumor Cells in Granulocyte-macrophage Colony-stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"DC-TC","termGroup":"AB","termSource":"NCI"},{"termName":"Melapuldencel-T","termGroup":"SY","termSource":"NCI"},{"termName":"NBS-20","termGroup":"CN","termSource":"NCI"},{"termName":"NBS20","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M2LBQ7RN2X"},{"name":"Maps_To","value":"Melapuldencel-T"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896681"}]}}{"C111569":{"preferredName":"MELK Inhibitor OTS167","code":"C111569","definitions":[{"definition":"An orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity. Upon administration, OTS167 binds to MELK, which prevents both MELK phosphorylation and activation; thus inhibiting the phosphorylation of downstream MELK substrates. This may lead to an inhibition of both cell proliferation and survival in MELK-expressing tumor cells. MELK, a serine/threonine kinase, is involved in cancer cell survival, invasiveness and cancer-stem cell formation and maintenance; it is highly upregulated in various types of cancer cells and absent in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MELK Inhibitor OTS167","termGroup":"PT","termSource":"NCI"},{"termName":"OTS-167","termGroup":"CN","termSource":"NCI"},{"termName":"OTS167","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1431697-89-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VY778IXU5T"},{"name":"Maps_To","value":"MELK Inhibitor OTS167"},{"name":"NCI_Drug_Dictionary_ID","value":"751983"},{"name":"NCI_META_CUI","value":"CL453977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751983"},{"name":"PDQ_Open_Trial_Search_ID","value":"751983"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C633":{"preferredName":"Melphalan","code":"C633","definitions":[{"definition":"A drug that is used to treat multiple myeloma and ovarian epithelial cancer and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melphalan","termGroup":"PT","termSource":"NCI"},{"termName":"4-[bis(2-chloroethyl)amino]-L-phenylalanine","termGroup":"SN","termSource":"NCI"},{"termName":"CB-3025","termGroup":"CN","termSource":"NCI"},{"termName":"L-PAM","termGroup":"AB","termSource":"NCI"},{"termName":"L-Phenylalanine Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"L-sarcolysin","termGroup":"SY","termSource":"NCI"},{"termName":"L-Sarcolysin Phenylalanine mustard","termGroup":"SY","termSource":"NCI"},{"termName":"L-Sarcolysine","termGroup":"SY","termSource":"NCI"},{"termName":"Melphalanum","termGroup":"FB","termSource":"NCI"},{"termName":"p-di(chloroethyl)amino-L-phenylalanine","termGroup":"SN","termSource":"NCI"},{"termName":"Phenylalanine Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"Phenylalanine Nitrogen Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoclorin","termGroup":"SY","termSource":"NCI"},{"termName":"Sarkolysin","termGroup":"FB","termSource":"NCI"},{"termName":"WR-19813","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; neuroblastoma; palliative treatment of multiple myeloma and nonresectable epithelial ovarian carcinoma; rhabdomyosarcoma"},{"name":"CAS_Registry","value":"148-82-3"},{"name":"CHEBI_ID","value":"CHEBI:28876"},{"name":"Chemical_Formula","value":"C13H18Cl2N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"Q41OR9510P"},{"name":"Legacy Concept Name","value":"Melphalan"},{"name":"Maps_To","value":"Melphalan"},{"name":"NCI_Drug_Dictionary_ID","value":"779085"},{"name":"NSC Number","value":"241286"},{"name":"NSC Number","value":"8806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779085"},{"name":"PDQ_Open_Trial_Search_ID","value":"779085"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025241"}]}}{"C107680":{"preferredName":"Melphalan Flufenamide","code":"C107680","definitions":[{"definition":"A peptide-drug conjugate composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to the alkylating agent melphalan, with potential antineoplastic and anti-angiogenic activities. Upon administration, the highly lipophilic melphalan flufenamide penetrates cell membranes and enters cells. In aminopeptidase-positive tumor cells, melphalan flufenamide is hydrolyzed by peptidases to release the hydrophilic alkylating agent melphalan. This results in the specific release and accumulation of melphalan in aminopeptidase-positive tumor cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells. The administration of melphalan flufenamide allows for enhanced efficacy and reduced toxicity compared to melphalan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melphalan Flufenamide","termGroup":"PT","termSource":"NCI"},{"termName":"Ethyl (2S)-2-((2S)-2-Amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate","termGroup":"SY","termSource":"NCI"},{"termName":"J-1","termGroup":"CN","termSource":"NCI"},{"termName":"J1","termGroup":"CN","termSource":"NCI"},{"termName":"L-melphalanyl-p-L-fluorophenylalanine Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Melflufen","termGroup":"SY","termSource":"NCI"},{"termName":"Prodrug J1","termGroup":"SY","termSource":"NCI"},{"termName":"Ygalo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"380449-51-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F70C5K4786"},{"name":"Maps_To","value":"Melphalan Flufenamide"},{"name":"NCI_Drug_Dictionary_ID","value":"751473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751473"},{"name":"PDQ_Open_Trial_Search_ID","value":"751473"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1435750"}]}}{"C48002":{"preferredName":"Melphalan Hydrochloride","code":"C48002","definitions":[{"definition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","type":"DEFINITION","source":"NCI"},{"definition":"A drug that is used to treat multiple myeloma and ovarian epithelial cancer and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Melphalan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"3-(p-(bis(2-chloroethyl)amino)phenyl)-L-Alanine, Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Alkeran","termGroup":"BR","termSource":"NCI"},{"termName":"Alkerana","termGroup":"FB","termSource":"NCI"},{"termName":"Evomela","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3223-07-2"},{"name":"Chemical_Formula","value":"C13H18Cl2N2O2.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1VXP4V453T"},{"name":"Legacy Concept Name","value":"Melphalan_Hydrochloride"},{"name":"Maps_To","value":"Melphalan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42973"},{"name":"NSC Number","value":"241286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42973"},{"name":"PDQ_Open_Trial_Search_ID","value":"42973"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771055"}]}}{"C84878":{"preferredName":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex","code":"C84878","definitions":[{"definition":"A propylene glycol-free intravenous formulation containing the hydrochloride salt of the nitrogen mustard phenylalanine derivative melphalan complexed with polyanionic sulfobutyl ether beta-cyclodextrin (SBE-CD) with potential antineoplastic activity. Upon administration, melphalan is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA; RNA and proteins may also be alkylated. Subsequently, RNA transcription and protein synthesis are inhibited, resulting in cell growth arrest. The addition of sulfobutyl ether beta-cyclodextrin to the formulation improves the solubility, stability and ease of use of melphalan; cyclodextrins are cyclic dextrins derived from starch.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex","termGroup":"PT","termSource":"NCI"},{"termName":"Captisol-enabled Melphalan IV","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"649061"},{"name":"NCI_META_CUI","value":"CL412380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649061"},{"name":"PDQ_Open_Trial_Search_ID","value":"649061"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84860":{"preferredName":"Onvitrelin Ucalontide","code":"C84860","definitions":[{"definition":"A water-soluble, positively charged fusion protein consisting of a luteinizing hormone releasing hormone (LHRH) receptor-targeting ligand conjugated to the membrane-disrupting peptide CLIP 71 with membrane-disrupting and potential antineoplastic activities. The LHRH ligand moiety of onvitrelin ucalontide specifically binds to LHRH receptors, which are upregulated on a variety of human cancer cell types. Subsequently, the positively charged CLIP 71 moiety of this agent interacts with the negatively charged membrane on the cancer cell surface, which may result in cell membrane disruption and cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onvitrelin Ucalontide","termGroup":"PT","termSource":"NCI"},{"termName":"EP-100","termGroup":"CN","termSource":"NCI"},{"termName":"Membrane-Disrupting Peptide EP-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620643-19-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UF1EL37E41"},{"name":"Maps_To","value":"Membrane-Disrupting Peptide EP-100"},{"name":"NCI_Drug_Dictionary_ID","value":"652192"},{"name":"NCI_META_CUI","value":"CL412421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"652192"},{"name":"PDQ_Open_Trial_Search_ID","value":"652192"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52194":{"preferredName":"Menatetrenone","code":"C52194","definitions":[{"definition":"A menaquinone compound and form of vitamin K2 with potential antineoplastic activity. Menatetrenone may act by modulating the signalling of certain tyrosine kinases, thereby affecting several transcription factors including c-myc and c-fos. This agent inhibits tumor cell growth by inducing apoptosis and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Menatetrenone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-3-trans-tetraprenyl-1,4-naphthoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"E0167","termGroup":"CN","termSource":"NCI"},{"termName":"Menaquinone K4","termGroup":"SY","termSource":"NCI"},{"termName":"Menaquinone-4","termGroup":"SN","termSource":"NCI"},{"termName":"Vitamin MK 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"863-61-6"},{"name":"Chemical_Formula","value":"C31H40O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27Y876D139"},{"name":"Legacy Concept Name","value":"Menatetrenone"},{"name":"Maps_To","value":"Menatetrenone"},{"name":"NCI_Drug_Dictionary_ID","value":"459755"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459755"},{"name":"PDQ_Open_Trial_Search_ID","value":"459755"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065936"}]}}{"C1389":{"preferredName":"Menogaril","code":"C1389","definitions":[{"definition":"A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Menogaril","termGroup":"PT","termSource":"NCI"},{"termName":"7-(R)-O-methylnogarol","termGroup":"SN","termSource":"NCI"},{"termName":"7-con-O-methylnogarol","termGroup":"SN","termSource":"NCI"},{"termName":"7-con-O-methylnorgarol","termGroup":"SN","termSource":"NCI"},{"termName":"7-OMEN","termGroup":"AB","termSource":"NCI"},{"termName":"[2R-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha)]-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione","termGroup":"SN","termSource":"NCI"},{"termName":"MEN","termGroup":"AB","termSource":"NCI"},{"termName":"Menogarol","termGroup":"BR","termSource":"NCI"},{"termName":"TUT-7","termGroup":"AB","termSource":"NCI"},{"termName":"U-52047","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71628-96-1"},{"name":"Chemical_Formula","value":"C28H31NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8JSV4O30HQ"},{"name":"Legacy Concept Name","value":"Menogaril"},{"name":"Maps_To","value":"Menogaril"},{"name":"NCI_Drug_Dictionary_ID","value":"40153"},{"name":"NSC Number","value":"269148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40153"},{"name":"PDQ_Open_Trial_Search_ID","value":"40153"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127527"}]}}{"C1390":{"preferredName":"Merbarone","code":"C1390","definitions":[{"definition":"A nonsedating derivative of thiobarbituric acid and a novel catalytic topoisomerase II inhibitor with antineoplastic activity. Merbarone interferes with DNA replication via binding directly to topoisomerase II at a domain that maybe shared by other topoisomerase II cleavage-enhancing agents, ex., etoposide. Its mechanism of action appears to be a novel one, since merbarone does not intercalate DNA nor stabilize DNA-topoisomerase II cleavable complexes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Merbarone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97534-21-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YWB9IF596V"},{"name":"Legacy Concept Name","value":"Merbarone"},{"name":"Maps_To","value":"Merbarone"},{"name":"NCI_Drug_Dictionary_ID","value":"40220"},{"name":"NSC Number","value":"336628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40220"},{"name":"PDQ_Open_Trial_Search_ID","value":"40220"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127565"}]}}{"C195":{"preferredName":"Mercaptopurine","code":"C195","definitions":[{"definition":"A drug used to treat acute lymphatic leukemia. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mercaptopurine","termGroup":"PT","termSource":"NCI"},{"termName":"1,7-Dihydro-6H-purine-6-thione","termGroup":"SN","termSource":"NCI"},{"termName":"1,7-Dihydro-6H-purine-6-thione Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"3H-Purine-6-thiol","termGroup":"SN","termSource":"NCI"},{"termName":"6 Thiohypoxanthine","termGroup":"SY","termSource":"NCI"},{"termName":"6 Thiopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6-Mercaptopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6-Mercaptopurine Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"6-MP","termGroup":"AB","termSource":"NCI"},{"termName":"6-Purinethiol","termGroup":"SY","termSource":"NCI"},{"termName":"6-Thiopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6-Thioxopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6H-Purine-6-thione, 1,7-dihydro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"7-Mercapto-1,3,4,6-tetrazaindene","termGroup":"SN","termSource":"NCI"},{"termName":"Alti-Mercaptopurine","termGroup":"FB","termSource":"NCI"},{"termName":"Azathiopurine","termGroup":"SY","termSource":"NCI"},{"termName":"BW 57-323H","termGroup":"CN","termSource":"NCI"},{"termName":"Flocofil","termGroup":"FB","termSource":"NCI"},{"termName":"Ismipur","termGroup":"FB","termSource":"NCI"},{"termName":"Leukerin","termGroup":"FB","termSource":"NCI"},{"termName":"Leupurin","termGroup":"SY","termSource":"NCI"},{"termName":"Mercaleukim","termGroup":"FB","termSource":"NCI"},{"termName":"Mercaleukin","termGroup":"SY","termSource":"NCI"},{"termName":"Mercaptina","termGroup":"FB","termSource":"NCI"},{"termName":"Mercapto-6-purine","termGroup":"SN","termSource":"NCI"},{"termName":"Mercaptopurinum","termGroup":"BR","termSource":"NCI"},{"termName":"Mercapurin","termGroup":"SY","termSource":"NCI"},{"termName":"Mern","termGroup":"SY","termSource":"NCI"},{"termName":"Puri-Nethol","termGroup":"FB","termSource":"NCI"},{"termName":"Purimethol","termGroup":"SY","termSource":"NCI"},{"termName":"Purine-6-thiol (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Purine-6-thiol Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Purine-6-thiol, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Purinethiol","termGroup":"FB","termSource":"NCI"},{"termName":"Purinethol","termGroup":"BR","termSource":"NCI"},{"termName":"U-4748","termGroup":"CN","termSource":"NCI"},{"termName":"WR-2785","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute myelogenous leukemia; Crohns disease; Hodgkins lymphoma in children; Lymphoblastic lymphoma; Ulcerative colitis"},{"name":"CAS_Registry","value":"6112-76-1"},{"name":"CHEBI_ID","value":"CHEBI:31822"},{"name":"Chemical_Formula","value":"C5H4N4S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"E7WED276I5"},{"name":"Legacy Concept Name","value":"Mercaptopurine"},{"name":"Maps_To","value":"Mercaptopurine"},{"name":"NCI_Drug_Dictionary_ID","value":"43436"},{"name":"NSC Number","value":"755"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43436"},{"name":"PDQ_Open_Trial_Search_ID","value":"43436"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0000618"}]}}{"C61832":{"preferredName":"Mercaptopurine Anhydrous","code":"C61832","definitions":[{"definition":"The anhydrous form of mercaptopurine, a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mercaptopurine Anhydrous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-44-2"},{"name":"CHEBI_ID","value":"CHEBI:2208"},{"name":"CHEBI_ID","value":"CHEBI:50667"},{"name":"Chemical_Formula","value":"C5H4N4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PKK6MUZ20G"},{"name":"Legacy Concept Name","value":"Mercaptopurine_Anhydrous"},{"name":"Maps_To","value":"Mercaptopurine Anhydrous"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881785"}]}}{"C111757":{"preferredName":"Mercaptopurine Oral Suspension","code":"C111757","definitions":[{"definition":"An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mercaptopurine Oral Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"6-MP Oral Suspension","termGroup":"SY","termSource":"NCI"},{"termName":"Purixan","termGroup":"BR","termSource":"NCI"},{"termName":"Xaluprine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute lymphoblastic leukemia (ALL)"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mercaptopurine Oral Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"752956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752956"},{"name":"PDQ_Open_Trial_Search_ID","value":"752956"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3820263"}]}}{"C95729":{"preferredName":"Merestinib","code":"C95729","definitions":[{"definition":"An orally available, small molecule inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Merestinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinecarboxamide, N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"LY-2801653","termGroup":"CN","termSource":"NCI"},{"termName":"LY2801653","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1206799-15-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5OGS5K699E"},{"name":"Maps_To","value":"Merestinib"},{"name":"NCI_Drug_Dictionary_ID","value":"694732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694732"},{"name":"PDQ_Open_Trial_Search_ID","value":"694732"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987379"}]}}{"C192":{"preferredName":"Mesna","code":"C192","definitions":[{"definition":"A drug that helps protect the kidneys and bladder from the toxic effects of anticancer drugs such as ifosfamide and cyclophosphamide.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesna","termGroup":"PT","termSource":"NCI"},{"termName":"2-Mercaptoethanesulfonic Acid Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Ausobronc","termGroup":"FB","termSource":"NCI"},{"termName":"D-7093","termGroup":"CN","termSource":"NCI"},{"termName":"Filesna","termGroup":"FB","termSource":"NCI"},{"termName":"Mercaptoethane Sulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Mercaptoethanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Mesnex","termGroup":"BR","termSource":"NCI"},{"termName":"Mesnil","termGroup":"FB","termSource":"NCI"},{"termName":"Mesnum","termGroup":"SY","termSource":"NCI"},{"termName":"Mexan","termGroup":"FB","termSource":"NCI"},{"termName":"Mistabron","termGroup":"FB","termSource":"NCI"},{"termName":"Mistabronco","termGroup":"FB","termSource":"NCI"},{"termName":"Mitexan","termGroup":"FB","termSource":"NCI"},{"termName":"Mucofluid","termGroup":"FB","termSource":"NCI"},{"termName":"Mucolene","termGroup":"FB","termSource":"NCI"},{"termName":"Sodium 2-Mercaptoethane Sulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Sodium 2-Mercaptoethanesulphonate","termGroup":"SN","termSource":"NCI"},{"termName":"UCB 3983","termGroup":"CN","termSource":"NCI"},{"termName":"Uromitexan","termGroup":"FB","termSource":"NCI"},{"termName":"Ziken","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Ifosfamide-induced hemorrhagic cystitis, prophylaxis"},{"name":"CAS_Registry","value":"19767-45-4"},{"name":"Chemical_Formula","value":"C2H5O3S2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NR7O1405Q9"},{"name":"Legacy Concept Name","value":"Mesna"},{"name":"Maps_To","value":"Mesna"},{"name":"NCI_Drug_Dictionary_ID","value":"39759"},{"name":"NSC Number","value":"113891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39759"},{"name":"PDQ_Open_Trial_Search_ID","value":"39759"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0000294"}]}}{"C162935":{"preferredName":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536","code":"C162935","definitions":[{"definition":"recombinant antibody derivative composed of a tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) mesothelin (MSLN) and the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes which are both linked to either side of an anti-albumin single domain antibody, with potential immunostimulating and antineoplastic activities. Upon administration of the MSLN/CD3e TriTAC HPN536, the anti-MSLN single antibody domain targets and binds MSLN on tumor cells and the anti-CD3e single-chain variable fragment (scFv) targets and binds to CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing MSLN-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of MSLN-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN536. MSLN is overexpressed on the surface of certain tumor cell types. Overexpression of MSLN is often associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536","termGroup":"PT","termSource":"NCI"},{"termName":"HPN 536","termGroup":"CN","termSource":"NCI"},{"termName":"HPN-536","termGroup":"CN","termSource":"NCI"},{"termName":"HPN536","termGroup":"CN","termSource":"NCI"},{"termName":"Mesothelin-targeting T-cell Engager HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"Mesothelin/CD3e-specific TriTAC HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"MSLN-specific TriTAC HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"MSLN/CD3e TriTAC HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"TriTAC HPN536","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536"},{"name":"NCI_Drug_Dictionary_ID","value":"799094"},{"name":"NCI_META_CUI","value":"CL973294"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799094"},{"name":"PDQ_Open_Trial_Search_ID","value":"799094"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148537":{"preferredName":"MET Kinase Inhibitor OMO-1","code":"C148537","definitions":[{"definition":"An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Kinase Inhibitor OMO-1","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-38877618","termGroup":"CN","termSource":"NCI"},{"termName":"OMO-1","termGroup":"CN","termSource":"NCI"},{"termName":"OMO1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_BMS-777607"},{"name":"Maps_To","value":"MET Kinase Inhibitor OMO-1"},{"name":"NCI_Drug_Dictionary_ID","value":"792712"},{"name":"NCI_META_CUI","value":"CL551128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792712"},{"name":"PDQ_Open_Trial_Search_ID","value":"792712"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74060":{"preferredName":"MET Tyrosine Kinase Inhibitor BMS-777607","code":"C74060","definitions":[{"definition":"An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor BMS-777607","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-777607","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1025720-94-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A3MMS6HDO1"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_BMS-777607"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor BMS-777607"},{"name":"NCI_Drug_Dictionary_ID","value":"587999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587999"},{"name":"PDQ_Open_Trial_Search_ID","value":"587999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346911"}]}}{"C91097":{"preferredName":"MET Tyrosine Kinase Inhibitor EMD 1204831","code":"C91097","definitions":[{"definition":"An inhibitor of the receptor tyrosine kinase Met (hepatocyte growth factor receptor) with potential antineoplastic activity. MET inhibitor EMD 1204831 selectively binds to Met tyrosine kinase, thereby disrupting MET mediated signal transduction pathways. This may induce cell death in tumor cells overexpressing this kinase. MET is overexpressed or mutated in many tumor cell types, and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor EMD 1204831","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 1204831","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor EMD 1204831"},{"name":"NCI_Drug_Dictionary_ID","value":"672542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672542"},{"name":"PDQ_Open_Trial_Search_ID","value":"672542"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984036"}]}}{"C78483":{"preferredName":"MET Tyrosine Kinase Inhibitor PF-04217903","code":"C78483","definitions":[{"definition":"An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. The receptor tyrosine kinase c-Met, also known as hepatocyte growth factor (HGF) receptor, is overexpressed or mutated in many tumor cell types, playing an important role in tumor cell proliferation, survival, invasion, and metastasis and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor PF-04217903","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol","termGroup":"SN","termSource":"NCI"},{"termName":"PF-04217903","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"956905-27-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CYJ9ATV1IJ"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_PF-04217903"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor PF-04217903"},{"name":"NCI_Drug_Dictionary_ID","value":"601032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601032"},{"name":"PDQ_Open_Trial_Search_ID","value":"601032"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703125"}]}}{"C97511":{"preferredName":"MET Tyrosine Kinase Inhibitor SAR125844","code":"C97511","definitions":[{"definition":"An inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Upon intravenous administration, c-Met inhibitor SAR125844 binds to c-Met, thereby disrupting c-Met-mediated signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of cancers, plays an important role in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor SAR125844","termGroup":"PT","termSource":"NCI"},{"termName":"SAR125844","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1116743-46-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XH93U6NIJE"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor SAR125844"},{"name":"NCI_Drug_Dictionary_ID","value":"703771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703771"},{"name":"PDQ_Open_Trial_Search_ID","value":"703771"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273459"}]}}{"C74062":{"preferredName":"MET Tyrosine Kinase Inhibitor SGX523","code":"C74062","definitions":[{"definition":"An orally bioavailable small molecule, c-Met inhibitor with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor SGX523","termGroup":"PT","termSource":"NCI"},{"termName":"SGX523","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1022150-57-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WH8SQN09KJ"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_SGX523"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor SGX523"},{"name":"NCI_Drug_Dictionary_ID","value":"588972"},{"name":"PDQ_Closed_Trial_Search_ID","value":"588972"},{"name":"PDQ_Open_Trial_Search_ID","value":"588972"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346913"}]}}{"C83946":{"preferredName":"Metamelfalan","code":"C83946","definitions":[{"definition":"The meta form of the levo isomer melphalan, an alkylating nitrogen mustard with potential antineoplastic activity. Metamelfalan causes crosslinking of DNA, thereby preventing DNA replication and eventually cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metamelfalan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1088-80-8"},{"name":"Chemical_Formula","value":"C13H18Cl2N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3B30XBE7S2"},{"name":"Maps_To","value":"Metamelfalan"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127767"}]}}{"C162480":{"preferredName":"MetAP2 Inhibitor APL-1202","code":"C162480","definitions":[{"definition":"An orally available inhibitor of methionine aminopeptidase II type (MetAP2) with potential antiangiogenic and antineoplastic activities. Upon administration, APL-1202 binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MetAP2 Inhibitor APL-1202","termGroup":"PT","termSource":"NCI"},{"termName":"APL 1202","termGroup":"CN","termSource":"NCI"},{"termName":"APL-1202","termGroup":"CN","termSource":"NCI"},{"termName":"APL1202","termGroup":"CN","termSource":"NCI"},{"termName":"Methionine Aminopeptidase Type II Inhibitor APL-1202","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MetAP2 Inhibitor APL-1202"},{"name":"NCI_Drug_Dictionary_ID","value":"798664"},{"name":"NCI_META_CUI","value":"CL970968"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798664"},{"name":"PDQ_Open_Trial_Search_ID","value":"798664"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128030":{"preferredName":"Evexomostat","code":"C128030","definitions":[{"definition":"A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent's efficacy as compared to non-polymer conjugates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evexomostat","termGroup":"PT","termSource":"NCI"},{"termName":"MetAP2 Inhibitor SDX-7320","termGroup":"SY","termSource":"NCI"},{"termName":"Methionine aminopeptidase type II Inhibitor SDX-7320","termGroup":"SY","termSource":"NCI"},{"termName":"SDX-7320","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416263-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z7116W3IFA"},{"name":"Maps_To","value":"MetAP2 Inhibitor SDX-7320"},{"name":"NCI_Drug_Dictionary_ID","value":"781275"},{"name":"NCI_META_CUI","value":"CL507924"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781275"},{"name":"PDQ_Open_Trial_Search_ID","value":"781275"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113294":{"preferredName":"Metatinib Tromethamine","code":"C113294","definitions":[{"definition":"An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL tyrosine kinase inhibitor BL001 may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metatinib Tromethamine","termGroup":"PT","termSource":"NCI"},{"termName":"BCR-ABL Tyrosine Kinase Inhibitor BL001","termGroup":"SY","termSource":"NCI"},{"termName":"BL001","termGroup":"CN","termSource":"NCI"},{"termName":"Metatinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metatinib Tromethamine"},{"name":"NCI_Drug_Dictionary_ID","value":"755994"},{"name":"NCI_META_CUI","value":"CL458141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755994"},{"name":"PDQ_Open_Trial_Search_ID","value":"755994"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61612":{"preferredName":"Metformin","code":"C61612","definitions":[{"definition":"A specific agent belonging to the biguanide class of antihyperglycemic agents","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Metformin is a type of antidiabetic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Metformin","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dimethylbiguanide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-dimethylbiguanide","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-Dimethylimidodicarbonimidic Diamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"657-24-9"},{"name":"CHEBI_ID","value":"CHEBI:6801"},{"name":"Chemical_Formula","value":"C4H11N5"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9100L32L2N"},{"name":"Legacy Concept Name","value":"Metformin"},{"name":"Maps_To","value":"Metformin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025598"}]}}{"C29251":{"preferredName":"Metformin Hydrochloride","code":"C29251","definitions":[{"definition":"A drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Glucophage is a type of antidiabetic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metformin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dimethylbiguanide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"APO-Metformin","termGroup":"SY","termSource":"NCI"},{"termName":"Cidophage","termGroup":"SY","termSource":"NCI"},{"termName":"Dimefor","termGroup":"FB","termSource":"NCI"},{"termName":"Glifage","termGroup":"FB","termSource":"NCI"},{"termName":"Glucoformin","termGroup":"FB","termSource":"NCI"},{"termName":"Glucophage","termGroup":"BR","termSource":"NCI"},{"termName":"Glucophage ER","termGroup":"BR","termSource":"NCI"},{"termName":"Metformin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-Dimethylimidodicarbonimidic Diamide Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Riomet","termGroup":"BR","termSource":"NCI"},{"termName":"Siofor","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1115-70-4"},{"name":"Chemical_Formula","value":"C4H11N5.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"786Z46389E"},{"name":"Legacy Concept Name","value":"Metformin_Hydrochloride"},{"name":"Maps_To","value":"Metformin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"593641"},{"name":"NSC Number","value":"91485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593641"},{"name":"PDQ_Open_Trial_Search_ID","value":"593641"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770893"}]}}{"C1159":{"preferredName":"Methanol Extraction Residue of BCG","code":"C1159","definitions":[{"definition":"A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methanol Extraction Residue of BCG","termGroup":"PT","termSource":"NCI"},{"termName":"MER-BCG","termGroup":"AB","termSource":"NCI"},{"termName":"Methanol Extraction Residue of Bacillus Calmette-Guerin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methanol_Extraction_Residue_of_BCG"},{"name":"Maps_To","value":"Methanol Extraction Residue of BCG"},{"name":"NCI_Drug_Dictionary_ID","value":"39495"},{"name":"NSC Number","value":"143769"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39495"},{"name":"PDQ_Open_Trial_Search_ID","value":"39495"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065973"}]}}{"C61318":{"preferredName":"Methazolamide","code":"C61318","definitions":[{"definition":"A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance resistance to cytotoxic therapy in some hypoxic tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methazolamide","termGroup":"PT","termSource":"NCI"},{"termName":"Glauctabs","termGroup":"BR","termSource":"NCI"},{"termName":"MZM","termGroup":"BR","termSource":"NCI"},{"termName":"N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"Neptazane","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"554-57-4"},{"name":"Chemical_Formula","value":"C5H8N4O3S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W733B0S9SD"},{"name":"Legacy Concept Name","value":"Methazolamide"},{"name":"Maps_To","value":"Methazolamide"},{"name":"NCI_Drug_Dictionary_ID","value":"484587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"484587"},{"name":"PDQ_Open_Trial_Search_ID","value":"484587"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025631"}]}}{"C142831":{"preferredName":"Methionine Aminopeptidase 2 Inhibitor M8891","code":"C142831","definitions":[{"definition":"A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methionine Aminopeptidase 2 Inhibitor M8891","termGroup":"PT","termSource":"NCI"},{"termName":"M8891","termGroup":"CN","termSource":"NCI"},{"termName":"MetAP2 Inhibitor M8891","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methionine Aminopeptidase 2 Inhibitor M8891"},{"name":"NCI_Drug_Dictionary_ID","value":"791701"},{"name":"NCI_META_CUI","value":"CL540704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791701"},{"name":"PDQ_Open_Trial_Search_ID","value":"791701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38129":{"preferredName":"Methionine Aminopeptidase 2 Inhibitor PPI-2458","code":"C38129","definitions":[{"definition":"A synthetic derivative of fumagillin with antineoplastic and cytotoxic properties.  PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methionine Aminopeptidase 2 Inhibitor PPI-2458","termGroup":"PT","termSource":"NCI"},{"termName":"MetAP-2 Inhibitor PPI-2458","termGroup":"SY","termSource":"NCI"},{"termName":"PPI-2458","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"431077-35-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NA0Y2SRR29"},{"name":"Legacy Concept Name","value":"PPI-2458"},{"name":"Maps_To","value":"Methionine Aminopeptidase 2 Inhibitor PPI-2458"},{"name":"NCI_Drug_Dictionary_ID","value":"415572"},{"name":"NSC Number","value":"720735"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415572"},{"name":"PDQ_Open_Trial_Search_ID","value":"415572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1505437"}]}}{"C1735":{"preferredName":"Methotrexate Sodium","code":"C1735","definitions":[{"definition":"The sodium salt of methotrexate, an antimetabolite with antineoplastic and immunomodulating properties.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Sodium Methotrexate","termGroup":"SY","termSource":"NCI"},{"termName":"Trexall","termGroup":"BR","termSource":"NCI"},{"termName":"Xatmep","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7413-34-5"},{"name":"CHEBI_ID","value":"CHEBI:50679"},{"name":"Chemical_Formula","value":"C20H20N8O5.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3IG1E710ZN"},{"name":"Legacy Concept Name","value":"Sodium_Methotrexate"},{"name":"Maps_To","value":"Methotrexate Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"41719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41719"},{"name":"PDQ_Open_Trial_Search_ID","value":"41719"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0949359"}]}}{"C17876":{"preferredName":"Methotrexate-E Therapeutic Implant","code":"C17876","definitions":[{"definition":"An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate-E Therapeutic Implant","termGroup":"PT","termSource":"NCI"},{"termName":"Methotrexate-E Therapeutic Implant","termGroup":"SY","termSource":"NCI"},{"termName":"Methotrexate-epinephrine therapeutic implant","termGroup":"SY","termSource":"NCI"},{"termName":"Methotrexate/epi","termGroup":"SY","termSource":"NCI"},{"termName":"MTX-e TI","termGroup":"SY","termSource":"NCI"},{"termName":"MTX/epi gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methotrexate-E_Therapeutic_Implant"},{"name":"Maps_To","value":"Methotrexate-E Therapeutic Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"41858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41858"},{"name":"PDQ_Open_Trial_Search_ID","value":"41858"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281425"}]}}{"C125656":{"preferredName":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","code":"C125656","definitions":[{"definition":"A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","termGroup":"PT","termSource":"NCI"},{"termName":"MTX-ATMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"778520"},{"name":"NCI_META_CUI","value":"CL504342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778520"},{"name":"PDQ_Open_Trial_Search_ID","value":"778520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C643":{"preferredName":"Methoxsalen","code":"C643","definitions":[{"definition":"A drug used together with UV light to treat psoriasis, vitiligo, and skin nodules of cutaneous T-cell lymphoma. It is also being studied in the treatment of graft-versus-host disease. It belongs to the family of drugs called psoralens and furocoumarins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxsalen","termGroup":"PT","termSource":"NCI"},{"termName":"8-Methoxypsoralen","termGroup":"SY","termSource":"NCI"},{"termName":"8-MOP","termGroup":"AB","termSource":"NCI"},{"termName":"9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one","termGroup":"SN","termSource":"NCI"},{"termName":"Ammoidin","termGroup":"BR","termSource":"NCI"},{"termName":"Deltasoralen","termGroup":"FB","termSource":"NCI"},{"termName":"Dermox","termGroup":"FB","termSource":"NCI"},{"termName":"Geralen","termGroup":"FB","termSource":"NCI"},{"termName":"Geroxalen","termGroup":"FB","termSource":"NCI"},{"termName":"Meladinina","termGroup":"FB","termSource":"NCI"},{"termName":"Meladinine","termGroup":"FB","termSource":"NCI"},{"termName":"Methoxypsoralen","termGroup":"SY","termSource":"NCI"},{"termName":"Metoxaleno","termGroup":"FB","termSource":"NCI"},{"termName":"Mopsoralen","termGroup":"FB","termSource":"NCI"},{"termName":"Oxsoralen","termGroup":"BR","termSource":"NCI"},{"termName":"Oxsoralen-Ultra","termGroup":"BR","termSource":"NCI"},{"termName":"Puvasoralen","termGroup":"FB","termSource":"NCI"},{"termName":"Ultramop","termGroup":"FB","termSource":"NCI"},{"termName":"Uvadex","termGroup":"BR","termSource":"NCI"},{"termName":"Xanthotoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cutaneous T-cell lymphoma; psoriasis; vitiligo"},{"name":"CAS_Registry","value":"298-81-7"},{"name":"CHEBI_ID","value":"CHEBI:18358"},{"name":"Chemical_Formula","value":"C12H8O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U4VJ29L7BQ"},{"name":"Legacy Concept Name","value":"Methoxsalen"},{"name":"Maps_To","value":"Methoxsalen"},{"name":"NCI_Drug_Dictionary_ID","value":"39499"},{"name":"NSC Number","value":"45923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39499"},{"name":"PDQ_Open_Trial_Search_ID","value":"39499"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025684"}]}}{"C78084":{"preferredName":"Methoxyamine","code":"C78084","definitions":[{"definition":"An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxyamine","termGroup":"PT","termSource":"NCI"},{"termName":"TRC102 Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67-62-9"},{"name":"Chemical_Formula","value":"CH5NO"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9TZH4WY30J"},{"name":"Legacy Concept Name","value":"Methoxyamine"},{"name":"Maps_To","value":"Methoxyamine"},{"name":"NCI_Drug_Dictionary_ID","value":"599836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599836"},{"name":"PDQ_Open_Trial_Search_ID","value":"599836"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066156"}]}}{"C78085":{"preferredName":"Methoxyamine Hydrochloride","code":"C78085","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks the ability of a cell to repair damage to its DNA and may kill cancer cells. It may also help some anticancer drugs work better. It is a type of antineoplastic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of methoxyamine, an alkoxyamine with potential chemotherapeutic adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic DNA damage sites and thereby inhibits base excision repair (BER) process, which may prevent repair of DNA strand breaks and result in an induction of apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxyamine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"TRC 102","termGroup":"CN","termSource":"NCI"},{"termName":"TRC-102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"593-56-6"},{"name":"Chemical_Formula","value":"CH5NO.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"203546OLMF"},{"name":"Legacy Concept Name","value":"Methoxyamine_Hydrochloride"},{"name":"Maps_To","value":"Methoxyamine Hydrochloride"},{"name":"NSC Number","value":"3801"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0951345"}]}}{"C2647":{"preferredName":"Methyl-5-Aminolevulinate Hydrochloride Cream","code":"C2647","definitions":[{"definition":"A drug used in photodynamic therapy; it is absorbed by tumor cells and, when exposed to light, becomes active and kills the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A topical cream formulation containing the hydrochloride salt of methyl-5-aminolevulinate, a lipophilic methyl ester of 5-aminolevulinic acid, with photosensitizer prodrug activity. Upon topical administration, methyl-5-aminolevulinate in the cream is selectively absorbed by tumor cells where it is converted to the photosensitizer protoporphyrin IX (PpIX). Upon photoirradiation, PpIX is activated and transfers energy to oxygen, generating singlet oxygen and superoxide and hydroxyl radicals, which may result in free-radical-mediated DNA damage and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methyl-5-Aminolevulinate Hydrochloride Cream","termGroup":"PT","termSource":"NCI"},{"termName":"Methyl Aminolevulinate Hydrochloride Cream","termGroup":"SY","termSource":"NCI"},{"termName":"Metvix","termGroup":"FB","termSource":"NCI"},{"termName":"Metvixia","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methyl-5-Aminolevulinate"},{"name":"Maps_To","value":"Methyl-5-Aminolevulinate Hydrochloride Cream"},{"name":"NCI_Drug_Dictionary_ID","value":"38410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38410"},{"name":"PDQ_Open_Trial_Search_ID","value":"38410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713112"}]}}{"C2352":{"preferredName":"Methylmercaptopurine Riboside","code":"C2352","definitions":[{"definition":"A purine derivative with antineoplastic and anti-angiogenic properties.  6-methylmercaptopurine riboside (6-MMPR) inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylmercaptopurine Riboside","termGroup":"PT","termSource":"NCI"},{"termName":"6-(methylmercapto)purine ribonucleoside","termGroup":"SN","termSource":"NCI"},{"termName":"6-(methylthio) inosine","termGroup":"SN","termSource":"NCI"},{"termName":"6-(methylthio)purine ribonucleoside","termGroup":"SN","termSource":"NCI"},{"termName":"6-(methylthio)purine riboside","termGroup":"SN","termSource":"NCI"},{"termName":"6-methyl MP riboside","termGroup":"SN","termSource":"NCI"},{"termName":"6-methylmercaptopurine riboside","termGroup":"SN","termSource":"NCI"},{"termName":"6-methylthioinosine","termGroup":"SN","termSource":"NCI"},{"termName":"6-MMPR","termGroup":"AB","termSource":"NCI"},{"termName":"9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl- (8CI 9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl-, dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"9H-purine, 6-(methylthio)-9beta-D-ribofuranosyl","termGroup":"SN","termSource":"NCI"},{"termName":"beta-D-ribosyl-6-methylthiopurine","termGroup":"SN","termSource":"NCI"},{"termName":"methylthioinosine","termGroup":"SY","termSource":"NCI"},{"termName":"MMPR","termGroup":"AB","termSource":"NCI"},{"termName":"NCI-C04784","termGroup":"CN","termSource":"NCI"},{"termName":"purine-6-thiol,6-methyl-9-ribofuranosyl","termGroup":"SN","termSource":"NCI"},{"termName":"SQ 21977","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"342-69-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y5G39SHR0V"},{"name":"Legacy Concept Name","value":"Methylmercaptopurine_Riboside"},{"name":"Maps_To","value":"Methylmercaptopurine Riboside"},{"name":"NCI_Drug_Dictionary_ID","value":"39497"},{"name":"NSC Number","value":"40774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39497"},{"name":"PDQ_Open_Trial_Search_ID","value":"39497"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025828"}]}}{"C647":{"preferredName":"Methylprednisolone","code":"C647","definitions":[{"definition":"A corticosteroid hormone replacement.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylprednisolone","termGroup":"PT","termSource":"NCI"},{"termName":"(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"6Alpha-Methylprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"Adlone","termGroup":"FB","termSource":"NCI"},{"termName":"Caberdelta M","termGroup":"FB","termSource":"NCI"},{"termName":"DepMedalone","termGroup":"FB","termSource":"NCI"},{"termName":"Depo Moderin","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Nisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Duralone","termGroup":"FB","termSource":"NCI"},{"termName":"Emmetipi","termGroup":"FB","termSource":"NCI"},{"termName":"Esametone","termGroup":"FB","termSource":"NCI"},{"termName":"Firmacort","termGroup":"FB","termSource":"NCI"},{"termName":"Medlone 21","termGroup":"BR","termSource":"NCI"},{"termName":"Medrol","termGroup":"BR","termSource":"NCI"},{"termName":"Medrol Veriderm","termGroup":"FB","termSource":"NCI"},{"termName":"Medrone","termGroup":"FB","termSource":"NCI"},{"termName":"Mega-Star","termGroup":"FB","termSource":"NCI"},{"termName":"Meprolone","termGroup":"BR","termSource":"NCI"},{"termName":"Methylprednisolonum","termGroup":"SY","termSource":"NCI"},{"termName":"Metilbetasone Solubile","termGroup":"FB","termSource":"NCI"},{"termName":"Metrocort","termGroup":"BR","termSource":"NCI"},{"termName":"Metypresol","termGroup":"FB","termSource":"NCI"},{"termName":"Metysolon","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-M-Tablinen","termGroup":"FB","termSource":"NCI"},{"termName":"Prednilen","termGroup":"FB","termSource":"NCI"},{"termName":"Radilem","termGroup":"FB","termSource":"NCI"},{"termName":"Sieropresol","termGroup":"FB","termSource":"NCI"},{"termName":"Solpredone","termGroup":"FB","termSource":"NCI"},{"termName":"Summicort","termGroup":"BR","termSource":"NCI"},{"termName":"Urbason","termGroup":"FB","termSource":"NCI"},{"termName":"Veriderm Medrol","termGroup":"FB","termSource":"NCI"},{"termName":"Wyacort","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adrenocortical insufficiency; Conditions requiring immunosuppression; Inflammatory conditions; Multiple Sclerosis; Nephrotic syndrome"},{"name":"CAS_Registry","value":"83-43-2"},{"name":"CHEBI_ID","value":"CHEBI:6888"},{"name":"Chemical_Formula","value":"C22H30O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"X4W7ZR7023"},{"name":"Legacy Concept Name","value":"Methylprednisolone"},{"name":"Maps_To","value":"Methylprednisolone"},{"name":"NCI_Drug_Dictionary_ID","value":"41528"},{"name":"NSC Number","value":"19987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41528"},{"name":"PDQ_Open_Trial_Search_ID","value":"41528"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025815"}]}}{"C48003":{"preferredName":"Methylprednisolone Acetate","code":"C48003","definitions":[{"definition":"The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylprednisolone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"D-Med","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Medrate","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Medrol","termGroup":"BR","termSource":"NCI"},{"termName":"Depo-Medrone","termGroup":"FB","termSource":"NCI"},{"termName":"ReadySharp MethylPrednisolone 80","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53-36-1"},{"name":"CHEBI_ID","value":"CHEBI:6889"},{"name":"Chemical_Formula","value":"C24H32O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43502P7F0P"},{"name":"Legacy Concept Name","value":"Methylprednisolone_Acetate"},{"name":"Maps_To","value":"Methylprednisolone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"41528"},{"name":"NSC Number","value":"48985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41528"},{"name":"PDQ_Open_Trial_Search_ID","value":"41528"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0600901"}]}}{"C48004":{"preferredName":"Methylprednisolone Sodium Succinate","code":"C48004","definitions":[{"definition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylprednisolone Sodium Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"A-MethaPred","termGroup":"FB","termSource":"NCI"},{"termName":"Asmacortone","termGroup":"FB","termSource":"NCI"},{"termName":"Cryosolona","termGroup":"FB","termSource":"NCI"},{"termName":"Medrate","termGroup":"FB","termSource":"NCI"},{"termName":"Metypred","termGroup":"BR","termSource":"NCI"},{"termName":"Prednilem","termGroup":"FB","termSource":"NCI"},{"termName":"Solu Moderin","termGroup":"FB","termSource":"NCI"},{"termName":"Solu-Medrol","termGroup":"BR","termSource":"NCI"},{"termName":"Solu-Medrone","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2375-03-3"},{"name":"Chemical_Formula","value":"C26H33O8.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LEC9GKY20K"},{"name":"Legacy Concept Name","value":"Methylprednisolone_Sodium_Succinate"},{"name":"Maps_To","value":"Methylprednisolone Sodium Succinate"},{"name":"NSC Number","value":"48989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700546"}]}}{"C63678":{"preferredName":"Methylselenocysteine","code":"C63678","definitions":[{"definition":"A naturally occurring organoselenium compound found in many plants, including garlic, onions, and broccoli, with potential antioxidant and chemopreventive activities. Se-Methyl-seleno-L-cysteine (MSC) is an amino acid analogue of cysteine in which a methylselenium moiety replaces the sulphur atom of cysteine. This agent acts as an antioxidant when incorporated into glutathione peroxidase and has been shown to exhibit potent chemopreventive activity in animal models.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that contains the element selenium (a nutrient that protects cells against damage) and is found in certain plants such as garlic and broccoli. Se-methyl-seleno-L-cysteine can act as an antioxidant and may help prevent or slow the growth of cancer cells. It is a type of amino acid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Methylselenocysteine","termGroup":"PT","termSource":"NCI"},{"termName":"3-(Methylseleno)-l-alanine","termGroup":"SN","termSource":"NCI"},{"termName":"L-Se-Methylselenocysteine","termGroup":"SY","termSource":"NCI"},{"termName":"Methylselenocycteine","termGroup":"SY","termSource":"NCI"},{"termName":"MSC","termGroup":"AB","termSource":"NCI"},{"termName":"Se-Methyl-seleno-L-cysteine","termGroup":"SY","termSource":"NCI"},{"termName":"Se-Methylselenocysteine","termGroup":"SN","termSource":"NCI"},{"termName":"Selenium-methylselenocystine","termGroup":"SY","termSource":"NCI"},{"termName":"SeMSC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26046-90-2"},{"name":"CHEBI_ID","value":"CHEBI:27812"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TWK220499Z"},{"name":"Legacy Concept Name","value":"Methylselenocysteine"},{"name":"Maps_To","value":"Methylselenocysteine"},{"name":"NCI_Drug_Dictionary_ID","value":"554706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"554706"},{"name":"PDQ_Open_Trial_Search_ID","value":"554706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074299"}]}}{"C648":{"preferredName":"Methyltestosterone","code":"C648","definitions":[{"definition":"A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methyltestosterone","termGroup":"PT","termSource":"NCI"},{"termName":"(17Beta)-17-hydroxy-17-methylandrost-4-en-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"17 Alpha-methyl-delta4-androsten-17beta-ol-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"17-Methyltestosterone","termGroup":"SY","termSource":"NCI"},{"termName":"Android","termGroup":"BR","termSource":"NCI"},{"termName":"Eldec","termGroup":"FB","termSource":"NCI"},{"termName":"Ero Test","termGroup":"FB","termSource":"NCI"},{"termName":"Estratest","termGroup":"BR","termSource":"NCI"},{"termName":"Glosso-Sterandryl","termGroup":"BR","termSource":"NCI"},{"termName":"Malogen","termGroup":"SY","termSource":"NCI"},{"termName":"Metandren","termGroup":"BR","termSource":"NCI"},{"termName":"Methitest","termGroup":"BR","termSource":"NCI"},{"termName":"Methyltestosteronum","termGroup":"SY","termSource":"NCI"},{"termName":"Neohombreol M","termGroup":"BR","termSource":"NCI"},{"termName":"Orchisterone-M","termGroup":"BR","termSource":"NCI"},{"termName":"Oreton Methyl","termGroup":"BR","termSource":"NCI"},{"termName":"Testomet","termGroup":"FB","termSource":"NCI"},{"termName":"Testotonic B","termGroup":"FB","termSource":"NCI"},{"termName":"Testovis","termGroup":"FB","termSource":"NCI"},{"termName":"Testred","termGroup":"BR","termSource":"NCI"},{"termName":"Virilon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58-18-4"},{"name":"CHEBI_ID","value":"CHEBI:27436"},{"name":"Chemical_Formula","value":"C20H30O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9EFU16ZIF"},{"name":"Legacy Concept Name","value":"Methyltestosterone"},{"name":"Maps_To","value":"Methyltestosterone"},{"name":"NSC Number","value":"9701"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025826"}]}}{"C1161":{"preferredName":"Metoprine","code":"C1161","definitions":[{"definition":"A diaminopyrimidine folate antagonist with potential antineoplastic activity.  Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metoprine","termGroup":"PT","termSource":"NCI"},{"termName":"BW 197U","termGroup":"CN","termSource":"NCI"},{"termName":"DDMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7761-45-7"},{"name":"Chemical_Formula","value":"C11H10Cl2N4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2L9RKX796Q"},{"name":"Legacy Concept Name","value":"Metoprine"},{"name":"Maps_To","value":"Metoprine"},{"name":"NCI_Drug_Dictionary_ID","value":"39206"},{"name":"NSC Number","value":"19494"},{"name":"NSC Number","value":"7364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39206"},{"name":"PDQ_Open_Trial_Search_ID","value":"39206"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066142"}]}}{"C87686":{"preferredName":"Mibefradil","code":"C87686","synonyms":[{"termName":"Mibefradil","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,2S)-(2-((3-(2-Benzimidazolyl)Propyl)Methylamino)Ethyl)-6-Fluoro-1,2,3,4-Tetrahydro-1-Isopropyl-2-Naphthyl Methoxyacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1S-cis)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"116644-53-2"},{"name":"Chemical_Formula","value":"C29H38FN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27B90X776A"},{"name":"Maps_To","value":"Mibefradil"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286185"}]}}{"C87687":{"preferredName":"Mibefradil Dihydrochloride","code":"C87687","synonyms":[{"termName":"Mibefradil Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,2S)-(2-((3-(2-Benzimidazolyl)Propyl)Methylamino)Ethyl)-6-Fluoro-1,2,3,4-Tetrahydro-1-Isopropyl-2-Naphthyl Methoxyacetate, Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Acetic Acid, Methoxy-, 2-(2-((3-(1H-Benzimidazol-2-yl)Propyl)Methylamino)Ethyl)-6-Fluoro-1,2,3,4-Tetrahydro-1-(1-Methylethyl)-2-Naphthalenyl Ester, Dihydrochloride, (1S-cis)-","termGroup":"SN","termSource":"NCI"},{"termName":"RO 40-5967/001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"116666-63-8"},{"name":"Chemical_Formula","value":"C29H38FN3O3.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"842TUP3PQ8"},{"name":"Maps_To","value":"Mibefradil Dihydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286186"}]}}{"C139003":{"preferredName":"Micellar Nanoparticle-encapsulated Epirubicin","code":"C139003","definitions":[{"definition":"A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micellar Nanoparticle-encapsulated Epirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"Epirubicin-incorporating Micelle","termGroup":"SY","termSource":"NCI"},{"termName":"K-912","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoparticle Epirubicin","termGroup":"SY","termSource":"NCI"},{"termName":"NC-6300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RQU6X0IM9R"},{"name":"Maps_To","value":"Micellar Nanoparticle-encapsulated Epirubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"790960"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790960"},{"name":"PDQ_Open_Trial_Search_ID","value":"790960"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2974723"}]}}{"C156665":{"preferredName":"Micro Needle Array-Doxorubicin","code":"C156665","definitions":[{"definition":"A formulation composed of dissolvable small, adhesive-like patches composed of a biocompatible material which is coated with the anthracycline antibiotic doxorubicin, with potential antineoplastic and immunomodulating activities. Upon cutaneous administration of the microneedle-array-doxorubicin, the microneedles degrade once inserted into the skin and doxorubicin is released from the dissolvable microneedle array delivery device directly into the tumor microenvironment (TME). Doxorubicin is taken up by tumor cells and intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. In addition, doxorubicin induces innate, adaptive, and tumor-specific effector and memory immune responses, thereby further killing the tumor cells. Delivery of doxorubicin using the microneedle array delivery system allows direct and specific administration of doxorubicin to the TME which may improve drug concentration into tumor cells and may reduce systemic toxicity, compared to the administration of systemic doxorubicin alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micro Needle Array-Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"D-MNA","termGroup":"AB","termSource":"NCI"},{"termName":"Dissolvable Microneedles-containing Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin-coated Patches","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin-loaded Patches","termGroup":"SY","termSource":"NCI"},{"termName":"Micro-needle Array Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Microneedle Applicator-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Microneedle Array Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"MNA-D","termGroup":"AB","termSource":"NCI"},{"termName":"MNA-D Patches","termGroup":"SY","termSource":"NCI"},{"termName":"MNA-Doxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Micro Needle Array-Doxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"795832"},{"name":"NCI_META_CUI","value":"CL935685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795832"},{"name":"PDQ_Open_Trial_Search_ID","value":"795832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64631":{"preferredName":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300","code":"C64631","definitions":[{"definition":"A formulation of a plasmid DNA encoding an inactivated form of the carcinogen activator cytochrome P450 1B1 (CYP1B1) encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles with potential antineoplastic activity. CYP1B1, an extrahepatic monooxygenase of the cytochrome P450 family, is overexpressed in many cancers with only restricted expression in normal tissues. Vaccination with ZYC300 may stimulate the immune system to elicit a cytotoxic T lymphocyte (CTL) response against the tumor associated antigen CYP1B1, thereby causing lysis of tumor cells expressing CYP1B1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300","termGroup":"PT","termSource":"NCI"},{"termName":"ZYC300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ZYC300"},{"name":"Maps_To","value":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300"},{"name":"NCI_Drug_Dictionary_ID","value":"513166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513166"},{"name":"PDQ_Open_Trial_Search_ID","value":"513166"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831967"}]}}{"C143158":{"preferredName":"Microtubule Inhibitor SCB01A","code":"C143158","definitions":[{"definition":"An aroylindole derivative and tubulin polymerization inhibitor, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activities. Upon administration, tubulin polymerization inhibitor SCB01A binds at the colchicine binding site of tubulin and prevents its polymerization in tumor blood vessel endothelial cells and in tumor cells. This blocks the formation of the mitotic spindle and leads to both cell cycle arrest at the G2/M phase and tumor cell apoptosis. Also, this agent's effect on the tumor blood vessel endothelial cells leads to a disruption of the tumor vasculature and tumor blood flow, which deprives tumor cells of nutrients and induces tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microtubule Inhibitor SCB01A","termGroup":"PT","termSource":"NCI"},{"termName":"6-Methoxy-3-(3',4',5'-trimethoxybenzoyl) Indole","termGroup":"SN","termSource":"NCI"},{"termName":"BPR 0L075","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR104","termGroup":"CN","termSource":"NCI"},{"termName":"SB 01","termGroup":"CN","termSource":"NCI"},{"termName":"SCB 01A","termGroup":"CN","termSource":"NCI"},{"termName":"SCB-01A","termGroup":"CN","termSource":"NCI"},{"termName":"SCB01A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microtubule Inhibitor SCB01A"},{"name":"NCI_Drug_Dictionary_ID","value":"791849"},{"name":"NCI_META_CUI","value":"CL541607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791849"},{"name":"PDQ_Open_Trial_Search_ID","value":"791849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1872":{"preferredName":"Midostaurin","code":"C1872","definitions":[{"definition":"A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called protein kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Midostaurin","termGroup":"PT","termSource":"NCI"},{"termName":"CGP41251","termGroup":"CN","termSource":"NCI"},{"termName":"N-Benzoyl-Staurosporine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Benzoylstaurosporine","termGroup":"SY","termSource":"NCI"},{"termName":"PKC-412","termGroup":"CN","termSource":"NCI"},{"termName":"PKC412","termGroup":"CN","termSource":"NCI"},{"termName":"Rydapt","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+)"},{"name":"CAS_Registry","value":"120685-11-2"},{"name":"CHEBI_ID","value":"CHEBI:63452"},{"name":"Chemical_Formula","value":"C35H30N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"ID912S5VON"},{"name":"Legacy Concept Name","value":"Midostaurin"},{"name":"Maps_To","value":"Midostaurin"},{"name":"NCI_Drug_Dictionary_ID","value":"462346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462346"},{"name":"PDQ_Open_Trial_Search_ID","value":"462346"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0526371"}]}}{"C1394":{"preferredName":"Mifamurtide","code":"C1394","definitions":[{"definition":"A drug being studied in the treatment of young adults with bone cancer that has gotten worse or come back. L-MTP-PE activates certain types of white blood cells and helps the immune system kill cancer cells. It is a type of immunostimulant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its half-life and enhances tissue targeting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mifamurtide","termGroup":"PT","termSource":"NCI"},{"termName":"CGP 19835A Lipid","termGroup":"CN","termSource":"NCI"},{"termName":"Junovan","termGroup":"BR","termSource":"NCI"},{"termName":"L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-((7R)-4-hydroxy-4-oxido-10-oxo-7-((1-oxohexadecyl)oxy)-3,5,9-trioxa-4-phosphapentacos-1-yl)-, Monosodium Salt, Hydrate","termGroup":"SN","termSource":"NCI"},{"termName":"L-MTP-PE","termGroup":"AB","termSource":"NCI"},{"termName":"Mepact","termGroup":"FB","termSource":"NCI"},{"termName":"MTP-PE Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Muramyl Tripeptide Phosphatidylethanolamine Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"MuramylNAc-Ala-isoGln-Lys-tripeptide-PE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"838853-48-8"},{"name":"Chemical_Formula","value":"C59H108N6O19P.Na.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"1LM890Q4FY"},{"name":"Legacy Concept Name","value":"Muramyl_Tripeptide_Phosphatidylethanolamine"},{"name":"Maps_To","value":"Mifamurtide"},{"name":"NCI_Drug_Dictionary_ID","value":"41541"},{"name":"NSC Number","value":"628280"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41541"},{"name":"PDQ_Open_Trial_Search_ID","value":"41541"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0129341"}]}}{"C655":{"preferredName":"Mifepristone","code":"C655","definitions":[{"definition":"A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to end early pregnancies. It is also being studied in the treatment of some types of cancer and other conditions. Mifepristone blocks the action of progesterone, a hormone that helps some cancers grow. It is a type of antiprogesterone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mifepristone","termGroup":"PT","termSource":"NCI"},{"termName":"(aa Beta, 17 beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"11 Beta-[4-(N,N-dimethylamino)phenyl]-17alpha-(propyl-1-ynyl)-delta-4,9-estradiene-17 beta-ol-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"11-((4-dimethylamino) phenyl)-17-Hydroxy-17-(1-propynyl) Estra-4,9- dien-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"Korlym","termGroup":"BR","termSource":"NCI"},{"termName":"Mifegyne","termGroup":"FB","termSource":"NCI"},{"termName":"Mifeprex","termGroup":"BR","termSource":"NCI"},{"termName":"RU 486","termGroup":"CN","termSource":"NCI"},{"termName":"RU-38486","termGroup":"CN","termSource":"NCI"},{"termName":"RU-486","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84371-65-3"},{"name":"CHEBI_ID","value":"CHEBI:50692"},{"name":"Chemical_Formula","value":"C29H35NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"320T6RNW1F"},{"name":"Legacy Concept Name","value":"Mifepristone"},{"name":"Maps_To","value":"Mifepristone"},{"name":"NCI_Drug_Dictionary_ID","value":"40888"},{"name":"NSC Number","value":"652104"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40888"},{"name":"PDQ_Open_Trial_Search_ID","value":"40888"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026088"}]}}{"C107384":{"preferredName":"Milademetan Tosylate","code":"C107384","definitions":[{"definition":"The tosylate form of milademetan, an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milademetan Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"DS-3032 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"DS-3032b","termGroup":"CN","termSource":"NCI"},{"termName":"DS-3032b Tosylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1398569-75-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6M27443B0N"},{"name":"Maps_To","value":"Milademetan Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"750863"},{"name":"NCI_META_CUI","value":"CL449595"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750863"},{"name":"PDQ_Open_Trial_Search_ID","value":"750863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66983":{"preferredName":"Milatuzumab","code":"C66983","definitions":[{"definition":"A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Milatuzumab specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. hLL1 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Milatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"hLL1","termGroup":"AB","termSource":"NCI"},{"termName":"Humanized Anti-CD74 Monoclonal Antibody hLL1","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-115","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody hLL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"899796-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2OP4E0GC6V"},{"name":"Legacy Concept Name","value":"Milatuzumab"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_hLL1"},{"name":"Maps_To","value":"Milatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"534127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"534127"},{"name":"PDQ_Open_Trial_Search_ID","value":"534127"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2716103"}]}}{"C91086":{"preferredName":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110","code":"C91086","definitions":[{"definition":"A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. IMMU-110 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate consisting of milatuzumab, a humanized monoclonal antibody against CD74, conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The milatuzumab moiety of this ADC selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage. As a result, this agent may inhibit the proliferation of cancer cells that overexpress CD74. CD74, an integral membrane protein and tumor associated antigen (TAA), is overexpressed in certain cancer cells and promotes survival in rapidly proliferating tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110","termGroup":"PT","termSource":"NCI"},{"termName":"hLL1-DOX","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110"},{"name":"NCI_Drug_Dictionary_ID","value":"671813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671813"},{"name":"PDQ_Open_Trial_Search_ID","value":"671813"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1615035"}]}}{"C88312":{"preferredName":"Milciclib Maleate","code":"C88312","definitions":[{"definition":"The maleate salt form of milciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milciclib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrazolo(4,3-H)quinazoline-3-carboxamide, 4,5-dihydro-N,1,4,4-tetramethyl-8-((4-(4-methyl-1-piperazinyl)phenyl)amino)-, (2Z)-2-Butenedioate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"N,1,4,4-Tetramethyl-8-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"PHA-848125 AC","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1253645-38-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82W826FL6S"},{"name":"Maps_To","value":"Milciclib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"660138"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660138"},{"name":"PDQ_Open_Trial_Search_ID","value":"660138"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934615"}]}}{"C29261":{"preferredName":"Milk Thistle","code":"C29261","definitions":[{"definition":"A plant that has been used in some cultures to treat certain medical problems, including stomach, liver, and gallbladder disorders. The active extract of milk thistle seeds is called silymarin. It is being studied in the prevention of liver damage caused by some cancer treatments.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milk Thistle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65666-07-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U946SH95EE"},{"name":"Legacy Concept Name","value":"Milk_Thistle"},{"name":"Maps_To","value":"Milk Thistle"},{"name":"NCI_Drug_Dictionary_ID","value":"459958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459958"},{"name":"PDQ_Open_Trial_Search_ID","value":"459958"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0937640"}]}}{"C1170":{"preferredName":"Miltefosine","code":"C1170","definitions":[{"definition":"An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity.  Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miltefosine","termGroup":"PT","termSource":"NCI"},{"termName":"2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt","termGroup":"SY","termSource":"NCI"},{"termName":"D-18506","termGroup":"CN","termSource":"NCI"},{"termName":"Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Hexadecylphosphocholine","termGroup":"SY","termSource":"NCI"},{"termName":"Miltefosin","termGroup":"SY","termSource":"NCI"},{"termName":"Miltefosina","termGroup":"SY","termSource":"NCI"},{"termName":"Miltefosinum","termGroup":"SY","termSource":"NCI"},{"termName":"Miltex","termGroup":"FB","termSource":"NCI"},{"termName":"n-Hexadecylphosphorylcholine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Skin metastasis of breast cancer"},{"name":"CAS_Registry","value":"58066-85-6"},{"name":"Chemical_Formula","value":"C21H46NO4P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53EY29W7EC"},{"name":"Legacy Concept Name","value":"Miltefosine"},{"name":"Maps_To","value":"Miltefosine"},{"name":"NCI_Drug_Dictionary_ID","value":"41212"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41212"},{"name":"PDQ_Open_Trial_Search_ID","value":"41212"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068006"}]}}{"C2567":{"preferredName":"Minretumomab","code":"C2567","definitions":[{"definition":"A second-generation murine monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Minretumomab","termGroup":"PT","termSource":"NCI"},{"termName":"Antibody CC49, Monoclonal","termGroup":"SY","termSource":"NCI"},{"termName":"CC-49 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MAb CC49","termGroup":"AB","termSource":"NCI"},{"termName":"MOAB CC-49/TAG72 (DW)","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb CC49","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody CC-49","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195189-17-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"235435CH6L"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"Minretumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"41760"},{"name":"NSC Number","value":"620537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41760"},{"name":"PDQ_Open_Trial_Search_ID","value":"41760"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281345"}]}}{"C90554":{"preferredName":"Mipsagargin","code":"C90554","definitions":[{"definition":"A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, mipsagargin targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. Mipsagargin is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, G-202 may be able to inhibit tumor growth. Compared to thapsigargin alone, thapsigargin prodrug G-202 is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mipsagargin","termGroup":"PT","termSource":"NCI"},{"termName":"G-202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1245732-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q032I35QMX"},{"name":"Maps_To","value":"Mipsagargin"},{"name":"NCI_Drug_Dictionary_ID","value":"666090"},{"name":"NCI_META_CUI","value":"CL416238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666090"},{"name":"PDQ_Open_Trial_Search_ID","value":"666090"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90633":{"preferredName":"Mirabegron","code":"C90633","definitions":[{"definition":"An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirabegron","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-Aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] Acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Thiazoleacetamide, 2-Amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Betanis","termGroup":"FB","termSource":"NCI"},{"termName":"Myrbetriq","termGroup":"BR","termSource":"NCI"},{"termName":"YM-178","termGroup":"CN","termSource":"NCI"},{"termName":"YM178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Overactive bladder with symptoms of urge incontinence"},{"name":"CAS_Registry","value":"223673-61-8"},{"name":"Chemical_Formula","value":"C21H24N4O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MVR3JL3B2V"},{"name":"Maps_To","value":"Mirabegron"},{"name":"NCI_Drug_Dictionary_ID","value":"767328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767328"},{"name":"PDQ_Open_Trial_Search_ID","value":"767328"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983812"}]}}{"C102566":{"preferredName":"Mirvetuximab Soravtansine","code":"C102566","definitions":[{"definition":"An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirvetuximab Soravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Elahere","termGroup":"BR","termSource":"NCI"},{"termName":"IMGN853","termGroup":"CN","termSource":"NCI"},{"termName":"M9346A-sulfo-SPDB-DM4","termGroup":"SY","termSource":"NCI"},{"termName":"Mirvetuximab Soravtansine-gynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer."},{"name":"CAS_Registry","value":"1453084-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"98DE7VN88D"},{"name":"Maps_To","value":"Mirvetuximab Soravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"734941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734941"},{"name":"PDQ_Open_Trial_Search_ID","value":"734941"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640818"}]}}{"C657":{"preferredName":"Misonidazole","code":"C657","definitions":[{"definition":"A nitroimidazole with radiosensitizing and antineoplastic properties. Exhibiting high electron affinity, misonidazole induces the formation of free radicals and depletes radioprotective thiols, thereby sensitizing hypoxic cells to the cytotoxic effects of ionizing radiation. This single-strand breaks in DNA induced by this agent result in the inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Misonidazole","termGroup":"PT","termSource":"NCI"},{"termName":"1-(alpha-methoxymethyl ethanol)-2-Nitroimidazole","termGroup":"SN","termSource":"NCI"},{"termName":"Ro-07-0582","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-7-0582","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13551-87-6"},{"name":"Chemical_Formula","value":"C7H11N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8FE7LTN8XE"},{"name":"Legacy Concept Name","value":"Misonidazole"},{"name":"Maps_To","value":"Misonidazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39504"},{"name":"NSC Number","value":"261037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39504"},{"name":"PDQ_Open_Trial_Search_ID","value":"39504"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026218"}]}}{"C29195":{"preferredName":"Mitindomide","code":"C29195","definitions":[{"definition":"A bisdioxopiperazines analog with antineoplastic activity.  Mitinomide inhibits topoisomerase II and slowly promotes DNA-interstrand cross-linking, thereby inhibiting DNA repair, RNA and protein synthesis.  This agent acts without increasing topoisomerase II-DNA covalent cleavable complex formation, as do most topoisomerase inhibitors. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitindomide","termGroup":"PT","termSource":"NCI"},{"termName":"4, 8-Ethenopyrrolo[3',4':3,4]cyclobut[1,2-f]isoindole-1,3,5,7(2H, 6H)tetrone, octahydro-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10403-51-7"},{"name":"Chemical_Formula","value":"C14H12N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DK61ZER6T7"},{"name":"Legacy Concept Name","value":"MITINDOMIDE"},{"name":"Maps_To","value":"Mitindomide"},{"name":"NSC Number","value":"284356"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066593"}]}}{"C659":{"preferredName":"Mitobronitol","code":"C659","definitions":[{"definition":"A brominated analog of mannitol with potential antineoplastic activity. Mitobronitol most likely acts through alkylation via derived epoxide groups.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitobronitol","termGroup":"PT","termSource":"NCI"},{"termName":"1,6-Dibromo-1,6-dideoxy-D-mannitol","termGroup":"SN","termSource":"NCI"},{"termName":"DBM","termGroup":"AB","termSource":"NCI"},{"termName":"Dibromomannitol","termGroup":"SY","termSource":"NCI"},{"termName":"Myelobromol","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"488-41-5"},{"name":"Chemical_Formula","value":"C6H12Br2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5UP30YED7N"},{"name":"Legacy Concept Name","value":"Mitobronitol"},{"name":"Maps_To","value":"Mitobronitol"},{"name":"NSC Number","value":"94100"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026236"}]}}{"C111758":{"preferredName":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101","code":"C111758","definitions":[{"definition":"An orally bioavailable inhibitor of mitochondrial oxidative phosphorylation with potential antineoplastic activity. Upon administration, ATR-101 inhibits the activity of F1F0-ATP synthase, elevates the mitochondrial membrane potential and depletes ATP in adrenocortical cells. The mitochondrial dysfunction caused by the release of reactive oxygen and triggered cytochrome c release leads to caspase-mediated cell death. ATR-101 may be useful in treating certain types of adrenocortical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101"},{"name":"NCI_Drug_Dictionary_ID","value":"753012"},{"name":"NCI_META_CUI","value":"CL454145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753012"},{"name":"PDQ_Open_Trial_Search_ID","value":"753012"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66164":{"preferredName":"Mitoclomine","code":"C66164","definitions":[{"definition":"An aromatic nitrogen mustard derivative with potential antineoplastic activity. Mitoclomine alkylates DNA and appears to concentrate primarily in the spleen and thymus where it causes lymphocyte depletion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoclomine","termGroup":"PT","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)4-amino-2-methyl-1-methoxy-naphthalene","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17692-54-5"},{"name":"Chemical_Formula","value":"C16H19Cl2NO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"02DQX562CR"},{"name":"Legacy Concept Name","value":"Mitoclomine"},{"name":"Maps_To","value":"Mitoclomine"},{"name":"NSC Number","value":"114575"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066605"}]}}{"C1101":{"preferredName":"Mitoflaxone","code":"C1101","definitions":[{"definition":"A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoflaxone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Phenyl-8-(carboxymethyl)-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"4H-1-benzopyran-8-acetic Acid, 4-Oxo-2-phenyl","termGroup":"SN","termSource":"NCI"},{"termName":"FAA","termGroup":"AB","termSource":"NCI"},{"termName":"Flavone Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Flavone-8-Acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LM 975","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87626-55-9"},{"name":"Chemical_Formula","value":"C17H12O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X230G6E63B"},{"name":"Legacy Concept Name","value":"Flavone_Acetic_Acid"},{"name":"Maps_To","value":"Mitoflaxone"},{"name":"NCI_Drug_Dictionary_ID","value":"40152"},{"name":"NSC Number","value":"347512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40152"},{"name":"PDQ_Open_Trial_Search_ID","value":"40152"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060441"}]}}{"C661":{"preferredName":"Mitoguazone","code":"C661","definitions":[{"definition":"A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoguazone","termGroup":"PT","termSource":"NCI"},{"termName":"1,1'-((methylethanediylidene)dinitrilo)diguanidine","termGroup":"SN","termSource":"NCI"},{"termName":"2,2\"-(methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]","termGroup":"SN","termSource":"NCI"},{"termName":"DRG-0223","termGroup":"CN","termSource":"NCI"},{"termName":"Me-GAG","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl GAG","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl-G","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl-GAG","termGroup":"FB","termSource":"NCI"},{"termName":"Methylglyoxal bis(amidinohydrazone)","termGroup":"SN","termSource":"NCI"},{"termName":"methylglyoxal bis(guanylhydrazone)","termGroup":"SY","termSource":"NCI"},{"termName":"Methylglyoxal Bisguanylhydrazone","termGroup":"SY","termSource":"NCI"},{"termName":"MGBG","termGroup":"AB","termSource":"NCI"},{"termName":"pyruvaldehyde bis(amidinohydrazone)","termGroup":"SY","termSource":"NCI"},{"termName":"Zyrkamine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"459-86-9"},{"name":"Chemical_Formula","value":"C5H12N8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OD5Q0L447W"},{"name":"Legacy Concept Name","value":"Mitoguazone"},{"name":"Maps_To","value":"Mitoguazone"},{"name":"NCI_Drug_Dictionary_ID","value":"39500"},{"name":"NSC Number","value":"32946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39500"},{"name":"PDQ_Open_Trial_Search_ID","value":"39500"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026251"}]}}{"C91409":{"preferredName":"Mitoguazone Dihydrochloride","code":"C91409","definitions":[{"definition":"A substance being studied in the treatment of some leukemias and lymphomas. It blocks the growth of cells and may cause cancer cells to die. It is a type of polyamine synthesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoguazone Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1,1'-((Methylethanediylidene)Dinitrilo)Diguanidine Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-(1-Methyl-1,2-Ethanediylidene)Bis(Hydrazinecarboximidamide) Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Methylglyoxal Bis(amidinohydrazone) Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"MGBG 2HCl","termGroup":"AB","termSource":"NCI"},{"termName":"Pyruvaldehyde Bis(amidinohydrazone) Hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7059-23-6"},{"name":"Chemical_Formula","value":"C5H12N8.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NNI098FX5Q"},{"name":"Maps_To","value":"Mitoguazone Dihydrochloride"},{"name":"NSC Number","value":"32946"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771772"}]}}{"C662":{"preferredName":"Mitolactol","code":"C662","definitions":[{"definition":"A synthetic derivative of hexitol with antineoplastic and radiosensitizing properties.  Mitolactol alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA and RNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mitolactol","termGroup":"PT","termSource":"NCI"},{"termName":"6-Dibromodideoxydulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"6-Dibromodulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"DBD","termGroup":"AB","termSource":"NCI"},{"termName":"Dibromdicil","termGroup":"SY","termSource":"NCI"},{"termName":"Dibromodulcitol","termGroup":"SY","termSource":"NCI"},{"termName":"Elobromol","termGroup":"FB","termSource":"NCI"},{"termName":"Mitolac","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10318-26-0"},{"name":"Chemical_Formula","value":"C6H12Br2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LJ2P1SIK8Y"},{"name":"Legacy Concept Name","value":"Mitolactol"},{"name":"Maps_To","value":"Mitolactol"},{"name":"NCI_Drug_Dictionary_ID","value":"39216"},{"name":"NSC Number","value":"104800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39216"},{"name":"PDQ_Open_Trial_Search_ID","value":"39216"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026252"}]}}{"C1820":{"preferredName":"Mitomycin","code":"C1820","definitions":[{"definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin","termGroup":"PT","termSource":"NCI"},{"termName":"(1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"[1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Ametycine","termGroup":"FB","termSource":"NCI"},{"termName":"Jelmyto","termGroup":"BR","termSource":"NCI"},{"termName":"MITO","termGroup":"AB","termSource":"NCI"},{"termName":"MITO-C","termGroup":"AB","termSource":"NCI"},{"termName":"Mito-Medac","termGroup":"FB","termSource":"NCI"},{"termName":"Mitocin","termGroup":"FB","termSource":"NCI"},{"termName":"Mitocin-C","termGroup":"FB","termSource":"NCI"},{"termName":"Mitolem","termGroup":"FB","termSource":"NCI"},{"termName":"Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycin-C","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycin-X","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycine C","termGroup":"SY","termSource":"NCI"},{"termName":"Mitosol","termGroup":"BR","termSource":"NCI"},{"termName":"Mitozytrex","termGroup":"BR","termSource":"NCI"},{"termName":"Mutamycin","termGroup":"BR","termSource":"NCI"},{"termName":"Mutamycine","termGroup":"FB","termSource":"NCI"},{"termName":"NCI-C04706","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastric Carcinoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Pancreatic Adenocarcinoma"},{"name":"CAS_Registry","value":"50-07-7"},{"name":"CHEBI_ID","value":"CHEBI:27504"},{"name":"Chemical_Formula","value":"C15H18N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"50SG953SK6"},{"name":"Legacy Concept Name","value":"Mitomycin_C"},{"name":"Maps_To","value":"Mitomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"42674"},{"name":"NSC Number","value":"26980"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42674"},{"name":"PDQ_Open_Trial_Search_ID","value":"42674"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002475"}]}}{"C1164":{"preferredName":"Mitomycin A","code":"C1164","definitions":[{"definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin A generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Mitomycin A is more toxic than mitomycin C due to increased and nonselective DNA cross-linking in both aerobic and hypoxic cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin A","termGroup":"PT","termSource":"NCI"},{"termName":"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4055-39-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"87TMG6FJHV"},{"name":"Legacy Concept Name","value":"Mitomycin_A"},{"name":"Maps_To","value":"Mitomycin A"},{"name":"NSC Number","value":"75986"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066608"}]}}{"C1392":{"preferredName":"Mitomycin B","code":"C1392","definitions":[{"definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin B generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin B","termGroup":"PT","termSource":"NCI"},{"termName":"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8a-hydroxy-8-(hydroxymethyl)-6-methoxy-1,5-dimethyl-, 8-carbamate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4055-40-7"},{"name":"Chemical_Formula","value":"C16H19N3O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VT1IGL3D7V"},{"name":"Legacy Concept Name","value":"Mitomycin_B"},{"name":"Maps_To","value":"Mitomycin B"},{"name":"NSC Number","value":"75987"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0128596"}]}}{"C1140":{"preferredName":"Mitomycin C Analog KW-2149","code":"C1140","definitions":[{"definition":"A semisynthetic water-soluble disulfide derivative of the antineoplastic antibiotic mitomycin C.  Activated by serum and glutathione, KW-2149 causes interstrand DNA cross-links and DNA-protein cross-links, resulting in single-strand DNA breaks and inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin C Analog KW-2149","termGroup":"PT","termSource":"NCI"},{"termName":"7-N-(2-((2-(gamma-L-Glutamylamino)ethyl)dithio)ethyl)mitomycin C","termGroup":"SN","termSource":"NCI"},{"termName":"KT6149","termGroup":"CN","termSource":"NCI"},{"termName":"KW 2149","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118359-59-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AK8DKI0KMN"},{"name":"Legacy Concept Name","value":"KW-2149"},{"name":"Maps_To","value":"Mitomycin C Analog KW-2149"},{"name":"NCI_Drug_Dictionary_ID","value":"42572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42572"},{"name":"PDQ_Open_Trial_Search_ID","value":"42572"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064443"}]}}{"C151933":{"preferredName":"Hec1/Nek2 Inhibitor T-1101 Tosylate","code":"C151933","definitions":[{"definition":"The tosylate salt form of T-1101, an orally bioavailable inhibitor of highly expressed in cancer 1 (Hec1) and NIMA-related kinase 2 (Nek2), with potential antineoplastic activity. Upon oral administration, T-1101 specifically targets, binds to and inhibits the interaction of Hec1 with Nek2. This prevents Hec1/Nek2-mediated signal transduction pathways, inhibits mitosis, induces apoptosis and tumor cell proliferation. Hec1, overexpressed in some cancers, is located at the centromere during cell mitosis and plays an essential role in the pathway of spindle checkpoint. It is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hec1/Nek2 Inhibitor T-1101 Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"T 1101 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"T1101 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"TAI-95","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitosis Inhibitor T 1101 Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"793127"},{"name":"NCI_META_CUI","value":"CL553272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793127"},{"name":"PDQ_Open_Trial_Search_ID","value":"793127"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C664":{"preferredName":"Mitotane","code":"C664","definitions":[{"definition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug used in treating adrenocortical cancer and ACTH-producing pituitary tumors (Cushing's disease).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mitotane","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane","termGroup":"SN","termSource":"NCI"},{"termName":"1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene","termGroup":"SN","termSource":"NCI"},{"termName":"2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane","termGroup":"SN","termSource":"NCI"},{"termName":"2,4'-Dichlorodiphenyldichloroethane","termGroup":"SN","termSource":"NCI"},{"termName":"2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane","termGroup":"SN","termSource":"NCI"},{"termName":"CB-313","termGroup":"CN","termSource":"NCI"},{"termName":"Chloditan","termGroup":"SY","termSource":"NCI"},{"termName":"Chlodithane","termGroup":"SY","termSource":"NCI"},{"termName":"DDD","termGroup":"AB","termSource":"NCI"},{"termName":"Khloditan","termGroup":"SY","termSource":"NCI"},{"termName":"Lisodren","termGroup":"FB","termSource":"NCI"},{"termName":"Lysodren","termGroup":"BR","termSource":"NCI"},{"termName":"Mytotan","termGroup":"SY","termSource":"NCI"},{"termName":"o,p' - DDD","termGroup":"AB","termSource":"NCI"},{"termName":"o,p'-DDD","termGroup":"SY","termSource":"NCI"},{"termName":"o,p'-DDD","termGroup":"AB","termSource":"NCI"},{"termName":"Ortho,para-DDD","termGroup":"SY","termSource":"NCI"},{"termName":"WR-13045","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adrenocortical carcinoma"},{"name":"CAS_Registry","value":"53-19-0"},{"name":"Chemical_Formula","value":"C14H10Cl4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"78E4J5IB5J"},{"name":"Legacy Concept Name","value":"Mitotane"},{"name":"Maps_To","value":"Mitotane"},{"name":"NCI_Drug_Dictionary_ID","value":"39506"},{"name":"NSC Number","value":"38721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39506"},{"name":"PDQ_Open_Trial_Search_ID","value":"39506"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026256"}]}}{"C66167":{"preferredName":"Mitotenamine","code":"C66167","definitions":[{"definition":"A nucleotoxic with potential antineoplastic activity. The mechanism of action through which mitotenamine exerts its effect has yet to be fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitotenamine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7696-00-6"},{"name":"Chemical_Formula","value":"C13H15BrClNS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2879S26V4P"},{"name":"Legacy Concept Name","value":"Mitotenamine"},{"name":"Maps_To","value":"Mitotenamine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881869"}]}}{"C62050":{"preferredName":"Mitoxantrone","code":"C62050","definitions":[{"definition":"A drug used to treat advanced prostate cancer that does not respond to hormones, adult acute nonlymphocytic leukemia, and advanced or chronic multiple sclerosis. It is also being studied in the treatment of other cancers. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydroxyanthracenedione","termGroup":"SY","termSource":"NCI"},{"termName":"Mitozantrone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65271-80-9"},{"name":"CHEBI_ID","value":"CHEBI:50729"},{"name":"Chemical_Formula","value":"C22H28N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"BZ114NVM5P"},{"name":"Legacy Concept Name","value":"Mitoxantrone_Base"},{"name":"Maps_To","value":"Mitoxantrone"},{"name":"NSC Number","value":"279836"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026259"}]}}{"C665":{"preferredName":"Mitoxantrone Hydrochloride","code":"C665","definitions":[{"definition":"A drug used to treat advanced prostate cancer that does not respond to hormones, adult acute nonlymphocytic leukemia, and advanced or chronic multiple sclerosis. It is also being studied in the treatment of other cancers. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CL 232315","termGroup":"CN","termSource":"NCI"},{"termName":"DHAD","termGroup":"AB","termSource":"NCI"},{"termName":"DHAQ","termGroup":"AB","termSource":"NCI"},{"termName":"Dihydroxyanthracenedione Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mitoxantrone Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mitoxantroni Hydrochloridum","termGroup":"SY","termSource":"NCI"},{"termName":"Mitozantrone Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mitroxone","termGroup":"FB","termSource":"NCI"},{"termName":"Neotalem","termGroup":"FB","termSource":"NCI"},{"termName":"Novantrone","termGroup":"AQS","termSource":"NCI"},{"termName":"Onkotrone","termGroup":"FB","termSource":"NCI"},{"termName":"Pralifan","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Leukemia; Breast cancer; Non Hodgkins Lymphoma; Multiple sclerosis; Prostate cancer"},{"name":"CAS_Registry","value":"70476-82-3"},{"name":"CHEBI_ID","value":"CHEBI:50727"},{"name":"Chemical_Formula","value":"C22H28N4O6.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U6USW86RD0"},{"name":"Legacy Concept Name","value":"Mitoxantrone"},{"name":"Maps_To","value":"Mitoxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39219"},{"name":"NSC Number","value":"301739"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39219"},{"name":"PDQ_Open_Trial_Search_ID","value":"39219"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700458"}]}}{"C1166":{"preferredName":"Mitozolomide","code":"C1166","definitions":[{"definition":"A prodrug of imidazotetrazine alkylating agent with antineoplastic property. Mitozolomide undergoes ring opening upon the nucleophilic attack at C-4 by an activated molecule of water within the major groove of DNA. The resulting bioactive mono-alkyltriazene species are capable of alkylating nucleophilic residues in the immediate vicinity such as N-7 and/or O-6 sites of guanine, thereby causes intra- or inter-stranded DNA cross-links and trigger apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitozolomide","termGroup":"PT","termSource":"NCI"},{"termName":"Azolastone","termGroup":"BR","termSource":"NCI"},{"termName":"imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3-(2-chloroethyl)-3,4-dihydro-4-oxo","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85622-95-3"},{"name":"Chemical_Formula","value":"C7H7ClN6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E3U7286V3W"},{"name":"Legacy Concept Name","value":"Mitozolomide"},{"name":"Maps_To","value":"Mitozolomide"},{"name":"NCI_Drug_Dictionary_ID","value":"40221"},{"name":"NSC Number","value":"353451"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40221"},{"name":"PDQ_Open_Trial_Search_ID","value":"40221"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066618"}]}}{"C113162":{"preferredName":"Mivavotinib","code":"C113162","definitions":[{"definition":"An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivavotinib","termGroup":"PT","termSource":"NCI"},{"termName":"3H-Pyrrolo(3,4-C)pyridin-3-one, 6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Spleen Tyrosine Kinase Inhibitor TAK659","termGroup":"SY","termSource":"NCI"},{"termName":"syk Inhibitor TAK-659","termGroup":"SY","termSource":"NCI"},{"termName":"syk Inhibitor TAK659","termGroup":"SY","termSource":"NCI"},{"termName":"syk-Inhibitor TAK-659","termGroup":"SY","termSource":"NCI"},{"termName":"syk-Inhibitor TAK659","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-659 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"TAK659 Free Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312691-33-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8QR88H79VX"},{"name":"Maps_To","value":"Mivavotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"755930"},{"name":"NCI_META_CUI","value":"CL455236"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755930"},{"name":"PDQ_Open_Trial_Search_ID","value":"755930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121829":{"preferredName":"Mivebresib","code":"C121829","definitions":[{"definition":"An inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, mivebresib binds to the acetyl-lysine binding site of  BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivebresib","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-075","termGroup":"CN","termSource":"NCI"},{"termName":"Ethanesulfonamide, N-(4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo(2,3-C)pyridin-4-yl)phenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1445993-26-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VR86R11J7J"},{"name":"Maps_To","value":"Mivebresib"},{"name":"NCI_Drug_Dictionary_ID","value":"773809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"773809"},{"name":"PDQ_Open_Trial_Search_ID","value":"773809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053689"}]}}{"C87698":{"preferredName":"Mivobulin","code":"C87698","definitions":[{"definition":"A synthetic, colchicine analogue with potential antineoplastic activity. Mivobulin targets and binds to colchicine-binding site on tubulin, thereby inhibiting microtubule polymerization, the assembly of the mitotic spindle and mitosis. This eventually results in cell cycle arrest, apoptosis and a reduction in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivobulin","termGroup":"PT","termSource":"NCI"},{"termName":"Carbamic Acid, (5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido(3,4-B)Pyrazin-7-Yl) Ethyl Ester, (S)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ethyl (S)-5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido(3,4-B)Pyrazine-7-Carbamate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"122332-18-7"},{"name":"Chemical_Formula","value":"C17H19N5O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96U5LG549X"},{"name":"Maps_To","value":"Mivobulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981335"}]}}{"C1357":{"preferredName":"Mivobulin Isethionate","code":"C1357","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The isethionate salt of mivobulin, a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivobulin Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"CI 980","termGroup":"CN","termSource":"NCI"},{"termName":"CI-980","termGroup":"CN","termSource":"NCI"},{"termName":"CI980","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"126268-81-3"},{"name":"Chemical_Formula","value":"C17H19N5O2.C2H6O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8J08028R66"},{"name":"Legacy Concept Name","value":"Mivobulin_Isethionate"},{"name":"Maps_To","value":"Mivobulin Isethionate"},{"name":"NCI_Drug_Dictionary_ID","value":"41656"},{"name":"NSC Number","value":"635370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41656"},{"name":"PDQ_Open_Trial_Search_ID","value":"41656"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0109740"}]}}{"C74063":{"preferredName":"Mixed Bacteria Vaccine","code":"C74063","definitions":[{"definition":"A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Bacteria Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Coley's Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"MBV","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Bacteria_Vaccine"},{"name":"Maps_To","value":"Mixed Bacteria Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"590146"},{"name":"NCI_META_CUI","value":"CL383537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590146"},{"name":"PDQ_Open_Trial_Search_ID","value":"590146"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49174":{"preferredName":"MK0731","code":"C49174","definitions":[{"definition":"A synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MK0731","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845256-65-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8HIJ5G3O02"},{"name":"Legacy Concept Name","value":"MK0731"},{"name":"Maps_To","value":"MK0731"},{"name":"NCI_Drug_Dictionary_ID","value":"446551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"446551"},{"name":"PDQ_Open_Trial_Search_ID","value":"446551"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708823"}]}}{"C2507":{"preferredName":"MKC-1","code":"C2507","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It may prevent cancer cells from dividing. It belongs to the family of drugs called cell cycle inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. In addition, this agent has been shown to inhibit the activities of the oncogenic kinase Akt, the mTOR pathway, and importin-beta, a protein essential to the transport of other proteins from the cytosol into the nucleus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MKC-1","termGroup":"PT","termSource":"NCI"},{"termName":"MKC-1","termGroup":"SY","termSource":"NCI"},{"termName":"R440","termGroup":"CN","termSource":"NCI"},{"termName":"Ro 31-7453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125313-92-0"},{"name":"Chemical_Formula","value":"C22H16N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DNZ11VPY7Q"},{"name":"Legacy Concept Name","value":"Ro_31-7453"},{"name":"Maps_To","value":"MKC-1"},{"name":"NCI_Drug_Dictionary_ID","value":"486351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486351"},{"name":"PDQ_Open_Trial_Search_ID","value":"486351"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796487"}]}}{"C121956":{"preferredName":"MKNK1 Inhibitor BAY 1143269","code":"C121956","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1), with potential antineoplastic activity. Upon oral administration, MKNK1 inhibitor BAY 1143269 binds to MKNK1, thereby preventing its activation and the downstream MKNK1-mediated phosphorylation and activation of eukaryotic translation initiation factor 4E (eIF4E). As eIF4E enhances the synthesis of oncogenic proteins, preventing eIF4E activity inhibits the synthesis of tumor angiogenic factors and leads to both the inhibition of cellular proliferation and apoptosis in susceptible tumor cells. eIF4E, overexpressed in a variety of cancer cells, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MKNK1 Inhibitor BAY 1143269","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1143269","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MKNK1 Inhibitor BAY 1143269"},{"name":"NCI_Drug_Dictionary_ID","value":"772160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772160"},{"name":"PDQ_Open_Trial_Search_ID","value":"772160"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053671"}]}}{"C2671":{"preferredName":"MMP Inhibitor S-3304","code":"C2671","definitions":[{"definition":"An orally-agent agent with potential antineoplastic activity.  S-3304 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MMP Inhibitor S-3304","termGroup":"PT","termSource":"NCI"},{"termName":"S-3304","termGroup":"CN","termSource":"NCI"},{"termName":"S3304","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203640-27-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK459F050X"},{"name":"Legacy Concept Name","value":"S-3304"},{"name":"Maps_To","value":"MMP Inhibitor S-3304"},{"name":"NCI_Drug_Dictionary_ID","value":"38596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38596"},{"name":"PDQ_Open_Trial_Search_ID","value":"38596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134613"}]}}{"C153262":{"preferredName":"Tinodasertib","code":"C153262","definitions":[{"definition":"A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, tinodasertib may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinodasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AUM-001","termGroup":"CN","termSource":"NCI"},{"termName":"AUM001","termGroup":"CN","termSource":"NCI"},{"termName":"ETC 1907206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC 206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC-1907206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC-206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC1907206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC206","termGroup":"CN","termSource":"NCI"},{"termName":"MNK1/2 Inhibitor ETC-1907206","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1464151-33-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MND3WX2R7I"},{"name":"Maps_To","value":"MNK1/2 Inhibitor ETC-1907206"},{"name":"NCI_Drug_Dictionary_ID","value":"794054"},{"name":"NCI_META_CUI","value":"CL554490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794054"},{"name":"PDQ_Open_Trial_Search_ID","value":"794054"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62521":{"preferredName":"Mocetinostat","code":"C62521","definitions":[{"definition":"A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mocetinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"MG-0103","termGroup":"CN","termSource":"NCI"},{"termName":"MGCD0103","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"726169-73-9"},{"name":"Chemical_Formula","value":"C23H20N6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A6GWB8T96J"},{"name":"Legacy Concept Name","value":"MGCD0103"},{"name":"Maps_To","value":"Mocetinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"486941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486941"},{"name":"PDQ_Open_Trial_Search_ID","value":"486941"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002471"}]}}{"C131824":{"preferredName":"Modified Vitamin D Binding Protein Macrophage Activator EF-022","code":"C131824","definitions":[{"definition":"A modified version of vitamin D binding protein (VDBP; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Vitamin D Binding Protein Macrophage Activator EF-022","termGroup":"PT","termSource":"NCI"},{"termName":"EF-022","termGroup":"CN","termSource":"NCI"},{"termName":"Modified VDBP-Macrophage Activator EF-022","termGroup":"SY","termSource":"NCI"},{"termName":"MVDP-Macrophage Activator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Modified Vitamin D Binding Protein Macrophage Activator EF-022"},{"name":"NCI_Drug_Dictionary_ID","value":"786093"},{"name":"NCI_META_CUI","value":"CL514564"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786093"},{"name":"PDQ_Open_Trial_Search_ID","value":"786093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C152075":{"preferredName":"Modotuximab","code":"C152075","definitions":[{"definition":"A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is often overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modotuximab","termGroup":"PT","termSource":"NCI"},{"termName":"1024 DS","termGroup":"CN","termSource":"NCI"},{"termName":"1024-DS","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human epidermal growth factor receptor extracellular domain III) (human-mus musculus monoclonal 1024 DS heavy chain), Disulfide with human-mus musculus monoclonal 1024 DS light chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Zatuximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1310460-86-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1W7BD1M08N"},{"name":"Maps_To","value":"Modotuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"793840"},{"name":"NCI_META_CUI","value":"CL553284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793840"},{"name":"PDQ_Open_Trial_Search_ID","value":"793840"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148280":{"preferredName":"MOF Compound RiMO-301","code":"C148280","definitions":[{"definition":"A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MOF Compound RiMO-301","termGroup":"PT","termSource":"NCI"},{"termName":"RiMO-301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MOF Compound RiMO-301"},{"name":"NCI_Drug_Dictionary_ID","value":"795715"},{"name":"NCI_META_CUI","value":"CL550908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795715"},{"name":"PDQ_Open_Trial_Search_ID","value":"795715"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63667":{"preferredName":"Mofarotene","code":"C63667","definitions":[{"definition":"An arotinoic acid derivative with a morpholine structure in the polar end group with differentiation inducing and antineoplastic activity. Like other retinoic acid agents, mofarotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells. In addition, this agent is able to inhibit melanoma cell motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mofarotene","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-4-[2-[4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]phenoxy]ethyl]morpholine","termGroup":"SN","termSource":"NCI"},{"termName":"Mofarontene","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 40-8757","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125533-88-2"},{"name":"Chemical_Formula","value":"C29H39NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8K3CVY8F8V"},{"name":"Legacy Concept Name","value":"Mofarotene"},{"name":"Maps_To","value":"Mofarotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0247161"}]}}{"C62510":{"preferredName":"Mogamulizumab","code":"C62510","definitions":[{"definition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mogamulizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"KM8761","termGroup":"CN","termSource":"NCI"},{"termName":"KW-0761","termGroup":"CN","termSource":"NCI"},{"termName":"Mogamulizumab-kpkc","termGroup":"SY","termSource":"NCI"},{"termName":"Poteligeo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS)"},{"name":"CAS_Registry","value":"1159266-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YI437801BE"},{"name":"Legacy Concept Name","value":"KW-0761"},{"name":"Maps_To","value":"Mogamulizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"500479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500479"},{"name":"PDQ_Open_Trial_Search_ID","value":"500479"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987603"}]}}{"C101538":{"preferredName":"Molibresib","code":"C101538","definitions":[{"definition":"A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Molibresib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK-525762A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK525762","termGroup":"CN","termSource":"NCI"},{"termName":"I-BET 762","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260907-17-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5QIO6SRZ2R"},{"name":"Maps_To","value":"Molibresib"},{"name":"NCI_Drug_Dictionary_ID","value":"733799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733799"},{"name":"PDQ_Open_Trial_Search_ID","value":"733799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2975231"}]}}{"C159943":{"preferredName":"Molibresib Besylate","code":"C159943","definitions":[{"definition":"The besylate salt of molibresib, a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Molibresib Besylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-((4S)-6-(4-Chlorophenyl)-8-methoxy-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepin-4-yl)-N-ethylacetamide monobenzenesulfonate salt","termGroup":"SN","termSource":"NCI"},{"termName":"GSK525762C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1895049-20-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K04D7I4BCH"},{"name":"Maps_To","value":"Molibresib Besylate"},{"name":"NCI_Drug_Dictionary_ID","value":"801626"},{"name":"NCI_META_CUI","value":"CL969105"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801626"},{"name":"PDQ_Open_Trial_Search_ID","value":"801626"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88311":{"preferredName":"Momelotinib","code":"C88311","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity. Upon oral administration, momelotinib competes with JAK1/2 for ATP binding, which results in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and leads to the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. In addition, the inhibition of ALK2 prevents liver hepcidin formation, increases iron availability and increases red blood cell (RBC) production. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Momelotinib","termGroup":"PT","termSource":"NCI"},{"termName":"CYT387","termGroup":"CN","termSource":"NCI"},{"termName":"GS-0387","termGroup":"CN","termSource":"NCI"},{"termName":"N-(Cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1056634-68-4"},{"name":"Chemical_Formula","value":"C23H22N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6O01GMS00P"},{"name":"Maps_To","value":"Momelotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"660135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2744845"}]}}{"C120208":{"preferredName":"Monalizumab","code":"C120208","definitions":[{"definition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"IPH-2201","termGroup":"CN","termSource":"NCI"},{"termName":"IPH2201","termGroup":"CN","termSource":"NCI"},{"termName":"NN-8765","termGroup":"CN","termSource":"NCI"},{"termName":"NN8765","termGroup":"CN","termSource":"NCI"},{"termName":"NN8765-3658","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228763-95-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3ZXZ2V0588"},{"name":"Maps_To","value":"Monalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"768226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768226"},{"name":"PDQ_Open_Trial_Search_ID","value":"768226"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896730"}]}}{"C105399":{"preferredName":"Monocarboxylate Transporter 1 Inhibitor AZD3965","code":"C105399","definitions":[{"definition":"An orally available inhibitor of monocarboxylate transporter 1 (MCT1), with potential antineoplastic activity. Upon oral administration, MCT1 inhibitor AZD3965 binds to MCT1 and prevents the transport of lactate into and out of the cell. This leads to an accumulation of lactate, intracellular acidification, and eventually cancer cell death. MCT1, a protein overexpressed on tumor cells, is responsible for the transport of monocarboxylates across the cell membrane and plays a key role in cell metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monocarboxylate Transporter 1 Inhibitor AZD3965","termGroup":"PT","termSource":"NCI"},{"termName":"AZD3965","termGroup":"CN","termSource":"NCI"},{"termName":"MCT1 Inhibitor AZD3965","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448671-31-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39OM5Y4K2F"},{"name":"Maps_To","value":"Monocarboxylate Transporter 1 Inhibitor AZD3965"},{"name":"NCI_Drug_Dictionary_ID","value":"746809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746809"},{"name":"PDQ_Open_Trial_Search_ID","value":"746809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642150"}]}}{"C2648":{"preferredName":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine","code":"C2648","definitions":[{"definition":"A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_105AD7_Anti-idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38413"},{"name":"PDQ_Open_Trial_Search_ID","value":"38413"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134469"}]}}{"C2446":{"preferredName":"Monoclonal Antibody 11D10","code":"C2446","definitions":[{"definition":"A murine monoclonal anti-idiotype antibody (anti-Id). Anti-Id 11D10 mimics a specific epitope of the high molecular weight human milk fat globule (HMFG) glycoprotein primarily expressed by human breast and some other tumor cells at high density. This specific HMFG epitope is identified by mAb BrE1, which was used as the immunizing antibody, or Ab1 to generate the anti-Id (Ab2) 11D10. Anti-ID 11D10 reacts specifically with breast tumor cells and with minimal reactivity with normal tissues. Vaccination with anti-Id 11D10 induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 11D10","termGroup":"PT","termSource":"NCI"},{"termName":"11D10","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 11D10","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_11D10"},{"name":"Maps_To","value":"Monoclonal Antibody 11D10"},{"name":"NCI_Drug_Dictionary_ID","value":"42822"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42822"},{"name":"PDQ_Open_Trial_Search_ID","value":"42822"},{"name":"PubMedID_Primary_Reference","value":"7533665"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677765"}]}}{"C2606":{"preferredName":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine","code":"C2606","definitions":[{"definition":"A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope.  Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"11D10 Anti-Idiotype Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TriAb","termGroup":"BR","termSource":"NCI"},{"termName":"TriAb anti-idiotype antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_11D10_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38135"},{"name":"PDQ_Open_Trial_Search_ID","value":"38135"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935720"}]}}{"C2368":{"preferredName":"Monoclonal Antibody 14G2A","code":"C2368","definitions":[{"definition":"A murine monoclonal antibody directed against the ganglioside GD2 with potential antineoplastic activity. Monoclonal antibody 14G2A binds to the ganglioside GD2 and induces antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 14G2A","termGroup":"PT","termSource":"NCI"},{"termName":"14G2A","termGroup":"SY","termSource":"NCI"},{"termName":"14G2A, monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody 14G2A, Monoclonal","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 14G2A","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TC4U60XS42"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_14G2A"},{"name":"Maps_To","value":"Monoclonal Antibody 14G2A"},{"name":"NCI_Drug_Dictionary_ID","value":"41244"},{"name":"NSC Number","value":"624345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41244"},{"name":"PDQ_Open_Trial_Search_ID","value":"41244"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280838"}]}}{"C29198":{"preferredName":"Monoclonal Antibody 1F5","code":"C29198","definitions":[{"definition":"A murine monoclonal antibody directed against CD20, a cross-membrane ion channel phosphoprotein expressed by B cells, with potential antineoplastic activity.  MOAB 1F5 binds to CD20, thereby directly inhibiting B-cell proliferation and differentiation. When cross-linked by secondary anti-mouse antibodies or Fc receptor-bearing cells, MOAB 1F5 may induce activation of B-cell protein tyrosine kinases, increases in B-cell intracellular calcium ion concentrations, and B-cell caspase activation, resulting in apoptosis of B cells expressing CD20. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 1F5","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody 1F5","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB 1F5","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_1F5"},{"name":"Maps_To","value":"Monoclonal Antibody 1F5"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513414"}]}}{"C2470":{"preferredName":"Monoclonal Antibody 3622W94","code":"C2470","definitions":[{"definition":"A humanized murine monoclonal antibody (MoAb) against the 17-1A antigen, with potential adjuvant therapeutic properties in colorectal cancer. 17-1A antigen (EpCAM), a human epithelial cell adhesion molecule, expresses in a variety of carcinoma tissues, such as those of colon and breast carcinomas. Immunization with MoAb 3622W94 may elicit immune responses, which could result in eradicating tumor cells expressing 17-1A antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 3622W94","termGroup":"PT","termSource":"NCI"},{"termName":"3622W94","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 3622W94","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_3622W94"},{"name":"Maps_To","value":"Monoclonal Antibody 3622W94"},{"name":"NCI_Drug_Dictionary_ID","value":"42985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42985"},{"name":"PDQ_Open_Trial_Search_ID","value":"42985"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677996"}]}}{"C2370":{"preferredName":"Monoclonal Antibody 3F8","code":"C2370","definitions":[{"definition":"A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody 3F8","termGroup":"PT","termSource":"NCI"},{"termName":"3F8","termGroup":"SY","termSource":"NCI"},{"termName":"3F8 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"anti-Ganglioside (GD2) Monoclonal Antibody 3F8","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 3F8","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3GFS72WN4M"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_3F8"},{"name":"Maps_To","value":"Monoclonal Antibody 3F8"},{"name":"NCI_Drug_Dictionary_ID","value":"41259"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41259"},{"name":"PDQ_Open_Trial_Search_ID","value":"41259"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280849"}]}}{"C2424":{"preferredName":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine","code":"C2424","definitions":[{"definition":"A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA).  This agent is used as a cancer vaccine against tumors that express CEA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"CEA-Vac","termGroup":"SY","termSource":"NCI"},{"termName":"CeaVac","termGroup":"BR","termSource":"NCI"},{"termName":"MoAb 3H1 anti-idiotype vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_3H1_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42652"},{"name":"NSC Number","value":"720063"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42652"},{"name":"PDQ_Open_Trial_Search_ID","value":"42652"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393051"}]}}{"C2227":{"preferredName":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine","code":"C2227","definitions":[{"definition":"A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities.  Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"4B5 monoclonal antibody anti-idiotype vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 4B5 anti-idiotype vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_4B5_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"37797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37797"},{"name":"PDQ_Open_Trial_Search_ID","value":"37797"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879386"}]}}{"C2739":{"preferredName":"Monoclonal Antibody 7C11","code":"C2739","definitions":[{"definition":"A murine IgM monoclonal antibody against Fas antigen with antineoplastic property. Fas antigen is a member of tumor necrosis factor family that mediates antibody-triggered apoptosis. Upon binds to Fas, monoclonal antibody 7C11 (MoAb 7C11) induces apoptosis in Fas-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 7C11","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb 7C11","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb IMC-7C11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_7C11"},{"name":"Maps_To","value":"Monoclonal Antibody 7C11"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513423"}]}}{"C1958":{"preferredName":"Monoclonal Antibody 81C6","code":"C1958","definitions":[{"definition":"A murine IgG2 monoclonal antibody (MoAb) 81C6 raised against the extracellular matrix antigen tenascin (hexabrachion), up-regulated in gliomas and other cancers. Conjugated MoAb 81C6 may be used in diagnosis or treatment of cancers that over-express tenascin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-tenascin Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-tenascin murine 81C6 mAb","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-tenascin murine 81C6 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"mu81C6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D18JQ86QNM"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_81C6"},{"name":"Maps_To","value":"Monoclonal Antibody 81C6"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1513424"}]}}{"C2436":{"preferredName":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine","code":"C2436","definitions":[{"definition":"An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"A1G4 anti-idiotype monoclonal antibody vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_A1G4_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42698"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42698"},{"name":"PDQ_Open_Trial_Search_ID","value":"42698"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677670"}]}}{"C2447":{"preferredName":"Monoclonal Antibody A27.15","code":"C2447","definitions":[{"definition":"A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27.15 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody A27.15","termGroup":"PT","termSource":"NCI"},{"termName":"A27.15","termGroup":"SY","termSource":"NCI"},{"termName":"ANTI-TRANSFERRIN MOAB 27.15","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb A27.15","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_A27_15"},{"name":"Maps_To","value":"Monoclonal Antibody A27.15"},{"name":"NCI_Drug_Dictionary_ID","value":"42834"},{"name":"NSC Number","value":"644261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42834"},{"name":"PDQ_Open_Trial_Search_ID","value":"42834"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677772"}]}}{"C2410":{"preferredName":"Monoclonal Antibody A33","code":"C2410","definitions":[{"definition":"A humanized monoclonal antibody directed against the human A33 antigen. Monoclonal antibody A33 recognizes the human A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, which is highly and homogenously expressed in 95% of colorectal cancer metastases with only restricted expression in normal colonic mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody A33","termGroup":"PT","termSource":"NCI"},{"termName":"A33","termGroup":"SY","termSource":"NCI"},{"termName":"A33 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb A33","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_A33"},{"name":"Maps_To","value":"Monoclonal Antibody A33"},{"name":"NCI_Drug_Dictionary_ID","value":"42527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42527"},{"name":"PDQ_Open_Trial_Search_ID","value":"42527"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0392959"}]}}{"C99162":{"preferredName":"Monoclonal Antibody AbGn-7","code":"C99162","definitions":[{"definition":"A chimeric monoclonal antibody against a Lewis-A-like glycotope (AbGn-7 antigen) with potential immunomodulating and antineoplastic activities. Monoclonal antibody AbGn-7 targets and binds to the carbohydrate AbGn-7 antigen on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), thereby killing AbGn-7-epitope positive tumor cells. AbGn-7 antigen is expressed on a variety of tumor cell types, including human colorectal, pancreatic and gastric tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody AbGn-7","termGroup":"PT","termSource":"NCI"},{"termName":"AbGn-7","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Monoclonal Antibody AbGn-7"},{"name":"NCI_Drug_Dictionary_ID","value":"717457"},{"name":"NCI_META_CUI","value":"CL433012"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717457"},{"name":"PDQ_Open_Trial_Search_ID","value":"717457"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129591":{"preferredName":"Lirentelimab","code":"C129591","definitions":[{"definition":"A humanized, nonfucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory receptor sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) expressed on human mast cells and eosinophils, with potential anti-inflammatory activity. Upon administration, lirentelimab targets and binds to Siglec-8 expressed on the surface of mast cells and eosinophils. This may inhibit mast cell activation and deplete eosinophils through antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. This may reduce abnormal proliferation of mast cells and eosinophils, which plays a key role in allergic and inflammatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirentelimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 002","termGroup":"CN","termSource":"NCI"},{"termName":"AK002","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody AK 002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2283348-97-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SWS48LJU3T"},{"name":"Maps_To","value":"Monoclonal Antibody AK002"},{"name":"NCI_Drug_Dictionary_ID","value":"783857"},{"name":"NCI_META_CUI","value":"CL512560"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783857"},{"name":"PDQ_Open_Trial_Search_ID","value":"783857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156402":{"preferredName":"Anti-NRP1 Antibody ASP1948","code":"C156402","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody directed against neuropilin-1 (NRP1; CD304; BDCA-4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-NRP1 antibody ASP1948 specifically targets and binds to NRP1. This prevents the binding of NRP1 to its ligand and may block the immune inhibitory actions of regulatory T-cells (Tregs) mediated by the interaction of NRP1 with its ligand. This may enhance the immune response against tumor cells. NRP1 is a transmembrane co-receptor protein expressed in Tregs; it plays an important role in maintaining the stability and function of Tregs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NRP1 Antibody ASP1948","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-neuropilin-1 Antibody ASP1948","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 1948","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1948","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1948","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ 329","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ-329","termGroup":"SY","termSource":"NCI"},{"termName":"PTZ329","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"857Y17E6U4"},{"name":"Maps_To","value":"Anti-NRP1 Antibody ASP1948"},{"name":"Maps_To","value":"Monoclonal Antibody ASP1948"},{"name":"NCI_Drug_Dictionary_ID","value":"795699"},{"name":"NCI_META_CUI","value":"CL563090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795699"},{"name":"PDQ_Open_Trial_Search_ID","value":"795699"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C2659":{"preferredName":"Monoclonal Antibody CAL","code":"C2659","definitions":[{"definition":"A humanized monoclonal antibody directed against parathyroid hormone-related protein (PTH-rP). As a poly-hormone with diverse biological roles, PTH-rP is expressed by normal tissues, acting in local tissue environments in a variety of ways; it is commonly overexpressed by breast, prostate, and other cancers, acting systemically by promoting bone resorption, inhibiting calcium excretion from the kidney, inducing hypercalcemia, and possibly playing a role in the formation of bony metastases. By blocking the effects of PTH-rP on calcium metabolism, monoclonal antibody CAL may inhibit cancer-related hypercalcemia. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody CAL","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CAL"},{"name":"Maps_To","value":"Monoclonal Antibody CAL"},{"name":"NCI_Drug_Dictionary_ID","value":"38505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38505"},{"name":"PDQ_Open_Trial_Search_ID","value":"38505"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1135160"}]}}{"C2698":{"preferredName":"Monoclonal Antibody CC49-delta CH2","code":"C2698","definitions":[{"definition":"A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody CC49-delta CH2","termGroup":"PT","termSource":"NCI"},{"termName":"CC-49 Delta CH2","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB CC49-deltaCH2","termGroup":"AB","termSource":"NCI"},{"termName":"MOAB HCC49DCH2","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb HuCC49DeltaCH2","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody HCC49DCH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CC49-delta_CH2"},{"name":"Maps_To","value":"Monoclonal Antibody CC49-delta CH2"},{"name":"NCI_Drug_Dictionary_ID","value":"38456"},{"name":"NSC Number","value":"696081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38456"},{"name":"PDQ_Open_Trial_Search_ID","value":"38456"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134500"}]}}{"C98296":{"preferredName":"Monoclonal Antibody CEP-37250/KHK2804","code":"C98296","definitions":[{"definition":"A humanized monoclonal antibody targeting glycolipids, with potential immunomodulating and antineoplastic activity. Upon administration, monoclonal antibody CEP-37250/KHK2804 targets and binds to a specific tumor antigen, thereby stimulating the immune system to exert an antibody-dependent cellular cytotoxicity (ADCC) against the tumor associated antigen (TAA)-expressing cancer cells. This agent has shown to be active in both wild-type and mutant K-RAS-expressing colorectal cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody CEP-37250/KHK2804","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-37250/KHK2804","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Monoclonal Antibody CEP-37250/KHK2804"},{"name":"NCI_Drug_Dictionary_ID","value":"714212"},{"name":"NCI_META_CUI","value":"CL432414"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714212"},{"name":"PDQ_Open_Trial_Search_ID","value":"714212"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2683":{"preferredName":"Monoclonal Antibody D6.12","code":"C2683","definitions":[{"definition":"A murine IgG2a monoclonal antibody directed against a 48 kDa antigen expressed on the cell surface of normal and malignant gastrointestinal epithelium. MoAb D6.12 has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This MoAb, either alone or in combination with other immunotherapeutic agents, may have possible diagnostic or therapeutic applications in gastrointestinal cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody D6.12","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb D6.12","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb D612","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_D6_12"},{"name":"Maps_To","value":"Monoclonal Antibody D6.12"},{"name":"NCI_Drug_Dictionary_ID","value":"38656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38656"},{"name":"PDQ_Open_Trial_Search_ID","value":"38656"},{"name":"PubMedID_Primary_Reference","value":"8402627"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134661"}]}}{"C2448":{"preferredName":"Monoclonal Antibody E2.3","code":"C2448","definitions":[{"definition":"A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody E2.3 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody E2.3","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Transferrin MOAB E2.3","termGroup":"SY","termSource":"NCI"},{"termName":"E2.3","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb E2.3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_E2_3"},{"name":"Maps_To","value":"Monoclonal Antibody E2.3"},{"name":"NCI_Drug_Dictionary_ID","value":"42835"},{"name":"NSC Number","value":"644262"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42835"},{"name":"PDQ_Open_Trial_Search_ID","value":"42835"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677773"}]}}{"C2514":{"preferredName":"Monoclonal Antibody F19","code":"C2514","definitions":[{"definition":"A murine monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby MoAb F19 has possible diagnostic and therapeutic applications in epithelial cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody F19","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-F19 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FAP (Fibroblast Activation Protein), F19 Epitope, Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"F19 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb F19","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_F19"},{"name":"Maps_To","value":"Monoclonal Antibody F19"},{"name":"NCI_Drug_Dictionary_ID","value":"43384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43384"},{"name":"PDQ_Open_Trial_Search_ID","value":"43384"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0796524"}]}}{"C26450":{"preferredName":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine","code":"C26450","definitions":[{"definition":"A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity.  Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).  GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_GD2_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"257174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257174"},{"name":"PDQ_Open_Trial_Search_ID","value":"257174"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328690"}]}}{"C2505":{"preferredName":"Monoclonal Antibody HeFi-1","code":"C2505","definitions":[{"definition":"A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody HeFi-1","termGroup":"PT","termSource":"NCI"},{"termName":"HeFi-1","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb HeFi-1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HeFi-1"},{"name":"Maps_To","value":"Monoclonal Antibody HeFi-1"},{"name":"NCI_Drug_Dictionary_ID","value":"43332"},{"name":"NSC Number","value":"603573"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43332"},{"name":"PDQ_Open_Trial_Search_ID","value":"43332"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0796480"}]}}{"C2547":{"preferredName":"Monoclonal Antibody Hu3S193","code":"C2547","definitions":[{"definition":"A humanized monoclonal antibody directed against the Lewis Y antigen, a tumor-associated epithelial antigen, with potential antineoplastic activity. Following binding, monoclonal antibody Hu3S193 triggers an antibody-dependent cell-mediated cytotoxicity in cells expressing Lewis Y antigen. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Hu3S193 binds to the protein Lewis(y), which is found on colon, breast, lung, ovary, and prostate cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody Hu3S193","termGroup":"PT","termSource":"NCI"},{"termName":"Hu3S193","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb Hu3S193","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946415-49-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Hu3S193"},{"name":"Maps_To","value":"Monoclonal Antibody Hu3S193"},{"name":"NCI_Drug_Dictionary_ID","value":"38031"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38031"},{"name":"PDQ_Open_Trial_Search_ID","value":"38031"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0879578"}]}}{"C48407":{"preferredName":"Monoclonal Antibody HuAFP31","code":"C48407","definitions":[{"definition":"A humanized monoclonal antibody directed against alpha fetoprotein with potential antineoplastic activity. Upon administration, monoclonal antibody HuAFP31 (mAb HuAFP31) binds to and stimulates a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of several types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuAFP31 attaches to tumor cells that make alpha fetoprotein (AFP). This makes it easier for T cells to find and kill the tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody HuAFP31","termGroup":"PT","termSource":"NCI"},{"termName":"hAFP-31","termGroup":"CN","termSource":"NCI"},{"termName":"MOAB HuAFP31","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuAPF31"},{"name":"Maps_To","value":"Monoclonal Antibody HuAFP31"},{"name":"NCI_Drug_Dictionary_ID","value":"425344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425344"},{"name":"PDQ_Open_Trial_Search_ID","value":"425344"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541524"}]}}{"C38697":{"preferredName":"Sontuzumab","code":"C38697","definitions":[{"definition":"A humanized monoclonal antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, sontuzumab targets and binds to MUC1 expressed on the surface of tumor cells, which may activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that binds to the protein MUC1, which is found on breast, ovarian, pancreatic, gastric, and colon cancer cells. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuHMFG1 is being studied in the treatment of some types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sontuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AS1402","termGroup":"CN","termSource":"NCI"},{"termName":"Epitumomab","termGroup":"SY","termSource":"NCI"},{"termName":"HuHMFG1","termGroup":"AB","termSource":"NCI"},{"termName":"R1550","termGroup":"CN","termSource":"NCI"},{"termName":"Therex","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"372075-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3VD89OE565"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuHMFG1"},{"name":"Maps_To","value":"Monoclonal Antibody HuHMFG1"},{"name":"NCI_Drug_Dictionary_ID","value":"322247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"322247"},{"name":"PDQ_Open_Trial_Search_ID","value":"322247"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328704"}]}}{"C2652":{"preferredName":"Rosopatamab","code":"C2652","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in the malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, over-expression indicates an aggressive phenotype of the prostate cancer. Rosopatamab was generated by replacing murine Ig sequences with human ones, thereby MoAb huJ591can be administered to patients on multiple occasions over long time periods without inducing an immune response. Radiolabelled MoAb huJ591 may be used in immunotherapy of prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosopatamab","termGroup":"PT","termSource":"NCI"},{"termName":"huJ591","termGroup":"CN","termSource":"NCI"},{"termName":"MLN591","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody huJ591","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2260767-49-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2TTE6SSR0J"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_huJ591"},{"name":"Maps_To","value":"Monoclonal Antibody huJ591"},{"name":"Maps_To","value":"Rosopatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"38425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38425"},{"name":"PDQ_Open_Trial_Search_ID","value":"38425"},{"name":"PubMedID_Primary_Reference","value":"14716739"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134478"}]}}{"C48408":{"preferredName":"Monoclonal Antibody HuPAM4","code":"C48408","definitions":[{"definition":"A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1 with potential antineoplastic activity. Monoclonal antibody HuPAM4 (mAb HuPAM4) binds to cells expressing MUC1 antigen; mAb HuPAM4 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody HuPAM4","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB HuPAM4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuPAM4"},{"name":"Maps_To","value":"Monoclonal Antibody HuPAM4"},{"name":"NCI_Drug_Dictionary_ID","value":"425351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425351"},{"name":"PDQ_Open_Trial_Search_ID","value":"425351"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541527"}]}}{"C29224":{"preferredName":"Monoclonal Antibody IMMU-14","code":"C29224","definitions":[{"definition":"An anti-carcinoembryonic antigen (anti-CEA) murine monoclonal immunoglobulin G (IgG) with potential antineoplastic activity.  CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers.  MOAB IMMU-14 can be conjugated with a radioactive element for use in radioimmunotherapy (RIT), a regimen that uses a tumor-specific monoclonal antibody to deliver targeted radiation to cancer cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody IMMU-14","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB IMMU-14","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_IMMU-14"},{"name":"Maps_To","value":"Monoclonal Antibody IMMU-14"},{"name":"NSC Number","value":"624339"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513453"}]}}{"C2372":{"preferredName":"Monoclonal Antibody L6","code":"C2372","definitions":[{"definition":"A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells.  This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody L6","termGroup":"PT","termSource":"NCI"},{"termName":"L6","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb L6","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_L6"},{"name":"Maps_To","value":"Monoclonal Antibody L6"},{"name":"NCI_Drug_Dictionary_ID","value":"41472"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41472"},{"name":"PDQ_Open_Trial_Search_ID","value":"41472"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0281019"}]}}{"C1561":{"preferredName":"Monoclonal Antibody Lym-1","code":"C1561","definitions":[{"definition":"A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells.  When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues.  This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody Lym-1","termGroup":"PT","termSource":"NCI"},{"termName":"IgG2a murine monoclonal antibody Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Lym-1","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody Lym-1, IgG2a Murine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Lym-1"},{"name":"Maps_To","value":"Monoclonal Antibody Lym-1"},{"name":"NCI_Drug_Dictionary_ID","value":"41126"},{"name":"NSC Number","value":"620858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41126"},{"name":"PDQ_Open_Trial_Search_ID","value":"41126"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0280726"}]}}{"C1959":{"preferredName":"Monoclonal Antibody m170","code":"C1959","definitions":[{"definition":"A panadenocarcinoma murine monoclonal antibody (MoAb) with potential antineoplastic activity. MoAb m170 recognizes MUC-1 antigen present on the surface of many adenocarcinomas. It may be conjugated with a radioactive element and used in radioimmunotherapy (RIT), a procedure that uses a tumor-specific monoclonal antibody to target radiation to cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody m170","termGroup":"PT","termSource":"NCI"},{"termName":"Monoclonal Antibody 170","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody M170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_170"},{"name":"Maps_To","value":"Monoclonal Antibody m170"},{"name":"NCI_Drug_Dictionary_ID","value":"38169"},{"name":"NCI_META_CUI","value":"CL448315"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38169"},{"name":"PDQ_Open_Trial_Search_ID","value":"38169"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"}]}}{"C2409":{"preferredName":"Monoclonal Antibody Me1-14 F(ab')2","code":"C2409","definitions":[{"definition":"The F(ab)2 fragment of Me1-14, a murine IgG2a monoclonal antibody directed against proteoglycan chondroitin sulfate-associated protein expressed by gliomas and melanomas.  By binding to proteoglycan chondroitin sulfate-associated protein, monoclonal antibody Me1-14 F(ab')2 conjugated to a radioisotope may localize gliomas and melanomas when used as a tracer in radioimaging applications; in radioimmunotherapeutic applications, this agent conjugated to a radioisotope may be used to deliver targeted radiotoxicity to these tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody Me1-14 F(ab')2","termGroup":"PT","termSource":"NCI"},{"termName":"Me1-14 F(ab')2","termGroup":"SY","termSource":"NCI"},{"termName":"Me1-14 F(ab')2 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Me1-14 F(ab')2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Me1-14_F_ab_2"},{"name":"Maps_To","value":"Monoclonal Antibody Me1-14 F(ab')2"},{"name":"NCI_Drug_Dictionary_ID","value":"42523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42523"},{"name":"PDQ_Open_Trial_Search_ID","value":"42523"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0392955"}]}}{"C2476":{"preferredName":"Monoclonal Antibody muJ591","code":"C2476","definitions":[{"definition":"A murine IgG monoclonal antibody against the external domain of the prostate-specific membrane antigen (PSMA), overexpressed in the malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, over-expression indicates an aggressive phenotype of the prostate cancer. Radiolabelled MoAb muJ591 may be used in prostate cancer diagnosis and therapy.","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody muJ591","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb muJ591","termGroup":"AB","termSource":"NCI"},{"termName":"muJ591","termGroup":"SY","termSource":"NCI"},{"termName":"muJ591 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_muJ591"},{"name":"Maps_To","value":"Monoclonal Antibody muJ591"},{"name":"NCI_Drug_Dictionary_ID","value":"43087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43087"},{"name":"PDQ_Open_Trial_Search_ID","value":"43087"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0678086"}]}}{"C2417":{"preferredName":"Monoclonal Antibody MX35 F(ab')2","code":"C2417","definitions":[{"definition":"The F(ab)2 fragment of monoclonal antibody (MoAb) MX35 that recognizes a 95 kD glycoprotein with homogeneous distribution on 80% of ovarian tumor specimens. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against tumor cells that express this glycoprotein. Containing only the antigen-binding fragment of the Ig molecule, MoAb MX35 F(ab')2 offers the advantages of smaller size and lower cross-reactivity compared to complete antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody MX35 F(ab')2","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb MX35 F(ab')2","termGroup":"AB","termSource":"NCI"},{"termName":"MX35 F(ab')2","termGroup":"SY","termSource":"NCI"},{"termName":"MX35 F(ab')2 monoclonal antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_MX35_F_ab_2"},{"name":"Maps_To","value":"Monoclonal Antibody MX35 F(ab')2"},{"name":"NCI_Drug_Dictionary_ID","value":"42598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42598"},{"name":"PDQ_Open_Trial_Search_ID","value":"42598"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0393012"}]}}{"C156398":{"preferredName":"Monoclonal Antibody NEO-201","code":"C156398","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody derived from an immunogenic preparation of tumor-associated antigens (TAAs) from pooled allogeneic colon cancer tissue extracts, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, monoclonal antibody NEO-201 targets and binds to malignant tissues with tumor-specific mutations in the membrane-anchored proteins, carcinoembryonic antigen-related cell adhesion molecules 5 and 6 (CEACAM5 and CEACAM6). This prevents the interaction between tumor cell CEACAM 5 and natural killer (NK) cell CEACAM1, and reverses CEACAM1-dependent inhibition of NK cytotoxicity. This may result in the activation of NKs and results in NK-mediated tumor cell killing. Additionally, monoclonal antibody NEO-201 may activate innate immune responses against tumor cells such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CEACAM 5, and 6 are members of the CEA family of proteins. These membrane proteins are over expressed in a variety of cancer cell types and play a key role in cell migration, invasion, and adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody NEO-201","termGroup":"PT","termSource":"NCI"},{"termName":"h16C3","termGroup":"SY","termSource":"NCI"},{"termName":"h16C3 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"NEO 201","termGroup":"CN","termSource":"NCI"},{"termName":"NEO-201","termGroup":"CN","termSource":"NCI"},{"termName":"NEO201","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen-targeting Antibody NEO-201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"41E6FO0DX2"},{"name":"Maps_To","value":"Monoclonal Antibody NEO-201"},{"name":"NCI_Drug_Dictionary_ID","value":"795513"},{"name":"NCI_META_CUI","value":"CL563093"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795513"},{"name":"PDQ_Open_Trial_Search_ID","value":"795513"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2349":{"preferredName":"Monoclonal Antibody R24","code":"C2349","definitions":[{"definition":"An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells.  Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody R24","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb R24","termGroup":"AB","termSource":"NCI"},{"termName":"R24","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_R24"},{"name":"Maps_To","value":"Monoclonal Antibody R24"},{"name":"NCI_Drug_Dictionary_ID","value":"39362"},{"name":"NSC Number","value":"608918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39362"},{"name":"PDQ_Open_Trial_Search_ID","value":"39362"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0279226"}]}}{"C48409":{"preferredName":"Monoclonal Antibody RAV12","code":"C48409","definitions":[{"definition":"A chimeric monoclonal antibody directed against a primate-restricted N-linked carbohydrate epitope (glycotope) expressed on various human carcinomas with potential antineoplastic activity. Following binding, monoclonal antibody RAV12 disrupts sodium channels of tumor cells expressing this glycotope, resulting in cell and organelle swelling, loss of membrane integrity, and cell death. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. It binds to a carbohydrate (sugar) molecule that is found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody RAV12","termGroup":"PT","termSource":"NCI"},{"termName":"anti-RAAG12 MOAB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_RAV12"},{"name":"Maps_To","value":"Monoclonal Antibody RAV12"},{"name":"NCI_Drug_Dictionary_ID","value":"415732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415732"},{"name":"PDQ_Open_Trial_Search_ID","value":"415732"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541489"}]}}{"C2005":{"preferredName":"Monoclonal Antibody SGN-14","code":"C2005","definitions":[{"definition":"A humanized monoclonal antibody targeting the CD40 antigen with potential antineoplastic activity. CD-40, an integral membrane protein found on the surface of B lymphocytes and member of the tumor necrosis factor receptor super-family, is highly overexpressed on the cell surface of a number of B-cell malignancies. Monoclonal antibody SGN-14 specifically binds to and inhibits CD-40, thereby inhibiting cell proliferation and inducing cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody SGN-14","termGroup":"PT","termSource":"NCI"},{"termName":"SGN-14","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SGN-14"},{"name":"Maps_To","value":"Monoclonal Antibody SGN-14"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1519138"}]}}{"C142826":{"preferredName":"Monoclonal Antibody TRK-950","code":"C142826","definitions":[{"definition":"A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody TRK-950","termGroup":"PT","termSource":"NCI"},{"termName":"TRK 950","termGroup":"CN","termSource":"NCI"},{"termName":"TRK-950","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L1R0M8P1GD"},{"name":"Maps_To","value":"Monoclonal Antibody TRK-950"},{"name":"NCI_Drug_Dictionary_ID","value":"791700"},{"name":"NCI_META_CUI","value":"CL540696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791700"},{"name":"PDQ_Open_Trial_Search_ID","value":"791700"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155907":{"preferredName":"Monoclonal Microbial EDP1503","code":"C155907","definitions":[{"definition":"An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Microbial EDP1503","termGroup":"PT","termSource":"NCI"},{"termName":"EDP 1503","termGroup":"CN","termSource":"NCI"},{"termName":"EDP-1503","termGroup":"CN","termSource":"NCI"},{"termName":"EDP1503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A69GHF9QFF"},{"name":"Maps_To","value":"Monoclonal Microbial EDP1503"},{"name":"NCI_Drug_Dictionary_ID","value":"795263"},{"name":"NCI_META_CUI","value":"CL562766"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795263"},{"name":"PDQ_Open_Trial_Search_ID","value":"795263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94208":{"preferredName":"Tebentafusp","code":"C94208","definitions":[{"definition":"A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tebentafusp","termGroup":"PT","termSource":"NCI"},{"termName":"IMCgp100","termGroup":"CN","termSource":"NCI"},{"termName":"ImmTAC-gp100","termGroup":"SY","termSource":"NCI"},{"termName":"KIMMTRAK","termGroup":"BR","termSource":"NCI"},{"termName":"Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100","termGroup":"SY","termSource":"NCI"},{"termName":"Tebentafusp-tebn","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma."},{"name":"CAS_Registry","value":"1874157-95-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"N658GY6L3E"},{"name":"Maps_To","value":"Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100"},{"name":"Maps_To","value":"Tebentafusp"},{"name":"NCI_Drug_Dictionary_ID","value":"686537"},{"name":"NCI_META_CUI","value":"CL426021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686537"},{"name":"PDQ_Open_Trial_Search_ID","value":"686537"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122637":{"preferredName":"Monomethyl Auristatin E","code":"C122637","definitions":[{"definition":"A dolastatin-10 peptide derivative with potent antimitotic activity and potential antineoplastic activity as part of an antibody-drug conjugate (ADC). Monomethyl auristatin E (MMAE) binds to tubulin, blocks tubulin polymerization, and inhibits microtubule formation, which results in both disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. To minimize toxicity and maximize efficacy, MMAE is conjugated, via a cleavable peptide linker, to a monoclonal antibody that specifically targets a patient's tumor. The linker is stable in the extracellular milieu but is readily cleaved to release MMAE following binding and internalization of the ADC by the target cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monomethyl Auristatin E","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide","termGroup":"SN","termSource":"NCI"},{"termName":"L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1- methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MMAE","termGroup":"AB","termSource":"NCI"},{"termName":"Monomethylauristatin E","termGroup":"SY","termSource":"NCI"},{"termName":"N(sup 2)-(N-methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2- phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N(sup 1)-methyl-L-valinamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"474645-27-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7I58RC5EJ"},{"name":"Maps_To","value":"Monomethyl Auristatin E"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1565020"}]}}{"C26662":{"preferredName":"Morinda Citrifolia Fruit Extract","code":"C26662","definitions":[{"definition":"An extract prepared from the fruit of Morinda citrifolia, a plant that yields various herbal preparations. Morinda citrifolia fruit juice has antioxidant properties and may prevent tumorigenesis via inhibition of DNA-carcinogen adduct formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Morinda Citrifolia Fruit Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Indian Mulberry Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Morinda citrifolia Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Noni","termGroup":"SY","termSource":"NCI"},{"termName":"Noni Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Noni Juice","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Morinda_citrifolia"},{"name":"Maps_To","value":"Morinda Citrifolia Fruit Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"304320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304320"},{"name":"PDQ_Open_Trial_Search_ID","value":"304320"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C1328724"}]}}{"C1442":{"preferredName":"Morpholinodoxorubicin","code":"C1442","definitions":[{"definition":"A semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin.  As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin.  Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II.  Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Morpholinodoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2, 3, 6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl] oxy]-, hydrochloride, (8S-cis)-","termGroup":"SN","termSource":"NCI"},{"termName":"morpholino-ADR","termGroup":"SY","termSource":"NCI"},{"termName":"morpholino-adriamycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89196-04-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X0N4EFN4AI"},{"name":"Legacy Concept Name","value":"Morpholinodoxorubicin"},{"name":"Maps_To","value":"Morpholinodoxorubicin"},{"name":"NSC Number","value":"354646"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0173377"}]}}{"C123775":{"preferredName":"Mosedipimod","code":"C123775","definitions":[{"definition":"A synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Although the exact mechanism of action through which EC-18 exerts its pharmacological effect has yet to be fully identified, upon administration, mosedipimod stimulates calcium influx into T-lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T- and B-lymphocytes, dendritic cells (DCs) and macrophages. Therefore, EC18 may stimulate the immune system to target cancer cells. In addition, EC-18 enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mosedipimod","termGroup":"PT","termSource":"NCI"},{"termName":"1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol","termGroup":"SY","termSource":"NCI"},{"termName":"9,12-Octadecadienoic acid (9Z,12Z)-, 1-((Acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"EC-18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"221139-79-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"88928BS57E"},{"name":"Maps_To","value":"Mosedipimod"},{"name":"NCI_Drug_Dictionary_ID","value":"775590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775590"},{"name":"PDQ_Open_Trial_Search_ID","value":"775590"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1455477"}]}}{"C129691":{"preferredName":"Mosunetuzumab","code":"C129691","definitions":[{"definition":"A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mosunetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A","termGroup":"SY","termSource":"NCI"},{"termName":"BTCT 4465A","termGroup":"CN","termSource":"NCI"},{"termName":"BTCT-4465A","termGroup":"CN","termSource":"NCI"},{"termName":"BTCT4465A","termGroup":"CN","termSource":"NCI"},{"termName":"CD20/CD3 BiMAb BTCT4465A","termGroup":"SY","termSource":"NCI"},{"termName":"Lunsumio","termGroup":"BR","termSource":"NCI"},{"termName":"Mosunetuzumab-axgb","termGroup":"SY","termSource":"NCI"},{"termName":"RG 7828","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7828","termGroup":"CN","termSource":"NCI"},{"termName":"RG7828","termGroup":"CN","termSource":"NCI"},{"termName":"RO7030816","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1905409-39-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LDJ89SS0YG"},{"name":"Maps_To","value":"Mosunetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"774847"},{"name":"NCI_META_CUI","value":"CL507850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774847"},{"name":"PDQ_Open_Trial_Search_ID","value":"774847"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71896":{"preferredName":"Motesanib","code":"C71896","definitions":[{"definition":"An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motesanib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"453562-69-1"},{"name":"CHEBI_ID","value":"CHEBI:51098"},{"name":"Chemical_Formula","value":"C22H23N5O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U1JK633AYI"},{"name":"Legacy Concept Name","value":"Motesanib"},{"name":"Maps_To","value":"Motesanib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347295"}]}}{"C48374":{"preferredName":"Motesanib Diphosphate","code":"C48374","definitions":[{"definition":"A substance that is being studied in the treatment of some types of cancer. It belongs to the families of drugs called angiogenesis inhibitors and protein kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motesanib Diphosphate","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"AMG 706","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857876-30-3"},{"name":"Chemical_Formula","value":"C22H23N5O.2H3O4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T6Q3060U91"},{"name":"Legacy Concept Name","value":"AMG706"},{"name":"Maps_To","value":"Motesanib Diphosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"391228"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391228"},{"name":"PDQ_Open_Trial_Search_ID","value":"391228"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541476"}]}}{"C1881":{"preferredName":"Motexafin Gadolinium","code":"C1881","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It is a type of metalloporphyrin complex.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motexafin Gadolinium","termGroup":"PT","termSource":"NCI"},{"termName":"API-GP3","termGroup":"CN","termSource":"NCI"},{"termName":"Gadolinium Texaphyrin","termGroup":"SY","termSource":"NCI"},{"termName":"Gd (III) Texaphryin","termGroup":"SY","termSource":"NCI"},{"termName":"Gd-Tex","termGroup":"AB","termSource":"NCI"},{"termName":"PCI-0120","termGroup":"CN","termSource":"NCI"},{"termName":"Xcytrin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156436-89-4"},{"name":"CHEBI_ID","value":"CHEBI:50161"},{"name":"CHEBI_ID","value":"CHEBI:50162"},{"name":"Chemical_Formula","value":"C48H66N5O10.2C2H3O2.Gd"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6433A42F4F"},{"name":"Legacy Concept Name","value":"Motexafin_Gadolinium"},{"name":"Maps_To","value":"Motexafin Gadolinium"},{"name":"NCI_Drug_Dictionary_ID","value":"42391"},{"name":"NSC Number","value":"695238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42391"},{"name":"PDQ_Open_Trial_Search_ID","value":"42391"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0964264"}]}}{"C1651":{"preferredName":"Motexafin Lutetium","code":"C1651","definitions":[{"definition":"A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer using photodynamic therapy. It belongs to the family of drugs called metallotexaphyrins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Motexafin Lutetium","termGroup":"PT","termSource":"NCI"},{"termName":"Antrin","termGroup":"BR","termSource":"NCI"},{"termName":"Lu-Tex","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium Texaphrin","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Texaphyrin","termGroup":"SY","termSource":"NCI"},{"termName":"Lutex","termGroup":"BR","termSource":"NCI"},{"termName":"Lutrin","termGroup":"BR","termSource":"NCI"},{"termName":"Optrin","termGroup":"BR","termSource":"NCI"},{"termName":"PCI-0123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156436-90-7"},{"name":"CAS_Registry","value":"246252-04-0"},{"name":"Chemical_Formula","value":"C48H66N5O10.2C2H3O2.Lu.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0A85BJ22L6"},{"name":"Legacy Concept Name","value":"Motexafin_Lutetium"},{"name":"Maps_To","value":"Motexafin Lutetium"},{"name":"NCI_Drug_Dictionary_ID","value":"42402"},{"name":"NSC Number","value":"695239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42402"},{"name":"PDQ_Open_Trial_Search_ID","value":"42402"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338310"}]}}{"C80521":{"preferredName":"Motolimod","code":"C80521","definitions":[{"definition":"A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. Motolimod binds to TLR8, present in cutaneous dendritic cells, monocytes/macrophages, and mast cells, which may result in the activation of the central transcription factor nuclear factor-B, the secretion of proinflammatory cytokines and other mediators, and a Th1-weighted antitumoral cellular immune response. Primarily localized to endosomal membranes intracellularly, TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motolimod","termGroup":"PT","termSource":"NCI"},{"termName":"Toll-like Receptor 8 Agonist VTX-2337","termGroup":"SY","termSource":"NCI"},{"termName":"VTX-2337","termGroup":"CN","termSource":"NCI"},{"termName":"VTX-378","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"926927-61-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WP6PY72ZH3"},{"name":"Legacy Concept Name","value":"TLR8_Agonist_VTX-2337"},{"name":"Maps_To","value":"Motolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"599455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599455"},{"name":"PDQ_Open_Trial_Search_ID","value":"599455"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825237"}]}}{"C2638":{"preferredName":"MOv-gamma Chimeric Receptor Gene","code":"C2638","definitions":[{"definition":"A recombinant engineered chimeric gene derived from the murine gene encoding the variable region of monoclonal antibody MOv18 against folate-binding protein, which is often overexpressed in human ovarian cancer cells, and the gene encoding the Fc receptor for the gamma subunit of human IgG and IgE. Peripheral blood lymphocytes expressing the MOv-gamma gene may be used in the immunotherapeutic treatment of ovarian cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MOv-gamma Chimeric Receptor Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MOv-g","termGroup":"SY","termSource":"NCI"},{"termName":"MOv-gamma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MOv-gamma_Chimeric_Receptor_Gene"},{"name":"Maps_To","value":"MOv-gamma Chimeric Receptor Gene"},{"name":"NCI_Drug_Dictionary_ID","value":"38341"},{"name":"NSC Number","value":"673412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38341"},{"name":"PDQ_Open_Trial_Search_ID","value":"38341"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935881"}]}}{"C68819":{"preferredName":"Moxetumomab Pasudotox","code":"C68819","definitions":[{"definition":"A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD22 immunotoxin CAT-8015 is made in the laboratory. It binds to CD22, a protein on the surface of normal B cells and B-cell tumors, and kills the cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moxetumomab Pasudotox","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD22 Immunotoxin CAT-8015","termGroup":"SY","termSource":"NCI"},{"termName":"CAT-8015","termGroup":"CN","termSource":"NCI"},{"termName":"GCR-8015","termGroup":"CN","termSource":"NCI"},{"termName":"HA22","termGroup":"CN","termSource":"NCI"},{"termName":"Immunotoxin CAT-8015","termGroup":"SY","termSource":"NCI"},{"termName":"Lumoxiti","termGroup":"BR","termSource":"NCI"},{"termName":"Moxetumomab Pasudotox-TDFK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory hairy cell leukemia (HCL)"},{"name":"CAS_Registry","value":"1020748-57-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2NDX4B6N8F"},{"name":"Legacy Concept Name","value":"Anti-CD22_Immunotoxin_CAT-8015"},{"name":"Maps_To","value":"Moxetumomab Pasudotox"},{"name":"NCI_Drug_Dictionary_ID","value":"540032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"540032"},{"name":"PDQ_Open_Trial_Search_ID","value":"540032"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2717021"}]}}{"C122707":{"preferredName":"Mps1 Inhibitor BAY 1217389","code":"C122707","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BAY 1217389 selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC), accelerates mitosis, causes chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for proper SAC functioning and chromosome alignment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mps1 Inhibitor BAY 1217389","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1217389","termGroup":"CN","termSource":"NCI"},{"termName":"TTK Inhibitor BAY 1217389","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mps1 Inhibitor BAY 1217389"},{"name":"NCI_Drug_Dictionary_ID","value":"769545"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769545"},{"name":"PDQ_Open_Trial_Search_ID","value":"769545"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053670"}]}}{"C155895":{"preferredName":"Mps1 Inhibitor BOS172722","code":"C155895","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BOS172722 binds to and inhibits the activity of Mps1, a core component of the spindle assembly checkpoint (SAC). Inhibition of Mps1 activity compromises spindle assembly checkpoint, increases chromosome missegregation errors and decreases cancer cell viability. Mps1, a dual-specificity protein kinase expressed in proliferating normal tissues and aberrantly overexpressed in certain tumor types, is activated during mitosis and is essential in proper SAC function and chromosomal alignment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mps1 Inhibitor BOS172722","termGroup":"PT","termSource":"NCI"},{"termName":"BOS 172722","termGroup":"CN","termSource":"NCI"},{"termName":"BOS172722","termGroup":"CN","termSource":"NCI"},{"termName":"Monopolar Spindle 1 Inhibitor BOS172722","termGroup":"SY","termSource":"NCI"},{"termName":"TTK Inhibitor BOS172722","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mps1 Inhibitor BOS172722"},{"name":"NCI_Drug_Dictionary_ID","value":"794872"},{"name":"NCI_META_CUI","value":"CL562779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794872"},{"name":"PDQ_Open_Trial_Search_ID","value":"794872"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146813":{"preferredName":"mRNA-based Personalized Cancer Vaccine mRNA-4157","code":"C146813","definitions":[{"definition":"An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, the mRNA-based PCV mRNA-4157 is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based Personalized Cancer Vaccine mRNA-4157","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA 4157","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-4157","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-based PCV mRNA-4157","termGroup":"SY","termSource":"NCI"},{"termName":"PCV mRNA-4157","termGroup":"SY","termSource":"NCI"},{"termName":"V 940","termGroup":"CN","termSource":"NCI"},{"termName":"V-940","termGroup":"CN","termSource":"NCI"},{"termName":"V940","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based Personalized Cancer Vaccine mRNA-4157"},{"name":"NCI_Drug_Dictionary_ID","value":"792256"},{"name":"NCI_META_CUI","value":"CL544754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792256"},{"name":"PDQ_Open_Trial_Search_ID","value":"792256"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148239":{"preferredName":"mRNA-based Personalized Cancer Vaccine NCI-4650","code":"C148239","definitions":[{"definition":"An mRNA-based therapeutic personalized cancer vaccine (PCV) targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed and subjected to RNA sequencing to identify mutant and immunogenic epitopes. The neoantigen epitopes are screened to select those that induce a strong immune response in tumor- infiltrating lymphocytes (TILs) isolated from the patient. The selected mRNA sequences encoding up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. Upon administration, the mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based Personalized Cancer Vaccine NCI-4650","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA-based PCV NCI-4650","termGroup":"SY","termSource":"NCI"},{"termName":"NCI 4650","termGroup":"CN","termSource":"NCI"},{"termName":"NCI-4650","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based Personalized Cancer Vaccine NCI-4650"},{"name":"NCI_Drug_Dictionary_ID","value":"795447"},{"name":"NCI_META_CUI","value":"CL550832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795447"},{"name":"PDQ_Open_Trial_Search_ID","value":"795447"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154274":{"preferredName":"mRNA-based TriMix Melanoma Vaccine ECI-006","code":"C154274","definitions":[{"definition":"A melanoma vaccine consisting of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and a TriMix platform comprised of three mRNAs encoding for constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70, with potential immunomodulatory and antineoplastic activities. Upon intranodal injection, mRNA based TriMix vaccine ECI-006 may stimulate the immune system to mount both humoral and cellular responses against tumor cells expressing the five TAAs specific to the vaccine, potentially decreasing cellular proliferation of cells expressing these antigens. The TriMix adjuvants CD40L and caTLR4 promote the generation of mature and active dendritic cells (DCs), and CD70 provides a costimulatory signal to CD27+ naive T-cells, thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based TriMix Melanoma Vaccine ECI-006","termGroup":"PT","termSource":"NCI"},{"termName":"ECI 006","termGroup":"CN","termSource":"NCI"},{"termName":"ECI-006","termGroup":"CN","termSource":"NCI"},{"termName":"ECI006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based TriMix Melanoma Vaccine ECI-006"},{"name":"NCI_Drug_Dictionary_ID","value":"794159"},{"name":"NCI_META_CUI","value":"CL555271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794159"},{"name":"PDQ_Open_Trial_Search_ID","value":"794159"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156926":{"preferredName":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902","code":"C156926","definitions":[{"definition":"An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the mRNA-based tumor-specific neoantigen boosting vaccine GRT-R902, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901.  The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902","termGroup":"PT","termSource":"NCI"},{"termName":"Boosting Cancer Vaccine GRT-R902","termGroup":"SY","termSource":"NCI"},{"termName":"GRT R902","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-R902","termGroup":"CN","termSource":"NCI"},{"termName":"GRTR902","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-based TSNA Boosting Vaccine GRT-R902","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902"},{"name":"NCI_Drug_Dictionary_ID","value":"796480"},{"name":"NCI_META_CUI","value":"CL935911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796480"},{"name":"PDQ_Open_Trial_Search_ID","value":"796480"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162186":{"preferredName":"mRNA-derived KRAS-targeted Vaccine V941","code":"C162186","definitions":[{"definition":"A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-derived KRAS-targeted Vaccine V941","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA 5671","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-5671","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-5671 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V 941","termGroup":"CN","termSource":"NCI"},{"termName":"V941","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-derived KRAS-targeted Vaccine V941"},{"name":"NCI_Drug_Dictionary_ID","value":"798633"},{"name":"NCI_META_CUI","value":"CL970771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798633"},{"name":"PDQ_Open_Trial_Search_ID","value":"798633"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111574":{"preferredName":"mRNA-derived Lung Cancer Vaccine BI 1361849","code":"C111574","definitions":[{"definition":"A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-derived Lung Cancer Vaccine BI 1361849","termGroup":"PT","termSource":"NCI"},{"termName":"BI 1361849","termGroup":"CN","termSource":"NCI"},{"termName":"BI1361849","termGroup":"CN","termSource":"NCI"},{"termName":"CV9202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-derived Lung Cancer Vaccine BI 1361849"},{"name":"NCI_Drug_Dictionary_ID","value":"752248"},{"name":"NCI_META_CUI","value":"CL453982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752248"},{"name":"PDQ_Open_Trial_Search_ID","value":"752248"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82654":{"preferredName":"mRNA-Derived Prostate Cancer Vaccine CV9103","code":"C82654","definitions":[{"definition":"A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-Derived Prostate Cancer Vaccine CV9103","termGroup":"PT","termSource":"NCI"},{"termName":"CV9103","termGroup":"CN","termSource":"NCI"},{"termName":"Messenger RNA-Derived Prostate Cancer Vaccine CV9103","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"mRNA-Derived_Prostate_Cancer_Vaccine_CV9103"},{"name":"Maps_To","value":"mRNA-Derived Prostate Cancer Vaccine CV9103"},{"name":"NCI_Drug_Dictionary_ID","value":"636121"},{"name":"NCI_META_CUI","value":"CL388486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636121"},{"name":"PDQ_Open_Trial_Search_ID","value":"636121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106231":{"preferredName":"mRNA-derived Prostate Cancer Vaccine CV9104","code":"C106231","definitions":[{"definition":"A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), and mucin 1 (MUC1), with potential antineoplastic and immunomodulating activities. Upon intradermal administration of mRNA-derived prostate cancer vaccine CV9104, this agent enters cells, the mRNAs are translated into the respective prostate specific antigens and may cause the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PAP- and MUC1-expressing prostate tumor cells. The mRNAs used in this vaccine are modified to have enhanced translational potency and adjuvant activities. PSA, PSMA, PAP and MUC1 are frequently upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-derived Prostate Cancer Vaccine CV9104","termGroup":"PT","termSource":"NCI"},{"termName":"CV9104","termGroup":"CN","termSource":"NCI"},{"termName":"RNActive-derived Prostate Cancer Vaccine CV9104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-derived Prostate Cancer Vaccine CV9104"},{"name":"NCI_Drug_Dictionary_ID","value":"748869"},{"name":"NCI_META_CUI","value":"CL447407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748869"},{"name":"PDQ_Open_Trial_Search_ID","value":"748869"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95724":{"preferredName":"MTF-1 Inhibitor APTO-253 HCl","code":"C95724","definitions":[{"definition":"The hydrochloride salt of a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1) with potential antitumor activity. MTF-1 inhibitor APTO-253 inhibits MTF-1 activity and thereby induces the expression of MTF-1 dependent tumor suppressor factor Kruppel like factor 4 (KLF4). This subsequently leads to the downregulation of cyclin D1, blocking cell cycle progression and proliferation. This agent also causes decreased expression of genes involved in tumor hypoxia and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MTF-1 Inhibitor APTO-253 HCl","termGroup":"PT","termSource":"NCI"},{"termName":"2-(6-Fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"APTO-253 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"LOR-253 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"LT-253 HCl","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422731-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"266N56YWTZ"},{"name":"Maps_To","value":"MTF-1 Inhibitor APTO-253 HCl"},{"name":"NCI_Drug_Dictionary_ID","value":"694483"},{"name":"NCI_META_CUI","value":"CL428185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694483"},{"name":"PDQ_Open_Trial_Search_ID","value":"694483"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133227":{"preferredName":"mTOR Inhibitor GDC-0349","code":"C133227","definitions":[{"definition":"An orally bioavailable, ATP-competitive, tetrahydroquinazoline (THQ)-based inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Upon administration, GDC-0349 selectively binds to and inhibits the activity of mTOR, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR Inhibitor GDC-0349","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"GDC 0349","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0349","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0349","termGroup":"CN","termSource":"NCI"},{"termName":"RG7603","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1207360-89-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"579255I6O9"},{"name":"Maps_To","value":"mTOR Inhibitor GDC-0349"},{"name":"NCI_Drug_Dictionary_ID","value":"700941"},{"name":"NCI_META_CUI","value":"CL433839"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700941"},{"name":"PDQ_Open_Trial_Search_ID","value":"700941"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78856":{"preferredName":"mTOR Kinase Inhibitor AZD8055","code":"C78856","definitions":[{"definition":"An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR Kinase Inhibitor AZD8055","termGroup":"PT","termSource":"NCI"},{"termName":"AZD8055","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1009298-09-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"970JJ37FPW"},{"name":"Legacy Concept Name","value":"mTOR_Kinase_Inhibitor_AZD8055"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor AZD8055"},{"name":"NCI_Drug_Dictionary_ID","value":"612860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612860"},{"name":"PDQ_Open_Trial_Search_ID","value":"612860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703143"}]}}{"C92575":{"preferredName":"Onatasertib","code":"C92575","definitions":[{"definition":"An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onatasertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATG-008","termGroup":"CN","termSource":"NCI"},{"termName":"CC-223","termGroup":"CN","termSource":"NCI"},{"termName":"TORKi","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11237","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228013-30-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I8RA3543SY"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor CC-223"},{"name":"Maps_To","value":"Onatasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"683644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683644"},{"name":"PDQ_Open_Trial_Search_ID","value":"683644"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985184"}]}}{"C78476":{"preferredName":"mTOR Kinase Inhibitor CERC-006","code":"C78476","definitions":[{"definition":"An orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor, with potential antineoplastic activity. Upon oral administration, mTOR kinase inhibitor CERC-006 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR Kinase Inhibitor CERC-006","termGroup":"PT","termSource":"NCI"},{"termName":"AEVI 006","termGroup":"CN","termSource":"NCI"},{"termName":"AEVI-006","termGroup":"CN","termSource":"NCI"},{"termName":"AEVI006","termGroup":"CN","termSource":"NCI"},{"termName":"ASP 7486","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-7486","termGroup":"CN","termSource":"NCI"},{"termName":"ASP7486","termGroup":"CN","termSource":"NCI"},{"termName":"CERC 006","termGroup":"CN","termSource":"NCI"},{"termName":"CERC-006","termGroup":"CN","termSource":"NCI"},{"termName":"CERC006","termGroup":"CN","termSource":"NCI"},{"termName":"Mammalian Target of Rapamycin Kinase Inhibitor OSI-027","termGroup":"SY","termSource":"NCI"},{"termName":"mTOR Kinase Inhibitor OSI-027","termGroup":"SY","termSource":"NCI"},{"termName":"OSI-027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936890-98-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25MKH1SZ0M"},{"name":"Legacy Concept Name","value":"mTOR_Kinase_Inhibitor_OSI-027"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor OSI-027"},{"name":"NCI_Drug_Dictionary_ID","value":"600513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600513"},{"name":"PDQ_Open_Trial_Search_ID","value":"600513"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703121"}]}}{"C128632":{"preferredName":"mTOR Kinase Inhibitor PP242","code":"C128632","synonyms":[{"termName":"mTOR Kinase Inhibitor PP242","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol","termGroup":"SN","termSource":"NCI"},{"termName":"PP-242","termGroup":"CN","termSource":"NCI"},{"termName":"PP242","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092351-67-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H5669VNZ7V"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor PP242"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3492864"}]}}{"C101132":{"preferredName":"mTOR1/2 Kinase Inhibitor ME-344","code":"C101132","definitions":[{"definition":"An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR1/2 Kinase Inhibitor ME-344","termGroup":"PT","termSource":"NCI"},{"termName":"ME-344","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1374524-68-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"843G0TDV51"},{"name":"Maps_To","value":"mTOR1/2 Kinase Inhibitor ME-344"},{"name":"NCI_Drug_Dictionary_ID","value":"728650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"728650"},{"name":"PDQ_Open_Trial_Search_ID","value":"728650"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3639999"}]}}{"C148528":{"preferredName":"mTORC 1/2 Inhibitor LXI-15029","code":"C148528","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTORC 1/2 Inhibitor LXI-15029","termGroup":"PT","termSource":"NCI"},{"termName":"LXI-15029","termGroup":"CN","termSource":"NCI"},{"termName":"LXI15029","termGroup":"CN","termSource":"NCI"},{"termName":"MTI-31","termGroup":"CN","termSource":"NCI"},{"termName":"SCC-31","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1567915-38-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RM15YYQ1CI"},{"name":"Maps_To","value":"mTORC 1/2 Inhibitor LXI-15029"},{"name":"NCI_Drug_Dictionary_ID","value":"792688"},{"name":"NCI_META_CUI","value":"CL551141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792688"},{"name":"PDQ_Open_Trial_Search_ID","value":"792688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122836":{"preferredName":"mTORC1/2 Kinase Inhibitor BI 860585","code":"C122836","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 kinase inhibitor BI 860585 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTORC1/2 Kinase Inhibitor BI 860585","termGroup":"PT","termSource":"NCI"},{"termName":"BI 860585","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mTORC1/2 Kinase Inhibitor BI 860585"},{"name":"NCI_Drug_Dictionary_ID","value":"753378"},{"name":"NCI_META_CUI","value":"CL471745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753378"},{"name":"PDQ_Open_Trial_Search_ID","value":"753378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117290":{"preferredName":"mTORC1/mTORC2/DHFR Inhibitor ABTL0812","code":"C117290","definitions":[{"definition":"An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, mTORC1/mTORC2/DHFR inhibitor ABTL0812 binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ABTL0812 inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This induces autophagy-induced cell death and further inhibition of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTORC1/mTORC2/DHFR Inhibitor ABTL0812","termGroup":"PT","termSource":"NCI"},{"termName":"9,12-Octadecadienoic Acid, 2-Hydroxy-, (9Z,12Z)-","termGroup":"SY","termSource":"NCI"},{"termName":"ABTL0812","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57818-44-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0DE74TJ7EZ"},{"name":"Maps_To","value":"mTORC1/mTORC2/DHFR Inhibitor ABTL0812"},{"name":"NCI_Drug_Dictionary_ID","value":"763422"},{"name":"NCI_META_CUI","value":"CL474116"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763422"},{"name":"PDQ_Open_Trial_Search_ID","value":"763422"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95722":{"preferredName":"MUC1-targeted Peptide GO-203-2C","code":"C95722","definitions":[{"definition":"An optimized small peptide drug candidate targeting epithelial mucin (MUC1) with antineoplastic activity. MUC1-targeted peptide GO-203-2C interacts with oncoprotein MUC1 C-terminal subunit on the cell surface, thereby impeding cell-cell interactions, signaling, and metastasis. MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is over-expressed in many diverse human carcinomas including those of the breast, prostate, lung, colon, pancreas, and ovary, and has been associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC1-targeted Peptide GO-203-2C","termGroup":"PT","termSource":"NCI"},{"termName":"GO-203-2C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1469735-88-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5YSY733NA3"},{"name":"Maps_To","value":"MUC1-targeted Peptide GO-203-2C"},{"name":"NCI_Drug_Dictionary_ID","value":"694292"},{"name":"NCI_META_CUI","value":"CL428184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694292"},{"name":"PDQ_Open_Trial_Search_ID","value":"694292"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107188":{"preferredName":"Mucoadhesive Paclitaxel Formulation","code":"C107188","definitions":[{"definition":"An orally available, mucoadhesive lipid preparation consisting of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, in a formulation that is comprised of a mixture of monoolein, tricarprylin, and Tween 80, with potential antineoplastic activity. Upon oral administration, DHP107 forms droplets and micelles in the intestine; these adhere to mucoepithelial cells in the gastrointestinal tract and are absorbed through lipid-based uptake mechanisms. Upon absorption, paclitaxel binds to and stabilizes tubulin molecules, which results in the inhibition of both microtubule depolymerization and cell division. This agent also induces apoptosis by both binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2).The mucoadhesive paclitaxel formulation does not contain P-glycoprotein inhibitors, the solvent cremophor or any other toxic solvent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucoadhesive Paclitaxel Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"DHP107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mucoadhesive Paclitaxel Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"750455"},{"name":"NCI_META_CUI","value":"CL449448"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750455"},{"name":"PDQ_Open_Trial_Search_ID","value":"750455"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101786":{"preferredName":"Multi-AGC Kinase Inhibitor AT13148","code":"C101786","definitions":[{"definition":"An orally available, small molecule inhibitor of AGC group kinases, with potential antineoplastic activity. AT13148 inhibits, in an ATP-competitive manner, the enzymatic activity of two AGC kinases, protein kinase B (PKB or AKT) and p70S6K which play key roles in the PI3K/PKB/mTOR signaling pathway. Blockade of this pathway leads to an inhibition of cell growth and the induction of apoptosis in susceptible tumor cells. PI3K/PKB/mTOR pathway is dysregulated in greater than 50% of tumors, and is often correlated with resistance and increased tumor survival. AGC group kinases are serine/threonine kinases that are regulated by secondary messengers such as cyclic AMP and lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-AGC Kinase Inhibitor AT13148","termGroup":"PT","termSource":"NCI"},{"termName":"AT13148","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1056901-62-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A49037RP1E"},{"name":"Maps_To","value":"Multi-AGC Kinase Inhibitor AT13148"},{"name":"NCI_Drug_Dictionary_ID","value":"732857"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732857"},{"name":"PDQ_Open_Trial_Search_ID","value":"732857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640215"}]}}{"C128898":{"preferredName":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200","code":"C128898","definitions":[{"definition":"A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor 1 (FOLR1; FR-alpha), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope anti-folate receptor peptide vaccine TPIV 200 may induce a cytotoxic T-lymphocyte (CTL) response against FR-alpha-overexpressing tumor cells. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200","termGroup":"PT","termSource":"NCI"},{"termName":"TPIV 200","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV 200 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TPIV-200","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV200","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV200/huFR-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200"},{"name":"NCI_Drug_Dictionary_ID","value":"782632"},{"name":"NCI_META_CUI","value":"CL512164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782632"},{"name":"PDQ_Open_Trial_Search_ID","value":"782632"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165292":{"preferredName":"Multi-epitope HER2 Peptide Vaccine H2NVAC","code":"C165292","definitions":[{"definition":"A peptide vaccine containing four immunogenic epitopes derived from the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; HER-2; ErbB2; Neu), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope HER2 peptide vaccine H2NVAC may induce a helper T-cell mediated immune response against HER2-overexpressing tumor cells. This may result in long-term immunopotentiation against HER2-expressing tumor cells by increasing the helper T-cell response. HER2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed in various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-epitope HER2 Peptide Vaccine H2NVAC","termGroup":"PT","termSource":"NCI"},{"termName":"H2NVAC","termGroup":"CN","termSource":"NCI"},{"termName":"HER2 Peptide Vaccine H2NVAC","termGroup":"SY","termSource":"NCI"},{"termName":"HER2 Specific Helper T-cell Epitope Vaccine H2NVAC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-epitope HER2 Peptide Vaccine H2NVAC"},{"name":"NCI_Drug_Dictionary_ID","value":"799763"},{"name":"NCI_META_CUI","value":"CL978527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799763"},{"name":"PDQ_Open_Trial_Search_ID","value":"799763"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124054":{"preferredName":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","code":"C124054","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","termGroup":"PT","termSource":"NCI"},{"termName":"ICT-107","termGroup":"CN","termSource":"NCI"},{"termName":"Multi-glioblastoma-peptide-pulsed Autologous DC Vaccine ICT-107","termGroup":"SY","termSource":"NCI"},{"termName":"Multi-glioblastoma-peptide-targeting Autologous DC Vaccine ICT-107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107"},{"name":"NCI_Drug_Dictionary_ID","value":"776267"},{"name":"NCI_META_CUI","value":"CL498408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776267"},{"name":"PDQ_Open_Trial_Search_ID","value":"776267"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162676":{"preferredName":"Elzovantinib","code":"C162676","definitions":[{"definition":"An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elzovantinib","termGroup":"PT","termSource":"NCI"},{"termName":"MET/Src/CSF1R Tyrosine Kinase Inhibitor TPX-0022","termGroup":"SY","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor TPX-0022","termGroup":"SY","termSource":"NCI"},{"termName":"Multikinase Inhibitor TPX-0022","termGroup":"SY","termSource":"NCI"},{"termName":"TPX 0022","termGroup":"CN","termSource":"NCI"},{"termName":"TPX-0022","termGroup":"CN","termSource":"NCI"},{"termName":"TPX0022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2271119-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TTY12Q00LY"},{"name":"Maps_To","value":"Multi-kinase Inhibitor TPX-0022"},{"name":"NCI_Drug_Dictionary_ID","value":"798966"},{"name":"NCI_META_CUI","value":"CL973112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798966"},{"name":"PDQ_Open_Trial_Search_ID","value":"798966"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161598":{"preferredName":"Zanzalintinib","code":"C161598","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, with potential anti-angiogenesis and antineoplastic activities. Upon oral administration, zanzalintinib targets and binds to c-Met, VEGFR2, AXL and MER, and prevents their RTK activity. This blocks c-Met/VEGFR2/AXL/MER-mediated signal transduction pathways, and inhibits the proliferation and migration of c-Met-, VEGFR2-, AXL- and MER-overexpressing tumor cells. c-Met, overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. VEGFR2, overexpressed in certain tumor types, plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells. AXL and MER, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanzalintinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-(4-((7-methoxy-6-((methylamino)carbonyl)-4-quinolinyl)oxy)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor XL092","termGroup":"SY","termSource":"NCI"},{"termName":"N-(4-Fluorophenyl)-N'-(4-((7-methoxy-6- (methylcarbamoyl)quinolin-4- yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"XL 092","termGroup":"CN","termSource":"NCI"},{"termName":"XL-092","termGroup":"CN","termSource":"NCI"},{"termName":"XL092","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2367004-54-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KC2JC2ZA04"},{"name":"Maps_To","value":"Multi-kinase Inhibitor XL092"},{"name":"NCI_Drug_Dictionary_ID","value":"798432"},{"name":"NCI_META_CUI","value":"CL970131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798432"},{"name":"PDQ_Open_Trial_Search_ID","value":"798432"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164211":{"preferredName":"Multi-mode Kinase Inhibitor EOC317","code":"C164211","definitions":[{"definition":"An orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-mode Kinase Inhibitor EOC317","termGroup":"PT","termSource":"NCI"},{"termName":"ACTB-1003","termGroup":"CN","termSource":"NCI"},{"termName":"EDP317","termGroup":"CN","termSource":"NCI"},{"termName":"EOC 317","termGroup":"CN","termSource":"NCI"},{"termName":"EOC-317","termGroup":"CN","termSource":"NCI"},{"termName":"EOC317","termGroup":"CN","termSource":"NCI"},{"termName":"ONC201MMKI EOC317","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"939805-30-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44750KD9OE"},{"name":"Maps_To","value":"Multi-mode Kinase Inhibitor EOC317"},{"name":"NCI_Drug_Dictionary_ID","value":"799401"},{"name":"NCI_META_CUI","value":"CL977499"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799401"},{"name":"PDQ_Open_Trial_Search_ID","value":"799401"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26645":{"preferredName":"Multi-neo-epitope Vaccine OSE 2101","code":"C26645","definitions":[{"definition":"A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. EP-2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes.  This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called cancer vaccines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multi-neo-epitope Vaccine OSE 2101","termGroup":"PT","termSource":"NCI"},{"termName":"EP-2101","termGroup":"CN","termSource":"NCI"},{"termName":"EP2101","termGroup":"CN","termSource":"NCI"},{"termName":"IDM2101","termGroup":"CN","termSource":"NCI"},{"termName":"OSE-2101","termGroup":"CN","termSource":"NCI"},{"termName":"Tedopi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EP-2101"},{"name":"Maps_To","value":"Multi-neo-epitope Vaccine OSE 2101"},{"name":"NCI_Drug_Dictionary_ID","value":"301640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301640"},{"name":"PDQ_Open_Trial_Search_ID","value":"301640"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2606659"}]}}{"C101260":{"preferredName":"Multifunctional/Multitargeted Anticancer Agent OMN54","code":"C101260","definitions":[{"definition":"An orally available, multivalent herbal formulation containing a novel mixture of whole extracts from three commonly used Chinese medicinal herbs Ganoderma lucidum (lingzhi mushroom), Salvia miltiorrhiza (Chinese sage, or danshen) and Scutellaria barbata (ban zhi lian), with potential immunomodulating, antiangiogenic, anti-inflammatory, antiproliferative and antiviral activities. Although the exact mechanism of action remains to be fully elucidated due to the complexity of the multiple phytochemicals, multifunctional/multitargeted anticancer agent OMN54 appears to work in an additive and synergistic manner by acting on a variety of signaling pathways and on multiple targets, such as vascular endothelial growth factor, nuclear factor kappa B, interleukin-1beta, fibroblast growth factor, and epidermal growth factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multifunctional/Multitargeted Anticancer Agent OMN54","termGroup":"PT","termSource":"NCI"},{"termName":"Aneustat","termGroup":"BR","termSource":"NCI"},{"termName":"MFMT OMN54","termGroup":"SY","termSource":"NCI"},{"termName":"OMN54","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multifunctional/Multitargeted Anticancer Agent OMN54"},{"name":"NCI_Drug_Dictionary_ID","value":"729454"},{"name":"NCI_META_CUI","value":"CL435508"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729454"},{"name":"PDQ_Open_Trial_Search_ID","value":"729454"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90553":{"preferredName":"Multikinase Inhibitor 4SC-203","code":"C90553","definitions":[{"definition":"A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multikinase Inhibitor 4SC-203","termGroup":"PT","termSource":"NCI"},{"termName":"4SC-203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"895533-09-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RFG3GJ6251"},{"name":"Maps_To","value":"Multikinase Inhibitor 4SC-203"},{"name":"NCI_Drug_Dictionary_ID","value":"666086"},{"name":"NCI_META_CUI","value":"CL416237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666086"},{"name":"PDQ_Open_Trial_Search_ID","value":"666086"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66947":{"preferredName":"Multikinase Inhibitor AT9283","code":"C66947","definitions":[{"definition":"A small synthetic molecule and aurora kinase (AK) inhibitor with potential antineoplastic activity. AT9283 selectively binds to and inhibits AKs A and B, which are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of these kinases results in an inhibition of cellular division and proliferation in tumor cells that overexpress AKs.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It blocks enzymes (Aurora kinases) involved in cell division and may kill cancer cells. AT9283 is a type of serine/threonine protein kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multikinase Inhibitor AT9283","termGroup":"PT","termSource":"NCI"},{"termName":"AT9283","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"896466-04-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XAV9KYN9WL"},{"name":"Legacy Concept Name","value":"AT9283"},{"name":"Maps_To","value":"Multikinase Inhibitor AT9283"},{"name":"NCI_Drug_Dictionary_ID","value":"534287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"534287"},{"name":"PDQ_Open_Trial_Search_ID","value":"534287"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879521"}]}}{"C88278":{"preferredName":"Multikinase Inhibitor SAR103168","code":"C88278","definitions":[{"definition":"A multikinase inhibitor with potential antineoplastic activity. Upon intravenous infusion, multikinase inhibitor SAR103168 may, through the inhibition of multiple kinases, inhibit the phosphorylation and activation of signal transducer and activator of transcription 5 (STAT5). STAT5, a protein often upregulated in cancer cells, plays a key role in signal transduction pathways and the suppression of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multikinase Inhibitor SAR103168","termGroup":"PT","termSource":"NCI"},{"termName":"SAR103168","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multikinase Inhibitor SAR103168"},{"name":"NCI_Drug_Dictionary_ID","value":"656309"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656309"},{"name":"PDQ_Open_Trial_Search_ID","value":"656309"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981800"}]}}{"C125692":{"preferredName":"Multipeptide Vaccine S-588210","code":"C125692","definitions":[{"definition":"A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multipeptide Vaccine S-588210","termGroup":"PT","termSource":"NCI"},{"termName":"S-488210/S-488211","termGroup":"SY","termSource":"NCI"},{"termName":"S-588210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multipeptide Vaccine S-588210"},{"name":"NCI_Drug_Dictionary_ID","value":"778596"},{"name":"NCI_META_CUI","value":"CL504368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778596"},{"name":"PDQ_Open_Trial_Search_ID","value":"778596"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77866":{"preferredName":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327","code":"C77866","definitions":[{"definition":"An orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). By inhibiting several different signaling molecules that play crucial roles at various stages in tumorigenesis, this agent may inhibit tumor growth, invasion, migration and metastasis. In addition, JNJ-26483327 crosses the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-26483327","termGroup":"CN","termSource":"NCI"},{"termName":"TKI JNJ-26483327","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"807640-87-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16720VER1H"},{"name":"Legacy Concept Name","value":"Multitargeted_Kinase_Inhibitor_JNJ-26483327"},{"name":"Maps_To","value":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327"},{"name":"NCI_Drug_Dictionary_ID","value":"596693"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596693"},{"name":"PDQ_Open_Trial_Search_ID","value":"596693"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713088"}]}}{"C38690":{"preferredName":"Muparfostat","code":"C38690","definitions":[{"definition":"A mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity. Muparfostat inhibits the endo-beta-D-glucuronidase heparanase, which may interfere with the heparanase-mediated degradation of heparan-sulfate proteoglycans in extracellular matrices, an important step in the metastatic process. This agent may also bind with high affinity to the heparan sulfate-binding domains of vascular endothelial growth factor (VEGF) and fibroblast growth factors 1 and 2, thereby reducing their functional activities and inhibiting VEGF and FGF stimulation of tumor angiogenesis. Increased heparanase activity has been implicated in tumor angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antiangiogenesis agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Muparfostat","termGroup":"PT","termSource":"NCI"},{"termName":"6-O-(dihydrogen Phosphate)-2,3,4-tris-O-(hydrogen Sulfate)-alpha-d-mannopyranosyl-(1->poly(3)-2,4,6-tris-O-(hydrogen Sulfate)-alpha-d-mannopyranosyl-(1->)2)-1,3,4,6-tetrakis-O-(hydrogen Sulfate)-d-mannopyranose","termGroup":"SY","termSource":"NCI"},{"termName":"alpha-D-Mannan, (1->3)-, 6-(Dihydrogen Phosphate) Tris(Hydrogen Sulfate)","termGroup":"SN","termSource":"NCI"},{"termName":"Phosphomannopentose Sulfate PI-88","termGroup":"SY","termSource":"NCI"},{"termName":"PI 88","termGroup":"CN","termSource":"NCI"},{"termName":"PI-88","termGroup":"CN","termSource":"NCI"},{"termName":"Sulfated Phosphomanno-oligosaccharide PI-88","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant melanoma"},{"name":"CAS_Registry","value":"1020105-89-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P2BKS6T40H"},{"name":"Legacy Concept Name","value":"PI-88"},{"name":"Maps_To","value":"Muparfostat"},{"name":"NCI_Drug_Dictionary_ID","value":"339562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"339562"},{"name":"PDQ_Open_Trial_Search_ID","value":"339562"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0769628"}]}}{"C2234":{"preferredName":"Mureletecan","code":"C2234","definitions":[{"definition":"A water-soluble prodrug, consisting of camptothecin covalently linked to polymeric backbone methacryloylglycynamide, with potential antineoplastic activity. After entering tumor cells, the active moiety camptothecin is slowly released from mureletecan via hydrolysis of the ester linkage. Camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces potentially lethal double-stranded DNA breaks when encountered by the DNA replication machinery, resulting in the inhibition of DNA replication and apoptosis. Compared to camtpothecin, this prodrug formulation increases camptothecin drug delivery to the tumor site while reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mureletecan","termGroup":"PT","termSource":"NCI"},{"termName":"MAG-Camptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"MAG-CPT","termGroup":"SY","termSource":"NCI"},{"termName":"PNU 166148","termGroup":"CN","termSource":"NCI"},{"termName":"PNU166148","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"246527-99-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TTJ03QI76T"},{"name":"Legacy Concept Name","value":"PNU_166148"},{"name":"Maps_To","value":"Mureletecan"},{"name":"NCI_Drug_Dictionary_ID","value":"43584"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43584"},{"name":"PDQ_Open_Trial_Search_ID","value":"43584"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527216"}]}}{"C148134":{"preferredName":"Safusidenib","code":"C148134","definitions":[{"definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), with potential antineoplastic activity. Upon oral administration, safusidenib specifically binds to and inhibits certain mutant forms of IDH1, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutations. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. Safusidenib minimally targets and affects wild-type IDH1, which is expressed in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Safusidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AB 218","termGroup":"CN","termSource":"NCI"},{"termName":"AB-218","termGroup":"CN","termSource":"NCI"},{"termName":"AB218","termGroup":"CN","termSource":"NCI"},{"termName":"DS 1001","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1001","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1001b","termGroup":"CN","termSource":"NCI"},{"termName":"Mutant Isocitrate Dehydrogenase Type 1 Inhibitor DS-1001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1898206-17-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RCK8KK7SB9"},{"name":"Maps_To","value":"Mutant IDH1 Inhibitor DS-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"792460"},{"name":"NCI_META_CUI","value":"CL550810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792460"},{"name":"PDQ_Open_Trial_Search_ID","value":"792460"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121951":{"preferredName":"Mutant p53 Activator COTI-2","code":"C121951","definitions":[{"definition":"An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon oral administration, mutant p53 activator COTI-2 targets and binds to the misfolded mutant forms of the p53 protein, which induces a conformational change that normalizes p53 and restores its activity. This induces apoptosis in tumor cells in which the p53 protein is mutated. In addition, COTI-2 inhibits the activation of Akt2 and prevents the activation of the PI3K/AKT/mTOR pathway, thereby inducing apoptosis in cancer cells in which this pathway is overexpressed. p53, a tumor suppressor protein, plays a key role in controlling cellular proliferation and survival. High levels of mutant p53 are seen in many cancers and are associated with uncontrolled cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutant p53 Activator COTI-2","termGroup":"PT","termSource":"NCI"},{"termName":"Coti-2","termGroup":"CN","termSource":"NCI"},{"termName":"COTI2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1039455-84-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BTA1O65BR"},{"name":"Maps_To","value":"Mutant p53 Activator COTI-2"},{"name":"NCI_Drug_Dictionary_ID","value":"772024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772024"},{"name":"PDQ_Open_Trial_Search_ID","value":"772024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053651"}]}}{"C119624":{"preferredName":"Mutant-selective EGFR Inhibitor PF-06459988","code":"C119624","definitions":[{"definition":"An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutant-selective EGFR Inhibitor PF-06459988","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06459988","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1428774-45-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5IE92SK9EB"},{"name":"Maps_To","value":"Mutant-selective EGFR Inhibitor PF-06459988"},{"name":"NCI_Drug_Dictionary_ID","value":"766942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766942"},{"name":"PDQ_Open_Trial_Search_ID","value":"766942"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896788"}]}}{"C162806":{"preferredName":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","code":"C162806","definitions":[{"definition":"An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","termGroup":"SY","termSource":"NCI"},{"termName":"Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-209-FSP","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP"},{"name":"NCI_Drug_Dictionary_ID","value":"800851"},{"name":"NCI_META_CUI","value":"CL973172"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800851"},{"name":"PDQ_Open_Trial_Search_ID","value":"800851"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88279":{"preferredName":"MVA-FCU1 TG4023","code":"C88279","definitions":[{"definition":"A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVA-FCU1 TG4023","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Ankara Virus-Mediated Suicide Gene Delivery Vector TG4023","termGroup":"SY","termSource":"NCI"},{"termName":"TG4023","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MVA-FCU1 TG4023"},{"name":"NCI_Drug_Dictionary_ID","value":"656523"},{"name":"NCI_META_CUI","value":"CL412469"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656523"},{"name":"PDQ_Open_Trial_Search_ID","value":"656523"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123382":{"preferredName":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1","code":"C123382","definitions":[{"definition":"A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient, and a capsule implanted with a genetically modified allogeneic cell line that continuously releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic cell capsules and the autologous irradiated cells isolated from the patient's tumor are co-localized in the patient's tissue. This permits the production of GM-CSF and exposes the immune system to the tumor-associated antigens (TAA) expressed by the autologous tumor cells at the injection site. Local expression of GM-CSF recruits and activates antigen-presenting cells (APC), which induces both antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site of the injection and systemically. This may lead to tumor regression. By using the patient's own irradiated cancer cells as vaccine antigens, the patient's immune system is exposed to the entire repertoire of this individual's TAAs. The encapsulated cell technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine, is a strong immune booster and plays an important role in the activation of immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1","termGroup":"PT","termSource":"NCI"},{"termName":"MVX-ONCO-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1"},{"name":"NCI_Drug_Dictionary_ID","value":"763210"},{"name":"NCI_META_CUI","value":"CL474106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763210"},{"name":"PDQ_Open_Trial_Search_ID","value":"763210"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C115108":{"preferredName":"MYC-targeting siRNA DCR-MYC","code":"C115108","definitions":[{"definition":"A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYC-targeting siRNA DCR-MYC","termGroup":"PT","termSource":"NCI"},{"termName":"DCR-M1711","termGroup":"CN","termSource":"NCI"},{"termName":"DCR-MYC","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MYC-targeting siRNA DCR-MYC"},{"name":"NCI_Drug_Dictionary_ID","value":"759983"},{"name":"NCI_META_CUI","value":"CL472639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759983"},{"name":"PDQ_Open_Trial_Search_ID","value":"759983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118445":{"preferredName":"Mycobacterium tuberculosis Arabinomannan Z-100","code":"C118445","definitions":[{"definition":"An extract from Mycobacterium tuberculosis (M. tuberculosis) containing the polysaccharide arabinomannan, with potential immunostimulating activity. Upon administration of M. tuberculosis arabinomannan Z-100, this agent may activate the immune system by increasing the expression of various cytokines, such as interferon-gamma (IFNg) and interleukin-12. This inhibits the activity of suppressor T-cells, increases T helper 1 cell (Th1) activity and may restore the balance between Th1/Th2 cells. Additionally, Z-100 may inhibit metastasis and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium tuberculosis Arabinomannan Z-100","termGroup":"PT","termSource":"NCI"},{"termName":"Z-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GE82Y78JTT"},{"name":"Maps_To","value":"Mycobacterium tuberculosis Arabinomannan Z-100"},{"name":"NCI_Drug_Dictionary_ID","value":"764997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764997"},{"name":"PDQ_Open_Trial_Search_ID","value":"764997"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0149256"}]}}{"C70969":{"preferredName":"Mycobacterium w","code":"C70969","definitions":[{"definition":"An attenuated strain of Mycobacterium w, a non-pathogenic, rapidly growing, atypical mycobacterium, with non-specific immunopotentiating properties. In addition to sharing a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis, Mycobacterium w (Mw) also shares an immunogenic determinant with prostate specific antigen (PSA). In vitro and in vivo studies have shown that heat-killed Mw can induce significant T-cell responses. This agent may induce host T-cell responses against tumor cells expressing PSA. PSA is a glycoprotein secreted by prostatic epithelial and ductal cells and may be overexpressed in prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium w","termGroup":"PT","termSource":"NCI"},{"termName":"Immuvac","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8R0TB70HKB"},{"name":"Legacy Concept Name","value":"Mycobacterium_w"},{"name":"Maps_To","value":"Mycobacterium w"},{"name":"NCI_Drug_Dictionary_ID","value":"571076"},{"name":"NCI_META_CUI","value":"CL375836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"571076"},{"name":"PDQ_Open_Trial_Search_ID","value":"571076"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C673":{"preferredName":"Mycophenolic Acid","code":"C673","definitions":[{"definition":"An antineoplastic antibiotic derived from various Penicillium fungal species.  Mycophenolic acid is an active metabolite of the prodrug mycophenolate mofetil.  Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate and synthesis of lymphocyte DNA that results in inhibition of lymphocyte proliferation, antibody production, cellular adhesion, and migration of T and B lymphocytes.  Mycophenolic acid also has antibacterial, antifungal, and antiviral activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycophenolic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"Acide mycophenolique","termGroup":"SY","termSource":"NCI"},{"termName":"Acido micofenolico","termGroup":"SY","termSource":"NCI"},{"termName":"Acidum mycophenolicum","termGroup":"SY","termSource":"NCI"},{"termName":"Lilly-68618","termGroup":"CN","termSource":"NCI"},{"termName":"Ly 68618","termGroup":"CN","termSource":"NCI"},{"termName":"MPA","termGroup":"AB","termSource":"NCI"},{"termName":"Myfortic","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prophylaxis of organ rejection after allogenic renal; cardiac; or hepatic transplants; psoriasis"},{"name":"CAS_Registry","value":"24280-93-1"},{"name":"CAS_Registry","value":"483-60-3"},{"name":"CHEBI_ID","value":"CHEBI:168396"},{"name":"Chemical_Formula","value":"C17H20O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HU9DX48N0T"},{"name":"Legacy Concept Name","value":"Mycophenolic_Acid"},{"name":"Maps_To","value":"Mycophenolic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"732227"},{"name":"NSC Number","value":"129185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732227"},{"name":"PDQ_Open_Trial_Search_ID","value":"732227"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026933"}]}}{"C44168":{"preferredName":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea","code":"C44168","definitions":[{"definition":"An orally available isoxazole urea with potential anti-tumor activity.  In preclinical trials, N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl)urea inhibited raf kinase, an enzyme capable of reversing the phenotype of ras-transformed cells and blocking tumor growth. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea","termGroup":"PT","termSource":"NCI"},{"termName":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl)urea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N-_5-tert-butyl-3-isoxazolyl_-N-_4-_4-pyridinyl_oxyphenyl_-Urea"},{"name":"Maps_To","value":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517613"}]}}{"C1163":{"preferredName":"N-Methylformamide","code":"C1163","definitions":[{"definition":"A water-soluble organic solvent.  As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N-Methylformamide","termGroup":"PT","termSource":"NCI"},{"termName":"EK 7011","termGroup":"CN","termSource":"NCI"},{"termName":"Formamide, N-methyl","termGroup":"SY","termSource":"NCI"},{"termName":"formylmethylamine","termGroup":"SY","termSource":"NCI"},{"termName":"monomethylformamide","termGroup":"SY","termSource":"NCI"},{"termName":"NMF","termGroup":"AB","termSource":"NCI"},{"termName":"X 188","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123-39-7"},{"name":"CHEBI_ID","value":"CHEBI:7438"},{"name":"Chemical_Formula","value":"C2H5NO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XPE4G7Y986"},{"name":"Legacy Concept Name","value":"N-Methylformamide"},{"name":"Maps_To","value":"N-Methylformamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39511"},{"name":"NSC Number","value":"3051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39511"},{"name":"PDQ_Open_Trial_Search_ID","value":"39511"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066373"}]}}{"C2084":{"preferredName":"N,N-Dibenzyl Daunomycin","code":"C2084","definitions":[{"definition":"The N-alkylated analogue of the anthracycline antineoplastic antibiotic daunomycin.  N,N-Dibenzyl Daunomycin interacts with topoisomerase II, thereby inhibiting DNA replication and repair and promoting DNA fragmentation.  This agent is less cardiotoxic than daunomycin. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N,N-Dibenzyl Daunomycin","termGroup":"PT","termSource":"NCI"},{"termName":"N,N-dibenzyl daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-dibenzyldaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-dibenzyldaunorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N_N-Dibenzyl_Daunomycin"},{"name":"Maps_To","value":"N,N-Dibenzyl Daunomycin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0067345"}]}}{"C37450":{"preferredName":"NA17-A Antigen","code":"C37450","definitions":[{"definition":"A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyltransferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NA17-A Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"NA17-A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NA17-A_Antigen"},{"name":"Maps_To","value":"NA17-A Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"38647"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38647"},{"name":"PDQ_Open_Trial_Search_ID","value":"38647"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134655"}]}}{"C2680":{"preferredName":"NA17.A2 Peptide Vaccine","code":"C2680","definitions":[{"definition":"A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NA17.A2 Peptide Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NA17.A2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NA17_A2_Antigen"},{"name":"Maps_To","value":"NA17.A2 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"685201"},{"name":"NCI_META_CUI","value":"CL423775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685201"},{"name":"PDQ_Open_Trial_Search_ID","value":"685201"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C2688":{"preferredName":"Nab-paclitaxel","code":"C2688","definitions":[{"definition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat breast cancer that has spread or that has come back within 6 months after chemotherapy. It is also being studied in the treatment of newly diagnosed breast cancer and other types of cancer. ABI-007 is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nab-paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"ABI 007","termGroup":"CN","termSource":"NCI"},{"termName":"ABI-007","termGroup":"CN","termSource":"NCI"},{"termName":"Abraxane","termGroup":"BR","termSource":"NCI"},{"termName":"Albumin-bound Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Albumin-Stabilized Nanoparticle Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Albumin-bound Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel Albumin","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel Nanoparticle Albumin-bound","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel Protein-Bound","termGroup":"SY","termSource":"NCI"},{"termName":"Protein-bound Paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic breast cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"ABI-007"},{"name":"Maps_To","value":"Nab-paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"38690"},{"name":"NSC Number","value":"736631"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38690"},{"name":"PDQ_Open_Trial_Search_ID","value":"38690"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134696"}]}}{"C131213":{"preferredName":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","code":"C131213","definitions":[{"definition":"A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","termGroup":"PT","termSource":"NCI"},{"termName":"Abraxane coated with Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"Abraxane Coated with Rituximab 160nm Nanoparticle","termGroup":"SY","termSource":"NCI"},{"termName":"Abraxane/Rituxan 160 Complex","termGroup":"SY","termSource":"NCI"},{"termName":"AR160","termGroup":"CN","termSource":"NCI"},{"termName":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160"},{"name":"NCI_Drug_Dictionary_ID","value":"786023"},{"name":"NCI_META_CUI","value":"CL514179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786023"},{"name":"PDQ_Open_Trial_Search_ID","value":"786023"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71011":{"preferredName":"Nadofaragene Firadenovec","code":"C71011","definitions":[{"definition":"A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nadofaragene Firadenovec","termGroup":"PT","termSource":"NCI"},{"termName":"Adstiladrin","termGroup":"BR","termSource":"NCI"},{"termName":"Instiladrin","termGroup":"BR","termSource":"NCI"},{"termName":"Nadofaragene Firadenovec-vncg","termGroup":"SY","termSource":"NCI"},{"termName":"Nadofaragene Firadenovec/Syn3","termGroup":"SY","termSource":"NCI"},{"termName":"rAd-IFN","termGroup":"AB","termSource":"NCI"},{"termName":"rAd-IFN-2b","termGroup":"AB","termSource":"NCI"},{"termName":"rAd-IFN/Syn3","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Adenovirus-Interferon SCH 721015","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Adenovirus-Interferon With Syn3","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Adenovirus-Interferon/Syn3","termGroup":"SY","termSource":"NCI"},{"termName":"SCH 721015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors."},{"name":"CAS_Registry","value":"1823059-12-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0OOS09O1FH"},{"name":"Legacy Concept Name","value":"Recombinant_Adenovirus-Interferon_SCH_721015"},{"name":"Maps_To","value":"Nadofaragene Firadenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"573538"},{"name":"NCI_META_CUI","value":"CL376219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573538"},{"name":"PDQ_Open_Trial_Search_ID","value":"573538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83981":{"preferredName":"Namirotene","code":"C83981","definitions":[{"definition":"A synthetic analogue of retinoic acid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, namirotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Namirotene","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101506-83-6"},{"name":"Chemical_Formula","value":"C17H18O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1FG8FGL0YI"},{"name":"Maps_To","value":"Namirotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827271"}]}}{"C79826":{"preferredName":"Namodenoson","code":"C79826","definitions":[{"definition":"An orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity. Namodenoson selectively binds to and activates the cell surface-expressed A3AR, deregulating Wnt and NF-kB signal transduction pathways downstream, which may result in apoptosis of A3AR-expressing tumor cells. A3AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of various solid tumor cell types, including hepatocellular carcinoma (HCC) cells, and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Namodenoson","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide","termGroup":"SN","termSource":"NCI"},{"termName":"2-Cl-IB-MECA","termGroup":"AB","termSource":"NCI"},{"termName":"A3AdR Agonist CF102","termGroup":"SY","termSource":"NCI"},{"termName":"Adenosine Receptor A3 Agonist CF102","termGroup":"SY","termSource":"NCI"},{"termName":"beta-D-Ribofuranuronamide, 1-(2-Chloro-6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-1-deoxy-N-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"C-Ibza-MU","termGroup":"AB","termSource":"NCI"},{"termName":"CF102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"163042-96-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z07JR07J6C"},{"name":"Legacy Concept Name","value":"Adenosine_A3_Receptor_Agonist_CF102"},{"name":"Maps_To","value":"Namodenoson"},{"name":"NCI_Drug_Dictionary_ID","value":"626663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626663"},{"name":"PDQ_Open_Trial_Search_ID","value":"626663"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0289969"}]}}{"C162742":{"preferredName":"NAMPT Inhibitor OT-82","code":"C162742","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon oral administration, NAMPT inhibitor OT-82 binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in cell death in NAMPT-overexpressing cancer cells. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is overexpressed in a variety of cancers and metabolic disorders; tumor cells rely on NAMPT activity for their NAD supply.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NAMPT Inhibitor OT-82","termGroup":"PT","termSource":"NCI"},{"termName":"NAMPTi OT-82","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotinamide Phosphoribosyltransferase Inhibitor OT-82","termGroup":"SY","termSource":"NCI"},{"termName":"OT 82","termGroup":"CN","termSource":"NCI"},{"termName":"OT-82","termGroup":"CN","termSource":"NCI"},{"termName":"OT82","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NAMPT Inhibitor OT-82"},{"name":"NCI_Drug_Dictionary_ID","value":"798968"},{"name":"NCI_META_CUI","value":"CL973230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798968"},{"name":"PDQ_Open_Trial_Search_ID","value":"798968"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C72594":{"preferredName":"Nanafrocin","code":"C72594","definitions":[{"definition":"A quinone antibiotic isolated from Streptomyces rosa var. notoensis with activity against gram-positive bacteria, mycoplasmas and fungi. Within an organism, nanaomycin A is first reduced by flavin or NADH dehydrogenase then rapidly autooxidized leading to the production of singlet molecular oxygen (O2-). The increase in intracellular O2- results in inhibition of DNA, RNA and cell-wall peptidoglycan synthesis. Further, nanaomycin A may have antineoplastic properties resulting from a reduction in DNA methylation by inhibiting DNA methyltransferase 3B (DNMT3B) and reactivating the tumor suppressor gene RASSF1A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanafrocin","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3R)-3,4,5,10-Tetrahydro-9-hydroxy-1-methyl-5,10-dioxo-1H-naphtho[2,3-c]pyran-3-acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Nanaomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"OS 3966-A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52934-83-5"},{"name":"CHEBI_ID","value":"CHEBI:48202"},{"name":"Chemical_Formula","value":"C16H14O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8XBV72641V"},{"name":"Legacy Concept Name","value":"Nanafrocin"},{"name":"Maps_To","value":"Nanafrocin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068391"}]}}{"C78475":{"preferredName":"Nanatinostat","code":"C78475","definitions":[{"definition":"An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC), with potential antineoplastic activity. Nanatinostat targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanatinostat","termGroup":"PT","termSource":"NCI"},{"termName":"5-Pyrimidinecarboxamide, 2-((1Alpha,5alpha,6alpha)-6-(((6-fluoro-2-quinolinyl)methyl)amino)-3-azabicyclo(3.1.0)hex-3-yl)-N-hydroxy-","termGroup":"SY","termSource":"NCI"},{"termName":"CHR 3996","termGroup":"CN","termSource":"NCI"},{"termName":"CHR-3996","termGroup":"CN","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor VRx-3996","termGroup":"SY","termSource":"NCI"},{"termName":"VRx 3996","termGroup":"CN","termSource":"NCI"},{"termName":"VRx-3996","termGroup":"CN","termSource":"NCI"},{"termName":"VRx3996","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10911","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1235859-13-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YTL7A418KQ"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_CHR-3996"},{"name":"Maps_To","value":"Nanatinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"600512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600512"},{"name":"PDQ_Open_Trial_Search_ID","value":"600512"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703120"}]}}{"C121214":{"preferredName":"Nanocell-encapsulated miR-16-based microRNA Mimic","code":"C121214","definitions":[{"definition":"A nanoparticle-based formulation composed of a microRNA 16 (miR-16) mimic, a double-stranded, 23 base pair, synthetic RNA molecule, encapsulated in nonliving bacterial minicells and coated with anti-epidermal growth factor receptor (EGFR) antibodies, with potential antineoplastic activity. Upon intravenous administration and subsequent transfection, nanocell-encapsulated miR-16-based microRNA mimic targets EGFR-expressing tumor cells and facilitates the restoration of expression of the miR-16 family. This leads to the downregulation of the expression of tumor promoting genes and the inhibition of tumor cell growth. In addition, restoration of miR-16 expression sensitizes the tumor cell to certain chemotherapeutic agents. miR-16, a family of microRNAs, is critical to the regulation of gene expression and appears to have a tumor suppressor function; its expression is downregulated in various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanocell-encapsulated miR-16-based microRNA Mimic","termGroup":"PT","termSource":"NCI"},{"termName":"TargomiRs","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanocell-encapsulated miR-16-based microRNA Mimic"},{"name":"NCI_Drug_Dictionary_ID","value":"769608"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769608"},{"name":"PDQ_Open_Trial_Search_ID","value":"769608"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054425"}]}}{"C71696":{"preferredName":"Nanoparticle Albumin-Bound Docetaxel","code":"C71696","definitions":[{"definition":"A nanoparticle albumin-bound formulation of the taxane docetaxel with antineoplastic activity. Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. This nanoparticle albumin-bound formulation solubilizes docetaxel without the use of the nonionic solubilizer Cremophor ELP, permitting the administration of larger doses of docetaxel while avoiding Cremophor ELP-associated toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle Albumin-Bound Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"ABI-008","termGroup":"CN","termSource":"NCI"},{"termName":"CPO 100","termGroup":"CN","termSource":"NCI"},{"termName":"CPO-100","termGroup":"CN","termSource":"NCI"},{"termName":"CPO100","termGroup":"CN","termSource":"NCI"},{"termName":"Docetaxel Albumin-bound","termGroup":"SY","termSource":"NCI"},{"termName":"DTX-HSA","termGroup":"AB","termSource":"NCI"},{"termName":"Nab-Docetaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nanoparticle_Albumin-Bound_Docetaxel"},{"name":"Maps_To","value":"Nanoparticle Albumin-Bound Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"557567"},{"name":"NCI_META_CUI","value":"CL376119"},{"name":"PDQ_Closed_Trial_Search_ID","value":"557567"},{"name":"PDQ_Open_Trial_Search_ID","value":"557567"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74065":{"preferredName":"Sirolimus Albumin-bound Nanoparticles","code":"C74065","definitions":[{"definition":"The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirolimus Albumin-bound Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"ABI-009","termGroup":"CN","termSource":"NCI"},{"termName":"Albumin-bound Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Fyarro","termGroup":"BR","termSource":"NCI"},{"termName":"Nab-Rapamycin","termGroup":"AB","termSource":"NCI"},{"termName":"Nab-sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Albumin-Bound Rapamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Albumin-bound Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Sirolimus Albumin-bound Particles","termGroup":"SY","termSource":"NCI"},{"termName":"Sirolimus Protein-bound Particles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"dult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Nanoparticle_Albumin-Bound_Rapamycin"},{"name":"Maps_To","value":"Nanoparticle Albumin-Bound Rapamycin"},{"name":"NCI_Drug_Dictionary_ID","value":"583541"},{"name":"NCI_META_CUI","value":"CL383470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583541"},{"name":"PDQ_Open_Trial_Search_ID","value":"583541"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116890":{"preferredName":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404","code":"C116890","definitions":[{"definition":"A nanoparticle albumin-bound formulation of a thiocolchicine dimer, an inhibitor of both microtubule and topoisomerase I (TOP1), with antineoplastic and vascular disrupting activities. Upon administration of nanoparticle albumin-bound thiocolchicine dimer nab-5404, this agent binds to tubulin and inhibits its polymerization, which blocks mitotic spindle formation and leads to cell cycle arrest and tumor endothelial cell apoptosis. This disrupts the tumor vasculature and leads to tumor necrosis. In addition, nab-5404 binds to topoisomerase I (TOPI) and inhibits its activity. This results in the inhibition of the repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. The nanoparticle albumin-based formulation permits the albumin-mediated endocytosis of the thiocolchicine dimer by tumor cells and endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404","termGroup":"PT","termSource":"NCI"},{"termName":"ABI-011","termGroup":"CN","termSource":"NCI"},{"termName":"IDN 5404","termGroup":"CN","termSource":"NCI"},{"termName":"nab-5404","termGroup":"CN","termSource":"NCI"},{"termName":"nab-Thiocolchicine Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"NTB-011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"361169-05-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5C3JG9RQU3"},{"name":"Maps_To","value":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404"},{"name":"NCI_Drug_Dictionary_ID","value":"682217"},{"name":"NCI_META_CUI","value":"CL421664"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682217"},{"name":"PDQ_Open_Trial_Search_ID","value":"682217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146821":{"preferredName":"Nanoparticle Paclitaxel Ointment SOR007","code":"C146821","definitions":[{"definition":"A topical ointment composed of the water-insoluble taxane paclitaxel that has been processed to form uncoated nanoparticles, with potential antineoplastic activity. Upon topical administration of nanoparticle paclitaxel ointment SOR007 to the affected area, and following epithelial and dermal penetration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The nanoparticles in the nanoparticle paclitaxel ointment are produced through a specific proprietary submicron particle production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle Paclitaxel Ointment SOR007","termGroup":"PT","termSource":"NCI"},{"termName":"NanoPac Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Nanopartcle Paclitaxel SOR007","termGroup":"SY","termSource":"NCI"},{"termName":"SOR007","termGroup":"CN","termSource":"NCI"},{"termName":"SOR007 Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Topical Nanoparticle Paclitaxel Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Uncoated Nanoparticle Paclitaxel Ointment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoparticle Paclitaxel Ointment SOR007"},{"name":"NCI_Drug_Dictionary_ID","value":"792258"},{"name":"NCI_META_CUI","value":"CL544868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792258"},{"name":"PDQ_Open_Trial_Search_ID","value":"792258"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118648":{"preferredName":"Nanoparticle-based Paclitaxel Suspension","code":"C118648","definitions":[{"definition":"A nanoparticle-based suspension containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intraperitoneal administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division. The nanoparticle-based formulation is devoid of toxic solvents, such as cremophor; therefore, this agent has fewer side effects than the standard, solvent-based paclitaxel formulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle-based Paclitaxel Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"Nanotax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoparticle-based Paclitaxel Suspension"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3898158"}]}}{"C102875":{"preferredName":"Nanoparticle-encapsulated Doxorubicin Hydrochloride","code":"C102875","definitions":[{"definition":"A formulation of nanoparticles encapsulating the hydrochloride salt form of the anthracycline antibiotic doxorubicin, with potential antitumor activity. Upon intravenous administration, doxorubicin intercalates DNA, interferes with the activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle-encapsulated Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BA-003","termGroup":"CN","termSource":"NCI"},{"termName":"Doxorubicin Transdrug","termGroup":"FB","termSource":"NCI"},{"termName":"Livatag","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoparticle-encapsulated Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"738259"},{"name":"NCI_META_CUI","value":"CL437178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738259"},{"name":"PDQ_Open_Trial_Search_ID","value":"738259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157499":{"preferredName":"Nanoscale Coordination Polymer Nanoparticles CPI-100","code":"C157499","definitions":[{"definition":"A preparation of self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles containing an as of yet undisclosed payload with potential immunostimulating and antineoplastic activities. Upon intravenous administration, NCP nanoparticle formulation CPI-100 delivers its payload to tumor cells, which may lead to enhanced immune-mediated killing and regression of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoscale Coordination Polymer Nanoparticles CPI-100","termGroup":"PT","termSource":"NCI"},{"termName":"CPI 100","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-100","termGroup":"CN","termSource":"NCI"},{"termName":"CPI100","termGroup":"CN","termSource":"NCI"},{"termName":"NCP Nanoparticles CPI-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoscale Coordination Polymer Nanoparticles CPI-100"},{"name":"NCI_Drug_Dictionary_ID","value":"796802"},{"name":"NCI_META_CUI","value":"CL937066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796802"},{"name":"PDQ_Open_Trial_Search_ID","value":"796802"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111570":{"preferredName":"Nanosomal Docetaxel Lipid Suspension","code":"C111570","definitions":[{"definition":"A lipid-based nanosomal formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel, with potential antineoplastic activity. Upon intravenous injection, docetaxel binds to and stabilizes tubulin, which inhibits microtubule disassembly and results in both cell cycle arrest at the G2/M phase and cell death. This liposomal formulation solubilizes docetaxel without the use of toxic solvents, such as polysorbate 80. This permits the administration of larger doses of docetaxel and improves the drug's safety profile by avoiding solvent-associated toxicities, such as hypersensitivity reactions and neurotoxicity. In addition, the nanosomal lipid-based delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, all of which prolong the duration of docetaxel's therapeutic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanosomal Docetaxel Lipid Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"DTX-LNS","termGroup":"AB","termSource":"NCI"},{"termName":"NDLS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanosomal Docetaxel Lipid Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"752055"},{"name":"NCI_META_CUI","value":"CL453978"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752055"},{"name":"PDQ_Open_Trial_Search_ID","value":"752055"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96429":{"preferredName":"Napabucasin","code":"C96429","definitions":[{"definition":"An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Napabucasin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Acetylnaphtho(2,3-b)furan-4,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"BB608","termGroup":"CN","termSource":"NCI"},{"termName":"BBI-608","termGroup":"CN","termSource":"NCI"},{"termName":"BBI608","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83280-65-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z1HHM49K7O"},{"name":"Maps_To","value":"Napabucasin"},{"name":"NCI_Drug_Dictionary_ID","value":"698351"},{"name":"NCI_META_CUI","value":"CL429115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698351"},{"name":"PDQ_Open_Trial_Search_ID","value":"698351"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102850":{"preferredName":"Naphthalimide Analogue UNBS5162","code":"C102850","definitions":[{"definition":"An amonafide (naphthalimide) derivative and pan-antagonist of chemokine ligand (CXCL) expression, with potential anti-angiogenic activity. Although UNBS5162 is a derivative of amonafide, this agent appears to have a different profile to that of amonafide and its exact mechanism of action remains to be fully elucidated. This agent seems to decrease the expression of various proangiogenic CXCL chemokines in vitro and may have synergistic effects with radiotherapy or chemotherapy. CXCLs are small cytokines in the CXC chemokine family that are overexpressed in certain cancers; CXCL-mediated signaling plays a key role in angiogenesis and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naphthalimide Analogue UNBS5162","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-(2-(Dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"UNBS5162","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"956590-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JY9JF7D78N"},{"name":"Maps_To","value":"Naphthalimide Analogue UNBS5162"},{"name":"NCI_Drug_Dictionary_ID","value":"737303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737303"},{"name":"PDQ_Open_Trial_Search_ID","value":"737303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2603824"}]}}{"C95789":{"preferredName":"Naptumomab Estafenatox","code":"C95789","definitions":[{"definition":"A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120), with immunomodulating and antineoplastic activities. The Fab moiety of naptumomab estafenatox binds to 5T4, an antigen expressed by various tumor cells. In turn, the superantigen binds to both major histocompatibility complex class II molecules and to the T-cell receptor beta chain, which results in a massive activation of T lymphocytes and induces a potent T-cell-mediated killing of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naptumomab Estafenatox","termGroup":"PT","termSource":"NCI"},{"termName":"ABR-217620","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"676258-98-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"93T929W6LC"},{"name":"Maps_To","value":"Naptumomab Estafenatox"},{"name":"NCI_Drug_Dictionary_ID","value":"355730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355730"},{"name":"PDQ_Open_Trial_Search_ID","value":"355730"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742795"}]}}{"C115110":{"preferredName":"Naquotinib","code":"C115110","definitions":[{"definition":"An orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naquotinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinecarboxamide, 6-Ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"ASP8273","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448232-80-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"47DD4548PB"},{"name":"Maps_To","value":"Naquotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"760029"},{"name":"NCI_META_CUI","value":"CL472641"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760029"},{"name":"PDQ_Open_Trial_Search_ID","value":"760029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91382":{"preferredName":"Narnatumab","code":"C91382","definitions":[{"definition":"A fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor), with potential antineoplastic activity. Anti-RON monoclonal antibody IMC-RON8 binds to RON, thereby preventing binding of its ligand hepatocyte growth factor-like protein (HGFL or macrophage-stimulating protein (MSP)). This may prevent RON receptor-mediated signaling and may prevent cellular proliferation in tumor cells overexpressing RON. RON, a receptor tyrosine kinase, is overexpressed in a variety of epithelial cancer cell types and plays an important role in cellular proliferation, migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Narnatumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-RON Monoclonal Antibody IMC-RON8","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-RON8","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188275-92-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R42YK40U9M"},{"name":"Maps_To","value":"Narnatumab"},{"name":"NCI_Drug_Dictionary_ID","value":"673714"},{"name":"NCI_META_CUI","value":"CL421584"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673714"},{"name":"PDQ_Open_Trial_Search_ID","value":"673714"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77862":{"preferredName":"Natalizumab","code":"C77862","definitions":[{"definition":"A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities.  Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue.  Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Natalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"AN100226","termGroup":"CN","termSource":"NCI"},{"termName":"Antegren","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-alph4 Integrin Monoclonal Antibody AN100226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VLA4","termGroup":"AB","termSource":"NCI"},{"termName":"Tysabri","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple sclerosis, Crohn's disease"},{"name":"CAS_Registry","value":"189261-10-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3JB47N2Q2P"},{"name":"Legacy Concept Name","value":"Natalizumab"},{"name":"Maps_To","value":"Natalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"596513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596513"},{"name":"PDQ_Open_Trial_Search_ID","value":"596513"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1172734"}]}}{"C71159":{"preferredName":"Natural IFN-alpha OPC-18","code":"C71159","definitions":[{"definition":"A proprietary preparation of natural human interferon alpha (IFN alpha) with potential immunomodulatory and antineoplastic activities. Natural human interferon alpha OPC-18 binds to cell-surface IFN alpha receptors (IFNARs), resulting in the transcription and translation of genes whose products mediate antiviral, antiproliferative, and immune-modulating effects. IFN alpha is a type I interferon produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products and is the primary interferon produced by virus-induced leukocyte cultures. In addition to its pronounced antiviral activity, it activates NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Natural IFN-alpha OPC-18","termGroup":"PT","termSource":"NCI"},{"termName":"nIFN-alpha OPC-18","termGroup":"AB","termSource":"NCI"},{"termName":"OPC-18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Natural_IFN-alpha_OPC-18"},{"name":"Maps_To","value":"Natural IFN-alpha OPC-18"},{"name":"NCI_Drug_Dictionary_ID","value":"571792"},{"name":"NCI_META_CUI","value":"CL376209"},{"name":"PDQ_Closed_Trial_Search_ID","value":"571792"},{"name":"PDQ_Open_Trial_Search_ID","value":"571792"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85466":{"preferredName":"Natural Killer Cells ZRx101","code":"C85466","definitions":[{"definition":"A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Natural Killer Cells ZRx101","termGroup":"PT","termSource":"NCI"},{"termName":"NK Cells ZRx101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Killer Cells ZRx101"},{"name":"NCI_Drug_Dictionary_ID","value":"643814"},{"name":"NCI_META_CUI","value":"CL412341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643814"},{"name":"PDQ_Open_Trial_Search_ID","value":"643814"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156730":{"preferredName":"Navarixin","code":"C156730","definitions":[{"definition":"An orally available small molecule antagonist of the C-X-C motif chemokine receptor 1 (CXCR1; interleukin-8 receptor alpha; IL8RA) and 2 (CXCR2; interleukin-8 receptor beta; IL8RB), with potential immunomodulating and antineoplastic activities. Upon administration, navarixin binds to and inhibits the activation of CXCR 1 and 2. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR 1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance, myeloid cell suppression, and inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navarixin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Hydroxy-N,N-dimethyl-3-((2-((1R)-1-(5-methylfuran-2-yl)propyl)amine)-3,4- dioxocyclobut-1-enyl)amino)benzamide Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"MK-7123","termGroup":"CN","termSource":"NCI"},{"termName":"PS291822","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 527123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"862464-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7V3BY6G538"},{"name":"Maps_To","value":"Navarixin"},{"name":"NCI_Drug_Dictionary_ID","value":"795588"},{"name":"NCI_META_CUI","value":"CL935858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795588"},{"name":"PDQ_Open_Trial_Search_ID","value":"795588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64776":{"preferredName":"Navitoclax","code":"C64776","definitions":[{"definition":"A substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying. It is a type of Bcl-2 family inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active, synthetic small molecule and an antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. Navitoclax selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w, which are frequently overexpressed in a wide variety of cancers, including those of the lymph, breast, lung, prostate, and colon, and are linked to tumor drug resistance. Inhibition of these apoptosis suppressors prevents their binding to the apoptotic effectors Bax and Bak proteins, thereby triggering apoptotic processes in cells overexpressing Bcl-2, Bcl-XL, and Bcl-w. This eventually reduces tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navitoclax","termGroup":"PT","termSource":"NCI"},{"termName":"A-855071.0","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-263","termGroup":"CN","termSource":"NCI"},{"termName":"BcI-2 Family Protein Inhibitor ABT-263","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923564-51-6"},{"name":"Chemical_Formula","value":"C47H55ClF3N5O6S3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XKJ5VVK2WD"},{"name":"Legacy Concept Name","value":"ABT-263"},{"name":"Maps_To","value":"Navitoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"523413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"523413"},{"name":"PDQ_Open_Trial_Search_ID","value":"523413"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2975395"}]}}{"C113793":{"preferredName":"Navoximod","code":"C113793","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, navoximod targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and plays an important role in immunosuppression. Tryptophan depletion is associated with immunosuppression caused by T-cell suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navoximod","termGroup":"PT","termSource":"NCI"},{"termName":"5H-Imidazo(5,1-a)isoindole-5-ethanol, 6-Fluoro-alpha-(trans-4-hydroxycyclohexyl)-, (AlphaR,5S)-","termGroup":"SN","termSource":"NCI"},{"termName":"GDC-0919","termGroup":"CN","termSource":"NCI"},{"termName":"NLG-919","termGroup":"CN","termSource":"NCI"},{"termName":"NLG919","termGroup":"CN","termSource":"NCI"},{"termName":"RG6078","termGroup":"CN","termSource":"NCI"},{"termName":"RO7077339-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402837-78-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"926SHL95NC"},{"name":"Maps_To","value":"Navoximod"},{"name":"NCI_Drug_Dictionary_ID","value":"757383"},{"name":"NCI_META_CUI","value":"CL471774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757383"},{"name":"PDQ_Open_Trial_Search_ID","value":"757383"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111687":{"preferredName":"Navy Bean Powder","code":"C111687","definitions":[{"definition":"The powder form of the cooked navy bean with potential antioxidant and chemopreventive activities. Navy beans are rich in fiber, minerals, vitamins, and phytochemicals such as flavonoids and phytosterols. They appear to prevent carcinogenesis by inducing tumor cell apoptosis. Intake of navy bean powder may have a beneficial effect on intestinal microflora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navy Bean Powder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Navy Bean Powder"},{"name":"NCI_Drug_Dictionary_ID","value":"752815"},{"name":"NCI_META_CUI","value":"CL454077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752815"},{"name":"PDQ_Open_Trial_Search_ID","value":"752815"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123428":{"preferredName":"Naxitamab","code":"C123428","definitions":[{"definition":"A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naxitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized","termGroup":"SY","termSource":"NCI"},{"termName":"Danyelza","termGroup":"BR","termSource":"NCI"},{"termName":"Hu3F8","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-GD2 Antibody 3F8","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Monoclonal Antibody Hu3f8-IGG1","termGroup":"SY","termSource":"NCI"},{"termName":"Naxitamab-gqgk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"high-risk neuroblastoma in bone or bone marrow"},{"name":"CAS_Registry","value":"1879925-92-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9K8GNJ2874"},{"name":"Maps_To","value":"Naxitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"778692"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778692"},{"name":"PDQ_Open_Trial_Search_ID","value":"778692"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054758"}]}}{"C115109":{"preferredName":"Nazartinib","code":"C115109","definitions":[{"definition":"An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nazartinib","termGroup":"PT","termSource":"NCI"},{"termName":"EGF 816","termGroup":"CN","termSource":"NCI"},{"termName":"EGF816","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1508250-71-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KE7K32EME8"},{"name":"Maps_To","value":"Nazartinib"},{"name":"NCI_Drug_Dictionary_ID","value":"760001"},{"name":"NCI_META_CUI","value":"CL472640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760001"},{"name":"PDQ_Open_Trial_Search_ID","value":"760001"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123825":{"preferredName":"Mulnitorsen","code":"C123825","definitions":[{"definition":"A proprietary antisense oligonucleotide targeting a novel non-coding mitochondrial RNA (ncmtRNA), with potential antineoplastic activity. Upon administration, mulnitorsen binds to ncmtRNA, which is overexpressed in rapidly proliferating cells, such as cancer cells, and not expressed in resting cells. This may decrease the expression of the ncmtRNA, which may inhibit cell proliferation and eventually induce apoptosis in susceptible cancer cells. The proprietary mitochondrial RNA (mtRNA) belongs to the family of non-coding RNAs (ncRNA); it contains an inverted repeat (IR) of 815 nucleotides (nt), which can form a covalent link to the 5' end of the mitochondrial 16S ribosomal RNA (16S mtrRNA).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mulnitorsen","termGroup":"PT","termSource":"NCI"},{"termName":"Andes-1537","termGroup":"CN","termSource":"NCI"},{"termName":"ncmtRNA Oligonucleotide Andes-1537","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2576358-63-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0DYR6BJ4AG"},{"name":"Maps_To","value":"ncmtRNA Oligonucleotide Andes-1537"},{"name":"NCI_Drug_Dictionary_ID","value":"775628"},{"name":"NCI_META_CUI","value":"CL498219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775628"},{"name":"PDQ_Open_Trial_Search_ID","value":"775628"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88281":{"preferredName":"Necitumumab","code":"C88281","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-11F8","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor (Receptor Tyrosine-Protein Kinase ErbB-1, EC 2.7.10.1)); Human Monoclonal IMC-11F8 Gamma1 Heavy Chain (224-214')-Disulfide with Human Monoclonal IMC-11F8 Kappa Light Chain, Dimer (230- 230'':233-233'')-Bisdisulfide","termGroup":"SY","termSource":"NCI"},{"termName":"Portrazza","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic squamous non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"906805-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2BT4C47RUI"},{"name":"Maps_To","value":"Necitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"656651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656651"},{"name":"PDQ_Open_Trial_Search_ID","value":"656651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2352806"}]}}{"C61099":{"preferredName":"Nedaplatin","code":"C61099","definitions":[{"definition":"A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nedaplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(Glycolato-O,O')diammineplatinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"254-S","termGroup":"CN","termSource":"NCI"},{"termName":"CDGP","termGroup":"AB","termSource":"NCI"},{"termName":"cis-Diammine(glucolato)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"NDP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95734-82-0"},{"name":"CHEBI_ID","value":"CHEBI:31898"},{"name":"Chemical_Formula","value":"C2H2O3.Pt.2H3N"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8UQ3W6JXAN"},{"name":"Legacy Concept Name","value":"Nedaplatin"},{"name":"Maps_To","value":"Nedaplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"468844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468844"},{"name":"PDQ_Open_Trial_Search_ID","value":"468844"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0093999"}]}}{"C136418":{"preferredName":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464","code":"C136418","definitions":[{"definition":"An inhibitor of NEDD8 (neural precursor cell expressed, developmentally down-regulated 8) activating enzyme E1 (NAE), with potential antineoplastic activity. Upon administration, TAS4464 selectively binds to and inhibits NAE, which prevents NAE/NEDD8-mediated signaling and prevents the NEDD8 conjugation of cullin-RING ligase complexes (CRLs). This inactivates the CRLs leading to an accumulation of CRL substrate proteins, such as CDT1, p27, p21 and phosphorylated IkappaB, and inactivates nuclear factor-kappaB (NF-kB) as well as downregulates anti-apoptotic proteins. This causes cell cycle dysregulation, induces apoptosis, and inhibits tumor cell proliferation and survival. NAE catalyzes the first step in the NEDD8 conjugation (neddylation) pathway which controls cancer cell growth and survival through activation of CRLs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464","termGroup":"PT","termSource":"NCI"},{"termName":"NAE Inhibitor TAS4464","termGroup":"SY","termSource":"NCI"},{"termName":"TAS4464","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464"},{"name":"NCI_Drug_Dictionary_ID","value":"789222"},{"name":"NCI_META_CUI","value":"CL523721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789222"},{"name":"PDQ_Open_Trial_Search_ID","value":"789222"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120036":{"preferredName":"Peposertib","code":"C120036","definitions":[{"definition":"An orally bioavailable inhibitor of DNA-dependent protein kinase (DNA-PK) with potential antineoplastic activity, and potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, peposertib binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peposertib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-","termGroup":"SY","termSource":"NCI"},{"termName":"M 3814","termGroup":"CN","termSource":"NCI"},{"termName":"M-3814","termGroup":"CN","termSource":"NCI"},{"termName":"M3814","termGroup":"CN","termSource":"NCI"},{"termName":"MSC 2490484A","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-2490484A","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2490484A","termGroup":"CN","termSource":"NCI"},{"termName":"Nedisertib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637542-33-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GN429E725A"},{"name":"Maps_To","value":"Nedisertib"},{"name":"Maps_To","value":"Peposertib"},{"name":"NCI_Drug_Dictionary_ID","value":"767372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767372"},{"name":"PDQ_Open_Trial_Search_ID","value":"767372"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896805"}]}}{"C1704":{"preferredName":"Nelarabine","code":"C1704","definitions":[{"definition":"A drug used to treat certain types of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nelarabine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino, 6-Methoxypurine Arabinoside","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine","termGroup":"SN","termSource":"NCI"},{"termName":"506U78","termGroup":"CN","termSource":"NCI"},{"termName":"Arranon","termGroup":"BR","termSource":"NCI"},{"termName":"Compound 506U78","termGroup":"SY","termSource":"NCI"},{"termName":"GW506U78","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma"},{"name":"CAS_Registry","value":"121032-29-9"},{"name":"CHEBI_ID","value":"CHEBI:63612"},{"name":"Chemical_Formula","value":"C11H15N5O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"60158CV180"},{"name":"Legacy Concept Name","value":"Nelarabine"},{"name":"Maps_To","value":"Nelarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"43260"},{"name":"NSC Number","value":"686673"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43260"},{"name":"PDQ_Open_Trial_Search_ID","value":"43260"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0907349"}]}}{"C117985":{"preferredName":"Nelipepimut-S","code":"C117985","definitions":[{"definition":"A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nelipepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"E75 Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-","termGroup":"SY","termSource":"NCI"},{"termName":"Nelipepimut S","termGroup":"SY","termSource":"NCI"},{"termName":"NeuVax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160212-35-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7M0A29CD8B"},{"name":"Maps_To","value":"Nelipepimut-S"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3898150"}]}}{"C99228":{"preferredName":"Nelipepimut-S Plus GM-CSF Vaccine","code":"C99228","definitions":[{"definition":"A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nelipepimut-S Plus GM-CSF Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"E75 Plus GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"E75 Vaccine Plus GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Nelipepimut-S Plus Sargramostim","termGroup":"SY","termSource":"NCI"},{"termName":"NeuVax Plus GM-CSF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nelipepimut-S Plus GM-CSF Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"719080"},{"name":"NCI_META_CUI","value":"CL433057"},{"name":"PDQ_Closed_Trial_Search_ID","value":"719080"},{"name":"PDQ_Open_Trial_Search_ID","value":"719080"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83999":{"preferredName":"Nemorubicin","code":"C83999","definitions":[{"definition":"A morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450 CYP3A enzyme to a highly cytotoxic derivative. Unlike most anthracyclines, nemorubicin is a topoisomerase I inhibitor and appears to exert its effect through the nucleotide excision repair (NER) system. In addition, this agent does not show cross-resistance with other anthracyclines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemorubicin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"108852-90-0"},{"name":"CHEBI_ID","value":"CHEBI:42053"},{"name":"Chemical_Formula","value":"C32H37NO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7618O47BQM"},{"name":"Maps_To","value":"Nemorubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827283"}]}}{"C84000":{"preferredName":"Nemorubicin Hydrochloride","code":"C84000","definitions":[{"definition":"The hydrochloride salt form of nemorubicin, a morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450 CYP3A enzyme to a highly cytotoxic derivative. Unlike most anthracyclines, nemorubicin is a topoisomerase I inhibitor and appears to exert its effect through the nucleotide excision repair (NER) system. In addition, this agent does not show cross-resistance with other anthracyclines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-10-((2,3,6-Trideoxy-3-((2S)-2-Methoxy-4-Morpholinyl)-Alpha-L-Lyxo-Hexopyranosyl)Oxy)-, Hydrochloride, (8S,10S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"108943-08-4"},{"name":"Chemical_Formula","value":"C32H37NO13.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2Q6F8JYX76"},{"name":"Maps_To","value":"Nemorubicin Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827284"}]}}{"C162874":{"preferredName":"Neoantigen Vaccine GEN-009","code":"C162874","definitions":[{"definition":"A peptide-based, personalized cancer vaccine consisting of patient-specific mutated synthetic long peptides (SLPs), which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon subcutaneous vaccination with the personalized neoantigen peptide vaccine GEN-009, and administration along with the immunoadjuvant poly-ICLC, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The Antigen Lead Acquisition System (ATLAS) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T-cells and will be incorporated into GEN-009 in the form of SLPs. Each personalized vaccine contains between four and twenty SLPs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen Vaccine GEN-009","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-009 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GEN009","termGroup":"CN","termSource":"NCI"},{"termName":"Personalized Cancer Vaccine GEN-009","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen Vaccine GEN-009"},{"name":"NCI_Drug_Dictionary_ID","value":"798938"},{"name":"NCI_META_CUI","value":"CL973355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798938"},{"name":"PDQ_Open_Trial_Search_ID","value":"798938"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118960":{"preferredName":"Neoantigen-based Glioblastoma Vaccine","code":"C118960","definitions":[{"definition":"A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes (neoantigens), with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based glioblastoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens are tumor-specific antigens derived from mutated proteins that are present only in a specific tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Glioblastoma Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NeoVax (TM) Glioblastoma Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen Glioblastoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Glioblastoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"766449"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766449"},{"name":"PDQ_Open_Trial_Search_ID","value":"766449"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3898149"}]}}{"C112003":{"preferredName":"Neoantigen-based Melanoma-Poly-ICLC Vaccine","code":"C112003","definitions":[{"definition":"A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Melanoma-Poly-ICLC Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NeoVax Melanoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Melanoma-Poly-ICLC Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"754239"},{"name":"NCI_META_CUI","value":"CL454292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754239"},{"name":"PDQ_Open_Trial_Search_ID","value":"754239"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158694":{"preferredName":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine","code":"C158694","definitions":[{"definition":"A peptide-based renal cell carcinoma (RCC) vaccine consisting of neoantigens and peptides derived from immunogenic epitopes identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based RCC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NeoVax RCC Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"NeoVax Renal Cell Carcinoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"797484"},{"name":"NCI_META_CUI","value":"CL950784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797484"},{"name":"PDQ_Open_Trial_Search_ID","value":"797484"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165514":{"preferredName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903","code":"C165514","definitions":[{"definition":"A cancer priming vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of neoantigen-based therapeutic cancer vaccine GRT-C903, followed by the boosting vaccine GRT-R904, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903","termGroup":"PT","termSource":"NCI"},{"termName":"GRT C903","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-C903","termGroup":"CN","termSource":"NCI"},{"termName":"GRTC903","termGroup":"CN","termSource":"NCI"},{"termName":"Priming Cancer Vaccine GRT-C903","termGroup":"SY","termSource":"NCI"},{"termName":"Priming Vaccine GRT-C903","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Neoantigen Cancer Vaccine Prime GRT-C903","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Neoantigen Priming Cancer Vaccine GRT-C903","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903"},{"name":"NCI_Drug_Dictionary_ID","value":"799972"},{"name":"NCI_META_CUI","value":"CL978704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799972"},{"name":"PDQ_Open_Trial_Search_ID","value":"799972"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165515":{"preferredName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904","code":"C165515","definitions":[{"definition":"A cancer boosting vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-based therapeutic cancer vaccine GRT-R904, which is administered after the initial administration of the priming vaccine GRT-C903, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904","termGroup":"PT","termSource":"NCI"},{"termName":"Boosting Cancer Vaccine GRT-R904","termGroup":"SY","termSource":"NCI"},{"termName":"Boosting Vaccine GRT-R904","termGroup":"SY","termSource":"NCI"},{"termName":"GRT R904","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-R904","termGroup":"CN","termSource":"NCI"},{"termName":"GRTR904","termGroup":"CN","termSource":"NCI"},{"termName":"Shared Neoantigen Boosting Cancer Vaccine GRT-R904","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Neoantigen Cancer Vaccine Boost GRT-R904","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904"},{"name":"NCI_Drug_Dictionary_ID","value":"799974"},{"name":"NCI_META_CUI","value":"CL978705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799974"},{"name":"PDQ_Open_Trial_Search_ID","value":"799974"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135018":{"preferredName":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017","code":"C135018","definitions":[{"definition":"A proprietary, personalized autologous synthetic cancer vaccine composed of patient-specific synthetic cancer neo-epitopes complexed with heat shock protein 70 (HSP 70; HSP70), with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-HSP70 peptide cancer vaccine AGEN2017, the HSPs present the neoantigens to antigen presenting cells (APCs) and help elicit a potent neoantigen-specific T-cell-based anti-tumor immune response, thereby killing the neoantigen-expressing cancer cells. HSP70 is able to the transport the neo-epitopes, activate APCs and enhance the T-cell-mediated immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 2017","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-2017","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN2017","termGroup":"CN","termSource":"NCI"},{"termName":"ASV","termGroup":"BR","termSource":"NCI"},{"termName":"ASV AGEN2017","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Cancer Vaccine AGEN2017","termGroup":"SY","termSource":"NCI"},{"termName":"AutoSynVax","termGroup":"BR","termSource":"NCI"},{"termName":"AutoSynVax AGEN2017","termGroup":"SY","termSource":"NCI"},{"termName":"AutoSynVax Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Neoantigen Vaccine AGEN2017","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017"},{"name":"NCI_Drug_Dictionary_ID","value":"788954"},{"name":"NCI_META_CUI","value":"CL523816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788954"},{"name":"PDQ_Open_Trial_Search_ID","value":"788954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49094":{"preferredName":"Neratinib","code":"C49094","definitions":[{"definition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neratinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide","termGroup":"SY","termSource":"NCI"},{"termName":"2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"HKI 272","termGroup":"CN","termSource":"NCI"},{"termName":"HKI-272","termGroup":"CN","termSource":"NCI"},{"termName":"PB 272","termGroup":"CN","termSource":"NCI"},{"termName":"PB-272","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"early stage HER2-overexpressed/amplified breast cancer"},{"name":"CAS_Registry","value":"698387-09-6"},{"name":"CHEBI_ID","value":"CHEBI:61397"},{"name":"Chemical_Formula","value":"C30H29ClN6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JJH94R3PWB"},{"name":"Legacy Concept Name","value":"KI-272"},{"name":"Maps_To","value":"Neratinib"},{"name":"NCI_Drug_Dictionary_ID","value":"453548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453548"},{"name":"PDQ_Open_Trial_Search_ID","value":"453548"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1704439"}]}}{"C136891":{"preferredName":"Neratinib Maleate","code":"C136891","definitions":[{"definition":"The maleate salt form of neratinib, an orally available, quinazoline-based, irreversible inhibitor of both the receptor tyrosine kinases (RTKs) human epidermal growth factor receptor 2 (HER2; ERBB2) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, neratinib targets and covalently binds to the cysteine residue in the ATP-binding pockets of both HER2 and EGFR. This inhibits their activity and results in the inhibition of downstream signal transduction events, induces cell cycle arrest, apoptosis and ultimately decreases cellular proliferation in HER2- and EGFR-expressing tumor cells. EGFR and HER2, RTKs that are mutated or overactivated in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neratinib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"HKI-272 Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"Nerlynx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"early stage HER2-overexpressed/amplified breast cancer"},{"name":"CAS_Registry","value":"915942-22-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RM7XY23ZS"},{"name":"Maps_To","value":"Neratinib Maleate"},{"name":"NCI_META_CUI","value":"CL524716"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95712":{"preferredName":"Nesvacumab","code":"C95712","definitions":[{"definition":"A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nesvacumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ANG2 MOAB REGN910","termGroup":"SY","termSource":"NCI"},{"termName":"REGN910","termGroup":"CN","termSource":"NCI"},{"termName":"SAR307746","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1296818-77-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WX8293WGLC"},{"name":"Maps_To","value":"Nesvacumab"},{"name":"NCI_Drug_Dictionary_ID","value":"693224"},{"name":"NCI_META_CUI","value":"CL428177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693224"},{"name":"PDQ_Open_Trial_Search_ID","value":"693224"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96232":{"preferredName":"NG-nitro-L-arginine","code":"C96232","definitions":[{"definition":"An amino acid derivative and nitric oxide synthase (NOS) inhibitor with potential antineoplastic and antiangiogenic activities. Upon administration, NG-nitro-L-arginine inhibits the enzyme nitric oxide synthase, thereby preventing the formation of nitric oxide (NO). By preventing NO generation, the vasodilatory effects of NO are abrogated leading to vasoconstriction, reduction in vascular permeability and an inhibition of angiogenesis. As blood flow to tumors is restricted, this may result in an inhibition of tumor cell proliferation. NO plays an important role in tumor blood flow and stimulation of angiogenesis, tumor progression, survival, migration and invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NG-nitro-L-arginine","termGroup":"PT","termSource":"NCI"},{"termName":"L-NNA","termGroup":"AB","termSource":"NCI"},{"termName":"NOLA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2149-70-4"},{"name":"CHEBI_ID","value":"CHEBI:27960"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7O8V7H6P2J"},{"name":"Maps_To","value":"NG-nitro-L-arginine"},{"name":"NCI_Drug_Dictionary_ID","value":"697835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697835"},{"name":"PDQ_Open_Trial_Search_ID","value":"697835"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068821"}]}}{"C2327":{"preferredName":"Niacinamide","code":"C2327","definitions":[{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacinamide helps some enzymes make energy in the cell. It is found in many plant and animal products. It is water-soluble (can dissolve in water) and must be taken in daily. It is being studied to increase the effect of radiation therapy on tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The active form of vitamin B3 and a component of the coenzyme nicotinamide adenine dinucleotide (NAD). Niacinamide acts as a chemo- and radio-sensitizing agent by enhancing tumor blood flow, thereby reducing tumor hypoxia.  This agent also inhibits poly(ADP-ribose) polymerases, enzymes involved in the rejoining of DNA strand breaks induced by radiation or chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niacinamide","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinecarboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Nicamid","termGroup":"FB","termSource":"NCI"},{"termName":"Nicosedine","termGroup":"FB","termSource":"NCI"},{"termName":"Nicotinamide","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotinamidum","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotinic Acid Amide","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotylamide","termGroup":"SY","termSource":"NCI"},{"termName":"Pellagra-Preventing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin PP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Pellegra, treatment and prophylaxis; Various dermatologic conditions"},{"name":"CAS_Registry","value":"98-92-0"},{"name":"CHEBI_ID","value":"CHEBI:17154"},{"name":"Chemical_Formula","value":"C6H6N2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25X51I8RD4"},{"name":"Legacy Concept Name","value":"Niacinamide"},{"name":"Maps_To","value":"Niacinamide"},{"name":"NCI_Drug_Dictionary_ID","value":"42044"},{"name":"NSC Number","value":"13128"},{"name":"NSC Number","value":"27452"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42044"},{"name":"PDQ_Open_Trial_Search_ID","value":"42044"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"UMLS_CUI","value":"C0028027"}]}}{"C66240":{"preferredName":"Niclosamide","code":"C66240","definitions":[{"definition":"An orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Upon oral administration, niclosamide specifically induces degradation of the androgen receptor (AR) variant V7 (AR-V7) through the proteasome-mediated pathway. This downregulates the expression of the AR variant, inhibits AR-V7-mediated transcriptional activity, and reduces AR-V7 recruitment to the prostate-specific antigen (PSA) gene promoter. Niclosamide also prevents AR-V7-mediated STAT3 phosphorylation and activation. This inhibits AR/STAT3-mediated signaling and prevents expression of STAT3 target genes. Altogether, this may inhibit growth of AR-V7-overexpressing cancer cells. The AR-V7 variant, which is encoded by contiguous splicing of AR exons 1/2/3/CE3, is upregulated in a variety of cancer cell types, and is associated with both cancer progression and resistance to AR-targeted therapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niclosamide","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Salicylanilide, 2',5-Dichloro-4'-nitro-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-65-7"},{"name":"Chemical_Formula","value":"C13H8Cl2N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8KK8CQ2K8G"},{"name":"Legacy Concept Name","value":"Niclosamide"},{"name":"Maps_To","value":"Niclosamide"},{"name":"NCI_Drug_Dictionary_ID","value":"775866"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775866"},{"name":"PDQ_Open_Trial_Search_ID","value":"775866"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699963"}]}}{"C158078":{"preferredName":"Nicotinamide Riboside","code":"C158078","definitions":[{"definition":"An orally available form of vitamin B3 and precursor of nicotinamide adenine dinucleotide (NAD+) with potential use in the treatment of chemotherapy induced peripheral neuropathy (CIPN). Upon oral administration, nicotinamide riboside (NR) is converted to nicotinamide mononucleotide by the NR kinases, nicotinamide riboside kinase 1 (NRK 1) and nicotinamide riboside kinase 2 (NRK 2), to which a second adenine is transferred by nicotinamide mononucleotide adenylyl transferase to generate NAD+. NAD+, an essential redox coenzyme, may offer protective effects against axonal injury from both mechanical and neurotoxic injury, and maintenance of NAD+ may be protective in mitochondrial disease. NR may help elevate and maintain NAD+ levels, which may ameliorate potential mechanisms implicated in the development of CIPN including mitochondrial dysfunction and peripheral nerve degeneration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nicotinamide Riboside","termGroup":"PT","termSource":"NCI"},{"termName":"Niagen","termGroup":"BR","termSource":"NCI"},{"termName":"NR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1341-23-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0I8H2M0L7N"},{"name":"Maps_To","value":"Nicotinamide Riboside"},{"name":"NCI_Drug_Dictionary_ID","value":"797351"},{"name":"NCI_META_CUI","value":"CL937699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797351"},{"name":"PDQ_Open_Trial_Search_ID","value":"797351"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Vitamin"}]}}{"C153375":{"preferredName":"Nidanilimab","code":"C153375","definitions":[{"definition":"A low fucose, fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) against the interleukin 1 receptor accessory protein (interleukin-1 receptor associated protein; IL1RAP), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, nidanilimab targets and binds to IL1RAP, thereby preventing IL1RAP-mediated signaling, and disrupting IL-1 and IL-33 mediated nuclear factor kappa beta (NFkB) activation. This prevents the secretion of tumor stimulating cytokines, decreases tumor inflammation and inhibits tumor cell proliferation. In addition, nidanilimab induces antibody-dependent cellular cytotoxicity (ADCC), and stimulates natural killer (NK) cells to attack tumor cells, thereby killing the IL1RAP-poisitive tumor cells. IL1RAP, a co-receptor of the IL-1 receptor (IL1R1) and the IL-33 receptor (ST2), is upregulated in certain tumor cells, and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nidanilimab","termGroup":"PT","termSource":"NCI"},{"termName":"CAN 04","termGroup":"CN","termSource":"NCI"},{"termName":"CAN-04","termGroup":"CN","termSource":"NCI"},{"termName":"CAN04","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2171061-85-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ND296JF21I"},{"name":"Maps_To","value":"Nidanilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"793891"},{"name":"NCI_META_CUI","value":"CL554531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793891"},{"name":"PDQ_Open_Trial_Search_ID","value":"793891"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71734":{"preferredName":"Nifurtimox","code":"C71734","definitions":[{"definition":"A nitrofuran derivative with antiprotozoal and potential antineoplastic activities. Nifurtimox is reduced by cytosol enzymes or flavin-containing microsomal enzymes to a highly reactive nitro anion free radical; autooxidation of the nitro anion free radical generates cytotoxic superoxide anion (02-). In addition, nifurtimox-derived nitro anion free radicals may alkylate macromolecules such as nucleic acids and proteins, resulting in the disruption of their structure and function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nifurtimox","termGroup":"PT","termSource":"NCI"},{"termName":"4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 2502","termGroup":"CN","termSource":"NCI"},{"termName":"BAYER 2502","termGroup":"CN","termSource":"NCI"},{"termName":"Lampit","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23256-30-6"},{"name":"Chemical_Formula","value":"C10H13N3O5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M84I3K7C2O"},{"name":"Legacy Concept Name","value":"Nifurtimox"},{"name":"Maps_To","value":"Nifurtimox"},{"name":"NCI_Drug_Dictionary_ID","value":"558911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558911"},{"name":"PDQ_Open_Trial_Search_ID","value":"558911"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028073"}]}}{"C48375":{"preferredName":"Nilotinib","code":"C48375","definitions":[{"definition":"A drug used to treat certain types of chronic myelogenous leukemia (CML). It is used in patients who have not gotten better after treatment with other anticancer drugs or who are not able to take imatinib mesylate. It is also being studied in the treatment of other types of cancer. Nilotinib blocks a protein called BCR/ABL which is made in CML cells that contain the Philadelphia chromosome (an abnormal chromosome 22 that has part of chromosome 9 attached). It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilotinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"AMN 107 Base Form","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"641571-10-0"},{"name":"CHEBI_ID","value":"CHEBI:52172"},{"name":"Chemical_Formula","value":"C28H22F3N7O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F41401512X"},{"name":"Legacy Concept Name","value":"AMN107"},{"name":"Maps_To","value":"Nilotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"435988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"435988"},{"name":"PDQ_Open_Trial_Search_ID","value":"435988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721377"}]}}{"C95223":{"preferredName":"Nilotinib Hydrochloride Anhydrous","code":"C95223","definitions":[{"definition":"The hydrochloride salt of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilotinib Hydrochloride Anhydrous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923288-95-3"},{"name":"Chemical_Formula","value":"C28H22F3N7O.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K37N7BYX3X"},{"name":"Maps_To","value":"Nilotinib Hydrochloride Anhydrous"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987005"}]}}{"C95229":{"preferredName":"Nilotinib Hydrochloride Monohydrate","code":"C95229","definitions":[{"definition":"The monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilotinib Hydrochloride Monohydrate","termGroup":"PT","termSource":"NCI"},{"termName":"4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"AMN107","termGroup":"CN","termSource":"NCI"},{"termName":"Nilotinib Monohydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Tasigna","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"923288-90-8"},{"name":"Chemical_Formula","value":"C28H22F3N7O.HCl.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5JHU0N1R6K"},{"name":"Maps_To","value":"Nilotinib Hydrochloride Monohydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"435988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"435988"},{"name":"PDQ_Open_Trial_Search_ID","value":"435988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1966375"}]}}{"C1173":{"preferredName":"Nilutamide","code":"C1173","definitions":[{"definition":"A drug that blocks the effects of male hormones in the body. It is a type of antiandrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilutamide","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-3,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"5,5-Dimethyl-3-[4-nitro-3-(trifluoro-methyl)phenyl]-2,4-imidazolidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"Anandron","termGroup":"FB","termSource":"NCI"},{"termName":"Nilandron","termGroup":"BR","termSource":"NCI"},{"termName":"RU-23908","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prostate cancer"},{"name":"CAS_Registry","value":"63612-50-0"},{"name":"CHEBI_ID","value":"CHEBI:7573"},{"name":"Chemical_Formula","value":"C12H10F3N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"51G6I8B902"},{"name":"Legacy Concept Name","value":"Nilutamide"},{"name":"Maps_To","value":"Nilutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"40450"},{"name":"NSC Number","value":"684588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40450"},{"name":"PDQ_Open_Trial_Search_ID","value":"40450"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0722107"}]}}{"C157231":{"preferredName":"Nimesulide-Hyaluronic Acid Conjugate CA102N","code":"C157231","definitions":[{"definition":"A covalently bound conjugate composed of the biological polymer sodium hyaluronate (NaHA) and the hydrophobic, cyclooxygenase 2 (COX-2) inhibitor and cytotoxic agent nimesulide (Nim), with potential antineoplastic activity. Upon intravenous administration of Nim-HA conjugate CA102N, the HA moiety targets and binds to CD44. Following endocytosis of CA102N and enzymatic degradation within the lysosomal compartment, Nim is released inside CD44-expressing tumor cells, causing Nim-mediated induction of cell cycle arrest tumor cell apoptosis and decreases tumor cell growth. In addition, Nim inhibits various tumor cell signaling pathways thereby further inhibiting tumor cell proliferation. CD44, a transmembrane glycoprotein and HA receptor expressed in healthy tissue, plays a key role in cellular growth, survival, differentiation and motility. Overexpressed in a variety of cancer cell types, CD44 plays a key role in tumor cell proliferation, migration and survival. Conjugation of HA to Nim allows for increased solubility of Nim and for targeted delivery of Nim to CD44-expressing tumor cells, thereby increasing efficacy and safety of Nim.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nimesulide-Hyaluronic Acid Conjugate CA102N","termGroup":"PT","termSource":"NCI"},{"termName":"CA 102N","termGroup":"CN","termSource":"NCI"},{"termName":"CA-102N","termGroup":"CN","termSource":"NCI"},{"termName":"CA102N","termGroup":"CN","termSource":"NCI"},{"termName":"HA-Nim Conjugate CA102N","termGroup":"SY","termSource":"NCI"},{"termName":"HA-Nimesulide","termGroup":"SY","termSource":"NCI"},{"termName":"Hyaluronic Acid Nimesulide-NH2 Bioconjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Nim-HA Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nimesulide-Hyaluronic Acid Conjugate CA102N"},{"name":"NCI_Drug_Dictionary_ID","value":"799428"},{"name":"NCI_META_CUI","value":"CL936840"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799428"},{"name":"PDQ_Open_Trial_Search_ID","value":"799428"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C692":{"preferredName":"Nimodipine","code":"C692","definitions":[{"definition":"A dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity. Nimodipine inhibits the transmembrane influx of calcium ions in response to depolarization in smooth muscle cells, thereby inhibiting vascular smooth muscle contraction and inducing vasodilatation. Nimodipine has a greater effect on cerebral arteries than on peripheral smooth muscle cells and myocardial cells, probably because this agent can cross the blood brain barrier due to its lipophilic nature. Furthermore, this agent also inhibits the drug efflux pump P-glycoprotein, which is overexpressed in some multi-drug resistant tumors, and may improve the efficacy of some antineoplastic agents.","type":"DEFINITION","source":"NCI"},{"definition":"Belongs to a family of drugs called calcium channel blockers. It is being investigated for use with anticancer drugs to prevent or overcome drug resistance and improve response to chemotherapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nimodipine","termGroup":"PT","termSource":"NCI"},{"termName":"NIMO","termGroup":"AB","termSource":"NCI"},{"termName":"Nimotop","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66085-59-4"},{"name":"CHEBI_ID","value":"CHEBI:7575"},{"name":"Chemical_Formula","value":"C21H26N2O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"57WA9QZ5WH"},{"name":"Legacy Concept Name","value":"Nimodipine"},{"name":"Maps_To","value":"Nimodipine"},{"name":"NCI_Drug_Dictionary_ID","value":"41210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41210"},{"name":"PDQ_Open_Trial_Search_ID","value":"41210"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678207"}]}}{"C2733":{"preferredName":"Nimotuzumab","code":"C2733","definitions":[{"definition":"A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Nimotuzumab binds the epidermal growth factor receptor (EGFR) and blocks cancer cells that depend on epidermal growth factor for growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nimotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"H-R3","termGroup":"CN","termSource":"NCI"},{"termName":"hR3","termGroup":"CN","termSource":"NCI"},{"termName":"Thera-CIM-hr3","termGroup":"SY","termSource":"NCI"},{"termName":"TheraCim hR3","termGroup":"SY","termSource":"NCI"},{"termName":"Theraloc","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Glioma"},{"name":"CAS_Registry","value":"828933-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6NS400BXKH"},{"name":"Legacy Concept Name","value":"TheraCim_hR3"},{"name":"Maps_To","value":"Nimotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"507582"},{"name":"PDQ_Closed_Trial_Search_ID","value":"507582"},{"name":"PDQ_Open_Trial_Search_ID","value":"507582"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1570482"}]}}{"C693":{"preferredName":"Nimustine","code":"C693","definitions":[{"definition":"A nitrosourea with antineoplastic activity. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of brain cancer. It belongs to the family of drugs called nitrosoureas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nimustine","termGroup":"PT","termSource":"NCI"},{"termName":"3-((4-Amino-2-Methyl-5-Pyrimidinyl)Methyl)-1-(2-Chloroethyl)-1-Nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"ACNU","termGroup":"AB","termSource":"NCI"},{"termName":"N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Nidran","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42471-28-3"},{"name":"Chemical_Formula","value":"C9H13ClN6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0S726V972K"},{"name":"Legacy Concept Name","value":"Nimustine"},{"name":"Maps_To","value":"Nimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"38853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38853"},{"name":"PDQ_Open_Trial_Search_ID","value":"38853"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028096"}]}}{"C95325":{"preferredName":"Nimustine Hydrochloride","code":"C95325","definitions":[{"definition":"The hydrochloride salt of nimustine, a nitrosourea with antineoplastic activity. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nimustine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"3-((4-Amino-2-Methyl-5-Pyrimidinyl)Methyl)-1-(2-Chloroethyl)-1-Nitrosourea Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ACNU HCl","termGroup":"AB","termSource":"NCI"},{"termName":"CS 439 HCl","termGroup":"SY","termSource":"NCI"},{"termName":"N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Nidran HCl","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42471-28-3"},{"name":"CHEBI_ID","value":"CHEBI:7576"},{"name":"Chemical_Formula","value":"C9H13ClN6O2.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DFR965WKBU"},{"name":"Maps_To","value":"Nimustine Hydrochloride"},{"name":"NSC Number","value":"245382"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771987"}]}}{"C148529":{"preferredName":"Ningetinib Tosylate","code":"C148529","definitions":[{"definition":"The tosylate salt form of ningetinib, an orally available inhibitor of the receptor tyrosine kinases c-MET/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR2 KDR), Axl (UFO), Mer, and Fms-like tyrosine kinase 3 (Flt3; CD135; STK1; FLK2), with antineoplastic activity. Upon administration, ningetinib binds to a variety of kinases, including c-Met, VEGFR2, Axl, Mer and Flt3, thereby inhibiting their signaling pathways. This inhibits growth, angiogenesis and metastasis of tumor cells that overexpress these kinases. c-Met, VEGFR2, Axl, Mer and Flt3 are overexpressed by many tumor cell types and play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ningetinib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"CT-053 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"CT-053-PTSA","termGroup":"CN","termSource":"NCI"},{"termName":"CT-053PTSA","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1394820-77-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R7I5725FES"},{"name":"Maps_To","value":"Ningetinib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"792698"},{"name":"NCI_META_CUI","value":"CL551136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792698"},{"name":"PDQ_Open_Trial_Search_ID","value":"792698"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62765":{"preferredName":"Nintedanib","code":"C62765","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. BIBF 1120 blocks enzymes needed for cells to grow, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nintedanib","termGroup":"PT","termSource":"NCI"},{"termName":"BIBF 1120","termGroup":"CN","termSource":"NCI"},{"termName":"BIBF-1120","termGroup":"CN","termSource":"NCI"},{"termName":"Intedanib","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"Multitargeted Tyrosine Kinase Inhibitor BIBF 1120","termGroup":"SY","termSource":"NCI"},{"termName":"Vargatef","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"656247-17-5"},{"name":"Chemical_Formula","value":"C31H33N5O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G6HRD2P839"},{"name":"Legacy Concept Name","value":"BIBF_1120"},{"name":"Maps_To","value":"Nintedanib"},{"name":"NCI_Drug_Dictionary_ID","value":"504524"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504524"},{"name":"PDQ_Open_Trial_Search_ID","value":"504524"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2930789"}]}}{"C80059":{"preferredName":"Niraparib","code":"C80059","definitions":[{"definition":"An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niraparib","termGroup":"PT","termSource":"NCI"},{"termName":"MK-4827","termGroup":"CN","termSource":"NCI"},{"termName":"MK4827","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1038915-60-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HMC2H89N35"},{"name":"Legacy Concept Name","value":"PARP_Inhibitor_MK4827"},{"name":"Maps_To","value":"Niraparib"},{"name":"NCI_Drug_Dictionary_ID","value":"615263"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615263"},{"name":"PDQ_Open_Trial_Search_ID","value":"615263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2744440"}]}}{"C133238":{"preferredName":"Niraparib Tosylate Monohydrate","code":"C133238","definitions":[{"definition":"An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niraparib Tosylate Monohydrate","termGroup":"PT","termSource":"NCI"},{"termName":"2H-Indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)-, 4-Methylbenzenesulfonate, Hydrate (1:1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Zejula","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer"},{"name":"CAS_Registry","value":"1613220-15-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"195Q483UZD"},{"name":"Maps_To","value":"Niraparib Tosylate Monohydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"615263"},{"name":"NCI_META_CUI","value":"CL520459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615263"},{"name":"PDQ_Open_Trial_Search_ID","value":"615263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82383":{"preferredName":"Nirogacestat","code":"C82383","definitions":[{"definition":"A selective gamma secretase (GS) inhibitor with antitumor activity. Upon administration, nirogacestat targets and binds to GS, thereby blocking the proteolytic activation of Notch receptors. This inhibits the Notch signaling pathway and results in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nirogacestat","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide","termGroup":"SY","termSource":"NCI"},{"termName":"PF-03084014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1290543-63-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QZ62892OFJ"},{"name":"Legacy Concept Name","value":"Gamma_Secretase_Inhibitor_PF-03084014"},{"name":"Maps_To","value":"Nirogacestat"},{"name":"NCI_Drug_Dictionary_ID","value":"641472"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641472"},{"name":"PDQ_Open_Trial_Search_ID","value":"641472"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830067"}]}}{"C61499":{"preferredName":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative","code":"C61499","definitions":[{"definition":"A nitric oxide (NO) donating derivative of acetylsalicylic acid with anti-inflammatory, analgesic, antipyretic, antithrombotic, gastroprotective and potential antitumor activities. The acetylsalicylic acid derivative moiety of this agent inhibits the activities of cyclooxygenase (COX) I and II, preventing the formation of prostaglandins and thromboxanes. A reduction in prostaglandin synthesis accounts for this agent's anti-inflammatory, anti-pyretic and analgesic activities; a reduction in thromboxane A2 synthesis results in an irreversible inhibition of platelet aggregation. NO donation by this agent, after cleavage from the acetylsalicylic acid derivative in vivo, may protect the gastric mucosa against the damaging effects of the aspirin derivative by modulating prostaglandins. In tumor cells, the NO donating moiety may block the cell cycle in the G1 and G2 phases and may induce apoptosis through caspase-mediated mechanisms.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the prevention of colorectal cancer. It is a form of aspirin that gives off nitric oxide gas and is less irritating to the lining of the stomach than plain aspirin. It is a type of nonsteroidal anti-inflammatory drug (NSAID).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic Acid, 2-(Acetyl-oxy)-3-[(nitrooxy)methyl]phenyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"NCX 4016","termGroup":"AB","termSource":"NCI"},{"termName":"Nitric Oxide-Releasing Aspirin Derivative","termGroup":"SY","termSource":"NCI"},{"termName":"Nitroaspirin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"175033-36-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EH04H13L6B"},{"name":"Legacy Concept Name","value":"Nitric_Oxide-Releasing_Acetylsalicylic_Acid_Derivative"},{"name":"Maps_To","value":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative"},{"name":"NCI_Drug_Dictionary_ID","value":"486415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486415"},{"name":"PDQ_Open_Trial_Search_ID","value":"486415"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0531264"}]}}{"C61590":{"preferredName":"Nitrogen Mustard Prodrug PR-104","code":"C61590","definitions":[{"definition":"A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous administration, PR-104 is converted by systemic phosphatases to the alcohol intermediate PR-104A, which is reduced to form the active DNA-crosslinking mustard species hydroxylamine PR-104H intracellularly under hypoxic conditions. PR-104H specifically crosslinks hypoxic tumor cell DNA, resulting in the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis in susceptible hypoxic tumor cell populations while sparing normoxic tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. PR-104 becomes active when cancer cells don't receive enough oxygen. It may kill cancer cells by damaging their DNA.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nitrogen Mustard Prodrug PR-104","termGroup":"PT","termSource":"NCI"},{"termName":"((2-Bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)-carbonyl)anilino)ethyl Methanesulphonate","termGroup":"SN","termSource":"NCI"},{"termName":"PR-104","termGroup":"CN","termSource":"NCI"},{"termName":"PR104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"851627-62-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V16D2ZT7DT"},{"name":"Legacy Concept Name","value":"PR-104"},{"name":"Maps_To","value":"Nitrogen Mustard Prodrug PR-104"},{"name":"NCI_Drug_Dictionary_ID","value":"492222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492222"},{"name":"PDQ_Open_Trial_Search_ID","value":"492222"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831907"}]}}{"C103272":{"preferredName":"Nitroglycerin Transdermal Patch","code":"C103272","definitions":[{"definition":"A sustained release transdermal patch containing the organic nitrate nitroglycerin, with vasodilator and potential immunomodulating activities. Upon application to the skin, nitroglycerin is continuously released from the patch and absorbed. In turn, nitroglycerin is converted into nitric oxide (NO), which activates guanylyl cyclase, increasing cyclic guanosine monophosphate concentration thus resulting in smooth muscle relaxation. In addition, activation of NO-mediated signaling pathways may inhibit hypoxia-induced tumor cell invasiveness, chemoresistance, evasion of immune cell recognition and cancer cell progression. Particularly, reactivation of NO-mediated signaling appears to inhibit the increased tumor cell shedding of the major histocompatibility complex class I chain-related (MIC) molecules MICA and MICB as is seen in hypoxic tumor environments; MIC molecules play key roles in tumor cell immune surveillance through their interaction with the C-type lectin-like NKG2D receptor on natural killer, lymphokine-activated killer and effector T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nitroglycerin Transdermal Patch","termGroup":"PT","termSource":"NCI"},{"termName":"Glyceryl Trinitrate Transdermal Patch","termGroup":"SY","termSource":"NCI"},{"termName":"GTN Transdermal Patch","termGroup":"SY","termSource":"NCI"},{"termName":"Minitran","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nitroglycerin Transdermal Patch"},{"name":"NCI_Drug_Dictionary_ID","value":"741836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741836"},{"name":"PDQ_Open_Trial_Search_ID","value":"741836"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699222"}]}}{"C68814":{"preferredName":"Nivolumab","code":"C68814","definitions":[{"definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nivolumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 206","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-263","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-936558","termGroup":"CN","termSource":"NCI"},{"termName":"CMAB819","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-1106","termGroup":"CN","termSource":"NCI"},{"termName":"NIVO","termGroup":"AB","termSource":"NCI"},{"termName":"Nivolumab Biosimilar ABP 206","termGroup":"SY","termSource":"NCI"},{"termName":"Nivolumab Biosimilar BCD-263","termGroup":"SY","termSource":"NCI"},{"termName":"Nivolumab Biosimilar CMAB819","termGroup":"SY","termSource":"NCI"},{"termName":"ONO-4538","termGroup":"CN","termSource":"NCI"},{"termName":"Opdivo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma; recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN); renal cell carcinoma (RCC) ; metastatic melanoma; non-small cell lung cancer (NSCLC); classical Hodgkin lymphoma (cHL); BRAF V600 wild-type, unresectable or metastatic melanoma; metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy."},{"name":"CAS_Registry","value":"946414-94-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"31YO63LBSN"},{"name":"Legacy Concept Name","value":"Anti-PD-1_Human_Monoclonal_Antibody_MDX-1106"},{"name":"Maps_To","value":"Nivolumab"},{"name":"NCI_Drug_Dictionary_ID","value":"539733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539733"},{"name":"PDQ_Open_Trial_Search_ID","value":"539733"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3657270"}]}}{"C155945":{"preferredName":"NLRP3 Agonist BMS-986299","code":"C155945","definitions":[{"definition":"A nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD Containing Protein 3; NALP3) agonist with potential immunomodulatory and antineoplastic activities. Upon administration, NLRP3 agonist BMS-986299 binds to and activates NLRP3, potentially promoting NLRP3 inflammasome-mediated secretion of interleukin-8 (IL-8), which may induce tumoricidal activity of natural killer (NK) cells against tumor cells. NLRP3, a sensor component of the NLRP3 inflammasome plays a significant role in immunity and inflammation, and may protect against tumorigenesis in some cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NLRP3 Agonist BMS-986299","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986299","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986299","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986299","termGroup":"CN","termSource":"NCI"},{"termName":"NLR Family Pyrin Domain Containing 3 Agonist BMS-986299","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2242952-69-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VS58MO4P47"},{"name":"Maps_To","value":"NLRP3 Agonist BMS-986299"},{"name":"NCI_Drug_Dictionary_ID","value":"795266"},{"name":"NCI_META_CUI","value":"CL562818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795266"},{"name":"PDQ_Open_Trial_Search_ID","value":"795266"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75228":{"preferredName":"Nocodazole","code":"C75228","definitions":[{"definition":"A synthetic tubulin-binding agent with antineoplastic activity. Nocodazole binds to beta-tubulin and disrupts microtubule assembly/disassembly dynamics. This prevents mitosis and induces apoptosis in tumor cells. Although nocodazole binding site overlaps with that of colchicine, the two agents are structurally quite different.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nocodazole","termGroup":"PT","termSource":"NCI"},{"termName":"Methyl (5-(2-thienylcarbonyl))-1H-benzimidazol-2-yl","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31430-18-9"},{"name":"CHEBI_ID","value":"CHEBI:34892"},{"name":"Chemical_Formula","value":"C14H11N3O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SH1WY3R615"},{"name":"Legacy Concept Name","value":"Nocodazole"},{"name":"Maps_To","value":"Nocodazole"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028247"}]}}{"C700":{"preferredName":"Nogalamycin","code":"C700","definitions":[{"definition":"An anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces nogalater.  Nogalamycin intercalates into DNA and interacts with topoisomerase I, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nogalamycin","termGroup":"PT","termSource":"NCI"},{"termName":"[2R-(2alpha,3beta,4alpha,5beta,6alpha,11beta,13alpha,14alpha)]-11-[(6-deoxy-3-C-methyl-2,3,4-tri-O-methyl-alpha-L-mannopyranosyl)oxy]-4(dimethylamino)-3,4,5,6,9,11,12,13,14,16-decahydro-3,5,8,10,13-pentahydroxy-6,13-dimethyl-9,16-dioxo-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-14-carboxylic acid methyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"Antibiotic 205T3","termGroup":"SY","termSource":"NCI"},{"termName":"U-15167","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1404-15-5"},{"name":"CHEBI_ID","value":"CHEBI:44504"},{"name":"Chemical_Formula","value":"C39H49NO16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L059DCD6IP"},{"name":"Legacy Concept Name","value":"Nogalamycin"},{"name":"Maps_To","value":"Nogalamycin"},{"name":"NSC Number","value":"70845"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028261"}]}}{"C1577":{"preferredName":"Nolatrexed Dihydrochloride","code":"C1577","definitions":[{"definition":"A substance that is being studied in the treatment of liver cancer. It belongs to the family of drugs called thymidylate synthase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nolatrexed Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydro-2-amino-6-methyl-4-oxy-5-(4-pyridylthio)-quinazoline Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"AG-337","termGroup":"CN","termSource":"NCI"},{"termName":"Nolatrexed Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Thymitaq","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular carcinoma"},{"name":"CAS_Registry","value":"152946-68-4"},{"name":"Chemical_Formula","value":"C14H12N4OS.2ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1XA69O733O"},{"name":"Legacy Concept Name","value":"Nolatrexed"},{"name":"Maps_To","value":"Nolatrexed Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42223"},{"name":"PDQ_Open_Trial_Search_ID","value":"42223"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796399"}]}}{"C84872":{"preferredName":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201","code":"C84872","definitions":[{"definition":"A non-small cell lung cancer (NSCLC) vaccine containing modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities. Upon subcutaneous administration, non-small cell lung cancer mRNA-derived vaccine CV9201 may stimulate the immune system to mount a cytotoxic, antigen-specific T lymphocyte response (CTL) against NSCLC cells. The modified mRNAs in this vaccine are taken up by cells after injection and exhibit enhanced translational potency. The five tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201","termGroup":"PT","termSource":"NCI"},{"termName":"CV9201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201"},{"name":"NCI_Drug_Dictionary_ID","value":"648549"},{"name":"NCI_META_CUI","value":"CL412376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648549"},{"name":"PDQ_Open_Trial_Search_ID","value":"648549"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C703":{"preferredName":"Norgestrel","code":"C703","definitions":[{"definition":"A synthetic progestin commonly used alone or in combination with an estrogen for contraception.  Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes.  This agent also exhibits antiproliferative activity in endometrial tissue and may exhibit chemopreventive and antineoplastic activities in endometrial carcinoma. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Norgestrel","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-13-Ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yne-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"Neogest","termGroup":"BR","termSource":"NCI"},{"termName":"Ovrette","termGroup":"BR","termSource":"NCI"},{"termName":"Wy-3707","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Oral contraception"},{"name":"CAS_Registry","value":"6533-00-2"},{"name":"CHEBI_ID","value":"CHEBI:50901"},{"name":"CHEBI_ID","value":"CHEBI:7630"},{"name":"Chemical_Formula","value":"C21H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3J8Q1747Z2"},{"name":"Legacy Concept Name","value":"Norgestrel"},{"name":"Maps_To","value":"Norgestrel"},{"name":"NCI_Drug_Dictionary_ID","value":"39310"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39310"},{"name":"PDQ_Open_Trial_Search_ID","value":"39310"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028368"}]}}{"C99122":{"preferredName":"North American Ginseng Extract AFX-2","code":"C99122","definitions":[{"definition":"An orally available proprietary aqueous extract from the North American ginseng (Panax quinquefolius) dried root, primarily containing poly-furanosyl-pyranosyl-saccharides, with potential immunostimulating activity. Upon administration, North American ginseng extract AFX-2 may stimulate the proliferation and activation of B-lymphocytes and stimulates IgG production by B cells. Also, this agent induces maturation of dendritic cells, induces T cell proliferation and activates peritoneal exudate macrophages leading to an increase in the production of the cytokines interleukin -1 and -6, tumor necrosis factor-alpha, interferon-gamma and nitric oxide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"North American Ginseng Extract AFX-2","termGroup":"PT","termSource":"NCI"},{"termName":"AFX-2","termGroup":"CN","termSource":"NCI"},{"termName":"COLD-fX","termGroup":"BR","termSource":"NCI"},{"termName":"CVT-E002","termGroup":"CN","termSource":"NCI"},{"termName":"Panax quinquefolius Extract AFX-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"North American Ginseng Extract AFX-2"},{"name":"NCI_Drug_Dictionary_ID","value":"715600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715600"},{"name":"PDQ_Open_Trial_Search_ID","value":"715600"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C1722695"}]}}{"C81423":{"preferredName":"Nortopixantrone","code":"C81423","definitions":[{"definition":"A 9-aza-anthrapyrazole-based antineoplastic antibiotic. Nortopixantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Nortopixantrone is less cardiotoxicity than anthracyclines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nortopixantrone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156090-17-4"},{"name":"Chemical_Formula","value":"C20H24N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PH2639TAB4"},{"name":"Legacy Concept Name","value":"Nortopixantrone"},{"name":"Maps_To","value":"Nortopixantrone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825625"}]}}{"C80589":{"preferredName":"Noscapine","code":"C80589","definitions":[{"definition":"A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Noscapine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"128-62-1"},{"name":"Chemical_Formula","value":"C22H23NO7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8V32U4AOQU"},{"name":"Legacy Concept Name","value":"Noscapine"},{"name":"Maps_To","value":"Noscapine"},{"name":"NSC Number","value":"5366"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028426"}]}}{"C61103":{"preferredName":"Noscapine Hydrochloride","code":"C61103","definitions":[{"definition":"The orally available hydrochloride salt of the opioid agonist noscapine, a phthalideisoquinoline alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine binds to tubulin and alters its conformation, resulting in a disruption of the dynamics of microtubule assembly (by increasing the time that microtubules spend idle in a paused state) and subsequently, the inhibition of mitosis and tumor cell death. Unlike other tubulin inhibitors such as the taxanes and vinca alkaloids, noscapine does not affect microtubule polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Noscapine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1(3H)Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3,-dioxolo(4,5-g)isoquinolin-5-yl)-hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Narcotine hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Noscapine HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cough"},{"name":"CAS_Registry","value":"912-60-7"},{"name":"Chemical_Formula","value":"C22H23NO7.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TTN62ITH9I"},{"name":"Legacy Concept Name","value":"Noscapine_Hydrochloride"},{"name":"Maps_To","value":"Noscapine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"469778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"469778"},{"name":"PDQ_Open_Trial_Search_ID","value":"469778"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1450474"}]}}{"C118569":{"preferredName":"Notch Signaling Inhibitor PF-06650808","code":"C118569","synonyms":[{"termName":"Notch Signaling Inhibitor PF-06650808","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06650808","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Notch Signaling Inhibitor PF-06650808"},{"name":"NCI_META_CUI","value":"CL474089"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49175":{"preferredName":"Notch Signaling Pathway Inhibitor MK0752","code":"C49175","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks signals between growing cells and may kill cancer cells. It is a type of signal transduction inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic small molecule with potential antineoplastic activity. MK0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated. The Notch signaling pathway plays an important role in cell-fate determination, cell survival, and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Notch Signaling Pathway Inhibitor MK0752","termGroup":"PT","termSource":"NCI"},{"termName":"MK-0752","termGroup":"CN","termSource":"NCI"},{"termName":"MK0752","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"471905-41-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9JD9B4S53T"},{"name":"Legacy Concept Name","value":"MK0752"},{"name":"Maps_To","value":"Notch Signaling Pathway Inhibitor MK0752"},{"name":"NCI_Drug_Dictionary_ID","value":"446541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"446541"},{"name":"PDQ_Open_Trial_Search_ID","value":"446541"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708824"}]}}{"C118948":{"preferredName":"Taletrectinib","code":"C118948","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, with potential antineoplastic activity. Upon oral administration, taletrectinib binds to and inhibits ROS1 and the NTRK family members. This inhibition leads to a disruption of ROS1- and NTRK-mediated signaling and eventually inhibits the growth of tumor cells that are overexpressing ROS1 and/or NTRKs. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells. NTRK mutations or rearrangements play a key role in cancer progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taletrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"AB 106","termGroup":"CN","termSource":"NCI"},{"termName":"AB-106","termGroup":"CN","termSource":"NCI"},{"termName":"AB106","termGroup":"CN","termSource":"NCI"},{"termName":"DS-6051A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1505514-27-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W4141180YD"},{"name":"Maps_To","value":"NTRK/ROS1 Inhibitor DS-6051b"},{"name":"Maps_To","value":"Taletrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"766123"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766123"},{"name":"PDQ_Open_Trial_Search_ID","value":"766123"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896871"}]}}{"C103297":{"preferredName":"Nucleolin Antagonist IPP-204106N","code":"C103297","definitions":[{"definition":"A synthetic, multivalent, lysine-rich, pseudopeptide and nucleolin antagonist with potential anti-angiogenic, antineoplastic and pro-apoptotic activities. Upon administration, IPP-204106N antagonizes nucleolin leading to a downregulation of cell-surface nucleolin; preventing the binding of certain growth promoting ligands to nucleolin may suppress tumor cell proliferation and angiogenesis. In addition, IPP-204106N is able to translocate to the nucleolus and bind to nucleolar nucleolin. This prevents nucleolin from binding to and stabilizing mRNA of the anti-apoptotic Bcl2; destabilizing Bcl2 mRNA leads to a reduction in Bcl2 protein synthesis and induces apoptosis. Further, this agent can antagonize nucleophosmin. Nucleolin, a nucleolar phosphoprotein, is overexpressed on the cell surface of certain cancer cells and binds ligands involved in cell proliferation, adhesion and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleolin Antagonist IPP-204106N","termGroup":"PT","termSource":"NCI"},{"termName":"IPP-204106","termGroup":"CN","termSource":"NCI"},{"termName":"N6L","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nucleolin Antagonist IPP-204106N"},{"name":"NCI_Drug_Dictionary_ID","value":"742115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742115"},{"name":"PDQ_Open_Trial_Search_ID","value":"742115"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641183"}]}}{"C116744":{"preferredName":"Nucleoside Analog DFP-10917","code":"C116744","definitions":[{"definition":"A deoxycytosine analog with potential antineoplastic activity. Upon administration, DFP-10917 is phosphorylated to generate its nucleotide form that functions as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, which results in G2/M phase-arrest and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleoside Analog DFP-10917","termGroup":"PT","termSource":"NCI"},{"termName":"2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine","termGroup":"SN","termSource":"NCI"},{"termName":"DFP-10917","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nucleoside Analog DFP-10917"},{"name":"NCI_Drug_Dictionary_ID","value":"741505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741505"},{"name":"PDQ_Open_Trial_Search_ID","value":"741505"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0091023"}]}}{"C156680":{"preferredName":"Fosifloxuridine Nafalbenamide","code":"C156680","definitions":[{"definition":"A phosphoramidate-based prodrug of the monophosphate (MP) form of 5-fluoro-2'-deoxyuridine (FUdR; FUDR), the active metabolite of fluorouracil (5-FU), an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity. Upon administration of the nucleotide analog prodrug fosifloxuridine nafalbenamide, fosifloxuridine nafalbenamide is readily taken up by tumor cells. In the tumor cell, the phosphoramidate moiety is removed and fosifloxuridine nafalbenamide is converted to its active form FUDR-MP. In turn, FUDR-MP binds to and inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate (TTP) and thus DNA synthesis. With the phosphoramidate moiety attached to FUDR-MP, fosifloxuridine nafalbenamide, compared to 5-FU, is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, thereby generating higher intracellular concentrations. In addition, compared to 5-FU, once inside the cell FUDR-MP does not need to be phosphorylated and is already in its active form. Unlike 5-FU, fosifloxuridine nafalbenamide does not get deactivated or converted into toxic metabolites by dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP), which leads to both a longer half-life and less toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosifloxuridine Nafalbenamide","termGroup":"PT","termSource":"NCI"},{"termName":"5-FU Analog Prodrug NUC-3373","termGroup":"SY","termSource":"NCI"},{"termName":"L-Alanine, N-(-2'-Deoxy-2',2'-difluoro-p-1-naphthalenyl-5'-cytidylyl)-, Phenylmethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"NUC 3373","termGroup":"CN","termSource":"NCI"},{"termName":"NUC-3373","termGroup":"CN","termSource":"NCI"},{"termName":"NUC3373","termGroup":"CN","termSource":"NCI"},{"termName":"Nucleotide Analog NUC-3373","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphoramidate-FUDR-MP Prodrug NUC-3373","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1332837-31-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4YO6QT3SZ9"},{"name":"Maps_To","value":"Fosifloxuridine Nafalbenamide"},{"name":"Maps_To","value":"Nucleotide Analog Prodrug NUC-3373"},{"name":"NCI_Drug_Dictionary_ID","value":"795584"},{"name":"NCI_META_CUI","value":"CL935731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795584"},{"name":"PDQ_Open_Trial_Search_ID","value":"795584"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71742":{"preferredName":"Nucleotide Analogue GS 9219","code":"C71742","definitions":[{"definition":"A prodrug of the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG) with potential antineoplastic activity. Formulated to selectively accumulate in lymphocytes, nucleotide analogue GS 9219 is converted to its active metabolite, PMEG diphosphate (PMEGpp), via enzymatic hydrolysis, deamination, and phosphorylation; subsequently, PMEGpp is incorporated into nascent DNA chains by DNA polymerases, which may result in the termination of DNA synthesis, S-phase cell cycle arrest, and the induction of apoptosis in susceptible lymphoma cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleotide Analogue GS 9219","termGroup":"PT","termSource":"NCI"},{"termName":"9-(2-phosphonylmethoxyethyl)guanine nucleotide analogue prodrug GS 9219","termGroup":"SY","termSource":"NCI"},{"termName":"GS9219","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nucleotide_Analogue_GS_9219"},{"name":"Maps_To","value":"Nucleotide Analogue GS 9219"},{"name":"NCI_Drug_Dictionary_ID","value":"560932"},{"name":"NCI_META_CUI","value":"CL376149"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560932"},{"name":"PDQ_Open_Trial_Search_ID","value":"560932"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74594":{"preferredName":"Rebemadlin","code":"C74594","definitions":[{"definition":"A small molecule and MDM2 (murine double minute 2) inhibitor, with potential antineoplastic activity. In cancer cells, rebemadlin antagonizes the binding of MDM2 to p53, thereby preventing MDM2-mediated p53 degradation. This results in stabilizing and activating p53-dependent cell cycle arrest and apoptosis. The protein MDM2, a negative regulator of p53 activity, is overexpressed in many cancer cell types; the tumor suppressor p53 is mutated or deleted in about 50% of all cancers but active in the other 50%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebemadlin","termGroup":"PT","termSource":"NCI"},{"termName":"Nutlin-3a","termGroup":"SY","termSource":"NCI"},{"termName":"SML-0580","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"675576-98-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L7C92IOE65"},{"name":"Legacy Concept Name","value":"Nutlin-3a"},{"name":"Maps_To","value":"Nutlin-3a"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1956368"}]}}{"C96036":{"preferredName":"Nutraceutical TBL-12","code":"C96036","definitions":[{"definition":"An orally available nutritional supplement and proprietary formulation containing extracts from the sea cucumber, sea sponge, shark fin, sea urchin and the marine grass Sargassum, with potential antioxidant, antitumor, anti-angiogenic and immunomodulating activities. TBL-12 contains various amino acids, minerals, vitamins and omega-3 fatty acids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nutraceutical TBL-12","termGroup":"PT","termSource":"NCI"},{"termName":"TBL-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nutraceutical TBL-12"},{"name":"NCI_Drug_Dictionary_ID","value":"696523"},{"name":"NCI_META_CUI","value":"CL428370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696523"},{"name":"PDQ_Open_Trial_Search_ID","value":"696523"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62452":{"preferredName":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611","code":"C62452","definitions":[{"definition":"A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1 plasmid DNA cancer vaccine pPJV7611 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1 is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611","termGroup":"PT","termSource":"NCI"},{"termName":"pPJV7611","termGroup":"CN","termSource":"NCI"},{"termName":"pPJV7611 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NY-ESO-1_Plasmid_DNA_Vaccine"},{"name":"Maps_To","value":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611"},{"name":"NCI_Drug_Dictionary_ID","value":"489121"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489121"},{"name":"PDQ_Open_Trial_Search_ID","value":"489121"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831877"}]}}{"C120557":{"preferredName":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301","code":"C120557","definitions":[{"definition":"Human peripheral blood T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and introduction into the patient, the NY-ESO-1-specific TCR gene-transduced T lymphocytes TBI-1301 bind to NY-ESO-1 on tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301","termGroup":"PT","termSource":"NCI"},{"termName":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"TBI-1301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301"},{"name":"NCI_Drug_Dictionary_ID","value":"769543"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769543"},{"name":"PDQ_Open_Trial_Search_ID","value":"769543"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053586"}]}}{"C113432":{"preferredName":"NY-ESO-1/GLA-SE Vaccine ID-G305","code":"C113432","definitions":[{"definition":"A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-1/GLA-SE Vaccine ID-G305","termGroup":"PT","termSource":"NCI"},{"termName":"ID-G305","termGroup":"CN","termSource":"NCI"},{"termName":"IDC-G305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NY-ESO-1/GLA-SE Vaccine ID-G305"},{"name":"NCI_Drug_Dictionary_ID","value":"756236"},{"name":"NCI_META_CUI","value":"CL458226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756236"},{"name":"PDQ_Open_Trial_Search_ID","value":"756236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26680":{"preferredName":"NY-ESO-B","code":"C26680","definitions":[{"definition":"A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NY-ESO-B"},{"name":"Maps_To","value":"NY-ESO-B"},{"name":"NCI_Drug_Dictionary_ID","value":"257347"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257347"},{"name":"PDQ_Open_Trial_Search_ID","value":"257347"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1327762"}]}}{"C1298":{"preferredName":"O-Chloroacetylcarbamoylfumagillol","code":"C1298","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"O-Chloroacetylcarbamoylfumagillol","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,4S,5S,6R)-5-Methoxy-4- [(2R,3R)-2-methyl-3-(3-methyl-2-butenyl) -oxiranyl]-1-oxaspiro [2,5] oct-6-yl(chloroacetyl) Carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl) carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"AGM-1470","termGroup":"CN","termSource":"NCI"},{"termName":"TNP-470","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129298-91-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X47GR46481"},{"name":"Legacy Concept Name","value":"TNP-470"},{"name":"Maps_To","value":"O-Chloroacetylcarbamoylfumagillol"},{"name":"NCI_Drug_Dictionary_ID","value":"41725"},{"name":"NSC Number","value":"642492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41725"},{"name":"PDQ_Open_Trial_Search_ID","value":"41725"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0081489"}]}}{"C1306":{"preferredName":"O6-Benzylguanine","code":"C1306","definitions":[{"definition":"A drug that may improve the response of cancer cells to chemotherapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"O6-Benzylguanine","termGroup":"PT","termSource":"NCI"},{"termName":"2-amino-6-(benzyloxy)purine","termGroup":"SN","termSource":"NCI"},{"termName":"2-amino-6-(phenylmethoxy)-9h-purine","termGroup":"SN","termSource":"NCI"},{"termName":"O(6)-Benzylguanine","termGroup":"SY","termSource":"NCI"},{"termName":"O-6-Benzylguanine","termGroup":"SN","termSource":"NCI"},{"termName":"O6-Benzylguanine","termGroup":"SN","termSource":"NCI"},{"termName":"O6-BG","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"19916-73-5"},{"name":"Chemical_Formula","value":"C12H11N5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01KC87F8FE"},{"name":"Legacy Concept Name","value":"O_6_Benzylguanine"},{"name":"Maps_To","value":"O6-Benzylguanine"},{"name":"NCI_Drug_Dictionary_ID","value":"42113"},{"name":"NSC Number","value":"637037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42113"},{"name":"PDQ_Open_Trial_Search_ID","value":"42113"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0083812"}]}}{"C62771":{"preferredName":"Obatoclax Mesylate","code":"C62771","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It is a form of obatoclax, which blocks the activity of certain proteins needed for cells to live and may cause tumor cells to die. It is a type of apoptosis inducer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of obatoclax, a synthetic small-molecule inhibitor of the bcl-2 family of proteins with potential pro-apoptotic and antineoplastic activities. Obatoclax binds to members of the Bcl-2 protein family, preventing the binding of these anti-apoptotic proteins to the pro-apoptotic proteins Bax and Bak and so promoting the activation of the apoptotic pathway in Bcl-2-overexpressing cells. The Bcl-2 family of proteins (bcl-2, bcl-xl, bcl-w, and Mcl-1) are overexpressed in a wide variety of cancers, including those of the lymphatic system, breast, lung, prostate, and colon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obatoclax Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylidene]-3-methoxy-2H-pyrrol-5-yl)-1H-indole Monomethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"GX15-070MS","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"803712-79-0"},{"name":"Chemical_Formula","value":"C20H19N3O.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39200FJ43J"},{"name":"Legacy Concept Name","value":"Obatoclax_Mesylate"},{"name":"Maps_To","value":"Obatoclax Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"504100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504100"},{"name":"PDQ_Open_Trial_Search_ID","value":"504100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831948"}]}}{"C70741":{"preferredName":"Obinutuzumab","code":"C70741","definitions":[{"definition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obinutuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Afutuzumab","termGroup":"AQS","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody R7159","termGroup":"SY","termSource":"NCI"},{"termName":"GA-101","termGroup":"CN","termSource":"NCI"},{"termName":"GA101","termGroup":"CN","termSource":"NCI"},{"termName":"Gazyva","termGroup":"BR","termSource":"NCI"},{"termName":"huMAB(CD20)","termGroup":"SY","termSource":"NCI"},{"termName":"R7159","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5072759","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5072759","termGroup":"CN","termSource":"NCI"},{"termName":"RO5072759","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"follicular lymphoma (FL); chronic lymphocytic leukemia"},{"name":"CAS_Registry","value":"949142-50-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"O43472U9X8"},{"name":"Legacy Concept Name","value":"Anti-CD20_Monoclonal_Antibody_R7159"},{"name":"Maps_To","value":"Obinutuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"570643"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570643"},{"name":"PDQ_Open_Trial_Search_ID","value":"570643"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742503"}]}}{"C66722":{"preferredName":"Oblimersen Sodium","code":"C66722","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs. It is a type of antisense oligodeoxyribonucleotide.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oblimersen Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Anticode G3139","termGroup":"SY","termSource":"NCI"},{"termName":"Augmerosen","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-2 Antisense Oligodeoxynucleotide G3139","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-2 Antisense/G3139","termGroup":"SY","termSource":"NCI"},{"termName":"G3139","termGroup":"CN","termSource":"NCI"},{"termName":"G3139 Antisense Oligonucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"G3139 BCL-2 Antisense Oligo","termGroup":"SY","termSource":"NCI"},{"termName":"G3139 BCL-2 Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"G3139 BCL-2 Antisense Oligonucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"Genasense","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"190977-41-4"},{"name":"Chemical_Formula","value":"C172H204N62O91P17S17.17Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SH55B0RQ9K"},{"name":"Legacy Concept Name","value":"Oblimersen_Sodium"},{"name":"Maps_To","value":"Oblimersen Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"42935"},{"name":"NSC Number","value":"683428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42935"},{"name":"PDQ_Open_Trial_Search_ID","value":"42935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935954"}]}}{"C2524":{"preferredName":"Ocaratuzumab","code":"C2524","definitions":[{"definition":"An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20. The Fc portion of this monoclonal antibody has been engineered to possess a higher binding affinity for variant Fc receptors on T helper cells, resulting in an augmentation of the anti-tumor immune response. Because of Fc engineering, this agent may be significantly more potent than rituximab in inducing B cell-directed ADCC. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ocaratuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AME-133v","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody AME-133v","termGroup":"SY","termSource":"NCI"},{"termName":"LY 2469298","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb CD20","termGroup":"AB","termSource":"NCI"},{"termName":"monoclonal antibody, CD20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1169956-08-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NTY9893GD0"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CD20"},{"name":"Maps_To","value":"Ocaratuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"500055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500055"},{"name":"PDQ_Open_Trial_Search_ID","value":"500055"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831936"}]}}{"C66250":{"preferredName":"Ocrelizumab","code":"C66250","definitions":[{"definition":"A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ocrelizumab","termGroup":"PT","termSource":"NCI"},{"termName":"PR070769","termGroup":"CN","termSource":"NCI"},{"termName":"PRO-70769","termGroup":"CN","termSource":"NCI"},{"termName":"PRO70769","termGroup":"CN","termSource":"NCI"},{"termName":"rhuMAb 2H7","termGroup":"SY","termSource":"NCI"},{"termName":"RO4964913","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"637334-45-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A10SJL62JY"},{"name":"Legacy Concept Name","value":"Ocrelizumab"},{"name":"Maps_To","value":"Ocrelizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"780147"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780147"},{"name":"PDQ_Open_Trial_Search_ID","value":"780147"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882138"}]}}{"C711":{"preferredName":"Octreotide","code":"C711","definitions":[{"definition":"A drug similar to the naturally occurring growth hormone inhibitor somatostatin. Octreotide is used to treat diarrhea and flushing associated with certain types of tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Octreotide","termGroup":"PT","termSource":"NCI"},{"termName":"D-Phenylalanyl-L-cysteinyl-L-phenyl-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2->7)-Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol Cyclic (2->7)-Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"SMS-201-995","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acromegaly; Diarrhea"},{"name":"CAS_Registry","value":"83150-76-9"},{"name":"CHEBI_ID","value":"CHEBI:7726"},{"name":"Chemical_Formula","value":"C49H66N10O10S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RWM8CCW8GP"},{"name":"Legacy Concept Name","value":"Octreotide"},{"name":"Maps_To","value":"Octreotide"},{"name":"PubMedID_Primary_Reference","value":"16917205"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028833"}]}}{"C53447":{"preferredName":"Octreotide Acetate","code":"C53447","definitions":[{"definition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Octreotide Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Longastatin","termGroup":"SY","termSource":"NCI"},{"termName":"Longastatina","termGroup":"FB","termSource":"NCI"},{"termName":"Samilstin","termGroup":"FB","termSource":"NCI"},{"termName":"Sandostatin","termGroup":"BR","termSource":"NCI"},{"termName":"Sandostatin LAR","termGroup":"SY","termSource":"NCI"},{"termName":"Sandostatin Lar Depot","termGroup":"BR","termSource":"NCI"},{"termName":"Sandostatina","termGroup":"FB","termSource":"NCI"},{"termName":"Sandostatine","termGroup":"FB","termSource":"NCI"},{"termName":"SMS 201-995","termGroup":"CN","termSource":"NCI"},{"termName":"SMS 201-995 AC","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acromegaly; Diarrhea"},{"name":"CAS_Registry","value":"79517-01-4"},{"name":"Chemical_Formula","value":"C49H66N10O10S2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"75R0U2568I"},{"name":"Legacy Concept Name","value":"Octreotide_Acetate"},{"name":"Maps_To","value":"Octreotide Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"38866"},{"name":"NSC Number","value":"671663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38866"},{"name":"PDQ_Open_Trial_Search_ID","value":"38866"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678117"}]}}{"C2402":{"preferredName":"Octreotide Pamoate","code":"C2402","definitions":[{"definition":"A synthetic long-acting octapeptide analogue of endogenous somatostatin.  Octreotide pamoate binds to somatostatin receptors expressed by some neuroendocrine and non-neuroendocrine tumor cells, thereby initiating somatostatin receptor-mediated apoptosis. Other possible antineoplastic activities of this agent include suppression of tumor angiogenesis and tumor growth-promoting insulin-like growth factor 1 (IGF-1).  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Octreotide Pamoate","termGroup":"PT","termSource":"NCI"},{"termName":"Octreotide Embpnate","termGroup":"SY","termSource":"NCI"},{"termName":"OncoLar","termGroup":"BR","termSource":"NCI"},{"termName":"OP LAR","termGroup":"SY","termSource":"NCI"},{"termName":"SMS 201-995 PA","termGroup":"CN","termSource":"NCI"},{"termName":"SMS 201-995 pa LAR","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135467-16-2"},{"name":"Chemical_Formula","value":"C49H66N10O10S2.C23H16O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MWH8YQ1AIO"},{"name":"Legacy Concept Name","value":"Octreotide_Pamoate"},{"name":"Maps_To","value":"Octreotide Pamoate"},{"name":"NCI_Drug_Dictionary_ID","value":"42358"},{"name":"NSC Number","value":"685403"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42358"},{"name":"PDQ_Open_Trial_Search_ID","value":"42358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338271"}]}}{"C66952":{"preferredName":"Ofatumumab","code":"C66952","definitions":[{"definition":"A drug used to treat chronic lymphocytic leukemia (CLL) that has not gotten better with other chemotherapy. It is also being studied in the treatment of other types of cancer, including follicular non-Hodgkin lymphoma. Arzerra binds to CD20, a protein on the surface of normal B cells and most B-cell tumors. This may kill the cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ofatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Arzerra","termGroup":"BR","termSource":"NCI"},{"termName":"GSK1841157","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-CD20","termGroup":"FB","termSource":"NCI"},{"termName":"HuMax-CD20, 2F2","termGroup":"AB","termSource":"NCI"},{"termName":"Kesimpta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia (CLL)"},{"name":"CAS_Registry","value":"679818-59-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M95KG522R0"},{"name":"Legacy Concept Name","value":"Ofatumumab"},{"name":"Maps_To","value":"Ofatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"530015"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530015"},{"name":"PDQ_Open_Trial_Search_ID","value":"530015"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832027"}]}}{"C2558":{"preferredName":"Oglufanide Disodium","code":"C2558","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disodium salt of a synthetic form of a naturally-occurring dipeptide consisting of L-glutamic acid and L-tryptophan with potential antiangiogenic and potential immunomodulating activities. Oglufanide inhibits vascular endothelial growth factor (VEGF), which may inhibit angiogenesis. This agent has also been reported to stimulate the immune response to hepatitic C virus and intracellular bacterial infections.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oglufanide Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Glufanide Disodium","termGroup":"SY","termSource":"NCI"},{"termName":"IM 862","termGroup":"CN","termSource":"NCI"},{"termName":"IM862","termGroup":"CN","termSource":"NCI"},{"termName":"L-Tryptophan, L-alpha-glutamyl-, disodium salt","termGroup":"SN","termSource":"NCI"},{"termName":"Oglufanide Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Thymogen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"237068-57-4"},{"name":"Chemical_Formula","value":"C16H17N3O5.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q60AU1LLNU"},{"name":"Legacy Concept Name","value":"Glufanide_Disodium"},{"name":"Maps_To","value":"Oglufanide Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43387"},{"name":"NCI_META_CUI","value":"CL032903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43387"},{"name":"PDQ_Open_Trial_Search_ID","value":"43387"},{"name":"PubMedID_Primary_Reference","value":"12180893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71721":{"preferredName":"Olaparib","code":"C71721","definitions":[{"definition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast, ovarian, and prostate cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. AZD2281 may cause cancer cells to die. It is a type of targeted therapy agent and a type of poly (ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Olaparib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 2281","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-2281","termGroup":"CN","termSource":"NCI"},{"termName":"AZD2281","termGroup":"CN","termSource":"NCI"},{"termName":"KU-0059436","termGroup":"CN","termSource":"NCI"},{"termName":"Lynparza","termGroup":"BR","termSource":"NCI"},{"termName":"Olanib","termGroup":"FB","termSource":"NCI"},{"termName":"Olaparix","termGroup":"FB","termSource":"NCI"},{"termName":"PARP Inhibitor AZD2281","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."},{"name":"Accepted_Therapeutic_Use_For","value":"deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer; deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer"},{"name":"CAS_Registry","value":"763113-22-0"},{"name":"Chemical_Formula","value":"C24H23FN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WOH1JD9AR8"},{"name":"Legacy Concept Name","value":"PARP_Inhibitor_AZD2281"},{"name":"Maps_To","value":"Olaparib"},{"name":"NCI_Drug_Dictionary_ID","value":"560191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560191"},{"name":"PDQ_Open_Trial_Search_ID","value":"560191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2316164"}]}}{"C99379":{"preferredName":"Olaptesed Pegol","code":"C99379","definitions":[{"definition":"A 45-mer L-stereoisomer RNA oligonucleotide linked to a 40 kDa polyethyleneglycol that targets the small chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) with potential antineoplastic and hematopoietic stem cell-mobilization activities. SDF-1 targeted agent NOX-A12 specifically binds to SDF-1 thereby preventing the binding of SDF-1 to its receptors CXCR4 and CXCR7 blocking the subsequent receptor activation. This may prevent angiogenesis, tumor cell proliferation, invasion and metastasis and could sensitize tumor cells to chemotherapy. In addition, inhibition of SDF-1/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into blood. The unique mirror-image configuration of this agent renders it resistant to hydrolysis and does not hybridize with native nucleic acids. Furthermore, this agent does not induce the innate immune response and has shown a favorable immunogenicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olaptesed Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"NOX-A12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1390628-22-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MTM792B442"},{"name":"Maps_To","value":"Olaptesed Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"719932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"719932"},{"name":"PDQ_Open_Trial_Search_ID","value":"719932"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274704"}]}}{"C79825":{"preferredName":"Olaratumab","code":"C79825","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of glioblastoma (a type of brain tumor) that has come back. It binds to receptors for a protein called platelet-derived growth factor (PDGF). This keeps PDGF from binding to the cells. This may stop the growth of cancer cells and blood vessels that have the receptors for PDGF. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Olaratumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PDGFR alpha Monoclonal Antibody IMC-3G3","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Platelet-Derived Growth Factor Receptor alpha Monoclonal Antibody IMC-3G3","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-3G3","termGroup":"CN","termSource":"NCI"},{"termName":"Lartruvo","termGroup":"BR","termSource":"NCI"},{"termName":"LY3012207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"soft tissue sarcoma (STS)"},{"name":"CAS_Registry","value":"1024603-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"TT6HN20MVF"},{"name":"Legacy Concept Name","value":"Anti-PDGFR_alpha_Monoclonal_Antibody_IMC-3G3"},{"name":"Maps_To","value":"Olaratumab"},{"name":"NCI_Drug_Dictionary_ID","value":"626630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626630"},{"name":"PDQ_Open_Trial_Search_ID","value":"626630"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703171"}]}}{"C90586":{"preferredName":"Oleandrin","code":"C90586","definitions":[{"definition":"A lipid soluble cardiac glycoside with potential antineoplastic activity. Upon administration, oleandrin specifically binds to and inhibits the alpha3 subunit of the Na/K-ATPase pump in human cancer cells. This may inhibit the phosphorylation of Akt, upregulate MAPK, inhibit NF-kb activation and inhibit FGF-2 export and may downregulate mTOR thereby inhibiting p70S6K and S6 protein expression. All of this may lead to an induction of apoptosis. As cancer cells with relatively higher expression of the alpha3 subunit and with limited expression of the alpha1 subunit are more sensitive to oleandrin, one may predict the tumor response to treatment with lipid-soluble cardiac glycosides such as oleandrin based on the tumors Na/K-ATPase pump protein subunit expression. Overexpression of the alpha3 subunit in tumor cells correlates with tumor proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oleandrin","termGroup":"PT","termSource":"NCI"},{"termName":"PBI-05204","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"465-16-7"},{"name":"CHEBI_ID","value":"CHEBI:59030"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"II95UDU7I4"},{"name":"Maps_To","value":"Oleandrin"},{"name":"NCI_Drug_Dictionary_ID","value":"579304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579304"},{"name":"PDQ_Open_Trial_Search_ID","value":"579304"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069397"}]}}{"C123914":{"preferredName":"Oleclumab","code":"C123914","definitions":[{"definition":"A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oleclumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD73 Monoclonal Antibody MEDI9447","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI9447","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1803176-05-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5CRY01URYQ"},{"name":"Maps_To","value":"Oleclumab"},{"name":"NCI_Drug_Dictionary_ID","value":"775839"},{"name":"NCI_META_CUI","value":"CL498278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775839"},{"name":"PDQ_Open_Trial_Search_ID","value":"775839"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61325":{"preferredName":"Oligonucleotide SPC2996","code":"C61325","definitions":[{"definition":"A synthetic antisense oligonucleotide against Bcl-2 messenger RNA with potential antitumor activity. Oligonucleotide SPC2996 binds to and inactivates Bcl-2 mRNA, thereby inhibiting the expression of Bcl-2 protein, promoting tumor cell apoptosis, and potentially enhancing the efficacy of standard cytotoxic chemotherapy. Linked to tumor drug resistance, the antiapoptotic protein Bcl-2 is upregulated in several types of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligonucleotide SPC2996","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SPC2996_Oligonucleotide"},{"name":"Maps_To","value":"Oligonucleotide SPC2996"},{"name":"NCI_Drug_Dictionary_ID","value":"485272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485272"},{"name":"PDQ_Open_Trial_Search_ID","value":"485272"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831825"}]}}{"C715":{"preferredName":"Olivomycin","code":"C715","definitions":[{"definition":"A preparation containing a mixture of glycosidic antibiotics isolated from Streptomyces olivoreticuli with fluorescent microscopy applications and potential antineoplastic activities. Olivomycin preferentially binds to DNA and can be utilized as a fluorescent marker during the characterization of heterochromatin. Additionally, binding to DNA inhibits both RNA transcription and RNA elongation by RNA polymerase; therefore protein synthesis is inhibited. In addition, olivomycin antibiotics are able to induce apoptosis in tumor cells through a mechanism that has not yet been fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olivomycin","termGroup":"PT","termSource":"NCI"},{"termName":"Oligomycin A, mixt. with oligomycin B","termGroup":"SY","termSource":"NCI"},{"termName":"Olivomycins","termGroup":"SY","termSource":"NCI"},{"termName":"Toyomycin R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11006-70-5"},{"name":"CHEBI_ID","value":"CHEBI:52515"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44003517D1"},{"name":"Legacy Concept Name","value":"Olivomycin_Antibiotic"},{"name":"Maps_To","value":"Olivomycin"},{"name":"NSC Number","value":"76411"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028967"}]}}{"C101791":{"preferredName":"Olmutinib","code":"C101791","definitions":[{"definition":"An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olmutinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"BI 1482694","termGroup":"CN","termSource":"NCI"},{"termName":"HM61713","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353550-13-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CHL9B67L95"},{"name":"Maps_To","value":"Olmutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"733621"},{"name":"NCI_META_CUI","value":"CL435909"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733621"},{"name":"PDQ_Open_Trial_Search_ID","value":"733621"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1177":{"preferredName":"Oltipraz","code":"C1177","definitions":[{"definition":"A drug used in cancer prevention.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. Although the exact mechanism through which the anti-angiogenesis effect remains to be fully elucidated, oltipraz maybe able to modulate the expression of a number of angiogenic factors, thereby blocking the sustained and focal neovascularization in multiple tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oltipraz","termGroup":"PT","termSource":"NCI"},{"termName":"3H-1,2-Dithiole-3-thione,4-methyl-5-pyrazinyl","termGroup":"SN","termSource":"NCI"},{"termName":"4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"5-[2-Pyrazinyl]-4-methyl-1,2-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"RP-35,972","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64224-21-1"},{"name":"Chemical_Formula","value":"C8H6N2S3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6N510JUL1Y"},{"name":"Legacy Concept Name","value":"Oltipraz"},{"name":"Maps_To","value":"Oltipraz"},{"name":"NCI_Drug_Dictionary_ID","value":"41866"},{"name":"NSC Number","value":"347901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41866"},{"name":"PDQ_Open_Trial_Search_ID","value":"41866"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069456"}]}}{"C129687":{"preferredName":"Olutasidenib","code":"C129687","definitions":[{"definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), with potential antineoplastic activity. Upon administration, olutasidenib specifically inhibits IDH1(R132), thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH(R132). IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olutasidenib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"FT 2102","termGroup":"CN","termSource":"NCI"},{"termName":"FT-2102","termGroup":"CN","termSource":"NCI"},{"termName":"IDH1-R132 Inhibitor FT-2102","termGroup":"SY","termSource":"NCI"},{"termName":"Rezlidhia","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1887014-12-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0T4IMT8S5Z"},{"name":"Maps_To","value":"Olutasidenib"},{"name":"NCI_Drug_Dictionary_ID","value":"780143"},{"name":"NCI_META_CUI","value":"CL507891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780143"},{"name":"PDQ_Open_Trial_Search_ID","value":"780143"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1127":{"preferredName":"Omacetaxine Mepesuccinate","code":"C1127","definitions":[{"definition":"A semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the plant alkaloid family of drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Omacetaxine Mepesuccinate","termGroup":"PT","termSource":"NCI"},{"termName":"Ceflatonin","termGroup":"BR","termSource":"NCI"},{"termName":"Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)","termGroup":"SN","termSource":"NCI"},{"termName":"Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"CGX-635","termGroup":"CN","termSource":"NCI"},{"termName":"HHT","termGroup":"AB","termSource":"NCI"},{"termName":"Omapro","termGroup":"FB","termSource":"NCI"},{"termName":"Synribo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26833-87-4"},{"name":"Chemical_Formula","value":"C29H39NO9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6FG8041S5B"},{"name":"Legacy Concept Name","value":"Homoharringtonine"},{"name":"Maps_To","value":"Omacetaxine Mepesuccinate"},{"name":"NCI_Drug_Dictionary_ID","value":"39476"},{"name":"NSC Number","value":"141633"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39476"},{"name":"PDQ_Open_Trial_Search_ID","value":"39476"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062941"}]}}{"C78480":{"preferredName":"Ombrabulin","code":"C78480","definitions":[{"definition":"A synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ombrabulin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-amino-3-hydroxy-n-(2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)propanamide","termGroup":"SN","termSource":"NCI"},{"termName":"AC7700","termGroup":"CN","termSource":"NCI"},{"termName":"AVE8062","termGroup":"CN","termSource":"NCI"},{"termName":"Combretastatin A4 Analogue AVE8062","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"181816-48-8"},{"name":"Chemical_Formula","value":"C21H26N2O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82JB1524Q6"},{"name":"Legacy Concept Name","value":"Combretastatin_A4_Analogue_AVE8062"},{"name":"Maps_To","value":"Ombrabulin"},{"name":"NCI_Drug_Dictionary_ID","value":"600816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600816"},{"name":"PDQ_Open_Trial_Search_ID","value":"600816"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0910081"}]}}{"C88270":{"preferredName":"Omipalisib","code":"C88270","definitions":[{"definition":"A small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. Omipalisib binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Omipalisib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, 2,4-Difluoro-N-(2-methoxy-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"GSK2126458","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1086062-66-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1X8F5A3NA0"},{"name":"Maps_To","value":"Omipalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"655580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655580"},{"name":"PDQ_Open_Trial_Search_ID","value":"655580"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981793"}]}}{"C85454":{"preferredName":"Onalespib","code":"C85454","definitions":[{"definition":"A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onalespib","termGroup":"PT","termSource":"NCI"},{"termName":"(2,4-Dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone","termGroup":"SN","termSource":"NCI"},{"termName":"AT 13387","termGroup":"CN","termSource":"NCI"},{"termName":"AT-13387","termGroup":"CN","termSource":"NCI"},{"termName":"AT13387","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"912999-49-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q7Y33N57ZZ"},{"name":"Maps_To","value":"Onalespib"},{"name":"NCI_Drug_Dictionary_ID","value":"642817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642817"},{"name":"PDQ_Open_Trial_Search_ID","value":"642817"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2975147"}]}}{"C129425":{"preferredName":"Onalespib Lactate","code":"C129425","definitions":[{"definition":"The lactate form of onalespib, a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onalespib Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"AT-13387 Lactate","termGroup":"CN","termSource":"NCI"},{"termName":"ATI-13387A","termGroup":"CN","termSource":"NCI"},{"termName":"ATI-13387AU","termGroup":"CN","termSource":"NCI"},{"termName":"Propanoic Acid, 2-Hydroxy-, (2S)-, Compound with (1,3-Dihydro-5-((4-methyl-1-piperazinyl)methyl)-2H-isoindol-2-yl)(2,4-dihydroxy-5-(1-methylethyl)phenyl)methanone (1:1)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1019889-35-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"66226JUH2I"},{"name":"Maps_To","value":"Onalespib Lactate"},{"name":"NCI_META_CUI","value":"CL512600"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82348":{"preferredName":"Onartuzumab","code":"C82348","definitions":[{"definition":"A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity. Anti-MET monoclonal antibody MetMAb binds to the extracellular domain of c-Met, preventing the binding of its ligand, hepatocyte growth factor (HGF); the activation of the c-Met signaling pathway is thus inhibited, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase, is overexpressed on the cell surfaces of a variety of cancer cell types and may play a key role in their proliferation, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onartuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-MET Monoclonal Antibody MetMAb","termGroup":"SY","termSource":"NCI"},{"termName":"MetMAb","termGroup":"CN","termSource":"NCI"},{"termName":"OA-5D5","termGroup":"CN","termSource":"NCI"},{"termName":"PRO 143966","termGroup":"CN","termSource":"NCI"},{"termName":"RO5490258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1133766-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MS1J9720WC"},{"name":"Legacy Concept Name","value":"Anti-MET_Monoclonal_Antibody_MetMAb"},{"name":"Maps_To","value":"Onartuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"639516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639516"},{"name":"PDQ_Open_Trial_Search_ID","value":"639516"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2826110"}]}}{"C74067":{"preferredName":"Tasadenoturev","code":"C74067","definitions":[{"definition":"An adenovirus serotype 5 strain, selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, with potential oncolytic activity. Tasadenoturev contains an integrin binding RGD-4C motif, allowing Coxsackie adenovirus receptor-independent infection of tumor cells, which are often deficient for Coxsackie and adenovirus receptors (CARs). Selectively replication competent in cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16), active replication of oncolytic adenovirus Ad5-Delta 24RGD in tumor cells may induce oncolysis or cell lysis. As integral components of the late G1 restriction point, the Rb gene product and p16 are negative regulators of the cell cycle; ovarian cancer cells and non-small cell lung cancer cells may be defective in the Rb/p16 pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasadenoturev","termGroup":"PT","termSource":"NCI"},{"termName":"Ad5-Delta24RGD","termGroup":"AB","termSource":"NCI"},{"termName":"DNX-2401","termGroup":"CN","termSource":"NCI"},{"termName":"DNX2401","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Ad5-Delta 24RGD","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenovirus Ad5-Delta 24RGD","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenovirus Ad5-DNX-2401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448774-00-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"79ME7DT193"},{"name":"Legacy Concept Name","value":"Oncolytic_Ad5-Delta_24RGD"},{"name":"Maps_To","value":"Oncolytic Adenovirus Ad5-DNX-2401"},{"name":"Maps_To","value":"Tasadenoturev"},{"name":"NCI_Drug_Dictionary_ID","value":"590711"},{"name":"NCI_META_CUI","value":"CL383850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590711"},{"name":"PDQ_Open_Trial_Search_ID","value":"590711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162635":{"preferredName":"Oncolytic HSV-1 C134","code":"C162635","definitions":[{"definition":"A neurovirulent, oncolytic second-generation, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1) where the gene for ICP34.5 has been deleted and the gene encoding the human cytomegalovirus (HCMV), protein kinase R (PKR) evasion protein IRS1, with potential oncolytic and immunostimulating activities. Upon intratumoral administration, oncolytic HSV-1 C134 specifically infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells. IRS1 expression allows the virus to replicate within tumors but limits viral spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 C134","termGroup":"PT","termSource":"NCI"},{"termName":"C 134","termGroup":"CN","termSource":"NCI"},{"termName":"C-134","termGroup":"CN","termSource":"NCI"},{"termName":"C134","termGroup":"CN","termSource":"NCI"},{"termName":"C134-HSV-1","termGroup":"SY","termSource":"NCI"},{"termName":"IRS-1 HSV C134","termGroup":"SY","termSource":"NCI"},{"termName":"oHSV C134","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 C134"},{"name":"NCI_Drug_Dictionary_ID","value":"798723"},{"name":"NCI_META_CUI","value":"CL971027"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798723"},{"name":"PDQ_Open_Trial_Search_ID","value":"798723"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C2676":{"preferredName":"Oncolytic HSV-1 G207","code":"C2676","definitions":[{"definition":"A neuroattenuated, replication-competent, recombinant herpes simplex virus-1 (HSV-1) with potential oncolytic activity. Upon intracerebral administration, oncolytic HSV-1 G207 preferentially replicates within glioma cells, which may elicit tumor-specific systemic immune and cytotoxic T lymphocyte (CTL) responses in addition to direct cytopathic effects. Derived from wild-type HSV-1 strain F, this agent has been neuroattenuated by deletions in both copies of the gamma34.5 gene, the major determinant of HSV neurovirulence. In addition, the HSV-1 gene UL39, encoding the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6), has been inactivated through the insertion of the Escherichia coli lacZ gene. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in nondividing cells but not in dividing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 G207","termGroup":"PT","termSource":"NCI"},{"termName":"G207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"G207"},{"name":"Maps_To","value":"Oncolytic HSV-1 G207"},{"name":"NCI_Drug_Dictionary_ID","value":"38634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38634"},{"name":"PDQ_Open_Trial_Search_ID","value":"38634"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1134718"}]}}{"C2623":{"preferredName":"Oncolytic HSV-1 NV1020","code":"C2623","definitions":[{"definition":"A genetically engineered oncolytic virus with potential antineoplastic property. NV1020 is constructed from the herpes simplex virus 1 (HSV-1) by the deletion of a single copy of the gamma (1)34.5 gene and the substitution of the UL23 region of the thymidine kinase (tk) gene with a DNA fragment from HSV-2, thereby resulting in a replication-competent, attenuated virus. This modified virus preferentially transfects rapidly dividing cells, which causes cell lysis in tumor cells. NV1020 has shown reduced virulence against normal tissues and a decreased neurovirulence in comparison with some other modified HSV strains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 NV1020","termGroup":"PT","termSource":"NCI"},{"termName":"NV1020","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NV1020"},{"name":"Maps_To","value":"Oncolytic HSV-1 NV1020"},{"name":"NCI_Drug_Dictionary_ID","value":"38237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38237"},{"name":"PDQ_Open_Trial_Search_ID","value":"38237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0935802"}]}}{"C139551":{"preferredName":"Oncolytic HSV-1 rQNestin34.5v.2","code":"C139551","definitions":[{"definition":"A neuroattenuated, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1), with potential oncolytic and immunostimulating activities. In rQNestin34.5v.2, the UL39 gene encoding for the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6) and both endogenous copies of the gamma34.5 gene that encodes for the RL1 neurovirulence protein infected cell protein 34.5 (ICP34.5), which is needed for robust viral growth in an infected cell, are deleted, and one copy of the gamma34.5 gene is reinserted under control of a nestin promoter, which is selectively activated in gliomas. Upon intratumoral administration, oncolytic HSV-1 rQNestin34.5v.2 preferentially infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. rQNestin34.5v.2 also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in non-dividing, healthy cells but not in dividing cells. Glioma-selective expression of ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 rQNestin34.5v.2","termGroup":"PT","termSource":"NCI"},{"termName":"Genetically Engineered HSV-1 Virus rQNestin34.5v.2","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic rQNestin34.5v.2","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic rQNestin34.5v.2 HSV Virus","termGroup":"SY","termSource":"NCI"},{"termName":"rQNestin34.5v.2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 rQNestin34.5v.2"},{"name":"NCI_Drug_Dictionary_ID","value":"791103"},{"name":"NCI_META_CUI","value":"CL526908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791103"},{"name":"PDQ_Open_Trial_Search_ID","value":"791103"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C90563":{"preferredName":"Oncolytic HSV-1 rRp450","code":"C90563","definitions":[{"definition":"A gene therapy agent containing an attenuated, replication-competent, genetically engineered mutant form of the Herpes simplex virus 1 (HSV-1) strain KOS with potential antineoplastic activity. Upon infusion into the hepatic artery, oncolytic HSV-1 rRp450 replicates in hepatocellular carcinoma (HCC) cells and exerts direct cytotoxic effects eventually disrupting cancer cell membranes and liberating progeny virions thereby infecting adjacent tumor cells. In addition, rRp450 expresses the cytochrome P450 transgene that activates oxazaphosphorines, such as cyclophosphamide (CPA). Therefore, CPA can become activated in the presence of rRp450 and exert its antineoplastic effect. rRp450 is deleted for the HSV-1 gene UL39, encoding the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6), thereby disrupting the activity of viral ribonucleotide reductase and resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in nondividing cells but not in dividing cells. UL39 is replaced by the rat CYP2B1 gene, encoding a cytochrome P450 enzyme that activates oxazaphosphorines. rRp450 also expresses viral thymidine kinase, which activates the cancer prodrug ganciclovir.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 rRp450","termGroup":"PT","termSource":"NCI"},{"termName":"rRp450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 rRp450"},{"name":"NCI_Drug_Dictionary_ID","value":"666906"},{"name":"NCI_META_CUI","value":"CL416247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666906"},{"name":"PDQ_Open_Trial_Search_ID","value":"666906"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84840":{"preferredName":"Oncolytic HSV1716","code":"C84840","definitions":[{"definition":"A neuroattenuated, replication-restricted, ICP34.5 deleted (RL1 gene)-mutant herpes simplex virus (HSV) type I, constructed from wild-type strain 17, with potential oncolytic activity. Upon intratumoral injection, oncolytic HSV1716 transfects, replicates in, and lyses rapidly dividing cells such as tumor cells. Because the RL1 gene is deleted, HSV1716 is unable to replicate in non-dividing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV1716","termGroup":"PT","termSource":"NCI"},{"termName":"HSV1716","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"26WEP2905N"},{"name":"Maps_To","value":"Oncolytic HSV1716"},{"name":"NCI_Drug_Dictionary_ID","value":"650036"},{"name":"NCI_META_CUI","value":"CL412391"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650036"},{"name":"PDQ_Open_Trial_Search_ID","value":"650036"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165457":{"preferredName":"Oncolytic Newcastle Disease Virus MEDI5395","code":"C165457","definitions":[{"definition":"An oncolytic viral agent containing the oncolytic, live-attenuated, replication-competent strain of the avian paramyxovirus Newcastle disease virus (NDV) that has been engineered to include a transgene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunostimulating activities. Upon administration, MEDI5395 specifically infects and replicates in cancer cells. This may result in a direct cytotoxic effect involving the lysis of tumor cells via apoptotic mechanisms and may eventually lead to an inhibition of cancer cell proliferation through the increased production and secretion of pro-inflammatory cytokines and chemokines which are able to recruit mediators of both the innate and adaptive immune responses. Additionally, the inclusion of the GM-CSF transgene in the viral construct leads to expression of GM-CSF, which may potentiate and strengthen the anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Newcastle Disease Virus MEDI5395","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI 5395","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-5395","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI5395","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic NDV MEDI5395","termGroup":"SY","termSource":"NCI"},{"termName":"recNDV(GM-CSF)","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant NDV Expressing GM-CSF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Newcastle Disease Virus MEDI5395"},{"name":"NCI_Drug_Dictionary_ID","value":"799776"},{"name":"NCI_META_CUI","value":"CL978581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799776"},{"name":"PDQ_Open_Trial_Search_ID","value":"799776"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C91700":{"preferredName":"Oncolytic Newcastle Disease Virus MTH-68H","code":"C91700","definitions":[{"definition":"An oncolytic viral agent containing the oncolytic, live-attenuated strain of the paramyxovirus Newcastle disease virus (NDV), with potential antineoplastic activity. Upon administration, NDV MTH-68H specifically infects and replicates in cancer cells. This may result in a direct cytotoxic effect involving the lysis of tumor cells via apoptotic mechanisms and may eventually lead to an inhibition of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Newcastle Disease Virus MTH-68H","termGroup":"PT","termSource":"NCI"},{"termName":"MTH-68H","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic NDV MTH-68H","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Newcastle Disease Virus MTH-68H"},{"name":"NCI_Drug_Dictionary_ID","value":"257613"},{"name":"NCI_META_CUI","value":"CL422080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257613"},{"name":"PDQ_Open_Trial_Search_ID","value":"257613"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C2799":{"preferredName":"Oncolytic Newcastle Disease Virus Strain PV701","code":"C2799","definitions":[{"definition":"A virus that is being studied in the treatment of cancer. It belongs to the family of viruses that cause Newcastle disease in birds.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An attenuated, replication-competent, oncolytic strain of Newcastle disease virus. PV701 selectively lyses tumor cells. The selectivity of this agent is related to defects in the interferon-mediated antiviral response found in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Newcastle Disease Virus Strain PV701","termGroup":"PT","termSource":"NCI"},{"termName":"PV701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PV701"},{"name":"Maps_To","value":"Oncolytic Newcastle Disease Virus Strain PV701"},{"name":"NCI_Drug_Dictionary_ID","value":"258388"},{"name":"NSC Number","value":"700553"},{"name":"PDQ_Closed_Trial_Search_ID","value":"258388"},{"name":"PDQ_Open_Trial_Search_ID","value":"258388"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1327815"}]}}{"C161021":{"preferredName":"Oncolytic Virus ASP9801","code":"C161021","definitions":[{"definition":"An engineered oncolytic virus with potential antineoplastic and immunomodulating activities. Upon intratumoral injection of ASP-9801, the oncolytic virus selectively targets and replicates in cancer cells without being able to infect and replicate in normal, healthy cells. This induces selective oncolytic virus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent tumor cells, which both induces further tumor cell oncolysis and may activate the immune system to exert an anti-tumor immune response against the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Virus ASP9801","termGroup":"PT","termSource":"NCI"},{"termName":"ASP 9801","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-9801","termGroup":"CN","termSource":"NCI"},{"termName":"ASP9801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Virus ASP9801"},{"name":"NCI_Drug_Dictionary_ID","value":"798437"},{"name":"NCI_META_CUI","value":"CL969987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798437"},{"name":"PDQ_Open_Trial_Search_ID","value":"798437"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C158074":{"preferredName":"Vusolimogene Oderparepvec","code":"C158074","definitions":[{"definition":"A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In RP1, ICP34.5 and 47 proteins of the HSV1 strain have been deleted; RP1 expresses a fusogenic protein for optimal tumor cell infection and killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vusolimogene Oderparepvec","termGroup":"PT","termSource":"NCI"},{"termName":"Genetically Modified HSV-1 Oncolytic Immunotherapeutic RP1","termGroup":"SY","termSource":"NCI"},{"termName":"HSV-1 Engineered RP1","termGroup":"SY","termSource":"NCI"},{"termName":"HSV-1 Oncolytic Viral Strain RP1","termGroup":"SY","termSource":"NCI"},{"termName":"HSV-1 RP1","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Virus RP1","termGroup":"SY","termSource":"NCI"},{"termName":"RP-1","termGroup":"CN","termSource":"NCI"},{"termName":"RP1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305659-09-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"45KLN7N6UV"},{"name":"Maps_To","value":"Oncolytic Virus RP1"},{"name":"NCI_Drug_Dictionary_ID","value":"797350"},{"name":"NCI_META_CUI","value":"CL937703"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797350"},{"name":"PDQ_Open_Trial_Search_ID","value":"797350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48007":{"preferredName":"Ondansetron Hydrochloride","code":"C48007","definitions":[{"definition":"The active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. It is a type of serotonin receptor antagonist and a type of antiemetic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the racemic form of ondansetron, a carbazole derivative and a selective, competitive serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist with antiemetic activity. Although its mechanism of action has not been fully characterized, ondansetron appears to competitively block the action of serotonin at 5HT3 receptors peripherally in the gastrointestinal tract as well as centrally in the area postrema of the CNS, where the chemoreceptor trigger zone (CTZ) for vomiting is located, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ondansetron Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Carbazol-4-one, 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, Monohydrochloride, (+-)-, Dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"GR 38032F","termGroup":"CN","termSource":"NCI"},{"termName":"GR-C507/75","termGroup":"CN","termSource":"NCI"},{"termName":"SN-307","termGroup":"CN","termSource":"NCI"},{"termName":"Zofran","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Nausea and vomiting prophylaxis, chemotherapy-induced and postoperative"},{"name":"CAS_Registry","value":"103639-04-9"},{"name":"Chemical_Formula","value":"C18H19N3O.HCl.2H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NMH84OZK2B"},{"name":"Legacy Concept Name","value":"Ondansetron_Hydrochloride"},{"name":"Maps_To","value":"Ondansetron Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"489533"},{"name":"NSC Number","value":"665799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489533"},{"name":"PDQ_Open_Trial_Search_ID","value":"489533"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700478"}]}}{"C82406":{"preferredName":"Ontuxizumab","code":"C82406","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Ontuxizumab binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ontuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Protein TEM1 (Tumor Endothelial Marker 1)) (Human-Mouse Monoclonal MORAb-004 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-004 kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb-004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946415-62-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0M2XT000YC"},{"name":"Legacy Concept Name","value":"Anti-Endosialin_Monoclonal_Antibody_MORAb-004"},{"name":"Maps_To","value":"Ontuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"638168"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638168"},{"name":"PDQ_Open_Trial_Search_ID","value":"638168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2826153"}]}}{"C143162":{"preferredName":"Onvansertib","code":"C143162","definitions":[{"definition":"An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onvansertib","termGroup":"PT","termSource":"NCI"},{"termName":"NMS-1286937","termGroup":"CN","termSource":"NCI"},{"termName":"PCM 075","termGroup":"CN","termSource":"NCI"},{"termName":"PCM-075","termGroup":"CN","termSource":"NCI"},{"termName":"PLK-1 Inhibitor PCM-075","termGroup":"SY","termSource":"NCI"},{"termName":"PLK1 Inhibitor PCM-075","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor NMS-1286937","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor PCM-075","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1034616-18-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67RM91WDHQ"},{"name":"Maps_To","value":"Onvansertib"},{"name":"Maps_To","value":"Polo-like Kinase 1 Inhibitor NMS-1286937"},{"name":"NCI_Drug_Dictionary_ID","value":"792149"},{"name":"NCI_META_CUI","value":"CL541611"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792149"},{"name":"PDQ_Open_Trial_Search_ID","value":"792149"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98278":{"preferredName":"Opaganib","code":"C98278","definitions":[{"definition":"An orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, opaganib competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2. SK2 and its isoenzyme SK1 are overexpressed in numerous cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opaganib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Pyridinylmethyl-3-(4-chlorophenyl) Adamantane Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"ABC 294640","termGroup":"CN","termSource":"NCI"},{"termName":"ABC294640","termGroup":"CN","termSource":"NCI"},{"termName":"SK2 inhibitor ABC294640","termGroup":"SY","termSource":"NCI"},{"termName":"Tricyclo(3.3.1.13,7)decane-1-carboxamide, 3-(4-Chlorophenyl)-N-(4-pyridinylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Yeliva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915385-81-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DRG21OQ517"},{"name":"Maps_To","value":"Opaganib"},{"name":"NCI_Drug_Dictionary_ID","value":"712053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712053"},{"name":"PDQ_Open_Trial_Search_ID","value":"712053"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933331"}]}}{"C90545":{"preferredName":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","code":"C90545","definitions":[{"definition":"A capsule containing a fermented soymilk extract and oligomeric proanthocyanidins (OPCs), green tea, spirullina, curcumin and antrodia camphorate powder, with potential antioxidant, immunomodulating, anti-infective and anti-cancer activities. OPCs/green tea/spirullina/curcumin/antrodia camphorate/fermented soymilk extract capsule may boost the immune system and may alleviate fatigue and poor appetite in cancer chemotherapy patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"MB-6","termGroup":"CN","termSource":"NCI"},{"termName":"Oligomeric Proanthocyanidins/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"665369"},{"name":"NCI_META_CUI","value":"CL416226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665369"},{"name":"PDQ_Open_Trial_Search_ID","value":"665369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48413":{"preferredName":"Opioid Growth Factor","code":"C48413","definitions":[{"definition":"A substance that relieves pain and is being studied in the treatment of some types of cancer. Opioid growth factors bind to cells in the body, including tumor cells, which have opioid growth factor receptors on the surface. This may help stop the growth of the tumor cells. It may also prevent the growth of blood vessels that tumors need to grow. An opioid growth factor is a type of biological response modifier and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An endogenous pentapeptide with potential antineoplastic and antiangiogenic activities. Opioid growth factor (OGF) binds to and activates the OGF receptor, present on some tumor cells and vascular cells, thereby inhibiting tumor cell proliferation and angiogenesis. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opioid Growth Factor","termGroup":"PT","termSource":"NCI"},{"termName":"OGF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Opioid_Growth_Factor"},{"name":"Maps_To","value":"Opioid Growth Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"428488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"428488"},{"name":"PDQ_Open_Trial_Search_ID","value":"428488"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541553"}]}}{"C61307":{"preferredName":"Oportuzumab Monatox","code":"C61307","definitions":[{"definition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of certain types of head and neck cancer. Anti-EpCAM-Pseudomonas-exotoxin fusion protein is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. It binds to EpCAM (a protein on the surface of epithelial cells and some types of cancer cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Oportuzumab Monatox","termGroup":"PT","termSource":"NCI"},{"termName":"Proxinium","termGroup":"BR","termSource":"NCI"},{"termName":"VB4 845","termGroup":"CN","termSource":"NCI"},{"termName":"VB4-845","termGroup":"CN","termSource":"NCI"},{"termName":"Vicinium","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced, recurrent head and neck cancer"},{"name":"CAS_Registry","value":"945228-48-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"945CY7ZMI2"},{"name":"Legacy Concept Name","value":"Anti-EpCAM-Pseudomonas-exotoxin_Fusion_Protein"},{"name":"Maps_To","value":"Oportuzumab Monatox"},{"name":"NCI_Drug_Dictionary_ID","value":"485164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485164"},{"name":"PDQ_Open_Trial_Search_ID","value":"485164"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831819"}]}}{"C91388":{"preferredName":"Oprozomib","code":"C91388","definitions":[{"definition":"An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oprozomib","termGroup":"PT","termSource":"NCI"},{"termName":"O-methyl-N-((2-methylthiazol-5-yl)carbonyl)-l-seryl-O-methyl-N-((1S)-1-benzyl-2-((2R)-2-methyloxiran-2-yl)-2-oxoethyl)-l-serinamide","termGroup":"SY","termSource":"NCI"},{"termName":"ONX 0912","termGroup":"CN","termSource":"NCI"},{"termName":"PR-047","termGroup":"CN","termSource":"NCI"},{"termName":"Proteasome Inhibitor ONX 0912","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"935888-69-0"},{"name":"Chemical_Formula","value":"C25H32N4O7S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MZ37792Y8J"},{"name":"Maps_To","value":"Oprozomib"},{"name":"NCI_Drug_Dictionary_ID","value":"674605"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674605"},{"name":"PDQ_Open_Trial_Search_ID","value":"674605"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2976183"}]}}{"C99763":{"preferredName":"Oral Aminolevulinic Acid Hydrochloride","code":"C99763","definitions":[{"definition":"A powder for an oral solution comprised of the hydrochloride salt of 5-aminolevulinic acid (ALA) with a potential application for photodynamic therapy. After oral administration, ALA is converted intracellularly into the photosensitizer protoporphyrin IX (PpIX). Upon exposure to light of appropriate wavelength (violet to blue range), excited PpIX emits a characteristic red fluorescence which could facilitate guided resection, and generates excited singlet oxygen molecules that could kill cells when appropriate laser dosage is applied. ALA is preferentially taken up by and accumulates in many types of cancer cells compared to normal, healthy cells. Consequently, cancer cells can be visualized and can be distinguished from normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Aminolevulinic Acid Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5-Aminolevulinic Acid Hydrochloride, Oral","termGroup":"SY","termSource":"NCI"},{"termName":"Gleolan","termGroup":"BR","termSource":"NCI"},{"termName":"Gliolan","termGroup":"FB","termSource":"NCI"},{"termName":"Oral 5-ALA","termGroup":"AB","termSource":"NCI"},{"termName":"Oral ALA HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adjunct for the visualization of malignant tissue (glioma) during surgery"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Aminolevulinic Acid Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"723865"},{"name":"NCI_META_CUI","value":"CL433488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"723865"},{"name":"PDQ_Open_Trial_Search_ID","value":"723865"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118288":{"preferredName":"Oral Azacitidine","code":"C118288","definitions":[{"definition":"An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Azacitidine","termGroup":"PT","termSource":"NCI"},{"termName":"Azacitidine Oral","termGroup":"SY","termSource":"NCI"},{"termName":"CC-486","termGroup":"CN","termSource":"NCI"},{"termName":"Onureg","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Oral Azacitidine"},{"name":"NCI_Drug_Dictionary_ID","value":"764239"},{"name":"NCI_META_CUI","value":"CL474140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764239"},{"name":"PDQ_Open_Trial_Search_ID","value":"764239"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159540":{"preferredName":"Oral Cancer Vaccine V3-OVA","code":"C159540","definitions":[{"definition":"An orally available cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. Upon oral administration of the oral cancer vaccine V3-OVA, the ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Cancer Vaccine V3-OVA","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine V3-OVA","termGroup":"SY","termSource":"NCI"},{"termName":"Tableted Vaccine V3-OVA","termGroup":"SY","termSource":"NCI"},{"termName":"V3 OVA","termGroup":"CN","termSource":"NCI"},{"termName":"V3-OVA","termGroup":"CN","termSource":"NCI"},{"termName":"V3OVA","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Cancer Vaccine V3-OVA"},{"name":"NCI_Drug_Dictionary_ID","value":"797490"},{"name":"NCI_META_CUI","value":"CL951378"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797490"},{"name":"PDQ_Open_Trial_Search_ID","value":"797490"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131903":{"preferredName":"Oral Docetaxel","code":"C131903","definitions":[{"definition":"An oral proprietary P-glycoprotein (P-gp) pump inhibitor-based formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, and a P-gp pump inhibitor, with potential antineoplastic activity. Upon administration of oral docetaxel, the P-gp pump inhibitor moiety, which is not absorbed, binds to the P-gp pump in the gastrointestinal (GI) tract and prevents the P-gp pump-mediated efflux of docetaxel from cells the docetaxel has been internalized by back into the GI tract. This decreases P-gp-mediated excretion and enhances absorption of docetaxel. Upon absorption, docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizes tubulin and inhibits microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. The P-gp pump inhibitor enhances the bioavailability of certain poorly bioavailable agents and thereby allows oral administration of those agents. P-gp, an efflux membrane transporter, plays a key role in active drug export, and prevents cellular uptake and accumulation of certain substances.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"Docetaxel-P-glycoprotein Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-P-gp Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"Oradoxel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"786271"},{"name":"NCI_META_CUI","value":"CL521226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786271"},{"name":"PDQ_Open_Trial_Search_ID","value":"786271"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64338":{"preferredName":"Oral Fludarabine Phosphate","code":"C64338","definitions":[{"definition":"An oral formulation of the phosphate salt of fludarabine, a synthetic purine nucleoside analogue antimetabolite with antineoplastic activity. Fudarabine is preferentially transported into malignant cells and metabolized by deoxycytidine kinase to its active form, 2-fluoro-ara-ATP; 2-fluoro-ara-ATP competes directly with deoxyadenosine triphosphate (dATP) and inhibits alpha DNA polymerase, RNA reductase, and DNA primase, which may result in inhibition of DNA synthesis and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Fludarabine Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Fludara Oral","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Fludarabine_Phosphate"},{"name":"Maps_To","value":"Oral Fludarabine Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"486428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486428"},{"name":"PDQ_Open_Trial_Search_ID","value":"486428"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831839"}]}}{"C78843":{"preferredName":"Oral Hsp90 Inhibitor IPI-493","code":"C78843","definitions":[{"definition":"An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Hsp90 Inhibitor IPI-493","termGroup":"PT","termSource":"NCI"},{"termName":"17-Aminodemethoxygeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"17-Aminogeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor IPI-493","termGroup":"SY","termSource":"NCI"},{"termName":"IPI-493","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64202-81-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SLQ1AJG3VB"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_IPI-493"},{"name":"Maps_To","value":"Oral Hsp90 Inhibitor IPI-493"},{"name":"NCI_Drug_Dictionary_ID","value":"610131"},{"name":"NSC Number","value":"255109"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610131"},{"name":"PDQ_Open_Trial_Search_ID","value":"610131"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703137"}]}}{"C63478":{"preferredName":"Oral Ixabepilone","code":"C63478","definitions":[{"definition":"An enteric-coated formulation of ixabepilone, a semisynthetic analogue of epothilone B and a non-taxane tubulin inhibitor, with antineoplastic activity. Ixabepilone binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in cell cycle arrest at the G2-M phase and leads to apoptosis within fast growing tumor cells. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. Compared to intravenously administered ixabepilone, the oral formulation provides a more manageable way to administer this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Ixabepilone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Ixabepilone"},{"name":"Maps_To","value":"Oral Ixabepilone"},{"name":"NCI_Drug_Dictionary_ID","value":"486610"},{"name":"NCI_META_CUI","value":"CL415081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486610"},{"name":"PDQ_Open_Trial_Search_ID","value":"486610"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71132":{"preferredName":"Oral Microencapsulated Diindolylmethane","code":"C71132","definitions":[{"definition":"An orally bioavailable microencapsulated formulation of diindolylmethane, an indole phytonutrient found in cruciferous vegetables, with estrogen-modulating, antiandrogenic, and potential antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) modulates estrogen balance by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of beneficial 2-hydroxy estrogen metabolites. DIM also antagonizes androgen receptor activity, which may result in diminished cell proliferation and apoptosis in susceptible tumor cell populations. Pure DIM, which is relatively hydrophobic, is poorly absorbed after oral administration. This oral formulation, which consists of DIM, d-alpha-tocopheryl acid succinate, phosphatidylcholine, and silica microencapsulated in starch, significantly improves the gastrointestinal absorption of DIM.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Microencapsulated Diindolylmethane","termGroup":"PT","termSource":"NCI"},{"termName":"BioResponse DIM","termGroup":"BR","termSource":"NCI"},{"termName":"BR-DIM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Microencapsulated_Diindolylmethane"},{"name":"Maps_To","value":"Oral Microencapsulated Diindolylmethane"},{"name":"NCI_Drug_Dictionary_ID","value":"577331"},{"name":"NCI_META_CUI","value":"CL377701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577331"},{"name":"PDQ_Open_Trial_Search_ID","value":"577331"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77880":{"preferredName":"Milataxel","code":"C77880","definitions":[{"definition":"An orally bioavailable taxane with potential antineoplastic activity. Upon oral administration, milataxel and its major active metabolite M-10 bind to and stabilize tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, milataxel appears to be a poor substrate for the multidrug resistance (MDR) membrane-associated P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milataxel","termGroup":"PT","termSource":"NCI"},{"termName":"MAC-321","termGroup":"CN","termSource":"NCI"},{"termName":"TL-00139","termGroup":"CN","termSource":"NCI"},{"termName":"TL139","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"352425-37-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J41Q4S20GS"},{"name":"Legacy Concept Name","value":"Oral_Milataxel"},{"name":"Maps_To","value":"Milataxel"},{"name":"Maps_To","value":"Oral Milataxel"},{"name":"NCI_Drug_Dictionary_ID","value":"597742"},{"name":"NCI_META_CUI","value":"CL387339"},{"name":"PDQ_Closed_Trial_Search_ID","value":"597742"},{"name":"PDQ_Open_Trial_Search_ID","value":"597742"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158745":{"preferredName":"Oral Myoma Vaccine V3-myoma","code":"C158745","definitions":[{"definition":"An orally available therapeutic myoma vaccine containing pooled antigens derived from hydrolyzed, inactivated blood and tumor tissue samples from patients with uterine myoma, with potential antineoplastic and immunomodulatory activities. Upon oral administration, V3-myoma may stimulate the immune system to mount a cytotoxic T-lymphocyte-mediated response against cells expressing myoma-associated antigens. This may reduce the myoma growth and improve myoma-related symptoms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Myoma Vaccine V3-myoma","termGroup":"PT","termSource":"NCI"},{"termName":"V3 Myoma","termGroup":"SY","termSource":"NCI"},{"termName":"V3 Myoma Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V3-myoma","termGroup":"SY","termSource":"NCI"},{"termName":"V3-myoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Myoma Vaccine V3-myoma"},{"name":"NCI_Drug_Dictionary_ID","value":"797410"},{"name":"NCI_META_CUI","value":"CL950711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797410"},{"name":"PDQ_Open_Trial_Search_ID","value":"797410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150400":{"preferredName":"Oral Pancreatic Cancer Vaccine V3-P","code":"C150400","definitions":[{"definition":"An orally bioavailable, therapeutic cancer vaccine composed of the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19.9; CA19-9) that is derived from pooled blood of pancreatic cancer patients, with potential immunomodulating activity. Upon oral administration of the oral pancreatic cancer vaccine V3-P, the CA19.9 antigens may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against pancreatic cancer cells expressing the CA19.9 antigen. CA19.9 is overexpressed on a number of different tumor cell types and plays a key role in tumor cell survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Pancreatic Cancer Vaccine V3-P","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine V3-P","termGroup":"SY","termSource":"NCI"},{"termName":"Oral Tableted Therapeutic Vaccine V3-P","termGroup":"SY","termSource":"NCI"},{"termName":"V3 P","termGroup":"CN","termSource":"NCI"},{"termName":"V3-P","termGroup":"CN","termSource":"NCI"},{"termName":"V3-P Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V3P","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Pancreatic Cancer Vaccine V3-P"},{"name":"NCI_Drug_Dictionary_ID","value":"792852"},{"name":"NCI_META_CUI","value":"CL552151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792852"},{"name":"PDQ_Open_Trial_Search_ID","value":"792852"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68924":{"preferredName":"Oral Picoplatin","code":"C68924","definitions":[{"definition":"An oral preparation of picoplatin, a third generation platinum compound with antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and RNA transcription and the induction of apoptosis. Because of the increase in steric bulk around the platinum center, there is a relative reduction in the inactivation of picoplatin by thiol-containing species such as glutathione and metallothionein in comparison to cisplatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Picoplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Picoplatin (Oral)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Picoplatin"},{"name":"Maps_To","value":"Oral Picoplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"551562"},{"name":"NCI_META_CUI","value":"CL374343"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551562"},{"name":"PDQ_Open_Trial_Search_ID","value":"551562"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67083":{"preferredName":"Oral Sodium Phenylbutyrate","code":"C67083","definitions":[{"definition":"An orally active derivative of the short-chain fatty acid butyrate with potential antineoplastic activity. 4-Phenylbutyrate inhibits histone deacetylase, resulting in cell cycle gene expression modulation, reduced cell proliferation, increased cell differentiation, and apoptosis. This agent also initiates fragmentation of genomic DNA, resulting in decreased DNA synthesis and the inhibition of tumor cell migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Sodium Phenylbutyrate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Sodium_Phenylbutyrate"},{"name":"Maps_To","value":"Oral Sodium Phenylbutyrate"},{"name":"NCI_Drug_Dictionary_ID","value":"41827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41827"},{"name":"PDQ_Open_Trial_Search_ID","value":"41827"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882164"}]}}{"C63477":{"preferredName":"Oral Topotecan Hydrochloride","code":"C63477","definitions":[{"definition":"An oral formulation of the hydrochloride salt of topotecan, a semisynthetic derivative of the quinoline alkaloid camptothecin, with potential antineoplastic activity. Topotecan selectively inhibits topoisomerase I activity by stabilizing topoisomerase I-DNA covalent complexes during the S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Topotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4'; 6,7] indolizino[1,2-b] quinoline-3,14-(4H,12H)-dione monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Oral Hycamtin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Topotecan_Hydrochloride"},{"name":"Maps_To","value":"Oral Topotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"489122"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489122"},{"name":"PDQ_Open_Trial_Search_ID","value":"489122"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831879"}]}}{"C1884":{"preferredName":"Orantinib","code":"C1884","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable receptor tyrosine kinase inhibitor.  SU6668 binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation.  SU6668 also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orantinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2,4-Dimethyl-5-((2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-1H-pyrrol-3-yl)propionic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Orantinibum","termGroup":"SY","termSource":"NCI"},{"termName":"SU6668","termGroup":"CN","termSource":"NCI"},{"termName":"Sugen SU6668","termGroup":"CN","termSource":"NCI"},{"termName":"TSU 68","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"252916-29-3"},{"name":"Chemical_Formula","value":"C18H18N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RL37ZZ665"},{"name":"Legacy Concept Name","value":"SU6668"},{"name":"Maps_To","value":"Orantinib"},{"name":"NCI_Drug_Dictionary_ID","value":"38421"},{"name":"NSC Number","value":"702827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38421"},{"name":"PDQ_Open_Trial_Search_ID","value":"38421"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2001702"}]}}{"C112000":{"preferredName":"Oraxol","code":"C112000","definitions":[{"definition":"A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oraxol","termGroup":"PT","termSource":"NCI"},{"termName":"Paclitaxel-HM30181 Methanesulfonate Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel/HM30181A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oraxol"},{"name":"NCI_Drug_Dictionary_ID","value":"754236"},{"name":"NCI_META_CUI","value":"CL454289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754236"},{"name":"PDQ_Open_Trial_Search_ID","value":"754236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1784":{"preferredName":"Oregovomab","code":"C1784","definitions":[{"definition":"A monoclonal antibody that is being studied in the treatment of ovarian cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Oregovomab binds to the CA-125 antigen, which is found on most ovarian cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oregovomab","termGroup":"PT","termSource":"NCI"},{"termName":"B43.13","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb B43.13","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody B43.13","termGroup":"SY","termSource":"NCI"},{"termName":"OvaRex","termGroup":"BR","termSource":"NCI"},{"termName":"OvaRex Monoclonal Antibody B43.13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Epithelial ovarian cancer"},{"name":"CAS_Registry","value":"213327-37-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HX101E7L6S"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_B43_13"},{"name":"Maps_To","value":"Oregovomab"},{"name":"NCI_Drug_Dictionary_ID","value":"43251"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43251"},{"name":"PDQ_Open_Trial_Search_ID","value":"43251"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664207"}]}}{"C1250":{"preferredName":"Ormaplatin","code":"C1250","definitions":[{"definition":"A platinum(IV) analogue with antineoplastic activity. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ormaplatin","termGroup":"PT","termSource":"NCI"},{"termName":"tetrachloro(1,2-cyclohexanediamine-N,N')-, (OC-6-22-(trans))Platinum","termGroup":"SN","termSource":"NCI"},{"termName":"Tetraplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62816-98-2"},{"name":"Chemical_Formula","value":"C6H14N2.4Cl.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SFK1SGY8V1"},{"name":"Legacy Concept Name","value":"Ormaplatin"},{"name":"Maps_To","value":"Ormaplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"41211"},{"name":"NSC Number","value":"363812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41211"},{"name":"PDQ_Open_Trial_Search_ID","value":"41211"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076329"}]}}{"C1867":{"preferredName":"Ortataxel","code":"C1867","definitions":[{"definition":"A semisynthetic, second-generation taxane derivative with potential antineoplastic activity. Ortataxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in the inhibition of cell division and cellular proliferation. As it represents a poor substrate for P-glycoprotein (P-gp), multi-drug resistance protein (MRP-1) and breast cancer resistance protein (BCRP) mediated efflux, ortataxel modulates multi-drug resistance mechanisms and may be useful for treating multi-drug resistant tumors that express Pgp, MRP-1 and BCRP.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called taxanes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ortataxel","termGroup":"PT","termSource":"NCI"},{"termName":"(3aS,4R,5E,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-Bis(acetyloxy)-13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano-13aH-oxeto(2',3':5',6')benzo(1',2':4,5)cyclodeca(1,2-d)-1,3-dioxol-4-yl(2R,3S)-3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methylhexanoate","termGroup":"SY","termSource":"NCI"},{"termName":"Bay 59-8862","termGroup":"CN","termSource":"NCI"},{"termName":"BAY59-8862","termGroup":"CN","termSource":"NCI"},{"termName":"IDN5109","termGroup":"CN","termSource":"NCI"},{"termName":"SB-T-101131","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186348-23-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8H61Y4E29N"},{"name":"Legacy Concept Name","value":"Orataxel"},{"name":"Maps_To","value":"Ortataxel"},{"name":"NCI_Drug_Dictionary_ID","value":"38635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38635"},{"name":"PDQ_Open_Trial_Search_ID","value":"38635"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527103"}]}}{"C90582":{"preferredName":"Orteronel","code":"C90582","definitions":[{"definition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orteronel","termGroup":"PT","termSource":"NCI"},{"termName":"6-((7S)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Androgen Synthesis Inhibitor TAK-700","termGroup":"SY","termSource":"NCI"},{"termName":"CYP17A1 Lyase Inhibitor TAK-700","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-700","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"566939-85-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"UE5K2FNS92"},{"name":"Maps_To","value":"Orteronel"},{"name":"NCI_Drug_Dictionary_ID","value":"583018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583018"},{"name":"PDQ_Open_Trial_Search_ID","value":"583018"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983781"}]}}{"C131535":{"preferredName":"Osilodrostat","code":"C131535","definitions":[{"definition":"An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), with potential anti-adrenal activity and ability to treat Cushing disease (CD). Upon administration, osilodrostat binds to and inhibits the activity of CYP11B1, the enzyme that catalyzes the final step of cortisol synthesis from the precursor 11-deoxycortisol, and CYP11B2, the enzyme that catalyzes aldosterone synthesis from corticosterone and 11-deoxycorticosterone in the adrenal gland. The inhibition of CYP11B1 prevents the production of excess cortisol, thereby decreasing and normalizing the levels of cortisol. CD is most often caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osilodrostat","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"LCI 699","termGroup":"CN","termSource":"NCI"},{"termName":"LCI-699","termGroup":"CN","termSource":"NCI"},{"termName":"LCI699","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"928134-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5YL4IQ1078"},{"name":"Maps_To","value":"Osilodrostat"},{"name":"NCI_Drug_Dictionary_ID","value":"786177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786177"},{"name":"PDQ_Open_Trial_Search_ID","value":"786177"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2976005"}]}}{"C116377":{"preferredName":"Osimertinib","code":"C116377","definitions":[{"definition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osimertinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-9291","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9291","termGroup":"CN","termSource":"NCI"},{"termName":"Mereletinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1421373-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3C06JJ0Z2O"},{"name":"Maps_To","value":"Osimertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"747632"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747632"},{"name":"PDQ_Open_Trial_Search_ID","value":"747632"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896906"}]}}{"C74006":{"preferredName":"Otlertuzumab","code":"C74006","definitions":[{"definition":"A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential immunostimulatory and antineoplastic activities. Otlertuzumab binds to CD37 on B-cells, which may result in antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. CD37 is a transmembrane glycoprotein expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. This agent may have a longer half-life in vivo than conventional monoclonal antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Otlertuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin, Anti-(Human CD Antigen CD37) (Synthetic Human-Mus Musculus Fragment TRU-016), Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"TRU 016","termGroup":"CN","termSource":"NCI"},{"termName":"TRU-016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1372645-37-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2MZ3L2664T"},{"name":"Legacy Concept Name","value":"Anti-CD37_Single-Chain_Polypeptide_TRU-016"},{"name":"Maps_To","value":"Otlertuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"589521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589521"},{"name":"PDQ_Open_Trial_Search_ID","value":"589521"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346800"}]}}{"C113651":{"preferredName":"Ovapuldencel-T","code":"C113651","definitions":[{"definition":"A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovapuldencel-T","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FK2WI4Y35P"},{"name":"Maps_To","value":"Ovapuldencel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"756846"},{"name":"NCI_META_CUI","value":"CL458364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756846"},{"name":"PDQ_Open_Trial_Search_ID","value":"756846"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96739":{"preferredName":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006","code":"C96739","definitions":[{"definition":"A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006","termGroup":"PT","termSource":"NCI"},{"termName":"DC-006","termGroup":"CN","termSource":"NCI"},{"termName":"DC-006 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006"},{"name":"NCI_Drug_Dictionary_ID","value":"699229"},{"name":"NCI_META_CUI","value":"CL429364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699229"},{"name":"PDQ_Open_Trial_Search_ID","value":"699229"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2350":{"preferredName":"Ovine Submaxillary Mucin","code":"C2350","definitions":[{"definition":"A naturally occurring mucin glycoprotein. Ovine submaxillary mucin (OSM), extracted from an ovine submaxillary gland, provides a rich source of the sialylated Tn antigen (sTn), which is a carbohydrate antigen found on mucins of many epithelial tumors. Vaccination with OSM may result in the production of antibodies as well as elicitation of a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing sTn, thereby results in decreased tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovine Submaxillary Mucin","termGroup":"PT","termSource":"NCI"},{"termName":"Ovine Sialomucin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovine_Submaxillary_Mucin"},{"name":"Maps_To","value":"Ovine Submaxillary Mucin"},{"name":"NCI_Drug_Dictionary_ID","value":"39375"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39375"},{"name":"PDQ_Open_Trial_Search_ID","value":"39375"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0279238"}]}}{"C160192":{"preferredName":"Tezemlimogene Daxadenorepvec","code":"C160192","definitions":[{"definition":"A selectively replication competent oncolytic adenovirus that is engineered to express OX40 ligand (OX40L) with potential oncolytic and immunostimulatory activities. Upon administration, tezemlimogene daxadenorepvec, which contains an integrin binding RGD-4C motif, infects tumor cells in a Coxsackievirus-adenovirus receptor-independent manner and selectively replicates in tumor cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16). Tumor cell selectivity is achieved through a 24-base pair deletion in the E1A gene, which renders the oncolytic adenovirus unable to replicate in normal cells that maintain a functional Rb pathway, but fully replication competent in Rb/p16 defective tumor cells.  Active replication of the OX40L-expressing oncolytic adenovirus within tumor cells may induce oncolysis and release of OX40L. OX40L may then bind to and activate signaling pathways downstream of its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes and promote the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. The Rb gene product and p16 are negative regulators of the cell cycle and are defective in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tezemlimogene Daxadenorepvec","termGroup":"PT","termSource":"NCI"},{"termName":"DNX 2440","termGroup":"CN","termSource":"NCI"},{"termName":"DNX-2440","termGroup":"CN","termSource":"NCI"},{"termName":"DNX2440","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenovirus Armed With OX40L DNX-2440","termGroup":"SY","termSource":"NCI"},{"termName":"OX40L-expressing Oncolytic Adenovirus DNX-2440","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2642046-11-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B7N7BR6M4A"},{"name":"Maps_To","value":"OX40L-expressing Oncolytic Adenovirus DNX-2440"},{"name":"NCI_Drug_Dictionary_ID","value":"797863"},{"name":"NCI_META_CUI","value":"CL969332"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797863"},{"name":"PDQ_Open_Trial_Search_ID","value":"797863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1181":{"preferredName":"Oxaliplatin","code":"C1181","definitions":[{"definition":"A drug used with other drugs to treat colorectal cancer that is advanced or has come back. It is also being studied in the treatment of other types of cancer. Eloxatin attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxaliplatin","termGroup":"PT","termSource":"NCI"},{"termName":"1-OHP","termGroup":"AB","termSource":"NCI"},{"termName":"[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum","termGroup":"SN","termSource":"NCI"},{"termName":"[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum","termGroup":"SN","termSource":"NCI"},{"termName":"Ai Heng","termGroup":"FB","termSource":"NCI"},{"termName":"Aiheng","termGroup":"FB","termSource":"NCI"},{"termName":"Dacotin","termGroup":"FB","termSource":"NCI"},{"termName":"Dacplat","termGroup":"FB","termSource":"NCI"},{"termName":"Diaminocyclohexane Oxalatoplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Eloxatin","termGroup":"BR","termSource":"NCI"},{"termName":"Eloxatine","termGroup":"FB","termSource":"NCI"},{"termName":"JM-83","termGroup":"CN","termSource":"NCI"},{"termName":"oxalato (1R,2R-cyclohexanediamine)platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"Oxalatoplatin","termGroup":"SY","termSource":"NCI"},{"termName":"Oxalatoplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"RP-54780","termGroup":"CN","termSource":"NCI"},{"termName":"SR-96669","termGroup":"CN","termSource":"NCI"},{"termName":"trans-l DACH oxalatoplatinum","termGroup":"SN","termSource":"NCI"},{"termName":"trans-l diaminocyclohexane oxalatoplatinum","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic colorectal cancer; ovarian cancer"},{"name":"CAS_Registry","value":"61825-94-3"},{"name":"CHEBI_ID","value":"CHEBI:31941"},{"name":"Chemical_Formula","value":"C8H14N2O4Pt"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"04ZR38536J"},{"name":"Legacy Concept Name","value":"Oxaliplatin"},{"name":"Maps_To","value":"Oxaliplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"42374"},{"name":"NSC Number","value":"266046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42374"},{"name":"PDQ_Open_Trial_Search_ID","value":"42374"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069717"}]}}{"C91074":{"preferredName":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome","code":"C91074","definitions":[{"definition":"A nanoparticle formulation containing N-glutaryl phosphatidylethanolamine (NGPE)-liposomes encapsulating oxaliplatin and conjugated to the human transferrin (Tf) ligand, with potential antineoplastic activity. Upon infusion of oxaliplatin-encapsulated transferrin-conjugated NGPE liposomes, the transferrin moiety targets and binds to the Tf receptor, which is overexpressed on a variety of human cancer cells. Upon binding and internalization, oxaliplatin is released and its active derivatives alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which results in an inhibition of DNA replication and transcription. By extending the circulation time and specifically targeting transferrin receptors, this formulation may improve the efficacy and safety of oxaliplatin therapy, compared to administration of oxaliplatin alone. NGPE, a reactive phospholipid, is used as a linker to attach the Tf ligand, to the liposome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"MBP-426","termGroup":"CN","termSource":"NCI"},{"termName":"Oxaliplatin-Encapsulated Tf-Conjugated NGPE-Liposome","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"669661"},{"name":"NCI_META_CUI","value":"CL416281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"669661"},{"name":"PDQ_Open_Trial_Search_ID","value":"669661"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C47643":{"preferredName":"Oxcarbazepine","code":"C47643","definitions":[{"definition":"A dibenzazepine carboxamide derivative with an anticonvulsant property. As a prodrug, oxcarbazepine is converted to its active metabolite, 10-monohydroxy. Although the mechanism of action has not been fully elucidated, electrophysiological studies indicate this agent blocks voltage-gated sodium channels, thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing the propagation of synaptic impulses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxcarbazepine","termGroup":"PT","termSource":"NCI"},{"termName":"10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Trileptal","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"28721-07-5"},{"name":"CHEBI_ID","value":"CHEBI:7824"},{"name":"Chemical_Formula","value":"C15H12N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VZI5B1W380"},{"name":"Legacy Concept Name","value":"Oxcarbazepine"},{"name":"Maps_To","value":"Oxcarbazepine"},{"name":"NCI_Drug_Dictionary_ID","value":"758784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758784"},{"name":"PDQ_Open_Trial_Search_ID","value":"758784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069751"}]}}{"C132271":{"preferredName":"Oxeclosporin","code":"C132271","synonyms":[{"termName":"Oxeclosporin","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclo(((2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-O-(2-hydroxyethyl)-D-seryl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclosporin A, 2-(O-(2-hydroxyethyl)-D-serine)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135548-15-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R7988D03JM"},{"name":"Maps_To","value":"Oxeclosporin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0170835"}]}}{"C130012":{"preferredName":"Oxidative Phosphorylation Inhibitor IACS-010759","code":"C130012","definitions":[{"definition":"An orally bioavailable oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration of the OxPhos inhibitor IACS-010759, this agent binds to and inhibits complex I of the electron transport chain (NADH ubiquinone oxidoreductase), thereby selectively depriving tumor cells of nutrients, and energy, and inhibiting nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation. Mitochondrial complex I, which is hyperactivated in cancer cells to meet their increased demands for energy, plays a key role in the promotion of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxidative Phosphorylation Inhibitor IACS-010759","termGroup":"PT","termSource":"NCI"},{"termName":"IACS-010759","termGroup":"CN","termSource":"NCI"},{"termName":"OXPHOS Inhibitor IACS-010759","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1570496-34-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42W52V11DJ"},{"name":"Maps_To","value":"Oxidative Phosphorylation Inhibitor IACS-010759"},{"name":"NCI_Drug_Dictionary_ID","value":"784867"},{"name":"NCI_META_CUI","value":"CL513977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784867"},{"name":"PDQ_Open_Trial_Search_ID","value":"784867"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153372":{"preferredName":"Lixumistat Acetate","code":"C153372","definitions":[{"definition":"The acetate salt form of lixumistat, an orally bioavailable biguanide compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration, lixumistat inhibits oxidative phosphorylation, decreases mitochondrial function, prevents tumor cell metabolism and deprives tumor cells of energy, thereby preventing tumor cell proliferation. Mitochondrial OxPhos is overactivated in cancer cells and plays a key role in tumor cell proliferation. Drug resistant tumor cells are very susceptible to decreased mitochondrial OxPhos as they cannot easily compensate for the decrease in mitochondrial function by increasing glycolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lixumistat Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"HL271 Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"IM 156","termGroup":"CN","termSource":"NCI"},{"termName":"IM-156","termGroup":"CN","termSource":"NCI"},{"termName":"IM156","termGroup":"CN","termSource":"NCI"},{"termName":"Mitochondrial Oxidative Phosphorylation Inhibitor IM156","termGroup":"SY","termSource":"NCI"},{"termName":"Oxidative Phosphorylation Inhibitor IM156","termGroup":"SY","termSource":"NCI"},{"termName":"OxPhos Inhibitor IM156","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422365-94-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8MS59W493C"},{"name":"Maps_To","value":"Oxidative Phosphorylation Inhibitor IM156"},{"name":"NCI_Drug_Dictionary_ID","value":"793779"},{"name":"NCI_META_CUI","value":"CL554528"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793779"},{"name":"PDQ_Open_Trial_Search_ID","value":"793779"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1316":{"preferredName":"Oxidopamine","code":"C1316","definitions":[{"definition":"An antagonist of the neurotransmitter dopamine with potential antineoplastic activity. 6-Hydroxydopamine (6-HOD) can be taken up by selective adrenergic terminals, thereby causing acute degeneration of adrenergic terminals that leads to depletion of norepinephrine, and of dopamine in the dopamine-sensitive sites. This agent is auto-oxidated at physiological pH that leads to the formation of reactive free radicals, thereby leading to cytotoxicity in neural cells.  6-Hydroxydopamine is often used to induce CNS and sympathetic neural lesions that model aging and various nervous disorders in animal systems.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxidopamine","termGroup":"PT","termSource":"NCI"},{"termName":"2,4,5-Trihydroxyphenethylamine","termGroup":"SN","termSource":"NCI"},{"termName":"5-(2-Aminoethyl)-1,2,4-benzenetriol","termGroup":"SN","termSource":"NCI"},{"termName":"6-Hydroxydopamine","termGroup":"SY","termSource":"NCI"},{"termName":"6-OHDA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1199-18-4"},{"name":"Chemical_Formula","value":"C8H11NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8HW4YBZ748"},{"name":"Legacy Concept Name","value":"_6-Hydroxydopamine"},{"name":"Maps_To","value":"Oxidopamine"},{"name":"NCI_Drug_Dictionary_ID","value":"41295"},{"name":"NSC Number","value":"233898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41295"},{"name":"PDQ_Open_Trial_Search_ID","value":"41295"},{"name":"PubMedID_Primary_Reference","value":"2511086"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0085196"}]}}{"C118283":{"preferredName":"OxPhos Inhibitor VLX600","code":"C118283","definitions":[{"definition":"A lipophilic cation-based triazinoindolyl-hydrazone compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon infusion, in normal cells and proliferating tumor cells where glucose is readily available, inhibition of OxPhos by VLX600 induces a hypoxia-inducible factor 1-alpha (HIF-1alpha)-dependent shift to, and an increase in glycolysis. Glycolysis alone does not produce enough energy to support the growth of tumor cells in this environment, and the induction of autophagy occurs. In the metabolically compromised tumor microenvironment, the availability of oxygen and glucose is limited due to poor vascularization and perfusion of tumor micro-areas. Tumor cells growing in this environment are thus unable to compensate for decreased mitochondrial function by increasing glycolysis. This leads to nutrient depletion, decreased energy production, induction of autophagy, tumor cell death and an inhibition of cell proliferation in quiescent tumor cells. Mitochondrial OxPhos, which is hyperactivated in cancer cells, plays a key role in the promotion of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OxPhos Inhibitor VLX600","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Pyridinyl)ethanone(6-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)hydrazone","termGroup":"SN","termSource":"NCI"},{"termName":"VLX-600","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"327031-55-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YZO6DG19MG"},{"name":"Maps_To","value":"OxPhos Inhibitor VLX600"},{"name":"NCI_Drug_Dictionary_ID","value":"764234"},{"name":"NCI_META_CUI","value":"CL474135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764234"},{"name":"PDQ_Open_Trial_Search_ID","value":"764234"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95214":{"preferredName":"Ozarelix","code":"C95214","definitions":[{"definition":"A highly modified, fourth generation linear decapeptide with gonadotropin-releasing hormone (GnRH or LHRH) antagonizing properties. Ozarelix competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ozarelix","termGroup":"PT","termSource":"NCI"},{"termName":"D 63153","termGroup":"CN","termSource":"NCI"},{"termName":"D-63 153","termGroup":"CN","termSource":"NCI"},{"termName":"D63 153","termGroup":"CN","termSource":"NCI"},{"termName":"D63153","termGroup":"CN","termSource":"NCI"},{"termName":"LHRH antagonist SPI-153","termGroup":"SY","termSource":"NCI"},{"termName":"SPI-153","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"295350-45-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1IF8M2YL3"},{"name":"Maps_To","value":"Ozarelix"},{"name":"NCI_Drug_Dictionary_ID","value":"690937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690937"},{"name":"PDQ_Open_Trial_Search_ID","value":"690937"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987000"}]}}{"C91723":{"preferredName":"P-cadherin Antagonist PF-03732010","code":"C91723","definitions":[{"definition":"An agent that inhibits P-cadherin (cdh3), with potential antineoplastic activity. PF-03732010 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of solid tumors, and plays a role in cell adhesion, motility, invasion and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-cadherin Antagonist PF-03732010","termGroup":"PT","termSource":"NCI"},{"termName":"PF-03732010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2070913-84-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LPW79O1J5Z"},{"name":"Maps_To","value":"P-cadherin Antagonist PF-03732010"},{"name":"NCI_Drug_Dictionary_ID","value":"580366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580366"},{"name":"PDQ_Open_Trial_Search_ID","value":"580366"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3179737"}]}}{"C121216":{"preferredName":"P-cadherin Inhibitor PCA062","code":"C121216","definitions":[{"definition":"An agent that inhibits p-cadherin, with potential antineoplastic activity. Upon intravenous infusion, PCA062 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-cadherin Inhibitor PCA062","termGroup":"PT","termSource":"NCI"},{"termName":"P-CAD Inhibitor PCA062","termGroup":"SY","termSource":"NCI"},{"termName":"P-cadherin Antagonist PCA062","termGroup":"SY","termSource":"NCI"},{"termName":"PCA062","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"P-cadherin Inhibitor PCA062"},{"name":"NCI_Drug_Dictionary_ID","value":"769816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769816"},{"name":"PDQ_Open_Trial_Search_ID","value":"769816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053579"}]}}{"C125607":{"preferredName":"P-cadherin-targeting Agent PF-06671008","code":"C125607","definitions":[{"definition":"An agent that targets p-cadherin (CDH3), with potential antineoplastic activity. Upon administration, PF-06671008 binds to and inhibits the activity of p-cadherin; this may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-cadherin-targeting Agent PF-06671008","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06671008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2GWZ8HN70W"},{"name":"Maps_To","value":"P-cadherin-targeting Agent PF-06671008"},{"name":"NCI_Drug_Dictionary_ID","value":"778591"},{"name":"NCI_META_CUI","value":"CL504311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778591"},{"name":"PDQ_Open_Trial_Search_ID","value":"778591"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113293":{"preferredName":"P-p68 Inhibitor RX-5902","code":"C113293","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, P-p68 inhibitor RX-5902 may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. p21 is a potent cyclin-dependent kinase inhibitor which regulates cell cycle progression and mediates both growth arrest and cellular senescence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-p68 Inhibitor RX-5902","termGroup":"PT","termSource":"NCI"},{"termName":"RX-5902","termGroup":"CN","termSource":"NCI"},{"termName":"Supinoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"888478-45-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZU8OM8V5WF"},{"name":"Maps_To","value":"P-p68 Inhibitor RX-5902"},{"name":"NCI_Drug_Dictionary_ID","value":"755944"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755944"},{"name":"PDQ_Open_Trial_Search_ID","value":"755944"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827081"}]}}{"C121456":{"preferredName":"Atuveciclib","code":"C121456","definitions":[{"definition":"An inhibitor of positive transcription elongation factor b (P-TEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin-T (CycT), with potential antineoplastic activity. Upon administration, atuveciclib binds to and inhibits the activity of P-TEFb, thereby preventing the phosphorylation of its downstream target, the carboxyl terminal domain (CTD) of RNA polymerase II (RNA Pol II), and inhibiting the activation of transcriptional elongation by RNA Pol II. This prevents the transcription of tumor promoting genes, induces tumor cell apoptosis, and inhibits tumor cell proliferation. P-TEFb plays an important role in the regulation of gene transcription; over-activation in cancer cells leads to both the transcription of key tumor-promoting genes and cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atuveciclib","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5-Triazin-2-amine, 4-(4-Fluoro-2-methoxyphenyl)-N-(3-((S-methylsulfonimidoyl)methyl)phenyl)-, (+)-","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 1143572","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1143572","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1414943-94-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"63Q7F59W0V"},{"name":"Maps_To","value":"Atuveciclib"},{"name":"Maps_To","value":"P-TEFb Inhibitor BAY1143572"},{"name":"NCI_Drug_Dictionary_ID","value":"753347"},{"name":"NCI_META_CUI","value":"CL471744"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753347"},{"name":"PDQ_Open_Trial_Search_ID","value":"753347"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160195":{"preferredName":"Inobrodib","code":"C160195","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, inobrodib selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inobrodib","termGroup":"PT","termSource":"NCI"},{"termName":"CCS 1477","termGroup":"CN","termSource":"NCI"},{"termName":"CCS-1477","termGroup":"CN","termSource":"NCI"},{"termName":"CCS1477","termGroup":"CN","termSource":"NCI"},{"termName":"p300 HAT/CREB Binding Protein Inhibitor CCS1477","termGroup":"SY","termSource":"NCI"},{"termName":"p300/CBP Bromodomain Inhibitor CCS1477","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222941-37-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BW5QA5GEW7"},{"name":"Maps_To","value":"p300/CBP Bromodomain Inhibitor CCS1477"},{"name":"NCI_Drug_Dictionary_ID","value":"797847"},{"name":"NCI_META_CUI","value":"CL969329"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797847"},{"name":"PDQ_Open_Trial_Search_ID","value":"797847"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99134":{"preferredName":"p38 MAPK Inhibitor LY3007113","code":"C99134","definitions":[{"definition":"An orally active p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activity. Upon administration, LY3007113 inhibits the activity of p38, thereby preventing p38 MAPK-mediated signaling. This may result in the inhibition of the production of proinflammatory cytokines and the induction of tumor cell apoptosis. p38 MAPK, a serine/threonine protein kinase often upregulated in cancer cells, plays a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p38 MAPK Inhibitor LY3007113","termGroup":"PT","termSource":"NCI"},{"termName":"LY3007113","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p38 MAPK Inhibitor LY3007113"},{"name":"NCI_Drug_Dictionary_ID","value":"716106"},{"name":"NCI_META_CUI","value":"CL432952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"716106"},{"name":"PDQ_Open_Trial_Search_ID","value":"716106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1986":{"preferredName":"p53 Peptide Vaccine MPS-128","code":"C1986","definitions":[{"definition":"A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p53 Peptide Vaccine MPS-128","termGroup":"PT","termSource":"NCI"},{"termName":"MPS-128","termGroup":"CN","termSource":"NCI"},{"termName":"MPS-128","termGroup":"SY","termSource":"NCI"},{"termName":"p53:264-272 Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"PR-147","termGroup":"CN","termSource":"NCI"},{"termName":"PR-147","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"p53_Peptide_Vaccine"},{"name":"Maps_To","value":"p53 Peptide Vaccine MPS-128"},{"name":"NCI_Drug_Dictionary_ID","value":"43633"},{"name":"NSC Number","value":"717111"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43633"},{"name":"PDQ_Open_Trial_Search_ID","value":"43633"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879339"}]}}{"C106120":{"preferredName":"p53-HDM2 Interaction Inhibitor MI-773","code":"C106120","definitions":[{"definition":"An orally available spiro-oxindole HDM2 (human double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, the p53-HDM2 protein-protein interaction inhibitor MI-773 binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p53-HDM2 Interaction Inhibitor MI-773","termGroup":"PT","termSource":"NCI"},{"termName":"MI-773","termGroup":"CN","termSource":"NCI"},{"termName":"p53-MDM2 Interaction Inhibitor MI-773","termGroup":"SY","termSource":"NCI"},{"termName":"SAR405838","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1303607-60-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8570LZ3RCA"},{"name":"Maps_To","value":"p53-HDM2 Interaction Inhibitor MI-773"},{"name":"NCI_Drug_Dictionary_ID","value":"737146"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737146"},{"name":"PDQ_Open_Trial_Search_ID","value":"737146"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853940"}]}}{"C132991":{"preferredName":"Alrizomadlin","code":"C132991","definitions":[{"definition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alrizomadlin","termGroup":"PT","termSource":"NCI"},{"termName":"AA-115","termGroup":"CN","termSource":"NCI"},{"termName":"APG 115","termGroup":"CN","termSource":"NCI"},{"termName":"APG-115","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2-p53 Inhibitor APG-115","termGroup":"SY","termSource":"NCI"},{"termName":"p53-HDM2 Protein-protein Interaction Inhibitor APG-115","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1818393-16-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15QAU0SI9J"},{"name":"Maps_To","value":"p53-HDM2 Protein-protein Interaction Inhibitor APG-115"},{"name":"NCI_Drug_Dictionary_ID","value":"787602"},{"name":"NCI_META_CUI","value":"CL520348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787602"},{"name":"PDQ_Open_Trial_Search_ID","value":"787602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104280":{"preferredName":"p53/HDM2 Interaction Inhibitor CGM097","code":"C104280","definitions":[{"definition":"An orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p53/HDM2 Interaction Inhibitor CGM097","termGroup":"PT","termSource":"NCI"},{"termName":"CGM097","termGroup":"CN","termSource":"NCI"},{"termName":"HDM2/p53 Inhibitor CGM097","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313363-54-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4UF6MSL0ZH"},{"name":"Maps_To","value":"p53/HDM2 Interaction Inhibitor CGM097"},{"name":"NCI_Drug_Dictionary_ID","value":"744999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744999"},{"name":"PDQ_Open_Trial_Search_ID","value":"744999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641742"}]}}{"C91393":{"preferredName":"p70S6K Inhibitor LY2584702","code":"C91393","definitions":[{"definition":"An orally available inhibitor of p70S6K signaling, with potential antineoplastic activity. p70S6K inhibitor LY2584702 inhibits ribosomal protein S6 Kinase (p70S6K), and prevents phosphorylation of the S6 subunit of ribosomes, thereby inhibiting normal ribosomal function within tumor cells leading to a decrease in protein synthesis and in cellular proliferation. P70S6K, a serine/threonine kinase, acts downstream of PIP3 and phosphoinositide-dependent kinase-1 in the PI3 kinase pathway, is often upregulated in a variety of cancer cells, and is involved in the regulation of cell growth, proliferation, motility, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p70S6K Inhibitor LY2584702","termGroup":"PT","termSource":"NCI"},{"termName":"LY2584702","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1082949-67-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I4965C6W4O"},{"name":"Maps_To","value":"p70S6K Inhibitor LY2584702"},{"name":"NCI_Drug_Dictionary_ID","value":"673507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673507"},{"name":"PDQ_Open_Trial_Search_ID","value":"673507"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984214"}]}}{"C112004":{"preferredName":"p70S6K/Akt Inhibitor M-2698","code":"C112004","definitions":[{"definition":"An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, p70S6K/Akt inhibitor M-2698 binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p70S6K/Akt Inhibitor M-2698","termGroup":"PT","termSource":"NCI"},{"termName":"MSC2363318A","termGroup":"CN","termSource":"NCI"},{"termName":"p70S6K/Akt Inhibitor MSC2363318A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1379545-95-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0DXG50I4WD"},{"name":"Maps_To","value":"p70S6K/Akt Inhibitor MSC2363318A"},{"name":"NCI_Drug_Dictionary_ID","value":"754258"},{"name":"NCI_META_CUI","value":"CL454293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754258"},{"name":"PDQ_Open_Trial_Search_ID","value":"754258"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118287":{"preferredName":"p97 Inhibitor CB-5083","code":"C118287","definitions":[{"definition":"An orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity. Upon oral administration, CB-5083 specifically binds to and inhibits the activity of p97. This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins. The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and inhibition of cell proliferation in susceptible tumor cells. p97, a type II AAA ATPase, plays a key role in cellular protein homeostasis. Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p97 Inhibitor CB-5083","termGroup":"PT","termSource":"NCI"},{"termName":"CB-5083","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1542705-92-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"591IV6UL6J"},{"name":"Maps_To","value":"p97 Inhibitor CB-5083"},{"name":"NCI_Drug_Dictionary_ID","value":"764238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764238"},{"name":"PDQ_Open_Trial_Search_ID","value":"764238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896891"}]}}{"C1411":{"preferredName":"Paclitaxel","code":"C1411","definitions":[{"definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine","termGroup":"SN","termSource":"NCI"},{"termName":"[2aR-[2a Alpha,4beta,4a beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Anzatax","termGroup":"FB","termSource":"NCI"},{"termName":"Asotax","termGroup":"FB","termSource":"NCI"},{"termName":"Bristaxol","termGroup":"FB","termSource":"NCI"},{"termName":"Praxel","termGroup":"FB","termSource":"NCI"},{"termName":"Taxol","termGroup":"AQS","termSource":"NCI"},{"termName":"Taxol Konzentrat","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"AIDS-related Kaposi's sarcoma; Bladder cancer; Breast cancer; Cervical cancer; Endometrial adenocarcinoma; Esophageal cancer; Head and Neck cancer; Lung cancer; non-small cell; Lymphoma; Ovarian cancer; Prostate cancer; Testicular cancer"},{"name":"CAS_Registry","value":"33069-62-4"},{"name":"CHEBI_ID","value":"CHEBI:45863"},{"name":"Chemical_Formula","value":"C47H51NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"P88XT4IS4D"},{"name":"Legacy Concept Name","value":"Paclitaxel"},{"name":"Maps_To","value":"Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"39762"},{"name":"NSC Number","value":"125973"},{"name":"NSC Number","value":"673089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39762"},{"name":"PDQ_Open_Trial_Search_ID","value":"39762"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0144576"}]}}{"C96934":{"preferredName":"Paclitaxel Ceribate","code":"C96934","definitions":[{"definition":"The ceribate ester form of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to and stabilizes tubulin thereby inhibiting the disassembly of microtubules, resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (BCL2).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Ceribate","termGroup":"PT","termSource":"NCI"},{"termName":"7beta-((2RS)-2,3-dihydroxypropoxycarbonyloxy)-1-hydroxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoate)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186040-50-6"},{"name":"Chemical_Formula","value":"C51H57NO18"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B3C86E80A0"},{"name":"Maps_To","value":"Paclitaxel Ceribate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273125"}]}}{"C96037":{"preferredName":"Paclitaxel Injection Concentrate for Nanodispersion","code":"C96037","definitions":[{"definition":"A nanoparticle-based injectable concentrate containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity.  Upon reconstitution and administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and allows for administration of higher doses resulting in higher concentrations of paclitaxel at the tumor site, and an increased safety profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Injection Concentrate for Nanodispersion","termGroup":"PT","termSource":"NCI"},{"termName":"PICN","termGroup":"AB","termSource":"NCI"},{"termName":"SPARC1023","termGroup":"CN","termSource":"NCI"},{"termName":"SPARC1028","termGroup":"CN","termSource":"NCI"},{"termName":"SPARC1210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paclitaxel Injection Concentrate for Nanodispersion"},{"name":"NCI_Drug_Dictionary_ID","value":"696555"},{"name":"NCI_META_CUI","value":"CL428371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696555"},{"name":"PDQ_Open_Trial_Search_ID","value":"696555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2631":{"preferredName":"Paclitaxel Liposome","code":"C2631","definitions":[{"definition":"A form of the anticancer drug paclitaxel that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of several types of cancer. Paclitaxel liposome blocks the ability of cells to divide and may kill cancer cells. It is a type of mitotic inhibitor and a type of antimicrotubule agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposome-encapsulated formulation of paclitaxel, a taxoid compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic property. Paclitaxel binds to tubulin and interferes with the assembly/disassembly dynamics of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"Liposome-Encapsulated Paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paclitaxel_Liposome"},{"name":"Maps_To","value":"Paclitaxel Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"38323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38323"},{"name":"PDQ_Open_Trial_Search_ID","value":"38323"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935868"}]}}{"C1795":{"preferredName":"Paclitaxel Poliglumex","code":"C1795","definitions":[{"definition":"A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Poliglumex","termGroup":"PT","termSource":"NCI"},{"termName":"CT-2103","termGroup":"CN","termSource":"NCI"},{"termName":"CT2103","termGroup":"CN","termSource":"NCI"},{"termName":"Paclitaxel Polyglutamate","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel-Polyglutamate Polymer","termGroup":"SY","termSource":"NCI"},{"termName":"PG-TXL","termGroup":"AB","termSource":"NCI"},{"termName":"Poly-L-Glutamic acid-Paclitaxel Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Polyglutamic Acid Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Xyotax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"263351-82-2"},{"name":"Chemical_Formula","value":"C10H16N2O7(C52H56N2O16)n(C5H7NO3)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TQ64FZ98ZN"},{"name":"Legacy Concept Name","value":"Paclitaxel_Polyglutamate"},{"name":"Maps_To","value":"Paclitaxel Poliglumex"},{"name":"NCI_Drug_Dictionary_ID","value":"38325"},{"name":"NSC Number","value":"724773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38325"},{"name":"PDQ_Open_Trial_Search_ID","value":"38325"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1702776"}]}}{"C148531":{"preferredName":"Paclitaxel Polymeric Micelle Formulation NANT-008","code":"C148531","definitions":[{"definition":"A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Polymeric Micelle Formulation NANT-008","termGroup":"PT","termSource":"NCI"},{"termName":"Cynviloq","termGroup":"BR","termSource":"NCI"},{"termName":"Genexol-PM","termGroup":"FB","termSource":"NCI"},{"termName":"IG-001","termGroup":"CN","termSource":"NCI"},{"termName":"Micellar Nanoparticle-encapsulated NANT-008","termGroup":"SY","termSource":"NCI"},{"termName":"NANT 008","termGroup":"CN","termSource":"NCI"},{"termName":"NANT-008","termGroup":"CN","termSource":"NCI"},{"termName":"Nant-paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"NANT008","termGroup":"CN","termSource":"NCI"},{"termName":"Paclitaxel-loaded Micellar Diblock Copolymer NANT-008","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel-loaded Polymeric Micelle NANT-008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paclitaxel Polymeric Micelle Formulation NANT-008"},{"name":"NCI_Drug_Dictionary_ID","value":"434427"},{"name":"NCI_META_CUI","value":"CL551138"},{"name":"PDQ_Closed_Trial_Search_ID","value":"434427"},{"name":"PDQ_Open_Trial_Search_ID","value":"434427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2785":{"preferredName":"Paclitaxel PPE Microspheres","code":"C2785","definitions":[{"definition":"A paclitaxel formulation containing paclitaxel incorporated in biodegradable polyphosphoester (PPE) polymer form with potential antineoplastic activity. Upon intraperitoneal delivery, paclitaxel PPE microspheres slowly and continuously dissolve and deliver paclitaxel to the tumor site, where it binds to tubulin and inhibits the dynamics of disassembly-assembly of microtubules. As a result, this formulation induces cell cycle arrest and leads to cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel PPE Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"Paclimer Microspheres","termGroup":"BR","termSource":"NCI"},{"termName":"Paclimer Microspheres (Polilactofate/Paclitaxel)","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel Biopolymer Formulation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paclitaxel_PPE_Microspheres"},{"name":"Maps_To","value":"Paclitaxel PPE Microspheres"},{"name":"NSC Number","value":"715074"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518843"}]}}{"C99461":{"preferredName":"Paclitaxel Trevatide","code":"C99461","definitions":[{"definition":"A peptide-drug conjugate containing the taxane paclitaxel covalently linked to the proprietary 19 amino acid peptide angiopep-2, in a 3:1 ratio, with potential antineoplastic activity. Upon administration, paclitaxel trevatide, via angiopep-2 moiety, binds to LRP-1 (low density lipoprotein receptor-related protein 1), which is highly expressed in blood brain barrier (BBB) and glioma cells. This binding allows the transcytosis of the agent across the BBB and the delivery of the cytotoxic agent paclitaxel. Compared to paclitaxel alone, GRN1005 is able to increase the concentration of paclitaxel in the brain and is also able to specifically deliver paclitaxel to LRP-1-overexpressing tumor cells, both in the brain and in the periphery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Trevatide","termGroup":"PT","termSource":"NCI"},{"termName":"ANG-1005","termGroup":"CN","termSource":"NCI"},{"termName":"ANG1005","termGroup":"CN","termSource":"NCI"},{"termName":"GRN1005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1075214-55-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8P77G99D3P"},{"name":"Maps_To","value":"Paclitaxel Trevatide"},{"name":"NCI_Drug_Dictionary_ID","value":"721733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721733"},{"name":"PDQ_Open_Trial_Search_ID","value":"721733"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2604058"}]}}{"C61079":{"preferredName":"Paclitaxel Vitamin E-Based Emulsion","code":"C61079","definitions":[{"definition":"A cremophor-free, P-glycoprotein-inhibiting, vitamin E-based emulsion particle formulation of paclitaxel with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2). The vitamin-E based emulsion allows bolus infusion without steroid premedication and may diminish hypersensitivity reactions. The tumor tissue may be passively targeted due to preferential deposition of emulsion particles while an emulsion formulation component inhibits the P-glycoprotein drug efflux pump.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Vitamin E-Based Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"Paclitaxel Injectable Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"PIE","termGroup":"AB","termSource":"NCI"},{"termName":"S-8184","termGroup":"CN","termSource":"NCI"},{"termName":"Tocosol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tocosol_Paclitaxel"},{"name":"Maps_To","value":"Paclitaxel Vitamin E-Based Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"474798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"474798"},{"name":"PDQ_Open_Trial_Search_ID","value":"474798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541793"}]}}{"C48415":{"preferredName":"Paclitaxel-Loaded Polymeric Micelle","code":"C48415","definitions":[{"definition":"A biodegradable poly(ethylene glycol)-poly(D,L-lactide) copolymer micelle nanoparticle-entrapped formulation of paclitaxel with antineoplastic activity. Paclitaxel promotes microtubule assembly and prevents depolymerization, thus interfering with normal mitosis. The copolymer residue increases the water-solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone.","type":"DEFINITION","source":"NCI"},{"definition":"A form of the anticancer drug paclitaxel used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used with another drug to treat non-small cell lung cancer. Paclitaxel is mixed with very tiny particles of a substance that makes it easier to dissolve in water. This allows higher doses of paclitaxel to be given. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Paclitaxel-Loaded Polymeric Micelle","termGroup":"PT","termSource":"NCI"},{"termName":"Cynviloq TM","termGroup":"SY","termSource":"NCI"},{"termName":"Genexol PM","termGroup":"FB","termSource":"NCI"},{"termName":"IG-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paclitaxel-Loaded_Polymeric_Micelle"},{"name":"Maps_To","value":"Paclitaxel-Loaded Polymeric Micelle"},{"name":"NCI_Drug_Dictionary_ID","value":"434427"},{"name":"PDQ_Closed_Trial_Search_ID","value":"434427"},{"name":"PDQ_Open_Trial_Search_ID","value":"434427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709446"}]}}{"C78837":{"preferredName":"Pacritinib","code":"C78837","definitions":[{"definition":"An orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, pacritinib competes with JAK2 and the JAK2 mutant JAK2V617F for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-signal transducer and activator of transcription (STAT) signaling pathway, and the induction of apoptosis. In addition, pacritinib targets, binds to and inhibits the activity of FLT3. This inhibits FLT3-mediated signaling and the proliferation of FLT3-expressing cancer cells. JAK2, often upregulated or mutated in a variety of cancer cells, plays a key role in tumor cell proliferation and survival. The JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. In addition, JAK2 and FLT3 play a key role in the regulation of the inflammatory response and dendritic cell (DC) proliferation, differentiation and function. Inhibition of JAK2- and FLT3-mediated signaling may suppress the generation and differentiation of DCs, and may regulate inflammatory and immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacritinib","termGroup":"PT","termSource":"NCI"},{"termName":"Oral JAK2 Inhibitor SB1518","termGroup":"SY","termSource":"NCI"},{"termName":"SB 1518","termGroup":"CN","termSource":"NCI"},{"termName":"SB-1518","termGroup":"CN","termSource":"NCI"},{"termName":"SB1518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"937272-79-2"},{"name":"Chemical_Formula","value":"C28H32N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G22N65IL3O"},{"name":"Legacy Concept Name","value":"JAK2_Inhibitor_SB1518"},{"name":"Maps_To","value":"Pacritinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703133"}]}}{"C78481":{"preferredName":"Padeliporfin","code":"C78481","definitions":[{"definition":"A vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative with potential antineoplastic activity. Upon administration, paldeliporfin is activated locally when the tumor bed is exposed to low-power laser light; reactive oxygen species (ROS) are formed upon activation and ROS-mediated necrosis may occur at the site of interaction between the photosensitizer, light and oxygen. Vascular-targeted photodynamic therapy (VTP) with padeliporfin may allow tumor-site specific cytotoxicity while sparing adjacent normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Padeliporfin","termGroup":"PT","termSource":"NCI"},{"termName":"Palladium-Bacteriochlorophyll Derivative WST11","termGroup":"SY","termSource":"NCI"},{"termName":"WST11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"759457-82-4"},{"name":"Chemical_Formula","value":"C37H43N5O9S.Pd"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EEO29FZT86"},{"name":"Legacy Concept Name","value":"Palladium-Bacteriochlorophyll_Derivative_WST11"},{"name":"Maps_To","value":"Padeliporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"600817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600817"},{"name":"PDQ_Open_Trial_Search_ID","value":"600817"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1610374"}]}}{"C61321":{"preferredName":"Padoporfin","code":"C61321","definitions":[{"definition":"A novel palladium-substituted bacteriochlorophyll derivative and photosensitizer with potential antitumor activity. Upon administration, inactive padoporfin is activated locally when the tumor bed is exposed to photoirradiation; the activated form induces local cytotoxic processes, resulting in local tissue damage, disruption of tumor vasculature, and tumor hypoxia and necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Padoporfin","termGroup":"PT","termSource":"NCI"},{"termName":"(Hydrogen 3-((2(sup 2)R,7R,8R,17S,18S)-12-acetyl-7-ethyl-2(sup 2)-(methoxycarbonyl)-3,8,13,17-tetramethyl-2(sup 1)-oxo-2(sup 1),2(sup 2),7,8,17,18-hexahydrocyclopenta(at)porphyrin-18-yl)propanoato-kappa4N(sup 21),N(sup 22),N(sup 23),N(sup 24))palladium","termGroup":"SY","termSource":"NCI"},{"termName":"Tookad","termGroup":"FB","termSource":"NCI"},{"termName":"WST09","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"274679-00-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OIH1H7CJCJ"},{"name":"Legacy Concept Name","value":"Palladium-Bacteriopheophorbide"},{"name":"Maps_To","value":"Padoporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"483132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"483132"},{"name":"PDQ_Open_Trial_Search_ID","value":"483132"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1136634"}]}}{"C84841":{"preferredName":"PAK4 Inhibitor PF-03758309","code":"C84841","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PAK4 inhibitor PF-03758309 binds to PAK4, inhibiting PAK4 activity and cancer cell growth. PAK4, a serine/threonine kinase belonging to the p21-activated kinase (PAK) family, is often upregulated in a variety of cancer cell types and plays an important role in cancer cell motility, proliferation, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAK4 Inhibitor PF-03758309","termGroup":"PT","termSource":"NCI"},{"termName":"PF-03758309","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"898044-15-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PK459EA5I2"},{"name":"Maps_To","value":"PAK4 Inhibitor PF-03758309"},{"name":"NCI_Drug_Dictionary_ID","value":"650124"},{"name":"NCI_META_CUI","value":"CL412392"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650124"},{"name":"PDQ_Open_Trial_Search_ID","value":"650124"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126646":{"preferredName":"Padnarsertib","code":"C126646","definitions":[{"definition":"An orally bioavailable inhibitor of both the serine/threonine kinase P21-activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon administration, padnarsertib allosterically binds to, destabilizes and causes degradation of PAK4. This inhibits PAK4-mediated signaling, induces cell death in, and inhibits the proliferation of PAK4-overexpressing tumor cells. In addition, padnarsertib binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in tumor cell death in NAMPT-overexpressing cancer cells. PAK4, a serine/threonine kinase and member of the PAK family of proteins upregulated in various cancer cell types, regulates cell motility, proliferation and survival. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is often overexpressed in a variety of cancers and metabolic disorders and tumor cells rely on NAMPT activity for their NAD supply.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Padnarsertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATG 019","termGroup":"CN","termSource":"NCI"},{"termName":"ATG-019","termGroup":"CN","termSource":"NCI"},{"termName":"ATG019","termGroup":"CN","termSource":"NCI"},{"termName":"KCP-9274","termGroup":"CN","termSource":"NCI"},{"termName":"KPT-9274","termGroup":"CN","termSource":"NCI"},{"termName":"PAK4/NAMPT Inhibitor ATG-019","termGroup":"SY","termSource":"NCI"},{"termName":"PAK4/NAMPT Inhibitor KPT-9274","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1643913-93-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9T56TV18X7"},{"name":"Maps_To","value":"PAK4/NAMPT Inhibitor KPT-9274"},{"name":"NCI_Drug_Dictionary_ID","value":"779707"},{"name":"NCI_META_CUI","value":"CL503763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779707"},{"name":"PDQ_Open_Trial_Search_ID","value":"779707"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49176":{"preferredName":"Palbociclib","code":"C49176","definitions":[{"definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palbociclib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one","termGroup":"SY","termSource":"NCI"},{"termName":"Ibrance","termGroup":"BR","termSource":"NCI"},{"termName":"PD 0332991","termGroup":"CN","termSource":"NCI"},{"termName":"PD 332991","termGroup":"CN","termSource":"NCI"},{"termName":"PD 991","termGroup":"CN","termSource":"NCI"},{"termName":"PD-0332991","termGroup":"CN","termSource":"NCI"},{"termName":"Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer"},{"name":"CAS_Registry","value":"571190-30-2"},{"name":"Chemical_Formula","value":"C24H29N7O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G9ZF61LE7G"},{"name":"Legacy Concept Name","value":"PD-0332991"},{"name":"Maps_To","value":"Palbociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"454586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454586"},{"name":"PDQ_Open_Trial_Search_ID","value":"454586"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853822"}]}}{"C120259":{"preferredName":"Palbociclib Isethionate","code":"C120259","definitions":[{"definition":"The isethionate salt form of palbociclib, an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palbociclib Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino(pyrido(2,3-d)pyrimidin-7(8h)-one mono(2-hydroxyethanesulfonate)","termGroup":"SN","termSource":"NCI"},{"termName":"PD 0332991-0054","termGroup":"CN","termSource":"NCI"},{"termName":"PF-00080665-73","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"827022-33-3"},{"name":"Chemical_Formula","value":"C24H29N7O2.C2-H6-O4-S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W1NYL2IRDR"},{"name":"Maps_To","value":"Palbociclib Isethionate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896941"}]}}{"C66990":{"preferredName":"Palifosfamide","code":"C66990","definitions":[{"definition":"A synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lysine for stability, palifosfamide irreversibly alkylates and cross-links DNA through GC base pairs, resulting in irreparable 7-atom inter-strand cross-links; inhibition of DNA replication and cell death follow. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palifosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"IPM-Lysine","termGroup":"AB","termSource":"NCI"},{"termName":"Isophosphoramide Mustard-Lysine","termGroup":"SY","termSource":"NCI"},{"termName":"N,N'-Di-(2-chloroethyl)phosphorodiamidic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ZIO-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31645-39-3"},{"name":"Chemical_Formula","value":"C4H11Cl2N2O2P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6A4U6NN813"},{"name":"Legacy Concept Name","value":"Isophosphoramide_Mustard-Lysine"},{"name":"Maps_To","value":"Palifosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"538996"},{"name":"NSC Number","value":"297900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"538996"},{"name":"PDQ_Open_Trial_Search_ID","value":"538996"},{"name":"PubMedID_Primary_Reference","value":"6821629"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064039"}]}}{"C95703":{"preferredName":"Palifosfamide Tromethamine","code":"C95703","definitions":[{"definition":"A synthetic mustard compound of the tromethamine (tris) salt of palifosfamide (Isophosphamide mustard), with potential antineoplastic activity. As the stabilized active metabolite of ifosfamide, palifosfamide irreversibly alkylates and crosslinks DNA through GC base pairs, resulting in irreparable 7-atom interstrand crosslinks. This leads to an inhibition of DNA replication and ultimately cell death. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide. Stabilization with tris instead of lysine further increases stability and may further decrease nephrotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palifosfamide Tromethamine","termGroup":"PT","termSource":"NCI"},{"termName":"Palifosfamide Tris","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphorodiamidic Acid, N,N'-bis(2-chloroethyl)-, Compd. with 2-Amino-2-(hydroxymethyl)-1,3-propanediol (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"ZIO-201-T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1070409-31-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0X5A3C04ID"},{"name":"Maps_To","value":"Palifosfamide Tromethamine"},{"name":"NCI_Drug_Dictionary_ID","value":"689807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689807"},{"name":"PDQ_Open_Trial_Search_ID","value":"689807"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987344"}]}}{"C2550":{"preferredName":"Palladium Pd-103","code":"C2550","definitions":[{"definition":"A radioactive form of palladium (a metallic element that resembles platinum). When used to treat prostate cancer, radioactive seeds (small pellets that contain radioactive palladium) are placed in the prostate. Cancer cells are killed by the energy given off as the radioactive material breaks down and becomes more stable.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioisotope of the metal palladium used in brachytherapy implants or 'seed'. With a half-life of 17 days, palladium 103 administered with brachytherapy allows continuous, tumor-site specific low-energy irradiation to the tumor cell population while sparing normal adjacent tissues from radiotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palladium Pd-103","termGroup":"PT","termSource":"NCI"},{"termName":"Palladium Pd 103","termGroup":"SY","termSource":"NCI"},{"termName":"Palladium-103","termGroup":"SY","termSource":"NCI"},{"termName":"Pd 103","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Early Stage Prostate Cancer; Localized Tumours of the Head, Neck, Lung, Pancreas, Breast, Intraocular and Uterus."},{"name":"CAS_Registry","value":"14967-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68QTV136DF"},{"name":"Legacy Concept Name","value":"Palladium_103"},{"name":"Maps_To","value":"Palladium Pd-103"},{"name":"NCI_Drug_Dictionary_ID","value":"38046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38046"},{"name":"PDQ_Open_Trial_Search_ID","value":"38046"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"UMLS_CUI","value":"C0303566"}]}}{"C47650":{"preferredName":"Palonosetron Hydrochloride","code":"C47650","definitions":[{"definition":"A drug used to treat nausea and vomiting caused by cancer treatment. It is a type of serotonin receptor antagonist and a type of antiemetic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of palonosetron, a carbazole derivative and a selective serotonin receptor antagonist with antiemetic activity. Palonosetron competitively blocks the action of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting. The CTZ is located in the area postrema on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle and outside the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palonosetron Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benz(de)isoquinolin-1-one, 2-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, Monohydrochloride,(3aS)-","termGroup":"SN","termSource":"NCI"},{"termName":"Aloxi","termGroup":"BR","termSource":"NCI"},{"termName":"palonosetron HCl","termGroup":"SY","termSource":"NCI"},{"termName":"RS 25259-197","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"prevention of chemotherapy-induced nausea and vomiting"},{"name":"CAS_Registry","value":"135729-62-3"},{"name":"Chemical_Formula","value":"C19H24N2O.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23310D4I19"},{"name":"Legacy Concept Name","value":"Palonosetron_Hydrochloride"},{"name":"Maps_To","value":"Palonosetron Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"486366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486366"},{"name":"PDQ_Open_Trial_Search_ID","value":"486366"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1310734"}]}}{"C1345":{"preferredName":"Pamidronate Disodium","code":"C1345","definitions":[{"definition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamidronate Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Aminomux","termGroup":"FB","termSource":"NCI"},{"termName":"Aredia","termGroup":"BR","termSource":"NCI"},{"termName":"GCP-23339A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypercalcemia of malignancy; Osteolytic bone lesions of multiple myeloma; Osteolytic bone metastases of breast cancer; Pagets disease"},{"name":"CAS_Registry","value":"109552-15-0"},{"name":"Chemical_Formula","value":"C3H9NO7P2.2Na.5H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8742T8ZQZA"},{"name":"Legacy Concept Name","value":"Pamidronate_Disodium"},{"name":"Maps_To","value":"Pamidronate Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39149"},{"name":"NSC Number","value":"720699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39149"},{"name":"PDQ_Open_Trial_Search_ID","value":"39149"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0356588"}]}}{"C61875":{"preferredName":"Pamidronic Acid","code":"C61875","definitions":[{"definition":"A drug that is used to treat hypercalcemia (too much calcium in the blood) and cancer that has spread to the bones. It belongs to the family of drugs called bisphosphonates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An amino- bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Pamidronic acid binds to and adsorbs onto hydroxyapatite crystals in the bone matrix, thereby preventing osteoclast resorption. This agent also binds to and inhibits farnesyl pyrophosphate synthase, an enzyme that plays an important role in the mevalonate pathway. This inhibits the formation of isoprenoid metabolites that are substrates for protein prenylation. This prevents farnesylation and geranylgeranylation of proteins essential for osteoclast function, leading to the induction of apoptosis of osteoclasts. By preventing osteoclast-mediated bone resorption, pamidronic acid decreases bone turnover rate, stabilizes the bone matrix and reduces hypercalcemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamidronic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Pamidronate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"40391-99-9"},{"name":"Chemical_Formula","value":"C3H11NO7P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OYY3447OMC"},{"name":"Legacy Concept Name","value":"Pamidronic_Acid"},{"name":"Maps_To","value":"Pamidronic Acid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043603"}]}}{"C120553":{"preferredName":"Pamiparib","code":"C120553","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamiparib","termGroup":"PT","termSource":"NCI"},{"termName":"5,6,7a,11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-Fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)-","termGroup":"SN","termSource":"NCI"},{"termName":"BGB-290","termGroup":"CN","termSource":"NCI"},{"termName":"PARP Inhibitor BGB-290","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446261-44-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8375F9S90C"},{"name":"Maps_To","value":"Pamiparib"},{"name":"NCI_Drug_Dictionary_ID","value":"769217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769217"},{"name":"PDQ_Open_Trial_Search_ID","value":"769217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053665"}]}}{"C124931":{"preferredName":"pan FGFR Inhibitor PRN1371","code":"C124931","definitions":[{"definition":"A highly specific covalent inhibitor of human fibroblast growth factor receptor types 1, 2, 3 and 4 (FGFR1-4) with potential antiangiogenic and antineoplastic activities. FGFR1-4 tyrosine kinase inhibitor PRN1371 specifically binds to a conserved cysteine residue in the glycine-rich loop in FGFRs and inhibits their tyrosine kinase activity, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation, proliferation and survival, and in tumor angiogenesis. This agent potently inhibits FGFR1-4 but does not inhibit other tyrosine kinases, even those that share the conserved cysteine, which may improve therapeutic responses and decrease toxicity when compared with less selective inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan FGFR Inhibitor PRN1371","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR 1-4 Inhibitor PRN1371","termGroup":"SY","termSource":"NCI"},{"termName":"pan FGFR Inhibitor PRN1371","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FGFR Tyrosine Kinase Inhibitor PRN1371","termGroup":"SY","termSource":"NCI"},{"termName":"PRN 1371","termGroup":"CN","termSource":"NCI"},{"termName":"PRN1371","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802929-43-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3OPE9IA3Q"},{"name":"Maps_To","value":"pan FGFR Inhibitor PRN1371"},{"name":"NCI_Drug_Dictionary_ID","value":"777939"},{"name":"NCI_META_CUI","value":"CL503800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777939"},{"name":"PDQ_Open_Trial_Search_ID","value":"777939"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68832":{"preferredName":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514","code":"C68832","definitions":[{"definition":"A pyrrolotriazine-based compound and a pan inhibitor of receptor tyrosine kinases with potential antineoplastic activity. Pan HER/VEGFR2 receptor tyrosine kinase inhibitor BMS-690514 binds to human epidermal growth factor receptors (EGFR) 1, 2 and 4 (HER1, HER2 and HER4) and vascular endothelial growth factor receptor 1, 2 and 3 (VEGFR-1, -2 and -3), all of which are frequently overexpressed by a variety of tumor types. Binding of this agent to these receptors may result in the inhibition of tumor cell proliferation; the inhibition of endothelial cell migration and proliferation and angiogenesis; and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-690514","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"859853-30-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VKU5X213Q7"},{"name":"Legacy Concept Name","value":"Pan_HER_VEGFR2_Receptor_Tyrosine_Kinase_Inhibitor_BMS-690154"},{"name":"Maps_To","value":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514"},{"name":"NCI_Drug_Dictionary_ID","value":"489386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489386"},{"name":"PDQ_Open_Trial_Search_ID","value":"489386"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831893"}]}}{"C128250":{"preferredName":"Pan-AKT Inhibitor ARQ751","code":"C128250","definitions":[{"definition":"An orally bioavailable pan inhibitor of the serine/threonine protein kinase AKT (protein kinase B) enzyme family with potential antineoplastic activity. Upon oral administration, AKT inhibitor ARQ 751 selectively binds to and inhibits the activity of the AKT isoforms 1, 2 and 3, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. This may lead to a reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-AKT Inhibitor ARQ751","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Inhibitor ARQ751","termGroup":"SY","termSource":"NCI"},{"termName":"ARQ 751","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ751","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-AKT Inhibitor ARQ751"},{"name":"NCI_Drug_Dictionary_ID","value":"781919"},{"name":"NCI_META_CUI","value":"CL507932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781919"},{"name":"PDQ_Open_Trial_Search_ID","value":"781919"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71711":{"preferredName":"Pan-AKT Kinase Inhibitor GSK690693","code":"C71711","definitions":[{"definition":"An aminofurazan-derived inhibitor of Akt kinases with potential antineoplastic activity. Pan-AKT kinase inhibitor GSK-690693 binds to and inhibits Akt kinases 1, 2, and 3, which may result in the inhibition of protein phosphorylation events downstream from Akt kinases in the PI3K/Akt signaling pathway, and, subsequently, the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. In addition, this agent may inhibit other protein kinases including protein kinase C (PKC) and protein kinase A (PKA). As serine/threonine protein kinases which are involved in a number of biological processes, AKT kinases promote cell survival by inhibiting apoptosis and are required for glucose transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-AKT Kinase Inhibitor GSK690693","termGroup":"PT","termSource":"NCI"},{"termName":"GSK690693","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"937174-76-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GWH480321B"},{"name":"Legacy Concept Name","value":"Pan-AKT_Inhibitor_GSK-690693"},{"name":"Maps_To","value":"Pan-AKT Kinase Inhibitor GSK690693"},{"name":"NCI_Drug_Dictionary_ID","value":"560189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560189"},{"name":"PDQ_Open_Trial_Search_ID","value":"560189"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347443"}]}}{"C139004":{"preferredName":"Pan-FGFR Inhibitor LY2874455","code":"C139004","definitions":[{"definition":"An orally bioavailable pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, FGFR inhibitor LY2874455 binds to and inhibits FGFR subtypes 1 (FGFR1), 2 (FGFR2), 3 (FGFR3) and 4 (FGFR4), which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-FGFR Inhibitor LY2874455","termGroup":"PT","termSource":"NCI"},{"termName":"LY2874455","termGroup":"CN","termSource":"NCI"},{"termName":"Pan FGFR Inhibitor LY2874455","termGroup":"SY","termSource":"NCI"},{"termName":"Pan Fibroblast Growth Factor Receptor Inhibitor LY2874455","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1254473-64-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E9M363811V"},{"name":"Maps_To","value":"Pan-FGFR Inhibitor LY2874455"},{"name":"NCI_Drug_Dictionary_ID","value":"790959"},{"name":"NCI_META_CUI","value":"CL433720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790959"},{"name":"PDQ_Open_Trial_Search_ID","value":"790959"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162573":{"preferredName":"Luxeptinib","code":"C162573","definitions":[{"definition":"An orally bioavailable reversible, pan-inhibitor of both FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) and Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon oral administration, luxeptinib targets, non-covalently binds to and inhibits the activity of both FLT3, including both wild-type (WT) FLT3 and FLT3-ITD (internal tandem duplications), tyrosine kinase domain (FLT3-TKD), and gatekeeper (FLT3-F691L) mutant forms, and BTK, including both the WT and its C481S mutant (BTK-C481S) form. This inhibits both uncontrolled FLT3-mediated and B-cell antigen receptor (BCR)-mediated signaling, respectively. This results in the inhibition of proliferation in tumor cells overexpressing FLT3 and BTK. In addition, CG-806 also inhibits, to a lesser degree, other oncogenic kinases, such as MET, RET, discoidin domain-containing receptor 2 (DDR2), Aurora kinase A, and interleukin-2-inducible T-cell kinase (ITK). FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs), and plays a key role in tumor cell proliferation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases essential to BCR signaling, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luxeptinib","termGroup":"PT","termSource":"NCI"},{"termName":"32,72,74,76-Tetrafluoro-14-methyl-21,23-dihydro-11h-4,6-diaza-2(4,7)-isoindola- 1(2)-imidazola-3(1,4),7(1)-dibenzenaheptaphane-2,35-dione","termGroup":"SY","termSource":"NCI"},{"termName":"CG 806","termGroup":"CN","termSource":"NCI"},{"termName":"CG'806","termGroup":"CN","termSource":"NCI"},{"termName":"CG-026806","termGroup":"CN","termSource":"NCI"},{"termName":"CG-806","termGroup":"CN","termSource":"NCI"},{"termName":"CG806","termGroup":"CN","termSource":"NCI"},{"termName":"FLT3/BTK Inhibitor CG 806","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FLT3/BTK Multi-Kinase Inhibitor CG 806","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FLT3/Pan-BTK Inhibitor CG-806","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616428-23-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TQ6PBX1JU0"},{"name":"Maps_To","value":"Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806"},{"name":"NCI_Drug_Dictionary_ID","value":"798821"},{"name":"NCI_META_CUI","value":"CL971079"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798821"},{"name":"PDQ_Open_Trial_Search_ID","value":"798821"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48380":{"preferredName":"pan-HER Kinase Inhibitor AC480","code":"C48380","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-HER Kinase Inhibitor AC480","termGroup":"PT","termSource":"NCI"},{"termName":"AC480","termGroup":"SY","termSource":"NCI"},{"termName":"AC480","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-599626","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"714971-09-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2252724U5N"},{"name":"Legacy Concept Name","value":"BMS-599626"},{"name":"Maps_To","value":"pan-HER Kinase Inhibitor AC480"},{"name":"NCI_Drug_Dictionary_ID","value":"655952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655952"},{"name":"PDQ_Open_Trial_Search_ID","value":"655952"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541473"}]}}{"C152914":{"preferredName":"Vorasidenib","code":"C152914","definitions":[{"definition":"An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically inhibits mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH mutations. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB). IDH1 and 2, metabolic enzymes that catalyze the conversion of isocitrate into a-KG, play key roles in energy production and are mutated in a variety of cancer cell types. In addition, mutant forms of IDH1 and 2 catalyze the formation of 2HG and drive cancer growth by blocking cellular differentiation and inducing cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorasidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AG 881","termGroup":"CN","termSource":"NCI"},{"termName":"AG-881","termGroup":"CN","termSource":"NCI"},{"termName":"AG881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1644545-52-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"789Q85GA8P"},{"name":"Maps_To","value":"Pan-IDH Mutant Inhibitor AG-881"},{"name":"Maps_To","value":"Vorasidenib"},{"name":"NCI_Drug_Dictionary_ID","value":"774431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774431"},{"name":"PDQ_Open_Trial_Search_ID","value":"774431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053681"}]}}{"C131690":{"preferredName":"Pan-Mutant-IDH1 Inhibitor Bay-1436032","code":"C131690","definitions":[{"definition":"An orally available pan-inhibitor of mutant forms of the metabolic enzyme isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including forms with mutations of arginine 132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, pan-mutant-IDH-1 inhibitor BAY-1436032 specifically inhibits the activity of IDH1 mutant forms, which prevents the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutant forms. IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-Mutant-IDH1 Inhibitor Bay-1436032","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2-((4-(Trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 1436032","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1436032","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1436032","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1803274-65-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-Mutant-IDH1 Inhibitor Bay-1436032"},{"name":"NCI_Drug_Dictionary_ID","value":"786302"},{"name":"NCI_META_CUI","value":"CL514346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786302"},{"name":"PDQ_Open_Trial_Search_ID","value":"786302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117230":{"preferredName":"pan-PI3K Inhibitor CLR457","code":"C117230","definitions":[{"definition":"An orally bioavailable pan inhibitor of phosphatidylinositol-3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, pan-PI3K inhibitor CLR457 inhibits all of the PI3K kinase isoforms, which may result in apoptosis and growth inhibition in tumor cells overexpressing PI3K. Activation of the PI3K pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PI3K Inhibitor CLR457","termGroup":"PT","termSource":"NCI"},{"termName":"CLR457","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pan-PI3K Inhibitor CLR457"},{"name":"NCI_Drug_Dictionary_ID","value":"763082"},{"name":"NCI_META_CUI","value":"CL474098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763082"},{"name":"PDQ_Open_Trial_Search_ID","value":"763082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85469":{"preferredName":"pan-PI3K/mTOR Inhibitor SF1126","code":"C85469","definitions":[{"definition":"A water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities. The targeting peptide SF1174 moiety of pan-PI3K/mTOR inhibitor SF1126 selectively binds to cell surface integrins and, upon cell entry, the agent is hydrolyzed to the active drug SF1101; SF1101 selectively inhibits all isoforms of phosphoinositide-3-kinase (PI3K) and other members of the PI3K superfamily, such as the mammalian target of rapamycin (mTOR) and DNA-PK. By inhibiting the PI3K signaling pathway, this agent may inhibit tumor cell and tumor endothelial cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PI3K/mTOR Inhibitor SF1126","termGroup":"PT","termSource":"NCI"},{"termName":"SF1126","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936487-67-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DL0Q912033"},{"name":"Maps_To","value":"pan-PI3K/mTOR Inhibitor SF1126"},{"name":"NCI_Drug_Dictionary_ID","value":"644818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"644818"},{"name":"PDQ_Open_Trial_Search_ID","value":"644818"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351370"}]}}{"C124226":{"preferredName":"Uzansertib","code":"C124226","definitions":[{"definition":"An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, uzansertib binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uzansertib","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 053914","termGroup":"CN","termSource":"NCI"},{"termName":"INCB053914","termGroup":"CN","termSource":"NCI"},{"termName":"INCB53914","termGroup":"CN","termSource":"NCI"},{"termName":"Pan-PIM Inhibitor INCB053914","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-PIM Kinase Inhibitor INCB053914","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620012-39-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0237X8153Q"},{"name":"Maps_To","value":"Pan-PIM Inhibitor INCB053914"},{"name":"Maps_To","value":"Uzansertib"},{"name":"NCI_Drug_Dictionary_ID","value":"776689"},{"name":"NCI_META_CUI","value":"CL502606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776689"},{"name":"PDQ_Open_Trial_Search_ID","value":"776689"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99380":{"preferredName":"pan-PIM Kinase Inhibitor AZD1208","code":"C99380","definitions":[{"definition":"An orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. Pan-PIM kinase inhibitor AZD1208 inhibits the activities of PIM1, PIM2 and PIM3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, thereby causing cell cycle arrest and inducing apoptosis in cells that overexpress PIMs. The growth inhibition of several leukemia cell lines by this agent is correlated with the expression levels of PIM1, which is the substrate of STAT transcription factors. PIM kinases are downstream effectors of many cytokine and growth factor signaling pathways and are upregulated in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PIM Kinase Inhibitor AZD1208","termGroup":"PT","termSource":"NCI"},{"termName":"AZD1208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pan-PIM Kinase Inhibitor AZD1208"},{"name":"NCI_Drug_Dictionary_ID","value":"720042"},{"name":"PDQ_Closed_Trial_Search_ID","value":"720042"},{"name":"PDQ_Open_Trial_Search_ID","value":"720042"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274705"}]}}{"C128615":{"preferredName":"pan-PIM Kinase Inhibitor NVP-LGB-321","code":"C128615","definitions":[{"definition":"An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, pan-PIM kinase inhibitor NVP-LGB-321 binds to and prevents the activation of the three PIM family kinases, PIM1, PIM2 and PIM3. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PIM Kinase Inhibitor NVP-LGB-321","termGroup":"PT","termSource":"NCI"},{"termName":"LGB321","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-LGB-321","termGroup":"CN","termSource":"NCI"},{"termName":"PIM Inhibitor NVP-LGB-321","termGroup":"SY","termSource":"NCI"},{"termName":"PIM Kinase Inhibitor NVP-LGB-321","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pan-PIM Kinase Inhibitor NVP-LGB-321"},{"name":"NCI_META_CUI","value":"CL509289"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125003":{"preferredName":"Naporafenib","code":"C125003","definitions":[{"definition":"An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naporafenib","termGroup":"PT","termSource":"NCI"},{"termName":"LXH 254","termGroup":"CN","termSource":"NCI"},{"termName":"LXH-254","termGroup":"CN","termSource":"NCI"},{"termName":"LXH254","termGroup":"CN","termSource":"NCI"},{"termName":"pan-RAF Inhibitor LXH254","termGroup":"SY","termSource":"NCI"},{"termName":"pan-RAF Kinase Inhibitor LXH254","termGroup":"SY","termSource":"NCI"},{"termName":"Raf Family Kinase Inhibitor LXH254","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1800398-38-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15JL80DG6H"},{"name":"Maps_To","value":"pan-RAF Inhibitor LXH254"},{"name":"NCI_Drug_Dictionary_ID","value":"778192"},{"name":"NCI_META_CUI","value":"CL503849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778192"},{"name":"PDQ_Open_Trial_Search_ID","value":"778192"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116861":{"preferredName":"Pan-RAF Inhibitor LY3009120","code":"C116861","definitions":[{"definition":"An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-RAF Inhibitor LY3009120","termGroup":"PT","termSource":"NCI"},{"termName":"DP-4978","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3009120","termGroup":"CN","termSource":"NCI"},{"termName":"LY3009120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1454682-72-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1GDT36RARO"},{"name":"Maps_To","value":"Pan-RAF Inhibitor LY3009120"},{"name":"NCI_Drug_Dictionary_ID","value":"756062"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756062"},{"name":"PDQ_Open_Trial_Search_ID","value":"756062"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896821"}]}}{"C121952":{"preferredName":"pan-RAF Kinase Inhibitor CCT3833","code":"C121952","definitions":[{"definition":"An orally available inhibitor of the serine/threonine protein kinase family Raf, including A-Raf, B-Raf and C-Raf, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor CCT3833 inhibits Raf-mediated signal transduction pathways, which may inhibit the proliferation of Raf-overexpressing tumor cells. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-RAF Kinase Inhibitor CCT3833","termGroup":"PT","termSource":"NCI"},{"termName":"BAL3833","termGroup":"CN","termSource":"NCI"},{"termName":"CCT3833","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pan-RAF Kinase Inhibitor CCT3833"},{"name":"NCI_Drug_Dictionary_ID","value":"772112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772112"},{"name":"PDQ_Open_Trial_Search_ID","value":"772112"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053656"}]}}{"C106254":{"preferredName":"Tovorafenib","code":"C106254","definitions":[{"definition":"An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tovorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BIIB-024","termGroup":"CN","termSource":"NCI"},{"termName":"DAY 101","termGroup":"CN","termSource":"NCI"},{"termName":"DAY-101","termGroup":"CN","termSource":"NCI"},{"termName":"DAY101","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-2480","termGroup":"CN","termSource":"NCI"},{"termName":"MLN2480","termGroup":"CN","termSource":"NCI"},{"termName":"Ojemda","termGroup":"BR","termSource":"NCI"},{"termName":"pan-RAF Kinase Inhibitor DAY101","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-580","termGroup":"CN","termSource":"NCI"},{"termName":"TAK580","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation."},{"name":"CAS_Registry","value":"1096708-71-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZN90E4027M"},{"name":"Maps_To","value":"pan-RAF Kinase Inhibitor TAK-580"},{"name":"NCI_Drug_Dictionary_ID","value":"710688"},{"name":"NCI_META_CUI","value":"CL433881"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710688"},{"name":"PDQ_Open_Trial_Search_ID","value":"710688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2062":{"preferredName":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550","code":"C2062","definitions":[{"definition":"An orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.  LGD 1550 selectively binds to all three retinoic acid receptors (RAR-alpha, RAR-beta, and RAR-gamma), resulting in alterations in the expression of genes responsible for cell differentiation and proliferation.  This agent also acts as an inhibitor of activator protein 1 (AP-1), a protein that mediates trophic responses and malignant transformation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550","termGroup":"PT","termSource":"NCI"},{"termName":"LGD 1550","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"178600-20-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LGD_1550"},{"name":"Maps_To","value":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517688"}]}}{"C140379":{"preferredName":"Pan-TRK Inhibitor ONO-7579","code":"C140379","definitions":[{"definition":"An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, ONO-7579 specifically targets and binds to TRK and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC).  This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes.The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-TRK Inhibitor ONO-7579","termGroup":"PT","termSource":"NCI"},{"termName":"ONO 7579","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-7579","termGroup":"CN","termSource":"NCI"},{"termName":"ONO7579","termGroup":"CN","termSource":"NCI"},{"termName":"TRK Inhibitor ONO-7579","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-TRK Inhibitor ONO-7579"},{"name":"NCI_Drug_Dictionary_ID","value":"793096"},{"name":"NCI_META_CUI","value":"CL538536"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793096"},{"name":"PDQ_Open_Trial_Search_ID","value":"793096"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82379":{"preferredName":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981","code":"C82379","definitions":[{"definition":"An orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR) and Tie2 receptor tyrosine kinases with potential antiangiogenic and antineoplastic activities. Pan-VEGFR/Tie2 tyrosine kinase inhibitor CEP-11981 selectively binds to VEGFR and Tie2 receptor tyrosine kinases, which may result in the inhibition of endothelial cell migration, proliferation and survival and the inhibition of tumor cell proliferation and tumor cell death. VEGFR and Tie2 are frequently overexpressed by a variety of tumor cell types and play crucial roles in the regulation of angiogenesis and the maintenance of tumor blood vessels. Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains) is activated by angiopoietin-1 (Ang-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Indazolo(5,4-a)pyrrolo(3,4-C)carbazol-4-one, 2,5,6,11,12,13-Hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-","termGroup":"SN","termSource":"NCI"},{"termName":"BOL-303213X","termGroup":"CN","termSource":"NCI"},{"termName":"CEP 11981","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-11981","termGroup":"CN","termSource":"NCI"},{"termName":"ESK 981","termGroup":"CN","termSource":"NCI"},{"termName":"ESK-981","termGroup":"SY","termSource":"NCI"},{"termName":"ESK981","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"856691-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J8AY0Z4CBP"},{"name":"Legacy Concept Name","value":"Oral_Pan-VEGFR_TIE2_Tyrosine_Kinase_Inhibitor_CEP-11981"},{"name":"Maps_To","value":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981"},{"name":"NCI_Drug_Dictionary_ID","value":"641461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641461"},{"name":"PDQ_Open_Trial_Search_ID","value":"641461"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830064"}]}}{"C1184":{"preferredName":"Pancratistatin","code":"C1184","definitions":[{"definition":"A isoquinoline alkaloid from amaryllis with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancratistatin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96281-31-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancratistatin"},{"name":"Maps_To","value":"Pancratistatin"},{"name":"NSC Number","value":"349156"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070005"}]}}{"C1857":{"preferredName":"Panitumumab","code":"C1857","definitions":[{"definition":"A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. ABX-EGF binds to the epidermal growth factor receptor (EGFR) and may block tumor cell growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Panitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABX-EGF","termGroup":"AB","termSource":"NCI"},{"termName":"ABX-EGF Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"ABX-EGF, Clone E7.6.3","termGroup":"SY","termSource":"NCI"},{"termName":"E7.6.3","termGroup":"CN","termSource":"NCI"},{"termName":"Human IgG2K Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb ABX-EGF","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb E7.6.3","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody ABX-EGF","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody E7.6.3","termGroup":"SY","termSource":"NCI"},{"termName":"Vectibix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced Stage Colorectal Cancer"},{"name":"CAS_Registry","value":"339177-26-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6A901E312A"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_ABX-EGF"},{"name":"Maps_To","value":"Panitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"37857"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37857"},{"name":"PDQ_Open_Trial_Search_ID","value":"37857"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1513448"}]}}{"C66948":{"preferredName":"Panobinostat","code":"C66948","definitions":[{"definition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"},{"definition":"A drug being studied in the treatment of cancer. It blocks enzymes needed for cells to grow and divide and may kill cancer cells. Panobinostat may also prevent the growth of new blood vessels that tumors need to grow. It is a type of histone deacetylase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Panobinostat","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"Faridak","termGroup":"FB","termSource":"NCI"},{"termName":"LBH589","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma (MM)"},{"name":"CAS_Registry","value":"404950-80-7"},{"name":"Chemical_Formula","value":"C21H23N3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9647FM7Y3Z"},{"name":"Legacy Concept Name","value":"LBH589"},{"name":"Maps_To","value":"Panobinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"530790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530790"},{"name":"PDQ_Open_Trial_Search_ID","value":"530790"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1998098"}]}}{"C150717":{"preferredName":"Panobinostat Nanoparticle Formulation MTX110","code":"C150717","definitions":[{"definition":"A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Panobinostat Nanoparticle Formulation MTX110","termGroup":"PT","termSource":"NCI"},{"termName":"MTX 110","termGroup":"CN","termSource":"NCI"},{"termName":"MTX-110","termGroup":"CN","termSource":"NCI"},{"termName":"MTX110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Panobinostat Nanoparticle Formulation MTX110"},{"name":"NCI_Drug_Dictionary_ID","value":"793526"},{"name":"NCI_META_CUI","value":"CL552518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793526"},{"name":"PDQ_Open_Trial_Search_ID","value":"793526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38693":{"preferredName":"Paricalcitol","code":"C38693","definitions":[{"definition":"A substance that is being used to treat overactive parathyroid glands in patients with kidney failure. It is also being studied in the treatment of cancer. Paricalcitol belongs to the family of drugs called vitamin D analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic noncalcemic, nonphosphatemic vitamin D analogue.  Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paricalcitol","termGroup":"PT","termSource":"NCI"},{"termName":"(7e,22e)-19-Nor-9,10-Secoergosta-5,7,22-Triene-1Alpha,3Beta,25-Triol","termGroup":"SN","termSource":"NCI"},{"termName":"Compound 49510","termGroup":"SY","termSource":"NCI"},{"termName":"Zemplar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Secondary hyperparathyroidism, prevention and treatment"},{"name":"CAS_Registry","value":"131918-61-1"},{"name":"CHEBI_ID","value":"CHEBI:7931"},{"name":"Chemical_Formula","value":"C27H44O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6702D36OG5"},{"name":"Legacy Concept Name","value":"Paricalcitol"},{"name":"Maps_To","value":"Paricalcitol"},{"name":"NCI_Drug_Dictionary_ID","value":"315740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"315740"},{"name":"PDQ_Open_Trial_Search_ID","value":"315740"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0724464"}]}}{"C154560":{"preferredName":"PARP 1/2 Inhibitor NOV1401","code":"C154560","definitions":[{"definition":"An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, NOV1401 selectively binds to PARP-1 and -2, thereby preventing PARP-1 and -2-mediated DNA repair. This promotes genetic instability and enhances the accumulation of single and double strand DNA breaks, ultimately leading to apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP 1/2 Inhibitor NOV1401","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP 1/2 Inhibitor NOV1401"},{"name":"NCI_Drug_Dictionary_ID","value":"794354"},{"name":"NCI_META_CUI","value":"CL555354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794354"},{"name":"PDQ_Open_Trial_Search_ID","value":"794354"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95201":{"preferredName":"PARP Inhibitor AZD2461","code":"C95201","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor AZD2461 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor AZD2461","termGroup":"PT","termSource":"NCI"},{"termName":"AZD2461","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP Inhibitor AZD2461"},{"name":"NCI_Drug_Dictionary_ID","value":"690473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690473"},{"name":"PDQ_Open_Trial_Search_ID","value":"690473"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986988"}]}}{"C84880":{"preferredName":"PARP Inhibitor CEP-9722","code":"C84880","definitions":[{"definition":"A small-molecule prodrug of CEP-8983, a novel 4-methoxy-carbazole inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration and conversion from CEP-9722, CEP-8983 selectively binds to PARP 1 and 2, preventing repair of damaged DNA via base excision repair (BER). This agent enhances the accumulation of DNA strand breaks and promotes genomic instability and apoptosis. CEP-8983 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and can be activated by single strand breaks in DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor CEP-9722","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-9722","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"916574-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B68083E4YG"},{"name":"Maps_To","value":"PARP Inhibitor CEP-9722"},{"name":"NCI_Drug_Dictionary_ID","value":"649505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649505"},{"name":"PDQ_Open_Trial_Search_ID","value":"649505"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827554"}]}}{"C91387":{"preferredName":"PARP Inhibitor E7016","code":"C91387","definitions":[{"definition":"An inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemo- and/or radiosensitizing activity. PARP inhibitor E7016 selectively binds to PARP and prevents PARP mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. In addition, this agent may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor E7016","termGroup":"PT","termSource":"NCI"},{"termName":"E7016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"902128-92-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M8926C7ILX"},{"name":"Maps_To","value":"PARP Inhibitor E7016"},{"name":"NCI_Drug_Dictionary_ID","value":"674406"},{"name":"NCI_META_CUI","value":"CL421589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674406"},{"name":"PDQ_Open_Trial_Search_ID","value":"674406"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96795":{"preferredName":"PARP-1/2 Inhibitor ABT-767","code":"C96795","definitions":[{"definition":"An orally available inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, ABT-767 selectively binds to PARP 1 and 2, thereby preventing repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of DNA strand breaks and promotes genomic instability eventually leading to apoptosis. ABT-767 may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and can be activated by single strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP-1/2 Inhibitor ABT-767","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-767","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP-1/2 Inhibitor ABT-767"},{"name":"NCI_Drug_Dictionary_ID","value":"699738"},{"name":"NCI_META_CUI","value":"CL429404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699738"},{"name":"PDQ_Open_Trial_Search_ID","value":"699738"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102746":{"preferredName":"PARP/Tankyrase Inhibitor 2X-121 ","code":"C102746","definitions":[{"definition":"An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, E7449 selectively binds to PARP 1 and 2, thereby preventing the repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of single and double strand DNA breaks and promotes genomic instability eventually leading to apoptosis. PARP 1/2 inhibitor E7449 may enhance the cytotoxicity of DNA-damaging agents and of radiotherapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP/Tankyrase Inhibitor 2X-121 ","termGroup":"PT","termSource":"NCI"},{"termName":"2X-121","termGroup":"CN","termSource":"NCI"},{"termName":"E-7449","termGroup":"CN","termSource":"NCI"},{"termName":"E7449","termGroup":"CN","termSource":"NCI"},{"termName":"PARP/TNKS Inhibitor 2X-121","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1140964-99-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9X5A2QIA7C"},{"name":"Maps_To","value":"PARP/Tankyrase Inhibitor 2X-121"},{"name":"NCI_Drug_Dictionary_ID","value":"735791"},{"name":"NCI_META_CUI","value":"CL601883"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735791"},{"name":"PDQ_Open_Trial_Search_ID","value":"735791"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90567":{"preferredName":"Parsatuzumab","code":"C90567","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parsatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epidermal Growth Factor-like Domain 7 Monoclonal Antibody MEGF0444A","termGroup":"SY","termSource":"NCI"},{"termName":"MEGF 0444A","termGroup":"CN","termSource":"NCI"},{"termName":"MEGF0444A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7414","termGroup":"CN","termSource":"NCI"},{"termName":"RG7414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312797-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"435M4HCP2M"},{"name":"Maps_To","value":"Parsatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"646991"},{"name":"NCI_META_CUI","value":"CL416251"},{"name":"PDQ_Closed_Trial_Search_ID","value":"646991"},{"name":"PDQ_Open_Trial_Search_ID","value":"646991"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96229":{"preferredName":"Parvovirus H-1","code":"C96229","definitions":[{"definition":"A replication-competent oncolytic parvovirus with potential antineoplastic activity. Upon infection of host cells, parvovirus H-1 preferentially replicates in tumor cells compared to healthy normal cells, thereby potentially resulting in tumor cell lysis and leading to an inhibition of tumor cell proliferation. In addition, H1-infected tumor cells strongly induce the release of the inducible heat shock protein 72 (Hsp72i), which chaperone tumor associated antigens in the H1-mediated tumor lysates and may activate antigen presenting cells (APCs), thereby leading to antitumor immune responses. Parvovirus H-1 does not cause any pathogenic effect in normal, healthy cells and is able to cross the blood brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parvovirus H-1","termGroup":"PT","termSource":"NCI"},{"termName":"H-1PV","termGroup":"AB","termSource":"NCI"},{"termName":"ParvOryx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Parvovirus H-1"},{"name":"NCI_Drug_Dictionary_ID","value":"697624"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697624"},{"name":"PDQ_Open_Trial_Search_ID","value":"697624"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0319116"}]}}{"C69131":{"preferredName":"Pasireotide","code":"C69131","definitions":[{"definition":"A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pasireotide","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-)","termGroup":"SN","termSource":"NCI"},{"termName":"SOM230","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"396091-73-9"},{"name":"Chemical_Formula","value":"C58H66N10O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98H1T17066"},{"name":"Legacy Concept Name","value":"Pasireotide"},{"name":"Maps_To","value":"Pasireotide"},{"name":"NCI_Drug_Dictionary_ID","value":"540440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"540440"},{"name":"PDQ_Open_Trial_Search_ID","value":"540440"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872203"}]}}{"C103827":{"preferredName":"Pasotuxizumab","code":"C103827","definitions":[{"definition":"A recombinant T-cell engaging bispecific monoclonal antibody (BiTE) directed against human prostate specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex, with potential immunostimulating and antineoplastic activities.  Pasotuxizumab possesses two antigen-recognition sites, one for PSMA, and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings PSMA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) together, which may result in the CTL-mediated cell death of PSMA-expressing cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pasotuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG-212","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2010112","termGroup":"CN","termSource":"NCI"},{"termName":"MT112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1442657-12-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9J6SW7G28J"},{"name":"Maps_To","value":"Pasotuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"742717"},{"name":"NCI_META_CUI","value":"CL438307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742717"},{"name":"PDQ_Open_Trial_Search_ID","value":"742717"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80063":{"preferredName":"Patidegib","code":"C80063","definitions":[{"definition":"An orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, patidegib binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signaling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patidegib","termGroup":"PT","termSource":"NCI"},{"termName":"FIN-5","termGroup":"CN","termSource":"NCI"},{"termName":"IP9 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"IPI-926","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-926 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"Saridegib","termGroup":"SY","termSource":"NCI"},{"termName":"Saridegib","termGroup":"AQS","termSource":"NCI"},{"termName":"Smoothened Antagonist IPI-926","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1037210-93-7"},{"name":"Chemical_Formula","value":"C29H48N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JT96FPU35X"},{"name":"Legacy Concept Name","value":"Smoothened_Antagonist_IPI-926"},{"name":"Maps_To","value":"Patidegib"},{"name":"NCI_Drug_Dictionary_ID","value":"616875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"616875"},{"name":"PDQ_Open_Trial_Search_ID","value":"616875"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703211"}]}}{"C158420":{"preferredName":"Patidegib Topical Gel","code":"C158420","definitions":[{"definition":"A topical gel containing patidegib, a cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon topical application of the patidegib gel, patidegib binds to and inhibits the activity of the G-protein coupled receptor smoothened (SMO), thereby inhibiting Hh pathway signaling. This decreases proliferation and survival in tumor cells in which the Hh pathway is overactivated. Upregulated Hh signaling is associated with uncontrolled tumor cell proliferation. Topical application of patidegib allows for local anti-tumor activity while avoiding systemic exposure and unwanted systemic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patidegib Topical Gel","termGroup":"PT","termSource":"NCI"},{"termName":"IPI-926 Topical Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Patidegib Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Patidegib Topical Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"802168"},{"name":"NCI_META_CUI","value":"CL937835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802168"},{"name":"PDQ_Open_Trial_Search_ID","value":"802168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78853":{"preferredName":"Patritumab","code":"C78853","definitions":[{"definition":"A fully human monoclonal antibody directed against the membrane-bound receptor HER3 (ERBB3) with potential antineoplastic activity. Patritumab binds to and inhibits HER3 activation, which may result in inhibition of HER3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patritumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 888","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1287","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1262787-83-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"86780VJI1Q"},{"name":"Legacy Concept Name","value":"Anti-HER3_Monoclonal_Antibody_U3-1287"},{"name":"Maps_To","value":"Patritumab"},{"name":"NCI_Drug_Dictionary_ID","value":"612849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612849"},{"name":"PDQ_Open_Trial_Search_ID","value":"612849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698144"}]}}{"C1623":{"preferredName":"Patupilone","code":"C1623","definitions":[{"definition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Patupilone may cause complete cell-cycle arrest.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of epothilone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Patupilone","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Epothilone B","termGroup":"SY","termSource":"NCI"},{"termName":"(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"EPO-906A","termGroup":"CN","termSource":"NCI"},{"termName":"Epothilone B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152044-54-7"},{"name":"Chemical_Formula","value":"C27H41NO6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UEC0H0URSE"},{"name":"Legacy Concept Name","value":"Epothilone_B"},{"name":"Maps_To","value":"Patupilone"},{"name":"NCI_Drug_Dictionary_ID","value":"38702"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38702"},{"name":"PDQ_Open_Trial_Search_ID","value":"38702"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0297960"}]}}{"C74547":{"preferredName":"Pazopanib","code":"C74547","definitions":[{"definition":"A drug that is used to treat kidney cancer and is being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. It is a type of protein tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pazopanib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"GW786034","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444731-52-6"},{"name":"CAS_Registry","value":"790713-33-6"},{"name":"Chemical_Formula","value":"C21H23N7O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7RN5DR86CK"},{"name":"Legacy Concept Name","value":"Pazopanib_Base"},{"name":"Maps_To","value":"Pazopanib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831796"}]}}{"C60779":{"preferredName":"Pazopanib Hydrochloride","code":"C60779","definitions":[{"definition":"A drug that is used to treat kidney cancer and is being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. It is a type of protein tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pazopanib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5-((4-((2,3-Dimethyl-2h-Indazol-6-Yl)Methylamino)Pyrimidin-2-yl)Amino)-2-Methylbenzenesulfonamide Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"GW786034B","termGroup":"CN","termSource":"NCI"},{"termName":"Pazopater","termGroup":"FB","termSource":"NCI"},{"termName":"Votrient","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"635702-64-6"},{"name":"Chemical_Formula","value":"C21H23N7O2S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33Y9ANM545"},{"name":"Legacy Concept Name","value":"Pazopanib"},{"name":"Maps_To","value":"Pazopanib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"476479"},{"name":"NSC Number","value":"737754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"476479"},{"name":"PDQ_Open_Trial_Search_ID","value":"476479"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872226"}]}}{"C99639":{"preferredName":"pbi-shRNA STMN1 Lipoplex","code":"C99639","definitions":[{"definition":"A proprietary RNA interference construct consisting of bifunctional short hairpin RNAs (shRNA) against human stathmin 1 (STMN1) encapsulated in the cationic bilamellar invaginated vesicle lipoplex (LP) with potential antineoplastic activity. pbi-shRNA STMN1 LP contains 2 stem-loop structures encoded by a plasmid vector. Upon intratumoral administration, one shRNA unit with a perfectly matched sequence renders the suppression of STMN1 mRNA translation (mRNA sequestration and cleavage-independent degradation) while the other unit with an imperfectly matched sequence renders STMN1 mRNA degradation via RNase H-like cleavage (cleavage-dependent mRNA silencing). The suppression of STMN1 expression in tumor cells result in a reduction of tumor cell proliferation. STMN1, a ubiquitous cytosolic phosphoprotein and tubulin modulator that plays a key role in mitosis, is overexpressed in a variety of tumors and correlates with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pbi-shRNA STMN1 Lipoplex","termGroup":"PT","termSource":"NCI"},{"termName":"pbi-shRNA STMN1 LP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0TG7ZQ45R5"},{"name":"Maps_To","value":"pbi-shRNA STMN1 Lipoplex"},{"name":"NCI_Drug_Dictionary_ID","value":"722324"},{"name":"NCI_META_CUI","value":"CL433303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"722324"},{"name":"PDQ_Open_Trial_Search_ID","value":"722324"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77600":{"preferredName":"Disufenton Sodium","code":"C77600","definitions":[{"definition":"A disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Disufenton Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Benzenedisulfonic Acid, 4-(((1,1-Dimethylethyl)oxidoimino)methyl), Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"2,4-Disulfonyl PBN","termGroup":"SY","termSource":"NCI"},{"termName":"2,4-Disulfophenyl-tert-butylnitrone Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"HPN-07","termGroup":"CN","termSource":"NCI"},{"termName":"NXY-059","termGroup":"CN","termSource":"NCI"},{"termName":"OKN-007","termGroup":"CN","termSource":"NCI"},{"termName":"OKN007","termGroup":"CN","termSource":"NCI"},{"termName":"PBN Derivative OKN-007","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"168021-79-2"},{"name":"Chemical_Formula","value":"C11H13NO7S2.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7M1J3HN9VO"},{"name":"Legacy Concept Name","value":"Disufenton_Sodium"},{"name":"Maps_To","value":"PBN Derivative OKN-007"},{"name":"NCI_Drug_Dictionary_ID","value":"739669"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1701245"}]}}{"C1186":{"preferredName":"PCNU","code":"C1186","definitions":[{"definition":"A chloroethylnitrosourea compound and an alkylating agent with antineoplastic property. PCNU inhibits DNA synthesis by alkylating DNA and causing DNA cross links, thereby inducing apoptosis. In addition, this agent may be associated with pulmonary, hepatic, and hematologic toxicities. Unlike other nitrosoureas, PCNU has strong alkylating while weak carbamoylating activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PCNU","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(2,6-Dioxo-3-Piperidyl)-1-Nitrourea","termGroup":"SN","termSource":"NCI"},{"termName":"Urea, N-(2-chloroethyl)-N'-(2,6-dioxo-3-piperidinyl)-N-nitroso-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13909-02-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AZW59V4Q3B"},{"name":"Legacy Concept Name","value":"PCNU"},{"name":"Maps_To","value":"PCNU"},{"name":"NCI_Drug_Dictionary_ID","value":"39549"},{"name":"NSC Number","value":"95466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39549"},{"name":"PDQ_Open_Trial_Search_ID","value":"39549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070165"}]}}{"C160716":{"preferredName":"PD-1 Directed Probody CX-188","code":"C160716","definitions":[{"definition":"A probody composed of a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), linked to a proprietary masking peptide that covers the active antigen binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of PD-1-directed probody CX-188, the masking peptide is cleaved by tumor-associated proteases within the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to PD-1, thereby disrupting PD-1 signaling. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-1 Directed Probody CX-188","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Probody CX-188","termGroup":"SY","termSource":"NCI"},{"termName":"CX 188","termGroup":"CA2","termSource":"NCI"},{"termName":"CX-188","termGroup":"CN","termSource":"NCI"},{"termName":"CX188","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-1 Directed Probody CX-188"},{"name":"NCI_Drug_Dictionary_ID","value":"797958"},{"name":"NCI_META_CUI","value":"CL969825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797958"},{"name":"PDQ_Open_Trial_Search_ID","value":"797958"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124946":{"preferredName":"PD1 Inhibitor","code":"C124946","definitions":[{"definition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD1 Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Agent","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1-targeting Agent","termGroup":"SY","termSource":"NCI"},{"termName":"Programmed Cell Death Protein 1 Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"Protein PD-1 Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-1 Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C4086713"}]}}{"C158532":{"preferredName":"PD-L1 Inhibitor INCB086550","code":"C158532","definitions":[{"definition":"An orally available, small molecule inhibitor of the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, PD-L1 inhibitor INCB086550 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1 Inhibitor INCB086550","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 086550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 86550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-086550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-86550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB086550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB86550","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 Ligand 1 Inhibitor INCB086550","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230911-59-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T8B91S15VF"},{"name":"Maps_To","value":"PD-L1 Inhibitor INCB086550"},{"name":"NCI_Drug_Dictionary_ID","value":"797120"},{"name":"NCI_META_CUI","value":"CL937968"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797120"},{"name":"PDQ_Open_Trial_Search_ID","value":"797120"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129594":{"preferredName":"PD-L1/PD-L2/VISTA Antagonist CA-170","code":"C129594","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1/PD-L2/VISTA Antagonist CA-170","termGroup":"PT","termSource":"NCI"},{"termName":"AUPM 170","termGroup":"CN","termSource":"NCI"},{"termName":"Aurigene 1","termGroup":"SY","termSource":"NCI"},{"termName":"CA-170","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1/PD-L2/VISTA Checkpoint Antagonist CA-170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1673534-76-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"646MN6KQ16"},{"name":"Maps_To","value":"PD-L1/PD-L2/VISTA Antagonist CA-170"},{"name":"NCI_Drug_Dictionary_ID","value":"783861"},{"name":"NCI_META_CUI","value":"CL512601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783861"},{"name":"PDQ_Open_Trial_Search_ID","value":"783861"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88271":{"preferredName":"PDK1 Inhibitor AR-12","code":"C88271","definitions":[{"definition":"An orally bioavailable, small-molecule, celecoxib-derived inhibitor of phosphoinositide-dependent kinase-1 (PDK1) with potential antineoplastic activity. Devoid of any COX inhibiting activity, PDK1 inhibitor AR-12 binds to and inhibits the phosphorylation of 3-phosphoinositide-dependent kinase-1 (PDK-1).; subsequently, the phosphorylation and activation of the serine/threonine protein kinase Akt (protein kinase B or PKB) is inhibited, which may result in inhibition of the PI3K/Akt signaling pathway, inhibition of tumor cell proliferation, and the induction of tumor cell apoptosis.  In addition, this agent appears to induce the activity of protein kinase R-like endoplasmic reticulum kinase (PERK), which plays a key role in the endoplasmic reticulum stress pathway. Activation and dysregulation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDK1 Inhibitor AR-12","termGroup":"PT","termSource":"NCI"},{"termName":"AR-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"742112-33-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EX3O2Q61UV"},{"name":"Maps_To","value":"PDK1 Inhibitor AR-12"},{"name":"NCI_Drug_Dictionary_ID","value":"655950"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655950"},{"name":"PDQ_Open_Trial_Search_ID","value":"655950"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1569671"}]}}{"C157262":{"preferredName":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0","code":"C157262","definitions":[{"definition":"A whole cell cancer vaccine composed of irradiated autologous whole tumor cells that are transfected, ex vivo, with a plasmid DNA encoding the highly immunogenic Streptococcus pyogenes (S. pyogenes) bacterial antigen Emm55, with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IFx-Hu2.0, the tumor cells expressing the Emm55 bacterial antigen on their cell surface are taken up and processed by antigen-presenting cells (APCs), thereby presenting both the Emm55 and the patient-specific tumor-associated antigens (TAAs) to the immune system. This activates the immune system to elicit a tumor antigen-specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Cancer Cell-transfected with Plasmid DNA Encoding for Emm55 Streptococcal Antigen IFx-Hu2.0","termGroup":"SY","termSource":"NCI"},{"termName":"IFx-Hu2.0","termGroup":"CN","termSource":"NCI"},{"termName":"ImmuneFx","termGroup":"BR","termSource":"NCI"},{"termName":"pDNA Autologous Cancer Cell Vaccine IFx-Hu2.0","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmid DNA Autologous Cancer Vaccine IFx-Hu2.0","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmid DNA Vaccine Encoding S. pyogenes Emm55 Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0"},{"name":"NCI_Drug_Dictionary_ID","value":"796807"},{"name":"NCI_META_CUI","value":"CL936865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796807"},{"name":"PDQ_Open_Trial_Search_ID","value":"796807"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126276":{"preferredName":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1","code":"C126276","definitions":[{"definition":"A fusion protein consisting of a peptide sequence of human papillomavirus (HPV) type 16 E7 nuclear protein and fused to the Pseudomonas aeruginosa exotoxin A (PE) and a endoplasmic reticulum (ER) retention signal (KDEL), with potential antineoplastic activity. Upon administration of PE/HPV16 E7/KDEL fusion protein TVGV-1, the PE moiety binds to CD91 (LRP1) expressed on a variety of cells, including antigen-presenting cells such as dendritic cells (DCs), which facilitates the internalization, through endocytosis, of TVGV-1. Following endocytosis, this agent is proteolytically cleaved by the proteasome and the epitopes from the HPV E7 protein become bound to MHC-I molecules and are presented on the DC-cell surface. This facilitates a cytotoxic T-cell- mediated immune response against HPV16 E7 expressing-tumor cells. KDEL targets the fusion protein to the ER, which increases this agent's potential to be bound by MHC-I molecules; this increases the immune response against HPV16 E7-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1","termGroup":"PT","termSource":"NCI"},{"termName":"PE-E7-KDEL/GPI-0100 TVGV-1","termGroup":"SY","termSource":"NCI"},{"termName":"PEK Fusion Protein/GPI-0100 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TVGV-1","termGroup":"CN","termSource":"NCI"},{"termName":"TVGV-1 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1"},{"name":"NCI_Drug_Dictionary_ID","value":"779306"},{"name":"NCI_META_CUI","value":"CL504853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779306"},{"name":"PDQ_Open_Trial_Search_ID","value":"779306"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1304":{"preferredName":"PEG-interleukin-2","code":"C1304","definitions":[{"definition":"A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEG-interleukin-2","termGroup":"PT","termSource":"NCI"},{"termName":"PEG-IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"Polyethylene Glycol-Modified Recombinant Interleukin-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PEG-interleukin-2"},{"name":"Maps_To","value":"PEG-interleukin-2"},{"name":"NCI_Drug_Dictionary_ID","value":"39577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39577"},{"name":"PDQ_Open_Trial_Search_ID","value":"39577"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0083036"}]}}{"C49178":{"preferredName":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001","code":"C49178","definitions":[{"definition":"A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) encapsulated in a biodegradable, biocompatible lipoplex composed of polyethylene glycol (PEG), polyethylenimine (PEI), and cholesterol, with potential immunoactivating and antineoplastic activities. Upon intraperitoneal (IP) delivery of the PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector IMNN-001, the lipoplex is endocytosed by nearby cells, and the plasmid DNA is transported into the nucleus, which leads to local expresssion of IL-12. In turn, the increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-cell responses against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 1","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1","termGroup":"CN","termSource":"NCI"},{"termName":"IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer","termGroup":"SY","termSource":"NCI"},{"termName":"IMNN 001","termGroup":"CN","termSource":"NCI"},{"termName":"IMNN-001","termGroup":"CN","termSource":"NCI"},{"termName":"IMNN001","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoparticle-encased IL-12 DNA Plasmid Vector","termGroup":"SY","termSource":"NCI"},{"termName":"phIL-12-005","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EGEN-001"},{"name":"Maps_To","value":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1"},{"name":"NCI_Drug_Dictionary_ID","value":"454593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454593"},{"name":"PDQ_Open_Trial_Search_ID","value":"454593"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707844"}]}}{"C111892":{"preferredName":"Ropeginterferon Alfa-2B","code":"C111892","definitions":[{"definition":"A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ropeginterferon Alfa-2B","termGroup":"PT","termSource":"NCI"},{"termName":"AOP2014","termGroup":"CN","termSource":"NCI"},{"termName":"Besremi","termGroup":"BR","termSource":"NCI"},{"termName":"P-1101","termGroup":"CN","termSource":"NCI"},{"termName":"P1101","termGroup":"CN","termSource":"NCI"},{"termName":"PEG-P-IFN-Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-P-IFN-Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-Proline-Interferon Alfa-2b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1335098-50-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"981TME683S"},{"name":"Maps_To","value":"PEG-Proline-Interferon Alfa-2b"},{"name":"Maps_To","value":"Ropeginterferon Alfa-2B"},{"name":"NCI_Drug_Dictionary_ID","value":"753252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753252"},{"name":"PDQ_Open_Trial_Search_ID","value":"753252"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827091"}]}}{"C91702":{"preferredName":"Pegargiminase","code":"C91702","definitions":[{"definition":"A substance being studied in the treatment of melanoma, liver cancer, and other types of cancer. It breaks down the amino acid arginine and may block the growth of cancer cells that need arginine to grow. It is a type of iminohydrolase.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An agent consisting of the arginine-degrading enzyme arginine deiminase combined with polyethylene glycol (20,000 MW) (ADI-PEG 20) with potential antineoplastic activity. Upon administration, pegargiminase breaks down the amino acid arginine into citrulline. Although arginine is a nonessential amino acid for normal human cells, certain cancer cells are autotrophic for arginine and need arginine in order to survive. Depletion of arginine may lead to an inhibition of cellular proliferation in those cancer cells. ADI is coupled to PEG in order to enhance this agent's half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegargiminase","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1394129-74-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0B7PYQ9YRT"},{"name":"Maps_To","value":"Pegargiminase"},{"name":"NCI_Drug_Dictionary_ID","value":"355725"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355725"},{"name":"PDQ_Open_Trial_Search_ID","value":"355725"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328192"}]}}{"C1200":{"preferredName":"Pegaspargase","code":"C1200","definitions":[{"definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the drug asparaginase that is linked to a substance called PEG, which makes the drug stay in the body longer. Asparaginase is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pegaspargase","termGroup":"PT","termSource":"NCI"},{"termName":"(Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase","termGroup":"SN","termSource":"NCI"},{"termName":"L-Asparaginase with Polyethylene Glycol","termGroup":"SY","termSource":"NCI"},{"termName":"Oncaspar","termGroup":"BR","termSource":"NCI"},{"termName":"Oncaspar-IV","termGroup":"BR","termSource":"NCI"},{"termName":"PEG-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-L-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"PEGLA","termGroup":"AB","termSource":"NCI"},{"termName":"Polyethylene Glycol-L-Asparaginase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"130167-69-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7D96IR0PPM"},{"name":"Legacy Concept Name","value":"Pegaspargase"},{"name":"Maps_To","value":"Pegaspargase"},{"name":"NCI_Drug_Dictionary_ID","value":"40312"},{"name":"NSC Number","value":"624239"},{"name":"NSC Number","value":"644954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40312"},{"name":"PDQ_Open_Trial_Search_ID","value":"40312"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071568"}]}}{"C62791":{"preferredName":"Pegdinetanib","code":"C62791","definitions":[{"definition":"A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. CT-322 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pegdinetanib","termGroup":"PT","termSource":"NCI"},{"termName":"Angiocept","termGroup":"BR","termSource":"NCI"},{"termName":"BMS-844203","termGroup":"CN","termSource":"NCI"},{"termName":"CT-322","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"906450-24-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SSB56T0M0L"},{"name":"Legacy Concept Name","value":"CT-322"},{"name":"Maps_To","value":"Pegdinetanib"},{"name":"NCI_Drug_Dictionary_ID","value":"575516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575516"},{"name":"PDQ_Open_Trial_Search_ID","value":"575516"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831965"}]}}{"C1854":{"preferredName":"Pegfilgrastim","code":"C1854","definitions":[{"definition":"A drug used to increase numbers of white blood cells in patients who are receiving chemotherapy. It is a type of colony-stimulating factor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegfilgrastim","termGroup":"PT","termSource":"NCI"},{"termName":"Dulastin","termGroup":"BR","termSource":"NCI"},{"termName":"Filgrastim SD-01","termGroup":"SY","termSource":"NCI"},{"termName":"Fulphila","termGroup":"BR","termSource":"NCI"},{"termName":"HSP-130","termGroup":"CN","termSource":"NCI"},{"termName":"Jinyouli","termGroup":"FB","termSource":"NCI"},{"termName":"Neulasta","termGroup":"BR","termSource":"NCI"},{"termName":"Neulastim","termGroup":"FB","termSource":"NCI"},{"termName":"Neupopeg","termGroup":"FB","termSource":"NCI"},{"termName":"Nyvepria","termGroup":"BR","termSource":"NCI"},{"termName":"Pegcyte","termGroup":"FB","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar HSP-130","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Nyvepria","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Pegcyte","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar PF-06881894","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Udenyca","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Ziextenzo","termGroup":"SY","termSource":"NCI"},{"termName":"pegfilgrastim-apgf","termGroup":"SY","termSource":"NCI"},{"termName":"pegfilgrastim-bmez","termGroup":"SY","termSource":"NCI"},{"termName":"pegfilgrastim-cbqv","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim-jmdb","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated G-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated GCSF","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Granulocyte Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"PF-06881894","termGroup":"CN","termSource":"NCI"},{"termName":"SD-01","termGroup":"SY","termSource":"NCI"},{"termName":"SD-01 sustained duration G-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Tripegfilgrastim","termGroup":"SY","termSource":"NCI"},{"termName":"Udenyca","termGroup":"BR","termSource":"NCI"},{"termName":"Ziextenzo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chemotherapy-induced neutropenia"},{"name":"CAS_Registry","value":"208265-92-3"},{"name":"Chemical_Formula","value":"C3H8NO(C2H4O)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"3A58010674"},{"name":"Legacy Concept Name","value":"Pegfilgrastim"},{"name":"Maps_To","value":"Pegfilgrastim"},{"name":"NCI_Drug_Dictionary_ID","value":"37807"},{"name":"NSC Number","value":"725961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37807"},{"name":"PDQ_Open_Trial_Search_ID","value":"37807"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1136535"}]}}{"C113295":{"preferredName":"Pegilodecakin","code":"C113295","definitions":[{"definition":"A covalent conjugate of recombinant human interleukin-10 (IL-10) and polyethylene glycol (PEG), with potential anti-fibrotic, anti-inflammatory, immunomodulating and antineoplastic activities. Upon subcutaneous administration, pegilodecakin may activate cell-mediated immunity against cancer cells by stimulating the differentiation and expansion of tumor specific cytotoxic CD8+ T cells. This agent may also lower serum cholesterol levels and reduce atherosclerotic plaques by inhibiting the synthesis of pro-inflammatory cytokines, such as Interferon-gamma, IL-2, IL-3, TNF-alpha, and GM-CSF. The PEG moiety inhibits proteolytic breakdown and clearance of AM0010, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegilodecakin","termGroup":"PT","termSource":"NCI"},{"termName":"AM-0010","termGroup":"CN","termSource":"NCI"},{"termName":"AM0010","termGroup":"CN","termSource":"NCI"},{"termName":"PEG-rHuIL-10 AM0010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1966111-35-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Z9850I25F"},{"name":"Maps_To","value":"Pegilodecakin"},{"name":"NCI_Drug_Dictionary_ID","value":"756011"},{"name":"NCI_META_CUI","value":"CL458142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756011"},{"name":"PDQ_Open_Trial_Search_ID","value":"756011"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C33987":{"preferredName":"Peginterferon Alfa-2a","code":"C33987","definitions":[{"definition":"A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peginterferon Alfa-2a","termGroup":"PT","termSource":"NCI"},{"termName":"PEG-Interferon Alfa-2a","termGroup":"SY","termSource":"NCI"},{"termName":"Pegasys","termGroup":"BR","termSource":"NCI"},{"termName":"Pegylated Interferon Alfa-2a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic hepatitis C; renal cell carcinoma; advanced melanoma; chronic myelogenous leukaemia"},{"name":"CAS_Registry","value":"198153-51-4"},{"name":"Chemical_Formula","value":"C10H18N3O5(C2H4O)n(C2H4O)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q46947FE7K"},{"name":"Legacy Concept Name","value":"PEG-Interferon_Alfa-2a"},{"name":"Maps_To","value":"Peginterferon Alfa-2a"},{"name":"NCI_Drug_Dictionary_ID","value":"335280"},{"name":"NSC Number","value":"729130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"335280"},{"name":"PDQ_Open_Trial_Search_ID","value":"335280"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391001"}]}}{"C1845":{"preferredName":"Peginterferon Alfa-2b","code":"C1845","definitions":[{"definition":"A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peginterferon Alfa-2b","termGroup":"PT","termSource":"NCI"},{"termName":"PEG Interferon Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG Intron","termGroup":"BR","termSource":"NCI"},{"termName":"PEG-IFN Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-IFN-a 2b","termGroup":"AB","termSource":"NCI"},{"termName":"PEG-Interferon Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-Intron","termGroup":"FB","termSource":"NCI"},{"termName":"PegIntron","termGroup":"BR","termSource":"NCI"},{"termName":"Pegylated Interferon alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Interferon Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"Polyethylene Glycol IFN-A2b","termGroup":"SY","termSource":"NCI"},{"termName":"Polyethylene Glycol Interferon Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"Sylatron","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic hepatitis C; renal cell carcinoma"},{"name":"CAS_Registry","value":"215647-85-1"},{"name":"CHEBI_ID","value":"CHEBI:63615"},{"name":"Chemical_Formula","value":"C2H4NO2(C2H4O)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G8RGG88B68"},{"name":"Legacy Concept Name","value":"PEG-Interferon_Alfa-2B"},{"name":"Maps_To","value":"Peginterferon Alfa-2b"},{"name":"NCI_Drug_Dictionary_ID","value":"43407"},{"name":"NSC Number","value":"720033"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43407"},{"name":"PDQ_Open_Trial_Search_ID","value":"43407"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796545"}]}}{"C61881":{"preferredName":"Pegvisomant","code":"C61881","definitions":[{"definition":"A pegylated, recombinant, human growth hormone (GH) structural analog with GH receptor antagonist activity. As a GH analog, the structure of pegvisomant is similar to that of native GH with the exception of 9 amino acid substitutions. Pegvisomant selectively binds to GH receptors on cell surfaces, interfering with endogenous GH receptor binding and so GH signal transduction. Inhibition of GH signal transduction results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and other GH-responsive serum proteins, including IGF binding protein-3 (IGFBP-3) and the acid-labile subunit (ALS), and may inhibit the growth of cancers in which IGF-1 is upregulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegvisomant","termGroup":"PT","termSource":"NCI"},{"termName":"Somatotropin (18-Aspartic Acid, 21-Asparagine, 120-Lysine, 167-Asparagine, 168-Alanine, 171-Serine, 172-Arginine, 174-Serine, 179-Threonine) (Human), Pegylated","termGroup":"SY","termSource":"NCI"},{"termName":"Somavert","termGroup":"BR","termSource":"NCI"},{"termName":"Trovert","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"218620-50-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N824AOU5XV"},{"name":"Legacy Concept Name","value":"Pegvisomant"},{"name":"Maps_To","value":"Pegvisomant"},{"name":"NCI_Drug_Dictionary_ID","value":"655949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655949"},{"name":"PDQ_Open_Trial_Search_ID","value":"655949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0913469"}]}}{"C162508":{"preferredName":"Pegylated Deoxycytidine Analogue DFP-14927","code":"C162508","definitions":[{"definition":"A pegylated formulation containing DFP-10917, an analogue of the nucleoside deoxycytidine, with potential antineoplastic activity. Upon administration, the pegylated deoxycytidine analogue DFP-14927 is incorporated into the DNA of rapidly proliferating cells, such as tumor cells, and directly inhibits the activity of DNA polymerase, which results in the inhibition of DNA replication and cell cycle arrest, DNA fragmentation, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Deoxycytidine Analogue DFP-14927","termGroup":"PT","termSource":"NCI"},{"termName":"DFP 14927","termGroup":"CN","termSource":"NCI"},{"termName":"DFP-14927","termGroup":"CN","termSource":"NCI"},{"termName":"DFP14927","termGroup":"CN","termSource":"NCI"},{"termName":"PEGylated DFP-10917","termGroup":"SY","termSource":"NCI"},{"termName":"Polymeric Nucleoside Analogue DFP-14927","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated Deoxycytidine Analogue DFP-14927"},{"name":"NCI_Drug_Dictionary_ID","value":"798748"},{"name":"NCI_META_CUI","value":"CL970946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798748"},{"name":"PDQ_Open_Trial_Search_ID","value":"798748"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2491":{"preferredName":"Pegylated Interferon Alfa","code":"C2491","definitions":[{"definition":"A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety.  Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Interferon Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"PEG-IFN-a","termGroup":"AB","termSource":"NCI"},{"termName":"PEG-interferon alfa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatitis C."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pegylated_Interferon_Alfa"},{"name":"Maps_To","value":"Pegylated Interferon Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"43151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43151"},{"name":"PDQ_Open_Trial_Search_ID","value":"43151"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0907160"}]}}{"C61437":{"preferredName":"Pegylated Liposomal Belotecan","code":"C61437","definitions":[{"definition":"A sterically stabilized, pegylated liposomal formulation containing belotecan, a semi-synthetic analogue of campthotecin with potential antitumor activity. Belotecan inhibits the action of topoisomerase I, an enzyme that produces reversible single-strand breaks in DNA during DNA replication. This agent stabilizes the topoisomerase I and DNA complex, resulting in the inhibition of religation of DNA breaks, inhibition of DNA replication, and apoptotic cell death. The polyethylene glycol coating allows for greater plasma circulation time, thus enhancing the concentration of belotecan at the tumor site. Encapsulation of belotecan preserves the active lactone form, resulting in an increased cytotoxic effect of belotecan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Belotecan","termGroup":"PT","termSource":"NCI"},{"termName":"S-CKD602","termGroup":"CN","termSource":"NCI"},{"termName":"STEALTH Liposomal Belotecan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"S-CKD602"},{"name":"Maps_To","value":"Pegylated Liposomal Belotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"471934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"471934"},{"name":"PDQ_Open_Trial_Search_ID","value":"471934"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831764"}]}}{"C1555":{"preferredName":"Pegylated Liposomal Doxorubicin Hydrochloride","code":"C1555","definitions":[{"definition":"A form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin. Doxil is used to treat ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma in patients whose disease has not gotten better after treatment with other anticancer drugs. It may be used together with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Doxil is a type of anthracycline antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ATI-0918","termGroup":"CN","termSource":"NCI"},{"termName":"Caelyx","termGroup":"FB","termSource":"NCI"},{"termName":"DOX-SL","termGroup":"BR","termSource":"NCI"},{"termName":"Doxil","termGroup":"BR","termSource":"NCI"},{"termName":"Doxilen","termGroup":"FB","termSource":"NCI"},{"termName":"Doxorubicin HCl Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin HCl Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin Hydrochloride Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Duomeisu","termGroup":"FB","termSource":"NCI"},{"termName":"Evacet","termGroup":"BR","termSource":"NCI"},{"termName":"LipoDox","termGroup":"BR","termSource":"NCI"},{"termName":"Lipodox 50","termGroup":"BR","termSource":"NCI"},{"termName":"Liposomal Adriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal-Encapsulated Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Doxorubicin HCl Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Liposomal Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"S-Liposomal Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Stealth Liposomal Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"TLC D-99","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Refractory metastatic carcinoma of the ovary; AIDS-related Kaposi's sarcoma; breast cancer; relapsed/refractory multiple myeloma (with bortezomib)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Doxorubicin_Hydrochloride_Liposome"},{"name":"Maps_To","value":"Pegylated Liposomal Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39424"},{"name":"NSC Number","value":"712227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39424"},{"name":"PDQ_Open_Trial_Search_ID","value":"39424"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522690"}]}}{"C62789":{"preferredName":"Pegylated Liposomal Irinotecan","code":"C62789","definitions":[{"definition":"A formulation of polyethylene glycol (PEG)-modified liposomes encapsulating the semisynthetic derivative of camptothecin irinotecan, with antineoplastic activity. As a prodrug, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. In turn, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA, resulting in DNA breaks. This results in an inhibition of DNA replication and an induction of apoptosis. Pegylated liposomal delivery of irinotecan improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of exposure while lowering systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Irinotecan","termGroup":"PT","termSource":"NCI"},{"termName":"IHL-305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liposomal_Irinotecan"},{"name":"Maps_To","value":"Pegylated Liposomal Irinotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"506099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"506099"},{"name":"PDQ_Open_Trial_Search_ID","value":"506099"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831956"}]}}{"C103276":{"preferredName":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug","code":"C103276","definitions":[{"definition":"A pegylated liposomal formulation comprised of a lipophilic prodrug of the antineoplastic antibiotic mitomycin C containing a cleavable disulfide bond (PL-MLP), with potential antineoplastic activity. Upon administration of the pegylated liposomal mitomycin C lipid-based prodrug, the MLP moiety becomes activated upon thiolysis at the tumor site, thereby releasing mitomycin C. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  The thiolytic environment and upregulated expression of thioredoxins at the tumor site allow for the activation and release of mitomycin C. This prodrug formulation allows for greater circulation time, less systemic toxicity and increased accumulation of mitomycin C at the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-27548547","termGroup":"CN","termSource":"NCI"},{"termName":"PL-MLP","termGroup":"AB","termSource":"NCI"},{"termName":"Promitil","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"303983-00-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3I8JKL1CHB"},{"name":"Maps_To","value":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug"},{"name":"NCI_Drug_Dictionary_ID","value":"741900"},{"name":"NCI_META_CUI","value":"CL438127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741900"},{"name":"PDQ_Open_Trial_Search_ID","value":"741900"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C131307":{"preferredName":"Pegylated Liposomal Mitoxantrone Hydrochloride","code":"C131307","definitions":[{"definition":"A pegylated liposomal mitoxantrone formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within pegylated small unilamellar vesicles (SUVs), with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in rapidly dividing cancer cells. The pegylated liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering toxic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Mitoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"PLM60","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated Liposomal Mitoxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"785702"},{"name":"NCI_META_CUI","value":"CL514320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785702"},{"name":"PDQ_Open_Trial_Search_ID","value":"785702"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116869":{"preferredName":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010","code":"C116869","definitions":[{"definition":"A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor's vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel's efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010","termGroup":"PT","termSource":"NCI"},{"termName":"MNK-010","termGroup":"CN","termSource":"NCI"},{"termName":"MP-3549-1","termGroup":"CN","termSource":"NCI"},{"termName":"Pegylated Liposomal Docetaxel Prodrug MNK-010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010"},{"name":"NCI_Drug_Dictionary_ID","value":"757071"},{"name":"NCI_META_CUI","value":"CL471764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757071"},{"name":"PDQ_Open_Trial_Search_ID","value":"757071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63476":{"preferredName":"Pegylated Paclitaxel","code":"C63476","definitions":[{"definition":"A formulation of polyethylene glycol (PEG) conjugated paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic activity. Paclitaxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2). Compared to paclitaxel alone, pegylated paclitaxel has an enhanced water solubility leading to an increase in bioavailability, and decreases its toxicity profile. Therefore, the pegylated formulation potentially supports delivery of higher doses of paclitaxel to the specific site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"PEG Paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pegylated_Paclitaxel"},{"name":"Maps_To","value":"Pegylated Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"363602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"363602"},{"name":"PDQ_Open_Trial_Search_ID","value":"363602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541201"}]}}{"C88286":{"preferredName":"Pegylated Recombinant Human Arginase I BCT-100","code":"C88286","definitions":[{"definition":"A recombinant human arginase I (liver arginase) covalently attached, via a succinamide propionic acid (SPA) linker, to a polyethylene glycol (PEG) of molecular weight 5,000 [rhArg-peg(5,000mw)] with potential antineoplastic activity. Upon intravenous administration of pegylated recombinant human arginase I BCT-100, arginase metabolizes the amino acid arginine to ornithine and urea, depleting intracellular arginine, which may inhibit proliferation of cells that are auxotrophic for arginine such as hepatocellular carcinoma (HCC) cells.  This agent may also work synergistically with various cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Recombinant Human Arginase I BCT-100","termGroup":"PT","termSource":"NCI"},{"termName":"BCT-100","termGroup":"CN","termSource":"NCI"},{"termName":"RH-ARG1-PEG-5,000 MW","termGroup":"SY","termSource":"NCI"},{"termName":"rhArgIpeg5000","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1433787-75-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3HC6XX81X"},{"name":"Maps_To","value":"Pegylated Recombinant Human Arginase I BCT-100"},{"name":"NCI_Drug_Dictionary_ID","value":"657226"},{"name":"NCI_META_CUI","value":"CL413535"},{"name":"PDQ_Closed_Trial_Search_ID","value":"657226"},{"name":"PDQ_Open_Trial_Search_ID","value":"657226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82659":{"preferredName":"Pegvorhyaluronidase Alfa","code":"C82659","definitions":[{"definition":"A pegylated formulation of a recombinant form of human hyaluronidase with potential antitumor activity. Upon intravenous administration, pegvorhyaluronidase alfa degrades hyaluronic acid (HA) coating tumor cells, which may result in the inhibition of tumor cell growth. In addition, the degradation of HA may result in a lowering of the interstitial fluid pressure (IFP), allowing better penetration of chemotherapeutic agents into the tumor bed. HA is a glycosaminoglycan found in the extracellular matrix (ECM) that is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increased tumor cell growth, metastatic potential, tumor progression, increased resistance to chemotherapeutic agents, and an elevation in tumor IFP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegvorhyaluronidase Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"PEGPH20","termGroup":"AB","termSource":"NCI"},{"termName":"Pegylated Recombinant Human Hyaluronidase PH20","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant Human PH20","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"PH20","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620390-06-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P01I4980ZS"},{"name":"Legacy Concept Name","value":"Pegylated_Recombinant_Human_Hyaluronidase_PH20"},{"name":"Maps_To","value":"Pegvorhyaluronidase Alfa"},{"name":"Maps_To","value":"Pegylated Recombinant Human Hyaluronidase PH20"},{"name":"NCI_Drug_Dictionary_ID","value":"636196"},{"name":"NCI_META_CUI","value":"CL388491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636196"},{"name":"PDQ_Open_Trial_Search_ID","value":"636196"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162645":{"preferredName":"Pegenzileukin","code":"C162645","definitions":[{"definition":"A pegylated recombinant, engineered variant of cytokine interleukin-2 (IL-2; IL2) where novel amino acid is encoded in the IL-2 gene that is leveraged for use in site-specific pegylation, with potential immunostimulating activity. Upon administration of pegenzileukin, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells, such as cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, thereby activating these cells and inducing their expansion. It also induces the expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. The addition of the novel amino acid and the concurrent pegylation prevents the binding of the IL-2 moiety to the IL-2 receptor alpha chain (IL2Ra), thereby blocking the IL2Ra-mediated activation of CD4-positive regulatory and immunosuppressive T-cells (Tregs). Since it cannot bind to IL2Ra expressed on innate lymphoid cells in the vascular endothelium, pegenzileukin prevents IL-2-mediated recruitment and activation of eosinophils, and inhibits the induction of eosinophil-mediated vascular leak syndrome (VLS). Pegylation also extends the half-life of pegenzileukin. Compared to recombinant IL-2, pegenzileukin allows for increased IL-2Rbg binding and proliferation of CTLs without stimulating the toxicity caused by binding to IL-2Ra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegenzileukin","termGroup":"PT","termSource":"NCI"},{"termName":"IL-2 Variant THOR-707","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant IL-2 Variant THOR-707","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant Interleukin-2 THOR-707","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 444245","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-444245","termGroup":"CN","termSource":"NCI"},{"termName":"SAR444245","termGroup":"CN","termSource":"NCI"},{"termName":"THOR 707","termGroup":"CN","termSource":"NCI"},{"termName":"THOR-707","termGroup":"CN","termSource":"NCI"},{"termName":"THOR707","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2573074-47-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"10WR240QN7"},{"name":"Maps_To","value":"Pegylated Recombinant Interleukin-2 THOR-707"},{"name":"NCI_Drug_Dictionary_ID","value":"798926"},{"name":"NCI_META_CUI","value":"CL971032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798926"},{"name":"PDQ_Open_Trial_Search_ID","value":"798926"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C170297":{"preferredName":"Pegcrisantaspase","code":"C170297","definitions":[{"definition":"A recombinant, pegylated form of Erwinia asparaginase (crisantaspase), derived from the bacterium Erwinia chrysanthemi and genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Recombinant Erwinia asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Recombinant Erwinia asparaginase can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegcrisantaspase","termGroup":"PT","termSource":"NCI"},{"termName":"Asparec","termGroup":"FB","termSource":"NCI"},{"termName":"JZP 416","termGroup":"CN","termSource":"NCI"},{"termName":"JZP-416","termGroup":"CN","termSource":"NCI"},{"termName":"JZP416","termGroup":"CN","termSource":"NCI"},{"termName":"mPEG-R-crisantaspase","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Erwinia asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant L-asparaginase Erwinia chrysanthemi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448590-54-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y8KTZ6Y35U"},{"name":"Maps_To","value":"Pegylated Recombinant L-asparaginase Erwinia chrysanthemi"},{"name":"NCI_Drug_Dictionary_ID","value":"729150"},{"name":"NCI_Drug_Dictionary_ID","value":"804180"},{"name":"NCI_META_CUI","value":"CL1382536"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125143":{"preferredName":"Pegzilarginase","code":"C125143","definitions":[{"definition":"A recombinant modified form of the human enzyme arginase 1 (ARG1), in which cobalt is substituted for manganese as a cofactor, covalently attached to polyethylene glycol (PEG), with potential arginine degrading and antineoplastic activities. Upon intravenous administration of pegzilarginase, ARG1 metabolizes the amino acid arginine to ornithine and urea, thereby lowering blood arginine levels. This normalizes blood arginine levels in patients with ARG1 deficiency and prevents hyperargininemia. This also inhibits the proliferation of cancer cells that are dependent on extracellular arginine uptake for their proliferation. In normal, healthy cells, arginine is synthesized intracellularly by the enzymes ornithine transcarbamylase (OTC), argininosuccinate synthase (ASS), and argininosuccinate lyase (ASL); thus they are not dependent on extracellular arginine for survival. In cancer cells these enzymes are disabled; therefore, this agent may inhibit proliferation and survival of these cells by depleting extracellular arginine. Pegylation improves blood circulation times and cobalt substitution increases the catalytic activity of ARG1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegzilarginase","termGroup":"PT","termSource":"NCI"},{"termName":"AEB-1102","termGroup":"CN","termSource":"NCI"},{"termName":"AEB1102","termGroup":"CN","termSource":"NCI"},{"termName":"Co-ArgI-PEG","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant Arginase AEB1102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1659310-95-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4YV4KW88GD"},{"name":"Maps_To","value":"Pegzilarginase"},{"name":"NCI_Drug_Dictionary_ID","value":"778251"},{"name":"NCI_META_CUI","value":"CL503972"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778251"},{"name":"PDQ_Open_Trial_Search_ID","value":"778251"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60774":{"preferredName":"Pelareorep","code":"C60774","definitions":[{"definition":"An isolate of the oncolytic, human wild-type serotype 3 Dearing (T3D) strain of the double-stranded RNA virus reovirus (Respiratory Enteric Orphan virus), with potential oncolytic activity. Upon administration, pelareorep is able to replicate specifically in cancer cells bearing an activated Ras pathway. This induces apoptosis in Ras-activated tumor cells and subsequently frees progeny viral particles to infect, replicate in and induce cell death of surrounding cancer cells. In addition, viral replication causes the activation of innate and adaptive immune responses, causing a natural killer (NK)-cell-mediated and a cytotoxic T-cell (CTL)-mediated killing of tumor cells, respectively. Ras-activated tumor cells are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelareorep","termGroup":"PT","termSource":"NCI"},{"termName":"PO BB0209","termGroup":"CN","termSource":"NCI"},{"termName":"PO-BB0209","termGroup":"CN","termSource":"NCI"},{"termName":"Reolysin","termGroup":"BR","termSource":"NCI"},{"termName":"Reovirus Serotype 3","termGroup":"SY","termSource":"NCI"},{"termName":"Wild-type Reovirus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1383626-61-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9J80L3D1U"},{"name":"Legacy Concept Name","value":"Reolysin"},{"name":"Maps_To","value":"Pelareorep"},{"name":"NCI_Drug_Dictionary_ID","value":"563224"},{"name":"NSC Number","value":"729968"},{"name":"PDQ_Closed_Trial_Search_ID","value":"563224"},{"name":"PDQ_Open_Trial_Search_ID","value":"563224"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882931"}]}}{"C1650":{"preferredName":"Peldesine","code":"C1650","definitions":[{"definition":"A pyrimidine analogue and purine nucleoside phosphorylase inhibitor with immunosuppressive and antineoplastic properties. Peldesine inhibits purine nucleoside phosphorylase (PNP) that plays a pivotal role in T-cell proliferation and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2'-deoxyribonucleosides. Inhibition of PNP results in accumulation of dGTP and the subsequent failure of DNA synthesis. This agent maybe used in T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohn s disease and T-cell cancers","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied for the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peldesine","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Pyrrolo(3,2-d)pyrimidin-4-one,1,5-dihydro-2-amino-7-(3-pyridinylmethyl)","termGroup":"SN","termSource":"NCI"},{"termName":"9-(3-Pyridinylmethyl)-7H-9-deazaguanine","termGroup":"SN","termSource":"NCI"},{"termName":"BCX-34","termGroup":"CN","termSource":"NCI"},{"termName":"Peldesina","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"133432-71-0"},{"name":"Chemical_Formula","value":"C12H11N5O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7B646RJ70F"},{"name":"Legacy Concept Name","value":"Peldesine"},{"name":"Maps_To","value":"Peldesine"},{"name":"NCI_Drug_Dictionary_ID","value":"42367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42367"},{"name":"PDQ_Open_Trial_Search_ID","value":"42367"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338278"}]}}{"C2713":{"preferredName":"Pelitinib","code":"C2713","definitions":[{"definition":"A 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.  Pelitinib irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called epidermal growth factor receptor inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pelitinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"EKB 569","termGroup":"CN","termSource":"NCI"},{"termName":"WAY-EKB 569","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"257933-82-7"},{"name":"CHEBI_ID","value":"CHEBI:38927"},{"name":"Chemical_Formula","value":"C24H23ClFN5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X5DWL380Z6"},{"name":"Legacy Concept Name","value":"EKB-569"},{"name":"Maps_To","value":"Pelitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"352165"},{"name":"NSC Number","value":"729742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352165"},{"name":"PDQ_Open_Trial_Search_ID","value":"352165"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0961045"}]}}{"C2633":{"preferredName":"Pelitrexol","code":"C2633","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called glycinamide ribonucleotide formyl transferase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelitrexol","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-(((5-(2-((6S)-2-Amino-4-oxo-1,4,5,6,7,8-hexahydropyrido(2,3-d)pyrimidin-6-yl)ethyl)-4-methylthiophen-2-yl)carbonyl)amino)pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"(2S)-2-[[[5-[2-[(6S)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophen-2-yl]carbonyl]amino]pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AG2037","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"446022-33-9"},{"name":"Chemical_Formula","value":"C20H25N5O6S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DHT6E8M4KP"},{"name":"Legacy Concept Name","value":"AG2037"},{"name":"Maps_To","value":"Pelitrexol"},{"name":"NCI_Drug_Dictionary_ID","value":"38329"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38329"},{"name":"PDQ_Open_Trial_Search_ID","value":"38329"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1871457"}]}}{"C106432":{"preferredName":"Pembrolizumab","code":"C106432","definitions":[{"definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pembrolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"BCD-201","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Keytruda","termGroup":"BR","termSource":"NCI"},{"termName":"Lambrolizumab","termGroup":"SY","termSource":"NCI"},{"termName":"MK-3475","termGroup":"CN","termSource":"NCI"},{"termName":"Pembrolizumab Biosimilar BCD-201","termGroup":"SY","termSource":"NCI"},{"termName":"Pembrolizumab Biosimilar QL2107","termGroup":"SY","termSource":"NCI"},{"termName":"QL2107","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900475","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer; recurrent or metastatic head and neck squamous cell carcinoma (HNSCC); metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1; unresectable or metastatic melanoma or melanoma with involvement of lymph node(s) following complete resection; metastatic small cell lung cancer (SCLC); advanced renal cell carcinoma (RCC); recurrent or metastatic cervical cancer; refractory primary mediastinal large B-cell lymphoma (PMBCL); urothelial cancer; hepatocellular carcinoma (HCC); recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)"},{"name":"Accepted_Therapeutic_Use_For","value":"soft tissue sarcoma (STS)"},{"name":"CAS_Registry","value":"1374853-91-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"DPT0O3T46P"},{"name":"Maps_To","value":"Pembrolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"695789"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695789"},{"name":"PDQ_Open_Trial_Search_ID","value":"695789"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658706"}]}}{"C61614":{"preferredName":"Pemetrexed","code":"C61614","definitions":[{"definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemetrexed","termGroup":"PT","termSource":"NCI"},{"termName":"L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)","termGroup":"SN","termSource":"NCI"},{"termName":"MTA","termGroup":"AB","termSource":"NCI"},{"termName":"Multitargeted Antifolate","termGroup":"SY","termSource":"NCI"},{"termName":"Pemfexy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"137281-23-3"},{"name":"CHEBI_ID","value":"CHEBI:63616"},{"name":"Chemical_Formula","value":"C20H21N5O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"04Q9AIZ7NO"},{"name":"Legacy Concept Name","value":"Pemetrexed_Base"},{"name":"Maps_To","value":"Pemetrexed"},{"name":"NSC Number","value":"698037"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0210657"}]}}{"C1533":{"preferredName":"Pemetrexed Disodium","code":"C1533","definitions":[{"definition":"A drug used alone or with another drug to treat certain types of non-small cell lung cancer and malignant pleural mesothelioma. It is being studied in the treatment of other types of cancer. Pemetrexed disodium blocks DNA synthesis and may kill cancer cells. It is a type of folate antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemetrexed Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Alimta","termGroup":"BR","termSource":"NCI"},{"termName":"Almita","termGroup":"FB","termSource":"NCI"},{"termName":"LY231514","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant pleural mesothelioma; Non-small cell lung cancer"},{"name":"CAS_Registry","value":"150399-23-8"},{"name":"CHEBI_ID","value":"CHEBI:63722"},{"name":"Chemical_Formula","value":"C20H19N5O6.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2PKU919BA9"},{"name":"Legacy Concept Name","value":"Pemetrexed"},{"name":"Maps_To","value":"Pemetrexed Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"42328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42328"},{"name":"PDQ_Open_Trial_Search_ID","value":"42328"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0936142"}]}}{"C121553":{"preferredName":"Pemigatinib","code":"C121553","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemigatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB054828","termGroup":"CN","termSource":"NCI"},{"termName":"Pemazyre","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement"},{"name":"CAS_Registry","value":"1513857-77-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Y6BX7BL23K"},{"name":"Maps_To","value":"Pemigatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"770381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770381"},{"name":"PDQ_Open_Trial_Search_ID","value":"770381"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053633"}]}}{"C124843":{"preferredName":"Pemlimogene Merolisbac","code":"C124843","definitions":[{"definition":"A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding the tumor-associated antigens (TAAs) epidermal growth factor receptor mutant form EGFRvIII and human mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the live-attenuated Listeria monocytogenes encoding EGFRvIII-mesothelin vaccine Pemlimogene merolisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). EGFRvIII and mesothelin are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against EGFRvIII- and mesothelin-expressing tumor cells, eventually resulting in tumor cell lysis. EGFRvIII and mesothelin are overexpressed in many types of cancer. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemlimogene Merolisbac","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-214","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64041757","termGroup":"SY","termSource":"NCI"},{"termName":"LADD Listeria monocytogenes JNJ-64041757","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S2EGO8116S"},{"name":"Maps_To","value":"Pemlimogene Merolisbac"},{"name":"NCI_Drug_Dictionary_ID","value":"778079"},{"name":"NCI_META_CUI","value":"CL503062"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778079"},{"name":"PDQ_Open_Trial_Search_ID","value":"778079"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1187":{"preferredName":"Penberol","code":"C1187","definitions":[{"definition":"A derivative of bromoacrylic acid with cytostatic activity. Although the mechanism of action is unclear, penberol might inhibit tumor growth mediated through inhibition of the cell energetic metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penberol","termGroup":"PT","termSource":"NCI"},{"termName":"cis-beta-4-pentoxy-benzoyl-beta-bromoacrylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"24740-92-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5KAI8N485T"},{"name":"Legacy Concept Name","value":"Penberol"},{"name":"Maps_To","value":"Penberol"},{"name":"NCI_Drug_Dictionary_ID","value":"39551"},{"name":"NSC Number","value":"172760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39551"},{"name":"PDQ_Open_Trial_Search_ID","value":"39551"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070218"}]}}{"C1188":{"preferredName":"Penclomedine","code":"C1188","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of pyrimidine with antineoplastic activity. Penclomedine alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis. This agent is more active against tumor cells that are defective in p53 function. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penclomedine","termGroup":"PT","termSource":"NCI"},{"termName":"3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine","termGroup":"SN","termSource":"NCI"},{"termName":"CRC 88-04","termGroup":"CN","termSource":"NCI"},{"termName":"PEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"108030-77-9"},{"name":"Chemical_Formula","value":"C8H6Cl5NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"66Q80IL7CW"},{"name":"Legacy Concept Name","value":"Penclomedine"},{"name":"Maps_To","value":"Penclomedine"},{"name":"NCI_Drug_Dictionary_ID","value":"41973"},{"name":"NSC Number","value":"338720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41973"},{"name":"PDQ_Open_Trial_Search_ID","value":"41973"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070220"}]}}{"C729":{"preferredName":"Penicillamine","code":"C729","definitions":[{"definition":"A beta dimethyl analog of the amino acid cysteine.  As a degradation product of penicillin antibiotics, penicillamine chelates with heavy metals and increases their urinary excretion.  Possessing antineoplastic properties, penicillamine induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that removes copper from the body and is used to treat diseases in which there is an excess of this metal. It is also being studied as a possible angiogenesis inhibitor in brain tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Penicillamine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Mercapto-D-valine","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-amino-beta-methyl-beta-mercaptobutyric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Atamir","termGroup":"FB","termSource":"NCI"},{"termName":"Beta,Beta-dimethylcysteine","termGroup":"SN","termSource":"NCI"},{"termName":"Beta-thiovaline","termGroup":"SN","termSource":"NCI"},{"termName":"Cuprenil","termGroup":"BR","termSource":"NCI"},{"termName":"Cuprimine","termGroup":"BR","termSource":"NCI"},{"termName":"Cupripen","termGroup":"FB","termSource":"NCI"},{"termName":"D-Mercaptovaline","termGroup":"SY","termSource":"NCI"},{"termName":"D-Penicillamine","termGroup":"SY","termSource":"NCI"},{"termName":"Depamine","termGroup":"SY","termSource":"NCI"},{"termName":"Depen","termGroup":"BR","termSource":"NCI"},{"termName":"Distamine","termGroup":"FB","termSource":"NCI"},{"termName":"Kelatin","termGroup":"FB","termSource":"NCI"},{"termName":"Mercaptyl","termGroup":"FB","termSource":"NCI"},{"termName":"Metalcaptase","termGroup":"FB","termSource":"NCI"},{"termName":"Pendramine","termGroup":"FB","termSource":"NCI"},{"termName":"Perdolat","termGroup":"BR","termSource":"NCI"},{"termName":"Sufortan","termGroup":"BR","termSource":"NCI"},{"termName":"Trolovol","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Wilsons disease; heavy metal intoxication; cystinuria; rheumatoid arthritis; primary biliary cirrhosis; Feltys syndrome; rheumatoid vasculitis"},{"name":"CAS_Registry","value":"52-67-5"},{"name":"CHEBI_ID","value":"CHEBI:7959"},{"name":"Chemical_Formula","value":"C5H11NO2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GNN1DV99GX"},{"name":"Legacy Concept Name","value":"Penicillamine"},{"name":"Maps_To","value":"Penicillamine"},{"name":"NCI_Drug_Dictionary_ID","value":"42546"},{"name":"NSC Number","value":"81549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42546"},{"name":"PDQ_Open_Trial_Search_ID","value":"42546"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030817"}]}}{"C1189":{"preferredName":"Pentamethylmelamine","code":"C1189","definitions":[{"definition":"A principal metabolite of hexamethylmelamine with antineoplastic activity.  Pentamethylmelamine alkylates DNA and other macromolecules and forms DNA intrastrand and DNA-protein crosslinks, thereby preventing DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pentamethylmelamine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5-Triazine-2,4,6-triamine, N,N,N',N', N''-pentamethyl-, monohydrochloride (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Melamine","termGroup":"SY","termSource":"NCI"},{"termName":"melamine, N2,N2,N4,N4,N6-pentamethyl-, monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N,N,N',N',N\"-pentamethyl-1,3,5-triazine","termGroup":"SN","termSource":"NCI"},{"termName":"Pentamethylmelamine MonoHCl","termGroup":"SY","termSource":"NCI"},{"termName":"Pentamethylmelamine Monohydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"PMM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"16268-62-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UEF6R96K8R"},{"name":"Legacy Concept Name","value":"Pentamethylmelamine"},{"name":"Maps_To","value":"Pentamethylmelamine"},{"name":"NCI_Drug_Dictionary_ID","value":"39553"},{"name":"NSC Number","value":"118742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39553"},{"name":"PDQ_Open_Trial_Search_ID","value":"39553"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070302"}]}}{"C66341":{"preferredName":"Pentamustine","code":"C66341","definitions":[{"definition":"A (2-chloroethy1)nitrosourea compound with antineoplastic activity. Petamustine was never marketed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pentamustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-neopentyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"NCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Neptamustine","termGroup":"SY","termSource":"NCI"},{"termName":"Salisburystin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73105-03-0"},{"name":"Chemical_Formula","value":"C8H16ClN3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VB67O9FBGM"},{"name":"Legacy Concept Name","value":"Pentamustine"},{"name":"Maps_To","value":"Pentamustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882315"}]}}{"C732":{"preferredName":"Pentostatin","code":"C732","definitions":[{"definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pentostatin","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol","termGroup":"SN","termSource":"NCI"},{"termName":"2'-Deoxycoformycin","termGroup":"SY","termSource":"NCI"},{"termName":"CI-825","termGroup":"CN","termSource":"NCI"},{"termName":"Co-Vidarabine","termGroup":"SY","termSource":"NCI"},{"termName":"Covidarabine","termGroup":"SY","termSource":"NCI"},{"termName":"DCF","termGroup":"AB","termSource":"NCI"},{"termName":"Deoxycoformycin","termGroup":"SY","termSource":"NCI"},{"termName":"Nipent","termGroup":"BR","termSource":"NCI"},{"termName":"PD-81565","termGroup":"CN","termSource":"NCI"},{"termName":"Pentostatine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic lymphocytic leukemia; Cutaneous t-cell lymphoma; Hairy cell leukemia"},{"name":"CAS_Registry","value":"53910-25-1"},{"name":"CAS_Registry","value":"63677-95-2"},{"name":"Chemical_Formula","value":"C11H16N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"395575MZO7"},{"name":"Legacy Concept Name","value":"Pentostatin"},{"name":"Maps_To","value":"Pentostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39210"},{"name":"NSC Number","value":"218321"},{"name":"NSC Number","value":"247520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39210"},{"name":"PDQ_Open_Trial_Search_ID","value":"39210"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030896"}]}}{"C733":{"preferredName":"Pentoxifylline","code":"C733","definitions":[{"definition":"A drug used to prevent blood clotting and as a treatment that may help decrease weight loss in people with cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pentoxifylline","termGroup":"PT","termSource":"NCI"},{"termName":"3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Oxpentifylline","termGroup":"SY","termSource":"NCI"},{"termName":"Pentoxyphylline","termGroup":"SY","termSource":"NCI"},{"termName":"PTX","termGroup":"AB","termSource":"NCI"},{"termName":"Trental","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6493-05-6"},{"name":"Chemical_Formula","value":"C13H18N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SD6QCT3TSU"},{"name":"Legacy Concept Name","value":"Pentoxifylline"},{"name":"Maps_To","value":"Pentoxifylline"},{"name":"NCI_Drug_Dictionary_ID","value":"41432"},{"name":"NSC Number","value":"637086"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41432"},{"name":"PDQ_Open_Trial_Search_ID","value":"41432"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030899"}]}}{"C148635":{"preferredName":"PEOX-based Polymer Encapsulated Paclitaxel FID-007","code":"C148635","definitions":[{"definition":"A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel's solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEOX-based Polymer Encapsulated Paclitaxel FID-007","termGroup":"PT","termSource":"NCI"},{"termName":"FID 007","termGroup":"CN","termSource":"NCI"},{"termName":"FID-007","termGroup":"CN","termSource":"NCI"},{"termName":"FID007","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoencapsulated Paclitaxel FID-007","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel in Polyethyloxazoline Polymer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cationic_Liposome-Encapsulated_Paclitaxel"},{"name":"Maps_To","value":"PEOX-based Polymer Encapsulated Paclitaxel FID-007"},{"name":"NCI_Drug_Dictionary_ID","value":"796978"},{"name":"NCI_META_CUI","value":"CL551158"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796978"},{"name":"PDQ_Open_Trial_Search_ID","value":"796978"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74070":{"preferredName":"PEP-3-KLH Conjugate Vaccine","code":"C74070","definitions":[{"definition":"A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEP-3-KLH Conjugate Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"PEP-3-KLH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PEP-3-KLH_Conjugate_Vaccine"},{"name":"Maps_To","value":"PEP-3-KLH Conjugate Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"391254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391254"},{"name":"PDQ_Open_Trial_Search_ID","value":"391254"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541477"}]}}{"C96222":{"preferredName":"Pepinemab","code":"C96222","definitions":[{"definition":"A humanized IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100) with potential immunomodulating and antineoplastic activities. Upon administration, pepinemab binds to and neutralizes SEMA4D, thereby preventing binding of SEMA4D to its receptor plexin-B1 (PLXNB1). By blocking the interaction of SEMA4D and PLXNB1, pepinemab may cause an inhibition of endothelial cell activation and migration, eventually leading to an inhibition of angiogenesis and tumor cell proliferation. Semaphorin 4D, a large cell surface antigen found on the resting T-cell and overexpressed in a variety of tumor cell types, plays an important role in vascular growth, tumor progression, invasion and immune cell regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pepinemab","termGroup":"PT","termSource":"NCI"},{"termName":"moAb VX15/2503","termGroup":"AB","termSource":"NCI"},{"termName":"VX15/2503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097151-87-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BPZ4A29SYE"},{"name":"Maps_To","value":"Pepinemab"},{"name":"NCI_Drug_Dictionary_ID","value":"697328"},{"name":"NCI_META_CUI","value":"CL429006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697328"},{"name":"PDQ_Open_Trial_Search_ID","value":"697328"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1399":{"preferredName":"Peplomycin","code":"C1399","definitions":[{"definition":"A semisynthetic analog of Bleomycin, a mixture of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peplomycin","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-n1-[3-[(1-phenylethyl)amino]propyl]bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"n1-[3[[(S)-alpha-methylbenzyl]amino]propyl]bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"PEP","termGroup":"AB","termSource":"NCI"},{"termName":"Pepleomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68247-85-8"},{"name":"Chemical_Formula","value":"C61H88N18O21S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56H9L80NIZ"},{"name":"Legacy Concept Name","value":"Peplomycin"},{"name":"Maps_To","value":"Peplomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39552"},{"name":"NSC Number","value":"276382"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39552"},{"name":"PDQ_Open_Trial_Search_ID","value":"39552"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0135981"}]}}{"C1400":{"preferredName":"Peplomycin Sulfate","code":"C1400","definitions":[{"definition":"The sulfate salt of the bleomycin analogue peplomycin.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peplomycin Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"N1-(3-(((S)-(alpha-methylbenzyl))amino)propyl)bleomycinamide Sulfate (1:1) (Salt)","termGroup":"SN","termSource":"NCI"},{"termName":"NK-631","termGroup":"CN","termSource":"NCI"},{"termName":"Pepleo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73228-94-1"},{"name":"Chemical_Formula","value":"C61H88N18O21S2.H2O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6A668951HW"},{"name":"Legacy Concept Name","value":"Peplomycin_Sulfate"},{"name":"Maps_To","value":"Peplomycin Sulfate"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0917878"}]}}{"C734":{"preferredName":"Peptichemio","code":"C734","definitions":[{"definition":"A mixture of six synthetic oligopeptides in which the peptides are conjugated to metamelphalan, with alkylating and potential antineoplastic activity. Peptichemio causes crosslinking of DNA, thereby preventing DNA replication and eventually cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptichemio","termGroup":"PT","termSource":"NCI"},{"termName":"Multialchilpeptide","termGroup":"SY","termSource":"NCI"},{"termName":"peptide bound m-L-sarcolysin","termGroup":"SY","termSource":"NCI"},{"termName":"PTC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9076-25-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peptichemio"},{"name":"Maps_To","value":"Peptichemio"},{"name":"NCI_Drug_Dictionary_ID","value":"39541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39541"},{"name":"PDQ_Open_Trial_Search_ID","value":"39541"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030927"}]}}{"C2466":{"preferredName":"Peptide 946 Melanoma Vaccine","code":"C2466","definitions":[{"definition":"A melanoma peptide vaccine with potential antineoplastic activity. Peptide 946 melanoma vaccine contains one of the peptide sequences for a melanoma-specific epitope that is recognized by melanoma-specific cytotoxic T lymphocytes (CTL). This vaccine contains a peptide sequence homologous to the native epitope and is often formulated with an adjuvant such as QS-21 or Montanide ISA-51 to boost its immune stimulation. Vaccination with peptide 946 vaccine may produce antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against cells expressing this antigen, resulting in decreased tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptide 946 Melanoma Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peptide_946_Melanoma_Vaccine"},{"name":"Maps_To","value":"Peptide 946 Melanoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42974"},{"name":"PDQ_Open_Trial_Search_ID","value":"42974"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677986"}]}}{"C2467":{"preferredName":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine","code":"C2467","definitions":[{"definition":"A melanoma peptide vaccine complexed with tetanus toxoid with potential antineoplastic activity. Peptide 946 contains a melanoma-specific epitope recognized by melanoma-specific cytotoxic T lymphocytes (CTL). In addition to the peptide 946 sequence, this vaccine contains tetanus toxin, a protein known to stimulate the induction of CD4+ T lymphocytes; it thereby enhances antigen processing and presentation. Vaccination with the peptide 946-tetanus conjugate melanoma vaccine may produce antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response in tumor cells expressing the 946 epitope, thereby decreasing tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peptide_946-Tetanus_Peptide_Conjugate_Melanoma_Vaccine"},{"name":"Maps_To","value":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42975"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42975"},{"name":"PDQ_Open_Trial_Search_ID","value":"42975"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677987"}]}}{"C87202":{"preferredName":"Peretinoin","code":"C87202","definitions":[{"definition":"An orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and activates nuclear retinoic acid receptors (RAR), which in turn recruit coactivator proteins and promote, with other transcriptional complexes, the transcription of target genes. As a result, this agent may modulate the expression of genes involved in the regulation of cell proliferation, cell differentiation, and apoptosis of both normal and tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"(2E,4E,6E,10E)-3,7,11,15-Tetramethylhexadeca-2,4,6,10,14-Pentaenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"NIK-333","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81485-25-8"},{"name":"Chemical_Formula","value":"C20H30O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"11ALM7A4RV"},{"name":"Maps_To","value":"Peretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"737371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737371"},{"name":"PDQ_Open_Trial_Search_ID","value":"737371"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1453741"}]}}{"C116804":{"preferredName":"Perflenapent Emulsion","code":"C116804","definitions":[{"definition":"An oil-in-water nano-emulsion composed of the perfluorocarbon perflenapent, that has oxygen-carrying capacity, can be used as a contrast agent and has potential antihypoxic and radiosensitizing activities. Upon intravenous administration of the perflenapent emulsion, this agent increases the oxygen-carrying capacity of blood, enhances the transport of oxygen to hypoxic and ischemic tissues and increases the oxygen concentration in these tissues. Hypoxic tumors are correlated with increased resistance to radiation treatment; therefore, since perflenapent may increase tumor oxygenation, it may improve the tumor's sensitivity to radiation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perflenapent Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"DDFP LIquid Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"Dodecafluoropentane Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"NVX-108","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perflenapent Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"763081"},{"name":"NCI_META_CUI","value":"CL473943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763081"},{"name":"PDQ_Open_Trial_Search_ID","value":"763081"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1423":{"preferredName":"Perfosfamide","code":"C1423","definitions":[{"definition":"The active metabolite of the nitrogen mustard cyclophosphamide with potent antineoplastic and immunosuppressive properties. Perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perfosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-[bis(2-chloroethyl)amino]-4-hydroperoxytetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Hydroperoxycyclophosphamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-HC","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hydroperoxycyclophosphamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Pergamid","termGroup":"SN","termSource":"NCI"},{"termName":"cis-2-[bis(2-chloroethyl)amino]tetrahydro-3H-1,3,2-oxazaphosphorin-4-yl hydroperoxide P-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"cis-4-hydroperoxycyclophosphamide","termGroup":"SN","termSource":"NCI"},{"termName":"Hydroperoxycyclophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Pergamid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia"},{"name":"CAS_Registry","value":"39800-16-3"},{"name":"CHEBI_ID","value":"CHEBI:196991"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O4P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U880A4FUDA"},{"name":"Legacy Concept Name","value":"Perfosfamide"},{"name":"Maps_To","value":"Perfosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"40474"},{"name":"NSC Number","value":"181815"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40474"},{"name":"PDQ_Open_Trial_Search_ID","value":"40474"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0163054"}]}}{"C1727":{"preferredName":"Perifosine","code":"C1727","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called alkylphospholipids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perifosine","termGroup":"PT","termSource":"NCI"},{"termName":"4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt","termGroup":"SN","termSource":"NCI"},{"termName":"D21266","termGroup":"CN","termSource":"NCI"},{"termName":"KRX-0401","termGroup":"CN","termSource":"NCI"},{"termName":"Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Octadecylphosphopiperidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157716-52-4"},{"name":"Chemical_Formula","value":"C25H52NO4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2GWV496552"},{"name":"Legacy Concept Name","value":"Perifosine"},{"name":"Maps_To","value":"Perifosine"},{"name":"NCI_Drug_Dictionary_ID","value":"43408"},{"name":"NSC Number","value":"639966"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43408"},{"name":"PDQ_Open_Trial_Search_ID","value":"43408"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0754570"}]}}{"C1461":{"preferredName":"Perillyl Alcohol","code":"C1461","definitions":[{"definition":"A naturally occurring monoterpene related to limonene with antineoplastic activity. Perillyl alcohol inhibits farnesyl transferase and geranylgeranyl transferase, thereby preventing post-translational protein farnesylation and isoprenylation and activation of oncoproteins such as p21-ras, and arresting tumor cells in the G1 phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cancer. It belongs to the family of plant drugs called monoterpenes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A terpene with two isoprene units forming a ring and with a hydroxyl group attached to the head methyl group. The chemical structure is CC(=C)C1CCC(=CC1)CO.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Perillyl Alcohol","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-(-)-Perillyl Alcohol","termGroup":"SN","termSource":"NCI"},{"termName":"1-Cyclohexene-1-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"4-(1-Methylethenyl)","termGroup":"SN","termSource":"NCI"},{"termName":"4-(1-Methylethenyl)-1-cyclohexene-1-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"4-Isopropenylcyclohex-1-ene-1-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydrocuminyl Alcohol","termGroup":"SY","termSource":"NCI"},{"termName":"NEO100","termGroup":"CN","termSource":"NCI"},{"termName":"p-Mentha-1,8-dien-7-ol","termGroup":"SN","termSource":"NCI"},{"termName":"Perilla Alcohol","termGroup":"SY","termSource":"NCI"},{"termName":"Perillic Alcohol","termGroup":"SY","termSource":"NCI"},{"termName":"Perillol","termGroup":"SY","termSource":"NCI"},{"termName":"POH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18457-55-1"},{"name":"CAS_Registry","value":"536-59-4"},{"name":"CHEBI_ID","value":"CHEBI:10782"},{"name":"CHEBI_ID","value":"CHEBI:15420"},{"name":"Chemical_Formula","value":"C10H16O"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"319R5C7293"},{"name":"Legacy Concept Name","value":"Perillyl_Alcohol"},{"name":"Maps_To","value":"Perillyl Alcohol"},{"name":"NCI_Drug_Dictionary_ID","value":"42334"},{"name":"NSC Number","value":"641066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42334"},{"name":"PDQ_Open_Trial_Search_ID","value":"42334"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0207661"}]}}{"C159601":{"preferredName":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine","code":"C159601","definitions":[{"definition":"An individualized peptide-based cancer vaccine comprised of three to five human leukocyte antigen (HLA) binding tumor-specific peptides obtained from the autologous mutated proteins from the tumor cells of patients with acute lymphoblastic leukemia (ALL), with potential immunomodulating and antineoplastic activity. Upon intradermal administration of the personalized multi-HLA-binding peptide vaccine, the peptides may induce a tumor-specific cytotoxic T-lymphocyte (CTL) response against the peptides that are expressed by the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Individualized Multi-HLA-binding Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Multi-HLA-binding Peptide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"797494"},{"name":"NCI_META_CUI","value":"CL951600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797494"},{"name":"PDQ_Open_Trial_Search_ID","value":"797494"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175745":{"preferredName":"Autogene Cevumeran","code":"C175745","definitions":[{"definition":"An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autogene Cevumeran","termGroup":"PT","termSource":"NCI"},{"termName":"BNT 122","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-122","termGroup":"CN","termSource":"NCI"},{"termName":"BNT122","termGroup":"CN","termSource":"NCI"},{"termName":"PCV RO7198457","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Cancer Vaccine RO7198457","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6180","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7198457","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7198457","termGroup":"CN","termSource":"NCI"},{"termName":"RO7198457","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2365453-34-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L8HDH9IB06"},{"name":"Maps_To","value":"Personalized Cancer Vaccine RO7198457"},{"name":"NCI_Drug_Dictionary_ID","value":"804149"},{"name":"NCI_META_CUI","value":"CL538249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162633":{"preferredName":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01","code":"C162633","definitions":[{"definition":"A peptide-based, personalized cancer vaccine consisting of patient-specific mutated long peptides, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized neoantigen peptide vaccine iNeo-Vac-P01, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01","termGroup":"PT","termSource":"NCI"},{"termName":"iNeo-Vac-P01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01"},{"name":"NCI_Drug_Dictionary_ID","value":"798703"},{"name":"NCI_META_CUI","value":"CL971029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798703"},{"name":"PDQ_Open_Trial_Search_ID","value":"798703"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158749":{"preferredName":"Personalized Neoepitope Yeast Vaccine YE-NEO-001","code":"C158749","definitions":[{"definition":"A cancer vaccine composed of a heat-killed yeast that has been genetically modified to express patient-specific neoantigen epitopes. Upon vaccination, neoepitope yeast vaccine YE-NEO-001 may elicit a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response against tumor cells expressing these specific epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoepitope Yeast Vaccine YE-NEO-001","termGroup":"PT","termSource":"NCI"},{"termName":"YE-NEO-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoepitope Yeast Vaccine YE-NEO-001"},{"name":"NCI_Drug_Dictionary_ID","value":"797413"},{"name":"NCI_META_CUI","value":"CL950715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797413"},{"name":"PDQ_Open_Trial_Search_ID","value":"797413"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129935":{"preferredName":"Personalized Peptide Cancer Vaccine NEO-PV-01","code":"C129935","definitions":[{"definition":"A synthetic peptide-based, personalized cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Peptide Cancer Vaccine NEO-PV-01","termGroup":"PT","termSource":"NCI"},{"termName":"NEO PV 01","termGroup":"CN","termSource":"NCI"},{"termName":"NEO-PV 01","termGroup":"CN","termSource":"NCI"},{"termName":"NEO-PV-01","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen-based Anticancer Vaccine NEO-PV-01","termGroup":"SY","termSource":"NCI"},{"termName":"Neoantigen-based Peptide Vaccine NEO-PV-01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Peptide Cancer Vaccine NEO-PV-01"},{"name":"NCI_META_CUI","value":"CL512888"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38692":{"preferredName":"Pertuzumab","code":"C38692","definitions":[{"definition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of cancer. Monoclonal antibodies are produced in the laboratory and can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pertuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"2C4","termGroup":"SY","termSource":"NCI"},{"termName":"2C4 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"BCD-178","termGroup":"CN","termSource":"NCI"},{"termName":"EG1206A","termGroup":"CN","termSource":"NCI"},{"termName":"HLX11","termGroup":"CN","termSource":"NCI"},{"termName":"HS627","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"MoAb 2C4","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody 2C4","termGroup":"SY","termSource":"NCI"},{"termName":"Omnitarg","termGroup":"SY","termSource":"NCI"},{"termName":"Perjeta","termGroup":"BR","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar BCD-178","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar EG1206A","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar HLX11","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar HS627","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar TQB2440","termGroup":"SY","termSource":"NCI"},{"termName":"Rhumab 2C4","termGroup":"SY","termSource":"NCI"},{"termName":"rhuMAb2C4","termGroup":"SY","termSource":"NCI"},{"termName":"RO4368451","termGroup":"CN","termSource":"NCI"},{"termName":"TQB 2440","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-2440","termGroup":"CN","termSource":"NCI"},{"termName":"TQB2440","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"380610-27-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K16AIQ8CTM"},{"name":"Legacy Concept Name","value":"Pertuzumab"},{"name":"Maps_To","value":"Pertuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"322808"},{"name":"NSC Number","value":"740102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"322808"},{"name":"PDQ_Open_Trial_Search_ID","value":"322808"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328025"}]}}{"C77906":{"preferredName":"Pevonedistat","code":"C77906","definitions":[{"definition":"A small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity. Pevonedistat binds to and inhibits NAE, which may result in the inhibition of tumor cell proliferation and survival. NAE activates Nedd8 (Neural precursor cell expressed, developmentally down-regulated 8), an ubiquitin-like (UBL) protein that modifies cellular targets in a pathway that is parallel to but distinct from the ubiquitin-proteasome pathway (UPP). Functioning in diverse regulatory activities, proteins conjugated to UBLs like Nedd8 typically are not targeted for proteasomal degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pevonedistat","termGroup":"PT","termSource":"NCI"},{"termName":"((1S,2S,4R)-4-(4-((1S)-2,3-Dihydro-1H-inden-1-ylamino)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulphamate","termGroup":"SN","termSource":"NCI"},{"termName":"MLN4924","termGroup":"CN","termSource":"NCI"},{"termName":"Nedd8-Activating Enzyme Inhibitor MLN4924","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"905579-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3AZD8D215"},{"name":"Legacy Concept Name","value":"NAE_Inhibitor_MLN4924"},{"name":"Maps_To","value":"Pevonedistat"},{"name":"NCI_Drug_Dictionary_ID","value":"596795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596795"},{"name":"PDQ_Open_Trial_Search_ID","value":"596795"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703093"}]}}{"C71533":{"preferredName":"Pexastimogene Devacirepvec","code":"C71533","definitions":[{"definition":"An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pexastimogene Devacirepvec","termGroup":"PT","termSource":"NCI"},{"termName":"JX 594","termGroup":"CN","termSource":"NCI"},{"termName":"JX-594","termGroup":"CN","termSource":"NCI"},{"termName":"JX594","termGroup":"CN","termSource":"NCI"},{"termName":"Pexa-vec","termGroup":"FB","termSource":"NCI"},{"termName":"TG-6006","termGroup":"CN","termSource":"NCI"},{"termName":"Thymidine Kinase (-) Vaccinia-GM-CSF JX-594 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Thymidine Kinase-deleted Vaccinia-hGM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"VAC GM-CSF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1058624-46-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K82DG47I0G"},{"name":"Legacy Concept Name","value":"Thymidine_Kinase-Deleted_Vaccinia-GM-CSF_JX-594_Vaccine"},{"name":"Maps_To","value":"Pexastimogene Devacirepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"579292"},{"name":"NCI_META_CUI","value":"CL378156"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579292"},{"name":"PDQ_Open_Trial_Search_ID","value":"579292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88303":{"preferredName":"Pexidartinib","code":"C88303","definitions":[{"definition":"A small-molecule receptor tyrosine kinase (RTK) inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), with antineoplastic activity. Upon oral administration, pexidartinib targets, binds to and inhibits phosphorylation of KIT, CSF1R and FLT3 harboring an internal tandem duplication (ITD) mutation. This results in the inhibition of tumor cell proliferation. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pexidartinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CML-261","termGroup":"CN","termSource":"NCI"},{"termName":"PLX3397","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1029044-16-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6783M2LV5X"},{"name":"Maps_To","value":"Pexidartinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981820"}]}}{"C85481":{"preferredName":"Pexmetinib","code":"C85481","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of p38 and Tie2 kinases with potential antineoplastic, anti-inflammatory and antiangiogenic activities. Pexmetinib binds to and inhibits the activities of p38 and Tie2 kinases, which may inhibit the production of proinflammatory cytokines and may decrease tumor angiogenesis and tumor cell growth and survival. p38 is a MAP kinase that is often upregulated in cancer cells, playing a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6. Tie2 is an endothelial cell specific receptor that is activated by angiopoietins, growth factors required for angiogenesis. This agent has also been reported to inhibit other kinases including vascular endothelial growth factor receptor (VEGFR2) and Src tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pexmetinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-614","termGroup":"CN","termSource":"NCI"},{"termName":"N-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)-N'-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945614-12-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3750D0U8B5"},{"name":"Maps_To","value":"Pexmetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"647828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647828"},{"name":"PDQ_Open_Trial_Search_ID","value":"647828"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830143"}]}}{"C78463":{"preferredName":"Odetiglucan","code":"C78463","definitions":[{"definition":"An injectable formulation of the polysaccharide beta-1,3/1,6 glucan derived from the cell wall of a strain from the yeast Saccharomyces cerevisiae and pathogen-associated molecular pattern (PAMP) molecule, with potential immunomodulating and antineoplastic activities. Upon administration, odetiglucan binds to innate immune effector cells through complement receptor 3 (CR3) and Fc gamma receptor IIA (FcgammaIIA; CD32A), thereby activating innate immune cells and enabling direct killing of tumor cells. In addition, odetiglucan repolarizes the immunosuppressive tumor microenvironment (TME), shifts the suppressive M2-state macrophages to a more M1 pro-inflammatory state, activates the maturation of antigen presenting cells (APCs), enables CD4 and CD8 T-cell expansion, and increases production of certain anti-tumor cytokines, such as interferon gamma (IFNg). Altogether, this induces and enhances anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odetiglucan","termGroup":"PT","termSource":"NCI"},{"termName":"BTH 1677","termGroup":"CN","termSource":"NCI"},{"termName":"BTH-1677","termGroup":"CN","termSource":"NCI"},{"termName":"BTH1677","termGroup":"CN","termSource":"NCI"},{"termName":"Imprime PGG","termGroup":"BR","termSource":"NCI"},{"termName":"PGG Beta-Glucan","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose Beta-glucan","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53238-80-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q6X9CNN54X"},{"name":"Legacy Concept Name","value":"PGG_Beta-Glucan"},{"name":"Maps_To","value":"PGG Beta-Glucan"},{"name":"NCI_Drug_Dictionary_ID","value":"599816"},{"name":"NCI_META_CUI","value":"CL387566"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599816"},{"name":"PDQ_Open_Trial_Search_ID","value":"599816"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71692":{"preferredName":"PGLA/PEG Copolymer-Based Paclitaxel","code":"C71692","definitions":[{"definition":"A controlled-release, intratumoral paclitaxel formulation in which paclitaxel is incorporated into a thermosensitive, biodegradable triblock copolymer consisting of poly(lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG). Upon intratumoral injection, paclitaxel is released slowly and continuously into tumor tissues from the gelled thermosensitive triblock copolymer over a period of 4 to 6 weeks; in tumor cells, paclitaxel binds to tubulin and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. The thermosensitive triblock copolymer component of this formulation transforms from a water-soluble polymer at room temperature to a water-insoluble, biodegradable gel depot at body temperature; intratumoral controlled-release of paclitaxel from the gel minimizes systemic exposure to paclitaxel and the paclitaxel toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PGLA/PEG Copolymer-Based Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"OncoGel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PGLA_PEG_Copolymer-Based_Paclitaxel"},{"name":"Maps_To","value":"PGLA/PEG Copolymer-Based Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"555445"},{"name":"NCI_META_CUI","value":"CL376115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"555445"},{"name":"PDQ_Open_Trial_Search_ID","value":"555445"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113790":{"preferredName":"PH20 Hyaluronidase-expressing Adenovirus VCN-01","code":"C113790","definitions":[{"definition":"An oncolytic, replication-competent adenovirus encoding the human glycosylphosphatidylinositol-anchored enzyme PH20 hyaluronidase with potential antitumor activity. After intratumoral administration, PH20 hyaluronidase-expressing adenovirus VCN-01 selectively replicates in tumor cells, which may both cause oncolytic virus-induced cell death and induce the infection of adjacent tumor cells. In addition, the virus expresses hyaluronidase, which hydrolyzes and degrades the hyaluronic acid (HA) that coats tumor cells. The degradation of HA may result in a decrease for both the viscosity of the interstitial space and the tumor's interstitial fluid pressure (IFP). This increases viral spread and may result in the inhibition of tumor cell growth. In addition, HA degradation facilitates the penetration of chemotherapeutic agents into the tumor. HA is a glycosaminoglycan found in the extracellular matrix (ECM) and is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increases in tumor cell growth, metastatic potential, tumor progression and resistance to chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PH20 Hyaluronidase-expressing Adenovirus VCN-01","termGroup":"PT","termSource":"NCI"},{"termName":"Genetically Modified Adenovirus-encoding Human PH20 Hyaluronidase VCN-01","termGroup":"SY","termSource":"NCI"},{"termName":"VCN-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PH20 Hyaluronidase-expressing Adenovirus VCN-01"},{"name":"NCI_Drug_Dictionary_ID","value":"757334"},{"name":"NCI_META_CUI","value":"CL471771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757334"},{"name":"PDQ_Open_Trial_Search_ID","value":"757334"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91739":{"preferredName":"Phaleria macrocarpa Extract DLBS-1425","code":"C91739","definitions":[{"definition":"An extract of the flesh from the fruit of Phaleria macrocarpa, an Indonesian herbal medicine, with potential antineoplastic activity. Although the active ingredients and exact components are unclear, gallic acid and its derivatives in DLBS-1425 appear to inhibit the phosphoinositide-3 kinase (PI3K)/protein kinase B (AKT) signaling pathway by reducing PI3K transcription followed by a reduction in AKT phosphorylation. This extract also appears to induce apoptosis through induction of pro-apoptotic genes such as BAX, BAD and PUMA and inhibition of the apoptosis suppressor Bcl-2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phaleria macrocarpa Extract DLBS-1425","termGroup":"PT","termSource":"NCI"},{"termName":"DLBS-1425","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phaleria macrocarpa Extract DLBS-1425"},{"name":"NCI_Drug_Dictionary_ID","value":"659153"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659153"},{"name":"PDQ_Open_Trial_Search_ID","value":"659153"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984527"}]}}{"C156461":{"preferredName":"Pharmacological Ascorbate","code":"C156461","definitions":[{"definition":"A high dose (HD) of ascorbic acid, a pro-oxidant agent, with potential antineoplastic and radio-chemo-sensitizing activities. Upon intravenous (IV) administration, pharmacological ascorbate is able to generate reactive oxygen species (ROS) by donating an electron to oxygen (O2) and forming hydrogen peroxide (H2O2), thereby causing oxidative stress and overwhelming the cell's anti-oxidant defense mechanisms. This induces DNA double-stranded breaks (DSBs) and cell death. Tumor cells are highly susceptible to ascorbate-mediated oxidative stress and cytotoxicity while normal, healthy cells are mostly unaffected. This induces the cell death of susceptible tumor cells and decreases tumor cell growth. Higher plasma ascorbate concentrations are achieved upon higher intravenous doses of ascorbate; oral administration of ascorbate is limited and uptake does not increase after a certain amount is administered. Only IV ascorbate produces plasma concentrations high enough to induce ascorbate-mediated cytotoxicity to susceptible tumor cells. In addition, HD parenteral ascorbate enhances radio- and chemo-sensitivity of susceptible cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pharmacological Ascorbate","termGroup":"PT","termSource":"NCI"},{"termName":"Ascorbate Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Ascorbic Acid Injection","termGroup":"SY","termSource":"NCI"},{"termName":"HD Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"HD P-AscH-","termGroup":"SY","termSource":"NCI"},{"termName":"HD Vitamin C","termGroup":"SY","termSource":"NCI"},{"termName":"High Dose Ascorbic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"High-dose Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"High-dose Ascorbic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"High-Dose Parenteral Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"High-Dose Vitamin C","termGroup":"SY","termSource":"NCI"},{"termName":"Intravenous Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"Intravenous High Dose Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"IV Ascorbate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharmacological Ascorbate"},{"name":"NCI_Drug_Dictionary_ID","value":"795829"},{"name":"NCI_META_CUI","value":"CL563189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795829"},{"name":"PDQ_Open_Trial_Search_ID","value":"795829"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103230":{"preferredName":"Phellodendron amurense Bark Extract","code":"C103230","definitions":[{"definition":"A proprietary formulation consisting of a Phellodendron amurense (Amur cork tree) bark extract, often used in traditional Chinese medicine, with anti-inflammatory, anti-oxidant and potential chemopreventive and antineoplastic activities. Phellodendron amurense bark extract contains certain isoquinoline alkaloids, flavone glycosides and phenolic compounds. Upon administration of Phellodendron amurense bark extract, the various phytochemicals in this formulation modulate multiple signal transduction pathways. This agent appears to block the activation of the transcription factor cAMP response binding protein (CREB) and inhibits Akt signaling, thereby inhibiting tumor cell growth and inducing apoptosis in Akt- and CREB-overexpressing cancer cells. In addition, this agent inhibits cyclooxygenase type 2 (COX-2), nuclear factor kappa b (NF-kB) and tumor necrosis factor alpha (TNF-a)-mediated signaling; COX-2, NF-kB and TNF-a are upregulated in certain types of cancer and during inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phellodendron amurense Bark Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Nexrutine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PBG27B754G"},{"name":"Maps_To","value":"Phellodendron amurense Bark Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"741824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741824"},{"name":"PDQ_Open_Trial_Search_ID","value":"741824"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3256251"}]}}{"C1190":{"preferredName":"Phenesterin","code":"C1190","definitions":[{"definition":"A steroidal nitrogen mustard with antineoplastic and mutagenic activities. After attachment to cell-surface steroid receptors and uptake, phenesterin enters the nucleus where it alkylates macromolecules, resulting in decreased cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenesterin","termGroup":"PT","termSource":"NCI"},{"termName":"(3-beta)-cholest-5-en-3-ol 4-(bis(2-chloroethyl)amino)benzeneacetate","termGroup":"SN","termSource":"NCI"},{"termName":"(4-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester","termGroup":"SN","termSource":"NCI"},{"termName":"(p-(bis(2-chloroethyl)amino)phenyl) acetate cholesterol","termGroup":"SN","termSource":"NCI"},{"termName":"(p-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester","termGroup":"SN","termSource":"NCI"},{"termName":"5-Cholesten-3-beta-ol 3-(p-(bis(2-chloroethyl)amino)phenyl)acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Cholest-5-en-3beta-ol 4-(bis(2-chloroethyl)amino)benzeneacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Cholesteryl p-bis(2-chloroethyl)aminophenylacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Fenesterin","termGroup":"SY","termSource":"NCI"},{"termName":"Fenestrin","termGroup":"SY","termSource":"NCI"},{"termName":"NCI-C01558","termGroup":"CN","termSource":"NCI"},{"termName":"p-bis(2-chloroethyl)amino phenylacetate cholesterol","termGroup":"SN","termSource":"NCI"},{"termName":"Phenesterine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3546-10-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"34021JC2Z6"},{"name":"Legacy Concept Name","value":"Phenesterin"},{"name":"Maps_To","value":"Phenesterin"},{"name":"NSC Number","value":"104469"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070556"}]}}{"C2233":{"preferredName":"Phenethyl Isothiocyanate","code":"C2233","definitions":[{"definition":"A substance being studied in the prevention of cancer. It is a naturally occurring compound found in some cruciferous vegetables.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An isothiocyanate found in cruciferous vegetables with chemopreventive and potential antitumor activities. Although the mechanism of action is unclear, phenethyl Isothiocyanate (PEITC) was shown to induce apoptosis in tumor cells, possibly mediated through its metabolic intermediates, reactive oxygen species (ROS). PEITC also is able to activate ERK and JNK signal transduction, which in turn induces expression of stress-responsive genes. Specifically, this agent has been shown to reactivate gene expression of a detoxification enzyme, glutathione S-transferase that is silenced in prostate carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenethyl Isothiocyanate","termGroup":"PT","termSource":"NCI"},{"termName":"(2-Isothiocyanatoethyl)benzene","termGroup":"SN","termSource":"NCI"},{"termName":"2-Phenylethyl Isothiocyanate","termGroup":"SN","termSource":"NCI"},{"termName":"PEITC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2257-09-2"},{"name":"CHEBI_ID","value":"CHEBI:351346"},{"name":"Chemical_Formula","value":"C9H9NS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6U7TFK75KV"},{"name":"Legacy Concept Name","value":"Phenethyl_Isothiocyanate"},{"name":"Maps_To","value":"Phenethyl Isothiocyanate"},{"name":"NCI_Drug_Dictionary_ID","value":"37977"},{"name":"NSC Number","value":"87868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37977"},{"name":"PDQ_Open_Trial_Search_ID","value":"37977"},{"name":"PubMedID_Primary_Reference","value":"16921492"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070558"}]}}{"C105392":{"preferredName":"Phenethyl Isothiocyanate-containing Watercress Juice","code":"C105392","definitions":[{"definition":"A juice extracted from watercress containing high amounts of phenethyl isothiocyanate (PEITC), with potential chemopreventive and antitumor activities. Although the mechanism(s) of action through which PEITC exerts its effect(s) has yet to be fully elucidated, PEITC is able to induce apoptosis in tumor cells through the induction of reactive oxygen species (ROS). Additionally, PEITC is able to modulate extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK) signal transduction pathways, activating the expression of stress-responsive genes and eventually inducing apoptosis. PEITC also inhibits the expression of genes involved in tumor progression such as HIF, STAT-3, HER2, BCL-XL, and XIAP and induces the expression of genes involved in tumor suppression such as p53, ATF-2, and p57. Furthermore, this agent has been shown to reactivate the gene expression of certain detoxification enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenethyl Isothiocyanate-containing Watercress Juice","termGroup":"PT","termSource":"NCI"},{"termName":"PEITC-containing Watercress Juice","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phenethyl Isothiocyanate-containing Watercress Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"746772"},{"name":"NCI_META_CUI","value":"CL446318"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746772"},{"name":"PDQ_Open_Trial_Search_ID","value":"746772"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1501":{"preferredName":"Phenyl Acetate","code":"C1501","definitions":[{"definition":"A drug being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenyl Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Acetic Acid Phenyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Acetylphenol","termGroup":"SY","termSource":"NCI"},{"termName":"Phenyl Acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adjunctive therapy for the prevention and treatment of hyperammonemia in the chronic management of patients with urea cycle enzymopathy"},{"name":"CAS_Registry","value":"122-79-2"},{"name":"CHEBI_ID","value":"CHEBI:8082"},{"name":"Chemical_Formula","value":"C8H8O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"355G9R500Y"},{"name":"Legacy Concept Name","value":"Phenyl_Acetate"},{"name":"Maps_To","value":"Phenyl Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"41664"},{"name":"NSC Number","value":"27795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41664"},{"name":"PDQ_Open_Trial_Search_ID","value":"41664"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0220893"}]}}{"C48011":{"preferredName":"Phenytoin Sodium","code":"C48011","definitions":[{"definition":"A drug used to treat or prevent seizures or convulsions that may be caused by epilepsy, brain surgery, or treatment for brain cancer. It is a type of anticonvulsant agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of phenytoin, a hydantoin derivate and non-sedative antiepileptic agent with anticonvulsant activity. Phenytoin sodium promotes sodium efflux from neurons located in the motor cortex, thereby stabilizing the neuron and inhibiting synaptic transmission. This leads to a reduction in posttetanic potentiation at synapses, an inhibition of repetitive firing of action potentials and ultimately inhibits the spread of seizure activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenytoin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"5,5-Diphenyl-2,4-imidazolidinedione, Monosodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Dilantin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"630-93-3"},{"name":"Chemical_Formula","value":"C15H11N2O2.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4182431BJH"},{"name":"Legacy Concept Name","value":"Phenytoin_Sodium"},{"name":"Maps_To","value":"Phenytoin Sodium"},{"name":"NSC Number","value":"8722"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0237417"}]}}{"C121375":{"preferredName":"Imifoplatin","code":"C121375","definitions":[{"definition":"A platinum (Pt)-based agent belonging to the phosphaplatin family comprised of Pt complexed to a pyrophosphate ligand, with potential antineoplastic activity. Although the exact mechanisms through which imifoplatin exerts its effect have yet to be fully elucidated, this agent, upon intravenous administration, binds to certain transmembrane proteins and activates several genes involved in tumor suppression and apoptosis. This leads to the activation of various signal transduction pathways, induces S/G2 phase cell cycle, and causes tumor cell apoptosis. In addition, imifoplatin may inhibit angiogenesis. Unlike conventional Pt-based chemotherapeutics, imifoplatin does not bind to DNA and is able to overcome drug resistance, which occurs with conventional Pt-based chemotherapeutics; it also has a more favorable side effect profile and is more stable in plasma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imifoplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclohexanediamine Pyrophosphatoplatinum(II), (1R,2R)-","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphaplatin PT-112","termGroup":"SY","termSource":"NCI"},{"termName":"PT 112","termGroup":"CN","termSource":"NCI"},{"termName":"PT-112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1339960-28-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F5I3T42BXC"},{"name":"Maps_To","value":"Imifoplatin"},{"name":"Maps_To","value":"Phosphaplatin PT-112"},{"name":"NCI_Drug_Dictionary_ID","value":"795706"},{"name":"NCI_META_CUI","value":"CL474103"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795706"},{"name":"PDQ_Open_Trial_Search_ID","value":"795706"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71883":{"preferredName":"Phosphatidylcholine-Bound Silybin","code":"C71883","definitions":[{"definition":"An oral preparation of the flavonoid silybin with potential antioxidant and chemopreventive activities. Silybin, also known as silibinin, is a mixture of two stereoisomers, denoted silybin A and silybin B, and is the major active constituent of silymarin, a mixture of flavonolignans extracted from blessed milk thistle (Silybum marianum). Silybin modulates P-glycoprotein (P-gp)-mediated cellular efflux; has oxygen radical-scavenging effects; inhibits the arachidonic acid pathway; and inhibits various cytochrome P450 enzymes. This agent may also exhibit anti-angiogenic activity, possibly by inducing endothelial cell apoptosis via modulation of the transcription factor NF-kB, the Bcl-2 family of proteins, and caspases. Complexing silybin with phosphatidylcholine increases its bioavailability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphatidylcholine-Bound Silybin","termGroup":"PT","termSource":"NCI"},{"termName":"Silybin-Phytosome","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Phosphatidylcholine-Bound_Silybin"},{"name":"Maps_To","value":"Phosphatidylcholine-Bound Silybin"},{"name":"NCI_Drug_Dictionary_ID","value":"558906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558906"},{"name":"PDQ_Open_Trial_Search_ID","value":"558906"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1873062"}]}}{"C84879":{"preferredName":"Iodine I 131 Iopofosine","code":"C84879","definitions":[{"definition":"A radioconjugate composed of iopofosine, a phospholipid ether analog, labeled with the radioactive isotope iodine I 131, with potential antineoplastic activity. Upon administration, iodine I 131 iopofosine selectively accumulates in and retains within tumor cells for a prolonged period of time due to the decreased activity of a phospholipase D (PLD) in tumor cells compared to normal cells, thereby delivering cytotoxic radiation specifically to tumor cells.  PLD is an enzyme found in the cell membrane of normal cells that degrades phospholipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Iopofosine","termGroup":"PT","termSource":"NCI"},{"termName":"131I-CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"131I-NM-404","termGroup":"SY","termSource":"NCI"},{"termName":"131I-NM404","termGroup":"SY","termSource":"NCI"},{"termName":"[(131)I]NM404","termGroup":"SY","termSource":"NCI"},{"termName":"[131I]-CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"CLR 131","termGroup":"CN","termSource":"NCI"},{"termName":"CLR 1404 I-131","termGroup":"SY","termSource":"NCI"},{"termName":"CLR-131","termGroup":"SY","termSource":"NCI"},{"termName":"CLR-1404 I-131","termGroup":"SY","termSource":"NCI"},{"termName":"CLR131","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 PLE Analogue CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"I-131-CLR1404","termGroup":"AB","termSource":"NCI"},{"termName":"I-131-CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"Iopofosine I 131","termGroup":"SY","termSource":"NCI"},{"termName":"NM-404 I-131","termGroup":"SY","termSource":"NCI"},{"termName":"PDC CLR 131","termGroup":"SY","termSource":"NCI"},{"termName":"Phospholipid Ether-drug Conjugate CLR 131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"873438-88-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R048696O9L"},{"name":"Maps_To","value":"Phospholipid Ether-drug Conjugate CLR 131"},{"name":"NCI_Drug_Dictionary_ID","value":"649140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649140"},{"name":"PDQ_Open_Trial_Search_ID","value":"649140"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045705"}]}}{"C29322":{"preferredName":"Phosphoramide Mustard","code":"C29322","definitions":[{"definition":"One of a number of chemically-related alkylating agents with antineoplastic properties.  The prototype of this group of agents is cyclophosphamide.  Most phosphoramide mustards are administered as prodrugs that undergo reductive activation in hypoxic environments to yield cytotoxic metabolites. These agents alkylate and crosslink DNA, resulting in inhibition of DNA replication. Phosphoramide mustards are also immunosuppressants, mutagens and teratogens. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphoramide Mustard","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:8163"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Phosphoramide_Mustard"},{"name":"Maps_To","value":"Phosphoramide Mustard"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0070913"}]}}{"C62518":{"preferredName":"Phosphorodiamidate Morpholino Oligomer AVI-4126","code":"C62518","definitions":[{"definition":"A c-Myc antisense phosphorodiamidate morpholino oligomer (PMO) with potential antineoplastic activity. Phosphorodiamidate morpholino oligomer AVI-4126 binds to c-Myc mRNA and blocks its translation, which may result in the death of tumor cells overexpressing c-Myc. Differing from traditional antisense oligodeoxynucleotides (ODNs), neutrally charged PMOs are composed of subunits of nucleic acid bases linked to a synthetic backbone and, so, are less prone to enzymatic degradation. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphorodiamidate Morpholino Oligomer AVI-4126","termGroup":"PT","termSource":"NCI"},{"termName":"AVI-4126","termGroup":"AB","termSource":"NCI"},{"termName":"Oncomyc-NG","termGroup":"SY","termSource":"NCI"},{"termName":"PMO AVI-4126","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AVI-4126"},{"name":"Maps_To","value":"Phosphorodiamidate Morpholino Oligomer AVI-4126"},{"name":"NCI_Drug_Dictionary_ID","value":"496940"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496940"},{"name":"PDQ_Open_Trial_Search_ID","value":"496940"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1450425"}]}}{"C1698":{"preferredName":"Phosphorus P-32","code":"C1698","definitions":[{"definition":"A radioactive form of phosphorus used in the treatment of cancer. It is also used to help locate areas of DNA damage.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphorus P-32","termGroup":"PT","termSource":"NCI"},{"termName":"P32","termGroup":"AB","termSource":"NCI"},{"termName":"Phosphorus P 32","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:37972"},{"name":"Chemical_Formula","value":"P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"690284A407"},{"name":"Legacy Concept Name","value":"Phosphorus-32"},{"name":"Maps_To","value":"Phosphorus P-32"},{"name":"NCI_Drug_Dictionary_ID","value":"39554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39554"},{"name":"PDQ_Open_Trial_Search_ID","value":"39554"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C0851287"}]}}{"C114382":{"preferredName":"Redaporfin","code":"C114382","definitions":[{"definition":"A bacteriochlorin-based photosensitizer, with antineoplastic activity upon photodynamic therapy (PDT). Following intravenous administration, redaporfin preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of laser light at the tumor site results in the absorption of light by this agent and a photodynamic reaction between LUZ 11 and oxygen. This results in the production of reactive oxygen species (ROS), which includes singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated DNA damage and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Redaporfin","termGroup":"PT","termSource":"NCI"},{"termName":"LUZ 11","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1224104-08-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZP3QP1H44W"},{"name":"Maps_To","value":"Photosensitizer LUZ 11"},{"name":"Maps_To","value":"Redaporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"758537"},{"name":"NCI_META_CUI","value":"CL471817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758537"},{"name":"PDQ_Open_Trial_Search_ID","value":"758537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126802":{"preferredName":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex","code":"C126802","definitions":[{"definition":"A photosensitizer composed of the sodium salt form of chlorin e6 and its derivatives complexed with a low-molecular weight polyvinylpyrrolidone (PVP) polymer component, with diagnostic and antineoplastic activities upon photodynamic therapy (PDT). Upon intravenous administration, the photosensitizer phytochlorin-PVP sodium complex preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of light with a certain wavelength to the tumor site results in the absorption of light by this agent leading to its photoactivation. This results in a photodynamic reaction between phytochlorin and oxygen, which causes the production of reactive oxygen species (ROS), including singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated oxidative DNA damage followed by apoptosis of tumor cells. Chlorin e6-PVP is able to penetrate deeply into tissues and is therefore able to treat hard-to-reach tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex","termGroup":"PT","termSource":"NCI"},{"termName":"BLC-1013","termGroup":"CN","termSource":"NCI"},{"termName":"Chlorin E6-polyvinylpyrrolidone","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorin E6-PVP","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorin E6/PVP","termGroup":"SY","termSource":"NCI"},{"termName":"Fotolon","termGroup":"FB","termSource":"NCI"},{"termName":"Photolon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"780299"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780299"},{"name":"PDQ_Open_Trial_Search_ID","value":"780299"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351765"}]}}{"C103861":{"preferredName":"PI3K Alpha/Beta Inhibitor BAY1082439","code":"C103861","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity. PI3K alpha/beta inhibitor BAY1082439 selectively inhibits both PI3K alpha, including mutated forms of PIK3CA, and PI3K beta in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K-expressing and/or PTEN-driven tumor cells. By specifically targeting class I PI3K alpha and beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in increased tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Alpha/Beta Inhibitor BAY1082439","termGroup":"PT","termSource":"NCI"},{"termName":"BAY1082439","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1375469-38-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"59784ZX4GD"},{"name":"Maps_To","value":"PI3K Alpha/Beta Inhibitor BAY1082439"},{"name":"NCI_Drug_Dictionary_ID","value":"743262"},{"name":"NCI_META_CUI","value":"CL438339"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743262"},{"name":"PDQ_Open_Trial_Search_ID","value":"743262"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97915":{"preferredName":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate","code":"C97915","definitions":[{"definition":"The mesylate salt form of PWT33597, an orally bioavailable dual inhibitor of phosphatidylinositide 3-kinase (PI3K) alpha and mammalian target of rapamycin (mTOR) kinase with potential antineoplastic activity. PI3K alpha/mTOR dual inhibitor PWT33597 selectively inhibits both PI3K alpha kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"PWT33597 Mesylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"708121"},{"name":"NCI_META_CUI","value":"CL430398"},{"name":"PDQ_Closed_Trial_Search_ID","value":"708121"},{"name":"PDQ_Open_Trial_Search_ID","value":"708121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95891":{"preferredName":"PI3K-delta Inhibitor AMG 319","code":"C95891","definitions":[{"definition":"A highly selective, potent, and orally bioavailable small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities.  PI3K-delta inhibitor AMG 319 prevents the activation of the PI3K signaling pathway through inhibition of the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), thus decreasing proliferation and inducing cell death.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-delta Inhibitor AMG 319","termGroup":"PT","termSource":"NCI"},{"termName":"ACP-319","termGroup":"CN","termSource":"NCI"},{"termName":"AMG 319","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor ACP-319","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1608125-21-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19DG7G1U5Q"},{"name":"Maps_To","value":"PI3K Inhibitor ACP-319"},{"name":"Maps_To","value":"PI3K-delta Inhibitor AMG 319"},{"name":"NCI_Drug_Dictionary_ID","value":"696292"},{"name":"NCI_META_CUI","value":"CL428288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696292"},{"name":"PDQ_Open_Trial_Search_ID","value":"696292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74073":{"preferredName":"PI3K Inhibitor BGT226","code":"C74073","definitions":[{"definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BGT226 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability; apoptotic cell death may ensue. Bax is a member of the proapoptotic Bcl2 family of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor BGT226","termGroup":"PT","termSource":"NCI"},{"termName":"BGT226","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-BGT-226","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-BGT226","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-BGT226 Free Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_BGT226"},{"name":"Maps_To","value":"PI3K Inhibitor BGT226"},{"name":"NCI_Drug_Dictionary_ID","value":"587478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587478"},{"name":"PDQ_Open_Trial_Search_ID","value":"587478"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347426"}]}}{"C116877":{"preferredName":"Paxalisib","code":"C116877","definitions":[{"definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. paxalisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paxalisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0084","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0084","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor GDC-0084","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1382979-44-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P5DKZ70636"},{"name":"Maps_To","value":"Paxalisib"},{"name":"Maps_To","value":"PI3K Inhibitor GDC-0084"},{"name":"NCI_Drug_Dictionary_ID","value":"728900"},{"name":"NCI_META_CUI","value":"CL446606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"728900"},{"name":"PDQ_Open_Trial_Search_ID","value":"728900"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132166":{"preferredName":"Inavolisib","code":"C132166","definitions":[{"definition":"An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inavolisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 0077","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0077","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0077","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor GDC0077","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6114","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6114","termGroup":"CN","termSource":"NCI"},{"termName":"RG6114","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7113755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2060571-02-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L4C1UY2NYH"},{"name":"Maps_To","value":"PI3K Inhibitor GDC0077"},{"name":"NCI_Drug_Dictionary_ID","value":"787122"},{"name":"NCI_META_CUI","value":"CL521134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787122"},{"name":"PDQ_Open_Trial_Search_ID","value":"787122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78470":{"preferredName":"PI3K Inhibitor GSK1059615","code":"C78470","definitions":[{"definition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GSK1059615 inhibits PI3K in the PI3K/AKT kinase signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane and an increase in mitochondrial membrane permeability, followed by apoptosis. Bax is a member of the proapoptotic Bcl-2 family of proteins. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor GSK1059615","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1059615","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"958852-01-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"07YMO87363"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_GSK1059615"},{"name":"Maps_To","value":"PI3K Inhibitor GSK1059615"},{"name":"NCI_Drug_Dictionary_ID","value":"600076"},{"name":"NCI_META_CUI","value":"CL387567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600076"},{"name":"PDQ_Open_Trial_Search_ID","value":"600076"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107386":{"preferredName":"PI3K Inhibitor WX-037","code":"C107386","definitions":[{"definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor WX-037 specifically inhibits PI3K, which prevents the activation of the PI3K/protein kinase B-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor WX-037","termGroup":"PT","termSource":"NCI"},{"termName":"WX-037","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K Inhibitor WX-037"},{"name":"NCI_Drug_Dictionary_ID","value":"750893"},{"name":"NCI_META_CUI","value":"CL449597"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750893"},{"name":"PDQ_Open_Trial_Search_ID","value":"750893"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95723":{"preferredName":"PI3K Inhibitor ZSTK474","code":"C95723","definitions":[{"definition":"An orally available, s-triazine derivative, ATP-competitive phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor ZSTK474 inhibits all four PI3K isoforms. Inhibiting the activation of the PI3K/AKT kinase (or protein kinase B) signaling pathway results in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. This agent does not induce apoptosis but rather induces strong G(0)/G(1) arrest, which might contribute to its favorable efficacy in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor ZSTK474","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol 3-kinase Inhibitor ZSTK474","termGroup":"SY","termSource":"NCI"},{"termName":"ZSTK474","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"475110-96-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K0068GK39A"},{"name":"Maps_To","value":"PI3K Inhibitor ZSTK474"},{"name":"NCI_Drug_Dictionary_ID","value":"694436"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694436"},{"name":"PDQ_Open_Trial_Search_ID","value":"694436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721602"}]}}{"C126271":{"preferredName":"PI3K p110beta/delta Inhibitor CVL237","code":"C126271","definitions":[{"definition":"A dual selective inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K-beta/delta), with potential antineoplastic activity. PI3K-beta/delta inhibitor CVL237 selectively inhibits the PI3K-beta and -delta isoforms and prevents their activation, which inhibits PI3K-beta/delta-mediated signal transduction pathways. This decreases proliferation and induces cell death in susceptible tumor cells. Unlike other isoforms of PI3K, PI3K-beta and -delta are overexpressed primarily in solid and hematological tumor cells and play crucial roles in tumor cell survival, and immunoregulation. The targeted inhibition of these PI3Ks allows this agent to potentially be more efficacious and less toxic than pan PI3K inhibitors, which also affect normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K p110beta/delta Inhibitor CVL237","termGroup":"PT","termSource":"NCI"},{"termName":"CVL 237","termGroup":"CN","termSource":"NCI"},{"termName":"CVL-237","termGroup":"CN","termSource":"NCI"},{"termName":"CVL237","termGroup":"CN","termSource":"NCI"},{"termName":"KA 2237","termGroup":"CN","termSource":"NCI"},{"termName":"KA2237","termGroup":"CN","termSource":"NCI"},{"termName":"PI3 Kinase b/d Inhibitor KA2237","termGroup":"SY","termSource":"NCI"},{"termName":"PI3K p110beta/delta Inhibitor KA2237","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K p110beta/delta Inhibitor KA2237"},{"name":"NCI_Drug_Dictionary_ID","value":"779211"},{"name":"NCI_META_CUI","value":"CL504848"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158603":{"preferredName":"Izorlisib","code":"C158603","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. Upon administration, izorlisib selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, izorlisib may be more efficacious and less toxic than pan-PI3K inhibitors. In addition, izorlisib also targets mutated forms of PI3K gamma (PI3Kg). It may also stimulate the immune system to restore CD8+ T-cell activation and cytotoxicity. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. In most solid tumors, the activation of the PI3K pathway is induced by mutations of PIK3CA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Izorlisib","termGroup":"PT","termSource":"NCI"},{"termName":"5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-selective PI3K Inhibitor MEN1611","termGroup":"SY","termSource":"NCI"},{"termName":"CH 5132799","termGroup":"CN","termSource":"NCI"},{"termName":"CH-5132799","termGroup":"CN","termSource":"NCI"},{"termName":"CH5132799","termGroup":"CN","termSource":"NCI"},{"termName":"MEN 1611","termGroup":"CN","termSource":"NCI"},{"termName":"MEN-1611","termGroup":"CN","termSource":"NCI"},{"termName":"MEN1611","termGroup":"CN","termSource":"NCI"},{"termName":"PA 799","termGroup":"CN","termSource":"NCI"},{"termName":"PA-799","termGroup":"CN","termSource":"NCI"},{"termName":"PA799","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K-alpha Inhibitor MEN1611","termGroup":"SY","termSource":"NCI"},{"termName":"PI3Kalpha Inhibitor MEN1611","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1007207-67-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JCL936W835"},{"name":"Maps_To","value":"PI3K-alpha Inhibitor MEN1611"},{"name":"NCI_Drug_Dictionary_ID","value":"797093"},{"name":"NCI_META_CUI","value":"CL938076"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797093"},{"name":"PDQ_Open_Trial_Search_ID","value":"797093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106261":{"preferredName":"PI3K-beta Inhibitor GSK2636771","code":"C106261","definitions":[{"definition":"An orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-beta Inhibitor GSK2636771","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2636771","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1372540-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DW94IAT0LS"},{"name":"Maps_To","value":"PI3K-beta Inhibitor GSK2636771"},{"name":"NCI_Drug_Dictionary_ID","value":"715683"},{"name":"NCI_META_CUI","value":"CL433894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715683"},{"name":"PDQ_Open_Trial_Search_ID","value":"715683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116882":{"preferredName":"PI3K-beta Inhibitor SAR260301","code":"C116882","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor SAR260301 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in apoptosis and growth inhibition in PI3K beta-expressing and/or phosphatase and tensin homolog (PTEN)-deficient tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and contributes to increased tumor cell growth, tumor cell survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan-PI3K inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-beta Inhibitor SAR260301","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"SAR 260301","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-260301","termGroup":"CN","termSource":"NCI"},{"termName":"SAR260301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260612-13-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33639WNC7Q"},{"name":"Maps_To","value":"PI3K-beta Inhibitor SAR260301"},{"name":"NCI_Drug_Dictionary_ID","value":"739784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739784"},{"name":"PDQ_Open_Trial_Search_ID","value":"739784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852556"}]}}{"C148532":{"preferredName":"Amdizalisib","code":"C148532","definitions":[{"definition":"An orally bioavailable selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (phosphoinositide 3'-kinase delta; PI3Kd; PI3K-d), with potential antineoplastic activity. Upon oral administration, amdizalisib selectively binds to and inhibits PI3Kd, and prevents the activation of the PI3Kd/AKT signaling pathway, and B-cell activation. This both decreases proliferation and induces cell death in PI3Kd-overexpressing tumor cells. PI3Kd plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of hematologic cancer cells. The targeted inhibition of PI3Kd is designed to preserve PI3K signaling in normal, non-neoplastic cells and thereby to minimize serious side effects. PI3Kd, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amdizalisib","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL 689","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-689","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL689","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K-d Inhibitor HMPL 689","termGroup":"SY","termSource":"NCI"},{"termName":"PI3K-delta Inhibitor HMPL 689","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1894229-05-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3YMY7783P"},{"name":"Maps_To","value":"PI3K-delta Inhibitor HMPL 689"},{"name":"NCI_Drug_Dictionary_ID","value":"792706"},{"name":"NCI_META_CUI","value":"CL551137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792706"},{"name":"PDQ_Open_Trial_Search_ID","value":"792706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113434":{"preferredName":"Parsaclisib","code":"C113434","definitions":[{"definition":"An inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parsaclisib","termGroup":"PT","termSource":"NCI"},{"termName":"(4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one","termGroup":"SY","termSource":"NCI"},{"termName":"IBI376","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 50465","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-50465","termGroup":"CN","termSource":"NCI"},{"termName":"INCB050465","termGroup":"CN","termSource":"NCI"},{"termName":"INCB50465","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10589","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1426698-88-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OS7097575K"},{"name":"Maps_To","value":"Parsaclisib"},{"name":"Maps_To","value":"PI3K-delta Inhibitor INCB050465"},{"name":"NCI_Drug_Dictionary_ID","value":"756266"},{"name":"NCI_META_CUI","value":"CL458228"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756266"},{"name":"PDQ_Open_Trial_Search_ID","value":"756266"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123925":{"preferredName":"Zandelisib","code":"C123925","definitions":[{"definition":"An orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zandelisib","termGroup":"PT","termSource":"NCI"},{"termName":"ME 401","termGroup":"CN","termSource":"NCI"},{"termName":"ME-401","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K-delta Inhibitor PWT143","termGroup":"SY","termSource":"NCI"},{"termName":"PWT-143","termGroup":"CN","termSource":"NCI"},{"termName":"PWT143","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401436-95-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8Z28M5SX0X"},{"name":"Maps_To","value":"PI3K-delta Inhibitor PWT143"},{"name":"Maps_To","value":"Zandelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"775930"},{"name":"NCI_META_CUI","value":"CL498289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775930"},{"name":"PDQ_Open_Trial_Search_ID","value":"775930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165266":{"preferredName":"PI3K-delta Inhibitor SHC014748M","code":"C165266","definitions":[{"definition":"An orally available selective inhibitor of the delta isoform of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, PI3K delta inhibitor SHC014748M selectively binds to and inhibits PI3K delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K delta over-expressing tumor cells. PI3K delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-delta Inhibitor SHC014748M","termGroup":"PT","termSource":"NCI"},{"termName":"PI3Kd Inhibitor SHC014748M","termGroup":"SY","termSource":"NCI"},{"termName":"SHC 014748M","termGroup":"CN","termSource":"NCI"},{"termName":"SHC-014748M","termGroup":"CN","termSource":"NCI"},{"termName":"SHC014748M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K-delta Inhibitor SHC014748M"},{"name":"NCI_Drug_Dictionary_ID","value":"799414"},{"name":"NCI_META_CUI","value":"CL978533"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799414"},{"name":"PDQ_Open_Trial_Search_ID","value":"799414"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158508":{"preferredName":"Linperlisib","code":"C158508","definitions":[{"definition":"An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linperlisib","termGroup":"PT","termSource":"NCI"},{"termName":"PI3K-delta Inhibitor YY-20394","termGroup":"SY","termSource":"NCI"},{"termName":"YY 20394","termGroup":"CN","termSource":"NCI"},{"termName":"YY-20394","termGroup":"CN","termSource":"NCI"},{"termName":"YY20394","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1702816-75-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05HYK3CV9N"},{"name":"Maps_To","value":"Linperlisib"},{"name":"Maps_To","value":"PI3K-delta Inhibitor YY-20394"},{"name":"NCI_Drug_Dictionary_ID","value":"797151"},{"name":"NCI_META_CUI","value":"CL938053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797151"},{"name":"PDQ_Open_Trial_Search_ID","value":"797151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125471":{"preferredName":"Eganelisib","code":"C125471","definitions":[{"definition":"An orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eganelisib","termGroup":"PT","termSource":"NCI"},{"termName":"IPI 549","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-549","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1693758-51-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FOF5155FMZ"},{"name":"Maps_To","value":"PI3K-gamma Inhibitor IPI-549"},{"name":"NCI_Drug_Dictionary_ID","value":"778361"},{"name":"NCI_META_CUI","value":"CL504218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778361"},{"name":"PDQ_Open_Trial_Search_ID","value":"778361"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148229":{"preferredName":"PI3K/BET Inhibitor LY294002","code":"C148229","definitions":[{"definition":"A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/BET Inhibitor LY294002","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","termGroup":"SY","termSource":"NCI"},{"termName":"2-Morpholin-4-yl-8-phenylchromen-4-one","termGroup":"SY","termSource":"NCI"},{"termName":"4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-","termGroup":"SN","termSource":"NCI"},{"termName":"LY 294002","termGroup":"CN","termSource":"NCI"},{"termName":"LY-294002","termGroup":"CN","termSource":"NCI"},{"termName":"LY294002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154447-36-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31M2U1DVID"},{"name":"Maps_To","value":"PI3K/BET Inhibitor LY294002"},{"name":"NCI_META_CUI","value":"CL550844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97254":{"preferredName":"PI3K/mTOR Kinase Inhibitor DS-7423","code":"C97254","definitions":[{"definition":"An orally bioavailable inhibitor of phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor DS-7423 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor DS-7423","termGroup":"PT","termSource":"NCI"},{"termName":"DS-7423","termGroup":"CN","termSource":"NCI"},{"termName":"Dual PI3 Kinase/mTOR Inhibitor DS-7423","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor DS-7423"},{"name":"NCI_Drug_Dictionary_ID","value":"701858"},{"name":"NCI_META_CUI","value":"CL429785"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701858"},{"name":"PDQ_Open_Trial_Search_ID","value":"701858"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84837":{"preferredName":"PI3K/mTOR Kinase Inhibitor PF-04691502","code":"C84837","definitions":[{"definition":"An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor PF-04691502 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor PF-04691502","termGroup":"PT","termSource":"NCI"},{"termName":"PF-04691502","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1013101-36-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4W39NS61KI"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor PF-04691502"},{"name":"NCI_Drug_Dictionary_ID","value":"649523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649523"},{"name":"PDQ_Open_Trial_Search_ID","value":"649523"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827515"}]}}{"C112497":{"preferredName":"PI3K/mTOR Kinase Inhibitor VS-5584","code":"C112497","definitions":[{"definition":"A potent and selective inhibitor of both phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor VS-5584 inhibits mTOR kinase and all class I PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR is a serine/threonine kinase downstream of PI3K, which also has PI3K-independent activity. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor VS-5584","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrimidinamine, 5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2-","termGroup":"SN","termSource":"NCI"},{"termName":"5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2-Pyrimidinamine","termGroup":"SN","termSource":"NCI"},{"termName":"PI3K/mTOR Inhibitor VS-5584","termGroup":"SY","termSource":"NCI"},{"termName":"SB 2343","termGroup":"SY","termSource":"NCI"},{"termName":"SB-2343","termGroup":"SY","termSource":"NCI"},{"termName":"SB2343","termGroup":"SY","termSource":"NCI"},{"termName":"VS 5584","termGroup":"SY","termSource":"NCI"},{"termName":"VS-5584","termGroup":"CN","termSource":"NCI"},{"termName":"VS5584","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1246560-33-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W71J4X250V"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor VS-5584"},{"name":"NCI_Drug_Dictionary_ID","value":"755179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755179"},{"name":"PDQ_Open_Trial_Search_ID","value":"755179"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3711165"}]}}{"C159499":{"preferredName":"PI3K/mTOR Kinase Inhibitor WXFL10030390","code":"C159499","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of certain phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon oral administration, PI3K/mTOR inhibitor WXFL10030390 (WX390) inhibits mTOR kinase and certain PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor WXFL10030390","termGroup":"PT","termSource":"NCI"},{"termName":"PI3K/mTOR Kinase Inhibitor WX390","termGroup":"SY","termSource":"NCI"},{"termName":"WX 390","termGroup":"CN","termSource":"NCI"},{"termName":"WX-390","termGroup":"SY","termSource":"NCI"},{"termName":"WX390","termGroup":"CN","termSource":"NCI"},{"termName":"WXFL 10030390","termGroup":"CN","termSource":"NCI"},{"termName":"WXFL-10030390","termGroup":"SY","termSource":"NCI"},{"termName":"WXFL10030390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor WXFL10030390"},{"name":"NCI_Drug_Dictionary_ID","value":"797519"},{"name":"NCI_META_CUI","value":"CL951457"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797519"},{"name":"PDQ_Open_Trial_Search_ID","value":"797519"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104292":{"preferredName":"Panulisib","code":"C104292","definitions":[{"definition":"An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, panulisib inhibits the activity of all four kinases. This prevents PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor types and increases endothelial cell proliferation and migration. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Panulisib","termGroup":"PT","termSource":"NCI"},{"termName":"AK15176","termGroup":"CN","termSource":"NCI"},{"termName":"P7170","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1356033-60-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9WA04F921"},{"name":"Maps_To","value":"Panulisib"},{"name":"Maps_To","value":"PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170"},{"name":"NCI_Drug_Dictionary_ID","value":"745036"},{"name":"NCI_META_CUI","value":"CL445627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745036"},{"name":"PDQ_Open_Trial_Search_ID","value":"745036"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116351":{"preferredName":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901","code":"C116351","definitions":[{"definition":"An inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity. Upon intravenous infusion, PI3K/mTORC1/mTORC2 inhibitor DCBCI0901 binds to and inhibits PI3K as well as both mTORC1 and mTORC2, which may result in both apoptosis and a decrease in cell proliferation in tumor cells overexpressing PI3K, mTORC1, and mTORC2. Activation of the PI3K/mTOR signaling pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901","termGroup":"PT","termSource":"NCI"},{"termName":"DCBCI0901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901"},{"name":"NCI_Drug_Dictionary_ID","value":"761750"},{"name":"NCI_META_CUI","value":"CL473670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761750"},{"name":"PDQ_Open_Trial_Search_ID","value":"761750"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90291":{"preferredName":"PI3Ka/mTOR Inhibitor PKI-179","code":"C90291","definitions":[{"definition":"A second generation, small-molecule mimetic of ATP that targets the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. PKI-179 selectively inhibits mTOR and phosphoinositide-3-kinase (PI3K) alpha. By inhibiting the PI3K/mTOR signaling pathway, this agent may inhibit tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Ka/mTOR Inhibitor PKI-179","termGroup":"PT","termSource":"NCI"},{"termName":"PKI-179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1197160-28-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CNN7Y60164"},{"name":"Maps_To","value":"PI3Ka/mTOR Inhibitor PKI-179"},{"name":"NCI_Drug_Dictionary_ID","value":"658412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658412"},{"name":"PDQ_Open_Trial_Search_ID","value":"658412"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933673"}]}}{"C118624":{"preferredName":"PI3Kalpha Inhibitor AZD8835","code":"C118624","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor AZD8835 selectively binds to and inhibits PIK3CA and its mutated forms, in the PI3K/Akt (protein kinase B) /mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, this agent may be more efficacious and less toxic than pan-PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Kalpha Inhibitor AZD8835","termGroup":"PT","termSource":"NCI"},{"termName":"AZD8835","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620576-64-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B97A88D35"},{"name":"Maps_To","value":"PI3Kalpha Inhibitor AZD8835"},{"name":"NCI_Drug_Dictionary_ID","value":"765451"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765451"},{"name":"PDQ_Open_Trial_Search_ID","value":"765451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896907"}]}}{"C107684":{"preferredName":"PI3Kbeta Inhibitor AZD8186","code":"C107684","definitions":[{"definition":"An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation and induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Kbeta Inhibitor AZD8186","termGroup":"PT","termSource":"NCI"},{"termName":"AZD-8186","termGroup":"CN","termSource":"NCI"},{"termName":"AZD8186","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1296270-45-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AIQ4OWD0RA"},{"name":"Maps_To","value":"PI3Kbeta Inhibitor AZD8186"},{"name":"NCI_Drug_Dictionary_ID","value":"751594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751594"},{"name":"PDQ_Open_Trial_Search_ID","value":"751594"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827157"}]}}{"C121374":{"preferredName":"PI3Kdelta Inhibitor GS-9901","code":"C121374","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3Kdelta) with potential immunomodulating and antineoplastic activities. Upon oral administration, PI3Kdelta inhibitor GS-9901 selectively binds to the delta isoform of PI3K and inhibits its activity. This inhibits the activation of the PI3Kdelta-mediated signaling pathway and prevents proliferation of PI3Kdelta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is expressed primarily in certain tumor cell types and plays a key role in tumor cell proliferation, motility and survival. The targeted inhibition of PI3Kdelta is designed to preserve PI3K signaling in normal, non-neoplastic cells and thus reduces toxicity to normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Kdelta Inhibitor GS-9901","termGroup":"PT","termSource":"NCI"},{"termName":"GS-9901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1640247-87-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U09Q76B8VK"},{"name":"Maps_To","value":"PI3Kdelta Inhibitor GS-9901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053639"}]}}{"C546":{"preferredName":"Pibenzimol","code":"C546","definitions":[{"definition":"A fluorescent dye of benzimidazole derivative.  Pibenzimol binds to AT-specific sites in the minor groove of duplex DNA and inhibits topoisomerase I, and DNA polymerase, thereby preventing DNA replication. This agent prolongs the G2 phase of the cell cycle and initiates apoptosis in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pibenzimol","termGroup":"PT","termSource":"NCI"},{"termName":"Bisbenzimidazole","termGroup":"SY","termSource":"NCI"},{"termName":"HOE 33258","termGroup":"CN","termSource":"NCI"},{"termName":"Hoechst 33258","termGroup":"CN","termSource":"NCI"},{"termName":"Hoechst Dye 33258","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 4-(5-(4-methyl-1-piperazinyl)(2,5'-bi-1H-benzimidazol)-2'-yl)-, Trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Phenol, p-[5-[5-(4-methyl-1-piperazinyl)-2-benzimidazolyl]-2- benzimidazolyl]-, Trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Pibenzimol Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23491-45-4"},{"name":"CHEBI_ID","value":"CHEBI:52082"},{"name":"Chemical_Formula","value":"C25H24N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LHQ7J5KV9B"},{"name":"Legacy Concept Name","value":"Pibenzimol"},{"name":"Maps_To","value":"Pibenzimol"},{"name":"NCI_Drug_Dictionary_ID","value":"39193"},{"name":"NSC Number","value":"322921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39193"},{"name":"PDQ_Open_Trial_Search_ID","value":"39193"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0019832"}]}}{"C1542":{"preferredName":"Pibrozelesin","code":"C1542","definitions":[{"definition":"A semisynthetic anticancer drug that is a type of antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2.  Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pibrozelesin","termGroup":"PT","termSource":"NCI"},{"termName":"Benzo(1,2-b:4,3-b')dipyrrole-1-carboxylic Acid, 8-(bromomethyl)-3,6,7,8-tetrahydro-2-methy-4-(((4-methyl-1-piperazinyl)carbonyl)oxy)-6-((5,6,7,-trimethoxy-1H-indol-2-yl)carbonyl)-, Methyl Ester (S)","termGroup":"SN","termSource":"NCI"},{"termName":"Duocamycin B2 Analog","termGroup":"SY","termSource":"NCI"},{"termName":"KW 2189","termGroup":"CN","termSource":"NCI"},{"termName":"KW-2189","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154889-68-6"},{"name":"Chemical_Formula","value":"C32H36BrN5O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IHK933KCIC"},{"name":"Legacy Concept Name","value":"KW_2189"},{"name":"Maps_To","value":"Pibrozelesin"},{"name":"NCI_Drug_Dictionary_ID","value":"42429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42429"},{"name":"PDQ_Open_Trial_Search_ID","value":"42429"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0254093"}]}}{"C73816":{"preferredName":"Pibrozelesin Hydrobromide","code":"C73816","definitions":[{"definition":"The hydrobromide salt form of pibrozelesin, a semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2, with antineoplastic activity. Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pibrozelesin Hydrobromide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"148778-32-9"},{"name":"Chemical_Formula","value":"C32H36BrN5O8.BrH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0481JCC90T"},{"name":"Legacy Concept Name","value":"Pibrozelesin_Hydrobromide"},{"name":"Maps_To","value":"Pibrozelesin Hydrobromide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347514"}]}}{"C745":{"preferredName":"Picibanil","code":"C745","definitions":[{"definition":"A lyophilized formulation containing cultures of a low-virulent strain of Streptococcus pyogenes, treated and killed with penicillin G, with potential sclerosing, immunostimulating and antineoplastic activity. Besides from picibanil's direct damaging effect as a sclerosing agent, it seems to have multiple effects on the immune system as a non-specific immunostimulant.  Picibanil activates the host immune system by stimulating the activity of natural killer cells, macrophages and lymphocytes, and by enhancing the production of several key immune mediators, including interleukins and tumor necrosis factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Picibanil","termGroup":"PT","termSource":"NCI"},{"termName":"OK-432","termGroup":"CN","termSource":"NCI"},{"termName":"Picibanil","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"39325-01-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2F42BH7X2L"},{"name":"Legacy Concept Name","value":"OK-432"},{"name":"Maps_To","value":"Picibanil"},{"name":"NCI_Drug_Dictionary_ID","value":"489137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489137"},{"name":"PDQ_Open_Trial_Search_ID","value":"489137"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0031875"}]}}{"C48416":{"preferredName":"Picoplatin","code":"C48416","definitions":[{"definition":"A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer.  It belongs to the family of drugs called platinum analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Picoplatin","termGroup":"PT","termSource":"NCI"},{"termName":"AMD473","termGroup":"CN","termSource":"NCI"},{"termName":"Cis-Amminedichloro (2-Methylpyridine) Platinum (II)","termGroup":"SN","termSource":"NCI"},{"termName":"JM473","termGroup":"CN","termSource":"NCI"},{"termName":"NX-473","termGroup":"CN","termSource":"NCI"},{"termName":"Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)-","termGroup":"SN","termSource":"NCI"},{"termName":"ZD0473","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"181630-15-9"},{"name":"Chemical_Formula","value":"C6H7N.2Cl.Pt.H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B5TAN0L720"},{"name":"Legacy Concept Name","value":"Picoplatin"},{"name":"Maps_To","value":"Picoplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"441243"},{"name":"PDQ_Closed_Trial_Search_ID","value":"441243"},{"name":"PDQ_Open_Trial_Search_ID","value":"441243"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0671135"}]}}{"C1771":{"preferredName":"Picrasinoside H","code":"C1771","definitions":[{"definition":"A quassinoid glycoside phytochemical isolated from the plant Picrasma ailanthoides with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Picrasinoside H","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-2-en-1-one, 13-(acetyloxy)-16-(beta-D-glucopyranosyloxy)-2-methoxy-11,12-(methylenebis(oxy))-, (11alpha,12beta,16alpha)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135638-54-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Picrasinoside_H"},{"name":"Maps_To","value":"Picrasinoside H"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0648685"}]}}{"C87736":{"preferredName":"Picropodophyllin","code":"C87736","definitions":[{"definition":"A cyclolignan alkaloid found in the mayapple plant family (Podophyllum peltatum), and a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Picropodophyllin specifically inhibits the activity and downregulates the cellular expression of IGF1R without interfering with activities of other growth factor receptors, such as receptors for insulin, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and mast/stem cell growth factor (KIT). This agent shows potent activity in the suppression o f tumor cell proliferation and the induction of tumor cell apoptosis. IGF1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a critical role in the growth and survival of many types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Picropodophyllin","termGroup":"PT","termSource":"NCI"},{"termName":"AXL1717","termGroup":"CN","termSource":"NCI"},{"termName":"Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one,5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-,(5R-(5-alpha,5a-alpha,8a-alpha,9-alpha))-","termGroup":"SN","termSource":"NCI"},{"termName":"Picropodophyllotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"477-47-4"},{"name":"Chemical_Formula","value":"C22H22O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0F35AOI227"},{"name":"Maps_To","value":"Picropodophyllin"},{"name":"NCI_Drug_Dictionary_ID","value":"729917"},{"name":"NSC Number","value":"36407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729917"},{"name":"PDQ_Open_Trial_Search_ID","value":"729917"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0961664"}]}}{"C165479":{"preferredName":"Pictilisib","code":"C165479","definitions":[{"definition":"A small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pictilisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-(1H-indazol-4-yl)-6-((4-(methanesulfonyl)piperazin-1-yl)methyl)-4-(morpholin-4-yl)thieno(3,2-d)pyrimidine","termGroup":"SY","termSource":"NCI"},{"termName":"4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno(3,2-d)pyrimidin-4-yl)morpholine","termGroup":"SY","termSource":"NCI"},{"termName":"GDC 0941","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0941","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0941","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"957054-30-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ICY00EMP8P"},{"name":"Maps_To","value":"Pictilisib"},{"name":"NCI_META_CUI","value":"CL978574"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82380":{"preferredName":"Pictilisib Bismesylate","code":"C82380","definitions":[{"definition":"The orally bioavailable bismesylate salt of pictilisib, a small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pictilisib Bismesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine, bimesylate salt","termGroup":"SN","termSource":"NCI"},{"termName":"GDC-0941 Bismesylate","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0941 Dimesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Pictilisib Dimesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Thieno(3,2-d)pyrimidine, 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)-, Methanesulfonate (1:2)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"957054-33-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G3D7HF2GS9"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_GDC-0941_Bismesylate"},{"name":"Maps_To","value":"Pictilisib Bismesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"641462"},{"name":"NCI_META_CUI","value":"CL408651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641462"},{"name":"PDQ_Open_Trial_Search_ID","value":"641462"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71014":{"preferredName":"Pidilizumab","code":"C71014","definitions":[{"definition":"A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pidilizumab","termGroup":"PT","termSource":"NCI"},{"termName":"CT 011","termGroup":"CN","termSource":"NCI"},{"termName":"CT-011","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal CT-011 Gamma1 Heavy Chain (220-213')-disulfide with Humanized Mouse Monoclonal CT-011 Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide, Glycosylated (CT-011 is Expressed in NSO Cells)","termGroup":"SN","termSource":"NCI"},{"termName":"MDV9300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1036730-42-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"B932PAQ1BQ"},{"name":"Legacy Concept Name","value":"Anti-PD-1_Monoclonal_Antibody_CT-011"},{"name":"Maps_To","value":"Pidilizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"573227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573227"},{"name":"PDQ_Open_Trial_Search_ID","value":"573227"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346821"}]}}{"C71705":{"preferredName":"Pilaralisib","code":"C71705","definitions":[{"definition":"An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Pilaralisib reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilaralisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino-N-(3-(N-(3-((2-chloro-5-methoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide","termGroup":"SY","termSource":"NCI"},{"termName":"SAR245408","termGroup":"CN","termSource":"NCI"},{"termName":"XL 147","termGroup":"CN","termSource":"NCI"},{"termName":"XL-147","termGroup":"CN","termSource":"NCI"},{"termName":"XL147","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934526-89-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"60ES45KTMK"},{"name":"Legacy Concept Name","value":"PI3K_Family_Kinase_Inhibitor_XL147"},{"name":"Maps_To","value":"Pilaralisib"},{"name":"NCI_Drug_Dictionary_ID","value":"558909"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558909"},{"name":"PDQ_Open_Trial_Search_ID","value":"558909"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347424"}]}}{"C106259":{"preferredName":"PIM Kinase Inhibitor LGH447","code":"C106259","definitions":[{"definition":"An orally available pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor LGH447 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of the pro-apoptotic Bcl2 protein and tumor cell apoptosis in cells that overexpress PIMs. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM Kinase Inhibitor LGH447","termGroup":"PT","termSource":"NCI"},{"termName":"LGH-447","termGroup":"CN","termSource":"NCI"},{"termName":"LGH447","termGroup":"CN","termSource":"NCI"},{"termName":"PIM 447","termGroup":"CN","termSource":"NCI"},{"termName":"PIM-447","termGroup":"CN","termSource":"NCI"},{"termName":"PIM447","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1210608-43-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9TG5O4V25H"},{"name":"Maps_To","value":"PIM Kinase Inhibitor LGH447"},{"name":"NCI_Drug_Dictionary_ID","value":"715643"},{"name":"NCI_META_CUI","value":"CL433893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715643"},{"name":"PDQ_Open_Trial_Search_ID","value":"715643"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82404":{"preferredName":"PIM Kinase Inhibitor SGI-1776","code":"C82404","definitions":[{"definition":"A small-molecule pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor SGI-1776 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of pro-apoptotic Bcl2 proteins and tumor cell apoptosis. PIM kinases play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM Kinase Inhibitor SGI-1776","termGroup":"PT","termSource":"NCI"},{"termName":"SGI-1776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1025065-69-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"72AUA0603W"},{"name":"Legacy Concept Name","value":"Pim_Kinase_Inhibitor_SGI-1776"},{"name":"Maps_To","value":"PIM Kinase Inhibitor SGI-1776"},{"name":"NCI_Drug_Dictionary_ID","value":"638088"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638088"},{"name":"PDQ_Open_Trial_Search_ID","value":"638088"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742218"}]}}{"C160203":{"preferredName":"PIM Kinase Inhibitor TP-3654","code":"C160203","definitions":[{"definition":"An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, PIM kinase inhibitor TP-3654 selectively binds to and prevents the activation of the PIM kinases. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIM. PIMs, constitutively active proto-oncogenic serine/threonine kinases, are upregulated in various types of cancers and play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM Kinase Inhibitor TP-3654","termGroup":"PT","termSource":"NCI"},{"termName":"2-((1R,4R)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol","termGroup":"SN","termSource":"NCI"},{"termName":"PIM Inhibitor TP-3654","termGroup":"SY","termSource":"NCI"},{"termName":"SGI 9481","termGroup":"CN","termSource":"NCI"},{"termName":"SGI-9481","termGroup":"CN","termSource":"NCI"},{"termName":"SGI9481","termGroup":"CN","termSource":"NCI"},{"termName":"TP 3654","termGroup":"CN","termSource":"NCI"},{"termName":"TP-3654","termGroup":"CN","termSource":"NCI"},{"termName":"TP3654","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1361951-15-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EOB0N7BOY4"},{"name":"Legacy Concept Name","value":"Pim_Kinase_Inhibitor_SGI-1776"},{"name":"Maps_To","value":"PIM Kinase Inhibitor TP-3654"},{"name":"NCI_Drug_Dictionary_ID","value":"797841"},{"name":"NCI_META_CUI","value":"CL969336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797841"},{"name":"PDQ_Open_Trial_Search_ID","value":"797841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133540":{"preferredName":"PIM/FLT3 Kinase Inhibitor SEL24","code":"C133540","definitions":[{"definition":"An orally available inhibitor of PIM family serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3; STK1) with potential antineoplastic activity. PIM/FLT3 kinase inhibitor SEL24 binds to and inhibits the kinase activities of PIM-1, -2 and -3, and mutant forms of FLT3, which may result in the interruption of the G1/S phase cell cycle transition, an inhibition of cell proliferation, and an induction of apoptosis in tumor cells that overexpress PIMs or express mutant forms of FLT3. FLT3, a tyrosine kinase receptor that is overexpressed or mutated in various cancers, plays a role in signaling pathways that regulate hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, including the FLT3 signaling pathway, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM/FLT3 Kinase Inhibitor SEL24","termGroup":"PT","termSource":"NCI"},{"termName":"Dual PIM/FLT3 Kinase Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"SEL 24","termGroup":"CN","termSource":"NCI"},{"termName":"SEL24","termGroup":"CN","termSource":"NCI"},{"termName":"SEL24-B489","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616359-00-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9M7X64VTLI"},{"name":"Maps_To","value":"PIM/FLT3 Kinase Inhibitor SEL24"},{"name":"NCI_Drug_Dictionary_ID","value":"788368"},{"name":"NCI_META_CUI","value":"CL520500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788368"},{"name":"PDQ_Open_Trial_Search_ID","value":"788368"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84864":{"preferredName":"Pimasertib","code":"C84864","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AS703026","termGroup":"CN","termSource":"NCI"},{"termName":"EMD 1036239","termGroup":"CN","termSource":"NCI"},{"termName":"MSC1936369","termGroup":"CN","termSource":"NCI"},{"termName":"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4- iodophenyl)amino]isonicotinamide Hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1236699-92-5"},{"name":"Chemical_Formula","value":"C15H15FIN3O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6ON9RK82AL"},{"name":"Maps_To","value":"Pimasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"653634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653634"},{"name":"PDQ_Open_Trial_Search_ID","value":"653634"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830124"}]}}{"C1279":{"preferredName":"Pingyangmycin","code":"C1279","definitions":[{"definition":"The naturally-occurring bleomycin antineoplastic antibiotic isolated from the bacterium Streptomyces pingyangensisn.  Pingyangmycin induces tumor cell apoptosis, possibly via a mechanism mediated by the mitogen-activated protein kinase (MAPK) pathway. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pingyangmycin","termGroup":"PT","termSource":"NCI"},{"termName":"Bleomycetin","termGroup":"SY","termSource":"NCI"},{"termName":"Bleomycin A5","termGroup":"SY","termSource":"NCI"},{"termName":"N1-(3-((4-Aminobutyl)amino)propyl)bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"Zhengguangmycin A5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"77108-50-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5DY91Y7601"},{"name":"Legacy Concept Name","value":"Pingyangmycin"},{"name":"Maps_To","value":"Pingyangmycin"},{"name":"NSC Number","value":"350895"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053847"}]}}{"C103179":{"preferredName":"Pinometostat","code":"C103179","definitions":[{"definition":"A small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Upon intravenous administration, pinometostat specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes. This eventually leads to an induction of apoptosis in the leukemic cells bearing the MLL gene translocations. DOT1L, a non-SET domain-containing histone methyltransferase, specifically methylates H3K79 and plays a key role in normal cell differentiation and in the development of leukemia with MLL gene rearrangement on chromosome 11 and promotes the expression of leukemia-causing genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pinometostat","termGroup":"PT","termSource":"NCI"},{"termName":"DOT1L Inhibitor EPZ-5676","termGroup":"SY","termSource":"NCI"},{"termName":"EPZ-5676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1380288-87-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8V9YR09EF3"},{"name":"Maps_To","value":"Pinometostat"},{"name":"NCI_Drug_Dictionary_ID","value":"740411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740411"},{"name":"PDQ_Open_Trial_Search_ID","value":"740411"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641112"}]}}{"C71633":{"preferredName":"Pioglitazone","code":"C71633","definitions":[{"definition":"A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth) from developing into cancer. It is a type of thiazolidinedione.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pioglitazone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111025-46-8"},{"name":"CHEBI_ID","value":"CHEBI:8228"},{"name":"Chemical_Formula","value":"C19H20N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X4OV71U42S"},{"name":"Legacy Concept Name","value":"Pioglitazone_Base"},{"name":"Maps_To","value":"Pioglitazone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071097"}]}}{"C29367":{"preferredName":"Pioglitazone Hydrochloride","code":"C29367","definitions":[{"definition":"A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth) from developing into cancer. It is a type of thiazolidinedione.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pioglitazone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Actos","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112529-15-4"},{"name":"Chemical_Formula","value":"C19H20N2O3S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JQT35NPK6C"},{"name":"Legacy Concept Name","value":"Pioglitazone"},{"name":"Maps_To","value":"Pioglitazone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"398145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"398145"},{"name":"PDQ_Open_Trial_Search_ID","value":"398145"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0872972"}]}}{"C1874":{"preferredName":"Pipendoxifene","code":"C1874","definitions":[{"definition":"A nonsteroidal 2-phenyl indole and a selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Pipendoxifene antagonizes binding of estradiol to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated gene expression, interfering with estrogen activity and inhibiting estrogen-stimulated growth in estrogen-dependent breast cancer. In addition, this agent also exerts intrinsic estrogenic activity depending on the tissue types.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to a family of drugs called antiestrogens.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pipendoxifene","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Hydroxyphenyl)-3-methyl-1-[4-(2-piperidin-1-ylethoxy)benzyl]-1H-indol-5-ol Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ERA 923","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198480-55-6"},{"name":"Chemical_Formula","value":"C29H32N2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TPC5Q8496G"},{"name":"Legacy Concept Name","value":"ERA_923"},{"name":"Maps_To","value":"Pipendoxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"38112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38112"},{"name":"PDQ_Open_Trial_Search_ID","value":"38112"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935699"}]}}{"C1401":{"preferredName":"Piperazinedione","code":"C1401","definitions":[{"definition":"A crystalline antibiotic fermentation product isolated from the bacterium Streptomyces griseoluteus with antineoplastic activity. Piperazinedione alkylates DNA at the N-7 position of guanine, inhibiting DNA replication and inducing cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piperazinedione","termGroup":"PT","termSource":"NCI"},{"termName":"2, 5-piperazinedione, 3,6-bis-(5-chloro-2-piperidyl)-, dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-piperazinedione, 3, 6-bis(5-chloro-2-piperidinyl)-, dihydrochloride, [3S-[3alpha(2S*,5R*),6alpha(2S*,5R*)]]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"593A","termGroup":"CN","termSource":"NCI"},{"termName":"Compound 593A","termGroup":"SY","termSource":"NCI"},{"termName":"Merck Compound 593A","termGroup":"SY","termSource":"NCI"},{"termName":"PZD","termGroup":"AB","termSource":"NCI"},{"termName":"PZD dihydrochloride, 3,6-bis(5-chloro-2-piperidinyl)-, dihydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41109-80-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Piperazinedione"},{"name":"Maps_To","value":"Piperazinedione"},{"name":"NCI_Drug_Dictionary_ID","value":"39556"},{"name":"NSC Number","value":"135758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39556"},{"name":"PDQ_Open_Trial_Search_ID","value":"39556"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0888240"}]}}{"C48417":{"preferredName":"Piperine Extract (Standardized)","code":"C48417","definitions":[{"definition":"A standardized extract containing the active alkaloid piperine, derived from the fruit of the plant Piper nigrum (black pepper) and/or the plant Piper longum L. (long pepper), with thermogenic properties. Co-ingestion of piperidine enhances the bioavailability of various nutrients, including beta-carotene, curcumin, selenium, pyridoxine and coenzyme Q10. In addition, this agent may exert anti-inflammatory and anti-tumor activities and may enhance the production of serotonin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piperine Extract (Standardized)","termGroup":"PT","termSource":"NCI"},{"termName":"Bioperine","termGroup":"BR","termSource":"NCI"},{"termName":"Standardized Piperine Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Piperine_Extract_Standardized"},{"name":"Maps_To","value":"Piperine Extract (Standardized)"},{"name":"NCI_Drug_Dictionary_ID","value":"440023"},{"name":"PDQ_Closed_Trial_Search_ID","value":"440023"},{"name":"PDQ_Open_Trial_Search_ID","value":"440023"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709545"}]}}{"C750":{"preferredName":"Pipobroman","code":"C750","definitions":[{"definition":"A piperazine derivative with potential antineoplastic alkyating activity. Although the exact mechanism of action of pipobroman has yet to be fully elucidated, this agent appears to act by alkylating DNA, leading to disruption of DNA replication and eventually cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pipobroman","termGroup":"PT","termSource":"NCI"},{"termName":"Amedel","termGroup":"BR","termSource":"NCI"},{"termName":"Vercyte","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54-91-1"},{"name":"Chemical_Formula","value":"C10H16Br2N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6Q99RDT97R"},{"name":"Legacy Concept Name","value":"Pipobroman"},{"name":"Maps_To","value":"Pipobroman"},{"name":"NSC Number","value":"25154"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0031965"}]}}{"C1783":{"preferredName":"Piposulfan","code":"C1783","definitions":[{"definition":"An alkyl sulfonate with potential antineoplastic activity.  Piposulfan alkylates DNA, thereby producing DNA interstrand crosslinks and DNA strand breaks and inhibiting DNA replication.  This agent has been shown to exhibit antitumor activity in an animal model of prostate cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piposulfan","termGroup":"PT","termSource":"NCI"},{"termName":"A-20968","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2608-24-4"},{"name":"Chemical_Formula","value":"C12H22N2O8S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VY5DPN1TDU"},{"name":"Legacy Concept Name","value":"Piposulfan"},{"name":"Maps_To","value":"Piposulfan"},{"name":"NSC Number","value":"47774"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0663942"}]}}{"C1197":{"preferredName":"Pirarubicin","code":"C1197","definitions":[{"definition":"An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(2\"R)-4'-O-Tetrahydropyranyladriamycin","termGroup":"SN","termSource":"NCI"},{"termName":"(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-3-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"1609-RB","termGroup":"CN","termSource":"NCI"},{"termName":"1609RB","termGroup":"CN","termSource":"NCI"},{"termName":"4'-O-Tetrahydropyranyl Doxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"[8S-[8Alpha,10alpha(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"Pinorubicin","termGroup":"FB","termSource":"NCI"},{"termName":"Tepirubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Tetrahydropyranyl-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Theprubicin","termGroup":"FB","termSource":"NCI"},{"termName":"Theprubicine","termGroup":"FB","termSource":"NCI"},{"termName":"Therarubicin","termGroup":"FB","termSource":"NCI"},{"termName":"THP-ADM","termGroup":"AB","termSource":"NCI"},{"termName":"THP-Adriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"THP-DOX","termGroup":"AB","termSource":"NCI"},{"termName":"THP-Doxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72496-41-4"},{"name":"Chemical_Formula","value":"C32H37NO12"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D58G680W0G"},{"name":"Legacy Concept Name","value":"Pirarubicin"},{"name":"Maps_To","value":"Pirarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"38775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38775"},{"name":"PDQ_Open_Trial_Search_ID","value":"38775"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071126"}]}}{"C95319":{"preferredName":"Pirarubicin Hydrochloride","code":"C95319","definitions":[{"definition":"The hydrochloride salt form of pirarubicin, an analogue of the anthracycline antineoplastic antibiotic doxorubicin with antineoplastic activity. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirarubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(2\"R)-4'-O-Tetrahydropyranyladriamycin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"4'-O-Tetrahydropyranyl Doxorubicin HCl","termGroup":"SN","termSource":"NCI"},{"termName":"THP-adriamycin Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72496-41-4"},{"name":"Chemical_Formula","value":"C32H37NO12.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E7V83174BE"},{"name":"Maps_To","value":"Pirarubicin Hydrochloride"},{"name":"NSC Number","value":"333054"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0898957"}]}}{"C2635":{"preferredName":"Pirfenidone","code":"C2635","definitions":[{"definition":"A substance that is being studied in the prevention and treatment of scar tissue caused by radiation therapy. It belongs to the family of drugs called anti-inflammatory agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirfenidone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53179-13-8"},{"name":"Chemical_Formula","value":"C12H11NO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D7NLD2JX7U"},{"name":"Legacy Concept Name","value":"Pirfenidone"},{"name":"Maps_To","value":"Pirfenidone"},{"name":"NCI_Drug_Dictionary_ID","value":"38334"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38334"},{"name":"PDQ_Open_Trial_Search_ID","value":"38334"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0298067"}]}}{"C1031":{"preferredName":"Piritrexim","code":"C1031","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called folate antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piritrexim","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"6-[(2,5-Dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"BW-301U","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72732-56-0"},{"name":"Chemical_Formula","value":"C17H19N5O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MK2A783ZUT"},{"name":"Legacy Concept Name","value":"Piritrexim"},{"name":"Maps_To","value":"Piritrexim"},{"name":"NCI_Drug_Dictionary_ID","value":"40070"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40070"},{"name":"PDQ_Open_Trial_Search_ID","value":"40070"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054332"}]}}{"C91407":{"preferredName":"Piritrexim Isethionate","code":"C91407","definitions":[{"definition":"The isethionate salt of piritrexim, a synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piritrexim Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine mono(2-hydroxyethanesulfonate)","termGroup":"SN","termSource":"NCI"},{"termName":"BW-301U Isethionate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"79483-69-5"},{"name":"Chemical_Formula","value":"C17H19N5O2.C2H6O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V77I71FH72"},{"name":"Maps_To","value":"Piritrexim Isethionate"},{"name":"NSC Number","value":"351521"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522061"}]}}{"C121960":{"preferredName":"Pirotinib","code":"C121960","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with potential antineoplastic activity. Upon administration, pirotinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4). This may result in the inhibition of cell growth and angiogenesis in tumors overexpressing these RTKs. EGFRs play major roles in both tumor cell proliferation and tumor vascularization, and are overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirotinib","termGroup":"PT","termSource":"NCI"},{"termName":"KBP-5209","termGroup":"CN","termSource":"NCI"},{"termName":"KBP5209","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pirotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"772247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772247"},{"name":"PDQ_Open_Trial_Search_ID","value":"772247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054177"}]}}{"C1182":{"preferredName":"Piroxantrone","code":"C1182","definitions":[{"definition":"An anthrapyrazole antineoplastic antibiotic.  Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piroxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra(1,9-cd)pyrazol-6(2H)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)","termGroup":"SN","termSource":"NCI"},{"termName":"CI-942","termGroup":"CN","termSource":"NCI"},{"termName":"Oxanthrazole","termGroup":"SY","termSource":"NCI"},{"termName":"Oxantrazole","termGroup":"SY","termSource":"NCI"},{"termName":"PD-111815","termGroup":"CN","termSource":"NCI"},{"termName":"Piroxantrone HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91441-23-5"},{"name":"Chemical_Formula","value":"C21H25N5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YL4TY9WH22"},{"name":"Legacy Concept Name","value":"Piroxantrone"},{"name":"Maps_To","value":"Piroxantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"40791"},{"name":"NSC Number","value":"349174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40791"},{"name":"PDQ_Open_Trial_Search_ID","value":"40791"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069736"}]}}{"C72829":{"preferredName":"Piroxantrone Hydrochloride","code":"C72829","definitions":[{"definition":"The hydrochloride salt form of piroxantrone, an anthrapyrazole antineoplastic antibiotic. Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piroxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"105118-12-5"},{"name":"Chemical_Formula","value":"C21H25N5O4.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PS51OZG63Z"},{"name":"Legacy Concept Name","value":"Piroxantrone_Hydrochloride"},{"name":"Maps_To","value":"Piroxantrone Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347520"}]}}{"C26663":{"preferredName":"Pixantrone","code":"C26663","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pixantrone","termGroup":"PT","termSource":"NCI"},{"termName":"6,9-Bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144510-96-3"},{"name":"Chemical_Formula","value":"C17H19N5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F5SXN2KNMR"},{"name":"Legacy Concept Name","value":"Pixantrone"},{"name":"Maps_To","value":"Pixantrone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253355"}]}}{"C82398":{"preferredName":"Pixantrone Dimaleate","code":"C82398","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pixantrone Dimaleate","termGroup":"PT","termSource":"NCI"},{"termName":"6,9-Bis((2-Aminoethyl)Amino)Benzo(g)Isoquinoline-5,10-Dione (2z)-But-2-Enedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"BBR 2778","termGroup":"CN","termSource":"NCI"},{"termName":"Benz(g)Isoquinoline-5,10-Dione, 6,9-Bis((2-Aminoethyl)Amino)-, (2z)-2-Butenedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"Pixantrone Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"Pixuvri","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-Hodgkin's lyphoma"},{"name":"CAS_Registry","value":"144675-97-8"},{"name":"Chemical_Formula","value":"C17H19N5O2.2C4H4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P0R64C4CR9"},{"name":"Legacy Concept Name","value":"Pixantrone_Dimaleate"},{"name":"Maps_To","value":"Pixantrone Dimaleate"},{"name":"NCI_Drug_Dictionary_ID","value":"269678"},{"name":"NCI_META_CUI","value":"CL408667"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269678"},{"name":"PDQ_Open_Trial_Search_ID","value":"269678"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1810":{"preferredName":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231","code":"C1810","definitions":[{"definition":"A drug that may inhibit the growth of malignant tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mixed backbone oligonucleotide exhibiting antitumor activity.  GEM-231 is complementary to the RI alpha subunit of Protein Kinase A (PKA), resulting in downregulation of PKA expression and ultimately tumor growth. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231","termGroup":"PT","termSource":"NCI"},{"termName":"GEM 231","termGroup":"CN","termSource":"NCI"},{"termName":"GEM-231","termGroup":"CN","termSource":"NCI"},{"termName":"GEM231","termGroup":"CN","termSource":"NCI"},{"termName":"Gene Expression Modulator 231","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GEM_231"},{"name":"Maps_To","value":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231"},{"name":"NCI_Drug_Dictionary_ID","value":"42971"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42971"},{"name":"PDQ_Open_Trial_Search_ID","value":"42971"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677981"}]}}{"C1788":{"preferredName":"Aprinocarsen","code":"C1788","definitions":[{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, aprinocarsen hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aprinocarsen","termGroup":"PT","termSource":"NCI"},{"termName":"Affinitac","termGroup":"BR","termSource":"NCI"},{"termName":"Affinitak","termGroup":"BR","termSource":"NCI"},{"termName":"CGP 64128A","termGroup":"CN","termSource":"NCI"},{"termName":"DNA, d(P-thio)(GTTCTCGCTGGTGAGTTTCA)","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 3521","termGroup":"CN","termSource":"NCI"},{"termName":"LY900003","termGroup":"CN","termSource":"NCI"},{"termName":"Protein Kinase C-Alpha Antisense","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151879-73-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FMT95051CQ"},{"name":"Legacy Concept Name","value":"ISIS_3521"},{"name":"Maps_To","value":"Aprinocarsen"},{"name":"Maps_To","value":"PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521"},{"name":"NCI_Drug_Dictionary_ID","value":"42953"},{"name":"NSC Number","value":"719337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42953"},{"name":"PDQ_Open_Trial_Search_ID","value":"42953"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0666551"}]}}{"C148422":{"preferredName":"PKC-beta Inhibitor MS-553","code":"C148422","definitions":[{"definition":"An orally available inhibitor of the beta-isoform of protein kinase C (PKC), with potential immunosuppressive and antineoplastic activities. Upon oral administration, PKC-beta inhibitor MS-553 selectively binds to and inhibits PKC-beta, which prevents the activation of PKC-beta-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC-beta, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PKC-beta Inhibitor MS-553","termGroup":"PT","termSource":"NCI"},{"termName":"MS 553","termGroup":"CN","termSource":"NCI"},{"termName":"MS-553","termGroup":"CN","termSource":"NCI"},{"termName":"MS553","termGroup":"CN","termSource":"NCI"},{"termName":"PKC-b Inhibitor MS-553","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PKC-beta Inhibitor MS-553"},{"name":"NCI_Drug_Dictionary_ID","value":"795373"},{"name":"NCI_META_CUI","value":"CL550994"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795373"},{"name":"PDQ_Open_Trial_Search_ID","value":"795373"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C753":{"preferredName":"Placebo","code":"C753","definitions":[{"definition":"A pharmaceutical preparation that does not contain the investigational agent and is generally prepared to be physically indistinguishable from the preparation containing the investigational product.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","type":"DEFINITION","source":"NCI"},{"definition":"Something that looks like the treatment being studied, but doesn't contain any medicine. (https://mrctcenter.org/glossaryterm/placebo/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Placebo","termGroup":"PT","termSource":"NCI"},{"termName":"PLCB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Placebo"},{"name":"Maps_To","value":"Placebo"},{"name":"NCI_Drug_Dictionary_ID","value":"43469"},{"name":"NCI_META_CUI","value":"CL473981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43469"},{"name":"PDQ_Open_Trial_Search_ID","value":"43469"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C69005":{"preferredName":"Pladienolide Derivative E7107","code":"C69005","definitions":[{"definition":"A synthetic urethane derivative of pladienolide D with potential antineoplastic activity. Pladienolide derivative E7107 is generated from the 12-membered macrolide pladienolide D, one of several macrolides derived from the bacterium Streptomyces platensis Mer-11107. This agent appears to bind to the 130-kDa subunit 3 (spliceosome-associated protein 130; SAP130) of the splicing factor 3b (SF3b), resulting in inhibition of pre-messenger RNA splicing and the arrest of cell-cycle progression. The splicing factor SF3b is a multiprotein complex integral to the accurate excision of introns from pre-messenger RNA; the subunit SAP130 associates with U2 snRNP and is recruited to prespliceosomal complexes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pladienolide Derivative E7107","termGroup":"PT","termSource":"NCI"},{"termName":"E7107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"630100-90-2"},{"name":"Chemical_Formula","value":"C40H66N2O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R60DZX1E2N"},{"name":"Legacy Concept Name","value":"Pladienolide_Derivative_E7107"},{"name":"Maps_To","value":"Pladienolide Derivative E7107"},{"name":"NCI_Drug_Dictionary_ID","value":"546981"},{"name":"NCI_META_CUI","value":"CL375254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546981"},{"name":"PDQ_Open_Trial_Search_ID","value":"546981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C756":{"preferredName":"Platinum","code":"C756","definitions":[{"definition":"A metal that is an important component of some anticancer drugs, such as cisplatin and carboplatin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An element with atomic symbol Pt, atomic number 78, and atomic weight 195.09.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum","termGroup":"PT","termSource":"NCI"},{"termName":"C.I. 77795","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum Metallicum","termGroup":"SY","termSource":"NCI"},{"termName":"Pt","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7440-06-4"},{"name":"CHEBI_ID","value":"CHEBI:33364"},{"name":"CHEBI_ID","value":"CHEBI:33400"},{"name":"Chemical_Formula","value":"Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49DFR088MY"},{"name":"Legacy Concept Name","value":"Platinum"},{"name":"Maps_To","value":"Platinum"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"UMLS_CUI","value":"C0032207"}]}}{"C153425":{"preferredName":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles","code":"C153425","definitions":[{"definition":"A preparation of platinum acetylacetonate supported by sol-gel technology functionalized titania, with potential antineoplastic activity. Upon intravenous administration, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the nanoparticle formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"NPt","termGroup":"CN","termSource":"NCI"},{"termName":"NPt Nanomaterial","termGroup":"SY","termSource":"NCI"},{"termName":"NPt Nanoparticles","termGroup":"SY","termSource":"NCI"},{"termName":"NPt-Ca","termGroup":"CN","termSource":"NCI"},{"termName":"Sol-gel NPt Nanomaterial","termGroup":"SY","termSource":"NCI"},{"termName":"Sol-gel NPt Nanoparticles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"793980"},{"name":"NCI_META_CUI","value":"CL554861"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793980"},{"name":"PDQ_Open_Trial_Search_ID","value":"793980"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1450":{"preferredName":"Platinum Compound","code":"C1450","definitions":[{"definition":"A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum Compound","termGroup":"PT","termSource":"NCI"},{"termName":"Platinum Agents","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum-Based Chemotherapeutic Agent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:33749"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Platinum_Compound"},{"name":"Maps_To","value":"Platinum Compound"},{"name":"Semantic_Type","value":"Chemical Viewed Structurally"},{"name":"UMLS_CUI","value":"C0206135"}]}}{"C1629":{"preferredName":"Plevitrexed","code":"C1629","definitions":[{"definition":"An orally bioavailable, small molecule, non-polyglutamatable, antifolate quinazoline derivative thymidine synthetase inhibitor with potential antineoplastic activity. Plevitrexed is transported into the cell via the physiological reduced folate carrier (RFC) system. Intracellularly, this agent selectively binds to the folate binding site of thymidylate synthase and inhibits thymidine synthesis, which may result in DNA synthesis inhibition and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plevitrexed","termGroup":"PT","termSource":"NCI"},{"termName":"(alphaS)-alpha-[[4-[[(1,4-Dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-1H-tetrazole-5-butanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BGC 9331","termGroup":"CN","termSource":"NCI"},{"termName":"Vamidex","termGroup":"SY","termSource":"NCI"},{"termName":"Vamydex","termGroup":"SY","termSource":"NCI"},{"termName":"ZD9331","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"153537-73-6"},{"name":"Chemical_Formula","value":"C26H25FN8O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L9P2881C3H"},{"name":"Legacy Concept Name","value":"ZD9331"},{"name":"Maps_To","value":"Plevitrexed"},{"name":"NCI_Drug_Dictionary_ID","value":"38264"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38264"},{"name":"PDQ_Open_Trial_Search_ID","value":"38264"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299046"}]}}{"C658":{"preferredName":"Plicamycin","code":"C658","definitions":[{"definition":"A drug used to treat some types of testicular cancer. It is also used to treat a higher-than-normal amounts of calcium in the blood or urine. Plicamycin binds to DNA and prevents cells from making RNA and proteins. It is a type of antineoplastic antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plicamycin","termGroup":"PT","termSource":"NCI"},{"termName":"A-2371","termGroup":"CN","termSource":"NCI"},{"termName":"Aureolic acid","termGroup":"SY","termSource":"NCI"},{"termName":"Mithracin","termGroup":"BR","termSource":"NCI"},{"termName":"Mithracine","termGroup":"FB","termSource":"NCI"},{"termName":"Mithramycin","termGroup":"SY","termSource":"NCI"},{"termName":"MTH","termGroup":"AB","termSource":"NCI"},{"termName":"PA-144","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18378-89-7"},{"name":"CHEBI_ID","value":"CHEBI:31856"},{"name":"Chemical_Formula","value":"C52H76O24"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NIJ123W41V"},{"name":"Legacy Concept Name","value":"Plicamycin"},{"name":"Maps_To","value":"Plicamycin"},{"name":"NCI_Drug_Dictionary_ID","value":"41738"},{"name":"NSC Number","value":"24559"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41738"},{"name":"PDQ_Open_Trial_Search_ID","value":"41738"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026234"}]}}{"C62444":{"preferredName":"Plinabulin","code":"C62444","definitions":[{"definition":"An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively targets and binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics. This disrupts mitotic spindle assembly leading to cell cycle arrest at M phase and blockage of cell division. In addition, plinabulin may also inhibit growth of proliferating vascular endothelial cells, thereby disrupting the function of tumor vasculature that further contributes to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plinabulin","termGroup":"PT","termSource":"NCI"},{"termName":"(3Z,6Z)-6-benzylidene-3-{[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylidene}piperazine-2,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"NPI-2358","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"714272-27-2"},{"name":"Chemical_Formula","value":"C19H20N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"986FY7F8XR"},{"name":"Legacy Concept Name","value":"NPI-2358"},{"name":"Maps_To","value":"Plinabulin"},{"name":"NCI_Drug_Dictionary_ID","value":"488984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488984"},{"name":"PDQ_Open_Trial_Search_ID","value":"488984"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1741609"}]}}{"C1689":{"preferredName":"Plitidepsin","code":"C1689","definitions":[{"definition":"A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It is obtained from a marine organism.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plitidepsin","termGroup":"PT","termSource":"NCI"},{"termName":"APLD","termGroup":"AB","termSource":"NCI"},{"termName":"Aplidin","termGroup":"BR","termSource":"NCI"},{"termName":"Aplidine","termGroup":"SY","termSource":"NCI"},{"termName":"DDB","termGroup":"AB","termSource":"NCI"},{"termName":"Dehydrodemnin B","termGroup":"SY","termSource":"NCI"},{"termName":"Dehydrodidemnin B","termGroup":"SY","termSource":"NCI"},{"termName":"N-[1-(1,2-Dioxopropyl)-L-prolyl]didemnin A","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"137219-37-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y76ID234HW"},{"name":"Legacy Concept Name","value":"Aplidine"},{"name":"Maps_To","value":"Plitidepsin"},{"name":"NCI_Drug_Dictionary_ID","value":"460052"},{"name":"NSC Number","value":"638719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"460052"},{"name":"PDQ_Open_Trial_Search_ID","value":"460052"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0388638"}]}}{"C49091":{"preferredName":"Plk1 Inhibitor BI 2536","code":"C49091","definitions":[{"definition":"A small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It prevents cells from dividing and may block the growth of some tumors. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plk1 Inhibitor BI 2536","termGroup":"PT","termSource":"NCI"},{"termName":"BI 2536","termGroup":"CN","termSource":"NCI"},{"termName":"BI-2536","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"755038-02-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4LJG22T9C6"},{"name":"Legacy Concept Name","value":"BI_2536"},{"name":"Maps_To","value":"Plk1 Inhibitor BI 2536"},{"name":"NCI_Drug_Dictionary_ID","value":"452943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"452943"},{"name":"PDQ_Open_Trial_Search_ID","value":"452943"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706888"}]}}{"C162375":{"preferredName":"Plogosertib","code":"C162375","definitions":[{"definition":"A competitive inhibitor for adenosine triphosphate (ATP) binding to polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, plogosertib selectively targets, binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation, transformation and invasion. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plogosertib","termGroup":"PT","termSource":"NCI"},{"termName":"CYC 140","termGroup":"CN","termSource":"NCI"},{"termName":"CYC-140","termGroup":"CN","termSource":"NCI"},{"termName":"CYC140","termGroup":"CN","termSource":"NCI"},{"termName":"PLK-1 Inhibitor CYC140","termGroup":"SY","termSource":"NCI"},{"termName":"PLK1 Inhibitor CYC140","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor CYC140","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1137212-79-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IW5U2LC9XI"},{"name":"Maps_To","value":"PLK1 Inhibitor CYC140"},{"name":"NCI_Drug_Dictionary_ID","value":"798706"},{"name":"NCI_META_CUI","value":"CL970820"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798706"},{"name":"PDQ_Open_Trial_Search_ID","value":"798706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92587":{"preferredName":"PLK1 Inhibitor TAK-960","code":"C92587","definitions":[{"definition":"An orally available, Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressed tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PLK1 Inhibitor TAK-960","termGroup":"PT","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor TAK-960","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-960","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1137868-52-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3831VFM1ZB"},{"name":"Maps_To","value":"PLK1 Inhibitor TAK-960"},{"name":"NCI_Drug_Dictionary_ID","value":"683854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683854"},{"name":"PDQ_Open_Trial_Search_ID","value":"683854"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985196"}]}}{"C95888":{"preferredName":"Plocabulin","code":"C95888","definitions":[{"definition":"A marine-derived, synthetically produced compound with potential antineoplastic activity. Plocabulin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plocabulin","termGroup":"PT","termSource":"NCI"},{"termName":"PM-060184","termGroup":"CN","termSource":"NCI"},{"termName":"PM060184","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"960210-99-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"52Y8L60CR7"},{"name":"Maps_To","value":"Plocabulin"},{"name":"NCI_Drug_Dictionary_ID","value":"696184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696184"},{"name":"PDQ_Open_Trial_Search_ID","value":"696184"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272412"}]}}{"C88308":{"preferredName":"Plozalizumab","code":"C88308","definitions":[{"definition":"A humanized monoclonal antibody directed against the human chemokine receptor 2 (CCR2), with potential antiangiogenic, immunomodulating, antimetastatic, and antineoplastic activities. Plozalizumab binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and so inhibition of angiogenesis, tumor cell migration, and tumor cell proliferation. In addition, this agent may reduce levels of C-reactive protein (CRP). The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied as a treatment for atherosclerosis (a build-up of fat in the arteries). It is also being studied in the treatment of cancers that spread to the bone. Anti-CCR2 monoclonal antibody MLN1202 binds to a protein called CCR2, which is found on the surface of certain bone cells, white blood cells, and cancer cells. Anti-CCR2 monoclonal antibody MLN1202 blocks the action of a substance that is involved in keeping healthy bone mass. It may help keep the cancer cells from spreading to and growing in the bone. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plozalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human CC Chemokine Receptor CCR2) (Human-mus musculus Monoclonal 1d9 Heavy Chain), Disulfide with Human-mus musculus Monoclonal 1d9 kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"MLN1202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610761-46-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4XG66BMN0D"},{"name":"Maps_To","value":"Plozalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"659685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659685"},{"name":"PDQ_Open_Trial_Search_ID","value":"659685"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981824"}]}}{"C126798":{"preferredName":"Pidnarulex","code":"C126798","definitions":[{"definition":"An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, pidnarulex selectively binds to and inhibits Pol I, prevents Pol I-mediated ribosomal RNA (rRNA) synthesis, induces apoptosis, and inhibits tumor cell growth. Pol I, the multiprotein complex that synthesizes rRNA, is upregulated in cancer cells and plays a key role in cell proliferation and survival. Hyperactivated rRNA transcription is associated with uncontrolled cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pidnarulex","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"2-(4-Methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"CX-5461","termGroup":"CN","termSource":"NCI"},{"termName":"CX5461","termGroup":"CN","termSource":"NCI"},{"termName":"Pol I Inhibitor CX5461","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Pol I Inhibitor CX5461","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1138549-36-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3R4C5YLB9I"},{"name":"Maps_To","value":"Pol I Inhibitor CX5461"},{"name":"NCI_Drug_Dictionary_ID","value":"780145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780145"},{"name":"PDQ_Open_Trial_Search_ID","value":"780145"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3180849"}]}}{"C104153":{"preferredName":"Polatuzumab Vedotin","code":"C104153","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polatuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DCDS4501A","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate DCDS4501A","termGroup":"SY","termSource":"NCI"},{"termName":"DCDS4501A","termGroup":"CN","termSource":"NCI"},{"termName":"FCU 2711","termGroup":"CN","termSource":"NCI"},{"termName":"polatuzumab vedotin-piiq","termGroup":"SY","termSource":"NCI"},{"termName":"Polivy","termGroup":"BR","termSource":"NCI"},{"termName":"RG7596","termGroup":"CN","termSource":"NCI"},{"termName":"Ro 5541077-000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"},{"name":"CAS_Registry","value":"1313206-42-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"KG6VO684Z6"},{"name":"Maps_To","value":"Polatuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"695317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695317"},{"name":"PDQ_Open_Trial_Search_ID","value":"695317"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4078806"}]}}{"C158511":{"preferredName":"Polidocanol","code":"C158511","definitions":[{"definition":"An alkyl polyglycol ether of lauryl alcohol with sclerosing and potential antineoplastic activities. Upon intralesional administration, polidocanol induces endothelial cell injury by disrupting calcium signaling and nitric oxide pathways. Following endothelial damage, platelets aggregate at the site of injury and attach to the venous wall, resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Inducing endothelial cell damage within melanoma metastases may incite an antitumor response in untreated bystander lesions and inhibit the growth of in transit metastases and other cutaneous lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polidocanol","termGroup":"PT","termSource":"NCI"},{"termName":"Aethoxysklerol","termGroup":"FB","termSource":"NCI"},{"termName":"Asclera","termGroup":"BR","termSource":"NCI"},{"termName":"Dodecylnonaoxyethylene Glycol Monoether","termGroup":"SY","termSource":"NCI"},{"termName":"Laureth 9","termGroup":"SY","termSource":"NCI"},{"termName":"Laureth-9","termGroup":"SY","termSource":"NCI"},{"termName":"Lauromacrogol 400","termGroup":"SY","termSource":"NCI"},{"termName":"Nonaethylene Glycol Monododecyl Ether","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3055-99-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0AWH8BFG9A"},{"name":"Maps_To","value":"Polidocanol"},{"name":"NCI_Drug_Dictionary_ID","value":"797212"},{"name":"NCI_META_CUI","value":"CL563467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797212"},{"name":"PDQ_Open_Trial_Search_ID","value":"797212"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157372":{"preferredName":"Poliglusam","code":"C157372","definitions":[{"definition":"A naturally occurring polysaccharide composed of beta-1,4-linked glucosamine residues with potential antineoplastic activity. Upon administration, poliglusam may, through a not yet fully elucidated mechanism, reduce advanced glycation end product (AGE) levels. This may reduce the interaction between AGEs and the receptor for advanced glycation end products (RAGE, AGER), which is overexpressed in some tumor types and is associated with poor patient outcomes. AGE-RAGE interaction may induce the phosphorylation and subsequent degradation of retinoblastoma protein (Rb), a key cell cycle inhibitor and tumor suppressor, through the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) signaling pathway. Hyperphosphorylation of Rb leads to the dissociation of the Rb-E2F complex, which triggers the activation of genes required for G1/S transition and tumorigenesis. Reducing AGE levels may limit AGE-RAGE interaction and normalize the G1 to S-phase transition, potentially reducing the development and progression of certain cancers. AGEs are non-enzymatic protein modifications produced during the normal aging process that have been shown to play a role in the development and progression of some cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poliglusam","termGroup":"PT","termSource":"NCI"},{"termName":"Chitosan","termGroup":"SY","termSource":"NCI"},{"termName":"Deacetylchitin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9012-76-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82LKS4QV2Y"},{"name":"Maps_To","value":"Poliglusam"},{"name":"NCI_Drug_Dictionary_ID","value":"796923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796923"},{"name":"PDQ_Open_Trial_Search_ID","value":"796923"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0162969"}]}}{"C70948":{"preferredName":"Polo-like Kinase 1 Inhibitor GSK461364","code":"C70948","definitions":[{"definition":"A small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polo-like Kinase 1 Inhibitor GSK461364","termGroup":"PT","termSource":"NCI"},{"termName":"GSK461364","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"929095-18-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8QO27TK6Q4"},{"name":"Legacy Concept Name","value":"Polo-like_Kinase_1_Inhibitor_GSK461364"},{"name":"Maps_To","value":"Polo-like Kinase 1 Inhibitor GSK461364"},{"name":"NCI_Drug_Dictionary_ID","value":"573587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573587"},{"name":"PDQ_Open_Trial_Search_ID","value":"573587"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347618"}]}}{"C82389":{"preferredName":"Polo-like Kinase 1 Inhibitor MK1496","code":"C82389","definitions":[{"definition":"An orally bioavailable Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor MK1496 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polo-like Kinase 1 Inhibitor MK1496","termGroup":"PT","termSource":"NCI"},{"termName":"MK1496","termGroup":"CN","termSource":"NCI"},{"termName":"PLK1 Inhibitor MK1496","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polo-like_Kinase_1_Inhibitor_MK1496"},{"name":"Maps_To","value":"Polo-like Kinase 1 Inhibitor MK1496"},{"name":"NCI_Drug_Dictionary_ID","value":"642286"},{"name":"NCI_META_CUI","value":"CL408660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642286"},{"name":"PDQ_Open_Trial_Search_ID","value":"642286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111990":{"preferredName":"Ocifisertib Fumarate","code":"C111990","definitions":[{"definition":"An orally available fumarate salt form of CFI-400945, a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon oral administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ocifisertib Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"CFI 400945 Fumarate","termGroup":"SY","termSource":"NCI"},{"termName":"CFI-400945","termGroup":"CN","termSource":"NCI"},{"termName":"CFI-400945 Fumarate","termGroup":"SY","termSource":"NCI"},{"termName":"PLK4 Inhibitor CFI-400945 Fumarate","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616420-30-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"09OB3E5QTD"},{"name":"Maps_To","value":"Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate"},{"name":"NCI_Drug_Dictionary_ID","value":"754001"},{"name":"NCI_META_CUI","value":"CL454279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754001"},{"name":"PDQ_Open_Trial_Search_ID","value":"754001"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101894":{"preferredName":"Poly-alendronate Dextran-Guanidine Conjugate","code":"C101894","definitions":[{"definition":"A polybisphosphonate dextran-guanidine conjugate with potential anti-resorptive and antineoplastic activities. Alendronic acid and aminoguanidine were conjugated sequentially to oxidized dextran resulting in an average of 8 alendronate and 50 guanidine groups coupled to the dextran backbone. Upon administration, the poly-alendronate dextran-guanidine conjugate inhibits the mevalonate pathway by inhibiting farnesyl diphosphate synthase (FDPS) which leads to a reduction in protein prenylation and to the loss of downstream metabolites essential for osteoclast function. This eventually leads to the induction of apoptosis in osteoclasts. Also, by preventing osteoclast-mediated bone resorption, this agent decreases bone turnover and stabilizes the bone matrix. The guanidine moiety increases the nitrogen content and possibly the activity of the bisphosphonate and its ability to inhibit FDPS. In addition, the guanidine moiety facilitates cell internalization and may contribute to this agent's cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly-alendronate Dextran-Guanidine Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"Dextran/Alendronate/Guanidine-containing Polybisphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"ODX","termGroup":"AB","termSource":"NCI"},{"termName":"Osteodex","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Poly-alendronate Dextran-Guanidine Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"733915"},{"name":"NCI_META_CUI","value":"CL436277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733915"},{"name":"PDQ_Open_Trial_Search_ID","value":"733915"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106124":{"preferredName":"Poly-gamma Glutamic Acid","code":"C106124","definitions":[{"definition":"A water-soluble and biodegradable polymer naturally synthesized by various strains of Bacillus and composed of D- and L-glutamic acid polymerized via gamma-amide linkages, with potential antineoplastic activity. Upon administration, poly-gamma glutamic acid may augment the immune response by increasing the production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) and inducing the activation of macrophage and natural killer (NK) cells. IFN-gamma is a major mediator of innate and adaptive immunity against viral and intracellular bacterial infections as well as for tumor control. TNF-alpha is a cytokine involved in systemic inflammation, which is capable of inducing apoptotic cell death and exhibits anti-tumoral effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly-gamma Glutamic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"gamma-PGA","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-polyglutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-gamma-glutamate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Poly-gamma Glutamic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"748858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748858"},{"name":"PDQ_Open_Trial_Search_ID","value":"748858"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723263"}]}}{"C38130":{"preferredName":"Polyamine Analog SL11093","code":"C38130","definitions":[{"definition":"A synthetic compound of the polyamine class of chemicals with potential antineoplastic activity. Natural endogenous polyamines bind to DNA and are involved in a number of cellular processes such as cell division, differentiation, and membrane function. SL11093 displaces these polyamines from their DNA binding sites, resulting in cessation of cell growth and cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyamine Analog SL11093","termGroup":"PT","termSource":"NCI"},{"termName":"3,8,13,18-Tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane Tetrahydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CGC 11093","termGroup":"CN","termSource":"NCI"},{"termName":"CGC-11093","termGroup":"CN","termSource":"NCI"},{"termName":"CGC11093","termGroup":"CN","termSource":"NCI"},{"termName":"SL 11093","termGroup":"CN","termSource":"NCI"},{"termName":"SL-11093","termGroup":"CN","termSource":"NCI"},{"termName":"SL11093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SL11093"},{"name":"Maps_To","value":"Polyamine Analog SL11093"},{"name":"NSC Number","value":"724908"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1259818"}]}}{"C60816":{"preferredName":"Polyamine Analogue PG11047","code":"C60816","definitions":[{"definition":"A second generation polyamine analogue, synthesized through the restriction of molecular conformations of parent polyamine compounds, with potential antineoplastic activity. Polyamine analogue PG11047 may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of lymphoma. It belongs to the family of drugs called polyamine analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Polyamine Analogue PG11047","termGroup":"PT","termSource":"NCI"},{"termName":"BESpm","termGroup":"AB","termSource":"NCI"},{"termName":"CGC-11047","termGroup":"CN","termSource":"NCI"},{"termName":"N(1),-N(12)-bis(ethyl)-cis-6,7-dehydrospermine","termGroup":"SN","termSource":"NCI"},{"termName":"N(1),-N(12)-bis(ethyl)-cis-6,7-dehydrospermine tetrahydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N(1),N(12)-bisethylspermine","termGroup":"SN","termSource":"NCI"},{"termName":"PG11047","termGroup":"CN","termSource":"NCI"},{"termName":"SL11047","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"206991-64-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HU43305R7O"},{"name":"Legacy Concept Name","value":"SL11047"},{"name":"Maps_To","value":"Polyamine Analogue PG11047"},{"name":"NCI_Drug_Dictionary_ID","value":"467739"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467739"},{"name":"PDQ_Open_Trial_Search_ID","value":"467739"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1963112"}]}}{"C142788":{"preferredName":"Ivospemin Hydrochloride","code":"C142788","definitions":[{"definition":"The hydrochloride salt form of ivospemin, an analogue of naturally occurring polyamine (PA), with potential antineoplastic activity. Upon subcutaneous administration,  ivospemin displaces endogenous PAs from PA-binding sites on the cell surface, which prevents internalization of PA. This inhibits PA-dependent cell cycle processes and results in cell cycle arrest, the induction of apoptosis, and inhibition of tumor cell proliferation. PA uptake is upregulated in various tumor types and increased levels of PA leads to enhanced tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivospemin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Diethyl Dihydroxyhomospermine","termGroup":"SY","termSource":"NCI"},{"termName":"HO2-DEHSPM","termGroup":"SY","termSource":"NCI"},{"termName":"Polyamine Analogue SBP-101","termGroup":"SY","termSource":"NCI"},{"termName":"SBP 101 Tetrahydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"SBP-101 Tetrahydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"259657-09-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2RKV12BBA7"},{"name":"Maps_To","value":"Polyamine Analogue SBP-101"},{"name":"NCI_Drug_Dictionary_ID","value":"791597"},{"name":"NCI_META_CUI","value":"CL540733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791597"},{"name":"PDQ_Open_Trial_Search_ID","value":"791597"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148487":{"preferredName":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate","code":"C148487","definitions":[{"definition":"The dicaprate salt form of AMXT-1501, an orally bioavailable polyamine transport inhibitor, with immunostimulating and antineoplastic activities.  Upon administration, AMXT-1501 targets, binds to and blocks polyamine transport from the bloodstream into the tumor microenvironment (TME), thereby preventing cancer cell uptake. This decreases polyamine concentrations inside the TME and tumor cell, inhibits tumor cell proliferation and induces apoptosis. In addition, AMXT-1501 may abrogate polyamine-mediated immune suppression in the TME. Polyamines, naturally found in normal, heathy cells, are required for normal cell growth and division. In cancer cells, polyamines play key roles in tumor cell proliferation and tumor-induced suppression of the patient's immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate","termGroup":"PT","termSource":"NCI"},{"termName":"AMX 513 Dicaprate","termGroup":"SY","termSource":"NCI"},{"termName":"AMX513 Dicaprate","termGroup":"SY","termSource":"NCI"},{"termName":"AMXT 1501 Dicaprate","termGroup":"SY","termSource":"NCI"},{"termName":"AMXT-1501 Dicaprate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate"},{"name":"NCI_Drug_Dictionary_ID","value":"792572"},{"name":"NCI_META_CUI","value":"CL551058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792572"},{"name":"PDQ_Open_Trial_Search_ID","value":"792572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1628":{"preferredName":"Polyandrol","code":"C1628","definitions":[{"definition":"A quassinoid phytochemical isolated from Castela polyandra and other plant species with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyandrol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polyandrol"},{"name":"Maps_To","value":"Polyandrol"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0298893"}]}}{"C92583":{"preferredName":"Polyethylene Glycol Recombinant Endostatin","code":"C92583","definitions":[{"definition":"A formulation containing recombinant endostatin attached to polyethylene glycol (PEG), with potential anti-angiogenic and antineoplastic activities. Endostatin, a 20 kDa C-terminal proteolytic fragment of collagen XVIII, induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction of tumor cell growth. Modification with PEG extends the circulation half-life of endostatin, improves stability and increases solubility in organic solvents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyethylene Glycol Recombinant Endostatin","termGroup":"PT","termSource":"NCI"},{"termName":"M2ES","termGroup":"CN","termSource":"NCI"},{"termName":"M2ES","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SLQ3VZ4GSC"},{"name":"Maps_To","value":"Polyethylene Glycol Recombinant Endostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"670652"},{"name":"NCI_META_CUI","value":"CL419349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670652"},{"name":"PDQ_Open_Trial_Search_ID","value":"670652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125243":{"preferredName":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318","code":"C125243","definitions":[{"definition":"A long-acting formulation composed of 7-ethyl-10-hydroxycamptothecin (SN38), a camptothecin derivative and active metabolite of irinotecan conjugated to polyethylene glycol (PEG), via a proprietary, cleavable linker, with potential antineoplastic activity. Upon administration, the proprietary linkage system allows for very slow release of SN38 from the formulation. Upon release, SN38 selectively stabilizes covalent topoisomerase I-DNA complexes, and results in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to other PEG-SN38-based formulations, the linker system in DFP-13318 increases its half-life and the exposure time for tumor cells, while decreasing both blood plasma concentrations and exposure to off-target organs; this results in increased efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318","termGroup":"PT","termSource":"NCI"},{"termName":"DFP-13318","termGroup":"CN","termSource":"NCI"},{"termName":"PEG SN38 DFP-13318","termGroup":"SY","termSource":"NCI"},{"termName":"PL 0264","termGroup":"CN","termSource":"NCI"},{"termName":"PL-0264","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-0264","termGroup":"CN","termSource":"NCI"},{"termName":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"Ultra-long Acting PEG-SN38","termGroup":"SY","termSource":"NCI"},{"termName":"Ultra-Long-Acting-PEG-SN-38","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318"},{"name":"NCI_Drug_Dictionary_ID","value":"778327"},{"name":"NCI_META_CUI","value":"CL504040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778327"},{"name":"PDQ_Open_Trial_Search_ID","value":"778327"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150508":{"preferredName":"Polymer-encapsulated Luteolin Nanoparticle","code":"C150508","definitions":[{"definition":"A nanoparticle formulation containing the poorly water-soluble naturally-occurring flavonoid luteolin encapsulated within a water-soluble polymer, with potential anti-oxidant, anti-inflammatory, apoptosis-inducing and chemopreventive activities. Upon administration of the polymer-encapsulated luteolin nanoparticle, luteolin scavenges free radicals, protects cells from reactive oxygen species (ROS)-induced damage and induces direct tumor cell cycle arrest and apoptosis in tumor cells. This inhibits tumor cell proliferation and suppresses metastasis. Compared to luteolin alone, encapsulation increases the delivery of luteolin to the tumor cells by protecting the drug against clearance and degradation, increases blood circulation time and enhances delivery into the tumor through the leaky vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymer-encapsulated Luteolin Nanoparticle","termGroup":"PT","termSource":"NCI"},{"termName":"3',4',5,7-Tetrahydroxyflavone-encapsulated Polymer Nanoparticles","termGroup":"SY","termSource":"NCI"},{"termName":"Nano-luteolin","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoluteolin","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle-based Luteolin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polymer-encapsulated Luteolin Nanoparticle"},{"name":"NCI_Drug_Dictionary_ID","value":"793030"},{"name":"NCI_META_CUI","value":"CL552290"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793030"},{"name":"PDQ_Open_Trial_Search_ID","value":"793030"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C69079":{"preferredName":"Polymeric Camptothecin Prodrug XMT-1001","code":"C69079","definitions":[{"definition":"A polymeric prodrug of camptothecin (CPT) with potential antineoplastic activity. Polymeric camptothecin prodrug XMT-1001 consists of CPT conjugated to the 60-70 kDa, inert, bio-degradable, hydrophilic copolymer poly[1-hydroxymethylene hydroxymethyl formal] (PHF). Through a dual-phase, non-enzymatic release mechanism, CPT is first released in plasma from XMT-1001 as the lipophilic prodrugs CPT-SI (a succinimidoglycinate derivative) and CPT-SA (a succinamidoyl glycinate derivative), which are then hydrolyzed within tissues to release the lactone form of CPT. CPT inhibits the catalytic activity of DNA topoisomerase I, thereby inhibiting DNA replication and inducing apoptosis. This agent may exhibit a more favorable pharmacokinetic profile than other agents in the same class.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymeric Camptothecin Prodrug XMT-1001","termGroup":"PT","termSource":"NCI"},{"termName":"MER-1001","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polymeric_Camptothecin_Prodrug_XMT-1001"},{"name":"Maps_To","value":"Polymeric Camptothecin Prodrug XMT-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"544567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"544567"},{"name":"PDQ_Open_Trial_Search_ID","value":"544567"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347623"}]}}{"C129595":{"preferredName":"Polypodium leucotomos Extract","code":"C129595","definitions":[{"definition":"A nutritional supplement composed of an aqueous extract derived from the leaves of the tropical fern belonging to the Polypodiaceae family, Polypodium leucotomos (PL; Phlebodium aureum), with potential photoprotective, skin protective, anti-inflammatory, immunomodulating and antioxidant activities. This extract contains many phenolic compounds, such as ferulic, caffeic, coumaric and vanillic acid, which are mainly responsible for this extract's effects. Upon administration, Polypodium leucotomos extract (PLE) exerts antioxidant activity by scavenging free radicals and inhibiting the generation and release of reactive oxygen species (ROS), thereby preventing ultraviolet (UV)-induced as well as ROS-induced DNA damage. In addition, the chemicals in this extract protect antioxidant enzymes and modulate expression of cancer and inflammation-related genes, including the induction of the expression of tumor suppressor genes and the inhibition of the expression of pro-inflammatory cytokines and inflammatory enzymes, thereby inhibiting the activation of signal transduction pathways involved in carcinogenesis and inflammation, respectively. PLE also stimulates tissue inhibitors of metalloproteinases (TIMPs) and inhibits matrix metalloproteinases (MMPs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polypodium leucotomos Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Fernblock","termGroup":"FB","termSource":"NCI"},{"termName":"PL Extract","termGroup":"SY","termSource":"NCI"},{"termName":"PLE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polypodium leucotomos Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"783987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783987"},{"name":"PDQ_Open_Trial_Search_ID","value":"783987"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1614561"}]}}{"C1204":{"preferredName":"Polysaccharide-K","code":"C1204","definitions":[{"definition":"A protein-bound polysaccharide derived from the mushroom Trametes versicolor (Turkey Tail) with immunoadjuvant and potential antitumor activities. Although its mechanism of action has yet to be fully elucidated, in vitro and in vivo studies indicate that polysaccharide-K induces peripheral blood monocyte secretion of IL-8 and TNF-alpha, induces T cell proliferation, and prevents cyclophosphamide-induced immunosuppression. This agent has also been reported to stimulate macrophages to produce reactive nitrogen intermediates and superoxide anions and to promote apoptosis in the promyelocytic leukemia cell line HL-60.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polysaccharide-K","termGroup":"PT","termSource":"NCI"},{"termName":"Krestin","termGroup":"BR","termSource":"NCI"},{"termName":"Krestin","termGroup":"FB","termSource":"NCI"},{"termName":"KS-2","termGroup":"AB","termSource":"NCI"},{"termName":"PSK","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66455-27-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polysaccharide-K"},{"name":"Maps_To","value":"Polysaccharide-K"},{"name":"NCI_Drug_Dictionary_ID","value":"39574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39574"},{"name":"PDQ_Open_Trial_Search_ID","value":"39574"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0072522"}]}}{"C1201":{"preferredName":"Polysialic Acid","code":"C1201","definitions":[{"definition":"A highly negative-charged carbohydrate composed of a linear polymer of alpha 2,8-linked sialic acid residue with potential immunotherapeutic activity. Polysialic acid (PSA) is mainly attached to the neural cell adhesion molecule (NCAM), a membrane-bound glycoprotein overexpressed in certain types of cancers. In embryonic tissue PSA-NCAM is abundantly expressed and PSA plays an important role in formation and remodeling of the neural system through modulation of the adhesive properties of NCAM, thereby reducing cell-cell interactions and promoting cellular mobility. In adult tissue however, the expression of PSA-NCAM is associated with a variety of malignant tumors, signifying its potential role in tumor metastasis. When administered in a vaccine formulation, PSA may stimulate a cytotoxic T cell response against tumors expressing PSA, thereby resulting in a reduction in tumor size.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polysialic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"PolySA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:26206"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polysialic_Acid"},{"name":"Maps_To","value":"Polysialic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"37839"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37839"},{"name":"PDQ_Open_Trial_Search_ID","value":"37839"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0071677"}]}}{"C67038":{"preferredName":"Polyunsaturated Fatty Acid","code":"C67038","definitions":[{"definition":"A class of dietary fatty acids containing two or more double bonds.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"A fatty acid containing more than one double bond (C=C). The essential fatty acids omega-3 and omega-6 are polyunsaturated fatty acids (PUFAs) that contain 2 or more cis double bonds. Dietary intake of some PUFAs may have beneficial effects on blood pressure, serum lipds, and inflammation. Some PUFAs, such as omega-3 PUFAs, may have antineoplastic or chemopreventive activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyunsaturated Fatty Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Fatty Acid, Total Polyunsaturated","termGroup":"SY","termSource":"NCI"},{"termName":"Polyunsaturated Fatty Acids","termGroup":"SY","termSource":"NCI"},{"termName":"PUFA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:26208"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"INFOODS","value":"FAPU"},{"name":"Legacy Concept Name","value":"Polyunsaturated_Fatty_Acid"},{"name":"Maps_To","value":"Polyunsaturated Fatty Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"539359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539359"},{"name":"PDQ_Open_Trial_Search_ID","value":"539359"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0032615"},{"name":"Unit","value":"g"},{"name":"USDA_ID","value":"646"}]}}{"C1633":{"preferredName":"Polyvalent Melanoma Vaccine","code":"C1633","definitions":[{"definition":"A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens.  Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyvalent Melanoma Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"PMCV","termGroup":"AB","termSource":"NCI"},{"termName":"Polyvalent Melanoma Cell Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polyvalent_Melanoma_Vaccine"},{"name":"Maps_To","value":"Polyvalent Melanoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43301"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43301"},{"name":"PDQ_Open_Trial_Search_ID","value":"43301"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299555"}]}}{"C72560":{"preferredName":"Pomalidomide","code":"C72560","definitions":[{"definition":"A substance being studied in the treatment of prostate cancer, multiple myeloma, and other types of cancer. Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pomalidomide","termGroup":"PT","termSource":"NCI"},{"termName":"3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Aminothalidomide","termGroup":"SY","termSource":"NCI"},{"termName":"Actimid","termGroup":"BR","termSource":"NCI"},{"termName":"CC-4047","termGroup":"CN","termSource":"NCI"},{"termName":"CC4047","termGroup":"CN","termSource":"NCI"},{"termName":"Imnovid","termGroup":"FB","termSource":"NCI"},{"termName":"Pomalyst","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative"},{"name":"CAS_Registry","value":"19171-19-8"},{"name":"Chemical_Formula","value":"C13H11N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D2UX06XLB5"},{"name":"Legacy Concept Name","value":"Pomalidomide"},{"name":"Maps_To","value":"Pomalidomide"},{"name":"NCI_Drug_Dictionary_ID","value":"653314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653314"},{"name":"PDQ_Open_Trial_Search_ID","value":"653314"},{"name":"PubMedID_Primary_Reference","value":"16085014"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347624"}]}}{"C26665":{"preferredName":"Pomegranate Juice","code":"C26665","definitions":[{"definition":"A natural juice isolated from the fruit of the plant Punica granatum with antioxidant, potential antineoplastic, and chemopreventive activities.  Pomegranate juice contains flavonoids which promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thereby inhibiting angiogenesis. The flavonoids in pomegranate juice also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pomegranate Juice","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"99S671U9KB"},{"name":"Legacy Concept Name","value":"Pomegranate_Juice"},{"name":"Maps_To","value":"Pomegranate Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"304321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304321"},{"name":"PDQ_Open_Trial_Search_ID","value":"304321"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C1327962"}]}}{"C78866":{"preferredName":"Pomegranate Liquid Extract","code":"C78866","definitions":[{"definition":"A liquid extract preparation derived from pomegranate (Punica granatum) seeds with antioxidant, and potential antineoplastic and chemopreventive activities. Pomegranate liquid extract contains flavonoids which may promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thus inhibiting angiogenesis. Pomegranate liquid extract flavanoids also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pomegranate Liquid Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Dadima Fruit Water","termGroup":"SY","termSource":"NCI"},{"termName":"Punica granatum Fruit Volatile Oil","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P52EO36K90"},{"name":"Legacy Concept Name","value":"Pomegranate_Liquid_Extract"},{"name":"Maps_To","value":"Pomegranate Liquid Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"613221"},{"name":"NCI_META_CUI","value":"CL387635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613221"},{"name":"PDQ_Open_Trial_Search_ID","value":"613221"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95777":{"preferredName":"Ponatinib","code":"C95777","definitions":[{"definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ponatinib","termGroup":"PT","termSource":"NCI"},{"termName":"AP-24534","termGroup":"CN","termSource":"NCI"},{"termName":"AP24534","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943319-70-8"},{"name":"Chemical_Formula","value":"C29H27F3N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4340891KFS"},{"name":"Maps_To","value":"Ponatinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987417"}]}}{"C78194":{"preferredName":"Ponatinib Hydrochloride","code":"C78194","definitions":[{"definition":"The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ponatinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"AP24534 HCl","termGroup":"AB","termSource":"NCI"},{"termName":"Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Iclusig","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1114544-31-8"},{"name":"Chemical_Formula","value":"C29H27F3N6O.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96R6PU3D8J"},{"name":"Legacy Concept Name","value":"Multitargeted_Receptor_Tyrosine_Kinase_Inhibitor_AP24534"},{"name":"Maps_To","value":"Ponatinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"595060"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595060"},{"name":"PDQ_Open_Trial_Search_ID","value":"595060"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981174"}]}}{"C146853":{"preferredName":"Porcupine Inhibitor CGX1321","code":"C146853","definitions":[{"definition":"An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic, protective and regenerative activities. Upon oral administration, PORCN inhibitor CGX1321 specifically targets and binds to PORCN in the endoplasmic reticulum (ER), thereby inhibiting the post-translational palmitoylation and secretion of Wnt ligands, thus preventing the activation of Wnt-mediated signaling, and inhibiting cell growth in Wnt-driven tumors. In addition, by inhibiting the secretion of Wnt ligands and preventing Wnt-mediated signaling, CGX1321 may also limit fibrosis and promote regeneration of certain tissues upon cell injury. PORCN catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers and plays a key role in tumor cell proliferation. It also plays a key role in tissue regeneration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor CGX1321","termGroup":"PT","termSource":"NCI"},{"termName":"CGX 1321","termGroup":"CN","termSource":"NCI"},{"termName":"CGX-1321","termGroup":"CN","termSource":"NCI"},{"termName":"CGX1321","termGroup":"CN","termSource":"NCI"},{"termName":"PORCN Inhibitor CGX1321","termGroup":"SY","termSource":"NCI"},{"termName":"WNT Signaling Inhibitor CGX1321","termGroup":"SY","termSource":"NCI"},{"termName":"WTN Inhibitor CGX1321","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Porcupine Inhibitor CGX1321"},{"name":"NCI_Drug_Dictionary_ID","value":"792268"},{"name":"NCI_META_CUI","value":"CL544835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792268"},{"name":"PDQ_Open_Trial_Search_ID","value":"792268"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123830":{"preferredName":"Porcupine Inhibitor ETC-1922159","code":"C123830","definitions":[{"definition":"An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, ETC-1922159 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational palmitoylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor ETC-1922159","termGroup":"PT","termSource":"NCI"},{"termName":"ETC-159","termGroup":"CN","termSource":"NCI"},{"termName":"ETC-1922159","termGroup":"CN","termSource":"NCI"},{"termName":"PORCN Inhibitor ETC-1922159","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638250-96-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5L854240DQ"},{"name":"Maps_To","value":"Porcupine Inhibitor ETC-1922159"},{"name":"NCI_Drug_Dictionary_ID","value":"775936"},{"name":"NCI_META_CUI","value":"CL498223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775936"},{"name":"PDQ_Open_Trial_Search_ID","value":"775936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156701":{"preferredName":"Zamaporvint","code":"C156701","definitions":[{"definition":"An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, zamaporvint binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zamaporvint","termGroup":"PT","termSource":"NCI"},{"termName":"Porcupine Inhibitor RXC004","termGroup":"SY","termSource":"NCI"},{"termName":"RXC 004","termGroup":"SY","termSource":"NCI"},{"termName":"RXC-004","termGroup":"SY","termSource":"NCI"},{"termName":"RXC004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1900754-56-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M56M7CHN8E"},{"name":"Maps_To","value":"Porcupine Inhibitor RXC004"},{"name":"NCI_Drug_Dictionary_ID","value":"795722"},{"name":"NCI_META_CUI","value":"CL935870"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795722"},{"name":"PDQ_Open_Trial_Search_ID","value":"795722"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116860":{"preferredName":"Porcupine Inhibitor WNT974","code":"C116860","definitions":[{"definition":"An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, WNT974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor WNT974","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2,3-Dimethyl-[2,4-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"LGK974","termGroup":"CN","termSource":"NCI"},{"termName":"PORCN inhibitor LGK974","termGroup":"SY","termSource":"NCI"},{"termName":"WNT974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1243244-14-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U27F40013Q"},{"name":"Maps_To","value":"Porcupine Inhibitor WNT974"},{"name":"NCI_Drug_Dictionary_ID","value":"700477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700477"},{"name":"PDQ_Open_Trial_Search_ID","value":"700477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3851400"}]}}{"C763":{"preferredName":"Porfiromycin","code":"C763","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An N-methyl derivative of the antineoplastic antibiotic mitomycin C isolated from the bacterium Streptomyces ardus and other Streptomyces bacterial species.  Bioreduced porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks, thereby inhibiting DNA synthesis.  Porfiromycin is preferentially toxic to hypoxic cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porfiromycin","termGroup":"PT","termSource":"NCI"},{"termName":"[1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Azirino[2',3':3,4]pyrrolo[1, 2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a, 8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-1,5-dimethyl-, carbamate (ester)(8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-,[1aR-(1a-alpha,8beta, 8a-alpha,8b-alpha)]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ENT-50825","termGroup":"CN","termSource":"NCI"},{"termName":"Methyl Mitomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Methylmitomycin","termGroup":"SY","termSource":"NCI"},{"termName":"N-methylmitomycin C","termGroup":"SN","termSource":"NCI"},{"termName":"Porfiromycine","termGroup":"SY","termSource":"NCI"},{"termName":"Porphyromycin","termGroup":"SY","termSource":"NCI"},{"termName":"Promycin","termGroup":"BR","termSource":"NCI"},{"termName":"U-14,743","termGroup":"CN","termSource":"NCI"},{"termName":"U-14743","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"801-52-5"},{"name":"Chemical_Formula","value":"C16H20N4O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H1WK901OA6"},{"name":"Legacy Concept Name","value":"Porfiromycin"},{"name":"Maps_To","value":"Porfiromycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39610"},{"name":"NSC Number","value":"56410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39610"},{"name":"PDQ_Open_Trial_Search_ID","value":"39610"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032697"}]}}{"C98838":{"preferredName":"Poziotinib","code":"C98838","definitions":[{"definition":"An orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poziotinib","termGroup":"PT","termSource":"NCI"},{"termName":"HM781-36","termGroup":"CN","termSource":"NCI"},{"termName":"NOV120101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092364-38-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OEI6OOU6IK"},{"name":"Maps_To","value":"Poziotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"715507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715507"},{"name":"PDQ_Open_Trial_Search_ID","value":"715507"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3180480"}]}}{"C2235":{"preferredName":"PR1 Leukemia Peptide Vaccine","code":"C2235","definitions":[{"definition":"A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PR1 Leukemia Peptide Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Peptide Vaccine, PR1","termGroup":"SY","termSource":"NCI"},{"termName":"Proteinase 3:PR1 Peptide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"182253-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54XUF2TZ7G"},{"name":"Legacy Concept Name","value":"PR1_Leukemia_Peptide_Vaccine"},{"name":"Maps_To","value":"PR1 Leukemia Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"37873"},{"name":"NSC Number","value":"698102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37873"},{"name":"PDQ_Open_Trial_Search_ID","value":"37873"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879440"}]}}{"C71708":{"preferredName":"Pracinostat","code":"C71708","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. SB939 blocks the action of an enzyme called histone deacetylase (HDAC) and may stop tumor cells from dividing. It is a type of HDAC inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pracinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1h-benzimidazol-5-yl)-N-hydroxy-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"HDAC Inhibitor SB939","termGroup":"SY","termSource":"NCI"},{"termName":"kaempferol 3-o-beta-d-(6-E-P-coumaroylglucoside)","termGroup":"SN","termSource":"NCI"},{"termName":"SB939","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"929016-96-6"},{"name":"Chemical_Formula","value":"C20H30N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"GPO2JN4UON"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_SB939"},{"name":"Maps_To","value":"Pracinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"559644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"559644"},{"name":"PDQ_Open_Trial_Search_ID","value":"559644"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467801"}]}}{"C2250":{"preferredName":"Pralatrexate","code":"C2250","definitions":[{"definition":"A drug used in the treatment of peripheral T-cell lymphoma (a fast-growing form of non-Hodgkin lymphoma). It is also being studied in the treatment of other types of cancer. Pralatrexate may block the growth of cancer cells and cause them to die. It is a type of dihydrofolate reductase (DHFR) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pralatrexate","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-[[4-[(1RS)-1-[(2, 4-Diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"10-Propargyl-10-Deazaaminopterin","termGroup":"SN","termSource":"NCI"},{"termName":"Folotyn","termGroup":"BR","termSource":"NCI"},{"termName":"N-(4-{1-[(2,4-Diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"PDX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"146464-95-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A8Q8I19Q20"},{"name":"Legacy Concept Name","value":"_10-Propargyl-10-Deazaaminopterin"},{"name":"Maps_To","value":"Pralatrexate"},{"name":"NCI_Drug_Dictionary_ID","value":"37828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37828"},{"name":"PDQ_Open_Trial_Search_ID","value":"37828"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879404"}]}}{"C128029":{"preferredName":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701","code":"C128029","definitions":[{"definition":"Human allogeneic T-lymphocytes transduced with a retroviral vector encoding a high-affinity T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-01-restricted, preferentially-expressed antigen in melanoma (PRAME) and containing the chemical induction of dimerization (CID) suicide/safety switch, composed of a drug binding domain coupled to the signaling domain of the suicide enzyme caspase-9, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-PRAME-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, PRAME-targeting T-cell receptor-based therapy BPX-701 binds to tumor cells expressing PRAME, which may induce cell death in and halt the growth of PRAME-expressing cancer cells. The tumor-associated antigen PRAME is overexpressed by a variety of cancer cell types. If potential T-cell toxicity due to graft-versus-host disease (GvHD) occurs, the chemical dimerizer rimiducid (AP1903) can be adminstered. Rimiducid binds to the drug binding domain expressed by the BPX-701 T-cells, and triggers activation of the caspase-9 domain, which leads to caspase 9-mediated signaling, the induction of apoptosis and to selective and complete elimination of BPX-701 cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701","termGroup":"PT","termSource":"NCI"},{"termName":"BPX-701","termGroup":"CN","termSource":"NCI"},{"termName":"CaspaCID-based PRAME-TCR Allogeneic T-lymphocytes BPX-701","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701"},{"name":"NCI_Drug_Dictionary_ID","value":"781247"},{"name":"NCI_META_CUI","value":"CL507923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781247"},{"name":"PDQ_Open_Trial_Search_ID","value":"781247"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29375":{"preferredName":"Pravastatin Sodium","code":"C29375","definitions":[{"definition":"A drug used to lower the amount of cholesterol in the blood and to prevent stroke and heart attack. It is also being studied in the treatment of cancer and other conditions. Pravastatin sodium blocks an enzyme that helps make cholesterol in the body. It may also make tumor cells more sensitive to anticancer drugs. It is a type of HMG-CoA reductase inhibitor, a type of statin, and a type of chemosensitizer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pravastatin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Pravachol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81131-70-6"},{"name":"CHEBI_ID","value":"CHEBI:8361"},{"name":"Chemical_Formula","value":"C23H35O7.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3M8608UQ61"},{"name":"Legacy Concept Name","value":"Pravastatin"},{"name":"Maps_To","value":"Pravastatin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"424450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"424450"},{"name":"PDQ_Open_Trial_Search_ID","value":"424450"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700474"}]}}{"C768":{"preferredName":"Prednimustine","code":"C768","definitions":[{"definition":"The prednisolone ester of chlorambucil and nitrogen mustard alkylating agent with antineoplastic activity. Prednimustine itself is not cytotoxic, however, it becomes cytotoxic upon hydrolysis by serum esterases to chlorambucil. Therefore, the increased potency of prednimustine is linked to the prolonged availability of free chlorambucil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednimustine","termGroup":"PT","termSource":"NCI"},{"termName":"11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-[4-[p-[bis(3-chloroethyl)amino]phenyl]butyrate]","termGroup":"SN","termSource":"NCI"},{"termName":"11beta-21-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxypregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Chlorambucil Prednisolone Ester","termGroup":"SY","termSource":"NCI"},{"termName":"LEO-1031","termGroup":"CN","termSource":"NCI"},{"termName":"Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-,21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate)","termGroup":"SN","termSource":"NCI"},{"termName":"Sterecyt","termGroup":"FB","termSource":"NCI"},{"termName":"Stereocyt","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"29069-24-7"},{"name":"Chemical_Formula","value":"C35H45Cl2NO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9403SIO2S8"},{"name":"Legacy Concept Name","value":"Prednimustine"},{"name":"Maps_To","value":"Prednimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"39560"},{"name":"NSC Number","value":"134087"},{"name":"NSC Number","value":"171345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39560"},{"name":"PDQ_Open_Trial_Search_ID","value":"39560"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032949"}]}}{"C769":{"preferredName":"Prednisolone","code":"C769","definitions":[{"definition":"A drug that lessens inflammation and suppresses the body's immune response. It may also kill cancer cells. Prednisolone is used to treat disorders in many organ systems and to treat the symptoms of several types of leukemia and lymphoma. It is also being studied in the treatment of other types of cancer. Prednisolone is a type of therapeutic glucocorticoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisolone","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1,2-Dehydrohydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"Adnisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Aprednislon","termGroup":"FB","termSource":"NCI"},{"termName":"Capsoid","termGroup":"FB","termSource":"NCI"},{"termName":"Cortalone","termGroup":"BR","termSource":"NCI"},{"termName":"Cortisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Dacortin H","termGroup":"FB","termSource":"NCI"},{"termName":"Decaprednil","termGroup":"FB","termSource":"NCI"},{"termName":"Decortin H","termGroup":"FB","termSource":"NCI"},{"termName":"Delta(1)Hydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Delta- Cortef","termGroup":"FB","termSource":"NCI"},{"termName":"Delta-Cortef","termGroup":"BR","termSource":"NCI"},{"termName":"Delta-Diona","termGroup":"FB","termSource":"NCI"},{"termName":"Delta-F","termGroup":"SY","termSource":"NCI"},{"termName":"Delta-Phoricol","termGroup":"FB","termSource":"NCI"},{"termName":"Delta1-dehydro-hydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltacortril","termGroup":"FB","termSource":"NCI"},{"termName":"Deltahydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltasolone","termGroup":"FB","termSource":"NCI"},{"termName":"Deltidrosol","termGroup":"FB","termSource":"NCI"},{"termName":"Dhasolone","termGroup":"FB","termSource":"NCI"},{"termName":"Di-Adreson-F","termGroup":"FB","termSource":"NCI"},{"termName":"Dontisolon D","termGroup":"FB","termSource":"NCI"},{"termName":"Estilsona","termGroup":"FB","termSource":"NCI"},{"termName":"Fisopred","termGroup":"FB","termSource":"NCI"},{"termName":"Frisolona","termGroup":"FB","termSource":"NCI"},{"termName":"Gupisone","termGroup":"FB","termSource":"NCI"},{"termName":"Hostacortin H","termGroup":"FB","termSource":"NCI"},{"termName":"Hydeltra","termGroup":"BR","termSource":"NCI"},{"termName":"Hydeltrasol","termGroup":"BR","termSource":"NCI"},{"termName":"Klismacort","termGroup":"FB","termSource":"NCI"},{"termName":"Kuhlprednon","termGroup":"FB","termSource":"NCI"},{"termName":"Lenisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Lepi-Cortinolo","termGroup":"FB","termSource":"NCI"},{"termName":"Linola-H N","termGroup":"FB","termSource":"NCI"},{"termName":"Linola-H-Fett N","termGroup":"FB","termSource":"NCI"},{"termName":"Longiprednil","termGroup":"FB","termSource":"NCI"},{"termName":"Metacortandralone","termGroup":"SY","termSource":"NCI"},{"termName":"Meti Derm","termGroup":"SY","termSource":"NCI"},{"termName":"Meticortelone","termGroup":"FB","termSource":"NCI"},{"termName":"Opredsone","termGroup":"FB","termSource":"NCI"},{"termName":"Panafcortelone","termGroup":"FB","termSource":"NCI"},{"termName":"Precortisyl","termGroup":"FB","termSource":"NCI"},{"termName":"Pred-Clysma","termGroup":"FB","termSource":"NCI"},{"termName":"Predeltilone","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-Coelin","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-Helvacort","termGroup":"FB","termSource":"NCI"},{"termName":"Prednicortelone","termGroup":"FB","termSource":"NCI"},{"termName":"Prednisolonum","termGroup":"SY","termSource":"NCI"},{"termName":"Prelone","termGroup":"BR","termSource":"NCI"},{"termName":"Prenilone","termGroup":"FB","termSource":"NCI"},{"termName":"Sterane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Inflammatory conditions; Allergic conditions; Hematologic conditions; Neoplastic conditions; Autoimmune conditions; Replacement therapy in adrenal insufficiency"},{"name":"CAS_Registry","value":"50-24-8"},{"name":"CHEBI_ID","value":"CHEBI:8378"},{"name":"Chemical_Formula","value":"C21H28O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9PHQ9Y1OLM"},{"name":"Legacy Concept Name","value":"Prednisolone"},{"name":"Maps_To","value":"Prednisolone"},{"name":"NCI_Drug_Dictionary_ID","value":"43296"},{"name":"NSC Number","value":"9120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43296"},{"name":"PDQ_Open_Trial_Search_ID","value":"43296"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032950"}]}}{"C1202":{"preferredName":"Prednisolone Acetate","code":"C1202","definitions":[{"definition":"The acetate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone acetate binds to specific intracellular glucocorticoid receptors, and causes the ligand-receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisolone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Ak-Tate","termGroup":"FB","termSource":"NCI"},{"termName":"Articulose-50","termGroup":"BR","termSource":"NCI"},{"termName":"Balpred","termGroup":"FB","termSource":"NCI"},{"termName":"Deltacortilen","termGroup":"FB","termSource":"NCI"},{"termName":"Deltastab","termGroup":"FB","termSource":"NCI"},{"termName":"Di-Adreson-F","termGroup":"FB","termSource":"NCI"},{"termName":"Diopred","termGroup":"FB","termSource":"NCI"},{"termName":"Econopred","termGroup":"BR","termSource":"NCI"},{"termName":"Flo-Pred","termGroup":"BR","termSource":"NCI"},{"termName":"Hexacortone","termGroup":"FB","termSource":"NCI"},{"termName":"Hydrocortancyl","termGroup":"FB","termSource":"NCI"},{"termName":"Inf-Oph","termGroup":"FB","termSource":"NCI"},{"termName":"Inflanefran","termGroup":"FB","termSource":"NCI"},{"termName":"Key-Pred","termGroup":"BR","termSource":"NCI"},{"termName":"Locaseptil-Neo","termGroup":"FB","termSource":"NCI"},{"termName":"Ophtho-Tate","termGroup":"FB","termSource":"NCI"},{"termName":"Pred Fort","termGroup":"FB","termSource":"NCI"},{"termName":"Pred Forte","termGroup":"BR","termSource":"NCI"},{"termName":"Pred Mild","termGroup":"BR","termSource":"NCI"},{"termName":"Predaject","termGroup":"BR","termSource":"NCI"},{"termName":"Predalone","termGroup":"FB","termSource":"NCI"},{"termName":"Predate","termGroup":"FB","termSource":"NCI"},{"termName":"Predcor","termGroup":"FB","termSource":"NCI"},{"termName":"Prednefrin SF","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-H","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-POS","termGroup":"FB","termSource":"NCI"},{"termName":"Prednihexal","termGroup":"FB","termSource":"NCI"},{"termName":"Predniocil","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52-21-1"},{"name":"Chemical_Formula","value":"C23H30O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B2807733D"},{"name":"Legacy Concept Name","value":"Prednisolone_Acetate"},{"name":"Maps_To","value":"Prednisolone Acetate"},{"name":"NSC Number","value":"10966"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071839"}]}}{"C1402":{"preferredName":"Prednisolone Sodium Phosphate","code":"C1402","definitions":[{"definition":"The sodium phosphate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone sodium phosphate binds to specific intracellular glucocorticoid receptors, and causes the ligand- receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisolone Sodium Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Ak-Pred","termGroup":"BR","termSource":"NCI"},{"termName":"Inflamase","termGroup":"BR","termSource":"NCI"},{"termName":"Key-Pred SP","termGroup":"BR","termSource":"NCI"},{"termName":"Millipred","termGroup":"BR","termSource":"NCI"},{"termName":"Orapred","termGroup":"BR","termSource":"NCI"},{"termName":"Orapred ODT","termGroup":"BR","termSource":"NCI"},{"termName":"Pediapred","termGroup":"BR","termSource":"NCI"},{"termName":"Polypred","termGroup":"FB","termSource":"NCI"},{"termName":"Predmix","termGroup":"FB","termSource":"NCI"},{"termName":"Prednabene","termGroup":"FB","termSource":"NCI"},{"termName":"Prednesol","termGroup":"FB","termSource":"NCI"},{"termName":"Prednisol","termGroup":"BR","termSource":"NCI"},{"termName":"Prednisolone Sodium Phosphate ODT","termGroup":"SY","termSource":"NCI"},{"termName":"Predsol","termGroup":"FB","termSource":"NCI"},{"termName":"Veripred 20","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125-02-0"},{"name":"CHEBI_ID","value":"CHEBI:8379"},{"name":"Chemical_Formula","value":"C21H27O8P.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IV021NXA9J"},{"name":"Legacy Concept Name","value":"Prednisolone_Sodium_Phosphate"},{"name":"Maps_To","value":"Prednisolone Sodium Phosphate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0138273"}]}}{"C770":{"preferredName":"Prednisone","code":"C770","definitions":[{"definition":"A drug used to lessen inflammation and lower the body's immune response. It is used with other drugs to treat leukemia and lymphoma and other types of cancer. It is also used alone or with other drugs to prevent or treat many other conditions. These include conditions related to cancer, such as anemia (a low level of red blood cells), allergic reactions, and loss of appetite. Prednisone is a type of therapeutic glucocorticoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisone","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Dehydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"17,21-Dihydroxypregna-1,4-diene-3,11,20-trione","termGroup":"SN","termSource":"NCI"},{"termName":"Adasone","termGroup":"FB","termSource":"NCI"},{"termName":"Cortancyl","termGroup":"FB","termSource":"NCI"},{"termName":"Dacortin","termGroup":"FB","termSource":"NCI"},{"termName":"DeCortin","termGroup":"FB","termSource":"NCI"},{"termName":"Decortisyl","termGroup":"FB","termSource":"NCI"},{"termName":"Decorton","termGroup":"FB","termSource":"NCI"},{"termName":"Delta 1-Cortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Delta-Dome","termGroup":"AQS","termSource":"NCI"},{"termName":"Deltacortene","termGroup":"FB","termSource":"NCI"},{"termName":"Deltacortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltadehydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltison","termGroup":"FB","termSource":"NCI"},{"termName":"Deltra","termGroup":"FB","termSource":"NCI"},{"termName":"Econosone","termGroup":"FB","termSource":"NCI"},{"termName":"Liquid Pred","termGroup":"AQS","termSource":"NCI"},{"termName":"Lisacort","termGroup":"AQS","termSource":"NCI"},{"termName":"Meprosona-F","termGroup":"FB","termSource":"NCI"},{"termName":"Metacortandracin","termGroup":"SY","termSource":"NCI"},{"termName":"Meticorten","termGroup":"AQS","termSource":"NCI"},{"termName":"Ofisolona","termGroup":"FB","termSource":"NCI"},{"termName":"Orasone","termGroup":"AQS","termSource":"NCI"},{"termName":"Panafcort","termGroup":"FB","termSource":"NCI"},{"termName":"Panasol-S","termGroup":"FB","termSource":"NCI"},{"termName":"Paracort","termGroup":"FB","termSource":"NCI"},{"termName":"Perrigo Prednisone","termGroup":"BR","termSource":"NCI"},{"termName":"PRED","termGroup":"AB","termSource":"NCI"},{"termName":"Predeltin","termGroup":"AQS","termSource":"NCI"},{"termName":"Predicor","termGroup":"FB","termSource":"NCI"},{"termName":"Predicorten","termGroup":"FB","termSource":"NCI"},{"termName":"Prednicen-M","termGroup":"AQS","termSource":"NCI"},{"termName":"Prednicort","termGroup":"FB","termSource":"NCI"},{"termName":"Prednidib","termGroup":"FB","termSource":"NCI"},{"termName":"Prednilonga","termGroup":"FB","termSource":"NCI"},{"termName":"Predniment","termGroup":"FB","termSource":"NCI"},{"termName":"Prednisone Intensol","termGroup":"SY","termSource":"NCI"},{"termName":"Prednisone Intensol","termGroup":"BR","termSource":"NCI"},{"termName":"Prednisonum","termGroup":"SY","termSource":"NCI"},{"termName":"Prednitone","termGroup":"FB","termSource":"NCI"},{"termName":"Promifen","termGroup":"FB","termSource":"NCI"},{"termName":"Rayos","termGroup":"BR","termSource":"NCI"},{"termName":"Servisone","termGroup":"FB","termSource":"NCI"},{"termName":"Sk-Prednisone","termGroup":"AQS","termSource":"NCI"},{"termName":"Sterapred","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Inflammatory conditions; Allergic conditions; Hematologic conditions; Neoplastic conditions; Autoimmune conditions; Replacement therapy in adrenal insufficiency"},{"name":"CAS_Registry","value":"53-03-2"},{"name":"CHEBI_ID","value":"CHEBI:8382"},{"name":"Chemical_Formula","value":"C21H26O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"VB0R961HZT"},{"name":"Legacy Concept Name","value":"Prednisone"},{"name":"Maps_To","value":"Prednisone"},{"name":"NCI_Drug_Dictionary_ID","value":"42487"},{"name":"NSC Number","value":"10023"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42487"},{"name":"PDQ_Open_Trial_Search_ID","value":"42487"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032952"}]}}{"C91392":{"preferredName":"Prexasertib","code":"C91392","definitions":[{"definition":"An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prexasertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinecarbonitrile, 5-((5-(2-(3-Aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"ACR 368","termGroup":"CN","termSource":"NCI"},{"termName":"ACR-368","termGroup":"CN","termSource":"NCI"},{"termName":"ACR368","termGroup":"CN","termSource":"NCI"},{"termName":"LY2606368","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1234015-52-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"820NH671E6"},{"name":"Maps_To","value":"Prexasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"673506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673506"},{"name":"PDQ_Open_Trial_Search_ID","value":"673506"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984213"}]}}{"C91736":{"preferredName":"Prexigebersen","code":"C91736","definitions":[{"definition":"A liposomal formulation containing the antisense oligodeoxynucleotide (ODN) growth factor receptor-bound protein 2 (Grb2), with potential antineoplastic activity. Upon administration, liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of cancer cells overexpressing Grb2. Grb2, an adaptor protein involved in growth signaling pathways, is upregulated in certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prexigebersen","termGroup":"PT","termSource":"NCI"},{"termName":"BP-100-1.01","termGroup":"CN","termSource":"NCI"},{"termName":"BP-1001","termGroup":"CN","termSource":"NCI"},{"termName":"BP1001","termGroup":"CN","termSource":"NCI"},{"termName":"Liposomal Grb2 AS ODN","termGroup":"SY","termSource":"NCI"},{"termName":"Liposome-Incorporated Grb2 Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"202484-91-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8W1O4Y961B"},{"name":"Maps_To","value":"Prexigebersen"},{"name":"NCI_Drug_Dictionary_ID","value":"681815"},{"name":"NCI_META_CUI","value":"CL421657"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681815"},{"name":"PDQ_Open_Trial_Search_ID","value":"681815"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85465":{"preferredName":"Eprenetapopt","code":"C85465","definitions":[{"definition":"A methylated derivative and structural analog of PRIMA-1 (p53 re-activation and induction of massive apoptosis), with potential antineoplastic activity. Upon administration, eprenetapopt covalently modifies the core domain of mutated forms of cellular tumor antigen p53 (p53) through the alkylation of thiol groups. These modifications restore both the wild-type conformation and function to mutant p53, which reconstitutes endogenous p53 activity, leading to cell cycle arrest and apoptosis in tumor cells. This agent may work synergistically with other antineoplastic agents. p53, a tumor suppressor and transcription factor normally activated upon DNA damage, is frequently mutated and overexpressed in cancer cells; it plays a key role in both DNA repair and the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eprenetapopt","termGroup":"PT","termSource":"NCI"},{"termName":"APR-246","termGroup":"CN","termSource":"NCI"},{"termName":"PRIMA-1MET","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5291-32-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z41TGB4080"},{"name":"Maps_To","value":"PRIMA-1 Analog APR-246"},{"name":"NCI_Drug_Dictionary_ID","value":"643796"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643796"},{"name":"PDQ_Open_Trial_Search_ID","value":"643796"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830138"}]}}{"C143059":{"preferredName":"Prime Cancer Vaccine MVA-BN-CV301","code":"C143059","definitions":[{"definition":"A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301, a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prime Cancer Vaccine MVA-BN-CV301","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara-Bavarian Nordic Vaccine CV301","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-BN Vaccine CV301","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-BN-CV301","termGroup":"SY","termSource":"NCI"},{"termName":"Prime Vaccine CV301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prime Cancer Vaccine MVA-BN-CV301"},{"name":"NCI_Drug_Dictionary_ID","value":"791888"},{"name":"NCI_META_CUI","value":"CL541455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791888"},{"name":"PDQ_Open_Trial_Search_ID","value":"791888"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C1811":{"preferredName":"Prinomastat","code":"C1811","definitions":[{"definition":"A synthetic hydroxamic acid derivative with potential antineoplastic activity.  Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  As a lipophilic agent, prinomastat crosses the blood-brain barrier. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Prinomastat is a matrix metalloproteinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Prinomastat","termGroup":"PT","termSource":"NCI"},{"termName":"(3S)-N-Hydroxy-2,2-dimethyl-4-{{4-(4-piridinyloxy)phenyl}sulfonyl}-3-thiomorpholinecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"AG3340","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192329-42-3"},{"name":"Chemical_Formula","value":"C18H21N3O5S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"10T6626FRK"},{"name":"Legacy Concept Name","value":"Prinomastat"},{"name":"Maps_To","value":"Prinomastat"},{"name":"NCI_Drug_Dictionary_ID","value":"43058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43058"},{"name":"PDQ_Open_Trial_Search_ID","value":"43058"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919273"}]}}{"C156759":{"preferredName":"PRMT1 Inhibitor GSK3368715","code":"C156759","definitions":[{"definition":"An orally available inhibitor of protein arginine N-methyltransferase 1 (PRMT1; Histone-arginine N-methyltransferase PRMT1; Interferon receptor 1-bound protein 4) with potential antineoplastic activity. Upon administration, GSK3368715 inhibits monomethylation and asymmetric dimethylation of arginine-bearing substrates, including histones, estrogen receptors, RNA-binding proteins, and numerous non-histone substrates catalyzed by PRMT1. This may inhibit tumor cell proliferation, migration, and invasion that is potentially driven by PRMT1 overexpression or dysregulation. PRMT1-mediated methylation plays a key role in the modulation of protein function, gene expression and cellular signaling. Dysregulation and overexpression of PRMT1 has been associated with a number of solid and hematopoietic cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRMT1 Inhibitor GSK3368715","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 3368715","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3368715","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3368715","termGroup":"CN","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 1 Inhibitor GSK3368715","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PRMT1 Inhibitor GSK3368715"},{"name":"NCI_Drug_Dictionary_ID","value":"795836"},{"name":"NCI_META_CUI","value":"CL935878"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795836"},{"name":"PDQ_Open_Trial_Search_ID","value":"795836"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163980":{"preferredName":"Onametostat","code":"C163980","definitions":[{"definition":"An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration,onametostat selectively targets and irreversibly binds to the S-adenosylmethionine (SAM)- and substrate-binding pockets of the PRMT5/methylosome protein 50 (MEP50) complex, and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onametostat","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 64619178","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64619178","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ64619178","termGroup":"CN","termSource":"NCI"},{"termName":"PRMT5 Inhibitor JNJ-64619178","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 5 Inhibitor JNJ-64619178","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2086772-26-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N8VKI8FPW0"},{"name":"Maps_To","value":"PRMT5 Inhibitor JNJ-64619178"},{"name":"NCI_Drug_Dictionary_ID","value":"799112"},{"name":"NCI_META_CUI","value":"CL977245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799112"},{"name":"PDQ_Open_Trial_Search_ID","value":"799112"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133019":{"preferredName":"Proapoptotic Sulindac Analog CP-461","code":"C133019","definitions":[{"definition":"An orally bioavailable second-generation selective apoptotic antineoplastic drug (SAAND) and analog of the nonsteroidal anti-inflammatory drug (NSAID) sulindac, with potential pro-apoptotic and antineoplastic activities. Upon administration, CP-461 specifically binds to and blocks the activity of cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway. Inhibition of cGMP-PDE permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. cGMP-PDE is overexpressed in a variety of cancer cell types; therefore, CP-461 selectively induces apoptosis in cancer cells, with minimal or no effect in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proapoptotic Sulindac Analog CP-461","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Indene-3-acetamide, 5-Fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, Monohydrochloride, (1Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"CEL 031","termGroup":"CN","termSource":"NCI"},{"termName":"CP 461","termGroup":"CN","termSource":"NCI"},{"termName":"CP-461","termGroup":"CN","termSource":"NCI"},{"termName":"CP461","termGroup":"CN","termSource":"NCI"},{"termName":"OSI 461","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"227619-96-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68OJX9I7DT"},{"name":"Maps_To","value":"Proapoptotic Sulindac Analog CP-461"},{"name":"NCI_Drug_Dictionary_ID","value":"354217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354217"},{"name":"PDQ_Open_Trial_Search_ID","value":"354217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1101538"}]}}{"C62072":{"preferredName":"Procarbazine","code":"C62072","definitions":[{"definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat advanced Hodgkin lymphoma and is being studied in the treatment of other types of cancer. Procarbazine blocks cells from making proteins and damages DNA. It may kill cancer cells. It is a type of antineoplastic agent and a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Procarbazine","termGroup":"PT","termSource":"NCI"},{"termName":"Benzethyzin","termGroup":"SY","termSource":"NCI"},{"termName":"Ibenzmethyzin","termGroup":"SY","termSource":"NCI"},{"termName":"N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-Methylhydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Procarbazin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"671-16-9"},{"name":"Chemical_Formula","value":"C12H19N3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"35S93Y190K"},{"name":"Legacy Concept Name","value":"Procarbazine_Base"},{"name":"Maps_To","value":"Procarbazine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0033223"}]}}{"C773":{"preferredName":"Procarbazine Hydrochloride","code":"C773","definitions":[{"definition":"A drug that is used to treat advanced Hodgkin lymphoma and is being studied in the treatment of other types of cancer. Matulane blocks cells from making proteins and damages DNA. It may kill cancer cells. It is a type of antineoplastic agent and a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Procarbazine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Matulane","termGroup":"BR","termSource":"NCI"},{"termName":"MIH hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Natulan","termGroup":"FB","termSource":"NCI"},{"termName":"Natulanar","termGroup":"FB","termSource":"NCI"},{"termName":"Natunalar","termGroup":"FB","termSource":"NCI"},{"termName":"NCI-C01810","termGroup":"CN","termSource":"NCI"},{"termName":"p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"p-toluamide, N-isopropyl-alpha-(2-methylhydrazino)-, monohydrochloride (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"PCB","termGroup":"AB","termSource":"NCI"},{"termName":"PCB Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"PCZ","termGroup":"AB","termSource":"NCI"},{"termName":"Ro 4-6467/1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Brain tumors; Hodgkins diseases; Non-Hodgkins lymphoma"},{"name":"CAS_Registry","value":"366-70-1"},{"name":"Chemical_Formula","value":"C12H19N3O.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XH0NPH5ZX8"},{"name":"Legacy Concept Name","value":"Procarbazine"},{"name":"Maps_To","value":"Procarbazine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41607"},{"name":"NSC Number","value":"77213"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41607"},{"name":"PDQ_Open_Trial_Search_ID","value":"41607"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0205909"}]}}{"C120318":{"preferredName":"Procaspase Activating Compound-1 VO-100","code":"C120318","definitions":[{"definition":"An orally bioavailable procaspase activating compound-1 (PAC-1), with potential proapoptotic and antineoplastic activities. Upon administration, VO-100 binds to and forms a chelating complex with zinc (Zn) ions inside cells, which prevents the binding of Zn ions to procaspase-3 (PC3) and abrogates the Zn-mediated inhibition of PC3. This allows for the proteolytic autoactivation of PC3 into the active form caspase-3. This results in the selective caspase-3-mediated induction of apoptosis and cell death in cancer cells. In addition, VO-100 is able to cross the blood-brain-barrier (BBB). PC3, a Zn-inhibited proenzyme, is upregulated in a variety of cancer cell types, while its expression is minimal in normal healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Procaspase Activating Compound-1 VO-100","termGroup":"PT","termSource":"NCI"},{"termName":"PAC-1","termGroup":"AB","termSource":"NCI"},{"termName":"PAC-1 VO-100","termGroup":"SY","termSource":"NCI"},{"termName":"VO-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"315183-21-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9LIS8N0B2C"},{"name":"Maps_To","value":"Procaspase Activating Compound-1 VO-100"},{"name":"NCI_Drug_Dictionary_ID","value":"768985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768985"},{"name":"PDQ_Open_Trial_Search_ID","value":"768985"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3889731"}]}}{"C184790":{"preferredName":"Progestational Intrauterine Device","code":"C184790","definitions":[{"definition":"An intrauterine device impregnated with progestin (synthetic progesterone) that can be inserted into the uterus to prevent conception.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progestational Intrauterine Device","termGroup":"PT","termSource":"NCI"},{"termName":"Progestational IUD","termGroup":"SY","termSource":"NCI"},{"termName":"Progestin IUD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progestational IUD"},{"name":"NCI_META_CUI","value":"CL763749"},{"name":"Semantic_Type","value":"Medical Device"}]}}{"C95709":{"preferredName":"Prohibitin-Targeting Peptide 1","code":"C95709","definitions":[{"definition":"A chimeric, 25-mer peptide that targets prohibitin, with potential antineoplastic activity. Prohibitin-targeting peptide 1 (prohibitin-TP01) consists of a fat-targeting motif (CKGGRAKDC), two repeats of a proapoptotic peptide motif (KLAKLAK) and a GG linker. This peptide binds specifically to prohibitin in the white adipose vasculature; upon receptor-mediated cell internalization, the ligand/receptor complex triggers apoptosis and results in ablation of white fat. Destruction of white fat may potentially have positive consequences for men with prostate cancer since a high level of white fat has been implicated as a critical contributing factor in poor prostate cancer outcome. Prohibitin, a multifunctional membrane-associated protein that is thought to regulate cell survival and growth, has been shown by immunohistochemical analysis to be expressed in the membrane of endothelial cells in white adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prohibitin-Targeting Peptide 1","termGroup":"PT","termSource":"NCI"},{"termName":"Prohibitin-TP01","termGroup":"SY","termSource":"NCI"},{"termName":"TP01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prohibitin-Targeting Peptide 1"},{"name":"NCI_Drug_Dictionary_ID","value":"691802"},{"name":"NCI_META_CUI","value":"CL428174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691802"},{"name":"PDQ_Open_Trial_Search_ID","value":"691802"},{"name":"PubMedID_Primary_Reference","value":"15133506"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129689":{"preferredName":"Palupiprant","code":"C129689","definitions":[{"definition":"An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palupiprant","termGroup":"PT","termSource":"NCI"},{"termName":"AN 0025","termGroup":"CN","termSource":"NCI"},{"termName":"AN-0025","termGroup":"CN","termSource":"NCI"},{"termName":"AN0025","termGroup":"CN","termSource":"NCI"},{"termName":"E 7046","termGroup":"CN","termSource":"NCI"},{"termName":"E-7046","termGroup":"CN","termSource":"NCI"},{"termName":"E7046","termGroup":"CN","termSource":"NCI"},{"termName":"EP4 Antagonist E7046","termGroup":"SY","termSource":"NCI"},{"termName":"EP4 Inhibitor E7046","termGroup":"SY","termSource":"NCI"},{"termName":"ER-886046","termGroup":"CN","termSource":"NCI"},{"termName":"Prostaglandin E EP4 Receptor Antagonist E7046","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 EP4 Receptor Inhibitor AN0025","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1369489-71-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YWY620GU8I"},{"name":"Maps_To","value":"Prostaglandin E2 EP4 Receptor Inhibitor AN0025"},{"name":"Maps_To","value":"Prostaglandin E2 EP4 Receptor Inhibitor E7046"},{"name":"NCI_Drug_Dictionary_ID","value":"792739"},{"name":"NCI_META_CUI","value":"CL507851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792739"},{"name":"PDQ_Open_Trial_Search_ID","value":"792739"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71723":{"preferredName":"Prostate Cancer Vaccine ONY-P1","code":"C71723","definitions":[{"definition":"A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Cancer Vaccine ONY-P1","termGroup":"PT","termSource":"NCI"},{"termName":"ONY-P1","termGroup":"CN","termSource":"NCI"},{"termName":"Onyvax-P","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prostate_Cancer_Vaccine_ONY-P1"},{"name":"Maps_To","value":"Prostate Cancer Vaccine ONY-P1"},{"name":"NCI_Drug_Dictionary_ID","value":"561135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561135"},{"name":"PDQ_Open_Trial_Search_ID","value":"561135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1667068"}]}}{"C77860":{"preferredName":"Prostate Health Cocktail Dietary Supplement","code":"C77860","definitions":[{"definition":"A dietary supplement consisting of a blend of 8 natural ingredients with potential antineoplastic and chemopreventive activities. This dietary supplement contains vitamin D3 (as cholecalciferol), vitamin E (as d-alpha tocopherol), selenium (as L-selenomethionine), epigallocatechin (green tea extract), saw palmetto (berry extract), lycopene, and the isoflavonoids daidzein and genistein. This combination preparation may decrease prostate cell growth and inhibit prostate carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Health Cocktail Dietary Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Cholecalciferol/d-Alpha Tocopherol/L-Selenomethionine/Green Tea Extract/Saw Palmetto Berry Extract/Daidzein/Genistein/Lycopene Prostate Health Supplement","termGroup":"SY","termSource":"NCI"},{"termName":"PHC","termGroup":"BR","termSource":"NCI"},{"termName":"Prostate Health Cocktail","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prostate_Health_Cocktail_Dietary_Supplement"},{"name":"Maps_To","value":"Prostate Health Cocktail Dietary Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"596155"},{"name":"NCI_META_CUI","value":"CL383736"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596155"},{"name":"PDQ_Open_Trial_Search_ID","value":"596155"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2548":{"preferredName":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024","code":"C2548","definitions":[{"definition":"A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024","termGroup":"PT","termSource":"NCI"},{"termName":"PA2024","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N5E5Q8249O"},{"name":"Legacy Concept Name","value":"Prostatic_Acid_Phosphatase-Sargramostim_Fusion_Protein"},{"name":"Maps_To","value":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024"},{"name":"NCI_Drug_Dictionary_ID","value":"38040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38040"},{"name":"PDQ_Open_Trial_Search_ID","value":"38040"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879585"}]}}{"C132192":{"preferredName":"Pacmilimab","code":"C132192","definitions":[{"definition":"A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacmilimab","termGroup":"PT","termSource":"NCI"},{"termName":"CX 072","termGroup":"CN","termSource":"NCI"},{"termName":"CX-072","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1 Probody Therapeutic CX-072","termGroup":"SY","termSource":"NCI"},{"termName":"Probody CX-072","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2101273-62-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZXP96ZI2RA"},{"name":"Maps_To","value":"Pacmilimab"},{"name":"Maps_To","value":"Protease-activated Anti-PD-L1 Antibody Prodrug CX-072"},{"name":"NCI_Drug_Dictionary_ID","value":"787226"},{"name":"NCI_META_CUI","value":"CL520194"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787226"},{"name":"PDQ_Open_Trial_Search_ID","value":"787226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142177":{"preferredName":"Pemrametostat","code":"C142177","definitions":[{"definition":"An orally available, selective small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not been completely determined, pemrametostat binds to the substrate recognition site of PRMT5 following oral administration and inhibits its methyltransferase activity, which decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cell proliferation. Therefore, this agent may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation and may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemrametostat","termGroup":"PT","termSource":"NCI"},{"termName":"EPZ015938","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3326595","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3326595","termGroup":"CN","termSource":"NCI"},{"termName":"PRMT5 Inhibitor GSK3326595","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 5 Inhibitor GSK3326595","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616392-22-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VXT8SZ6875"},{"name":"Maps_To","value":"Protein Arginine Methyltransferase 5 Inhibitor GSK3326595"},{"name":"NCI_Drug_Dictionary_ID","value":"791458"},{"name":"NCI_META_CUI","value":"CL540166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791458"},{"name":"PDQ_Open_Trial_Search_ID","value":"791458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158100":{"preferredName":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999","code":"C158100","definitions":[{"definition":"An orally available inhibitor of protein arginine N-methyltransferase 5 (histone-arginine N-methyltransferase PRMT5; PRMT5) with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not yet been fully elucidated, orally administered PRMT5 inhibitor PF-06939999 inhibits the methyltransferase activity of PRMT5, thereby decreasing the levels of monomethylated and dimethylated arginine residues in histones H2A, H3, and H4, and modulating the expression of genes involved in several cellular processes including cell proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, and may decrease the growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999","termGroup":"PT","termSource":"NCI"},{"termName":"PF 06939999","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06939999","termGroup":"CN","termSource":"NCI"},{"termName":"PF06939999","termGroup":"CN","termSource":"NCI"},{"termName":"PRMT5 Inhibitor PF-06939999","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2159123-14-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JY9FEZ3ZDX"},{"name":"Maps_To","value":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999"},{"name":"NCI_Drug_Dictionary_ID","value":"797355"},{"name":"NCI_META_CUI","value":"CL937738"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797355"},{"name":"PDQ_Open_Trial_Search_ID","value":"797355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162454":{"preferredName":"Protein Arginine Methyltransferase 5 Inhibitor PRT543","code":"C162454","definitions":[{"definition":"An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the exact mechanism of action has not been completely determined, upon oral administration, PRMT5 inhibitor PRT543 selectively binds to the substrate recognition site of PRMT5 and inhibits its methyltransferase activity. This decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cellular proliferation. As a result, PRT543 may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Arginine Methyltransferase 5 Inhibitor PRT543","termGroup":"PT","termSource":"NCI"},{"termName":"PRMT5 inhibitor PRT543","termGroup":"SY","termSource":"NCI"},{"termName":"PRT 543","termGroup":"CN","termSource":"NCI"},{"termName":"PRT-543","termGroup":"CN","termSource":"NCI"},{"termName":"PRT543","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Protein Arginine Methyltransferase 5 Inhibitor PRT543"},{"name":"NCI_Drug_Dictionary_ID","value":"798738"},{"name":"NCI_META_CUI","value":"CL970998"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798738"},{"name":"PDQ_Open_Trial_Search_ID","value":"798738"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124796":{"preferredName":"Darovasertib","code":"C124796","definitions":[{"definition":"An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, darovasertib inds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darovasertib","termGroup":"PT","termSource":"NCI"},{"termName":"IDE 196","termGroup":"CN","termSource":"NCI"},{"termName":"IDE-196","termGroup":"CN","termSource":"NCI"},{"termName":"IDE196","termGroup":"CN","termSource":"NCI"},{"termName":"LXS196","termGroup":"CN","termSource":"NCI"},{"termName":"PKC Inhibitor IDE196","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase C Inhibitor IDE196","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase C Inhibitor LXS196","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1874276-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E0YF0M8O09"},{"name":"Maps_To","value":"Protein Kinase C Inhibitor IDE196"},{"name":"NCI_Drug_Dictionary_ID","value":"777033"},{"name":"NCI_META_CUI","value":"CL503026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777033"},{"name":"PDQ_Open_Trial_Search_ID","value":"777033"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106430":{"preferredName":"Protein Phosphatase 2A Inhibitor LB-100","code":"C106430","definitions":[{"definition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Phosphatase 2A Inhibitor LB-100","termGroup":"PT","termSource":"NCI"},{"termName":"LB-100","termGroup":"CN","termSource":"NCI"},{"termName":"PP2A Inhibitor LB-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1632032-53-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0C1JUU9S0L"},{"name":"Maps_To","value":"Protein Phosphatase 2A Inhibitor LB-100"},{"name":"NCI_Drug_Dictionary_ID","value":"749984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749984"},{"name":"PDQ_Open_Trial_Search_ID","value":"749984"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827105"}]}}{"C90534":{"preferredName":"Protein Stabilized Liposomal Docetaxel Nanoparticles","code":"C90534","definitions":[{"definition":"A formulation containing protein-stabilized liposome nanoparticles encapsulating the poorly water-soluble, second-generation taxane analog docetaxel with antineoplastic activity. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Compared to the use of toxic carriers to increase solubilization of docetaxel, protein-stabilized liposomal docetaxel improves drug solubility while avoiding carrier-associated toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Stabilized Liposomal Docetaxel Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"ATI-1123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Protein Stabilized Liposomal Docetaxel Nanoparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"663670"},{"name":"NCI_META_CUI","value":"CL413616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663670"},{"name":"PDQ_Open_Trial_Search_ID","value":"663670"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130036":{"preferredName":"Proxalutamide","code":"C130036","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon oral administration, proxalutamide binds to AR in target tissues, inhibits androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. In addition, proxalutamide induces AR downregulation, thereby further preventing AR-mediated signaling. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells. AR is overexpressed in prostate cancer and plays a key role in prostate cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proxalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"GT-0918","termGroup":"CN","termSource":"NCI"},{"termName":"GT0918","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1398046-21-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QX6O64GP40"},{"name":"Maps_To","value":"Proxalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"784935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784935"},{"name":"PDQ_Open_Trial_Search_ID","value":"784935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4043276"}]}}{"C114289":{"preferredName":"PSA/IL-2/GM-CSF Vaccine","code":"C114289","definitions":[{"definition":"A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSA/IL-2/GM-CSF Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"ProscaVax","termGroup":"SY","termSource":"NCI"},{"termName":"Prostatac","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSA/IL-2/GM-CSF Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"758104"},{"name":"NCI_META_CUI","value":"CL471798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758104"},{"name":"PDQ_Open_Trial_Search_ID","value":"758104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123283":{"preferredName":"PSA/PSMA DNA Plasmid INO-5150","code":"C123283","definitions":[{"definition":"A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSA/PSMA DNA Plasmid INO-5150","termGroup":"PT","termSource":"NCI"},{"termName":"INO 5150","termGroup":"CN","termSource":"NCI"},{"termName":"INO-5150","termGroup":"CN","termSource":"NCI"},{"termName":"PSA/PSMA Synthetic DNA Vaccine INO-5150","termGroup":"SY","termSource":"NCI"},{"termName":"PSA/PSMA-encoding DNA Plasmid INO-5150","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSA/PSMA DNA Plasmid INO-5150"},{"name":"NCI_Drug_Dictionary_ID","value":"775020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775020"},{"name":"PDQ_Open_Trial_Search_ID","value":"775020"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053631"}]}}{"C87389":{"preferredName":"Pseudoisocytidine","code":"C87389","definitions":[{"definition":"A synthetic, pyrimidine C-5 nucleoside with antineoplastic activity. Pseudoisocytidine, after conversion into pseudoisocytidine triphosphate, is incorporated into DNA and RNA eventually halting tumor cell proliferation. Compared to 5-azacytidine and cytarabine, this agent shows enhanced stability and resistance to enzymatic deamination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pseudoisocytidine","termGroup":"PT","termSource":"NCI"},{"termName":"4(1H)-Pyrimidinone, 2-Amino-5-Beta-D-Ribofuranosyl-","termGroup":"SN","termSource":"NCI"},{"termName":"5-(Beta-D-Ribofuranosyl)Isocytosine","termGroup":"SN","termSource":"NCI"},{"termName":"psi Icyd","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57100-18-2"},{"name":"Chemical_Formula","value":"C9H13N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TDH73L8XQD"},{"name":"Maps_To","value":"Pseudoisocytidine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0072540"}]}}{"C95892":{"preferredName":"PSMA-targeted Docetaxel Nanoparticles BIND-014","code":"C95892","definitions":[{"definition":"A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane antigen (PSMA), with antineoplastic activity. PSMA-targeted docetaxel nanoparticles BIND-014 carry docetaxel within a matrix of polylactic acid covered with a coating of polyethylene glycol; embedded on the surface of the polyethylene glycol coating are ligands targeted to PSMA. BIND-014 allows gradual release of docetaxel upon degradation of the polylactic acid, and the PEG encapsulation escapes the host immune response while PSMA ligands on the surface restrict the cytotoxic effect to PSMA-expressing cells. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. PSMA is a cell-surface antigen that is abundantly present on the surface of cancer cells and on the neovasculature that feeds a wide variety of tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA-targeted Docetaxel Nanoparticles BIND-014","termGroup":"PT","termSource":"NCI"},{"termName":"BIND-014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSMA-targeted Docetaxel Nanoparticles BIND-014"},{"name":"NCI_Drug_Dictionary_ID","value":"696293"},{"name":"NCI_META_CUI","value":"CL428289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696293"},{"name":"PDQ_Open_Trial_Search_ID","value":"696293"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117291":{"preferredName":"PSMA-targeted Tubulysin B-containing Conjugate EC1169","code":"C117291","definitions":[{"definition":"An injectable, water soluble, small molecule drug conjugate (SMDC) containing a ligand specific for prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to the cytotoxic agent tubulysin B hydrazide (TubBH), with potential antineoplastic activity. Upon administration of PSMA-targeted tubulysin B-containing conjugate EC1169, the PSMA ligand specifically targets and binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells as well as on the neovasculature of many solid tumors. This allows for the specific delivery of TubBH to PSMA-expressing cancer cells. Upon internalization and cleavage, tubulysin B binds to tubulin and inhibits microtubule polymerization, which blocks cell division and results in G2/M phase arrest, tumor cell apoptosis and a decrease in PSMA-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA-targeted Tubulysin B-containing Conjugate EC1169","termGroup":"PT","termSource":"NCI"},{"termName":"EC1169","termGroup":"CN","termSource":"NCI"},{"termName":"EC1719","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSMA-targeted Tubulysin B-containing Conjugate EC1169"},{"name":"NCI_Drug_Dictionary_ID","value":"763440"},{"name":"NCI_META_CUI","value":"CL474117"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763440"},{"name":"PDQ_Open_Trial_Search_ID","value":"763440"},{"name":"Semantic_Type","value":"Chemical"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"}]}}{"C156681":{"preferredName":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424","code":"C156681","definitions":[{"definition":"A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA; FOLH1) and the CD3 antigen found on T-lymphocytes and an albumin-binding domain, with potential immunostimulating and antineoplastic activities.  Upon administration, PSMA/CD3 tri-specific T-cell antibody construct HPN424 targets and binds PSMA on tumor cells and CD3 on cytotoxic T-lymphocytes (CTLs), thereby bringing PSMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN424. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA/CD3 TriTAC HPN424","termGroup":"SY","termSource":"NCI"},{"termName":"HPN 424","termGroup":"CN","termSource":"NCI"},{"termName":"HPN-424","termGroup":"CN","termSource":"NCI"},{"termName":"HPN424","termGroup":"CN","termSource":"NCI"},{"termName":"PSMA/CD3 TriTAC HPN424","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA/CD3-specific TriTAC HPN424","termGroup":"SY","termSource":"NCI"},{"termName":"TriTAC HPN424","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAA5KE2UAS"},{"name":"Maps_To","value":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424"},{"name":"NCI_Drug_Dictionary_ID","value":"795833"},{"name":"NCI_META_CUI","value":"CL935732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795833"},{"name":"PDQ_Open_Trial_Search_ID","value":"795833"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128266":{"preferredName":"Enitociclib","code":"C128266","definitions":[{"definition":"An inhibitor of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF- b; PTEFb), with potential antineoplastic activity. Upon administration, enitociclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. The protein complex PTEF-b, a heterodimer consisting of CDK9 and a regulatory cyclin subunit of the T family, is over-activated in various tumor cell types; it plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enitociclib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1251152","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1251152","termGroup":"CN","termSource":"NCI"},{"termName":"PTEF-b/CDK9 Inhibitor BAY1251152","termGroup":"SY","termSource":"NCI"},{"termName":"PTEF-b/CDK9 Inhibitor VIP152","termGroup":"SY","termSource":"NCI"},{"termName":"VIP 152","termGroup":"CN","termSource":"NCI"},{"termName":"VIP-152","termGroup":"CN","termSource":"NCI"},{"termName":"VIP152","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610408-97-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1255AT22ZJ"},{"name":"Maps_To","value":"PTEF-b/CDK9 Inhibitor BAY1251152"},{"name":"NCI_Drug_Dictionary_ID","value":"806116"},{"name":"NCI_META_CUI","value":"CL507865"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153353":{"preferredName":"Pterostilbene","code":"C153353","definitions":[{"definition":"A naturally-derived stilbenoid structurally related to resveratrol, with potential antioxidant, anti-inflammatory, pro-apoptotic, antineoplastic and cytoprotective activities. Upon administration, pterostilbene exerts its anti-oxidant activity by scavenging reactive oxygen species (ROS), thereby preventing oxidative stress and ROS-induced cell damage. It may also activate the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated pathway and increase the expression of various antioxidant enzymes, such as superoxide dismutase (SOD).  In addition, pterostilbene is able to inhibit inflammation by reducing the expression of various inflammatory mediators, such as interleukin (IL) 1beta, tumor necrosis factor alpha (TNF-a), inducible nitric oxide synthase (iNOS), cyclooxygenases (COX), and nuclear factor kappa B (NF-kB). It also inhibits or prevents the activation of many signaling pathways involved in carcinogenesis, and increases expression of various tumor suppressor genes while decreasing expression of certain tumor promoting genes. It also directly induces apoptosis in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pterostilbene","termGroup":"PT","termSource":"NCI"},{"termName":"3',5'-Dimethoxy-4-stilbenol","termGroup":"SY","termSource":"NCI"},{"termName":"3,5-Dimethoxy-4'-hydroxystilbene","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 4-(2-(3,5-Dimethoxyphenyl)ethenyl)-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"Trans-3,5-dimethoxy-4-hydroxystilbene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"537-42-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"26R60S6A5I"},{"name":"Maps_To","value":"Pterostilbene"},{"name":"NCI_Drug_Dictionary_ID","value":"794141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794141"},{"name":"PDQ_Open_Trial_Search_ID","value":"794141"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664965"}]}}{"C73239":{"preferredName":"Pumitepa","code":"C73239","definitions":[{"definition":"A thiotepa derivative with potential antineoplastic alkylating activity. Although the exact mechanism of action of pumitepa has yet to be fully elucidated, this agent appears to work through alkylation, thereby causing DNA damage and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pumitepa","termGroup":"PT","termSource":"NCI"},{"termName":"Fopurin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42061-52-9"},{"name":"Chemical_Formula","value":"C12H19N8OP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7AYY495RE0"},{"name":"Legacy Concept Name","value":"Pumitepa"},{"name":"Maps_To","value":"Pumitepa"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060632"}]}}{"C162555":{"preferredName":"Puquitinib","code":"C162555","definitions":[{"definition":"An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puquitinib","termGroup":"PT","termSource":"NCI"},{"termName":"XC-302 Free Base","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"916890-10-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WFG29AB872"},{"name":"Maps_To","value":"Puquitinib"},{"name":"NCI_META_CUI","value":"CL971126"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162556":{"preferredName":"Puquitinib Mesylate","code":"C162556","definitions":[{"definition":"The mesylate salt of puquitinib, an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puquitinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"XC-302 Anhydrous","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1018818-41-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z4NA6BNF2L"},{"name":"Maps_To","value":"Puquitinib Mesylate"},{"name":"NCI_META_CUI","value":"CL971077"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C787":{"preferredName":"Puromycin","code":"C787","definitions":[{"definition":"An aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger.  Acting as an analog of the 3' terminal end of aminoacyl-tRNA, puromycin incorporates itself into a growing polypeptide chain and causes its premature termination, thereby inhibiting protein synthesis.  This agent has antimicrobial, antitrypanosomal, and antineoplastic properties; it is used as an antibiotic in cell culture. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puromycin","termGroup":"PT","termSource":"NCI"},{"termName":"Adenosine, 3'-((2-amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyl-, (S)-","termGroup":"SN","termSource":"NCI"},{"termName":"Adenosine, 3'-(alpha-amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyl-, L-","termGroup":"SN","termSource":"NCI"},{"termName":"CL 16536","termGroup":"CN","termSource":"NCI"},{"termName":"L-3'-(alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine","termGroup":"SN","termSource":"NCI"},{"termName":"P-638","termGroup":"CN","termSource":"NCI"},{"termName":"Puromicina","termGroup":"SY","termSource":"NCI"},{"termName":"Puromycine","termGroup":"SY","termSource":"NCI"},{"termName":"Puromycinum","termGroup":"SY","termSource":"NCI"},{"termName":"Stillomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Stylomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53-79-2"},{"name":"CHEBI_ID","value":"CHEBI:17939"},{"name":"Chemical_Formula","value":"C22H29N7O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4A6ZS6Q2CL"},{"name":"Legacy Concept Name","value":"Puromycin"},{"name":"Maps_To","value":"Puromycin"},{"name":"NSC Number","value":"3055"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034145"}]}}{"C75148":{"preferredName":"Puromycin Hydrochloride","code":"C75148","definitions":[{"definition":"The hydrochloride salt form of puromycin, an aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger. Acting as an analog of the 3' terminal end of aminoacyl-tRNA, puromycin incorporates itself into a growing polypeptide chain and causes its premature termination, thereby inhibiting protein synthesis. This agent has antimicrobial, antitrypanosomal, and antineoplastic properties; it is used as an antibiotic in cell culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puromycin Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58-58-2"},{"name":"Chemical_Formula","value":"C22H29N7O5.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PGN54228S5"},{"name":"Legacy Concept Name","value":"Puromycin_Hydrochloride"},{"name":"Maps_To","value":"Puromycin Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282329"}]}}{"C53412":{"preferredName":"Rose Bengal Solution PV-10","code":"C53412","definitions":[{"definition":"An injectable ten percent solution of rose bengal disodium, an iodinated fluorescein derivative, with potential antineoplastic and radiosensitizing activities. When injected into tumor tissue, PV-10 specifically targets and concentrates in tumor cells, producing cytotoxic singlet oxygen when exposed to ionizing radiation. In addition, PV-10 may stimulate an anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rose Bengal Solution PV-10","termGroup":"PT","termSource":"NCI"},{"termName":"4,5,6,7-Tetrachloro-2',4',5',7'-tetraiodofluorescein Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Injectable Rose Bengal 10%","termGroup":"SY","termSource":"NCI"},{"termName":"Provecta","termGroup":"BR","termSource":"NCI"},{"termName":"PV-10","termGroup":"CN","termSource":"NCI"},{"termName":"Rose Bengal Disodium 10%","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PV-10"},{"name":"Maps_To","value":"PV-10"},{"name":"Maps_To","value":"Rose Bengal Solution PV-10"},{"name":"NCI_Drug_Dictionary_ID","value":"463937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"463937"},{"name":"PDQ_Open_Trial_Search_ID","value":"463937"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709443"}]}}{"C71149":{"preferredName":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride","code":"C71149","definitions":[{"definition":"An embolic material composed of microspheres of polyvinyl alcohol (PVA) polymers loaded with doxorubicin hydrochloride with antineoplastic activity. Doxorubicin hydrochloride-loaded microspheres may be used as a drug delivery vehicle during embolization of tumor vasculature. Doxorubicin intercalates DNA, interferes with catalytic activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. When used in tumor vasculature embolization, this preparation may provide more tumor-specific treatment with doxorubicin compared to the systemic administration of doxorubicin, thereby reducing the systemic toxicity of doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"HepaSphere Microspheres/Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"QuadraSphere Microspheres/Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PVA_Microporous_Hydrospheres_Doxorubicin_Hydrochloride"},{"name":"Maps_To","value":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"574045"},{"name":"NCI_META_CUI","value":"CL376223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574045"},{"name":"PDQ_Open_Trial_Search_ID","value":"574045"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29395":{"preferredName":"Pyrazinamide","code":"C29395","definitions":[{"definition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyrazinamide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98-96-4"},{"name":"CHEBI_ID","value":"CHEBI:45285"},{"name":"Chemical_Formula","value":"C5H5N3O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2KNI5N06TI"},{"name":"Legacy Concept Name","value":"Pyrazinamide"},{"name":"Maps_To","value":"Pyrazinamide"},{"name":"NCI_Drug_Dictionary_ID","value":"701809"},{"name":"NSC Number","value":"14911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701809"},{"name":"PDQ_Open_Trial_Search_ID","value":"701809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034239"}]}}{"C1564":{"preferredName":"Pyrazoloacridine","code":"C1564","definitions":[{"definition":"A 9-methoxy acridine compound containing a reducible 5-nitro substituent.  Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called acridines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pyrazoloacridine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99009-20-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L24XJN68OW"},{"name":"Legacy Concept Name","value":"Pyrazoloacridine"},{"name":"Maps_To","value":"Pyrazoloacridine"},{"name":"NCI_Drug_Dictionary_ID","value":"41418"},{"name":"NSC Number","value":"366140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41418"},{"name":"PDQ_Open_Trial_Search_ID","value":"41418"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280970"}]}}{"C1852":{"preferredName":"Pyridyl Cyanoguanidine CHS 828","code":"C1852","definitions":[{"definition":"A drug that is being studied as a treatment for solid tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyridyl cyanoguanidine that exhibits antitumor activity by an unknown mechanism. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyridyl Cyanoguanidine CHS 828","termGroup":"PT","termSource":"NCI"},{"termName":"CHS 828","termGroup":"CN","termSource":"NCI"},{"termName":"CHS-828","termGroup":"CN","termSource":"NCI"},{"termName":"N-(6-(4-Chlorophenoxy)hexyl)-N'-Cyano-N''-4-Pyridylcyanoguanidine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"200484-11-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8LAP87DNSZ"},{"name":"Legacy Concept Name","value":"CHS_828"},{"name":"Maps_To","value":"Pyridyl Cyanoguanidine CHS 828"},{"name":"NCI_Drug_Dictionary_ID","value":"43567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43567"},{"name":"PDQ_Open_Trial_Search_ID","value":"43567"},{"name":"PubMedID_Primary_Reference","value":"18201551"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879285"}]}}{"C111895":{"preferredName":"Pyrotinib","code":"C111895","definitions":[{"definition":"An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyrotinib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1269662-73-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CJN36EQM0H"},{"name":"Maps_To","value":"Pyrotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"753336"},{"name":"NCI_META_CUI","value":"CL454228"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753336"},{"name":"PDQ_Open_Trial_Search_ID","value":"753336"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162554":{"preferredName":"Pyrotinib Dimaleate","code":"C162554","definitions":[{"definition":"The dimaleate ester of pyrotinib, an orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR, ErbB1 or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyrotinib Dimaleate","termGroup":"PT","termSource":"NCI"},{"termName":"Pyrotinib Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"SHR-1258 Maleate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1397922-61-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"85KUE857XM"},{"name":"Maps_To","value":"Pyrotinib Dimaleate"},{"name":"NCI_Drug_Dictionary_ID","value":"801532"},{"name":"NCI_META_CUI","value":"CL971127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801532"},{"name":"PDQ_Open_Trial_Search_ID","value":"801532"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2801":{"preferredName":"Pyroxamide","code":"C2801","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called histone deacetylase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of hydroxamic acid with antineoplastic properties, Pyroxamide inhibits histone deacetylases involved in transcription; induces hyperacetylation of core histones, modulating chromatin structure and affecting transcription of some genes that inhibit tumor growth; and induces growth arrest and apoptosis. Pyroxamide is used in clinical studies for cancer chemotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyroxamide","termGroup":"PT","termSource":"NCI"},{"termName":"Suberoyl-3-aminopyridineamide Hydroxamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"382180-17-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"12N86DSS23"},{"name":"Legacy Concept Name","value":"Pyroxamide"},{"name":"Maps_To","value":"Pyroxamide"},{"name":"NCI_Drug_Dictionary_ID","value":"256405"},{"name":"NSC Number","value":"696085"},{"name":"PDQ_Closed_Trial_Search_ID","value":"256405"},{"name":"PDQ_Open_Trial_Search_ID","value":"256405"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0966748"}]}}{"C67087":{"preferredName":"Pyruvate Kinase Inhibitor TLN-232","code":"C67087","definitions":[{"definition":"A synthetic cyclic heptapeptide with potential antineoplastic activity. Pyruvate kinase (PK) inhibitor TLN-232 targets pyruvate kinase M2 (M2PK), which may disrupt tumor cell anaerobic glycolysis. M2PK is a dimeric isoform of PK and the predominant PK isoform found in tumor cells","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyruvate Kinase Inhibitor TLN-232","termGroup":"PT","termSource":"NCI"},{"termName":"CAP-232","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CAP-232"},{"name":"Maps_To","value":"Pyruvate Kinase Inhibitor TLN-232"},{"name":"NCI_Drug_Dictionary_ID","value":"536241"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536241"},{"name":"PDQ_Open_Trial_Search_ID","value":"536241"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0531400"}]}}{"C155882":{"preferredName":"Qilisheng Immunoregulatory Oral Solution","code":"C155882","definitions":[{"definition":"An oral solution containing Spondias axillaris, Panax ginseng, schisandra berry, hawthorn, soybean and an as of yet not elucidated bacterium, with potential immunomodulating activity. Upon oral administration of the qilisheng immunoregulatory oral solution, the ingredients in qilisheng may modulate the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Qilisheng Immunoregulatory Oral Solution","termGroup":"PT","termSource":"NCI"},{"termName":"Qilisheng","termGroup":"SY","termSource":"NCI"},{"termName":"Qilisheng Solution","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Qilisheng Immunoregulatory Oral Solution"},{"name":"NCI_Drug_Dictionary_ID","value":"794790"},{"name":"NCI_META_CUI","value":"CL562700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794790"},{"name":"PDQ_Open_Trial_Search_ID","value":"794790"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61087":{"preferredName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","code":"C61087","definitions":[{"definition":"A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.","type":"DEFINITION","source":"NCI"},{"definition":"A vaccine used to prevent cervical, vulvar, and vaginal cancer caused by human papillomavirus (HPV) types 16 and 18 and genital warts caused by HPV types 6 and 11. It is also used to prevent lesions that are caused by these viruses and that can lead to cervical, vulvar, or vaginal cancer. Quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine is used in females aged 9-26 years. It is also used to prevent genital warts in males aged 9-26 years. Quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine is being studied in the treatment of other medical conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Gardasil","termGroup":"BR","termSource":"NCI"},{"termName":"Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Quadrivalent_Human_Papillomavirus_Recombinant_Vaccine"},{"name":"Maps_To","value":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"476576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"476576"},{"name":"PDQ_Open_Trial_Search_ID","value":"476576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831799"}]}}{"C71726":{"preferredName":"Quarfloxin","code":"C71726","definitions":[{"definition":"A fluoroquinolone derivative with antineoplastic activity. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis that is overexpressed in cancer cells; disruption of this G-quadruplex DNA:protein interaction in aberrant rRNA biogenesis may result in the inhibition of ribosome synthesis and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quarfloxin","termGroup":"PT","termSource":"NCI"},{"termName":"3H-Benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide, 5-fluoro-N-(2-((2S)- 1-methyl-2-pyrrolidinyl)ethyl)-3-oxo-6-(3-pyrazinyl-1-pyrrolidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-N-(2-((2S)-1-methylpyrrolidin-2-yl)ethyl)-3-oxo-6-(3-(pyrazin-2- yl)pyrrolidin-1-yl)-3H-benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CX-3543","termGroup":"CN","termSource":"NCI"},{"termName":"Quarfloxacin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"865311-47-3"},{"name":"Chemical_Formula","value":"C35H33FN6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8M31J5031Q"},{"name":"Legacy Concept Name","value":"Quarfloxacin"},{"name":"Maps_To","value":"Quarfloxin"},{"name":"NCI_Drug_Dictionary_ID","value":"558903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558903"},{"name":"PDQ_Open_Trial_Search_ID","value":"558903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713025"}]}}{"C67059":{"preferredName":"Quinacrine Hydrochloride","code":"C67059","definitions":[{"definition":"The dihydrochloride salt of the 9-aminoacridine derivative quinacrine with potential antineoplastic and antiparasitic activities. Quinacrine may inhibit the transcription and activity of both basal and inducible nuclear factor-kappaB (NF-kappaB), which may result in the induction of tumor suppressor p53 transcription, the restoration of p53-dependent apoptotic pathways, and tumor cell apoptosis. Continuous NF-kappaB signaling, present in many tumors and in chronic inflammatory processes, promotes the expression of antiapoptotic proteins and cytokines while downregulating the expression of proapoptotic proteins, such as p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quinacrine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"6-Chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Atabrine Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mepacrine Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Quinacrine Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"SN 390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6151-30-0"},{"name":"Chemical_Formula","value":"C23H30ClN3O.2ClH.2H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G6242H2NAA"},{"name":"Legacy Concept Name","value":"Quinacrine_Dihydrochloride"},{"name":"Maps_To","value":"Quinacrine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"531122"},{"name":"NCI_META_CUI","value":"CL550623"},{"name":"NSC Number","value":"14229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531122"},{"name":"PDQ_Open_Trial_Search_ID","value":"531122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C794":{"preferredName":"Quinine","code":"C794","definitions":[{"definition":"A quinidine alkaloid isolated from the bark of the cinchona tree. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quinine","termGroup":"PT","termSource":"NCI"},{"termName":"QUIN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130-95-0"},{"name":"CHEBI_ID","value":"CHEBI:15854"},{"name":"Chemical_Formula","value":"C20H24N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A7V27PHC7A"},{"name":"Legacy Concept Name","value":"Quinine"},{"name":"Maps_To","value":"Quinine"},{"name":"NCI_Drug_Dictionary_ID","value":"41253"},{"name":"NSC Number","value":"192949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41253"},{"name":"PDQ_Open_Trial_Search_ID","value":"41253"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034417"}]}}{"C77912":{"preferredName":"Quisinostat","code":"C77912","definitions":[{"definition":"An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quisinostat","termGroup":"PT","termSource":"NCI"},{"termName":"HDAC Inhibitor JNJ-26481585","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ-26481585","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"875320-29-9"},{"name":"Chemical_Formula","value":"C21H26N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9BJ85K1J8S"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_JNJ-26481585"},{"name":"Maps_To","value":"Quisinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"596704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596704"},{"name":"PDQ_Open_Trial_Search_ID","value":"596704"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703097"}]}}{"C68936":{"preferredName":"Quizartinib","code":"C68936","definitions":[{"definition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quizartinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide","termGroup":"SN","termSource":"NCI"},{"termName":"AC-220","termGroup":"CN","termSource":"NCI"},{"termName":"AC010220","termGroup":"CN","termSource":"NCI"},{"termName":"AC220","termGroup":"CN","termSource":"NCI"},{"termName":"ASP 2689","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-2689","termGroup":"CN","termSource":"NCI"},{"termName":"ASP2689","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea","termGroup":"SN","termSource":"NCI"},{"termName":"Vanflyta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"950769-58-1"},{"name":"Chemical_Formula","value":"C29H32N6O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7LA4O6Q0D3"},{"name":"Legacy Concept Name","value":"FLT-3_Kinase_Inhibitor_AC220"},{"name":"Maps_To","value":"Quizartinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2980091"}]}}{"C78348":{"preferredName":"R-(-)-Gossypol Acetic Acid","code":"C78348","definitions":[{"definition":"The orally bioavailable solvate of the R-(-) enantiomer of gossypol and acetic acid with potential antineoplastic activity. As a BH3 mimetic, R-(-)-gossypol binds to the hydrophobic surface binding groove BH3 of the anti-apoptotic proteins Bcl-2 and Bcl-xL, blocking their heterodimerization with pro-apoptotic members of the Bcl-2 family of proteins such as Bad, Bid, and Bim; this may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Racemic gossypol is a polyphenolic compound isolated from cottonseed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"R-(-)-Gossypol Acetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Gossypol Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"(2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-(R)-5,5'-bis(1-methylethyl)-, (2R)-, compd. with acetic acid (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"AT 101","termGroup":"CN","termSource":"NCI"},{"termName":"AT-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"866541-93-7"},{"name":"Chemical_Formula","value":"C30H30O8.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U9GNI6VT5N"},{"name":"Legacy Concept Name","value":"R-Gossypol_Acetic_Acid"},{"name":"Maps_To","value":"R-(-)-Gossypol Acetic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"594869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594869"},{"name":"PDQ_Open_Trial_Search_ID","value":"594869"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831824"}]}}{"C81937":{"preferredName":"Rabusertib","code":"C81937","definitions":[{"definition":"An inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rabusertib","termGroup":"PT","termSource":"NCI"},{"termName":"1-[5-bromo-4-methyl-2-S-(morpholin-2-yl-methoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea","termGroup":"SN","termSource":"NCI"},{"termName":"Checkpoint Kinase 2 Inhibitor LY2603618","termGroup":"SY","termSource":"NCI"},{"termName":"LY2603618","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911222-45-2"},{"name":"Chemical_Formula","value":"C18H22BrN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S9L1NU6U7"},{"name":"Legacy Concept Name","value":"CHK2_Inhibitor_LY2603618"},{"name":"Maps_To","value":"Rabusertib"},{"name":"NCI_Drug_Dictionary_ID","value":"637612"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637612"},{"name":"PDQ_Open_Trial_Search_ID","value":"637612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825835"}]}}{"C95024":{"preferredName":"Racotumomab","code":"C95024","definitions":[{"definition":"An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Racotumomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-P3 Antibody Idiotype Monoclonal Antibody 1E10","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 1E10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946832-34-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"52G405U1E5"},{"name":"Maps_To","value":"Racotumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"689646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689646"},{"name":"PDQ_Open_Trial_Search_ID","value":"689646"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986854"}]}}{"C165436":{"preferredName":"Emzadirib","code":"C165436","definitions":[{"definition":"An orally bioavailable inhibitor of the DNA damage repair protein RAD51, with potential antineoplastic and sensitizing activities. Upon oral administration, emzadirib targets, binds to and inhibits the activity of RAD51. This prevents RAD51-mediated DNA damage repair in susceptible tumor cells and induces tumor cell apoptosis. RAD51, the central protein involved in homologous repair (HR) of DNA double-strand breaks (DSBs), is overexpressed in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emzadirib","termGroup":"PT","termSource":"NCI"},{"termName":"CYT 0851","termGroup":"CN","termSource":"NCI"},{"termName":"CYT-0851","termGroup":"CN","termSource":"NCI"},{"termName":"CYT0851","termGroup":"CN","termSource":"NCI"},{"termName":"RAD51 Inhibitor CYT-0851","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2301085-04-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B7AM3X83ZO"},{"name":"Maps_To","value":"RAD51 Inhibitor CYT-0851"},{"name":"NCI_Drug_Dictionary_ID","value":"799774"},{"name":"NCI_META_CUI","value":"CL978621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799774"},{"name":"PDQ_Open_Trial_Search_ID","value":"799774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2462":{"preferredName":"Radioactive Iodine","code":"C2462","definitions":[{"definition":"A radioactive form of iodine, often used for imaging tests or to treat an overactive thyroid, thyroid cancer, and certain other cancers. For imaging tests, the patient takes a small dose of radioactive iodine that collects in thyroid cells and certain kinds of tumors and can be detected by a scanner. To treat thyroid cancer, the patient takes a large dose of radioactive iodine, which kills thyroid cells. Radioactive iodine is also used in internal radiation therapy for prostate cancer, intraocular (eye) melanoma, and carcinoid tumors. Radioactive iodine is given by mouth as a liquid or in capsules, by infusion, or sealed in seeds, which are placed in or near the tumor to kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radioactive Iodine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radioactive_Iodine"},{"name":"Maps_To","value":"Radioactive Iodine"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C1441129"}]}}{"C2729":{"preferredName":"Radiolabeled CC49","code":"C2729","definitions":[{"definition":"A radioimmunoconjugate comprised of a humanized monoclonal antibody with antitumor activity. The monoclonal antibody CC49 is developed from the murine monoclonal antibody B72.3 and is humanized by grafting the hypervariable regions onto the variable light (VL) and variable heavy (VH) frameworks of the monoclonal antibodies LEN and 21/28' CL. The resultant antibody binds the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Furthermore, the antibody is commonly radiolabeled resulting in an effective agent for use in radioimmunotherapy for treatment of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiolabeled CC49","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiolabeled_CC49"},{"name":"Maps_To","value":"Radiolabeled CC49"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514701"}]}}{"C62535":{"preferredName":"Radium Ra 223 Dichloride","code":"C62535","definitions":[{"definition":"A radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium Ra 223, with antineoplastic activity. Like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. Radium Ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. The radioisotope Ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing DNA double-strand breaks and tumor regression in the skeleton. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy bone tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radium Ra 223 Dichloride","termGroup":"PT","termSource":"NCI"},{"termName":"Alpharadin","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 88-8223","termGroup":"CN","termSource":"NCI"},{"termName":"BAY88-8223","termGroup":"CN","termSource":"NCI"},{"termName":"Radium 223 Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Radium-223 Chloride","termGroup":"SY","termSource":"NCI"},{"termName":"Radium-223 Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Xofigo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444811-40-9"},{"name":"Chemical_Formula","value":"2Cl.Ra"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RJ00KV3VTG"},{"name":"Legacy Concept Name","value":"Radium-223"},{"name":"Maps_To","value":"Radium Ra 223 Dichloride"},{"name":"NCI_Drug_Dictionary_ID","value":"749662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749662"},{"name":"PDQ_Open_Trial_Search_ID","value":"749662"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3541342"}]}}{"C159537":{"preferredName":"Radium Ra 224-labeled Calcium Carbonate Microparticles","code":"C159537","definitions":[{"definition":"A radiopharmaceutical composed of biodegradable calcium carbonate microspheres labeled with the alpha-emitting radioisotope radium Ra 224, with antineoplastic activity. Upon intraperitoneal (IP) administration of the radium Ra 224-labeled calcium carbonate microparticles, Ra 224 kills tumor cells through local emission of high energy alpha particles, causing DNA double-strand breaks. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radium Ra 224-labeled Calcium Carbonate Microparticles","termGroup":"PT","termSource":"NCI"},{"termName":"224Ra-labeled Calcium Carbonate Micro-particles","termGroup":"SY","termSource":"NCI"},{"termName":"Alpha-emitting 224Ra Calcium Carbonate Microspheres","termGroup":"SY","termSource":"NCI"},{"termName":"Ra-224 Alpha-emitting Calcium Carbonate Microparticles","termGroup":"SY","termSource":"NCI"},{"termName":"Radspherin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radium Ra 224-labeled Calcium Carbonate Microparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"797476"},{"name":"NCI_META_CUI","value":"CL951431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797476"},{"name":"PDQ_Open_Trial_Search_ID","value":"797476"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113297":{"preferredName":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement","code":"C113297","definitions":[{"definition":"A traditional Chinese medicine comprising of Radix Angelicae Sinensis (RAS) and Radix Astragali (RA), with potential anti-inflammatory, immunostimulatory, neuroprotective, anti-hepatotoxic and antineoplastic activities. The main chemical constituents of RAS include ferulic acid, Z-ligustilide, butylidenephthalide and various polysaccharides. RA is the dried root of Astragalus membranaceus with primary constituents such polysaccharides, triterpenoids as well as isoflavones. Though their mechanisms of action remain largely elusive, Radix Angelicae Sinensis/Radix Astragali herbal supplements are commonly used for the treatment of various health conditions affecting women including premenstrual syndrome, dysmenorrhea, pelvic pain, recovery from childbirth and menopausal symptoms. These agents are also used for alleviating constipation, preventing and treating anemia and allergic attacks, and for the management of hypertension, joint pain and ulcers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Danggui Buxue Decoction No.1","termGroup":"CN","termSource":"NCI"},{"termName":"DB1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"756038"},{"name":"NCI_META_CUI","value":"CL471832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756038"},{"name":"PDQ_Open_Trial_Search_ID","value":"756038"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99644":{"preferredName":"Radotinib Hydrochloride","code":"C99644","definitions":[{"definition":"An orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent efficacy in CML cells that are resistant to the first-generation standard tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radotinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"IY5511HCl","termGroup":"CN","termSource":"NCI"},{"termName":"Supect","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"926037-85-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EF516G9REZ"},{"name":"Maps_To","value":"Radotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"723999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"723999"},{"name":"PDQ_Open_Trial_Search_ID","value":"723999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467958"}]}}{"C121646":{"preferredName":"Belvarafenib","code":"C121646","definitions":[{"definition":"An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belvarafenib","termGroup":"PT","termSource":"NCI"},{"termName":"HM95573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446113-23-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31M3WLJ3KG"},{"name":"Maps_To","value":"Belvarafenib"},{"name":"Maps_To","value":"Raf Kinase Inhibitor HM95573"},{"name":"NCI_Drug_Dictionary_ID","value":"770820"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770820"},{"name":"PDQ_Open_Trial_Search_ID","value":"770820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053637"}]}}{"C2722":{"preferredName":"RAF Kinase Inhibitor L-779450","code":"C2722","definitions":[{"definition":"A synthetic triarylimidazole with potential antineoplastic activity.  As a Raf kinase inhibitor, L-779450 competes with ATP for binding to the Raf-1 and A-Raf catalytic sites, thus inhibiting their enzymatic activities and blocking various signal transduction pathways that depend on Raf-1 kinase (particularly the Ras-Raf-MEK-ERK cascade which is often up-regulated in neoplasms). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAF Kinase Inhibitor L-779450","termGroup":"PT","termSource":"NCI"},{"termName":"L-779,450","termGroup":"CN","termSource":"NCI"},{"termName":"L-779450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"L-779450"},{"name":"Maps_To","value":"RAF Kinase Inhibitor L-779450"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517681"}]}}{"C69135":{"preferredName":"RAF Kinase Inhibitor XL281","code":"C69135","definitions":[{"definition":"An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. RAS mutations may result in constitutive activation of the RAS/RAF/MEK/ERK kinase signaling pathway, and have been found to occur frequently in human tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAF Kinase Inhibitor XL281","termGroup":"PT","termSource":"NCI"},{"termName":"XL-281","termGroup":"CN","termSource":"NCI"},{"termName":"XL281","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"RAF_Kinase_Inhibitor_XL281"},{"name":"Maps_To","value":"RAF Kinase Inhibitor XL281"},{"name":"NCI_Drug_Dictionary_ID","value":"543515"},{"name":"NCI_META_CUI","value":"CL371855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543515"},{"name":"PDQ_Open_Trial_Search_ID","value":"543515"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124654":{"preferredName":"Ralaniten Acetate","code":"C124654","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the acetate form of ralaniten, a N-terminal domain (NTD) of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration of ralaniten acetate, ralaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ralaniten Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Propanediol, 3-(4-(1-(4-((2S)-2-(acetyloxy)-3-chloropropoxy)phenyl)-1-methylethyl)phenoxy)-, 1,2-Diacetate, (2S)-","termGroup":"SN","termSource":"NCI"},{"termName":"AR Inhibitor EPI-506","termGroup":"SY","termSource":"NCI"},{"termName":"EPI-506","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637573-04-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L10K286T2H"},{"name":"Maps_To","value":"Ralaniten Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"777367"},{"name":"NCI_META_CUI","value":"CL502886"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777367"},{"name":"PDQ_Open_Trial_Search_ID","value":"777367"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105853":{"preferredName":"Ralimetinib Mesylate","code":"C105853","definitions":[{"definition":"The dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities. Upon administration, ralimetinib inhibits the activity of p38, particularly the alpha and beta isoforms, thereby inhibiting MAPKAPK2 phosphorylation and preventing p38 MAPK-mediated signaling. This may inhibit the production of a variety of cytokines involved in inflammation, cellular proliferation and angiogenesis such as tumor necrosis factor alpha (TNFa), interleukin (IL)-1, -6 and -8, vascular endothelial growth factor, and macrophage inflammatory protein-1 alpha. Ultimately this induces apoptosis and reduces tumor cell proliferation. In addition, inhibition of the p38 MAPK pathway by LY2228820 increases the antineoplastic activity of certain chemotherapeutic agents. p38 MAPK, a serine/threonine protein kinase that is often upregulated in cancer cells, plays a crucial role in tumor cell proliferation, angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ralimetinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, Methanesulfonate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"LY-2228820","termGroup":"CN","termSource":"NCI"},{"termName":"LY2228820","termGroup":"CN","termSource":"NCI"},{"termName":"LY2228820 Dimesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Ralimetinib Dimesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"862507-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QUW7B71FO9"},{"name":"Maps_To","value":"Ralimetinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"687387"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687387"},{"name":"PDQ_Open_Trial_Search_ID","value":"687387"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659483"}]}}{"C1518":{"preferredName":"Raloxifene","code":"C1518","definitions":[{"definition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who have osteoporosis. It is also used to prevent and treat osteoporosis in postmenopausal women. It is also being studied in the prevention of breast cancer in certain premenopausal women and in the prevention and treatment of other conditions. Raloxifene blocks the effects of the hormone estrogen in the breast and increases the amount of calcium in bone. It is a type of selective estrogen receptor modulator (SERM).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Raloxifene","termGroup":"PT","termSource":"NCI"},{"termName":"[6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone","termGroup":"SN","termSource":"NCI"},{"termName":"Keoxifene","termGroup":"SY","termSource":"NCI"},{"termName":"LY 139481","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Cardiovascular Disease prophylaxis; Osteoporosis"},{"name":"CAS_Registry","value":"84449-90-1"},{"name":"CHEBI_ID","value":"CHEBI:8772"},{"name":"Chemical_Formula","value":"C28H27NO4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YX9162EO3I"},{"name":"Legacy Concept Name","value":"Raloxifene"},{"name":"Maps_To","value":"Raloxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"43109"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43109"},{"name":"PDQ_Open_Trial_Search_ID","value":"43109"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0752233"}]}}{"C1762":{"preferredName":"Raloxifene Hydrochloride","code":"C1762","definitions":[{"definition":"A drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who have osteoporosis. It is also used to prevent and treat osteoporosis in postmenopausal women. It is also being studied in the prevention of breast cancer in certain premenopausal women and in the prevention and treatment of other conditions. Evista blocks the effects of the hormone estrogen in the breast and increases the amount of calcium in bone. It is a type of selective estrogen receptor modulator (SERM).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raloxifene Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Evista","termGroup":"BR","termSource":"NCI"},{"termName":"Keoxifene Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"LY-156758","termGroup":"CN","termSource":"NCI"},{"termName":"Optruma","termGroup":"FB","termSource":"NCI"},{"termName":"Raloxifene HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer prevention"},{"name":"CAS_Registry","value":"82640-04-8"},{"name":"CHEBI_ID","value":"CHEBI:50740"},{"name":"Chemical_Formula","value":"C28H27NO4S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4F86W47BR6"},{"name":"Legacy Concept Name","value":"Raloxifene_Hydrochloride"},{"name":"Maps_To","value":"Raloxifene Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"43109"},{"name":"NSC Number","value":"706725"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43109"},{"name":"PDQ_Open_Trial_Search_ID","value":"43109"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0618111"}]}}{"C1804":{"preferredName":"Raltitrexed","code":"C1804","definitions":[{"definition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that stops tumor cells from growing by blocking the ability of cells to make DNA. It belongs to the family of drugs called thymidylate synthase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Raltitrexed","termGroup":"PT","termSource":"NCI"},{"termName":"D1694","termGroup":"CN","termSource":"NCI"},{"termName":"ICI D1694","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-[N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ZD 1694","termGroup":"CN","termSource":"NCI"},{"termName":"ZD-1694","termGroup":"CN","termSource":"NCI"},{"termName":"ZD1694","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112887-68-0"},{"name":"Chemical_Formula","value":"C21H22N4O6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"FCB9EGG971"},{"name":"Legacy Concept Name","value":"Raltitrexed"},{"name":"Maps_To","value":"Raltitrexed"},{"name":"NCI_Drug_Dictionary_ID","value":"42625"},{"name":"NSC Number","value":"639186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42625"},{"name":"PDQ_Open_Trial_Search_ID","value":"42625"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677667"}]}}{"C70792":{"preferredName":"Ramucirumab","code":"C70792","definitions":[{"definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ramucirumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B","termGroup":"SY","termSource":"NCI"},{"termName":"Cyramza","termGroup":"BR","termSource":"NCI"},{"termName":"IMC-1121B","termGroup":"CN","termSource":"NCI"},{"termName":"LY3009806","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody HGS-ETR2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic colorectal cancer (mCRC); advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma; hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of >= 400 ng/mL"},{"name":"Accepted_Therapeutic_Use_For","value":"multicentric Castleman's disease (MCD)"},{"name":"CAS_Registry","value":"947687-13-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D99YVK4L0X"},{"name":"Legacy Concept Name","value":"Anti-VEGFR-2_Fully_Human_Monoclonal_Antibody_IMC-1121B"},{"name":"Maps_To","value":"Ramucirumab"},{"name":"NCI_Drug_Dictionary_ID","value":"570535"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570535"},{"name":"PDQ_Open_Trial_Search_ID","value":"570535"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742502"}]}}{"C67562":{"preferredName":"Ranibizumab","code":"C67562","definitions":[{"definition":"A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ranibizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain","termGroup":"SY","termSource":"NCI"},{"termName":"Lucentis","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"347396-82-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL1R02VT79"},{"name":"Legacy Concept Name","value":"Ranibizumab"},{"name":"Maps_To","value":"Ranibizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"544572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"544572"},{"name":"PDQ_Open_Trial_Search_ID","value":"544572"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566537"}]}}{"C1515":{"preferredName":"Ranimustine","code":"C1515","definitions":[{"definition":"A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ranimustine","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-D-glucopyranoside, methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Cymer","termGroup":"FB","termSource":"NCI"},{"termName":"Cymerin","termGroup":"FB","termSource":"NCI"},{"termName":"MCNU","termGroup":"AB","termSource":"NCI"},{"termName":"methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl) amino)-6-deoxy-alpha-D-glucopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"methyl 6-(3-(2-chloroethyl)-3-nitrosoiureido)-6-deoxy-alpha-D-glucopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"methyl 6-(3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy-alpha-D-glucopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"Ranomustine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58994-96-0"},{"name":"Chemical_Formula","value":"C10H18ClN3O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RYH2T97J77"},{"name":"Legacy Concept Name","value":"Ranimustine"},{"name":"Maps_To","value":"Ranimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"470235"},{"name":"NSC Number","value":"270516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"470235"},{"name":"PDQ_Open_Trial_Search_ID","value":"470235"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0243666"}]}}{"C66507":{"preferredName":"Ranolazine","code":"C66507","definitions":[{"definition":"An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti-ischemic effects has yet to be fully elucidated but may involve the alteration of the trans-cellular late sodium current in the ischemic myocyte. By preventing the rise of intracellular sodium levels, ranolazine may affect the transport activity of sodium-dependent calcium channels and prevent the calcium overload during myocardial ischemia, thereby preventing cellular injury. Ranolazine's potential antineoplastic effect may depend on its inhibitory effect on fatty acid oxidation, which may sensitize tumor cells to apoptosis and decrease tumor cell proliferation; fatty acid oxidation provides energy and promotes tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ranolazine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ranexa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95635-55-5"},{"name":"Chemical_Formula","value":"C24H33N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A6IEZ5M406"},{"name":"Legacy Concept Name","value":"Ranolazine"},{"name":"Maps_To","value":"Ranolazine"},{"name":"NCI_Drug_Dictionary_ID","value":"753754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753754"},{"name":"PDQ_Open_Trial_Search_ID","value":"753754"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073633"}]}}{"C1183":{"preferredName":"Ranpirnase","code":"C1183","definitions":[{"definition":"A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens.  Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of ribonuclease enzyme.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ranpirnase","termGroup":"PT","termSource":"NCI"},{"termName":"Onconase","termGroup":"BR","termSource":"NCI"},{"termName":"P-30","termGroup":"SY","termSource":"NCI"},{"termName":"P-30 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"P30","termGroup":"SY","termSource":"NCI"},{"termName":"P30 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"RANPIRNASE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Mesothelioma"},{"name":"CAS_Registry","value":"196488-72-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZE15FIT23E"},{"name":"Legacy Concept Name","value":"Ranpirnase"},{"name":"Maps_To","value":"Ranpirnase"},{"name":"NCI_Drug_Dictionary_ID","value":"41305"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41305"},{"name":"PDQ_Open_Trial_Search_ID","value":"41305"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069919"}]}}{"C77899":{"preferredName":"RARalpha Agonist IRX5183","code":"C77899","definitions":[{"definition":"An orally bioavailable retinoid acid receptor alpha (RARalpha) agonist and vitamin A derivative, with potential antineoplastic activity. Upon administration, RARalpha agonist IRX5183 binds to and activates RARalpha, which promotes RARalpha-mediated signaling. This results in the transcription of RARalpha-responsive genes, which are responsible for cellular differentiation and proliferation. This results in the induction of cellular differentiation and apoptosis, and leads to the inhibition of cellular proliferation and tumorigenesis. RARalpha is a nuclear receptor and a member of the steroid receptor superfamily; reduced RARalpha signaling is correlated with cancer development in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RARalpha Agonist IRX5183","termGroup":"PT","termSource":"NCI"},{"termName":"AGN 195183","termGroup":"CN","termSource":"NCI"},{"termName":"AGN-195183","termGroup":"CN","termSource":"NCI"},{"termName":"IRX 5183","termGroup":"CN","termSource":"NCI"},{"termName":"IRX5183","termGroup":"CN","termSource":"NCI"},{"termName":"NRX 195183","termGroup":"CN","termSource":"NCI"},{"termName":"NRX195183","termGroup":"CN","termSource":"NCI"},{"termName":"RARa Agonist IRX5183","termGroup":"SY","termSource":"NCI"},{"termName":"VTP 195183","termGroup":"CN","termSource":"NCI"},{"termName":"VTP-195183","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"367273-07-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RC87L028HU"},{"name":"Legacy Concept Name","value":"Retinoid_Analogue_NRX_195183"},{"name":"Maps_To","value":"RARalpha Agonist IRX5183"},{"name":"NCI_Drug_Dictionary_ID","value":"596530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596530"},{"name":"PDQ_Open_Trial_Search_ID","value":"596530"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527761"}]}}{"C1902":{"preferredName":"Ras Inhibitor","code":"C1902","definitions":[{"definition":"An agent designed to inhibit the signal transduction process by interfering with the action of the ras family of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Inhibitor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Examples include carboxyaminoimidazole (CAI), Iovastatin, limonene, and perillyl alcohol."},{"name":"Legacy Concept Name","value":"Ras_Inhibitor"},{"name":"Maps_To","value":"Ras Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C1514727"}]}}{"C2802":{"preferredName":"Ras Peptide ASP","code":"C2802","definitions":[{"definition":"A synthetic form of the ras peptide containing a point mutation at position 12 (glycine to aspartic acid) with potential antineoplastic activity.  Vaccination with ras peptide Asp may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this ras mutation, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Peptide ASP","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ras_Peptide_ASP"},{"name":"Maps_To","value":"Ras Peptide ASP"},{"name":"NSC Number","value":"667938"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514728"}]}}{"C2803":{"preferredName":"Ras Peptide CYS","code":"C2803","definitions":[{"definition":"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to cysteine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Peptide CYS","termGroup":"PT","termSource":"NCI"},{"termName":"Ras (sub 5-17) Peptide (C12)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ras_Peptide_CYS"},{"name":"Maps_To","value":"Ras Peptide CYS"},{"name":"NSC Number","value":"667937"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514729"}]}}{"C2804":{"preferredName":"Ras Peptide VAL","code":"C2804","definitions":[{"definition":"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to valine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Peptide VAL","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ras_Peptide_VAL"},{"name":"Maps_To","value":"Ras Peptide VAL"},{"name":"NSC Number","value":"665824"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514730"}]}}{"C801":{"preferredName":"Razoxane","code":"C801","definitions":[{"definition":"An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Razoxane","termGroup":"PT","termSource":"NCI"},{"termName":"ICI 59118","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF 159","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF-159","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF159","termGroup":"CN","termSource":"NCI"},{"termName":"Razoxin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"21416-67-1"},{"name":"CAS_Registry","value":"21416-87-5"},{"name":"CHEBI_ID","value":"CHEBI:50225"},{"name":"Chemical_Formula","value":"C11H16N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5AR83PR647"},{"name":"Legacy Concept Name","value":"Razoxane"},{"name":"Maps_To","value":"Razoxane"},{"name":"NCI_Drug_Dictionary_ID","value":"39480"},{"name":"NSC Number","value":"129943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39480"},{"name":"PDQ_Open_Trial_Search_ID","value":"39480"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034738"}]}}{"C117289":{"preferredName":"Realgar-Indigo naturalis Formulation","code":"C117289","definitions":[{"definition":"An orally bioavailable, traditional Chinese medicine (TCM)-based formulation composed of Realgar-Indigo naturalis formula (RIF) with potential antineoplastic activity. The main constituents in RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (As4S4), indirubin and tanshinone IIA as the main active ingredients, respectively, which appear to exert synergistic effects on cancer cells. Tetraarsenic tetrasulfide specifically induces the ubiquitination and degradation of promyelocytic leukemia retinoic acid receptor alpha (PML-RARalpha) oncoprotein. In addition, the active ingredients in the Realgar-Indigo naturalis formulation enhance the expression of myeloid differentiation genes, and induce G(1)/G(0) cell cycle arrest. PML-RARalpha, an acute promyelocytic leukemia (APL)-specific fusion gene, inhibits differentiation and promotes survival of myeloid precursor cells","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Realgar-Indigo naturalis Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"RIF","termGroup":"AB","termSource":"NCI"},{"termName":"RIF Formula","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Realgar-Indigo naturalis Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"763399"},{"name":"NCI_META_CUI","value":"CL474115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763399"},{"name":"PDQ_Open_Trial_Search_ID","value":"763399"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82693":{"preferredName":"Rebastinib Tosylate","code":"C82693","definitions":[{"definition":"The tosylate salt of rebastinib, an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Rebastinib binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebastinib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"DCC-2036","termGroup":"CN","termSource":"NCI"},{"termName":"DP-1919.TO","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1033893-29-6"},{"name":"CHEBI_ID","value":"CHEBI:62166"},{"name":"Chemical_Formula","value":"C30H28FN7O3.C7H8O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"042A5NJE6B"},{"name":"Legacy Concept Name","value":"Multitargeted_Tyrosine_Kinase_Inhibitor_DCC-2036"},{"name":"Maps_To","value":"Rebastinib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"634547"},{"name":"PDQ_Closed_Trial_Search_ID","value":"634547"},{"name":"PDQ_Open_Trial_Search_ID","value":"634547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830217"}]}}{"C1213":{"preferredName":"Rebeccamycin","code":"C1213","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antineoplastic antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolocarbazole glycoside antineoplastic antibiotic isolated from the bacterium Saccharothrix aerocolonigenes.  Rebeccamycin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebeccamycin","termGroup":"PT","termSource":"NCI"},{"termName":"5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione,1,11-dichloro-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"BRN 4732638","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93908-02-2"},{"name":"CHEBI_ID","value":"CHEBI:135511"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y96MQM21V9"},{"name":"Legacy Concept Name","value":"Rebeccamycin"},{"name":"Maps_To","value":"Rebeccamycin"},{"name":"NSC Number","value":"359079"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073012"}]}}{"C1875":{"preferredName":"Rebimastat","code":"C1875","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebimastat","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-275291","termGroup":"CN","termSource":"NCI"},{"termName":"D2163","termGroup":"CN","termSource":"NCI"},{"termName":"N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"259188-38-0"},{"name":"Chemical_Formula","value":"C23H41N5O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1B47R6ZX4K"},{"name":"Legacy Concept Name","value":"BMS-275291"},{"name":"Maps_To","value":"Rebimastat"},{"name":"NCI_Drug_Dictionary_ID","value":"38088"},{"name":"NSC Number","value":"713763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38088"},{"name":"PDQ_Open_Trial_Search_ID","value":"38088"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935902"}]}}{"C71710":{"preferredName":"Receptor Tyrosine Kinase Inhibitor R1530","code":"C71710","definitions":[{"definition":"A pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. Mitosis-angiogenesis inhibitor (MAI) R1530 inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta, FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Receptor Tyrosine Kinase Inhibitor R1530","termGroup":"PT","termSource":"NCI"},{"termName":"MAI R1530","termGroup":"AB","termSource":"NCI"},{"termName":"R1530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mitosis_and_Apoptosis_Inhibitor_R1530"},{"name":"Maps_To","value":"Receptor Tyrosine Kinase Inhibitor R1530"},{"name":"NCI_Drug_Dictionary_ID","value":"560180"},{"name":"NCI_META_CUI","value":"CL376137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560180"},{"name":"PDQ_Open_Trial_Search_ID","value":"560180"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2423":{"preferredName":"Recombinant Adenovirus-p53 SCH-58500","code":"C2423","definitions":[{"definition":"A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that has been studied in the treatment of some types of cancer. rAd/p53 is a weakened adenovirus that carries the p53 gene into tumor cells, causing them to die. It is a type of gene therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Adenovirus-p53 SCH-58500","termGroup":"PT","termSource":"NCI"},{"termName":"rAd/p53","termGroup":"AB","termSource":"NCI"},{"termName":"SCH 58500","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-58500","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Primary ovarian cancer"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Adenovirus-p53"},{"name":"Maps_To","value":"Recombinant Adenovirus-p53 SCH-58500"},{"name":"NCI_Drug_Dictionary_ID","value":"42631"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42631"},{"name":"PDQ_Open_Trial_Search_ID","value":"42631"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514767"}]}}{"C116880":{"preferredName":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A","code":"C116880","definitions":[{"definition":"An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A","termGroup":"PT","termSource":"NCI"},{"termName":"ASCI GSK2302024A","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2302024A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A"},{"name":"NCI_Drug_Dictionary_ID","value":"687580"},{"name":"NCI_META_CUI","value":"CL433728"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687580"},{"name":"PDQ_Open_Trial_Search_ID","value":"687580"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60882":{"preferredName":"Recombinant Bispecific Single-Chain Antibody rM28","code":"C60882","definitions":[{"definition":"A recombinant, bispecific, single-chain antibody directed against both the T-cell surface-associated costimulatory molecule CD28 and a melanoma-associated proteoglycan (MAPG) with potential antitumor activity. By targeting both CD28 and MAPG, recombinant bispecific single-chain antibody rM28 enhances cytotoxic T-cell recognition of melanoma cells, which may result in immune effector cell-mediated tumor cell death and a decrease in distant metastases. This agent appears to have a long serum half-life secondary to the formation of dimers. When activated, CD28 facilitates interactions between T-cells and other immune effector cells resulting in cytotoxic T-lymphocyte responses; MAPG is a surface antigen expressed on the majority of melanomas, including primary cutaneous, ocular, and metastatic melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Bispecific Single-Chain Antibody rM28","termGroup":"PT","termSource":"NCI"},{"termName":"rM28","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Bispecific_Single-Chain_Antibody_rM28"},{"name":"Maps_To","value":"Recombinant Bispecific Single-Chain Antibody rM28"},{"name":"NCI_Drug_Dictionary_ID","value":"467183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467183"},{"name":"PDQ_Open_Trial_Search_ID","value":"467183"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1831730"}]}}{"C1437":{"preferredName":"Recombinant CD40-Ligand","code":"C1437","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to CD40-ligand. CD40-ligand, also known as CD40L/TRAP and CD154, is a type II membrane protein which binds to CD40, a cell surface receptor that belongs to the tumor necrosis factor receptor family; CD40 is expressed on B lymphocytes, monocytes, dendritic cells (DC), hematopoietic progenitors, endothelial cells and epithelial cells. Recombinant CD40-ligand may be used to activate DC ex vivo via CD40 binding; CD40-ligand-activated DC may provide or augment a protective antitumor immunity when administered in dendritic cell cancer vaccines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant CD40-Ligand","termGroup":"PT","termSource":"NCI"},{"termName":"CD154 antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD40L","termGroup":"AB","termSource":"NCI"},{"termName":"gp39","termGroup":"SY","termSource":"NCI"},{"termName":"rhu CD40L","termGroup":"AB","termSource":"NCI"},{"termName":"T-BAM","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Antigen gp39","termGroup":"SY","termSource":"NCI"},{"termName":"TNF-Related Activation Protein","termGroup":"SY","termSource":"NCI"},{"termName":"TRAP Ligand","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"147205-72-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_CD40-Ligand"},{"name":"Maps_To","value":"Recombinant CD40-Ligand"},{"name":"NCI_Drug_Dictionary_ID","value":"43639"},{"name":"NSC Number","value":"696600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43639"},{"name":"PDQ_Open_Trial_Search_ID","value":"43639"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527003"}]}}{"C477":{"preferredName":"Recombinant Erythropoietin","code":"C477","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Erythropoietin","termGroup":"PT","termSource":"NCI"},{"termName":"Erythrocyte Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Erythropoietin","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietin","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant EPO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11096-26-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"64FS3BFH5W"},{"name":"Legacy Concept Name","value":"Recombinant_Erythropoietin"},{"name":"Maps_To","value":"Recombinant Erythropoietin"},{"name":"NSC Number","value":"628281"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0376541"}]}}{"C1538":{"preferredName":"Recombinant Fas Ligand","code":"C1538","definitions":[{"definition":"A recombinant agent, which is chemically identical to or similar to the endogenous protein Fas ligand, a protein related to tumor necrosis factor (TNF) with potential antineoplastic activity.  Fas ligand binds to the Fas receptor, thereby activating caspases and inducing apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Fas Ligand","termGroup":"PT","termSource":"NCI"},{"termName":"Fas Ligand","termGroup":"SY","termSource":"NCI"},{"termName":"Fas-L","termGroup":"AB","termSource":"NCI"},{"termName":"FAS-Ligand","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Fas_Ligand"},{"name":"Maps_To","value":"Recombinant Fas Ligand"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515370"}]}}{"C2257":{"preferredName":"Recombinant Fractalkine","code":"C2257","definitions":[{"definition":"A pro-inflammatory delta chemokine with potential antineoplastic activity.  Fractalkine induces the adhesion and migration of T lymphocytes, monocytes and natural killer (NK) cells.  In lymphomas, this agent may promote cell-mediated lympholysis by recruiting activated NK cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Fractalkine","termGroup":"PT","termSource":"NCI"},{"termName":"CX3CL1","termGroup":"SY","termSource":"NCI"},{"termName":"Fractalkine","termGroup":"SY","termSource":"NCI"},{"termName":"Neurotactin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Fractalkine"},{"name":"Maps_To","value":"Recombinant Fractalkine"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522507"}]}}{"C1288":{"preferredName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","code":"C1288","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Colony-Stimulating Factor, Granulocyte-Macrophage","termGroup":"SY","termSource":"NCI"},{"termName":"CSF 39300","termGroup":"CN","termSource":"NCI"},{"termName":"CSF 39300/GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"CSF-GM (Hoechst)","termGroup":"SY","termSource":"NCI"},{"termName":"GM CSF","termGroup":"AB","termSource":"NCI"},{"termName":"GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"GM-CSF (Schering)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinanr Colony-Stimulating Factor 2","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Colony-Stimulating Factor 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83869-56-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Granulocyte-Macrophage_Colony-Stimulating_Factor"},{"name":"Maps_To","value":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor"},{"name":"NSC Number","value":"613795"},{"name":"NSC Number","value":"617589"},{"name":"NSC Number","value":"622183"},{"name":"NSC Number","value":"643496"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0376563"}]}}{"C1792":{"preferredName":"Recombinant Human 6Ckine","code":"C1792","definitions":[{"definition":"A therapeutic recombinant analogue of a member of the endogenous CC chemokines with potential antineoplastic activity. Expressed by various lymphoid tissues, endogenous 6Ckine is chemotactic for B and T lymphocytes and dendritic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human 6Ckine","termGroup":"PT","termSource":"NCI"},{"termName":"6ckine","termGroup":"SY","termSource":"NCI"},{"termName":"CCL21","termGroup":"SY","termSource":"NCI"},{"termName":"ck beta 9","termGroup":"SY","termSource":"NCI"},{"termName":"Exodus-2","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Secondary Lymphoid-Tissue Chemokine","termGroup":"SY","termSource":"NCI"},{"termName":"Secondary Lymphoid-Tissue Chemokine","termGroup":"SY","termSource":"NCI"},{"termName":"TCA4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Secondary_Lymphoid-Tissue_Chemokine"},{"name":"Maps_To","value":"Recombinant Human 6Ckine"},{"name":"NCI_Drug_Dictionary_ID","value":"459900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459900"},{"name":"PDQ_Open_Trial_Search_ID","value":"459900"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1523979"}]}}{"C107504":{"preferredName":"Recombinant Human Adenovirus Type 5 H101","code":"C107504","definitions":[{"definition":"A replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. Upon intratumoral injection of recombinant human adenovirus type 5, the adenovirus selectively replicates in cancer cells while preventing viral replication in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. In addition, viral spread to adjacent cells, following lysis of infected cells, may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation, which promotes viral replication; deletion of E1B allows for p53 activation in normal cells, which prevents viral replication in normal, healthy cells. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of E3, encoding the adenovirus death protein, enhances the safety profile of the administered adenovirus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Adenovirus Type 5 H101","termGroup":"PT","termSource":"NCI"},{"termName":"H101","termGroup":"CN","termSource":"NCI"},{"termName":"Oncorine","termGroup":"FB","termSource":"NCI"},{"termName":"rAd5 H101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802358-15-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QH36X20ODG"},{"name":"Maps_To","value":"Recombinant Human Adenovirus Type 5 H101"},{"name":"NCI_Drug_Dictionary_ID","value":"751381"},{"name":"NCI_META_CUI","value":"CL451750"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751381"},{"name":"PDQ_Open_Trial_Search_ID","value":"751381"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85447":{"preferredName":"Alunacedase Alfa","code":"C85447","definitions":[{"definition":"A recombinant, soluble glycosylated form of human angiotensin converting enzyme 2 (rhACE2) with antihypertensive and potential antineoplastic activities. Alunacedase Alfa may normalize ACE2 levels, cleaving angiotensin II to create angiotensin-(1-7) and restoring the function of the renin-angiotensin system (RAS). ACE2, a homolog of ACE1, appears to function as a negative regulator of the RAS system by converting angiotensin II to angiotensin-(1-7), a peptide with actions that counteract the cardiovascular actions of angiotensin II. In addition, angiotensin-(1-7) may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) G protein-coupled receptor Mas, resulting in diminished tumor cell proliferation. ACE2 levels may be reduced in malignancy and diabetes and in liver, cardiovascular and lung diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alunacedase Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"APN01","termGroup":"CN","termSource":"NCI"},{"termName":"rhACE2 APN01","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416824-55-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FA2I4Z873U"},{"name":"Maps_To","value":"Recombinant Human Angiotensin Converting Enzyme 2 APN01"},{"name":"NCI_Drug_Dictionary_ID","value":"642531"},{"name":"NCI_META_CUI","value":"CL412316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642531"},{"name":"PDQ_Open_Trial_Search_ID","value":"642531"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116864":{"preferredName":"Recombinant Human Apolipoprotein(a) Kringle V MG1102","code":"C116864","definitions":[{"definition":"An 86 amino-acid long polypeptide fragment of a recombinant form of human apolipoprotein (a) (apo(a)) kringle V, with potential anti-angiogenic and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration, recombinant human apo(a) kringle V MG1102 inhibits the fibronectin-mediated migration of endothelial cells, binds to and blocks the activity of alpha 3 beta 1 integrin (a3b1 integrin), inhibits the activation of focal adhesion kinase (FAK) and FAK-mediated signaling, and leads to the inhibition of the p130 Crk-associated substrate (p130CAS)-c-Jun NH2-terminal kinase (JNK) pathway. This inhibits tumor angiogenesis, induces mitochondrial-mediated apoptosis of tumor cells and tumor-associated endothelial cells, and suppresses tumor growth and metastasis. Apo(a), a glycoprotein component of human lipoprotein(a), contains repeated kringle domains; certain kringle domains of apo(a), including the plasminogen kringle V homolog (KV), have anti-angiogenic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Apolipoprotein(a) Kringle V MG1102","termGroup":"PT","termSource":"NCI"},{"termName":"MG1102","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Human Apo (a) Kringle V MG1102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Apolipoprotein(a) Kringle V MG1102"},{"name":"NCI_Drug_Dictionary_ID","value":"688419"},{"name":"NCI_META_CUI","value":"CL433737"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688419"},{"name":"PDQ_Open_Trial_Search_ID","value":"688419"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70674":{"preferredName":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine","code":"C70674","definitions":[{"definition":"A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Center of Molecular Immunology Epidermal Growth Factor Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CimaVax","termGroup":"SY","termSource":"NCI"},{"termName":"CIMAvax EGF","termGroup":"AB","termSource":"NCI"},{"termName":"CIMAvax Epidermal Growth Factor Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CimaVax Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CIMAvax-EGF","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Human EGF-P64K/Montanide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Human_EGF-rP64K_Montanide_ISA_51_Vaccine"},{"name":"Maps_To","value":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"570107"},{"name":"NCI_META_CUI","value":"CL376048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570107"},{"name":"PDQ_Open_Trial_Search_ID","value":"570107"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C45515":{"preferredName":"Recombinant Human Endostatin","code":"C45515","definitions":[{"definition":"A recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. Endostatin induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction in tumor burden. This agent also may decrease hepatic metastasis by inhibiting proinflammatory cytokines and vascular cell adhesion molecule (VCAM)-dependent cell attachment to the hepatic microvasculature.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Endostatin is made from a type of collagen (a protein found in cartilage and other connective tissue). It may prevent the growth of new blood vessels that tumors need to grow. Endostatin is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Human Endostatin","termGroup":"PT","termSource":"NCI"},{"termName":"Endostar","termGroup":"FB","termSource":"NCI"},{"termName":"Endostatin","termGroup":"SY","termSource":"NCI"},{"termName":"N-Terminal-MGGSHHHHH-Endostatin (Human Recombinant)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Endostatin","termGroup":"SY","termSource":"NCI"},{"termName":"rhEndostatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67RHC0R671"},{"name":"Legacy Concept Name","value":"Recombinant_Endostatin"},{"name":"Maps_To","value":"Recombinant Human Endostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"459758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459758"},{"name":"PDQ_Open_Trial_Search_ID","value":"459758"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1705207"}]}}{"C103830":{"preferredName":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine","code":"C103830","definitions":[{"definition":"A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"742760"},{"name":"NCI_META_CUI","value":"CL438310"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742760"},{"name":"PDQ_Open_Trial_Search_ID","value":"742760"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48395":{"preferredName":"Recombinant Human Papillomavirus Bivalent Vaccine","code":"C48395","definitions":[{"definition":"A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.","type":"DEFINITION","source":"NCI"},{"definition":"A vaccine used to prevent cervical cancer caused by human papillomaviruses (HPV) types 16 and 18. It is also used to prevent lesions that are caused by these viruses and that can lead to cervical, vulvar, or vaginal cancer. Cervarix is used in females aged 10-25 years. It is also being studied in the treatment of other medical conditions. It is a type of bivalent vaccine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Human Papillomavirus Bivalent Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Cervarix","termGroup":"BR","termSource":"NCI"},{"termName":"HPV-16/18 VLP/AS04 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Vaccine L1 16,18","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Vaccine, L1 Type 16, 18","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant HPV Bivalent Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus_16_18_L1_Virus-Like_Particle_AS04_Vaccine"},{"name":"Maps_To","value":"Recombinant Human Papillomavirus Bivalent Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"442270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"442270"},{"name":"PDQ_Open_Trial_Search_ID","value":"442270"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721789"}]}}{"C119664":{"preferredName":"Recombinant Human Papillomavirus Nonavalent Vaccine","code":"C119664","definitions":[{"definition":"A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Papillomavirus Nonavalent Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Gardasil 9","termGroup":"BR","termSource":"NCI"},{"termName":"Nonavalent HPV VLP Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant HPV Nonavalent Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Papillomavirus 9-valent Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Papillomavirus Nonavalent Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"767261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767261"},{"name":"PDQ_Open_Trial_Search_ID","value":"767261"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3864947"}]}}{"C162524":{"preferredName":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828","code":"C162524","definitions":[{"definition":"A recombinant human plasminogen kringle 5 domain with potential antiangiogenic and antineoplastic activities. Upon administration, recombinant human plasminogen kringle 5 domain ABT 828 may promote caspase activity and apoptosis in proliferating endothelial cells, thereby inhibiting migration. Kringle 5 (K5), an internal proteolytic fragment of plasminogen specifically inhibits endothelial cell growth via its interaction with endothelial cell surface ATP synthase, which sequentially triggers the activation of caspases -8, -9, and -3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828","termGroup":"PT","termSource":"NCI"},{"termName":"ABT 828","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-828","termGroup":"CN","termSource":"NCI"},{"termName":"ABT828","termGroup":"CN","termSource":"NCI"},{"termName":"rhK5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828"},{"name":"NCI_META_CUI","value":"CL971108"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C584":{"preferredName":"Recombinant Interferon","code":"C584","definitions":[{"definition":"One of a group of recombinant therapeutic glycoprotein cytokines with antiviral, anti-proliferative, and immunomodulating activities. Interferons bind to specific cell-surface receptors, leading to the transcription and translation of genes with interferon-specific response elements (ISREs). The resultant proteins mediate many complex effects, ultimately leading to inhibition of viral protein synthesis and cellular growth, alteration of cellular differentiation, interference with oncogene expression, activation of natural killer cells, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity. The production of endogenous interferons is induced in response to foreign agents such as bacteria, viruses and parasites and to tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon","termGroup":"PT","termSource":"NCI"},{"termName":"Human Leukocyte Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Human Lymphoblastoid Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN","termGroup":"AB","termSource":"NCI"},{"termName":"Interferons","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9008-1-11"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon"},{"name":"Maps_To","value":"Recombinant Interferon"},{"name":"NCI_Drug_Dictionary_ID","value":"40863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40863"},{"name":"PDQ_Open_Trial_Search_ID","value":"40863"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522537"}]}}{"C225":{"preferredName":"Recombinant Interferon Alfa","code":"C225","definitions":[{"definition":"A class of naturally-isolated or recombinant therapeutic peptides used as antiviral and anti-tumor agents.  Alpha interferons are cytokines produced by nucleated cells (predominantly natural killer (NK) leukocytes) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products.  These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element.  The proteins so produced mediate many complex effects, including antiviral effects (viral protein synthesis); antiproliferative effects (cellular growth inhibition and alteration of cellular differentiation); anticancer effects (interference with oncogene expression); and immune-modulating effects (natural killer cell activation, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Alferon","termGroup":"BR","termSource":"NCI"},{"termName":"Alpha Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"alpha-Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoblast Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoblastoid Interferon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"See specific agents."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon_Alfa"},{"name":"Maps_To","value":"Recombinant Interferon Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"40467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40467"},{"name":"PDQ_Open_Trial_Search_ID","value":"40467"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002199"}]}}{"C53411":{"preferredName":"Recombinant Interferon Alfa-1b","code":"C53411","definitions":[{"definition":"The non-glycosylated recombinant interferon alpha, subtype 1b, with immunostimulatory and antineoplastic activities. Alpha interferon-1b binds to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa-1b","termGroup":"PT","termSource":"NCI"},{"termName":"IFN-alfa-1b","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon Alfa-1b","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Interferon Alpha-1b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G7407IV2FS"},{"name":"Legacy Concept Name","value":"Interferon_Alfa-1b"},{"name":"Maps_To","value":"Recombinant Interferon Alfa-1b"},{"name":"NCI_Drug_Dictionary_ID","value":"466520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"466520"},{"name":"PDQ_Open_Trial_Search_ID","value":"466520"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831728"}]}}{"C1952":{"preferredName":"Recombinant Interferon Alfa-2a","code":"C1952","definitions":[{"definition":"A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa-2a","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha 2 Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN alpha-2A","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-Alpha 2","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon alfa 2a","termGroup":"SY","termSource":"NCI"},{"termName":"Laroferon","termGroup":"FB","termSource":"NCI"},{"termName":"Recombinant Interferon Alpha-2a","termGroup":"SY","termSource":"NCI"},{"termName":"rHuIFN-a 2a","termGroup":"AB","termSource":"NCI"},{"termName":"Roceron-A","termGroup":"FB","termSource":"NCI"},{"termName":"Roferon A","termGroup":"BR","termSource":"NCI"},{"termName":"Roferon-A","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia; hairy cell leukemia; chronic hepatitis C; AIDs-related Kaposis sarcoma; bladder; ovarian; cervical cancer; non-Hodgkins lymphoma; renal cell carcinoma; melanoma."},{"name":"CAS_Registry","value":"76543-88-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"47RRR83SK7"},{"name":"Legacy Concept Name","value":"Interferon_Alpha-2a"},{"name":"Maps_To","value":"Recombinant Interferon Alfa-2a"},{"name":"NCI_Drug_Dictionary_ID","value":"467189"},{"name":"NSC Number","value":"367982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467189"},{"name":"PDQ_Open_Trial_Search_ID","value":"467189"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021734"}]}}{"C1953":{"preferredName":"Recombinant Interferon Alfa-2b","code":"C1953","definitions":[{"definition":"A drug used to treat some infections caused by viruses and several types of cancer. These include hairy cell leukemia, melanoma, and follicular lymphoma. It is a form of interferon alfa (a substance normally made by cells of the immune system) that is made in the laboratory. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa-2b","termGroup":"PT","termSource":"NCI"},{"termName":"Alfatronol","termGroup":"FB","termSource":"NCI"},{"termName":"Glucoferon","termGroup":"FB","termSource":"NCI"},{"termName":"Heberon Alfa","termGroup":"FB","termSource":"NCI"},{"termName":"IFN alpha-2B","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon alfa 2b","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Alfa-2B","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"Intron A","termGroup":"BR","termSource":"NCI"},{"termName":"Sch 30500","termGroup":"CN","termSource":"NCI"},{"termName":"Urifron","termGroup":"FB","termSource":"NCI"},{"termName":"Viraferon","termGroup":"BR","termSource":"NCI"},{"termName":"Viraferon","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98530-12-2"},{"name":"CAS_Registry","value":"99210-65-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"43K1W2T1M6"},{"name":"Legacy Concept Name","value":"Recombinant_Interferon_Alfa-2b"},{"name":"Maps_To","value":"Recombinant Interferon Alfa-2b"},{"name":"NCI_Drug_Dictionary_ID","value":"462279"},{"name":"NSC Number","value":"377523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462279"},{"name":"PDQ_Open_Trial_Search_ID","value":"462279"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021735"}]}}{"C97503":{"preferredName":"Recombinant Interferon Alpha 2b-like Protein","code":"C97503","definitions":[{"definition":"A proprietary recombinant protein highly resembling human interferon alpha 2b (IFN-a2b), with potential anti-tumor, anti-inflammatory, immunomodulating and antiviral activities. Upon injection, recombinant IFN alpha 2b-like protein binds to specific IFN alpha cell surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs). This may activate the immune system, including the activation of natural killer cells (NKs) and may result in an inhibition of tumor cell proliferation, tumor angiogenesis, metastasis and an induction of apoptosis. Compared to human IFN-a2b (HuINF-a2b), this agent exhibits enhanced antiviral and antiproliferative activities. In addition, this agent exhibits antiviral activity against a variety of viruses, including hepatitis B and C viruses, human immunodeficiency virus (HIV) and Avian Influenza.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alpha 2b-like Protein","termGroup":"PT","termSource":"NCI"},{"termName":"Novaferon","termGroup":"BR","termSource":"NCI"},{"termName":"Recombinant IFN Alfa-2b-like Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H9CK7SS0T6"},{"name":"Maps_To","value":"Recombinant Interferon Alpha 2b-like Protein"},{"name":"NCI_Drug_Dictionary_ID","value":"703323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703323"},{"name":"PDQ_Open_Trial_Search_ID","value":"703323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273451"}]}}{"C495":{"preferredName":"Recombinant Interferon Beta","code":"C495","definitions":[{"definition":"A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Beta","termGroup":"PT","termSource":"NCI"},{"termName":"Beta Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Betantrone","termGroup":"FB","termSource":"NCI"},{"termName":"Feron","termGroup":"FB","termSource":"NCI"},{"termName":"Human Interferon Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon, Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon-B","termGroup":"SY","termSource":"NCI"},{"termName":"Naferon","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple sclerosis"},{"name":"CAS_Registry","value":"77238-31-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9GU1EM8SF"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon_Beta"},{"name":"Maps_To","value":"Recombinant Interferon Beta"},{"name":"NCI_Drug_Dictionary_ID","value":"40468"},{"name":"NSC Number","value":"373361"},{"name":"NSC Number","value":"658933"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40468"},{"name":"PDQ_Open_Trial_Search_ID","value":"40468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015980"}]}}{"C583":{"preferredName":"Recombinant Interferon Gamma","code":"C583","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous lymphokine interferon gamma (IFN-gamma) with antineoplastic, immunoregulatory, and antiviral activities. Therapeutic IFN-gamma binds to and activates the cell-surface IFN-gamma receptor, stimulating antibody-dependent cytotoxicity and enhances natural killer cell attachment to tumor cells. This agent also activates caspases, thereby inducing apoptosis in malignant cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Gamma","termGroup":"PT","termSource":"NCI"},{"termName":"Gamma Interferon (GEN)","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma Interferon-SCH","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Ginterferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-g","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon Gamma (BIO)","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon, Gamma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic granulomatous disease; Osteopetrosis"},{"name":"CAS_Registry","value":"82115-62-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P050J5FWC5"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon_Gamma"},{"name":"Maps_To","value":"Recombinant Interferon Gamma"},{"name":"NCI_Drug_Dictionary_ID","value":"40469"},{"name":"NSC Number","value":"600662"},{"name":"NSC Number","value":"635256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40469"},{"name":"PDQ_Open_Trial_Search_ID","value":"40469"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3539881"}]}}{"C1380":{"preferredName":"Edodekin alfa","code":"C1380","definitions":[{"definition":"A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity.  Edodekin alfa binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-12 is made mainly by B lymphocytes and macrophages. It causes other immune cells to make cytokines and increases the growth of T lymphocytes. It may also block the growth of new blood vessels. Interleukin-12 made in the laboratory is used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-12 is a type of cytokine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Edodekin alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Cytotoxic Lymphocyte Maturation Factor","termGroup":"SY","termSource":"NCI"},{"termName":"IL-12","termGroup":"AB","termSource":"NCI"},{"termName":"Natural Killer Cell Stimulatory Factor","termGroup":"SY","termSource":"NCI"},{"termName":"NM-IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant human interleukin-12 (IL-12) cytokine","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 24-7472","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"187348-17-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31Z82G8ME1"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-12"},{"name":"Maps_To","value":"Edodekin alfa"},{"name":"Maps_To","value":"Recombinant Interleukin-12"},{"name":"NCI_Drug_Dictionary_ID","value":"42153"},{"name":"NSC Number","value":"672423"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42153"},{"name":"PDQ_Open_Trial_Search_ID","value":"42153"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1524115"}]}}{"C1489":{"preferredName":"Recombinant Interleukin-13","code":"C1489","definitions":[{"definition":"The recombinant analogue of an endogenous cytokine interleukin 13 with potential antineoplastic activity. Produced by lymphocytes and exhibiting a variety of functions, interleukin-13 (therapeutic) inhibits DNA synthesis and regulates inflammatory and immune responses. In animal models, this agent has been shown to kill tumor cells both directly and indirectly by activating the host immune system at the tumor site. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interleukin-13","termGroup":"PT","termSource":"NCI"},{"termName":"IL-13","termGroup":"AB","termSource":"NCI"},{"termName":"Interleukin 13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"148157-34-0"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-13"},{"name":"Maps_To","value":"Recombinant Interleukin-13"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522557"}]}}{"C587":{"preferredName":"Recombinant Interleukin-2","code":"C587","definitions":[{"definition":"Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-2 is made by a type of T lymphocyte. It increases the growth and activity of other T lymphocytes and B lymphocytes, and affects the development of the immune system. Aldesleukin (interleukin-2 made in the laboratory) is being used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-2 is a type of cytokine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Interleukin-2","termGroup":"PT","termSource":"NCI"},{"termName":"IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"Interleukin II","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Mitogenic Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogenic Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Ro-236019","termGroup":"CN","termSource":"NCI"},{"termName":"T-Cell Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"TCGF","termGroup":"AB","termSource":"NCI"},{"termName":"Thymocyte Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"TSF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colorectal cancer; metastatic melanoma; metastatic renal cell carcinoma; Non-Hodgkins lymphoma"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FNO32LO217"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-2"},{"name":"Maps_To","value":"Recombinant Interleukin-2"},{"name":"NCI_Drug_Dictionary_ID","value":"812847"},{"name":"NSC Number","value":"373364"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919268"}]}}{"C591":{"preferredName":"Recombinant Interleukin-6","code":"C591","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-6 (IL-6) with antiapoptotic, proinflammatory, antiinflammatory, proproliferative and proangiogenic activities. IL-6 binds to its receptor (IL-6R), activating a receptor-CD130 receptor complex; the CD130 portion of the complex is a signal transduction protein that activates JAK kinases and Ras-mediated signaling pathways, which in turn activate downstream signaling pathways, resulting in the activation of various transcription factors (STAT, ELK-1, NF-IL-6, etc.) and gene transcription. The physiological effects of IL-6 are complex and varied and include hematopoietic, pyrogenic and thermogenic, proinflammatory, antiinflammatory, proproliferative (anti-apoptotic), and angiogenic effects.","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-6 is made mainly by some T lymphocytes. It causes B lymphocytes to make more antibodies and also causes fever by affecting areas of the brain that control body temperature. Interleukin-6 made in the laboratory is used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-6 is a type of cytokine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Interleukin-6","termGroup":"PT","termSource":"NCI"},{"termName":"B Cell Differentiation Factor 2","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Stimulatory Factor-2","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatocyte Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"HPGF","termGroup":"AB","termSource":"NCI"},{"termName":"HSF","termGroup":"AB","termSource":"NCI"},{"termName":"Hybridoma Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"IFN Beta 2","termGroup":"SY","termSource":"NCI"},{"termName":"IL-6","termGroup":"AB","termSource":"NCI"},{"termName":"Myeloid Differentiation Inducing Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytoma Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Sigosix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O4QWG0B3C"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-6"},{"name":"Maps_To","value":"Recombinant Interleukin-6"},{"name":"NCI_Drug_Dictionary_ID","value":"41474"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41474"},{"name":"PDQ_Open_Trial_Search_ID","value":"41474"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527132"}]}}{"C28721":{"preferredName":"Recombinant KSA Glycoprotein CO17-1A","code":"C28721","definitions":[{"definition":"A recombinant counterpart of tumor-associated KSA antigen (Ep-CAM), a type-I transmembrane glycoprotein cellular adhesion molecule with a molecular mass of 40 kDa, overexpressed on the majority of tumor cells of most human epithelia in a of variety of tumor tissues such as stomach, colon, pancreas, gall bladder, bile duct, mammary gland, breast, and lung carcinoma. It has been suggested to be involved in the differentiation, growth, and organization of epithelial cells within tissues under normal physiological conditions. The antigen has been used as a target for diagnosis and for passive and active immunotherapy of colorectal cancer. Immunization with KSA Glycoprotein elicits both humoral and Th1-associated cellular immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant KSA Glycoprotein CO17-1A","termGroup":"PT","termSource":"NCI"},{"termName":"CO17-1A","termGroup":"SY","termSource":"NCI"},{"termName":"EGP","termGroup":"SY","termSource":"NCI"},{"termName":"Ep-CAM","termGroup":"SY","termSource":"NCI"},{"termName":"GA733","termGroup":"SY","termSource":"NCI"},{"termName":"KSA Glycoprotein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_KSA_Glycoprotein"},{"name":"Maps_To","value":"Recombinant KSA Glycoprotein CO17-1A"},{"name":"NCI_Drug_Dictionary_ID","value":"43440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43440"},{"name":"PDQ_Open_Trial_Search_ID","value":"43440"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1527244"}]}}{"C2413":{"preferredName":"Recombinant Leukocyte Interleukin","code":"C2413","definitions":[{"definition":"A cocktail preparation of synthetic interleukin (IL) -1, IL-2, IL-6, tumor necrosis factor (TNF)-alpha, interferon gamma and other cytokines that are chemically identical to or similar to signaling molecules secreted by leukocyte cells. Leukocyte interleukins are essential in many immune responses, such as antibodies production, modulating secretion of other cytokines, and activation of bone marrow stem cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Leukocyte Interleukin","termGroup":"PT","termSource":"NCI"},{"termName":"BC-IL","termGroup":"AB","termSource":"NCI"},{"termName":"Buffy Coat Interleukin","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Interleukin, Inj.","termGroup":"SY","termSource":"NCI"},{"termName":"Multikine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"neoadjuvant therapy for patients with squamous cell carcinoma of the head and neck"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Leukocyte_Interleukin"},{"name":"Maps_To","value":"Recombinant Leukocyte Interleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"42580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42580"},{"name":"PDQ_Open_Trial_Search_ID","value":"42580"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0392999"}]}}{"C1143":{"preferredName":"Recombinant Leukoregulin","code":"C1143","definitions":[{"definition":"A formulated therapeutic analog of the endogenous lymphokine leukoregulin with potential antineoplastic activity.  Leukoregulin displays direct and indirect cytotoxicity through tumor cell lysis and enhancing tumor cell susceptibility to natural killer cell-mediated cytotoxicity.  This agent enhances membrane permeability and decreases p-glycoprotein expression, thereby promoting cytotoxic drug uptake into tumor cells.  Leukoregulin also induces the synthesis of collagenase and hyaluronan, expression and secretion of interleukin-8, and upregulates stromelysin-1 gene expression in human fibroblasts, thereby regulating extracellular matrix degradation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Leukoregulin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Leukoregulin"},{"name":"Maps_To","value":"Recombinant Leukoregulin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515385"}]}}{"C612":{"preferredName":"Recombinant Luteinizing Hormone","code":"C612","definitions":[{"definition":"A hormone made in the pituitary gland. In females, it acts on the ovaries to make follicles release their eggs and to make hormones that get the uterus ready for a fertilized egg to be implanted. In males, it acts on the testes to cause cells to grow and make testosterone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any recombinant form of the endogenously produced heterodimer glycoprotein luteinizing hormone (LH) normally made by the anterior pituitary gland, that can be used for the treatment of LH deficiency. Upon administration, recombinant LH mimics the biological activity of endogenous LH. In females, this triggers ovulation and the development of the corpus luteum. In males, LH stimulates Leydig cells to produce testosterone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Luteinizing Hormone","termGroup":"PT","termSource":"NCI"},{"termName":"Interstitial Cell-Stimulating Hormone","termGroup":"SY","termSource":"NCI"},{"termName":"Leuteinizing Hormone","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinizing Hormone","termGroup":"SY","termSource":"NCI"},{"termName":"Lutropin","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant LH","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic LH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9002-67-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8XA4VN1LH4"},{"name":"Legacy Concept Name","value":"Therapeutic_Luteinizing_Hormone"},{"name":"Maps_To","value":"Recombinant Luteinizing Hormone"},{"name":"NCI_Drug_Dictionary_ID","value":"811468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1704298"}]}}{"C1290":{"preferredName":"Recombinant Macrophage Colony-Stimulating Factor","code":"C1290","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous protein cytokine macrophage colony-stimulating factor (M-CSF). Synthesized endogenously by mesenchymal cells, M-CSF stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series and can reverse treatment-related neutropenias. Recombinant M-CSF may also enhance antigen presentation and activate antitumoral cytotoxic T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Macrophage Colony-Stimulating Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Macrophage Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Colony Stimulating Factor 1","termGroup":"SY","termSource":"NCI"},{"termName":"rM-CSF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81627-83-0"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Macrophage_Colony-Stimulating_Factor"},{"name":"Maps_To","value":"Recombinant Macrophage Colony-Stimulating Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"40240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40240"},{"name":"PDQ_Open_Trial_Search_ID","value":"40240"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079784"}]}}{"C38724":{"preferredName":"Recombinant MAGE-3.1 Antigen","code":"C38724","definitions":[{"definition":"A recombinant tumor-specific melanoma antigen. Vaccination with recombinant MAGE-3.1 antigen may induce a host immune response against MAGE-expressing cells, resulting in antitumoral T cell-mediated cytotoxicity. MAGE-expressing cells are found in melanoma, non-small-cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma, transitional cell carcinoma of the bladder, and esophageal carcinoma. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant MAGE-3.1 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"MAGE-3","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-3.1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_MAGE-3-1_Antigen"},{"name":"Maps_To","value":"Recombinant MAGE-3.1 Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"42271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42271"},{"name":"PDQ_Open_Trial_Search_ID","value":"42271"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1510427"}]}}{"C98294":{"preferredName":"Nagrestipen","code":"C98294","definitions":[{"definition":"A recombinant form of a human macrophage inflammatory protein-1 alpha (MIP1-alpha) with a substitution of aspartate to alanine at position 26, with potential immunomodulating and radiotherapy potentiating activity. Intravenous administration of nagrestipen after local tumor irradiation enhances the anti-tumor effect of ionizing radiation at the irradiated site as well as the antitumor effect at non-irradiated tumor sites (known as the abscopal effect). The abscopal effect appears to be attributed to this agent's ability to recruit and activate leukocytes, such as monocytes, dendritic cells, natural killer cells and T lymphocytes, thereby initiating an anti-tumor immune response against cancer cells. MIP1-alpha, also known as chemokine (C-C motif) ligand 3, is a ligand for the chemokine receptors CCR1, CCR4 and CCR5 that are involved in immune and inflammatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nagrestipen","termGroup":"PT","termSource":"NCI"},{"termName":"26-L-Alaninelymphokine MIP 1alpha (Human clone pAT464 MacrophageIinflammatory)","termGroup":"SY","termSource":"NCI"},{"termName":"BB-10010","termGroup":"CN","termSource":"NCI"},{"termName":"ECI301","termGroup":"CN","termSource":"NCI"},{"termName":"eMIP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"166089-33-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9350121Z8S"},{"name":"Maps_To","value":"Nagrestipen"},{"name":"Maps_To","value":"Recombinant MIP1-alpha Variant ECI301"},{"name":"NCI_Drug_Dictionary_ID","value":"713863"},{"name":"NCI_META_CUI","value":"CL432412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713863"},{"name":"PDQ_Open_Trial_Search_ID","value":"713863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49087":{"preferredName":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine","code":"C49087","definitions":[{"definition":"A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant MVA-5T4 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Pox Virus Encoding 5T4 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TroVax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P258UUW1OD"},{"name":"Legacy Concept Name","value":"Recombinant_Modified_Vaccinia_Ankara-5T4_Vaccine"},{"name":"Maps_To","value":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"449683"},{"name":"PDQ_Closed_Trial_Search_ID","value":"449683"},{"name":"PDQ_Open_Trial_Search_ID","value":"449683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541801"}]}}{"C99459":{"preferredName":"Recombinant Oncolytic Poliovirus PVS-RIPO","code":"C99459","definitions":[{"definition":"A recombinant, live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. Upon intratumoral administration of recombinant oncolytic poliovirus PVS-RIPO, the poliovirus is selectively taken up by and replicates in tumor cells expressing CD155 (poliovirus receptor, PVR or NECL5) eventually causing tumor cell lysis. CD155, an oncofetal cell adhesion molecule and tumor antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme (GMB), and plays an important role in tumor cell migration, invasion, and metastasis. Due to the heterologous HRV2 IRES in this recombinant virus, PVS-RIPO only propagates in susceptible, nonneuronal cells (e.g., GBM).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Oncolytic Poliovirus PVS-RIPO","termGroup":"PT","termSource":"NCI"},{"termName":"PVS-RIPO","termGroup":"CN","termSource":"NCI"},{"termName":"PVSRIPO","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Oncolytic Poliovirus PVS-RIPO"},{"name":"NCI_Drug_Dictionary_ID","value":"721361"},{"name":"NCI_META_CUI","value":"CL433215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721361"},{"name":"PDQ_Open_Trial_Search_ID","value":"721361"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C2251":{"preferredName":"Iroplact","code":"C2251","definitions":[{"definition":"A recombinant form of the endogenous chemokine platelet factor 4 with potential antiangiogenesis and antineoplastic activities. As a heparin-binding tetramer, iroplact inhibits growth factor-stimulated endothelial cell proliferation, migration, and angiogenesis; it has been shown that this agent inhibits fibroblast growth factor 2 (FGF2) angiogenic activity downstream from the FGF2 receptor. Its activity is antagonized by heparin. Recombinant platelet factor 4 may also directly inhibit the proliferation of some tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iroplact","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant CXCL4","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Platelet Factor 4","termGroup":"SY","termSource":"NCI"},{"termName":"rhPF4","termGroup":"AB","termSource":"NCI"},{"termName":"rPF4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37270-94-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T381WW8L8Y"},{"name":"Legacy Concept Name","value":"Therapeutic_Platelet_Factor_4"},{"name":"Maps_To","value":"Iroplact"},{"name":"Maps_To","value":"Recombinant Platelet Factor 4"},{"name":"NCI_Drug_Dictionary_ID","value":"42317"},{"name":"NSC Number","value":"671662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42317"},{"name":"PDQ_Open_Trial_Search_ID","value":"42317"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3887655"}]}}{"C92586":{"preferredName":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A","code":"C92586","definitions":[{"definition":"A recombinant form of the human PRAME (Preferentially Expressed Antigen of Melanoma) protein combined with the AS15 adjuvant, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, GSK2302025A may stimulate the host immune response to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress the PRAME protein, resulting in tumor cell lysis. The tumor-associated antigen PRAME is often overexpressed by a variety of tumor cell types. AS15 is an potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid, and QS-21.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A"},{"name":"NCI_Drug_Dictionary_ID","value":"681046"},{"name":"NCI_META_CUI","value":"CL421638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681046"},{"name":"PDQ_Open_Trial_Search_ID","value":"681046"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82371":{"preferredName":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207","code":"C82371","definitions":[{"definition":"A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207","termGroup":"PT","termSource":"NCI"},{"termName":"GI-6207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FIJ3OLQ3N8"},{"name":"Legacy Concept Name","value":"Recombinant_Saccharomyces_Cerevisia-CEA_610D_Expressing_Vaccine_GI-6207"},{"name":"Maps_To","value":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207"},{"name":"NCI_Drug_Dictionary_ID","value":"641167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641167"},{"name":"PDQ_Open_Trial_Search_ID","value":"641167"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830061"}]}}{"C121542":{"preferredName":"Recombinant Super-compound Interferon","code":"C121542","definitions":[{"definition":"A recombinant form of the naturally-occurring cytokine interferon-alpha (IFN-a) that has a modified spatial configuration, with immunomodulating, antiviral and antineoplastic activities. Upon administration of recombinant super-compound interferon (rSIFN-co), this agent binds to IFN-specific cell surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects. The 3-dimensional conformational change improves efficacy and causes less side effects compared to IFN-a.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Super-compound Interferon","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant Super Compound Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"rSIFN-co","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Super-compound Interferon"},{"name":"NCI_Drug_Dictionary_ID","value":"770206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770206"},{"name":"PDQ_Open_Trial_Search_ID","value":"770206"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053486"}]}}{"C884":{"preferredName":"Recombinant Thyroglobulin","code":"C884","definitions":[{"definition":"A recombinant form of thyroglobulin identical to or similar to the endogenous iodine-containing glycoprotein. Thyroglobulin is synthesized in the thyroid follicular cell, and is the precursor of thyroid hormones T3 and T4. Thyroglobulin levels can serve as a tumor marker for monitoring the status of differentiated thyroid carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Thyroglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"Proloid","termGroup":"BR","termSource":"NCI"},{"termName":"Therapeutic TG","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroglobulin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypothyroidism"},{"name":"CAS_Registry","value":"9010-34-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NN2P9VPL7M"},{"name":"Legacy Concept Name","value":"Therapeutic_Thyroglobulin"},{"name":"Maps_To","value":"Recombinant Thyroglobulin"},{"name":"NCI_Drug_Dictionary_ID","value":"39300"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39300"},{"name":"PDQ_Open_Trial_Search_ID","value":"39300"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527123"}]}}{"C61322":{"preferredName":"Recombinant Thyrotropin Alfa","code":"C61322","definitions":[{"definition":"A form of thyroid-stimulating hormone (TSH) that is made in the laboratory. It is used to test for remaining or recurring cancer cells in patients who have been treated for thyroid cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant form of the human anterior pituitary glycoprotein thyroid stimulating hormone (TSH) with use in the diagnostic setting. With an amino acid sequence identical to that of human TSH, thyrotropin alfa binds to TSH receptors on normal thyroid epithelial cells or well-differentiated thyroid cancer cells, stimulating iodine uptake and organification, synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Thyrotropin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant Thyrotropin Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant TSH Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Thyrogen","termGroup":"BR","termSource":"NCI"},{"termName":"Thyroid Stimulating Hormone Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Thyrotropin Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"TSH-alpha","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194100-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AVX3D5A4LM"},{"name":"Legacy Concept Name","value":"Recombinant_Thyrotropin_Alfa"},{"name":"Maps_To","value":"Recombinant Thyrotropin Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"481277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481277"},{"name":"PDQ_Open_Trial_Search_ID","value":"481277"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2587204"}]}}{"C898":{"preferredName":"Recombinant Transforming Growth Factor-Beta","code":"C898","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine transforming growth factor-beta (TGF-beta) with proapoptotic and antineoplastic properties. TGF-beta may suppress tumor cell growth by decreasing the expression of cyclin D1, a cell cycle regulatory protein, and downregulating the expression of the oncogene c-myc. This agent is also involved in T cell-mediated immunosuppression by CD4+CD25+ T cells, which permits cancer cells to evade immune surveillance. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Transforming Growth Factor-Beta","termGroup":"PT","termSource":"NCI"},{"termName":"Bone-Derived Transforming Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"rTGF-Beta","termGroup":"SY","termSource":"NCI"},{"termName":"TGF-Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic Milk Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic TGF B","termGroup":"AB","termSource":"NCI"},{"termName":"Therapeutic TGF-Beta","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Transforming_Growth_Factor-Beta"},{"name":"Maps_To","value":"Recombinant Transforming Growth Factor-Beta"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527196"}]}}{"C1286":{"preferredName":"Recombinant Transforming Growth Factor-Beta-2","code":"C1286","definitions":[{"definition":"A recombinant polypeptide chemically identical to or similar to the endogenous cytokine transforming growth factor-beta-2 (TGF-beta-2). TGF-beta-2 modulates cell growth and immune function and may promote or inhibit tumor growth, depending on the tumor cell type. TGF-beta-2 may also suppress host immune system recognition of and/or response to tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Transforming Growth Factor-Beta-2","termGroup":"PT","termSource":"NCI"},{"termName":"Cartilage-Inducing Factor-B","termGroup":"SY","termSource":"NCI"},{"termName":"Glioblastoma-Derived T-Cell Suppressor Factor","termGroup":"SY","termSource":"NCI"},{"termName":"TGF-Beta 2","termGroup":"SY","termSource":"NCI"},{"termName":"Transforming Growth Factor-Beta 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157238-32-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"693Y43MXY4"},{"name":"Legacy Concept Name","value":"Therapeutic_Transforming_Growth_Factor-Beta_2"},{"name":"Maps_To","value":"Recombinant Transforming Growth Factor-Beta-2"},{"name":"NCI_Drug_Dictionary_ID","value":"42024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42024"},{"name":"PDQ_Open_Trial_Search_ID","value":"42024"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522073"}]}}{"C913":{"preferredName":"Recombinant Tumor Necrosis Factor-Alpha","code":"C913","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine tumor necrosis factor-alpha with antineoplastic properties.  Tumor necrosis factor-alpha binds to and activates \"death receptors\" on the cell surface, resulting in apoptosis and cell death by the p53-independent extrinsic pathway. This agent also disrupts tumor vascularization. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Tumor Necrosis Factor-Alpha","termGroup":"PT","termSource":"NCI"},{"termName":"Cachectin","termGroup":"SY","termSource":"NCI"},{"termName":"TNF-Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"TNFA","termGroup":"AB","termSource":"NCI"},{"termName":"Tumor Necrosis Factor (TNF-alpha)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"308079-78-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X2C8Z061MB"},{"name":"Legacy Concept Name","value":"Therapeutic_Tumor_Necrosis_Factor-Alpha"},{"name":"Maps_To","value":"Recombinant Tumor Necrosis Factor-Alpha"},{"name":"NCI_Drug_Dictionary_ID","value":"43225"},{"name":"NSC Number","value":"697068"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43225"},{"name":"PDQ_Open_Trial_Search_ID","value":"43225"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522669"}]}}{"C38682":{"preferredName":"Recombinant Tyrosinase-Related Protein-2","code":"C38682","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to an endogenous non-mutated melanocyte differentiation antigen expressed by both normal and malignant melanocytes. Vaccinations with recombinant tyrosinase-related protein-2 may elicit an antitumoral cytotoxic T-cell response against tumor cells and some normal cells that express tyrosinase-related protein-2. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Tyrosinase-Related Protein-2","termGroup":"PT","termSource":"NCI"},{"termName":"TRP-2","termGroup":"AB","termSource":"NCI"},{"termName":"Tyrosinase-Related Protein-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Tyrosinase-Related_Protein-2"},{"name":"Maps_To","value":"Recombinant Tyrosinase-Related Protein-2"},{"name":"NCI_Drug_Dictionary_ID","value":"38407"},{"name":"NCI_META_CUI","value":"CL035331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38407"},{"name":"PDQ_Open_Trial_Search_ID","value":"38407"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C131580":{"preferredName":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","code":"C131580","definitions":[{"definition":"A recombinant, replication competent form of the oncolytic RNA virus vesicular stomatitis virus (VSV), based on the Indiana strain of VSV, that is genetically engineered to express the genes for the human cytokine interferon beta (IFNbeta) and the human thyroidal sodium-iodide symporter (NIS), with potential oncolytic and imaging activities. Upon intravenous administration, VSV-hIFNbeta-NIS is preferentially taken up by tumor cells, resulting in tumor cell infection, viral replication and a direct virus-mediated cytolytic effect against the infected tumor cells. IFN-mediated signaling is defective in tumor cells and tumor cells are unable to exert an anti-viral response against VSV. As normal, healthy cells secrete and respond normally to IFNbeta and are able to activate IFN-mediated anti-viral pathways, the expressed IFNbeta from the VSV-infected tumor cells helps protect normal cells from VSV infection. Upon subsequent administration of certain isotope-containing imaging agents, NIS expression by the infected tumor cells allows visualization and tracking of VSV biodistribution, and analysis and quantification of VSV-infected tumor cells by positron emission tomography (PET). Also, upon subsequent administration of the radioisotope iodine I 131 (I131), I131 can be taken up by NIS and allows for a cytotoxic dose of radiation to accumulate in the NIS-expressing VSV-infected tumor cells, which also leads to tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","termGroup":"PT","termSource":"NCI"},{"termName":"Oncolytic VSV-hIFNbeta-NIS","termGroup":"SY","termSource":"NCI"},{"termName":"Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","termGroup":"SY","termSource":"NCI"},{"termName":"Voyager-V1","termGroup":"BR","termSource":"NCI"},{"termName":"VSV-expressing hIFNb and NIS","termGroup":"SY","termSource":"NCI"},{"termName":"VSV-hIFNb-NIS","termGroup":"SY","termSource":"NCI"},{"termName":"VSV-hIFNbeta-NIS","termGroup":"SY","termSource":"NCI"},{"termName":"VV1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter"},{"name":"NCI_Drug_Dictionary_ID","value":"788964"},{"name":"NCI_META_CUI","value":"CL514461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788964"},{"name":"PDQ_Open_Trial_Search_ID","value":"788964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C74059":{"preferredName":"Refametinib","code":"C74059","definitions":[{"definition":"An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refametinib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 869766","termGroup":"CN","termSource":"NCI"},{"termName":"BAY86-9766","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor RDEA119","termGroup":"SY","termSource":"NCI"},{"termName":"RDEA119","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923032-37-5"},{"name":"Chemical_Formula","value":"C19H20F3IN2O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JPX07AFM0N"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_RDEA119"},{"name":"Maps_To","value":"Refametinib"},{"name":"NCI_Drug_Dictionary_ID","value":"589128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589128"},{"name":"PDQ_Open_Trial_Search_ID","value":"589128"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346909"}]}}{"C78204":{"preferredName":"Regorafenib","code":"C78204","definitions":[{"definition":"The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 73-4506","termGroup":"AB","termSource":"NCI"},{"termName":"Regorafenib Anhydrous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hepatocellular carcinoma (HCC)"},{"name":"CAS_Registry","value":"755037-03-7"},{"name":"Chemical_Formula","value":"C21H15ClF4N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"24T2A1DOYB"},{"name":"Legacy Concept Name","value":"Multitargeted_Receptor_Tyrosine_Kinase_Inhibitor_BAY_73-4506"},{"name":"Maps_To","value":"Regorafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"595192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595192"},{"name":"PDQ_Open_Trial_Search_ID","value":"595192"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2980094"}]}}{"C127838":{"preferredName":"Relacorilant","code":"C127838","definitions":[{"definition":"An orally available antagonist of the glucocorticoid receptor (GR), with potential antineoplastic activity. Upon administration,  relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. This decreases the negative effects that result from excess levels of endogenous glucocorticoids, like those seen when tumors overproduce glucocorticoids. In addition, by binding to GRs and preventing their activity, inhibition with CORT125134 also inhibits the proliferation of GR-overexpressing cancer cells. GRs are overexpressed in certain tumor cell types and promote tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relacorilant","termGroup":"PT","termSource":"NCI"},{"termName":"((4aR)-1-(4-Fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone","termGroup":"SY","termSource":"NCI"},{"termName":"CORT-125134","termGroup":"CN","termSource":"NCI"},{"termName":"CORT125134","termGroup":"CN","termSource":"NCI"},{"termName":"Methanone, ((4aR)-1-(4-Fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1496510-51-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2158753C7E"},{"name":"Maps_To","value":"Relacorilant"},{"name":"NCI_Drug_Dictionary_ID","value":"781149"},{"name":"NCI_META_CUI","value":"CL507918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781149"},{"name":"PDQ_Open_Trial_Search_ID","value":"781149"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111999":{"preferredName":"Relatlimab","code":"C111999","definitions":[{"definition":"A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T-lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relatlimab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986016","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986016","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1673516-98-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AF75XOF6W3"},{"name":"Maps_To","value":"Relatlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"754229"},{"name":"NCI_META_CUI","value":"CL454288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754229"},{"name":"PDQ_Open_Trial_Search_ID","value":"754229"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114498":{"preferredName":"Relugolix","code":"C114498","definitions":[{"definition":"An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relugolix","termGroup":"PT","termSource":"NCI"},{"termName":"N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea","termGroup":"SY","termSource":"NCI"},{"termName":"Orgovyx","termGroup":"BR","termSource":"NCI"},{"termName":"Relugolix","termGroup":"SY","termSource":"NCI"},{"termName":"Relumina","termGroup":"FB","termSource":"NCI"},{"termName":"TAK 385","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-385","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with advanced prostate cancer."},{"name":"CAS_Registry","value":"737789-87-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"P76B05O5V6"},{"name":"Maps_To","value":"Relugolix"},{"name":"NCI_Drug_Dictionary_ID","value":"759257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759257"},{"name":"PDQ_Open_Trial_Search_ID","value":"759257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3252109"}]}}{"C97513":{"preferredName":"Remetinostat","code":"C97513","definitions":[{"definition":"A topical formulation containing the histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Upon cutaneous administration, SHP-141 selectively binds to and inhibits HDAC, resulting in an accumulation of highly acetylated histones in the skin (dermis and epidermis), the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. These events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. Topical administration of SHP-141 allows for high concentrations of this agent locally while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Remetinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Methyl 4-((8-(Hydroxyamino)-8-Oxooctanoyl)oxy)benzoate","termGroup":"SN","termSource":"NCI"},{"termName":"Methylparaben Suberohydroxamic Acid Phenyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"SHAPE","termGroup":"AB","termSource":"NCI"},{"termName":"SHP-141","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946150-57-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37NT056AT4"},{"name":"Maps_To","value":"Remetinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"703816"},{"name":"NCI_META_CUI","value":"CL430257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703816"},{"name":"PDQ_Open_Trial_Search_ID","value":"703816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70968":{"preferredName":"Renal Cell Carcinoma Peptides Vaccine IMA901","code":"C70968","definitions":[{"definition":"A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Cell Carcinoma Peptides Vaccine IMA901","termGroup":"PT","termSource":"NCI"},{"termName":"IMA901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Cell_Carcinoma_Peptides_Vaccine_IMA901"},{"name":"Maps_To","value":"Renal Cell Carcinoma Peptides Vaccine IMA901"},{"name":"NCI_Drug_Dictionary_ID","value":"570963"},{"name":"NCI_META_CUI","value":"CL375872"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570963"},{"name":"PDQ_Open_Trial_Search_ID","value":"570963"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66515":{"preferredName":"Reparixin","code":"C66515","definitions":[{"definition":"An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration, reparixin allosterically binds to CXCR1 and prevents CXCR1 activation by its ligand interleukin 8 (IL-8 or CXCL8). This may cause cancer stem cell (CSC) apoptosis and may inhibit tumor cell progression and metastasis. CXCR1, overexpressed on CSCs, plays a key role in CSC survival and the ability of CSC to self-renew; it is also linked to tumor resistance to chemotherapy. Inhibition of the IL-8/CXCR1 interaction also potentiates the cytotoxic effect of chemotherapeutic agents. In addition, reparixin inhibits CXCR2 activation and may reduce both neutrophil recruitment and vascular permeability during inflammation or injury.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reparixin","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Isobutylphenyl)propionylmethanesulfonamide","termGroup":"SY","termSource":"NCI"},{"termName":"Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-N- (methylsulfonyl)- (alphaR)-","termGroup":"SN","termSource":"NCI"},{"termName":"DF 1681Y","termGroup":"CN","termSource":"NCI"},{"termName":"Repertaxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"266359-83-5"},{"name":"Chemical_Formula","value":"C14H21NO3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U604E1NB3K"},{"name":"Legacy Concept Name","value":"Reparixin"},{"name":"Maps_To","value":"Reparixin"},{"name":"NCI_Drug_Dictionary_ID","value":"750172"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750172"},{"name":"PDQ_Open_Trial_Search_ID","value":"750172"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506747"}]}}{"C133821":{"preferredName":"Repotrectinib","code":"C133821","definitions":[{"definition":"An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Repotrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005","termGroup":"SY","termSource":"NCI"},{"termName":"Augtyro","termGroup":"BR","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor TPX-0005","termGroup":"SY","termSource":"NCI"},{"termName":"Multikinase Inhibitor TPX-0005","termGroup":"SY","termSource":"NCI"},{"termName":"TPX-0005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"ocally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)."},{"name":"CAS_Registry","value":"1802220-02-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"08O3FQ4UNP"},{"name":"Maps_To","value":"Repotrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"788549"},{"name":"NCI_META_CUI","value":"CL521742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788549"},{"name":"PDQ_Open_Trial_Search_ID","value":"788549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63958":{"preferredName":"Resiquimod","code":"C63958","definitions":[{"definition":"A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An imidazoquinolinamine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic cells, macrophages, and B-lymphocytes. This induces the nuclear translocation of the transcription activator NF-kB as well as activation of other transcription factors. This may lead to an increase in mRNA levels and subsequent production of cytokines, especially interferon-alpha (INF-a) and other cytokines, thereby enhancing T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate Langerhans' cells, leading to an enhanced activation of T-lymphocytes. Due to its immunostimulatory activity, this agent may potentially be useful as a vaccine adjuvant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resiquimod","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol","termGroup":"SN","termSource":"NCI"},{"termName":"R848","termGroup":"CN","termSource":"NCI"},{"termName":"S 28463","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144875-48-9"},{"name":"CHEBI_ID","value":"CHEBI:36706"},{"name":"Chemical_Formula","value":"C17H22N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V3DMU7PVXF"},{"name":"Legacy Concept Name","value":"Resiquimod"},{"name":"Maps_To","value":"Resiquimod"},{"name":"NCI_Drug_Dictionary_ID","value":"544217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"544217"},{"name":"PDQ_Open_Trial_Search_ID","value":"544217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0389573"}]}}{"C88259":{"preferredName":"Resiquimod Topical Gel","code":"C88259","definitions":[{"definition":"A topical gel containing the Toll-like receptor (TLR) agonist resiquimod, an imidazoquinolinamine and with potential immunomodulating activity. Resiquimod binds toTLR7 and 8, mainly on dendritic cells, macrophages, and B-lymphocytes, and activates the TLR signaling pathway, resulting in the induction of the nuclear translocation of transcription activator NF-kB and activation of other transcription factors; subsequently, gene expression increases and the production of cytokines increases, especially interferon-alpha (INF-a), resulting in the enhancement of T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate epidermal Langerhans cells, leading to an enhanced activation of T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resiquimod Topical Gel","termGroup":"PT","termSource":"NCI"},{"termName":"R848 Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resiquimod Topical Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"654328"},{"name":"NCI_META_CUI","value":"CL412435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654328"},{"name":"PDQ_Open_Trial_Search_ID","value":"654328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94233":{"preferredName":"Resistant Starch","code":"C94233","definitions":[{"definition":"A form of dietary fiber that resists degradation by gastrointestinal (GI) enzymes in the small intestine with potential chemopreventive and prebiotic activity. Upon consumption of resistant starch, the fiber is not metabolized or absorbed in the small intestine and enters the colon unaltered. Once in the colon, the starch is fermented by anaerobic colonic bacteria and produces short-chain fatty acids (SCFA), including butyrate, which has anti-inflammatory and immunoregulatory activities. In addition, butyrate appears to exert antitumor effects by inhibiting tumor cell proliferation, inducing tumor cell differentiation and promoting apoptosis in colorectal cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resistant Starch","termGroup":"PT","termSource":"NCI"},{"termName":"RS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resistant Starch"},{"name":"NCI_Drug_Dictionary_ID","value":"687429"},{"name":"NCI_META_CUI","value":"CL426045"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687429"},{"name":"PDQ_Open_Trial_Search_ID","value":"687429"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C84856":{"preferredName":"Resminostat","code":"C84856","definitions":[{"definition":"An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, inhibition of the transcription of tumor suppressor genes, inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resminostat","termGroup":"PT","termSource":"NCI"},{"termName":"4SC-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"864814-88-0"},{"name":"Chemical_Formula","value":"C16H19N3O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1578EUB98L"},{"name":"Maps_To","value":"Resminostat"},{"name":"NCI_Drug_Dictionary_ID","value":"651465"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651465"},{"name":"PDQ_Open_Trial_Search_ID","value":"651465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2935131"}]}}{"C1215":{"preferredName":"Resveratrol","code":"C1215","definitions":[{"definition":"A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A substance found in the skins of grapes and in certain other plants, fruits, and seeds. It is made by various plants to help defend against invading fungi, stress, injury, infection, and too much sunlight. It is being studied in the prevention of cancer and heart disease. It is a type of antioxidant and a type of polyphenol.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Resveratrol","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol","termGroup":"SN","termSource":"NCI"},{"termName":"3,4',5-Stilbenetriol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501-36-0"},{"name":"CHEBI_ID","value":"CHEBI:27881"},{"name":"CHEBI_ID","value":"CHEBI:45713"},{"name":"Chemical_Formula","value":"C14H12O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q369O8926L"},{"name":"Legacy Concept Name","value":"Resveratrol"},{"name":"Maps_To","value":"Resveratrol"},{"name":"NCI_Drug_Dictionary_ID","value":"405819"},{"name":"NSC Number","value":"327430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"405819"},{"name":"PDQ_Open_Trial_Search_ID","value":"405819"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073096"}]}}{"C85484":{"preferredName":"Resveratrol Formulation SRT501","code":"C85484","definitions":[{"definition":"A proprietary formulation of resveratrol, a polyphenolic phytoalexin derived from grapes and other food products with potential antioxidant, anti-obesity, antidiabetic and chemopreventive activities. Resveratrol may activate sirtuin subtype 1 (SIRT-1). SIRT1 activation has been reported to inhibit tumorigenesis and tumor cell proliferation. SIRT-1 is a member of the silent information regulator 2 (SIR2) (or sirtuin) family of enzymes that plays an important role in mitochondrial activity and acts as a protein deacetylase. SIRT1 appears to be involved in the regulation of numerous transcription factors such as NF-kB and p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resveratrol Formulation SRT501","termGroup":"PT","termSource":"NCI"},{"termName":"SRT501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resveratrol Formulation SRT501"},{"name":"NCI_Drug_Dictionary_ID","value":"648245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648245"},{"name":"PDQ_Open_Trial_Search_ID","value":"648245"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002402"}]}}{"C158093":{"preferredName":"Zeteletinib","code":"C158093","definitions":[{"definition":"An orally bioavailable selective inhibitor of wild-type, fusion products and mutated forms, including gatekeeper mutations, of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, zeteletinib selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zeteletinib","termGroup":"PT","termSource":"NCI"},{"termName":"BOS 172738","termGroup":"CN","termSource":"NCI"},{"termName":"BOS-172738","termGroup":"CN","termSource":"NCI"},{"termName":"BOS172738","termGroup":"CN","termSource":"NCI"},{"termName":"CAXM-1190B","termGroup":"CN","termSource":"NCI"},{"termName":"DS 5010B","termGroup":"CN","termSource":"NCI"},{"termName":"DS-5010B","termGroup":"CN","termSource":"NCI"},{"termName":"DS5010B","termGroup":"CN","termSource":"NCI"},{"termName":"RET Inhibitor DS-5010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2216753-97-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EP0P7SHM0U"},{"name":"Maps_To","value":"RET Inhibitor DS-5010"},{"name":"NCI_Drug_Dictionary_ID","value":"796992"},{"name":"NCI_META_CUI","value":"CL937686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796992"},{"name":"PDQ_Open_Trial_Search_ID","value":"796992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132295":{"preferredName":"Pralsetinib","code":"C132295","definitions":[{"definition":"An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pralsetinib","termGroup":"PT","termSource":"NCI"},{"termName":"(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BLU-667","termGroup":"CN","termSource":"NCI"},{"termName":"BLU667","termGroup":"CN","termSource":"NCI"},{"termName":"Gavreto","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"2097132-94-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1WPE73O1WV"},{"name":"Maps_To","value":"Pralsetinib"},{"name":"Maps_To","value":"RET Mutation/Fusion Inhibitor BLU-667"},{"name":"NCI_Drug_Dictionary_ID","value":"787354"},{"name":"NCI_META_CUI","value":"CL520212"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787354"},{"name":"PDQ_Open_Trial_Search_ID","value":"787354"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80378":{"preferredName":"Retaspimycin","code":"C80378","definitions":[{"definition":"A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retaspimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-Allylamino-17-demethoxygeldanamycin Hydroquinone","termGroup":"SN","termSource":"NCI"},{"termName":"Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857402-23-4"},{"name":"Chemical_Formula","value":"C31H45N3O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"BZF2ZM0I5Z"},{"name":"Legacy Concept Name","value":"Retaspimycin"},{"name":"Maps_To","value":"Retaspimycin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1743502"}]}}{"C48401":{"preferredName":"Retaspimycin Hydrochloride","code":"C48401","definitions":[{"definition":"The hydrochloride salt of a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retaspimycin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"17-Allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"IPI-504","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857402-63-2"},{"name":"Chemical_Formula","value":"C31H45N3O8.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"928Q33Q049"},{"name":"Legacy Concept Name","value":"IPI-504"},{"name":"Maps_To","value":"Retaspimycin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"437784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"437784"},{"name":"PDQ_Open_Trial_Search_ID","value":"437784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708447"}]}}{"C73241":{"preferredName":"Retelliptine","code":"C73241","definitions":[{"definition":"An ellipticine derivative and topoisomerase II inhibitor with antineoplastic activity. Retelliptine intercalates with DNA and inhibits topoisomerase II during DNA replication. In addition, this agent appears to induce cell cycle arrest at G2/M phase and apoptosis mediated through the Fas/Fas ligand death receptor and the mitochondrial pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retelliptine","termGroup":"PT","termSource":"NCI"},{"termName":"1-((3-(Diethylamino)propyl)amino)-5,11-dimethyl-9-methoxy-6H-pyrido(4,3-b)carbazole","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72238-02-9"},{"name":"Chemical_Formula","value":"C25H32N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SZ0F94M68J"},{"name":"Legacy Concept Name","value":"Retelliptine"},{"name":"Maps_To","value":"Retelliptine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084319"}]}}{"C64174":{"preferredName":"Retinoic Acid Agent Ro 16-9100","code":"C64174","definitions":[{"definition":"A synthetic retinoid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, Ro 16-9100 binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinoic Acid Agent Ro 16-9100","termGroup":"PT","termSource":"NCI"},{"termName":"Retinoid Ro 16-9100","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 16-9100","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-16-9100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160372-07-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ro_16-9100"},{"name":"Maps_To","value":"Retinoic Acid Agent Ro 16-9100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0913966"}]}}{"C80061":{"preferredName":"Retinoid 9cUAB30","code":"C80061","definitions":[{"definition":"A substance being studied in the treatment and prevention of cancer. It blocks an enzyme that keeps cells alive by adding material to the ends of chromosomes.  Blocking this enzyme may cause the cancer cells to die. 9cUAB30 is a type of retinoic acid and a type of telomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analogue of 9-cis retinoic acid with potential antineoplastic and chemopreventive activities. Retinoid 9cUAB30 binds to and activates retinoid X receptor (RXR) homodimers and/or and retinoic acid receptor (RAR)/RXR heterodimers, which may result in the dissociation of corepressor protein and the recruitment of coactivator protein, followed by transcription of downstream target genes into mRNAs and protein translation. Gene transcription regulated by these transcription factors may result in inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinoid 9cUAB30","termGroup":"PT","termSource":"NCI"},{"termName":"(9Z)-UAB-30","termGroup":"SY","termSource":"NCI"},{"termName":"UAB-30","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"205252-57-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PFP09575EX"},{"name":"Legacy Concept Name","value":"Retinoid_9cUAB30"},{"name":"Maps_To","value":"Retinoid 9cUAB30"},{"name":"NCI_Drug_Dictionary_ID","value":"614594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614594"},{"name":"PDQ_Open_Trial_Search_ID","value":"614594"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311390"}]}}{"C68302":{"preferredName":"Retinol","code":"C68302","definitions":[{"definition":"Retinoid with a hydroxyl group. Active form of vitamin A which can be converted to the other usable forms; retinal (an aldehyde) and retinoic acid (a carboxylic acid).","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"The fat soluble vitamin retinol. Vitamin A binds to and activates retinoid receptors (RARs), thereby inducing cell differentiation and apoptosis of some cancer cell types and inhibiting carcinogenesis. Vitamin A plays an essential role in many physiologic processes, including proper functioning of the retina, growth and differentiation of target tissues, proper functioning of the reproductive organs, and modulation of immune function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinol","termGroup":"PT","termSource":"NCI"},{"termName":"3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol","termGroup":"SN","termSource":"NCI"},{"termName":"All Trans Retinol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11103-57-4"},{"name":"CAS_Registry","value":"68-26-8"},{"name":"CHEBI_ID","value":"CHEBI:17336"},{"name":"Chemical_Formula","value":"C20H30O"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G2SH0XKK91"},{"name":"INFOODS","value":"RETOL"},{"name":"Legacy Concept Name","value":"Retinol"},{"name":"Maps_To","value":"Retinol"},{"name":"NCI_Drug_Dictionary_ID","value":"39735"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39735"},{"name":"PDQ_Open_Trial_Search_ID","value":"39735"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"UMLS_CUI","value":"C0087161"},{"name":"Unit","value":"mcg"},{"name":"USDA_ID","value":"322"}]}}{"C1216":{"preferredName":"Retinyl Acetate","code":"C1216","definitions":[{"definition":"A naturally-occurring fatty acid ester form of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Retinyl acetate binds to and activates retinoid receptors, inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation in some cancer cell types and exhibits immunomodulatory properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinyl Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Retinol Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"vitamin A acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dietary supplement; vitamin A deficiency"},{"name":"CAS_Registry","value":"127-47-9"},{"name":"CHEBI_ID","value":"CHEBI:32095"},{"name":"Chemical_Formula","value":"C22H32O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3LE3D9D6OY"},{"name":"Legacy Concept Name","value":"Retinyl_Acetate"},{"name":"Maps_To","value":"Retinyl Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"40313"},{"name":"NSC Number","value":"122045"},{"name":"NSC Number","value":"122760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40313"},{"name":"PDQ_Open_Trial_Search_ID","value":"40313"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073109"}]}}{"C1217":{"preferredName":"Retinyl Palmitate","code":"C1217","definitions":[{"definition":"A drug being studied in cancer prevention.  It belongs to the family of drugs called retinoids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally-occurring phenyl analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  As the most common form of vitamin A taken for dietary supplementation, retinyl palmitate binds to and activates retinoid receptors, thereby inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation, induces apoptosis in some cancer cell types, and exhibits immunomodulatory properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinyl Palmitate","termGroup":"PT","termSource":"NCI"},{"termName":"Palmitate-1-14C","termGroup":"SN","termSource":"NCI"},{"termName":"Retinol Hexadecanoate","termGroup":"SY","termSource":"NCI"},{"termName":"Retinol Palmitate","termGroup":"SY","termSource":"NCI"},{"termName":"Retinol-15-3H","termGroup":"SN","termSource":"NCI"},{"termName":"Retinyl-10,11-14C2","termGroup":"SN","termSource":"NCI"},{"termName":"Vitamin A Palmitate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dietary supplement; vitamin A deficiency; reduction in falciparum malaria episodes in children older than 12 months old; acne; diminishing malignant cell growth; enhancing the immune system; reduction in mortality of HIV-infected children"},{"name":"CAS_Registry","value":"79-81-2"},{"name":"CHEBI_ID","value":"CHEBI:17616"},{"name":"Chemical_Formula","value":"C36H60O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1D1K0N0VVC"},{"name":"Legacy Concept Name","value":"Retinyl_Palmitate"},{"name":"Maps_To","value":"Retinyl Palmitate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073115"}]}}{"C49082":{"preferredName":"Retrovector Encoding Mutant Anti-Cyclin G1","code":"C49082","definitions":[{"definition":"A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retrovector Encoding Mutant Anti-Cyclin G1","termGroup":"PT","termSource":"NCI"},{"termName":"DeltaRex-G","termGroup":"BR","termSource":"NCI"},{"termName":"Mx-dnG1","termGroup":"SY","termSource":"NCI"},{"termName":"REXIN-G","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retrovector_Encoding_Anti-Cyclin_G"},{"name":"Maps_To","value":"Retrovector Encoding Mutant Anti-Cyclin G1"},{"name":"NCI_Drug_Dictionary_ID","value":"446577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"446577"},{"name":"PDQ_Open_Trial_Search_ID","value":"446577"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709935"}]}}{"C74076":{"preferredName":"Rexinoid NRX 194204","code":"C74076","definitions":[{"definition":"An orally bioavailable synthetic retinoid X receptor (RXR) agonist with potential antineoplastic and anti-inflammatory activities. Rexinoid NRX 194204 selectively binds to and activates RXRs. Because RXRs can form heterodimers with several nuclear receptors (NRs), RXR activation by this agent may result in a broad range of gene expression depending on the effector DNA response elements activated. Rexinoid NRX 194204 may inhibit the tumor-necrosis factor (TNF)-mediated release of nitric oxide (NO) and interleukin 6 (IL6) and may inhibit tumor cell proliferation. This agent appears to be less toxic than RAR-selective ligands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rexinoid NRX 194204","termGroup":"PT","termSource":"NCI"},{"termName":"AGN194204","termGroup":"CN","termSource":"NCI"},{"termName":"NRX194204","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"260262-39-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"877M97Z38Y"},{"name":"Legacy Concept Name","value":"Rexinoid_NRX_194204"},{"name":"Maps_To","value":"Rexinoid NRX 194204"},{"name":"NCI_Drug_Dictionary_ID","value":"592353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592353"},{"name":"PDQ_Open_Trial_Search_ID","value":"592353"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0967787"}]}}{"C61498":{"preferredName":"RFT5-dgA Immunotoxin IMTOX25","code":"C61498","definitions":[{"definition":"A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of melanoma that has spread to distant parts of the body. IgG-RFT5-dgA is made in the laboratory. It can find and kill certain white blood cells that prevent the immune system from killing cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant immunotoxin consisting of the anti-CD25 monoclonal antibody RFT5 fused to the deglycosylated ricin A-chain (dgA) with potential antitumor activity.  The monoclonal antibody moiety of RFT5-dgA immunotoxin attaches to CD25 (the alpha chain of the IL-2 receptor complex) on the cell membrane; after internalization, the dgA moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death.  CD25 is expressed on activated normal T and B cells and macrophages and is frequently upregulated in many hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RFT5-dgA Immunotoxin IMTOX25","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD25 Immunotoxin IMTOX25","termGroup":"SY","termSource":"NCI"},{"termName":"IgG-RFT5-dgA","termGroup":"AB","termSource":"NCI"},{"termName":"IMTOX25","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"RFT5-dgA_Immunotoxin"},{"name":"Maps_To","value":"RFT5-dgA Immunotoxin IMTOX25"},{"name":"NCI_Drug_Dictionary_ID","value":"486413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486413"},{"name":"PDQ_Open_Trial_Search_ID","value":"486413"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831838"}]}}{"C118670":{"preferredName":"Rhenium Re 188 BMEDA-labeled Liposomes","code":"C118670","definitions":[{"definition":"A liposome-based preparation consisting of the beta- and gamma-emitting radionuclide rhenium Re 188 (Re 188) linked to the chelator N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA) and encapsulated in liposomes, with potential tumor imaging and antineoplastic activities. Upon intravenous infusion of rhenium Re 188 BMEDA-labeled liposomes, the liposomes selectively target tumor cells, facilitate the retention of the radioisotope by those cells, and cause localized antitumor radiocytotoxicity while sparing surrounding normal, healthy cells. In addition, Re 188 BMEDA-labeled liposomes can be used for imaging purposes. Re 188 has a short half-life and a short path length, which further contribute to limiting the radiotoxicity to the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re 188 BMEDA-labeled Liposomes","termGroup":"PT","termSource":"NCI"},{"termName":"(188) Re-BMEDA-liposomes","termGroup":"SY","termSource":"NCI"},{"termName":"188Re-BMEDA-liposomes","termGroup":"SY","termSource":"NCI"},{"termName":"188Re-N,N-bis (2-Mercaptoethyl)-N',N'-diethylethylenediamine-labeled Liposomes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rhenium Re 188 BMEDA-labeled Liposomes"},{"name":"NCI_Drug_Dictionary_ID","value":"765863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765863"},{"name":"PDQ_Open_Trial_Search_ID","value":"765863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897117"}]}}{"C1562":{"preferredName":"Rhenium Re 186 Etidronate","code":"C1562","definitions":[{"definition":"An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re 186 Etidronate","termGroup":"PT","termSource":"NCI"},{"termName":"186Re-Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Re 186 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Re-186 HEDP","termGroup":"AB","termSource":"NCI"},{"termName":"Re-186 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium Re-186 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-186 HEDP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"140709-07-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DV7W6W681S"},{"name":"Legacy Concept Name","value":"Re_186_Hydroxyethylidene_Diphosphonate"},{"name":"Maps_To","value":"Rhenium Re-186 Hydroxyethylidene Diphosphonate"},{"name":"NCI_Drug_Dictionary_ID","value":"41205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41205"},{"name":"PDQ_Open_Trial_Search_ID","value":"41205"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280809"}]}}{"C91390":{"preferredName":"Rhenium Re-188 Ethiodized Oil","code":"C91390","definitions":[{"definition":"A rhenium (Re) 188 conjugate of ethiodized oil (lipiodol), an iodinated ethyl ester derived from poppy seed oil, with potential antineoplastic activity. Upon hepatic intra-arterial injection rhenium Re 188 ethiodized oil accumulates in hepatocellular carcinoma (HCC) tumor cells, thereby delivering a cytotoxic dose of radiation through Re 188 directly to the tumor cells. This may kill tumor cells while sparing surrounding normal cells and tissues. Compared to iodine I 131, Re 188 has a shorter half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re-188 Ethiodized Oil","termGroup":"PT","termSource":"NCI"},{"termName":"Rhenium Re 188 Lipiodol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rhenium Re-188 Ethiodized Oil"},{"name":"NCI_Drug_Dictionary_ID","value":"674326"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674326"},{"name":"PDQ_Open_Trial_Search_ID","value":"674326"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1530677"}]}}{"C156698":{"preferredName":"Rhenium Re-188 Etidronate","code":"C156698","definitions":[{"definition":"A synthetic compound containing the bisphosphonate etidronate (hydroxyethylidene diphosphonate, HEDP) labeled with rhenium Re188, a beta-emitting radioisotope with potential antineoplastic activity. Upon administration, Re-188 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. The beta-radiation may provide localized anti-tumor radiotoxicity while sparing extramedullary bone marrow tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re-188 Etidronate","termGroup":"PT","termSource":"NCI"},{"termName":"188Re-HEDP","termGroup":"SY","termSource":"NCI"},{"termName":"88Re-Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Re 188 Etidronic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Re 188 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Re-188 Etidronate","termGroup":"AB","termSource":"NCI"},{"termName":"Re-188 HEDP","termGroup":"SY","termSource":"NCI"},{"termName":"Re-188 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Re-188Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium Re-188 Hydroxyethylidene Diphosphonate (SY)","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-188 Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-188 HEDP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XWW2JNQ850"},{"name":"Maps_To","value":"Rhenium Re-188 Etidronate"},{"name":"NCI_Drug_Dictionary_ID","value":"795714"},{"name":"NCI_META_CUI","value":"CL935713"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795714"},{"name":"PDQ_Open_Trial_Search_ID","value":"795714"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1218":{"preferredName":"Rhizoxin","code":"C1218","definitions":[{"definition":"A macrocyclic lactone. Rhizoxin binds to tubulin and inhibits microtubule assembly, thereby inducing cytotoxicity. This agent also may inhibit endothelial cell-induced angiogenic activity, which may result in decreased tumor cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It comes from a fungus and is similar to vinca alkaloid drugs. It belongs to the family of drugs called antimitotic agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rhizoxin","termGroup":"PT","termSource":"NCI"},{"termName":"WF-1360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"90996-54-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C1V1Y784E4"},{"name":"Legacy Concept Name","value":"Rhizoxin"},{"name":"Maps_To","value":"Rhizoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"41718"},{"name":"NSC Number","value":"332598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41718"},{"name":"PDQ_Open_Trial_Search_ID","value":"41718"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073184"}]}}{"C151937":{"preferredName":"Onilcamotide","code":"C151937","definitions":[{"definition":"A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onilcamotide","termGroup":"PT","termSource":"NCI"},{"termName":"RhoC Peptide Vaccine RV001V","termGroup":"SY","termSource":"NCI"},{"termName":"RV 001","termGroup":"CN","termSource":"NCI"},{"termName":"RV 001V","termGroup":"CN","termSource":"NCI"},{"termName":"RV001 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"RV001V","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1164096-85-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UQE6KP7T0D"},{"name":"Maps_To","value":"RhoC Peptide Vaccine RV001V"},{"name":"NCI_Drug_Dictionary_ID","value":"793139"},{"name":"NCI_META_CUI","value":"CL553276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793139"},{"name":"PDQ_Open_Trial_Search_ID","value":"793139"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95701":{"preferredName":"Ribociclib","code":"C95701","definitions":[{"definition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribociclib","termGroup":"PT","termSource":"NCI"},{"termName":"7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Kisqali","termGroup":"BR","termSource":"NCI"},{"termName":"LEE-011","termGroup":"CN","termSource":"NCI"},{"termName":"LEE011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"breast cancer"},{"name":"CAS_Registry","value":"1211441-98-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"TK8ERE8P56"},{"name":"Maps_To","value":"Ribociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"689330"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689330"},{"name":"PDQ_Open_Trial_Search_ID","value":"689330"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045494"}]}}{"C154675":{"preferredName":"Ribociclib/Letrozole","code":"C154675","definitions":[{"definition":"An orally available co-packaged agent combination of ribociclib, a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Ribociclib specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribociclib/Letrozole","termGroup":"PT","termSource":"NCI"},{"termName":"Kisqali and Femara Co-pack","termGroup":"BR","termSource":"NCI"},{"termName":"Kisqali Femara Co-pack","termGroup":"SY","termSource":"NCI"},{"termName":"Kisqali/Femara","termGroup":"BR","termSource":"NCI"},{"termName":"Ribociclib + Letrozole","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib and Letrozole Co-pack","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib Plus Letrozole","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib-Letrozole","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib-Letrozole Regimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ribociclib/Letrozole"},{"name":"NCI_META_CUI","value":"CL759918"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82689":{"preferredName":"Ribonuclease QBI-139","code":"C82689","definitions":[{"definition":"A nuclease of mammalian origin that cleaves the phosphodiester bond between nucleotides of ribonucleic acids with potential antineoplastic activity. Ribonuclease QBI-139 catalyzes the hydrolysis and degradation of RNA leading to the inhibition of protein synthesis and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribonuclease QBI-139","termGroup":"PT","termSource":"NCI"},{"termName":"QBI-139","termGroup":"CN","termSource":"NCI"},{"termName":"RNase QBI-139","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ribonuclease_QBI-139"},{"name":"Maps_To","value":"Ribonuclease QBI-139"},{"name":"NCI_Drug_Dictionary_ID","value":"633695"},{"name":"NCI_META_CUI","value":"CL388476"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633695"},{"name":"PDQ_Open_Trial_Search_ID","value":"633695"},{"name":"Semantic_Type","value":"Enzyme"}]}}{"C78188":{"preferredName":"Aviscumine","code":"C78188","definitions":[{"definition":"A recombinant protein that inactivates the ribosome with potential antineoplastic and immunomodulating activities. Aviscumine binds to the cell surface sialyltransferase CD75 and is internalized; intracellularly, aviscumine cleaves an adenine-specific N-glycosidic bond on the 28S ribosomal subunit, which may result in tumor cell apoptosis. This agent has also been shown to activate natural killer (NK) cells, induce cytokine receptor expression, and stimulate the release of cytokines. CD75 is expressed on mature B-cells and subsets of T-cells and erythrocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aviscumine","termGroup":"PT","termSource":"NCI"},{"termName":"CY 503","termGroup":"CN","termSource":"NCI"},{"termName":"CY-503","termGroup":"CN","termSource":"NCI"},{"termName":"CY503","termGroup":"CN","termSource":"NCI"},{"termName":"Toxin ML-I (Mistletoe Lectin I) (Viscum album)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"223577-45-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4B18YVW82N"},{"name":"Legacy Concept Name","value":"Ribosome-Inactivating_Protein_CY503"},{"name":"Maps_To","value":"Aviscumine"},{"name":"Maps_To","value":"Ribosome-Inactivating Protein CY503"},{"name":"NCI_Drug_Dictionary_ID","value":"594770"},{"name":"NCI_META_CUI","value":"CL383580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594770"},{"name":"PDQ_Open_Trial_Search_ID","value":"594770"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1865":{"preferredName":"Ribozyme RPI.4610","code":"C1865","definitions":[{"definition":"A nuclease-stabilized synthetic ribozyme (ribonucleic acid enzyme) with potential anti-angiogenesis activity. Ribozyme RPI.4610 specifically recognizes the mRNA for FLT1 (vascular endothelial growth factor receptor 1; VEGFR1), and hydrolyzes the mRNA, thereby preventing VEGFR1 proteins from being made. This may prevent VEGF-stimulated angiogenesis in cancerous tissue and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. RPI.4610 is a special type of RNA made in the laboratory. It stops a protein called vascular endothelial growth factor receptor (VEGFR) from being made. This may prevent the growth of new blood vessels that tumors need to grow. It is a type of angiogenesis inhibitor and a type of ribozyme.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ribozyme RPI.4610","termGroup":"PT","termSource":"NCI"},{"termName":"Angiozyme","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-Flt-1 Ribozyme","termGroup":"SY","termSource":"NCI"},{"termName":"RPI.4610","termGroup":"CN","termSource":"NCI"},{"termName":"RPI4610","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Angiozyme"},{"name":"Maps_To","value":"Ribozyme RPI.4610"},{"name":"NCI_Drug_Dictionary_ID","value":"38358"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38358"},{"name":"PDQ_Open_Trial_Search_ID","value":"38358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0908892"}]}}{"C111686":{"preferredName":"Rice Bran","code":"C111686","definitions":[{"definition":"The nutrient-rich hard outer layer of the rice cereal grain, with potential chemopreventive, antioxidant, iron chelating, anticholesterol and anti-inflammatory activities. Rice bran is rich in fiber, such as beta-glucan, pectin and gum; it also comprises vitamins and minerals, such as iron, magnesium and phosphorus, and essential fatty acids. In addition, Rice bran contains various bioactive components, including ferulic acid, tricin, beta-sitosterol, gamma-oryzanol, phytic acid, and inositol hexaphosphate (IP6). The potential anticancer activity of rice bran may be due to the synergistic effects of these phytochemicals on their ability to induce apoptosis, inhibit cell proliferation, and alter cell cycle progression in cancer cells. Rice bran's bioactive components also protect against tissue damage by scavenging free radicals and blocking chronic inflammatory responses. In addition, they are able to modulate the gut microflora and carcinogen-metabolizing enzymes, thereby further exerting a chemopreventive effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rice Bran","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R60QEP13IC"},{"name":"Maps_To","value":"Rice Bran"},{"name":"NCI_Drug_Dictionary_ID","value":"752814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752814"},{"name":"PDQ_Open_Trial_Search_ID","value":"752814"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3810876"}]}}{"C96431":{"preferredName":"Ricolinostat","code":"C96431","definitions":[{"definition":"An orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Ricolinostat selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ricolinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ACY-1215","termGroup":"CN","termSource":"NCI"},{"termName":"Histone Deacetylase 6 Inhibitor ACY-1215","termGroup":"SY","termSource":"NCI"},{"termName":"Rocilinostat","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1316214-52-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WKT909C62B"},{"name":"Maps_To","value":"Ricolinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"698408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698408"},{"name":"PDQ_Open_Trial_Search_ID","value":"698408"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3492270"}]}}{"C49061":{"preferredName":"Ridaforolimus","code":"C49061","definitions":[{"definition":"A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of soft tissue and bone cancers. It is also being studied in the treatment of other solid tumors and hematologic cancer. Ridaforolimus stops cells from dividing and may cause cancer cells to die. It is a type of mTOR inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ridaforolimus","termGroup":"PT","termSource":"NCI"},{"termName":"AP23573","termGroup":"CN","termSource":"NCI"},{"termName":"Deforolimus","termGroup":"SY","termSource":"NCI"},{"termName":"MK-8669","termGroup":"CN","termSource":"NCI"},{"termName":"Rapamycin, 42-(dimethylphosphinate)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"572924-54-0"},{"name":"Chemical_Formula","value":"C53H84NO14P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48Z35KB15K"},{"name":"Legacy Concept Name","value":"AP23573"},{"name":"Maps_To","value":"Ridaforolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"354223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354223"},{"name":"PDQ_Open_Trial_Search_ID","value":"354223"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713007"}]}}{"C152216":{"preferredName":"Rigosertib","code":"C152216","definitions":[{"definition":"A synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rigosertib","termGroup":"PT","termSource":"NCI"},{"termName":"Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) methyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-(2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) phenyl)glycine","termGroup":"SY","termSource":"NCI"},{"termName":"ON 01910","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"592542-59-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67DOW7F9GL"},{"name":"Maps_To","value":"Rigosertib"},{"name":"NCI_META_CUI","value":"CL553420"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71355":{"preferredName":"Rigosertib Sodium","code":"C71355","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain proteins that are needed for cell growth and may kill cancer cells. ON 01910.Na is a type of protein kinase inhibitor and a type of benzyl styryl sulfone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of rigosertib, a synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rigosertib Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"ON 01910.Na","termGroup":"CN","termSource":"NCI"},{"termName":"Polo-like kinase 1 Inhibitor ON 01910.Na","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"592542-60-4"},{"name":"Chemical_Formula","value":"C21H24NO8S.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"406FL5G00V"},{"name":"Legacy Concept Name","value":"Polo-like_kinase_1_Inhibitor_ON_01910_Na"},{"name":"Maps_To","value":"Rigosertib Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"573371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573371"},{"name":"PDQ_Open_Trial_Search_ID","value":"573371"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467794"}]}}{"C38681":{"preferredName":"Rilimogene Galvacirepvec","code":"C38681","definitions":[{"definition":"A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilimogene Galvacirepvec","termGroup":"PT","termSource":"NCI"},{"termName":"PROSTVAC","termGroup":"BR","termSource":"NCI"},{"termName":"Prostvac-V","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Vaccinia-PSA(L155)-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Vaccinia-PSA(L155)/TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Vaccinia-PSA(L155)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"rVaccinia-Prostate-Specific Antigen/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"rVaccinia-PSA(L155)-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1225283-43-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"59WJ3TGA5K"},{"name":"Legacy Concept Name","value":"Vaccinia-PSA-TRICOM_Vaccine"},{"name":"Maps_To","value":"Rilimogene Galvacirepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"305934"},{"name":"NSC Number","value":"717170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"305934"},{"name":"PDQ_Open_Trial_Search_ID","value":"305934"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1519903"}]}}{"C132990":{"preferredName":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","code":"C132990","definitions":[{"definition":"A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","termGroup":"PT","termSource":"NCI"},{"termName":"PROSTVAC","termGroup":"BR","termSource":"NCI"},{"termName":"PROSTVAC-V-PROSTVAC-F","termGroup":"SY","termSource":"NCI"},{"termName":"PROSTVAC-V/F","termGroup":"SY","termSource":"NCI"},{"termName":"PROSTVAC-VF-TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"PROSTVAC-VF/TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Vaccinia-Fowlpox-Prostate-specific Antigen-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Rilimogene Galvacirepvec-Rilimogene Glafolivec","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rilimogene Galvacirepvec/Rilimogene Glafolivec"},{"name":"NCI_Drug_Dictionary_ID","value":"787601"},{"name":"NCI_META_CUI","value":"CL520248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787601"},{"name":"PDQ_Open_Trial_Search_ID","value":"787601"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C29560":{"preferredName":"Rilimogene Glafolivec","code":"C29560","definitions":[{"definition":"A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM).  Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilimogene Glafolivec","termGroup":"PT","termSource":"NCI"},{"termName":"PROSTVAC-F","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"rFowlpox-PSA(L155)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1225283-42-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7PLH7RM47T"},{"name":"Legacy Concept Name","value":"rFowlpox-PSA_L155_TRICOM"},{"name":"Maps_To","value":"Rilimogene Glafolivec"},{"name":"NCI_Drug_Dictionary_ID","value":"305933"},{"name":"NSC Number","value":"717171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"305933"},{"name":"PDQ_Open_Trial_Search_ID","value":"305933"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515688"}]}}{"C67079":{"preferredName":"Rilotumumab","code":"C67079","definitions":[{"definition":"A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It binds to a protein called hepatocyte growth factor (HGF), which may cause cancer cells to grow. Blocking this may cause cancer cells to die. AMG 102 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rilotumumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 102","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-HGF Monoclonal Antibody AMG 102","termGroup":"SY","termSource":"NCI"},{"termName":"Fully Human Anti-HGF Monoclonal Antibody AMG 102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"872514-65-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"51WEW898IJ"},{"name":"Legacy Concept Name","value":"Anti-HGF_Monoclonal_Antibody_AMG_102"},{"name":"Maps_To","value":"Rilotumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"536240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536240"},{"name":"PDQ_Open_Trial_Search_ID","value":"536240"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2743963"}]}}{"C69076":{"preferredName":"Rindopepimut","code":"C69076","definitions":[{"definition":"A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rindopepimut","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFRvIII Vaccine CDX-110","termGroup":"SY","termSource":"NCI"},{"termName":"CDX-110","termGroup":"CN","termSource":"NCI"},{"termName":"L-Cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-(1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)-, complex with hemocyanin (Megathura crenulata)","termGroup":"SN","termSource":"NCI"},{"termName":"PF-04948568","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Immunotherapy for glioblastoma multiforme"},{"name":"CAS_Registry","value":"946156-74-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K3L4X0501F"},{"name":"Legacy Concept Name","value":"Anti-EGFRvIII_Vaccine_CDX-110"},{"name":"Maps_To","value":"Rindopepimut"},{"name":"NCI_Drug_Dictionary_ID","value":"546970"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546970"},{"name":"PDQ_Open_Trial_Search_ID","value":"546970"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3181262"}]}}{"C156737":{"preferredName":"RIPK1 Inhibitor GSK3145095","code":"C156737","definitions":[{"definition":"An orally available, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential antineoplastic and immunomodulatory activities.  Upon administration, GSK3145095 disrupts RIPK1-mediated signaling, which may reduce C-X-C motif chemokine ligand 1 (CXCL1)-driven recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME). This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. RIPK1, a serine-threonine kinase that normally plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition, is overexpressed in certain cancer types and may be associated with oncogenesis and promotion of the immunosuppressive nature of the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RIPK1 Inhibitor GSK3145095","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 3145095","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3145095","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3145095","termGroup":"CN","termSource":"NCI"},{"termName":"Receptor-interacting Serine/Threonine-protein Kinase 1 Inhibitor GSK3145095","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622849-43-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B4D3WPS7JY"},{"name":"Maps_To","value":"RIPK1 Inhibitor GSK3145095"},{"name":"NCI_Drug_Dictionary_ID","value":"795835"},{"name":"NCI_META_CUI","value":"CL935900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795835"},{"name":"PDQ_Open_Trial_Search_ID","value":"795835"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124067":{"preferredName":"Ripretinib","code":"C124067","definitions":[{"definition":"An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ripretinib","termGroup":"PT","termSource":"NCI"},{"termName":"1-N'-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxyphenyl]-1-N'-phenylcyclopropane-1,1-dicarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"DCC-2618","termGroup":"CN","termSource":"NCI"},{"termName":"DCC2618","termGroup":"CN","termSource":"NCI"},{"termName":"Qinlock","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib."},{"name":"CAS_Registry","value":"1225278-16-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9XW757O13D"},{"name":"Maps_To","value":"Ripertamab"},{"name":"Maps_To","value":"Ripretinib"},{"name":"NCI_Drug_Dictionary_ID","value":"776638"},{"name":"NCI_META_CUI","value":"CL502501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776638"},{"name":"PDQ_Open_Trial_Search_ID","value":"776638"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131306":{"preferredName":"Risperidone Formulation in Rumenic Acid","code":"C131306","definitions":[{"definition":"An orally bioavailable capsule formulation containing the antipsychotic agent risperidone suspended in the lipid rumenic acid, with potential antineoplastic activity. Upon administration of VAL401, risperidone may, through an as of yet not elucidated mechanism of action, reduce cellular activity and tumor cell proliferation in multiple cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Risperidone Formulation in Rumenic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Risperidone Lipid Formulation VAL401","termGroup":"SY","termSource":"NCI"},{"termName":"VAL-401","termGroup":"CN","termSource":"NCI"},{"termName":"VAL401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Risperidone Formulation in Rumenic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"785676"},{"name":"NCI_META_CUI","value":"CL514450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785676"},{"name":"PDQ_Open_Trial_Search_ID","value":"785676"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75294":{"preferredName":"Ritrosulfan","code":"C75294","definitions":[{"definition":"A sulfonate-based alkylation agent with potential antineoplastic activity. Ritrosulfan appears to alkylate DNA, thereby producing DNA crosslinks, resulting in cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ritrosulfan","termGroup":"PT","termSource":"NCI"},{"termName":"Lycurim","termGroup":"BR","termSource":"NCI"},{"termName":"R-74","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4148-16-7"},{"name":"Chemical_Formula","value":"C10H24N2O8S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YIY0662KX9"},{"name":"Legacy Concept Name","value":"Ritrosulfan"},{"name":"Maps_To","value":"Ritrosulfan"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073401"}]}}{"C1702":{"preferredName":"Rituximab","code":"C1702","definitions":[{"definition":"A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rituximab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 798","termGroup":"CN","termSource":"NCI"},{"termName":"BI 695500","termGroup":"CN","termSource":"NCI"},{"termName":"C2B8 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric Anti-CD20 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"CT-P10","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-102","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-C2B8","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-C2B8 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Ikgdar","termGroup":"FB","termSource":"NCI"},{"termName":"Mabtas","termGroup":"FB","termSource":"NCI"},{"termName":"MabThera","termGroup":"FB","termSource":"NCI"},{"termName":"Monoclonal Antibody IDEC-C2B8","termGroup":"SY","termSource":"NCI"},{"termName":"PF-05280586","termGroup":"CN","termSource":"NCI"},{"termName":"Riabni","termGroup":"BR","termSource":"NCI"},{"termName":"Rituxan","termGroup":"BR","termSource":"NCI"},{"termName":"Rituximab ABBS","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab ARRX","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar ABP 798","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar BI 695500","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar CT-P10","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar GB241","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar IBI301","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar JHL1101","termGroup":"CN","termSource":"NCI"},{"termName":"Rituximab Biosimilar PF-05280586","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar RTXM83","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar SAIT101","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar SIBP-02","termGroup":"SY","termSource":"NCI"},{"termName":"rituximab biosimilar TQB2303","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab PVVR","termGroup":"SY","termSource":"NCI"},{"termName":"rituximab-abbs","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab-arrx","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab-pvvr","termGroup":"SY","termSource":"NCI"},{"termName":"RTXM83","termGroup":"CN","termSource":"NCI"},{"termName":"Ruxience","termGroup":"BR","termSource":"NCI"},{"termName":"Truxima","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diffuse Large B-cell, CD20-positive, Non-Hodgkins Lymphoma (NHL)"},{"name":"CAS_Registry","value":"174722-31-7"},{"name":"CHEBI_ID","value":"CHEBI:64357"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4F4X42SYQ6"},{"name":"Legacy Concept Name","value":"Rituximab"},{"name":"Maps_To","value":"Rituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"42613"},{"name":"NSC Number","value":"687451"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42613"},{"name":"PDQ_Open_Trial_Search_ID","value":"42613"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393022"}]}}{"C136821":{"preferredName":"Rituximab and Hyaluronidase Human","code":"C136821","definitions":[{"definition":"A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).  When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.  CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rituximab and Hyaluronidase Human","termGroup":"PT","termSource":"NCI"},{"termName":"Rituxan Hycela","termGroup":"BR","termSource":"NCI"},{"termName":"Rituximab Plus Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab/Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab/Hyaluronidase Human","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Rituximab and Hyaluronidase Human"},{"name":"NCI_Drug_Dictionary_ID","value":"789585"},{"name":"NCI_META_CUI","value":"CL524655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789585"},{"name":"PDQ_Open_Trial_Search_ID","value":"789585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148162":{"preferredName":"Rituximab Conjugate CON-4619","code":"C148162","definitions":[{"definition":"A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rituximab Conjugate CON-4619","termGroup":"PT","termSource":"NCI"},{"termName":"Aurixim","termGroup":"BR","termSource":"NCI"},{"termName":"Aurixim Antibody Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"CON-4619","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rituximab Conjugate CON-4619"},{"name":"NCI_Drug_Dictionary_ID","value":"792533"},{"name":"NCI_META_CUI","value":"CL550782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792533"},{"name":"PDQ_Open_Trial_Search_ID","value":"792533"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64762":{"preferredName":"Riviciclib","code":"C64762","definitions":[{"definition":"A flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Riviciclib","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor P276","termGroup":"SY","termSource":"NCI"},{"termName":"P-276-00 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"P276","termGroup":"CN","termSource":"NCI"},{"termName":"P276-00","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"920113-02-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9EK26WE8QN"},{"name":"Legacy Concept Name","value":"P276"},{"name":"Maps_To","value":"Riviciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"529362"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529362"},{"name":"PDQ_Open_Trial_Search_ID","value":"529362"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832023"}]}}{"C152237":{"preferredName":"Rivoceranib","code":"C152237","definitions":[{"definition":"An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rivoceranib","termGroup":"PT","termSource":"NCI"},{"termName":"-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"Apatinib","termGroup":"SY","termSource":"NCI"},{"termName":"Apatinib Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"YN968D1 Free Base","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"811803-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5S371K6132"},{"name":"Maps_To","value":"Rivoceranib"},{"name":"NCI_META_CUI","value":"CL553441"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74012":{"preferredName":"Rivoceranib Mesylate","code":"C74012","definitions":[{"definition":"The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rivoceranib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Aitan","termGroup":"FB","termSource":"NCI"},{"termName":"Apatinib Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"YN-968D1","termGroup":"CN","termSource":"NCI"},{"termName":"YN968D1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1218779-75-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TK02X14ASJ"},{"name":"Legacy Concept Name","value":"Rivoceranib Mesylate"},{"name":"Maps_To","value":"Rivoceranib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"592508"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592508"},{"name":"PDQ_Open_Trial_Search_ID","value":"592508"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346836"}]}}{"C114976":{"preferredName":"RNR Inhibitor COH29","code":"C114976","definitions":[{"definition":"An orally available, aromatically substituted thiazole and inhibitor of the human ribonucleotide reductase (RNR), with potential antineoplastic activity. Upon oral administration, the RNR inhibitor COH29 binds to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail. This blocks the interaction between the hRRM1 and hRRM2 subunits and interferes with the assembly of the active hRRM1/hRRM2 complex of RNR. Inhibition of RNR activity decreases the pool of deoxyribonucleotide triphosphates available for DNA synthesis. The resulting decrease in DNA synthesis causes cell cycle arrest and growth inhibition. In addition, this agent may inhibit the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 1, which prevents the repair of damaged DNA, and causes both the accumulation of single and double strand DNA breaks and the induction of apoptosis. RNR, an enzyme that catalyzes the conversion of ribonucleoside diphosphate to deoxyribonucleoside diphosphate, is essential for de novo DNA synthesis and plays an important role in cell growth; it is overexpressed in many cancer cell types and is associated with increased drug resistance, cancer cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RNR Inhibitor COH29","termGroup":"PT","termSource":"NCI"},{"termName":"COH-29","termGroup":"CN","termSource":"NCI"},{"termName":"COH29","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Ribonucleotide Reductase Holoenzyme Inhibitor COH29","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1190932-38-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"07802BU06S"},{"name":"Maps_To","value":"RNR Inhibitor COH29"},{"name":"NCI_Drug_Dictionary_ID","value":"759501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759501"},{"name":"PDQ_Open_Trial_Search_ID","value":"759501"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896938"}]}}{"C71527":{"preferredName":"Robatumumab","code":"C71527","definitions":[{"definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Robatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal SCH 717454 Heavy Chain), Disulfide with Human Monoclonal SCH 717454 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Sch717454","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934235-44-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V983921H3B"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Recombinant_Monoclonal_Antibody_SCH_717454"},{"name":"Maps_To","value":"Robatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"577364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577364"},{"name":"PDQ_Open_Trial_Search_ID","value":"577364"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467798"}]}}{"C77907":{"preferredName":"Rocapuldencel-T","code":"C77907","definitions":[{"definition":"A cancer vaccine in which autologous dendritic cells are transfected with patient-specific renal cell carcinoma (RCC) RNA and a synthetic, truncated human CD40 ligand (CD40L) RNA with potential immunostimulatory and antineoplastic activities. Individual RCC-specific RNA, encoding a unique repertoire of tumor-associated antigens (TAAs) (including telomerase reverse transcriptase, G250, and oncofetal antigen) is electroporated into autologous dendritic cells (DCs), transfected with synthetic RNA that encodes a truncated version of the T-cell protein CD40L; the transfected autologous DCs express and process both patient-specific RCC TAAs and the truncated CD40L protein. When reintroduced back to the patient, rocapuldencel-T may elicit a highly specific cytotoxic T-cell (CTL) response against RCC cells expressing the patient-specific RCC TAA repertoire. The signal cascade initiated by stimulation of the truncated, ectopically expressed co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12 downstream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rocapuldencel-T","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-003","termGroup":"CN","termSource":"NCI"},{"termName":"CMN-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8I9S6401XZ"},{"name":"Legacy Concept Name","value":"Renal_Tumor_RNA_CD40L-Transfected_Dendritic_Cell_Vaccine"},{"name":"Maps_To","value":"Rocapuldencel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"599024"},{"name":"NCI_META_CUI","value":"CL387046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599024"},{"name":"PDQ_Open_Trial_Search_ID","value":"599024"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99905":{"preferredName":"Rociletinib","code":"C99905","definitions":[{"definition":"An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rociletinib","termGroup":"PT","termSource":"NCI"},{"termName":"CO-1686","termGroup":"CN","termSource":"NCI"},{"termName":"N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"Rociletinib","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1374640-70-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"72AH61702G"},{"name":"Maps_To","value":"Rociletinib"},{"name":"NCI_Drug_Dictionary_ID","value":"725346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"725346"},{"name":"PDQ_Open_Trial_Search_ID","value":"725346"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045493"}]}}{"C97275":{"preferredName":"Rodorubicin","code":"C97275","definitions":[{"definition":"A synthetic tetraglycosidic anthracycline antibiotic with antineoplastic activity. Rodorubicin appears to intercalate DNA and causes cell death. Due to its severe cardiotoxic effects, this agent was never marketed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rodorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"Cytorhodin S","termGroup":"SY","termSource":"NCI"},{"termName":"HLB 817","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96497-67-5"},{"name":"Chemical_Formula","value":"C48H64N2O17"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XCZ4D2241Y"},{"name":"Maps_To","value":"Rodorubicin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073554"}]}}{"C1832":{"preferredName":"Rofecoxib","code":"C1832","definitions":[{"definition":"A drug that was being used for pain relief and was being studied for its ability to prevent cancer and to prevent the growth of new blood vessels that tumors need to grow. It is a type of nonsteroidal anti-inflammatory drug and a type of antiangiogenesis agent. Rofecoxib was taken off the market in the U.S. because of safety concerns.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties.  Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins.  COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rofecoxib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone","termGroup":"SN","termSource":"NCI"},{"termName":"MK 966","termGroup":"CN","termSource":"NCI"},{"termName":"Vioxx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Pain; dysmenorrhea; osteoarthritis; rheumatoid arthritis"},{"name":"CAS_Registry","value":"162011-90-7"},{"name":"CHEBI_ID","value":"CHEBI:8887"},{"name":"Chemical_Formula","value":"C17H14O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0QTW8Z7MCR"},{"name":"Legacy Concept Name","value":"Rofecoxib"},{"name":"Maps_To","value":"Rofecoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"38568"},{"name":"NSC Number","value":"720256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38568"},{"name":"PDQ_Open_Trial_Search_ID","value":"38568"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762662"}]}}{"C76890":{"preferredName":"Roflumilast","code":"C76890","definitions":[{"definition":"An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR signaling pathway, which may result in the induction of apoptosis. PDE4, a member of the PDE superfamily that hydrolyses cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates, is upregulated in a variety of cancers and may contribute to chemoresistance; it also plays a key role in inflammation, especially in inflammatory airway diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roflumilast","termGroup":"PT","termSource":"NCI"},{"termName":"3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"B9302-107","termGroup":"CN","termSource":"NCI"},{"termName":"BY217","termGroup":"CN","termSource":"NCI"},{"termName":"BYK20869","termGroup":"CN","termSource":"NCI"},{"termName":"Daliresp","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Obstructive Pulmonary Disease (COPD)"},{"name":"CAS_Registry","value":"162401-32-3"},{"name":"Chemical_Formula","value":"C17H14Cl2F2N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0P6C6ZOP5U"},{"name":"Legacy Concept Name","value":"Roflumilast"},{"name":"Maps_To","value":"Roflumilast"},{"name":"NCI_Drug_Dictionary_ID","value":"750521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750521"},{"name":"PDQ_Open_Trial_Search_ID","value":"750521"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0965618"}]}}{"C112205":{"preferredName":"Rogaratinib","code":"C112205","definitions":[{"definition":"A pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Rogaratinib inhibits the activities of FGFRs, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rogaratinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-((4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)methyl)piperazin-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"BAY-1163877","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1163877","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443530-05-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98BSN6N516"},{"name":"Maps_To","value":"Rogaratinib"},{"name":"NCI_Drug_Dictionary_ID","value":"754526"},{"name":"NCI_META_CUI","value":"CL454405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754526"},{"name":"PDQ_Open_Trial_Search_ID","value":"754526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1427":{"preferredName":"Rogletimide","code":"C1427","definitions":[{"definition":"An orally active aminoglutethimide derivative with potential antineoplastic activity. Rogletimide reversibly inhibits the activity of aromatase, a cytochrome P450 family enzyme found in many tissues and the key enzyme in the oxidative aromatization process of androgens to estrogens. In estrogen-dependent cancers, the inhibition of aromatase by this agent leads to a reduction in the synthesis of estrogen, thereby inhibiting estrogen-mediated signal transduction and consequently reducing tumor cell growth. In addition, rogletimide also inhibits enzymes that catalyzing conversion of cholesterol to corticosteroids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rogletimide","termGroup":"PT","termSource":"NCI"},{"termName":"Pyridoglutethimide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92788-10-8"},{"name":"Chemical_Formula","value":"C12H14N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14P4QR28QF"},{"name":"Legacy Concept Name","value":"Rogletimide"},{"name":"Maps_To","value":"Rogletimide"},{"name":"NCI_Drug_Dictionary_ID","value":"41461"},{"name":"NSC Number","value":"619778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41461"},{"name":"PDQ_Open_Trial_Search_ID","value":"41461"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0164550"}]}}{"C1544":{"preferredName":"Romidepsin","code":"C1544","definitions":[{"definition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Romidepsin is a type of depsipeptide and histone deacetylase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Romidepsin","termGroup":"PT","termSource":"NCI"},{"termName":"Antibiotic FR 901228","termGroup":"SY","termSource":"NCI"},{"termName":"Depsipeptide","termGroup":"SY","termSource":"NCI"},{"termName":"FK228","termGroup":"CN","termSource":"NCI"},{"termName":"FR901228","termGroup":"CN","termSource":"NCI"},{"termName":"Istodax","termGroup":"BR","termSource":"NCI"},{"termName":"L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))-","termGroup":"SN","termSource":"NCI"},{"termName":"N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"128517-07-7"},{"name":"CHEBI_ID","value":"CHEBI:61080"},{"name":"Chemical_Formula","value":"C24H36N4O6S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CX3T89XQBK"},{"name":"Legacy Concept Name","value":"Depsipeptide"},{"name":"Maps_To","value":"Romidepsin"},{"name":"NCI_Drug_Dictionary_ID","value":"42600"},{"name":"NSC Number","value":"630176"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42600"},{"name":"PDQ_Open_Trial_Search_ID","value":"42600"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527027"}]}}{"C92579":{"preferredName":"Roniciclib","code":"C92579","definitions":[{"definition":"An orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Roniciclib selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roniciclib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY1000394","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1223498-69-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0W9Q8U337A"},{"name":"Maps_To","value":"Roniciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"684718"},{"name":"NCI_META_CUI","value":"CL423828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684718"},{"name":"PDQ_Open_Trial_Search_ID","value":"684718"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48813":{"preferredName":"Ropidoxuridine","code":"C48813","definitions":[{"definition":"An orally available 5-substituted 2-pyrimidinone-2'-deoxyribonucleoside analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Upon oral administration, ropidoxuridine (IPdR) is efficiently converted to idoxuridine (IUdR) by a hepatic aldehyde oxidase. In turn, IUdR is incorporated into DNA during replication, thereby sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ropidoxuridine","termGroup":"PT","termSource":"NCI"},{"termName":"2(1H)-Pyrimidinone, 1-(2-deoxy-beta-D-erythro-pentofuranosyl)-5-iodo-","termGroup":"SN","termSource":"NCI"},{"termName":"5-Iodo-2-pyrimidinone 2' deoxyribonucleoside","termGroup":"SY","termSource":"NCI"},{"termName":"5-Iodo-2-pyrimidinone-2'-deoxyribose","termGroup":"SY","termSource":"NCI"},{"termName":"IPdR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93265-81-7"},{"name":"Chemical_Formula","value":"C9H11IN2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3HX21A3SQF"},{"name":"Legacy Concept Name","value":"_5-Iodo-2-Pyrimidinone-2-Deoxyribose"},{"name":"Maps_To","value":"Ropidoxuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"770080"},{"name":"NSC Number","value":"726188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770080"},{"name":"PDQ_Open_Trial_Search_ID","value":"770080"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0088688"}]}}{"C1519":{"preferredName":"Roquinimex","code":"C1519","definitions":[{"definition":"A quinoline-3-carboxamide with potential antineoplastic activity.  Roquinimex inhibits endothelial cell proliferation, migration, and basement membrane invasion; reduces the secretion of the angiogenic factor tumor necrosis factor alpha by tumor-associated macrophages (TAMs); and inhibits angiogenesis.  This agent is also an immune modulator that appears to alter cytokine profiles and enhance the activity of T cells, natural killer cells, and macrophages. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roquinimex","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-3-quinolinecarboxanilide","termGroup":"SN","termSource":"NCI"},{"termName":"1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"FCF 89","termGroup":"CN","termSource":"NCI"},{"termName":"Linomide","termGroup":"BR","termSource":"NCI"},{"termName":"LS 2616","termGroup":"CN","termSource":"NCI"},{"termName":"N-Phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84088-42-6"},{"name":"Chemical_Formula","value":"C18H16N2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"372T2944C0"},{"name":"Legacy Concept Name","value":"Roquinimex"},{"name":"Maps_To","value":"Roquinimex"},{"name":"NCI_Drug_Dictionary_ID","value":"41410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41410"},{"name":"PDQ_Open_Trial_Search_ID","value":"41410"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244748"}]}}{"C131294":{"preferredName":"Cintirorgon","code":"C131294","definitions":[{"definition":"An orally bioavailable agonist of retinoic acid-related orphan receptor gamma (RORg), with potential immunomodulatory and antineoplastic activities. Upon oral administration of cintirorgon, this agent selectively binds to the nuclear receptor transcription factor RORg, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T-cells, including Th17 (helper T-cells) and Tc17 (cytotoxic T-cells). This may increase the expression of co-stimulatory molecules and decrease the expression of co-inhibitory molecules on T-cells leading to increased production of cytokines and chemokines by T-cells, decreased proliferation of regulatory T-cells (Tregs), and abrogation of tumor-induced immunosuppression. This ultimately induces a T-cell-mediated immune response against cancer cells and leads to a reduction in tumor cell growth. RORg, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cintirorgon","termGroup":"PT","termSource":"NCI"},{"termName":"LYC-55716","termGroup":"CN","termSource":"NCI"},{"termName":"LYC55716","termGroup":"CN","termSource":"NCI"},{"termName":"RORg Agonist LYC-55716","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2055536-64-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LPN433P0EA"},{"name":"Maps_To","value":"Cintirorgon"},{"name":"Maps_To","value":"RORgamma Agonist LYC-55716"},{"name":"NCI_Drug_Dictionary_ID","value":"786008"},{"name":"NCI_META_CUI","value":"CL514576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786008"},{"name":"PDQ_Open_Trial_Search_ID","value":"786008"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77066":{"preferredName":"Rosabulin","code":"C77066","definitions":[{"definition":"A small molecule vascular disrupting agent, with potential antimitotic and antineoplastic activities. Rosabulin binds to tubulin in a similar manner as colchicine and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest and blockage of cell division. By destroying proliferating vascular cells, blood flow to the tumor is reduced and eventually leads to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosabulin","termGroup":"PT","termSource":"NCI"},{"termName":"3-[(4-Cyanophenyl)methyl]-N-(3-methyl-5-isothiazolyl)-alpha-oxo-1-indolizineacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"STA-5312","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501948-05-6"},{"name":"Chemical_Formula","value":"C22H16N4O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Z674O12T6"},{"name":"Legacy Concept Name","value":"Rosabulin"},{"name":"Maps_To","value":"Rosabulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541461"}]}}{"C2583":{"preferredName":"Rosiglitazone Maleate","code":"C2583","definitions":[{"definition":"A drug that helps control the amount of glucose (sugar) in the blood and is being studied in the prevention and treatment of some types of cancer. Avandia stops cells from growing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of thiazolidinedione and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.  Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosiglitazone Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, ( Z )-2-Butenedioate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Avandia","termGroup":"BR","termSource":"NCI"},{"termName":"BRL49653","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Insulin-Dependent Diabetes Mellitus and Type II Diabetes Mellitus"},{"name":"Accepted_Therapeutic_Use_For","value":"Type 2 diabetes"},{"name":"CAS_Registry","value":"155141-29-0"},{"name":"CHEBI_ID","value":"CHEBI:8892"},{"name":"Chemical_Formula","value":"C18H19N3O3S.C4H4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KX2339DP44"},{"name":"Legacy Concept Name","value":"Rosiglitazone"},{"name":"Maps_To","value":"Rosiglitazone Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"37793"},{"name":"NSC Number","value":"717764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37793"},{"name":"PDQ_Open_Trial_Search_ID","value":"37793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0795660"}]}}{"C122921":{"preferredName":"Rosmantuzumab","code":"C122921","definitions":[{"definition":"An immunoglobulin (Ig) G1 humanized monoclonal antibody targeting human R-spondin 3 (RSPO3), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, rosmantuzumab targets and binds to RSPO3 expressed on tumor cells. This prevents the activation of RSPO3, and inhibits both the binding of RSPO3 to leucine-rich repeat-containing G-coupled receptors (LGRs) and the activation of the RSPO-LGR pathway. This may result in an inhibition of both cancer stem cell (CSC) survival and the proliferation of cancer cells in which this pathway is overactivated. The RSPO-LGR pathway is a CSC pathway activated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosmantuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"OMP-131R10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1684393-04-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VD026R6TCI"},{"name":"Maps_To","value":"Rosmantuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"774650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774650"},{"name":"PDQ_Open_Trial_Search_ID","value":"774650"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053609"}]}}{"C66523":{"preferredName":"Rosuvastatin","code":"C66523","definitions":[{"definition":"A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosuvastatin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"287714-41-4"},{"name":"CHEBI_ID","value":"CHEBI:38545"},{"name":"Chemical_Formula","value":"C22H28FN3O6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"413KH5ZJ73"},{"name":"Legacy Concept Name","value":"Rosuvastatin"},{"name":"Maps_To","value":"Rosuvastatin"},{"name":"NCI_Drug_Dictionary_ID","value":"654583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654583"},{"name":"PDQ_Open_Trial_Search_ID","value":"654583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0965129"}]}}{"C107678":{"preferredName":"Rovalpituzumab Tesirine","code":"C107678","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a humanized IgG1 monoclonal antibody (MAb) directed against the delta-like protein 3 (DLL3), conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a maleimide-containing linker with an eight-carbon polyethylene glycol spacer and a cathepsin B-cleavable valine-alanine dipeptide, with potential antineoplastic activity. The MAb moiety of rovalpituzumab tesirine selectively binds to DLL3 on tumor cell surfaces. Upon internalization of the ADC, the dipeptide linker is cleaved and D6.5 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rovalpituzumab Tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"Rova-T","termGroup":"AB","termSource":"NCI"},{"termName":"SC16LD6.5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1613313-09-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P256HB60FF"},{"name":"Maps_To","value":"Rovalpituzumab Tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"751419"},{"name":"NCI_META_CUI","value":"CL451868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751419"},{"name":"PDQ_Open_Trial_Search_ID","value":"751419"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1485":{"preferredName":"Rubitecan","code":"C1485","definitions":[{"definition":"A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.  Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An alkaloid drug belonging to a class of anticancer agents called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rubitecan","termGroup":"PT","termSource":"NCI"},{"termName":"9-NC","termGroup":"AB","termSource":"NCI"},{"termName":"9-Nitro-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"9-nitrocamptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"Camptogen","termGroup":"BR","termSource":"NCI"},{"termName":"Nitrocamptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"Orathecin","termGroup":"BR","termSource":"NCI"},{"termName":"RFS 2000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"AIDs, pediatric; HIV infection, pediatric"},{"name":"CAS_Registry","value":"91421-42-0"},{"name":"Chemical_Formula","value":"C20H15N3O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H19C446XXB"},{"name":"Legacy Concept Name","value":"Rubitecan"},{"name":"Maps_To","value":"Rubitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"42528"},{"name":"NSC Number","value":"603070"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42528"},{"name":"PDQ_Open_Trial_Search_ID","value":"42528"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0213800"}]}}{"C137800":{"preferredName":"Rucaparib","code":"C137800","definitions":[{"definition":"An orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucaparib","termGroup":"PT","termSource":"NCI"},{"termName":"6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"ecurrent ovarian, fallopian tube, or primary peritoneal cancer"},{"name":"CAS_Registry","value":"283173-50-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8237F3U7EH"},{"name":"Maps_To","value":"Rucaparib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661315"}]}}{"C131178":{"preferredName":"Rucaparib Camsylate","code":"C131178","definitions":[{"definition":"The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucaparib Camsylate","termGroup":"PT","termSource":"NCI"},{"termName":"8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Bicyclo(2.2.1)heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, Compound with 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"C0-338","termGroup":"CN","termSource":"NCI"},{"termName":"Rubraca","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer"},{"name":"Accepted_Therapeutic_Use_For","value":"patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy."},{"name":"CAS_Registry","value":"1859053-21-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"41AX9SJ8KO"},{"name":"Maps_To","value":"Rucaparib Camsylate"},{"name":"NCI_Drug_Dictionary_ID","value":"785902"},{"name":"NCI_META_CUI","value":"CL513492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785902"},{"name":"PDQ_Open_Trial_Search_ID","value":"785902"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78186":{"preferredName":"Rucaparib Phosphate","code":"C78186","definitions":[{"definition":"A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. AG014699 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The phosphate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucaparib Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"AG-014699","termGroup":"CN","termSource":"NCI"},{"termName":"AG014699","termGroup":"CN","termSource":"NCI"},{"termName":"PARP1 Inhibitor PF-01367338","termGroup":"SY","termSource":"NCI"},{"termName":"PF-01367338","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"459868-92-9"},{"name":"Chemical_Formula","value":"C19H18FN3O.H3O4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H3M9955244"},{"name":"Legacy Concept Name","value":"PARP-1_Inhibitor_AG014699"},{"name":"Maps_To","value":"Rucaparib Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"594405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594405"},{"name":"PDQ_Open_Trial_Search_ID","value":"594405"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2603422"}]}}{"C38686":{"preferredName":"Ruthenium Ru-106","code":"C38686","definitions":[{"definition":"A radioactive isotope of the rare element ruthenium, a member of the light platinum group. A radioactive plaque containing ruthenium 106 may be inserted into the eye to irradiate ophthalmic tumors. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruthenium Ru-106","termGroup":"PT","termSource":"NCI"},{"termName":"Ru-106","termGroup":"AB","termSource":"NCI"},{"termName":"Ruthenium Ru 106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ruthenium_106"},{"name":"Maps_To","value":"Ruthenium Ru-106"},{"name":"NCI_Drug_Dictionary_ID","value":"357497"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357497"},{"name":"PDQ_Open_Trial_Search_ID","value":"357497"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"UMLS_CUI","value":"C0303733"}]}}{"C97948":{"preferredName":"Ruthenium-based Transferrin Targeting Agent NKP-1339","code":"C97948","definitions":[{"definition":"A ruthenium-containing cancer agent targeting transferrin with potential antineoplastic activity. Upon intravenous administration, NKP-1339 (Ru3+) binds to transferrin (Tf) and is taken up via Tf receptors (TfR), which are overexpressed on cancer cells. Once inside the cell, NKP-1339 is released from Tf and is reduced, within the acidic environment of the endosomes, to its active form NKP-119 (Ru2+). In turn, the active form induces a redox reaction, thereby leading to the formation of reactive oxygen species (ROS) which inhibits GRP78 and SOD, endoplasmic reticulum-stress modulating molecules as well as BAG4 and ERK, program cell death regulating molecules. This eventually induces caspase-dependent apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruthenium-based Transferrin Targeting Agent NKP-1339","termGroup":"PT","termSource":"NCI"},{"termName":"NKP-1339","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197723-00-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7OSJ9KS483"},{"name":"Maps_To","value":"Ruthenium-based Transferrin Targeting Agent NKP-1339"},{"name":"NCI_Drug_Dictionary_ID","value":"709242"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709242"},{"name":"PDQ_Open_Trial_Search_ID","value":"709242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273716"}]}}{"C77888":{"preferredName":"Ruxolitinib","code":"C77888","definitions":[{"definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruxolitinib","termGroup":"PT","termSource":"NCI"},{"termName":"(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile","termGroup":"SN","termSource":"NCI"},{"termName":"INCB-18424","termGroup":"CN","termSource":"NCI"},{"termName":"INCB18424","termGroup":"CN","termSource":"NCI"},{"termName":"Oral JAK Inhibitor INCB18424","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"steroid-refractory acute graft-versus-host disease (GVHD)"},{"name":"CAS_Registry","value":"941678-49-5"},{"name":"Chemical_Formula","value":"C17H18N6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"82S8X8XX8H"},{"name":"Legacy Concept Name","value":"Oral_JAK_Inhibitor_INCB18424"},{"name":"Maps_To","value":"Ruxolitinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2715577"}]}}{"C97937":{"preferredName":"Ruxolitinib Phosphate","code":"C97937","definitions":[{"definition":"The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruxolitinib Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile Phosphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-, phosphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"INCB-18424 Phosphate","termGroup":"CN","termSource":"NCI"},{"termName":"Jakafi","termGroup":"BR","termSource":"NCI"},{"termName":"Jakavi","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092939-17-7"},{"name":"Chemical_Formula","value":"C17H18N6H3O4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"436LRU32H5"},{"name":"Maps_To","value":"Ruxolitinib Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"593437"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593437"},{"name":"PDQ_Open_Trial_Search_ID","value":"593437"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3247913"}]}}{"C63661":{"preferredName":"S-Adenosylmethionine","code":"C63661","definitions":[{"definition":"A nutritional supplement that is synthesized from adenosine triphosphate (ATP) and the amino acid methionine by the endogenous essential enzyme methionine adenosyltransferase (MAT), with potential antineoplastic activity.  Upon administration, S-adenosylmethionine acts as a methyl donor for various transmethylation reactions. In cancer cells, this agent induces the methylation of tumor promoting genes, reverses DNA hypomethylation, and leads to the suppression of oncogene transcription. This induces apoptosis in and inhibits proliferation of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"S-Adenosylmethionine","termGroup":"PT","termSource":"NCI"},{"termName":"5'-[(3-Amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine Hydroxide, Inner Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Active Methionine","termGroup":"SY","termSource":"NCI"},{"termName":"S-Adenosyl-l-methionine","termGroup":"SY","termSource":"NCI"},{"termName":"S-Adenosyl-l-methionine 1,4-Butanedisulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"S-Adenosyl-methionine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"29908-03-0"},{"name":"CHEBI_ID","value":"CHEBI:15414"},{"name":"Chemical_Formula","value":"C15H22N6O5S"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"S-Adenosylmethionine"},{"name":"Maps_To","value":"S-Adenosylmethionine"},{"name":"NCI_Drug_Dictionary_ID","value":"776686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776686"},{"name":"PDQ_Open_Trial_Search_ID","value":"776686"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0036002"}]}}{"C120313":{"preferredName":"S-equol","code":"C120313","definitions":[{"definition":"An orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"S-equol","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Equol","termGroup":"SY","termSource":"NCI"},{"termName":"(3S)-3,4-dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol","termGroup":"SY","termSource":"NCI"},{"termName":"2H-1-benzopyran-7-ol, 3,4-Dihydro-3-(4-hydroxyphenyl)-, (3S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"531-95-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2T6D2HPX7Q"},{"name":"Maps_To","value":"S-equol"},{"name":"NCI_Drug_Dictionary_ID","value":"768802"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768802"},{"name":"PDQ_Open_Trial_Search_ID","value":"768802"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896945"}]}}{"C106368":{"preferredName":"Mocravimod Hydrochloride","code":"C106368","definitions":[{"definition":"The hydrochloride salt form of mocravimod, a sphingosine 1-phosphate (S1P) receptor agonist, with potential immunosuppressive activity. Upon administration of mocravimod, this agent binds to S1P receptors on lymphocytes, which prevents binding of serum S1P to S1P receptors and leads to S1P receptor internalization. This reduces the number of circulating blood leukocytes and accelerates lymphocyte homing into peripheral lymph nodes, thereby preventing their infiltration into peripheral inflammatory sites. This agent also decreases the production of inflammatory cytokines by lymphocytes, such as interferon gamma (IFN-g), interleukin-12 (IL-12), and tumor necrosis factor (TNF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mocravimod Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino-2-propanediol Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"KRP-203","termGroup":"CN","termSource":"NCI"},{"termName":"KRP203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"509088-69-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3YH0N35CE3"},{"name":"Maps_To","value":"S1P Receptor Agonist KRP203"},{"name":"NCI_Drug_Dictionary_ID","value":"749378"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749378"},{"name":"PDQ_Open_Trial_Search_ID","value":"749378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1570777"}]}}{"C1706":{"preferredName":"Sabarubicin","code":"C1706","definitions":[{"definition":"A disaccharide analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Sabarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces apoptosis through a p53-independent mechanism.  Sabarubicin is less cardiotoxic than doxorubicin.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sabarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(7S,9S)-7-{(4-O-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)oxy}-6,9,11-trihydroxy-9-(hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-195615","termGroup":"CN","termSource":"NCI"},{"termName":"MEN-10755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"211100-13-9"},{"name":"Chemical_Formula","value":"C32H37NO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XS499WOZ93"},{"name":"Legacy Concept Name","value":"MEN-10755"},{"name":"Maps_To","value":"Sabarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"42684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42684"},{"name":"PDQ_Open_Trial_Search_ID","value":"42684"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664590"}]}}{"C102783":{"preferredName":"Sacituzumab Govitecan","code":"C102783","definitions":[{"definition":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sacituzumab Govitecan","termGroup":"PT","termSource":"NCI"},{"termName":"hRS7-SN38 Antibody Drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-132","termGroup":"CN","termSource":"NCI"},{"termName":"RS7-SN38","termGroup":"AB","termSource":"NCI"},{"termName":"Sacituzumab Govitecan-hziy","termGroup":"SY","termSource":"NCI"},{"termName":"Trodelvy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC); advanced urothelial cancer."},{"name":"CAS_Registry","value":"1491917-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M9BYU8XDQ6"},{"name":"Maps_To","value":"Sacituzumab Govitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"736415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736415"},{"name":"PDQ_Open_Trial_Search_ID","value":"736415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640943"}]}}{"C162629":{"preferredName":"Sacubitril/Valsartan","code":"C162629","definitions":[{"definition":"A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sacubitril/Valsartan","termGroup":"PT","termSource":"NCI"},{"termName":"3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate","termGroup":"SY","termSource":"NCI"},{"termName":"Entresto","termGroup":"BR","termSource":"NCI"},{"termName":"L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. with alpha-ethyl(alphaR,gammaS)-gamma-((3-carboxy-1-oxopropyl)amino)-alpha-methyl(1,1'-biphenyl)-4-pentanoate, sodium salt, hydrate (2:2:6:5)","termGroup":"SY","termSource":"NCI"},{"termName":"LCZ 696","termGroup":"CN","termSource":"NCI"},{"termName":"LCZ-696","termGroup":"SY","termSource":"NCI"},{"termName":"LCZ696","termGroup":"CN","termSource":"NCI"},{"termName":"Sacubitril Mixture With Valsartan","termGroup":"SY","termSource":"NCI"},{"termName":"Sacubitril-Valsartan","termGroup":"SY","termSource":"NCI"},{"termName":"Sacubitril/Valsartan Sodium Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) hemipentahydrate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936623-90-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WB8FT61183"},{"name":"Maps_To","value":"Sacubitril/Valsartan"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933614"}]}}{"C1568":{"preferredName":"Safingol","code":"C1568","definitions":[{"definition":"A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), safingol competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Safingol","termGroup":"PT","termSource":"NCI"},{"termName":"(2S,3S)-2-Amino-1,3-Octadecanediol","termGroup":"SN","termSource":"NCI"},{"termName":"Kynacyte","termGroup":"BR","termSource":"NCI"},{"termName":"L-(-)-threo-Sphingnine","termGroup":"SY","termSource":"NCI"},{"termName":"L-threo-2-Amino-1,3-octadecanediol","termGroup":"SY","termSource":"NCI"},{"termName":"L-Threo-Dihydrosphingosine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Threo-Dihydrosphingosine","termGroup":"SN","termSource":"NCI"},{"termName":"SPC-100270","termGroup":"CN","termSource":"NCI"},{"termName":"Sphinganine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15639-50-6"},{"name":"Chemical_Formula","value":"C18H39NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OWA98U788S"},{"name":"Legacy Concept Name","value":"Dihydrosphingosine"},{"name":"Maps_To","value":"Safingol"},{"name":"NCI_Drug_Dictionary_ID","value":"41910"},{"name":"NSC Number","value":"714503"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41910"},{"name":"PDQ_Open_Trial_Search_ID","value":"41910"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281466"}]}}{"C61072":{"preferredName":"Sagopilone","code":"C61072","definitions":[{"definition":"A form of the substance epothilone that is made in the laboratory. It is being studied in the treatment of some types of cancer. Epothilone ZK2219477 stops the growth of tumor cells by blocking cell division. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fully synthetic low-molecular-weight epothilone with potential antineoplastic activity. Sagopilone binds to tubulin and induces microtubule polymerization while stabilizing microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. The agent is not a substrate for the P-glycoprotein (P-gp) efflux pump and so may exhibit activity in multidrug-resistant (MDR) tumors. The epothilone class of metabolites was originally isolated from the myxobacterium Solangium cellulosum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sagopilone","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"DE-03757","termGroup":"CN","termSource":"NCI"},{"termName":"Epothilone ZK219477","termGroup":"SY","termSource":"NCI"},{"termName":"SH-Y03757A","termGroup":"CN","termSource":"NCI"},{"termName":"ZK-219477","termGroup":"CN","termSource":"NCI"},{"termName":"ZK-EPO","termGroup":"AB","termSource":"NCI"},{"termName":"ZK-Epothilone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"305841-29-6"},{"name":"Chemical_Formula","value":"C30H41NO6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KY72JU32FO"},{"name":"Legacy Concept Name","value":"ZK219477"},{"name":"Maps_To","value":"Sagopilone"},{"name":"NCI_Drug_Dictionary_ID","value":"615854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615854"},{"name":"PDQ_Open_Trial_Search_ID","value":"615854"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2355512"}]}}{"C71146":{"preferredName":"Salirasib","code":"C71146","definitions":[{"definition":"A salicylic acid derivative with potential antineoplastic activity. Salirasib dislodges all Ras isoforms from their membrane-anchoring sites, thereby preventing activation of RAS signaling cascades that mediated cell proliferation, differentiation, and senescence. RAS signaling is believed to be abnormally activated in one-third of human cancers, including cancers of the pancreas, colon, lung and breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salirasib","termGroup":"PT","termSource":"NCI"},{"termName":"2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"S-Farnesylthiosalicylic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"162520-00-5"},{"name":"Chemical_Formula","value":"C22H30O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MZH0OM550M"},{"name":"Legacy Concept Name","value":"Salirasib"},{"name":"Maps_To","value":"Salirasib"},{"name":"NCI_Drug_Dictionary_ID","value":"573226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573226"},{"name":"PDQ_Open_Trial_Search_ID","value":"573226"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0297001"}]}}{"C2556":{"preferredName":"Salmonella VNP20009","code":"C2556","definitions":[{"definition":"A genetically modified Salmonella bacterium that is injected into the tumor.  It is being studied for its ability to shrink solid tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A genetically stable Salmonella typhimurium strain, attenuated by chromosomal deletion of the purI and msbB genes, with tumor-targeting activity. In rodent models, salmonella VNP20009 has been shown to selectively accumulate and grow in a variety of tumor types, inhibiting the growth of primary and metastatic tumors. This agent may be genetically engineered to contain transgenes that express therapeutic agents or cell surface tumor-associated antigen-specific antibodies, such as CEA-specific antibodies, which may improve its tumor targeting and therapeutic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salmonella VNP20009","termGroup":"PT","termSource":"NCI"},{"termName":"Auxotrophic Lipid A S. Typhimurium mutant","termGroup":"SY","termSource":"NCI"},{"termName":"Live, Attenuated Salmonella Typhimurium","termGroup":"SY","termSource":"NCI"},{"termName":"VNP 20009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"VNP20009"},{"name":"Maps_To","value":"Salmonella VNP20009"},{"name":"NCI_Drug_Dictionary_ID","value":"37800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37800"},{"name":"PDQ_Open_Trial_Search_ID","value":"37800"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879622"}]}}{"C97663":{"preferredName":"Sam68 Modulator CWP232291","code":"C97663","definitions":[{"definition":"A small molecule and prodrug of CWP232204 targeting Src associated in mitosis, of 68 kDa (Sam68 or KHDRBS1), with potential antineoplastic activity. CWP232291 is converted in serum into its active form CWP232204 which binds to Sam68, thereby resulting in the induction of apoptosis in selective cancer cells. Due to the multimodular structure of Sam68, the apoptosis mediated by CWP232204-Sam68 interaction can attribute from 1) activation of transcription factor NF-kB induced by tumor necrosis factor alpha signaling, 2) alternative splicing of BCL-2 apoptosis gene, driving the balance towards pro-apoptotic as opposed to anti-apoptotic isoforms, 3) down-regulation of the anti-apoptotic protein survivin via Wnt signaling. Sam68, a KH domain RNA-binding protein belonging to the signal transduction and activation of RNA (STAR) family, plays a key role in various cellular processes including cell cycle progression and apoptosis; it is upregulated in many types of cancer cells and its expression is associated with increased cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sam68 Modulator CWP232291","termGroup":"PT","termSource":"NCI"},{"termName":"CWP232291","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sam68 Modulator CWP232291"},{"name":"NCI_Drug_Dictionary_ID","value":"706549"},{"name":"NCI_META_CUI","value":"CL430318"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706549"},{"name":"PDQ_Open_Trial_Search_ID","value":"706549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77891":{"preferredName":"Samalizumab","code":"C77891","definitions":[{"definition":"A humanized monoclonal antibody directed against the human immunosuppressive molecule CD200 (OX-2) with potential immunomodulating and antineoplastic activities. Samalizumab binds to CD200, blocking the binding of CD200 to its receptor, CD200R, present on cells of the macrophage lineage; inhibition of CD200 may augment the cytotoxic T-lymphocyte (CTL) mediated immune response against CD200-expressing tumor cells.  CD200 is a type 1a transmembrane protein, related to the B7 family of co-stimulatory receptors, and is upregulated on the surface of multiple hematologic malignant cells; this transmembrane protein appears to be involved in the downregulation of a Th1 (helper T cell) immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"ALXN6000","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-(CD200 (Antigen)) (Human-mouse Monoclonal ALXN6000 Heavy Chain), Disulfide with Human-mouse Monoclonal ALXN6000 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1073059-33-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"64EUX713G6"},{"name":"Legacy Concept Name","value":"Anti-CD200_Monoclonal_Antibody_ALXN6000"},{"name":"Maps_To","value":"Samalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"593933"},{"name":"NCI_META_CUI","value":"CL383569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593933"},{"name":"PDQ_Open_Trial_Search_ID","value":"593933"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165558":{"preferredName":"Samarium Sm 153-DOTMP","code":"C165558","definitions":[{"definition":"A radioconjugate composed of the phosphonic acid chelator DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid) conjugated to the beta- and gamma-emitting radioisotope samarium Sm 153, with potential antineoplastic activity. Upon administration of samarium Sm 153-DOTMP, the DOTMP moiety targets and binds to growing bone, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to bone tumor and metastases, which may help destroy bone metastases and mitigate pain from bone metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samarium Sm 153-DOTMP","termGroup":"PT","termSource":"NCI"},{"termName":"153 Sm-DOTMP","termGroup":"SY","termSource":"NCI"},{"termName":"153Sm-DOTMP","termGroup":"SY","termSource":"NCI"},{"termName":"CycloSam","termGroup":"BR","termSource":"NCI"},{"termName":"Sm-153-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra(methylene)phosphonic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Sm-153-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene)tetrakisphosphonic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Sm-153-DOTMP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"633308-21-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S5NN2E9ZKF"},{"name":"Maps_To","value":"Samarium Sm 153-DOTMP"},{"name":"NCI_Drug_Dictionary_ID","value":"799673"},{"name":"NCI_META_CUI","value":"CL978665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799673"},{"name":"PDQ_Open_Trial_Search_ID","value":"799673"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121817":{"preferredName":"Samotolisib","code":"C121817","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of certain class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Samotolisib inhibits both certain PI3K isoforms and mTOR in an ATP-competitive manner which may inhibit both the PI3K/mTOR signaling pathway in and proliferation of tumor cells overexpressing PI3K and/or mTOR. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone. In addition, LY3023414 may inhibit DNA-dependent protein kinase (DNA-PK), thereby inhibiting the ability of tumor cells to repair damaged DNA. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samotolisib","termGroup":"PT","termSource":"NCI"},{"termName":"2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3023414","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3023414","termGroup":"CN","termSource":"NCI"},{"termName":"LY3023414","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10889","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1386874-06-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C88817F47Y"},{"name":"Maps_To","value":"Samotolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"738090"},{"name":"NCI_META_CUI","value":"CL446628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738090"},{"name":"PDQ_Open_Trial_Search_ID","value":"738090"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64541":{"preferredName":"Sapacitabine","code":"C64541","definitions":[{"definition":"An orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine is hydrolyzed by amidases to the deoxycytosine analogue CNDAC (2'-Cyano-2'-deoxyarabinofuranosylcytosine), which is then phosphorylated into the active triphosphate form. As an analogue of deoxycytidine triphosphate, CNDAC triphosphate incorporates into DNA strands during replication, resulting in single-stranded DNA breaks during polymerization due to beta-elimination during the fidelity checkpoint process; cell cycle arrest in the G2 phase and apoptosis ensue. The unmetabolized prodrug may exhibit antineoplastic activity as well.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sapacitabine","termGroup":"PT","termSource":"NCI"},{"termName":"CS-682","termGroup":"CN","termSource":"NCI"},{"termName":"CYC682","termGroup":"CN","termSource":"NCI"},{"termName":"N-(1-(2-Cyano-2-deoxy-beta-D-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4-yl)-hexadecanamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151823-14-2"},{"name":"Chemical_Formula","value":"C26H42N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"W335P73C3L"},{"name":"Legacy Concept Name","value":"Sapacitabine"},{"name":"Maps_To","value":"Sapacitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"513165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513165"},{"name":"PDQ_Open_Trial_Search_ID","value":"513165"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0764827"}]}}{"C90548":{"preferredName":"Sapanisertib","code":"C90548","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity. Sapanisertib binds to and inhibits both TORC1 and TORC2 complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sapanisertib","termGroup":"PT","termSource":"NCI"},{"termName":"INK-128","termGroup":"CN","termSource":"NCI"},{"termName":"INK128","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-0128","termGroup":"CN","termSource":"NCI"},{"termName":"MLN0128","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1224844-38-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JGH0DF1U03"},{"name":"Maps_To","value":"Sapanisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"665687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665687"},{"name":"PDQ_Open_Trial_Search_ID","value":"665687"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983747"}]}}{"C77887":{"preferredName":"Sapitinib","code":"C77887","definitions":[{"definition":"An erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. erbB kinase inhibitor AZD8931 binds to and inhibits erbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing erbB. The erbB protein family, also called the epidermal growth factor receptor (EGFR) family, plays major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sapitinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-((4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"AZD8931","termGroup":"CN","termSource":"NCI"},{"termName":"ErbB Kinase Inhibitor AZD8931","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848942-61-0"},{"name":"Chemical_Formula","value":"C23H25ClFN5O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3499328002"},{"name":"Legacy Concept Name","value":"ErbB_Kinase_Inhibitor_AZD8931"},{"name":"Maps_To","value":"Sapitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"593099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593099"},{"name":"PDQ_Open_Trial_Search_ID","value":"593099"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703086"}]}}{"C48378":{"preferredName":"Saracatinib","code":"C48378","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. AZD0530 blocks enzymes needed for cancer growth. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saracatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-","termGroup":"SN","termSource":"NCI"},{"termName":"AZD0530","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-Chloro-1,3-Benzodioxol-4-Yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Oxan-4-yl)Oxy)Quinazolin-4-Amine","termGroup":"SN","termSource":"NCI"},{"termName":"SRC Kinase Inhibitor AZD0530","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"379231-04-6"},{"name":"Chemical_Formula","value":"C27H32ClN5O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9KD24QGH76"},{"name":"Legacy Concept Name","value":"AZD0530"},{"name":"Maps_To","value":"Saracatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"453588"},{"name":"NSC Number","value":"735464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453588"},{"name":"PDQ_Open_Trial_Search_ID","value":"453588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2828242"}]}}{"C95224":{"preferredName":"Saracatinib Difumarate","code":"C95224","definitions":[{"definition":"The difumarate salt of saracatinib, an orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saracatinib Difumarate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(5-Chloro-1,3-Benzodioxol-4-yl)-7-(2-(4-Methyl-1-Piperazinyl)Ethoxy)-5-((Tetrahydro-2H-Pyran-4-yl)Oxy)-, (2e)-2-Butenedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-0530 Difumarate","termGroup":"CN","termSource":"NCI"},{"termName":"AZD0530 Difumarate","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-Chloro-1,3-Benzodioxol-4-yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-(Tetrahydro-2H-Pyran-4-yloxy)Quinazolin-4-Amine Di((2e)-but-2-Enedioate)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"893428-72-3"},{"name":"Chemical_Formula","value":"C27H32ClN5O5.2C4H4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8R1DYT4EAW"},{"name":"Maps_To","value":"Saracatinib Difumarate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987006"}]}}{"C963":{"preferredName":"SarCNU","code":"C963","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An alkylating chloroethylnitrosourea with antineoplastic activity.  Selectively accumulating in some tumor cells, SarCNU forms covalent linkages with nucleophilic centers in DNA, causing depurination, base pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SarCNU","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloroethyl-3-Sarcosinamide-1-Nitrosourea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92891-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BHB013S3MO"},{"name":"Legacy Concept Name","value":"SarCNU"},{"name":"Maps_To","value":"SarCNU"},{"name":"NCI_Drug_Dictionary_ID","value":"43325"},{"name":"NSC Number","value":"364432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43325"},{"name":"PDQ_Open_Trial_Search_ID","value":"43325"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045644"}]}}{"C1673":{"preferredName":"Sardomozide","code":"C1673","definitions":[{"definition":"A methylglyoxal-bis(guanylhydrazone) (MGBG) derivative with potential antineoplastic and antiviral properties. Sardomozide selectively binds to and inhibits S-adenosylmethionine decarboxylase (SAMDC), an enzyme essential for the biosynthesis of polyamines, such as spermine and spermidine that bind to DNA and play critical roles in cell division, cell differentiation and membrane function. By inhibiting SAMDC, sardomozide reduces the intracellular polyamine concentration, thereby interfering with cell growth and differentiation. In addition, this agent also exhibits anti-HIV effect via suppressing expression of eukaryotic translation initiation factor 5A (eIF-5A), which is essential for retroviral replication.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called S-adenosylmethionine decarboxylase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sardomozide","termGroup":"PT","termSource":"NCI"},{"termName":"2-[4-(Aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene]hydrazinecarboximidamide","termGroup":"SN","termSource":"NCI"},{"termName":"Amidinoindan-1-one.2'-amidinohydrazone","termGroup":"SN","termSource":"NCI"},{"termName":"CGP-48664","termGroup":"CN","termSource":"NCI"},{"termName":"SAM 486A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149400-88-4"},{"name":"Chemical_Formula","value":"C11H14N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CEB05S0B9I"},{"name":"Legacy Concept Name","value":"Sardomozide"},{"name":"Maps_To","value":"Sardomozide"},{"name":"NCI_Drug_Dictionary_ID","value":"42601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42601"},{"name":"PDQ_Open_Trial_Search_ID","value":"42601"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0960654"}]}}{"C1492":{"preferredName":"Sargramostim","code":"C1492","definitions":[{"definition":"A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23.  Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets. It is a cytokine that is a type of hematopoietic (blood-forming) agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sargramostim","termGroup":"PT","termSource":"NCI"},{"termName":"23-L-Leucinecolony-Stimulating Factor 2","termGroup":"SY","termSource":"NCI"},{"termName":"DRG-0012","termGroup":"CN","termSource":"NCI"},{"termName":"Leukine","termGroup":"BR","termSource":"NCI"},{"termName":"Prokine","termGroup":"BR","termSource":"NCI"},{"termName":"rhu GM-CFS","termGroup":"AB","termSource":"NCI"},{"termName":"Sagramostim","termGroup":"SY","termSource":"NCI"},{"termName":"Sargramostatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Melanoma; Neutropenia-chemotherapy induced"},{"name":"CAS_Registry","value":"123774-72-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5TAA004E22"},{"name":"Legacy Concept Name","value":"Sargramostim"},{"name":"Maps_To","value":"Sargramostim"},{"name":"NCI_Drug_Dictionary_ID","value":"40566"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40566"},{"name":"PDQ_Open_Trial_Search_ID","value":"40566"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0216231"}]}}{"C1493":{"preferredName":"Satraplatin","code":"C1493","definitions":[{"definition":"A substance being studied in the treatment of prostate and other types of cancer. It contains the metal platinum and may kill cancer cells by damaging their DNA and stopping them from dividing. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Satraplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"BMY-45594","termGroup":"CN","termSource":"NCI"},{"termName":"JM-216","termGroup":"CN","termSource":"NCI"},{"termName":"Orplatna","termGroup":"BR","termSource":"NCI"},{"termName":"platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129580-63-8"},{"name":"Chemical_Formula","value":"C6H13N.2C2H3O2.2Cl.Pt.H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8D7B37T28G"},{"name":"Legacy Concept Name","value":"Satraplatin"},{"name":"Maps_To","value":"Satraplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"42141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42141"},{"name":"PDQ_Open_Trial_Search_ID","value":"42141"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1142934"}]}}{"C104732":{"preferredName":"Savolitinib","code":"C104732","definitions":[{"definition":"An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Savolitinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 6094","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6094","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-504","termGroup":"CN","termSource":"NCI"},{"termName":"Volitinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313725-88-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2A2DA6857R"},{"name":"Maps_To","value":"Savolitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"745761"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745761"},{"name":"PDQ_Open_Trial_Search_ID","value":"745761"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642466"}]}}{"C29418":{"preferredName":"SBIL-2","code":"C29418","definitions":[{"definition":"An retroviral vector encoding human IL-2 with potential antineoplastic property. SBIL-2 (Surgery Branch IL-2) can be used to transfect tumor infiltrating lymphocytes, which can then be re-introduced back to cancer patients, thereby stimulate T cell activation and immunopotentiation responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SBIL-2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SBIL-2"},{"name":"Maps_To","value":"SBIL-2"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519128"}]}}{"C126100":{"preferredName":"Scopoletin","code":"C126100","definitions":[{"definition":"A coumarin compound found in several plants including those in the genus Scopolia and the genus Brunfelsia, as well as chicory (Cichorium), redstem wormwood (Artemisia scoparia), stinging nettle (Urtica dioica), passion flower (Passiflora), noni (Morinda citrifolia fruit) and European black nightshade (Solanum nigrum) that is comprised of umbelliferone with a methoxy group substituent at position 6. Scopoletin is used to standardize and establish pharmacokinetic properties for products derived from the plants that produce it, such as noni extract. Although the mechanism(s) of action have not yet been established, this agent has potential antineoplastic, antidopaminergic, antioxidant, anti-inflammatory and anticholinesterase effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scopoletin","termGroup":"PT","termSource":"NCI"},{"termName":"2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"6-Methoxyumbelliferone","termGroup":"SY","termSource":"NCI"},{"termName":"6-Methylesculetin","termGroup":"SY","termSource":"NCI"},{"termName":"6-O-Methylesculetin","termGroup":"SY","termSource":"NCI"},{"termName":"7-Hydroxy-5-Methoxycoumarin","termGroup":"SY","termSource":"NCI"},{"termName":"7-Hydroxy-6-Methoxychromen-2-One","termGroup":"SN","termSource":"NCI"},{"termName":"7-Hydroxy-6-Methoxycoumarin","termGroup":"SN","termSource":"NCI"},{"termName":"Chrysatropic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Coumarin, 7-Hydroxy-6-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Escopoletin","termGroup":"SY","termSource":"NCI"},{"termName":"Esculetin-6-Methyl Ether","termGroup":"SY","termSource":"NCI"},{"termName":"Gelseminic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Methylesculetin","termGroup":"SY","termSource":"NCI"},{"termName":"Murrayetin","termGroup":"SY","termSource":"NCI"},{"termName":"Scopoletine","termGroup":"SY","termSource":"NCI"},{"termName":"Scopoletol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92-61-5"},{"name":"CHEBI_ID","value":"CHEBI:17488"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KLF1HS0SXJ"},{"name":"Maps_To","value":"Scopoletin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0036447"}]}}{"C154328":{"preferredName":"Seclidemstat","code":"C154328","definitions":[{"definition":"An orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seclidemstat","termGroup":"PT","termSource":"NCI"},{"termName":"LSD1 Inhibitor SP-2577","termGroup":"SY","termSource":"NCI"},{"termName":"SP 2577","termGroup":"CN","termSource":"NCI"},{"termName":"SP-2577","termGroup":"CN","termSource":"NCI"},{"termName":"SP2577","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1423715-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TYH386V3WJ"},{"name":"Maps_To","value":"Seclidemstat"},{"name":"NCI_Drug_Dictionary_ID","value":"794410"},{"name":"NCI_META_CUI","value":"CL555222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794410"},{"name":"PDQ_Open_Trial_Search_ID","value":"794410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1576":{"preferredName":"Sedoxantrone Trihydrochloride","code":"C1576","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. Sedoxantrone trihydrochloride binds to DNA and stops cells, including cancer cells, from repairing damage to DNA and from making more DNA, RNA, and protein. It is a type of DNA intercalator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The trihydrochloride salt of the anthrapyrazole antineoplastic antibiotic sedoxantrone with potential antineoplastic activity. Sedoxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sedoxantrone Trihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2H-(1)Benzothiopyrano(4,3,2-cd)indazol-8-ol, 5-((2-aminoethyl)amino)-2-(2-(diethylamino)ethyl)-, Trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CI 958","termGroup":"CN","termSource":"NCI"},{"termName":"CI-958","termGroup":"CN","termSource":"NCI"},{"termName":"Ledoxantrone Trihydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"119221-49-7"},{"name":"Chemical_Formula","value":"C21H27N5OS.3ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X9GSL37ED0"},{"name":"Legacy Concept Name","value":"Sedoxantrone_Trihydrochloride"},{"name":"Maps_To","value":"Sedoxantrone Trihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42217"},{"name":"NSC Number","value":"635371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42217"},{"name":"PDQ_Open_Trial_Search_ID","value":"42217"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281727"}]}}{"C111764":{"preferredName":"Selatinib Ditosilate","code":"C111764","definitions":[{"definition":"An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selatinib Ditosilate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1452886-38-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Q2E32HVE7"},{"name":"Maps_To","value":"Selatinib Ditosilate"},{"name":"NCI_Drug_Dictionary_ID","value":"753197"},{"name":"NCI_META_CUI","value":"CL454151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753197"},{"name":"PDQ_Open_Trial_Search_ID","value":"753197"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137950":{"preferredName":"Vosilasarm","code":"C137950","definitions":[{"definition":"An orally bioavailable, non-steroidal selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activities. Upon oral administration, vosilasarm acts as an agonist in select tissues, such as skeletal muscle and bone, where it binds to and activates androgen receptors (ARs). In the prostate and breasts, vosilasarm acts as an antagonist and blocks AR activation and AR-mediated cellular proliferation. Therefore, this agent may improve bone formation and muscle mass and strength, and may inhibit both the growth of the prostate in males and AR-dependent breast cancer cell proliferation. Compared to anabolic agents, SARMs have reduced androgenic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vosilasarm","termGroup":"PT","termSource":"NCI"},{"termName":"EP 0062","termGroup":"CN","termSource":"NCI"},{"termName":"EP-0062","termGroup":"CN","termSource":"NCI"},{"termName":"EP0062","termGroup":"CN","termSource":"NCI"},{"termName":"RAD 140","termGroup":"CN","termSource":"NCI"},{"termName":"RAD-140","termGroup":"CN","termSource":"NCI"},{"termName":"RAD140","termGroup":"CN","termSource":"NCI"},{"termName":"SARM RAD140","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Androgen Receptor Modulator RAD140","termGroup":"SY","termSource":"NCI"},{"termName":"Testolone","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1182367-47-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O87Q44KNC"},{"name":"Maps_To","value":"Selective Androgen Receptor Modulator RAD140"},{"name":"Maps_To","value":"Vosilasarm"},{"name":"NCI_Drug_Dictionary_ID","value":"790616"},{"name":"NCI_META_CUI","value":"CL524969"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790616"},{"name":"PDQ_Open_Trial_Search_ID","value":"790616"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2210":{"preferredName":"Selective Cytokine Inhibitory Drug CC-1088","code":"C2210","definitions":[{"definition":"A drug that is being studied in the treatment of cancer. It is similar but not identical to thalidomide. CC-1088 belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analog of thalidomide with potential antineoplastic activity that belongs to the functional class of agents called selective cytokine inhibitory drugs (SelCIDs).  SelCIDs inhibit phosphodiesterase-4 (PDE 4), an enzyme involved in tumor necrosis factor alpha (TNF alpha) production.  CC-1088 inhibits production of the cytokines vascular endothelial growth factor (VEGF) (a pro-angiogenic factor) and interleukin-6 (IL-6). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Cytokine Inhibitory Drug CC-1088","termGroup":"PT","termSource":"NCI"},{"termName":"CC-1088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192819-27-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"95HB56U8P8"},{"name":"Legacy Concept Name","value":"CC-1088"},{"name":"Maps_To","value":"Selective Cytokine Inhibitory Drug CC-1088"},{"name":"NCI_Drug_Dictionary_ID","value":"38051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38051"},{"name":"PDQ_Open_Trial_Search_ID","value":"38051"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879595"}]}}{"C122834":{"preferredName":"Selective Estrogen Receptor Degrader AZD9496","code":"C122834","definitions":[{"definition":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader AZD9496","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 9496","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-9496","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9496","termGroup":"CN","termSource":"NCI"},{"termName":"SERD AZD9496","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1639042-08-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DA9P7LN909"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader AZD9496"},{"name":"NCI_Drug_Dictionary_ID","value":"764993"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764993"},{"name":"PDQ_Open_Trial_Search_ID","value":"764993"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053676"}]}}{"C160603":{"preferredName":"Camizestrant","code":"C160603","definitions":[{"definition":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camizestrant","termGroup":"PT","termSource":"NCI"},{"termName":"AZ-14066724","termGroup":"CN","termSource":"NCI"},{"termName":"AZD 9833","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-9833","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9833","termGroup":"CN","termSource":"NCI"},{"termName":"N-(1-(3-Fluoropropyl)-3-azetidinyl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader AZD9833","termGroup":"SY","termSource":"NCI"},{"termName":"SERD AZD9833","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222844-89-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JUP57A8EPZ"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader AZD9833"},{"name":"NCI_Drug_Dictionary_ID","value":"799429"},{"name":"NCI_META_CUI","value":"CL969664"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799429"},{"name":"PDQ_Open_Trial_Search_ID","value":"799429"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128280":{"preferredName":"Selective Estrogen Receptor Degrader LSZ102","code":"C128280","definitions":[{"definition":"An selective estrogen receptor (ER) degrader (SERD), with potential antineoplastic activity. Upon administration of LSZ102, this agent binds to the ER and induces the degradation of the receptor. This prevents ER activation and ER-mediated signaling, and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader LSZ102","termGroup":"PT","termSource":"NCI"},{"termName":"LSZ 102","termGroup":"CN","termSource":"NCI"},{"termName":"LSZ102","termGroup":"CN","termSource":"NCI"},{"termName":"SERD LSZ 102","termGroup":"SY","termSource":"NCI"},{"termName":"SERD LSZ102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2135600-76-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0Y175XGX4P"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader LSZ102"},{"name":"NCI_Drug_Dictionary_ID","value":"782046"},{"name":"NCI_META_CUI","value":"CL507934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782046"},{"name":"PDQ_Open_Trial_Search_ID","value":"782046"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120037":{"preferredName":"Selective Estrogen Receptor Degrader SRN-927","code":"C120037","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD SRN-927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader SRN-927","termGroup":"PT","termSource":"NCI"},{"termName":"SERD SRN-927","termGroup":"SY","termSource":"NCI"},{"termName":"SRN-927","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader SRN-927"},{"name":"NCI_Drug_Dictionary_ID","value":"767384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767384"},{"name":"PDQ_Open_Trial_Search_ID","value":"767384"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896765"}]}}{"C38711":{"preferredName":"Selective Estrogen Receptor Modulator CC-8490","code":"C38711","definitions":[{"definition":"A benzopyran with potential antineoplastic activity.  CC-8490 acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells.  This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of brain cancer. It belongs to the family of drugs called benzopyrans.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Selective Estrogen Receptor Modulator CC-8490","termGroup":"PT","termSource":"NCI"},{"termName":"CC-8490","termGroup":"CN","termSource":"NCI"},{"termName":"SPC8490","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CC-8490"},{"name":"Maps_To","value":"Selective Estrogen Receptor Modulator CC-8490"},{"name":"NCI_Drug_Dictionary_ID","value":"346082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346082"},{"name":"PDQ_Open_Trial_Search_ID","value":"346082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328106"}]}}{"C61494":{"preferredName":"Selective Estrogen Receptor Modulator TAS-108","code":"C61494","definitions":[{"definition":"A synthetic, antiestrogenic steroidal compound with potential antitumor activity. TAS-108 binds to and inhibits estrogenic receptor alpha (ERa), mainly expressed in the mammary gland and uterus and upregulated in estrogen-dependent tumors. Blockage of ERa by TAS-108 prevents the binding and effects of estrogen and may lead to an inhibition of estrogen-dependent cancer cell proliferation. TAS-108 also is a partial agonist of the estrogenic receptor beta (ERb), expressed in many tissues including the central nervous system, urogenital tract, bone and cardiovascular system, thereby exerting a positive effect on these tissues. In addition, TAS-108 activates the co-repressor Silencing Mediator for Retinoid and Thyroid hormone receptor (SMRT), a protein that inhibits the activities of the estrogen receptors, which may contribute to the antitumor activity of TAS-108.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Modulator TAS-108","termGroup":"PT","termSource":"NCI"},{"termName":"(7)-21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"SR16234","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"354808-47-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9B29N23K7E"},{"name":"Legacy Concept Name","value":"TAS-108"},{"name":"Maps_To","value":"Selective Estrogen Receptor Modulator TAS-108"},{"name":"NCI_Drug_Dictionary_ID","value":"486347"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486347"},{"name":"PDQ_Open_Trial_Search_ID","value":"486347"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1435232"}]}}{"C153309":{"preferredName":"Exicorilant","code":"C153309","definitions":[{"definition":"An orally available, selective glucocorticoid receptor (GR) antagonist, with potential antineoplastic activity. Upon oral administration, exicorilant competitively and selectively binds to GRs, inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exicorilant","termGroup":"PT","termSource":"NCI"},{"termName":"CORT 125281","termGroup":"CN","termSource":"NCI"},{"termName":"CORT-1252","termGroup":"CN","termSource":"NCI"},{"termName":"CORT125281","termGroup":"CN","termSource":"NCI"},{"termName":"Glucocorticoid Receptor Antagonist CORT125281","termGroup":"SY","termSource":"NCI"},{"termName":"Methanone, ((4aR,8aS)-1-(4-Fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"WHO 10854","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1781244-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GTB859B7K8"},{"name":"Maps_To","value":"Exicorilant"},{"name":"Maps_To","value":"Selective Glucocorticoid Receptor Antagonist CORT125281"},{"name":"NCI_Drug_Dictionary_ID","value":"794071"},{"name":"NCI_META_CUI","value":"CL554423"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794071"},{"name":"PDQ_Open_Trial_Search_ID","value":"794071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150363":{"preferredName":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","code":"C150363","definitions":[{"definition":"A benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol","termGroup":"SN","termSource":"NCI"},{"termName":"ERa Partial Agonist TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Mimic TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Modulator TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"SEM TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"ShERPA TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"TTC 352","termGroup":"CN","termSource":"NCI"},{"termName":"TTC-352","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1607819-68-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65ILH3Y0MI"},{"name":"Maps_To","value":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352"},{"name":"NCI_Drug_Dictionary_ID","value":"793141"},{"name":"NCI_META_CUI","value":"CL552181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793141"},{"name":"PDQ_Open_Trial_Search_ID","value":"793141"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62783":{"preferredName":"Seliciclib","code":"C62783","definitions":[{"definition":"An orally available small molecule and cyclin-dependent kinase (CDK) inhibitor with potential apoptotic and antineoplastic activity. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Seliciclib primarily inhibits CDK 2, 7, and 9 by competing for the ATP binding sites on these kinases, leading to a disruption of cell cycle progression. In addition, this agent seems to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, thereby inhibiting RNA polymerase II-dependent transcription. This may lead to the down-regulation of anti-apoptotic factors, such as myeloid cell leukemia sequence 1 (Mcl-1), a protein crucial for the survival of a range of tumor cell types. The down-regulation of anti-apoptotic factors may lead to an induction of apoptosis, thereby further contributing to seliciclib's antiproliferative effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seliciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CYC202","termGroup":"CN","termSource":"NCI"},{"termName":"R-roscovitine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186692-46-6"},{"name":"Chemical_Formula","value":"C19H26N6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0ES1C2KQ94"},{"name":"Legacy Concept Name","value":"Seliciclib"},{"name":"Maps_To","value":"Seliciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"511023"},{"name":"PDQ_Closed_Trial_Search_ID","value":"511023"},{"name":"PDQ_Open_Trial_Search_ID","value":"511023"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1436187"}]}}{"C102546":{"preferredName":"Selinexor","code":"C102546","definitions":[{"definition":"An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selinexor","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenoic Acid, 3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-Pyrazinyl)hydrazide, (2Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"ATG-010","termGroup":"CN","termSource":"NCI"},{"termName":"CRM1 Nuclear Export Inhibitor KPT-330","termGroup":"SY","termSource":"NCI"},{"termName":"KPT-330","termGroup":"CN","termSource":"NCI"},{"termName":"Nexpovio","termGroup":"FB","termSource":"NCI"},{"termName":"Selective Inhibitor of Nuclear Export KPT-330","termGroup":"SY","termSource":"NCI"},{"termName":"SINE KPT-330","termGroup":"SY","termSource":"NCI"},{"termName":"Xpovio","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma"},{"name":"CAS_Registry","value":"1393477-72-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"31TZ62FO8F"},{"name":"Maps_To","value":"Selinexor"},{"name":"NCI_Drug_Dictionary_ID","value":"734824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734824"},{"name":"PDQ_Open_Trial_Search_ID","value":"734824"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640806"}]}}{"C138160":{"preferredName":"Selitrectinib","code":"C138160","definitions":[{"definition":"An orally bioavailable, selective tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, LOXO-195 specifically targets and binds to TRK, including the fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1), 2 (NTRK2), and 3 (NTRK3).  This prevents neurotrophin-TRK interaction and TRK activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. LOXO-195 targets specific point mutations that occur after treatment with and result in acquired resistance to another TRK inhibitor; therefore, LOXO-195 is able to overcome acquired resistance to other TRK inhibitors. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of or fusion proteins involving NTRK family members results in uncontrolled TRK signaling and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selitrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 2731954","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO 195","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO-195","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO195","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097002-61-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0J45910S3X"},{"name":"Maps_To","value":"Selitrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"790661"},{"name":"NCI_META_CUI","value":"CL525677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790661"},{"name":"PDQ_Open_Trial_Search_ID","value":"790661"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121943":{"preferredName":"Selonsertib","code":"C121943","definitions":[{"definition":"An orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. Upon oral administration, selonsertib targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. This prevents the phosphorylation of downstream kinases, such as c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK). By preventing the activation of ASK1-dependent signal transduction pathways, GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. ASK1, also called mitogen-activated protein kinase kinase kinase 5 (MAP3K5), is activated in response to oxidative and endoplasmic reticulum (ER) stress, calcium influx and infection. It plays a key role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, as well as certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selonsertib","termGroup":"PT","termSource":"NCI"},{"termName":"GS-4997","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448428-04-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NS3988A2TC"},{"name":"Maps_To","value":"Selonsertib"},{"name":"NCI_Drug_Dictionary_ID","value":"773700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"773700"},{"name":"PDQ_Open_Trial_Search_ID","value":"773700"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053640"}]}}{"C134987":{"preferredName":"Selpercatinib","code":"C134987","definitions":[{"definition":"An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selpercatinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"LOXO-292","termGroup":"CN","termSource":"NCI"},{"termName":"RET Kinase Inhibitor LOXO-292","termGroup":"SY","termSource":"NCI"},{"termName":"Retevmo","termGroup":"BR","termSource":"NCI"},{"termName":"Retsevmo","termGroup":"FB","termSource":"NCI"},{"termName":"WHO 10967","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); • Adult and pediatric patients >=12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; • Adult and pediatric patients >=12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)."},{"name":"CAS_Registry","value":"2152628-33-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CEGM9YBNGD"},{"name":"Maps_To","value":"Selpercatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"789226"},{"name":"NCI_META_CUI","value":"CL522497"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789226"},{"name":"PDQ_Open_Trial_Search_ID","value":"789226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66939":{"preferredName":"Selumetinib","code":"C66939","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. AZD6244 blocks proteins needed for cell growth and may kill cancer cells. It is a type of protein kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selumetinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-142886","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6244","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor AZD6244","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"606143-52-6"},{"name":"Chemical_Formula","value":"C17H15BrClFN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6UH91I579U"},{"name":"Legacy Concept Name","value":"AZD6244"},{"name":"Maps_To","value":"Selumetinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832054"}]}}{"C95225":{"preferredName":"Selumetinib Sulfate","code":"C95225","definitions":[{"definition":"The sulfate salt of selumetinib, an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selumetinib Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benzimidazole-6-Carboxamide, 5-((4-Bromo-2-Chlorophenyl)Amino)-4-Fluoro-N-(2- Hydroxyethoxy)-1-Methyl-, Sulfate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"1h-Benzimidazole-6-Carboxamide,5-((4-Bromo-2-Chlorophenyl)Amino)-4-Fluoro-N-(2- Hydroxyethoxy)-1-Methyl-, Sulphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"5-((4-Bromo-2-Chlorophenyl)amino)-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H- Benzimidazole-6-Carboxamide Sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"5-((4-Bromo-2-Chlorophenyl)amino)-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H- Benzimidazole-6-Carboxamide Sulphate","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-6244 Hydrogen Sulfate","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6244 Hydrogen Sulfate","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6244 Hydrogen Sulphate","termGroup":"CN","termSource":"NCI"},{"termName":"Koselugo","termGroup":"BR","termSource":"NCI"},{"termName":"Selumetinib Sulphate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)."},{"name":"CAS_Registry","value":"943332-08-9"},{"name":"Chemical_Formula","value":"C17H15BrClFN4O3.H2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"807ME4B7IJ"},{"name":"Maps_To","value":"Selumetinib Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"532294"},{"name":"PDQ_Closed_Trial_Search_ID","value":"532294"},{"name":"PDQ_Open_Trial_Search_ID","value":"532294"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987007"}]}}{"C1831":{"preferredName":"Semaxanib","code":"C1831","definitions":[{"definition":"A quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that has been studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Semaxanib","termGroup":"PT","termSource":"NCI"},{"termName":"H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-","termGroup":"SN","termSource":"NCI"},{"termName":"Semoxind","termGroup":"SY","termSource":"NCI"},{"termName":"SU5416","termGroup":"CN","termSource":"NCI"},{"termName":"Sugen 5416","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194413-58-6"},{"name":"Chemical_Formula","value":"C15H14N2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71IA9S35AJ"},{"name":"Legacy Concept Name","value":"Semaxanib"},{"name":"Maps_To","value":"Semaxanib"},{"name":"NCI_Drug_Dictionary_ID","value":"43310"},{"name":"NSC Number","value":"696819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43310"},{"name":"PDQ_Open_Trial_Search_ID","value":"43310"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1135174"}]}}{"C78447":{"preferredName":"Semuloparin","code":"C78447","definitions":[{"definition":"An ultralow-molecular-weight heparin (ULMWH) (Mw: 2000-3000 daltons)consisting of a polydisperse mixture of oligomeric heparin fragments with potential anticoagulant activity. Ultralow-molecular-weight heparin AVE5026 binds to and activates antithrombin III (ATIII), which may result in the inhibition of activated factor Xa and, to a much lesser extent, factor IIa (thrombin) and so the inhibition of fibrin formation. Compared to low-molecular-weight heparins (LMWHs), AVE5026 exhibits an even higher ratio of anti-Factor Xa to anti-Factor IIa activity (>30:1). Compared to unfractionated heparins, the use of LMWHs is associated with lower incidences of major bleeding, osteoporosis and heparin-induced thrombocytopenia. Like LMWHs, this agent may inhibit tumor growth by regulating angiogenesis and apoptosis. AVE5026 is prepared by partial depolymerization of unfractionated porcine mucosal heparin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Semuloparin","termGroup":"PT","termSource":"NCI"},{"termName":"AVE-5026","termGroup":"CN","termSource":"NCI"},{"termName":"AVE5026","termGroup":"CN","termSource":"NCI"},{"termName":"ULMW heparin AVE5026","termGroup":"AB","termSource":"NCI"},{"termName":"Ultra-low-molecular-weight Heparin (2000-3000 MW; Phosphazene Depolymerization)","termGroup":"SY","termSource":"NCI"},{"termName":"Ultralow-Molecular-Weight Heparin AVE5026","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9005-49-6"},{"name":"CHEBI_ID","value":"CHEBI:28304"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4QW4AN84NQ"},{"name":"Legacy Concept Name","value":"Ultralow-Molecular-Weight_Heparin_AVE5026"},{"name":"Maps_To","value":"Semuloparin"},{"name":"NCI_Drug_Dictionary_ID","value":"599247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599247"},{"name":"PDQ_Open_Trial_Search_ID","value":"599247"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700104"}]}}{"C827":{"preferredName":"Semustine","code":"C827","definitions":[{"definition":"A methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Semustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(Trans-4-Methylcyclohexane)-1-Nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Lomustine, Methyl","termGroup":"SY","termSource":"NCI"},{"termName":"MCCNU","termGroup":"AB","termSource":"NCI"},{"termName":"MeCCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl CCNU","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl Lomustine","termGroup":"SY","termSource":"NCI"},{"termName":"trans-Methyl-CCNU","termGroup":"SY","termSource":"NCI"},{"termName":"urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-, trans- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"urea, N-(2-chloroethyl)-N'-(4-methylcyclohexyl)-N-nitroso-, trans- (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13909-09-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6YY7T1T567"},{"name":"Legacy Concept Name","value":"Semustine"},{"name":"Maps_To","value":"Semustine"},{"name":"NCI_Drug_Dictionary_ID","value":"43727"},{"name":"NSC Number","value":"95441"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43727"},{"name":"PDQ_Open_Trial_Search_ID","value":"43727"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0036637"}]}}{"C62524":{"preferredName":"Seneca Valley Virus-001","code":"C62524","definitions":[{"definition":"A replication-competent oncolytic picornavirus with potential antineoplastic activity. Administered systemically, Seneca Valley virus-001 specifically targets and infects tumor cells with neuroendocrine characteristics. Upon infection, this agent replicates intracellularly, resulting in tumor cell lysis and reduced tumor cell proliferation. The selective tropism of virus replication may involve receptor-mediated internalization.","type":"DEFINITION","source":"NCI"},{"definition":"A virus being studied in the treatment of neuroendocrine tumors and other types of cancer. Neuroendocrine tumors form from cells that release hormones in response to a signal from the nervous system. The virus infects and breaks down these tumor cells but not normal cells. It is a type of oncolytic virus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Seneca Valley Virus-001","termGroup":"PT","termSource":"NCI"},{"termName":"NTX-010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Seneca_Valley_Virus"},{"name":"Maps_To","value":"Seneca Valley Virus-001"},{"name":"NCI_Drug_Dictionary_ID","value":"488482"},{"name":"NCI_META_CUI","value":"CL365090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488482"},{"name":"PDQ_Open_Trial_Search_ID","value":"488482"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C26669":{"preferredName":"Seocalcitol","code":"C26669","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called vitamin D analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A vitamin D3 analogue with potential antineoplastic activity. Seocalcitol binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, seocalcitol may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seocalcitol","termGroup":"PT","termSource":"NCI"},{"termName":"(1R-(1alpha(1R*,2E,4E),3abeta,4E(1R*,3S*,5Z),7aalpha))-5-((1-(6-Ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-1,3-cyclohexanediol","termGroup":"SN","termSource":"NCI"},{"termName":"1(S),3(R)-Dihydroxy-20(R)-(5'-ethyl-5'-hydroxyhepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene","termGroup":"SN","termSource":"NCI"},{"termName":"EB1089","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134404-52-7"},{"name":"Chemical_Formula","value":"C30H46O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q0OZ0D9223"},{"name":"Legacy Concept Name","value":"Seocalcitol"},{"name":"Maps_To","value":"Seocalcitol"},{"name":"NCI_Drug_Dictionary_ID","value":"298863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"298863"},{"name":"PDQ_Open_Trial_Search_ID","value":"298863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0905598"}]}}{"C61091":{"preferredName":"Sepantronium Bromide","code":"C61091","definitions":[{"definition":"A small-molecule proapoptotic agent with potential antineoplastic activity. Sepantronium bromide selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sepantronium Bromide","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Naphth(2,3-d)imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazinylmethyl)-, Bromide","termGroup":"SN","termSource":"NCI"},{"termName":"Survivin Inhibitor YM155","termGroup":"SY","termSource":"NCI"},{"termName":"YM-155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"781661-94-7"},{"name":"Chemical_Formula","value":"C20H19N4O3.Br"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7H5Q4J1CM5"},{"name":"Legacy Concept Name","value":"YM155"},{"name":"Maps_To","value":"Sepantronium Bromide"},{"name":"NCI_Drug_Dictionary_ID","value":"476771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"476771"},{"name":"PDQ_Open_Trial_Search_ID","value":"476771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002939"}]}}{"C98844":{"preferredName":"Serabelisib","code":"C98844","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha isoform with potential antineoplastic activity. Serabelisib selectively inhibits PI3K alpha kinase, including mutations of PIK3CA, in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K alpha-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy; PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serabelisib","termGroup":"PT","termSource":"NCI"},{"termName":"(6-(2-Amino-5-benzoxazolyl)imidazo(1,2-a)pyridin-3-yl)-4-morpholinylmethanone","termGroup":"SY","termSource":"NCI"},{"termName":"INK1117","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-1117","termGroup":"CN","termSource":"NCI"},{"termName":"MLN1117","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 117","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-117","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268454-23-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43J9Q56T3W"},{"name":"Maps_To","value":"Serabelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"714372"},{"name":"NCI_META_CUI","value":"CL432860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714372"},{"name":"PDQ_Open_Trial_Search_ID","value":"714372"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156735":{"preferredName":"Taragarestrant","code":"C156735","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, taragarestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taragarestrant","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-3-(3,5-Dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1hpyrido(3,4-b)indol-1-yl)phenyl)prop-2-enoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"2-Propenoic acid, 3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1H-pyrido(3,4-b)indol-1-yl)phenyl)-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"D 0502","termGroup":"CN","termSource":"NCI"},{"termName":"D-0502","termGroup":"CN","termSource":"NCI"},{"termName":"D0502","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator D-0502","termGroup":"SY","termSource":"NCI"},{"termName":"SERD D-0502","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2118899-51-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KD4HIM135V"},{"name":"Maps_To","value":"SERD D-0502"},{"name":"NCI_Drug_Dictionary_ID","value":"795596"},{"name":"NCI_META_CUI","value":"CL935902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795596"},{"name":"PDQ_Open_Trial_Search_ID","value":"795596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175853":{"preferredName":"Rintodestrant","code":"C175853","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, rintodestrant specifically targets and binds to the estrogen receptor alpha (ERalpha; ERa; ESR1) and induces a conformational change that promotes ERalpha degradation and downregulation. This prevents ERalpha-mediated signaling and inhibits both the growth and survival of ERalpha-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rintodestrant","termGroup":"PT","termSource":"NCI"},{"termName":"G1T48","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader G1T48","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator G1T48","termGroup":"SY","termSource":"NCI"},{"termName":"SERD G1T48","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2088518-51-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W3Y784Y0ES"},{"name":"Maps_To","value":"SERD G1T48"},{"name":"NCI_Drug_Dictionary_ID","value":"793441"},{"name":"NCI_META_CUI","value":"CL552249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147030":{"preferredName":"Giredestrant","code":"C147030","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giredestrant","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 9545","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-49545","termGroup":"CN","termSource":"NCI"},{"termName":"RG6171","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader GDC-9545","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator GDC-9545","termGroup":"SY","termSource":"NCI"},{"termName":"SERD GDC-9545","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1953133-47-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"28P3DU6DB3"},{"name":"Maps_To","value":"Giredestrant"},{"name":"Maps_To","value":"SERD GDC-9545"},{"name":"NCI_Drug_Dictionary_ID","value":"792379"},{"name":"NCI_META_CUI","value":"CL545029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792379"},{"name":"PDQ_Open_Trial_Search_ID","value":"792379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174915":{"preferredName":"Amcenestrant","code":"C174915","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, amcenestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amcenestrant","termGroup":"PT","termSource":"NCI"},{"termName":"SAR 439859","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-439859","termGroup":"CN","termSource":"NCI"},{"termName":"SAR439859","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader SAR439859","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator SAR439859","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2114339-57-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TBF1NHY02O"},{"name":"Maps_To","value":"SERD SAR439859"},{"name":"NCI_Drug_Dictionary_ID","value":"793484"},{"name":"NCI_META_CUI","value":"CL538418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793484"},{"name":"PDQ_Open_Trial_Search_ID","value":"793484"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165550":{"preferredName":"SERD SHR9549","code":"C165550","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD SHR9549 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SERD SHR9549","termGroup":"PT","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader SHR9549","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator SHR9549","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 9549","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-9549","termGroup":"CN","termSource":"NCI"},{"termName":"SHR9549","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SERD SHR9549"},{"name":"NCI_Drug_Dictionary_ID","value":"799640"},{"name":"NCI_META_CUI","value":"CL978680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799640"},{"name":"PDQ_Open_Trial_Search_ID","value":"799640"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77904":{"preferredName":"Serdemetan","code":"C77904","definitions":[{"definition":"An orally bioavailable HDM2 antagonist with potential antineoplastic activity. Serdemetan inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serdemetan","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 26854165","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-26854165","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-(1H-Indol-3-yl)ethyl)-n'-(pyridin-4-yl)benzene-1,4-diamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"881202-45-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ID6YB4W3V8"},{"name":"Legacy Concept Name","value":"HDM2_Inhibitor_JNJ-26854165"},{"name":"Maps_To","value":"Serdemetan"},{"name":"NCI_Drug_Dictionary_ID","value":"596734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596734"},{"name":"PDQ_Open_Trial_Search_ID","value":"596734"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703092"}]}}{"C1763":{"preferredName":"Sergiolide","code":"C1763","definitions":[{"definition":"A quassinoid phytochemical isolated from Cedronia granatensis and other plant species with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sergiolide","termGroup":"PT","termSource":"NCI"},{"termName":"Sergeolide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sergiolide"},{"name":"Maps_To","value":"Sergiolide"},{"name":"NSC Number","value":"344025"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0624649"}]}}{"C78859":{"preferredName":"Seribantumab","code":"C78859","definitions":[{"definition":"A fully human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Seribantumab binds to and inhibits ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seribantumab","termGroup":"PT","termSource":"NCI"},{"termName":"MM-121","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 256212","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1334296-12-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1N3L70MDFX"},{"name":"Legacy Concept Name","value":"Anti-ErbB3_Receptor_Monoclonal_Antibody_MM-121"},{"name":"Maps_To","value":"Seribantumab"},{"name":"NCI_Drug_Dictionary_ID","value":"613844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613844"},{"name":"PDQ_Open_Trial_Search_ID","value":"613844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4042753"}]}}{"C71529":{"preferredName":"Serine/Threonine Kinase Inhibitor CBP501","code":"C71529","definitions":[{"definition":"A peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C); disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2/cyclin B, preventing entry into the mitotic phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serine/Threonine Kinase Inhibitor CBP501","termGroup":"PT","termSource":"NCI"},{"termName":"CBP 501","termGroup":"CN","termSource":"NCI"},{"termName":"CBP-501","termGroup":"CN","termSource":"NCI"},{"termName":"CBP501","termGroup":"CN","termSource":"NCI"},{"termName":"Cdc25C Phosphatase (211-221)","termGroup":"SY","termSource":"NCI"},{"termName":"D-Arginine, 4-Benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D- arginyl-D-arginyl-D-glutaminyl-D-arginyl-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"565434-85-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XH2662798I"},{"name":"Legacy Concept Name","value":"Serine_Threonine_Kinase_Inhibitor_CBP501"},{"name":"Maps_To","value":"Serine/Threonine Kinase Inhibitor CBP501"},{"name":"NCI_Drug_Dictionary_ID","value":"577812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577812"},{"name":"PDQ_Open_Trial_Search_ID","value":"577812"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348193"}]}}{"C68963":{"preferredName":"Serine/Threonine Kinase Inhibitor XL418","code":"C68963","definitions":[{"definition":"A selective, orally active small molecule, targeting protein kinase B (PKB or AKT) and ribosomal protein S6 Kinase (p70S6K), with potential antineoplastic activity. XL418 inhibits the activities of PKB and p70S6K, both acting downstream of phosphoinosotide-3 kinase (PI3K). These kinases are often upregulated in a variety of cancers. Inhibition of PKB by this agent will induce apoptosis, while inhibition of p70S6K will result in the inhibition of translation within tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serine/Threonine Kinase Inhibitor XL418","termGroup":"PT","termSource":"NCI"},{"termName":"XL418","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871343-09-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OLJ18SRI8A"},{"name":"Legacy Concept Name","value":"Serine_Threonine_Kinase_Inhibitor_XL418"},{"name":"Maps_To","value":"Serine/Threonine Kinase Inhibitor XL418"},{"name":"NCI_Drug_Dictionary_ID","value":"546978"},{"name":"NCI_META_CUI","value":"CL374493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546978"},{"name":"PDQ_Open_Trial_Search_ID","value":"546978"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122403":{"preferredName":"Suvemcitug","code":"C122403","definitions":[{"definition":"A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, suvemcitug specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suvemcitug","termGroup":"PT","termSource":"NCI"},{"termName":"APX 003","termGroup":"CN","termSource":"NCI"},{"termName":"BD 0801","termGroup":"CN","termSource":"NCI"},{"termName":"BD-0801","termGroup":"CN","termSource":"NCI"},{"termName":"BD0801","termGroup":"CN","termSource":"NCI"},{"termName":"Sevacizumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610010-57-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T7Y5VC4ERJ"},{"name":"Maps_To","value":"Sevacizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"772607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772607"},{"name":"PDQ_Open_Trial_Search_ID","value":"772607"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054033"}]}}{"C113652":{"preferredName":"Seviteronel","code":"C113652","definitions":[{"definition":"An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, seviteronel selectively inhibits the enzymatic activity of the cytochrome P450 C17,20 lyase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The lyase-selective activity of seviteronel prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seviteronel","termGroup":"PT","termSource":"NCI"},{"termName":"1H-1,2,3-Triazole-5-methanol, Alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (AlphaS)-","termGroup":"SN","termSource":"NCI"},{"termName":"VT-464","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610537-15-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8S5OIN36X4"},{"name":"Maps_To","value":"Seviteronel"},{"name":"NCI_Drug_Dictionary_ID","value":"756850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756850"},{"name":"PDQ_Open_Trial_Search_ID","value":"756850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827068"}]}}{"C29424":{"preferredName":"Shared Anti-Idiotype-AB-S006","code":"C29424","definitions":[{"definition":"A murine monoclonal anti-idiotype antibody that targets human B-cell lymphomas with potential antineoplastic activity.  Shared Anti-Id-Ab-S006 binds to antigens on neoplastic B cells, resulting in tumor cell destruction by the reticuloendothelial system or cytotoxic T lymphocytes (CTL). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shared Anti-Idiotype-AB-S006","termGroup":"PT","termSource":"NCI"},{"termName":"Murine Monoclonal Antibody To Human B Cell Lymphomas (Anti- Idiotypes) (S006)","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Anti-Idiotype AB-S006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Shared_Anti-Idiotype-AB-S006"},{"name":"Maps_To","value":"Shared Anti-Idiotype-AB-S006"},{"name":"NSC Number","value":"655532"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519287"}]}}{"C29432":{"preferredName":"Shared Anti-Idiotype-AB-S024A","code":"C29432","definitions":[{"definition":"A murine monoclonal anti-idiotype antibody with potential antineoplastic activity. Shared anti-id-Ab-S024A binds to tumor-associated antigens (TAAs) on the surface of neoplastic cells resulting in tumor cell destruction by the reticuloendothelial system or cytotoxic T lymphocytes (CTL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shared Anti-Idiotype-AB-S024A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Shared_Anti-Idiotype-AB-S024A"},{"name":"Maps_To","value":"Shared Anti-Idiotype-AB-S024A"},{"name":"NSC Number","value":"655540"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519294"}]}}{"C2318":{"preferredName":"Shark Cartilage","code":"C2318","definitions":[{"definition":"A nutritional supplement gleaned from the exoskeleton of the shark. Shark cartilage inhibits metalloproteinases (MMPs) and possesses antiangiogenic and antimetastatic properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shark Cartilage","termGroup":"PT","termSource":"NCI"},{"termName":"BeneFin (Lane Shark Cartilage Powder)","termGroup":"BR","termSource":"NCI"},{"termName":"Cartilade","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"305838-77-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D2YCN1I522"},{"name":"Legacy Concept Name","value":"Shark_Cartilage"},{"name":"Maps_To","value":"Shark Cartilage"},{"name":"NCI_Drug_Dictionary_ID","value":"304435"},{"name":"NSC Number","value":"706457"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304435"},{"name":"PDQ_Open_Trial_Search_ID","value":"304435"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281563"}]}}{"C1798":{"preferredName":"Shark Cartilage Extract AE-941","code":"C1798","definitions":[{"definition":"A multifunctional antiangiogenic agent derived from shark cartilage with potential antineoplastic activity. Shark cartilage extract AE-941 competitively inhibits the binding of pro-angiogenic vascular endothelial growth factor (VEGF) to its cellular receptor, thereby inhibiting endothelial cell proliferation. This agent also inhibits matrix metalloproteinases (MMPs), stimulates tissue plasminogen activator (tPA), and activates caspase-mediated apoptotic pathways in endothelial cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance made from shark cartilage that is being studied for its ability to prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Shark Cartilage Extract AE-941","termGroup":"PT","termSource":"NCI"},{"termName":"[AElig]-941","termGroup":"CN","termSource":"NCI"},{"termName":"AE-941","termGroup":"CN","termSource":"NCI"},{"termName":"Neovastat","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"305838-77-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neovastat"},{"name":"Maps_To","value":"Shark Cartilage Extract AE-941"},{"name":"NCI_Drug_Dictionary_ID","value":"42021"},{"name":"NSC Number","value":"706456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42021"},{"name":"PDQ_Open_Trial_Search_ID","value":"42021"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1963096"}]}}{"C2690":{"preferredName":"Sho-Saiko-To","code":"C2690","definitions":[{"definition":"A Japanese formulation of seven Chinese herbs that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A botanical formulation with potential chemopreventive activities. Sho-Saiko-to, an herbal mixture, contains seven herbal extracts whose mechanism of action if not fully understood. There is evidence of antiproliferative effects against hepatocellular carcinoma in vitro. Other effects of this agent described in animal models include the prevention of liver injury and hepatocyte-regenerating activity. Antitumor effects associated with this herbal product may include induction of apoptosis, cell cycle arrest at the G0/G1 phase, and activation of an immune response, characterized by the release of cytokines as well as activation of effector cells, such as macrophages and natural killer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sho-Saiko-To","termGroup":"PT","termSource":"NCI"},{"termName":"Keisho-To","termGroup":"SY","termSource":"NCI"},{"termName":"Minor Bupleurum Formula","termGroup":"SY","termSource":"NCI"},{"termName":"TJ-9","termGroup":"CN","termSource":"NCI"},{"termName":"Xiao Chai Hu Tang","termGroup":"SY","termSource":"NCI"},{"termName":"Xiao-Chai-Hu-Tang","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sho-Saiko-To"},{"name":"Maps_To","value":"Sho-Saiko-To"},{"name":"NCI_Drug_Dictionary_ID","value":"38708"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38708"},{"name":"PDQ_Open_Trial_Search_ID","value":"38708"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1138004"}]}}{"C156695":{"preferredName":"SHP-1 Agonist SC-43","code":"C156695","definitions":[{"definition":"An orally available, small molecule agonist of Src homology region 2 domain-containing phosphatase-1 (SHP-1; tyrosine-protein phosphatase non-receptor type 6; PTPN6) with potential antineoplastic activity. Upon administration, SHP-1 agonist SC-43 enhances SHP-1 activity by impairing the association between the N-terminal Src homology 2 (N-SH2) domain and the protein tyrosine phosphatase (PTP) domain of SHP-1, triggering a conformational change of SHP-1 and relieving its autoinhibition. Activation of SHP-1 represses signal transducer and activator of transcription 3 (STAT3) signaling by inhibiting constitutive and interleukin-6 (IL-6)-induced STAT3 phosphorylation. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence, stemness, and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP-1 Agonist SC-43","termGroup":"PT","termSource":"NCI"},{"termName":"1-[4-Chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] Urea","termGroup":"SN","termSource":"NCI"},{"termName":"SC 43","termGroup":"CN","termSource":"NCI"},{"termName":"SC-43","termGroup":"CN","termSource":"NCI"},{"termName":"SC-43 Oral Solution","termGroup":"SY","termSource":"NCI"},{"termName":"SC43","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1400989-25-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OT4AQX5MLU"},{"name":"Maps_To","value":"SHP-1 Agonist SC-43"},{"name":"NCI_Drug_Dictionary_ID","value":"795711"},{"name":"NCI_META_CUI","value":"CL935710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795711"},{"name":"PDQ_Open_Trial_Search_ID","value":"795711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160207":{"preferredName":"SHP2 Inhibitor JAB-3068","code":"C160207","definitions":[{"definition":"An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3068 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP2 Inhibitor JAB-3068","termGroup":"PT","termSource":"NCI"},{"termName":"JAB 3068","termGroup":"CN","termSource":"NCI"},{"termName":"JAB-3068","termGroup":"CN","termSource":"NCI"},{"termName":"JAB3068","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V6Q7413SA8"},{"name":"Maps_To","value":"SHP2 Inhibitor JAB-3068"},{"name":"NCI_Drug_Dictionary_ID","value":"797845"},{"name":"NCI_META_CUI","value":"CL969346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797845"},{"name":"PDQ_Open_Trial_Search_ID","value":"797845"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155850":{"preferredName":"Vociprotafib","code":"C155850","definitions":[{"definition":"An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, vociprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-MEK-ERK signaling pathway. The RAS-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vociprotafib","termGroup":"PT","termSource":"NCI"},{"termName":"(6-((2-Amino-3-chloropyridin-4-yl)sulfanyl)-3-((3S,4S)-4-amino- 3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)- 5-methylpyrazin-2-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyrazinemethanol, 6-((2-amino-3-chloro-4-pyridinyl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-5-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"PTPN11 Inhibitor RMC-4630","termGroup":"SY","termSource":"NCI"},{"termName":"RMC 4630","termGroup":"CN","termSource":"NCI"},{"termName":"RMC-4630","termGroup":"CN","termSource":"NCI"},{"termName":"RMC4630","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 442720","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442720","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442720","termGroup":"CN","termSource":"NCI"},{"termName":"SHP2 Inhibitor RMC-4630","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2172652-48-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C4YBF9170L"},{"name":"Maps_To","value":"SHP2 Inhibitor RMC-4630"},{"name":"NCI_Drug_Dictionary_ID","value":"798916"},{"name":"NCI_META_CUI","value":"CL562678"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798916"},{"name":"PDQ_Open_Trial_Search_ID","value":"798916"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139559":{"preferredName":"Batoprotafib","code":"C139559","definitions":[{"definition":"An inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration,batoprotafib binds to and inhibits SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-ERK signaling pathway. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Batoprotafib","termGroup":"PT","termSource":"NCI"},{"termName":"PTPN11 Inhibitor TNO155","termGroup":"SY","termSource":"NCI"},{"termName":"SHP2 Inhibitor TNO155","termGroup":"SY","termSource":"NCI"},{"termName":"TNO155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801765-04-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FPJWORQEGI"},{"name":"Maps_To","value":"SHP2 Inhibitor TNO155"},{"name":"NCI_Drug_Dictionary_ID","value":"791106"},{"name":"NCI_META_CUI","value":"CL526915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791106"},{"name":"PDQ_Open_Trial_Search_ID","value":"791106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120207":{"preferredName":"Shu Yu Wan Formula","code":"C120207","definitions":[{"definition":"A traditional Chinese medicine comprising different herbs that may be used for a variety of medical purposes. Shu Yu Wan contains the following herbs: Da Zao (Fructus Jujubae), Shu Yu (Radix Dioscoreae Quinquelobae), Gan Cao (Radix Glycyrrhizae Uralensis), Shu Di Huang (Radix Rehmanniae Glutinosae Praeparata), Dang Gui (Radix Angelicae Sinensis), Shen Qu (Massa Medica Fermentata), Gui Zhi (Ramulus Cinnamomi Cassiae), Da Dou Juan (Semen Glycines Germinatum), E Jiao (Gelatinum Corii Asini), Ren Shen (Radix Ginseng), Bai Zhu (Rhizoma Atractylodis Macrocephalae), Fu Ling (Sclerotium Poriae Cocos), Chuan Xiong (Radix Ligustici Wallichii), Bai Shao Yao (Radix Paeoniae Lactiflorae), Mai Men Dong (Tuber Ophiopogonis Japonici), Chai Hu (Radix Bupleuri), Fang Feng (Radix Ledebouriellae Divaricatae), Jie Geng (Radix Platycodi Grandiflori), Xing Ren (Semen Pruni Armeniacae), Bai Lian (Radix Ampelopsis Japonicae) and Sheng Jiang (Rhizoma Zingiberis Officinalis Recens). This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shu Yu Wan Formula","termGroup":"PT","termSource":"NCI"},{"termName":"Pill of Chinese Yam","termGroup":"SY","termSource":"NCI"},{"termName":"Shu Yu Wan","termGroup":"SY","termSource":"NCI"},{"termName":"Shuyu Wan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Shu Yu Wan Formula"},{"name":"NCI_Drug_Dictionary_ID","value":"768217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768217"},{"name":"PDQ_Open_Trial_Search_ID","value":"768217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897616"}]}}{"C1226":{"preferredName":"Sialyl Tn Antigen","code":"C1226","definitions":[{"definition":"A tumor-associated core-region carbohydrate antigen of epithelial mucin, expressed in most colon carcinoma, mucinous carcinoma, pancreatic cancer, gastric, lung, breast, and ovarian carcinoma. Sialosyl-Tn (STn) antigen has been shown to be highly sensitive and a specific marker of colorectal cancer, associated with more aggressive diseases and poor prognosis. STn antigen and its immediate precursor, Tn antigen, are mucin type glycoprotein structures associated with the earliest steps of mucin O-linked glycosylation. When combined with a carrier molecule, keyhole limpet hemocyanin (KLH), this antigen may be co-administered with oral cyclophosphamide as an immune modulator.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialyl Tn Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"CD175s","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl-Tn","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl-Tn Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"STn","termGroup":"AB","termSource":"NCI"},{"termName":"STn Antigen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sialyl_Tn_Antigen"},{"name":"Maps_To","value":"Sialyl Tn Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"41616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41616"},{"name":"PDQ_Open_Trial_Search_ID","value":"41616"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0074480"}]}}{"C1690":{"preferredName":"Sialyl Tn-KLH Vaccine","code":"C1690","definitions":[{"definition":"A vaccine composed of a substance that enhances immunity plus an antigen found on some tumors of the colon, breast, lung, ovary, pancreas, and stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialyl Tn-KLH Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Sialyl Tn-KLH","termGroup":"SY","termSource":"NCI"},{"termName":"STn-KLH Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Theratope","termGroup":"BR","termSource":"NCI"},{"termName":"Theratope siayl-Tn-KLH vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Theratope STn-KLH Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Theratope Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sialyl_Tn-KLH_Vaccine"},{"name":"Maps_To","value":"Sialyl Tn-KLH Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43279"},{"name":"PDQ_Open_Trial_Search_ID","value":"43279"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0388828"}]}}{"C156438":{"preferredName":"Sibrotuzumab","code":"C156438","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby sibrotuzumab has possible diagnostic and therapeutic applications in epithelial cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sibrotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Humanized F19 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"HuMoAb F19","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"216669-97-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"552U6E1NIW"},{"name":"Maps_To","value":"Sibrotuzumab"},{"name":"NCI_META_CUI","value":"CL563157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95772":{"preferredName":"siG12D LODER","code":"C95772","definitions":[{"definition":"A proprietary, miniature biodegradable polymeric matrix containing small-interfering RNAs for the mutated KRAS oncogene, KRASG12D, (siG12D), with potential antitumor activity. Upon intratumoral injection, this siG12D is released locally, thereby preventing translation of KRAS proteins and potentially inhibiting growth of tumor cells overexpressing KRAS. KRAS, a member of the small GTPase superfamily, is mutated in over 90% of human pancreatic ductal adenocarcinomas (PDAC) and is associated with tumor cell proliferation and reduced survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"siG12D LODER","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NNQ0PKZ9EV"},{"name":"Maps_To","value":"siG12D LODER"},{"name":"NCI_Drug_Dictionary_ID","value":"685237"},{"name":"NCI_META_CUI","value":"CL428214"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685237"},{"name":"PDQ_Open_Trial_Search_ID","value":"685237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64618":{"preferredName":"Silatecan AR-67","code":"C64618","definitions":[{"definition":"A synthetic, highly lipophilic derivative of camptothecin, with potential antineoplastic and radiosensitizing activities. 7-tert-butyldimethylsilyl-10-hydroxycamptothecin binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces lethal double-stranded DNA breaks when encountered by the DNA replication machinery, thereby inhibiting DNA replication and inducing apoptosis. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active lactone structure to an inactive carboxylate form. Modifications on the E ring of camptothecin prevent binding of human serum albumin, which prefers the inactive carboxylate form, thereby enhancing the stability of the active lactone structure and resulting in prolonged agent activity. In addition, this agent sensitizes tumor cells toward radiation treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silatecan AR-67","termGroup":"PT","termSource":"NCI"},{"termName":"7-t-butyldimethylsilyl-10-hydroxycamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"7-Tert-butyldimethylsilyl-10-hydroxycamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"AR-67","termGroup":"CN","termSource":"NCI"},{"termName":"DB-67","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220913-32-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3YEA04NV6H"},{"name":"Legacy Concept Name","value":"_7-Tert-butyldimethylsilyl-10-hydroxycamptothecin"},{"name":"Maps_To","value":"Silatecan AR-67"},{"name":"NCI_Drug_Dictionary_ID","value":"522726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"522726"},{"name":"PDQ_Open_Trial_Search_ID","value":"522726"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1955483"}]}}{"C152359":{"preferredName":"Silibinin","code":"C152359","synonyms":[{"termName":"Silibinin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1265089-69-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4RKY41TBTF"},{"name":"Maps_To","value":"Silibinin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0600334"}]}}{"C2651":{"preferredName":"Silicon Phthalocyanine 4","code":"C2651","definitions":[{"definition":"A substance being studied in the treatment of cancer. When absorbed by cancer cells and exposed to light, it becomes active and kills the cancer cells. It is a type of photodynamic therapy agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic photosensitizer agent containing a large macrocyclic ring chelated with silicon. Silicon phthalocyanine 4 localizes primarily in mitochondrial cytosolic membranes and, after photoexcitation, forms reactive oxygen species that induce apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silicon Phthalocyanine 4","termGroup":"PT","termSource":"NCI"},{"termName":"Pc-4 (Silicone phthalocyanine)","termGroup":"SY","termSource":"NCI"},{"termName":"Pc4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135719-28-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VM2R9Z8DTW"},{"name":"Legacy Concept Name","value":"Silicon_Phthalocyanine_4"},{"name":"Maps_To","value":"Silicon Phthalocyanine 4"},{"name":"NCI_Drug_Dictionary_ID","value":"38423"},{"name":"NSC Number","value":"676418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38423"},{"name":"PDQ_Open_Trial_Search_ID","value":"38423"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328695"}]}}{"C85460":{"preferredName":"Silmitasertib Sodium","code":"C85460","definitions":[{"definition":"The sodium salt form of silmitasertib, an orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and immunomodulatory activities. Upon oral administration, silmitasertib selectively binds to and inhibits the activity of CK2. This may inhibit proliferation of CK2-expressing tumor cells, and may also inhibit the replication of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). In addition, this may restore normal host cell cytokine regulation, prevent cytokine storm and suppress the hyperactivation of the innate immune system. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. CK2 regulates a diverse array of pro-survival cellular processes including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT/mTOR signaling, hedgehog (Hh) signaling, Hsp90 machinery, hypoxia, and interleukin (IL)-6 expression. CK2 also regulates the activity of XRCC1 and MDC1, two mediator/adaptor proteins that are essential for DNA repair. CK2 is upregulated by SARS-COV-2 and is associated with SARS-COV-2 viral replication and the development of cytokine storm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silmitasertib Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"5-((3-chlorophenyl)amino)-benzo(c)-2,6-naphthyridine-8-carboxylic Acid Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"CK2 Inhibitor CX-4945","termGroup":"SY","termSource":"NCI"},{"termName":"CX 4945 Sodium","termGroup":"CN","termSource":"NCI"},{"termName":"CX-4945 Sodium","termGroup":"CN","termSource":"NCI"},{"termName":"CX4945 Sodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1309357-15-0"},{"name":"Chemical_Formula","value":"C19H11ClN3O2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N1E607PU86"},{"name":"Maps_To","value":"Silmitasertib Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"643477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643477"},{"name":"PDQ_Open_Trial_Search_ID","value":"643477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830136"}]}}{"C61084":{"preferredName":"Siltuximab","code":"C61084","definitions":[{"definition":"A chimeric (made from human and mouse proteins) monoclonal antibody being studied in the treatment of advanced kidney cancer and other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-IL-6 chimeric monoclonal antibody works by blocking inflammation and tumor growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Siltuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-6 Chimeric Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"cCLB8","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO-328","termGroup":"CN","termSource":"NCI"},{"termName":"Sylvant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multicentric Castleman's disease (MCD)"},{"name":"CAS_Registry","value":"541502-14-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T4H8FMA7IM"},{"name":"Legacy Concept Name","value":"Anti-IL-6_Chimeric_Monoclonal_Antibody"},{"name":"Maps_To","value":"Siltuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"475765"},{"name":"NCI_META_CUI","value":"CL776663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"475765"},{"name":"PDQ_Open_Trial_Search_ID","value":"475765"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1227":{"preferredName":"Simalikalactone D","code":"C1227","definitions":[{"definition":"A quassinoid phytochemical isolated from Simaba multiflora, Quassia africana and other plant species with potential antineoplastic activity.  This agent also has antimalarial and antiviral properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simalikalactone D","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-ene-2,16-dione, 13,20-epoxy-1,11,12-trihydroxy-15-(2-methyl-1-oxobutoxy)-, (11beta)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"35321-80-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Simalikalactone_D"},{"name":"Maps_To","value":"Simalikalactone D"},{"name":"NSC Number","value":"266494"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074548"}]}}{"C129015":{"preferredName":"Simeprevir","code":"C129015","definitions":[{"definition":"An orally bioavailable inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with activity against HCV genotype 1. Upon administration, simeprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simeprevir","termGroup":"PT","termSource":"NCI"},{"termName":"HSDB 8227","termGroup":"CN","termSource":"NCI"},{"termName":"N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"Olysio","termGroup":"BR","termSource":"NCI"},{"termName":"TMC 435","termGroup":"CN","termSource":"NCI"},{"termName":"TMC-435","termGroup":"CN","termSource":"NCI"},{"termName":"TMC435","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923604-59-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9WS5RD66HZ"},{"name":"Maps_To","value":"Simeprevir"},{"name":"NCI_Drug_Dictionary_ID","value":"783151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783151"},{"name":"PDQ_Open_Trial_Search_ID","value":"783151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2605855"}]}}{"C116871":{"preferredName":"Simotaxel","code":"C116871","definitions":[{"definition":"A semi-synthetic, orally bioavailable, third-generation taxane derivative and microtubule-stabilizing agent, with potential antineoplastic activity. Upon administration, simotaxel binds to tubulin, promotes microtubule assembly and stabilization, and prevents microtubule depolymerization. This results in G2/M arrest, apoptosis and the inhibition of cell proliferation in susceptible tumor cells. This agent is a poor substrate for P-glycoprotein-related drug resistance mechanisms; therefore, it may be useful for treating multi-drug resistant tumors. MST-997 is more potent than paclitaxel and docetaxel and overcomes paclitaxel and docetaxel resistance in certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simotaxel","termGroup":"PT","termSource":"NCI"},{"termName":"5Beta,20-epoxy-1,2alpa,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one-4-acetate 2-benzoate Ester with (2R,3S)-N-Isopropoxycarbonyl-3-(2-thienyl) Isoserine","termGroup":"SN","termSource":"NCI"},{"termName":"MST-997","termGroup":"CN","termSource":"NCI"},{"termName":"Taxane-997","termGroup":"SY","termSource":"NCI"},{"termName":"TL-909","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"791635-59-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E1M30YOE59"},{"name":"Maps_To","value":"Simotaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"387809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"387809"},{"name":"PDQ_Open_Trial_Search_ID","value":"387809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541465"}]}}{"C91735":{"preferredName":"Simtuzumab","code":"C91735","definitions":[{"definition":"A humanized monoclonal antibody against lysyl oxidase-like 2 (LOXL2), with potential antineoplastic activity. Anti-LOXL2 monoclonal antibody GS 6624 targets and specifically binds to the scavenger receptor cysteine rich domain 4 (SRCR-4) on LOXL2, thereby preventing the crosslinking of collagen and inhibiting the recruitment and activation of fibroblasts. Inhibiting fibroblast activation and the subsequent production of growth factors and chemokines may lead to an inhibition of tumor cell proliferation. LOXL2, a member of the lysyl oxidase (LO) gene family, is an extracellular, copper-dependent enzyme overexpressed in a variety of tumor cell types, and contributes to tumor cell invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simtuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AB-0024","termGroup":"CN","termSource":"NCI"},{"termName":"AB0024","termGroup":"CN","termSource":"NCI"},{"termName":"GS 6624","termGroup":"CN","termSource":"NCI"},{"termName":"GS-6624","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1318075-13-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"11Z5AIU653"},{"name":"Maps_To","value":"Simtuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"681814"},{"name":"NCI_META_CUI","value":"CL421656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681814"},{"name":"PDQ_Open_Trial_Search_ID","value":"681814"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132992":{"preferredName":"Sintilimab","code":"C132992","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sintilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody IBI308","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDCD1 Monoclonal Antibody IBI308","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 308","termGroup":"CN","termSource":"NCI"},{"termName":"IBI308","termGroup":"CN","termSource":"NCI"},{"termName":"Tyvyt","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2072873-06-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8FU7FQ8UPK"},{"name":"Maps_To","value":"Sintilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"787603"},{"name":"NCI_META_CUI","value":"CL520576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787603"},{"name":"PDQ_Open_Trial_Search_ID","value":"787603"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38685":{"preferredName":"Siplizumab","code":"C38685","definitions":[{"definition":"A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of certain lymphoproliferative disorders and psoriasis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Siplizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human CD2 (Antigen))(Human-rat Monoclonal MEDI-507 G1-chain), Disulfide with Human-rat Monoclonal MEDI-507 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-507","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"T-cell lymphoma"},{"name":"CAS_Registry","value":"288392-69-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KUW1QG1ZM3"},{"name":"Legacy Concept Name","value":"Siplizumab"},{"name":"Maps_To","value":"Siplizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"346499"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346499"},{"name":"PDQ_Open_Trial_Search_ID","value":"346499"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328709"}]}}{"C1985":{"preferredName":"Sipuleucel-T","code":"C1985","definitions":[{"definition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat prostate cancer that has spread. It is made from immune system cells collected from a patient with prostate cancer. The cells are treated with a protein that is made by combining a protein found on prostate cancer cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate cancer cells. Provenge is a type of vaccine and a type of cellular adoptive immunotherapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sipuleucel-T","termGroup":"PT","termSource":"NCI"},{"termName":"APC8015","termGroup":"CN","termSource":"NCI"},{"termName":"APC8015 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Provenge","termGroup":"BR","termSource":"NCI"},{"termName":"SipT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917381-47-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"8Q622VDR18"},{"name":"Legacy Concept Name","value":"APC8015_Vaccine"},{"name":"Maps_To","value":"Sipuleucel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"38038"},{"name":"NSC Number","value":"720270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38038"},{"name":"PDQ_Open_Trial_Search_ID","value":"38038"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706668"}]}}{"C116353":{"preferredName":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401","code":"C116353","definitions":[{"definition":"Autologous peripheral blood mononuclear cells (PBMCs) transfected ex vivo with small-interfering ribonucleic acid (siRNA) directed against the E3 ubiquitin ligase casitas B-lineage lymphoma-b gene (Cbl-b), with potential immunoactivating and antineoplastic activities. The Cbl-b gene is silenced ex vivo through the binding of Cbl-b siRNA to Cbl-b mRNA, which prevents the translation of the Cbl-b protein in T-lymphocytes. Upon infusion, the activated, Cbl-b-silenced T-lymphocytes are able to increase the production of cytokines, proliferate and activate the immune system, which leads to cancer cell eradication. Cbl-b, a negative regulator of the immune system, is mutated in a variety of cancer cell types. Its expression is inversely correlated with activation of T-lymphocytes and tumor cell eradication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401","termGroup":"PT","termSource":"NCI"},{"termName":"APN401","termGroup":"CN","termSource":"NCI"},{"termName":"siRNA-transfected PBMC APN401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401"},{"name":"NCI_Drug_Dictionary_ID","value":"761870"},{"name":"NCI_META_CUI","value":"CL473671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761870"},{"name":"PDQ_Open_Trial_Search_ID","value":"761870"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1212":{"preferredName":"Sirolimus","code":"C1212","definitions":[{"definition":"A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamune blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamune was previously called rapamycin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirolimus","termGroup":"PT","termSource":"NCI"},{"termName":"9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2","termGroup":"SN","termSource":"NCI"},{"termName":"AY 22989","termGroup":"CN","termSource":"NCI"},{"termName":"RAPA","termGroup":"AB","termSource":"NCI"},{"termName":"Rapamune","termGroup":"BR","termSource":"NCI"},{"termName":"Rapamycin","termGroup":"SY","termSource":"NCI"},{"termName":"SILA 9268A","termGroup":"CN","termSource":"NCI"},{"termName":"WY-090217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Kidney transplant rejection, prevention"},{"name":"CAS_Registry","value":"53123-88-9"},{"name":"CHEBI_ID","value":"CHEBI:9168"},{"name":"Chemical_Formula","value":"C51H79NO13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"W36ZG6FT64"},{"name":"Legacy Concept Name","value":"Sirolimus"},{"name":"Maps_To","value":"Sirolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"42555"},{"name":"NSC Number","value":"226080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42555"},{"name":"PDQ_Open_Trial_Search_ID","value":"42555"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0072980"}]}}{"C125718":{"preferredName":"Ontorpacept","code":"C125718","definitions":[{"definition":"A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ontorpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ontorpacept","termGroup":"PT","termSource":"NCI"},{"termName":"SIRPa-Fc Fusion Protein TTI-621","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPaFc","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 621","termGroup":"CN","termSource":"NCI"},{"termName":"TTI-621","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2131089-46-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q8A4U1Z9N2"},{"name":"Maps_To","value":"Ontorpacept"},{"name":"Maps_To","value":"SIRPa-Fc Fusion Protein TTI-621"},{"name":"NCI_META_CUI","value":"CL504374"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150756":{"preferredName":"Maplirpacept","code":"C150756","definitions":[{"definition":"A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, maplirpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maplirpacept","termGroup":"PT","termSource":"NCI"},{"termName":"PF 07901801","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07901801","termGroup":"CN","termSource":"NCI"},{"termName":"PF07901801","termGroup":"CN","termSource":"NCI"},{"termName":"SIRPa-IgG4 Fc","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-IgG4 Fc TTI-622","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-IgG4-Fc Fusion Protein TTI-622","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 622","termGroup":"CN","termSource":"NCI"},{"termName":"TTI-622","termGroup":"CN","termSource":"NCI"},{"termName":"TTI622","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44D51T6SZH"},{"name":"Maps_To","value":"SIRPa-IgG4-Fc Fusion Protein TTI-622"},{"name":"NCI_Drug_Dictionary_ID","value":"793524"},{"name":"NCI_META_CUI","value":"CL552621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793524"},{"name":"PDQ_Open_Trial_Search_ID","value":"793524"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162553":{"preferredName":"Sitimagene Ceradenovec","code":"C162553","definitions":[{"definition":"A replication-deficient adenovirus type 5 (Ad5) with E1 and partial E3 deletions containing cDNA for the herpes simplex virus thymidine kinase (HSV-Tk), which, when administered in combination with ganciclovir (GCV), possesses potential antineoplastic activity. Following administration, transgene-expressing cells produce thymidine kinase, which phosphorylates GCV to ganciclovir triphosphate, a cytotoxic nucleotide analog that is incorporated into DNA resulting in chain termination and induction of apoptosis in rapidly dividing cells. This process spares normal neurons as they do not proliferate and are therefore not susceptible to the toxic effects of GCV metabolites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sitimagene Ceradenovec","termGroup":"PT","termSource":"NCI"},{"termName":"EG 009","termGroup":"CN","termSource":"NCI"},{"termName":"EG-009","termGroup":"CN","termSource":"NCI"},{"termName":"EG009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"898830-54-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sitimagene Ceradenovec"},{"name":"NCI_META_CUI","value":"CL971128"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117734":{"preferredName":"Sitravatinib","code":"C117734","definitions":[{"definition":"An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, sitravatinib binds to and inhibits the activity of several RTKs including hepatocyte growth factor receptor (HGFR; c-Met; MET), tyrosine-protein kinase receptor UFO (AXL receptor tyrosine kinase; AXL), mast/stem cell growth factor receptor (SCFR; c-kit; KIT), the receptor tyrosine kinase MER, discoidin domain receptor 2 (DDR2), vascular endothelial growth factor receptor (VEGFR) types 1 (VEGFR-1; FLT1), 2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3), members of the platelet-derived growth factor receptor (PDGFR) family, RET (rearranged during transfection), tropomyosin-related kinases (TRK) and members of the ephrin (Eph) family of receptor tyrosine kinases. This may result in both the inhibition of signal transduction pathways mediated by these RTKs and the reduction of tumor cell proliferation in cancer cell types that overexpress these RTKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sitravatinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N-(3-Fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-N'-(4-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"MGCD516","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1123837-84-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CWG62Q1VTB"},{"name":"Maps_To","value":"Sitravatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"764051"},{"name":"NCI_META_CUI","value":"CL474129"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764051"},{"name":"PDQ_Open_Trial_Search_ID","value":"764051"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61305":{"preferredName":"Sivifene","code":"C61305","definitions":[{"definition":"The phenylhydrazone 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone formulated as a topical agent with immunomodulating and potential antineoplastic activities. Applied topically as a gel, sivifene may stimulate a local immune response against human papillomavirus (HPV)-induced cervical intraepithelial neoplasia (CIN).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sivifene","termGroup":"PT","termSource":"NCI"},{"termName":"4,4'-Dihydroxybenzophenone 2,4-dinitrophenylhydrazone","termGroup":"SY","termSource":"NCI"},{"termName":"A-007","termGroup":"AB","termSource":"NCI"},{"termName":"Aryl Hydrazone A-007 Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2675-35-6"},{"name":"Chemical_Formula","value":"C19H14N4O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XAV05295I5"},{"name":"Legacy Concept Name","value":"A-007"},{"name":"Maps_To","value":"Sivifene"},{"name":"NCI_Drug_Dictionary_ID","value":"485274"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485274"},{"name":"PDQ_Open_Trial_Search_ID","value":"485274"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385861"}]}}{"C824":{"preferredName":"Sizofiran","code":"C824","definitions":[{"definition":"A soluble beta-D-glucan produced by the Basidiomycetes fungus, Schizophyllum commune Fries, with potential immunomodulating and antitumor activities. Although sizofiran's exact mechanism of action has yet to be fully elucidated, this agent appears to stimulate the immune system by increasing cytokine production, activating macrophages and enhancing the activity of polymorphonuclear leukocytes (PML) and natural killer (NK) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sizofiran","termGroup":"PT","termSource":"NCI"},{"termName":"MC-Glucan","termGroup":"BR","termSource":"NCI"},{"termName":"Poly(3-(O-beta-D-glucopyranosyl-(1-3)-O-(beta-D-glucopyranosyl-(1-6))-O-beta-D-glucopyranosyl-(1-3)-O-beta-D-glucopyranosyl)-1)","termGroup":"SN","termSource":"NCI"},{"termName":"Schizophyllan","termGroup":"SY","termSource":"NCI"},{"termName":"Schizophyllan","termGroup":"BR","termSource":"NCI"},{"termName":"Schizophyllane","termGroup":"SY","termSource":"NCI"},{"termName":"Sixofilan","termGroup":"BR","termSource":"NCI"},{"termName":"Sonifilan","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9050-67-3"},{"name":"CHEBI_ID","value":"CHEBI:50653"},{"name":"Chemical_Formula","value":"(C24H38O19)n"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7F763NNC9X"},{"name":"Legacy Concept Name","value":"Sizofiran"},{"name":"Maps_To","value":"Sizofiran"},{"name":"NCI_Drug_Dictionary_ID","value":"752996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752996"},{"name":"PDQ_Open_Trial_Search_ID","value":"752996"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0036359"}]}}{"C153354":{"preferredName":"Ompenaclid","code":"C153354","definitions":[{"definition":"An orally available, small molecule inhibitor of the creatine transporter, solute carrier family 6, member 8 (SLC6a8), with potential antineoplastic activity. Upon oral administration, ompenaclid inhibits phosphocreatine uptake by SLC6a8, thereby reducing intracellular levels of phosphocreatine available for ATP synthesis in tumor cells. SLC6a8 is overexpressed in some cancer types and inhibition of its activity may potentially limit tumor cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ompenaclid","termGroup":"PT","termSource":"NCI"},{"termName":"RGX 202","termGroup":"CN","termSource":"NCI"},{"termName":"RGX-202","termGroup":"CN","termSource":"NCI"},{"termName":"RGX-202-01","termGroup":"CN","termSource":"NCI"},{"termName":"RGX202","termGroup":"CN","termSource":"NCI"},{"termName":"SLC6A8 Inhibitor RGX-202","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"353-09-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UL1984YRKA"},{"name":"Maps_To","value":"SLC6A8 Inhibitor RGX-202"},{"name":"NCI_Drug_Dictionary_ID","value":"794147"},{"name":"NCI_META_CUI","value":"CL554455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794147"},{"name":"PDQ_Open_Trial_Search_ID","value":"794147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C184909":{"preferredName":"Ezurpimtrostat","code":"C184909","definitions":[{"definition":"An orally bioavailable, quinolone-derived, small molecule inhibitor of palmitoyl-protein thioesterase 1 (PPT1), with potential antineoplastic activity. Upon oral administration, ezurpimtrostat targets and inhibits the activity of PPT1 and induces lysosomal disruption, which results in the inhibition of autophagy and the induction of apoptosis via caspase activation. This may inhibit tumor cell proliferation and tumor growth. PPT1, a lysosomal thioesterase that plays an important role in lysosomal function and autophagy, is overexpressed in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ezurpimtrostat","termGroup":"PT","termSource":"NCI"},{"termName":"GNS 561","termGroup":"CN","termSource":"NCI"},{"termName":"GNS-561","termGroup":"CN","termSource":"NCI"},{"termName":"GNS561","termGroup":"CN","termSource":"NCI"},{"termName":"SLCT Inhibitor GNS561","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1914148-72-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MS6LGW5JFK"},{"name":"Maps_To","value":"SLCT Inhibitor GNS561"},{"name":"NCI_Drug_Dictionary_ID","value":"794352"},{"name":"NCI_META_CUI","value":"CL555353"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150507":{"preferredName":"SMAC Mimetic BI 891065","code":"C150507","definitions":[{"definition":"A mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins), with potential antineoplastic activity. Upon administration, Smac mimetic BI 891065 targets and binds to the Smac binding groove on IAPs, including the caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting certain caspases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAC Mimetic BI 891065","termGroup":"PT","termSource":"NCI"},{"termName":"BI 891065","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SMAC Mimetic BI 891065"},{"name":"NCI_Drug_Dictionary_ID","value":"793013"},{"name":"NCI_META_CUI","value":"CL552291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793013"},{"name":"PDQ_Open_Trial_Search_ID","value":"793013"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88274":{"preferredName":"Smac Mimetic GDC-0152","code":"C88274","definitions":[{"definition":"A second mitochondrial activator of caspases (Smac) mimetic inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0152 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2, which may inhibit their activities and promote the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains. Smac, the endogenous IAP antagonist, relies on its N-terminal four amino-acid motif for binding to IAPs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smac Mimetic GDC-0152","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0152","termGroup":"CN","termSource":"NCI"},{"termName":"IAP Antagonist GDC-0152","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"873652-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4KW1M48SHS"},{"name":"Maps_To","value":"Smac Mimetic GDC-0152"},{"name":"NCI_Drug_Dictionary_ID","value":"655953"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655953"},{"name":"PDQ_Open_Trial_Search_ID","value":"655953"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981796"}]}}{"C103825":{"preferredName":"Smac Mimetic GDC-0917","code":"C103825","definitions":[{"definition":"An orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0917 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smac Mimetic GDC-0917","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC 427","termGroup":"CN","termSource":"NCI"},{"termName":"CUDC-427","termGroup":"CN","termSource":"NCI"},{"termName":"CUDC427","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0917","termGroup":"CN","termSource":"NCI"},{"termName":"IAP Antagonist GDC-0917","termGroup":"SY","termSource":"NCI"},{"termName":"L-Prolinamide, N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-(2-(2-oxazolyl)-4-phenyl-5-thiazolyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"RG 7459","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7459","termGroup":"CN","termSource":"NCI"},{"termName":"RG7459","termGroup":"CN","termSource":"NCI"},{"termName":"SMAC/DIABLO Mimetic GDC-0917","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446182-94-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KWH46ZDG32"},{"name":"Maps_To","value":"Smac Mimetic GDC-0917"},{"name":"NCI_Drug_Dictionary_ID","value":"688091"},{"name":"NCI_META_CUI","value":"CL433733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688091"},{"name":"PDQ_Open_Trial_Search_ID","value":"688091"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91079":{"preferredName":"Smac Mimetic LCL161","code":"C91079","definitions":[{"definition":"An orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity. SMAC mimetic LCL161 binds to IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding and inhibiting active caspases-3, -7 and -9, which play essential roles in apoptosis (programmed cell death), necrosis and inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smac Mimetic LCL161","termGroup":"PT","termSource":"NCI"},{"termName":"LCL161","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005342-46-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6TNS415Y3P"},{"name":"Maps_To","value":"Smac Mimetic LCL161"},{"name":"NCI_Drug_Dictionary_ID","value":"670651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670651"},{"name":"PDQ_Open_Trial_Search_ID","value":"670651"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984020"}]}}{"C159535":{"preferredName":"SMO Protein Inhibitor ZSP1602","code":"C159535","definitions":[{"definition":"An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMO Protein Inhibitor ZSP1602","termGroup":"PT","termSource":"NCI"},{"termName":"Smoothened Inhibitor ZSP1602","termGroup":"SY","termSource":"NCI"},{"termName":"ZSP 1602","termGroup":"CN","termSource":"NCI"},{"termName":"ZSP-1602","termGroup":"CN","termSource":"NCI"},{"termName":"ZSP1602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Smoothened_Antagonist_BMS-833923"},{"name":"Maps_To","value":"SMO Protein Inhibitor ZSP1602"},{"name":"NCI_Drug_Dictionary_ID","value":"797467"},{"name":"NCI_META_CUI","value":"CL951429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797467"},{"name":"PDQ_Open_Trial_Search_ID","value":"797467"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77861":{"preferredName":"Smoothened Antagonist BMS-833923","code":"C77861","definitions":[{"definition":"An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist BMS-833923","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-833923","termGroup":"CN","termSource":"NCI"},{"termName":"Smoothened Antagonist BMS-833923","termGroup":"SY","termSource":"NCI"},{"termName":"XL139","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"483ONS63WN"},{"name":"Legacy Concept Name","value":"Smoothened_Antagonist_BMS-833923"},{"name":"Maps_To","value":"Smoothened Antagonist BMS-833923"},{"name":"NCI_Drug_Dictionary_ID","value":"596304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596304"},{"name":"PDQ_Open_Trial_Search_ID","value":"596304"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699316"}]}}{"C88337":{"preferredName":"Smoothened Antagonist LDE225 Topical","code":"C88337","definitions":[{"definition":"A topical formulation of the small-molecule Smoothened (Smo) antagonist LDE225 with potential antineoplastic activity. Upon topical application, smoothened antagonist LDE225 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist LDE225 Topical","termGroup":"PT","termSource":"NCI"},{"termName":"LDE225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoothened Antagonist LDE225 Topical"},{"name":"NCI_Drug_Dictionary_ID","value":"662542"},{"name":"NCI_META_CUI","value":"CL413601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662542"},{"name":"PDQ_Open_Trial_Search_ID","value":"662542"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91089":{"preferredName":"Smoothened Antagonist LEQ506","code":"C91089","definitions":[{"definition":"An orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Smoothened antagonist LEQ506 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway, thereby inhibiting tumor cell growth. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Dysregulated activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist LEQ506","termGroup":"PT","termSource":"NCI"},{"termName":"LEQ506","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204975-42-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SJX1T5HJD"},{"name":"Maps_To","value":"Smoothened Antagonist LEQ506"},{"name":"NCI_Drug_Dictionary_ID","value":"671850"},{"name":"NCI_META_CUI","value":"CL421477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671850"},{"name":"PDQ_Open_Trial_Search_ID","value":"671850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116874":{"preferredName":"Smoothened Antagonist TAK-441","code":"C116874","definitions":[{"definition":"An orally bioavailable pyrrolopyridine derivative and Smoothened (Smo) antagonist with potential antineoplastic activity. Smo antagonist TAK-441 selectively binds to and inhibits the activity Smo, which is a cell surface co-receptor for ligands in the Hedgehog (Hh) family. This may result in a suppression of Hh-mediated signaling pathways, thereby inhibiting the growth of tumor cells in which this pathway is aberrantly activated.  Smo is a G-protein coupled receptor that lies just downstream of the Hh cell surface receptor Patched-1 in the Hh pathway; in the absence of ligand, Patched-1 (Ptch1) inhibits Smo, and ligand binding to Ptch1 results in increased levels of Smo. The Hh-mediated signaling pathways play an important role in cellular growth and differentiation, and tissue repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist TAK-441","termGroup":"PT","termSource":"NCI"},{"termName":"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"TAK-441","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1186231-83-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CY3QT94KWP"},{"name":"Maps_To","value":"Smoothened Antagonist TAK-441"},{"name":"NCI_Drug_Dictionary_ID","value":"686270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686270"},{"name":"PDQ_Open_Trial_Search_ID","value":"686270"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660685"}]}}{"C71521":{"preferredName":"SN-38-Loaded Polymeric Micelles NK012","code":"C71521","definitions":[{"definition":"A formulation consisting of polymeric micelles loaded with the irinotecan metabolite SN-38 with potential antineoplastic activity. SN-38-loaded polymeric micelles NK012 is an SN-38-releasing nanodevice constructed by covalently attaching SN-38 to the block copolymer PEG-PGlu, followed by self-assembly of amphiphilic block copolymers in an aqueous milieu. SN-38 (7-ethyl-10-hydroxy-camptothecin), a biological active metabolite of the prodrug irinotecan (CPT-11), binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. SN-38 has been reported to exhibit up to 1,000-fold more cytotoxic activity against various cancer cells in vitro than irinotecan. This formulation increases the water-solubility of SN-38 and allows the delivery of higher doses of SN-38 than those achievable with SN-38 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SN-38-Loaded Polymeric Micelles NK012","termGroup":"PT","termSource":"NCI"},{"termName":"NK012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SN-38-Loaded_Polymeric_Micelle"},{"name":"Maps_To","value":"SN-38-Loaded Polymeric Micelles NK012"},{"name":"NCI_Drug_Dictionary_ID","value":"574615"},{"name":"NCI_META_CUI","value":"CL376227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574615"},{"name":"PDQ_Open_Trial_Search_ID","value":"574615"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98288":{"preferredName":"SNS01-T Nanoparticles","code":"C98288","definitions":[{"definition":"A colloidal mixture of nanoparticles consisting of small interfering RNA (siRNA) targeting the native eukaryotic translation initiation factor 5A (eIF5A), plasmids expressing a pro-apoptotic mutant of elF5A under the control of a B-cell specific promoter (B29), and a synthetic cationic polymer polyethylenimine (PEI) as a delivery vehicle, with potential antineoplastic activity. Upon administration, the siRNA component of SNS01-T suppresses elF5A expression, thereby interfering with translation of eIF5A and reducing levels of hypusinated elF5A in cancer cells. In turn, this inhibits activation of the transcription factor NF-kB and induces apoptosis. In addition, the B-cell specific plasmid component expresses an arginine substituted form of eIF5A, eIF5AK50R, which can not be hypusinated, thus leads to a selective induction of apoptosis in B-cells. The native unhypusinated form of eIF5A is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (DHS) and subsequently deoxyhypusine hydroxylase (DHH), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. The delivery vehicle protects the siRNA and plasmid from degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SNS01-T Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"SNS01-T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SNS01-T Nanoparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"712786"},{"name":"NCI_META_CUI","value":"CL432406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712786"},{"name":"PDQ_Open_Trial_Search_ID","value":"712786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66540":{"preferredName":"Sobuzoxane","code":"C66540","definitions":[{"definition":"The orally available active prodrug of ICRF-154, a bisdioxopiperazine derivative, with cardioprotective and antineoplastic activities. Like other ICRF compounds, sobuzoxane and its active metabolite ICRF-154 interfere with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition. Furthermore, sobuzoxane chelates metal cations thereby limiting the formation of free radical-generating anthracycline-metal complexes and may prevent anthracycline-induced oxidative damage to cardiac and soft tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sobuzoxane","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Bis(4-isobutoxycarbonyloxymethyl-3,5-dioxo-piperazin-1-yl)ethane","termGroup":"SN","termSource":"NCI"},{"termName":"MST-16","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98631-95-9"},{"name":"Chemical_Formula","value":"C22H34N4O10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1308VH37P"},{"name":"Legacy Concept Name","value":"Sobuzoxane"},{"name":"Maps_To","value":"Sobuzoxane"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0378253"}]}}{"C2208":{"preferredName":"Sodium Borocaptate","code":"C2208","definitions":[{"definition":"A boron-carrying compound. After parenteral administration, sodium borocaptate accumulates preferentially in tumor cells. When exposed to neutron irradiation, borocaptate absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance used in a type of radiation therapy called boron neutron capture therapy. Sodium borocaptate is injected into a vein and becomes concentrated in tumor cells. The patient then receives radiation treatment with atomic particles called neutrons. The neutrons react with the boron in sodium borocaptate and make radioactive particles that kill the tumor cells without harming normal cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sodium Borocaptate","termGroup":"PT","termSource":"NCI"},{"termName":"Borocaptate Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Borocarpin","termGroup":"FB","termSource":"NCI"},{"termName":"BSH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80-17-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Borocaptate_Sodium"},{"name":"Maps_To","value":"Sodium Borocaptate"},{"name":"NCI_Drug_Dictionary_ID","value":"306451"},{"name":"NSC Number","value":"643"},{"name":"PDQ_Closed_Trial_Search_ID","value":"306451"},{"name":"PDQ_Open_Trial_Search_ID","value":"306451"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127575"}]}}{"C2337":{"preferredName":"Sodium Butyrate","code":"C2337","definitions":[{"definition":"The sodium salt of butyrate with potential antineoplastic activity. Butyrate, a short chain fatty acid, competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). This binding affects hyperacetylation of histones, resulting in a modified DNA conformation, which subsequently leads to the uncoiling or relaxing of chromatin. Enhanced accessibility of chromatin to transcription-regulatory complexes leads to increased transcriptional activation of various epigenetically suppressed genes. Butyrate, a HDAC inhibitor, induces cell cycle arrest in G1 or G2/M and also increases the expression of other genes and proteins involved in cellular differentiation and apoptotic signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Butyrate","termGroup":"PT","termSource":"NCI"},{"termName":"Butyrate","termGroup":"SY","termSource":"NCI"},{"termName":"butyric acid, sodium salt","termGroup":"SY","termSource":"NCI"},{"termName":"sodium butanoate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156-54-7"},{"name":"CHEBI_ID","value":"CHEBI:64103"},{"name":"Chemical_Formula","value":"C4H7O2.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8RAS91C36W"},{"name":"Legacy Concept Name","value":"Sodium_Butyrate"},{"name":"Maps_To","value":"Sodium Butyrate"},{"name":"NCI_Drug_Dictionary_ID","value":"39601"},{"name":"NSC Number","value":"174280"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39601"},{"name":"PDQ_Open_Trial_Search_ID","value":"39601"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0142812"}]}}{"C73591":{"preferredName":"Sodium Dichloroacetate","code":"C73591","definitions":[{"definition":"The sodium salt of dichloroacetic acid with potential antineoplastic activity. Dichloroacetate ion inhibits pyruvate dehydrogenase kinase, resulting in the inhibition of glycolysis and a decrease in lactate production. This agent may stimulate apoptosis in cancer cells by restoring normal mitochondrial-induced apoptotic signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Dichloroacetate","termGroup":"PT","termSource":"NCI"},{"termName":"CPC 211","termGroup":"CN","termSource":"NCI"},{"termName":"Dichloroacetic Acid, Sodium Salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2156-56-1"},{"name":"Chemical_Formula","value":"C2HCl2O2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42932X67B5"},{"name":"Legacy Concept Name","value":"Sodium_Dichloroacetate"},{"name":"Maps_To","value":"Sodium Dichloroacetate"},{"name":"NCI_Drug_Dictionary_ID","value":"582893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"582893"},{"name":"PDQ_Open_Trial_Search_ID","value":"582893"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0037501"}]}}{"C47725":{"preferredName":"Sodium Iodide I-131","code":"C47725","definitions":[{"definition":"A radiopharmaceutical containing the beta- and gamma-emitting radioisotope I-131. After absorption, the iodide is distributed through the extracellular fluid of the body and accumulates in the thyroid gland, thereby allowing the imaging of the thyroid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Iodide I-131","termGroup":"PT","termSource":"NCI"},{"termName":"(131-I)Sodium Iodide","termGroup":"SY","termSource":"NCI"},{"termName":"HICON","termGroup":"BR","termSource":"NCI"},{"termName":"I 131 Mini","termGroup":"SY","termSource":"NCI"},{"termName":"Iodotope I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Natrium Radio-iodatum(131 I)","termGroup":"SY","termSource":"NCI"},{"termName":"Oriodide","termGroup":"SY","termSource":"NCI"},{"termName":"Radiocaps-131","termGroup":"SY","termSource":"NCI"},{"termName":"Sodium Iodide (131I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7790-26-3"},{"name":"Chemical_Formula","value":"I.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29VCO8ACHH"},{"name":"Legacy Concept Name","value":"Sodium_Iodide_I-131"},{"name":"Maps_To","value":"Sodium Iodide I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"721984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721984"},{"name":"PDQ_Open_Trial_Search_ID","value":"721984"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0304982"}]}}{"C91098":{"preferredName":"Sodium Metaarsenite","code":"C91098","definitions":[{"definition":"A highly soluble, orally available trivalent arsenic-containing telomerase inhibitor with potential antitumor activity. Although the exact mechanism through which sodium metaarsenite exerts its effect has yet to be fully elucidated, this agent appears to target and bind to telomeric sequences, specifically TTAGGG repeats, leading to a shortening of telomeres, and subsequent induction of apoptosis and inhibition of tumor cell growth. In addition, sodium metaarsenite also leads to the translocation of the catalytic subunit of telomerase into the cytoplasm and inhibition of the activity of telomerase. Telomerase is active in most tumors cells and is responsible for the maintenance of telomere length and plays a key role in cellular proliferation, but is quiescent in normal, healthy cells. The susceptibility to sodium metaarsenite seems to be inversely correlated with initial length of telomeres.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Metaarsenite","termGroup":"PT","termSource":"NCI"},{"termName":"KML-001","termGroup":"CN","termSource":"NCI"},{"termName":"Sodium Arsenite","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7784-46-5"},{"name":"CHEBI_ID","value":"CHEBI:29678"},{"name":"Chemical_Formula","value":"AsO2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48OVY2OC72"},{"name":"Maps_To","value":"Sodium Metaarsenite"},{"name":"NCI_Drug_Dictionary_ID","value":"672554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672554"},{"name":"PDQ_Open_Trial_Search_ID","value":"672554"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074719"}]}}{"C1440":{"preferredName":"Sodium Phenylbutyrate","code":"C1440","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called differentiating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Phenylbutyrate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Phenylbutyric Acid, Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Buphenyl","termGroup":"BR","termSource":"NCI"},{"termName":"Phenylbutyrate Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Sodium 4-Phenylbutyrate","termGroup":"SN","termSource":"NCI"},{"termName":"SPB11","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adjunctive therapy for urea cycle disorders involving deficiencies of carbamoylphosphate synthetase; ornithine transcarbamylase; or argininosuccinic acid synthetase; S-S and S-C sickle cell disease; S-thalassemia hemoglobinopathy"},{"name":"CAS_Registry","value":"1716-12-7"},{"name":"Chemical_Formula","value":"C10H11O2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NT6K61736T"},{"name":"Legacy Concept Name","value":"_4-Phenylbutyrate"},{"name":"Maps_To","value":"Sodium Phenylbutyrate"},{"name":"NCI_Drug_Dictionary_ID","value":"536018"},{"name":"NSC Number","value":"657802"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536018"},{"name":"PDQ_Open_Trial_Search_ID","value":"536018"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0718066"}]}}{"C834":{"preferredName":"Sodium Salicylate","code":"C834","definitions":[{"definition":"A drug that is a type of nonsteroidal anti-inflammatory drug. Sodium salicylate may be tolerated by people who are sensitive to aspirin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of salicylic acid. As a nonsteroidal anti-inflammatory drug (NSAID), sodium salicylate irreversibly acetylates cyclooxygenases I and II, thereby inhibiting prostaglandin synthesis and associated inflammation and pain.  This agent may also activate mitogen-activated protein kinase (p38MAPK), thereby inducing apoptosis in cancer cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Salicylate","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic acid, 2-hydroxy-, monosodium salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Fever; Inflammatory conditions; Pain"},{"name":"CAS_Registry","value":"54-21-7"},{"name":"Chemical_Formula","value":"C7H5O3.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WIQ1H85SYP"},{"name":"Legacy Concept Name","value":"Sodium_Salicylate"},{"name":"Maps_To","value":"Sodium Salicylate"},{"name":"NCI_Drug_Dictionary_ID","value":"43094"},{"name":"NSC Number","value":"202167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43094"},{"name":"PDQ_Open_Trial_Search_ID","value":"43094"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0037549"}]}}{"C87346":{"preferredName":"Sodium Selenite","code":"C87346","definitions":[{"definition":"An inorganic form of the trace element selenium with potential antineoplastic activity. Selenium, administered in the form of sodium selenite, is reduced to hydrogen selenide (H2Se) in the presence of glutathione (GSH) and subsequently generates superoxide radicals upon reaction with oxygen. This may inhibit the expression and activity of the transcription factor Sp1; in turn Sp1 down-regulates androgen receptor (AR) expression and blocks AR signaling. Eventually, selenium may induce apoptosis in prostate cancer cells and inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Selenite","termGroup":"PT","termSource":"NCI"},{"termName":"Disodium Selenium Trioxide","termGroup":"SY","termSource":"NCI"},{"termName":"Selenious Acid Disodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Selenious Acid, Sodium Salt (1:2)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10102-18-8"},{"name":"CHEBI_ID","value":"CHEBI:48843"},{"name":"Chemical_Formula","value":"2Na.O3Se"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HIW548RQ3W"},{"name":"Maps_To","value":"Sodium Selenite"},{"name":"NCI_Drug_Dictionary_ID","value":"681583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681583"},{"name":"PDQ_Open_Trial_Search_ID","value":"681583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0142923"}]}}{"C61083":{"preferredName":"Sodium Stibogluconate","code":"C61083","definitions":[{"definition":"A substance being studied in the treatment of certain solid tumors, lymphoma, and myeloma. Sodium stibogluconate may block enzymes needed for cancer growth. It is a type of pentavalent antimonial.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phosphorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Stibogluconate","termGroup":"PT","termSource":"NCI"},{"termName":"Antimony Sodium Gluconate","termGroup":"SY","termSource":"NCI"},{"termName":"Lenocta","termGroup":"BR","termSource":"NCI"},{"termName":"Myostibin","termGroup":"FB","termSource":"NCI"},{"termName":"Pentostam","termGroup":"FB","termSource":"NCI"},{"termName":"Solustibosan","termGroup":"FB","termSource":"NCI"},{"termName":"Solustin","termGroup":"FB","termSource":"NCI"},{"termName":"SSG","termGroup":"AB","termSource":"NCI"},{"termName":"VQD001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12001-86-4"},{"name":"CAS_Registry","value":"16037-91-5"},{"name":"CHEBI_ID","value":"CHEBI:28148"},{"name":"Chemical_Formula","value":"C12H18O17Sb2.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V083S0159D"},{"name":"Legacy Concept Name","value":"Sodium_Stibogluconate"},{"name":"Maps_To","value":"Sodium Stibogluconate"},{"name":"NCI_Drug_Dictionary_ID","value":"475763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"475763"},{"name":"PDQ_Open_Trial_Search_ID","value":"475763"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030895"}]}}{"C156728":{"preferredName":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108","code":"C156728","definitions":[{"definition":"A small-molecule, inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with potential antineoplastic activity. Upon administration, RX108 inhibits the activity of the Na+/K+-ATPase, which prevents the activation of various signal transduction pathways that play a key role in tumor proliferation. This may lead to cell-cycle arrest, apoptosis, and autophagic cell death. Na+/K+-ATPase is overexpressed in certain tumor types and may serve as a scaffold for the assembly of multiple-protein signaling complexes that regulate cell proliferation and motility. In normal, healthy cells, the Na+/K+-ATPase controls transportation of Na+ and K+ across the cell membrane and is essential for electrochemical gradient maintenance, osmotic balance, and cellular pH.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108","termGroup":"PT","termSource":"NCI"},{"termName":"Na+/K+-ATPase Inhibitor RX108","termGroup":"SY","termSource":"NCI"},{"termName":"RX 108","termGroup":"CN","termSource":"NCI"},{"termName":"RX-108","termGroup":"CN","termSource":"NCI"},{"termName":"RX108","termGroup":"CN","termSource":"NCI"},{"termName":"Sodium-Potassium Pump Inhibitor RX10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108"},{"name":"NCI_Drug_Dictionary_ID","value":"795834"},{"name":"NCI_META_CUI","value":"CL935853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795834"},{"name":"PDQ_Open_Trial_Search_ID","value":"795834"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106119":{"preferredName":"Sofituzumab Vedotin","code":"C106119","definitions":[{"definition":"An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of sofituzumab vedotin selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sofituzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"DMUC5754A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1418200-58-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2X3CKG601L"},{"name":"Maps_To","value":"Sofituzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"699480"},{"name":"NCI_META_CUI","value":"CL433830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699480"},{"name":"PDQ_Open_Trial_Search_ID","value":"699480"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77854":{"preferredName":"Solitomab","code":"C77854","definitions":[{"definition":"A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating and antineoplastic activities. Solitomab attaches to both CD3-expressing T lymphocytes and EpCAM-expressing tumor cells, thereby selectively cross-linking tumor and T lymphocytes; this may result in the recruitment of cytotoxic T lymphocytes (CTL) to T lymphocyte/tumor cell aggregates and the CTL-mediated death of EpCAM-expressing tumor cells. CD3 is an antigen expressed on mature T cells; EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EpCAM BiTE","termGroup":"AB","termSource":"NCI"},{"termName":"MT110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005198-65-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZQQ51B5708"},{"name":"Legacy Concept Name","value":"Anti-EpCAM_Anti-CD3_Recombinant_Bispecific_Monoclonal_Antibody_MT110"},{"name":"Maps_To","value":"Solitomab"},{"name":"NCI_Drug_Dictionary_ID","value":"592863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592863"},{"name":"PDQ_Open_Trial_Search_ID","value":"592863"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642415"}]}}{"C78195":{"preferredName":"Sonepcizumab","code":"C78195","definitions":[{"definition":"A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonepcizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Asonep","termGroup":"BR","termSource":"NCI"},{"termName":"LT1009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1031360-18-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O4T5UXS4P2"},{"name":"Legacy Concept Name","value":"Sonepcizumab"},{"name":"Maps_To","value":"Sonepcizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"595163"},{"name":"NCI_META_CUI","value":"CL383585"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595163"},{"name":"PDQ_Open_Trial_Search_ID","value":"595163"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82385":{"preferredName":"Sonidegib","code":"C82385","definitions":[{"definition":"An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonidegib","termGroup":"PT","termSource":"NCI"},{"termName":"(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-","termGroup":"SN","termSource":"NCI"},{"termName":"Erismodegib","termGroup":"SY","termSource":"NCI"},{"termName":"LDE-225","termGroup":"CN","termSource":"NCI"},{"termName":"LDE225","termGroup":"CN","termSource":"NCI"},{"termName":"Odomzo","termGroup":"BR","termSource":"NCI"},{"termName":"Smoothened Antagonist LDE225","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced basal cell carcinoma (BCC)"},{"name":"CAS_Registry","value":"956697-53-3"},{"name":"Chemical_Formula","value":"C26H26F3N3O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0RLU3VTK5M"},{"name":"Legacy Concept Name","value":"Oral_Smoothened_Antagonist_LDE225"},{"name":"Maps_To","value":"Sonidegib"},{"name":"NCI_Drug_Dictionary_ID","value":"641974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641974"},{"name":"PDQ_Open_Trial_Search_ID","value":"641974"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830069"}]}}{"C78848":{"preferredName":"Sonolisib","code":"C78848","definitions":[{"definition":"A small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonolisib","termGroup":"PT","termSource":"NCI"},{"termName":"(4E)-4-(((Bis(prop-2-en-1-yl)amino)methylidene)-6-hydroxy-1alpha-(methoxymethyl)-3,7,17-trioxo-2-oxaandrosta-5,8-dien-11alpha-yl Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"acetic acid (1S,4E,10R,11R,13S,14R)-4-diallylaminomethylene-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,3,4,7,10,11,12,13,14,15,16,17-dodecahydro-2-oxa-cyclopenta[a]phenanthren-11-yl ester","termGroup":"SN","termSource":"NCI"},{"termName":"acetic acid 4-diallylaminomethylene-6-hydroxy-1-alpha 12-methoxymethyl-10beta,13beta-dimethyl-3,7,17-trioxo-1,3,4,7,10,11beta,12,13,14alpha,15,16,17-dodecahydro-2-oxa-cyclopenta[a]phenanthren-11-yl ester","termGroup":"SN","termSource":"NCI"},{"termName":"PX 866","termGroup":"CN","termSource":"NCI"},{"termName":"PX-866","termGroup":"CN","termSource":"NCI"},{"termName":"PX866","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"502632-66-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"987796874T"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_PX-866"},{"name":"Maps_To","value":"Sonolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"612038"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612038"},{"name":"PDQ_Open_Trial_Search_ID","value":"612038"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566038"}]}}{"C61948":{"preferredName":"Sorafenib","code":"C61948","definitions":[{"definition":"A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Sorafenib stops cells from dividing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"BA4 43 9006","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 43-9006","termGroup":"CN","termSource":"NCI"},{"termName":"Bay-439006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"284461-73-0"},{"name":"CHEBI_ID","value":"CHEBI:50924"},{"name":"Chemical_Formula","value":"C21H16ClF3N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"9ZOQ3TZI87"},{"name":"Legacy Concept Name","value":"Sorafenib"},{"name":"Maps_To","value":"Sorafenib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516119"}]}}{"C2194":{"preferredName":"Sorafenib Tosylate","code":"C2194","definitions":[{"definition":"A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Nexavar stops cells from dividing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorafenib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic Acid Methyamide-4-methylbenzenesulfonate Tosylate","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 43-9006 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 54-9085","termGroup":"CN","termSource":"NCI"},{"termName":"Nexavar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced renal cell carcinoma; Metastatic Colorectal Cancer"},{"name":"Accepted_Therapeutic_Use_For","value":"Major Depressive Disorder"},{"name":"CAS_Registry","value":"475207-59-1"},{"name":"CHEBI_ID","value":"CHEBI:50928"},{"name":"Chemical_Formula","value":"C21H16ClF3N4O3.C7H8O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5T62Q3B36J"},{"name":"Legacy Concept Name","value":"BAY_43-9006"},{"name":"Maps_To","value":"Sorafenib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"299013"},{"name":"NSC Number","value":"724772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299013"},{"name":"PDQ_Open_Trial_Search_ID","value":"299013"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1676709"}]}}{"C111681":{"preferredName":"Sorghum bicolor Supplement","code":"C111681","definitions":[{"definition":"An herbal-based nutritional supplement containing the leaf sheaths of the plant Sorghum bicolor, with potential antioxidant, anti-inflammatory, chemopreventive and immunomodulating activities. Sorghum bicolor supplement contains various phytochemicals, including phenolic acids and polyphenols such as proanthocyanidins. Sorghum bicolor supplement is particularly rich in 3-deoxyanthocyanins, such as luteolinidin and apigeninidin, and appears to induce apoptosis and inhibit cell proliferation in cancer cells through the stimulation of various apoptosis promoter genes and the downregulation of certain apoptosis inhibitor genes. In addition, due to the strong antioxidant nature of the phytochemicals, these compounds are able to scavenge free radicals and prevent tissue damage. Also, intake of this supplement modulates the immune system by both increasing the activity of natural killer (NK) cells and initiating the activation of macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorghum bicolor Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Jobelyn","termGroup":"FB","termSource":"NCI"},{"termName":"Sorghum bicolor Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sorghum bicolor Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"752436"},{"name":"NCI_META_CUI","value":"CL454073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752436"},{"name":"PDQ_Open_Trial_Search_ID","value":"752436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80630":{"preferredName":"Sotrastaurin","code":"C80630","definitions":[{"definition":"An orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively. Both PKCs are important in the activation of nuclear factor-kappaB (NF-kB). Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotrastaurin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"425637-18-9"},{"name":"Chemical_Formula","value":"C25H22N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7I279E1NZ8"},{"name":"Legacy Concept Name","value":"Sotrastaurin"},{"name":"Maps_To","value":"Sotrastaurin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742796"}]}}{"C80631":{"preferredName":"Sotrastaurin Acetate","code":"C80631","definitions":[{"definition":"The acetate salt form of sotrastaurin, an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively. Both PKCs are important in the activation of nuclear factor-kappaB (NF-kB). Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotrastaurin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4- yl)-1H-pyrrole-2,5-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"AEB 071","termGroup":"CN","termSource":"NCI"},{"termName":"AEB071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"908351-31-5"},{"name":"Chemical_Formula","value":"C25H22N6O2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1SIA15KZ1"},{"name":"Legacy Concept Name","value":"Sotrastaurin_Acetate"},{"name":"Maps_To","value":"Sotrastaurin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"708113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"708113"},{"name":"PDQ_Open_Trial_Search_ID","value":"708113"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830197"}]}}{"C65152":{"preferredName":"Soy Isoflavones","code":"C65152","definitions":[{"definition":"A dietary supplement isolated from soybeans containing phytoestrogen isoflavones. Although the mechanism of action is unclear, soy isoflavones mimic estrogen action mediated through estrogen receptors. In addition, this agent also modulates estrogen metabolism. As a result, soy isoflavones have been shown to reduce tumor cell proliferation and induce tumor cell apoptosis, as well as to be able to regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soy Isoflavones","termGroup":"PT","termSource":"NCI"},{"termName":"NovaSoy","termGroup":"BR","termSource":"NCI"},{"termName":"Solgen 40","termGroup":"BR","termSource":"NCI"},{"termName":"Soybean Isoflavone Mixture","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71B37NR06D"},{"name":"Legacy Concept Name","value":"Soy_Isoflavones"},{"name":"Maps_To","value":"Soy Isoflavones"},{"name":"NCI_Drug_Dictionary_ID","value":"466602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"466602"},{"name":"PDQ_Open_Trial_Search_ID","value":"466602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4076257"}]}}{"C1803":{"preferredName":"Soy Protein Isolate","code":"C1803","definitions":[{"definition":"A dietary protein isolated from soybeans that contains isoflavone phytoestrogens.  Soy protein isolate has been shown to reduce tumor incidence and growth in some animal studies, possibly by modulating estrogen metabolism, reducing tumor cell proliferation, and inducing tumor cell apoptosis.  Soy protein isolate may also inhibit endothelial cell proliferation.  Isoflavone phytoestrogens display mild estrogen-like activities which may regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soy Protein Isolate","termGroup":"PT","termSource":"NCI"},{"termName":"Soybean Protein Isolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Heart disease prevention; hyperlipidemia; menopausal symptoms"},{"name":"CAS_Registry","value":"9010-10-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R44IWB3RN5"},{"name":"Legacy Concept Name","value":"Soy_Protein_Isolate"},{"name":"Maps_To","value":"Soy Protein Isolate"},{"name":"NCI_Drug_Dictionary_ID","value":"42493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42493"},{"name":"PDQ_Open_Trial_Search_ID","value":"42493"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677666"}]}}{"C2353":{"preferredName":"Sparfosate Sodium","code":"C2353","definitions":[{"definition":"The disodium salt form of N-phosphonacetyl-L-aspartate (PALA), a pyrimidine antimetabolite with antineoplastic activity.  PALA inhibits pyrimidine biosynthesis and increases the extent to which fluorouracil is incorporated into RNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sparfosate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"CI-882","termGroup":"CN","termSource":"NCI"},{"termName":"L-Aspartic Acid, N-(phosphonoacetyl)-, Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"N-Phosphonacetyl-L-aspartate Disodium","termGroup":"SN","termSource":"NCI"},{"termName":"PALA Disodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66569-27-5"},{"name":"Chemical_Formula","value":"C6H8NO8P.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5R33Q73DYD"},{"name":"Legacy Concept Name","value":"PALA_Disodium"},{"name":"Maps_To","value":"Sparfosate Sodium"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518775"}]}}{"C1398":{"preferredName":"Sparfosic Acid","code":"C1398","definitions":[{"definition":"A stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is being studied to increase the effectiveness of the chemotherapy drug fluorouracil.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sparfosic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"L-Aspartic acid, N-(phosphonoacetyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-phosphonacetyl-L-aspartate","termGroup":"SN","termSource":"NCI"},{"termName":"PALA","termGroup":"AB","termSource":"NCI"},{"termName":"Phosphonacetyl-L-aspartic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Sparfosate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51321-79-0"},{"name":"Chemical_Formula","value":"C6H10NO8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78QVZ7RG8L"},{"name":"Legacy Concept Name","value":"N-Phosphonacetyl-L-aspartate"},{"name":"Maps_To","value":"Sparfosic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"39547"},{"name":"NSC Number","value":"224131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39547"},{"name":"PDQ_Open_Trial_Search_ID","value":"39547"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0135096"}]}}{"C121625":{"preferredName":"Spartalizumab","code":"C121625","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spartalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"PDR-001","termGroup":"CN","termSource":"NCI"},{"termName":"PDR001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1935694-88-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QOG25L6Z8Z"},{"name":"Maps_To","value":"Spartalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"770801"},{"name":"NCI_META_CUI","value":"CL507832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770801"},{"name":"PDQ_Open_Trial_Search_ID","value":"770801"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97037":{"preferredName":"Spebrutinib","code":"C97037","definitions":[{"definition":"An orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, spebrutinib targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spebrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"AVL-292","termGroup":"CN","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor CC-292","termGroup":"SY","termSource":"NCI"},{"termName":"CC-292","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1202757-89-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DRU6NG543J"},{"name":"Maps_To","value":"Spebrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"700570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700570"},{"name":"PDQ_Open_Trial_Search_ID","value":"700570"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642455"}]}}{"C131368":{"preferredName":"Spherical Nucleic Acid Nanoparticle NU-0129","code":"C131368","definitions":[{"definition":"A spherical nucleic acid (SNA) gold nanoparticle formulation composed of small interfering RNAs (siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence and conjugated to gold nanoparticles, with potential antineoplastic activity. Upon administration of SNA NU-0129, the siRNA prevents the translation of the BCL2L12 gene. Inhibiting the expression of BCL2L12 by NU-0129 induces tumor cell apoptosis. Bcl2L12, a protein belonging to the Bcl-2 protein family, is overexpressed in glioblastoma multiforme (GBM) and plays a role in tumor cell progression and tumor cell resistance to apoptosis. NU-0129 is able to cross the blood brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spherical Nucleic Acid Nanoparticle NU-0129","termGroup":"PT","termSource":"NCI"},{"termName":"NU-0129","termGroup":"CN","termSource":"NCI"},{"termName":"SNA Gold Nanoparticle NU-0129","termGroup":"SY","termSource":"NCI"},{"termName":"SNA NU-0129","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spherical Nucleic Acid Nanoparticle NU-0129"},{"name":"NCI_Drug_Dictionary_ID","value":"786841"},{"name":"NCI_META_CUI","value":"CL514431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786841"},{"name":"PDQ_Open_Trial_Search_ID","value":"786841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1232":{"preferredName":"Spirogermanium","code":"C1232","definitions":[{"definition":"A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spirogermanium","termGroup":"PT","termSource":"NCI"},{"termName":"2-[3-(Dimethyl-amino)propyl]-8,8-diethyl-2-aza-8-germaspiro[4,5]decane","termGroup":"SN","termSource":"NCI"},{"termName":"8,8-Diethyl-N,N-dimethyl-3-aza-8-germaspiro[4,5]decane-2-propanamine","termGroup":"SN","termSource":"NCI"},{"termName":"S 99 A","termGroup":"CN","termSource":"NCI"},{"termName":"SPG","termGroup":"AB","termSource":"NCI"},{"termName":"Spiro-32","termGroup":"AB","termSource":"NCI"},{"termName":"Spirogermanium Compound","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41992-23-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1F01P3Y61E"},{"name":"Legacy Concept Name","value":"Spirogermanium"},{"name":"Maps_To","value":"Spirogermanium"},{"name":"NCI_Drug_Dictionary_ID","value":"39605"},{"name":"NSC Number","value":"192965"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39605"},{"name":"PDQ_Open_Trial_Search_ID","value":"39605"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075018"}]}}{"C1233":{"preferredName":"Spiromustine","code":"C1233","definitions":[{"definition":"A bifunctional nitrogen alkylating agent with antineoplastic activity and lipophilic properties. Containing a lipophilic hydantoin group that serves as a carrier to cross the blood brain barrier, spiromustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spiromustine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-diazaspiro(4,5)decane-2,4-dione,3-(2-(bis-chloroethyl)amino)ethyl","termGroup":"SN","termSource":"NCI"},{"termName":"SHM","termGroup":"AB","termSource":"NCI"},{"termName":"Spirohydantoin Mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56605-16-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J3HB83X76Z"},{"name":"Legacy Concept Name","value":"Spiromustine"},{"name":"Maps_To","value":"Spiromustine"},{"name":"NCI_Drug_Dictionary_ID","value":"39441"},{"name":"NSC Number","value":"172112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39441"},{"name":"PDQ_Open_Trial_Search_ID","value":"39441"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075019"}]}}{"C1234":{"preferredName":"Spiroplatin","code":"C1234","definitions":[{"definition":"A synthetic derivative of cyclohexane sulfatoplatinum with antineoplastic properties.  Spiroplatin induces DNA cross-links, thereby inhibiting DNA replication and RNA and protein synthesis. Similar to other platinum compounds, this agent has been shown to be mutagenic and carcinogenic. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spiroplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-1,1-diamino-methylcyclohexane sulfato-platinum","termGroup":"SN","termSource":"NCI"},{"termName":"Platinum, (1,1-cyclohexanedimethanamine-n,n')(sulfato(2-)-O,O')-, (sp-4-2)-","termGroup":"SN","termSource":"NCI"},{"termName":"TNO-6","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74790-08-2"},{"name":"Chemical_Formula","value":"C8H18N2.O4S.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H2V318W7LE"},{"name":"Legacy Concept Name","value":"Spiroplatin"},{"name":"Maps_To","value":"Spiroplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39763"},{"name":"NSC Number","value":"311056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39763"},{"name":"PDQ_Open_Trial_Search_ID","value":"39763"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075022"}]}}{"C129546":{"preferredName":"Splicing Inhibitor H3B-8800","code":"C129546","definitions":[{"definition":"An orally bioavailable inhibitor of the splicing factor 3B subunit 1 (SF3B1), with potential antineoplastic activity. Upon administration, H3B-8800 binds to and blocks the activity of SF3B1, a core spliceosome protein that is mutated in various cancer cells. This modulates RNA splicing by preventing aberrant mRNA splicing by the spliceosome, blocks RNA mis-splicing, enhances proper RNA splicing and prevents the expression of certain tumor-associated genes. This leads to an induction of apoptosis and prevents tumor cell proliferation. In many cancer cells, core spliceosome proteins, including SF3B1, U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2) and U2 small nuclear ribonucleoprotein auxiliary factor subunit-related protein 2 (ZRSR2), are mutated and aberrantly activated leading to a dysregulation of mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splicing Inhibitor H3B-8800","termGroup":"PT","termSource":"NCI"},{"termName":"H3B 8800","termGroup":"CN","termSource":"NCI"},{"termName":"H3B-8800","termGroup":"CN","termSource":"NCI"},{"termName":"Splicing Factor Inhibitor H3B-8800","termGroup":"SY","termSource":"NCI"},{"termName":"Splicing Modulator H3B-8800","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1825302-42-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"90YLS47BRX"},{"name":"Maps_To","value":"Splicing Inhibitor H3B-8800"},{"name":"NCI_Drug_Dictionary_ID","value":"784315"},{"name":"NCI_META_CUI","value":"CL512654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784315"},{"name":"PDQ_Open_Trial_Search_ID","value":"784315"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2051":{"preferredName":"Spongistatin","code":"C2051","definitions":[{"definition":"A highly cytotoxic macrocyclic lactone polyether with antitumor activity. Spongistatin, originally isolated from marine Spongia species, binds to the vinca domain of tubulin, thereby interferes with microtubule assembly and results in inhibition of mitosis. This agent does not affect the binding of colchicine to tubulin, but it was a potent inhibitor of the binding of vinblastine and GTP to tubulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spongistatin","termGroup":"PT","termSource":"NCI"},{"termName":"Altohyrtin A","termGroup":"SY","termSource":"NCI"},{"termName":"Spongistatin 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"148179-94-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spongistatin"},{"name":"Maps_To","value":"Spongistatin"},{"name":"PubMedID_Primary_Reference","value":"8232226"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0248118"}]}}{"C1482":{"preferredName":"Squalamine Lactate","code":"C1482","definitions":[{"definition":"A drug that belongs to the family of drugs called angiogenesis inhibitors. It prevents the growth of new blood vessels into a solid tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lactate salt form of squalamine, an aminosterol isolated from tissues of the dogfish shark Squalus acanthias.  Possessing anti-angiogenic properties, squalamine inhibits the sodium-hydrogen exchanger NHE3, resulting in suppression of endothelial cell proliferation and migration.  This agent also has broad-spectrum antimicrobial properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squalamine Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"MSI-1256F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"320725-47-1"},{"name":"Chemical_Formula","value":"C34H65N3O5S.C3H6O3.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4WE915J1KX"},{"name":"Legacy Concept Name","value":"Squalamine"},{"name":"Maps_To","value":"Squalamine Lactate"},{"name":"NCI_Drug_Dictionary_ID","value":"43041"},{"name":"NSC Number","value":"715056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43041"},{"name":"PDQ_Open_Trial_Search_ID","value":"43041"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0213314"}]}}{"C61435":{"preferredName":"SR-BP1/HSI Inhibitor SR31747A","code":"C61435","definitions":[{"definition":"A synthetic peripheral sigma receptor ligand with immunomodulatory and potential antitumor activities. Although the exact mechanism by which SR31747A exerts its antitumor effects has not been fully established, SR31747A binds to and inhibits the sigma1 receptor (SR31747A-binding protein-1 or SR-BP1), human sterol isomerase (HSI), also known as emopamil-binding protein (EBP), and the sigma2 receptor, which may result in a reduction in tumor cell proliferation and tumor cell apoptosis. In addition, this agent inhibits the production of pro-inflammatory cytokines while increasing anti-inflammatory cytokines. Upregulated in various cancers, the sigma1 and sigma2 receptors and human sterol isomerase are proteins that are involved in the regulation of cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SR-BP1/HSI Inhibitor SR31747A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SR31747A"},{"name":"Maps_To","value":"SR-BP1/HSI Inhibitor SR31747A"},{"name":"NCI_Drug_Dictionary_ID","value":"471256"},{"name":"NCI_META_CUI","value":"CL937293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"471256"},{"name":"PDQ_Open_Trial_Search_ID","value":"471256"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99460":{"preferredName":"SR-T100 Gel","code":"C99460","definitions":[{"definition":"A cutaneous gel preparation containing an extract from Solanum incanum with potential antineoplastic activity. SR-T100 gel contains high amounts of the steroidal alkaloid glycoside solamargine. Solamargine is able to upregulate expression of tumor necrosis factor receptors 1 (TNFR1) and 6 (TNFRSF6 or Fas), and their signaling adaptors TNFR1-associated death domain, and Fas-associated death domain. In addition, this agent is able to upregulate expression of apoptosis promoter Bax, and suppress the expression of the anti-apoptotic proteins Bcl-xL and Bcl-2. Altogether, this induces apoptosis in tumor cells and may lead to an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SR-T100 Gel","termGroup":"PT","termSource":"NCI"},{"termName":"SR-T100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SR-T100 Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"721725"},{"name":"NCI_META_CUI","value":"CL433216"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721725"},{"name":"PDQ_Open_Trial_Search_ID","value":"721725"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162533":{"preferredName":"Src Kinase Inhibitor AP 23846","code":"C162533","definitions":[{"definition":"A novel small molecule Src family kinase inhibitor with potential antiangiogenic activity. Upon administration, Src kinase inhibitor AP23846 selectively binds to and stabilizes an inactive ATP-binding site conformation leading to reduced Src kinase activity. This may reduce the production of pro-angiogenic factors, vascular endothelial growth factor (VEGF) and interleukin (IL)-8. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src Kinase Inhibitor AP 23846","termGroup":"PT","termSource":"NCI"},{"termName":"AP 23846","termGroup":"CN","termSource":"NCI"},{"termName":"AP-23846","termGroup":"CN","termSource":"NCI"},{"termName":"AP23846","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"878654-51-4"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Src Kinase Inhibitor AP 23846"},{"name":"NCI_META_CUI","value":"CL971115"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74077":{"preferredName":"Tirbanibulin","code":"C74077","definitions":[{"definition":"A substance being studied in the treatment of cancer. KX2-391 blocks an enzyme needed for growth of cells and may kill cancer cells. It is a type of Src kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tirbanibulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridineacetamide, 5-(4-(2-(4-Morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"KX01","termGroup":"CN","termSource":"NCI"},{"termName":"KX2-391","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897016-82-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4V9848RS5G"},{"name":"Legacy Concept Name","value":"Src_Kinase_Inhibitor_KX2-391"},{"name":"Maps_To","value":"Src Kinase Inhibitor KX2-391"},{"name":"Maps_To","value":"Tirbanibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"590687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590687"},{"name":"PDQ_Open_Trial_Search_ID","value":"590687"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348411"}]}}{"C120210":{"preferredName":"Topical Tirbanibulin","code":"C120210","definitions":[{"definition":"An ointment containing an inhibitor for both Src tyrosine kinase and tubulin polymerization, with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin binds to the peptide substrate binding site of Src kinase, upon topical application. This inhibits both downstream signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. Tirbanibulin also binds to tubulin heterodimers and inhibits microtubule polymerization, which disrupts microtubule formation and mitosis, leading to further inhibition of cell proliferation. In addition, Tirbanibulin inhibits T-cell migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Tirbanibulin","termGroup":"PT","termSource":"NCI"},{"termName":"KX2 391 Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"KX2-391 Ointment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Src Kinase Inhibitor KX2-391 Ointment"},{"name":"NCI_Drug_Dictionary_ID","value":"768270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768270"},{"name":"PDQ_Open_Trial_Search_ID","value":"768270"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897543"}]}}{"C162339":{"preferredName":"Src Kinase Inhibitor M475271","code":"C162339","definitions":[{"definition":"An inhibitor of Src tyrosine kinase, with potential antineoplastic activity. Upon administration, Src kinase inhibitor M-475271 targets and binds to Src kinase. This inhibits Src-mediated signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src Kinase Inhibitor M475271","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-","termGroup":"SY","termSource":"NCI"},{"termName":"AZM 475271","termGroup":"CN","termSource":"NCI"},{"termName":"AZM-475271","termGroup":"CN","termSource":"NCI"},{"termName":"AZM475271","termGroup":"CN","termSource":"NCI"},{"termName":"M 475271","termGroup":"CN","termSource":"NCI"},{"termName":"M-475271","termGroup":"CN","termSource":"NCI"},{"termName":"M475271","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-Chloro-5-methoxyphenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"476159-98-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0361Z8214O"},{"name":"Maps_To","value":"Src Kinase Inhibitor M475271"},{"name":"NCI_META_CUI","value":"CL970844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102976":{"preferredName":"Src/Abl Kinase Inhibitor AZD0424","code":"C102976","definitions":[{"definition":"An orally bioavailable small molecule tyrosine kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Upon oral administration, AZD0424 selectively inhibits both Src and Abl kinase activity which may result in the inhibition of tumor growth in susceptible tumor cells. Src and Abl kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src/Abl Kinase Inhibitor AZD0424","termGroup":"PT","termSource":"NCI"},{"termName":"AZD0424","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"692054-06-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"642PS51324"},{"name":"Maps_To","value":"Src/Abl Kinase Inhibitor AZD0424"},{"name":"NCI_Drug_Dictionary_ID","value":"739328"},{"name":"NCI_META_CUI","value":"CL437215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739328"},{"name":"PDQ_Open_Trial_Search_ID","value":"739328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120101":{"preferredName":"Src/tubulin Inhibitor KX2-361","code":"C120101","definitions":[{"definition":"A lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral administration,Src/tubulin Inhibitor KX2-361 binds to and inhibits the activity of Src kinase. This inhibits both downstream signaling and the proliferation of Src kinase-expressing tumor cells. KX02 also binds to tubulin heterodimers and inhibits microtubule polymerization, thereby disrupting microtubule formation, mitosis, and further proliferation. Src, a non-receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, angiogenesis, migration, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src/tubulin Inhibitor KX2-361","termGroup":"PT","termSource":"NCI"},{"termName":"KX02","termGroup":"CN","termSource":"NCI"},{"termName":"KX2-361","termGroup":"CN","termSource":"NCI"},{"termName":"Src/tubulin Inhibitor KX02","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897016-26-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RVW387BA9U"},{"name":"Maps_To","value":"Src/tubulin Inhibitor KX02"},{"name":"NCI_Drug_Dictionary_ID","value":"767819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767819"},{"name":"PDQ_Open_Trial_Search_ID","value":"767819"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896828"}]}}{"C150401":{"preferredName":"ssRNA-based Immunomodulator CV8102","code":"C150401","definitions":[{"definition":"A 547 nucleotide (nt), noncoding, uncapped single-stranded RNA (ssRNA) containing several polyU-repeats complexed with a polymeric carrier formed by disulfide-crosslinked cationic peptides, with potential immunostimulating activity. Upon intratumoral injection, the ssRNA in CV8102 activates toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG I; RIG-I; DDX58). This stimulates a T-helper type 1 cell (Th1) response, the production of a variety of pro-inflammatory cytokines and chemokines, and activates a systemic cytotoxic-T-lymphocyte (CTL)-mediated immune response against the tumor cells when simultaneously exposed to tumor-associated antigens (TAAs). The cationic carrier peptides protect the ssRNA from RNase degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ssRNA-based Immunomodulator CV8102","termGroup":"PT","termSource":"NCI"},{"termName":"CV 8102","termGroup":"CN","termSource":"NCI"},{"termName":"CV-8102","termGroup":"CN","termSource":"NCI"},{"termName":"CV8102","termGroup":"CN","termSource":"NCI"},{"termName":"RNA-based Adjuvant CV8102","termGroup":"SY","termSource":"NCI"},{"termName":"RNAdjuvant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ULM5THL8W5"},{"name":"Maps_To","value":"ssRNA-based Immunomodulator CV8102"},{"name":"NCI_Drug_Dictionary_ID","value":"792862"},{"name":"NCI_META_CUI","value":"CL552154"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792862"},{"name":"PDQ_Open_Trial_Search_ID","value":"792862"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131562":{"preferredName":"Nendratareotide Uzatansine","code":"C131562","definitions":[{"definition":"A miniaturized drug conjugate composed of a peptide analog of somatostatin that targets the somatostatin receptor 2 (SSTR2) and is conjugated, through a cleavable linker, to the microtubule-binding cytotoxic maytansinoid DM1 (mertansine), with potential anti-tumor activity. Upon administration, the peptide ligand moiety of nendratareotide uzatansine targets and binds to SSTR2, which is overexpressed on certain tumor cell types. Binding stimulates SSTR2-mediated endocytosis of the agent; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of SSTR2-expressing cancer cells. Compared to antibody-drug conjugates (ADCs), miniaturized drug conjugates are much smaller and can more easily penetrate and distribute in dense tumor tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nendratareotide Uzatansine","termGroup":"PT","termSource":"NCI"},{"termName":"PEN 221","termGroup":"CN","termSource":"NCI"},{"termName":"PEN-221","termGroup":"CN","termSource":"NCI"},{"termName":"PEN221","termGroup":"CN","termSource":"NCI"},{"termName":"SSTR2-targeting Protein/DM1 Conjugate PEN-221","termGroup":"SY","termSource":"NCI"},{"termName":"SSTR2PEN-221","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1853254-97-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L8993M383E"},{"name":"Maps_To","value":"SSTR2-targeting Protein/DM1 Conjugate PEN-221"},{"name":"NCI_Drug_Dictionary_ID","value":"786270"},{"name":"NCI_META_CUI","value":"CL514580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786270"},{"name":"PDQ_Open_Trial_Search_ID","value":"786270"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2589":{"preferredName":"St. John's Wort","code":"C2589","definitions":[{"definition":"An herbal extract prepared from the plant Hypericum perforatum (St. John's wort) with photodynamic, antineoplastic, and antidepressant activities. Hypericin, one of the active compounds found in Hypericum perforatum, is a photosensitizer that, when exposed to a particular wavelength and intensity of light, may induce tumor cell apoptosis. Another compound, hyperforin, induces caspase-dependent apoptosis in certain tumor cell lines. Hypericum perforatum preparations may also stimulate the activity of cytochrome P450 enzymes and P-glycoprotein drug transporters, resulting in increased metabolism and decreased efficacy of various chemotherapeutic agents and other drugs.","type":"DEFINITION","source":"NCI"},{"definition":"An herbal product sold as an over-the-counter treatment for depression. It is being studied for its ability to lessen certain side effects of cancer treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"St. John's Wort","termGroup":"PT","termSource":"NCI"},{"termName":"Hypericum Perforatum Extract","termGroup":"SY","termSource":"NCI"},{"termName":"St John's Wort","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84082-80-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UFH8805FKA"},{"name":"Legacy Concept Name","value":"Hypericum_Perforatum"},{"name":"Maps_To","value":"St. John's Wort"},{"name":"NCI_Drug_Dictionary_ID","value":"37989"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37989"},{"name":"PDQ_Open_Trial_Search_ID","value":"37989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0813171"}]}}{"C1517":{"preferredName":"Stallimycin","code":"C1517","definitions":[{"definition":"An oligopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces distallicus.  Distamycin preferentially binds to adenine-thymine (A-T) rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and RNA transcription.  In addition to antitumor effects, distamycin also possesses antiviral and antiprotozoal activities and is used as a chromosome dye. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stallimycin","termGroup":"PT","termSource":"NCI"},{"termName":"Distamycin 3","termGroup":"SY","termSource":"NCI"},{"termName":"Distamycin A","termGroup":"SY","termSource":"NCI"},{"termName":"Herperetin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"636-47-5"},{"name":"Chemical_Formula","value":"C22H27N9O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"80O63P88IS"},{"name":"Legacy Concept Name","value":"Distamycin"},{"name":"Maps_To","value":"Stallimycin"},{"name":"NSC Number","value":"82150"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244119"}]}}{"C1083":{"preferredName":"Staphylococcal Enterotoxin A","code":"C1083","definitions":[{"definition":"A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin A (SEA), a gram positive bacterial superantigen (SAg), is a potent stimulator of T-cell activation. SEA superantigen binds directly to class II major histocompatibility complex (MHC) molecules and to the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEA, both CD4+ and CD8+ cells proliferate, secrete cytokines, and demonstrate enhanced cytotoxic activity against a broad range of antigens. Vaccination with the SEA protein, administered by direct transfection into tumor cells, may elicit a non-specific cytotoxic T-cell (CTL) response and result in decreased tumor cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"The biotoxin Staphylococcal enterotoxin A.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staphylococcal Enterotoxin A","termGroup":"PT","termSource":"NCI"},{"termName":"SEA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37337-57-8"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Staphylococcal_Enterotoxin_A"},{"name":"Maps_To","value":"Staphylococcal Enterotoxin A"},{"name":"NCI_Drug_Dictionary_ID","value":"42927"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42927"},{"name":"PDQ_Open_Trial_Search_ID","value":"42927"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0059385"}]}}{"C1084":{"preferredName":"Staphylococcal Enterotoxin B","code":"C1084","definitions":[{"definition":"A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin B (SEB), a gram positive superantigen produced by Staphylococcus aureus, is a potent stimulator of T-cell activation. SEB binds directly to class II major histocompatibility complex (MHC) molecules and the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEB, both CD4+ and CD8+ cells proliferate, secrete cytokines and demonstrate enhanced cytotoxic activity against a broad range of antigens. Co-administration of SEB with interleukin-2 (IL-2) by direct injection into tumor cells, may induce clonal T-cell expansion and potentiate apoptosis of tumor cells, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"},{"definition":"The biotoxin Staphylococcal enterotoxin B.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staphylococcal Enterotoxin B","termGroup":"PT","termSource":"NCI"},{"termName":"SEB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"39424-53-8"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Staphylococcal_Enterotoxin_B"},{"name":"Maps_To","value":"Staphylococcal Enterotoxin B"},{"name":"NCI_Drug_Dictionary_ID","value":"37929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37929"},{"name":"PDQ_Open_Trial_Search_ID","value":"37929"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0059386"}]}}{"C116873":{"preferredName":"STAT Inhibitor OPB-111077","code":"C116873","definitions":[{"definition":"An orally bioavailable inhibitor of one or more signal transducer and activator of transcription (STAT) protein(s), with potential antineoplastic activity. Upon oral administration, OPB-111077 binds to and inhibits the phosphorylation of STATs. This prevents binding of STATs to DNA sequences on a variety of STAT-responsive gene promoters, which may result in the inhibition of both STAT-mediated transcription and tumor cell proliferation. STATs are constitutively activated in a variety of cancers and play a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT Inhibitor OPB-111077","termGroup":"PT","termSource":"NCI"},{"termName":"OPB-111077","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT Inhibitor OPB-111077"},{"name":"NCI_Drug_Dictionary_ID","value":"742040"},{"name":"NCI_META_CUI","value":"CL446660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742040"},{"name":"PDQ_Open_Trial_Search_ID","value":"742040"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151994":{"preferredName":"STAT3 Inhibitor DSP-0337","code":"C151994","definitions":[{"definition":"An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor DSP-0337","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Stemness Inhibitor DSP-0337","termGroup":"SY","termSource":"NCI"},{"termName":"DSP 0337","termGroup":"CN","termSource":"NCI"},{"termName":"DSP-0337","termGroup":"CN","termSource":"NCI"},{"termName":"Napabucasin Prodrug DSP-0337","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT3 Inhibitor DSP-0337"},{"name":"NCI_Drug_Dictionary_ID","value":"793774"},{"name":"NCI_META_CUI","value":"CL553215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793774"},{"name":"PDQ_Open_Trial_Search_ID","value":"793774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90588":{"preferredName":"STAT3 Inhibitor OPB-31121","code":"C90588","definitions":[{"definition":"An orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. OPB-31121 inhibits the phosphorylation of STAT3, which prevents binding of STAT3 to DNA sequences on a variety of STAT3-responsive promoters and may result in the inhibition of STAT3-mediated transcription and, potentially, the inhibition of tumor cell proliferation. STAT3 is constitutively activated in a variety of cancers, contributing to the loss of cell growth control and neoplastic transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor OPB-31121","termGroup":"PT","termSource":"NCI"},{"termName":"OPB-31121","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT3 Inhibitor OPB-31121"},{"name":"NCI_Drug_Dictionary_ID","value":"570187"},{"name":"NCI_META_CUI","value":"CL376190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570187"},{"name":"PDQ_Open_Trial_Search_ID","value":"570187"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95889":{"preferredName":"STAT3 Inhibitor OPB-51602","code":"C95889","definitions":[{"definition":"An orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. STAT3 inhibitor OPB-51602 inhibits the phosphorylation and thus the activation of STAT3 protein, impeding STAT3 protein from translocating from the cytoplasm to the nucleus and thereby blocking STAT3's regulation of gene expression through direct binding to the promoters of responsive genes. STAT3 regulates the cellular functions that lead to the cancer phenotype, and constitutive activation of STAT3 is observed in a wide range of human cancers, inducing uncontrolled proliferation and neoplastic transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor OPB-51602","termGroup":"PT","termSource":"NCI"},{"termName":"OPB-51602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT3 Inhibitor OPB-51602"},{"name":"NCI_Drug_Dictionary_ID","value":"684303"},{"name":"NCI_META_CUI","value":"CL428286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684303"},{"name":"PDQ_Open_Trial_Search_ID","value":"684303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151932":{"preferredName":"STAT3 Inhibitor C-188-9","code":"C151932","definitions":[{"definition":"An orally bioavailable, binaphthol-sulfonamide-based inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, the STAT3 inhibitor C-188-9 specifically targets and binds to the phosphotyrosyl peptide binding site within the Src homology 2 (SH2) domain of STAT3. This inhibits the Janus kinase (JAK)-mediated tyrosine phosphorylation and activation of STAT3. This impedes nuclear translocation of STAT3, prevents STAT3 binding to responsive gene promoters and blocks STAT3-mediated regulation of gene expression. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor C-188-9","termGroup":"PT","termSource":"NCI"},{"termName":"C188-9","termGroup":"CN","termSource":"NCI"},{"termName":"STAT3 Inhibitor TTI-101","termGroup":"SY","termSource":"NCI"},{"termName":"STAT3 Inhibitor XIII","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 101","termGroup":"CN","termSource":"NCI"},{"termName":"TTI-101","termGroup":"CN","termSource":"NCI"},{"termName":"TTI101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"432001-19-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KZ3DLD11RQ"},{"name":"Maps_To","value":"STAT3 Inhibitor TTI-101"},{"name":"NCI_Drug_Dictionary_ID","value":"793126"},{"name":"NCI_META_CUI","value":"CL553271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793126"},{"name":"PDQ_Open_Trial_Search_ID","value":"793126"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111042":{"preferredName":"STAT3 Inhibitor WP1066","code":"C111042","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of signaling transducer and activator 3 (STAT3), with potential antineoplastic and immunomodulatory activities. Upon administration, STAT3 inhibitor WP1066 blocks the intranuclear translocation of p-STAT, thereby suppressing STAT3 signaling and decreasing the levels of downstream products including c-Myc. Additionally, WP1066 may upregulate costimulatory molecules including CD80 and CD86 on human microglia, and reverse glioma cancer stem cell (gCSC)-mediated innate and adaptive immune suppression allowing for the restoration of antitumor effector immune responses. The STAT3 pathway is overly active in many cancer types and is implicated in CSC-mediated growth, recurrence and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor WP1066","termGroup":"PT","termSource":"NCI"},{"termName":"(S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide","termGroup":"SN","termSource":"NCI"},{"termName":"WP 1066","termGroup":"CN","termSource":"NCI"},{"termName":"WP-1066","termGroup":"CN","termSource":"NCI"},{"termName":"WP1066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857064-38-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"63V8AIE65T"},{"name":"Maps_To","value":"STAT3 Inhibitor WP1066"},{"name":"NCI_Drug_Dictionary_ID","value":"751888"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751888"},{"name":"PDQ_Open_Trial_Search_ID","value":"751888"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1957161"}]}}{"C1237":{"preferredName":"Staurosporine","code":"C1237","definitions":[{"definition":"A cell permeable alkaloid isolated from Streptomyces staurosporeus exhibiting anti-cancer activity.  Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C.  This agent induces apoptosis by an undetermined mechanism. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that belongs to the family of drugs called alkaloids. It is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Staurosporine","termGroup":"PT","termSource":"NCI"},{"termName":"(9alpha,10beta,11beta,13alpha)-(+)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H-9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one","termGroup":"SN","termSource":"NCI"},{"termName":"8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-","termGroup":"SN","termSource":"NCI"},{"termName":"AM-2282","termGroup":"CN","termSource":"NCI"},{"termName":"Antibiotic 230","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic AM 2282","termGroup":"SY","termSource":"NCI"},{"termName":"CGP-39360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62996-74-1"},{"name":"CHEBI_ID","value":"CHEBI:15738"},{"name":"Chemical_Formula","value":"C28H26N4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H88EPA0A3N"},{"name":"Legacy Concept Name","value":"Staurosporine"},{"name":"Maps_To","value":"Staurosporine"},{"name":"NSC Number","value":"618487"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075193"}]}}{"C132258":{"preferredName":"Ulevostinag","code":"C132258","definitions":[{"definition":"A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulevostinag","termGroup":"PT","termSource":"NCI"},{"termName":"MK 1454","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1454","termGroup":"CN","termSource":"NCI"},{"termName":"STING Agonist MK-1454","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2082743-96-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CKP8AS5W73"},{"name":"Maps_To","value":"STING Agonist MK-1454"},{"name":"NCI_Drug_Dictionary_ID","value":"787239"},{"name":"NCI_META_CUI","value":"CL520450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787239"},{"name":"PDQ_Open_Trial_Search_ID","value":"787239"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125902":{"preferredName":"STING-activating Cyclic Dinucleotide Agonist MIW815","code":"C125902","definitions":[{"definition":"A synthetic, cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the STING agonist MIW815 binds to STING and stimulates STING-mediated pathways. This activates the immune response through the activation of certain immune cells, including dendritic cells (DCs), which induces the expression of cytokines and chemokines, and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING-activating Cyclic Dinucleotide Agonist MIW815","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-S100","termGroup":"CN","termSource":"NCI"},{"termName":"CDN Agonist ADU-S100","termGroup":"SY","termSource":"NCI"},{"termName":"MIW815","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638750-95-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FMW9ZVF53N"},{"name":"Maps_To","value":"STING-activating Cyclic Dinucleotide Agonist MIW815"},{"name":"NCI_Drug_Dictionary_ID","value":"778826"},{"name":"NCI_META_CUI","value":"CL504551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778826"},{"name":"PDQ_Open_Trial_Search_ID","value":"778826"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C844":{"preferredName":"Streptonigrin","code":"C844","definitions":[{"definition":"An aminoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces flocculus.  Streptonigrin complexes with DNA and topoisomerase II, resulting in DNA cleavage and inhibition of DNA replication and RNA synthesis.  This agent also acts as a reverse transcriptase inhibitor and causes free radical-mediated cellular damage. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Streptonigrin","termGroup":"PT","termSource":"NCI"},{"termName":"5-Amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl-2-pyridinecarboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-6-(70-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpicolinic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BA-163","termGroup":"CN","termSource":"NCI"},{"termName":"Bruneomycin","termGroup":"SY","termSource":"NCI"},{"termName":"PC-501","termGroup":"CN","termSource":"NCI"},{"termName":"Rufocromomycin","termGroup":"SY","termSource":"NCI"},{"termName":"STN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3930-19-6"},{"name":"CHEBI_ID","value":"CHEBI:9287"},{"name":"Chemical_Formula","value":"C25H22N4O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"261Q3JB310"},{"name":"Legacy Concept Name","value":"Streptonigrin"},{"name":"Maps_To","value":"Streptonigrin"},{"name":"NCI_Drug_Dictionary_ID","value":"39703"},{"name":"NSC Number","value":"45383"},{"name":"NSC Number","value":"83950"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39703"},{"name":"PDQ_Open_Trial_Search_ID","value":"39703"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038427"}]}}{"C845":{"preferredName":"Streptozocin","code":"C845","definitions":[{"definition":"A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Streptozocin","termGroup":"PT","termSource":"NCI"},{"termName":"2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"2-deoxy-2-[[(methylnitrosamino)-carbonyl]amino]-D-glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"Streptozotocin","termGroup":"SY","termSource":"NCI"},{"termName":"STZ","termGroup":"AB","termSource":"NCI"},{"termName":"U-9889","termGroup":"CN","termSource":"NCI"},{"termName":"Zanosar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Carcinoid tumor and syndrome; Colorectal cancer, palliative; Hodgkin's disease; Metastatic islet cell carcinoma of the pancreas"},{"name":"CAS_Registry","value":"18883-66-4"},{"name":"CHEBI_ID","value":"CHEBI:9288"},{"name":"Chemical_Formula","value":"C8H15N3O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5W494URQ81"},{"name":"Legacy Concept Name","value":"Streptozocin"},{"name":"Maps_To","value":"Streptozocin"},{"name":"NCI_Drug_Dictionary_ID","value":"42831"},{"name":"NSC Number","value":"85998"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42831"},{"name":"PDQ_Open_Trial_Search_ID","value":"42831"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038432"}]}}{"C1238":{"preferredName":"Strontium Chloride Sr-89","code":"C1238","definitions":[{"definition":"A salt form of the radioactive metal strontium-89 that is absorbed by a part of growing bone. It is being studied in the treatment of bone pain caused by cancer that has spread to the bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Strontium Chloride Sr-89","termGroup":"PT","termSource":"NCI"},{"termName":"Metastron","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Palliation of pain in bone metastases"},{"name":"CAS_Registry","value":"38270-90-5"},{"name":"Chemical_Formula","value":"2Cl.Sr"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5R78837D4A"},{"name":"Legacy Concept Name","value":"Strontium_Chloride_Sr_89"},{"name":"Maps_To","value":"Strontium Chloride Sr-89"},{"name":"NCI_Drug_Dictionary_ID","value":"41810"},{"name":"NSC Number","value":"721349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41810"},{"name":"PDQ_Open_Trial_Search_ID","value":"41810"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919292"}]}}{"C162773":{"preferredName":"Submicron Particle Paclitaxel Sterile Suspension","code":"C162773","definitions":[{"definition":"A suspension composed of uncoated, stable, submicron particles of the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intra-tumoral administration of the submicron particle paclitaxel sterile suspension, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The submicron particle paclitaxel is produced through a specific proprietary method of submicron particle production without the need for coating agents or carriers and allows for prolonged retention and sustained release at the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Submicron Particle Paclitaxel Sterile Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"NanoPac","termGroup":"BR","termSource":"NCI"},{"termName":"Sterile Nanoparticle-based Paclitaxel Suspension","termGroup":"SY","termSource":"NCI"},{"termName":"Sterile Nanoparticulate Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Submicron Particle Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Submicron Particle Paclitaxel Formulation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Submicron Particle Paclitaxel Sterile Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"799071"},{"name":"NCI_META_CUI","value":"CL973205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799071"},{"name":"PDQ_Open_Trial_Search_ID","value":"799071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116066":{"preferredName":"Sulfatinib","code":"C116066","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulfatinib","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL-012","termGroup":"CN","termSource":"NCI"},{"termName":"Surufatinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1308672-74-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B2K5L1L8S9"},{"name":"Maps_To","value":"Sulfatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"760894"},{"name":"NCI_META_CUI","value":"CL473485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760894"},{"name":"PDQ_Open_Trial_Search_ID","value":"760894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1424":{"preferredName":"Sulforaphane","code":"C1424","definitions":[{"definition":"A naturally-occurring phytochemical belonging to the class of isothiocyanates.  As the aglycone metabolite of glucosinolate glucoraphanin (sulforaphane glucosinolate), sulforaphane acts as an antioxidant and potent stimulator of endogenous detoxifying enzymes.  This agent displays anticarcinogenic properties due to its ability to induce phase II detoxification enzymes, such as glutathione S-transferase and quinone reductase, thereby providing protection against certain carcinogens and toxic, reactive oxygen species.  Broccoli sprouts contain large amounts of sulforaphane, which is also found in other cruciferous vegetables including cabbage and kale. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An isothiocyanate with a methylsulphinyl butane chain. The chemical structure is CS(=O)CCCCN=C=S.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Sulforaphane","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-Sulforaphane","termGroup":"SY","termSource":"NCI"},{"termName":"1-Isothiocyanato-4-(methylsulfinyl)butane","termGroup":"SN","termSource":"NCI"},{"termName":"Sulfaforaphane","termGroup":"SY","termSource":"NCI"},{"termName":"Sulforafan","termGroup":"SY","termSource":"NCI"},{"termName":"Sulphoraphane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4478-93-7"},{"name":"CHEBI_ID","value":"CHEBI:47807"},{"name":"Chemical_Formula","value":"C6H11NOS2"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GA49J4310U"},{"name":"Legacy Concept Name","value":"Sulforaphane"},{"name":"Maps_To","value":"Sulforaphane"},{"name":"NCI_Drug_Dictionary_ID","value":"691987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691987"},{"name":"PDQ_Open_Trial_Search_ID","value":"691987"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0163159"}]}}{"C850":{"preferredName":"Sulindac","code":"C850","definitions":[{"definition":"A nonsteroidal anti-inflammatory drug (NSAID) that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulindac","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Aflodac","termGroup":"BR","termSource":"NCI"},{"termName":"Algocetil","termGroup":"FB","termSource":"NCI"},{"termName":"Apo-Sulin","termGroup":"FB","termSource":"NCI"},{"termName":"Arthrocine","termGroup":"FB","termSource":"NCI"},{"termName":"Artribid","termGroup":"FB","termSource":"NCI"},{"termName":"cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Citireuma","termGroup":"FB","termSource":"NCI"},{"termName":"Clinoril","termGroup":"BR","termSource":"NCI"},{"termName":"Clisundac","termGroup":"FB","termSource":"NCI"},{"termName":"Imbaral","termGroup":"FB","termSource":"NCI"},{"termName":"MK-231","termGroup":"CN","termSource":"NCI"},{"termName":"Novo-Sundac","termGroup":"FB","termSource":"NCI"},{"termName":"Reumofil","termGroup":"FB","termSource":"NCI"},{"termName":"Reumyl","termGroup":"FB","termSource":"NCI"},{"termName":"Sudac","termGroup":"FB","termSource":"NCI"},{"termName":"Sulindac Sulfoxide","termGroup":"SY","termSource":"NCI"},{"termName":"Sulinol","termGroup":"FB","termSource":"NCI"},{"termName":"Sulreuma","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Arthritis; inflammatory conditions"},{"name":"CAS_Registry","value":"38194-50-2"},{"name":"CHEBI_ID","value":"CHEBI:9352"},{"name":"Chemical_Formula","value":"C20H17FO3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"184SNS8VUH"},{"name":"Legacy Concept Name","value":"Sulindac"},{"name":"Maps_To","value":"Sulindac"},{"name":"NCI_Drug_Dictionary_ID","value":"41538"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41538"},{"name":"PDQ_Open_Trial_Search_ID","value":"41538"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038792"}]}}{"C1432":{"preferredName":"Sulofenur","code":"C1432","definitions":[{"definition":"A diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulofenur","termGroup":"PT","termSource":"NCI"},{"termName":"LY186641","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110311-27-8"},{"name":"Chemical_Formula","value":"C16H15ClN2O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z45N070N3S"},{"name":"Legacy Concept Name","value":"Sulofenur"},{"name":"Maps_To","value":"Sulofenur"},{"name":"NCI_Drug_Dictionary_ID","value":"41122"},{"name":"NSC Number","value":"656667"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41122"},{"name":"PDQ_Open_Trial_Search_ID","value":"41122"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165187"}]}}{"C156270":{"preferredName":"Subasumstat","code":"C156270","definitions":[{"definition":"A small molecule inhibitor of sumoylation, with potential immune-activating and antineoplastic activities. Upon intravenous administration, subasumstat targets and covalently binds to the small ubiquitin-like modifier (SUMO; small ubiquitin-related modifier) protein, forming an adduct with SUMO protein (subasumstat-SUMO adduct). This prevents the transfer of SUMO from the SUMO-activating enzyme (SAE) to SUMO-conjugating enzyme UBC9. This prevents SUMO conjugation to lysine residues on target proteins and abrogates many sumoylated protein-mediated cellular processes that play key roles in tumor cells, including proliferation, DNA repair, metastasis and survival. In addition, by preventing sumoylation, subasumstat is able to increase the production of type 1 interferon (IFN), thereby increasing type 1 IFN-mediated signaling, activating innate effector cells and enhancing the antitumor innate immune responses. This may further increase tumor cell killing. Sumoylation, a post-translational modification that attaches the SUMO protein to target proteins, plays a key role in regulating their activity, function, subcellular localization and stability.  Sumoylation also plays a key role in inhibiting innate immune responses, specifically by inhibiting the pattern recognition receptor (PRR) pathway and preventing type 1 IFN expression. Abnormal sumoylation of target proteins is associated with many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subasumstat","termGroup":"PT","termSource":"NCI"},{"termName":"TAK 981","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-981","termGroup":"CN","termSource":"NCI"},{"termName":"TAK981","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858276-04-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XQ43H3V6M1"},{"name":"Maps_To","value":"Sumoylation Inhibitor TAK-981"},{"name":"NCI_Drug_Dictionary_ID","value":"795544"},{"name":"NCI_META_CUI","value":"CL562995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795544"},{"name":"PDQ_Open_Trial_Search_ID","value":"795544"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71622":{"preferredName":"Sunitinib","code":"C71622","definitions":[{"definition":"A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). Sunitinib is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sunitinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"557795-19-4"},{"name":"CHEBI_ID","value":"CHEBI:38940"},{"name":"Chemical_Formula","value":"C22H27FN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"V99T50803M"},{"name":"Legacy Concept Name","value":"Sunitinib"},{"name":"Maps_To","value":"Sunitinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1176020"}]}}{"C26673":{"preferredName":"Sunitinib Malate","code":"C26673","definitions":[{"definition":"A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). SU011248 is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sunitinib Malate","termGroup":"PT","termSource":"NCI"},{"termName":"Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"SU011248","termGroup":"CN","termSource":"NCI"},{"termName":"SU11248","termGroup":"CN","termSource":"NCI"},{"termName":"Sutent","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastrointestinal Stromal Tumor; Advanced Metastatic Renal Cell Carcinoma"},{"name":"CAS_Registry","value":"341031-54-7"},{"name":"Chemical_Formula","value":"C22H27FN4O2.C4H6O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LVX8N1UT73"},{"name":"Legacy Concept Name","value":"SU11248"},{"name":"Maps_To","value":"Sunitinib Malate"},{"name":"NCI_Drug_Dictionary_ID","value":"299061"},{"name":"NSC Number","value":"736511"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299061"},{"name":"PDQ_Open_Trial_Search_ID","value":"299061"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1700685"}]}}{"C158082":{"preferredName":"Super Enhancer Inhibitor GZ17-6.02","code":"C158082","definitions":[{"definition":"A synthetic formulation of the Arum palaestinum plant that has been fortified with the already naturally occurring constituents of isovanillin, linolenic acid, and beta-sitosterol, with potential antineoplastic activity. Upon oral administration, GZ17-6.02 may induce apoptosis through caspase-3 activation and poly(ADP-ribose) polymerase (PARP) cleavage, inhibit tumor cell progression by attenuating macrophage infiltration, and inhibit the phosphorylation of several mediators of tumor cell proliferation including Src kinase, extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), epidermal growth factor receptor (EGFR), serine/threonine protein kinase AKT (protein kinase B), signal transducer and activator of transcription 2 (STAT-2), and serine/threonine-protein kinase Chk2 (Chk-2). GZ17-6.02 may also inhibit certain super enhancers (SEs) that play an important role in the regulation of the sonic hedgehog (SHH) pathway and cancer stem cell activity. Super enhancers (SEs) are unique areas of the genome that are densely bound by numerous transcription factors and play a pivotal role in the cell, including tissue specification, identity and maintenance. SEs are known to regulate the expression of associated genes and often drive high-level transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Super Enhancer Inhibitor GZ17-6.02","termGroup":"PT","termSource":"NCI"},{"termName":"GZ17 6.02","termGroup":"CN","termSource":"NCI"},{"termName":"GZ17-6.02","termGroup":"CN","termSource":"NCI"},{"termName":"GZ176.02","termGroup":"CN","termSource":"NCI"},{"termName":"Synthetic Arum palaestinum derivative GZ17-6.02","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Super Enhancer Inhibitor GZ17-6.02"},{"name":"NCI_Drug_Dictionary_ID","value":"797048"},{"name":"NCI_META_CUI","value":"CL937695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797048"},{"name":"PDQ_Open_Trial_Search_ID","value":"797048"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107503":{"preferredName":"Nogapendekin Alfa","code":"C107503","definitions":[{"definition":"A mutated form of the cytokine interleukin (IL)-15 (IL-15N72D), with potential immunomodulating and antineoplastic activities. Upon administration, nogapendekin alfa binds to the IL-15 receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory T-cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nogapendekin Alfa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622189-43-8"},{"name":"CAS_Registry","value":"1850381-92-8 (ALT-803)"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7TK323DLA0"},{"name":"Maps_To","value":"Nogapendekin Alfa"},{"name":"Maps_To","value":"Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658787"}]}}{"C853":{"preferredName":"Suramin","code":"C853","definitions":[{"definition":"A drug that is used to treat infections caused by parasites. It is also being studied in the treatment of cancer. It belongs to the families of drugs called antiprotozoals and anthelmintics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suramin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Trypanosomiasis; hormone-refractory prostate cancer"},{"name":"CAS_Registry","value":"145-63-1"},{"name":"CHEBI_ID","value":"CHEBI:45906"},{"name":"Chemical_Formula","value":"C51H40N6O23S6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6032D45BEM"},{"name":"Legacy Concept Name","value":"Suramin"},{"name":"Maps_To","value":"Suramin"},{"name":"NCI_Drug_Dictionary_ID","value":"40052"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40052"},{"name":"PDQ_Open_Trial_Search_ID","value":"40052"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038880"}]}}{"C1848":{"preferredName":"Suramin Sodium","code":"C1848","definitions":[{"definition":"A sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suramin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"309 F","termGroup":"FB","termSource":"NCI"},{"termName":"8,8'-(Carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid Hexasodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Antrypol","termGroup":"FB","termSource":"NCI"},{"termName":"Bayer 205","termGroup":"CN","termSource":"NCI"},{"termName":"Belganyl","termGroup":"FB","termSource":"NCI"},{"termName":"CI-1003","termGroup":"CN","termSource":"NCI"},{"termName":"Fourneau 309","termGroup":"FB","termSource":"NCI"},{"termName":"Germanin","termGroup":"FB","termSource":"NCI"},{"termName":"Metaret","termGroup":"BR","termSource":"NCI"},{"termName":"Moranyl","termGroup":"FB","termSource":"NCI"},{"termName":"Naganin","termGroup":"FB","termSource":"NCI"},{"termName":"Naganinum","termGroup":"FB","termSource":"NCI"},{"termName":"Naganol","termGroup":"FB","termSource":"NCI"},{"termName":"Naphuride","termGroup":"FB","termSource":"NCI"},{"termName":"Sodium Suramin","termGroup":"SY","termSource":"NCI"},{"termName":"Suramin Hexasodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"African trypanosomiasis; onchocerciasis"},{"name":"CAS_Registry","value":"129-46-4"},{"name":"Chemical_Formula","value":"C51H34N6O23S6.6Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"89521262IH"},{"name":"Legacy Concept Name","value":"Suramin_Sodium"},{"name":"Maps_To","value":"Suramin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"40052"},{"name":"NSC Number","value":"34936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40052"},{"name":"PDQ_Open_Trial_Search_ID","value":"40052"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0813205"}]}}{"C37449":{"preferredName":"Survivin Antigen","code":"C37449","definitions":[{"definition":"A tumor-associated antigen. Vaccination with survivin antigen may result in a cytotoxic T-cell response against survivin antigen-expressing tumor cells, resulting in decreased tumor cell proliferation and tumor cell death. Overexpressed in many tumors, endogenous survivin inhibits tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Survivin Antigen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Survivin_Antigen"},{"name":"Maps_To","value":"Survivin Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"346072"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346072"},{"name":"PDQ_Open_Trial_Search_ID","value":"346072"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1515097"}]}}{"C97951":{"preferredName":"Maveropepimut-S","code":"C97951","definitions":[{"definition":"A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of Maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maveropepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"DPX-Survivac","termGroup":"SY","termSource":"NCI"},{"termName":"MVP-S","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Survivin Antigen Vaccine DPX-Survivac"},{"name":"NCI_Drug_Dictionary_ID","value":"709395"},{"name":"NCI_META_CUI","value":"CL430558"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709395"},{"name":"PDQ_Open_Trial_Search_ID","value":"709395"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92578":{"preferredName":"Survivin mRNA Antagonist EZN-3042","code":"C92578","definitions":[{"definition":"A locked nucleic acid (LNA) antisense oligonucleotide targeting survivin mRNA, with potential antineoplastic activity. EZN-3042 hybridizes to survivin mRNA, thereby blocking translation of survivin protein and inhibiting survivin-induced anti-apoptotic activity and promoting tumor cell apoptosis in survivin-overexpressing tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. LNAs contain a methylene bridge linking 2'-oxygen and 4'-carbon of ribose sugar rings, thereby increasing their stability and decreasing degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Survivin mRNA Antagonist EZN-3042","termGroup":"PT","termSource":"NCI"},{"termName":"EZN-3042","termGroup":"CN","termSource":"NCI"},{"termName":"LNA-RNA Antagonist EZN-3042","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Survivin mRNA Antagonist EZN-3042"},{"name":"NCI_Drug_Dictionary_ID","value":"684391"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684391"},{"name":"PDQ_Open_Trial_Search_ID","value":"684391"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2973480"}]}}{"C158607":{"preferredName":"Survivin-expressing CVD908ssb-TXSVN Vaccine","code":"C158607","definitions":[{"definition":"An orally bioavailable Salmonella-based survivin vaccine composed of a weakened form of a live strain of  Salmonella bacteria (CVD908ssb strain) that has been genetically modified to produce the tumor-associated antigen (TAA) survivin, with potential immunopotentiating and antineoplastic activities. Upon administration of the CVD908ssb-TXSVN vaccine, the expressed survivin stimulates the immune response to elicit a cytotoxic T-lymphocyte (CTL)-mediated immune response against survivin-expressing cancer cells, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Survivin-expressing CVD908ssb-TXSVN Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"CVD908ssb-TXSVN","termGroup":"CN","termSource":"NCI"},{"termName":"Salmonella-based Survivin Vaccine CVD908ssb-TXSVN","termGroup":"SY","termSource":"NCI"},{"termName":"TXSVN","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Survivin-expressing CVD908ssb-TXSVN Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"797123"},{"name":"NCI_META_CUI","value":"CL938073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797123"},{"name":"PDQ_Open_Trial_Search_ID","value":"797123"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116884":{"preferredName":"Sustained-release Lipid Inhaled Cisplatin","code":"C116884","definitions":[{"definition":"A sustained-release formulation for inhalation in which the inorganic platinum (Pt) agent cisplatin is encapsulated in lipids, with potential antineoplastic activity. Upon inhalation of the sustained-release lipid inhalation targeting (SLIT) cisplatin into the lungs, this agent forms highly reactive, positively charged, Pt complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. Pt complex binding introduces intrastrand and interstrand DNA cross-links, and DNA-Pt-protein cross-links. These cross-links result in apoptosis and cell growth inhibition of lung cancer cells. Encasement in liposomes prolongs cisplatin's efficacy when compared to intravenously administered cisplatin; inhalation of cisplatin improves its concentration at tumor sites in the lungs while minimizing its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sustained-release Lipid Inhaled Cisplatin","termGroup":"PT","termSource":"NCI"},{"termName":"SLIT Cisplatin","termGroup":"BR","termSource":"NCI"},{"termName":"SR Inhaled Lipid Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained-release Lipid Inhalation Targeting Cisplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sustained-release Lipid Inhaled Cisplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"420851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"420851"},{"name":"PDQ_Open_Trial_Search_ID","value":"420851"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541510"}]}}{"C126642":{"preferredName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101","code":"C126642","definitions":[{"definition":"A sustained-release (SR) hydrogel polymer-based formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon local administration of the SR MMC hydrogel formulation to the upper urinary tract via a ureteral catheter, the gel solidifies and deposits MMC locally to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures and solidifies at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for upper tract urothelial carcinoma (UTUC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101","termGroup":"PT","termSource":"NCI"},{"termName":"Mitogel","termGroup":"BR","termSource":"NCI"},{"termName":"MP77-08","termGroup":"CN","termSource":"NCI"},{"termName":"RTGel with Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"RTGel with MMC","termGroup":"SY","termSource":"NCI"},{"termName":"SR Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained-release Mitomycin C Gel Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"UGN-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101"},{"name":"NCI_Drug_Dictionary_ID","value":"779705"},{"name":"NCI_META_CUI","value":"CL503759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779705"},{"name":"PDQ_Open_Trial_Search_ID","value":"779705"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C158422":{"preferredName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102","code":"C158422","definitions":[{"definition":"A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-102, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in UGN-102 the strength of MMC is lower.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102","termGroup":"PT","termSource":"NCI"},{"termName":"Intravesical Mitomycin Gel UGN-102","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycin Urothelial Gel UGN-102","termGroup":"SY","termSource":"NCI"},{"termName":"MMC + UG-1 Gel","termGroup":"SY","termSource":"NCI"},{"termName":"RTGel with Mitomycin C UGN-102","termGroup":"SY","termSource":"NCI"},{"termName":"UGN 102","termGroup":"CN","termSource":"NCI"},{"termName":"UGN-102","termGroup":"CN","termSource":"NCI"},{"termName":"UGN102","termGroup":"CN","termSource":"NCI"},{"termName":"Vesigel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102"},{"name":"NCI_Drug_Dictionary_ID","value":"797493"},{"name":"NCI_META_CUI","value":"CL937895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797493"},{"name":"PDQ_Open_Trial_Search_ID","value":"797493"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C123912":{"preferredName":"Sovleplenib","code":"C123912","definitions":[{"definition":"An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration of sovleplenib, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sovleplenib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-7-(4-(1-(Methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido(4,3-b)pyrazin-5-amine","termGroup":"SN","termSource":"NCI"},{"termName":"HMPL 523","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-523","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL523","termGroup":"CN","termSource":"NCI"},{"termName":"Spleen Tyrosine Kinase Inhibitor HMPL-523","termGroup":"SY","termSource":"NCI"},{"termName":"Syk Inhibitor HMPL-523","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415792-84-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9CL6353KHO"},{"name":"Maps_To","value":"Syk Inhibitor HMPL-523"},{"name":"NCI_Drug_Dictionary_ID","value":"775837"},{"name":"NCI_META_CUI","value":"CL498276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775837"},{"name":"PDQ_Open_Trial_Search_ID","value":"775837"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2650":{"preferredName":"Synchrotope TA2M Plasmid DNA Vaccine","code":"C2650","definitions":[{"definition":"A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synchrotope TA2M Plasmid DNA Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synchrotope_TA2M_Plasmid_DNA_Vaccine"},{"name":"Maps_To","value":"Synchrotope TA2M Plasmid DNA Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38415"},{"name":"PDQ_Open_Trial_Search_ID","value":"38415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134471"}]}}{"C28549":{"preferredName":"Synchrovax SEM Plasmid DNA Vaccine","code":"C28549","definitions":[{"definition":"A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synchrovax SEM Plasmid DNA Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Synchrotope MA2M Plasmid DNA Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synchrovax_SEM_Plasmid_DNA_Vaccine"},{"name":"Maps_To","value":"Synchrovax SEM Plasmid DNA Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38555"},{"name":"PDQ_Open_Trial_Search_ID","value":"38555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134580"}]}}{"C62763":{"preferredName":"Synthetic Alkaloid PM00104","code":"C62763","definitions":[{"definition":"A synthetic alkaloid compound, related to natural alkaloid compounds, found in molluscs (jorumycin) and sponges (renieramycins), with potential antineoplastic activity. PM00104 reversibly binds to DNA, thereby inducing cytotoxicity due to its interference with DNA replication, transcription, and translation processes. DNA binding by this agent does not trigger DNA damage checkpoint responses, hence PM00104 demonstrates a manageable and reversible cytotoxicity as part of its antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Alkaloid PM00104","termGroup":"PT","termSource":"NCI"},{"termName":"Zalypsis","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"308359-57-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C21EZR41AY"},{"name":"Legacy Concept Name","value":"PM00104"},{"name":"Maps_To","value":"Synthetic Alkaloid PM00104"},{"name":"NCI_Drug_Dictionary_ID","value":"502184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"502184"},{"name":"PDQ_Open_Trial_Search_ID","value":"502184"},{"name":"PubMedID_Primary_Reference","value":"19584237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1568937"}]}}{"C116332":{"preferredName":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2","code":"C116332","definitions":[{"definition":"A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient's own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2","termGroup":"PT","termSource":"NCI"},{"termName":"APVAC2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2"},{"name":"NCI_Drug_Dictionary_ID","value":"761688"},{"name":"NCI_META_CUI","value":"CL473666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761688"},{"name":"PDQ_Open_Trial_Search_ID","value":"761688"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116331":{"preferredName":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1","code":"C116331","definitions":[{"definition":"A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1","termGroup":"PT","termSource":"NCI"},{"termName":"APVAC1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1"},{"name":"NCI_Drug_Dictionary_ID","value":"761678"},{"name":"NCI_META_CUI","value":"CL473665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761678"},{"name":"PDQ_Open_Trial_Search_ID","value":"761678"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120118":{"preferredName":"Synthetic hTERT DNA Vaccine INO-1400","code":"C120118","definitions":[{"definition":"A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic hTERT DNA Vaccine INO-1400","termGroup":"PT","termSource":"NCI"},{"termName":"INO-1400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic hTERT DNA Vaccine INO-1400"},{"name":"NCI_Drug_Dictionary_ID","value":"768008"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768008"},{"name":"PDQ_Open_Trial_Search_ID","value":"768008"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896835"}]}}{"C142139":{"preferredName":"Synthetic hTERT DNA Vaccine INO-1401","code":"C142139","definitions":[{"definition":"A DNA vaccine consisting of a plasmid encoding a synthetic, full-length sequence of the tumor-associated antigen (TAA) telomerase reverse transcriptase (TERT), which was derived from the consensus sequence from humans and primates and contains two immunogenic mutations (SynCon TERT), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of INO-1401 in combination with electroporation, TERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. TERT is the catalytic subunit of telomerase and synthesizes telomeric DNA at the chromosome ends. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, TERT is expressed by many types of human cancer cells, but its expression is low or non-existent in normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic hTERT DNA Vaccine INO-1401","termGroup":"PT","termSource":"NCI"},{"termName":"INO-1401","termGroup":"CN","termSource":"NCI"},{"termName":"SynCon TERT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic hTERT DNA Vaccine INO-1401"},{"name":"NCI_Drug_Dictionary_ID","value":"791450"},{"name":"NCI_META_CUI","value":"CL540179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791450"},{"name":"PDQ_Open_Trial_Search_ID","value":"791450"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122400":{"preferredName":"Synthetic Hypericin","code":"C122400","definitions":[{"definition":"A topical ointment formulation containing a synthetic form of hypericin, an anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John's wort), with potential antineoplastic and photosensitizing activities. Upon topical administration of the ointment to the tumor site, hypericin becomes activated through the application of visible fluorescent light. During photoactivation, hypericin generates singlet oxygen, which induces DNA damage, necrosis and apoptosis, thereby inhibiting tumor cell growth. The use of visible light for activation avoids the risk of developing secondary malignancies, which are frequently associated with other photodynamic therapies that are dependent on ultraviolet A exposure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Hypericin","termGroup":"PT","termSource":"NCI"},{"termName":"Topical SGX301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Hypericin"},{"name":"NCI_Drug_Dictionary_ID","value":"772561"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772561"},{"name":"PDQ_Open_Trial_Search_ID","value":"772561"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053962"}]}}{"C129652":{"preferredName":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201","code":"C129652","definitions":[{"definition":"A therapeutic peptide vaccine consisting of two highly immunogenic synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoprotein E6, and conjugated to a proprietary toll-like receptor 2 (TLR2) ligand (TLR2-L) immunoadjuvant, with potential immunostimulating and antitumor activities. Upon administration, the TLR2-L moiety of the synthetic long E6 peptides TLR ligand conjugate vaccine targets and binds to TLRs expressed on antigen-presenting cells (APCs), particularly dendritic cells (DCs). This increases the direct targeting of, binding to, uptake by, and processing of the SLPs into small pieces by the DCs. The processed viral epitopes are presented by DCs, which activate and stimulate the host immune system to mount specific cytotoxic T-lymphocyte (CTL) and helper T (Th) cell responses against HPV E6-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased growth of HPV E6-expressing tumor cells. The E6 oncoprotein is implicated in tumorigenesis in a variety of cancers. The TLR2-L improves antigen processing and presentation by, and activation of APCs, thereby improving the immunostimulatory effect of the vaccine. The two peptides cover the most immunodominant regions of the HPV16 E6 oncogenic protein and contain both Th and CTL epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201","termGroup":"PT","termSource":"NCI"},{"termName":"Hespecta","termGroup":"FB","termSource":"NCI"},{"termName":"HPV E Six Peptide Conjugated to Amplivant","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16 peptides AMPLIVANT Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"ISA201","termGroup":"CN","termSource":"NCI"},{"termName":"PV E6 Peptides-Amplivant","termGroup":"SY","termSource":"NCI"},{"termName":"PV16 E6 Peptide Conjugated to Amplivant","termGroup":"SY","termSource":"NCI"},{"termName":"SLP HPV16 E6/Amplivant Vaccine ISA201","termGroup":"SY","termSource":"NCI"},{"termName":"SLP-Amplivant ISA201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201"},{"name":"NCI_Drug_Dictionary_ID","value":"784216"},{"name":"NCI_META_CUI","value":"CL512627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784216"},{"name":"PDQ_Open_Trial_Search_ID","value":"784216"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111037":{"preferredName":"Synthetic Long E6/E7 Peptides Vaccine HPV-01","code":"C111037","definitions":[{"definition":"A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Long E6/E7 Peptides Vaccine HPV-01","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-01","termGroup":"CN","termSource":"NCI"},{"termName":"ISA101","termGroup":"CN","termSource":"NCI"},{"termName":"SLP-HPV-01","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Long E6/E7 Peptides Vaccine HPV-01"},{"name":"NCI_Drug_Dictionary_ID","value":"751803"},{"name":"NCI_META_CUI","value":"CL453544"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751803"},{"name":"PDQ_Open_Trial_Search_ID","value":"751803"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150809":{"preferredName":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b","code":"C150809","definitions":[{"definition":"A therapeutic peptide vaccine consisting of nine overlapping synthetic long peptides (SLPs), 25 to 32 amino acids in size, derived from the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E6 and three SLPs, each 35 amino acids in size, derived from HPV16 E7, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the synthetic long HPV16 E6/E7 peptides vaccine ISA101b is taken up and the long peptides are proteolytically degraded to form shorter peptide epitopes by dendritic cells (DCs). The processed viral epitopes are presented by DCs, which stimulate the host immune system to mount helper T-cell and cytotoxic T-lymphocyte (CTL) responses against HPV16 E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The HPV16 E6 and E7 oncoproteins are implicated in the tumorigenesis of a variety of cancers. The SLPs allow optimal presentation by antigen-presenting cells (APCs). Compared to ISA101, the E6 SLPs in ISA101b are identical, overlap by ten to eighteen residues and cover the complete sequence of HPV16 E6. However, ISA101 has four overlapping SLPs E7 peptides while ISA101b has three E7 SLPs, which leaves seven amino acids of the E7 SLPs uncovered in ISA101b but this modification is not likely to alter the immunogenicity of ISA101b.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E6/E7-SLP ISA101b","termGroup":"SY","termSource":"NCI"},{"termName":"ISA 101b","termGroup":"CN","termSource":"NCI"},{"termName":"ISA-101b","termGroup":"CN","termSource":"NCI"},{"termName":"ISA101b","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b"},{"name":"NCI_Drug_Dictionary_ID","value":"793552"},{"name":"NCI_META_CUI","value":"CL552668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793552"},{"name":"PDQ_Open_Trial_Search_ID","value":"793552"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26674":{"preferredName":"T900607","code":"C26674","definitions":[{"definition":"A pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called tubulin-binding agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"T900607","termGroup":"PT","termSource":"NCI"},{"termName":"T900607","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"261944-52-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IC9O2HT1X1"},{"name":"Legacy Concept Name","value":"T900607"},{"name":"Maps_To","value":"T900607"},{"name":"NCI_Drug_Dictionary_ID","value":"271169"},{"name":"PDQ_Closed_Trial_Search_ID","value":"271169"},{"name":"PDQ_Open_Trial_Search_ID","value":"271169"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327873"}]}}{"C91727":{"preferredName":"Tabalumab","code":"C91727","definitions":[{"definition":"A human IgG4 monoclonal antibody against B-cell activating factor (BAFF), with potential immunomodulating and antineoplastic activities. Tabalumab binds to and inhibits the activity of both soluble and cell surface-bound BAFF. This may reduce the activity, proliferation and survival of B-cells. A dysregulated expression of BAFF, a member of the tumor necrosis factor (TNF) family of proteins, is often seen in certain autoimmune diseases and certain cancers, and may promote B lymphocyte activation, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tabalumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BAFF Monoclonal Antibody LY2127399","termGroup":"SY","termSource":"NCI"},{"termName":"LY2127399","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1143503-67-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PQP8VH3MJW"},{"name":"Maps_To","value":"Tabalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"600180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600180"},{"name":"PDQ_Open_Trial_Search_ID","value":"600180"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984518"}]}}{"C143140":{"preferredName":"Tabelecleucel","code":"C143140","definitions":[{"definition":"Allogeneic cytotoxic T-lymphocytes (CTLs) selective for the tumor-associated antigens (TAAs) expressed by the Epstein-Barr virus (EBV), with potential immunostimulating and antineoplastic activities. Upon administration, and after hematopoietic cell transplants (HCT) or solid organ transplants (SOT), or during certain other immunocompromised states, tabelecleucel targets and binds to EBV-associated antigens expressed on EBV-infected cells. This results in lysis of EBV-infected cells and prevents growth of EBV-associated cancer cells. EBV is associated with a variety of cancers and post-transplant lymphoproliferative disorders (EBV+ PTLD).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tabelecleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic EBV-specific CTLs ATA129","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic EBV-specific Cytotoxic T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"ATA 129","termGroup":"CN","termSource":"NCI"},{"termName":"ATA129","termGroup":"CN","termSource":"NCI"},{"termName":"CTLs ATA129","termGroup":"SY","termSource":"NCI"},{"termName":"EBV-CTLs","termGroup":"SY","termSource":"NCI"},{"termName":"Ebvallo","termGroup":"FB","termSource":"NCI"},{"termName":"Tab-cel","termGroup":"FB","termSource":"NCI"},{"termName":"Teb-cel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G3NJ7M8N4H"},{"name":"Maps_To","value":"Tabelecleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"792147"},{"name":"NCI_META_CUI","value":"CL541621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792147"},{"name":"PDQ_Open_Trial_Search_ID","value":"792147"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2202":{"preferredName":"Tacedinaline","code":"C2202","definitions":[{"definition":"A substance being studied in the treatment of non-small cell lung cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by the induction of differentiation, the inhibition of cell proliferation, and apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tacedinaline","termGroup":"PT","termSource":"NCI"},{"termName":"4-(Acetylamino)-N-(2-aminophenyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Acetyldinaline","termGroup":"SY","termSource":"NCI"},{"termName":"CI-994","termGroup":"CN","termSource":"NCI"},{"termName":"GOE5549","termGroup":"CN","termSource":"NCI"},{"termName":"N-acetyl Dinaline","termGroup":"SN","termSource":"NCI"},{"termName":"N-acetyldinaline","termGroup":"SN","termSource":"NCI"},{"termName":"PD 123654","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112522-64-2"},{"name":"Chemical_Formula","value":"C15H15N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UMF554N5FG"},{"name":"Legacy Concept Name","value":"Acetyldinaline"},{"name":"Maps_To","value":"Tacedinaline"},{"name":"NCI_Drug_Dictionary_ID","value":"37825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37825"},{"name":"PDQ_Open_Trial_Search_ID","value":"37825"},{"name":"PubMedID_Primary_Reference","value":"18497959"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0217598"}]}}{"C64769":{"preferredName":"Tagraxofusp-erzs","code":"C64769","definitions":[{"definition":"A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with potential antineoplastic activity. Upon intravenous administration of tagraxofusp-erzs, the IL3 moiety binds to IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin both catalyzes the ADP-ribosylation of, and inactivates, translation elongation factor 2 (EF-2), which results in the inhibition of translation during protein synthesis. IL3 may be overexpressed by a variety of cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia (AML).","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of myeloid leukemia (a disease in which too many immature non-lymphocyte white blood cells are found in the blood and bone marrow). DT388IL3 fusion protein is made by combining IL-3 with a toxic substance. The IL-3 attaches to the cancer cells and the toxic substance kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tagraxofusp-erzs","termGroup":"PT","termSource":"NCI"},{"termName":"Diphtheria Toxin(388)-Interleukin-3 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"DT(388)-IL3 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Elzonris","termGroup":"BR","termSource":"NCI"},{"termName":"IL3R-targeting Fusion Protein SL-401","termGroup":"SY","termSource":"NCI"},{"termName":"S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"SL-401","termGroup":"CN","termSource":"NCI"},{"termName":"Tagraxofusp","termGroup":"SY","termSource":"NCI"},{"termName":"Tagraxofusp ERZS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"blastic plasmacytoid dendritic cell neoplasm (BPDCN)"},{"name":"CAS_Registry","value":"2055491-00-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8ZHS5657EH"},{"name":"Legacy Concept Name","value":"Diphtheria_Toxin_388_Interleukin-3_Fusion_Protein"},{"name":"Maps_To","value":"Tagraxofusp-erzs"},{"name":"NCI_Drug_Dictionary_ID","value":"516002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"516002"},{"name":"PDQ_Open_Trial_Search_ID","value":"516002"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3886200"}]}}{"C48264":{"preferredName":"Talabostat","code":"C48264","definitions":[{"definition":"A small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer, including certain types of lung, pancreas, and brain cancer. Talabostat may help the immune system block the growth of cancer cells. It may also increase the growth of new blood cells. It is a type of enzyme inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Talabostat","termGroup":"PT","termSource":"NCI"},{"termName":"[(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BXCL 701","termGroup":"CN","termSource":"NCI"},{"termName":"BXCL-701","termGroup":"CN","termSource":"NCI"},{"termName":"BXCL701","termGroup":"CN","termSource":"NCI"},{"termName":"PT-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149682-77-9"},{"name":"Chemical_Formula","value":"C9H19BN2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KZ1O2SH88Z"},{"name":"Legacy Concept Name","value":"Talabostat"},{"name":"Maps_To","value":"Talabostat"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002307"}]}}{"C80682":{"preferredName":"Talabostat Mesylate","code":"C80682","definitions":[{"definition":"A substance being studied in the treatment of cancer, including certain types of lung, pancreas, and brain cancer. Talabostat mesylate may help the immune system block the growth of cancer cells. It may also increase the growth of new blood cells. It is a type of enzyme inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of an orally active small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talabostat Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"((2R)-1-((2S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)boronic Acid Methanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Val-boro-Pro","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"150080-09-4"},{"name":"Chemical_Formula","value":"C9H19BN2O3.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V8ZG4Y1B51"},{"name":"Legacy Concept Name","value":"Talabostat_Mesylate"},{"name":"Maps_To","value":"Talabostat Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"372906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"372906"},{"name":"PDQ_Open_Trial_Search_ID","value":"372906"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311786"}]}}{"C102784":{"preferredName":"Talacotuzumab","code":"C102784","definitions":[{"definition":"A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talacotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-3 Receptor Alpha Monoclonal Antibody CSL362","termGroup":"SY","termSource":"NCI"},{"termName":"CSL 362","termGroup":"CN","termSource":"NCI"},{"termName":"CSL362","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-56022473","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ56022473","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1826831-79-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X8JR0I7JE1"},{"name":"Maps_To","value":"Talacotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"736467"},{"name":"NCI_META_CUI","value":"CL437022"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736467"},{"name":"PDQ_Open_Trial_Search_ID","value":"736467"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78460":{"preferredName":"Talactoferrin Alfa","code":"C78460","definitions":[{"definition":"A drug being studied in the treatment of kidney cancer that has spread. It is also being studied in the treatment of other types of cancer and other conditions. Talactoferrin increases the activity of dendritic cells (a type of immune cell) to help kill cancer cells. It is a form of human lactoferrin (a protein found in milk, tears, mucus, bile, and some white blood cells) that is made in the laboratory. Talactoferrin is a type of recombinant protein and a type of immunomodulatory protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable recombinant human lactoferrin produced in the fungus Aspergillus niger with potential antineoplastic and immunomodulating activities. Upon oral administration, talactoferrin is transported into small intestinal Peyer's patches of the gut-associated lymphoreticular tissues (GALT), where it recruits circulating immature dendritic cells (DCs) bearing tumor antigens and induces their maturation. In the GALT, DC maturation in the presence of tumor antigens and lymphoid effector cells may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells; activation of tumor-draining lymph nodes, cellular infiltration of distant tumors, and tumor-cell death may follow. Raising the initial immune response in the GALT, distant from the primary tumor, may counter local tumor-mediated immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talactoferrin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Oral Recombinant Human Lactoferrin","termGroup":"SY","termSource":"NCI"},{"termName":"Oral rhLF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"renal cell carcinoma"},{"name":"CAS_Registry","value":"308240-58-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7A055A9QRR"},{"name":"Legacy Concept Name","value":"Talactoferrin"},{"name":"Maps_To","value":"Talactoferrin Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"394101"},{"name":"PDQ_Closed_Trial_Search_ID","value":"394101"},{"name":"PDQ_Open_Trial_Search_ID","value":"394101"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872514"}]}}{"C103826":{"preferredName":"Taladegib","code":"C103826","definitions":[{"definition":"An orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity. Taladegib inhibits signaling that is mediated by the Hh pathway protein Smo, which may result in a suppression of the Hh signaling pathway and may lead to the inhibition of the proliferation of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taladegib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Benzamide, 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"LY-2940680","termGroup":"CN","termSource":"NCI"},{"termName":"LY2940680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1258861-20-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QY8BWX1LJ5"},{"name":"Maps_To","value":"Taladegib"},{"name":"NCI_Drug_Dictionary_ID","value":"688313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688313"},{"name":"PDQ_Open_Trial_Search_ID","value":"688313"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641628"}]}}{"C38139":{"preferredName":"Talampanel","code":"C38139","definitions":[{"definition":"A substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity.  Talampanel antagonizes the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talampanel","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-(-)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine","termGroup":"SN","termSource":"NCI"},{"termName":"GYKI-53773","termGroup":"CN","termSource":"NCI"},{"termName":"LY-300164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"161832-65-1"},{"name":"Chemical_Formula","value":"C19H19N3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CVS43XG1L5"},{"name":"Legacy Concept Name","value":"Talampanel"},{"name":"Maps_To","value":"Talampanel"},{"name":"NCI_Drug_Dictionary_ID","value":"315898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"315898"},{"name":"PDQ_Open_Trial_Search_ID","value":"315898"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0250723"}]}}{"C26675":{"preferredName":"Talaporfin Sodium","code":"C26675","definitions":[{"definition":"A drug used in photodynamic therapy. When absorbed by cancer cells and exposed to light, the drug becomes active and kills the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.  After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talaporfin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Laserphyrin","termGroup":"FB","termSource":"NCI"},{"termName":"LS11","termGroup":"CN","termSource":"NCI"},{"termName":"ME2906","termGroup":"CN","termSource":"NCI"},{"termName":"Mono-L-aspartyl Chlorin e6","termGroup":"SN","termSource":"NCI"},{"termName":"NPe6","termGroup":"AB","termSource":"NCI"},{"termName":"Taporfin Sodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220201-34-3"},{"name":"Chemical_Formula","value":"C38H37N5O9.4Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L63605PZ70"},{"name":"Legacy Concept Name","value":"Taporfin_Sodium"},{"name":"Maps_To","value":"Talaporfin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"258313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"258313"},{"name":"PDQ_Open_Trial_Search_ID","value":"258313"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350202"}]}}{"C95733":{"preferredName":"Talazoparib","code":"C95733","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talazoparib","termGroup":"PT","termSource":"NCI"},{"termName":"BMN 673","termGroup":"CN","termSource":"NCI"},{"termName":"BMN-673","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1207456-01-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9QHX048FRV"},{"name":"Maps_To","value":"Talazoparib"},{"name":"NCI_Drug_Dictionary_ID","value":"694964"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694964"},{"name":"PDQ_Open_Trial_Search_ID","value":"694964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4042960"}]}}{"C61314":{"preferredName":"Talimogene Laherparepvec","code":"C61314","definitions":[{"definition":"An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talimogene Laherparepvec","termGroup":"PT","termSource":"NCI"},{"termName":"ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Imlygic","termGroup":"BR","termSource":"NCI"},{"termName":"JS1 34.5-hGMCSF 47- pA-","termGroup":"CN","termSource":"NCI"},{"termName":"OncoVEX GM-CSF","termGroup":"AQS","termSource":"NCI"},{"termName":"T-VEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery"},{"name":"CAS_Registry","value":"1187560-31-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"07730V90L6"},{"name":"Legacy Concept Name","value":"GM-CSF-Encoding_Oncolytic_Herpes_Simplex_Virus_Vaccine"},{"name":"Maps_To","value":"Talimogene Laherparepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"485296"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485296"},{"name":"PDQ_Open_Trial_Search_ID","value":"485296"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831828"}]}}{"C1603":{"preferredName":"Tallimustine","code":"C1603","definitions":[{"definition":"A benzoyl mustard derivative of the antiviral agent distamycin A with potential antineoplastic activity. Tallimustine selectively binds to A-T rich regions in the minor groove of DNA and alkylates at the N3 position of adenine in a highly sequence-specific manner. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. Moreover, unlike other clinical nitrogen mustards, tallimustine does not carry out guanine-N7 alkylation in the major groove of DNA, which may lead to a high selectivity of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tallimustine","termGroup":"PT","termSource":"NCI"},{"termName":"FCE 24517","termGroup":"CN","termSource":"NCI"},{"termName":"PNU-152241","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"115308-98-0"},{"name":"Chemical_Formula","value":"C32H38Cl2N10O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71193OXG6S"},{"name":"Legacy Concept Name","value":"Tallimustine"},{"name":"Maps_To","value":"Tallimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"42145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42145"},{"name":"PDQ_Open_Trial_Search_ID","value":"42145"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286890"}]}}{"C79841":{"preferredName":"Talmapimod","code":"C79841","definitions":[{"definition":"An orally bioavailable, small-molecule, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activities. Talmapimod specifically binds to and inhibits the phosphorylation of p38 MAPK, which may result in the induction of tumor cell apoptosis, the inhibition of tumor cell proliferation, and the inhibition of tumor angiogenesis. This agent may also enhance proteasome inhibitor-induced apoptosis. p38 MAPK is a serine/threonine protein kinase involved in a MAPK signaling cascade that controls cellular responses to various environmental stresses, cytokines, and endotoxins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talmapimod","termGroup":"PT","termSource":"NCI"},{"termName":"1H-indole-3-acetamide, 6-Chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1- piperazinyl]carbonyl]-N,N,1-trimethyl-alpha-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"2-[6-Chloro-5-[[(2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazin-1-yl]carbonyl]-1- methyl-1H-indol-3-yl]-N,N-dimethyl-2-oxoacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"SCIO 469","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"309913-83-5"},{"name":"Chemical_Formula","value":"C27H30ClFN4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B1E00KQ6NT"},{"name":"Legacy Concept Name","value":"Talmapimod"},{"name":"Maps_To","value":"Talmapimod"},{"name":"NCI_Drug_Dictionary_ID","value":"387795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"387795"},{"name":"PDQ_Open_Trial_Search_ID","value":"387795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541463"}]}}{"C29341":{"preferredName":"Talotrexin","code":"C29341","definitions":[{"definition":"A substance that is being studied in the treatment of leukemia and some other types of cancer. It belongs to the family of drugs called antifolates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talotrexin","termGroup":"PT","termSource":"NCI"},{"termName":"N(alpha)-(4-Amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine","termGroup":"SN","termSource":"NCI"},{"termName":"PT523","termGroup":"CN","termSource":"NCI"},{"termName":"Talopterin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"113857-87-7"},{"name":"Chemical_Formula","value":"C27H27N9O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A8E516A20K"},{"name":"Legacy Concept Name","value":"PT523"},{"name":"Maps_To","value":"Talotrexin"},{"name":"NSC Number","value":"623017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0251361"}]}}{"C80159":{"preferredName":"Talotrexin Ammonium","code":"C80159","definitions":[{"definition":"An ammonium salt of tallotrexin, an analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talotrexin Ammonium","termGroup":"PT","termSource":"NCI"},{"termName":"2-(((4S)-4-Carboxy-4-((4-(((2,4-diaminopteridin-6-yl)methyl)amino)benzoyl)amino)butyl)carbamoyl)benzoic Acid Monoammonium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"PT-523","termGroup":"CN","termSource":"NCI"},{"termName":"PT523","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"648420-92-2"},{"name":"Chemical_Formula","value":"C27H27N9O6.H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"686WJT9102"},{"name":"Legacy Concept Name","value":"Talotrexin_Ammonium"},{"name":"Maps_To","value":"Talotrexin Ammonium"},{"name":"NCI_Drug_Dictionary_ID","value":"387796"},{"name":"NSC Number","value":"712783"},{"name":"PDQ_Closed_Trial_Search_ID","value":"387796"},{"name":"PDQ_Open_Trial_Search_ID","value":"387796"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0288639"}]}}{"C75998":{"preferredName":"Taltobulin","code":"C75998","definitions":[{"definition":"An analogue of the naturally occurring tripeptide hemiasterlin, with potential antimitotic and antineoplastic activities. Taltobulin binds tubulin in a similar manner as colchicine and inhibits tubulin polymerization. This results in the disruption of the cytoskeleton, ultimately leading to cell cycle arrest in G2/M phase, blockage of cell division and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taltobulin","termGroup":"PT","termSource":"NCI"},{"termName":"HTI-286","termGroup":"CN","termSource":"NCI"},{"termName":"SPA-110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"228266-40-8"},{"name":"Chemical_Formula","value":"C27H43N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J6D6912BXS"},{"name":"Legacy Concept Name","value":"Taltobulin"},{"name":"Maps_To","value":"Taltobulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1258191"}]}}{"C150585":{"preferredName":"TAM/c-Met Inhibitor RXDX-106","code":"C150585","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinase (RTK) activity of both hepatocyte growth factor receptor (c-Met; HGFR) and receptors in the TYRO3, AXL, and MER (TAM) family, with potential immunomodulating and antineoplastic activities. Upon oral administration of TAM/c-Met inhibitor RXDX-106, this agent selectively targets and binds to TYRO3, AXL, MER and c-Met, and prevents their RTK activity. This blocks TYRO3/AXL/MER/c-Met-mediated signal transduction pathways, and inhibits the proliferation and migration of TYRO3-, AXL-, MER- and c-Met-overexpressing tumor cells. Inhibition of the TAM family in the tumor microenvironment (TME) activates the immune system in the TME, reverses TAM mediated immunosuppression and enhances the anti-tumor immune response, which lead to immune-mediated tumor cell killing. TYRO3, AXL and MER, members of the TAM family of RTKs, are overexpressed in many tumor cell types. TAMs play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis. c-Met, also overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. In the TME, TAM expression on immune cells contributes to tumor cell evasion of immune surveillance and to the negative regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAM/c-Met Inhibitor RXDX-106","termGroup":"PT","termSource":"NCI"},{"termName":"CEP 40783","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-40783","termGroup":"CN","termSource":"NCI"},{"termName":"CEP40783","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-(6,7-Dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"RXDX 106","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-106","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX106","termGroup":"CN","termSource":"NCI"},{"termName":"TYRO3/AXL/MER/c-Met Inhibitor RXDX-106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1437321-24-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1969ZJE05Q"},{"name":"Maps_To","value":"TAM/c-Met Inhibitor RXDX-106"},{"name":"NCI_Drug_Dictionary_ID","value":"793447"},{"name":"NCI_META_CUI","value":"CL552337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793447"},{"name":"PDQ_Open_Trial_Search_ID","value":"793447"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71025":{"preferredName":"Tamibarotene","code":"C71025","definitions":[{"definition":"An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamibarotene","termGroup":"PT","termSource":"NCI"},{"termName":"4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)","termGroup":"SY","termSource":"NCI"},{"termName":"Am-80","termGroup":"CN","termSource":"NCI"},{"termName":"Am80","termGroup":"CN","termSource":"NCI"},{"termName":"Benzoic Acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-Tetramethyl-2-naphthalenyl)amino)carbonyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INNO-507","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Retinobenzoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"SY-1425","termGroup":"CN","termSource":"NCI"},{"termName":"TM-411","termGroup":"CN","termSource":"NCI"},{"termName":"TOS-80T","termGroup":"CN","termSource":"NCI"},{"termName":"Z-208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"94497-51-5"},{"name":"CHEBI_ID","value":"CHEBI:32181"},{"name":"Chemical_Formula","value":"C22H25NO3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"08V52GZ3H9"},{"name":"Legacy Concept Name","value":"Tamibarotene"},{"name":"Maps_To","value":"Tamibarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"571791"},{"name":"NSC Number","value":"608000"},{"name":"PDQ_Closed_Trial_Search_ID","value":"571791"},{"name":"PDQ_Open_Trial_Search_ID","value":"571791"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567753"}]}}{"C121664":{"preferredName":"Taminadenant","code":"C121664","definitions":[{"definition":"An orally bioavailable adenosine A2A receptor (A2AR) antagonist, with potential antineoplastic activity. Upon administration, A2AR antagonist PBF-509 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This abrogates the adenosine/A2AR-mediated inhibition of T-lymphocytes and activates a T-cell-mediated immune response against tumor cells, thereby reducing proliferation of susceptible tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often produced in excess by cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taminadenant","termGroup":"PT","termSource":"NCI"},{"termName":"4-Pyrimidinamine, 5-Bromo-2,6-di-1H-pyrazol-1-yl-","termGroup":"SY","termSource":"NCI"},{"termName":"A2AR Antagonist PBF-509","termGroup":"SY","termSource":"NCI"},{"termName":"PBF-509","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1337962-47-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"84I5UEP321"},{"name":"Maps_To","value":"Taminadenant"},{"name":"NCI_Drug_Dictionary_ID","value":"770798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770798"},{"name":"PDQ_Open_Trial_Search_ID","value":"770798"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053608"}]}}{"C62078":{"preferredName":"Tamoxifen","code":"C62078","definitions":[{"definition":"A drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamoxifen","termGroup":"PT","termSource":"NCI"},{"termName":"1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene","termGroup":"SN","termSource":"NCI"},{"termName":"TMX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10540-29-1"},{"name":"CHEBI_ID","value":"CHEBI:41774"},{"name":"Chemical_Formula","value":"C26H29NO"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"094ZI81Y45"},{"name":"Legacy Concept Name","value":"Tamoxifen_Base"},{"name":"Maps_To","value":"Tamoxifen"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039286"}]}}{"C855":{"preferredName":"Tamoxifen Citrate","code":"C855","definitions":[{"definition":"A drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen citrate is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen citrate is a type of antiestrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamoxifen Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"(Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate","termGroup":"SN","termSource":"NCI"},{"termName":"1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene Citrate","termGroup":"SN","termSource":"NCI"},{"termName":"Apo-Tamox","termGroup":"FB","termSource":"NCI"},{"termName":"Clonoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Dignotamoxi","termGroup":"FB","termSource":"NCI"},{"termName":"Ebefen","termGroup":"FB","termSource":"NCI"},{"termName":"Emblon","termGroup":"FB","termSource":"NCI"},{"termName":"Estroxyn","termGroup":"FB","termSource":"NCI"},{"termName":"Fentamox","termGroup":"FB","termSource":"NCI"},{"termName":"Gen-Tamoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Genox","termGroup":"FB","termSource":"NCI"},{"termName":"ICI 46,474","termGroup":"CN","termSource":"NCI"},{"termName":"ICI-46474","termGroup":"CN","termSource":"NCI"},{"termName":"Jenoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Kessar","termGroup":"FB","termSource":"NCI"},{"termName":"Ledertam","termGroup":"FB","termSource":"NCI"},{"termName":"Lesporene","termGroup":"FB","termSource":"NCI"},{"termName":"Nolgen","termGroup":"FB","termSource":"NCI"},{"termName":"Noltam","termGroup":"FB","termSource":"NCI"},{"termName":"Nolvadex","termGroup":"BR","termSource":"NCI"},{"termName":"Nolvadex-D","termGroup":"FB","termSource":"NCI"},{"termName":"Nourytam","termGroup":"FB","termSource":"NCI"},{"termName":"Novo-Tamoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Novofen","termGroup":"FB","termSource":"NCI"},{"termName":"Noxitem","termGroup":"FB","termSource":"NCI"},{"termName":"Oestrifen","termGroup":"FB","termSource":"NCI"},{"termName":"Oncotam","termGroup":"FB","termSource":"NCI"},{"termName":"PMS-Tamoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Soltamox","termGroup":"BR","termSource":"NCI"},{"termName":"TAM","termGroup":"AB","termSource":"NCI"},{"termName":"Tamax","termGroup":"FB","termSource":"NCI"},{"termName":"Tamaxin","termGroup":"FB","termSource":"NCI"},{"termName":"Tamifen","termGroup":"FB","termSource":"NCI"},{"termName":"Tamizam","termGroup":"FB","termSource":"NCI"},{"termName":"Tamofen","termGroup":"FB","termSource":"NCI"},{"termName":"Tamoxasta","termGroup":"FB","termSource":"NCI"},{"termName":"Tamoxifeni Citras","termGroup":"FB","termSource":"NCI"},{"termName":"Zemide","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Endometrial cancer; Gynecomastia; Melanoma; Ovarian cancer"},{"name":"CAS_Registry","value":"54965-24-1"},{"name":"CHEBI_ID","value":"CHEBI:9397"},{"name":"Chemical_Formula","value":"C26H29NO.C6H8O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7FRV7310N6"},{"name":"Legacy Concept Name","value":"Tamoxifen"},{"name":"Maps_To","value":"Tamoxifen Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"42901"},{"name":"NSC Number","value":"180973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42901"},{"name":"PDQ_Open_Trial_Search_ID","value":"42901"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700621"}]}}{"C48404":{"preferredName":"Tandutinib","code":"C48404","definitions":[{"definition":"A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It may stop cancer cell growth by blocking certain enzymes. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tandutinib","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CT53518","termGroup":"CN","termSource":"NCI"},{"termName":"MLN 518","termGroup":"CN","termSource":"NCI"},{"termName":"MLN518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"387867-13-2"},{"name":"Chemical_Formula","value":"C31H42N6O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E1IO3ICJ9A"},{"name":"Legacy Concept Name","value":"MLN518"},{"name":"Maps_To","value":"Tandutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"353146"},{"name":"NSC Number","value":"726292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"353146"},{"name":"PDQ_Open_Trial_Search_ID","value":"353146"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1143028"}]}}{"C37899":{"preferredName":"Tanespimycin","code":"C37899","definitions":[{"definition":"A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin.  Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is made from an antibiotic called geldanamycin. Tanespimycin helps cause the breakdown of certain proteins in the cell, and may kill cancer cells. It is a type of antineoplastic antibiotic and a type of HSP90 inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tanespimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-(Allylamino)-17-demethoxygeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"17-AAG","termGroup":"AB","termSource":"NCI"},{"termName":"17-Allylamino-17-demethoxygeldanamycin","termGroup":"SN","termSource":"NCI"},{"termName":"17-Demethoxy-17-(2-propenylamino)geldanamycin","termGroup":"SN","termSource":"NCI"},{"termName":"17-N-allylamino-17-demethoxygeldanamycin","termGroup":"SN","termSource":"NCI"},{"termName":"KOS-953","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Myelogenous Leukemia"},{"name":"CAS_Registry","value":"75747-14-7"},{"name":"CHEBI_ID","value":"CHEBI:64153"},{"name":"Chemical_Formula","value":"C31H43N3O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4GY0AVT3L4"},{"name":"Legacy Concept Name","value":"_17-Allylamino_17-demethoxygeldanamycin"},{"name":"Maps_To","value":"Tanespimycin"},{"name":"NCI_Drug_Dictionary_ID","value":"43635"},{"name":"NSC Number","value":"330507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43635"},{"name":"PDQ_Open_Trial_Search_ID","value":"43635"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0675974"}]}}{"C102877":{"preferredName":"Olinvacimab","code":"C102877","definitions":[{"definition":"A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olinvacimab","termGroup":"PT","termSource":"NCI"},{"termName":"TTAC-0001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095504-49-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VFH55IZ5VI"},{"name":"Maps_To","value":"Olinvacimab"},{"name":"Maps_To","value":"Tanibirumab"},{"name":"NCI_Drug_Dictionary_ID","value":"738495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738495"},{"name":"PDQ_Open_Trial_Search_ID","value":"738495"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490677"}]}}{"C1705":{"preferredName":"Tanomastat","code":"C1705","definitions":[{"definition":"A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tanomastat","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-3-[(4'-Chloro-4-biphenylyl)carbonyl]-2-[(phenylthio)methyl]propionic acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-[4-(chlorophenyl)phenyl]-4-oxo-2S-(phenylthiomethyl) butanoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 12-9566","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-12-9566","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"179545-77-8"},{"name":"Chemical_Formula","value":"C23H19ClO3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AM1ZX94EXH"},{"name":"Legacy Concept Name","value":"Tanomastat"},{"name":"Maps_To","value":"Tanomastat"},{"name":"NCI_Drug_Dictionary_ID","value":"42675"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42675"},{"name":"PDQ_Open_Trial_Search_ID","value":"42675"},{"name":"PubMedID_Primary_Reference","value":"16442153"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393069"}]}}{"C26666":{"preferredName":"Tarenflurbil","code":"C26666","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active synthetic enantiomer of flurbiprofen.  Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tarenflurbil","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"E-7869","termGroup":"CN","termSource":"NCI"},{"termName":"Flurizan","termGroup":"BR","termSource":"NCI"},{"termName":"MPC-7869","termGroup":"CN","termSource":"NCI"},{"termName":"R-flurbiprofen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51543-40-9"},{"name":"CHEBI_ID","value":"CHEBI:38666"},{"name":"Chemical_Formula","value":"C15H13FO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"501W00OOWA"},{"name":"Legacy Concept Name","value":"R-flurbiprofen"},{"name":"Maps_To","value":"Tarenflurbil"},{"name":"NCI_Drug_Dictionary_ID","value":"257154"},{"name":"NSC Number","value":"685699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257154"},{"name":"PDQ_Open_Trial_Search_ID","value":"257154"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527219"}]}}{"C95719":{"preferredName":"Tarextumab","code":"C95719","definitions":[{"definition":"A monoclonal antibody directed against the Notch receptor with potential antineoplastic activity. Tarextumab binds to Notch on the cell surface, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Notch receptors are important for cell-cell communication, which involves gene regulation mechanisms that control multiple cell differentiation processes during embryonic and adult life. Dysregulated Notch signaling is implicated in many diseases including T-ALL (T-cell acute lymphoblastic leukemia), CADASIL (Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy), MS (Multiple Sclerosis), and many other disease states.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tarextumab","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb OMP-59R5","termGroup":"AB","termSource":"NCI"},{"termName":"OMP 59R5","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-59R5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1359940-55-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"333YMY788E"},{"name":"Maps_To","value":"Tarextumab"},{"name":"NCI_Drug_Dictionary_ID","value":"693946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693946"},{"name":"PDQ_Open_Trial_Search_ID","value":"693946"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053948"}]}}{"C2246":{"preferredName":"Tariquidar","code":"C2246","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It may help tumor cells respond again to drugs they have become resistant (unable to respond) to. Tariquidar is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tariquidar","termGroup":"PT","termSource":"NCI"},{"termName":"XR9576","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"206873-63-4"},{"name":"Chemical_Formula","value":"C38H38N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J58862DTVD"},{"name":"Legacy Concept Name","value":"Tariquidar"},{"name":"Maps_To","value":"Tariquidar"},{"name":"NCI_Drug_Dictionary_ID","value":"37877"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37877"},{"name":"PDQ_Open_Trial_Search_ID","value":"37877"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879444"}]}}{"C116876":{"preferredName":"Taselisib","code":"C116876","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taselisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0032","termGroup":"CN","termSource":"NCI"},{"termName":"RO5537381","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1282512-48-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L08J2O299M"},{"name":"Maps_To","value":"Taselisib"},{"name":"NCI_Drug_Dictionary_ID","value":"695816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695816"},{"name":"PDQ_Open_Trial_Search_ID","value":"695816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660928"}]}}{"C77067":{"preferredName":"Tasidotin","code":"C77067","definitions":[{"definition":"A third generation, synthetic, water-soluble, pentapeptide analog of the marine depsipeptide dolastatin 15, with potential antimitotic and antineoplastic activities. Tasidotin and its metabolite, tasidotin C-carboxylate, suppress the dynamic instability behavior of the microtubules through a reduction of the shortening rate (disassembly); reduction of the switching frequency from growth to shortening; and by reducing microtubules growth time. This may eventually result in a reduction of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasidotin","termGroup":"PT","termSource":"NCI"},{"termName":"ILX651","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192658-64-3"},{"name":"Chemical_Formula","value":"C32H58N6O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05G07285DK"},{"name":"Legacy Concept Name","value":"Tasidotin"},{"name":"Maps_To","value":"Tasidotin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1610484"}]}}{"C62794":{"preferredName":"Tasisulam","code":"C62794","definitions":[{"definition":"An acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasisulam","termGroup":"PT","termSource":"NCI"},{"termName":"LY-573636","termGroup":"CN","termSource":"NCI"},{"termName":"LY573636","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"519055-62-0"},{"name":"Chemical_Formula","value":"C11H6BrCl2NO3S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1YC4W9MSLJ"},{"name":"Legacy Concept Name","value":"LY573636"},{"name":"Maps_To","value":"Tasisulam"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831958"}]}}{"C88304":{"preferredName":"Tasisulam Sodium","code":"C88304","definitions":[{"definition":"The sodium salt of an acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasisulam Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-[(5-Bromo-2-thienyl)sulfonyl]-2,4-dichloro-, Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"LY-573636.Na","termGroup":"CN","termSource":"NCI"},{"termName":"LY573636-Sodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"519055-63-1"},{"name":"Chemical_Formula","value":"C11H5BrCl2NO3S2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3955SHR9J"},{"name":"Maps_To","value":"Tasisulam Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"506118"},{"name":"PDQ_Closed_Trial_Search_ID","value":"506118"},{"name":"PDQ_Open_Trial_Search_ID","value":"506118"},{"name":"PubMedID_Primary_Reference","value":"18949427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537265"}]}}{"C74080":{"preferredName":"Tasquinimod","code":"C74080","definitions":[{"definition":"A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasquinimod","termGroup":"PT","termSource":"NCI"},{"termName":"ABR-215050","termGroup":"CN","termSource":"NCI"},{"termName":"TASQ","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"254964-60-8"},{"name":"Chemical_Formula","value":"C20H17F3N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"756U07KN1R"},{"name":"Legacy Concept Name","value":"Tasquinimod"},{"name":"Maps_To","value":"Tasquinimod"},{"name":"NCI_Drug_Dictionary_ID","value":"581229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581229"},{"name":"PDQ_Open_Trial_Search_ID","value":"581229"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1956491"}]}}{"C2639":{"preferredName":"Taurolidine","code":"C2639","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called anti-infectives.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic broad-spectrum antimicrobial with antibacterial, antifungal, anticoagulant, and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taurolidine","termGroup":"PT","termSource":"NCI"},{"termName":"Bis(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)-methane","termGroup":"SN","termSource":"NCI"},{"termName":"Taurolin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bronchiectasis; Catheter-Related Sepsis; Otitis Media; Peritonitis; Thoracic Empyema"},{"name":"CAS_Registry","value":"19388-87-5"},{"name":"Chemical_Formula","value":"C7H16N4O4S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8OBZ1M4V3V"},{"name":"Legacy Concept Name","value":"Taurolidine"},{"name":"Maps_To","value":"Taurolidine"},{"name":"NCI_Drug_Dictionary_ID","value":"38354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38354"},{"name":"PDQ_Open_Trial_Search_ID","value":"38354"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0144567"}]}}{"C954":{"preferredName":"Tauromustine","code":"C954","definitions":[{"definition":"A water-soluble taurine-based nitrosourea with potential antineoplastic activity. Tauromustine alkylates DNA and causes DNA cross links independent of cell cycle, thereby resulting in disruption of DNA function and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tauromustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"LS-2667","termGroup":"CN","termSource":"NCI"},{"termName":"TCNU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85977-49-7"},{"name":"Chemical_Formula","value":"C7H15ClN4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"511F69K76Y"},{"name":"Legacy Concept Name","value":"Tauromustine"},{"name":"Maps_To","value":"Tauromustine"},{"name":"NCI_Drug_Dictionary_ID","value":"40279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40279"},{"name":"PDQ_Open_Trial_Search_ID","value":"40279"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044133"}]}}{"C75290":{"preferredName":"Taurultam","code":"C75290","definitions":[{"definition":"A reversible metabolite of taurolidine and an amino acid taurine derivative, with antibacterial and antineoplastic activity. Taurultam, like its congener taurolidine, inhibits proliferation of microvascular endothelial cells, although to a lesser extent, by selectively inhibiting the adhesion of endothelial cells to laminin but not to collagen I and fibronectin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taurultam","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38668-01-8"},{"name":"Chemical_Formula","value":"C3H8N2O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LIX7OM008P"},{"name":"Legacy Concept Name","value":"Taurultam"},{"name":"Maps_To","value":"Taurultam"},{"name":"PubMedID_Primary_Reference","value":"17395893"},{"name":"PubMedID_Primary_Reference","value":"9552463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0673101"}]}}{"C159500":{"preferredName":"Misetionamide","code":"C159500","definitions":[{"definition":"An oxathiazine-based structural analogue of taurultam (TRLT), which is the main derivative of the anti-infective agent taurolidine (TRD), with potential antineoplastic activity. Upon administration,misetionamide selectively induces reactive oxygen species (ROS)-mediated apoptosis in and inhibits proliferation of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Misetionamide","termGroup":"PT","termSource":"NCI"},{"termName":"GP 2250","termGroup":"CN","termSource":"NCI"},{"termName":"GP-2250","termGroup":"CN","termSource":"NCI"},{"termName":"GP2250","termGroup":"CN","termSource":"NCI"},{"termName":"Taurultam Analogue GP-2250","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"856785-75-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"489TQ24FC1"},{"name":"Maps_To","value":"Taurultam Analogue GP-2250"},{"name":"NCI_Drug_Dictionary_ID","value":"797809"},{"name":"NCI_META_CUI","value":"CL951458"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797809"},{"name":"PDQ_Open_Trial_Search_ID","value":"797809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156363":{"preferredName":"Tavokinogene Telseplasmid","code":"C156363","definitions":[{"definition":"A DNA plasmid that encodes genes for both the p35 and p40 subunits of the heterodimeric human interleukin 12 (hIL-12) protein that are separated by an internal ribosome entry site (IRES) and under the control of a single cytomegalovirus (CMV) promoter, with potential immunomodulatory and antineoplastic activities. Upon administration via intratumoral injection and electroporation, the plasmid is introduced into human cells resulting in expression and highly-localized secretion of a functional IL-12 p70 protein into the tumor microenvironment (TME). IL-12 is a pro-inflammatory cytokine that plays a significant role in priming and maintaining T-helper (Th) cells, activating natural killer (NK) cells, and regulating the reactivation and survival of memory T-cells (Tm). Increased levels of IL-12 in the TME may augment host immune response against tumor cells by inhibiting regulatory T-cells (Tregs), T-helper 2 (Th2) responses, and myeloid-derived suppressor cells (MDSCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tavokinogene Telseplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"IT-Tavo-EP","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmid IL-12 pUMVC3-hIL-12-NGVL3","termGroup":"SY","termSource":"NCI"},{"termName":"Tavo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1971880-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MF4P7VQ2K8"},{"name":"Maps_To","value":"Tavokinogene Telseplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"795694"},{"name":"NCI_META_CUI","value":"CL563071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795694"},{"name":"PDQ_Open_Trial_Search_ID","value":"795694"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120041":{"preferredName":"Tavolimab","code":"C120041","definitions":[{"definition":"An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, tavolimab selectively binds to and activates the OX40 receptor. OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this agent may promote an immune response against TAAs-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tavolimab","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI-0562","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI0562","termGroup":"CN","termSource":"NCI"},{"termName":"Tavolixizumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1635395-25-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4LU9B48U4D"},{"name":"Maps_To","value":"Tavolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"767471"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767471"},{"name":"PDQ_Open_Trial_Search_ID","value":"767471"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896818"}]}}{"C48424":{"preferredName":"Taxane Analogue TPI 287","code":"C48424","definitions":[{"definition":"A synthetic, third generation taxane with potential antineoplastic activity. TPI 287 binds to tubulin and stabilizes microtubules, resulting in inhibition of microtubule assembly/disassembly dynamics, cell cycle arrest at the G2/M phase, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taxane Analogue TPI 287","termGroup":"PT","termSource":"NCI"},{"termName":"TPI 287","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849213-15-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TPI_287"},{"name":"Maps_To","value":"Taxane Analogue TPI 287"},{"name":"NCI_Drug_Dictionary_ID","value":"438803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"438803"},{"name":"PDQ_Open_Trial_Search_ID","value":"438803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1710314"}]}}{"C1490":{"preferredName":"Taxane Compound","code":"C1490","definitions":[{"definition":"A type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Taxane Compound","termGroup":"PT","termSource":"NCI"},{"termName":"Taxanes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1605-68-1"},{"name":"CHEBI_ID","value":"CHEBI:36064"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Taxane_Compound"},{"name":"Maps_To","value":"Taxane Compound"},{"name":"Semantic_Type","value":"Chemical Viewed Structurally"},{"name":"UMLS_CUI","value":"C0796419"}]}}{"C84839":{"preferredName":"Taxol Analogue SID 530","code":"C84839","definitions":[{"definition":"An intravenous formulation containing docetaxel, a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata, with potential antineoplastic activity. Taxol analogue SID 530 binds to and stabilizes tubulin, inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taxol Analogue SID 530","termGroup":"PT","termSource":"NCI"},{"termName":"SID 530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Taxol Analogue SID 530"},{"name":"NCI_Drug_Dictionary_ID","value":"650025"},{"name":"NCI_META_CUI","value":"CL412390"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650025"},{"name":"PDQ_Open_Trial_Search_ID","value":"650025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29487":{"preferredName":"Tazarotene","code":"C29487","definitions":[{"definition":"A drug used on the skin to treat several skin conditions. It is also being studied in the treatment of basal cell skin cancer and basal cell nevus syndrome. Tazarotene is related to vitamin A and is made in the laboratory. It turns on a gene that may help stop the growth of skin cancer cells. Tazarotene is a type of synthetic retinoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, topical retinoid.  Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.  In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tazarotene","termGroup":"PT","termSource":"NCI"},{"termName":"6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-Pyridinecarboxylic Acid, Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"AGN-190168","termGroup":"CN","termSource":"NCI"},{"termName":"Avage","termGroup":"BR","termSource":"NCI"},{"termName":"Ethyl 6-(2-(4,4-Dimethylthiochroman-6-yl)ethynyl)nicotinate","termGroup":"SN","termSource":"NCI"},{"termName":"Tazorac","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Topical treatment of facial acne vulgaris; stable plaque psoriasis; mitigation (palliation) of facial fine wrinkling; facial mottled hyper- and hypopigmentation; benign facial lentigines"},{"name":"CAS_Registry","value":"118292-40-3"},{"name":"CHEBI_ID","value":"CHEBI:32184"},{"name":"Chemical_Formula","value":"C21H21NO2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81BDR9Y8PS"},{"name":"Legacy Concept Name","value":"Tazarotene"},{"name":"Maps_To","value":"Tazarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"553530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"553530"},{"name":"PDQ_Open_Trial_Search_ID","value":"553530"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0288792"}]}}{"C107506":{"preferredName":"Tazemetostat","code":"C107506","definitions":[{"definition":"An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tazemetostat","termGroup":"PT","termSource":"NCI"},{"termName":"E7438","termGroup":"CN","termSource":"NCI"},{"termName":"EPZ-6438","termGroup":"CN","termSource":"NCI"},{"termName":"EPZ6438","termGroup":"CN","termSource":"NCI"},{"termName":"N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1403254-99-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q40W93WPE1"},{"name":"Maps_To","value":"Tazemetostat"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827128"}]}}{"C1605":{"preferredName":"Tecogalan Sodium","code":"C1605","definitions":[{"definition":"A sulfated polysaccharide isolated from various Arthrobacter bacterial species.  Possessing potential antiangiogenic and antineoplastic properties, tecogalan binds to basic fibroblast growth factor (bFGF), thereby preventing bFGF from binding to its receptors.  Disruption of this receptor binding results in the inhibition of bFGF-stimulated endothelial cell growth, proliferation, and migration. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tecogalan Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"DS-4152","termGroup":"CN","termSource":"NCI"},{"termName":"SP-PG","termGroup":"AB","termSource":"NCI"},{"termName":"Sulfated Polysaccharide Tecogalan DS-4152","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tecogalan_Sodium"},{"name":"Maps_To","value":"Tecogalan Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"42149"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42149"},{"name":"PDQ_Open_Trial_Search_ID","value":"42149"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0212199"}]}}{"C513":{"preferredName":"Tegafur","code":"C513","definitions":[{"definition":"A congener of the antimetabolite fluorouracil with antineoplastic activity. Tegafur is a prodrug that is gradually converted to fluorouracil in the liver by the cytochrome P-450 enzyme. Subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by inhibiting thymidylate synthase and reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tegafur","termGroup":"PT","termSource":"NCI"},{"termName":"5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-(1H,3H)-pyrimidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-1-(tetrahydro-2-furyl)-uracil","termGroup":"SN","termSource":"NCI"},{"termName":"Citofur","termGroup":"FB","termSource":"NCI"},{"termName":"Coparogin","termGroup":"FB","termSource":"NCI"},{"termName":"Exonal","termGroup":"FB","termSource":"NCI"},{"termName":"Fental","termGroup":"FB","termSource":"NCI"},{"termName":"Florafur","termGroup":"BR","termSource":"NCI"},{"termName":"Fluorofur","termGroup":"BR","termSource":"NCI"},{"termName":"FT","termGroup":"AB","termSource":"NCI"},{"termName":"FT-207","termGroup":"CN","termSource":"NCI"},{"termName":"Ftorafur","termGroup":"FB","termSource":"NCI"},{"termName":"Ftoral","termGroup":"FB","termSource":"NCI"},{"termName":"Ftoralon","termGroup":"FB","termSource":"NCI"},{"termName":"Fulaid","termGroup":"FB","termSource":"NCI"},{"termName":"Fulfeel","termGroup":"FB","termSource":"NCI"},{"termName":"Furafluor","termGroup":"FB","termSource":"NCI"},{"termName":"Furofutran","termGroup":"FB","termSource":"NCI"},{"termName":"Futraful","termGroup":"FB","termSource":"NCI"},{"termName":"Lamar","termGroup":"FB","termSource":"NCI"},{"termName":"Lifril","termGroup":"FB","termSource":"NCI"},{"termName":"MJF-12264","termGroup":"CN","termSource":"NCI"},{"termName":"N1-(2'-Furanidyl)-5-fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"Neberk","termGroup":"FB","termSource":"NCI"},{"termName":"Nitobanil","termGroup":"FB","termSource":"NCI"},{"termName":"Riol","termGroup":"FB","termSource":"NCI"},{"termName":"Sinoflurol","termGroup":"FB","termSource":"NCI"},{"termName":"Sunfural","termGroup":"FB","termSource":"NCI"},{"termName":"Tefsiel","termGroup":"FB","termSource":"NCI"},{"termName":"Utefos","termGroup":"FB","termSource":"NCI"},{"termName":"WR-220066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17902-23-7"},{"name":"Chemical_Formula","value":"C8H9FN2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1548R74NSZ"},{"name":"Legacy Concept Name","value":"Tegafur"},{"name":"Maps_To","value":"Tegafur"},{"name":"NCI_Drug_Dictionary_ID","value":"39248"},{"name":"NSC Number","value":"148958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39248"},{"name":"PDQ_Open_Trial_Search_ID","value":"39248"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016778"}]}}{"C1833":{"preferredName":"Tegafur-gimeracil-oteracil Potassium","code":"C1833","definitions":[{"definition":"A drug that is being studied for its ability to enhance the effectiveness of fluorouracil and prevent gastrointestinal side effects caused by fluorouracil. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tegafur-gimeracil-oteracil Potassium","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 247616","termGroup":"CN","termSource":"NCI"},{"termName":"S-1","termGroup":"CN","termSource":"NCI"},{"termName":"Tegafur, mixture with Gimeracil and Potassium Oxonate","termGroup":"SY","termSource":"NCI"},{"termName":"Tegafur/Gimeracil/Oteracil","termGroup":"SY","termSource":"NCI"},{"termName":"Teysuno","termGroup":"FB","termSource":"NCI"},{"termName":"TS-1","termGroup":"CN","termSource":"NCI"},{"termName":"TS-One","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154239-56-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"S-1"},{"name":"Maps_To","value":"Tegafur-gimeracil-oteracil Potassium"},{"name":"NCI_Drug_Dictionary_ID","value":"43548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43548"},{"name":"PDQ_Open_Trial_Search_ID","value":"43548"},{"name":"PubMedID_Primary_Reference","value":"15224197"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879262"}]}}{"C120099":{"preferredName":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation","code":"C120099","definitions":[{"definition":"An orally bioavailable granular formulation composed of the fluoropyrimidine antagonist tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and oteracil potassium, and the folic acid derivative leucovorin calcium, with potential antineoplastic activity. Tegafur is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that is further metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits thymidylate synthase, DNA synthesis and cell division; FUTP competes with uridine triphosphate (UTP), thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Oteracil potassium preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), which converts tegafur to 5-FU. This decreases the amount of 5-FU in the gut and prevents activated 5-FU-related gastrointestinal (GI) toxicity. Leucovorin calcium, an active metabolite of folic acid, counteracts the toxic effects of 5-FU, thereby 'rescuing' the patient while permitting the antitumor activity of 5-FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"TAS-118","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"767716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767716"},{"name":"PDQ_Open_Trial_Search_ID","value":"767716"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897369"}]}}{"C9506":{"preferredName":"Tegafur-Uracil","code":"C9506","definitions":[{"definition":"A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It is a combination of tegafur and uracil. The tegafur is taken up by the cancer cells and breaks down into 5-FU, a substance that kills tumor cells. The uracil causes higher amounts of 5-FU to stay inside the cells and kill them. Tegafur-uracil is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tegafur-Uracil","termGroup":"PT","termSource":"NCI"},{"termName":"Oral Fluorouracil-Uracil","termGroup":"SY","termSource":"NCI"},{"termName":"Tefudex","termGroup":"FB","termSource":"NCI"},{"termName":"Tegafur and Uracil","termGroup":"SY","termSource":"NCI"},{"termName":"UFT","termGroup":"AB","termSource":"NCI"},{"termName":"Uftoral","termGroup":"FB","termSource":"NCI"},{"termName":"Uftoral","termGroup":"BR","termSource":"NCI"},{"termName":"Ufur","termGroup":"FB","termSource":"NCI"},{"termName":"Uracil and Ftorafur","termGroup":"SY","termSource":"NCI"},{"termName":"Uracil and Tegafur","termGroup":"SY","termSource":"NCI"},{"termName":"Uracil and Tetrahydrofuranyl-5-Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"Uracil/Tegafur (UFT)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74578-38-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HMI5GR78FR"},{"name":"Legacy Concept Name","value":"Tegafur_Uracil"},{"name":"Maps_To","value":"Tegafur-Uracil"},{"name":"NCI_Drug_Dictionary_ID","value":"461135"},{"name":"NSC Number","value":"719164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"461135"},{"name":"PDQ_Open_Trial_Search_ID","value":"461135"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1446539"}]}}{"C155885":{"preferredName":"Tegavivint","code":"C155885","definitions":[{"definition":"A small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tegavivint","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-","termGroup":"SN","termSource":"NCI"},{"termName":"BC 2059","termGroup":"CN","termSource":"NCI"},{"termName":"BC-2059","termGroup":"CN","termSource":"NCI"},{"termName":"BC2059","termGroup":"CN","termSource":"NCI"},{"termName":"Tegatrabetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227637-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"18AP231HUP"},{"name":"Maps_To","value":"Tegavivint"},{"name":"NCI_Drug_Dictionary_ID","value":"795712"},{"name":"NCI_META_CUI","value":"CL562695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795712"},{"name":"PDQ_Open_Trial_Search_ID","value":"795712"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90746":{"preferredName":"Teglarinad","code":"C90746","definitions":[{"definition":"A water-soluble prodrug of a pyridyl cyanoguanidine compound and an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with potential antineoplastic activity. Teglarinad is rapidly converted in the bloodstream into an active compound through hydrolytic cleavage of the carbonate ester bond. The activated form inhibits NAMPT, thereby inhibiting nicotinamide adenine dinucleotide (NAD+) biosynthesis and induces a rapid decline in intracellular NAD+ followed by ATP reduction. As NAD+ is essential for tumor cell growth, inhibition of NAMPT induces tumor cell death. NAMPT is an essential enzyme in the synthesis of NAD+ and is upregulated in some cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teglarinad","termGroup":"PT","termSource":"NCI"},{"termName":"Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]amino](cyanoamino)methylene]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"766501-75-1"},{"name":"Chemical_Formula","value":"C30H43ClN5O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NUG9P5GWZB"},{"name":"Maps_To","value":"Teglarinad"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983861"}]}}{"C68931":{"preferredName":"Teglarinad Chloride","code":"C68931","definitions":[{"definition":"A water-soluble prodrug of a cyanoguanidine compound with potential antineoplastic activity. In vivo, teglarinad chloride is rapidly converted into active drug through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, the active drug appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teglarinad Chloride","termGroup":"PT","termSource":"NCI"},{"termName":"CHS828 Prodrug","termGroup":"SY","termSource":"NCI"},{"termName":"EB1627","termGroup":"SY","termSource":"NCI"},{"termName":"GMX1777","termGroup":"CN","termSource":"NCI"},{"termName":"Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]amino](cyanoamino) methylene]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)-, chloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"432037-57-5"},{"name":"Chemical_Formula","value":"C30H43ClN5O8.Cl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D6V5QYX9MZ"},{"name":"Legacy Concept Name","value":"Apoptosis_Inducer_GMX1777"},{"name":"Maps_To","value":"Teglarinad Chloride"},{"name":"NCI_Drug_Dictionary_ID","value":"547816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"547816"},{"name":"PDQ_Open_Trial_Search_ID","value":"547816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346839"}]}}{"C104057":{"preferredName":"Telapristone","code":"C104057","definitions":[{"definition":"An orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, telapristone competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telapristone","termGroup":"PT","termSource":"NCI"},{"termName":"11Beta-(4-(dimethylamino)phenyl)-17-hydroxy-21-methoxy-19- norpregna-4,9-diene-3,20-dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198414-30-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65703MV349"},{"name":"Maps_To","value":"Telapristone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641719"}]}}{"C104055":{"preferredName":"Telapristone Acetate","code":"C104055","definitions":[{"definition":"The acetate form of the 21-substituted-19-nor-progestin telapristone, an orally available selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, CDB-4124 competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telapristone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,11R,13S,14S,17R)-11-(4-(Dimethylamino)phenyl)-17-(2-methoxyacetyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"CDB-4124","termGroup":"CN","termSource":"NCI"},{"termName":"Proellex","termGroup":"SY","termSource":"NCI"},{"termName":"Progenta","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198414-31-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1K9EYK92PQ"},{"name":"Maps_To","value":"Telapristone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"598776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598776"},{"name":"PDQ_Open_Trial_Search_ID","value":"598776"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3501648"}]}}{"C87837":{"preferredName":"Telatinib Mesylate","code":"C87837","definitions":[{"definition":"The orally bioavailable mesylate salt of the 17-allylaminogeldanamycin (17-AAG) small-molecule inhibitor of several receptor protein tyrosine kinases with potential antiangiogenic and antineoplastic activities. Telatinib binds to and inhibits the vascular endothelial growth factor receptors (VEGFRs) type 2 and 3, platelet-derived growth factor receptor beta (PDGFRb) and c-Kit, which may result in the inhibition of angiogenesis and cellular proliferation in tumors in which these receptors are upregulated. These telatinib-inhibited receptor protein tyrosine kinases are overexpressed or mutated in many tumor cell types and may play key roles in tumor angiogenesis and tumor cell proliferation. 17-AAG is a synthetic analogue of the benzoquinone ansamycin antibiotic geldanamycin and has also been found to inhibit the molecular chaperone Hsp90.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"17-Demethoxy-17-Allylaminogeldanamycin Mesylate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"332013-26-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"571LVA9UMS"},{"name":"Maps_To","value":"Telatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"652798"},{"name":"NCI_META_CUI","value":"CL415590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"652798"},{"name":"PDQ_Open_Trial_Search_ID","value":"652798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118571":{"preferredName":"Telisotuzumab Vedotin","code":"C118571","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telisotuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 399","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-399","termGroup":"CN","termSource":"NCI"},{"termName":"ABT 399","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-399","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-700-VCMMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1714088-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"976X9VXC3Z"},{"name":"Maps_To","value":"Telisotuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"759579"},{"name":"NCI_META_CUI","value":"CL474084"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759579"},{"name":"PDQ_Open_Trial_Search_ID","value":"759579"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2715":{"preferredName":"Telomerase Inhibitor FJ5002","code":"C2715","definitions":[{"definition":"A derivative of rhodacyanine with potential antineoplastic activity.  FJ5002 inhibits telomerase by interfering with holoenzyme assembly and telomere interaction, thus leading to replication-dependent shortening of telomeres with a concurrent increase in aneuploid metaphases and apoptotic cells.  Telomerase is active in most tumors cells, but is quiescent in adjacent normal cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telomerase Inhibitor FJ5002","termGroup":"PT","termSource":"NCI"},{"termName":"FJ5002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"FJ5002"},{"name":"Maps_To","value":"Telomerase Inhibitor FJ5002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0908717"}]}}{"C119617":{"preferredName":"Suratadenoturev","code":"C119617","definitions":[{"definition":"A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. Suratadenoturev contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suratadenoturev","termGroup":"PT","termSource":"NCI"},{"termName":"OBP-301","termGroup":"CN","termSource":"NCI"},{"termName":"Telomelycin","termGroup":"SY","termSource":"NCI"},{"termName":"Telomelysin","termGroup":"BR","termSource":"NCI"},{"termName":"Telomerase-specific Type 5 Adenovirus OBP-301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268642-13-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FV0JG1SX76"},{"name":"Maps_To","value":"Telomerase-specific Type 5 Adenovirus OBP-301"},{"name":"NCI_Drug_Dictionary_ID","value":"766745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766745"},{"name":"PDQ_Open_Trial_Search_ID","value":"766745"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896800"}]}}{"C1520":{"preferredName":"Teloxantrone","code":"C1520","definitions":[{"definition":"An anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teloxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra(1,9-cd)pyrazol-6(2H)-one,7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"CI-937","termGroup":"CN","termSource":"NCI"},{"termName":"Moxantrazole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91441-48-4"},{"name":"Chemical_Formula","value":"C21H25N5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96521WL61B"},{"name":"Legacy Concept Name","value":"Teloxantrone"},{"name":"Maps_To","value":"Teloxantrone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244823"}]}}{"C74544":{"preferredName":"Teloxantrone Hydrochloride","code":"C74544","definitions":[{"definition":"The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teloxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra(1,9-cd)pyrazol-6(2H)-one,7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino) Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CI-937 Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"DUP 937","termGroup":"CN","termSource":"NCI"},{"termName":"Moxantrazole Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"132937-88-3"},{"name":"Chemical_Formula","value":"C21H25N5O4.2HCl.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7ZQK8VIO6V"},{"name":"Legacy Concept Name","value":"Teloxantrone_Hydrochloride"},{"name":"Maps_To","value":"Teloxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39411"},{"name":"NSC Number","value":"355644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39411"},{"name":"PDQ_Open_Trial_Search_ID","value":"39411"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0970561"}]}}{"C124653":{"preferredName":"Telratolimod","code":"C124653","definitions":[{"definition":"A toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, telratolimod binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telratolimod","termGroup":"PT","termSource":"NCI"},{"termName":"3M 052","termGroup":"CN","termSource":"NCI"},{"termName":"3M-052","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI 9197","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-9197","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI9197","termGroup":"CN","termSource":"NCI"},{"termName":"TLR7/TLR8 Dual Agonist MEDI9197","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor 7/8 Agonist MEDI9197","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1359993-59-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16598XQ2BT"},{"name":"Maps_To","value":"Telratolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"777376"},{"name":"NCI_META_CUI","value":"CL502885"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777376"},{"name":"PDQ_Open_Trial_Search_ID","value":"777376"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63953":{"preferredName":"Temarotene","code":"C63953","definitions":[{"definition":"A synthetic bioactive retinoid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, temarotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temarotene","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3,4-Tetrahydro-1,1,4,4-tetramethyl-6-[(1E)-1-methyl-2-phenylethenyl]naphthalene","termGroup":"SN","termSource":"NCI"},{"termName":"Ro 15-0778","termGroup":"CN","termSource":"NCI"},{"termName":"Temaroten","termGroup":"SY","termSource":"NCI"},{"termName":"TTNPB, Decarboxylated Analog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75078-91-0"},{"name":"Chemical_Formula","value":"C23H28"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A28G39IJ7K"},{"name":"Legacy Concept Name","value":"Temarotene"},{"name":"Maps_To","value":"Temarotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076076"}]}}{"C1669":{"preferredName":"Temoporfin","code":"C1669","definitions":[{"definition":"A synthetic light-activated chlorin with photodynamic activity. Upon systemic administration, temoporfin distributes throughout the body and is taken up by tumor cells. Upon stimulation of temoporfin by non-thermal laser light (at 652 nm), and in the presence of oxygen, this agent produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to tumor cells. This may kill tumor cells and may reduce the tumor size.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called photosensitizing agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Temoporfin","termGroup":"PT","termSource":"NCI"},{"termName":"5,10,15,20-Tetra-(m-hydroxyphenyl)chlorin","termGroup":"SN","termSource":"NCI"},{"termName":"Foscan","termGroup":"FB","termSource":"NCI"},{"termName":"m-Tetrahydroxyphenyl-chlorin","termGroup":"SY","termSource":"NCI"},{"termName":"meta-Tetrahydroxyphenyl Chlorin","termGroup":"SN","termSource":"NCI"},{"termName":"meta-Tetrahydroxyphenylchlorin","termGroup":"SN","termSource":"NCI"},{"termName":"mTHPC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"122341-38-2"},{"name":"CHEBI_ID","value":"CHEBI:9437"},{"name":"Chemical_Formula","value":"C44H32N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FU21S769PF"},{"name":"Legacy Concept Name","value":"Temoporfin"},{"name":"Maps_To","value":"Temoporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"42851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42851"},{"name":"PDQ_Open_Trial_Search_ID","value":"42851"},{"name":"PubMedID_Primary_Reference","value":"17516041"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0379149"}]}}{"C1244":{"preferredName":"Temozolomide","code":"C1244","definitions":[{"definition":"A drug that is used to treat certain types of brain tumors in adults and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temozolomide","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"CCRG-81045","termGroup":"CN","termSource":"NCI"},{"termName":"Gliotem","termGroup":"FB","termSource":"NCI"},{"termName":"imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"M & B 39831","termGroup":"CN","termSource":"NCI"},{"termName":"M and B 39831","termGroup":"CN","termSource":"NCI"},{"termName":"Methazolastone","termGroup":"BR","termSource":"NCI"},{"termName":"RP-46161","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 52365","termGroup":"CN","termSource":"NCI"},{"termName":"Temcad","termGroup":"FB","termSource":"NCI"},{"termName":"Temizole","termGroup":"FB","termSource":"NCI"},{"termName":"Temodal","termGroup":"FB","termSource":"NCI"},{"termName":"Temodar","termGroup":"BR","termSource":"NCI"},{"termName":"Temomedac","termGroup":"SY","termSource":"NCI"},{"termName":"TMZ","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant glioma (Anaplastic astrocytoma; Anaplastic oligodendrogliomas; Anaplastic oligoastrocytomas; Glioblastoma multiforme); Metastatic melanoma"},{"name":"CAS_Registry","value":"85622-93-1"},{"name":"Chemical_Formula","value":"C6H6N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YF1K15M17Y"},{"name":"Legacy Concept Name","value":"Temozolomide"},{"name":"Maps_To","value":"Temozolomide"},{"name":"NCI_Drug_Dictionary_ID","value":"41671"},{"name":"NSC Number","value":"362856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41671"},{"name":"PDQ_Open_Trial_Search_ID","value":"41671"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076080"}]}}{"C1844":{"preferredName":"Temsirolimus","code":"C1844","definitions":[{"definition":"A drug used to treat advanced renal cell carcinoma (a type of kidney cancer). It is also being studied in the treatment of other types of cancer. Temsirolimus blocks a protein involved in cell division, and may kill cancer cells. It is a type of rapamycin analog and a type of serine/threonine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temsirolimus","termGroup":"PT","termSource":"NCI"},{"termName":"42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin","termGroup":"SN","termSource":"NCI"},{"termName":"CCI-779","termGroup":"CN","termSource":"NCI"},{"termName":"CCI-779 Rapamycin Analog","termGroup":"SY","termSource":"NCI"},{"termName":"Cell Cycle Inhibitor 779","termGroup":"SY","termSource":"NCI"},{"termName":"Rapamycin Analog","termGroup":"SY","termSource":"NCI"},{"termName":"Rapamycin Analog CCI-779","termGroup":"SY","termSource":"NCI"},{"termName":"Torisel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced renal cell carcinoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Renal Cell Carcinoma"},{"name":"CAS_Registry","value":"162635-04-3"},{"name":"Chemical_Formula","value":"C56H87NO16"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"624KN6GM2T"},{"name":"Legacy Concept Name","value":"CCI-779"},{"name":"Maps_To","value":"Temsirolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"43369"},{"name":"NSC Number","value":"683864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43369"},{"name":"PDQ_Open_Trial_Search_ID","value":"43369"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707080"}]}}{"C113433":{"preferredName":"Tenalisib","code":"C113433","definitions":[{"definition":"An orally active, highly selective, small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, tenalisib inhibits the PI3K delta and gamma isoforms and prevents the activation of the PI3K/AKT-mediated signaling pathway. This may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. In addition, this agent modulates inflammatory responses through various mechanisms, including the inhibition of both the release of reactive oxygen species (ROS) from neutrophils and tumor necrosis factor (TNF)-alpha activity. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and in inflammatory and autoimmune diseases. By selectively targeting these isoforms, PI3K signaling in normal, non-neoplastic cells is minimally impacted or not affected at all, which minimizes the side effect profile for this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tenalisib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(3-Fluorophenyl)-2-((1S)-1-((7H-purin-6-yl)amino)propyl)-4H-1-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"4H-1-Benzopyran-4-one, 3-(3-fluorophenyl)-2-((1S)-1-(9H-purin-6-ylamino)propyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"RP 6530","termGroup":"CN","termSource":"NCI"},{"termName":"RP-6530","termGroup":"CN","termSource":"NCI"},{"termName":"RP6530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1639417-53-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2261HH611H"},{"name":"Maps_To","value":"Tenalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"756264"},{"name":"NCI_META_CUI","value":"CL458227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756264"},{"name":"PDQ_Open_Trial_Search_ID","value":"756264"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64772":{"preferredName":"Tenifatecan","code":"C64772","definitions":[{"definition":"A highly lipophilic preparation of 7-Ethyl-10-hydroxycamptothecin (SN-38) with potential antineoplastic activity. SN2310 is an oil-in-water emulsion of tocopherol covalently linked, via a succinate linker, to SN-38, a synthetic derivative of the cytotoxic alkaloid camptothecin. After succinate linker is hydrolyzed in vivo, the active moiety SN-38 is released and selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks and inducing lethal double-stranded DNA breaks. This inhibits DNA replication and triggers programmed cell death. SN2310 emulsion provides longer circulation time and potentiates drug exposure as compared to the unconjugated SN-38.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tenifatecan","termGroup":"PT","termSource":"NCI"},{"termName":"(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin- 9-yl (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl Butanedioate","termGroup":"SN","termSource":"NCI"},{"termName":"SN-2310","termGroup":"CN","termSource":"NCI"},{"termName":"SN2310","termGroup":"CN","termSource":"NCI"},{"termName":"Tocopherol Succinate 7-Ethyl-10-Hydroxycamptothecin","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850728-18-6"},{"name":"Chemical_Formula","value":"C55H72N2O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7G0Y719Q80"},{"name":"Legacy Concept Name","value":"Tocopherol_Succinate_7-Ethyl-10-Hydroxycamptothecin"},{"name":"Maps_To","value":"Tenifatecan"},{"name":"NCI_Drug_Dictionary_ID","value":"518315"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518315"},{"name":"PDQ_Open_Trial_Search_ID","value":"518315"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1883354"}]}}{"C857":{"preferredName":"Teniposide","code":"C857","definitions":[{"definition":"A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Teniposide","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside)","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside","termGroup":"SN","termSource":"NCI"},{"termName":"[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one","termGroup":"SN","termSource":"NCI"},{"termName":"EPT","termGroup":"AB","termSource":"NCI"},{"termName":"PTG","termGroup":"AB","termSource":"NCI"},{"termName":"Thenylidene Lignan","termGroup":"SY","termSource":"NCI"},{"termName":"Vehem","termGroup":"FB","termSource":"NCI"},{"termName":"VM-26","termGroup":"CN","termSource":"NCI"},{"termName":"Vumon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"29767-20-2"},{"name":"Chemical_Formula","value":"C32H32O13S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"957E6438QA"},{"name":"Legacy Concept Name","value":"Teniposide"},{"name":"Maps_To","value":"Teniposide"},{"name":"NCI_Drug_Dictionary_ID","value":"43671"},{"name":"NSC Number","value":"122819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43671"},{"name":"PDQ_Open_Trial_Search_ID","value":"43671"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039512"}]}}{"C95797":{"preferredName":"Teprotumumab","code":"C95797","definitions":[{"definition":"A human monoclonal antibody being studied in the treatment of several types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. R1507 blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teprotumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Monoclonal Antibody R1507","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I Receptor)(Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"R1507","termGroup":"CN","termSource":"NCI"},{"termName":"RG1507","termGroup":"CN","termSource":"NCI"},{"termName":"RO4858696-000","termGroup":"CN","termSource":"NCI"},{"termName":"RV001 Monoclonal","termGroup":"SY","termSource":"NCI"},{"termName":"Teprotumumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of solid and hematologic tumors"},{"name":"CAS_Registry","value":"89957-37-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y64GQ0KC0A"},{"name":"Maps_To","value":"Teprotumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"557569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"557569"},{"name":"PDQ_Open_Trial_Search_ID","value":"557569"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3181764"}]}}{"C61441":{"preferredName":"Terameprocol","code":"C61441","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks proteins needed for cancer growth. It is a type of transcriptional inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In virally-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2), survivin, and vascular endothelial growth factor (VEGF), which are overexpressed in a variety of cancers. By suppressing Sp1-regulated transcription of these genes, terameprocol may reduce tumor angiogenesis and tumor cell proliferation and induce tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Terameprocol","termGroup":"PT","termSource":"NCI"},{"termName":"1,1'-(2,3-Dimethyl-1,4-butanediyl)bis(3,4-dimethoxybenzene)","termGroup":"SN","termSource":"NCI"},{"termName":"EM-1421","termGroup":"CN","termSource":"NCI"},{"termName":"M4N","termGroup":"AB","termSource":"NCI"},{"termName":"Tetra-O-methyl Nordihydroguaiaretic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Tetra-O-methyl-NDGA","termGroup":"SN","termSource":"NCI"},{"termName":"Tetramethoxynordihydroguaiaretic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"TMNDGA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"24150-24-1"},{"name":"Chemical_Formula","value":"C22H30O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53YET703F2"},{"name":"Legacy Concept Name","value":"EM-1421"},{"name":"Maps_To","value":"Terameprocol"},{"name":"NCI_Drug_Dictionary_ID","value":"472205"},{"name":"NSC Number","value":"136955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"472205"},{"name":"PDQ_Open_Trial_Search_ID","value":"472205"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0654036"}]}}{"C75292":{"preferredName":"Terfluranol","code":"C75292","definitions":[{"definition":"A trifluoroethyl derivative with antineoplastic agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Terfluranol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64396-09-4"},{"name":"Chemical_Formula","value":"C17H17F3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WUF1DL156G"},{"name":"Legacy Concept Name","value":"Terfluranol"},{"name":"Maps_To","value":"Terfluranol"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699917"}]}}{"C66985":{"preferredName":"Tergenpumatucel-L","code":"C66985","definitions":[{"definition":"An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a 'xenograft'. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tergenpumatucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Hyperacute Lung Cancer Vaccine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alpha-1_3-Galactosyltransferase-Expressing_Allogeneic_Lung_Tumor_Cell_Vaccine"},{"name":"Maps_To","value":"Tergenpumatucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"539100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539100"},{"name":"PDQ_Open_Trial_Search_ID","value":"539100"},{"name":"PubMedID_Primary_Reference","value":"15161001"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879682"}]}}{"C2320":{"preferredName":"Teroxirone","code":"C2320","definitions":[{"definition":"A triazene triepoxide with antineoplastic activity. Teroxine alkylates and cross-links DNA, thereby inhibiting DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teroxirone","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-1,3,5-triglycidyl-s-triazinetrione","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-TGI","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-Triglycidyl Isocyanurate","termGroup":"SN","termSource":"NCI"},{"termName":"Henkel's Compound","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59653-73-5"},{"name":"Chemical_Formula","value":"C12H15N3O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"456V4159SL"},{"name":"Legacy Concept Name","value":"Teroxirone"},{"name":"Maps_To","value":"Teroxirone"},{"name":"NCI_Drug_Dictionary_ID","value":"39722"},{"name":"NSC Number","value":"296934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39722"},{"name":"PDQ_Open_Trial_Search_ID","value":"39722"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043891"}]}}{"C62756":{"preferredName":"Tertomotide","code":"C62756","definitions":[{"definition":"A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tertomotide","termGroup":"PT","termSource":"NCI"},{"termName":"GV 1001","termGroup":"CN","termSource":"NCI"},{"termName":"GV-1001","termGroup":"CN","termSource":"NCI"},{"termName":"GV1001","termGroup":"CN","termSource":"NCI"},{"termName":"Human Telomerase Reverse Transcriptase (EC 2.7.7.49)-(611-626)-Peptide (Telomerase Catalytic Subunit Fragment)","termGroup":"SN","termSource":"NCI"},{"termName":"PrimoVax","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915019-08-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"55R7RG342O"},{"name":"Legacy Concept Name","value":"GV1001"},{"name":"Maps_To","value":"Tertomotide"},{"name":"NCI_Drug_Dictionary_ID","value":"502114"},{"name":"PDQ_Closed_Trial_Search_ID","value":"502114"},{"name":"PDQ_Open_Trial_Search_ID","value":"502114"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831942"}]}}{"C37451":{"preferredName":"Tesetaxel","code":"C37451","definitions":[{"definition":"A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic and antiangiogenic properties. Tesetaxel binds to and stabilizes tubulin, promoting microtubule assembly and thereby preventing microtubule depolymerization. This may lead to cell cycle arrest and an inhibition of cell proliferation. This agent may also inhibit pro-angiogenic factors such as vascular endothelial growth factor (VEGF). As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of taxane derivative.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tesetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"DJ-927","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"333754-36-2"},{"name":"Chemical_Formula","value":"C46H60FN3O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"UG97LO5M8Y"},{"name":"Legacy Concept Name","value":"DJ-927"},{"name":"Maps_To","value":"Tesetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"346914"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346914"},{"name":"PDQ_Open_Trial_Search_ID","value":"346914"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872681"}]}}{"C62496":{"preferredName":"Tesevatinib","code":"C62496","definitions":[{"definition":"An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tesevatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta(c)pyrrol-5-yl)methoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"EXEL 7647","termGroup":"CN","termSource":"NCI"},{"termName":"KD 019","termGroup":"CN","termSource":"NCI"},{"termName":"KD019","termGroup":"CN","termSource":"NCI"},{"termName":"XL647","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"781613-23-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6XM2TN5A1"},{"name":"Legacy Concept Name","value":"XL647"},{"name":"Maps_To","value":"Tesevatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"386183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"386183"},{"name":"PDQ_Open_Trial_Search_ID","value":"386183"},{"name":"PubMedID_Primary_Reference","value":"22011666"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541356"}]}}{"C129315":{"preferredName":"Tesidolumab","code":"C129315","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the complement pathway protein C5, with complement pathway inhibitory activity and potential immunomodulating activity. Upon administration, tesidolumab targets and binds to C5, thereby preventing both C5 convertase-mediated cleavage of C5 and the formation of C5a and C5b. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction. C5 plays a key role in the activation of the complement cascade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tesidolumab","termGroup":"PT","termSource":"NCI"},{"termName":"LFG-316","termGroup":"CN","termSource":"NCI"},{"termName":"LFG316","termGroup":"CN","termSource":"NCI"},{"termName":"NOV-4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1531594-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3FO6689MSD"},{"name":"Maps_To","value":"Tesidolumab"},{"name":"NCI_Drug_Dictionary_ID","value":"783588"},{"name":"NCI_META_CUI","value":"CL512306"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783588"},{"name":"PDQ_Open_Trial_Search_ID","value":"783588"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2301":{"preferredName":"Testolactone","code":"C2301","definitions":[{"definition":"A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testolactone","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic Acid Delta-Lactone","termGroup":"SN","termSource":"NCI"},{"termName":"1-Dehydrotestololactone","termGroup":"SN","termSource":"NCI"},{"termName":"13-Hydroxy-3-0x0-13,17-secoandrosta-1,4-dien-17-oic Acid Delta-Lactone","termGroup":"SN","termSource":"NCI"},{"termName":"17Alpha-oxo-D-homo-1,4-androstadiene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Delta-1-Testololactone","termGroup":"SN","termSource":"NCI"},{"termName":"Fludestrin","termGroup":"SY","termSource":"NCI"},{"termName":"SQ-9538","termGroup":"CN","termSource":"NCI"},{"termName":"Teslac","termGroup":"BR","termSource":"NCI"},{"termName":"Therapeutic Testolactone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"968-93-4"},{"name":"CHEBI_ID","value":"CHEBI:9460"},{"name":"Chemical_Formula","value":"C19H24O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6J9BLA949Q"},{"name":"Legacy Concept Name","value":"Testolactone"},{"name":"Maps_To","value":"Testolactone"},{"name":"NCI_Drug_Dictionary_ID","value":"42916"},{"name":"NSC Number","value":"23759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42916"},{"name":"PDQ_Open_Trial_Search_ID","value":"42916"},{"name":"Semantic_Type","value":"Hormone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039600"}]}}{"C1247":{"preferredName":"Testosterone Enanthate","code":"C1247","definitions":[{"definition":"A long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males, delayed puberty, and metastatic mammary cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testosterone Enanthate","termGroup":"PT","termSource":"NCI"},{"termName":"Andro LA","termGroup":"BR","termSource":"NCI"},{"termName":"Androtardyl","termGroup":"FB","termSource":"NCI"},{"termName":"Delatestryl","termGroup":"BR","termSource":"NCI"},{"termName":"Everone","termGroup":"BR","termSource":"NCI"},{"termName":"Primosteston","termGroup":"BR","termSource":"NCI"},{"termName":"Testate","termGroup":"SY","termSource":"NCI"},{"termName":"Testinon","termGroup":"FB","termSource":"NCI"},{"termName":"Testo-Enant","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Male Hypogonadotrophic Hypogonadism; Delayed Puberty-Male and Primary Hypogonadism."},{"name":"CAS_Registry","value":"315-37-7"},{"name":"CHEBI_ID","value":"CHEBI:9464"},{"name":"Chemical_Formula","value":"C26H40O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7Z6522T8N9"},{"name":"Legacy Concept Name","value":"Testosterone_Enanthate"},{"name":"Maps_To","value":"Testosterone Enanthate"},{"name":"NCI_Drug_Dictionary_ID","value":"795022"},{"name":"NSC Number","value":"17591"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795022"},{"name":"PDQ_Open_Trial_Search_ID","value":"795022"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076189"}]}}{"C2660":{"preferredName":"Tetanus Toxoid Vaccine","code":"C2660","definitions":[{"definition":"A preparation of formaldehyde-deactivated toxin isolated from the bacterium Clostridium tetani. Tetanus toxoid is used for booster injection and can stimulate the production of antitoxin antibodies. This agent may be used as an adjuvant in cancer vaccines.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is derived from the toxin released by the bacterium that causes the disease tetanus.  It is used as a vaccine to prevent tetanus or to help boost the immune response to other vaccines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tetanus Toxoid Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Tetanus Toxoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Tetanus Prophylaxis"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Tetanus_Toxoid"},{"name":"Maps_To","value":"Tetanus Toxoid Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38508"},{"name":"NSC Number","value":"722666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38508"},{"name":"PDQ_Open_Trial_Search_ID","value":"38508"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0305062"}]}}{"C866":{"preferredName":"Tetradecanoylphorbol Acetate","code":"C866","definitions":[{"definition":"A phorbol ester with potential antineoplastic effects.  Tetradecanoylphorbol acetate (TPA) induces maturation and differentiation of hematopoietic cell lines, including leukemic cells. This agent may induce gene expression and protein kinase C (PKC) activity.  In addition to potential antineoplastic effects, TPA may exhibit tumor promoting activity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of leukemias and lymphomas. It is also being studied in the treatment of other types of cancer. Tetradecanoylphorbol acetate affects many cell actions and may cause tumor cells to die. It is a type of phorbol ester.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tetradecanoylphorbol Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"12-O-tetradecanoylphorbol-13-acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Lonomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Phorbol Myristate Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"PMA","termGroup":"AB","termSource":"NCI"},{"termName":"TPA (Phorbol Ester)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"16561-29-8"},{"name":"CHEBI_ID","value":"CHEBI:37537"},{"name":"Chemical_Formula","value":"C36H56O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NI40JAQ945"},{"name":"Legacy Concept Name","value":"Tetradecanoylphorbol_Acetate"},{"name":"Maps_To","value":"Tetradecanoylphorbol Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"43661"},{"name":"NSC Number","value":"262244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43661"},{"name":"PDQ_Open_Trial_Search_ID","value":"43661"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039654"}]}}{"C868":{"preferredName":"Tetrahydrouridine","code":"C868","definitions":[{"definition":"A substance that makes tumor cells more sensitive to radiation therapy and is being studied in the treatment of cancer. It belongs to the families of drugs called cytidine deaminase inhibitors, multidrug resistance modulators, and radiosensitizers.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2'-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2'-deoxycytidine monophosphate (CldCMP) to 5-chloro-2'-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2'-deoxyuridine). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetrahydrouridine","termGroup":"PT","termSource":"NCI"},{"termName":"2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-","termGroup":"SN","termSource":"NCI"},{"termName":"THU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18771-50-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0NIZ8H6OL8"},{"name":"Legacy Concept Name","value":"Tetrahydrouridine"},{"name":"Maps_To","value":"Tetrahydrouridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39710"},{"name":"NSC Number","value":"112907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39710"},{"name":"PDQ_Open_Trial_Search_ID","value":"39710"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039677"}]}}{"C88344":{"preferredName":"Fimaporfin A","code":"C88344","definitions":[{"definition":"The A isomer of fimaporfin, a synthetic light-activated compound, with potential photosensitizing activity. Upon administration, fimaporfin A incorporates into the cell's endosome and lysosome membranes. Subsequently, cytotoxic agents are administered and accumulate in endosomal and lysosomal compartments; upon local activation by light, fimaporfin A produces reactive oxygen species (ROS), such as singlet oxygen, damaging endo/lysosomal membranes and accumulated cytotoxic agents are released into the tumor cell cytosol. This photochemical internalization (PCI) method can enhance the efficacy and selectivity of cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fimaporfin A","termGroup":"PT","termSource":"NCI"},{"termName":"Amphinex","termGroup":"FB","termSource":"NCI"},{"termName":"Disulfonated Tetraphenylchlorin","termGroup":"SY","termSource":"NCI"},{"termName":"Tetraphenyl Chlorin Disulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"TPCS2a","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501083-97-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P4BBY8S91N"},{"name":"Maps_To","value":"Fimaporfin A"},{"name":"Maps_To","value":"Tetraphenyl Chlorin Disulfonate"},{"name":"NCI_Drug_Dictionary_ID","value":"658036"},{"name":"NCI_META_CUI","value":"CL413542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658036"},{"name":"PDQ_Open_Trial_Search_ID","value":"658036"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160684":{"preferredName":"Tetrathiomolybdate","code":"C160684","definitions":[{"definition":"An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetrathiomolybdate","termGroup":"PT","termSource":"NCI"},{"termName":"CCRIS 9412","termGroup":"CN","termSource":"NCI"},{"termName":"Molybdate(2-), Tetrathioxo-, (T-4)- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Tetrathioxomolybdate(2-)","termGroup":"SY","termSource":"NCI"},{"termName":"TM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"16330-92-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91U3TGV99T"},{"name":"Maps_To","value":"Tetrathiomolybdate"},{"name":"NCI_META_CUI","value":"CL969619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1539":{"preferredName":"Tezacitabine","code":"C1539","definitions":[{"definition":"A drug that belongs to a family of drugs called ribonucleotide reductase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication. This agent is relatively resistant to metabolic deactivation by cytidine deaminase. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates necessary for DNA synthesis and is overexpressed in many tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tezacitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-2'-(fluoromethylene)cytidine","termGroup":"SN","termSource":"NCI"},{"termName":"FMdC","termGroup":"AB","termSource":"NCI"},{"termName":"MDL 101,731","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"171176-43-5"},{"name":"Chemical_Formula","value":"C10H12FN3O4.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UCC4EQS7WL"},{"name":"Legacy Concept Name","value":"Tezacitabine"},{"name":"Maps_To","value":"Tezacitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"354256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354256"},{"name":"PDQ_Open_Trial_Search_ID","value":"354256"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253087"}]}}{"C95916":{"preferredName":"Tezacitabine Anhydrous","code":"C95916","definitions":[{"definition":"The anhydrous form of tezacitabine, a synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and eventually tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, thereby further inhibiting DNA replication. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates, a necessary step for DNA synthesis, and is overexpressed in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tezacitabine Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-2'-(fluoromethylene)cytidine Anhydrous","termGroup":"SN","termSource":"NCI"},{"termName":"FMdC Anhydrous","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130306-02-4"},{"name":"Chemical_Formula","value":"C10H12FN3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7607Y95N9S"},{"name":"Maps_To","value":"Tezacitabine Anhydrous"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272436"}]}}{"C160258":{"preferredName":"TGF-beta Receptor 1 Inhibitor PF-06952229","code":"C160258","definitions":[{"definition":"An orally bioavailable inhibitor of transforming growth factor-beta receptor 1 (TGFbR1), with potential antineoplastic activity. Upon administration, TGF-betaR1 inhibitor PF-06952229 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGF-beta Receptor 1 Inhibitor PF-06952229","termGroup":"PT","termSource":"NCI"},{"termName":"PF 06952229","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06952229","termGroup":"CN","termSource":"NCI"},{"termName":"PF06952229","termGroup":"CN","termSource":"NCI"},{"termName":"TGFbR1 Inhibitor PF-06952229","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TGF-beta Receptor 1 Inhibitor PF-06952229"},{"name":"NCI_Drug_Dictionary_ID","value":"798316"},{"name":"NCI_META_CUI","value":"CL969270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798316"},{"name":"PDQ_Open_Trial_Search_ID","value":"798316"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29483":{"preferredName":"TGFa-PE38 Immunotoxin","code":"C29483","definitions":[{"definition":"A recombinant, chimeric toxin composed of human transforming growth factor alpha (TGF-alpha) fused to a fragment of Pseudomonas exotoxin (PE38) without its cell-binding domain.  The TGF-alpha moiety of the agent attaches to tumor cells expressing the epithelial growth factor receptor (EGFR); the exotoxin induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of brain tumors. It combines a protein that binds to certain tumor cells with a bacterial toxin that kills tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"TGFa-PE38 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Cervene","termGroup":"BR","termSource":"NCI"},{"termName":"TP-38","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TP-38"},{"name":"Maps_To","value":"TGFa-PE38 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"346468"},{"name":"NSC Number","value":"726586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346468"},{"name":"PDQ_Open_Trial_Search_ID","value":"346468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328109"}]}}{"C132013":{"preferredName":"TGFbeta Inhibitor LY3200882","code":"C132013","definitions":[{"definition":"An orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGFbeta Inhibitor LY3200882","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3200882","termGroup":"CN","termSource":"NCI"},{"termName":"LY3200882","termGroup":"CN","termSource":"NCI"},{"termName":"TGFb Inhibitor LY 3200882","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1898283-02-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19HY34R6UN"},{"name":"Maps_To","value":"TGFbeta Inhibitor LY3200882"},{"name":"NCI_Drug_Dictionary_ID","value":"787604"},{"name":"NCI_META_CUI","value":"CL520999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787604"},{"name":"PDQ_Open_Trial_Search_ID","value":"787604"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159817":{"preferredName":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein BMS-986416","code":"C159817","definitions":[{"definition":"A fusion protein composed of the ectodomain of the transforming growth factor (TGF) beta (TGF-beta; TGFb) receptor fused to the human immunoglobulin G (IgG) Fc domain, with potential antineoplastic, immunomodulating and anti-fibrotic activities. Upon administration of the TGFb receptor ectodomain-IgG Fc fusion protein BMS-986416, the fusion protein specifically and selectively targets, binds to and neutralizes the TGF ligands TGF-beta isoform 1 (TGFb1) and 3 (TGFb3). This prevents TGF ligands from binding to TGF receptors and prevents TGFb-mediated signaling. This abrogates TGFb1/3-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. By preventing TGFb1/3-mediated signaling, BMS-986416 also prevents bone marrow fibrosis and promotes the proliferation of normal hematopoietic progenitors. TGFb, overproduced in myelodysplastic syndrome (MDS) and in many other types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression. The TGFb1 and TGFb3 isoforms are negative regulators of hematopoiesis that play key roles in the pathogenesis and progression of fibrotic diseases. By selectively targeting only specific isoforms of TGFb with minimal activity against TGFb2, BMS-986416 minimizes the potential for cardiotoxicity and promotion of metastasis. The TGFb2 isoform promotes hematopoiesis and plays a key role in normal cardiac function while the inhibition of the TGFb2 isoform promotes metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein BMS-986416","termGroup":"PT","termSource":"NCI"},{"termName":"AVID 200","termGroup":"CN","termSource":"NCI"},{"termName":"AVID-200","termGroup":"CN","termSource":"NCI"},{"termName":"AVID200","termGroup":"CN","termSource":"NCI"},{"termName":"BMS 986416","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986416","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986416","termGroup":"CN","termSource":"NCI"},{"termName":"TGF-beta 1/3 Inhibitor AVID200","termGroup":"SY","termSource":"NCI"},{"termName":"TGFb Inhibitor AVID200","termGroup":"SY","termSource":"NCI"},{"termName":"TGFbeta Ligand Trap AVID200","termGroup":"SY","termSource":"NCI"},{"termName":"TGFbeta-neutralizing Agent AVID200","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2269485-28-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6EX05GL2VK"},{"name":"Maps_To","value":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200"},{"name":"NCI_Drug_Dictionary_ID","value":"797961"},{"name":"NCI_META_CUI","value":"CL951620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797961"},{"name":"PDQ_Open_Trial_Search_ID","value":"797961"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C869":{"preferredName":"Thalicarpine","code":"C869","definitions":[{"definition":"A natural aporphine benzylisoquinoline vinca alkaloid with antineoplastic activity. Thalicarpine binds to and inhibits p-glycoprotein, the multidrug resistance efflux pump. Thalicarpine also induces single-strand breaks in DNA and arrests cancer cells at the G2/M and G1 phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thalicarpine","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Dibenzo[de,g]quinoline, 5,6,6a, 7-tetrahydro-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-1,2,10-trimethoxy-6-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"4H-dibenzo[de,g]quinoline, 9-[4, 5-dimethoxy-2-[(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, [S-(R*,R*)]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"6a-Alpha-aporphine, 9-[[4, 5-dimethoxy-alpha-(1beta,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1,2, 10-trimethoxy- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"6a-Alpha-aporphine, 9-[[4,5-dimethoxy-alpha-((S)-1,2,3, 4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1, 2,10-trimethoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"[S-(R*,R*)]-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)-methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-4H-dibenzo[de,g]quinoline","termGroup":"SN","termSource":"NCI"},{"termName":"Taliblastine","termGroup":"SY","termSource":"NCI"},{"termName":"Thaliblastine","termGroup":"SY","termSource":"NCI"},{"termName":"Thalicarpin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5373-42-2"},{"name":"CHEBI_ID","value":"CHEBI:9509"},{"name":"Chemical_Formula","value":"C41H48N2O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8X1D791RF6"},{"name":"Legacy Concept Name","value":"Thalicarpine"},{"name":"Maps_To","value":"Thalicarpine"},{"name":"NCI_Drug_Dictionary_ID","value":"39712"},{"name":"NSC Number","value":"68075"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39712"},{"name":"PDQ_Open_Trial_Search_ID","value":"39712"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039735"}]}}{"C870":{"preferredName":"Thalidomide","code":"C870","definitions":[{"definition":"A drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalomid belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thalidomide","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Dioxo-3-phthalimidopiperidine","termGroup":"SN","termSource":"NCI"},{"termName":"2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"3-Phthalimidoglutarimide","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-Phthalimidoglutarimide","termGroup":"SY","termSource":"NCI"},{"termName":"Contergan","termGroup":"FB","termSource":"NCI"},{"termName":"Distaval","termGroup":"FB","termSource":"NCI"},{"termName":"Kevadon","termGroup":"FB","termSource":"NCI"},{"termName":"N-(2,6-Dioxo-3-piperidyl)phthalimide","termGroup":"SN","termSource":"NCI"},{"termName":"N-Phthaloylglutamimide","termGroup":"SY","termSource":"NCI"},{"termName":"N-Phthalylglutamic Acid Imide","termGroup":"SY","termSource":"NCI"},{"termName":"Neurosedyn","termGroup":"FB","termSource":"NCI"},{"termName":"Pantosediv","termGroup":"FB","termSource":"NCI"},{"termName":"Sedalis","termGroup":"FB","termSource":"NCI"},{"termName":"Sedoval K-17","termGroup":"FB","termSource":"NCI"},{"termName":"Sedoval K17","termGroup":"FB","termSource":"NCI"},{"termName":"Softenon","termGroup":"FB","termSource":"NCI"},{"termName":"Synovir","termGroup":"BR","termSource":"NCI"},{"termName":"Talimol","termGroup":"FB","termSource":"NCI"},{"termName":"Thalomid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Aphthous stomatitis; Crohns disease; cutaneous manifestations of erythema nodosum leprosum; GVHD; HIV-associated wasting syndrome; Karposi sarcoma; lepromatous leprosy; multiple myeloma; mycobacterium tuberculosis and nontuberculosis; primary brain tumors"},{"name":"CAS_Registry","value":"50-35-1"},{"name":"CHEBI_ID","value":"CHEBI:9513"},{"name":"Chemical_Formula","value":"C13H10N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4Z8R6ORS6L"},{"name":"Legacy Concept Name","value":"Thalidomide"},{"name":"Maps_To","value":"Thalidomide"},{"name":"NCI_Drug_Dictionary_ID","value":"42332"},{"name":"NSC Number","value":"66847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42332"},{"name":"PDQ_Open_Trial_Search_ID","value":"42332"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039736"}]}}{"C162552":{"preferredName":"Xiliertinib","code":"C162552","definitions":[{"definition":"An orally available, ATP-competitive inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, xiliertinib binds to and inhibits the activity of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xiliertinib","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL 309","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-309","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL309","termGroup":"CN","termSource":"NCI"},{"termName":"Theliatinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353644-70-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6ZZ3B7NZ0B"},{"name":"Maps_To","value":"Theliatinib"},{"name":"Maps_To","value":"Xiliertinib"},{"name":"NCI_META_CUI","value":"CL971129"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2385":{"preferredName":"Theramide","code":"C2385","definitions":[{"definition":"A lipophilic disaccharide derivative of muramyl dipeptide (MDP) with strong immunostimulating activity and used as a vaccine adjuvant. MDP, a component of bacterial cell wall, is the minimum chemical structure required for macrophage activation. Due to MDP's toxicity and short duration of action, theramide was developed with improved stability, and can be administered without a liposome carrier. Theramide stimulates macrophage activity, which in turn potentiates other immune responses, including the release of proinflammatory interleukins and tumor necrosis factor alpha (TNF alpha). The release of these cytokines further augments the activation of cellular and humoral immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Theramide","termGroup":"PT","termSource":"NCI"},{"termName":"DTP-DPP","termGroup":"AB","termSource":"NCI"},{"termName":"N-acetylglucsamnmyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Theramide"},{"name":"Maps_To","value":"Theramide"},{"name":"NCI_Drug_Dictionary_ID","value":"42146"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42146"},{"name":"PDQ_Open_Trial_Search_ID","value":"42146"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281665"}]}}{"C68962":{"preferredName":"Therapeutic Angiotensin-(1-7)","code":"C68962","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. Therapeutic angiotensin-(1-7) is a hormone that is made in the laboratory, and helps control blood pressure. It may stop the growth of some types of cancer cells and may stop the growth of blood vessels needed by tumors to grow. It is a type of antiproliferative agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic heptapeptide identical to endogenous angiotensin-(1-7) with vasodilator and antiproliferative activities. Therapeutic angiotensin 1-7 may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) receptor Mas, resulting in diminished tumor cell proliferation. Activation of the angiotensin-(1-7) receptor Mas, a G-protein coupled, seven transmembrane protein, may down-regulate the phosphorylation and activation of Erk1 and Erk2 in the Erk1/Erk2 MAPK signaling pathway. In the renin-angiotensin system, the vasodilating activity of angiotensin- (1-7), hydrolysed from angiotensin II by the type I transmembrane metallopeptidase and carboxypeptidase angiotensin converting enzyme 2 (ACE2) in vivo, counteracts the vasoconstricting activity of angiotensin II.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Angiotensin-(1-7)","termGroup":"PT","termSource":"NCI"},{"termName":"Ang 1-7","termGroup":"SY","termSource":"NCI"},{"termName":"Angiotensin 1-7","termGroup":"SY","termSource":"NCI"},{"termName":"TXA 127","termGroup":"CN","termSource":"NCI"},{"termName":"TXA-127","termGroup":"CN","termSource":"NCI"},{"termName":"TXA127","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51833-78-4"},{"name":"CHEBI_ID","value":"CHEBI:55438"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IJ3FUK8MOF"},{"name":"Legacy Concept Name","value":"Therapeutic_Angiotensin_1-7"},{"name":"Maps_To","value":"Therapeutic Angiotensin-(1-7)"},{"name":"NCI_Drug_Dictionary_ID","value":"543940"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543940"},{"name":"PDQ_Open_Trial_Search_ID","value":"543940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0103306"}]}}{"C91077":{"preferredName":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907","code":"C91077","definitions":[{"definition":"A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): Topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907","termGroup":"PT","termSource":"NCI"},{"termName":"DPX-0907","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907"},{"name":"NCI_Drug_Dictionary_ID","value":"670456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670456"},{"name":"PDQ_Open_Trial_Search_ID","value":"670456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984018"}]}}{"C478":{"preferredName":"Therapeutic Estradiol","code":"C478","definitions":[{"definition":"A synthetic form of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females, that may be used as hormone replacement therapy. Typically esterified, estradiol derivatives are formulated for oral, intravaginal, transdermal, or parenteral administration. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. It may play a role in immune and inflammatory processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Estradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17beta)-Estra-1,3,5(10)-triene-3,17-diol","termGroup":"SN","termSource":"NCI"},{"termName":"17 Beta-Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"Aquadiol","termGroup":"BR","termSource":"NCI"},{"termName":"Climara","termGroup":"BR","termSource":"NCI"},{"termName":"Dimenformon","termGroup":"FB","termSource":"NCI"},{"termName":"Diogyn","termGroup":"FB","termSource":"NCI"},{"termName":"Diogynets","termGroup":"FB","termSource":"NCI"},{"termName":"Estrace","termGroup":"BR","termSource":"NCI"},{"termName":"Estraldine","termGroup":"SY","termSource":"NCI"},{"termName":"Ovocylin","termGroup":"FB","termSource":"NCI"},{"termName":"Progynon","termGroup":"FB","termSource":"NCI"},{"termName":"Vagifem","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-28-2"},{"name":"CHEBI_ID","value":"CHEBI:16469"},{"name":"Chemical_Formula","value":"C18H24O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4TI98Z838E"},{"name":"Legacy Concept Name","value":"Therapeutic_Estradiol"},{"name":"Maps_To","value":"Therapeutic Estradiol"},{"name":"NCI_Drug_Dictionary_ID","value":"39236"},{"name":"NSC Number","value":"20293"},{"name":"NSC Number","value":"9895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39236"},{"name":"PDQ_Open_Trial_Search_ID","value":"39236"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699359"}]}}{"C555":{"preferredName":"Therapeutic Hydrocortisone","code":"C555","definitions":[{"definition":"A drug used to relieve the symptoms of certain hormone shortages and to suppress an immune response.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Hydrocortisone","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Aeroseb-HC","termGroup":"BR","termSource":"NCI"},{"termName":"Barseb-HC","termGroup":"SY","termSource":"NCI"},{"termName":"Cetacort","termGroup":"BR","termSource":"NCI"},{"termName":"Cort-Dome","termGroup":"BR","termSource":"NCI"},{"termName":"Cortef","termGroup":"BR","termSource":"NCI"},{"termName":"Cortenema","termGroup":"BR","termSource":"NCI"},{"termName":"Cortifan","termGroup":"SY","termSource":"NCI"},{"termName":"Cortisol","termGroup":"SY","termSource":"NCI"},{"termName":"Cortispray","termGroup":"BR","termSource":"NCI"},{"termName":"Cortril","termGroup":"BR","termSource":"NCI"},{"termName":"Dermacort","termGroup":"BR","termSource":"NCI"},{"termName":"Domolene","termGroup":"SY","termSource":"NCI"},{"termName":"Eldecort","termGroup":"BR","termSource":"NCI"},{"termName":"Hautosone","termGroup":"SY","termSource":"NCI"},{"termName":"Heb-Cort","termGroup":"SY","termSource":"NCI"},{"termName":"Hydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Hydrocortone","termGroup":"BR","termSource":"NCI"},{"termName":"Hytone","termGroup":"BR","termSource":"NCI"},{"termName":"Komed-HC","termGroup":"SY","termSource":"NCI"},{"termName":"Nutracort","termGroup":"BR","termSource":"NCI"},{"termName":"Proctocort","termGroup":"BR","termSource":"NCI"},{"termName":"Rectoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-23-7"},{"name":"CHEBI_ID","value":"CHEBI:17650"},{"name":"Chemical_Formula","value":"C21H30O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"WI4X0X7BPJ"},{"name":"Legacy Concept Name","value":"Therapeutic_Hydrocortisone"},{"name":"Maps_To","value":"Therapeutic Hydrocortisone"},{"name":"NCI_Drug_Dictionary_ID","value":"39274"},{"name":"NSC Number","value":"10482"},{"name":"NSC Number","value":"10483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39274"},{"name":"PDQ_Open_Trial_Search_ID","value":"39274"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020268"}]}}{"C151942":{"preferredName":"Therapeutic Liver Cancer Peptide Vaccine IMA970A","code":"C151942","definitions":[{"definition":"An off-the-shelf hepatocellular cancer (HCC) multi-peptide-based therapeutic vaccine composed of sixteen peptides derived from tumor-associated antigens (TAAs) expressed by hepatic tumor cells, of which seven are restricted to human leukocyte antigen (HLA)-A2 (HLA-A*02), five to HLA-A*24 and four to HLA class II, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the therapeutic liver cancer peptide vaccine IMA970A, the liver-specific peptides in the vaccine activate the immune system to exert both CD4+ T-helper and CD8+ cytotoxic T-lymphocyte (CTL)-mediated immune responses against liver cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Liver Cancer Peptide Vaccine IMA970A","termGroup":"PT","termSource":"NCI"},{"termName":"HCC Vaccine IMA970A","termGroup":"SY","termSource":"NCI"},{"termName":"IMA970A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Therapeutic Liver Cancer Peptide Vaccine IMA970A"},{"name":"NCI_Drug_Dictionary_ID","value":"793143"},{"name":"NCI_META_CUI","value":"CL553170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793143"},{"name":"PDQ_Open_Trial_Search_ID","value":"793143"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92589":{"preferredName":"Thiarabine","code":"C92589","definitions":[{"definition":"A analog of antimetabolite cytarabine (ara-C), with potential antineoplastic activity. Upon administration, thiarabine (T-araC) is phosphorylated to the triphosphate form T-araCTP and competes with cytidine for incorporation into DNA. This results in an inhibition of DNA replication and RNA synthesis, chain termination and may eventually decrease tumor cell proliferation. Compared to ara-C, T-araC appears to have a longer half-life and has a higher efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thiarabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-thio-araC","termGroup":"AB","termSource":"NCI"},{"termName":"GS7836","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-7836","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26599-17-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YCO2764D5Z"},{"name":"Maps_To","value":"Thiarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"675426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675426"},{"name":"PDQ_Open_Trial_Search_ID","value":"675426"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0915967"}]}}{"C75295":{"preferredName":"Thiodiglycol","code":"C75295","definitions":[{"definition":"A hydrolysis product of mustard gas, an alkylating agent, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thiodiglycol","termGroup":"PT","termSource":"NCI"},{"termName":"beta-Hydroxyethyl Sulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Bis(2-hydroxyethyl)sulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Thiodiethylene Glycol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111-48-8"},{"name":"Chemical_Formula","value":"C4H10O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9BW5T43J04"},{"name":"Legacy Concept Name","value":"Thiodiglycol"},{"name":"Maps_To","value":"Thiodiglycol"},{"name":"NSC Number","value":"6289"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045267"}]}}{"C876":{"preferredName":"Thioguanine","code":"C876","definitions":[{"definition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thioguanine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino 6MP","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-1,7-dihydro-6H-purine-6-thione","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-6-mercaptopurine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-6-purinethiol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurin-6-thiol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurine-6(1H)-thione","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurine-6-thiol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurine-6-thiol Hemihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"6 Mercaptoguanine","termGroup":"SN","termSource":"NCI"},{"termName":"6 Thioguanine","termGroup":"SN","termSource":"NCI"},{"termName":"6-Mercapto-2-aminopurine","termGroup":"SN","termSource":"NCI"},{"termName":"6-TG","termGroup":"AB","termSource":"NCI"},{"termName":"6-Thioguanine","termGroup":"SN","termSource":"NCI"},{"termName":"6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"BW 5071","termGroup":"CN","termSource":"NCI"},{"termName":"Lanvis","termGroup":"FB","termSource":"NCI"},{"termName":"Tabloid","termGroup":"BR","termSource":"NCI"},{"termName":"Thioguanine Hemihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Thioguanine Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Tioguanin","termGroup":"SY","termSource":"NCI"},{"termName":"Tioguanine","termGroup":"SY","termSource":"NCI"},{"termName":"Wellcome U3B","termGroup":"CN","termSource":"NCI"},{"termName":"WR-1141","termGroup":"CN","termSource":"NCI"},{"termName":"X 27","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute nonlymphocytic leukemia"},{"name":"CAS_Registry","value":"5580-03-0"},{"name":"Chemical_Formula","value":"C5H5N5S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"FTK8U1GZNX"},{"name":"Legacy Concept Name","value":"Thioguanine"},{"name":"Maps_To","value":"Thioguanine"},{"name":"NCI_Drug_Dictionary_ID","value":"43669"},{"name":"NSC Number","value":"752"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43669"},{"name":"PDQ_Open_Trial_Search_ID","value":"43669"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039902"}]}}{"C61970":{"preferredName":"Thioguanine Anhydrous","code":"C61970","definitions":[{"definition":"The anhydrous salt form of thioguanine, a synthetic guanosine analogue antimetabolite, with antineoplastic activity. Thioguanine is phosphorylated by hypoxanthine-guanine phosphoribosyltransferase to 6-thioguanylic acid (TGMP) and upon conversion to thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP), this agent is incorporated into DNA and RNA, resulting in inhibition of DNA and RNA synthesis and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine ribonulceotide synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioguanine Anhydrous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154-42-7"},{"name":"Chemical_Formula","value":"C5H5N5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WIX31ZPX66"},{"name":"Legacy Concept Name","value":"Thioguanine_Anhydrous"},{"name":"Maps_To","value":"Thioguanine Anhydrous"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1883309"}]}}{"C877":{"preferredName":"Thioinosine","code":"C877","definitions":[{"definition":"A sulfhydryl analog of inosine and an antimetabolite with potential antineoplastic and immunosuppressive properties. Thioinosine interferes with de novo purine synthesis and perturbs the pool of nucleotides necessary for DNA replication. As a result, this agent inhibits DNA synthesis, blocks cellular proliferation and induces apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioinosine","termGroup":"PT","termSource":"NCI"},{"termName":"6-mercaptopurine ribonucleoside","termGroup":"SN","termSource":"NCI"},{"termName":"6-mercaptopurine riboside","termGroup":"SN","termSource":"NCI"},{"termName":"inosine, 6-thio","termGroup":"SN","termSource":"NCI"},{"termName":"Mercaptopurine Riboside","termGroup":"SY","termSource":"NCI"},{"termName":"ribosyl-6-mercaptopurine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"574-25-4"},{"name":"Chemical_Formula","value":"C10H12N4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46S541971T"},{"name":"Legacy Concept Name","value":"Thioinosine"},{"name":"Maps_To","value":"Thioinosine"},{"name":"NCI_Drug_Dictionary_ID","value":"39496"},{"name":"NSC Number","value":"4911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39496"},{"name":"PDQ_Open_Trial_Search_ID","value":"39496"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039904"}]}}{"C74082":{"preferredName":"Thioredoxin-1 Inhibitor PX-12","code":"C74082","definitions":[{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. Thioredoxin-1 inhibitor PX-12 irreversibly binds to thioredoxin-1 (Trx-1) and inhibits its activity, which may result in growth inhibition and the induction of apoptosis. Overexpressed in many cancer cell types, the low molecular weight redox protein Trx-1 regulates transcription factor activity and inhibits apoptosis, promoting cell growth and survival; it also interacts with growth factors extracellularly to stimulate cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioredoxin-1 Inhibitor PX-12","termGroup":"PT","termSource":"NCI"},{"termName":"1-Methylpropyl 2-Imidazolyl Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"PX-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"141400-58-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8PQ9CZ8BTJ"},{"name":"Legacy Concept Name","value":"Thioredoxin-1_Inhibitor_PX-12"},{"name":"Maps_To","value":"Thioredoxin-1 Inhibitor PX-12"},{"name":"NCI_Drug_Dictionary_ID","value":"590656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590656"},{"name":"PDQ_Open_Trial_Search_ID","value":"590656"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0960559"}]}}{"C875":{"preferredName":"Thiotepa","code":"C875","definitions":[{"definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thiotepa","termGroup":"PT","termSource":"NCI"},{"termName":"1,1',1\"-phosphinothioylidynetrisaziridine","termGroup":"SN","termSource":"NCI"},{"termName":"1,1',1''-Phosphinothioyldynetrisaziridine","termGroup":"SN","termSource":"NCI"},{"termName":"N,N',N''-triethylenethiophosphoramide","termGroup":"SN","termSource":"NCI"},{"termName":"Tepadina","termGroup":"BR","termSource":"NCI"},{"termName":"Tepadina","termGroup":"FB","termSource":"NCI"},{"termName":"TESPA","termGroup":"AB","termSource":"NCI"},{"termName":"Thiofosfamide","termGroup":"SY","termSource":"NCI"},{"termName":"Thiophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Thiophosphoamide","termGroup":"SY","termSource":"NCI"},{"termName":"Thiophosphoramide","termGroup":"SY","termSource":"NCI"},{"termName":"Thioplex","termGroup":"AQS","termSource":"NCI"},{"termName":"Triethylene Thiophosphoramide","termGroup":"SY","termSource":"NCI"},{"termName":"triethylenethiophosphoramide","termGroup":"SY","termSource":"NCI"},{"termName":"tris(1-aziridinyl)phosphine sulfide","termGroup":"SN","termSource":"NCI"},{"termName":"TSPA","termGroup":"AB","termSource":"NCI"},{"termName":"WR 45312","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Breast cancer; Ovarian cancer; Hodgkins lymphoma; Non-hodgkins lymphoma"},{"name":"CAS_Registry","value":"52-24-4"},{"name":"Chemical_Formula","value":"C6H12N3PS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"905Z5W3GKH"},{"name":"Legacy Concept Name","value":"Thiotepa"},{"name":"Maps_To","value":"Thiotepa"},{"name":"NCI_Drug_Dictionary_ID","value":"42933"},{"name":"NSC Number","value":"6396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42933"},{"name":"PDQ_Open_Trial_Search_ID","value":"42933"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039871"}]}}{"C102881":{"preferredName":"Thioureidobutyronitrile","code":"C102881","definitions":[{"definition":"A water-soluble, small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. Upon intravenous administration, thioureidobutyronitrile activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis. Thioureidobutyronitrile may be effective in drug-resistant cancers with mutated p53. p53 tumor suppressor, a transcription factor regulating the expression of many stress response genes and mediating various anti-proliferative processes, is often mutated in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioureidobutyronitrile","termGroup":"PT","termSource":"NCI"},{"termName":"4-Isothioureidobutyronitrile","termGroup":"SY","termSource":"NCI"},{"termName":"Carbamimidothioic Acid, 3-Cyanopropyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Kevetrin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"500863-50-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C3059TG1KN"},{"name":"Maps_To","value":"Thioureidobutyronitrile"},{"name":"NCI_Drug_Dictionary_ID","value":"739050"},{"name":"NCI_META_CUI","value":"CL437184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739050"},{"name":"PDQ_Open_Trial_Search_ID","value":"739050"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88275":{"preferredName":"THL-P","code":"C88275","definitions":[{"definition":"A proprietary, oral Chinese medicinal herb preparation with potential antioxidant, immunomodulating, and antineoplastic activities. THL-P (Tien-Hsien Liquid-P) contains fourteen Chinese medicinal herbs including: Cordyceps sinensis, Oldenlandia diffusa, Indigo pulverata levis, Polyporus umbellatus, Radix astragali, Panax ginseng, Solanum nigrum L., Pogostemon cablin, Atractylodis macrocephalae rhizoma, Trichosanthes radix, Clematis radix, Margarite, Ligustrum lucidum Ait and Glycyrrhiza radix. Administered as an oral liquid, THL-P may modulate the activity of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs), macrophages and polymorphonuclear leukocytes, and enhance the secretion of interleukins (ILs) and interferon-gamma (IFN-gamma). This agent may also induce G2/M cell cycle arrest and downregulate several important oncogenic signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"THL-P","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"THL-P"},{"name":"NCI_Drug_Dictionary_ID","value":"655959"},{"name":"NCI_META_CUI","value":"CL412464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655959"},{"name":"PDQ_Open_Trial_Search_ID","value":"655959"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155977":{"preferredName":"Thorium Th 227 Anetumab Corixetan","code":"C155977","definitions":[{"definition":"A radioimmunoconjugate consisting of anetumab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein mesothelin, conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 anetumab corixetan, the anetumab moiety binds to the tumor-associated antigen (TAA) mesothelin, delivering a cytotoxic dose of alpha radiation to cells expressing mesothelin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thorium Th 227 Anetumab Corixetan","termGroup":"PT","termSource":"NCI"},{"termName":"227Th Anetumab Corixetan","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2287411","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2287411","termGroup":"CN","termSource":"NCI"},{"termName":"Thorium Th 227 Monoclonal Antibody BAY2287411","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Anetumab","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Antibody-chelator Conjugate BAY2287411","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222980-98-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22OG9ZC9MN"},{"name":"Maps_To","value":"Thorium Th 227 Anetumab"},{"name":"Maps_To","value":"Thorium Th 227 Anetumab Corixetan"},{"name":"NCI_Drug_Dictionary_ID","value":"795118"},{"name":"NCI_META_CUI","value":"CL562713"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795118"},{"name":"PDQ_Open_Trial_Search_ID","value":"795118"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128288":{"preferredName":"Luvixasertib","code":"C128288","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the dual specificity protein kinase TTK (monopolar spindle 1 kinase, Mps1), with potential antineoplastic activity. Upon administration, luvixasertib selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC) and accelerates mitosis, which results in chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a tyrosine and serine/threonine kinase expressed in proliferating normal tissues, is essential for proper SAC functioning and chromosome alignment. Overexpressed in various human tumors, Mps1 plays a key role in uncontrolled tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luvixasertib","termGroup":"PT","termSource":"NCI"},{"termName":"CFI-402257","termGroup":"CN","termSource":"NCI"},{"termName":"MSP1 Inhibitor CFI-402257","termGroup":"SY","termSource":"NCI"},{"termName":"N-cyclopropyl-4-(7-((((1s,3s)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-2-yloxy)pyrazolo[1,5-a]pyridin-3-yl)-2-methylbenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Threonine Tyrosine Kinase Inhibitor CFI-402257","termGroup":"SY","termSource":"NCI"},{"termName":"TTK Inhibitor CFI-402257","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610759-22-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HE97PTK3Q6"},{"name":"Maps_To","value":"Threonine Tyrosine Kinase Inhibitor CFI-402257"},{"name":"NCI_Drug_Dictionary_ID","value":"782180"},{"name":"NCI_META_CUI","value":"CL507939"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782180"},{"name":"PDQ_Open_Trial_Search_ID","value":"782180"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116720":{"preferredName":"Thymidylate Synthase Inhibitor DFP-11207","code":"C116720","definitions":[{"definition":"An orally available thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon oral administration, DFP-11207 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymidylate Synthase Inhibitor DFP-11207","termGroup":"PT","termSource":"NCI"},{"termName":"DFP-11207","termGroup":"CN","termSource":"NCI"},{"termName":"TS Inhibitor DFP-11207","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1296177-16-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33RN5G108E"},{"name":"Maps_To","value":"Thymidylate Synthase Inhibitor DFP-11207"},{"name":"NCI_Drug_Dictionary_ID","value":"762603"},{"name":"NCI_META_CUI","value":"CL473914"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762603"},{"name":"PDQ_Open_Trial_Search_ID","value":"762603"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1294":{"preferredName":"Thymopentin","code":"C1294","definitions":[{"definition":"A synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin enhances the production of thymic T cells and may help restore immunocompetence in immunosuppressed subjects. This agent also augments the effects of ionizing radiation by arresting cancer cells in the G2/M phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymopentin","termGroup":"PT","termSource":"NCI"},{"termName":"Immunox","termGroup":"BR","termSource":"NCI"},{"termName":"Mepentil","termGroup":"FB","termSource":"NCI"},{"termName":"N-(N-(N-(N(2)-L-Arginyl-L-Lysyl)-L-alpha-Aspartyl)-L-Valyl)-L-Tyrosine","termGroup":"SN","termSource":"NCI"},{"termName":"ORF-15244","termGroup":"CN","termSource":"NCI"},{"termName":"Sintomodulina","termGroup":"FB","termSource":"NCI"},{"termName":"Timunox","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69558-55-0"},{"name":"Chemical_Formula","value":"C30H49N9O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3Y80ZF13F"},{"name":"Legacy Concept Name","value":"Thymopentin"},{"name":"Maps_To","value":"Thymopentin"},{"name":"NCI_Drug_Dictionary_ID","value":"41655"},{"name":"NSC Number","value":"645363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41655"},{"name":"PDQ_Open_Trial_Search_ID","value":"41655"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0080225"}]}}{"C2565":{"preferredName":"Thyroid Extract","code":"C2565","definitions":[{"definition":"An animal source of thyroid used in hormonal replacement therapy. Thyroid extract or desiccated thyroid contains both levothyroxine (thyroxine or T4) and liothyronine (triiodothyronine or T3). Levothyroxine is deiodinated in the peripheral tissues to produce increased levels of its active form, liothyronine (T3). Thyroid hormones play an important role in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation as well as regulating the metabolism of proteins, carbohydrates, and lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Armour Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Levothyroxine/Liothyronine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Extract"},{"name":"Maps_To","value":"Thyroid Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"39301"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39301"},{"name":"PDQ_Open_Trial_Search_ID","value":"39301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0718658"}]}}{"C1254":{"preferredName":"Tiazofurin","code":"C1254","definitions":[{"definition":"A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug being studied to stop cell growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tiazofurin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Beta-D-ribofuranosyl-4-thiazolecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"2-Beta-D-ribofuranosylthiazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Thiazolecarboxamide, 2-Beta-D-ribofuranosyl- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Riboxamide","termGroup":"BR","termSource":"NCI"},{"termName":"TCAR","termGroup":"AB","termSource":"NCI"},{"termName":"Tiazofurine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60084-10-8"},{"name":"Chemical_Formula","value":"C9H12N2O5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ULJ82834RE"},{"name":"Legacy Concept Name","value":"Tiazofurin"},{"name":"Maps_To","value":"Tiazofurin"},{"name":"NCI_Drug_Dictionary_ID","value":"39717"},{"name":"NSC Number","value":"286193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39717"},{"name":"PDQ_Open_Trial_Search_ID","value":"39717"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076656"}]}}{"C146820":{"preferredName":"Tidutamab","code":"C146820","definitions":[{"definition":"A humanized, Fc domain-containing, bispecific monoclonal antibody targeting human CD3, a T-cell surface antigen, and somatostatin receptor 2 (SSTR2), a tumor-associated antigen (TAA) expressed on certain cancer cells, with potential antineoplastic activity. Upon administration, tidutamab binds to both T-cells and SSTR2-expressing cancer cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the SSTR2-expressing cancer cells. The inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tidutamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-SSTR2 x Anti-CD3 Monoclonal Antibody XmAb18087","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb 18087","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb-18087","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb18087","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2148354-90-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"88635FW2QX"},{"name":"Maps_To","value":"Tidutamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792257"},{"name":"NCI_META_CUI","value":"CL544867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792257"},{"name":"PDQ_Open_Trial_Search_ID","value":"792257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78474":{"preferredName":"Tigapotide","code":"C78474","definitions":[{"definition":"A synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tigapotide","termGroup":"PT","termSource":"NCI"},{"termName":"PCK3145","termGroup":"CN","termSource":"NCI"},{"termName":"Prostate-Secretory Protein-94-Derived Peptide PCK3145","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848084-83-3"},{"name":"Chemical_Formula","value":"C82H119N21O34S3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1WZ6S45S94"},{"name":"Legacy Concept Name","value":"PSP-94-Derived_Synthetic_Peptide_PCK3145"},{"name":"Maps_To","value":"Tigapotide"},{"name":"NCI_Drug_Dictionary_ID","value":"600185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600185"},{"name":"PDQ_Open_Trial_Search_ID","value":"600185"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1670100"}]}}{"C62482":{"preferredName":"Tigatuzumab","code":"C62482","definitions":[{"definition":"A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tigatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-[Homo sapiens TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily Member 10B, DR5, TRAIL-R2, CD262)] Humanized Monoclonal TRA-8","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-DR5 MoAb","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TRAIL-R2 MoAb","termGroup":"SY","termSource":"NCI"},{"termName":"CS-1008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"918127-53-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"237GB6IDKO"},{"name":"Legacy Concept Name","value":"CS-1008"},{"name":"Maps_To","value":"Tigatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"489323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489323"},{"name":"PDQ_Open_Trial_Search_ID","value":"489323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2973415"}]}}{"C140041":{"preferredName":"Vibostolimab","code":"C140041","definitions":[{"definition":"An antagonistic agent targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin and ITIM domain), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vibostolimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells, and activates CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, is overexpressed on tumor antigen-specific CD8+ T-cells and CD8+ TILs and plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vibostolimab","termGroup":"PT","termSource":"NCI"},{"termName":"MK 7684","termGroup":"CN","termSource":"NCI"},{"termName":"MK-7684","termGroup":"CN","termSource":"NCI"},{"termName":"MK7684","termGroup":"CN","termSource":"NCI"},{"termName":"T-cell Immunoglobulin and Immunoreceptor Tyrosine-based Inhibitory Motif Inhibitor MK-7684","termGroup":"SY","termSource":"NCI"},{"termName":"TIGIT Inhibitor MK-7684","termGroup":"SY","termSource":"NCI"},{"termName":"TIGIT-targeting Agent MK-7684","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231305-30-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5XO3JF0FEK"},{"name":"Maps_To","value":"TIGIT-targeting Agent MK-7684"},{"name":"Maps_To","value":"Vibostolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791161"},{"name":"NCI_META_CUI","value":"CL538225"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791161"},{"name":"PDQ_Open_Trial_Search_ID","value":"791161"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1178":{"preferredName":"Tilarginine","code":"C1178","definitions":[{"definition":"A pan-nitric oxide synthase (NOS) inhibitor, with potential immunomodulating and antineoplastic activities. Upon administration, tilarginine binds to and inhibits NOS, a free radical signaling molecule that promotes angiogenesis, metastasis, and immunosuppression in the tumor microenvironment (TME). Reduction in NOS activity may abrogate the immunosuppressive TME, enhance tumor antigen-specific immune response and inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"An amino acid derivative used to counteract high blood pressure caused by interleukin-2.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tilarginine","termGroup":"PT","termSource":"NCI"},{"termName":"L-NMMA","termGroup":"AB","termSource":"NCI"},{"termName":"MMA","termGroup":"SY","termSource":"NCI"},{"termName":"Monomethylarginine","termGroup":"SN","termSource":"NCI"},{"termName":"N-Methylarginine","termGroup":"SY","termSource":"NCI"},{"termName":"N5-(Methylamidino)-L-ornithine","termGroup":"SN","termSource":"NCI"},{"termName":"NG-Monomethyl-L-Arginine","termGroup":"SN","termSource":"NCI"},{"termName":"NMA","termGroup":"AB","termSource":"NCI"},{"termName":"omega-N-Monomethylarginine","termGroup":"SN","termSource":"NCI"},{"termName":"Targinine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17035-90-4"},{"name":"CHEBI_ID","value":"CHEBI:28229"},{"name":"Chemical_Formula","value":"C7H16N4O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27JT06E6GR"},{"name":"Legacy Concept Name","value":"NG-Monomethyl-L-Arginine"},{"name":"Maps_To","value":"Tilarginine"},{"name":"NCI_Drug_Dictionary_ID","value":"42258"},{"name":"NSC Number","value":"683245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42258"},{"name":"PDQ_Open_Trial_Search_ID","value":"42258"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069477"}]}}{"C125080":{"preferredName":"Tilsotolimod Sodium","code":"C125080","definitions":[{"definition":"The sodium salt form of tilsotolimod, a proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tilsotolimod Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"IMO 2125","termGroup":"CN","termSource":"NCI"},{"termName":"IMO-2125","termGroup":"CN","termSource":"NCI"},{"termName":"TLR9 Agonist IMO-2125","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2089768-67-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I6CNU8SY0F"},{"name":"Maps_To","value":"Tilsotolimod Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"777995"},{"name":"NCI_META_CUI","value":"CL503920"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777995"},{"name":"PDQ_Open_Trial_Search_ID","value":"777995"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2354":{"preferredName":"Timonacic","code":"C2354","definitions":[{"definition":"A cyclic sulfur amino acid derivative with potential antineoplastic and antioxidant activities. Acting on cellular membranes of malignant cells through an unknown mechanism, timonacic may induce malignant cells to revert back to an untransformed state. This agent may also restore contact inhibition, a phenomenon characterized by the paracrine inhibition of mitosis following the formation of a critical cell mass, presumably the result of cell-to-cell signal transfer. Timonacic may also produce antioxidant effects secondary to its release of cysteine and restoration of glutathione concentrations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Timonacic","termGroup":"PT","termSource":"NCI"},{"termName":"4-Thiazolidine Carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-Thiazolidinecarboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ATC","termGroup":"AB","termSource":"NCI"},{"termName":"Detoxepa","termGroup":"FB","termSource":"NCI"},{"termName":"Hepalidine","termGroup":"FB","termSource":"NCI"},{"termName":"Heparegen","termGroup":"FB","termSource":"NCI"},{"termName":"Thiaproline","termGroup":"SY","termSource":"NCI"},{"termName":"Thiazolidine Carboxylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Thiazolidine-4-carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Thiazolidinecarboxylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Thioproline","termGroup":"SY","termSource":"NCI"},{"termName":"Tiazolidin","termGroup":"SY","termSource":"NCI"},{"termName":"Timonacic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444-27-9"},{"name":"CHEBI_ID","value":"CHEBI:64564"},{"name":"Chemical_Formula","value":"C4H7NO2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E5913T3IBL"},{"name":"Legacy Concept Name","value":"Thiazolidine_Carboxylic_Acid"},{"name":"Maps_To","value":"Timonacic"},{"name":"NCI_Drug_Dictionary_ID","value":"39714"},{"name":"NSC Number","value":"25855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39714"},{"name":"PDQ_Open_Trial_Search_ID","value":"39714"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076425"}]}}{"C1255":{"preferredName":"Tin Ethyl Etiopurpurin","code":"C1255","definitions":[{"definition":"A synthetic purpurin with photosensitizing activity.  Tin ethyl etiopurpurin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called photosensitizing agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tin Ethyl Etiopurpurin","termGroup":"PT","termSource":"NCI"},{"termName":"DRG-0268","termGroup":"CN","termSource":"NCI"},{"termName":"SnET2","termGroup":"AB","termSource":"NCI"},{"termName":"Tin, (ethyl tetramethyl-20-phorbinecarboxylato(2-)-N23,N24,N25,N26)-, (SP-4-2)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"113471-15-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tin_Ethyl_Etiopurpurin"},{"name":"Maps_To","value":"Tin Ethyl Etiopurpurin"},{"name":"NCI_Drug_Dictionary_ID","value":"42606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42606"},{"name":"PDQ_Open_Trial_Search_ID","value":"42606"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076691"}]}}{"C126105":{"preferredName":"Tinostamustine","code":"C126105","definitions":[{"definition":"An alkylating histone-deacetylase inhibitor (HDACi) fusion molecule composed of the alkylating agent bendamustine fused to the pan-HDACi vorinostat, with potential bi-functional antineoplastic activity. Upon administration of tinostamustine the vorinostat moiety targets and binds to HDACs. This leads to an accumulation of highly acetylated histones, which results in an induction of chromatin remodeling, a modulation of gene expression, an inhibition of tumor cell division and the induction of tumor cell apoptosis. The bendamustine moiety binds to, alkylates and crosslinks macromolecules, inhibiting DNA, RNA and protein synthesis, which also results in tumor cell apoptosis. Thus, tinostamustine shows superior efficacy compared to the activity of either agent alone. In addition, the inhibition of HDAC6 activity by tinostamustine induces the activation of inositol-requiring enzyme 1 (IRE-1), the key regulatory protein for the unfolded protein response (UPR). Induction of the UPR increases the sensitivity of certain cancer cell types to certain chemotherapeutic agents, such as proteasome inhibitors. Therefore, tinostamustine may work synergistically with proteasome inhibitors. HDACs, enzymes that deacetylate chromatin histone proteins, are overexpressed in various cancers and play a key role in proliferation and resistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinostamustine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benzimidazole-2-heptanamide, 5-(Bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-","termGroup":"SY","termSource":"NCI"},{"termName":"7-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide","termGroup":"SN","termSource":"NCI"},{"termName":"EDO-S 101","termGroup":"CN","termSource":"NCI"},{"termName":"EDO-S-101","termGroup":"CN","termSource":"NCI"},{"termName":"EDO-S101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1236199-60-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29DKI2H2NY"},{"name":"Maps_To","value":"Tinostamustine"},{"name":"NCI_Drug_Dictionary_ID","value":"779305"},{"name":"NCI_META_CUI","value":"CL504700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779305"},{"name":"PDQ_Open_Trial_Search_ID","value":"779305"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60810":{"preferredName":"Tinzaparin Sodium","code":"C60810","definitions":[{"definition":"A drug that is used with another drug, warfarin, to treat blood clots that form deep in the veins and to prevent new blood clots from forming. It is a type of anticoagulant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties.  Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinzaparin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Enzyme Depolymerized Heparin (MW 6500)","termGroup":"SY","termSource":"NCI"},{"termName":"Inno-hep","termGroup":"BR","termSource":"NCI"},{"termName":"Innohep","termGroup":"BR","termSource":"NCI"},{"termName":"LNH-1","termGroup":"CN","termSource":"NCI"},{"termName":"Logiparin","termGroup":"FB","termSource":"NCI"},{"termName":"Tinzaparin","termGroup":"SY","termSource":"NCI"},{"termName":"Tinzaparin Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Tinzaparin Sodium Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of acute symptomatic deep venous thrombosis (DVT) with or without a pulmonary embolism (PE), in conjunction with warfarin."},{"name":"CAS_Registry","value":"9041-08-1"},{"name":"Chemical_Formula","value":"(C14H18NO11)n.2(C12H15NO13S)n.3Na.3O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S182ET3UA"},{"name":"Legacy Concept Name","value":"Tinzaparin"},{"name":"Maps_To","value":"Tinzaparin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"467737"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467737"},{"name":"PDQ_Open_Trial_Search_ID","value":"467737"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0354599"}]}}{"C74001":{"preferredName":"Tiomolibdate Diammonium","code":"C74001","definitions":[{"definition":"A substance being studied in the treatment of many types of cancer. Ammonium tetrathiomolybdate removes extra copper from the body. Removing the copper may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. Ammonium tetrathiomolybdate is a type of chelating agent and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tiomolibdate Diammonium","termGroup":"PT","termSource":"NCI"},{"termName":"Ammonium Molybdenum Sulfide","termGroup":"SY","termSource":"NCI"},{"termName":"Ammonium Tetrathiomolybdate","termGroup":"SY","termSource":"NCI"},{"termName":"ATTM","termGroup":"AB","termSource":"NCI"},{"termName":"Coprexa","termGroup":"BR","termSource":"NCI"},{"termName":"Diammonium Tetrathiomolybdate","termGroup":"SY","termSource":"NCI"},{"termName":"Molybdate(2-), Tetrathioxo-, Ammonium (1:2), (T-4)-","termGroup":"SN","termSource":"NCI"},{"termName":"Molybdate(2-), Tetrathioxo-, Diammonium, (T-4)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15060-55-6"},{"name":"Chemical_Formula","value":"MoS4.2H4N"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4V6I63LW1E"},{"name":"Legacy Concept Name","value":"Ammonium_Tetrathiomolybdate"},{"name":"Maps_To","value":"Tiomolibdate Diammonium"},{"name":"NCI_Drug_Dictionary_ID","value":"467218"},{"name":"NSC Number","value":"286644"},{"name":"NSC Number","value":"714598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467218"},{"name":"PDQ_Open_Trial_Search_ID","value":"467218"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076339"}]}}{"C88326":{"preferredName":"Tipapkinogene Sovacivec","code":"C88326","definitions":[{"definition":"A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with tipapkinogene sovacivec stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tipapkinogene Sovacivec","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E6/E7-encoding MVA Vaccine TG4001","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-HPV-IL2","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-HPV16E6/E7-IL2","termGroup":"SY","termSource":"NCI"},{"termName":"R3484","termGroup":"CN","termSource":"NCI"},{"termName":"RG3484","termGroup":"CN","termSource":"NCI"},{"termName":"RO5217790","termGroup":"CN","termSource":"NCI"},{"termName":"TG 4001","termGroup":"CN","termSource":"NCI"},{"termName":"TG-4001","termGroup":"CN","termSource":"NCI"},{"termName":"TG4001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1052105-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P34L5Y2SR5"},{"name":"Maps_To","value":"Tipapkinogene Sovacivec"},{"name":"NCI_Drug_Dictionary_ID","value":"661166"},{"name":"NCI_META_CUI","value":"CL413588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661166"},{"name":"PDQ_Open_Trial_Search_ID","value":"661166"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1703":{"preferredName":"Tipifarnib","code":"C1703","definitions":[{"definition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tipifarnib","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone","termGroup":"SN","termSource":"NCI"},{"termName":"R115777","termGroup":"CN","termSource":"NCI"},{"termName":"Zarnestra","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192185-72-1"},{"name":"Chemical_Formula","value":"C27H22Cl2N4O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MAT637500A"},{"name":"Legacy Concept Name","value":"Tipifarnib"},{"name":"Maps_To","value":"Tipifarnib"},{"name":"NCI_Drug_Dictionary_ID","value":"42626"},{"name":"NSC Number","value":"702818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42626"},{"name":"PDQ_Open_Trial_Search_ID","value":"42626"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1176289"}]}}{"C152646":{"preferredName":"Tipiracil","code":"C152646","synonyms":[{"termName":"Tipiracil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183204-74-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NGO10K751P"},{"name":"Maps_To","value":"Tipiracil"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4056441"}]}}{"C152647":{"preferredName":"Tipiracil Hydrochloride","code":"C152647","synonyms":[{"termName":"Tipiracil Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183204-72-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4H59KLQ0A4"},{"name":"Maps_To","value":"Tipiracil Hydrochloride"},{"name":"NCI_META_CUI","value":"CL553979"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102876":{"preferredName":"Tirabrutinib","code":"C102876","definitions":[{"definition":"An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B cell receptor signaling and impeding B cell development. As a result, this agent may inhibit the proliferation of B cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tirabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one","termGroup":"SY","termSource":"NCI"},{"termName":"8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)","termGroup":"SY","termSource":"NCI"},{"termName":"GS-4059","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-4059","termGroup":"CN","termSource":"NCI"},{"termName":"ONO4059","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1351636-18-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LXG44NDL2T"},{"name":"Maps_To","value":"Tirabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"738477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738477"},{"name":"PDQ_Open_Trial_Search_ID","value":"738477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640989"}]}}{"C131291":{"preferredName":"Tiragolumab","code":"C131291","definitions":[{"definition":"A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tiragolumab","termGroup":"PT","termSource":"NCI"},{"termName":"MTIG7192A","termGroup":"CN","termSource":"NCI"},{"termName":"RG6058","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1918185-84-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6XG22YQM2Z"},{"name":"Maps_To","value":"Tiragolumab"},{"name":"NCI_Drug_Dictionary_ID","value":"782262"},{"name":"NCI_META_CUI","value":"CL507941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782262"},{"name":"PDQ_Open_Trial_Search_ID","value":"782262"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1464":{"preferredName":"Tirapazamine","code":"C1464","definitions":[{"definition":"A benzotriazine di-N-oxide with potential antineoplastic activity.  Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.  This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that makes tumor cells more sensitive to radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tirapazamine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Amino-1,2,4-benzotriazine-1,4-dioxide","termGroup":"SN","termSource":"NCI"},{"termName":"SR 4233","termGroup":"CN","termSource":"NCI"},{"termName":"SR4233","termGroup":"CN","termSource":"NCI"},{"termName":"Tirazone","termGroup":"BR","termSource":"NCI"},{"termName":"WIN 59075","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"27314-97-2"},{"name":"Chemical_Formula","value":"C7H6N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1UD32YR59G"},{"name":"Legacy Concept Name","value":"Tirapazamine"},{"name":"Maps_To","value":"Tirapazamine"},{"name":"NCI_Drug_Dictionary_ID","value":"42158"},{"name":"NSC Number","value":"130181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42158"},{"name":"PDQ_Open_Trial_Search_ID","value":"42158"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0208407"}]}}{"C102758":{"preferredName":"Tisagenlecleucel","code":"C102758","definitions":[{"definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tisagenlecleucel","termGroup":"PT","termSource":"NCI"},{"termName":"CART-19","termGroup":"AB","termSource":"NCI"},{"termName":"CART19","termGroup":"AB","termSource":"NCI"},{"termName":"CTL019","termGroup":"CN","termSource":"NCI"},{"termName":"CTL019 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Kymriah","termGroup":"BR","termSource":"NCI"},{"termName":"Tisagenlecleucel-T","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma and DLBCL arising from follicular lymphoma"},{"name":"CAS_Registry","value":"1823078-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q6C9WHR03O"},{"name":"Maps_To","value":"Tisagenlecleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"736184"},{"name":"NCI_META_CUI","value":"CL437013"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736184"},{"name":"PDQ_Open_Trial_Search_ID","value":"736184"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121775":{"preferredName":"Tislelizumab","code":"C121775","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tislelizumab","termGroup":"PT","termSource":"NCI"},{"termName":"BGB-A317","termGroup":"CN","termSource":"NCI"},{"termName":"Tevimbra","termGroup":"BR","termSource":"NCI"},{"termName":"Tirelizumab","termGroup":"SY","termSource":"NCI"},{"termName":"Tislelizumab-jsgr","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858168-59-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0KVO411B3N"},{"name":"Maps_To","value":"Tislelizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"770893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770893"},{"name":"PDQ_Open_Trial_Search_ID","value":"770893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053664"}]}}{"C113164":{"preferredName":"Tisotumab Vedotin","code":"C113164","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic activities. Upon administration of tisotumab vedotin, the tisotumab moiety binds to cell surface TF and is internalized. Tisotumab binds to factor VIIa (FVIIa), which interferes with the activation of factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. After internalization of the agent, the MMAE moiety is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor-resident endothelial cells. Expression of TF is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tisotumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"HuMax-TF-ADC","termGroup":"SY","termSource":"NCI"},{"termName":"Tisotumab Vedotin-tftv","termGroup":"SY","termSource":"NCI"},{"termName":"Tivdak","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with recurrent or metastatic cervical cancer."},{"name":"CAS_Registry","value":"1418731-10-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T41737F88A"},{"name":"Maps_To","value":"Tisotumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"755933"},{"name":"NCI_META_CUI","value":"CL455237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755933"},{"name":"PDQ_Open_Trial_Search_ID","value":"755933"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62437":{"preferredName":"Tivantinib","code":"C62437","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tivantinib","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"ARQ 197","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ-197","termGroup":"CN","termSource":"NCI"},{"termName":"c-Met Inhibitor ARQ 197","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"905854-02-6"},{"name":"Chemical_Formula","value":"C23H19N3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PJ4H73IL17"},{"name":"Legacy Concept Name","value":"ARQ_197"},{"name":"Maps_To","value":"Tivantinib"},{"name":"NCI_Drug_Dictionary_ID","value":"488957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488957"},{"name":"PDQ_Open_Trial_Search_ID","value":"488957"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831873"}]}}{"C85444":{"preferredName":"Tivozanib","code":"C85444","definitions":[{"definition":"An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.  Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tivozanib","termGroup":"PT","termSource":"NCI"},{"termName":"AV-951","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"475108-18-0"},{"name":"Chemical_Formula","value":"C22H19ClN4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"172030934T"},{"name":"Maps_To","value":"Tivozanib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827667"}]}}{"C2102":{"preferredName":"TLC ELL-12","code":"C2102","definitions":[{"definition":"A liposomal formulation of the ether lipid 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with potential antineoplastic activity.  TLC ELL-12 induces tumor cell apoptosis via mitochondria- and caspase-mediated mechanisms.  Liposomal encapsulation reduces the free agent's hemolytic toxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLC ELL-12","termGroup":"PT","termSource":"NCI"},{"termName":"1-0-Octadecyl-2-O-methyl-Sn-3-glycero-phosphocholine Liposome","termGroup":"SN","termSource":"NCI"},{"termName":"ELL-12","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TLC_ELL-12"},{"name":"Maps_To","value":"TLC ELL-12"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1313443"}]}}{"C156395":{"preferredName":"TLR Agonist BDB001","code":"C156395","definitions":[{"definition":"A toll-like receptor (TLR) agonist with potential immunostimulating and antineoplastic activities. Upon administration, TLR agonist BDB001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha (IFNa); production of proinflammatory cytokines; upregulation of co-stimulatory molecules; enhanced T- and B-cell stimulatory responses; T-cell proliferation; and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR Agonist BDB001","termGroup":"PT","termSource":"NCI"},{"termName":"BDB 001","termGroup":"CN","termSource":"NCI"},{"termName":"BDB-001","termGroup":"CN","termSource":"NCI"},{"termName":"BDB001","termGroup":"CN","termSource":"NCI"},{"termName":"Toll-like Receptor Agonist BDB001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR Agonist BDB001"},{"name":"NCI_Drug_Dictionary_ID","value":"795388"},{"name":"NCI_META_CUI","value":"CL563098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795388"},{"name":"PDQ_Open_Trial_Search_ID","value":"795388"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158747":{"preferredName":"TLR Agonist BSG-001","code":"C158747","definitions":[{"definition":"A toll-like receptor (TLR) agonist with potential immunomodulating and antineoplastic activities. Upon inhalation, TLR agonist BSG-001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation, secretion of interferon alpha (IFNa), production of proinflammatory cytokines, upregulation of co-stimulatory molecules, enhanced T- and B-cell stimulatory responses, T-cell proliferation and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others. Immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR Agonist BSG-001","termGroup":"PT","termSource":"NCI"},{"termName":"BSG 001","termGroup":"CN","termSource":"NCI"},{"termName":"BSG-001","termGroup":"CN","termSource":"NCI"},{"termName":"BSG001","termGroup":"CN","termSource":"NCI"},{"termName":"Syngenon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR Agonist BSG-001"},{"name":"NCI_Drug_Dictionary_ID","value":"797412"},{"name":"NCI_META_CUI","value":"CL950713"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797412"},{"name":"PDQ_Open_Trial_Search_ID","value":"797412"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77884":{"preferredName":"TLR Agonist CADI-05","code":"C77884","definitions":[{"definition":"A poly-Toll-like receptor (TLR) agonist polyantigenic vaccine containing heat killed Mycobacterium indicus pranii (Mycobacterium w or Mw) with potential immunostimulating and antineoplastic activities. Upon administration, poly-TLR agonist polyantigenic vaccine activates a number of TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha; production of pro-inflammatory cytokines; upregulation of co-stimulatory molecules, enhanced T and B-cell stimulatory responses; T cell proliferation, and a Th1 immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in antineoplastic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR Agonist CADI-05","termGroup":"PT","termSource":"NCI"},{"termName":"CADI-05","termGroup":"CN","termSource":"NCI"},{"termName":"Mycobacterium Indicus Pranii (Heat Killed)","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor Agonist CADI-05","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M4PN1DW08K"},{"name":"Legacy Concept Name","value":"TLR_Agonist_CADI-05"},{"name":"Maps_To","value":"TLR Agonist CADI-05"},{"name":"NCI_Drug_Dictionary_ID","value":"598873"},{"name":"NCI_META_CUI","value":"CL387125"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598873"},{"name":"PDQ_Open_Trial_Search_ID","value":"598873"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82353":{"preferredName":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100","code":"C82353","definitions":[{"definition":"A cationic lipid DNA complex (CLDC) consisting of DOTIM/cholesterol liposomes and plasmid DNA, containing immunostimulatory CpG and non-CpG motifs, with potential immunostimulating and antineoplastic activities. Upon systemic administration, TLR-directed cationic lipid-DNA complex JVRS-100 enters dendritic cells (DCs) and macrophages; immunostimulatory DNA binds to and activates Toll-like receptors (TLRs), which may result in the generation of anti-tumor natural killer (NK) cell and T-cell responses by the innate immune system. In addition, as a vaccine adjuvant, this agent may induce a strong cytotoxic T-lymphocyte (CTL) response to co-administered antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100","termGroup":"PT","termSource":"NCI"},{"termName":"JVRS-100","termGroup":"CN","termSource":"NCI"},{"termName":"Toll-Like Receptor-Directed Cationic Lipid-DNA Complex JVRS-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cationic_Lipid-DNA_Complex_JVRS-100"},{"name":"Maps_To","value":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100"},{"name":"NCI_Drug_Dictionary_ID","value":"639691"},{"name":"NCI_META_CUI","value":"CL408634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639691"},{"name":"PDQ_Open_Trial_Search_ID","value":"639691"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61104":{"preferredName":"TLR7 Agonist 852A","code":"C61104","definitions":[{"definition":"A substance being studied in the treatment of certain adult and childhood blood cancers and other types of cancer. 852A may help the patient's immune system block tumor growth. It is a type of immune system modulator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic imidazoquinoline Toll-like receptor 7 (TLR7) agonist with immunostimulating and potential antitumor activities. TLR7 agonist 852A binds to and activates TLR7, thereby stimulating plasmacytoid dendritic cells (pDC) through the TLR7-MyD88-dependent signaling pathway. Activation of pDC results in secretion of interferon alpha, the production of proimflammatory cytokines, the upregulation of co-stimulatory molecules, and enhanced T and B-cell stimulatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR7 Agonist 852A","termGroup":"PT","termSource":"NCI"},{"termName":"852A","termGroup":"CN","termSource":"NCI"},{"termName":"PF-4878691","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"532959-63-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6PJC3KPK6S"},{"name":"Legacy Concept Name","value":"_852A"},{"name":"Maps_To","value":"TLR7 Agonist 852A"},{"name":"NCI_Drug_Dictionary_ID","value":"396824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"396824"},{"name":"PDQ_Open_Trial_Search_ID","value":"396824"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541384"}]}}{"C114975":{"preferredName":"Bazlitoran","code":"C114975","definitions":[{"definition":"An oligonucleotide targeted to the mRNA of MYD88 L265P, a mutant form of the linker protein MYD88, with potential antitumor activity. Bazlitoran binds to and inhibits the translation of mutated MYD88 L265P mRNA. This prevents overactivation of signaling pathways mediated by toll-like receptors (TLRs) 7, 8, and 9, nuclear factor-kappa B (NF-kB) activity, Janus-associated kinases-signal transducer and activator of transcription (JAK-STAT) signaling and the production of various cytokines. Together, this leads to an induction of apoptosis and an inhibition of tumor cell proliferation in MYD88 L265P-expressing tumor cells. MYD88, a key adaptor protein in the TLR signaling pathway, is mutated in a variety of B-cell lymphomas, including Waldenstrom's macroglobulinemia (WM) and activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bazlitoran","termGroup":"PT","termSource":"NCI"},{"termName":"IMO-8400","termGroup":"CN","termSource":"NCI"},{"termName":"Oligonucleotide IMO-8400","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1378549-07-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2U46M95B5M"},{"name":"Maps_To","value":"Bazlitoran"},{"name":"Maps_To","value":"TLR7/8/9 Antagonist IMO-8400"},{"name":"NCI_Drug_Dictionary_ID","value":"759500"},{"name":"NCI_META_CUI","value":"CL472572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759500"},{"name":"PDQ_Open_Trial_Search_ID","value":"759500"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160500":{"preferredName":"TLR8 Agonist DN1508052","code":"C160500","definitions":[{"definition":"A small molecule Toll-like receptor 8 (TLR8; CD288) agonist with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, TLR8 agonist DN1508052 binds to TLR8, which is expressed in myeloid dendritic cells (mDCs), monocytes, and natural killer (NK) cells. This may lead to the activation of nuclear factor NF-kappa-B, the release of proinflammatory cytokines and a Th1-weighted anti-tumor immune response. Additionally, activation of TLR8 signaling in tumor cells may block the induction and reverse the suppression of senescent naive and tumor-specific T-cells, resulting in enhanced anti-tumor immunity. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR8 Agonist DN1508052","termGroup":"PT","termSource":"NCI"},{"termName":"DN A1","termGroup":"CN","termSource":"NCI"},{"termName":"DN-1508052","termGroup":"CN","termSource":"NCI"},{"termName":"DN-A1","termGroup":"CN","termSource":"NCI"},{"termName":"DN1508052","termGroup":"CN","termSource":"NCI"},{"termName":"DN1508052-01","termGroup":"CN","termSource":"NCI"},{"termName":"DNA1","termGroup":"CN","termSource":"NCI"},{"termName":"TLR8 Agonist DN-A1","termGroup":"SY","termSource":"NCI"},{"termName":"TLR8 Agonist DN1508052-01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR8 Agonist DN1508052"},{"name":"NCI_Drug_Dictionary_ID","value":"798329"},{"name":"NCI_META_CUI","value":"CL969563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798329"},{"name":"PDQ_Open_Trial_Search_ID","value":"798329"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157771":{"preferredName":"Cavrotolimod","code":"C157771","definitions":[{"definition":"A spherical nucleic acid (SN)-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, cavrotolimod targets and is able to enter various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and B cells, through endocytosis. Within the endosome, it binds to and activates TLR9. TLR9 activation induces immune signaling pathways and activates various immune cells, including B-cells, pDCs, NKs, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response as well as a cytotoxic T-lymphocyte (CTL)-based immune response against tumor cells. This results in an inhibition of tumor cell proliferation. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate and adaptive immune responses. The SNA is a dense, radial arrangement of nucleic acids (DNA) on the surface of liposomal nanoparticles, providing a 3D-construct, that has a high cellular uptake and an increased presentation of the DNA for TLR9 agonism. It also protects against breakdown by nucleases and increases the half-life of the construct compared to linear oligonucleotides that are not in SNA format.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cavrotolimod","termGroup":"PT","termSource":"NCI"},{"termName":"AST 008","termGroup":"CN","termSource":"NCI"},{"termName":"AST-008","termGroup":"CN","termSource":"NCI"},{"termName":"AST008","termGroup":"CN","termSource":"NCI"},{"termName":"SNA AST-008","termGroup":"SY","termSource":"NCI"},{"termName":"TLR9 Agonist AST-008","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor 9 Activator AST-008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2378664-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2Z5JOV1PPN"},{"name":"Maps_To","value":"TLR9 Agonist AST-008"},{"name":"NCI_Drug_Dictionary_ID","value":"797159"},{"name":"NCI_META_CUI","value":"CL937384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797159"},{"name":"PDQ_Open_Trial_Search_ID","value":"797159"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84217":{"preferredName":"Tocilizumab","code":"C84217","definitions":[{"definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tocilizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Actemra","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MRA","termGroup":"AB","termSource":"NCI"},{"termName":"R-1569","termGroup":"CN","termSource":"NCI"},{"termName":"RoActemra","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of COVID-19-emergency use authorization (EUA)."},{"name":"CAS_Registry","value":"375823-41-9"},{"name":"CHEBI_ID","value":"CHEBI:64360"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I031V2H011"},{"name":"Maps_To","value":"Tocilizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"713832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713832"},{"name":"PDQ_Open_Trial_Search_ID","value":"713832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1609165"}]}}{"C2571":{"preferredName":"Tocladesine","code":"C2571","definitions":[{"definition":"A substance that is being studied as an anticancer drug.  It is an analogue of a substance that occurs naturally in the body (cyclic adenosine monophosphate).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite and a chlorine derivative of the intracellular secondary messenger, cyclic adenosine 3,5-monophosphate (cAMP), with potential antineoplastic activity. Tocladesine appears to be converted to 8-chloro-adenosine by phosphodiesterases and subsequently phosphorylated to 8-chloro-ATP, which functions as a purine analogue and competes with ATP in transcription. In addition, generation of 8-chloro-ATP depletes endogenous ATP pool that is essential for many biological reactions in intracellular energy transfer. As a result, this agent causes RNA synthesis inhibition, blocks cellular proliferation, and induces apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tocladesine","termGroup":"PT","termSource":"NCI"},{"termName":"8-Chloro Cyclic AMP","termGroup":"SY","termSource":"NCI"},{"termName":"8-Chloroadenosine Cyclic 3':5'-Monophosphate","termGroup":"SN","termSource":"NCI"},{"termName":"8-Cl-cAMP","termGroup":"AB","termSource":"NCI"},{"termName":"Adenazole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41941-56-4"},{"name":"Chemical_Formula","value":"C10H11ClN5O6P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BQ94Z7E5OR"},{"name":"Legacy Concept Name","value":"Tocladesine"},{"name":"Maps_To","value":"Tocladesine"},{"name":"NCI_Drug_Dictionary_ID","value":"42670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42670"},{"name":"PDQ_Open_Trial_Search_ID","value":"42670"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050063"}]}}{"C68318":{"preferredName":"Tocotrienol","code":"C68318","definitions":[{"definition":"Any of the four forms, alpha, beta, gamma and delta, of a member of the vitamin E family, with potential hypocholesterolemic, antithrombotic, antioxidant, immunomodulating and antineoplastic activities. Tocotrienol inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thereby lowering cholesterol levels. In addition, tocotrienol acts through multiple signal transduction pathways to induce cell cycle arrest and caspase-mediated apoptosis, and to decrease tumor cell proliferation. In addition, this agent may inhibit angiogenesis through the blockage of vascular endothelial growth factor receptor (VEGFR) and the subsequent inhibition of tumor cell-induced vessel formation. Also, this agent prevents free radical formation and inhibits lipid peroxidation, thereby preventing DNA cell damage. Tocotrienol farnesyl isoprenoid side chains contain 3 double bonds, which are absent in tocopherols, likely contribute to its anti-cancer activities.","type":"DEFINITION","source":"NCI"},{"definition":"Class of compounds having one to three methyl groups on a chromanol ring with a long unsaturated 12-carbon side chain with three methyl groups along the chain and two methyl groups at the end; may contribute to vitamin E activity.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Tocotrienol","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-Tocotrienol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6829-55-6"},{"name":"CHEBI_ID","value":"CHEBI:33235"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0867I0N41V"},{"name":"Legacy Concept Name","value":"Tocotrienol"},{"name":"Maps_To","value":"Tocotrienol"},{"name":"NCI_Drug_Dictionary_ID","value":"779794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779794"},{"name":"PDQ_Open_Trial_Search_ID","value":"779794"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0949647"},{"name":"Unit","value":"mg"}]}}{"C101518":{"preferredName":"Tocotrienol-rich Fraction","code":"C101518","definitions":[{"definition":"An orally available nutritional supplement containing high amounts of the vitamin E family member tocotrienol with antioxidant, hypolipidemic and potential immunomodulating and antiproliferative activity. Upon oral administration, tocotrienol-rich fraction (TRF) accumulates in tumor cells and induces cell cycle arrest, programmed cell death, and inhibits tumor cell proliferation. In addition, this agent suppresses 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity and inhibits angiogenesis. Rice bran oil, palm oil and annatto seed oil are common sources of TRF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tocotrienol-rich Fraction","termGroup":"PT","termSource":"NCI"},{"termName":"TRF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tocotrienol-rich Fraction"},{"name":"NCI_Drug_Dictionary_ID","value":"730662"},{"name":"NCI_META_CUI","value":"CL435775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730662"},{"name":"PDQ_Open_Trial_Search_ID","value":"730662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153314":{"preferredName":"Guretolimod","code":"C153314","definitions":[{"definition":"A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of  cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guretolimod","termGroup":"PT","termSource":"NCI"},{"termName":"(((4-((2-Amino-4-(((3s)-1-hydroxyhexan-3-yl)amino)-6-methylpyrimidin-5-yl)methyl)-3- methoxyphenyl)methyl)(2,2,2-trifluoroethyl)amino)acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"DSP 0509","termGroup":"CN","termSource":"NCI"},{"termName":"DSP-0509","termGroup":"CN","termSource":"NCI"},{"termName":"DSP0509","termGroup":"CN","termSource":"NCI"},{"termName":"TLR7 Agonist DSP-0509","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor 7 Agonist DSP-0509","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1488364-57-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2UG29YVL56"},{"name":"Maps_To","value":"Toll-like Receptor 7 Agonist DSP-0509"},{"name":"NCI_Drug_Dictionary_ID","value":"794076"},{"name":"NCI_META_CUI","value":"CL554427"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794076"},{"name":"PDQ_Open_Trial_Search_ID","value":"794076"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75293":{"preferredName":"Tolnidamine","code":"C75293","definitions":[{"definition":"An indazole carboxylic acid derivative with antispermatogenic and potential antineoplastic activity. As a male contraceptive, tolnidamine may irreversibly inhibit sperm production. This agent is less nephrotoxic than ionidamide, but it is just as effective in antispermatogenic action to ionidamide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tolnidamine","termGroup":"PT","termSource":"NCI"},{"termName":"1b Indozadole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50454-68-7"},{"name":"Chemical_Formula","value":"C16H13ClN2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z5M7SC6D5P"},{"name":"Legacy Concept Name","value":"Tolnidamine"},{"name":"Maps_To","value":"Tolnidamine"},{"name":"NSC Number","value":"283448"},{"name":"PubMedID_Primary_Reference","value":"17040103"},{"name":"PubMedID_Primary_Reference","value":"8415857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076802"}]}}{"C120554":{"preferredName":"Tomaralimab","code":"C120554","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2), with potential anti-inflammatory and antineoplastic activities. Upon intravenous administration, tomaralimab binds to the ligand-binding site on the TLR2 receptor and blocks the activation of TLR2-mediated innate immunity signaling. This prevents the TLR2-mediated production of pro-inflammatory mediators and prevents inflammation. TLR2, a member of the TLR family primarily found on leukocytes, plays a key role in the activation of innate immunity; it is overexpressed in various inflammatory diseases and in certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tomaralimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TLR2 Monoclonal Antibody OPN-305","termGroup":"SY","termSource":"NCI"},{"termName":"OPN-305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1449294-76-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P45C2W27DU"},{"name":"Maps_To","value":"Tomaralimab"},{"name":"NCI_Drug_Dictionary_ID","value":"769468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769468"},{"name":"PDQ_Open_Trial_Search_ID","value":"769468"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3712029"}]}}{"C88300":{"preferredName":"Tomato-Soy Juice","code":"C88300","definitions":[{"definition":"A juice containing tomato extract and soy protein with potential chemopreventive and antiproliferative activities. Tomato-soy juice contains phytochemicals, including flavonoids, such as the soy isoflavone genistein, and carotenoids, including lycopene. These phytochemicals may exhibit antioxidative activity, antitumor activity by modulating certain tumor-associated signal transduction pathways, and apoptosis-inducing activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tomato-Soy Juice","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tomato-Soy Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"659065"},{"name":"NCI_META_CUI","value":"CL413551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659065"},{"name":"PDQ_Open_Trial_Search_ID","value":"659065"},{"name":"Semantic_Type","value":"Food"}]}}{"C125062":{"preferredName":"Tomivosertib","code":"C125062","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase (MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic activity. Upon oral administration, tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling. This inhibits tumor cell proliferation in MNK1/2-overexpressing tumor cells. MNK1/2 are overexpressed in a variety of tumor cell types and promote phosphorylation of eIF4E; eIF4E is overexpressed in many tumor cell types and contributes to tumor development, maintenance and resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tomivosertib","termGroup":"PT","termSource":"NCI"},{"termName":"EFT-508","termGroup":"CN","termSource":"NCI"},{"termName":"eFT508","termGroup":"CN","termSource":"NCI"},{"termName":"Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1849590-01-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U2H19X4WBV"},{"name":"Maps_To","value":"Tomivosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"777456"},{"name":"NCI_META_CUI","value":"CL503903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777456"},{"name":"PDQ_Open_Trial_Search_ID","value":"777456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78477":{"preferredName":"Topical Betulinic Acid","code":"C78477","definitions":[{"definition":"A topical formulation of a pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial factors involved in apoptosis, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Betulinic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Topical ALS-357","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Topical_Betulinic_Acid"},{"name":"Maps_To","value":"Topical Betulinic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"600544"},{"name":"NCI_META_CUI","value":"CL387585"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600544"},{"name":"PDQ_Open_Trial_Search_ID","value":"600544"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148519":{"preferredName":"Topical Celecoxib","code":"C148519","definitions":[{"definition":"A topical cream formulation containing celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), with anti-inflammatory and potential keratolytic, chemopreventive and antineoplastic activities. Upon topical application to the affected area, celecoxib selectively binds to and inhibits cyclooxygenase-2 activity (COX-2), which may result in localized keratinocyte apoptosis. The breakdown of keratinocytes prevents their proliferation locally and may reduce tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Celecoxib","termGroup":"PT","termSource":"NCI"},{"termName":"Celecoxib Cream","termGroup":"SY","termSource":"NCI"},{"termName":"Celecoxib Topical","termGroup":"SY","termSource":"NCI"},{"termName":"DFD-07","termGroup":"CN","termSource":"NCI"},{"termName":"DFD07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Celecoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"792678"},{"name":"NCI_META_CUI","value":"CL551149"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792678"},{"name":"PDQ_Open_Trial_Search_ID","value":"792678"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125194":{"preferredName":"Topical Fluorouracil","code":"C125194","definitions":[{"definition":"A topical formulation containing the antimetabolite 5-fluorouracil (5-FU), with antineoplastic activity. Upon topical administration, 5-FU is converted into the active metabolite 5-fluoroxyuridine monophosphate (F-UMP), which competes with uracil during RNA synthesis and inhibits RNA processing. Conversion of 5-FU into another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase; this results in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in DNA synthesis, and thus inhibits DNA synthesis. Altogether, this prevents the proliferation of tumor cells locally.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Fluorouracil","termGroup":"PT","termSource":"NCI"},{"termName":"Actino-Hermal","termGroup":"FB","termSource":"NCI"},{"termName":"Arumel","termGroup":"FB","termSource":"NCI"},{"termName":"Carac","termGroup":"BR","termSource":"NCI"},{"termName":"Cytosafe","termGroup":"FB","termSource":"NCI"},{"termName":"Efudex","termGroup":"BR","termSource":"NCI"},{"termName":"Efurix","termGroup":"FB","termSource":"NCI"},{"termName":"Fiverocil","termGroup":"FB","termSource":"NCI"},{"termName":"Fluoroplex","termGroup":"BR","termSource":"NCI"},{"termName":"Flurox","termGroup":"FB","termSource":"NCI"},{"termName":"Timazin","termGroup":"FB","termSource":"NCI"},{"termName":"Tolak","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Fluorouracil"},{"name":"NCI_Drug_Dictionary_ID","value":"777929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777929"},{"name":"PDQ_Open_Trial_Search_ID","value":"777929"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0720488"}]}}{"C74085":{"preferredName":"Topical Gemcitabine Hydrochloride","code":"C74085","definitions":[{"definition":"A topical preparation of gemcitabine hydrochloride with antineoplastic activity. Gemcitabine, an analogue of the antimetabolite nucleoside deoxycytidine, is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Gemcitabine Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Topical_Gemcitabine_Hydrochloride"},{"name":"Maps_To","value":"Topical Gemcitabine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"587041"},{"name":"NCI_META_CUI","value":"CL383495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587041"},{"name":"PDQ_Open_Trial_Search_ID","value":"587041"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151946":{"preferredName":"Topical Potassium Dobesilate","code":"C151946","definitions":[{"definition":"A topical formulation composed of an inhibitor of fibroblast growth factor (FGF), with potential antineoplastic activity. Upon topical administration potassium dobesilate selectively binds to and blocks the activity of FGF, interferes with the binding of FGF to FGFR and prevents FGFR-mediated signaling. This inhibits angiogenesis and tumor cell proliferation, and induces cell death in FGFR-overexpressing tumor cells. FGF plays a key role in angiogenesis, tumor cell proliferation, survival and invasiveness, and is upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Potassium Dobesilate","termGroup":"PT","termSource":"NCI"},{"termName":"AM-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Potassium Dobesilate"},{"name":"NCI_Drug_Dictionary_ID","value":"793156"},{"name":"NCI_META_CUI","value":"CL553174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793156"},{"name":"PDQ_Open_Trial_Search_ID","value":"793156"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125002":{"preferredName":"Topical Trichloroacetic Acid","code":"C125002","definitions":[{"definition":"A topical solution containing the caustic agent trichloroacetic acid (TCA), with potential keratolytic, anti-viral and antineoplastic activities. Upon topical application to the affected area, TCA causes tissue necrosis through coagulation of proteins, leads to the destruction of human papilloma virus (HPV)-associated warts and inhibits HPV-driven proliferation of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Trichloroacetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Topical TCA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Trichloroacetic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"777303"},{"name":"NCI_META_CUI","value":"CL503848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777303"},{"name":"PDQ_Open_Trial_Search_ID","value":"777303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75124":{"preferredName":"Topixantrone","code":"C75124","definitions":[{"definition":"A 9-aza-anthrapyrazole antineoplastic antibiotic. Topixantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Compared to other DNA intercalators, this agent shows minimal cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topixantrone","termGroup":"PT","termSource":"NCI"},{"termName":"BBR 3576","termGroup":"CN","termSource":"NCI"},{"termName":"Indazolo(4,3-gh)isoquinolin-6(2H)-one, 5-((2-(dimethylamino)ethyl)amino)-2-(2-((2-hydroxyethyl)amino)ethyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156090-18-5"},{"name":"Chemical_Formula","value":"C21H26N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R40RXC296C"},{"name":"Legacy Concept Name","value":"Topixantrone"},{"name":"Maps_To","value":"Topixantrone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1528075"}]}}{"C84851":{"preferredName":"Topoisomerase I Inhibitor Genz-644282","code":"C84851","definitions":[{"definition":"A non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I Inhibitor Genz-644282","termGroup":"PT","termSource":"NCI"},{"termName":"Genz-644282","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"529488-28-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"717I541I2R"},{"name":"Maps_To","value":"Topoisomerase I Inhibitor Genz-644282"},{"name":"NCI_Drug_Dictionary_ID","value":"651243"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651243"},{"name":"PDQ_Open_Trial_Search_ID","value":"651243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827528"}]}}{"C90594":{"preferredName":"Topoisomerase I Inhibitor LMP400","code":"C90594","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain enzymes that break and rejoin DNA strands. These enzymes are needed for cells to divide and grow. Blocking them may cause cancer cells to die. LMP400 also helps anticancer drugs kill cancers that are resistant to some other drugs. LMP400 is a type of indenoisoquinoline and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP400 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I Inhibitor LMP400","termGroup":"PT","termSource":"NCI"},{"termName":"LMP400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topoisomerase I Inhibitor LMP400"},{"name":"NCI_Drug_Dictionary_ID","value":"663024"},{"name":"NCI_META_CUI","value":"CL413610"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663024"},{"name":"PDQ_Open_Trial_Search_ID","value":"663024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90595":{"preferredName":"Topoisomerase I Inhibitor LMP776","code":"C90595","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain enzymes that break and rejoin DNA strands. These enzymes are needed for cells to divide and grow. Blocking them may cause cancer cells to die. LMP776 also helps anticancer drugs kill cancers that are resistant to some other drugs. LMP776 is a type of indenoisoquinoline and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP776 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I Inhibitor LMP776","termGroup":"PT","termSource":"NCI"},{"termName":"LMP776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topoisomerase I Inhibitor LMP776"},{"name":"NCI_Drug_Dictionary_ID","value":"663025"},{"name":"NCI_META_CUI","value":"CL413611"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663025"},{"name":"PDQ_Open_Trial_Search_ID","value":"663025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128557":{"preferredName":"Topoisomerase I/II Inhibitor NEV-801","code":"C128557","definitions":[{"definition":"A multi-targeted agent with potential antineoplastic activity. Upon administration, NEV-801 appears to selectively inhibit topoisomerase (Topo) I and II, and activates hypoxia-inducible factor 1 (HIF-1) transcription and the expression of vascular endothelial growth factor (VEGF) mRNA. NEV-801 is also able to overcome multidrug resistance (MDR) 1-mediated resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I/II Inhibitor NEV-801","termGroup":"PT","termSource":"NCI"},{"termName":"NEV-801","termGroup":"CN","termSource":"NCI"},{"termName":"NEV801","termGroup":"CN","termSource":"NCI"},{"termName":"TopI/II NEV-801","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topoisomerase I/II Inhibitor NEV-801"},{"name":"NCI_Drug_Dictionary_ID","value":"782337"},{"name":"NCI_META_CUI","value":"CL507943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782337"},{"name":"PDQ_Open_Trial_Search_ID","value":"782337"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127900":{"preferredName":"Topoisomerase-1 Inhibitor LMP744","code":"C127900","definitions":[{"definition":"An indenoisoquinoline derivative and topoisomerase 1 (Top1) inhibitor, with potential antineoplastic activity. Upon administration, LMP744 binds to and stabilizes cleaved DNA-Top1 complexes, which prevents DNA re-ligation, induces stable, irreversible DNA strand breaks, prevents DNA repair, and leads to cell cycle arrest and apoptosis. As tumor cells proliferate at a much higher rate than normal cells, LMP744 specifically targets cancer cells. Top1, a DNA modifying enzyme essential for transcription, replication, and repair of double-strand DNA breaks, is overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase-1 Inhibitor LMP744","termGroup":"PT","termSource":"NCI"},{"termName":"5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-Hydroxyethyl)amino)propyl)-2,3-dimethoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Indenoisoquinoline LMP744","termGroup":"SY","termSource":"NCI"},{"termName":"LMP-744","termGroup":"CN","termSource":"NCI"},{"termName":"LMP744","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"308246-52-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29BY7HQV0T"},{"name":"Maps_To","value":"Topoisomerase-1 Inhibitor LMP744"},{"name":"NCI_Drug_Dictionary_ID","value":"787756"},{"name":"NCI_META_CUI","value":"CL509262"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787756"},{"name":"PDQ_Open_Trial_Search_ID","value":"787756"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2825":{"preferredName":"Topoisomerase-II Inhibitor Racemic XK469","code":"C2825","definitions":[{"definition":"The racemic form of a synthetic quinoxaline phenoxypropionic acid derivative with antineoplastic properties. XK469R selectively inhibits topoisomerase II by stabilizing the enzyme-DNA intermediates in which topoisomerase subunits are covalently linked to DNA through 5-phosphotyrosyl linkages, thereby interfering with DNA repair and replication, RNA and protein synthesis. This agent possesses unusual solid tumor selectivity and activity against multidrug-resistant cancer cells. XK469R is more water soluble and active than the pure isomers, R(+)XK469 and S(-)XK469. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase-II Inhibitor Racemic XK469","termGroup":"PT","termSource":"NCI"},{"termName":"Propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]-phenoxy]-, (+ /-)-","termGroup":"SN","termSource":"NCI"},{"termName":"XK469 Racemic","termGroup":"SY","termSource":"NCI"},{"termName":"XK469R","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157542-91-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XK469R"},{"name":"Maps_To","value":"Topoisomerase-II Inhibitor Racemic XK469"},{"name":"NCI_Drug_Dictionary_ID","value":"440966"},{"name":"NSC Number","value":"698215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"440966"},{"name":"PDQ_Open_Trial_Search_ID","value":"440966"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1611867"}]}}{"C2662":{"preferredName":"Topoisomerase-II-beta Inhibitor Racemic XK469","code":"C2662","definitions":[{"definition":"A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The R-isomer of a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase-II-beta Inhibitor Racemic XK469","termGroup":"PT","termSource":"NCI"},{"termName":"2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy]-, (+ )-(R)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XK469"},{"name":"Maps_To","value":"Topoisomerase-II-beta Inhibitor Racemic XK469"},{"name":"NCI_Drug_Dictionary_ID","value":"38517"},{"name":"NSC Number","value":"698215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38517"},{"name":"PDQ_Open_Trial_Search_ID","value":"38517"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0765292"}]}}{"C1413":{"preferredName":"Topotecan","code":"C1413","definitions":[{"definition":"A drug used to treat certain types of ovarian cancer, lung cancer, and cervical cancer. Topotecan is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan","termGroup":"PT","termSource":"NCI"},{"termName":"(s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"Hycamptamine","termGroup":"SY","termSource":"NCI"},{"termName":"Topotecan Lactone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123948-87-8"},{"name":"CHEBI_ID","value":"CHEBI:63632"},{"name":"Chemical_Formula","value":"C23H23N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7M7YKX2N15"},{"name":"Legacy Concept Name","value":"Topotecan"},{"name":"Maps_To","value":"Topotecan"},{"name":"NSC Number","value":"641007"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0146224"}]}}{"C2828":{"preferredName":"Topotecan Hydrochloride","code":"C2828","definitions":[{"definition":"A drug used to treat certain types of ovarian cancer, lung cancer, and cervical cancer. Hycamtin is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Camptothecin is a cytotoxic quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino[1,2-b] quinoline-3,14-(4H,12H)-dione Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Evotopin","termGroup":"FB","termSource":"NCI"},{"termName":"Hycamptamine","termGroup":"SY","termSource":"NCI"},{"termName":"Hycamtin","termGroup":"BR","termSource":"NCI"},{"termName":"Potactasol","termGroup":"FB","termSource":"NCI"},{"termName":"SKF S-104864-A","termGroup":"CN","termSource":"NCI"},{"termName":"Topotec","termGroup":"FB","termSource":"NCI"},{"termName":"Topotecan HCl","termGroup":"SY","termSource":"NCI"},{"termName":"topotecan hydrochloride (oral)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Small Cell Lung Carcinoma; Cervical Cancer"},{"name":"CAS_Registry","value":"119413-54-6"},{"name":"Chemical_Formula","value":"C23H23N3O5.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"956S425ZCY"},{"name":"Legacy Concept Name","value":"Topotecan_Hydrochloride"},{"name":"Maps_To","value":"Topotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41185"},{"name":"NSC Number","value":"609699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41185"},{"name":"PDQ_Open_Trial_Search_ID","value":"41185"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0886549"}]}}{"C80065":{"preferredName":"Topotecan Hydrochloride Liposomes","code":"C80065","definitions":[{"definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin mixed with sphingomyelin/cholesterol and sonicated to form small unilamellar vesicles containing topotecan, with potential antineoplastic activity. Topotecan hydrochloride liposomes mediates efficient drug delivery of topotecan into the cytosol from the endosome compartment. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan Hydrochloride Liposomes","termGroup":"PT","termSource":"NCI"},{"termName":"Brakiva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Topotecan_Hydrochloride_Liposomes"},{"name":"Maps_To","value":"Topotecan Hydrochloride Liposomes"},{"name":"NCI_Drug_Dictionary_ID","value":"617377"},{"name":"NCI_META_CUI","value":"CL388400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617377"},{"name":"PDQ_Open_Trial_Search_ID","value":"617377"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64779":{"preferredName":"Topsalysin","code":"C64779","definitions":[{"definition":"A targeted prodrug consisting of a recombinant modified form of the Aeromonas protoxin, proaerolysin (PA), bearing a prostate-specific protease cleavage site, with potential antineoplastic activity. When injected directly into the prostate, topsalysin is hydrolyzed to the active toxin aerolysin by the serine protease prostate specific antigen (PSA), a protein overexpressed by prostate cancers and prostate cells in hyperplastic prostatic tissue. Aerolysin molecules then oligomerize to form ring-like heptamers that are incorporated into the lipid bilayers of cell membranes, forming large membrane channels and resulting in the leakage of cellular contents and lysis of PSA-expressing prostate cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topsalysin","termGroup":"PT","termSource":"NCI"},{"termName":"Pore-forming Protein (Synthetic Proaerolysin) Fusion Protein with Prostate-specific Antigen (Human)","termGroup":"SY","termSource":"NCI"},{"termName":"PORxin 302","termGroup":"SY","termSource":"NCI"},{"termName":"PRX 302","termGroup":"CN","termSource":"NCI"},{"termName":"PSA-PAH1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917121-25-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LSA9D0A43Q"},{"name":"Legacy Concept Name","value":"PRX302"},{"name":"Maps_To","value":"Topsalysin"},{"name":"NCI_Drug_Dictionary_ID","value":"517173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"517173"},{"name":"PDQ_Open_Trial_Search_ID","value":"517173"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831975"}]}}{"C101795":{"preferredName":"TORC1/2 Kinase Inhibitor DS-3078a","code":"C101795","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mTOR protein complex (TORC1) and rictor-mTOR protein complex (TORC2) with potential antineoplastic activity. TORC1/2 inhibitor DS-3078a binds to and inhibits both TORC1 and TORC2, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TORC1/2 Kinase Inhibitor DS-3078a","termGroup":"PT","termSource":"NCI"},{"termName":"DS-3078a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TORC1/2 Kinase Inhibitor DS-3078a"},{"name":"NCI_Drug_Dictionary_ID","value":"733685"},{"name":"NCI_META_CUI","value":"CL435913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733685"},{"name":"PDQ_Open_Trial_Search_ID","value":"733685"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1256":{"preferredName":"Toremifene","code":"C1256","definitions":[{"definition":"A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antiestrogens. Toremifene blocks the effect of the hormone estrogen in the body. It may help control some cancers from growing, and it may delay or reduce the risk of cancer recurrence.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Toremifene","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine","termGroup":"SN","termSource":"NCI"},{"termName":"(Z)-4-Chloro-1,2-diphenyl-1[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene","termGroup":"SN","termSource":"NCI"},{"termName":"Farestone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Desmoid tumors"},{"name":"CAS_Registry","value":"89778-26-7"},{"name":"CHEBI_ID","value":"CHEBI:9635"},{"name":"Chemical_Formula","value":"C26H28ClNO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7NFE54O27T"},{"name":"Legacy Concept Name","value":"Toremifene"},{"name":"Maps_To","value":"Toremifene"},{"name":"NCI_Drug_Dictionary_ID","value":"41103"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41103"},{"name":"PDQ_Open_Trial_Search_ID","value":"41103"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076836"}]}}{"C1756":{"preferredName":"Toremifene Citrate","code":"C1756","definitions":[{"definition":"The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toremifene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)- N,N-dimethylethylamine citrate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Acapodene","termGroup":"BR","termSource":"NCI"},{"termName":"Fareston","termGroup":"BR","termSource":"NCI"},{"termName":"FC-1157a","termGroup":"CN","termSource":"NCI"},{"termName":"GTx-006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89778-27-8"},{"name":"Chemical_Formula","value":"C26H28ClNO.C6H8O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2498Y783QT"},{"name":"Legacy Concept Name","value":"Toremifene_Citrate"},{"name":"Maps_To","value":"Toremifene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"41103"},{"name":"NSC Number","value":"613680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41103"},{"name":"PDQ_Open_Trial_Search_ID","value":"41103"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0117339"}]}}{"C131334":{"preferredName":"Toripalimab","code":"C131334","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toripalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody JS001","termGroup":"SY","termSource":"NCI"},{"termName":"JS001","termGroup":"CN","termSource":"NCI"},{"termName":"Loqtorzi","termGroup":"BR","termSource":"NCI"},{"termName":"TAB 001","termGroup":"CN","termSource":"NCI"},{"termName":"TAB-001","termGroup":"CN","termSource":"NCI"},{"termName":"Toripalimab-tpzi","termGroup":"SY","termSource":"NCI"},{"termName":"Tuoyi","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"recurrent unresectable or metastatic NPC"},{"name":"CAS_Registry","value":"1924598-82-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8JXN261VVA"},{"name":"Maps_To","value":"Toripalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"785704"},{"name":"NCI_META_CUI","value":"CL514245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785704"},{"name":"PDQ_Open_Trial_Search_ID","value":"785704"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70650":{"preferredName":"Tosedostat","code":"C70650","definitions":[{"definition":"A proprietary orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Aminopeptidase inhibitor CHR-2797 is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid deprivation, inhibition of protein synthesis due to a decrease in the intracellular free amino acid pool, an increase in the level of the proapoptotic protein Noxa, and cell death. Noxa is a member of the BH3 (Bcl-2 homology 3)-only subgroup of the proapoptotic Bcl-2 (B-cell CLL/lymphoma 2) protein family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tosedostat","termGroup":"PT","termSource":"NCI"},{"termName":"Aminopeptidase inhibitor CHR-2797","termGroup":"SY","termSource":"NCI"},{"termName":"CHR-2797","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclopentyl (2S)-2-{(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4- methylpentanamido}-2-phenylacetate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"238750-77-1"},{"name":"Chemical_Formula","value":"C21H30N2O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"KZK563J2UW"},{"name":"Legacy Concept Name","value":"Aminopeptidase_Inhibitor_CHR-2797"},{"name":"Maps_To","value":"Tosedostat"},{"name":"NCI_Drug_Dictionary_ID","value":"570670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570670"},{"name":"PDQ_Open_Trial_Search_ID","value":"570670"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2606804"}]}}{"C2543":{"preferredName":"Tositumomab","code":"C2543","definitions":[{"definition":"A monoclonal antibody that is used in the treatment of certain types of non-Hodgkin lymphoma. When tositumomab and iodine I 131 tositumomab (a form of tositumomab that has been chemically changed by adding radioactive iodine) are given together, the combination is called the Bexxar regimen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tositumomab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Anti-B1","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-B1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"CD20 Positive Follicular Non-Hodgkins Lymphoma Refractory to Rituximab"},{"name":"CAS_Registry","value":"192391-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0343IGH41U"},{"name":"Legacy Concept Name","value":"Tositumomab"},{"name":"Maps_To","value":"Tositumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"37818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37818"},{"name":"PDQ_Open_Trial_Search_ID","value":"37818"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879399"}]}}{"C94614":{"preferredName":"Total Androgen Blockade","code":"C94614","definitions":[{"definition":"Therapy used to eliminate male sex hormones (androgens) in the body. This may be done with surgery, hormonal therapy, or a combination.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Total Androgen Blockade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Total Androgen Blockade"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2986598"}]}}{"C82684":{"preferredName":"Tovetumab","code":"C82684","definitions":[{"definition":"A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Tovetumab inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tovetumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Platelet-Derived Growth Factor Receptor Alpha Monoclonal Antibody MEDI-575","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-575","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1243266-04-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2XY62K75UV"},{"name":"Legacy Concept Name","value":"Anti-PDGFR_Alpha_Monoclonal_Antibody_MEDI-575"},{"name":"Maps_To","value":"Tovetumab"},{"name":"NCI_Drug_Dictionary_ID","value":"633312"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633312"},{"name":"PDQ_Open_Trial_Search_ID","value":"633312"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830210"}]}}{"C61319":{"preferredName":"Tozasertib Lactate","code":"C61319","definitions":[{"definition":"The lactate salt of tozasertib, a synthetic, small-molecule Aurora kinase inhibitor with potential antitumor activity. Tozasertib binds to and inhibits Aurora kinases (AKs), thereby inducing apoptosis in tumor cells in which AKs are overexpressed. AKs, a family of serine-threonine kinases, are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tozasertib Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"Aurora Kinase Inhibitor MK-0457","termGroup":"SY","termSource":"NCI"},{"termName":"L-001281814","termGroup":"CN","termSource":"NCI"},{"termName":"MK-0457","termGroup":"CN","termSource":"NCI"},{"termName":"Propanoic acid, 2-hydroxy-, (2S)-, compd. with N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)cyclopropanecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"VX-680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"899827-04-4"},{"name":"Chemical_Formula","value":"C23H28N8OS.C3H6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CN8EF9N084"},{"name":"Legacy Concept Name","value":"MK-0457"},{"name":"Maps_To","value":"Tozasertib Lactate"},{"name":"NCI_Drug_Dictionary_ID","value":"485305"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485305"},{"name":"PDQ_Open_Trial_Search_ID","value":"485305"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451033"}]}}{"C2374":{"preferredName":"TP40 Immunotoxin","code":"C2374","definitions":[{"definition":"A chimeric fusion protein containing human transforming growth factor alpha (TGF-a) covalently linked to a truncated form of the bacterial toxin Pseudomonas exotoxin A, PE40, with potential antitumor activity. PE40 lacks the cell-binding domain, but retains domains II and III that are involved in membrane translocation and inhibition of protein synthesis in eukaryotic cells. TGF-a moiety of the TP40 immunotoxin binds to and activates epidermal growth factor receptor (EGFR), a tyrosine kinase receptor overexpressed on certain cancer cells. After internalization, the endotoxin moiety of the immunotoxin-receptor complex causes protein synthesis inhibition via modifying translation elongation factor 2 (EF-2), thereby impedes tumor cell growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TP40 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"TP40","termGroup":"SY","termSource":"NCI"},{"termName":"Transforming Growth Factor-Alpha-Pseudomonas Exotoxin-40","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TP40_Immunotoxin"},{"name":"Maps_To","value":"TP40 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"41531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41531"},{"name":"PDQ_Open_Trial_Search_ID","value":"41531"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0247342"}]}}{"C1691":{"preferredName":"Trabectedin","code":"C1691","definitions":[{"definition":"A substance that comes from a type of sea squirt and is being studied in the treatment of cancer. It binds to DNA and causes breaks in the DNA. It also blocks the ability of the cell to repair the DNA damage, and may cause cancer cells to die. Trabectedin is also made in the laboratory. It is a type of DNA excision repair inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabectedin","termGroup":"PT","termSource":"NCI"},{"termName":"Ecteinascidin","termGroup":"SY","termSource":"NCI"},{"termName":"Ecteinascidin 743","termGroup":"SY","termSource":"NCI"},{"termName":"ET-743","termGroup":"AB","termSource":"NCI"},{"termName":"Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-Octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-","termGroup":"SN","termSource":"NCI"},{"termName":"Yondelis","termGroup":"BR","termSource":"NCI"},{"termName":"Yondelis","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable or metastatic liposarcoma or leiomyosarcoma"},{"name":"CAS_Registry","value":"114899-77-3"},{"name":"Chemical_Formula","value":"C39H43N3O11S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ID0YZQ2TCP"},{"name":"Legacy Concept Name","value":"Ecteinascidin_743"},{"name":"Maps_To","value":"Trabectedin"},{"name":"NCI_Drug_Dictionary_ID","value":"42577"},{"name":"NSC Number","value":"648766"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42577"},{"name":"PDQ_Open_Trial_Search_ID","value":"42577"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311070"}]}}{"C80066":{"preferredName":"Trabedersen","code":"C80066","definitions":[{"definition":"A transforming growth factor (TGF)-beta2 specific phosphorothioate antisense oligodeoxynucleotide with the sequence 5'-CGGCATGTCTATTTTGTA-3', with potential antineoplastic activity. Trebedersen binds to TGF-beta2 mRNA causing inhibition of protein translation, thereby decreasing TGF-beta2 protein levels; decreasing intratumoral TGF-beta2 levels may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabedersen","termGroup":"PT","termSource":"NCI"},{"termName":"AP 12009","termGroup":"CN","termSource":"NCI"},{"termName":"OT 101","termGroup":"CN","termSource":"NCI"},{"termName":"OT-101","termGroup":"CN","termSource":"NCI"},{"termName":"OT101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"925681-61-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98OYR854NY"},{"name":"Legacy Concept Name","value":"Trabedersen"},{"name":"Maps_To","value":"Trabedersen"},{"name":"NCI_Drug_Dictionary_ID","value":"617455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617455"},{"name":"PDQ_Open_Trial_Search_ID","value":"617455"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699985"}]}}{"C146854":{"preferredName":"Eftozanermin Alfa","code":"C146854","definitions":[{"definition":"A fusion protein composed of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist consisting of six receptor binding domains (RBDs) of TRAIL fused to the Fc-domain of a human immunoglobulin G1 (IgG1) antibody, with potential pro-apoptotic and antineoplastic activities. Upon administration of eftozanermin alfa, this fusion protein binds to TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby inducing tumor cell apoptosis.  ABBV-621 is designed to maximize receptor clustering for optimal efficacy. TRAIL, a member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eftozanermin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 621","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-621","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV621","termGroup":"CN","termSource":"NCI"},{"termName":"APG880","termGroup":"CN","termSource":"NCI"},{"termName":"HERA Ligand ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"Hexavalent TRAIL Receptor Agonist ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL Receptor Agonist ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL-Fc Protein ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL-receptor Agonist Fusion Protein ABBV-621","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1820660-69-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1K9TTP1WS"},{"name":"Maps_To","value":"Eftozanermin Alfa"},{"name":"Maps_To","value":"TRAIL Receptor Agonist ABBV-621"},{"name":"NCI_Drug_Dictionary_ID","value":"792269"},{"name":"NCI_META_CUI","value":"CL544836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792269"},{"name":"PDQ_Open_Trial_Search_ID","value":"792269"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77908":{"preferredName":"Trametinib","code":"C77908","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trametinib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 1120212","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-1120212","termGroup":"CN","termSource":"NCI"},{"termName":"GSK1120212","termGroup":"CN","termSource":"NCI"},{"termName":"JTP-74057","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor GSK1120212","termGroup":"SY","termSource":"NCI"},{"termName":"N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation; unresectable or metastatic melanoma with BRAF V600E or V600K mutations"},{"name":"CAS_Registry","value":"871700-17-3"},{"name":"Chemical_Formula","value":"C26H23FIN5O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"33E86K87QN"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_GSK1120212"},{"name":"Maps_To","value":"Trametinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697961"}]}}{"C152711":{"preferredName":"Trametinib Dimethyl Sulfoxide","code":"C152711","definitions":[{"definition":"A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trametinib Dimethyl Sulfoxide","termGroup":"PT","termSource":"NCI"},{"termName":"Mekinist","termGroup":"BR","termSource":"NCI"},{"termName":"Meqsel","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1187431-43-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BSB9VJ5TUT"},{"name":"Maps_To","value":"Trametinib Dimethyl Sulfoxide"},{"name":"NCI_Drug_Dictionary_ID","value":"599034"},{"name":"NCI_META_CUI","value":"CL553915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599034"},{"name":"PDQ_Open_Trial_Search_ID","value":"599034"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82695":{"preferredName":"Trans Sodium Crocetinate","code":"C82695","definitions":[{"definition":"The sodium salt of the trans-isomer of the carotenoid crocetin with potential antihypoxic and radiosensitizing activities. Trans sodium crocetinate (TSC) increases the diffusion rate of oxygen in aqueous solutions such as from plasma to body tissue. The agent has been shown to increase available oxygen during hypoxic and ischemic conditions that may occur in hemorrhage, vascular and neurological disorders, and in the tumor microenvionment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trans Sodium Crocetinate","termGroup":"PT","termSource":"NCI"},{"termName":"2,4,6,8,10,12,14-Hexadecaheptaenedioic Acid, 2,6,11,15-Tetramethyl-, Sodium Salt (1:2), (2E,4E,6E,8E,10E,12E,14E)-","termGroup":"SN","termSource":"NCI"},{"termName":"TSC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"591230-99-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YP57637WMX"},{"name":"Legacy Concept Name","value":"Trans_Sodium_Crocetinate"},{"name":"Maps_To","value":"Trans Sodium Crocetinate"},{"name":"NCI_Drug_Dictionary_ID","value":"634790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"634790"},{"name":"PDQ_Open_Trial_Search_ID","value":"634790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1453926"}]}}{"C120308":{"preferredName":"Transdermal 17beta-Estradiol Gel BHR-200","code":"C120308","definitions":[{"definition":"A proprietary, transdermal, hydroalcoholic gel formulation containing 17beta-estradiol, with potential antineoplastic activity. Upon topical administration, 17beta-estradiol exerts its antineoplastic effect(s) through as of yet not fully elucidated mechanism(s) of action(s). This formulation may induce feedback inhibition via the hypothalamic-pituitary-gonadal axis feedback loop, block the secretion of luteinizing hormone (LH) and prevent the release of testosterone from Leydig cells in the testes, thus suppressing testosterone secretion. In addition, 17beta-estradiol inhibits enzymes involved in steroidogenesis, thereby further inhibiting androgen production. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In addition, 17beta-estradiol prevents bone loss, and suppresses andropause symptoms, such as hot flashes, which appear during androgen-deprivation therapy (ADT) where the standard of care is the use of gonadotrophin releasing hormone (GnRH) analogs. Compared to oral estrogens, the topical gel formulation lowers the risk of cardiovascular side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transdermal 17beta-Estradiol Gel BHR-200","termGroup":"PT","termSource":"NCI"},{"termName":"BHR-200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transdermal 17beta-Estradiol Gel BHR-200"},{"name":"NCI_Drug_Dictionary_ID","value":"768720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768720"},{"name":"PDQ_Open_Trial_Search_ID","value":"768720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896903"}]}}{"C114103":{"preferredName":"Transdermal 4-Hydroxytestosterone","code":"C114103","definitions":[{"definition":"A transdermal formulation containing 4-hydroxytestosterone (4-OHT), a steroidal aromatase inhibitor (AI) and androgen receptor (AR) antagonist, with potential antineoplastic activity. 4-OHT is largely converted into 4-hydroxyandrostenedione (4-OHA) and irreversibly binds to and inhibits aromatase, thereby blocking the conversion of androstenedione to estrone, and testosterone to estradiol. This may inhibit tumor cell proliferation in estrogen-dependent tumor cells. In addition, 4-OHT binds to the AR and may inhibit AR-mediated tumor cell growth. Aromatase, a cytochrome P-450 enzyme, is overexpressed in a variety of cancer cells; it plays a key role in estrogen biosynthesis. Compared to oral 4-OHT, the transdermal formulation allows for continuous release of 4-OHT into the bloodstream and prevents first pass metabolism by the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transdermal 4-Hydroxytestosterone","termGroup":"PT","termSource":"NCI"},{"termName":"Transdermal 4-OHT","termGroup":"SY","termSource":"NCI"},{"termName":"Transdermal CR1447","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transdermal 4-Hydroxytestosterone"},{"name":"NCI_Drug_Dictionary_ID","value":"758421"},{"name":"NCI_META_CUI","value":"CL471813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758421"},{"name":"PDQ_Open_Trial_Search_ID","value":"758421"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78450":{"preferredName":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01","code":"C78450","definitions":[{"definition":"A proprietary transferrin receptor-targeted nanoparticle preparation of a non-chemically modified small-interfering RNA (siRNA) directed against the M2 subunit of ribonucleotide reductase (RRM2) with potential antineoplastic activity. Upon administration, transferrin receptor-targeted anti-RRM2 siRNA CALAA-01 binds to transferrin receptors (TfRs), releasing anti-RRM2 siRNA after endocytosis; anti-RRM2 siRNA silences the expression of RRM2 via the RNAi pathway, impeding the assembly of the holoenzyme ribonucleotide reductase (RR) which catalyzes the production of deoxyribonucleotides. As a result, inhibition of cellular proliferation may occur in cells expressing TfR, a cell surface protein overexpressed on various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01","termGroup":"PT","termSource":"NCI"},{"termName":"CALAA-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transferrin_Receptor-Targeted_Nanocomplexed_Anti-R2_siRNA_CALAA-01"},{"name":"Maps_To","value":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01"},{"name":"NCI_Drug_Dictionary_ID","value":"599463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599463"},{"name":"PDQ_Open_Trial_Search_ID","value":"599463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703116"}]}}{"C29474":{"preferredName":"Transferrin Receptor-Targeted Liposomal p53 cDNA","code":"C29474","definitions":[{"definition":"A cationic liposomal, tumor-targeting p53 (TP53) gene delivery system with potential anti-tumor activity. Transferrin receptor-targeted liposomal p53 cDNA contains plasmid DNA encoding the tumor suppressor protein p53 packaged in membrane-like liposome capsules that are complexed with anti-transferrin receptor single-chain antibody (TfRscFv). Upon systemic administration, the anti-TfRscFv selectively binds to tumor cells expressing transferrin receptors. The p53 plasmid is delivered into the nucleus and as a result, p53 protein is produced in tumor cells that have altered p53 function. This results in the restoration of normal cell growth control mechanisms as well as normal response mechanisms to DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transferrin Receptor-Targeted Liposomal p53 cDNA","termGroup":"PT","termSource":"NCI"},{"termName":"SGT-53","termGroup":"AB","termSource":"NCI"},{"termName":"Synerlip p53","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synerlip_p53"},{"name":"Maps_To","value":"Transferrin Receptor-Targeted Liposomal p53 cDNA"},{"name":"NCI_Drug_Dictionary_ID","value":"551892"},{"name":"NCI_META_CUI","value":"CL319865"},{"name":"NSC Number","value":"709399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551892"},{"name":"PDQ_Open_Trial_Search_ID","value":"551892"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26676":{"preferredName":"Transferrin-CRM107","code":"C26676","definitions":[{"definition":"A substance being studied in the treatment of brain tumors. Transferrin-CRM107 is made by linking a diphtheria toxin to transferrin, a protein that binds to fast growing cells, such as tumor cells. The diphtheria toxin then kills the tumor cells. Transferrin-CRM107 is a type of immunotoxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic targeted protein toxin which consists of human transferrin (Tf) conjugated to a diphtheria toxin that contains a point mutation (CRM107). After binding to the transferrin receptor expressed on the tumor cell surface, transferrin-CRM107 is internalized, where the diphtheria toxin moiety exerts its cytotoxic effect intracellularly by inhibiting protein synthesis through ADP-ribosylation of elongation factor. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transferrin-CRM107","termGroup":"PT","termSource":"NCI"},{"termName":"HN-66000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transferrin-CRM107"},{"name":"Maps_To","value":"Transferrin-CRM107"},{"name":"NCI_Drug_Dictionary_ID","value":"269064"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269064"},{"name":"PDQ_Open_Trial_Search_ID","value":"269064"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0912205"}]}}{"C61980":{"preferredName":"Tranylcypromine Sulfate","code":"C61980","definitions":[{"definition":"The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tranylcypromine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-Trans-2-Phenylcyclopropylamine Sulfate (2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"1-Amino-2-phenylcyclopropane Sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"Parnate","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13492-01-8"},{"name":"CHEBI_ID","value":"CHEBI:9653"},{"name":"Chemical_Formula","value":"2C9H11N.H2SO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7ZAT6ES870"},{"name":"Legacy Concept Name","value":"Tranylcypromine_Sulfate"},{"name":"Maps_To","value":"Tranylcypromine Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"765903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765903"},{"name":"PDQ_Open_Trial_Search_ID","value":"765903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0304369"}]}}{"C1665":{"preferredName":"Trapoxin","code":"C1665","definitions":[{"definition":"An epoxide-containing cyclotetrapeptide with antitumor activity.  It is an irreversible inhibitor of histone deacetylase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trapoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclo((S)-gamma-oxo-L-alpha-aminooxiraneoctanoyl-L-phenylalanyl-L-phenylalanyl-D-2-piperidinecarbonyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclo((S)-phenylalanyl-(S)-phenylalanyl-(R)-pipecolinyl-(2S,9S)-2-amino-8-oxo-9,10-epoxydecanoyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclo(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8-oxo -9,10-epoxy - decanoyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Trapoxin A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"133155-89-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GSS8DX555X"},{"name":"Legacy Concept Name","value":"Trapoxin"},{"name":"Maps_To","value":"Trapoxin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084839"}]}}{"C148165":{"preferredName":"Trastuzumab Conjugate BI-CON-02","code":"C148165","definitions":[{"definition":"A conjugated form of trastuzumab, a humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ERBB2), with potential immunomodulating and antineoplastic activities. Upon administration, the trastuzumab conjugate BI-CON-02 targets and binds to HER2 on the tumor cell surface, thereby inducing both cytotoxic T-lymphocyte (CTL) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Conjugate BI-CON-02","termGroup":"PT","termSource":"NCI"},{"termName":"BI-CON-02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trastuzumab Conjugate BI-CON-02"},{"name":"NCI_Drug_Dictionary_ID","value":"792543"},{"name":"NCI_META_CUI","value":"CL550783"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792543"},{"name":"PDQ_Open_Trial_Search_ID","value":"792543"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118674":{"preferredName":"Trastuzumab Duocarmazine","code":"C118674","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA), with potential antineoplastic activity. Upon administration of trastuzumab duocarmazine, the trastuzumab moiety binds to HER2 on the tumor cell surface, which triggers the endocytosis of this agent. The linker is then cleaved inside the tumor cell by proteases at the dipeptide valine-citrulline (vc), and releases the active moiety, duocarmycin. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. In addition, trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed by many carcinomas and is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Duocarmazine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SYD985","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate SYD985","termGroup":"SY","termSource":"NCI"},{"termName":"SYD985","termGroup":"CN","termSource":"NCI"},{"termName":"Trastuzumab VC-seco-DUBA","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-drug Conjugate SYD985","termGroup":"SY","termSource":"NCI"},{"termName":"vic-Trastuzumab Duocarmazine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1642152-40-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XCR2BZ80N7"},{"name":"Maps_To","value":"Trastuzumab Duocarmazine"},{"name":"NCI_Drug_Dictionary_ID","value":"766012"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766012"},{"name":"PDQ_Open_Trial_Search_ID","value":"766012"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896762"}]}}{"C82492":{"preferredName":"Trastuzumab Emtansine","code":"C82492","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Emtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Ado Trastuzumab Emtansine","termGroup":"SY","termSource":"NCI"},{"termName":"ADO-Trastuzumab Emtansine","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine","termGroup":"SN","termSource":"NCI"},{"termName":"Kadcyla","termGroup":"BR","termSource":"NCI"},{"termName":"PRO132365","termGroup":"CN","termSource":"NCI"},{"termName":"RO5304020","termGroup":"CN","termSource":"NCI"},{"termName":"T-DM1","termGroup":"AB","termSource":"NCI"},{"termName":"TDM1","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-MCC-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-MCC-DM1 Antibody-Drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-MCC-DM1 Immunoconjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2-positive, metastatic breast cancer"},{"name":"CAS_Registry","value":"1018448-65-1"},{"name":"Chemical_Formula","value":"C47H63ClN5O13S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"SE2KH7T06F"},{"name":"Legacy Concept Name","value":"Trastuzumab-MCC-DM1_Conjugate"},{"name":"Maps_To","value":"Trastuzumab Emtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"564399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564399"},{"name":"PDQ_Open_Trial_Search_ID","value":"564399"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2935436"}]}}{"C158060":{"preferredName":"Trastuzumab/Hyaluronidase-oysk","code":"C158060","definitions":[{"definition":"A ready-to-use combination of trastuzumab, a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 (rHuPH20), that may be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-oysk temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of trastuzumab into the bloodstream. Trastuzumab binds to the extracellular ligand-binding domain of HER2 and mediates the activation of an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab/Hyaluronidase-oysk","termGroup":"PT","termSource":"NCI"},{"termName":"Herceptin Hylecta","termGroup":"BR","termSource":"NCI"},{"termName":"Trastuzumab and Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab and Hyaluronidase-oysk","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab and Recombinant Human Hyaluronidase PH20","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab and rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-Hyaluronidase-oysk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2 overexpressing breast cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Trastuzumab/Hyaluronidase-oysk"},{"name":"NCI_Drug_Dictionary_ID","value":"797111"},{"name":"NCI_META_CUI","value":"CL937577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797111"},{"name":"PDQ_Open_Trial_Search_ID","value":"797111"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139800":{"preferredName":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502","code":"C139800","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an engineered version of the humanized monoclonal anti-human epidermal growth factor receptor 2 (HER2) immunoglobulin G1 (IgG1) trastuzumab that is site-specifically conjugated, via a cleavable linker, to the cytotoxic, DNA cross-linking pyrrolobenzodiazepine (PBD) dimer-based drug tesirine, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the trastuzumab moiety of trastuzumab/tesirine ADC ADCT-502 targets the cell surface antigen HER2, which is expressed on various cancer cells. Upon antibody/antigen binding, internalization of the ADC and cleavage of the linker, the cytotoxic PBD moiety is released. The imine groups of tesirine bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death and inhibits the proliferation of HER2-overexpressing tumor cells. The tumor-associated antigen (TAA) HER2 is expressed by various solid tumors and is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-502","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT 502","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT-502","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT502","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-HER2/PBD ADC ADCT 502","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502"},{"name":"NCI_Drug_Dictionary_ID","value":"791110"},{"name":"NCI_META_CUI","value":"CL537974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791110"},{"name":"PDQ_Open_Trial_Search_ID","value":"791110"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91711":{"preferredName":"Trebananib","code":"C91711","definitions":[{"definition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trebananib","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 386","termGroup":"CN","termSource":"NCI"},{"termName":"AMG386","termGroup":"CN","termSource":"NCI"},{"termName":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"894356-79-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"X8Y5U6NC7E"},{"name":"Maps_To","value":"Trebananib"},{"name":"NCI_Drug_Dictionary_ID","value":"423474"},{"name":"PDQ_Closed_Trial_Search_ID","value":"423474"},{"name":"PDQ_Open_Trial_Search_ID","value":"423474"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541521"}]}}{"C49085":{"preferredName":"Tremelimumab","code":"C49085","definitions":[{"definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of melanoma and some other types of cancer. Ticilimumab is made in the laboratory and binds to a protein called CTLA-4 on T cells (a type of white blood cell). CTLA-4 is involved in preventing the activation of T-cells. Ticilimumab may block CTLA-4 and help the immune system kill cancer cells. It is a type of immunomodulatory agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tremelimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA4 Human Monoclonal Antibody CP-675,206","termGroup":"SY","termSource":"NCI"},{"termName":"CP-675","termGroup":"CN","termSource":"NCI"},{"termName":"CP-675,206","termGroup":"CN","termSource":"NCI"},{"termName":"CP-675206","termGroup":"CN","termSource":"NCI"},{"termName":"Imjudo","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Ticilimumab","termGroup":"SY","termSource":"NCI"},{"termName":"Tremelimumab-actl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab."},{"name":"CAS_Registry","value":"745013-59-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"QEN1X95CIX"},{"name":"Legacy Concept Name","value":"Anti-CTLA4_Human_Monoclonal_Antibody_CP-675_206"},{"name":"Maps_To","value":"Tremelimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"448620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"448620"},{"name":"PDQ_Open_Trial_Search_ID","value":"448620"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351038"}]}}{"C1257":{"preferredName":"Treosulfan","code":"C1257","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treosulfan","termGroup":"PT","termSource":"NCI"},{"termName":"(S-(R*,R*))-1,2,3,4-butanetetrol,1,4-dimethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydroxybusulfan","termGroup":"SY","termSource":"NCI"},{"termName":"L-Threitol 1,4-dimethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Ovastat","termGroup":"FB","termSource":"NCI"},{"termName":"Trecondi","termGroup":"FB","termSource":"NCI"},{"termName":"Treosulphan","termGroup":"SY","termSource":"NCI"},{"termName":"Tresulfon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"299-75-2"},{"name":"Chemical_Formula","value":"C6H14O8S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CO61ER3EPI"},{"name":"Legacy Concept Name","value":"Treosulfan"},{"name":"Maps_To","value":"Treosulfan"},{"name":"NCI_Drug_Dictionary_ID","value":"39720"},{"name":"NSC Number","value":"39069"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39720"},{"name":"PDQ_Open_Trial_Search_ID","value":"39720"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076959"}]}}{"C81554":{"preferredName":"Tretazicar","code":"C81554","definitions":[{"definition":"A prodrug of a bifunctional alkylating, dinitrobenzamide derivative with antineoplastic activity. Tretazicar can be activated by the human enzyme quinone oxidoreductase 2 (NQO2) in the presence of the cosubstrate caricotamide, an analogue of the natural cosubstrate dihydronicotinamide riboside (NRH), which acts as an electron donor. The resulting active, but short-lived metabolite, dinitrobenzamide, leads to DNA replication inhibition and the induction of apoptosis in NQO2 expressing cancer cells. Due to the lack of the natural cosubstrate NRH, NQO2 expression is normally latent but is upregulated in certain types of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tretazicar","termGroup":"PT","termSource":"NCI"},{"termName":"CB1954","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"21919-05-1"},{"name":"Chemical_Formula","value":"C9H8N4O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7865D5D01M"},{"name":"Legacy Concept Name","value":"Tretazicar"},{"name":"Maps_To","value":"Tretazicar"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0097964"}]}}{"C900":{"preferredName":"Tretinoin","code":"C900","definitions":[{"definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient that that body needs in small amounts to function and stay healthy. All-trans retinoic acid is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. A form of all-trans retinoic acid made in the laboratory is put on the skin to treat conditions such as acne and is taken by mouth to treat acute promyelocytic leukemia (a fast-growing cancer in which there are too many immature blood-forming cells in the blood and bone marrow). All-trans retinoic acid is being studied in the prevention and treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Aberel","termGroup":"BR","termSource":"NCI"},{"termName":"Airol","termGroup":"FB","termSource":"NCI"},{"termName":"Aknoten","termGroup":"BR","termSource":"NCI"},{"termName":"All-trans Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"All-trans Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"ATRA","termGroup":"AB","termSource":"NCI"},{"termName":"Avita","termGroup":"BR","termSource":"NCI"},{"termName":"beta-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Cordes Vas","termGroup":"FB","termSource":"NCI"},{"termName":"Dermairol","termGroup":"FB","termSource":"NCI"},{"termName":"Epi-Aberel","termGroup":"FB","termSource":"NCI"},{"termName":"Eudyna","termGroup":"FB","termSource":"NCI"},{"termName":"Renova","termGroup":"BR","termSource":"NCI"},{"termName":"Retin-A","termGroup":"BR","termSource":"NCI"},{"termName":"Retin-A MICRO","termGroup":"BR","termSource":"NCI"},{"termName":"Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Retisol-A","termGroup":"FB","termSource":"NCI"},{"termName":"Ro 5488","termGroup":"CN","termSource":"NCI"},{"termName":"Stieva-A","termGroup":"FB","termSource":"NCI"},{"termName":"Stieva-A Forte","termGroup":"FB","termSource":"NCI"},{"termName":"Trans Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Trans Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"trans-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Tretinoinum","termGroup":"SY","termSource":"NCI"},{"termName":"Vesanoid","termGroup":"BR","termSource":"NCI"},{"termName":"Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Vitinoin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"(Oral) Acute promyelocytic leukemia (APL), characterized by the t(15;17) translocation or the PML/RARa gene refractory to or have relapsed from anthracycline chemotherapy, or for where anthracycline-based chemotherapy is contraindicated"},{"name":"Accepted_Therapeutic_Use_For","value":"(Topical) acne vulgaris; other dermatologic conditions; some skin cancers"},{"name":"CAS_Registry","value":"302-79-4"},{"name":"CHEBI_ID","value":"CHEBI:15367"},{"name":"Chemical_Formula","value":"C20H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"5688UTC01R"},{"name":"Legacy Concept Name","value":"Vitamin_A_Acid"},{"name":"Maps_To","value":"Tretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"41258"},{"name":"NSC Number","value":"122758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41258"},{"name":"PDQ_Open_Trial_Search_ID","value":"41258"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040845"}]}}{"C2398":{"preferredName":"Tretinoin Liposome","code":"C2398","definitions":[{"definition":"An intravenous formulation of tretinoin (vitamin A acid or all-trans retinoic acid) encased in liposomes. Tretinoin is a naturally occurring retinoic acid agent that binds to and activates retinoic acid receptors (RAR), effecting changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of carcinogenesis.  This agent also inhibits telomerase, leading to telomere shortening and eventual apoptosis of certain tumor cell types. Liposome encapsulation extends the half-life of intravenously administered tretinoin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tretinoin Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"All-trans-retinoic acid liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"AR-623","termGroup":"CN","termSource":"NCI"},{"termName":"Atragen","termGroup":"BR","termSource":"NCI"},{"termName":"Liposomal all-trans-retinoic acid","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal tretinoin","termGroup":"SY","termSource":"NCI"},{"termName":"Tretinoin Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"TretinoinLF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tretinoin_Liposome"},{"name":"Maps_To","value":"Tretinoin Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"42285"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42285"},{"name":"PDQ_Open_Trial_Search_ID","value":"42285"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338222"}]}}{"C48027":{"preferredName":"Triamcinolone Acetonide","code":"C48027","definitions":[{"definition":"The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triamcinolone Acetonide","termGroup":"PT","termSource":"NCI"},{"termName":"9-alpha-Fluoro-11-beta,21-dihydroxy-16-alpha-isopropylidenedioxy-1,4-pregnadiene,3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"AllerNaze","termGroup":"BR","termSource":"NCI"},{"termName":"Aristocort A","termGroup":"BR","termSource":"NCI"},{"termName":"Kenalog","termGroup":"BR","termSource":"NCI"},{"termName":"Nasacort","termGroup":"BR","termSource":"NCI"},{"termName":"ReadySharp Triamcinolone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Allergic Rhinitis"},{"name":"CAS_Registry","value":"76-25-5"},{"name":"Chemical_Formula","value":"C24H31FO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F446C597KA"},{"name":"Legacy Concept Name","value":"Triamcinolone_Acetonide"},{"name":"Maps_To","value":"Triamcinolone Acetonide"},{"name":"NCI_Drug_Dictionary_ID","value":"649799"},{"name":"NSC Number","value":"21916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649799"},{"name":"PDQ_Open_Trial_Search_ID","value":"649799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040866"}]}}{"C48026":{"preferredName":"Triamcinolone Hexacetonide","code":"C48026","definitions":[{"definition":"The hexacetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone hexacetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triamcinolone Hexacetonide","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta,16alpha)-21-(3,3-Dimethyl-1-oxobutoxy)-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))pregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Aristospan","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5611-51-8"},{"name":"Chemical_Formula","value":"C30H41FO7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I7GT1U99Y9"},{"name":"Legacy Concept Name","value":"Triamcinolone_Hexacetonide"},{"name":"Maps_To","value":"Triamcinolone Hexacetonide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077004"}]}}{"C2242":{"preferredName":"Triapine","code":"C2242","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. This agent has been shown to inhibit tumor growth in vitro. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triapine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone","termGroup":"SN","termSource":"NCI"},{"termName":"3-AP","termGroup":"AB","termSource":"NCI"},{"termName":"3-Apct","termGroup":"AB","termSource":"NCI"},{"termName":"OCX-191","termGroup":"CN","termSource":"NCI"},{"termName":"OCX191","termGroup":"CN","termSource":"NCI"},{"termName":"PAN-811","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"236392-56-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U4XIL4091C"},{"name":"Legacy Concept Name","value":"Triapine"},{"name":"Maps_To","value":"Triapine"},{"name":"NCI_Drug_Dictionary_ID","value":"37830"},{"name":"NSC Number","value":"663249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37830"},{"name":"PDQ_Open_Trial_Search_ID","value":"37830"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0210403"}]}}{"C2367":{"preferredName":"Triazene Derivative CB10-277","code":"C2367","definitions":[{"definition":"A synthetic derivative of dimethylphenyl-triazene related to dacarbazine, with antineoplastic properties.  Related to the agent dacarbazine, CB10-277 is converted in vivo to a monomethyl triazene form that alkylates DNA, resulting in inhibition of DNA replication and repair; in addition, this agent may act as a purine analogue, resulting in inhibition of DNA synthesis, and may interact with protein sulfhydryl groups. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triazene Derivative CB10-277","termGroup":"PT","termSource":"NCI"},{"termName":"1-p-carboxy-3,3-dimethylphenyltriazine","termGroup":"SN","termSource":"NCI"},{"termName":"CB10-277","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CB10-277"},{"name":"Maps_To","value":"Triazene Derivative CB10-277"},{"name":"NCI_Drug_Dictionary_ID","value":"41154"},{"name":"NSC Number","value":"208107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41154"},{"name":"PDQ_Open_Trial_Search_ID","value":"41154"},{"name":"PubMedID_Primary_Reference","value":"phase II trial shown to be inactive; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394365/"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0088835"}]}}{"C95208":{"preferredName":"Triazene Derivative TriN2755","code":"C95208","definitions":[{"definition":"A synthetic triazene derivative with antineoplastic activity. Upon metabolic activation via N-demethylation, TriN2755 is converted into highly reactive carbocations that can alkylate DNA and other macromolecules, thereby resulting in DNA cross links, inhibiting DNA replication and repair, and subsequently inducing apoptosis. This agent has high hydrophilicity and photostability and shows a favorable toxicity profile over the other triazenes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triazene Derivative TriN2755","termGroup":"PT","termSource":"NCI"},{"termName":"TriN2755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Triazene Derivative TriN2755"},{"name":"NCI_Drug_Dictionary_ID","value":"691486"},{"name":"NCI_META_CUI","value":"CL426697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691486"},{"name":"PDQ_Open_Trial_Search_ID","value":"691486"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1258":{"preferredName":"Triazinate","code":"C1258","definitions":[{"definition":"A synthetic dihydrotriazine derivative with antineoplastic properties.  As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis.  Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triazinate","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-(2-chloro-4-(4,6-diamino-2,2-dimethyl-s-trizin-1(2H)-yl)phenoxy)-N,N-dimethyl-m-toluamide ethanesulfonic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BAF","termGroup":"AB","termSource":"NCI"},{"termName":"Baker's Antifol","termGroup":"SY","termSource":"NCI"},{"termName":"Baker's Antifolate","termGroup":"SY","termSource":"NCI"},{"termName":"Bakers Antifol","termGroup":"SY","termSource":"NCI"},{"termName":"Bakers Antifolate","termGroup":"SY","termSource":"NCI"},{"termName":"benzenesulfonyl fluoride, 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenyl]butyl]-, monoethanesulfonate (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Ethanesulfonic Acid Compound","termGroup":"SY","termSource":"NCI"},{"termName":"ethanesulfonic acid compound with 3-((2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenoxy)methyl)-N,N-dimethylben zamide (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride","termGroup":"SN","termSource":"NCI"},{"termName":"ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3, 5-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Soluble Baker's Antifol","termGroup":"SY","termSource":"NCI"},{"termName":"TZT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41191-04-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DD99Y262WC"},{"name":"Legacy Concept Name","value":"Triazinate"},{"name":"Maps_To","value":"Triazinate"},{"name":"NCI_Drug_Dictionary_ID","value":"39162"},{"name":"NSC Number","value":"139105"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39162"},{"name":"PDQ_Open_Trial_Search_ID","value":"39162"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077008"}]}}{"C903":{"preferredName":"Triaziquone","code":"C903","definitions":[{"definition":"An aziridinylbenzoquinone-based alkylating agent with potential antineoplastic activity. The alkylating group in triaziquone becomes activated upon reduction of quinone to the hydroquinone form. This eventually results in the alkylation and crosslinking of DNA, thereby inhibiting DNA replication followed by an induction of apoptosis. In addition, reactive oxygen species may form during redox cycling which may contribute to this agent's cytotoxic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triaziquone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68-76-8"},{"name":"CHEBI_ID","value":"CHEBI:27090"},{"name":"Chemical_Formula","value":"C12H13N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3D5D9P25I"},{"name":"Legacy Concept Name","value":"Triaziquone"},{"name":"Maps_To","value":"Triaziquone"},{"name":"NSC Number","value":"29215"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040878"}]}}{"C1260":{"preferredName":"Tributyrin","code":"C1260","definitions":[{"definition":"A triglyceride drug that may inhibit cell growth and induce cell differentiation. Differentiating agents may be effective in changing cancer cells back into normal cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triglyceride prodrug of butyric acid with potential antineoplastic activity. Butyrate, the active metabolite of tributyrin, inhibits histone deacetylase, resulting in increased differentiation, decreased proliferation, cell cycle arrest, and apoptosis in some tumor cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tributyrin","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3-Propanetriyl Butanoate","termGroup":"SN","termSource":"NCI"},{"termName":"1,2,3-Tributyrylglycerol","termGroup":"SN","termSource":"NCI"},{"termName":"Butanoic Acid 1,2,3-Propanetriyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Butyryl Triglyceride","termGroup":"SY","termSource":"NCI"},{"termName":"Glyceryl Tributyrate","termGroup":"SY","termSource":"NCI"},{"termName":"TB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60-01-5"},{"name":"Chemical_Formula","value":"C15H26O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S05LZ624MF"},{"name":"Legacy Concept Name","value":"Tributyrin"},{"name":"Maps_To","value":"Tributyrin"},{"name":"NCI_Drug_Dictionary_ID","value":"42290"},{"name":"NSC Number","value":"661583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42290"},{"name":"PDQ_Open_Trial_Search_ID","value":"42290"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077025"}]}}{"C1262":{"preferredName":"Triciribine Phosphate","code":"C1262","definitions":[{"definition":"The phosphate salt of the synthetic, cell-permeable tricyclic nucleoside triciribine with potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Akts are anti-apoptotic serine/threonine-specific protein kinases that phosphorylate and inactivate components of the apoptotic machinery, including Bcl-xL/Bcl-2-associated death promoter (BAD) and caspase 9.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triciribine Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine","termGroup":"SN","termSource":"NCI"},{"termName":"1,4, 5,6,8-pentaazaacenaphthylen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"1,4,5,6, 8-pentaazaacenaphthalen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"3-amino-1, 5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene 5'-(dihydrogen phosphate)","termGroup":"SN","termSource":"NCI"},{"termName":"TCN","termGroup":"AB","termSource":"NCI"},{"termName":"Triciribine","termGroup":"SY","termSource":"NCI"},{"termName":"Tricyclic Nucleoside 5'-Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Tricycloside Phosphate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"61966-08-3"},{"name":"Chemical_Formula","value":"C13H17N6O7P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5L5GE3DV88"},{"name":"Legacy Concept Name","value":"Triciribine_Phosphate"},{"name":"Maps_To","value":"Triciribine Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"39723"},{"name":"NSC Number","value":"280594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39723"},{"name":"PDQ_Open_Trial_Search_ID","value":"39723"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077070"}]}}{"C61987":{"preferredName":"Trientine Hydrochloride","code":"C61987","definitions":[{"definition":"The hydrochloride salt form of a metal chelating agent with potential anti-angiogenic activity. Trientine chelates excess copper (Cu) ions in the body; the excess copper is subsequently removed from the body through the kidneys. As Cu is an essential cofactor for cuproenzymes, such as superoxide dismutase 1 (SOD1), depletion of copper may inhibit the activation of signal transduction pathways required for cellular proliferation and angiogenesis. In addition, trientine may inhibit copper-induced secretion of interleukin-8 (IL-8).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trientine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"N,N-bis (2-aminoethyl)-1,2-ethanediamine Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Syprine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38260-01-4"},{"name":"Chemical_Formula","value":"C6H18N4.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HC3NX54582"},{"name":"Legacy Concept Name","value":"Trientine_Hydrochloride"},{"name":"Maps_To","value":"Trientine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"683662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683662"},{"name":"PDQ_Open_Trial_Search_ID","value":"683662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770325"}]}}{"C29858":{"preferredName":"Triethylenemelamine","code":"C29858","definitions":[{"definition":"A trisaziridine alkylating agent with antineoplastic and carcinogenic properties.  Used to induce cancer in experimental animal models, triethylenemelamine ethylates DNA, resulting in inhibition of DNA replication, unscheduled DNA synthesis, chromosomal aberrations, and sister chromatid exchanges.  This agent also exhibits reproductive toxicities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triethylenemelamine","termGroup":"PT","termSource":"NCI"},{"termName":"TEM","termGroup":"AB","termSource":"NCI"},{"termName":"Tretamine","termGroup":"SY","termSource":"NCI"},{"termName":"Triethylene Melamine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51-18-3"},{"name":"CHEBI_ID","value":"CHEBI:27919"},{"name":"Chemical_Formula","value":"C9H12N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F7IY6HZG9D"},{"name":"Legacy Concept Name","value":"Triethylenemelamine"},{"name":"Maps_To","value":"Triethylenemelamine"},{"name":"NSC Number","value":"9706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040975"}]}}{"C905":{"preferredName":"Trifluridine","code":"C905","definitions":[{"definition":"A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trifluridine","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-5-trifluoromethyluridine","termGroup":"SN","termSource":"NCI"},{"termName":"F3TdR","termGroup":"AB","termSource":"NCI"},{"termName":"Triflorothymidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70-00-8"},{"name":"Chemical_Formula","value":"C10H11F3N2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RMW9V5RW38"},{"name":"Legacy Concept Name","value":"Trifluridine"},{"name":"Maps_To","value":"Trifluridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39240"},{"name":"NSC Number","value":"75520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39240"},{"name":"PDQ_Open_Trial_Search_ID","value":"39240"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040987"}]}}{"C102554":{"preferredName":"Trifluridine and Tipiracil Hydrochloride","code":"C102554","definitions":[{"definition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trifluridine and Tipiracil Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Lonsurf","termGroup":"BR","termSource":"NCI"},{"termName":"TAS 102","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-102","termGroup":"CN","termSource":"NCI"},{"termName":"Thymidine, Alpha,alpha,alpha-trifluoro-, Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Tipiracil Hydrochloride Mixture with Trifluridine","termGroup":"SY","termSource":"NCI"},{"termName":"Trifluridine and Tipiracil","termGroup":"SY","termSource":"NCI"},{"termName":"Trifluridine/Tipiracil","termGroup":"SY","termSource":"NCI"},{"termName":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic colorectal cancer; metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma"},{"name":"CAS_Registry","value":"733030-01-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Trifluridine and Tipiracil Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"734891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734891"},{"name":"PDQ_Open_Trial_Search_ID","value":"734891"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451803"}]}}{"C142847":{"preferredName":"Troriluzole","code":"C142847","definitions":[{"definition":"A formulation comprised of a prodrug form of the benzothiazole derivative riluzole, with potential anti-depressant, anxiolytic and antineoplastic activities. Following oral administration, troriluzole is converted into the active form riluzole. While the mechanism of action of riluzole is unknown, its pharmacological activities, some of which may be related to its effect, include the following: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. These activities may result in myorelaxation and sedation due to the blockade of glutamatergic neurotransmission. Additionally, these activities may result in the inhibition of enzymes that are necessary for cell growth, which may decrease tumor cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Troriluzole","termGroup":"PT","termSource":"NCI"},{"termName":"BHV 4157","termGroup":"CN","termSource":"NCI"},{"termName":"BHV-4157","termGroup":"CN","termSource":"NCI"},{"termName":"Glycinamide, Glycylglycyl-N2-methyl-N-(6-(trifluoromethoxy)-2-benzothiazolyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"Trigriluzole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1926203-09-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S7H48S6K7H"},{"name":"Maps_To","value":"Trigriluzole"},{"name":"Maps_To","value":"Troriluzole"},{"name":"NCI_Drug_Dictionary_ID","value":"791792"},{"name":"NCI_META_CUI","value":"CL540756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791792"},{"name":"PDQ_Open_Trial_Search_ID","value":"791792"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123281":{"preferredName":"Trilaciclib","code":"C123281","definitions":[{"definition":"A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), with potential antineoplastic and chemoprotective activities. Upon intravenous administration, trilaciclib binds to and inhibits the activity of CDK4/6, thereby blocking the phosphorylation of the retinoblastoma protein (Rb) in early G1. This prevents G1/S phase transition, causes cell cycle arrest in the G1 phase, induces apoptosis, and inhibits the proliferation of CDK4/6-overexpressing tumor cells. In patients with CDK4/6-independent tumor cells, G1T28 may protect against multi-lineage chemotherapy-induced myelosuppression (CIM) by transiently and reversibly inducing G1 cell cycle arrest in hematopoietic stem and progenitor cells (HSPCs) and preventing transition to the S phase. This protects all hematopoietic lineages, including red blood cells, platelets, neutrophils and lymphocytes, from the DNA-damaging effects of certain chemotherapeutics and preserves the function of the bone marrow and the immune system. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. HSPCs are dependent upon CDK4/6 for proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trilaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one","termGroup":"SY","termSource":"NCI"},{"termName":"G1T28","termGroup":"CN","termSource":"NCI"},{"termName":"Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1374743-00-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U6072DO9XG"},{"name":"Maps_To","value":"Trilaciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"775021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775021"},{"name":"PDQ_Open_Trial_Search_ID","value":"775021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053642"}]}}{"C29485":{"preferredName":"Trimelamol","code":"C29485","definitions":[{"definition":"A synthetic derivative of trimethylmelamine with antineoplastic properties.  An analogue of siderophores (microbial iron chelators), trimelamol induces the formation of a reactive iminium species which may crosslink DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimelamol","termGroup":"PT","termSource":"NCI"},{"termName":"BRN 4261541","termGroup":"CN","termSource":"NCI"},{"termName":"Methanol, ((s-triazine-2,4,6-triyl)trimethyltrinitrilo)tri-","termGroup":"SN","termSource":"NCI"},{"termName":"Trimethyloltrimethylmelamine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64124-21-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UST4Z70290"},{"name":"Legacy Concept Name","value":"Trimelamole"},{"name":"Maps_To","value":"Trimelamol"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077149"}]}}{"C143155":{"preferredName":"Trimeric GITRL-Fc OMP-336B11","code":"C143155","definitions":[{"definition":"A Fc-engineered human fusion protein composed of two trimers of tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18; GlTRL) linked to an immunoglobulin Fc domain (GITRL-Fc), with potential immunostimulatory and antineoplastic activities. Upon administration, trimeric GITRL-Fc OMP-336B11 targets, binds to and activates its co-stimulatory surface receptor (glucocorticoid-induced tumor necrosis factor receptor (GITR; TNFRSF18) expressed on T-lymphocytes and certain tumor cell types. This activates T-lymphocytes, causes T-lymphocyte proliferation and suppresses the activity of regulatory T-cells (Treg). This promotes cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells. GITRL, a member of the tumor necrosis factor (TNF) family of ligands, functions to activate the co-stimulatory receptor GITR to enhance T-cell modulated immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimeric GITRL-Fc OMP-336B11","termGroup":"PT","termSource":"NCI"},{"termName":"GITRL-Fc","termGroup":"SY","termSource":"NCI"},{"termName":"GITRL-Fc Trimer","termGroup":"SY","termSource":"NCI"},{"termName":"OMP 336B11","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-336B11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trimeric GITRL-Fc OMP-336B11"},{"name":"NCI_Drug_Dictionary_ID","value":"791681"},{"name":"NCI_META_CUI","value":"CL541604"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791681"},{"name":"PDQ_Open_Trial_Search_ID","value":"791681"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1264":{"preferredName":"Trimethylcolchicinic Acid","code":"C1264","definitions":[{"definition":"A colchicine analog with potential antineoplastic activity.  Trimethylcolchicinic acid binds to tubulin, inhibiting its polymerization into microtubules and preventing cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimethylcolchicinic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Colchicinic Acid, Trimethyl-","termGroup":"SY","termSource":"NCI"},{"termName":"Desacetyl Colchicine D-tartrate","termGroup":"SY","termSource":"NCI"},{"termName":"Desacetylcholchiceine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Deacetylcolchiceine","termGroup":"SN","termSource":"NCI"},{"termName":"SKF 284","termGroup":"CN","termSource":"NCI"},{"termName":"TMCA","termGroup":"AB","termSource":"NCI"},{"termName":"Trimethylcolchicinic Acid Methyl Ether d-tartrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3482-37-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"333BVY614O"},{"name":"Legacy Concept Name","value":"Trimethylcolchicinic_Acid"},{"name":"Maps_To","value":"Trimethylcolchicinic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"39719"},{"name":"NSC Number","value":"36796"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39719"},{"name":"PDQ_Open_Trial_Search_ID","value":"39719"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077183"}]}}{"C1314":{"preferredName":"Trimetrexate","code":"C1314","definitions":[{"definition":"A methotrexate derivative with potential antineoplastic activity.  Trimetrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate also exhibits antiviral activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimetrexate","termGroup":"PT","termSource":"NCI"},{"termName":"5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine","termGroup":"SN","termSource":"NCI"},{"termName":"CI-898","termGroup":"CN","termSource":"NCI"},{"termName":"TMQ","termGroup":"AB","termSource":"NCI"},{"termName":"Trimexate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52128-35-5"},{"name":"Chemical_Formula","value":"C19H23N5O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"UPN4ITI8T4"},{"name":"Legacy Concept Name","value":"Trimetrexate"},{"name":"Maps_To","value":"Trimetrexate"},{"name":"NSC Number","value":"249008"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0085176"}]}}{"C1265":{"preferredName":"Trimetrexate Glucuronate","code":"C1265","definitions":[{"definition":"A drug that belongs to the family of drugs called antimetabolites. It is used in the treatment of pneumocystis carinii pneumonia and is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimetrexate Glucuronate","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline mono-D-glucuronate","termGroup":"SN","termSource":"NCI"},{"termName":"Neutrexin","termGroup":"BR","termSource":"NCI"},{"termName":"TMTX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Head and neck cancer; Metastatic colorectal adenocarcinoma; Non-small cell lung cancer; Osteogenic sarcoma; Pancreatic adenocarcinoma; Pneumocystitis carinii pneumonia"},{"name":"CAS_Registry","value":"82952-64-5"},{"name":"Chemical_Formula","value":"C19H23N5O3.C6H10O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L137U4A79K"},{"name":"Legacy Concept Name","value":"Trimetrexate_Glucuronate"},{"name":"Maps_To","value":"Trimetrexate Glucuronate"},{"name":"NCI_Drug_Dictionary_ID","value":"39764"},{"name":"NSC Number","value":"352122"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39764"},{"name":"PDQ_Open_Trial_Search_ID","value":"39764"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077209"}]}}{"C1266":{"preferredName":"Trioxifene","code":"C1266","definitions":[{"definition":"A nonsteroidal selective estrogen receptor modulator (SERM) with potential antineoplastic activity.  Trioxifene competes with estradiol in binding to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated signal transduction and gene expression. In addition, trioxifene exerts intrinsic estrogenic activity depending on the tissue. Clinical development of trioxifene has not been preceded due to its side effect profile and lack of increased efficacy over tamoxifen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trioxifene","termGroup":"PT","termSource":"NCI"},{"termName":"(3,4-Dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl) Methanone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63619-84-1"},{"name":"Chemical_Formula","value":"C30H31NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R0130F043H"},{"name":"Legacy Concept Name","value":"Trioxifene"},{"name":"Maps_To","value":"Trioxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"39726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39726"},{"name":"PDQ_Open_Trial_Search_ID","value":"39726"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077238"}]}}{"C1827":{"preferredName":"Triplatin Tetranitrate","code":"C1827","definitions":[{"definition":"A cationic tri-nuclear platinum complex related to cisplatin.  BBR 3464 binds to and forms DNA crosslinks and platinum-DNA adducts, preventing DNA replication and tumor cell division.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as an anticancer drug.  It belongs to the family of platinum-based drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Triplatin Tetranitrate","termGroup":"PT","termSource":"NCI"},{"termName":"BBR 3464","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"172903-00-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HAJ1000ARC"},{"name":"Legacy Concept Name","value":"BBR_3464"},{"name":"Maps_To","value":"Triplatin Tetranitrate"},{"name":"NCI_Drug_Dictionary_ID","value":"38246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38246"},{"name":"PDQ_Open_Trial_Search_ID","value":"38246"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0756613"}]}}{"C111762":{"preferredName":"Triptolide Analog","code":"C111762","definitions":[{"definition":"A water soluble analog of the diterpenoid triepoxide triptolide isolated from the Chinese herb Tripterygium wilfordii Hook.f., with potential antineoplastic activity. Upon intravenous administration, the triptolide analog inhibits heat shock protein 70 (HSP70) and prevents HSP70-mediated inhibition of apoptosis. This leads to both the induction of apoptosis and a reduction of cancer cell growth. HSP70, a molecular chaperone upregulated in various cancer cells, plays a key role in the inhibition of caspase-dependent and -independent apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triptolide Analog","termGroup":"PT","termSource":"NCI"},{"termName":"Minnelide","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1254702-87-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1CIV2UMO40"},{"name":"Maps_To","value":"Triptolide Analog"},{"name":"NCI_Drug_Dictionary_ID","value":"753195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753195"},{"name":"PDQ_Open_Trial_Search_ID","value":"753195"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3657815"}]}}{"C1267":{"preferredName":"Triptorelin","code":"C1267","definitions":[{"definition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triptorelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Tryptophan-LH-RH","termGroup":"SY","termSource":"NCI"},{"termName":"6-D-Tryptophanluteinizing Hormone-releasing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"AY-25650","termGroup":"CN","termSource":"NCI"},{"termName":"AY25650","termGroup":"CN","termSource":"NCI"},{"termName":"CL-118,532","termGroup":"CN","termSource":"NCI"},{"termName":"CL118532","termGroup":"CN","termSource":"NCI"},{"termName":"Detryptoreline","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Palliative treatment prostate carcinoma"},{"name":"CAS_Registry","value":"57773-63-4"},{"name":"CHEBI_ID","value":"CHEBI:63633"},{"name":"Chemical_Formula","value":"C64H82N18O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"9081Y98W2V"},{"name":"Legacy Concept Name","value":"Triptorelin"},{"name":"Maps_To","value":"Triptorelin"},{"name":"NCI_Drug_Dictionary_ID","value":"42944"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42944"},{"name":"PDQ_Open_Trial_Search_ID","value":"42944"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077275"}]}}{"C29523":{"preferredName":"Triptorelin Pamoate","code":"C29523","definitions":[{"definition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triptorelin Pamoate","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Tryptophan-, 4,4'Mmethylenebis(3-hydroxy-2-naphthalenecarboxylate) (Salt)","termGroup":"SN","termSource":"NCI"},{"termName":"Decapeptyl","termGroup":"FB","termSource":"NCI"},{"termName":"Diphereline","termGroup":"FB","termSource":"NCI"},{"termName":"Pamorelin","termGroup":"SY","termSource":"NCI"},{"termName":"Trelstar","termGroup":"BR","termSource":"NCI"},{"termName":"Triptorelin Embonate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124508-66-3"},{"name":"Chemical_Formula","value":"C64H82N18O13.C23H16O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"08AN7WA2G0"},{"name":"Legacy Concept Name","value":"Triptorelin_Pamoate"},{"name":"Maps_To","value":"Triptorelin Pamoate"},{"name":"NCI_Drug_Dictionary_ID","value":"468834"},{"name":"NSC Number","value":"724666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468834"},{"name":"PDQ_Open_Trial_Search_ID","value":"468834"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1137102"}]}}{"C1758":{"preferredName":"Tritylcysteine","code":"C1758","definitions":[{"definition":"A derivative of cysteine with antimitotic activity and potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tritylcysteine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Tritylthio-L-Alanine","termGroup":"SY","termSource":"NCI"},{"termName":"S-Trityl-L-Cysteine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2799-07-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tritylcysteine"},{"name":"Maps_To","value":"Tritylcysteine"},{"name":"NSC Number","value":"124663"},{"name":"NSC Number","value":"83265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0601886"}]}}{"C80491":{"preferredName":"TRK Inhibitor AZD6918","code":"C80491","definitions":[{"definition":"An orally available liquid suspension containing the tropomyosin receptor kinase (Trk) inhibitor AZD6918 with potential antineoplastic activity. AZD6918 binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, and may eventually result in cell cycle arrest and apoptosis of tumor cells that express Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRK Inhibitor AZD6918","termGroup":"PT","termSource":"NCI"},{"termName":"AZD6918","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AZD6918"},{"name":"Maps_To","value":"TRK Inhibitor AZD6918"},{"name":"NCI_Drug_Dictionary_ID","value":"613519"},{"name":"NCI_META_CUI","value":"CL388367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613519"},{"name":"PDQ_Open_Trial_Search_ID","value":"613519"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153116":{"preferredName":"TrkA Inhibitor VMD-928","code":"C153116","definitions":[{"definition":"An orally bioavailable, selective inhibitor of tropomyosin receptor kinase A (TrkA; neurotrophic tyrosine receptor kinase (NTRK) type 1; NTRK1; TRK1-transforming tyrosine kinase protein), with potential antineoplastic activity. Upon oral administration, VMD-928 specifically targets and binds to TrkA, inhibits neurotrophin-TrkA interaction and prevents TrkA activation. This prevents the activation of downstream signaling pathways and inhibits cell growth in tumors that overexpress TrkA. Uncontrolled TrkA signaling plays an important role in tumor cell growth, survival, invasion and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TrkA Inhibitor VMD-928","termGroup":"PT","termSource":"NCI"},{"termName":"NTRK1 Inhibitor VMD-928","termGroup":"SY","termSource":"NCI"},{"termName":"VMD 928","termGroup":"CN","termSource":"NCI"},{"termName":"VMD-928","termGroup":"CN","termSource":"NCI"},{"termName":"VMD928","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TrkA Inhibitor VMD-928"},{"name":"NCI_Drug_Dictionary_ID","value":"793945"},{"name":"NCI_META_CUI","value":"CL554374"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793945"},{"name":"PDQ_Open_Trial_Search_ID","value":"793945"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123882":{"preferredName":"Trodusquemine","code":"C123882","definitions":[{"definition":"A naturally-occurring cholestane and non-competitive, allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B), with potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation. In addition, as trodusquemine can cross the blood-brain barrier (BBB), it centrally suppresses appetite and causes weight loss. PTP1B, a tyrosine phosphatase, is elevated in certain cancer cells; it is specifically upregulated in human epidermal growth factor receptor 2 (HER2)-driven cancers where it promotes cell growth, and is correlated with a poor prognosis and increased metastatic potential. In diabetes, PTP1B upregulation plays a major role in insulin resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trodusquemine","termGroup":"PT","termSource":"NCI"},{"termName":"(24R)-3beta-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-7alpha-hydroxy-5alpha-cholestan-24-yl Hydrogen Sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"Cholestane-7,24-diol, 3-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-, 24-(Hydrogen Sulfate), (3beta,5alpha,7alpha,24R)-","termGroup":"SN","termSource":"NCI"},{"termName":"MSI-1436","termGroup":"CN","termSource":"NCI"},{"termName":"MSI-1436C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186139-09-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KKC12PIF16"},{"name":"Maps_To","value":"Trodusquemine"},{"name":"NCI_Drug_Dictionary_ID","value":"775873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775873"},{"name":"PDQ_Open_Trial_Search_ID","value":"775873"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099662"}]}}{"C1268":{"preferredName":"Trofosfamide","code":"C1268","definitions":[{"definition":"An orally bioavailable oxazaphosphorine prodrug with antineoplastic activity. Trofosfamide (TFF) is metabolized predominantly to the cyclophosphamide analogue ifosfamide (IFO), which is then metabolized by liver cytochrome P450s to the active isophosphoramide mustard (IPM). IPM alkylates DNA to form DNA-DNA cross-links, which may result in inhibition of DNA, RNA and protein synthesis, and ultimately lead to tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trofosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxaphosphorine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"A-4828","termGroup":"CN","termSource":"NCI"},{"termName":"Genoxal Trofosfamida","termGroup":"FB","termSource":"NCI"},{"termName":"Ixoten","termGroup":"BR","termSource":"NCI"},{"termName":"N,N,3-tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N,N'-tris(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide","termGroup":"SN","termSource":"NCI"},{"termName":"Trilophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Trofosfamid","termGroup":"SY","termSource":"NCI"},{"termName":"Trophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Z-4828","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"22089-22-1"},{"name":"Chemical_Formula","value":"C9H18Cl3N2O2P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H64JRU6GJ0"},{"name":"Legacy Concept Name","value":"Trofosfamide"},{"name":"Maps_To","value":"Trofosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39725"},{"name":"NSC Number","value":"109723"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39725"},{"name":"PDQ_Open_Trial_Search_ID","value":"39725"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077375"}]}}{"C1522":{"preferredName":"Troglitazone","code":"C1522","definitions":[{"definition":"An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity.  Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Troglitazone","termGroup":"PT","termSource":"NCI"},{"termName":"5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"CI-991","termGroup":"CN","termSource":"NCI"},{"termName":"CS-045","termGroup":"CN","termSource":"NCI"},{"termName":"Prelay","termGroup":"BR","termSource":"NCI"},{"termName":"Rezulin","termGroup":"BR","termSource":"NCI"},{"termName":"Romozin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97322-87-7"},{"name":"CHEBI_ID","value":"CHEBI:9753"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I66ZZ0ZN0E"},{"name":"Legacy Concept Name","value":"Troglitazone"},{"name":"Maps_To","value":"Troglitazone"},{"name":"NCI_Drug_Dictionary_ID","value":"42706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42706"},{"name":"PDQ_Open_Trial_Search_ID","value":"42706"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245514"}]}}{"C99161":{"preferredName":"Utatrectinib","code":"C99161","definitions":[{"definition":"A tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. Upon administration, utatrectinib binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Utatrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD7451","termGroup":"CN","termSource":"NCI"},{"termName":"TRK Inhibitor AZD7451","termGroup":"SY","termSource":"NCI"},{"termName":"Tropomyosin Receptor Kinase Inhibitor AZD7451","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1079274-94-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VNM956Y27V"},{"name":"Maps_To","value":"Tropomyosin Receptor Kinase Inhibitor AZD7451"},{"name":"NCI_Drug_Dictionary_ID","value":"717230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717230"},{"name":"PDQ_Open_Trial_Search_ID","value":"717230"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274575"}]}}{"C1438":{"preferredName":"Troxacitabine","code":"C1438","definitions":[{"definition":"A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A drug being studied for use as an anticancer agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Troxacitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2(1H)-Pyrimidinone, 4-amino-1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BCH-4556","termGroup":"CN","termSource":"NCI"},{"termName":"L-Oddc","termGroup":"CN","termSource":"NCI"},{"termName":"Troxatyl","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145918-75-8"},{"name":"Chemical_Formula","value":"C8H11N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"60KQZ0388Y"},{"name":"Legacy Concept Name","value":"Troxacitabine"},{"name":"Maps_To","value":"Troxacitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"43646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43646"},{"name":"PDQ_Open_Trial_Search_ID","value":"43646"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0877874"}]}}{"C157496":{"preferredName":"Fostroxacitabine Bralpamide","code":"C157496","definitions":[{"definition":"A liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, fostroxacitabine bralpamide is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fostroxacitabine Bralpamide","termGroup":"PT","termSource":"NCI"},{"termName":"MIV 818","termGroup":"CN","termSource":"NCI"},{"termName":"MIV-818","termGroup":"CN","termSource":"NCI"},{"termName":"MIV818","termGroup":"CN","termSource":"NCI"},{"termName":"Troxacitabine Nucleotide Prodrug MIV-818","termGroup":"SY","termSource":"NCI"},{"termName":"Troxacitabine Prodrug MIV-818","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2129993-56-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1I6YZ0NGF"},{"name":"Maps_To","value":"Troxacitabine Nucleotide Prodrug MIV-818"},{"name":"NCI_Drug_Dictionary_ID","value":"796799"},{"name":"NCI_META_CUI","value":"CL937071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796799"},{"name":"PDQ_Open_Trial_Search_ID","value":"796799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162345":{"preferredName":"TRPM8 Agonist D-3263","code":"C162345","definitions":[{"definition":"A small-molecule agonist for transient receptor potential melastatin member 8 (TRPM8 or Trp-p8), with potential antineoplastic activity. Upon administration, TRPM8 agonist D-3263 targets, binds to and activates TRPM8, which may result in an increase in intracellular calcium and sodium influx; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. This agent may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and benign prostatic hyperplasia (BPH). TRPM8 is a transmembrane calcium channel protein that is normally expressed in prostate cells and appears to be overexpressed in BPH and in prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRPM8 Agonist D-3263","termGroup":"PT","termSource":"NCI"},{"termName":"D 3263","termGroup":"CN","termSource":"NCI"},{"termName":"D-3263","termGroup":"CN","termSource":"NCI"},{"termName":"D3263","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"947257-66-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"70FBL3TX3E"},{"name":"Legacy Concept Name","value":"Enteric-Coated_TRPM8_Agonist_D-3263_Hydrochloride"},{"name":"Maps_To","value":"TRPM8 Agonist D-3263"},{"name":"NCI_META_CUI","value":"CL970854"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101525":{"preferredName":"TRPV6 Calcium Channel Inhibitor SOR-C13","code":"C101525","definitions":[{"definition":"An inhibitor of transient receptor potential cation channel vanilloid family member 6 (TRPV6, CaT1 or CATL) with potential antineoplastic activity. TRPV6 calcium channel inhibitor SOR-C13 binds to TRPV6 and prevents the influx of calcium ions into TRPV6-expressing tumor cells. This inhibits the activation of nuclear factor of activated T-cell (NFAT) transcription complex which may result in an inhibition of calcium-dependent cancer cell proliferation and an induction of apoptosis in tumor cells overexpressing TRPV6. The TRPV6 ion channel plays a key role in calcium homeostasis and is highly selective for calcium compared to other cations; it is overexpressed in a variety of tumors and initiates tumor cell growth, proliferation and metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRPV6 Calcium Channel Inhibitor SOR-C13","termGroup":"PT","termSource":"NCI"},{"termName":"SOR-C13","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1187852-48-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C79B5A73C4"},{"name":"Maps_To","value":"TRPV6 Calcium Channel Inhibitor SOR-C13"},{"name":"NCI_Drug_Dictionary_ID","value":"732361"},{"name":"NCI_META_CUI","value":"CL435782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732361"},{"name":"PDQ_Open_Trial_Search_ID","value":"732361"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C37447":{"preferredName":"TSP-1 Mimetic ABT-510","code":"C37447","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1).  ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSP-1 Mimetic ABT-510","termGroup":"PT","termSource":"NCI"},{"termName":"ABT510","termGroup":"CN","termSource":"NCI"},{"termName":"L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl-","termGroup":"SN","termSource":"NCI"},{"termName":"NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt","termGroup":"SY","termSource":"NCI"},{"termName":"TSP-1-mimetic Peptide ABT-510","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"251579-55-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CRR8E37XOB"},{"name":"Legacy Concept Name","value":"ABT-510"},{"name":"Maps_To","value":"TSP-1 Mimetic ABT-510"},{"name":"NCI_Drug_Dictionary_ID","value":"350157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350157"},{"name":"PDQ_Open_Trial_Search_ID","value":"350157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1704426"}]}}{"C82384":{"preferredName":"TSP-1 Mimetic Fusion Protein CVX-045","code":"C82384","definitions":[{"definition":"A fusion protein containing two thrombospondin (TSP-1)-derived nonamer peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic monoclonal aldolase monoclonal antibody with potential antiangiogenic and antineoplastic activities.  The TSP-1 mimetic peptide moieties of TSP-1 mimetic fusion protein CVX-045 bind to TSP-1 receptors, such as CD36, and inhibit tumor angiogenesis, which may result in the inhibition of tumor cell proliferation. The proprietary humanized catalytic monoclonal aldolase monoclonal antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the TSP-1 mimetic peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSP-1 Mimetic Fusion Protein CVX-045","termGroup":"PT","termSource":"NCI"},{"termName":"CVX-045","termGroup":"CN","termSource":"NCI"},{"termName":"Thrombospondin-1 Mimetic Fusion Protein CVX-045","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TSP-1_Mimetic_Fusion_Protein_CVX-045"},{"name":"Maps_To","value":"TSP-1 Mimetic Fusion Protein CVX-045"},{"name":"NCI_Drug_Dictionary_ID","value":"641917"},{"name":"NCI_META_CUI","value":"CL408655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641917"},{"name":"PDQ_Open_Trial_Search_ID","value":"641917"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C911":{"preferredName":"Tubercidin","code":"C911","definitions":[{"definition":"An antibiotic and adenosine analog isolated from the bacterium Streptomyces tubercidicus with potential antineoplastic activity.  Tubercidin is incorporated into DNA and inhibits polymerases, thereby inhibiting DNA replication and RNA and protein synthesis.  This agent also exhibits antifungal and antiviral activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubercidin","termGroup":"PT","termSource":"NCI"},{"termName":"4-amino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine","termGroup":"SN","termSource":"NCI"},{"termName":"7-deazaadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"U-10071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69-33-0"},{"name":"CHEBI_ID","value":"CHEBI:48267"},{"name":"Chemical_Formula","value":"C11H14N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M351LCX45Y"},{"name":"Legacy Concept Name","value":"Tubercidin"},{"name":"Maps_To","value":"Tubercidin"},{"name":"NCI_Drug_Dictionary_ID","value":"39728"},{"name":"NSC Number","value":"56408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39728"},{"name":"PDQ_Open_Trial_Search_ID","value":"39728"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0041286"}]}}{"C78842":{"preferredName":"Tubulin Inhibitor ALB 109564 Dihydrochloride","code":"C78842","definitions":[{"definition":"A semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB 109564 dihydrochloride binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin Inhibitor ALB 109564 Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"ALB-109564 dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Alb-109564(a)","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1300114-12-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G2Z7R4P95M"},{"name":"Maps_To","value":"Tubulin Inhibitor ALB 109564 Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"610130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610130"},{"name":"PDQ_Open_Trial_Search_ID","value":"610130"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703136"}]}}{"C162527":{"preferredName":"Tubulin Inhibitor ALB-109564","code":"C162527","definitions":[{"definition":"A semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB-109564 binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle. Check for active clinical trials using this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin Inhibitor ALB-109564","termGroup":"PT","termSource":"NCI"},{"termName":"ALB 109564","termGroup":"CN","termSource":"NCI"},{"termName":"ALB-109564","termGroup":"CN","termSource":"NCI"},{"termName":"ALB109564","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"854756-74-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EUY2631TAL"},{"name":"Maps_To","value":"Tubulin Inhibitor ALB-109564"},{"name":"NCI_META_CUI","value":"CL971105"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162525":{"preferredName":"Tubulin Polymerization Inhibitor AEZS 112","code":"C162525","definitions":[{"definition":"An orally bioavailable small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Upon oral administration, tubulin polymerization inhibitor AEZS 112 binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin Polymerization Inhibitor AEZS 112","termGroup":"PT","termSource":"NCI"},{"termName":"AEZS 112","termGroup":"CN","termSource":"NCI"},{"termName":"AEZS-112","termGroup":"CN","termSource":"NCI"},{"termName":"AEZS112","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN 012","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN-012","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1214741-69-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tubulin Polymerization Inhibitor AEZS 112"},{"name":"NCI_META_CUI","value":"CL971107"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101264":{"preferredName":"Valecobulin","code":"C101264","definitions":[{"definition":"A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activity. Upon administration, valecobulin is converted into its active metabolite S-516 that binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valecobulin","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-(4-(3-(1H-1,2,4-Triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CKD-516","termGroup":"CN","termSource":"NCI"},{"termName":"Tubulin Polymerization Inhibitor CKD-516","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188371-47-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P48P97V001"},{"name":"Maps_To","value":"Tubulin Polymerization Inhibitor CKD-516"},{"name":"Maps_To","value":"Valecobulin"},{"name":"NCI_Drug_Dictionary_ID","value":"729699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729699"},{"name":"PDQ_Open_Trial_Search_ID","value":"729699"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2974542"}]}}{"C158517":{"preferredName":"Sabizabulin","code":"C158517","definitions":[{"definition":"An orally bioavailable, small molecule tubulin inhibitor, with potential antineoplastic, antiviral and anti-inflammatory activities. Upon oral administration, sabizabulin binds to the colchicine-binding site of alpha- and beta-tubulin subunits of microtubules and crosslinks the microtubules, thereby inhibiting microtubule polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature, tumor blood flow, deprives tumor cells of nutrients, and induces apoptosis. In addition, as microtubules plays an important role in intracellular transport, the inhibition of its polymerization may disrupt the transport of the androgen receptor (AR) into the cell nucleus, as well as virus trafficking around the cell. This may decrease viral replication and assembly. Inhibition of tubulin polymerization may also inhibit the release of pro-inflammatory cytokines and disrupt inflammatory cell activities. Sabizabulin is not a substrate of P-glycoprotein (Pgp), an efflux pump that when overexpressed, may confer resistance to taxane agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sabizabulin","termGroup":"PT","termSource":"NCI"},{"termName":"VERU 111","termGroup":"CN","termSource":"NCI"},{"termName":"VERU-111","termGroup":"CN","termSource":"NCI"},{"termName":"VERU111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1332881-26-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37L1JX37J5"},{"name":"Maps_To","value":"Tubulin Polymerization Inhibitor VERU-111"},{"name":"NCI_Drug_Dictionary_ID","value":"797224"},{"name":"NCI_META_CUI","value":"CL1659534"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797224"},{"name":"PDQ_Open_Trial_Search_ID","value":"797224"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71525":{"preferredName":"Tubulin-Binding Agent SSR97225","code":"C71525","definitions":[{"definition":"An antimitotic tubulin-binding agent with potential antineoplastic activity. Tubulin-binding agent SSR97225 binds to tubulin, arresting the cell cycle at the G2/M checkpoint and preventing mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin-Binding Agent SSR97225","termGroup":"PT","termSource":"NCI"},{"termName":"SSR 97225","termGroup":"CN","termSource":"NCI"},{"termName":"SSR-97225","termGroup":"CN","termSource":"NCI"},{"termName":"SSR97225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SSR97225"},{"name":"Maps_To","value":"Tubulin-Binding Agent SSR97225"},{"name":"NCI_Drug_Dictionary_ID","value":"576686"},{"name":"NCI_META_CUI","value":"CL378284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"576686"},{"name":"PDQ_Open_Trial_Search_ID","value":"576686"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77896":{"preferredName":"Tucatinib","code":"C77896","definitions":[{"definition":"An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tucatinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-380","termGroup":"CN","termSource":"NCI"},{"termName":"Irbinitinib","termGroup":"SY","termSource":"NCI"},{"termName":"N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"ONT-380","termGroup":"CN","termSource":"NCI"},{"termName":"Tukysa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting."},{"name":"CAS_Registry","value":"937263-43-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"234248D0HH"},{"name":"Legacy Concept Name","value":"ErbB-2_Inhibitor_ARRY-380"},{"name":"Maps_To","value":"Tucatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"594366"},{"name":"NCI_META_CUI","value":"CL383576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594366"},{"name":"PDQ_Open_Trial_Search_ID","value":"594366"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97263":{"preferredName":"Tucidinostat","code":"C97263","definitions":[{"definition":"An orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Upon administration, tucidinostat binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins. This agent also inhibits the expression of kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, a class of enzymes that deacetylate chromatin histone proteins, are upregulated in many tumor types and play key roles in gene expression. Compared to some other benzamide-type HDAC inhibitors, chidamide is more stable, more resistant to degradation and has a longer half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tucidinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Chidamide","termGroup":"SY","termSource":"NCI"},{"termName":"CS-055","termGroup":"CN","termSource":"NCI"},{"termName":"CS055","termGroup":"CN","termSource":"NCI"},{"termName":"Epidaza","termGroup":"SY","termSource":"NCI"},{"termName":"HBI-8000","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-amino-5-fluorine benzyl)-4-[N-(pyridine-3-acrylyl) ammonia methyl] Benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-(2-amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616493-44-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"87CIC980Y0"},{"name":"Maps_To","value":"Tucidinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"702501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"702501"},{"name":"PDQ_Open_Trial_Search_ID","value":"702501"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2932486"}]}}{"C2630":{"preferredName":"Tucotuzumab Celmoleukin","code":"C2630","definitions":[{"definition":"A recombinant fusion protein comprised of a human monoclonal antibody directed against the epithelial cell adhesion molecule (EpCAM or KS) linked to an active interleukin-2 (IL2) molecule with potential antineoplastic activity. Tucotuzumab Celmoleukin recognizes and binds to EpCAM, a cell surface epithelial protein that is expressed on a wide variety of cancer cells, thereby concentrating IL2 in EpCAM-expressing tumor tissue. Subsequently, the localized IL2 moiety of the fusion protein may stimulate a cytotoxic T-cell antitumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tucotuzumab Celmoleukin","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 273066","termGroup":"CN","termSource":"NCI"},{"termName":"EMD-273066","termGroup":"CN","termSource":"NCI"},{"termName":"huKS-IL2 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"KSA-IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"KSA-interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"KSA-Interleukin-2 Fusion Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"339986-90-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4ON7FF680U"},{"name":"Legacy Concept Name","value":"KSA-Interleukin-2_Fusion_Protein"},{"name":"Maps_To","value":"Tucotuzumab Celmoleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"456358"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456358"},{"name":"PDQ_Open_Trial_Search_ID","value":"456358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721369"}]}}{"C77856":{"preferredName":"Tyroserleutide","code":"C77856","definitions":[{"definition":"A tripeptide consisting of tyrosine, serine, and leucine with potential antineoplastic activity. Although the mechanism of its antitumor activity has yet to be fully elucidated, tyroserleutide appears to inhibit the expression of ICAM-1 (CD54), a cell adhesion factor of the immunoglobulin (Ig) superfamily that plays an important role in the invasion, adhesion, and metastasis of tumor cells. In addition, this agent may influence the Ca2+/calmodulin pathway, inhibiting phosphatidylinositol 3 kinase (PI3K); PI3K is upregulated in tumor cells and is involved in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyroserleutide","termGroup":"PT","termSource":"NCI"},{"termName":"CMS 024","termGroup":"CN","termSource":"NCI"},{"termName":"YSL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"138168-48-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L9TIM50J8N"},{"name":"Legacy Concept Name","value":"Tyroserleutide"},{"name":"Maps_To","value":"Tyroserleutide"},{"name":"NCI_Drug_Dictionary_ID","value":"593430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593430"},{"name":"PDQ_Open_Trial_Search_ID","value":"593430"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451018"}]}}{"C2401":{"preferredName":"Tyrosinase Peptide","code":"C2401","definitions":[{"definition":"A protein that is made from tumor cells and is used in a vaccine against melanoma. A tyrosinase peptide vaccine may stimulate the body's immune system to find and kill melanoma cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of a number of recombinant peptides consisting of amino acid residues of the enzyme tyrosinase, a protein frequently expressed by melanoma cells.  Vaccination with tyrosinase peptide may stimulate cytotoxic T lymphocyte response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinase Peptide","termGroup":"PT","termSource":"NCI"},{"termName":"Tyrosinase Peptides","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosinase_Peptide"},{"name":"Maps_To","value":"Tyrosinase Peptide"},{"name":"NCI_Drug_Dictionary_ID","value":"42338"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42338"},{"name":"PDQ_Open_Trial_Search_ID","value":"42338"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338254"}]}}{"C2384":{"preferredName":"Tyrosinase-KLH","code":"C2384","definitions":[{"definition":"A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinase-KLH","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosinase-KLH"},{"name":"Maps_To","value":"Tyrosinase-KLH"},{"name":"NCI_Drug_Dictionary_ID","value":"42106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42106"},{"name":"PDQ_Open_Trial_Search_ID","value":"42106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281633"}]}}{"C48630":{"preferredName":"Tyrosinase:146-156 Peptide","code":"C48630","definitions":[{"definition":"A synthetic peptide consisting of amino acid residues 146 through 156 of the enzyme tyrosinase, a protein frequently expressed by melanoma cells, with antitumor activity. Vaccination with tyrosinase:146-156 peptide may stimulate cytotoxic T lymphocyte response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth and cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinase:146-156 Peptide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosinase_146-156_Peptide"},{"name":"Maps_To","value":"Tyrosinase:146-156 Peptide"},{"name":"NSC Number","value":"731579"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1710512"}]}}{"C1967":{"preferredName":"Tyrosine Kinase Inhibitor","code":"C1967","definitions":[{"definition":"A drug that interferes with cell communication and growth and may prevent tumor growth. Some tyrosine kinase inhibitors are used to treat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Kinase Inhibitors","termGroup":"SY","termSource":"NCI"},{"termName":"PTK Inhibitors","termGroup":"SY","termSource":"NCI"},{"termName":"TK Inhibitors","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:38637"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C1268567"}]}}{"C70981":{"preferredName":"Tyrosine Kinase Inhibitor OSI-930","code":"C70981","definitions":[{"definition":"A selective thiophene-derived tyrosine kinase inhibitor with potential antineoplastic activity. Tyrosine kinase inhibitor OSI-930 inhibits stem cell factor receptor (c-Kit) and the vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of both tumor cell proliferation and tumor angiogenesis. Both c-Kit and VEGFR2 are overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor OSI-930","termGroup":"PT","termSource":"NCI"},{"termName":"OSI-930","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"728033-96-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G1PEG5Q9Y2"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor_OSI-930"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor OSI-930"},{"name":"NCI_Drug_Dictionary_ID","value":"566188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"566188"},{"name":"PDQ_Open_Trial_Search_ID","value":"566188"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1615605"}]}}{"C1725":{"preferredName":"Tyrosine Kinase Inhibitor SU5402","code":"C1725","definitions":[{"definition":"An indolinone-based small molecule selective tyrosine kinase inhibitor with potential antineoplastic activity. SU5402 blocks the activities of vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor 1 (FGFR1) via competing with ATP for the specific binding site within the catalytic domain of these receptors. This agent was shown to inhibit cell growth, decrease cell viability in dose-dependent manner, and induce apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor SU5402","termGroup":"PT","termSource":"NCI"},{"termName":"3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone","termGroup":"SN","termSource":"NCI"},{"termName":"SU 5402","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:63449"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SU5402"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor SU5402"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0538431"}]}}{"C68929":{"preferredName":"Tyrosine Kinase Inhibitor XL228","code":"C68929","definitions":[{"definition":"A synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis. In addition, this agent may be a potent inhibitor of the T315I mutant form of the Abl protein, which is associated with the resistance of chronic myelogenous leukemia (CML) to other tyrosine kinase inhibitors. IGF1R and Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. Bcr-Abl translocation leads to constitutive activation of ABL kinase and is commonly associated with Philadelphia-positive acute lymphocytic leukemia (ALL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor XL228","termGroup":"PT","termSource":"NCI"},{"termName":"XL228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"898280-07-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33M2XSK003"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor_XL228"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor XL228"},{"name":"NCI_Drug_Dictionary_ID","value":"549001"},{"name":"NCI_META_CUI","value":"CL374367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"549001"},{"name":"PDQ_Open_Trial_Search_ID","value":"549001"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113788":{"preferredName":"UAE Inhibitor TAK-243","code":"C113788","definitions":[{"definition":"A small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity. UAE inhibitor TAK-243 binds to and inhibits UAE, which prevents both protein ubiquitination and subsequent protein degradation by the proteasome. This results in an excess of proteins in the cells and may lead to endoplasmic reticulum (ER) stress-mediated apoptosis. This inhibits tumor cell proliferation and survival. UAE, also called ubiquitin E1 enzyme (UBA1; E1), is more active in cancer cells than in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"UAE Inhibitor TAK-243","termGroup":"PT","termSource":"NCI"},{"termName":"AOB87172","termGroup":"CN","termSource":"NCI"},{"termName":"MLN7243","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-243","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1450833-55-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9GGV0YCDI"},{"name":"Maps_To","value":"UAE Inhibitor TAK-243"},{"name":"NCI_Drug_Dictionary_ID","value":"757275"},{"name":"NCI_META_CUI","value":"CL471769"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757275"},{"name":"PDQ_Open_Trial_Search_ID","value":"757275"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1015":{"preferredName":"Ubenimex","code":"C1015","definitions":[{"definition":"A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ubenimex","termGroup":"PT","termSource":"NCI"},{"termName":"[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"[S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"Bestatin","termGroup":"SY","termSource":"NCI"},{"termName":"N-[(2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl]-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"NK 421","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58970-76-6"},{"name":"Chemical_Formula","value":"C16H24N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I0J33N5627"},{"name":"Legacy Concept Name","value":"Ubenimex"},{"name":"Maps_To","value":"Ubenimex"},{"name":"NCI_Drug_Dictionary_ID","value":"39164"},{"name":"NSC Number","value":"265489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39164"},{"name":"PDQ_Open_Trial_Search_ID","value":"39164"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053355"}]}}{"C118621":{"preferredName":"Ubidecarenone Nanodispersion BPM31510n","code":"C118621","definitions":[{"definition":"A nanodispersion containing the benzoquinone ubidecarenone (coenzyme Q10), with potential protective, antioxidant and antineoplastic activities. Upon administration, ubidecarenone nanodispersion BPM31510 modulates tumor cell metabolism and causes an anti-Warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. This inhibits tumor cell proliferation. BPM 31510 also induces the activation and maturation of T-lymphocytes, and changes the surface expression of certain immune checkpoint modulators. In addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of LDL-cholesterol. Ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (ATP).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ubidecarenone Nanodispersion BPM31510n","termGroup":"PT","termSource":"NCI"},{"termName":"BP31510","termGroup":"CN","termSource":"NCI"},{"termName":"Coenzyme Q10 Injectable Nanosuspension","termGroup":"SY","termSource":"NCI"},{"termName":"Ubiquinone Injectable Nanosuspension","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ubidecarenone Nanodispersion BPM31510n"},{"name":"NCI_Drug_Dictionary_ID","value":"791848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791848"},{"name":"PDQ_Open_Trial_Search_ID","value":"791848"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897258"}]}}{"C91078":{"preferredName":"Ublituximab","code":"C91078","definitions":[{"definition":"A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ublituximab","termGroup":"PT","termSource":"NCI"},{"termName":"LFB-R603","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1101","termGroup":"CN","termSource":"NCI"},{"termName":"TG-20","termGroup":"CN","termSource":"NCI"},{"termName":"TGTX-1101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1174014-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U59UGK3IPC"},{"name":"Maps_To","value":"Ublituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"670500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670500"},{"name":"PDQ_Open_Trial_Search_ID","value":"670500"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934225"}]}}{"C102851":{"preferredName":"Ulinastatin","code":"C102851","definitions":[{"definition":"A multivalent Kunitz-type serine protease inhibitor derived from human urine, with potential protective, anti-fibrinolytic and anticoagulant activities. Upon administration, ulinastatin (or urinary trypsinogen inhibitor) inhibits the activities of a variety of enzymes, including trypsin, chymotrypsin, thrombin, kallikrein, plasmin, elastase, cathepsin, lipase, hyaluronidase, factors IXa, Xa, XIa, and XlIa, and polymorphonuclear leukocyte elastase. In addition, ulinastatin inhibits the excessive release of proinflammatory mediators, such as tumor necrosis factor-alpha, interleukin-6 and -8, and chemokines. Altogether, this agent may improve the microcirculation, perfusion and function of tissues and may protect organ injury.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulinastatin","termGroup":"PT","termSource":"NCI"},{"termName":"Bikunin","termGroup":"SY","termSource":"NCI"},{"termName":"Trypsin Inhibitor, Bikunin","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Trypsin Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"UTI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80449-32-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OR3S9IF86U"},{"name":"Maps_To","value":"Ulinastatin"},{"name":"NCI_Drug_Dictionary_ID","value":"737612"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737612"},{"name":"PDQ_Open_Trial_Search_ID","value":"737612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077906"}]}}{"C104744":{"preferredName":"Ulixertinib","code":"C104744","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, ulixertinib inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulixertinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BVD-523","termGroup":"CN","termSource":"NCI"},{"termName":"VRT752271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"869886-67-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16ZDH50O1U"},{"name":"Maps_To","value":"Ulixertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"746054"},{"name":"NCI_META_CUI","value":"CL445815"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746054"},{"name":"PDQ_Open_Trial_Search_ID","value":"746054"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95755":{"preferredName":"Ulocuplumab","code":"C95755","definitions":[{"definition":"An orally bioavailable monoclonal antibody against CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. Ulocuplumab binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulocuplumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 936564","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-1338","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1375830-34-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7KNP87L4X4"},{"name":"Maps_To","value":"Ulocuplumab"},{"name":"NCI_Drug_Dictionary_ID","value":"673715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673715"},{"name":"PDQ_Open_Trial_Search_ID","value":"673715"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658941"}]}}{"C104413":{"preferredName":"Umbralisib","code":"C104413","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity.  PI3K-delta inhibitor TGR-1202 inhibits PI3K and prevents the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in susceptible tumor cells.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in tumor cells and cells of the hematopoietic lineage. The targeted inhibition of PI3K-delta allows for PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Umbralisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one","termGroup":"SY","termSource":"NCI"},{"termName":"RP-5264","termGroup":"CN","termSource":"NCI"},{"termName":"RP5264","termGroup":"CN","termSource":"NCI"},{"termName":"TGR-1202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1532533-67-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"38073MQB2A"},{"name":"Maps_To","value":"Umbralisib"},{"name":"NCI_META_CUI","value":"CL445680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113799":{"preferredName":"Uncaria tomentosa Extract","code":"C113799","definitions":[{"definition":"An extract of Uncaria tomentosa (U. tomentosa), also called Cat's claw, a native Amazonian plant belonging to the Rubiaceae species, with potential anti-inflammatory, immunomodulating, antioxidant and antineoplastic activities. Although the exact mechanism(s) by which U. tomentosa extract exerts its effect(s) has yet to be fully elucidated, this extract may inhibit the proliferation of certain types of cancer cells. This extract may modulate inflammatory and immune responses through the stimulation of T- and B-lymphocytes and certain cytokines, including interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-a). Components in U. tomentosa may both induce repair of chemically-induced DNA damage and scavenge free radicals, which may protect against reactive oxygen species (ROS)-mediated cellular damage. In addition, this extract stimulates myelopoiesis, which may prevent chemotherapy-induced neutropenia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uncaria tomentosa Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Cat's Claw Herbal Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9060PRM18Q"},{"name":"Maps_To","value":"Uncaria tomentosa Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"757651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757651"},{"name":"PDQ_Open_Trial_Search_ID","value":"757651"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0939876"}]}}{"C73985":{"preferredName":"Upamostat","code":"C73985","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks the action of certain enzymes, and it may help keep cancer cells from growing and spreading. It is a type of serine protease inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, upamostat is converted to the active N alpha-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upamostat","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazinecarboxylic Acid, 4-((2S)-3-(3-((E)-Amino(hydroxyimino)methyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"WX-671","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1191101-18-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S5M7KW6U17"},{"name":"Legacy Concept Name","value":"Serine_Protease_Inhibitor_WX-671"},{"name":"Maps_To","value":"Upamostat"},{"name":"NCI_Drug_Dictionary_ID","value":"557106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"557106"},{"name":"PDQ_Open_Trial_Search_ID","value":"557106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348191"}]}}{"C119743":{"preferredName":"Uproleselan","code":"C119743","definitions":[{"definition":"A synthetic, glycomimetic molecule and E-selectin (CD62E) antagonist, with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Upon administration, uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. GMI-1271 also interferes with the binding of selectin E-expressing vascular endothelial cells to selectin-E ligand-expressing monocytes and neutrophils, thereby disrupting their activation. Consequently, this inhibits both the activation of the coagulation cascade and thrombus formation. This agent also prevents both leukocyte activation and inflammation. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis; it also plays a crucial role in inflammatory processes and cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uproleselan","termGroup":"PT","termSource":"NCI"},{"termName":"GMI-1271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1983970-12-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PE952ANF83"},{"name":"Maps_To","value":"Uproleselan"},{"name":"NCI_Drug_Dictionary_ID","value":"767121"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767121"},{"name":"PDQ_Open_Trial_Search_ID","value":"767121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896849"}]}}{"C84870":{"preferredName":"Uprosertib","code":"C84870","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Uprosertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uprosertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Furancarboxamide, N-((1S)-2-Amino-1-((3,4-difluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"GSK2141795","termGroup":"CN","termSource":"NCI"},{"termName":"Oral Akt Inhibitor GSK2141795","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1047634-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZXM835LQ5E"},{"name":"Maps_To","value":"Uprosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"648336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648336"},{"name":"PDQ_Open_Trial_Search_ID","value":"648336"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830127"}]}}{"C91083":{"preferredName":"Uracil Ointment","code":"C91083","definitions":[{"definition":"A 0.1% topical formulation of uracil used potentially to lower the incidence of hand-foot syndrome (HFS) (or palmar-plantar erythrodysesthesia) during 5-fluorouracil (5-FU) or 5-FU prodrug capecitabine chemotherapy. Upon local administration of uracil ointment to the skin, uracil competes with capecitabine or 5-FU as substrates for the activating enzyme thymidine phosphorylase and the metabolizing enzyme dihydropyrimidine dehydrogenase. This may prevent the production of 5-FU as well as the breakdown of 5-FU into the toxic metabolites locally. As the 5-FU metabolites are responsible for the presentation of HFS, inhibiting their formation may prevent this adverse effect. By applying a high concentration of uracil locally, the skin toxicities of 5-FU may be countered while preserving the systemic anti-cancer activity of the 5FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uracil Ointment","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uracil Ointment"},{"name":"NCI_Drug_Dictionary_ID","value":"670894"},{"name":"NCI_META_CUI","value":"CL416292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670894"},{"name":"PDQ_Open_Trial_Search_ID","value":"670894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62449":{"preferredName":"Urelumab","code":"C62449","definitions":[{"definition":"A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137 monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes; its ligand has been found to play an important role in the regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urelumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-663513","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934823-49-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"230902QLLC"},{"name":"Legacy Concept Name","value":"Anti-CD137_Monoclonal_Antibody"},{"name":"Maps_To","value":"Urelumab"},{"name":"NCI_Drug_Dictionary_ID","value":"489120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489120"},{"name":"PDQ_Open_Trial_Search_ID","value":"489120"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831875"}]}}{"C162545":{"preferredName":"Uroacitides","code":"C162545","definitions":[{"definition":"A mixture of peptides, organic acids, pigments, and phenylacetylglutamine isolated from healthy human urine with potential antineoplastic activity. Upon administration, uroacitides, also known as cell differentiation agent II (CDA-II) may inhibit telomerase activity in tumor cells. This may lead to an accumulation of tumor cells in G1 phase and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uroacitides","termGroup":"PT","termSource":"NCI"},{"termName":"CDA-II","termGroup":"AB","termSource":"NCI"},{"termName":"Cell Differentiation Agent II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uroacitides"},{"name":"NCI_META_CUI","value":"CL971119"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C91709":{"preferredName":"Urokinase-Derived Peptide A6","code":"C91709","definitions":[{"definition":"A substance being studied in the treatment of cancer. A6 is a small piece of a protein called urokinase (an enzyme that dissolves blood clots or prevents them from forming). It is a type of antiangiogenesis agent and a type of antimetastatic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urokinase-Derived Peptide A6","termGroup":"PT","termSource":"NCI"},{"termName":"A6","termGroup":"CN","termSource":"NCI"},{"termName":"uPA-derived Peptide A6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220334-14-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KM64V5W7RA"},{"name":"Maps_To","value":"Urokinase-Derived Peptide A6"},{"name":"NCI_Drug_Dictionary_ID","value":"377541"},{"name":"NCI_META_CUI","value":"CL433998"},{"name":"PDQ_Closed_Trial_Search_ID","value":"377541"},{"name":"PDQ_Open_Trial_Search_ID","value":"377541"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121215":{"preferredName":"USP14/UCHL5 Inhibitor VLX1570","code":"C121215","definitions":[{"definition":"An inhibitor of the 19S proteasome-specific deubiquitylating enzymes (DUBs) USP14 and UCHL5, with apoptosis-inducing and antineoplastic activities. Upon administration, VLX1570 specifically binds to both USP14 and UCHL5, thereby blocking their deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. USP14 and UCHL5, overexpressed in various tumor cell types, play a key role in the correct folding and deubiquitination of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"USP14/UCHL5 Inhibitor VLX1570","termGroup":"PT","termSource":"NCI"},{"termName":"VLX1570","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1956378-23-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K6067N5M6N"},{"name":"Maps_To","value":"USP14/UCHL5 Inhibitor VLX1570"},{"name":"NCI_Drug_Dictionary_ID","value":"769736"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769736"},{"name":"PDQ_Open_Trial_Search_ID","value":"769736"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053575"}]}}{"C116619":{"preferredName":"Utomilumab","code":"C116619","definitions":[{"definition":"A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Utomilumab","termGroup":"PT","termSource":"NCI"},{"termName":"PF 05082566","termGroup":"CN","termSource":"NCI"},{"termName":"PF 5082566","termGroup":"CN","termSource":"NCI"},{"termName":"PF-05082566","termGroup":"CN","termSource":"NCI"},{"termName":"PF-2566","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1417318-27-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YY8O697VF"},{"name":"Maps_To","value":"Utomilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"696781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696781"},{"name":"PDQ_Open_Trial_Search_ID","value":"696781"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3529795"}]}}{"C61069":{"preferredName":"V930 Vaccine","code":"C61069","definitions":[{"definition":"A novel cancer vaccine designed to treat HER-2- and/or CEA-expressing cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"V930 Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"V930_Vaccine"},{"name":"Maps_To","value":"V930 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"473030"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473030"},{"name":"PDQ_Open_Trial_Search_ID","value":"473030"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831771"}]}}{"C2542":{"preferredName":"Vaccine-Sensitized Draining Lymph Node Cells","code":"C2542","definitions":[{"definition":"Cells isolated from lymph nodes from patients, and activated in vitro to generate tumor-specific effector T cells.  Lymph nodes in the lymphatics draining tumors often contain T cells that are immunologically sensitized but functionally deficient. Vaccine-sensitized draining lymph node cells are prepared by isolating these lymphocytes in vitro and stimulating them with cytokines to differentiate into mature effector cells.  Vaccine-draining lymph node cells may also be produced by pharmacological activation of lymph node-derived lymphocytes with drugs such as ionomycin or with bacterial toxin; these activated lymphocytes may be expanded in culture with cytokines such as interleukin-2 prior to infusion into the patient. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vaccine-Sensitized Draining Lymph Node Cells","termGroup":"PT","termSource":"NCI"},{"termName":"VDLN Cells","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vaccine-Sensitized_Draining_Lymph_Node_Cells"},{"name":"Maps_To","value":"Vaccine-Sensitized Draining Lymph Node Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"43655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43655"},{"name":"PDQ_Open_Trial_Search_ID","value":"43655"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879357"}]}}{"C102748":{"preferredName":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules","code":"C102748","definitions":[{"definition":"A proprietary suspension formulation prepared from granules of standardized extracts from the fruits of Vaccinium myrtillus, the aerial parts of Macleaya cordata and the roots of Echinacea angustifolia, with potential anti-mucositis, anti-inflammatory, and analgesic activities. The main active ingredients of this formulation include anthocyanosides and procyanidins, benzophenanthridinic alkaloids, and alkylamides from V. myrtillus, M. cordata and E. angustifolia extracts, respectively. Upon administration in the mucosal cavity, the anthocyanosides scavenge free radicals, form a protective barrier on the mucosa, and protect the integrity of the capillary vessels; the benzophenanthridine alkaloids prevent the production of pro-inflammatory cytokines by inhibiting NF-kB and may halt the growth of microorganisms; the alkylamides inhibit cyclooxygenase and 5-lipoxygenase thereby blocking productions of prostaglandin and leukotriene. Furthermore, alkylamides modulate the expression of tumor necrosis factor alpha and other cytokines involved in inflammation processes through cannabinoid type 2 receptors and as cannabinomimetics they may also exert analgesic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules","termGroup":"PT","termSource":"NCI"},{"termName":"Samital Granules","termGroup":"FB","termSource":"NCI"},{"termName":"V. myrtillus/M. cordata/E. angustfolia Extract Granules","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules"},{"name":"NCI_Drug_Dictionary_ID","value":"735790"},{"name":"NCI_META_CUI","value":"CL437005"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735790"},{"name":"PDQ_Open_Trial_Search_ID","value":"735790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116357":{"preferredName":"Vactosertib","code":"C116357","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vactosertib","termGroup":"PT","termSource":"NCI"},{"termName":"TEW-7197","termGroup":"CN","termSource":"NCI"},{"termName":"TEW7197","termGroup":"CN","termSource":"NCI"},{"termName":"TGFBR1 Inhibitor TEW-7197","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1352608-82-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6T4O391P5Y"},{"name":"Maps_To","value":"Vactosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"762093"},{"name":"NCI_META_CUI","value":"CL473674"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762093"},{"name":"PDQ_Open_Trial_Search_ID","value":"762093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133718":{"preferredName":"Vadacabtagene Leraleucel","code":"C133718","definitions":[{"definition":"Genetically modified CD3-positive-enriched autologous T-lymphocytes transduced with a replication incompetent gamma retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, vadacabtagene leraleucel,is directed to CD19-expressing tumor cells, and, upon binding to the T-cells, induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vadacabtagene Leraleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/CD28/zeta Modified CAR CD3+ T Lymphocytes JCAR015","termGroup":"SY","termSource":"NCI"},{"termName":"JCAR 015","termGroup":"CN","termSource":"NCI"},{"termName":"JCAR 15","termGroup":"CN","termSource":"NCI"},{"termName":"JCAR015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Clinical trial NCT02973191 has been terminated due to incidence of neurotoxicity and related deaths. 04/18/2017"},{"name":"FDA_UNII_Code","value":"A4O2H9W17Y"},{"name":"Maps_To","value":"Vadacabtagene Leraleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"788214"},{"name":"NCI_META_CUI","value":"CL520442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788214"},{"name":"PDQ_Open_Trial_Search_ID","value":"788214"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111039":{"preferredName":"Vadastuximab Talirine","code":"C111039","definitions":[{"definition":"An immunoconjugate consisting of a humanized monoclonal antibody that is engineered to contain cysteine residues that are conjugated to the synthetic, DNA cross-linking, pyrrolobenzodiazepine dimer SGD-1882, via the protease-cleavable linker maleimidocaproyl-valine-alanine dipeptide, with potential antineoplastic activity. The monoclonal antibody portion of vadastuximab talirine specifically binds to the cell surface antigen CD33. This causes the internalization of SGN-CD33A, and the release of the cytotoxic moiety SGD-1882. SGD-1882 binds to and crosslinks DNA, which results in both cell cycle arrest and the induction of apoptosis in CD33-expressing tumor cells. CD33, a transmembrane receptor, is expressed on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vadastuximab Talirine","termGroup":"PT","termSource":"NCI"},{"termName":"SGN-CD33A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1436390-64-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T13V17U431"},{"name":"Maps_To","value":"Vadastuximab Talirine"},{"name":"NCI_Drug_Dictionary_ID","value":"751848"},{"name":"NCI_META_CUI","value":"CL453546"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751848"},{"name":"PDQ_Open_Trial_Search_ID","value":"751848"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2504":{"preferredName":"Vadimezan","code":"C2504","definitions":[{"definition":"A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis.  This agent also stimulates the anti-tumor activity of tumor-associated macrophages.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vadimezan","termGroup":"PT","termSource":"NCI"},{"termName":"5,6-Dimethylxanthenone-4-Acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5,6-MexXAA","termGroup":"AB","termSource":"NCI"},{"termName":"ASA404","termGroup":"CN","termSource":"NCI"},{"termName":"Dimethyloxoxanthene Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylxanthenone Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"DMXAA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"117570-53-3"},{"name":"Chemical_Formula","value":"C17H14O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0829J8133H"},{"name":"Legacy Concept Name","value":"Dimethylxanthenone_Acetic_Acid"},{"name":"Maps_To","value":"Vadimezan"},{"name":"NCI_Drug_Dictionary_ID","value":"43320"},{"name":"NSC Number","value":"640488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43320"},{"name":"PDQ_Open_Trial_Search_ID","value":"43320"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2930490"}]}}{"C29536":{"preferredName":"Valproic Acid","code":"C29536","definitions":[{"definition":"A drug used to treat epileptic seizures and bipolar disorder and to prevent migraine headaches. It is also being studied in the treatment of several types of cancer. It blocks an enzyme that cells need to grow and may cause cancer cells to die. It also blocks the growth of new blood vessels that tumors need to grow. It is a type of anticonvulsant, histone deacetylase (HDAC) inhibitor, antimaniacal, migraine headache prophylactic, and antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valproic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propylpentanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"2-Propylvaleric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Depakene","termGroup":"BR","termSource":"NCI"},{"termName":"Di-n-propylacetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Valproate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Epilepsy; Mania; Migraine"},{"name":"CAS_Registry","value":"99-66-1"},{"name":"CHEBI_ID","value":"CHEBI:39867"},{"name":"Chemical_Formula","value":"C8H16O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"614OI1Z5WI"},{"name":"Legacy Concept Name","value":"Valproic_Acid"},{"name":"Maps_To","value":"Valproic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"350047"},{"name":"NSC Number","value":"93819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350047"},{"name":"PDQ_Open_Trial_Search_ID","value":"350047"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042291"}]}}{"C1340":{"preferredName":"Valrubicin","code":"C1340","definitions":[{"definition":"A drug used to treat bladder cancer that does not respond to BCG (Bacillus Calmette Guerin). It is an anthracycline and is a type of antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valrubicin","termGroup":"PT","termSource":"NCI"},{"termName":"AD 32","termGroup":"CN","termSource":"NCI"},{"termName":"AD-32","termGroup":"CN","termSource":"NCI"},{"termName":"N-Trifluoroacetyladriamycin-14-valerate","termGroup":"SN","termSource":"NCI"},{"termName":"Valstar","termGroup":"BR","termSource":"NCI"},{"termName":"Valtaxin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56124-62-0"},{"name":"Chemical_Formula","value":"C34H36F3NO13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2C6NUM6878"},{"name":"Legacy Concept Name","value":"Valrubicin"},{"name":"Maps_To","value":"Valrubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39135"},{"name":"NSC Number","value":"246131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39135"},{"name":"PDQ_Open_Trial_Search_ID","value":"39135"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068314"}]}}{"C1405":{"preferredName":"Valspodar","code":"C1405","definitions":[{"definition":"A substance that is being studied for its ability to prevent or overcome the resistance of tumor cells to some anticancer drugs. It belongs to the family of drugs called cyclosporine analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valspodar","termGroup":"PT","termSource":"NCI"},{"termName":"6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic Acid]cyclosporin D","termGroup":"SN","termSource":"NCI"},{"termName":"Amdray","termGroup":"BR","termSource":"NCI"},{"termName":"Cyclo((2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl)-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-me","termGroup":"SN","termSource":"NCI"},{"termName":"PSC-833","termGroup":"CN","termSource":"NCI"},{"termName":"PSC833","termGroup":"CN","termSource":"NCI"},{"termName":"SZD PSC 833","termGroup":"CN","termSource":"NCI"},{"termName":"VP16","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"121584-18-7"},{"name":"Chemical_Formula","value":"C63H111N11O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q7ZP55KF3X"},{"name":"Legacy Concept Name","value":"Valspodar"},{"name":"Maps_To","value":"Valspodar"},{"name":"NCI_Drug_Dictionary_ID","value":"41750"},{"name":"NSC Number","value":"648265"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41750"},{"name":"PDQ_Open_Trial_Search_ID","value":"41750"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0753474"}]}}{"C2737":{"preferredName":"Vandetanib","code":"C2737","definitions":[{"definition":"A substance being studied in the treatment of lung cancer and other types of cancer. It may block the growth and spread of tumor cells and prevent the growth of new blood vessels that tumors need to grow. Vandetanib is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vandetanib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD6474","termGroup":"CN","termSource":"NCI"},{"termName":"Caprelsa","termGroup":"BR","termSource":"NCI"},{"termName":"Lucivand","termGroup":"FB","termSource":"NCI"},{"termName":"Zactima","termGroup":"BR","termSource":"NCI"},{"termName":"ZD-6474","termGroup":"CN","termSource":"NCI"},{"termName":"ZD6474","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Thyroid Cancer"},{"name":"CAS_Registry","value":"443913-73-3"},{"name":"CHEBI_ID","value":"CHEBI:49960"},{"name":"Chemical_Formula","value":"C22H24BrFN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YO460OQ37K"},{"name":"Legacy Concept Name","value":"ZD-6474"},{"name":"Maps_To","value":"Vandetanib"},{"name":"NCI_Drug_Dictionary_ID","value":"269177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269177"},{"name":"PDQ_Open_Trial_Search_ID","value":"269177"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1384659"}]}}{"C150384":{"preferredName":"Vandetanib-eluting Radiopaque Bead BTG-002814","code":"C150384","definitions":[{"definition":"Radiopaque drug-eluting beads (DEBs) that are loaded with vandetanib, a dual inhibitor of both vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with potential antineoplastic, anti-angiogenic and imaging activities. Upon intra-arterial hepatic artery administration of vandetanib (VTB)-eluting Radiopaque beads (VERBs) BTG-002814, the DEBs occlude the tumor blood vessels and deprive tumor cells of oxygen and nutrients, thereby causing hepatic arterial embolization and direct tumor cell death. The VERBs release vandetanib from the beads in a sustained manner. Vandetanib selectively inhibits the tyrosine kinase activity of both VEGFR and EGFR, thereby blocking both VEGF/VEGFR- and EGF/EGFR-stimulated signaling and inhibiting cell proliferation, migration and angiogenesis in VEGFR/EGFR-expressing hepatic tumor cells. The DEBs, controlled release microspherical devices, cause low systemic exposure and prevent systemic toxicity of vandetanib. DEBs also deliver high concentrations of vandetanib in the tumor for a controlled and extended period of time. Use of radiopaque DEBs allows for visualization of both the bead location and the degree of embolization upon imaging.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vandetanib-eluting Radiopaque Bead BTG-002814","termGroup":"PT","termSource":"NCI"},{"termName":"BTG-002814","termGroup":"CN","termSource":"NCI"},{"termName":"Vandetanib-eluting Radiopaque Embolic Beads","termGroup":"SY","termSource":"NCI"},{"termName":"VERB","termGroup":"AB","termSource":"NCI"},{"termName":"VERB BTG-002814","termGroup":"SY","termSource":"NCI"},{"termName":"VTB-loaded Beads","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vandetanib-eluting Radiopaque Bead BTG-002814"},{"name":"NCI_Drug_Dictionary_ID","value":"792793"},{"name":"NCI_META_CUI","value":"CL552167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792793"},{"name":"PDQ_Open_Trial_Search_ID","value":"792793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116748":{"preferredName":"Vandortuzumab Vedotin","code":"C116748","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the six transmembrane epithelial antigen of the prostate 1 (STEAP1), and conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of vandortuzumab vedotin, the monoclonal antibody moiety of vandortuzumab vedotin binds to STEAP1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. STEAP1, a tumor-associated antigen (TAA), is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vandortuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"DSTP3086S","termGroup":"CN","termSource":"NCI"},{"termName":"MSTP2109A","termGroup":"CN","termSource":"NCI"},{"termName":"RG7450","termGroup":"CN","termSource":"NCI"},{"termName":"Thio-anti-STEAP1-MC-vc-PAB-MMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1471985-92-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44OUQ00D1U"},{"name":"Maps_To","value":"Vandortuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"694576"},{"name":"NCI_META_CUI","value":"CL433770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694576"},{"name":"PDQ_Open_Trial_Search_ID","value":"694576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96799":{"preferredName":"Vantictumab","code":"C96799","definitions":[{"definition":"A monoclonal antibody directed against the Wnt signaling pathway with potential antineoplastic activity. Upon administration, vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This may result in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. The Wnt signaling pathway is dysregulated in many cancer cell types and appears to play a major role in CSC regulation and activity; CSC are tumor initiating cells that are able to self-renew and are responsible for tumor growth and resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vantictumab","termGroup":"PT","termSource":"NCI"},{"termName":"OMP-18R5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1345009-45-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"88WBI2D80S"},{"name":"Maps_To","value":"Vantictumab"},{"name":"NCI_Drug_Dictionary_ID","value":"700131"},{"name":"NCI_META_CUI","value":"CL429406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700131"},{"name":"PDQ_Open_Trial_Search_ID","value":"700131"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118578":{"preferredName":"Vanucizumab","code":"C118578","definitions":[{"definition":"A humanized bispecific immunoglobulin G (IgG1) monoclonal antibody targeting both the vascular endothelial growth factor receptor (VEGFR) ligand VEGF-A and the Tie2 receptor ligand angiopoietin-2 (Ang-2), with potential antineoplastic and anti-angiogenic activities. Upon administration of vanucizumab, the anti-VEGF-A arm, which is based on bevacizumab, targets and binds to VEGF-A and the anti-Ang2 arm, which is based on the anti-Ang-2 antibody LC06, targets and binds to Ang2, thereby simultaneously binding and neutralizing both VEGF-A and Ang2. This prevents the activation of both VEGF-A/VEGFR- and Ang2/Tie2-mediated signaling pathways. Altogether, this results in the inhibition of proliferation of VEGF-A- and/or Ang2-overexpressing tumor cells. VEGF-A and Ang2, both upregulated in a variety of tumor cell types, play key roles in tumor cell proliferation, angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vanucizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Ang2-VEGF-A CrossMab RO5520985","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Recombined G1-kappa/lambda, Anti-(Homo sapiens Angpt2 (Angiopoietin 2, Ang2))/Anti-Homo sapiens VEGFa (Vascular Endothelial Growth Factor A, VEGF-a, VEGF)), Humanized Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"RG-7221","termGroup":"CN","termSource":"NCI"},{"termName":"RG7221","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5520985","termGroup":"CN","termSource":"NCI"},{"termName":"RO5520985","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448221-05-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B800Z06O8K"},{"name":"Maps_To","value":"Vanucizumab"},{"name":"NCI_META_CUI","value":"CL446653"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1429":{"preferredName":"Vapreotide","code":"C1429","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called somatostatin analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic cyclic octapeptide analogue of somatostatin with direct and indirect antitumor effects. Vapreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and to SSTR-5 with a lesser affinity, in the similar behaviors as other octapeptide somatostatin analogues. Like octreotide, this agent has direct and indirect antitumor effects via inhibiting the release of growth hormone and other peptides that regulate release of insulin, gastrointestinal hormones. Furthermore, vapreotide may also be useful for inducing hemostasis in cases of acute hemorrhage of the upper gastrointestinal tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vapreotide","termGroup":"PT","termSource":"NCI"},{"termName":"BMY-41606","termGroup":"CN","termSource":"NCI"},{"termName":"Docrised","termGroup":"FB","termSource":"NCI"},{"termName":"RC-160","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103222-11-3"},{"name":"Chemical_Formula","value":"C57H70N12O9S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2PK59M9GFF"},{"name":"Legacy Concept Name","value":"Vapreotide"},{"name":"Maps_To","value":"Vapreotide"},{"name":"NCI_Drug_Dictionary_ID","value":"38258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38258"},{"name":"PDQ_Open_Trial_Search_ID","value":"38258"},{"name":"PubMedID_Primary_Reference","value":"16917205"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0164678"}]}}{"C99127":{"preferredName":"Varlilumab","code":"C99127","definitions":[{"definition":"A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of varlilumab, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Varlilumab","termGroup":"PT","termSource":"NCI"},{"termName":"CDX 1127","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-1127","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1393344-72-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0125DUV5XC"},{"name":"Maps_To","value":"Varlilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"715751"},{"name":"NCI_META_CUI","value":"CL432946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715751"},{"name":"PDQ_Open_Trial_Search_ID","value":"715751"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62530":{"preferredName":"Varlitinib","code":"C62530","definitions":[{"definition":"An orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Varlitinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-334543","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845272-21-1"},{"name":"Chemical_Formula","value":"C22H19ClN6O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"846Y8197W1"},{"name":"Legacy Concept Name","value":"ARRY-334543"},{"name":"Maps_To","value":"Varlitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"487532"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487532"},{"name":"PDQ_Open_Trial_Search_ID","value":"487532"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831861"}]}}{"C95226":{"preferredName":"Varlitinib Tosylate","code":"C95226","definitions":[{"definition":"The tosylate salt form of varlitinib, an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Varlitinib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"4,6-Quinazolinediamine, N(Sup 4)-(3-Chloro-4-(2-Thiazolylmethoxy)Phenyl)-N(Sup 6)-((4r)-4,5-Dihydro-4-Methyl-2-Oxazolyl)-, 4-Methylbenzenesulphonate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"4-N-(3-Chloro-4-(Thiazol-2-Ylmethoxy)Phenyl)-6-N-((4r)-4-Methyl-4,5-Dihydrooxazol-2- Yl)Quinazoline-4,6-Diamine Bis(4-Methylbenzenesulphonate)","termGroup":"SN","termSource":"NCI"},{"termName":"AR00334543 Ditosilate","termGroup":"CN","termSource":"NCI"},{"termName":"AR00334543 Ditosylate","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-334543 Ditosylate","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-543 Ditosilate","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-543 Ditosylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1146629-86-8"},{"name":"Chemical_Formula","value":"C22H19ClN6O2S.2C7H8O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V4M8FWS152"},{"name":"Maps_To","value":"Varlitinib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"793457"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793457"},{"name":"PDQ_Open_Trial_Search_ID","value":"793457"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987008"}]}}{"C162343":{"preferredName":"Vascular Disrupting Agent BNC105","code":"C162343","definitions":[{"definition":"A vascular disrupting agent (VDA), with potential anti-vascular and antineoplastic activities. Upon administration, vascular disrupting agent BNC105 binds to tubulin and inhibits its polymerization, which results in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. This deprives tumor cells of nutrients and results in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Disrupting Agent BNC105","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran","termGroup":"SY","termSource":"NCI"},{"termName":"BNC 105","termGroup":"CN","termSource":"NCI"},{"termName":"BNC-105","termGroup":"CN","termSource":"NCI"},{"termName":"BNC105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945771-74-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z3S2Z6H7B0"},{"name":"Maps_To","value":"Vascular Disrupting Agent BNC105"},{"name":"NCI_META_CUI","value":"CL970840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88338":{"preferredName":"Vascular Disrupting Agent BNC105P","code":"C88338","definitions":[{"definition":"A benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Disrupting Agent BNC105P","termGroup":"PT","termSource":"NCI"},{"termName":"BNC105P","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945771-96-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E3052198GM"},{"name":"Maps_To","value":"Vascular Disrupting Agent BNC105P"},{"name":"NCI_Drug_Dictionary_ID","value":"662727"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662727"},{"name":"PDQ_Open_Trial_Search_ID","value":"662727"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981856"}]}}{"C2736":{"preferredName":"Vascular Disrupting Agent ZD6126","code":"C2736","definitions":[{"definition":"A substance that has been studied in the treatment of several types of cancer. ZD6126 destroys blood vessels in tumors and may prevent the growth of new blood vessels that tumors need to grow. It is a type of vascular targeting agent and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. ZD-6126 is converted in vivo into N-acetylcolchinol. N-acetylcolchinol binds to and destabilizes the tubulin cytoskeleton of endothelial cells in tumor blood vessels, which may result in tumor endothelial cell apoptosis, the selective occlusion of tumor blood vessels, cessation of tumor blood flow, and tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Disrupting Agent ZD6126","termGroup":"PT","termSource":"NCI"},{"termName":"ANG453","termGroup":"CN","termSource":"NCI"},{"termName":"N-[(5S)-6,7-Dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-acetylcochinol-O-phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"ZD-6126","termGroup":"CN","termSource":"NCI"},{"termName":"ZD6126","termGroup":"SY","termSource":"NCI"},{"termName":"ZM-445526","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"219923-05-4"},{"name":"Chemical_Formula","value":"C20H24NO8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GBO3S6M9W7"},{"name":"Legacy Concept Name","value":"ZD-6126"},{"name":"Maps_To","value":"Vascular Disrupting Agent ZD6126"},{"name":"NCI_Drug_Dictionary_ID","value":"353153"},{"name":"PDQ_Closed_Trial_Search_ID","value":"353153"},{"name":"PDQ_Open_Trial_Search_ID","value":"353153"},{"name":"PubMedID_Primary_Reference","value":"18219445"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122628"}]}}{"C1868":{"preferredName":"Vatalanib","code":"C1868","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and VEGF receptor kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vatalanib","termGroup":"PT","termSource":"NCI"},{"termName":"CGP 79787","termGroup":"CN","termSource":"NCI"},{"termName":"CGP-79787","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine","termGroup":"SN","termSource":"NCI"},{"termName":"PTK787","termGroup":"CN","termSource":"NCI"},{"termName":"ZK-232934","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"212141-54-3"},{"name":"Chemical_Formula","value":"C20H15ClN4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5DX9U76296"},{"name":"Legacy Concept Name","value":"PTK787"},{"name":"Maps_To","value":"Vatalanib"},{"name":"NCI_Drug_Dictionary_ID","value":"43530"},{"name":"NSC Number","value":"719335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43530"},{"name":"PDQ_Open_Trial_Search_ID","value":"43530"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0912586"}]}}{"C74945":{"preferredName":"Vatalanib Succinate","code":"C74945","definitions":[{"definition":"The succinate salt of vatalanib, an anilinophthalazine derivative, with antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vatalanib Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"1-[4-Chloroanilino]-4-[4-pyridylmethyl]phthalazine Succinate","termGroup":"SN","termSource":"NCI"},{"termName":"CGP 79787D","termGroup":"CN","termSource":"NCI"},{"termName":"PTK 787","termGroup":"CN","termSource":"NCI"},{"termName":"PTK-787","termGroup":"CN","termSource":"NCI"},{"termName":"PTK787","termGroup":"CN","termSource":"NCI"},{"termName":"ZK 222584","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"212142-18-2"},{"name":"Chemical_Formula","value":"C20H15ClN4.C4H6O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V5FUB77031"},{"name":"Legacy Concept Name","value":"Vatalanib_Succinate"},{"name":"Maps_To","value":"Vatalanib Succinate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1524078"}]}}{"C136416":{"preferredName":"Vecabrutinib","code":"C136416","definitions":[{"definition":"An orally available second-generation, reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, vecabrutinib non-covalently binds to and inhibits the activity of both wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, SNS-062 does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. Other irreversible BTK inhibitors covalently bind to the C481 site to inhibit BTK's activity; the C481S mutation prevents that binding. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vecabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB-062","termGroup":"CN","termSource":"NCI"},{"termName":"BIIB062","termGroup":"CN","termSource":"NCI"},{"termName":"BSK-4841","termGroup":"CN","termSource":"NCI"},{"termName":"FP-182","termGroup":"CN","termSource":"NCI"},{"termName":"SNS 062","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-062","termGroup":"CN","termSource":"NCI"},{"termName":"SNS062","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1510829-06-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PQ7O0OB5GU"},{"name":"Maps_To","value":"Vecabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"789221"},{"name":"NCI_META_CUI","value":"CL523719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789221"},{"name":"PDQ_Open_Trial_Search_ID","value":"789221"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70971":{"preferredName":"Vector-peptide Conjugated Paclitaxel","code":"C70971","definitions":[{"definition":"A proprietary conjugate of paclitaxel with antineoplastic activity. Similar to the free drug, the paclitaxel moiety in vector-peptide conjugated paclitaxel binds to and stabilizes tubulin molecules, promoting assembly of microtubules and inhibiting tubulin disassembly which results in the inhibition of cell division. The Kunitz domain-derived vector-peptide carries the conjugated paclitaxel through the blood brain barrier (BBB), bypassing the transmembrane p-glycoprotein (P-gp) efflux pump, which may result in higher concentrations of paclitaxel in the brain parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vector-peptide Conjugated Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"Taxol-Angiopep Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vector-peptide_Conjugated_Paclitaxel"},{"name":"Maps_To","value":"Vector-peptide Conjugated Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"574047"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574047"},{"name":"PDQ_Open_Trial_Search_ID","value":"574047"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2349111"}]}}{"C95798":{"preferredName":"Vedolizumab","code":"C95798","definitions":[{"definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vedolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Entyvio","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Integrin LPAM-1 (Lymphocyte Peyer's Patch Adhesion Molecule 1)) (Human-Mus musculus Heavy Chain), Disulfide with Human-Mus musculus kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"LDP 02","termGroup":"CN","termSource":"NCI"},{"termName":"LDP-02","termGroup":"CN","termSource":"NCI"},{"termName":"LDP02","termGroup":"CN","termSource":"NCI"},{"termName":"MLN0002","termGroup":"CN","termSource":"NCI"},{"termName":"MLN02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of ulcerative colitis and Crohn's disease"},{"name":"CAS_Registry","value":"943609-66-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RV78Q2002"},{"name":"Maps_To","value":"Vedolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"781604"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781604"},{"name":"PDQ_Open_Trial_Search_ID","value":"781604"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742797"}]}}{"C91100":{"preferredName":"Emvododstat","code":"C91100","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor (VEGF) synthesis with potential antiangiogenesis and antineoplastic activities. Emvododstat targets post-transcriptionally by selectively binding the 5'- and 3'-untranslated regions (UTR) of VEGF messenger RNA (mRNA), thereby preventing translation of VEGF. This inhibits VEGF protein production and decreases its levels in the tumor and bloodstream. In turn, this may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and eventually the induction of tumor cell death. VEGFs are upregulated in a variety of tumor cell types and play key roles during angiogenesis. In addition, emvododstat may enhance the antitumor activity of other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emvododstat","termGroup":"PT","termSource":"NCI"},{"termName":"PTC299","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256565-36-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"053QD2I96A"},{"name":"Maps_To","value":"VEGF Inhibitor PTC299"},{"name":"NCI_Drug_Dictionary_ID","value":"564407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564407"},{"name":"PDQ_Open_Trial_Search_ID","value":"564407"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984037"}]}}{"C117236":{"preferredName":"VEGF/HGF-targeting DARPin MP0250","code":"C117236","definitions":[{"definition":"A designed ankyrin repeat proteins (DARPin)-based agent targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), with potential antiangiogenic and antineoplastic activities. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the VEGF/HGF-targeting DARPin MP0250 binds to and inhibits both HGF and VEGF. This prevents HGF- and VEGF-mediated signaling, and inhibits the growth of HGF/VEGF-overexpressing tumor cells. This agent also prevents osteolysis, due to the inhibitory effect on HGF signaling. HGF and VEGF are overexpressed in a variety of cancer cell types and are associated with increased cell proliferation, migration and adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGF/HGF-targeting DARPin MP0250","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific VEGF/HGF-targeting Darpin","termGroup":"SY","termSource":"NCI"},{"termName":"MP0250","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1816305-70-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UGI01OSA4N"},{"name":"Maps_To","value":"VEGF/HGF-targeting DARPin MP0250"},{"name":"NCI_Drug_Dictionary_ID","value":"763220"},{"name":"NCI_META_CUI","value":"CL474108"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763220"},{"name":"PDQ_Open_Trial_Search_ID","value":"763220"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88267":{"preferredName":"VEGFR Inhibitor KRN951","code":"C88267","definitions":[{"definition":"An orally bioavailable quinoline-urea derivative inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1 and 2 with potential antiangiogenesis and antineoplastic activities. VEGFR inhibitor KRN951 inhibits VEGF-induced phosphorylation of VEGFRs 1 and 2, which may result in inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR Inhibitor KRN951","termGroup":"PT","termSource":"NCI"},{"termName":"KRN951","termGroup":"CN","termSource":"NCI"},{"termName":"N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) Urea Hydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"VEGFR Inhibitor KRN951"},{"name":"NCI_Drug_Dictionary_ID","value":"655018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655018"},{"name":"PDQ_Open_Trial_Search_ID","value":"655018"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2976524"}]}}{"C99378":{"preferredName":"VEGFR-2 DNA Vaccine VXM01","code":"C99378","definitions":[{"definition":"An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR-2 DNA Vaccine VXM01","termGroup":"PT","termSource":"NCI"},{"termName":"VXM01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"VEGFR-2 DNA Vaccine VXM01"},{"name":"NCI_Drug_Dictionary_ID","value":"719728"},{"name":"NCI_META_CUI","value":"CL433162"},{"name":"PDQ_Closed_Trial_Search_ID","value":"719728"},{"name":"PDQ_Open_Trial_Search_ID","value":"719728"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118628":{"preferredName":"VEGFR/FGFR Inhibitor ODM-203","code":"C118628","definitions":[{"definition":"An orally available inhibitor of the human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), with potential antiangiogenic and antineoplastic activities. VEGFR/FGFR inhibitor ODM-203 inhibits both VEGFRs and FGFRs, which may result in the inhibition of VEGFR- and FGFR-mediated signaling. This leads to an inhibition of angiogenesis and cell proliferation in tumor cells overexpressing VEGFR and/or FGFR. Both VEGFRs and FGFRs belong to the superfamily of receptor tyrosine kinases and are upregulated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR/FGFR Inhibitor ODM-203","termGroup":"PT","termSource":"NCI"},{"termName":"ODM 203","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1430723-35-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y7HJ4D4CRT"},{"name":"Maps_To","value":"VEGFR/FGFR Inhibitor ODM-203"},{"name":"NCI_Drug_Dictionary_ID","value":"765615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765615"},{"name":"PDQ_Open_Trial_Search_ID","value":"765615"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896799"}]}}{"C79794":{"preferredName":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593","code":"C79794","definitions":[{"definition":"An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593","termGroup":"PT","termSource":"NCI"},{"termName":"TAK-593","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005780-62-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H3I42X8XX7"},{"name":"Legacy Concept Name","value":"VEGFR_PDGFR_Tyrosine_Kinase_Inhibitor_TAK-593"},{"name":"Maps_To","value":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593"},{"name":"NCI_Drug_Dictionary_ID","value":"618858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"618858"},{"name":"PDQ_Open_Trial_Search_ID","value":"618858"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703162"}]}}{"C97950":{"preferredName":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210","code":"C97950","definitions":[{"definition":"An orally available ATP-competitive inhibitor of the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, the VEGFR2 tyrosine kinase inhibitor PF-00337210 selectively binds to VEGFR2 and prevents its phosphorylation which may result in an inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and may eventually cause tumor cell death. VEGFR2, a receptor tyrosine kinase, is frequently overexpressed by a variety of tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210","termGroup":"PT","termSource":"NCI"},{"termName":"PF-00337210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"854514-88-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3K3KYC9LES"},{"name":"Maps_To","value":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210"},{"name":"NCI_Drug_Dictionary_ID","value":"709389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709389"},{"name":"PDQ_Open_Trial_Search_ID","value":"709389"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3253799"}]}}{"C61507":{"preferredName":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813","code":"C61507","definitions":[{"definition":"An orally-active, tyrosine kinase receptor inhibitor with potential antitumor activity. SU014813 binds to and inhibits the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-Kit and Fms-related tyrosine kinase 3 (Flt-3). This leads to an inhibition of cellular proliferation and angiogenesis and an induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"452105-23-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZZ6VH5MZ17"},{"name":"Legacy Concept Name","value":"SU014813"},{"name":"Maps_To","value":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813"},{"name":"NCI_Drug_Dictionary_ID","value":"486831"},{"name":"NCI_META_CUI","value":"CL937294"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486831"},{"name":"PDQ_Open_Trial_Search_ID","value":"486831"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60768":{"preferredName":"Veliparib","code":"C60768","definitions":[{"definition":"A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. ABT-888 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Veliparib","termGroup":"PT","termSource":"NCI"},{"termName":"2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ABT-888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"912444-00-9"},{"name":"CHEBI_ID","value":"CHEBI:62880"},{"name":"Chemical_Formula","value":"C13H16N4O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"01O4K0631N"},{"name":"Legacy Concept Name","value":"ABT-888"},{"name":"Maps_To","value":"Veliparib"},{"name":"NCI_Drug_Dictionary_ID","value":"496464"},{"name":"NSC Number","value":"737664"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496464"},{"name":"PDQ_Open_Trial_Search_ID","value":"496464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1958300"}]}}{"C48406":{"preferredName":"Veltuzumab","code":"C48406","definitions":[{"definition":"A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in cells that overexpress CD20. CD20 antigen is a hydrophobic transmembrane protein located on pre-B and mature B lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. IMMU-106 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Veltuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody hA20","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-106","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb hA20","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody hA20","termGroup":"SY","termSource":"NCI"},{"termName":"Veltuzumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-Hodgkin's lymphoma"},{"name":"CAS_Registry","value":"728917-18-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"BPD4DGQ314"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_hA20"},{"name":"Maps_To","value":"Veltuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"428486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"428486"},{"name":"PDQ_Open_Trial_Search_ID","value":"428486"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2746054"}]}}{"C64768":{"preferredName":"Vemurafenib","code":"C64768","definitions":[{"definition":"A substance being studied in the treatment of cancer. BRAF (V600E) kinase is a mutated (changed) form of a cell protein called BRAF. It is found in several types of cancer, including melanoma (a type of skin cancer). Inhibiting this kinase may cause cancer cells to die. BRAF (V600E) kinase is a type of serine/threonine kinase inhibitor and a type of targeted therapy agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vemurafenib","termGroup":"PT","termSource":"NCI"},{"termName":"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BRAF(V600E) Kinase Inhibitor RO5185426","termGroup":"SY","termSource":"NCI"},{"termName":"PLX-4032","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7204","termGroup":"CN","termSource":"NCI"},{"termName":"RG7204","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5185426","termGroup":"CN","termSource":"NCI"},{"termName":"Zelboraf","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced Melanoma"},{"name":"CAS_Registry","value":"918504-65-1"},{"name":"CHEBI_ID","value":"CHEBI:63637"},{"name":"Chemical_Formula","value":"C23H18ClF2N3O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"207SMY3FQT"},{"name":"Legacy Concept Name","value":"PLX4032"},{"name":"Maps_To","value":"Vemurafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"528954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"528954"},{"name":"PDQ_Open_Trial_Search_ID","value":"528954"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832009"}]}}{"C103147":{"preferredName":"Venetoclax","code":"C103147","definitions":[{"definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venetoclax","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"ABT-0199","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-199","termGroup":"CN","termSource":"NCI"},{"termName":"ABT199","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0199","termGroup":"CN","termSource":"NCI"},{"termName":"RG7601","termGroup":"CN","termSource":"NCI"},{"termName":"Venclexta","termGroup":"BR","termSource":"NCI"},{"termName":"Venclyxto","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia (CLL) with 17p deletion and or small lymphocytic lymphoma (SLL)"},{"name":"CAS_Registry","value":"1257044-40-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"N54AIC43PW"},{"name":"Maps_To","value":"Venetoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"698675"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698675"},{"name":"PDQ_Open_Trial_Search_ID","value":"698675"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659811"}]}}{"C928":{"preferredName":"Verapamil","code":"C928","definitions":[{"definition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verapamil","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52-53-9"},{"name":"CHEBI_ID","value":"CHEBI:9948"},{"name":"Chemical_Formula","value":"C27H38N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CJ0O37KU29"},{"name":"Legacy Concept Name","value":"Verapamil"},{"name":"Maps_To","value":"Verapamil"},{"name":"NCI_Drug_Dictionary_ID","value":"39730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39730"},{"name":"PDQ_Open_Trial_Search_ID","value":"39730"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042523"}]}}{"C2811":{"preferredName":"Verpasep Caltespen","code":"C2811","definitions":[{"definition":"A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7.  Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers.  E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cancer. It belongs to the family of drugs called fusion proteins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Verpasep Caltespen","termGroup":"PT","termSource":"NCI"},{"termName":"BCG65-E7","termGroup":"SY","termSource":"NCI"},{"termName":"Bovine HSP fusion with E7 of HPV16","termGroup":"SY","termSource":"NCI"},{"termName":"HPV 16 E7/HSP65 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HPV E7 Peptide Epitope Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HspE7","termGroup":"AB","termSource":"NCI"},{"termName":"SGN-00101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"295371-00-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z7T0JI2E2I"},{"name":"Legacy Concept Name","value":"HspE7"},{"name":"Maps_To","value":"Verpasep Caltespen"},{"name":"NCI_Drug_Dictionary_ID","value":"269165"},{"name":"NSC Number","value":"713219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269165"},{"name":"PDQ_Open_Trial_Search_ID","value":"269165"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327844"}]}}{"C96747":{"preferredName":"Verubulin","code":"C96747","definitions":[{"definition":"A quinazoline derivative with potential antineoplastic activities. Verubulin binds to and inhibits tubulin polymerization and interrupts microtubule formation, resulting in disruption of mitotic spindle assembly, cell cycle arrest in the G2/M phase, and cell death. This agent is not a substrate for several subtypes of multidrug resistance ABC transporters, and may be useful for treating multidrug resistant tumors. In addition, as a vascular disrupting agent, verubulin disrupts tumor microvasculature specifically, which may result in acute ischemia and massive tumor cell death. In addition, verubulin is able to cross the blood-brain barrier and accumulate in the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verubulin","termGroup":"PT","termSource":"NCI"},{"termName":"4-quinazolinamine, N-(4-methoxyphenyl)-N,2-dimethyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MX-128495","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"827031-83-4"},{"name":"Chemical_Formula","value":"C17H17N3O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X97O9FTB92"},{"name":"Maps_To","value":"Verubulin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002404"}]}}{"C64782":{"preferredName":"Verubulin Hydrochloride","code":"C64782","definitions":[{"definition":"The hydrochloride salt form of verubulin, a quinazoline derivative with potential dual antineoplastic activities. Verubulin binds to and inhibits tubulin polymerization and interrupts microtubule formation, resulting in disruption of mitotic spindle assembly, cell cycle arrest in the G2/M phase, and cell death. This agent is not a substrate for several subtypes of multidrug resistance ABC transporters, such as P-glycoprotein, multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1); therefore, it may be useful for treating multidrug resistant (MDR) tumors that express these transporters. In addition, as a vascular disrupting agent (VDA), verubulin appears to disrupt tumor microvasculature specifically, which may result in acute ischemia and massive tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verubulin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Azixa","termGroup":"BR","termSource":"NCI"},{"termName":"Microtubule Inhibitor MPC-6827","termGroup":"SY","termSource":"NCI"},{"termName":"MPC-6827","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-methoxyphenyl)-n,2-dimethylquinazolin-4-amine Hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917369-31-4"},{"name":"Chemical_Formula","value":"C17H17N3O.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33380QZ0QW"},{"name":"Legacy Concept Name","value":"MPC-6827"},{"name":"Maps_To","value":"Verubulin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"526176"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526176"},{"name":"PDQ_Open_Trial_Search_ID","value":"526176"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832001"}]}}{"C113653":{"preferredName":"Vesigenurtucel-L","code":"C113653","definitions":[{"definition":"An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of vesigenurtucel-L, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vesigenurtucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"HS-410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9IE620X9FY"},{"name":"Maps_To","value":"Vesigenurtucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"756851"},{"name":"NCI_META_CUI","value":"CL458366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756851"},{"name":"PDQ_Open_Trial_Search_ID","value":"756851"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2016":{"preferredName":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220","code":"C2016","definitions":[{"definition":"A mixed-backbone antisense oligonucleotide that is complementary to a pro-angiogenic vascular endothelial growth factor (VEGF) mRNA sequence.  Because of its antiangiogenic properties, GEM 220 has been studied as a potential antineoplastic agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220","termGroup":"PT","termSource":"NCI"},{"termName":"GEM 220","termGroup":"CN","termSource":"NCI"},{"termName":"Gene Expression Modulator 220","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GEM_220"},{"name":"Maps_To","value":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517360"}]}}{"C49090":{"preferredName":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820","code":"C49090","definitions":[{"definition":"An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the receptor tyrosine kinases for vascular endothelial growth factor (VEGF), c-kit, and platelet-derived growth factor (PDGF). In tumor models of breast carcinomas, gliomas, and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820","termGroup":"PT","termSource":"NCI"},{"termName":"XL 820","termGroup":"CN","termSource":"NCI"},{"termName":"XL-820","termGroup":"CN","termSource":"NCI"},{"termName":"XL820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XL820"},{"name":"Maps_To","value":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820"},{"name":"NCI_Drug_Dictionary_ID","value":"452042"},{"name":"NCI_META_CUI","value":"CL937288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"452042"},{"name":"PDQ_Open_Trial_Search_ID","value":"452042"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61073":{"preferredName":"Viagenpumatucel-L","code":"C61073","definitions":[{"definition":"A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Viagenpumatucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Gp96-Ig Fusion Protein-Expressing Non-Small Cell Lung Cancer Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HS-110","termGroup":"CN","termSource":"NCI"},{"termName":"HS110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"13H90KC831"},{"name":"Legacy Concept Name","value":"Gp96-Ig_Fusion_Protein-Expressing_Non-Small_Cell_Lung_Cancer_Cell_Vaccine"},{"name":"Maps_To","value":"Viagenpumatucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"473873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473873"},{"name":"PDQ_Open_Trial_Search_ID","value":"473873"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831778"}]}}{"C148505":{"preferredName":"Vilaprisan","code":"C148505","definitions":[{"definition":"An orally available progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, vilaprisan competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system and may inhibit PR-mediated proliferative effects in cells overexpressing PRs. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue or uterine fibroid formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vilaprisan","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 1002670","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1002670","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1002670","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1262108-14-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IN59K53GI9"},{"name":"Maps_To","value":"Vilaprisan"},{"name":"NCI_Drug_Dictionary_ID","value":"792636"},{"name":"NCI_META_CUI","value":"CL551037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792636"},{"name":"PDQ_Open_Trial_Search_ID","value":"792636"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C930":{"preferredName":"Vinblastine","code":"C930","definitions":[{"definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used together with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Vinblastine comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vinblastine","termGroup":"PT","termSource":"NCI"},{"termName":"Vincaleucoblastine","termGroup":"SY","termSource":"NCI"},{"termName":"VLB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Breast cancer; Choriocarcinoma; Germ cell tumors; Idiopathic thrombocytopenic purpura; Kaposi sarcoma; Letterer-Siwe disease; Various Lymphomas; Melanoma; Mycosis fungoides; Prostate cancer; Testicular cancer"},{"name":"CAS_Registry","value":"865-21-4"},{"name":"CHEBI_ID","value":"CHEBI:27375"},{"name":"Chemical_Formula","value":"C46H58N4O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"5V9KLZ54CY"},{"name":"Legacy Concept Name","value":"Vinblastine"},{"name":"Maps_To","value":"Vinblastine"},{"name":"NCI_Drug_Dictionary_ID","value":"42951"},{"name":"NSC Number","value":"90636"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42951"},{"name":"PDQ_Open_Trial_Search_ID","value":"42951"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042670"}]}}{"C931":{"preferredName":"Vinblastine Sulfate","code":"C931","definitions":[{"definition":"A drug used with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Velban comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties.  Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinblastine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"29060-LE","termGroup":"CN","termSource":"NCI"},{"termName":"Exal","termGroup":"FB","termSource":"NCI"},{"termName":"Velban","termGroup":"BR","termSource":"NCI"},{"termName":"Velbe","termGroup":"FB","termSource":"NCI"},{"termName":"Velsar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"143-67-9"},{"name":"CHEBI_ID","value":"CHEBI:9984"},{"name":"Chemical_Formula","value":"C46H58N4O9.H2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N00W22YO2B"},{"name":"Legacy Concept Name","value":"Vinblastine_Sulfate"},{"name":"Maps_To","value":"Vinblastine Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"688303"},{"name":"NSC Number","value":"49842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688303"},{"name":"PDQ_Open_Trial_Search_ID","value":"688303"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042671"}]}}{"C933":{"preferredName":"Vincristine","code":"C933","definitions":[{"definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vincristine","termGroup":"PT","termSource":"NCI"},{"termName":"22-Oxovincaleukoblastine","termGroup":"SN","termSource":"NCI"},{"termName":"LCR","termGroup":"AB","termSource":"NCI"},{"termName":"Leurocristine","termGroup":"SY","termSource":"NCI"},{"termName":"VCR","termGroup":"AB","termSource":"NCI"},{"termName":"Vincrystine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute leukemia; Brain tumors; Chronic lymphocytic leukemia; Gestational trophoblastic neoplasms; Head and Neck squamous cell carcinoma; Kaposis sarcoma; Liver cancer;"},{"name":"Accepted_Therapeutic_Use_For","value":"Lymphoma, Hodgkins, Non-Hodgkins; Malignant thymoma; Multiple myeloma; Osteogenic sarcoma; Ovarian cancer; Pheochromocytoma; Retinoblastoma; Rhabdomyosarcoma; Soft tissue sarcoma; Testicular cancer; Wilms tumor"},{"name":"CAS_Registry","value":"57-22-7"},{"name":"CHEBI_ID","value":"CHEBI:28445"},{"name":"Chemical_Formula","value":"C46H56N4O10"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"5J49Q6B70F"},{"name":"Legacy Concept Name","value":"Vincristine"},{"name":"Maps_To","value":"Vincristine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042679"}]}}{"C2104":{"preferredName":"Vincristine Liposomal","code":"C2104","definitions":[{"definition":"A liposomal formulation of Vincristine designed to reduce toxicity and improve efficacy.  Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vincristine Liposomal","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid-Encapsulated Vincristine","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Vincristine","termGroup":"SY","termSource":"NCI"},{"termName":"Onco TCS","termGroup":"BR","termSource":"NCI"},{"termName":"Vincacine","termGroup":"SY","termSource":"NCI"},{"termName":"VincaXome","termGroup":"BR","termSource":"NCI"},{"termName":"Vincristine Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Vincristine, Liposomal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Vincristine_Liposomal"},{"name":"Maps_To","value":"Vincristine Liposomal"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519991"}]}}{"C1739":{"preferredName":"Vincristine Sulfate","code":"C1739","definitions":[{"definition":"A drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Oncovin is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vincristine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"Kyocristine","termGroup":"FB","termSource":"NCI"},{"termName":"Leurocristine Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"Oncovin","termGroup":"BR","termSource":"NCI"},{"termName":"Vincasar","termGroup":"FB","termSource":"NCI"},{"termName":"Vincasar PFS","termGroup":"AQS","termSource":"NCI"},{"termName":"Vincosid","termGroup":"BR","termSource":"NCI"},{"termName":"Vincrex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Neuroblastoma"},{"name":"CAS_Registry","value":"2068-78-2"},{"name":"Chemical_Formula","value":"C46H56N4O10.H2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T5IRO3534A"},{"name":"Legacy Concept Name","value":"Vincristine_Sulfate"},{"name":"Maps_To","value":"Vincristine Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"42251"},{"name":"NSC Number","value":"67574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42251"},{"name":"PDQ_Open_Trial_Search_ID","value":"42251"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042680"}]}}{"C2702":{"preferredName":"Vincristine Sulfate Liposome","code":"C2702","definitions":[{"definition":"A sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid isolated from the plant Vinca rosea, irreversibly binds to and stabilizes tubulin, thereby interrupting microtubule assembly/disassembly dynamics, thereby preventing the formation of the mitotic spindle and leading to cell cycle arrest in metaphase. Liposomal encapsulation prolongs bioavailability of vincristine, increases its delivery to tumor tissues and reduces its toxicity profile. Compared to standard liposomal delivery, sphingosomal drug delivery further increases circulation time of serum drug and enhances drug accumulation at tumor sites, thereby leading to a further increase in efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vincristine Sulfate Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"Marqibo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute lymphoblastic leukemia (ALL)"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vincristine_Sulfate_Liposomes"},{"name":"Maps_To","value":"Vincristine Sulfate Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"38100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38100"},{"name":"PDQ_Open_Trial_Search_ID","value":"38100"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935690"}]}}{"C934":{"preferredName":"Vindesine","code":"C934","definitions":[{"definition":"A synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of plant drugs called vinca alkaloids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vindesine","termGroup":"PT","termSource":"NCI"},{"termName":"3-(Aminocarbonyl)-O4-deacetyl-3-de-(methoxycarbonyl)vincaleukoblastine","termGroup":"SN","termSource":"NCI"},{"termName":"Compound 112531","termGroup":"SY","termSource":"NCI"},{"termName":"DAVA","termGroup":"AB","termSource":"NCI"},{"termName":"Deacetyl Vinblastine Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Deacetylvinblastine Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Desacetylvinblastine Amide","termGroup":"SY","termSource":"NCI"},{"termName":"DVA","termGroup":"AB","termSource":"NCI"},{"termName":"Lilly CT-3231","termGroup":"CN","termSource":"NCI"},{"termName":"VDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53643-48-4"},{"name":"CHEBI_ID","value":"CHEBI:36373"},{"name":"Chemical_Formula","value":"C43H55N5O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RSA8KO39WH"},{"name":"Legacy Concept Name","value":"Vindesine"},{"name":"Maps_To","value":"Vindesine"},{"name":"NCI_Drug_Dictionary_ID","value":"39732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39732"},{"name":"PDQ_Open_Trial_Search_ID","value":"39732"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042682"}]}}{"C1274":{"preferredName":"Vinepidine","code":"C1274","definitions":[{"definition":"A vinca alkaloid compound and semi-synthetic vincristine derivative with antineoplastic activity. Vinepidine binds to and stabilizes tubulin, thereby preventing tubulin polymerization and depolymerization, which result in microtubule assembly and disassembly, respectively. Treated cells are unable to complete mitosis process and are arrested in the metaphase, thereby leading to an inhibition of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinepidine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxyepivincristine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68170-69-4"},{"name":"Chemical_Formula","value":"C46H56N4O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W3375J6V0Y"},{"name":"Legacy Concept Name","value":"Vinepidine"},{"name":"Maps_To","value":"Vinepidine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0078255"}]}}{"C61564":{"preferredName":"Vinflunine","code":"C61564","definitions":[{"definition":"A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of bladder cancer, lung cancer, and other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vinflunine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxy-20',20'-difluoro-C'-norvincaleukoblastine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"162652-95-1"},{"name":"Chemical_Formula","value":"C45H54F2N4O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5BF646324K"},{"name":"Legacy Concept Name","value":"Vinflunine"},{"name":"Maps_To","value":"Vinflunine"},{"name":"NCI_Drug_Dictionary_ID","value":"419548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"419548"},{"name":"PDQ_Open_Trial_Search_ID","value":"419548"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0672663"}]}}{"C76266":{"preferredName":"Vinflunine Ditartrate","code":"C76266","definitions":[{"definition":"A substance being studied in the treatment of bladder cancer, lung cancer, and other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The ditartrate salt of vinflunine, a bi-fluorinated derivative of the semisynthetic vinca alkaloid vinorelbine with potential antimitotic and antineoplastic activities. Vinflunine binds to tubulin and inhibits tubulin assembly and disrupts microtubule assembly dynamics. This results in cell cycle arrest in mitosis and an induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinflunine Ditartrate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194468-36-5"},{"name":"Chemical_Formula","value":"C45H54F2N4O8.2C4H6O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33MG53C7XW"},{"name":"Legacy Concept Name","value":"Vinflunine_Ditartrate"},{"name":"Maps_To","value":"Vinflunine Ditartrate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700251"}]}}{"C2378":{"preferredName":"Vinfosiltine","code":"C2378","definitions":[{"definition":"An aminophosphonate derivative of a vinca alkaloid with potential antineoplastic activity. Vinfosiltine exerts its antineoplastic action just like its parent compound, vinblastine, by immobilizing tubulin molecules, thereby interrupting microtubule assembly/disassembly dynamics. As a result, vinfosiltine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinfosiltine","termGroup":"PT","termSource":"NCI"},{"termName":"S12363","termGroup":"CN","termSource":"NCI"},{"termName":"Vincaleukoblastine, O4-Deacetyl-3-de(methoxycarbonyl)-3-(((1-(diethoxyphosphinyl)-2-methylpropyl)amin)carbonyl)-,(3(S))-,Sulfate(Salt)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123286-00-0"},{"name":"Chemical_Formula","value":"C51H72N5O10P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AW1UYE6Q9I"},{"name":"Legacy Concept Name","value":"Vinfosiltine"},{"name":"Maps_To","value":"Vinfosiltine"},{"name":"NCI_Drug_Dictionary_ID","value":"41716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41716"},{"name":"PDQ_Open_Trial_Search_ID","value":"41716"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084429"}]}}{"C1275":{"preferredName":"Vinorelbine","code":"C1275","definitions":[{"definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of plant drugs called vinca alkaloids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vinorelbine","termGroup":"PT","termSource":"NCI"},{"termName":"3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine","termGroup":"SN","termSource":"NCI"},{"termName":"5'-Nor-Anhydrovinblastine","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydroxydeoxynorvinkaleukoblastine","termGroup":"SY","termSource":"NCI"},{"termName":"nor-5'-Anhydrovinblastine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Cervical cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer"},{"name":"CAS_Registry","value":"71486-22-1"},{"name":"CHEBI_ID","value":"CHEBI:480999"},{"name":"Chemical_Formula","value":"C45H54N4O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"Q6C979R91Y"},{"name":"Legacy Concept Name","value":"Vinorelbine"},{"name":"Maps_To","value":"Vinorelbine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0078257"}]}}{"C1395":{"preferredName":"Vinorelbine Tartrate","code":"C1395","definitions":[{"definition":"A drug used to treat advanced non-small cell lung cancer. It blocks cell growth by stopping cell division and may cause cancer cells to die. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinorelbine Tartrate","termGroup":"PT","termSource":"NCI"},{"termName":"Biovelbin","termGroup":"FB","termSource":"NCI"},{"termName":"Eunades","termGroup":"FB","termSource":"NCI"},{"termName":"KW-2307","termGroup":"CN","termSource":"NCI"},{"termName":"Navelbine","termGroup":"FB","termSource":"NCI"},{"termName":"Navelbine Ditartrate","termGroup":"SY","termSource":"NCI"},{"termName":"NVB","termGroup":"AB","termSource":"NCI"},{"termName":"Vinorelbine Ditartrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-small cell lung cancer; metastatic breast cancer; uterine and cervical cancer; desmoid tumors; advanced Kaposi's sarcoma"},{"name":"CAS_Registry","value":"125317-39-7"},{"name":"CHEBI_ID","value":"CHEBI:32296"},{"name":"Chemical_Formula","value":"C45H54N4O8.2C4H6O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"253GQW851Q"},{"name":"Legacy Concept Name","value":"Vinorelbine_Ditartrate"},{"name":"Maps_To","value":"Vinorelbine Tartrate"},{"name":"NCI_Drug_Dictionary_ID","value":"40449"},{"name":"NSC Number","value":"608210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40449"},{"name":"PDQ_Open_Trial_Search_ID","value":"40449"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0377401"}]}}{"C66943":{"preferredName":"Vinorelbine Tartrate Emulsion","code":"C66943","definitions":[{"definition":"An emulsion containing the tartrate salt of the semisynthetic vinca alkaloid vinorelbine with antineoplastic activity. Vinorelbine binds to tubulin, inhibiting tubulin polymerization into microtubules; cell division is prevented, the cell cycle is arrested metaphase and cell death ensues. In this formulation vinorelbine is emulsified in a homogeneous suspension of nanoparticles, which protects the venous endothelium from coming into direct contact with the active ingredient, potentially reducing vinorelbine-associated venous toxicity at the venous injection site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinorelbine Tartrate Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"ANX-530","termGroup":"CN","termSource":"NCI"},{"termName":"Vinorelbine Tartrate Injectable Emulsion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vinorelbine_Tartrate_Emulsion"},{"name":"Maps_To","value":"Vinorelbine Tartrate Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"538399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"538399"},{"name":"PDQ_Open_Trial_Search_ID","value":"538399"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1883539"}]}}{"C85457":{"preferredName":"Vinorelbine Tartrate Oral","code":"C85457","definitions":[{"definition":"An orally bioavailable tartrate salt of vinorelbine, a semisynthetic vinca alkaloid with potential antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinorelbine Tartrate Oral","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vinorelbine Tartrate Oral"},{"name":"NCI_Drug_Dictionary_ID","value":"642976"},{"name":"NCI_META_CUI","value":"CL412328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642976"},{"name":"PDQ_Open_Trial_Search_ID","value":"642976"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62525":{"preferredName":"Vintafolide","code":"C62525","definitions":[{"definition":"A water-soluble, folate-receptor-targeted conjugate of folate and the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) with potential antineoplastic activity. The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis. Folic acid receptors are frequently upregulated on the surfaces of many tumor cell types. DAVLBH is a derivative of the natural product vinblastine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vintafolide","termGroup":"PT","termSource":"NCI"},{"termName":"EC145","termGroup":"CN","termSource":"NCI"},{"termName":"Folate-Vinca Alkaloid Conjugate EC145","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"742092-03-1"},{"name":"Chemical_Formula","value":"C86H109N21O26S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"36O410ZD4I"},{"name":"Legacy Concept Name","value":"EC145"},{"name":"Maps_To","value":"Vintafolide"},{"name":"NCI_Drug_Dictionary_ID","value":"488470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488470"},{"name":"PDQ_Open_Trial_Search_ID","value":"488470"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831870"}]}}{"C1276":{"preferredName":"Vinzolidine","code":"C1276","definitions":[{"definition":"An orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinzolidine","termGroup":"PT","termSource":"NCI"},{"termName":"2H-3,7-Methanoazacycloundecino(5,4-b)indole-9-carboxylic acid, 9-((2-beta,3-beta,4-beta,5-alpha,12-beta,19-alpha)-4-(acetyloxy)-3'-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2',4'-dioxospiro(aspidospermidine-3,5'-oxazolidin)-15-yl)-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3R-(3R*,5S*,7R*,9S*))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67699-40-5"},{"name":"Chemical_Formula","value":"C48H58ClN5O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"533U947V6Q"},{"name":"Legacy Concept Name","value":"Vinzolidine"},{"name":"Maps_To","value":"Vinzolidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39733"},{"name":"PDQ_Open_Trial_Search_ID","value":"39733"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0078282"}]}}{"C87288":{"preferredName":"Vinzolidine Sulfate","code":"C87288","definitions":[{"definition":"The sulfate salt of vinzolidine, an orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinzolidine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"2h-3,7-Methanoazacycloundecino(5,4-Beta)Indole-9-Carboxylic Acid, 9-((2Beta,3Beta,4Beta,5Alpha,12Beta,19Alpha)-4-(Acetyloxy)-3'-(2-Chloroethyl)-6,7-Didehydro-16-Methoxy-1-Methyl-2',4'-Dioxospiro(Aspidospermidine-3,5'-Oxazolidin)-15-Yl)-5-Ethy","termGroup":"SN","termSource":"NCI"},{"termName":"LY104208","termGroup":"CN","termSource":"NCI"},{"termName":"Methyl (3R,5S,7R,9S)-9-[3'-(2-Chloroethyl)-6,7-Didehydro-4Beta-Hydroxy-16-Methoxy-1-Methyl-2',4'-Dioxo-2Beta,3Beta,5Alpha,12Beta,19Alpha-Spiro(Aspidospermidine-3,5'-Oxazolidin]-15-yl)-5-Ethyl-1,4,5,6,7,8,9,10-Octahydro-5-Hydroxy-2H-3,7-Methano","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67699-41-6"},{"name":"Chemical_Formula","value":"C48H58ClN5O9.H2O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78NZ2PMP25"},{"name":"Maps_To","value":"Vinzolidine Sulfate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2828244"}]}}{"C26677":{"preferredName":"Virulizin","code":"C26677","definitions":[{"definition":"A natural biological response modifier (BRM) isolated from bovine reticuloendothelial tissue. Viruzlin may enhance cell-mediated immune response to tumor cells by direct macrophage activation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that activates some types of immune system cells, and is being studied as a treatment for cancer. It belongs to the family of drugs called biological therapy agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Virulizin","termGroup":"PT","termSource":"NCI"},{"termName":"Bos Taurus Bile Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Bos Taurus Bile Immunomodulator","termGroup":"SY","termSource":"NCI"},{"termName":"Bovine Bile Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Bovine Bile Immunomodulator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"216586-46-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E5SF1Z7U1S"},{"name":"Legacy Concept Name","value":"Virulizin"},{"name":"Maps_To","value":"Virulizin"},{"name":"NCI_Drug_Dictionary_ID","value":"257159"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257159"},{"name":"PDQ_Open_Trial_Search_ID","value":"257159"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0254455"}]}}{"C74038":{"preferredName":"Vismodegib","code":"C74038","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells. It is a type of Hedgehog signaling pathway antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vismodegib","termGroup":"PT","termSource":"NCI"},{"termName":"2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Erivedge","termGroup":"BR","termSource":"NCI"},{"termName":"GDC-0449","termGroup":"CN","termSource":"NCI"},{"termName":"Hedgehog Antagonist GDC-0449","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"basal cell carcinoma"},{"name":"CAS_Registry","value":"879085-55-9"},{"name":"Chemical_Formula","value":"C19H14Cl2N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"25X868M3DS"},{"name":"Legacy Concept Name","value":"Hedgehog_Antagonist_GDC-0449"},{"name":"Maps_To","value":"Vismodegib"},{"name":"NCI_Drug_Dictionary_ID","value":"586417"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586417"},{"name":"PDQ_Open_Trial_Search_ID","value":"586417"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348949"}]}}{"C88329":{"preferredName":"Vistusertib","code":"C88329","definitions":[{"definition":"An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vistusertib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 2014","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-2014","termGroup":"CN","termSource":"NCI"},{"termName":"AZD2014","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1009298-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0BSC3P4H5X"},{"name":"Maps_To","value":"Vistusertib"},{"name":"NCI_Drug_Dictionary_ID","value":"662098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662098"},{"name":"PDQ_Open_Trial_Search_ID","value":"662098"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981846"}]}}{"C1883":{"preferredName":"Vitamin D3 Analogue ILX23-7553","code":"C1883","definitions":[{"definition":"A substance that is being studied as an anticancer drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A vitamin D3 analogue with potential antineoplastic activity.  ILX23-7553 binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, ILX23-7553 may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vitamin D3 Analogue ILX23-7553","termGroup":"PT","termSource":"NCI"},{"termName":"1,25-dihydroxy-16-ene-23-yne-cholecalciferol","termGroup":"SN","termSource":"NCI"},{"termName":"16-23-D3","termGroup":"SY","termSource":"NCI"},{"termName":"9,10-Secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol, (1alpha,3beta,5Z,7E)-","termGroup":"SN","termSource":"NCI"},{"termName":"BXL 353","termGroup":"CN","termSource":"NCI"},{"termName":"ILEX 23-7553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX 237553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX-237553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX23-7553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX237553","termGroup":"CN","termSource":"NCI"},{"termName":"RO 237553","termGroup":"CN","termSource":"NCI"},{"termName":"RO-237553","termGroup":"CN","termSource":"NCI"},{"termName":"Ro23-7553","termGroup":"CN","termSource":"NCI"},{"termName":"RO237553","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118694-43-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O13QTC8612"},{"name":"Legacy Concept Name","value":"ILX23-7553"},{"name":"Maps_To","value":"Vitamin D3 Analogue ILX23-7553"},{"name":"NCI_Drug_Dictionary_ID","value":"37861"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37861"},{"name":"PDQ_Open_Trial_Search_ID","value":"37861"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0966846"}]}}{"C942":{"preferredName":"Vitamin E Compound","code":"C942","definitions":[{"definition":"A fat-soluble vitamin which is primarily a chain-breaking antioxidant that prevents the propagation of lipid peroxidation.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"A natural fat-soluble antioxidant with potential chemopreventive activity. Also known as tocopherol, vitamin E ameliorates free-radical damage to biological membranes, protecting polyunsaturated fatty acids (PUFA) within membrane phospholipids and within circulating lipoproteins. Peroxyl radicals react 1000-fold faster with vitamin E than with PUFA.  In the case of oxygen free radical-mediated tumorigenesis, vitamin E may be chemopreventive. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient that the body needs in small amounts to function and stay healthy. Vitamin E helps prevent cell damage caused by free radicals (highly reactive chemicals). It is fat-soluble (can dissolve in fats and oils) and is found in seeds, nuts, leafy vegetables, and vegetable oils. Not enough vitamin E can result in infertility (the inability to produce children). It is being studied in the prevention and treatment of some types of cancer. Vitamin E is a type of antioxidant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vitamin E Compound","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol","termGroup":"SN","termSource":"NCI"},{"termName":"5,7,8-Trimethyltocol","termGroup":"SN","termSource":"NCI"},{"termName":"E Vitamin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Vitamin E deficiency"},{"name":"CAS_Registry","value":"1406-18-4"},{"name":"CHEBI_ID","value":"CHEBI:33234"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vitamin_E"},{"name":"Maps_To","value":"Vitamin E Compound"},{"name":"Micronutrient","value":"Y"},{"name":"NCI_Drug_Dictionary_ID","value":"38321"},{"name":"Nutrient","value":"Y"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38321"},{"name":"PDQ_Open_Trial_Search_ID","value":"38321"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"Tolerable_Level","value":"Y"},{"name":"UMLS_CUI","value":"C0042874"},{"name":"Unit","value":"mg"},{"name":"US_Recommended_Intake","value":"Y"}]}}{"C2432":{"preferredName":"Vitespen","code":"C2432","definitions":[{"definition":"A vaccine made from a patient's tumor cells that may help the body's immune system kill cancer cells. This vaccine is used to treat kidney cancer, a type of brain cancer called glioma, and metastatic melanoma (a type of skin cancer that has spread). It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autologous cancer vaccine derived from tumor-specific gp96 heat shock proteins.  Heat shock proteins chaperone peptides through the endoplasmic reticulum, are key regulators of dendritic cell maturation, migration and antigen processing, and are involved in T-cell activation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vitespen","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous gp96 Heat Shock Protein Peptide Complex Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"gp96 Heat Shock Protein-Peptide Complex","termGroup":"SY","termSource":"NCI"},{"termName":"gp96 HSP-Peptide Complex","termGroup":"SY","termSource":"NCI"},{"termName":"Heat Shock Protein Peptide Complex-96","termGroup":"SY","termSource":"NCI"},{"termName":"HSP gp96-Peptide Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HSPPC-96","termGroup":"CN","termSource":"NCI"},{"termName":"Oncophage","termGroup":"BR","termSource":"NCI"},{"termName":"Recombinant Human Tumor Rejection Antigen 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"492448-75-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H3598Y1TLJ"},{"name":"Legacy Concept Name","value":"Autologous_gp96_Heat_Shock_Protein_Peptide_Complex_Vaccine"},{"name":"Maps_To","value":"Vitespen"},{"name":"NCI_Drug_Dictionary_ID","value":"42682"},{"name":"NSC Number","value":"725085"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42682"},{"name":"PDQ_Open_Trial_Search_ID","value":"42682"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935952"}]}}{"C175875":{"preferredName":"Vidutolimod","code":"C175875","definitions":[{"definition":"A virus-like particle (VLP) composed of the Qbeta bacteriophage capsid encapsulating the toll-like receptor 9 (TLR9) agonist G10, an unmethylated CpG-A oligodeoxynucleotide (ODN), with potential immunostimulating and antineoplastic activities. Upon administration of vidutolimod, the VLPs are specifically taken up by and release the oligonucleotide into antigen-presenting cells (APCs), including dendritic cells (DCs). In turn, the oligonucleotide binds to and activates intracellular TLR9. This stimulates immune signaling pathways, induces the innate immune system and may promote the immune system to attack tumor cells. VLPs stimulate the immune system. TLR9, a member of the TLR family, plays a key role in both pathogen recognition and the activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vidutolimod","termGroup":"PT","termSource":"NCI"},{"termName":"ARB-1598","termGroup":"CN","termSource":"NCI"},{"termName":"CMP-001","termGroup":"CN","termSource":"NCI"},{"termName":"CYT 003","termGroup":"CN","termSource":"NCI"},{"termName":"CYT-003","termGroup":"CN","termSource":"NCI"},{"termName":"QbG10","termGroup":"CN","termSource":"NCI"},{"termName":"VLP-encapsulated TLR9 Agonist CMP-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"147063-80-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D68OW5RS98"},{"name":"Maps_To","value":"VLP-encapsulated TLR9 Agonist CMP-001"},{"name":"NCI_Drug_Dictionary_ID","value":"779977"},{"name":"NCI_META_CUI","value":"CL1413087"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91734":{"preferredName":"Vocimagene Amiretrorepvec","code":"C91734","definitions":[{"definition":"A replication competent retroviral vector, derived from the Moloney murine leukemia virus (MoMLV), encoding a modified form of the yeast suicide gene cytosine deaminase (CD) (Toca 511) used as an antineoplastic adjuvant. Upon transcranial injection, vocimagene amiretrorepvec preferentially enters and transfects tumor cells, and expresses cytosine deaminase, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vocimagene Amiretrorepvec","termGroup":"PT","termSource":"NCI"},{"termName":"DNA (Synthetic Toca 511-encoding Retroviral Vector AC3-yCD2(V))","termGroup":"SY","termSource":"NCI"},{"termName":"Toca 511","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1300724-82-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DC4WO3WA4Q"},{"name":"Maps_To","value":"Vocimagene Amiretrorepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"681586"},{"name":"NCI_META_CUI","value":"CL421655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681586"},{"name":"PDQ_Open_Trial_Search_ID","value":"681586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C116863":{"preferredName":"Vofatamab","code":"C116863","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3), with potential antineoplastic activity. Upon intravenous administration, vofatamab specifically binds to and inhibits both wild-type and mutated forms of FGFR3. This may result in the inhibition of FGFR3 phosphorylation, and thereby preventing its activation and FGFR3-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vofatamab","termGroup":"PT","termSource":"NCI"},{"termName":"B-701","termGroup":"CN","termSource":"NCI"},{"termName":"MFGR-1877S","termGroup":"CN","termSource":"NCI"},{"termName":"MFGR1877A","termGroup":"CN","termSource":"NCI"},{"termName":"MFGR1877S","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7444","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312305-12-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JMH6YR91PG"},{"name":"Maps_To","value":"Vofatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"673995"},{"name":"NCI_META_CUI","value":"CL421586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673995"},{"name":"PDQ_Open_Trial_Search_ID","value":"673995"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79844":{"preferredName":"Volasertib","code":"C79844","definitions":[{"definition":"A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Volasertib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-(Trans-4-(4-(Cyclopropylmethyl)-1-Piperazinyl)Cyclohexyl)-4-(((7r)-7-Ethyl-5,6,7,8-Tetrahydro-5-Methyl-8-(1-Methylethyl)-6-Oxo-2-Pteridinyl)Amino)-3-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"BI 6727","termGroup":"CN","termSource":"NCI"},{"termName":"BI-6727","termGroup":"CN","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor BI 6727","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"755038-65-4"},{"name":"Chemical_Formula","value":"C34H50N8O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6EM57086EA"},{"name":"Legacy Concept Name","value":"Polo-like_Kinase_1_Inhibitor_BI_6727"},{"name":"Maps_To","value":"Volasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"630756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"630756"},{"name":"PDQ_Open_Trial_Search_ID","value":"630756"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703181"}]}}{"C48426":{"preferredName":"Volociximab","code":"C48426","definitions":[{"definition":"A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Volociximab binds to a protein that is found on cells that line some tumor blood vessels. It is a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Volociximab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-a5-beta1 Integrin","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-alpha5-beta1 Integrin","termGroup":"SY","termSource":"NCI"},{"termName":"M200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"558480-40-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"496K5Z02NW"},{"name":"Legacy Concept Name","value":"Volociximab"},{"name":"Maps_To","value":"Volociximab"},{"name":"NCI_Drug_Dictionary_ID","value":"415313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415313"},{"name":"PDQ_Open_Trial_Search_ID","value":"415313"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541160"}]}}{"C121376":{"preferredName":"Vonlerolizumab","code":"C121376","definitions":[{"definition":"An agonistic humanized monoclonal antibody against the receptor, OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, vonlerolizumab selectively binds to and activates OX40, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 activation induces proliferation of effector T-lymphocytes and inhibits the activity of regulatory T-cells. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vonlerolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"MOXR0916","termGroup":"CN","termSource":"NCI"},{"termName":"Pogalizumab","termGroup":"SY","termSource":"NCI"},{"termName":"RG 7888","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7888","termGroup":"CN","termSource":"NCI"},{"termName":"RG7888","termGroup":"CN","termSource":"NCI"},{"termName":"RO7021608","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638935-72-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C78148TF1D"},{"name":"Maps_To","value":"Vonlerolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"792458"},{"name":"NCI_META_CUI","value":"CL474130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792458"},{"name":"PDQ_Open_Trial_Search_ID","value":"792458"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129876":{"preferredName":"Vopratelimab","code":"C129876","definitions":[{"definition":"An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, anti-ICOS agonist monoclonal antibody JTX-2011 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vopratelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS Agonist MAb JTX-2011","termGroup":"SY","termSource":"NCI"},{"termName":"ICOS Agonist Monoclonal Antibody JTX-2011","termGroup":"SY","termSource":"NCI"},{"termName":"JTX-2011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2039148-04-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QXN20J93AH"},{"name":"Maps_To","value":"Vopratelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"784959"},{"name":"NCI_META_CUI","value":"CL512902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784959"},{"name":"PDQ_Open_Trial_Search_ID","value":"784959"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1796":{"preferredName":"Vorinostat","code":"C1796","definitions":[{"definition":"A drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Vorinostat is a type of histone deacetylase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorinostat","termGroup":"PT","termSource":"NCI"},{"termName":"L-001079038","termGroup":"CN","termSource":"NCI"},{"termName":"MSK-390","termGroup":"CN","termSource":"NCI"},{"termName":"N-Hydroxy-N'-phenyloctanediamide","termGroup":"SN","termSource":"NCI"},{"termName":"SAHA","termGroup":"AB","termSource":"NCI"},{"termName":"Suberanilohydroxamic Acid","termGroup":"CN","termSource":"NCI"},{"termName":"Suberoylanilide Hydroxamic Acid","termGroup":"CN","termSource":"NCI"},{"termName":"Zolinza","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cutaneous T-cell Lymphoma"},{"name":"CAS_Registry","value":"149647-78-9"},{"name":"Chemical_Formula","value":"C14H20N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"58IFB293JI"},{"name":"Legacy Concept Name","value":"Suberoylanilide_Hydroxamic_Acid"},{"name":"Maps_To","value":"Vorinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"37944"},{"name":"NSC Number","value":"701852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37944"},{"name":"PDQ_Open_Trial_Search_ID","value":"37944"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0672708"}]}}{"C95896":{"preferredName":"Vorolanib","code":"C95896","definitions":[{"definition":"An orally available small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with antiangiogenic and antineoplastic activities. Vorolanib inhibits all isoforms of VEGFR and PDGFR, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and PDGFRs are receptor tyrosine kinases that may be upregulated in various tumor cell types. Vorolanib has been shown to reduce tissue toxicity by 95 percent compared with first-generation kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorolanib","termGroup":"PT","termSource":"NCI"},{"termName":"(S,Z)-N-(1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CM 082","termGroup":"CN","termSource":"NCI"},{"termName":"CM-082","termGroup":"CN","termSource":"NCI"},{"termName":"CM082","termGroup":"CN","termSource":"NCI"},{"termName":"X 82","termGroup":"CN","termSource":"NCI"},{"termName":"X-82","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1013920-15-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YP8G3I74EL"},{"name":"Maps_To","value":"Vorolanib"},{"name":"NCI_Drug_Dictionary_ID","value":"695817"},{"name":"NCI_META_CUI","value":"CL428293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695817"},{"name":"PDQ_Open_Trial_Search_ID","value":"695817"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88315":{"preferredName":"Vorsetzumab Mafodotin","code":"C88315","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to the auristatin analogue monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. The anti-CD70 antibody moiety of vorsetuzumab mafodotin selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the MMAF moiety is released, binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest, tumor cell apoptosis and inhibition of cellular proliferation in tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorsetzumab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 MoAb SGN70-MMAF Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"SGN 75","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-75","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1165741-01-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"699619YVTQ"},{"name":"Maps_To","value":"Vorsetzumab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"660730"},{"name":"NCI_META_CUI","value":"CL413570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660730"},{"name":"PDQ_Open_Trial_Search_ID","value":"660730"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95148":{"preferredName":"Vosaroxin","code":"C95148","definitions":[{"definition":"A small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result, inhibition of DNA replication, RNA and protein synthesis occurs, followed by cell cycle arrest at G2 phase and induced p53-independent apoptosis. This agent shows a favorable toxicity profile in several aspects: it does not generate reactive oxygen species, as do anthracyclines, hence reducing the risk of cardiotoxicity; it is not a P-glycoprotein (P-gp) substrate, and thereby evades the common mechanism for multidrug resistance; and it has limited distribution to normal tissues and a more chemically stable molecular structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vosaroxin","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"AG-7352","termGroup":"CN","termSource":"NCI"},{"termName":"SNS 595","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-595","termGroup":"CN","termSource":"NCI"},{"termName":"SPC 595","termGroup":"CN","termSource":"NCI"},{"termName":"Voreloxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"175414-77-4"},{"name":"Chemical_Formula","value":"C18H19N5O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K6A90IIZ19"},{"name":"Maps_To","value":"Vosaroxin"},{"name":"NCI_Drug_Dictionary_ID","value":"393833"},{"name":"PDQ_Closed_Trial_Search_ID","value":"393833"},{"name":"PDQ_Open_Trial_Search_ID","value":"393833"},{"name":"PubMedID_Primary_Reference","value":"20233886"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451341"}]}}{"C71704":{"preferredName":"Voxtalisib","code":"C71704","definitions":[{"definition":"An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Voxtalisib","termGroup":"PT","termSource":"NCI"},{"termName":"SAR-245409","termGroup":"CN","termSource":"NCI"},{"termName":"SAR245409","termGroup":"CN","termSource":"NCI"},{"termName":"XL-765","termGroup":"CN","termSource":"NCI"},{"termName":"XL765","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934493-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CVL1685GPH"},{"name":"Legacy Concept Name","value":"Dual_Kinase_Inhibitor_XL765"},{"name":"Maps_To","value":"Voxtalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"558907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558907"},{"name":"PDQ_Open_Trial_Search_ID","value":"558907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348352"}]}}{"C1658":{"preferredName":"Warfarin Sodium","code":"C1658","definitions":[{"definition":"The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins.  As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Warfarin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Coumadin","termGroup":"BR","termSource":"NCI"},{"termName":"Marevan","termGroup":"FB","termSource":"NCI"},{"termName":"Panwarfin","termGroup":"BR","termSource":"NCI"},{"termName":"Prothromadin","termGroup":"SY","termSource":"NCI"},{"termName":"Tintorane","termGroup":"SY","termSource":"NCI"},{"termName":"Waran","termGroup":"FB","termSource":"NCI"},{"termName":"Warfilone","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129-06-6"},{"name":"CHEBI_ID","value":"CHEBI:10034"},{"name":"Chemical_Formula","value":"C19H15O4.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6153CWM0CL"},{"name":"Legacy Concept Name","value":"Warfarin_Sodium"},{"name":"Maps_To","value":"Warfarin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39740"},{"name":"PDQ_Open_Trial_Search_ID","value":"39740"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0376218"}]}}{"C126649":{"preferredName":"White Carrot","code":"C126649","definitions":[{"definition":"A vegetable, also known as Arracacha, with potential chemoprevenitve, anti-oxidant and protective activities. White carrot contains a variety of nutrients, including minerals and vitamins. Polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate are mainly responsible for its potential anti-cancer activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"White Carrot","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"White Carrot"},{"name":"NCI_Drug_Dictionary_ID","value":"779793"},{"name":"NCI_META_CUI","value":"CL503765"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779793"},{"name":"PDQ_Open_Trial_Search_ID","value":"779793"},{"name":"Semantic_Type","value":"Food"}]}}{"C122693":{"preferredName":"Wnt Signaling Inhibitor SM04755","code":"C122693","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, Wnt signaling inhibitor SM04755 targets and binds to an as of yet undisclosed target in the Wnt signaling pathway, thereby preventing Wnt-mediated signaling. This may inhibit growth of tumor cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is upregulated in many cancers and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wnt Signaling Inhibitor SM04755","termGroup":"PT","termSource":"NCI"},{"termName":"SM04755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wnt Signaling Inhibitor SM04755"},{"name":"NCI_META_CUI","value":"CL474102"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142777":{"preferredName":"Wnt Signaling Pathway Inhibitor SM08502","code":"C142777","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, SM08502 inhibits the expression of genes involved in the Wnt signaling pathway through an as of yet not fully elucidated mechanism. This decreased expression of Wnt pathway-related genes prevents Wnt signaling and may inhibit proliferation of cancer cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is dysregulated in many cancer cell types and plays a crucial role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wnt Signaling Pathway Inhibitor SM08502","termGroup":"PT","termSource":"NCI"},{"termName":"SM 08502","termGroup":"CN","termSource":"NCI"},{"termName":"SM-08502","termGroup":"CN","termSource":"NCI"},{"termName":"SM08502","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wnt Signaling Pathway Inhibitor SM08502"},{"name":"NCI_Drug_Dictionary_ID","value":"791574"},{"name":"NCI_META_CUI","value":"CL540726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791574"},{"name":"PDQ_Open_Trial_Search_ID","value":"791574"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113435":{"preferredName":"Wnt-5a Mimic Hexapeptide Foxy-5","code":"C113435","definitions":[{"definition":"A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wnt-5a Mimic Hexapeptide Foxy-5","termGroup":"PT","termSource":"NCI"},{"termName":"Foxy-5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"881188-51-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CBZ9UL0ARB"},{"name":"Maps_To","value":"Wnt-5a Mimic Hexapeptide Foxy-5"},{"name":"NCI_Drug_Dictionary_ID","value":"756269"},{"name":"NCI_META_CUI","value":"CL458229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756269"},{"name":"PDQ_Open_Trial_Search_ID","value":"756269"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28501":{"preferredName":"Wobe-Mugos E","code":"C28501","definitions":[{"definition":"A mixture made from an extract of the calf thymus gland and enzymes (proteins that speed up chemical reactions in the body) from the papaya plant, the pancreas of cows, and the pancreas of pigs. It has been used in Europe as a treatment for a variety of cancers and for herpes virus infections.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An enzymatic preparation containing proteolytic enzymes papain, trypsin and chymotrypsin with potential anti-inflammatory and anticarcinogenic activities. Papain can be extracted from the fruit of the papaya plant. Trypsin and chymotrypsin are serine proteases produced and secreted by the pancreas. Although its exact mechanisms has yet to be fully illustrated, Wobe-Mugos E appears to have the ability to modulate the immune system by degrading cytokines, and cytokine receptors and clearing circulating immune protein complexes, as well as disrupting adhesion molecules. This agent has been shown to reduce chemotherapy-induced toxicity, inhibit tumor cell proliferation and prolong survival rates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wobe-Mugos E","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Wobe-Mugos_E"},{"name":"Maps_To","value":"Wobe-Mugos E"},{"name":"NCI_Drug_Dictionary_ID","value":"38247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38247"},{"name":"PDQ_Open_Trial_Search_ID","value":"38247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935809"}]}}{"C106257":{"preferredName":"WT1 Peptide Vaccine OCV-501","code":"C106257","definitions":[{"definition":"A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Peptide Vaccine OCV-501","termGroup":"PT","termSource":"NCI"},{"termName":"OCV-501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1 Peptide Vaccine OCV-501"},{"name":"NCI_Drug_Dictionary_ID","value":"713831"},{"name":"NCI_META_CUI","value":"CL433890"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713831"},{"name":"PDQ_Open_Trial_Search_ID","value":"713831"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102751":{"preferredName":"WT1 Peptide Vaccine WT2725","code":"C102751","definitions":[{"definition":"A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Peptide Vaccine WT2725","termGroup":"PT","termSource":"NCI"},{"termName":"WT2725","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1 Peptide Vaccine WT2725"},{"name":"NCI_Drug_Dictionary_ID","value":"735821"},{"name":"NCI_META_CUI","value":"CL437008"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735821"},{"name":"PDQ_Open_Trial_Search_ID","value":"735821"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121957":{"preferredName":"WT1 Protein-derived Peptide Vaccine DSP-7888","code":"C121957","definitions":[{"definition":"A peptide cancer vaccine comprised of peptides derived from the Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT1 protein-derived peptide vaccine DSP-7888 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. In addition, DSP-7888 induces a helper T-lymphocyte-mediated immune response against WT1 expressing tumor cells. WT1 protein, a zinc finger DNA-binding protein and transcription factor, is overexpressed in leukemic cells and in many non-hematological solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Protein-derived Peptide Vaccine DSP-7888","termGroup":"PT","termSource":"NCI"},{"termName":"DSP-7888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1 Protein-derived Peptide Vaccine DSP-7888"},{"name":"NCI_Drug_Dictionary_ID","value":"772161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772161"},{"name":"PDQ_Open_Trial_Search_ID","value":"772161"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053649"}]}}{"C78865":{"preferredName":"WT1-A10/AS01B Immunotherapeutic GSK2130579A","code":"C78865","definitions":[{"definition":"An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities.  Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1-A10/AS01B Immunotherapeutic GSK2130579A","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2130579A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WT1_Vaccine_GSK2130579A"},{"name":"Maps_To","value":"WT1-A10/AS01B Immunotherapeutic GSK2130579A"},{"name":"NCI_Drug_Dictionary_ID","value":"610132"},{"name":"NCI_META_CUI","value":"CL387745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610132"},{"name":"PDQ_Open_Trial_Search_ID","value":"610132"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148480":{"preferredName":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401","code":"C148480","definitions":[{"definition":"A preparation composed of three separate DNA plasmids encoding the tumor-associated antigens (TAAs) Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), with potential immunostimulating and antineoplastic activites. Upon intramuscular delivery and electroporation of the WT1/PSMA/hTERT-encoding plasmid DNA INO-5401, the genes are translated into their respective proteins inside the cell. The expressed proteins activate the immune system and induce a cytotoxic T-lymphocyte (CTL)-mediated response against cells expressing the WT1, PSMA and hTERT antigens, causing tumor cell lysis. hTERT, WT1 and PSMA are upregulated in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401","termGroup":"PT","termSource":"NCI"},{"termName":"INO 5401","termGroup":"CN","termSource":"NCI"},{"termName":"INO-5401","termGroup":"CN","termSource":"NCI"},{"termName":"INO5401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401"},{"name":"NCI_Drug_Dictionary_ID","value":"795318"},{"name":"NCI_META_CUI","value":"CL551059"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795318"},{"name":"PDQ_Open_Trial_Search_ID","value":"795318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121950":{"preferredName":"Xanthohumol","code":"C121950","definitions":[{"definition":"A prenylated flavonoid derived from the female flowers of the hops plant (Humulus lupulus L), with potential chemopreventive and antineoplastic activities. Upon administration, xanthohumol scavenges reactive oxygen species (ROS), thereby preventing DNA damage due to oxidative stress. In addition, xanthohumol is able to increase the expression of phase II cytoprotective enzymes, thereby inactivating carcinogens. This agent exerts anti-inflammatory activity, through the inhibition of inflammation-inducing enzymes, inhibits DNA synthesis, and induces apoptosis of susceptible cancer cells. Xanthohumol also decreases the expression of C-X-C chemokine receptor 4 (CXCR4), thereby preventing cancer cell invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xanthohumol","termGroup":"PT","termSource":"NCI"},{"termName":"3'-[3,3-Dimethyl allyl]-2',4',4-trihydroxy-6'-methoxychalcone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6754-58-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T4467YT1NT"},{"name":"Maps_To","value":"Xanthohumol"},{"name":"NCI_Drug_Dictionary_ID","value":"772021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772021"},{"name":"PDQ_Open_Trial_Search_ID","value":"772021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0536128"}]}}{"C103823":{"preferredName":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","code":"C103823","definitions":[{"definition":"A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.  The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","termGroup":"PT","termSource":"NCI"},{"termName":"PVX-410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410"},{"name":"NCI_Drug_Dictionary_ID","value":"742602"},{"name":"NCI_META_CUI","value":"CL438306"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742602"},{"name":"PDQ_Open_Trial_Search_ID","value":"742602"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106118":{"preferredName":"Xentuzumab","code":"C106118","definitions":[{"definition":"A humanized IgG1 insulin-like growth factor (IGF) monoclonal antibody targeting the IGF ligands 1 (IGF-1) and 2 (IGF-2), with potential antineoplastic activity. Upon administration, xentuzumab binds to both IGF-1 and IGF-2 and inhibits the binding of these ligands to their receptor, IGF-1R. This blocks the insulin growth factor (IGF) signaling pathway, which is upregulated in a number of cancer cell types and plays a key role in cancer cell proliferation and chemoresistance. In addition, BI 836845 prevents the binding of IGF-2 to insulin receptor variant A (IR-A), preventing its activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xentuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"BI 836845","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I) (Human Monoclonal PS05388 Heavy Chain), Disulfide with Human Monoclonal PS05388 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1417158-65-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X86Z1O656G"},{"name":"Maps_To","value":"Xentuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"697680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697680"},{"name":"PDQ_Open_Trial_Search_ID","value":"697680"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827152"}]}}{"C165272":{"preferredName":"Xiaoai Jiedu Decoction","code":"C165272","definitions":[{"definition":"A traditional Chinese medicine (TCM) decoction composed of Oldenlandia, Kuh-seng, Codonopsis pilosula, bighead atractylodes rhizome, smoked plum, the rhizome of Chinese goldthread, rhizome zingiberis preparata and semen Coicis, with potential chemopreventive and antineoplastic activities. Upon administration of Xiaoai Jiedu decoction, the active ingredients in this decoction may inhibit a variety of signal transduction pathways involved in carcinogenesis. This may induce cell cycle arrest and tumor cell apoptosis and inhibit tumor cell formation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xiaoai Jiedu Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"Xiaoai Jiedu Recipe","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Xiaoai Jiedu Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"799435"},{"name":"NCI_META_CUI","value":"CL978539"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799435"},{"name":"PDQ_Open_Trial_Search_ID","value":"799435"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49180":{"preferredName":"XIAP Antisense Oligonucleotide AEG35156","code":"C49180","definitions":[{"definition":"A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. AEG35156 may kill cancer cells by blocking the production of a protein called XIAP that helps cells live longer. It also makes cancer cells more sensitive to anticancer drugs. It is a type of antisense oligonucleotide, and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"XIAP Antisense Oligonucleotide AEG35156","termGroup":"PT","termSource":"NCI"},{"termName":"GEM640","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AEG35156"},{"name":"Maps_To","value":"XIAP Antisense Oligonucleotide AEG35156"},{"name":"NCI_Drug_Dictionary_ID","value":"492218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492218"},{"name":"PDQ_Open_Trial_Search_ID","value":"492218"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567121"}]}}{"C123913":{"preferredName":"Tolinapant","code":"C123913","definitions":[{"definition":"An orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptotic activities. Upon administration, tolinapant selectively binds to and inhibits the activity of XIAP and cIAP1. This restores and promotes the induction of apoptotic signaling pathways in cancer cells, and inactivates the nuclear factor-kappa B (NF-kB)-mediated survival pathway. XIAP and cIAP1 are overexpressed by many cancer cell types and suppress apoptosis by inhibiting the activity of certain caspases; they promote both cancer cell survival and chemotherapy resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tolinapant","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 660","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX660","termGroup":"CN","termSource":"NCI"},{"termName":"XIAP/cIAP1 Antagonist ASTX660","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1799328-86-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2LHZ9ZC3YO"},{"name":"Maps_To","value":"XIAP/cIAP1 Antagonist ASTX660"},{"name":"NCI_Drug_Dictionary_ID","value":"775838"},{"name":"NCI_META_CUI","value":"CL498277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775838"},{"name":"PDQ_Open_Trial_Search_ID","value":"775838"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171660":{"preferredName":"Felezonexor","code":"C171660","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear export protein exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic and pro-apoptotic activities. Upon administration, felezonexor reversibly binds to the cargo binding site of XPO1, and prevents the XPO1-mediated nuclear export of cargo proteins, including tumor suppressor proteins (TSPs), such as p53, FOXO, p21, and p27, and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), SL-801 restores the nuclear localization and function of TSPs, which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins and RNA from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The dysregulated export of TSPs into the cytoplasm prevents TSP-initiated apoptosis. XPO1 overexpression leads to uncontrolled tumor cell proliferation and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Felezonexor","termGroup":"PT","termSource":"NCI"},{"termName":"CBS 9106","termGroup":"CN","termSource":"NCI"},{"termName":"SL 801","termGroup":"CN","termSource":"NCI"},{"termName":"SL-801","termGroup":"CN","termSource":"NCI"},{"termName":"XPO1 Inhibitor SL-801","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1076235-04-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PAW9EP9BXO"},{"name":"Maps_To","value":"XPO1 Inhibitor SL-801"},{"name":"NCI_Drug_Dictionary_ID","value":"782045"},{"name":"NCI_META_CUI","value":"CL1405652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2597":{"preferredName":"Y 90 Monoclonal Antibody CC49","code":"C2597","definitions":[{"definition":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with Yttrium 90 (Y-90). MoAb CC49 recognizes the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Y-90 MoAb CC49 delivers beta particles emitting Y-90 radionuclide directly to tumor cells that express TAG-72, thereby this agent may be used in radioimmunotherapeutic treatment of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody CC49","termGroup":"PT","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody CC49"},{"name":"NCI_Drug_Dictionary_ID","value":"38082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38082"},{"name":"PDQ_Open_Trial_Search_ID","value":"38082"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935674"}]}}{"C2541":{"preferredName":"Y 90 Monoclonal Antibody HMFG1","code":"C2541","definitions":[{"definition":"A radioimmunoconjugate consisting of HMFG1, a humanized monoclonal antibody directed against the tumor associated antigen mucin-1 (MUC-1), labeled with the beta-emitting radioisotope yttrium 90 (Y-90), with potential antineoplastic activities. Upon administration, the monoclonal antibody moiety targets and binds to MUC-1 on the surface of certain tumor cells. Upon binding and internalization, pemtumomab and delivers a cytotoxic dose of beta radiation to MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody HMFG1","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB HMFG1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody HMFG1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Theragyn","termGroup":"FB","termSource":"NCI"},{"termName":"Y 90 MoAb HMFG1","termGroup":"AB","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB HMFG1","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody HMFG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_HMFG1"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody HMFG1"},{"name":"NCI_Drug_Dictionary_ID","value":"43644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43644"},{"name":"PDQ_Open_Trial_Search_ID","value":"43644"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879349"}]}}{"C2247":{"preferredName":"Y 90 Monoclonal Antibody Lym-1","code":"C2247","definitions":[{"definition":"A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. Y-90 MoAb Lym-1 delivers Y-90 radionuclide directly to tumor cells that express HLA-DR antigen, thereby this agent may be used in radioimmunotherapy of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody Lym-1","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB Lym-1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody Lym-1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb Lym-1","termGroup":"AB","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody Lym-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_Lym-1"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody Lym-1"},{"name":"NCI_Drug_Dictionary_ID","value":"43509"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43509"},{"name":"PDQ_Open_Trial_Search_ID","value":"43509"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796675"}]}}{"C2532":{"preferredName":"Y 90 Monoclonal Antibody m170","code":"C2532","definitions":[{"definition":"A radioimmunoconjugate of m170 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb m170 is a murine MoAb that recognizes MUC-1 antigen present on the surface of many adenocarcinomas. This radioimmunoconjugate emits beta particles that cause cytotoxicity in tumor cells and has both imaging and therapeutic uses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody m170","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB m170, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody m170, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb m170","termGroup":"AB","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB m170","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody m170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_m170"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody m170"},{"name":"NCI_Drug_Dictionary_ID","value":"43501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43501"},{"name":"PDQ_Open_Trial_Search_ID","value":"43501"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796669"}]}}{"C2248":{"preferredName":"Y 90 Monoclonal Antibody M195","code":"C2248","definitions":[{"definition":"A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface antigen CD33, a glycoprotein found on myeloid leukemia blasts and early hematopoietic progenitor cells but not on normal stem cells. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody M195","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB M195, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody M195, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb M195","termGroup":"AB","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody M195","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_M195"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody M195"},{"name":"NCI_Drug_Dictionary_ID","value":"38025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38025"},{"name":"PDQ_Open_Trial_Search_ID","value":"38025"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879572"}]}}{"C132024":{"preferredName":"Yang Yin Fu Zheng","code":"C132024","definitions":[{"definition":"A traditional Chinese medicine (TCM)-based formulation, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, Yang Yin Fu Zheng may activate the immune system and may help inhibit tumor cell proliferation. This TCM may also help remove toxic substances.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yang Yin Fu Zheng","termGroup":"PT","termSource":"NCI"},{"termName":"Fu Zheng Yang Yin","termGroup":"SY","termSource":"NCI"},{"termName":"Fu Zheng Yang Yin Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"TCM Yang Yin Fu Zheng","termGroup":"SY","termSource":"NCI"},{"termName":"Yang Yin Fu Zheng Jie Du","termGroup":"SY","termSource":"NCI"},{"termName":"Yangyin Fuzheng Jiedu","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yang Yin Fu Zheng"},{"name":"NCI_Drug_Dictionary_ID","value":"786518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786518"},{"name":"PDQ_Open_Trial_Search_ID","value":"786518"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2355396"}]}}{"C111897":{"preferredName":"Yangzheng Xiaoji Extract","code":"C111897","definitions":[{"definition":"A traditional Chinese medicine (TCM)-based formulation containing the Yangzheng Xiaoji (YZXJ) extract, consisting of various components, with potential antineoplastic and anti-angiogenic activities. Some of the main components in Yangzheng Xiaoji are Radix Astragali, Fructus Ligustri Lucidi, Radix Ginseng, Ganoderma, Rhizoma Curcumac, Fried Rhizoma Atractylodis, Macrocephalae and Herba Hedyotidis. Although the exact mechanism(s) through which Yangzheng Xiaoji exerts its effects have yet to be fully elucidated, this agent, upon administration, inhibits the activation of various signaling protein kinases, such as focal adhesion kinase (FAK) and paxillin. This prevents signal transduction pathways that are upregulated in cancer, prevents the adhesion and migration of tumor cells and inhibits tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yangzheng Xiaoji Extract","termGroup":"PT","termSource":"NCI"},{"termName":"DME25","termGroup":"CN","termSource":"NCI"},{"termName":"YZXJ Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yangzheng Xiaoji Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"753388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753388"},{"name":"PDQ_Open_Trial_Search_ID","value":"753388"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827131"}]}}{"C132026":{"preferredName":"Yiqi-yangyin-jiedu Herbal Decoction","code":"C132026","definitions":[{"definition":"A traditional Chinese medicine (TCM) based formulation consisting of milkvetch root, glehnia root, asparagus root, lilyturf root, grossy privet fruit, spikemoss herb, Chinese sage herb, and manyleaf paris rhizome, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, yiqi-yangyin-jiedu decoction (YYJD) may activate the immune system by enhancing T-lymphocyte activity, and inhibiting tumor cell proliferation. YYJD may also ameliorate the qi-yin deficiency syndrome by strengthening qi and nourishing yin. YYJD may help remove toxic substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yiqi-yangyin-jiedu Herbal Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"TCM Yiqi-yangyin-jiedu Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"Yiqi Yangyin Jiedu Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"YYJ Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"YYJD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yiqi-yangyin-jiedu Herbal Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"786577"},{"name":"NCI_META_CUI","value":"CL521287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786577"},{"name":"PDQ_Open_Trial_Search_ID","value":"786577"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74092":{"preferredName":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12","code":"C74092","definitions":[{"definition":"A radioimmunoconjugate consisting of the murine IgG1 anti-CD19 monoclonal antibody (MoAb) BU12 labeled with the beta-emitting radioisotope yttrium Y 90 with radioisotopic and antibody activities. Yttrium Y 90 anti-CD19 monoclonal antibody BU12 binds to the CD19 molecule, specifically delivering cytotoxic beta radiation to CD19-expressing B cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Anti-CD19_Monoclonal_Antibody_BU12"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12"},{"name":"NCI_Drug_Dictionary_ID","value":"592567"},{"name":"NCI_META_CUI","value":"CL383553"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592567"},{"name":"PDQ_Open_Trial_Search_ID","value":"592567"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74093":{"preferredName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12","code":"C74093","definitions":[{"definition":"A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal antibody AHN-12 binds to the tyrosine phosphatase CD45, expressed on the surface of normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12","termGroup":"PT","termSource":"NCI"},{"termName":"Y 90 AHN-12","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Anti-CD45_Monoclonal_Antibody_AHN-12"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12"},{"name":"NCI_Drug_Dictionary_ID","value":"587979"},{"name":"NCI_META_CUI","value":"CL383503"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587979"},{"name":"PDQ_Open_Trial_Search_ID","value":"587979"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95698":{"preferredName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","code":"C95698","definitions":[{"definition":"A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with yttrium 90 (Y90), with potential immunotherapeutic activity. Yttrium Y 90 anti-CD45 monoclonal antibody BC8 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Anti-CD45 MoAb BC8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8"},{"name":"NCI_Drug_Dictionary_ID","value":"688830"},{"name":"NCI_META_CUI","value":"CL428164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688830"},{"name":"PDQ_Open_Trial_Search_ID","value":"688830"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122405":{"preferredName":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","code":"C122405","definitions":[{"definition":"A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","termGroup":"PT","termSource":"NCI"},{"termName":"FF-21101(90Y)","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101"},{"name":"NCI_Drug_Dictionary_ID","value":"772801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772801"},{"name":"PDQ_Open_Trial_Search_ID","value":"772801"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053526"}]}}{"C77885":{"preferredName":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66","code":"C77885","definitions":[{"definition":"A radioimmunoconjugate comprised of a chimeric monoclonal antibody against human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y90 DOTA anti-CEA monoclonal antibody cT84.66 binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66","termGroup":"PT","termSource":"NCI"},{"termName":"cT84.66","termGroup":"CN","termSource":"NCI"},{"termName":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody cT84.66","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Anti-CEA_Monoclonal_Antibody_cT84_66"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66"},{"name":"NCI_Drug_Dictionary_ID","value":"592860"},{"name":"NCI_META_CUI","value":"CL387153"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592860"},{"name":"PDQ_Open_Trial_Search_ID","value":"592860"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99167":{"preferredName":"Yttrium Y 90 Basiliximab","code":"C99167","definitions":[{"definition":"A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium Y 90 basiliximab selectively binds to IL-2R alpha expressed on the surface of activated T-lymphocytes, thereby preventing IL-2 binding and blocking the IL-2-mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the IL-2 receptor. This may prevent T cell-mediated activation of the immune system against a certain transplant and may prevent transplant rejection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Basiliximab","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Basiliximab","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90-DOTA-Basiliximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Basiliximab"},{"name":"NCI_Drug_Dictionary_ID","value":"717514"},{"name":"NCI_META_CUI","value":"CL433016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717514"},{"name":"PDQ_Open_Trial_Search_ID","value":"717514"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114495":{"preferredName":"Yttrium Y 90 Colloid","code":"C114495","definitions":[{"definition":"An injectable, colloidal formulation of the radioisotope yttrium Y 90, with potential antineoplastic activity. When injected into the tumor, the yttrium Y 90 colloid selectively delivers a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Colloid","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Colloid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Colloid"},{"name":"NCI_Drug_Dictionary_ID","value":"759092"},{"name":"NCI_META_CUI","value":"CL472321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759092"},{"name":"PDQ_Open_Trial_Search_ID","value":"759092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2600":{"preferredName":"Yttrium Y 90 Daclizumab","code":"C2600","definitions":[{"definition":"A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity.  Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes.  As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Daclizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Y90 Daclizumab","termGroup":"SY","termSource":"NCI"},{"termName":"Y90 MOAB Anti-Tac","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Daclizumab"},{"name":"Maps_To","value":"Yttrium Y 90 Daclizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38097"},{"name":"PDQ_Open_Trial_Search_ID","value":"38097"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935688"}]}}{"C77853":{"preferredName":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A","code":"C77853","definitions":[{"definition":"A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. M5A is a monoclonal antibody that binds to a protein called CEA on the surface of some tumor cells. It is linked to a radioisotope called yttrium Y 90, which may help kill the cancer cells. Yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A is a type of radioimmunoconjugate and a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A","termGroup":"PT","termSource":"NCI"},{"termName":"Y90-DOTA-M5A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I9O4Z8CE5L"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Anti-CEA_Monoclonal_Antibody_M5A"},{"name":"Maps_To","value":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A"},{"name":"NCI_Drug_Dictionary_ID","value":"592693"},{"name":"NCI_META_CUI","value":"CL383554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592693"},{"name":"PDQ_Open_Trial_Search_ID","value":"592693"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38679":{"preferredName":"Yttrium Y 90 Glass Microspheres","code":"C38679","definitions":[{"definition":"An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90.  When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Glass Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"TheraSphere","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular carcinoma, transarterial internal radiation"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Glass_Microspheres"},{"name":"Maps_To","value":"Y-90 Therasphere"},{"name":"Maps_To","value":"Yttrium Y 90 Glass Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"38672"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38672"},{"name":"PDQ_Open_Trial_Search_ID","value":"38672"},{"name":"Semantic_Type","value":"Drug Delivery Device"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134675"}]}}{"C2614":{"preferredName":"Yttrium Y 90 Monoclonal Antibody B3","code":"C2614","definitions":[{"definition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody B3","termGroup":"PT","termSource":"NCI"},{"termName":"90 Y-B3","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB B3, Yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 Monoclonal Antibody B3","termGroup":"SY","termSource":"NCI"},{"termName":"Y90-B3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Monoclonal_Antibody_B3"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody B3"},{"name":"NCI_Drug_Dictionary_ID","value":"38188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38188"},{"name":"PDQ_Open_Trial_Search_ID","value":"38188"},{"name":"PubMedID_Primary_Reference","value":"10815890"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935761"}]}}{"C2607":{"preferredName":"Yttrium Y 90 Monoclonal Antibody BrE-3","code":"C2607","definitions":[{"definition":"A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody BrE-3","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB BrE-3, Yttrium Y 90","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Monoclonal_Antibody_BrE-3"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody BrE-3"},{"name":"NCI_Drug_Dictionary_ID","value":"38148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38148"},{"name":"PDQ_Open_Trial_Search_ID","value":"38148"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935731"}]}}{"C38678":{"preferredName":"Yttrium Y 90 Monoclonal Antibody Hu3S193","code":"C38678","definitions":[{"definition":"A radioimmunotherapeutic agent consisting of a humanized murine monoclonal antibody (hu3S193) directed against the tumor-associated Lewis Y epithelial antigen chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody Hu3S193 binds to Lewis Y epithelial antigen-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody Hu3S193","termGroup":"PT","termSource":"NCI"},{"termName":"Y90 MOAB Hu3S193","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Monoclonal_Antibody_Hu3S193"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody Hu3S193"},{"name":"NCI_Drug_Dictionary_ID","value":"340956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"340956"},{"name":"PDQ_Open_Trial_Search_ID","value":"340956"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328082"}]}}{"C2249":{"preferredName":"Yttrium Y 90 Monoclonal Antibody MN-14","code":"C2249","definitions":[{"definition":"A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody MN-14","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB MN-14, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody MN-14, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb MN-14","termGroup":"AB","termSource":"NCI"},{"termName":"Y 90 Monoclonal Antibody MN-14","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium 90 Monoclonal Antibody MN-14","termGroup":"SY","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB MN-14","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_MN-14"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody MN-14"},{"name":"NCI_Drug_Dictionary_ID","value":"43511"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43511"},{"name":"PDQ_Open_Trial_Search_ID","value":"43511"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879253"}]}}{"C64539":{"preferredName":"Yttrium Y 90 Resin Microspheres","code":"C64539","definitions":[{"definition":"An injectable formulation of the radioisotope yttrium Y 90 encapsulated in resin microspheres with potential antineoplastic activity. When injected into arterial vasculature supplying the tumor, yttrium Y 90 resin microspheres occlude tumor blood vessels and selectively deliver a cytotoxic dose of beta emitting yttrium Y 90 to the tumor site, which may result in tumor cell death and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Resin Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"SIR-Spheres","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular carcinoma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Resin_Microspheres"},{"name":"Maps_To","value":"Y-90 Sirsphere"},{"name":"Maps_To","value":"Yttrium Y 90 Resin Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"523414"},{"name":"PDQ_Closed_Trial_Search_ID","value":"523414"},{"name":"PDQ_Open_Trial_Search_ID","value":"523414"},{"name":"Semantic_Type","value":"Drug Delivery Device"},{"name":"UMLS_CUI","value":"C1831993"}]}}{"C1808":{"preferredName":"Yttrium Y 90-DOTA-Biotin","code":"C1808","definitions":[{"definition":"A compound that contains the radioisotope yttrium Y 90 linked to the chemical biotin. Biotin is a molecule that binds strongly to the chemical streptavidin. Yttrium Y 90 DOTA-biotin will find tumor cells in the body that have been targeted by an antibody linked to streptavidin and kill them. It is being studied together with CC49-streptavidin in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioconjugate of biotin and yttrium Y 90 (Y-90) linked through the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) with radioimmunotherapy property. Biotin is a water-soluble B-complex vitamin, present in minute amounts in every living cell, while its level in cancerous tissue is higher than that of normal tissue. Y 90-DOTA-Biotin could be used in 3-step pre-targeting radioimmunotherapy that employs a tumor targeting antibody conjugated with streptavidin, the natural ligand of biotin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90-DOTA-Biotin","termGroup":"PT","termSource":"NCI"},{"termName":"90Y-DOTA-Biotin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_90Y-DOTA-Biotin"},{"name":"Maps_To","value":"Yttrium Y 90-DOTA-Biotin"},{"name":"NCI_Drug_Dictionary_ID","value":"365680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365680"},{"name":"PDQ_Open_Trial_Search_ID","value":"365680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677849"}]}}{"C119738":{"preferredName":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","code":"C119738","definitions":[{"definition":"A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the beta-emitting radionuclide yttrium 90 (Y-90), with radioimmunotherapeutic activity. After pre-treating and targeting tumor cells with a bi-specific monoclonal antibody (BiMoAB) directed against both a tumor-associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of the administered yttrium Y 90-DOTA-di-HSG peptide IMP-288 binds to the anti-HSG sequence on the BiMoAB. In turn, Y-90 delivers a cytotoxic dose of beta radiation to tumor cells expressing the specific TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","termGroup":"PT","termSource":"NCI"},{"termName":"90-Y-IMP-288","termGroup":"AB","termSource":"NCI"},{"termName":"90Y-IMP288","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288"},{"name":"NCI_Drug_Dictionary_ID","value":"766993"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766993"},{"name":"PDQ_Open_Trial_Search_ID","value":"766993"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896702"}]}}{"C2601":{"preferredName":"Yttrium Y 90-Edotreotide","code":"C2601","definitions":[{"definition":"A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. Yttrium Y 90 edotreotide contains yttrium Y 90 (a radioactive form of the metal yttrium) attached to a molecule that binds to certain types of neuroendocrine tumors (tumors that come from cells that release hormones). The radioactivity from yttrium Y 90 may kill the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y 90-Edotreotide","termGroup":"PT","termSource":"NCI"},{"termName":"90Y-DOTA-3-Tyr-Octreotide","termGroup":"SY","termSource":"NCI"},{"termName":"OctreoTher","termGroup":"BR","termSource":"NCI"},{"termName":"Onalta","termGroup":"BR","termSource":"NCI"},{"termName":"Yttrium Y 90 -DOTATOC","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 SMT 487","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90-DOTA-3-tyrosine-octreotide","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90-DOTA-Tyr3-Octreotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"322407-70-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ABF7OG3FA3"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_SMT_487"},{"name":"Maps_To","value":"Yttrium Y 90-Edotreotide"},{"name":"NCI_Drug_Dictionary_ID","value":"38102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38102"},{"name":"PDQ_Open_Trial_Search_ID","value":"38102"},{"name":"PubMedID_Primary_Reference","value":"20168290"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2003893"}]}}{"C99168":{"preferredName":"Yttrium Y 90 Tabituximab Barzuxetan","code":"C99168","definitions":[{"definition":"A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) OTSA101 against FZD10 and labeled with yttrium y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101 binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except for the placenta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Tabituximab Barzuxetan","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Tabituximab Barzuxetan","termGroup":"SY","termSource":"NCI"},{"termName":"OTSA101-DTPA-90Y","termGroup":"AB","termSource":"NCI"},{"termName":"Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Tabituximab Barzuxetan"},{"name":"Maps_To","value":"Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101"},{"name":"NCI_Drug_Dictionary_ID","value":"717536"},{"name":"NCI_META_CUI","value":"CL433017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717536"},{"name":"PDQ_Open_Trial_Search_ID","value":"717536"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48429":{"preferredName":"Yttrium Y-90 Clivatuzumab Tetraxetan","code":"C48429","definitions":[{"definition":"A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of advanced pancreatic cancer. HuPAM4 is a monoclonal antibody that can locate and bind to pancreatic cancer cells. It is linked to a radioactive substance called yttrium Y90, which may help kill cancer cells. Yttrium Y 90 DOTA monoclonal antibody HuPAM4 is a type of radioimmunoconjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y-90 Clivatuzumab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"90Y-hPAM4","termGroup":"AB","termSource":"NCI"},{"termName":"hPAM4-Cide","termGroup":"BR","termSource":"NCI"},{"termName":"hPAM4-DOTA","termGroup":"CN","termSource":"NCI"},{"termName":"IMMU-107","termGroup":"CN","termSource":"NCI"},{"termName":"Yttrium (90Y) Clivatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Clivatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 DOTA Monoclonal Antibody HuPAM4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943976-23-6"},{"name":"Chemical_Formula","value":"C16H25N5O7.Y"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2L271110ED"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Monoclonal_Antibody_HuPAM4"},{"name":"Maps_To","value":"Yttrium Y-90 Clivatuzumab Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"425350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425350"},{"name":"PDQ_Open_Trial_Search_ID","value":"425350"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541526"}]}}{"C2582":{"preferredName":"Yttrium Y-90 Epratuzumab Tetraxetan","code":"C2582","definitions":[{"definition":"A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y-90 Epratuzumab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"Monoclonal antibody LL2, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 Humanized Monoclonal Antibody LL2","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb LL2","termGroup":"AB","termSource":"NCI"},{"termName":"Y 90 monoclonal antibody LL2","termGroup":"SY","termSource":"NCI"},{"termName":"Y90 Humanized Epratuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Humanized Epratuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Humanized Monoclonal Antibody LL2","termGroup":"SY","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB LL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501423-25-2"},{"name":"Chemical_Formula","value":"C16H25N5O7.Y"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J36232195E"},{"name":"Legacy Concept Name","value":"Y_90_Humanized_Monoclonal_Antibody_LL2"},{"name":"Maps_To","value":"Yttrium Y-90 Epratuzumab Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"43648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43648"},{"name":"PDQ_Open_Trial_Search_ID","value":"43648"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879352"}]}}{"C1812":{"preferredName":"Yttrium Y-90 Ibritumomab Tiuxetan","code":"C1812","definitions":[{"definition":"A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. Y 90 ibritumomab tiuxetan is a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y-90 Ibritumomab Tiuxetan","termGroup":"PT","termSource":"NCI"},{"termName":"IDEC-Y2B8","termGroup":"AB","termSource":"NCI"},{"termName":"Y 90 Ibritumomab Tiuxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Ibritumomab Tiuxetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Hodgkin's Lymphoma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QA846JAV5B"},{"name":"Legacy Concept Name","value":"Y_90_Ibritumomab_Tiuxetan"},{"name":"Maps_To","value":"Yttrium Y-90 Ibritumomab Tiuxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"38483"},{"name":"NSC Number","value":"710085"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38483"},{"name":"PDQ_Open_Trial_Search_ID","value":"38483"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879283"}]}}{"C48428":{"preferredName":"Yttrium Y-90 Tacatuzumab Tetraxetan","code":"C48428","definitions":[{"definition":"A radioimmunoconjugate comprised of the humanized monoclonal antibody tacatuzumab, directed against alpha fetoprotein, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, thereby selectively delivering a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of liver cancer. HuAFP31 is a monoclonal antibody that can bind to tumor cells that make a protein called alpha fetoprotein (AFP). It is linked to a radioactive substance called yttrium Y 90, which may help kill the cancer cells. Yttrium Y 90 DOTA monoclonal antibody HuAFP31 is a type of radioimmunoconjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y-90 Tacatuzumab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"AFP-Cide","termGroup":"BR","termSource":"NCI"},{"termName":"Y-90 hAFP-31","termGroup":"AB","termSource":"NCI"},{"termName":"Yttrium (90Y) Tacatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Tacatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y-90 Tacatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"476413-07-7"},{"name":"Chemical_Formula","value":"C16H25N5O7.Y"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GJ2416WK6Y"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Monoclonal_Antibody_HuAFP31"},{"name":"Maps_To","value":"Yttrium Y-90 Tacatuzumab Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"425347"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425347"},{"name":"PDQ_Open_Trial_Search_ID","value":"425347"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541525"}]}}{"C80739":{"preferredName":"Yttrium-90 Polycarbonate Brachytherapy Plaque","code":"C80739","definitions":[{"definition":"A polycarbonate-based semicylindrical plaque impregnated with yttrium Y 90 with radioisotopic and antineoplastic activities. An yttrium-90 polycarbonate brachytherapy plaque may be applied to a tumor site with a special brachytherapy applicator for a predetermined interval of time, selectively delivering a cytotoxic dose of beta-emitting yttrium Y 90.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium-90 Polycarbonate Brachytherapy Plaque","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Plaque_Applicator"},{"name":"Maps_To","value":"Yttrium-90 Polycarbonate Brachytherapy Plaque"},{"name":"NCI_Drug_Dictionary_ID","value":"600953"},{"name":"NCI_META_CUI","value":"CL388351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600953"},{"name":"PDQ_Open_Trial_Search_ID","value":"600953"},{"name":"Semantic_Type","value":"Drug Delivery Device"}]}}{"C95713":{"preferredName":"Endoxifen Hydrochloride","code":"C95713","definitions":[{"definition":"The hydrochloride salt and the z (cis-) stereoisomer of endoxifen with potential antineoplastic activity. Endoxifen, the active metabolite of tamoxifen, competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA and thus reducing DNA synthesis. Unlike tamoxifen, however, which relies on CYP2D6 activity for its conversion to the active metabolite endoxifen, the direct administration of endoxifen bypasses the CYP2D6 route. As CYP2D6 activity can vary widely among individuals due to genetic CYP2D6 polymorphisms, endoxifen is therefore theoretically more potent and more uniform in its bioavailability across patient populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endoxifen Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hydroxy-N-Desmethyltamoxifen Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Z-Endoxifen HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Z-Endoxifen Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032008-74-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"308PA1L567"},{"name":"Maps_To","value":"Z-Endoxifen Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"693335"},{"name":"NCI_META_CUI","value":"CL428178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693335"},{"name":"PDQ_Open_Trial_Search_ID","value":"693335"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C430":{"preferredName":"Zalcitabine","code":"C430","definitions":[{"definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zalcitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2',3'-Dideoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"ddC","termGroup":"AB","termSource":"NCI"},{"termName":"Dideoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Hivid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7481-89-2"},{"name":"CHEBI_ID","value":"CHEBI:10101"},{"name":"Chemical_Formula","value":"C9H13N3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6L3XT8CB3I"},{"name":"Legacy Concept Name","value":"Zalcitabine"},{"name":"Maps_To","value":"Zalcitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"40349"},{"name":"NSC Number","value":"606170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40349"},{"name":"PDQ_Open_Trial_Search_ID","value":"40349"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012132"}]}}{"C126113":{"preferredName":"Zalifrelimab","code":"C126113","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zalifrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN-1884","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1884","termGroup":"CN","termSource":"NCI"},{"termName":"UGN 301","termGroup":"CN","termSource":"NCI"},{"termName":"UGN-301","termGroup":"CN","termSource":"NCI"},{"termName":"UGN301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2148321-69-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FE7L22H028"},{"name":"Maps_To","value":"Zalifrelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"779578"},{"name":"NCI_META_CUI","value":"CL504706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779578"},{"name":"PDQ_Open_Trial_Search_ID","value":"779578"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64620":{"preferredName":"Zalutumumab","code":"C64620","definitions":[{"definition":"A fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR is a cell surface receptor tyrosine kinase, overexpressed on many cancer cells. Zalutumumab selectively binds to and blocks binding of EGF and transforming growth factor-alpha (TGF-a) to the EGFR receptor, thereby interfering with cellular signaling, leading to cell growth inhibition and apoptosis in tumor cells. In addition, zalutumumab also triggers cell lysis mediated through antibody dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zalutumumab","termGroup":"PT","termSource":"NCI"},{"termName":"2FB","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-EGFr, 2F8","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"667901-13-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DA709Q5020"},{"name":"Legacy Concept Name","value":"Zalutumumab"},{"name":"Maps_To","value":"Zalutumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"518289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518289"},{"name":"PDQ_Open_Trial_Search_ID","value":"518289"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831978"}]}}{"C91701":{"preferredName":"Zanolimumab","code":"C91701","definitions":[{"definition":"A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities. Zanolimumab targets and binds to the CD4 receptor on certain T-cells thereby preventing the interaction between the CD4 receptor and the major histocompatibility complex class II molecule. This prevents activation of CD4 positive T cells. In addition, zanolimumab is able to induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD4-expressing tumor cells. CD4, a receptor located on a subset of T-lymphocytes, is upregulated in T-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanolimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD4 Monoclonal Antibody HuMax","termGroup":"SY","termSource":"NCI"},{"termName":"HuMax-CD4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"652153-01-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HG3L8885M0"},{"name":"Maps_To","value":"Zanolimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"352000"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352000"},{"name":"PDQ_Open_Trial_Search_ID","value":"352000"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1957794"}]}}{"C141428":{"preferredName":"Zanubrutinib","code":"C141428","definitions":[{"definition":"An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanubrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BGB-3111","termGroup":"CN","termSource":"NCI"},{"termName":"Brukinsa","termGroup":"BR","termSource":"NCI"},{"termName":"BTK-InhB","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"CAS_Registry","value":"1691249-45-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"AG9MHG098Z"},{"name":"Maps_To","value":"Zanubrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"768510"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768510"},{"name":"PDQ_Open_Trial_Search_ID","value":"768510"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896894"}]}}{"C37455":{"preferredName":"Zebularine","code":"C37455","definitions":[{"definition":"A synthetic cytidine analogue and a cytidine deaminase inhibitor with anticancer activity. Following metabolic activation by phosphorylation and incorporation into DNA, zebularine inhibits DNA methyltransferase through covalent complex formation between the enzyme and zebularine-substituted DNA, hence resulting in non-specific, genome-wide induction of demethylation including the removal of aberrant methylation of promoter regions of genes critical for normal cellular functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zebularine","termGroup":"PT","termSource":"NCI"},{"termName":"1-beta-D-Ribofuranosyl-2(1H)-pyrimidinone","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyrimidone-1-beta-D-riboside","termGroup":"SN","termSource":"NCI"},{"termName":"4-Deoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Pyrimidin-2-one beta-Ribofuranoside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3690-10-6"},{"name":"CHEBI_ID","value":"CHEBI:46938"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7A9Y5SX0GY"},{"name":"Legacy Concept Name","value":"Zebularine"},{"name":"Maps_To","value":"Zebularine"},{"name":"NSC Number","value":"309132"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084253"}]}}{"C48430":{"preferredName":"Zibotentan","code":"C48430","definitions":[{"definition":"A substance that is being studied in the treatment of prostate cancer. It belongs to the family of drugs called endothelin-receptor antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zibotentan","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pridine-3- sulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"ZD-4054","termGroup":"SY","termSource":"NCI"},{"termName":"ZD4054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186497-07-4"},{"name":"Chemical_Formula","value":"C19H16N6O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8054MM4902"},{"name":"Legacy Concept Name","value":"ZD4054"},{"name":"Maps_To","value":"Zibotentan"},{"name":"NCI_Drug_Dictionary_ID","value":"355727"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355727"},{"name":"PDQ_Open_Trial_Search_ID","value":"355727"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328193"}]}}{"C129588":{"preferredName":"Zinc Finger Nuclease ZFN-603","code":"C129588","definitions":[{"definition":"A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-603 into HPV16-positive cells, ZFN-603 targets, binds to and cleaves the HPV16 E7 oncogene in HPV16-infected cells. By cleaving the HPV16 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and inhibition of tumor cell proliferation in HPV16-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinc Finger Nuclease ZFN-603","termGroup":"PT","termSource":"NCI"},{"termName":"ZFN ZFN-603","termGroup":"SY","termSource":"NCI"},{"termName":"ZFN-603","termGroup":"CN","termSource":"NCI"},{"termName":"ZFN603","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Zinc Finger Nuclease ZFN-603"},{"name":"NCI_Drug_Dictionary_ID","value":"783802"},{"name":"NCI_META_CUI","value":"CL512593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783802"},{"name":"PDQ_Open_Trial_Search_ID","value":"783802"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129589":{"preferredName":"Zinc Finger Nuclease ZFN-758","code":"C129589","definitions":[{"definition":"A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 18 (HPV18) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-758 into HPV18-positive cells, ZFN-758 targets, binds to and cleaves the HPV18 E7 oncogene in HPV18-infected cells. By cleaving the HPV18 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and an inhibition of tumor cell proliferation in HPV18-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinc Finger Nuclease ZFN-758","termGroup":"PT","termSource":"NCI"},{"termName":"ZFN ZFN-758","termGroup":"SY","termSource":"NCI"},{"termName":"ZFN-758","termGroup":"CN","termSource":"NCI"},{"termName":"ZFN758","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Zinc Finger Nuclease ZFN-758"},{"name":"NCI_Drug_Dictionary_ID","value":"783803"},{"name":"NCI_META_CUI","value":"CL512594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783803"},{"name":"PDQ_Open_Trial_Search_ID","value":"783803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C682":{"preferredName":"Zinostatin","code":"C682","definitions":[{"definition":"An enediyne antineoplastic antibiotic hybrid containing an aminoglycoside chromophore.  Zinostatin is isolated from the bacterium Streptomyces carzinostaticus.  The aminoglycoside component of zinostatin intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-strand breaks in DNA and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinostatin","termGroup":"PT","termSource":"NCI"},{"termName":"A 8544527G1","termGroup":"CN","termSource":"NCI"},{"termName":"Holoneocarzinostatin","termGroup":"SY","termSource":"NCI"},{"termName":"NCS","termGroup":"AB","termSource":"NCI"},{"termName":"Neocarzinostatin","termGroup":"SY","termSource":"NCI"},{"termName":"Vinostatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9014-02-2"},{"name":"Chemical_Formula","value":"C35H35NO12"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PP082U6W1L"},{"name":"Legacy Concept Name","value":"Zinostatin"},{"name":"Maps_To","value":"Zinostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39510"},{"name":"NSC Number","value":"157365"},{"name":"NSC Number","value":"69856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39510"},{"name":"PDQ_Open_Trial_Search_ID","value":"39510"},{"name":"PubMedID_Primary_Reference","value":"20735485"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0027597"}]}}{"C162544":{"preferredName":"Zinostatin Stimalamer","code":"C162544","definitions":[{"definition":"A highly lipophilic conjugate protein comprised of the lipophilic antitumor protein, neocarzinostatin (NCS), conjugated with a water-soluble copolymer of styrene-maleic acid (SMA) with potential antineoplastic activity. Upon intra-hepatic arterial administration, zinostatin stimalamer is deposited within tumor tissues, where the NCS moiety induces sequence-specific single and double-stranded breaks via free-radical based mechanisms, resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinostatin Stimalamer","termGroup":"PT","termSource":"NCI"},{"termName":"SMANCS","termGroup":"FB","termSource":"NCI"},{"termName":"YM 881","termGroup":"CN","termSource":"NCI"},{"termName":"YM-881","termGroup":"SY","termSource":"NCI"},{"termName":"YM881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123760-07-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Zinostatin Stimalamer"},{"name":"NCI_META_CUI","value":"CL971120"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156043":{"preferredName":"Zirconium Zr 89 Panitumumab","code":"C156043","definitions":[{"definition":"A radioimmunoconjugate composed of panitumumab, a human immunoglobulin G2 (IgG2) monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 panitumumab, the antibody moiety targets and binds to the extracellular domain of EGFR on tumor cells. Upon PET imaging, EGFR-expressing tumor cells can be visualized and assessed. This allows quantification of EGFR-expressing tumor cells and may allow selection of patients that would respond to panitumumab therapy. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zirconium Zr 89 Panitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"89Zr-labeled Panitumumab","termGroup":"SY","termSource":"NCI"},{"termName":"89Zr-panitumumab","termGroup":"SY","termSource":"NCI"},{"termName":"Zr 89-Panitumumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9S814K02BB"},{"name":"Maps_To","value":"Zirconium Zr 89 Panitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"795428"},{"name":"NCI_META_CUI","value":"CL562883"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795428"},{"name":"PDQ_Open_Trial_Search_ID","value":"795428"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2682":{"preferredName":"Ziv-Aflibercept","code":"C2682","definitions":[{"definition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of several types of cancer. Vascular endothelial growth factor trap blocks the action of vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ziv-Aflibercept","termGroup":"PT","termSource":"NCI"},{"termName":"Aflibercept","termGroup":"SY","termSource":"NCI"},{"termName":"AVE0005","termGroup":"SY","termSource":"NCI"},{"termName":"Eylea","termGroup":"BR","termSource":"NCI"},{"termName":"Vascular Endothelial Growth Factor Trap","termGroup":"SY","termSource":"NCI"},{"termName":"VEGF Trap R1R2","termGroup":"SY","termSource":"NCI"},{"termName":"Zaltrap","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"862111-32-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"15C2VL427D"},{"name":"Legacy Concept Name","value":"VEGF_Trap"},{"name":"Maps_To","value":"Ziv-Aflibercept"},{"name":"NCI_Drug_Dictionary_ID","value":"38652"},{"name":"NSC Number","value":"724770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38652"},{"name":"PDQ_Open_Trial_Search_ID","value":"38652"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134659"}]}}{"C85475":{"preferredName":"Zolbetuximab","code":"C85475","definitions":[{"definition":"A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, zolbetuximab specifically targets and binds to CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zolbetuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Claudiximab","termGroup":"SY","termSource":"NCI"},{"termName":"IMAB 362","termGroup":"CN","termSource":"NCI"},{"termName":"IMAB-362","termGroup":"CN","termSource":"NCI"},{"termName":"IMAB362","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1496553-00-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TF5MPQ8WGY"},{"name":"Maps_To","value":"Zolbetuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"647103"},{"name":"NCI_META_CUI","value":"CL554291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647103"},{"name":"PDQ_Open_Trial_Search_ID","value":"647103"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1699":{"preferredName":"Zoledronic Acid","code":"C1699","definitions":[{"definition":"A drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zoledronic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Aclasta","termGroup":"FB","termSource":"NCI"},{"termName":"CGP 42446","termGroup":"CN","termSource":"NCI"},{"termName":"CGP42446A","termGroup":"CN","termSource":"NCI"},{"termName":"NDC-Zoledronate","termGroup":"SY","termSource":"NCI"},{"termName":"Reclast","termGroup":"BR","termSource":"NCI"},{"termName":"ZOL 446","termGroup":"CN","termSource":"NCI"},{"termName":"Zoledronate","termGroup":"SY","termSource":"NCI"},{"termName":"Zometa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypercalcemia of malignancy; Multiple myeloma and metastatic bone lesions from solid tumors; Paget's disease"},{"name":"CAS_Registry","value":"165800-06-6"},{"name":"Chemical_Formula","value":"C5H10N2O7P2.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"6XC1PAD3KF"},{"name":"Legacy Concept Name","value":"Zoledronate"},{"name":"Maps_To","value":"Zoledronic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"42507"},{"name":"NSC Number","value":"721517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42507"},{"name":"PDQ_Open_Trial_Search_ID","value":"42507"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0257685"}]}}{"C74025":{"preferredName":"Zoptarelin Doxorubicin","code":"C74025","definitions":[{"definition":"A peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Zoptarelin doxorubicin binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zoptarelin Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"AEZS-108","termGroup":"CN","termSource":"NCI"},{"termName":"AEZS108","termGroup":"CN","termSource":"NCI"},{"termName":"AN 152","termGroup":"CN","termSource":"NCI"},{"termName":"AN-152","termGroup":"CN","termSource":"NCI"},{"termName":"Doxorubicin-GNRH Agonist Conjugate AEZS-108","termGroup":"SY","termSource":"NCI"},{"termName":"ZEN-008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"139570-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27844X2J29"},{"name":"Legacy Concept Name","value":"Doxorubicin-GNRH_Agonist_Conjugate_AEZS-108"},{"name":"Maps_To","value":"Zoptarelin Doxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"583257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583257"},{"name":"PDQ_Open_Trial_Search_ID","value":"583257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0658619"}]}}{"C91365":{"preferredName":"Zorubicin","code":"C91365","definitions":[{"definition":"A benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S-cis)-Benzoic Acid[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"Benzoic Acid Hydrazide 3-Hydrazone with Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Benzoylhydrazone Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Daunomycin Benzoylhydrazone","termGroup":"SY","termSource":"NCI"},{"termName":"Rubidazon","termGroup":"SY","termSource":"NCI"},{"termName":"Rubidazone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54083-22-6"},{"name":"Chemical_Formula","value":"C34H35N3O10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V25F9362OP"},{"name":"Maps_To","value":"Zorubicin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073688"}]}}{"C1458":{"preferredName":"Zorubicin Hydrochloride","code":"C1458","definitions":[{"definition":"A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin.  Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(2S-cis)-Benzoic Acid[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3-naphthacenyl]ethylidene]hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"Benzoyl Hydrazone Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicin Benzoylhydrazone Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"RP 22,050 Hydrochloride","termGroup":"CN","termSource":"NCI"},{"termName":"Rubidazone","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"36508-71-1"},{"name":"Chemical_Formula","value":"C34H35N3O10.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WXM8D9M6DE"},{"name":"Legacy Concept Name","value":"Zorubicin"},{"name":"Maps_To","value":"Zorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39590"},{"name":"NSC Number","value":"164011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39590"},{"name":"PDQ_Open_Trial_Search_ID","value":"39590"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0206788"}]}}{"C28322":{"preferredName":"Zuclomiphene Citrate","code":"C28322","definitions":[{"definition":"The cis isomer of clomiphene which exhibits weak estrogen agonist activity evaluated for antineoplastic activity against breast cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zuclomiphene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-Clomiphene Citrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cisclomiphene Citrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7619-53-6"},{"name":"Chemical_Formula","value":"C26H28ClNO.C6H8O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UY5X264QZV"},{"name":"Legacy Concept Name","value":"Cisclomiphene"},{"name":"Maps_To","value":"Zuclomiphene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"798814"},{"name":"NSC Number","value":"151466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798814"},{"name":"PDQ_Open_Trial_Search_ID","value":"798814"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522596"}]}}{"C171381":{"preferredName":"3'-dA Phosphoramidate NUC-7738","code":"C171381","definitions":[{"definition":"A phosphoramidate derivative of the monophosphate form of cordycepin (3'-deoxyadenosine; 3'-dA), an adenosine derivative first isolated from Cordyceps sinensis, with potential antineoplastic, antioxidant, and anti-inflammatory activities. Upon administration and cellular uptake of NUC-7738 by passive diffusion, cordycepin monophosphate (3'-dAMP) is converted into its active anti-cancer metabolite 3'-deoxyadenosine triphosphate (3'-dATP). 3'-dATP functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis. Also, 3'-dAMP activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling. This prevents the hyperphosphorylation of the translation repressor protein 4E-BP1. This results in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers. Compared to cordycepin alone, the addition of the phosphoramidate moiety may overcome cancer resistance and allow for greater cytotoxicity as NUC-7738 does not require a nucleoside transporter for cellular uptake, is independent of  enzymatic activation by adenosine kinase (AK) and is not susceptible to enzymatic degradation by adenosine deaminase (ADA). Altogether, this may help overcome cancer resistance to cordycepin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"3'-dA Phosphoramidate NUC-7738","termGroup":"PT","termSource":"NCI"},{"termName":"NUC 7738","termGroup":"CN","termSource":"NCI"},{"termName":"NUC-7738","termGroup":"CN","termSource":"NCI"},{"termName":"NUC7738","termGroup":"CN","termSource":"NCI"},{"termName":"Nucleoside Analog NUC-7738","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3'-dA Phosphoramidate NUC-7738"},{"name":"NCI_Drug_Dictionary_ID","value":"800960"},{"name":"NCI_META_CUI","value":"CL1405486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800960"},{"name":"PDQ_Open_Trial_Search_ID","value":"800960"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172109":{"preferredName":"Inupadenant","code":"C172109","definitions":[{"definition":"An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, inupadenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inupadenant","termGroup":"PT","termSource":"NCI"},{"termName":"A2A Receptor Antagonist EOS100850","termGroup":"SY","termSource":"NCI"},{"termName":"EOS 100850","termGroup":"CN","termSource":"NCI"},{"termName":"EOS-100850","termGroup":"CN","termSource":"NCI"},{"termName":"EOS100850","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2246607-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HQ700V0X06"},{"name":"Maps_To","value":"A2A Receptor Antagonist EOS100850"},{"name":"NCI_Drug_Dictionary_ID","value":"801361"},{"name":"NCI_META_CUI","value":"CL1413218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801361"},{"name":"PDQ_Open_Trial_Search_ID","value":"801361"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175468":{"preferredName":"Adenosine A2A Receptor Antagonist CS3005","code":"C175468","definitions":[{"definition":"An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist CS3005 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2A Receptor Antagonist CS3005","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR Antagonist CS3005","termGroup":"SY","termSource":"NCI"},{"termName":"CS 3005","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3005","termGroup":"CN","termSource":"NCI"},{"termName":"CS3005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist CS3005"},{"name":"NCI_Drug_Dictionary_ID","value":"802908"},{"name":"NCI_META_CUI","value":"CL1412853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802908"},{"name":"PDQ_Open_Trial_Search_ID","value":"802908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173640":{"preferredName":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","code":"C173640","definitions":[{"definition":"A recombinant adenoviral serotype 5 (Ad5) in which the Ad5-based vector fiber is replaced by the fiber from the human B adenovirus serotype 35 (F35), encoding for the human guanylyl cyclase C (hGCC), and fused to the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the Ad5/F35-hGCC-PADRE, the Ad5/F35 targets CD46, which is expressed widely on most tumor cells, and the virus is taken up by cells. Once inside the cells, the virus expresses hGCC. The expressed hGCC induces both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated killing of tumor cells. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response. The inclusion of the chimeric Ad5/F35 fiber increases viral uptake in cells through CD46.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","termGroup":"PT","termSource":"NCI"},{"termName":"Ad5.F35-hGCC-PADRE","termGroup":"SY","termSource":"NCI"},{"termName":"Ad5/F35-hGCC-PADRE","termGroup":"SY","termSource":"NCI"},{"termName":"Adenovirus 5/F35-HGCC-PADRE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE"},{"name":"NCI_Drug_Dictionary_ID","value":"802251"},{"name":"NCI_META_CUI","value":"CL1407372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802251"},{"name":"PDQ_Open_Trial_Search_ID","value":"802251"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167360":{"preferredName":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918","code":"C167360","definitions":[{"definition":"A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 16 (HPV16), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV16 vaccine JNJ-63682918, the adenovirus infects and expresses HPV16. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 antigens, thereby inducing tumor cell lysis. HPV16 infection plays a key role in the development of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918","termGroup":"PT","termSource":"NCI"},{"termName":"Ad26-expressing HPV16 Vaccine JNJ-63682918","termGroup":"SY","termSource":"NCI"},{"termName":"Ad26.HPV16 JNJ-63682918","termGroup":"SY","termSource":"NCI"},{"termName":"Adenovirus Serotype 26-Human Papillomavirus 16 JNJ-63682918","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63682918","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63682918","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63682918","termGroup":"CN","termSource":"NCI"},{"termName":"Monovalent HPV16 Ad26-vectored Vaccine JNJ-63682918","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918"},{"name":"NCI_Drug_Dictionary_ID","value":"810657"},{"name":"NCI_META_CUI","value":"CL972334"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167361":{"preferredName":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931","code":"C167361","definitions":[{"definition":"A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV18 vaccine JNJ-63682931, the adenovirus infects and expresses HPV18. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV18 antigens, thereby inducing tumor cell lysis. HPV18 infection plays a key role in the development of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931","termGroup":"PT","termSource":"NCI"},{"termName":"Ad26-expressing HPV18 Vaccine JNJ-63682931","termGroup":"SY","termSource":"NCI"},{"termName":"Ad26.HPV18 JNJ-63682931","termGroup":"SY","termSource":"NCI"},{"termName":"Adenovirus Serotype 26-Human Papillomavirus 18 JNJ-63682931","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63682931","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63682931","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63682931","termGroup":"CN","termSource":"NCI"},{"termName":"Monovalent HPV18 Ad26-vectored Vaccine JNJ-63682931","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931"},{"name":"NCI_Drug_Dictionary_ID","value":"810658"},{"name":"NCI_META_CUI","value":"CL972333"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171615":{"preferredName":"ALK Inhibitor TAE684","code":"C171615","definitions":[{"definition":"A small molecule inhibitor of the receptor tyrosine kinases (RTKs) anaplastic lymphoma kinase (ALK) and nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), with potential antineoplastic activity. Upon administration, TAE684 binds to and inhibits ALK and NPM-ALK tyrosine kinases, which leads to a disruption of ALK- and NPM-ALK mediated signaling and eventually inhibits tumor cell growth in ALK- and NPM-ALK overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. NPM-ALK is an oncogenic fusion protein associated with ALK-positive anaplastic large cell lymphoma. ALK mutations are also associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor TAE684","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-n4-(2-(isopropylsulfonyl)phenyl)-n2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"NPM-ALK Inhibitor TAE684","termGroup":"SY","termSource":"NCI"},{"termName":"NVP-TAE684","termGroup":"CN","termSource":"NCI"},{"termName":"TAE 684","termGroup":"CN","termSource":"NCI"},{"termName":"TAE-684","termGroup":"CN","termSource":"NCI"},{"termName":"TAE684","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"761439-42-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EH1713MN4K"},{"name":"Maps_To","value":"ALK Inhibitor TAE684"},{"name":"NCI_META_CUI","value":"CL1405839"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173430":{"preferredName":"Unecritinib","code":"C173430","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK), C-ros oncogene 1 (ROS1) and Met (hepatocyte growth factor receptor; HGFR; c-Met), with potential antineoplastic activity. Upon oral administration,unecritinib targets, binds to and inhibits the activity of ALK, ROS1 and c-Met, which leads to the disruption of ALK-, ROS1- and c-Met-mediated signaling and the inhibition of cell growth in ALK-, ROS1- and c-Met-expressing tumor cells. ALK, ROS1 and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unecritinib","termGroup":"PT","termSource":"NCI"},{"termName":"ALK/ROS1/Met Inhibitor TQ-B3101","termGroup":"SY","termSource":"NCI"},{"termName":"TQB 3101","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3101","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1418026-92-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4T3Z98RR86"},{"name":"Maps_To","value":"ALK/ROS1/Met Inhibitor TQ-B3101"},{"name":"NCI_Drug_Dictionary_ID","value":"801758"},{"name":"NCI_META_CUI","value":"CL1407437"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801758"},{"name":"PDQ_Open_Trial_Search_ID","value":"801758"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165779":{"preferredName":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715","code":"C165779","definitions":[{"definition":"A preparation of allogeneic, 'off-the-shelf' (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are deleted from the CAR T-cells. Upon administration, the allogeneic anti-BCMA CAR-transduced T-cells ALLO-715 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. Deletion of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The donor-derived, gene-edited CAR T cells have reduced production times and have increased availability when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. In addition, if the ALLO-715 cells cause unacceptable side effects, the incorporated CD20-based off-switch permits selective depletion of the ALLO-715 cells when the anti-CD20 monoclonal antibody rituximab is administered.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715","termGroup":"PT","termSource":"NCI"},{"termName":"ALLO 715","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-715","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-715 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ALLO715","termGroup":"CN","termSource":"NCI"},{"termName":"ALLOCar T ALLO-715","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA Allogeneic CAR T Cells ALLO-715","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q137JC2CLV"},{"name":"Maps_To","value":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715"},{"name":"NCI_Drug_Dictionary_ID","value":"800201"},{"name":"NCI_META_CUI","value":"CL979064"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800201"},{"name":"PDQ_Open_Trial_Search_ID","value":"800201"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171066":{"preferredName":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A","code":"C171066","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-BCMA-CAR T-cells PBCAR269A specifically recognize and kill BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A"},{"name":"NCI_Drug_Dictionary_ID","value":"801229"},{"name":"NCI_META_CUI","value":"CL1405454"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801229"},{"name":"PDQ_Open_Trial_Search_ID","value":"801229"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173967":{"preferredName":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells","code":"C173967","definitions":[{"definition":"A preparation of allogeneic T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting both the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-BCMA/CS1 bispecific CAR-T cells target and bind to tumor cells expressing BCMA and/or CS1 and induce selective cytotoxicity in those cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells. Targeting the two different TAAs highly expressed on malignant plasma cells may improve coverage and protect against antigen escape and resistance as tumor cells would need to lose both antigens. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-BCMA/CS1 Bispecific CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-BCMA/SLAMF7 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic BCMA/CS1 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic BCMA/SLAMF7 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802179"},{"name":"NCI_META_CUI","value":"CL1407845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802179"},{"name":"PDQ_Open_Trial_Search_ID","value":"802179"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172708":{"preferredName":"Cemacabtagene Ansegedleucel","code":"C172708","definitions":[{"definition":"A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon administration, cemacabtagene ansegedleucel specifically targets and binds to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemacabtagene Ansegedleucel","termGroup":"PT","termSource":"NCI"},{"termName":"ALLO 501A","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-501A","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO501A","termGroup":"CN","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 CAR T-cells ALLO-501A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 CAR T-lymphocytes ALLO-501A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 CAR-T Cells ALLO-501A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic CD19-specific CAR T-cells ALLO-501A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W3X22HS7XD"},{"name":"Maps_To","value":"Allogeneic Anti-CD19 CAR T-cells ALLO-501A"},{"name":"NCI_Drug_Dictionary_ID","value":"802025"},{"name":"NCI_META_CUI","value":"CL1406567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802025"},{"name":"PDQ_Open_Trial_Search_ID","value":"802025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173959":{"preferredName":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101","code":"C173959","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), universal, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 universal CAR-T cells CTA101 specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. CTA101 is genetically engineered to prevent graft-versus-host disease (GvHD) by the donor T-cells. OTS CAR-T cells require reduced production times when compared to autologous CAR-T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 UCAR-T Cells CTA101","termGroup":"SY","termSource":"NCI"},{"termName":"CTA 101","termGroup":"CN","termSource":"NCI"},{"termName":"CTA-101","termGroup":"CN","termSource":"NCI"},{"termName":"CTA101","termGroup":"CN","termSource":"NCI"},{"termName":"Universal CD19-directed CAR-T Cells CTA101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101"},{"name":"NCI_Drug_Dictionary_ID","value":"802167"},{"name":"NCI_META_CUI","value":"CL1407868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802167"},{"name":"PDQ_Open_Trial_Search_ID","value":"802167"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174397":{"preferredName":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S","code":"C174397","definitions":[{"definition":"A preparation of donor-derived T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T-cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S","termGroup":"PT","termSource":"NCI"},{"termName":"LUCAR 20S","termGroup":"CN","termSource":"NCI"},{"termName":"LUCAR-20S","termGroup":"CN","termSource":"NCI"},{"termName":"LUCAR-20S CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"LUCAR20S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S"},{"name":"NCI_Drug_Dictionary_ID","value":"802323"},{"name":"NCI_META_CUI","value":"CL1411949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802323"},{"name":"PDQ_Open_Trial_Search_ID","value":"802323"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168570":{"preferredName":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A","code":"C168570","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), T-lymphocytes, derived from healthy donors, that have been genetically modified using a proprietary synthetic endonuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20-CAR T-cells PBCAR20A specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-CD20 CAR T-lymphocytes PBCAR20A","termGroup":"SY","termSource":"NCI"},{"termName":"PBCAR 20A","termGroup":"CN","termSource":"NCI"},{"termName":"PBCAR-20A","termGroup":"CN","termSource":"NCI"},{"termName":"PBCAR20A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A"},{"name":"NCI_Drug_Dictionary_ID","value":"800688"},{"name":"NCI_META_CUI","value":"CL972895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800688"},{"name":"PDQ_Open_Trial_Search_ID","value":"800688"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165696":{"preferredName":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22","code":"C165696","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, allogeneic CD22-specific universal CAR-expressing T-lymphocytes UCART22 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Gene-edited CAR T-Cells UCART22","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic TALEN Gene-edited CAR T-Cells UCART22","termGroup":"SY","termSource":"NCI"},{"termName":"Allogenic Engineered T-cells Expressing Anti- CD22 CAR UCART22","termGroup":"SY","termSource":"NCI"},{"termName":"UCART 22","termGroup":"CN","termSource":"NCI"},{"termName":"UCART-22","termGroup":"CN","termSource":"NCI"},{"termName":"UCART22","termGroup":"CN","termSource":"NCI"},{"termName":"UCART22 Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22"},{"name":"NCI_Drug_Dictionary_ID","value":"800127"},{"name":"NCI_META_CUI","value":"CL978908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800127"},{"name":"PDQ_Open_Trial_Search_ID","value":"800127"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173877":{"preferredName":"Taniraleucel","code":"C173877","definitions":[{"definition":"A population of cryopreserved, off-the-shelf (OTS) allogeneic natural killer (NK) cells derived from human placental hematopoietic stem cells (HSCs) and expressing the CD56 surface antigen and exhibiting a lack of CD3, with potential immunomodulating, antineoplastic and antiviral activities. Upon infusion of taniraleucel, these cells are able to recognize tumor cells as well as virally-infected cells, secrete perforins, granzymes and cytokines, and induce apoptosis in tumor and virally-infected cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taniraleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic CD56+/CD3- Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"CD56+/CD3- NK Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"CYNK 001","termGroup":"CN","termSource":"NCI"},{"termName":"CYNK-001","termGroup":"CN","termSource":"NCI"},{"termName":"CYNK001","termGroup":"CN","termSource":"NCI"},{"termName":"Human Placental HSC-derived CD56+/CD3- NKs CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XO25H8E4QP"},{"name":"Maps_To","value":"Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001"},{"name":"NCI_Drug_Dictionary_ID","value":"802398"},{"name":"NCI_META_CUI","value":"CL1407641"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802398"},{"name":"PDQ_Open_Trial_Search_ID","value":"802398"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170887":{"preferredName":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001","code":"C170887","definitions":[{"definition":"A preparation of allogeneic CD8+ T cells targeting multiple undisclosed leukemia-associated antigens, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection from the original stem cell donor and ex vivo priming and expansion, the allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001 are re-introduced into the leukemia patient, where they target and kill tumor cells expressing these leukemia-associated antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001","termGroup":"PT","termSource":"NCI"},{"termName":"NEXI 001","termGroup":"CN","termSource":"NCI"},{"termName":"NEXI-001","termGroup":"CN","termSource":"NCI"},{"termName":"NEXI001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001"},{"name":"NCI_Drug_Dictionary_ID","value":"801194"},{"name":"NCI_META_CUI","value":"CL1383035"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801194"},{"name":"PDQ_Open_Trial_Search_ID","value":"801194"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172741":{"preferredName":"Motacabtagene Lurevgedleucel","code":"C172741","definitions":[{"definition":"A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, motacabtagene lurevgedleucel recognize and bind to BCMA-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of BCMA-positive tumor cells. BCMA, a receptor for proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. The disruption of endogenous TCR prevents graft-versus-host disease (GvHD). The disruption of MHC class I molecules increases the persistence of the CAR T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motacabtagene Lurevgedleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120","termGroup":"SY","termSource":"NCI"},{"termName":"CRISPR/Cas9 Gene-edited Allogeneic Anti-BCMA CAR-T Cells CTX120","termGroup":"SY","termSource":"NCI"},{"termName":"CTX 120","termGroup":"CN","termSource":"NCI"},{"termName":"CTX-120","termGroup":"CN","termSource":"NCI"},{"termName":"CTX120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7CH7MR6SN5"},{"name":"Maps_To","value":"Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120"},{"name":"NCI_Drug_Dictionary_ID","value":"802026"},{"name":"NCI_META_CUI","value":"CL1406620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802026"},{"name":"PDQ_Open_Trial_Search_ID","value":"802026"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173153":{"preferredName":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130","code":"C173153","definitions":[{"definition":"A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD70 CAR T-cells CTX130 recognize and bind to CD70-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. Disruption of endogenous TCR prevents graft-versus-host disease (GvHD); the disruption of MHC class I molecules increases the persistence of the CAR T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic CRISPR-Cas9-engineered T Cells CTX130","termGroup":"SY","termSource":"NCI"},{"termName":"CRISPR/Cas9 Gene-edited Allogeneic Anti-CD70 CAR-T Cells CTX130","termGroup":"SY","termSource":"NCI"},{"termName":"CTX 130","termGroup":"CN","termSource":"NCI"},{"termName":"CTX-130","termGroup":"CN","termSource":"NCI"},{"termName":"CTX130","termGroup":"CN","termSource":"NCI"},{"termName":"Donor-derived Gene-edited Allogeneic CAR-T Cells CTX130","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130"},{"name":"NCI_Drug_Dictionary_ID","value":"802058"},{"name":"NCI_META_CUI","value":"CL1407020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802058"},{"name":"PDQ_Open_Trial_Search_ID","value":"802058"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165661":{"preferredName":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A","code":"C165661","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon transfusion of allogeneic CS1-specific universal CAR-expressing T-lymphocytes UCARTCS1A, these cells target and bind to cancer cells expressing CS1. This induces selective toxicity in and causes lysis of CS1-expressing tumor cells. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Gene-edited CAR T-Cells UCARTCS1A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic TALEN Gene-edited CAR T-Cells UCARTCS1A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogenic Engineered T-cells Expressing Anti- CS1 CAR UCARTCS1A","termGroup":"SY","termSource":"NCI"},{"termName":"UCART CS1A","termGroup":"CN","termSource":"NCI"},{"termName":"UCART-CS1A","termGroup":"CN","termSource":"NCI"},{"termName":"UCARTCS1A","termGroup":"CN","termSource":"NCI"},{"termName":"UCARTCS1A Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A"},{"name":"NCI_Drug_Dictionary_ID","value":"800121"},{"name":"NCI_META_CUI","value":"CL978955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800121"},{"name":"PDQ_Open_Trial_Search_ID","value":"800121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173427":{"preferredName":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01","code":"C173427","definitions":[{"definition":"An off-the-shelf (OTS) preparation composed of irradiated allogeneic plasmacytoid dendritic cells (pDCs) loaded with seven immunogenic, human leukocyte antigen (HLA)-A*02:01 serotype-restricted peptides derived from the lung tumor antigens cancer/testis antigen 1 (NY-ESO-1), melanoma antigen A3 (MAGE-A3), MAGE-A4, multi-MAGE, a peptide shared by multiple MAGE-A proteins, survivin, mucin1 (MUC1) and melanoma antigen recognized by T-cells 1 (Mart-1; Melan-A), with potential immunostimulating and antineoplastic activities. Upon administration of the allogeneic pDCs expressing lung tumor antigens PDC*lung01, the pDCs may activate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against HLA-A*0201 positive lung cancer cells expressing the TAAs NY-ESO-1, MAGE-A3, MAGEA4, multi-MAGE, survivin, MUC1 and melan-A. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic pDCs- expressing Lung Tumor Antigens PDC*lung01","termGroup":"SY","termSource":"NCI"},{"termName":"PDC*lung01","termGroup":"CN","termSource":"NCI"},{"termName":"PDClung01","termGroup":"CN","termSource":"NCI"},{"termName":"Therapeutic Cancer Vaccine PDC*lung01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01"},{"name":"NCI_Drug_Dictionary_ID","value":"801755"},{"name":"NCI_META_CUI","value":"CL1407435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801755"},{"name":"PDQ_Open_Trial_Search_ID","value":"801755"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174401":{"preferredName":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19","code":"C174401","definitions":[{"definition":"A preparation of allogeneic, third-party, CD4+ T-lymphocytes that specifically recognizes the human leukocyte antigen (HLA)-DPB1*0401 and transduced with a suicide gene, with potential antineoplastic activity. Upon administration, allogeneic third-party suicide gene-transduced anti-HLA-DPB1*0401 CD4+ T-cells CTL 19 specifically target and kill HLA-DPB1*0401-positive leukemic cells. The suicide gene causes the destruction of the T-cell clone upon the administration and presence of ganciclovir, which enhances the safety of the agent. HLA-DP is expressed by many leukemic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19","termGroup":"PT","termSource":"NCI"},{"termName":"CTL 19","termGroup":"CN","termSource":"NCI"},{"termName":"CTL-19","termGroup":"CN","termSource":"NCI"},{"termName":"CTL19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19"},{"name":"NCI_Drug_Dictionary_ID","value":"802327"},{"name":"NCI_META_CUI","value":"CL1411953"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802327"},{"name":"PDQ_Open_Trial_Search_ID","value":"802327"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171059":{"preferredName":"Tuxobertinib","code":"C171059","definitions":[{"definition":"An orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. Upon oral administration, tuxobertinib selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations. EGFR and HER2, ErbB receptor tyrosine kinases mutated or overexpressed in many tumor cell types, play a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuxobertinib","termGroup":"PT","termSource":"NCI"},{"termName":"Allosteric ErbB Inhibitor BDTX-189","termGroup":"SY","termSource":"NCI"},{"termName":"BDTX 189","termGroup":"CN","termSource":"NCI"},{"termName":"BDTX-189","termGroup":"CN","termSource":"NCI"},{"termName":"BDTX189","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/HER2 Inhibitor BDTX-189","termGroup":"SY","termSource":"NCI"},{"termName":"ErbB Mutant-specific Inhibitor BDTX-189","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2414572-47-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6CE2107J4T"},{"name":"Maps_To","value":"Allosteric ErbB Inhibitor BDTX-189"},{"name":"NCI_Drug_Dictionary_ID","value":"801228"},{"name":"NCI_META_CUI","value":"CL1405430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801228"},{"name":"PDQ_Open_Trial_Search_ID","value":"801228"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170744":{"preferredName":"Alofanib","code":"C170744","definitions":[{"definition":"An inhibitor of the fibroblast growth factor receptor (FGFR) type 2 (FGFR2), with potential antineoplastic and anti-angiogenic activities. Upon administration, alofanib targets, allosterically binds to the extracellular domain of FGFR2 and inhibits the activity of FGFR2, which may result in the inhibition of basic FGF (bFGF)/FGFR2-related signal transduction pathways. This inhibits FGF-induced endothelial cell proliferation and migration, and inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alofanib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic Acid, 3-(((4-Methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"ES000835","termGroup":"CN","termSource":"NCI"},{"termName":"RPT 835","termGroup":"CN","termSource":"NCI"},{"termName":"RPT-835","termGroup":"CN","termSource":"NCI"},{"termName":"RPT835","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1612888-66-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LQX7RFK8MZ"},{"name":"Maps_To","value":"Alofanib"},{"name":"NCI_Drug_Dictionary_ID","value":"800699"},{"name":"NCI_META_CUI","value":"CL1383158"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800699"},{"name":"PDQ_Open_Trial_Search_ID","value":"800699"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172097":{"preferredName":"Alpha V Beta 8 Antagonist PF-06940434","code":"C172097","definitions":[{"definition":"An antagonist of integrin alpha v beta 8, with potential antineoplastic activity. Upon administration, PF-06940434 selectively binds to and blocks the receptor for integrin alpha v beta 8, thereby preventing integrin alpha v beta 8 binding. This may result in the inhibition of cell adhesion in the tumor microenvironment (TME) and blocks the activation of the cytokine transforming growth factor-beta 1 (TGF-b1), preventing TGF-b1-mediated signal transduction. This abrogates TGF-b1-mediated immunosuppression, enhances anti-tumor immunity in the TME and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGF-b1-dependent proliferation of cancer cells. Alpha v beta 8 integrin plays a key role in tumor initiation, growth, and progression through TGF-b1 activation. It is expressed in a variety of tumor cell types and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha V Beta 8 Antagonist PF-06940434","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha V Beta 8 Inhibitor PF-06940434","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06940434","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06940434","termGroup":"CN","termSource":"NCI"},{"termName":"PF06940434","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alpha V Beta 8 Antagonist PF-06940434"},{"name":"NCI_Drug_Dictionary_ID","value":"802007"},{"name":"NCI_META_CUI","value":"CL1406223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802007"},{"name":"PDQ_Open_Trial_Search_ID","value":"802007"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173364":{"preferredName":"Androgen Receptor Degrader CC-94676","code":"C173364","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, AR degrader CC-94676 causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Degrader CC-94676","termGroup":"PT","termSource":"NCI"},{"termName":"AR Degrader CC-94676","termGroup":"SY","termSource":"NCI"},{"termName":"CC 94676","termGroup":"CN","termSource":"NCI"},{"termName":"CC-94676","termGroup":"CN","termSource":"NCI"},{"termName":"CC94676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VA228VR2DI"},{"name":"Maps_To","value":"Androgen Receptor Degrader CC-94676"},{"name":"NCI_Drug_Dictionary_ID","value":"801809"},{"name":"NCI_META_CUI","value":"CL1407191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801809"},{"name":"PDQ_Open_Trial_Search_ID","value":"801809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173374":{"preferredName":"Masofaniten","code":"C173374","definitions":[{"definition":"An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, masofaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. Masofaniten may be more active and metabolically stable than first-generation AR NTD inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masofaniten","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Inhibitor EPI-7386","termGroup":"SY","termSource":"NCI"},{"termName":"AR Inhibitor EPI-7386","termGroup":"SY","termSource":"NCI"},{"termName":"EPI 7386","termGroup":"CN","termSource":"NCI"},{"termName":"EPI-7386","termGroup":"CN","termSource":"NCI"},{"termName":"EPI7386","termGroup":"CN","termSource":"NCI"},{"termName":"Methanesulfonamide, N-(4-((4-(1-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)-1-methylethyl)phenoxy)methyl)-2-pyrimidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-(4-((4-(2-(3-Chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416716-62-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OQ2SF7P8B2"},{"name":"Maps_To","value":"Androgen Receptor Inhibitor EPI-7386"},{"name":"NCI_Drug_Dictionary_ID","value":"801842"},{"name":"NCI_META_CUI","value":"CL1407198"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801842"},{"name":"PDQ_Open_Trial_Search_ID","value":"801842"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172104":{"preferredName":"Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10","code":"C172104","definitions":[{"definition":"An orally bioavailable steroidal cortexolone derivative and antagonist of the androgen receptor (AR) and glucocorticoid receptor (GR), with potential antineoplastic activity. Upon oral administration, AR/GR antagonist CB-03-10 specifically binds to AR and GR, inhibits AR and GR activation, and prevents AR- and GR-mediated signaling. This leads to an induction of both extrinsic and intrinsic apoptotic pathways and inhibits cell growth in AR- and GR-overexpressing tumor cells. AR and GR are overexpressed in certain types of cancer cells and are involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10","termGroup":"PT","termSource":"NCI"},{"termName":"AR/GR Antagonist CB-03-10","termGroup":"SY","termSource":"NCI"},{"termName":"CB 03 10","termGroup":"CN","termSource":"NCI"},{"termName":"CB-03-10","termGroup":"CN","termSource":"NCI"},{"termName":"CB0310","termGroup":"CN","termSource":"NCI"},{"termName":"Cortexolone 17alpha-Valerate-21-propionate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10"},{"name":"NCI_Drug_Dictionary_ID","value":"801352"},{"name":"NCI_META_CUI","value":"CL1406219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801352"},{"name":"PDQ_Open_Trial_Search_ID","value":"801352"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168687":{"preferredName":"Anhydrous Enol-oxaloacetate","code":"C168687","definitions":[{"definition":"The anhydrous form of enol-oxaloacetate, a small molecule blood glutamate scavenger, that can be used to lower glutamate plasma levels, and has potential neuroprotective activity. Upon administration, enol-oxaloacetate targets and binds to glutamate in the bloodstream. This lowers glutamate plasma levels and lowers the free glutamate available to be picked up by cells, such as tumor brain cells, thereby preventing glutamate metabolism and glutamate-mediated signaling. This prevents the proliferation of rapidly growing cells, such as brain tumor cells. And by lowering glutamate plasma levels, a molecular imbalance is formed and glutamate is excreted across the blood-brain barrier, resulting in lower free brain glutamate.  This may help protect the brain from excitotoxicity in conditions where there is a surge of glutamate production, such as traumatic brain injury, thereby protecting neuronal cells. Glutamate, a non-essential amino acid and the major excitatory neurotransmitter in the central nervous system (CNS), provides energy and generates building blocks for the production of macromolecules, which are needed for cellular growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anhydrous Enol-oxaloacetate","termGroup":"PT","termSource":"NCI"},{"termName":"AEO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"328-42-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2F399MM81J"},{"name":"Maps_To","value":"Anhydrous Enol-oxaloacetate"},{"name":"NCI_Drug_Dictionary_ID","value":"800694"},{"name":"NCI_META_CUI","value":"CL1378618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800694"},{"name":"PDQ_Open_Trial_Search_ID","value":"800694"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173556":{"preferredName":"Anti-5T4 Antibody-drug Conjugate ASN004","code":"C173556","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody directed against 5T4 and conjugated, via a non-cleavable linker, to a proprietary polymer carrying multiple auristatin analog molecules via a cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of ASN004 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell cytosol, free auristatin analog molecules binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-5T4 Antibody-drug Conjugate ASN004","termGroup":"PT","termSource":"NCI"},{"termName":"5T4-ADC ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"5T4-targeted Antibody-drug Conjugate ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"5T4-targeted Dolaflexin ADC ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-5T4 ADC ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"ASN 004","termGroup":"CN","termSource":"NCI"},{"termName":"ASN-004","termGroup":"CN","termSource":"NCI"},{"termName":"ASN004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-5T4 Antibody-drug Conjugate ASN004"},{"name":"NCI_Drug_Dictionary_ID","value":"801910"},{"name":"NCI_META_CUI","value":"CL1407317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801910"},{"name":"PDQ_Open_Trial_Search_ID","value":"801910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175444":{"preferredName":"Anti-5T4 Antibody-drug Conjugate SYD1875","code":"C175444","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the oncofetal antigen 5T4 and site-specifically conjugated to a duocarmycin-based linker-drug valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA), with potential antineoplastic activity. Upon administration, the antibody moiety of SYD1875 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell by proteases, the free and activated duocarmycin payload binds to the minor groove of DNA and alkylates adenine at the N3 position, which eventually leads to tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-5T4 Antibody-drug Conjugate SYD1875","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SYD1875","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-5T4 ADC SYD1875","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate SYD1875","termGroup":"SY","termSource":"NCI"},{"termName":"SYD 1875","termGroup":"CN","termSource":"NCI"},{"termName":"SYD-1875","termGroup":"CN","termSource":"NCI"},{"termName":"SYD1875","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-5T4 Antibody-drug Conjugate SYD1875"},{"name":"NCI_Drug_Dictionary_ID","value":"802782"},{"name":"NCI_META_CUI","value":"CL1412814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802782"},{"name":"PDQ_Open_Trial_Search_ID","value":"802782"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171577":{"preferredName":"Ifinatamab Deruxtecan","code":"C171577","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-B7-H3/DXd ADC DS-7300a, the anti-B7-H3 antibody targets and binds to B7-H3-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifinatamab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B7-H3/DXd ADC DS-7300a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-B7H3/DXd Antibody-drug Conjugate DS-7300a","termGroup":"SY","termSource":"NCI"},{"termName":"DS 7300","termGroup":"CN","termSource":"NCI"},{"termName":"DS 7300a","termGroup":"CN","termSource":"NCI"},{"termName":"DS-7300","termGroup":"CN","termSource":"NCI"},{"termName":"DS-7300a","termGroup":"CN","termSource":"NCI"},{"termName":"DS7300","termGroup":"CN","termSource":"NCI"},{"termName":"DS7300a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2484870-92-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C6I0GC0GX5"},{"name":"Maps_To","value":"Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a"},{"name":"NCI_Drug_Dictionary_ID","value":"801901"},{"name":"NCI_META_CUI","value":"CL1405790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801901"},{"name":"PDQ_Open_Trial_Search_ID","value":"801901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170915":{"preferredName":"Ispectamab Debotansine","code":"C170915","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of ispectamab, a humanized immunoglobulin G1 (IgG1)-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor (TNF) receptor superfamily, member 17; TNFRSF17) site-specifically conjugated, with a non-cleavable linker, to a maytansinoid payload, with potential antineoplastic activity. Upon administration of ispectamab debotansine, the ispectamab moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon binding and internalization, the maytansinoid payload binds to tubulin, thereby affecting microtubule assembly/disassembly dynamic, and prevents cell division and reduces cell growth of BCMA-expressing cancer cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; TNF ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is overexpressed on malignant plasma cells and plays a key role in plasma survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ispectamab Debotansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA ADC CC-99712","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA Antibody Drug Conjugate CC-99712","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA Antibody-drug Conjugate CC-99712","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986352","termGroup":"CN","termSource":"NCI"},{"termName":"CC 99712","termGroup":"CN","termSource":"NCI"},{"termName":"CC-99712","termGroup":"CN","termSource":"NCI"},{"termName":"CC99712","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2413386-21-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WY39ZX6NZU"},{"name":"Maps_To","value":"Anti-BCMA Antibody-drug Conjugate CC-99712"},{"name":"NCI_Drug_Dictionary_ID","value":"800869"},{"name":"NCI_META_CUI","value":"CL1383075"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800869"},{"name":"PDQ_Open_Trial_Search_ID","value":"800869"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167337":{"preferredName":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA","code":"C167337","definitions":[{"definition":"An immunotherapeutic combination agent composed of antigen receptor complex T cells (ARC-T cells) which contain a proprietary binding domain specific for a universal TAG instead of a single chain variable fragment (scFv) binding domain, and a tumor-targeting antigen protein, soluble protein antigen-receptor X-linker (sparX) protein, containing a TAG moiety fused to two B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) binding domains, with potential antineoplastic activities. Upon administration of the anti-BCMA sparX protein plus BCMA-directed ARC T-cells CART-ddBCMA, the sparX protein, with its two BCMA binding domains, specifically targets and binds to two BCMA expressed on tumor cells. In turn, the ARC-T cells, with their anti-TAG domain, target and bind to the TAG domain on the sparX protein. This directly links the ARC-T cells to the BCMA-expressing tumor cells, through the ARC-T cell- sparX -tumor cell complex formation, thereby causing direct tumor cell killing. BCMA, a tumor-associated antigen (TAA), is found on the surfaces of plasma cells and is overexpressed on a variety of tumor cell types. Compared to anti-BCMA CAR-T cells, CART-ddBCMA, containing ARC-T cells that are re-programmed in vivo by the TAG sparX protein, shows enhanced efficiency and an improved safety profile. As ARC-T activity is dependent on the sparX dose administered, the rate of tumor cell killing, and related toxicities are also dependent on the sparX dose administered.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein","termGroup":"SY","termSource":"NCI"},{"termName":"ARC-T Plus Anti-BCMA SparX","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA","termGroup":"SY","termSource":"NCI"},{"termName":"TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA"},{"name":"NCI_Drug_Dictionary_ID","value":"800471"},{"name":"NCI_META_CUI","value":"CL972316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800471"},{"name":"PDQ_Open_Trial_Search_ID","value":"800471"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165656":{"preferredName":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459","code":"C165656","definitions":[{"definition":"A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody REGN5459 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 Bispecific Antibody REGN5459","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD3/Anti-BCMA Bispecific Antibody REGN5459","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5459","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5459","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5459","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459"},{"name":"NCI_Drug_Dictionary_ID","value":"800119"},{"name":"NCI_META_CUI","value":"CL978958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800119"},{"name":"PDQ_Open_Trial_Search_ID","value":"800119"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168617":{"preferredName":"Tifcemalimab","code":"C168617","definitions":[{"definition":"A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and antineoplastic activities. Upon intravenous infusion administration, tifcemalimab targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells (DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tifcemalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B- and T-lymphocyte Attenuator Monoclonal Antibody TAB004","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BTLA Monoclonal Antibody TAB004","termGroup":"SY","termSource":"NCI"},{"termName":"Icatolimab","termGroup":"SY","termSource":"NCI"},{"termName":"JS 004","termGroup":"CN","termSource":"NCI"},{"termName":"JS-004","termGroup":"CN","termSource":"NCI"},{"termName":"JS004","termGroup":"CN","termSource":"NCI"},{"termName":"TAB 004","termGroup":"CN","termSource":"NCI"},{"termName":"TAB-004","termGroup":"CN","termSource":"NCI"},{"termName":"TAB004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2236068-83-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D40H7X1YZ0"},{"name":"Maps_To","value":"Anti-BTLA Monoclonal Antibody TAB004"},{"name":"NCI_Drug_Dictionary_ID","value":"800693"},{"name":"NCI_META_CUI","value":"CL1378714"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800693"},{"name":"PDQ_Open_Trial_Search_ID","value":"800693"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175508":{"preferredName":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01","code":"C175508","definitions":[{"definition":"A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-BTN3A agonistic monoclonal antibody ICT01 targets and binds to BTN3A present on epithelial and tumor cells. BTN3A binding may sensitize tumor cells to gamma 9 delta 2 (Vg9Vd2) T cell killing. The Vg9Vd2 T cells secrete effector cytokines and exert a cytolytic effect on tumor cells. This may abrogate BTN3A-mediated tumor immunity and may enhance anti-tumor immune response. BTN3A, a member of the butyrophilin superfamily of immunomodulators, is upregulated in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BTN3A Agonist Monoclonal Antibody ICT01","termGroup":"SY","termSource":"NCI"},{"termName":"ICT 01","termGroup":"CN","termSource":"NCI"},{"termName":"ICT-01","termGroup":"CN","termSource":"NCI"},{"termName":"ICT01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01"},{"name":"NCI_Drug_Dictionary_ID","value":"802942"},{"name":"NCI_META_CUI","value":"CL1412871"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802942"},{"name":"PDQ_Open_Trial_Search_ID","value":"802942"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174391":{"preferredName":"Anti-c-Met Monoclonal Antibody HLX55","code":"C174391","definitions":[{"definition":"A humanized immunoglobulin (Ig) G2 monoclonal antibody directed against the human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-c-Met monoclonal antibody HLX55 specifically binds to the semaphorin (Sema)/Plexins-Semaphorins-Integrins (PSI) domain of c-Met, which prevents the binding of c-Met to its ligand HGF and the subsequent activation of the HGF/c-Met signaling pathway. In addition, HLX55 promotes c-Met degradation, which further inhibits c-Met-mediated signaling. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Monoclonal Antibody HLX55","termGroup":"PT","termSource":"NCI"},{"termName":"HLX 55","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-55","termGroup":"CN","termSource":"NCI"},{"termName":"HLX55","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Monoclonal Antibody HLX55"},{"name":"NCI_Drug_Dictionary_ID","value":"802302"},{"name":"NCI_META_CUI","value":"CL1411962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802302"},{"name":"PDQ_Open_Trial_Search_ID","value":"802302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175477":{"preferredName":"Anti-CCR7 Antibody-drug Conjugate JBH492","code":"C175477","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody targeting CC chemokine receptor 7 (CCR7) and conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-CCR7 ADC JBH492, the antibody moiety targets and binds to CCR7 on tumor cells. Upon antibody/antigen binding and internalization, the ADC releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics. This results in the inhibition of cell division and cell growth of CCR7-expressing tumor cells. CCR7, a G-protein coupled receptor, is normally expressed by subsets of immune cells and overexpressed by various types of cancer cells. Its overexpression has been associated with lymph node metastasis and poor survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CCR7 Antibody-drug Conjugate JBH492","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CCR7 ADC JBH492","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CCR7-DM4 Antibody-drug Conjugate JBH492","termGroup":"SY","termSource":"NCI"},{"termName":"JBH 492","termGroup":"CN","termSource":"NCI"},{"termName":"JBH-492","termGroup":"CN","termSource":"NCI"},{"termName":"JBH492","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CCR7 Antibody-drug Conjugate JBH492"},{"name":"NCI_Drug_Dictionary_ID","value":"802920"},{"name":"NCI_META_CUI","value":"CL1412845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802920"},{"name":"PDQ_Open_Trial_Search_ID","value":"802920"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174050":{"preferredName":"Briquilimab","code":"C174050","definitions":[{"definition":"A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs). Upon administration, briquilimab targets and binds to CD117. This prevents the binding of stem cell factor (SCF) to its receptor CD117 on HSCs.  As CD117 binding to SCF is critical for survival and maintenance of blood forming stem cells, blocking this interaction causes the HSCs that are present in the bone marrow niches to be depleted. Briquilimab can potentially be used as a conditioning regimen to prepare patients for hematopoietic stem cell transplantation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Briquilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 191","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-191","termGroup":"CN","termSource":"NCI"},{"termName":"AMG191","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-c-Kit Monoclonal Antibody JSP191","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD117 Monoclonal Antibody JSP191","termGroup":"SY","termSource":"NCI"},{"termName":"JSP 191","termGroup":"CN","termSource":"NCI"},{"termName":"JSP-191","termGroup":"CN","termSource":"NCI"},{"termName":"JSP191","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2574591-89-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QWX84D0DRC"},{"name":"Maps_To","value":"Anti-CD117 Monoclonal Antibody JSP191"},{"name":"NCI_Drug_Dictionary_ID","value":"802461"},{"name":"NCI_META_CUI","value":"CL1407956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802461"},{"name":"PDQ_Open_Trial_Search_ID","value":"802461"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168522":{"preferredName":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373","code":"C168522","definitions":[{"definition":"A conditionally-active, fully human immunoglobulin G1 (IgG1) agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody AGEN2373 targets and binds to a non-ligand blocking epitope on CD137, thereby activating CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. In addition, as AGEN2373 engages with CD137 only in the presence of CD137 ligand and/or Fc gamma receptor-expressing antigen-presenting cells (APCs), this agent may have a decreased toxicity profile and improved tolerability compared to other agents that activate CD137 signaling beyond the tumor site in humans.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 2373","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-2373","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN2373","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody AGEN2373","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonist Monoclonal Antibody AGEN2373","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Monoclonal Antibody AGEN2373","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373"},{"name":"NCI_Drug_Dictionary_ID","value":"800682"},{"name":"NCI_META_CUI","value":"CL972852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800682"},{"name":"PDQ_Open_Trial_Search_ID","value":"800682"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173548":{"preferredName":"Evunzekibart","code":"C173548","definitions":[{"definition":"A humanized agonistic immunoglobulin G4 (IgG4) monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, evunzekibart targets and binds to CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells, and CD137 is activated upon crosslinking to Fc-gamma receptors (FcgRs) on macrophages. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. 4-1BB and FcgRs are both highly expressed in the tumor environment (TME) while their co-expression in non-tumor tissues is low. This may prevent systemic adverse effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evunzekibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-4-1BB Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonist Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"ATOR 1017","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR-1017","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR1017","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2639688-77-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AKZ8CT8FMF"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017"},{"name":"NCI_Drug_Dictionary_ID","value":"801898"},{"name":"NCI_META_CUI","value":"CL1407499"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801898"},{"name":"PDQ_Open_Trial_Search_ID","value":"801898"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171541":{"preferredName":"Exlinkibart","code":"C171541","definitions":[{"definition":"A humanized agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, exlinkibart targets and binds to CD137, thereby activating CD137 expressed on avariety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exlinkibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonist Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonistic Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"LVGN 6051","termGroup":"CN","termSource":"NCI"},{"termName":"LVGN-6051","termGroup":"CN","termSource":"NCI"},{"termName":"LVGN6051","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2642171-64-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23C7TO9S06"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody LVGN6051"},{"name":"NCI_Drug_Dictionary_ID","value":"801858"},{"name":"NCI_META_CUI","value":"CL1405761"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801858"},{"name":"PDQ_Open_Trial_Search_ID","value":"801858"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C172202":{"preferredName":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003","code":"C172202","definitions":[{"definition":"A preparation of T-lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T-cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 AbTCR-expressing T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19-TCR T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"CD19-targeted T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"ET 019003","termGroup":"CN","termSource":"NCI"},{"termName":"ET-019003","termGroup":"CN","termSource":"NCI"},{"termName":"ET019003","termGroup":"CN","termSource":"NCI"},{"termName":"ET019003-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003"},{"name":"NCI_Drug_Dictionary_ID","value":"801620"},{"name":"NCI_META_CUI","value":"CL1406089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801620"},{"name":"PDQ_Open_Trial_Search_ID","value":"801620"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170903":{"preferredName":"Anti-CD19 iCAR NK Cells","code":"C170903","definitions":[{"definition":"A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 iCAR NK Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 iCAR Natural Killer Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 iCAR-NK Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 Inhibitory Chimeric Antigen Receptor-Natural Killer Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 iCAR NK Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"800852"},{"name":"NCI_META_CUI","value":"CL1383049"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800852"},{"name":"PDQ_Open_Trial_Search_ID","value":"800852"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170904":{"preferredName":"Anti-CD19/CD22 CAR NK Cells","code":"C170904","definitions":[{"definition":"A preparation of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD22 CAR-NK cells target and bind to CD19 and CD22 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/CD22 CAR NK Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/Anti-CD22 CAR Natural Killer Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/CD22 CAR-Natural Killer Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/CD22 CAR-NK Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/CD22 Chimeric Antigen Receptor-Natural Killer Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19/CD22 CAR NK Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"800858"},{"name":"NCI_META_CUI","value":"CL1383046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800858"},{"name":"PDQ_Open_Trial_Search_ID","value":"800858"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173955":{"preferredName":"Anti-CD20 Monoclonal Antibody BAT4306F","code":"C173955","definitions":[{"definition":"A recombinant, glycosylation-modified monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody BAT4306F, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The complete defucosylation of BAT4306F may result in enhanced ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody BAT4306F","termGroup":"PT","termSource":"NCI"},{"termName":"BAT 4306F","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-4306F","termGroup":"CN","termSource":"NCI"},{"termName":"BAT4306F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody BAT4306F"},{"name":"NCI_Drug_Dictionary_ID","value":"802165"},{"name":"NCI_META_CUI","value":"CL1407872"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802165"},{"name":"PDQ_Open_Trial_Search_ID","value":"802165"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166140":{"preferredName":"Anti-CD20 Monoclonal Antibody MIL62","code":"C166140","definitions":[{"definition":"A glyco-engineered recombinant humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody MIL62, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, MIL62 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody MIL62","termGroup":"PT","termSource":"NCI"},{"termName":"MIL 62","termGroup":"CN","termSource":"NCI"},{"termName":"MIL-62","termGroup":"CN","termSource":"NCI"},{"termName":"MIL62","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody MIL62"},{"name":"NCI_Drug_Dictionary_ID","value":"799905"},{"name":"NCI_META_CUI","value":"CL979195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799905"},{"name":"PDQ_Open_Trial_Search_ID","value":"799905"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165598":{"preferredName":"Anti-CD205 Antibody-drug Conjugate OBT076","code":"C165598","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of an anti-CD205 (lymphocyte antigen 75; Ly75) humanized immunoglobin G1 (IgG1) monoclonal antibody conjugated to DM4, a maytansinoid microtubule disruptor, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate (SPDB) linker, with potential antineoplastic activity. Upon intravenous administration, anti-CD205 ADC OBT076 specifically targets and binds to CD205, a receptor involved in antigen capture and endocytosis, expressed on tumor cells. Following rapid internalization of the ADC/CD205 complex, OBT076 releases its DM4 payload due to cleavage of the SPDB linker by intracellular proteases. Then the DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of both cell division and cell growth of CD205-expressing tumor cells. CD205, a type I transmembrane surface glycoprotein belonging to the C-type lectin receptor family, is normally expressed on various antigen-presenting cells (APCs) and some leukocyte sub-populations but it is overexpressed in multiple cancer types where it plays a key role in facilitating metastatic invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD205 Antibody-drug Conjugate OBT076","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD205 ADC OBT076","termGroup":"SY","termSource":"NCI"},{"termName":"MEN 1309","termGroup":"CN","termSource":"NCI"},{"termName":"MEN-1309","termGroup":"CN","termSource":"NCI"},{"termName":"MEN1309","termGroup":"CN","termSource":"NCI"},{"termName":"OBT 076","termGroup":"CN","termSource":"NCI"},{"termName":"OBT-076","termGroup":"CN","termSource":"NCI"},{"termName":"OBT076","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD205 Antibody-drug Conjugate OBT076"},{"name":"NCI_Drug_Dictionary_ID","value":"799986"},{"name":"NCI_META_CUI","value":"CL978811"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799986"},{"name":"PDQ_Open_Trial_Search_ID","value":"799986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168772":{"preferredName":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A","code":"C168772","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized antibody targeting the cell surface antigen cluster of differentiation (CD228; melanotransferrin; MFI2; MELTF) that is conjugated, via a beta-glucuronidase-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-CD228/MMAE ADC SGN-CD228A targets and binds to CD228 on the surface of tumor cells. Following internalization of SGN-CD228A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD228 Antibody-drug Conjugate SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD228-MMAE ADC SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD228/MMAE ADC SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-melanotransferrin ADC SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD228A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD228A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD228A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A"},{"name":"NCI_Drug_Dictionary_ID","value":"800848"},{"name":"NCI_META_CUI","value":"CL1378671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800848"},{"name":"PDQ_Open_Trial_Search_ID","value":"800848"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173969":{"preferredName":"Vopikitug","code":"C173969","definitions":[{"definition":"A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, vopikitug targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vopikitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD25 Monoclonal Antibody RG6292","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD25 Monoclonal Antibody RO7296682","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6292","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6292","termGroup":"CN","termSource":"NCI"},{"termName":"RG6292","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7296682","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7296682","termGroup":"CN","termSource":"NCI"},{"termName":"RO7296682","termGroup":"CN","termSource":"NCI"},{"termName":"T-regulatory Cell-depleting Antibody RO7296682","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2733581-99-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HV8TQI2IKP"},{"name":"Maps_To","value":"Anti-CD25 Monoclonal Antibody RO7296682"},{"name":"NCI_Drug_Dictionary_ID","value":"802183"},{"name":"NCI_META_CUI","value":"CL1407855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802183"},{"name":"PDQ_Open_Trial_Search_ID","value":"802183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172056":{"preferredName":"Boserolimab","code":"C172056","definitions":[{"definition":"A humanized agonistic monoclonal antibody targeting the cell surface antigen CD27, with potential immunostimulatory and antineoplastic activities. Upon administration, boserolimab targets and binds to CD27 on a variety of immune cell types, including most T-lymphocytes. This induces CD27-dependent signaling pathways and enhances T-cell-mediated responses, including the expansion of antigen-activated T-cells and the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes, memory B-cells and natural killer (NK) cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation. It is overexpressed in certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Boserolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD27 Agonist Monoclonal Antibody MK-5890","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD27 Agonistic Monoclonal Antibody MK-5890","termGroup":"SY","termSource":"NCI"},{"termName":"MK 5890","termGroup":"CN","termSource":"NCI"},{"termName":"MK-5890","termGroup":"CN","termSource":"NCI"},{"termName":"MK5890","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2209116-30-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"576SCZ7V2P"},{"name":"Maps_To","value":"Anti-CD27 Agonistic Monoclonal Antibody MK-5890"},{"name":"NCI_Drug_Dictionary_ID","value":"802005"},{"name":"NCI_META_CUI","value":"CL1406192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802005"},{"name":"PDQ_Open_Trial_Search_ID","value":"802005"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173369":{"preferredName":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044","code":"C173369","definitions":[{"definition":"A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD3/anti-5T4 bispecific antibody GEN1044 simultaneously targets and binds to CD3 expressed on T-cells and 5T4 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/5T4 Bispecific Antibody GEN1044","termGroup":"SY","termSource":"NCI"},{"termName":"DuoBody-CD3x5T4","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1044","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1044","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044"},{"name":"NCI_Drug_Dictionary_ID","value":"801833"},{"name":"NCI_META_CUI","value":"CL1407193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801833"},{"name":"PDQ_Open_Trial_Search_ID","value":"801833"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166258":{"preferredName":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119","code":"C166258","definitions":[{"definition":"A bispecific antibody against human CD3, a T-cell surface antigen, and human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential antineoplastic activity. Upon administration, anti-CD3/anti-GUCY2C bispecific antibody PF-07062119 targets and binds to both CD3 on T-cells and GUCY2C expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3 x Anti-GUCY2C Bispecific Antibody PF-07062119","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GUCY2C/Anti-CD3 Bispecific Antibody PF-07062119","termGroup":"SY","termSource":"NCI"},{"termName":"PF 07062119","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07062119","termGroup":"CN","termSource":"NCI"},{"termName":"PF07062119","termGroup":"CN","termSource":"NCI"},{"termName":"T-cell Bispecific Antibody PF-07062119","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119"},{"name":"NCI_Drug_Dictionary_ID","value":"800221"},{"name":"NCI_META_CUI","value":"CL971303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800221"},{"name":"PDQ_Open_Trial_Search_ID","value":"800221"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165583":{"preferredName":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin","code":"C165583","definitions":[{"definition":"An immunotoxin (IT) combination composed of two antibody-drug conjugates (ADCs), one containing a monoclonal antibody against CD3 and one against the CD7 antigen on activated T-cells and natural killer (NK) cells, and both conjugated to ricin toxin A (RTA), the A-chain form of the potent plant toxin ricin, that can potentially be used to destroy activated T- and NK cells. Upon administration of the anti-CD3/CD7-RTA immunotoxin, the anti-CD3 antibody moiety targets and binds to activated T-cells; the anti-CD7 antibody moiety targets and binds to CD7 on activated T-cells and NK cells. Upon internalization and cleavage, the RTA moiety irreversibly inhibits protein synthesis and induces apoptosis in the activated T-cells. This may eliminate activated T-cells and may improve conditions such as graft-versus-host-disease (GvHD). In addition, the binding and blocking of the anti-CD3 antibody to the T-cell receptor/CD3 complex (TCR/CD3) results in activation-induced cell death (AICD) and immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/CD7-RTA Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"CD3/CD7-Ricin A IT","termGroup":"SY","termSource":"NCI"},{"termName":"T-Guard","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"799985"},{"name":"NCI_META_CUI","value":"CL978824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799985"},{"name":"PDQ_Open_Trial_Search_ID","value":"799985"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172064":{"preferredName":"Anti-CD30/DM1 Antibody-drug Conjugate F0002","code":"C172064","definitions":[{"definition":"An antibody drug conjugate (ADC) consisting of a monoclonal antibody directed against the tumor necrosis factor (TNF) receptor CD30 conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of F0002 targets and binds to CD30-expressing tumor cells. Upon cellular uptake and internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits both cell division and the proliferation of tumor cells that express CD30. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8; TNFRSF8) may be constitutively expressed in some hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD30/DM1 Antibody-drug Conjugate F0002","termGroup":"PT","termSource":"NCI"},{"termName":"ADC F0002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD30/DM1 ADC F0002","termGroup":"SY","termSource":"NCI"},{"termName":"F 0002","termGroup":"CN","termSource":"NCI"},{"termName":"F-0002","termGroup":"CN","termSource":"NCI"},{"termName":"F0002","termGroup":"CN","termSource":"NCI"},{"termName":"F0002-ADC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD30/DM1 Antibody-drug Conjugate F0002"},{"name":"NCI_Drug_Dictionary_ID","value":"801498"},{"name":"NCI_META_CUI","value":"CL1406212"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801498"},{"name":"PDQ_Open_Trial_Search_ID","value":"801498"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172443":{"preferredName":"Ivicentamab","code":"C172443","definitions":[{"definition":"An Fc-engineered, humanized, bispecific hexamer formation-enhanced immunoglobulin (Ig) G1 monoclonal antibody that targets two separate epitopes on the tumor-associated antigen (TAA) CD37, with the E430G hexamerization-enhancing mutation, with potential immunomodulating and antineoplastic activities. Upon administration, ivicentamab specifically targets and binds to two non-overlapping CD37 epitopes, thereby inducing an assembly of antibody hexamers through intermolecular Fc-Fc interactions at the cell surface of CD37-overexpressing tumor cells. These hexamers recruit and activate C1, the first component of complement, thereby triggering the complement cascade which activates the immune system to induce complement-dependent cytotoxicity (CDC). In addition, the binding of ivicentamab to the CD37-overexpressing tumor cells also causes antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). CD37, a member of the tetraspanin superfamily of cell surface antigens, is expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. The E430G mutation in the Fc domains enhances Fc-mediated IgG hexamerization upon cellular target binding, and enhances CDC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivicentamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD37 Bispecific Monoclonal Antibody GEN3009","termGroup":"SY","termSource":"NCI"},{"termName":"DuoHexaBody-CD37","termGroup":"SY","termSource":"NCI"},{"termName":"DuoHexaBody-CD37 GEN3009","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 3009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-3009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN3009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2364496-42-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O7JS64H45"},{"name":"Maps_To","value":"Anti-CD37 Bispecific Monoclonal Antibody GEN3009"},{"name":"NCI_Drug_Dictionary_ID","value":"802024"},{"name":"NCI_META_CUI","value":"CL1406362"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802024"},{"name":"PDQ_Open_Trial_Search_ID","value":"802024"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174057":{"preferredName":"Anti-CD38 Antibody-drug Conjugate STI-6129","code":"C174057","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of STI-5171, a fully human monoclonal antibody targeting human cell surface glycoprotein and tumor-associated antigen (TAA) CD38, site-specifically conjugated, via a non-polyethylene glycol linker, to a monomethyl auristatin F (MMAF)-derived cytotoxic payload, with potential antineoplastic activity. Upon administration of anti-CD38 ADC STI-6129, the antibody moiety targets and binds to CD38 on tumor cells. Upon antibody/antigen binding and internalization, the MMAF derivative binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38 Antibody-drug Conjugate STI-6129","termGroup":"PT","termSource":"NCI"},{"termName":"ADC STI-6129","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38 ADC STI-6129","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38-Duostatin 5.2 ADC STI-6129","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-077","termGroup":"CN","termSource":"NCI"},{"termName":"LNDS1001","termGroup":"CN","termSource":"NCI"},{"termName":"STI 6129","termGroup":"CN","termSource":"NCI"},{"termName":"STI-6129","termGroup":"CN","termSource":"NCI"},{"termName":"STI6129","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD38 Antibody-drug Conjugate STI-6129"},{"name":"NCI_Drug_Dictionary_ID","value":"802462"},{"name":"NCI_META_CUI","value":"CL1407961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802462"},{"name":"PDQ_Open_Trial_Search_ID","value":"802462"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166376":{"preferredName":"Anti-CD38 Monoclonal Antibody SAR442085","code":"C166376","definitions":[{"definition":"A preparation of Fc-engineered monoclonal antibody that targets the cell surface glycoprotein CD-38 with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SAR442085 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38 Monoclonal Antibody SAR442085","termGroup":"PT","termSource":"NCI"},{"termName":"SAR 442085","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442085","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442085","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD38 Monoclonal Antibody SAR442085"},{"name":"NCI_Drug_Dictionary_ID","value":"800231"},{"name":"NCI_META_CUI","value":"CL971630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800231"},{"name":"PDQ_Open_Trial_Search_ID","value":"800231"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173645":{"preferredName":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257","code":"C173645","definitions":[{"definition":"A tri-specific T-cell engager and monoclonal antibody targeting CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), CD3, a T-cell surface antigen, and CD28, a T-cell specific surface glycoprotein and co-stimulatory molecule, with potential antineoplastic activity. Upon intravenous administration, anti-CD38/CD3/CD28 tri-specific monoclonal antibody SAR442257 targets and binds to CD3 and CD28 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. In addition, SAR442257 can also directly target CD28 expressed on tumor cells, such as multiple myeloma cells, thereby enhancing the anti-tumor activity of this agent and allowing it to bind to tumor cells when CD38 is occupied by other antibodies. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257","termGroup":"PT","termSource":"NCI"},{"termName":"SAR 442257","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442257","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442257","termGroup":"CN","termSource":"NCI"},{"termName":"Tri-specific T-cell Engager SAR442257","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257"},{"name":"NCI_Drug_Dictionary_ID","value":"802010"},{"name":"NCI_META_CUI","value":"CL1407369"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802010"},{"name":"PDQ_Open_Trial_Search_ID","value":"802010"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171450":{"preferredName":"Perenostobart","code":"C171450","definitions":[{"definition":"A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, perenostobart specifically binds to the CD39 antigen, thereby preventing the conversion and degradation of adenosine triphosphate (ATP) to adenosine monophosphate (AMP). This leads to an increase in the extracellular levels of immunogenic ATP and a decrease in the levels of immunosuppressive adenosine within the tumor microenvironment (TME). A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic and other myeloid-derived cells that are necessary for innate and adaptive immunity. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy. Blocking its action may improve anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perenostobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD39 Monoclonal Antibody SRF617","termGroup":"SY","termSource":"NCI"},{"termName":"SRF 617","termGroup":"CN","termSource":"NCI"},{"termName":"SRF-617","termGroup":"CN","termSource":"NCI"},{"termName":"SRF617","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2643331-31-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O84ZK2F68E"},{"name":"Maps_To","value":"Anti-CD39 Monoclonal Antibody SRF617"},{"name":"NCI_Drug_Dictionary_ID","value":"801999"},{"name":"NCI_META_CUI","value":"CL1405530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801999"},{"name":"PDQ_Open_Trial_Search_ID","value":"801999"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168604":{"preferredName":"Tecaginlimab","code":"C168604","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1, Fc-silenced, bispecific, agonistic monoclonal antibody targeting both CD40 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration,  tecaginlimab simultaneously binds to CD40 and 4-1BB, crosslinks CD40 and 4-1BB positive cells, induces conditional stimulation, and activates both CD40- and 4-1BB-medicated signaling. The activation of CD40-mediated signaling triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The activation of 4-1BB-mediated signaling induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system. 4-1BB, a surface glycoprotein of the TNFRSF, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tecaginlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40/Anti-CD137 Bispecific Agonist Monoclonal Antibody GEN1042","termGroup":"SY","termSource":"NCI"},{"termName":"BNT 312","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-312","termGroup":"CN","termSource":"NCI"},{"termName":"BNT312","termGroup":"CN","termSource":"NCI"},{"termName":"DuoBody-CD40x4-1BB GEN1042","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1042","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1042","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1042","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253891-70-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27X2015N23"},{"name":"Maps_To","value":"Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042"},{"name":"NCI_Drug_Dictionary_ID","value":"800410"},{"name":"NCI_META_CUI","value":"CL972921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800410"},{"name":"PDQ_Open_Trial_Search_ID","value":"800410"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173421":{"preferredName":"Anti-CD47 ADC SGN-CD47M","code":"C173421","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against human cell surface antigen CD47 conjugated to an as of yet not fully elucidated toxin, with potential antineoplastic activity. Upon administration of SGN-CD47M, the anti-CD47 monoclonal antibody moiety targets and binds to CD47 on tumor cell surfaces; upon internalization, the toxin moiety kills tumor cells through a mechanism of action that has not been elucidated. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 ADC SGN-CD47M","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD47M","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD47 Antibody-drug Conjugate SGN-CD47M","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD47M","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD47M","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD47M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 ADC SGN-CD47M"},{"name":"NCI_Drug_Dictionary_ID","value":"801749"},{"name":"NCI_META_CUI","value":"CL1407430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801749"},{"name":"PDQ_Open_Trial_Search_ID","value":"801749"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174192":{"preferredName":"Anti-CD47 Monoclonal Antibody IMC-002","code":"C174192","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody IMC-002 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. IMC-002 does not bind to red blood cells (RBCs). This may prevent adverse effects such as anemia that can result from the blockade of CD47 expressed on RBCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody IMC-002","termGroup":"PT","termSource":"NCI"},{"termName":"IMC 002","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-002","termGroup":"CN","termSource":"NCI"},{"termName":"IMC002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody IMC-002"},{"name":"NCI_Drug_Dictionary_ID","value":"802480"},{"name":"NCI_META_CUI","value":"CL1407837"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802480"},{"name":"PDQ_Open_Trial_Search_ID","value":"802480"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166137":{"preferredName":"Zeripatamig","code":"C166137","definitions":[{"definition":"A bispecific monoclonal antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of zeripatamig, the anti-CD19 moiety selectively targets and binds to CD19 on CD19-positive B-cells, thereby improving binding of the anti-CD47 moiety to the CD19+ malignant B-cells. The CD47 binding by TG-1801 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD19/CD47-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD19/CD47-expressing tumor cells. In addition, zeripatamig induces an anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. CD19 is a membrane antigen that is widely expressed during B-cell development and in B-cell malignancies. By co-targeting CD47 and CD19, zeripatamig has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs) which causes unwanted macrophage-mediated phagocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zeripatamig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Monoclonal Antibody TG-1801","termGroup":"SY","termSource":"NCI"},{"termName":"TG 1801","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1801","termGroup":"CN","termSource":"NCI"},{"termName":"TG1801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2607644-43-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK3WC9ZP7A"},{"name":"Maps_To","value":"Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801"},{"name":"NCI_Drug_Dictionary_ID","value":"799809"},{"name":"NCI_META_CUI","value":"CL979205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799809"},{"name":"PDQ_Open_Trial_Search_ID","value":"799809"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173724":{"preferredName":"Anti-claudin18.2 Monoclonal Antibody AB011","code":"C173724","definitions":[{"definition":"A recombinant humanized monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-claudin18.2 monoclonal antibody AB011 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-claudin18.2 Monoclonal Antibody AB011","termGroup":"PT","termSource":"NCI"},{"termName":"AB 011","termGroup":"CN","termSource":"NCI"},{"termName":"AB-011","termGroup":"CN","termSource":"NCI"},{"termName":"AB011","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CLDN18.2 Monoclonal Antibody AB011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-claudin18.2 Monoclonal Antibody AB011"},{"name":"NCI_Drug_Dictionary_ID","value":"802013"},{"name":"NCI_META_CUI","value":"CL1407568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802013"},{"name":"PDQ_Open_Trial_Search_ID","value":"802013"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173726":{"preferredName":"Osemitamab","code":"C173726","definitions":[{"definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, osemitamab specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation.  CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. Osemitamab is produced with reduced fucosylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osemitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Claudin18.2 Monoclonal Antibody TST001","termGroup":"SY","termSource":"NCI"},{"termName":"TST 001","termGroup":"CN","termSource":"NCI"},{"termName":"TST-001","termGroup":"CN","termSource":"NCI"},{"termName":"TST001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460539-61-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H14V1A2F4D"},{"name":"Maps_To","value":"Anti-Claudin18.2 Monoclonal Antibody TST001"},{"name":"NCI_Drug_Dictionary_ID","value":"802035"},{"name":"NCI_META_CUI","value":"CL1407570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802035"},{"name":"PDQ_Open_Trial_Search_ID","value":"802035"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C166139":{"preferredName":"Firastotug","code":"C166139","definitions":[{"definition":"A human monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, firastotug targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Firastotug","termGroup":"PT","termSource":"NCI"},{"termName":"ADG 116","termGroup":"CN","termSource":"NCI"},{"termName":"ADG-116","termGroup":"CN","termSource":"NCI"},{"termName":"ADG116","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody ADG116","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2750031-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B1J60R28A"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody ADG116"},{"name":"NCI_Drug_Dictionary_ID","value":"799904"},{"name":"NCI_META_CUI","value":"CL979207"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799904"},{"name":"PDQ_Open_Trial_Search_ID","value":"799904"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173540":{"preferredName":"Porustobart","code":"C173540","definitions":[{"definition":"A recombinant human heavy chain only antibody (HCAb) directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, porustobart targets and binds to CTLA-4 expressed on T-cells, and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. In addition, porustobart induces an antibody-dependent cell cytotoxicity (ADCC). CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. Porustobart, being a HCAb, is smaller than conventional antibodies which may allow for increased tissue penetration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porustobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody HBM4003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA4 Monoclonal Antibody HBM4003","termGroup":"SY","termSource":"NCI"},{"termName":"HBM 4003","termGroup":"CN","termSource":"NCI"},{"termName":"HBM-4003","termGroup":"CN","termSource":"NCI"},{"termName":"HBM4003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649372-91-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JJY4JHN685"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody HBM4003"},{"name":"NCI_Drug_Dictionary_ID","value":"801868"},{"name":"NCI_META_CUI","value":"CL1407491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801868"},{"name":"PDQ_Open_Trial_Search_ID","value":"801868"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173547":{"preferredName":"Gotistobart","code":"C173547","definitions":[{"definition":"A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, gotistobart targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. As gotistobart is dissociated from CTLA-4 under low pH, it does not cause lysosomal degradation of CTLA-4, preserving CTLA-4 and allowing the recycling of CTLA-4. This may result in more efficient and selective CTLA-4-targeted regulatory T-cell (Treg) depletion within the tumor microenvironment (TME) while preserving CTLA-4 functions outside the TME, thereby reducing toxicities. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gotistobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody ONC-392","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA4 Monoclonal Antibody ONC-392","termGroup":"SY","termSource":"NCI"},{"termName":"ONC 392","termGroup":"CN","termSource":"NCI"},{"termName":"ONC-392","termGroup":"CN","termSource":"NCI"},{"termName":"ONC392","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226344-78-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4R46M31XXP"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody ONC-392"},{"name":"NCI_Drug_Dictionary_ID","value":"801887"},{"name":"NCI_META_CUI","value":"CL1407498"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801887"},{"name":"PDQ_Open_Trial_Search_ID","value":"801887"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173435":{"preferredName":"Anti-CTLA-4 Probody BMS-986288","code":"C173435","definitions":[{"definition":"A probody composed of a modified version of ipilimumab, a recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of anti-CTLA-4 probody BMS-986288, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986288 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4 Probody BMS-986288","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986288","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986288","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986288","termGroup":"CN","termSource":"NCI"},{"termName":"Probody BMS-986288","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4 Probody BMS-986288"},{"name":"NCI_Drug_Dictionary_ID","value":"801762"},{"name":"NCI_META_CUI","value":"CL1407418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801762"},{"name":"PDQ_Open_Trial_Search_ID","value":"801762"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172196":{"preferredName":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","code":"C172196","definitions":[{"definition":"A fixed dose combination of two monoclonal antibodies of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217 targets and binds to both PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4/PD-1 Monoclonal Antibody Combination BCD-217","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA4/Anti-PD1 Monoclonal Antibody Combination BCD-217","termGroup":"SY","termSource":"NCI"},{"termName":"BCD 217","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-217","termGroup":"CN","termSource":"NCI"},{"termName":"BCD217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217"},{"name":"NCI_Drug_Dictionary_ID","value":"801536"},{"name":"NCI_META_CUI","value":"CL1406094"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801536"},{"name":"PDQ_Open_Trial_Search_ID","value":"801536"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173422":{"preferredName":"Anti-CTLA4 Antibody Fc Fusion Protein KN044","code":"C173422","definitions":[{"definition":"A recombinant, humanized fusion protein consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) single domain antibody linked to a Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 antibody Fc fusion protein KN044 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA4 Antibody Fc Fusion Protein KN044","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA4 Antibody Fusion Protein KN044","termGroup":"SY","termSource":"NCI"},{"termName":"KN 044","termGroup":"CN","termSource":"NCI"},{"termName":"KN-044","termGroup":"CN","termSource":"NCI"},{"termName":"KN044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA4 Antibody Fc Fusion Protein KN044"},{"name":"NCI_Drug_Dictionary_ID","value":"801856"},{"name":"NCI_META_CUI","value":"CL1407438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801856"},{"name":"PDQ_Open_Trial_Search_ID","value":"801856"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171163":{"preferredName":"Anti-EGFR/CD16A Bispecific Antibody AFM24","code":"C171163","definitions":[{"definition":"A human, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor (EGFR) and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-EGFR/CD16A bispecific antibody AFM24 simultaneously targets and binds to the CD16A expressed on natural killer (NK) cells and macrophages, and to EGFR on EGFR-expressing tumor cells, thereby selectively cross-linking EGFR-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and eventually tumor cell lysis. EGFR, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. CD16A is specifically expressed on the surface of NK cells and macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR/CD16A Bispecific Antibody AFM24","termGroup":"PT","termSource":"NCI"},{"termName":"AFM 24","termGroup":"CN","termSource":"NCI"},{"termName":"AFM-24","termGroup":"CN","termSource":"NCI"},{"termName":"AFM24","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-EGFR/Anti-CD16A Bispecific Antibody AFM24","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/CD16A Tetravalent Bispecific Antibody AFM24","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific EGFR/CD16A Innate Cell Engager AFM24","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR/CD16A Bispecific Antibody AFM24"},{"name":"NCI_Drug_Dictionary_ID","value":"801966"},{"name":"NCI_META_CUI","value":"CL1405396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801966"},{"name":"PDQ_Open_Trial_Search_ID","value":"801966"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173946":{"preferredName":"Farletuzumab Ecteribulin","code":"C173946","definitions":[{"definition":"An antibody drug conjugate (ADC) composed of farletuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the folate receptor alpha (FRA; FolRa; FOLR1), and conjugated, via a cathepsin B-cleavable linker, to the microtubule-targeting agent (MTA) eribulin, a derivative of the macrocyclic polyether natural product halichondrin B, with potential antineoplastic activity. Upon administration of farletuzumab ecteribulin, the farletuzumab moiety targets and binds to FRA expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and the induction of tumor cell death in FRA-expressing cells. FRA is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Farletuzumab Ecteribulin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FRA ADC MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FRA/Eribulin ADC MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb 202","termGroup":"CN","termSource":"NCI"},{"termName":"MORAb-202","termGroup":"CN","termSource":"NCI"},{"termName":"MORAb202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2407465-18-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UVG3B5TZN3"},{"name":"Maps_To","value":"Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802404"},{"name":"NCI_META_CUI","value":"CL1407865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802404"},{"name":"PDQ_Open_Trial_Search_ID","value":"802404"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165684":{"preferredName":"Livmoniplimab","code":"C165684","definitions":[{"definition":"A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T-cells (Tregs).  Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Livmoniplimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 151","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-151","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV151","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-GARP Monoclonal Antibody ABBV-151","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-glycoprotein A Repetitions Predominant Monoclonal Antibody ABBV-151","termGroup":"SY","termSource":"NCI"},{"termName":"ARGX 115","termGroup":"CN","termSource":"NCI"},{"termName":"ARGX-115","termGroup":"CN","termSource":"NCI"},{"termName":"ARGX115","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2412004-88-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42SH7JCD82"},{"name":"Maps_To","value":"Anti-GARP Monoclonal Antibody ABBV-151"},{"name":"NCI_Drug_Dictionary_ID","value":"800125"},{"name":"NCI_META_CUI","value":"CL978918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800125"},{"name":"PDQ_Open_Trial_Search_ID","value":"800125"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165657":{"preferredName":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999","code":"C165657","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of OBI-888 (OBI 888), a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) globohexaosylceramide (globo H), covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-globo H/MMAE ADC OBI 999, the antibody moiety of OBI 999, OBI 888, targets and binds to globo H on tumor cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE targets and binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in globo H-expressing tumor cells. Globo H, a hexasaccharide glycosphingolipid, is (over)expressed on the surface of many types of tumor cells. Globo H is minimally or not expressed on healthy, normal cells; its expression on cancer cells is associated with increased proliferation and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999","termGroup":"PT","termSource":"NCI"},{"termName":"ADC OBI 999","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Globo H/MMAE ADC OBI 999","termGroup":"SY","termSource":"NCI"},{"termName":"OBI 999","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-888/MMAE ADC OBI-999","termGroup":"SY","termSource":"NCI"},{"termName":"OBI-999","termGroup":"CN","termSource":"NCI"},{"termName":"OBI999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999"},{"name":"NCI_Drug_Dictionary_ID","value":"800120"},{"name":"NCI_META_CUI","value":"CL978959"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800120"},{"name":"PDQ_Open_Trial_Search_ID","value":"800120"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172987":{"preferredName":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a","code":"C172987","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the G protein-coupled receptor 20 (GPR20) conjugated to the cytotoxic DNA topoisomerase I inhibitor and exatecan derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-GPR20/DXd ADC DS-6157a, the anti-GPR20 antibody targets and binds to GPR20-expressing tumor cells. Upon cellular uptake, the DXd moiety targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of GPR20-expressing tumor cells. GPR20 is overexpressed on certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DS-6157a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GPR20 ADC DS-6157a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GPR20/DXd ADC DS-6157a","termGroup":"SY","termSource":"NCI"},{"termName":"DS 6157a","termGroup":"CN","termSource":"NCI"},{"termName":"DS-6157a","termGroup":"CN","termSource":"NCI"},{"termName":"DS6157a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a"},{"name":"NCI_Drug_Dictionary_ID","value":"802044"},{"name":"NCI_META_CUI","value":"CL1406780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802044"},{"name":"PDQ_Open_Trial_Search_ID","value":"802044"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173701":{"preferredName":"Ginisortamab","code":"C173701","definitions":[{"definition":"A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration, ginisortamab specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ginisortamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GREM1 Monoclonal Antibody UCB6114","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-gremlin-1 Monoclonal Antibody UCB6114","termGroup":"SY","termSource":"NCI"},{"termName":"UCB 6114","termGroup":"CN","termSource":"NCI"},{"termName":"UCB-6114","termGroup":"CN","termSource":"NCI"},{"termName":"UCB6114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2390147-17-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6808SG2XRK"},{"name":"Maps_To","value":"Anti-gremlin-1 Monoclonal Antibody UCB6114"},{"name":"NCI_Drug_Dictionary_ID","value":"802055"},{"name":"NCI_META_CUI","value":"CL1407518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802055"},{"name":"PDQ_Open_Trial_Search_ID","value":"802055"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173076":{"preferredName":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702","code":"C173076","definitions":[{"definition":"An off-the-shelf preparation of natural killer (NK) cells conjugated to a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential antineoplastic activity. Upon administration of anti-HER2 antibody conjugated natural killer cells ACE1702, the antibody moiety targets and binds to HER2 on tumor cells, which may lead to cell lysis of HER2-expressing tumor cells by the NK cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702","termGroup":"PT","termSource":"NCI"},{"termName":"ACE 1702","termGroup":"CN","termSource":"NCI"},{"termName":"ACE-1702","termGroup":"CN","termSource":"NCI"},{"termName":"ACE1702","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-HER2 Antibody Conjugated NK Cells ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Antibody Natural Killer Cell Conjugate ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Conjugated NK Cells ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 NK Cells ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 oNK Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702"},{"name":"NCI_Drug_Dictionary_ID","value":"802031"},{"name":"NCI_META_CUI","value":"CL1406967"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802031"},{"name":"PDQ_Open_Trial_Search_ID","value":"802031"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173966":{"preferredName":"Anti-HER2 Antibody-drug Conjugate BAT8001","code":"C173966","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated via an uncleavable linker to an as of yet undisclosed maytansine derivative, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC BAT8001, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the cytotoxic maytansine derivative binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits tumor cell proliferation and induces apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Antibody-drug Conjugate BAT8001","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BAT8001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC BAT8001","termGroup":"SY","termSource":"NCI"},{"termName":"BAT 8001","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-8001","termGroup":"CN","termSource":"NCI"},{"termName":"BAT8001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate BAT8001"},{"name":"NCI_Drug_Dictionary_ID","value":"802162"},{"name":"NCI_META_CUI","value":"CL1407842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802162"},{"name":"PDQ_Open_Trial_Search_ID","value":"802162"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173962":{"preferredName":"Anti-HER2 Antibody-drug Conjugate DP303c","code":"C173962","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC DP303c, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Antibody-drug Conjugate DP303c","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DP303c","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate DP303c","termGroup":"SY","termSource":"NCI"},{"termName":"DP 303c","termGroup":"CN","termSource":"NCI"},{"termName":"DP-303c","termGroup":"CN","termSource":"NCI"},{"termName":"DP303c","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate DP303c"},{"name":"NCI_Drug_Dictionary_ID","value":"802152"},{"name":"NCI_META_CUI","value":"CL1407846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802152"},{"name":"PDQ_Open_Trial_Search_ID","value":"802152"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174121":{"preferredName":"Anti-HER2 Monoclonal Antibody B002","code":"C174121","definitions":[{"definition":"A humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody B002 targets and binds to HER2 on HER2-expressing tumor cells. This prevents HER2-mediated signaling and may lead to antitumor activity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Monoclonal Antibody B002","termGroup":"PT","termSource":"NCI"},{"termName":"B 002","termGroup":"CN","termSource":"NCI"},{"termName":"B-002","termGroup":"CN","termSource":"NCI"},{"termName":"B002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody B002"},{"name":"NCI_Drug_Dictionary_ID","value":"802228"},{"name":"NCI_META_CUI","value":"CL1407790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802228"},{"name":"PDQ_Open_Trial_Search_ID","value":"802228"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172198":{"preferredName":"Anti-HER2 Monoclonal Antibody HLX22","code":"C172198","definitions":[{"definition":"A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody HLX22 targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-lymphocyte (CTL) response as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Monoclonal Antibody HLX22","termGroup":"PT","termSource":"NCI"},{"termName":"HLX 22","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-22","termGroup":"CN","termSource":"NCI"},{"termName":"HLX22","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody HLX22"},{"name":"NCI_Drug_Dictionary_ID","value":"801537"},{"name":"NCI_META_CUI","value":"CL1406092"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801537"},{"name":"PDQ_Open_Trial_Search_ID","value":"801537"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173420":{"preferredName":"Anti-HER2-DM1 ADC B003","code":"C173420","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC), with potential antineoplastic activity. Upon administration of B003, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics, inhibiting cell division and the proliferation of cancer cells that overexpress HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2-DM1 ADC B003","termGroup":"PT","termSource":"NCI"},{"termName":"ADC B003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2-DM1 Antibody-drug Conjugate B003","termGroup":"SY","termSource":"NCI"},{"termName":"B 003","termGroup":"CN","termSource":"NCI"},{"termName":"B-003","termGroup":"CN","termSource":"NCI"},{"termName":"B003","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Humanized Anti-HER2 Monoclonal Antibody-MCC-DM1 B003","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2-DM1 ADC B003"},{"name":"NCI_Drug_Dictionary_ID","value":"801748"},{"name":"NCI_META_CUI","value":"CL1407429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801748"},{"name":"PDQ_Open_Trial_Search_ID","value":"801748"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173827":{"preferredName":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001","code":"C173827","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated, via a site-specific linker, to the cytotoxic maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration of anti-HER2-DM1 ADC GQ1001, the antibody moiety targets and binds to HER2 on tumor cell surfaces. Upon cellular uptake and internalization, DM1 binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits cell division and the proliferation of tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001","termGroup":"PT","termSource":"NCI"},{"termName":"ADC GQ1001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2-DM1 ADC GQ1001","termGroup":"SY","termSource":"NCI"},{"termName":"GQ 1001","termGroup":"CN","termSource":"NCI"},{"termName":"GQ-1001","termGroup":"CN","termSource":"NCI"},{"termName":"GQ1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001"},{"name":"NCI_Drug_Dictionary_ID","value":"802397"},{"name":"NCI_META_CUI","value":"CL1407629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802397"},{"name":"PDQ_Open_Trial_Search_ID","value":"802397"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174205":{"preferredName":"Trastuzumab Vedotin","code":"C174205","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab vedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MRG002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/MMAE ADC MRG002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/MMAE Antibody-drug Conjugate MRG002","termGroup":"SY","termSource":"NCI"},{"termName":"MRG 002","termGroup":"CN","termSource":"NCI"},{"termName":"MRG-002","termGroup":"CN","termSource":"NCI"},{"termName":"MRG002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2740607-04-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W95G28K44S"},{"name":"Maps_To","value":"Anti-HER2/MMAE Antibody-drug Conjugate MRG002"},{"name":"NCI_Drug_Dictionary_ID","value":"804156"},{"name":"NCI_META_CUI","value":"CL1411781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"804156"},{"name":"PDQ_Open_Trial_Search_ID","value":"804156"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175374":{"preferredName":"Anti-HLA-G Antibody TTX-080","code":"C175374","definitions":[{"definition":"An antibody targeting HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G antibody TTX-080 targets and binds to HLA-G, thereby preventing the binding of HLA-G to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs). This may prevent the HLA-G-mediated immune suppression, thereby activating both innate and adaptive immune responses. This may activate anti-tumor immune responses. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HLA-G Antibody TTX-080","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-G Antagonist TTX-080","termGroup":"SY","termSource":"NCI"},{"termName":"TTX 080","termGroup":"CN","termSource":"NCI"},{"termName":"TTX-080","termGroup":"CN","termSource":"NCI"},{"termName":"TTX080","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HLA-G Antibody TTX-080"},{"name":"NCI_Drug_Dictionary_ID","value":"803279"},{"name":"NCI_META_CUI","value":"CL1412700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803279"},{"name":"PDQ_Open_Trial_Search_ID","value":"803279"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172391":{"preferredName":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A","code":"C172391","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized antibody targeting integrin beta-6 and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-integrin beta-6/MMAE ADC SGN-B6A targets and binds to integrin beta-6 on the surface of tumor cells. Following internalization of SGN-B6A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in integrin beta-6-expressing tumor cells. Integrin beta-6 is a subunit of integrin alpha-V beta-6 (aVb6). Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-integrin Beta-6 Antibody-drug Conjugate SGN-B6A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-integrin Beta-6-MMAE ADC SGN-B6A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-integrin Beta-6/MMAE ADC SGN-B6A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN B6A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-B6A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNB6A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A"},{"name":"NCI_Drug_Dictionary_ID","value":"802023"},{"name":"NCI_META_CUI","value":"CL1406348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802023"},{"name":"PDQ_Open_Trial_Search_ID","value":"802023"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173725":{"preferredName":"Frenlosirsen","code":"C173725","definitions":[{"definition":"An antisense oligonucleotide (ASO) targeting the interferon regulatory factor 4 (IRF4) mRNA, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, frenlosirsen hybridizes with IRF4 mRNA, which blocks translation of the IRF4 protein. Reduction of IRF4 levels prevents the expression of IRF4-controlled tumor promoter genes, and may enhance tumor cell apoptosis and prevent T-cell exhaustion. IRF4, a transcription factor expressed in lymphocytes and essential for plasma cell differentiation, is involved in immune cell development and plays a key role in T-cell functions. It is overexpressed in certain tumor cell types and is a key regulator of multiple genes controlling tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Frenlosirsen","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IRF4 Antisense Oligonucleotide ION251","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IRF4 ASO ION251","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IRF4 ASO IONIS-IRF4-2.5Rx","termGroup":"SY","termSource":"NCI"},{"termName":"ION 251","termGroup":"CN","termSource":"NCI"},{"termName":"ION-251","termGroup":"CN","termSource":"NCI"},{"termName":"ION251","termGroup":"CN","termSource":"NCI"},{"termName":"IONIS-IRF4-2.5Rx","termGroup":"SY","termSource":"NCI"},{"termName":"ON-935918","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2304711-81-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J2Y9QT3BWL"},{"name":"Maps_To","value":"Anti-IRF4 Antisense Oligonucleotide ION251"},{"name":"NCI_Drug_Dictionary_ID","value":"802018"},{"name":"NCI_META_CUI","value":"CL1407569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802018"},{"name":"PDQ_Open_Trial_Search_ID","value":"802018"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168603":{"preferredName":"Negalstobart","code":"C168603","definitions":[{"definition":"A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, negalstobart targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Negalstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody IBI-110","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody IBI110","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 110","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-110","termGroup":"CN","termSource":"NCI"},{"termName":"IBI110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2360418-68-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZH12W2AA34"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody IBI-110"},{"name":"NCI_Drug_Dictionary_ID","value":"800401"},{"name":"NCI_META_CUI","value":"CL972918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800401"},{"name":"PDQ_Open_Trial_Search_ID","value":"800401"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173598":{"preferredName":"Linavonkibart","code":"C173598","definitions":[{"definition":"A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, linavonkibart specifically targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linavonkibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-latent TGF-b1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-latent TGFb1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TGF-beta 1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"SRK 181","termGroup":"CN","termSource":"NCI"},{"termName":"SRK-181","termGroup":"CN","termSource":"NCI"},{"termName":"SRK181","termGroup":"CN","termSource":"NCI"},{"termName":"SRT-BETA-1-AB3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2640981-30-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8SSL98OST3"},{"name":"Maps_To","value":"Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181"},{"name":"NCI_Drug_Dictionary_ID","value":"802238"},{"name":"NCI_META_CUI","value":"CL1407357"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802238"},{"name":"PDQ_Open_Trial_Search_ID","value":"802238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175411":{"preferredName":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102","code":"C175411","definitions":[{"definition":"A humanized monoclonal antibody directed against human tumor-associated carbohydrate antigens (TACAs) Lewis B (LeB) and Lewis Y (LeY), with potential antineoplastic activity. Upon administration, anti-LeB/LeY monoclonal antibody GNX102 binds to branched LeB and LeY glycans, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against LeB- and LeY-expressing tumor cells. LeB and LeY antigens, tetrasaccharides with low to moderate expression in monomeric form in normal adult tissues, is overexpressed in branched form in multiple forms of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-branched Lewis B/Lewis Y Monoclonal Antibody GNX102","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LeB/LeY Monoclonal Antibody GNX102","termGroup":"SY","termSource":"NCI"},{"termName":"GNX 102","termGroup":"CN","termSource":"NCI"},{"termName":"GNX-102","termGroup":"CN","termSource":"NCI"},{"termName":"GNX102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102"},{"name":"NCI_Drug_Dictionary_ID","value":"803029"},{"name":"NCI_META_CUI","value":"CL1412719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803029"},{"name":"PDQ_Open_Trial_Search_ID","value":"803029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174485":{"preferredName":"Anti-LILRB4 Monoclonal Antibody IO-202","code":"C174485","definitions":[{"definition":"A monoclonal antibody directed against the immune inhibitory receptor leukocyte immunoglobulin-like receptor B4 (LILRB4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody IO-202 targets, binds to and inhibits LILRB4 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells, and inhibit tumor infiltration. LILRB4, an immune inhibitory receptor normally expressed on monocytic cells and highly expressed on monocytic acute myeloid leukemia (AML) cells, functions as an immune checkpoint that negatively regulates T-cell activation as its extracellular domain inhibits T-cell activity. It plays an important role in tumor infiltration in leukemias through multiple signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LILRB4 Monoclonal Antibody IO-202","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-leukocyte Immunoglobulin-like Receptor B4 Monoclonal Antibody IO-202","termGroup":"SY","termSource":"NCI"},{"termName":"IO 202","termGroup":"CN","termSource":"NCI"},{"termName":"IO-202","termGroup":"CN","termSource":"NCI"},{"termName":"IO202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LILRB4 Monoclonal Antibody IO-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802926"},{"name":"NCI_META_CUI","value":"CL1411991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802926"},{"name":"PDQ_Open_Trial_Search_ID","value":"802926"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174395":{"preferredName":"Anti-mesothelin/MMAE Antibody-drug Conjugate RC88","code":"C174395","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody directed against the human cell surface glycoprotein mesothelin and conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-mesothelin/MMAE ADC RC88 targets and binds to the tumor associated antigen (TAA) mesothelin on the surface of tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-mesothelin/MMAE Antibody-drug Conjugate RC88","termGroup":"PT","termSource":"NCI"},{"termName":"ADC RC88","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-mesothelin Antibody-drug Conjugate RC88","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-mesothelin/MMAE ADC RC88","termGroup":"SY","termSource":"NCI"},{"termName":"RC 88","termGroup":"CN","termSource":"NCI"},{"termName":"RC-88","termGroup":"CN","termSource":"NCI"},{"termName":"RC88","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-mesothelin/MMAE Antibody-drug Conjugate RC88"},{"name":"NCI_Drug_Dictionary_ID","value":"802312"},{"name":"NCI_META_CUI","value":"CL1411951"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802312"},{"name":"PDQ_Open_Trial_Search_ID","value":"802312"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165588":{"preferredName":"Vepsitamab","code":"C165588","definitions":[{"definition":"A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T-lymphocytes, with potential antineoplastic activity. Upon administration vepsitamab binds to both CD3 on T-cells and MUC17 expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vepsitamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 199","termGroup":"CN","termSource":"NCI"},{"termName":"AMG199","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-MUC17 x Anti-CD3 BiTE AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-MUC17/CD3 Bispecific Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-MUC17/CD3 BiTE Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"MUC17/CD3-directed Bispecific T-cell Engager Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"MUC17xCD3 Bispecific T-cell Engager AMG 199","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2413453-53-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZR1EEO1ZLS"},{"name":"Maps_To","value":"Anti-MUC17/CD3 BiTE Antibody AMG 199"},{"name":"NCI_Drug_Dictionary_ID","value":"799758"},{"name":"NCI_META_CUI","value":"CL978828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799758"},{"name":"PDQ_Open_Trial_Search_ID","value":"799758"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173702":{"preferredName":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592","code":"C173702","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of XMT-1535, a humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), that is site-specifically bioconjugated to the cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upon administration of anti-NaPi2b ADC XMT-1592, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Following internalization of XMT-1592 and release of AF-HPA, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-NaPi2b ADC XMT-1592","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b/Auristatin F-HPA ADC XMT-1592","termGroup":"SY","termSource":"NCI"},{"termName":"NaPi2b-targeted Antibody-drug Conjugate XMT-1592","termGroup":"SY","termSource":"NCI"},{"termName":"XMT 1592","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1592","termGroup":"CN","termSource":"NCI"},{"termName":"XMT1592","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592"},{"name":"NCI_Drug_Dictionary_ID","value":"802039"},{"name":"NCI_META_CUI","value":"CL1407519"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802039"},{"name":"PDQ_Open_Trial_Search_ID","value":"802039"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175453":{"preferredName":"Anti-OX40 Agonist Monoclonal Antibody BGB-A445","code":"C175453","definitions":[{"definition":"An agonistic monoclonal antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 agonist monoclonal antibody BGB-A445 selectively binds to OX40, thereby activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OX40 Agonist Monoclonal Antibody BGB-A445","termGroup":"PT","termSource":"NCI"},{"termName":"BGB A445","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A445","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA445","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-OX40 Agonist Monoclonal Antibody BGB-A445"},{"name":"NCI_Drug_Dictionary_ID","value":"802825"},{"name":"NCI_META_CUI","value":"CL1412805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802825"},{"name":"PDQ_Open_Trial_Search_ID","value":"802825"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173983":{"preferredName":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106","code":"C173983","definitions":[{"definition":"An agonistic, recombinant, humanized, hexavalent immunoglobulin G (IgG) antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 hexavalent agonist antibody INBRX-106 selectively binds to six OX40 receptors per molecule, thereby clustering and activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells. Utilizing a hexavalent OX40 antibody may improve receptor clustering and downstream signaling over tetravalent or bivalent OX40 antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Agonistic Antibody INBRX-106","termGroup":"SY","termSource":"NCI"},{"termName":"ES 102","termGroup":"CN","termSource":"NCI"},{"termName":"ES-102","termGroup":"CN","termSource":"NCI"},{"termName":"ES102","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX 106","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX-106","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106"},{"name":"NCI_Drug_Dictionary_ID","value":"802449"},{"name":"NCI_META_CUI","value":"CL1407892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802449"},{"name":"PDQ_Open_Trial_Search_ID","value":"802449"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174140":{"preferredName":"Latikafusp","code":"C174140","definitions":[{"definition":"An antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the cytokine interleukin-21 (IL-21), with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of latikafusp, the antibody moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The IL-21 mutein moiety binds to the IL-21 receptor and activates IL-21 cytokine signaling in PD-1-expressing cells. This may modulate the proliferation and/or differentiation, promote survival, and increase the cytolytic activity of PD-1-expressing T-cells, thereby enhancing T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-21 plays an important role in the regulation of cellular immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Latikafusp","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 256","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-256","termGroup":"CN","termSource":"NCI"},{"termName":"AMG256","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Antibody-IL-21 Mutein Fusion Protein AMG 256","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1-targeted IL-21 Receptor Agonist AMG 256","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2552814-07-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F188ZI78F7"},{"name":"Maps_To","value":"Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256"},{"name":"NCI_Drug_Dictionary_ID","value":"802477"},{"name":"NCI_META_CUI","value":"CL1407782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802477"},{"name":"PDQ_Open_Trial_Search_ID","value":"802477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172820":{"preferredName":"Anti-PD-1 Monoclonal Antibody 609A","code":"C172820","definitions":[{"definition":"A recombinant immunoglobulin G4 (IgG4) kappa monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody 609A targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody 609A","termGroup":"PT","termSource":"NCI"},{"termName":"609 A","termGroup":"CN","termSource":"NCI"},{"termName":"609-A","termGroup":"CN","termSource":"NCI"},{"termName":"609A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody 609A"},{"name":"NCI_Drug_Dictionary_ID","value":"801688"},{"name":"NCI_META_CUI","value":"CL1406852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801688"},{"name":"PDQ_Open_Trial_Search_ID","value":"801688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170758":{"preferredName":"Finotonlimab","code":"C170758","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, finotonlimab targets, binds to, and inhibits PD-1 and its downstream signaling pathways. This may restore immune functions through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Finotonlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody SCT-I10A","termGroup":"SY","termSource":"NCI"},{"termName":"SCT I10A","termGroup":"CN","termSource":"NCI"},{"termName":"SCT-I10A","termGroup":"CN","termSource":"NCI"},{"termName":"SCTI10A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2350298-85-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"533Z4G2286"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody SCT-I10A"},{"name":"NCI_Drug_Dictionary_ID","value":"800786"},{"name":"NCI_META_CUI","value":"CL1383152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800786"},{"name":"PDQ_Open_Trial_Search_ID","value":"800786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174419":{"preferredName":"Fidasimtamab","code":"C174419","definitions":[{"definition":"A recombinant human immunoglobulin G1 (IgG1) bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fidasimtamab simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fidasimtamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315","termGroup":"SY","termSource":"NCI"},{"termName":"BH 2950","termGroup":"CN","termSource":"NCI"},{"termName":"BH-2950","termGroup":"CN","termSource":"NCI"},{"termName":"BH2950","termGroup":"CN","termSource":"NCI"},{"termName":"HER2/PD-1 Bi-specific Antibody BH 2950","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 315","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-315","termGroup":"CN","termSource":"NCI"},{"termName":"IBI315","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2377419-89-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JXN644CQ6P"},{"name":"Maps_To","value":"Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315"},{"name":"NCI_Drug_Dictionary_ID","value":"802264"},{"name":"NCI_META_CUI","value":"CL1411981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802264"},{"name":"PDQ_Open_Trial_Search_ID","value":"802264"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173539":{"preferredName":"Tobemstomig","code":"C173539","definitions":[{"definition":"A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tobemstomig targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobemstomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD1/Anti-LAG3 Bispecific Antibody RO7247669","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7247669","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7247669","termGroup":"CN","termSource":"NCI"},{"termName":"RO7247669","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2648839-43-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"93NRF4S9HR"},{"name":"Maps_To","value":"Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669"},{"name":"NCI_Drug_Dictionary_ID","value":"801886"},{"name":"NCI_META_CUI","value":"CL1407490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801886"},{"name":"PDQ_Open_Trial_Search_ID","value":"801886"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171938":{"preferredName":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","code":"C171938","definitions":[{"definition":"A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody IBI318 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1, which is expressed on tumor cells. This crosslinks PD-1-expressing T cells and PD-L1-expressing tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/PD-L1 Bispecific Antibody IBI318","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody IBI318","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 318","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-318","termGroup":"CN","termSource":"NCI"},{"termName":"IBI318","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318"},{"name":"NCI_Drug_Dictionary_ID","value":"801472"},{"name":"NCI_META_CUI","value":"CL1405902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801472"},{"name":"PDQ_Open_Trial_Search_ID","value":"801472"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C168600":{"preferredName":"Anti-PD-1/CD47 Infusion Protein HX009","code":"C168600","definitions":[{"definition":"A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 infusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1/CD47 Infusion Protein HX009","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1/CD47 Bi-specific Antibody Fusion Protein HX009","termGroup":"SY","termSource":"NCI"},{"termName":"HX 009","termGroup":"CN","termSource":"NCI"},{"termName":"HX-009","termGroup":"CN","termSource":"NCI"},{"termName":"HX009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1/CD47 Infusion Protein HX009"},{"name":"NCI_Drug_Dictionary_ID","value":"800318"},{"name":"NCI_META_CUI","value":"CL972917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800318"},{"name":"PDQ_Open_Trial_Search_ID","value":"800318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171937":{"preferredName":"Volrustomig","code":"C171937","definitions":[{"definition":"An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. In addition, volrustomig is internalized and is able to degrade PD-1. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with volrustomig may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. It may also decrease toxicity by avoiding the binding to CTLA-4-expressing T-cells that are devoid of PD-1. The engineered Fc domain may reduce Fc effector function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Volrustomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 x CTLA-4 Bispecific Antibody MEDI5752","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-CTLA-4 Bispecific Antibody MEDI5752","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 5752","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-5752","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI5752","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2407760-40-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K96EGJ218N"},{"name":"Maps_To","value":"Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752"},{"name":"NCI_Drug_Dictionary_ID","value":"802004"},{"name":"NCI_META_CUI","value":"CL1405903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802004"},{"name":"PDQ_Open_Trial_Search_ID","value":"802004"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C184865":{"preferredName":"Ivonescimab","code":"C184865","definitions":[{"definition":"A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, ivonescimab simultaneously targets and binds to both PD-1 expressed on certain T-cells and VEGF expressed on tumor cells. The binding of ivonescimab to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of ivonescimab to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1 and/or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivonescimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 112","termGroup":"CN","termSource":"NCI"},{"termName":"AK-112","termGroup":"CN","termSource":"NCI"},{"termName":"AK112","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-VEGF Bispecific Antibody AK112","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/VEGF Bispecific Antibody AK112","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1/VEGF Bispecific Antibody AK112","termGroup":"SY","termSource":"NCI"},{"termName":"SMT 112","termGroup":"CN","termSource":"NCI"},{"termName":"SMT-112","termGroup":"CN","termSource":"NCI"},{"termName":"SMT112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2428381-53-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y0O332CU66"},{"name":"Maps_To","value":"Anti-PD-1/VEGF Bispecific Antibody AK112"},{"name":"NCI_Drug_Dictionary_ID","value":"800843"},{"name":"NCI_META_CUI","value":"CL1772938"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172819":{"preferredName":"Danburstotug","code":"C172819","definitions":[{"definition":"A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, danburstotug specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, anti-PD-L1 monoclonal antibody IMC-001 also induces antibody-dependent cell-mediated cytotoxicity (ADCC). PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Danburstotug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody IMC-001","termGroup":"SY","termSource":"NCI"},{"termName":"IMC 001","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-001","termGroup":"CN","termSource":"NCI"},{"termName":"IMC001","termGroup":"CN","termSource":"NCI"},{"termName":"STI 3031","termGroup":"CN","termSource":"NCI"},{"termName":"STI3031","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2307144-65-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F44C4N45HG"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody IMC-001"},{"name":"NCI_Drug_Dictionary_ID","value":"801687"},{"name":"NCI_META_CUI","value":"CL1406853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801687"},{"name":"PDQ_Open_Trial_Search_ID","value":"801687"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C174520":{"preferredName":"Anti-PD-L1 Monoclonal Antibody RC98","code":"C174520","definitions":[{"definition":"A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody RC98 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody RC98","termGroup":"PT","termSource":"NCI"},{"termName":"RC 98","termGroup":"CN","termSource":"NCI"},{"termName":"RC-98","termGroup":"CN","termSource":"NCI"},{"termName":"RC98","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody RC98"},{"name":"NCI_Drug_Dictionary_ID","value":"802372"},{"name":"NCI_META_CUI","value":"CL1411836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802372"},{"name":"PDQ_Open_Trial_Search_ID","value":"802372"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172194":{"preferredName":"Acasunlimab","code":"C172194","definitions":[{"definition":"A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, acasunlimab simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, acasunlimab acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, acasunlimab prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acasunlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046","termGroup":"SY","termSource":"NCI"},{"termName":"BNT 311","termGroup":"CN","termSource":"NCI"},{"termName":"DuoBody PD-L1 x 4-1BB GEN1046","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1046","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1046","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1046","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253937-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H52ITZ9X9D"},{"name":"Maps_To","value":"Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046"},{"name":"NCI_Drug_Dictionary_ID","value":"801584"},{"name":"NCI_META_CUI","value":"CL1406283"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801584"},{"name":"PDQ_Open_Trial_Search_ID","value":"801584"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173592":{"preferredName":"Anti-PD-L1/IL-15 Fusion Protein KD033","code":"C173592","definitions":[{"definition":"A fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) fused to the immunostimulatory cytokine interleukin-15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration of the anti-PD-L1/IL-15 fusion protein KD033, the anti-PD-L1 antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor microenvironment (TME). In turn, IL-15 stimulates the proliferation of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the TME, which induces an anti-tumor immune response. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. PD-L1, a transmembrane protein, is expressed on the surface of antigen presenting cells (APCs) and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1/IL-15 Fusion Protein KD033","termGroup":"PT","termSource":"NCI"},{"termName":"KD 033","termGroup":"CN","termSource":"NCI"},{"termName":"KD-033","termGroup":"CN","termSource":"NCI"},{"termName":"KD033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1/IL-15 Fusion Protein KD033"},{"name":"NCI_Drug_Dictionary_ID","value":"802237"},{"name":"NCI_META_CUI","value":"CL1407359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802237"},{"name":"PDQ_Open_Trial_Search_ID","value":"802237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170976":{"preferredName":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C","code":"C170976","definitions":[{"definition":"A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon administration of IMC-F106C, the TCR moiety of this agent targets and binds to PRAME on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C","termGroup":"PT","termSource":"NCI"},{"termName":"ImmTAC IMC-F106C","termGroup":"SY","termSource":"NCI"},{"termName":"ImmTAC Molecule IMC-F106C","termGroup":"SY","termSource":"NCI"},{"termName":"Immune Mobilizing Monoclonal TCR Against Cancer IMC-F106C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C"},{"name":"NCI_Drug_Dictionary_ID","value":"801222"},{"name":"NCI_META_CUI","value":"CL1383231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801222"},{"name":"PDQ_Open_Trial_Search_ID","value":"801222"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169053":{"preferredName":"Anti-PSMA/CD3 Bispecific Antibody CCW702","code":"C169053","definitions":[{"definition":"A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-PSMA/CD3 bispecific antibody CCW702, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA/CD3 Bispecific Antibody CCW702","termGroup":"PT","termSource":"NCI"},{"termName":"CCW 702","termGroup":"CN","termSource":"NCI"},{"termName":"CCW-702","termGroup":"CN","termSource":"NCI"},{"termName":"CCW702","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA/CD3 Bispecific Antibody CCW702"},{"name":"NCI_Drug_Dictionary_ID","value":"800617"},{"name":"NCI_META_CUI","value":"CL1378858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800617"},{"name":"PDQ_Open_Trial_Search_ID","value":"800617"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174406":{"preferredName":"Anti-RANKL Monoclonal Antibody GB-223","code":"C174406","definitions":[{"definition":"A monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with potential antiosteoclast and antineoplastic activities. Upon administration, anti-RANKL monoclonal antibody GB-223 specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This results in the inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. By blocking the activation of the RANK/RANKL-mediated signaling pathway, GB-223 may also reduce tumor-associated bone destruction and may result in tumor regression in bone tumors with high RANK and RANKL expressions. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-RANKL Monoclonal Antibody GB-223","termGroup":"PT","termSource":"NCI"},{"termName":"GB 223","termGroup":"CN","termSource":"NCI"},{"termName":"GB-223","termGroup":"CN","termSource":"NCI"},{"termName":"GB223","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-RANKL Monoclonal Antibody GB-223"},{"name":"NCI_Drug_Dictionary_ID","value":"802325"},{"name":"NCI_META_CUI","value":"CL1411946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802325"},{"name":"PDQ_Open_Trial_Search_ID","value":"802325"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C190458":{"preferredName":"Narlumosbart","code":"C190458","definitions":[{"definition":"A recombinant, human, immunoglobulin G4 (IgG4) monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL), with potential antiosteoclast and bone-sparing activities. Upon administration, narlumosbart specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This may inhibit osteoclast activity, decrease bone resorption, increase bone mineral density, and may protect bones from tumor metastasis. This may abrogate hypercalcemia of malignancy and may correct serum calcium levels. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Narlumosbart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-RANKL Monoclonal Antibody JMT103","termGroup":"SY","termSource":"NCI"},{"termName":"JMT 103","termGroup":"CN","termSource":"NCI"},{"termName":"JMT-103","termGroup":"CN","termSource":"NCI"},{"termName":"JMT103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J38KT46AH8"},{"name":"Maps_To","value":"Anti-RANKL Monoclonal Antibody JMT103"},{"name":"NCI_Drug_Dictionary_ID","value":"802778"},{"name":"NCI_META_CUI","value":"CL1798893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172924":{"preferredName":"Alextatug","code":"C172924","definitions":[{"definition":"An engineered, human immunoglobulin (Ig) G1 monoclonal antibody directed against a ribonucleoprotein (RNP) complex, with potential immunostimulating and antineoplastic activities. Upon administration, alextatug targets and binds to its RNP complex antigen on tumor cells. This may activate the innate immune system, change the local tumor microenvironment (TME) and promote T cell-mediated killing of tumor cells. The tumor-restricted RNP complex is expressed in a variety of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alextatug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Ribonucleoprotein Antibody ATRC-101","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-RNP Antibody ATRC-101","termGroup":"SY","termSource":"NCI"},{"termName":"ATRC 101","termGroup":"CN","termSource":"NCI"},{"termName":"ATRC-101","termGroup":"CN","termSource":"NCI"},{"termName":"ATRC101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2768264-93-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LF64CQ4EC6"},{"name":"Maps_To","value":"Anti-Ribonucleoprotein Antibody ATRC-101"},{"name":"NCI_Drug_Dictionary_ID","value":"802038"},{"name":"NCI_META_CUI","value":"CL1406946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802038"},{"name":"PDQ_Open_Trial_Search_ID","value":"802038"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174012":{"preferredName":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002","code":"C174012","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) site-specifically conjugated to a derivative of the highly potent anthracycline PNU-159682, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of NBE-002 targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the anthracycline-based toxin intercalates into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication and repair, and prevents RNA and protein synthesis. This kills the ROR1-expressing cancer cells. In addition, the PNU-159682 derivate may promote immunogenic cell death (ICD) and activate a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response, thereby further killing the ROR1-expressing tumor cells. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002","termGroup":"PT","termSource":"NCI"},{"termName":"ADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anthracycline-based Immune-stimulatory ADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ROR1/PNU-159682 Derivative ADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"iADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"NBE 002","termGroup":"CN","termSource":"NCI"},{"termName":"NBE-002","termGroup":"CN","termSource":"NCI"},{"termName":"NBE002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002"},{"name":"NCI_Drug_Dictionary_ID","value":"802454"},{"name":"NCI_META_CUI","value":"CL1407925"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802454"},{"name":"PDQ_Open_Trial_Search_ID","value":"802454"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170906":{"preferredName":"Ociperlimab","code":"C170906","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, ociperlimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ociperlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIGIT Monoclonal Antibody BGB-A1217","termGroup":"SY","termSource":"NCI"},{"termName":"BGB A1217","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A1217","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA1217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2342597-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7JNY4KV3NK"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody BGB-A1217"},{"name":"NCI_Drug_Dictionary_ID","value":"800838"},{"name":"NCI_META_CUI","value":"CL1383052"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800838"},{"name":"PDQ_Open_Trial_Search_ID","value":"800838"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174037":{"preferredName":"Anti-TIGIT Monoclonal Antibody COM902","code":"C174037","definitions":[{"definition":"A fully human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody COM902 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIGIT Monoclonal Antibody COM902","termGroup":"PT","termSource":"NCI"},{"termName":"COM 902","termGroup":"CN","termSource":"NCI"},{"termName":"COM-902","termGroup":"CN","termSource":"NCI"},{"termName":"COM902","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody COM902"},{"name":"NCI_Drug_Dictionary_ID","value":"802457"},{"name":"NCI_META_CUI","value":"CL1407907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802457"},{"name":"PDQ_Open_Trial_Search_ID","value":"802457"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173630":{"preferredName":"Anti-TIGIT Monoclonal Antibody SGN-TGT","code":"C173630","definitions":[{"definition":"A nonfucosylated human immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody SGN-TGT targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs). This prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), and enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This enhances depletion of TIGIT-positive regulatory T-cells (Tregs) and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIGIT Monoclonal Antibody SGN-TGT","termGroup":"PT","termSource":"NCI"},{"termName":"SEA TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SEA-TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SEATGT","termGroup":"CN","termSource":"NCI"},{"termName":"SGN TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SGNTGT","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody SGN-TGT"},{"name":"NCI_Drug_Dictionary_ID","value":"802244"},{"name":"NCI_META_CUI","value":"CL1407380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802244"},{"name":"PDQ_Open_Trial_Search_ID","value":"802244"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172108":{"preferredName":"Anti-TIM3 Monoclonal Antibody SHR-1702","code":"C172108","definitions":[{"definition":"A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIM3 monoclonal antibody SHR-1702 targets and binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM3 Monoclonal Antibody SHR-1702","termGroup":"PT","termSource":"NCI"},{"termName":"SHR 1702","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1702","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1702","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TIM3 Monoclonal Antibody SHR-1702"},{"name":"NCI_Drug_Dictionary_ID","value":"801357"},{"name":"NCI_META_CUI","value":"CL1406215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801357"},{"name":"PDQ_Open_Trial_Search_ID","value":"801357"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173541":{"preferredName":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711","code":"C173541","definitions":[{"definition":"A tetravalent bispecific antibody targeting both the pro-apoptotic death receptor tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2; death receptor 5; DR5) and cadherin-17 (CDH17), with potential pro-apoptotic and antineoplastic activities. Upon administration of anti-TRAILR2/CDH17 tetravalent bispecific antibody BI 905711, the antibody targets and binds to both TRAILR2 and CDH17, expressed on tumor cells. Receptor clustering and activation of TRAILR2 induces apoptosis in CDH17-positive cancer cells. Activation of TRAILR2 plays a key role in the induction of apoptosis. CDH17-dependent clustering of TRAILR2 allows BI 905711 to selectively induce apoptosis in CDH17-expressing tumor cells thereby increasing efficacy and decreasing liver toxicity. CDH17 is overexpressed in a variety of cancer cell types while its expression is restricted in normal liver tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711","termGroup":"PT","termSource":"NCI"},{"termName":"BI 905711","termGroup":"CN","termSource":"NCI"},{"termName":"BI-905711","termGroup":"CN","termSource":"NCI"},{"termName":"Bi-specific Agent BI 905711","termGroup":"SY","termSource":"NCI"},{"termName":"BI905711","termGroup":"CN","termSource":"NCI"},{"termName":"CDH17-targeting TRAILR2 Agonist BI 905711","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711"},{"name":"NCI_Drug_Dictionary_ID","value":"801873"},{"name":"NCI_META_CUI","value":"CL1407500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801873"},{"name":"PDQ_Open_Trial_Search_ID","value":"801873"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172060":{"preferredName":"Anti-TROP2 Antibody-drug Conjugate BAT8003","code":"C172060","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated via an uncleavable linker to an as of yet undisclosed maytansine derivative toxin, with potential antineoplastic activity. Upon administration of the anti-TROP2 ADC BAT8003, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the cytotoxic maytansine derivative binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TROP2 Antibody-drug Conjugate BAT8003","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BAT8003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Trop-2 Antibody-drug Conjugate BAT8003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2 ADC BAT8003","termGroup":"SY","termSource":"NCI"},{"termName":"BAT 8003","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-8003","termGroup":"CN","termSource":"NCI"},{"termName":"BAT8003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TROP2 Antibody-drug Conjugate BAT8003"},{"name":"NCI_Drug_Dictionary_ID","value":"801492"},{"name":"NCI_META_CUI","value":"CL1406188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801492"},{"name":"PDQ_Open_Trial_Search_ID","value":"801492"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166409":{"preferredName":"Sacituzumab Tirumotecan","code":"C166409","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration sacituzumab tirumotecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sacituzumab Tirumotecan","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MK-2870","termGroup":"SY","termSource":"NCI"},{"termName":"ADC SKB264","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2 Antibody-drug Conjugate MK-2870","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2 Antibody-drug Conjugate SKB264","termGroup":"SY","termSource":"NCI"},{"termName":"MK 2870","termGroup":"CN","termSource":"NCI"},{"termName":"MK-2870","termGroup":"CN","termSource":"NCI"},{"termName":"MK2870","termGroup":"CN","termSource":"NCI"},{"termName":"SKB 264","termGroup":"CN","termSource":"NCI"},{"termName":"SKB-264","termGroup":"CN","termSource":"NCI"},{"termName":"SKB264","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2768350-77-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3DV5TD1VL3"},{"name":"Maps_To","value":"Anti-TROP2 Antibody-drug Conjugate SKB264"},{"name":"NCI_Drug_Dictionary_ID","value":"800236"},{"name":"NCI_META_CUI","value":"CL971661"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800236"},{"name":"PDQ_Open_Trial_Search_ID","value":"800236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174422":{"preferredName":"Anti-VEGFR2 Monoclonal Antibody MSB0254","code":"C174422","definitions":[{"definition":"A humanized monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, anti-VEGFR2 monoclonal antibody MSB0254 specifically binds to and inhibits VEGFR2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGFR2 Monoclonal Antibody MSB0254","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR-2 Monoclonal Antibody MSB0254","termGroup":"SY","termSource":"NCI"},{"termName":"MSB 0254","termGroup":"CN","termSource":"NCI"},{"termName":"MSB-0254","termGroup":"CN","termSource":"NCI"},{"termName":"MSB0254","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGFR2 Monoclonal Antibody MSB0254"},{"name":"NCI_Drug_Dictionary_ID","value":"802274"},{"name":"NCI_META_CUI","value":"CL1411984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802274"},{"name":"PDQ_Open_Trial_Search_ID","value":"802274"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162452":{"preferredName":"Antisense Oligonucleotide QR-313","code":"C162452","definitions":[{"definition":"A twenty-one nucleotide-containing antisense oligonucleotide (AON) with potential use in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene. Upon topical administration, QR-313 hybridizes to a specific sequence in COL7A1 pre-mRNA, resulting in exclusion of exon 73 from mRNA and translation of a functional type VII collagen protein. This may restore functionality of integument anchoring fibrils, prevent blistering, and improve wound healing in patients with DEB. Type VII collagen is a major component of anchoring fibrils, attachment structures that mediate dermal-epidermal adherence in human skin. DEB is an inherited mechano-bullous disorder caused by mutations in the COL7A1 gene, which lead to perturbations in anchoring fibrils.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antisense Oligonucleotide QR-313","termGroup":"PT","termSource":"NCI"},{"termName":"QR 313","termGroup":"CN","termSource":"NCI"},{"termName":"QR-313","termGroup":"CN","termSource":"NCI"},{"termName":"QR313","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antisense Oligonucleotide QR-313"},{"name":"NCI_Drug_Dictionary_ID","value":"798741"},{"name":"NCI_META_CUI","value":"CL971000"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798741"},{"name":"PDQ_Open_Trial_Search_ID","value":"798741"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171151":{"preferredName":"Aryl Hydrocarbon Receptor Inhibitor IK-175","code":"C171151","definitions":[{"definition":"An orally bioavailable selective inhibitor of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76), with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR inhibitor IK-175 specifically targets and binds to AhR, inhibits AhR activation, prevents AhR-mediated signaling, and AhR-dependent tumor cell proliferation. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs), regulatory T-cells (Tregs) and decreases suppressive cytokines in the tumor microenvironment (TME). It stimulates cytotoxic T-cell activation and expansion. This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, plays key roles in regulating immunity and cellular differentiation. It mediates the expression of multiple immune related and tumor cell signal transduction and proliferation genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aryl Hydrocarbon Receptor Inhibitor IK-175","termGroup":"PT","termSource":"NCI"},{"termName":"AhR Antagonist IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"AhR Inhibitor IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"AhRi IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"AhRi KYN-175","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Antagonist IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Antagonist KYN-175","termGroup":"SY","termSource":"NCI"},{"termName":"IK 175","termGroup":"CN","termSource":"NCI"},{"termName":"IK-175","termGroup":"CN","termSource":"NCI"},{"termName":"IK175","termGroup":"CN","termSource":"NCI"},{"termName":"KYN 175","termGroup":"CN","termSource":"NCI"},{"termName":"KYN-175","termGroup":"CN","termSource":"NCI"},{"termName":"KYN175","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aryl Hydrocarbon Receptor Inhibitor IK-175"},{"name":"NCI_Drug_Dictionary_ID","value":"801964"},{"name":"NCI_META_CUI","value":"CL1405381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801964"},{"name":"PDQ_Open_Trial_Search_ID","value":"801964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174206":{"preferredName":"Camonsertib","code":"C174206","definitions":[{"definition":"An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, camonsertib selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camonsertib","termGroup":"PT","termSource":"NCI"},{"termName":"1R,3R,5S)-3-(6-((R)-3-Methylmorpholino)-1-(1H-pyrazol-3-yl)-1H-pyrazolo(3,4-b)pyridin-4-yl)-8-oxabicyclo(3.2.1)octan-3-ol","termGroup":"SN","termSource":"NCI"},{"termName":"8-Oxabicyclo(3.2.1)octan-3-ol, 3-(6-((3R)-3-methyl-4-morpholinyl)-1-(1H-pyrazol-3-yl)-1H-pyrazolo(3,4-b)pyridin-4-yl)-, (3-endo)-","termGroup":"SN","termSource":"NCI"},{"termName":"ATR Inhibitor RP-3500","termGroup":"SY","termSource":"NCI"},{"termName":"RP 3500","termGroup":"CN","termSource":"NCI"},{"termName":"RP-3500","termGroup":"CN","termSource":"NCI"},{"termName":"RP3500","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417489-10-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S1Z7Y5G56T"},{"name":"Maps_To","value":"ATR Inhibitor RP-3500"},{"name":"NCI_Drug_Dictionary_ID","value":"803074"},{"name":"NCI_META_CUI","value":"CL1411776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803074"},{"name":"PDQ_Open_Trial_Search_ID","value":"803074"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171067":{"preferredName":"Tuvusertib","code":"C171067","definitions":[{"definition":"An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, tuvusertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuvusertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATR Kinase Inhibitor M1774","termGroup":"SY","termSource":"NCI"},{"termName":"M 1774","termGroup":"CN","termSource":"NCI"},{"termName":"M-1774","termGroup":"CN","termSource":"NCI"},{"termName":"M1774","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JE1BE6ZGZ7"},{"name":"Maps_To","value":"ATR Kinase Inhibitor M1774"},{"name":"NCI_Drug_Dictionary_ID","value":"801231"},{"name":"NCI_META_CUI","value":"CL1405453"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801231"},{"name":"PDQ_Open_Trial_Search_ID","value":"801231"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175440":{"preferredName":"Attenuated Measles Virus Encoding SCD Transgene TMV-018","code":"C175440","definitions":[{"definition":"A recombinant, attenuated oncolytic measles virus (MV) encoding the prodrug converting enzyme super cytosine deaminase (SCD), that can potentially be used as an antineoplastic adjuvant and with potential antineoplastic activity. Upon intra-tumoral injection, TMV-018 preferentially enters and transfects tumor cells, and expresses SCD, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-fluorocytosine; 5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU by SCD. In addition, the oncolytic MV may infect and lyse tumor cells. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. This may further eradicate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Attenuated Measles Virus Encoding SCD Transgene TMV-018","termGroup":"PT","termSource":"NCI"},{"termName":"TMV 018","termGroup":"CN","termSource":"NCI"},{"termName":"TMV-018","termGroup":"CN","termSource":"NCI"},{"termName":"TMV018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Attenuated Measles Virus Encoding SCD Transgene TMV-018"},{"name":"NCI_Drug_Dictionary_ID","value":"802771"},{"name":"NCI_META_CUI","value":"CL1412818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802771"},{"name":"PDQ_Open_Trial_Search_ID","value":"802771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173429":{"preferredName":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055","code":"C173429","definitions":[{"definition":"A preparation of human autologous T-lymphocytes transduced with a lentiviral vector encoding for a T-cell receptor (TCR) recognizing the human leukocyte antigen (HLA)-A*02:01 restricted human alpha-fetoprotein (AFP) 158-166 peptide (FMNKFIYEI), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the AFP specific TCR transduced T cells recognize and bind to AFP antigen-positive cells, which results in lysis and killing of AFP-positive cancer cells. AFP is overexpressed in a variety of cancers while its expression is restricted in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous AFP-specific TCR-transduced T-cells C-TCR055","termGroup":"SY","termSource":"NCI"},{"termName":"C-TCR 055","termGroup":"SY","termSource":"NCI"},{"termName":"C-TCR-055","termGroup":"CN","termSource":"NCI"},{"termName":"C-TCR055","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055"},{"name":"NCI_Drug_Dictionary_ID","value":"801757"},{"name":"NCI_META_CUI","value":"CL1407436"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801757"},{"name":"PDQ_Open_Trial_Search_ID","value":"801757"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174124":{"preferredName":"Autologous Anti-BCMA CAR T-cells PHE885","code":"C174124","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential antineoplastic activity. Upon administration, the autologous anti-BCMA CAR T-cells PHE885 recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA CAR T-cells PHE885","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous BCMA-specific CAR T-cells PHE885","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-directed Autologous CAR-T Cells PHE885","termGroup":"SY","termSource":"NCI"},{"termName":"PHE 885","termGroup":"CN","termSource":"NCI"},{"termName":"PHE-885","termGroup":"CN","termSource":"NCI"},{"termName":"PHE885","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA CAR T-cells PHE885"},{"name":"NCI_Drug_Dictionary_ID","value":"802475"},{"name":"NCI_META_CUI","value":"CL1407791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802475"},{"name":"PDQ_Open_Trial_Search_ID","value":"802475"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173434":{"preferredName":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11","code":"C173434","definitions":[{"definition":"A preparation of autologous CD8-positive T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA CD8+ CAR T-cells Descartes-11 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD8+ T-cells Expressing Anti-BCMA CAR Descartes-11","termGroup":"SY","termSource":"NCI"},{"termName":"Descartes 11","termGroup":"CN","termSource":"NCI"},{"termName":"Descartes-011","termGroup":"CN","termSource":"NCI"},{"termName":"Descartes-11","termGroup":"CN","termSource":"NCI"},{"termName":"Descartes11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11"},{"name":"NCI_Drug_Dictionary_ID","value":"801760"},{"name":"NCI_META_CUI","value":"CL1407417"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801760"},{"name":"PDQ_Open_Trial_Search_ID","value":"801760"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170747":{"preferredName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088","code":"C170747","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the epitome cluster E3 in the extracellular domain (ECD) of the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous BCMA-directed CAR-T Cells C-CAR088","termGroup":"SY","termSource":"NCI"},{"termName":"C-CAR 088","termGroup":"CN","termSource":"NCI"},{"termName":"C-CAR-088","termGroup":"CN","termSource":"NCI"},{"termName":"C-CAR088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088"},{"name":"NCI_Drug_Dictionary_ID","value":"800733"},{"name":"NCI_META_CUI","value":"CL1383157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800733"},{"name":"PDQ_Open_Trial_Search_ID","value":"800733"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171167":{"preferredName":"Autologous Anti-CD123 CAR-T Cells","code":"C171167","definitions":[{"definition":"A preparation of autologous T-cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD123 CAR-T cells target and bind to CD123 expressed on the surface of tumor cells. This induces selective toxicity in CD123-expressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. It is overexpressed on a variety of cancers, including myeloid leukemia, and the increased expression of CD123 on leukemic stem cells (LSCs) is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD123 CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD123 CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD123 Chimeric Antigen Receptor T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123 CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD123 CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801968"},{"name":"NCI_META_CUI","value":"CL1405393"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801968"},{"name":"PDQ_Open_Trial_Search_ID","value":"801968"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173622":{"preferredName":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx","code":"C173622","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR T-cells 19(T2)28z1xx specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells. CD28 and CD3zeta provide co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T-cells. The 19(T2)28z1xx CAR T-cells include a 1928zeta mutant, 1xx, which contains one instead of all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation and exhaustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx","termGroup":"PT","termSource":"NCI"},{"termName":"19(T2)28z1xx","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous 19(T2)28z1xx CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells 19(T2)28z1xx","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-Targeted CAR T-cells 19(T2)28z1xx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx"},{"name":"NCI_Drug_Dictionary_ID","value":"802242"},{"name":"NCI_META_CUI","value":"CL1407373"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802242"},{"name":"PDQ_Open_Trial_Search_ID","value":"802242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175465":{"preferredName":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19","code":"C175465","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells CNCT19","termGroup":"SY","termSource":"NCI"},{"termName":"CNCT 19","termGroup":"CN","termSource":"NCI"},{"termName":"CNCT-19","termGroup":"CN","termSource":"NCI"},{"termName":"CNCT19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19"},{"name":"NCI_Drug_Dictionary_ID","value":"802902"},{"name":"NCI_META_CUI","value":"CL1412856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802902"},{"name":"PDQ_Open_Trial_Search_ID","value":"802902"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172746":{"preferredName":"Obecabtagene Autoleucel","code":"C172746","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obecabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"AUTO 1","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO-1","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO1","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO1 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-lymphocytes AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-targeted CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"CD19CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"CD19CAT-41BBZ CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Obe-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"760HJB0YRD"},{"name":"Maps_To","value":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1"},{"name":"NCI_Drug_Dictionary_ID","value":"801949"},{"name":"NCI_META_CUI","value":"CL1406598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801949"},{"name":"PDQ_Open_Trial_Search_ID","value":"801949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172055":{"preferredName":"Autologous Anti-CD19 TAC-T cells TAC01-CD19","code":"C172055","definitions":[{"definition":"A preparation of autologous T-lymphocytes genetically engineered with a T cell Antigen Coupler (TAC), comprising of a domain that targets the tumor-associated antigen (TAA) cluster of differentiation 19 (CD 19) and another domain that binds to the endogenous T cell receptor (TCR), anchored in the membrane via the CD4 co-receptor domain, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 TAC-T cells TAC01-CD19 targets and binds to CD19-expressing tumor cells and activates TCR-mediated signaling pathways, leading to T cell-mediated killing of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 TAC-T cells TAC01-CD19","termGroup":"PT","termSource":"NCI"},{"termName":"CD19-targeted T Cell Antigen Coupler TAC01-CD19","termGroup":"SY","termSource":"NCI"},{"termName":"TAC01 CD19","termGroup":"CN","termSource":"NCI"},{"termName":"TAC01-CD19","termGroup":"CN","termSource":"NCI"},{"termName":"TAC01CD19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 TAC-T cells TAC01-CD19"},{"name":"NCI_Drug_Dictionary_ID","value":"801474"},{"name":"NCI_META_CUI","value":"CL1406193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801474"},{"name":"PDQ_Open_Trial_Search_ID","value":"801474"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172057":{"preferredName":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells","code":"C172057","definitions":[{"definition":"A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that is nanobody-based and specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19/CD20 bispecific nanobody-based CAR-T cells target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19/20 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19/CD20 Bispecific Nanobody-derived CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19/CD20 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801489"},{"name":"NCI_META_CUI","value":"CL1406191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801489"},{"name":"PDQ_Open_Trial_Search_ID","value":"801489"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155897":{"preferredName":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells","code":"C155897","definitions":[{"definition":"A preparation of autologous human T-lymphocytes engineered to express dual chimeric antigen receptors (CARs) consisting of both anti-CD19 and anti-CD22 binding domains, fused to an as of yet undisclosed co-stimulatory domain, and linked to truncated forms of the human epidermal growth factor receptor 2 (HER2t) and the human epidermal growth factor receptor (EGFRt), respectively with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against tumor cells expressing CD19 and CD22. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt and HER2t facilitate both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through an antibody-dependent cellular cytotoxicity (ADCC) response. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells"},{"name":"NCI_Drug_Dictionary_ID","value":"794873"},{"name":"NCI_META_CUI","value":"CL562780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794873"},{"name":"PDQ_Open_Trial_Search_ID","value":"794873"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172063":{"preferredName":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1","code":"C172063","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), and CD4/CD8 enriched, with potential immunostimulating and antineoplastic activities. Upon administration, MB-CART20.1 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies and certain melanoma cell subpopulations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 CAR T Cells MB-CART20.1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD20-targeted CAR-transduced CD4/CD8 Enriched T Cells MB-CART20.1","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-targeting CAR T Cells MB-CART20.1","termGroup":"SY","termSource":"NCI"},{"termName":"MB-CART20.1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1"},{"name":"NCI_Drug_Dictionary_ID","value":"801497"},{"name":"NCI_META_CUI","value":"CL1406185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801497"},{"name":"PDQ_Open_Trial_Search_ID","value":"801497"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173958":{"preferredName":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes","code":"C173958","definitions":[{"definition":"A preparation of autologous, C-X-C chemokine receptor type 5 (CXCR 5)-modified T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes target and bind to EGFR-expressing tumor cells, thereby inducing selective toxicity in EGFR-expressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. CXCR5, and its ligand C-X-C motif chemokine 13 (CXCL13), are associated with a variety of tumors. CXCR5-CXCL13 interactions may be involved in the regulation of lymphocyte infiltration within the tumor microenvironment (TME).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CXCR5-modified Anti-EGFR CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"802166"},{"name":"NCI_META_CUI","value":"CL1407866"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802166"},{"name":"PDQ_Open_Trial_Search_ID","value":"802166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172197":{"preferredName":"Autologous Anti-FLT3 CAR T Cells AMG 553","code":"C172197","definitions":[{"definition":"A preparation of autologous T-lymphocytes genetically engineered with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-FLT3 CAR T cells AMG 553 target and bind to tumor cells expressing FLT3, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of FLT3-expressing tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-FLT3 CAR T Cells AMG 553","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 553","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-553","termGroup":"CN","termSource":"NCI"},{"termName":"AMG553","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous Anti-FLT3 CAR T-lymphocytes AMG 553","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous FLT3 CAR-T Cells AMG 553","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-FLT3 CAR T Cells AMG 553"},{"name":"NCI_Drug_Dictionary_ID","value":"801528"},{"name":"NCI_META_CUI","value":"CL1406093"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801528"},{"name":"PDQ_Open_Trial_Search_ID","value":"801528"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173378":{"preferredName":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100","code":"C173378","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) containing the Inserted (I) domain variant of lymphocyte function-associated antigen-1 (LFA-1) which targets intercellular adhesion molecule-1 (ICAM-1 or CD54), and the co-stimulatory signaling domains of CD28, 4-1BB (CD137) and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100 recognize and kill ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers. CAR T-cells AIC100 are also engineered to express somatostatin receptor subtype 2 (SSTR2), allowing the imaging of the CAR T-cells in patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100","termGroup":"PT","termSource":"NCI"},{"termName":"AIC 100","termGroup":"CN","termSource":"NCI"},{"termName":"AIC-100","termGroup":"CN","termSource":"NCI"},{"termName":"AIC100","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous ICAM-1-targeted CAR T Cells AIC100","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ICAM-1-targeted CAR T-cells AIC100","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ICAM-1-targeted CAR T-lymphocytes AIC100","termGroup":"SY","termSource":"NCI"},{"termName":"CAR T-cells AIC100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100"},{"name":"NCI_Drug_Dictionary_ID","value":"801844"},{"name":"NCI_META_CUI","value":"CL1407200"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801844"},{"name":"PDQ_Open_Trial_Search_ID","value":"801844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175446":{"preferredName":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes","code":"C175446","definitions":[{"definition":"A preparation of autologous T-lymphocytes (ATL) that have been genetically modified to express a chimeric antigen receptor (CAR) directed against the kappa light chain of immunoglobulin (Ig) and linked to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-kappa light chain CAR-CD28-expressing T-lymphocytes target and bind to the kappa light chain of Ig expressed on tumor cells, resulting in T-cell-mediated tumor cell lysis. In some B-cell malignancies, the expression of the Ig light chain kappa may be increased compared to the expression of Ig light chain lambda.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"ATLCAR.κ.28 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CAR.k.28 Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"802840"},{"name":"NCI_META_CUI","value":"CL1412808"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802840"},{"name":"PDQ_Open_Trial_Search_ID","value":"802840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172191":{"preferredName":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes","code":"C172191","definitions":[{"definition":"A preparation of autologous tumor infiltrating lymphocytes (TILs) activated by an anti-programmed cell death protein 1 (PD1) antibody, with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and ex-vivo activated in the presence of anti-PD-1 antibody. Upon infusion of the autologous anti-PD1 antibody-activated TILs back into the patient, the cells specifically target and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1 Antibody-activated Autologous TILs","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-PD-1 Antibody-activated TILs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"801527"},{"name":"NCI_META_CUI","value":"CL1406286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801527"},{"name":"PDQ_Open_Trial_Search_ID","value":"801527"},{"name":"Semantic_Type","value":"Cell"}]}}{"C175511":{"preferredName":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101","code":"C175511","definitions":[{"definition":"A preparation of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac), encoding both a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA), and a human-derived safety switch that can be activated by rimiducid, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-PSMA CAR-T cells P-PSMA-101 specifically recognize and induce selective toxicity in PSMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than CAR T-cells based on antibody-derived single chain variable fragments (scFv), and may allow for increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can be activated by the administration of rimiducid, which results in the rapid attenuation or elimination of P-PSMA-101. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-PSMA CAR T Cells P-PSMA-101","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-PSMA CAR T-cells P-PSMA-101","termGroup":"SY","termSource":"NCI"},{"termName":"P-PSMA 101","termGroup":"CN","termSource":"NCI"},{"termName":"P-PSMA-101","termGroup":"CN","termSource":"NCI"},{"termName":"P-PSMA101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101"},{"name":"NCI_Drug_Dictionary_ID","value":"803027"},{"name":"NCI_META_CUI","value":"CL1412868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803027"},{"name":"PDQ_Open_Trial_Search_ID","value":"803027"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173699":{"preferredName":"Autologous BCMA-targeted CAR T Cells CC-98633","code":"C173699","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T cells CC-98633 specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous BCMA-targeted CAR T Cells CC-98633","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous BCMA-targeted CAR T-cells CC-98633","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA-targeted NEX-T CAR T Cells CC-98633","termGroup":"SY","termSource":"NCI"},{"termName":"CC 98633","termGroup":"CN","termSource":"NCI"},{"termName":"CC-98633","termGroup":"CN","termSource":"NCI"},{"termName":"CC98633","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous BCMA-targeted CAR T Cells CC-98633"},{"name":"NCI_Drug_Dictionary_ID","value":"802040"},{"name":"NCI_META_CUI","value":"CL1407516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802040"},{"name":"PDQ_Open_Trial_Search_ID","value":"802040"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175471":{"preferredName":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F","code":"C175471","definitions":[{"definition":"A preparation of autologous T-lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific BCMA/CD19-targeted CAR-T cells GC012F specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. The processing platform used, FasT CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA/CD19 Dual CAR T Cells GC012F","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous GC012F CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"GC 012F","termGroup":"CN","termSource":"NCI"},{"termName":"GC-012F","termGroup":"CN","termSource":"NCI"},{"termName":"GC012F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F"},{"name":"NCI_Drug_Dictionary_ID","value":"802916"},{"name":"NCI_META_CUI","value":"CL1412846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802916"},{"name":"PDQ_Open_Trial_Search_ID","value":"802916"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171093":{"preferredName":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022","code":"C171093","definitions":[{"definition":"A preparation of autologous human T-lymphocytes engineered to express chimeric T-cell receptors (chimeric antigen receptors or CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific CD19/CD22-targeted CAR-T cells GC022 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific CAR T Cells GC022","termGroup":"SY","termSource":"NCI"},{"termName":"Dual CAR-T Cells GC022","termGroup":"SY","termSource":"NCI"},{"termName":"GC 022","termGroup":"CN","termSource":"NCI"},{"termName":"GC-022","termGroup":"CN","termSource":"NCI"},{"termName":"GC022","termGroup":"CN","termSource":"NCI"},{"termName":"GC022F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022"},{"name":"NCI_Drug_Dictionary_ID","value":"800937"},{"name":"NCI_META_CUI","value":"CL1405322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800937"},{"name":"PDQ_Open_Trial_Search_ID","value":"800937"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172103":{"preferredName":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1","code":"C172103","definitions":[{"definition":"A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with the lentiviral vector pLTG1563 expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD19 CAR-transduced CD4/CD8 Enriched T-cells MB-CART19.1","termGroup":"SY","termSource":"NCI"},{"termName":"MB CART19.1","termGroup":"SY","termSource":"NCI"},{"termName":"MB-CART19.1","termGroup":"CN","termSource":"NCI"},{"termName":"MBCART19.1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1"},{"name":"NCI_Drug_Dictionary_ID","value":"801342"},{"name":"NCI_META_CUI","value":"CL1406220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801342"},{"name":"PDQ_Open_Trial_Search_ID","value":"801342"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175049":{"preferredName":"Autologous CD19-targeted CAR T Cells CC-97540","code":"C175049","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD19-targeted CAR T cells CC-97540 specifically target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19-targeted CAR T Cells CC-97540","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD19-targeted CAR T-cells CC-97540","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-targeted NEX-T CAR T Cells CC-97540","termGroup":"SY","termSource":"NCI"},{"termName":"CC 97540","termGroup":"CN","termSource":"NCI"},{"termName":"CC-97540","termGroup":"CN","termSource":"NCI"},{"termName":"CC97540","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19-targeted CAR T Cells CC-97540"},{"name":"NCI_Drug_Dictionary_ID","value":"802907"},{"name":"NCI_META_CUI","value":"CL1412307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802907"},{"name":"PDQ_Open_Trial_Search_ID","value":"802907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171092":{"preferredName":"Autologous CD19-targeted CAR-T Cells GC007F","code":"C171092","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to as of yet not fully elucidated co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, autologous CD19-targeted CAR-T cells GC007F target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The processing platform used, FasT (F) CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19-targeted CAR-T Cells GC007F","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19-CAR-T Cells GC007F","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T Cells GC007F","termGroup":"SY","termSource":"NCI"},{"termName":"CD19 FasT CAR-T Cells GC007F","termGroup":"SY","termSource":"NCI"},{"termName":"FasT CAR-19","termGroup":"SY","termSource":"NCI"},{"termName":"FasTCAR-19","termGroup":"SY","termSource":"NCI"},{"termName":"GC 007F","termGroup":"CN","termSource":"NCI"},{"termName":"GC-007F","termGroup":"CN","termSource":"NCI"},{"termName":"GC007F","termGroup":"CN","termSource":"NCI"},{"termName":"GC007F CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19-targeted CAR-T Cells GC007F"},{"name":"NCI_Drug_Dictionary_ID","value":"800931"},{"name":"NCI_META_CUI","value":"CL1405323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800931"},{"name":"PDQ_Open_Trial_Search_ID","value":"800931"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172387":{"preferredName":"Autologous CD19/PD-1 Bispecific CAR-T Cells","code":"C172387","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) and a programmed cell death protein 1 (PD1)/CD28 chimera, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD19/PD-1 bispecific CAR-T cells target and bind to CD19 and the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2), expressed on tumor cells. The binding to CD19 leads to a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and cell lysis of these cells. The binding of the PD1/CD28 chimera to PD-L1 prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This enhances T-lymphocyte proliferation and anti-tumor activity. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. PD-1 protein, found on activated T-cells, negatively regulates T-cell activity. It plays a key role in immune evasion and prevents tumor cell lysis. The construct of the PD1/CD28 chimera converts PD-L1 into a co-stimulation ligand of primary human CD8+ cytotoxic T-lymphocytes (CTLs). CD28 is a costimulatory molecule expressed by T-cells that enhances T-lymphocyte proliferation and activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19/PD-1 Bispecific CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19/PD-1 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD19/PD-1 Bispecific CAR T-Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MC-19PD1 CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19/PD-1 Bispecific CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801669"},{"name":"NCI_META_CUI","value":"CL1406515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801669"},{"name":"PDQ_Open_Trial_Search_ID","value":"801669"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171097":{"preferredName":"Autologous Clonal Neoantigen T Cells ATL001","code":"C171097","definitions":[{"definition":"A preparation of personalized tumor-derived T-lymphocytes composed of tumor infiltrating lymphocytes (TILs) that are reactive to clonal cancer neoantigens, with potential immunostimulating and antineoplastic activities. The TILs are removed from the suppressive tumor microenvironment (TME) and re-activated. Upon reintroduction into the patient, the clonal neoantigen T (cNeT) cells recognize and bind to tumor cells expressing the targeted neoantigen, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Clonal Neoantigen T Cells ATL001","termGroup":"PT","termSource":"NCI"},{"termName":"ATL 001","termGroup":"CN","termSource":"NCI"},{"termName":"ATL-001","termGroup":"CN","termSource":"NCI"},{"termName":"ATL001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Clonal Neoantigen T Cells ATL001"},{"name":"NCI_Drug_Dictionary_ID","value":"800942"},{"name":"NCI_META_CUI","value":"CL1405344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800942"},{"name":"PDQ_Open_Trial_Search_ID","value":"800942"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170914":{"preferredName":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19","code":"C170914","definitions":[{"definition":"A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, and electroporated with clustered regularly interspaced short palindromic repeats (CRISPR) guide RNA to disrupt expression of endogenous hematopoietic progenitor kinase 1 (HPK1), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the autologous CRISPR-edited anti-CD19 CAR T-cells XYF19 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Disrupting the expression of HPK1 may enhance immune response and autoimmunity. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. HPK1 is a Ste20-like serine/threonine kinase that suppresses immune responses and autoimmunity. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CRISPR-edited CD19-specific CAR-T Cells XYF19","termGroup":"SY","termSource":"NCI"},{"termName":"CAR-T Cells XYF19","termGroup":"SY","termSource":"NCI"},{"termName":"CRISPR (HPK1)-edited CD19-specific CAR-T Cells XYF19","termGroup":"SY","termSource":"NCI"},{"termName":"XYF 19","termGroup":"CN","termSource":"NCI"},{"termName":"XYF-19","termGroup":"CN","termSource":"NCI"},{"termName":"XYF19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19"},{"name":"NCI_Drug_Dictionary_ID","value":"800868"},{"name":"NCI_META_CUI","value":"CL1383074"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800868"},{"name":"PDQ_Open_Trial_Search_ID","value":"800868"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173442":{"preferredName":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC","code":"C173442","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous, monocyte-derived dendritic cells (mDCs) pulsed with tumor cell lysate containing tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration,the autologous tumor cell lysate-pulsed mDCs vaccine PV-001-DC may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the patient's tumor cell-specific TAAs, which may result in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Monocyte-derived Lysate Pulsed DCs PV-001-DC","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cells PV-001-DC","termGroup":"SY","termSource":"NCI"},{"termName":"PV-001-DC","termGroup":"CN","termSource":"NCI"},{"termName":"PV-001-Dendritic Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC"},{"name":"NCI_Drug_Dictionary_ID","value":"801794"},{"name":"NCI_META_CUI","value":"CL1407425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801794"},{"name":"PDQ_Open_Trial_Search_ID","value":"801794"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170908":{"preferredName":"Autologous Multi-lineage Potential Cells","code":"C170908","definitions":[{"definition":"A preparation of autologous multi-lineage potential cells (AMPC) which were induced to de-differentiate from somatic leukocytes from peripheral blood, with potential immunomodulating and antineoplastic activities. Upon introduction into the patient, the AMPC may help replace the abnormal cells in the body to create healthy bone marrow in the treatment of acute myeloid leukemia (AML).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Multi-lineage Potential Cells","termGroup":"PT","termSource":"NCI"},{"termName":"AMPC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Multi-lineage Potential Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"800860"},{"name":"NCI_META_CUI","value":"CL1383050"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800860"},{"name":"PDQ_Open_Trial_Search_ID","value":"800860"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172386":{"preferredName":"Autologous Nectin-4/FAP-targeted CAR-T Cells","code":"C172386","definitions":[{"definition":"A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) nectin-4 and cell surface protein fibroblast activation protein (FAP), and additionally an inducible expression cassette encoding transgenic interleukin (IL) 7 (IL-7) or 12 (IL-12), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the autologous nectin-4/FAP-targeted CAR-T cells target and bind to nectin-4-expressing tumor cells and FAP-expressing cancer associated fibroblasts (CAFs). This results in a cytotoxic T-lymphocyte (CTL) response against nectin-4-expressing tumor cells and FAP-expressing CAFs, leading to cell lysis of these cells. Upon the binding to nectin-4 and FAP and the activation of the CAR-T cells, cytokine IL-7 or IL-12 is also released. This further augments the immune responses against the tumor cells, which may include the attack of nectin-4-negative tumor cells by tumor necrosis factor alpha (TNFa). Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer. FAP, a cell surface glycoprotein, is overexpressed on CAFs but minimally expressed on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Nectin-4/FAP-targeted CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-nectin-4/Anti-FAP CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-nectin-4/FAP CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Nectin4/FAP-targeted CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Nectin-4/FAP-targeted CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801659"},{"name":"NCI_META_CUI","value":"CL1406512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801659"},{"name":"PDQ_Open_Trial_Search_ID","value":"801659"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173710":{"preferredName":"Autologous NKG2D CAR T-cells CYAD-02","code":"C173710","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a retroviral vector to co-express a chimeric antigen receptor (CAR) encoding human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) with a short hairpin RNA (shRNA) targeting MHC class I chain-related protein A (MICA) and MICB, with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR T-cells CYAD-02 specifically recognize and bind to tumor cells expressing NKG2D ligands, resulting in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-02 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MICA, MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The shRNA downregulates the expression of MICA and MICB on the CAR-T cells, which increases in-vitro cell expansion. This may enhance their persistence and increase anti-tumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous NKG2D CAR T-cells CYAD-02","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous NKG2D CAR T-lymphocytes CYAD-02","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKG2D CAR-T Cells CYAD-02","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKG2D-based CAR T-cells CYAD-02","termGroup":"SY","termSource":"NCI"},{"termName":"CYAD 02","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD-02","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous NKG2D CAR T-cells CYAD-02"},{"name":"NCI_Drug_Dictionary_ID","value":"802256"},{"name":"NCI_META_CUI","value":"CL1407525"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802256"},{"name":"PDQ_Open_Trial_Search_ID","value":"802256"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173968":{"preferredName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine","code":"C173968","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate and mRNA containing and encoding tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration by perinodal injection using ultrasound guidance, the autologous pancreatic adenocarcinoma lysate and mRNA-loaded DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the patient's tumor cell-specific TAAs, which may result in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded DC Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded DCs","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"802181"},{"name":"NCI_META_CUI","value":"CL1407844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802181"},{"name":"PDQ_Open_Trial_Search_ID","value":"802181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167208":{"preferredName":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001","code":"C167208","definitions":[{"definition":"A preparation of autologous peripheral blood lymphocytes (PBLs) harvested from chronic lymphocytic leukemia (CLL) patients previously treated with the Brutons' tyrosine kinase (BTK) inhibitor ibrutinib with potential immunostimulating and antineoplastic activities. Upon intravenous administration, IOV-2001 generates an enhanced cytotoxic T-cell response against autologous leukemic B-cells in patients who have relapsed during treatment with ibrutinib. IOV-2001 is mostly comprised of T-cells of which the majority are of the effector memory phenotype which augments the specificity of the immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous PBLs from Ibrutinib-treated CLL Patients","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PBLs IOV-2001","termGroup":"SY","termSource":"NCI"},{"termName":"IOV 2001","termGroup":"CN","termSource":"NCI"},{"termName":"IOV-2001","termGroup":"CN","termSource":"NCI"},{"termName":"IOV2001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001"},{"name":"NCI_Drug_Dictionary_ID","value":"800421"},{"name":"NCI_META_CUI","value":"CL972433"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800421"},{"name":"PDQ_Open_Trial_Search_ID","value":"800421"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174405":{"preferredName":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201","code":"C174405","definitions":[{"definition":"A preparation of autologous rapamycin-resistant Th1/Tc1 cells, with potential immunomodulating activity. Upon administration, autologous rapamycin-resistant Th1/Tc1 cells RAPA-201 may recognize and kill tumor cells. Ex-vivo induction of rapamycin-resistance may increase the persistence of T-cells after adoptive transfer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201","termGroup":"PT","termSource":"NCI"},{"termName":"RAPA 201","termGroup":"CN","termSource":"NCI"},{"termName":"RAPA-201","termGroup":"CN","termSource":"NCI"},{"termName":"RAPA201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201"},{"name":"NCI_Drug_Dictionary_ID","value":"802318"},{"name":"NCI_META_CUI","value":"CL1411941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802318"},{"name":"PDQ_Open_Trial_Search_ID","value":"802318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175306":{"preferredName":"Autologous TCRm-expressing T-cells ET140203","code":"C175306","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) construct targeting as of yet undisclosed tumor associated antigen(s) (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration, the autologous TCRm-expressing T-cells ET140203 specifically recognize and selectively bind to the as of yet undisclosed TAA(s). This results in cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells expressing the TAA(s).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TCRm-expressing T-cells ET140203","termGroup":"PT","termSource":"NCI"},{"termName":"ET 140203","termGroup":"CN","termSource":"NCI"},{"termName":"ET-140203","termGroup":"CN","termSource":"NCI"},{"termName":"ET140203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCRm-expressing T-cells ET140203"},{"name":"NCI_Drug_Dictionary_ID","value":"803275"},{"name":"NCI_META_CUI","value":"CL1412643"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803275"},{"name":"PDQ_Open_Trial_Search_ID","value":"803275"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168775":{"preferredName":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG","code":"C168775","definitions":[{"definition":"A therapeutic cancer vaccine composed of autologous, dendritic cells (DCs) that have been loaded with a proprietary selection of four antigens that covers more than ninety percent of all non-small cell lung cancer (NSCLC) patients, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous tetravalent dendritic cell vaccine MIDRIX4-LUNG may induce and stimulate both T-helper and antigen-specific cytotoxic T-lymphocyte (CTL) responses, leading to tumor cell lysis in patients with NSCLC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous DC Vaccine MIDRIX4-LUNG","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tetravalent DC Vaccine MIDRIX4-LUNG","termGroup":"SY","termSource":"NCI"},{"termName":"MIDRIX4-LUNG","termGroup":"CN","termSource":"NCI"},{"termName":"Tetravalent Autologous Dendritic Cell Vaccine MIDRIX4-LUNG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG"},{"name":"NCI_Drug_Dictionary_ID","value":"800431"},{"name":"NCI_META_CUI","value":"CL1378684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800431"},{"name":"PDQ_Open_Trial_Search_ID","value":"800431"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173508":{"preferredName":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1","code":"C173508","definitions":[{"definition":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating and antineoplastic activities. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145-S1 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous TILs LN-145-S1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tumor-infiltrating Lymphocytes LN-145-S1","termGroup":"SY","termSource":"NCI"},{"termName":"LN 145-S1","termGroup":"CN","termSource":"NCI"},{"termName":"LN-145-S1","termGroup":"CN","termSource":"NCI"},{"termName":"LN145-S1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1"},{"name":"NCI_Drug_Dictionary_ID","value":"802231"},{"name":"NCI_META_CUI","value":"CL1407476"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802231"},{"name":"PDQ_Open_Trial_Search_ID","value":"802231"},{"name":"Semantic_Type","value":"Cell"}]}}{"C175463":{"preferredName":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T","code":"C175463","definitions":[{"definition":"A preparation of autologous T-lymphocytes that has been genetically engineered to express a fully humanized, universal, second generation chimeric antigen receptor (CAR) with a CD28/CD3zeta co-stimulatory domain, and a binding domain that can recognize a peptide motive of an antigen-specific targeting module (TM), with potential immunomodulating and antineoplastic activities. Upon administration, autologous universal CAR-expressing T-lymphocytes UniCAR02-T remain inactivated. Upon administration of an antigen-specific TM, the binding domain of UniCAR02-T binds to the nuclear antigen motif of the TM, and UniCAR02-T is activated when the antigen-binding moiety of the TM binds to the specific antigen expressed on tumor cells. This induces selective toxicity in and causes lysis of tumor cells expressing the specific antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Universal CAR-T Cells UniCAR02-T","termGroup":"SY","termSource":"NCI"},{"termName":"UniCAR-T","termGroup":"SY","termSource":"NCI"},{"termName":"UniCAR02 T","termGroup":"CN","termSource":"NCI"},{"termName":"UniCAR02-T","termGroup":"CN","termSource":"NCI"},{"termName":"UniCAR02-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"UniCAR02T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T"},{"name":"NCI_Drug_Dictionary_ID","value":"802895"},{"name":"NCI_META_CUI","value":"CL1412854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802895"},{"name":"PDQ_Open_Trial_Search_ID","value":"802895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173362":{"preferredName":"AXL Inhibitor SLC-391","code":"C173362","definitions":[{"definition":"An orally bioavailable and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential immunostimulating and antineoplastic activities. Upon oral administration, SLC-391 targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways, and inhibits both AXL-mediated tumor cell growth, proliferation and migration and AXL-mediated immunosuppression. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types and also expressed in a variety of immune cells including macrophages, natural killer (NK) cells, and regulatory T-cells (Tregs). It plays a key role in tumor cell proliferation, survival, invasion and metastasis, and is a mediator of immunosuppression. Its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL Inhibitor SLC-391","termGroup":"PT","termSource":"NCI"},{"termName":"SLC 391","termGroup":"CN","termSource":"NCI"},{"termName":"SLC-391","termGroup":"CN","termSource":"NCI"},{"termName":"SLC391","termGroup":"CN","termSource":"NCI"},{"termName":"XZB 0004","termGroup":"CN","termSource":"NCI"},{"termName":"XZB-0004","termGroup":"CN","termSource":"NCI"},{"termName":"XZB0004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL Inhibitor SLC-391"},{"name":"NCI_Drug_Dictionary_ID","value":"801796"},{"name":"NCI_META_CUI","value":"CL1407197"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801796"},{"name":"PDQ_Open_Trial_Search_ID","value":"801796"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173961":{"preferredName":"AXL/FLT3/VEGFR2 Inhibitor KC1036","code":"C173961","definitions":[{"definition":"An orally bioavailable inhibitor of three receptor tyrosine kinases: AXL (UFO), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2), and the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon oral administration, KC1036 targets, binds to and prevents the activation of AXL, FLT3 and VEGFR2. This blocks AXL, FLT3 and VEGFR2-mediated signal transduction pathways, and inhibits both AXL-, FLT3- and VEGFR2-mediated proliferation of tumor cells and the VEGFR2-mediated proliferation, survival and migration of endothelial cells. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types and also expressed in a variety of immune cells including macrophages, natural killer (NK) cells, and regulatory T-cells (Tregs). It plays a key role in tumor cell proliferation, survival, invasion and metastasis, and is a mediator of immunosuppression. Its expression is associated with drug resistance and poor prognosis. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias. VEGFR2 is frequently overexpressed by a variety of tumor types and tumor-associated endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL/FLT3/VEGFR2 Inhibitor KC1036","termGroup":"PT","termSource":"NCI"},{"termName":"KC 1036","termGroup":"CN","termSource":"NCI"},{"termName":"KC-1036","termGroup":"CN","termSource":"NCI"},{"termName":"KC1036","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL/FLT3/VEGFR2 Inhibitor KC1036"},{"name":"NCI_Drug_Dictionary_ID","value":"802085"},{"name":"NCI_META_CUI","value":"CL1407847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802085"},{"name":"PDQ_Open_Trial_Search_ID","value":"802085"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175543":{"preferredName":"Axl/Mer Inhibitor PF-07265807","code":"C175543","definitions":[{"definition":"An inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, Axl/Mer inhibitor PF-07265807 specifically targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axl/Mer Inhibitor PF-07265807","termGroup":"PT","termSource":"NCI"},{"termName":"PF 07265807","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07265807","termGroup":"CN","termSource":"NCI"},{"termName":"PF07265807","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Axl/Mer Inhibitor INCB081776"},{"name":"Maps_To","value":"Axl/Mer Inhibitor PF-07265807"},{"name":"NCI_Drug_Dictionary_ID","value":"803296"},{"name":"NCI_META_CUI","value":"CL1412891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803296"},{"name":"PDQ_Open_Trial_Search_ID","value":"803296"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175489":{"preferredName":"Sonrotoclax","code":"C175489","definitions":[{"definition":"An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, sonrotoclax specifically binds to and inhibits the activity of the pro-survival protein Bcl-2. This restores apoptotic processes and inhibits cell proliferation in Bcl-2-overexpressing tumor cells. Bcl-2, a protein that belongs to the Bcl-2 family, is overexpressed in various tumor cell types and plays an important role in the negative regulation of apoptosis. Its tumor expression is associated with increased drug resistance and cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonrotoclax","termGroup":"PT","termSource":"NCI"},{"termName":"B-cell Lymphoma-2 Inhibitor BGB-11417","termGroup":"SY","termSource":"NCI"},{"termName":"Bcl-2 Inhibitor BGB-11417","termGroup":"SY","termSource":"NCI"},{"termName":"BGB 11417","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-11417","termGroup":"CN","termSource":"NCI"},{"termName":"BGB11417","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2383086-06-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"30R67U9KYS"},{"name":"Maps_To","value":"Bcl-2 Inhibitor BGB-11417"},{"name":"NCI_Drug_Dictionary_ID","value":"803186"},{"name":"NCI_META_CUI","value":"CL1412833"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803186"},{"name":"PDQ_Open_Trial_Search_ID","value":"803186"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173536":{"preferredName":"Bcl-2 Inhibitor LP-108","code":"C173536","synonyms":[{"termName":"Bcl-2 Inhibitor LP-108","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Mon Feb 26 11:38:41 EST 2024 - See 'Lacutoclax(C203075)'"},{"name":"NCI_META_CUI","value":"CL1407495"},{"name":"OLD_PARENT","value":"C159200"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171631":{"preferredName":"BCMA/CD3e Tri-specific T-cell Activating Construct HPN217","code":"C171631","definitions":[{"definition":"A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; TNFRSF17), the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes, and albumin, with potential immunostimulating and antineoplastic activities. Upon administration, BCMA/CD3e TriTAC HPN217 targets and binds to BCMA on tumor cells and CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing BCMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN217. BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF), is overexpressed on malignant plasma cells and plays a key role in plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCMA/CD3e Tri-specific T-cell Activating Construct HPN217","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA/CD3e TriTAC HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3 Tri-specific T-cell Activating Construct HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3e TriTAC HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3e-specific TriTAC HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"HPN 217","termGroup":"CN","termSource":"NCI"},{"termName":"HPN-217","termGroup":"CN","termSource":"NCI"},{"termName":"HPN217","termGroup":"CN","termSource":"NCI"},{"termName":"TriTAC HPN217","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BCMA-CD19 Compound CAR T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802002"},{"name":"NCI_META_CUI","value":"CL1405854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802002"},{"name":"PDQ_Open_Trial_Search_ID","value":"802002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174412":{"preferredName":"BCMA-CD19 Compound CAR T Cells","code":"C174412","definitions":[{"definition":"A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the BCMA-CD19 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCMA-CD19 Compound CAR T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"BCMA-CD19 cCAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-CD19 cCAR T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BCMA/CD3e Tri-specific T-cell Activating Construct HPN217"},{"name":"NCI_META_CUI","value":"CL1411933"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172188":{"preferredName":"Betaglucin Gel","code":"C172188","definitions":[{"definition":"A soluble gel containing the beta-glucan betaglucin, with potential immunostimulating activity. Upon topical administration of the betaglucin gel, betaglucin is able to increase the number of macrophages and natural killer (NK) cells. NK cells and macrophages may kill a variety of tumor cells, and virally infected cells. This may treat human papillomavirus (HPV)-related anogenital warts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Betaglucin Gel","termGroup":"PT","termSource":"NCI"},{"termName":"Betaglucin Soluble Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Epiglucan Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Essential_Amino_Acid","value":"NCT03901690"},{"name":"Maps_To","value":"Betaglucin Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"801525"},{"name":"NCI_META_CUI","value":"CL1406289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801525"},{"name":"PDQ_Open_Trial_Search_ID","value":"801525"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171161":{"preferredName":"Bispecific Antibody AGEN1223","code":"C171161","definitions":[{"definition":"A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens co-expressed specifically on tumor-infiltrating regulatory T-cells (Tregs), with potential immunomodulating and antineoplastic activities. Upon administration, AGEN1223 targets and binds to the two antigens co-expressed specifically on tumor-infiltrating Tregs. This leads to the selective depletion of immunosuppressive Tregs in the tumor microenvironment (TME), while sparing peripheral Tregs and effector T-cells, enhancing the overall antitumor response. AGEN1223 may also co-stimulate antigen-specific effector T-cells, resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody AGEN1223","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 1223","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-1223","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1223","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bispecific Antibody AGEN1223"},{"name":"NCI_Drug_Dictionary_ID","value":"801965"},{"name":"NCI_META_CUI","value":"CL1405398"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801965"},{"name":"PDQ_Open_Trial_Search_ID","value":"801965"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168580":{"preferredName":"Xaluritamig","code":"C168580","definitions":[{"definition":"A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, xaluritamig targets and binds to the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xaluritamig","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 509","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-509","termGroup":"CN","termSource":"NCI"},{"termName":"AMG509","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Antibody AMG 509","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ODG03B9M4U"},{"name":"Maps_To","value":"Bispecific Antibody AMG 509"},{"name":"NCI_Drug_Dictionary_ID","value":"800690"},{"name":"NCI_META_CUI","value":"CL972905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800690"},{"name":"PDQ_Open_Trial_Search_ID","value":"800690"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167206":{"preferredName":"Dalutrafusp Alfa","code":"C167206","definitions":[{"definition":"A bispecific antibody that simultaneously binds two different as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, dalutrafusp alfa targets and binds the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dalutrafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 1423","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-1423","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1423","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Antibody GS-1423","termGroup":"SY","termSource":"NCI"},{"termName":"GS 1423","termGroup":"CN","termSource":"NCI"},{"termName":"GS-1423","termGroup":"CN","termSource":"NCI"},{"termName":"GS1423","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2419918-89-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KNL22F1WCK"},{"name":"Maps_To","value":"Bispecific Antibody GS-1423"},{"name":"NCI_Drug_Dictionary_ID","value":"800422"},{"name":"NCI_META_CUI","value":"CL972431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800422"},{"name":"PDQ_Open_Trial_Search_ID","value":"800422"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C184829":{"preferredName":"Gresonitamab","code":"C184829","definitions":[{"definition":"A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, gresonitamab simultaneously binds to both CD3-expressing T-cells and CLDN18.2-expressing cancer cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gresonitamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 910","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-910","termGroup":"CN","termSource":"NCI"},{"termName":"AMG910","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Antibody AMG 910","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager AMG 910","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 910","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 910","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2413817-97-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0SIB91V6TP"},{"name":"Maps_To","value":"BiTE Antibody AMG 910"},{"name":"NCI_Drug_Dictionary_ID","value":"801178"},{"name":"NCI_META_CUI","value":"CL1382994"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173633":{"preferredName":"BRAF Inhibitor BGB-3245","code":"C173633","definitions":[{"definition":"An orally available inhibitor of both monomer and dimer forms of activating mutations of the serine/threonine-protein kinase BRAF (B-raf) protein, including V600 BRAF mutations, non-V600 BRAF mutations, and RAF fusions, with potential antineoplastic activity. Upon administration, BRAF inhibitor BGB-3245 targets and binds to both monomeric and dimeric forms of activating BRAF mutations and fusions. This may result in the inhibition of BRAF-mediated signaling and inhibit proliferation in tumor cells expressing BRAF mutations and fusions. BRAF belongs to the RAF family of serine/threonine protein kinases and plays a role in regulating the mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. BRAF mutations and fusions have been identified in a number of solid tumors and are drivers of cancer growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF Inhibitor BGB-3245","termGroup":"PT","termSource":"NCI"},{"termName":"BGB 3245","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-3245","termGroup":"CN","termSource":"NCI"},{"termName":"BGB3245","termGroup":"CN","termSource":"NCI"},{"termName":"BRAF Monomer/Dimer Inhibitor BGB-3245","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF Inhibitor BGB-3245"},{"name":"NCI_Drug_Dictionary_ID","value":"802245"},{"name":"NCI_META_CUI","value":"CL1407365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802245"},{"name":"PDQ_Open_Trial_Search_ID","value":"802245"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170951":{"preferredName":"BRAF(V600E) Kinase Inhibitor ABM-1310","code":"C170951","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of mutant (V600E) v-raf murine sarcoma viral oncogene homolog B1 (BRAF) with potential antineoplastic activity. Upon oral administration, BRAF(V600E) kinase inhibitor ABM-1310 selectively binds to and inhibits the activity of BRAF(V600E) kinase, which may result in the inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. BRAF belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway. The valine to glutamic acid substitution at residue 600 accounts for about 90% of BRAF gene mutations. The oncogenic product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) mutation has been found to occur in about 8% of all tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF(V600E) Kinase Inhibitor ABM-1310","termGroup":"PT","termSource":"NCI"},{"termName":"ABM 1310","termGroup":"CN","termSource":"NCI"},{"termName":"ABM-1310","termGroup":"CN","termSource":"NCI"},{"termName":"ABM1310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF(V600E) Kinase Inhibitor ABM-1310"},{"name":"NCI_Drug_Dictionary_ID","value":"801208"},{"name":"NCI_META_CUI","value":"CL1383226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801208"},{"name":"PDQ_Open_Trial_Search_ID","value":"801208"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174394":{"preferredName":"BTK Inhibitor HZ-A-018","code":"C174394","definitions":[{"definition":"An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, BTK inhibitor HZ-A-018 targets, binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor HZ-A-018","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor HZ-A-018","termGroup":"SY","termSource":"NCI"},{"termName":"HZ-A 018","termGroup":"CN","termSource":"NCI"},{"termName":"HZ-A-018","termGroup":"CN","termSource":"NCI"},{"termName":"HZ-A018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor HZ-A-018"},{"name":"NCI_Drug_Dictionary_ID","value":"802311"},{"name":"NCI_META_CUI","value":"CL1411950"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802311"},{"name":"PDQ_Open_Trial_Search_ID","value":"802311"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170765":{"preferredName":"c-Met Inhibitor ABN401","code":"C170765","definitions":[{"definition":"An orally bioavailable, highly selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, ABN401 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor ABN401","termGroup":"PT","termSource":"NCI"},{"termName":"ABN 401","termGroup":"CN","termSource":"NCI"},{"termName":"ABN-401","termGroup":"CN","termSource":"NCI"},{"termName":"ABN401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor ABN401"},{"name":"NCI_Drug_Dictionary_ID","value":"800797"},{"name":"NCI_META_CUI","value":"CL1383179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800797"},{"name":"PDQ_Open_Trial_Search_ID","value":"800797"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175449":{"preferredName":"c-Met Inhibitor GST-HG161","code":"C175449","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, c-Met inhibitor GST-HG161 targets and binds to c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor GST-HG161","termGroup":"PT","termSource":"NCI"},{"termName":"GST HG161","termGroup":"CN","termSource":"NCI"},{"termName":"GST-HG161","termGroup":"CN","termSource":"NCI"},{"termName":"GSTHG161","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor GST-HG161"},{"name":"NCI_Drug_Dictionary_ID","value":"802843"},{"name":"NCI_META_CUI","value":"CL1412809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802843"},{"name":"PDQ_Open_Trial_Search_ID","value":"802843"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174169":{"preferredName":"Lucicebtide","code":"C174169","definitions":[{"definition":"A peptide antagonist of the transcription factor CCAAT/enhancer-binding protein beta (C/EBP beta), with potential antineoplastic activity. Upon administration, lucicebtide targets and inhibits the activity of C/EBP beta. This prevents the expression of C/EBP beta target genes and proteins, including the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), cyclins and inhibitor of differentiation (ID) family of proteins, which are involved in cell proliferation, differentiation, and cell cycle regulation. This may lead to apoptosis in tumor cells. C/EBP beta is overexpressed in many cancers and plays an important role in the regulation of cell differentiation; its expression is associated with tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucicebtide","termGroup":"PT","termSource":"NCI"},{"termName":"C/EBP Beta Antagonist ST101","termGroup":"SY","termSource":"NCI"},{"termName":"CCAAT/Enhancer-binding Protein Beta Inhibitor ST101","termGroup":"SY","termSource":"NCI"},{"termName":"ST 101","termGroup":"CN","termSource":"NCI"},{"termName":"ST-101","termGroup":"CN","termSource":"NCI"},{"termName":"ST101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2407100-74-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CT77XS2YLT"},{"name":"Maps_To","value":"C/EBP Beta Antagonist ST101"},{"name":"NCI_Drug_Dictionary_ID","value":"802478"},{"name":"NCI_META_CUI","value":"CL1407795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802478"},{"name":"PDQ_Open_Trial_Search_ID","value":"802478"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166417":{"preferredName":"Zegocractin","code":"C166417","definitions":[{"definition":"A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential anti-inflammatory and protective activities. Upon administration, zegocractin targets, binds to and inhibits the calcium release-activated calcium channel protein 1 (Orai1), which forms the pore of CRAC, and is expressed on both parenchymal cells and immune cells. This prevents the transport of extracellular Ca2+ into the cell and inhibits the subsequent activation of Ca2+-mediated signaling and transcription of target genes. This may prevent Ca2+ entry-mediated cell death. It may also inhibit the proliferation of immune cells and prevents the release of various inflammatory cytokines in immune cells, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a). This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), mediate store operated Ca2+ entry (SOCE) and play a key role in calcium homeostasis. CRACs are overactivated in a variety of cell types, especially certain immune cells during inflammation, including T-lymphocytes, neutrophils and macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zegocractin","termGroup":"PT","termSource":"NCI"},{"termName":"Calcium Release-activated Channel Inhibitor CM4620","termGroup":"SY","termSource":"NCI"},{"termName":"CM 4620","termGroup":"CN","termSource":"NCI"},{"termName":"CM-4620","termGroup":"CN","termSource":"NCI"},{"termName":"CM4620","termGroup":"CN","termSource":"NCI"},{"termName":"CRAC Inhibitor CM4620","termGroup":"SY","termSource":"NCI"},{"termName":"Orai Ca2+ Channel Inhibitor CM4620","termGroup":"SY","termSource":"NCI"},{"termName":"Orai1 Inhibitor CM4620","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1713240-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"564AW1RR37"},{"name":"Maps_To","value":"Calcium Release-activated Channel Inhibitor CM4620"},{"name":"NCI_Drug_Dictionary_ID","value":"800239"},{"name":"NCI_META_CUI","value":"CL971668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800239"},{"name":"PDQ_Open_Trial_Search_ID","value":"800239"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173441":{"preferredName":"Carbon C 14-pamiparib","code":"C173441","definitions":[{"definition":"An orally bioavailable radioconjugate composed of pamiparib, a nuclear enzyme poly(ADP-ribose) polymerase (PARP) inhibitor, radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of pamiparib. Pamiparib targets, binds to and inhibits PARP, which results in the inhibition of tumor cell proliferation and survival. Labeling of pamiparib with the radioactive tracer carbon C 14 allows for the evaluation of pamiparib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carbon C 14-pamiparib","termGroup":"PT","termSource":"NCI"},{"termName":"14C-pamiparib","termGroup":"SY","termSource":"NCI"},{"termName":"[14C]-pamiparib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Carbon C 14-pamiparib"},{"name":"NCI_Drug_Dictionary_ID","value":"801792"},{"name":"NCI_META_CUI","value":"CL1407424"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801792"},{"name":"PDQ_Open_Trial_Search_ID","value":"801792"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171374":{"preferredName":"Cationic Peptide Cream Cypep-1","code":"C171374","definitions":[{"definition":"A topical cream containing Cypep-1, a cationic lytic peptide of 27 amino acids, with potential antineoplastic activity. Upon topical administration, Cypep-1 selectively targets tumor cells with negatively charged cell membranes and ruptures the cell membranes. This leads to tumor cell lysis and the release of neoantigens into the tumor microenvironment (TME) and circulation. This elicits a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens. Warts are benign skin tumors caused by human papilloma virus (HPV).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cationic Peptide Cream Cypep-1","termGroup":"PT","termSource":"NCI"},{"termName":"Cypep-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cationic Peptide Cream Cypep-1"},{"name":"NCI_Drug_Dictionary_ID","value":"801302"},{"name":"NCI_META_CUI","value":"CL1405490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801302"},{"name":"PDQ_Open_Trial_Search_ID","value":"801302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165605":{"preferredName":"CD11b Agonist GB1275","code":"C165605","definitions":[{"definition":"An orally bioavailable small molecule agonist of CD11b (integrin alpha-M; ITGAM; integrin alpha M chain), with potential immunomodulating activity. Upon administration, CD11b agonist GB1275 targets and binds to CD11b, thereby activating CD11b. This leads to CD11b-mediated signaling and promotes pro-inflammatory macrophage polarization while suppressing immunosuppressive macrophage polarization. This reduces influx of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), promotes anti-tumor immune responses, induces cytotoxic T-lymphocytes (CTLs) and suppresses tumor growth. CD11b, a member of the integrin family of cell adhesion receptors highly expressed on immune system cells, is a negative regulator of immune suppression and activates anti-tumor innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD11b Agonist GB1275","termGroup":"PT","termSource":"NCI"},{"termName":"GB 1275","termGroup":"CN","termSource":"NCI"},{"termName":"GB-1275","termGroup":"CN","termSource":"NCI"},{"termName":"GB1275","termGroup":"CN","termSource":"NCI"},{"termName":"Integrin Alpha-M Agonist GB1275","termGroup":"SY","termSource":"NCI"},{"termName":"Integrin CD11b Agonist GB1275","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD11b Agonist GB1275"},{"name":"NCI_Drug_Dictionary_ID","value":"799988"},{"name":"NCI_META_CUI","value":"CL978817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799988"},{"name":"PDQ_Open_Trial_Search_ID","value":"799988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173970":{"preferredName":"CD123-CD33 Compound CAR T Cells","code":"C173970","definitions":[{"definition":"A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the CD123 (interleukin-3 receptor alpha chain or IL3RA) antigen and one specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, the CD123-CD33 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing CD123 and/or CD33. This induces selective toxicity in tumor cells that express the CD123 antigen and/or the CD33 antigen. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens. Additionally, the CD123-CD33 cCAR T cells express CD52 on the cell surface. This allows the depletion of the CD123-CD33 cCAR T cells with the administration of the anti-CD52 monoclonal antibody alemtuzumab, in case of unacceptable side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD123-CD33 Compound CAR T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"123b-33bcCAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-CD33 cCAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-CD33 cCAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123/CD33-expressing Compound CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD123-CD33 Compound CAR T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802178"},{"name":"NCI_META_CUI","value":"CL1407854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802178"},{"name":"PDQ_Open_Trial_Search_ID","value":"802178"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175461":{"preferredName":"CD123-specific Targeting Module TM123","code":"C175461","definitions":[{"definition":"A preparation of soluble adapter molecules consisting of an antigen-binding moiety targeting CD123 linked to a peptide motif recognizable by UniCAR02-T, that may be used to activate UniCAR02-T.  Upon administration of CD123-specific targeting module (TM) TM123, and upon co-administration of UniCAR02-T, the antigen-binding moiety of TM123 targets and binds to cancer cells expressing CD123, and the binding domain of UniCAR02-T binds to the nuclear antigen motif of TM123. This activates UniCAR02-T, and induces selective toxicity in and causes lysis of CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD123-specific Targeting Module TM123","termGroup":"PT","termSource":"NCI"},{"termName":"CD123 Target Module TM123","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-specific TM TM123","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Antibody Derivative TM123","termGroup":"SY","termSource":"NCI"},{"termName":"TM 123","termGroup":"CN","termSource":"NCI"},{"termName":"TM-123","termGroup":"CN","termSource":"NCI"},{"termName":"TM123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD123-specific Targeting Module TM123"},{"name":"NCI_Drug_Dictionary_ID","value":"802894"},{"name":"NCI_META_CUI","value":"CL1412859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802894"},{"name":"PDQ_Open_Trial_Search_ID","value":"802894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173960":{"preferredName":"CD20-CD19 Compound CAR T Cells","code":"C173960","definitions":[{"definition":"A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the CD20-CD19 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing CD20 and/or CD19. This induces selective toxicity in tumor cells that express CD20 and/or CD19. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD20-CD19 Compound CAR T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"CD19/CD20-expressing Compound CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-CD19 cCAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-CD19 cCAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD20-CD19 Compound CAR T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802177"},{"name":"NCI_META_CUI","value":"CL1407867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802177"},{"name":"PDQ_Open_Trial_Search_ID","value":"802177"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C179069":{"preferredName":"Acazicolcept","code":"C179069","definitions":[{"definition":"An Fc fusion protein comprised of a human inducible T-cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD) that binds to both inducible T-cell costimulator (ICOS; CD278) and cluster of differentiation 28 (CD28), with potential immunomodulating activity. Upon administration, acazicolcept targets and binds to both CD28 and ICOS expressed on certain T-cells. This prevents the activation of CD28 and ICOS by its ligands, thereby blocking the two T-cell costimulatory pathways and the resulting T-cell activation. CD28 is involved in initiation of the pathogenic process in graft versus host disease (GVHD). Following initial activation, CD28 is often downregulated while ICOS is upregulated, possibly sustaining GVHD. Dual blockade of CD28 and ICOS may be superior to individual blockade of CD28 or ICOS alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acazicolcept","termGroup":"PT","termSource":"NCI"},{"termName":"ALPN 101","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN-101","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN101","termGroup":"CN","termSource":"NCI"},{"termName":"CD28/ICOS Antagonist ALPN-101","termGroup":"SY","termSource":"NCI"},{"termName":"ICOSL vIgD-Fc","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2270247-50-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W507556HV0"},{"name":"Maps_To","value":"CD28/ICOS Antagonist ALPN-101"},{"name":"NCI_Drug_Dictionary_ID","value":"800691"},{"name":"NCI_META_CUI","value":"CL972908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173368":{"preferredName":"CD44v6-specific CAR T-cells","code":"C173368","definitions":[{"definition":"A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector encoding a fourth-generation specific chimeric antigen receptor (4SCAR) specific for CD44 variant domain 6 (CD44v6), with potential immunomodulating and antineoplastic activities. Upon administration, CD44v6-specific CAR T-cells specifically recognize and kill CD44v6-expressing tumor cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types. CD44v6, the isoform containing the variant domain 6 of CD44 gene, plays a key role in tumor cell invasion, proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD44v6-specific CAR T-cells","termGroup":"PT","termSource":"NCI"},{"termName":"4SCAR-CD44v6 T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR-CD44v6 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD44v6 CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD44v6 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD44v6-specific CAR Gene-engineered T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD44v6-specific CAR T-cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801822"},{"name":"NCI_META_CUI","value":"CL1407192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801822"},{"name":"PDQ_Open_Trial_Search_ID","value":"801822"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167156":{"preferredName":"Quemliclustat","code":"C167156","definitions":[{"definition":"A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon administration, quemliclustat targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quemliclustat","termGroup":"PT","termSource":"NCI"},{"termName":"AB 680","termGroup":"CN","termSource":"NCI"},{"termName":"AB-680","termGroup":"CN","termSource":"NCI"},{"termName":"AB680","termGroup":"CN","termSource":"NCI"},{"termName":"CD73 Inhibitor AB680","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2105904-82-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J6K8WSV73A"},{"name":"Maps_To","value":"CD73 Inhibitor AB680"},{"name":"NCI_Drug_Dictionary_ID","value":"800218"},{"name":"NCI_META_CUI","value":"CL972383"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800218"},{"name":"PDQ_Open_Trial_Search_ID","value":"800218"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170952":{"preferredName":"CD73 Inhibitor LY3475070","code":"C170952","definitions":[{"definition":"An orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon oral administration, CD73 inhibitor LY3475070 targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against tumor cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine. It is upregulated in a number of cancer cell types and plays a key role in adenosine-mediated immunosuppression within the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD73 Inhibitor LY3475070","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3475070","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3475070","termGroup":"CN","termSource":"NCI"},{"termName":"LY3475070","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AKA9175T4N"},{"name":"Maps_To","value":"CD73 Inhibitor LY3475070"},{"name":"NCI_Drug_Dictionary_ID","value":"801213"},{"name":"NCI_META_CUI","value":"CL1383223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801213"},{"name":"PDQ_Open_Trial_Search_ID","value":"801213"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174515":{"preferredName":"Davoceticept","code":"C174515","definitions":[{"definition":"A fusion protein composed of the N-terminal Ig variable-like (IgV) domain of CD80 fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration, davoceticept targets and binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) expressed on tumor cells, which blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279), and leads to PD-L1-dependent CD28 binding and co-stimulation in the local tumor microenvironment (TME). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling, leads to the co-stimulation of T-cell responses including the activation of naïve and memory T-cells in the TME and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, davoceticept targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4) expressed on T-cells. This prevents the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation. This further promotes T-cell activity. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells (APCs) that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Davoceticept","termGroup":"PT","termSource":"NCI"},{"termName":"ALPN 202","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN-202","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN202","termGroup":"CN","termSource":"NCI"},{"termName":"CD80 vIgD-Fc Fusion Protein ALPN-202","termGroup":"SY","termSource":"NCI"},{"termName":"CD80-Fc Fusion Protein ALPN-202","termGroup":"SY","termSource":"NCI"},{"termName":"CD80-vlgD-Fc ALPN-202","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2307144-64-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DE9GN7CD21"},{"name":"Maps_To","value":"CD80-Fc Fusion Protein ALPN-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802337"},{"name":"NCI_META_CUI","value":"CL1412018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802337"},{"name":"PDQ_Open_Trial_Search_ID","value":"802337"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169063":{"preferredName":"CD80-Fc Fusion Protein FPT155","code":"C169063","definitions":[{"definition":"A recombinant fusion protein composed of the extracellular domain (ECD) of human CD80 (B7.1) fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration of CD80-Fc fusion protein FPT155, the CD80 moiety targets and binds to CD28, which in the presence of antigenic T-cell receptor (TCR) signaling, leads to the co-stimulation of T-cell responses including the activation of naïve and memory T-cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. FPT155 also targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4), preventing the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation in the tumor microenvironment. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD80-Fc Fusion Protein FPT155","termGroup":"PT","termSource":"NCI"},{"termName":"FPT 155","termGroup":"CN","termSource":"NCI"},{"termName":"FPT-155","termGroup":"CN","termSource":"NCI"},{"termName":"FPT155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2337381-31-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WK58XJB6UK"},{"name":"Maps_To","value":"CD80-Fc Fusion Protein FPT155"},{"name":"NCI_Drug_Dictionary_ID","value":"800619"},{"name":"NCI_META_CUI","value":"CL1378876"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800619"},{"name":"PDQ_Open_Trial_Search_ID","value":"800619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175251":{"preferredName":"Tagtociclib","code":"C175251","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, tagtociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tagtociclib","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,3S)-3-(3-(3-(Methoxymethyl)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-5-yl)cyclopentyl isopropylcarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"CDK2 Inhibitor PF-07104091","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-dependent Kinase 2 Inhibitor PF-07104091","termGroup":"SY","termSource":"NCI"},{"termName":"PF 07104091","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07104091","termGroup":"CN","termSource":"NCI"},{"termName":"PF07104091","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460249-19-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XBD0JF5EHJ"},{"name":"Maps_To","value":"CDK2 Inhibitor PF-07104091"},{"name":"NCI_Drug_Dictionary_ID","value":"803259"},{"name":"NCI_META_CUI","value":"CL1412749"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803259"},{"name":"PDQ_Open_Trial_Search_ID","value":"803259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174417":{"preferredName":"CDK4/6 Inhibitor CS3002","code":"C174417","definitions":[{"definition":"An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor CS3002 selectively targets and inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor CS3002","termGroup":"PT","termSource":"NCI"},{"termName":"CS 3002","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3002","termGroup":"CN","termSource":"NCI"},{"termName":"CS3002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor CS3002"},{"name":"NCI_Drug_Dictionary_ID","value":"802263"},{"name":"NCI_META_CUI","value":"CL1411938"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802263"},{"name":"PDQ_Open_Trial_Search_ID","value":"802263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170749":{"preferredName":"CDK4/6 Inhibitor HS-10342","code":"C170749","definitions":[{"definition":"An orally bioavailable, small molecular, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor HS-10342 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor HS-10342","termGroup":"PT","termSource":"NCI"},{"termName":"HS 10342","termGroup":"CN","termSource":"NCI"},{"termName":"HS-10342","termGroup":"CN","termSource":"NCI"},{"termName":"HS10342","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor HS-10342"},{"name":"NCI_Drug_Dictionary_ID","value":"800781"},{"name":"NCI_META_CUI","value":"CL1383163"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800781"},{"name":"PDQ_Open_Trial_Search_ID","value":"800781"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171344":{"preferredName":"CDK4/6 Inhibitor TQB3616","code":"C171344","definitions":[{"definition":"An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor TQB3616 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor TQB3616","termGroup":"PT","termSource":"NCI"},{"termName":"TQB 3616","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3616","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3616","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor TQB3616"},{"name":"NCI_Drug_Dictionary_ID","value":"801305"},{"name":"NCI_META_CUI","value":"CL1405461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801305"},{"name":"PDQ_Open_Trial_Search_ID","value":"801305"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172390":{"preferredName":"CDK7 Inhibitor SY-5609","code":"C172390","definitions":[{"definition":"An orally bioavailable, selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon oral administration, SY-5609 selectively targets, binds to and inhibits the activity of CDK7, thereby inhibiting CDK7-mediated signaling. Specifically, inhibition of CDK7 prevents phosphorylation of the carboxy-terminal domain (CTD) of RNA Polymerase II, thereby preventing transcription of important cancer-promoting genes. In addition, it prevents phosphorylation of the cell cycle kinases CDK1, 2, 4, and 6, thereby disrupting uncontrolled cell cycle progression. Altogether, this may induce apoptosis, cause cell cycle arrest, inhibit DNA damage repair and inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc and beta-catenin, through the phosphorylation of RNA polymerase II.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK7 Inhibitor SY-5609","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin-dependent Kinase 7 Inhibitor SY-5609","termGroup":"SY","termSource":"NCI"},{"termName":"SY 5609","termGroup":"CN","termSource":"NCI"},{"termName":"SY-5609","termGroup":"CN","termSource":"NCI"},{"termName":"SY5609","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK7 Inhibitor SY-5609"},{"name":"NCI_Drug_Dictionary_ID","value":"802022"},{"name":"NCI_META_CUI","value":"CL1406516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802022"},{"name":"PDQ_Open_Trial_Search_ID","value":"802022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165747":{"preferredName":"CDK8/19 Inhibitor SEL 120","code":"C165747","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor SEL 120 targets, binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDK8/19, serine/threonine kinases involved in the regulation of the cell cycle, are overexpressed in certain cancer cell types and play key roles in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK8/19 Inhibitor SEL 120","termGroup":"PT","termSource":"NCI"},{"termName":"SEL 120","termGroup":"CN","termSource":"NCI"},{"termName":"SEL 120-34","termGroup":"CN","termSource":"NCI"},{"termName":"SEL 120-34A","termGroup":"CN","termSource":"NCI"},{"termName":"SEL-120","termGroup":"CN","termSource":"NCI"},{"termName":"SEL120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429515-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SDM3M518PJ"},{"name":"Maps_To","value":"CDK8/19 Inhibitor SEL 120"},{"name":"NCI_Drug_Dictionary_ID","value":"800129"},{"name":"NCI_META_CUI","value":"CL978865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800129"},{"name":"PDQ_Open_Trial_Search_ID","value":"800129"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171649":{"preferredName":"Cedazuridine/Azacitidine Combination Agent ASTX030","code":"C171649","definitions":[{"definition":"An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite azacitidine, with potential antineoplastic activity. Upon oral administration of the cedazuridine/azacitidine combination agent ASTX030, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of azacitidine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of azacitidine. Azacitidine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase (DNMT), thereby blocking DNA methylation and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cedazuridine/Azacitidine Combination Agent ASTX030","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 030","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX-030","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX030","termGroup":"CN","termSource":"NCI"},{"termName":"AZA/CDZ Combination","termGroup":"SY","termSource":"NCI"},{"termName":"Cedazuridine + Azacitidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cedazuridine/Azacitidine Combination Agent ASTX030"},{"name":"NCI_Drug_Dictionary_ID","value":"802003"},{"name":"NCI_META_CUI","value":"CL1405630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802003"},{"name":"PDQ_Open_Trial_Search_ID","value":"802003"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172396":{"preferredName":"Golcadomide","code":"C172396","definitions":[{"definition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, golcadomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golcadomide","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986369","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986369","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986369","termGroup":"CN","termSource":"NCI"},{"termName":"CC -99282","termGroup":"CN","termSource":"NCI"},{"termName":"CC 99282","termGroup":"CN","termSource":"NCI"},{"termName":"CC99282","termGroup":"CN","termSource":"NCI"},{"termName":"CelMod CC-99282","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ubiquitin Ligase Modulating Drug CC-99282","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon Modulator CC-99282","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"953769-46-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29HLR8Z5BR"},{"name":"Maps_To","value":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282"},{"name":"NCI_Drug_Dictionary_ID","value":"801633"},{"name":"NCI_META_CUI","value":"CL1406350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801633"},{"name":"PDQ_Open_Trial_Search_ID","value":"801633"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167056":{"preferredName":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes","code":"C167056","definitions":[{"definition":"A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of a CD28 co-stimulatory signaling domain fused to the zeta chain of the TCR/CD3 complex (CD3zeta), a truncated form of CD19 (CD19t), an immunoglobulin (Ig) G4-Fc (EQ) spacer, and a peptide derived from chlorotoxin (CLTX), with potential imaging and antineoplastic activities. Upon administration, chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes are re-directed to specific tumor cells in the brain inducing selective toxicity in these tumor cells. CLTX, a 36-amino acid peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus) and a chloride channel blocker, preferentially binds to glioma (and other neuroectodermal origin) cells via membrane bound forms of the endopeptidase matrix metalloproteinase-2 (MMP-2). This may direct the T-lymphocytes to and induce selective toxicity in MMP-2-expressing tumor cells. Additionally, binding to MMP-2 on glioma cells may both interfere with transmembrane chloride exchange and inhibit proteolytic extracellular matrix remodeling by MMP-2, which may further limit the spread of these tumor cells. MMP-2 is specifically upregulated in gliomas and related cancers, but is not normally expressed in brain. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling; its inclusion may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3 zeta chain alone. IgG4-Fc (EQ) contains two point mutations in its spacer region which prevents recognition of the CAR by Fc receptors (FcRs) without altering the ability of the CAR to mediate antigen-specific lysis. CD19t, which lacks the cytoplasmic signaling tail, provides a non-immunogenic surface marker that allows for accurate measurement, efficient cell tracking and/or imaging of the therapeutic T-cells in vivo following adoptive transfer. Additionally, co-expression of CD19t functions as a \"suicide\" switch via clinically available antibodies or immunotoxins which can be used to selectively eliminate the genetically modified cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"802824"},{"name":"NCI_META_CUI","value":"CL972048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802824"},{"name":"PDQ_Open_Trial_Search_ID","value":"802824"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169027":{"preferredName":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51","code":"C169027","definitions":[{"definition":"The ditosylated salt of A51, an orally bioavailable inhibitor of casein kinase 1alpha (CK1alpha) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), with potential antineoplastic activity. Upon administration, BTX-A51 binds to and inhibits the activity of CK1alpha, CDK7, and CDK9. Blocking the phosphorylation and kinase activity of CK1alpha prevents the enhanced binding of murine double minute X (MDMX) to p53, the formation of CK1alpha and MDM2 complex, and the resulting inhibition of p53. This induces p53-mediated cell cycle arrest, slowing tumor cell proliferation. Blocking the phosphorylation and kinase activity of CDK7 and CDK9 prevents the positive transcription elongation factor b (PTEFb)-mediated activation of RNA polymerase II (RNA Pol II) and leads to the inhibition of gene transcription of various anti-apoptotic proteins. This also induces cell cycle arrest and apoptosis, slowing tumor cell proliferation. CK1alpha, a serine/threonine kinase and a leukemic stem cell target, acts as a tumor suppressor in several cancers through the negative regulation of Wnt/beta-catenin signaling and p53. It negatively regulates p53 by phosphorylating MDMX, thus enhancing binding of MDMX to p53, as well as by forming a complex with MDM2. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA Pol II. CDK9, also a serine/threonine kinase, regulates elongation of transcription through phosphorylation of RNA Pol II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of RNA Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51","termGroup":"PT","termSource":"NCI"},{"termName":"BTX A51","termGroup":"CN","termSource":"NCI"},{"termName":"BTX-A51","termGroup":"CN","termSource":"NCI"},{"termName":"BTXA51","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51"},{"name":"NCI_Drug_Dictionary_ID","value":"801169"},{"name":"NCI_META_CUI","value":"CL1378832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801169"},{"name":"PDQ_Open_Trial_Search_ID","value":"801169"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167393":{"preferredName":"Commensal Bacterial Strain Formulation VE800","code":"C167393","definitions":[{"definition":"An orally bioavailable formulation composed of eleven alive, distinct nonpathogenic, nontoxigenic, human commensal bacterial strains, isolated from healthy human donor feces, with potential immunostimulating and antineoplastic activities. Upon administration of the commensal bacterial strain formulation VE800, the bacterial strains induce an interferon-gamma (IFN-g)-producing CD8-positive T-cell-mediated immune response in the intestines. This may activate an IFN-g-expressing CD8+ T-cell -mediated anti-cancer immune response and may eradicate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Commensal Bacterial Strain Formulation VE800","termGroup":"PT","termSource":"NCI"},{"termName":"Bacterial Consortium-based Formulation VE800","termGroup":"SY","termSource":"NCI"},{"termName":"LBP VE800","termGroup":"SY","termSource":"NCI"},{"termName":"Live Biotherapeutic Product VE800","termGroup":"SY","termSource":"NCI"},{"termName":"VE 800","termGroup":"CN","termSource":"NCI"},{"termName":"VE-800","termGroup":"CN","termSource":"NCI"},{"termName":"VE800","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Commensal Bacterial Strain Formulation VE800"},{"name":"NCI_Drug_Dictionary_ID","value":"802787"},{"name":"NCI_META_CUI","value":"CL972578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802787"},{"name":"PDQ_Open_Trial_Search_ID","value":"802787"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171370":{"preferredName":"Copper Cu 67 Ucasareotide Dasaroxetan","code":"C171370","definitions":[{"definition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional chelator 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar) and radiolabeled with the beta-emitting radioisotope copper Cu 67, with potential antineoplastic activity. Upon administration, copper Cu 67 ucasareotide dasaroxetan binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. TATE is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copper Cu 67 Ucasareotide Dasaroxetan","termGroup":"PT","termSource":"NCI"},{"termName":"67Cu-labeled MeCOSar-Tyr3-octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"67Cu-SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Copper 67 SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Copper Cu 67 TATE","termGroup":"SY","termSource":"NCI"},{"termName":"Copper Cu 67 Tyr3-octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Copper Cu 67-SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Cu-67 SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Ucasareotide Dasaroxetan Cu-67","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y6WKJ2X9X8"},{"name":"Maps_To","value":"Copper Cu 67 Tyr3-octreotate"},{"name":"NCI_Drug_Dictionary_ID","value":"801332"},{"name":"NCI_META_CUI","value":"CL1405493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801332"},{"name":"PDQ_Open_Trial_Search_ID","value":"801332"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172058":{"preferredName":"Cord Blood Derived CAR T-Cells","code":"C172058","definitions":[{"definition":"A preparation of umbilical cord blood (CB)-derived T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of the cord blood derived CAR T-cells, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cord Blood Derived CAR T-Cells","termGroup":"PT","termSource":"NCI"},{"termName":"CB Derived CAR T-Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Cord Blood CAR T-Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cord Blood Derived CAR T-Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801490"},{"name":"NCI_META_CUI","value":"CL1406190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801490"},{"name":"PDQ_Open_Trial_Search_ID","value":"801490"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173651":{"preferredName":"Pimicotinib","code":"C173651","definitions":[{"definition":"An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon oral administration, pimicotinib targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimicotinib","termGroup":"PT","termSource":"NCI"},{"termName":"ABSK 021","termGroup":"CN","termSource":"NCI"},{"termName":"ABSK-021","termGroup":"CN","termSource":"NCI"},{"termName":"ABSK021","termGroup":"CN","termSource":"NCI"},{"termName":"CSF-1R Inhibitor ABSK021","termGroup":"SY","termSource":"NCI"},{"termName":"CSF1R Inhibitor ABSK021","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HV1XI8HST2"},{"name":"Maps_To","value":"CSF1R Inhibitor ABSK021"},{"name":"NCI_Drug_Dictionary_ID","value":"802252"},{"name":"NCI_META_CUI","value":"CL1407395"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802252"},{"name":"PDQ_Open_Trial_Search_ID","value":"802252"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167271":{"preferredName":"CXCR4/E-selectin Antagonist GMI-1359","code":"C167271","definitions":[{"definition":"An antagonist of both the C-X-C chemokine receptor type 4 (CXCR4) and E-selectin (CD62E), with potential antineoplastic activity. Upon administration, CXCR4/E-selectin antagonist GMI-1359 binds to both CXCR4 and E-selectin expressed on endothelial cells. The binding to CXCR4 prevents the binding of stromal-cell derived factor-1 (SDF-1; CXCL12) to CXCR4 and inhibits CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. The binding to E-selectin expressed on endothelial cells prevents their interaction with E-selectin ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis. Its overexpression has been associated with tumor angiogenesis and metastasis in several cancers. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4/E-selectin Antagonist GMI-1359","termGroup":"PT","termSource":"NCI"},{"termName":"GMI 1359","termGroup":"CN","termSource":"NCI"},{"termName":"GMI-1359","termGroup":"CN","termSource":"NCI"},{"termName":"GMI1359","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CXCR4/E-selectin Antagonist GMI-1359"},{"name":"NCI_Drug_Dictionary_ID","value":"802777"},{"name":"NCI_META_CUI","value":"CL972258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802777"},{"name":"PDQ_Open_Trial_Search_ID","value":"802777"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172052":{"preferredName":"CYP11A1 Inhibitor ODM-209","code":"C172052","definitions":[{"definition":"An orally bioavailable inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc)(CYP11A1), with potential antineoplastic activity. Upon oral administration, CYP11A1 inhibitor ODM-209 targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit the proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-limiting step in steroid hormone biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP11A1 Inhibitor ODM-209","termGroup":"PT","termSource":"NCI"},{"termName":"ODM 209","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-209","termGroup":"CN","termSource":"NCI"},{"termName":"ODM209","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CYP11A1 Inhibitor ODM-209"},{"name":"NCI_Drug_Dictionary_ID","value":"801473"},{"name":"NCI_META_CUI","value":"CL1406195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801473"},{"name":"PDQ_Open_Trial_Search_ID","value":"801473"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173660":{"preferredName":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466","code":"C173660","definitions":[{"definition":"A drug-dendrimer conjugate composed of a B-cell lymphoma 2 (Bcl-2)/Bcl-XL inhibitor AZD4320 that is chemically conjugated to a proprietary 5-generation pegylated poly-lysine dendrimer via a hydrolytically labile linker, with potential pro-apoptotic and antineoplastic activities. Upon administration of AZD0466, AZD4320 is released through hydrolytic cleavage of the linker. AZD4320 is a Bcl2-homology domain 3 (BH3) mimetic that specifically binds to and inhibits the activity of the anti-apoptotic proteins Bcl-2 and Bcl-XL. This restores apoptotic processes and inhibits cell proliferation in Bcl-2/Bcl-XL-dependent tumor cells. Bcl-2 and Bcl-XL, proteins belonging to the Bcl-2 family that are overexpressed in many cancers, play an important role in the negative regulation of apoptosis. Their expression in tumors is associated with increased drug resistance and cancer cell survival. The conjugation of AZD 4320 to the dendrimer construct may allow extended release of the agent, which may improve efficacy and lower toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 0466","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-0466","termGroup":"CN","termSource":"NCI"},{"termName":"AZD0466","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4320-dendrimer Conjugate AZD0466","termGroup":"SY","termSource":"NCI"},{"termName":"Bcl-2/Bcl-XL Inhibitor-dendrimer Conjugate AZD0466","termGroup":"SY","termSource":"NCI"},{"termName":"Bcl-2/Bcl-XL Inhibitor-DEP Dendrimer Conjugate AZD0466","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466"},{"name":"NCI_Drug_Dictionary_ID","value":"802253"},{"name":"NCI_META_CUI","value":"CL1407404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802253"},{"name":"PDQ_Open_Trial_Search_ID","value":"802253"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173443":{"preferredName":"Dengue Virus Adjuvant PV-001-DV","code":"C173443","definitions":[{"definition":"An attenuated strain of dengue virus that was originally developed as a potential preventative vaccine for dengue fever by the US Army as Dengue Virus-1 #45AZ5, with potential immunostimulating activity. Upon administration of dengue virus adjuvant PV-001-DV, the virus may activate both the innate and adaptive immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dengue Virus Adjuvant PV-001-DV","termGroup":"PT","termSource":"NCI"},{"termName":"Dengue Virus-1 PV-001-DV","termGroup":"SY","termSource":"NCI"},{"termName":"PV 001-DV","termGroup":"CN","termSource":"NCI"},{"termName":"PV-001-Dengue Virus","termGroup":"SY","termSource":"NCI"},{"termName":"PV-001-DV","termGroup":"CN","termSource":"NCI"},{"termName":"PV001-DV","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dengue Virus Adjuvant PV-001-DV"},{"name":"NCI_Drug_Dictionary_ID","value":"801795"},{"name":"NCI_META_CUI","value":"CL1407426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801795"},{"name":"PDQ_Open_Trial_Search_ID","value":"801795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168692":{"preferredName":"DNA-PK inhibitor AZD7648","code":"C168692","definitions":[{"definition":"An orally bioavailable ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK), with potential chemo/radiosensitizing and antineoplastic activites. Upon oral administration, DNA-PK inhibitor AZD7648 selectively targets, binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity leading to enhanced tumor cell death. AZD7648 may also increase the effect of poly(ADP-ribose) polymerase (PARP) inhibitors and may work as a monotherapy in tumors with high endogenous levels of DNA damage resulting from defects in other DNA repair pathways. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. DNA-PK plays a key role in the NHEJ pathway and DSB repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-PK inhibitor AZD7648","termGroup":"PT","termSource":"NCI"},{"termName":"7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 7648","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-7648","termGroup":"CN","termSource":"NCI"},{"termName":"AZD7648","termGroup":"CN","termSource":"NCI"},{"termName":"DNA-dependent Protein Kinase Inhibitor AZD7648","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230820-11-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"97A09L5JCK"},{"name":"Maps_To","value":"DNA-PK inhibitor AZD7648"},{"name":"NCI_Drug_Dictionary_ID","value":"800695"},{"name":"NCI_META_CUI","value":"CL1378628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800695"},{"name":"PDQ_Open_Trial_Search_ID","value":"800695"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172111":{"preferredName":"DNA-PK/PI3K-delta Inhibitor BR101801","code":"C172111","definitions":[{"definition":"An orally bioavailable inhibitor of phosphoinositide 3-kinase delta (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta) and DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and immunomodulating activities. Upon oral administration, the DNA-PK/PI3K-delta inhibitor BR101801 inhibits the activity of both PI3K-delta and DNA-PK. This prevents PI3K-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K-overexpressing tumor cells. Specifically, since PI3K regulates c-myc expression, inhibition of PI3K signaling may lead to a decrease in proliferation of c-myc-expressing tumor cells. Also, by inhibiting the activity of DNA-PK, this agent interferes with the non-homologous end joining (NHEJ) process and prevents the repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity by inhibiting the ability of tumor cells to repair damaged DNA. The PI3K pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. In addition, BR101801 is able to decrease Tregs and increase CD8 lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-PK/PI3K-delta Inhibitor BR101801","termGroup":"PT","termSource":"NCI"},{"termName":"BR 101801","termGroup":"CN","termSource":"NCI"},{"termName":"BR-101801","termGroup":"CN","termSource":"NCI"},{"termName":"BR101801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA-PK/PI3K-delta Inhibitor BR101801"},{"name":"NCI_Drug_Dictionary_ID","value":"801432"},{"name":"NCI_META_CUI","value":"CL1406238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801432"},{"name":"PDQ_Open_Trial_Search_ID","value":"801432"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174424":{"preferredName":"DNMT1 Inhibitor NTX-301","code":"C174424","definitions":[{"definition":"An orally bioavailable inhibitor of human DNA methyltransferase 1 (DNMT1), with potential antineoplastic activity. Upon oral administration, DNMT1 inhibitor NTX-301 targets ad binds to DNMT1, thereby inhibiting the activity of DNMT1. This may prevent DNA methylation, induce DNA hypomethylation, and activate tumor suppressor genes silenced by hypermethylation. This may inhibit tumor cell proliferation. DNMT1, a member of the DNA methyltransferase (DNMT) family, plays an important role in maintaining the DNA methylation pattern. Dysregulation of DNMT1 has been associated with a number of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNMT1 Inhibitor NTX-301","termGroup":"PT","termSource":"NCI"},{"termName":"NTX 301","termGroup":"CN","termSource":"NCI"},{"termName":"NTX-301","termGroup":"CN","termSource":"NCI"},{"termName":"NTX301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNMT1 Inhibitor NTX-301"},{"name":"NCI_Drug_Dictionary_ID","value":"802300"},{"name":"NCI_META_CUI","value":"CL1411982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802300"},{"name":"PDQ_Open_Trial_Search_ID","value":"802300"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167221":{"preferredName":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370","code":"C167221","definitions":[{"definition":"A formulation consisting of SQL70, a prodrug-activating biomaterial, and SQP33, a prodrug of the anthracycline antineoplastic antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of SQ3370, which consists of the injection of SQL70 at the tumor site followed by the intravenous administration of SQ3370, the prodrug SQP33 binds to, through an as of yet not identifiable mechanism, to SQL70 at the tumor site. After binding, doxorubicin is released over a period of days, intercalates into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication and repair, and prevents RNA and protein synthesis. Compared to the systemic administration of doxorubicin alone, SQ3370 may allow for higher and sustained delivery of active doxorubicin directly to the tumor, which may increase its efficacy and limit its off-site, systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370","termGroup":"PT","termSource":"NCI"},{"termName":"Doxorubicin Prodrug SQP33/Prodrug-activating Biomaterial SQL7","termGroup":"SY","termSource":"NCI"},{"termName":"SQ 3370","termGroup":"CN","termSource":"NCI"},{"termName":"SQ-3370","termGroup":"CN","termSource":"NCI"},{"termName":"SQ3370","termGroup":"CN","termSource":"NCI"},{"termName":"SQL70-SQP33","termGroup":"SY","termSource":"NCI"},{"termName":"SQL70/SQP33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370"},{"name":"NCI_Drug_Dictionary_ID","value":"800071"},{"name":"NCI_META_CUI","value":"CL972446"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800071"},{"name":"PDQ_Open_Trial_Search_ID","value":"800071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173999":{"preferredName":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555","code":"C173999","definitions":[{"definition":"An orally bioavailable combination of DTRMWXHS-12, a Bruton's tyrosine kinase (BTK) inhibitor, everolimus, a mammalian Target of Rapamycin (mTOR) inhibitor, and pomalidomide, an immunomodulatory drug (IMiD), that may be used for the treatment of B-cell malignancies. Upon oral administration of DTRM-555, the DTRMWXHS-12 component inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, and leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes. The everolimus component binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of mTOR, a key regulatory kinase. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway. The pomalidomide component may inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoiesis. The combination of a BTK inhibitor, an mTOR inhibitor and an IMiD may work synergistically to kill malignant B-cells and prevent drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555","termGroup":"PT","termSource":"NCI"},{"termName":"DTRM 555","termGroup":"CN","termSource":"NCI"},{"termName":"DTRM-555","termGroup":"CN","termSource":"NCI"},{"termName":"DTRM555","termGroup":"CN","termSource":"NCI"},{"termName":"DTRMWXHS-12-Everolimus-Pomalidomide","termGroup":"SY","termSource":"NCI"},{"termName":"DTRMWXHS-12/Everolimus/Pomalidomide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555"},{"name":"NCI_Drug_Dictionary_ID","value":"802451"},{"name":"NCI_META_CUI","value":"CL1407876"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802451"},{"name":"PDQ_Open_Trial_Search_ID","value":"802451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175445":{"preferredName":"EGFR Inhibitor TY-9591","code":"C175445","definitions":[{"definition":"An orally available inhibitor of epidermal growth factor receptor (EGFR), including activating mutations, with potential antineoplastic activity. Upon administration, the EGFR inhibitor TY-9591 binds to and inhibits EGFR activating mutations, including the resistance mutation T790M, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Inhibitor TY-9591","termGroup":"PT","termSource":"NCI"},{"termName":"EGFR Tyrosine Kinase Inhibitor TY-9591","termGroup":"SY","termSource":"NCI"},{"termName":"TY 9591","termGroup":"CN","termSource":"NCI"},{"termName":"TY-9591","termGroup":"CN","termSource":"NCI"},{"termName":"TY9591","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Inhibitor TY-9591"},{"name":"NCI_Drug_Dictionary_ID","value":"802783"},{"name":"NCI_META_CUI","value":"CL1412813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802783"},{"name":"PDQ_Open_Trial_Search_ID","value":"802783"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173415":{"preferredName":"EGFR Mutant-selective Inhibitor TQB3804","code":"C173415","definitions":[{"definition":"A fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor TQB3804 binds to and inhibits the activity of mutant forms of EGFR, including the C797S EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. TQB3804 inhibits mutated forms of EGFR including C797S, which prevents covalent bond formation with third-generation EGFR inhibitor osimertinib leading to drug resistance. TQB3804 may have enhanced anti-tumor effects in tumors with C797S-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Mutant-selective Inhibitor TQB3804","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermal Growth Factor Receptor Inhibitor TQB3804","termGroup":"SY","termSource":"NCI"},{"termName":"TQB 3804","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3804","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3804","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Mutant-selective  Inhibitor TQB3804"},{"name":"NCI_Drug_Dictionary_ID","value":"801857"},{"name":"NCI_META_CUI","value":"CL1407432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801857"},{"name":"PDQ_Open_Trial_Search_ID","value":"801857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165778":{"preferredName":"EGFR/EGFRvIII Inhibitor WSD0922-FU","code":"C165778","definitions":[{"definition":"A blood-brain-barrier (BBB) penetrable selective inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including but not limited to the EGFR variant III (EGFRvIII) mutant form, with potential antineoplastic activity. Upon administration of EGFR/EGFRvIII inhibitor WSD0922-FU, this agent is able to penetrate the BBB and specifically targets, binds to and inhibits EGFR and specific EGFR mutations, which prevents EGFR/EGFR mutant-mediated signaling and leads to cell death in EGFR/EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors that are not able to penetrate the BBB, WSD0922-FU may have therapeutic benefits in brain tumors, such as glioblastoma (GBM) and metastatic CNS tumors. EGFR, a receptor tyrosine kinase (RTK) that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/EGFRvIII Inhibitor WSD0922-FU","termGroup":"PT","termSource":"NCI"},{"termName":"BBB Penetrable EGFR/EGFRvIII Inhibitor WSD0922-FU","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR Mutant Inhibitor WSD0922-FU","termGroup":"SY","termSource":"NCI"},{"termName":"WSD 0922-FU","termGroup":"CN","termSource":"NCI"},{"termName":"WSD-0922-FU","termGroup":"CN","termSource":"NCI"},{"termName":"WSD0922-FU","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR/EGFRvIII Inhibitor WSD0922-FU"},{"name":"NCI_Drug_Dictionary_ID","value":"800200"},{"name":"NCI_META_CUI","value":"CL979063"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800200"},{"name":"PDQ_Open_Trial_Search_ID","value":"800200"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167205":{"preferredName":"Sunvozertinib","code":"C167205","definitions":[{"definition":"An orally available, irreversible, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that shows similar activity against certain activating mutations, including exon 20 insertions (exon20ins), with potential antineoplastic activity. Upon oral administration,sunvozertinib binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. In contrast to other agents active against exon20ins mutations, sunvozertinib appears to be more selective against mutated EGFR than wild-type (wt) EGFR. This may lessen wtEGFR-related dose-limiting toxicity and may allow for the administration of the desired therapeutic dose of sunvozertinib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sunvozertinib","termGroup":"PT","termSource":"NCI"},{"termName":"DZD 9008","termGroup":"CN","termSource":"NCI"},{"termName":"DZD-9008","termGroup":"CN","termSource":"NCI"},{"termName":"DZD9008","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/HER2 Inhibitor DZD9008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2370013-12-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L1Q2K5JYO8"},{"name":"Maps_To","value":"EGFR/HER2 Inhibitor DZD9008"},{"name":"NCI_Drug_Dictionary_ID","value":"800418"},{"name":"NCI_META_CUI","value":"CL972432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800418"},{"name":"PDQ_Open_Trial_Search_ID","value":"800418"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173165":{"preferredName":"Ficerafusp Alfa","code":"C173165","definitions":[{"definition":"A bifunctional monoclonal antibody targeting both the receptor tyrosine kinase epidermal growth factor receptor (EGFR) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration of ficerafusp alfa, the anti-EGFR moiety targets, binds to and prevents activation of EGFR-mediated signaling. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. The anti-TGFb moiety targets and binds to TGFb, thereby preventing the activation of TGFb-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGFb is overactivated. EGFR and TGFb, mutated and/or overexpressed on the surfaces of various tumor cell types, play key roles in tumor cell proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ficerafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR/TGFb Bispecific Monoclonal Antibody BCA101","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/TGFb Monoclonal Antibody BCA101","termGroup":"SY","termSource":"NCI"},{"termName":"BCA 101","termGroup":"CN","termSource":"NCI"},{"termName":"BCA-101","termGroup":"CN","termSource":"NCI"},{"termName":"BCA101","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/TGFb Fusion Monoclonal Antibody BCA101","termGroup":"SY","termSource":"NCI"},{"termName":"FMAB2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2764727-44-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LZ88YF62H2"},{"name":"Maps_To","value":"EGFR/TGFb Fusion Monoclonal Antibody BCA101"},{"name":"NCI_Drug_Dictionary_ID","value":"802059"},{"name":"NCI_META_CUI","value":"CL1407043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802059"},{"name":"PDQ_Open_Trial_Search_ID","value":"802059"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173436":{"preferredName":"EGFR/VEGFR/RET Inhibitor HA121-28","code":"C173436","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR), the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET) and vascular endothelial growth factor receptor (VEGFR), with potential anti-angiogenic and antineoplastic activities. Upon oral administration of HA121-28, this agent targets, binds to and inhibits the activity of EGFR, RET and VEGFR. This prevents EGFR-, RET- and VEGFR-mediated signaling, and may lead to the induction of apoptosis and inhibition of tumor growth in EGFR-, RET- and VEGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Dysregulation of RET activity plays a key role in the development and progression of a variety of cancers. Expression of VEGFR is upregulated in a variety of tumor cell types; it plays a key role in the migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/VEGFR/RET Inhibitor HA121-28","termGroup":"PT","termSource":"NCI"},{"termName":"HA 121-28","termGroup":"CN","termSource":"NCI"},{"termName":"HA-121 28","termGroup":"CN","termSource":"NCI"},{"termName":"HA121-28","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR/VEGFR/RET Inhibitor HA121-28"},{"name":"NCI_Drug_Dictionary_ID","value":"801763"},{"name":"NCI_META_CUI","value":"CL1407411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801763"},{"name":"PDQ_Open_Trial_Search_ID","value":"801763"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168790":{"preferredName":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641","code":"C168790","definitions":[{"definition":"An oncolytic adenoviral vector, a transgene-modified variant of enadenotucirev (EnAd), that expresses a bi-specific T-cell activator molecule FAP-TAc together with immune enhancer molecules C-X-C motif chemokine 9 (CXCL9), C-X-C motif chemokine 10 (CXCL10) and interferon alpha (IFNalpha), with potential immunomodulating and antineoplastic activities. Upon administration of NG-641, EnAd specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses FAP-TAc. The locally expressed FAP-TAc targets and binds to both fibroblast activating protein (FAP) on cancer associated fibroblasts (CAFs) and CD3 on T-cells. This leads to T-cell activation and T-cell mediated killing of CAFs in tumor stroma. NG-641 also encodes the transgenes CXCL9, CXCL10 and IFNalpha. The production of CXCL9, CXCL10 and IFNalpha leads to the recruitment and further activation of T-cells, enhancing the overall immune response and cancer cell killing. FAP, a cell surface glycoprotein, is overexpressed on tumor-associated fibroblasts but minimally expressed on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641","termGroup":"PT","termSource":"NCI"},{"termName":"NG 641","termGroup":"CN","termSource":"NCI"},{"termName":"NG-641","termGroup":"CN","termSource":"NCI"},{"termName":"NG641","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector Expressing FAP/CD3 Bispecific Molecule NG-641","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector-expressing FAP/CD3 Bispecific FAP-TAc NG-641","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L93WSG9AAU"},{"name":"Maps_To","value":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641"},{"name":"NCI_Drug_Dictionary_ID","value":"800703"},{"name":"NCI_META_CUI","value":"CL1378696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800703"},{"name":"PDQ_Open_Trial_Search_ID","value":"800703"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173879":{"preferredName":"Encapsulated Rapamycin","code":"C173879","definitions":[{"definition":"An orally bioavailable nanoparticle-based formulation composed of sub-micron particles of the macrolide antibiotic rapamycin incorporated into a pH-sensitive poly(methyl methacrylate) polymer, with potential immunomodulating and antineoplastic activities. Upon oral administration of the encapsulated rapamycin, the nanoparticle specifically delivers rapamycin at the tumor site. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR), a key regulatory kinase. This may suppress mTORC1 activity. In addition, inhibition of mTOR may modulate central memory CD8 T cells, CD3+/CD56+ natural killer (NK) cells and CD8 T-cell responses. This may kill tumor cells. Compared to the administration of rapamycin alone, this formulation improves oral bioavailability of rapamycin with more consistent rapamycin levels, thereby allowing for administration of lower rapamycin dosage, which improves and minimizes rapamycin's toxicity. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encapsulated Rapamycin","termGroup":"PT","termSource":"NCI"},{"termName":"Encapsulated Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"eRapa (TM)","termGroup":"CN","termSource":"NCI"},{"termName":"Microencapsulated Rapamycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encapsulated Rapamycin"},{"name":"NCI_Drug_Dictionary_ID","value":"802399"},{"name":"NCI_META_CUI","value":"CL1407680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802399"},{"name":"PDQ_Open_Trial_Search_ID","value":"802399"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175447":{"preferredName":"Vodudeutentan Sodium","code":"C175447","definitions":[{"definition":"An antagonist of the immune checkpoint endothelin B receptor (ETBR; EDNRB), with potential immunomodulating and antineoplastic activities. Upon administration, the ETBR blocker ENB 003 selectively targets and binds to ETBR expressed on tumor cells. This prevents ETBR-mediated signaling and may abrogate the immunosuppressive tumor microenvironment (TME), may enhance a T-cell mediated anti-tumor immune response and may inhibit proliferation of ETBR-expressing tumor cells. ETBR, a G-protein coupled receptor, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis. It also plays a role in tumor immunosuppression and blocks T-cell trafficking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vodudeutentan Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"ENB 003","termGroup":"CN","termSource":"NCI"},{"termName":"ENB-003","termGroup":"CN","termSource":"NCI"},{"termName":"ENB003","termGroup":"CN","termSource":"NCI"},{"termName":"Endothelin B Receptor Blocker ENB 003","termGroup":"SY","termSource":"NCI"},{"termName":"ETBR Blocker ENB 003","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2364572-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AAY8R26VDX"},{"name":"Maps_To","value":"Endothelin B Receptor Blocker ENB 003"},{"name":"NCI_Drug_Dictionary_ID","value":"802784"},{"name":"NCI_META_CUI","value":"CL1412807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802784"},{"name":"PDQ_Open_Trial_Search_ID","value":"802784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172990":{"preferredName":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240","code":"C172990","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS) red blood cells (RBCs) engineered to express both the co-stimulatory molecule tumor necrosis factor ligand superfamily (TNFSF) member 9 (TNFSF9; 4-1BBL) and a fusion protein composed of the trans-presented cytokine interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) (IL-15TP) with potential modulating and antineoplastic activities. CD34+ hematopoietic precursor cells (HPC) are collected by apheresis from a healthy O negative donor, purified, and engineered with a lentiviral vector to express 4-1BBL and IL-15TP. The cells are then further expanded and differentiated until the nucleus is ejected, resulting in a mature reticulocyte. Upon administration of the engineered red blood cells co-expressing 4-1BBL and IL-15TP RTX-240, the RBCs express both 4-1BBL and IL-15TP on their cell surfaces. 4-1BBL and IL-15TP bind to and subsequently induce the proliferation and activation of natural killer (NK) cells and T-cells. This enhances the secretion of cytokine interferon-gamma (IFN-g) and results in the induction of an anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Red Cells Expressing 4-1BBL and IL-15TP","termGroup":"SY","termSource":"NCI"},{"termName":"Engineered RBCs Co-expressing 4-1BBL and IL-15TP RTX-240","termGroup":"SY","termSource":"NCI"},{"termName":"RTX 240","termGroup":"CN","termSource":"NCI"},{"termName":"RTX-240","termGroup":"CN","termSource":"NCI"},{"termName":"RTX240","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240"},{"name":"NCI_Drug_Dictionary_ID","value":"802047"},{"name":"NCI_META_CUI","value":"CL1406781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802047"},{"name":"PDQ_Open_Trial_Search_ID","value":"802047"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173707":{"preferredName":"Engineered Toxin Body Targeting CD38 TAK-169","code":"C173707","definitions":[{"definition":"An engineered toxin body (ETB) containing a single chain variable fragment (scFv) from an antibody targeting the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) that is fused to a cytotoxic payload composed of the enzymatically active, de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration, the anti-CD38 scFv moiety of TAK-169 specifically targets and binds to CD38-expressing tumor cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and removes an adenine nucleobase from the 28S RNA component of the 60S ribosomal subunit.of ribosomes This prevents ribosome activity,  This inhibits protein synthesis and leads to apoptosis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Toxin Body Targeting CD38 TAK-169","termGroup":"PT","termSource":"NCI"},{"termName":"CD38-targeted ETB TAK-169","termGroup":"SY","termSource":"NCI"},{"termName":"ETB Targeting CD38 TAK-169","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 169","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-169","termGroup":"CN","termSource":"NCI"},{"termName":"TAK169","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Toxin Body Targeting CD38 TAK-169"},{"name":"NCI_Drug_Dictionary_ID","value":"802255"},{"name":"NCI_META_CUI","value":"CL1407530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802255"},{"name":"PDQ_Open_Trial_Search_ID","value":"802255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174460":{"preferredName":"EP2/EP4 Antagonist TPST-1495","code":"C174460","definitions":[{"definition":"An orally bioavailable, dual antagonist of the human prostaglandin E2 receptor subtypes 2 (EP2) and 4 (EP4), with potential immunomodulating and antineoplastic activities. Upon oral administration, the EP2/EP4 antagonist TPST-1495 selectively targets and binds to EP2 and EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP2 and EP4. This prevents the activation of EP2 and EP4, and inhibits PGE2-EP2/EP4-mediated signaling. This inhibits PGE2-driven immune suppression by preventing the PGE2-mediated inhibition of anti-tumor immune effector cells in the tumor microenvironment (TME), such as natural killer (NK) cells, T-lymphocytes, dendritic cells (DCs) and M1 macrophages, and blocking the PGE2-mediated increase in suppressive immune cells, such as myeloid derived suppressor cells (MDSCs), M2 macrophages, and regulatory T cells (Tregs). This inhibits the proliferation of tumor cells in which the PGE2-EP2/4 signaling pathway is over-activated. EP2 and EP4, G protein-coupled receptors (GPCRs) that are overexpressed in certain types of cancers, promote tumor cell proliferation, invasion, survival, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP2/EP4 Antagonist TPST-1495","termGroup":"PT","termSource":"NCI"},{"termName":"Dual EP2/4 Antagonist TPST-1495","termGroup":"SY","termSource":"NCI"},{"termName":"PGE2 EP2/EP4 Receptor Antagonist TPST-1495","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 Receptor EP2/EP4 Antagonist TPST-1495","termGroup":"SY","termSource":"NCI"},{"termName":"TPST 1495","termGroup":"CN","termSource":"NCI"},{"termName":"TPST-1495","termGroup":"CN","termSource":"NCI"},{"termName":"TPST1495","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EP2/EP4 Antagonist TPST-1495"},{"name":"NCI_Drug_Dictionary_ID","value":"803116"},{"name":"NCI_META_CUI","value":"CL1412010"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803116"},{"name":"PDQ_Open_Trial_Search_ID","value":"803116"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173520":{"preferredName":"EP4 Antagonist INV-1120","code":"C173520","definitions":[{"definition":"A small molecule and antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist INV-1120 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP4 Antagonist INV-1120","termGroup":"PT","termSource":"NCI"},{"termName":"EP4 Receptor Antagonist INV-1120","termGroup":"SY","termSource":"NCI"},{"termName":"INV 1120","termGroup":"CN","termSource":"NCI"},{"termName":"INV-1120","termGroup":"CN","termSource":"NCI"},{"termName":"INV1120","termGroup":"CN","termSource":"NCI"},{"termName":"PGE2 Receptor Antagonist INV-1120","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 Receptor Antagonist INV-1120","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EP4 Antagonist INV-1120"},{"name":"NCI_Drug_Dictionary_ID","value":"802232"},{"name":"NCI_META_CUI","value":"CL1407506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802232"},{"name":"PDQ_Open_Trial_Search_ID","value":"802232"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171425":{"preferredName":"EphA2-targeting Bicycle Toxin Conjugate BT5528","code":"C171425","definitions":[{"definition":"A bicyclic peptide targeting Ephrin receptor A2 (EphA2) and conjugated, through an inert sarcosine spacer chain and a valine-citrulline cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon administration of the EphA2-targeting bicycle toxin conjugate BT5528, this agent targets and binds to EphA2-expressing tumor cells. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAE binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types. EphA2 expression is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EphA2-targeting Bicycle Toxin Conjugate BT5528","termGroup":"PT","termSource":"NCI"},{"termName":"Bicycle BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"Bicycle Toxin Conjugate-targeting EphA2 BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"Bicyclic Peptide Conjugate BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"BT 5528","termGroup":"CN","termSource":"NCI"},{"termName":"BT-5528","termGroup":"CN","termSource":"NCI"},{"termName":"BT5528","termGroup":"CN","termSource":"NCI"},{"termName":"BTC BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"EphA2-targeting BTC BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"EphA2-targeting-MMAE Bicycle Toxin BT5528","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EphA2-targeting Bicycle Toxin Conjugate BT5528"},{"name":"NCI_Drug_Dictionary_ID","value":"801972"},{"name":"NCI_META_CUI","value":"CL1405523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801972"},{"name":"PDQ_Open_Trial_Search_ID","value":"801972"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172805":{"preferredName":"ERK1/2 Inhibitor HH2710","code":"C172805","definitions":[{"definition":"An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERK1/2 inhibitor HH2710 specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor HH2710","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor HH2710","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor HH2710","termGroup":"SY","termSource":"NCI"},{"termName":"HH 2710","termGroup":"CN","termSource":"NCI"},{"termName":"HH-2710","termGroup":"CN","termSource":"NCI"},{"termName":"HH2710","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor HH2710"},{"name":"NCI_Drug_Dictionary_ID","value":"802029"},{"name":"NCI_META_CUI","value":"CL1406865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802029"},{"name":"PDQ_Open_Trial_Search_ID","value":"802029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174203":{"preferredName":"ERK1/2 Inhibitor JSI-1187","code":"C174203","definitions":[{"definition":"An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERK1/2 inhibitor JSI-1187 specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor JSI-1187","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor JSI-1187","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor JSI-1187","termGroup":"SY","termSource":"NCI"},{"termName":"JSI 1187","termGroup":"CN","termSource":"NCI"},{"termName":"JSI-1187","termGroup":"CN","termSource":"NCI"},{"termName":"JSI1187","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor JSI-1187"},{"name":"NCI_Drug_Dictionary_ID","value":"801859"},{"name":"NCI_META_CUI","value":"CL1407830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801859"},{"name":"PDQ_Open_Trial_Search_ID","value":"801859"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173523":{"preferredName":"Extended Release Metformin Hydrochloride","code":"C173523","definitions":[{"definition":"An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin, with antihyperglycemic and potential prostate-cancer protective and antineoplastic activities. Upon oral administration, metformin targets and inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. This lowers blood glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. It also reduces cyclin D1. This inhibits cancer cell proliferation. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Also, metformin reduces hyperinsulinemia which may contribute to an anti-tumor effect. Metformin may increase the prostate-specific antigen (PSA) doubling time and may lower serum PSA levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extended Release Metformin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"ER Metformin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-release Metformin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Glucophage XR","termGroup":"BR","termSource":"NCI"},{"termName":"Glumetza","termGroup":"BR","termSource":"NCI"},{"termName":"Metformin Hydrochloride Extended Release","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extended Release Metformin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"802233"},{"name":"NCI_META_CUI","value":"CL1407513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802233"},{"name":"PDQ_Open_Trial_Search_ID","value":"802233"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173698":{"preferredName":"EZH1/2 Inhibitor HH2853","code":"C173698","definitions":[{"definition":"An orally bioavailable inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH1/2 inhibitor HH2853 inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH1/2 Inhibitor HH2853","termGroup":"PT","termSource":"NCI"},{"termName":"EZH1 and EZH2 Inhibitor HH2853","termGroup":"SY","termSource":"NCI"},{"termName":"HH 2853","termGroup":"CN","termSource":"NCI"},{"termName":"HH-2853","termGroup":"CN","termSource":"NCI"},{"termName":"HH2853","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EZH1/2 Inhibitor HH2853"},{"name":"NCI_Drug_Dictionary_ID","value":"802064"},{"name":"NCI_META_CUI","value":"CL1407522"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802064"},{"name":"PDQ_Open_Trial_Search_ID","value":"802064"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167347":{"preferredName":"Tulmimetostat","code":"C167347","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, tulmimetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tulmimetostat","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Benzodioxole-5-carboxamide, 7-chloro-N-((1,2-dihydro-6-methyl-4-(methylthio)-2-oxo-3-pyridinyl)methyl)-2-(trans-4-(3-methoxy-1-azetidinyl)cyclohexyl)-2,4-dimethyl-, (2R)-","termGroup":"SN","termSource":"NCI"},{"termName":"CPI 0209","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-0209","termGroup":"CN","termSource":"NCI"},{"termName":"CPI0209","termGroup":"CN","termSource":"NCI"},{"termName":"EZH2 Inhibitor CPI-0209","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2567686-02-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OUQ4N85Z0B"},{"name":"Maps_To","value":"EZH2 inhibitor CPI-0209"},{"name":"NCI_Drug_Dictionary_ID","value":"800217"},{"name":"NCI_META_CUI","value":"CL972321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800217"},{"name":"PDQ_Open_Trial_Search_ID","value":"800217"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172193":{"preferredName":"FAK/ALK/ROS1 Inhibitor APG-2449","code":"C172193","definitions":[{"definition":"An orally available kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and the receptor tyrosine kinase C-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon administration, ALK/FAK/ROS1 inhibitor APG-2449 selectively binds to and inhibits ALK, FAK and ROS1 kinases. The inhibition leads to disruption of ALK-, FAK- and ROS1-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and ROS1-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK/ALK/ROS1 Inhibitor APG-2449","termGroup":"PT","termSource":"NCI"},{"termName":"APG 2449","termGroup":"CN","termSource":"NCI"},{"termName":"APG-2449","termGroup":"CN","termSource":"NCI"},{"termName":"APG2449","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8L976E3N4N"},{"name":"Maps_To","value":"FAK/ALK/ROS1 Inhibitor APG-2449"},{"name":"NCI_Drug_Dictionary_ID","value":"801583"},{"name":"NCI_META_CUI","value":"CL1406284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801583"},{"name":"PDQ_Open_Trial_Search_ID","value":"801583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170894":{"preferredName":"FAP/4-1BB-targeting DARPin MP0310","code":"C170894","definitions":[{"definition":"A designed ankyrin repeat proteins (DARPin)-based agent targeting the tumor-associated protein fibroblast  activation protein (FAP) and the T-cell co-stimulatory immune receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunomodulating and antineoplastic activities. Upon administration, the FAP/4-1BB-targeting DARPin MP0310 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer associated fibroblasts in the majority of solid tumors. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAP/4-1BB-targeting DARPin MP0310","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 506","termGroup":"CN","termSource":"NCI"},{"termName":"FAP x 4-1BB-targeting DARPin MP0310","termGroup":"SY","termSource":"NCI"},{"termName":"FAP/4-1BB-targeting Designed Ankyrin Repeat Protein MP0310","termGroup":"SY","termSource":"NCI"},{"termName":"MP 0310","termGroup":"CN","termSource":"NCI"},{"termName":"MP-0310","termGroup":"CN","termSource":"NCI"},{"termName":"MP0310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FAP/4-1BB-targeting DARPin MP0310"},{"name":"NCI_Drug_Dictionary_ID","value":"800803"},{"name":"NCI_META_CUI","value":"CL1383054"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800803"},{"name":"PDQ_Open_Trial_Search_ID","value":"800803"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175490":{"preferredName":"FAP/4-1BB-targeting Fusion Protein RO7122290","code":"C175490","definitions":[{"definition":"A bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. Upon administration, the FAP/4-1BB-targeting fusion protein RO7122290 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer-associated fibroblasts in the majority of solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAP/4-1BB-targeting Fusion Protein RO7122290","termGroup":"PT","termSource":"NCI"},{"termName":"RO 7122290","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7122290","termGroup":"CN","termSource":"NCI"},{"termName":"RO7122290","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FAP/4-1BB-targeting Fusion Protein RO7122290"},{"name":"NCI_Drug_Dictionary_ID","value":"803283"},{"name":"NCI_META_CUI","value":"CL1412832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803283"},{"name":"PDQ_Open_Trial_Search_ID","value":"803283"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167326":{"preferredName":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells","code":"C167326","definitions":[{"definition":"A donor graft derived from allogeneic filgrastim (granulocyte-colony stimulating factor; G-CSF)-mobilized peripheral blood cells (MPBC) that have been incubated with the recombinant human Fas ligand (FasL) APO010 ex vivo, and that can potentially be used for immune reconstitution purposes. The incubation of the hematopoietic stem cell graft with the apoptotic mediator Fas ligand (FasL) selectively induces apoptosis of mature T-cells which express high levels of Fas receptor, such as T stem cell memory (TSCM), T central memory (TCM), and T effector memory (TEM) cells and the pro-inflammatory T-helper cells (Th) Th1 and Th17 subsets while sparing CD34-positive stem and progenitor cells. Upon washing and further ex vivo preparations, and upon allogeneic hematopoietic stem cell transplantation (HSCT) with the FasL-treated allogeneic MPBCs, these cells provide hematopoietic cell recovery, preserve the graft-versus-leukemia (GvL) effects, and may prevent graft-versus-host disease (GvHD).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Apograft Stem Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Apograft-incubated Mobilized Peripheral Blood Stem Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Apograft-treated Allogeneic MPBCs","termGroup":"SY","termSource":"NCI"},{"termName":"Apograft-treated MPBCs","termGroup":"SY","termSource":"NCI"},{"termName":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"FasL-treated Mobilized Peripheral Blood Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells"},{"name":"NCI_META_CUI","value":"CL972303"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170762":{"preferredName":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11","code":"C170762","definitions":[{"definition":"A Fc-engineered agonistic antibody targeting the human B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, 2141-V11 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11","termGroup":"PT","termSource":"NCI"},{"termName":"2141 V-11","termGroup":"CN","termSource":"NCI"},{"termName":"2141 V11","termGroup":"CN","termSource":"NCI"},{"termName":"2141-V11","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD40 Agonist Antibody 2141-V11","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Agonistic Antibody 2141-V11","termGroup":"SY","termSource":"NCI"},{"termName":"Fc-engineered Anti-CD40 Agonistic Antibody 2141-V11","termGroup":"SY","termSource":"NCI"},{"termName":"Fc-enhanced Anti-CD40 Antibody 2141-V11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11"},{"name":"NCI_Drug_Dictionary_ID","value":"800787"},{"name":"NCI_META_CUI","value":"CL1383172"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800787"},{"name":"PDQ_Open_Trial_Search_ID","value":"800787"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175469":{"preferredName":"Fenretinide Phospholipid Suspension ST-001","code":"C175469","definitions":[{"definition":"An intravenous formulation composed of a phospholipid suspension of nanoparticles containing the synthetic retinoid derivative fenretinide, with potential antineoplastic activity. Upon intravenous administration, fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in susceptible tumor cell types. Fenretinide also binds to and inhibits the activity of mammalian target of rapamycin (mTOR), which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Independent of RAR activation and mTOR inhibition, this agent may also modulate gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenretinide Phospholipid Suspension ST-001","termGroup":"PT","termSource":"NCI"},{"termName":"nanoFenretinide ST-001","termGroup":"SY","termSource":"NCI"},{"termName":"ST 001","termGroup":"CN","termSource":"NCI"},{"termName":"ST-001","termGroup":"CN","termSource":"NCI"},{"termName":"ST001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fenretinide Phospholipid Suspension ST-001"},{"name":"NCI_Drug_Dictionary_ID","value":"802915"},{"name":"NCI_META_CUI","value":"CL1412852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802915"},{"name":"PDQ_Open_Trial_Search_ID","value":"802915"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173964":{"preferredName":"FGFR Inhibitor CPL304110","code":"C173964","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor CPL304110 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR Inhibitor CPL304110","termGroup":"PT","termSource":"NCI"},{"termName":"CPL 304110","termGroup":"CN","termSource":"NCI"},{"termName":"CPL-304110","termGroup":"CN","termSource":"NCI"},{"termName":"CPL304110","termGroup":"CN","termSource":"NCI"},{"termName":"PG19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR Inhibitor CPL304110"},{"name":"NCI_Drug_Dictionary_ID","value":"802158"},{"name":"NCI_META_CUI","value":"CL1407848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802158"},{"name":"PDQ_Open_Trial_Search_ID","value":"802158"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175460":{"preferredName":"FGFR/CSF-1R Inhibitor 3D185","code":"C175460","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon administration, FGFR/CSF-1R inhibitor 3D185 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-mediated signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. 3D185 also targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR/CSF-1R Inhibitor 3D185","termGroup":"PT","termSource":"NCI"},{"termName":"3D 185","termGroup":"CN","termSource":"NCI"},{"termName":"3D-185","termGroup":"CN","termSource":"NCI"},{"termName":"3D185","termGroup":"CN","termSource":"NCI"},{"termName":"HH185","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR/CSF-1R Inhibitor 3D185"},{"name":"NCI_Drug_Dictionary_ID","value":"802839"},{"name":"NCI_META_CUI","value":"CL1412860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802839"},{"name":"PDQ_Open_Trial_Search_ID","value":"802839"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174208":{"preferredName":"Lirafugratinib","code":"C174208","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirafugratinib","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR2 Inhibitor RLY-4008","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 2 Inhibitor RLY-4008","termGroup":"SY","termSource":"NCI"},{"termName":"RLY 4008","termGroup":"CN","termSource":"NCI"},{"termName":"RLY-4008","termGroup":"CN","termSource":"NCI"},{"termName":"RLY4008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2549174-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7HY6IMH87S"},{"name":"Maps_To","value":"FGFR2 Inhibitor RLY-4008"},{"name":"NCI_Drug_Dictionary_ID","value":"803114"},{"name":"NCI_META_CUI","value":"CL1411775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803114"},{"name":"PDQ_Open_Trial_Search_ID","value":"803114"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174049":{"preferredName":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01","code":"C174049","definitions":[{"definition":"An oncolytic vaccinia virus (VV; VACV) genetically engineered to express an Fms-like tyrosine kinase 3 (Flt3) ligand, an antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the human pro-inflammatory cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon administration of the Flt3 ligand/anti-CTLA-4 antibody/IL-12 engineered oncolytic VV RIVAL-01, the virus preferentially targets, infects and replicates in tumor cells, causing oncolysis. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. In addition, the Flt3 ligand, the anti-ctla-4 antibody and IL-12 are expressed by the VV in the cancer cells and may activate the immune system within the tumor microenvironment (TME), thereby stimulating both innate and adaptive immune responses. The anti-CTLA-4 antibody targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation, which promotes T-cell activation. Flt3 ligand binds to the Flt3 tyrosine kinase receptor and promotes Flt3 signaling which plays an important role in expanding the population of antigen-presenting dendritic cells (DCs). IL-12 activates natural killer cells (NKs), induces the secretion of interferon-gamma and promotes CD8 cytotoxic T-cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01","termGroup":"PT","termSource":"NCI"},{"termName":"Engineered Oncolytic Vaccinia Virus TBio-6517","termGroup":"SY","termSource":"NCI"},{"termName":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic VV RIVAL-01","termGroup":"SY","termSource":"NCI"},{"termName":"RIVAL 01","termGroup":"CN","termSource":"NCI"},{"termName":"RIVAL-01","termGroup":"CN","termSource":"NCI"},{"termName":"RIVAL01","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-605","termGroup":"CN","termSource":"NCI"},{"termName":"TBio 6517","termGroup":"CN","termSource":"NCI"},{"termName":"TBio-6517","termGroup":"CN","termSource":"NCI"},{"termName":"TBio6517","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01"},{"name":"NCI_Drug_Dictionary_ID","value":"802460"},{"name":"NCI_META_CUI","value":"CL1407953"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802460"},{"name":"PDQ_Open_Trial_Search_ID","value":"802460"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C174517":{"preferredName":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279","code":"C174517","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration of FLT3/FGFR dual kinase inhibitor MAX-40279, this agent binds to and inhibits both FGFR and FLT3, including FLT3 mutant forms, which results in the inhibition of FGFR/FLT3-mediated signal transduction pathways. This inhibits proliferation in FGFR/FLT3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases, is upregulated in many tumor cell types. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. They both play key roles in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3/FGFR Kinase Inhibitor MAX-40279","termGroup":"SY","termSource":"NCI"},{"termName":"Max 4","termGroup":"CN","termSource":"NCI"},{"termName":"MAX 40279","termGroup":"CN","termSource":"NCI"},{"termName":"MAX-40279","termGroup":"CN","termSource":"NCI"},{"termName":"MAX-40279-01","termGroup":"CN","termSource":"NCI"},{"termName":"MAX40279","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2070931-57-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DL772G3NN7"},{"name":"Maps_To","value":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279"},{"name":"NCI_Drug_Dictionary_ID","value":"802333"},{"name":"NCI_META_CUI","value":"CL1412016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802333"},{"name":"PDQ_Open_Trial_Search_ID","value":"802333"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172195":{"preferredName":"FLT3/KIT/CSF1R Inhibitor NMS-03592088","code":"C172195","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), the mast/stem cell factor receptor c-Kit (SCFR; KIT) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic and immunomodulating activities Upon administration, FLT3/KIT/CSF1R inhibitor NMS-03592088 binds to and inhibits the activity of FLT3, KIT and CSF1R. This prevents FLT3, KIT and CSF1R-mediated signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3, KIT and CSF1R. In addition, NMS-03592088 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), NMS-03592088 inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemia (AML), and plays a key role in tumor cell proliferation. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/KIT/CSF1R Inhibitor NMS-03592088","termGroup":"PT","termSource":"NCI"},{"termName":"NMS 03592088","termGroup":"CN","termSource":"NCI"},{"termName":"NMS P088","termGroup":"CN","termSource":"NCI"},{"termName":"NMS-03592088","termGroup":"CN","termSource":"NCI"},{"termName":"NMS03592088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3/KIT/CSF1R Inhibitor NMS-03592088"},{"name":"NCI_Drug_Dictionary_ID","value":"801585"},{"name":"NCI_META_CUI","value":"CL1406095"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801585"},{"name":"PDQ_Open_Trial_Search_ID","value":"801585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120100":{"preferredName":"Fluorine F 18 Ara-G","code":"C120100","definitions":[{"definition":"A radioconjugate composed of the guanosine analog arabinosyl guanine (Ara-G), a high-affinity substrate for both cytoplasmic deoxycytidine kinase (DCK) and mitochondrial deoxyguanosine kinase (dGK), labeled with fluorine F 18, that can potentially be used as a tracer for imaging of activated T-lymphocytes during positron emission tomography (PET). Upon administration, fluorine F 18 ara-G is taken up by and accumulates in activated T-lymphocytes with high levels of DCK and dGK. After phosphorylation by DCK and dGK, the 18F moiety can be visualized by PET imaging. Fluorine F 18 ara-G can potentially be used as an imaging agent to detect anti-tumor immune responses and to predict the therapeutic efficacy of immunotherapies. DCK and dGK, both nucleoside salvage pathway enzymes, are overexpressed in activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorine F 18 Ara-G","termGroup":"PT","termSource":"NCI"},{"termName":"(18F)F-Arag","termGroup":"SY","termSource":"NCI"},{"termName":"18F-F-Ara-G","termGroup":"SY","termSource":"NCI"},{"termName":"2'-Deoxy-2'-[18F]Fluoro-9-beta-D-arabinofuranosylguanine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-9-((2R,3S,4R,5R)-3-fluoranyl-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6-one","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]-AraG","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]F-ara-G","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]F-AraG","termGroup":"SY","termSource":"NCI"},{"termName":"F-ARAG F-18","termGroup":"SY","termSource":"NCI"},{"termName":"VisAcT","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268848-88-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X96PT3B08G"},{"name":"Maps_To","value":"Fluorine F 18 Ara-G"},{"name":"NCI_Drug_Dictionary_ID","value":"767684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767684"},{"name":"PDQ_Open_Trial_Search_ID","value":"767684"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896947"}]}}{"C175475":{"preferredName":"Foritinib Succinate","code":"C175475","definitions":[{"definition":"The succinate salt form of foritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, foritinib targets, binds to and inhibits the activity of ALK and ROS1, which leads to the disruption of ALK- and ROS1-mediated signaling and the inhibition of cell growth in ALK- and ROS1-expressing tumor cells. In addition, foritinib is able to cross the blood brain barrier. ALK and ROS1, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foritinib Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"SAF 189s","termGroup":"CN","termSource":"NCI"},{"termName":"SAF-189s","termGroup":"CN","termSource":"NCI"},{"termName":"SAF189s","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foritinib Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"802918"},{"name":"NCI_META_CUI","value":"CL1412842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802918"},{"name":"PDQ_Open_Trial_Search_ID","value":"802918"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165626":{"preferredName":"G Protein-coupled Estrogen Receptor Agonist LNS8801","code":"C165626","definitions":[{"definition":"An orally bioavailable selective agonist of the G protein-coupled estrogen receptor (G protein-coupled estrogen receptor 1; GPER; GPER1; GPR30), with potential immunomodulating and antineoplastic activities. Upon oral administration, LNS8801 targets, binds to and activates GPER. This activates GPER-mediated signaling and suppresses the expression of various tumor-associated genes, such as c-Myc and programmed cell death-ligand 1 (PD-L1). This leads to an inhibition of tumor cell proliferation. GPER activation may also induce immune memory. GPER is a membrane protein and a member of the G-protein coupled receptors (GPCRs) that are widely distributed in various tissues. GPER is a tumor suppressor in a wide range of cell cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"G Protein-coupled Estrogen Receptor Agonist LNS8801","termGroup":"PT","termSource":"NCI"},{"termName":"GPER Agonist LNS8801","termGroup":"SY","termSource":"NCI"},{"termName":"LNS 8801","termGroup":"CN","termSource":"NCI"},{"termName":"LNS-8801","termGroup":"CN","termSource":"NCI"},{"termName":"LNS8801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"925419-53-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TFS4QE36ZG"},{"name":"Maps_To","value":"G Protein-coupled Estrogen Receptor Agonist LNS8801"},{"name":"NCI_Drug_Dictionary_ID","value":"799991"},{"name":"NCI_META_CUI","value":"CL978801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799991"},{"name":"PDQ_Open_Trial_Search_ID","value":"799991"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165650":{"preferredName":"Gallium-based Bone Resorption Inhibitor AP-002","code":"C165650","definitions":[{"definition":"An orally bioavailable gallium (Ga)-based small molecule agent with potential anti-bone resorption and antineoplastic activities. Upon oral administration, AP-002 selectively inhibits osteoclast differentiation and bone resorption, and may promote the growth of osteoblasts thereby improving the skeletal sequelae of bony metastases which include pain, spinal cord compression, fractures and hypercalcemia of malignancy. Additionally, AP-002 may, through an as of yet undescribed mechanism of action, directly target and kill bone tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gallium-based Bone Resorption Inhibitor AP-002","termGroup":"PT","termSource":"NCI"},{"termName":"AP 002","termGroup":"CN","termSource":"NCI"},{"termName":"AP-002","termGroup":"CN","termSource":"NCI"},{"termName":"AP002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"14642-34-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R3G3HB38O4"},{"name":"Maps_To","value":"Gallium-based Bone Resorption Inhibitor AP-002"},{"name":"NCI_Drug_Dictionary_ID","value":"800117"},{"name":"NCI_META_CUI","value":"CL978946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800117"},{"name":"PDQ_Open_Trial_Search_ID","value":"800117"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172199":{"preferredName":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine","code":"C172199","definitions":[{"definition":"An orally bioavailable, immunotherapeutic vaccine composed of hydrolyzed and formulated glioblastoma multiforme (GBM) antigens and alloantigens derived from a pool of patients' cancer cells in the blood and samples of tumor tissues, with potential immunomodulating and antineoplastic activities. Upon oral administration of the GBM antigens and alloantigens immunotherapeutic vaccine, the GBM antigens and alloantigens may stimulate the host immune system via antigen-presenting cells (APCs) lining the gut to mount an immune response against tumor cells expressing these antigens. This may lead to tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"V-Boost","termGroup":"BR","termSource":"NCI"},{"termName":"V-Boost Immunitor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"801582"},{"name":"NCI_META_CUI","value":"CL1406091"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801582"},{"name":"PDQ_Open_Trial_Search_ID","value":"801582"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171371":{"preferredName":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum","code":"C171371","definitions":[{"definition":"A live, genetically modified probiotic bacteria Bifidobacterium longum (B. longum) engineered to deliver genetic material encoding the human pro-inflammatory transgene interleukin-12 (IL-12), with potential immunoactivating activity. Upon administration of genetically modified IL-12 transgene-encoding B. longum, the bacteria selectively colonize hypoxic tumor tissues and deliver plasmid DNA encoding the IL-12 transgene within the tumor microenvironment (TME). IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum","termGroup":"PT","termSource":"NCI"},{"termName":"bacTRL-IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"Bifidobacterium longum Encoding IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"Genetically Modified IL-12 Transgene-encoding Bifidobacterium longum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum"},{"name":"NCI_Drug_Dictionary_ID","value":"801308"},{"name":"NCI_META_CUI","value":"CL1405492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801308"},{"name":"PDQ_Open_Trial_Search_ID","value":"801308"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148486":{"preferredName":"Glofitamab","code":"C148486","definitions":[{"definition":"A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glofitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7082859","termGroup":"CN","termSource":"NCI"},{"termName":"RO7082859","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2229047-91-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"06P3KLK2J8"},{"name":"Maps_To","value":"Glofitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792571"},{"name":"NCI_META_CUI","value":"CL551055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792571"},{"name":"PDQ_Open_Trial_Search_ID","value":"792571"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165612":{"preferredName":"Glutaminase-1 Inhibitor IACS-6274","code":"C165612","definitions":[{"definition":"An orally bioavailable inhibitor of the metabolic enzyme glutaminase-1 (GLS1), with potential antineoplastic and immunostimulating activities. Upon oral administration, IACS-6274 selectively targets, binds to and inhibits human GLS1, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glutaminase-1 Inhibitor IACS-6274","termGroup":"PT","termSource":"NCI"},{"termName":"GLS1 Inhibitor IACS-6274","termGroup":"SY","termSource":"NCI"},{"termName":"IACS 6274","termGroup":"CN","termSource":"NCI"},{"termName":"IACS-6274","termGroup":"CN","termSource":"NCI"},{"termName":"IACS6274","termGroup":"CN","termSource":"NCI"},{"termName":"IPN 60090","termGroup":"CN","termSource":"NCI"},{"termName":"IPN-60090","termGroup":"CN","termSource":"NCI"},{"termName":"IPN60090","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1874231-60-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O6ZT4D087I"},{"name":"Maps_To","value":"Glutaminase Inhibitor IPN60090"},{"name":"NCI_Drug_Dictionary_ID","value":"799989"},{"name":"NCI_META_CUI","value":"CL978797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799989"},{"name":"PDQ_Open_Trial_Search_ID","value":"799989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174038":{"preferredName":"Sirpiglenastat","code":"C174038","definitions":[{"definition":"A broad acting glutamine antagonist, with potential immunomodulatory and antineoplastic activities. Upon administration, DON (6-Diazo-5-oxo-L-norleucine), the active moiety of sirpiglenastat, irreversibly inhibits multiple enzymes involved in glutamine metabolism. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors rely heavily on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, blocking glutamine metabolism leads to the accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon tumor cell death. As glutamine is essential for T-cell generation, DON may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells. The conversion of sirpiglenastat to the active moiety DON occurs primarily in tumor cells, allowing glutamine metabolism in healthy cells which may lessen adverse effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirpiglenastat","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-Isopropyl 2-((S)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate","termGroup":"SY","termSource":"NCI"},{"termName":"DRP 104","termGroup":"CN","termSource":"NCI"},{"termName":"DRP-104","termGroup":"CN","termSource":"NCI"},{"termName":"DRP104","termGroup":"CN","termSource":"NCI"},{"termName":"Glutamine Antagonist DRP-104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2079939-05-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9GGE6A0ZMK"},{"name":"Maps_To","value":"Glutamine Antagonist DRP-104"},{"name":"NCI_Drug_Dictionary_ID","value":"802458"},{"name":"NCI_META_CUI","value":"CL1407906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802458"},{"name":"PDQ_Open_Trial_Search_ID","value":"802458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174039":{"preferredName":"HER2 Inhibitor DZD1516","code":"C174039","definitions":[{"definition":"An orally bioavailable, blood brain barrier (BBB) penetrable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor DZD1516 selectively binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Inhibitor DZD1516","termGroup":"PT","termSource":"NCI"},{"termName":"DZD 1516","termGroup":"CN","termSource":"NCI"},{"termName":"DZD-1516","termGroup":"CN","termSource":"NCI"},{"termName":"DZD1516","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2 Inhibitor DZD1516"},{"name":"NCI_Drug_Dictionary_ID","value":"802459"},{"name":"NCI_META_CUI","value":"CL1407916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802459"},{"name":"PDQ_Open_Trial_Search_ID","value":"802459"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172279":{"preferredName":"HER2 Tri-specific Natural Killer Cell Engager DF1001","code":"C172279","definitions":[{"definition":"An engineered molecule based on tri-specific natural killer (NK) cell engager therapies (TriNKET) that is directed against human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential immunostimulating and antineoplastic activities. Upon administration, HER2 tri-specific NK cell engager DF1001 targets and binds to HER2 on tumor cells and simultaneously binds to NK cells, thereby bringing HER2-expressing tumor cells and NK cells together, which stimulates the NK cells and results in the selective NK cell-mediated tumor cell lysis of HER2-expressing tumor cells. The binding of HER2-expressing tumor cells and NK cells may also lead to the activation of T-cells and B-cells, potentiating the immune response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Tri-specific Natural Killer Cell Engager DF1001","termGroup":"PT","termSource":"NCI"},{"termName":"DF 1001","termGroup":"CN","termSource":"NCI"},{"termName":"DF-1001","termGroup":"CN","termSource":"NCI"},{"termName":"DF1001","termGroup":"CN","termSource":"NCI"},{"termName":"HER2 Tri-specific NK Cell Engager DF1001","termGroup":"SY","termSource":"NCI"},{"termName":"Tri-specific Natural Killer Cell Engager DF1001","termGroup":"SY","termSource":"NCI"},{"termName":"Tri-specific NK Cell Engager DF1001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2 Tri-specific Natural Killer Cell Engager DF1001"},{"name":"NCI_Drug_Dictionary_ID","value":"801897"},{"name":"NCI_META_CUI","value":"CL1406166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801897"},{"name":"PDQ_Open_Trial_Search_ID","value":"801897"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174010":{"preferredName":"Pertuzumab Zuvotolimod","code":"C174010","definitions":[{"definition":"An immunotherapeutic composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a Toll-like receptor 8 (TLR8; CD288) agonist, with potential immunostimulating and antineoplastic activities. Upon intravenous administration pertuzumab zuvotolimod, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells, thereby localizing the TLR8 agonist directly to the tumor site. In turn, the TLR8 agonist moiety binds to TLR8 expressed on myeloid cells within the tumor microenvironment (TME). This activates myeloid cells, including tumor-associated macrophages (TAMs), myeloid cell-derived suppressive cells (MDSCs), and conventional dendritic cells (cDCs). This may lead to the activation of nuclear factor NF-kappa-B, the production of pro-inflammatory cytokines and chemokines, macrophage-induced tumor cell killing, inflammasome activation, activation of cytolytic natural killer (NK) cells and neutrophils, and the induction of a Th1-weighted anti-tumor immune response. It also reverses the suppression of senescent naive and tumor-specific T-cells, and enhances the anti-tumor cytotoxic T-lymphocyte (CTL) immune response. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pertuzumab Zuvotolimod","termGroup":"PT","termSource":"NCI"},{"termName":"HER2-directed TLR8 Agonist SBT6050","termGroup":"SY","termSource":"NCI"},{"termName":"HER2-directed TLR8 ImmunoTAC SBT6050","termGroup":"SY","termSource":"NCI"},{"termName":"ImmunoTAC SBT6050","termGroup":"SY","termSource":"NCI"},{"termName":"SBT 6050","termGroup":"CN","termSource":"NCI"},{"termName":"SBT-6050","termGroup":"CN","termSource":"NCI"},{"termName":"SBT6050","termGroup":"CN","termSource":"NCI"},{"termName":"TLR8 Agonist-HER2-directed Monoclonal Antibody Conjugate SBT6050","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2500674-05-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H4LR6V1LWG"},{"name":"Maps_To","value":"HER2-directed TLR8 Agonist SBT6050"},{"name":"NCI_Drug_Dictionary_ID","value":"802452"},{"name":"NCI_META_CUI","value":"CL1407923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802452"},{"name":"PDQ_Open_Trial_Search_ID","value":"802452"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170918":{"preferredName":"Zifcasiran","code":"C170918","definitions":[{"definition":"An RNA interference (RNAi) targeting hypoxia-inducible factor 2alpha (HIF-2a), with potential antineoplastic activity. Upon administration, zifcasiran binds to and neutralizes mRNA HIF2a, thereby preventing the production of HIF2a. This may lead to an inhibition of tumor cell proliferation. HIF2a, overexpressed in certain cell types, plays a key role in proliferation, progression and metastasis of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zifcasiran","termGroup":"PT","termSource":"NCI"},{"termName":"ADS-007","termGroup":"CN","termSource":"NCI"},{"termName":"ARO HIF2","termGroup":"CN","termSource":"NCI"},{"termName":"ARO-HIF2","termGroup":"CN","termSource":"NCI"},{"termName":"AROHIF2","termGroup":"CN","termSource":"NCI"},{"termName":"HIF2a RNAi ARO-HIF2","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Interference Therapeutic ARO-HIF2","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted RNAi Molecule ARO-HIF2","termGroup":"SY","termSource":"NCI"},{"termName":"TRiM ARO-HIF2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2437257-11-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5G6HL9K2G4"},{"name":"Maps_To","value":"HIF2a RNAi ARO-HIF2"},{"name":"NCI_Drug_Dictionary_ID","value":"801198"},{"name":"NCI_META_CUI","value":"CL1383073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801198"},{"name":"PDQ_Open_Trial_Search_ID","value":"801198"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173149":{"preferredName":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202","code":"C173149","definitions":[{"definition":"A cancer vaccine consisting of replication-attenuated arenavirus encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV 16 E6/E7-encoding arenavirus vaccine HB-202 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202","termGroup":"PT","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine HB-202","termGroup":"SY","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine-expressing HPV 16 E7E6 HB-202","termGroup":"SY","termSource":"NCI"},{"termName":"HB 202","termGroup":"CN","termSource":"NCI"},{"termName":"HB-202","termGroup":"CN","termSource":"NCI"},{"termName":"HB-202 Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HB202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802056"},{"name":"NCI_META_CUI","value":"CL1407016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802056"},{"name":"PDQ_Open_Trial_Search_ID","value":"802056"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167349":{"preferredName":"HPV E6/E7-encoding Arenavirus Vaccine HB-201","code":"C167349","definitions":[{"definition":"A cancer vaccine consisting of a replication-attenuated arenavirus lymphocytic choriomeningitis virus (LCMV) encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV E6/E7-encoding arenavirus vaccine HB-201 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV E6/E7-encoding Arenavirus Vaccine HB-201","termGroup":"PT","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine HB-201","termGroup":"SY","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine-expressing HPV 16 E7E6 HB-201","termGroup":"SY","termSource":"NCI"},{"termName":"HB 201","termGroup":"CN","termSource":"NCI"},{"termName":"HB-201","termGroup":"CN","termSource":"NCI"},{"termName":"HB-201 Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HB201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV E6/E7-encoding Arenavirus Vaccine HB-201"},{"name":"NCI_Drug_Dictionary_ID","value":"800472"},{"name":"NCI_META_CUI","value":"CL972322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800472"},{"name":"PDQ_Open_Trial_Search_ID","value":"800472"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173718":{"preferredName":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107","code":"C173718","definitions":[{"definition":"A DNA vaccine consisting of plasmids encoding E6 and E7 genes of human papilloma virus subtype 6 (HPV-6) and 11 (HPV-11), with potential immunostimulating and antineoplastic activities. Upon administration via intramuscular electroporation, the HPV-6/11-targeted DNA plasmid vaccine INO-3107 expresses the HPV-6/11 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing HPV6 and/or HPV11 E6 and E7 proteins, resulting in tumor cell lysis. HPV-6/11 infections are associated with aerodigestive malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-6/11-targeting Immunotherapeutic Vaccine INO-3107","termGroup":"SY","termSource":"NCI"},{"termName":"HPV6/11-targeted DNA Plasmid Immunotherapeutic INO-3107","termGroup":"SY","termSource":"NCI"},{"termName":"INO 3107","termGroup":"CN","termSource":"NCI"},{"termName":"INO-3107","termGroup":"CN","termSource":"NCI"},{"termName":"INO3107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107"},{"name":"NCI_Drug_Dictionary_ID","value":"802021"},{"name":"NCI_META_CUI","value":"CL1407562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802021"},{"name":"PDQ_Open_Trial_Search_ID","value":"802021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173550":{"preferredName":"Hsp90 Inhibitor TQB3474","code":"C173550","definitions":[{"definition":"An inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration, Hsp90 inhibitor TQB3474 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor TQB3474","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor TQB3474","termGroup":"SY","termSource":"NCI"},{"termName":"TQB 3474","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3474","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3474","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hsp90 Inhibitor TQB3474"},{"name":"NCI_Drug_Dictionary_ID","value":"801900"},{"name":"NCI_META_CUI","value":"CL1407320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801900"},{"name":"PDQ_Open_Trial_Search_ID","value":"801900"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172190":{"preferredName":"Hsp90-targeted Photosensitizer HS-201","code":"C172190","definitions":[{"definition":"A conjugate consisting of a heat shock protein 90 (Hsp90) inhibitor connected via a linker to verteporfin, a photosensitizing agent, with potential imaging, photodynamic and antineoplastic activities. Upon administration, the Hsp90 inhibitor moiety of HS-201 selectively binds to the Hsp90 ATP binding domain in tumor cells and HS-201 accumulates in tumor cells. The verteporfin moiety of HS-201 allows for visualization and photodynamic therapy of the tumors. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins. Verteporfin is a synthetic photosensitizer with photodynamic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90-targeted Photosensitizer HS-201","termGroup":"PT","termSource":"NCI"},{"termName":"HS 201","termGroup":"CN","termSource":"NCI"},{"termName":"HS-201","termGroup":"CN","termSource":"NCI"},{"termName":"HS201","termGroup":"CN","termSource":"NCI"},{"termName":"Hsp90 Inhibitor-linked Verteporfin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hsp90-targeted Photosensitizer HS-201"},{"name":"NCI_Drug_Dictionary_ID","value":"801530"},{"name":"NCI_META_CUI","value":"CL1406287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801530"},{"name":"PDQ_Open_Trial_Search_ID","value":"801530"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173339":{"preferredName":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab","code":"C173339","definitions":[{"definition":"A ready-to-use fixed-dose combination of pertuzumab and trastuzumab, both recombinant humanized monoclonal antibodies directed against the tyrosine kinase receptor (TKR) human epidermal growth factor receptor 2 (HER2; HER-2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-zzxf, a biosimilar of the recombinant form of the naturally occurring endoglycosidase hyaluronidase, with antineoplastic activity that can be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-zzxf temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows both pertuzumab and trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of both antibodies into the bloodstream. Pertuzumab targets and binds to the extracellular dimerization domain (subdomain II) of HER2 and blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4. This inhibits ligand-initiated intracellular signaling and prevents the activation of the mitogen-activated protein (MAP) kinase and the phosphoinositide 3-kinase (PI3K) signaling pathways, leading to growth arrest and apoptosis in HER2-overexpressing tumor cells, respectively. Trastuzumab targets and binds to subdomain IV of HER2 and inhibits ligand-independent, HER2 mediated cell proliferation and inhibits the PI3K signaling pathway in HER2-overexpressing tumor cells. Both antibodies induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab/Trastuzumab/Hyaluronidase-zzxf","termGroup":"SY","termSource":"NCI"},{"termName":"Phesgo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2 overexpressing breast cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"801876"},{"name":"NCI_META_CUI","value":"CL1636756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801876"},{"name":"PDQ_Open_Trial_Search_ID","value":"801876"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175542":{"preferredName":"Crelosidenib","code":"C175542","definitions":[{"definition":"An orally available inhibitor of mutant form of the isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including the substitution mutation at arginine (R) in position 132, IDH1(R132), with potential antineoplastic activity. Upon oral administration, crelosidenib specifically and covalently binds to and modifies a single cysteine (Cys269) in the allosteric binding pocket of mutant forms of IDH1, thereby inactivating IDH1. This inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This depletes 2-HG levels, prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing mutant forms of IDH1. In addition, crelosidenib has the ability to cross the blood-brain barrier (BBB). IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crelosidenib","termGroup":"PT","termSource":"NCI"},{"termName":"IDH1 Inhibitor LY3410738","termGroup":"SY","termSource":"NCI"},{"termName":"IDH1 Mutant Inhibitor LY3410738","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3410738","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3410738","termGroup":"CN","termSource":"NCI"},{"termName":"LY3410738","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230263-60-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A4DU555RMD"},{"name":"Maps_To","value":"IDH1 Mutant Inhibitor LY3410738"},{"name":"NCI_Drug_Dictionary_ID","value":"803295"},{"name":"NCI_META_CUI","value":"CL1412892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803295"},{"name":"PDQ_Open_Trial_Search_ID","value":"803295"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171343":{"preferredName":"IDO/TDO Inhibitor LY-01013","code":"C171343","definitions":[{"definition":"An orally bioavailable, small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor LY-01013 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, LY-01013 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO/TDO Inhibitor LY-01013","termGroup":"PT","termSource":"NCI"},{"termName":"LPM 3480226","termGroup":"CN","termSource":"NCI"},{"termName":"LPM-3480226","termGroup":"CN","termSource":"NCI"},{"termName":"LPM3480226","termGroup":"CN","termSource":"NCI"},{"termName":"LY 01013","termGroup":"CN","termSource":"NCI"},{"termName":"LY-01013","termGroup":"CN","termSource":"NCI"},{"termName":"LY01013","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO/TDO Inhibitor LY-01013"},{"name":"NCI_Drug_Dictionary_ID","value":"801300"},{"name":"NCI_META_CUI","value":"CL1405462"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801300"},{"name":"PDQ_Open_Trial_Search_ID","value":"801300"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168808":{"preferredName":"IDO1/TDO2 Inhibitor M4112","code":"C168808","definitions":[{"definition":"An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor M4112 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (Kyn). This inhibits the IDO1/TDO2-Kyn-AhR pathway and abrogates AhR activation. This prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME), and may restore the immune response by stimulating a cytotoxic T-lymphocyte (CTL) immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types and plays a key role in immunosuppression. Its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1/TDO2 Inhibitor M4112","termGroup":"PT","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase-1/Tryptophan 2,3-Dioxygenase 2 Inhibitor M4112","termGroup":"SY","termSource":"NCI"},{"termName":"M 4112","termGroup":"CN","termSource":"NCI"},{"termName":"M-4112","termGroup":"CN","termSource":"NCI"},{"termName":"M4112","termGroup":"CN","termSource":"NCI"},{"termName":"MS201408-0005","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1/TDO2 Inhibitor M4112"},{"name":"NCI_Drug_Dictionary_ID","value":"800701"},{"name":"NCI_META_CUI","value":"CL1378711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800701"},{"name":"PDQ_Open_Trial_Search_ID","value":"800701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166375":{"preferredName":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000","code":"C166375","definitions":[{"definition":"An immunotherapeutic agent utilizing mRNA to encode the cytokines interleukin-12sc (IL-12sc), interleukin-15sushi (IL-15sushi), interferon alpha (IFNa) and granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based immunotherapeutic agent SAR441000, mRNA is picked up by nearby cells, translated and released into the local tumor microenvironment (TME). Secretion of these cytokines activate the immune system by promoting the activation of natural killer cells (NKs) and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in an immune-mediated destruction of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000","termGroup":"PT","termSource":"NCI"},{"termName":"BNT 131","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-131","termGroup":"CN","termSource":"NCI"},{"termName":"BNT131","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 441000","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-441000","termGroup":"CN","termSource":"NCI"},{"termName":"SAR441000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000"},{"name":"NCI_Drug_Dictionary_ID","value":"800230"},{"name":"NCI_META_CUI","value":"CL971627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800230"},{"name":"PDQ_Open_Trial_Search_ID","value":"800230"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170893":{"preferredName":"Inactivated Oncolytic Virus Particle GEN0101","code":"C170893","definitions":[{"definition":"An inactivated, non-replicating particle of hemagglutinating virus of Japan (HVJ), an oncolytic virus of the paramyxovirus family, with potential immunostimulating and antineoplastic activities. Upon intracutaneous administration, GEN0101 targets and binds to the cytosolic nucleic acid receptor retinoic acid-inducible gene I (RIG-I). This induces RIG-I-mediated signaling and a potent innate immune response against tumor cells, leading to the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTL), and apoptosis in tumor cells. GEN0101 also activates dendritic cells (DCs) to produce cytokine interleukin-6 (IL-6), suppressing the function of regulatory T cells (Treg), a negative regulator of immune responses. The suppression of Treg activity helps maintain the induced immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inactivated Oncolytic Virus Particle GEN0101","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 0101","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-0101","termGroup":"CN","termSource":"NCI"},{"termName":"GEN0101","termGroup":"CN","termSource":"NCI"},{"termName":"HVJ-E","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated Hemagglutinating Virus of Japan Envelope GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated Hemagglutinating Virus of Japan Envelope Immunotherapy GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated HVJ Particle GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated HVJ-E GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated HVJ-E Immunotherapy GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Non-replicating Oncolytic Virus Particle GEN0101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inactivated Oncolytic Virus Particle GEN0101"},{"name":"NCI_Drug_Dictionary_ID","value":"800846"},{"name":"NCI_META_CUI","value":"CL1383056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800846"},{"name":"PDQ_Open_Trial_Search_ID","value":"800846"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171392":{"preferredName":"Individualized MVA-based Vaccine TG4050","code":"C171392","definitions":[{"definition":"An off-the-shelf (OTS) individualized vaccine comprised of a modified Vaccinia virus Ankara (MVA) viral vector encoding tumor-specific neoantigens (TSNAs), with potential immunostimulatory and antineoplastic activities. Following administration of the individualized MVA-based vaccine TG4050, the neoantigens are expressed and presented to the immune system, which induces the activation of a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the patient-specific neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Individualized MVA-based Vaccine TG4050","termGroup":"PT","termSource":"NCI"},{"termName":"MVA-Neoantigen Vaccine TG4050","termGroup":"SY","termSource":"NCI"},{"termName":"Neoantigen-expressing MVA-based Vaccine TG4050","termGroup":"SY","termSource":"NCI"},{"termName":"TG 4050","termGroup":"CN","termSource":"NCI"},{"termName":"TG-4050","termGroup":"CN","termSource":"NCI"},{"termName":"TG4050","termGroup":"CN","termSource":"NCI"},{"termName":"TG4050 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Individualized MVA-based Vaccine TG4050"},{"name":"NCI_Drug_Dictionary_ID","value":"801297"},{"name":"NCI_META_CUI","value":"CL1405501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801297"},{"name":"PDQ_Open_Trial_Search_ID","value":"801297"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172187":{"preferredName":"iNKT Cell Agonist ABX196","code":"C172187","definitions":[{"definition":"A synthetic glycolipid agonist for natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon infusion of the iNKT cell agonist ABX196, this agent targets and binds to iNKTs, thereby activating iNKTs. In turn, iNKTs recognize CD1d-restricted lipid ligands, which are expressed on certain tumor cells, and secrete large amounts of various cytokines. This may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iNKT Cell Agonist ABX196","termGroup":"PT","termSource":"NCI"},{"termName":"ABX 196","termGroup":"CN","termSource":"NCI"},{"termName":"ABX-196","termGroup":"CN","termSource":"NCI"},{"termName":"ABX196","termGroup":"CN","termSource":"NCI"},{"termName":"Invariant NKT Cell Agonist ABX196","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1161877-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SOI87F7GN2"},{"name":"Maps_To","value":"iNKT Cell Agonist ABX196"},{"name":"NCI_Drug_Dictionary_ID","value":"801520"},{"name":"NCI_META_CUI","value":"CL1406290"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801520"},{"name":"PDQ_Open_Trial_Search_ID","value":"801520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173371":{"preferredName":"Interleukin-12-Fc Fusion Protein DF6002","code":"C173371","definitions":[{"definition":"A fusion protein composed of human interleukin-12 (IL-12) fused to a Fc fragment, with potential immunomodulatory and antineoplastic activities. Upon administration of IL-12-Fc fusion protein DF6002, the IL-12 moiety binds to the IL-12 receptor. This may activate the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-12-Fc Fusion Protein DF6002","termGroup":"PT","termSource":"NCI"},{"termName":"DF 6002","termGroup":"CN","termSource":"NCI"},{"termName":"DF-6002","termGroup":"CN","termSource":"NCI"},{"termName":"DF6002","termGroup":"CN","termSource":"NCI"},{"termName":"IL-12-Fc Fusion Protein DF6002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interleukin-12-Fc Fusion Protein DF6002"},{"name":"NCI_Drug_Dictionary_ID","value":"801838"},{"name":"NCI_META_CUI","value":"CL1407203"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801838"},{"name":"PDQ_Open_Trial_Search_ID","value":"801838"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171385":{"preferredName":"Interleukin-15 Agonist Fusion Protein SHR1501","code":"C171385","definitions":[{"definition":"A human Fc fusion protein composed of the cytokine interleukin (IL)-15 cross-linked with the high-affinity binding sushi domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activity. Upon administration, SHR-1501 activates and increases the levels of natural killer (NK) cells and memory CD8+ T-cells without stimulating regulatory T-cells (Tregs). The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. SHR1501 is more potent than unmodified IL-15 and does not require endogenous IL-15Ra for its action. The Fc moiety allows for an extended half-life of SHR-1501 while cross linking IL-15 with IL-15Ra sushi domain improves stability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-15 Agonist Fusion Protein SHR1501","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15 Agonist Fusion Protein SHR1501","termGroup":"SY","termSource":"NCI"},{"termName":"IL-15 Super-agonist SHR1501","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SHR1501","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 1501","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1501","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interleukin-15 Agonist Fusion Protein SHR1501"},{"name":"NCI_Drug_Dictionary_ID","value":"801247"},{"name":"NCI_META_CUI","value":"CL1405483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801247"},{"name":"PDQ_Open_Trial_Search_ID","value":"801247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172075":{"preferredName":"Interleukin-15 Fusion Protein BJ-001","code":"C172075","definitions":[{"definition":"A human fusion protein composed of the cytokine interleukin (IL)-15 linked with an integrins-targeting moiety, with potential antineoplastic activity. Upon subcutaneous administration, the integrins-targeting moiety of BJ-001 targets tumor cells that overexpress integrins such as alpha v beta 3 (avb3), alpha v beta 5 (avb5) and alpha v beta 6 (avb6) and the IL-15 moiety binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) cells and CD8+ T-lymphocytes. This activates and increases the levels of NK cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T- and NK cell development, activation and proliferation. Integrins are involved in tumor growth, angiogenesis, and metastasis and they are overexpressed in a variety of tumor cell types. The linkage of the two moieties may limit the effects of IL-15 to the local tumor microenvironment (TME), increasing efficacy while reducing systemic toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-15 Fusion Protein BJ-001","termGroup":"PT","termSource":"NCI"},{"termName":"BJ 001","termGroup":"CN","termSource":"NCI"},{"termName":"BJ-001","termGroup":"CN","termSource":"NCI"},{"termName":"BJ001","termGroup":"CN","termSource":"NCI"},{"termName":"IL-15 Fusion Protein BJ-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interleukin-15 Fusion Protein BJ-001"},{"name":"NCI_Drug_Dictionary_ID","value":"802006"},{"name":"NCI_META_CUI","value":"CL1406211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802006"},{"name":"PDQ_Open_Trial_Search_ID","value":"802006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170890":{"preferredName":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306","code":"C170890","definitions":[{"definition":"An interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain, with potential antineoplastic activity. Upon administration, XmAb24306 stimulates the proliferation of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. XmAb24306 does not require endogenous IL-15Ra for its activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306","termGroup":"PT","termSource":"NCI"},{"termName":"IL15/IL15Ra Complex-Fc Fusion Protein XmAb24306","termGroup":"SY","termSource":"NCI"},{"termName":"IL15/IL15Ra-Fc Fusion Protein XmAb24306","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7310729","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7310729","termGroup":"CN","termSource":"NCI"},{"termName":"RO7310729","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb 24306","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb-24306","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb24306","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306"},{"name":"NCI_Drug_Dictionary_ID","value":"801195"},{"name":"NCI_META_CUI","value":"CL1383037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801195"},{"name":"PDQ_Open_Trial_Search_ID","value":"801195"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170516":{"preferredName":"Nanrilkefusp Alfa","code":"C170516","definitions":[{"definition":"A human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activities. Upon administration, nanrilkefusp alfa activates and increases the levels of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. Nanrilkefusp alfa is more potent than unmodified IL-15 and does not require endogenous IL-15Ra for its action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanrilkefusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15/IL-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SOT101","termGroup":"SY","termSource":"NCI"},{"termName":"RLI 15","termGroup":"CN","termSource":"NCI"},{"termName":"RLI-15","termGroup":"CN","termSource":"NCI"},{"termName":"RLI15","termGroup":"CN","termSource":"NCI"},{"termName":"SO C101","termGroup":"CN","termSource":"NCI"},{"termName":"SO-C101","termGroup":"CN","termSource":"NCI"},{"termName":"SOC101","termGroup":"CN","termSource":"NCI"},{"termName":"SOT 101","termGroup":"CN","termSource":"NCI"},{"termName":"SOT-101","termGroup":"CN","termSource":"NCI"},{"termName":"SOT101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1416390-27-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UM4VY7ZEC9"},{"name":"Maps_To","value":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101"},{"name":"NCI_Drug_Dictionary_ID","value":"801174"},{"name":"NCI_META_CUI","value":"CL1382942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801174"},{"name":"PDQ_Open_Trial_Search_ID","value":"801174"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171348":{"preferredName":"Iodine I 131 IPA","code":"C171348","definitions":[{"definition":"A radioconjugate consisting of the tumor-specific amino acid derivative 4-iodo-L-phenylalanine labeled with iodine I 131, a beta emitting radionuclide, with potential antineoplastic activity. Upon administration, iodine I 131 IPA actively crosses the blood-brain barrier and accumulates specifically in gliomas, via the amino acid transport system l-amino acid transporter 1 (LAT1) over-expressed in malignant glioma cells. where it delivers a cytotoxic dose of beta radiation. Cells that are exposed to radiation may also release potent toxins into the intracellular environment, leading to radiation-induced biological bystander effects (RIBBE) and killing cells not directly exposed to the radiation. Iodine I 131 IPA may also act synergistically with external irradiation due to its radiosensitizing property.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 IPA","termGroup":"PT","termSource":"NCI"},{"termName":"131I-IPA","termGroup":"SY","termSource":"NCI"},{"termName":"4-[131I]iodo-L-phenylalanine","termGroup":"SY","termSource":"NCI"},{"termName":"4-L-[131I]iodo-phenylalanine","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 IPA","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 IPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 IPA"},{"name":"NCI_Drug_Dictionary_ID","value":"801303"},{"name":"NCI_META_CUI","value":"CL1405459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801303"},{"name":"PDQ_Open_Trial_Search_ID","value":"801303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170800":{"preferredName":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","code":"C170800","definitions":[{"definition":"An allogeneic, off-the-shelf, chimeric antigen receptor (CAR)-natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a NK cell-specific anti-CD19 CAR, a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF), with potential immunostimulatory and antineoplastic activities. Upon administration, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15RF enhances the cytotoxic effect of the NK cells and the activated anti-tumor T-cells. When used in combination with monoclonal antibodies, the hnCD16 Fc receptor of FT596 binds to the Fc portion of tumor cell-bound monoclonal antibodies, leading to NK cell activation, cytokine secretion and enhanced antibody-dependent cellular cytotoxicity (ADCC). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","termGroup":"PT","termSource":"NCI"},{"termName":"FT 596","termGroup":"CN","termSource":"NCI"},{"termName":"FT-596","termGroup":"CN","termSource":"NCI"},{"termName":"FT596","termGroup":"CN","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","termGroup":"SY","termSource":"NCI"},{"termName":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-Natural Killer Cells FT596","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596"},{"name":"NCI_Drug_Dictionary_ID","value":"801177"},{"name":"NCI_META_CUI","value":"CL1383208"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801177"},{"name":"PDQ_Open_Trial_Search_ID","value":"801177"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165639":{"preferredName":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130","code":"C165639","definitions":[{"definition":"An allogeneic irradiated human lung cancer cell vaccine expressing a fusion protein composed of the OX40 ligand (OX40L) linked to an immunoglobulin (Ig) (OX40L-Ig), with potential immunomodulating and antineoplastic activities. Upon intradermal administration of irradiated allogeneic human lung cancer cells expressing OX40L-Ig vaccine HS-130, the irradiated lung cancer cells continuously express OX40L-Ig. OX40L may then target, bind to and activate its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40; CD134), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, and induces the proliferation and activation of memory and effector T-lymphocytes against the human lung cancer cells. In turn, this promotes a CTL-mediated immune response against the endogenous lung cancer cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130","termGroup":"PT","termSource":"NCI"},{"termName":"HS 130","termGroup":"CN","termSource":"NCI"},{"termName":"HS-130","termGroup":"CN","termSource":"NCI"},{"termName":"HS130","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130"},{"name":"NCI_Drug_Dictionary_ID","value":"799760"},{"name":"NCI_META_CUI","value":"CL978790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799760"},{"name":"PDQ_Open_Trial_Search_ID","value":"799760"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172200":{"preferredName":"JAK Inhibitor","code":"C172200","definitions":[{"definition":"A substance that inhibits the biological action of tyrosine-protein kinase JAK1, an enzyme that plays a key role in certain types of cancer and cytokine signaling","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Janus Kinase Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JAK Inhibitor"},{"name":"NCI_Drug_Dictionary_ID","value":"802011"},{"name":"NCI_META_CUI","value":"CL1406090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802011"},{"name":"PDQ_Open_Trial_Search_ID","value":"802011"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168608":{"preferredName":"Kanitinib","code":"C168608","definitions":[{"definition":"A tyrosine kinase inhibitor targeting the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR; MET) and vascular endothelial growth factor receptor 2 (VEGFR2), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, kanitinib targets and binds to c-Met and VEGFR2, thereby disrupting c-Met- and VEGFR2-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met and/or VEGFR2 protein. c-Met and VEGFR2 are both overexpressed in many tumor cell types and play key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kanitinib","termGroup":"PT","termSource":"NCI"},{"termName":"CX 1003","termGroup":"CN","termSource":"NCI"},{"termName":"CX-1003","termGroup":"CN","termSource":"NCI"},{"termName":"CX1003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kanitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"800350"},{"name":"NCI_META_CUI","value":"CL972814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800350"},{"name":"PDQ_Open_Trial_Search_ID","value":"800350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173995":{"preferredName":"Divarasib","code":"C173995","definitions":[{"definition":"An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Divarasib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 6036","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-6036","termGroup":"CN","termSource":"NCI"},{"termName":"GDC6036","termGroup":"CN","termSource":"NCI"},{"termName":"KRAS G12C Inhibitor GDC-6036","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417917-17-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E6S21PVT91"},{"name":"Maps_To","value":"KRAS G12C Inhibitor GDC-6036"},{"name":"NCI_Drug_Dictionary_ID","value":"802450"},{"name":"NCI_META_CUI","value":"CL1407880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802450"},{"name":"PDQ_Open_Trial_Search_ID","value":"802450"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166410":{"preferredName":"KRAS G12C Inhibitor LY3499446","code":"C166410","definitions":[{"definition":"An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, LY3499446 targets and covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRAS G12C Inhibitor LY3499446","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3499446","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3499446","termGroup":"CN","termSource":"NCI"},{"termName":"LY3499446","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2409131-50-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QZJ1I2EN1V"},{"name":"Maps_To","value":"KRAS G12C Inhibitor LY3499446"},{"name":"NCI_Drug_Dictionary_ID","value":"800237"},{"name":"NCI_META_CUI","value":"CL971660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800237"},{"name":"PDQ_Open_Trial_Search_ID","value":"800237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167157":{"preferredName":"KRAS G12C Inhibitor JNJ-74699157","code":"C167157","definitions":[{"definition":"An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRAS G12C Inhibitor JNJ-74699157","termGroup":"PT","termSource":"NCI"},{"termName":"ARS 3248","termGroup":"CN","termSource":"NCI"},{"termName":"ARS-3248","termGroup":"CN","termSource":"NCI"},{"termName":"ARS3248","termGroup":"CN","termSource":"NCI"},{"termName":"G12C Mutant KRAS Protein Inhibitor JNJ-74699157","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 74699157","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-74699157","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ74699157","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"KRASG12C Inhibitor JNJ-74699157"},{"name":"NCI_Drug_Dictionary_ID","value":"800416"},{"name":"NCI_META_CUI","value":"CL972386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800416"},{"name":"PDQ_Open_Trial_Search_ID","value":"800416"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173559":{"preferredName":"LAIR-2 Fusion Protein NC410","code":"C173559","definitions":[{"definition":"A fusion protein of leukocyte-associated immunoglobulin (Ig)-like receptor (LAIR)-2, a high-affinity collagen receptor, with potential immunomodulatory and antineoplastic activities. Upon administration, LAIR-2 fusion protein NC410 binds to the ligand collagen of LAIR-1 (CD305), thereby blocking the binding of LAIR-1 to its ligand collagen and inhibiting LAIR-1-mediated immune suppression. This may result in enhanced T-cell and dendritic cell (DC) activities, and cytotoxic T-lymphocyte (CTL) and anti-tumor immune responses. LAIR-1, a collagen-receptor and an inhibitory immune receptor belonging to the Ig superfamily, is expressed on many peripheral blood mononuclear cells (PBMC) including T-cells and DCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LAIR-2 Fusion Protein NC410","termGroup":"PT","termSource":"NCI"},{"termName":"Leukocyte-associated Immunoglobulin-like Receptor-2 Fusion Protein NC410","termGroup":"SY","termSource":"NCI"},{"termName":"NC 410","termGroup":"CN","termSource":"NCI"},{"termName":"NC-410","termGroup":"CN","termSource":"NCI"},{"termName":"NC410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LAIR-2 Fusion Protein NC410"},{"name":"NCI_Drug_Dictionary_ID","value":"801912"},{"name":"NCI_META_CUI","value":"CL1407327"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801912"},{"name":"PDQ_Open_Trial_Search_ID","value":"801912"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172062":{"preferredName":"Larotinib Mesylate","code":"C172062","definitions":[{"definition":"The mesylate salt form of larotinib, a reversible pan-ErbB inhibitor with potential antineoplastic activity. Upon administration, larotinib binds to and inhibits ErbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing ErbB. The ErbB protein family, also called the epidermal growth factor receptor (EGFR) family, plays major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larotinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Z 650","termGroup":"CN","termSource":"NCI"},{"termName":"Z-650","termGroup":"CN","termSource":"NCI"},{"termName":"Z650","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Larotinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"801495"},{"name":"NCI_META_CUI","value":"CL1406186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801495"},{"name":"PDQ_Open_Trial_Search_ID","value":"801495"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165685":{"preferredName":"Lilotomab","code":"C165685","definitions":[{"definition":"A murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. Upon administration, lilotomab both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lilotomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD37 Monoclonal Antibody HH1","termGroup":"SY","termSource":"NCI"},{"termName":"HH1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453362-55-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"58I6YNR7BV"},{"name":"Maps_To","value":"Lilotomab"},{"name":"NCI_Drug_Dictionary_ID","value":"800126"},{"name":"NCI_META_CUI","value":"CL978919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800126"},{"name":"PDQ_Open_Trial_Search_ID","value":"800126"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170753":{"preferredName":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006","code":"C170753","definitions":[{"definition":"A biodegradable, lyophilized lipid nanoparticle (LNP) encapsulating small interfering ribonucleic acid (siRNA) directed against glutathione S-transferase P (GSTP), with potential antineoplastic activity. Upon administration of LNP encapsulating GSTP siRNA NBF-006, the LNP formulation delivers the siRNA particles to the tumor cells where the GSTP siRNA targets and binds to GSTP mRNA. This results in the inhibition of the translation and expression of GSTP and may inhibit proliferation of KRAS-overexpressing tumor cells. GSTP, an enzyme overexpressed in many tumor cell types, is involved in modulating MAP kinase-related cell-signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulating GSTP siRNA NBF-006","termGroup":"SY","termSource":"NCI"},{"termName":"NBF 006","termGroup":"CN","termSource":"NCI"},{"termName":"NBF-006","termGroup":"CN","termSource":"NCI"},{"termName":"NBF006","termGroup":"CN","termSource":"NCI"},{"termName":"siRNA-based Lipid Nanoparticle NBF-006","termGroup":"SY","termSource":"NCI"},{"termName":"siRNA-based LNP NBF-006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006"},{"name":"NCI_Drug_Dictionary_ID","value":"800779"},{"name":"NCI_META_CUI","value":"CL1383151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800779"},{"name":"PDQ_Open_Trial_Search_ID","value":"800779"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170743":{"preferredName":"Liposomal Bcl-2 Antisense Oligonucleotide BP1002","code":"C170743","definitions":[{"definition":"A liposomal-based nanoparticle composed of an uncharged P-ethoxy antisense oligodeoxynucleotide (ODN) targeting Bcl-2 mRNA and incorporated in liposomes, with potential antineoplastic activity. Upon administration of liposomal Bcl-2 antisense oligonucleotide BP1002, this agent targets and hybridizes with Bcl-2 mRNA and inhibits the expression of Bcl-2 protein. This may induce tumor cell apoptosis of Bcl2-overexpressing tumor cells and may decrease tumor cell proliferation. Bcl2, a protein involved in regulating programmed cell death, is overexpressed in a wide variety of tumors. It promotes cellular survival and inhibits apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Bcl-2 Antisense Oligonucleotide BP1002","termGroup":"PT","termSource":"NCI"},{"termName":"BP 1002","termGroup":"CN","termSource":"NCI"},{"termName":"BP-100-1.02","termGroup":"CN","termSource":"NCI"},{"termName":"BP-1002","termGroup":"CN","termSource":"NCI"},{"termName":"BP1002","termGroup":"CN","termSource":"NCI"},{"termName":"L-Bcl-2 Antisense Oligonucleotide BP1002","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Bcl-2 Antisense BP1002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Bcl-2 Antisense Oligonucleotide  BP1002"},{"name":"NCI_Drug_Dictionary_ID","value":"800679"},{"name":"NCI_META_CUI","value":"CL1383140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800679"},{"name":"PDQ_Open_Trial_Search_ID","value":"800679"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174421":{"preferredName":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1","code":"C174421","definitions":[{"definition":"A vaccine consisting of messenger RNA (mRNA) encoding three tumor-associated antigens (TAAs) specific for ovarian cancer that are encapsulated in liposomes, with potential immunomodulating and antineoplastic activities. Upon administration of the liposome-encapsulated TAAs mRNA vaccine W_ova1, the liposomes bind to the plasma membrane of cells and release the mRNA into the cells. The mRNA is then translated by ribosomes to produce the TAAs. The TAAs are presented to the immune system which may activate both humoral and cellular immune responses against the ovarian cancer cells expressing these TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1","termGroup":"PT","termSource":"NCI"},{"termName":"BNT-115","termGroup":"CN","termSource":"NCI"},{"termName":"Liposome Formulated mRNA Vaccine W_ova1","termGroup":"SY","termSource":"NCI"},{"termName":"mRNA Vaccine W_ova1","termGroup":"SY","termSource":"NCI"},{"termName":"W_ova1","termGroup":"CN","termSource":"NCI"},{"termName":"W_ova1 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1"},{"name":"NCI_Drug_Dictionary_ID","value":"802273"},{"name":"NCI_META_CUI","value":"CL1411979"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802273"},{"name":"PDQ_Open_Trial_Search_ID","value":"802273"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172395":{"preferredName":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes","code":"C172395","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A02:01/24:02/11:01-restricted Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Upon administration, the autologous LMP1/LMP2/EBNA1-specific, HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001 recognize and bind to HLA-presented EBV peptides, which may promote cell death and inhibit the growth of tumor cells expressing LMP1, LMP2 or EBNA1. LMP1, LMP2, and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"LMP2 Antigen-specific TCR T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"801627"},{"name":"NCI_META_CUI","value":"CL1406351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801627"},{"name":"PDQ_Open_Trial_Search_ID","value":"801627"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169060":{"preferredName":"LMP7 Inhibitor M3258","code":"C169060","definitions":[{"definition":"An orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, Beta5i, PSMB8), a chymotrypsin-like, proteolytic subunit of the immunoproteasome, with potential antineoplastic activity. Upon oral administration, LMP7 inhibitor M3258 targets and inhibits the proteolytic activity of the LMP7 subunit of immunoproteasome, thereby blocking its deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. Proteasomes are large multi-subunit protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated, thereby restoring protein homeostasis. Unlike the constitutive proteasome, which is expressed in most tissues, immunoproteasome is specifically present in normal and malignant hematopoietic cells, including multiple myeloma. Immunoproteasome degrades ubiquitinated proteins, generates peptides for presentation on MHC class I, and plays a key role in the adaptive immune response and inflammatory diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP7 Inhibitor M3258","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoproteasome Inhibitor M3258","termGroup":"SY","termSource":"NCI"},{"termName":"M 3258","termGroup":"CN","termSource":"NCI"},{"termName":"M-3258","termGroup":"CN","termSource":"NCI"},{"termName":"M3258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LMP7 Inhibitor M3258"},{"name":"NCI_Drug_Dictionary_ID","value":"800618"},{"name":"NCI_META_CUI","value":"CL1378863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800618"},{"name":"PDQ_Open_Trial_Search_ID","value":"800618"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171102":{"preferredName":"LRP5 Antagonist BI 905681","code":"C171102","definitions":[{"definition":"An antagonist of the lipoprotein receptor-related protein (LRP) 5, with potential antineoplastic and immunomodulating activities. Upon administration, LRP5 antagonist BI 905681 targets and binds to LRP5, thereby blocking the binding of Wnt ligands to LRP5. This prevents the formation of the serpentine receptor Frizzled (FZD)-Wnt-LRP5 trimeric complex and prevents the inactivation of the beta-catenin degradation complex, which leads to beta-catenin degradation. This inhibits the Wnt/beta-catenin signaling pathway, prevents the beta-catenin-mediated activation of Wnt target genes, and inhibits the proliferation and survival of Wnt/beta-catenin-driven tumor cells. In addition, inhibition of Wnt signaling by BI 905681 prevents Wnt-mediated immune escape, thereby re-activating the immune system, specifically inducing the activation of dendritic cells (DCs) and activation as well as infiltration of cytotoxic T-cells into the tumor tissue. The FZD-Wnt-LRP5 trimeric complex induces phosphorylation of LRP5 intracellular domain leading to inactivation of the beta-catenin degradation complex, allowing beta-catenin accumulation; stabilized beta-catenin enters the nucleus and acts as a transcriptional activator of Wnt target genes. Wnt/beta-catenin signaling plays a key role in tumor cell proliferation and survival, and resistance to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRP5 Antagonist BI 905681","termGroup":"PT","termSource":"NCI"},{"termName":"BI 905681","termGroup":"CN","termSource":"NCI"},{"termName":"BI-905681","termGroup":"CN","termSource":"NCI"},{"termName":"BI905681","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LRP5 Antagonist BI 905681"},{"name":"NCI_Drug_Dictionary_ID","value":"802154"},{"name":"NCI_META_CUI","value":"CL1405341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802154"},{"name":"PDQ_Open_Trial_Search_ID","value":"802154"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173722":{"preferredName":"LSD1 Inhibitor SYHA1807","code":"C173722","definitions":[{"definition":"An orally available inhibitor of lysine-specific demethylase 1 (LSD1; KDM1A), with potential antineoplastic activity. Upon oral administration, LSD1 inhibitor SYHA1807 targets, binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1 is overexpressed in a number of tumor cell types. LSD1 acts on histone H3 as a transcription co-repressor through demethylation of lysine 4 (H3K4) or as a transcription co-activator through demethylation of lysine 9 (H3K9).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LSD1 Inhibitor SYHA1807","termGroup":"PT","termSource":"NCI"},{"termName":"Lysine-specific Demethylase 1 Inhibitor SYHA1807","termGroup":"SY","termSource":"NCI"},{"termName":"SYHA 1807","termGroup":"CN","termSource":"NCI"},{"termName":"SYHA-1807","termGroup":"CN","termSource":"NCI"},{"termName":"SYHA1807","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LSD1 Inhibitor SYHA1807"},{"name":"NCI_Drug_Dictionary_ID","value":"801980"},{"name":"NCI_META_CUI","value":"CL1407574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801980"},{"name":"PDQ_Open_Trial_Search_ID","value":"801980"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174423":{"preferredName":"Lutetium Lu 177-DTPA-omburtamab","code":"C174423","definitions":[{"definition":"A radioimmunoconjugate consisting of omburtamab, a murine immunoglobulin G1 (IgG1) antibody directed against the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3, CD276), conjugated, via the chelating agent diethylenetriaminepentaacetic acid (DTPA), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intracerebroventricular administration of lutetium Lu 177-DTPA-omburtamab, the omburtamab moiety binds to B7-H3 expressed on certain tumor cells. Upon binding, lutetium Lu 177-DTPA-omburtamab delivers a cytotoxic dose of beta radiation to B7-H3-expressing cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-DTPA-omburtamab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DTPA-omburtamab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177-DTPA-omburtamab"},{"name":"NCI_Drug_Dictionary_ID","value":"802279"},{"name":"NCI_META_CUI","value":"CL1411985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802279"},{"name":"PDQ_Open_Trial_Search_ID","value":"802279"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174518":{"preferredName":"Maackia amurensis Seed Lectin","code":"C174518","definitions":[{"definition":"A preparation of lectin extracted from the seeds of Maackia amurensis, with potential antineoplastic activity. Upon administration, Maackia amurensis seed lectin (MASL) may target and bind to podoplanin (PDPN), thereby blocking the activation of PDPN by endogenous ligands. This may inhibit tumor cell growth, migration and metastasis that result from PDPN activation. PDPN, a transmembrane receptor glycoprotein that is overexpressed in some cancer types, promotes tumor cell migration, invasion, and metastasis upon activation by various endogenous ligands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maackia amurensis Seed Lectin","termGroup":"PT","termSource":"NCI"},{"termName":"MASL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maackia amurensis Seed Lectin"},{"name":"NCI_Drug_Dictionary_ID","value":"802340"},{"name":"NCI_META_CUI","value":"CL1412017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802340"},{"name":"PDQ_Open_Trial_Search_ID","value":"802340"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166141":{"preferredName":"Macrocycle-bridged STING Agonist E7766","code":"C166141","definitions":[{"definition":"An agonist of macrocycle-bridged stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, macrocycle-bridged STING agonist (MBSA) E7766 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Compared to conventional STING agonists, MBSA E7766 allows for conformational rigidity of the unique macrocycle bridge which enhances its stability and STING affinity, thereby increasing its efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macrocycle-bridged STING Agonist E7766","termGroup":"PT","termSource":"NCI"},{"termName":"E 7766","termGroup":"CN","termSource":"NCI"},{"termName":"E-7766","termGroup":"CN","termSource":"NCI"},{"termName":"E7766","termGroup":"CN","termSource":"NCI"},{"termName":"MBSA E7766","termGroup":"SY","termSource":"NCI"},{"termName":"Stimulator of Interferon Genes Agonist E7766","termGroup":"SY","termSource":"NCI"},{"termName":"Sting Agonist E7766","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J81GDR86J9"},{"name":"Maps_To","value":"Macrocycle-bridged STING Agonist E7766"},{"name":"NCI_Drug_Dictionary_ID","value":"799924"},{"name":"NCI_META_CUI","value":"CL979196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799924"},{"name":"PDQ_Open_Trial_Search_ID","value":"799924"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174139":{"preferredName":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells","code":"C174139","definitions":[{"definition":"A preparation of autologous CD4- and CD8-positive T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets the human melanoma-associated antigen A1 (MAGE-A1), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A1-specific TCR-transduced autologous T-cells bind to tumor cells expressing MAGE-A1, which may halt the growth of and kill MAGE-A1-expressing cancer cells. MAGE-A1 is a tumor-associated antigen (TAA) overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells","termGroup":"PT","termSource":"NCI"},{"termName":"MAGE-A1-specific T Cell Receptor-transduced Autologous CD8+ and CD4+ T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A1-specific TCR-transduced Autologous T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802464"},{"name":"NCI_META_CUI","value":"CL1407779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802464"},{"name":"PDQ_Open_Trial_Search_ID","value":"802464"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174400":{"preferredName":"MCL-1 Inhibitor ABBV-467","code":"C174400","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor ABBV-467 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MCL-1 Inhibitor ABBV-467","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 467","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-467","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV467","termGroup":"CN","termSource":"NCI"},{"termName":"Myeloid Cell Leukemia-1 Inhibitor ABBV-467","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MCL-1 Inhibitor ABBV-467"},{"name":"NCI_Drug_Dictionary_ID","value":"802326"},{"name":"NCI_META_CUI","value":"CL1411952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802326"},{"name":"PDQ_Open_Trial_Search_ID","value":"802326"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171616":{"preferredName":"MDM2 Inhibitor AMGMDS3","code":"C171616","definitions":[{"definition":"An inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon administration, MDM2 inhibitor AMGMDS3 binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Inhibitor AMGMDS3","termGroup":"PT","termSource":"NCI"},{"termName":"2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AMGMDS3","termGroup":"CN","termSource":"NCI"},{"termName":"Q59770979","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MDM2 Inhibitor AMGMDS3"},{"name":"NCI_META_CUI","value":"CL1405838"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172382":{"preferredName":"MEK 1/2 Inhibitor FCN-159","code":"C172382","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration, MEK 1/2 Inhibitor FCN-159 selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK 1/2 Inhibitor FCN-159","termGroup":"PT","termSource":"NCI"},{"termName":"FCN 159","termGroup":"CN","termSource":"NCI"},{"termName":"FCN-159","termGroup":"CN","termSource":"NCI"},{"termName":"FCN159","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor FCN-159","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK 1/2 Inhibitor FCN-159"},{"name":"NCI_Drug_Dictionary_ID","value":"801657"},{"name":"NCI_META_CUI","value":"CL1406509"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801657"},{"name":"PDQ_Open_Trial_Search_ID","value":"801657"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173437":{"preferredName":"Tunlametinib","code":"C173437","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon administration, tunlametinib selectively binds to and inhibits the activity of MEK, preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a threonine/tyrosine kinase, plays a key role in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tunlametinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Fluoro-5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-6-benzothiazolecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"6-Benzothiazolecarboxamide, 4-fluoro-5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"HL 085","termGroup":"CN","termSource":"NCI"},{"termName":"HL-085","termGroup":"CN","termSource":"NCI"},{"termName":"HL085","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor HL-085","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801756-06-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IF25NR1PV3"},{"name":"Maps_To","value":"MEK Inhibitor HL-085"},{"name":"NCI_Drug_Dictionary_ID","value":"801764"},{"name":"NCI_META_CUI","value":"CL1407412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801764"},{"name":"PDQ_Open_Trial_Search_ID","value":"801764"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165776":{"preferredName":"Revumenib","code":"C165776","definitions":[{"definition":"An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Revumenib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613","termGroup":"SY","termSource":"NCI"},{"termName":"Menin-MLL Inhibitor SNDX-5613","termGroup":"SY","termSource":"NCI"},{"termName":"Menin-MLL Interaction Inhibitor SNDX-5613","termGroup":"SY","termSource":"NCI"},{"termName":"SNDX 5613","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX-5613","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX5613","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169919-21-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LZ0M43NNF2"},{"name":"Maps_To","value":"Menin-MLL Interaction Inhibitor SNDX-5613"},{"name":"NCI_Drug_Dictionary_ID","value":"800199"},{"name":"NCI_META_CUI","value":"CL978854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800199"},{"name":"PDQ_Open_Trial_Search_ID","value":"800199"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167188":{"preferredName":"Davutamig","code":"C167188","definitions":[{"definition":"A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, davutamig targets and binds to two different, non-overlapping epitopes on MET expressed on thd tumor cell surface, thereby forming unique davutamig-MET complexes. The binding of davutamig to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Davutamig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-c-Met Bispecific Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"MET x MET Bispecific Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"METxMET Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"METxMET Bispecific Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5093","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5093","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2648058-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N2H0RP6IHR"},{"name":"Maps_To","value":"MET x MET Bispecific Antibody REGN5093"},{"name":"NCI_Drug_Dictionary_ID","value":"800420"},{"name":"NCI_META_CUI","value":"CL972415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800420"},{"name":"PDQ_Open_Trial_Search_ID","value":"800420"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168544":{"preferredName":"Metarrestin","code":"C168544","definitions":[{"definition":"An orally available small molecule inhibitor of perinucleolar compartment (PNC), with potential antineoplastic activities. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon oral administration, metarrestin disrupts the structure of PNC and inhibits RNA polymerase (Pol) I transcription. This leads to the reduction in the prevalence of PNC in cancer cells and decrease in tumor growth and spread. PNC is a subnuclear structure and a phenotypic marker of metastatic cancer cells. A high PNC prevalence has been associated with disease progression and poor patient outcomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metarrestin","termGroup":"PT","termSource":"NCI"},{"termName":"ML 246","termGroup":"CN","termSource":"NCI"},{"termName":"ML-246","termGroup":"CN","termSource":"NCI"},{"termName":"ML246","termGroup":"CN","termSource":"NCI"},{"termName":"Trans-4-(7-benzyl-4-imino-5,6-diphenylpyrrolo[2,3-d]pyrimidin-3-yl)cyclohexan-1-ol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443414-10-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q6A9F9DSX5"},{"name":"Maps_To","value":"Metarrestin"},{"name":"NCI_Drug_Dictionary_ID","value":"800687"},{"name":"NCI_META_CUI","value":"CL972873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800687"},{"name":"PDQ_Open_Trial_Search_ID","value":"800687"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173446":{"preferredName":"Methylcantharidimide","code":"C173446","definitions":[{"definition":"An orally bioavailable derivative of the terpenoid cantharidin, which is a natural toxin extracted from blister beetles, with potential antineoplastic activity. Although the exact mechanism of action through which methylcantharidimide exerts its effect has yet to be fully elucidated, this agent, upon oral administration, may exert a direct tumor cell killing effect in susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylcantharidimide","termGroup":"PT","termSource":"NCI"},{"termName":"N-methylcantharidimide","termGroup":"SY","termSource":"NCI"},{"termName":"NMC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"76970-78-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"62T9S2Y75E"},{"name":"Maps_To","value":"Methylcantharidimide"},{"name":"NCI_Drug_Dictionary_ID","value":"801753"},{"name":"NCI_META_CUI","value":"CL1407421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801753"},{"name":"PDQ_Open_Trial_Search_ID","value":"801753"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171422":{"preferredName":"Microbiome GEN-001","code":"C171422","definitions":[{"definition":"A microbiome therapeutic composed of a single-strain bacterium, isolated from the gut of healthy donors, with potential anti-tumor and immunomodulating activities. Upon oral administration, the metabolites of GEN-001 may activate dendritic cells and macrophages in the gut and increase the expression of the cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15), which stimulates the proliferation of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. GEN-001 may improve therapeutic responses to other therapies, such as anti-PD-1 therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microbiome GEN-001","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 001","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-001","termGroup":"CN","termSource":"NCI"},{"termName":"GEN001","termGroup":"CN","termSource":"NCI"},{"termName":"Microbiome-based Therapeutic GEN-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microbiome GEN-001"},{"name":"NCI_Drug_Dictionary_ID","value":"801465"},{"name":"NCI_META_CUI","value":"CL1405526"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801465"},{"name":"PDQ_Open_Trial_Search_ID","value":"801465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165646":{"preferredName":"Microbiome-derived Peptide Vaccine EO2401","code":"C165646","definitions":[{"definition":"A donor-derived, off-the-shelf, microbiome therapeutic cancer peptide vaccine composed of three bacterial onco-mimics, immunogenic microbiome-derived peptides that are highly homologous to tumor-associated antigens (TAAs), that are obtained and selected from the human gut microbiome and are specific for brain tumors, including glioblastoma, with potential immunomodulating and antineoplastic activities. The three microbiome-derived bacterial antigens in EO2401 mimic three TAAs that are highly expressed by brain tumors. Upon administration of microbiome-derived peptide vaccine EO2401, the peptides are taken up by and presented on dendritic cells (DCs) to T-cells. As the presented antigens display molecular mimicry with selected TAAs on brain cancer cells, a memory T-cell and cytotoxic T-lymphocyte (CTL)-mediated immune response may be mounted against the TAAs expressed on the brain cancer cells, thereby eradicating the brain cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microbiome-derived Peptide Vaccine EO2401","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine EO2401","termGroup":"SY","termSource":"NCI"},{"termName":"EO 2401","termGroup":"CN","termSource":"NCI"},{"termName":"EO-2401","termGroup":"CN","termSource":"NCI"},{"termName":"EO2401","termGroup":"CN","termSource":"NCI"},{"termName":"Microbial-derived Peptide Vaccine EO2401","termGroup":"SY","termSource":"NCI"},{"termName":"Microbiome-derived Therapeutic Cancer Vaccine EO2401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microbiome-derived Peptide Vaccine EO2401"},{"name":"NCI_Drug_Dictionary_ID","value":"799761"},{"name":"NCI_META_CUI","value":"CL978949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799761"},{"name":"PDQ_Open_Trial_Search_ID","value":"799761"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167362":{"preferredName":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208","code":"C167362","definitions":[{"definition":"A booster cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) Bavarian Nordic (MVA-BN) strain encoding the oncogenic human papillomavirus types 16 (HPV16) and 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of MVA-vectored HPV16/18 vaccine JNJ-65195208, and after the administration of the prime vaccine(s) adenovirus serotype 26 (Ad26)-expressing HPV16 vaccine JNJ-63682918 and/or Ad26-expressing HPV18 vaccine JNJ-63682931, this vaccine further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16/18 proteins, resulting in tumor cell lysis. HPV16/18 infection plays a key role in the development of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 65195208","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-65195208","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ65195208","termGroup":"CN","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara-HPV16/18 JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA BN HPV16/18 JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-HPV16/18 Vaccine JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-vectored HPV16/18 Vaccine JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-vectored Vaccine JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA.HPV16/18 JNJ-65195208","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208"},{"name":"NCI_META_CUI","value":"CL972336"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174519":{"preferredName":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells","code":"C174519","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) loaded with the human tumor-associated antigens (TAAs) mucin-1 (MUC1) and Wilms tumor protein 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon vaccination, the MUC-1/WT1 peptide-primed autologous DCs expose the immune system to MUC1 and WT1 peptides and may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against MUC1 and WT1-expressing cancer cells, which could result in cancer cell lysis. MUC1 and WT1, are overexpressed in a variety of tumor types and play an important role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells","termGroup":"PT","termSource":"NCI"},{"termName":"MUC-1/WT1 Peptide-loaded Autologous Dendritic Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MUC-1/WT1 Peptide-primed Autologous DCs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802334"},{"name":"NCI_META_CUI","value":"CL1411835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802334"},{"name":"PDQ_Open_Trial_Search_ID","value":"802334"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173525":{"preferredName":"Multi-epitope HER2 Peptide Vaccine TPIV100","code":"C173525","definitions":[{"definition":"A cancer peptide vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. Upon administration of the multi-epitope HER2 peptide vaccine TPIV100, the four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types. To enhance immunity, the peptides are admixed with the adjuvant granulocyte macrophage-colony-stimulating factor (GM-CSF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-epitope HER2 Peptide Vaccine TPIV100","termGroup":"PT","termSource":"NCI"},{"termName":"HER2/Neu Peptide Vaccine TPIV100","termGroup":"SY","termSource":"NCI"},{"termName":"Peptide Vaccine TPIV100","termGroup":"SY","termSource":"NCI"},{"termName":"TPIV 100","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV-100","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-epitope HER2 Peptide Vaccine TPIV100"},{"name":"NCI_Drug_Dictionary_ID","value":"802235"},{"name":"NCI_META_CUI","value":"CL1407515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802235"},{"name":"PDQ_Open_Trial_Search_ID","value":"802235"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175526":{"preferredName":"Muscadine Grape Extract","code":"C175526","definitions":[{"definition":"An extract derived from the Muscadine grape (Vitis rotundifolia), with potential anti-inflammatory, antioxidant, anti-lipidemic and chemopreventive activities. The muscadine grape extract (MGE) contains numerous phytochemicals including hydrolyzable tannins and flavonoids, such as resveratrol, anthocyanin 3,5-diglucosides, quercetin, ellagic acid, myricetin, and kaempferol glycosides. Upon administration, the active components in the MGE scavenge free radicals, protect against oxidation of low-density lipoprotein (LDL), and inhibit cell damage due to reactive oxygen species (ROS). This inhibits oxidative stress and protects against DNA damage. MGE also inhibits enzymes involved in inflammation, cell replication and DNA synthesis, and induces the expression of anti-oxidant enzymes. The active ingredients may also inhibit certain signaling pathways upregulated in some tumor cell types, eventually leading to apoptosis and a reduction in tumor cell proliferation. MGE may also boost energy and prevent fatigue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Muscadine Grape Extract","termGroup":"PT","termSource":"NCI"},{"termName":"MGE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscadine Grape Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"803286"},{"name":"NCI_META_CUI","value":"CL1412905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803286"},{"name":"PDQ_Open_Trial_Search_ID","value":"803286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173552":{"preferredName":"MVA-BN Smallpox Vaccine","code":"C173552","definitions":[{"definition":"A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, with potential antineoplastic activity. Upon intratumoral administration, MVA-BN smallpox vaccine may induce both cellular and humoral immune responses, which may lead to tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVA-BN Smallpox Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Imvamune","termGroup":"FB","termSource":"NCI"},{"termName":"Imvanex","termGroup":"FB","termSource":"NCI"},{"termName":"JYNNEOS","termGroup":"BR","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara - Bavarian Nordic Smallpox Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara Smallpox Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"MVA Smallpox Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1026718-04-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TU8J357395"},{"name":"Maps_To","value":"MVA-BN Smallpox Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"801908"},{"name":"NCI_META_CUI","value":"CL1407321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801908"},{"name":"PDQ_Open_Trial_Search_ID","value":"801908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173438":{"preferredName":"N-dihydrogalactochitosan","code":"C173438","definitions":[{"definition":"A carbohyrate polymer in which galactose molecules are attached to the amino groups of the glucosamine polymer chitosan, with potential imunostimulating activity. After a tumor ablation and upon intratumoral injection directly into the location of the ablated tumor, N-dihydrogalactochitosan may trigger a tumor-specific systemic immune response when exposed to tumor-associated neoantigens that are liberated by tumor ablation. This may kill tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N-dihydrogalactochitosan","termGroup":"PT","termSource":"NCI"},{"termName":"IP 001","termGroup":"CN","termSource":"NCI"},{"termName":"IP-001","termGroup":"CN","termSource":"NCI"},{"termName":"IP001","termGroup":"CN","termSource":"NCI"},{"termName":"N-dihydro-galacto-chitosan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N-dihydrogalactochitosan"},{"name":"NCI_Drug_Dictionary_ID","value":"801765"},{"name":"NCI_META_CUI","value":"CL1407413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801765"},{"name":"PDQ_Open_Trial_Search_ID","value":"801765"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170752":{"preferredName":"Oligo-fucoidan","code":"C170752","definitions":[{"definition":"A sulfated polysaccharide low-molecular-weight fucoidan, with potential antioxidant, anti-inflammatory, antiproliferative, anti-angiogenic and pro-apoptotic activities. Upon administration of oligo-fucoidan, this agent seems to exert numerous effects through various mechanisms of action, some of which remain to be fully elucidated. Oligo-fucoidan induces cell cycle arrest, activates caspases, induces apoptosis, and inhibits tumor cell proliferation in susceptible tumor cells. It also increases the expression of tumor suppressors, such as p53, while decreasing levels of certain tumor promoters. Oligo-fucoidan also promotes the degradation of transforming growth factor-beta (TGFb) receptor and the inhibition of epithelial-mesenchymal transition (EMT). It prevents tumor progression, alters tumor microenvironment (TME) and decreases the tumor-promoting M2 macrophages in the TME. Oligo-fucoidan has anti-inflammatory effects that suppress the expression of nitric oxide synthase (iNOS), cyclooxygenase (COX)-2 and monocyte chemoattractant protein-1 (MCP-1/CCL2), and decrease the production of certain pro-inflammatory cytokines, such as interleukin-1beta (IL-1b) and tumor necrosis factor (TNF)-alpha (TNFa). This agent may also suppress angiogenic activity by inhibiting vascular endothelial growth factor (VEGF) receptor expression and VEGF-induced endothelial cell proliferation. As an antioxidant, this agent protects cells against oxidative stress by scavenging superoxide radicals and induces the expression of the anti-oxidant nuclear factor erythroid-2-related factor 2 and that of its target gene, superoxide dismutase; and prevents reactive oxidative species (ROS) generation in cancer cells and ROS release into the TME. Fucoidan also has immune-modulatory effects and enhances the proliferation of natural killer (NKs) cells and cytotoxic T-cells (CTLs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligo-fucoidan","termGroup":"PT","termSource":"NCI"},{"termName":"Low-molecular-weight Fucoidan","termGroup":"SY","termSource":"NCI"},{"termName":"Oligo Fucoidan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oligo-fucoidan"},{"name":"NCI_Drug_Dictionary_ID","value":"800738"},{"name":"NCI_META_CUI","value":"CL1383150"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800738"},{"name":"PDQ_Open_Trial_Search_ID","value":"800738"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168607":{"preferredName":"Oncolytic Adenovirus ORCA-010","code":"C168607","definitions":[{"definition":"A replication competent, oncolytic adenovirus serotype 5 (Ad5) that has been modified with a delta24 (d24) deletion, an incorporation of an RGD-4C motif in the Ad fiber protein, and an insertion of the T1 mutation in E3/19K gene, with potential oncolytic activity. Upon administration, oncolytic adenovirus ORCA-010 binds to specific Ad3 receptors that are highly expressed on certain tumor cells. This results in the replication of oncolytic adenovirus Ad5/3-delta24 in tumor cells and induces tumor cell lysis which may potentially result in the activation of a systemic immune response against tumor-associated antigens (TAAs). The Ad5/3-delta24 has a 24 base pair deletion in constant region 2 of the E1A gene which allows for selective replication in cells that are defective in the retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (CDKN2A or p16INK4a). As most tumor cells are defective in the Rb/p16 pathway, this virus selectively replicates in these cells. The RGD-4C motif is a 9-amino acid peptide that binds to various and enhances viral-cell receptor binding by allowing for a Coxsackie-adenovirus receptor (CAR)-independent infection of tumor cells, which is the natural route of viral binding, as CAR expression is often deficient on cancer cells. As integrins are often overexpressed on tumor cell surfaces, integrin receptor binding enhances tumor cells binding and infection by the Ad. The T1 mutation enhances the Ad5 release from tumor cells and promotes spreading throughout the tumor, thereby enhancing anti-tumor activity. The T1 mutation, a single Adenine insertion at position 445 of the nucleotide sequence of the E3/19K gene of Adenovirus, creates a truncated E3/19K protein that is relocated to the plasma membrane due to the disruption of its ER retention signal. This increases plasma membrane permeability and enhances the release of Ad5.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Adenovirus ORCA-010","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Ad5 ORCA-010","termGroup":"SY","termSource":"NCI"},{"termName":"ORCA 010","termGroup":"CN","termSource":"NCI"},{"termName":"ORCA-010","termGroup":"CN","termSource":"NCI"},{"termName":"ORCA010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Adenovirus ORCA-010"},{"name":"NCI_Drug_Dictionary_ID","value":"800320"},{"name":"NCI_META_CUI","value":"CL972811"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800320"},{"name":"PDQ_Open_Trial_Search_ID","value":"800320"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C171540":{"preferredName":"Oncolytic Herpes Simplex Virus-1 ONCR-177","code":"C171540","definitions":[{"definition":"A recombinant, genetically modified, microRNA (miRNA)-attenuated oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. In ONCR-177, a dual bidirectional promoter enables the expression of five different transgenes: the natural killer (NK) cell and T-cell activating cytokine interleuin-12 (IL-12), the chemokines C-C motif chemokine 4 (CCL4) and the extracellular domain of the Fms-related tyrosine kinase 3 ligand (FLT3LG), to allow for expansion and recruitment of classical dendritic cells (DCs), and antagonists to the immune checkpoints programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to counter T cell exhaustion. Upon intra-tumoral administration, the oncolytic HSV-1 ONCR-177 specifically targets, infects and selectively replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles then infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. In addition, the expressed transgenes that are released upon tumor cell lysis induce a systemic tumor-specific immune response and activate NKs, DCs and cytotoxic T-lymphocytes (CTLs) while inhibiting regulatory T-cells (Tregs). This further kills nearby non-infected tumor cells. In ONCR-177, the neurovirulence gene ICP34.5 allows for potent oncolysis, even in the presence of host cell antiviral responses. To ensure selective replication and oncolysis in cancer cells while attenuating replication in healthy tissue, tissue specific miRNA-binding cassettes (miR-T) are inserted into early genes essential for viral replication. In addition, UL37 mutation suppresses latent infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Herpes Simplex Virus-1 ONCR-177","termGroup":"PT","termSource":"NCI"},{"termName":"oHSV-1 ONCR-177","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic HSV-1 ONCR-177","termGroup":"SY","termSource":"NCI"},{"termName":"ONCR 177","termGroup":"CN","termSource":"NCI"},{"termName":"ONCR-177","termGroup":"CN","termSource":"NCI"},{"termName":"ONCR177","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"83P3OQ67ZT"},{"name":"Maps_To","value":"Oncolytic Herpes Simplex Virus-1 ONCR-177"},{"name":"NCI_Drug_Dictionary_ID","value":"802000"},{"name":"NCI_META_CUI","value":"CL1405762"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802000"},{"name":"PDQ_Open_Trial_Search_ID","value":"802000"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C175473":{"preferredName":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","code":"C175473","definitions":[{"definition":"A genetically engineered oncolytic herpes simplex virus type 1 (oHSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12) and an antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intratumoral administration, oHSV-1 expressing IL-12 and anti-PD-1 antibody T3011 infects and replicates in tumor cells causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In addition, oHSV-1 expressing IL-12 and anti-PD-1 antibody T3011 promotes the secretion of IL-12 and anti-PD-1 antibody by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Anti-PD-1 antibody targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","termGroup":"PT","termSource":"NCI"},{"termName":"MVR-T3011","termGroup":"CN","termSource":"NCI"},{"termName":"oHSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic HSV-1 Expressing IL-12 and PD-1 Antibody T3011","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic HSV-1 Expressing IL-12/Anti-PD-1 Antibody T3011","termGroup":"SY","termSource":"NCI"},{"termName":"T 3011","termGroup":"CN","termSource":"NCI"},{"termName":"T-3011","termGroup":"CN","termSource":"NCI"},{"termName":"T3011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011"},{"name":"NCI_Drug_Dictionary_ID","value":"802928"},{"name":"NCI_META_CUI","value":"CL1412848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802928"},{"name":"PDQ_Open_Trial_Search_ID","value":"802928"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173889":{"preferredName":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein","code":"C173889","definitions":[{"definition":"An attenuated oncolytic Edmonston (Ed) strain of measles virus (MV) encoding the N-terminus of the human lambda immunoglobulin light chain containing the Helicobacter pylori neutrophil-activating protein (NAP), with potential immunostimulating and antineoplastic activities. Upon administration, the oncolytic measles virus encoding H. pylori NAP selectively infects and replicates in tumor cells, leading to syncytia formation and tumor cell lysis. The expressed NAP, a toll-like receptor-2 (TLR2) agonist, may stimulate the secretion of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1 and IL-6, leading to local inflammatory reaction in the tumor microenvironment (TME). H. pylori NAP, a bacterial antigen and potent immunomodulator, may enhance the antitumor effect of oncolytic MV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein","termGroup":"PT","termSource":"NCI"},{"termName":"MV Encoding NAP","termGroup":"SY","termSource":"NCI"},{"termName":"MV-s-NAP","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Measles Virus Encoding H. pylori NAP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein"},{"name":"NCI_Drug_Dictionary_ID","value":"802401"},{"name":"NCI_META_CUI","value":"CL1407687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802401"},{"name":"PDQ_Open_Trial_Search_ID","value":"802401"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C172098":{"preferredName":"Oxaliplatin Eluting Beads","code":"C172098","definitions":[{"definition":"A formulation of drug-eluting beads (DEB) consisting of polymeric microbeads impregnated with the organoplatinum complex and alkylating agent oxaliplatin, with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with oxaliplatin. During transarterial chemoembolization (TACE) in the hepatic artery, the oxaliplatin eluting beads occlude tumor blood vessels that feed the tumor and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. The beads release cytotoxic oxaliplatin locally, which may result in oxaliplatin-mediated inhibition of tumor cell proliferation through formation of both inter- and intra-strand platinum-DNA crosslinks, and the inhibition of DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxaliplatin Eluting Beads","termGroup":"PT","termSource":"NCI"},{"termName":"CalliSpheres Drug-Eluting Beads with Oxaliplatin","termGroup":"SY","termSource":"NCI"},{"termName":"DEB with Oxaliplatin","termGroup":"SY","termSource":"NCI"},{"termName":"Deboxa","termGroup":"SY","termSource":"NCI"},{"termName":"Drug-Eluting Beads with Oxaliplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oxaliplatin Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"801475"},{"name":"NCI_META_CUI","value":"CL1406222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801475"},{"name":"PDQ_Open_Trial_Search_ID","value":"801475"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167257":{"preferredName":"p97 Inhibitor CB-5339","code":"C167257","definitions":[{"definition":"An orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including ER-associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p97 Inhibitor CB-5339","termGroup":"PT","termSource":"NCI"},{"termName":"CB 5339","termGroup":"CN","termSource":"NCI"},{"termName":"CB-5339","termGroup":"CN","termSource":"NCI"},{"termName":"CB5339","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p97 Inhibitor CB-5339"},{"name":"NCI_Drug_Dictionary_ID","value":"800449"},{"name":"NCI_META_CUI","value":"CL972245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800449"},{"name":"PDQ_Open_Trial_Search_ID","value":"800449"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167262":{"preferredName":"p97 Inhibitor CB-5339 Tosylate","code":"C167262","definitions":[{"definition":"The tosylate salt of  CB-5339, an orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including endoplasmic reticulum associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p97 Inhibitor CB-5339 Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"CB 5339 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"CB-5339 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"CB5339 Tosylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p97 Inhibitor CB-5339 Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"800450"},{"name":"NCI_META_CUI","value":"CL972249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800450"},{"name":"PDQ_Open_Trial_Search_ID","value":"800450"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166138":{"preferredName":"Pan-KRAS Inhibitor BI 1701963","code":"C166138","definitions":[{"definition":"An orally available protein-protein interaction (PPI) inhibitor that targets the guanine nucleotide exchange factor Son of sevenless homolog 1 (SOS1), with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BI 1701963 selectively targets and binds to SOS1, thereby preventing the interaction of SOS1 with Kirsten rat sarcoma viral oncogene homolog (KRAS) in the guanosine diphosphate (GDP)-bound 'off' state, which is the inactivated state of KRAS. This abrogates the exchange of RAS-bound GDP for guanosine triphosphate (GTP) and prevents the formation of GTP-loaded KRAS, which is the activated 'on' state of KRAS. This prevents activation of downstream RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway by GTP-loaded KRAS. This inhibits mutant KRAS-dependent signaling and may inhibit growth and survival of KRAS-expressing tumor cells. KRAS is a member of the RAS family of oncogenes that is mutated in many cancer cell types. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, survival, invasion, and metastasis. SOS1 regulates the KRAS GDP-GTP cycle and promotes nucleotide exchange and formation of 'active' KRAS-GTP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-KRAS Inhibitor BI 1701963","termGroup":"PT","termSource":"NCI"},{"termName":"BI 1701963","termGroup":"CN","termSource":"NCI"},{"termName":"BI-1701963","termGroup":"CN","termSource":"NCI"},{"termName":"BI1701963","termGroup":"CN","termSource":"NCI"},{"termName":"PPI Inhibitor BI 1701963","termGroup":"SY","termSource":"NCI"},{"termName":"Protein-protein Interaction Inhibitor BI 1701963","termGroup":"SY","termSource":"NCI"},{"termName":"SOS1:KRAS Interaction Inhibitor BI 1701963","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-KRAS Inhibitor BI 1701963"},{"name":"NCI_Drug_Dictionary_ID","value":"799903"},{"name":"NCI_META_CUI","value":"CL979206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799903"},{"name":"PDQ_Open_Trial_Search_ID","value":"799903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165567":{"preferredName":"Zipalertinib","code":"C165567","definitions":[{"definition":"An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), with potential antineoplastic activity. CLN-081 is also active against other EGFR mutations including exon 19 deletions (exon19del), L858R, and T790M, as well as the less common G719X, L861Q and S768I mutations. Upon administration, zipalertinib specifically and covalently binds to and inhibits a variety of EGFR mutations, with particularly high selectivity against EGFR Ex20ins, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CLN-081 may have therapeutic benefits in tumors with EGFR Ex20ins, as most EGFR mutant-selective inhibitors are not active against EGFR Ex20ins. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zipalertinib","termGroup":"PT","termSource":"NCI"},{"termName":"CLN 081","termGroup":"CN","termSource":"NCI"},{"termName":"CLN-081","termGroup":"CN","termSource":"NCI"},{"termName":"CLN081","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR Mutant-specific Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"Mutation-specific EGFR TKI TAS6417","termGroup":"SY","termSource":"NCI"},{"termName":"Pan- EGFR Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-mutation-selective EGFR Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-mutation-selective EGFR Tyrosine Kinase Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"TAS 6417","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-6417","termGroup":"CN","termSource":"NCI"},{"termName":"TAS6417","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1661854-97-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T4YMU8TW9H"},{"name":"Maps_To","value":"Pan-mutation-selective EGFR Inhibitor CLN-081"},{"name":"NCI_Drug_Dictionary_ID","value":"799981"},{"name":"NCI_META_CUI","value":"CL978830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799981"},{"name":"PDQ_Open_Trial_Search_ID","value":"799981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172394":{"preferredName":"Boditrectinib","code":"C172394","definitions":[{"definition":"An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, boditrectinib specifically targets and binds to TRK, TRK mutations and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC). This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Boditrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"AUM-601","termGroup":"CN","termSource":"NCI"},{"termName":"CHC 2014","termGroup":"CN","termSource":"NCI"},{"termName":"CHC-2014","termGroup":"CN","termSource":"NCI"},{"termName":"HL5101","termGroup":"CN","termSource":"NCI"},{"termName":"NOV 1601","termGroup":"CN","termSource":"NCI"},{"termName":"NOV-1601","termGroup":"CN","termSource":"NCI"},{"termName":"NOV1601","termGroup":"CN","termSource":"NCI"},{"termName":"Pan-TRK Inhibitor NOV1601","termGroup":"SY","termSource":"NCI"},{"termName":"TRK Inhibitor NOV1601","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1940165-80-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M359MC7QGE"},{"name":"Maps_To","value":"Pan-TRK Inhibitor NOV1601"},{"name":"NCI_Drug_Dictionary_ID","value":"801625"},{"name":"NCI_META_CUI","value":"CL1406349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801625"},{"name":"PDQ_Open_Trial_Search_ID","value":"801625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168601":{"preferredName":"Senaparib","code":"C168601","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, senaparib selectively binds to PARP 1 and 2 and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Senaparib","termGroup":"PT","termSource":"NCI"},{"termName":"IMP 4297","termGroup":"CN","termSource":"NCI"},{"termName":"IMP-4297","termGroup":"CN","termSource":"NCI"},{"termName":"IMP4297","termGroup":"CN","termSource":"NCI"},{"termName":"PARP 1/2 Inhibitor IMP4297","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401682-78-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MNZ4OP95CF"},{"name":"Maps_To","value":"PARP 1/2 Inhibitor IMP4297"},{"name":"NCI_Drug_Dictionary_ID","value":"800374"},{"name":"NCI_META_CUI","value":"CL972916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800374"},{"name":"PDQ_Open_Trial_Search_ID","value":"800374"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167278":{"preferredName":"PARP Inhibitor NMS-03305293","code":"C167278","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, PARP inhibitor NMS-03305293 selectively binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor NMS-03305293","termGroup":"PT","termSource":"NCI"},{"termName":"NMS 03305293","termGroup":"CN","termSource":"NCI"},{"termName":"NMS-03305293","termGroup":"CN","termSource":"NCI"},{"termName":"NMS03305293","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP Inhibitor NMS-03305293"},{"name":"NCI_Drug_Dictionary_ID","value":"802331"},{"name":"NCI_META_CUI","value":"CL972264"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802331"},{"name":"PDQ_Open_Trial_Search_ID","value":"802331"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170764":{"preferredName":"Atamparib","code":"C170764","definitions":[{"definition":"An orally available small molecule inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration,atamparib selectively binds to PARP7 and restores interferon (type 1) signaling.  This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atamparib","termGroup":"PT","termSource":"NCI"},{"termName":"PARP7 Inhibitor RBN-2397","termGroup":"SY","termSource":"NCI"},{"termName":"RBN 2397","termGroup":"CN","termSource":"NCI"},{"termName":"RBN-2397","termGroup":"CN","termSource":"NCI"},{"termName":"RBN2397","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2381037-82-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B1MW2ME77A"},{"name":"Maps_To","value":"PARP7 Inhibitor RBN-2397"},{"name":"NCI_Drug_Dictionary_ID","value":"800790"},{"name":"NCI_META_CUI","value":"CL1383178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800790"},{"name":"PDQ_Open_Trial_Search_ID","value":"800790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166387":{"preferredName":"Parsaclisib Hydrochloride","code":"C166387","definitions":[{"definition":"The hydrochloride salt form of parsaclisib, an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parsaclisib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(4R)-4-(3-((1S)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-onehydrochloric Acid (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, Hydrochloride (1:1), (4R)-","termGroup":"SY","termSource":"NCI"},{"termName":"INCB 50465 Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"INCB050465 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1995889-48-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S0GJ8VM4P9"},{"name":"Maps_To","value":"Parsaclisib Hydrochloride"},{"name":"NCI_META_CUI","value":"CL971639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167207":{"preferredName":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201","code":"C167207","definitions":[{"definition":"A T-regulatory (Treg) cell donor graft that has been partially engineered by depleting all the T-cells and then enriching the graft with infusions of conventional T-cells, Tregs and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors, with potential immunomodulating activity. Upon administration of the partially engineered T-regulatory cell donor graft TRGFT-201 following myeloablation, the allograft may induce tolerance in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) as treatment for hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201","termGroup":"PT","termSource":"NCI"},{"termName":"Orca-T","termGroup":"BR","termSource":"NCI"},{"termName":"Partially Engineered and Enriched Treg Donor Graft TRGFT-201","termGroup":"SY","termSource":"NCI"},{"termName":"T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"TregGraft","termGroup":"BR","termSource":"NCI"},{"termName":"TRGFT 201","termGroup":"CN","termSource":"NCI"},{"termName":"TRGFT-201","termGroup":"CN","termSource":"NCI"},{"termName":"TRGFT201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201"},{"name":"NCI_Drug_Dictionary_ID","value":"800419"},{"name":"NCI_META_CUI","value":"CL972434"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800419"},{"name":"PDQ_Open_Trial_Search_ID","value":"800419"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170900":{"preferredName":"PD-L1 Inhibitor GS-4224","code":"C170900","definitions":[{"definition":"An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory, anti-viral and antineoplastic activities. Upon administration, PD-L1 inhibitor GS-4224 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. It may also enhance hepatitis B virus (HBV)-specific CD8+ T-cell function, thereby killing HBV-infected cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells. It is also upregulated in HBV-positive patients and contributes to immune dysfunction against HBV infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1 Inhibitor GS-4224","termGroup":"PT","termSource":"NCI"},{"termName":"GS 4224","termGroup":"CN","termSource":"NCI"},{"termName":"GS-4224","termGroup":"CN","termSource":"NCI"},{"termName":"GS4224","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 Ligand 1 Inhibitor GS-4224","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-L1 Inhibitor GS-4224"},{"name":"NCI_Drug_Dictionary_ID","value":"800806"},{"name":"NCI_META_CUI","value":"CL1383048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800806"},{"name":"PDQ_Open_Trial_Search_ID","value":"800806"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174020":{"preferredName":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480","code":"C174020","definitions":[{"definition":"A recombinant, trispecific monovalent antibody-based molecule targeting the human programmed death-ligand 1 (PD-L1), 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and human serum albumin (HSA), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. PD-L1/4-1BB/HSA trispecific fusion protein NM21-1480 consists of three monovalent antibody Fvs specific for PD-L1, HSA and 4-1BB fused in a single chain. Upon administration, PD-L1/4-1BB/HSA trispecific fusion protein NM21-1480 simultaneously targets and binds to a membrane-distal epitope of 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. The simultaneous binding to PD-L1 enables clustering of 4-1BB and thereby allows for conditional stimulation of 4-1BB signaling in the tumor microenvironment (TME) only upon binding to PD-L1 on tumor cells. 4-1BB activation results in T-cell stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, NM21-1480 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. HSA fusion prolongs the half-life of NM21-1480. The conditional activation of 4-1BB signaling prevents systemic T-cell activation and lowers toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480","termGroup":"PT","termSource":"NCI"},{"termName":"alphaPD-L1/4-1BB/HSA NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"alphaPD-L1/alpha4-1BB/alphaHSA NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"ND 021","termGroup":"CN","termSource":"NCI"},{"termName":"ND-021","termGroup":"CN","termSource":"NCI"},{"termName":"ND021","termGroup":"CN","termSource":"NCI"},{"termName":"NM21 1480","termGroup":"CN","termSource":"NCI"},{"termName":"NM21-1480","termGroup":"CN","termSource":"NCI"},{"termName":"NM211480","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1/4-1BB/HSA Trispecific scDb-scFv NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"PD-L1/4-1BB/HSA Trispecific scMATCH3 NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"Trispecific Anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) scFv Fusion Protein NM21-1480","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E6OIF2QOI3"},{"name":"Maps_To","value":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480"},{"name":"NCI_Drug_Dictionary_ID","value":"802455"},{"name":"NCI_META_CUI","value":"CL1407921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802455"},{"name":"PDQ_Open_Trial_Search_ID","value":"802455"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167334":{"preferredName":"Pegylated SN-38 Conjugate PLX038","code":"C167334","definitions":[{"definition":"A pegylated conjugate of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon administration, the proprietary linker slowly releases SN-38 from the pegylated SN-38 conjugate PLX038. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Compared with irinotecan, this formulation allows higher accumulation in solid tumors due to its nanoparticle size and long half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated SN-38 Conjugate PLX038","termGroup":"PT","termSource":"NCI"},{"termName":"Pegylated SN-38 PLX038","termGroup":"SY","termSource":"NCI"},{"termName":"PLX 038","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-038","termGroup":"CN","termSource":"NCI"},{"termName":"PLX038","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated SN-38 Conjugate PLX038"},{"name":"NCI_Drug_Dictionary_ID","value":"800470"},{"name":"NCI_META_CUI","value":"CL972311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800470"},{"name":"PDQ_Open_Trial_Search_ID","value":"800470"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173152":{"preferredName":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC","code":"C173152","definitions":[{"definition":"A peptide-based, personalized cancer therapeutic vaccine consisting of up to 8 patient-specific tumor peptides, which are immunogenic and unique to the patient's tumor and identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), with potential immunomodulating and antineoplastic activities. Upon administration, personalized and adjusted neoantigen peptide vaccine PANDA-VAC stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens. The vaccine may be adjusted after initial therapy according to sequencing data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC","termGroup":"PT","termSource":"NCI"},{"termName":"PANDA-VAC","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen Peptide Vaccine PANDA-VAC","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen Peptide-poly-ICLC Vaccine PANDA-VAC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC"},{"name":"NCI_Drug_Dictionary_ID","value":"802057"},{"name":"NCI_META_CUI","value":"CL1407017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802057"},{"name":"PDQ_Open_Trial_Search_ID","value":"802057"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171430":{"preferredName":"Personalized Neoantigen DNA Vaccine GNOS-PV01","code":"C171430","definitions":[{"definition":"A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon administration of GNOS-PV01, the patient-specific neoantigens are translated in cells and elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. Each patient specific formulation may contain multiple DNA plasmids, and each plasmid may contain multiple neoantigen DNA sequences, allowing the delivery of multiple neoantigen DNA sequences simultaneously.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoantigen DNA Vaccine GNOS-PV01","termGroup":"PT","termSource":"NCI"},{"termName":"GNOS-PV01","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen Vaccine GNOS-PV01","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen-based Vaccine GNOS-PV01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoantigen DNA Vaccine GNOS-PV01"},{"name":"NCI_Drug_Dictionary_ID","value":"801973"},{"name":"NCI_META_CUI","value":"CL1405519"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801973"},{"name":"PDQ_Open_Trial_Search_ID","value":"801973"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170950":{"preferredName":"Personalized Neoantigen DNA Vaccine GNOS-PVO2","code":"C170950","definitions":[{"definition":"A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon intradermal delivery by electroporation of GNOS-PVO2, the patient-specific neoantigens are translated in cells and elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. Each patient specific formulation may contain multiple DNA plasmids, and each plasmid may contain multiple neoantigen DNA sequences, allowing the delivery of multiple neoantigen DNA sequences simultaneously.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoantigen DNA Vaccine GNOS-PVO2","termGroup":"PT","termSource":"NCI"},{"termName":"GNOS-PVO2","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen Vaccine GNOS-PVO2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoantigen DNA Vaccine GNOS-PVO2"},{"name":"NCI_Drug_Dictionary_ID","value":"801211"},{"name":"NCI_META_CUI","value":"CL1383225"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801211"},{"name":"PDQ_Open_Trial_Search_ID","value":"801211"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172822":{"preferredName":"Photodynamic Compound TLD-1433","code":"C172822","definitions":[{"definition":"A non-toxic ruthenium-based coordination-complex and photosensitizer, with potential antineoplastic activity upon photodynamic therapy (PDT). Upon intravesical administration, light-activated photodynamic compound (PDC) TLD-1433 targets and binds to transferrin (Tf) and is subsequently taken up by Tf receptors which are located on tumor cells. Upon exposure to green light (525nm), TLD-1433 becomes activated locally and induces the generation of reactive oxygen species (ROS) and singlet oxygen. The release of free radicals may induce apoptosis and destroy the tumor cells. Cancer cells have many more Tf receptors than normal cells,","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Photodynamic Compound TLD-1433","termGroup":"PT","termSource":"NCI"},{"termName":"PDC TLD-1433","termGroup":"SY","termSource":"NCI"},{"termName":"TLD 1433","termGroup":"CN","termSource":"NCI"},{"termName":"TLD-1433","termGroup":"CN","termSource":"NCI"},{"termName":"TLD1433","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1471479-22-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L59D69SZN5"},{"name":"Maps_To","value":"Photodynamic Compound TLD-1433"},{"name":"NCI_Drug_Dictionary_ID","value":"801697"},{"name":"NCI_META_CUI","value":"CL1406854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801697"},{"name":"PDQ_Open_Trial_Search_ID","value":"801697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171387":{"preferredName":"Plasmid DNA Vaccine pING-hHER3FL","code":"C171387","definitions":[{"definition":"A plasmid DNA cancer vaccine encoding the tumor-associated antigen (TAA) human epidermal growth factor receptor type-3 (HER-3; HER3), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the plasmid DNA vaccine pING-hHER3FL and after cellular uptake by muscle cells, the plasmid DNA expresses HER-3 which, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-3. HER-3 plays a key role in tumor cell proliferation and its overexpression is associated with poor prognosis. HER-3 is associated with tumor cell resistance to anti-HER-2 therapeutics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plasmid DNA Vaccine pING-hHER3FL","termGroup":"PT","termSource":"NCI"},{"termName":"pING-hHER3FL","termGroup":"CN","termSource":"NCI"},{"termName":"pING-hHER3FL Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Plasmid DNA Vaccine pING-hHER3FL"},{"name":"NCI_Drug_Dictionary_ID","value":"801289"},{"name":"NCI_META_CUI","value":"CL1405505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801289"},{"name":"PDQ_Open_Trial_Search_ID","value":"801289"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175536":{"preferredName":"pNGVL4a-CRT-E6E7L2 DNA Vaccine","code":"C175536","definitions":[{"definition":"A therapeutic DNA vaccine encoding human calreticulin (CRT) linked to human papillomavirus (HPV) type 16 E6, E7, and L2 proteins, with potential immunomodulating and antineoplastic activities. Upon administration via intramuscular injection with electroporation, the pNGVL4a-CRT-E6E7L2 DNA vaccine expresses HPV16 E6, E7 and L2 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response and humoral immune responses against tumor cells expressing these proteins, resulting in tumor cell lysis and tumor cell death. In addition, HPV16 L2-specific neutralizing antibody may prevent a broad spectrum of HPV infections and HPV-associated cancers. The heat shock protein CRT may potentiate MHC class I presentation to antigen-specific CD8-positive T-cells, enhancing the induction of cellular immunity and the potency of the vaccine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pNGVL4a-CRT-E6E7L2 DNA Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"pNGVL4a-CRT-E6E7L2","termGroup":"CN","termSource":"NCI"},{"termName":"pNGVL4a-CRTE6E7L2","termGroup":"CN","termSource":"NCI"},{"termName":"pNGVL4aCRTE6E7L2","termGroup":"CN","termSource":"NCI"},{"termName":"pNGVL4aCRTE6E7L2 DNA Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pNGVL4a-CRT-E6E7L2 DNA Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"803294"},{"name":"NCI_META_CUI","value":"CL1412894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803294"},{"name":"PDQ_Open_Trial_Search_ID","value":"803294"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172205":{"preferredName":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2","code":"C172205","definitions":[{"definition":"A cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential immunostimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. HPV16 L2/E6/E7 fusion protein TA-CIN vaccine is a recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\\E6\\E7). Upon administration, this boost vaccine may stimulate the immune system to generate HPV16 E6\\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2","termGroup":"PT","termSource":"NCI"},{"termName":"PVX 2","termGroup":"CN","termSource":"NCI"},{"termName":"PVX-2","termGroup":"CN","termSource":"NCI"},{"termName":"PVX2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2"},{"name":"NCI_Drug_Dictionary_ID","value":"801534"},{"name":"NCI_META_CUI","value":"CL1406087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801534"},{"name":"PDQ_Open_Trial_Search_ID","value":"801534"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165666":{"preferredName":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255","code":"C165666","definitions":[{"definition":"A long-acting formulation composed of the human cytokine interleukin-15 (IL-15) that is conjugated by polymers, with potential immunomodulating and anti-tumor activities. Upon administration of polymer-conjugated IL-15 receptor agonist NKTR-255, the IL-15 moiety targets and binds to the alpha subunit of the IL-15 receptor on natural killer (NK) and T-cells, thereby activating the IL-15-mediated pathway. This leads to the expansion and activation of natural killer (NK) cells and memory CD8+ T-cells, thereby enhancing the anti-tumor activity of NKs and long-term memory T-lymphocyte immune responses. This may increase tumor cell killing and decrease tumor cell proliferation. In addition, NKTR-255 may, when combined with a tumor-directed antibody, enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. IL-15 is a pro-inflammatory cytokine that plays a key role in the regulation of T- and NK cell activation, proliferation and promotion of their anti-tumor effects. Compared to IL-15 alone, the polymer formulation allows for increased retention at the tumor site and reduced clearance, thereby increasing the effect of IL-15.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15 Receptor Agonist NKTR-255","termGroup":"SY","termSource":"NCI"},{"termName":"Long-acting Polymer-engineered IL-15 Conjugate NKTR-255","termGroup":"SY","termSource":"NCI"},{"termName":"NKTR 255","termGroup":"CN","termSource":"NCI"},{"termName":"NKTR-255","termGroup":"CN","termSource":"NCI"},{"termName":"NKTR255","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255"},{"name":"NCI_Drug_Dictionary_ID","value":"800122"},{"name":"NCI_META_CUI","value":"CL978933"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800122"},{"name":"PDQ_Open_Trial_Search_ID","value":"800122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172189":{"preferredName":"Porcupine Inhibitor XNW7201","code":"C172189","definitions":[{"definition":"An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, PORCN inhibitor XNW7201 targets, binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. PORCN, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers and plays a key role in cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor XNW7201","termGroup":"PT","termSource":"NCI"},{"termName":"PORCN Inhibitor XNW7201","termGroup":"SY","termSource":"NCI"},{"termName":"XNW 7201","termGroup":"CN","termSource":"NCI"},{"termName":"XNW-7201","termGroup":"CN","termSource":"NCI"},{"termName":"XNW7201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Porcupine Inhibitor XNW7201"},{"name":"NCI_Drug_Dictionary_ID","value":"801526"},{"name":"NCI_META_CUI","value":"CL1406288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801526"},{"name":"PDQ_Open_Trial_Search_ID","value":"801526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169105":{"preferredName":"PPAR Alpha Antagonist TPST-1120","code":"C169105","definitions":[{"definition":"An orally bioavailable, small molecule, selective and competitive antagonist of peroxisome proliferator activated receptor alpha (PPARa), with potential immunomodulating and antineoplastic activities. Upon oral administration, TPST-1120 targets, binds to and blocks the activity of PPARa, thereby blocking transcription of PPARa target genes leading to an intracellular metabolism shift from fatty acid oxidation (FAO) to glycolysis in FAO-dependent tumors and reducing the production of fatty acids in the tumor microenvironment (TME). As fatty acids are essential for tumor cell growth in FAO-dependent tumor cells and are needed for the metabolism of suppressive immune cells in the TME, including regulatory T-cells (Tregs), reducing the amount of fatty acids leads to a direct killing of FAO-dependent tumor cells. It also skews macrophages from the immune suppressive M2 phenotype to an effector M1 phenotype and facilitates the cytotoxicity of immune effector cells, thereby stimulating an anti-tumor immune response and further killing tumor cells. TPST-1120 also restores the natural inhibitor of angiogenesis thrombospondin-1 (TSP-1) and stimulator of interferon genes (STING) in the TME. PPARa, a ligand-activated nuclear transcription factor and metabolic checkpoint, regulates the expression of FAO genes and lipid metabolism. It plays a key role in immunosuppression in the TME. FAO is a metabolic pathway essential to tumor growth, survival and immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPAR Alpha Antagonist TPST-1120","termGroup":"PT","termSource":"NCI"},{"termName":"Peroxisome Proliferator Activated Receptor Alpha Antagonist TPST-1120","termGroup":"SY","termSource":"NCI"},{"termName":"PPARA Antagonist TPST-1120","termGroup":"SY","termSource":"NCI"},{"termName":"PPARalpha Antagonist TPST-1120","termGroup":"SY","termSource":"NCI"},{"termName":"TPST 1120","termGroup":"CN","termSource":"NCI"},{"termName":"TPST-1120","termGroup":"CN","termSource":"NCI"},{"termName":"TPST1120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PPAR Alpha Antagonist TPST-1120"},{"name":"NCI_Drug_Dictionary_ID","value":"800961"},{"name":"NCI_META_CUI","value":"CL1382244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800961"},{"name":"PDQ_Open_Trial_Search_ID","value":"800961"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168531":{"preferredName":"PRMT5 Inhibitor PRT811","code":"C168531","definitions":[{"definition":"An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration, PRMT5 inhibitor PRT811 selectively binds to PRMT5 and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRMT5 Inhibitor PRT811","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 5 Inhibitor PRT811","termGroup":"SY","termSource":"NCI"},{"termName":"PRT 811","termGroup":"CN","termSource":"NCI"},{"termName":"PRT-811","termGroup":"CN","termSource":"NCI"},{"termName":"PRT811","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PRMT5 Inhibitor PRT811"},{"name":"NCI_Drug_Dictionary_ID","value":"800369"},{"name":"NCI_META_CUI","value":"CL972859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800369"},{"name":"PDQ_Open_Trial_Search_ID","value":"800369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166122":{"preferredName":"Ifebemtinib","code":"C166122","definitions":[{"definition":"An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) with potential antineoplastic activity. Upon oral administration, ifebemtinib targets and inhibits, in an adenosine triphosphate (ATP)-competitive manner, PTK2. This prevents PTK2-mediated downstream signaling and inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells. The cytoplasmic tyrosine kinase PTK2, a signal transducer for integrins overexpressed in various tumor cell types, is involved in tumor cell invasion, migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifebemtinib","termGroup":"PT","termSource":"NCI"},{"termName":"BI 853520","termGroup":"CN","termSource":"NCI"},{"termName":"BI-853520","termGroup":"CN","termSource":"NCI"},{"termName":"BI853520","termGroup":"CN","termSource":"NCI"},{"termName":"FAK1 Inhibitor IN10018","termGroup":"SY","termSource":"NCI"},{"termName":"IN 10018","termGroup":"CN","termSource":"NCI"},{"termName":"IN-10018","termGroup":"CN","termSource":"NCI"},{"termName":"IN10018","termGroup":"CN","termSource":"NCI"},{"termName":"Protein Tyrosine Kinase 2 Inhibitor BI 853520","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Tyrosine Kinase 2 Inhibitor IN10018","termGroup":"SY","termSource":"NCI"},{"termName":"PTK2 Inhibitor IN10018","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227948-82-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C57O858DKU"},{"name":"Maps_To","value":"Protein Tyrosine Kinase 2 Inhibitor IN10018"},{"name":"NCI_Drug_Dictionary_ID","value":"699455"},{"name":"NCI_META_CUI","value":"CL979217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699455"},{"name":"PDQ_Open_Trial_Search_ID","value":"699455"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175380":{"preferredName":"Pyruvate Kinase M2 Isoform Activator TP-1454","code":"C175380","definitions":[{"definition":"An orally bioavailable activator of pyruvate kinase M2 isoform (PKM2), with potential immunomodulating and antineoplastic activities. Upon oral administration, PKM2 activator TP-1454 locks PKM2 into the active tetrameric form. This may prevent the production of glycolytic intermediates by the less active dimer form of PKM2, depleting the supply of glycolytic intermediates which are needed for tumor cell growth. This may also inhibit immune suppression mediated by the dimer form of PKM2. Altogether, this may slow tumor cell growth and enhance anti-tumor immune responses, thereby inhibiting tumor cell proliferation. PKM2, the predominant PK isoform found in tumor cells, is responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyruvate Kinase M2 Isoform Activator TP-1454","termGroup":"PT","termSource":"NCI"},{"termName":"PKM2 Activator TP-1454","termGroup":"SY","termSource":"NCI"},{"termName":"TP 1454","termGroup":"CN","termSource":"NCI"},{"termName":"TP-1454","termGroup":"CN","termSource":"NCI"},{"termName":"TP1454","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pyruvate Kinase M2 Isoform Activator TP-1454"},{"name":"NCI_Drug_Dictionary_ID","value":"803280"},{"name":"NCI_META_CUI","value":"CL1412698"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803280"},{"name":"PDQ_Open_Trial_Search_ID","value":"803280"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170742":{"preferredName":"Recombinant Bacterial Minicells VAX014","code":"C170742","definitions":[{"definition":"A population of recombinant bacterial minicells (rBMCs) engineered to express the alpha3beta1 (a3b1) and alpha5beta1 (a5b1) integrin-targeting invasion and that contain a bacterial protein toxin, perfringolysin O (PFO), with potential antineoplastic activity. Upon intravesical administration, VAX014 selectively targets and binds to tumor cells expressing un-ligated a3b1 and/or a5b1 integrins and delivers PFO, leading to destabilization of tumor cell membranes and tumor cell lysis. By targeting un-ligated a3b1 and/or a5b1 integrins, VAX014 selectively targets tumor cells over normal cells, with potentially less adverse effects in comparison with first generation integrin-targeted therapies.      ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Bacterial Minicells VAX014","termGroup":"PT","termSource":"NCI"},{"termName":"rBMCs VAX014","termGroup":"SY","termSource":"NCI"},{"termName":"VAX 014","termGroup":"CN","termSource":"NCI"},{"termName":"VAX-014","termGroup":"CN","termSource":"NCI"},{"termName":"VAX-IP","termGroup":"SY","termSource":"NCI"},{"termName":"VAX-IP Minicells","termGroup":"SY","termSource":"NCI"},{"termName":"VAX014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Bacterial Minicells VAX014"},{"name":"NCI_Drug_Dictionary_ID","value":"801175"},{"name":"NCI_META_CUI","value":"CL1383139"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801175"},{"name":"PDQ_Open_Trial_Search_ID","value":"801175"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168605":{"preferredName":"Recombinant Human Papillomavirus 11-valent Vaccine","code":"C168605","definitions":[{"definition":"A recombinant, 11-valent, human papillomavirus (HPV) vaccine, produced in Hansenula polymorpha, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant HPV 11-valent vaccine may generate humoral and cellular immunity against the 11 undisclosed types of HPV antigens, thereby preventing cervical infection upon exposure to these 11 types of HPV. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Papillomavirus 11-valent Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"11-valent Recombinant HPV Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"11-valent Recombinant Human Papillomavirus Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"11-valent Recombinant Human Papillomavirus Vaccine (Hansenula polymorpha)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Papillomavirus 11-valent Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"800414"},{"name":"NCI_META_CUI","value":"CL972920"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800414"},{"name":"PDQ_Open_Trial_Search_ID","value":"800414"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170907":{"preferredName":"Rilunermin Alfa","code":"C170907","definitions":[{"definition":"A recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L), with potential pro-apoptotic and antineoplastic activities. The binding of TRAIL to the Trimer-Tag allows TRAIL to form a stable covalently-linked homotrimer. Upon administration rilunermin alfa targets, binds to and trimerizes the TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby activating caspases and inducing apoptosis in TRAIL-R1/R2-expressing tumor cells. TRAIL, a homotrimeric type II transmembrane protein and member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types; The induction of receptor trimerization is needed for the initiation of the apoptotic signaling pathway. The TRAIL-Trimer retains similar bioactivity and receptor binding kinetics as native TRAIL but has more favorable pharmacokinetics and antitumor activity than native TRAIL.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilunermin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant Human TRAIL-Trimer Fusion Protein SCB-313","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant TNF-related Apoptosis-inducing Ligand-trimer Fusion Protein SCB-313","termGroup":"SY","termSource":"NCI"},{"termName":"SCB 313","termGroup":"CN","termSource":"NCI"},{"termName":"SCB-313","termGroup":"CN","termSource":"NCI"},{"termName":"SCB313","termGroup":"CN","termSource":"NCI"},{"termName":"TRAIL-Trimer Fusion Protein SCB-313","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL-Trimer SCB-313","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9XNC6EH85J"},{"name":"Maps_To","value":"Recombinant Human TRAIL-Trimer Fusion Protein SCB-313"},{"name":"NCI_Drug_Dictionary_ID","value":"800842"},{"name":"NCI_META_CUI","value":"CL1383053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800842"},{"name":"PDQ_Open_Trial_Search_ID","value":"800842"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171377":{"preferredName":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301","code":"C171377","definitions":[{"definition":"A glyco-engineered heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization (ECD) domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, recombinant humanized anti-HER-2 bispecific monoclonal antibody MBS301 simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2. This prevents the activation of HER-2 signaling pathways. Also, by binding to HER-2, MBS301 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific Anti-HER2 Antibody MBS301","termGroup":"SY","termSource":"NCI"},{"termName":"MBS 301","termGroup":"CN","termSource":"NCI"},{"termName":"MBS-301","termGroup":"CN","termSource":"NCI"},{"termName":"MBS301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301"},{"name":"NCI_Drug_Dictionary_ID","value":"801299"},{"name":"NCI_META_CUI","value":"CL1405488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801299"},{"name":"PDQ_Open_Trial_Search_ID","value":"801299"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167210":{"preferredName":"Enbezotinib","code":"C167210","definitions":[{"definition":"An orally bioavailable selective dual inhibitor of fusions and mutations involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (ret) and the src family tyrosine kinases, with potential antineoplastic activity. Upon oral administration, enbezotinib specifically targets and binds to ret mutants and ret-containing fusion products. This results in an inhibition of cell growth of tumor cells that exhibit increased ret activity. By inhibiting src kinase-mediated signaling and reducing the src-initiated recruitment of multiple receptor tyrosine kinases involved in bypass resistance, enbezotinib may be able to overcome tumor resistance which may increase its therapeutic effect. Ret overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of ret tyrosine kinase activity in various cancer cell types; dysregulation of ret activity plays a key role in the development and progression of these cancers. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis. Src upregulation is seen in tumors with acquired resistance to RET inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enbezotinib","termGroup":"PT","termSource":"NCI"},{"termName":"(3aR,11S,20aS)-7-Fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-17,19-metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aR,11S,20aS)-","termGroup":"SN","termSource":"NCI"},{"termName":"RET/SRC Inhibitor TPX-0046","termGroup":"SY","termSource":"NCI"},{"termName":"RET/SRC Tyrosine Kinase Inhibitor TPX-0046","termGroup":"SY","termSource":"NCI"},{"termName":"TPX 0046","termGroup":"CN","termSource":"NCI"},{"termName":"TPX-0046","termGroup":"CN","termSource":"NCI"},{"termName":"TPX0046","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2359649-81-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6EVK907XR"},{"name":"Maps_To","value":"RET/SRC Inhibitor TPX-0046"},{"name":"NCI_Drug_Dictionary_ID","value":"802260"},{"name":"NCI_META_CUI","value":"CL972435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802260"},{"name":"PDQ_Open_Trial_Search_ID","value":"802260"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172380":{"preferredName":"ROBO1-targeted BiCAR-NKT Cells","code":"C172380","definitions":[{"definition":"A preparation of natural killer T (NKT) cells engineered to express a chimeric antigen receptor (CAR) specific for roundabout homolog 1 (ROBO1, Robo1), with potential immunostimulating and antineoplastic activities. Upon administration, the ROBO1-targeted BiCAR-NK/T cells target and bind to ROBO1 expressed on the surface of tumor cells. This induces selective toxicity in ROBO1-expressing tumor cells. ROBO1, a member of the axon guidance receptor family, is often overexpressed in a variety of tumor types. It is involved in axon guidance, cell proliferation, cell motility and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ROBO1-targeted BiCAR-NKT Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ROBO1 BiCAR-NK/T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ROBO1 CAR-NK/T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ROBO1-targeted Bi-CAR-NK/T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ROBO1-targeted BiCAR-NKT Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801656"},{"name":"NCI_META_CUI","value":"CL1406507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801656"},{"name":"PDQ_Open_Trial_Search_ID","value":"801656"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166135":{"preferredName":"RSK1-4 Inhibitor PMD-026","code":"C166135","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine kinase p90 ribosomal S6 kinase (p90RSK; RSK) subtypes 1-4, with high selectivity for RSK subtype 2 (RSK2), with potential antineoplastic activity. Upon administration of the RSK1-4 inhibitor PMD-026, this agent targets and inhibits the RSK subtypes, thereby inhibiting RSK-mediated signaling. This prevents the phosphorylation and activation of the transcription factor Y-box binding protein-1 (YB-1) and leads to cell cycle arrest, an induction of apoptosis, and an inhibition of tumor cell proliferation in RSK-expressing tumor cells. RSK is overexpressed in a variety of cancers, especially in triple negative breast cancer (TNBC). It plays a key role in tumor cell proliferation, differentiation, survival, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RSK1-4 Inhibitor PMD-026","termGroup":"PT","termSource":"NCI"},{"termName":"PMD 026","termGroup":"CN","termSource":"NCI"},{"termName":"PMD-026","termGroup":"CN","termSource":"NCI"},{"termName":"PMD026","termGroup":"CN","termSource":"NCI"},{"termName":"RSK Inhibitor PMD-026","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RSK1-4 Inhibitor PMD-026"},{"name":"NCI_Drug_Dictionary_ID","value":"799807"},{"name":"NCI_META_CUI","value":"CL979208"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799807"},{"name":"PDQ_Open_Trial_Search_ID","value":"799807"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173373":{"preferredName":"Ruthenium-based Small Molecule Therapeutic BOLD-100","code":"C173373","definitions":[{"definition":"A ruthenium-based, small molecule that selectively inhibits stress-induced upregulation of GRP78, with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, BOLD-100 may selectively inhibit stress-induced upregulation of GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking GRP78-induced suppression of apoptotic pathways. This may lead to the induction of tumor cell apoptosis and slow tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types. Its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruthenium-based Small Molecule Therapeutic BOLD-100","termGroup":"PT","termSource":"NCI"},{"termName":"BOLD 100","termGroup":"CN","termSource":"NCI"},{"termName":"BOLD-100","termGroup":"CN","termSource":"NCI"},{"termName":"BOLD100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ruthenium-based Small Molecule Therapeutic BOLD-100"},{"name":"NCI_Drug_Dictionary_ID","value":"801840"},{"name":"NCI_META_CUI","value":"CL1407205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801840"},{"name":"PDQ_Open_Trial_Search_ID","value":"801840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170746":{"preferredName":"SDF-1 Receptor Antagonist PTX-9908","code":"C170746","definitions":[{"definition":"A stromal cell-derived factor 1 (SDF-1; CXCL12) analog and inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, PTX-9908 selectively targets and binds to CXCR4, thereby preventing the binding of CXCR4 to its ligand SDF-1. This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. The G protein-coupled receptor CXCR4, which is overexpressed in several tumor cell types, promotes tumor angiogenesis, tumor cell proliferation, survival, invasion and metastasis. SDF-1, a major chemotactic factor, plays a key role in mediating cell trafficking via selective binding to CXCR4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDF-1 Receptor Antagonist PTX-9908","termGroup":"PT","termSource":"NCI"},{"termName":"CTCE 9908","termGroup":"CN","termSource":"NCI"},{"termName":"CTCE-9908","termGroup":"CN","termSource":"NCI"},{"termName":"CTCE9908","termGroup":"CN","termSource":"NCI"},{"termName":"CXCR4 Antagonist CTCE-9908","termGroup":"SY","termSource":"NCI"},{"termName":"PTX 9908","termGroup":"CN","termSource":"NCI"},{"termName":"PTX-9908","termGroup":"CN","termSource":"NCI"},{"termName":"PTX9908","termGroup":"CN","termSource":"NCI"},{"termName":"SDF-1 Analog PTX-9908","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1030384-98-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NF0BX95A31"},{"name":"Maps_To","value":"SDF-1 Receptor Antagonist PTX-9908"},{"name":"NCI_Drug_Dictionary_ID","value":"800729"},{"name":"NCI_META_CUI","value":"CL1383156"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800729"},{"name":"PDQ_Open_Trial_Search_ID","value":"800729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168606":{"preferredName":"Selective Estrogen Receptor Degrader LX-039","code":"C168606","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD LX-039 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader LX-039","termGroup":"PT","termSource":"NCI"},{"termName":"LX 039","termGroup":"CN","termSource":"NCI"},{"termName":"LX-039","termGroup":"CN","termSource":"NCI"},{"termName":"LX039","termGroup":"CN","termSource":"NCI"},{"termName":"SERD LX-039","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader LX-039"},{"name":"NCI_Drug_Dictionary_ID","value":"800319"},{"name":"NCI_META_CUI","value":"CL972812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800319"},{"name":"PDQ_Open_Trial_Search_ID","value":"800319"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174042":{"preferredName":"Imlunestrant","code":"C174042","definitions":[{"definition":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imlunestrant","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3484356","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3484356","termGroup":"CN","termSource":"NCI"},{"termName":"LY3484356","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader LY3484356","termGroup":"SY","termSource":"NCI"},{"termName":"SERD LY3484356","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2408840-26-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9CXQ3PF69U"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader LY3484356"},{"name":"NCI_Drug_Dictionary_ID","value":"802339"},{"name":"NCI_META_CUI","value":"CL1407918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802339"},{"name":"PDQ_Open_Trial_Search_ID","value":"802339"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167267":{"preferredName":"SERD ZN-c5","code":"C167267","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD ZN-c5 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SERD ZN-c5","termGroup":"PT","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader ZN-c5","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator ZN-c5","termGroup":"SY","termSource":"NCI"},{"termName":"ZN c5","termGroup":"CN","termSource":"NCI"},{"termName":"ZN-c5","termGroup":"CN","termSource":"NCI"},{"termName":"ZNc5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SERD ZN-c5"},{"name":"NCI_Drug_Dictionary_ID","value":"802322"},{"name":"NCI_META_CUI","value":"CL972255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802322"},{"name":"PDQ_Open_Trial_Search_ID","value":"802322"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171384":{"preferredName":"Shenqi Fuzheng Injection SQ001","code":"C171384","definitions":[{"definition":"An injectable formulation composed of the two Chinese medicinal herbs Radix astragali, the root of astragalus membranaceus (huangqi) and Radix codonopsis, the root of Codonopsis pilosula (dangshen), with potential antineoplastic adjuvant and chemoprotective activities that may prevent cancer-related fatigue. Although the exact mechanisms by which shenqi fuzheng injection (SFI) have yet to be fully elucidated, the herbs may improve tumor response and/or reduce the toxicity of certain chemotherapeutics when administered together. It may also alleviate chemotherapy-associated immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shenqi Fuzheng Injection SQ001","termGroup":"PT","termSource":"NCI"},{"termName":"SFI","termGroup":"AB","termSource":"NCI"},{"termName":"SQ 001","termGroup":"CN","termSource":"NCI"},{"termName":"SQ-001","termGroup":"CN","termSource":"NCI"},{"termName":"SQ001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Shenqi Fuzheng Injection SQ001"},{"name":"NCI_Drug_Dictionary_ID","value":"801246"},{"name":"NCI_META_CUI","value":"CL1405484"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801246"},{"name":"PDQ_Open_Trial_Search_ID","value":"801246"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172988":{"preferredName":"SHP2 Inhibitor RLY-1971","code":"C172988","definitions":[{"definition":"An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor RLY-1971 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP2 Inhibitor RLY-1971","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 1971","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-1971","termGroup":"CN","termSource":"NCI"},{"termName":"GDC1971","termGroup":"CN","termSource":"NCI"},{"termName":"RLY 1971","termGroup":"CN","termSource":"NCI"},{"termName":"RLY-1971","termGroup":"CN","termSource":"NCI"},{"termName":"RLY1971","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SHP2 Inhibitor RLY-1971"},{"name":"NCI_Drug_Dictionary_ID","value":"802046"},{"name":"NCI_META_CUI","value":"CL1406779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802046"},{"name":"PDQ_Open_Trial_Search_ID","value":"802046"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170763":{"preferredName":"Simmitinib","code":"C170763","definitions":[{"definition":"An orally bioavailable inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), and colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antiangiogenic and antineoplastic activities. Upon oral administration, simmitinib binds to and inhibits the activities of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR2, and CSF1R are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simmitinib","termGroup":"PT","termSource":"NCI"},{"termName":"SOMCL-15-290","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Simmitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"800788"},{"name":"NCI_META_CUI","value":"CL1383173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800788"},{"name":"PDQ_Open_Trial_Search_ID","value":"800788"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174171":{"preferredName":"SIRPa-4-1BBL Fusion Protein DSP107","code":"C174171","definitions":[{"definition":"A bi-functional, trimeric, fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) fused to a 4-1BB ligand (4-1BBL), with potential immune checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, the SIRPa-4-1BBL fusion protein DSP107 selectively targets and binds to both CD47 expressed on tumor cells and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) expressed on T-cells and natural killer (NK) cells. Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of 4-1BBL to 4-1BB activates 4-1BB-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as NK-mediated tumor cell killing. The crosslinking specifically enables the activation of 4-1BB-mediated signaling in T-cells and NK cells in the tumor microenvironment (TME), allowing targeted immune responses in the TME. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIRPa-4-1BBL Fusion Protein DSP107","termGroup":"PT","termSource":"NCI"},{"termName":"CD172a-4-1BBL Trimeric Fusion Protein DSP107","termGroup":"SY","termSource":"NCI"},{"termName":"DSP 107","termGroup":"CN","termSource":"NCI"},{"termName":"DSP-107","termGroup":"CN","termSource":"NCI"},{"termName":"DSP107","termGroup":"CN","termSource":"NCI"},{"termName":"SIRPa-4-1BBL DSP107","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-4-1BBL Dual Signaling Protein DSP107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SIRPa-4-1BBL Fusion Protein DSP107"},{"name":"NCI_Drug_Dictionary_ID","value":"802479"},{"name":"NCI_META_CUI","value":"CL1407805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802479"},{"name":"PDQ_Open_Trial_Search_ID","value":"802479"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173706":{"preferredName":"SIRPa-Fc-CD40L Fusion Protein SL-172154","code":"C173706","definitions":[{"definition":"A bi-functional fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) and CD40 ligand (CD40L; CD154; TRAP; TNFSF5) linked via a human Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the SIRPa-Fc-CD40L fusion protein SL-172154 selectively targets and binds to both CD47 expressed on tumor cells and CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family, expressed on antigen-presenting cells (APCs). Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of CD40L to CD40 activates CD40, increases CD40-mediated signaling and induces proliferation and activation of B-lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived dendritic cells (moDCs), and leads to the secretion of inflammatory cytokines. This activates the immune system to induce the proliferation and activation of cytotoxic T-lymphocytes (CTLs) against tumor cells. The crosslinking specifically enhances antigen presentation to CD8+ and CD4+ T lymphocytes and tumor cell phagocytosis by the APC. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIRPa-Fc-CD40L Fusion Protein SL-172154","termGroup":"PT","termSource":"NCI"},{"termName":"CD172a-Fc-CD40L Chimeric Protein SL-172154","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-Fc-CD40L SL-172154","termGroup":"SY","termSource":"NCI"},{"termName":"SL 172154","termGroup":"CN","termSource":"NCI"},{"termName":"SL-172154","termGroup":"CN","termSource":"NCI"},{"termName":"SL172154","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SIRPa-Fc-CD40L Fusion Protein SL-172154"},{"name":"NCI_Drug_Dictionary_ID","value":"801935"},{"name":"NCI_META_CUI","value":"CL1407529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801935"},{"name":"PDQ_Open_Trial_Search_ID","value":"801935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111571":{"preferredName":"Spanlecortemlocel","code":"C111571","definitions":[{"definition":"A preparation of allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) expanded in culture with the stimulatory cytokines stem cell factor (SCF; Kit ligand; mast cell growth factor; MGF), FMS-like tyrosine kinase 3 ligand (Flt3L), interleukin 6 (IL-6), and thrombopoietin, in the presence of an aryl hydrocarbon receptor (AHR) antagonist LHD221 (StemRegenin-1; SR-1), with potential to improve hematopoietic recovery following myeloablative conditioning. Upon administration of Spanlecortemlocel, these cells increase and restore the number of HSPCs, which may prevent or decrease the risk of infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation. LHD221, an AHR antagonist facilitates the expansion of CD34-positive hematopoietic progenitors and impedes HSPC differentiation during cytokine-driven expansion in culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spanlecortemlocel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic UCB-derived HSPCs MGTA 456","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Umbilical Cord Blood-derived Hematopoietic Stem and Progenitor Cells MGTA-456","termGroup":"SY","termSource":"NCI"},{"termName":"Expanded Umbilical Cord Blood Product HSC835","termGroup":"SY","termSource":"NCI"},{"termName":"HSC 835","termGroup":"CN","termSource":"NCI"},{"termName":"HSC835","termGroup":"CN","termSource":"NCI"},{"termName":"MGTA 456","termGroup":"CN","termSource":"NCI"},{"termName":"MGTA-456","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D8O38M043D"},{"name":"Maps_To","value":"Spanlecortemlocel"},{"name":"NCI_Drug_Dictionary_ID","value":"752075"},{"name":"NCI_META_CUI","value":"CL453979"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752075"},{"name":"PDQ_Open_Trial_Search_ID","value":"752075"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175512":{"preferredName":"Emidurdar","code":"C175512","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/arginine-rich splicing factor protein kinase 1 (SRPK1) and the ATP-binding cassette sub-family G member 2 (ABCG2), with potential chemosensitizing and antineoplastic activities. Upon oral administration, emidurdar targets, binds to and inhibits the activity of SRPK1 and ABCG2. Inhibition of the cellular efflux pump ABCG2 by emidurdar prevents the efflux of co-administered chemotherapeutic agents from cancer cells. This may abrogate cancer cell drug resistance and may re-sensitize cancer cells to the chemotherapeutic agents. Inhibition of SRPK1 kinase by emidurdar inhibits the SRPK1-mediated phosphorylation of splicing factors rich in serine/arginine domains, thereby inhibiting the activation of proteins that are involved in the regulation of alternative splicing. This may inhibit cancer cell proliferation. SRPK1 is upregulated in various cancer cell types. Its upregulation is correlated with higher tumor staging, grading, and shorter survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emidurdar","termGroup":"PT","termSource":"NCI"},{"termName":"Endovion","termGroup":"SY","termSource":"NCI"},{"termName":"N-(4-bromo-2-(1h-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"NS 3728","termGroup":"CN","termSource":"NCI"},{"termName":"NS-3728","termGroup":"CN","termSource":"NCI"},{"termName":"NS3728","termGroup":"CN","termSource":"NCI"},{"termName":"SCO 101","termGroup":"CN","termSource":"NCI"},{"termName":"SCO-101","termGroup":"CN","termSource":"NCI"},{"termName":"SCO101","termGroup":"CN","termSource":"NCI"},{"termName":"SRPK1/ABCG2 Inhibitor SCO-101","termGroup":"SY","termSource":"NCI"},{"termName":"Urea, N-(3,5-bis(trifluoromethyl)phenyl)-N'-(4-bromo-2-(1H-tetrazol-5-yl)phenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"265646-85-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"943YH53W21"},{"name":"Maps_To","value":"SRPK1/ABCG2 Inhibitor SCO-101"},{"name":"NCI_Drug_Dictionary_ID","value":"803025"},{"name":"NCI_META_CUI","value":"CL1412867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803025"},{"name":"PDQ_Open_Trial_Search_ID","value":"803025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167292":{"preferredName":"STING Agonist BMS-986301","code":"C167292","definitions":[{"definition":"An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon administration, STING agonist BMS-986301 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist BMS-986301","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986301","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986301","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist BMS-986301"},{"name":"NCI_Drug_Dictionary_ID","value":"800468"},{"name":"NCI_META_CUI","value":"CL972276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800468"},{"name":"PDQ_Open_Trial_Search_ID","value":"800468"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165748":{"preferredName":"STING Agonist GSK3745417","code":"C165748","definitions":[{"definition":"An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist GSK3745417 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist GSK3745417","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 3745417","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3745417","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3745417","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist GSK3745417"},{"name":"NCI_Drug_Dictionary_ID","value":"800130"},{"name":"NCI_META_CUI","value":"CL978866"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800130"},{"name":"PDQ_Open_Trial_Search_ID","value":"800130"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165655":{"preferredName":"STING Agonist IMSA101","code":"C165655","definitions":[{"definition":"A small molecule analogue of cyclic GMP-AMP (cGAMP) that acts as an agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173) with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING agonist IMSA101 binds to STING and activates STING-mediated pathways. This activates the immune response through the activation of certain immune cells which induces the expression of pro-inflammatory cytokines and chemokines, promotes tumor-associated antigen (TAA) processing and presentation by dendritic cells (DCs) and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist IMSA101","termGroup":"PT","termSource":"NCI"},{"termName":"IMSA 101","termGroup":"CN","termSource":"NCI"},{"termName":"IMSA-101","termGroup":"CN","termSource":"NCI"},{"termName":"IMSA101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist IMSA101"},{"name":"NCI_Drug_Dictionary_ID","value":"800118"},{"name":"NCI_META_CUI","value":"CL978957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800118"},{"name":"PDQ_Open_Trial_Search_ID","value":"800118"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165566":{"preferredName":"STING Agonist SB 11285","code":"C165566","definitions":[{"definition":"An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist SB 11285 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist SB 11285","termGroup":"PT","termSource":"NCI"},{"termName":"SB 11285","termGroup":"CN","termSource":"NCI"},{"termName":"SB-11285","termGroup":"CN","termSource":"NCI"},{"termName":"SB11285","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist SB 11285"},{"name":"NCI_Drug_Dictionary_ID","value":"799980"},{"name":"NCI_META_CUI","value":"CL978836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799980"},{"name":"PDQ_Open_Trial_Search_ID","value":"799980"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173377":{"preferredName":"Dazostinag Disodium","code":"C173377","definitions":[{"definition":"The disodium salt form of dazostinag, an agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, dazostinag targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dazostinag Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"STING Agonist TAK-676","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 676","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-676","termGroup":"CN","termSource":"NCI"},{"termName":"TAK676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2553413-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GQ7GWR7ISX"},{"name":"Maps_To","value":"STING Agonist TAK-676"},{"name":"NCI_Drug_Dictionary_ID","value":"801843"},{"name":"NCI_META_CUI","value":"CL1407199"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801843"},{"name":"PDQ_Open_Trial_Search_ID","value":"801843"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167270":{"preferredName":"STING-expressing E. coli SYNB1891","code":"C167270","definitions":[{"definition":"A non-pathogenic strain of Escherichia coli (E. coli) bacteria that has been engineered to express stimulator of interferon genes (STING; transmembrane protein 173; TMEM173) protein, with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING-expressing E. coli SYNB1891 are engulfed by antigen presenting cells (APCs) within the tumor. STING-mediated pathways within the APCs are then activated resulting in a type I interferon (IFN) response which promotes initiation and propagation of tumor-specific T-cell responses. In addition, the bacterial component of SYNB1891 may further stimulate the innate immune system via Toll-like receptors (TLRs) which may enhance the magnitude of the overall immune response. STING, a transmembrane protein that activates immune cells in the tumor microenvironment (TME), plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING-expressing E. coli SYNB1891","termGroup":"PT","termSource":"NCI"},{"termName":"STING-expressing Escherichia coli strain SYNB1891","termGroup":"SY","termSource":"NCI"},{"termName":"SYNB 1891","termGroup":"CN","termSource":"NCI"},{"termName":"SYNB-1891","termGroup":"CN","termSource":"NCI"},{"termName":"SYNB1891","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING-expressing E. coli SYNB1891"},{"name":"NCI_Drug_Dictionary_ID","value":"800451"},{"name":"NCI_META_CUI","value":"CL972256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800451"},{"name":"PDQ_Open_Trial_Search_ID","value":"800451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173664":{"preferredName":"Rucosopasem Manganese","code":"C173664","definitions":[{"definition":"A mimetic of the enzyme superoxide dismutase (SOD) that may potentially be used to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). Upon administration, rucosopasem manganese may mimic native SODs and catalyze the formation of molecular oxygen and hydrogen peroxide from the burst of superoxide anion present in the irradiated tissues upon radiation. As hydrogen peroxide is less toxic than superoxide to normal tissues, but more toxic to cancer cells, this may increase the anti-cancer efficacy of SBRT and decrease its damage to normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucosopasem Manganese","termGroup":"PT","termSource":"NCI"},{"termName":"Avasopasem Manganese Dipropionate","termGroup":"SY","termSource":"NCI"},{"termName":"GC 4711 ","termGroup":"CN","termSource":"NCI"},{"termName":"GC-4711 ","termGroup":"CN","termSource":"NCI"},{"termName":"GC4711 ","termGroup":"CN","termSource":"NCI"},{"termName":"SOD Mimetic GC4711","termGroup":"SY","termSource":"NCI"},{"termName":"Superoxide Dismutase Mimetic GC4711","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2248030-85-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FW5T90VM32"},{"name":"Maps_To","value":"Superoxide Dismutase Mimetic GC4711"},{"name":"NCI_Drug_Dictionary_ID","value":"802254"},{"name":"NCI_META_CUI","value":"CL1407386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802254"},{"name":"PDQ_Open_Trial_Search_ID","value":"802254"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166377":{"preferredName":"Synthetic Plumbagin PCUR-101","code":"C166377","definitions":[{"definition":"A synthetic form of the plant-derived medicinal agent, plumbagin, with potential antineoplastic activity.  Plumbagin may act by inhibiting the expression of protein kinase C epsilon (PKCe), signal transducers and activators of transcription 3 phosphorylation (Stat3), protein kinase B (AKT), and certain epithelial-to-mesenchymal transition (EMT) markers, including vimentin and slug. This results in possible inhibition of proliferation in susceptible tumor cells.  PKCe, Stat3, AKT, and the EMT markers vimentin and slug have been linked to the induction and progression of prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Plumbagin PCUR-101","termGroup":"PT","termSource":"NCI"},{"termName":"PCUR 101","termGroup":"CN","termSource":"NCI"},{"termName":"PCUR-101","termGroup":"CN","termSource":"NCI"},{"termName":"PCUR101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"481-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YAS4TBQ4OQ"},{"name":"Maps_To","value":"Synthetic Plumbagin PCUR-101"},{"name":"NCI_Drug_Dictionary_ID","value":"792711"},{"name":"NCI_META_CUI","value":"CL971629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792711"},{"name":"PDQ_Open_Trial_Search_ID","value":"792711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174060":{"preferredName":"Basroparib","code":"C174060","definitions":[{"definition":"An orally bioavailable inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme tankyrase, with potential antineoplastic activity. Upon administration, basroparib selectively binds to and inhibits the activity of tankyrase. This may block the tankyrase-mediated poly(ADP-ribosyl)ation of multiple target proteins including various tumor suppressors. This may include the blockage of the poly(ADP-ribosyl)ation and destabilization of AXIN, a negative regulator of beta-catenin, and prevents Wnt/beta-catenin signaling. This may inhibit the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. Tankyrase, a member of the PARP family, plays an important role in the regulation of the Wnt/beta-catenin signaling pathway, tumor suppressors, as well as telomere maintenance and mitosis regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basroparib","termGroup":"PT","termSource":"NCI"},{"termName":"STP 1002","termGroup":"CN","termSource":"NCI"},{"termName":"STP-1002","termGroup":"CN","termSource":"NCI"},{"termName":"STP1002","termGroup":"CN","termSource":"NCI"},{"termName":"Tankyrase Inhibitor STP1002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858179-75-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P5LYN8CD74"},{"name":"Maps_To","value":"Tankyrase Inhibitor STP1002"},{"name":"NCI_Drug_Dictionary_ID","value":"802474"},{"name":"NCI_META_CUI","value":"CL1407962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802474"},{"name":"PDQ_Open_Trial_Search_ID","value":"802474"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173370":{"preferredName":"TGF-beta Receptor 1 Kinase Inhibitor SH3051","code":"C173370","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the serine/threonine kinase transforming growth factor-beta (TGF-beta) receptor 1 (TGFbR1; activin receptor-like kinase 5; ALK5), with potential antineoplastic and immunomodulating activities. Upon administration, TGFbR1 inhibitor SH3051 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of tumor cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME and cancer cell progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGF-beta Receptor 1 Kinase Inhibitor SH3051","termGroup":"PT","termSource":"NCI"},{"termName":"SH 3051","termGroup":"CN","termSource":"NCI"},{"termName":"SH-3051","termGroup":"CN","termSource":"NCI"},{"termName":"SH3051","termGroup":"CN","termSource":"NCI"},{"termName":"TGFbR1 Inhibitor SH3051","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TGF-beta Receptor 1 Kinase Inhibitor SH3051"},{"name":"NCI_Drug_Dictionary_ID","value":"801834"},{"name":"NCI_META_CUI","value":"CL1407202"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801834"},{"name":"PDQ_Open_Trial_Search_ID","value":"801834"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172107":{"preferredName":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027","code":"C172107","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine kinase transforming growth factor-beta receptor 1 (TGFbR1; activin receptor-like kinase 5; ALK5), with potential antineoplastic and immunomodulating activities. Upon administration, TGF-betaR1 inhibitor YL-13027 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME and cancer cell progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027","termGroup":"PT","termSource":"NCI"},{"termName":"TGFbR1 Inhibitor YL-13027","termGroup":"SY","termSource":"NCI"},{"termName":"YL 13027","termGroup":"CN","termSource":"NCI"},{"termName":"YL-13027","termGroup":"CN","termSource":"NCI"},{"termName":"YL13027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027"},{"name":"NCI_Drug_Dictionary_ID","value":"801356"},{"name":"NCI_META_CUI","value":"CL1406216"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801356"},{"name":"PDQ_Open_Trial_Search_ID","value":"801356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165621":{"preferredName":"Therapeutic Cancer Vaccine ATP128","code":"C165621","definitions":[{"definition":"A self-adjuvanted chimeric recombinant protein vaccine, based on the self-adjuvanting KISIMA immunization platform, composed of three components: the 42 residue fragment Z12, a cell penetrating peptide (CPP) derived from the ZEBRA protein transduction domain, a toll-like receptor (TLR) peptide agonist as an adjuvant and a chimeric cargo, a multiple antigenic domain (MAD; MultiE), that contains an as of yet not disclosed amount of major histocompatibility class (MHC)-restricted peptides derived from as of yet undisclosed tumor-associated antigens (TAAs) that are specific for colorectal cancer (CRC) patients, with potential immunomodulating and antineoplastic activities. Upon administration of ATP128, the Z12 moiety targets, binds to and penetrates antigen-presenting cells (APCs), specifically dendritic cells (DCs) and promotes the loading of the epitopes into the DCs and transports antigenic cargoes into both endosomal and cytosolic compartments. Upon processing and antigen presentation by MHC II and I, the immune system is stimulated and activates specific CD4+ and CD8+ T-cells, respectively, against the multi-epitopes specific for the CRC cells, thereby killing the CRC cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Cancer Vaccine ATP128","termGroup":"PT","termSource":"NCI"},{"termName":"ATP 128","termGroup":"CN","termSource":"NCI"},{"termName":"ATP-128","termGroup":"CN","termSource":"NCI"},{"termName":"ATP128","termGroup":"CN","termSource":"NCI"},{"termName":"Z12-MultiE/TLR Agonist Domain ATP128","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Therapeutic Cancer Vaccine ATP128"},{"name":"NCI_Drug_Dictionary_ID","value":"799990"},{"name":"NCI_META_CUI","value":"CL978804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799990"},{"name":"PDQ_Open_Trial_Search_ID","value":"799990"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C168996":{"preferredName":"Thorium Th 227 Trastuzumab Corixetan","code":"C168996","definitions":[{"definition":"A radioimmunoconjugate consisting of trastuzumab, a monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 trastuzumab corixetan, the trastuzumab moiety targets and specifically binds to HER2 on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thorium Th 227 Trastuzumab Corixetan","termGroup":"PT","termSource":"NCI"},{"termName":"227Th Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"227Th Trastuzumab Corixetan","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2701439","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2701439","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2701439","termGroup":"CN","termSource":"NCI"},{"termName":"HER2-TTC","termGroup":"SY","termSource":"NCI"},{"termName":"Th 227 Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Th-227-Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 MOAB BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Corixetan Thorium Th-227","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QC6MLG1NN6"},{"name":"Maps_To","value":"Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439"},{"name":"NCI_Drug_Dictionary_ID","value":"800871"},{"name":"NCI_META_CUI","value":"CL1378806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800871"},{"name":"PDQ_Open_Trial_Search_ID","value":"800871"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175301":{"preferredName":"Thorium Th 227 Pelgifatamab Corixetan","code":"C175301","definitions":[{"definition":"A radioimmunoconjugate consisting of pelgifatamab, a monoclonal antibody targeting the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), conjugated to the chelator corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 pelgifatamab corixetan, the pelgifatamab moiety targets and specifically binds to PSMA on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing PSMA. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thorium Th 227 Pelgifatamab Corixetan","termGroup":"PT","termSource":"NCI"},{"termName":"227Th-Pelgifatamab Corixetan","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2315497","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2315497","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2315497","termGroup":"CN","termSource":"NCI"},{"termName":"PSMA-targeted Thorium-227 Conjugate BAY-2315497","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA-TTC BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted Thorium Conjugate BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 Monoclonal Antibody BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Anti-PSMA Monoclonal Antibody BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Antibody-chelator Conjugate BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Immunoconjugate BAY-2315497","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497"},{"name":"NCI_Drug_Dictionary_ID","value":"803273"},{"name":"NCI_META_CUI","value":"CL1412652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803273"},{"name":"PDQ_Open_Trial_Search_ID","value":"803273"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168609":{"preferredName":"Thymidylate Synthase Inhibitor CX1106","code":"C168609","definitions":[{"definition":"A thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon administration, TS inhibitor CX1106 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymidylate Synthase Inhibitor CX1106","termGroup":"PT","termSource":"NCI"},{"termName":"CX 1106","termGroup":"CN","termSource":"NCI"},{"termName":"CX-1106","termGroup":"CN","termSource":"NCI"},{"termName":"CX1106","termGroup":"CN","termSource":"NCI"},{"termName":"TS Inhibitor CX1106","termGroup":"SY","termSource":"NCI"},{"termName":"TSI CX1106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thymidylate Synthase Inhibitor CX1106"},{"name":"NCI_Drug_Dictionary_ID","value":"800351"},{"name":"NCI_META_CUI","value":"CL972813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800351"},{"name":"PDQ_Open_Trial_Search_ID","value":"800351"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173891":{"preferredName":"Dargistotug","code":"C173891","definitions":[{"definition":"An inhibitor of T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), a co-inhibitory molecule and immune checkpoint inhibitor, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dargistotug targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dargistotug","termGroup":"PT","termSource":"NCI"},{"termName":"M 6223","termGroup":"CN","termSource":"NCI"},{"termName":"M-6223","termGroup":"CN","termSource":"NCI"},{"termName":"M6223","termGroup":"CN","termSource":"NCI"},{"termName":"TIGIT Inhibitor M6223","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649362-29-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O3LRM3I5J"},{"name":"Maps_To","value":"TIGIT Inhibitor M6223"},{"name":"NCI_Drug_Dictionary_ID","value":"802403"},{"name":"NCI_META_CUI","value":"CL1407689"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802403"},{"name":"PDQ_Open_Trial_Search_ID","value":"802403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167350":{"preferredName":"TLR7 agonist BNT411","code":"C167350","definitions":[{"definition":"A Toll-like receptor (TLR) 7 agonist with potential immunostimulating and antitumor activities. Upon administration, TLR7 agonist BNT411 binds to and activates TLR7. This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells, B cells, and innate immune cells including natural killer (NK) cells and macrophages. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR7 agonist BNT411","termGroup":"PT","termSource":"NCI"},{"termName":"BNT 411","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-411","termGroup":"CN","termSource":"NCI"},{"termName":"BNT411","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR7 agonist BNT411"},{"name":"NCI_Drug_Dictionary_ID","value":"800313"},{"name":"NCI_META_CUI","value":"CL972325"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800313"},{"name":"PDQ_Open_Trial_Search_ID","value":"800313"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166362":{"preferredName":"TLR7 Agonist LHC165","code":"C166362","definitions":[{"definition":"A benzonapthyridine Toll-like receptor (TLR) 7 agonist that is adsorbed to aluminum hydroxide with immunostimulating and potential antitumor activities. Upon intratumoral administration of TLR7 agonist LHC165, the agent is slowly released and targets, binds to and activates TLR7.  This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells and natural killer (NK) cells, the blockage of the suppressive function of regulatory T cells (Tregs), and the production of interferon alpha (IFNa).  TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR7 Agonist LHC165","termGroup":"PT","termSource":"NCI"},{"termName":"LHC 165","termGroup":"CN","termSource":"NCI"},{"termName":"LHC-165","termGroup":"CN","termSource":"NCI"},{"termName":"LHC165","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1258595-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RD02U4QLM1"},{"name":"Maps_To","value":"TLR7 Agonist LHC165"},{"name":"NCI_Drug_Dictionary_ID","value":"800232"},{"name":"NCI_META_CUI","value":"CL971618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800232"},{"name":"PDQ_Open_Trial_Search_ID","value":"800232"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173965":{"preferredName":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells","code":"C173965","definitions":[{"definition":"A mixed preparation of allogeneic T-lymphocytes that have been genetically modified to express either a chimeric antigen receptor (CAR) specific for the antigen transmembrane 4 L six family member 1 (TM4SF1) (CART-TM4SF1) or a CAR specific for epithelial cell adhesion molecule (EpCAM) (CART-EpCAM), with potential immunostimulating and antineoplastic activities. Upon administration of the TM4SF1-CAR/EpCAM-CAR-expressing autologous T cells, the TM4SF1-CAR-expressing autologous T-cells specifically recognize and bind to TM4SF1-expressing tumor cells and the EpCAM-CAR-expressing autologous T-cells specifically recognize and bind to EpCAM-expressing tumor cells, resulting in tumor cell lysis. TM4SF1 and EpCAM are expressed by a variety of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CART-TM4SF1 Cells/CART-EpCAM Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TM4SF1-targeting CAR T-cells and EpCAM-targeting CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"TM4SF1-CAR Autologous T-cells/EpCAM-CAR Autologous T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802161"},{"name":"NCI_META_CUI","value":"CL1407843"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802161"},{"name":"PDQ_Open_Trial_Search_ID","value":"802161"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173549":{"preferredName":"Tolebrutinib","code":"C173549","definitions":[{"definition":"An orally bioavailable, brain-penetrant, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, tolebrutinib is able to cross the blood-brain barrier and inhibits the activity of BTK both peripherally and in the central nervous system (CNS). This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway, and the resulting immune activation and inflammation. The inhibition of BTK activity also prevents microglial inflammatory signaling in the CNS, and the resulting immune activation, neuroinflammation and neurodegeneration. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. In addition to B cells, BTK is also expressed in innate immune cells, including macrophages and microglia, and plays an important role in the regulation of microglial inflammatory signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tolebrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor SAR442168","termGroup":"SY","termSource":"NCI"},{"termName":"BTK Inhibitor SAR442168","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 442168","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442168","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442168","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1971920-73-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8CZ82ZYY9X"},{"name":"Maps_To","value":"Tolebrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"801899"},{"name":"NCI_META_CUI","value":"CL1407319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801899"},{"name":"PDQ_Open_Trial_Search_ID","value":"801899"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173363":{"preferredName":"Topotecan Sustained-release Episcleral Plaque","code":"C173363","definitions":[{"definition":"An episcleral plaque containing sustained-release (SR) topotecan, a semisynthetic derivative of camptothecin and a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic activity. Upon local application of the topotecan SR episcleral plaque to the eye, topotecan is released in a sustained manner and inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The episcleral plaque allows for local delivery of topotecan for the potential treatment of retinoblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan Sustained-release Episcleral Plaque","termGroup":"PT","termSource":"NCI"},{"termName":"Chemoplaque","termGroup":"BR","termSource":"NCI"},{"termName":"Episcleral Topotecan","termGroup":"SY","termSource":"NCI"},{"termName":"SR Topotecan Episcleral Plaque","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained Release Episcleral Topotecan","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained-release Topotecan Episcleral Plaque","termGroup":"SY","termSource":"NCI"},{"termName":"Topotecan SR Episcleral Plaque","termGroup":"SY","termSource":"NCI"},{"termName":"Transscleral Topotecan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topotecan Sustained-release Episcleral Plaque"},{"name":"NCI_Drug_Dictionary_ID","value":"801808"},{"name":"NCI_META_CUI","value":"CL1407190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801808"},{"name":"PDQ_Open_Trial_Search_ID","value":"801808"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172821":{"preferredName":"Trastuzumab/MMAF Antibody-drug Conjugate IKS014","code":"C172821","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting the tumor-associated antigen (TAA) epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), site-specifically conjugated, via a tumor-selective beta-glucuronide linker, to the auristatin analog and potent microtubule inhibitor monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of trastuzumab/MMAF ADC IKS014, the trastuzumab moiety targets and binds to HER2 expressed on tumor cells. Upon binding, internalization and linker cleavage, MMAF is released. MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab/MMAF Antibody-drug Conjugate IKS014","termGroup":"PT","termSource":"NCI"},{"termName":"ADC FS-1502","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC FS-1502","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate FS-1502","termGroup":"SY","termSource":"NCI"},{"termName":"FS 1502","termGroup":"CN","termSource":"NCI"},{"termName":"FS-1502","termGroup":"CN","termSource":"NCI"},{"termName":"FS1502","termGroup":"CN","termSource":"NCI"},{"termName":"IKS 014","termGroup":"CN","termSource":"NCI"},{"termName":"IKS-014","termGroup":"CN","termSource":"NCI"},{"termName":"IKS014","termGroup":"CN","termSource":"NCI"},{"termName":"LCB 14","termGroup":"CN","termSource":"NCI"},{"termName":"LCB-14","termGroup":"CN","termSource":"NCI"},{"termName":"LCB14","termGroup":"CN","termSource":"NCI"},{"termName":"LCB14-0110","termGroup":"CN","termSource":"NCI"},{"termName":"Trastuzumab MMAF","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Monomethyl Auristatin F","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab/MMAF ADC IKS014","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trastuzumab Monomethyl Auristatin F"},{"name":"NCI_Drug_Dictionary_ID","value":"801696"},{"name":"NCI_META_CUI","value":"CL1406855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801696"},{"name":"PDQ_Open_Trial_Search_ID","value":"801696"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172388":{"preferredName":"Trastuzumab Imbotolimod","code":"C172388","definitions":[{"definition":"An immune stimulating antibody conjugate (ISAC) consisting of trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, conjugated to a Toll-like receptor (TLR) 7/8 dual agonist, with potential immunostimulating and antineoplastic activities. Upon administration of trastuzumab imbotolimod, the trastuzumab moiety targets and binds to HER2 expressed on tumor cells and, simultaneously, the TLR 7/8 dual agonist moiety targets, binds to and activates TLR7/8 expressed on antigen-presenting cells (APCs), specifically dendritic cells (DCs), in the tumor microenvironment (TME). The trastuzumab binding to the tumor cells causes the engulfment of the trastuzumab imbotolimod-bound tumor cells by tumor-associated myeloid (TAM) cells and the TAMs travel to the lymph nodes. The DCs activated by the TLR7/8 agonist causes the activation of TLR7/8-mediated pathways, and stimulates the maturation and activation of DCs, thereby re-activating the immune system against the tumor cells. Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses against tumor-associated antigens (TAAs), which lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation. HER2 is overexpressed by a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Imbotolimod","termGroup":"PT","termSource":"NCI"},{"termName":"BDC 1001","termGroup":"CN","termSource":"NCI"},{"termName":"BDC-1001","termGroup":"CN","termSource":"NCI"},{"termName":"BDC1001","termGroup":"CN","termSource":"NCI"},{"termName":"Immune Stimulating Antibody Conjugate BDC-1001","termGroup":"SY","termSource":"NCI"},{"termName":"ISAC BDC-1001","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-TLR 7/8 Agonist BDC-1001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2643926-85-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LNG8RG3NMF"},{"name":"Maps_To","value":"Trastuzumab-TLR 7/8 Agonist BDC-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"802017"},{"name":"NCI_META_CUI","value":"CL1406514"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802017"},{"name":"PDQ_Open_Trial_Search_ID","value":"802017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126803":{"preferredName":"Tris-acryl Gelatin Microspheres","code":"C126803","definitions":[{"definition":"An embolic particle composed of water-soluble, compressible, nonabsorbable microspheres composed of tris-acryl gelatin, with potential use for embolization. Upon administration, the tris-acryl gelatin microspheres (TAGM) serve as an embolic agent before surgery for highly vascularized areas, such as those seen in certain tumors, by penetrating into the blood vessel system and blocking blood flow. These microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as drug delivery vehicles during embolization of tumor vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tris-acryl Gelatin Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"Embospheres","termGroup":"BR","termSource":"NCI"},{"termName":"TAGM","termGroup":"AB","termSource":"NCI"},{"termName":"Trisacryl Gelatin Microspheres","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tris-acryl Gelatin Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"780376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780376"},{"name":"PDQ_Open_Trial_Search_ID","value":"780376"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566001"}]}}{"C173560":{"preferredName":"TRK Inhibitor TQB3558","code":"C173560","definitions":[{"definition":"An orally available inhibitor of tropomyosin receptor kinase (Trk), with potential antineoplastic activity. Upon oral administration, Trk inhibitor TQB3558 targets and binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation. This may lead to apoptosis of Trk-expressing tumor cells and the inhibition of tumor cell proliferation in Trk-expressing tumors. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRK Inhibitor TQB3558","termGroup":"PT","termSource":"NCI"},{"termName":"TQB 3558","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3558","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3558","termGroup":"CN","termSource":"NCI"},{"termName":"Tropomyosin Receptor Kinase Inhibitor TQB3558","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TRK Inhibitor TQB3558"},{"name":"NCI_Drug_Dictionary_ID","value":"801913"},{"name":"NCI_META_CUI","value":"CL1407328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801913"},{"name":"PDQ_Open_Trial_Search_ID","value":"801913"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172809":{"preferredName":"Tyrosine Kinase Inhibitor TL-895","code":"C172809","synonyms":[{"termName":"Tyrosine Kinase Inhibitor TL-895","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Jan 24 10:59:02 EST 2024 - See 'BTK Inhibitor M7583(C129710)'"},{"name":"NCI_META_CUI","value":"CL1406868"},{"name":"OLD_PARENT","value":"C1967"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172843":{"preferredName":"Ursolic Acid","code":"C172843","definitions":[{"definition":"A pentacyclic triterpenoid found in various fruits, vegetables and medicinal herbs, with a variety of potential pharmacologic activities including anti-inflammatory, antioxidative, antiviral, serum lipid-lowering, and antineoplastic activities. Upon administration, ursolic acid may promote apoptosis and inhibit cancer cell proliferation through multiple mechanisms. This may include the regulation of mitochondrial function through various pathways including the ROCK/PTEN and p53 pathways, the suppression of the nuclear factor-kappa B (NF-kB) pathways, and the increase in caspase-3, caspase-8 and caspase-9 activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ursolic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(3beta)-3-Hydroxyurs-12-en-28-oic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"77-52-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P3M2575F3F"},{"name":"Maps_To","value":"Ursolic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"801981"},{"name":"NCI_META_CUI","value":"CL1406899"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801981"},{"name":"PDQ_Open_Trial_Search_ID","value":"801981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167064":{"preferredName":"Azenosertib","code":"C167064","definitions":[{"definition":"An inhibitor of the tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu) with potential antineoplastic sensitizing activity. Although the exact mechanism of action by which this agent inhibits Wee1 has yet to be disclosed, upon administration of ZN-c3, this agent targets and inhibits Wee1. Inhibition of Wee1 promotes both premature mitosis and a prolonged mitotic arrest leading to cell death in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, upon treatment with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis; it negatively regulates the G2 checkpoint by disallowing entry into mitosis in response to DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azenosertib","termGroup":"PT","termSource":"NCI"},{"termName":"Wee1 Inhibitor ZN-c3","termGroup":"SY","termSource":"NCI"},{"termName":"ZN c3","termGroup":"CN","termSource":"NCI"},{"termName":"ZN-c3","termGroup":"CN","termSource":"NCI"},{"termName":"ZNc3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2376146-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9J13XU96Z1"},{"name":"Maps_To","value":"Wee1 Inhibitor ZN-c3"},{"name":"NCI_Drug_Dictionary_ID","value":"802182"},{"name":"NCI_META_CUI","value":"CL972056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802182"},{"name":"PDQ_Open_Trial_Search_ID","value":"802182"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173426":{"preferredName":"Wee1 Kinase Inhibitor Debio 0123","code":"C173426","definitions":[{"definition":"An orally bioavailable inhibitor of the human tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu), with potential antineoplastic sensitizing activity. Upon oral administration of Debio 0123, this agent targets, binds to and inhibits Wee1. Inhibition of Wee1 inhibits Cdk1 (Cdc2) phosphorylation, promotes both premature mitosis and a prolonged mitotic arrest, which results in the accumulation of unrepaired DNA damage. This leads to apoptosis in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, especially in combination with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis. The Wee1 tyrosine kinase is activated upon DNA damage and regulates the G2-M and S cell cycle checkpoints.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wee1 Kinase Inhibitor Debio 0123","termGroup":"PT","termSource":"NCI"},{"termName":"Debio 0123","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-0123","termGroup":"CN","termSource":"NCI"},{"termName":"Debio0123","termGroup":"CN","termSource":"NCI"},{"termName":"Wee1 Inhibitor Debio 0123","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wee1 Kinase Inhibitor Debio 0123"},{"name":"NCI_Drug_Dictionary_ID","value":"801754"},{"name":"NCI_META_CUI","value":"CL1407441"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801754"},{"name":"PDQ_Open_Trial_Search_ID","value":"801754"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171173":{"preferredName":"Gruticibart","code":"C171173","definitions":[{"definition":"A humanized anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, gruticibart targets and binds to the apple 2 domain of FXI, thereby preventing the binding of FXI to factor XIIa (FXIIa). This blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT), and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gruticibart","termGroup":"PT","termSource":"NCI"},{"termName":"AB 023","termGroup":"CN","termSource":"NCI"},{"termName":"AB-023","termGroup":"CN","termSource":"NCI"},{"termName":"AB023","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-factor XI Monoclonal Antibody Xisomab 3G3","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FXI Antibody Xisomab 3G3","termGroup":"SY","termSource":"NCI"},{"termName":"Xisomab 3G3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2704554-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K8A4DG9RWV"},{"name":"Maps_To","value":"Xisomab 3G3"},{"name":"NCI_Drug_Dictionary_ID","value":"801969"},{"name":"NCI_META_CUI","value":"CL1405388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801969"},{"name":"PDQ_Open_Trial_Search_ID","value":"801969"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165746":{"preferredName":"Zotatifin","code":"C165746","definitions":[{"definition":"A selective inhibitor of the eukaryotic translation initiation factor 4A (eIF4A), with potential antineoplastic activity. Upon administration of zotatifin, this agent targets and binds to elF4A, and promotes eIF4A binding to mRNA with specific polypurine motifs within their 5'-untranslated region (5'-UTR), leading to the formation of a stable sequence-specific ternary complex with eIF4A and mRNA (elF4A- zotatifin-mRNA). This results in the translational repression of key oncogenes and anti-apoptotic proteins involved in tumor cell proliferation, survival and metastasis, such as KRAS, Myc, myeloid cell leukemia-1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), cyclin-dependent kinase (CDK) 4 and 6, cyclin D, fibroblast growth factor receptor (FGFR) 1 and 2, human epidermal growth factor receptor 2 (HER2; ERBB2), and beta-catenin. The inhibition of the expression of these oncogenes leads to the inhibition of various oncogenic signal transduction pathways. This inhibits proliferation and induces apoptosis in tumor cells. eIF4A, a RNA helicase and the rate-limiting component of the eukaryotic translation initiation complex, catalyzes the ATP-dependent unwinding of RNA duplexes and facilitates 43S ribosome scanning within the 5'-UTR. elF4A is activated by various oncogenic signaling pathways, including RAS/mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)/AKT pathways, and regulates the translation of oncogenes and tumor survival factors with complex secondary structures within the 5'-UTRs that are required for tumor cell proliferation, survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zotatifin","termGroup":"PT","termSource":"NCI"},{"termName":"4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)benzonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"eFT 226","termGroup":"CN","termSource":"NCI"},{"termName":"eFT-226","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098191-53-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2EWN8Z05CN"},{"name":"Maps_To","value":"Zotatifin"},{"name":"NCI_Drug_Dictionary_ID","value":"800362"},{"name":"NCI_META_CUI","value":"CL978864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800362"},{"name":"PDQ_Open_Trial_Search_ID","value":"800362"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66721":{"preferredName":"Levoleucovorin Calcium","code":"C66721","definitions":[{"definition":"A drug used to lessen the toxic effects of substances that block the action of folic acid, especially the anticancer drug methotrexate. Calcium levoleucovorin is used to treat some types of anemia and is also used with fluorouracil to treat colorectal cancer. It is also being studied in the treatment of other types of cancer and other conditions. Calcium levoleucovorin is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A levo isoform of leucovorin calcium with antineoplastic activity. Levoleucovorin is an active metabolite of folic acid, which does not require metabolism by dihydrofolate reductase. This agent counteracts the toxic effects of other folic acid derivative agents, rescuing the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levoleucovorin Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"Fusilev","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colorectal Cancer"},{"name":"CAS_Registry","value":"80433-71-2"},{"name":"Chemical_Formula","value":"C20H21N7O7.Ca"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"778XL6VBS8"},{"name":"Legacy Concept Name","value":"Levoleucovorin_Calcium"},{"name":"Maps_To","value":"Levoleucovorin Calcium"},{"name":"NCI_Drug_Dictionary_ID","value":"748638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748638"},{"name":"PDQ_Open_Trial_Search_ID","value":"748638"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881372"}]}}{"C2703":{"preferredName":"Mistletoe Extract","code":"C2703","definitions":[{"definition":"A substance that comes from the mistletoe plant and that is being studied as a treatment for cancer. A lectin is a complex molecule that has both protein and sugars. Lectins are able to bind to the outside of a cell and cause biochemical changes in it. Lectins are made by both animals and plants.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An extract of the whole plant Viscum album (mistletoe) with potential biological response modifier (BRM) activity. Mistletoe extract may both stimulate the antitumoral functions of the immune system and have a direct toxic effect on tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mistletoe Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Abnobaviscum","termGroup":"FB","termSource":"NCI"},{"termName":"Apotheker Bauer's Misteltinktur","termGroup":"FB","termSource":"NCI"},{"termName":"Cefalektin","termGroup":"FB","termSource":"NCI"},{"termName":"Eurixor","termGroup":"FB","termSource":"NCI"},{"termName":"Helixor","termGroup":"FB","termSource":"NCI"},{"termName":"Iscador","termGroup":"FB","termSource":"NCI"},{"termName":"Isorel","termGroup":"FB","termSource":"NCI"},{"termName":"Isugran","termGroup":"FB","termSource":"NCI"},{"termName":"Lektinol","termGroup":"FB","termSource":"NCI"},{"termName":"Mistel Curarina","termGroup":"FB","termSource":"NCI"},{"termName":"Mistel- Krautertabletten","termGroup":"FB","termSource":"NCI"},{"termName":"Mistelol-Kapseln","termGroup":"FB","termSource":"NCI"},{"termName":"Plenosol N","termGroup":"FB","termSource":"NCI"},{"termName":"Viscum","termGroup":"SY","termSource":"NCI"},{"termName":"Viscum Album Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Viscysat","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84929-55-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK9092J5MP"},{"name":"Legacy Concept Name","value":"Mistletoe_Extract"},{"name":"Maps_To","value":"Mistletoe Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"41724"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41724"},{"name":"PDQ_Open_Trial_Search_ID","value":"41724"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062189"}]}}{"C80971":{"preferredName":"Canakinumab","code":"C80971","definitions":[{"definition":"A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canakinumab","termGroup":"PT","termSource":"NCI"},{"termName":"ACZ885","termGroup":"CN","termSource":"NCI"},{"termName":"Ilaris","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"cryopyrin-associated periodic syndrome, Muckle-Wells syndrome, rheumatoid arthritis"},{"name":"Accepted_Therapeutic_Use_For","value":"Muckle-Wells syndrome, rheumatoid arthritis, other inflammatory conditions"},{"name":"CAS_Registry","value":"914613-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37CQ2C7X93"},{"name":"Legacy Concept Name","value":"Canakinumab"},{"name":"Maps_To","value":"Canakinumab"},{"name":"NCI_Drug_Dictionary_ID","value":"795723"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795723"},{"name":"PDQ_Open_Trial_Search_ID","value":"795723"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2718773"}]}}{"C77995":{"preferredName":"Rivaroxaban","code":"C77995","definitions":[{"definition":"An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rivaroxaban","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)- 1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 59-7939","termGroup":"CN","termSource":"NCI"},{"termName":"Xarelto","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Deep Vein Thrombosis Prophylaxis"},{"name":"CAS_Registry","value":"366789-02-8"},{"name":"Chemical_Formula","value":"C19H18ClN3O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9NDF7JZ4M3"},{"name":"Legacy Concept Name","value":"Rivaroxaban"},{"name":"Maps_To","value":"Rivaroxaban"},{"name":"NCI_Drug_Dictionary_ID","value":"701565"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701565"},{"name":"PDQ_Open_Trial_Search_ID","value":"701565"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1739768"}]}}{"C74084":{"preferredName":"TLR9 Agonist SD-101","code":"C74084","definitions":[{"definition":"A proprietary oligonucleotide with immunostimulatory activity. Immunostimulatory phosphorothiolate oligodeoxyribonucleotide SD-101 targets Toll-Like Receptor 9 (TLR9) found on a specialized subset of dendritic cells. The interaction of TLR9 with SD-101, in conjunction with an allergen or antigen, induces activation of memory T helper cells 1 (Th1) against a specific pathogen or allergen, thereby leading to long-lasting therapeutic effects. Furthermore, this agent does not cause a generalized activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR9 Agonist SD-101","termGroup":"PT","termSource":"NCI"},{"termName":"ISS-ODN SD-101","termGroup":"AB","termSource":"NCI"},{"termName":"SD-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TLR9_Agonist_SD-101"},{"name":"Maps_To","value":"TLR9 Agonist SD-101"},{"name":"NCI_Drug_Dictionary_ID","value":"706877"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706877"},{"name":"PDQ_Open_Trial_Search_ID","value":"706877"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348637"}]}}{"C179426":{"preferredName":"Ancient DNA Isolation","code":"C179426","definitions":[{"definition":"Any method that extracts and purifies DNA from ancient, historical, mummified or fossilized biological samples.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancient DNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"aDNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"aDNA Isolation","termGroup":"SY","termSource":"NCI"},{"termName":"aDNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"aDNA Purification","termGroup":"SY","termSource":"NCI"},{"termName":"Ancient DNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"Ancient DNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"Ancient DNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"aDNA Preparation Type"},{"name":"NCI_META_CUI","value":"CL1662202"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179428":{"preferredName":"AllPrep FFPE DNA Isolation","code":"C179428","definitions":[{"definition":"A method that extracts and purifies DNA from formalin-fixed paraffin-embedded samples using the proprietary AllPrep kit (Qiagen).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AllPrep FFPE DNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"AllPrep FFPE DNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep FFPE DNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep FFPE DNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allprep FFPE DNA"},{"name":"NCI_META_CUI","value":"CL1662198"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179430":{"preferredName":"AllPrep RNA Isolation","code":"C179430","definitions":[{"definition":"A method to isolate total RNA from a biospecimen that uses the proprietary AllPrep RNeasy MinElute spin column (Qiagen).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AllPrep RNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"AllPrep RNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep RNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep RNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allprep RNA Extraction"},{"name":"NCI_META_CUI","value":"CL1662200"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179431":{"preferredName":"Chemical Lysis DNA Extraction","code":"C179431","definitions":[{"definition":"Any method of DNA extraction that uses chemicals, rather than mechanical or enzymatic means, to disrupt the cells in the sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chemical Lysis DNA Extraction","termGroup":"PT","termSource":"NCI"},{"termName":"Chemical Lysis DNA Preparation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chemical Lysis DNA Extraction"},{"name":"NCI_META_CUI","value":"CL1662199"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179436":{"preferredName":"FFPE MicroRNA Isolation","code":"C179436","definitions":[{"definition":"A method that extracts RNA from formalin-fixed paraffin-embedded samples and then isolates the microRNA fraction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FFPE MicroRNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE miRNA Fractionation","termGroup":"SY","termSource":"NCI"},{"termName":"FFPE miRNA Isolation","termGroup":"SY","termSource":"NCI"},{"termName":"FFPE miRNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"FFPE miRNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HighPure miRNA (Allprep DNA) FFPE RNA"},{"name":"NCI_META_CUI","value":"CL1662204"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179449":{"preferredName":"Pre-extracted DNA Received by TSS Indicator","code":"C179449","definitions":[{"definition":"An indication that a DNA sample received by the tissue sample coordination site (TSS) had been isolated by the site that initially collected the tissue samples from the subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-extracted DNA Received by TSS Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Pre-extracted DNA Received by Tissue Sample Coordination Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pre-extracted DNA received by TSS"},{"name":"NCI_META_CUI","value":"CL1662309"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C3038":{"preferredName":"Fever","code":"C3038","definitions":[{"definition":"A disorder characterized by elevation of the body's temperature above the upper limit of normal.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An increase in body temperature above normal (98.6 degrees F), usually caused by disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Elevation of body temperature above normal due to inflammatory or immune responses.","type":"DEFINITION","source":"NCI"},{"definition":"Elevation of body temperature above normal due to the bodies own responses.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Elevation of body temperature above normal due to the production of more heat than the body is able to dissipate.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Temperature greater than or equal to 100.4 degrees F (38.0 degrees C)","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The elevation of the body's temperature above the upper limit of normal, usually taken as 37.7 degrees Celsius.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Fever","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Fever"},{"name":"Maps_To","value":"Fever"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C0015967"},{"name":"Use_For","value":"Pyrogenic"},{"name":"Use_For","value":"Pyrogenic reaction"},{"name":"Use_For","value":"Reaction, pyrogenic"},{"name":"xRef","value":"IMDRF:E230101"}]}}{"C3279":{"preferredName":"Night Sweats","code":"C3279","definitions":[{"definition":"Nocturnal perspiration that is unrelated to environmental temperature.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Perspiration experienced nocturnally that is unrelated to environmental temperature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Night Sweats","termGroup":"PT","termSource":"NCI"},{"termName":"Night Sweating","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Night_Sweating"},{"name":"Maps_To","value":"Night Sweats"},{"name":"Maps_To","value":"Night sweats"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C0028081"}]}}{"C3445":{"preferredName":"Weight Loss","code":"C3445","definitions":[{"definition":"A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A reduction in total body weight.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A reduction in total body weight.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Weight Loss","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Weight_Loss"},{"name":"Maps_To","value":"Weight loss"},{"name":"Maps_To","value":"Weight Loss"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1262477"}]}}{"C16237":{"preferredName":"Validation","code":"C16237","definitions":[{"definition":"Process of establishing suitability to purpose. NOTE: Validation is accomplished by planning how to measure and/or evaluate suitability to purpose; then executing the plan and documenting the results. [ICH E6] See also software validation, data validation, psychometric validation, criterion validation (COA), content validation (COA), construct validation (COA).","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"The act of validating; finding or testing the truth of something.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Validation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Validation"},{"name":"Maps_To","value":"Validation"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C1519941"}]}}{"C48227":{"preferredName":"Lost To Follow-Up","code":"C48227","definitions":[{"definition":"The loss or lack of continuation of a subject to follow-up.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The loss or lack of continuation of subject participation after a study has officially closed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lost To Follow-Up","termGroup":"PT","termSource":"NCI"},{"termName":"Lost To Follow-up","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Lost_To_Follow_Up"},{"name":"Maps_To","value":"lost to follow-up"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1302313"}]}}{"C202277":{"preferredName":"Affymetrix Genome-Wide Human SNP Array 6.0","code":"C202277","definitions":[{"definition":"A proprietary system comprised of a single microarray with over 900,000 single nucleotide polymorphisms (SNPs) for genome-wide profiling and approximately 945,000 non-polymorphic probes for detection of copy number variation across a genomic sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Affymetrix Genome-Wide Human SNP Array 6.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Affymetrix SNP 6.0"},{"name":"NCI_META_CUI","value":"CL1921237"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C182456":{"preferredName":"Comma Separated Values Format","code":"C182456","definitions":[{"definition":"A text file format that separates data elements with commas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Comma Separated Values Format","termGroup":"PT","termSource":"NCI"},{"termName":"Comma-separated Values Format","termGroup":"SY","termSource":"NCI"},{"termName":"CSV","termGroup":"AB","termSource":"NCI"},{"termName":"CSV Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CSV"},{"name":"NCI_META_CUI","value":"CL1771138"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184763":{"preferredName":"Hierarchical Data Format 5","code":"C184763","definitions":[{"definition":"A hierarchical, filesystem-like data format that can store metadata in the form of user-defined, named attributes, which are attached to groups and datasets, and representations of images and tables built up using datasets, groups and attributes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hierarchical Data Format 5","termGroup":"PT","termSource":"NCI"},{"termName":"HDF5","termGroup":"AB","termSource":"NCI"},{"termName":"Hierarchical Data Format Version 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDF5"},{"name":"NCI_META_CUI","value":"CL1773084"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184778":{"preferredName":"MEX Format","code":"C184778","definitions":[{"definition":"A minimal base ASCII file format to facilitate the exchange of data matrices.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEX Format","termGroup":"PT","termSource":"NCI"},{"termName":"Market Exchange Format","termGroup":"SY","termSource":"NCI"},{"termName":"Matrix Market Exchange Format","termGroup":"SY","termSource":"NCI"},{"termName":"MEX","termGroup":"SY","termSource":"NCI"},{"termName":"MM Exchange Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The MEX format can be used to represent the gene-barcode matrix output generated by a Cell Ranger sequence analysis pipeline. (https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/output/matrices)"},{"name":"Maps_To","value":"MEX"},{"name":"NCI_META_CUI","value":"CL1773103"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C97927":{"preferredName":"Gene Variant","code":"C97927","definitions":[{"definition":"A variation in the nucleic acid sequence of a specific gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Mutant","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Simple Nucleotide Variation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0678941"}]}}{"C47845":{"preferredName":"FASTA Format","code":"C47845","definitions":[{"definition":"A text-based format for representing either nucleotide sequences or peptide sequences. It consists of a single-line description, followed by lines of sequence data.  Sequences are represented in the standard IUPAC-IUB (International Union of Pure and Applied Chemistry-International Union of Biochemistry Commission on Biochemical Nomenclature) single letter amino acid and nucleic acid base codes. It is an extension of the FAST-P (protein) and FAST-N (nucleotide) alignment tools.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FASTA Format","termGroup":"PT","termSource":"NCI"},{"termName":"FASTA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"FASTA_Format"},{"name":"Maps_To","value":"FASTA"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1708003"}]}}{"C184749":{"preferredName":"BEDPE Format","code":"C184749","definitions":[{"definition":"A text file format used to store genomic paired-end sequencing data that includes coordinates and associated metadata.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BEDPE Format","termGroup":"PT","termSource":"NCI"},{"termName":"BEDPE","termGroup":"AB","termSource":"NCI"},{"termName":"Browser Extensible Data Paired-End Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BEDPE"},{"name":"NCI_META_CUI","value":"CL1773066"},{"name":"PubMedID_Primary_Reference","value":"17087822"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184761":{"preferredName":"Genome Variation Format","code":"C184761","definitions":[{"definition":"A tab-delimited nine-column file to describe nucleotide sequence variation data. The Genome Variation Format (GVF) is based on the Generic Feature Format Version 3 (GFF3) but the GVF specifies additional text format constraints and allows for additional attributes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genome Variation Format","termGroup":"PT","termSource":"NCI"},{"termName":"GVF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The nine columns in a GVF file are as follows: 1) the sequence identifier where the variant is located (seqid), 2) the source for the variation data (source), 3) the type of variation as described by a code or term from the Sequence Ontology (type), 4) the integer representing the start coordinate of the sequence (start), 5) an integer representing the end coordinate of the sequence (end), 6) the quality score for the sequencing run (score), 7) the nucleotide strand where the variant was found (strand), 8) an integer representing the start of the next codon from the 5' end of the sequence (phase) and 9) feature attributes (attributes). (https://github.com/The-Sequence-Ontology/Specifications/blob/master/gvf.md)"},{"name":"Maps_To","value":"GVF"},{"name":"NCI_META_CUI","value":"CL1773086"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184769":{"preferredName":"JSON Format","code":"C184769","definitions":[{"definition":"A common open standard file format and data interchange format that uses human-readable text consisting of attribute-value pairs and arrays to store and transmit data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JSON Format","termGroup":"PT","termSource":"NCI"},{"termName":"JavaScript Object Notation","termGroup":"SY","termSource":"NCI"},{"termName":"JavaScript Object Notation Format","termGroup":"SY","termSource":"NCI"},{"termName":"JSON","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JSON"},{"name":"NCI_META_CUI","value":"CL1773094"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C64783":{"preferredName":"Gram per Deciliter","code":"C64783","definitions":[{"definition":"A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gram per Deciliter","termGroup":"PT","termSource":"NCI"},{"termName":"g%","termGroup":"AB","termSource":"NCI"},{"termName":"g/dL","termGroup":"AB","termSource":"NCI"},{"termName":"Gram Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Gram-Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Gram/Deciliter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_Deciliter"},{"name":"Maps_To","value":"g/dL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439267"}]}}{"C64572":{"preferredName":"Microgram per Milliliter","code":"C64572","definitions":[{"definition":"A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of concentration or mass density equal to one microgram of substance per milliliter of solution or one milligram of substance per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Microgram per Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"g/m3","termGroup":"AB","termSource":"NCI"},{"termName":"Gram per Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"gram/cubic meter","termGroup":"SY","termSource":"NCI"},{"termName":"mcg/mL","termGroup":"AB","termSource":"NCI"},{"termName":"mg/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"mg/L","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram/Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Cubic Decimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Liter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanogram per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"ng/uL","termGroup":"AB","termSource":"NCI"},{"termName":"ug/mL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_Cubic_Meter"},{"name":"Maps_To","value":"mcg/mL"},{"name":"Maps_To","value":"mg/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439268"}]}}{"C64387":{"preferredName":"Millimole per Liter","code":"C64387","definitions":[{"definition":"A unit of concentration (molarity unit) equal to one millimole of solute per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Millimole per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"amol/fL","termGroup":"AB","termSource":"NCI"},{"termName":"Attomole per Femtoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Femtomole per Picoliter","termGroup":"SY","termSource":"NCI"},{"termName":"fmol/pL","termGroup":"AB","termSource":"NCI"},{"termName":"Micromole per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"Millimolar","termGroup":"SY","termSource":"NCI"},{"termName":"Millimole/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"mmol/L","termGroup":"AB","termSource":"NCI"},{"termName":"Mole per Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanomole per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"nmol/uL","termGroup":"AB","termSource":"NCI"},{"termName":"Picomole per Nanoliter","termGroup":"SY","termSource":"NCI"},{"termName":"pmol/nL","termGroup":"AB","termSource":"NCI"},{"termName":"umol/mL","termGroup":"AB","termSource":"NCI"},{"termName":"ymol/zL","termGroup":"AB","termSource":"NCI"},{"termName":"Yoctomole per Zeptoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Zeptomole per Attoliter","termGroup":"SY","termSource":"NCI"},{"termName":"zmol/aL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Millimole_per_Liter"},{"name":"Maps_To","value":"mmol/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1532563"}]}}{"C105522":{"preferredName":"Unit Per Gram Hemoglobin","code":"C105522","definitions":[{"definition":"A unit of concentration (biologic activity) equal to one unit of substance per gram of hemoglobin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of hemoglobin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unit Per Gram Hemoglobin","termGroup":"PT","termSource":"NCI"},{"termName":"U/g Hemoglobin","termGroup":"SY","termSource":"NCI"},{"termName":"U/g HGB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"U/g Hb"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C3642223"}]}}{"C77607":{"preferredName":"Unit per Milliliter","code":"C77607","definitions":[{"definition":"A unit of substance content expressed in unit(s) per milliliter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An arbitrary unit of substance content expressed in unit(s) per milliliter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unit per Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"U/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Unit/Milliliter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unit_per_Milliliter"},{"name":"Maps_To","value":"U/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C2945590"}]}}{"C67456":{"preferredName":"Unit per Liter","code":"C67456","definitions":[{"definition":"A unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unit per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"Microunit per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"Milliunit per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"mU/mL","termGroup":"AB","termSource":"NCI"},{"termName":"U/L","termGroup":"AB","termSource":"NCI"},{"termName":"Unit/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"uU/uL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Unit_per_Liter"},{"name":"Maps_To","value":"U/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439339"}]}}{"C67397":{"preferredName":"Microkatal per Liter","code":"C67397","definitions":[{"definition":"Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.","type":"DEFINITION","source":"NCI"},{"definition":"Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Microkatal per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"akat/pL","termGroup":"AB","termSource":"NCI"},{"termName":"Attokatal per Picoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Femtokatal per Nanoliter","termGroup":"SY","termSource":"NCI"},{"termName":"fkat/nL","termGroup":"AB","termSource":"NCI"},{"termName":"Microkatal/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanokatal per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"nkat/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Picokatal per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"pkat/uL","termGroup":"AB","termSource":"NCI"},{"termName":"ukat/L","termGroup":"AB","termSource":"NCI"},{"termName":"ykat/aL","termGroup":"AB","termSource":"NCI"},{"termName":"Yoctokatal per Attoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Zeptokatal per Femtoliter","termGroup":"SY","termSource":"NCI"},{"termName":"zkat/fL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Microkatal_per_Liter"},{"name":"Maps_To","value":"ukat/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1881822"}]}}{"C48508":{"preferredName":"Micromole per Liter","code":"C48508","definitions":[{"definition":"A concentration of 1/1,000,000 (one millionth) molecular weight per liter (mol/L).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A unit of concentration (molarity unit) equal to one micromole of solute per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of concentration (molarity unit) equal to one one-millionth of a mole (10E-6 mole) of solute per one liter of solution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micromole per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"amol/pL","termGroup":"AB","termSource":"NCI"},{"termName":"Attomole per Picoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Femtomole per Nanoliter","termGroup":"SY","termSource":"NCI"},{"termName":"fmol/nL","termGroup":"AB","termSource":"NCI"},{"termName":"mcmol/L","termGroup":"AB","termSource":"NCI"},{"termName":"Micromolar","termGroup":"SY","termSource":"NCI"},{"termName":"Nanomole per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"nmol/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Picomole per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"pmol/uL","termGroup":"AB","termSource":"NCI"},{"termName":"umol/L","termGroup":"AB","termSource":"NCI"},{"termName":"Zeptomole per Femtoliter","termGroup":"SY","termSource":"NCI"},{"termName":"zmol/fL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Micromolar"},{"name":"Maps_To","value":"umol/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439300"}]}}{"C67244":{"preferredName":"Thousand Cells per Microliter","code":"C67244","definitions":[{"definition":"A unit of cell concentration expressed as a number of cells in thousands per unit volume equal to one microliter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thousand Cells per Microliter","termGroup":"PT","termSource":"NCI"},{"termName":"10^3 Cells/uL","termGroup":"SY","termSource":"NCI"},{"termName":"10^3{Cells}/uL","termGroup":"SY","termSource":"NCI"},{"termName":"10E3 Cells/uL","termGroup":"SY","termSource":"NCI"},{"termName":"Thousand Cells/cu mm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Thousand_Cells_per_Microliter"},{"name":"Maps_To","value":"x10^3 cells/mcL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1883312"}]}}{"C67249":{"preferredName":"Billion Cells per Liter","code":"C67249","definitions":[{"definition":"A unit of cell concentration expressed as a number of cells in billions per unit volume equal to one liter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Billion Cells per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"10^9 Cells/L","termGroup":"SY","termSource":"NCI"},{"termName":"10^9{Cells}/L","termGroup":"SY","termSource":"NCI"},{"termName":"10E9 Cells/L","termGroup":"SY","termSource":"NCI"},{"termName":"Billion Cells/Liter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Billion_Cells_per_Liter"},{"name":"Maps_To","value":"x10^9 cells/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0456524"}]}}{"C65104":{"preferredName":"Square Millimeter","code":"C65104","definitions":[{"definition":"A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Square Millimeter","termGroup":"PT","termSource":"NCI"},{"termName":"Millimeter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"mm2","termGroup":"AB","termSource":"NCI"},{"termName":"sq. mm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Square_Millimeter"},{"name":"Maps_To","value":"mm^2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0456786"}]}}{"C184780":{"preferredName":"Milliunits per Mole Hemoglobin","code":"C184780","definitions":[{"definition":"A unit of concentration equal to the concentration in milliunits of substance per mole of hemoglobin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milliunits per Mole Hemoglobin","termGroup":"PT","termSource":"NCI"},{"termName":"mU/mol Hb","termGroup":"SY","termSource":"NCI"},{"termName":"mU/mol Hemoglobin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mU/mol Hb"},{"name":"NCI_META_CUI","value":"CL1773101"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C67306":{"preferredName":"Microgram per Liter","code":"C67306","definitions":[{"definition":"A unit of concentration or mass density equal to one nanogram of substance per milliliter of solution or one microgram of substance per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microgram per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"mcg/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"mcg/L","termGroup":"AB","termSource":"NCI"},{"termName":"mg/m3","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Cubic Decimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Microgram/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanogram per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"ng/mL","termGroup":"AB","termSource":"NCI"},{"termName":"pg/uL","termGroup":"AB","termSource":"NCI"},{"termName":"Picogram per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"ug/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"ug/L","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Microgram_per_Liter"},{"name":"Maps_To","value":"mcg/L"},{"name":"Maps_To","value":"ng/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439275"}]}}{"C48570":{"preferredName":"Percent Unit","code":"C48570","definitions":[{"definition":"A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Percent Unit","termGroup":"PT","termSource":"NCI"},{"termName":"%","termGroup":"AB","termSource":"NCI"},{"termName":"Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Percentage","termGroup":"SY","termSource":"NCI"},{"termName":"Unit of Percent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Percent_Unit"},{"name":"Maps_To","value":"percent"},{"name":"NCI_META_CUI","value":"CL343029"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C74919":{"preferredName":"Cells per Milliliter","code":"C74919","definitions":[{"definition":"A unit of cell concentration expressed in cells per unit of volume equal to one milliliter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cells per Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"cells/cm3","termGroup":"SY","termSource":"NCI"},{"termName":"Cells/Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"Cells/mL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cells_per_Milliliter"},{"name":"Maps_To","value":"cells/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C2699156"}]}}{"C36015":{"preferredName":"Asbestos Body","code":"C36015","synonyms":[{"termName":"Asbestos Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Asbestos_Body"},{"name":"Maps_To","value":"Asbestos bodies"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0333598"}]}}{"C34584":{"preferredName":"Endocervical Polyp","code":"C34584","definitions":[{"definition":"A polyp that arises from the endocervix. It is characterized by the presence of endocervical glands and a fibrovascular stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endocervical Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endocervical_Polyp"},{"name":"Maps_To","value":"Benign endocervical polyp"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0014126"}]}}{"C180523":{"preferredName":"Clostridium difficile Infection","code":"C180523","definitions":[{"definition":"A bacterial infection caused by Clostridium difficile (Clostridioides difficile), which is a spore-forming, toxin-producing Gram-positive anaerobic bacillus that is transmitted by the fecal-oral route. Infection may cause symptoms ranging from diarrhea to life-threatening inflammation of the colon, and risk factors include use of antibiotic medication, advanced age, and hospital or long-term care facility admission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clostridium difficile Infection","termGroup":"PT","termSource":"NCI"},{"termName":"C. diff Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Clostridioides difficile Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clostridioides difficile (c. diff)"},{"name":"NCI_META_CUI","value":"CL1663067"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C147558":{"preferredName":"Platinum-Resistant Disease","code":"C147558","definitions":[{"definition":"A finding indicating that a cancer is resistant to platinum therapy. For non-gynecologic cancers, the terms \"platinum-resistant\" and \"platinum-refractory\" are used interchangeably. For gynecologic cancers, it refers to cancer progression between one and six months of completing the last platinum therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum-Resistant Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Platinum-Resistant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Platinum-resistant"},{"name":"NCI_META_CUI","value":"CL545408"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188349":{"preferredName":"Percent Follicular Component Less than or Equal to 10 Percent","code":"C188349","definitions":[{"definition":"A semi-quantitative microscopic finding indicating that less than or equal to 10 percent of the area of a tissue section has follicular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Percent Follicular Component Less than or Equal to 10 Percent","termGroup":"PT","termSource":"NCI"},{"termName":"Percent Follicular Component Less than or Equal to 10%","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Percent follicular component <= 10%"},{"name":"NCI_META_CUI","value":"CL1793618"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188350":{"preferredName":"Percent Follicular Component Greater than 10 Percent","code":"C188350","definitions":[{"definition":"A semi-quantitative microscopic finding indicating more than 10 percent of the area of a tissue section has follicular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Percent Follicular Component Greater than 10 Percent","termGroup":"PT","termSource":"NCI"},{"termName":"Percent Follicular Component Greater than 10%","termGroup":"SY","termSource":"NCI"},{"termName":"Percent Follicular Component More than 10 Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Percent Follicular Component More than 10%","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Percent follicular component > 10%"},{"name":"NCI_META_CUI","value":"CL1793617"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188351":{"preferredName":"PD-L1 Combined Positive Score 20","code":"C188351","definitions":[{"definition":"A quantitative immunohistochemical finding indicating that the number of all PD-L1-expressing cells divided by the total number of viable tumor cells in a sample multiplied by 100 is 20.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1 Combined Positive Score 20","termGroup":"PT","termSource":"NCI"},{"termName":"CD274 CPS 20","termGroup":"SY","termSource":"NCI"},{"termName":"PD-L1 CPS 20","termGroup":"SY","termSource":"NCI"},{"termName":"PDL1 CPS 20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-L1 CPS (223C LDT) - 20%"},{"name":"NCI_META_CUI","value":"CL1793616"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C198920":{"preferredName":"Concordant Bone Marrow Histology","code":"C198920","definitions":[{"definition":"A finding, usually associated with lymphoma with bone marrow involvement, where the morphology observed in the bone marrow is the same as that found in the primary nodal site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Concordant Bone Marrow Histology","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone marrow concordant histology"},{"name":"NCI_META_CUI","value":"CL1906365"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198921":{"preferredName":"Discordant Bone Marrow Histology","code":"C198921","definitions":[{"definition":"A finding, usually associated with lymphoma with bone marrow involvement, where the morphology observed in the bone marrow is different from that found in the primary nodal site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Discordant Bone Marrow Histology","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone marrow discordant histology"},{"name":"NCI_META_CUI","value":"CL1906364"},{"name":"Semantic_Type","value":"Finding"}]}}{"C6433":{"preferredName":"Endometrial Polyp","code":"C6433","definitions":[{"definition":"A benign nodular lesion protruding above the surface of the endometrium. It is composed of a fibrous stroma that contains thick-walled blood vessels and dilated endometrial glands. Polypectomy is the treatment of choice. Only few cases with recurrence have been reported.","type":"DEFINITION","source":"NCI"},{"definition":"A benign polypoid neoplasm of the endometrium projecting into the endometrial cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endometrial Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrial Stromal Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of the Endometrium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrial_Polyp"},{"name":"Maps_To","value":"Endometrial polyp"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704273"}]}}{"C111025":{"preferredName":"Extravascular Matrix Loops","code":"C111025","definitions":[{"definition":"A microscopic finding indicating the presence or absence of extravascular matrix loops in uveal melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extravascular Matrix Loops","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extravascular Matrix Loops"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3830280"}]}}{"C111024":{"preferredName":"Presence of Extravascular Matrix Patterns","code":"C111024","definitions":[{"definition":"A microscopic finding indicating the presence of patterns formed by malignant cells outside the blood vessel circulation in uveal melanoma.  The patterns are detectable using PAS stain without counterstaining with hematoxylin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Presence of Extravascular Matrix Patterns","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Complex Extravascular Matrix Patterns"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828484"}]}}{"C14167":{"preferredName":"Poorly Differentiated","code":"C14167","definitions":[{"definition":"Describes tumor cells that generally have lost most of the appearance of normal cells. They tend to grow and spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated","termGroup":"PT","termSource":"NCI"},{"termName":"G3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated"},{"name":"Maps_To","value":"Poorly Differentiated"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205617"}]}}{"C14171":{"preferredName":"Well Differentiated","code":"C14171","definitions":[{"definition":"Describes tumor cells that generally retain the appearance of normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated","termGroup":"PT","termSource":"NCI"},{"termName":"G1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Well_Differentiated"},{"name":"Maps_To","value":"Well Differentiated"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205615"}]}}{"C49069":{"preferredName":"Open","code":"C49069","definitions":[{"definition":"Affording unobstructed entrance and exit; affording free passage or access; accessible to all.","type":"DEFINITION","source":"NCI"},{"definition":"Visible; not closed.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Open","termGroup":"PT","termSource":"NCI"},{"termName":"Opened","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Open"},{"name":"Maps_To","value":"open"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0175566"}]}}{"C42729":{"preferredName":"Review","code":"C42729","definitions":[{"definition":"The act of appraisal, evaluation, or analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Review","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Review"},{"name":"Maps_To","value":"review"},{"name":"NCI_META_CUI","value":"CL1412614"},{"name":"Semantic_Type","value":"Activity"}]}}{"C25695":{"preferredName":"Submission","code":"C25695","definitions":[{"definition":"The act of referring for judgment or consideration by others; the act of handing over something.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Submission","termGroup":"PT","termSource":"NCI"},{"termName":"Submitted","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Submitted"},{"name":"Maps_To","value":"submitted"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1515023"}]}}{"C48177":{"preferredName":"Processing","code":"C48177","definitions":[{"definition":"The act of preparing or putting through a prescribed procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Processing","termGroup":"PT","termSource":"NCI"},{"termName":"Processing Technique","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Processing_Technique"},{"name":"Maps_To","value":"processing"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C1709694"}]}}{"C49070":{"preferredName":"Closed","code":"C49070","definitions":[{"definition":"Not affording passage or access; blocked against entry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Closed","termGroup":"PT","termSource":"NCI"},{"termName":"Close","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Closed"},{"name":"Maps_To","value":"closed"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0587267"}]}}{"C184772":{"preferredName":"Legacy Project","code":"C184772","definitions":[{"definition":"An indication that project information or documentation has been deprecated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Legacy Project","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"legacy"},{"name":"NCI_META_CUI","value":"CL1773093"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184788":{"preferredName":"Processed Project","code":"C184788","definitions":[{"definition":"An indication that information or documentation associated with a project has been processed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Processed Project","termGroup":"PT","termSource":"NCI"},{"termName":"Project Processed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"processed"},{"name":"NCI_META_CUI","value":"CL1773314"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C62669":{"preferredName":"Proteomic Profiling","code":"C62669","definitions":[{"definition":"A laboratory procedure that determines both the identity and levels of expression of the proteins in a biological sample or specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proteomic Profiling","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Expression Profiling","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Proteomic_Profiling"},{"name":"Maps_To","value":"Proteome Profiling"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1327760"}]}}{"C63480":{"preferredName":"Protein Expression Analysis","code":"C63480","definitions":[{"definition":"Any method of protein detection that can be used to quantify the level of a protein in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Expression Analysis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Protein_Expression_Analysis"},{"name":"Maps_To","value":"Protein Expression Quantification"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1882495"}]}}{"C48329":{"preferredName":"Green","code":"C48329","definitions":[{"definition":"The hue of that portion of the visible spectrum lying between yellow and blue, evoked in the human observer by radiant energy with wavelengths of approximately 490 to 570 nanometers; any of a group of colors that may vary in lightness and saturation and whose hue is that of the emerald or somewhat less yellow than that of growing grass.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Green","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Green"},{"name":"Maps_To","value":"Green"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0332583"}]}}{"C48326":{"preferredName":"Red","code":"C48326","definitions":[{"definition":"The hue of the long-wave end of the visible spectrum, evoked in the human observer by radiant energy with wavelengths of approximately 630 to 750 nanometers; any of a group of colors that may vary in lightness and saturation and whose hue resembles that of blood","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Red","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Red"},{"name":"Maps_To","value":"Red"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1260956"}]}}{"C153194":{"preferredName":"Transcriptome","code":"C153194","definitions":[{"definition":"The complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcriptome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"NCI_META_CUI","value":"CL554321"},{"name":"Semantic_Type","value":"Classification"}]}}{"C38267":{"preferredName":"Intrathecal Route of Administration","code":"C38267","definitions":[{"definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","type":"DEFINITION","source":"NCI"},{"definition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product through the dura to the subarachnoid cavity.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Intrathecal Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intrathecal","termGroup":"SY","termSource":"NCI"},{"termName":"IT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intrathecal_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intrathecal"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0677897"}]}}{"C38276":{"preferredName":"Intravenous Route of Administration","code":"C38276","definitions":[{"definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","type":"DEFINITION","source":"NCI"},{"definition":"Administration within or into a vein or veins. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into a vein.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Intravenous Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intravenous","termGroup":"SY","termSource":"NCI"},{"termName":"IV","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intravenous_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intravenous Route of Administration"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522726"}]}}{"C38288":{"preferredName":"Oral Route of Administration","code":"C38288","definitions":[{"definition":"Administration to or by way of the mouth. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Taking a medicinal product by means of swallowing.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Oral","termGroup":"SY","termSource":"NCI"},{"termName":"Orally","termGroup":"SY","termSource":"NCI"},{"termName":"Per Os","termGroup":"SY","termSource":"NCI"},{"termName":"PO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Oral_Route_of_Drug_administration"},{"name":"Maps_To","value":"Oral"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1527415"}]}}{"C38248":{"preferredName":"Intrahepatic Route of Administration","code":"C38248","definitions":[{"definition":"Administration into the liver.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Intrahepatic route of drug administration is a method of drug delivery within the liver, predominantly via hepatic vein or artery. Regimen might be more beneficial then systemic one by delivering a higher dose of drug to the liver and reducing overall systemic exposure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intrahepatic Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"IH","termGroup":"AB","termSource":"NCI"},{"termName":"Intrahepatic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intrahepatic_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intrahepatic"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1512952"}]}}{"C28161":{"preferredName":"Intramuscular Route of Administration","code":"C28161","definitions":[{"definition":"Administration within a muscle. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into muscular tissue.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"Intramuscular injection is a route of drug administration via injection into muscle tissue. Aqueous or oleaginous solutions and emulsions or suspensions may be administered. Absorption rates, delay in availability of the drug to the systemic circulation, and duration of effect are perfusion-limited, depend on molecular size of the agent, volume, and osmolarity of the drug solution, fat content of the injection site, and patient physical activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramuscular Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"IM","termGroup":"AB","termSource":"NCI"},{"termName":"INTRAMUSCULAR","termGroup":"SY","termSource":"NCI"},{"termName":"Intramuscular Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intramuscular_Injection"},{"name":"Maps_To","value":"Intramuscular"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1556154"}]}}{"C38258":{"preferredName":"Intraperitoneal Route of Administration","code":"C38258","definitions":[{"definition":"A method of delivering fluids and drugs directly into the abdominal cavity through a thin tube.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Administration of a drug via injection or infusion of a substance into the peritoneum, where it is absorbed by the lining.","type":"DEFINITION","source":"NCI"},{"definition":"Administration within the peritoneal cavity. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into the peritoneal cavity.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Intraperitoneal Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intraperitoneal","termGroup":"SY","termSource":"NCI"},{"termName":"Intraperitoneal Infusion","termGroup":"SY","termSource":"NCI"},{"termName":"IP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intraperitoneal_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intraperitoneal"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522583"}]}}{"C38269":{"preferredName":"Intratumoral Route of Administration","code":"C38269","definitions":[{"definition":"Administration within a tumor. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into a tumor.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"The administration of a drug within or introduced directly into a tumor. Method allows to achieve high concentration of the agent in the tumor and delay drug release in systemic circulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intratumoral Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"I-TUMOR","termGroup":"AB","termSource":"NCI"},{"termName":"Intratumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intratumoral_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intratumoral"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1517565"}]}}{"C38278":{"preferredName":"Intravesical Route of Administration","code":"C38278","definitions":[{"definition":"Administration of a medicinal product to the urinary bladder.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"Administration within the bladder. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The administration of a drug within the urinary bladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intravesical Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"I-VESIC","termGroup":"AB","termSource":"NCI"},{"termName":"Intravesical","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intravesical_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intravesical"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522448"}]}}{"C38299":{"preferredName":"Subcutaneous Route of Administration","code":"C38299","definitions":[{"definition":"Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Drug administration beneath the skin. It provides for relatively slow, sustained release of the drug. The rate of absorption into the blood is perfusion-limited, proportional to the amount of drug at the site and can be enhanced by chemical or physical stimulation of blood flow. Subcutaneous administration minimizes the risks associated with intravascular injection: for subcutaneous infusions, external and implantable pumps are used.","type":"DEFINITION","source":"NCI"},{"definition":"Injection of a medicinal product directly underneath the skin, i.e. subdermally","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Subcutaneous Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"SC","termGroup":"AB","termSource":"NCI"},{"termName":"Subcutaneous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Subcutaneous_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Subcutaneous"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522438"}]}}{"C111017":{"preferredName":"Amber","code":"C111017","definitions":[{"definition":"A yellowish-orange color.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amber","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amber"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3714553"}]}}{"C48333":{"preferredName":"Blue","code":"C48333","definitions":[{"definition":"The hue of that portion of the visible spectrum lying between green and indigo, evoked in the human observer by radiant energy with wavelengths of approximately 420 to 490 nanometers; any of a group of colors that may vary in lightness and saturation, whose hue is that of a clear daytime sky.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Blue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Blue"},{"name":"Maps_To","value":"Blue"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1260957"}]}}{"C48332":{"preferredName":"Brown","code":"C48332","definitions":[{"definition":"Any of a group of colors between red and yellow in hue that are medium to low in lightness and low to moderate in saturation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Brown","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Brown"},{"name":"Maps_To","value":"Brown"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0678579"}]}}{"C48324":{"preferredName":"Gray","code":"C48324","definitions":[{"definition":"An achromatic color of any lightness between the extremes of black and white.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Gray","termGroup":"PT","termSource":"NCI"},{"termName":"Gray Color","termGroup":"SY","termSource":"NCI"},{"termName":"Grey","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Gray_Color"},{"name":"Maps_To","value":"Gray"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1269776"}]}}{"C111018":{"preferredName":"Hazel","code":"C111018","definitions":[{"definition":"A color that consists of brown-gold and green.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hazel","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hazel"},{"name":"NCI_META_CUI","value":"CL455349"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C157431":{"preferredName":"Red and Violet","code":"C157431","definitions":[{"definition":"The combination of red and violet colors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Red and Violet","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Red & Violet"},{"name":"NCI_META_CUI","value":"CL937124"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C160244":{"preferredName":"Other Eye Color","code":"C160244","definitions":[{"definition":"The color of the eye was identified in the study but is not present in the form.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Eye Color","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other"},{"name":"NCI_META_CUI","value":"CL971190"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C111066":{"preferredName":"Orchiopexy","code":"C111066","definitions":[{"definition":"A surgical procedure in which an undescended testis is fixated inside the scrotum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orchiopexy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Orchiopexy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194907"}]}}{"C184803":{"preferredName":"Spontaneous Descent of Undescended Testis","code":"C184803","definitions":[{"definition":"An indication that a subject previously diagnosed with undescended testicle experienced spontaneous resolution without intervention.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spontaneous Descent of Undescended Testis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spontaneous Descent"},{"name":"NCI_META_CUI","value":"CL1772997"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156018":{"preferredName":"Archive","code":"C156018","definitions":[{"definition":"A place or collection containing records, documents, or other materials, especially those of historical interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Archive","termGroup":"PT","termSource":"NCI"},{"termName":"Archival","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Archive"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0003738"}]}}{"C184805":{"preferredName":"TARGZ Format","code":"C184805","definitions":[{"definition":"An electronic file containing multiple files archived using the Unix-based tape archive (tar) utility and then compressed with the GNU zip (gzip) utility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TARGZ Format","termGroup":"PT","termSource":"NCI"},{"termName":"tar.gz","termGroup":"SY","termSource":"NCI"},{"termName":"TARGZ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TARGZ"},{"name":"NCI_META_CUI","value":"CL1772995"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C131459":{"preferredName":"Microsatellite Stable","code":"C131459","definitions":[{"definition":"Indicates that no positive loci have been detected in the microsatellite instability (MSI) biomarkers in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microsatellite Stable","termGroup":"PT","termSource":"NCI"},{"termName":"MSI Stable","termGroup":"SY","termSource":"NCI"},{"termName":"MSS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MSS"},{"name":"NCI_META_CUI","value":"CL514319"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C60763":{"preferredName":"Supplement","code":"C60763","definitions":[{"definition":"Textual matter that is added onto a publication or document, usually at the end; a section added to a book or document to give further information or to correct errors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supplement_Document"},{"name":"Maps_To","value":"Supplementary Files"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C1947943"}]}}{"C184767":{"preferredName":"Protein Isoform Measurement","code":"C184767","definitions":[{"definition":"The determination of the amount of a specific protein isoform in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Isoform Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Isoform Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Isoform Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Isoform Quantitation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Isoform Expression Quantification"},{"name":"NCI_META_CUI","value":"CL1773096"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184779":{"preferredName":"MicroRNA Measurement","code":"C184779","definitions":[{"definition":"A determination of the amount of microRNA in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MicroRNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"MicroRNA Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA Quantitation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"miRNA Expression Quantification"},{"name":"NCI_META_CUI","value":"CL1773100"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C185075":{"preferredName":"Personal History of Pheochromocytoma or Paraganglioma","code":"C185075","definitions":[{"definition":"An individual history of pheochromocytoma or paraganglioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Pheochromocytoma or Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"History of Pheochromocytoma or Paraganglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phenochromocytoma or Paraganglioma"},{"name":"NCI_META_CUI","value":"CL1773130"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C198972":{"preferredName":"Personal History of Colorectal Cancer","code":"C198972","definitions":[{"definition":"An individual history of colorectal cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Colorectal Cancer","termGroup":"PT","termSource":"NCI"},{"termName":"History of Colorectal Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colorectal Cancer"},{"name":"NCI_META_CUI","value":"CL1797588"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C198973":{"preferredName":"Personal History of Low Grade Glioma","code":"C198973","definitions":[{"definition":"An individual history of low grade glioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Low Grade Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"History of Low Grade Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lower Grade Glioma"},{"name":"NCI_META_CUI","value":"CL1906399"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184801":{"preferredName":"Somatic Cytogenetic Abnormality Analysis","code":"C184801","definitions":[{"definition":"A technique to detect and/or identify cytogenetic abnormalities in non-germline (somatic) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Somatic Cytogenetic Abnormality Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Somatic Structural Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Structural Abnormality Analysis","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Structural Variation","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Structural Variation Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Somatic Structural Variation"},{"name":"NCI_META_CUI","value":"CL1772999"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C2950":{"preferredName":"Cytogenetic Abnormality","code":"C2950","definitions":[{"definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytogenetic Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Aberrant Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Abnormalities","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Alterations","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Alterations","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Anomalies","termGroup":"SY","termSource":"NCI"},{"termName":"Cytogenetic Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Structural Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Chromosomal_Aberration"},{"name":"Maps_To","value":"Structural Alteration"},{"name":"Maps_To","value":"Structural Variation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0008625"}]}}{"C184762":{"preferredName":"IDAT Format","code":"C184762","definitions":[{"definition":"A proprietary, encrypted XML-based, compressed electronic file format from Illumina Inc. for storing genome-wide profiling data. The data contains a summary of the intensity data generated from each probe used during a sequencing run.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDAT Format","termGroup":"PT","termSource":"NCI"},{"termName":"IDAT","termGroup":"SY","termSource":"NCI"},{"termName":"Intensity Data","termGroup":"SY","termSource":"NCI"},{"termName":"Intensity Data Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDAT"},{"name":"NCI_META_CUI","value":"CL1773087"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184806":{"preferredName":"TBI Format","code":"C184806","definitions":[{"definition":"A tab-delimited file that contains an index for the genome positions in a compressed (zipped) variant call format file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TBI Format","termGroup":"PT","termSource":"NCI"},{"termName":"Tabix","termGroup":"SY","termSource":"NCI"},{"termName":"TBI","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TBI"},{"name":"NCI_META_CUI","value":"CL1772996"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184741":{"preferredName":"Aggregated Somatic Variation Data","code":"C184741","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has been aggregated across samples or sequencing runs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggregated Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Aggregated Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aggregated Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773058"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184742":{"preferredName":"Aligned Reads Index","code":"C184742","definitions":[{"definition":"The full-text index utilized to align nucleotide sequencing read data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Reads Index","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aligned Reads Index"},{"name":"NCI_META_CUI","value":"CL1773059"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184745":{"preferredName":"Allele-Specific Copy Number Segment Data","code":"C184745","definitions":[{"definition":"Nucleotide sequence data where repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number of specified alleles in each region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allele-Specific Copy Number Segment Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allele-Specific Copy Number Segment"},{"name":"NCI_META_CUI","value":"CL1773070"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184744":{"preferredName":"Copy Number Segment Data","code":"C184744","definitions":[{"definition":"Nucleotide sequence data where repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number for each region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copy Number Segment Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Copy Number Segment"},{"name":"NCI_META_CUI","value":"CL1773073"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184776":{"preferredName":"Masked Copy Number Segment Data","code":"C184776","definitions":[{"definition":"Nucleotide sequence data where the low-quality base calls have been masked and repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number for each region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Copy Number Segment Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Copy Number Segment"},{"name":"NCI_META_CUI","value":"CL1773105"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184746":{"preferredName":"Annotated Somatic Variation Data","code":"C184746","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has been annotated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annotated Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Annotated Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Annotated Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773071"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184775":{"preferredName":"Masked Annotated Somatic Variation Data","code":"C184775","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has been annotated and where the low-quality base calls have been masked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Annotated Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Masked Annotated Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Annotated Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773104"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184752":{"preferredName":"Cohort Level Copy Number Scores","code":"C184752","definitions":[{"definition":"The number of DNA sequence copies found over the entire genome of a cohort.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cohort Level Copy Number Scores","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cohort Level Copy Number Scores"},{"name":"NCI_META_CUI","value":"CL1773081"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C181336":{"preferredName":"Number of Gene Copies","code":"C181336","definitions":[{"definition":"The number of replicas of a particular gene sequence in a genome.","type":"DEFINITION","source":"NCI"},{"definition":"The number of replicas of a particular gene sequence in a genome.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Number of Gene Copies","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gene Level Copy Number"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0178655"}]}}{"C184759":{"preferredName":"Gene Level Copy Number Scores","code":"C184759","definitions":[{"definition":"The number of copies of a specified gene found over an entire genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Level Copy Number Scores","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gene Level Copy Number Scores"},{"name":"NCI_META_CUI","value":"CL1773088"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184755":{"preferredName":"Differential Gene Expression Level Analysis","code":"C184755","definitions":[{"definition":"The determination and comparison of the levels of gene transcription in a set of at least two biospecimens (often a comparison of expression levels for a diseased- or tumor-derived sample versus a normal sample).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Differential Gene Expression Level Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Differential Gene Expression","termGroup":"SY","termSource":"NCI"},{"termName":"Differential Gene Expression Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Differential Gene Expression"},{"name":"NCI_META_CUI","value":"CL1773076"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184799":{"preferredName":"Single Cell Data","code":"C184799","definitions":[{"definition":"Any data from investigations or experiments performed on samples derived from single cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Single Cell Data","termGroup":"PT","termSource":"NCI"},{"termName":"Single Cell Analysis Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Single Cell Analysis"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C0597452"}]}}{"C184756":{"preferredName":"Exon RNA Measurement","code":"C184756","definitions":[{"definition":"The determination of the amount of RNA encoded by a specific exon in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exon RNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Exon Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal RNA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal RNA Quantitation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Exon Expression Quantification"},{"name":"NCI_META_CUI","value":"CL1773077"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C135484":{"preferredName":"Gene Expression Level Analysis","code":"C135484","definitions":[{"definition":"The determination of the level of gene transcription in a biological specimen. (CDISC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Expression Level Analysis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gene Expression Quantification"},{"name":"NCI_META_CUI","value":"CL522851"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184802":{"preferredName":"Splice Junction Measurement","code":"C184802","definitions":[{"definition":"A determination of the number of transcript splice junctions based on nucleotide sequencing reads extending across the start and/or end of a junction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splice Junction Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"RNA Transcript Splice Junction Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Junction Quantification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Splice Junction Quantification"},{"name":"NCI_META_CUI","value":"CL1773000"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184774":{"preferredName":"Masked Intensity Sequencing Data","code":"C184774","definitions":[{"definition":"Sequencing chromatogram data where the low-quality base calls have been masked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Intensity Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Masked Intensity Data","termGroup":"SY","termSource":"NCI"},{"termName":"Masked Intensity Nucleotide Sequencing Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Intensities"},{"name":"NCI_META_CUI","value":"CL1773091"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184777":{"preferredName":"Masked Somatic Variation Data","code":"C184777","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples where the low-quality base calls have been masked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Masked Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773102"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184795":{"preferredName":"Raw Somatic Variation Data","code":"C184795","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw Somatic Mutation Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw Somatic Variant Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw Simple Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1772989"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184793":{"preferredName":"Raw Intensity Sequencing Data","code":"C184793","definitions":[{"definition":"The four-color nucleotide sequencing chromatogram generated by the sequencing instrument that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw Intensity Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw Nucleic Acid Sequencing Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw Nucleotide Sequencing Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw Intensities"},{"name":"NCI_META_CUI","value":"CL1772991"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184800":{"preferredName":"Somatic Variation Rate","code":"C184800","definitions":[{"definition":"The frequency of mutations in a sample derived from non-germline cells or tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Somatic Variation Rate","termGroup":"PT","termSource":"NCI"},{"termName":"Somatic Mutation Index","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Mutation Rate","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Variation Index","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Somatic Mutation Index"},{"name":"NCI_META_CUI","value":"CL1773001"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C184809":{"preferredName":"Fusion Transcript Sequencing","code":"C184809","definitions":[{"definition":"Transcriptome sequencing where either sequencing reads are aligned to reference genes or genomes and then analyzed by software to identify discordant sequences associated with rearrangements are present or samples are subjected to direct sequencing approaches where either each read pair maps to opposite sides of a chimeric junction or where chimeric transcripts overlapping the fusion junction are identified in the reads.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fusion Transcript Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Fusion Transcript Detection","termGroup":"SY","termSource":"NCI"},{"termName":"Transcript Fusion Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transcript Fusion"},{"name":"NCI_META_CUI","value":"CL1773006"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184807":{"preferredName":"TARGET Data Coordinating Center Archive","code":"C184807","definitions":[{"definition":"A storage location for historical digital data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project data coordinating center.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TARGET Data Coordinating Center Archive","termGroup":"PT","termSource":"NCI"},{"termName":"TARGET DCC Archive","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutically Applicable Research to Generate Effective Treatments Data Coordinating Center Archive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TARGET DCC Archive"},{"name":"NCI_META_CUI","value":"CL1773008"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C184808":{"preferredName":"TCGA Data Coordinating Center Archive","code":"C184808","definitions":[{"definition":"A storage location for historical digital data from The Cancer Genome Atlas (TCGA) project data coordinating center.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCGA Data Coordinating Center Archive","termGroup":"PT","termSource":"NCI"},{"termName":"TCGA DCC Archive","termGroup":"SY","termSource":"NCI"},{"termName":"The Cancer Genome Atlas Data Coordinating Center Archive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TCGA DCC Archive"},{"name":"NCI_META_CUI","value":"CL1773009"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C184797":{"preferredName":"Reverse Phase Protein Array","code":"C184797","definitions":[{"definition":"A high-throughput antibody-based functional proteomic microarray that can quantify basal protein expression and characterize as well as quantify post-translational modifications in a series of samples of body fluids or those derived from tissue or cellular lysates. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An antibody-based functional proteomic microarray that can characterize basal protein expression and levels of protein modifications in a series of samples of body fluids or those derived from tissue or cellular lysates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reverse Phase Protein Array","termGroup":"PT","termSource":"NCI"},{"termName":"Reverse Phase Protein Microarray","termGroup":"SY","termSource":"NCI"},{"termName":"RPMA","termGroup":"SY","termSource":"NCI"},{"termName":"RPPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Reverse Phase Protein Array"},{"name":"Maps_To","value":"RPPA"},{"name":"NCI_META_CUI","value":"CL1772987"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C184743":{"preferredName":"Sequence Alignment Workflow","code":"C184743","definitions":[{"definition":"A workflow leveraged to align nucleotide sequencing data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sequence Alignment Workflow","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleotide Sequence Alignment Workflow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"alignment_workflow"},{"name":"NCI_META_CUI","value":"CL1773072"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C45527":{"preferredName":"Amosite Asbestos","code":"C45527","definitions":[{"definition":"A naturally occurring, fibrous amphibole asbestos mineral with a color ranging from gray to greenish-brown. Amosite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Amosite asbestos is a known human carcinogen. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amosite Asbestos","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12172-73-5"},{"name":"CHEBI_ID","value":"CHEBI:46678"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"321T905Y7I"},{"name":"Legacy Concept Name","value":"Amosite_Asbestos"},{"name":"Maps_To","value":"Amosite"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0051740"}]}}{"C29816":{"preferredName":"Crocidolite Asbestos","code":"C29816","definitions":[{"definition":"A naturally occurring, blue, fibrous amphibole asbestos mineral. Crocidolite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Crocidolite asbestos is a known human carcinogen. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crocidolite Asbestos","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12001-28-4"},{"name":"CHEBI_ID","value":"CHEBI:46666"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CK28D16OLZ"},{"name":"Legacy Concept Name","value":"Crocidolite_Asbestos"},{"name":"Maps_To","value":"Crocidolite"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0056502"}]}}{"C521":{"preferredName":"Therapeutic Glucocorticoid","code":"C521","definitions":[{"definition":"Synthetically derived forms of the naturally occurring Glucocorticoids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Glucocorticoid","termGroup":"PT","termSource":"NCI"},{"termName":"Glucocorticoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Glucocorticoid"},{"name":"Maps_To","value":"Glucocorticoid"},{"name":"NCI_META_CUI","value":"CL448480"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C530":{"preferredName":"Recombinant Growth Factor","code":"C530","definitions":[{"definition":"Formulated therapeutic proteins that are either isolated from endogenous sources or manufactured in a laboratory.  Growth factors bind to specific receptors expressed by various cell types, thereby stimulating cell differentiation and/or proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Growth Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Growth Agents","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Growth_Factor"},{"name":"Maps_To","value":"Growth factor"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515377"}]}}{"C62554":{"preferredName":"Poly (ADP-Ribose) Polymerase Inhibitor","code":"C62554","definitions":[{"definition":"A substance that blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. It may cause cancer cells to die. It is a type of targeted therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any substance that inhibits Poly (ADP-Ribose) polymerase, an enzyme involved in detecting DNA single strand breaks and the initiation of DNA repair. Inhibition of Poly (ADP-Ribose) polymerase has direct cytotoxic effects by inhibiting DNA repair and causing cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly (ADP-Ribose) Polymerase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"PARP Inhibitor","termGroup":"AB","termSource":"NCI"},{"termName":"Poly(ADP-Ribose) Polymerase Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:62913"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poly_ADP-Ribose_Polymerase_Inhibitor"},{"name":"Maps_To","value":"PARP inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C1882413"}]}}{"C38705":{"preferredName":"Absorbable Gelatin Sponge","code":"C38705","definitions":[{"definition":"A sterile hemostatic agent composed of purified porcine-derived gelatin.  In regional chemotherapy, absorbable gelatin sponge may be used to embolize arteries in the region of a tumor in order to block or retard blood flow; this blockage results in a locally increased concentration of chemotherapeutic agents delivered to the tumor when chemotherapeutic agents are infused into the embolized arterial circulation upstream of the blockage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Absorbable Gelatin Sponge","termGroup":"PT","termSource":"NCI"},{"termName":"Gelatin Sponge, Absorbable","termGroup":"SY","termSource":"NCI"},{"termName":"Gelfoam","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Homeostasis"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Absorbable_Gelatin_Sponge"},{"name":"Maps_To","value":"Gelfoam"},{"name":"NCI_Drug_Dictionary_ID","value":"355797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355797"},{"name":"PDQ_Open_Trial_Search_ID","value":"355797"},{"name":"Semantic_Type","value":"Medical Device"},{"name":"UMLS_CUI","value":"C0017238"}]}}{"C487":{"preferredName":"Ethiodized Oil","code":"C487","definitions":[{"definition":"A form of poppy seed oil that contains iodine. Ethiodized oil is given by injection and builds up in the blood and lymph vessels in tumors. It is used for imaging (taking pictures) of the salivary glands and the lymph system. It is also being studied in the imaging of other organs such as the liver, lung, stomach, and thyroid. It is a type of diagnostic imaging agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic iodine addition product of the ethyl ester of the fatty acids of poppy seed oil. Ethiodized oil contains 37% organically bound iodine and is used as a diagnostic radiopaque medium or, labeled with I-131, as an antineoplastic agent. Selectively retained in tumor vessels for long periods, ethiodized oil is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodol can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethiodized Oil","termGroup":"PT","termSource":"NCI"},{"termName":"Ethiodol","termGroup":"SY","termSource":"NCI"},{"termName":"Iodized Oil","termGroup":"SY","termSource":"NCI"},{"termName":"Lipiodol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diagnostic imaging, hysterosalpingography and lymphography"},{"name":"CAS_Registry","value":"8008-53-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KZW0R0686Q"},{"name":"Legacy Concept Name","value":"Ethiodized_Oil"},{"name":"Maps_To","value":"Lipiodol"},{"name":"NCI_Drug_Dictionary_ID","value":"355795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355795"},{"name":"PDQ_Open_Trial_Search_ID","value":"355795"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Substance"},{"name":"UMLS_CUI","value":"C0015018"}]}}{"C97233":{"preferredName":"Plastic Embolic Bead","code":"C97233","definitions":[{"definition":"An embolic bead that is made from a plastic-like resin or polymer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plastic Embolic Bead","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Plastic Beads"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273295"}]}}{"C71147":{"preferredName":"PVA Microporous Hydrospheres","code":"C71147","definitions":[{"definition":"An embolic material composed of microspheres of polyvinyl alcohol (PVA) polymers. These water-soluble, compressible microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as a drug delivery vehicle during embolization of tumor vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PVA Microporous Hydrospheres","termGroup":"PT","termSource":"NCI"},{"termName":"Bead Block Compressible Microspheres","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PVA_Microporous_Hydrospheres"},{"name":"Maps_To","value":"PVA Particles"},{"name":"NCI_Drug_Dictionary_ID","value":"574044"},{"name":"NCI_META_CUI","value":"CL376222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574044"},{"name":"PDQ_Open_Trial_Search_ID","value":"574044"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97230":{"preferredName":"Embolic Bead","code":"C97230","definitions":[{"definition":"An embolic agent that is in the form of a small sphere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embolic Bead","termGroup":"PT","termSource":"NCI"},{"termName":"Embolization Bead","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spherical Particles"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273292"}]}}{"C188376":{"preferredName":"Secondary Exposure Indicator","code":"C188376","definitions":[{"definition":"An indication that a subject was indirectly exposed to potentially harmful agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Exposure Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Secondary Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Secondary"},{"name":"NCI_META_CUI","value":"CL1794629"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C16929":{"preferredName":"Occupational Exposure","code":"C16929","definitions":[{"definition":"The exposure to agents that occurs as a result of one's occupation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The exposure to potentially harmful agents that occurs as a result of one's occupation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Work-related Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Occupational_Exposure"},{"name":"Maps_To","value":"Occupational"},{"name":"Maps_To","value":"Work"},{"name":"Semantic_Type","value":"Human-caused Phenomenon or Process"},{"name":"UMLS_CUI","value":"C0028798"}]}}{"C202294":{"preferredName":"Home-related Exposure","code":"C202294","definitions":[{"definition":"Exposure to potentially harmful chemical, physical, or biological agents in the home.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Home-related Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Home Exposure","termGroup":"SY","termSource":"NCI"},{"termName":"Household Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Home"},{"name":"NCI_META_CUI","value":"CL1921273"},{"name":"Semantic_Type","value":"Finding"}]}}{"C202295":{"preferredName":"Social Setting-related Exposure","code":"C202295","definitions":[{"definition":"Exposure to potentially harmful chemical, physical, or biological agents when interacting with other individuals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Social Setting-related Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Social Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social"},{"name":"NCI_META_CUI","value":"CL1921274"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188386":{"preferredName":"Maximum Tumor Bulk No Known Nodal Involvement","code":"C188386","definitions":[{"definition":"A response indicating that no lymph node involvement was detected when the location of a tumor bulk maximum was examined.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maximum Tumor Bulk No Known Nodal Involvement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No known nodal involvement"},{"name":"NCI_META_CUI","value":"CL1793628"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C159203":{"preferredName":"Ascites Fluid Sample","code":"C159203","definitions":[{"definition":"A biospecimen of ascitic fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ascites Fluid Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Ascites/peritoneum"},{"name":"NCI_META_CUI","value":"CL951255"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"xRef","value":"UBERON:0007795"}]}}{"C159355":{"preferredName":"Abdominal Peritoneum","code":"C159355","definitions":[{"definition":"A membranous lining of the abdominal cavity and abdominal organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abdominal Peritoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal Peritoneum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0817432"}]}}{"C137974":{"preferredName":"Adnexa","code":"C137974","definitions":[{"definition":"An appendage or accessory structure of an adjacent or related organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adnexa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adnexa"},{"name":"NCI_META_CUI","value":"CL524965"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"}]}}{"C32959":{"preferredName":"Left Fallopian Tube","code":"C32959","definitions":[{"definition":"The fallopian tube that extends from the uterus to the ovary in the left side of the pelvic cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Left Fallopian Tube","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Left_Fallopian_Tube"},{"name":"Maps_To","value":"Fallopian Tube, Left"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227902"}]}}{"C33475":{"preferredName":"Right Fallopian Tube","code":"C33475","definitions":[{"definition":"The fallopian tube that extends from the uterus to the ovary in the right side of the pelvic cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Right Fallopian Tube","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Fallopian_Tube"},{"name":"Maps_To","value":"Fallopian Tube, Right"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227900"}]}}{"C93180":{"preferredName":"Lower Pole of Kidney","code":"C93180","definitions":[{"definition":"The lowermost portion of the kidney.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The pole of the kidney located in the lowest region of the kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower Pole of Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Inferior Pole of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Lower Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Lower Lobe of Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney, Lower Pole"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2985481"}]}}{"C186124":{"preferredName":"Kidney Interpolar Region","code":"C186124","definitions":[{"definition":"The portion of the kidney that is located between the upper and lower poles and contains the renal hilum.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the kidney that is located between the upper and lower poles and contains the renal hilum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kidney Interpolar Region","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney, Middle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C2326831"}]}}{"C93179":{"preferredName":"Upper Pole of Kidney","code":"C93179","definitions":[{"definition":"The pole of the kidney located in the uppermost region of the kidney.","type":"DEFINITION","source":"NCI"},{"definition":"The uppermost portion of the kidney.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Upper Pole of Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Upper Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Pole of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Lobe of Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney, Upper Pole"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2985480"}]}}{"C32969":{"preferredName":"Left Ovary","code":"C32969","definitions":[{"definition":"The ovary that is located in the left side of the pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Left Ovary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Left_Ovary"},{"name":"Maps_To","value":"Ovary, Left"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227874"}]}}{"C33487":{"preferredName":"Right Ovary","code":"C33487","definitions":[{"definition":"The ovary that is located in the right side of the pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Right Ovary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Ovary"},{"name":"Maps_To","value":"Ovary, Right"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227873"}]}}{"C159344":{"preferredName":"Pelvic Peritoneum","code":"C159344","definitions":[{"definition":"A membranous lining of the pelvic organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelvic Peritoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic Peritoneum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0230295"}]}}{"C33301":{"preferredName":"Perineum","code":"C33301","definitions":[{"definition":"The area located between the anus and vulva in females, and anus and scrotum in males.","type":"DEFINITION","source":"NCI"},{"definition":"The area located between the anus and vulva in females, and anus and scrotum in males. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Perineum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Perineum"},{"name":"Maps_To","value":"Perineum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0031066"}]}}{"C173496":{"preferredName":"Peripheral Blood","code":"C173496","definitions":[{"definition":"Blood drawn from a limb.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Blood","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Peripheral blood"},{"name":"Maps_To","value":"Peripheral Blood NOS"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0229664"},{"name":"xRef","value":"UBERON:0013756"}]}}{"C12465":{"preferredName":"Peripheral Nervous System","code":"C12465","definitions":[{"definition":"That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Nervous System","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peripheral_Nervous_System"},{"name":"Maps_To","value":"Peripheral nervous system"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0206417"}]}}{"C26990":{"preferredName":"Transplanted Kidney Complication","code":"C26990","definitions":[{"definition":"A disease or disorder that is associated with a transplanted kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transplanted Kidney Complication","termGroup":"PT","termSource":"NCI"},{"termName":"Complication of Transplanted Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transplanted_Kidney_Complication"},{"name":"Maps_To","value":"Transplanted kidney"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1261281"}]}}{"C159213":{"preferredName":"Central Lung Parenchyma Tumor","code":"C159213","definitions":[{"definition":"A response that the parenchyma tumor is in the central lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Lung Parenchyma Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Central Lung"},{"name":"NCI_META_CUI","value":"CL951264"},{"name":"Semantic_Type","value":"Finding"}]}}{"C32671":{"preferredName":"Gastrosplenic Ligament","code":"C32671","definitions":[{"definition":"The portion of the greater omentum between the greater curvature of the stomach and the hilum of the spleen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrosplenic Ligament","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrosplenic_Omentum"},{"name":"Maps_To","value":"Gastrosplenic Ligament"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230230"}]}}{"C159212":{"preferredName":"Peripheral Lung Parenchyma Tumor","code":"C159212","definitions":[{"definition":"A response that the parenchyma tumor is in the peripheral lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Lung Parenchyma Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Lung"},{"name":"NCI_META_CUI","value":"CL951263"},{"name":"Semantic_Type","value":"Finding"}]}}{"C102955":{"preferredName":"Great Blood Vessel","code":"C102955","definitions":[{"definition":"Any of the major arteries or veins attached to the cardiac atria or ventricles.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any of the major arteries or veins attached to the cardiac atria or ventricles. This includes the aorta, superior and inferior vena cava and the pulmonary arteries and veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Blood Vessel","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Great Blood Vessel"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3641002"}]}}{"C12815":{"preferredName":"Inferior Vena Cava","code":"C12815","definitions":[{"definition":"A large vein that empties into the heart. It carries blood from the legs and feet and from organs in the abdomen and pelvis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A large vein that returns blood from the lower half of the body to the heart.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A large vein that returns blood from the lower half of the body to the heart.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inferior Vena Cava","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inferior_Vena_Cava"},{"name":"Maps_To","value":"Inferior Vena Cava"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042458"}]}}{"C32887":{"preferredName":"Thyroid Gland Isthmus","code":"C32887","definitions":[{"definition":"The narrow, central portion of the thyroid gland that crosses the trachea anteriorly and connects the lateral lobes of the gland. When present, the normal variant pyramidal lobe may extend from the isthmus.","type":"DEFINITION","source":"NCI"},{"definition":"The narrow, central portion of the thyroid gland that crosses the trachea anteriorly and connects the two lobes of the gland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thyroid Gland Isthmus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Isthmus"},{"name":"Maps_To","value":"Thyroid Gland Isthmus"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229583"}]}}{"C128572":{"preferredName":"Central Zone of Prostate","code":"C128572","definitions":[{"definition":"This region of the prostate gland that is located between the peripheral and transition zones, surrounding the ejaculatory ducts. It gives rise to a very small percentage of prostate cancers, though these cancers are frequently more aggressive, often resulting in invasion of the seminal vesicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Zone of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Central zone"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0458698"}]}}{"C157522":{"preferredName":"Overlapping/Multiple Zones of Prostate","code":"C157522","definitions":[{"definition":"A term that indicates involvement of multiple zones of prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Overlapping/Multiple Zones of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Overlapping/multiple zones"},{"name":"NCI_META_CUI","value":"CL937104"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C128570":{"preferredName":"Peripheral Zone of Prostate","code":"C128570","definitions":[{"definition":"The region of the prostate that is located most superficial and posterior as compared to the other prostate zones. It is located closest to the rectum, and is easily palpated on digital rectal exam. This zone of the prostate surrounds the distal urethra, and is the zone of origin for the vast majority of prostatic cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Zone of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral zone"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0458696"}]}}{"C128571":{"preferredName":"Transition Zone of Prostate","code":"C128571","definitions":[{"definition":"The region of the prostate gland that is located deep to both the central and peripheral zones; it surrounds the proximal urethra, and is the zone of the prostate gland that grows throughout life, most often causing a condition called benign prostatic hypertrophy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transition Zone of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transition zone"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1261214"}]}}{"C160198":{"preferredName":"Unknown Tumor Zone","code":"C160198","definitions":[{"definition":"An indication that the tumor zone is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unknown Tumor Zone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unknown zone"},{"name":"NCI_META_CUI","value":"CL969339"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C191737":{"preferredName":"Affymetrix CEL Format","code":"C191737","definitions":[{"definition":"A type of file that stores the results of intensity calculations of pixel values for DNA microarray image analysis. The data includes an intensity value, standard deviation of the intensity, the number of pixels used to calculate the intensity value, a flag to indicate an outlier as calculated by the algorithm, and a user defined flag indicating whether the feature should be excluded from future analysis. The file also stores the previously stated data for each feature on the probe array.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Affymetrix CEL Format","termGroup":"PT","termSource":"NCI"},{"termName":"Affymetrix CEL","termGroup":"SY","termSource":"NCI"},{"termName":"CEL","termGroup":"SY","termSource":"NCI"},{"termName":"CEL File","termGroup":"SY","termSource":"NCI"},{"termName":"CEL Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEL"},{"name":"NCI_META_CUI","value":"CL1905198"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C190163":{"preferredName":"BAI File","code":"C190163","definitions":[{"definition":"An index file found in the same directory as the binary alignment map (BAM) file, a compressed binary version of a sequence alignment/map (SAM) file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BAI File","termGroup":"PT","termSource":"NCI"},{"termName":"BAI","termGroup":"SY","termSource":"NCI"},{"termName":"BAM Indexing File","termGroup":"SY","termSource":"NCI"},{"termName":"BAM Indexing Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BAI"},{"name":"NCI_META_CUI","value":"CL1798763"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C198923":{"preferredName":"Daily Drinker","code":"C198923","definitions":[{"definition":"An individual who drinks one or more alcoholic beverages each day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daily Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Daily Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0556339"}]}}{"C198924":{"preferredName":"Weekly Drinker","code":"C198924","definitions":[{"definition":"An individual who drinks alcoholic beverages once a week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Weekly Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Weekly Drinker"},{"name":"NCI_META_CUI","value":"CL1906360"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C3239":{"preferredName":"Monosomy","code":"C3239","definitions":[{"definition":"A chromosomal abnormality consisting of the absence of one chromosome from the normal diploid number.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Monosomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monosomy"},{"name":"Maps_To","value":"Monosomy"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0026499"}]}}{"C3421":{"preferredName":"Trisomy","code":"C3421","definitions":[{"definition":"A chromosomal abnormality consisting of the presence of one chromosome in addition to the normal diploid number.","type":"DEFINITION","source":"NCI"},{"definition":"The presence of an extra chromosome, resulting in a total of three copies of that chromosome instead of the normal 2 copies (e.g., trisomy 21, or Down syndrome).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Trisomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trisomy"},{"name":"Maps_To","value":"Trisomy"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0041107"}]}}{"C15406":{"preferredName":"Cancer Screening","code":"C15406","definitions":[{"definition":"Clinical testing designed to identify the presence of a specific cancer in an asymptomatic individual or population thought to be at risk of that specific cancer. The intent is to find cancers at the earliest possible stage in their development, in order to improve the chances for disease cure.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The use of any device, marker, or other means for the purpose of detecting the presence of a tumor, usually before there are any symptoms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Screening","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Screening for Patients","termGroup":"SY","termSource":"NCI"},{"termName":"Early Cancer Detection","termGroup":"SY","termSource":"NCI"},{"termName":"Screening of Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cancer_Screening"},{"name":"Maps_To","value":"Screening"},{"name":"Maps_To","value":"Special screening examination for neoplasms"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0199230"}]}}{"C15719":{"preferredName":"Surveillance","code":"C15719","definitions":[{"definition":"In medicine, the ongoing collection of information about a disease, such as cancer, in a certain group of people. The information collected may include where the disease occurs in a population and whether it affects people of a certain gender, age, or ethnic group.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The systematic collection, analysis, and interpretation of health data on an ongoing basis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surveillance","termGroup":"PT","termSource":"NCI"},{"termName":"Epidemiology / Surveillance","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Surveillance"},{"name":"Maps_To","value":"Surveillance"},{"name":"NCI_META_CUI","value":"CL426379"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C168447":{"preferredName":"Symptomatic Presentation","code":"C168447","definitions":[{"definition":"A clinical description in which a patient demonstrates evidence of greater than or equal to 1 clinical finding suggestive of underlying pathology.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"A clinical description in which a patient demonstrates evidence of more than one clinical finding suggestive of underlying pathology. (ACC/AHA)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Symptomatic Presentation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Symptomatic"},{"name":"NCI_META_CUI","value":"CL972723"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198925":{"preferredName":"Agent Orange Exposure","code":"C198925","definitions":[{"definition":"A finding indicating that an individual has been exposed to the herbicide agent orange.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agent Orange Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agent Orange"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4273835"}]}}{"C198926":{"preferredName":"Aluminum Exposure","code":"C198926","definitions":[{"definition":"A finding indicating that an individual has been exposed to aluminum or aluminum-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aluminum Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aluminum"},{"name":"NCI_META_CUI","value":"CL1906361"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165476":{"preferredName":"Arsenic Exposure","code":"C165476","definitions":[{"definition":"A finding indicating that an individual has been exposed to arsenic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arsenic Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arsenic"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0238690"}]}}{"C36251":{"preferredName":"Benzene Exposure","code":"C36251","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to benzene, benzene-containing compounds or benzene derivatives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benzene Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benzene_Exposure"},{"name":"Maps_To","value":"Benzene"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0238760"}]}}{"C198927":{"preferredName":"Cadmium Exposure","code":"C198927","definitions":[{"definition":"A finding indicating that an individual has been exposed to cadmium or cadmium-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cadmium Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cadmium"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0238876"}]}}{"C198934":{"preferredName":"Chromium Exposure","code":"C198934","definitions":[{"definition":"A finding indicating that an individual has been exposed to chromium or chromium-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromium Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chromium"},{"name":"NCI_META_CUI","value":"CL1907621"},{"name":"Semantic_Type","value":"Finding"}]}}{"C157008":{"preferredName":"Coke Oven Emission Exposure","code":"C157008","definitions":[{"definition":"Occupational exposure to gases and particulates produced when coal is processed in a coke oven.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coke Oven Emission Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coke Oven Emission"},{"name":"NCI_META_CUI","value":"CL936080"},{"name":"Semantic_Type","value":"Human-caused Phenomenon or Process"}]}}{"C198935":{"preferredName":"Copper Exposure","code":"C198935","definitions":[{"definition":"A finding indicating that an individual has been exposed to copper or copper-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copper Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Copper"},{"name":"NCI_META_CUI","value":"CL1906374"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198936":{"preferredName":"Diesel Exhaust Exposure","code":"C198936","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to volatiles and particulates present in diesel exhaust.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diesel Exhaust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diesel Exhaust"},{"name":"NCI_META_CUI","value":"CL1906373"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198937":{"preferredName":"Disinfectant Exposure","code":"C198937","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to epoxy compounds and other volatile chemicals associated with production, handling and use of disinfectants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Disinfectant Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Disinfectant"},{"name":"NCI_META_CUI","value":"CL1906375"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198938":{"preferredName":"Formaldehyde Exposure","code":"C198938","definitions":[{"definition":"A finding indicating that an individual has been exposed to formaldehyde.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formaldehyde Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Formaldehyde"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0239686"}]}}{"C198939":{"preferredName":"Methylene Chloride Exposure","code":"C198939","definitions":[{"definition":"A finding indicating that an individual has been exposed to methylene chloride.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylene Chloride Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"DCM Exposure","termGroup":"SY","termSource":"NCI"},{"termName":"Dichloromethane Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methylene Chloride"},{"name":"NCI_META_CUI","value":"CL1906370"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198940":{"preferredName":"Crude Oil Exposure","code":"C198940","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to volatiles derived from the organic compounds and polycyclic aromatic hydrocarbons and particulates that are present in crude oil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crude Oil Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oil"},{"name":"NCI_META_CUI","value":"CL1907612"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198941":{"preferredName":"Pesticide Exposure","code":"C198941","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to pesticides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pesticide Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pesticide"},{"name":"NCI_META_CUI","value":"CL1906372"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198942":{"preferredName":"Petroleum Hydrocarbon Compound Exposure","code":"C198942","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to the volatile organic compounds and polycyclic aromatic hydrocarbons that are present in and produced during refinement of petroleum products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Petroleum Hydrocarbon Compound Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Petroleum Hydrocarbon Compound"},{"name":"NCI_META_CUI","value":"CL1906371"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198943":{"preferredName":"Resin Fume Exposure","code":"C198943","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure epoxy compounds and other volatile chemicals associated with production and handling of resins (liquid plastics).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resin Fume Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resin Fumes"},{"name":"NCI_META_CUI","value":"CL1906380"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198944":{"preferredName":"Sodium Borate Exposure","code":"C198944","definitions":[{"definition":"A finding indicating that an individual has been exposed to sodium borate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Borate Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sodium Borate"},{"name":"NCI_META_CUI","value":"CL1906379"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198945":{"preferredName":"Solvent Exposure","code":"C198945","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to volatiles associated with production, handling and use of chemical solvents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solvent Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solvent"},{"name":"NCI_META_CUI","value":"CL1906382"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198946":{"preferredName":"Tetrachloroethylene Exposure","code":"C198946","definitions":[{"definition":"A finding indicating that an individual has been exposed to tetrachloroethylene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetrachloroethylene Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"PCE Exposure","termGroup":"SY","termSource":"NCI"},{"termName":"Perchloroethylene Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tetrachloroethylene"},{"name":"NCI_META_CUI","value":"CL1906381"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198947":{"preferredName":"Toluene Exposure","code":"C198947","definitions":[{"definition":"A finding indicating that an individual has been exposed to toluene or toluene-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toluene Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Toluene"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0241422"}]}}{"C168758":{"preferredName":"t(10;11)(p11.2;q23)","code":"C168758","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 10 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/ABI1 fusions and acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(10;11)(p11.2;q23)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"t(10;11)(p11.2;q23)"},{"name":"NCI_META_CUI","value":"CL1378668"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C36371":{"preferredName":"t(11;19)(q23.3;p13.1)","code":"C36371","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the long arm (q23.3) of chromosome 11 and the short arm (p13.1) of chromosome 19. It is associated with the development of acute myeloid leukemia with variant MLL translocations and topoisomerase II inhibitor-related acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(11;19)(q23.3;p13.1)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_11_19_q23_p13_1"},{"name":"Maps_To","value":"t(11;19)(q23;p13.1)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515710"}]}}{"C36415":{"preferredName":"t(3;5)(q25;q34)","code":"C36415","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the long arm (q25) of chromosome 3 and the long arm (q34) of chromosome 5. It is associated with the development of acute myeloid leukemia arising from myelodysplastic syndrome, acute myeloid leukemia with multilineage dysplasia, and acute myeloid leukemia with myelodysplasia-related changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(3;5)(q25;q34)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_3_5_q25_q34"},{"name":"Maps_To","value":"t(3;5)(q25;q34)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515766"}]}}{"C36610":{"preferredName":"t(6;11)(q27;q23)","code":"C36610","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the long arm (q27) of chromosome 6 and the long arm (q23) of chromosome 11. It is associated with the development of de novo acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(6;11)(q27;q23)","termGroup":"PT","termSource":"NCI"},{"termName":"t(6;11)(q27;q23.3)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_6_11_q27_q23"},{"name":"Maps_To","value":"t(6;11)(q27;q23)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515779"}]}}{"C128650":{"preferredName":"t(6;9)","code":"C128650","definitions":[{"definition":"A cytogenetic abnormality that involves a translocation between chromosomes 6 and 9.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(6;9)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"t(6;9)"},{"name":"NCI_META_CUI","value":"CL509592"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C119608":{"preferredName":"t(8;21)","code":"C119608","definitions":[{"definition":"A cytogenetic abnormality that involves a translocation between chromosomes 8 and 21.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(8;21)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"t(8;21)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C3897139"}]}}{"C36370":{"preferredName":"t(9;11)(p21.3;q23.3)","code":"C36370","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the short arm (p21.3) of chromosome 9 and the long arm (q23.3) of chromosome 11. It is associated with the development of acute myeloid leukemia with the MLLT3-MLL fusion gene transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(9;11)(p21.3;q23.3)","termGroup":"PT","termSource":"NCI"},{"termName":"t(9;11)(p22;q23)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_9_11_p22_q23"},{"name":"Maps_To","value":"t(9;11)(p22;q23)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515800"}]}}{"C198952":{"preferredName":"Short Arm of Chromosome","code":"C198952","definitions":[{"definition":"The shorter arm of the chromosome based on the distance from the most distal point to the centromere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Short Arm of Chromosome","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Short Arm","termGroup":"SY","termSource":"NCI"},{"termName":"p Arm","termGroup":"SY","termSource":"NCI"},{"termName":"Proximal Arm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p"},{"name":"NCI_META_CUI","value":"CL565050"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198953":{"preferredName":"Long Arm of Chromosome","code":"C198953","definitions":[{"definition":"The longer arm of the chromosome based on the distance from the most distal point to the centromere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Long Arm of Chromosome","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Long Arm","termGroup":"SY","termSource":"NCI"},{"termName":"Distal Arm","termGroup":"SY","termSource":"NCI"},{"termName":"q Arm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"q"},{"name":"NCI_META_CUI","value":"CL568361"},{"name":"Semantic_Type","value":"Finding"}]}}{"C84637":{"preferredName":"Chronic Pancreatitis","code":"C84637","definitions":[{"definition":"A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Pancreatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic Pancreatitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014770"}]}}{"C2993":{"preferredName":"Down Syndrome","code":"C2993","definitions":[{"definition":"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. Down syndrome occurs in approximately 1:700 live births. Abnormalities are variable from individual to individual and may include mental retardation, retarded growth, flat hypoplastic face with short nose, prominent epicanthic skin folds, small low-set ears with prominent antihelix, fissured and thickened tongue, laxness of joint ligaments, pelvic dysplasia, broad hands and feet, stubby fingers, transverse palmar crease, lenticular opacities and heart disease. Patients with Down syndrome have an estimated 10 to 30-fold increased risk for leukemia; most have symptoms of Alzheimer's disease by age 40. Also known as trisomy 21 syndrome.","type":"DEFINITION","source":"NCI"},{"definition":"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. This condition is characterized by distinctive facial and physical features: short stature, developmental delay, cardiac defects (atrioventricular septal defect, tetralogy of Fallot), hypo- and hyperthyroidism, autoimmune disease (type 1 diabetes mellitus), and hypogonadism.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder caused by the presence of an extra chromosome 21 and characterized by mental retardation and distinguishing physical features.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Down Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Trisomy 21 (Down Syndrome)","termGroup":"SY","termSource":"NCI"},{"termName":"Trisomy 21 Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Down_Syndrome"},{"name":"Maps_To","value":"Down Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0013080"}]}}{"C154329":{"preferredName":"Smoking","code":"C154329","definitions":[{"definition":"The act of puffing and/or inhaling the combustion products of a substance so as to be tasted and absorbed into the bloodstream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoking","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoking"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0037369"}]}}{"C190189":{"preferredName":"TAR Format","code":"C190189","definitions":[{"definition":"A file format generated by the Unix command-line utility tar (tape archive). It is used for collecting many files into one archive file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAR Format","termGroup":"PT","termSource":"NCI"},{"termName":"Tape Archive File Format","termGroup":"SY","termSource":"NCI"},{"termName":"TAR","termGroup":"SY","termSource":"NCI"},{"termName":"TAR File Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TAR"},{"name":"NCI_META_CUI","value":"CL1799248"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C198955":{"preferredName":"Intermediate Analysis Archive","code":"C198955","definitions":[{"definition":"A preserved or historical dataset comprised of items used in or generated by preliminary or interim data analysis processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermediate Analysis Archive","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate Analysis Archive"},{"name":"NCI_META_CUI","value":"CL1906384"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C198967":{"preferredName":"Extensive Extracapsular Extention","code":"C198967","definitions":[{"definition":"A morphological finding indicating that the tumor cell invasion outside the lymph node capsule was greater than 1 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extensive Extracapsular Extention","termGroup":"PT","termSource":"NCI"},{"termName":"Extensive ECE","termGroup":"SY","termSource":"NCI"},{"termName":"Extensive ECS","termGroup":"SY","termSource":"NCI"},{"termName":"Extensive Extracapsular Spread","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extensive"},{"name":"NCI_META_CUI","value":"CL1906401"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198968":{"preferredName":"Focal Extracapsular Extention","code":"C198968","definitions":[{"definition":"A morphological finding indicating that the tumor cell invasion outside the lymph node capsule was less than or equal to 1 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Focal Extracapsular Extention","termGroup":"PT","termSource":"NCI"},{"termName":"Focal ECE","termGroup":"SY","termSource":"NCI"},{"termName":"Focal ECS","termGroup":"SY","termSource":"NCI"},{"termName":"Focal Extracapsular Spread","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Focal"},{"name":"NCI_META_CUI","value":"CL1906400"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198969":{"preferredName":"Gross Extranodal Extension","code":"C198969","definitions":[{"definition":"An indication that the lymph node metastases of a malignant neoplasm have invaded adjacent organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gross Extranodal Extension","termGroup":"PT","termSource":"NCI"},{"termName":"gENE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gross Extension"},{"name":"NCI_META_CUI","value":"CL1907630"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198970":{"preferredName":"Microscopic Extranodal Extension","code":"C198970","definitions":[{"definition":"An indication that extension of a malignant neoplasm beyond the lymph node was less than or equal to 2 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microscopic Extranodal Extension","termGroup":"PT","termSource":"NCI"},{"termName":"miENE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microscopic Extension"},{"name":"NCI_META_CUI","value":"CL1906402"},{"name":"Semantic_Type","value":"Finding"}]}}{"C160838":{"preferredName":"Extranodal Tumor Extension Absent","code":"C160838","definitions":[{"definition":"A response that the extranodal tumor extension is absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extranodal Tumor Extension Absent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Extranodal Extension"},{"name":"NCI_META_CUI","value":"CL969923"},{"name":"Semantic_Type","value":"Finding"}]}}{"C118962":{"preferredName":"Clinical Trial Censoring","code":"C118962","definitions":[{"definition":"When information on time-to-event is not available due to loss to follow-up or non-occurrence of outcome event before the trial end. The data on that participant is banned or removed from the study data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical Trial Censoring","termGroup":"PT","termSource":"NCI"},{"termName":"Censoring","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Censored"},{"name":"Semantic_Type","value":"Activity"},{"name":"UMLS_CUI","value":"C3889990"}]}}{"C199218":{"preferredName":"Death without Remission","code":"C199218","definitions":[{"definition":"An indication that a subject died during treatment but had not achieved remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Death without Remission","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death without Remission"},{"name":"NCI_META_CUI","value":"CL1906161"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25499":{"preferredName":"Event","code":"C25499","definitions":[{"definition":"Something that happens at a given place and time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Event","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Event"},{"name":"Maps_To","value":"Event"},{"name":"Semantic_Type","value":"Event"},{"name":"UMLS_CUI","value":"C0441471"}]}}{"C121972":{"preferredName":"Induction Death","code":"C121972","definitions":[{"definition":"Death of the patient due to the toxic side effects of induction therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Induction Death","termGroup":"PT","termSource":"NCI"},{"termName":"Death After Induction Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Death During Induction Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Induction Death"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4054731"}]}}{"C70622":{"preferredName":"Primary Induction Failure","code":"C70622","definitions":[{"definition":"A disease status whereby the patient does not achieve a complete remission. It may not be limited to the first/initial course of therapy; it may represent all courses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Induction Failure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Induction_Failure"},{"name":"Maps_To","value":"Induction Failure"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2347677"}]}}{"C95606":{"preferredName":"Second Primary Malignant Neoplasm","code":"C95606","definitions":[{"definition":"A primary malignant neoplasm in a patient who has been already diagnosed with a primary malignant neoplasm in another anatomic site.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to a new primary cancer in a person with a history of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Second Primary Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Second Primary Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Second Malignant Neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751623"}]}}{"C199151":{"preferredName":"Renal Involvement","code":"C199151","definitions":[{"definition":"A finding indicating the spread of disease to a kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Involvement","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Involvement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney Involvement"},{"name":"NCI_META_CUI","value":"CL1478078"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199154":{"preferredName":"Liver Involvement","code":"C199154","definitions":[{"definition":"A finding indicating the spread of disease to the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liver Involvement","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatic Involvement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liver Involvement"},{"name":"NCI_META_CUI","value":"CL1482212"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199155":{"preferredName":"Lung Involvement","code":"C199155","definitions":[{"definition":"A finding indicating the spread of disease to a lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Involvement","termGroup":"PT","termSource":"NCI"},{"termName":"Pulmonary Involvement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lung Involvement"},{"name":"NCI_META_CUI","value":"CL1906099"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199157":{"preferredName":"Retroperitoneal Lymph Node Involvement","code":"C199157","definitions":[{"definition":"A finding indicating the spread of disease to a retroperitoneal lymph node.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retroperitoneal Lymph Node Involvement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retroperitoneal Lymph Node Involvement"},{"name":"NCI_META_CUI","value":"CL1906101"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199158":{"preferredName":"Vena Cava Involvement or Thrombus","code":"C199158","definitions":[{"definition":"A finding indicating a vena cava thrombus or other evidence of disease spread to the vena cava.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vena Cava Involvement or Thrombus","termGroup":"PT","termSource":"NCI"},{"termName":"Vena Cava Involvement/Thrombus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vena Cava Involvement/Thrombus"},{"name":"NCI_META_CUI","value":"CL1906100"},{"name":"Semantic_Type","value":"Finding"}]}}{"C148527":{"preferredName":"Bilateral Modified Radical Neck Dissection","code":"C148527","definitions":[{"definition":"A surgical procedure in which all the bilateral cervical lymph node groups of the neck are removed but the internal jugular veins, sternocleidomastoid muscles, and/or spinal accessory nerves are preserved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bilateral Modified Radical Neck Dissection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Functional (Limited) Neck Dissection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193866"}]}}{"C51904":{"preferredName":"Modified Radical Neck Dissection","code":"C51904","definitions":[{"definition":"A surgical procedure in which all the ipsilateral cervical lymph node groups of the neck are removed but the internal jugular vein, sternocleidomastoid muscle, and/or spinal accessory nerve are preserved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Radical Neck Dissection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Modified_Radical_Neck_Dissection"},{"name":"Maps_To","value":"Modified Radical Neck Dissection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193864"}]}}{"C51759":{"preferredName":"Radical Neck Dissection","code":"C51759","definitions":[{"definition":"A surgical procedure in which all the ipsilateral cervical lymph node groups of the neck, internal jugular vein, sternocleidomastoid muscle, spinal accessory nerve, and submandibular gland are removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Neck Dissection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radical_Neck_Dissection"},{"name":"Maps_To","value":"Radical Neck Dissection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0034542"}]}}{"C198715":{"preferredName":"Administration Professional","code":"C198715","definitions":[{"definition":"Occupations held by individuals who analyze management and organization, administer and develop policies, handle human resources and train and develop staff.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Administration Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Administration Professionals"},{"name":"NCI_META_CUI","value":"CL1905864"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198716":{"preferredName":"Administrative and Specialized Secretary","code":"C198716","definitions":[{"definition":"Occupations held by secretaries who perform administrative duties in the office, and may have specialized knowledge in other professions, such as legal or medical.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Administrative and Specialized Secretary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Administrative and Specialized Secretaries"},{"name":"NCI_META_CUI","value":"CL1905867"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C97632":{"preferredName":"Farming, Fishing, and Forestry Occupations","code":"C97632","definitions":[{"definition":"A class of professional or vocational positions of employment that involve farming, fishing or forestry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Farming, Fishing, and Forestry Occupations","termGroup":"PT","termSource":"NCI"},{"termName":"Agricultural, Forestry and Fishery Laborer","termGroup":"SY","termSource":"NCI"},{"termName":"Farming, Fishing, and Forestry","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agricultural, Forestry and Fishery Labourers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C3273533"}]}}{"C198717":{"preferredName":"Animal Producer","code":"C198717","definitions":[{"definition":"Occupations held by individuals who work to propagate species of animals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Animal Producer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Animal Producers"},{"name":"NCI_META_CUI","value":"CL1905866"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198718":{"preferredName":"Architect, Planner, Surveyor and Designer","code":"C198718","definitions":[{"definition":"Occupations held by individuals who plan and design landscapes, building exteriors and interiors, products for manufacture and visual and audiovisual content for the communication of information.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Architect, Planner, Surveyor and Designer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Architects, Planners, Surveyors and Designers"},{"name":"NCI_META_CUI","value":"CL1905876"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198719":{"preferredName":"Armed Forces Occupation, Other Rank","code":"C198719","definitions":[{"definition":"Occupations held by individuals who are part of a community dedicated to protect a geographic location.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Armed Forces Occupation, Other Rank","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Armed Forces Occupations, Other Ranks"},{"name":"NCI_META_CUI","value":"CL1905875"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198720":{"preferredName":"Artistic, Cultural and Culinary Associate Professional","code":"C198720","definitions":[{"definition":"Occupations held by individuals who combine creative skills and technical and cultural knowledge in taking and processing still photographs; design and decoration of theater sets, shop displays and the interiors of homes; preparation of objects for display; maintenance of library and gallery collections, records and cataloging systems; creation of menus and preparation and presentation of food; provision of support for stage, film and television production; and in other areas of artistic and cultural endeavor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Artistic, Cultural and Culinary Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Artistic, Cultural and Culinary Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905877"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198721":{"preferredName":"Assembler","code":"C198721","definitions":[{"definition":"Occupations held by individuals who assemble prefabricated parts of components to form subassemblies, products and equipment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Assembler","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Assemblers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0558478"}]}}{"C198722":{"preferredName":"Author, Journalist and Linguist","code":"C198722","definitions":[{"definition":"Occupations held by individuals who conceive and create literary works; interpret and communicate news and public affairs through the medial and translate or interpret from one language into another.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Author, Journalist and Linguist","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Authors, Journalists and Linguists"},{"name":"NCI_META_CUI","value":"CL1905872"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198723":{"preferredName":"Blacksmith, Toolmaker and Related Trades Worker","code":"C198723","definitions":[{"definition":"Occupations held by individuals who hammer and forge bars, rods or ingots of iron, steel and other metals to make and repair various kinds of tools, equipment and other articles; set machine tools for operators, or set and operate various machine tools; and polish and sharpen surfaces.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Blacksmith, Toolmaker and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blacksmiths, Toolmakers and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905871"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198724":{"preferredName":"Building and Housekeeping Supervisor","code":"C198724","definitions":[{"definition":"Occupations held by individuals who build houses, lay bricks, work stone, place concrete, carpenters and joiners.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Building and Housekeeping Supervisor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Building and Housekeeping Supervisors"},{"name":"NCI_META_CUI","value":"CL1905874"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198725":{"preferredName":"Building Finisher and Related Trades Worker","code":"C198725","definitions":[{"definition":"Occupations held by individuals who put the finishing touches on buildings and the trades related to such activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Building Finisher and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Building Finishers and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905873"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198726":{"preferredName":"Building Frame and Related Trades Worker","code":"C198726","definitions":[{"definition":"Occupations held by individuals who lay roofing material, put down floors and set tiles, plaster, insulate, glaze, plumb and pipe fit and work on air conditioning and refrigeration.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Building Frame and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Building Frame and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905883"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198727":{"preferredName":"Business Services Agent","code":"C198727","definitions":[{"definition":"Occupations held by individuals who establish contacts to sell various business services such as advertising space in the media, carry out customs clearance activities, match jobseekers; find workers for employers; arrange contracts or the performance of athletes, entertainers and artists, as well as for the publication of books, the production of plays, or the recording, performance and sale of music; and plan and organize conferences and similar events.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Business Services Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Business Services Agents"},{"name":"NCI_META_CUI","value":"CL1905882"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198728":{"preferredName":"Business Services and Administration Manager","code":"C198728","definitions":[{"definition":"Occupations held by individuals who manage finance, human resources, and policy and planning.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Business Services and Administration Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Business Services and Administration Managers"},{"name":"NCI_META_CUI","value":"CL1905885"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198729":{"preferredName":"Car, Van and Motorcycle Driver","code":"C198729","definitions":[{"definition":"Occupations held by individuals who drive and tend motorcycles, motorized tricycles, cars or vans to transport passengers, materials or goods.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Car, Van and Motorcycle Driver","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Car, Van and Motorcycle Drivers"},{"name":"NCI_META_CUI","value":"CL1905884"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198730":{"preferredName":"Cashier and Ticket Clerk","code":"C198730","definitions":[{"definition":"Occupations held by individuals who operate cash registers, optical price scanners, computers or other equipment to record and accept payment for the purchase of goods, services and admissions in settings such as stores, restaurants and ticket offices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Cashier and Ticket Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cashiers and Ticket Clerks"},{"name":"NCI_META_CUI","value":"CL1905879"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198731":{"preferredName":"Chemical and Photographic Products Plant and Machine Operator","code":"C198731","definitions":[{"definition":"Occupations held by individuals who monitor and operate machines which process a variety of chemicals and other ingredients to produce pharmaceuticals, toiletries, explosives and photographic or other chemical products.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Chemical and Photographic Products Plant and Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chemical and Photographic Products Plant and Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905878"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198732":{"preferredName":"Child Care Worker and Teachers' Aide","code":"C198732","definitions":[{"definition":"Occupations held by individuals who tend to the care of children and assist teachers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Child Care Worker and Teachers' Aide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Child Care Workers and Teachers' Aides"},{"name":"NCI_META_CUI","value":"CL1905881"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198733":{"preferredName":"Client Information Worker","code":"C198733","definitions":[{"definition":"Occupations held by individuals who advise in the context of travel consulting, contact center information, telephone switchboard operators, hotel receptionists, inquiry clerks, general receptionists and survey and market research interviewers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Client Information Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Client Information Workers"},{"name":"NCI_META_CUI","value":"CL1905880"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198734":{"preferredName":"Commissioned Armed Forces Officer","code":"C198734","definitions":[{"definition":"Occupations held by individuals who have received a commission in the armed forces military. They provide leadership and management to organizational units in the armed forces and/or perform similar tasks to those performed in a variety of civilian occupations outside the armed forces.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Commissioned Armed Forces Officer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Commissioned Armed Forces Officers"},{"name":"NCI_META_CUI","value":"CL1905891"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122440":{"preferredName":"Cooks and Food Preparation Workers","code":"C122440","definitions":[{"definition":"Workers who prepare, season, and cook foods, as well as workers who perform routine tasks under the direction of cooks, chefs, or food service managers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cooks and Food Preparation Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Cook","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cooks"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4055181"}]}}{"C80245":{"preferredName":"Artist","code":"C80245","definitions":[{"definition":"One who uses imagination and talent or skill to create works of aesthetic value.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artist","termGroup":"PT","termSource":"NCI"},{"termName":"Creative and Performing Artist","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Artist"},{"name":"Maps_To","value":"Creative and Performing Artists"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0402043"}]}}{"C198735":{"preferredName":"Database and Network Professional","code":"C198735","definitions":[{"definition":"Occupations held by individuals who design and administrate databases, systems administrators and computer network professionals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Database and Network Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Database and Network Professionals"},{"name":"NCI_META_CUI","value":"CL1905890"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198736":{"preferredName":"Domestic, Hotel and Office Cleaner and Helper","code":"C198736","definitions":[{"definition":"Occupations held by individuals who clean in the home, hotel or office environment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Domestic, Hotel and Office Cleaner and Helper","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Domestic, Hotel and Office Cleaners and Helpers"},{"name":"NCI_META_CUI","value":"CL1905893"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122446":{"preferredName":"Electrical and Electronic Equipment Mechanics, Installers, and Repairers","code":"C122446","definitions":[{"definition":"Workers who install, repair, or replace a variety of electrical equipment in telecommunications, transportation, utilities, and other industries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electrical and Electronic Equipment Mechanics, Installers, and Repairers","termGroup":"PT","termSource":"NCI"},{"termName":"Electrical Equipment Installer and Repairer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrical Equipment Installers and Repairers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4055072"}]}}{"C198737":{"preferredName":"Electronics and Telecommunications Installer and Repairer","code":"C198737","definitions":[{"definition":"Workers who install or repair a variety of electrical equipment in telecommunications, transportation, utilities, and other industries.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Electronics and Telecommunications Installer and Repairer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electronics and Telecommunications Installers and Repairers"},{"name":"NCI_META_CUI","value":"CL1905892"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198738":{"preferredName":"Electrotechnology Engineer","code":"C198738","definitions":[{"definition":"Occupations held by individuals who conduct research on and design, advise, plan and direct the construction and operation of electronic, electrical and telecommunications systems, components, motors and equipment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Electrotechnology Engineer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrotechnology Engineers"},{"name":"NCI_META_CUI","value":"CL1905887"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122447":{"preferredName":"Engineers","code":"C122447","definitions":[{"definition":"A professional practitioner of engineering, concerned with applying scientific knowledge, mathematics, and ingenuity to develop solutions for technical, societal and commercial problems. Engineers design materials, structures, and systems while considering the limitations imposed by practicality, regulation, safety, and cost.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineers","termGroup":"PT","termSource":"NCI"},{"termName":"Engineering Professional (Excluding Electrotechnology)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineering Professionals (excluding Electrotechnology)"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0878517"}]}}{"C122452":{"preferredName":"Financial Specialists","code":"C122452","definitions":[{"definition":"Workers who meet with customers to help them determine their short-term and long-term financial goals and provide insurance, investment services, certificates of deposits and other financial instruments. They also contact prospective customers, evaluate costs and revenue, make financial presentations and review business trends.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Financial Specialists","termGroup":"PT","termSource":"NCI"},{"termName":"Finance Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Finance Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054955"}]}}{"C198739":{"preferredName":"Financial and Mathematical Associate Professional","code":"C198739","definitions":[{"definition":"Occupations held by individuals who are securities and finance dealers and brokers, credit and loan officers, accounting associate professionals, statistical, math and related associate professionals, valuers and assessors.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Financial and Mathematical Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Financial and Mathematical Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905886"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198740":{"preferredName":"Fishery Worker, Hunter and Trapper","code":"C198740","definitions":[{"definition":"Workers who gather fish or other aquatic animals for human consumption or other uses and/or hunt and trap wild animals for human consumption, fur, feed, bait, or other purposes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Fishery Worker, Hunter and Trapper","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fishery Workers, Hunters and Trappers"},{"name":"NCI_META_CUI","value":"CL1905889"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198741":{"preferredName":"Food and Related Products Machine Operator","code":"C198741","definitions":[{"definition":"Occupations held by individuals who are butchers, fishmongers, and related food preparers bakers, pastry-cooks and confectionery makers; dairy products makers; fruit, vegetable and related preservers, food and beverage tasters and graders, tobacco preparers, and tobacco products makers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Food and Related Products Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Food and Related Products Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905888"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198742":{"preferredName":"Food Preparation Assistant","code":"C198742","definitions":[{"definition":"Occupations held by individuals who set, operate and attend machinery used to slaughter animals and trim meat from carcasses, and to bake, freeze, heat, crush, mix, blend and otherwise process foodstuffs, beverages and tobacco leaves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Food Preparation Assistant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Food Preparation Assistants"},{"name":"NCI_META_CUI","value":"CL1905898"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198743":{"preferredName":"Food Processing and Related Trades Worker","code":"C198743","definitions":[{"definition":"Occupations held by individuals involved in the manufacturing, transportation or serving of food or food products.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Food Processing and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Food Processing and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905897"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198744":{"preferredName":"Forestry and Related Worker","code":"C198744","definitions":[{"definition":"Occupations held by individuals who plan, organize and perform operations to cultivate, conserve and exploit natural and plantation forests.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Forestry and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Forestry and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905900"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198745":{"preferredName":"Garment and Related Trades Worker","code":"C198745","definitions":[{"definition":"Occupations held by individuals who are tailors, dressmakers, furriers, hatters; garment and related patternmakers and cutters; sewing, embroidery and related workers; upholsterers and related workers; pelt dressers, tanners and fellmongers; and shoemakers and related workers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Garment and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Garment and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905899"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198746":{"preferredName":"General Office Clerk","code":"C198746","definitions":[{"definition":"Occupations held by individuals who perform a range of clerical and administrative tasks according to established procedures.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"General Office Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"General Office Clerks"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335238"}]}}{"C198747":{"preferredName":"Government Regulatory Associate Professional","code":"C198747","definitions":[{"definition":"Occupations held by individuals who work with customs and border inspectors, government tax and excise officials, government social benefits, government licensing, police inspectors and detectives, government regulatory associate professionals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Government Regulatory Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Government Regulatory Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905894"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198748":{"preferredName":"Hairdresser, Beautician and Related Worker","code":"C198748","definitions":[{"definition":"Occupations held by individuals who cut and dress hair, shave and trim beards, give beauty treatments, apply cosmetics and make-up and give other kinds of treatment to individuals in order to improve their appearance.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Hairdresser, Beautician and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hairdressers, Beauticians and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905896"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198749":{"preferredName":"Handicraft Worker","code":"C198749","definitions":[{"definition":"Occupations that rely upon use of the hands, including precision instrument or musical instrument makers and repairers, jewelry makers, potters, signmakers and painters, and workers in wood, textiles, and related materials.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Handicraft Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Handicraft Workers"},{"name":"NCI_META_CUI","value":"CL1905895"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198750":{"preferredName":"Heavy Truck and Bus Driver","code":"C198750","definitions":[{"definition":"Occupations that include driving heavy vehicles such as large buses and trucks.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Heavy Truck and Bus Driver","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heavy Truck and Bus Drivers"},{"name":"NCI_META_CUI","value":"CL1905905"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198751":{"preferredName":"Hotel and Restaurant Manager","code":"C198751","definitions":[{"definition":"Occupations that comprise hotel and restaurant managers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Hotel and Restaurant Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hotel and Restaurant Managers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335308"}]}}{"C198752":{"preferredName":"Information and Communications Technology Operations and User Support Technician","code":"C198752","definitions":[{"definition":"Information and communications occupations that include technicians and operators of computer networks, computer systems, internet systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Information and Communications Technology Operations and User Support Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Information and Communications Technology Operations and User Support Technicians"},{"name":"NCI_META_CUI","value":"CL1905907"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198753":{"preferredName":"Information and Communications Technology Service Manager","code":"C198753","definitions":[{"definition":"Workers who supervise the technicians and operators of computer networks, computer systems, internet systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Information and Communications Technology Service Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Information and Communications Technology Service managers"},{"name":"NCI_META_CUI","value":"CL1905906"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198754":{"preferredName":"Keyboard Operator","code":"C198754","definitions":[{"definition":"Clerical support workers that input and process text and data, and prepare, edit and generate documents for storage, processing, publication and transmission.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Keyboard Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Keyboard Operators"},{"name":"NCI_META_CUI","value":"CL1905902"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C97637":{"preferredName":"Legal Occupations","code":"C97637","definitions":[{"definition":"A class of professional or vocational positions of employment that involve legal activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Legal Occupations","termGroup":"PT","termSource":"NCI"},{"termName":"Legal Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Legal Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C1277117"}]}}{"C198822":{"preferredName":"Legal, Social and Religious Associate Professional","code":"C198822","definitions":[{"definition":"Professionals who provide technical and practical services and support functions in legal processes and investigations, social and community assistance programs, and religious activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Legal, Social and Religious Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Legal, Social and Religious Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1906271"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198755":{"preferredName":"Legislator and Senior Official","code":"C198755","definitions":[{"definition":"Government workers who determine, formulate, advise on and direct the implementation of policies of national, state, regional, or local governments or communities, and of special interest organizations.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Legislator and Senior Official","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Legislators and Senior Officials"},{"name":"NCI_META_CUI","value":"CL1905901"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122473":{"preferredName":"Librarians, Curators, and Archivists","code":"C122473","definitions":[{"definition":"Workers who appraise, edit, and maintain permanent records and historically valuable documents; oversee collections of artwork and historic items; restore objects and documents in museum collections and exhibits, and/or help people find information and conduct research for personal and professional use.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Librarians, Curators, and Archivists","termGroup":"PT","termSource":"NCI"},{"termName":"Librarian, Archivist and Curator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Librarians, Archivists and Curators"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335110"}]}}{"C122474":{"preferredName":"Life Scientists","code":"C122474","definitions":[{"definition":"The group of science professions that include animal scientists, biochemists and biophysicists, epidemiologists, food scientists and technologists, medical scientists, microbiologists, zoologists and wildlife biologists, and soil and plant scientists.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Life Scientists","termGroup":"PT","termSource":"NCI"},{"termName":"Life Science Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Life Science Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054649"}]}}{"C198756":{"preferredName":"Life Science Technician and Related Associate Professional","code":"C198756","definitions":[{"definition":"Technicians and other associates who perform technical tasks connected with research and operations in life sciences, which includes biology, botany, biochemistry, agriculture, and forestry.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Life Science Technician and Related Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Life Science Technicians and Related Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905904"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198757":{"preferredName":"Locomotive Engine Driver and Related Worker","code":"C198757","definitions":[{"definition":"The occupations consisting of locomotive drivers and railway brake, signal, and switch operators.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Locomotive Engine Driver and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Locomotive Engine Drivers and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905903"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198758":{"preferredName":"Machinery Mechanics and Repairer","code":"C198758","definitions":[{"definition":"Occupations involved with the maintenance or repair of machinery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Machinery Mechanics and Repairer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Machinery Mechanics and Repairers"},{"name":"NCI_META_CUI","value":"CL1905913"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198759":{"preferredName":"Managing Director and Chief Executive","code":"C198759","definitions":[{"definition":"Individuals that formulate and review the policies, and plan, direct, coordinate, and evaluate the overall activities of enterprises or organizations, with the support of other managers, usually within guidelines established by a board of directors or a governing body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Managing Director and Chief Executive","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Managing Directors and Chief Executives"},{"name":"NCI_META_CUI","value":"CL1905912"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C25392":{"preferredName":"Manufacturer","code":"C25392","definitions":[{"definition":"A person, enterprise, or entity that produces finished goods.","type":"DEFINITION","source":"NCI"},{"definition":"The organization defined as being responsible for creating the product as stated on the package in which the product is supplied.","type":"ALT_DEFINITION","source":"BRIDG 3.0.3"},{"definition":"The organization defined as being responsible for creating the product as stated on the package in which the product is supplied. (BRIDG)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Manufacturer","termGroup":"PT","termSource":"NCI"},{"termName":"Make","termGroup":"SY","termSource":"NCI"},{"termName":"Maker","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturer","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturer Name","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturing","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturing Laborer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Manufacturer_Name"},{"name":"Maps_To","value":"Manufacturing Labourers"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0947322"}]}}{"C198760":{"preferredName":"Manufacturing, Mining, Construction and Distribution Manager","code":"C198760","definitions":[{"definition":"A manager in charge of manufacturing, mining, or construction and distribution workers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Manufacturing, Mining, Construction and Distribution Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Manufacturing, Mining, Construction and Distribution Managers"},{"name":"NCI_META_CUI","value":"CL1905915"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198761":{"preferredName":"Market Gardener and Crop Grower","code":"C198761","definitions":[{"definition":"Gardeners or growers that raise crops for market.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Market Gardener and Crop Grower","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Market Gardeners and Crop Growers"},{"name":"NCI_META_CUI","value":"CL1905914"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198762":{"preferredName":"Material Recording and Transport Clerk","code":"C198762","definitions":[{"definition":"A clerk for material recording or shipment and receiving of goods.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Material Recording and Transport Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Material Recording and Transport Clerks"},{"name":"NCI_META_CUI","value":"CL1905909"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198763":{"preferredName":"Mathematician, Actuary and Statistician","code":"C198763","definitions":[{"definition":"Mathematicians doing actuarial or statistical work.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mathematician, Actuary and Statistician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mathematicians, Actuaries and Statisticians"},{"name":"NCI_META_CUI","value":"CL1905908"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198764":{"preferredName":"Medical and Pharmaceutical Technician","code":"C198764","definitions":[{"definition":"Technicians in medical or pharmaceutical fields.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Medical and Pharmaceutical Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medical and Pharmaceutical Technicians"},{"name":"NCI_META_CUI","value":"CL1905911"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C25741":{"preferredName":"Physician","code":"C25741","definitions":[{"definition":"A doctor; a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon.","type":"DEFINITION","source":"NCI"},{"definition":"Medical doctor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Physician","termGroup":"PT","termSource":"NCI"},{"termName":"Doctor","termGroup":"SY","termSource":"NCI"},{"termName":"DR","termGroup":"AB","termSource":"NCI"},{"termName":"Medical Doctor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Physician"},{"name":"Maps_To","value":"Medical Doctors"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C0031831"}]}}{"C198765":{"preferredName":"Metal Processing and Finishing Plant Operator","code":"C198765","definitions":[{"definition":"An operator in charge of a metal processor or finishing plant machine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Metal Processing and Finishing Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metal Processing and Finishing Plant Operators"},{"name":"NCI_META_CUI","value":"CL1905910"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198766":{"preferredName":"Mining and Construction Laborer","code":"C198766","definitions":[{"definition":"Individuals who do hands-on work in mining or construction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mining and Construction Laborer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mining and Construction Labourers"},{"name":"NCI_META_CUI","value":"CL1905921"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198767":{"preferredName":"Mining and Mineral Processing Plant Operator","code":"C198767","definitions":[{"definition":"An operator in charge of a mining or mineral processing plant machine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mining and Mineral Processing Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mining and Mineral Processing Plant Operators"},{"name":"NCI_META_CUI","value":"CL1905920"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198768":{"preferredName":"Mining, Manufacturing and Construction Supervisor","code":"C198768","definitions":[{"definition":"Workers who directly supervise and coordinate the activities of mining, manufacturing, or construction workers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mining, Manufacturing and Construction Supervisor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mining, Manufacturing and Construction Supervisors"},{"name":"NCI_META_CUI","value":"CL1905923"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198769":{"preferredName":"Mixed Crop and Animal Producer","code":"C198769","definitions":[{"definition":"Workers who plan, organize and perform farming operations to breed and raise domesticated or non-domesticated animals for meat or animal products or farmers raising mixed crops.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mixed Crop and Animal Producer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed Crop and Animal Producers"},{"name":"NCI_META_CUI","value":"CL1905922"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198770":{"preferredName":"Mobile Plant Operator","code":"C198770","definitions":[{"definition":"Operators that drive backhoes, bulldozers, excavators, front- end loaders, graders, scrapers, skid-steer loaders, rollers and forklift trucks to level, excavate, move and load earth, rock and other material.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mobile Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mobile Plant Operators"},{"name":"NCI_META_CUI","value":"CL1905917"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198771":{"preferredName":"Non-commissioned Armed Forces Officer","code":"C198771","definitions":[{"definition":"A military enlistee who has achieved sergeant, or equivalent rank.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Non-commissioned Armed Forces Officer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-commissioned Armed Forces Officers"},{"name":"NCI_META_CUI","value":"CL1905916"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198772":{"preferredName":"Numerical Clerk","code":"C198772","definitions":[{"definition":"Clerks who do accounting, bookkeeping, statistical, financial, and other numerical data, and take charge of cash transactions incidental to business matters.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Numerical Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Numerical Clerks"},{"name":"NCI_META_CUI","value":"CL1905919"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198773":{"preferredName":"Nursing and Midwifery Associate Professional","code":"C198773","definitions":[{"definition":"Occupations held by individuals who give assistance in basic nursing and personal care for people who are physically or mentally ill, disabled or infirm, and others in need of care due to potential risks to health including before, during and after childbirth. They generally work under the supervision of, and in support of implementation of health care, treatment and referrals plans established by, medical, nursing, midwifery and other health professionals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Nursing and Midwifery Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nursing and Midwifery Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905918"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"}]}}{"C198774":{"preferredName":"Nursing and Midwifery Professional","code":"C198774","definitions":[{"definition":"Occupations held by individuals who plan, provide or manage basic nursing and personal care for people who are physically or mentally ill, disabled or infirm, and others in need of care due to potential risks to health including before, during and after childbirth. This includes delivery of infants and planning, providing, and managing prenatal and postpartum care, newborn care, and some routine care (such as gynecological exams) for women.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Nursing and Midwifery Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nursing and Midwifery Professionals"},{"name":"NCI_META_CUI","value":"CL1905929"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"}]}}{"C198775":{"preferredName":"Other Clerical Support Worker","code":"C198775","definitions":[{"definition":"A clerical support worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Clerical Support Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Clerical Support Workers"},{"name":"NCI_META_CUI","value":"CL1905928"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198776":{"preferredName":"Other Craft and Related Worker","code":"C198776","definitions":[{"definition":"A craft and related worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Craft and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Craft and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905931"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198777":{"preferredName":"Other Elementary Worker","code":"C198777","definitions":[{"definition":"An elementary worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Elementary Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Elementary Workers"},{"name":"NCI_META_CUI","value":"CL1905930"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198778":{"preferredName":"Other Health Associate Professional","code":"C198778","definitions":[{"definition":"A health associate professional not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Health Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Health Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905925"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198779":{"preferredName":"Other Health Professional","code":"C198779","definitions":[{"definition":"A health professional not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Health Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Health Professionals"},{"name":"NCI_META_CUI","value":"CL1905924"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"}]}}{"C198780":{"preferredName":"Other Personal Services Worker","code":"C198780","definitions":[{"definition":"A personal service worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Personal Services Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Personal Services Workers"},{"name":"NCI_META_CUI","value":"CL1905927"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122555":{"preferredName":"Other Sales and Related Workers","code":"C122555","definitions":[{"definition":"Sales and related workers not specifically identified elsewhere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Sales and Related Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Other Sales Worker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Sales Workers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054293"}]}}{"C198781":{"preferredName":"Other Services Manager","code":"C198781","definitions":[{"definition":"A service manager not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Services Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Services Managers"},{"name":"NCI_META_CUI","value":"CL1905926"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198782":{"preferredName":"Other Stationary Plant and Machine Operator","code":"C198782","definitions":[{"definition":"A stationary plant or machine operator not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Stationary Plant and Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Stationary Plant and Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905937"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122556":{"preferredName":"Other Teachers and Instructors","code":"C122556","definitions":[{"definition":"Teachers and instructors not specifically identified elsewhere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Teachers and Instructors","termGroup":"PT","termSource":"NCI"},{"termName":"Other Teaching Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Teaching Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0401921"}]}}{"C198783":{"preferredName":"Painter, Building Structure Cleaner and Related Trades Worker","code":"C198783","definitions":[{"definition":"Occupations held by individuals who prepare the outer surfaces or interiors of buildings, vehicles or other structures or large manufactured articles and apply paint, wallpaper or fabric, and those who clean exterior surfaces, chimneys and other structures associated with buildings.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Painter, Building Structure Cleaner and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Painters, Building Structure Cleaners and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905936"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C53420":{"preferredName":"Paramedic","code":"C53420","definitions":[{"definition":"An individual trained and certified to provide all basic and intermediate life support measures in addition to using invasive medical procedures (including intravenous therapy, cardiac defibrillation, administering medications and solutions, and using ventilation devices) as dictated by state law and performed under medical control in case of medical emergencies, hazardous materials exposure, child birth, abuse, fires, flood, accidents, trauma, and psychiatric crises.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paramedic","termGroup":"PT","termSource":"NCI"},{"termName":"Paramedical Practitioner","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paramedic"},{"name":"Maps_To","value":"Paramedical Practitioners"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0030450"}]}}{"C198784":{"preferredName":"Personal Care Workers in Health Service","code":"C198784","definitions":[{"definition":"Occupations held by individuals who provide personal care, mobility assistance and help with daily activities to patients, elderly or disabled individuals in health care and residential settings.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Personal Care Workers in Health Service","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personal Care Workers in Health Services"},{"name":"NCI_META_CUI","value":"CL1905939"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198785":{"preferredName":"Physical and Earth Science Professional","code":"C198785","definitions":[{"definition":"Occupations held by individuals who do research and contribute to the development of concepts, theories, methods and applications of physical sciences, including astronomy, chemistry, geology, meteorology and physics.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Physical and Earth Science Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Physical and Earth Science Professionals"},{"name":"NCI_META_CUI","value":"CL1905938"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198786":{"preferredName":"Physical and Engineering Science Technician","code":"C198786","definitions":[{"definition":"Occupations held by individuals who aid in the research and applications of physical science principles in engineering, technical drawing and manufacturing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Physical and Engineering Science Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Physical and Engineering Science Technicians"},{"name":"NCI_META_CUI","value":"CL1905933"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198787":{"preferredName":"Primary School and Early Childhood Teacher","code":"C198787","definitions":[{"definition":"Occupations held by individuals who teach a range of subjects at the primary educational level and those who organize educational activities for children younger than primary school age.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Primary School and Early Childhood Teacher","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Primary School and Early Childhood Teachers"},{"name":"NCI_META_CUI","value":"CL1905932"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122501":{"preferredName":"Printing Workers","code":"C122501","definitions":[{"definition":"Printing workers produce print material in three stages: prepress, press, and binding and finishing. They review specifications, calibrate color settings on printers, identify and fix problems with printing equipment, and assemble pages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Printing Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Printing Trades Worker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Printing Trades Workers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4053770"}]}}{"C198788":{"preferredName":"Process Control Technician","code":"C198788","definitions":[{"definition":"Occupations held by individuals who manage, operate and or maintain equipment and machinery used in complex processes including, electrical power production, waste and water management and treatment, chemical manufacturing, and refining of petroleum, natural gas and metals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Process Control Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Process Control Technicians"},{"name":"NCI_META_CUI","value":"CL1905935"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198789":{"preferredName":"Production Manager in Agriculture, Forestry and Fishery","code":"C198789","definitions":[{"definition":"Occupations held by individuals who plan, direct and coordinate productivity of large-scale agricultural, horticultural, forestry, aquacultural and fishery operations.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Production Manager in Agriculture, Forestry and Fishery","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Production Managers in Agriculture, Forestry and Fisheries"},{"name":"NCI_META_CUI","value":"CL1905934"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198790":{"preferredName":"Professional Services Manager","code":"C198790","definitions":[{"definition":"Occupations held by individuals who plan, direct and coordinate the provision of social care services (child care, health care, welfare and educational services) and other professional services, and those who are branch managers for institutions that provide financial and insurance services.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Professional Services Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Professional Services Managers"},{"name":"NCI_META_CUI","value":"CL1905944"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C97643":{"preferredName":"Protective Service Occupations","code":"C97643","definitions":[{"definition":"A class of professional or vocational positions of employment that involve protective services.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protective Service Occupations","termGroup":"PT","termSource":"NCI"},{"termName":"Protective Services","termGroup":"SY","termSource":"NCI"},{"termName":"Protective Services Worker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Protective Services Workers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0600092"}]}}{"C198791":{"preferredName":"Refuse Worker","code":"C198791","definitions":[{"definition":"Occupations held by individuals who collect, sort, process and recycle garbage from various locations or those that keep streets, parks or other public spaces clean.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Refuse Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Refuse Workers"},{"name":"NCI_META_CUI","value":"CL1905943"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198792":{"preferredName":"Retail and Wholesale Trade Manager","code":"C198792","definitions":[{"definition":"Occupations held by individuals who plan, organize and coordinate the operations for retail and wholesale establishments that sell goods.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Retail and Wholesale Trade Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retail and Wholesale Trade Managers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335260"}]}}{"C198793":{"preferredName":"Rubber, Plastic and Paper Products Machine Operator","code":"C198793","definitions":[{"definition":"Occupations held by individuals who operate and monitor machines that blend natural or synthetic rubber compounds and various components to produce various rubber-containing products including the manufacture of composite goods that also include plastic or paper components.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Rubber, Plastic and Paper Products Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rubber, Plastic and Paper Products Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905945"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198794":{"preferredName":"Sales and Purchasing Agent and Broker","code":"C198794","definitions":[{"definition":"Occupations held by individuals who represent companies, governments or other organizations that buy and sell commodities, goods or insurance or provide shipping and other services to other establishments.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sales and Purchasing Agent and Broker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sales and Purchasing Agents and Brokers"},{"name":"NCI_META_CUI","value":"CL1905941"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198795":{"preferredName":"Sales, Marketing and Development Manager","code":"C198795","definitions":[{"definition":"Occupations held by individuals who plan and manage public relations, sales, marketing and research and development activities for goods and services provided by companies or organizations.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sales, Marketing and Development Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sales, Marketing and Development Managers"},{"name":"NCI_META_CUI","value":"CL1905940"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198796":{"preferredName":"Sales, Marketing and Public Relations Professional","code":"C198796","definitions":[{"definition":"Occupations held by individuals who plan develop, coordinate and implement programs to disseminate information related to organizations, companies, goods or services, and those who promote marketing and sales of goods and services.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sales, Marketing and Public Relations Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sales, Marketing and Public Relations Professionals"},{"name":"NCI_META_CUI","value":"CL1905942"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198797":{"preferredName":"Secondary Education Teacher","code":"C198797","definitions":[{"definition":"Occupations held by individuals who teach one or more subjects at the secondary education level, excluding vocational/occupational subjects.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Secondary Education Teacher","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Secondary Education Teachers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0401908"}]}}{"C198798":{"preferredName":"Secretary (General)","code":"C198798","definitions":[{"definition":"Occupations held by individuals who provide a range of administrative support services. This may include use of word processing equipment to transcribe and format correspondence, dictated or draft minutes and reports and other documents to conform to business rules, handling of incoming and outgoing mail and other correspondence, organizing and filing of documents, and surveying and recording of requests for meetings, appointments and staff leave.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Secretary (General)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Secretaries (general)"},{"name":"NCI_META_CUI","value":"CL1905951"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198799":{"preferredName":"Sheet and Structural Metal Worker, Molder and Welder, and Related Worker","code":"C198799","definitions":[{"definition":"Occupations held by individuals who make molds and cores for casting metal, those who cast, weld, shape or repair metals or objects made of metals (such as sheet metals), and those who install, construct, maintain and repair heavy metal-containing structures and equipment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sheet and Structural Metal Worker, Molder and Welder, and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sheet and Structural Metal Workers, Moulders and Welders, and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905950"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198800":{"preferredName":"Ship and Aircraft Controller and Technician","code":"C198800","definitions":[{"definition":"Occupations held by individuals who manage the operation of all equipment used on board a ship, boat or aircraft, those who command, pilot, navigate, control and/or direct the movement of ships, boats or aircraft, and those who develop and maintain navigation systems for ships, boats or aircraft and air traffic control systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Ship and Aircraft Controller and Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ship and Aircraft Controllers and Technicians"},{"name":"NCI_META_CUI","value":"CL1905953"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198801":{"preferredName":"Ships' Deck Crew and Related Worker","code":"C198801","definitions":[{"definition":"Occupations held by individuals who carry out duties associated with being on board ships and other watercraft.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Ships' Deck Crew and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ships' Deck Crews and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905952"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C75553":{"preferredName":"Salesperson","code":"C75553","definitions":[{"definition":"A person employed to sell goods or services especially to customers in a store or to customers that are visited within a geographic area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salesperson","termGroup":"PT","termSource":"NCI"},{"termName":"Sales","termGroup":"SY","termSource":"NCI"},{"termName":"Selling Occupation","termGroup":"SY","termSource":"NCI"},{"termName":"Shop Salesperson","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salesperson"},{"name":"Maps_To","value":"Shop Salespersons"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0402546"}]}}{"C198802":{"preferredName":"Social and Religious Professional","code":"C198802","definitions":[{"definition":"Occupations held by individuals who research, analyze, improve or develop theories regarding historical and current events, those who apply solutions to philosophical, political, economic and social problems and those who provide social services to meet the needs of individuals or families in the community.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Social and Religious Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social and Religious Professionals"},{"name":"NCI_META_CUI","value":"CL1905947"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198803":{"preferredName":"Software and Applications Developer and Analyst","code":"C198803","definitions":[{"definition":"Occupations held by individuals who research, plan, design, write, test, improve, analyze or set requirements for technology systems and their components, which includes hardware, software and other applications.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Software and Applications Developer and Analyst","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Software and Applications Developers and Analysts"},{"name":"NCI_META_CUI","value":"CL1905946"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198804":{"preferredName":"Sports and Fitness Worker","code":"C198804","definitions":[{"definition":"Occupations held by individuals who provide instruction and promote participation in exercise, sports and other recreational activities, those who train for and compete in sporting events, those who provide performance enhancement training and/or coaching for those participating in sports, and those who organize and officiate sporting events.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sports and Fitness Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sports and Fitness Workers"},{"name":"NCI_META_CUI","value":"CL1905949"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198805":{"preferredName":"Street and Market Salesperson","code":"C198805","definitions":[{"definition":"Occupations held by individuals who are permitted to sell goods or prepare and sell hot or cold food and beverages from stalls in public places such as streets or markets.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Street and Market Salesperson","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Street and Market Salespersons"},{"name":"NCI_META_CUI","value":"CL1905948"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198806":{"preferredName":"Street and Related Service Worker","code":"C198806","definitions":[{"definition":"Occupations held by individuals who provide on the spot services in public places including shoe, car and windshield cleaning, running errands and handing out leaflets or other publications.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Street and Related Service Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Street and Related Service Workers"},{"name":"NCI_META_CUI","value":"CL1906255"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198807":{"preferredName":"Street Vendor (Excluding Food)","code":"C198807","definitions":[{"definition":"Occupations held by individuals who sell goods and products (excluding food) in streets and public places or by going house to house.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Street Vendor (Excluding Food)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Street Vendors (excluding Food)"},{"name":"NCI_META_CUI","value":"CL1906254"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198808":{"preferredName":"Subsistence Crop Farmer","code":"C198808","definitions":[{"definition":"Occupations held by individuals who grow and harvest field-grown crops and edible products from other plants to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Crop Farmer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Crop Farmers"},{"name":"NCI_META_CUI","value":"CL1906257"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198809":{"preferredName":"Subsistence Fisherman, Hunter, Trapper and Gatherer","code":"C198809","definitions":[{"definition":"Occupations held by individuals who gather wild plants for food or medicinal purposes, hunt and trap animals, and catch fish and other aquatic animals to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Fisherman, Hunter, Trapper and Gatherer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Fishers, Hunters, Trappers and Gatherers"},{"name":"NCI_META_CUI","value":"CL1906256"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198810":{"preferredName":"Subsistence Livestock Farmer","code":"C198810","definitions":[{"definition":"Occupations held by individuals who breed, raise and tend livestock to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Livestock Farmer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Livestock Farmers"},{"name":"NCI_META_CUI","value":"CL1906251"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198811":{"preferredName":"Subsistence Mixed Crop and Livestock Farmer","code":"C198811","definitions":[{"definition":"Occupations held by individuals who breed, raise and tend livestock and who grow and harvest field-grown crops and edible products from other plants to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Mixed Crop and Livestock Farmer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Mixed Crop and Livestock Farmers"},{"name":"NCI_META_CUI","value":"CL1906250"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198812":{"preferredName":"Telecommunications and Broadcasting Technician","code":"C198812","definitions":[{"definition":"Occupations held by individuals who ensure all technical equipment for recording, editing and transmission of radio and television broadcasts or other telecommunication signals remains functional. This also includes those who design, develop and perform research for telecommunication systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Telecommunications and Broadcasting Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Telecommunications and Broadcasting Technicians"},{"name":"NCI_META_CUI","value":"CL1906253"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122451":{"preferredName":"Financial Clerks","code":"C122451","definitions":[{"definition":"Workers who do administrative work for financial institutions or within the financial industries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Financial Clerks","termGroup":"PT","termSource":"NCI"},{"termName":"Teller, Money Collector and Related Clerk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tellers, Money Collectors and Related Clerks"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054956"}]}}{"C198813":{"preferredName":"Textile, Fur and Leather Products Machine Operator","code":"C198813","definitions":[{"definition":"Occupations held by individuals who operate machinery to prepare, process and chemically treat raw textiles, leather and fur products, those who process yarn or thread to manufacture fabrics, and those who use machines to process textiles, leather, fur, yarn, thread or fabrics in the production or repair of items such as: footwear, baggage, rugs/carpets, handbags or garments.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Textile, Fur and Leather Products Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Textile, Fur and Leather Products Machine Operators"},{"name":"NCI_META_CUI","value":"CL1906252"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198814":{"preferredName":"Traditional and Complementary Medicine Associate Professional","code":"C198814","definitions":[{"definition":"Occupations held by individuals who assist in the providence of health care-related services based on traditional and/or complementary medical practices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Traditional and Complementary Medicine Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Traditional and Complementary Medicine Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1906263"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198815":{"preferredName":"Traditional and Complementary Medicine Professional","code":"C198815","definitions":[{"definition":"Occupations held by individuals who provide health care-related services based on traditional and/or complementary medical practices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Traditional and Complementary Medicine Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Traditional and Complementary Medicine Professionals"},{"name":"NCI_META_CUI","value":"CL1906262"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198816":{"preferredName":"Transport and Storage Laborer","code":"C198816","definitions":[{"definition":"Occupations held by individuals who operate and drive vehicles to transport passengers, goods and or freight, those who pack, carry, load and hand deliver goods and freight, and those who stock shelves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Transport and Storage Laborer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transport and Storage Labourers"},{"name":"NCI_META_CUI","value":"CL1906265"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198817":{"preferredName":"Travel Attendant, Conductor and Guide","code":"C198817","definitions":[{"definition":"Occupations held by individuals who provide services in connection with travel or tours/excursions. The services may include provision of information for and during travel, and the collection or issuance of tickets to, ensuring safety of, and serving of food/refreshments to passengers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Travel Attendant, Conductor and Guide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Travel Attendants, Conductors and Guides"},{"name":"NCI_META_CUI","value":"CL1906264"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122499":{"preferredName":"Postsecondary Teachers","code":"C122499","definitions":[{"definition":"Postsecondary teachers instruct students in a wide variety of academic and vocational subjects beyond the high school level. They also conduct research and publish scholarly papers and books.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Postsecondary Teachers","termGroup":"PT","termSource":"NCI"},{"termName":"University and Higher Education Teacher","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"University and Higher Education Teachers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054161"}]}}{"C198818":{"preferredName":"Vehicle, Window, Laundry and Other Hand Cleaning Worker","code":"C198818","definitions":[{"definition":"Occupations held by individuals who clean windows, building surfaces, vehicles or textiles by hand.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Vehicle, Window, Laundry and Other Hand Cleaning Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vehicle, Window, Laundry and Other Hand Cleaning Workers"},{"name":"NCI_META_CUI","value":"CL1906259"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C82470":{"preferredName":"Veterinarian","code":"C82470","synonyms":[{"termName":"Veterinarian","termGroup":"PT","termSource":"NCI"},{"termName":"Veterinarian","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Veterinarian"},{"name":"Maps_To","value":"Veterinarians"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C0242856"}]}}{"C82473":{"preferredName":"Veterinary Staff","code":"C82473","synonyms":[{"termName":"Veterinary Staff","termGroup":"PT","termSource":"NCI"},{"termName":"Veterinary Technician and Assistant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Veterinary_Staff"},{"name":"Maps_To","value":"Veterinary Technicians and Assistants"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C2826215"}]}}{"C198819":{"preferredName":"Vocational Education Teacher","code":"C198819","definitions":[{"definition":"Occupations held by individuals who teach or provide instruction in vocational or occupational subjects to adults and senior students in secondary schools, colleges and institutions of further education.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Vocational Education Teacher","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vocational education teachers"},{"name":"NCI_META_CUI","value":"CL1906258"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122460":{"preferredName":"Food and Beverage Serving Workers","code":"C122460","definitions":[{"definition":"Workers who perform a variety of customer service, food preparation, and cleaning duties in restaurants, cafeterias, and other eating and drinking establishments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Food and Beverage Serving Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Waiter and Bartender","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Waiters and Bartenders"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054937"}]}}{"C198820":{"preferredName":"Wood Processing and Papermaking Plant Operator","code":"C198820","definitions":[{"definition":"Occupations held by individuals who operate machinery to produce products from raw lumber including wood veneer, plywood, pulp and paper.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Wood Processing and Papermaking Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood Processing and Papermaking Plant Operators"},{"name":"NCI_META_CUI","value":"CL1906261"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198821":{"preferredName":"Wood Treater, Cabinet-maker and Related Trades Worker","code":"C198821","definitions":[{"definition":"Occupations held by individuals who are involved in the preservation and treatment of wood, in the construction, decoration and repair of wooden furniture and other wooden products, and in the assembly, operation and maintenance of woodworking machines and tools.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Wood Treater, Cabinet-maker and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood Treaters, Cabinet-makers and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1906260"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C199161":{"preferredName":"Lesion with Diameter Greater than 20 mm","code":"C199161","definitions":[{"definition":"A semi-quantitative finding indicating that the largest diameter for a lesion is greater than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lesion with Diameter Greater than 20 mm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":">20 mm"},{"name":"NCI_META_CUI","value":"CL1906111"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199163":{"preferredName":"Lesion with Diameter at Least 1 mm and at Most 10 mm","code":"C199163","definitions":[{"definition":"A semi-quantitative finding indicating that the largest diameter for a lesion was at least 1 mm and at most 10 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lesion with Diameter at Least 1 mm and at Most 10 mm","termGroup":"PT","termSource":"NCI"},{"termName":"Lesion with Diameter 1-10 mm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1-10 mm"},{"name":"NCI_META_CUI","value":"CL1906105"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199164":{"preferredName":"Lesion with Diameter at Least 11 mm and at Most 20 mm","code":"C199164","definitions":[{"definition":"A semi-quantitative finding indicating that the largest diameter for a lesion was at least 11 mm and at most 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lesion with Diameter at Least 11 mm and at Most 20 mm","termGroup":"PT","termSource":"NCI"},{"termName":"Lesion with Diameter 11-20 mm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"11-20 mm"},{"name":"NCI_META_CUI","value":"CL1906104"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199165":{"preferredName":"Macroscopic Disease Negative","code":"C199165","definitions":[{"definition":"An indication that macroscopic evidence of disease was not detected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macroscopic Disease Negative","termGroup":"PT","termSource":"NCI"},{"termName":"No Macroscopic Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No macroscopic disease"},{"name":"NCI_META_CUI","value":"CL1906107"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199177":{"preferredName":"Biochemical Assessment Indicator","code":"C199177","definitions":[{"definition":"An indication that a finding or diagnosis was assigned based on biochemical test results.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biochemical Assessment Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biochemical Assessment"},{"name":"NCI_META_CUI","value":"CL1906127"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C199179":{"preferredName":"Clinical and Biochemical Assessments Indicator","code":"C199179","definitions":[{"definition":"An indication that a finding or diagnosis was assigned based on both clinical observations and biochemical test results.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical and Biochemical Assessments Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Both Clinical and Biochemical Assessments"},{"name":"NCI_META_CUI","value":"CL1906121"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C199178":{"preferredName":"Clinical Assessment Indicator","code":"C199178","definitions":[{"definition":"An indication that a finding or diagnosis was assigned based on clinical observations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical Assessment Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clinical Assessment"},{"name":"NCI_META_CUI","value":"CL1906126"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C113215":{"preferredName":"Androgen Excess","code":"C113215","definitions":[{"definition":"Excessive secretion of androgens by the adrenal glands and/or gonads.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Excessive secretion of androgens from the adrenal glands or gonads. Clinical manifestations may include virilization.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Androgen Excess","termGroup":"PT","termSource":"NCI"},{"termName":"Hyperandrogenism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Androgen Excess"},{"name":"Maps_To","value":"Hyperandrogenism"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0206081"}]}}{"C113208":{"preferredName":"Hypercortisolemia","code":"C113208","definitions":[{"definition":"Abnormally high level of cortisol in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Abnormally high levels of cortisol in the blood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hypercortisolemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Cortisol Excess"},{"name":"Maps_To","value":"Hypercortisolemia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0001622"}]}}{"C113344":{"preferredName":"Hyperestrogenism","code":"C113344","definitions":[{"definition":"Abnormally high level of estrogen.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Abnormally high level of estrogen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Hyperestrogenism","termGroup":"PT","termSource":"NCI"},{"termName":"Estrogen Excess","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Estrogen Excess"},{"name":"Maps_To","value":"Hyperestrogenism"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0154209"}]}}{"C35064":{"preferredName":"Hereditary Hemorrhagic Telangiectasia","code":"C35064","definitions":[{"definition":"An autosomal dominant hereditary disorder caused by mutations in the ACVRL1, ENG, and SMAD4 genes. It is characterized by the presence of telangiectasias in the skin, mucous membranes, lungs, brain, liver, and gastrointestinal tract. It results in hemorrhages from the affected areas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Hemorrhagic Telangiectasia","termGroup":"PT","termSource":"NCI"},{"termName":"Osler-Weber-Rendu Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Telangiectasia, Hereditary Hemorrahagic, of Rendu, Osler","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Hereditary_Hemorrhagic_Telangiectasia"},{"name":"Maps_To","value":"Hereditary Hemorrhagic Telangiectasia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0039445"}]}}{"C3101":{"preferredName":"Genetic Disorder","code":"C3101","definitions":[{"definition":"Genetic diseases are diseases in which inherited genes predispose to increased risk. The genetic disorders associated with cancer often result from an alteration or mutation in a single gene. The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer. Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genetic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Genetic Condition","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Diseases","termGroup":"SY","termSource":"NCI"},{"termName":"Inherited Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Molecular Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Genetic_Disorder"},{"name":"Maps_To","value":"Inherited Genetic Syndrome, NOS"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019247"}]}}{"C198986":{"preferredName":"Mineralocorticoid Excess","code":"C198986","definitions":[{"definition":"A finding indicating that the concentration of mineralocorticoids in a sample is greater than normal values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mineralocorticoid Excess","termGroup":"PT","termSource":"NCI"},{"termName":"Mineralocorticoids Excess","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mineralocorticoids Excess"},{"name":"NCI_META_CUI","value":"CL1906416"},{"name":"Semantic_Type","value":"Finding"}]}}{"C84932":{"preferredName":"Neurocysticercosis","code":"C84932","definitions":[{"definition":"A central nervous system infection that results from the inactive parenchymal or ventricular stage of Taenia solium. While many infections are asymptomatic, seizures are the most common symptom.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurocysticercosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Neurocysticercosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0338437"}]}}{"C85051":{"preferredName":"Rubella Infection","code":"C85051","definitions":[{"definition":"A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by the rubella virus; it is characterized by a descending, non-coalescing macular or maculopapular rash and, generally, a mild systemic illness.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Rubella Infection","termGroup":"PT","termSource":"NCI"},{"termName":"German Measles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Rubella"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035920"}]}}{"C131437":{"preferredName":"Nodular Goiter","code":"C131437","definitions":[{"definition":"Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.","type":"DEFINITION","source":"NCI"},{"definition":"Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Nodular Goiter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Thyroid Nodular Hyperplasia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018023"}]}}{"C164008":{"preferredName":"CD38-targeting Agent","code":"C164008","definitions":[{"definition":"Any agent that targets CD38.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD38-targeting Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"NCI_META_CUI","value":"CL977220"},{"name":"Semantic_Type","value":"Classification"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C199216":{"preferredName":"Peripheral Blood Components","code":"C199216","definitions":[{"definition":"A specimen containing undefined components from peripheral blood collected from an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Blood Components","termGroup":"PT","termSource":"NCI"},{"termName":"Peripheral Blood Components, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Blood Components, NOS"},{"name":"NCI_META_CUI","value":"CL1906159"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C39298":{"preferredName":"Adolescence","code":"C39298","definitions":[{"definition":"A human life stage that begins at twelve years of age and continues until twenty-one complete years of age, generally marked by the beginning of puberty and lasting to the beginning of adulthood.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A human life stage that begins at twelve years of age and continues until twenty-one complete years of age, generally marked by the beginning of puberty and lasting to the beginning of adulthood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Adolescence","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Adolescence"},{"name":"Maps_To","value":"Adolescence"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0001578"}]}}{"C199314":{"preferredName":"Adulthood","code":"C199314","definitions":[{"definition":"A time period in the human lifespan when full physical and intellectual maturity have been attained, which generally follows adolescence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adulthood","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Life Stage","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adulthood"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0700597"}]}}{"C89345":{"preferredName":"Childhood","code":"C89345","definitions":[{"definition":"A time period that begins at the beginning of the human embryonic stage and continues until the end of adolescence.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A time period that begins at the beginning of the human embryonic stage and continues until the end of adolescence.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Childhood"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0231335"}]}}{"C16033":{"preferredName":"Follow-Up","code":"C16033","definitions":[{"definition":"Monitoring a person's health over time after treatment. This includes keeping track of the health of people who participate in a clinical study or clinical trial for a period of time, both during the study and after the study ends.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The process by which information about the health status of a subject is obtained after the subject is no longer receiving study medication.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follow-Up","termGroup":"PT","termSource":"NCI"},{"termName":"Active Follow-up","termGroup":"SY","termSource":"NCI"},{"termName":"Follow Up","termGroup":"SY","termSource":"NCI"},{"termName":"Followup","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Follow-up"},{"name":"Maps_To","value":"Follow-up"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C1522577"}]}}{"C199315":{"preferredName":"Last Contact Event Occurrence Indicator","code":"C199315","definitions":[{"definition":"An indication that an individual has had their last contact event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Last Contact Event Occurrence Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Last Contact"},{"name":"NCI_META_CUI","value":"CL1906249"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C158707":{"preferredName":"Post-Adjuvant Therapy","code":"C158707","definitions":[{"definition":"Therapy administered after to the initial therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post-Adjuvant Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post Adjuvant Therapy"},{"name":"NCI_META_CUI","value":"CL950738"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C199316":{"preferredName":"After Hormone Therapy","code":"C199316","definitions":[{"definition":"Relating to or occurring after hormone therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"After Hormone Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Post Hormone Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Post-Hormone Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post Hormone Therapy"},{"name":"NCI_META_CUI","value":"CL1906244"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C158753":{"preferredName":"Post-secondary Therapy","code":"C158753","definitions":[{"definition":"Therapy administered after the second treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post-secondary Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post Secondary Therapy"},{"name":"NCI_META_CUI","value":"CL950719"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C28006":{"preferredName":"Postoperative","code":"C28006","definitions":[{"definition":"After surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Relating to or occurring during the period immediately following a surgical operation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Postoperative","termGroup":"PT","termSource":"NCI"},{"termName":"Post-Operative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Postoperative"},{"name":"Maps_To","value":"Postoperative"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0032790"}]}}{"C54732":{"preferredName":"Preoperative","code":"C54732","definitions":[{"definition":"Relating to or occurring during the period immediately before a surgical operation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Preoperative","termGroup":"PT","termSource":"NCI"},{"termName":"Pre-operative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Preoperative"},{"name":"Maps_To","value":"Preoperative"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0445204"}]}}{"C199317":{"preferredName":"Pre-Diagnosis","code":"C199317","definitions":[{"definition":"Relating to or occurring before a diagnosis was received.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Diagnosis","termGroup":"PT","termSource":"NCI"},{"termName":"Before Diagnosis","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Diagnostic","termGroup":"SY","termSource":"NCI"},{"termName":"Prior to Diagnosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prior to Diagnosis"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0332132"}]}}{"C54734":{"preferredName":"Pre-Therapy","code":"C54734","definitions":[{"definition":"Occurring before a therapeutic procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Before Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Pretreatment","termGroup":"SY","termSource":"NCI"},{"termName":"Prior to Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Pre-Therapy"},{"name":"Maps_To","value":"Prior to Treatment"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C1882440"}]}}{"C158754":{"preferredName":"Progression of Disease at Recurrence","code":"C158754","definitions":[{"definition":"At the time of the progression or recurrence of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progression of Disease at Recurrence","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrence/Progression"},{"name":"NCI_META_CUI","value":"CL950720"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C200432":{"preferredName":"Within 3 Months of Surgery","code":"C200432","definitions":[{"definition":"Occurring within the period 3 months prior to or 3 months following a surgical procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Within 3 Months of Surgery","termGroup":"PT","termSource":"NCI"},{"termName":"Within Three Months of Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Within 3 Months of Surgery"},{"name":"NCI_META_CUI","value":"CL1907443"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C199318":{"preferredName":"End of Consolidation Therapy Occurrence Indicator","code":"C199318","definitions":[{"definition":"An indication that consolidation therapy has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Consolidation Therapy Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Consolidation Therapy Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Consolidation Therapy"},{"name":"NCI_META_CUI","value":"CL1906246"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199320":{"preferredName":"End of Treatment Course 1 Occurrence Indicator","code":"C199320","definitions":[{"definition":"An indication that the first treatment course has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Treatment Course 1 Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Treatment Course 1 Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Treatment Course 1"},{"name":"NCI_META_CUI","value":"CL1906738"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199321":{"preferredName":"End of Treatment Course 2 Occurrence Indicator","code":"C199321","definitions":[{"definition":"An indication that the second treatment course has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Treatment Course 2 Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Treatment Course 2 Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Treatment Course 2"},{"name":"NCI_META_CUI","value":"CL1906737"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199319":{"preferredName":"End of Treatment Course Occurrence Indicator","code":"C199319","definitions":[{"definition":"An indication that a treatment course has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Treatment Course Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Treatment Course Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Treatment Course"},{"name":"NCI_META_CUI","value":"CL1906245"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199322":{"preferredName":"First Complete Response Occurrence Indicator","code":"C199322","definitions":[{"definition":"An indication that the first observation of a complete disease response has occurred.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Complete Response Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"First Complete Response Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First Complete Response"},{"name":"NCI_META_CUI","value":"CL1906740"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199323":{"preferredName":"Pre-Procurement","code":"C199323","definitions":[{"definition":"Relating to or occurring before obtaining goods, services, supplies, specimens, equipment or other required materials.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Procurement","termGroup":"PT","termSource":"NCI"},{"termName":"Prior to Procurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prior to Procurement"},{"name":"NCI_META_CUI","value":"CL1906739"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C199324":{"preferredName":"Pre-Registration","code":"C199324","definitions":[{"definition":"Relating to or occurring before registration into a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Registration","termGroup":"PT","termSource":"NCI"},{"termName":"Prior to Registration","termGroup":"SY","termSource":"NCI"},{"termName":"Prior to Study/Trial Registration","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prior to Study Registration"},{"name":"NCI_META_CUI","value":"CL1906734"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C199325":{"preferredName":"Four Tumor Grade Evaluation Tiers","code":"C199325","definitions":[{"definition":"Four clinical evidence tiers were present in the system used to evaluate the tumor grade for a subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Four Tumor Grade Evaluation Tiers","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Four Tier"},{"name":"NCI_META_CUI","value":"CL1906733"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C199326":{"preferredName":"Three Tumor Grade Evaluation Tiers","code":"C199326","definitions":[{"definition":"Three clinical evidence tiers were present in the system used to evaluate the tumor grade for a subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Three Tumor Grade Evaluation Tiers","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Three Tier"},{"name":"NCI_META_CUI","value":"CL1906736"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C13087":{"preferredName":"Apex of the Prostate","code":"C13087","definitions":[{"definition":"The lowest part of the prostate gland adjacent to the superior fascia of the urogenital diaphragm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apex of the Prostate","termGroup":"PT","termSource":"NCI"},{"termName":"Apex of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Apical Prostate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Apex_of_the_Prostate"},{"name":"Maps_To","value":"Apex"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227959"}]}}{"C13088":{"preferredName":"Base of the Prostate","code":"C13088","definitions":[{"definition":"The uppermost part of the prostate gland adjacent to the bladder wall.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Base of the Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Base_of_the_Prostate"},{"name":"Maps_To","value":"Base"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227958"}]}}{"C13094":{"preferredName":"Middle Lobe of the Prostate","code":"C13094","definitions":[{"definition":"The upper, smaller part of the prostate between the ejaculatory ducts and the urethra.","type":"DEFINITION","source":"NCI"},{"definition":"The upper, smaller part of the prostate between the ejaculatory ducts and the urethra. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Middle Lobe of the Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Middle_Lobe_of_the_Prostate"},{"name":"Maps_To","value":"Middle"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227972"}]}}{"C54566":{"preferredName":"Fourth","code":"C54566","definitions":[{"definition":"Following the third position in an ordering or series; coming next after the third and just before the fifth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fourth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fourth"},{"name":"Maps_To","value":"4th"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205438"}]}}{"C54567":{"preferredName":"Fifth","code":"C54567","definitions":[{"definition":"Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fifth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fifth"},{"name":"Maps_To","value":"5th"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205439"}]}}{"C54568":{"preferredName":"Sixth","code":"C54568","definitions":[{"definition":"Following the fifth position in an ordering or series; coming next after the fifth and just before the seventh in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sixth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sixth"},{"name":"Maps_To","value":"6th"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205440"}]}}{"C133531":{"preferredName":"Seventh","code":"C133531","definitions":[{"definition":"Following the sixth position in an ordering or series; coming next after the sixth and just before the eighth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seventh","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"7th"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0205441"}]}}{"C133533":{"preferredName":"Eighth","code":"C133533","definitions":[{"definition":"Following the seventh position in an ordering or series; coming next after the seventh and just before the ninth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eighth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8th"},{"name":"NCI_META_CUI","value":"CL521180"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C35962":{"preferredName":"Atypical Mitotic Figures","code":"C35962","definitions":[{"definition":"A morphologic finding indicating the presence of atypical mitoses in malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Mitotic Figures","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Mitotic_Figures"},{"name":"Maps_To","value":"Atypical Mitotic Figures"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1332352"}]}}{"C199327":{"preferredName":"Presence of Clear Cytoplasm Less than or Equal to 25 Percent","code":"C199327","definitions":[{"definition":"A finding indicating that less than or equal to 25 percent of the cells in a sample have clear or vacuolated cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Presence of Clear Cytoplasm Less than or Equal to 25 Percent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytoplasm presence <= to 25%"},{"name":"NCI_META_CUI","value":"CL1906735"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35903":{"preferredName":"Diffuse Pattern","code":"C35903","definitions":[{"definition":"A morphologic architectural pattern in which a cellular population is distributed in a relatively uniform fashion throughout a specified tissue area; not focal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Architectural Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Pattern"},{"name":"Maps_To","value":"Diffuse Architecture"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1333299"}]}}{"C199328":{"preferredName":"Tumor Capsule Invasion Present","code":"C199328","definitions":[{"definition":"A morphologic finding indicating that tumor cells have infiltrated the surrounding capsule of connective tissue and invaded nearby tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Capsule Invasion Present","termGroup":"PT","termSource":"NCI"},{"termName":"Tumor Capsule Invasion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasion of Tumor Capsule"},{"name":"NCI_META_CUI","value":"CL1906742"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54007":{"preferredName":"More than 5 Mitoses per 50 HPF","code":"C54007","definitions":[{"definition":"A morphologic finding indicating the presence of more than five mitotic figures per fifty high power fields in a cellular infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"More than 5 Mitoses per 50 HPF","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"More_than_5_Mitoses_per_50HPF"},{"name":"Maps_To","value":"Mitotic Rate > 5/50 HPF"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709073"}]}}{"C36184":{"preferredName":"Necrotic Change","code":"C36184","definitions":[{"definition":"A finding indicating the presence of cellular necrosis in a tissue specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necrotic Change","termGroup":"PT","termSource":"NCI"},{"termName":"Necrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Necrotic_Change"},{"name":"Maps_To","value":"Necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1334928"}]}}{"C104011":{"preferredName":"Nuclear Grade III or IV","code":"C104011","definitions":[{"definition":"Nuclear pleomorphism in tumor cells defined either as grade III or IV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nuclear Grade III or IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nuclear Grade III or IV"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3641689"}]}}{"C39615":{"preferredName":"Sinusoidal Infiltration","code":"C39615","definitions":[{"definition":"A microscopic finding indicating the invasion of sinusoidal spaces by malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinusoidal Infiltration","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sinusoidal_Infiltration"},{"name":"Maps_To","value":"Sinusoid Invasion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1519333"}]}}{"C47849":{"preferredName":"Venous Invasion","code":"C47849","definitions":[{"definition":"A term referring to the presence of tumor emboli or tumor masses within veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venous Invasion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Venous_Invasion"},{"name":"Maps_To","value":"Venous Invasion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1710625"}]}}{"C94812":{"preferredName":"Clark Level I","code":"C94812","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma is confined to the epidermis and does not invade the dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that is found only in the epidermis (outer layer of skin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"I"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986693"}]}}{"C94813":{"preferredName":"Clark Level II","code":"C94813","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded part of the papillary dermis but the malignant cellular infiltrate has not reached the papillary-reticular dermis interface.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread from the epidermis (outer layer of skin) down into the papillary dermis (the thin top layer of the dermis).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"II"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986694"}]}}{"C94814":{"preferredName":"Clark Level III","code":"C94814","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded the entire thickness of the papillary dermis but the malignant cellular infiltrate does not extend into the reticular dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread down through the papillary dermis (the thin top layer of the dermis) but not into the reticular dermis (the thick bottom layer of the dermis).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"III"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986695"}]}}{"C94815":{"preferredName":"Clark Level IV","code":"C94815","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded the reticular dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread down into the reticular dermis (the thick bottom layer of the dermis).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IV"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986696"}]}}{"C94816":{"preferredName":"Clark Level V","code":"C94816","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded the subcutaneous tissue.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread down into the subcutaneous tissue (tissue beneath the skin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level V","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"V"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986697"}]}}{"C159746":{"preferredName":"College Completion","code":"C159746","definitions":[{"definition":"Completion of education at an institution of higher education created to educate and grant degrees; often a part of a university.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Indicates that a person has attended college and receive a degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"College Completion","termGroup":"PT","termSource":"NCI"},{"termName":"College Degree","termGroup":"SY","termSource":"NCI"},{"termName":"College Graduate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"College Degree"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0682187"}]}}{"C67136":{"preferredName":"High School Completion","code":"C67136","definitions":[{"definition":"Completed secondary education through 12th or 13th grade as required by the school system.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Indicates that a person has attended high school and has received a high school diploma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High School Completion","termGroup":"PT","termSource":"NCI"},{"termName":"High School","termGroup":"SY","termSource":"NCI"},{"termName":"High School Diploma Received","termGroup":"SY","termSource":"NCI"},{"termName":"High School Graduate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"High_School_Graduate"},{"name":"Maps_To","value":"High School Graduate or GED"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0870649"}]}}{"C67135":{"preferredName":"General Equivalency Diploma Completion","code":"C67135","definitions":[{"definition":"Indicates that a person has received a General Equivalency Diploma in lieu of a high school diploma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"General Equivalency Diploma Completion","termGroup":"PT","termSource":"NCI"},{"termName":"GED","termGroup":"AB","termSource":"NCI"},{"termName":"GED or Equivalent","termGroup":"SY","termSource":"NCI"},{"termName":"General Equivalency Diploma","termGroup":"SY","termSource":"NCI"},{"termName":"General Equivalency Diploma Received","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"General_Equivalency_Diploma"},{"name":"Maps_To","value":"High School Graduate or GED"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1880947"}]}}{"C70558":{"preferredName":"Professional Doctorate Degree Completion","code":"C70558","definitions":[{"definition":"Indicates that a person has received a degree allowing them to practice a profession, such as law, medicine, music, or ministry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Professional Doctorate Degree Completion","termGroup":"PT","termSource":"NCI"},{"termName":"Professional Doctoral Degree","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctoral Degree Completion","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctoral Degree Received","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctorate Degree","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctorate Degree Received","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Professional_Doctorate_Degree_Completion"},{"name":"Maps_To","value":"Professional or Graduate Degree"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C2347690"}]}}{"C168226":{"preferredName":"Graduate Studies Completion","code":"C168226","definitions":[{"definition":"Completion of a program of study of at least the full-time equivalent of greater than or equal to 1 academic years of work beyond the bachelor's degree.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Indicates that a person has completed a graduate studies program beyond a bachelor's degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Graduate Studies Completion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Professional or Graduate Degree"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0013630"}]}}{"C198650":{"preferredName":"Some High School, No Diploma","code":"C198650","definitions":[{"definition":"Indicates that a person has attended high school, but not to completion and did not receive a diploma. The person may have dropped out in or after 9th, 10th, or 11th grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Some High School, No Diploma","termGroup":"PT","termSource":"NCI"},{"termName":"Attended High School","termGroup":"SY","termSource":"NCI"},{"termName":"Some High School","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Some High School or Less"},{"name":"NCI_META_CUI","value":"CL1905805"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C67141":{"preferredName":"Vocational Program Completion","code":"C67141","definitions":[{"definition":"Indicates that a person has attended or received a degree from an occupational, technical, or vocational program as their highest level of educational achievement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vocational Program Completion","termGroup":"PT","termSource":"NCI"},{"termName":"Vocational Degree","termGroup":"SY","termSource":"NCI"},{"termName":"Vocational Degree Completion","termGroup":"SY","termSource":"NCI"},{"termName":"Vocational Degree Received","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Vocational_Degree"},{"name":"Maps_To","value":"Vocational College or Some College"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1883542"}]}}{"C67137":{"preferredName":"Some College Completion","code":"C67137","definitions":[{"definition":"Indicates that a person has attended college but that they did not receive any degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Some College Completion","termGroup":"PT","termSource":"NCI"},{"termName":"Some College","termGroup":"SY","termSource":"NCI"},{"termName":"Some College Attendence","termGroup":"SY","termSource":"NCI"},{"termName":"Some College, No Degree","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Some_College"},{"name":"Maps_To","value":"Vocational College or Some College"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1883065"}]}}{"C104028":{"preferredName":"cM0 ENSAT Staging Finding v7","code":"C104028","definitions":[{"definition":"Adrenal cancer with no involvement of distant organs or tissues. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cM0 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641706"}]}}{"C104029":{"preferredName":"cM1 ENSAT Staging Finding v7","code":"C104029","definitions":[{"definition":"Adrenal cancer with involvement of distant organs or tissues such as liver, bone or brain. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cM1 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641707"}]}}{"C104024":{"preferredName":"pN0 ENSAT Staging Finding v7","code":"C104024","definitions":[{"definition":"Adrenal cancer with no involvement of regional lymph nodes. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641702"}]}}{"C104025":{"preferredName":"pN1 ENSAT Staging Finding v7","code":"C104025","definitions":[{"definition":"Adrenal cancer with involvement of regional lymph nodes. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN1 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641703"}]}}{"C104031":{"preferredName":"ENSAT Stage I Adrenal Cortical Carcinoma","code":"C104031","definitions":[{"definition":"Stage I includes: T1, N0, M0.  Tumor 5 cm or less in greatest dimension. The tumor has not invaded the surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues.  (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage I Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage I Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641709"}]}}{"C104032":{"preferredName":"ENSAT Stage II Adrenal Cortical Carcinoma","code":"C104032","definitions":[{"definition":"Stage II includes: T2, N0, M0. Tumor greater than 5 cm. The tumor has not invaded surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues. (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage II Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage II Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641710"}]}}{"C104033":{"preferredName":"ENSAT Stage III Adrenal Cortical Carcinoma","code":"C104033","definitions":[{"definition":"Stage III includes: T3/T4, N0/N1, M0.  Tumor of any size that has spread to the fat outside the adrenal gland or into nearby organs or tissues and/or has spread to the regional lymph nodes. (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage III Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage III Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641711"}]}}{"C104034":{"preferredName":"ENSAT Stage IV Adrenal Cortical Carcinoma","code":"C104034","definitions":[{"definition":"Stage IV includes: Any T, Any N, M1. Tumor of any size that involves distant organs such as liver, bone or brain. The tumor may or may not involve nearby organs, tissues or lymph nodes. (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage IV Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage IV Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641712"}]}}{"C104019":{"preferredName":"pT1 ENSAT Staging Finding v7","code":"C104019","definitions":[{"definition":"Adrenal cancer with tumor size equal or less than 5.0 cm.  There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT1 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641697"}]}}{"C104020":{"preferredName":"pT2 ENSAT Staging Finding v7","code":"C104020","definitions":[{"definition":"Adrenal cancer with tumor size more than 5.0 cm. There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT2 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641698"}]}}{"C104021":{"preferredName":"pT3 ENSAT Staging Finding v7","code":"C104021","definitions":[{"definition":"Adrenal cancer with tumor of any size.  There is invasion of the fat that surrounds the adrenal gland. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT3 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641699"}]}}{"C104022":{"preferredName":"pT4 ENSAT Staging Finding v7","code":"C104022","definitions":[{"definition":"Adrenal cancer with tumor of any size.  There is invasion of nearby organs such as the kidney, pancreas, spleen or liver. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT4 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641700"}]}}{"C51776":{"preferredName":"Divorced","code":"C51776","definitions":[{"definition":"Indicates a person whose marriage has been legally dissolved and has not remarried.","type":"DEFINITION","source":"NCI"},{"definition":"Marriage contract has been declared dissolved and inactive. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Divorced","termGroup":"PT","termSource":"NCI"},{"termName":"Divorced Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Divorced_Status"},{"name":"Maps_To","value":"Divorced"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0012828"}]}}{"C51773":{"preferredName":"Married","code":"C51773","definitions":[{"definition":"A current marriage contract is active. (HL7)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Indicates a person currently joined in a legally binding matrimonial union.  Classify common law marriage as married.  Includes married couples living together and not living together.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Married","termGroup":"PT","termSource":"NCI"},{"termName":"Married Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Married_Status"},{"name":"Maps_To","value":"Married"},{"name":"NCI_META_CUI","value":"CL355270"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C51774":{"preferredName":"Never Married","code":"C51774","definitions":[{"definition":"Indicates a person who has never been married or whose marriages have been annulled.","type":"DEFINITION","source":"NCI"},{"definition":"No marriage contract has ever been entered. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Never Married","termGroup":"PT","termSource":"NCI"},{"termName":"Never Married Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Never_Married_Status"},{"name":"Maps_To","value":"Never Married"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0027952"}]}}{"C156541":{"preferredName":"Separated","code":"C156541","definitions":[{"definition":"A person who is separated from their spouse, whether or not there is a legal arrangement.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A person who is separated from their spouse, whether or not there is a legal arrangement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Separated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Separated"},{"name":"NCI_META_CUI","value":"CL935649"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C51775":{"preferredName":"Widowed","code":"C51775","definitions":[{"definition":"Indicates a person who is no longer married because of the death of his/her spouse and has not remarried.","type":"DEFINITION","source":"NCI"},{"definition":"The spouse has died. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Widowed","termGroup":"PT","termSource":"NCI"},{"termName":"Widowed Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Widowed_Status"},{"name":"Maps_To","value":"Widowed"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0206275"}]}}{"C93286":{"preferredName":"Radiologic Examination","code":"C93286","definitions":[{"definition":"A test that uses radiation or other imaging procedures to find signs of cancer or other abnormalities.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The use of x-rays, or other radiologic imaging modalities, for visualizing body spaces and organs, usually for diagnosis or screening of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiologic Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Radiologic Exam","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiologic"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C2985535"}]}}{"C200433":{"preferredName":"Sonographic Examination","code":"C200433","definitions":[{"definition":"A medical examination of the internal anatomy of a subject using high-frequency sound waves to generate images.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonographic Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Echographic Examination","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasonographic Examination","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Echographic"},{"name":"NCI_META_CUI","value":"CL1907442"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C49668":{"preferredName":"Centimeter","code":"C49668","definitions":[{"definition":"A basic unit of length equal to one hundredth of a meter or approximately 0.393700787 inch.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.","type":"DEFINITION","source":"NCI"},{"definition":"A measure of length in the metric system. There are 100 centimeters in a meter and 2 1/2 centimeters in an inch.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Centimeter","termGroup":"PT","termSource":"NCI"},{"termName":"cm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Centimeter"},{"name":"Maps_To","value":"Centimeters"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0475210"}]}}{"C28251":{"preferredName":"Millimeter","code":"C28251","definitions":[{"definition":"A measure of length in the metric system. A millimeter is one thousandth of a meter. There are 25 millimeters in an inch.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A metric unit of length equal to one thousandth of a meter (10E-3 meter) or approximately 0.03937 inch.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of measure equal to one thousandth of a meter. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Millimeter","termGroup":"PT","termSource":"NCI"},{"termName":"mm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Millimeter"},{"name":"Maps_To","value":"Millimeters"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439200"}]}}{"C51137":{"preferredName":"Deep Lesion","code":"C51137","definitions":[{"definition":"A lesion that has invaded into or beyond the deep fascia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Deep_Lesion"},{"name":"Maps_To","value":"Deep"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1707653"}]}}{"C36109":{"preferredName":"Superficial Lesion","code":"C36109","definitions":[{"definition":"A lesion with limited invasion of deeper tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Superficial_Lesion"},{"name":"Maps_To","value":"Superficial"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1336528"}]}}{"C64942":{"preferredName":"Few","code":"C64942","definitions":[{"definition":"An indefinite but relatively small number.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Few","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Few"},{"name":"Maps_To","value":"Few"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205388"}]}}{"C78728":{"preferredName":"Many","code":"C78728","definitions":[{"definition":"An indefinite large quantity that is considered to be greater than several.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Many","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Many"},{"name":"Maps_To","value":"Many"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0439064"}]}}{"C61376":{"preferredName":"Moderate","code":"C61376","definitions":[{"definition":"Middling or intermediate in degree, quality or extent.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The quality of being within reasonable or average limits; not excessive or extreme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderate","termGroup":"PT","termSource":"NCI"},{"termName":"Moderately","termGroup":"AD","termSource":"NCI"},{"termName":"Moderation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Moderation"},{"name":"Maps_To","value":"Moderate"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205081"}]}}{"C47826":{"preferredName":"Diffuse Lesion","code":"C47826","definitions":[{"definition":"A lesion that is not confined to the primary site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Lesion"},{"name":"Maps_To","value":"Diffuse"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1707743"}]}}{"C54253":{"preferredName":"Dome-Shaped Lesion","code":"C54253","definitions":[{"definition":"A lesion having the shape of a dome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dome-Shaped Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dome-Shaped_Lesion"},{"name":"Maps_To","value":"Dome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1711316"}]}}{"C111029":{"preferredName":"Mushroom-Shaped Lesion","code":"C111029","definitions":[{"definition":"A lesion having the shape of a mushroom.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mushroom-Shaped Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mushroom"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828878"}]}}{"C3415":{"preferredName":"Thyroid Gland Nodule","code":"C3415","definitions":[{"definition":"A discrete tissue mass in the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A nodular lesion that develops in the thyroid gland.  Causes include adenoma, thyroiditis, fluid-filled cyst, multinodular goiter, and carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Nodule","termGroup":"PT","termSource":"NCI"},{"termName":"Nodule of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Nodule of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Nodule of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Nodule of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Nodule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Thyroid_Nodule"},{"name":"Maps_To","value":"Benign Thyroid Nodule"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040137"}]}}{"C26785":{"preferredName":"Goiter","code":"C26785","definitions":[{"definition":"An enlarged thyroid. It may be caused by too little iodine in the diet or by other conditions. Most goiters are not cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing.","type":"DEFINITION","source":"NCI"},{"definition":"Enlargement of the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Goiter","termGroup":"PT","termSource":"NCI"},{"termName":"Thyromegaly","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Goiter"},{"name":"Maps_To","value":"Goiter"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231190"}]}}{"C3071":{"preferredName":"Graves Disease","code":"C3071","definitions":[{"definition":"An autoimmune condition characterized by excessive immunoglobulin stimulation of the thyroid gland resulting in hyperthyroidism.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Graves Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Graves' Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Graves_Disease"},{"name":"Maps_To","value":"Graves' Disease"},{"name":"Maps_To","value":"Graves' disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018213"}]}}{"C48259":{"preferredName":"Hyperparathyroidism","code":"C48259","definitions":[{"definition":"A condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Elevated concentration of parathyroid hormone. Causes include conditions originating within the parathyroid glands (primary), in response to hypocalcemia and hyperphosphatemia (secondary), and renal disease (tertiary). Characteristics may include polyuria, polydipsia, constipation, lethargy, cognitive dysfunction, hypercalciuria, nephrolithiasis, and bone demineralization or reduced bone mineral density.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperparathyroidism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hyperparathyroidism"},{"name":"Maps_To","value":"Hyperparathyroidism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0020502"}]}}{"C3123":{"preferredName":"Hyperthyroidism","code":"C3123","definitions":[{"definition":"A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Increased secretion of thyroid hormone(s) by the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.","type":"DEFINITION","source":"NCI"},{"definition":"Too much thyroid hormone. Symptoms include weight loss, chest pain, cramps, diarrhea, and nervousness.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hyperthyroidism","termGroup":"PT","termSource":"NCI"},{"termName":"Overactive Thyroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hyperthyroidism"},{"name":"Maps_To","value":"Hyperthyroidism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231189"}]}}{"C102532":{"preferredName":"Lymphoid Hyperplasia","code":"C102532","definitions":[{"definition":"A benign or malignant, diffuse and/or follicular lymphocytic proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoid Hyperplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphoid Hyperplasia"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0333997"}]}}{"C202212":{"preferredName":"Exercised Five or More Days per Week","code":"C202212","definitions":[{"definition":"A response indicating that a subject exercised 5 or more days per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exercised Five or More Days per Week","termGroup":"PT","termSource":"NCI"},{"termName":"Exercised 5 or More Days per Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5 or More Days"},{"name":"NCI_META_CUI","value":"CL1921179"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C202213":{"preferredName":"Exercised Three to Four Days per Week","code":"C202213","definitions":[{"definition":"A response indicating that a subject exercised 3 to 4 days per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exercised Three to Four Days per Week","termGroup":"PT","termSource":"NCI"},{"termName":"Exercised 3 to 4 Days per Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3 to 4 Days"},{"name":"NCI_META_CUI","value":"CL1921180"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C202214":{"preferredName":"Exercised One to Two Days per Week","code":"C202214","definitions":[{"definition":"A response indicating that a subject exercised 1 to 2 days per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exercised One to Two Days per Week","termGroup":"PT","termSource":"NCI"},{"termName":"Exercised 1 to 2 Days per Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1 to 2 Days"},{"name":"NCI_META_CUI","value":"CL1921177"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C202215":{"preferredName":"0-30 Days","code":"C202215","definitions":[{"definition":"A time period between 0 and 30 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"0-30 Days","termGroup":"PT","termSource":"NCI"},{"termName":"Zero to Thirty Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0-30 Days"},{"name":"NCI_META_CUI","value":"CL1921178"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C202216":{"preferredName":"31-90 Days","code":"C202216","definitions":[{"definition":"A time period between 31 and 90 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"31-90 Days","termGroup":"PT","termSource":"NCI"},{"termName":"Thirty One to Ninety Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"31-90 Days"},{"name":"NCI_META_CUI","value":"CL1921188"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C202217":{"preferredName":"91-180 Days","code":"C202217","definitions":[{"definition":"A time period between 91 and 180 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"91-180 Days","termGroup":"PT","termSource":"NCI"},{"termName":"Ninety One to One Hundred Eighty Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"91-180 Days"},{"name":"NCI_META_CUI","value":"CL1921189"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C202218":{"preferredName":"Greater than or Equal to 181 Days","code":"C202218","definitions":[{"definition":"A time period of at least 181 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Greater than or Equal to 181 Days","termGroup":"PT","termSource":"NCI"},{"termName":">=181 Days","termGroup":"SY","termSource":"NCI"},{"termName":"At Least 181 Days","termGroup":"SY","termSource":"NCI"},{"termName":"Greater than or Equal to One Hundred Eighty One Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":">=181 Days"},{"name":"NCI_META_CUI","value":"CL1921187"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C36132":{"preferredName":"Poorly Differentiated Lesion","code":"C36132","definitions":[{"definition":"A lesion comprised of neoplastic cells that generally have lost most of the morphological features that are indicative of normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Lesion"},{"name":"Maps_To","value":"Poorly differentiated"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1335443"}]}}{"C112014":{"preferredName":"Myasthenia Gravis Foundation of America Class I","code":"C112014","definitions":[{"definition":"Myasthenia gravis presenting with any ocular weakness; may have weakness of eye closure. All other muscles strength is normal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class I","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class I"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828874"}]}}{"C112015":{"preferredName":"Myasthenia Gravis Foundation of America Class II","code":"C112015","definitions":[{"definition":"Myasthenia gravis presenting with mild weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class II","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class II"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828872"}]}}{"C112016":{"preferredName":"Myasthenia Gravis Foundation of America Class III","code":"C112016","definitions":[{"definition":"Myasthenia gravis presenting with moderate weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class III","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class III"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828871"}]}}{"C112017":{"preferredName":"Myasthenia Gravis Foundation of America Class IV","code":"C112017","definitions":[{"definition":"Myasthenia gravis presenting with severe weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class IV","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class IV"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828870"}]}}{"C112018":{"preferredName":"Myasthenia Gravis Foundation of America Class V","code":"C112018","definitions":[{"definition":"Myasthenia gravis presenting with severe muscle weakness that requires intubation, with or without mechanical ventilation, except when employed during routine postoperative management.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class V","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class V","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class V"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828869"}]}}{"C198":{"preferredName":"Acetaminophen","code":"C198","definitions":[{"definition":"A drug that reduces pain and fever (but not inflammation).  It belongs to the family of drugs called analgesics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acetaminophen","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hydroxyacetanilide","termGroup":"SN","termSource":"NCI"},{"termName":"APAP","termGroup":"AB","termSource":"NCI"},{"termName":"N-(4-Hydroxyphenyl)acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"Paracetamol","termGroup":"SY","termSource":"NCI"},{"termName":"Tylenol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103-90-2"},{"name":"CHEBI_ID","value":"CHEBI:46195"},{"name":"Chemical_Formula","value":"C8H9NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"362O9ITL9D"},{"name":"Legacy Concept Name","value":"Acetaminophen"},{"name":"Maps_To","value":"Acetaminophen"},{"name":"NCI_Drug_Dictionary_ID","value":"39129"},{"name":"NSC Number","value":"109028"},{"name":"NSC Number","value":"3991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39129"},{"name":"PDQ_Open_Trial_Search_ID","value":"39129"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0000970"}]}}{"C287":{"preferredName":"Aspirin","code":"C287","definitions":[{"definition":"A drug that reduces pain, fever, inflammation, and blood clotting. Aspirin belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is also being studied in cancer prevention.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Acetylsalicylic acid decreases synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aspirin","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Acetyloxy)benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Acetylsalicylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"ASA","termGroup":"AB","termSource":"NCI"},{"termName":"Aspergum","termGroup":"BR","termSource":"NCI"},{"termName":"Ecotrin","termGroup":"BR","termSource":"NCI"},{"termName":"Empirin","termGroup":"BR","termSource":"NCI"},{"termName":"Entericin","termGroup":"BR","termSource":"NCI"},{"termName":"Extren","termGroup":"BR","termSource":"NCI"},{"termName":"Measurin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Mild to moderate pain; fever; prevention of arterial and venous thrombosis"},{"name":"CAS_Registry","value":"50-78-2"},{"name":"CHEBI_ID","value":"CHEBI:15365"},{"name":"Chemical_Formula","value":"C9H8O4"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R16CO5Y76E"},{"name":"Legacy Concept Name","value":"Acetylsalicylic_Acid"},{"name":"Maps_To","value":"Aspirin"},{"name":"NCI_Drug_Dictionary_ID","value":"39152"},{"name":"NSC Number","value":"406186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39152"},{"name":"PDQ_Open_Trial_Search_ID","value":"39152"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004057"}]}}{"C1655":{"preferredName":"HMG-CoA Reductase Inhibitor","code":"C1655","definitions":[{"definition":"An HMG-CoA reductase inhibitor (\"statin\"). Lipid-lowering medications with proven ASCVD benefits.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Any of a group of drugs that lower the amount of cholesterol and certain fats in the blood. Statins inhibit a key enzyme that helps make cholesterol. Statin drugs are being studied in the prevention and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Inhibition of HMG-CoA reductase acts to lower plasma cholesterol and lipoprotein levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMG-CoA Reductase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Hydroxymethylglutaryl CoenzymeA Reductase Inhibitors","termGroup":"SY","termSource":"NCI"},{"termName":"Statin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:35664"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HMG-CoA_Reductase_Inhibitor"},{"name":"Maps_To","value":"Statin, NOS"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0360714"}]}}{"C202296":{"preferredName":"Continuous Oxygen Administration","code":"C202296","definitions":[{"definition":"Long-term administration of supplementary oxygen at a constant rate using a continuous flow device.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Continuous Oxygen Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Continuous O2 Administration","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Continuous"},{"name":"NCI_META_CUI","value":"CL1921286"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C202297":{"preferredName":"Intermittent Oxygen Administration","code":"C202297","definitions":[{"definition":"Administration of supplementary oxygen over a short period of time using a non-continuous flow device.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermittent Oxygen Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intermittent O2 Administration","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermittent"},{"name":"NCI_META_CUI","value":"CL1921287"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C2959":{"preferredName":"Complication","code":"C2959","definitions":[{"definition":"Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure.","type":"DEFINITION","source":"NCI"},{"definition":"In medicine, a medical problem that occurs during a disease, or after a procedure or treatment. The complication may be caused by the disease, procedure, or treatment or may be unrelated to them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Complication","termGroup":"PT","termSource":"NCI"},{"termName":"Medical Complication","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Complication"},{"name":"Maps_To","value":"Adverse Event/Complications"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0009566"}]}}{"C202267":{"preferredName":"Treatment not Administered per the Discretion of the Health Care Provider","code":"C202267","definitions":[{"definition":"The treatment was not administered per the discretion of the health care provider.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treatment not Administered per the Discretion of the Health Care Provider","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Not Done per Treating Physician's Discretion"},{"name":"NCI_META_CUI","value":"CL1921260"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C192979":{"preferredName":"Refusal of Treatment by Patient","code":"C192979","definitions":[{"definition":"An indication that the patient has refused treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refusal of Treatment by Patient","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Participant Refusal"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C0040809"}]}}{"C185642":{"preferredName":"Scheduling Issue","code":"C185642","definitions":[{"definition":"A problem scheduling an event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scheduling Issue","termGroup":"PT","termSource":"NCI"},{"termName":"Scheduling Problem","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Scheduling Problems"},{"name":"NCI_META_CUI","value":"CL1773880"},{"name":"Semantic_Type","value":"Phenomenon or Process"}]}}{"C202268":{"preferredName":"Three Point Scale for Staining Intensity","code":"C202268","definitions":[{"definition":"A scale for staining intensity with three values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Three Point Scale for Staining Intensity","termGroup":"PT","termSource":"NCI"},{"termName":"3 Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"3 Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"},{"termName":"3-Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"3-Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The values in a 3 point scale could be either 0, 1+ and 2+ or 1+, 2+ and 3+."},{"name":"Maps_To","value":"3 Point Scale"},{"name":"NCI_META_CUI","value":"CL1921257"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C202269":{"preferredName":"Four Point Scale for Staining Intensity","code":"C202269","definitions":[{"definition":"A scale for staining intensity with four values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Four Point Scale for Staining Intensity","termGroup":"PT","termSource":"NCI"},{"termName":"4 Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"4 Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"},{"termName":"4-Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"4-Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The values in a 4 point scale could be either 0, 1+, 2+ and 3+, or 1+, 2+, 3+ and 4+."},{"name":"Maps_To","value":"4 Point Scale"},{"name":"NCI_META_CUI","value":"CL1921258"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C186199":{"preferredName":"Staining Intensity 0","code":"C186199","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.","type":"DEFINITION","source":"NCI"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staining Intensity 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0"},{"name":"NCI_META_CUI","value":"CL1778742"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C186200":{"preferredName":"Staining Intensity 1+","code":"C186200","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.","type":"DEFINITION","source":"NCI"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staining Intensity 1+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1+"},{"name":"NCI_META_CUI","value":"CL1778743"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C186201":{"preferredName":"Staining Intensity 2+","code":"C186201","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.","type":"DEFINITION","source":"NCI"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staining Intensity 2+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2+"},{"name":"NCI_META_CUI","value":"CL1778671"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C186202":{"preferredName":"Staining Intensity 3+","code":"C186202","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity 3+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3+"},{"name":"NCI_META_CUI","value":"CL1778672"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C202273":{"preferredName":"Staining Intensity 4+","code":"C202273","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 4+.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity 4+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"4+"},{"name":"NCI_META_CUI","value":"CL1921241"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C202276":{"preferredName":"Once a Week for at Least a Year","code":"C202276","definitions":[{"definition":"An indication that something was scheduled, or occurred, once a week for at least a year.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Once a Week for at Least a Year","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Once a Week for at Least a Year"},{"name":"NCI_META_CUI","value":"CL1921236"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C151974":{"preferredName":"Occasionally","code":"C151974","definitions":[{"definition":"Not frequently or regularly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occasionally","termGroup":"PT","termSource":"NCI"},{"termName":"Occasionally","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Occasionally"},{"name":"NCI_META_CUI","value":"CL553196"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C172572":{"preferredName":"Never Dosed","code":"C172572","definitions":[{"definition":"An indication that a subject has not ever been dosed with the study treatment or investigational product.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An indication that a subject has not ever been dosed with the study treatment or investigational product.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Never Dosed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"NCI_META_CUI","value":"CL1406672"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}
\ No newline at end of file
+{"C128274":{"preferredName":"Circulating Cell-Free DNA","code":"C128274","definitions":[{"definition":"DNA found in blood plasma and other bodily fluids that is not associated with cells.","type":"DEFINITION","source":"NCI"},{"definition":"DNA in blood plasma and other body fluids that has been released from a cell due to a biological process.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Circulating Cell-Free DNA","termGroup":"PT","termSource":"NCI"},{"termName":"cfDNA","termGroup":"AB","termSource":"NCI"},{"termName":"Circulating DNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"cfDNA"},{"name":"NCI_META_CUI","value":"CL509041"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C449":{"preferredName":"DNA","code":"C449","definitions":[{"definition":"A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone and found in the nucleus of a cell; associated with the transmission of genetic information.","type":"DEFINITION","source":"NCI"},{"definition":"A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone; associated with the transmission of genetic information.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The molecules inside cells that carry genetic information and pass it from one generation to the next.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Deoxyribonucleic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9007-49-2"},{"name":"CHEBI_ID","value":"CHEBI:16991"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"DNA is a double-stranded molecule held together by weak bonds between base pairs of nucleotides. DNA contain the four nucleotide bases adenine (A), guanine (G), cytosine (C), and thymine (T). In nature, base pairs form only between A and T and between G and C; thus the base sequence of each single strand can be deduced from that of its partner."},{"name":"Legacy Concept Name","value":"Deoxyribonucleic_Acid"},{"name":"Maps_To","value":"DNA"},{"name":"NSC Number","value":"77460"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0012854"}]}}{"C163993":{"preferredName":"EBV Immortalized Lymphocytes","code":"C163993","definitions":[{"definition":"A biospecimen consisting of lymphocytes that have been isolated from whole blood and are then infected in vitro by Epstein-Barr virus (EBV; HHV4). The infected cells are then cultured to select indefinitely proliferating colonies that can be maintained in tissue culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV Immortalized Lymphocytes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EBV Immortalized"},{"name":"Maps_To","value":"EBV Immortalized Lymphocytes"},{"name":"NCI_META_CUI","value":"CL977260"},{"name":"Semantic_Type","value":"Cell"}]}}{"C156435":{"preferredName":"Formalin-Fixed Paraffin-Embedded DNA","code":"C156435","definitions":[{"definition":"A DNA sample derived from a formalin-fixed paraffin-embedded tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded DNA","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE DNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE DNA"},{"name":"NCI_META_CUI","value":"CL563154"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C156436":{"preferredName":"Formalin-Fixed Paraffin-Embedded RNA","code":"C156436","definitions":[{"definition":"An RNA sample derived from a formalin-fixed paraffin-embedded tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded RNA","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE RNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE RNA"},{"name":"NCI_META_CUI","value":"CL563155"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C128787":{"preferredName":"GenomePlex Whole Genome Amplification","code":"C128787","definitions":[{"definition":"A proprietary method for whole genome amplification (WGA) from very small samples using random fragmentation of genomic DNA and conversion of the resulting small fragments to a library of PCR-amplifiable molecules flanked by universal priming sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GenomePlex Whole Genome Amplification","termGroup":"PT","termSource":"NCI"},{"termName":"GenomePlex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genomeplex"},{"name":"Maps_To","value":"GenomePlex (Rubicon) Amplified DNA"},{"name":"NCI_META_CUI","value":"CL509071"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C174108":{"preferredName":"Nucleic RNA Sample","code":"C174108","definitions":[{"definition":"A biological specimen comprised of the RNA isolated from the nuclei of cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleic RNA Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleic RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nuclei RNA"},{"name":"NCI_META_CUI","value":"CL1407752"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C128788":{"preferredName":"REPLI-g Whole Genome Amplification","code":"C128788","definitions":[{"definition":"A proprietary method for whole genome amplification (WGA) from small samples using high-fidelity enzyme Phi 29 polymerase to amplify complex genomic DNA using Multiple Displacement Amplification (MDA) technology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REPLI-g Whole Genome Amplification","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Repli-G"},{"name":"Maps_To","value":"Repli-G (Qiagen) DNA"},{"name":"NCI_META_CUI","value":"CL509311"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C156437":{"preferredName":"REPLI-g Pooled DNA","code":"C156437","definitions":[{"definition":"A genomic DNA sample produced from a pool of samples from several subjects that is amplified using REPLI-g technology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REPLI-g Pooled DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Repli-G Pooled (Qiagen) DNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Repli-G Pooled (Qiagen) DNA"},{"name":"NCI_META_CUI","value":"CL563156"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C156439":{"preferredName":"REPLI-g X DNA","code":"C156439","definitions":[{"definition":"A genomic DNA sample that has been produced by two rounds of REPLI-g amplification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REPLI-g X DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Repli-G X (Qiagen) DNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Repli-G X"},{"name":"Maps_To","value":"Repli-G X (Qiagen) DNA"},{"name":"NCI_META_CUI","value":"CL563177"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C812":{"preferredName":"Ribonucleic Acid","code":"C812","definitions":[{"definition":"One of two types of nucleic acid made by cells. Ribonucleic acid contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of ribonucleic acid, and each form has a specific job in the cell. Many forms of ribonucleic acid have functions related to making proteins. Ribonucleic acid is also the genetic material of some viruses instead of DNA. Ribonucleic acid can be made in the laboratory and used in research studies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Single-stranded long chain of nucleotides containing ribose. It is the end product of DNA transcription by the enzyme RNA polymerase. It is essential in protein synthesis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Single-stranded long chain of nucleotides containing ribose. It is the end product of DNA transcription by the enzyme RNA polymerase. It is essential in protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribonucleic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63231-63-0"},{"name":"CHEBI_ID","value":"CHEBI:33697"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ribonucleic_Acid"},{"name":"Maps_To","value":"RNA"},{"name":"NSC Number","value":"77461"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0035668"}]}}{"C163995":{"preferredName":"Total RNA","code":"C163995","definitions":[{"definition":"A biological sample comprised of all of the RNA collected from an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total RNA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Total RNA"},{"name":"NCI_META_CUI","value":"CL973034"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C188352":{"preferredName":"N6-Methyladenine Enriched RNA","code":"C188352","definitions":[{"definition":"A biological sample comprised of RNA that has subjected to an immunoprecipitation procedure using an antibody designed to select for sequences containing N6-methyladenine modifications.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N6-Methyladenine Enriched RNA","termGroup":"PT","termSource":"NCI"},{"termName":"m6A Enriched RNA","termGroup":"SY","termSource":"NCI"},{"termName":"m6A-Enriched RNA","termGroup":"SY","termSource":"NCI"},{"termName":"N6-Methyladenine-Enriched RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"m6A Enriched RNA"},{"name":"NCI_META_CUI","value":"CL1793611"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"}]}}{"C179446":{"preferredName":"mirVana RNA Isolation","code":"C179446","definitions":[{"definition":"A proprietary, rapid procedure using a glass fiber filter (GFF)-based method to purify total RNA from a sample. The total RNA can then be reapplied to a second GFF to purify small RNAs (miRNAs, siRNAs, and/or snRNAs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mirVana RNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"mirVana RNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"mirVana RNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mirVana (Allprep DNA) RNA"},{"name":"NCI_META_CUI","value":"CL1662297"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C153329":{"preferredName":"Sequencing Data","code":"C153329","definitions":[{"definition":"A collection of digital nucleic acid sequences, protein sequences, or other polymer sequences stored on a computer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Sequence Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sequencing Data"},{"name":"NCI_META_CUI","value":"CL554436"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C153349":{"preferredName":"Nucleotide Sequence Read","code":"C153349","definitions":[{"definition":"The manual or automated determination of the nucleotide order in a nucleic acid fragment obtained after the completion of a sequencing process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleotide Sequence Read","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleotide Sequencing Read","termGroup":"SY","termSource":"NCI"},{"termName":"Read","termGroup":"SY","termSource":"NCI"},{"termName":"Sequence Read","termGroup":"SY","termSource":"NCI"},{"termName":"Sequencing Read","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sequencing Reads"},{"name":"NCI_META_CUI","value":"CL554563"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C165232":{"preferredName":"Raw Sequencing Data","code":"C165232","definitions":[{"definition":"Nucleic acid sequence data that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw Nucleic Acid Sequencing Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw Nucleotide Sequencing Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw Sequencing Data"},{"name":"NCI_META_CUI","value":"CL978384"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C165211":{"preferredName":"Analysis Metadata","code":"C165211","definitions":[{"definition":"Supporting information that describes the processes used to analyze the experimental data in a study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Analysis Metadata","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Analysis Metadata"},{"name":"NCI_META_CUI","value":"CL978393"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184804":{"preferredName":"SRA-XML Format","code":"C184804","definitions":[{"definition":"An XML-based electronic file format used by the NCBI Sequence Read Archive (SRA) and the European Nucleotide Archive (ENA) to store raw sequencing data from next generation sequencing platforms and any corresponding sequence analysis data and associated metadata for the study, sample and experiment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution"}]}],"synonyms":[{"termName":"SRA-XML Format","termGroup":"PT","termSource":"NCI"},{"termName":"Short Read Archive eXtensible Markup Language Format","termGroup":"SY","termSource":"NCI"},{"termName":"SRA-XML","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SRA XML"},{"name":"NCI_META_CUI","value":"CL1772998"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C82937":{"preferredName":"MAGE-TAB","code":"C82937","definitions":[{"definition":"A tab-delimited, spreadsheet-based format that can be used for annotating and communicating microarray data with experimental details in a MIAME (Minimum Information About a Microarray Experiment) compliant fashion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-TAB","termGroup":"PT","termSource":"NCI"},{"termName":"MicroArray Gene Expression Tabular","termGroup":"SY","termSource":"NCI"},{"termName":"MicroArray Gene Expression Tabular Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MAGE-TAB"},{"name":"Maps_To","value":"MAGE-TAB"},{"name":"Maps_To","value":"MAGETAB"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2826580"}]}}{"C172211":{"preferredName":"Sample and Data Relationship Format","code":"C172211","definitions":[{"definition":"A tab-delimited file describing the relationships between samples, arrays, data and other objects used or produced during a microarray experiment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sample and Data Relationship Format","termGroup":"PT","termSource":"NCI"},{"termName":"SDRF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SDRF"},{"name":"NCI_META_CUI","value":"CL1406086"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172212":{"preferredName":"Investigation Description Format","code":"C172212","definitions":[{"definition":"A a tab-delimited containing information about an investigation, including its name, a description, the investigator's contact details, bibliographic references, and free text descriptions of any relevant protocols.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"BMC Bioinformatics. 2006; 7. https://doi.org/10.1186/1471-2105-7-489."}]}],"synonyms":[{"termName":"Investigation Description Format","termGroup":"PT","termSource":"NCI"},{"termName":"IDF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDF"},{"name":"NCI_META_CUI","value":"CL1406085"},{"name":"PubMedID_Primary_Reference","value":"17087822"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172213":{"preferredName":"Array Design Format","code":"C172213","definitions":[{"definition":"A tab-delimited file defining how each array in an investigation is used. This data includes what sequence is located at each position in an array and what the annotation of this sequence is; cross-references to entries in a public repository can be used if available.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"BMC Bioinformatics. 2006; 7. https://doi.org/10.1186/1471-2105-7-489."}]}],"synonyms":[{"termName":"Array Design Format","termGroup":"PT","termSource":"NCI"},{"termName":"ADF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ADF"},{"name":"NCI_META_CUI","value":"CL1406109"},{"name":"PubMedID_Primary_Reference","value":"17087822"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C49488":{"preferredName":"Yes","code":"C49488","definitions":[{"definition":"ICD: a battery-powered electrical impulse generator implanted in patients at risk of sudden cardiac death to detect cardiac arrhythmia and correct it by delivering a jolt of electricity. This would include BiV-ICDs.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The affirmative response to a question.","type":"DEFINITION","source":"NCI"},{"definition":"The affirmative response to a question. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Yes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"PRO-CTCAE"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Yes"},{"name":"Maps_To","value":"yes"},{"name":"Maps_To","value":"Yes"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C1298907"}]}}{"C49487":{"preferredName":"No","code":"C49487","definitions":[{"definition":"The non-affirmative response to a question.","type":"DEFINITION","source":"NCI"},{"definition":"The non-affirmative response to a question. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"No","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"PRO-CTCAE"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"No"},{"name":"Maps_To","value":"No"},{"name":"Maps_To","value":"no"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1298908"}]}}{"C17998":{"preferredName":"Unknown","code":"C17998","definitions":[{"definition":"A proper value is applicable but not known.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Not known, not observed, not recorded, or refused.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"SPL"}]},{"definition":"Not known, not observed, not recorded, or refused.","type":"ALT_DEFINITION","source":"PQCMC"},{"definition":"Not known, not observed, not recorded, or refused. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","type":"DEFINITION","source":"NCI"},{"definition":"Reported as unknown by the data contributor.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]}],"synonyms":[{"termName":"Unknown","termGroup":"PT","termSource":"NCI"},{"termName":"Not Known","termGroup":"SY","termSource":"NCI"},{"termName":"Unknown/Not Stated","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Contributing_Source","value":"UCUM"},{"name":"DesignNote","value":"Used for Cancer Activities Coding when cancer activity is not specified."},{"name":"Legacy Concept Name","value":"Unknown"},{"name":"Maps_To","value":"unknown"},{"name":"Maps_To","value":"Unknown"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C0439673"},{"name":"Use_For","value":"Nonspecific"}]}}{"C43234":{"preferredName":"Not Reported","code":"C43234","definitions":[{"definition":"Not provided or available.","type":"DEFINITION","source":"NCI"},{"definition":"Not provided or available.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Not Reported","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Not_Stated"},{"name":"Maps_To","value":"Not Reported"},{"name":"Maps_To","value":"not reported"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1706613"}]}}{"C141478":{"preferredName":"Not Allowed To Collect","code":"C141478","definitions":[{"definition":"An indicator that specifies that a collection event was not permitted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Not Allowed To Collect","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Not Allowed To Collect"},{"name":"Maps_To","value":"not allowed to collect"},{"name":"NCI_META_CUI","value":"CL539590"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C70699":{"preferredName":"Biospecimen","code":"C70699","definitions":[{"definition":"A substance or portion of material originally obtained from an entity for use in testing, examination, or study.  EXAMPLE(S): Blood obtained by a specimen collection activity performed on a study subject. A few grains of cattle feed obtained from a feed sack. A randomly selected pill from a blister pack. A serum specimen that resulted from Centrifugation procedure performed on a blood specimen. A DNA specimen extraction from a saliva specimen. A Formalin-Fixed, Paraffin-Embedded (FFPE) block that resulted from a paraffin embedding procedure performed on a formalin fixed tissue specimen. A pooled blood sample that resulted from a mixing procedure performed on several blood samples taken from individual animals.  OTHER NAME(S): Biologic specimen Product specimen  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"A substance or portion of material originally obtained from an entity for use in testing, examination, or study. EXAMPLE(S): Blood obtained by a specimen collection activity performed on a study subject. A few grains of cattle feed obtained from a feed sack. A randomly selected pill from a blister pack. A serum specimen that resulted from Centrifugation procedure performed on a blood specimen. A DNA specimen extraction from a saliva specimen. A Formalin-Fixed, Paraffin-Embedded (FFPE) block that resulted from a paraffin embedding procedure performed on a formalin fixed tissue specimen. A pooled blood sample that resulted from a mixing procedure performed on several blood samples taken from individual animals. OTHER NAME(S): Biologic specimen; Product specimen.","type":"ALT_DEFINITION","source":"BRIDG 3.0.3"},{"definition":"Any material collected from a biological entity for testing, diagnostic, propagation, treatment, or research purposes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","type":"DEFINITION","source":"NCI"},{"definition":"Samples of material, such as urine, blood, tissue, cells, DNA, RNA, and protein from humans, animals, or plants. Biospecimens are stored in a biorepository and are used for laboratory research. If the samples are from people, medical information may also be stored along with a written consent to use the samples in laboratory studies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Biospecimen","termGroup":"PT","termSource":"NCI"},{"termName":"Bio-Specimen","termGroup":"SY","termSource":"NCI"},{"termName":"Biological Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Biological Specimen","termGroup":"SY","termSource":"NCI"},{"termName":"Biospecimen","termGroup":"SY","termSource":"NCI"},{"termName":"Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Biospecimen"},{"name":"Maps_To","value":"Biospecimen"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C2347026"}]}}{"C164025":{"preferredName":"Biospecimen Data Supplement","code":"C164025","definitions":[{"definition":"Additional documentation or textual matter added to a study report that contains biospecimen data or related information.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biospecimen Data Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Biospecimen Supplement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biospecimen Supplement"},{"name":"NCI_META_CUI","value":"CL977234"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C190164":{"preferredName":"BCR Biotab Format","code":"C190164","definitions":[{"definition":"Files that consist of aggregate clinical and biospecimen data across all cases of the given project. Biotab files are supplemental files that are available in the Genomic Data Commons (GDC) Legacy Archive as tab-delimited files on a project level basis. These may also include fields that are not available in the GDC application programming interface (API).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCR Biotab Format","termGroup":"PT","termSource":"NCI"},{"termName":"BCR Biotab","termGroup":"SY","termSource":"NCI"},{"termName":"BCR Biotab File Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BCR Biotab"},{"name":"NCI_META_CUI","value":"CL1798764"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C164049":{"preferredName":"Tab-Separated Value Format","code":"C164049","definitions":[{"definition":"A file format where each line in the file contains a single piece of data and where each field or value in a line of data is separated from the next by a tab character.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tab-Separated Value Format","termGroup":"PT","termSource":"NCI"},{"termName":"Tab-Delimited File Format","termGroup":"SY","termSource":"NCI"},{"termName":"Tab-Delimited Format","termGroup":"SY","termSource":"NCI"},{"termName":"Tab-Delimited Value Format","termGroup":"SY","termSource":"NCI"},{"termName":"Tab-Delimited Values","termGroup":"SY","termSource":"NCI"},{"termName":"TSV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TSV"},{"name":"NCI_META_CUI","value":"CL977213"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C164050":{"preferredName":"Excel Open XML Format","code":"C164050","definitions":[{"definition":"A proprietary file format developed by Microsoft that allows the user to save a spreadsheet created in Excel in an open XML-format. The file then can be read and opened by other spreadsheet-compatible applications.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Excel Open XML Format","termGroup":"PT","termSource":"NCI"},{"termName":"XLSX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"XLSX"},{"name":"NCI_META_CUI","value":"CL977212"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172262":{"preferredName":"Consent Exemption for Use of Post-mortem Samples","code":"C172262","definitions":[{"definition":"An exemption that allows research sponsors to use samples obtained from a subject after his/her death because these samples are not subject to human subject use regulations and do not require documentation of informed consent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Consent Exemption for Use of Post-mortem Samples","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Consent by Death"},{"name":"NCI_META_CUI","value":"CL1406151"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C79226":{"preferredName":"Exemption from Informed Consent for Research","code":"C79226","synonyms":[{"termName":"Exemption from Informed Consent for Research","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Exemption_From_Informed_Consent_For_Research"},{"name":"Maps_To","value":"Consent Exemption"},{"name":"Semantic_Type","value":"Regulation or Law"},{"name":"UMLS_CUI","value":"C2700032"}]}}{"C103270":{"preferredName":"Consent Waiver","code":"C103270","definitions":[{"definition":"The release from the requirement to obtain informed consent during a study that is granted by Human Subject Protection committee for a research institution for a protocol that is being reviewed by the Institutional Review Board.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Consent Waiver","termGroup":"PT","termSource":"NCI"},{"termName":"Waiver Of Informed Consent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Consent Waiver"},{"name":"Semantic_Type","value":"Governmental or Regulatory Activity"},{"name":"UMLS_CUI","value":"C3641166"}]}}{"C16735":{"preferredName":"Informed Consent","code":"C16735","definitions":[{"definition":"A process in which a person is given important facts about a medical procedure or treatment, a clinical trial, or genetic testing before deciding whether or not to participate. It also includes informing the patient when there is new information that may affect his or her decision to continue. Informed consent includes information about the possible risks, benefits, and limits of the procedure, treatment, trial, or genetic testing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An ongoing process that provides the subject with explanations that will help in making educated decisions about whether to begin or continue participating in a trial. informed consent is an ongoing, interactive process rather than a one-time information session. NOTE: Under 21 CFR 50.20, no informed consent form may include any \"language through which the subject or the representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability for negligence.\" In some cases, when the prospective subject is unable to provide legal consent, permission to participate may be obtained from a legally-authorized representative. See also consent form.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.","type":"DEFINITION","source":"NCI"},{"definition":"Consent given by a subject, or in the case of an individual that can only give assent, by a parent or legal guardian, for the participation in a clinical study only after having achieved an understanding of both the relevant medical facts and the relevant risks involved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The process of learning and discussing the details of a research study before deciding whether to take part. (https://mrctcenter.org/glossaryterm/informed-consent/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Informed Consent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Informed_Consent"},{"name":"Maps_To","value":"Informed Consent"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0021430"}]}}{"C4197":{"preferredName":"Acinar Cell Neoplasm","code":"C4197","definitions":[{"definition":"A benign or malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. It includes the acinar cell adenoma and acinar cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acinar Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8550/1"},{"name":"Legacy Concept Name","value":"Acinar_Cell_Neoplasm"},{"name":"Maps_To","value":"8550/1"},{"name":"Maps_To","value":"Acinar Cell Neoplasms"},{"name":"Maps_To","value":"Acinar cell tumor"},{"name":"Maps_To","value":"Acinic cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334390"}]}}{"C4463":{"preferredName":"Skin Appendage Neoplasm","code":"C4463","definitions":[{"definition":"A benign or malignant neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Appendage Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Adnexal Neoplasm of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Neoplasm of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Tumor of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Tumor of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Appendageal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Adnexal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendage Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendageal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_Appendage_Neoplasm"},{"name":"Maps_To","value":"Adnexal and Skin Appendage Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0345988"}]}}{"C3784":{"preferredName":"Basal Cell Neoplasm","code":"C3784","definitions":[{"definition":"A neoplastic proliferation of basal cells in the epidermis (part of the skin) or other anatomic sites (most frequently the salivary glands).  The basal cell neoplastic proliferation in the epidermis results in basal cell carcinomas.  The basal cell neoplastic proliferation in the salivary glands can be benign, resulting in basal cell adenomas or malignant, resulting in basal cell adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basal Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8090/1"},{"name":"Legacy Concept Name","value":"Basal_Cell_Neoplasm"},{"name":"Maps_To","value":"8090/1"},{"name":"Maps_To","value":"Basal Cell Neoplasms"},{"name":"Maps_To","value":"Basal cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206710"}]}}{"C7387":{"preferredName":"Blood Vessel Neoplasm","code":"C7387","definitions":[{"definition":"A neoplasm arising from arteries or veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Vessel Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Vessel Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blood_Vessel_Neoplasm"},{"name":"Maps_To","value":"Blood Vessel Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0282607"}]}}{"C4345":{"preferredName":"Myeloproliferative Neoplasm","code":"C4345","definitions":[{"definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","type":"DEFINITION","source":"NCI"},{"definition":"A group of slow growing blood cancers, including chronic myelogenous leukemia, in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Myeloproliferative Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"CMPD","termGroup":"AB","termSource":"NCI"},{"termName":"MPN","termGroup":"AB","termSource":"NCI"},{"termName":"Myeloproliferative Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloproliferative Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9960/3"},{"name":"ICD-O-3_Code","value":"9975/1"},{"name":"Legacy Concept Name","value":"Chronic_Myeloproliferative_Disorder"},{"name":"Maps_To","value":"Chronic myeloproliferative disease"},{"name":"Maps_To","value":"Chronic myeloproliferative disorder"},{"name":"Maps_To","value":"Chronic Myeloproliferative Disorders"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292778"}]}}{"C4198":{"preferredName":"Complex Epithelial Neoplasm","code":"C4198","synonyms":[{"termName":"Complex Epithelial Neoplasm","termGroup":"AQ","termSource":"NCI"},{"termName":"Complex Epithelial Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Neoplasm of Epithelium","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Neoplasm of the Epithelium","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Tumor of Epithelium","termGroup":"AQS","termSource":"NCI"},{"termName":"Complex Tumor of the Epithelium","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Complex_Epithelial_Neoplasm"},{"name":"Maps_To","value":"Complex Epithelial Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334391"}]}}{"C3709":{"preferredName":"Epithelial Neoplasm","code":"C3709","definitions":[{"definition":"A benign, borderline, or malignant neoplasm that arises from and is composed of epithelial cells. Representative examples include adenomas and carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Neoplasms, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epithelial_Neoplasm"},{"name":"Maps_To","value":"Epithelial Neoplasms, NOS"},{"name":"Maps_To","value":"Epithelioma, malignant"},{"name":"Maps_To","value":"Epithelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368683"}]}}{"C3743":{"preferredName":"Fibroepithelial Neoplasm","code":"C3743","definitions":[{"definition":"A benign, borderline, or malignant neoplasm characterized by the presence of an epithelial and a fibrous component.  Representative examples are fibroadenoma and phyllodes tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroepithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroepithelial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fibroepithelial_Neoplasm"},{"name":"Maps_To","value":"Fibroepithelial Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206649"}]}}{"C3708":{"preferredName":"Germ Cell Tumor","code":"C3708","definitions":[{"definition":"A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","type":"DEFINITION","source":"NCI"},{"definition":"A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, dysgerminoma, and germinoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of tumor that begins in the cells that give rise to sperm or eggs. Germ cell tumors can occur almost anywhere in the body and can be either benign or malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Germ Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Germ Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Germ Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Germ Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Germ_Cell_Neoplasm"},{"name":"Maps_To","value":"9064/3"},{"name":"Maps_To","value":"Germ Cell Neoplasms"},{"name":"Maps_To","value":"Germ cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205851"}]}}{"C3055":{"preferredName":"Giant Cell Tumor","code":"C3055","definitions":[{"definition":"A benign, intermediate, or malignant tumor that arises from the bone or soft tissue. It is characterized by the presence of multinucleated osteoclast-like giant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Giant_Cell_Tumor"},{"name":"Maps_To","value":"Giant Cell Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017525"}]}}{"C3059":{"preferredName":"Glioma","code":"C3059","definitions":[{"definition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","type":"DEFINITION","source":"NCI"},{"definition":"A general term for tumors of the central nervous system, including astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroectodermal tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Glial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Neuroglia","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Neuroglia","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroglial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Neuroglia","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Neuroglia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Neuroglial_Tumor"},{"name":"Maps_To","value":"9380/3"},{"name":"Maps_To","value":"Glioma, NOS"},{"name":"Maps_To","value":"Gliomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017638"}]}}{"C9357":{"preferredName":"Hodgkin Lymphoma","code":"C9357","definitions":[{"definition":"A cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Symptoms include the painless enlargement of lymph nodes, spleen, or other immune tissue. Other symptoms include fever, weight loss, fatigue, or night sweats.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the lymphatic system that is comprised of abnormal lymphocytes and is characterized by the presence of Reed-Sternberg cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"HL","termGroup":"AB","termSource":"NCI"},{"termName":"Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9650/3"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9650/3"},{"name":"Maps_To","value":"Hodgkin disease, NOS"},{"name":"Maps_To","value":"Hodgkin Lymphoma"},{"name":"Maps_To","value":"Hodgkin lymphoma"},{"name":"Maps_To","value":"Hodgkin lymphoma, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin lymphoma, unspecified, unspecified site"},{"name":"Maps_To","value":"Hodgkin's disease"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving intrapelvic lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin's disease, unspecified type, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Hodgkin's lymphoma"},{"name":"Maps_To","value":"Malignant lymphoma, Hodgkin"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019829"}]}}{"C3161":{"preferredName":"Leukemia","code":"C3161","definitions":[{"definition":"A cancer of the blood or bone marrow that is characterized by increased production of abnormal blood cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells, originating from myeloid or lymphoid stem cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of blood cells to be produced and enter the bloodstream.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Blood (Leukemia)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9800/3"},{"name":"Legacy Concept Name","value":"Leukemia"},{"name":"Maps_To","value":"9800/3"},{"name":"Maps_To","value":"Leukaemia of unspecified cell type"},{"name":"Maps_To","value":"Leukaemia, unspecified"},{"name":"Maps_To","value":"Leukemia"},{"name":"Maps_To","value":"Leukemia of unspecified cell type"},{"name":"Maps_To","value":"Leukemia, NOS"},{"name":"Maps_To","value":"Leukemia, unspecified not having achieved remission"},{"name":"Maps_To","value":"Leukemias, NOS"},{"name":"Maps_To","value":"Other leukaemias of specified cell type"},{"name":"Maps_To","value":"Other leukemia of unspecified cell type"},{"name":"Maps_To","value":"Other leukemia of unspecified cell type without mention of having achieved remission"},{"name":"Maps_To","value":"Other specified leukaemias"},{"name":"Maps_To","value":"Other specified leukemia"},{"name":"Maps_To","value":"Other specified leukemias"},{"name":"Maps_To","value":"Other specified leukemias not having achieved remission"},{"name":"Maps_To","value":"Unspecified leukemia"},{"name":"Maps_To","value":"Unspecified leukemia without mention of having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023418"}]}}{"C4248":{"preferredName":"Lipomatous Neoplasm","code":"C4248","definitions":[{"definition":"A benign, intermediate, or malignant mesenchymal neoplasm composed of adipose (fatty) tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipomatous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Adipose Tissue Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adipose Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Lipomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Adipose Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lipomatous_Neoplasm"},{"name":"Maps_To","value":"Lipomatous Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206631"}]}}{"C3723":{"preferredName":"Lymphatic Vessel Neoplasm","code":"C3723","definitions":[{"definition":"A benign or malignant neoplasm arising from the lymphatic vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphatic Vessel Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Vessel Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Vessel Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphatic Vessel Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Lymphatic Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Lymphatic Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Lymphatic Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Lymph Vessel","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Lymphatic Vessel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphatic_Vessel_Neoplasm"},{"name":"Maps_To","value":"Lymphatic Vessel Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206619"}]}}{"C7539":{"preferredName":"Lymphoid Leukemia","code":"C7539","definitions":[{"definition":"A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood.  This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells, originating from lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer in which the bone marrow makes too many lymphocytes (white blood cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphoid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"981-983"},{"name":"ICD-O-3_Code","value":"9820/3"},{"name":"Legacy Concept Name","value":"Lymphoid_Leukemia"},{"name":"Maps_To","value":"9820/3"},{"name":"Maps_To","value":"Lymphatic leukemic, NOS"},{"name":"Maps_To","value":"Lymphocytic leukemia, NOS"},{"name":"Maps_To","value":"Lymphoid leukaemia"},{"name":"Maps_To","value":"Lymphoid leukaemia, unspecified"},{"name":"Maps_To","value":"Lymphoid leukemia"},{"name":"Maps_To","value":"Lymphoid leukemia, NOS"},{"name":"Maps_To","value":"Lymphoid leukemia, subacute"},{"name":"Maps_To","value":"Lymphoid leukemia, unspecified not having achieved remission"},{"name":"Maps_To","value":"Lymphoid Leukemias"},{"name":"Maps_To","value":"Lymphosarcoma cell leukemia"},{"name":"Maps_To","value":"Other lymphoid leukemia"},{"name":"Maps_To","value":"Other lymphoid leukemia not having achieved remission"},{"name":"Maps_To","value":"Other lymphoid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Unspecified lymphoid leukemia"},{"name":"Maps_To","value":"Unspecified lymphoid leukemia without mention of having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023448"}]}}{"C3208":{"preferredName":"Lymphoma","code":"C3208","definitions":[{"definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A malignant neoplasm composed of lymphocytes of B- or T/NK-cell phenotype.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm of the lymphatic system that is comprised of abnormal lymphocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphoma (Hodgkin and Non-Hodgkin)","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoma (Hodgkin's and Non-Hodgkin's)","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphomatous","termGroup":"AD","termSource":"NCI"},{"termName":"Malignant Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9590/3"},{"name":"Legacy Concept Name","value":"Lymphoma"},{"name":"Maps_To","value":"9590/3"},{"name":"Maps_To","value":"Lymphoma"},{"name":"Maps_To","value":"Lymphoma, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, NOS"},{"name":"Maps_To","value":"Malignant Lymphomas, NOS or Diffuse"},{"name":"Maps_To","value":"Other malignant lymphomas"},{"name":"Maps_To","value":"Other malignant lymphomas involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Other malignant lymphomas involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Other malignant lymphomas involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Other malignant lymphomas involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Other malignant lymphomas involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Other malignant lymphomas, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4227552"},{"name":"xRef","value":"IMDRF:E180104"}]}}{"C9295":{"preferredName":"Mast Cell Neoplasm","code":"C9295","definitions":[{"definition":"A growth or lump of mast cells (a type of white blood cell). Mast cell tumors can involve the skin, subcutaneous tissue, and muscle tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A heterogeneous group of disorders characterized by the abnormal growth and accumulation of mast cells in one or more organ systems.  Recent data suggest that most variants of mast cell neoplasms are clonal disorders. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Mast Cell Proliferative Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Mast Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Mast Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Mast Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Mast Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Mast Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mast_Cell_Neoplasm"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Mast cell tumor, NOS"},{"name":"Maps_To","value":"Mast Cell Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334664"}]}}{"C7056":{"preferredName":"Mature B-Cell Non-Hodgkin Lymphoma","code":"C7056","definitions":[{"definition":"A non-Hodgkin lymphoma that originates from mature B lymphocytes. Representative examples include diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mature B-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mature B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature B-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mature_B-Cell_Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"Mature B-Cell Lymphomas"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334634"}]}}{"C3468":{"preferredName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","code":"C3468","definitions":[{"definition":"One of a group of aggressive (fast-growing) non-Hodgkin lymphomas that begins in mature T lymphocytes (T cells that have matured in the thymus gland and goes to other lymphatic sites in the body, including lymph nodes, bone marrow, and spleen.)","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative disease entities include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mature T-and NK-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature T-Cell and NK-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature T-Cell and NK-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mature T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PTCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9702/3"},{"name":"Legacy Concept Name","value":"Mature_T-Cell_and_NK-Cell_Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"Mature T- and NK-Cell Lymphomas"},{"name":"Maps_To","value":"Mature T/NK-cell lymphoma, unspecified"},{"name":"Maps_To","value":"Mature T/NK-cell lymphomas"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079774"}]}}{"C3230":{"preferredName":"Meningioma","code":"C3230","definitions":[{"definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A type of slow-growing tumor that forms in the meninges (thin layers of tissue that cover and protect the brain and spinal cord). Meningiomas usually occur in adults.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually benign tumor that develops in the meninges.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9530/0"},{"name":"Legacy Concept Name","value":"Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Meningioma"},{"name":"Maps_To","value":"Meningioma, NOS"},{"name":"Maps_To","value":"Meningiomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4012135"}]}}{"C40141":{"preferredName":"Wolffian Tumor","code":"C40141","definitions":[{"definition":"An adnexal epithelial neoplasm of Wolffian (mesonephric) origin. It predominantly affects the broad ligament and presents as a unilateral adnexal mass. Most tumors behave in a benign fashion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wolffian Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"FATWO","termGroup":"AB","termSource":"NCI"},{"termName":"Female Adnexal Tumor of Probable Wolffian Origin","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephric Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephroma","termGroup":"SY","termSource":"NCI"},{"termName":"Retiform Wolffian Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"WAT","termGroup":"AB","termSource":"NCI"},{"termName":"Wolffian Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Adnexal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Adnexal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Duct Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Duct Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Wolffian Duct Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9110/0"},{"name":"ICD-O-3_Code","value":"9110/1"},{"name":"Legacy Concept Name","value":"Wolffian_Adnexal_Tumor"},{"name":"Maps_To","value":"9110/0"},{"name":"Maps_To","value":"9110/1"},{"name":"Maps_To","value":"Mesonephric adenoma"},{"name":"Maps_To","value":"Mesonephric tumor, NOS"},{"name":"Maps_To","value":"Mesonephroma, benign"},{"name":"Maps_To","value":"Mesonephroma, NOS"},{"name":"Maps_To","value":"Mesonephromas"},{"name":"Maps_To","value":"Wolffian duct adenoma"},{"name":"Maps_To","value":"Wolffian duct tumor"},{"name":"Maps_To","value":"Wolffian tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1520159"}]}}{"C3786":{"preferredName":"Mesothelial Neoplasm","code":"C3786","definitions":[{"definition":"A benign (noncancerous) or malignant (cancerous) tumor affecting the lining of the chest or abdomen.  Exposure to asbestos particles in the air increases the risk of developing malignant mesothelioma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm characterized by the proliferation of neoplastic mesothelial cells. It usually arises from the pleura or peritoneum. This category includes malignant mesothelioma, adenomatoid tumor (benign mesothelioma), well differentiated papillary mesothelial tumor, and multicystic mesothelioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesothelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mesothelial_Neoplasm"},{"name":"Maps_To","value":"9050/3"},{"name":"Maps_To","value":"Mesothelial Neoplasms"},{"name":"Maps_To","value":"Mesothelioma"},{"name":"Maps_To","value":"Mesothelioma of other sites"},{"name":"Maps_To","value":"Mesothelioma, NOS"},{"name":"Maps_To","value":"Mesothelioma, unspecified"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3714739"}]}}{"C9343":{"preferredName":"Bone Neoplasm","code":"C9343","definitions":[{"definition":"A benign, intermediate, or malignant neoplasm involving the bone or articular cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Tumors","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bone_Neoplasm"},{"name":"Maps_To","value":"Miscellaneous Bone Tumors"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of bone and articular cartilage"},{"name":"Maps_To","value":"Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0005967"}]}}{"C102883":{"preferredName":"Miscellaneous Neoplasm","code":"C102883","definitions":[{"definition":"A benign or malignant neoplasm which is not further characterized.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miscellaneous Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Miscellaneous Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3540828"}]}}{"C3247":{"preferredName":"Myelodysplastic Syndrome","code":"C3247","definitions":[{"definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A group of diseases in which the bone marrow does not make enough healthy blood cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pre-malignant disorder characterized by blood cytopenias and abnormalities in bone marrow morphology.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Dysmyelopoietic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"MDN","termGroup":"AB","termSource":"NCI"},{"termName":"MDS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome/Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Oligoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Preleukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Smoldering Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9989/3"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"High grade myelodysplastic syndrome lesions"},{"name":"Maps_To","value":"Low grade myelodysplastic syndrome lesions"},{"name":"Maps_To","value":"Myelodysplastic Syndrome"},{"name":"Maps_To","value":"Myelodysplastic syndrome"},{"name":"Maps_To","value":"Myelodysplastic syndrome, unspecified"},{"name":"Maps_To","value":"Myelodysplastic Syndromes"},{"name":"Maps_To","value":"Myelodysplastic syndromes"},{"name":"Maps_To","value":"Other myelodysplastic syndromes"},{"name":"Maps_To","value":"Preleukemia"},{"name":"Maps_To","value":"Preleukemic syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3463824"}]}}{"C3172":{"preferredName":"Myeloid Leukemia","code":"C3172","definitions":[{"definition":"A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells, originating from immature granulocytes.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Lymphoblastic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9860/3"},{"name":"Legacy Concept Name","value":"Myeloid_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"Granulocytic leukemia, NOS"},{"name":"Maps_To","value":"Myelocytic leukemia, NOS"},{"name":"Maps_To","value":"Myelogenous leukemia, NOS"},{"name":"Maps_To","value":"Myeloid leukaemia"},{"name":"Maps_To","value":"Myeloid leukaemia, unspecified"},{"name":"Maps_To","value":"Myeloid leukemia"},{"name":"Maps_To","value":"Myeloid leukemia, NOS"},{"name":"Maps_To","value":"Myeloid leukemia, subacute"},{"name":"Maps_To","value":"Myeloid Leukemias"},{"name":"Maps_To","value":"Non-lymphocytic leukemia, NOS"},{"name":"Maps_To","value":"Other myeloid leukaemia"},{"name":"Maps_To","value":"Other myeloid leukemia"},{"name":"Maps_To","value":"Other myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Subacute myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Unspecified myeloid leukemia"},{"name":"Maps_To","value":"Unspecified myeloid leukemia without mention of having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023470"}]}}{"C4063":{"preferredName":"Myomatous Neoplasm","code":"C4063","definitions":[{"definition":"A benign or malignant mesenchymal neoplasm arising from smooth, skeletal, or cardiac muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myomatous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Muscle Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Myomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Muscle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myomatous_Neoplasm"},{"name":"Maps_To","value":"Myomatous Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0282606"}]}}{"C3262":{"preferredName":"Neoplasm","code":"C3262","definitions":[{"definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","type":"DEFINITION","source":"NCI"},{"definition":"An abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Neoplasms may be benign (not cancer), or malignant (cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplastic Growth","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Neoplasm"},{"name":"Maps_To","value":"8000/1"},{"name":"Maps_To","value":"Neoplasm of unspecified nature, site unspecified"},{"name":"Maps_To","value":"Neoplasm, NOS"},{"name":"Maps_To","value":"Neoplasms of unspecified nature"},{"name":"Maps_To","value":"Neoplasms, NOS"},{"name":"Maps_To","value":"Tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Publish_Value_Set","value":"Yes"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0375111"},{"name":"xRef","value":"IMDRF:E18"}]}}{"C4972":{"preferredName":"Nerve Sheath Neoplasm","code":"C4972","definitions":[{"definition":"A benign or malignant neoplasm arising from the perineural cells in the sheaths surrounding the nerves. Representative examples include neurofibroma, schwannoma, and malignant peripheral nerve sheath tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve Sheath Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Nerve Sheath","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peripheral_Nerve_Sheath_Neoplasm"},{"name":"Maps_To","value":"Nerve sheath tumor, NOS"},{"name":"Maps_To","value":"Nerve Sheath Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206727"}]}}{"C3787":{"preferredName":"Neuroepithelial Neoplasm","code":"C3787","definitions":[{"definition":"A neoplasm of the nervous system that arises from the neuroepithelial tissues.  Representative examples include astrocytic tumors, oligodendroglial tumors, ependymal tumors, and primitive neuroectodermal tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroepithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Neuroepithelial Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Neuroepithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Neuroepithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tissue Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelial Tumors","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Neuroepithelial Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Neuroepithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Neuroepithelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neuroepithelial_Neoplasm"},{"name":"Maps_To","value":"Neuroepitheliomatous Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206715"}]}}{"C3286":{"preferredName":"Odontogenic Neoplasm","code":"C3286","definitions":[{"definition":"A benign or malignant neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Benign neoplasms are slow growing and are not associated with specific clinical symptoms. Pain is absent or slight. Malignant neoplasms are usually associated with rapid swelling and pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9270/1"},{"name":"Legacy Concept Name","value":"Odontogenic_Neoplasm"},{"name":"Maps_To","value":"9270/1"},{"name":"Maps_To","value":"Odontogenic tumor, NOS"},{"name":"Maps_To","value":"Odontogenic Tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0028880"}]}}{"C184783":{"preferredName":"Personal History of Other Hematologic Disorder","code":"C184783","definitions":[{"definition":"An individual history of a hematologic disorder, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Hematologic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Hematologic Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Hematologic Disorders"},{"name":"NCI_META_CUI","value":"CL1773110"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184784":{"preferredName":"Personal History of Other Leukemia","code":"C184784","definitions":[{"definition":"An individual history of leukemia, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Personal History of Other Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Leukemias"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0260442"}]}}{"C4665":{"preferredName":"Plasma Cell Neoplasm","code":"C4665","definitions":[{"definition":"A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes multiple myeloma, plasma cell leukemia, plasmacytoma, and plasma cell post-transplant lymphoproliferative disorder.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of plasma cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tumor that begins in plasma cells (white blood cells that produce antibodies). Multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), and plasmacytoma are types of plasma cell tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plasma Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Plasma Cell Dyscrasia","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytic Tumour","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Plasma_Cell_Neoplasm"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Multiple myeloma and malignant plasma cell neoplasms"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of plasma cells"},{"name":"Maps_To","value":"Plasma cell tumor"},{"name":"Maps_To","value":"Plasma Cell Tumors"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1136084"}]}}{"C9360":{"preferredName":"Lymphoblastic Lymphoma","code":"C9360","definitions":[{"definition":"A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of lymphoblasts (lymphoid precursor cells).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive (fast-growing) type of non-Hodgkin lymphoma in which too many lymphoblasts (immature white blood cells) are found in the lymph nodes and the thymus gland. These lymphoblasts may spread to other places in the body. It is most common in teenagers and young adults and affects more males than females. It may be a T or B cell type.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphoblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"LBL","termGroup":"AB","termSource":"NCI"},{"termName":"Precursor Cell Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9727/3"},{"name":"Legacy Concept Name","value":"Precursor_Lymphoblastic_Lymphoma"},{"name":"Maps_To","value":"9727/3"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Lymphoblastic (diffuse) lymphoma, unspecified site"},{"name":"Maps_To","value":"Lymphoblastoma"},{"name":"Maps_To","value":"Malignant lymphoma, lymphoblastic, NOS"},{"name":"Maps_To","value":"Precursor Cell Lymphoblastic Lymphoma"},{"name":"Maps_To","value":"Precursor cell lymphoblastic lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079748"}]}}{"C3792":{"preferredName":"Squamous Cell Neoplasm","code":"C3792","definitions":[{"definition":"A neoplasm that is composed of squamous epithelial cells.  Squamous cell carcinoma is a representative example.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Neoplasm"},{"name":"Maps_To","value":"Squamous Cell Neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206720"}]}}{"C3411":{"preferredName":"Thymoma","code":"C3411","definitions":[{"definition":"A neoplasm arising from the epithelial cells of the thymus.  Although thymomas are usually encapsulated tumors, they may invade the capsule and infiltrate the surrounding tissues or even metastasize to distant anatomic sites.  The following morphologic subtypes are currently recognized: type A, type B, type AB, metaplastic, micronodular, microscopic, and sclerosing thymoma.  Thymomas type B are further subdivided into types B1, B2, and B3. Thymoma type B3 usually has the most aggressive clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor of the thymus, an organ that is part of the lymphatic system and is located in the chest, behind the breastbone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8580/1"},{"name":"Legacy Concept Name","value":"Thymoma"},{"name":"Maps_To","value":"8580/1"},{"name":"Maps_To","value":"Thymic Epithelial Neoplasms"},{"name":"Maps_To","value":"Thymoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040100"}]}}{"C3422":{"preferredName":"Trophoblastic Tumor","code":"C3422","definitions":[{"definition":"A gestational or non-gestational neoplasm characterized by excessive proliferation of trophoblastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trophoblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Trophoblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Trophoblastic Neoplasms","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trophoblastic_Neoplasm"},{"name":"Maps_To","value":"Trophoblastic neoplasms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0041182"}]}}{"C48660":{"preferredName":"Not Applicable","code":"C48660","definitions":[{"definition":"A report has been received but the description provided does not appear to relate to an adverse event. This code allows a report to be recorded for administration purposes, even if it doesn't meet the requirements for adverse event reporting.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Determination of a value is not relevant in the current context.","type":"ALT_DEFINITION","source":"PQCMC"},{"definition":"Determination of a value is not relevant in the current context.","type":"DEFINITION","source":"NCI"},{"definition":"Determination of a value is not relevant in the current context.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"SPL"}]},{"definition":"Determination of a value is not relevant in the current context. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Not Applicable","termGroup":"PT","termSource":"NCI"},{"termName":"Does Not Apply","termGroup":"SY","termSource":"NCI"},{"termName":"N/A","termGroup":"SY","termSource":"NCI"},{"termName":"not applicable","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"PRO-CTCAE"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Device Problem Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Not_Applicable"},{"name":"Maps_To","value":"N/A"},{"name":"Maps_To","value":"Not Applicable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1272460"},{"name":"xRef","value":"IMDRF:A25"}]}}{"C164339":{"preferredName":"Date of Diagnosis","code":"C164339","definitions":[{"definition":"The date on which a diagnosis of disease was made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Date of Diagnosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"Diagnosis"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C2316983"}]}}{"C164021":{"preferredName":"First Patient Visit Date","code":"C164021","definitions":[{"definition":"The date for the first patient visit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Patient Visit Date","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First Patient Visit"},{"name":"NCI_META_CUI","value":"CL977238"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C164022":{"preferredName":"First Treatment Date","code":"C164022","definitions":[{"definition":"The date for the initiation of a patient treatment plan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Treatment Date","termGroup":"PT","termSource":"NCI"},{"termName":"Date of First Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Date of First Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Date of Initial Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Initial Treatment Date","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First Treatment"},{"name":"NCI_META_CUI","value":"CL977237"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C164023":{"preferredName":"Initial Genomic Sequencing Date","code":"C164023","definitions":[{"definition":"The date for the first round of genomic sequencing of a subject's DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Initial Genomic Sequencing Date","termGroup":"PT","termSource":"NCI"},{"termName":"Date of Initial Genomic Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Initial Genomic Sequencing"},{"name":"NCI_META_CUI","value":"CL977236"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C171136":{"preferredName":"Date of Recurrence","code":"C171136","definitions":[{"definition":"The date on which diagnosis of a recurring disease was made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Date of Recurrence","termGroup":"PT","termSource":"NCI"},{"termName":"Date of Diagnosis of Recurrence","termGroup":"SY","termSource":"NCI"},{"termName":"Recurrence Date","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrence"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0807712"}]}}{"C164024":{"preferredName":"Sample Procurement Date","code":"C164024","definitions":[{"definition":"The date that a sample was collected or obtained.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sample Procurement Date","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sample Procurement"},{"name":"NCI_META_CUI","value":"CL977235"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C139171":{"preferredName":"Date of First Enrollment into Study","code":"C139171","definitions":[{"definition":"Date or date and time of first subject enrollment into a study, as verifiable by a convention that is consistent with authoritative regulatory criteria. [Modified from ICH E3] (CDISC Glossary)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Date or date and time of first subject enrollment into a study, as verifiable by a convention that is consistent with authoritative regulatory criteria. [Modified from ICH E3] Compare to study start date.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"The calendar date on which the first subject was enrolled into a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Date of First Enrollment into Study","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Study Enrollment"},{"name":"NCI_META_CUI","value":"CL526607"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C12763":{"preferredName":"Paranasal Sinus","code":"C12763","definitions":[{"definition":"Any one of the air-filled spaces within the ethmoid, frontal, maxillary, or sphenoid bones, which communicate with the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"One of many small hollow spaces in the bones around the nose. Paranasal sinuses are named after the bones that contain them: frontal (the lower forehead), maxillary (cheekbones), ethmoid (beside the upper nose), and sphenoid (behind the nose). The paranasal sinuses open into the nasal cavity (space inside the nose) and are lined with cells that make mucus to keep the nose from drying out during breathing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The air-filled cavities adjacent to the nasal cavity lined by a mucous membrane and located in the bones of the skull.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The paired air-filled cavities surrounded by the bones of the face that are lined by mucous membranes and are continuous with the nasal cavity.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Paranasal Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Accessory Sinus","termGroup":"SY","termSource":"NCI"},{"termName":"Accessory Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Nasal and Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Nasal Sinus","termGroup":"SY","termSource":"NCI"},{"termName":"Nasal Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Paranasal Sinuses","termGroup":"SY","termSource":"NCI"},{"termName":"Sinuses, Nasal","termGroup":"SY","termSource":"NCI"},{"termName":"Sinuses, Paranasal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Paranasal_Sinus"},{"name":"Maps_To","value":"Accessory sinus, NOS"},{"name":"Maps_To","value":"Accessory sinuses"},{"name":"Maps_To","value":"Paranasal Sinuses"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0030471"},{"name":"xRef","value":"UBERON:0001825"}]}}{"C12666":{"preferredName":"Adrenal Gland","code":"C12666","definitions":[{"definition":"A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).","type":"DEFINITION","source":"NCI"},{"definition":"A small gland that makes steroid hormones, adrenaline, and noradrenaline. These hormones help control heart rate, blood pressure, and other important body functions. There are two adrenal glands, one on top of each kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Either of a pair of complex endocrine organs near the anterior medial border of the kidney consisting of a mesodermal cortex that produces glucocorticoid, mineralocorticoid, and androgenic hormones and an ectodermal medulla that produces epinephrine and norepinephrine.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The endocrine glands adjacent to the kidneys that consist of the outer adrenal cortex and the inner adrenal medulla in mammals.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adrenal Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Glands","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenals","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Adrenal_Gland"},{"name":"Maps_To","value":"Adrenal"},{"name":"Maps_To","value":"Adrenal gland"},{"name":"Maps_To","value":"Adrenal gland, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0001625"},{"name":"xRef","value":"UBERON:0002369"}]}}{"C12228":{"preferredName":"Base of Tongue","code":"C12228","definitions":[{"definition":"The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oro-pharynx responsible for swallowing and modification of the voice in speech.","type":"DEFINITION","source":"NCI"},{"definition":"The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oro-pharynx.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Base of Tongue","termGroup":"PT","termSource":"NCI"},{"termName":"Base of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Posterior Tongue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Base_of_the_Tongue"},{"name":"Maps_To","value":"Base of tongue"},{"name":"Maps_To","value":"Base of tongue, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226958"}]}}{"C12414":{"preferredName":"Bladder","code":"C12414","definitions":[{"definition":"Distensible musculomembranous organ situated in the anterior part of the pelvic cavity in which urine collects before excretion.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.","type":"DEFINITION","source":"NCI"},{"definition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organ that stores urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary System, Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bladder"},{"name":"Maps_To","value":"Bladder"},{"name":"Maps_To","value":"Bladder, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005682"},{"name":"xRef","value":"UBERON:0001255"}]}}{"C164038":{"preferredName":"Limb Skeletal System","code":"C164038","definitions":[{"definition":"The bones, joints, ligaments and cartilage found in the limbs (extremities).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Limb Skeletal System","termGroup":"PT","termSource":"NCI"},{"termName":"Skeletal System of the Extremities","termGroup":"SY","termSource":"NCI"},{"termName":"Skeletal System of the Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bones, joints and articular cartilage of limbs"},{"name":"NCI_META_CUI","value":"CL977192"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C12439":{"preferredName":"Brain","code":"C12439","definitions":[{"definition":"An organ composed of gray and white matter that is the center for intelligence and reasoning. It is protected by the bony cranium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.","type":"DEFINITION","source":"NCI"},{"definition":"The brain is the center of the nervous system in all vertebrate, and most invertebrate, animals. Some primitive animals such as jellyfish and starfish have a decentralized nervous system without a brain, while sponges lack any nervous system at all. In vertebrates, the brain is located in the head, protected by the skull and close to the primary sensory apparatus of vision, hearing, balance, taste, and smell.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Brain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Brain"},{"name":"Maps_To","value":"Brain"},{"name":"Maps_To","value":"Brain, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006104"},{"name":"xRef","value":"UBERON:0000955"}]}}{"C12971":{"preferredName":"Breast","code":"C12971","definitions":[{"definition":"Glandular organ located on the chest. The breast is made up of connective tissue, fat, and breast tissue that contains the glands that can make milk.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","type":"DEFINITION","source":"NCI"},{"definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Breasts","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Breast"},{"name":"Maps_To","value":"Breast"},{"name":"Maps_To","value":"Breast, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006141"}]}}{"C92218":{"preferredName":"Lung/Bronchus","code":"C92218","definitions":[{"definition":"A sample that contains lung and bronchial tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A specimen that contains lung and bronchial tissues.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lung/Bronchus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchus and lung"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0545675"}]}}{"C12311":{"preferredName":"Cervix Uteri","code":"C12311","definitions":[{"definition":"Lower, narrow portion of the uterus where it joins with the top end of the vagina.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.","type":"DEFINITION","source":"NCI"},{"definition":"The lower, narrow end of the uterus that forms a canal between the uterus and vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the uterus (or uterine horns) that empties into the vagina.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cervix Uteri","termGroup":"PT","termSource":"NCI"},{"termName":"Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Genital System, Female, Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Uterus, Cervix","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cervix"},{"name":"Maps_To","value":"Cervix"},{"name":"Maps_To","value":"Cervix uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007874"},{"name":"xRef","value":"UBERON:0000002"}]}}{"C12382":{"preferredName":"Colon","code":"C12382","definitions":[{"definition":"The longest part of the large intestine, which is a tube-like organ connected to the small intestine at one end and the anus at the other. The colon removes water and some nutrients and electrolytes from partially digested food. The remaining material, solid waste called stool, moves through the colon to the rectum and leaves the body through the anus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the large intestine which extends from the cecum (or small intestine in animals that don't have a cecum) to the rectum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Colon"},{"name":"Maps_To","value":"Colon"},{"name":"Maps_To","value":"Colon, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009368"},{"name":"xRef","value":"UBERON:0001155"}]}}{"C12964":{"preferredName":"Connective and Soft Tissue","code":"C12964","definitions":[{"definition":"The supporting connective tissue of an organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Connective and Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Connective_and_Soft_Tissue"},{"name":"Maps_To","value":"Connective, subcutaneous and other soft tissues"},{"name":"Maps_To","value":"Connective, subcutaneous and other soft tissues, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C1516798"}]}}{"C12316":{"preferredName":"Corpus Uteri","code":"C12316","definitions":[{"definition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.","type":"DEFINITION","source":"NCI"},{"definition":"The body of the uterus.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The body of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Corpus Uteri","termGroup":"PT","termSource":"NCI"},{"termName":"Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Uterus, Corpus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Corpus_Uteri"},{"name":"Maps_To","value":"Corpus uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227813"}]}}{"C12389":{"preferredName":"Esophagus","code":"C12389","definitions":[{"definition":"The muscular tube through which food passes from the throat to the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the digestive tract between the pharynx and stomach.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tube that connects the pharynx to the stomach. In mammals, the esophagus connects the buccal cavity with the stomach. The stratified squamous non-keratinized epithelium lining the buccal cavity is continued through the pharynx down into the esophagus. The lowest part of the esophagus (ca. 2 cm) is lined with gastric mucosa and covered by peritoneum. The main body of the esophagus is lined with small, simple mucous glands. Each gland opens into the lumen by a long duct which pierces the muscularis mucosae (Wilson and Washington, 1989). A sphincter is situated at the point where the esophagus enters the stomach to prevent gastro-esophageal reflux, i.e. to prevent acidic gastric contents from reaching stratified epithelia of the esophagus, where they can cause inflammation and irritation (Wilson and Washington, 1989; Brown et al., 1993).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Esophagus"},{"name":"Maps_To","value":"Esophagus"},{"name":"Maps_To","value":"Esophagus, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014876"},{"name":"xRef","value":"UBERON:0001043"}]}}{"C54187":{"preferredName":"Floor of Mouth","code":"C54187","definitions":[{"definition":"The area of the mouth under the ventral surface of the tongue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The horseshoe-shaped part of the oral cavity bounded superiorly by the ventral surface of the tongue, inferiorly by the mylohyoid muscle, anterolaterally by the gingival surfaces of the mandible, and posteriorly by the anterior tonsillar pillar.","type":"DEFINITION","source":"NCI"},{"definition":"The ventral area of the mouth. In organisms with a tongue, this is the area under the ventral surface of the tongue.","type":"ALT_DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Floor of Mouth","termGroup":"PT","termSource":"NCI"},{"termName":"Floor of the Mouth","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Floor_of_the_Mouth"},{"name":"Maps_To","value":"Floor of mouth"},{"name":"Maps_To","value":"Floor of Mouth"},{"name":"Maps_To","value":"Floor Of Mouth"},{"name":"Maps_To","value":"Floor of mouth, NOS"},{"name":"NCI_META_CUI","value":"CL435388"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"xRef","value":"UBERON:0003679"}]}}{"C12377":{"preferredName":"Gallbladder","code":"C12377","definitions":[{"definition":"A pear-shaped organ located under the liver that stores and concentrates bile secreted by the liver. From the gallbladder the bile is delivered through the bile ducts into the intestine thereby aiding the digestion of fat-containing foods.","type":"DEFINITION","source":"NCI"},{"definition":"A sac-like organ located adjacent to the liver that stores and concentrates bile produced by the liver.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ that aids digestion and stores bile produced by the liver.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The pear-shaped organ found below the liver. Bile is concentrated and stored in the gallbladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gallbladder","termGroup":"PT","termSource":"NCI"},{"termName":"Gallbladder / Biliar","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Gall Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gallbladder"},{"name":"Maps_To","value":"Gallbladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016976"},{"name":"xRef","value":"UBERON:0002110"}]}}{"C32677":{"preferredName":"Gingiva","code":"C32677","definitions":[{"definition":"The fibrous investing tissue, covered by keratinized epithelium, that immediately surrounds a tooth and is contiguous with its periodontal ligament and with the mucosal tissues of the mouth.","type":"ALT_DEFINITION","source":"NCI"},{"definition":"The soft tissue surrounding the neck of individual teeth as well as covering the alveolar bone. The tissue is fibrous and continuous with the periodontal ligament and mucosal covering.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue surrounding the neck of individual teeth as well as covering the alveolar bone. The tissue is fibrous and continuous with the periodontal ligament and mucosal covering. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissue of the upper and lower jaws that surrounds the base of the teeth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gingiva","termGroup":"PT","termSource":"NCI"},{"termName":"Gingival","termGroup":"AD","termSource":"NCI"},{"termName":"Gum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gingiva"},{"name":"Maps_To","value":"Gum"},{"name":"Maps_To","value":"Gum, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0017562"},{"name":"xRef","value":"UBERON:0001828"}]}}{"C12246":{"preferredName":"Hypopharynx","code":"C12246","definitions":[{"definition":"Bottom part of the pharynx that connects to the esophagus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bottom part of the throat. Cancer of the hypopharynx is also called hypopharyngeal cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lower part of the pharynx that connects to the esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"The lower part of the pharynx that connects to the esophagus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hypopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Laryngopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hypopharynx"},{"name":"Maps_To","value":"Hypopharynx"},{"name":"Maps_To","value":"Hypopharynx, NOS"},{"name":"Maps_To","value":"Laryngopharynx"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020629"},{"name":"xRef","value":"UBERON:0001051"}]}}{"C12415":{"preferredName":"Kidney","code":"C12415","definitions":[{"definition":"A paired organ of the urinary tract which has the production of urine as its primary function.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of organs in the abdomen. Kidneys remove waste from the blood (as urine), produce erythropoietin (a substance that stimulates red blood cell production), and play a role in blood pressure regulation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secrete metabolic products and minerals from the blood, thus maintaining homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.","type":"DEFINITION","source":"NCI"},{"definition":"The organs of the urinary tract located in the retroperitoneal cavity adjacent to the spine and composed of the renal cortex and the renal medulla.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Kidneys","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary System, Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Kidney"},{"name":"Maps_To","value":"Kidney"},{"name":"Maps_To","value":"Kidney, NOS"},{"name":"Maps_To","value":"Renal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022646"},{"name":"xRef","value":"UBERON:0002113"}]}}{"C12420":{"preferredName":"Larynx","code":"C12420","definitions":[{"definition":"A continuation of the pharynx that is involved in breathing, sound production, and protecting the trachea against food aspiration.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The area of the throat containing the vocal cords and used for breathing, swallowing, and talking.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The cartilaginous structure of the respiratory tract between the pharynx and the trachea.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larynx","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Larynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Larynx"},{"name":"Maps_To","value":"Larynx"},{"name":"Maps_To","value":"Larynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0023078"},{"name":"xRef","value":"UBERON:0001737"}]}}{"C12220":{"preferredName":"Lip","code":"C12220","definitions":[{"definition":"Fleshy fold which surrounds the opening of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"Fleshy fold which surrounds the opening of the mouth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the two fleshy folds which surround the opening of the mouth.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lip"},{"name":"Maps_To","value":"Lip"},{"name":"Maps_To","value":"Lip, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0023759"},{"name":"xRef","value":"UBERON:0001833"}]}}{"C12745":{"preferredName":"Lymph Node","code":"C12745","definitions":[{"definition":"A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","type":"DEFINITION","source":"NCI"},{"definition":"A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Lymph nodes filter lymph (lymphatic fluid), and they store lymphocytes (white blood cells). They are located along lymphatic vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any of the rounded masses of lymphoid tissue that are surrounded by a capsule of connective tissue, are distributed along the lymphatic vessels, and contain numerous lymphocytes which filter the flow of lymph.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Secondary lymphoid organ associated with lymphatic vessels and consisting of an outer cortex, inner medulla and sinuses.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Nodes","termGroup":"SY","termSource":"NCI"},{"termName":"Reticuloendothelial System, Lymph Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lymph_Node"},{"name":"Maps_To","value":"Lymph Noce"},{"name":"Maps_To","value":"Lymph Node"},{"name":"Maps_To","value":"Lymph node, NOS"},{"name":"Maps_To","value":"Lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024204"},{"name":"xRef","value":"UBERON:0000029"}]}}{"C12348":{"preferredName":"Meninges","code":"C12348","definitions":[{"definition":"Any one of three membranes that surround the brain and spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"Any one of three membranes that surround the brain and spinal cord. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The three thin layers of tissue that cover and protect the brain and spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Meninges","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Meninges"},{"name":"Maps_To","value":"Meninges"},{"name":"Maps_To","value":"Meninges, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0025285"}]}}{"C12423":{"preferredName":"Nasopharynx","code":"C12423","definitions":[{"definition":"The part of the pharynx above the soft palate, which is continuous with the nasal cavity and extends to the oropharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.","type":"DEFINITION","source":"NCI"},{"definition":"The section of the pharynx that lies above the soft palate.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper part of the throat behind the nose. An opening on each side of the nasopharynx leads into the ear.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nasopharynx","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Nasopharynx"},{"name":"Maps_To","value":"Nasopharynx"},{"name":"Maps_To","value":"Nasopharynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0027442"},{"name":"xRef","value":"UBERON:0001728"}]}}{"C12762":{"preferredName":"Oropharynx","code":"C12762","definitions":[{"definition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the throat at the back of the mouth behind the oral cavity. It includes the back third of the tongue, the soft palate, the side and back walls of the throat, and the tonsils.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the pharynx that lies between the soft palate and the upper edge of the epiglottis.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Oropharynx","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Oropharynx"},{"name":"Maps_To","value":"Oropharynx"},{"name":"Maps_To","value":"Oropharynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0521367"},{"name":"xRef","value":"UBERON:0001729"}]}}{"C148335":{"preferredName":"Other and Ill Defined Digestive Organs ICD-O-3","code":"C148335","definitions":[{"definition":"Digestive organs that are referenced in topographic category C26 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill Defined Digestive Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill Defined Digestive Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and ill-defined digestive organs"},{"name":"NCI_META_CUI","value":"CL018352"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148336":{"preferredName":"Other and Ill-Defined Sites ICD-O-3","code":"C148336","definitions":[{"definition":"Other anatomic sites that are referenced in topographic category C76 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill-Defined Sites ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill-Defined Sites","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and ill-defined sites"},{"name":"NCI_META_CUI","value":"CL018612"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148337":{"preferredName":"Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx ICD-O-3","code":"C148337","definitions":[{"definition":"Anatomic sites in the lip, oral cavity and pharynx that are referenced in topographic category C14 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and ill-defined sites in lip, oral cavity and pharynx"},{"name":"NCI_META_CUI","value":"CL025608"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148338":{"preferredName":"Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs ICD-O-3","code":"C148338","definitions":[{"definition":"Anatomic sites within the respiratory system and intrathoracic organs that are referenced in topographic category C39 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ill-defined sites within respiratory system"},{"name":"Maps_To","value":"Other and ill-defined sites within respiratory system and intrathoracic organs"},{"name":"NCI_META_CUI","value":"CL025607"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148339":{"preferredName":"Other and Unspecified Female Genital Organs ICD-O-3","code":"C148339","definitions":[{"definition":"Female genital organs that are referenced in topographic category C57 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Female Genital Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Female Genital Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified female genital organs"},{"name":"Maps_To","value":"Other specified parts of female genital organs"},{"name":"NCI_META_CUI","value":"CL025605"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148340":{"preferredName":"Other and Unspecified Major Salivary Glands ICD-O-3","code":"C148340","definitions":[{"definition":"Major salivary glands that are referenced in topographic category C08 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Major Salivary Glands ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Major Salivary Glands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified major salivary glands"},{"name":"NCI_META_CUI","value":"CL018317"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148341":{"preferredName":"Other and Unspecified Male Genital Organs ICD-O-3","code":"C148341","definitions":[{"definition":"Male genital organs that are referenced in topographic category C63 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Male Genital Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Male Genital Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified male genital organs"},{"name":"Maps_To","value":"Other specified parts of male genital organs"},{"name":"NCI_META_CUI","value":"CL365219"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148342":{"preferredName":"Other and Unspecified Parts of Biliary Tract ICD-O-3","code":"C148342","definitions":[{"definition":"Components of the biliary tract that are referenced in topographic category C24 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Parts of Biliary Tract ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Parts of Biliary Tract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified parts of biliary tract"},{"name":"NCI_META_CUI","value":"CL018343"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148343":{"preferredName":"Other and Unspecified Parts of Mouth ICD-O-3","code":"C148343","definitions":[{"definition":"Components of the mouth that are referenced in topographic category C06 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Parts of Mouth ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Parts of Mouth","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified parts of mouth"},{"name":"NCI_META_CUI","value":"CL025603"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148344":{"preferredName":"Other and Unspecified Parts of Tongue ICD-O-3","code":"C148344","definitions":[{"definition":"Components of the tongue that are referenced in topographic category C02 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Parts of Tongue ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Parts of Tongue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified parts of tongue"},{"name":"NCI_META_CUI","value":"CL018300"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148345":{"preferredName":"Other and Unspecified Urinary Organs ICD-O-3","code":"C148345","definitions":[{"definition":"Urinary organs that are referenced in topographic category C68 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other and Unspecified Urinary Organs ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other and Unspecified Urinary Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other and unspecified urinary organs"},{"name":"NCI_META_CUI","value":"CL550961"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C148346":{"preferredName":"Other Endocrine Glands and Related Structures ICD-O-3","code":"C148346","definitions":[{"definition":"Endocrine glands and related structures that are referenced in topographic category C75 of ICD-O-3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Endocrine Glands and Related Structures ICD-O-3","termGroup":"PT","termSource":"NCI"},{"termName":"Other Endocrine Glands and Related Structures","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other endocrine glands and related structures"},{"name":"NCI_META_CUI","value":"CL025599"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C12404":{"preferredName":"Ovary","code":"C12404","definitions":[{"definition":"One of the paired female reproductive glands containing the ova or germ cells; the ovary's stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.","type":"DEFINITION","source":"NCI"},{"definition":"The female gonad.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The gonad of a female organism which contains germ cells.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The pair of female reproductive glands in which the ova, or eggs, are formed. The ovaries are located in the pelvis, one on each side of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ovary","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Female, Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovaries","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ovary"},{"name":"Maps_To","value":"Ovary"},{"name":"Maps_To","value":"Ovary, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0029939"},{"name":"xRef","value":"UBERON:0000992"}]}}{"C12229":{"preferredName":"Palate","code":"C12229","definitions":[{"definition":"The roof of the mouth. The front portion is bony (hard palate), and the back portion is muscular (soft palate).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The roof of the oral cavity. It separates the oral cavity from the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The roof of the oral cavity. It separates the oral cavity from the nasal cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Palate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palate"},{"name":"Maps_To","value":"Palate"},{"name":"Maps_To","value":"Palate, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0700374"}]}}{"C12393":{"preferredName":"Pancreas","code":"C12393","definitions":[{"definition":"A digestive organ in the abdomen that has both endocrine and exocrine functions.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A glandular organ located in the abdomen. It makes pancreatic juices, which contain enzymes that aid in digestion, and it produces several hormones, including insulin. The pancreas is surrounded by the stomach, intestines, and other organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating hormones.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from Diabetes Dictionary: http://www.childrenwithdiabetes.com/dictionary"}]}],"synonyms":[{"termName":"Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pancreas"},{"name":"Maps_To","value":"Pancreas"},{"name":"Maps_To","value":"Pancreas, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030274"},{"name":"xRef","value":"UBERON:0001264"}]}}{"C12427":{"preferredName":"Parotid Gland","code":"C12427","definitions":[{"definition":"The largest of the three paired salivary glands, located in front of the ear.","type":"DEFINITION","source":"NCI"},{"definition":"The parotid gland is the largest of the salivary glands. It is found wrapped around the mandibular ramus, and it secretes saliva through Stensen's duct into the oral cavity, to facilitate mastication and swallowing. [WP,unvetted].","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The salivary gland located adjacent to the ear.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Parotid Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Parotid Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Parotid_Gland"},{"name":"Maps_To","value":"Parotid Gland"},{"name":"Maps_To","value":"Parotid gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030580"},{"name":"xRef","value":"UBERON:0001831"}]}}{"C12409":{"preferredName":"Penis","code":"C12409","definitions":[{"definition":"An external male reproductive organ. It contains a tube called the urethra, which carries semen and urine to the outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intromittent organ in certain biologically male organisms. In placental mammals, this also serves as the organ of urination.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The male organ of urination and copulation.","type":"DEFINITION","source":"NCI"},{"definition":"The male organ of urination and copulation. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Penis","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Male, Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Penis"},{"name":"Maps_To","value":"Penis"},{"name":"Maps_To","value":"Penis, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030851"},{"name":"xRef","value":"UBERON:0000989"}]}}{"C13272":{"preferredName":"Placenta","code":"C13272","definitions":[{"definition":"An organ present in some vertebrates during embryonic gestation that surrounds the fetus and provides it with nutrients and oxygen, facilitates gas and waste exchange between the fetus and mother, and provides parasitic cloaking from the mother's immune system by excretion of neurokinin B.","type":"DEFINITION","source":"NCI"},{"definition":"An organ present in true mammals during embryonic developmen that provides the fetus with nutrients and oxygen, facilitates gas and waste exchange between the fetus and mother.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin[GO]. The fetal portion of the placenta is known as the villous chorion. The maternal portion is known as the decidua basalis. The two portions are held together by anchoring villi that are anchored to the decidua basalis by the cytotrophoblastic shell.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The organ that nourishes the developing fetus in the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Placenta","termGroup":"PT","termSource":"NCI"},{"termName":"Placental","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Placenta"},{"name":"Maps_To","value":"Placenta"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0032043"},{"name":"xRef","value":"UBERON:0001987"}]}}{"C12410":{"preferredName":"Prostate Gland","code":"C12410","definitions":[{"definition":"A gland in the male reproductive system. The prostate surrounds the part of the urethra (the tube that empties the bladder) just below the bladder, and produces a fluid that forms part of the semen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The male reproductive accessory gland that produces prostatic fluid and is located adjacent to or around the urethra distal to the urinary bladder in mammals.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The prostate gland is a partly muscular, partly glandular body that is situated near the base of the mammalian male urethra and secretes an alkaline viscid fluid which is a major constituent of the ejaculatory fluid.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Male, Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Prostatic Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Prostate_Gland"},{"name":"Maps_To","value":"Prostate"},{"name":"Maps_To","value":"Prostate gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0033572"},{"name":"xRef","value":"UBERON:0002367"}]}}{"C33439":{"preferredName":"Pyriform Sinus","code":"C33439","definitions":[{"definition":"A pear-shaped fossa in the wall of the laryngeal pharynx lateral to the arytenoid cartilage and medial to the lamina of the thyroid cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyriform Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Piriform Recess","termGroup":"SY","termSource":"NCI"},{"termName":"Piriform Sinus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pyriform_Sinus"},{"name":"Maps_To","value":"Pyriform sinus"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227170"}]}}{"C54188":{"preferredName":"Rectosigmoid Region","code":"C54188","definitions":[{"definition":"An anatomical junction that is between the sigmoid colon and rectum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The area where the sigmoid colon joins the rectum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The area where the sigmoid colon joins the rectum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rectosigmoid Region","termGroup":"PT","termSource":"NCI"},{"termName":"Rectosigmoid Junction","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Rectosigmoid_Region"},{"name":"Maps_To","value":"Rectosigmoid Junction"},{"name":"Maps_To","value":"Rectosigmoid junction"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1709868"},{"name":"xRef","value":"UBERON:0036214"}]}}{"C12390":{"preferredName":"Rectum","code":"C12390","definitions":[{"definition":"The last several inches of the large intestine closest to the anus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.","type":"DEFINITION","source":"NCI"},{"definition":"The terminal portion of the intestinal tube, terminating with the anus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The terminal portion of the large intestine extending from the terminus of the colon to the anus or anal canal.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Rectum","termGroup":"PT","termSource":"NCI"},{"termName":"Hemorrhoidal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Rectum"},{"name":"Maps_To","value":"Rectum"},{"name":"Maps_To","value":"Rectum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0034896"},{"name":"xRef","value":"UBERON:0001052"}]}}{"C12887":{"preferredName":"Renal Pelvis","code":"C12887","definitions":[{"definition":"The area at the center of the kidney. Urine collects here and is funneled into the ureter, the tube that connects the kidney to the bladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The funnel-shaped proximal portion of the ureter located within the kidney into which urine is secreted, from the collecting duct system of the kidney.","type":"DEFINITION","source":"NCI"},{"definition":"The funnel-shaped proximal portion of the ureter located within the kidney into which urine is secreted, from the collecting duct system of the kidney. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Renal Pelvis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Renal_Pelvis"},{"name":"Maps_To","value":"Renal pelvis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227666"}]}}{"C156712":{"preferredName":"Peritoneum and Retroperitoneum","code":"C156712","definitions":[{"definition":"A term that refers to the peritoneum and the space behind it (retroperitoneum).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneum and Retroperitoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retroperitoneum and peritoneum"},{"name":"NCI_META_CUI","value":"CL018479"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C12470":{"preferredName":"Skin","code":"C12470","definitions":[{"definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.","type":"DEFINITION","source":"NCI"},{"definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organ covering the body that consists of the dermis and epidermis.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Integument","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"DesignNote","value":"ICDO3: excludes skin of vulva C51._, skin of penis C60.9, skin of scrotum C63.2"},{"name":"Legacy Concept Name","value":"Skin"},{"name":"Maps_To","value":"Skin"},{"name":"Maps_To","value":"Skin, NOS"},{"name":"Maps_To","value":"Skin, total"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1123023"},{"name":"xRef","value":"UBERON:0000014"},{"name":"xRef","value":"UBERON:0002097"}]}}{"C12386":{"preferredName":"Small Intestine","code":"C12386","definitions":[{"definition":"Subdivision of digestive tract that connects the stomach to the large intestine and is where much of the digestion and absorption of food takes place (with the exception of ruminants). The mammalian small intestine is long and coiled and can be differentiated histologically into: duodenum, jejunum, ileum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the digestive tract that is located between the stomach and the large intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The section of the intestines between the pylorus and cecum. The small intestine is approximately 20 feet long and consists of the duodenum, the jejunum, and the ileum. Its main function is to absorb nutrients from food as the food is transported to the large intestine.","type":"DEFINITION","source":"NCI"},{"definition":"The villous section of the intestine extending from the pylorus to the proximal large intestine.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Small Intestine","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Small Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Small Bowel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Small_Intestine"},{"name":"Maps_To","value":"Small Bowel"},{"name":"Maps_To","value":"Small intestine"},{"name":"Maps_To","value":"Small intestine, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0021852"},{"name":"xRef","value":"UBERON:0002108"}]}}{"C12391":{"preferredName":"Stomach","code":"C12391","definitions":[{"definition":"An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An organ that is part of the digestive system. It helps in the digestion of food by mixing it with digestive juices and churning it into a thin liquid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the gastrointestinal tract located between the esophagus and the proximal duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The primary organ of food digestion. It is located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stomach","termGroup":"PT","termSource":"NCI"},{"termName":"Gastric","termGroup":"AD","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Stomach"},{"name":"Maps_To","value":"Stomach"},{"name":"Maps_To","value":"Stomach, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0038351"},{"name":"xRef","value":"UBERON:0000945"}]}}{"C12412":{"preferredName":"Testis","code":"C12412","definitions":[{"definition":"A gonad of a male animal. A gonad produces and releases sperm.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Either of the paired male reproductive glands that produce the male germ cells and the male hormones.","type":"DEFINITION","source":"NCI"},{"definition":"One of two egg-shaped glands inside the scrotum that produce sperm and male hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The male gonad.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Testis","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Male, Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Testes","termGroup":"SY","termSource":"NCI"},{"termName":"Testicle","termGroup":"SY","termSource":"NCI"},{"termName":"Testicles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Testis"},{"name":"Maps_To","value":"Testes"},{"name":"Maps_To","value":"Testis"},{"name":"Maps_To","value":"Testis, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0039597"},{"name":"xRef","value":"UBERON:0000473"}]}}{"C12433":{"preferredName":"Thymus Gland","code":"C12433","definitions":[{"definition":"A bi-lobed organ surrounded by a connective tissue capsule. It is located in the upper anterior portion of the chest, behind the sternum. It is composed predominantly of lymphocytes and fewer epithelial cells. Connective tissue septa separate the lobes into lobules. The lobules contain an outer portion (cortical zone) which is rich in lymphocytes and an inner portion (medullary zone) which is rich in epithelial cells. It is an organ essential for the development of the immune system. Its function is the maturation of the progenitor lymphoid cells to thymocytes and subsequently to mature T-cells. It reaches its greatest weight at puberty and subsequently begins to involute.","type":"DEFINITION","source":"NCI"},{"definition":"A primary lymphoid organ generally located in the mediastinum near the thoracic inlet and/or along lateral aspects of the neck.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ that is part of the lymphatic system, in which T lymphocytes grow and multiply. The thymus is in the chest behind the breastbone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Anatomical structure of largely lymphoid tissue that functions in cell-mediated immunity by being the site where T cells develop.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Thymus Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Thymus","termGroup":"SY","termSource":"NCI"},{"termName":"Thymus","termGroup":"SY","termSource":"NCI"},{"termName":"Thymus Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thymus_Gland"},{"name":"Maps_To","value":"Thymus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040113"},{"name":"xRef","value":"UBERON:0002370"}]}}{"C12400":{"preferredName":"Thyroid Gland","code":"C12400","definitions":[{"definition":"A gland located beneath the larynx (voice box) that makes thyroid hormone and calcitonin. The thyroid gland helps regulate growth and metabolism.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A two-lobed endocrine gland found in all vertebrates, located in front of and on either side of the trachea in humans, and producing various hormones, such as triiodothyronine and calcitonin.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.","type":"DEFINITION","source":"NCI"},{"definition":"Endocrine gland(s) adjacent to the trachea in mammals that produce thyroxine and other hormones.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thyroid Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thyroid_Gland"},{"name":"Maps_To","value":"Thyroid"},{"name":"Maps_To","value":"Thyroid gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040132"},{"name":"xRef","value":"UBERON:0002046"}]}}{"C12802":{"preferredName":"Tonsil","code":"C12802","definitions":[{"definition":"A secondary lymphoid tissue in the mucosa of the pharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of the two small almond-shaped masses of lymph tissue found on either side of the oropharynx.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of two small masses of lymphoid tissue on either side of the throat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.","type":"DEFINITION","source":"NCI"},{"definition":"excludes lingual tonsil C02.4 and pharyngeal tonsil C11.1","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Tonsil","termGroup":"PT","termSource":"NCI"},{"termName":"Tonsils","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tonsil"},{"name":"Maps_To","value":"Tonsil"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0836921"},{"name":"xRef","value":"UBERON:0002372"}]}}{"C12428":{"preferredName":"Trachea","code":"C12428","definitions":[{"definition":"The airway that leads from the larynx (voice box) to the bronchi (large airways that lead to the lungs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fibrocartilaginous tube extending from the larynx to the bronchi.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fibrocartilaginous, mucous-lined tube passing from the larynx to the bronchi.","type":"DEFINITION","source":"NCI"},{"definition":"The trachea is the portion of the airway that attaches to the bronchi as it branches.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Trachea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Trachea"},{"name":"Maps_To","value":"Trachea"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040578"},{"name":"xRef","value":"UBERON:0003126"}]}}{"C12416":{"preferredName":"Ureter","code":"C12416","definitions":[{"definition":"Muscular duct that propels urine from the kidneys to the urinary bladder, or related organs.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The thick-walled tube that carries urine from each kidney to the bladder.","type":"DEFINITION","source":"NCI"},{"definition":"The tube that carries urine from the kidney to the bladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tube that extends from each kidney to the urinary bladder.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ureter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ureter"},{"name":"Maps_To","value":"Ureter"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0041951"},{"name":"xRef","value":"UBERON:0000056"}]}}{"C12405":{"preferredName":"Uterus","code":"C12405","definitions":[{"definition":"A hollow muscular organ within which the fertilized egg implants and the embryo/fetus develops during pregnancy.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.","type":"DEFINITION","source":"NCI"},{"definition":"The female muscular organ of gestation in which the developing embryo or fetus is nourished until birth.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The small, hollow, pear-shaped organ in a woman's pelvis. This is the organ in which a fetus develops.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Uterus","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Female, Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine","termGroup":"AD","termSource":"NCI"},{"termName":"Utero","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Uterus"},{"name":"Maps_To","value":"Uterus"},{"name":"Maps_To","value":"Uterus, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042149"},{"name":"xRef","value":"UBERON:0000995"}]}}{"C12407":{"preferredName":"Vagina","code":"C12407","definitions":[{"definition":"A fibromuscular tubular tract leading from the uterus to the exterior of the body in female placental mammals and marsupials, or to the cloaca in female birds, monotremes, and some reptiles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The female genital canal, extending from the uterus to the vulva.","type":"DEFINITION","source":"NCI"},{"definition":"The female genital canal, extending from the uterus to the vulva. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The muscular canal extending from the uterus to the exterior of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vagina","termGroup":"PT","termSource":"NCI"},{"termName":"Genital System, Female, Vagina","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vagina"},{"name":"Maps_To","value":"Vagina"},{"name":"Maps_To","value":"Vagina, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042232"},{"name":"xRef","value":"UBERON:0000996"}]}}{"C12408":{"preferredName":"Vulva","code":"C12408","definitions":[{"definition":"External genital organs of the female mammal.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The external, visible part of the female genitalia surrounding the urethral and vaginal opening(s).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external, visible part of the female genitalia surrounding the urethral and vaginal opening. The vulva includes the clitoris and inner as well as outer labia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vulva","termGroup":"PT","termSource":"NCI"},{"termName":"External Genitalia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vulva"},{"name":"Maps_To","value":"Vulva"},{"name":"Maps_To","value":"Vulva, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042993"},{"name":"xRef","value":"UBERON:0000997"}]}}{"C15783":{"preferredName":"Clinical Data","code":"C15783","definitions":[{"definition":"Data obtained through patient examination or treatment.","type":"DEFINITION","source":"NCI"},{"definition":"Data pertaining to the medical well-being or status of a patient. Category also includes clinical reports and individual patient data (IPD) as defined in the EMA Policy 0070 Implementation Guide. [http://www.ema.eoropa.eu/docs/en_GB/document_library/REPORT/2014/10/WC500174378.PDF]","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Clinical Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clinical_Data"},{"name":"Maps_To","value":"Clinical"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C1516606"}]}}{"C164028":{"preferredName":"Clincal Data Supplement","code":"C164028","definitions":[{"definition":"Additional documentation or textual matter added to a study report that contains clinical data or related information.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clincal Data Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical Supplement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clinical Supplement"},{"name":"NCI_META_CUI","value":"CL977231"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C172217":{"preferredName":"Data Release","code":"C172217","definitions":[{"definition":"The act of making data or other structured information accessible to the public or to the user group of a database.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Data Release","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"data_release"},{"name":"NCI_META_CUI","value":"CL1406105"},{"name":"Semantic_Type","value":"Activity"}]}}{"C156427":{"preferredName":"Cancer-Related Death","code":"C156427","definitions":[{"definition":"A death attributed to the progression of a cancer-related pathologic condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer-Related Death","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Death","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Related Death","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cancer Related"},{"name":"NCI_META_CUI","value":"CL563161"},{"name":"Semantic_Type","value":"Finding"}]}}{"C2931":{"preferredName":"Cardiovascular Disorder","code":"C2931","definitions":[{"definition":"A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cardiovascular Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiovascular Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Cardiovascular Disease (CVD)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Cardiovascular_Disorder"},{"name":"Maps_To","value":"Cardiovascular Disorder, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007222"}]}}{"C9439":{"preferredName":"Chronic Kidney Disease, Stage 5","code":"C9439","definitions":[{"definition":"Long-standing and persistent renal disease with glomerular filtration rate (GFR) less than 15 ml/min.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Kidney Disease, Stage 5","termGroup":"PT","termSource":"NCI"},{"termName":"End Stage Kidney Disease","termGroup":"SY","termSource":"NCI"},{"termName":"End Stage Kidney Failure","termGroup":"SY","termSource":"NCI"},{"termName":"End Stage Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"End Stage Renal Failure","termGroup":"SY","termSource":"NCI"},{"termName":"ESRD","termGroup":"SY","termSource":"NCI"},{"termName":"ESRD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"End_Stage_Renal_Disease"},{"name":"Maps_To","value":"End-stage Renal Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4015547"}]}}{"C26726":{"preferredName":"Infectious Disorder","code":"C26726","definitions":[{"definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Invasion and multiplication of germs in the body. Infections can occur in any part of the body and can spread throughout the body. The germs may be bacteria, viruses, yeast, or fungi. They can cause a fever and other problems, depending on where the infection occurs. When the body's natural defense system is strong, it can often fight the germs and prevent infection. Some cancer treatments can weaken the natural defense system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The report describes a non-specific or unidentified infection. Note: Please use the appropriate term if the report describes a specific infection. i.e. Bacterial Infection E1901, Fungal Infection E1902, Viral Infection E1907, or a relevant Level 3 term where more detail is available.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Infectious Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Infectious","termGroup":"AD","termSource":"NCI"},{"termName":"Infectious Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Infectious Diseases and Manifestations","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Infectious_Disorder"},{"name":"Maps_To","value":"Infection"},{"name":"Maps_To","value":"Other and unspecified infectious diseases"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009450"},{"name":"xRef","value":"IMDRF:E1906"}]}}{"C156428":{"preferredName":"Non-Cancer Related Death","code":"C156428","definitions":[{"definition":"A death attributed to any cause other than the progression of a cancer-related pathologic condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Cancer Related Death","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Cancer Death","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Not Cancer Related"},{"name":"NCI_META_CUI","value":"CL563162"},{"name":"Semantic_Type","value":"Finding"}]}}{"C3149":{"preferredName":"Kidney Disorder","code":"C3149","definitions":[{"definition":"A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kidney Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Renal_Disorder"},{"name":"Maps_To","value":"Kidney Disease"},{"name":"Maps_To","value":"Renal Disorder, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014900"}]}}{"C85075":{"preferredName":"Spinal Muscular Atrophy","code":"C85075","definitions":[{"definition":"An inherited disorder characterized by degeneration of the spinal cord and the cerebellum. Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spinal Muscular Atrophy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Spinal Muscular Atrophy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026847"}]}}{"C164157":{"preferredName":"Surgical Complication","code":"C164157","definitions":[{"definition":"A disease or disorder that occurs during, soon after or as a result of a surgical procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surgical Complication","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Surgical Complications"},{"name":"NCI_META_CUI","value":"CL977348"},{"name":"Semantic_Type","value":"Finding"}]}}{"C27990":{"preferredName":"Toxicity","code":"C27990","definitions":[{"definition":"The extent to which something is poisonous or harmful.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The finding of bodily harm due to the poisonous effects of something.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toxicity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Toxicity"},{"name":"Maps_To","value":"Toxicity"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0600688"}]}}{"C25153":{"preferredName":"Autopsy","code":"C25153","definitions":[{"definition":"A postmortem examination of the body that includes an examination of the internal organs and structures after dissection to determine the cause of death and the nature of pathological changes.","type":"DEFINITION","source":"NCI"},{"definition":"A postmortem examination of the body.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Autopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Autopsy"},{"name":"Maps_To","value":"Autopsy"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0004398"}]}}{"C163970":{"preferredName":"Death Certificate","code":"C163970","definitions":[{"definition":"A certified document issued by either a medical practitioner or a governmental agency that details the date, location and cause of a death of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Death Certificate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death Certificate"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C0011066"}]}}{"C45258":{"preferredName":"Medical Record","code":"C45258","definitions":[{"definition":"A chronological written account of a patient's examination and treatment that includes the patient's medical history and complaints, the physician's physical findings, the results of diagnostic tests and procedures, and medications and therapeutic procedures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medical Record","termGroup":"PT","termSource":"NCI"},{"termName":"Medical Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Medical_Record"},{"name":"Maps_To","value":"Medical Record"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0025102"}]}}{"C107424":{"preferredName":"Social Security Death Index","code":"C107424","definitions":[{"definition":"A publically-accessible database derived from the Social Security Administration's (SSA) Death Master File Extract. It includes a listing of the vital statistics of a majority of decedents reported to the SSA since 1962.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Social Security Death Index","termGroup":"PT","termSource":"NCI"},{"termName":"SSDI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social Security Death Index"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3814049"}]}}{"C16267":{"preferredName":"Afghanistan","code":"C16267","definitions":[{"definition":"A country in Southern Asia, north and west of Pakistan, east of Iran. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, north and west of Pakistan, east of Iran.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Afghanistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Afghanistan"},{"name":"Maps_To","value":"Afghanistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0001732"}]}}{"C16271":{"preferredName":"Albania","code":"C16271","definitions":[{"definition":"A country in Southeastern Europe, bordering the Adriatic Sea and Ionian Sea, between Greece and Serbia and Montenegro. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Adriatic and Ionian Seas, between Greece and Montenegro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Albania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Albania"},{"name":"Maps_To","value":"Albania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0001909"}]}}{"C16274":{"preferredName":"Algeria","code":"C16274","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Algeria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Algeria"},{"name":"Maps_To","value":"Algeria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0002037"}]}}{"C16289":{"preferredName":"Andorra","code":"C16289","definitions":[{"definition":"A country in Southwestern Europe, between France and Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Europe, between France and Spain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Andorra","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Andorra"},{"name":"Maps_To","value":"Andorra"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0002838"}]}}{"C16292":{"preferredName":"Angola","code":"C16292","definitions":[{"definition":"A country in Southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Angola","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Angola"},{"name":"Maps_To","value":"Angola"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003023"}]}}{"C20133":{"preferredName":"Anguilla","code":"C20133","definitions":[{"definition":"A group of islands in the Caribbean Sea, east of the Virgin Islands and north of Saint Kitts and Nevis.","type":"DEFINITION","source":"NCI"},{"definition":"An island in the Caribbean Sea, east of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Anguilla","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anguilla"},{"name":"Maps_To","value":"Anguilla"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003353"}]}}{"C16303":{"preferredName":"Antigua and Barbuda","code":"C16303","definitions":[{"definition":"A group of islands in the Caribbean Sea, east of Saint Kitts and Nevis.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, east-southeast of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Antigua and Barbuda","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antigua_and_Barbuda"},{"name":"Maps_To","value":"Antigua and Barbuda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003354"}]}}{"C16305":{"preferredName":"Argentina","code":"C16305","definitions":[{"definition":"A country in Southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Argentina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Argentina"},{"name":"Maps_To","value":"Argentina"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003761"}]}}{"C16306":{"preferredName":"Armenia","code":"C16306","definitions":[{"definition":"A country in Southwestern Asia, east of Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Asia, east of Turkey and south of Georgia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Armenia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Armenia"},{"name":"Maps_To","value":"Armenia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0003798"}]}}{"C17884":{"preferredName":"Aruba","code":"C17884","definitions":[{"definition":"An island in the Caribbean Sea, north of Venezuela and west of Curacao.","type":"DEFINITION","source":"NCI"},{"definition":"Island in the Caribbean Sea, north of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Aruba","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aruba"},{"name":"Maps_To","value":"Aruba"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282379"}]}}{"C16311":{"preferredName":"Australia","code":"C16311","definitions":[{"definition":"The continent and country between the Indian Ocean and the South Pacific Ocean, south of Asia.","type":"DEFINITION","source":"NCI"},{"definition":"The continent between the Indian Ocean and the South Pacific Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Australia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The US State Department considers Ashmore and Cartier Islands and the Coral Sea Islands as a separate entities, each with its own code (AT and CR, respectively)."},{"name":"Legacy Concept Name","value":"Australia"},{"name":"Maps_To","value":"Australia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004340"}]}}{"C16312":{"preferredName":"Austria","code":"C16312","definitions":[{"definition":"A country in Central Europe, north of Italy and Slovenia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, northeast of Italy and southeast of Germany.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Austria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Austria"},{"name":"Maps_To","value":"Austria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004348"}]}}{"C16316":{"preferredName":"Azerbaijan","code":"C16316","definitions":[{"definition":"A country in Southwestern Asia, bordering the Caspian Sea, between Iran and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Asia, bordering the Caspian Sea, between Iran and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Azerbaijan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Azerbaijan"},{"name":"Maps_To","value":"Azerbaijan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004486"}]}}{"C16321":{"preferredName":"Bahamas","code":"C16321","definitions":[{"definition":"A chain of islands in the North Atlantic Ocean, southeast of Florida and north of Cuba.","type":"DEFINITION","source":"NCI"},{"definition":"A chain of islands in the North Atlantic Ocean, southeast of Florida. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bahamas","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bahamas"},{"name":"Maps_To","value":"Bahamas"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004683"}]}}{"C16322":{"preferredName":"Bahrain","code":"C16322","definitions":[{"definition":"An archipelago in the Persian Gulf, east of Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An archipelago in the Persian Gulf, on the east coast of Saudi Arabia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bahrain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bahrain"},{"name":"Maps_To","value":"Bahrain"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004684"}]}}{"C16323":{"preferredName":"Bangladesh","code":"C16323","definitions":[{"definition":"A country in Southern Asia, bordering the Bay of Bengal, between Burma and India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, bordering the Bay of Bengal, between Burma and India.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Bangladesh","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bangladesh"},{"name":"Maps_To","value":"Bangladesh"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004732"}]}}{"C16324":{"preferredName":"Barbados","code":"C16324","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, east of Saint Vincent and the Grenadines.","type":"DEFINITION","source":"NCI"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Barbados","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Barbados"},{"name":"Maps_To","value":"Barbados"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004739"}]}}{"C16372":{"preferredName":"Belarus","code":"C16372","definitions":[{"definition":"A country in Eastern Europe, east of Poland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, east of Poland and north of Ukraine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belarus","termGroup":"PT","termSource":"NCI"},{"termName":"Byelarus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Belarus"},{"name":"Maps_To","value":"Belarus"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006539"}]}}{"C16329":{"preferredName":"Belgium","code":"C16329","definitions":[{"definition":"A country in Western Europe, bordering the North Sea, between France and the Netherlands. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the North Sea, between France and the Netherlands.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Belgium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Belgium"},{"name":"Maps_To","value":"Belgium"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004950"}]}}{"C16331":{"preferredName":"Belize","code":"C16331","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea, between Guatemala and Mexico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central America, bordering the Caribbean Sea, between Guatemala and Mexico.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Belize","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Belize"},{"name":"Maps_To","value":"Belize"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0004952"}]}}{"C16333":{"preferredName":"Benin","code":"C16333","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Benin","termGroup":"PT","termSource":"NCI"},{"termName":"Benin Republic","termGroup":"SY","termSource":"NCI"},{"termName":"Bénin","termGroup":"SY","termSource":"NCI"},{"termName":"Bénin Republic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benin_Republic"},{"name":"Maps_To","value":"Benin"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005005"}]}}{"C16334":{"preferredName":"Bermuda","code":"C16334","definitions":[{"definition":"A group of islands in the North Atlantic Ocean, east of South Carolina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A group of islands in the North Atlantic Ocean, east of South Carolina. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bermuda","termGroup":"PT","termSource":"NCI"},{"termName":"Bermuda Islands","termGroup":"SY","termSource":"NCI"},{"termName":"Bermudas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bermuda"},{"name":"Maps_To","value":"Bermuda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005126"}]}}{"C16336":{"preferredName":"Bhutan","code":"C16336","definitions":[{"definition":"A country in Southern Asia, between China and India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, between China and India, east of Nepal and north of Bangladesh.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bhutan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bhutan"},{"name":"Maps_To","value":"Bhutan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005341"}]}}{"C16359":{"preferredName":"Bolivia, Plurinational State of","code":"C16359","definitions":[{"definition":"A country in Central South America, southwest of Brazil. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central South America, southwest of Brazil.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Bolivia, Plurinational State of","termGroup":"PT","termSource":"NCI"},{"termName":"Bolivia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bolivia"},{"name":"Maps_To","value":"Bolivia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0005918"}]}}{"C16361":{"preferredName":"Bosnia and Herzegovina","code":"C16361","definitions":[{"definition":"A country in Southeastern Europe, bordering the Adriatic Sea and Croatia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Adriatic Sea, between Croatia and Serbia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bosnia and Herzegovina","termGroup":"PT","termSource":"NCI"},{"termName":"Bosnia-Herzegovina","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bosnia-Herzegovina"},{"name":"Maps_To","value":"Bosnia and Herzegovina"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006036"}]}}{"C16363":{"preferredName":"Botswana","code":"C16363","definitions":[{"definition":"A country in Southern Africa, north of South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, north of South Africa and east of Namibia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botswana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Botswana"},{"name":"Maps_To","value":"Botswana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006041"}]}}{"C16364":{"preferredName":"Brazil","code":"C16364","definitions":[{"definition":"A country in Eastern South America, bordering the Atlantic Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern South America, bordering the Atlantic Ocean.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Brazil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brazil"},{"name":"Maps_To","value":"Brazil"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006137"}]}}{"C16367":{"preferredName":"Brunei Darussalam","code":"C16367","definitions":[{"definition":"A country in Southeastern Asia, bordering the South China Sea and Malaysia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the South China Sea and surrounded by Malaysia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brunei Darussalam","termGroup":"PT","termSource":"NCI"},{"termName":"Brunei","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brunei"},{"name":"Maps_To","value":"Brunei"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006320"}]}}{"C16368":{"preferredName":"Bulgaria","code":"C16368","definitions":[{"definition":"A country in Southeastern Europe, bordering the Black Sea, between Romania and Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Black Sea, between Romania and Turkey.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Bulgaria","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Bulgaria","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bulgaria"},{"name":"Maps_To","value":"Bulgaria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006368"}]}}{"C16369":{"preferredName":"Burkina Faso","code":"C16369","definitions":[{"definition":"A country in Western Africa, north of Ghana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, between Mali and Ghana.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burkina Faso","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Burkina_Faso"},{"name":"Maps_To","value":"Burkina Faso"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006409"}]}}{"C16371":{"preferredName":"Burundi","code":"C16371","definitions":[{"definition":"A country in Central Africa, east of Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, east of the Democratic Republic of the Congo and south of Rwanda.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burundi","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Burundi"},{"name":"Maps_To","value":"Burundi"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006448"}]}}{"C16378":{"preferredName":"Cambodia","code":"C16378","definitions":[{"definition":"A country in Southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Cambodia","termGroup":"PT","termSource":"NCI"},{"termName":"Kampuchea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cambodia"},{"name":"Maps_To","value":"Cambodia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006797"}]}}{"C16379":{"preferredName":"Cameroon","code":"C16379","definitions":[{"definition":"A country in Western Africa, bordering the Bight of Biafra, between Equatorial Guinea and Nigeria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Equatorial Guinea and Nigeria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cameroon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cameroon"},{"name":"Maps_To","value":"Cameroon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006802"}]}}{"C16380":{"preferredName":"Canada","code":"C16380","definitions":[{"definition":"A country in Northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Canada","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Canada"},{"name":"Maps_To","value":"Canada"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006823"}]}}{"C16382":{"preferredName":"Cabo Verde","code":"C16382","definitions":[{"definition":"A group of islands in the North Atlantic Ocean, west of Senegal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A group of islands in the North Atlantic Ocean, west of Senegal. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cabo Verde","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cape_Verde"},{"name":"Maps_To","value":"Cape Verde"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006893"}]}}{"C16391":{"preferredName":"Cayman Islands","code":"C16391","definitions":[{"definition":"An island group in the Caribbean Sea, nearly one-half of the way from Cuba to Honduras. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island group in the Caribbean Sea, south of Cuba and west of Jamaica.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cayman Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cayman_Islands"},{"name":"Maps_To","value":"Cayman Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0007481"}]}}{"C16409":{"preferredName":"Central African Republic","code":"C16409","definitions":[{"definition":"A country in Central Africa, north of Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, north of Democratic Republic of the Congo, between Cameroon and South Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central African Republic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_African_Republic"},{"name":"Maps_To","value":"Central African Republic"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0007673"}]}}{"C16412":{"preferredName":"Chad","code":"C16412","definitions":[{"definition":"A country in Central Africa, south of Libya. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, south of Libya, between Niger and Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chad","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chad"},{"name":"Maps_To","value":"Chad"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0007928"}]}}{"C16427":{"preferredName":"Chile","code":"C16427","definitions":[{"definition":"A country in Southern South America, bordering the South Atlantic Ocean and South Pacific Ocean, between Argentina and Peru. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern South America, bordering the South Pacific Ocean, between Argentina and Peru.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chile","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chile"},{"name":"Maps_To","value":"Chile"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0008107"}]}}{"C16428":{"preferredName":"China","code":"C16428","definitions":[{"definition":"A country in Eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, between North Korea and Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, south of Kazakhstan, Mongolia and Russia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"China","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"China"},{"name":"Maps_To","value":"China"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0008115"}]}}{"C16449":{"preferredName":"Colombia","code":"C16449","definitions":[{"definition":"A country in Northern South America, bordering the Caribbean Sea, between Panama and Venezuela, and bordering the North Pacific Ocean, between Ecuador and Panama. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the Caribbean Sea and the North Pacific Ocean, between Ecuador and Venezuela.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colombia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colombia"},{"name":"Maps_To","value":"Colombia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C3245499"}]}}{"C16458":{"preferredName":"Comoros","code":"C16458","definitions":[{"definition":"A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique, northwest of Mayotte.","type":"DEFINITION","source":"NCI"},{"definition":"A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Comoros","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Comoros"},{"name":"Maps_To","value":"Comoros"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0009490"}]}}{"C16467":{"preferredName":"Congo","code":"C16467","definitions":[{"definition":"A country in Western Africa, bordering the South Atlantic Ocean, between Angola and Gabon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the South Atlantic Ocean, between Gabon and the Democratic Republic of the Congo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Congo","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of the Congo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Congo"},{"name":"Maps_To","value":"Congo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0009738"}]}}{"C16469":{"preferredName":"Cook Islands","code":"C16469","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of islands in the South Pacific Ocean, east of Australia, between Tonga and French Polynesia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cook Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cook_Islands"},{"name":"Maps_To","value":"Cook Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0009956"}]}}{"C16470":{"preferredName":"Costa Rica","code":"C16470","definitions":[{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Costa Rica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Costa_Rica"},{"name":"Maps_To","value":"Costa Rica"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010182"}]}}{"C16762":{"preferredName":"Cote d'Ivoire","code":"C16762","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Cote d'Ivoire","termGroup":"PT","termSource":"NCI"},{"termName":"Côte d'Ivoire","termGroup":"SY","termSource":"NCI"},{"termName":"Ivory Coast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cote_dIvoire"},{"name":"Maps_To","value":"Cote d'Ivoire"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022326"}]}}{"C16474":{"preferredName":"Croatia","code":"C16474","definitions":[{"definition":"A country in Southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Croatia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Croatia"},{"name":"Maps_To","value":"Croatia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010343"}]}}{"C16477":{"preferredName":"Cuba","code":"C16477","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cuba","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cuba"},{"name":"Maps_To","value":"Cuba"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010435"}]}}{"C101225":{"preferredName":"Curacao","code":"C101225","definitions":[{"definition":"An island in the Caribbean Sea, north of Venezuela and east of Aruba, a constituent country of the Kingdom of the Netherlands.","type":"DEFINITION","source":"NCI"},{"definition":"An island nation located in the Caribbean Sea off the coast of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Curacao","termGroup":"PT","termSource":"NCI"},{"termName":"Curaçao","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Curacao"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0454665"}]}}{"C16480":{"preferredName":"Cyprus","code":"C16480","definitions":[{"definition":"An island in the Mediterranean Sea, south of Turkey.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island in the Mediterranean Sea, south of Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cyprus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cyprus"},{"name":"Maps_To","value":"Cyprus"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0010622"}]}}{"C17668":{"preferredName":"Czechia","code":"C17668","definitions":[{"definition":"A country in Central Europe, southeast of Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, southeast of Germany and southwest of Poland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Czechia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Czech_Republic"},{"name":"Maps_To","value":"Czech Republic (Czechia)"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0206578"}]}}{"C17266":{"preferredName":"Congo, the Democratic Republic of the","code":"C17266","definitions":[{"definition":"A country in Central Africa, northeast of Angola. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, northeast of Angola.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Congo, the Democratic Republic of the","termGroup":"PT","termSource":"NCI"},{"termName":"Democratic Republic of the Congo","termGroup":"SY","termSource":"NCI"},{"termName":"Zaire","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Democratic_Republic_of_the_Congo"},{"name":"Maps_To","value":"Democratic Republic of the Congo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043444"}]}}{"C16496":{"preferredName":"Denmark","code":"C16496","definitions":[{"definition":"A country in Northern Europe, bordering the Baltic Sea and the North Sea, on a peninsula north of Germany (Jutland); also includes two major islands (Sjaelland and Fyn). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the Baltic Sea and the North Sea, consisting of a peninsula on the north coast of Germany and several major islands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denmark","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Denmark"},{"name":"Maps_To","value":"Denmark"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0011318"}]}}{"C16506":{"preferredName":"Djibouti","code":"C16506","definitions":[{"definition":"A country in Eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Djibouti","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Djibouti"},{"name":"Maps_To","value":"Djibouti"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0012836"}]}}{"C16519":{"preferredName":"Dominica","code":"C16519","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, about one-half of the way from Puerto Rico to Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, south of Guadeloupe and north of Martinique.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dominica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dominica"},{"name":"Maps_To","value":"Dominica"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013013"}]}}{"C16520":{"preferredName":"Dominican Republic","code":"C16520","definitions":[{"definition":"A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Dominican Republic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dominican_Republic"},{"name":"Maps_To","value":"Dominican Republic"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013014"}]}}{"C16528":{"preferredName":"Ecuador","code":"C16528","definitions":[{"definition":"A country in Western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ecuador","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ecuador"},{"name":"Maps_To","value":"Ecuador"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013593"}]}}{"C16530":{"preferredName":"Egypt","code":"C16530","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, east of Libya and north of Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Egypt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Egypt"},{"name":"Maps_To","value":"Egypt"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013715"}]}}{"C16532":{"preferredName":"El Salvador","code":"C16532","definitions":[{"definition":"A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"El Salvador","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"El_Salvador"},{"name":"Maps_To","value":"El Salvador"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0013754"}]}}{"C16557":{"preferredName":"Equatorial Guinea","code":"C16557","definitions":[{"definition":"A country in Western Africa, bordering the Bight of Biafra, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Equatorial Guinea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Equatorial_Guinea"},{"name":"Maps_To","value":"Equatorial Guinea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0014651"}]}}{"C16558":{"preferredName":"Eritrea","code":"C16558","definitions":[{"definition":"A country in Eastern Africa, bordering the Red Sea, between Djibouti and Sudan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Red Sea, between Sudan and Ethiopia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eritrea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eritrea"},{"name":"Maps_To","value":"Eritrea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C2711724"}]}}{"C16562":{"preferredName":"Estonia","code":"C16562","definitions":[{"definition":"A country in Eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Finland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estonia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Estonia"},{"name":"Maps_To","value":"Estonia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0014908"}]}}{"C17179":{"preferredName":"Eswatini","code":"C17179","definitions":[{"definition":"A country in Southern Africa, between Mozambique and South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, between Mozambique and South Africa.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Eswatini","termGroup":"PT","termSource":"NCI"},{"termName":"Eswatini","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Swaziland"},{"name":"Maps_To","value":"Eswatini"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038983"}]}}{"C16563":{"preferredName":"Ethiopia","code":"C16563","definitions":[{"definition":"A country in Eastern Africa, west of Somalia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, between Somalia and Sudan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethiopia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ethiopia"},{"name":"Maps_To","value":"Ethiopia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0015024"}]}}{"C17954":{"preferredName":"Falkland Islands (Malvinas)","code":"C17954","definitions":[{"definition":"A group of islands in the South Atlantic Ocean, east of southern Argentina.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the South Atlantic Ocean, east of southern Argentina. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Falkland Islands (Malvinas)","termGroup":"PT","termSource":"NCI"},{"termName":"Falkland Islands","termGroup":"SY","termSource":"NCI"},{"termName":"Islas Malvinas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Falkland_Islands"},{"name":"Maps_To","value":"Falkland Islands (Malvinas)"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0349396"}]}}{"C16573":{"preferredName":"Faroe Islands","code":"C16573","definitions":[{"definition":"An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Faroe Islands","termGroup":"PT","termSource":"NCI"},{"termName":"Faeroe Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Faroe_Islands"},{"name":"Maps_To","value":"Faroe Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0015541"}]}}{"C17881":{"preferredName":"Micronesia, Federated States of","code":"C17881","definitions":[{"definition":"An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia, west of the Marshall Islands and north of the Solomon Islands.","type":"DEFINITION","source":"NCI"},{"definition":"An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Micronesia, Federated States of","termGroup":"PT","termSource":"NCI"},{"termName":"Federated States of Micronesia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Federated_States_of_Micronesia"},{"name":"Maps_To","value":"Federated States of Micronesia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282244"}]}}{"C16582":{"preferredName":"Fiji","code":"C16582","definitions":[{"definition":"A group of islands in the South Pacific Ocean, southwest of Wallis and Fortuna and east of Vanuatu.","type":"DEFINITION","source":"NCI"},{"definition":"An island group in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fiji","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Fiji","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fiji"},{"name":"Maps_To","value":"Fiji"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016080"}]}}{"C16584":{"preferredName":"Finland","code":"C16584","definitions":[{"definition":"A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the Baltic Sea, between Sweden and Russia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Finland","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Finland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Finland"},{"name":"Maps_To","value":"Finland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016132"}]}}{"C16592":{"preferredName":"France","code":"C16592","definitions":[{"definition":"A country in Western Europe, bordering the Bay of Biscay and English Channel, between Belgium and Spain, southeast of the UK; bordering the Mediterranean Sea, between Italy and Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the Bay of Biscay and the English Channel, between Germany and Spain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"France","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"France"},{"name":"Maps_To","value":"France"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016674"}]}}{"C16593":{"preferredName":"French Guiana","code":"C16593","definitions":[{"definition":"A country in Northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"French Guiana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"French_Guiana"},{"name":"Maps_To","value":"French Guiana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016703"}]}}{"C16594":{"preferredName":"French Polynesia","code":"C16594","definitions":[{"definition":"An archipelago in the South Pacific Ocean, about one-half of the way from South America to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An archipelago in the South Pacific Ocean, east of the Cook Islands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"French Polynesia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"French_Polynesia"},{"name":"Maps_To","value":"French Polynesia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016704"}]}}{"C16596":{"preferredName":"Gabon","code":"C16596","definitions":[{"definition":"A country in Western Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gabon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gabon"},{"name":"Maps_To","value":"Gabon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016910"}]}}{"C16598":{"preferredName":"The Gambia","code":"C16598","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean and Senegal. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean and surrounded by Senegal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"The Gambia","termGroup":"PT","termSource":"NCI"},{"termName":"Gambia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gambia"},{"name":"Maps_To","value":"Gambia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0016993"}]}}{"C16634":{"preferredName":"Georgia (Republic)","code":"C16634","definitions":[{"definition":"A country in Southwestern Asia, bordering the Black Sea, between Turkey and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Asia, bordering the Black Sea, between Turkey and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Georgia (Republic)","termGroup":"PT","termSource":"NCI"},{"termName":"Georgia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Georgia"},{"name":"Maps_To","value":"Georgia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017454"}]}}{"C16636":{"preferredName":"Germany","code":"C16636","definitions":[{"definition":"A country in Central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Germany","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Germany"},{"name":"Maps_To","value":"Germany"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017480"}]}}{"C26330":{"preferredName":"Ghana","code":"C26330","definitions":[{"definition":"A country in Western Africa, bordering the Gulf of Guinea, between Cote d'Ivoire and Togo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Cote d'Ivoire and Togo.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ghana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ghana"},{"name":"Maps_To","value":"Ghana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017516"}]}}{"C16638":{"preferredName":"Gibraltar","code":"C16638","definitions":[{"definition":"A dependency in Southwestern Europe, bordering the Strait of Gibraltar, on the southern coast of Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A dependency in southwestern Europe, on the southern coast of Spain, bordering the Strait of Gibraltar.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gibraltar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gibraltar"},{"name":"Maps_To","value":"Gibraltar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017540"}]}}{"C16645":{"preferredName":"Greece","code":"C16645","definitions":[{"definition":"A country in Southern Europe, bordering the Aegean Sea, Ionian Sea, and the Mediterranean Sea, between Albania and Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, bordering the Aegean, Ionian, and Mediterranean Seas, between Albania and Turkey.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Greece","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Greece"},{"name":"Maps_To","value":"Greece"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018226"}]}}{"C16646":{"preferredName":"Greenland","code":"C16646","definitions":[{"definition":"An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Greenland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Greenland"},{"name":"Maps_To","value":"Greenland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018229"}]}}{"C16647":{"preferredName":"Grenada","code":"C16647","definitions":[{"definition":"An island between the Caribbean Sea and Atlantic Ocean, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island between the Caribbean Sea and Atlantic Ocean, south of Saint Vincent and the Grenadines and north of Trinidad and Tobago.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grenada","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grenada"},{"name":"Maps_To","value":"Grenada"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018232"}]}}{"C16651":{"preferredName":"Guadeloupe","code":"C16651","definitions":[{"definition":"A group of islands in the Caribbean Seas, southeast of Montserrat.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the eastern Caribbean Sea, southeast of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guadeloupe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guadeloupe"},{"name":"Maps_To","value":"Guadeloupe"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018301"}]}}{"C16652":{"preferredName":"Guam","code":"C16652","definitions":[{"definition":"An island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines, south of the Northern Mariana Islands.","type":"DEFINITION","source":"NCI"},{"definition":"Island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guam","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Guam"},{"name":"Maps_To","value":"Guam"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018309"}]}}{"C16654":{"preferredName":"Guatemala","code":"C16654","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea and the North Pacific Ocean, east of Mexico and west of Belize and Honduras.","type":"DEFINITION","source":"NCI"},{"definition":"A country in Central America, bordering the Caribbean Sea, between Honduras and Belize and bordering the North Pacific Ocean, between El Salvador and Mexico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guatemala","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guatemala"},{"name":"Maps_To","value":"Guatemala"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018367"}]}}{"C64375":{"preferredName":"Guernsey","code":"C64375","definitions":[{"definition":"A British Crown dependency in the English Channel, between England and France.","type":"DEFINITION","source":"NCI"},{"definition":"The island of Guernsey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy, which held sway in both France and England. Guernsey is a British crown dependency, but is not part of the UK. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guernsey","termGroup":"PT","termSource":"NCI"},{"termName":"Bailiwick of Guernsey","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guernsey"},{"name":"Maps_To","value":"Guernsey"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018370"}]}}{"C16655":{"preferredName":"Guinea","code":"C16655","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Guinea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guinea"},{"name":"Maps_To","value":"Guinea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018381"}]}}{"C16656":{"preferredName":"Guinea-Bissau","code":"C16656","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Guinea-Bissau","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guinea-Bissau"},{"name":"Maps_To","value":"Guinea-Bissau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018387"}]}}{"C16657":{"preferredName":"Guyana","code":"C16657","definitions":[{"definition":"A country in Northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Guyana","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guyana"},{"name":"Maps_To","value":"Guyana"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018408"}]}}{"C16660":{"preferredName":"Haiti","code":"C16660","definitions":[{"definition":"A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Haiti","termGroup":"PT","termSource":"NCI"},{"termName":"Haïti","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Haiti"},{"name":"Maps_To","value":"Haiti"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0018510"}]}}{"C17249":{"preferredName":"Holy See (Vatican City State)","code":"C17249","definitions":[{"definition":"An enclave of Rome (Italy).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An enclave of Rome (Italy). (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Holy See (Vatican City State)","termGroup":"PT","termSource":"NCI"},{"termName":"Holy See","termGroup":"SY","termSource":"NCI"},{"termName":"Vatican City","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vatican_City"},{"name":"Maps_To","value":"Holy See"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042427"}]}}{"C16694":{"preferredName":"Honduras","code":"C16694","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua and bordering the North Pacific Ocean, between El Salvador and Nicaragua. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Honduras","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Honduras"},{"name":"Maps_To","value":"Honduras"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0019905"}]}}{"C16695":{"preferredName":"Hong Kong","code":"C16695","definitions":[{"definition":"A special administrative region of China, bordering the South China Sea and China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A special administrative region of China, bordering the South China Sea, east of Macao.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hong Kong","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hong_Kong"},{"name":"Maps_To","value":"Hong Kong"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0019907"}]}}{"C16699":{"preferredName":"Hungary","code":"C16699","definitions":[{"definition":"A country in Central Europe, northwest of Romania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, northwest of Romania and south of Slovakia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hungary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hungary"},{"name":"Maps_To","value":"Hungary"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0020174"}]}}{"C16704":{"preferredName":"Iceland","code":"C16704","definitions":[{"definition":"A country in Northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Iceland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iceland"},{"name":"Maps_To","value":"Iceland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0020750"}]}}{"C16727":{"preferredName":"India","code":"C16727","definitions":[{"definition":"A country in Southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Pakistan and China.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"India","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"India"},{"name":"Maps_To","value":"India"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0021201"}]}}{"C16728":{"preferredName":"Indonesia","code":"C16728","definitions":[{"definition":"A country in Southeastern Asia, comprising the archipelago between the Indian Ocean and the Pacific Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprising the archipelago and islands between the Indian Ocean and the Pacific Ocean, north of Australia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indonesia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Indonesia"},{"name":"Maps_To","value":"Indonesia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0021247"}]}}{"C16755":{"preferredName":"Iran, Islamic Republic of","code":"C16755","definitions":[{"definition":"A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Iran, Islamic Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Iran","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iran"},{"name":"Maps_To","value":"Iran"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022065"}]}}{"C16756":{"preferredName":"Iraq","code":"C16756","definitions":[{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iran and Kuwait. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iran and Syria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iraq","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iraq"},{"name":"Maps_To","value":"Iraq"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022066"}]}}{"C16757":{"preferredName":"Ireland","code":"C16757","definitions":[{"definition":"A country in Western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ireland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ireland"},{"name":"Maps_To","value":"Ireland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022067"}]}}{"C44480":{"preferredName":"Isle of Man","code":"C44480","definitions":[{"definition":"An island in the Irish Sea, between Great Britain and Ireland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"An island in the Irish Sea, between Great Britain and Ireland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Isle of Man","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isle_of_Man"},{"name":"Maps_To","value":"Isle of Man"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022132"}]}}{"C16760":{"preferredName":"Israel","code":"C16760","definitions":[{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Israel","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Israel"},{"name":"Maps_To","value":"Israel"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022271"}]}}{"C16761":{"preferredName":"Italy","code":"C16761","definitions":[{"definition":"A country in Southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Italy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Italy"},{"name":"Maps_To","value":"Italy"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022277"}]}}{"C16763":{"preferredName":"Jamaica","code":"C16763","definitions":[{"definition":"An island in the Caribbean Sea, south of Cuba, between the Cayman Islands and Haiti.","type":"DEFINITION","source":"NCI"},{"definition":"An island in the Caribbean Sea, south of Cuba. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jamaica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jamaica"},{"name":"Maps_To","value":"Jamaica"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022337"}]}}{"C16764":{"preferredName":"Japan","code":"C16764","definitions":[{"definition":"A country in Eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Japan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Japan"},{"name":"Maps_To","value":"Japan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022341"}]}}{"C64374":{"preferredName":"Jersey","code":"C64374","definitions":[{"definition":"A British Crown dependency in the English Channel southeast of Guernsey.","type":"DEFINITION","source":"NCI"},{"definition":"Jersey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy that held sway in both France and England. Jersey is a British crown dependency, but is not part of the UK. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jersey","termGroup":"PT","termSource":"NCI"},{"termName":"Bailiwick of Jersey","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jersey"},{"name":"Maps_To","value":"Jersey"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0454673"}]}}{"C16765":{"preferredName":"Jordan","code":"C16765","definitions":[{"definition":"A country in the Middle East, northwest of Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, northwest of Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jordan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jordan"},{"name":"Maps_To","value":"Jordan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022418"}]}}{"C20107":{"preferredName":"Kazakhstan","code":"C20107","definitions":[{"definition":"A country in Central Asia, northwest of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, northwest of China and south of Russia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kazakhstan","termGroup":"PT","termSource":"NCI"},{"termName":"Kazakstan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kazakhstan"},{"name":"Maps_To","value":"Kazakhstan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022537"}]}}{"C16769":{"preferredName":"Kenya","code":"C16769","definitions":[{"definition":"A country in Eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Kenya","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kenya"},{"name":"Maps_To","value":"Kenya"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022558"}]}}{"C16639":{"preferredName":"Kiribati","code":"C16639","definitions":[{"definition":"A group of 33 coral atolls in the Pacific Ocean, south of Hawaii and northeast of Jarvis Island.","type":"DEFINITION","source":"NCI"},{"definition":"A group of 33 coral atolls in the Pacific Ocean, straddling the equator; the capital Tarawa is about one-half of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kiribati","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Kiribati","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kiribati"},{"name":"Maps_To","value":"Kiribati"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0017550"}]}}{"C123740":{"preferredName":"Kosovo","code":"C123740","definitions":[{"definition":"A southeastern European country between Servia and Macedonia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kosovo","termGroup":"PT","termSource":"NCI"},{"termName":"901","termGroup":"CNU","termSource":"NCI"},{"termName":"XK","termGroup":"CA2","termSource":"NCI"},{"termName":"XKS","termGroup":"CA3","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kosovo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0206003"}]}}{"C16775":{"preferredName":"Kuwait","code":"C16775","definitions":[{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kuwait","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kuwait"},{"name":"Maps_To","value":"Kuwait"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022804"}]}}{"C16771":{"preferredName":"Kyrgyzstan","code":"C16771","definitions":[{"definition":"A country in Central Asia, west of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, between southern Kazakhstan and western China.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kyrgyzstan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kyrgyzstan"},{"name":"Maps_To","value":"Kyrgyzstan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022718"}]}}{"C16780":{"preferredName":"Lao People's Democratic Republic","code":"C16780","definitions":[{"definition":"A country in Southeastern Asia, northeast of Thailand, west of Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, north and east of Thailand, west of Vietnam.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lao People's Democratic Republic","termGroup":"PT","termSource":"NCI"},{"termName":"Laos","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lao_Peoples_Democratic_Republic"},{"name":"Maps_To","value":"Laos"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023034"}]}}{"C16783":{"preferredName":"Latvia","code":"C16783","definitions":[{"definition":"A country in Eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Latvia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Latvia"},{"name":"Maps_To","value":"Latvia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023128"}]}}{"C16784":{"preferredName":"Lebanon","code":"C16784","definitions":[{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lebanon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lebanon"},{"name":"Maps_To","value":"Lebanon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023190"}]}}{"C16787":{"preferredName":"Lesotho","code":"C16787","definitions":[{"definition":"A country in Southern Africa, an enclave of South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, an enclave of South Africa.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Lesotho","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesotho"},{"name":"Maps_To","value":"Lesotho"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023376"}]}}{"C16791":{"preferredName":"Liberia","code":"C16791","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Liberia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liberia"},{"name":"Maps_To","value":"Liberia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023617"}]}}{"C16793":{"preferredName":"Libya","code":"C16793","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Egypt and Tunisia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, between Egypt and Algeria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Libya","termGroup":"PT","termSource":"NCI"},{"termName":"Libyan Arab Jamahiriya","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Libyan_Arab_Jamahiriya"},{"name":"Maps_To","value":"Libya"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023634"}]}}{"C16794":{"preferredName":"Liechtenstein","code":"C16794","definitions":[{"definition":"A country in Central Europe, between Austria and Switzerland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, between Austria and Switzerland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Liechtenstein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liechtenstein"},{"name":"Maps_To","value":"Liechtenstein"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023668"}]}}{"C16799":{"preferredName":"Lithuania","code":"C16799","definitions":[{"definition":"A country in Eastern Europe, bordering the Baltic Sea, between Latvia and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Baltic Sea, between Latvia and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Lithuania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lithuania"},{"name":"Maps_To","value":"Lithuania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0023879"}]}}{"C16803":{"preferredName":"Luxembourg","code":"C16803","definitions":[{"definition":"A country in Western Europe, between France, Belgium, and Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, between France, Belgium, and Germany.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Luxembourg","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Luxembourg"},{"name":"Maps_To","value":"Luxembourg"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024176"}]}}{"C16807":{"preferredName":"Macau","code":"C16807","definitions":[{"definition":"A country in Eastern Asia, bordering the South China Sea and China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A special administrative region of China, bordering the South China Sea, west of Hong Kong.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macau","termGroup":"PT","termSource":"NCI"},{"termName":"Macao","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Macau"},{"name":"Maps_To","value":"Macau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024403"}]}}{"C16808":{"preferredName":"Madagascar","code":"C16808","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Indian Ocean, east of Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Indian Ocean, east of Mozambique.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Madagascar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Madagascar"},{"name":"Maps_To","value":"Madagascar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024443"}]}}{"C16813":{"preferredName":"Malawi","code":"C16813","definitions":[{"definition":"A country in Southern Africa, east of Zambia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, east of Zambia and west of Mozambique and Tanzania.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malawi","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malawi"},{"name":"Maps_To","value":"Malawi"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024548"}]}}{"C16814":{"preferredName":"Malaysia","code":"C16814","definitions":[{"definition":"A country in Southeastern Asia, occupying a peninsula and the northern one-third of the island of Borneo, bordering Indonesia and the South China Sea, south of Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia bordering Indonesia and the South China Sea, occupying a peninsula south of Thailand and the northern one-third of the island of Borneo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malaysia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malaysia"},{"name":"Maps_To","value":"Malaysia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024552"}]}}{"C16815":{"preferredName":"Maldives","code":"C16815","definitions":[{"definition":"A country in Southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India and north of the British Indian Ocean Territory.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maldives","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Maldives"},{"name":"Maps_To","value":"Maldives"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024553"}]}}{"C16816":{"preferredName":"Mali","code":"C16816","definitions":[{"definition":"A country in Western Africa, southwest of Algeria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, southwest of Algeria and east of Mauritania.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mali","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mali"},{"name":"Maps_To","value":"Mali"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024581"}]}}{"C16817":{"preferredName":"Malta","code":"C16817","definitions":[{"definition":"A country in Southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Malta","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malta"},{"name":"Maps_To","value":"Malta"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024653"}]}}{"C16822":{"preferredName":"Marshall Islands","code":"C16822","definitions":[{"definition":"A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia, south of Wake Island and north of Nauru.","type":"DEFINITION","source":"NCI"},{"definition":"A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Marshall Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Marshall_Islands"},{"name":"Maps_To","value":"Marshall Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C2711078"}]}}{"C16823":{"preferredName":"Martinique","code":"C16823","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, south of Dominica and north of Saint Lucia.","type":"DEFINITION","source":"NCI"},{"definition":"An island in the Caribbean Sea, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Martinique","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Martinique"},{"name":"Maps_To","value":"Martinique"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0454677"}]}}{"C16826":{"preferredName":"Mauritania","code":"C16826","definitions":[{"definition":"A country in Northern Africa, bordering the North Atlantic Ocean, between Senegal and Western Sahara. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the North Atlantic Ocean, between Senegal, Western Sahara, and Mali.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mauritania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mauritania"},{"name":"Maps_To","value":"Mauritania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024943"}]}}{"C16827":{"preferredName":"Mauritius","code":"C16827","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Indian Ocean, off the coast of Madagascar, east of Reunion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mauritius","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mauritius"},{"name":"Maps_To","value":"Mauritius"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024944"}]}}{"C16828":{"preferredName":"Mayotte","code":"C16828","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique, southeast of Comoros.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mayotte","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mayotte"},{"name":"Maps_To","value":"Mayotte"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0024974"}]}}{"C16850":{"preferredName":"Mexico","code":"C16850","definitions":[{"definition":"A country in Central America, bordering the Caribbean Sea and the Gulf of Mexico, between Belize and the US and bordering the North Pacific Ocean, between Guatemala and the US. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern North America, bordering the North Pacific Ocean and the Gulf of Mexico, south of the US.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mexico","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mexico"},{"name":"Maps_To","value":"Mexico"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0025885"}]}}{"C16871":{"preferredName":"Moldova, Republic of","code":"C16871","definitions":[{"definition":"A country in Eastern Europe, northeast of Romania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, northeast of Romania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Moldova, Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Moldova","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Moldova","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Moldova"},{"name":"Maps_To","value":"Moldova"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026374"}]}}{"C16874":{"preferredName":"Monaco","code":"C16874","definitions":[{"definition":"A country in Western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Monaco","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monaco"},{"name":"Maps_To","value":"Monaco"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026405"}]}}{"C16875":{"preferredName":"Mongolia","code":"C16875","definitions":[{"definition":"A country in Northern Asia, between China and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Asia, between China and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Mongolia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mongolia"},{"name":"Maps_To","value":"Mongolia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026410"}]}}{"C64378":{"preferredName":"Montenegro","code":"C64378","definitions":[{"definition":"A country in southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina.","type":"DEFINITION","source":"NCI"},{"definition":"A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Montenegro","termGroup":"PT","termSource":"NCI"},{"termName":"People's Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Socialist Republic of Serbia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Montenegro"},{"name":"Maps_To","value":"Montenegro"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026510"}]}}{"C16876":{"preferredName":"Montserrat","code":"C16876","definitions":[{"definition":"A country in the Caribbean, occupying an island in the Caribbean Sea, southeast of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island in the Caribbean Seas, southeast of Saint Kitts and Nevis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Montserrat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Montserrat"},{"name":"Maps_To","value":"Montserrat"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026514"}]}}{"C16878":{"preferredName":"Morocco","code":"C16878","definitions":[{"definition":"A country in Northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, between Algeria and Western Sahara. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, south of Spain and between Algeria and Western Sahara.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Morocco","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Morocco"},{"name":"Maps_To","value":"Morocco"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026544"}]}}{"C16882":{"preferredName":"Mozambique","code":"C16882","definitions":[{"definition":"A country in Southern Africa, bordering the Mozambique Channel, between South Africa and Tanzania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Africa, bordering the Mozambique Channel, between South Africa and Tanzania.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mozambique","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mozambique"},{"name":"Maps_To","value":"Mozambique"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0026655"}]}}{"C16370":{"preferredName":"Myanmar","code":"C16370","definitions":[{"definition":"A country in Southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, between Bangladesh and Thailand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, southwest of China, between Bangladesh and Thailand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myanmar","termGroup":"PT","termSource":"NCI"},{"termName":"Burma","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of the Union of Myanmar","termGroup":"SY","termSource":"NCI"},{"termName":"Union of Burma","termGroup":"SY","termSource":"NCI"},{"termName":"Union of Myanmar","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myanmar"},{"name":"Maps_To","value":"Myanmar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0006416"}]}}{"C16891":{"preferredName":"Namibia","code":"C16891","definitions":[{"definition":"A country in Southern Africa, bordering the South Atlantic Ocean, between Angola and South Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Africa, bordering the South Atlantic Ocean, between Angola and South Africa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Namibia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Namibia"},{"name":"Maps_To","value":"Namibia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027366"}]}}{"C16896":{"preferredName":"Nauru","code":"C16896","definitions":[{"definition":"A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nauru","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nauru"},{"name":"Maps_To","value":"Nauru"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027496"}]}}{"C16901":{"preferredName":"Nepal","code":"C16901","definitions":[{"definition":"A country in Southern Asia, between China and India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, between China and India, west of Bhutan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nepal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nepal"},{"name":"Maps_To","value":"Nepal"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027689"}]}}{"C16903":{"preferredName":"Netherlands","code":"C16903","definitions":[{"definition":"A country in Western Europe, bordering the North Sea, between Belgium and Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, bordering the North Sea, between Belgium and Germany.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Netherlands","termGroup":"PT","termSource":"NCI"},{"termName":"Kingdom of the Netherlands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Netherlands"},{"name":"Maps_To","value":"Netherlands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027778"}]}}{"C16913":{"preferredName":"New Caledonia","code":"C16913","definitions":[{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"New Caledonia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"New_Caledonia"},{"name":"Maps_To","value":"New Caledonia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027964"}]}}{"C16914":{"preferredName":"New Zealand","code":"C16914","definitions":[{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"New Zealand","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"New_Zealand"},{"name":"Maps_To","value":"New Zealand"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0027978"}]}}{"C16915":{"preferredName":"Nicaragua","code":"C16915","definitions":[{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nicaragua","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nicaragua"},{"name":"Maps_To","value":"Nicaragua"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028002"}]}}{"C16916":{"preferredName":"Niger","code":"C16916","definitions":[{"definition":"A country in Western Africa, southeast of Algeria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, southeast of Algeria and north of Nigeria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niger","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Niger"},{"name":"Maps_To","value":"Niger"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028074"}]}}{"C16917":{"preferredName":"Nigeria","code":"C16917","definitions":[{"definition":"A country in Western Africa, bordering the Gulf of Guinea, between Benin and Cameroon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Benin and Cameroon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Nigeria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nigeria"},{"name":"Maps_To","value":"Nigeria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028075"}]}}{"C16918":{"preferredName":"Niue","code":"C16918","definitions":[{"definition":"A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga and south of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Niue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Niue"},{"name":"Maps_To","value":"Niue"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028219"}]}}{"C16773":{"preferredName":"Korea, Democratic People's Republic of","code":"C16773","definitions":[{"definition":"A country in Eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Korea, Democratic People's Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"North Korea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"North_Korea"},{"name":"Maps_To","value":"North Korea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022772"}]}}{"C17654":{"preferredName":"North Macedonia","code":"C17654","definitions":[{"definition":"A country in Southeastern Europe, north of Greece. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, north of Greece, between Albania and Bulgaria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"North Macedonia","termGroup":"PT","termSource":"NCI"},{"termName":"Macedonia","termGroup":"SY","termSource":"NCI"},{"termName":"Macedonia (Republic)","termGroup":"SY","termSource":"NCI"},{"termName":"Macedonia, Former Yugoslav Republic of","termGroup":"SY","termSource":"NCI"},{"termName":"Macedonia, the Former Yugoslav Republic of","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Macedonia","termGroup":"SY","termSource":"NCI"},{"termName":"The Former Yugoslav Republic of Macedonia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"The_Former_Yugoslav_Republic_of_Macedonia"},{"name":"Maps_To","value":"North Macedonia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0700290"}]}}{"C17882":{"preferredName":"Northern Mariana Islands","code":"C17882","definitions":[{"definition":"A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines, north of Guam.","type":"DEFINITION","source":"NCI"},{"definition":"A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Northern Mariana Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Northern_Mariana_Islands"},{"name":"Maps_To","value":"Northern Mariana Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282245"}]}}{"C16920":{"preferredName":"Norway","code":"C16920","definitions":[{"definition":"A country in Northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Norway","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Norway"},{"name":"Maps_To","value":"Norway"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028423"}]}}{"C16933":{"preferredName":"Oman","code":"C16933","definitions":[{"definition":"A country in the Middle East, bordering the Arabian Sea, Gulf of Oman, and Persian Gulf, between Yemen and the United Arab Emirates. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in the Middle East, bordering the Arabian Sea, southeast of Saudi Arabia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oman","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oman"},{"name":"Maps_To","value":"Oman"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0028971"}]}}{"C16949":{"preferredName":"Pakistan","code":"C16949","definitions":[{"definition":"A country in Southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Pakistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pakistan"},{"name":"Maps_To","value":"Pakistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030211"}]}}{"C17733":{"preferredName":"Palau","code":"C17733","definitions":[{"definition":"A country in the Pacific, comprising a group of islands in the North Pacific Ocean, southeast of the Philippines and northwest of Papua New Guinea.","type":"DEFINITION","source":"NCI"},{"definition":"A country in the Pacific, comprising a group of islands in the North Pacific Ocean, southeast of the Philippines. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Palau","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palau"},{"name":"Maps_To","value":"Palau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C2711193"}]}}{"C16951":{"preferredName":"Panama","code":"C16951","definitions":[{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Panama","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Panama"},{"name":"Maps_To","value":"Panama"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030266"}]}}{"C16952":{"preferredName":"Papua New Guinea","code":"C16952","definitions":[{"definition":"A country in Southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Papua New Guinea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papua_New_Guinea"},{"name":"Maps_To","value":"Papua New Guinea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030375"}]}}{"C16953":{"preferredName":"Paraguay","code":"C16953","definitions":[{"definition":"A country in Central South America, northeast of Argentina. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central South America, northeast of Argentina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Paraguay","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paraguay"},{"name":"Maps_To","value":"Paraguay"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0030428"}]}}{"C16972":{"preferredName":"Peru","code":"C16972","definitions":[{"definition":"A country in Western South America, bordering the South Pacific Ocean, between Chile and Ecuador. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western South America, bordering the South Pacific Ocean, between Chile and Ecuador.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Peru","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peru"},{"name":"Maps_To","value":"Peru"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0031238"}]}}{"C16978":{"preferredName":"Philippines","code":"C16978","definitions":[{"definition":"A country in Southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Philippines","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Philippines"},{"name":"Maps_To","value":"Philippines"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0031529"}]}}{"C17002":{"preferredName":"Poland","code":"C17002","definitions":[{"definition":"A country in Central Europe, east of Germany. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, east of Germany.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Poland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poland"},{"name":"Maps_To","value":"Poland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0032356"}]}}{"C17006":{"preferredName":"Portugal","code":"C17006","definitions":[{"definition":"A country in Southwestern Europe, bordering the North Atlantic Ocean, west of Spain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Europe, bordering the North Atlantic Ocean, west of Spain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Portugal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Portugal"},{"name":"Maps_To","value":"Portugal"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0032729"}]}}{"C17043":{"preferredName":"Puerto Rico","code":"C17043","definitions":[{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic and west of the British Virgin Islands.","type":"DEFINITION","source":"NCI"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Puerto Rico","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Puerto_Rico"},{"name":"Maps_To","value":"Puerto Rico"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0034044"}]}}{"C17045":{"preferredName":"Qatar","code":"C17045","definitions":[{"definition":"A country in the Middle East, occupying a peninsula bordering the Persian Gulf and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, occupying a peninsula bordering the Persian Gulf and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Qatar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Qatar"},{"name":"Maps_To","value":"Qatar"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0034366"}]}}{"C17095":{"preferredName":"Reunion","code":"C17095","definitions":[{"definition":"A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, occupying an island in the Indian Ocean, east of Madagascar and west of Mauritius.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reunion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Reunion"},{"name":"Maps_To","value":"Reunion"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035373"}]}}{"C17108":{"preferredName":"Romania","code":"C17108","definitions":[{"definition":"A country in Southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Romania","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Romania"},{"name":"Maps_To","value":"Romania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035826"}]}}{"C17111":{"preferredName":"Russian Federation","code":"C17111","definitions":[{"definition":"A country in Northern Asia (that part west of the Urals is sometimes included with Europe), bordering the Arctic Ocean, between Europe and the North Pacific Ocean. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Asia, bordering the Arctic Ocean, between Europe and the North Pacific Ocean.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Russian Federation","termGroup":"PT","termSource":"NCI"},{"termName":"Russia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The part of Russia west of the Urals is sometimes included with Europe."},{"name":"Legacy Concept Name","value":"Russia"},{"name":"Maps_To","value":"Russia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035970"}]}}{"C17112":{"preferredName":"Rwanda","code":"C17112","definitions":[{"definition":"A country in Central Africa, east of Democratic Republic of the Congo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Africa, between the Democratic Republic of the Congo and Tanzania and north of Burundi.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rwanda","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rwanda"},{"name":"Maps_To","value":"Rwanda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0035978"}]}}{"C17164":{"preferredName":"Saint Helena, Ascension and Tristan da Cunha","code":"C17164","definitions":[{"definition":"A group of islands in the South Atlantic Ocean, about midway between South America and Africa, west of Angola and South Africa.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the South Atlantic Ocean, about midway between South America and Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Saint Helena, Ascension and Tristan da Cunha","termGroup":"PT","termSource":"NCI"},{"termName":"Saint Helena","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Helena"},{"name":"Maps_To","value":"Saint Helena, Ascension and Tristan da Cunha"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038108"}]}}{"C17885":{"preferredName":"Saint Kitts and Nevis","code":"C17885","definitions":[{"definition":"A group of islands in the Caribbean Sea, east of the Virgin Islands and south of Anguilla.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the Caribbean Sea, about one-third of the way from Puerto Rico to Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Saint Kitts and Nevis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Kitts_and_Nevis"},{"name":"Maps_To","value":"Saint Kitts and Nevis"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0282380"}]}}{"C17113":{"preferredName":"Saint Lucia","code":"C17113","definitions":[{"definition":"A country in the Caribbean, occupying an island between the Caribbean Sea and North Atlantic Ocean, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An island between the Caribbean Sea and the North Atlantic Ocean, south of Martinique and north of Saint Vincent and the Grenadines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saint Lucia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Lucia"},{"name":"Maps_To","value":"Saint Lucia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036056"}]}}{"C17165":{"preferredName":"Saint Pierre and Miquelon","code":"C17165","definitions":[{"definition":"A country in Northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Saint Pierre and Miquelon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Pierre_and_Miquelon"},{"name":"Maps_To","value":"Saint Pierre and Miquelon"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038111"}]}}{"C17114":{"preferredName":"Saint Vincent and the Grenadines","code":"C17114","definitions":[{"definition":"A country in the Caribbean, comprised of islands in the Caribbean Sea, north of Trinidad and Tobago. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, south of Saint Lucia and north of Granada.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saint Vincent and the Grenadines","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saint_Vincent_and_the_Grenadines"},{"name":"Maps_To","value":"Saint Vincent and the Grenadines"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036057"}]}}{"C17740":{"preferredName":"Samoa","code":"C17740","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about half way from Hawaii to New Zealand, west of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Samoa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Samoa"},{"name":"Maps_To","value":"Samoa"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0242537"}]}}{"C17115":{"preferredName":"San Marino","code":"C17115","definitions":[{"definition":"A country in Southern Europe, an enclave in central Italy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Europe, an enclave in central Italy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"San Marino","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"San_Marino"},{"name":"Maps_To","value":"San Marino"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036154"}]}}{"C17116":{"preferredName":"Sao Tome and Principe","code":"C17116","definitions":[{"definition":"A country in Western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Sao Tome and Principe","termGroup":"PT","termSource":"NCI"},{"termName":"São Tomé and Príncipe","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sao_Tome_and_Principe"},{"name":"Maps_To","value":"Sao Tome and Principe"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036183"}]}}{"C17117":{"preferredName":"Saudi Arabia","code":"C17117","definitions":[{"definition":"A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Saudi Arabia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Saudi_Arabia"},{"name":"Maps_To","value":"Saudi Arabia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036243"}]}}{"C17121":{"preferredName":"Senegal","code":"C17121","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Mauritania. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Mauritania.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Senegal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Senegal"},{"name":"Maps_To","value":"Senegal"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036644"}]}}{"C64377":{"preferredName":"Serbia","code":"C64377","definitions":[{"definition":"A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A republic in southeastern Europe, between Romania and Bosnia and Herzegovina.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serbia","termGroup":"PT","termSource":"NCI"},{"termName":"People's Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Republic of Serbia","termGroup":"SY","termSource":"NCI"},{"termName":"Socialist Republic of Serbia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Serbia"},{"name":"Maps_To","value":"Serbia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036708"}]}}{"C17129":{"preferredName":"Seychelles","code":"C17129","definitions":[{"definition":"A country in Eastern Africa, comprised of a group of islands in the Indian Ocean, northeast of Madagascar. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, comprised of a group of islands in the Indian Ocean, northeast of Madagascar and east of Kenya.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seychelles","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Seychelles"},{"name":"Maps_To","value":"Seychelles"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0036919"}]}}{"C17130":{"preferredName":"Sierra Leone","code":"C17130","definitions":[{"definition":"A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Liberia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the North Atlantic Ocean, between Guinea and Liberia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Sierra Leone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sierra_Leone"},{"name":"Maps_To","value":"Sierra Leone"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037063"}]}}{"C17134":{"preferredName":"Singapore","code":"C17134","definitions":[{"definition":"A country in Southeastern Asia, comprised of islands between Malaysia and Indonesia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, comprised of the southern tip of the Malaysian peninsula and nearby islands between Malaysia and Indonesia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Singapore","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Singapore"},{"name":"Maps_To","value":"Singapore"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037173"}]}}{"C17669":{"preferredName":"Slovakia","code":"C17669","definitions":[{"definition":"A country in Central Europe, south of Poland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, south of Poland and north of Hungary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Slovakia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Slovakia"},{"name":"Maps_To","value":"Slovakia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0206579"}]}}{"C17138":{"preferredName":"Slovenia","code":"C17138","definitions":[{"definition":"A country in Central Europe, bordering the Adriatic Sea, between Austria and Croatia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, bordering the Adriatic Sea, between Austria and Croatia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Slovenia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Slovenia"},{"name":"Maps_To","value":"Slovenia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037334"}]}}{"C17148":{"preferredName":"Solomon Islands","code":"C17148","definitions":[{"definition":"A group of islands in the South Pacific Ocean, east of Papua New Guinea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A group of islands in the South Pacific Ocean, east of Papua New Guinea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Solomon Islands","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solomon_Islands"},{"name":"Maps_To","value":"Solomon Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037623"}]}}{"C17149":{"preferredName":"Somalia","code":"C17149","definitions":[{"definition":"A country in Eastern Africa, bordering the Gulf of Aden and the Indian Ocean, east of Ethiopia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Gulf of Aden and the Indian Ocean, east of Ethiopia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Somalia","termGroup":"PT","termSource":"NCI"},{"termName":"Federal Republic of Somalia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Somalia"},{"name":"Maps_To","value":"Somalia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037640"}]}}{"C17151":{"preferredName":"South Africa","code":"C17151","definitions":[{"definition":"A country in Southern Africa, at the southern tip of the continent of Africa. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, at the southern tip of the continent of Africa.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"South Africa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"South_Africa"},{"name":"Maps_To","value":"South Africa"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037712"}]}}{"C16774":{"preferredName":"Korea, Republic of","code":"C16774","definitions":[{"definition":"A country in Eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Korea, Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Korea","termGroup":"SY","termSource":"NCI"},{"termName":"South Korea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"South_Korea"},{"name":"Maps_To","value":"South Korea"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0022773"}]}}{"C97351":{"preferredName":"South Sudan","code":"C97351","definitions":[{"definition":"A country in east central Africa south of Sudan, north of Uganda and Kenya, and west of Ethiopia.","type":"DEFINITION","source":"NCI"},{"definition":"A northeastern African country located in the Sahel region and bordered by Sudan in the north, Uganda and Kenya in the south and Ethiopia in the west. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"South Sudan","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of South Sudan","termGroup":"SY","termSource":"NCI"},{"termName":"Southern Sudan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"South Sudan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C3273373"}]}}{"C17152":{"preferredName":"Spain","code":"C17152","definitions":[{"definition":"A country in Southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, North Atlantic Ocean, and Pyrenees Mountains, southwest of France. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, and North Atlantic Ocean, southwest of France.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spain"},{"name":"Maps_To","value":"Spain"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0037747"}]}}{"C17163":{"preferredName":"Sri Lanka","code":"C17163","definitions":[{"definition":"A country in Southern Asia, occupying an island in the Indian Ocean, south of India. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Asia, occupying an island in the Indian Ocean, southeast of India.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sri Lanka","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sri_Lanka"},{"name":"Maps_To","value":"Sri Lanka"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038088"}]}}{"C20110":{"preferredName":"State of Palestine","code":"C20110","definitions":[{"definition":"A collective name for the West Bank and the Gaza Strip, two territories in Palestine. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sovereign state in western Africa consisting of the West Bank and the Gaza Strip. Its capital is Jerusalem.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"State of Palestine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palestinian_Territory_Occupied"},{"name":"Maps_To","value":"State of Palestine"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1518860"}]}}{"C17170":{"preferredName":"Sudan","code":"C17170","definitions":[{"definition":"A country in Northern Africa, bordering the Red Sea, between Egypt and Eritrea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northeastern Africa, bordering the Red Sea, between Egypt and Eritrea.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sudan","termGroup":"PT","termSource":"NCI"},{"termName":"736","termGroup":"AQS","termSource":"NCI"},{"termName":"Republic of the Sudan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sudan"},{"name":"Maps_To","value":"Sudan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038642"}]}}{"C17175":{"preferredName":"Suriname","code":"C17175","definitions":[{"definition":"A country in Northern South America, bordering the North Atlantic Ocean, between French Guiana and Guyana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the North Atlantic Ocean, between French Guiana and Guyana.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Suriname","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Suriname"},{"name":"Maps_To","value":"Suriname"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038944"}]}}{"C17178":{"preferredName":"Svalbard and Jan Mayen","code":"C17178","definitions":[{"definition":"A group of islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Svalbard and Jan Mayen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The US State Department considers these as separate entities, each with its own code: Svalbard (SV), and Jan Mayen (JN)"},{"name":"Legacy Concept Name","value":"Svalbard_and_Jan_Mayen"},{"name":"Maps_To","value":"Svalbard & Jan Mayen Islands"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1515101"}]}}{"C17180":{"preferredName":"Sweden","code":"C17180","definitions":[{"definition":"A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, Kattegat, and Skagerrak, between Finland and Norway. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Europe, bordering the Baltic Sea, between Finland and Norway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sweden","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sweden"},{"name":"Maps_To","value":"Sweden"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0038995"}]}}{"C17181":{"preferredName":"Switzerland","code":"C17181","definitions":[{"definition":"A country in Central Europe, east of France, north of Italy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Europe, east of France and north of Italy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Switzerland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Switzerland"},{"name":"Maps_To","value":"Switzerland"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039021"}]}}{"C17182":{"preferredName":"Syrian Arab Republic","code":"C17182","definitions":[{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Lebanon and Turkey.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook"}]},{"definition":"A country in the Middle East, bordering the Mediterranean Sea, between Lebanon and Turkey. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Syrian Arab Republic","termGroup":"PT","termSource":"NCI"},{"termName":"Syria","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Syria"},{"name":"Maps_To","value":"Syria"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039138"}]}}{"C17184":{"preferredName":"Taiwan","code":"C17184","definitions":[{"definition":"A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, north of the Philippines, off the southeastern coast of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, off the southeastern coast of China north of the Philippines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taiwan","termGroup":"PT","termSource":"NCI"},{"termName":"Taiwan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Taiwan"},{"name":"Maps_To","value":"Taiwan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039260"}]}}{"C17183":{"preferredName":"Tajikistan","code":"C17183","definitions":[{"definition":"A country in Central Asia, west of China. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, south of Kyrgyzstan and west of China.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tajikistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tajikistan"},{"name":"Maps_To","value":"Tajikistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039247"}]}}{"C17185":{"preferredName":"Tanzania, United Republic of","code":"C17185","definitions":[{"definition":"A country in Eastern Africa, bordering the Indian Ocean, between Kenya and Mozambique. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, bordering the Indian Ocean, between Kenya and Mozambique.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Tanzania, United Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Tanzania","termGroup":"SY","termSource":"NCI"},{"termName":"United Republic of Tanzania","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tanzania"},{"name":"Maps_To","value":"Tanzania"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039298"}]}}{"C17192":{"preferredName":"Thailand","code":"C17192","definitions":[{"definition":"A country in Southeastern Asia, bordering the Andaman Sea and the Gulf of Thailand, southeast of Burma. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Andaman Sea and the Gulf of Thailand, southeast of Burma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Thailand","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thailand"},{"name":"Maps_To","value":"Thailand"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0039725"}]}}{"C17200":{"preferredName":"Timor-Leste","code":"C17200","definitions":[{"definition":"A country in Southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Timor-Leste","termGroup":"PT","termSource":"NCI"},{"termName":"East Timor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"East_Timor"},{"name":"Maps_To","value":"Timor-Leste"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1452561"}]}}{"C17202":{"preferredName":"Togo","code":"C17202","definitions":[{"definition":"A country in Western Africa, bordering the Bight of Benin, between Benin and Ghana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Africa, bordering the Gulf of Guinea, between Benin and Ghana.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Togo","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Togo"},{"name":"Maps_To","value":"Togo"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0040363"}]}}{"C17704":{"preferredName":"Tokelau","code":"C17704","definitions":[{"definition":"A group of three atolls in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand, west of Tuvalu and north of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"A group of three atolls in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tokelau","termGroup":"PT","termSource":"NCI"},{"termName":"Union Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tokelau"},{"name":"Maps_To","value":"Tokelau"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0220928"}]}}{"C17205":{"preferredName":"Tonga","code":"C17205","definitions":[{"definition":"An archipelago in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand, southeast of Fiji.","type":"DEFINITION","source":"NCI"},{"definition":"An archipelago in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tonga","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonga"},{"name":"Maps_To","value":"Tonga"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0040407"}]}}{"C17217":{"preferredName":"Trinidad and Tobago","code":"C17217","definitions":[{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, off the northeast coast of Venezuela.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Trinidad and Tobago","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trinidad_and_Tobago"},{"name":"Maps_To","value":"Trinidad and Tobago"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041061"}]}}{"C17221":{"preferredName":"Tunisia","code":"C17221","definitions":[{"definition":"A country in Northern Africa, bordering the Mediterranean Sea, between Algeria and Libya. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the Mediterranean Sea, between Algeria and Libya.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Tunisia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tunisia"},{"name":"Maps_To","value":"Tunisia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041388"}]}}{"C17222":{"preferredName":"Turkey","code":"C17222","definitions":[{"definition":"A country in southeastern Europe and southwestern Asia (that portion of Turkey west of the Bosporus is geographically part of Europe), bordering the Black Sea, between Bulgaria and Georgia, and bordering the Aegean Sea and the Mediterranean Sea, between Greece and Syria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Europe and southwestern Asia, between the Black Sea and Mediterranean Sea, east of Greece and north of Syria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Turkey","termGroup":"PT","termSource":"NCI"},{"termName":"Republic of Turkey","termGroup":"SY","termSource":"NCI"},{"termName":"Turkiye","termGroup":"SY","termSource":"NCI"},{"termName":"Turkiye Cumhuriyeti","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The portion of Turkey west of the Bosporus is geographically part of Europe."},{"name":"Legacy Concept Name","value":"Turkey"},{"name":"Maps_To","value":"Turkey"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041400"}]}}{"C17223":{"preferredName":"Turkmenistan","code":"C17223","definitions":[{"definition":"A country in Central Asia, bordering the Caspian Sea, between Iran and Kazakhstan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, bordering the Caspian Sea, between Iran and Kazakhstan.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Turkmenistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Turkmenistan"},{"name":"Maps_To","value":"Turkmenistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041403"}]}}{"C17225":{"preferredName":"Tuvalu","code":"C17225","definitions":[{"definition":"A group of islands consisting of nine coral atolls in the South Pacific Ocean, about one-half of the way from Hawaii to Australia, west of Tokelau and north of Fiji.","type":"DEFINITION","source":"NCI"},{"definition":"An island group consisting of nine coral atolls in the South Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tuvalu","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tuvalu"},{"name":"Maps_To","value":"Tuvalu"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041413"}]}}{"C17228":{"preferredName":"Uganda","code":"C17228","definitions":[{"definition":"A country in Eastern Africa, west of Kenya. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Africa, west of Kenya.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Uganda","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uganda"},{"name":"Maps_To","value":"Uganda"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041573"}]}}{"C17229":{"preferredName":"Ukraine","code":"C17229","definitions":[{"definition":"A country in Eastern Europe, bordering the Black Sea, between Poland and Russia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in eastern Europe, bordering the Black Sea, between Poland and Russia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Ukraine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ukraine"},{"name":"Maps_To","value":"Ukraine"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041580"}]}}{"C17232":{"preferredName":"United Arab Emirates","code":"C17232","definitions":[{"definition":"A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"United Arab Emirates","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"United_Arab_Emirates"},{"name":"Maps_To","value":"United Arab Emirates"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041698"}]}}{"C17233":{"preferredName":"United Kingdom","code":"C17233","definitions":[{"definition":"A country in Western Europe, comprising islands, including the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in western Europe, comprising islands, including England, Scotland, Wales, and the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from CIA World Factbook 2002"}]}],"synonyms":[{"termName":"United Kingdom","termGroup":"PT","termSource":"NCI"},{"termName":"United Kingdom of Great Britain and Northern Ireland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"United_Kingdom"},{"name":"Maps_To","value":"United Kingdom"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041700"}]}}{"C17234":{"preferredName":"United States","code":"C17234","definitions":[{"definition":"A country in North America, between Canada and Mexico, bordering both the North Atlantic Ocean and the North Pacific Ocean.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in North America, bordering both the North Atlantic Ocean and the North Pacific Ocean, between Canada and Mexico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"United States","termGroup":"PT","termSource":"NCI"},{"termName":"United States of America","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"United_States"},{"name":"Maps_To","value":"United States"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0041703"}]}}{"C17244":{"preferredName":"Uruguay","code":"C17244","definitions":[{"definition":"A country in Southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Uruguay","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uruguay"},{"name":"Maps_To","value":"Uruguay"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042113"}]}}{"C17246":{"preferredName":"Uzbekistan","code":"C17246","definitions":[{"definition":"A country in Central Asia, north of Afghanistan. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in central Asia, north of Afghanistan, between Turkmenistan and Kazakhstan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uzbekistan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uzbekistan"},{"name":"Maps_To","value":"Uzbekistan"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042177"}]}}{"C17247":{"preferredName":"Vanuatu","code":"C17247","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about three-quarters of the way from Hawaii to Australia.","type":"DEFINITION","source":"NCI"},{"definition":"A group of islands in the South Pacific Ocean, about three-quarters of the way from Hawaii to Australia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Vanuatu","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vanuatu"},{"name":"Maps_To","value":"Vanuatu"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042321"}]}}{"C17250":{"preferredName":"Venezuela, Bolivarian Republic of","code":"C17250","definitions":[{"definition":"A country in Northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Venezuela, Bolivarian Republic of","termGroup":"PT","termSource":"NCI"},{"termName":"Venezuela","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Venezuela"},{"name":"Maps_To","value":"Venezuela"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042469"}]}}{"C17252":{"preferredName":"Viet Nam","code":"C17252","definitions":[{"definition":"A country in Southeastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, alongside China, Laos, and Cambodia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southeastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, alongside China, Laos, and Cambodia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Viet Nam","termGroup":"PT","termSource":"NCI"},{"termName":"Vietnam","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vietnam"},{"name":"Maps_To","value":"Vietnam"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042658"}]}}{"C17653":{"preferredName":"Virgin Islands, British","code":"C17653","definitions":[{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of the US Virgin Islands.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Virgin Islands, British","termGroup":"PT","termSource":"NCI"},{"termName":"British Virgin Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"British_Virgin_Islands"},{"name":"Maps_To","value":"Virgin Islands, British"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0205999"}]}}{"C17255":{"preferredName":"Virgin Islands, U.S.","code":"C17255","definitions":[{"definition":"A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico and west of the British Virgin Islands.","type":"DEFINITION","source":"NCI"},{"definition":"Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Virgin Islands, U.S.","termGroup":"PT","termSource":"NCI"},{"termName":"United States Virgin Islands","termGroup":"SY","termSource":"NCI"},{"termName":"Virgin Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"United_States_Virgin_Islands"},{"name":"Maps_To","value":"Virgin Islands, U.S."},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0042752"}]}}{"C17259":{"preferredName":"Wallis and Futuna","code":"C17259","definitions":[{"definition":"A group of islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand, northeast of Fiji and west of American Samoa.","type":"DEFINITION","source":"NCI"},{"definition":"Islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Wallis and Futuna","termGroup":"PT","termSource":"NCI"},{"termName":"Wallis and Futuna Islands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Wallis_and_Futuna_Islands"},{"name":"Maps_To","value":"Wallis and Futuna"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043021"}]}}{"C20113":{"preferredName":"Western Sahara","code":"C20113","definitions":[{"definition":"A country in Northern Africa, bordering the North Atlantic Ocean, between Mauritania and Morocco. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in northern Africa, bordering the North Atlantic Ocean, between Mauritania and Morocco.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]}],"synonyms":[{"termName":"Western Sahara","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Western_Sahara"},{"name":"Maps_To","value":"Western Sahara"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C1520135"}]}}{"C17264":{"preferredName":"Yemen","code":"C17264","definitions":[{"definition":"A country in the Middle East, bordering the Arabian Sea, Gulf of Aden, and Red Sea, between Oman and Saudi Arabia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CIA World Factbook 2002"}]},{"definition":"A country in the Middle East, bordering the Arabian Sea, Gulf of Aden, and Red Sea, between Oman and Saudi Arabia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Yemen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yemen"},{"name":"Maps_To","value":"Yemen"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043402"}]}}{"C17267":{"preferredName":"Zambia","code":"C17267","definitions":[{"definition":"A country in Southern Africa, east of Angola. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, east of Angola and north of Zimbabwe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zambia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Zambia"},{"name":"Maps_To","value":"Zambia"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043445"}]}}{"C17268":{"preferredName":"Zimbabwe","code":"C17268","definitions":[{"definition":"A country in Southern Africa, between South Africa and Zambia. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A country in southern Africa, between South Africa and Zambia, west of Mozambique.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zimbabwe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Zimbabwe"},{"name":"Maps_To","value":"Zimbabwe"},{"name":"Semantic_Type","value":"Geographic Area"},{"name":"UMLS_CUI","value":"C0043476"}]}}{"C17459":{"preferredName":"Hispanic or Latino","code":"C17459","definitions":[{"definition":"A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Includes individuals of Mexican, Puerto Rican, Salvadoran, Cuban, Dominican, Guatemalan, and other Central or South American or Spanish culture or origin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Hispanic or Latino","termGroup":"PT","termSource":"NCI"},{"termName":"Hispanic","termGroup":"SY","termSource":"NCI"},{"termName":"Hispanic Populations","termGroup":"SY","termSource":"NCI"},{"termName":"Hispanics or Latinos","termGroup":"SY","termSource":"NCI"},{"termName":"Latino Population","termGroup":"SY","termSource":"NCI"},{"termName":"Spanish Origin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Hispanic"},{"name":"Maps_To","value":"hispanic or latino"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0086409"}]}}{"C41222":{"preferredName":"Not Hispanic or Latino","code":"C41222","definitions":[{"definition":"A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.","type":"DEFINITION","source":"NCI"},{"definition":"A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Not Hispanic or Latino","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Hispanic","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Hispanic or Latino","termGroup":"SY","termSource":"NCI"},{"termName":"Not Hispanic/Spanish origin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Not_Hispanic_or_Latino"},{"name":"Maps_To","value":"not hispanic or latino"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C1518424"}]}}{"C16576":{"preferredName":"Female","code":"C16576","definitions":[{"definition":"A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.","type":"DEFINITION","source":"NCI"},{"definition":"A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Female","termGroup":"PT","termSource":"NCI"},{"termName":"F","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Female"},{"name":"Maps_To","value":"female"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0015780"}]}}{"C20197":{"preferredName":"Male","code":"C20197","definitions":[{"definition":"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.","type":"DEFINITION","source":"NCI"},{"definition":"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Male","termGroup":"PT","termSource":"NCI"},{"termName":"Human, Male","termGroup":"SY","termSource":"NCI"},{"termName":"M","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Male"},{"name":"Maps_To","value":"male"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0086582"}]}}{"C38046":{"preferredName":"Unspecified","code":"C38046","definitions":[{"definition":"Not stated explicitly or in detail.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Not stated explicitly or in detail.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unspecified","termGroup":"PT","termSource":"NCI"},{"termName":"Not Assigned","termGroup":"SY","termSource":"NCI"},{"termName":"Not Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Unspecified"},{"name":"Maps_To","value":"Grade Not Assigned"},{"name":"Maps_To","value":"unspecified"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205370"}]}}{"C41261":{"preferredName":"White","code":"C41261","definitions":[{"definition":"Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of Europe, including for example, English, German, Irish, Italian, Polish, and Scottish.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"White","termGroup":"PT","termSource":"NCI"},{"termName":"Caucasian","termGroup":"SY","termSource":"NCI"},{"termName":"Caucasians","termGroup":"SY","termSource":"NCI"},{"termName":"Caucasoid","termGroup":"SY","termSource":"NCI"},{"termName":"Occidental","termGroup":"SY","termSource":"NCI"},{"termName":"Whites","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"White"},{"name":"Maps_To","value":"white"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0043157"}]}}{"C41259":{"preferredName":"American Indian or Alaska Native","code":"C41259","definitions":[{"definition":"A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of North, Central, and South America, including, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Marrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, and Maya.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"American Indian or Alaska Native","termGroup":"PT","termSource":"NCI"},{"termName":"First Nations","termGroup":"SY","termSource":"NCI"},{"termName":"Native American","termGroup":"SY","termSource":"NCI"},{"termName":"Native Americans","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"American_Indian_or_Alaska_Native"},{"name":"Maps_To","value":"american indian or alaska native"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0282204"}]}}{"C16352":{"preferredName":"Black or African American","code":"C16352","definitions":[{"definition":"A person having origins in any of the black racial groups of Africa. Terms such as \"Haitian\" or \"Negro\" can be used in addition to \"Black or African American.\" (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the Black racial groups of Africa, including, for example, African American, Jamaican, Haitian, Nigerian, Ethiopian. and Somali.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Black or African American","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"African_American"},{"name":"Maps_To","value":"black or african american"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0085756"}]}}{"C41260":{"preferredName":"Asian","code":"C41260","definitions":[{"definition":"A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of Central or East Asia, Southeast Asia, or South Asia including, for example, Chinese, Asian Indian, Filipino, Vietnamese, Korean, and Japanese.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Asian","termGroup":"PT","termSource":"NCI"},{"termName":"Asian Ancestry","termGroup":"SY","termSource":"NCI"},{"termName":"Asians","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Asian"},{"name":"Maps_To","value":"asian"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0078988"}]}}{"C41219":{"preferredName":"Native Hawaiian or Other Pacific Islander","code":"C41219","definitions":[{"definition":"Denotes a person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. The term covers particularly people who identify themselves as part-Hawaiian, Native Hawaiian, Guamanian or Chamorro, Carolinian, Samoan, Chuu. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Individuals with origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands, including, for example, Native Hawaiian, Samoan, Chamorro, Tongan, Fijian, and Marshallese.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"OMB"}]}],"synonyms":[{"termName":"Native Hawaiian or Other Pacific Islander","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Native_Hawaiian_or_Other_Pacific_Islander"},{"name":"Maps_To","value":"native hawaiian or other pacific islander"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C1513907"}]}}{"C17649":{"preferredName":"Other","code":"C17649","definitions":[{"definition":"A proper value is applicable but not known.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Different than the one(s) previously specified or mentioned.","type":"DEFINITION","source":"NCI"},{"definition":"Different than the one(s) previously specified or mentioned. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Different than the one(s) previously specified or mentioned. (NCI)","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Other (COT/POT/OM)","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"eCTD"}]}],"synonyms":[{"termName":"Other","termGroup":"PT","termSource":"NCI"},{"termName":"Other or Miscellaneous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Device Problem Code (Appendix B)"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Other"},{"name":"Maps_To","value":"other"},{"name":"Maps_To","value":"Other"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205394"}]}}{"C37987":{"preferredName":"Alive","code":"C37987","definitions":[{"definition":"Living; showing characteristics of life.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Showing characteristics of life; displaying signs of life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alive","termGroup":"PT","termSource":"NCI"},{"termName":"Living","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Life"},{"name":"Maps_To","value":"Alive"},{"name":"Maps_To","value":"alive"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0376558"}]}}{"C28554":{"preferredName":"Dead","code":"C28554","definitions":[{"definition":"A cessation of life that cannot be attributed to a CTCAE term associated with Grade 5.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Dead.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The absence of life or state of being dead. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cessation of life.","type":"DEFINITION","source":"NCI"},{"definition":"The cessation of life.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The cessation of life.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Dead","termGroup":"PT","termSource":"NCI"},{"termName":"Deceased","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Death"},{"name":"Maps_To","value":"dead"},{"name":"Maps_To","value":"Dead"},{"name":"Maps_To","value":"Death"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0011065"},{"name":"xRef","value":"IMDRF:F02"}]}}{"C48699":{"preferredName":"M0 TNM Finding","code":"C48699","definitions":[{"definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M0 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M0","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Cancer Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M0_Stage_Finding"},{"name":"Maps_To","value":"M0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445034"}]}}{"C48700":{"preferredName":"M1 TNM Finding","code":"C48700","definitions":[{"definition":"A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1_Stage_Finding"},{"name":"Maps_To","value":"M1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441971"}]}}{"C48701":{"preferredName":"M1a TNM Finding","code":"C48701","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1a TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node); for prostate cancer it refers to metastasis to non-regional lymph node(s); for bone cancer it refers to metastasis to the lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1a","termGroup":"SY","termSource":"NCI"},{"termName":"M1a Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1a Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1a_Stage_Finding"},{"name":"Maps_To","value":"M1a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445036"}]}}{"C48702":{"preferredName":"M1b TNM Finding","code":"C48702","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1b","termGroup":"SY","termSource":"NCI"},{"termName":"M1b Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1b Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1b_Stage_Finding"},{"name":"Maps_To","value":"M1b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445064"}]}}{"C48703":{"preferredName":"M1c TNM Finding","code":"C48703","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to metastasis to anatomic site(s) other than bone, with or without bone disease; for retinoblastoma it refers to central nervous system metastasis; for melanoma of the uvea it refers to distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1c","termGroup":"SY","termSource":"NCI"},{"termName":"M1c Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1c Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"M1c_Stage_Finding"},{"name":"Maps_To","value":"M1c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445037"}]}}{"C48704":{"preferredName":"MX TNM Finding","code":"C48704","definitions":[{"definition":"A distant metastasis TNM finding indicating that the status of distant metastasis cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MX TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"MX","termGroup":"SY","termSource":"NCI"},{"termName":"MX Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"MX Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MX_Stage_Finding"},{"name":"Maps_To","value":"MX"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445039"}]}}{"C95956":{"preferredName":"cM0 (i+) TNM Finding","code":"C95956","definitions":[{"definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis clinically or by radiologic studies, but there are small numbers of cells detected by special studies in the blood and bone marrow, or there is tiny metastasis (no larger than 0.2 mm) detected in nonregional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cM0 (i+) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"cM0 (i+) Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"cM0 (i+)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272458"}]}}{"C48705":{"preferredName":"N0 TNM Finding","code":"C48705","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N0 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0","termGroup":"SY","termSource":"NCI"},{"termName":"N0 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N0 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N0 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N0_Stage_Finding"},{"name":"Maps_To","value":"N0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441959"}]}}{"C95922":{"preferredName":"pN0 (i+) TNM Finding","code":"C95922","definitions":[{"definition":"A regional lymph node TNM finding indicating that there are malignant cells in regional lymph node(s) no greater than 0.2 mm and are detected by hematoxylin and eosin stain or immunohistochemistry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (i+) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (i+)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (i+) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (i+)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272441"}]}}{"C95921":{"preferredName":"pN0 (i-) TNM Finding","code":"C95921","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically, and immunohistochemistry is negative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (i-) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (i-)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (i-) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (i-)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272440"}]}}{"C95925":{"preferredName":"pN0 (mol+) TNM Finding","code":"C95925","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and by immunohistochemistry, but the molecular analysis (RT-PCR) is positive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (mol+) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (mol+)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (mol+) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (mol+)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272443"}]}}{"C95923":{"preferredName":"pN0 (mol-) TNM Finding","code":"C95923","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and molecular analysis (RT-PCR) is negative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 (mol-) TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N0 (mol-)","termGroup":"SY","termSource":"NCI"},{"termName":"N0 (mol-) TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0 (mol-)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272442"}]}}{"C48706":{"preferredName":"N1 TNM Finding","code":"C48706","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1","termGroup":"SY","termSource":"NCI"},{"termName":"N1 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1_Stage_Finding"},{"name":"Maps_To","value":"N1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441962"}]}}{"C48707":{"preferredName":"N1a TNM Finding","code":"C48707","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastasis in 1 to 3 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in one regional lymph node.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1a","termGroup":"SY","termSource":"NCI"},{"termName":"N1a Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1a Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1a Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1a_Stage_Finding"},{"name":"Maps_To","value":"N1a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0456906"}]}}{"C48708":{"preferredName":"N1b TNM Finding","code":"C48708","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for cutaneous melanoma it refers to macrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in 2-3 regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1b","termGroup":"SY","termSource":"NCI"},{"termName":"N1b Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1b Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1b Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1b_Stage_Finding"},{"name":"Maps_To","value":"N1b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0456908"}]}}{"C95929":{"preferredName":"N1bI Stage Finding","code":"C95929","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is metastasis to 1-3 nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bI Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bI"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272446"}]}}{"C95935":{"preferredName":"N1bII Stage Finding","code":"C95935","definitions":[{"definition":"A regional lymph node TNM finding indicating that there is metastasis to four or more nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bII Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bII"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272449"}]}}{"C95936":{"preferredName":"N1bIII Stage Finding","code":"C95936","definitions":[{"definition":"A regional lymph node TNM finding indicating that the tumor extends beyond the lymph node capsule and is less than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bIII Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bIII"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272450"}]}}{"C95937":{"preferredName":"N1bIV Stage Finding","code":"C95937","definitions":[{"definition":"A regional lymph node TNM finding indicating that the metastases to the lymph nodes are more than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1bIV Stage Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1bIV"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272451"}]}}{"C48709":{"preferredName":"N1c TNM Finding","code":"C48709","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 1 to 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for colorectal cancer it refers to tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1c","termGroup":"SY","termSource":"NCI"},{"termName":"N1c Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1c Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N1c Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N1c_Stage_Finding"},{"name":"Maps_To","value":"N1c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709107"}]}}{"C95955":{"preferredName":"N1mi TNM Finding","code":"C95955","definitions":[{"definition":"A regional lymph node TNM finding indicating the presence of micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N1mi TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N1mi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1mi"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869928"}]}}{"C48786":{"preferredName":"N2 TNM Finding","code":"C48786","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes. The definition of N2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4-9 axillary lymph nodes; for cutaneous melanoma it refers to metastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4 or more regional lymph nodes; and for bladder cancer it refers to metastases in multiple regional lymph nodes in the true pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2","termGroup":"SY","termSource":"NCI"},{"termName":"N2 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2_Stage_Finding"},{"name":"Maps_To","value":"N2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441960"}]}}{"C48711":{"preferredName":"N2a TNM Finding","code":"C48711","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4-6 regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2a","termGroup":"SY","termSource":"NCI"},{"termName":"N2a Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2a Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2a Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2a_Stage_Finding"},{"name":"Maps_To","value":"N2a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445079"}]}}{"C48712":{"preferredName":"N2b TNM Finding","code":"C48712","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases only in clinically detected ipsilateral internal mammary nodes and in the absence of clinically evident level I, II axillary lymph node metastases; for cutaneous melanoma it refers to macrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in seven or more regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2b","termGroup":"SY","termSource":"NCI"},{"termName":"N2b Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2b Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2b Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2b_Stage_Finding"},{"name":"Maps_To","value":"N2b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445080"}]}}{"C48713":{"preferredName":"N2c TNM Finding","code":"C48713","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2c TNM finding depends on the specific type of cancer that it refers to; for example, for cutaneous melanoma it refers to intralymphatic metastases (in transit or satellite metastases) without metastatic nodes; for lip and oral cavity cancer it refers to metastases in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N2c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N2c","termGroup":"SY","termSource":"NCI"},{"termName":"N2c Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2c Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N2c Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N2c_Stage_Finding"},{"name":"Maps_To","value":"N2c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833426"}]}}{"C48714":{"preferredName":"N3 TNM Finding","code":"C48714","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes; for cutaneous melanoma it refers to metastases in 4 or more regional lymph nodes; for gastric cancer it refers to metastases in 7 or more regional lymph nodes; and for bladder cancer it refers to metastases in common iliac lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3","termGroup":"SY","termSource":"NCI"},{"termName":"N3 Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3 Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3 Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3_Stage_Finding"},{"name":"Maps_To","value":"N3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0441961"}]}}{"C48715":{"preferredName":"N3a TNM Finding","code":"C48715","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm) or metastases to the infraclavicular (level III axillary) lymph nodes; for gastric cancer it refers to metastases in 7-15 regional lymph nodes; for nasopharyngeal cancer it refers to metastases to one or more lymph nodes greater than 6 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3a","termGroup":"SY","termSource":"NCI"},{"termName":"N3a Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3a Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3a Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3a_Stage_Finding"},{"name":"Maps_To","value":"N3a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3831805"}]}}{"C48716":{"preferredName":"N3b TNM Finding","code":"C48716","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in clinically detected ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes, or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for gastric cancer it refers to metastases in sixteen or more regional lymph nodes; for nasopharyngeal cancer it refers to extension to the supraclavicular fossa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3b","termGroup":"SY","termSource":"NCI"},{"termName":"N3b Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3b Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3b Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3b_Stage_Finding"},{"name":"Maps_To","value":"N3b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833393"}]}}{"C48717":{"preferredName":"N3c TNM Finding","code":"C48717","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in ipsilateral supraclavicular lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N3c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N3c","termGroup":"SY","termSource":"NCI"},{"termName":"N3c Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3c Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"N3c Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N3c_Stage_Finding"},{"name":"Maps_To","value":"N3c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709110"}]}}{"C96026":{"preferredName":"N4 TNM Finding","code":"C96026","definitions":[{"definition":"A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N4 TNM finding depends on the specific type of cancer that it refers to; for example, for ocular adnexal lymphoma it refers to metastases to central lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N4 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"N4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0332382"}]}}{"C48718":{"preferredName":"NX TNM Finding","code":"C48718","definitions":[{"definition":"A regional lymph node TNM finding indicating that the status of regional lymph nodes cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NX TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"NX","termGroup":"SY","termSource":"NCI"},{"termName":"NX Lymph Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"NX Node Finding","termGroup":"SY","termSource":"NCI"},{"termName":"NX Regional Lymph Nodes Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NX_Stage_Finding"},{"name":"Maps_To","value":"NX"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0445085"}]}}{"C28051":{"preferredName":"Stage 0","code":"C28051","definitions":[{"definition":"Cancer confined to the epithelium without invasion of the basement membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0"},{"name":"Maps_To","value":"Stage 0"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441763"}]}}{"C27964":{"preferredName":"Stage 0a","code":"C27964","definitions":[{"definition":"Cancer confined to the epithelium with formation of papillary structures without invasion of the basement membrane or noninvasive localized squamous cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0a","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0a"},{"name":"Maps_To","value":"Stage 0a"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441764"}]}}{"C27965":{"preferredName":"Stage 0is","code":"C27965","definitions":[{"definition":"Cancer confined to the epithelium with formation of a flat surface without invasion of the basement membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0is","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0is"},{"name":"Maps_To","value":"Stage 0is"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441765"}]}}{"C27966":{"preferredName":"Stage I","code":"C27966","definitions":[{"definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage I","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_I"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441766"}]}}{"C27975":{"preferredName":"Stage IA","code":"C27975","definitions":[{"definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IA is defined as follows: T1, N0, M0. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IA is defined as follows: T1, N0, M0, G1, GX. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 8th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IA"},{"name":"Maps_To","value":"Stage IA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456595"}]}}{"C27983":{"preferredName":"Stage IA1","code":"C27983","definitions":[{"definition":"A stage term referring to invasive cervical and lung cancer.  For cervical cancer, it includes: T1a1, N0, M0.  T1a1: Tumor with stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IA1"},{"name":"Maps_To","value":"Stage IA1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0458828"}]}}{"C27984":{"preferredName":"Stage IA2","code":"C27984","definitions":[{"definition":"A stage term referring to invasive cervical cancer and invasive lung cancer. For cervical cancer, it includes: T1a2, N0, M0.  T1a2: Tumor with stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IA2"},{"name":"Maps_To","value":"Stage IA2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0458829"}]}}{"C27976":{"preferredName":"Stage IB","code":"C27976","definitions":[{"definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IB is defined as follows: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IB is defined as follows: (T2, N0, M0, G1, G2, GX); (T3, N0, M0, G1, G2, GX). T2: Tumor more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. G2: Moderately differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IB"},{"name":"Maps_To","value":"Stage IB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456597"}]}}{"C28052":{"preferredName":"Stage IB1","code":"C28052","definitions":[{"definition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0. (partially adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IB1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IB1"},{"name":"Maps_To","value":"Stage IB1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C1519505"}]}}{"C28053":{"preferredName":"Stage IB2","code":"C28053","definitions":[{"definition":"A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b2, N0, M0.  (partially adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IB2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IB2"},{"name":"Maps_To","value":"Stage IB2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C1519506"}]}}{"C27981":{"preferredName":"Stage IC","code":"C27981","definitions":[{"definition":"A cancer stage generally indicating the local invasion of tissues by cancer at the primary site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IC"},{"name":"Maps_To","value":"Stage IC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456607"}]}}{"C28054":{"preferredName":"Stage II","code":"C28054","definitions":[{"definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage II","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_II"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441767"}]}}{"C27967":{"preferredName":"Stage IIA","code":"C27967","definitions":[{"definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIA is defined as follows: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIA is defined as follows: T1, N0, M0, G3, G4. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIA"},{"name":"Maps_To","value":"Stage IIA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441768"}]}}{"C95177":{"preferredName":"Stage IIA1","code":"C95177","definitions":[{"definition":"A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures 4.0 cm or less in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986966"}]}}{"C95178":{"preferredName":"Stage IIA2","code":"C95178","definitions":[{"definition":"A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures more than 4.0 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986967"}]}}{"C27968":{"preferredName":"Stage IIB","code":"C27968","definitions":[{"definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIB is defined as follows: (T2, N1, MO); (T3, NO, MO). T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIB is defined as follows: T2, N0, M0, G3, G4. T2: Tumor more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIB"},{"name":"Maps_To","value":"Stage IIB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441769"}]}}{"C27969":{"preferredName":"Stage IIC","code":"C27969","definitions":[{"definition":"A cancer stage generally indicating the invasion of adjacent structures by cancer without distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIC"},{"name":"Maps_To","value":"Stage IIC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441770"}]}}{"C27970":{"preferredName":"Stage III","code":"C27970","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage III","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_III"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441771"}]}}{"C27977":{"preferredName":"Stage IIIA","code":"C27977","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIIA"},{"name":"Maps_To","value":"Stage IIIA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456598"}]}}{"C27978":{"preferredName":"Stage IIIB","code":"C27978","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIIB"},{"name":"Maps_To","value":"Stage IIIB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456599"}]}}{"C27982":{"preferredName":"Stage IIIC","code":"C27982","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIC depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIC is defined as follows: Any T, N3, M0. N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for appendix carcinoma, stage IIIC is defined as follows: Any T, N2, M0. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IIIC"},{"name":"Maps_To","value":"Stage IIIC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456608"}]}}{"C95179":{"preferredName":"Stage IIIC1","code":"C95179","definitions":[{"definition":"A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades the stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue. There is regional lymph node metastasis to the pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIC1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986968"}]}}{"C95180":{"preferredName":"Stage IIIC2","code":"C95180","definitions":[{"definition":"A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue.  There is regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIC2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C2986969"}]}}{"C28285":{"preferredName":"Stage IS","code":"C28285","definitions":[{"definition":"Testicular cancer found in the testicle, spermatic cord and scrotum, associated with slightly elevated levels of all tumor markers or moderately/highly elevated levels of one or more tumor markers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IS","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 1S","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_Is"},{"name":"Maps_To","value":"Stage IS"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0730490"}]}}{"C27971":{"preferredName":"Stage IV","code":"C27971","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IV","termGroup":"PT","termSource":"NCI"},{"termName":"Stage 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stage_IV"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441772"}]}}{"C27979":{"preferredName":"Stage IVA","code":"C27979","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVA depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVA is defined as follows: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Distant metastasis to lung; for vaginal cancer, stage IVA is defined as follows: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IVA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IVA"},{"name":"Maps_To","value":"Stage IVA"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456600"}]}}{"C27980":{"preferredName":"Stage IVB","code":"C27980","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVB depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVB is defined as follows: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis to other distant sites; for vaginal cancer, stage IVB is defined as follows: Any T, Any N, M1. M1: Distant metastasis. (partially adapted from AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IVB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IVB"},{"name":"Maps_To","value":"Stage IVB"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0456601"}]}}{"C28055":{"preferredName":"Stage IVC","code":"C28055","definitions":[{"definition":"Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVC depends on the particular type of cancer that it refers to; for example, for head and neck carcinomas (lip and oral cavity carcinoma, laryngeal carcinoma, nasal cavity and paranasal sinus carcinoma, pharynx carcinoma, thyroid gland carcinoma, and major salivary gland carcinoma) and head and neck mucosal melanoma, stage IVC is defined as follows: any T, any N, M1; for appendix carcinoma, stage IVC is defined as follows: any T, any N, M1b, any G. M1: Distant metastasis.  M1b: Nonperitoneal metastasis.  G: Grade (cellular differentiation).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IVC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_IVC"},{"name":"Maps_To","value":"Stage IVC"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0441774"}]}}{"C48738":{"preferredName":"pTis TNM Finding","code":"C48738","definitions":[{"definition":"A term that refers to a TNM finding of a primary tumor microscopically defined as carcinoma in situ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pTis TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Tis","termGroup":"SY","termSource":"NCI"},{"termName":"Tis Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Tis TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Tis Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tis_Stage_Finding"},{"name":"Maps_To","value":"Stage Tis"},{"name":"Maps_To","value":"Tis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475413"}]}}{"C95957":{"preferredName":"Stage X","code":"C95957","definitions":[{"definition":"A stage term that is applied to patients who have not been evaluated, but are presumed to have cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage X","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage X"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272459"}]}}{"C136485":{"preferredName":"Stage IA3","code":"C136485","definitions":[{"definition":"A stage term referring to invasive lung cancer. It includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IA3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA3"},{"name":"NCI_META_CUI","value":"CL523788"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C48719":{"preferredName":"T0 TNM Finding","code":"C48719","definitions":[{"definition":"A primary tumor TNM finding indicating that there is no evidence of primary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T0 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T0","termGroup":"SY","termSource":"NCI"},{"termName":"T0 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T0 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T0_Stage_Finding"},{"name":"Maps_To","value":"T0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475371"}]}}{"C48720":{"preferredName":"T1 TNM Finding","code":"C48720","definitions":[{"definition":"A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1","termGroup":"SY","termSource":"NCI"},{"termName":"T1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1_Stage_Finding"},{"name":"Maps_To","value":"T1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475372"}]}}{"C48721":{"preferredName":"T1a TNM Finding","code":"C48721","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.1cm, but not more than 0.5 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is 4 cm or less in greatest dimension; and for thyroid cancer it refers to a primary tumor that is 1 cm or less in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1a","termGroup":"SY","termSource":"NCI"},{"termName":"T1a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1a_Stage_Finding"},{"name":"Maps_To","value":"T1a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475383"}]}}{"C188292":{"preferredName":"T1a1 Stage Finding","code":"C188292","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1a1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion equal or less than 3 mm in depth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1a1 Stage Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1a1","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Cancer Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Primary Tumor Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Stage","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a1 Tumor Stage","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Stage T1a1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1a1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3846406"}]}}{"C188293":{"preferredName":"T1a2 Stage Finding","code":"C188293","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1a2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion of more than 3.0 mm and equal or less than 5.0 mm in depth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1a2 Stage Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1a2","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Cancer Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Primary Tumor Stage Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Stage","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1a2 Tumor Stage","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Stage T1a2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1a2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3811917"}]}}{"C48722":{"preferredName":"T1b TNM Finding","code":"C48722","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is more than 4 cm, but not more than 7 cm in greatest dimension; and for thyroid cancer it refers to a primary tumor that is more than 1 cm but not more than 2 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1b","termGroup":"SY","termSource":"NCI"},{"termName":"T1b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1b_Stage_Finding"},{"name":"Maps_To","value":"T1b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475385"}]}}{"C188294":{"preferredName":"T1b1 TNM Finding","code":"C188294","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1b1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion measuring more than 5 mm in depth and equal or less than 2 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1b1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1b1","termGroup":"SY","termSource":"NCI"},{"termName":"T1b1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1b1 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1b1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3846407"}]}}{"C188295":{"preferredName":"T1b2 TNM Finding","code":"C188295","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1b2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates stromal invasion measuring more than 2 cm and equal or less than 4 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1b2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1b2","termGroup":"SY","termSource":"NCI"},{"termName":"T1b2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1b2 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1b2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3846408"}]}}{"C48723":{"preferredName":"T1c TNM Finding","code":"C48723","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T1c","termGroup":"SY","termSource":"NCI"},{"termName":"T1c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T1c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T1c_Stage_Finding"},{"name":"Maps_To","value":"T1c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3834244"}]}}{"C95805":{"preferredName":"T1mi TNM Finding","code":"C95805","definitions":[{"definition":"A term that refers to a TNM finding of a primary tumor limited to the site of growth and indicates microinvasion only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T1mi TNM Finding","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1mi"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869913"}]}}{"C48724":{"preferredName":"T2 TNM Finding","code":"C48724","definitions":[{"definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2","termGroup":"SY","termSource":"NCI"},{"termName":"T2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2_Stage_Finding"},{"name":"Maps_To","value":"T2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475373"}]}}{"C48725":{"preferredName":"T2a TNM Finding","code":"C48725","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 7 cm but less than or equal to 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the superficial muscularis propria (inner half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is no parametrial invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2a","termGroup":"SY","termSource":"NCI"},{"termName":"T2a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2a Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2a_Stage_Finding"},{"name":"Maps_To","value":"T2a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475387"}]}}{"C188296":{"preferredName":"T2a1 TNM Finding","code":"C188296","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T2a1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates involvement limited to the upper two-thirds of the vagina without parametrial invasion measuring 4.0 cm or less in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2a1 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2a1","termGroup":"SY","termSource":"NCI"},{"termName":"T2a1 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2a1 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2a1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869936"}]}}{"C188297":{"preferredName":"T2a2 TNM Finding","code":"C188297","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T2a2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates involvement limited to the upper two-thirds of the vagina without parametrial invasion measuring more than 4.0 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2a2 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2a2","termGroup":"SY","termSource":"NCI"},{"termName":"T2a2 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2a2 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2a2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869849"}]}}{"C48726":{"preferredName":"T2b TNM Finding","code":"C48726","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2b","termGroup":"SY","termSource":"NCI"},{"termName":"T2b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2b_Stage_Finding"},{"name":"Maps_To","value":"T2b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833471"}]}}{"C48727":{"preferredName":"T2c TNM Finding","code":"C48727","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to a primary tumor that involves both lobes of the prostate gland; for ovarian cancer it refers to a primary tumor that involves one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings; for fallopian tube cancer it refers to a primary tumor with pelvic extension and malignant cells in ascites or peritoneal washings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2c","termGroup":"SY","termSource":"NCI"},{"termName":"T2c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T2c_Stage_Finding"},{"name":"Maps_To","value":"T2c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475389"}]}}{"C148411":{"preferredName":"T2d TNM Finding","code":"C148411","definitions":[{"definition":"A TNM stage finding term that refers to choroidal and ciliary body melanoma or conjunctival melanoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 2 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means caruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T2d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T2d","termGroup":"SY","termSource":"NCI"},{"termName":"T2d Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T2d Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3854130"}]}}{"C48728":{"preferredName":"T3 TNM Finding","code":"C48728","definitions":[{"definition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3","termGroup":"SY","termSource":"NCI"},{"termName":"T3 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3_Stage_Finding"},{"name":"Maps_To","value":"Minimal (T3)"},{"name":"Maps_To","value":"T3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475374"}]}}{"C48729":{"preferredName":"T3a TNM Finding","code":"C48729","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the renal vein or its segmental (muscle containing) branches or the tumor invades perirenal and/or renal sinus fat but does not extends beyond Gerota's fascia; for cervical cancer it refers to a primary tumor that involves the lower third of vagina, without extension to pelvic wall; for liver cancer it refers to the presence of multiple tumors measuring more than 5 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3a","termGroup":"SY","termSource":"NCI"},{"termName":"T3a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3a Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3a_Stage_Finding"},{"name":"Maps_To","value":"T3a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475390"}]}}{"C48730":{"preferredName":"T3b TNM Finding","code":"C48730","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava below the diaphragm; for cervical cancer it refers to a primary tumor that extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney; for liver cancer it refers to a single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3b","termGroup":"SY","termSource":"NCI"},{"termName":"T3b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3b_Stage_Finding"},{"name":"Maps_To","value":"T3b"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475391"}]}}{"C48731":{"preferredName":"T3c TNM Finding","code":"C48731","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3c TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava above the diaphragm, or invades the wall of the vena cava; for fallopian tube cancer it refers to a primary tumor with peritoneal metastasis outside the pelvis measuring more than 2 cm in diameter; for melanoma of the conjunctiva it refers to a primary tumor invading the orbit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3c","termGroup":"SY","termSource":"NCI"},{"termName":"T3c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T3c_Stage_Finding"},{"name":"Maps_To","value":"T3c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475394"}]}}{"C148412":{"preferredName":"T3d TNM Finding","code":"C148412","definitions":[{"definition":"A TNM finding term that refers to choroidal and ciliary body melanoma, conjunctival melanoma, or retinoblastoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 3 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. For retinoblastoma it means hyphema and/or massive vitreous hemorrhage (clinical) or full-thickness invasion into the outer third of the sclera and/or invasion into or around emissary channels (pathologic). (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T3d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T3d","termGroup":"SY","termSource":"NCI"},{"termName":"T3d Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T3d Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T3d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3854131"}]}}{"C48732":{"preferredName":"T4 TNM Finding","code":"C48732","definitions":[{"definition":"A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4 TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4","termGroup":"SY","termSource":"NCI"},{"termName":"T4 Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4 Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4_Stage_Finding"},{"name":"Maps_To","value":"T4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475751"}]}}{"C48733":{"preferredName":"T4a TNM Finding","code":"C48733","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4a TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the prostatic stroma, uterus, and vagina; for gastric cancer it refers to a primary tumor that invades the serosa (visceral peritoneum); for colorectal cancer it refers to a primary tumor that penetrates to the surface of the visceral peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4a TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4a","termGroup":"SY","termSource":"NCI"},{"termName":"T4a Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4a Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4a_Stage_Finding"},{"name":"Maps_To","value":"Moderate/Advanced (T4a)"},{"name":"Maps_To","value":"T4a"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475395"}]}}{"C48734":{"preferredName":"T4b TNM Finding","code":"C48734","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4b TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the pelvic wall and abdominal wall; for gastric cancer it refers to a primary tumor that invades adjacent structures; for colorectal cancer it refers to a primary tumor with direct invasion or adherence to other organs or structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4b TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4b","termGroup":"SY","termSource":"NCI"},{"termName":"T4b Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4b Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4b_Stage_Finding"},{"name":"Maps_To","value":"T4b"},{"name":"Maps_To","value":"Very Advanced (T4b)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475396"}]}}{"C48735":{"preferredName":"T4c TNM Finding","code":"C48735","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that extends to the chest wall, not including the pectoralis muscle, and with edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin nodules confined to the same breast; for ocular adnexal lymphoma it refers to a primary tumor that Involves the maxillofacial, ethmoidal, and/or frontal sinuses; for carcinoma of the conjunctiva it refers to a primary tumor that invades adjacent paranasal sinuses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4c TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4c","termGroup":"SY","termSource":"NCI"},{"termName":"T4c Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4c Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4c_Stage_Finding"},{"name":"Maps_To","value":"T4c"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0475397"}]}}{"C48736":{"preferredName":"T4d TNM Finding","code":"C48736","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4d TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that meets the clinical-pathologic criteria of inflammatory carcinoma; for ocular adnexal lymphoma it refers to a primary tumor with intracranial spread; for carcinoma of the conjunctiva it refers to a primary tumor that invades the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4d","termGroup":"SY","termSource":"NCI"},{"termName":"T4d Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4d Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T4d_Stage_Finding"},{"name":"Maps_To","value":"T4d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3833423"}]}}{"C188298":{"preferredName":"T4e TNM Finding","code":"C188298","definitions":[{"definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4e TNM finding depends on the specific type of cancer that it refers: for example, for choroidal and ciliary body melanoma it indicates any tumor size category with extraocular extension more than 5 mm in largest diameter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T4e TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"T4e","termGroup":"SY","termSource":"NCI"},{"termName":"T4e Primary Tumor Finding","termGroup":"SY","termSource":"NCI"},{"termName":"T4e Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T4e"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C5703412"}]}}{"C48737":{"preferredName":"TX TNM Finding","code":"C48737","definitions":[{"definition":"A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TX TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"TX","termGroup":"SY","termSource":"NCI"},{"termName":"TX Primary Tumor Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TX_Stage_Finding"},{"name":"Maps_To","value":"TX"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0332377"}]}}{"C96025":{"preferredName":"pTa TNM Finding","code":"C96025","definitions":[{"definition":"A term that refers to a TNM finding of a primary, non-invasive, papillary cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pTa TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Ta TNM Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ta"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272501"}]}}{"C139414":{"preferredName":"Breast Cancer pTis (DCIS) TNM Finding v8","code":"C139414","definitions":[{"definition":"Breast cancer with a finding of ductal carcinoma in situ. Lobular carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Cancer pTis (DCIS) TNM Finding v8","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Carcinoma pTis (DCIS) TNM Finding v8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tis (DCIS)"},{"name":"NCI_META_CUI","value":"CL526812"},{"name":"Semantic_Type","value":"Finding"}]}}{"C48976":{"preferredName":"Breast Cancer pTis (LCIS) TNM Finding v6 and v7","code":"C48976","definitions":[{"definition":"Breast cancer with a finding of lobular carcinoma in situ. (from AJCC 6th and 7th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Cancer pTis (LCIS) TNM Finding v6 and v7","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Cancer pTis (LCIS) TNM Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer pTis (LCIS) TNM Finding v6","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer pTis (LCIS) TNM Finding v7","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Breast Cancer v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Breast Carcinoma v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Cancer of Breast v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Cancer of the Breast v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Carcinoma of Breast v6","termGroup":"SY","termSource":"NCI"},{"termName":"pTis (LCIS) Carcinoma of the Breast v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Breast_Cancer_pTis_LCIS_TNM_Finding"},{"name":"Maps_To","value":"Tis (LCIS)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1707040"}]}}{"C47858":{"preferredName":"Breast Paget Disease without Invasive Carcinoma","code":"C47858","definitions":[{"definition":"Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease without Invasive Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Paget Disease of the Breast without Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast without Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tis (Paget)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_of_the_Breast_without_Invasive_Carcinoma"},{"name":"Maps_To","value":"Tis (Paget's)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709447"}]}}{"C188299":{"preferredName":"Stage M2","code":"C188299","definitions":[{"definition":"A stage term that refers to central nervous system embryonal tumor or ependymoma in which visible metastasis is present in the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage M2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M2"},{"name":"NCI_META_CUI","value":"CL1794622"},{"name":"Semantic_Type","value":"Classification"}]}}{"C188301":{"preferredName":"M1d TNM Finding","code":"C188301","definitions":[{"definition":"A TNM finding indicating the spread of cancer to distant anatomic sites. The definition of M1d TNM finding depends on the specific type of cancer to which it refers: for example, for cutaneous melanoma it indicates distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease. LDH level not recorded or unspecified.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"M1d TNM Finding","termGroup":"PT","termSource":"NCI"},{"termName":"M1d","termGroup":"SY","termSource":"NCI"},{"termName":"M1d Distant Metastasis Finding","termGroup":"SY","termSource":"NCI"},{"termName":"M1d Metastasis Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M1d"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3869910"}]}}{"C137676":{"preferredName":"Stage IIID","code":"C137676","definitions":[{"definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIID depends on the particular type of cancer that it refers to; for example, for cutaneous melanoma, stage IIID is defined as follows: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (partially adapted from AJCC 8th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIID","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIID"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3846374"}]}}{"C139980":{"preferredName":"Stage IIIA1","code":"C139980","definitions":[{"definition":"A stage term that applies to ovarian and fallopian tube carcinoma and indicates that the tumor is limited to ovaries (one or both) or fallopian tube(s) or the tumor involves one or both ovaries or fallopian tubes with pelvic extension below pelvic brim. There are positive retroperitoneal lymph nodes only (histologically confirmed) and no distant metastasis. (adapted from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1"},{"name":"NCI_META_CUI","value":"CL538160"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C139981":{"preferredName":"Stage IIIA2","code":"C139981","definitions":[{"definition":"A stage term that applies to ovarian and fallopian tube carcinoma and indicates the presence of microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. There is no distant metastasis. (adapted from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage IIIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA2"},{"name":"NCI_META_CUI","value":"CL538159"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C139415":{"preferredName":"Breast Cancer pTis (Paget) TNM Finding v8","code":"C139415","definitions":[{"definition":"Paget disease of the nipple not associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted. (from AJCC 8th Ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Cancer pTis (Paget) TNM Finding v8","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Carcinoma pTis (Paget) TNM Finding v8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tis (Paget's)"},{"name":"NCI_META_CUI","value":"CL526811"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25509":{"preferredName":"First","code":"C25509","definitions":[{"definition":"Preceding all others in time or space or degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First","termGroup":"PT","termSource":"NCI"},{"termName":"Initial","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First"},{"name":"Maps_To","value":"1st"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205435"}]}}{"C25666":{"preferredName":"Second","code":"C25666","definitions":[{"definition":"Coming next after the first in position in space or time or degree or magnitude.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Second","termGroup":"PT","termSource":"NCI"},{"termName":"Second Ordinal","termGroup":"SY","termSource":"NCI"},{"termName":"Secondary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Second"},{"name":"Maps_To","value":"2nd"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205436"}]}}{"C25260":{"preferredName":"Third","code":"C25260","definitions":[{"definition":"Following the second position in an ordering or series; coming next after the second and just before the fourth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Third","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Third"},{"name":"Maps_To","value":"3rd"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205437"}]}}{"C191343":{"preferredName":"AJCC Cancer Staging Manual 4th Edition","code":"C191343","definitions":[{"definition":"AJCC Manual for Staging of Cancer 4th Edition (AJCC V4) (Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. AJCC manual for staging of cancer (4th ed). Philadelphia, PA: J.B. Lippincott; 1992). No part of the AJCC V4 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright J.B. Lippincott Company 1992. All rights reserved.","type":"DEFINITION","source":"NCI"},{"definition":"AJCC Manual for Staging of Cancer 4th Edition (AJCC V4) (Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. AJCC manual for staging of cancer (4th ed). Philadelphia, PA: J.B. Lippincott; 1992). No part of the AJCC V4 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright J.B. Lippincott Company 1992. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 4th Edition","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"4th"},{"name":"NCI_META_CUI","value":"CL1904801"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C191344":{"preferredName":"AJCC Cancer Staging Manual 5th Edition","code":"C191344","definitions":[{"definition":"AJCC Cancer Staging Manual 5th Edition (AJCC V5) (Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbo JW, editors. AJCC cancer staging manual (5th ed). Philadelphia, PA: Lippincott-Raven; 1997). No part of the AJCC V5 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Lippincott-Raven 1997. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"AJCC Cancer Staging Manual 5th Edition (AJCC V5) (Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbo JW, editors. AJCC cancer staging manual (5th ed). Philadelphia, PA: Lippincott-Raven; 1997). No part of the AJCC V5 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Lippincott-Raven 1997. All rights reserved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 5th Edition","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5th"},{"name":"NCI_META_CUI","value":"CL1904800"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C186612":{"preferredName":"AJCC Cancer Staging Manual 6th Edition","code":"C186612","definitions":[{"definition":"AJCC Cancer Staging Manual 6th Edition (AJCC V6) (Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. AJCC cancer staging manual (6th ed). New York, NY: Springer; 2002). No part of the AJCC V6 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Springer 2002. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The 6th edition of the criteria developed by the American Joint Committee on Cancer (AJCC) and used for the classification and staging of neoplastic diseases. It was published in 2002 and was in effect 2003-2009.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 6th Edition","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6th"},{"name":"NCI_META_CUI","value":"CL1778764"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C125755":{"preferredName":"AJCC Cancer Staging Manual 7th Edition","code":"C125755","definitions":[{"definition":"AJCC TNM Staging System 7th Edition (AJCC V7) (Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010). No part of the AJCC V7 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright Springer 2010. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The 7th edition of the criteria developed by the American Joint Committee on Cancer (AJCC) in 2010, used for the classification and staging of neoplastic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 7th Edition","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC v7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"7th"},{"name":"NCI_META_CUI","value":"CL504410"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146985":{"preferredName":"AJCC Cancer Staging Manual 8th Edition","code":"C146985","definitions":[{"definition":"AJCC TNM Staging System 8th Edition (AJCC V8) (Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017. AJCC Cancer Staging Manual, Eighth Edition. Copyright 2017 American College of Surgeons. All rights reserved). No part of the AJCC V8 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Springer and payment of any applicable fees. Copyright American College of Surgeons 2017. All rights reserved.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The 8th edition of the criteria developed by the American Joint Committee on Cancer (AJCC), implemented in 2018, used for the classification and staging of neoplastic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AJCC Cancer Staging Manual 8th Edition","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC Ed. 8","termGroup":"SY","termSource":"NCI"},{"termName":"AJCC Edition 8","termGroup":"SY","termSource":"NCI"},{"termName":"AJCC v8","termGroup":"SY","termSource":"NCI"},{"termName":"American Joint Committee on Cancer Staging Manual, Edition 8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"8th"},{"name":"NCI_META_CUI","value":"CL544955"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C48190":{"preferredName":"Absent","code":"C48190","definitions":[{"definition":"Not existing in a specified place at a specified time.","type":"DEFINITION","source":"NCI"},{"definition":"Not existing in a specified place at a specified time. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Absent","termGroup":"PT","termSource":"NCI"},{"termName":"Not Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Absent"},{"name":"Maps_To","value":"Absent"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0332197"}]}}{"C14175":{"preferredName":"Diffuse","code":"C14175","definitions":[{"definition":"Widely spread; not localized or confined.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Widely spread; not localized or confined.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Widely spread; not localized or confined.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse"},{"name":"Maps_To","value":"Diffuse"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205219"}]}}{"C86071":{"preferredName":"Equivocal","code":"C86071","definitions":[{"definition":"Open to question.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Open to question.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Equivocal","termGroup":"PT","termSource":"NCI"},{"termName":"Questionable","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Equivocal"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0332241"}]}}{"C28224":{"preferredName":"Focal","code":"C28224","definitions":[{"definition":"In terms of cancer, limited to a specific area.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Limited to a specific area.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Limited to a specific area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Focal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Focal"},{"name":"Maps_To","value":"Focal"},{"name":"Semantic_Type","value":"Spatial Concept"},{"name":"UMLS_CUI","value":"C0205234"}]}}{"C36113":{"preferredName":"Anaplastic Lesion","code":"C36113","definitions":[{"definition":"A morphologic finding indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Lesion","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Anaplastic Change","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anaplastic_Lesion"},{"name":"Maps_To","value":"Anaplastic"},{"name":"Maps_To","value":"Present"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0002793"}]}}{"C69309":{"preferredName":"Sclerosis","code":"C69309","definitions":[{"definition":"A pathological hardening or thickening of tissue, especially that of the interstitial substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosis","termGroup":"PT","termSource":"NCI"},{"termName":"Sclerotic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sclerosis"},{"name":"Maps_To","value":"Sclerosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0036429"}]}}{"C125472":{"preferredName":"Ann Arbor Clinical Stage I","code":"C125472","definitions":[{"definition":"A clinical stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085956"}]}}{"C125474":{"preferredName":"Ann Arbor Clinical Stage II","code":"C125474","definitions":[{"definition":"A clinical stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085954"}]}}{"C125476":{"preferredName":"Ann Arbor Clinical Stage III","code":"C125476","definitions":[{"definition":"A clinical stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085953"}]}}{"C125478":{"preferredName":"Ann Arbor Clinical Stage IV","code":"C125478","definitions":[{"definition":"A clinical stage that refers to diffuse extralymphatic involvement by lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Clinical Stage IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085955"}]}}{"C125473":{"preferredName":"Ann Arbor Pathologic Stage I","code":"C125473","definitions":[{"definition":"A pathologic stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085960"}]}}{"C125475":{"preferredName":"Ann Arbor Pathologic Stage II","code":"C125475","definitions":[{"definition":"A pathologic stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085958"}]}}{"C125477":{"preferredName":"Ann Arbor Pathologic Stage III","code":"C125477","definitions":[{"definition":"A pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085957"}]}}{"C125479":{"preferredName":"Ann Arbor Pathologic Stage IV","code":"C125479","definitions":[{"definition":"A pathologic stage that refers to diffuse extralymphatic involvement by lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ann Arbor Pathologic Stage IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C4085959"}]}}{"C15675":{"preferredName":"Adjuvant Therapy","code":"C15675","definitions":[{"definition":"Another treatment used together with the primary treatment. Its purpose is to assist the primary treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adjuvant Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Legacy Concept Name","value":"Adjuvant_Therapy"},{"name":"Maps_To","value":"Adjuvant Therapy"},{"name":"Maps_To","value":"AJ-Adjuvant Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0677850"}]}}{"C17747":{"preferredName":"Disease Progression","code":"C17747","definitions":[{"definition":"A disease, condition, or injury that is increasing in extent or severity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A process that manifests as the worsening of a disease over time.","type":"DEFINITION","source":"NCI"},{"definition":"An illness getting worse over time. (https://mrctcenter.org/glossaryterm/disease-progression/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"In medicine, the course of a disease, such as cancer, as it becomes worse or spreads in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Disease Progression","termGroup":"PT","termSource":"NCI"},{"termName":"Progression","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis."},{"name":"Legacy Concept Name","value":"Disease_Progression"},{"name":"Maps_To","value":"CPD-Clinical Progression"},{"name":"Maps_To","value":"Disease Progression"},{"name":"Maps_To","value":"Progression"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0242656"}]}}{"C4870":{"preferredName":"Complete Remission","code":"C4870","definitions":[{"definition":"The disappearance of all signs of cancer in response to treatment.","type":"DEFINITION","source":"NCI"},{"definition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disappearance of all signs of cancer in response to treatment. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Complete Remission","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer-Free","termGroup":"SY","termSource":"NCI"},{"termName":"CR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Complete_Remission"},{"name":"Maps_To","value":"Complete Response"},{"name":"Maps_To","value":"CR-Complete Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0677874"}]}}{"C165198":{"preferredName":"Complete Response Unconfirmed","code":"C165198","definitions":[{"definition":"An indication that a finding of complete response to treatment has not been confirmed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complete Response Unconfirmed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"CRU-Complete Response Unconfirmed"},{"name":"NCI_META_CUI","value":"CL978410"},{"name":"Semantic_Type","value":"Finding"}]}}{"C71687":{"preferredName":"Unchanged","code":"C71687","definitions":[{"definition":"In an unchanged or similar condition.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The status is unaltered or similar to the previous state.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unchanged","termGroup":"PT","termSource":"NCI"},{"termName":"About The Same","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"About_The_Same"},{"name":"Maps_To","value":"DU-Disease Unchanged"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2346711"}]}}{"C131144":{"preferredName":"Immunoresponse","code":"C131144","definitions":[{"definition":"A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoresponse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IMR-Immunoresponse"},{"name":"NCI_META_CUI","value":"CL514173"},{"name":"Semantic_Type","value":"Finding"}]}}{"C131143":{"preferredName":"Immunoprogression","code":"C131143","definitions":[{"definition":"A marked increase in contrast enhancement that is not due to actual tumor growth, but that may be due to a reaction to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoprogression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IPD-Immunoprogression"},{"name":"NCI_META_CUI","value":"CL514172"},{"name":"Semantic_Type","value":"Finding"}]}}{"C123598":{"preferredName":"Minimal Response","code":"C123598","definitions":[{"definition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","type":"DEFINITION","source":"NCI"},{"definition":"A finding that refers to hematologic and solid malignancies and indicates that there is a minor improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Minimal Response","termGroup":"PT","termSource":"NCI"},{"termName":"MR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MR-Minimal/Marginal response"},{"name":"Maps_To","value":"MR-Minimal/Marginal Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4050513"}]}}{"C165202":{"preferredName":"Mixed Response","code":"C165202","definitions":[{"definition":"An indication that some disease characteristics are improving while others are worsening over time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Response","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed Response"},{"name":"Maps_To","value":"MX-Mixed Response"},{"name":"NCI_META_CUI","value":"CL978414"},{"name":"Semantic_Type","value":"Finding"}]}}{"C96700":{"preferredName":"Non Complete Response/Non Progressive Disease","code":"C96700","definitions":[{"definition":"Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (RECIST)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non Complete Response/Non Progressive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-CR/Non-PD-Non-CR/Non-PD"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3272974"}]}}{"C165204":{"preferredName":"No Palliative Benefit","code":"C165204","definitions":[{"definition":"An indication that the treatment for a patient is not relieving symptoms or providing comfort.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Palliative Benefit","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NPB-No Palliative Benefit"},{"name":"NCI_META_CUI","value":"CL978416"},{"name":"Semantic_Type","value":"Finding"}]}}{"C123600":{"preferredName":"No Response","code":"C123600","definitions":[{"definition":"No apparent change or worsening in lesion staging classification.","type":"DEFINITION","source":"NCI"},{"definition":"No apparent change or worsening in lesion staging classification.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"No Response","termGroup":"PT","termSource":"NCI"},{"termName":"NR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Response"},{"name":"Maps_To","value":"NR-No Response"},{"name":"NCI_META_CUI","value":"CL498430"},{"name":"Semantic_Type","value":"Finding"}]}}{"C15292":{"preferredName":"Palliative Therapy","code":"C15292","definitions":[{"definition":"The patient- and family-centered active holistic care of patients with advanced, progressive disease. Essential components of palliative care are: pain and symptom control, communication regarding treatment and alternatives, prognosis, and available services, rehabilitation services, care that addresses treatment and palliative concerns, intellectual, emotional, social, and spiritual needs, terminal care, support in bereavement. The goal of palliative care is an achievement of the best quality of life for patients and their families.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment given to relieve the symptoms and reduce the suffering caused by cancer and other life-threatening diseases. Palliative cancer therapies are given together with other cancer treatments, from the time of diagnosis, through treatment, survivorship, recurrent or advanced disease, and at the end of life.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Palliative Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Comfort Care","termGroup":"SY","termSource":"NCI"},{"termName":"Palliative Care","termGroup":"SY","termSource":"NCI"},{"termName":"Palliative Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Symptom Management","termGroup":"SY","termSource":"NCI"},{"termName":"Symptoms Management","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Palliative_Care"},{"name":"Maps_To","value":"PA-Palliative Therapy"},{"name":"Maps_To","value":"Palliative"},{"name":"Maps_To","value":"Palliative care"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0030231"}]}}{"C101516":{"preferredName":"Palliative","code":"C101516","definitions":[{"definition":"Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.","type":"DEFINITION","source":"NCI"},{"definition":"Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Palliative","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Maps_To","value":"PB-Palliative Benefit"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1285530"}]}}{"C8510":{"preferredName":"Progressive Neoplastic Disease","code":"C8510","definitions":[{"definition":"Cancer that is growing, spreading, or getting worse.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Progressive Neoplastic Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Legacy Concept Name","value":"Progressive_Neoplastic_Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0677932"}]}}{"C98298":{"preferredName":"Pseudoprogression","code":"C98298","definitions":[{"definition":"A radiologic finding observed during magnetic resonance imaging of brain glioblastoma, following concurrent radiotherapy and temozolomide treatment or vaccine therapy. It refers to the false positive finding of progression and enhancement of the lesion. It is considered a treatment effect due to tumor cell necrosis and subsequent edema formation and increased vascular permeability.","type":"DEFINITION","source":"NCI"},{"definition":"Apparent increase in lesion burden, not proven to be disease progression.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pseudoprogression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PPD-Pseudoprogression"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3273948"}]}}{"C18058":{"preferredName":"Partial Remission","code":"C18058","definitions":[{"definition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A finding indicating that there is a decrease based on a predetermined threshold in the size and the extent of tissue involvement by cancer.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Remission","termGroup":"PT","termSource":"NCI"},{"termName":"Partial Response","termGroup":"SY","termSource":"NCI"},{"termName":"PR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Partial_Remission"},{"name":"Maps_To","value":"Partial Response"},{"name":"Maps_To","value":"PR-Partial Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1521726"}]}}{"C131142":{"preferredName":"Pseudoresponse","code":"C131142","definitions":[{"definition":"A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to anti-angiogenic therapy or an increase in steroid dosage.","type":"DEFINITION","source":"NCI"},{"definition":"Apparent decrease in lesion burden, not proven to be favorable treatment response.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pseudoresponse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSR-Pseudoresponse"},{"name":"NCI_META_CUI","value":"CL513188"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165206":{"preferredName":"Responsive Disease","code":"C165206","definitions":[{"definition":"An indication that a patient's disease is responding to treatment.","type":"DEFINITION","source":"NCI"},{"definition":"In medicine, an improvement related to treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Responsive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RD-Responsive Disease"},{"name":"Maps_To","value":"RP-Response"},{"name":"NCI_META_CUI","value":"CL978418"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165208":{"preferredName":"Radiographic Progressive Disease","code":"C165208","definitions":[{"definition":"An indication that the radiographically detectable signs of disease are becoming more prominent over time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiographic Progressive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RPD-Radiographic Progressive Disease"},{"name":"NCI_META_CUI","value":"CL978420"},{"name":"Semantic_Type","value":"Finding"}]}}{"C123614":{"preferredName":"Stringent Complete Response","code":"C123614","definitions":[{"definition":"The confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the CR.","type":"DEFINITION","source":"NCI"},{"definition":"The disappearance of all signs of cancer, including the absence of molecular or cytogenetic markers of disease, supported by additional biochemical, immunological and histopathological analyses.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Stringent Complete Response","termGroup":"PT","termSource":"NCI"},{"termName":"sCR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"sCR-Stringent Complete Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4050416"}]}}{"C18213":{"preferredName":"Stable Disease","code":"C18213","definitions":[{"definition":"A disease that is neither decreasing nor increasing in extent or severity.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that is neither decreasing nor increasing in extent or severity based on predetermined boundaries. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that is neither decreasing nor increasing in extent or severity.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stable Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stable_Disease"},{"name":"Maps_To","value":"SD-Stable Disease"},{"name":"Maps_To","value":"Stable Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0677946"}]}}{"C133441":{"preferredName":"Too Early","code":"C133441","definitions":[{"definition":"At a point before the usual, expected, or specified time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Too Early","termGroup":"PT","termSource":"NCI"},{"termName":"Premature","termGroup":"SY","termSource":"NCI"},{"termName":"Too Soon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TE-Too Early"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C4018905"}]}}{"C123618":{"preferredName":"Very Good Partial Response","code":"C123618","definitions":[{"definition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Very Good Partial Response","termGroup":"PT","termSource":"NCI"},{"termName":"VGPR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Very Good Partial Response"},{"name":"Maps_To","value":"VGPR-Very Good Partial Response"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4053871"}]}}{"C27122":{"preferredName":"Endemic Burkitt Lymphoma","code":"C27122","definitions":[{"definition":"A clinical variant of Burkitt lymphoma that occurs in equatorial Africa.  The Epstein-Barr virus has been detected in all patients.  It is the most common malignancy of childhood in this area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endemic Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"African Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"African Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Endemic Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endemic_Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"Endemic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0343640"}]}}{"C27915":{"preferredName":"Immunodeficiency-Related Burkitt Lymphoma","code":"C27915","definitions":[{"definition":"Burkitt lymphoma in a patient with immunodeficiency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunodeficiency-Related Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Immunodeficiency Associated Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency Associated Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency Related Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency Related Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency-Associated Burkitt Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency-Associated Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Immunodeficiency-Related Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Immunodeficiency-Related_Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"Immunodeficiency-associated, adult"},{"name":"Maps_To","value":"Immunodeficiency-associated, pediatric"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334158"}]}}{"C27914":{"preferredName":"Sporadic Burkitt Lymphoma","code":"C27914","definitions":[{"definition":"A clinical variant of Burkitt lymphoma that occurs throughout the world.  It affects both children and adults and is more frequently seen in males.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sporadic Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sporadic Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sporadic_Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"Sporadic, adult"},{"name":"Maps_To","value":"Sporadic, pediatric"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336077"}]}}{"C113691":{"preferredName":"Child-Pugh Class A","code":"C113691","definitions":[{"definition":"Child-Pugh score indicating one-year survival of 100% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"A"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3831117"}]}}{"C146790":{"preferredName":"Child-Pugh Class A5","code":"C146790","definitions":[{"definition":"A total score of 5 for hepatic function, corresponding to class A in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class A5","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade A5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"A5"},{"name":"NCI_META_CUI","value":"CL544764"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146791":{"preferredName":"Child-Pugh Class A6","code":"C146791","definitions":[{"definition":"A total score of 6 for hepatic function, corresponding to class A in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class A6","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade A6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"A6"},{"name":"NCI_META_CUI","value":"CL544765"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C113692":{"preferredName":"Child-Pugh Class B","code":"C113692","definitions":[{"definition":"Child-Pugh score indicating one-year survival of 80% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3831116"}]}}{"C146792":{"preferredName":"Child-Pugh Class B7","code":"C146792","definitions":[{"definition":"A total score of 7 for hepatic function, corresponding to class B in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B7","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade B7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B7"},{"name":"NCI_META_CUI","value":"CL544766"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146793":{"preferredName":"Child-Pugh Class B8","code":"C146793","definitions":[{"definition":"A total score of 8 for hepatic function, corresponding to class B in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B8","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade B8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B8"},{"name":"NCI_META_CUI","value":"CL544767"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146794":{"preferredName":"Child-Pugh Class B9","code":"C146794","definitions":[{"definition":"A total score of 9 for hepatic function, corresponding to class B in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class B9","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade B9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B9"},{"name":"NCI_META_CUI","value":"CL544768"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C113694":{"preferredName":"Child-Pugh Class C","code":"C113694","definitions":[{"definition":"Child-Pugh score indicating one-year survival of 45% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3831115"}]}}{"C146795":{"preferredName":"Child-Pugh Class C10","code":"C146795","definitions":[{"definition":"A total score of 10 for hepatic function, corresponding to class C in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C10","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade C10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C10"},{"name":"NCI_META_CUI","value":"CL544769"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146796":{"preferredName":"Child-Pugh Class C11","code":"C146796","definitions":[{"definition":"A total score of 11 for hepatic function, corresponding to class C in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C11","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade C11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C11"},{"name":"NCI_META_CUI","value":"CL544770"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146797":{"preferredName":"Child-Pugh Class C12","code":"C146797","definitions":[{"definition":"A total score of 12 for hepatic function, corresponding to class C in the Child-Pugh classification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child-Pugh Class C12","termGroup":"PT","termSource":"NCI"},{"termName":"Child-Pugh Grade C12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C12"},{"name":"NCI_META_CUI","value":"CL544771"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C40557":{"preferredName":"Metastatic Lesion","code":"C40557","definitions":[{"definition":"A tumor arising at a location distant to the primary lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Lesion","termGroup":"PT","termSource":"NCI"},{"termName":"Metastases","termGroup":"SY","termSource":"NCI"},{"termName":"Metastasis","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Metastatic_Lesion"},{"name":"Maps_To","value":"metastasis"},{"name":"Maps_To","value":"Metastasis, NOS"},{"name":"Maps_To","value":"Metastatic"},{"name":"Maps_To","value":"Presented with Metastases"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1513183"}]}}{"C36032":{"preferredName":"Premalignant Neoplasm","code":"C36032","definitions":[{"definition":"A neoplasm that is composed of dysplastic cells and there is no morphologic evidence of infiltration of the surrounding tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Premalignant Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Premalignant_Neoplasm"},{"name":"Maps_To","value":"Premalignant"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335472"}]}}{"C8509":{"preferredName":"Primary Neoplasm","code":"C8509","definitions":[{"definition":"A tumor at the original site of origin.","type":"DEFINITION","source":"NCI"},{"definition":"The original tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Primary_Neoplasm"},{"name":"Maps_To","value":"Primary"},{"name":"Maps_To","value":"primary"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677930"}]}}{"C17609":{"preferredName":"Tumor Progression","code":"C17609","definitions":[{"definition":"A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a neoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Progression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The process of tumor progression is thought to be driven by clonal evolution. The initiating event is a mutation that gives a cell the ability to divide when it shouldn't.  As a result a small group of related cells, called a clone because they are identical to each other, grows. Clonal evolution occurs like a tree with mutations causing many clones to branch off continuously."},{"name":"Legacy Concept Name","value":"Tumor_Progression"},{"name":"Maps_To","value":"Progression"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0178874"}]}}{"C4798":{"preferredName":"Recurrent Neoplasm","code":"C4798","definitions":[{"definition":"The reemergence of a neoplasm after a period of remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recurrent Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm Recurrence","termGroup":"SY","termSource":"NCI"},{"termName":"Recurrent Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recurrent_Neoplasm"},{"name":"Maps_To","value":"recurrence"},{"name":"Maps_To","value":"Recurrence"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0521158"}]}}{"C54621":{"preferredName":"Synchronous Lesion","code":"C54621","definitions":[{"definition":"Two or more primary lesions that are diagnosed at the same time in the same patient, or soon after the diagnosis of the first primary lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synchronous Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synchronous_Lesion"},{"name":"Maps_To","value":"Synchronous primary"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1883252"}]}}{"C156806":{"preferredName":"New Primary Tumor","code":"C156806","definitions":[{"definition":"A finding indicating the development of a tumor in a patient with a history of a previously diagnosed tumor with a different histopathologic profile in another anatomic site as compared to the most recent one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"New Primary Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"New Primary"},{"name":"Maps_To","value":"Prior primary"},{"name":"Maps_To","value":"Subsequent Primary"},{"name":"NCI_META_CUI","value":"CL935850"},{"name":"Semantic_Type","value":"Finding"}]}}{"C102401":{"preferredName":"High Risk","code":"C102401","definitions":[{"definition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Risk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Risk"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0332167"}]}}{"C102402":{"preferredName":"Intermediate Risk","code":"C102402","definitions":[{"definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","type":"DEFINITION","source":"NCI"},{"definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intermediate Risk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate Risk"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C3640764"}]}}{"C102403":{"preferredName":"Low Risk","code":"C102403","definitions":[{"definition":"The potential future harm that may arise from some present action or attribute or condition is small.","type":"DEFINITION","source":"NCI"},{"definition":"The potential future harm that may arise from some present action or attribute or condition is small.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Low Risk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Risk"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C3538919"}]}}{"C140301":{"preferredName":"SIOP/COG/NWTSG Stage I","code":"C140301","definitions":[{"definition":"Wilms' tumor is limited to the kidney and completely excised; the tumor was not ruptured before or during removal; the vessels of the renal sinus are not involved beyond 2 mm; there is no residual tumor present beyond the margins of excision.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"NCI_META_CUI","value":"CL538470"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140303":{"preferredName":"SIOP/COG/NWTSG Stage II","code":"C140303","definitions":[{"definition":"Wilms' tumor extends beyond the kidney but is completely excised; no residual tumor is apparent at or beyond the margins of the excision; tumor thrombus in vessels outside the kidney is Stage II if the thrombus is removed en bloc with the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"NCI_META_CUI","value":"CL538468"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140305":{"preferredName":"SIOP/COG/NWTSG Stage III","code":"C140305","definitions":[{"definition":"Residual Wilms' tumor confined to the abdomen; Lymph nodes in the renal hilum, the periaortic chains, or beyond are found to contain tumor; diffuse peritoneal contamination by the tumor; implants are found on the peritoneal surfaces; tumor extends beyond the surgical margins either microscopically or grossly; tumor is not completely resectable because of local infiltration into vital structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"NCI_META_CUI","value":"CL538466"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140307":{"preferredName":"SIOP/COG/NWTSG Stage IV","code":"C140307","definitions":[{"definition":"Presence of hematogenous metastases or metastases to distant lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIOP/COG/NWTSG Stage IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"NCI_META_CUI","value":"CL538464"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C188368":{"preferredName":"ELN Adverse-Risk Category","code":"C188368","definitions":[{"definition":"A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating unfavorable cytogenetics and a poor prognosis, which includes an unfavorable disease response to conventional consolidation therapy. In these cases, autologous or allogeneic hematopoietic stem cell transplantation is recommended.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Adverse-Risk Category","termGroup":"PT","termSource":"NCI"},{"termName":"ELN Adverse Risk Category","termGroup":"SY","termSource":"NCI"},{"termName":"ELN Adverse-Risk","termGroup":"SY","termSource":"NCI"},{"termName":"European LeukemiaNet Adverse Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adverse"},{"name":"NCI_META_CUI","value":"CL1793644"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C188369":{"preferredName":"ELN Favorable-Risk Category","code":"C188369","definitions":[{"definition":"A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating a favorable prognosis following conventional consolidation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Favorable-Risk Category","termGroup":"PT","termSource":"NCI"},{"termName":"ELN Favorable Risk Category","termGroup":"SY","termSource":"NCI"},{"termName":"ELN Favorable-Risk","termGroup":"SY","termSource":"NCI"},{"termName":"European LeukemiaNet Favorable Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Favorable"},{"name":"NCI_META_CUI","value":"CL1793643"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C188370":{"preferredName":"ELN Intermediate-Risk Category","code":"C188370","definitions":[{"definition":"A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating an intermediate chance for relapse following treatment and remission. Subjects in this risk group are recommended to receive conventional consolidation therapy followed by allogeneic hematopoietic stem cell transplantation to achieve remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Intermediate-Risk Category","termGroup":"PT","termSource":"NCI"},{"termName":"ELN Intermediate Risk Category","termGroup":"SY","termSource":"NCI"},{"termName":"ELN Intermediate-Risk","termGroup":"SY","termSource":"NCI"},{"termName":"European LeukemiaNet Intermediate Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate"},{"name":"NCI_META_CUI","value":"CL1794623"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140261":{"preferredName":"Enneking High Surgical Grade","code":"C140261","definitions":[{"definition":"A high-grade lesion, corresponding to Broder's Grades 3 and 4, having a higher incidence of metastasis and characterized histologically by mitotic figures, prominent nucleoli, and pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking High Surgical Grade","termGroup":"PT","termSource":"NCI"},{"termName":"G2","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS High Surgical Grade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Grade (G2)"},{"name":"NCI_META_CUI","value":"CL538400"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140260":{"preferredName":"Enneking Low Surgical Grade","code":"C140260","definitions":[{"definition":"A low-grade lesion, corresponding to Broder's Grades 1 or 2, with a low risk for distant spread (< 25%). These tumors are characterized by low mitotic rates, low nuclear to cytoplasmic ratio, and limited pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Low Surgical Grade","termGroup":"PT","termSource":"NCI"},{"termName":"G1","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS Low Surgical Grade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Grade (G1)"},{"name":"NCI_META_CUI","value":"CL538401"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C147528":{"preferredName":"Enneking Metastasis M0","code":"C147528","definitions":[{"definition":"No metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Metastasis M0","termGroup":"PT","termSource":"NCI"},{"termName":"M0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Metastasis (M0)"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C3869912"}]}}{"C147529":{"preferredName":"Enneking Metastasis M1","code":"C147529","definitions":[{"definition":"Regional or distant metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Metastasis M1","termGroup":"PT","termSource":"NCI"},{"termName":"M1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regional or Distant Metastasis (M1)"},{"name":"NCI_META_CUI","value":"CL545425"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146701":{"preferredName":"Enneking Stage IA","code":"C146701","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by low grade (G1), intracomparmental site (T1), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA"},{"name":"NCI_META_CUI","value":"CL544728"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146702":{"preferredName":"Enneking Stage IB","code":"C146702","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by low grade (G1), extracomparmental site (T2), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB"},{"name":"NCI_META_CUI","value":"CL544729"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146703":{"preferredName":"Enneking Stage IIA","code":"C146703","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T1), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA"},{"name":"NCI_META_CUI","value":"CL544730"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146704":{"preferredName":"Enneking Stage IIB","code":"C146704","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T2), and no metastasis (M0).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage IIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIB"},{"name":"NCI_META_CUI","value":"CL544731"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C146705":{"preferredName":"Enneking Stage III","code":"C146705","definitions":[{"definition":"A stage for malignant musculoskeletal tumors characterized by any grade, any site, and regional or distant metastasis (M1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enneking Stage III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"NCI_META_CUI","value":"CL544732"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140265":{"preferredName":"Extracompartmental Tumor","code":"C140265","definitions":[{"definition":"Bone tumors extend beyond the bone cortex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extracompartmental Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Extracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS Extracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"T2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extracompartmental (T2)"},{"name":"NCI_META_CUI","value":"CL545898"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C140263":{"preferredName":"Intracompartmental Tumor","code":"C140263","definitions":[{"definition":"Bone tumors are confined within the cortex of the bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intracompartmental Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Intracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"MSTS Intracompartmental","termGroup":"SY","termSource":"NCI"},{"termName":"T1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intracompartmental (T1)"},{"name":"NCI_META_CUI","value":"CL541312"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C156083":{"preferredName":"High Grade Dysplasia","code":"C156083","definitions":[{"definition":"A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysplasia; high grade"},{"name":"Maps_To","value":"High Grade"},{"name":"Maps_To","value":"High Grade Dysplasia"},{"name":"NCI_META_CUI","value":"CL562934"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164039":{"preferredName":"Indefinite Dysplasia","code":"C164039","definitions":[{"definition":"An indication that there is an ambiguous morphological pattern in a tissue sample such that the presence or absence of dysplasia cannot be determined.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indefinite Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Indefinite for Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indefinite"},{"name":"Maps_To","value":"Indefinite for Dysplasia"},{"name":"NCI_META_CUI","value":"CL977191"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156084":{"preferredName":"Low Grade Dysplasia","code":"C156084","definitions":[{"definition":"A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be low.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysplasia; low grade"},{"name":"Maps_To","value":"Low Grade"},{"name":"Maps_To","value":"Low Grade Dysplasia"},{"name":"NCI_META_CUI","value":"CL562935"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164040":{"preferredName":"Dysplasia Negative","code":"C164040","definitions":[{"definition":"An indication that signs of dysplasia were not found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dysplasia Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Negative for Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"No Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Negative/ No Dysplasia"},{"name":"Maps_To","value":"No Dysplasia"},{"name":"NCI_META_CUI","value":"CL977190"},{"name":"Semantic_Type","value":"Finding"}]}}{"C96243":{"preferredName":"FIGO Stage 0","code":"C96243","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers and refers to carcinoma in situ.  For cervical cancer, it used to refer to cancer that is confined to the cervical epithelium without stromal invasion; for endometrial cancer, it used to refer to cancer that is confined to the endometrium without myometrial invasion.  FIGO no longer includes stage 0 cervical or endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 0"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272670"}]}}{"C96244":{"preferredName":"FIGO Stage I","code":"C96244","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is confined to the cervix; for endometrial cancer, it refers to cancer confined to the corpus uteri with no or less than one-half myometrial invasion (IA) or invasion of one-half or more of the myometrium (IB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage I","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272671"}]}}{"C96245":{"preferredName":"FIGO Stage IA","code":"C96245","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion has a maximum depth of 5.00 mm and a horizontal spread of 7.00 mm or less; for endometrial cancer, it refers to cancer limited to endometrium or invades less than one-half of the myometrium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272672"}]}}{"C96246":{"preferredName":"FIGO Stage IA1","code":"C96246","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion has a maximum depth of 3.00 mm and a horizontal spread of 7.00 mm or less; there is no FIGO stage IA1 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272673"}]}}{"C96247":{"preferredName":"FIGO Stage IA2","code":"C96247","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion is more than 3.00 mm but no more than 5.00 mm with a horizontal spread of 7.00 mm or less; there is no FIGO stage A2 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IA2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272674"}]}}{"C96248":{"preferredName":"FIGO Stage IB","code":"C96248","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is clinically visible and is confined to the cervix or it is diagnosed microscopically and the stromal invasion is more than 5.00 mm and the horizontal spread is more than 7.00 mm; for endometrial cancer, it refers to cancer that is confined to the uterine body and invades one-half or more of the myometrium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272675"}]}}{"C96249":{"preferredName":"FIGO Stage IB1","code":"C96249","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to clinically visible lesions that measure 4.0 cm or less in diameter; there is no FIGO stage IB1 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IB1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272676"}]}}{"C96250":{"preferredName":"FIGO Stage IB2","code":"C96250","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to clinically visible lesions that measure more than 4.0 cm in diameter; there is no FIGO stage IB2 for endometrial cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IB2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IB2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272677"}]}}{"C96251":{"preferredName":"FIGO Stage IC","code":"C96251","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, there is no FIGO stage IC; for endometrial cancer, in the older FIGO classification stage scheme, it referred to invasion of more than a half of the myometrium.  Stage IC for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272678"}]}}{"C128099":{"preferredName":"FIGO Stage IC1","code":"C128099","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with surgical spill.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC1"},{"name":"NCI_META_CUI","value":"CL508831"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128100":{"preferredName":"FIGO Stage IC2","code":"C128100","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with capsule rupture before surgery or tumor on ovarian surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC2"},{"name":"NCI_META_CUI","value":"CL508833"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128101":{"preferredName":"FIGO Stage IC3","code":"C128101","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with malignant cells in the ascites or peritoneal washings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IC3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IC3"},{"name":"NCI_META_CUI","value":"CL508835"},{"name":"Semantic_Type","value":"Classification"}]}}{"C96252":{"preferredName":"FIGO Stage II","code":"C96252","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina; for endometrial cancer, it refers to cancer that invades the stromal connective tissue of the cervix, but it does not extend beyond the uterus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage II","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272679"}]}}{"C96253":{"preferredName":"FIGO Stage IIA","code":"C96253","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina and there is no parametrial invasion; for endometrial cancer, in the older FIGO classification stage scheme, it referred to endocervical glandular involvement only.  Stage IIA for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272680"}]}}{"C162223":{"preferredName":"FIGO Stage IIA1","code":"C162223","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, less than 4 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA1"},{"name":"NCI_META_CUI","value":"CL970741"},{"name":"Semantic_Type","value":"Classification"}]}}{"C162224":{"preferredName":"FIGO Stage IIA2","code":"C162224","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIA2"},{"name":"NCI_META_CUI","value":"CL970753"},{"name":"Semantic_Type","value":"Classification"}]}}{"C96254":{"preferredName":"FIGO Stage IIB","code":"C96254","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina and there is parametrial invasion; for endometrial cancer, in the older FIGO classification stage scheme, it referred to cervical stromal invasion.  Stage IIB for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272681"}]}}{"C188300":{"preferredName":"FIGO Stage IIC","code":"C188300","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer of aggressive histological type with any myometrial invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIC"},{"name":"NCI_META_CUI","value":"CL1793032"},{"name":"Semantic_Type","value":"Classification"}]}}{"C96255":{"preferredName":"FIGO Stage III","code":"C96255","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that extends to the pelvic wall, and/or involves the lower third of vagina, and/or causes hydronephrosis or non-functioning kidney; for endometrial cancer, FIGO stage III is subdivided into stages IIIA and IIIB; in FIGO stage IIIA, there is involvement of the serosa and/or the adnexa; for FIGO stage IIIB, there is vaginal or parametrial involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage III","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272682"}]}}{"C96256":{"preferredName":"FIGO Stage IIIA","code":"C96256","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that involves the lower third of vagina and there is no extension to the pelvic wall; for endometrial cancer, it refers to cancer with involvement of the serosa and/or the adnexa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272683"}]}}{"C128102":{"preferredName":"FIGO Stage IIIA1","code":"C128102","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1"},{"name":"NCI_META_CUI","value":"CL508844"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128105":{"preferredName":"FIGO Stage IIIA2","code":"C128105","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with microscopic, extrapelvic (above the brim) peritoneal involvement +/- positive retroperitoneal lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA2"},{"name":"NCI_META_CUI","value":"CL508846"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128103":{"preferredName":"FIGO Stage IIIA1i","code":"C128103","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA1i","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage IIIA1(i)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1(i)"},{"name":"NCI_META_CUI","value":"CL508841"},{"name":"Semantic_Type","value":"Classification"}]}}{"C128104":{"preferredName":"FIGO Stage IIIA1ii","code":"C128104","definitions":[{"definition":"A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIA1ii","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage IIIA1(ii)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIA1(ii)"},{"name":"NCI_META_CUI","value":"CL508843"},{"name":"Semantic_Type","value":"Classification"}]}}{"C96257":{"preferredName":"FIGO Stage IIIB","code":"C96257","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that extends to the pelvic wall, and/or causes hydronephrosis or non-functioning kidney; for endometrial cancer, it refers to cancer with vaginal or parametrial involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272684"}]}}{"C96258":{"preferredName":"FIGO Stage IIIC","code":"C96258","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer with metastasis to the pelvic or para-aortic lymph nodes or both.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIC","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272685"}]}}{"C96259":{"preferredName":"FIGO Stage IIIC1","code":"C96259","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer with regional metastasis to pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIC1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272686"}]}}{"C96260":{"preferredName":"FIGO Stage IIIC2","code":"C96260","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to it refers to cancer with regional metastasis to para-aortic lymph nodes with or without metastasis to pelvic lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IIIC2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIIC2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272687"}]}}{"C96261":{"preferredName":"FIGO Stage IV","code":"C96261","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades the mucosa of bladder or rectum, and/or extends beyond the true pelvis (FIGO stage IVA), or to cancer with distant metastases (FIGO stage IVB); for endometrial cancer, it refers to cancer that invades the bladder mucosa and/or the bowel mucosa (FIGO stage IVA), or to cancer with distant metastases (FIGO stage IVB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IV","termGroup":"PT","termSource":"NCI"},{"termName":"FIGO Stage 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272688"}]}}{"C96262":{"preferredName":"FIGO Stage IVA","code":"C96262","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades the mucosa of bladder or rectum, and/or extends beyond the true pelvis; for endometrial cancer, it refers to cancer that invades the bladder mucosa and/or the bowel mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IVA","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVA"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272689"}]}}{"C96263":{"preferredName":"FIGO Stage IVB","code":"C96263","definitions":[{"definition":"A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer with distant metastases, including peritoneal involvement, involvement of the supraclavicular or mediastinal lymph nodes, and metastases to the lung, bone, or liver; for endometrial cancer, it refers to cancer with distant metastases, including metastases to the inguinal lymph nodes, intraperitoneal involvement, or metastases to the lung, bone, or liver.  Endometrial cancer metastases to the para-aortic lymph nodes, vagina, adnexa, or pelvic serosa are excluded from this stage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIGO Stage IVB","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVB"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C3272690"}]}}{"C121628":{"preferredName":"Altered Mental Status","code":"C121628","definitions":[{"definition":"A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Altered Mental Status","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Altered Mental Status"},{"name":"Maps_To","value":"Mental status changes"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0278061"}]}}{"C34661":{"preferredName":"Headache","code":"C34661","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Head pain or discomfort.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Pain in any region of the head.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Pain in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Pain in various parts of the head, not confined to the area of distribution of any nerve.","type":"DEFINITION","source":"NCI"},{"definition":"Pain in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Headache","termGroup":"PT","termSource":"NCI"},{"termName":"Cephalalgia","termGroup":"SY","termSource":"NCI"},{"termName":"Cephalgia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Headache"},{"name":"Maps_To","value":"Headache"},{"name":"Maps_To","value":"Headaches"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0018681"},{"name":"xRef","value":"IMDRF:E0116"}]}}{"C157433":{"preferredName":"Motor / Movement Change","code":"C157433","definitions":[{"definition":"An alteration in the motor/movement of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motor / Movement Change","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Motor / Movement Change"},{"name":"Maps_To","value":"Motor or Movement Changes"},{"name":"NCI_META_CUI","value":"CL937125"},{"name":"Semantic_Type","value":"Finding"}]}}{"C2962":{"preferredName":"Seizure","code":"C2962","definitions":[{"definition":"A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A paroxysmal surge of electrical activity in the brain that may result in physical or behavioral changes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Convulsion; a sudden, involuntary movement of the muscles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Convulsions, sensory, cognitive disturbances, or loss of consciousness resulting from abnormal electrical discharges in the brain in a patient with probable or confirmed COVID-19.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"DEFINITION","source":"NCI"},{"definition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Seizure","termGroup":"PT","termSource":"NCI"},{"termName":"Convulsion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Seizure"},{"name":"Maps_To","value":"Other convulsions"},{"name":"Maps_To","value":"Seizure"},{"name":"Maps_To","value":"Seizures"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2748942"},{"name":"xRef","value":"IMDRF:E0109"}]}}{"C157429":{"preferredName":"Sensory Change","code":"C157429","definitions":[{"definition":"An alteration in the perceptual senses an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sensory Change","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sensory Changes"},{"name":"NCI_META_CUI","value":"CL937129"},{"name":"Semantic_Type","value":"Finding"}]}}{"C157424":{"preferredName":"Visual Change","code":"C157424","definitions":[{"definition":"An alteration in the visual system of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Visual Change","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vision Changes"},{"name":"Maps_To","value":"Visual Changes"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0750280"}]}}{"C137992":{"preferredName":"Gleason Grade Group 1","code":"C137992","definitions":[{"definition":"Gleason grade defined by Gleason score less than or equal to 6. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 1","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 1"},{"name":"NCI_META_CUI","value":"CL525030"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137993":{"preferredName":"Gleason Grade Group 2","code":"C137993","definitions":[{"definition":"Gleason grade defined by Gleason score 3+4=7. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 2","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 2"},{"name":"NCI_META_CUI","value":"CL525029"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137994":{"preferredName":"Gleason Grade Group 3","code":"C137994","definitions":[{"definition":"Gleason grade defined by Gleason score 4+3=7. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 3","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 3"},{"name":"NCI_META_CUI","value":"CL525028"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137995":{"preferredName":"Gleason Grade Group 4","code":"C137995","definitions":[{"definition":"Gleason grade defined by Gleason score 4+4=8, Gleason score 3+5=8, or Gleason score 5+3=8. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 4","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 4"},{"name":"NCI_META_CUI","value":"CL525035"},{"name":"Semantic_Type","value":"Classification"}]}}{"C137996":{"preferredName":"Gleason Grade Group 5","code":"C137996","definitions":[{"definition":"Gleason grade defined by Gleason score 9-10. (ISUP, 2014)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Grade Group 5","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Group 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group 5"},{"name":"NCI_META_CUI","value":"CL525034"},{"name":"Semantic_Type","value":"Classification"}]}}{"C28088":{"preferredName":"Gleason Pattern 4","code":"C28088","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of fused, cribriform, or poorly defined glands. There is partial loss of normal epithelial polarity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 4","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_4"},{"name":"Maps_To","value":"Pattern 4"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0332329"}]}}{"C28089":{"preferredName":"Gleason Pattern 5","code":"C28089","definitions":[{"definition":"A pattern of prostate carcinoma characterized by almost complete loss of epithelial polarity and luminal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 5","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_5"},{"name":"Maps_To","value":"Pattern 5"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276443"}]}}{"C177313":{"preferredName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Good","code":"C177313","definitions":[{"definition":"The good prognosis category refers to any primary site and no nonpulmonary visceral metastases and normal AFP, any hCG, any LDH.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Good","termGroup":"PT","termSource":"NCI"},{"termName":"Seminoma IGCCC, Good","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Good Prognosis"},{"name":"NCI_META_CUI","value":"CL1643274"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177310":{"preferredName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Good","code":"C177310","definitions":[{"definition":"The good prognosis category refers to testes/retroperitoneal primary and no nonpulmonary visceral metastases and the following markers: AFP less than 1,000 ng/mL, hCG less than 5,000 IU/L and LDH less than 1.5 x ULN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Good","termGroup":"PT","termSource":"NCI"},{"termName":"NSGCT IGCCC, Good","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Good Prognosis"},{"name":"NCI_META_CUI","value":"CL1643273"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177314":{"preferredName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Intermediate","code":"C177314","definitions":[{"definition":"The intermediate prognosis category refers to any primary site and nonpulmonary visceral metastases and normal AFP, any hCG, any LDH.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seminoma International Germ Cell Tumor Consensus Risk Classification, Intermediate","termGroup":"PT","termSource":"NCI"},{"termName":"Seminoma IGCCC, Intermediate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate Prognosis"},{"name":"NCI_META_CUI","value":"CL1643277"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177311":{"preferredName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Intermediate","code":"C177311","definitions":[{"definition":"The intermediate risk group refers to testes/retroperitoneal primary and no nonpulmonary visceral metastases and the following markers: AFP greater than or equal to 1,000 ng/mL and less than or equal to 10,000 ng/mL, or hCG greater than or equal to 5,000 IU/L and less than or equal to 50,000 ng/mL or LDH greater than or equal to 1.5 x ULN and less than or equal to 10 x ULN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Intermediate","termGroup":"PT","termSource":"NCI"},{"termName":"NSGCT IGCCC, Intermediate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Intermediate Prognosis"},{"name":"NCI_META_CUI","value":"CL1643272"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C177312":{"preferredName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Poor","code":"C177312","definitions":[{"definition":"The poor prognosis category refers to mediastinal primary or nonpulmonary visceral metastases or markers with the following: AFP greater than 10,000 ng/mL or hCG  greater than 50,000 IU/L or LDH greater than 10 x ULN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Seminomatous Germ Cell Tumor International Consensus Risk Classification, Poor","termGroup":"PT","termSource":"NCI"},{"termName":"NSGCT IGCCC, Poor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Poor Prognosis"},{"name":"NCI_META_CUI","value":"CL1643275"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C42048":{"preferredName":"Differentiating Neuroblastoma","code":"C42048","definitions":[{"definition":"A neuroblastoma in which the differentiating neuroblasts constitute more than five-percent of the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Differentiating Neuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Differentiating_Neuroblastoma"},{"name":"Maps_To","value":"Differentiating"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511934"}]}}{"C42047":{"preferredName":"Poorly Differentiated Neuroblastoma","code":"C42047","definitions":[{"definition":"A neuroblastoma in which the differentiating neuroblasts constitute less than five-percent of the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Neuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Neuroblastoma"},{"name":"Maps_To","value":"Poorly Differentiated"},{"name":"Maps_To","value":"Undifferentiated or Poorly Differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1514225"}]}}{"C42046":{"preferredName":"Undifferentiated Neuroblastoma","code":"C42046","definitions":[{"definition":"A neuroblastoma characterized by the absence of differentiating neuroblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Neuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Undifferentiated_Neuroblastoma"},{"name":"Maps_To","value":"Undifferentiated"},{"name":"Maps_To","value":"Undifferentiated or Poorly Differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519787"}]}}{"C102560":{"preferredName":"Favorable","code":"C102560","definitions":[{"definition":"Expressing something as positive, advantageous or desired.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Favorable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Favorable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3640814"}]}}{"C102561":{"preferredName":"Unfavorable","code":"C102561","definitions":[{"definition":"Expressing something as negative, undesired or adverse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unfavorable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unfavorable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3640815"}]}}{"C133428":{"preferredName":"INRG Stage L1","code":"C133428","definitions":[{"definition":"Locoregional neuroblastoma without image defined risk factors (IDRFs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage L1","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"L1"},{"name":"NCI_META_CUI","value":"CL520040"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C133429":{"preferredName":"INRG Stage L2","code":"C133429","definitions":[{"definition":"Locoregional neuroblastoma with one or more image defined risk factors (IDRFs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage L2","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage L2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"L2"},{"name":"NCI_META_CUI","value":"CL520041"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C133430":{"preferredName":"INRG Stage M","code":"C133430","definitions":[{"definition":"Neuroblastoma with distant metastatic disease (except MS).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage M","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage M","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M"},{"name":"NCI_META_CUI","value":"CL520043"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C133431":{"preferredName":"INRG Stage MS","code":"C133431","definitions":[{"definition":"INRG stage L1 or L2 neuroblastoma with metastatic disease confined to the skin and/or liver and/or bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INRG Stage MS","termGroup":"PT","termSource":"NCI"},{"termName":"International Neuroblastoma Risk Group Stage MS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ms"},{"name":"NCI_META_CUI","value":"CL520042"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C85417":{"preferredName":"INSS Stage 1","code":"C85417","definitions":[{"definition":"The tumor is confined to the original site of growth; no metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 1"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827642"}]}}{"C85418":{"preferredName":"INSS Stage 2A","code":"C85418","definitions":[{"definition":"The tumor is unilateral and the resection is grossly incomplete; no evidence of lymph node involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 2A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 2A"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827643"}]}}{"C85419":{"preferredName":"INSS Stage 2B","code":"C85419","definitions":[{"definition":"The tumor is unilateral and the resection is complete or incomplete; ipsilateral lymph nodes are involved by tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 2B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 2B"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827644"}]}}{"C85420":{"preferredName":"INSS Stage 3","code":"C85420","definitions":[{"definition":"The tumor extends across the midline and the regional lymph nodes may or may not be involved by tumor; or the tumor is unilateral and the contralateral lymph nodes are involved by tumor; or the tumor is in midline and there is bilateral lymph node involvement by tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 3"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827645"}]}}{"C85421":{"preferredName":"INSS Stage 4","code":"C85421","definitions":[{"definition":"Tumor spread to distant lymph nodes, bone marrow, bones, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 4","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 4"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827646"}]}}{"C85422":{"preferredName":"INSS Stage 4S","code":"C85422","definitions":[{"definition":"Patients are less than one year old with localized primary tumor and dissemination limited to the following specific anatomic sites: liver, skin, or bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INSS Stage 4S","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage 4S"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C2827647"}]}}{"C161806":{"preferredName":"International Prognostic Index Low Risk Group","code":"C161806","definitions":[{"definition":"A risk group associated with a total score of 0 or 1 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 73%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index Low Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"IPI Low Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI Low Risk Group","termGroup":"SY","termSource":"NCI"},{"termName":"Low Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Risk"},{"name":"NCI_META_CUI","value":"CL970425"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C161807":{"preferredName":"International Prognostic Index Low-Intermediate Risk Group","code":"C161807","definitions":[{"definition":"A risk group associated with a total score of 2 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 69%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index Low-Intermediate Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"IPI Low-Intermediate Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI Low-Intermediate Risk Group","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Intermediate Risk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low-Intermediate Risk"},{"name":"NCI_META_CUI","value":"CL970424"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C161808":{"preferredName":"International Prognostic Index High-Intermediate Risk Group","code":"C161808","definitions":[{"definition":"A risk group associated with a total score of 3 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 46%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index High-Intermediate Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"High-Intermediate Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI High-Intermediate Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI High-Intermediate Risk Group","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High-Intermediate Risk"},{"name":"NCI_META_CUI","value":"CL970423"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C161809":{"preferredName":"International Prognostic Index High Risk Group","code":"C161809","definitions":[{"definition":"A risk group associated with a total score of 4 or 5 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 32%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Prognostic Index High Risk Group","termGroup":"PT","termSource":"NCI"},{"termName":"High Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI High Risk","termGroup":"SY","termSource":"NCI"},{"termName":"IPI Low High Group","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Risk"},{"name":"NCI_META_CUI","value":"CL970375"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148012":{"preferredName":"Intergroup Rhabdomyosarcoma Group I","code":"C148012","definitions":[{"definition":"Localized disease, excised.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group I","termGroup":"PT","termSource":"NCI"},{"termName":"Group I","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group I"},{"name":"NCI_META_CUI","value":"CL546054"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148013":{"preferredName":"Intergroup Rhabdomyosarcoma Group Ia","code":"C148013","definitions":[{"definition":"Confined to site of origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group Ia","termGroup":"PT","termSource":"NCI"},{"termName":"Group Ia","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group Ia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group Ia"},{"name":"NCI_META_CUI","value":"CL545835"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148014":{"preferredName":"Intergroup Rhabdomyosarcoma Group Ib","code":"C148014","definitions":[{"definition":"Infiltrative, beyond site of origin; negative lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group Ib","termGroup":"PT","termSource":"NCI"},{"termName":"Group Ib","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group Ib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group Ib"},{"name":"NCI_META_CUI","value":"CL545836"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148015":{"preferredName":"Intergroup Rhabdomyosarcoma Group II","code":"C148015","definitions":[{"definition":"Total gross resection with regional disease spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group II","termGroup":"PT","termSource":"NCI"},{"termName":"Group II","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group II"},{"name":"NCI_META_CUI","value":"CL545823"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148016":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIa","code":"C148016","definitions":[{"definition":"Localized tumor with microscopic residual disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIa","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIa","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIa"},{"name":"NCI_META_CUI","value":"CL545824"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148017":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIb","code":"C148017","definitions":[{"definition":"Regional disease with positive lymph nodes, excised.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIb","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIb","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIb"},{"name":"NCI_META_CUI","value":"CL545825"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148018":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIc","code":"C148018","definitions":[{"definition":"Regional disease with positive lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIc","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIc","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIc","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIc"},{"name":"NCI_META_CUI","value":"CL545826"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148019":{"preferredName":"Intergroup Rhabdomyosarcoma Group III","code":"C148019","definitions":[{"definition":"Gross residual disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group III","termGroup":"PT","termSource":"NCI"},{"termName":"Group III","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group III"},{"name":"NCI_META_CUI","value":"CL545827"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148020":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIIa","code":"C148020","definitions":[{"definition":"Localized or regional disease; biopsy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIIa","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIIa","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIIa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIIa"},{"name":"NCI_META_CUI","value":"CL545828"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148021":{"preferredName":"Intergroup Rhabdomyosarcoma Group IIIb","code":"C148021","definitions":[{"definition":"Localized or regional disease; resection (debulking of more than 50% of tumor).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IIIb","termGroup":"PT","termSource":"NCI"},{"termName":"Group IIIb","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IIIb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IIIb"},{"name":"NCI_META_CUI","value":"CL545829"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C148022":{"preferredName":"Intergroup Rhabdomyosarcoma Group IV","code":"C148022","definitions":[{"definition":"Distant metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergroup Rhabdomyosarcoma Group IV","termGroup":"PT","termSource":"NCI"},{"termName":"Group IV","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdomyosarcoma Group IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Group IV"},{"name":"NCI_META_CUI","value":"CL545830"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C95150":{"preferredName":"Ishak Score 0","code":"C95150","definitions":[{"definition":"No evidence of fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0 - No Fibrosis"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C2986946"}]}}{"C157159":{"preferredName":"Ishak Score 1-2","code":"C157159","definitions":[{"definition":"Portal fibrosis is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 1-2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1,2 - Portal Fibrosis"},{"name":"NCI_META_CUI","value":"CL936900"},{"name":"Semantic_Type","value":"Classification"}]}}{"C157161":{"preferredName":"Ishak Score 3-4","code":"C157161","definitions":[{"definition":"Fibrosis extends beyond the portal areas and bridging fibrosis is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 3-4","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3,4 - Fibrous Septa"},{"name":"NCI_META_CUI","value":"CL936896"},{"name":"Semantic_Type","value":"Classification"}]}}{"C95155":{"preferredName":"Ishak Score 5","code":"C95155","definitions":[{"definition":"Marked bridging fibrosis with formation of occasional hepatic nodules is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 5","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5 - Nodular Formation and Incomplete Cirrhosis"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C2986951"}]}}{"C95156":{"preferredName":"Ishak Score 6","code":"C95156","definitions":[{"definition":"Marked fibrosis with cirrhosis is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ishak Score 6","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6 - Established Cirrhosis"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C2986952"}]}}{"C70658":{"preferredName":"ISS Stage I Multiple Myeloma","code":"C70658","definitions":[{"definition":"Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS Stage I Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"International Staging System Stage I Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"International Staging System Stage I Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"ISS Stage I Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Myeloma Stage I","termGroup":"SY","termSource":"NCI"},{"termName":"Stage I Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage I Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ISS_Stage_I_Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"I"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2346458"}]}}{"C70659":{"preferredName":"ISS Stage II Multiple Myeloma","code":"C70659","definitions":[{"definition":"Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS Stage II Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"International Staging System Stage II Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"International Staging System Stage II Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"ISS Stage II Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Myeloma Stage II","termGroup":"SY","termSource":"NCI"},{"termName":"Stage II Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage II Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ISS_Stage_II_Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"II"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2346457"}]}}{"C70660":{"preferredName":"ISS Stage III Multiple Myeloma","code":"C70660","definitions":[{"definition":"Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS Stage III Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"International Staging System Stage III Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"International Staging System Stage III Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"ISS Stage III Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Myeloma Stage III","termGroup":"SY","termSource":"NCI"},{"termName":"Stage III Multiple Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage III Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ISS_Stage_III_Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2346456"}]}}{"C53696":{"preferredName":"Lesion with Diameter of 2 cm or Less","code":"C53696","synonyms":[{"termName":"Lesion with Diameter of 2 cm or Less","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesion_with_Diameter_of_2cm_or_Less"},{"name":"Maps_To","value":"Macroscopic (2cm or less)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1708687"}]}}{"C51138":{"preferredName":"Lesion with Diameter Greater than 2 cm","code":"C51138","synonyms":[{"termName":"Lesion with Diameter Greater than 2 cm","termGroup":"PT","termSource":"NCI"},{"termName":"Lesion with Diameter of More than 2 cm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesion_with_Diameter_of_More_than_2cm"},{"name":"Maps_To","value":"Macroscopic (greater than 2cm)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1708689"}]}}{"C25252":{"preferredName":"Microscopic","code":"C25252","definitions":[{"definition":"Too small to be seen except under a microscope.","type":"DEFINITION","source":"NCI"},{"definition":"Too small to be seen without a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Microscopic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microscopic"},{"name":"Maps_To","value":"Micro"},{"name":"Maps_To","value":"Microscopic"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0205288"}]}}{"C35933":{"preferredName":"Distantly Metastatic Malignant Neoplasm","code":"C35933","definitions":[{"definition":"A malignant tumor that has spread from its original (primary) site of growth to another site distant from the primary site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Distantly Metastatic Malignant Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Distantly_Metastatic_Neoplasm"},{"name":"Maps_To","value":"Distant met recurrence/progression"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333309"}]}}{"C8524":{"preferredName":"Locally Advanced Malignant Neoplasm","code":"C8524","definitions":[{"definition":"A malignant neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that has spread from where it started to nearby tissue or lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Refers to cancer that has grown beyond the original (primary) tumor to nearby lymph nodes or organs and tissues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Locally Advanced Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Locally Advanced Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Locally Metastatic Malignant Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Locally_Advanced_Malignant_Neoplasm"},{"name":"Legacy Concept Name","value":"Locally_Metastatic_Neoplasm"},{"name":"Maps_To","value":"Loco-regional recurrence/progression"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677984"}]}}{"C165197":{"preferredName":"Biochemical Evidence of Disease without Structural Correlate","code":"C165197","definitions":[{"definition":"An indication that biochemical markers of a disease are present but morphological markers are absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biochemical Evidence of Disease without Structural Correlate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biochemical evidence of disease without structural correlate"},{"name":"NCI_META_CUI","value":"CL978409"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156848":{"preferredName":"Tumor Free","code":"C156848","definitions":[{"definition":"There is no evidence of a tumor in the individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Free","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TF-Tumor Free"},{"name":"Maps_To","value":"Tumor free"},{"name":"NCI_META_CUI","value":"CL935966"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C158709":{"preferredName":"Unknown Tumor Status","code":"C158709","definitions":[{"definition":"The tumor status is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unknown Tumor Status","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unknown tumor status"},{"name":"NCI_META_CUI","value":"CL950740"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C156849":{"preferredName":"With Tumor","code":"C156849","definitions":[{"definition":"There is evidence of a tumor in an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"With Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"With tumor"},{"name":"Maps_To","value":"WT-With Tumor"},{"name":"NCI_META_CUI","value":"CL935963"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C13332":{"preferredName":"Bilateral","code":"C13332","definitions":[{"definition":"Affecting both sides of the body or a matched pair of organs.","type":"DEFINITION","source":"NCI"},{"definition":"Affecting both sides of the body, or a pair of organs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Affecting both the right and left sides of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bilateral","termGroup":"PT","termSource":"NCI"},{"termName":"Right and Left","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Bilateral"},{"name":"Maps_To","value":"Bilateral"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0238767"}]}}{"C25229":{"preferredName":"Left","code":"C25229","definitions":[{"definition":"Being or located on or directed toward the side of the body to the west when facing north.","type":"DEFINITION","source":"NCI"},{"definition":"Being or located on or directed toward the side of the body to the west when facing north.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Left","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Left"},{"name":"Maps_To","value":"Left"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205091"}]}}{"C81170":{"preferredName":"Midline","code":"C81170","definitions":[{"definition":"A medial line, especially the medial line or medial plane of the body (or some part of the body).","type":"DEFINITION","source":"NCI"},{"definition":"A medial line, especially the medial line or medial plane of the body (or some part of the body).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Midline","termGroup":"PT","termSource":"NCI"},{"termName":"Mesial","termGroup":"AD","termSource":"NCI"},{"termName":"Midplane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Midline"},{"name":"Maps_To","value":"Midline"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0549183"}]}}{"C25228":{"preferredName":"Right","code":"C25228","definitions":[{"definition":"Being or located on or directed toward the side of the body to the east when facing north.","type":"DEFINITION","source":"NCI"},{"definition":"Being or located on or directed toward the side of the body to the east when facing north.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Right","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Right"},{"name":"Maps_To","value":"Right"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205090"}]}}{"C28012":{"preferredName":"Unilateral","code":"C28012","definitions":[{"definition":"Affecting one side of the body or one of a pair of organs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Having to do with one side of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Unilateral","termGroup":"PT","termSource":"NCI"},{"termName":"Unilateral Anatomic Qualifier","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"unilateral"},{"name":"Maps_To","value":"Unilateral"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205092"}]}}{"C12904":{"preferredName":"Axillary Lymph Node","code":"C12904","definitions":[{"definition":"A lymph node in the armpit region that drains lymph from the breast and nearby areas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Lymph node(s) in the axillary region.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axillary Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"ALN","termGroup":"AB","termSource":"NCI"},{"termName":"Axillary Lymph Nodes","termGroup":"SY","termSource":"NCI"},{"termName":"Axillary Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Axillary_Lymph_Node"},{"name":"Maps_To","value":"Axillary"},{"name":"Maps_To","value":"Axillary lymph nodes"},{"name":"Maps_To","value":"Lymph Node(s) Axilla"},{"name":"Maps_To","value":"Lymph Node, Axillary"},{"name":"Maps_To","value":"Lymph nodes of axilla or arm"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0729594"}]}}{"C32298":{"preferredName":"Cervical Lymph Node","code":"C32298","definitions":[{"definition":"Any of the lymph nodes located in the neck.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in the cervical region, or neck.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cervical Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Cervical_Lymph_Node"},{"name":"Maps_To","value":"Cervical lymph nodes"},{"name":"Maps_To","value":"Cervical, NOS"},{"name":"Maps_To","value":"Lymph Node(s) Cervical"},{"name":"Maps_To","value":"Lymph Node, Cervical"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0588054"}]}}{"C98182":{"preferredName":"Epitrochlear Lymph Node","code":"C98182","definitions":[{"definition":"A lymph node located above and adjacent to the elbow.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located above and adjacent to the elbow. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Epitrochlear Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Epitrochlear"},{"name":"Maps_To","value":"Lymph Node(s) Epitrochlear"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229847"}]}}{"C98183":{"preferredName":"Femoral Lymph Node","code":"C98183","definitions":[{"definition":"A lymph node located in the upper inner portion of the thigh.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the upper inner portion of the thigh. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Femoral Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Femoral"},{"name":"Maps_To","value":"Lymph Node(s) Femoral"},{"name":"Maps_To","value":"Lymph Node, Femoral"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0877794"}]}}{"C102330":{"preferredName":"Perihilar Lymph Node","code":"C102330","definitions":[{"definition":"A lymph node located in the area around the hilum of an organ.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the area around the hilum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Perihilar Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Hilar"},{"name":"Maps_To","value":"Lymph Node(s) Hilar"},{"name":"Maps_To","value":"Lymph Node, Hilar"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3640700"}]}}{"C103384":{"preferredName":"Common Iliac Lymph Node","code":"C103384","definitions":[{"definition":"A lymph node located adjacent to the common iliac artery. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A lymph node located adjacent to the common iliac artery. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Common Iliac Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Iliac-common"},{"name":"Maps_To","value":"Lymph Node(s) Iliac-Common"},{"name":"Maps_To","value":"Lymph Node, Iliac-Common"},{"name":"NCI_META_CUI","value":"CL438194"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"xRef","value":"UBERON:0015878"}]}}{"C88143":{"preferredName":"External Iliac Lymph Node","code":"C88143","definitions":[{"definition":"A lymph node located along the external iliac artery.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located along the external iliac artery. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external iliac lymph nodes, from eight to ten in number, lie along the external iliac vessels. They are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent. Their principal afferents are derived from the inguinal lymph nodes, the deep lymphatics of the abdominal wall below the umbilicus and of the adductor region of the thigh, and the lymphatics from the glans penis vel clitoridis, the membranous urethra, the prostate, the fundus of the urinary bladder, the cervix uteri, and upper part of the vagina.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"External Iliac Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Iliac-external"},{"name":"Maps_To","value":"Lymph Node(s) Iliac-External"},{"name":"Maps_To","value":"Lymph Node, Iliac-External"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229815"},{"name":"xRef","value":"UBERON:0015880"}]}}{"C32761":{"preferredName":"Iliac Lymph Node","code":"C32761","definitions":[{"definition":"Lymph node(s) adjacent to the iliac vessels in the iliosacral region and cranial to the iliofemoral lymph node.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the three lymph nodes of the pelvis: the superior gluteal, interior gluteal or sacral.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iliac Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Iliac_Lymph_Node"},{"name":"Maps_To","value":"Iliac, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229807"}]}}{"C32801":{"preferredName":"Inguinal Lymph Node","code":"C32801","definitions":[{"definition":"A superficial or deep lymph node located in the inguinal area.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in the inguinal region.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Inguinal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Inguinal_Lymph_Node"},{"name":"Maps_To","value":"Inguinal"},{"name":"Maps_To","value":"Lymph Node(s) Inguinal"},{"name":"Maps_To","value":"Lymph Node, Inguinal"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0729596"}]}}{"C33073":{"preferredName":"Mediastinal Lymph Node","code":"C33073","definitions":[{"definition":"A lymph node located in the mediastinum. Mediastinal lymph nodes are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node that is part of a mediastinum. Each consists of several lymph node groups, especially along the trachea (5 groups), along the esophagus and between the lung and the diaphragm. In the mediastinal lymph nodes arises lymphatic ducts, which drains the lymph to the left subclavian vein (to the venous angle in the confluence of the subclavian and deep jugular veins). The mediastinal lymph nodes along the esophagus are in tight connection with the abdominal lymph nodes along the esophagus and the stomach. That fact facilitates spreading of tumors cells through these lymphatics in cases of cancers of the stomach and particularly of the esophagus. Through the mediastinum, the main lymphatic drainage from the abdominal organs goes via the thoracic duct (ductus thoracicus), which drains majority of the lymph from the abdomen to the above mentioned left venous angle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Lymph node(s) in the mediastinal region.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mediastinal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mediastinal_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Mediastinal"},{"name":"Maps_To","value":"Lymph Node, Mediastinal"},{"name":"Maps_To","value":"Lymph Nodes(s) Mediastinal"},{"name":"Maps_To","value":"Mediastinal"},{"name":"Maps_To","value":"Mediastinal lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0588055"},{"name":"xRef","value":"UBERON:0002524"}]}}{"C77641":{"preferredName":"Mesenteric Lymph Node","code":"C77641","definitions":[{"definition":"A lymph node located in the mesentery.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in or adjacent to the mesentery.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymph nodes located in the mesentery, of which there are 3 classes: ileocolic, juxtaintestinal mesenteric, and central superior group.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Mesenteric Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mesenteric_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Mesenteric"},{"name":"Maps_To","value":"Lymph Node, Mesenteric"},{"name":"Maps_To","value":"Mesenteric"},{"name":"Maps_To","value":"Mesenteric lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229792"},{"name":"xRef","value":"UBERON:0002509"}]}}{"C41132":{"preferredName":"None","code":"C41132","definitions":[{"definition":"No person or thing, nobody, not any.","type":"DEFINITION","source":"NCI"},{"definition":"No person or thing, nobody, not any. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"None","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"PRO-CTCAE"},{"name":"Legacy Concept Name","value":"None"},{"name":"Maps_To","value":"No Treatment"},{"name":"Maps_To","value":"None"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0549184"}]}}{"C98188":{"preferredName":"Occipital Lymph Node","code":"C98188","definitions":[{"definition":"A lymph node located in the back of the head adjacent to the trapezius muscle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located in the back of the head adjacent to the trapezius muscle.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the back of the head adjacent to the trapezius muscle.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Occipital Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Lymph Node(s) Occipital"},{"name":"Maps_To","value":"Occipital"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229711"},{"name":"xRef","value":"UBERON:0035204"}]}}{"C77643":{"preferredName":"Paraaortic Lymph Node","code":"C77643","definitions":[{"definition":"A lymph node located adjacent to the lumbar region of the spine.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) adjacent to the lumbar vertebral column.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The paraaortic lymph nodes (also known as para-aortic, periaortic, and peri-aortic) are a group of lymph nodes that lie in front of the lumbar vertebral bodies near the aorta. These lymph nodes receive drainage from the lower gastrointestinal tract and the pelvic organs.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Paraaortic Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Aortic Lymph Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Paraaortic_Lymph_Node"},{"name":"Maps_To","value":"Aortic"},{"name":"Maps_To","value":"Lymph Node(s) Paraaortic"},{"name":"Maps_To","value":"Lymph Node, Para-Aortic"},{"name":"Maps_To","value":"Paraaortic"},{"name":"Maps_To","value":"Paraaortic lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229789"},{"name":"xRef","value":"UBERON:0016386"}]}}{"C33278":{"preferredName":"Parotid Gland Lymph Node","code":"C33278","definitions":[{"definition":"A lymph node found near the parotid gland.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located close to, on, or within the parotid gland.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) in or adjacent to the parotid gland.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Parotid Gland Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Parotid_Gland_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Parotid"},{"name":"Maps_To","value":"Parotid"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229715"},{"name":"xRef","value":"UBERON:0015857"}]}}{"C53146":{"preferredName":"Popliteal Lymph Node","code":"C53146","definitions":[{"definition":"Lymph node located within the fat layer of the knee joint.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) adjacent to the femorotibial joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymph nodes which drain the legs; contained in the popliteal fossa.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Popliteal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Popliteal_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Popliteal"},{"name":"Maps_To","value":"Popliteal"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0588057"},{"name":"xRef","value":"UBERON:0001543"}]}}{"C98189":{"preferredName":"Retroperitoneal Lymph Node","code":"C98189","definitions":[{"definition":"A lymph node located in the retroperitoneal space.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the retroperitoneal space.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located in the retroperitoneal space. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Retroperitoneal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Lymph Node(s) Retroperitoneal"},{"name":"Maps_To","value":"Lymph Node, Retroperitoneal"},{"name":"Maps_To","value":"Retroperitoneal"},{"name":"Maps_To","value":"Retroperitoneal lymph nodes"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229802"},{"name":"xRef","value":"UBERON:0035371"}]}}{"C142320":{"preferredName":"Splenic Lymph Node","code":"C142320","definitions":[{"definition":"Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes.","type":"DEFINITION","source":"NCI"},{"definition":"The splenic lymph nodes (or pancreaticolienal) accompany the lienal (splenic) artery, and are situated in relation to the posterior surface and upper border of the pancreas; one or two members of this group are found in the gastrolienal ligament. Their afferents are derived from the stomach, spleen, and pancreas, their efferents join the celiac group of preaortic glands.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Splenic Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Lymph Node(s) Splenic"},{"name":"Maps_To","value":"Lymph Node, Splenic"},{"name":"Maps_To","value":"Splenic"},{"name":"Maps_To","value":"Splenic lymph nodes"},{"name":"NCI_META_CUI","value":"CL540362"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"xRef","value":"UBERON:0015469"}]}}{"C77650":{"preferredName":"Submandibular Lymph Node","code":"C77650","definitions":[{"definition":"A lymph node located beneath the floor of the oral cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) adjacent to the mandible.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The submandibular lymph nodes (submaxillary glands in older texts), three to six in number, are placed beneath the body of the mandible in the submaxillary triangle, and rest on the superficial surface of the submaxillary salivary gland. One gland, the middle gland of Stahr, which lies on the external maxillary artery as it turns over the mandible, is the most constant of the series; small lymph glands are sometimes found on the deep surface of the submaxillary salivary glands. The afferents of the submaxillary glands drain the medial palpebral commissure, the cheek, the side of the nose, the upper lip, the lateral part of the lower lip, the gums, and the anterior part of the margin of the tongue. Efferent vessels from the facial and submental glands also enter the submaxillary glands. Their efferent vessels pass to the superior deep cervical glands.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Submandibular Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Submandibular_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Submandibular"},{"name":"Maps_To","value":"Lymph Node, Submandibular"},{"name":"Maps_To","value":"Submandibular"},{"name":"Maps_To","value":"Submandibular lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229722"},{"name":"xRef","value":"UBERON:0002520"}]}}{"C12903":{"preferredName":"Supraclavicular Lymph Node","code":"C12903","definitions":[{"definition":"A lymph node which is located above the clavicle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node which is located above the clavicle.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node which is located above the clavicle. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Lymph nodes located above the clavicle (collarbone).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Supraclavicular Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Supraclavicular Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Supraclavicular_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Supraclavicular"},{"name":"Maps_To","value":"Lymph Node, Supraclavicular"},{"name":"Maps_To","value":"Supraclavicular"},{"name":"Maps_To","value":"Supraclavicular lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229730"},{"name":"xRef","value":"UBERON:0035279"}]}}{"C162125":{"preferredName":"Gerota Fascia","code":"C162125","definitions":[{"definition":"A fibrous connective tissue covering the kidney and adrenal gland, which separates the perinephric fat from paranephric fat.","type":"DEFINITION","source":"NCI"},{"definition":"A fibrous envelope of tissue that surrounds the kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gerota Fascia","termGroup":"PT","termSource":"NCI"},{"termName":"Anterior Perirenal Fascia","termGroup":"SY","termSource":"NCI"},{"termName":"Gerota's Fascia","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Fascia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gerota Fascia"},{"name":"NCI_META_CUI","value":"CL970599"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"}]}}{"C74601":{"preferredName":"Parenchyma","code":"C74601","definitions":[{"definition":"The essential or functional elements of an organ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tissue that constitutes the essential part of an organ as contrasted with e.g., connective tissue and blood vessels.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Parenchyma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Parenchyma"},{"name":"Maps_To","value":"Parenchyma"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0933845"}]}}{"C162218":{"preferredName":"Perinephric Fat","code":"C162218","definitions":[{"definition":"A layer of fatty tissue surrounding the kidney, bounded by the renal capsule and the renal fascia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perinephric Fat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perinephric Fat"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227617"}]}}{"C12885":{"preferredName":"Renal Capsule","code":"C12885","definitions":[{"definition":"A layer of dense connective tissue that covers the outer surface of each kidney.","type":"DEFINITION","source":"NCI"},{"definition":"The fibrous connective tissue that surrounds each kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Renal Capsule","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Capsule"},{"name":"Maps_To","value":"Renal Capsule"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227637"}]}}{"C162219":{"preferredName":"Renal Sinus","code":"C162219","definitions":[{"definition":"A cavity in the kidney containing the pelvicalyceal system, blood vessels, nerves and fat. It communicates with the perinephric space.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Sinus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Sinus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227672"}]}}{"C33462":{"preferredName":"Renal Vein","code":"C33462","definitions":[{"definition":"A vein arising from the kidney; in general it drains into the caudal vena cava vein.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The veins which return blood from the kidneys to the vena cava.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Vein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Vein"},{"name":"Maps_To","value":"Renal Vein"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0035092"}]}}{"C112007":{"preferredName":"Masaoka-Koga Stage I","code":"C112007","definitions":[{"definition":"The tumor is completely encapsulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829188"}]}}{"C112008":{"preferredName":"Masaoka-Koga Stage IIa","code":"C112008","definitions":[{"definition":"The tumor shows microscopic invasion into the capsule.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IIa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIa"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829187"}]}}{"C112009":{"preferredName":"Masaoka-Koga Stage IIb","code":"C112009","definitions":[{"definition":"The tumor shows invasion through the capsule and into the surrounding fatty tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IIb","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage IIb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IIb"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829186"}]}}{"C112010":{"preferredName":"Masaoka-Koga Stage III","code":"C112010","definitions":[{"definition":"The tumor shows invasion into the neighboring tissues and organs of the lower neck or upper chest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage III","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829185"}]}}{"C112011":{"preferredName":"Masaoka-Koga Stage IVa","code":"C112011","definitions":[{"definition":"The tumor shows metastasis throughout the pleural and/or pericardial spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IVa","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage IVa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVa"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829184"}]}}{"C112012":{"preferredName":"Masaoka-Koga Stage IVb","code":"C112012","definitions":[{"definition":"The tumor shows lymphogenous or hematogenous metastasis to distant sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masaoka-Koga Stage IVb","termGroup":"PT","termSource":"NCI"},{"termName":"Masaoka Stage IVb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IVb"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3829183"}]}}{"C129447":{"preferredName":"Medulloblastoma, Not Otherwise Specified","code":"C129447","definitions":[{"definition":"A medulloblastoma which has not been further characterized.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Medulloblastoma, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9470/3"},{"name":"Maps_To","value":"Medulloblastoma, NOS"},{"name":"Maps_To","value":"Not Determined"},{"name":"NCI_META_CUI","value":"CL512714"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129444":{"preferredName":"Medulloblastoma, Non-WNT/Non-SHH","code":"C129444","definitions":[{"definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. TP53 mutations are absent. This molecular subtype includes medulloblastomas numerically designated as \"group 3\" and \"group 4\".","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Non-WNT/Non-SHH","termGroup":"PT","termSource":"NCI"},{"termName":"Non-WNT/Non-SHH Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9477/3"},{"name":"Maps_To","value":"Medulloblastoma, non-WNT/non-SHH"},{"name":"Maps_To","value":"Non-WNT/non-SHH Activated"},{"name":"NCI_META_CUI","value":"CL512713"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129441":{"preferredName":"Medulloblastoma, SHH-Activated","code":"C129441","definitions":[{"definition":"A molecular subtype of medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway. TP53 mutations may be present or absent. Patients in this group are young children and adults. Overall survival is variable and depends on the presence or absence of metastatic disease, histology, and the age at diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, SHH-Activated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SHH-Activated"},{"name":"NCI_META_CUI","value":"CL512717"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129440":{"preferredName":"Medulloblastoma, WNT-Activated","code":"C129440","definitions":[{"definition":"A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, WNT-Activated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9475/3"},{"name":"Maps_To","value":"Medulloblastoma, WNT-activated"},{"name":"Maps_To","value":"Medulloblastoma, WNT-activated, NOS"},{"name":"Maps_To","value":"WNT-Activated"},{"name":"NCI_META_CUI","value":"CL512718"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C18206":{"preferredName":"Distant Metastasis","code":"C18206","definitions":[{"definition":"A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Distant Metastasis","termGroup":"PT","termSource":"NCI"},{"termName":"Distant","termGroup":"SY","termSource":"NCI"},{"termName":"Distant Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Distant_Metastasis"},{"name":"Maps_To","value":"Distant Metastasis"},{"name":"NCI_META_CUI","value":"CL1793019"},{"name":"Semantic_Type","value":"Pathologic Function"}]}}{"C164041":{"preferredName":"Metastasis Negative","code":"C164041","definitions":[{"definition":"An indication that signs of metastasis were not found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasis Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Negative for Metastasis","termGroup":"SY","termSource":"NCI"},{"termName":"No Metastasis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Metastasis"},{"name":"NCI_META_CUI","value":"CL979263"},{"name":"Semantic_Type","value":"Finding"}]}}{"C172220":{"preferredName":"Regional Metastasis Present","code":"C172220","definitions":[{"definition":"An indication that cancer cells have migrated from the primary tumor site and have been detected in adjacent tissues and/or regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regional Metastasis Present","termGroup":"PT","termSource":"NCI"},{"termName":"Regional Metastasis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regional Metastasis"},{"name":"NCI_META_CUI","value":"CL1406102"},{"name":"Semantic_Type","value":"Finding"}]}}{"C12664":{"preferredName":"Abdomen","code":"C12664","definitions":[{"definition":"The area of the body that contains the pancreas, stomach, intestine, liver, gallbladder, and other organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The body cavity between the thoracic and pelvic cavities in mammals.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.","type":"DEFINITION","source":"NCI"},{"definition":"The subdivision of the vertebrate body between the thorax and pelvis. The ventral part of the abdomen contains the abdominal cavity and visceral organs. The dorsal part includes the abdominal section of the vertebral column.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Abdomen","termGroup":"PT","termSource":"NCI"},{"termName":"Abdominal Cavity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Abdominal_Cavity"},{"name":"Maps_To","value":"Abdomen"},{"name":"Maps_To","value":"Abdomen, NOS"},{"name":"Maps_To","value":"Abdomen, total"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0230168"},{"name":"xRef","value":"UBERON:0003684"}]}}{"C2885":{"preferredName":"Peritoneal Effusion","code":"C2885","definitions":[{"definition":"A clinical finding in which there is accumulation of interstitial fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormal buildup of fluid in the abdomen that may cause swelling. In late-stage cancer, tumor cells may be found in the fluid in the abdomen. Ascites also occurs in patients with liver disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Abnormal collection of fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Accumulation of fluid in the peritoneal cavity. The fluid may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Intra-abdominal fluid accumulation as determined by physical examination.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","type":"DEFINITION","source":"NCI"},{"definition":"The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Peritoneal Effusion","termGroup":"PT","termSource":"NCI"},{"termName":"Ascites","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Ascites"},{"name":"Legacy Concept Name","value":"Peritoneal_Effusion"},{"name":"Maps_To","value":"Ascites"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3554541"},{"name":"xRef","value":"IMDRF:E1004"}]}}{"C12366":{"preferredName":"Bone","code":"C12366","definitions":[{"definition":"Calcified connective tissue that forms the skeletal components of the body. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Bones","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Bone"},{"name":"Maps_To","value":"Bone"},{"name":"Maps_To","value":"Bone, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0262950"},{"name":"xRef","value":"UBERON:0001474"},{"name":"xRef","value":"UBERON:0002481"}]}}{"C12431":{"preferredName":"Bone Marrow","code":"C12431","definitions":[{"definition":"The soft tissue that fills the cavities of bones.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","type":"DEFINITION","source":"NCI"},{"definition":"The tissue occupying the spaces of some bones. It consists of blood vessel sinuses and a network of hematopoietic cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bone Marrow","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Bone Marrow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bone_Marrow"},{"name":"Maps_To","value":"Bone marrow"},{"name":"Maps_To","value":"Bone Marrow"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005953"},{"name":"xRef","value":"UBERON:0002371"}]}}{"C12438":{"preferredName":"Central Nervous System","code":"C12438","definitions":[{"definition":"The brain and spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the neural tube derivatives: the brain and spinal cord. In invertebrates it includes central ganglia plus nerve cord.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Central Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Nervous System, CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Central_Nervous_System"},{"name":"Maps_To","value":"Central nervous system"},{"name":"Maps_To","value":"Central Nervous System"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C3714787"},{"name":"xRef","value":"UBERON:0001017"}]}}{"C12692":{"preferredName":"Cerebrospinal Fluid","code":"C12692","definitions":[{"definition":"A clear, colorless, bodily fluid, that occupies the subarachnoid space and the ventricular system around and inside the brain and spinal cord.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fluid that flows in and around the hollow spaces of the brain and spinal cord, and between two of the meninges (the thin layers of tissue that cover and protect the brain and spinal cord). CSF is made by tissue called the choroid plexus in the ventricles (hollow spaces) in the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cerebrospinal Fluid","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebral Spinal Fluid","termGroup":"SY","termSource":"NCI"},{"termName":"CSF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cerebrospinal_Fluid"},{"name":"Maps_To","value":"Cerebrospinal Fluid"},{"name":"Maps_To","value":"Cerebrospinal fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0007806"},{"name":"xRef","value":"UBERON:0001359"}]}}{"C172221":{"preferredName":"Metastasis Present in Distant Lymph Node","code":"C172221","definitions":[{"definition":"An indication that cancer cells have migrated from the primary tumor site and have been detected in one or more distant lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasis Present in Distant Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Metastasis in Distant Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Metastasis in Distant Lymph Node Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Nodes"},{"name":"NCI_META_CUI","value":"CL1406101"},{"name":"Semantic_Type","value":"Finding"}]}}{"C172223":{"preferredName":"Metastasis Present in Distant Organ","code":"C172223","definitions":[{"definition":"An indication that cancer cells have migrated and spread to one or more organs that are distant from the primary tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasis Present in Distant Organ","termGroup":"PT","termSource":"NCI"},{"termName":"Metastasis in Distant Organ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Organ"},{"name":"NCI_META_CUI","value":"CL1406099"},{"name":"Semantic_Type","value":"Finding"}]}}{"C12726":{"preferredName":"Inguinal Region","code":"C12726","definitions":[{"definition":"The area where the thigh meets the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The external junctural region between the lower part of the abdomen and the thigh.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower region of the anterior abdominal wall located laterally to the pubic region.","type":"DEFINITION","source":"NCI"},{"definition":"The lower region of the anterior abdominal wall located laterally to the pubic region. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Inguinal Region","termGroup":"PT","termSource":"NCI"},{"termName":"Groin","termGroup":"SY","termSource":"NCI"},{"termName":"Inguinal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Inguinal_Region"},{"name":"Maps_To","value":"Groin"},{"name":"Maps_To","value":"Inguinal"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0018246"},{"name":"xRef","value":"UBERON:0008337"}]}}{"C12392":{"preferredName":"Liver","code":"C12392","definitions":[{"definition":"A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.","type":"DEFINITION","source":"NCI"},{"definition":"An abdominal organ that has variable lobation which are composed mainly of hepatic lobules.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Liver","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Hepatic","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Hepatic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Liver"},{"name":"Maps_To","value":"Liver"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0023884"},{"name":"xRef","value":"UBERON:0002107"}]}}{"C12468":{"preferredName":"Lung","code":"C12468","definitions":[{"definition":"A thoracic organ that has variable lobation and is the primary respiratory organ of mammals.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of a pair of organs in the chest that supplies the body with oxygen, and removes carbon dioxide from the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.","type":"DEFINITION","source":"NCI"},{"definition":"Respiration organ that develops as an outpocketing of the esophagus.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lungs","termGroup":"SY","termSource":"NCI"},{"termName":"Respiratory System, Lung","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lung"},{"name":"Maps_To","value":"Lung"},{"name":"Maps_To","value":"Lung, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024109"},{"name":"xRef","value":"UBERON:0002048"}]}}{"C12748":{"preferredName":"Mediastinum","code":"C12748","definitions":[{"definition":"An anatomic site along the midline and under the sternum that contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.","type":"DEFINITION","source":"NCI"},{"definition":"The area between the lungs. The organs in this area include the heart and its large blood vessels, the trachea, the esophagus, the thymus, and lymph nodes but not the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The central part of the thoracic cavity enclosed by the left and right pleurae.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The central region of the thoracic cavity of mammals containing a group of organs surrounded by loose connective tissue, which separates the two pleural sacs.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mediastinum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mediastinum"},{"name":"Maps_To","value":"Mediastinum"},{"name":"Maps_To","value":"Mediastinum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0025066"},{"name":"xRef","value":"UBERON:0003728"}]}}{"C33209":{"preferredName":"Omentum","code":"C33209","definitions":[{"definition":"A double layer of peritoneum covering abdominal organs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A fold of peritoneum originating at the stomach and supporting the viscera.","type":"DEFINITION","source":"NCI"},{"definition":"A fold of peritoneum originating at the stomach and supporting the viscera.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A fold of the peritoneum (the thin tissue that lines the abdomen) that surrounds the stomach and other organs in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Omentum","termGroup":"PT","termSource":"NCI"},{"termName":"Omental Fat","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Omentum"},{"name":"Maps_To","value":"Omentum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0028977"},{"name":"xRef","value":"UBERON:0003688"}]}}{"C12767":{"preferredName":"Pelvis","code":"C12767","definitions":[{"definition":"The bony, basin-shaped structure formed by the bones of the pelvis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.","type":"DEFINITION","source":"NCI"},{"definition":"The lower part of the abdomen, located between the hip bones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lower segment of the trunk, inferoposterior to the abdomen proper, in the transition area between the trunk and the lower limbs.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pelvis","termGroup":"PT","termSource":"NCI"},{"termName":"Pelvic","termGroup":"SY","termSource":"NCI"},{"termName":"Pelvic Cavity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pelvis"},{"name":"Maps_To","value":"Pelvis"},{"name":"Maps_To","value":"Pelvis, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0030797"},{"name":"xRef","value":"UBERON:0001270"},{"name":"xRef","value":"UBERON:0002355"}]}}{"C12769":{"preferredName":"Peritoneal Cavity","code":"C12769","definitions":[{"definition":"A part of the abdominal cavity that lies between the visceral and parietal peritoneum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Anatomical cavity bounded by visceral and parietal peritoneum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The potential space located between the parietal and visceral layers of the peritoneum.","type":"DEFINITION","source":"NCI"},{"definition":"The space within the abdomen that contains the intestines, the stomach, and the liver. It is bound by thin membranes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peritoneal Cavity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Peritoneal_Cavity"},{"name":"Maps_To","value":"Peritoneal Cavity"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C1704247"},{"name":"xRef","value":"UBERON:0001179"}]}}{"C12770":{"preferredName":"Peritoneum","code":"C12770","definitions":[{"definition":"A serous membrane that lines the peritoneal cavity.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The membrane that lines the abdominal and pelvic cavities.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissue that lines the abdominal wall and covers most of the organs in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tissue that lines the wall of the abdominal cavity, intestine, mesentery, and pelvic organs. It consists of the parietal peritoneum and the visceral peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Peritoneum"},{"name":"Maps_To","value":"Peritoneum"},{"name":"Maps_To","value":"Peritoneum, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0031153"},{"name":"xRef","value":"UBERON:0002358"}]}}{"C12469":{"preferredName":"Pleura","code":"C12469","definitions":[{"definition":"A thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity. It protects and cushions the lungs. This tissue secretes a small amount of fluid that acts as a lubricant, allowing the lungs to move smoothly in the chest cavity while breathing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The invaginated serous membrane that surrounds the lungs (the visceral portion) and lines the walls of the pleural cavity (parietal portion).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The serous membrane that lines the wall of the thoracic cavity and the surface of the lungs.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissue that lines the wall of the thoracic cavity and the surface of the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleura","termGroup":"PT","termSource":"NCI"},{"termName":"PLEURA","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pleural_Tissue"},{"name":"Maps_To","value":"Pleura"},{"name":"Maps_To","value":"Pleura, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0032225"},{"name":"xRef","value":"UBERON:0000977"}]}}{"C89807":{"preferredName":"Scalp","code":"C89807","definitions":[{"definition":"The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendonous galea aponeurotica; Loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The skin which covers the top of the head and which is usually covered by hair.","type":"DEFINITION","source":"NCI"},{"definition":"The skin which covers the top of the head and which is usually covered by hair. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Scalp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Scalp"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036270"},{"name":"xRef","value":"UBERON:0000403"}]}}{"C12471":{"preferredName":"Soft Tissue","code":"C12471","definitions":[{"definition":"A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Refers to muscle, fat, fibrous tissue, blood vessels, organ parenchyma, or other supporting tissue of the body.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Soft_Tissue"},{"name":"Maps_To","value":"Soft Tissue"},{"name":"Maps_To","value":"Soft tissue"},{"name":"Maps_To","value":"Soft tissue (muscle, ligaments, subcutaneous)"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0225317"},{"name":"xRef","value":"UBERON:0034929"}]}}{"C12464":{"preferredName":"Spinal Cord","code":"C12464","definitions":[{"definition":"A column of nerve tissue that runs from the base of the skull down the back. It is surrounded by three protective membranes, and is enclosed within the vertebrae (back bones). The spinal cord and the brain make up the central nervous system, and spinal cord nerves carry most messages between the brain and the rest of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Part of the central nervous system located in the vertebral canal continuous with and caudal to the brain; demarcated from brain by plane of foramen magnum. It is composed of an inner core of gray matter in which nerve cells predominate, and an outer layer of white matter in which myelinated nerve fibers predominate, and surrounds the central canal.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The elongated, approximately cylindrical part of the central nervous system of vertebrates that lies in the vertebral canal and from which the spinal nerves emerge.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The portion of the central nervous system that lies within the vertebral canal and from which the spinal nerves emerge.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Spinal Cord","termGroup":"PT","termSource":"NCI"},{"termName":"Medulla Spinalis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Spinal_Cord"},{"name":"Maps_To","value":"Spinal cord"},{"name":"Maps_To","value":"Spinal Cord"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037925"},{"name":"xRef","value":"UBERON:0002240"}]}}{"C34082":{"preferredName":"Gastrointestinal Tract","code":"C34082","definitions":[{"definition":"A tube extending from the mouth to the anus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff.","type":"DEFINITION","source":"NCI"},{"definition":"The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gastrointestinal Tract","termGroup":"PT","termSource":"NCI"},{"termName":"Alimentary Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Digestive Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Gut","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Tract"},{"name":"Maps_To","value":"Gastrointestinal Tract"},{"name":"Maps_To","value":"Gastrointestinal tract, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0017189"},{"name":"xRef","value":"UBERON:0001555"}]}}{"C12727":{"preferredName":"Heart","code":"C12727","definitions":[{"definition":"A hollow muscular organ which receives the blood from the veins and pumps it into the arteries.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A hollow organ located slightly to the left of the middle portion of the chest. It is composed of muscle and it is divided by a septum into two sides: the right side which receives de-oxygenated blood from the body and the left side which sends newly oxygenated blood to the body. Each side is composed of two chambers: the atrium (receiving blood) and ventricle (ejecting blood).","type":"DEFINITION","source":"NCI"},{"definition":"A myogenic muscular circulatory organ found in the vertebrate cardiovascular system composed of chambers of cardiac muscle. It is the primary circulatory organ.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Heart","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiac","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Heart"},{"name":"Maps_To","value":"Heart"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0018787"},{"name":"xRef","value":"IMDRF:E06"},{"name":"xRef","value":"UBERON:0000948"}]}}{"C13063":{"preferredName":"Neck","code":"C13063","definitions":[{"definition":"An organism subdivision that extends from the head to the pectoral girdle, encompassing the cervical vertebral column.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region that connects the head to the rest of the body.","type":"DEFINITION","source":"NCI"},{"definition":"The region that connects the head to the rest of the body. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Neck","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Neck"},{"name":"Maps_To","value":"Neck"},{"name":"Maps_To","value":"Neck, Left"},{"name":"Maps_To","value":"Neck, NOS"},{"name":"Maps_To","value":"Neck, Right"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0027530"},{"name":"xRef","value":"UBERON:0000974"}]}}{"C12298":{"preferredName":"Retroperitoneum","code":"C12298","definitions":[{"definition":"Anatomical space in the abdominal cavity behind (retro) the peritoneum. It has no specific delineating anatomical structures. Organs are retroperitoneal if they only have peritoneum on their anterior side.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The back of the abdomen where the kidneys lie and the great blood vessels run.","type":"DEFINITION","source":"NCI"},{"definition":"The region of the abdomen outside the peritoneum, where the kidneys lie and the great blood vessels run.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Retroperitoneum","termGroup":"PT","termSource":"NCI"},{"termName":"Retroperitoneal Cavity","termGroup":"SY","termSource":"NCI"},{"termName":"Retroperitoneal Space","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Retroperitoneum"},{"name":"Maps_To","value":"Retroperitoneum"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0035359"},{"name":"xRef","value":"UBERON:0003693"}]}}{"C12417":{"preferredName":"Urethra","code":"C12417","definitions":[{"definition":"The fibromuscular tubular canal through which urine is discharged from the bladder to the exterior via the external urinary meatus; in males, the urethra is joined by the ejaculatory ducts and serves as a passageway for semen during ejaculation, as well as a canal for urine during voiding; in females, the urethra is shorter and emerges above the vaginal opening.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The tube carrying urine from the bladder to outside of the body.","type":"DEFINITION","source":"NCI"},{"definition":"The tube that extends from the urinary bladder to the urethral opening.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tube through which urine leaves the body. It empties urine from the bladder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Urethra","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Urethra"},{"name":"Maps_To","value":"Urethra"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0041967"},{"name":"xRef","value":"UBERON:0000057"}]}}{"C12321":{"preferredName":"Appendage of the Uterus","code":"C12321","definitions":[{"definition":"The accessory structures of the uterus, including the ovaries, fallopian tubes, broad ligament, and the ovarian and uterine ligaments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Appendage of the Uterus","termGroup":"PT","termSource":"NCI"},{"termName":"Uterine Adnexa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Appendage_of_the_Uterus"},{"name":"Maps_To","value":"Uterine adnexa"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0001575"}]}}{"C33869":{"preferredName":"Vertebral Canal","code":"C33869","definitions":[{"definition":"The space formed by the series of vertebral foramina that courses the length of the vertebral column, and which houses the spinal cord and meninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vertebral Canal","termGroup":"PT","termSource":"NCI"},{"termName":"Spinal Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Vertebral_Canal"},{"name":"Maps_To","value":"Vertebral Canal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037922"}]}}{"C117873":{"preferredName":"Subcarinal Lymph Node","code":"C117873","definitions":[{"definition":"A lymph node located in the thoracic cavity between the lungs. It is bordered by the carina of the trachea, lower lobe bronchus on the left and the bronchus intermedius on the right.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the thoracic cavity between the lungs. It is bordered by the carina of the trachea, lower lobe bronchus on the left and the bronchus intermedius on the right. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Subcarinal Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node, Subcarinal"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229753"}]}}{"C12683":{"preferredName":"Bronchus","code":"C12683","definitions":[{"definition":"The large air passages that lead from the trachea (windpipe) to the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The upper conducting airways of the lung; these airways arise from the terminus of the trachea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole).","type":"DEFINITION","source":"NCI"},{"definition":"Tubular structure in continuation with the trachea, serving as an air passage.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bronchus","termGroup":"PT","termSource":"NCI"},{"termName":"Bronchi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bronchus"},{"name":"Maps_To","value":"Bronchus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006255"},{"name":"xRef","value":"UBERON:0002185"}]}}{"C49018":{"preferredName":"Regional Lymph Node","code":"C49018","definitions":[{"definition":"A lymph node that drains lymph from a region of interest.","type":"DEFINITION","source":"NCI"},{"definition":"In oncology, a lymph node that drains lymph from the region around a tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Lymph node(s) that drains the lymph from a region of interest.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Regional Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Regional_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Regional"},{"name":"Maps_To","value":"Lymph Node, Regional"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1184738"}]}}{"C12432":{"preferredName":"Spleen","code":"C12432","definitions":[{"definition":"An abdominal organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule. It is located in the left hypochondriac region. Its functions include lymphocyte production, blood cell storage, and blood cell destruction.","type":"DEFINITION","source":"NCI"},{"definition":"An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The organ that functions to filter blood and to store red corpuscles and platelets.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Spleen","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Spleen"},{"name":"Maps_To","value":"Spleen"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037993"},{"name":"xRef","value":"UBERON:0002106"}]}}{"C15189":{"preferredName":"Biopsy","code":"C15189","definitions":[{"definition":"Patient required removal of tissue or fluid specimen to establish a diagnosis.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Bx","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Biopsy"},{"name":"Maps_To","value":"Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0005558"},{"name":"xRef","value":"IMDRF:F2201"}]}}{"C17610":{"preferredName":"Blood Sample","code":"C17610","definitions":[{"definition":"A small volume of blood removed for testing or storage.","type":"DEFINITION","source":"NCI"},{"definition":"Taking a sample of blood by using a needle. (https://mrctcenter.org/glossaryterm/blood-draw/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Blood Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Blood_Sample"},{"name":"Maps_To","value":"Blood Draw"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0178913"}]}}{"C133261":{"preferredName":"Bone Marrow Aspirate","code":"C133261","definitions":[{"definition":"Aspirate from bone marrow.","type":"DEFINITION","source":"NCI"},{"definition":"The liquid portion of bone marrow, consisting of small tissue fragments, hematopoietic cells, and peripheral blood.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bone Marrow Aspirate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone Marrow Aspirate"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0857285"}]}}{"C15680":{"preferredName":"Core Biopsy","code":"C15680","definitions":[{"definition":"A type of biopsy in which a tissue sample is removed using a needle with a relatively large diameter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of a tissue sample with a wide needle for examination under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Core Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Core Needle Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Core_Biopsy"},{"name":"Maps_To","value":"Core Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C1318309"}]}}{"C16491":{"preferredName":"Cytology","code":"C16491","definitions":[{"definition":"The light microscopic study of normal and abnormal cells in fine needle aspirates (FNAs), body cavity fluids, and smears.","type":"DEFINITION","source":"NCI"},{"definition":"The study of cells using a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cytology","termGroup":"PT","termSource":"NCI"},{"termName":"Histology, Cytology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Cytology"},{"name":"Maps_To","value":"Cytology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0010819"}]}}{"C16482":{"preferredName":"Cystoscopy","code":"C16482","definitions":[{"definition":"Endoscopic examination of the urinary bladder or urethra.","type":"DEFINITION","source":"NCI"},{"definition":"Endoscopic examination of the urinary bladder or urethra.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Examination of the bladder and urethra using a cystoscope, inserted into the urethra. A cystoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cystoscopy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystoscopy"},{"name":"Maps_To","value":"Cystoscopy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0553652"}]}}{"C15749":{"preferredName":"Tumor Debulking","code":"C15749","definitions":[{"definition":"Surgical removal of as much of a tumor as possible. Tumor debulking may increase the chance that chemotherapy or radiation therapy will kill all the tumor cells. It may also be done to relieve symptoms or help the patient live longer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of as much of a malignant tumor as is reasonably possible. This procedure increases the effectiveness of the subsequent administration of chemotherapy and/or radiation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Debulking","termGroup":"PT","termSource":"NCI"},{"termName":"Debulking","termGroup":"SY","termSource":"NCI"},{"termName":"Debulking Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Debulking Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tumor_Debulking"},{"name":"Maps_To","value":"Debulking"},{"name":"Maps_To","value":"Tumor Debulking"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0439805"}]}}{"C16502":{"preferredName":"Diagnostic Imaging","code":"C16502","definitions":[{"definition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diagnostic Imaging","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diagnostic_Imaging"},{"name":"Maps_To","value":"Diagnostic Imaging"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0011923"}]}}{"C15226":{"preferredName":"Dilation and Curettage","code":"C15226","definitions":[{"definition":"A minor operation in which the cervix is expanded enough (dilation) to permit the cervical canal and uterine lining to be scraped with a spoon-shaped instrument called a curette (curettage).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A surgical scraping and removal of the inner lining of the uterus through direct dilation of the uterine cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dilation and Curettage","termGroup":"PT","termSource":"NCI"},{"termName":"D and C","termGroup":"SY","termSource":"NCI"},{"termName":"Dilation and Curettage of the Uterus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dilation_and_Curettage"},{"name":"Maps_To","value":"Dilation and Curettage Procedure"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C4067681"}]}}{"C48601":{"preferredName":"Enucleation","code":"C48601","definitions":[{"definition":"A surgical procedure by which tissue or an organ (usually containing a tumor) is removed without rupture from a specific anatomic site.","type":"DEFINITION","source":"NCI"},{"definition":"In medicine, the removal of an organ or tumor in such a way that it comes out clean and whole, like a nut from its shell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Enucleation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Enucleation"},{"name":"Maps_To","value":"Enucleation"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0014392"}]}}{"C15385":{"preferredName":"Excisional Biopsy","code":"C15385","definitions":[{"definition":"A surgical procedure in which an entire lesion is removed for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"A surgical procedure in which an entire lump or suspicious area is removed for diagnosis. The tissue is then examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of biopsy in which an entire lesion is removed for microscopic examination.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Excisional Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Excisional_Biopsy"},{"name":"Maps_To","value":"Biopsy, Excisional"},{"name":"Maps_To","value":"Excisional Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0184921"}]}}{"C15361":{"preferredName":"Fine-Needle Aspiration","code":"C15361","definitions":[{"definition":"The removal of tissue or fluid with a thin needle for examination under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of tissue or fluid with a thin needle for examination under a microscope.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of tissue specimens or fluid from the living body with a thin needle.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fine-Needle Aspiration","termGroup":"PT","termSource":"NCI"},{"termName":"Aspirate, Fine Needle","termGroup":"SY","termSource":"NCI"},{"termName":"Fine Needle Aspiration","termGroup":"SY","termSource":"NCI"},{"termName":"Fine Needle Biopsy","termGroup":"SY","termSource":"NCI"},{"termName":"FNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Fine-Needle_Aspiration"},{"name":"Maps_To","value":"Fine Needle Aspiration"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C1510483"}]}}{"C17369":{"preferredName":"Imaging Technique","code":"C17369","definitions":[{"definition":"A method of producing pictures of areas inside the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.","type":"DEFINITION","source":"NCI"},{"definition":"Method of imaging used to visualize and aspect of the patient for use in diagnosis or treatment.","type":"ALT_DEFINITION","source":"OORO","qualifiers":[{"type":"attribution","value":"PC"}]}],"synonyms":[{"termName":"Imaging Technique","termGroup":"PT","termSource":"NCI"},{"termName":"Diagnostic Imaging Technique","termGroup":"SY","termSource":"NCI"},{"termName":"Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"Imaging Procedures","termGroup":"SY","termSource":"NCI"},{"termName":"Imaging Technique","termGroup":"SY","termSource":"NCI"},{"termName":"Medical Imaging","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Imaging_Technique"},{"name":"Maps_To","value":"Imaging"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0079595"}]}}{"C15386":{"preferredName":"Incisional Biopsy","code":"C15386","definitions":[{"definition":"A procedure in which a surgical incision (cut) is made through the skin to expose and remove tissues. The biopsy tissue is examined under a microscope by a pathologist. An open biopsy may be done in the doctor's office or in the hospital, and may use local anesthesia or general anesthesia. A lumpectomy to remove a breast tumor is a type of open biopsy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A surgical procedure in which part of a lesion is removed for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"A type of biopsy in which part of a lesion is removed for microscopic examination.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Incisional Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Open Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Incisional_Biopsy"},{"name":"Maps_To","value":"Biopsy, Incisional"},{"name":"Maps_To","value":"Incisional Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0184922"}]}}{"C16969":{"preferredName":"Laparoscopy","code":"C16969","definitions":[{"definition":"A procedure that uses a laparoscope, inserted through the abdominal wall, to examine the inside of the abdomen. A laparoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A surgical procedure during which a laparoscope is inserted into the abdomen to view the abdominopelvic contents for diagnostic and/or therapeutic purposes.","type":"DEFINITION","source":"NCI"},{"definition":"A technique used to examine the abdominopelvic region with a laparoscope.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Laparoscopy","termGroup":"PT","termSource":"NCI"},{"termName":"Laparoscopic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laparoscopy"},{"name":"Maps_To","value":"Laparoscopy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0031150"}]}}{"C15266":{"preferredName":"Laparotomy","code":"C15266","definitions":[{"definition":"A surgical incision made in the wall of the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Creation of a surgical opening into the abdominal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparotomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laparotomy"},{"name":"Maps_To","value":"Laparotomy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0023038"}]}}{"C17348":{"preferredName":"Pap Smear","code":"C17348","definitions":[{"definition":"A biospecimen collection and staining procedure in which secretions and superficial cells of the cervix are collected and stained with the Papanicolaou stain followed by microscopic examination to identify the presence of abnormal cells.","type":"DEFINITION","source":"NCI"},{"definition":"A biospecimen collection and staining procedure in which secretions and superficial cells of the cervix are collected and stained with the Papanicolaou stain followed by microscopic examination to identify the presence of abnormal cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A procedure in which cells are scraped from the cervix for examination under a microscope. It is used to detect cancer and changes that may lead to cancer. A Pap smear can also show conditions, such as infection or inflammation, that are not cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pap Smear","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical Smear Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Smear Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Pap Smear Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Pap Test","termGroup":"SY","termSource":"NCI"},{"termName":"Papanicolaou Smear Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Papanicolaou Test","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Smears","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pap_Smear"},{"name":"Maps_To","value":"Pap Smear"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0079104"}]}}{"C20989":{"preferredName":"Physical Examination","code":"C20989","definitions":[{"definition":"A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment.","type":"DEFINITION","source":"NCI"},{"definition":"An exam of the body to check for general signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Physical Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Assessment","termGroup":"SY","termSource":"NCI"},{"termName":"Physical","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Assessment","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Exam","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Physical_Examination"},{"name":"Maps_To","value":"Physical Exam"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0031809"}]}}{"C125006":{"preferredName":"Pathologic Examination","code":"C125006","definitions":[{"definition":"An appraisal by a pathologist that is based on microscopic and macroscopic structural and functional changes that result from disease processes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An assessment of disease process to include cause, development, and/or structural and functional changes associated with the disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pathologic Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Pathology Examination","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pathologic"},{"name":"Maps_To","value":"Pathologic Review"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C4086729"}]}}{"C158758":{"preferredName":"Resection","code":"C158758","definitions":[{"definition":"A surgical procedure in which tissue is removed from the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Removal by surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of an organ or a part of an organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resection","termGroup":"PT","termSource":"NCI"},{"termName":"Surgical Resection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgical Resection"},{"name":"NCI_META_CUI","value":"CL950724"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C15392":{"preferredName":"Thoracentesis","code":"C15392","definitions":[{"definition":"Removal of fluid from the pleural cavity through a needle inserted between the ribs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of excess fluid via needle puncture from the thoracic cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of excess fluid via needle puncture from the thoracic cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thoracentesis","termGroup":"PT","termSource":"NCI"},{"termName":"Chest Aspiration","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Cavity Tap","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Tap","termGroup":"SY","termSource":"NCI"},{"termName":"Pleurocentesis","termGroup":"SY","termSource":"NCI"},{"termName":"Puncture of Pleural Cavity for Aspiration","termGroup":"SY","termSource":"NCI"},{"termName":"Thoracic Paracentesis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thoracentesis"},{"name":"Maps_To","value":"Thoracentesis"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189477"}]}}{"C93022":{"preferredName":"Ultrasound-Guided Biopsy","code":"C93022","definitions":[{"definition":"A biopsy procedure that uses an ultrasound imaging device to find an abnormal area of tissue and guide its removal for examination under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Biopsy of tissue using ultrasound imaging as an aid in directing a biopsy needle into the area of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ultrasound-Guided Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Ultrasound Guided Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0456900"}]}}{"C118358":{"preferredName":"Exoresection","code":"C118358","definitions":[{"definition":"A surgical technique for the transscleral resection of large, anteriorly located uveal melanomas with ciliary body and/or iris involvement. This approach is most common when conservative therapy is either unlikely to help, or likely to cause complications.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exoresection","termGroup":"PT","termSource":"NCI"},{"termName":"Exoresection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Exoresection"},{"name":"Maps_To","value":"Local Resection (Exoresection; wall resection)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3899237"}]}}{"C25227":{"preferredName":"High","code":"C25227","definitions":[{"definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High","termGroup":"PT","termSource":"NCI"},{"termName":"Higher","termGroup":"AD","termSource":"NCI"},{"termName":"Highly","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"High"},{"name":"Maps_To","value":"High"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1561957"}]}}{"C73705":{"preferredName":"Intermediate","code":"C73705","definitions":[{"definition":"Located between two points or extremes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Lying between two extremes in time or space or degree.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Intermediate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intermediate"},{"name":"Maps_To","value":"Intermediate"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205103"}]}}{"C54722":{"preferredName":"Low","code":"C54722","definitions":[{"definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Low"},{"name":"Maps_To","value":"Low"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205251"}]}}{"C3677":{"preferredName":"Benign Neoplasm","code":"C3677","definitions":[{"definition":"A general term used to describe autonomous growth of tissue where the originating cell type has not been characterized. The term benign indicates the absence of morphologic features associated with malignancy (for instance severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A growth that is not cancer. It does not invade nearby tissue or spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8000/0"},{"name":"Legacy Concept Name","value":"Benign_Neoplasm"},{"name":"Maps_To","value":"8000/0"},{"name":"Maps_To","value":"Benign neoplasm of other and unspecified sites"},{"name":"Maps_To","value":"Benign neoplasm: Other specified sites"},{"name":"Maps_To","value":"Neoplasm, benign"},{"name":"Maps_To","value":"Tumor, benign"},{"name":"Maps_To","value":"Unclassified tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0086692"}]}}{"C65157":{"preferredName":"Neoplasm, Uncertain Whether Benign or Malignant","code":"C65157","definitions":[{"definition":"A neoplasm which, on morphologic grounds, can not be classified with certainty as benign or malignant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoplasm, Uncertain Whether Benign or Malignant","termGroup":"HD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8000/1"},{"name":"Legacy Concept Name","value":"Neoplasm_Uncertain_Whether_Primary_or_Metastatic"},{"name":"Maps_To","value":"8000/1"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of other and unspecified sites and tissues"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of other specified sites"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior, site unspecified"},{"name":"Maps_To","value":"Neoplasm of uncertain or unknown behaviour of other and unspecified sites"},{"name":"Maps_To","value":"Neoplasm of unspecified behavior of other specified sites"},{"name":"Maps_To","value":"Neoplasm of unspecified behavior of unspecified site"},{"name":"Maps_To","value":"Neoplasm, uncertain whether benign or malignant"},{"name":"Maps_To","value":"Unclassified tumor, borderline malignancy"},{"name":"Maps_To","value":"Unclassified tumor, uncertain whether benign or malignant"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677041"}]}}{"C9305":{"preferredName":"Malignant Neoplasm","code":"C9305","definitions":[{"definition":"A general term for autonomous tissue growth exhibiting morphologic features of malignancy (e.g. severe atypia, nuclear pleomorphism, tumor cell necrosis, abnormal mitoses, tissue invasiveness) and for which the transformed cell type has not been specifically identified.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A group of diseases in which abnormal cells divide without control, invade nearby tissues and may also spread to other parts of the body through the blood and lymph systems.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","type":"DEFINITION","source":"NCI"},{"definition":"A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Malignant cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of malignancy. Carcinoma is a malignancy that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are malignancies that begin in the cells of the immune system. Central nervous system cancers are malignancies that begin in the tissues of the brain and spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Uncontrolled growth of abnormal cells with potential for metastatic spread.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"CA","termGroup":"AB","termSource":"NCI"},{"termName":"Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"ICD-O-3_Code","value":"8000/3"},{"name":"Legacy Concept Name","value":"Malignant_Neoplasm"},{"name":"Maps_To","value":"8000/3"},{"name":"Maps_To","value":"Cancer"},{"name":"Maps_To","value":"Malignancy"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites: Lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites: Overlapping lesion of other and ill-defined sites"},{"name":"Maps_To","value":"Malignant neoplasm of other specified sites"},{"name":"Maps_To","value":"Malignant neoplasm without specification of site"},{"name":"Maps_To","value":"Malignant neoplasm, primary site unknown, so stated"},{"name":"Maps_To","value":"Malignant neoplasm, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm, without specification of site"},{"name":"Maps_To","value":"Neoplasm, malignant"},{"name":"Maps_To","value":"Other malignant neoplasm of unspecified site"},{"name":"Maps_To","value":"Tumor, malignant, NOS"},{"name":"Maps_To","value":"Unclassified tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1861853"},{"name":"xRef","value":"IMDRF:E1801"}]}}{"C8997":{"preferredName":"Blastoma","code":"C8997","definitions":[{"definition":"A mass of rapidly growing cells that begins in embryonic (fetal) tissue. Embryomas may be benign or malignant, and include neuroblastomas and Wilms tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare embryonal neoplasm affecting children. It is associated with DICER1 gene mutation. This category includes pituitary gland blastoma and pleuropulmonary blastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Embryoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8981/3"},{"name":"Legacy Concept Name","value":"Blastoma"},{"name":"Maps_To","value":"8000/3"},{"name":"Maps_To","value":"Blastoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0936282"}]}}{"C36255":{"preferredName":"Secondary Neoplasm","code":"C36255","definitions":[{"definition":"A neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Secondary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secondary_Neoplasm"},{"name":"Maps_To","value":"8000/6"},{"name":"Maps_To","value":"Neoplasm, secondary"},{"name":"Maps_To","value":"Tumor, secondary"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2939419"}]}}{"C3005":{"preferredName":"Tumor Embolism","code":"C3005","definitions":[{"definition":"A tumor embolism involves sudden blockage of an artery by a clot or by other material from tumor fragments transported by the blood stream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Embolism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tumor_Embolism"},{"name":"Maps_To","value":"8000/6"},{"name":"Maps_To","value":"Tumor embolus"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0013930"}]}}{"C3261":{"preferredName":"Metastatic Neoplasm","code":"C3261","definitions":[{"definition":"A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Metastatic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Related_Lash_Concept: metastasis"},{"name":"ICD-O-3_Code","value":"8000/6"},{"name":"Legacy Concept Name","value":"Metastatic_Neoplasm"},{"name":"Maps_To","value":"8000/6"},{"name":"Maps_To","value":"Neoplasm, metastatic"},{"name":"Maps_To","value":"Tumor, metastatic"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2939420"}]}}{"C65153":{"preferredName":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","code":"C65153","definitions":[{"definition":"A malignant neoplasm in which the examined tissue can not be determined with certainty if it represents the primary site of tumor growth or tumor spread from another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Neoplasm, Uncertain Whether Primary or Metastatic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8000/9"},{"name":"Legacy Concept Name","value":"Malignant_Neoplasm_Uncertain_Whether_Primary_or_Metastatic"},{"name":"Maps_To","value":"8000/9"},{"name":"Maps_To","value":"Neoplasm, malignant, uncertain whether primary or metastatic"},{"name":"Maps_To","value":"Unclassified tumor, malignant, uncertain whether primary or metastatic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334224"}]}}{"C36122":{"preferredName":"Benign Cellular Infiltrate","code":"C36122","definitions":[{"definition":"A morphologic finding indicating the presence of a cellular infiltrate without atypia in a tumor sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Cellular Infiltrate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Cellular_Infiltrate"},{"name":"Maps_To","value":"8001/0"},{"name":"Maps_To","value":"Tumor cells, benign"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1332480"}]}}{"C12922":{"preferredName":"Neoplastic Cell","code":"C12922","definitions":[{"definition":"Cells of, or derived from, a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoplastic Cell","termGroup":"PT","termSource":"NCI"},{"termName":"Tumor Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neoplastic_Cell"},{"name":"Maps_To","value":"8001/1"},{"name":"Maps_To","value":"Tumor cells, NOS"},{"name":"Maps_To","value":"Tumor cells, uncertain whether benign or malignant"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0597032"}]}}{"C12917":{"preferredName":"Malignant Cell","code":"C12917","definitions":[{"definition":"Cells of, or derived from, a malignant tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Cell","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Malignant_Cell"},{"name":"Maps_To","value":"8001/3"},{"name":"Maps_To","value":"Tumor cells, malignant"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0334227"}]}}{"C65154":{"preferredName":"Malignant Tumor, Small Cell Type","code":"C65154","definitions":[{"definition":"A malignant neoplasm characterized by the presence of small atypical cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Tumor, Small Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8002/3"},{"name":"Legacy Concept Name","value":"Malignant_Tumor_Small_Cell_Type"},{"name":"Maps_To","value":"8002/3"},{"name":"Maps_To","value":"Malignant tumor, small cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334228"}]}}{"C4090":{"preferredName":"Malignant Giant Cell Neoplasm","code":"C4090","definitions":[{"definition":"A malignant neoplasm characterized by then presence of atypical giant cells.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of bone comprised of giant cells (osteoclast-like) and mononuclear cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Giant Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8003/3"},{"name":"Legacy Concept Name","value":"Malignant_Giant_Cell_Neoplasm"},{"name":"Maps_To","value":"8003/3"},{"name":"Maps_To","value":"Malignant tumor, giant cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334229"}]}}{"C27091":{"preferredName":"Malignant Spindle Cell Neoplasm","code":"C27091","definitions":[{"definition":"A neoplasm characterized by the presence of malignant spindle cells.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that begins in the skin or in tissues that line or cover internal organs and that contains long spindle-shaped cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Spindle Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8004/3"},{"name":"Legacy Concept Name","value":"Malignant_Spindle_Cell_Neoplasm"},{"name":"Maps_To","value":"8004/3"},{"name":"Maps_To","value":"Malignant tumor, fusiform cell type"},{"name":"Maps_To","value":"Malignant tumor, spindle cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334230"}]}}{"C66752":{"preferredName":"Clear Cell Neoplasm","code":"C66752","definitions":[{"definition":"A purely morphologic term that describes a neoplasm in which all or the majority of the neoplastic cells have a clear cytoplasm, when examined under light microscopy, using the conventional staining method (H-E). This term does not provide any information about the nature of the neoplasm (benign or malignant), cell of origin (e.g. epithelial versus mesenchymal versus hematopoietic), or prognosis. Further examination using special stains and/or immunohistochemistry is required to appropriately classify this tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Neoplasm","termGroup":"AQ","termSource":"NCI"},{"termName":"Clear Cell Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8005/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Tumor"},{"name":"Maps_To","value":"8005/0"},{"name":"Maps_To","value":"Clear cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265994"}]}}{"C40077":{"preferredName":"Malignant Ovarian Clear Cell Tumor","code":"C40077","definitions":[{"definition":"An invasive malignant neoplasm that arises from the ovary and is characterized by a predominance of clear and hobnail malignant epithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Clear Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ovarian Clear Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Clear_Cell_Tumor"},{"name":"Maps_To","value":"8005/3"},{"name":"Maps_To","value":"Malignant tumor, clear cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265995"}]}}{"C4092":{"preferredName":"Benign Epithelial Neoplasm","code":"C4092","definitions":[{"definition":"A benign neoplasm arising from epithelial cells of the skin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm that arises from epithelial cells and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Epithelial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Epithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of Epithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Epithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Epithelium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Epithelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/0"},{"name":"ICD-O-3_Code","value":"8011/0"},{"name":"Legacy Concept Name","value":"Benign_Epithelial_Neoplasm"},{"name":"Maps_To","value":"8010/0"},{"name":"Maps_To","value":"8011/0"},{"name":"Maps_To","value":"Epithelial tumor, benign"},{"name":"Maps_To","value":"Epithelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334232"}]}}{"C2917":{"preferredName":"Carcinoma In Situ","code":"C2917","definitions":[{"definition":"A group of abnormal cells that remain in the place where they first formed. They have not spread. These abnormal cells may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant epithelial neoplasm confined to the epithelial layer and without evidence of further tissue invasion.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"CIS","termGroup":"AB","termSource":"NCI"},{"termName":"Intraepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-invasive Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8010/2"},{"name":"Legacy Concept Name","value":"Carcinoma_in_situ"},{"name":"Maps_To","value":"8010/2"},{"name":"Maps_To","value":"Carcinoma in situ"},{"name":"Maps_To","value":"Carcinoma in situ of other and unspecified genital organs"},{"name":"Maps_To","value":"Carcinoma in situ of other and unspecified sites"},{"name":"Maps_To","value":"Carcinoma in situ of unspecified female genital organs"},{"name":"Maps_To","value":"Carcinoma in situ, NOS"},{"name":"Maps_To","value":"Carcinoma in situ, site unspecified"},{"name":"Maps_To","value":"Carcinoma in situ, unspecified"},{"name":"Maps_To","value":"Carcinoma in situ: Thyroid and other endocrine glands"},{"name":"Maps_To","value":"Intraepithelial carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0851135"}]}}{"C2916":{"preferredName":"Carcinoma","code":"C2916","definitions":[{"definition":"A malignant epithelial neoplasm.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that begins in the skin or in tissues that line or cover internal organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/3"},{"name":"ICD-O-3_Code","value":"8011/3"},{"name":"Legacy Concept Name","value":"Carcinoma"},{"name":"Maps_To","value":"8010/3"},{"name":"Maps_To","value":"8011/3"},{"name":"Maps_To","value":"Carcinoma, NOS"},{"name":"Maps_To","value":"Epithelial tumor, malignant"},{"name":"Maps_To","value":"Epithelioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007097"}]}}{"C3482":{"preferredName":"Metastatic Carcinoma","code":"C3482","definitions":[{"definition":"Carcinoma that has spread from its original site of growth to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/6"},{"name":"Legacy Concept Name","value":"Metastatic_Carcinoma"},{"name":"Maps_To","value":"8010/6"},{"name":"Maps_To","value":"Carcinoma, metastatic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384494"}]}}{"C3693":{"preferredName":"Carcinomatosis","code":"C3693","definitions":[{"definition":"A condition in which cancer is spread widely throughout the body, or, in some cases, to a relatively large region of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma that has spread diffusely to an anatomic site or throughout the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8010/9"},{"name":"Legacy Concept Name","value":"Carcinomatosis"},{"name":"Maps_To","value":"8010/9"},{"name":"Maps_To","value":"Carcinomatosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205699"}]}}{"C3780":{"preferredName":"Large Cell Carcinoma","code":"C3780","definitions":[{"definition":"A malignant epithelial neoplasm composed of large, atypical cells.","type":"DEFINITION","source":"NCI"},{"definition":"Lung cancer in which the cells are large and look abnormal when viewed under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Large Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma, Large Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8012/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Carcinoma"},{"name":"Maps_To","value":"8012/3"},{"name":"Maps_To","value":"Large cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206704"}]}}{"C6875":{"preferredName":"Large Cell Neuroendocrine Carcinoma","code":"C6875","definitions":[{"definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant large cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Large Cell Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Large Cell NEC","termGroup":"SY","termSource":"NCI"},{"termName":"Large-cell neuroendocrine carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LCNEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8013/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8013/3"},{"name":"Maps_To","value":"Large cell neuroendocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265996"}]}}{"C6876":{"preferredName":"Lung Large Cell Carcinoma with Rhabdoid Phenotype","code":"C6876","definitions":[{"definition":"A large cell lung carcinoma characterized by the presence of rhabdoid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Large Cell Carcinoma with Rhabdoid Phenotype","termGroup":"PT","termSource":"NCI"},{"termName":"Large Cell Carcinoma with Rhabdoid Phenotype","termGroup":"SY","termSource":"NCI"},{"termName":"Large Cell Lung Carcinoma with Rhabdoid Phenotype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8014/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Lung_Carcinoma_with_Rhabdoid_Phenotype"},{"name":"Maps_To","value":"8014/3"},{"name":"Maps_To","value":"Large cell carcinoma with rhabdoid phenotype"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265997"}]}}{"C65159":{"preferredName":"Glassy Cell Carcinoma","code":"C65159","definitions":[{"definition":"A malignant epithelial neoplasm composed of atypical cells with glassy cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glassy Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8015/3"},{"name":"Legacy Concept Name","value":"Glassy_Cell_Carcinoma"},{"name":"Maps_To","value":"8015/3"},{"name":"Maps_To","value":"Glassy cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1265998"}]}}{"C3692":{"preferredName":"Undifferentiated Carcinoma","code":"C3692","definitions":[{"definition":"A malignant epithelial neoplasm exhibiting poor differentiation (anaplasia).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma, Undifferentiated","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8020/3"},{"name":"ICD-O-3_Code","value":"8021/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Carcinoma"},{"name":"Maps_To","value":"8020/3"},{"name":"Maps_To","value":"8021/3"},{"name":"Maps_To","value":"Carcinoma, anaplastic, NOS"},{"name":"Maps_To","value":"Carcinoma, undifferentiated, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205698"}]}}{"C4094":{"preferredName":"Pleomorphic Carcinoma","code":"C4094","definitions":[{"definition":"A usually aggressive malignant epithelial neoplasm composed of cells with significant cytologic atypia and nuclear pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8022/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Carcinoma"},{"name":"Maps_To","value":"8022/3"},{"name":"Maps_To","value":"Pleomorphic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334233"}]}}{"C45716":{"preferredName":"NUT Carcinoma","code":"C45716","definitions":[{"definition":"A rare, highly aggressive and lethal carcinoma that affects children and young adults.  It arises from midline epithelial structures, most commonly the head, neck, and mediastinum.  It is a poorly differentiated carcinoma and is characterized by mutations and rearrangement of the NUT gene.  A balanced translocation t(15;19) is present that results in the creation of a fusion gene involving the NUT gene, most commonly BRD4-NUT fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUT Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma with t(15;19)(q13;p13.1) Translocation","termGroup":"SY","termSource":"NCI"},{"termName":"Midline Carcinoma of Children and Young Adults with NUT Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"NMC","termGroup":"AB","termSource":"NCI"},{"termName":"Nuclear Protein in Testis (NUT) Midline Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Protein in Testis Midline Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Midline Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carcinoma_with_t_15_19_q13_p13_1_Translocation"},{"name":"Maps_To","value":"Midline carcinoma of children and young adults with NUT rearrangement"},{"name":"Maps_To","value":"Nuclear protein in testis (NUT)-associated carcinoma"},{"name":"Maps_To","value":"NUT carcinoma"},{"name":"Maps_To","value":"NUT midline carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707291"}]}}{"C65160":{"preferredName":"Giant Cell and Spindle Cell Carcinoma","code":"C65160","definitions":[{"definition":"A malignant epithelial neoplasm composed of giant, pleomorphic cells and spindle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell and Spindle Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8030/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_and_Spindle_Cell_Carcinoma"},{"name":"Maps_To","value":"8030/3"},{"name":"Maps_To","value":"Giant cell and spindle cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334234"}]}}{"C3779":{"preferredName":"Giant Cell Carcinoma","code":"C3779","definitions":[{"definition":"A malignant epithelial neoplasm composed of giant, pleomorphic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma, Giant Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8031/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Carcinoma"},{"name":"Maps_To","value":"8031/3"},{"name":"Maps_To","value":"Giant cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206703"}]}}{"C27004":{"preferredName":"Sarcomatoid Carcinoma","code":"C27004","definitions":[{"definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that begins in the skin or in tissues that line or cover internal organs and that contains long spindle-shaped cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sarcomatoid Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pseudosarcomatous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8032/3"},{"name":"ICD-O-3_Code","value":"8033/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Carcinoma"},{"name":"Maps_To","value":"8032/3"},{"name":"Maps_To","value":"8033/3"},{"name":"Maps_To","value":"Pseudosarcomatous carcinoma"},{"name":"Maps_To","value":"Sarcomatoid carcinoma"},{"name":"Maps_To","value":"Spindle cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205697"}]}}{"C65161":{"preferredName":"Polygonal Cell Carcinoma","code":"C65161","definitions":[{"definition":"A malignant epithelial neoplasm composed of atypical polygonal cells with a large amount of eosinophilic cytoplasm. A representative example is the fibrolamellar hepatocellular carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polygonal Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8034/3"},{"name":"Legacy Concept Name","value":"Polygonal_Cell_Carcinoma"},{"name":"Maps_To","value":"8034/3"},{"name":"Maps_To","value":"Polygonal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334236"}]}}{"C63622":{"preferredName":"Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","code":"C63622","definitions":[{"definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular or squamous differentiation and giant cells resembling osteoclasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8035/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Carcinoma_with_Osteoclast-Like_Giant_Cells"},{"name":"Maps_To","value":"8035/3"},{"name":"Maps_To","value":"Carcinoma with osteoclast-like giant cells"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1883424"}]}}{"C65162":{"preferredName":"Tumorlet","code":"C65162","definitions":[{"definition":"A tiny localized pulmonary nodule characterized by neuroendocrine cell proliferation. It is usually discovered as an incidental finding during routine histologic examination of tissue sections or during radiologic examination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumorlet","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Tumorlet","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8040/0"},{"name":"ICD-O-3_Code","value":"8040/1"},{"name":"Legacy Concept Name","value":"Tumorlet"},{"name":"Maps_To","value":"8040/0"},{"name":"Maps_To","value":"8040/1"},{"name":"Maps_To","value":"Tumorlet, benign"},{"name":"Maps_To","value":"Tumorlet, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1266001"}]}}{"C3915":{"preferredName":"Small Cell Neuroendocrine Carcinoma","code":"C3915","definitions":[{"definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant small cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Oat Cell Cancer","termGroup":"AQS","termSource":"NCI"},{"termName":"Oat Cell Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"SCNEC","termGroup":"AB","termSource":"NCI"},{"termName":"Small Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell NEC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8041/3"},{"name":"ICD-O-3_Code","value":"8042/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Carcinoma"},{"name":"Maps_To","value":"8041/3"},{"name":"Maps_To","value":"8042/3"},{"name":"Maps_To","value":"Oat cell carcinoma"},{"name":"Maps_To","value":"Reserve cell carcinoma"},{"name":"Maps_To","value":"Round cell carcinoma"},{"name":"Maps_To","value":"Small cell carcinoma, NOS"},{"name":"Maps_To","value":"Small cell neuroendocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0262584"}]}}{"C27092":{"preferredName":"Small Cell Carcinoma, Fusiform Cell Type","code":"C27092","definitions":[{"definition":"A neuroendocrine carcinoma composed of malignant fusiform small cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Carcinoma, Fusiform Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8043/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Carcinoma_Fusiform_Cell_Type"},{"name":"Maps_To","value":"8043/3"},{"name":"Maps_To","value":"Small cell carcinoma, fusiform cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334238"}]}}{"C4099":{"preferredName":"Small Cell Intermediate Cell Carcinoma","code":"C4099","definitions":[{"definition":"A neuroendocrine carcinoma composed of malignant small cells of intermediate shape.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Carcinoma, Intermediate Cell","termGroup":"AQS","termSource":"NCI"},{"termName":"Small Cell Intermediate Cell Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8044/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Intermediate_Cell_Carcinoma"},{"name":"Maps_To","value":"8044/3"},{"name":"Maps_To","value":"Small cell carcinoma, intermediate cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334239"}]}}{"C9137":{"preferredName":"Combined Lung Small Cell Carcinoma","code":"C9137","definitions":[{"definition":"A morphologic variant of small cell lung carcinoma in combination with a non-small cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Lung Small Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Small and Large Cell Lung Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell-Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell-Large Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Type Small Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Type Small Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Type Small Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Small Cell and Large Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Small Cell and Large Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Small Cell and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell and Large Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell and Large Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell and Large Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8045/3"},{"name":"Legacy Concept Name","value":"Combined_Type_Small_Cell_Lung_Carcinoma"},{"name":"Maps_To","value":"8045/3"},{"name":"Maps_To","value":"Combined small cell carcinoma"},{"name":"Maps_To","value":"Combined small cell-squamous cell carcinoma"},{"name":"Maps_To","value":"Mixed small cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334240"}]}}{"C65151":{"preferredName":"Non-Small Cell Carcinoma","code":"C65151","definitions":[{"definition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Small Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8046/3"},{"name":"Legacy Concept Name","value":"Non-Small_Cell_Carcinoma"},{"name":"Maps_To","value":"8046/3"},{"name":"Maps_To","value":"Non-small cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266002"}]}}{"C7440":{"preferredName":"Papilloma","code":"C7440","definitions":[{"definition":"A benign epithelial neoplasm that projects above the surrounding epithelial surface and consists of villous or arborescent outgrowths of fibrovascular stroma.","type":"DEFINITION","source":"NCI"},{"definition":"A benign epithelial neoplasm that projects above the surrounding epithelial surface.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8050/0"},{"name":"Legacy Concept Name","value":"Papilloma"},{"name":"Maps_To","value":"8050/0"},{"name":"Maps_To","value":"Papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030354"}]}}{"C65163":{"preferredName":"Papillary Carcinoma In Situ","code":"C65163","definitions":[{"definition":"An epithelial neoplasm with a papillary growth pattern in which the malignant cells are confined to the epithelium, without evidence of invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Carcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8050/2"},{"name":"Legacy Concept Name","value":"Papillary_Carcinoma_In_Situ"},{"name":"Maps_To","value":"8050/2"},{"name":"Maps_To","value":"Papillary carcinoma in situ"},{"name":"Maps_To","value":"Papillary carcinoma in situ, NOS"},{"name":"Maps_To","value":"Solid papillary carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334242"}]}}{"C2927":{"preferredName":"Papillary Carcinoma","code":"C2927","definitions":[{"definition":"A malignant epithelial neoplasm characterized by a papillary growth pattern. A papillary carcinoma may be composed of glandular cells (papillary adenocarcinoma), squamous cells (papillary squamous cell carcinoma), or transitional cells (papillary transitional cell carcinoma). Bladder carcinoma is a representative example of papillary transitional cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8050/3"},{"name":"Legacy Concept Name","value":"Papillary_Carcinoma"},{"name":"Maps_To","value":"8050/3"},{"name":"Maps_To","value":"Papillary carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007133"}]}}{"C4101":{"preferredName":"Verrucous Papilloma","code":"C4101","definitions":[{"definition":"A benign epithelial neoplasm characterized by a papillary growth pattern, lack of significant cytologic atypia, and a wart-like appearance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verrucous Papilloma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8051/0"},{"name":"Legacy Concept Name","value":"Verrucous_Papilloma"},{"name":"Maps_To","value":"8051/0"},{"name":"Maps_To","value":"Verrucous papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334243"}]}}{"C3781":{"preferredName":"Verrucous Carcinoma","code":"C3781","definitions":[{"definition":"A well differentiated squamous cell carcinoma characterized by a papillary growth pattern, acanthosis, mild cytologic atypia, and pushing tumor margins. The most commonly affected anatomic sites are the oral cavity, nasal cavity, larynx, esophagus, anus, vagina, vulva, and the plantar region of the foot.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verrucous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Verrucous Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Verrucous Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Verrucous Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Verrucous Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8051/3"},{"name":"Legacy Concept Name","value":"Verrucous_Carcinoma"},{"name":"Maps_To","value":"8051/3"},{"name":"Maps_To","value":"Condylomatous carcinoma"},{"name":"Maps_To","value":"Verrucous carcinoma, NOS"},{"name":"Maps_To","value":"Verrucous epidermoid carcinoma"},{"name":"Maps_To","value":"Verrucous squamous cell carcinoma"},{"name":"Maps_To","value":"Warty carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206706"}]}}{"C3712":{"preferredName":"Squamous Papilloma","code":"C3712","definitions":[{"definition":"A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells without morphologic evidence of malignancy. Most frequently it arises in the oral cavity, nasopharynx, larynx, esophagus, vagina, and vulva.","type":"DEFINITION","source":"NCI"},{"definition":"A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Squamous Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Cell Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Keratotic Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8052/0"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Papilloma"},{"name":"Maps_To","value":"8052/0"},{"name":"Maps_To","value":"Keratotoc papilloma"},{"name":"Maps_To","value":"Squamous cell papilloma, NOS"},{"name":"Maps_To","value":"Squamous papilloma"},{"name":"Maps_To","value":"Squamous papilloma; solitary"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205874"}]}}{"C65164":{"preferredName":"Non-Invasive Papillary Squamous Cell Carcinoma","code":"C65164","definitions":[{"definition":"A well differentiated squamous cell carcinoma characterized by a papillary, exophytic growth pattern, hyperkeratosis, and absence of invasion of adjacent tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Invasive Papillary Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8052/2"},{"name":"Legacy Concept Name","value":"Non-Invasive_Papillary_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8052/2"},{"name":"Maps_To","value":"Papillary squamous cell carcinoma in situ"},{"name":"Maps_To","value":"Papillary squamous cell carcinoma, non-invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266003"}]}}{"C4102":{"preferredName":"Papillary Squamous Cell Carcinoma","code":"C4102","definitions":[{"definition":"A well differentiated squamous cell carcinoma characterized by a papillary, exophytic growth pattern and hyperkeratosis. The most commonly affected anatomic sites are the larynx, penis, cervix, vagina, and vulva.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Squamous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8052/3"},{"name":"Legacy Concept Name","value":"Papillary_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8052/3"},{"name":"Maps_To","value":"Papillary epidermoid carcinoma"},{"name":"Maps_To","value":"Papillary squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334244"}]}}{"C65165":{"preferredName":"Inverted Squamous Papilloma","code":"C65165","definitions":[{"definition":"A benign epithelial neoplasm characterized by an endophytic growth, papillary pattern, and proliferation of neoplastic squamous cells without morphologic evidence of malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inverted Squamous Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Inverted Squamous Cell Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8053/0"},{"name":"Legacy Concept Name","value":"Inverted_Squamous_Cell_Papilloma"},{"name":"Maps_To","value":"8053/0"},{"name":"Maps_To","value":"Squamous cell papilloma, inverted"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881254"}]}}{"C9009":{"preferredName":"Squamous Papillomatosis","code":"C9009","definitions":[{"definition":"A benign squamous neoplasm characterized by a papillary growth pattern, diffusely involving a specific anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8060/0"},{"name":"Legacy Concept Name","value":"Squamous_Papillomatosis"},{"name":"Maps_To","value":"8060/0"},{"name":"Maps_To","value":"Squamous papillomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378340"}]}}{"C3713":{"preferredName":"Papillomatosis","code":"C3713","definitions":[{"definition":"Glandular or squamous cell neoplastic proliferations characterized by the formation of multiple papillary structures diffusely involving a specific anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillomatosis"},{"name":"Maps_To","value":"8060/0"},{"name":"Maps_To","value":"Papillomatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205875"}]}}{"C27093":{"preferredName":"Stage 0 Squamous Cell Carcinoma","code":"C27093","definitions":[{"definition":"A malignant epithelial neoplasm confined to the squamous epithelium, without invasion of the underlying tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant epithelial neoplasm confined to the squamous epithelium, without invasion of underlying tissues.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Stage 0 Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 SIN","termGroup":"AB","termSource":"NCI"},{"termName":"Grade 3 Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III SIN","termGroup":"AB","termSource":"NCI"},{"termName":"Grade III Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SCC in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma in-situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8070/2"},{"name":"ICD-O-3_Code","value":"8077/2"},{"name":"Legacy Concept Name","value":"Stage_0_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Epidermoid carcinoma in situ, NOS"},{"name":"Maps_To","value":"Intraepidermal carcinoma, NOS"},{"name":"Maps_To","value":"Intraepithelial squamous cell carcinoma"},{"name":"Maps_To","value":"Squamous cell carcinoma in situ, NOS"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334245"}]}}{"C2929":{"preferredName":"Squamous Cell Carcinoma","code":"C2929","definitions":[{"definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from squamous epithelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epidermoid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epidermoid Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Squamous Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Squamous Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"SCC","termGroup":"AB","termSource":"NCI"},{"termName":"Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8070/3"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8070/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, NOS"},{"name":"Maps_To","value":"Squamous carcinoma"},{"name":"Maps_To","value":"Squamous cell carcinoma, NOS"},{"name":"Maps_To","value":"Squamous cell epithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3151392"}]}}{"C4104":{"preferredName":"Metastatic Squamous Cell Carcinoma","code":"C4104","definitions":[{"definition":"A carcinoma that arises from squamous cells and has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8070/6"},{"name":"Legacy Concept Name","value":"Metastatic_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8070/6"},{"name":"Maps_To","value":"Squamous cell carcinoma, metastatic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334246"}]}}{"C4105":{"preferredName":"Keratinizing Squamous Cell Carcinoma","code":"C4105","definitions":[{"definition":"Squamous cell carcinomas with morphologically prominent production of keratin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Keratinizing Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8071/3"},{"name":"Legacy Concept Name","value":"Keratinizing_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8071/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, keratinizing"},{"name":"Maps_To","value":"Squamous cell carcinoma, keratinizing, NOS"},{"name":"Maps_To","value":"Squamous cell carcinoma, large cell, keratinizing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334247"}]}}{"C65173":{"preferredName":"Non-Keratinizing Large Cell Squamous Cell Carcinoma","code":"C65173","definitions":[{"definition":"A squamous cell carcinoma composed of large atypical cells, without morphologic evidence of keratin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Keratinizing Large Cell Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8072/3"},{"name":"Legacy Concept Name","value":"Non-Keratinizing_Large_Cell_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8072/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, large cell, nonkeratinizing"},{"name":"Maps_To","value":"Squamous cell carcinoma, large cell, nonkeratinizing, NOS"},{"name":"Maps_To","value":"Squamous cell carcinoma, nonkeratinizing, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334248"}]}}{"C65175":{"preferredName":"Non-Keratinizing Small Cell Squamous Cell Carcinoma","code":"C65175","definitions":[{"definition":"A squamous cell carcinoma composed of small atypical cells, without morphologic evidence of keratin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Keratinizing Small Cell Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8073/3"},{"name":"Legacy Concept Name","value":"Non-Keratinizing_Small_Cell_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8073/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, small cell, nonkeratinizing"},{"name":"Maps_To","value":"Squamous cell carcinoma, small cell, nonkeratinizing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334249"}]}}{"C27084":{"preferredName":"Spindle Cell Squamous Carcinoma","code":"C27084","definitions":[{"definition":"A poorly differentiated squamous cell carcinoma characterized by the presence of malignant cells with spindle cell features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Squamous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatoid Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell (Sarcomatoid) Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma, Sarcomatoid","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma, Spindle Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma, Spindle Cell Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8074/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8074/3"},{"name":"Maps_To","value":"Epidermoid carcinoma, spindle cell"},{"name":"Maps_To","value":"Squamous cell carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Squamous cell carcinoma, spindle cell"},{"name":"NCI_META_CUI","value":"CL388688"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4106":{"preferredName":"Pseudoglandular Squamous Cell Carcinoma","code":"C4106","definitions":[{"definition":"A squamous cell carcinoma characterized by the formation of gland-like structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pseudoglandular Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoid Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoid Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudoglandular Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudoglandular Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudoglandular Squamous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8075/3"},{"name":"Legacy Concept Name","value":"Pseudoglandular_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8075/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, acantholytic"},{"name":"Maps_To","value":"Squamous cell carcinoma, adenoid"},{"name":"Maps_To","value":"Squamous cell carcinoma, pseudoglandular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334250"}]}}{"C65176":{"preferredName":"Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion","code":"C65176","definitions":[{"definition":"A malignant epithelial neoplasm involving all the layers of the squamous epithelium, but it is not certain if it is confined to the squamous epithelium or it has invaded the basement membrane and the underlying stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8076/2"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma_In_Situ_with_Questionable_Stromal_Invasion"},{"name":"Maps_To","value":"8076/2"},{"name":"Maps_To","value":"Epidermoid carcinoma in situ with questionable stromal invasion"},{"name":"Maps_To","value":"Squamous cell carcinoma in situ with questionable stromal invasion"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334251"}]}}{"C65178":{"preferredName":"Microinvasive Squamous Cell Carcinoma","code":"C65178","definitions":[{"definition":"A squamous cell carcinoma with minimal stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microinvasive Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8076/3"},{"name":"Legacy Concept Name","value":"Microinvasive_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8076/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, microinvasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334252"}]}}{"C7351":{"preferredName":"Grade II Squamous Intraepithelial Neoplasia","code":"C7351","synonyms":[{"termName":"Grade II Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Grade_II_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, grade II"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302798"}]}}{"C27427":{"preferredName":"Low Grade Esophageal Squamous Intraepithelial Neoplasia","code":"C27427","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities are confined to the lower half of the esophageal squamous epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Esophageal Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal Low Grade Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade Esophageal Squamous Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Esophageal_Low-Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Esophageal squamous intraepithelial neoplasia (dysplasia), low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333458"}]}}{"C8335":{"preferredName":"Low Grade Squamous Intraepithelial Neoplasia","code":"C8335","definitions":[{"definition":"A condition in which the cells of the uterine cervix are slightly abnormal. Low-grade squamous intraepithelial lesion is not cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A precancerous neoplastic process characterized by the presence of mild dysplastic cytological changes which are usually present in the lower part of the squamous epithelium.  Representative examples include the low grade esophageal squamous intraepithelial neoplasia, low grade cervical squamous intraepithelial neoplasia, low grade vaginal intraepithelial neoplasia, and low grade vulvar intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"},{"termName":"LSIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Low_Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, grade I"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302773"}]}}{"C4630":{"preferredName":"Low Grade Cervical Intraepithelial Neoplasia","code":"C4630","definitions":[{"definition":"Squamous or glandular cervical intraepithelial neoplasia characterized by the presence of mild dysplastic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Cervical Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Low-Grade Cervix Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Cervix Uteri Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of the Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intraepithelial Neoplasia of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Uterine Cervix Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/0"},{"name":"Legacy Concept Name","value":"Low-Grade_Cervical_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/0"},{"name":"Maps_To","value":"Cervical intraepithelial neoplasia, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349458"}]}}{"C8336":{"preferredName":"High Grade Squamous Intraepithelial Neoplasia","code":"C8336","definitions":[{"definition":"A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Cells of the uterine cervix that are moderately or severely abnormal and may become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"High Grade Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"High-Grade Squamous Intraepithelial Lesion","termGroup":"SY","termSource":"NCI"},{"termName":"HSIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/2"},{"name":"Legacy Concept Name","value":"High-Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Squamous intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0333875"}]}}{"C157575":{"preferredName":"Anal Intraepithelial Neoplasia 3","code":"C157575","definitions":[{"definition":"Anal canal or perianal skin intraepithelial neoplasia with severe dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Intraepithelial Neoplasia 3","termGroup":"PT","termSource":"NCI"},{"termName":"AIN3","termGroup":"AB","termSource":"NCI"},{"termName":"Anal Squamous Intraepithelial Neoplasia 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"AIN III"},{"name":"Maps_To","value":"Anal intraepithelial neoplasia, grade III"},{"name":"NCI_META_CUI","value":"CL937283"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7855":{"preferredName":"Stage 0 Vaginal Cancer AJCC v6","code":"C7855","definitions":[{"definition":"Stage 0 includes: (Tis, N0, M0).  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Vaginal Cancer AJCC v6","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC Stage 0 Vaginal Cancer v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Vagina AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Vagina AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Vagina","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Vagina","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vagina Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vaginal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Vaginal Intraepithelial Neoplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Vaginal Intraepithelial Neoplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Vagina Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Vagina Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vagina Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Cancer Stage 0 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"VAIN 3 AJCC v6","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"VAIN III AJCC v6","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0_Vaginal_Cancer"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Vaginal intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0686277"}]}}{"C4000":{"preferredName":"Stage 0 Cervical Cancer AJCC v6","code":"C4000","definitions":[{"definition":"Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Cervical Cancer AJCC v6","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma in situ of Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical cancer stage 0 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"CIN 3 AJCC v6","termGroup":"AB","termSource":"NCI"},{"termName":"CIN Grade 3 AJCC v6","termGroup":"AB","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Cervical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Cervix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Cervix Uteri Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Uterine Cervix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Cervical Intraepithelial Neoplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Cervix Uteri Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Cervix Uteri Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of the Uterine Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasia of Uterine Cervix Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Cervical Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of the Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of the Cervix Uteri AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of the Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Severe Dysplasia of Uterine Cervix AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Intraepithelial Neoplasia Grade 3 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Severe Dysplasia AJCC v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0_Cervical_Cancer"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"Cervical intraepithelial neoplasia, grade III"},{"name":"Maps_To","value":"CIN III with severe dysplasia"},{"name":"Maps_To","value":"Cin III, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0851140"}]}}{"C4522":{"preferredName":"Stage 0 Vulvar Cancer AJCC v6","code":"C4522","definitions":[{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (preinvasive carcinoma. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Vulvar Cancer AJCC v6","termGroup":"PT","termSource":"NCI"},{"termName":"AJCC Stage 0 Vulvar Cancer v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of the Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Carcinoma of Vulva AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vulva Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FIGO Stage 0 Vulvar Carcinoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vulval Cancer AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vulval Carcinoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vulvar Carcinoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vulva Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Cancer Stage 0 AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Carcinoma in situ AJCC v6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stage_0_Vulvar_Cancer"},{"name":"Maps_To","value":"8077/2"},{"name":"Maps_To","value":"VIN III"},{"name":"Maps_To","value":"Vulvar intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278729"}]}}{"C65179":{"preferredName":"Squamous Cell Carcinoma with Horn Formation","code":"C65179","definitions":[{"definition":"A keratinizing squamous cell carcinoma characterized by the presence of horn pearls. Representative examples include squamous cell carcinomas of the face presenting as a cutaneous horn.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma with Horn Formation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8078/3"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma_with_Horn_Formation"},{"name":"Maps_To","value":"8078/3"},{"name":"Maps_To","value":"Squamous cell carcinoma with horn formation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266004"}]}}{"C27790":{"preferredName":"Penile Carcinoma In Situ","code":"C27790","definitions":[{"definition":"Abnormal cells are found on the surface of the skin of the penis. These abnormal cells may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penile Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Bowen Disease of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Bowen's Disease of Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Bowen's Disease of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma in situ of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Erythroplasia of Queyrat","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Penile Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Squamous Intraepithelial Lesion of Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Squamous Intraepithelial Lesion of the Penis","termGroup":"SY","termSource":"NCI"},{"termName":"Penile Carcinoma In Situ AJCC v7","termGroup":"SY","termSource":"NCI"},{"termName":"Queyrat Erythroplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Queyrat's Erythroplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8080/2"},{"name":"Legacy Concept Name","value":"Penile_Carcinoma_in_situ"},{"name":"Maps_To","value":"8080/2"},{"name":"Maps_To","value":"Queyrat erythroplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0154089"}]}}{"C62571":{"preferredName":"Bowen Disease of the Skin","code":"C62571","definitions":[{"definition":"A form of squamous cell carcinoma in situ. It is a distinct clinicopathological entity and arises from the skin or the mucocutaneous junction. It affects predominantly white males in their 6-8th decades of life. Exposed and non-exposed skin sites are equally affected. UV damage and ingestion of inorganic arsenic may play a role in the development of the disease. On the skin surface, it presents as a single or multiple erythematous, scaly, keratotic patches or plaques. The clinical entity of erythroplasia of Queyrat is regarded as Bowen disease of the penis and it presents as an asymptomatic, red, circumscribed plaque. Morphologically, Bowen disease is characterized by the presence of hyperkeratosis, parakeratosis, dyskeratosis, and acanthosis. The keratotic squamous cells are atypical and display hyperchromatism and abnormal mitotic figures. The dermoepidermal basement membrane is intact. Complete surgical removal of the lesion may be curative.","type":"DEFINITION","source":"NCI"},{"definition":"A skin disease marked by scaly or thickened patches on the skin and often caused by prolonged exposure to arsenic. The patches often occur on sun-exposed areas of the skin and in older white men. These patches may become malignant (cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bowen Disease of the Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Bowen Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Bowen's Disease of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepidermal Squamous Cell Carcinoma, Bowen Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8081/2"},{"name":"Legacy Concept Name","value":"Bowen_Disease_of_the_Skin"},{"name":"Maps_To","value":"8081/2"},{"name":"Maps_To","value":"Bowen disease"},{"name":"Maps_To","value":"Intraepidermal squamous cell carcinoma, Bowen type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0006079"}]}}{"C4107":{"preferredName":"Nasopharyngeal-Type Undifferentiated Carcinoma","code":"C4107","definitions":[{"definition":"A nonkeratinizing carcinoma which occurs predominantly in the nasopharynx but also in the tonsils and rarely in other anatomic sites.  It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nasopharyngeal-Type Undifferentiated Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphoepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioma-Like Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nasopharyngeal Type Undifferentiated Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Schmincke Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8082/3"},{"name":"Legacy Concept Name","value":"Nasopharyngeal_Type_Undifferentiated_Carcinoma"},{"name":"Maps_To","value":"8082/3"},{"name":"Maps_To","value":"Lymphoepithelial carcinoma"},{"name":"Maps_To","value":"Lymphoepithelioma"},{"name":"Maps_To","value":"Lymphoepithelioma-like carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334254"}]}}{"C54244":{"preferredName":"Basaloid Squamous Cell Carcinoma","code":"C54244","definitions":[{"definition":"A squamous cell carcinoma characterized by the presence of cells with hyperchromatic nuclei, scant amount of cytoplasm, and peripheral nuclear palisading.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basaloid Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8083/3"},{"name":"Legacy Concept Name","value":"Basaloid_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8083/3"},{"name":"Maps_To","value":"Basaloid squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266005"}]}}{"C65180":{"preferredName":"Squamous Cell Carcinoma, Clear Cell Type","code":"C65180","definitions":[{"definition":"A squamous cell carcinoma characterized by the presence of malignant cells with clear cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma, Clear Cell Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8084/3"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Carcinoma_Clear_Cell_Type"},{"name":"Maps_To","value":"8084/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, clear cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266006"}]}}{"C27683":{"preferredName":"Human Papillomavirus-Related Squamous Cell Carcinoma","code":"C27683","definitions":[{"definition":"A squamous cell carcinoma associated with the presence of human papillomavirus infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-Related Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-Related Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus Related Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus-Related Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papilloma_Virus-Related_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV positive"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV-positive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334057"}]}}{"C164250":{"preferredName":"Human Papillomavirus-Independent Squamous Cell Carcinoma","code":"C164250","definitions":[{"definition":"A squamous cell carcinoma not associated with human papilloma virus infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-Independent Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-Independent Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-Negative Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus-Negative Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8086/3"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV negative"},{"name":"Maps_To","value":"Squamous cell carcinoma, HPV-negative"},{"name":"NCI_META_CUI","value":"CL973823"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2921":{"preferredName":"Skin Basal Cell Carcinoma","code":"C2921","definitions":[{"definition":"Cancer that begins in the lower part of the epidermis (the outer layer of the skin). It may appear as a small white or flesh-colored bump that grows slowly and may bleed. Basal cell cancers are usually found on areas of the body exposed to the sun. Basal cell cancers rarely metastasize (spread) to other parts of the body. They are the most common form of skin cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Carcinoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Carcinoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Skin Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"BCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8090/3"},{"name":"Legacy Concept Name","value":"Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8090/3"},{"name":"Maps_To","value":"Basal Cell Cancer"},{"name":"Maps_To","value":"Basal Cell Carcinoma"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of left eyelid, including canthus"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of other and unspecified parts of face"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of other part of trunk"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of other parts of face"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of right eyelid, including canthus"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of trunk, except scrotum"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of unspecified eyelid, including canthus"},{"name":"Maps_To","value":"Basal cell carcinoma of skin of unspecified parts of face"},{"name":"Maps_To","value":"Basal cell carcinoma of skin, site unspecified"},{"name":"Maps_To","value":"Basal cell carcinoma of skin, unspecified"},{"name":"Maps_To","value":"Basal cell carcinoma, NOS"},{"name":"Maps_To","value":"Basal cell epithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007117"}]}}{"C9359":{"preferredName":"Skin Pigmented Basal Cell Carcinoma","code":"C9359","definitions":[{"definition":"A basal cell carcinoma that contains large amounts of melanin.  The melanin is produced by symbiotic nontumoral proliferating melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Pigmented Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pigmented Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pigmented_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8090/3"},{"name":"Maps_To","value":"Pigmented basal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368275"}]}}{"C156767":{"preferredName":"Basal Cell Carcinoma","code":"C156767","definitions":[{"definition":"A carcinoma involving the basal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Basal_Cell_Neoplasm"},{"name":"Maps_To","value":"8090/3"},{"name":"Maps_To","value":"Basal cell carcinoma, NOS"},{"name":"NCI_META_CUI","value":"CL935818"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4108":{"preferredName":"Superficial Multifocal Basal Cell Carcinoma","code":"C4108","definitions":[{"definition":"A superficial basal cell carcinoma of the skin characterized by the presence of lobules of basaloid cells which are separated by large distances and represent multifocal discrete tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Multifocal Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Multicentric Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8091/3"},{"name":"Legacy Concept Name","value":"Superficial_Multifocal_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8091/3"},{"name":"Maps_To","value":"Multicentric basal cell carcinoma"},{"name":"Maps_To","value":"Multifocal superficial basal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334256"}]}}{"C27182":{"preferredName":"Skin Sclerosing/Morphoeic Basal Cell Carcinoma","code":"C27182","definitions":[{"definition":"A histologic variant of basal cell carcinoma of the skin characterized by the presence of strands and nests of malignant cells that are embedded in a dense fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Sclerosing/Morphoeic Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Carcinoma Sclerosing Type","termGroup":"SY","termSource":"NCI"},{"termName":"Morphea-Type (Sclerosing) Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Morphea-Type Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Morpheaform Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Type Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Morphea-Type (Sclerosing) Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Morphea-Type_Sclerosing_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8092/3"},{"name":"Maps_To","value":"Infiltrating basal cell carcinoma, sclerosing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0555191"}]}}{"C27539":{"preferredName":"Skin Infiltrating Basal Cell Carcinoma","code":"C27539","definitions":[{"definition":"A variant of basal cell carcinoma presenting as a pale, indurated plaque, usually in the upper trunk or face. Morphologically, it is characterized by the presence of strands, cords, and columns of basaloid cells infiltrating the dermis. Perineural invasion may be present and the basaloid cell infiltrate may extend into deeper tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Infiltrating Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8092/3"},{"name":"Legacy Concept Name","value":"Infiltrating_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8092/3"},{"name":"Maps_To","value":"Basal cell carcinoma, desmoplastic type"},{"name":"Maps_To","value":"Basal cell carcinoma, morpheic"},{"name":"Maps_To","value":"Infiltrating basal cell carcinoma, non-sclerosing"},{"name":"Maps_To","value":"Infiltrating basal cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334257"}]}}{"C4109":{"preferredName":"Skin Fibroepithelial Basal Cell Carcinoma","code":"C4109","definitions":[{"definition":"A variant of basal cell carcinoma presenting as an elevated or erythematous nodular lesion usually in the back. Morphologically, it is characterized by the presence of cords of basaloid cells extending from the epidermis into the dermis, creating a fenestrating pattern. It follows an indolent course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Fibroepithelial Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroepithelial Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroepithelioma of Pinkus","termGroup":"SY","termSource":"NCI"},{"termName":"Pinkus Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8093/3"},{"name":"Legacy Concept Name","value":"Fibroepithelioma_of_Pinkus"},{"name":"Maps_To","value":"8093/3"},{"name":"Maps_To","value":"Basal cell carcinoma, fibroepithelial"},{"name":"Maps_To","value":"Fibroepithelial basal cell carcinoma, Pinkus type"},{"name":"Maps_To","value":"Fibroepithelioma of Pinkus type"},{"name":"Maps_To","value":"Fibroepithelioma, NOS"},{"name":"Maps_To","value":"Pinkus tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346013"}]}}{"C2922":{"preferredName":"Skin Basosquamous Cell Carcinoma","code":"C2922","definitions":[{"definition":"A basal cell carcinoma (skin neoplasm) which displays squamous differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A basal cell carcinoma which displays squamous differentiation. The neoplastic cells have more abundant cytoplasm with more marked keratinization than typical basal cell carcinomas. It usually has a more aggressive clinical course compared to typical basal cell carcinoma, and it may produce regional or widespread metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Basosquamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basosquamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Basosquamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Metatypical Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Metatypical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Mixed Basal and Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8094/3"},{"name":"ICD-O-3_Code","value":"8095/3"},{"name":"Legacy Concept Name","value":"Basosquamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8094/3"},{"name":"Maps_To","value":"8095/3"},{"name":"Maps_To","value":"Basosquamous carcinoma"},{"name":"Maps_To","value":"Metatypical carcinoma"},{"name":"Maps_To","value":"Mixed basal-squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007118"}]}}{"C4110":{"preferredName":"Intraepidermal Epithelioma of Jadassohn","code":"C4110","definitions":[{"definition":"A rare cutaneous lesion presenting as a scaly verrucous plaque. Morphologically, the plaque contains nests of basaloid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borst-Jadassohn Intraepidermal Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intraepidermal Epithelioma of Jadassohn","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8096/0"},{"name":"Legacy Concept Name","value":"Intraepidermal_Epithelioma_of_Jadassohn"},{"name":"Maps_To","value":"8096/0"},{"name":"Maps_To","value":"Intraepidermal epithelioma of Jadassohn"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2937231"}]}}{"C27541":{"preferredName":"Skin Micronodular Basal Cell Carcinoma","code":"C27541","definitions":[{"definition":"A basal cell carcinoma of the skin characterized by the presence of small nodules that permeate the dermis.  It presents as an elevated or flat infiltrating tumor, usually in the back.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Micronodular Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Micronodular Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Micronodular_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8097/3"},{"name":"Maps_To","value":"Basal cell carcinoma, micronodular"},{"name":"NCI_META_CUI","value":"CL331352"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C62282":{"preferredName":"Skin Nodular Basal Cell Carcinoma","code":"C62282","definitions":[{"definition":"A basal cell carcinoma of the skin that often appears as elevated nodules which may become ulcerated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Nodular Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Nodular Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Basal Cell Carcinoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Basal Cell Carcinoma of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_Nodular_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8097/3"},{"name":"Maps_To","value":"Basal cell carcinoma, nodular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367861"}]}}{"C27535":{"preferredName":"Skin Adenoid Basal Cell Carcinoma","code":"C27535","definitions":[{"definition":"A variant of basal cell carcinoma morphologically characterized by the presence of thin strands of basaloid cells forming a reticulate pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Adenoid Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoid Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8098/3"},{"name":"Legacy Concept Name","value":"Adenoid_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"8098/3"},{"name":"Maps_To","value":"Adenoid basal carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266007"}]}}{"C27132":{"preferredName":"Trichoblastoma","code":"C27132","definitions":[{"definition":"A benign hair follicle neoplasm with trichoblastic differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign hair follicle neoplasm with trichoblastic differentiation. It usually presents as a solitary papular lesion It most often presents on the head and neck area, but it may develop in any anatomic site containing hair follicles. Because of its benign nature, treatment usually is not required, provided that the diagnosis has been established with certainty.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Brooke's Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Trichoblastic Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Trichoepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Trichogenic Adnexal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Trichogenic Trichoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8100/0"},{"name":"Legacy Concept Name","value":"Trichogenic_Trichoblastoma"},{"name":"Maps_To","value":"8100/0"},{"name":"Maps_To","value":"Brooke tumor"},{"name":"Maps_To","value":"Epithelioma adenoides cysticum"},{"name":"Maps_To","value":"Trichoepithelioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349658"}]}}{"C4112":{"preferredName":"Trichofolliculoma","code":"C4112","definitions":[{"definition":"A hair follicle lesion that presents as a solitary, colored, dome-shaped small papule. It consists of a central cystic follicular infundibulum from which numerous smaller hair follicles emanate into the surrounding dermis. The clinical course is benign.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichofolliculoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8101/0"},{"name":"Legacy Concept Name","value":"Trichofolliculoma"},{"name":"Maps_To","value":"8101/0"},{"name":"Maps_To","value":"Trichofolliculoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334262"}]}}{"C4113":{"preferredName":"Trichilemmoma","code":"C4113","definitions":[{"definition":"A benign hair follicle neoplasm in the outer hair sheath and infundibulum, characterized by central cells showing highly eosinophilic amorphous keratin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm arising from the outer hair sheath and infundibulum. It occurs in the head and neck, usually on the face. It usually presents as an exophytic wart-like lesion or a dome-shaped lesion with a smooth surface. Morphologically, it is characterized by the proliferation of cuboidal cells with clear or eosinophilic cytoplasm in the dermis with connection to the epidermis/hair follicle. There is peripheral cellular palisading, and the lesion is surrounded by a hyaline band.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichilemmoma","termGroup":"PT","termSource":"NCI"},{"termName":"Tricholemmoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8102/0"},{"name":"ICD-O-3_Code","value":"8102/2"},{"name":"Legacy Concept Name","value":"Trichilemmoma"},{"name":"Maps_To","value":"8102/0"},{"name":"Maps_To","value":"Trichilemmoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334263"}]}}{"C43326":{"preferredName":"Trichilemmal Carcinoma","code":"C43326","definitions":[{"definition":"A rare malignant tumor arising from the outer hair sheath and infundibulum on the face. It is considered the malignant counterpart of tricholemmoma. Complete surgical excision is required.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichilemmal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Trichilemmocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tricholemmal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8102/3"},{"name":"Legacy Concept Name","value":"Trichilemmal_Carcinoma"},{"name":"Maps_To","value":"8102/3"},{"name":"Maps_To","value":"Trichilemmal carcinoma"},{"name":"Maps_To","value":"Trichilemmocarcinoma"},{"name":"Maps_To","value":"Trichoblastic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266009"}]}}{"C27125":{"preferredName":"Proliferating Trichilemmal Tumor","code":"C27125","definitions":[{"definition":"A neoplasm with tricholemmal differentiation. It affects women more frequently than men. It usually presents on the scalp as a solitary, multilobular, large, exophytic mass. Morphologically, it may display benign cytological features and appear as a circumscribed solid-cystic neoplasm or it may display malignant characteristics and invasive features. Cases without malignant characteristics usually have an indolent course. Complete surgical excision is recommended in such cases to avoid recurrences and to allow complete examination of the specimen. Cases with malignant characteristics may have a locally aggressive clinical course, recur, or metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proliferating Trichilemmal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Pilar Cyst","termGroup":"SY","termSource":"NCI"},{"termName":"Pilar Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Pilar Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Trichilemmal Cyst","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Trichilemmal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Tricholemmal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"PTT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8103/0"},{"name":"ICD-O-3_Code","value":"8103/1"},{"name":"Legacy Concept Name","value":"Pilar_Tumor"},{"name":"Maps_To","value":"8103/0"},{"name":"Maps_To","value":"Pilar tumor"},{"name":"Maps_To","value":"Proliferating trichilemmal cyst"},{"name":"Maps_To","value":"Proliferating trichilemmal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0086809"}]}}{"C7368":{"preferredName":"Pilomatricoma","code":"C7368","definitions":[{"definition":"A benign adnexal neoplasm arising from hair-bearing skin surfaces, usually the head and neck and upper extremities. It usually presents as a solitary, slow-growing nodular mass. Morphologically, it displays differentiation towards the matrix and inner sheath of the normal hair follicle and the hair cortex. Complete surgical excision is usually curative. Occasionally, it may recur.","type":"DEFINITION","source":"NCI"},{"definition":"A benign hair follicle neoplasm in the outer hair sheath and infundibulum, characterized by abrupt keratinization and central lumen with ghost cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pilomatricoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Pilomatricoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Pilomatrixoma","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Epithelioma of Malherbe","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrixoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8110/0"},{"name":"Legacy Concept Name","value":"Pilomatricoma"},{"name":"Maps_To","value":"8110/0"},{"name":"Maps_To","value":"Calcifying epithelioma of Malherbe"},{"name":"Maps_To","value":"Pilomatricoma, NOS"},{"name":"Maps_To","value":"Pilomatrixoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206711"}]}}{"C4114":{"preferredName":"Pilomatrical Carcinoma","code":"C4114","definitions":[{"definition":"A very rare, locally aggressive, malignant neoplasm of the hair follicle. The majority of the cases arise de novo, however malignant transformation from a pre-existing pilomatricoma has been reported. It usually presents as a solitary nodule in the head and neck, upper extremities, or buttocks. Morphologically, it is characterized by the presence of aggregates of basaloid cells infiltrating the dermis. Masses of ghost cells are present in the cellular aggregates. Complete surgical excision is the treatment of choice. If it is not completely removed, it usually recurs, but it rarely metastasizes to distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilomatrical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Pilomatrixoma","termGroup":"SY","termSource":"NCI"},{"termName":"Matrical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Carcinoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Carcinoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Pilomatrix Skin Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8110/3"},{"name":"Legacy Concept Name","value":"Pilomatrix_Carcinoma"},{"name":"Maps_To","value":"8110/3"},{"name":"Maps_To","value":"Matrical carcinoma"},{"name":"Maps_To","value":"Pilomatrical carcinoma"},{"name":"Maps_To","value":"Pilomatricoma, malignant"},{"name":"Maps_To","value":"Pilomatrix carcinoma"},{"name":"Maps_To","value":"Pilomatrixoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0585475"}]}}{"C4115":{"preferredName":"Transitional Cell Papilloma","code":"C4115","definitions":[{"definition":"A benign papillary neoplasm composed of transitional cells which show preservation of the nuclear polarity.","type":"DEFINITION","source":"NCI"},{"definition":"A benign papillary neoplasm composed of urothelial cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Transitional Cell Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8120/0"},{"name":"Legacy Concept Name","value":"Transitional_Cell_Papilloma"},{"name":"Maps_To","value":"8120/1"},{"name":"Maps_To","value":"Transitional cell papilloma, benign"},{"name":"Maps_To","value":"Transitional cell papilloma, NOS"},{"name":"Maps_To","value":"Transitional papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334266"}]}}{"C3842":{"preferredName":"Urothelial Papilloma","code":"C3842","definitions":[{"definition":"A rare benign neoplasm that arises from the urinary tract and is characterized by the presence of a papillary growth with a central fibrovascular core. The latter is lined by normal urothelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urothelial Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8120/1"},{"name":"Legacy Concept Name","value":"Urothelial_Papilloma"},{"name":"Maps_To","value":"8120/1"},{"name":"Maps_To","value":"Papilloma of bladder"},{"name":"Maps_To","value":"Urothelial papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0235754"}]}}{"C4116":{"preferredName":"Stage 0 Transitional Cell Carcinoma","code":"C4116","definitions":[{"definition":"A lesion in which the surface epithelium of the bladder or the renal pelvis and ureter contains transitional cells which display malignant cytologic characteristics.  There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Transitional Cell Carcinoma in situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8120/2"},{"name":"Legacy Concept Name","value":"Stage_0_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8120/2"},{"name":"Maps_To","value":"Transitional cell carcinoma in situ"},{"name":"Maps_To","value":"Urothelial carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334267"}]}}{"C2930":{"preferredName":"Transitional Cell Carcinoma","code":"C2930","definitions":[{"definition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from transitional epithelium.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that forms in transitional cells in the lining of the bladder, ureter, or renal pelvis (the part of the kidney that collects, holds, and drains urine). Transitional cells are cells that can change shape and stretch without breaking apart.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8120/3"},{"name":"Legacy Concept Name","value":"Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8120/3"},{"name":"Maps_To","value":"Transitional carcinoma"},{"name":"Maps_To","value":"Transitional cell carcinoma"},{"name":"Maps_To","value":"Transitional cell carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007138"}]}}{"C4030":{"preferredName":"Urothelial Carcinoma","code":"C4030","definitions":[{"definition":"A carcinoma arising from the urothelial lining of the urinary tract (bladder, renal pelvis, ureter, or urethra).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Cell Carcinoma of the Urinary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Uroepithelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urothelial_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8120/3"},{"name":"Maps_To","value":"Urothelial carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2145472"}]}}{"C4117":{"preferredName":"Sinonasal Papilloma","code":"C4117","definitions":[{"definition":"A benign neoplasm that arises from the ciliated respiratory mucosa that lines the nasal cavity and paranasal sinuses.  It is classified as inverted papilloma, oncocytic papilloma, and exophytic papilloma. Clinical manifestations include nasal obstruction, epistaxis, and anosmia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8121/0"},{"name":"Legacy Concept Name","value":"Schneiderian_Papilloma"},{"name":"Maps_To","value":"8121/0"},{"name":"Maps_To","value":"Schneiderian papilloma, NOS"},{"name":"Maps_To","value":"Sinonasal papilloma"},{"name":"Maps_To","value":"Sinonasal papilloma, exophytic"},{"name":"Maps_To","value":"Sinonasal papilloma, fungiform"},{"name":"Maps_To","value":"Sinonasal papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334268"}]}}{"C4118":{"preferredName":"Inverted Transitional Cell Papilloma","code":"C4118","definitions":[{"definition":"A benign papillary neoplasm composed of transitional cells and characterized by an endophytic growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inverted Transitional Cell Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Inverted Transitional Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8121/1"},{"name":"Legacy Concept Name","value":"Inverted_Transitional_Cell_Papilloma"},{"name":"Maps_To","value":"8121/0"},{"name":"Maps_To","value":"8121/1"},{"name":"Maps_To","value":"Transitional cell papilloma, inverted, benign"},{"name":"Maps_To","value":"Transitional cell papilloma, inverted, NOS"},{"name":"Maps_To","value":"Transitional papilloma, inverted, benign"},{"name":"Maps_To","value":"Transitional papilloma, inverted, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334269"}]}}{"C6871":{"preferredName":"Sinonasal Inverted Papilloma","code":"C6871","definitions":[{"definition":"A benign neoplasm that arises from the ciliated respiratory mucosa that lines the nasal cavity or paranasal sinuses.  It results from the invagination and proliferation of epithelial cells in the underlying stroma.  Clinical manifestations include nasal obstruction, epistaxis, and anosmia. It has the tendency to recur and extend to adjacent structures.  Inverted papillomas are occasionally associated with the development or presence of carcinomas, usually squamous cell carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Inverted Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Inverted Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Inverted Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Papilloma, Inverted Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inverted_Schneiderian_Papilloma"},{"name":"Maps_To","value":"8121/1"},{"name":"Maps_To","value":"Schneiderian papilloma, inverted"},{"name":"Maps_To","value":"Sinonasal papilloma, inverted"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1537102"}]}}{"C54345":{"preferredName":"Sinonasal Oncocytic Papilloma","code":"C54345","definitions":[{"definition":"A benign neoplasm with exophytic and endophytic growth arising from the lateral nasal wall or the paranasal sinuses. It is characterized by the proliferation of columnar cells with oncocytic features. Microcysts containing mucin and neutrophils are present in the epithelium. Clinical manifestations include nasal obstruction and epistaxis. Occasionally, it is associated with the development or presence of a carcinoma, usually squamous cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Oncocytic Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Oncocytic Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Oncocytic Schneiderian Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Papilloma, Oncocytic Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oncocytic_Schneiderian_Papilloma"},{"name":"Maps_To","value":"8121/1"},{"name":"Maps_To","value":"Oncocytic Schneiderian papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704453"}]}}{"C54287":{"preferredName":"Sinonasal Non-Keratinizing Squamous Cell Carcinoma","code":"C54287","definitions":[{"definition":"A squamous cell carcinoma of the sinonasal tract characterized by a plexiform or ribbon-like growth pattern, cytological atypia, and lack of histological evidence of keratinization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinonasal Non-Keratinizing Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Keratinizing Sinonasal Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ringertz Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Schneiderian Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Cylindrical Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Schneiderian Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Transitional Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8121/3"},{"name":"Legacy Concept Name","value":"Non-Keratinizing_Sinonasal_Squamous_Cell_Carcinoma"},{"name":"Maps_To","value":"8121/3"},{"name":"Maps_To","value":"Cylindrical cell carcinoma"},{"name":"Maps_To","value":"Schneiderian carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334270"}]}}{"C4120":{"preferredName":"Sarcomatoid Transitional Cell Carcinoma","code":"C4120","definitions":[{"definition":"A poorly differentiated transitional cell carcinoma characterized by the presence of malignant cells with spindle cell morphologic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Transitional Cell Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Transitional Spindle Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8122/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8122/3"},{"name":"Maps_To","value":"Transitional cell carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Transitional cell carcinoma, spindle cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334271"}]}}{"C4121":{"preferredName":"Basaloid Carcinoma","code":"C4121","definitions":[{"definition":"A malignant epithelial neoplasm characterized by the presence of neoplastic cells with hyperchromatic nuclei, small amount of cytoplasm, and peripheral nuclear palisading.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basaloid Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8123/3"},{"name":"Legacy Concept Name","value":"Basaloid_Carcinoma"},{"name":"Maps_To","value":"8123/3"},{"name":"Maps_To","value":"Basaloid carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704216"}]}}{"C8255":{"preferredName":"Anal Canal Cloacogenic Carcinoma","code":"C8255","definitions":[{"definition":"An anal carcinoma arising from the transitional zone of the anal canal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Canal Cloacogenic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anal Canal Transitional Zone Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Anal Cloacogenic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Anal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Carcinoma of Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Cloacogenic Carcinoma of the Anus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8124/3"},{"name":"Legacy Concept Name","value":"Anal_Cloacogenic_Carcinoma"},{"name":"Maps_To","value":"8124/3"},{"name":"Maps_To","value":"Cloacogenic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334273"}]}}{"C191672":{"preferredName":"Papillary Urothelial Neoplasm of Low Malignant Potential","code":"C191672","definitions":[{"definition":"A papillary neoplasm of the urothelium. The papillary structures exhibit minimal architectural distortion and minimal atypia. Mitoses are infrequent. It usually occurs in the urinary bladder, but it can arise from other sites in the urinary tract. Patients are at an increased risk of developing new papillary lesions. Occasionally, the new lesions are urothelial carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Urothelial Neoplasm of Low Malignant Potential","termGroup":"PT","termSource":"NCI"},{"termName":"PUNLMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8130/1"},{"name":"Maps_To","value":"Papillary transitional cell neoplasm of low malignant potential"},{"name":"Maps_To","value":"Papillary urothelial neoplasm of low malignant potential"},{"name":"NCI_META_CUI","value":"CL1905256"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C65181":{"preferredName":"Non-Invasive Papillary Transitional Cell Carcinoma","code":"C65181","definitions":[{"definition":"A transitional cell carcinoma characterized by a papillary growth pattern and lack of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Invasive Papillary Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8130/2"},{"name":"Legacy Concept Name","value":"Non-Invasive_Papillary_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8130/2"},{"name":"Maps_To","value":"Papillary transitional cell carcinoma, non-invasive"},{"name":"Maps_To","value":"Papillary urothelial carcinoma, non-invasive"},{"name":"NCI_META_CUI","value":"CL017895"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4122":{"preferredName":"Papillary Transitional Cell Carcinoma","code":"C4122","definitions":[{"definition":"A non-invasive or invasive transitional cell carcinoma characterized by a papillary growth pattern. It may occur in the bladder or the renal pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Transitional Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8130/3"},{"name":"Legacy Concept Name","value":"Papillary_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8130/3"},{"name":"Maps_To","value":"Papillary transitional cell carcinoma"},{"name":"Maps_To","value":"Papillary urothelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334274"}]}}{"C65182":{"preferredName":"Micropapillary Transitional Cell Carcinoma","code":"C65182","definitions":[{"definition":"A transitional cell carcinoma characterized by a micropapillary growth pattern. Typical example is the micropapillary variant of infiltrating bladder urothelial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micropapillary Transitional Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8131/3"},{"name":"Legacy Concept Name","value":"Micropapillary_Transitional_Cell_Carcinoma"},{"name":"Maps_To","value":"8131/3"},{"name":"Maps_To","value":"Transitional cell carcinoma, micropapillary"},{"name":"Maps_To","value":"Urothelial carcinoma, micropapillary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266012"}]}}{"C2855":{"preferredName":"Adenoma","code":"C2855","definitions":[{"definition":"A benign neoplasm arising from epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that is not cancer. It starts in gland-like cells of the epithelial tissue (thin layer of tissue that covers organs, glands, and other structures within the body).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/0"},{"name":"Legacy Concept Name","value":"Adenoma"},{"name":"Maps_To","value":"8140/0"},{"name":"Maps_To","value":"Adenoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001430"}]}}{"C3494":{"preferredName":"Lung Papillary Adenoma","code":"C3494","definitions":[{"definition":"A benign lung neoplasm characterized by the presence of a fibrovascular stroma lined by cuboidal to columnar cells. Patients are usually asymptomatic and it is incidentally discovered as a pulmonary nodule during chest X-ray examination. Surgical excision is curative.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasia of the lung, arising from bronchial epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that forms in tissues of the bronchi (large air passages in the lungs including those that lead to the lungs from the windpipe).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lung Papillary Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Bronchus","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Bronchus","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchial Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Adenoma of Type II Pneumocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Papillary Tumor of Type II Pneumocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Type II Pneumocyte Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8260/0"},{"name":"Legacy Concept Name","value":"Bronchial_Adenoma"},{"name":"Maps_To","value":"8140/1"},{"name":"Maps_To","value":"Bronchial adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0149845"}]}}{"C7559":{"preferredName":"Atypical Adenoma","code":"C7559","definitions":[{"definition":"An adenoma characterized by increased cellularity and nuclear atypia without evidence of vascular or capsular invasion. A representative example is thyroid gland atypical follicular adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/1"},{"name":"Legacy Concept Name","value":"Atypical_Adenoma"},{"name":"Maps_To","value":"8140/1"},{"name":"Maps_To","value":"Atypical adenoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1305409"}]}}{"C4123":{"preferredName":"Adenocarcinoma In Situ","code":"C4123","definitions":[{"definition":"A lesion in which the normally situated glands are partially or completely replaced by atypical cells with malignant characteristics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ"},{"name":"Maps_To","value":"8140/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334276"}]}}{"C2852":{"preferredName":"Adenocarcinoma","code":"C2852","definitions":[{"definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from glandular cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8140/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma"},{"name":"Maps_To","value":"8140/3"},{"name":"Maps_To","value":"Adenocarcinoma"},{"name":"Maps_To","value":"Adenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2750272"}]}}{"C4124":{"preferredName":"Metastatic Adenocarcinoma","code":"C4124","definitions":[{"definition":"An adenocarcinoma that has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8140/6"},{"name":"Legacy Concept Name","value":"Metastatic_Adenocarcinoma"},{"name":"Maps_To","value":"8140/6"},{"name":"Maps_To","value":"Adenocarcinoma, metastatic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334277"}]}}{"C2928":{"preferredName":"Scirrhous Adenocarcinoma","code":"C2928","definitions":[{"definition":"A malignant neoplasm originating from glandular cells with a fibrous or fibroblastic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating adenocarcinoma characterized by the presence of desmoplastic stromal reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scirrhous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma with Productive Fibrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8141/3"},{"name":"Legacy Concept Name","value":"Scirrhous_Adenocarcinoma"},{"name":"Maps_To","value":"8141/3"},{"name":"Maps_To","value":"Carcinoma with productive fibrosis"},{"name":"Maps_To","value":"Scirrhous adenocarcinoma"},{"name":"Maps_To","value":"Scirrhous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007135"}]}}{"C3190":{"preferredName":"Linitis Plastica","code":"C3190","definitions":[{"definition":"A cancer-related condition in which the gastric wall becomes thickened and rubbery (leather-bottle stomach). It is most often associated with diffuse gastric adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linitis Plastica","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8142/3"},{"name":"Legacy Concept Name","value":"Linitis_Plastica"},{"name":"Maps_To","value":"8142/3"},{"name":"Maps_To","value":"Linitis plastica"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0023743"}]}}{"C4125":{"preferredName":"Superficial Spreading Adenocarcinoma","code":"C4125","definitions":[{"definition":"An adenocarcinoma which has spread within the mucosa without further invasion of the underlying tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Spreading Adenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8143/3"},{"name":"Legacy Concept Name","value":"Superficial_Spreading_Adenocarcinoma"},{"name":"Maps_To","value":"8143/3"},{"name":"Maps_To","value":"Superficial spreading adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334278"}]}}{"C4126":{"preferredName":"Intestinal-Type Adenocarcinoma","code":"C4126","definitions":[{"definition":"An adenocarcinoma arising from epithelium which has undergone intestinal metaplasia. Representative examples include gastric, gallbladder, and ampulla of Vater intestinal type adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intestinal-Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma, Intestinal Type","termGroup":"SY","termSource":"NCI"},{"termName":"Intestinal Type Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8144/3"},{"name":"Legacy Concept Name","value":"Intestinal_Type_Adenocarcinoma"},{"name":"Maps_To","value":"8144/3"},{"name":"Maps_To","value":"Adenocarcinoma, intestinal type"},{"name":"Maps_To","value":"Carcinoma, intestinal type"},{"name":"Maps_To","value":"Intestinal-type adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334279"}]}}{"C4127":{"preferredName":"Diffuse Type Adenocarcinoma","code":"C4127","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a diffuse cellular infiltrate which is composed of poorly cohesive cells with minimal or no glandular formations. Representative example is the gastric diffuse adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma, Diffuse Type","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Type Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8145/3"},{"name":"Legacy Concept Name","value":"Diffuse_Type_Adenocarcinoma"},{"name":"Maps_To","value":"8145/3"},{"name":"Maps_To","value":"Adenocarcinoma, diffuse type"},{"name":"Maps_To","value":"Carcinoma, diffuse type"},{"name":"Maps_To","value":"Poorly cohesive carcinoma"},{"name":"NCI_META_CUI","value":"CL523903"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3686":{"preferredName":"Salivary Gland Monomorphic Adenoma","code":"C3686","definitions":[{"definition":"A benign epithelial neoplasm arising from the salivary glands. It is characterized by the presence of a monomorphic cellular infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Monomorphic Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8146/0"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Monomorphic_Adenoma"},{"name":"Maps_To","value":"8146/0"},{"name":"Maps_To","value":"Monomorphic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205649"}]}}{"C5950":{"preferredName":"Basal Cell Adenoma","code":"C5950","definitions":[{"definition":"A salivary gland benign epithelial neoplasm with a uniform, monomorphic appearance that is dominated by basal cells forming trabecular structures. It is rare and occurs mostly on the parotid gland. The average age of patients has been reported to be 58 years. Swelling is the most constant clinical finding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basal Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Adenoma of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Adenoma of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"BCA","termGroup":"AB","termSource":"NCI"},{"termName":"Salivary Gland Basal Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8147/0"},{"name":"Legacy Concept Name","value":"Benign_Basal_Cell_Neoplasm"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Basal_Cell_Adenoma"},{"name":"Maps_To","value":"8147/0"},{"name":"Maps_To","value":"Basal cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205646"}]}}{"C3678":{"preferredName":"Salivary Gland Basal Cell Adenocarcinoma","code":"C3678","definitions":[{"definition":"A rare adenocarcinoma of the major and minor salivary glands, originating from basaloid, myoepithelial and ductal cells.  While morphologically resembling basal cell carcinomas, it is a distinct entity.  The tumor is not encapsulated, may invade locally, and less frequently may metastasize.  It usually occurs in older patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Basal Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Adenocarcinoma of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Adenocarcinoma of the Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8147/3"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Basal_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8147/3"},{"name":"Maps_To","value":"Basal cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205641"}]}}{"C7660":{"preferredName":"Grade II Glandular Intraepithelial Neoplasia","code":"C7660","synonyms":[{"termName":"Grade II Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Moderate Glandular Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/0"},{"name":"Legacy Concept Name","value":"Grade_II_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/0"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, grade II"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333861"}]}}{"C7661":{"preferredName":"Low Grade Glandular Intraepithelial Neoplasia","code":"C7661","synonyms":[{"termName":"Low Grade Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/0"},{"name":"Legacy Concept Name","value":"Low_Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/0"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, grade I"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334423"}]}}{"C27428":{"preferredName":"Low Grade Esophageal Glandular Intraepithelial Neoplasia","code":"C27428","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities are confined to the lower half of the esophageal glandular epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Esophageal Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal Low Grade Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade Esophageal Glandular Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/0"},{"name":"Legacy Concept Name","value":"Esophageal_Low-Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/0"},{"name":"Maps_To","value":"Esophageal glandular dysplasia (intraepithelial neoplasia), low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333457"}]}}{"C6877":{"preferredName":"Grade III Glandular Intraepithelial Neoplasia","code":"C6877","definitions":[{"definition":"A high grade intraepithelial neoplasia in which there is marked architectural distortion and crowding of the glands, associated with severe cellular atypia. The neoplastic cells display pleomorphic and hyperchromatic nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade III Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Grade_III_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266013"}]}}{"C27429":{"preferredName":"High Grade Esophageal Glandular Intraepithelial Neoplasia","code":"C27429","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities involve both the lower and the upper half of the esophageal glandular epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Esophageal Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal High-Grade Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Glandular Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Glandular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Esophageal_High-Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Esophageal glandular dysplasia (intraepithelial neoplasia), high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333449"}]}}{"C27425":{"preferredName":"Esophageal High Grade Intraepithelial Neoplasia","code":"C27425","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities involve both the lower and the upper half of the esophageal mucosa.  It includes lesions termed moderate dysplasia, and carcinoma in situ (severe dysplasia).  (WHO, 2000)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esophageal High Grade Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal High-Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Esophageal High-Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Esophageal_High-Grade_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Esophageal intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333450"}]}}{"C67493":{"preferredName":"High-Grade Biliary Intraepithelial Neoplasia","code":"C67493","definitions":[{"definition":"Biliary intraepithelial neoplasia characterized by the presence of high grade epithelial dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High-Grade Biliary Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Biliary Intraepithelial Neoplasia-3","termGroup":"SY","termSource":"NCI"},{"termName":"BilIN-3","termGroup":"AB","termSource":"NCI"},{"termName":"Grade 3 Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade BilIN","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade BilIN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"Grade_3_Biliary_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Biliary intraepithelial neoplasia, grade 3"},{"name":"Maps_To","value":"Biliary intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2348875"}]}}{"C3642":{"preferredName":"Grade III Prostatic Intraepithelial Neoplasia","code":"C3642","definitions":[{"definition":"High grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade III Prostatic Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma in situ of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma in situ of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 PIN","termGroup":"AB","termSource":"NCI"},{"termName":"Grade 3 Prostatic Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III PIN","termGroup":"AB","termSource":"NCI"},{"termName":"Prostate Adenocarcinoma in situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Grade_III_Prostatic_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Carcinoma in situ of prostate"},{"name":"Maps_To","value":"Carcinoma in situ: Prostate"},{"name":"Maps_To","value":"PIN III"},{"name":"Maps_To","value":"Prostatic intraepithelial neoplasia, grade III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0154088"}]}}{"C7662":{"preferredName":"High Grade Glandular Intraepithelial Neoplasia","code":"C7662","definitions":[{"definition":"This lesion shows moderate or marked architectural distortion with glandular crowding and prominent cellular atypia.  It includes moderate dysplasia and severe dysplasia.  (WHO, 2000)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Glandular Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8148/2"},{"name":"Legacy Concept Name","value":"High_Grade_Glandular_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8148/2"},{"name":"Maps_To","value":"Glandular intraepithelial neoplasia, high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334014"}]}}{"C5979":{"preferredName":"Salivary Gland Canalicular Adenoma","code":"C5979","definitions":[{"definition":"A benign epithelial neoplasm primarily composed of branching and interconnecting cords of single and double-cell thick rows of columnar epithelium in a very loose stroma. It often occurs in the upper lip, where only pleomorphic adenoma is more frequent. Asymptomatic swelling of the upper lip is the most common clinical finding. It may present clinically and histologically as a multifocal lesion, a feature not generally seen with other intraoral salivary gland tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Canalicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Canalicular Adenoma of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Canalicular Adenoma of the Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8149/0"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Canalicular_Adenoma"},{"name":"Maps_To","value":"8149/0"},{"name":"Maps_To","value":"Canalicular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266014"}]}}{"C27720":{"preferredName":"Pancreatic Neuroendocrine Tumor","code":"C27720","definitions":[{"definition":"A mass of abnormal cells that forms in the endocrine (hormone-producing) tissues of the pancreas. Islet cell tumors may be benign (not cancer) or malignant (cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Islet Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Well Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Well-Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"PanNET","termGroup":"AB","termSource":"NCI"},{"termName":"Well Differentiated Pancreatic Endocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well Differentiated Pancreatic Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Pancreatic Endocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Pancreatic Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/1"},{"name":"Legacy Concept Name","value":"Well-Differentiated_Pancreatic_Endocrine_Neoplasm"},{"name":"Maps_To","value":"8150/0"},{"name":"Maps_To","value":"Benign neoplasm: Endocrine pancreas"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, benign"},{"name":"NCI_META_CUI","value":"CL480914"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27031":{"preferredName":"Pancreatic Neuroendocrine Neoplasm","code":"C27031","definitions":[{"definition":"A neoplasm with neuroendocrine differentiation that arises from the pancreas.  It includes neuroendocrine tumors and neuroendocrine carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Endocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"PanNEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/1"},{"name":"Legacy Concept Name","value":"Pancreatic_Endocrine_Neoplasm"},{"name":"Maps_To","value":"8150/1"},{"name":"Maps_To","value":"Islet cell tumor, NOS"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, NOS"},{"name":"NCI_META_CUI","value":"CL973078"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3770":{"preferredName":"Pancreatic Neuroendocrine Carcinoma","code":"C3770","definitions":[{"definition":"A malignant endocrine neoplasm arising from islets of Langerhans of the pancreas.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer arising from cells in the islets of Langerhans, which are found in the pancreas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"High Grade Pancreatic Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Pancreatic Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Islet Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Endocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic NEC","termGroup":"SY","termSource":"NCI"},{"termName":"PanNEC","termGroup":"AB","termSource":"NCI"},{"termName":"Poorly Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Poorly Differentiated Pancreatic Endocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/3"},{"name":"Legacy Concept Name","value":"Pancreatic_Endocrine_Carcinoma"},{"name":"Maps_To","value":"8150/3"},{"name":"Maps_To","value":"Islet cell adenocarcinoma"},{"name":"Maps_To","value":"Islet cell carcinoma"},{"name":"Maps_To","value":"Malignant neoplasm of islets of Langerhans"},{"name":"Maps_To","value":"Malignant neoplasm: Endocrine pancreas"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1328479"}]}}{"C67457":{"preferredName":"Pancreatic Beta Cell Adenoma","code":"C67457","definitions":[{"definition":"An adenoma arising from the beta cells of the pancreas.  It produces insulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Beta Cell Adenoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Pancreatic Beta Islet Cell Adenoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Beta_Cell_Adenoma"},{"name":"Maps_To","value":"8151/0"},{"name":"Maps_To","value":"Beta cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279719"}]}}{"C95598":{"preferredName":"Pancreatic Insulinoma","code":"C95598","definitions":[{"definition":"A usually benign tumor of insulin secreting pancreatic beta cells, associated with hypoglycemia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An abnormal mass that grows in the beta cells of the pancreas that make insulin. Beta cell neoplasms are usually benign (not cancer). They secrete insulin and are the most common cause of low blood sugar caused by having too much insulin in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas. Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Insulinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Insulinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"8151/0"},{"name":"Maps_To","value":"Insulinoma"},{"name":"Maps_To","value":"Insulinoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0021670"}]}}{"C65186":{"preferredName":"Malignant Pancreatic Insulinoma","code":"C65186","definitions":[{"definition":"An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Pancreatic Insulinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Insulinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Beta Islet Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Insulin Producing Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8151/3"},{"name":"Legacy Concept Name","value":"Malignant_Insulinoma"},{"name":"Maps_To","value":"8151/3"},{"name":"Maps_To","value":"Beta cell tumor, malignant"},{"name":"Maps_To","value":"Insulinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334281"}]}}{"C95597":{"preferredName":"Pancreatic Glucagonoma","code":"C95597","definitions":[{"definition":"A rare pancreatic tumor that produces a hormone called glucagon. Glucagonomas can produce symptoms similar to diabetes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually malignant, glucagon-producing neuroendocrine tumor arising from the pancreatic alpha cells. It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia. Almost 25% of patients experience thromboembolic complications, and 50% have liver metastases at the time of diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Glucagonoma","termGroup":"PT","termSource":"NCI"},{"termName":"Glucagonoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8152/1"},{"name":"Maps_To","value":"Glucagonoma"},{"name":"Maps_To","value":"Glucagonoma, NOS"},{"name":"NCI_META_CUI","value":"CL428078"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C65191":{"preferredName":"Malignant Enteroglucagonoma","code":"C65191","definitions":[{"definition":"A glucagon-producing malignant endocrine neoplasm. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Enteroglucagonoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8152/3"},{"name":"ICD-O-3_Code","value":"8157/3"},{"name":"Legacy Concept Name","value":"Malignant_Enteroglucagonoma"},{"name":"Maps_To","value":"8152/3"},{"name":"Maps_To","value":"Enteroglucagonoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266017"}]}}{"C65187":{"preferredName":"Malignant Pancreatic Glucagonoma","code":"C65187","definitions":[{"definition":"A glucagon-producing neuroendocrine tumor arising from the alpha cells of the pancreas.  It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia.  It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Pancreatic Glucagonoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Glucagonoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Alpha Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8152/3"},{"name":"Legacy Concept Name","value":"Malignant_Glucagonoma"},{"name":"Maps_To","value":"8152/3"},{"name":"Maps_To","value":"Alpha cell tumor, malignant"},{"name":"Maps_To","value":"Glucagonoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334282"}]}}{"C3050":{"preferredName":"Gastrin-Producing Neuroendocrine Tumor","code":"C3050","definitions":[{"definition":"A gastrin-producing neuroendocrine tumor. It is usually located in the pancreas but it is also found at other anatomic sites, including the stomach and small intestine.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that causes overproduction of gastric acid. It usually begins in the duodenum (first part of the small intestine that connects to the stomach) or the islet cells of the pancreas. Rarely, it may also begin in other organs, including the stomach, liver, jejunum (the middle part of the small intestine), biliary tract (organs and ducts that make and store bile), mesentery, or heart. It is a type of neuroendocrine tumor, and it may metastasize (spread) to the liver and the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastrin-Producing Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"G Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"G-Cell Gastrin Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"G-Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrin Secreting Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrin-Producing NET","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8153/1"},{"name":"Legacy Concept Name","value":"G-Cell_Gastrin_Producing_Neoplasm"},{"name":"Maps_To","value":"8153/1"},{"name":"Maps_To","value":"G cell tumor, NOS"},{"name":"Maps_To","value":"Gastrin cell tumor"},{"name":"Maps_To","value":"Gastrinoma"},{"name":"Maps_To","value":"Gastrinoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017150"}]}}{"C65188":{"preferredName":"Malignant Gastrinoma","code":"C65188","definitions":[{"definition":"A gastrin-producing neuroendocrine tumor.  It is characterized by inappropriate secretion of gastrin and associated with Zollinger Ellison syndrome.  It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Gastrinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8153/3"},{"name":"Legacy Concept Name","value":"Malignant_Gastrinoma"},{"name":"Maps_To","value":"8153/3"},{"name":"Maps_To","value":"G cell tumor, malignant"},{"name":"Maps_To","value":"Gastrin cell tumor, malignant"},{"name":"Maps_To","value":"Gastrinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334283"}]}}{"C164255":{"preferredName":"Mixed Neuroendocrine Non-Neuroendocrine Neoplasm","code":"C164255","definitions":[{"definition":"A rare neoplasm that consists of neuroendocrine and non-neuroendocrine cellular components. At least 30% of either component should be present for the diagnosis to be made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Neuroendocrine Non-Neuroendocrine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"MINEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8154/3"},{"name":"Maps_To","value":"Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334284"}]}}{"C45843":{"preferredName":"Pancreatic Mixed Adenoneuroendocrine Carcinoma","code":"C45843","definitions":[{"definition":"A rare carcinoma with a poor prognosis, characterized by the presence of a mixture of exocrine and neuroendocrine malignant epithelial cells in both the pancreas and metastatic sites.  Symptoms include jaundice, abdominal pain, and weight loss.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mixed Adenoneuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Exocrine-Endocrine Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Carcinoma with Mixed Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mixed Neuroendocrine-Non-Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8154/3"},{"name":"Legacy Concept Name","value":"Mixed_Exocrine-Endocrine_Carcinoma"},{"name":"Maps_To","value":"8154/3"},{"name":"Maps_To","value":"Mixed pancreatic endocrine and exocrine tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709050"}]}}{"C26749":{"preferredName":"VIP-Producing Neuroendocrine Tumor","code":"C26749","definitions":[{"definition":"An often clinically aggressive neuroendocrine tumor located in the pancreas or small intestine.  It is composed of cells containing vasoactive intestinal peptide.  It may cause intractable diarrhea and metabolic disturbances.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VIP-Producing Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Vasoactive Intestinal Peptide Producing Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Vasoactive Intestinal Peptide Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Vasoactive Intestinal Peptide Secreting Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"VIP Producing Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"VIP- Secreting Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"VIP- Secreting Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"VIP-Producing NET","termGroup":"SY","termSource":"NCI"},{"termName":"VIPoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8155/1"},{"name":"Legacy Concept Name","value":"Vasoactive_Intestinal_Peptide_Producing_Neoplasm"},{"name":"Maps_To","value":"8155/1"},{"name":"Maps_To","value":"Vipoma"},{"name":"Maps_To","value":"Vipoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0011993"}]}}{"C65189":{"preferredName":"Malignant Vipoma","code":"C65189","definitions":[{"definition":"An aggressive neuroendocrine tumor located in the pancreas or small intestine. It is composed of cells containing vasoactive intestinal peptide.  It is associated with watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Vipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8155/3"},{"name":"Legacy Concept Name","value":"Malignant_Vipoma"},{"name":"Maps_To","value":"8155/3"},{"name":"Maps_To","value":"Vipoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881600"}]}}{"C3379":{"preferredName":"Somatostatin-Producing Neuroendocrine Tumor","code":"C3379","definitions":[{"definition":"A rare, usually malignant neuroendocrine tumor arizing from delta cells.  This neoplasm produces large amounts of somatostatin, which may result in a syndrome characterized by diarrhea, steatorrhea, weight loss, and gastric hyposecretion. Sixty percent are found in the pancreas and 40% in the duodenum or jejunum. The peak incidence occurs between 40 and 60 years of age; women are affected more than men by 2:1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Somatostatin-Producing Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Delta Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin-Producing NET","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatin-Producing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Somatostatinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Delta Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Delta Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8156/1"},{"name":"Legacy Concept Name","value":"Delta_Cell_Somatostatin_Producing_Neoplasm"},{"name":"Maps_To","value":"8156/1"},{"name":"Maps_To","value":"Somatostatin cell tumor, NOS"},{"name":"Maps_To","value":"Somatostatinoma"},{"name":"Maps_To","value":"Somatostatinoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0037661"}]}}{"C65190":{"preferredName":"Malignant Somatostatinoma","code":"C65190","definitions":[{"definition":"A neuroendocrine tumor arising from delta cells which produce somatostatin. It displays vascular invasion and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Somatostatinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Delta Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8156/3"},{"name":"Legacy Concept Name","value":"Malignant_Somatostatinoma"},{"name":"Maps_To","value":"8156/3"},{"name":"Maps_To","value":"Somatostatin cell tumor, malignant"},{"name":"Maps_To","value":"Somatostatinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266015"}]}}{"C94759":{"preferredName":"Functioning Endocrine Neoplasm","code":"C94759","definitions":[{"definition":"A hormone producing endocrine neoplasm, associated with a hormonal syndrome.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that is found in endocrine tissue and makes hormones (chemicals that travel in the bloodstream and control the actions of other cells or organs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Functioning Endocrine Neoplasm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8158/1"},{"name":"Maps_To","value":"8158/1"},{"name":"Maps_To","value":"Endocrine tumor, functioning, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2986655"}]}}{"C2942":{"preferredName":"Bile Duct Adenoma","code":"C2942","definitions":[{"definition":"A benign neoplasm arising from/comprising cells resembling those of bile ducts.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well-demarcated polypoid neoplasm arising from the bile duct epithelium. According to the growth pattern, it is classified as tubular, papillary, or tubulopapillary. Adenomas arising from the extrahepatic bile ducts usually produce symptoms related to biliary obstruction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"BDA","termGroup":"AB","termSource":"NCI"},{"termName":"Cholangioadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cholangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8160/0"},{"name":"Legacy Concept Name","value":"Bile_Duct_Adenoma"},{"name":"Maps_To","value":"8160/0"},{"name":"Maps_To","value":"Bile duct adenoma"},{"name":"Maps_To","value":"Cholangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008309"}]}}{"C4436":{"preferredName":"Cholangiocarcinoma","code":"C4436","definitions":[{"definition":"A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from/comprising cells resembling those of bile ducts.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare type of cancer that develops in cells that line the bile ducts in the liver. Cancer that forms where the right and left ducts meet is called Klatskin tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cholangiocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"CC","termGroup":"AB","termSource":"NCI"},{"termName":"Cholangiocellular Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8160/3"},{"name":"Legacy Concept Name","value":"Cholangiocarcinoma"},{"name":"Maps_To","value":"8160/3"},{"name":"Maps_To","value":"Cholangiocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206698"}]}}{"C27813":{"preferredName":"Bile Duct Adenocarcinoma","code":"C27813","definitions":[{"definition":"An adenocarcinoma arising from the intrahepatic or extrahepatic bile ducts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bile_Duct_Adenocarcinoma"},{"name":"Maps_To","value":"8160/3"},{"name":"Maps_To","value":"Bile duct adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370800"}]}}{"C27814":{"preferredName":"Bile Duct Carcinoma","code":"C27814","definitions":[{"definition":"A carcinoma arising from the intrahepatic or extrahepatic bile ducts.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in a bile duct. A bile duct is a tube that carries bile (fluid made by the liver that helps digest fat) between the liver and gallbladder and the intestine. Bile ducts include the common hepatic, cystic, and common bile ducts. Bile duct cancer may be found inside the liver (intrahepatic) or outside the liver (extrahepatic).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bile Duct Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bile_Duct_Carcinoma"},{"name":"Maps_To","value":"8160/3"},{"name":"Maps_To","value":"Bile Duct Cancer"},{"name":"Maps_To","value":"Bile duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0740277"}]}}{"C4129":{"preferredName":"Bile Duct Mucinous Cystic Neoplasm","code":"C4129","definitions":[{"definition":"An epithelial, usually multiloculated neoplasm arising from the intrahepatic or extrahepatic bile ducts. It occurs predominantly in females. Signs and symptoms include abdominal mass, abdominal pain, and jaundice. Morphologically, the cystic spaces are lined by columnar epithelium and contain mucinous or serous fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Mucinous Cystic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct MCN","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenoma of Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenoma of the Bile Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8161/0"},{"name":"Legacy Concept Name","value":"Bile_Duct_Cystadenoma"},{"name":"Maps_To","value":"8161/0"},{"name":"Maps_To","value":"Bile duct cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334285"}]}}{"C4130":{"preferredName":"Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma","code":"C4130","definitions":[{"definition":"A mucinous cystic neoplasm that arises from the intrahepatic or extrahepatic bile ducts and it is associated with an invasive carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct MCN with an Associated Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenocarcinoma of Bile Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Cystadenocarcinoma of the Bile Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8161/3"},{"name":"Legacy Concept Name","value":"Biliary_Cystadenocarcinoma"},{"name":"Maps_To","value":"8161/3"},{"name":"Maps_To","value":"Bile duct cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334286"}]}}{"C36077":{"preferredName":"Hilar Cholangiocarcinoma","code":"C36077","definitions":[{"definition":"A carcinoma that arises from the junction, or adjacent to the junction, of the right and left hepatic ducts.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that develops in cells that line the bile ducts in the liver, where the right and left ducts meet. It is a type of cholangiocarcinoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hilar Cholangiocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hilar CC","termGroup":"SY","termSource":"NCI"},{"termName":"Klatskin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Perihilar Cholangiocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hilar_Cholangiocarcinoma"},{"name":"Maps_To","value":"8162/3"},{"name":"Maps_To","value":"Klatskin tumor"},{"name":"Maps_To","value":"Perihilar cholangiocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206702"}]}}{"C95914":{"preferredName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia","code":"C95914","definitions":[{"definition":"An ampullary noninvasive papillary neoplasm of the pancreatobiliary type characterized by the presence of low grade dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Ampullary Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/0"},{"name":"Maps_To","value":"8163/0"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3272434"}]}}{"C95913":{"preferredName":"Ampullary Noninvasive Papillary Neoplasm, Pancreatobiliary Type","code":"C95913","definitions":[{"definition":"An exophytic, preinvasive, papillary epithelial neoplasm that arises from the ampulla of Vater.  Histologically it resembles the papillary neoplasms of the biliary tree.  This category includes neoplasms with low grade dysplasia and high grade dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampullary Noninvasive Papillary Neoplasm, Pancreatobiliary Type","termGroup":"PT","termSource":"NCI"},{"termName":"Noninvasive Papillary Neoplasm, Pancreatobiliary Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/0"},{"name":"Maps_To","value":"8163/0"},{"name":"Maps_To","value":"Pancreatobiliary neoplasm, non-invasive"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3272433"}]}}{"C95915":{"preferredName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia","code":"C95915","definitions":[{"definition":"An ampullary noninvasive papillary neoplasm of the pancreatobiliary type characterized by the presence of high grade dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Ampullary High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/2"},{"name":"Maps_To","value":"8163/2"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia"},{"name":"Maps_To","value":"Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia"},{"name":"Maps_To","value":"Papillary neoplasm, pancreatobiliary type, with high grade intraepithelial neoplasia"},{"name":"Maps_To","value":"Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472606"}]}}{"C95963":{"preferredName":"Ampulla of Vater Pancreatobiliary Type Adenocarcinoma","code":"C95963","definitions":[{"definition":"An invasive adenocarcinoma that arises from the ampulla of Vater. It is characterized by the presence of malignant cells that resemble the malignant cells of the pancreatic ductal or extrahepatic bile duct carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampulla of Vater Pancreatobiliary Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8163/3"},{"name":"Maps_To","value":"8163/3"},{"name":"Maps_To","value":"Pancreatobiliary type carcinoma"},{"name":"Maps_To","value":"Pancreatobiliary-type carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472607"}]}}{"C3758":{"preferredName":"Hepatocellular Adenoma","code":"C3758","definitions":[{"definition":"A benign epithelial neoplasm arising from hepatocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign epithelial neoplasm arising from the hepatocytes. Grossly, it appears as a soft, round mass which often contains areas of hemorrhage and necrosis. Morphologically, the neoplastic cells resemble normal hepatocytes and form plates separated by sinusoids. Most patients have a history of contraceptive or anabolic steroids use.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatocellular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"HCA","termGroup":"AB","termSource":"NCI"},{"termName":"Liver Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8170/0"},{"name":"Legacy Concept Name","value":"Hepatocellular_Adenoma"},{"name":"Maps_To","value":"8170/0"},{"name":"Maps_To","value":"Hepatocellular adenoma"},{"name":"Maps_To","value":"Hepatoma, benign"},{"name":"Maps_To","value":"Liver cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206669"}]}}{"C3099":{"preferredName":"Hepatocellular Carcinoma","code":"C3099","definitions":[{"definition":"A malignant neoplasm arising from hepatocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","type":"DEFINITION","source":"NCI"},{"definition":"A type of adenocarcinoma and the most common type of liver tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"HCC","termGroup":"AB","termSource":"NCI"},{"termName":"Hepatoma","termGroup":"SY","termSource":"NCI"},{"termName":"LIHC","termGroup":"AB","termSource":"NCI"},{"termName":"Liver Cell Cancer (Hepatocellular Carcinoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8170/3"},{"name":"Legacy Concept Name","value":"Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8170/3"},{"name":"Maps_To","value":"Hepatocarcinoma"},{"name":"Maps_To","value":"Hepatocellular carcinoma, NOS"},{"name":"Maps_To","value":"Hepatoma, malignant"},{"name":"Maps_To","value":"Hepatoma, NOS"},{"name":"Maps_To","value":"Liver cell carcinoma"},{"name":"Maps_To","value":"Malignant neoplasm: Liver cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019204"}]}}{"C4131":{"preferredName":"Fibrolamellar Carcinoma","code":"C4131","definitions":[{"definition":"A distinctive type of liver cell carcinoma that arises in non-cirrhotic livers and is seen predominantly in young patients.  The tumor cells are polygonal and deeply eosinophilic, and are embedded in a fibrous stroma.  The prognosis is similar to classical hepatocellular carcinoma that arises in non-cirrhotic livers, and better than hepatocellular carcinoma that arises in cirrhotic livers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrolamellar Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibrolamellar Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrolamellar Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrolamellar Hepatocellular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FLC","termGroup":"AB","termSource":"NCI"},{"termName":"Hepatocellular Fibrolamellar Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cell Fibrolamellar Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Hepatocellular Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Polygonal Cell Type Hepatocellular Carcinoma with Fibrous Stroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8171/3"},{"name":"Legacy Concept Name","value":"Fibrolamellar_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8171/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, fibrolamellar"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334287"}]}}{"C27388":{"preferredName":"Scirrhous Hepatocellular Carcinoma","code":"C27388","definitions":[{"definition":"An uncommon type of hepatocelluar carcinoma, morphologically characterized by significant fibrosis around the sinusoid-like spaces and atrophy of the tumor trabeculae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scirrhous Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sclerosing Hepatic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Hepatocellular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8172/3"},{"name":"Legacy Concept Name","value":"Sclerosing_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8172/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, scirrhous"},{"name":"Maps_To","value":"Sclerosing hepatic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266018"}]}}{"C43627":{"preferredName":"Sarcomatoid Hepatocellular Carcinoma","code":"C43627","definitions":[{"definition":"A morphologic variant of hepatocellular carcinoma characterized by the presence of malignant spindle cells or atypical giant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcomatous Hepatocellular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8173/3"},{"name":"Legacy Concept Name","value":"Sarcomatous_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8173/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Hepatocellular carcinoma, spindle cell variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1710014"}]}}{"C5754":{"preferredName":"Clear Cell Hepatocellular Carcinoma","code":"C5754","definitions":[{"definition":"A morphologic variant of hepatocellular carcinoma characterized by the presence of clear cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of the Liver Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatocellular Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cell Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8174/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8174/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, clear cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333067"}]}}{"C43625":{"preferredName":"Pleomorphic Hepatocellular Carcinoma","code":"C43625","definitions":[{"definition":"A morphologic variant of hepatocellular carcinoma, characterized by the presence of malignant cells which show marked variation in their size and shape. Bizarre mononuclear or multinucleated giant cells are often present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Hepatocellular Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8175/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Hepatocellular_Carcinoma"},{"name":"Maps_To","value":"8175/3"},{"name":"Maps_To","value":"Hepatocellular carcinoma, pleomorphic type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709568"}]}}{"C3828":{"preferredName":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma","code":"C3828","definitions":[{"definition":"A rare tumor containing unequivocal elements of both hepatocellular and cholangiocarcinoma that are intimately admixed.  This tumor should be distinguished from separate hepatocellular carcinoma and cholangiocarcinoma arising in the same liver.  The prognosis of this tumor is poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"cHCC-CCA","termGroup":"AB","termSource":"NCI"},{"termName":"Cholangiohepatoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatocholangiocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Biliary Tract Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Hepatocellular Cholangiocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8180/3"},{"name":"Legacy Concept Name","value":"Combined_Hepatocellular_Carcinoma_and_Cholangiocarcinoma"},{"name":"Maps_To","value":"8180/3"},{"name":"Maps_To","value":"Combined hepatocellular carcinoma and cholangiocarcinoma"},{"name":"Maps_To","value":"Hepatocholangiocarcinoma"},{"name":"Maps_To","value":"Mixed hepatocellular and bile duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221287"}]}}{"C3688":{"preferredName":"Trabecular Adenoma","code":"C3688","definitions":[{"definition":"A benign epithelial neoplasm characterized by the presence of a trabecular glandular architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabecular Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8190/0"},{"name":"Legacy Concept Name","value":"Trabecular_Adenoma"},{"name":"Maps_To","value":"8190/0"},{"name":"Maps_To","value":"Trabecular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205651"}]}}{"C4068":{"preferredName":"Trabecular Adenocarcinoma","code":"C4068","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a trabecular glandular architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabecular Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Trabecular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8190/3"},{"name":"ICD-O-3_Code","value":"8332/3"},{"name":"Legacy Concept Name","value":"Trabecular_Adenocarcinoma"},{"name":"Maps_To","value":"8190/3"},{"name":"Maps_To","value":"Trabecular adenocarcinoma"},{"name":"Maps_To","value":"Trabecular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302182"}]}}{"C27253":{"preferredName":"Metanephric Adenoma","code":"C27253","definitions":[{"definition":"A benign, well-circumscribed renal cortical neoplasm affecting females more often than males.  Polycythemia has been reported in twelve-percent of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metanephric Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Embryonal Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8191/0"},{"name":"ICD-O-3_Code","value":"8325/0"},{"name":"Legacy Concept Name","value":"Metanephric_Adenoma"},{"name":"Maps_To","value":"8191/0"},{"name":"Maps_To","value":"Embryonal adenoma"},{"name":"Maps_To","value":"Metanephric adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266045"}]}}{"C43352":{"preferredName":"Turban Tumor Syndrome","code":"C43352","definitions":[{"definition":"A rare autosomal dominant genodermatosis associated with germline mutations of the CYLD tumor suppressor gene. It is characterized by the development of multiple adnexal tumors (usually cylindromas and trichoepitheliomas), typically in the skin of the scalp. It manifests with numerous papules and/or large dome-shaped nodules on the scalp, resembling a turban.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Turban Tumor Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Ancell-Spiegler Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Brooke-Spiegler Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"TTS","termGroup":"AB","termSource":"NCI"},{"termName":"Turban Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Turban_Tumor"},{"name":"Maps_To","value":"8200/0"},{"name":"Maps_To","value":"Turban tumor"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1851526"}]}}{"C27094":{"preferredName":"Cylindroma","code":"C27094","definitions":[{"definition":"A benign sweat gland neoplasm usually occurring in the scalp or the face. It may present as solitary or multiple papular or nodular lesions. It may be a sporadic lesion or part of Brooke-Spiegler syndrome. It arises from the dermis and has a multinodular, circumscribed appearance. The nodules contain basaloid cells with small, dark nuclei. Complete excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cylindroma","termGroup":"PT","termSource":"NCI"},{"termName":"Cylindroma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Cylindroma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Dermal Cylindroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8200/0"},{"name":"Legacy Concept Name","value":"Cylindroma"},{"name":"Maps_To","value":"8200/0"},{"name":"Maps_To","value":"Cylindroma of skin"},{"name":"Maps_To","value":"Eccrine dermal cylindroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1305968"}]}}{"C2970":{"preferredName":"Adenoid Cystic Carcinoma","code":"C2970","definitions":[{"definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of cancer that usually begins in the salivary glands.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenoid Cystic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocystic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cylindroid Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8200/3"},{"name":"Legacy Concept Name","value":"Adenoid_Cystic_Carcinoma"},{"name":"Maps_To","value":"8200/3"},{"name":"Maps_To","value":"Adenocarcinoma, cylindroid"},{"name":"Maps_To","value":"Adenocystic carcinoma"},{"name":"Maps_To","value":"Adenoid cystic carcinoma"},{"name":"Maps_To","value":"Cylindroma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010606"}]}}{"C162973":{"preferredName":"Non-Invasive Cribriform Carcinoma","code":"C162973","definitions":[{"definition":"A carcinoma characterized by the presence of a cribriform architectural pattern. There is no evidence of surrounding stromal invasion by the malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Invasive Cribriform Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8201/2"},{"name":"Maps_To","value":"Cribriform carcinoma in situ"},{"name":"NCI_META_CUI","value":"CL973264"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3680":{"preferredName":"Cribriform Carcinoma","code":"C3680","definitions":[{"definition":"A carcinoma characterized by the presence of a cribriform architectural pattern. Representative examples include the intraductal cribriform breast carcinoma and invasive cribriform breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cribriform Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8201/3"},{"name":"Legacy Concept Name","value":"Cribriform_Carcinoma"},{"name":"Maps_To","value":"8201/3"},{"name":"Maps_To","value":"Cribriform carcinoma, NOS"},{"name":"Maps_To","value":"Ductal carcinoma, cribriform type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205643"}]}}{"C3685":{"preferredName":"Microcystic Adenoma","code":"C3685","definitions":[{"definition":"A benign epithelial neoplasm characterized by a microcystic pattern. The cystic spaces are lined by small cuboidal cells without evidence of significant cytologic atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microcystic Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8202/0"},{"name":"Legacy Concept Name","value":"Microcystic_Adenoma"},{"name":"Maps_To","value":"8202/0"},{"name":"Maps_To","value":"Microcystic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205648"}]}}{"C9473":{"preferredName":"Lactating Adenoma","code":"C9473","definitions":[{"definition":"A tubular type adenoma of the breast in which, during pregnancy and lactation, the epithelial cells show extensive secretory changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lactating Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pregnancy Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8204/0"},{"name":"Legacy Concept Name","value":"Lactating_Adenoma"},{"name":"Maps_To","value":"8204/0"},{"name":"Maps_To","value":"Lactating adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266023"}]}}{"C3764":{"preferredName":"Adenomatous Polyp","code":"C3764","definitions":[{"definition":"A polypoid neoplasm arising from the glandular epithelium of the gastrointestinal tract. There is proliferation of glandular cells which may display dysplastic cytologic features. Representative examples include the adenomatous polyps of the colon and rectum..","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenomatous Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Adenomatous Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Adenomatous Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Polypoid Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8210/0"},{"name":"Legacy Concept Name","value":"Adenomatous_Polyp"},{"name":"Maps_To","value":"8210/0"},{"name":"Maps_To","value":"Adenomatous polyp, NOS"},{"name":"Maps_To","value":"Polypoid adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206677"}]}}{"C7678":{"preferredName":"Adenocarcinoma In Situ in Adenomatous Polyp","code":"C7678","definitions":[{"definition":"A non-invasive adenocarcinoma arising from the neoplastic glandular cells in an adenomatous polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Adenomatous Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8210/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Adenomatous_Polyp"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in adenomatous polyp"},{"name":"Maps_To","value":"Adenocarcinoma in situ in polypoid adenoma"},{"name":"Maps_To","value":"Carcinoma in situ in adenomatous polyp"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334290"}]}}{"C7680":{"preferredName":"Adenocarcinoma In Situ in a Polyp","code":"C7680","definitions":[{"definition":"An adenocarcinoma arising in a polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in a Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_a_Polyp"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in a polyp, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377630"}]}}{"C7679":{"preferredName":"Adenocarcinoma In Situ in Tubular Adenoma","code":"C7679","definitions":[{"definition":"An intraepithelial adenocarcinoma arising from a tubular adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Tubular Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Tubular_Adenoma"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in tubular adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377632"}]}}{"C7681":{"preferredName":"Carcinoma In Situ in a Polyp","code":"C7681","definitions":[{"definition":"An intraepithelial adenocarcinoma arising in a polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma In Situ in a Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carcinoma_in_situ_in_a_Polyp"},{"name":"Maps_To","value":"8210/2"},{"name":"Maps_To","value":"Carcinoma in situ in a polyp, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377629"}]}}{"C7676":{"preferredName":"Adenocarcinoma in Adenomatous Polyp","code":"C7676","definitions":[{"definition":"A non-invasive or invasive adenocarcinoma arising from the neoplastic glandular cells in an adenomatous polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Adenomatous Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8210/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Adenomatous_Polyp"},{"name":"Maps_To","value":"8210/3"},{"name":"Maps_To","value":"Adenocarcinoma in a polyp, NOS"},{"name":"Maps_To","value":"Adenocarcinoma in adenomatous polyp"},{"name":"Maps_To","value":"Adenocarcinoma in polypoid adenoma"},{"name":"Maps_To","value":"Carcinoma in adenomatous polyp"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321861"}]}}{"C7677":{"preferredName":"Adenocarcinoma in Tubular Adenoma","code":"C7677","definitions":[{"definition":"An adenocarcinoma arising from a tubular adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Tubular Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Tubular_Adenoma"},{"name":"Maps_To","value":"8210/3"},{"name":"Maps_To","value":"Adenocarcinoma in tubular adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377621"}]}}{"C7682":{"preferredName":"Carcinoma in a Polyp","code":"C7682","definitions":[{"definition":"Carcinoma arising in a polyp.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma in a Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carcinoma_in_a_Polyp"},{"name":"Maps_To","value":"8210/3"},{"name":"Maps_To","value":"Carcinoma in a polyp, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377617"}]}}{"C4133":{"preferredName":"Tubular Adenoma","code":"C4133","definitions":[{"definition":"A benign neoplasm arising from glandular epithelium, characterized by a tubular architectural pattern.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Tubular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Tubular Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8211/0"},{"name":"Legacy Concept Name","value":"Tubular_Adenoma"},{"name":"Maps_To","value":"8211/0"},{"name":"Maps_To","value":"Tubular adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334292"}]}}{"C65192":{"preferredName":"Tubular Adenocarcinoma","code":"C65192","definitions":[{"definition":"A malignant glandular neoplasm exhibiting tubular structures.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating adenocarcinoma in which the malignant cells form tubular structures. Representative examples include the tubular breast carcinoma and the gastric tubular adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubular Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8211/3"},{"name":"Legacy Concept Name","value":"Tubular_Carcinoma"},{"name":"Maps_To","value":"8211/3"},{"name":"Maps_To","value":"Tubular adenocarcinoma"},{"name":"Maps_To","value":"Tubular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205645"}]}}{"C65193":{"preferredName":"Flat Adenoma","code":"C65193","definitions":[{"definition":"An adenoma of the gastrointestinal tract mucosa which grossly and morphologically does not appear as an elevated or polypoid lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flat Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Flat Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Flat Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8212/0"},{"name":"Legacy Concept Name","value":"Flat_Adenoma"},{"name":"Maps_To","value":"8212/0"},{"name":"Maps_To","value":"Flat adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266024"}]}}{"C38458":{"preferredName":"Traditional Serrated Adenoma","code":"C38458","definitions":[{"definition":"An adenoma that arises from the large intestine and the appendix.  It is characterized by prominent serration of the glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Traditional Serrated Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Serrated Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Serrated Adenoma Type II","termGroup":"SY","termSource":"NCI"},{"termName":"Traditional Serrated Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"TSA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8213/0"},{"name":"Legacy Concept Name","value":"Serrated_Adenoma"},{"name":"Maps_To","value":"8213/0"},{"name":"Maps_To","value":"Mixed adenomatous and hyperplastic polyp"},{"name":"Maps_To","value":"Serrated adenoma"},{"name":"Maps_To","value":"Serrated adenoma, NOS"},{"name":"Maps_To","value":"Traditional serrated adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266025"}]}}{"C96414":{"preferredName":"Serrated Lesions and Polyps","code":"C96414","definitions":[{"definition":"Polyps that arises from the large intestine and the appendix. They are characterized by the presence of serrated glands and the absence of generalized dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serrated Lesions and Polyps","termGroup":"PT","termSource":"NCI"},{"termName":"Serrated Adenoma Type I","termGroup":"SY","termSource":"NCI"},{"termName":"Serrated Lesions and Polyps","termGroup":"SY","termSource":"NCI"},{"termName":"Serrated Polyp with Abnormal Proliferation","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Adenoma/Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Sessile Serrated Polyp/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"SSA","termGroup":"AB","termSource":"NCI"},{"termName":"SSA/P","termGroup":"AB","termSource":"NCI"},{"termName":"SSP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8213/0"},{"name":"Maps_To","value":"8213/0"},{"name":"Maps_To","value":"Sessile serrated adenoma"},{"name":"Maps_To","value":"Sessile serrated polyp"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2732618"}]}}{"C96485":{"preferredName":"Colorectal Serrated Adenocarcinoma","code":"C96485","definitions":[{"definition":"A rare, invasive colorectal adenocarcinoma characterized by the presence of a malignant infiltrate with serrated glandular architecture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colorectal Serrated Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8213/3"},{"name":"Maps_To","value":"8213/3"},{"name":"Maps_To","value":"Serrated adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472623"}]}}{"C65194":{"preferredName":"Gastric Parietal Cell Adenocarcinoma","code":"C65194","definitions":[{"definition":"An adenocarcinoma of the stomach arising from the parietal cells. It is characterized by the presence of malignant cells with eosinophilic, finely granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastric Parietal Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Parietal Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8214/3"},{"name":"Legacy Concept Name","value":"Parietal_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8214/3"},{"name":"Maps_To","value":"Parietal cell adenocarcinoma"},{"name":"Maps_To","value":"Parietal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266026"}]}}{"C5609":{"preferredName":"Anal Glands Adenocarcinoma","code":"C5609","definitions":[{"definition":"An anal adenocarcinoma arising from the epithelium of the anal glands.  The overlying anal mucosa does not show evidence of neoplastic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Glands Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Anal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of Anal Glands","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Anal Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8215/3"},{"name":"Legacy Concept Name","value":"Anal_Glands_Adenocarcinoma"},{"name":"Maps_To","value":"8215/3"},{"name":"Maps_To","value":"Adenocarcinoma of anal ducts"},{"name":"Maps_To","value":"Adenocarcinoma of anal glands"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266027"}]}}{"C3339":{"preferredName":"Familial Adenomatous Polyposis","code":"C3339","definitions":[{"definition":"An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited condition in which numerous polyps (growths that protrude from mucous membranes) form on the inside walls of the colon and rectum. It increases the risk for colon cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Familial Adenomatous Polyposis","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"APC - Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Adenomatous Polyposis 1","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Adenomatous Polyposis Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"FAP","termGroup":"AB","termSource":"NCI"},{"termName":"Hereditary Adenomatous Polyposis Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Polyposis Coli","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8220/0"},{"name":"Legacy Concept Name","value":"Familial_Adenomatous_Polyposis"},{"name":"Maps_To","value":"8220/0"},{"name":"Maps_To","value":"Adenomatous polyposis coli"},{"name":"Maps_To","value":"Adenomatous Polyposis Coli"},{"name":"Maps_To","value":"Familial Adenomatous Polyposis"},{"name":"Maps_To","value":"Familial polyposis coli"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0032580"}]}}{"C4134":{"preferredName":"Adenocarcinoma in Adenomatous Polyposis Coli","code":"C4134","definitions":[{"definition":"Adenocarcinomas developing in colorectal adenomas in patients with a history of adenomatous polyposis coli. The mean age of development of adenocarcinoma is about 40 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Adenomatous Polyposis Coli","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8220/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Adenomatous_Polyposis_Coli"},{"name":"Maps_To","value":"8220/3"},{"name":"Maps_To","value":"Adenocarcinoma in adenomatous polyposis coli"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334293"}]}}{"C4135":{"preferredName":"Multiple Adenomatous Polyps","code":"C4135","definitions":[{"definition":"A condition in which multiple adenomas develop in the gastrointestinal tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multiple Adenomatous Polyps","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Multiple Adenomatous Polyps","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Multiple Adenomatous Polyps","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8221/0"},{"name":"Legacy Concept Name","value":"Multiple_Adenomatous_Polyps"},{"name":"Maps_To","value":"8221/0"},{"name":"Maps_To","value":"Multiple adenomatous polyps"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334294"}]}}{"C4136":{"preferredName":"Adenocarcinoma in Multiple Adenomatous Polyps","code":"C4136","definitions":[{"definition":"Adenocarcinomas developing in gastrointestinal tract adenomas in patients with multiple adenomatous polyps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Multiple Adenomatous Polyps","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8221/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Multiple_Adenomatous_Polyps"},{"name":"Maps_To","value":"8221/3"},{"name":"Maps_To","value":"Adenocarcinoma in multiple adenomatous polyps"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334295"}]}}{"C66933":{"preferredName":"Breast Ductal Carcinoma In Situ, Solid Type","code":"C66933","definitions":[{"definition":"Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, Solid Type","termGroup":"PT","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma in Situ, Solid Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8230/2"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_of_the_Breast_Solid_Type"},{"name":"Maps_To","value":"8230/2"},{"name":"Maps_To","value":"Ductal carcinoma in situ, solid type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1880424"}]}}{"C4137":{"preferredName":"Solid Carcinoma","code":"C4137","definitions":[{"definition":"A carcinoma morphologically characterized by the presence of solid sheets of malignant epithelial cells in tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8230/3"},{"name":"Legacy Concept Name","value":"Solid_Carcinoma"},{"name":"Maps_To","value":"8230/3"},{"name":"Maps_To","value":"Solid carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334296"}]}}{"C65195":{"preferredName":"Carcinoma Simplex","code":"C65195","definitions":[{"definition":"An undifferentiated malignant epithelial neoplasm which tends to infiltrate the surrounding tissues and spread to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma Simplex","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8231/3"},{"name":"Legacy Concept Name","value":"Carcinoma_Simplex"},{"name":"Maps_To","value":"8231/3"},{"name":"Maps_To","value":"Carcinoma simplex"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334297"}]}}{"C65196":{"preferredName":"Carcinoid Tumor of Uncertain Malignant Potential","code":"C65196","definitions":[{"definition":"A carcinoid tumor that shows atypical characteristics and has borderline malignant potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoid Tumor of Uncertain Malignant Potential","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8240/1"},{"name":"Legacy Concept Name","value":"Carcinoid_Tumor_of_Uncertain_Malignant_Potential"},{"name":"Maps_To","value":"8240/1"},{"name":"Maps_To","value":"Carcinoid tumor of uncertain malignant potential"},{"name":"NCI_META_CUI","value":"CL017920"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C35727":{"preferredName":"Grade I Neuroendocrine Carcinoma","code":"C35727","synonyms":[{"termName":"Grade I Neuroendocrine Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8240/3"},{"name":"Legacy Concept Name","value":"Grade_I_Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8240/3"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, low grade"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, well-differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266147"}]}}{"C188218":{"preferredName":"Neuroendocrine Tumor","code":"C188218","definitions":[{"definition":"A slow-growing type of tumor usually found in the gastrointestinal system (most often in the appendix), and sometimes in the lungs or other sites. Carcinoid tumors may spread to the liver or other sites in the body, and they may secrete substances such as serotonin or prostaglandins, causing carcinoid syndrome.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A well-differentiated neuroendocrine neoplasm of low, intermediate, or high grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"APUDoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Carcinoid Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Enterochromaffin Cell Carcinoid","termGroup":"AQS","termSource":"NCI"},{"termName":"Well Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8240/3"},{"name":"ICD-O-3_Code","value":"8241/3"},{"name":"ICD-O-3_Code","value":"8248/1"},{"name":"Legacy Concept Name","value":"Carcinoid_Tumor"},{"name":"Legacy Concept Name","value":"Neoplasm_of_the_Diffuse_Neuroendocrine_System"},{"name":"Maps_To","value":"8240/3"},{"name":"Maps_To","value":"8241/3"},{"name":"Maps_To","value":"8248/1"},{"name":"Maps_To","value":"Apudoma"},{"name":"Maps_To","value":"Carcinoid tumor, NOS"},{"name":"Maps_To","value":"Carcinoid, NOS"},{"name":"Maps_To","value":"Enterochromaffin cell carcinoid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0003650"}]}}{"C27252":{"preferredName":"Enterochromaffin-Like Cell Neuroendocrine Tumor G1","code":"C27252","definitions":[{"definition":"A well differentiated, low grade neuroendocrine neoplasm (carcinoid tumor) arising from the gastrointestinal tract. It is characterized by the presence of enterochromaffin-like type granules in the neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enterochromaffin-Like Cell Neuroendocrine Tumor G1","termGroup":"PT","termSource":"NCI"},{"termName":"ECL Cell NET G1","termGroup":"SY","termSource":"NCI"},{"termName":"Enterochromaffin-Like Cell Carcinoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Enterochromaffin-Like Cell NET G1","termGroup":"SY","termSource":"NCI"},{"termName":"Enterochromaffin-Like Cell Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8242/1"},{"name":"ICD-O-3_Code","value":"8242/3"},{"name":"Legacy Concept Name","value":"Enterochromaffin-Like_Cell_Carcinoid_Tumor"},{"name":"Maps_To","value":"8242/1"},{"name":"Maps_To","value":"8242/3"},{"name":"Maps_To","value":"ECL cell carcinoid, malignant"},{"name":"Maps_To","value":"ECL cell carcinoid, NOS"},{"name":"Maps_To","value":"Enterochromaffin-like cell carcinoid, NOS"},{"name":"Maps_To","value":"Enterochromaffin-like cell tumor"},{"name":"Maps_To","value":"Enterochromaffin-like cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266030"}]}}{"C201135":{"preferredName":"Goblet Cell Adenocarcinoma","code":"C201135","definitions":[{"definition":"A rare adenocarcinoma that exhibits neuroendocrine differentiation and is associated with the presence of neoplastic signet-ring cells resembling goblet cells of the intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goblet Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Composite Carcinoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"GCA","termGroup":"AB","termSource":"NCI"},{"termName":"Goblet Cell Carcinoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8244/3"},{"name":"ICD-O-3_Code","value":"8245/3"},{"name":"Maps_To","value":"8243/3"},{"name":"Maps_To","value":"8245/3"},{"name":"Maps_To","value":"Adenocarcinoid tumor"},{"name":"Maps_To","value":"Composite carcinoid"},{"name":"Maps_To","value":"Goblet Cell Carcinoid"},{"name":"Maps_To","value":"Goblet cell carcinoid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205695"}]}}{"C95406":{"preferredName":"Digestive System Mixed Adenoneuroendocrine Carcinoma","code":"C95406","definitions":[{"definition":"A carcinoma that arises from the digestive system and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component. At least 30% of either component should be present for the diagnosis to be made.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Digestive System Mixed Adenoneuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal MANEC","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrointestinal Mixed Adenoneuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MANEC","termGroup":"AB","termSource":"NCI"},{"termName":"Mixed Adenoneuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8244/3"},{"name":"Maps_To","value":"8244/3"},{"name":"Maps_To","value":"MANEC"},{"name":"Maps_To","value":"Mixed adenoneuroendocrine carcinoma"},{"name":"Maps_To","value":"Mixed carcinoid-adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2987129"}]}}{"C43565":{"preferredName":"Appendix Tubular Carcinoid","code":"C43565","definitions":[{"definition":"A neuroendocrine tumor that arises from the appendix.  It does not show the morphologic characteristics of typical carcinoid tumors (neoplastic cells forming solid nests). In contrast, the tumor cells form small discrete tubules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Appendix Tubular Carcinoid","termGroup":"PT","termSource":"NCI"},{"termName":"Appendix Tubular Carcinoid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8245/1"},{"name":"Legacy Concept Name","value":"Appendix_Tubular_Carcinoid"},{"name":"Maps_To","value":"8245/1"},{"name":"Maps_To","value":"Tubular carcinoid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266031"}]}}{"C3773":{"preferredName":"Neuroendocrine Carcinoma","code":"C3773","definitions":[{"definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"High-Grade Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"NEC","termGroup":"AB","termSource":"NCI"},{"termName":"Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8246/3"},{"name":"Legacy Concept Name","value":"Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8246/3"},{"name":"Maps_To","value":"Malignant neuroendocrine tumors"},{"name":"Maps_To","value":"Malignant poorly differentiated neuroendocrine carcinoma, any site"},{"name":"Maps_To","value":"Malignant poorly differentiated neuroendocrine tumors"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, NOS"},{"name":"Maps_To","value":"Other malignant neuroendocrine tumors"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206695"}]}}{"C9231":{"preferredName":"Merkel Cell Carcinoma","code":"C9231","definitions":[{"definition":"A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Merkel Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"MCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8247/3"},{"name":"Legacy Concept Name","value":"Neuroendocrine_Carcinoma_of_the_Skin"},{"name":"Maps_To","value":"8247/3"},{"name":"Maps_To","value":"Merkel cell carcinoma"},{"name":"Maps_To","value":"Merkel cell carcinoma of other sites"},{"name":"Maps_To","value":"Merkel cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007129"}]}}{"C173385":{"preferredName":"Cutaneous Merkel Cell Carcinoma","code":"C173385","definitions":[{"definition":"A rare aggressive neuroendocrine carcinoma that arises from the skin and most often affects older individuals. It is usually located in the head, neck, and extremities. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of cancer that forms on or just beneath the skin, usually in parts of the body that have been exposed to the sun. It is most common in older people and in people with weakened immune systems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cutaneous Merkel Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroendocrine Carcinoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroendocrine Carcinoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Merkel Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Trabecular Skin Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Primary cutaneous neuroendocrine carcinoma"},{"name":"NCI_META_CUI","value":"CL1407234"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C35725":{"preferredName":"Grade II Neuroendocrine Carcinoma","code":"C35725","synonyms":[{"termName":"Grade II Neuroendocrine Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8249/3"},{"name":"Legacy Concept Name","value":"Grade_II_Neuroendocrine_Carcinoma"},{"name":"Maps_To","value":"8249/3"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, moderately differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266148"}]}}{"C72074":{"preferredName":"Neuroendocrine Tumor G2","code":"C72074","definitions":[{"definition":"A well-differentiated, intermediate-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system, lung, and head and neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Tumor G2","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Carcinoid Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"NET G2","termGroup":"AB","termSource":"NCI"},{"termName":"Neuroendocrine Tumor Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Atypical_Carcinoid_Tumor"},{"name":"Maps_To","value":"8249/3"},{"name":"Maps_To","value":"Atypical carcinoid tumor"},{"name":"Maps_To","value":"G2"},{"name":"Maps_To","value":"Malignant carcinoid tumor of unknown primary site"},{"name":"Maps_To","value":"Malignant carcinoid tumor of unspecified site"},{"name":"Maps_To","value":"Malignant carcinoid tumors of other and unspecified sites"},{"name":"Maps_To","value":"Malignant carcinoid tumors of other sites"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0391970"}]}}{"C3763":{"preferredName":"Pulmonary Adenomatosis","code":"C3763","definitions":[{"definition":"This is a non-human neoplastic process described in sheep.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Adenomatosis","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8250/1"},{"name":"Legacy Concept Name","value":"Pulmonary_Adenomatosis"},{"name":"Maps_To","value":"8250/1"},{"name":"Maps_To","value":"Pulmonary adenomatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206676"}]}}{"C136716":{"preferredName":"Lung Non-Mucinous Adenocarcinoma In Situ","code":"C136716","definitions":[{"definition":"Lung adenocarcinoma in situ characterized by the presence of type II pneumocyte and/or Clara cell differentiation. Almost all cases of lung adenocarcinoma in situ are non-mucinous.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Non-Mucinous Adenocarcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenocarcinoma in situ of lung, non-mucinous"},{"name":"Maps_To","value":"Adenocarcinoma in situ, non-mucinous"},{"name":"NCI_META_CUI","value":"CL554697"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2923":{"preferredName":"Minimally Invasive Lung Adenocarcinoma","code":"C2923","definitions":[{"definition":"A malignant lung neoplasm originating from the alveolar/bronchiolar epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"BAC","termGroup":"AB","termSource":"NCI"},{"termName":"Bronchioalveolar Adenocarcinoma of Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioalveolar Adenocarcinoma of the Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchiolo-Alveolar Carcinoma of Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchiolo-Alveolar Carcinoma of the Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchiolo-Alveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Adenocarcinoma of Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Adenocarcinoma of the Lung","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Bronchioloalveolar Lung Adenocarcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8250/3"},{"name":"ICD-O-3_Code","value":"8251/3"},{"name":"Legacy Concept Name","value":"Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"8250/3"},{"name":"Maps_To","value":"8251/3"},{"name":"Maps_To","value":"Alveolar adenocarcinoma"},{"name":"Maps_To","value":"Alveolar carcinoma"},{"name":"Maps_To","value":"Alveolar cell carcinoma"},{"name":"Maps_To","value":"Bronchiolar adenocarcinoma"},{"name":"Maps_To","value":"Bronchiolar carcinoma"},{"name":"Maps_To","value":"Bronchiolo-alveolar adenocarcinoma, NOS"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, NOS"},{"name":"Maps_To","value":"Minimally invasive adenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2750265"}]}}{"C4140":{"preferredName":"Alveolar Adenoma","code":"C4140","definitions":[{"definition":"A benign lung neoplasm arising from the alveolar/bronchiolar epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well circumscribed lung neoplasm morphologically characterized by the presence of cystic spaces resembling alveoli, lined by a simple cuboidal epithelium. The cystic spaces are surrounded by a spindle cell stroma which may show myxoid changes. It is a solitary, usually peripheral lung lesion. Patients are usually asymptomatic and its discovery is an incidental finding during chest X-ray examination. Surgical excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alveolar Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Alveoli","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Alveoli","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8251/0"},{"name":"Legacy Concept Name","value":"Alveolar_Adenoma"},{"name":"Maps_To","value":"8251/0"},{"name":"Maps_To","value":"Alveolar adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334303"}]}}{"C7269":{"preferredName":"Minimally Invasive Lung Non-Mucinous Adenocarcinoma","code":"C7269","definitions":[{"definition":"A morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of Clara cells and/or type II cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Non-Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Mucinous Bronchioloalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Mucinous Bronchoalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-Mucinous Minimally Invasive Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8252/3"},{"name":"Legacy Concept Name","value":"Non-Mucinous_Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"8252/3"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, Clara cell"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, non- mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, non-mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma; type II pneumocyte"},{"name":"Maps_To","value":"Minimally invasive adenocarcinoma, non-mucinous"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266034"}]}}{"C136709":{"preferredName":"Invasive Lung Mucinous Adenocarcinoma","code":"C136709","definitions":[{"definition":"An invasive adenocarcinoma that arises from the lung. It is characterized by the presence of tall columnar cells and mucin production. This category refers to cases formerly classified as mucinous bronchioloalveolar carcinoma, excluding cases that meet the criteria for adenocarcinoma in situ or mucinous minimally invasive adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Lung Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Invasive Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8253/3"},{"name":"Maps_To","value":"Adenocarcinoma of lung, mucinous"},{"name":"Maps_To","value":"Bronchio-alveolar carcinoma, mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, mucinous"},{"name":"Maps_To","value":"Invasive mucinous adenocarcinoma"},{"name":"NCI_META_CUI","value":"CL524517"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7270":{"preferredName":"Minimally Invasive Lung Mixed Non-Mucinous and Mucinous Adenocarcinoma","code":"C7270","definitions":[{"definition":"A morphologic variant of minimally invasive lung adenocarcinoma characterized by the presence of Clara cells and/or type II cells, tall columnar cells, and mucin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Mixed Non-Mucinous and Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Indeterminate Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Mucinous and Non-Mucinous Bronchioloalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Mucinous and Non-Mucinous Bronchoalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8254/3"},{"name":"Legacy Concept Name","value":"Mixed_Mucinous_and_Non-Mucinous_Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"8254/3"},{"name":"Maps_To","value":"Adenocarcinoma of lung, mixed mucinous and non-mucinous"},{"name":"Maps_To","value":"Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, indeterminate type"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, mixed mucinous and non-mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266036"}]}}{"C45508":{"preferredName":"Lung Adenocarcinoma, Mixed Subtype","code":"C45508","definitions":[{"definition":"The most frequently seen morphologic variant of lung adenocarcinoma characterized by a mixture of architectural patterns, including acinar, papillary, bronchioloalveolar, and solid pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Adenocarcinoma, Mixed Subtype","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Adenocarcinoma_Mixed_Subtype"},{"name":"Maps_To","value":"8255/3"},{"name":"Maps_To","value":"Adenocarcinoma combined with other types of carcinoma"},{"name":"Maps_To","value":"Adenocarcinoma with mixed subtypes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708765"}]}}{"C7268":{"preferredName":"Minimally Invasive Lung Mucinous Adenocarcinoma","code":"C7268","definitions":[{"definition":"A morphologic variant of minimally invasive lung adenocarcinoma characterized by tall columnar cells and mucin production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Lung Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucinous Bronchioloalveolar Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Bronchioloalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Bronchoalveolar Lung Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucinous Minimally Invasive Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8253/3"},{"name":"Legacy Concept Name","value":"Mucinous_Bronchiolo-Alveolar_Lung_Carcinoma"},{"name":"Maps_To","value":"Bronchio-alveolar carcinoma, mucinous"},{"name":"Maps_To","value":"Bronchiolo-alveolar carcinoma, goblet cell type"},{"name":"Maps_To","value":"Minimally invasive adenocarcinoma, mucinous"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266035"}]}}{"C79951":{"preferredName":"Papillary Adenoma","code":"C79951","definitions":[{"definition":"A benign epithelial neoplasm characterized by the presence of papillary epithelial patterns.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenoma characterized by the presence of papillary epithelial patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Adenomatous_Lesion"},{"name":"Maps_To","value":"8260/0"},{"name":"Maps_To","value":"Papillary adenoma, NOS"},{"name":"NCI_META_CUI","value":"CL388631"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4035":{"preferredName":"Thyroid Gland Papillary Carcinoma","code":"C4035","definitions":[{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.","type":"DEFINITION","source":"NCI"},{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei. The nuclei also display clearing or have a ground glass appearance.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that forms in follicular cells in the thyroid and grows in small finger-like shapes. It grows slowly, is more common in women than in men, and often occurs before age 45. It is the most common type of thyroid cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Cancer of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cancer of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cancer of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cancer of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"PTC","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Papillary_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8260/3"},{"name":"Maps_To","value":"Papillary carcinoma of thyroid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3149311"}]}}{"C2853":{"preferredName":"Papillary Adenocarcinoma","code":"C2853","definitions":[{"definition":"A morphologic variant of adenocarcinoma. It is characterized by the presence of a papillary growth pattern. Representative examples include thyroid gland papillary carcinoma, invasive papillary breast carcinoma, and ovarian serous surface papillary adenocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"An adenocarcinoma with papillary growth pattern.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8260/3"},{"name":"Legacy Concept Name","value":"Papillary_Adenocarcinoma"},{"name":"Maps_To","value":"8260/3"},{"name":"Maps_To","value":"Papillary adenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001420"}]}}{"C6975":{"preferredName":"Papillary Renal Cell Carcinoma","code":"C6975","definitions":[{"definition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chromophil Carcinoma of Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophil Carcinoma of the Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophil Renal Cell Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary (Chromophil) Renal Cell Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary RCC","termGroup":"SY","termSource":"NCI"},{"termName":"PRCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"51"},{"name":"Maps_To","value":"71"},{"name":"Maps_To","value":"8260/3"},{"name":"Maps_To","value":"Papillary Renal Cell"},{"name":"Maps_To","value":"Papillary renal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306837"}]}}{"C7399":{"preferredName":"Villous Adenoma","code":"C7399","definitions":[{"definition":"A neoplasm that grows in the colon and other places in the gastrointestinal tract and sometimes in other parts of the body. These adenomas may become malignant (cancerous).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Villous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Villous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Villous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8261/0"},{"name":"Legacy Concept Name","value":"Villous_Adenoma"},{"name":"Maps_To","value":"8261/0"},{"name":"Maps_To","value":"Villous adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206674"}]}}{"C8376":{"preferredName":"Adenocarcinoma In Situ in Villous Adenoma","code":"C8376","definitions":[{"definition":"A non-invasive adenocarcinoma arising from a villous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Villous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8261/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Villous_Adenoma"},{"name":"Maps_To","value":"8261/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in villous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334304"}]}}{"C4141":{"preferredName":"Adenocarcinoma in Villous Adenoma","code":"C4141","definitions":[{"definition":"A non-invasive or invasive adenocarcinoma arising from a villous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Villous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8261/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Villous_Adenoma"},{"name":"Maps_To","value":"8261/3"},{"name":"Maps_To","value":"Adenocarcinoma in villous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334305"}]}}{"C4142":{"preferredName":"Villous Adenocarcinoma","code":"C4142","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a villous architectural pattern. It may arise from a villous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Villous Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8262/3"},{"name":"Legacy Concept Name","value":"Villous_Adenocarcinoma"},{"name":"Maps_To","value":"8262/3"},{"name":"Maps_To","value":"Villous adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334306"}]}}{"C4143":{"preferredName":"Tubulovillous Adenoma","code":"C4143","definitions":[{"definition":"A neoplasm that grows in the colon and other places in the gastrointestinal tract and sometimes in other parts of the body. These adenomas may become malignant (cancerous).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular and a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulovillous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Tract Tubulovillous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"GI Tract Tubulovillous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8263/0"},{"name":"Legacy Concept Name","value":"Tubulovillous_Adenoma"},{"name":"Maps_To","value":"8263/0"},{"name":"Maps_To","value":"Papillotubular adenoma"},{"name":"Maps_To","value":"Tubulo-papillary adenoma"},{"name":"Maps_To","value":"Tubulovillous adenoma, NOS"},{"name":"Maps_To","value":"Villoglandular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334307"}]}}{"C4144":{"preferredName":"Adenocarcinoma In Situ in Tubulovillous Adenoma","code":"C4144","definitions":[{"definition":"A non-invasive adenocarcinoma arising from a tubulovillous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma In Situ in Tubulovillous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8263/2"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_situ_in_Tubulovillous_Adenoma"},{"name":"Maps_To","value":"8263/2"},{"name":"Maps_To","value":"Adenocarcinoma in situ in tubulovillous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334308"}]}}{"C4145":{"preferredName":"Adenocarcinoma in Tubulovillous Adenoma","code":"C4145","definitions":[{"definition":"A non-invasive or invasive adenocarcinoma arising from a tubulovillous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma in Tubulovillous Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8263/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_in_Tubulovillous_Adenoma"},{"name":"Maps_To","value":"8263/3"},{"name":"Maps_To","value":"Adenocarcinoma in tubolovillous adenoma"},{"name":"Maps_To","value":"Adenocarcinoma in tubulovillous adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334309"}]}}{"C6881":{"preferredName":"Bile Duct Intraductal Papillary Neoplasm","code":"C6881","definitions":[{"definition":"An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Intraductal Papillary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct IPN","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Papillomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary Papillomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Legacy Concept Name","value":"Bile_Duct_Papillomatosis"},{"name":"Maps_To","value":"8264/0"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Biliary papillomatosis"},{"name":"Maps_To","value":"Intraductal papillary neoplasm, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879344"}]}}{"C65198":{"preferredName":"Glandular Papillomatosis","code":"C65198","definitions":[{"definition":"Multifocal neoplastic proliferations of the glandular epithelium displaying a papillary pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glandular Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8264/0"},{"name":"Legacy Concept Name","value":"Glandular_Papillomatosis"},{"name":"Maps_To","value":"8264/0"},{"name":"Maps_To","value":"Papillomatosis, glandular"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266038"}]}}{"C128847":{"preferredName":"Lung Micropapillary Adenocarcinoma","code":"C128847","definitions":[{"definition":"An aggressive variant of lung adenocarcinoma that exhibits a micropapillary architectural pattern. The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Micropapillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8265/3"},{"name":"Maps_To","value":"Micropapillary carcinoma, NOS"},{"name":"NCI_META_CUI","value":"CL536215"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2857":{"preferredName":"Pituitary Gland Chromophobe Adenoma","code":"C2857","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells do not stain with acidic or basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromophobe Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophobe Adenoma of Pituitary Gland","termGroup":"AQS","termSource":"NCI"},{"termName":"Chromophobe Adenoma of the Pituitary Gland","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Chromophobe Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Chromophobe Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8270/0"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Chromophobe_Adenoma"},{"name":"Maps_To","value":"8270/0"},{"name":"Maps_To","value":"Chromophobe adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001432"}]}}{"C4146":{"preferredName":"Chromophobe Renal Cell Carcinoma","code":"C4146","definitions":[{"definition":"A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical), eosinophilic, or oncocytic.  It has a much better prognosis than other renal cell carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromophobe Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chromophobe Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Cell Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe Cell Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Chromophobe RCC","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Chromophobe Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8270/3"},{"name":"ICD-O-3_Code","value":"8317/3"},{"name":"Legacy Concept Name","value":"Chromophobe_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"8270/3"},{"name":"Maps_To","value":"8317/3"},{"name":"Maps_To","value":"Chromophobe adenocarcinoma"},{"name":"Maps_To","value":"Chromophobe carcinoma"},{"name":"Maps_To","value":"Chromophobe cell renal carcinoma"},{"name":"Maps_To","value":"Renal cell carcinoma, chromophobe type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266042"}]}}{"C3342":{"preferredName":"Lactotroph Pituitary Neuroendocrine Tumor","code":"C3342","definitions":[{"definition":"A pituitary neuroendocrine tumor that produces prolactin.","type":"DEFINITION","source":"NCI"},{"definition":"A pituitary neuroendocrine tumor that produces prolactin.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Lactotroph Pituitary Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Lactotrope Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lactotroph Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lactotroph PitNET/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lactotroph Pituitary Neuroendocrine Tumor/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Gland Prolactinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Prolactinoma","termGroup":"SY","termSource":"NCI"},{"termName":"PRL Producing Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Adenoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Pituitary Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Producing Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Adenoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Pituitary Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin Secreting Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactin-Producing Pituitary Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Prolactinoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8271/0"},{"name":"Legacy Concept Name","value":"Prolactin_Secreting_Pituitary_Gland_Adenoma"},{"name":"Maps_To","value":"8271/0"},{"name":"Maps_To","value":"Lactotroph adenoma"},{"name":"Maps_To","value":"Prolactinoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0033375"}]}}{"C3329":{"preferredName":"Pituitary Neuroendocrine Tumor","code":"C3329","definitions":[{"definition":"A benign neoplasm of the anterior lobe of the pituitary gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-metastasizing tumor that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A well-differentiated neuroendocrine neoplasm that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. It has a low frequency of metastatic spread. When metastatic, the term metastatic pituitary neuroendocrine tumor is endorsed instead of pituitary carcinoma. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pituitary Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"PitNET","termGroup":"AB","termSource":"NCI"},{"termName":"PitNET/Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Neuroendocrine Tumor (Formerly Pituitary Adenoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Neuroendocrine Tumor/Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8272/0"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Adenoma"},{"name":"Maps_To","value":"8272/0"},{"name":"Maps_To","value":"Pituitary adenoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0032000"}]}}{"C4536":{"preferredName":"Metastatic Pituitary Neuroendocrine Tumor","code":"C4536","definitions":[{"definition":"Pituitary neuroendocrine tumor that has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Pituitary Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic PitNET","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Pituitary Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Gland Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Gland Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8272/3"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Carcinoma"},{"name":"Maps_To","value":"8272/3"},{"name":"Maps_To","value":"Pituitary carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346300"}]}}{"C6780":{"preferredName":"Pituitary Gland Acidophil Adenoma","code":"C6780","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acidophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eosinophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Acidophil Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8280/0"},{"name":"Legacy Concept Name","value":"Acidophil_Adenoma"},{"name":"Maps_To","value":"8280/0"},{"name":"Maps_To","value":"Acidophil adenoma"},{"name":"Maps_To","value":"Eosinophil adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001433"}]}}{"C4147":{"preferredName":"Pituitary Gland Acidophil Carcinoma","code":"C4147","definitions":[{"definition":"A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acidophil Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Acidophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eosinophil Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eosinophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Acidophil Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8280/3"},{"name":"Legacy Concept Name","value":"Acidophil_Adenocarcinoma"},{"name":"Maps_To","value":"8280/3"},{"name":"Maps_To","value":"Acidophil adenocarcinoma"},{"name":"Maps_To","value":"Acidophil carcinoma"},{"name":"Maps_To","value":"Eosinophil adenocarcinoma"},{"name":"Maps_To","value":"Eosinophil carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334311"}]}}{"C4148":{"preferredName":"Pituitary Gland Mixed Acidophil-Basophil Adenoma","code":"C4148","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic and basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Acidophil-Basophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Eosinophil-Basophil Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Mixed Acidophil-Basophil Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8281/0"},{"name":"Legacy Concept Name","value":"Mixed_Acidophil-Basophil_Adenoma"},{"name":"Maps_To","value":"8281/0"},{"name":"Maps_To","value":"Mixed acidophil-basophil adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334312"}]}}{"C4149":{"preferredName":"Pituitary Gland Mixed Acidophil-Basophil Carcinoma","code":"C4149","definitions":[{"definition":"A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic and basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Acidophil-Basophil Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Acidophil-Basophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Eosinophil-Basophil Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Mixed Acidophil-Basophil Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8281/3"},{"name":"Legacy Concept Name","value":"Mixed_Acidophil-Basophil_Carcinoma"},{"name":"Maps_To","value":"8281/3"},{"name":"Maps_To","value":"Mixed acidophil-basophil carcinoma"},{"name":"NCI_META_CUI","value":"CL448681"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3759":{"preferredName":"Oncocytic Adenoma","code":"C3759","definitions":[{"definition":"A benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.  Representative examples include oncocytic adenomas of the thyroid gland, parathyroid gland, and pituitary gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Oxyphilic Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8290/0"},{"name":"Legacy Concept Name","value":"Oxyphilic_Adenoma"},{"name":"Maps_To","value":"8290/0"},{"name":"Maps_To","value":"Follicular adenoma, oxyphilic cell"},{"name":"Maps_To","value":"Oncocytic adenoma"},{"name":"Maps_To","value":"Oxyphilic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1510502"}]}}{"C6042":{"preferredName":"Thyroid Gland Oncocytic Adenoma","code":"C6042","definitions":[{"definition":"A thyroid gland adenoma composed of large cells with abundant granular eosinophilic cytoplasm and large nuclei with prominent nucleoli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Oncocytic Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Oncocytoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Oncocytoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Oncocytoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Oncocytoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Thyroid Gland Oncocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Thyroid Oncocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid Gland of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid Gland of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Follicular Adenoma of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Follicular Adenoma of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Follicular Adenoma of Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Follicular Adenoma of the Oxyphilic Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Hurthle Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Oncocytic Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Hurthle_Cell_Adenoma"},{"name":"Maps_To","value":"8290/0"},{"name":"Maps_To","value":"Hurthle cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336750"}]}}{"C3679":{"preferredName":"Oncocytic Adenocarcinoma","code":"C3679","definitions":[{"definition":"A malignant neoplasm composed of large epithelial cells with abundant granular eosinophilic cytoplasm (oncocytes).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenocarcinoma characterized by the presence of large malignant epithelial cells with abundant granular eosinophilic cytoplasm (oncocytes). Representative examples include thyroid gland oncocytic follicular carcinoma, oncocytic breast carcinoma, and salivary gland oncocytic carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hurthle Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Oxyphilic Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8290/3"},{"name":"Legacy Concept Name","value":"Oxyphilic_Adenocarcinoma"},{"name":"Maps_To","value":"8290/3"},{"name":"Maps_To","value":"Follicular carcinoma, oxyphilic cell"},{"name":"Maps_To","value":"Hurthle cell adenocarcinoma"},{"name":"Maps_To","value":"Hurthle cell carcinoma"},{"name":"Maps_To","value":"Oncocytic adenocarcinoma"},{"name":"Maps_To","value":"Oncocytic carcinoma"},{"name":"Maps_To","value":"Oxyphilic adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205642"}]}}{"C2856":{"preferredName":"Pituitary Gland Basophil Adenoma","code":"C2856","definitions":[{"definition":"An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basophilic Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Basophilic Pituitary Gland Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Mucoid Cell Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Basophilic Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Pituitary Gland Basophil Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8300/0"},{"name":"Legacy Concept Name","value":"Basophilic_Adenoma"},{"name":"Maps_To","value":"8300/0"},{"name":"Maps_To","value":"Basophil adenoma"},{"name":"Maps_To","value":"Mucoid cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001431"}]}}{"C4150":{"preferredName":"Basophilic Adenocarcinoma","code":"C4150","definitions":[{"definition":"A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with basic dyes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basophilic Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Basophilic Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8300/3"},{"name":"Legacy Concept Name","value":"Basophilic_Adenocarcinoma"},{"name":"Maps_To","value":"8300/3"},{"name":"Maps_To","value":"Basophil adenocarcinoma"},{"name":"Maps_To","value":"Basophil carcinoma"},{"name":"Maps_To","value":"Mucoid cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334314"}]}}{"C4151":{"preferredName":"Clear Cell Adenoma","code":"C4151","definitions":[{"definition":"A benign neoplasm composed of glands containing epithelial clear cells.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm comprising glands containing epithelial clear cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Clear Cell Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8310/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adenoma"},{"name":"Maps_To","value":"8310/0"},{"name":"Maps_To","value":"Clear cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334315"}]}}{"C3766":{"preferredName":"Clear Cell Adenocarcinoma","code":"C3766","definitions":[{"definition":"A malignant neoplasm composed of glandular epithelial clear cells.  Various architectural patterns may be seen, including papillary, tubulocystic, and solid.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm comprising glandular epithelial clear cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare type of tumor, usually of the female genital tract, in which the insides of the cells look clear when viewed under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephroid Clear Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephroid Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8310/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8310/3"},{"name":"Maps_To","value":"Clear cell adenocarcinoma, mesonephroid"},{"name":"Maps_To","value":"Clear cell adenocarcinoma, NOS"},{"name":"Maps_To","value":"Clear cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206681"}]}}{"C4033":{"preferredName":"Clear Cell Renal Cell Carcinoma","code":"C4033","definitions":[{"definition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","type":"DEFINITION","source":"NCI"},{"definition":"The most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"CCRCC","termGroup":"AB","termSource":"NCI"},{"termName":"Clear Cell Adenocarcinoma of Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Clear Cell Adenocarcinoma of the Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Clear Cell Adenocarcinoma, Kidney","termGroup":"AQS","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell RCC","termGroup":"SY","termSource":"NCI"},{"termName":"Conventional (Clear Cell) Renal Cell Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Conventional (Clear Cell) Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Conventional Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grawitz Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Hypernephroma","termGroup":"AQS","termSource":"NCI"},{"termName":"Kidney Clear Cell Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Kidney Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Clear Cell Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Renal Clear Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Conventional_Clear_Cell_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"50"},{"name":"Maps_To","value":"63"},{"name":"Maps_To","value":"64"},{"name":"Maps_To","value":"65"},{"name":"Maps_To","value":"70"},{"name":"Maps_To","value":"8311/1"},{"name":"Maps_To","value":"8312/3"},{"name":"Maps_To","value":"Grawitz tumor"},{"name":"Maps_To","value":"Hypernephroid tumor"},{"name":"Maps_To","value":"Hypernephroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4225533"}]}}{"C51302":{"preferredName":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","code":"C51302","definitions":[{"definition":"A rare inherited disorder that increases the risk of developing benign (not cancer) tumors of the skin and the uterus (leiomyomas) and malignant (cancer) tumors of the uterus (leiomyosarcoma) and the kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant inherited syndrome caused by germline mutations in the FH gene. It is characterized by predisposition to renal cell carcinoma, leiomyomas of the skin and uterus, and leiomyosarcoma of the uterus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"FH Deficiency","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Leiomyomatosis and Renal Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"HLRCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Leiomyomatosis_and_Renal_Cell_Cancer"},{"name":"Maps_To","value":"Hereditary leiomyomatosis & RCC-associated renal cell carcinoma"},{"name":"Maps_To","value":"Hereditary Leiomyomatosis and Renal Cell Carcinoma"},{"name":"Maps_To","value":"Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated renal cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708350"}]}}{"C191370":{"preferredName":"Renal Cell Carcinoma, Not Otherwise Specified","code":"C191370","definitions":[{"definition":"A renal cell carcinoma that cannot be classified into one of the established subtypes of renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Cell Carcinoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"RCC-NEC","termGroup":"SY","termSource":"NCI"},{"termName":"RCC-NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Not Elsewhere Classified","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Unclassified","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unclassified_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"8312/3"},{"name":"Maps_To","value":"Renal cell carcinoma, NOS"},{"name":"Maps_To","value":"Renal cell carcinoma, unclassified"},{"name":"NCI_META_CUI","value":"CL1904778"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8988":{"preferredName":"Clear Cell Cystadenofibroma","code":"C8988","definitions":[{"definition":"A benign or borderline neoplasm characterized by the presence of cystic glandular and fibrous tissues and clear cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clear_Cell_Cystadenofibroma"},{"name":"Maps_To","value":"8313/0"},{"name":"Maps_To","value":"Clear cell cystadenofibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377853"}]}}{"C8987":{"preferredName":"Clear Cell Adenofibroma","code":"C8987","definitions":[{"definition":"A benign or borderline neoplasm characterized by the presence of glandular structures which contain clear cells and a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8313/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adenofibroma"},{"name":"Maps_To","value":"8313/0"},{"name":"Maps_To","value":"Clear cell adenofibroma"},{"name":"NCI_META_CUI","value":"CL448546"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40080":{"preferredName":"Borderline Ovarian Clear Cell Tumor","code":"C40080","definitions":[{"definition":"An epithelial neoplasm with low malignant potential affecting the ovary.  It is characterized by the presence of clear or hobnail cells.  In some cases, the cells may display nuclear atypia and prominent nucleoli.  When such cells are present, they remain confined to the glands.  There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Clear Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Ovarian Clear Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Clear_Cell_Tumor"},{"name":"Maps_To","value":"8313/1"},{"name":"Maps_To","value":"8444/1"},{"name":"Maps_To","value":"Clear cell borderline tumor"},{"name":"Maps_To","value":"Clear cell cystic tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279676"}]}}{"C40081":{"preferredName":"Borderline Ovarian Clear Cell Adenofibroma","code":"C40081","definitions":[{"definition":"An epithelial neoplasm with low malignant potential affecting the ovary. It is characterized by the presence of atypical glands and/or cystic spaces lined with clear or hobnail cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Clear Cell Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8313/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Clear_Cell_Adenofibroma"},{"name":"Maps_To","value":"8313/1"},{"name":"Maps_To","value":"Clear cell adenofibroma of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266039"}]}}{"C40079":{"preferredName":"Ovarian Clear Cell Adenocarcinofibroma","code":"C40079","definitions":[{"definition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells with clear cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Clear Cell Adenocarcinofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Clear Cell Malignant Adenofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8313/3"},{"name":"Legacy Concept Name","value":"Ovarian_Clear_Cell_Adenocarcinofibroma"},{"name":"Maps_To","value":"8313/3"},{"name":"Maps_To","value":"Clear cell adenocarcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266040"}]}}{"C4152":{"preferredName":"Lipid-Rich Carcinoma","code":"C4152","definitions":[{"definition":"A carcinoma characterized by the presence of malignant epithelial cells with clear cytoplasm which contains neutral lipids. A representative example is the lipid-rich breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid-Rich Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8314/3"},{"name":"Legacy Concept Name","value":"Lipid-Rich_Carcinoma"},{"name":"Maps_To","value":"8314/3"},{"name":"Maps_To","value":"Lipid-rich carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334318"}]}}{"C4153":{"preferredName":"Glycogen-Rich Carcinoma","code":"C4153","definitions":[{"definition":"A carcinoma characterized by the presence of malignant epithelial cells with abundant clear cytoplasm which contains glycogen. A representative example is the glycogen-rich, clear cell breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glycogen-Rich Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8315/3"},{"name":"Legacy Concept Name","value":"Glycogen-Rich_Carcinoma"},{"name":"Maps_To","value":"8315/3"},{"name":"Maps_To","value":"Glycogen-rich carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334319"}]}}{"C157718":{"preferredName":"Acquired Cystic Disease-Associated Renal Cell Carcinoma","code":"C157718","definitions":[{"definition":"The most common renal cell carcinoma that develops in patients with end-stage renal disease and acquired cystic disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acquired Cystic Disease-Associated Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ACD-RCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8316/3"},{"name":"Maps_To","value":"Acquired cystic disease-associated renal cell carcinoma (RCC)"},{"name":"Maps_To","value":"Cyst-associated renal cell carcinoma"},{"name":"NCI_META_CUI","value":"CL558162"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27893":{"preferredName":"Sarcomatoid Renal Cell Carcinoma","code":"C27893","definitions":[{"definition":"A high grade carcinoma of the kidney.  It is not a distinct clinicopathological entity and includes a diverse group of renal cell carcinomas which have been transformed from a lower to a higher grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Sarcomatoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8318/3"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"8318/3"},{"name":"Maps_To","value":"Renal cell carcinoma, sarcomatoid"},{"name":"Maps_To","value":"Renal cell carcinoma, spindle cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266043"}]}}{"C6194":{"preferredName":"Collecting Duct Carcinoma","code":"C6194","definitions":[{"definition":"A rare type of kidney cancer that grows and spreads quickly. It begins in the duct of Bellini in the kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Collecting Duct Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bellini Duct Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Carcinoma of Collecting Ducts of Bellini","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Kidney Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Renal Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Kidney Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Renal Collecting Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Collecting Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Collecting Duct Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8319/3"},{"name":"Legacy Concept Name","value":"Collecting_Duct_Carcinoma"},{"name":"Maps_To","value":"8319/3"},{"name":"Maps_To","value":"Bellini duct carcinoma"},{"name":"Maps_To","value":"Collecting duct carcinoma"},{"name":"Maps_To","value":"Renal carcinoma, collecting duct type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266044"}]}}{"C3681":{"preferredName":"Granular Cell Carcinoma","code":"C3681","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant epithelial cells with granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granular Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Granular Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8320/3"},{"name":"Legacy Concept Name","value":"Granular_Cell_Carcinoma"},{"name":"Maps_To","value":"8320/3"},{"name":"Maps_To","value":"Granular cell adenocarcinoma"},{"name":"Maps_To","value":"Granular cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205644"}]}}{"C4154":{"preferredName":"Parathyroid Gland Chief Cell Adenoma","code":"C4154","definitions":[{"definition":"A parathyroid gland adenoma composed predominantly of neoplastic chief cells.  These cells have either slightly eosinophilic or vacuolated cytoplasm, and round nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parathyroid Gland Chief Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chief Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of Parathyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of Parathyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of the Parathyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Chief Cell Adenoma of the Parathyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Parathyroid Chief Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8321/0"},{"name":"Legacy Concept Name","value":"Parathyroid_Chief_Cell_Adenoma"},{"name":"Maps_To","value":"8321/0"},{"name":"Maps_To","value":"Chief cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334320"}]}}{"C4155":{"preferredName":"Parathyroid Gland Water-Clear Cell Adenoma","code":"C4155","definitions":[{"definition":"A rare parathyroid gland adenoma composed of neoplastic cells with abundant cytoplasm.  The cytoplasm of the neoplastic cells is usually not entirely clear, and is often variably vacuolated, foamy, and granular.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parathyroid Gland Water-Clear Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Water-Clear Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8322/0"},{"name":"Legacy Concept Name","value":"Water-Clear_Cell_Adenoma"},{"name":"Maps_To","value":"8322/0"},{"name":"Maps_To","value":"Water-clear cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334321"}]}}{"C4156":{"preferredName":"Water-Clear Cell Adenocarcinoma","code":"C4156","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant epithelial cells with clear, often vacuolated or foamy cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Water-Clear Cell Adenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8322/3"},{"name":"Legacy Concept Name","value":"Water-Clear_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8322/3"},{"name":"Maps_To","value":"Water-clear cell adenocarcinoma"},{"name":"Maps_To","value":"Water-clear cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334322"}]}}{"C4157":{"preferredName":"Mixed Cell Adenoma","code":"C4157","definitions":[{"definition":"An adenoma characterized by the presence of a mixed epithelial cell population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Cell Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8323/0"},{"name":"Legacy Concept Name","value":"Mixed_Cell_Adenoma"},{"name":"Maps_To","value":"8323/0"},{"name":"Maps_To","value":"Mixed cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334323"}]}}{"C4158":{"preferredName":"Mixed Cell Adenocarcinoma","code":"C4158","definitions":[{"definition":"An adenocarcinoma characterized by the presence of a mixed malignant glandular cell population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Cell Adenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8323/3"},{"name":"Legacy Concept Name","value":"Mixed_Cell_Adenocarcinoma"},{"name":"Maps_To","value":"8323/3"},{"name":"Maps_To","value":"Mixed cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334324"}]}}{"C4159":{"preferredName":"Lipoadenoma","code":"C4159","definitions":[{"definition":"An adenoma in which the neoplastic epithelial cells are admixed with adipose tissue cells.","type":"DEFINITION","source":"NCI"},{"definition":"Benign mixed neoplasm comprised of epithelial/glandular and lipomatous structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lipoadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8324/0"},{"name":"Legacy Concept Name","value":"Lipoadenoma"},{"name":"Maps_To","value":"8324/0"},{"name":"Maps_To","value":"Adenolipoma"},{"name":"Maps_To","value":"Lipoadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334325"}]}}{"C3502":{"preferredName":"Thyroid Gland Follicular Adenoma","code":"C3502","definitions":[{"definition":"A benign neoplasm arising from follicular cells of the thyroid gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, encapsulated neoplasm arising from the follicular cells of the thyroid gland. It may be associated with thyroid hormone secretion but it does not have malignant characteristics.","type":"DEFINITION","source":"NCI"},{"definition":"A non-malignant neoplasm of the thyroid gland arising from epithelial cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Thyroid Gland Follicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Adenoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8330/0"},{"name":"Legacy Concept Name","value":"Thyroid_Adenoma"},{"name":"Maps_To","value":"8330/0"},{"name":"Maps_To","value":"Follicular adenoma"},{"name":"Maps_To","value":"Follicular Adenoma"},{"name":"Maps_To","value":"Follicular adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0151468"}]}}{"C27729":{"preferredName":"Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential","code":"C27729","definitions":[{"definition":"An encapsulated or well-circumscribed thyroid gland tumor composed of well-differentiated follicular cells with well-developed or partially developed nuclear features of papillary thyroid carcinoma and with questionable capsular or vascular invasion. This is a tumor indeterminate between follicular adenoma and follicular carcinoma. Tumors in which vascular invasion has been excluded by all means are called non-invasive follicular thyroid neoplasms with papillary-like nuclear features. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Atypical Follicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Well-Differentiated Neoplasm of Uncertain Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"WDT-UMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8330/1"},{"name":"Legacy Concept Name","value":"Atypical_Follicular_Adenoma"},{"name":"Maps_To","value":"8330/1"},{"name":"Maps_To","value":"Atypical follicular adenoma"},{"name":"Maps_To","value":"Well differentiated tumor of uncertain malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266046"}]}}{"C8054":{"preferredName":"Thyroid Gland Follicular Carcinoma","code":"C8054","definitions":[{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  The nuclear features which characterize the thyroid gland papillary carcinoma are absent.  Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers.  Clinically, it usually presents as a solitary mass in the thyroid gland.  It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.","type":"DEFINITION","source":"NCI"},{"definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The nuclear features which characterize the thyroid gland papillary carcinoma are absent.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neoplasia arising from follicular cells of the thyroid gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that forms in follicular cells in the thyroid. It grows slowly and is highly treatable.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Follicular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Cancer of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"FTC","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Follicular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Follicular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Follicular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8330/3"},{"name":"ICD-O-3_Code","value":"8331/3"},{"name":"Legacy Concept Name","value":"Follicular_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8330/3"},{"name":"Maps_To","value":"8331/3"},{"name":"Maps_To","value":"Follicular adenocarcinoma, NOS"},{"name":"Maps_To","value":"Follicular adenocarcinoma, well differentiated"},{"name":"Maps_To","value":"Follicular carcinoma, NOS"},{"name":"Maps_To","value":"Follicular carcinoma, well differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206682"}]}}{"C46095":{"preferredName":"Solid/Trabecular Variant Thyroid Gland Papillary Carcinoma","code":"C46095","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland that predominantly affects children.  It is characterized by the presence of a solid growth pattern.  The malignant cells have nuclear features that are characteristic of papillary carcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid/Trabecular Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Variant_Thyroid_Gland_Papillary_Carcinoma"},{"name":"Maps_To","value":"8332/3"},{"name":"Maps_To","value":"Follicular adenocarcinoma, trabecular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334327"}]}}{"C4160":{"preferredName":"Thyroid Gland Microfollicular Adenoma","code":"C4160","definitions":[{"definition":"A thyroid gland adenoma composed of microfollicular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Microfollicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Microfollicular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Fetal Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8333/0"},{"name":"Legacy Concept Name","value":"Microfollicular_Adenoma"},{"name":"Maps_To","value":"8333/0"},{"name":"Maps_To","value":"Fetal adenoma"},{"name":"Maps_To","value":"Microfollicular adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334328"}]}}{"C45509":{"preferredName":"Lung Fetal Adenocarcinoma","code":"C45509","definitions":[{"definition":"A rare morphologic variant of lung adenocarcinoma characterized by the presence of glandular structures containing glycogen-rich cells forming tubules that resemble fetal lung tubules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Fetal Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Adenocarcinoma of Fetal Type","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Endodermal Tumor Resembling Fetal Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Fetal Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8333/3"},{"name":"Legacy Concept Name","value":"Fetal_Lung_Adenocarcinoma"},{"name":"Maps_To","value":"8333/3"},{"name":"Maps_To","value":"Fetal adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708045"}]}}{"C4161":{"preferredName":"Thyroid Gland Macrofollicular Adenoma","code":"C4161","definitions":[{"definition":"A thyroid gland adenoma composed of large size follicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Macrofollicular Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Colloid Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Macrofollicular Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8334/0"},{"name":"Legacy Concept Name","value":"Macrofollicular_Adenoma"},{"name":"Maps_To","value":"8334/0"},{"name":"Maps_To","value":"Colloid adenoma"},{"name":"Maps_To","value":"Macrofollicular adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334329"}]}}{"C65200":{"preferredName":"Thyroid Gland Follicular Carcinoma, Minimally Invasive","code":"C65200","definitions":[{"definition":"A follicular carcinoma of the thyroid gland showing capsular invasion only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Follicular Carcinoma, Minimally Invasive","termGroup":"PT","termSource":"NCI"},{"termName":"FTC, Minimally Invasive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8335/3"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Follicular_Carcinoma_Minimally_Invasive"},{"name":"Maps_To","value":"8335/3"},{"name":"Maps_To","value":"Follicular carcinoma, minimally invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266048"}]}}{"C6846":{"preferredName":"Thyroid Gland Hyalinizing Trabecular Tumor","code":"C6846","definitions":[{"definition":"A rare, circumscribed or encapsulated tumor arising from the follicular cells of the thyroid gland.  It is characterized by a trabecular growth pattern and hyalinized stroma formation.  The vast majority of cases have a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Hyalinizing Trabecular Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"HTT","termGroup":"AB","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Adenoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Adenoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Hyalinizing Trabecular Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma-like Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"PLAT","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Hyalinizing Trabecular Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8336/0"},{"name":"Legacy Concept Name","value":"Thyroid_Hyalinizing_Trabecular_Adenoma"},{"name":"Maps_To","value":"8336/0"},{"name":"Maps_To","value":"Hyalinizing trabecular adenoma"},{"name":"Maps_To","value":"Hyalinizing trabecular tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266049"}]}}{"C6040":{"preferredName":"Poorly Differentiated Thyroid Gland Carcinoma","code":"C6040","definitions":[{"definition":"A follicular-derived thyroid gland carcinoma that is histologically poorly differentiated and has high-grade features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Thyroid Gland Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Insular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"PDTC","termGroup":"AB","termSource":"NCI"},{"termName":"Poorly Differentiated Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Poorly Differentiated Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Poorly Differentiated Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Poorly Differentiated Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8337/3"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8337/3"},{"name":"Maps_To","value":"Insular carcinoma"},{"name":"Maps_To","value":"Poorly differentiated thyroid carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266050"}]}}{"C156122":{"preferredName":"Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive","code":"C156122","definitions":[{"definition":"An encapsulated follicular carcinoma of the thyroid gland which shows angioinvasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive","termGroup":"PT","termSource":"NCI"},{"termName":"FTC, Encapsulated Angioinvasive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Follicular carcinoma, encapsulated, angioinvasive"},{"name":"Maps_To","value":"Follicular thyroid carcinoma (FTC), encapsulated angioinvasive"},{"name":"NCI_META_CUI","value":"CL562836"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7380":{"preferredName":"Thyroid Gland Papillary and Follicular Carcinoma","code":"C7380","synonyms":[{"termName":"Papillary and Follicular Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary and Follicular Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Thyroid Gland Papillary and Follicular Carcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_and_Follicular_Adenocarcinoma"},{"name":"Maps_To","value":"8340/3"},{"name":"Maps_To","value":"Papillary and follicular adenocarcinoma"},{"name":"Maps_To","value":"Papillary and follicular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206683"}]}}{"C126594":{"preferredName":"Follicular Variant Thyroid Gland Papillary Carcinoma","code":"C126594","definitions":[{"definition":"An encapsulated or nonencapsulated variant of papillary carcinoma of the thyroid gland characterized by the predominance of follicular structures. The malignant follicular cells display the nuclear features that characterize the papillary adenocarcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follicular Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"FVPTC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8340/3"},{"name":"Maps_To","value":"Papillary carcinoma, follicular variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346398"}]}}{"C46004":{"preferredName":"Thyroid Gland Papillary Microcarcinoma","code":"C46004","definitions":[{"definition":"A papillary carcinoma of the thyroid gland measuring 10mm or less in diameter.  The survival rates of patients with this type of carcinoma are the same with those of the normal population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Papillary Microcarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Microcarcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Microcarcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Gland Microcarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Thyroid Microcarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8341/3"},{"name":"Legacy Concept Name","value":"Papillary_Thyroid_Gland_Microcarcinoma"},{"name":"Maps_To","value":"8341/3"},{"name":"Maps_To","value":"Papillary microcarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709457"}]}}{"C46093":{"preferredName":"Oncocytic Variant Thyroid Gland Papillary Carcinoma","code":"C46093","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of papillary or follicular structures, containing malignant follicular cells with abundant granular eosinophilic cytoplasm. These cells have the nuclear features that characterize the papillary carcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Oxyphilic Variant Thyroid Gland Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8342/3"},{"name":"Legacy Concept Name","value":"Oncocytic_Variant_Thyroid_Gland_Papillary_Carcinoma"},{"name":"Maps_To","value":"8342/3"},{"name":"Maps_To","value":"Papillary carcinoma, oncocytic variant"},{"name":"Maps_To","value":"Papillary carcinoma, oxyphilic cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709312"}]}}{"C126598":{"preferredName":"Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features","code":"C126598","definitions":[{"definition":"A benign or malignant thyroid tumor arising from follicular cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A non-invasive neoplasm of thyroid follicular cells with a follicular growth pattern and nuclear features of papillary thyroid carcinoma that has an extremely low malignant potential. These tumors were formerly classified as non-invasive encapsulated follicular variant of papillary thyroid carcinoma or well-differentiated tumor of uncertain malignant potential. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features","termGroup":"PT","termSource":"NCI"},{"termName":"NIEFVPTC","termGroup":"AB","termSource":"NCI"},{"termName":"NIFTP","termGroup":"AB","termSource":"NCI"},{"termName":"Noninvasive Encapsulated Follicular Variant Papillary Thyroid Gland Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Noninvasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Noninvasive Follicular Thyroid Gland Neoplasm with Papillary-Like Nuclear Features","termGroup":"SY","termSource":"NCI"},{"termName":"Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Noninvasive Follicular Tumor with Papillary-Like Nuclear Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Non-invasive EFVPTC"},{"name":"Maps_To","value":"Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)"},{"name":"Maps_To","value":"Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)"},{"name":"Maps_To","value":"Non-invasive FTP"},{"name":"NCI_META_CUI","value":"CL505049"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C156034":{"preferredName":"Encapsulated Variant Thyroid Gland Papillary Carcinoma","code":"C156034","definitions":[{"definition":"A typical papillary thyroid gland carcinoma that is totally surrounded by a fibrous capsule, which may be intact or only focally infiltrated by tumor growth. It accounts for about 10% of all cases of papillary thyroid gland carcinoma and has an excellent prognosis. Regional nodal metastases may be present, but bloodborne metastases are rare. The survival rate is nearly 100%. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encapsulated Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8343/3"},{"name":"Maps_To","value":"Encapsulated papillary carcinoma"},{"name":"Maps_To","value":"Papillary carcinoma, encapsulated"},{"name":"Maps_To","value":"Papillary carcinoma, encapsulated, of thyroid"},{"name":"NCI_META_CUI","value":"CL562888"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C35830":{"preferredName":"Columnar Cell Variant Thyroid Gland Papillary Carcinoma","code":"C35830","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of pseudostratified malignant follicular cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Columnar Cell Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Columnar Cell Variant Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Columnar Cell Variant Papillary Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8344/3"},{"name":"Legacy Concept Name","value":"Columnar_Cell_Variant_Papillary_Carcinoma"},{"name":"Maps_To","value":"8344/3"},{"name":"Maps_To","value":"Papillary carcinoma, columnar cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266054"}]}}{"C35558":{"preferredName":"Tall Cell Variant Thyroid Gland Papillary Carcinoma","code":"C35558","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of tall malignant follicular cells, arranged in papillary and trabecular patterns.  Necrotic changes and high mitotic activity are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tall Cell Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Tall Cell Variant Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tall_Cell_Variant_Papillary_Carcinoma"},{"name":"Maps_To","value":"8344/3"},{"name":"Maps_To","value":"Papillary carcinoma, tall cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336695"}]}}{"C4193":{"preferredName":"Thyroid Gland Medullary Carcinoma with Amyloid Stroma","code":"C4193","definitions":[{"definition":"A medullary thyroid gland carcinoma characterized by the presence of amyloid stroma.  The majority of medullary carcinomas of the thyroid gland are associated with amyloid deposits.  The latter are highlighted with Congo red staining method.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Medullary Carcinoma with Amyloid Stroma","termGroup":"PT","termSource":"NCI"},{"termName":"C Cell Adenocarcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"C Cell Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Adenocarcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Gland Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Parafollicular Cell Adenocarcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Parafollicular Cell Carcinoma with Amyloid Stroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8345/3"},{"name":"Legacy Concept Name","value":"Medullary_Carcinoma_with_Amyloid_Stroma"},{"name":"Maps_To","value":"8345/3"},{"name":"Maps_To","value":"Medullary carcinoma with amyloid stroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334379"}]}}{"C3879":{"preferredName":"Thyroid Gland Medullary Carcinoma","code":"C3879","definitions":[{"definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","type":"DEFINITION","source":"NCI"},{"definition":"A neuroendocrine malignant epithelial neoplasm arising from C-cells of the thyroid gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cancer that develops in C cells of the thyroid. The C cells make a hormone (calcitonin) that helps maintain a healthy level of calcium in the blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma arising from the C-cells of the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Thyroid Gland Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"C Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"C-Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Thyroid Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MTC","termGroup":"AB","termSource":"NCI"},{"termName":"Parafollicular Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Medullary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Medullary_Thyroid_Carcinoma"},{"name":"Maps_To","value":"8345/3"},{"name":"Maps_To","value":"C cell carcinoma"},{"name":"Maps_To","value":"Medullary thyroid carcinoma"},{"name":"Maps_To","value":"Parafollicular cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0238462"}]}}{"C46104":{"preferredName":"Thyroid Gland Mixed Medullary and Follicular Cell-Derived Carcinoma","code":"C46104","definitions":[{"definition":"A primary carcinoma of the thyroid gland containing a medullary carcinoma component that is immunohistochemically positive for calcitonin, and follicular cell-derived carcinoma component that is immunohistochemically positive for thyroglobulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Mixed Medullary and Follicular Cell-Derived Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Medullary and Follicular Cell-Derived Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MMFCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Legacy Concept Name","value":"Thyroid_Gland_Mixed_Medullary_and_Follicular_Cell_Carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1710414"}]}}{"C7427":{"preferredName":"Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma","code":"C7427","definitions":[{"definition":"A morphologic variant of papillary carcinoma of the thyroid gland that more often affects young patients and commonly metastasizing to the lungs.  It is characterized by a diffuse infiltration of the thyroid gland by malignant follicular cells, squamous metaplasia, stromal fibrosis, and lymphocytic infiltration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Papillary Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nonencapsulated Sclerosing Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Diffuse Sclerosing Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8350/3"},{"name":"Legacy Concept Name","value":"Nonencapsulated_Sclerosing_Carcinoma"},{"name":"Maps_To","value":"8350/3"},{"name":"Maps_To","value":"Nonencapsulated sclerosing adenocarcinoma"},{"name":"Maps_To","value":"Nonencapsulated sclerosing carcinoma"},{"name":"Maps_To","value":"Nonencapsulated sclerosing tumor"},{"name":"Maps_To","value":"Papillary carcinoma, diffuse sclerosing"},{"name":"NCI_META_CUI","value":"CL017960"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6432":{"preferredName":"Multiple Endocrine Neoplasia","code":"C6432","definitions":[{"definition":"A genetically heterogenous group of autosomal dominant neoplastic syndromes characterized by the development of neoplasms in various endocrine organs.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An autosomal dominant inherited neoplastic syndrome characterized by the development of various endocrine neoplasms and abnormalities in various anatomic sites. There are four types recognized: type 1 (MEN 1), caused by inactivation of the tumor suppressor gene MEN-1, type 2A (MEN 2A), caused by mutation of the RET gene, type 2B (MEN 2B) also caused by mutation of the RET gene, and type 4 (MEN 4) caused by mutation of the CDKN1B gene. Patients with MEN 1 may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. Patients with MEN 2A develop medullary thyroid carcinomas and may also develop pheochromocytomas and parathyroid gland hyperplasia. Patients with MEN 2B develop medullary thyroid carcinomas and numerous neural defects including neuromas. Patients with MEN 4 develop endocrine neoplasms, particularly in the parathyroid glands, pituitary, and pancreas.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited condition that may result in the development of cancers of the endocrine system. There are several types of multiple endocrine neoplasia syndrome, and patients with each type may develop different types of cancer. The altered genes that cause each type can be detected with a blood test.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multiple Endocrine Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"MEN","termGroup":"AB","termSource":"NCI"},{"termName":"Multiple Endocrine Adenomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Endocrine Neoplasia Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8360/1"},{"name":"Legacy Concept Name","value":"Multiple_Endocrine_Neoplasia"},{"name":"Maps_To","value":"8360/1"},{"name":"Maps_To","value":"Endocrine adenomatosis"},{"name":"Maps_To","value":"Multiple endocrine adenomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1955745"}]}}{"C4162":{"preferredName":"Juxtaglomerular Cell Tumor","code":"C4162","definitions":[{"definition":"A benign, well circumscribed neoplasm arising from the cortex of the kidney. It secrets renin and the patients usually present with severe hypertension and marked hypokalemia. Morphologically, it is characterized by the presence of sheets of polygonal or spindle-shaped neoplastic cells forming a hemangiopericytic pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Juxtaglomerular Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtaglomerular Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Juxtaglomerular Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Reninoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8361/0"},{"name":"Legacy Concept Name","value":"Juxtaglomerular_Cell_Tumor"},{"name":"Maps_To","value":"8361/0"},{"name":"Maps_To","value":"Juxtaglomerular tumor"},{"name":"Maps_To","value":"Reninoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334331"}]}}{"C9003":{"preferredName":"Adrenal Cortical Adenoma","code":"C9003","definitions":[{"definition":"A benign neoplasm arising from any of the adrenal cortical layers.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm that can arise from any of the adrenal cortical layers.  It can be associated with the overproduction of glucocorticoids (Cushing's syndrome), androgenic or estrogenic steroids (adrenogenital syndrome), or mineralocorticoids (Conn's syndrome). (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adenoma of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adenoma of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adrenal Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adrenal Gland Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8370/0"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex_Adenoma"},{"name":"Maps_To","value":"8370/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206667"}]}}{"C2858":{"preferredName":"Adrenal Cortical Neoplasm","code":"C2858","definitions":[{"definition":"A benign or malignant (primary or metastatic) neoplasm affecting the adrenal cortex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex_Neoplasm"},{"name":"Maps_To","value":"8370/0"},{"name":"Maps_To","value":"Adrenal cortical tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001618"}]}}{"C9004":{"preferredName":"Benign Adrenal Cortical Neoplasm","code":"C9004","definitions":[{"definition":"A neoplasm that arises from the adrenal cortex and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Adrenal Cortical Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Adrenal Cortex Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Adrenal Cortex Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Adrenal_Cortex_Neoplasm"},{"name":"Maps_To","value":"8370/0"},{"name":"Maps_To","value":"Adrenal cortical tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368669"}]}}{"C9325":{"preferredName":"Adrenal Cortical Carcinoma","code":"C9325","definitions":[{"definition":"A malignant epithelial neoplasm arising from adrenal cortical cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare cancer that forms in the outer layer of tissue of the adrenal gland (a small organ on top of each kidney that makes steroid hormones, adrenaline, and noradrenaline to control heart rate, blood pressure, and other body functions).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Cortical Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenocortical Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8370/3"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex_Carcinoma"},{"name":"Maps_To","value":"8370/3"},{"name":"Maps_To","value":"Adrenal cortical adenocarcinoma"},{"name":"Maps_To","value":"Adrenal cortical carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206686"}]}}{"C9327":{"preferredName":"Malignant Adrenal Cortical Neoplasm","code":"C9327","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the adrenal cortex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Adrenal Cortical Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Adrenal Cortex Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Cortex Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenocortical Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenocortical Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Adrenal Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Adrenal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Adrenal_Cortex_Neoplasm"},{"name":"Maps_To","value":"8370/3"},{"name":"Maps_To","value":"Adrenal cortical tumor, malignant"},{"name":"Maps_To","value":"Malignant neoplasm of cortex of left adrenal gland"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346402"}]}}{"C4163":{"preferredName":"Adrenal Cortical Compact Cell Adenoma","code":"C4163","definitions":[{"definition":"An adenoma of the adrenal cortex composed of neoplastic compact cells with eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Compact Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Compact Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Compact Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Compact Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Compact Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Compact Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8371/0"},{"name":"Legacy Concept Name","value":"Compact_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8371/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, compact cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334332"}]}}{"C4164":{"preferredName":"Pigmented Adrenal Cortical Adenoma","code":"C4164","definitions":[{"definition":"A usually functioning adenoma of the adrenal cortex. Grossly, it has a dark brown appearance and is characterized by the presence of neoplastic cells containing abundant intracytoplasmic lipofuscin. It may be associated with Cushing syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Adrenal Cortical Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Black Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Heavily Pigmented Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Heavily Pigmented Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Heavily Pigmented Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Adrenal Gland Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8372/0"},{"name":"Legacy Concept Name","value":"Heavily_Pigmented_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8372/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, pigmented"},{"name":"Maps_To","value":"Black adenoma"},{"name":"Maps_To","value":"Pigmented adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334333"}]}}{"C4165":{"preferredName":"Adrenal Cortical Clear Cell Adenoma","code":"C4165","definitions":[{"definition":"An adenoma of the adrenal cortex composed of neoplastic clear cells containing intracytoplasmic lipid droplets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Clear Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Clear Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Clear Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8373/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8373/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, clear cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334334"}]}}{"C4166":{"preferredName":"Adrenal Cortical Glomerulosa Cell Adenoma","code":"C4166","definitions":[{"definition":"An adenoma of the adrenal cortex composed of neoplastic cells with cytologic features of glomerulosa cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Glomerulosa Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Glomerulosa Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Glomerulosa Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Glomerulosa Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Glomerulosa Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Glomerulosa Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8374/0"},{"name":"Legacy Concept Name","value":"Glomerulosa_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8374/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, glomerulosa cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334335"}]}}{"C4167":{"preferredName":"Adrenal Cortical Mixed Cell Adenoma","code":"C4167","definitions":[{"definition":"An adenoma of the adrenal cortex composed of a mixed neoplastic cellular population, including varying numbers of neoplastic clear and compact cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortical Mixed Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortex Mixed Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Mixed Cell Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cell Adrenal Cortex Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cell Adrenal Cortical Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cell Adrenocortical Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8375/0"},{"name":"Legacy Concept Name","value":"Mixed_Cell_Adrenal_Cortical_Adenoma"},{"name":"Maps_To","value":"8375/0"},{"name":"Maps_To","value":"Adrenal cortical adenoma, mixed cell"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334336"}]}}{"C27287":{"preferredName":"Ovarian Endometrioid Adenofibroma","code":"C27287","definitions":[{"definition":"A benign neoplasm of the ovary characterized by the presence of glandular structures with endometrial-type well-differentiated cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Endometrioid Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8380/0"},{"name":"ICD-O-3_Code","value":"8381/0"},{"name":"Legacy Concept Name","value":"Ovarian_Endometrioid_Adenofibroma"},{"name":"Maps_To","value":"8380/0"},{"name":"Maps_To","value":"8381/0"},{"name":"Maps_To","value":"Endometrioid adenofibroma, NOS"},{"name":"Maps_To","value":"Endometrioid adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334337"}]}}{"C7983":{"preferredName":"Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor","code":"C7983","definitions":[{"definition":"An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is often fibrotic. There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Endometrioid Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Endometrioid Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Endometrioid Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Endometrioid Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Endometrioid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Endometrioid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"EBT/APET","termGroup":"AB","termSource":"NCI"},{"termName":"Endometrioid Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrioid Neoplasm with Proliferating Activity, Ovarian","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrioid Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrioid Tumor with Proliferating Activity, Ovarian","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Endometrioid Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Ovarian Endometrioid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Ovarian Endometrioid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Borderline Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Borderline Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Neoplasm with Proliferating Activity","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Endometrioid Tumor with Proliferating Activity","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Endometrioid Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Endometrioid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Endometrioid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8380/1"},{"name":"ICD-O-3_Code","value":"8381/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Endometrioid_Tumor"},{"name":"Maps_To","value":"8380/1"},{"name":"Maps_To","value":"Atypical proliferative endometrioid tumor"},{"name":"Maps_To","value":"Endometrioid adenoma, borderline malignancy"},{"name":"Maps_To","value":"Endometrioid cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Endometrioid tumor of low malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334338"}]}}{"C27789":{"preferredName":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","code":"C27789","definitions":[{"definition":"A neoplastic clonal expansion of endometrial glands characterized by cytologic changes of the epithelium and the presence of an increased number of endometrial glands. The glands form crowded aggregates with tubular or branching patterns which are cytologically distinct from the background architectural and cytological pattern. It is associated with molecular changes seen in endometrioid endometrial carcinoma, including microsatellite instability, PAX2 inactivation, and PTEN, KRAS, and CTNNB1 gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Endometrial Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Hyperplasia of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Hyperplasia of the Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"EAH/EIN","termGroup":"AB","termSource":"NCI"},{"termName":"EIN","termGroup":"AB","termSource":"NCI"},{"termName":"EmGD","termGroup":"AB","termSource":"NCI"},{"termName":"Endometrial Glandular Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Hyperplasia with Atypia","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Endometrial_Hyperplasia"},{"name":"Legacy Concept Name","value":"Endometrial_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"8380/2"},{"name":"Maps_To","value":"Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN)"},{"name":"Maps_To","value":"Atypical hyperplasia/Endometrioid intraepithelial neoplasm"},{"name":"Maps_To","value":"Endometrioid intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349579"}]}}{"C3769":{"preferredName":"Endometrioid Adenocarcinoma","code":"C3769","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrioid Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrioid Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8380/3"},{"name":"Legacy Concept Name","value":"Endometrioid_Carcinoma"},{"name":"Maps_To","value":"8380/3"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, NOS"},{"name":"Maps_To","value":"Endometrioid carcinoma, NOS"},{"name":"Maps_To","value":"Endometrioid cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206687"}]}}{"C27288":{"preferredName":"Ovarian Endometrioid Cystadenofibroma","code":"C27288","definitions":[{"definition":"A benign neoplasm of the ovary characterized by the presence of cystic structures lined by endometrial-type well-differentiated cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Endometrioid Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Endometrioid_Cystadenofibroma"},{"name":"Maps_To","value":"8381/0"},{"name":"Maps_To","value":"Endometrioid cystadenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335158"}]}}{"C40069":{"preferredName":"Borderline Ovarian Endometrioid Adenofibroma","code":"C40069","definitions":[{"definition":"An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Endometrioid Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Endometrioid_Adenofibroma"},{"name":"Maps_To","value":"8381/1"},{"name":"Maps_To","value":"Endometrioid adenofibroma, borderline malignancy"},{"name":"Maps_To","value":"Endometrioid cystadenofibroma, borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511262"}]}}{"C40060":{"preferredName":"Ovarian Endometrioid Adenocarcinofibroma","code":"C40060","definitions":[{"definition":"A malignant neoplasm of the ovary characterized by the presence of malignant glandular cells resembling endometrial cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Endometrioid Adenocarcinofibroma","termGroup":"AQ","termSource":"NCI"},{"termName":"Ovarian Endometrioid Malignant Adenofibroma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8381/3"},{"name":"Legacy Concept Name","value":"Ovarian_Endometrioid_Adenocarcinofibroma"},{"name":"Maps_To","value":"8381/3"},{"name":"Maps_To","value":"Endometrioid adenofibroma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518711"}]}}{"C27839":{"preferredName":"Endometrial Endometrioid Adenocarcinoma, Secretory Variant","code":"C27839","definitions":[{"definition":"An endometrioid adenocarcinoma arising from the endometrium. Morphologically it is characterized by the presence of malignant glandular cells containing glycogen vacuoles which are usually subnuclear and reminiscent of early secretory endometrium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Endometrioid Adenocarcinoma, Secretory Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Secretory Uterine Corpus Endometrioid Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8382/3"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Endometrioid_Adenocarcinoma_Secretory_Variant"},{"name":"Maps_To","value":"8382/3"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, secretory variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266057"}]}}{"C27848":{"preferredName":"Endometrial Endometrioid Adenocarcinoma, Ciliated Variant","code":"C27848","definitions":[{"definition":"An endometrioid adenocarcinoma arising from the endometrium, in which ciliated cells line the majority of the malignant glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Endometrioid Adenocarcinoma, Ciliated Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Ciliated Uterine Corpus Endometrioid Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8383/3"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Endometrioid_Adenocarcinoma_Ciliated_Variant"},{"name":"Maps_To","value":"8383/3"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, ciliated cell variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266058"}]}}{"C66951":{"preferredName":"Adenocarcinoma, Endocervical Type","code":"C66951","definitions":[{"definition":"An adenocarcinoma characterized by the presence of malignant glandular epithelium resembling the endocervical epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma, Endocervical Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Jul 21 16:11:01 EDT 2021 - See 'Cervical Adenocarcinoma, Usual-Type(C127907)'"},{"name":"ICD-O-3_Code","value":"8384/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_Endocervical_Type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"OLD_PARENT","value":"C127907"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7580":{"preferredName":"Skin Appendage Adenoma","code":"C7580","definitions":[{"definition":"A benign epithelial neoplasm arising from the sebaceous or sweat glands.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign epithelial neoplasm arising from the sebaceous or sweat glands. Representative examples include sebaceous adenoma, tubular apocrine adenoma, and hidradenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Appendage Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Adnexa","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of Skin Appendage","termGroup":"SY","termSource":"NCI"},{"termName":"Adnexal Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8390/0"},{"name":"Legacy Concept Name","value":"Skin_Appendage_Adenoma"},{"name":"Maps_To","value":"8390/0"},{"name":"Maps_To","value":"Adnexal tumor, benign"},{"name":"Maps_To","value":"Skin appendage adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334342"}]}}{"C3775":{"preferredName":"Adnexal Carcinoma","code":"C3775","definitions":[{"definition":"A carcinoma arising from the sebaceous glands, sweat glands, or the hair follicles. Representative examples include sebaceous carcinoma, apocrine carcinoma, eccrine carcinoma, and pilomatrical carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant epithelial neoplasm arising from sebaceous or sweat glands or from hair follicles.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adnexal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Adnexa","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Skin Appendage","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendage Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8390/3"},{"name":"Legacy Concept Name","value":"Adnexal_Carcinoma"},{"name":"Maps_To","value":"8390/3"},{"name":"Maps_To","value":"Adnexal carcinoma"},{"name":"Maps_To","value":"Skin appendage carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206697"}]}}{"C4470":{"preferredName":"Perifollicular Fibroma","code":"C4470","definitions":[{"definition":"A rare cutaneous hamartoma that arises from the connective tissue sheath of the hair follicle. It is characterized by the presence of fibroblasts surrounding the hair follicle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perifollicular Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"PFF","termGroup":"AB","termSource":"NCI"},{"termName":"Trichoblastic Fibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Perifollicular_Fibroma"},{"name":"Maps_To","value":"8391/0"},{"name":"Maps_To","value":"Perifollicular fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704236"}]}}{"C206079":{"preferredName":"Trichodiscoma","code":"C206079","definitions":[{"definition":"A rare hamartomatous papular lesion that arises from the hair follicle. It shares morphological features with fibrofolliculoma, but in contrast to fibrofolliculoma, the predominant component is stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trichodiscoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8391/0"},{"name":"Maps_To","value":"Trichodiscoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C43331":{"preferredName":"Fibrofolliculoma","code":"C43331","definitions":[{"definition":"A rare hamartomatous papular lesion that arises from the hair follicle. It is characterized by the presence of a central dilated infundibulum from which epithelial strands and sebaceous glands emerge. The stroma is composed of collagen, spindle-shaped fibrocytes, and mucin. Patients with Birt-Hogg-Dube syndrome may develop multiple follicular fibromas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrofolliculoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8391/0"},{"name":"Legacy Concept Name","value":"Fibrofolliculoma"},{"name":"Maps_To","value":"8391/0"},{"name":"Maps_To","value":"Fibrofolliculoma"},{"name":"Maps_To","value":"Follicular fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346011"}]}}{"C43356":{"preferredName":"Syringofibroadenoma","code":"C43356","definitions":[{"definition":"A rare benign eccrine lesion usually arising on acral areas as a solitary papule or nodule. Multiple lesions are referred as syringofibroadenomatosis. It is characterized by the presence of epithelial cuboidal cells forming anastomosing cords in a fibrovascular stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syringofibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acrosyringeal Adenomatosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Acrosyringeal Nevus","termGroup":"AQS","termSource":"NCI"},{"termName":"Eccrine Poromatosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Eccrine Syringofibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Syringofibroadenoma of Mascaro","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Syringofibroadenomatous Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"ESFA","termGroup":"AB","termSource":"NCI"},{"termName":"Linear Eccrine Poroma","termGroup":"AQS","termSource":"NCI"},{"termName":"SFA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8392/0"},{"name":"Legacy Concept Name","value":"Eccrine_Syringofibroadenoma"},{"name":"Maps_To","value":"8392/0"},{"name":"Maps_To","value":"Syringofibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266060"}]}}{"C7560":{"preferredName":"Sweat Gland Adenoma","code":"C7560","definitions":[{"definition":"A benign epithelial neoplasm arising from the sweat glands. Representative examples include tubular apocrine adenoma, syringofibroadenoma, and hidradenoma.","type":"DEFINITION","source":"NCI"},{"definition":"A benign epithelias neoplasm arising from sweat glands.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sweat Gland Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Sweat Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8400/0"},{"name":"Legacy Concept Name","value":"Sweat_Gland_Adenoma"},{"name":"Maps_To","value":"8400/0"},{"name":"Maps_To","value":"Sweat gland adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019522"}]}}{"C7563":{"preferredName":"Hidradenoma","code":"C7563","definitions":[{"definition":"A benign epithelial neoplasm arising from the sweat glands. Variants include the clear cell, nodular, and solid cystic hidradenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidradenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acrospiroma","termGroup":"AQS","termSource":"NCI"},{"termName":"Eccrine Acrospiroma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hidradenoma"},{"name":"Maps_To","value":"8400/0"},{"name":"Maps_To","value":"8402/0"},{"name":"Maps_To","value":"Eccrine acrospiroma"},{"name":"Maps_To","value":"Hidradenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206671"}]}}{"C4879":{"preferredName":"Benign Sweat Gland Neoplasm","code":"C4879","definitions":[{"definition":"An epithelial neoplasm that arises from the sweat gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Sweat Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasm of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Sweat Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Neoplasm, Benign","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Sweat_Gland_Neoplasm"},{"name":"Maps_To","value":"8400/0"},{"name":"Maps_To","value":"Sweat gland tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0684354"}]}}{"C3398":{"preferredName":"Sweat Gland Neoplasm","code":"C3398","definitions":[{"definition":"A benign or malignant neoplasm arising from the sweat glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sweat Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Sweat Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8400/1"},{"name":"Legacy Concept Name","value":"Sweat_Gland_Neoplasm"},{"name":"Maps_To","value":"8400/1"},{"name":"Maps_To","value":"Sweat gland tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0038987"}]}}{"C6938":{"preferredName":"Sweat Gland Carcinoma","code":"C6938","definitions":[{"definition":"A carcinoma that arises from the sweat glands. Representative examples include porocarcinoma, hidradenocarcinoma, microcystic adnexal carcinoma, skin adenoid cystic carcinoma, apocrine carcinoma, and digital papillary adenocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from sweat glands.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sweat Gland Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8400/3"},{"name":"Legacy Concept Name","value":"Sweat_Gland_Carcinoma"},{"name":"Maps_To","value":"8400/3"},{"name":"Maps_To","value":"Sweat gland adenocarcinoma"},{"name":"Maps_To","value":"Sweat gland carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1412016"}]}}{"C4810":{"preferredName":"Malignant Sweat Gland Neoplasm","code":"C4810","definitions":[{"definition":"A malignant neoplasm that arises from the sweat glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Sweat Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Sweat Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sweat Gland Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Sweat_Gland_Neoplasm"},{"name":"Maps_To","value":"8400/3"},{"name":"Maps_To","value":"Sweat gland tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321904"}]}}{"C4615":{"preferredName":"Benign Skin Appendage Neoplasm","code":"C4615","definitions":[{"definition":"A neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands. It is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include cylindroma, hidrocystoma, hidradenoma, and sebaceoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Skin Appendage Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Appendageal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Cutaneous Adnexal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Skin Appendageal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Skin Appendageal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Skin_Appendage_Neoplasm"},{"name":"Maps_To","value":"8400/3"},{"name":"Maps_To","value":"Skin appendage tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0347391"}]}}{"C4168":{"preferredName":"Apocrine Adenoma","code":"C4168","definitions":[{"definition":"A benign epithelial neoplasm arising from the apocrine sweat glands. Representative examples include tubular apocrine adenoma and external auditory canal ceruminous adenoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apocrine Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8401/0"},{"name":"Legacy Concept Name","value":"Apocrine_Adenoma"},{"name":"Maps_To","value":"8401/0"},{"name":"Maps_To","value":"Apocrine adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334345"}]}}{"C205459":{"preferredName":"Apocrine Cystadenoma","code":"C205459","definitions":[{"definition":"A rare, benign cystic neoplasm that arises from the apocrine gland. It is characterized by the presence of papillary-like epithelial projections and more complex architectural patterns compared to apocrine hidrocystoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apocrine Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Apocrine Gland Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8401/0"},{"name":"Maps_To","value":"Apocrine cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4169":{"preferredName":"Apocrine Carcinoma","code":"C4169","definitions":[{"definition":"A carcinoma with apocrine differentiation arising from the sweat glands. It presents as single or multiple nodular lesions which may be ulcerated or hemorrhagic and is usually in the axilla and less often in the anogenital region. It grows in the dermis and infiltrates subcutaneous tissues. It is characterized by the presence of large cells with abundant eosinophilic cytoplasm and large often vesicular nuclei. Most cases are slow growing tumors and have a prolonged course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Apocrine Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Apocrine Gland Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Apocrine Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8401/3"},{"name":"Legacy Concept Name","value":"Apocrine_Carcinoma"},{"name":"Maps_To","value":"8401/3"},{"name":"Maps_To","value":"Apocrine adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1706827"}]}}{"C7568":{"preferredName":"Nodular Hidradenoma","code":"C7568","definitions":[{"definition":"A hidradenoma characterized by a nodular growth pattern. It presents as a nodular lesion usually in the scalp, trunk, and proximal extremities. Complete excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Hidradenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8402/0"},{"name":"Legacy Concept Name","value":"Nodular_Hidradenoma"},{"name":"Maps_To","value":"8402/0"},{"name":"Maps_To","value":"Nodular hidradenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370700"}]}}{"C7567":{"preferredName":"Clear Cell Hidradenoma","code":"C7567","definitions":[{"definition":"A hidradenoma with apocrine differentiation. It is characterized by the presence of cells with vesicular nuclei and eosinophilic cytoplasm and cells with clear cytoplasm and often eccentrically located nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Hidradenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hidradenoma with Apocrine Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clear_Cell_Hidradenoma"},{"name":"Maps_To","value":"8402/0"},{"name":"Maps_To","value":"Clear cell hidradenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370701"}]}}{"C54664":{"preferredName":"Hidradenocarcinoma","code":"C54664","definitions":[{"definition":"A carcinoma with apocrine and less often eccrine differentiation, arising from the sweat glands. It usually presents as a solitary slow growing nodule in the dermis or subcutaneous tissues. It is characterized by a nodular growth pattern and it is often associated with necrotic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidradenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8402/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Eccrine_Carcinoma"},{"name":"Maps_To","value":"8402/3"},{"name":"Maps_To","value":"Hidradenocarcinoma"},{"name":"Maps_To","value":"Nodular hidradenoma, malignant"},{"name":"NCI_META_CUI","value":"CL480948"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4170":{"preferredName":"Spiradenoma","code":"C4170","definitions":[{"definition":"A benign epithelial neoplasm with eccrine or apocrine differentiation, arising from the sweat glands. It usually presents as a solitary, well circumscribed, firm nodule in the face and upper trunk. It is characterized by the presence of basaloid cells forming nodules in the dermis. Cases of carcinoma arising from long standing spiradenomas have been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spiradenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8403/0"},{"name":"Legacy Concept Name","value":"Eccrine_Spiradenoma"},{"name":"Maps_To","value":"8403/0"},{"name":"Maps_To","value":"Eccrine spiradenoma"},{"name":"Maps_To","value":"Spiradenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334347"}]}}{"C5117":{"preferredName":"Carcinoma Arising from Spiradenoma","code":"C5117","definitions":[{"definition":"A very rare, aggressive carcinoma of the sweat glands arising from malignant transformation of a long standing spiradenoma. It usually grows in the upper extremities, lower extremities, trunk, and head and neck. It has the tendency to recur and metastasize most often to the lymph nodes, bones, and lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma Arising from Spiradenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma ex Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Eccrine Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm Arising from Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Spiradenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spiradenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8403/3"},{"name":"Legacy Concept Name","value":"Malignant_Eccrine_Spiradenoma"},{"name":"Maps_To","value":"8403/3"},{"name":"Maps_To","value":"Malignant eccrine spiradenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266063"}]}}{"C3760":{"preferredName":"Hidrocystoma","code":"C3760","definitions":[{"definition":"A benign cystic proliferation of the sweat glands with apocrine or eccrine differentiation. It usually presents as a dome-shaped, cystic papular or nodular lesion usually in the face and neck. It is a unilocular or mutlilocular lesion lined by an inner and an outer layer of epithelium. Complete excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidrocystoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hydrocystoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8404/0"},{"name":"Legacy Concept Name","value":"Hidrocystoma"},{"name":"Maps_To","value":"8404/0"},{"name":"Maps_To","value":"Hidrocystoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206672"}]}}{"C7565":{"preferredName":"Eccrine Hidrocystoma","code":"C7565","definitions":[{"definition":"A benign sweat gland cystic lesion that arises from the dermis. It is lined by a thin epithelial layer of cells with a slightly eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eccrine Hidrocystoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eccrine_Cystadenoma"},{"name":"Maps_To","value":"8404/0"},{"name":"Maps_To","value":"Eccrine cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704334"}]}}{"C4171":{"preferredName":"Hidradenoma Papilliferum","code":"C4171","definitions":[{"definition":"A benign neoplasm arising from the sweat glands. It presents as a slow growing cystic nodular lesion most often in the skin of the vulva and the perianal region. It is characterized by the presence of cystic and large papillary structures. The papillary structures contain connective tissue and are covered by two layers of epithelium. Complete excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hidradenoma Papilliferum","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Hidradenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8405/0"},{"name":"Legacy Concept Name","value":"Papillary_Hidradenoma_Hidradenoma_Papilliferum"},{"name":"Maps_To","value":"8405/0"},{"name":"Maps_To","value":"Hidradenoma papilliferum"},{"name":"Maps_To","value":"Papillary hidradenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334348"}]}}{"C4172":{"preferredName":"Syringocystadenoma Papilliferum","code":"C4172","definitions":[{"definition":"A benign adnexal neoplasm occurring during childhood or adolescence. It usually presents as a papular lesion or a plaque on the head and neck. It may arise in an organoid nevus such as sebaceous. It is characterized by an endophytic invagination of the epithelium into the dermis. There are dermal cystic spaces present, containing villous projections. Complete excision is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syringocystadenoma Papilliferum","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Syringadenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Papillary Syringocystadenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"SCAP","termGroup":"AB","termSource":"NCI"},{"termName":"Syringadenoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8406/0"},{"name":"Legacy Concept Name","value":"Papillary_Syringadenoma_Syringocystadenoma_Papilliferum"},{"name":"Maps_To","value":"8406/0"},{"name":"Maps_To","value":"Papillary syringadenoma"},{"name":"Maps_To","value":"Papillary syringocystadenoma"},{"name":"Maps_To","value":"Syringocystadenoma papilliferum"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0406803"}]}}{"C3761":{"preferredName":"Syringoma","code":"C3761","definitions":[{"definition":"A benign sweat gland neoplasm usually affecting the lower eyelids and upper cheeks. The lesions are papular and are usually numerous. Morphologically, there are nests, cords, and tubules of epithelial cells present, surrounded by a dense stroma in the reticular dermis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syringoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Syringoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8407/0"},{"name":"Legacy Concept Name","value":"Syringoma"},{"name":"Maps_To","value":"8407/0"},{"name":"Maps_To","value":"Syringoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206673"}]}}{"C7581":{"preferredName":"Microcystic Adnexal Carcinoma","code":"C7581","definitions":[{"definition":"A low grade adenocarcinoma with ductal differentiation, arising from the sweat glands. It presents as a scar usually in the face. It is characterized by the formation of small ducts and it frequently involves nerves and perineural spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microcystic Adnexal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"MAC","termGroup":"AB","termSource":"NCI"},{"termName":"Syringomatous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8407/3"},{"name":"Legacy Concept Name","value":"Microcystic_Adnexal_Carcinoma"},{"name":"Maps_To","value":"8407/3"},{"name":"Maps_To","value":"Microcystic adnexal carcinoma"},{"name":"Maps_To","value":"Sclerosing sweat duct carcinoma"},{"name":"Maps_To","value":"Syringomatous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346027"}]}}{"C27527":{"preferredName":"Tubular Apocrine Adenoma","code":"C27527","definitions":[{"definition":"A benign dermal adnexal neoplasm with apocrine differentiation.  It usually occurs in the scalp and has a female predilection.  It presents as an asymptomatic solitary nodule.  It is characterized by a lobular architecture.  The lobules are composed by tubular structures lined by epithelial cells.  There is no cytologic atypia or mitotic figures present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubular Apocrine Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Tubular Papillary Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8408/0"},{"name":"Legacy Concept Name","value":"Tubular_Apocrine_Adenoma"},{"name":"Maps_To","value":"8408/0"},{"name":"Maps_To","value":"Eccrine papillary adenoma"},{"name":"NCI_META_CUI","value":"CL448474"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334350"}]}}{"C27534":{"preferredName":"Digital Papillary Adenocarcinoma","code":"C27534","definitions":[{"definition":"An adenocarcinoma arising from the sweat glands. Most cases present as nodular lesions on the digits, usually in the hands. It is characterized by the presence of epithelial cells in the dermis forming nodules. Cystic structures containing papillary projections are also present. It may recur and metastasize, most commonly to the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Digital Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive Digital Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Aggressive Digital Papillary Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Digital Papillary Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Digital Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Digital Papillary Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Digital Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8408/1"},{"name":"ICD-O-3_Code","value":"8408/3"},{"name":"Legacy Concept Name","value":"Aggressive_Digital_Papillary_Adenocarcinoma"},{"name":"Maps_To","value":"8408/1"},{"name":"Maps_To","value":"8408/3"},{"name":"Maps_To","value":"Aggressive digital papillary adenoma"},{"name":"Maps_To","value":"Digital papillary adenocarcinoma"},{"name":"Maps_To","value":"Eccrine papillary adenocarcinoma"},{"name":"NCI_META_CUI","value":"CL053818"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266064"},{"name":"UMLS_CUI","value":"C1367789"}]}}{"C205462":{"preferredName":"Eccrine Poroma","code":"C205462","definitions":[{"definition":"A poroma with eccrine differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eccrine Poroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eccrine poroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C5560":{"preferredName":"Porocarcinoma","code":"C5560","definitions":[{"definition":"A carcinoma with eccrine differentiation arising from the sweat glands. It may arise de novo or as a malignant transformation of a pre-existing poroma. It usually grows in the legs, buttocks, feet, and trunk and usually presents as an ulcerative plaque. It is characterized by the presence of intraepidermal and dermal nests of malignant epithelial cells. It may recur after excision and metastasize to the lymph nodes and less frequently to distal anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Porocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermotropic Eccrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Eccrine Poroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8409/3"},{"name":"Legacy Concept Name","value":"Eccrine_Porocarcinoma"},{"name":"Maps_To","value":"8409/3"},{"name":"Maps_To","value":"Eccrine poroma, malignant"},{"name":"Maps_To","value":"Porocarcinoma"},{"name":"Maps_To","value":"Porocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266065"}]}}{"C4346":{"preferredName":"Skin Basal Cell Carcinoma with Sebaceous Differentiation","code":"C4346","definitions":[{"definition":"A basal cell carcinoma of the skin that is characterized by sebaceous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Basal Cell Carcinoma with Sebaceous Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Carcinoma with Sebaceous Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Basal Cell Epithelioma with Sebaceous Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Basosebaceous Epithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Epithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sebaceous_Epithelioma"},{"name":"Maps_To","value":"8410/0"},{"name":"Maps_To","value":"Sebaceous epithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334683"}]}}{"C4174":{"preferredName":"Sebaceous Adenoma","code":"C4174","definitions":[{"definition":"A benign adenoma neoplasm with sebaceous differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well circumscribed neoplasm arising from the sebaceous glands. It usually presents as a small yellowish tumor in the sun exposed skin of head and neck. It is characterized by the presence of sebaceous cells aggregates with a peripheral rim of basaloid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sebaceous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Gland Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Appendage Sebaceous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8410/0"},{"name":"Legacy Concept Name","value":"Sebaceous_Adenoma"},{"name":"Maps_To","value":"8410/0"},{"name":"Maps_To","value":"Sebaceous adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368816"}]}}{"C40310":{"preferredName":"Sebaceous Carcinoma","code":"C40310","definitions":[{"definition":"A malignant adenocarcinoma with sebaceous differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenocarcinoma with sebaceous differentiation. It presents as a painless mass and it may be multifocal. It grows in the ocular adnexae and in the skin of head and neck, trunk, genitals, and extremities. It is characterized by the presence of malignant cells with multivesicular and clear cytoplasm. It may recur and metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sebaceous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Sebaceous Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sebaceous Gland Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8410/3"},{"name":"Legacy Concept Name","value":"Sebaceous_Carcinoma"},{"name":"Maps_To","value":"8410/3"},{"name":"Maps_To","value":"Sebaceous adenocarcinoma"},{"name":"Maps_To","value":"Sebaceous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206684"}]}}{"C27255":{"preferredName":"Eccrine Carcinoma","code":"C27255","definitions":[{"definition":"A malignant carcinoma with eccrine differentiation arising from the sweat glands.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adenocarcinoma with eccrine differentiation arising from the sweat glands. It includes the following subtypes: ductal eccrine adenocarcinoma, papillary eccrine carcinoma, and eccrine porocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eccrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Eccrine Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Gland Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Eccrine Gland Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8413/3"},{"name":"Legacy Concept Name","value":"Eccrine_Adenocarcinoma"},{"name":"Maps_To","value":"8413/3"},{"name":"Maps_To","value":"Eccrine adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302864"}]}}{"C6088":{"preferredName":"Ceruminous Adenoma","code":"C6088","definitions":[{"definition":"A benign epithelial neoplasm derived from ceruminous glands in the external auditory canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign epithelial neoplasm derived from ceruminous glands in the external auditory canal. It presents as a grey mass covered by skin. It is characterized by a proliferation of glands composed of cells with abundant eosinophilic and granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceruminous Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ceruminoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ceruminous Adenoma of External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Ceruminous Adenoma of the External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"External Auditory Canal Ceruminous Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8420/0"},{"name":"Legacy Concept Name","value":"External_Auditory_Canal_Ceruminous_Adenoma"},{"name":"Maps_To","value":"8420/0"},{"name":"Maps_To","value":"Ceruminous adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334352"}]}}{"C4176":{"preferredName":"Ceruminous Adenocarcinoma","code":"C4176","definitions":[{"definition":"A malignant neoplasm derived from ceruminous glands in the external auditory canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating adenocarcinoma derived from ceruminous glands in the external auditory canal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceruminous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ceruminous Adenocarcinoma of the External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"External Auditory Canal Ceruminous Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8420/3"},{"name":"Legacy Concept Name","value":"Ceruminous_Adenocarcinoma"},{"name":"Maps_To","value":"8420/3"},{"name":"Maps_To","value":"Ceruminous adenocarcinoma"},{"name":"Maps_To","value":"Ceruminous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334353"}]}}{"C3772":{"preferredName":"Mucoepidermoid Carcinoma","code":"C3772","definitions":[{"definition":"A carcinoma morphologically characterized the presence of cuboidal mucous cells, goblet-like mucous cells, squamoid cells, cystic changes, and a fibrotic stromal formation. It can occur in several anatomic sites, including parotid gland, oral cavity, paranasal sinus, skin, breast, lung, larynx, and lacrimal ducts. It is classified as low or high grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucoepidermoid Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"MEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8430/1"},{"name":"ICD-O-3_Code","value":"8430/3"},{"name":"Legacy Concept Name","value":"Mucoepidermoid_Carcinoma"},{"name":"Maps_To","value":"8430/1"},{"name":"Maps_To","value":"Mucoepidermoid carcinoma"},{"name":"Maps_To","value":"Mucoepidermoid tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206694"}]}}{"C2972":{"preferredName":"Cystadenoma","code":"C2972","definitions":[{"definition":"A benign cystic epithelial neoplasm arising from glandular epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign or borderline cystic epithelial neoplasm arising from the glandular epithelium.  The epithelial cells line the cystic spaces which contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cystoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8440/0"},{"name":"Legacy Concept Name","value":"Cystadenoma"},{"name":"Maps_To","value":"8440/0"},{"name":"Maps_To","value":"Cystadenoma, NOS"},{"name":"Maps_To","value":"Cystoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010633"}]}}{"C2971":{"preferredName":"Cystadenocarcinoma","code":"C2971","definitions":[{"definition":"A malignant cystic epithelial neoplasm arising from glandular epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant cystic epithelial neoplasm arising from the glandular epithelium.  The malignant epithelial cells invade the stroma.  The cystic spaces contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8440/3"},{"name":"Legacy Concept Name","value":"Cystadenocarcinoma"},{"name":"Maps_To","value":"8440/3"},{"name":"Maps_To","value":"Cystadenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010631"}]}}{"C3783":{"preferredName":"Serous Cystadenoma","code":"C3783","definitions":[{"definition":"A serous neoplasm in which the cysts and papillae are lined by a single layer of cells without atypia, architectural complexity or invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Serous Cystoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8441/0"},{"name":"Legacy Concept Name","value":"Serous_Cystadenoma"},{"name":"Maps_To","value":"8441/0"},{"name":"Maps_To","value":"Serous cystadenoma, NOS"},{"name":"Maps_To","value":"Serous cystoma"},{"name":"Maps_To","value":"Serous microcystic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206709"}]}}{"C126449":{"preferredName":"Serous Tubal Intraepithelial Carcinoma","code":"C126449","definitions":[{"definition":"A non-invasive serous carcinoma arising from the fallopian tube.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Tubal Intraepithelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"STIC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serous tubal intraepithelial carcinoma"},{"name":"Maps_To","value":"Serous tubal intraepithelial carcinoma (STIC)"},{"name":"NCI_META_CUI","value":"CL504982"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3778":{"preferredName":"Serous Cystadenocarcinoma","code":"C3778","definitions":[{"definition":"A malignant serous cystic neoplasm usually involving the ovary or the pancreas. It is characterized by the presence of invasive malignant glandular epithelial cells which often form papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Serous Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8441/3"},{"name":"Legacy Concept Name","value":"Serous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8441/3"},{"name":"Maps_To","value":"Serous adenocarcinoma, NOS"},{"name":"Maps_To","value":"Serous carcinoma, NOS"},{"name":"Maps_To","value":"Serous cystadenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206701"}]}}{"C4177":{"preferredName":"Borderline Serous Cystadenoma","code":"C4177","definitions":[{"definition":"A serous cystic glandular epithelial neoplasm of low malignant potential. It is characterized by the presence of atypical or malignant glandular epithelial cells with an absence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Serous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Serous Tumor of Borderline Malignant Potential","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8442/1"},{"name":"Legacy Concept Name","value":"Borderline_Serous_Cystadenoma"},{"name":"Maps_To","value":"8442/1"},{"name":"Maps_To","value":"Atypical proliferating serous tumor"},{"name":"Maps_To","value":"Serous cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Serous tumor, NOS, of low malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334355"}]}}{"C65203":{"preferredName":"Clear Cell Papillary Cystadenoma","code":"C65203","definitions":[{"definition":"A benign cystic glandular epithelial neoplasm characterized by the presence of neoplastic clear or hobnail cells which form papillary structures. There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Papillary Cystadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8443/0"},{"name":"Legacy Concept Name","value":"Clear_Cell_Papillary_Cystadenoma"},{"name":"Maps_To","value":"8443/0"},{"name":"Maps_To","value":"Clear cell cystadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266068"}]}}{"C2974":{"preferredName":"Papillary Cystadenoma","code":"C2974","definitions":[{"definition":"A benign cystic epithelial neoplasm arising from glandular epithelium exhibiting papillary structures.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A serous or mucinous benign or low malignant potential cystic epithelial neoplasm. It is characterized by the presence of glandular epithelial cells forming papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Cystadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8450/0"},{"name":"Legacy Concept Name","value":"Papillary_Cystadenoma"},{"name":"Maps_To","value":"8450/0"},{"name":"Maps_To","value":"Papillary cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010636"}]}}{"C3777":{"preferredName":"Papillary Cystadenocarcinoma","code":"C3777","definitions":[{"definition":"A malignant cystic epithelial neoplasm arising from glandular epithelium exhibiting papillary structures.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant cystic serous or mucinous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8450/3"},{"name":"Legacy Concept Name","value":"Papillary_Cystadenocarcinoma"},{"name":"Maps_To","value":"8450/3"},{"name":"Maps_To","value":"Papillary cystadenocarcinoma, NOS"},{"name":"Maps_To","value":"Papillocystic adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206700"}]}}{"C4178":{"preferredName":"Borderline Papillary Cystadenoma","code":"C4178","definitions":[{"definition":"A serous or mucinous cystic glandular epithelial neoplasm of low malignant potential. It is characterized by the presence of atypical or malignant glandular epithelial cells forming papillary structures with an absence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Papillary Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8451/1"},{"name":"Legacy Concept Name","value":"Borderline_Papillary_Cystadenoma"},{"name":"Maps_To","value":"8451/1"},{"name":"Maps_To","value":"Papillary cystadenoma, borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334356"}]}}{"C201136":{"preferredName":"Solid Pseudopapillary Neoplasm","code":"C201136","definitions":[{"definition":"A low-grade malignant neoplasm that arises from the exocrine pancreas. Rare cases arising from ectopic pancreatic tissue in the ovary have also been described. It is characterized by the presence of uniform cells that form solid and pseudopapillary patterns, cystic changes, and hemorrhage. It usually presents as an encapsulated, solitary, and lobulated mass. It occurs predominantly in young women. Complete removal of the tumor is curative in the majority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Pseudopapillary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Frantz Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Solid Pseudopapillary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8452/1"},{"name":"Maps_To","value":"8452/1"},{"name":"Maps_To","value":"Solid pseudopapillary tumor"},{"name":"NCI_META_CUI","value":"CL1920478"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C37212":{"preferredName":"Solid Pseudopapillary Neoplasm of the Pancreas","code":"C37212","definitions":[{"definition":"A low-grade malignant neoplasm that arises from the exocrine pancreas. It is characterized by the presence of uniform cells that form solid and pseudopapillary patterns, cystic changes, and hemorrhage. Perineural invasion, vascular invasion, and invasion into surrounding tissues may be present. It usually presents as an encapsulated, solitary, and lobulated pancreatic mass. It is usually found incidentally during physical examination or it may present with abdominal discomfort and pain. It occurs predominantly in young women. Complete removal of the tumor is curative in the majority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Pseudopapillary Neoplasm of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Pseudopapillary Tumor of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Pseudopapillary_Tumor_of_the_Pancreas"},{"name":"Maps_To","value":"8452/3"},{"name":"Maps_To","value":"Solid pseudopapillary neoplasm of pancreas"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336030"}]}}{"C5728":{"preferredName":"Solid Pseudopapillary Carcinoma of the Pancreas","code":"C5728","definitions":[{"definition":"A malignant neoplasm arising from the exocrine pancreas. It occurs predominantly in young women. It is characterized by the presence of extensive necrosis and hemorrhage and is composed of polyhedral cells forming solid and pseudopapillary patterns. There is morphologic evidence of perineural invasion, vascular invasion, or extensive invasion into the surrounding tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Solid Pseudopapillary Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Solid Pseudopapillary Carcinoma of Pancreas","termGroup":"AQS","termSource":"NCI"},{"termName":"Solid Pseudopapillary Carcinoma of the Pancreas","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8452/3"},{"name":"Legacy Concept Name","value":"Solid_Pseudopapillary_Carcinoma_of_the_Pancreas"},{"name":"Maps_To","value":"8452/3"},{"name":"Maps_To","value":"Solid pseudopapillary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336029"}]}}{"C95514":{"preferredName":"Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type","code":"C95514","definitions":[{"definition":"A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells with abundant eosinophilic granular cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Oncocytic Papillary Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic IOPN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8453/0"},{"name":"Maps_To","value":"Intraductal papillary mucinous adenoma"},{"name":"Maps_To","value":"Intraductal papillary-mucinous adenoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2987197"}]}}{"C41251":{"preferredName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm, High Grade","code":"C41251","definitions":[{"definition":"A non-invasive pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that exhibit loss of polarity, nuclear stratification, hyperchromasia, and pleomorphism.  There is severe architectural atypia and frequent mitotic figures present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary Mucinous Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm, High-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Non-Invasive Intraductal Papillary-Mucinous Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8453/2"},{"name":"Legacy Concept Name","value":"Pancreatic_Non-Invasive_Intraductal_Papillary-Mucinous_Carcinoma"},{"name":"Maps_To","value":"8453/2"},{"name":"Maps_To","value":"Intraductal papillary mucinous neoplasm with high grade dysplasia"},{"name":"Maps_To","value":"Intraductal papillary-mucinous carcinoma, non-invasive"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3532881"}]}}{"C5726":{"preferredName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma","code":"C5726","definitions":[{"definition":"A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of a focal or multifocal invasive carcinomatous component.  The invasive carcinoma is either colloid or ductal adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary Mucinous Neoplasm with an Associated Invasive Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Invasive Intraductal Papillary-Mucinous Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8453/3"},{"name":"Legacy Concept Name","value":"Pancreatic_Invasive_Papillary-Mucinous_Carcinoma"},{"name":"Maps_To","value":"8453/3"},{"name":"Maps_To","value":"Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma"},{"name":"Maps_To","value":"Intraductal papillary mucinous neoplasm with an associated invasive carcinoma"},{"name":"Maps_To","value":"Intraductal papillary-mucinous carcinoma, invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518871"}]}}{"C45754":{"preferredName":"Cystic Tumor of the Atrioventricular Node","code":"C45754","definitions":[{"definition":"A multicystic tumor arising in the inferior interatrial septum in the region of the atrioventricular node. The vast majority of patients present with complete heart block and a minority with partial heart block. Sudden death is reported in approximately 10% of the cases. It is a morphologically benign tumor composed of cuboidal, transitional, or squamoid cells. The cells may also show sebaceous differentiation and originate from the endoderm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystic Tumor of the Atrioventricular Node","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Mesothelioma of Mahaim","termGroup":"SY","termSource":"NCI"},{"termName":"Cystic Tumor of Atrioventricular Node","termGroup":"SY","termSource":"NCI"},{"termName":"Endodermal Rest","termGroup":"SY","termSource":"NCI"},{"termName":"Intracardiac Endodermal Heterotopia","termGroup":"SY","termSource":"NCI"},{"termName":"Mesothelioma of Atrioventricular Node","termGroup":"SY","termSource":"NCI"},{"termName":"Tawarian Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8454/0"},{"name":"Legacy Concept Name","value":"Cystic_Tumor_of_Atrioventricular_Node"},{"name":"Maps_To","value":"8454/0"},{"name":"Maps_To","value":"Cystic tumor of atrio-ventricular node"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266075"}]}}{"C4180":{"preferredName":"Papillary Serous Cystadenoma","code":"C4180","definitions":[{"definition":"A serous benign or low malignant potential cystic epithelial neoplasm characterized by the presence of glandular epithelial cells forming papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Serous Cystadenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8460/0"},{"name":"Legacy Concept Name","value":"Papillary_Serous_Cystadenoma"},{"name":"Maps_To","value":"8460/0"},{"name":"Maps_To","value":"Papillary serous cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334358"}]}}{"C122585":{"preferredName":"Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma","code":"C122585","definitions":[{"definition":"A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low grade serous carcinoma"},{"name":"Maps_To","value":"Serous borderline tumor-micropapillary variant"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4055371"}]}}{"C8377":{"preferredName":"Papillary Serous Cystadenocarcinoma","code":"C8377","definitions":[{"definition":"A malignant cystic serous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive cancer that usually affects the uterus/endometrium, peritoneum, or ovary.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Papillary Serous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Serous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Serous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8460/3"},{"name":"Legacy Concept Name","value":"Papillary_Serous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8460/3"},{"name":"Maps_To","value":"Papillary serous adenocarcinoma"},{"name":"Maps_To","value":"Papillary serous cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334359"}]}}{"C6882":{"preferredName":"Micropapillary Serous Carcinoma","code":"C6882","definitions":[{"definition":"An adenocarcinoma usually arising from the ovary. It is characterized by the presence of complex micropapillary structures covered by round and cuboidal cells with a high nuclear to cytoplasmic ratio.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micropapillary Serous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Micropapillary Variant of Serous Borderline Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"MPSC","termGroup":"AB","termSource":"NCI"},{"termName":"SBT-MP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Micropapillary_Serous_Carcinoma"},{"name":"Maps_To","value":"8460/3"},{"name":"Maps_To","value":"Micropapillary serous carcinoma"},{"name":"Maps_To","value":"Serous borderline tumor, micropapillary variant"},{"name":"NCI_META_CUI","value":"CL017991"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4181":{"preferredName":"Serous Surface Papilloma","code":"C4181","definitions":[{"definition":"A non-invasive papillary serous epithelial neoplasm usually arising from the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Surface Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8461/0"},{"name":"Legacy Concept Name","value":"Serous_Surface_Papilloma"},{"name":"Maps_To","value":"8461/0"},{"name":"Maps_To","value":"Serous surface papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334360"}]}}{"C7695":{"preferredName":"Primary Peritoneal Serous Papillary Adenocarcinoma","code":"C7695","definitions":[{"definition":"A rare, serous papillary adenocarcinoma that arises from the lining of the peritoneum. It affects females. The clinical behavior and pathologic characteristics are similar to the serous papillary adenocarcinoma that arises from the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Peritoneal Serous Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Peritoneal Serous Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Serous Papillary Carcinoma of Peritoneum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Serous_Papillary_Carcinoma_of_Peritoneum"},{"name":"Maps_To","value":"8461/3"},{"name":"Maps_To","value":"Primary serous papillary carcinoma of peritoneum"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368918"}]}}{"C4182":{"preferredName":"Serous Surface Papillary Carcinoma","code":"C4182","definitions":[{"definition":"An invasive serous adenocarcinoma arising from the ovary and rarely the peritoneum. Morphologically, it may be a well, moderately, or poorly differentiated neoplasm. It is characterized by a papillary growth pattern often associated with the presence of psammoma bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Surface Papillary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8461/3"},{"name":"Legacy Concept Name","value":"Serous_Surface_Papillary_Carcinoma"},{"name":"Maps_To","value":"8461/3"},{"name":"Maps_To","value":"Serous surface papillary carcinoma"},{"name":"NCI_META_CUI","value":"CL512816"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4183":{"preferredName":"Borderline Papillary Serous Cystadenoma","code":"C4183","definitions":[{"definition":"A low malignant potential cystic serous epithelial neoplasm arising from the ovary. Cases with identical morphology have been described arising from the peritoneum as well. It is characterized by an atypical epithelial proliferation and a papillary growth pattern. There is no evidence of destructive stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Papillary Serous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Serous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Papillary Serous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignant Potential Papillary Serous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Serous Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Serous Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8462/1"},{"name":"Legacy Concept Name","value":"Borderline_Papillary_Serous_Cystadenoma"},{"name":"Maps_To","value":"8462/1"},{"name":"Maps_To","value":"Atypical proliferative papillary serous tumor"},{"name":"Maps_To","value":"Papillary serous cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Papillary serous tumor of low malignant potential"},{"name":"Maps_To","value":"Serous papillary cystic tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334362"}]}}{"C7315":{"preferredName":"Borderline Ovarian Serous Surface Papillary Tumor","code":"C7315","definitions":[{"definition":"A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of papillary proliferations that contain atypical serous epithelial cells in the outer surface of the ovary.  There is no evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Serous Surface Papillary Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Borderline Ovarian Serous Surface Papillary Tumor","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8463/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Serous_Papillary_Neoplasm"},{"name":"Maps_To","value":"8463/1"},{"name":"Maps_To","value":"Serous surface papillary tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511269"}]}}{"C2973":{"preferredName":"Mucinous Cystadenoma","code":"C2973","definitions":[{"definition":"A benign or low malignant potential cystic epithelial neoplasm composed of cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","type":"DEFINITION","source":"NCI"},{"definition":"A benign, cystic epithelial neoplasm comprising cells containing intracytoplasmic mucin.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mucinous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucinous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Cystoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/0"},{"name":"ICD-O-3_Code","value":"8480/0"},{"name":"Legacy Concept Name","value":"Mucinous_Cystadenoma"},{"name":"Maps_To","value":"8470/0"},{"name":"Maps_To","value":"Mucinous adenoma"},{"name":"Maps_To","value":"Mucinous cystadenoma, NOS"},{"name":"Maps_To","value":"Mucinous cystoma"},{"name":"Maps_To","value":"Pseudomucinous cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010635"}]}}{"C6883":{"preferredName":"Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia","code":"C6883","definitions":[{"definition":"A non-invasive mucinous cystic neoplasm that arises from the pancreas and is characterized by the presence of moderate dysplasia.  The neoplastic columnar mucin-producing epithelial cells form papillary projections or crypt-like invaginations. There is cellular pseudostratification and mitotic activity present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/0"},{"name":"ICD-O-3_Code","value":"8470/1"},{"name":"ICD-O-3_Code","value":"8472/1"},{"name":"Legacy Concept Name","value":"Pancreatic_Mucinous_Cystic_Neoplasm_with_Moderate_Dysplasia"},{"name":"Maps_To","value":"8470/0"},{"name":"Maps_To","value":"Mucinous cystic tumor with moderate dysplasia"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2063870"}]}}{"C41245":{"preferredName":"Pancreatic Non-Invasive Mucinous Cystadenocarcinoma","code":"C41245","definitions":[{"definition":"A non-invasive malignant cystic epithelial neoplasm arising from the exocrine pancreas. It occurs almost exclusively in women. Small tumors are usually found incidentally. Larger tumors usually produce symptoms related to compression of the adjacent structures. It is characterized by the presence of columnar, mucin-producing epithelial cells which often form papillary projections with irregular branching and budding. There is cellular stratification, severe dysplasia, and high mitotic activity present. Complete surgical removal is usually associated with an excellent prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Non-Invasive Mucinous Cystadenocarcinoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/2"},{"name":"Legacy Concept Name","value":"Pancreatic_Non-Invasive_Mucinous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8470/2"},{"name":"Maps_To","value":"Mucinous cystadenocarcinoma, non-invasive"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518874"}]}}{"C95493":{"preferredName":"Pancreatic Mucinous-Cystic Neoplasm, High Grade","code":"C95493","definitions":[{"definition":"A non-invasive mucinous cystic neoplasm that arises from the pancreas and is characterized by the presence of severe dysplasia.  The neoplastic columnar mucin-producing epithelial cells form papillae with irregular branching and budding.  There is nuclear stratification, prominent nucleoli, and cellular pleomorphism.  Mitotic activity is present and the mitoses may be atypical.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mucinous-Cystic Neoplasm, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Mucinous Cystic Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mucinous-Cystic Neoplasm with High Grade Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mucinous-Cystic Neoplasm, High-Grade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/2"},{"name":"Maps_To","value":"8470/2"},{"name":"Maps_To","value":"Mucinous cystic neoplasm with high grade dysplasia"},{"name":"Maps_To","value":"Mucinous cystic neoplasm with high-grade dysplasia"},{"name":"NCI_META_CUI","value":"CL497910"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3776":{"preferredName":"Mucinous Cystadenocarcinoma","code":"C3776","definitions":[{"definition":"An invasive adenocarcinoma characterized by cystic changes and the presence of malignant glandular cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pseudomucinous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pseudomucinous Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8470/3"},{"name":"Legacy Concept Name","value":"Mucinous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8470/3"},{"name":"Maps_To","value":"Mucinous cystadenocarcinoma, NOS"},{"name":"Maps_To","value":"Pseudomucinous adenocarcinoma"},{"name":"Maps_To","value":"Pseudomucinous cystadenocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206699"}]}}{"C4184":{"preferredName":"Papillary Mucinous Cystadenoma","code":"C4184","definitions":[{"definition":"A usually benign and less often low malignant potential cystic epithelial neoplasm composed of cells which contain intracytoplasmic mucin. It is characterized by the presence of papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Mucinous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8471/0"},{"name":"Legacy Concept Name","value":"Papillary_Mucinous_Cystadenoma"},{"name":"Maps_To","value":"8471/0"},{"name":"Maps_To","value":"Papillary mucinous cystadenoma, NOS"},{"name":"Maps_To","value":"Papillary pseudomucinous cystadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334363"}]}}{"C65204":{"preferredName":"Papillary Mucinous Cystadenocarcinoma","code":"C65204","definitions":[{"definition":"An invasive adenocarcinoma characterized by cystic changes, papillary growth pattern, and the presence of malignant glandular cells which contain intracytoplasmic mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Mucinous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8471/3"},{"name":"Legacy Concept Name","value":"Papillary_Mucinous_Cystadenocarcinoma"},{"name":"Maps_To","value":"8471/3"},{"name":"Maps_To","value":"Papillary mucinous cystadenocarcinoma"},{"name":"Maps_To","value":"Papillary pseudomucinous cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334364"}]}}{"C201978":{"preferredName":"Pulmonary Mucinous Cystic Tumor of Borderline Malignancy","code":"C201978","definitions":[{"definition":"A very rare, non-invasive epithelial neoplasm that arises from the lung. It is composed of multilocular cysts filled with mucus. The cysts are lined with columnar mucinous epithelium. Focal cellular atypia is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Mucinous Cystic Tumor of Borderline Malignancy","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Mucinous Cystic Tumor of Borderline Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Mucinous Cystic Tumor of Low or Borderline Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Mucinous Cystic Tumor of Low or Borderline Malignancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8472/1"},{"name":"Maps_To","value":"Mucinous cystic tumor of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334365"}]}}{"C4186":{"preferredName":"Borderline Papillary Mucinous Cystadenoma","code":"C4186","definitions":[{"definition":"A low malignant potential cystic epithelial neoplasm usually arising from the ovary. It is composed of glandular cells with intracytoplasmic mucin. It is characterized by an atypical epithelial proliferation and a papillary growth pattern. There is no evidence of destructive stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Papillary Mucinous Cystadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Mucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Malignancy Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Mucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Papillary Pseudomucinous Cystadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Mucinous Neoplasm of Low Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Mucinous Tumor of Low Malignant Potential","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8473/1"},{"name":"Legacy Concept Name","value":"Borderline_Papillary_Mucinous_Cystadenoma"},{"name":"Maps_To","value":"8473/1"},{"name":"Maps_To","value":"Papillary mucinous cystadenoma, borderline malignancy"},{"name":"Maps_To","value":"Papillary mucinous tumor of low malignant potential"},{"name":"Maps_To","value":"Papillary pseudomucinous cystadenoma, borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334366"}]}}{"C7281":{"preferredName":"Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor","code":"C7281","definitions":[{"definition":"A low grade, non-invasive ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"ICD-O-3_Code","value":"8323/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Mixed_Epithelial_Neoplasm"},{"name":"Maps_To","value":"Seromucinous borderline tumor"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332596"}]}}{"C40090":{"preferredName":"Ovarian Seromucinous Carcinoma","code":"C40090","definitions":[{"definition":"A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Seromucinous Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Mixed_Epithelial_Tumor"},{"name":"Maps_To","value":"Seromucinous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279392"}]}}{"C42598":{"preferredName":"Low Grade Appendix Mucinous Neoplasm","code":"C42598","definitions":[{"definition":"A well differentiated mucinous neoplasm that arises from the appendix.  It is characterized by slow growth and it is associated with the development of pseudomyxoma peritonei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Appendix Mucinous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Appendix Well Differentiated Mucinous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LAMN","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Appendiceal Mucinous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Appendiceal Mucinous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Appendix Mucinous Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8480/1"},{"name":"Legacy Concept Name","value":"Low_Grade_Appendix_Mucinous_Neoplasm"},{"name":"Maps_To","value":"8480/1"},{"name":"Maps_To","value":"Low grade appendiceal mucinous neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708747"}]}}{"C26712":{"preferredName":"Mucinous Adenocarcinoma","code":"C26712","definitions":[{"definition":"A type of cancer that begins in cells that line certain internal organs and produce mucin (the main component of mucus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An adenocarcinoma comprising neoplastic glandular cells containing intracytoplasmic mucin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An invasive adenocarcinoma composed of malignant glandular cells that contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Colloid Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Colloid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gelatinous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gelatinous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucoid Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucous Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucous Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8480/3"},{"name":"Legacy Concept Name","value":"Mucinous_Adenocarcinoma"},{"name":"Maps_To","value":"8480/3"},{"name":"Maps_To","value":"Colloid adenocarcinoma"},{"name":"Maps_To","value":"Colloid carcinoma"},{"name":"Maps_To","value":"Gelatinous adenocarcinoma"},{"name":"Maps_To","value":"Gelatinous carcinoma"},{"name":"Maps_To","value":"Mucinous adenocarcinoma"},{"name":"Maps_To","value":"Mucinous carcinoma"},{"name":"Maps_To","value":"Mucoid adenocarcinoma"},{"name":"Maps_To","value":"Mucoid carcinoma"},{"name":"Maps_To","value":"Mucous adenocarcinoma"},{"name":"Maps_To","value":"Mucous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007130"}]}}{"C3345":{"preferredName":"Pseudomyxoma Peritonei","code":"C3345","definitions":[{"definition":"A build-up of mucus in the peritoneal cavity. The mucus may come from ruptured ovarian cysts, from the appendix, or from other abdominal tissues. Mucus-secreting cells may attach to the peritoneal lining and continue to secrete mucus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually well differentiated mucinous adenocarcinoma of the peritoneum.  The majority of cases represent tumor spread from a primary low grade mucinous neoplasm of the appendix.  Cases of pseudomyxoma peritonei associated with mucinous adenocarcinomas of the gallbladder, stomach, colon, rectum, pancreas, lung, breast, and fallopian tubes have also been reported.  In the past, the ovary has been considered as a common primary site associated with pseudomyxoma peritonei.  However, there is recent evidence based on immunohistochemistry and molecular genetic analysis suggesting that most cases of pseudomyxoma peritonei probably represent metastasis from an appendiceal and not ovarian primary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pseudomyxoma Peritonei","termGroup":"PT","termSource":"NCI"},{"termName":"Gelatinous Ascites","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Ascites","termGroup":"SY","termSource":"NCI"},{"termName":"Mucinous Carcinoma Peritonei","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoma Peritonei","termGroup":"SY","termSource":"NCI"},{"termName":"Peritoneal Cavity Pseudomyxoma Peritonei","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8480/6"},{"name":"Legacy Concept Name","value":"Pseudomyxoma_Peritonei"},{"name":"Maps_To","value":"8480/6"},{"name":"Maps_To","value":"Pseudomyxoma peritonei"},{"name":"Maps_To","value":"Pseudomyxoma peritonei with unknown primary site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0033822"}]}}{"C27825":{"preferredName":"Mucin-Producing Carcinoma","code":"C27825","definitions":[{"definition":"A carcinoma that produces mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucin-Producing Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucin-Secreting_Carcinoma"},{"name":"Maps_To","value":"8481/3"},{"name":"Maps_To","value":"Mucin-producing carcinoma"},{"name":"Maps_To","value":"Mucin-secreting carcinoma"},{"name":"NCI_META_CUI","value":"CL054990"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27379":{"preferredName":"Mucin-Producing Adenocarcinoma","code":"C27379","definitions":[{"definition":"An invasive adenocarcinoma composed of malignant glandular cells which produce mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucin-Producing Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8481/3"},{"name":"Legacy Concept Name","value":"Mucin-Secreting_Adenocarcinoma"},{"name":"Maps_To","value":"8481/3"},{"name":"Maps_To","value":"Mucin-producing adenocarcinoma"},{"name":"Maps_To","value":"Mucin-secreting adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334368"}]}}{"C66953":{"preferredName":"Mucinous Adenocarcinoma, Endocervical Type","code":"C66953","definitions":[{"definition":"A mucinous adenocarcinoma characterized by the presence of malignant glandular cells which resemble the endocervical epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Adenocarcinoma, Endocervical Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Tue Jul 20 15:15:35 EDT 2021 - See 'Cervical Mucinous Adenocarcinoma, Not Otherwise Specified(C40202)'"},{"name":"ICD-O-3_Code","value":"8482/3"},{"name":"Legacy Concept Name","value":"Mucinous_Adenocarcinoma_Endocervical_Type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"OLD_PARENT","value":"C127907"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3774":{"preferredName":"Signet Ring Cell Adenocarcinoma","code":"C3774","definitions":[{"definition":"A highly malignant type of cancer typically found in glandular cells that line the digestive organs. The cells resemble signet rings when examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Signet Ring Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Signet Ring Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Signet-Ring Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8490/3"},{"name":"Legacy Concept Name","value":"Signet_Ring_Cell_Carcinoma"},{"name":"Maps_To","value":"8490/3"},{"name":"Maps_To","value":"Signet ring cell adenocarcinoma"},{"name":"Maps_To","value":"Signet ring cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206696"}]}}{"C66717":{"preferredName":"Metastatic Signet Ring Cell Adenocarcinoma","code":"C66717","definitions":[{"definition":"A signet ring cell carcinoma that has spread from its original site of growth to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Signet Ring Cell Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Metastatic Signet Ring Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Signet-Ring Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8490/6"},{"name":"Legacy Concept Name","value":"Metastatic_Signet_Ring_Cell_Carcinoma"},{"name":"Maps_To","value":"8490/6"},{"name":"Maps_To","value":"Metastatic signet ring cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881801"}]}}{"C3153":{"preferredName":"Krukenberg Tumor","code":"C3153","definitions":[{"definition":"A tumor in the ovary caused by the spread of stomach cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Metastatic signet-ring cell carcinoma in the ovary. The primary site is the gastrointestinal tract or breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Krukenberg Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Krukenberg Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Krukenberg_Tumor"},{"name":"Maps_To","value":"8490/6"},{"name":"Maps_To","value":"Krukenberg tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0022790"}]}}{"C2924":{"preferredName":"Breast Ductal Carcinoma In Situ","code":"C2924","definitions":[{"definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","type":"DEFINITION","source":"NCI"},{"definition":"A noninvasive condition in which abnormal cells are found in the lining of a breast duct. The abnormal cells have not spread outside the duct to other tissues in the breast. In some cases, ductal carcinoma in situ may become invasive cancer and spread to other tissues, although it is not known at this time how to predict which lesions will become invasive.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Ductal Carcinoma In Situ, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS","termGroup":"AB","termSource":"NCI"},{"termName":"DCIS, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma In Situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma In Situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Adenocarcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Adenocarcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8500/2"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_of_the_Breast"},{"name":"Maps_To","value":"8500/2"},{"name":"Maps_To","value":"DCIS, NOS"},{"name":"Maps_To","value":"Ductal carcinoma in situ, NOS"},{"name":"Maps_To","value":"Intraductal adenocarcinoma, noninfiltrating, NOS"},{"name":"Maps_To","value":"Intraductal carcinoma in situ of left breast"},{"name":"Maps_To","value":"Intraductal carcinoma in situ of right breast"},{"name":"Maps_To","value":"Intraductal carcinoma in situ of unspecified breast"},{"name":"Maps_To","value":"Intraductal carcinoma, noninfiltrating, NOS"},{"name":"Maps_To","value":"Intraductal carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007124"}]}}{"C7949":{"preferredName":"Breast Ductal Carcinoma In Situ, High Grade","code":"C7949","definitions":[{"definition":"A condition in which cells that look very different from normal cells under a microscope are found in the lining of a breast duct. There may also be areas of dead cells in the abnormal tissue. The abnormal cells have not spread outside the duct to other tissues in the breast. Grade III ductal carcinoma in situ tends to grow more quickly than grade I or grade II ductal carcinoma in situ and is more likely to come back or spread to other tissues. Also called grade III DCIS, high-grade DCIS, and high-grade ductal carcinoma in situ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"DCIS Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"DIN 3","termGroup":"AB","termSource":"NCI"},{"termName":"Ductal Intraepithelial Neoplasia, Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Ductal Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade DCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade DCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Ductal Carcinoma In Situ of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8501/2"},{"name":"Legacy Concept Name","value":"High-Grade_Ductal_Carcinoma_In_Situ_of_the_Breast"},{"name":"Maps_To","value":"8500/2"},{"name":"Maps_To","value":"DIN 3"},{"name":"Maps_To","value":"Ductal intraepithelial neoplasia 3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334002"}]}}{"C4017":{"preferredName":"Breast Ductal Carcinoma","code":"C4017","definitions":[{"definition":"A breast carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive breast carcinoma of no special type. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.","type":"DEFINITION","source":"NCI"},{"definition":"The most common type of breast cancer. It begins in the cells that line the milk ducts in the breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Ductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Duct Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ductal_Breast_Carcinoma"},{"name":"Maps_To","value":"8500/3"},{"name":"Maps_To","value":"Duct adenocarcinoma, NOS"},{"name":"Maps_To","value":"Duct carcinoma, NOS"},{"name":"Maps_To","value":"Duct cell carcinoma"},{"name":"Maps_To","value":"Ductal carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1527349"}]}}{"C4194":{"preferredName":"Invasive Breast Carcinoma of No Special Type","code":"C4194","definitions":[{"definition":"A term that refers to a large and heterogeneous group of invasive breast carcinomas that cannot be classified morphologically as any of the special histological types. (WHO 2019)","type":"DEFINITION","source":"NCI"},{"definition":"The most common type of invasive breast cancer. It starts in the cells that line the milk ducts in the breast, grows outside the ducts, and often spreads to the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Invasive Breast Carcinoma of No Special Type","termGroup":"PT","termSource":"NCI"},{"termName":"IBC NST","termGroup":"AB","termSource":"NCI"},{"termName":"Infiltrating Ductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, No Specific Type","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal Carcinoma, NST","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8500/3"},{"name":"ICD-O-3_Code","value":"8521/3"},{"name":"Legacy Concept Name","value":"Invasive_Ductal_Carcinoma_not_Otherwise_Specified"},{"name":"Maps_To","value":"8500/3"},{"name":"Maps_To","value":"Infiltrating duct adenocarcinoma"},{"name":"Maps_To","value":"Infiltrating duct carcinoma, NOS"},{"name":"Maps_To","value":"Infiltrating ductular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1134719"}]}}{"C4188":{"preferredName":"Comedo-Type Adenocarcinoma","code":"C4188","definitions":[{"definition":"A high grade carcinoma characterized by the presence of comedo-type tumor cell necrosis in which the necrotic areas are surrounded by a solid proliferation of malignant pleomorphic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Comedo-Type Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Comedocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8501/3"},{"name":"Legacy Concept Name","value":"Comedocarcinoma"},{"name":"Maps_To","value":"8501/3"},{"name":"Maps_To","value":"Comedocarcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334370"}]}}{"C4189":{"preferredName":"Breast Secretory Carcinoma","code":"C4189","definitions":[{"definition":"A rare, low grade invasive adenocarcinoma of the breast characterized by the presence of cells that secrete milk-like material. Morphologically, it usually appears as a circumscribed lesion, composed of cystic spaces, tubular structures, and solid areas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Secretory Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cystic Hypersecretory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cystic Hypersecretory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cystic Hypersecretory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Cystic Hypersecretory Duct Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Cystic Hypersecretory Duct Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Secretory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Secretory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Secretory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Secretory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8502/3"},{"name":"ICD-O-3_Code","value":"8508/3"},{"name":"Legacy Concept Name","value":"Secretory_Breast_Carcinoma"},{"name":"Maps_To","value":"8508/3"},{"name":"Maps_To","value":"Cystic hypersecretory carcinoma"},{"name":"Maps_To","value":"Juvenile carcinoma of breast"},{"name":"Maps_To","value":"Secretory carcinoma"},{"name":"Maps_To","value":"Secretory carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334371"}]}}{"C96877":{"preferredName":"Gallbladder Intracholecystic Papillary Neoplasm, Low Grade","code":"C96877","definitions":[{"definition":"An intracholecystic papillary neoplasm that arises from the epithelium of the gallbladder. It is characterized by the presence of mild epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gallbladder Intracholecystic Papillary Neoplasm, Low Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Gallbladder ICPN with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracholecystic Papillary (Tubular) Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracholecystic Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracholecystic Papillary Neoplasm, Low-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Intracystic/Intaductal Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"AQS","termSource":"NCI"},{"termName":"Intracystic Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Intracystic papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273093"}]}}{"C96807":{"preferredName":"Bile Duct Intraductal Papillary Neoplasm, Low Grade","code":"C96807","definitions":[{"definition":"An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts. It is characterized by the presence of mild epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Intraductal Papillary Neoplasm, Low Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm, Low-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct IPN with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Neoplasm with Low Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273049"}]}}{"C3785":{"preferredName":"Intraductal Papilloma","code":"C3785","definitions":[{"definition":"A benign (not cancer), wart-like growth in a milk duct of the breast. It is usually found close to the nipple and may cause a discharge from the nipple. It may also cause pain and a lump in the breast that can be felt. It usually affects women aged 35-55 years. Having a single papilloma does not increase the risk of breast cancer. When there are multiple intraductal papillomas, they are usually found farther from the nipple. There may not be a nipple discharge and the papillomas may not be felt. Having multiple intraductal papillomas may increase the risk of breast cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intraluminal papillary epithelial neoplasm arising within the ducts. Representative examples are the intraductal breast papilloma and the salivary gland intraductal papilloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraductal Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Duct Adenoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Ductal Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Legacy Concept Name","value":"Intraductal_Papilloma"},{"name":"Maps_To","value":"8503/0"},{"name":"Maps_To","value":"Duct adenoma, NOS"},{"name":"Maps_To","value":"Ductal papilloma"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with intermediate grade neoplasia"},{"name":"Maps_To","value":"Intraductal papilloma"},{"name":"Maps_To","value":"Intraglandular papillary neoplasm with low grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206713"}]}}{"C96809":{"preferredName":"Bile Duct Intraductal Papillary Neoplasm, High Grade","code":"C96809","definitions":[{"definition":"An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts. It is characterized by the presence of severe epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bile Duct Intraductal Papillary Neoplasm, High Grade","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Intraductal Papillary Neoplasm, High-Grade","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct IPN with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bile Duct Papillary Neoplasm with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Neoplasm with High Grade Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/2"},{"name":"Maps_To","value":"8503/2"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with high grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273051"}]}}{"C4190":{"preferredName":"Breast Papillary Ductal Carcinoma In Situ","code":"C4190","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Papillary Ductal Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intracystic Papillary Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Breast Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Papillary DCIS","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Papillary Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Intraductal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Papillary Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary DCIS","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Ductal Carcinoma In Situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/2"},{"name":"Legacy Concept Name","value":"Intraductal_Papillary_Breast_Carcinoma"},{"name":"Maps_To","value":"8503/2"},{"name":"Maps_To","value":"DCIS, papillary"},{"name":"Maps_To","value":"Ductal carcinoma in situ, papillary"},{"name":"Maps_To","value":"Intraductal papillary adenocarcinoma, NOS"},{"name":"Maps_To","value":"Intraductal papillary carcinoma"},{"name":"Maps_To","value":"Noninfiltrating intraductal papillary adenocarcinoma"},{"name":"Maps_To","value":"Noninfiltrating intraductal papillary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334372"}]}}{"C7439":{"preferredName":"Breast Papillary Ductal Carcinoma In Situ with Invasion","code":"C7439","definitions":[{"definition":"A breast adenocarcinoma characterized by the presence of intraductal and invasive papillary carcinomatous components.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Papillary Ductal Carcinoma In Situ with Invasion","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal Papillary Adenocarcinoma with Invasion","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papillary Adenocarcinoma with Invasion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/3"},{"name":"Legacy Concept Name","value":"Intraductal_Papillary_Adenocarcinoma_with_Invasion"},{"name":"Maps_To","value":"8503/3"},{"name":"Maps_To","value":"Intraductal papillary adenocarcinoma with invasion"},{"name":"Maps_To","value":"Intraductal papillary neoplasm with associated invasive carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334373"}]}}{"C7438":{"preferredName":"Invasive Papillary Adenocarcinoma","code":"C7438","definitions":[{"definition":"A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Papillary Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Papillary Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Papillary_Adenocarcinoma"},{"name":"Maps_To","value":"8503/3"},{"name":"Maps_To","value":"Infiltrating and papillary adenocarcinoma"},{"name":"Maps_To","value":"Infiltrating papillary adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321863"}]}}{"C3863":{"preferredName":"Breast Intraductal Papilloma","code":"C3863","definitions":[{"definition":"A benign (not cancer), wart-like growth in a milk duct of the breast. It is usually found close to the nipple and may cause a discharge from the nipple. It may also cause pain and a lump in the breast that can be felt. It usually affects women aged 35-55 years. Having a single papilloma does not increase the risk of breast cancer. When there are multiple intraductal breast papillomas, they are usually found farther from the nipple. There may not be a nipple discharge and the papillomas may not be felt. Having multiple intraductal breast papillomas may increase the risk of breast cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign papillary neoplasm that arises anywhere in the ductal system of the breast. It is characterized by the presence of fibrovascular structures lined by benign epithelial and myoepithelial proliferations.  Intraductal breast papillomas are classified as central, when they arise in large ducts, or peripheral, when they arise in the terminal ductal lobular units.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Intraductal Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intracystic Papilloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Breast Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Duct Papilloma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Duct Papilloma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracystic Papilloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intraductal Breast Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papilloma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Papilloma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Papilloma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Papilloma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8504/0"},{"name":"Legacy Concept Name","value":"Intracystic_Papilloma"},{"name":"Legacy Concept Name","value":"Intraductal_Breast_Papilloma"},{"name":"Maps_To","value":"8504/0"},{"name":"Maps_To","value":"Intracystic papillary adenoma"},{"name":"Maps_To","value":"Intracystic papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0238034"}]}}{"C7645":{"preferredName":"Breast Intracystic Papillary Carcinoma","code":"C7645","definitions":[{"definition":"An intraductal breast carcinoma characterized by a papillary growth within a large cystic duct. There is no evidence of invasion of the breast parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Intracystic Papillary Carcinoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Intracystic Breast Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intracystic Papillary Adenocarcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intracystic Papillary Breast Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Noninfiltrating Intracystic Breast Carcinoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8504/2"},{"name":"ICD-O-3_Code","value":"8504/3"},{"name":"Legacy Concept Name","value":"Intracystic_Papillary_Carcinoma"},{"name":"Maps_To","value":"8504/2"},{"name":"Maps_To","value":"8504/3"},{"name":"Maps_To","value":"Intracystic carcinoma, NOS"},{"name":"Maps_To","value":"Intracystic papillary adenocarcinoma"},{"name":"Maps_To","value":"Noninfiltrating intracystic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334376"}]}}{"C7363":{"preferredName":"Intraductal Papillomatosis","code":"C7363","definitions":[{"definition":"A neoplastic process characterized by the presence of multiple intraductal papillomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraductal Papillomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8505/0"},{"name":"Legacy Concept Name","value":"Intraductal_Papillomatosis"},{"name":"Maps_To","value":"8505/0"},{"name":"Maps_To","value":"Intraductal papillomatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334377"}]}}{"C4192":{"preferredName":"Nipple Adenoma","code":"C4192","definitions":[{"definition":"A benign epithelial neoplasm arising from the nipple. Signs and symptoms include serous or sanguineous nipple discharge and nipple erosion. It is characterized by the presence of aggregates of small tubules replacing the nipple stroma. The tubules are lined by epithelial and myoepithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nipple Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoma of Nipple","termGroup":"SY","termSource":"NCI"},{"termName":"Adenoma of the Nipple","termGroup":"SY","termSource":"NCI"},{"termName":"Erosive Nipple Adenomatosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Subareolar Duct Papillomatosis","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8506/0"},{"name":"Legacy Concept Name","value":"Nipple_Adenoma"},{"name":"Maps_To","value":"8506/0"},{"name":"Maps_To","value":"Adenoma of nipple"},{"name":"Maps_To","value":"Subareolar duct papillomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334378"}]}}{"C5139":{"preferredName":"Breast Micropapillary Ductal Carcinoma In Situ","code":"C5139","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Micropapillary Ductal Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal Micropapillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Micropapillary DCIS","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary DCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary DCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Micropapillary Ductal Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Micropapillary Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Micropapillary Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8507/2"},{"name":"Legacy Concept Name","value":"Intraductal_Micropapillary_Breast_Carcinoma"},{"name":"Maps_To","value":"8507/2"},{"name":"Maps_To","value":"Intraductal micropapillary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334249"}]}}{"C36084":{"preferredName":"Invasive Breast Micropapillary Carcinoma","code":"C36084","definitions":[{"definition":"An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Micropapillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Micropapillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Micropapillary_Breast_Carcinoma"},{"name":"Maps_To","value":"8507/3"},{"name":"Maps_To","value":"Invasive micropapillary carcinoma"},{"name":"Maps_To","value":"Invasive micropapillary carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3838947"}]}}{"C6870":{"preferredName":"Breast Solid Papillary Carcinoma","code":"C6870","definitions":[{"definition":"A well circumscribed, low grade neoplasm that arises from the breast.  It is characterized by the presence of sheets of malignant epithelial cells that are supported by fibrovascular structures.  When there is an invasive component present, it is usually a mucinous carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Solid Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Papillary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Solid Papillary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Papillary_Carcinoma_of_the_Breast"},{"name":"Maps_To","value":"Solid papillary carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336027"}]}}{"C66850":{"preferredName":"Invasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma","code":"C66850","definitions":[{"definition":"A papillary carcinoma of the thyroid gland which is encapsulated and resembles an encapsulated follicular neoplasm. Capsular invasion is present. The malignant follicular cells display the nuclear features that characterize the papillary adenocarcinomas of the thyroid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Variant Thyroid Gland Papillary Carcinoma, Encapsulated Subtype with Invasion","termGroup":"SY","termSource":"NCI"},{"termName":"IEFVPTC","termGroup":"AB","termSource":"NCI"},{"termName":"Invasive Encapsulated Follicular Variant Papillary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8343/3"},{"name":"Legacy Concept Name","value":"Encapsulated_Thyroid_Gland_Papillary_Carcinoma"},{"name":"Maps_To","value":"8509/3"},{"name":"Maps_To","value":"Encapsulated papillary carcinoma with invasion"},{"name":"Maps_To","value":"Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)"},{"name":"Maps_To","value":"Solid papillary carcinoma with invasion"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1880498"}]}}{"C66718":{"preferredName":"Medullary Carcinoma, Not Otherwise Specified","code":"C66718","definitions":[{"definition":"A term referring to medullary carcinomas which can develop in various anatomic sites such as the thyroid gland, breast, colon, rectum, and small intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medullary Carcinoma, NOS","termGroup":"AQS","termSource":"NCI"},{"termName":"Medullary Carcinoma, Not Otherwise Specified","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8510/3"},{"name":"Legacy Concept Name","value":"Medullary_Carcinoma_NOS"},{"name":"Maps_To","value":"8510/3"},{"name":"Maps_To","value":"Medullary carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206693"}]}}{"C9119":{"preferredName":"Breast Medullary Carcinoma","code":"C9119","definitions":[{"definition":"A rare type of breast cancer that often can be treated successfully. It is marked by lymphocytes (a type of white blood cell) in and around the tumor that can be seen when viewed under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An infiltrating breast carcinoma with a relatively favorable prognosis.  It is an uncommon carcinoma, accounting for less than 1% of all infiltrating breast carcinomas.  It is well circumscribed, with soft cut surface and often of considerable size.  Microscopically, the predominant growth pattern is syncytial with broad anastomosing bands or sheets of malignant cells.  The malignant cells are round with abundant cytoplasm and vesicular nuclei.  The sheets of malignant cells are associated with a marked lymphoplasmacytic infiltrate.  Glandular or tubular structures are absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Medullary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Medullary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Medullary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Medullary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Medullary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Breast Carcinoma with Lymphoid Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8512/3"},{"name":"Legacy Concept Name","value":"Medullary_Breast_Carcinoma"},{"name":"Maps_To","value":"8512/3"},{"name":"Maps_To","value":"Medullary carcinoma with lymphoid stroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0860580"}]}}{"C66719":{"preferredName":"Breast Atypical Medullary Carcinoma","code":"C66719","definitions":[{"definition":"An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Atypical Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Medullary Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Ductal Breast Carcinoma with Medullary Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8513/3"},{"name":"Legacy Concept Name","value":"Atypical_Medullary_Breast_Carcinoma"},{"name":"Maps_To","value":"8513/3"},{"name":"Maps_To","value":"Atypical medullary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879758"}]}}{"C7362":{"preferredName":"Breast Scirrhous Carcinoma","code":"C7362","definitions":[{"definition":"An infiltrating ductal breast carcinoma associated with stromal fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Scirrhous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of Breast with Fibrotic Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of the Breast with Fibrotic Stroma","termGroup":"SY","termSource":"NCI"},{"termName":"Scirrhous Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Scirrhous Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Scirrhous Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8514/3"},{"name":"Legacy Concept Name","value":"Scirrhous_Carcinoma_of_the_Breast"},{"name":"Maps_To","value":"8514/3"},{"name":"Maps_To","value":"Duct carcinoma, desmoplastic type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346151"}]}}{"C137839":{"preferredName":"Breast Pleomorphic Lobular Carcinoma In Situ","code":"C137839","definitions":[{"definition":"Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Pleomorphic Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Invasive Pleomorphic Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"pLCIS","termGroup":"AB","termSource":"NCI"},{"termName":"Pleomorphic Lobular Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Pleomorphic Lobular Carcinoma in Situ of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Maps_To","value":"Lobular carcinoma in situ, pleomorphic"},{"name":"Maps_To","value":"Pleomorphic lobular carcinoma in situ"},{"name":"NCI_META_CUI","value":"CL524883"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4018":{"preferredName":"Breast Lobular Carcinoma In Situ","code":"C4018","definitions":[{"definition":"A condition in which abnormal cells are found in the lobules of the breast. Lobular carcinoma in situ seldom becomes invasive cancer; however, having it in one breast increases the risk of developing breast cancer in either breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"LCIS","termGroup":"AB","termSource":"NCI"},{"termName":"Lobular Breast Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Ca in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Ca in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma In Situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma In Situ of the Breast (LCIS)","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8520/2"},{"name":"Legacy Concept Name","value":"Lobular_Carcinoma_in_situ_of_the_Breast"},{"name":"Maps_To","value":"8520/2"},{"name":"Maps_To","value":"LCIS, NOS"},{"name":"Maps_To","value":"Lobular carcinoma in situ, NOS"},{"name":"Maps_To","value":"Lobular carcinoma, noninfiltrating"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279563"}]}}{"C3771":{"preferredName":"Breast Lobular Carcinoma","code":"C3771","definitions":[{"definition":"An adenocarcinoma of the breast arising from the lobules.  This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that begins in the lobules (the glands that make milk) of the breast. Lobular carcinoma in situ (LCIS) is a condition in which abnormal cells are found only in the lobules. When cancer has spread from the lobules to surrounding tissues, it is invasive lobular carcinoma. LCIS does not become invasive lobular carcinoma very often, but having LCIS in one breast increases the risk of developing invasive cancer in either breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lobular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8520/3"},{"name":"Legacy Concept Name","value":"Lobular_Breast_Carcinoma"},{"name":"Maps_To","value":"8520/3"},{"name":"Maps_To","value":"Lobular adenocarcinoma"},{"name":"Maps_To","value":"Lobular carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206692"}]}}{"C7950":{"preferredName":"Invasive Breast Lobular Carcinoma","code":"C7950","definitions":[{"definition":"An infiltrating lobular adenocarcinoma of the breast.  The malignant cells lack cohesion and are arranged individually or in a linear manner (Indian files), or as narrow trabeculae within the stroma.  The malignant cells are usually smaller than those of ductal carcinoma, are less pleomorphic, and have fewer mitotic figures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Classic Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Lobular Carcinoma, Classic Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Lobular_Breast_Carcinoma"},{"name":"Maps_To","value":"8520/3"},{"name":"Maps_To","value":"Infiltrating lobular carcinoma, NOS"},{"name":"Maps_To","value":"Invasive lobular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279565"}]}}{"C4195":{"preferredName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma In Situ","code":"C4195","definitions":[{"definition":"The co-existence of ductal and lobular carcinoma in situ in the breast, without evidence of stromal invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"DCIS and LCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS and LCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal and Lobular Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal and Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal and Lobular Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ with Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ with Lobular Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Carcinoma and Lobular Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal and Non-Infiltrating Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal with Non-Infiltrating Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal with Non-Infiltrating Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal and Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal and Non-Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Breast Carcinoma with Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma with Non-Invasive Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal Carcinoma with Non-Invasive Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Ductal with Non-Invasive Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8522/2"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_and_Lobular_Carcinoma_in_situ"},{"name":"Maps_To","value":"8522/2"},{"name":"Maps_To","value":"Intraductal carcinoma and lobular carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334383"}]}}{"C7690":{"preferredName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma","code":"C7690","definitions":[{"definition":"A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ and Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraductal_and_Lobular_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"Intraductal and lobular carcinoma"},{"name":"NCI_META_CUI","value":"CL028597"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6939":{"preferredName":"Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma","code":"C6939","definitions":[{"definition":"A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"DCIS and ILC","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS and Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Breast Carcinoma In Situ and Invasive Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ and Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma and ILC","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ductal_Carcinoma_in_situ_and_Infiltrating_Lobular_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"8524/3"},{"name":"Maps_To","value":"Infiltrating lobular carcinoma and ductal carcinoma in situ"},{"name":"Maps_To","value":"Infiltrating lobular mixed with other types of carcinoma"},{"name":"NCI_META_CUI","value":"CL018755"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C5160":{"preferredName":"Breast Mixed Ductal and Lobular Carcinoma","code":"C5160","definitions":[{"definition":"A breast carcinoma characterized by the presence of a lobular and a ductal component. The ductal component comprises less than 50 percent of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Mixed Ductal and Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal and Lobular Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Lobular and Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Lobular_and_Ductal_Breast_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"Lobular and ductal carcinoma"},{"name":"NCI_META_CUI","value":"CL007210"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7688":{"preferredName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma","code":"C7688","definitions":[{"definition":"An invasive ductal breast carcinoma associated with a lobular carcinomatous component. The lobular carcinomatous component may be in situ or invasive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Duct and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal and Lobular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8522/3"},{"name":"Legacy Concept Name","value":"Invasive_Ductal_and_Lobular_Carcinoma"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"8523/3"},{"name":"Maps_To","value":"Infiltrating duct and lobular carcinoma"},{"name":"Maps_To","value":"Infiltrating duct mixed with other types of carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334277"}]}}{"C7689":{"preferredName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma In Situ","code":"C7689","definitions":[{"definition":"An invasive ductal breast carcinoma associated with an in situ lobular carcinomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Ductal Carcinoma and Lobular Carcinoma In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Ductal and Lobular Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Ductal and Lobular Carcinoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"LCIS and Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ and Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lobular Carcinoma in situ and Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Ductal_and_Lobular_Carcinoma_in_situ"},{"name":"Maps_To","value":"8522/3"},{"name":"Maps_To","value":"Infiltrating duct and lobular carcinoma in situ"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334384"}]}}{"C35702":{"preferredName":"Salivary Gland Polymorphous Adenocarcinoma","code":"C35702","definitions":[{"definition":"A low grade malignant epithelial neoplasm arising from the salivary gland. It usually arises from the oral cavity, with approximately 60% of the cases involving the palate. The most common presenting sign is a painless mass in the palate. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern. There is a variety of morphologic patterns which may be present within an individual tumor, including lobular, papillary, papillary-cystic, cribriform, and trabecular pattern. It usually has a favorable clinical outcome and a low metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Polymorphous Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Salivary Gland PmA","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Polymorphous Adenocarcinoma, Classical Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Polymorphous Low Grade Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Terminal Duct Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8525/3"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Polymorphous_Low-Grade_Adenocarcinoma"},{"name":"Maps_To","value":"8525/3"},{"name":"Maps_To","value":"Polymorphous adenocarcinoma"},{"name":"Maps_To","value":"Polymorphous low grade adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335907"}]}}{"C4001":{"preferredName":"Breast Inflammatory Carcinoma","code":"C4001","definitions":[{"definition":"A type of breast cancer in which the breast looks red and swollen and feels warm. The skin of the breast may also show the pitted appearance called peau d'orange (like the skin of an orange). The redness and warmth occur because the cancer cells block the lymph vessels in the skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Inflammatory Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Inflammatory Breast Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mastitis Carcinomatosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8530/3"},{"name":"Legacy Concept Name","value":"Inflammatory_Breast_Carcinoma"},{"name":"Maps_To","value":"8530/3"},{"name":"Maps_To","value":"Inflammatory carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278601"}]}}{"C47857":{"preferredName":"Breast Paget Disease","code":"C47857","definitions":[{"definition":"A malignant neoplasm in which there is infiltration of the skin overlying the breast by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It is almost always associated with an intraductal or invasive ductal carcinoma of the breast. The clinical features include focal skin reddening, and eczema. Retraction of the nipple may sometimes occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Mammary Paget Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Mammary Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8540/3"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_of_the_Breast"},{"name":"Maps_To","value":"8540/3"},{"name":"Maps_To","value":"Paget disease of breast"},{"name":"Maps_To","value":"Paget disease, mammary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030185"}]}}{"C7951":{"preferredName":"Breast Paget Disease with Invasive Ductal Carcinoma","code":"C7951","definitions":[{"definition":"Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease with Invasive Ductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Paget Disease and Infiltrating Duct Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease of the Breast with Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Infiltrating Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Infiltrating Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Invasive Ductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Invasive Ductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast with Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast with Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast with Infiltrating Ductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast with Invasive Ductal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8541/3"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_of_the_Breast_with_Invasive_Ductal_Carcinoma"},{"name":"Maps_To","value":"8541/3"},{"name":"Maps_To","value":"Paget disease and infiltrating duct carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279567"}]}}{"C3302":{"preferredName":"Extramammary Paget Disease","code":"C3302","definitions":[{"definition":"A malignant neoplasm in which there is infiltration of the skin by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It may affect the anus, penis, scrotum, and vulva.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extramammary Paget Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"EMPD","termGroup":"AB","termSource":"NCI"},{"termName":"Extramammary Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease Extramammary","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Disease, Extramammary","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Skin Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8542/3"},{"name":"Legacy Concept Name","value":"Extramammary_Paget_s_Disease"},{"name":"Maps_To","value":"8542/3"},{"name":"Maps_To","value":"Paget disease, extramammary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030186"}]}}{"C4019":{"preferredName":"Breast Paget Disease and Intraductal Carcinoma","code":"C4019","definitions":[{"definition":"Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Paget Disease and Intraductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Paget Disease and Intraductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Intraductal Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease and Intraductal Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of Breast with Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Disease of the Breast with Intraductal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8543/3"},{"name":"Legacy Concept Name","value":"Paget_s_Disease_and_Intraductal_Carcinoma_of_the_Breast"},{"name":"Maps_To","value":"8543/3"},{"name":"Maps_To","value":"Paget disease and intraductal carcinoma of breast"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279566"}]}}{"C4196":{"preferredName":"Acinar Cell Adenoma","code":"C4196","definitions":[{"definition":"A benign glandular epithelial neoplasm comprising secretory cells forming acinar patterns.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign glandular epithelial neoplasm consisting of secretory cells forming acinar patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acinar Cell Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinic Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8550/0"},{"name":"Legacy Concept Name","value":"Acinar_Cell_Adenoma"},{"name":"Maps_To","value":"8550/0"},{"name":"Maps_To","value":"Acinar adenoma"},{"name":"Maps_To","value":"Acinar cell adenoma"},{"name":"Maps_To","value":"Acinic cell adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334389"}]}}{"C3768":{"preferredName":"Acinar Cell Carcinoma","code":"C3768","definitions":[{"definition":"A malignant glandular epithelial neoplasm comprising secretory cells forming acinar patterns.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acinar Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinic Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinic Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8550/3"},{"name":"Legacy Concept Name","value":"Acinar_Cell_Carcinoma"},{"name":"Maps_To","value":"8550/1"},{"name":"Maps_To","value":"Acinar adenocarcinoma"},{"name":"Maps_To","value":"Acinar carcinoma"},{"name":"Maps_To","value":"Acinar cell carcinoma"},{"name":"Maps_To","value":"Acinic cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206685"}]}}{"C5727":{"preferredName":"Pancreatic Acinar Cell Cystadenocarcinoma","code":"C5727","definitions":[{"definition":"A cystic adenocarcinoma characterized by the presence of relatively uniform neoplastic cells which produce pancreatic enzymes and are arranged in acinar patterns. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It usually has an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Acinar Cell Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acinar Cell Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Cell Cystadenocarcinoma of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Acinar Cell Cystadenocarcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8551/3"},{"name":"Legacy Concept Name","value":"Pancreatic_Acinar_Cell_Cystadenocarcinoma"},{"name":"Maps_To","value":"8551/3"},{"name":"Maps_To","value":"Acinar cell cystadenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266087"}]}}{"C95458":{"preferredName":"Pancreatic Mixed Acinar-Ductal Carcinoma","code":"C95458","definitions":[{"definition":"A carcinoma that arises from the pancreas showing either extensive mucin accumulation and acinar neoplastic cells or a mixture of columnar or signet-ring cells and acinar neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mixed Acinar-Ductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Acinar-Ductal Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8552/3"},{"name":"Maps_To","value":"8552/3"},{"name":"Maps_To","value":"Mixed acinar-ductal carcinoma"},{"name":"Maps_To","value":"Mixed acinar-endocrine-ductal carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472609"}]}}{"C45602":{"preferredName":"Bronchial Mixed Squamous Cell and Glandular Papilloma","code":"C45602","definitions":[{"definition":"An exceedingly rare benign endobronchial neoplasm characterized by the presence of fibrovascular cores which are lined by both squamous and glandular epithelium. Patients present with obstructive symptoms. Complete resection is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bronchial Mixed Squamous Cell and Glandular Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Mixed Squamous and Glandular Papilloma","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Mixed Squamous Cell and Glandular Papilloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8560/0"},{"name":"Legacy Concept Name","value":"Lung_Mixed_Squamous_and_Glandular_Papilloma"},{"name":"Maps_To","value":"8560/0"},{"name":"Maps_To","value":"Mixed squamous cell and glandular papilloma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1314684"}]}}{"C3727":{"preferredName":"Adenosquamous Carcinoma","code":"C3727","definitions":[{"definition":"A type of cancer that contains two types of cells: squamous cells (thin, flat cells that line certain organs) and gland-like cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An epithelial neoplasm composed of malignant glandular and malignant squamous cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosquamous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Epidermoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Epidermoid Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Squamous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Adenocarcinoma and Squamous Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8560/3"},{"name":"Legacy Concept Name","value":"Adenosquamous_Carcinoma"},{"name":"Maps_To","value":"8560/3"},{"name":"Maps_To","value":"Adenosquamous carcinoma"},{"name":"Maps_To","value":"Mixed adenocarcinoma and epidermoid carcinoma"},{"name":"Maps_To","value":"Mixed adenocarcinoma and squamous cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206623"}]}}{"C2854":{"preferredName":"Warthin Tumor","code":"C2854","definitions":[{"definition":"An adenoma characterized by an oncocytic, often papillary, epithelial component, dense lymphoid stroma, and cystic spaces. It occurs primarily in the parotid gland, and is the second most common benign parotid salivary gland tumor. A strong association with smoking has been reported. It typically presents as a painless swelling in the lower portion of the parotid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Warthin Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adenolymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Cystadenoma Lymphomatosum","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Warthin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Warthin's Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8561/0"},{"name":"Legacy Concept Name","value":"Warthin_s_Tumor"},{"name":"Maps_To","value":"8561/0"},{"name":"Maps_To","value":"Adenolymphoma"},{"name":"Maps_To","value":"Papillary cystadenoma lymphomatosum"},{"name":"Maps_To","value":"Warthin tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001429"}]}}{"C4199":{"preferredName":"Epithelial-Myoepithelial Carcinoma","code":"C4199","definitions":[{"definition":"A malignant neoplasm which occurs mostly in the major salivary glands (most frequently in the parotid gland), but also in the minor salivary glands of the oral mucosa and the tracheobronchial tree. It is characterized by the presence of ductal structures which are lined by an inner layer of cuboidal epithelial-type cells and an outer layer of myoepithelial cells with clear or eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelial-Myoepithelial Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8562/3"},{"name":"Legacy Concept Name","value":"Epithelial-Myoepithelial_Carcinoma"},{"name":"Maps_To","value":"8562/3"},{"name":"Maps_To","value":"Epithelial-myoepithelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334392"}]}}{"C4200":{"preferredName":"Adenocarcinoma with Squamous Metaplasia","code":"C4200","definitions":[{"definition":"A malignant neoplasm arising from glandular cells that includes focal or extensive areas of squamous metaplasia.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An invasive adenocarcinoma characterized by the presence of focal or extensive transformation of malignant glandular cells to squamous epithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Squamous Metaplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoacanthoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8570/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Squamous_Metaplasia"},{"name":"Maps_To","value":"8570/3"},{"name":"Maps_To","value":"Adenoacanthoma"},{"name":"Maps_To","value":"Adenocarcinoma with squamous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334393"}]}}{"C7685":{"preferredName":"Adenocarcinoma with Cartilaginous Metaplasia","code":"C7685","definitions":[{"definition":"An adenocarcinoma characterized by the presence of cartilaginous metaplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Cartilaginous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Cartilaginous_Metaplasia"},{"name":"Maps_To","value":"8571/3"},{"name":"Maps_To","value":"Adenocarcinoma with cartilaginous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377647"}]}}{"C7684":{"preferredName":"Adenocarcinoma with Osseous Metaplasia","code":"C7684","definitions":[{"definition":"An adenocarcinoma characterized by the presence of osseous metaplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Osseous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Osseous_Metaplasia"},{"name":"Maps_To","value":"8571/3"},{"name":"Maps_To","value":"Adenocarcinoma with osseous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377648"}]}}{"C7683":{"preferredName":"Adenocarcinoma with Cartilaginous and Osseous Metaplasia","code":"C7683","definitions":[{"definition":"An invasive adenocarcinoma characterized by focal or extensive cartilage and/or bone formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Cartilaginous and Osseous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8571/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Cartilaginous_and_Osseous_Metaplasia"},{"name":"Maps_To","value":"8571/3"},{"name":"Maps_To","value":"Adenocarcinoma with cartilaginous and osseous metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334394"}]}}{"C4201":{"preferredName":"Adenocarcinoma with Spindle Cell Metaplasia","code":"C4201","definitions":[{"definition":"An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to spindle-shaped cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Spindle Cell Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8572/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Spindle_Cell_Metaplasia"},{"name":"Maps_To","value":"8572/3"},{"name":"Maps_To","value":"Adenocarcinoma with spindle cell metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334395"}]}}{"C4202":{"preferredName":"Adenocarcinoma with Apocrine Metaplasia","code":"C4202","definitions":[{"definition":"An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to cells with abundant, usually granular eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Apocrine Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8573/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Apocrine_Metaplasia"},{"name":"Maps_To","value":"8573/3"},{"name":"Maps_To","value":"Adenocarcinoma with apocrine metaplasia"},{"name":"Maps_To","value":"Carcinoma with apocrine metaplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334396"}]}}{"C66745":{"preferredName":"Adenocarcinoma with Neuroendocrine Differentiation","code":"C66745","definitions":[{"definition":"An invasive adenocarcinoma characterized by the presence of focal or extensive neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenocarcinoma with Neuroendocrine Differentiation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8574/3"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_with_Neuroendocrine_Differentiation"},{"name":"Maps_To","value":"8574/3"},{"name":"Maps_To","value":"Adenocarcinoma with neuroendocrine differentiation"},{"name":"Maps_To","value":"Carcinoma with neuroendocrine differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266088"}]}}{"C27949":{"preferredName":"Metaplastic Carcinoma","code":"C27949","definitions":[{"definition":"A general term used to describe cancer that begins in cells that have changed into another cell type (for example, a squamous cell of the esophagus changing to resemble a cell of the stomach).  In some cases, metaplastic changes alone may mean there is an increased chance of cancer developing at the site.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cells type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metaplastic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8575/3"},{"name":"Legacy Concept Name","value":"Metaplastic_Carcinoma"},{"name":"Maps_To","value":"8575/3"},{"name":"Maps_To","value":"Metaplastic carcinoma of no special type"},{"name":"Maps_To","value":"Metaplastic carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266089"}]}}{"C66950":{"preferredName":"Hepatoid Adenocarcinoma","code":"C66950","definitions":[{"definition":"An adenocarcinoma with morphologic characteristics similar to hepatocellular carcinoma, arising from an anatomic site other than the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatoid Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatoid Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8576/3"},{"name":"Legacy Concept Name","value":"Hepatoid_Carcinoma"},{"name":"Maps_To","value":"8576/3"},{"name":"Maps_To","value":"Hepatoid adenocarcinoma"},{"name":"Maps_To","value":"Hepatoid carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266090"}]}}{"C66746":{"preferredName":"Benign Thymoma","code":"C66746","definitions":[{"definition":"A thymoma that is completely surrounded by a capsule, without evidence of capsular invasion, infiltration of the surrounding tissues, and metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Thymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8580/0"},{"name":"Legacy Concept Name","value":"Benign_Thymoma"},{"name":"Maps_To","value":"8580/0"},{"name":"Maps_To","value":"Thymoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040101"}]}}{"C7612":{"preferredName":"Malignant Thymoma","code":"C7612","definitions":[{"definition":"A malignant neoplasm of the thymus, originating from epithelial thymus cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thymoma that has an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.  Although any morphologic subtype of thymoma may eventually have a malignant clinical course, this term is most often associated with thymoma types B3 and C.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8580/3"},{"name":"Legacy Concept Name","value":"Malignant_Thymoma"},{"name":"Maps_To","value":"8580/3"},{"name":"Maps_To","value":"Thymoma, malignant, NOS"},{"name":"NCI_META_CUI","value":"CL371354"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6454":{"preferredName":"Thymoma Type A","code":"C6454","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of spindle and/or oval neoplastic epithelial cells. Lymphocytic infiltration is minimal or absent. It may be associated with myasthenia gravis or pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. Approximately 20% of the cases occur as stage II or stage III tumors. Type A thymoma generally behaves as a benign tumor and the overall survival is reported to be 100% at 5 and 10 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type A","termGroup":"PT","termSource":"NCI"},{"termName":"Medullary Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8581/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_A"},{"name":"Maps_To","value":"8581/1"},{"name":"Maps_To","value":"Thymoma, medullary, NOS"},{"name":"Maps_To","value":"Thymoma, spindle cell, NOS"},{"name":"Maps_To","value":"Thymoma, type A, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266091"}]}}{"C7999":{"preferredName":"Malignant Type A Thymoma","code":"C7999","definitions":[{"definition":"A type A thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type A Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8581/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_A_Thymoma"},{"name":"Maps_To","value":"8581/3"},{"name":"Maps_To","value":"Thymoma, medullary, malignant"},{"name":"Maps_To","value":"Thymoma, spindle cell, malignant"},{"name":"Maps_To","value":"Thymoma, type A"},{"name":"Maps_To","value":"Thymoma, type A, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279707"}]}}{"C6885":{"preferredName":"Thymoma Type AB","code":"C6885","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of a lymphocyte-poor component similar to that seen in type A thymoma and a lymphocyte-rich component which contains neoplastic small polygonal epithelial cells. It may be associated with myasthenia gravis and pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II or stage III tumors. The overall survival is reported to be 80-100% at 5 and 10 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type AB","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Type Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8582/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_AB"},{"name":"Maps_To","value":"8582/1"},{"name":"Maps_To","value":"Thymoma, mixed type, NOS"},{"name":"Maps_To","value":"Thymoma, type AB, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266092"}]}}{"C6886":{"preferredName":"Malignant Type AB Thymoma","code":"C6886","definitions":[{"definition":"A type AB thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type AB Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8582/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_AB_Thymoma"},{"name":"Maps_To","value":"8582/3"},{"name":"Maps_To","value":"Thymoma, mixed type, malignant"},{"name":"Maps_To","value":"Thymoma, type AB"},{"name":"Maps_To","value":"Thymoma, type AB, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266093"}]}}{"C6887":{"preferredName":"Thymoma Type B1","code":"C6887","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of expanded areas which resemble the normal thymic cortex. The neoplastic epithelial cells are small and scant and there is a dense T-lymphocytic component present. Areas of medullary differentiation with or without Hassall's corpuscles are also present. It may be associated with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia. It has a low grade malignant potential. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type B1","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphocyte-Predominant Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Rich Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Organoid Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Predominantly Cortical Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8583/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_B1"},{"name":"Maps_To","value":"8583/1"},{"name":"Maps_To","value":"Thymoma, lymphocyte-rich, NOS"},{"name":"Maps_To","value":"Thymoma, lymphocytic, NOS"},{"name":"Maps_To","value":"Thymoma, organoid, NOS"},{"name":"Maps_To","value":"Thymoma, predominantly cortical, NOS"},{"name":"Maps_To","value":"Thymoma, type B1, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266094"}]}}{"C7996":{"preferredName":"Malignant Type B1 Thymoma","code":"C7996","definitions":[{"definition":"A type B1 thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type B1 Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8583/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_B1_Thymoma"},{"name":"Maps_To","value":"8583/3"},{"name":"Maps_To","value":"Thymoma, lymphocyte-rich, malignant"},{"name":"Maps_To","value":"Thymoma, lymphocytic, malignant"},{"name":"Maps_To","value":"Thymoma, organoid, malignant"},{"name":"Maps_To","value":"Thymoma, predominantly cortical, malignant"},{"name":"Maps_To","value":"Thymoma, type B1"},{"name":"Maps_To","value":"Thymoma, type B1, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279704"}]}}{"C6888":{"preferredName":"Thymoma Type B2","code":"C6888","definitions":[{"definition":"A thymic epithelial neoplasm characterized by the presence of neoplastic large, polygonal epithelial cells with large vesicular nuclei and prominent nucleoli. The neoplastic cells are arranged around perivascular spaces and along septa. Immature T-lymphocytes are also present. It may be associated with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia. It is a tumor of moderate malignancy. The majority of cases occur in the anterior mediastinum as Masaoka stage I, stage II, or stage III tumors. Metastatic, stage IV tumors occur less frequently.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type B2","termGroup":"PT","termSource":"NCI"},{"termName":"Cortical Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Polygonal Cell Thymoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8584/1"},{"name":"Legacy Concept Name","value":"Thymoma_Type_B2"},{"name":"Maps_To","value":"8584/1"},{"name":"Maps_To","value":"Thymoma, cortical, NOS"},{"name":"Maps_To","value":"Thymoma, type B2, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266095"}]}}{"C6889":{"preferredName":"Malignant Type B2 Thymoma","code":"C6889","definitions":[{"definition":"A type B2 thymoma which is characterized by an aggressive clinical course (capsular invasion, infiltration of the surrounding tissues) and can metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Type B2 Thymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8584/3"},{"name":"Legacy Concept Name","value":"Malignant_Type_B2_Thymoma"},{"name":"Maps_To","value":"8584/3"},{"name":"Maps_To","value":"Thymoma, cortical, malignant"},{"name":"Maps_To","value":"Thymoma, type B2"},{"name":"Maps_To","value":"Thymoma, type B2, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266096"}]}}{"C7997":{"preferredName":"Thymoma Type B3","code":"C7997","definitions":[{"definition":"Also known as well-differentiated thymic carcinoma, atypical thymoma, or epithelial thymoma, this type of thymoma displays morphologic characteristics of a well-differentiated carcinoma.  The majority of cases occur in the anterior mediastinum as Masaoka stage II or stage III tumors.  It is almost always invasive, it recurs frequently, and metastasizes in approximately 20% of the cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymoma Type B3","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Malignant Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thymoma Type B3","termGroup":"SY","termSource":"NCI"},{"termName":"Squamoid Thymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well Differentiated Thymic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Thymic Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8585/1"},{"name":"ICD-O-3_Code","value":"8585/3"},{"name":"Legacy Concept Name","value":"Thymoma_Type_B3"},{"name":"Maps_To","value":"8585/1"},{"name":"Maps_To","value":"8585/3"},{"name":"Maps_To","value":"Thymoma, atypical, malignant"},{"name":"Maps_To","value":"Thymoma, atypical, NOS"},{"name":"Maps_To","value":"Thymoma, epithelial, malignant"},{"name":"Maps_To","value":"Thymoma, epithelial, NOS"},{"name":"Maps_To","value":"Thymoma, type B3"},{"name":"Maps_To","value":"Thymoma, type B3, malignant"},{"name":"Maps_To","value":"Thymoma, type B3, NOS"},{"name":"Maps_To","value":"Well differentiated thymic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279705"}]}}{"C7569":{"preferredName":"Thymic Carcinoma","code":"C7569","definitions":[{"definition":"A diverse group of carcinomas of the thymus gland, previously known as thymoma type C.  It includes morphologic variants derived from purely epithelial cells, as well as from cells with neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of thymus gland cancer. It usually spreads, has a high risk of recurrence, and has a poor survival rate. Thymic carcinoma is divided into subtypes, depending on the types of cells in which the cancer began.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thymic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Thymic Carcinoma (Excluding Well Differentiated Thymic Carcinoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Thymic Carcinoma Excluding Well Differentiated Thymic Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thymoma Type C","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8586/3"},{"name":"Legacy Concept Name","value":"Thymoma_Type_C"},{"name":"Maps_To","value":"8586/3"},{"name":"Maps_To","value":"Thymic carcinoma, NOS"},{"name":"Maps_To","value":"Thymoma, type C"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205969"}]}}{"C53595":{"preferredName":"Branchioma","code":"C53595","definitions":[{"definition":"A rare, benign, well-circumscribed or encapsulated tumor that arises from the neck and occurs in adults. It is characterized by the presence of spindle cells, epithelial islands, and adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Branchioma","termGroup":"PT","termSource":"NCI"},{"termName":"Biphenotypic Branchioma","termGroup":"SY","termSource":"NCI"},{"termName":"Branchial Anlage Mixed Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Ectopic Hamartomatous Thymoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Neck Branchioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8587/0"},{"name":"Legacy Concept Name","value":"Ectopic_Hamartomatous_Thymoma"},{"name":"Maps_To","value":"8587/0"},{"name":"Maps_To","value":"Ectopic hamartomatous thymoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266098"}]}}{"C46105":{"preferredName":"Thyroid Gland Spindle Epithelial Tumor with Thymus-Like Elements","code":"C46105","definitions":[{"definition":"A rare, slow growing malignant tumor of the thyroid gland arising from intrathyroidal thymic tissue. It is characterized by a lobulated architectural pattern and the presence of a biphasic cellular population composed of spindle epithelial cells and glandular cells.  A small number of cases are composed exclusively of spindle epithelial cells or glandular cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Spindle Epithelial Tumor with Thymus-Like Elements","termGroup":"PT","termSource":"NCI"},{"termName":"SETTLE","termGroup":"AB","termSource":"NCI"},{"termName":"Spindle Epithelial Tumor with Thymus-Like Elements","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8588/3"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Spindle_Cell_Tumor_with_Thymus-Like_Differentiation"},{"name":"Maps_To","value":"8588/3"},{"name":"Maps_To","value":"SETTLE"},{"name":"Maps_To","value":"Spindle epithelial tumor with thymus-like differentiation"},{"name":"Maps_To","value":"Spindle epithelial tumor with thymus-like element"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266099"}]}}{"C46106":{"preferredName":"Intrathyroid Thymic Carcinoma","code":"C46106","definitions":[{"definition":"A rare primary carcinoma of the thyroid gland, composed of groups of carcinoma cells with thymic epithelial differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intrathyroid Thymic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"CASTLE","termGroup":"AB","termSource":"NCI"},{"termName":"CD5-Positive Thyroid Carcinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Intrathyroidal Carcinoma Showing Thymus-Like Elements","termGroup":"AQS","termSource":"NCI"},{"termName":"Thyroid Gland Carcinoma Showing Thymus-Like Differentiation","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8589/3"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Carcinoma_Showing_Thymus-Like_Differentiation"},{"name":"Maps_To","value":"8589/3"},{"name":"Maps_To","value":"Carcinoma showing thymus-like differentiation"},{"name":"Maps_To","value":"Carcinoma showing thymus-like element"},{"name":"Maps_To","value":"CASTLE"},{"name":"Maps_To","value":"Intrathyroid thymic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266100"}]}}{"C4862":{"preferredName":"Ovarian Sex Cord-Stromal Tumor","code":"C4862","definitions":[{"definition":"A benign or malignant neoplasm that arises from the ovary and is composed of granulosa cells, Sertoli cells, Leydig cells, theca cells, and fibroblasts.  Representative examples include thecoma, fibroma, Sertoli cell tumor, and granulosa cell tumor.","type":"DEFINITION","source":"NCI"},{"definition":"A sex cord-stromal tumor that occurs in the ovary.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Ovarian Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Sex Cord-Stromal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Stromal Tumor of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Ovarian_Sex_Cord-Stromal_Tumor"},{"name":"Maps_To","value":"8590/1"},{"name":"Maps_To","value":"Ovarian stromal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0600113"}]}}{"C3794":{"preferredName":"Sex Cord-Stromal Tumor","code":"C3794","definitions":[{"definition":"A neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, 10% of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of cancer that forms in the tissues that support the ovaries or testes. These tumors may release sex hormones. Sex cord-gonadal stromal tumors include granulosa cell, Sertoli cell, and Leydig cell tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor arising in the ovary or testis. It is composed of one or more of the following: granulosa cells, Leydig cells, Sertoli cells, and/or fibroblasts.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Sex Cord-Stromal Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8590/1"},{"name":"Legacy Concept Name","value":"Sex_Cord-Stromal_Tumor"},{"name":"Maps_To","value":"8590/1"},{"name":"Maps_To","value":"Gonadal stromal tumor, NOS"},{"name":"Maps_To","value":"Sex cord tumor, NOS"},{"name":"Maps_To","value":"Sex cord-gonadal stromal tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206724"}]}}{"C66748":{"preferredName":"Testicular Sex Cord-Stromal Tumor, Not Otherwise Specified","code":"C66748","definitions":[{"definition":"A sex cord-stromal tumor of the testis in which the neoplastic cells do not show specific differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Sex Cord-Stromal Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Gonadal Stromal Tumor with Indeterminate Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Gonadal Stromal Tumor, Incompletely Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Stromal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Testicular Sex Cord-Gonadal Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Testicular Sex Cord-Stromal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8591/1"},{"name":"Legacy Concept Name","value":"Sex_Cord-Gonadal_Stromal_Tumor_Incompletely_Differentiated"},{"name":"Maps_To","value":"8591/1"},{"name":"Maps_To","value":"Sex cord-gonadal stromal tumor, incompletely differentiated"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266102"}]}}{"C66991":{"preferredName":"Testicular Mixed Sex Cord-Stromal Tumor","code":"C66991","definitions":[{"definition":"A sex cord-stromal tumor of the testis which may contain any combination of cell types, for example Sertoli cells, Leydig cells, and granulosa cells. Symptoms include testicular swelling and gynecomastia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Mixed Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Testicular Sex Cord-Gonadal Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Testicular Sex Cord-Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Cord-Gonadal Stromal Tumor, Mixed Forms","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Sex Cord-Gonadal Stromal Tumor, Mixed Forms","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8592/1"},{"name":"Legacy Concept Name","value":"Testicular_Sex_Cord-Gonadal_Stromal_Tumor_Mixed_Forms"},{"name":"Maps_To","value":"8592/1"},{"name":"Maps_To","value":"Sex cord-gonadal stromal tumor, mixed forms"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266103"}]}}{"C66749":{"preferredName":"Ovarian Stromal Tumor with Minor Sex Cord Elements","code":"C66749","definitions":[{"definition":"A rare, benign sex cord-stromal tumor of the ovary characterized by the presence of a fibrothecomatous stroma and scattered sex cord elements. Although it is usually hormonally inactive, cases associated with endometrial hyperplasia or adenocarcinoma have been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Stromal Tumor with Minor Sex Cord Elements","termGroup":"PT","termSource":"NCI"},{"termName":"Stromal Tumor with Minor Sex Cord Elements","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8593/1"},{"name":"Legacy Concept Name","value":"Stromal_Tumor_with_Minor_Sex_Cord_Elements"},{"name":"Maps_To","value":"8593/1"},{"name":"Maps_To","value":"Stromal tumor with minor sex cord elements"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1883177"}]}}{"C5241":{"preferredName":"Mixed Germ Cell-Sex Cord-Stromal Tumor","code":"C5241","definitions":[{"definition":"A biphasic neoplasm that arises from the ovary or the testis. It is characterized by the presence of neoplastic germ cells and neoplastic sex cord-stromal cells. It includes the gonadoblastoma and mixed germ cell-sex cord stromal tumor, unclassifiable.","type":"DEFINITION","source":"NCI"},{"definition":"A biphasic tumor that arises from the ovary or the testis. It is characterized by the presence of neoplastic germ cells and neoplastic sex cord-stromal cells; examples include the gonadoblastoma and mixed germ cell-sex cord stromal tumor, unclassifiable.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Mixed Germ Cell-Sex Cord-Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Germ Cell-Sex Cord Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Germ Cell-Sex Cord Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Germ Cell-Sex Cord-Stromal Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Mixed_Germ_Cell-Sex_Cord-Stromal_Tumor"},{"name":"Maps_To","value":"8594/1"},{"name":"Maps_To","value":"Mixed germ cell-sex cord-stromal tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321220"}]}}{"C3405":{"preferredName":"Thecoma","code":"C3405","definitions":[{"definition":"An ovarian or testicular stromal tumor characterized by the presence of lipid-rich neoplastic spindle cells. In females, uterine bleeding is the most common symptom. A minority of post-menopausal women with thecoma have an associated endometrial adenocarcinoma or rarely a malignant mixed mullerian tumor or endometrial stromal sarcoma. Rare cases with nuclear atypia and mitotic activity may metastasize. In males, thecomas are rare and they usually present as slow growing, sometimes painful masses. Metastases have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thecoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8600/0"},{"name":"Legacy Concept Name","value":"Thecoma"},{"name":"Maps_To","value":"8600/0"},{"name":"Maps_To","value":"Theca cell tumor"},{"name":"Maps_To","value":"Thecoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0039747"}]}}{"C6929":{"preferredName":"Malignant Ovarian Thecoma","code":"C6929","definitions":[{"definition":"A malignant sex-cord neoplasm of the ovary, originating from theca cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thecoma of the ovary which may metastasize to another anatomic site. It is usually characterized by nuclear atypia and mitotic activity. Malignant thecomas are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Thecoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ovarian Thecal Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ovarian Thecal Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecal Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Thecoma of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8600/3"},{"name":"Legacy Concept Name","value":"Malignant_Thecoma"},{"name":"Maps_To","value":"8600/3"},{"name":"Maps_To","value":"Thecoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334398"}]}}{"C4203":{"preferredName":"Ovarian Luteinized Thecoma","code":"C4203","definitions":[{"definition":"A variant of ovarian thecoma characterized by the presence of lutein cells. It is associated with a lower frequency of estrogenic manifestations compared to typical thecomas. In a minority of cases androgenic manifestations are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Luteinized Thecoma","termGroup":"PT","termSource":"NCI"},{"termName":"Luteinized Ovarian Thecoma","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinized Thecoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinized Thecoma of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8601/0"},{"name":"Legacy Concept Name","value":"Luteinized_Thecoma"},{"name":"Maps_To","value":"8601/0"},{"name":"Maps_To","value":"Thecoma, luteinized"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334399"}]}}{"C4204":{"preferredName":"Ovarian Sclerosing Stromal Tumor","code":"C4204","definitions":[{"definition":"A benign ovarian stromal tumor characterized by the presence of cellular areas which contain fibroblasts and round cells. The cellular areas are separated by sclerotic or edematous hypocellular tissue. Symptoms include abdominal discomfort and menstrual abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sclerosing Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Sclerosing Stromal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Stromal Tumor of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8602/0"},{"name":"Legacy Concept Name","value":"Ovarian_Sclerosing_Stromal_Tumor"},{"name":"Maps_To","value":"8602/0"},{"name":"Maps_To","value":"Sclerosing stromal tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334400"}]}}{"C3202":{"preferredName":"Ovarian Stromal Luteoma","code":"C3202","definitions":[{"definition":"A benign neoplasm of the ovary, composed of leuteinized granulosa-theca cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign ovarian stromal tumor in which more than 90% of the tumor cells resemble steroid hormone-secreting cells. Crystals of Reinke are not present. It occurs in post-menopausal women and it is usually associated with estrogenic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Stromal Luteoma","termGroup":"PT","termSource":"NCI"},{"termName":"Luteal Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Luteal Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Luteoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8610/0"},{"name":"Legacy Concept Name","value":"Luteoma"},{"name":"Maps_To","value":"8610/0"},{"name":"Maps_To","value":"Luteinoma"},{"name":"Maps_To","value":"Luteoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024167"}]}}{"C66750":{"preferredName":"Adult Granulosa Cell Tumor","code":"C66750","definitions":[{"definition":"A low-grade malignant sex cord-stromal tumor occurring in the ovary and rarely in the testis. It is composed of granulosa cells in an often fibrothecomatous stroma. The neoplastic cells may form various patterns including the microfollicular, which is characterized by the presence of Call-Exner bodies, macrofollicular, insular, trabecular, and diffuse pattern. In females, it affects middle aged to post-menopausal women. Signs and symptoms include abdominal mass, hemoperitoneum, and ascites. Estrogenic and rarely androgenic manifestations may be present. The vast majority of cases present as stage I tumors; however, all tumors have a potential for aggressive clinical course. In males, it is reported in the age range of 16-76 years and the average age at presentation is 44 years. A minority of patients have gynecomastia. Metastases have been reported in a minority of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Type Granulosa Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8620/1"},{"name":"Legacy Concept Name","value":"Adult_Type_Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8620/1"},{"name":"Maps_To","value":"Adult granulosa cell tumor"},{"name":"Maps_To","value":"Granulosa cell tumor, adult type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879643"}]}}{"C3070":{"preferredName":"Granulosa Cell Tumor","code":"C3070","definitions":[{"definition":"A slow-growing sex cord-stromal tumor characterized by the presence of granulosa-like cells and Call-Exner bodies. It is almost always found in the ovary and rarely in the testis. There are two types of granulosa cell tumors: the adult and the juvenile.","type":"DEFINITION","source":"NCI"},{"definition":"A slow-growing, malignant tumor that is characterized by the presence of granulosa-like cells, and which is almost always found in the ovary. In rare cases, it has also been found in the testicle.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of slow-growing, malignant tumor that usually affects the ovary.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Granulosa Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8620/1"},{"name":"Maps_To","value":"Granulosa cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018206"}]}}{"C4205":{"preferredName":"Malignant Granulosa Cell Tumor","code":"C4205","definitions":[{"definition":"A granulosa cell tumor which has an aggressive clinical course and metastasizes to other anatomic sites.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the ovary, originating from granulosa cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Granulosa Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8620/3"},{"name":"Legacy Concept Name","value":"Malignant_Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8620/3"},{"name":"Maps_To","value":"Granulosa cell carcinoma"},{"name":"Maps_To","value":"Granulosa cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334401"}]}}{"C66751":{"preferredName":"Granulosa Cell-Theca Cell Tumor","code":"C66751","definitions":[{"definition":"A general term used to describe sex cord-stromal tumors characterized by the presence of granulosa cells in a thecomatous/fibrothecomatous background.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granulosa Cell-Theca Cell Tumor","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8621/1"},{"name":"Legacy Concept Name","value":"Granulosa_Cell-Theca_Cell_Neoplasm"},{"name":"Maps_To","value":"8621/1"},{"name":"Maps_To","value":"Granulosa cell-theca cell tumor"},{"name":"Maps_To","value":"Theca cell-granulosa cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334402"}]}}{"C4207":{"preferredName":"Juvenile Granulosa Cell Tumor","code":"C4207","definitions":[{"definition":"A rare type of tumor derived from the granulosa cells in the ovary or testis. Ninety percent of girls with the tumor will have low stage disease, which is curable with surgery alone. In males, it usually presents in infancy (median age, 6 days), which is treated with surgery alone.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A sex cord-stromal tumor occurring in the ovary and testis. In females it occurs predominantly in the first three decades of life and presents unilaterally as stage I disease in the vast majority of cases. It is characterized by the presence of granulosa cells forming macrofollicular structures. The majority of cases have a good prognosis. In males it represents the most frequent congenital testicular neoplasm, and the vast majority of cases occur in the perinatal period. It presents as a scrotal or abdominal mass, and it more often affects the left testis. Approximately 20% of the patients have ambiguous external genitalia. It is characterized by the presence of cystic spaces lined by granulosa cells and cells resembling theca cells. Metastases have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Juvenile Granulosa Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Juvenile Type Granulosa Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Type Granulosa Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8622/1"},{"name":"Legacy Concept Name","value":"Juvenile_Granulosa_Cell_Tumor"},{"name":"Maps_To","value":"8622/1"},{"name":"Maps_To","value":"Granulosa cell tumor, juvenile"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334403"}]}}{"C4208":{"preferredName":"Ovarian Sex Cord Tumor with Annular Tubules","code":"C4208","definitions":[{"definition":"An ovarian sex cord-stromal tumor characterized by the presence of Sertoli cells forming annular tubules. It may be associated with Peutz-Jeghers syndrome. Cases associated with Peutz-Jeghers syndrome have followed a benign clinical course. Cases which are not associated with Peutz-Jeghers syndrome have been reported having a clinically malignant course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sex Cord Tumor with Annular Tubules","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Sertoli Cell Tumor, Annular Tubular Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Sex Cord Neoplasm with Annular Tubules","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8623/1"},{"name":"Legacy Concept Name","value":"Sex_Cord_Tumor_with_Annular_Tubules"},{"name":"Maps_To","value":"8623/1"},{"name":"Maps_To","value":"Sex cord tumor with annular tubules"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519276"}]}}{"C67012":{"preferredName":"Benign Sertoli Cell Tumor","code":"C67012","definitions":[{"definition":"A Sertoli cell tumor of the testis or the ovary which remains localized and does not metastasize to another anatomic site.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the testis or ovary, originating from Sertoli cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Benign Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8630/0"},{"name":"Legacy Concept Name","value":"Benign_Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8630/0"},{"name":"Maps_To","value":"Androblastoma, benign"},{"name":"Maps_To","value":"Arrhenoblastoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334405"}]}}{"C39976":{"preferredName":"Sertoli Cell Tumor","code":"C39976","definitions":[{"definition":"A sex cord-stromal tumor of the testis or the ovary. It is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent. It may be associated with Peutz-Jeghers syndrome.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A sex cord-stromal tumor of the testis or the ovary. It is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent. It may be associated with Peutz-Jeghers syndrome. In males, the presenting symptom is a slow growing testicular mass. Most cases follow a benign clinical course. In females it may present with estrogenic or androgenic manifestations. The vast majority of cases have a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8630/1"},{"name":"ICD-O-3_Code","value":"8640/1"},{"name":"Legacy Concept Name","value":"Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8640/1"},{"name":"Maps_To","value":"Androblastoma, NOS"},{"name":"Maps_To","value":"Arrhenoblastoma, NOS"},{"name":"Maps_To","value":"Pick tubular adenoma"},{"name":"Maps_To","value":"Sertoli cell adenoma"},{"name":"Maps_To","value":"Sertoli cell tumor, NOS"},{"name":"Maps_To","value":"Testicular adenoma"},{"name":"Maps_To","value":"Tubular androblastoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036769"}]}}{"C67006":{"preferredName":"Malignant Sertoli Cell Tumor","code":"C67006","definitions":[{"definition":"A Sertoli cell tumor that arises from the testis or the ovary. It is characterized by nuclear pleomorphism, increased mitotic activity and necrotic changes. Metastases may be present at diagnosis.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the testis or ovary, originating from Sertoli cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8630/3"},{"name":"ICD-O-3_Code","value":"8640/3"},{"name":"Legacy Concept Name","value":"Malignant_Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8640/3"},{"name":"Maps_To","value":"Androblastoma, malignant"},{"name":"Maps_To","value":"Arrhenoblastoma, malignant"},{"name":"Maps_To","value":"Sertoli cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334406"}]}}{"C4209":{"preferredName":"Well Differentiated Ovarian Sertoli-Leydig Cell Tumor","code":"C4209","definitions":[{"definition":"A Sertoli-Leydig tumor of the ovary characterized by the presence of Sertoli cells in tubules without evidence of significant nuclear atypia or mitotic activity. Primitive gonadal stromal cells are not present. It usually follows a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8631/0"},{"name":"Legacy Concept Name","value":"Benign_Androblastoma"},{"name":"Maps_To","value":"8631/0"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, well differentiated"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1314745"}]}}{"C39968":{"preferredName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor","code":"C39968","definitions":[{"definition":"A Sertoli-Leydig cell tumor of the ovary characterized by the presence of spindle-shaped gonadal stromal cells and Sertoli cells, some of which are atypical. Leydig cells are also present forming clusters at the periphery of the cellular aggregates. Metastases have been reported in a minority of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Intermediate Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8631/1"},{"name":"Legacy Concept Name","value":"Intermediate_Differentiated_Ovarian_Sertoli-Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8631/1"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor of intermediate differentiation"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor of intermediate differentiation, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1318541"}]}}{"C2880":{"preferredName":"Ovarian Sertoli-Leydig Cell Tumor","code":"C2880","definitions":[{"definition":"A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. It may be associated with trisomy 8.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. Signs and symptoms include hirsutism, menorrhagia and metrorrhagia. It may be associated with trisomy 8.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of ovarian tumor in which the tumor cells secrete a male sex hormone. This may cause virilization (the appearance of male physical characteristics in females).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Androblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Arrhenoblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Sertoli-Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Sertoli-Leydig Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Androblastoma"},{"name":"Maps_To","value":"8631/1"},{"name":"Maps_To","value":"Androblastoma, NOS"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0003810"}]}}{"C4210":{"preferredName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor","code":"C4210","definitions":[{"definition":"A Sertoli-Leydig tumor of the ovary characterized by the presence of a sarcomatoid stroma which contains primitive gonadal stromal cells. It may behave in a malignant fashion and metastasize to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8631/3"},{"name":"Legacy Concept Name","value":"Malignant_Androblastoma"},{"name":"Maps_To","value":"8631/3"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, poorly differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266105"}]}}{"C3072":{"preferredName":"Ovarian Gynandroblastoma","code":"C3072","definitions":[{"definition":"A rare neoplasm arising from the ovary. Although it may occur at any age, it is more often seen in young females. Morphologically, it is characterized by a mixture of two cellular populations: well differentiated Sertoli cells and granulosa cells, with the latter constituting at least ten percent of the neoplasm. The vast majority of cases are stage I lesions at presentation and produce either estrogenic or androgenic manifestations. Although it may present as a massive ovarian tumor, it usually follows a benign clinical course. Very rare case reports of testicular lesions morphologically resembling gynandroblastomas are in fact variants of juvenile granulose cell tumor, or Sertoli cell tumor, or a combination of both.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Gynandroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gynandroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gynandroblastoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Gynandroblastoma of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8632/1"},{"name":"Legacy Concept Name","value":"Gynandroblastoma"},{"name":"Maps_To","value":"8632/1"},{"name":"Maps_To","value":"Gynandroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018413"}]}}{"C39974":{"preferredName":"Ovarian Sertoli-Leydig Cell Tumor with Retiform Elements","code":"C39974","definitions":[{"definition":"A Sertoli-Leydig cell tumor characterized by the presence of spaces that resemble rete testis (retiform elements).  These spaces form anastomosing patterns and comprise at least ten percent but less than ninety percent of the tumor.  When the retiform elements comprise ninety percent or more of the tumor, the term retiform Sertoli-Leydig cell tumor is used.  A minority of patients may have an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sertoli-Leydig Cell Tumor with Retiform Elements","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Sertoli-Leydig_Cell_Tumor_with_Retiform_Elements"},{"name":"Maps_To","value":"8633/1"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, retiform"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266106"}]}}{"C39972":{"preferredName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","code":"C39972","definitions":[{"definition":"An ovarian Sertoli-Leydig cell tumor of intermediate differentiation, characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","termGroup":"PT","termSource":"NCI"},{"termName":"Intermediate Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8634/1"},{"name":"Legacy Concept Name","value":"Intermediate_Differentiated_Ovarian_Sertoli-Leydig_Cell_Tumor_Variant_with_Heterologous_Elements"},{"name":"Maps_To","value":"8634/1"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266107"}]}}{"C39973":{"preferredName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","code":"C39973","definitions":[{"definition":"An ovarian poorly differentiated Sertoli-Leydig cell tumor. It is characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8634/3"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Ovarian_Sertoli-Leydig_Cell_Tumor_Variant_with_Heterologous_Elements"},{"name":"Maps_To","value":"8634/3"},{"name":"Maps_To","value":"Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266108"}]}}{"C4211":{"preferredName":"Ovarian Sertoli Cell Tumor with Lipid Storage","code":"C4211","definitions":[{"definition":"A Sertoli cell tumor that arises from the ovary and is characterized by the presence of cells that are distended by the presence of intracytoplasmic lipid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Sertoli Cell Tumor with Lipid Storage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tubular_Androblastoma_with_Lipid_Storage"},{"name":"Maps_To","value":"8641/0"},{"name":"Maps_To","value":"Sertoli cell tumor with lipid storage"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334408"}]}}{"C39944":{"preferredName":"Testicular Large Cell Calcifying Sertoli Cell Tumor","code":"C39944","definitions":[{"definition":"A testicular Sertoli cell tumor characterized by the presence of large polygonal cells with eosinophilic cytoplasm in a myxoid and hyalinized stroma. Calcifications may be present in the stroma. Malignant behavior is uncommon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Large Cell Calcifying Sertoli Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"LCCSCT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8642/1"},{"name":"Legacy Concept Name","value":"Testicular_Large_Cell_Calcifying_Sertoli_Cell_Tumor"},{"name":"Maps_To","value":"8642/1"},{"name":"Maps_To","value":"Large cell calcifying Sertoli cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266109"}]}}{"C4212":{"preferredName":"Benign Leydig Cell Tumor","code":"C4212","definitions":[{"definition":"A Leydig cell tumor which does not recur or metastasize. Morphologically, there is no evidence of cellular atypia, increased mitotic activity, necrosis, or vascular invasion.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the testis originating from interstitial (Leydig) cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Benign Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Interstitial Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Interstitial Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8650/0"},{"name":"Legacy Concept Name","value":"Benign_Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8650/0"},{"name":"Maps_To","value":"Interstitial cell tumor, benign"},{"name":"Maps_To","value":"Leydig cell tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334409"}]}}{"C3188":{"preferredName":"Leydig Cell Tumor","code":"C3188","definitions":[{"definition":"A sex cord-stromal tumor occurring in the testis and rarely in the ovary. It is predominantly or completely composed of Leydig cells which may contain crystals of Reinke. In males it usually presents as a painless testicular enlargement and it may be associated with gynecomastia and decreased libido. The majority of the cases have a benign clinical course. Approximately 10% of the cases have a malignant clinical course and metastasize. In females it may be associated with androgenic manifestations and it follows a benign clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"A sex cord-stromal tumor, comprising Leydig cells, either predominantly or completely, occurring in the testis and rarely in the ovary.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Interstitial Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Interstitial Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8650/1"},{"name":"Legacy Concept Name","value":"Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8650/1"},{"name":"Maps_To","value":"Interstitial cell tumor, NOS"},{"name":"Maps_To","value":"Leydig cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023601"}]}}{"C4213":{"preferredName":"Malignant Leydig Cell Tumor","code":"C4213","definitions":[{"definition":"A Leydig cell tumor characterized by large tumor size, the presence of cytologic atypia, increased mitotic activity, necrosis, and vascular invasion. Approximately 10% of the testicular Leydig cell tumors show malignant characteristics and metastasize. Leydig cell tumors of the ovary follow a benign clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the testis originating from interstitial (Leydig) cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Leydig Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Interstitial Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Interstitial Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Leydig Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8650/3"},{"name":"Legacy Concept Name","value":"Malignant_Leydig_Cell_Tumor"},{"name":"Maps_To","value":"8650/3"},{"name":"Maps_To","value":"Interstitial cell tumor, malignant"},{"name":"Maps_To","value":"Leydig cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334410"}]}}{"C4214":{"preferredName":"Ovarian Hilus Cell Tumor","code":"C4214","definitions":[{"definition":"A benign Leydig cell tumor which arises in the hilar area of the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Hilus Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Hilar Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hilar Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Hilar Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Hilus Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hilus Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Hilar Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8660/0"},{"name":"Legacy Concept Name","value":"Hilar_Cell_Tumor"},{"name":"Maps_To","value":"8660/0"},{"name":"Maps_To","value":"Hilar cell tumor"},{"name":"Maps_To","value":"Hilus cell tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346179"}]}}{"C4215":{"preferredName":"Ovarian Steroid Cell Tumor","code":"C4215","definitions":[{"definition":"An ovarian tumor in which the vast majority of the cells (more than 90% of the tumor cells) resemble steroid hormone-secreting cells. It usually presents with androgenic manifestations. Approximately one-third of the cases follow a malignant clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Steroid Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Cell Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Cell Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Lipid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Lipid Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Lipoid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Steroid Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Steroid Cell Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Steroid Cell Tumor of the Ovary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8670/0"},{"name":"Legacy Concept Name","value":"Steroid_Cell_Tumor_of_the_Ovary"},{"name":"Maps_To","value":"8670/0"},{"name":"Maps_To","value":"Lipid cell tumor of ovary"},{"name":"Maps_To","value":"Lipoid cell tumor of ovary"},{"name":"Maps_To","value":"Masculinovoblastoma"},{"name":"Maps_To","value":"Steroid cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334412"}]}}{"C39981":{"preferredName":"Malignant Ovarian Steroid Cell Tumor","code":"C39981","definitions":[{"definition":"A steroid tumor of the ovary which has an aggressive clinical course and metastasizes to other anatomic sites. It is usually of large size and is characterized by nuclear atypia, increased mitotic activity, hemorrhage, and necrosis. Sometimes, patients have abdominal metastases at presentation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Steroid Cell Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8670/3"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Steroid_Cell_Tumor"},{"name":"Maps_To","value":"8670/3"},{"name":"Maps_To","value":"Steroid cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266110"}]}}{"C2860":{"preferredName":"Adrenal Rest Tumor","code":"C2860","definitions":[{"definition":"A benign, testicular or ovarian tumor, derived from adrenal embryonic rest cells. It is composed of hyperplastic adrenal cortical tissue, and it is associated with congenital adrenal hyperplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Rest Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Rest Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8671/0"},{"name":"Legacy Concept Name","value":"Adrenal_Rest_Neoplasm"},{"name":"Maps_To","value":"8671/0"},{"name":"Maps_To","value":"Adrenal rest tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001630"}]}}{"C48314":{"preferredName":"Non-Metastatic Paraganglioma","code":"C48314","definitions":[{"definition":"A benign neoplasm arising from paraganglia located along nerves composed of neoplastic neuroectodermal chromaffin cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A paraganglioma that is confined to the site of origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Metastatic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8680/0"},{"name":"Legacy Concept Name","value":"Benign_Paraganglionic_Neoplasm"},{"name":"Maps_To","value":"8680/0"},{"name":"Maps_To","value":"Paraganglioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346416"}]}}{"C3308":{"preferredName":"Paraganglioma","code":"C3308","definitions":[{"definition":"A neoplasm arising from paraganglia located along the sympathetic or parasympathetic nerves.  Infrequently, it may arise outside the usual distribution of the sympathetic and parasympathetic paraganglia.  Tumors arising from the adrenal gland medulla are called pheochromocytomas.  Morphologically, paragangliomas usually display a nesting (Zellballen) growth pattern.  There are no reliable morphologic criteria to distinguish between benign and malignant paragangliomas.  The only definitive indicator of malignancy is the presence of regional or distant metastases.","type":"DEFINITION","source":"NCI"},{"definition":"A rare, usually benign tumor that develops from cells of the paraganglia. Paraganglia are a collection of cells that came from embryonic nervous tissue, and are found near the adrenal glands and some blood vessels and nerves. Paragangliomas that develop in the adrenal gland are called pheochromocytomas. Those that develop outside of the adrenal glands near blood vessels or nerves are called glomus tumors or chemodectomas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglion Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglion Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglionic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Paraganglion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8680/1"},{"name":"Legacy Concept Name","value":"Paraganglionic_Neoplasm"},{"name":"Maps_To","value":"8680/1"},{"name":"Maps_To","value":"Paraganglioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0030421"}]}}{"C8559":{"preferredName":"Metastatic Paraganglioma","code":"C8559","definitions":[{"definition":"A malignant neoplasm arising from paraganglia located along nerves composed of neoplastic neuroectodermal chromaffin cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A paraganglioma that metastasizes to regional or distant anatomic sites.  Extraadrenal paragangliomas have a higher tendency to metastasize, as compared to pheochromocytomas.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglion Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglion Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Paraganglionic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Paraganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglion Neoplasm, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8680/3"},{"name":"Legacy Concept Name","value":"Malignant_Paraganglionic_Neoplasm"},{"name":"Maps_To","value":"8680/3"},{"name":"Maps_To","value":"Malignant neoplasm of aortic body and other paraganglia"},{"name":"Maps_To","value":"Malignant neoplasm: Aortic body and other paraganglia"},{"name":"Maps_To","value":"Paraganglioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1533592"}]}}{"C4216":{"preferredName":"Sympathetic Paraganglioma","code":"C4216","definitions":[{"definition":"A paraganglioma arising from the chromaffin cells of the paraganglia that are located along the sympathetic nerves.  It includes extra-adrenal paragangliomas and paragangliomas that arise from the adrenal medulla.  The latter are commonly referred to as pheochromocytomas.  Representative examples of extra-adrenal sympathetic paragangliomas include the bladder, and superior and inferior paraaortic paragangliomas.  Clinical signs are related to the secretion of catecholamines resulting in hypertension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sympathetic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Chromaffin Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Chromaffin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Chromaffinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sympathetic Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8681/1"},{"name":"Legacy Concept Name","value":"Sympathetic_Paraganglioma"},{"name":"Maps_To","value":"8700/0"},{"name":"Maps_To","value":"Chromaffin tumor"},{"name":"Maps_To","value":"Chromaffinoma"},{"name":"Maps_To","value":"Sympathetic paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334415"}]}}{"C4217":{"preferredName":"Parasympathetic Paraganglioma","code":"C4217","definitions":[{"definition":"An extra-adrenal paraganglioma that arises from paraganglia located along the parasympathetic nerves.  Representative examples include aorticopulmonary, carotid body, jugulotympanic, and mediastinal paragangliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parasympathetic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Parasympathetic Extra-Adrenal Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Parasympathetic Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8682/1"},{"name":"Legacy Concept Name","value":"Parasympathetic_Paraganglioma"},{"name":"Maps_To","value":"8682/1"},{"name":"Maps_To","value":"Parasympathetic paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334416"}]}}{"C188229":{"preferredName":"Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor","code":"C188229","definitions":[{"definition":"A usually indolent neuroendocrine neoplasm that almost exclusively arises in the second part of the duodenum. Rare sites of involvement include jejunum, pylorus, appendix, thymus, and lung. It is a triphasic tumor consisting of a mixture of epithelioid neuroendocrine cells, Schwann-like cells, and ganglion cell-like elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"CoGNET","termGroup":"AB","termSource":"NCI"},{"termName":"Gangliocytic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Gangliocytic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Gangliocytic Paraganglioma","termGroup":"AQS","termSource":"NCI"},{"termName":"MiGNeN","termGroup":"AB","termSource":"NCI"},{"termName":"Mixed Ganglioneuroma-Neuroendocrine Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8683/0"},{"name":"Maps_To","value":"Gangliocytic paraganglioma"},{"name":"NCI_META_CUI","value":"CL1793076"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3061":{"preferredName":"Jugulotympanic Paraganglioma","code":"C3061","definitions":[{"definition":"An extra-adrenal parasympathetic paraganglioma arising from paraganglia in the base of the skull and middle ear.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Jugulotympanic Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Glomus Jugulare Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Glomus Jugulare Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Jugular Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Glomus Jugulare","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Glomus Jugulare","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Glomus Jugulare","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Glomus Jugulare","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8690/1"},{"name":"Legacy Concept Name","value":"Jugulotympanic_Paraganglioma"},{"name":"Maps_To","value":"8690/1"},{"name":"Maps_To","value":"Glomus jugulare tumor, NOS"},{"name":"Maps_To","value":"Jugular paraganglioma"},{"name":"Maps_To","value":"Jugulotympanic paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017671"}]}}{"C4218":{"preferredName":"Aorticopulmonary Paraganglioma","code":"C4218","definitions":[{"definition":"An extra-adrenal parasympathetic paraganglioma that arises from paraganglia adjacent to the base of the heart and great vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aorticopulmonary Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Aortic Body Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Aortic Body Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Aortic Body Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of the Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Aortic Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Aortic Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8691/1"},{"name":"Legacy Concept Name","value":"Aortic_Body_Paraganglioma"},{"name":"Maps_To","value":"8691/1"},{"name":"Maps_To","value":"Aortic body paraganglioma"},{"name":"Maps_To","value":"Aortic body tumor"},{"name":"Maps_To","value":"Aorticopulmonary paraganglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334417"}]}}{"C2932":{"preferredName":"Carotid Body Paraganglioma","code":"C2932","definitions":[{"definition":"A parasympathetic paraganglioma arising from paraganglia adjacent to or in the bifurcation of the common carotid artery.  Most patients present with a slow growing, painless mass in the neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carotid Body Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Carotid Body Chemodectoma","termGroup":"SY","termSource":"NCI"},{"termName":"Carotid Body Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Chemodectoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of Carotid Body","termGroup":"SY","termSource":"NCI"},{"termName":"Paraganglioma of the Carotid Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Carotid Body","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Carotid Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8692/1"},{"name":"Legacy Concept Name","value":"Carotid_Body_Paraganglioma"},{"name":"Maps_To","value":"8693/1"},{"name":"Maps_To","value":"Carotid body paraganglioma"},{"name":"Maps_To","value":"Carotid body tumor"},{"name":"Maps_To","value":"Chemodectoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1866553"}]}}{"C3309":{"preferredName":"Extra-Adrenal Paraganglioma","code":"C3309","definitions":[{"definition":"A paraganglioma arising from sympathetic or parasympathetic paraganglia outside the adrenal gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extra-Adrenal Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Extra-Adrenal Paraganglionic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Extraadrenal Paraganglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8693/1"},{"name":"Legacy Concept Name","value":"Extra-Adrenal_Paraganglioma"},{"name":"Maps_To","value":"8693/1"},{"name":"Maps_To","value":"Extra-adrenal paraganglioma, NOS"},{"name":"NCI_META_CUI","value":"CL497918"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4219":{"preferredName":"Metastatic Extra-Adrenal Paraganglioma","code":"C4219","definitions":[{"definition":"An extra-adrenal paraganglioma that metastasizes to regional or distant anatomic sites.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Extra-Adrenal Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Extra-Adrenal Paraganglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8693/3"},{"name":"Legacy Concept Name","value":"Malignant_Extra-Adrenal_Paraganglioma"},{"name":"Maps_To","value":"8693/3"},{"name":"Maps_To","value":"Extra-adrenal paraganglioma, malignant"},{"name":"Maps_To","value":"Nonchromaffin paraganglioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334418"}]}}{"C3326":{"preferredName":"Adrenal Gland Pheochromocytoma","code":"C3326","definitions":[{"definition":"A neuroendocrine neoplasm of the sympathetic nervous system that arises from the chromaffin cells of the adrenal medulla and secretes catecholamines. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","type":"DEFINITION","source":"NCI"},{"definition":"Tumor that forms in the center of the adrenal gland (gland located above the kidney) that causes it to make too much adrenaline. Pheochromocytomas are usually benign (not cancer) but can cause high blood pressure, pounding headaches, heart palpitations, flushing of the face, nausea, and vomiting.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adrenal Gland Pheochromocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Gland Chromaffin Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Chromaffinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Medullary Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Medullary Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chromaffin Paraganglioma of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Intraadrenal Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"PCC","termGroup":"AB","termSource":"NCI"},{"termName":"Pheochromocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8700/0"},{"name":"Legacy Concept Name","value":"Pheochromocytoma"},{"name":"Maps_To","value":"8700/0"},{"name":"Maps_To","value":"Adrenal medullary paraganglioma"},{"name":"Maps_To","value":"Chromaffin paraganglioma"},{"name":"Maps_To","value":"Pheochromocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1861851"}]}}{"C4220":{"preferredName":"Metastatic Adrenal Gland Pheochromocytoma","code":"C4220","definitions":[{"definition":"A malignant neoplasm of the adrenal gland medulla.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A pheochromocytoma that metastasizes to other anatomic sites.  Common sites of metastasis include lymph nodes, bones, liver, and lung.  Morphologic features associated with malignant pheochromocytomas include: atypical mitotic figures, capsular and vascular invasion, tumor cell necrosis, and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Adrenal Gland Pheochromocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffin Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffin Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Chromaffinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Medullary Paraganglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Medullary Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Metastatic Pheochromocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pheochromoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8700/3"},{"name":"Legacy Concept Name","value":"Malignant_Pheochromocytoma"},{"name":"Legacy Concept Name","value":"Metastatic_Pheochromocytoma"},{"name":"Maps_To","value":"8700/3"},{"name":"Maps_To","value":"Adrenal medullary paraganglioma, malignant"},{"name":"Maps_To","value":"Pheochromoblastoma"},{"name":"Maps_To","value":"Pheochromocytoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708998"}]}}{"C4221":{"preferredName":"Malignant Glomus Tumor","code":"C4221","definitions":[{"definition":"A very rare morphologic variant of glomus tumor with a size greater than 2 cm.  The tumor arises in subfascial or visceral tissues. It is characterized by the presence of atypical mitotic figures, or marked nuclear atypia, or the combination of both.  It has an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Glomus Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Glomangiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Glomus Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8710/3"},{"name":"ICD-O-3_Code","value":"8711/3"},{"name":"Legacy Concept Name","value":"Malignant_Glomus_Tumor"},{"name":"Maps_To","value":"8710/3"},{"name":"Maps_To","value":"8711/3"},{"name":"Maps_To","value":"Glomangiosarcoma"},{"name":"Maps_To","value":"Glomoid sarcoma"},{"name":"Maps_To","value":"Glomus tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266111"}]}}{"C3060":{"preferredName":"Glomus Tumor","code":"C3060","definitions":[{"definition":"A rare benign or malignant mesenchymal neoplasm arising from cells that resemble the modified smooth muscle cells of the glomus body. The majority of glomus tumors occur in the distal extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomus Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Glomus Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8711/0"},{"name":"Legacy Concept Name","value":"Glomus_Tumor"},{"name":"Maps_To","value":"8711/0"},{"name":"Maps_To","value":"Glomus tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017653"}]}}{"C4222":{"preferredName":"Glomangioma","code":"C4222","definitions":[{"definition":"A morphologic variant of the glomus tumor characterized by the presence of dilated veins, surrounded by small clusters of glomus cells. Glomangiomas are most often present in patients with multiple lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Glomuvenous Malformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8712/0"},{"name":"Legacy Concept Name","value":"Glomangioma"},{"name":"Maps_To","value":"8712/0"},{"name":"Maps_To","value":"Glomangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334421"}]}}{"C4223":{"preferredName":"Glomangiomyoma","code":"C4223","definitions":[{"definition":"A morphologic variant of the glomus tumor with architectural features similar to solid glomus tumor.  It is characterized by the presence of elongated glomus cells which resemble mature smooth muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomangiomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8713/0"},{"name":"Legacy Concept Name","value":"Glomangiomyoma"},{"name":"Maps_To","value":"8713/0"},{"name":"Maps_To","value":"Glomangiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334422"}]}}{"C121792":{"preferredName":"Malignant PEComa","code":"C121792","definitions":[{"definition":"A usually large and aggressive tumor with perivascular epithelioid cell differentiation characterized by the presence of marked nuclear atypia, pleomorphism, increased mitotic activity, necrosis, and infiltrative margins.  The most common metastatic sites are liver, lungs, lymph nodes, and bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant PEComa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PEComa, malignant"},{"name":"Maps_To","value":"Perivascular epithelioid cell tumor, malignant"},{"name":"Maps_To","value":"Perivascular epithelioid tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839062"}]}}{"C7570":{"preferredName":"Melanocytic Nevus","code":"C7570","definitions":[{"definition":"A benign (not cancer) growth on the skin that is formed by a cluster of melanocytes (cells that make a substance called melanin, which gives color to skin and eyes). A mole is usually dark and may be raised from the skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm composed of melanocytes that usually appears as a dark spot on the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Melanotic Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanocytic_Nevus"},{"name":"Maps_To","value":"8720/0"},{"name":"Maps_To","value":"Melanocytic nevus"},{"name":"Maps_To","value":"Nevus, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027960"}]}}{"C27816":{"preferredName":"Pigmented Nevus","code":"C27816","definitions":[{"definition":"A nevus characterised by the presence of excessive pigment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8720/0"},{"name":"Legacy Concept Name","value":"Pigmented_Nevus"},{"name":"Maps_To","value":"8720/0"},{"name":"Maps_To","value":"Pigmented nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3553699"}]}}{"C3074":{"preferredName":"Hairy Nevus","code":"C3074","definitions":[{"definition":"A usually benign congenital skin growth that is often pigmented and sometimes develop coarse surface hair. There is a lifetime risk of transformation to malignant melanoma which varies depending on the size of the lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hairy Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Hair Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Nevoid Hypertrichosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hairy_Nevus"},{"name":"Maps_To","value":"8720/0"},{"name":"Maps_To","value":"Hairy nevus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018508"}]}}{"C8423":{"preferredName":"Stage 0 Cutaneous Melanoma AJCC v6 and v7","code":"C8423","definitions":[{"definition":"Abnormal melanocytes (cells that make melanin, the pigment that gives skin its color) are found in the epidermis (outer layer of the skin). These abnormal melanocytes may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Melanoma in situ.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Cutaneous Melanoma AJCC v6 and v7","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Cutaneous Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma in situ of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma in situ of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Melanoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Cutaneous Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Malignant Cutaneous Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Malignant Skin Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Melanoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Melanoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Skin Melanoma AJCC v6","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Skin Melanoma AJCC v6 and v7","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Skin Melanoma AJCC v7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8720/2"},{"name":"Legacy Concept Name","value":"Stage_0_Melanoma_of_the_Skin"},{"name":"Maps_To","value":"8720/2"},{"name":"Maps_To","value":"Melanoma in situ"},{"name":"Maps_To","value":"Melanoma in situ of other part of trunk"},{"name":"Maps_To","value":"Melanoma in situ of other sites"},{"name":"Maps_To","value":"Melanoma in situ of scalp and neck"},{"name":"Maps_To","value":"Melanoma in situ, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346040"}]}}{"C3224":{"preferredName":"Melanoma","code":"C3224","definitions":[{"definition":"A form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm composed of melanocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm comprised of melanocytes typically arising in the skin.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8720/3"},{"name":"Legacy Concept Name","value":"Melanoma"},{"name":"Maps_To","value":"8720/3"},{"name":"Maps_To","value":"Malignant melanoma, NOS"},{"name":"Maps_To","value":"Melanoma"},{"name":"Maps_To","value":"Melanoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025202"}]}}{"C205125":{"preferredName":"Nodular Melanoma","code":"C205125","definitions":[{"definition":"A melanoma that arises from the skin and mucosal sites. It is characterized by a vertical growth phase and lacks a significant radial growth phase. It may or may not arise from a pre-existing nevus. Morphologically, it is characterized by the presence of cohesive aggregates of neoplastic melanocytes in the dermis that often exhibit an epithelioid appearance. The overlying epidermis is often involved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Melanoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8721/3"},{"name":"Maps_To","value":"Nodular melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4226":{"preferredName":"Balloon Cell Nevus","code":"C4226","definitions":[{"definition":"An uncommon variant of melanocytic nevus. It presents as a small pigmented skin lesion. It is characterized by the presence of large melanocytes with clear, foamy or finely vacuolated cytoplasm. It may recur if it is not completely excised.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balloon Cell Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8722/0"},{"name":"Legacy Concept Name","value":"Balloon_Cell_Nevus"},{"name":"Maps_To","value":"8722/0"},{"name":"Maps_To","value":"Balloon cell nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334425"}]}}{"C4227":{"preferredName":"Balloon Cell Melanoma","code":"C4227","definitions":[{"definition":"A rare variant of melanoma with a vertical growth phase. It presents as a nodular or polypoid skin lesion. It is characterized by the presence of nodules which contain large melanoma cells with clear, foamy or finely vacuolated cytoplasm. The prognosis is similar to that of other melanomas matched for depth of invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balloon Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Balloon Cell Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Malignant Melanoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Malignant Melanoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Malignant Skin Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Balloon Cell Skin Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8722/3"},{"name":"Legacy Concept Name","value":"Balloon_Cell_Malignant_Skin_Melanoma"},{"name":"Maps_To","value":"8722/3"},{"name":"Maps_To","value":"Balloon cell melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334426"}]}}{"C7602":{"preferredName":"Halo Nevus","code":"C7602","definitions":[{"definition":"A melanocytic nevus characterized by circumferential depigmentation. It is usually associated with a brisk lymphocytic infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halo Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Leukoderma Acquisitum Centrifugum","termGroup":"SY","termSource":"NCI"},{"termName":"Perinevoid Leukoderma","termGroup":"SY","termSource":"NCI"},{"termName":"Perinevoid Vitiligo","termGroup":"SY","termSource":"NCI"},{"termName":"Sutton Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8723/0"},{"name":"Legacy Concept Name","value":"Halo_Nevus"},{"name":"Maps_To","value":"8723/0"},{"name":"Maps_To","value":"Halo nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474824"}]}}{"C7603":{"preferredName":"Regressing Nevus","code":"C7603","definitions":[{"definition":"A nevus associated with focal regression-like changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regressing Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Regressing_Nevus"},{"name":"Maps_To","value":"8723/0"},{"name":"Maps_To","value":"Regressing nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377589"}]}}{"C4228":{"preferredName":"Regressing Melanoma","code":"C4228","definitions":[{"definition":"A skin lesion characterized by the disappearance of the melanoma cells from the primary melanoma site. The disappearance of the malignant cells is associated with fibroplasia of the papillary dermis. According to some authors, complete regression of the primary melanoma may occur in 4-8% of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regressing Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Regressing Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8723/3"},{"name":"Legacy Concept Name","value":"Regressing_Melanoma"},{"name":"Maps_To","value":"8723/3"},{"name":"Maps_To","value":"Malignant melanoma, regressing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334427"}]}}{"C4229":{"preferredName":"Neuronevus","code":"C4229","definitions":[{"definition":"An intradermal nevus characterized by the presence of nests of atrophic nevus cells which are hyalinized and resemble nerve bundles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuronevus","termGroup":"PT","termSource":"NCI"},{"termName":"Neural Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8725/0"},{"name":"Legacy Concept Name","value":"Neuronevus"},{"name":"Maps_To","value":"8725/0"},{"name":"Maps_To","value":"Neuronevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334430"}]}}{"C9498":{"preferredName":"Melanocytoma","code":"C9498","definitions":[{"definition":"A usually benign neoplasm that arises from the sun-exposed skin, eye, and meninges. It is composed of spindle and/or epithelioid melanocytes and melanophages. It rarely progresses to melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Magnocellular Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanocytoma"},{"name":"Maps_To","value":"8726/0"},{"name":"Maps_To","value":"Magnocellular nevus"},{"name":"Maps_To","value":"Melanocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334431"}]}}{"C3694":{"preferredName":"Dysplastic Nevus","code":"C3694","definitions":[{"definition":"A type of nevus (mole) that looks different from a common mole. A dysplastic nevus is often larger with borders that are not easy to see. Its color is usually uneven and can range from pink to dark brown. Parts of the mole may be raised above the skin surface. A dysplastic nevus may develop into malignant melanoma (a type of skin cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Solitary or multiple, slightly raised pigmented melanocytic lesions with irregular borders, usually measuring more than 0.6cm in greatest dimension. Morphologically, there is melanocytic atypia and the differential diagnosis from melanoma may be difficult. Patients are at an increased risk for the development of melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dysplastic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Clark Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Clark's Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"NAD","termGroup":"AB","termSource":"NCI"},{"termName":"Nevus with Architectural Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Nevus with Architectural Disorder and Cytologic Atypia of Melanocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8727/0"},{"name":"Legacy Concept Name","value":"Dysplastic_Nevus"},{"name":"Maps_To","value":"8727/0"},{"name":"Maps_To","value":"Dysplastic nevus"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205748"}]}}{"C6890":{"preferredName":"Meningeal Melanocytosis","code":"C6890","definitions":[{"definition":"A diffuse or multifocal proliferation of uniform nevoid polygonal cells in the leptomeninges. Cells may spread into the Virchow-Robin spaces without frank invasion of the brain. Diffuse melanocytosis carries a poor prognosis even in the absence of histologic malignancy. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Melanocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Melanosis","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Meningeal Melanocytosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8728/0"},{"name":"Legacy Concept Name","value":"Diffuse_Melanocytosis"},{"name":"Maps_To","value":"8728/0"},{"name":"Maps_To","value":"Diffuse melanocytosis"},{"name":"Maps_To","value":"Meningeal melanocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266112"}]}}{"C4662":{"preferredName":"Meningeal Melanocytoma","code":"C4662","definitions":[{"definition":"A usually well differentiated melanocytic neoplasm arising from the meninges. It is characterized by the presence of epithelioid, fusiform, polyhedral, and spindle melanocytes without evidence of hemorrhage, necrosis, or high mitotic activity. Presenting symptoms include headache, vomiting, and neurological manifestations. Complete excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Leptomeningeal Melanocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytoma of Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytoma of the Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Meninges Melanocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8728/1"},{"name":"Legacy Concept Name","value":"Meningeal_Melanocytoma"},{"name":"Maps_To","value":"8728/1"},{"name":"Maps_To","value":"Meningeal melanocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266113"}]}}{"C6891":{"preferredName":"Meningeal Melanomatosis","code":"C6891","definitions":[{"definition":"A rare condition in patients with leptomeningeal melanoma characterized by diffuse or multifocal proliferation of melanoma cells in the leptomeninges. It is often associated with invasion of the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Leptomeningeal Melanomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Melanomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8728/3"},{"name":"Legacy Concept Name","value":"Melanomatosis"},{"name":"Legacy Concept Name","value":"Meningeal_Melanomatosis"},{"name":"Maps_To","value":"8728/3"},{"name":"Maps_To","value":"Meningeal melanomatosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266114"},{"name":"UMLS_CUI","value":"C1334691"}]}}{"C27095":{"preferredName":"Nonpigmented Nevus","code":"C27095","definitions":[{"definition":"A benign nevus characterized by the absence of melanin pigment in the melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonpigmented Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8730/0"},{"name":"Legacy Concept Name","value":"Nonpigmented_Nevus"},{"name":"Maps_To","value":"8730/0"},{"name":"Maps_To","value":"Achromic nevus"},{"name":"Maps_To","value":"Nonpigmented nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334432"}]}}{"C3802":{"preferredName":"Amelanotic Melanoma","code":"C3802","definitions":[{"definition":"A malignant neoplasm composed of melanocytes, which lack melanin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A melanoma characterized by the complete absence of melanin pigment in the melanoma cells. It occurs more frequently on the face and it is often associated with desmoplastic reaction.","type":"DEFINITION","source":"NCI"},{"definition":"A type of skin cancer in which the cells do not make melanin. Skin lesions are often irregular and may be pink, red, or have light brown, tan, or gray at the edges.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Amelanotic Melanoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8730/3"},{"name":"Legacy Concept Name","value":"Amelanotic_Melanoma"},{"name":"Maps_To","value":"8730/3"},{"name":"Maps_To","value":"Amelanotic melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206735"}]}}{"C4231":{"preferredName":"Junctional Nevus","code":"C4231","definitions":[{"definition":"A nevus characterized by the presence of an intraepidermal proliferation of nevus cells. The nevus cells form multiple nests in the dermal-epidermal junction. It presents as a small, slightly raised, pigmented skin lesion.","type":"DEFINITION","source":"NCI"},{"definition":"A type of nevus (mole) found at the junction (border) between the epidermis (outer) and the dermis (inner) layers of the skin. These moles may be colored and slightly raised.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Junctional Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Intraepidermal Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepidermal Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepidermal Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Junction Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Melanocytic Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Junctional Skin Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8740/0"},{"name":"Legacy Concept Name","value":"Junction_Nevus"},{"name":"Maps_To","value":"8740/0"},{"name":"Maps_To","value":"Intraepidermal nevus"},{"name":"Maps_To","value":"Junction nevus"},{"name":"Maps_To","value":"Junctional nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334433"}]}}{"C4232":{"preferredName":"Melanoma in Junctional Nevus","code":"C4232","definitions":[{"definition":"A melanoma arising from a melanocytic nevus which involves the dermal-epidermal junction of the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma in Junctional Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanoma in Junctional Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanoma of Skin in Junctional Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanoma of the Skin in Junctional Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Melanoma in Junctional Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8740/3"},{"name":"Legacy Concept Name","value":"Melanoma_in_Junctional_Nevus"},{"name":"Maps_To","value":"8740/3"},{"name":"Maps_To","value":"Malignant melanoma in junctional nevus"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334434"}]}}{"C4233":{"preferredName":"Precancerous Melanosis","code":"C4233","synonyms":[{"termName":"Precancerous Melanosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8741/2"},{"name":"Legacy Concept Name","value":"Precancerous_Melanosis"},{"name":"Maps_To","value":"8741/2"},{"name":"Maps_To","value":"Precancerous melanosis, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334435"}]}}{"C66753":{"preferredName":"Melanoma in Precancerous Melanosis","code":"C66753","definitions":[{"definition":"A melanoma arising from an atypical intraepithelial melanocytic hyperplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma in Precancerous Melanosis","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanoma in Precancerous Melanosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8741/3"},{"name":"Legacy Concept Name","value":"Malignant_Melanoma_in_Precancerous_Melanosis"},{"name":"Maps_To","value":"8741/3"},{"name":"Maps_To","value":"Malignant melanoma in precancerous melanosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431098"}]}}{"C43372":{"preferredName":"Lentigo Maligna","code":"C43372","definitions":[{"definition":"An atypical proliferation of atypical melanocytes in the dermal-epidermal junction, without infiltration of the papillary or reticular dermis. The melanocytic proliferation is associated with actinic damage and epidermal atrophy.  It usually occurs in the sun-exposed skin of elderly people.  It is a form of melanoma in situ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lentigo Maligna","termGroup":"PT","termSource":"NCI"},{"termName":"Hutchinson Melanotic Freckle","termGroup":"AQS","termSource":"NCI"},{"termName":"Hutchinson's Melanotic Freckle","termGroup":"AQS","termSource":"NCI"},{"termName":"Lentigo Maligna Melanoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"LMM In Situ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8742/2"},{"name":"Legacy Concept Name","value":"Lentigo_Maligna"},{"name":"Maps_To","value":"8742/2"},{"name":"Maps_To","value":"Hutchinson melanotic freckle, NOS"},{"name":"Maps_To","value":"Lentigo maligna"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0149722"}]}}{"C9151":{"preferredName":"Lentigo Maligna Melanoma","code":"C9151","definitions":[{"definition":"A melanoma of the skin characterized by single cell infiltration of the papillary dermis by atypical melanocytes, in a background of lentigo maligna changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lentigo Maligna Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"LMM","termGroup":"AB","termSource":"NCI"},{"termName":"Malignant Lentigo Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma in Hutchinson Melanotic Freckle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8742/3"},{"name":"Legacy Concept Name","value":"Lentigo_Maligna_Melanoma"},{"name":"Maps_To","value":"8742/3"},{"name":"Maps_To","value":"Lentigo maligna melanoma"},{"name":"Maps_To","value":"Malignant melanoma in Hutchinson melanotic freckle"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2739810"}]}}{"C204843":{"preferredName":"Low-CSD Melanoma, Superficial Spreading Melanoma Subtype","code":"C204843","definitions":[{"definition":"A cutaneous melanoma that develops on sun exposed sites with low cumulative sun damage (CSD). It is characterized by a prominent junctional and intraepidermal component with intraepidermal proliferation of individual atypical melanocytes and formation of nests of atypical melanocytes along the dermal-epidermal junction. The dermal component is composed of atypical melanocytes that fail to mature. The atypical melanocytes have large nuclei, prominent nucleoli, and eosinophilic or lightly pigmented cytoplasm. It is the most common melanoma subtype in the Western world.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low-CSD Melanoma, Superficial Spreading Melanoma Subtype","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Superficial Spreading Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low-CSD Melanoma, SSM Subtype","termGroup":"SY","termSource":"NCI"},{"termName":"Low-CSD Melanoma, Superficial Spreading Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low-CSD Melanoma, Superficial Spreading Melanoma (SSM)","termGroup":"SY","termSource":"NCI"},{"termName":"Low-CSD Melanoma/SSM","termGroup":"SY","termSource":"NCI"},{"termName":"Low-CSD Melanoma/Superficial Spreading Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pagetoid Melanoma","termGroup":"AQS","termSource":"NCI"},{"termName":"SSM","termGroup":"AB","termSource":"NCI"},{"termName":"Superficial Spreading Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Spreading Melanoma of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8743/3"},{"name":"Maps_To","value":"Low cumulative sun damage melanoma"},{"name":"Maps_To","value":"Superficial spreading melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4022":{"preferredName":"Acral Lentiginous Melanoma","code":"C4022","definitions":[{"definition":"A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin.  It presents as a pigmented macular lesion with irregular borders.  Morphologically, it consists of atypical spindled and dendritic melanocytes.  The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acral Lentiginous Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acral Lentiginous Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acral Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8744/3"},{"name":"Legacy Concept Name","value":"Acral_Lentiginous_Malignant_Melanoma"},{"name":"Maps_To","value":"8744/3"},{"name":"Maps_To","value":"Acral lentiginous melanoma, malignant"},{"name":"Maps_To","value":"Acral melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346037"}]}}{"C37257":{"preferredName":"Desmoplastic Melanoma","code":"C37257","definitions":[{"definition":"A melanoma of the skin characterized by a proliferation of atypical spindled melanocytes in the dermis, in a background of abundant collagen. It usually presents as an amelanotic raised nodular lesion.","type":"DEFINITION","source":"NCI"},{"definition":"A rare form of malignant melanoma marked by nonpigmented lesions on sun-exposed areas of the body, most commonly on the head and neck.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Desmoplastic Melanoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8745/3"},{"name":"Legacy Concept Name","value":"Desmoplastic_Melanoma"},{"name":"Maps_To","value":"8745/3"},{"name":"Maps_To","value":"Desmoplastic melanoma, amelanotic"},{"name":"Maps_To","value":"Desmoplastic melanoma, malignant"},{"name":"Maps_To","value":"Desmoplastic melanoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334439"}]}}{"C48622":{"preferredName":"Mucosal Lentiginous Melanoma","code":"C48622","definitions":[{"definition":"An acral lentiginous melanoma affecting mucosal surfaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucosal Lentiginous Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mucosal Lentiginous Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8746/3"},{"name":"Legacy Concept Name","value":"Mucosal_Lentiginous_Melanoma"},{"name":"Maps_To","value":"8746/3"},{"name":"Maps_To","value":"Mucosal lentiginous melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266115"}]}}{"C3804":{"preferredName":"Dermal Nevus","code":"C3804","definitions":[{"definition":"A nevus characterized by the proliferation of nevus cells in the dermis without involvement of the dermal-epidermal junction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dermal Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Intradermal Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8750/0"},{"name":"Legacy Concept Name","value":"Intradermal_Nevus"},{"name":"Maps_To","value":"8750/0"},{"name":"Maps_To","value":"Dermal nevus"},{"name":"Maps_To","value":"Intradermal nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206737"}]}}{"C3901":{"preferredName":"Compound Nevus","code":"C3901","definitions":[{"definition":"A nevus composed of neoplastic melanocytes that infiltrate both the epidermis and the dermis.","type":"DEFINITION","source":"NCI"},{"definition":"A type of mole formed by groups of nevus cells found in the epidermis and dermis (the two main layers of tissue that make up the skin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Compound Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Compound Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Compound Nevus of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8760/0"},{"name":"Legacy Concept Name","value":"Compound_Nevus"},{"name":"Maps_To","value":"8760/0"},{"name":"Maps_To","value":"Compound nevus"},{"name":"Maps_To","value":"Dermal and epidermal nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259781"}]}}{"C3944":{"preferredName":"Congenital Melanocytic Nevus","code":"C3944","definitions":[{"definition":"A melanocytic nevus that is present at birth. It may present as a small macular, papular, or plaque-like lesion or as a large brown to black hairy skin lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"CMN","termGroup":"AB","termSource":"NCI"},{"termName":"Congenital Melanocytic Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Melanocytic Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pigmented Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pigmented Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pigmented Skin Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Skin Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Congenital_Melanocytic_Skin_Nevus"},{"name":"Maps_To","value":"8761/0"},{"name":"Maps_To","value":"Congenital melanocytic nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1318558"}]}}{"C66754":{"preferredName":"Small Congenital Melanocytic Nevus","code":"C66754","definitions":[{"definition":"A congenital melanocytic nevus of small size, with a diameter smaller than 15 mm. It presents as a macular, papular or plaque-like lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Small Congenital Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8761/0"},{"name":"Legacy Concept Name","value":"Small_Congenital_Melanocytic_Nevus"},{"name":"Maps_To","value":"8761/0"},{"name":"Maps_To","value":"Small congenital nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1883045"}]}}{"C4234":{"preferredName":"Giant Congenital Melanocytic Nevus","code":"C4234","definitions":[{"definition":"A congenital melanocytic nevus that measures more than 200 mm or is unresectable. It usually presents as a dark brown to black hairy lesion. Morphologically, it is characterized by the presence of a compound or intradermal nevus. There is an increased risk of malignant transformation to melanoma, rhabdomyosarcoma, and poorly differentiated malignant tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Bathing Trunk Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"GCN","termGroup":"AB","termSource":"NCI"},{"termName":"Giant Congenital Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Pigmented Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Pigmented Nevus of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8761/1"},{"name":"Legacy Concept Name","value":"Giant_Pigmented_Nevus"},{"name":"Maps_To","value":"8761/1"},{"name":"Maps_To","value":"Giant pigmented nevus, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1842036"}]}}{"C4235":{"preferredName":"Melanoma Arising in Giant Congenital Nevus","code":"C4235","definitions":[{"definition":"A melanoma arising in a giant congenital melanocytic nevus. The risk of developing a melanoma in a giant congenital melanocytic nevus has been reported to be between 5% and 50%. The incidence of developing melanoma is higher before the age of 10 and in adult life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma Arising in Giant Congenital Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8761/3"},{"name":"Legacy Concept Name","value":"Skin_Melanoma_in_Giant_Pigmented_Nevus"},{"name":"Maps_To","value":"8761/3"},{"name":"Maps_To","value":"Malignant melanoma arising in giant congenital nevus"},{"name":"Maps_To","value":"Malignant melanoma in congenital melanocytic nevus"},{"name":"Maps_To","value":"Malignant melanoma in giant pigmented nevus"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334441"}]}}{"C66755":{"preferredName":"Proliferative Nodules in Congenital Melanocytic Nevus","code":"C66755","definitions":[{"definition":"A benign proliferation of epithelioid or spindled melanocytes usually in the upper or mid dermis in a background of congenital melanocytic nevus. The congenital melanocytic nevus is usually of the deep type, involving the dermis and extending into the subcutaneous tissue. It presents as a dark plaque or nodule above a giant congenital melanocytic nevus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proliferative Nodules in Congenital Melanocytic Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Proliferative Dermal Lesion in Congenital Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8762/1"},{"name":"Legacy Concept Name","value":"Proliferative_Dermal_Lesion_in_Congenital_Nevus"},{"name":"Maps_To","value":"8762/1"},{"name":"Maps_To","value":"Proliferative dermal lesion in congenital nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266117"}]}}{"C27007":{"preferredName":"Spitz Nevus","code":"C27007","definitions":[{"definition":"An acquired or congenital benign skin melanocytic neoplasm. It can occur on any area of the body, but most commonly occurs on the face of children and the thighs of young females. It is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes in the dermal-epidermal junction. The melanocytic proliferation subsequently extends into the dermis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spitz Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Juvenile Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle and/ or Epithelioid Cell Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8770/0"},{"name":"Legacy Concept Name","value":"Spitz_Spindle_Cell_Nevus"},{"name":"Maps_To","value":"8770/0"},{"name":"Maps_To","value":"Epithelioid and spindle cell nevus"},{"name":"Maps_To","value":"Juvenile melanoma"},{"name":"Maps_To","value":"Juvenile nevus"},{"name":"Maps_To","value":"Spindle cell nevus, NOS"},{"name":"Maps_To","value":"Spitz nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206739"}]}}{"C4751":{"preferredName":"Pigmented Spindle Cell Nevus","code":"C4751","definitions":[{"definition":"A subtype of Spitz nevus characterized by the presence of heavily pigmented spindle-shaped melanocytes that proliferate in the epidermis or in the epidermis and superficial dermis. It presents as a small and slightly elevated brown or black skin lesion with usually well-demarcated borders. Sometimes the clinical and morphologic features may be difficult to distinguish from melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Spindle Cell Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Pigmented Spindle Cell Nevus of Reed","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Spindle Cell Spitz Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Spindle Cell Variant of Spitz Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"PSCN","termGroup":"AB","termSource":"NCI"},{"termName":"Reed Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Nevus of Reed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pigmented_Spindle_Cell_Nevus"},{"name":"Maps_To","value":"8770/0"},{"name":"Maps_To","value":"Pigmented spindle cell nevus of Reed"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474967"}]}}{"C66756":{"preferredName":"Mixed Epithelioid and Spindle Cell Melanoma","code":"C66756","definitions":[{"definition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes and malignant spindle-shaped melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Epithelioid and Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8770/3"},{"name":"Legacy Concept Name","value":"Mixed_Epithelioid_and_Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8770/3"},{"name":"Maps_To","value":"Mixed epithelioid and spindle cell melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334442"}]}}{"C66757":{"preferredName":"Epithelioid Cell Nevus","code":"C66757","definitions":[{"definition":"A Spitz nevus characterized by the presence of large epithelioid melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Cell Nevus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8771/0"},{"name":"Legacy Concept Name","value":"Epithelioid_Cell_Nevus"},{"name":"Maps_To","value":"8771/0"},{"name":"Maps_To","value":"Epithelioid cell nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259820"}]}}{"C4236":{"preferredName":"Epithelioid Cell Melanoma","code":"C4236","definitions":[{"definition":"A melanoma characterized by the presence of malignant large epithelioid melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Cell Malignant Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8771/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Cell_Melanoma"},{"name":"Maps_To","value":"8771/3"},{"name":"Maps_To","value":"Epithelioid cell melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334443"}]}}{"C4237":{"preferredName":"Spindle Cell Melanoma","code":"C4237","definitions":[{"definition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8772/3"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8772/3"},{"name":"Maps_To","value":"Spindle cell melanoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334444"}]}}{"C4238":{"preferredName":"Type A Spindle Cell Melanoma","code":"C4238","definitions":[{"definition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes with slender nuclei and no visible nucleoli. Representative example is the type A spindle cell uveal melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Type A Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Type A Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Type A Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8773/3"},{"name":"Legacy Concept Name","value":"Type_A_Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8773/3"},{"name":"Maps_To","value":"Spindle cell melanoma, type A"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334445"}]}}{"C4239":{"preferredName":"Type B Spindle Cell Melanoma","code":"C4239","definitions":[{"definition":"A melanoma characterized by the presence of malignant spindle-shaped melanocytes with larger nuclei and distinct nucleoli. Representative example is the type B spindle cell uveal melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Type B Spindle Cell Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Spindle Cell Type B Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Type B Malignant Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8774/3"},{"name":"Legacy Concept Name","value":"Type_B_Spindle_Cell_Melanoma"},{"name":"Maps_To","value":"8774/3"},{"name":"Maps_To","value":"Spindle cell melanoma, type B"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334446"}]}}{"C3803":{"preferredName":"Blue Nevus","code":"C3803","definitions":[{"definition":"An intradermal nevus characterized by the presence of benign pigmented dendritic spindle-shaped melanocytes. It most frequently occurs in the skin of the distal upper extremities, followed by the lower extremities, scalp, face, and buttocks. It usually presents as a single blue or blue-black papular lesion less than 1cm in diameter. Simple excision is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blue Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Blue Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Blue Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Blue Skin Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8780/0"},{"name":"Legacy Concept Name","value":"Blue_Nevus"},{"name":"Maps_To","value":"8780/0"},{"name":"Maps_To","value":"Blue nevus, NOS"},{"name":"Maps_To","value":"Jadassohn blue nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206736"}]}}{"C4240":{"preferredName":"Melanoma Arising in Blue Nevus","code":"C4240","definitions":[{"definition":"A rare melanoma which develops in a pre-existing blue nevus. It occurs more frequently on the scalp, face, orbit, back, buttocks, extremities, hands, and feet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma Arising in Blue Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"Blue Nevus-Like Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Blue Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Blue Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Blue Nevus of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Cutaneous Blue Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Blue Nevus","termGroup":"SY","termSource":"NCI"},{"termName":"MBN","termGroup":"AB","termSource":"NCI"},{"termName":"Melanoma Arising from Blue Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8780/3"},{"name":"Legacy Concept Name","value":"Blue_Nevus-Like_Melanoma"},{"name":"Maps_To","value":"8780/3"},{"name":"Maps_To","value":"Blue nevus, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334447"}]}}{"C4241":{"preferredName":"Cellular Blue Nevus","code":"C4241","definitions":[{"definition":"A blue nevus characterized by a multinodular cellular infiltrate with a dumb-bell architecture occupying the reticular dermis. The cellular infiltrate often extends into the subcutaneous tissue. The cellular infiltrate is composed of spindle-shaped melanocytes with pale cytoplasm alternating with bundles of pigmented spindle-shaped melanocytes. In occasional cases an increased mitotic activity, focal necrosis, and nuclear pleomorphism may be seen. Such cases with atypical features may have an uncertain malignant potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Blue Nevus","termGroup":"PT","termSource":"NCI"},{"termName":"CBN","termGroup":"AB","termSource":"NCI"},{"termName":"Cellular Blue Nevus of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Cellular Blue Nevus of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8790/0"},{"name":"Legacy Concept Name","value":"Cellular_Blue_Nevus"},{"name":"Maps_To","value":"8790/0"},{"name":"Maps_To","value":"Cellular blue nevus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334448"}]}}{"C4242":{"preferredName":"Benign Soft Tissue Neoplasm","code":"C4242","definitions":[{"definition":"A neoplasm that arises from soft tissue and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Soft Tissue Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasm of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Soft Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8800/0"},{"name":"Legacy Concept Name","value":"Benign_Soft_Tissue_Neoplasm"},{"name":"Maps_To","value":"8800/0"},{"name":"Maps_To","value":"Soft tissue tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334450"}]}}{"C4867":{"preferredName":"Malignant Soft Tissue Neoplasm","code":"C4867","definitions":[{"definition":"A malignant neoplasm arising exclusively from the soft tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Soft Tissue Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Soft Tissue Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Soft_Tissue_Neoplasm"},{"name":"Maps_To","value":"8800/3"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of abdomen"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of head, face, and neck"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of pelvis"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of thorax"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of trunk, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of connective and other soft tissue, site unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of left lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of right lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of other connective and soft tissue"},{"name":"Maps_To","value":"Malignant neoplasm of other specified sites of connective and other soft tissue"},{"name":"Maps_To","value":"Malignant neoplasm of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of abdomen"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of head, face and neck"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of pelvis"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of thorax"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of trunk, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue of upper limb, including shoulder"},{"name":"Maps_To","value":"Malignant neoplasm: Connective and soft tissue, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Overlapping lesion of connective and soft tissue"},{"name":"Maps_To","value":"Soft tissue tumor, malignant"},{"name":"NCI_META_CUI","value":"CL336320"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9118":{"preferredName":"Sarcoma","code":"C9118","definitions":[{"definition":"A cancer of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant mesenchymal neoplasm. A general term for which the transformed cell type has not been specified.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"SAR","termGroup":"AB","termSource":"NCI"},{"termName":"Sarcoma of Soft Tissue and Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Soft Tissue and Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8800/3"},{"name":"Legacy Concept Name","value":"Sarcoma_of_the_Soft_Tissue_and_Bone"},{"name":"Maps_To","value":"8800/3"},{"name":"Maps_To","value":"Mesenchymal tumor, malignant"},{"name":"Maps_To","value":"Sarcoma"},{"name":"Maps_To","value":"Sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1261473"}]}}{"C9306":{"preferredName":"Soft Tissue Sarcoma","code":"C9306","definitions":[{"definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","type":"DEFINITION","source":"NCI"},{"definition":"A solid, malignant neoplasm originating in muscle, tendon, fat, blood vessels, nerves, connective or joint tissue.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Soft Tissue Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcoma of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Soft_Tissue_Sarcoma"},{"name":"Maps_To","value":"8800/3"},{"name":"Maps_To","value":"Soft tissue sarcoma"},{"name":"Maps_To","value":"Soft tissue sarcoma, non-rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2211494"}]}}{"C4243":{"preferredName":"Sarcomatosis","code":"C4243","definitions":[{"definition":"The occurrence of several sarcomas in different anatomic locations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8800/9"},{"name":"Legacy Concept Name","value":"Sarcomatosis"},{"name":"Maps_To","value":"8800/9"},{"name":"Maps_To","value":"Sarcomatosis, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334451"}]}}{"C27005":{"preferredName":"Spindle Cell Sarcoma","code":"C27005","definitions":[{"definition":"A malignant mesenchymal neoplasm composed of spindle-shaped cells.  This is a morphologic term which can be applied to a wide range of sarcomas.","type":"DEFINITION","source":"NCI"},{"definition":"A type of connective tissue cancer in which the cells are spindle-shaped when examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Spindle Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8801/3"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Sarcoma"},{"name":"Maps_To","value":"8801/3"},{"name":"Maps_To","value":"Spindle cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205945"}]}}{"C66759":{"preferredName":"Giant Cell Sarcoma","code":"C66759","definitions":[{"definition":"A sarcoma characterized by the presence of large, anaplastic malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Sarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8802/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Sarcoma"},{"name":"Maps_To","value":"8802/3"},{"name":"Maps_To","value":"Giant cell sarcoma"},{"name":"Maps_To","value":"Pleomorphic cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1261358"}]}}{"C3746":{"preferredName":"Small Cell Sarcoma","code":"C3746","definitions":[{"definition":"A sarcoma characterized by the presence of small round or elongated malignant cells with a small amount of cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Small Cell Sarcomas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8803/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Sarcoma"},{"name":"Maps_To","value":"8803/3"},{"name":"Maps_To","value":"Small cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206652"}]}}{"C3714":{"preferredName":"Epithelioid Sarcoma","code":"C3714","definitions":[{"definition":"An aggressive malignant neoplasm of uncertain differentiation, characterized by the presence of epithelioid cells forming nodular patterns.  The nodules often undergo central necrosis, resulting in a pseudogranulomatous growth pattern.  It usually occurs in young adults.  The most common sites of involvement are the extremities (distal-type epithelioid sarcoma), and less frequently the pelvis, perineum, and genital organs (proximal-type epithelioid sarcoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"ES","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8804/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Sarcoma"},{"name":"Maps_To","value":"8804/3"},{"name":"Maps_To","value":"Epithelioid cell sarcoma"},{"name":"Maps_To","value":"Epithelioid sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205944"}]}}{"C121793":{"preferredName":"Undifferentiated Soft Tissue Sarcoma","code":"C121793","definitions":[{"definition":"A term that refers to a heterogeneous group of uncommon soft tissue sarcomas that do not show an identifiable line of differentiation using currently available technologies.  This is a diagnosis of exclusion and includes undifferentiated pleomorphic sarcoma (also known as malignant fibrous histiocytoma), undifferentiated spindle cell sarcoma, undifferentiated round cell sarcoma, and undifferentiated epithelioid sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Soft Tissue Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Undifferentiated Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated/Unclassified Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated/Unclassified Soft Tissue Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"USTS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8805/3"},{"name":"Maps_To","value":"Undifferentiated sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2188153"}]}}{"C8300":{"preferredName":"Desmoplastic Small Round Cell Tumor","code":"C8300","definitions":[{"definition":"A rare, aggressive cancer that usually affects young males and usually is located in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant soft tissue neoplasm of uncertain differentiation.  It is characterized by a recurrent chromosomal translocation t(11;22)(p13;q12) and the presence of small round cells in a desmoplastic stroma.  It usually affects children and young adults.  The most common site of involvement is the abdomen.  Patients usually present with abdominal distention, pain, ascites, and a palpable abdominal mass.  The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Small Round Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Desmoplastic Small Round-Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoplastic Small Round-Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"DSRCT","termGroup":"AB","termSource":"NCI"},{"termName":"Polyphenotypic Small Round Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8806/3"},{"name":"Legacy Concept Name","value":"Desmoplastic_Small_Round_Cell_Tumor"},{"name":"Maps_To","value":"8806/3"},{"name":"Maps_To","value":"Desmoplastic small round cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0281508"}]}}{"C3041":{"preferredName":"Fibroma","code":"C3041","definitions":[{"definition":"A benign neoplasm arising from fibrous tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-metastasizing neoplasm arising from the fibrous tissue. It is characterized by the presence of spindle-shaped fibroblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8810/0"},{"name":"Legacy Concept Name","value":"Fibroma"},{"name":"Maps_To","value":"8810/0"},{"name":"Maps_To","value":"Fibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0016045"}]}}{"C3043":{"preferredName":"Fibrosarcoma","code":"C3043","definitions":[{"definition":"A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant mesenchymal neoplasm of the soft tissue and bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fibrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8810/3"},{"name":"Legacy Concept Name","value":"Fibrosarcoma"},{"name":"Maps_To","value":"8810/3"},{"name":"Maps_To","value":"Fibrosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0016057"}]}}{"C6892":{"preferredName":"Cellular Fibroma","code":"C6892","definitions":[{"definition":"A morphologic variant of fibroma characterized by increased cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8810/1"},{"name":"Legacy Concept Name","value":"Cellular_Fibroma"},{"name":"Maps_To","value":"8810/1"},{"name":"Maps_To","value":"Cellular fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266118"}]}}{"C66760":{"preferredName":"Fibromyxoid Tumor","code":"C66760","definitions":[{"definition":"A benign soft-tissue neoplasm of uncertain lineage, characterized by the presence of neoplastic spindle-shaped to round cells and a fibromyxoid stroma.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A soft tissue tumor of uncertain lineage characterized by the presence of neoplastic spindle-shaped to round cells in a fibromyxoid stroma. Metaplastic bone formation may or may not be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibromyxoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibromyxoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Fibromyxoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8811/0"},{"name":"Legacy Concept Name","value":"Fibromyxoid_Neoplasm"},{"name":"Maps_To","value":"8811/0"},{"name":"Maps_To","value":"Fibromyxoma"},{"name":"Maps_To","value":"Fibromyxoma, NOS"},{"name":"Maps_To","value":"Myxofibroma, NOS"},{"name":"Maps_To","value":"Myxoid fibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205766"}]}}{"C49025":{"preferredName":"Myxoinflammatory Fibroblastic Sarcoma","code":"C49025","definitions":[{"definition":"A low grade, locally aggressive, fibroblastic neoplasm that occurs primarily in the distal extremities.  It is characterized by the presence of spindle-shaped fibroblasts, multivacuolated lipoblast-like cells, bizarre ganglion-like cells with inclusion-like nuclei, myxoid stroma formation, and a mixture of acute and chronic inflammatory cells.  Distant metastases are very rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxoinflammatory Fibroblastic Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acral Myxoinflammatory Fibroblastic Sarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Inflammatory Myxohyaline Tumor of the Distal Extremities with Virocyte/Reed-Sternberg-Like Cells","termGroup":"AQS","termSource":"NCI"},{"termName":"Inflammatory Myxoid Tumor of the Soft Parts with Bizarre Giant Cells","termGroup":"AQS","termSource":"NCI"},{"termName":"MIFS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myxoinflammatory_Fibroblastic_Sarcoma"},{"name":"Maps_To","value":"Myxoinflammatory fibroblastic sarcoma"},{"name":"Maps_To","value":"Myxoinflammatory fibroblastic sarcoma (MIFS)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709103"}]}}{"C6496":{"preferredName":"Myxofibrosarcoma","code":"C6496","definitions":[{"definition":"A malignant fibroblastic neoplasm arising from the soft tissue. It is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxofibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Myxoid Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Myxoid MFH","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8811/3"},{"name":"Legacy Concept Name","value":"Myxoid_Malignant_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8811/3"},{"name":"Maps_To","value":"Fibromyxosarcoma"},{"name":"Maps_To","value":"Myxofibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334454"}]}}{"C66761":{"preferredName":"Periosteal Fibroma","code":"C66761","definitions":[{"definition":"A benign fibrous neoplasm arising from the periosteal connective tissue that surrounds a bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8812/0"},{"name":"Legacy Concept Name","value":"Periosteal_Fibroma"},{"name":"Maps_To","value":"8812/0"},{"name":"Maps_To","value":"Periosteal fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334455"}]}}{"C66763":{"preferredName":"Periosteal Fibrosarcoma","code":"C66763","definitions":[{"definition":"A malignant fibroblastic tumor arising from the periosteal connective tissue that surrounds a bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Fibrosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8812/3"},{"name":"Legacy Concept Name","value":"Periosteal_Fibrosarcoma"},{"name":"Maps_To","value":"8812/3"},{"name":"Maps_To","value":"Periosteal fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334456"}]}}{"C66764":{"preferredName":"Fascial Fibroma","code":"C66764","definitions":[{"definition":"A benign fibrous tumor arising from the fascial connective tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fascial Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8813/0"},{"name":"Legacy Concept Name","value":"Fascial_Fibroma"},{"name":"Maps_To","value":"8813/0"},{"name":"Maps_To","value":"Fascial fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334457"}]}}{"C66765":{"preferredName":"Fascial Fibrosarcoma","code":"C66765","definitions":[{"definition":"A malignant fibroblastic neoplasm arising from the fascial connective tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fascial Fibrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8813/3"},{"name":"Legacy Concept Name","value":"Fascial_Fibrosarcoma"},{"name":"Maps_To","value":"8813/3"},{"name":"Maps_To","value":"Fascial fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334458"}]}}{"C4244":{"preferredName":"Infantile Fibrosarcoma","code":"C4244","definitions":[{"definition":"A fibrosarcoma that occurs in infants.  It shares identical morphologic features with adult fibrosarcoma but carries the t(12;15)(p13;q25) translocation that results in ETV6-NTRK3 gene fusion.  It usually affects the superficial and deep soft tissues of the extremities.  The prognosis is generally much more favorable than for adult fibrosarcoma, and it rarely metastasizes.","type":"DEFINITION","source":"NCI"},{"definition":"A fibrosarcoma typically congenital, and occurring most commonly within the first three months of life, sharing identical morphologic features with adult fibrosarcoma but rarely metastatic. It usually affects the superficial and deep soft tissues of the extremities. The majority of infantile fibrosarcomas carry the t(12;15)(p13;q25) translocation.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Infantile Fibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Congenital Fibrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"IFS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8814/3"},{"name":"Legacy Concept Name","value":"Infantile_Fibrosarcoma"},{"name":"Maps_To","value":"8814/3"},{"name":"Maps_To","value":"Congenital fibrosarcoma"},{"name":"Maps_To","value":"Infantile fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334459"}]}}{"C7634":{"preferredName":"Solitary Fibrous Tumor","code":"C7634","definitions":[{"definition":"A localized neoplasm of probable fibroblastic derivation. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Fibrous Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Localized Fibrous Mesothelioma","termGroup":"AQS","termSource":"NCI"},{"termName":"Localized Fibrous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"SFT","termGroup":"AB","termSource":"NCI"},{"termName":"Submesothelial Fibroma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8815/0"},{"name":"ICD-O-3_Code","value":"8815/1"},{"name":"ICD-O-3_Code","value":"9051/0"},{"name":"Legacy Concept Name","value":"Solitary_Fibrous_Tumor"},{"name":"Maps_To","value":"8815/0"},{"name":"Maps_To","value":"Localized fibrous tumor"},{"name":"Maps_To","value":"Solitary fibrous tumor"},{"name":"Maps_To","value":"Solitary fibrous tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266119"}]}}{"C129528":{"preferredName":"Central Nervous System Solitary Fibrous Tumor, Grade 2","code":"C129528","definitions":[{"definition":"A solitary fibrous tumor that arises from the central nervous system. It corresponds to the more cellular, less collagenous tumor with plump cells and staghorn vasculature which was diagnosed as central nervous system hemangiopericytoma in the past.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Solitary Fibrous Tumor, Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor, Grade 2","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)"},{"name":"NCI_META_CUI","value":"CL512611"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6894":{"preferredName":"Malignant Solitary Fibrous Tumor","code":"C6894","definitions":[{"definition":"A malignant neoplasm of probable fibroblastic derivation. It is characterized by the presence of atypical round to spindle-shaped cells, increased cellularity, necrotic change and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Solitary Fibrous Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8815/3"},{"name":"Legacy Concept Name","value":"Malignant_Solitary_Fibrous_Tumor"},{"name":"Maps_To","value":"8815/3"},{"name":"Maps_To","value":"Solitary fibrous tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266120"}]}}{"C4245":{"preferredName":"Elastofibroma","code":"C4245","definitions":[{"definition":"A benign, slow-growing tumor arising from the soft tissues usually in the mid-thoracic region of the elderly. It is characterized by the presence of paucicellular collagenous tissue, adipocytes and a predominance of large coarse elastic fibers arranged in globules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elastofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Elastofibroma Dorsi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8820/0"},{"name":"Legacy Concept Name","value":"Elastofibroma"},{"name":"Maps_To","value":"8820/0"},{"name":"Maps_To","value":"Elastofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334460"}]}}{"C6489":{"preferredName":"Extraabdominal Fibromatosis","code":"C6489","definitions":[{"definition":"An insidious poorly circumscribed neoplasm arising from the soft tissues outside the abdomen. It is characterized by the presence of elongated spindle-shaped fibroblasts, vascular collagenous stroma formation, and an infiltrative growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraabdominal Fibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Extraabdominal Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Extraabdominal Desmoid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Extraabdominal_Fibromatosis"},{"name":"Maps_To","value":"8821/1"},{"name":"Maps_To","value":"Extra-abdominal desmoid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275420"}]}}{"C9182":{"preferredName":"Desmoid Fibromatosis","code":"C9182","definitions":[{"definition":"A tumor of the tissue that surrounds muscles, usually in the abdomen. A desmoid tumor rarely metastasizes (spreads to other parts of the body).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An insidious, locally aggressive, poorly circumscribed neoplasm arising from the deep soft tissues. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern. It lacks metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoid Fibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Fibromatosis/Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoid-Type Fibromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8821/1"},{"name":"Legacy Concept Name","value":"Deep_Fibromatosis_Desmoid_Tumor"},{"name":"Maps_To","value":"8821/1"},{"name":"Maps_To","value":"Aggressive fibromatosis"},{"name":"Maps_To","value":"Desmoid, NOS"},{"name":"Maps_To","value":"Invasive fibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079218"}]}}{"C3741":{"preferredName":"Abdominal (Mesenteric) Fibromatosis","code":"C3741","definitions":[{"definition":"An insidious poorly circumscribed neoplasm arising from the deep soft tissues of the abdomen. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abdominal (Mesenteric) Fibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Abdominal Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Abdominal Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Abdominal Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Intraabdominal Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Intraabdominal Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Intraabdominal Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Mesenteric Desmoid","termGroup":"SY","termSource":"NCI"},{"termName":"Mesenteric Desmoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mesenteric Fibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Peritoneal Desmoid Fibromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8822/1"},{"name":"Legacy Concept Name","value":"Abdominal_Fibromatosis"},{"name":"Maps_To","value":"8822/1"},{"name":"Maps_To","value":"Abdominal desmoid"},{"name":"Maps_To","value":"Abdominal fibromatosis"},{"name":"Maps_To","value":"Mesenteric fibromatosis"},{"name":"Maps_To","value":"Retroperitoneal fibromatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206646"}]}}{"C3740":{"preferredName":"Desmoplastic Fibroma","code":"C3740","definitions":[{"definition":"A benign neoplasm characterized by osteolysis and the presence of a rich collagenous stroma and spindle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, benign, locally aggressive osteolytic neoplasm. It is characterized by the presence of a rich collagenous stroma and spindle cells with minimal cellular atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Desmoplastic Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoid Tumor of Bone","termGroup":"AQS","termSource":"NCI"},{"termName":"Desmoplastic Fibroma of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoplastic Fibroma of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Desmoplastic Fibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8823/0"},{"name":"Legacy Concept Name","value":"Bone_Desmoplastic_Fibroma"},{"name":"Maps_To","value":"8823/0"},{"name":"Maps_To","value":"Desmoplastic fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206645"}]}}{"C7052":{"preferredName":"Myofibroma","code":"C7052","definitions":[{"definition":"A benign, localized, nodular and well-circumscribed neoplasm usually seen as a congenital neoplasm or in the first year of life. It is characterized by a biphasic growth pattern and is composed of small, undifferentiated mesenchymal cells associated with branching thin-walled vessels and more mature neoplastic spindle cells with abundant eosinophilic cytoplasm in a collagenous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8824/0"},{"name":"Legacy Concept Name","value":"Solitary_Myofibromatosis"},{"name":"Maps_To","value":"8824/0"},{"name":"Maps_To","value":"Myofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4228279"}]}}{"C3742":{"preferredName":"Myofibromatosis","code":"C3742","definitions":[{"definition":"A benign, multifocal, nodular and well-circumscribed neoplasm usually seen as a congenital neoplasm or in the first year of life. It is characterized by a biphasic growth pattern and is composed of small, undifferentiated mesenchymal cells associated with branching thin-walled vessels and more mature neoplastic spindle cells with abundant eosinophilic cytoplasm in a collagenous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myofibromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Infantile Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Infantile Myofibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Multicentric Myofibromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8824/1"},{"name":"Legacy Concept Name","value":"Myofibromatosis"},{"name":"Maps_To","value":"8824/1"},{"name":"Maps_To","value":"Infantile myofibromatosis"},{"name":"Maps_To","value":"Myofibromatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206648"}]}}{"C49012":{"preferredName":"Myofibroblastoma","code":"C49012","definitions":[{"definition":"A benign, well circumscribed soft tissue neoplasm characterized by the presence of spindle shaped myofibroblasts and mast cells in a collagenous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myofibroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8825/0"},{"name":"Legacy Concept Name","value":"Myofibroblastoma"},{"name":"Maps_To","value":"8825/0"},{"name":"Maps_To","value":"Myofibroblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0242404"}]}}{"C6481":{"preferredName":"Inflammatory Myofibroblastic Tumor","code":"C6481","definitions":[{"definition":"A multinodular intermediate fibroblastic neoplasm that arises from soft tissue or viscera, in children and young adults.  It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes, and plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inflammatory Myofibroblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"IMT","termGroup":"AB","termSource":"NCI"},{"termName":"Inflammatory Fibrosarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Inflammatory Myofibroblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Pseudotumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8825/1"},{"name":"Legacy Concept Name","value":"Inflammatory_Myofibroblastic_Tumor"},{"name":"Maps_To","value":"Inflammatory myofibroblastic tumor"},{"name":"Maps_To","value":"Myofibroblastic tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334121"}]}}{"C49024":{"preferredName":"Low Grade Myofibroblastic Sarcoma","code":"C49024","definitions":[{"definition":"A low-grade malignant neoplasm arising from the soft tissue and rarely bone. It is characterized by the presence of spindle-shaped myofibroblasts and collagenous stroma formation in a storiform growth pattern. Metastasis is very rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Myofibroblastic Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Low-Grade Myofibroblastic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myofibroblastic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myofibrosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8825/3"},{"name":"Legacy Concept Name","value":"Low_Grade_Myofibroblastic_Sarcoma"},{"name":"Maps_To","value":"8825/3"},{"name":"Maps_To","value":"Low-grade myofibroblastic sarcoma"},{"name":"Maps_To","value":"Myofibroblastic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708751"}]}}{"C49016":{"preferredName":"Angiomyofibroblastoma","code":"C49016","definitions":[{"definition":"A benign myofibroblastic neoplasm, usually arising in the pelviperineal region. It is characterized by the presence of neoplastic spindle to round cells, dilated thin walled vessels, and stromal edema.  Most patients present with painless circumscribed masses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomyofibroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8826/0"},{"name":"Legacy Concept Name","value":"Angiomyofibroblastoma"},{"name":"Maps_To","value":"8826/0"},{"name":"Maps_To","value":"Angiomyofibroblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266123"}]}}{"C142823":{"preferredName":"Congenital Peribronchial Myofibroblastic Tumor","code":"C142823","definitions":[{"definition":"A rare lung neoplasm that occurs in the intrauterine and perinatal period. It is characterized by the proliferation of spindle cells in an interstitial, peribronchial pattern. Surgical resection of the involved lung parenchyma is the treatment of choice.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Congenital Peribronchial Myofibroblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Congenital Bronchopulmonary Leiomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Fibrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Mesenchymal Malformation of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Congenital Pulmonary Myofibroblastic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neonatal Pulmonary Hamartoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8827/1"},{"name":"Maps_To","value":"Congenital peribronchial myofibroblastic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266124"}]}}{"C39740":{"preferredName":"Lung Inflammatory Myofibroblastic Tumor","code":"C39740","definitions":[{"definition":"An intermediate fibroblastic neoplasm arising from the lung.  It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes and plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Inflammatory Myofibroblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Myofibroblastic Tumor, Peribronchial","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8827/1"},{"name":"Legacy Concept Name","value":"Lung_Inflammatory_Myofibroblastic_Tumor"},{"name":"Maps_To","value":"8827/1"},{"name":"Maps_To","value":"Myofibroblastic tumor, peribronchial"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518038"}]}}{"C3739":{"preferredName":"Fibrous Histiocytoma","code":"C3739","definitions":[{"definition":"A benign neoplasm composed of a fibroblastic and a histiocytic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm composed of fibroblastic spindle cells in a whorled storiform pattern.  It is characterized by the presence of foam cells, inflammatory cells, hemosiderin deposition and stromal hemorrhage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8830/0"},{"name":"Legacy Concept Name","value":"Benign_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8830/0"},{"name":"Maps_To","value":"Benign fibrous histiocytoma"},{"name":"Maps_To","value":"Benign fibrous histiocytoma, NOS"},{"name":"Maps_To","value":"Fibrous histiocytoma, NOS"},{"name":"Maps_To","value":"Fibroxanthoma, NOS"},{"name":"Maps_To","value":"Xanthofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206644"}]}}{"C4246":{"preferredName":"Atypical Fibroxanthoma","code":"C4246","definitions":[{"definition":"An intermediate cutaneous mesenchymal neoplasm of uncertain differentiation, usually affecting the actinic-damaged skin of the elderly.  The tumor presents as a single cutaneous nodule which is often ulcerated.  Microscopically, it is characterized by the presence of highly atypical cytologic features, pleomorphism and abundant mitotic figures. The vast majority of patients have an excellent prognosis following conservative therapy. Recurrences are infrequent, and metastasis is rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Fibroxanthoma","termGroup":"PT","termSource":"NCI"},{"termName":"AFX","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Cutaneous Fibroxanthoma","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Fibroxanthoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Fibroxanthoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Skin Fibroxanthoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8830/1"},{"name":"Legacy Concept Name","value":"Atypical_Fibroxanthoma"},{"name":"Maps_To","value":"8830/1"},{"name":"Maps_To","value":"Atypical fibrous histiocytoma"},{"name":"Maps_To","value":"Atypical fibroxanthoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346053"}]}}{"C4247":{"preferredName":"Undifferentiated Pleomorphic Sarcoma","code":"C4247","definitions":[{"definition":"A malignant neoplasm composed of a fibroblastic and a histiocytic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A soft tissue sarcoma that usually occurs in the limbs, most commonly the legs, and may also occur in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate.  It is also known as malignant fibrous histiocytoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Pleomorphic Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroxanthosarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibroxanthoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MFH","termGroup":"AB","termSource":"NCI"},{"termName":"Storiform-Pleomorphic Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Storiform-Pleomorphic Malignant Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Storiform-Pleomorphic MFH","termGroup":"AQS","termSource":"NCI"},{"termName":"Unclassified Pleomorphic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Pleomorphic Sarcoma (Formerly \"Malignant Fibrous Histiocytoma\")","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassified Pleomorphic Sarcoma (Formerly \"MFH\")","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Pleomorphic Soft Tissue Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"UPS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8830/3"},{"name":"Legacy Concept Name","value":"Malignant_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8830/3"},{"name":"Maps_To","value":"Fibroxanthoma, malignant"},{"name":"Maps_To","value":"Malignant fibrous histiocytoma"},{"name":"Maps_To","value":"Undifferentiated pleomorphic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3549501"}]}}{"C35765":{"preferredName":"Histiocytoma","code":"C35765","definitions":[{"definition":"A mesenchymal tumor composed of fibroblastic and histiocytic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histiocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8831/0"},{"name":"Legacy Concept Name","value":"Histiocytoma"},{"name":"Maps_To","value":"8831/0"},{"name":"Maps_To","value":"Histiocytoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1509147"}]}}{"C3356":{"preferredName":"Solitary Reticulohistiocytoma","code":"C3356","definitions":[{"definition":"A rare cutaneous lesion composed of eosinophilic histiocytes, which are often multinucleated.  The lesions are yellow-brown papules affecting any part of the body.  Patients are usually adult men.  The prognosis is excellent. -- 2003","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Reticulohistiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Reticulohistiocytic Granuloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solitary_Reticulohistiocytoma"},{"name":"Maps_To","value":"8831/0"},{"name":"Maps_To","value":"Reticulohistiocytoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035290"}]}}{"C6492":{"preferredName":"Deep Fibrous Histiocytoma","code":"C6492","definitions":[{"definition":"A rare, well-circumscribed, pseudo-encapsulated benign fibrous histiocytoma that arises entirely within the subcutaneous tissue or deep soft tissue.  It usually affects the extremities or the head and neck region.  It recurs locally in a minority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Deep Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Benign Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Deep_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8831/0"},{"name":"Maps_To","value":"Deep histiocytoma"},{"name":"Maps_To","value":"Juvenile histiocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266125"}]}}{"C7159":{"preferredName":"Subepidermal Nodular Fibrosis","code":"C7159","synonyms":[{"termName":"Subepidermal Nodular Fibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Subepidermal_Nodular_Fibrosis"},{"name":"Maps_To","value":"8832/0"},{"name":"Maps_To","value":"Subepidermal nodular fibrosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1509149"}]}}{"C6801":{"preferredName":"Skin Fibrous Histiocytoma","code":"C6801","definitions":[{"definition":"A solitary, slowly growing, nodular tumor most often affecting the extremities. It is composed of fibrous and histiocytic cells which infiltrate the dermis and occasionally the underlying subcutaneous tissue.  Usually local excision is curative. Recurrences are reported only in a small minority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cutaneous Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Fibrous Cutaneous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Fibrous Histiocytoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Fibrous Histiocytoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Skin Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Dermatofibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrous Histiocytoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrous Histiocytoma of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8832/0"},{"name":"Legacy Concept Name","value":"Benign_Cutaneous_Fibrohistiocytic_Neoplasm"},{"name":"Legacy Concept Name","value":"Cutaneous_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8832/0"},{"name":"Maps_To","value":"Cutaneous histiocytoma, NOS"},{"name":"Maps_To","value":"Dermatofibroma lenticulare"},{"name":"Maps_To","value":"Dermatofibroma, NOS"},{"name":"Maps_To","value":"Sclerosing hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002991"},{"name":"UMLS_CUI","value":"C1274305"}]}}{"C4683":{"preferredName":"Dermatofibrosarcoma Protuberans","code":"C4683","definitions":[{"definition":"A low grade fibroblastic neoplasm presenting as a nodular cutaneous mass, most often on the trunk and the proximal extremities.  The tumor diffusely infiltrates the dermis and the subcutaneous tissues.  It is considered a locally aggressive neoplasm, which often recurs but rarely metastasizes.","type":"DEFINITION","source":"NCI"},{"definition":"A type of tumor that begins as a hard nodule and grows slowly. These tumors are usually found in the dermis (the inner layer of the two main layers of tissue that make up the skin) of the limbs or trunk of the body. They can grow into surrounding tissue but do not spread to other parts of the body. These tumors are related to giant cell fibroblastomas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dermatofibrosarcoma Protuberans","termGroup":"PT","termSource":"NCI"},{"termName":"Dermatofibrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"DFSP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8832/3"},{"name":"Legacy Concept Name","value":"Dermatofibrosarcoma_Protuberans"},{"name":"Maps_To","value":"8832/3"},{"name":"Maps_To","value":"Dermatofibrosarcoma protuberans, NOS"},{"name":"Maps_To","value":"Dermatofibrosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0392784"}]}}{"C9430":{"preferredName":"Pigmented Dermatofibrosarcoma Protuberans","code":"C9430","definitions":[{"definition":"A morphologic variant of dermatofibrosarcoma protuberans characterized by the presence of melanin-pigmented dendritic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pigmented Dermatofibrosarcoma Protuberans","termGroup":"PT","termSource":"NCI"},{"termName":"Bednar Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Dermatofibrosarcoma Protuberans (Bednar Tumor)","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented DFSP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8833/3"},{"name":"Legacy Concept Name","value":"Pigmented_Dermatofibrosarcoma_Protuberans_Bednar_Tumor"},{"name":"Maps_To","value":"8833/3"},{"name":"Maps_To","value":"Bednar tumor"},{"name":"Maps_To","value":"Pigmented dermatofibrosarcoma protuberans"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334464"}]}}{"C4700":{"preferredName":"Giant Cell Fibroblastoma","code":"C4700","definitions":[{"definition":"A morphologic variant of dermatofibrosarcoma protuberans that is most often seen in childhood and is characterized by the presence of spindle-shaped fibroblastic cells, a storiform growth pattern, numerous multinucleated giant cells, wide vessel-like spaces, and extensive myxoid change.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of soft tissue tumor marked by painless nodules in the dermis (the inner layer of the two main layers of tissue that make up the skin) and subcutaneous (beneath the skin) tissue. These tumors may come back after surgery, but they do not spread to other parts of the body. They occur mostly in boys and are related to dermatofibrosarcoma protuberans.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Giant Cell Fibroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"GCF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8834/1"},{"name":"Legacy Concept Name","value":"Dermatofibrosarcoma_Protuberans_with_Giant_Cell_Fibroblastoma-Like_Differentiation"},{"name":"Legacy Concept Name","value":"Giant_Cell_Fibroblastoma"},{"name":"Maps_To","value":"8834/1"},{"name":"Maps_To","value":"Giant cell fibroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0406579"},{"name":"UMLS_CUI","value":"C1333277"}]}}{"C6493":{"preferredName":"Plexiform Fibrohistiocytic Tumor","code":"C6493","definitions":[{"definition":"An intermediate fibrohistiocytic neoplasm of the skin that usually affects children and young adults. It is a multinodular, poorly circumscribed tumor characterized by the presence of multinucleated giant cells, mononuclear histiocyte-like cells, and spindle fibroblast-like cells arranged in a plexiform pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plexiform Fibrohistiocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"PFHT","termGroup":"AB","termSource":"NCI"},{"termName":"Plexiform Fibrohistiocytic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8835/1"},{"name":"Legacy Concept Name","value":"Intermediate_Cutaneous_Fibrohistiocytic_Neoplasm"},{"name":"Legacy Concept Name","value":"Plexiform_Fibrohistiocytic_Tumor"},{"name":"Maps_To","value":"8835/1"},{"name":"Maps_To","value":"Plexiform fibrohistiocytic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266126"},{"name":"UMLS_CUI","value":"C1334211"}]}}{"C6494":{"preferredName":"Angiomatoid Fibrous Histiocytoma","code":"C6494","definitions":[{"definition":"A low malignant potential soft tissue neoplasm of uncertain differentiation.  It typically affects young patients, presenting as a slowly growing nodular or cystic tumor mass, most often in the subcutaneous tissues of the extremities.  Occasionally, patients have systemic symptoms (anemia, fever, and weight loss).  This tumor has a relatively good prognosis.  A minority of patients develop local recurrences.  Metastases are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomatoid Fibrous Histiocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"AFH","termGroup":"AB","termSource":"NCI"},{"termName":"Angiomatoid Malignant Fibrous Histiocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8836/1"},{"name":"Legacy Concept Name","value":"Angiomatoid_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"8836/1"},{"name":"Maps_To","value":"Angiomatoid fibrous histiocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266127"}]}}{"C6577":{"preferredName":"Myxoma","code":"C6577","definitions":[{"definition":"A benign soft tissue neoplasm characterized by the presence of spindle and stellate cells, lobulated growth pattern, and myxoid stroma formation.","type":"DEFINITION","source":"NCI"},{"definition":"A benign soft tissue neoplasm with a myxoid stroma formation.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Myxoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8840/0"},{"name":"Legacy Concept Name","value":"Myxoma"},{"name":"Maps_To","value":"8840/0"},{"name":"Maps_To","value":"Myxoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027149"}]}}{"C3255":{"preferredName":"Myxosarcoma","code":"C3255","definitions":[{"definition":"A malignant soft tissue neoplasm with a myxoid stroma formation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating malignant soft tissue neoplasm characterized by the presence of immature undifferentiated cells and abundant myxoid stroma formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8840/3"},{"name":"Legacy Concept Name","value":"Myxosarcoma"},{"name":"Maps_To","value":"8840/3"},{"name":"Maps_To","value":"Myxosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027155"}]}}{"C6936":{"preferredName":"Deep (Aggressive) Angiomyxoma","code":"C6936","definitions":[{"definition":"A locally infiltrating, non-metastasizing angiomyxoma arising from the pelviperineal region.  It may recur following resection","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep (Aggressive) Angiomyxoma","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive Angiomyxoma","termGroup":"SY","termSource":"NCI"},{"termName":"Deep \"Aggressive\" Angiomyxoma","termGroup":"SY","termSource":"NCI"},{"termName":"Deep Angiomyxoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8841/0"},{"name":"ICD-O-3_Code","value":"8841/1"},{"name":"Legacy Concept Name","value":"Aggressive_Angiomyxoma"},{"name":"Legacy Concept Name","value":"Angiomyxoma"},{"name":"Maps_To","value":"8841/1"},{"name":"Maps_To","value":"Aggressive angiomyxoma"},{"name":"Maps_To","value":"Angiomyxoma"},{"name":"Maps_To","value":"Angiomyxoma, NOS"},{"name":"NCI_META_CUI","value":"CL329980"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306242"}]}}{"C6582":{"preferredName":"Ossifying Fibromyxoid Tumor","code":"C6582","definitions":[{"definition":"A rare soft tissue tumor of uncertain lineage characterized by the presence of neoplastic spindle to round cells forming cords in a fibromyxoid stroma.  The lesions are associated with the formation of metaplastic bone.  Most patients present with painless subcutaneous masses.  Recurrences have been reported in a minority of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ossifying Fibromyxoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"OFMT","termGroup":"AB","termSource":"NCI"},{"termName":"Ossifying Fibromyxoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Ossifying Fibromyxoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8842/0"},{"name":"Legacy Concept Name","value":"Ossifying_Fibromyxoid_Neoplasm"},{"name":"Maps_To","value":"8842/0"},{"name":"Maps_To","value":"Ossifying fibromyxoid tumor"},{"name":"Maps_To","value":"Ossifying fibromyxoid tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266128"}]}}{"C142827":{"preferredName":"Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion","code":"C142827","definitions":[{"definition":"A sarcoma that arises from the lung. It is related to a bronchus and is often predominantly endobronchial. It is characterized by the proliferation of round and spindle cells within a myxoid stroma. It is associated with the presence of an EWSR1::CREB1 fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion","termGroup":"PT","termSource":"NCI"},{"termName":"Low-Grade Malignant Myxoid Endobronchial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"PPMS","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Pulmonary Myxoid Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Pulmonary Myxoid Sarcoma with EWSR1::CREB1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation"},{"name":"NCI_META_CUI","value":"CL536391"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3192":{"preferredName":"Lipoma","code":"C3192","definitions":[{"definition":"A benign (not cancer) tumor made of fat cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign neoplasm composed of adipose tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8850/0"},{"name":"Legacy Concept Name","value":"Lipoma"},{"name":"Maps_To","value":"8850/0"},{"name":"Maps_To","value":"Lipoma of other specified sites"},{"name":"Maps_To","value":"Lipoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023798"}]}}{"C6505":{"preferredName":"Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C6505","definitions":[{"definition":"A locally aggressive mesenchymal neoplasm composed either entirely or partly of an adipocytic proliferation showing at least focal nuclear atypia in both adipocytes and stromal cells. \"Atypical lipomatous tumor\" and \"well-differentiated liposarcoma\" are synonyms describing lesions that are morphologically and genetically identical. Amplification of MDM2 and/or CDK4 is almost always present. (WHO 2020)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ALT","termGroup":"AB","termSource":"NCI"},{"termName":"ALT/WDLPS","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Lipoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Atypical Lipomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8850/1"},{"name":"ICD-O-3_Code","value":"8851/3"},{"name":"Legacy Concept Name","value":"Atypical_Lipoma"},{"name":"Legacy Concept Name","value":"Well-Differentiated_Liposarcoma"},{"name":"Maps_To","value":"8851/3"},{"name":"Maps_To","value":"Atypical lipoma"},{"name":"Maps_To","value":"Atypical lipomatous tumor"},{"name":"Maps_To","value":"Liposarcoma, differentiated"},{"name":"Maps_To","value":"Liposarcoma, well differentiated"},{"name":"Maps_To","value":"Liposarcoma, well differentiated, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266129"}]}}{"C3194":{"preferredName":"Liposarcoma","code":"C3194","definitions":[{"definition":"A malignant neoplasm composed of adipose tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Lipomatous Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8850/3"},{"name":"Legacy Concept Name","value":"Liposarcoma"},{"name":"Legacy Concept Name","value":"Malignant_Lipomatous_Neoplasm"},{"name":"Maps_To","value":"8850/3"},{"name":"Maps_To","value":"Fibroliposarcoma"},{"name":"Maps_To","value":"Liposarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346117"}]}}{"C4249":{"preferredName":"Fibrolipoma","code":"C4249","definitions":[{"definition":"A benign neoplasm comprising mature adipocytes, characterized by areas of abundant fibrous tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign well-circumscribed tumor composed of mature adipocytes, characterized by areas of abundant fibrous tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8851/0"},{"name":"Legacy Concept Name","value":"Fibrolipoma"},{"name":"Maps_To","value":"8851/0"},{"name":"Maps_To","value":"Fibrolipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334467"}]}}{"C6508":{"preferredName":"Inflammatory Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C6508","definitions":[{"definition":"A rare morphologic variant of atypical lipomatous tumor/well differentiated liposarcoma occurring most often in the retroperitoneum. It is characterized by the presence of a predominant chronic inflammatory infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inflammatory Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Inflammatory ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammatory Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inflammatory_Liposarcoma"},{"name":"Maps_To","value":"8851/3"},{"name":"Maps_To","value":"Inflammatory liposarcoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370890"}]}}{"C6507":{"preferredName":"Sclerosing Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C6507","definitions":[{"definition":"An atypical lipomatous tumor/well differentiated liposarcoma characterized by the presence of bizarre hyperchromatic stromal cells and rare multivacuolated lipoblasts within a fibrous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosing Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sclerosing ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sclerosing Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sclerosing_Liposarcoma"},{"name":"Maps_To","value":"8851/3"},{"name":"Maps_To","value":"Sclerosing liposarcoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334469"}]}}{"C4251":{"preferredName":"Fibromyxolipoma","code":"C4251","definitions":[{"definition":"A benign well-circumscribed tumor composed of mature adipocytes, characterized by areas of abundant fibrous tissue and extensive myxoid change.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibromyxolipoma","termGroup":"PT","termSource":"NCI"},{"termName":"Myxolipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8852/0"},{"name":"Legacy Concept Name","value":"Fibromyxolipoma"},{"name":"Maps_To","value":"8852/0"},{"name":"Maps_To","value":"Fibromyxolipoma"},{"name":"Maps_To","value":"Myxolipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334470"}]}}{"C27781":{"preferredName":"Myxoid Liposarcoma","code":"C27781","definitions":[{"definition":"A liposarcoma characterized by the presence of round non-lipogenic primitive mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a branching vascular pattern.  This category includes hypercellular lesions with round cell morphology, formerly known as round cell liposarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxoid Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"MLPS","termGroup":"AB","termSource":"NCI"},{"termName":"Myxoid Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid/Round Cell Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8852/3"},{"name":"Legacy Concept Name","value":"Myxoid_Round_Cell_Liposarcoma"},{"name":"Maps_To","value":"8852/3"},{"name":"Maps_To","value":"Myxoid liposarcoma"},{"name":"Maps_To","value":"Myxoliposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206634"}]}}{"C4252":{"preferredName":"Round Cell Liposarcoma","code":"C4252","definitions":[{"definition":"A poorly differentiated liposarcoma, characterized by the presence of solid sheets of primitive round mesenchymal cells and the absence of myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Myxoid Liposarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Round Cell Liposarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8853/3"},{"name":"Legacy Concept Name","value":"Round_Cell_Liposarcoma"},{"name":"Maps_To","value":"8853/3"},{"name":"Maps_To","value":"Round cell liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334471"}]}}{"C3703":{"preferredName":"Pleomorphic Lipoma","code":"C3703","definitions":[{"definition":"A benign circumscribed tumor characterized by small spindle cells, rounded hyperchromatic cells and multinucleated giant cells with radially arranged nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Lipoma","termGroup":"PT","termSource":"NCI"},{"termName":"PL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8854/0"},{"name":"Legacy Concept Name","value":"Pleomorphic_Lipoma"},{"name":"Maps_To","value":"8854/0"},{"name":"Maps_To","value":"Pleomorphic lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205823"}]}}{"C3705":{"preferredName":"Pleomorphic Liposarcoma","code":"C3705","definitions":[{"definition":"A rare, aggressive liposarcoma characterized by the presence of varying proportions of pleomorphic lipoblasts in a background that resembles undifferentiated pleomorphic sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Liposarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8854/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Liposarcoma"},{"name":"Maps_To","value":"8854/3"},{"name":"Maps_To","value":"Pleomorphic liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205825"}]}}{"C4253":{"preferredName":"Mixed Liposarcoma","code":"C4253","definitions":[{"definition":"A malignant neoplasm characterized by the presence of a combination of liposarcomatous morphologic subtypes: myxoid/round cell and well differentiated/dedifferentiated liposarcoma or myxoid/round cell and pleomorphic liposarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Liposarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8855/3"},{"name":"Legacy Concept Name","value":"Mixed_Liposarcoma"},{"name":"Maps_To","value":"8855/3"},{"name":"Maps_To","value":"Mixed liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334472"}]}}{"C7451":{"preferredName":"Infiltrating Lipoma","code":"C7451","definitions":[{"definition":"A benign tumor, composed of lobules of mature adipocytes, that penetrates the surrounding tissue from which it arises. There is usually a higher local recurrence rate when compared with non-infiltrating lipomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infiltrating Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Lipoma"},{"name":"Maps_To","value":"8856/0"},{"name":"Maps_To","value":"Infiltrating lipoma"},{"name":"NCI_META_CUI","value":"CL028013"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7450":{"preferredName":"Intramuscular Lipoma","code":"C7450","definitions":[{"definition":"A benign tumor, composed of mature adipocytes, that arises within skeletal muscle fibers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramuscular Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8856/0"},{"name":"Legacy Concept Name","value":"Intramuscular_Lipoma"},{"name":"Maps_To","value":"8856/0"},{"name":"Maps_To","value":"Intramuscular lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334473"}]}}{"C7449":{"preferredName":"Infiltrating Angiolipoma","code":"C7449","definitions":[{"definition":"An uncommon lipoma characterized by prominent vascularity that invades the surrounding deep tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infiltrating Angiolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infiltrating_Angiolipoma"},{"name":"Maps_To","value":"8856/0"},{"name":"Maps_To","value":"Infiltrating angiolipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1305256"}]}}{"C4254":{"preferredName":"Spindle Cell Lipoma","code":"C4254","definitions":[{"definition":"A benign circumscribed tumor composed of spindled cells, adipocytes, and collagen bundles.  There is no evidence of nuclear hyperchromasia or mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Lipoma","termGroup":"PT","termSource":"NCI"},{"termName":"SCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8857/0"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Lipoma"},{"name":"Maps_To","value":"8857/0"},{"name":"Maps_To","value":"Spindle cell lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334474"}]}}{"C6509":{"preferredName":"Fibroblastic Liposarcoma","code":"C6509","definitions":[{"definition":"A liposarcoma characterized by the presence of a fibroblastic component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroblastic Liposarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8857/3"},{"name":"Legacy Concept Name","value":"Fibroblastic_Liposarcoma"},{"name":"Maps_To","value":"8857/3"},{"name":"Maps_To","value":"Fibroblastic liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266130"}]}}{"C3704":{"preferredName":"Dedifferentiated Liposarcoma","code":"C3704","definitions":[{"definition":"An atypical lipomatous tumor/well differentiated liposarcoma that shows progression to a usually non-lipomatous, high grade sarcoma.  The non-lipomatous sarcoma component may be present in the primary lesion or at the site of recurrence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dedifferentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"DDLPS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8858/3"},{"name":"Legacy Concept Name","value":"Dedifferentiated_Liposarcoma"},{"name":"Maps_To","value":"8858/3"},{"name":"Maps_To","value":"Dedifferentiated liposarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205824"}]}}{"C3734":{"preferredName":"Angiomyolipoma","code":"C3734","definitions":[{"definition":"A benign (noncancer) tumor of fat and muscle tissue that usually is found in the kidney. Angiomyolipomas rarely cause symptoms, but may bleed or grow large enough to be painful or cause kidney failure. They are common in patients with tuberous sclerosis (a genetic disorder in which benign tumors grow in the kidneys, brain, eyes, heart, lungs, and skin, causing seizures, mental problems, and skin lesions).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplasm with perivascular epithelioid cell differentiation often associated with tuberous sclerosis.  It is characterized by a mixture of epithelioid cells, smooth muscle, vessels, and mature adipose tissue.  The kidney is the most common site of involvement.  Other sites of involvement include the liver, lung, lymph nodes, and retroperitoneum.  The vast majority of cases follow a benign clinical course.  However, cases of metastatic angiomyolipomas with sarcomatoid features have been described.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomyolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8860/0"},{"name":"Legacy Concept Name","value":"Angiomyolipoma"},{"name":"Maps_To","value":"8860/0"},{"name":"Maps_To","value":"Angiomyolipoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206633"}]}}{"C3733":{"preferredName":"Angiolipoma","code":"C3733","definitions":[{"definition":"A lipoma characterized by prominent vascularization.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A lipoma with prominent vascularity. The vascular tissue is more abundant at the periphery of the tumor and contains fibrin thrombi. It occurs more frequently in younger individuals as a painful subcutaneous nodule, often on the arms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiolipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8861/0"},{"name":"Legacy Concept Name","value":"Angiolipoma"},{"name":"Maps_To","value":"8861/0"},{"name":"Maps_To","value":"Angiolipoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206632"}]}}{"C6503":{"preferredName":"Chondroid Lipoma","code":"C6503","definitions":[{"definition":"A rare benign adipose tissue neoplasm characterized by nests and cord of abundant univacuolated and multivacuolated lipoblasts and mature adipocytes in a prominent myxoid to hyalinized chondroid matrix admix. It predominantly affects females.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroid Lipoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8862/0"},{"name":"Legacy Concept Name","value":"Chondroid_Lipoma"},{"name":"Maps_To","value":"8862/0"},{"name":"Maps_To","value":"Chondroid lipoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266131"}]}}{"C3736":{"preferredName":"Adrenal Gland Myelolipoma","code":"C3736","definitions":[{"definition":"A benign soft tissue lesion arising from the adrenal gland.  It is composed of mature adipose and hematopoietic/lymphoid tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A benign tumor of the adrenal gland composed of adipocytes and hematopoietic/lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adrenal Gland Myelolipoma","termGroup":"PT","termSource":"NCI"},{"termName":"Myelolipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8870/0"},{"name":"Legacy Concept Name","value":"Myelolipoma"},{"name":"Maps_To","value":"8870/0"},{"name":"Maps_To","value":"Myelolipoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0206635"}]}}{"C3702":{"preferredName":"Hibernoma","code":"C3702","definitions":[{"definition":"A benign neoplasm of the brown adipose tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare benign slow growing adipose tissue tumor, characterized by the presence of polygonal brown fat cells with multivacuolated and/or granular cytoplasm.  The tumor is usually painless and is most often seen in young adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hibernoma","termGroup":"PT","termSource":"NCI"},{"termName":"Brown Fat Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Brown Fat Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Fetal Fat Cell Lipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8880/0"},{"name":"Legacy Concept Name","value":"Hibernoma"},{"name":"Maps_To","value":"8880/0"},{"name":"Maps_To","value":"Brown fat tumor"},{"name":"Maps_To","value":"Fetal fat cell lipoma"},{"name":"Maps_To","value":"Hibernoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205822"}]}}{"C27483":{"preferredName":"Lipoblastoma","code":"C27483","definitions":[{"definition":"A lipoma usually occurring in the extremities of young children (usually boys). It is characterized by lobules of adipose tissue, separated by fibrous septa.  The adipose tissue is composed of mature adipocytes and lipoblasts. The lipoblasts may be scarce, depending on the age of the patient.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonic Lipoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fetal Lipoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infantile Lipoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lipoblastoma"},{"name":"Maps_To","value":"8881/0"},{"name":"Maps_To","value":"Fetal lipoma, NOS"},{"name":"Maps_To","value":"Lipoblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260965"}]}}{"C4255":{"preferredName":"Lipoblastomatosis","code":"C4255","definitions":[{"definition":"A neoplastic process characterized by the presence of multiple lipoblastomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoblastomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Lipomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8881/0"},{"name":"Legacy Concept Name","value":"Lipoblastomatosis"},{"name":"Maps_To","value":"8881/0"},{"name":"Maps_To","value":"Fetal lipomatosis"},{"name":"Maps_To","value":"Lipoblastomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334475"}]}}{"C3434":{"preferredName":"Uterine Corpus Leiomyoma","code":"C3434","definitions":[{"definition":"A benign smooth muscle neoplasm arising from the body of the uterus. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Body of Uterus Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Body of Uterus Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Corpus Uteri Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Corpus Uteri Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of the Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroid of Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Body of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Corpus Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of the Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Uterine Body","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoma of Uterine Corpus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Body Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Body Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Leiomyomata","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Fibroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Leiomyoma"},{"name":"Maps_To","value":"8890/0"},{"name":"Maps_To","value":"Fibroid uterus"},{"name":"Maps_To","value":"Fibromyoma"},{"name":"Maps_To","value":"Leiomyofibroma"},{"name":"Maps_To","value":"Leiomyoma of uterus, unspecified"},{"name":"Maps_To","value":"Submucous leiomyoma of uterus"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0042133"}]}}{"C3157":{"preferredName":"Leiomyoma","code":"C3157","definitions":[{"definition":"A benign neoplasm, originating from smooth muscle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign smooth muscle tumor, usually in the uterus or gastrointestinal tract.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A well-circumscribed benign smooth muscle neoplasm characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroid","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyomatous Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8890/0"},{"name":"Legacy Concept Name","value":"Leiomyoma"},{"name":"Maps_To","value":"8890/0"},{"name":"Maps_To","value":"Leiomyoma"},{"name":"Maps_To","value":"Leiomyoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302742"}]}}{"C3748":{"preferredName":"Leiomyomatosis","code":"C3748","definitions":[{"definition":"A condition characterized by the presence of numerous small benign smooth muscle neoplasms located throughout the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leiomyomatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8890/1"},{"name":"Legacy Concept Name","value":"Leiomyomatosis"},{"name":"Maps_To","value":"8890/1"},{"name":"Maps_To","value":"Leiomyomatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206654"}]}}{"C3158":{"preferredName":"Leiomyosarcoma","code":"C3158","definitions":[{"definition":"A malignant (cancer) tumor of smooth muscle cells that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm, originating from smooth muscle cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor of smooth muscle cells that can arise almost anywhere in the body but is most common in the uterus, abdomen, or pelvis.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leiomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8890/3"},{"name":"Legacy Concept Name","value":"Leiomyosarcoma"},{"name":"Maps_To","value":"8890/3"},{"name":"Maps_To","value":"Leiomyosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023269"},{"name":"xRef","value":"IMDRF:E180103"}]}}{"C40164":{"preferredName":"Uterine Corpus Epithelioid Leiomyoma","code":"C40164","definitions":[{"definition":"A morphologic variant of uterine corpus leiomyoma characterized by the presence of round or polygonal epithelioid smooth muscle cells forming clusters.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Epithelioid Leiomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Epithelioid_Leiomyoma"},{"name":"Maps_To","value":"8891/0"},{"name":"Maps_To","value":"Epithelioid leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519850"}]}}{"C3700":{"preferredName":"Epithelioid Leiomyosarcoma","code":"C3700","definitions":[{"definition":"A morphologic variant of leiomyosarcoma characterized by the presence of epithelioid round cells with eosinophilic to clear cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Leiomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8891/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Leiomyosarcoma"},{"name":"Maps_To","value":"8891/3"},{"name":"Maps_To","value":"Epithelioid leiomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205815"}]}}{"C4256":{"preferredName":"Cellular Leiomyoma","code":"C4256","definitions":[{"definition":"A morphologic variant of classic leiomyoma characterized by a dense cellular infiltrate composed of spindle or round cells with scant cytoplasm and a less obvious interlacing fascicle pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Leiomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8892/0"},{"name":"Legacy Concept Name","value":"Cellular_Leiomyoma"},{"name":"Maps_To","value":"8892/0"},{"name":"Maps_To","value":"Cellular leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334477"}]}}{"C4257":{"preferredName":"Bizarre Leiomyoma","code":"C4257","definitions":[{"definition":"A morphologic variant of leiomyoma characterized by the presence of pleomorphic muscle cells with bizarre hyperchromatic nuclei and eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bizarre Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Leiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pleomorphic Leiomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8893/0"},{"name":"Legacy Concept Name","value":"Bizarre_Leiomyoma"},{"name":"Maps_To","value":"8893/0"},{"name":"Maps_To","value":"Atypical leiomyoma"},{"name":"Maps_To","value":"Bizarre leiomyoma"},{"name":"Maps_To","value":"Pleomorphic leiomyoma"},{"name":"Maps_To","value":"Symplastic leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334478"}]}}{"C3747":{"preferredName":"Angioleiomyoma","code":"C3747","definitions":[{"definition":"A benign, slow-growing neoplasm that arises from the dermis or subcutaneous tissue. It is characterized by the presence of well-differentiated smooth muscle cells which are arranged around numerous vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angioleiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Vascular Leiomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8894/0"},{"name":"Legacy Concept Name","value":"Angiomyoma"},{"name":"Maps_To","value":"8894/0"},{"name":"Maps_To","value":"Angioleiomyoma"},{"name":"Maps_To","value":"Angiomyoma"},{"name":"Maps_To","value":"Vascular leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206653"}]}}{"C66771":{"preferredName":"Angiomyosarcoma","code":"C66771","definitions":[{"definition":"A malignant smooth muscle neoplasm characterized by the presence of atypical spindle cells and formation of vascular channels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomyosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8894/3"},{"name":"Legacy Concept Name","value":"Angiomyosarcoma"},{"name":"Maps_To","value":"8894/3"},{"name":"Maps_To","value":"Angiomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334479"}]}}{"C4882":{"preferredName":"Benign Muscle Neoplasm","code":"C4882","definitions":[{"definition":"A mesenchymal neoplasm that arises from smooth, skeletal, or cardiac muscle and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Muscle Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Myoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8895/0"},{"name":"Legacy Concept Name","value":"Benign_Muscle_Neoplasm"},{"name":"Maps_To","value":"8895/0"},{"name":"Maps_To","value":"Myoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027086"}]}}{"C4883":{"preferredName":"Malignant Muscle Neoplasm","code":"C4883","definitions":[{"definition":"A malignant neoplasm affecting the skeletal or smooth muscles.  Malignant neoplasms arising from the skeletal muscles are called rhabdomyosarcomas.  Malignant neoplasms arising from the smooth muscles are called leiomyosarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Muscle Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Myosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8895/3"},{"name":"Legacy Concept Name","value":"Malignant_Muscle_Neoplasm"},{"name":"Maps_To","value":"8895/3"},{"name":"Maps_To","value":"Myosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0684743"}]}}{"C3701":{"preferredName":"Myxoid Leiomyosarcoma","code":"C3701","definitions":[{"definition":"A morphologic variant of leiomyosarcoma characterized by the presence of cellular pleomorphism, malignant cells with large nuclei, and a myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxoid Leiomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8896/3"},{"name":"Legacy Concept Name","value":"Myxoid_Leiomyosarcoma"},{"name":"Maps_To","value":"8896/3"},{"name":"Maps_To","value":"Myxoid leiomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205816"}]}}{"C40177":{"preferredName":"Uterine Corpus Smooth Muscle Tumor of Uncertain Malignant Potential","code":"C40177","definitions":[{"definition":"A smooth muscle neoplasm that arises from the uterine corpus and cannot be reliably diagnosed as benign or malignant because of the presence of ambiguous morphologic findings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Smooth Muscle Tumor of Uncertain Malignant Potential","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Uterine Corpus Smooth Muscle Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Smooth Muscle Neoplasm of Uncertain Malignant Potential","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus STUMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8897/1"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Smooth_Muscle_Neoplasm_of_Uncertain_Malignant_Potential"},{"name":"Maps_To","value":"8897/1"},{"name":"Maps_To","value":"Smooth muscle tumor of uncertain malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519864"}]}}{"C40173":{"preferredName":"Uterine Corpus Metastasizing Leiomyoma","code":"C40173","definitions":[{"definition":"A cytologically benign smooth muscle neoplasm that arises from the uterine corpus and has metastasized to the lungs, abdomen, or lymph nodes. It usually presents in women with a history of benign uterine leiomyomas that have been surgically removed years before the extrauterine neoplasm spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Metastasizing Leiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Metastasizing Leiomyoma of the Uterine Corpus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8898/1"},{"name":"Legacy Concept Name","value":"Benign_Metastasizing_Leiomyoma"},{"name":"Maps_To","value":"8898/1"},{"name":"Maps_To","value":"Metastasizing leiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511090"}]}}{"C3358":{"preferredName":"Rhabdomyoma","code":"C3358","definitions":[{"definition":"A benign mesenchymal tumor arising from skeletal or cardiac muscle.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm arising from skeletal or cardiac muscle, characterized by the presence of rhabdomyoblasts.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Rhabdomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8900/0"},{"name":"Legacy Concept Name","value":"Rhabdomyoma"},{"name":"Maps_To","value":"8900/0"},{"name":"Maps_To","value":"Rhabdomyoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0035411"}]}}{"C3359":{"preferredName":"Rhabdomyosarcoma","code":"C3359","definitions":[{"definition":"A malignant mesenchymal neoplasm arising from skeletal muscle.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from skeletal myocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the soft tissues in a type of muscle called striated muscle. Rhabdomyosarcoma can occur anywhere in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"8900/3"},{"name":"Legacy Concept Name","value":"Rhabdomyosarcoma"},{"name":"Maps_To","value":"8900/3"},{"name":"Maps_To","value":"Rhabdomyosarcoma"},{"name":"Maps_To","value":"Rhabdomyosarcoma, NOS"},{"name":"Maps_To","value":"Rhabdosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1276181"}]}}{"C4258":{"preferredName":"Pleomorphic Rhabdomyosarcoma","code":"C4258","definitions":[{"definition":"An aggressive malignant mesenchymal neoplasm with skeletal muscle differentiation, occurring in adults and rarely in children.  The tumor is characterized by the presence of bizarre round, spindle, and polygonal cells.  Clinical presentation includes a rapidly enlarging painful mass usually of the lower extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleomorphic_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8901/3"},{"name":"Maps_To","value":"Pleomorphic rhabdomyosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334480"}]}}{"C27369":{"preferredName":"Adult Pleomorphic Rhabdomyosarcoma","code":"C27369","definitions":[{"definition":"An aggressive rhabdomyosarcoma occurring in adults.  The neoplasm is characterized by the presence of bizarre round, spindle, and polygonal cells.  Clinical presentation includes a rapidly enlarging painful mass usually in the lower extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Pleomorphic Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8901/3"},{"name":"Legacy Concept Name","value":"Adult_Pleomorphic_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8901/3"},{"name":"Maps_To","value":"Pleomorphic rhabdomyosarcoma, adult type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332211"}]}}{"C4259":{"preferredName":"Rhabdomyosarcoma with Mixed Embryonal and Alveolar Features","code":"C4259","definitions":[{"definition":"A rhabdomyosarcoma composed of embryonic and alveolar components. It is characterized by the presence of spindle cells with myoblastic differentiation, a myxoid stroma, and fibrous septa.  These tumors were previously considered variants of alveolar rhabdomyosarcoma.  The lack of PAX3-FOXO1 fusions in most of these tumors suggests that are biologically and clinically related to embryonal rhabdomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhabdomyosarcoma with Mixed Embryonal and Alveolar Features","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Alveolar Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Type Alveolar Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8902/3"},{"name":"Legacy Concept Name","value":"Mixed_Type_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8902/3"},{"name":"Maps_To","value":"Mixed type rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709053"}]}}{"C4260":{"preferredName":"Fetal Rhabdomyoma","code":"C4260","definitions":[{"definition":"A rare benign mesenchymal neoplasm arising from skeletal muscle. It is characterized by the presence of immature spindle and polygonal cells within a scant myxoid stroma. It usually develops in the head and neck region of young children.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fetal Rhabdomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8903/0"},{"name":"Legacy Concept Name","value":"Fetal_Rhabdomyoma"},{"name":"Maps_To","value":"8903/0"},{"name":"Maps_To","value":"Fetal rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334482"}]}}{"C4261":{"preferredName":"Adult Extracardiac Rhabdomyoma","code":"C4261","definitions":[{"definition":"A benign mesenchymal neoplasm arising from skeletal muscle and occurring in adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Extracardiac Rhabdomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Extracardiac Rhabdomyomatous Hamartoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8904/0"},{"name":"Legacy Concept Name","value":"Adult_Rhabdomyoma"},{"name":"Maps_To","value":"8904/0"},{"name":"Maps_To","value":"Adult rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4055487"}]}}{"C45747":{"preferredName":"Adult Cardiac Cellular Rhabdomyoma","code":"C45747","definitions":[{"definition":"A rare cardiac rhabdomyoma occurring in adults.  It is characterized by the presence of neoplastic striated muscle cells with eosinophilic granular cytoplasm and increased cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Cardiac Cellular Rhabdomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Heart Cellular Rhabdomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Cardiac_Cellular_Rhabdomyoma"},{"name":"Maps_To","value":"8904/0"},{"name":"Maps_To","value":"Adult cellular rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1706729"}]}}{"C6517":{"preferredName":"Genital Rhabdomyoma","code":"C6517","definitions":[{"definition":"A rare benign skeletal muscle neoplasm arising from the female genital tract. It is characterized by the presence of small nucleated rhabdomyoblasts within a fibrous and myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genital Rhabdomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8905/0"},{"name":"Legacy Concept Name","value":"Genital_Rhabdomyoma"},{"name":"Maps_To","value":"8905/0"},{"name":"Maps_To","value":"Genital rhabdomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266133"}]}}{"C9150":{"preferredName":"Botryoid-Type Embryonal Rhabdomyosarcoma","code":"C9150","definitions":[{"definition":"A morphologic variant of embryonal rhabdomyosarcoma arising from organs with a mucosal epithelial surface.  It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botryoid-Type Embryonal Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Botryoid Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma Botryoides","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Botryoid-Type_Embryonal_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8910/3"},{"name":"Maps_To","value":"Botryoid sarcoma"},{"name":"Maps_To","value":"Sarcoma botryoides"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306573"}]}}{"C8971":{"preferredName":"Embryonal Rhabdomyosarcoma","code":"C8971","definitions":[{"definition":"A poorly circumscribed morphologic variant of rhabdomyosarcoma.  It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that is most common in infants and young children. It begins in muscles, usually in the head, neck, or genitourinary tract.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Embryonal Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ERMS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8910/3"},{"name":"Legacy Concept Name","value":"Embryonal_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8910/3"},{"name":"Maps_To","value":"Embryonal rhabdomyosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206656"}]}}{"C6519":{"preferredName":"Spindle Cell Rhabdomyosarcoma","code":"C6519","definitions":[{"definition":"An uncommon variant of rhabdomyosarcoma characterized by the presence of whorls of spindle cells forming a storiform pattern. In children it usually arises in the paratesticular region. In adults it usually arises from the deep soft tissues in the head and neck.","type":"DEFINITION","source":"NCI"},{"definition":"An uncommon variant of rhabdomyosarcoma that is characterized by the presence of whorls of spindle cells forming a storiform pattern. In children, it usually arises in the paratesticular region; in adults it usually arises from the deep soft tissues in the head and neck.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Spindle Cell Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8912/3"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8912/3"},{"name":"Maps_To","value":"Spindle cell rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266134"}]}}{"C3749":{"preferredName":"Alveolar Rhabdomyosarcoma","code":"C3749","definitions":[{"definition":"A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that is most common in older children and teenagers. It begins in embryonic muscle cells (cells that develop into muscles in the body). It can occur at many places in the body, but usually occurs in the trunk, arms, or legs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alveolar Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ARMS","termGroup":"AB","termSource":"NCI"},{"termName":"Monomorphous Round Cell Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8920/3"},{"name":"Legacy Concept Name","value":"Alveolar_Rhabdomyosarcoma"},{"name":"Maps_To","value":"8920/3"},{"name":"Maps_To","value":"Alveolar rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206655"}]}}{"C4716":{"preferredName":"Ectomesenchymoma","code":"C4716","definitions":[{"definition":"A rare, fast-growing tumor of the nervous system or soft tissue that occurs in children and young adults. Ectomesenchymomas may form in the head and neck, abdomen, perineum, scrotum, or limbs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An exceedingly rare, aggressive malignant mesenchymal neoplasm characterized by the presence of a sarcomatous component and a ganglionic or a neuroectodermal component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ectomesenchymoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ectomesenchymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma with Ganglionic or Neuroectodermal Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8921/3"},{"name":"Legacy Concept Name","value":"Rhabdomyosarcoma_with_Ganglionic_Differentiation"},{"name":"Maps_To","value":"8921/3"},{"name":"Maps_To","value":"Ectomesenchymoma"},{"name":"Maps_To","value":"Rhabdomyosarcoma with ganglionic differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431111"}]}}{"C4262":{"preferredName":"Endometrial Stromal Nodule","code":"C4262","definitions":[{"definition":"A non-infiltrating, benign mesenchymal neoplasm arising from the uterine corpus. It is characterized by the presence of neoplastic cells that resemble the cells of the proliferative phase of endometrial stroma and numerous thin-walled small vessels. It usually presents with abnormal uterine bleeding and menorrhagia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Stromal Nodule","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8930/0"},{"name":"Legacy Concept Name","value":"Endometrial_Stromal_Nodule"},{"name":"Maps_To","value":"8930/0"},{"name":"Maps_To","value":"Endometrial stromal nodule"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334485"}]}}{"C8973":{"preferredName":"Endometrioid Stromal Sarcoma","code":"C8973","definitions":[{"definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant, mesenchymal tumor of the uterine stroma.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endometrioid Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"ESS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8930/3"},{"name":"Legacy Concept Name","value":"Endometrial_Stromal_Sarcoma"},{"name":"Maps_To","value":"8930/3"},{"name":"Maps_To","value":"Endometrial sarcoma, NOS"},{"name":"Maps_To","value":"Endometrial stromal sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206630"}]}}{"C126998":{"preferredName":"Uterine Corpus High Grade Endometrial Stromal Sarcoma","code":"C126998","definitions":[{"definition":"A rare, high grade sarcoma that arises from the endometrial stroma. It is characterized by round cell morphology. It was previously also known as undifferentiated uterine sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. It appears to have a prognosis that falls between low grade endometrial stromal sarcoma and undifferentiated sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus High Grade Endometrial Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrial Stromal Sarcoma, High Grade","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade ESS","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus High Grade ESS","termGroup":"SY","termSource":"NCI"},{"termName":"YWHAE-FAM22 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"YWHAE-FAM22 ESS","termGroup":"AB","termSource":"NCI"},{"termName":"YWHAE::FAM22 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8930/3"},{"name":"Maps_To","value":"Endometrial stromal sarcoma, high grade"},{"name":"NCI_META_CUI","value":"CL508195"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40223":{"preferredName":"Uterine Corpus Low Grade Endometrial Stromal Sarcoma","code":"C40223","definitions":[{"definition":"A rare, indolent, invasive mesenchymal tumor that arises from the endometrial stroma. It is characterized by the presence of a plexiform vasculature, infrequent mitoses, and insignificant cytologic atypia. Late recurrences may occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Low Grade Endometrial Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"JAZF1-SUZ12 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"JAZF1-SUZ12 ESS","termGroup":"AB","termSource":"NCI"},{"termName":"JAZF1::SUZ12 Endometrial Stromal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Low Grade ESS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Low_Grade_Endometrial_Stromal_Sarcoma"},{"name":"Maps_To","value":"8931/3"},{"name":"Maps_To","value":"Endometrial stromal sarcoma, low grade"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519857"}]}}{"C4263":{"preferredName":"Low Grade Endometrioid Stromal Sarcoma","code":"C4263","definitions":[{"definition":"An infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. It is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. It is usually characterized by indolent growth and late recurrences.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Endometrioid Stromal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Endolymphatic Stromal Myosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8931/3"},{"name":"Legacy Concept Name","value":"Low_Grade_Endometrial_Stromal_Sarcoma"},{"name":"Maps_To","value":"8931/3"},{"name":"Maps_To","value":"Endolymphatic stromal myosis"},{"name":"Maps_To","value":"Endometrial stromatosis"},{"name":"Maps_To","value":"Stromal endometriosis"},{"name":"Maps_To","value":"Stromal myosis, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334486"}]}}{"C3726":{"preferredName":"Adenomyoma","code":"C3726","definitions":[{"definition":"A benign neoplasm characterized by the presence of a glandular and a mesenchymal (fibromyomatous) component. It occurs in the uterine corpus, cervix, and uterine ligaments. A variant of adenomyoma associated with glandular architectural complexity is called atypical polypoid adenomyoma. Simple polypectomy is usually curative. Atypical polypoid adenomyoma may recur following polypectomy.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm characterized by the presence of a glandular and a mesenchymal component.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adenomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8932/0"},{"name":"Legacy Concept Name","value":"Adenomyoma"},{"name":"Maps_To","value":"8932/0"},{"name":"Maps_To","value":"Adenomyoma"},{"name":"Maps_To","value":"Adenomyoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206622"}]}}{"C6895":{"preferredName":"Atypical Polypoid Adenomyoma","code":"C6895","definitions":[{"definition":"An adenomyoma characterized by the presence of marked glandular architectural complexity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Polypoid Adenomyoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Polypoid_Adenomyoma"},{"name":"Maps_To","value":"8932/0"},{"name":"Maps_To","value":"Atypical polypoid adenomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1300347"}]}}{"C9474":{"preferredName":"Adenosarcoma","code":"C9474","definitions":[{"definition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that is a mixture of an adenoma (a tumor that starts in the gland-like cells of epithelial tissue) and a sarcoma (a tumor that starts in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue). An example of an adenosarcoma is Wilms tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adenosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mullerian Adenosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Müllerian Adenosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8933/3"},{"name":"Legacy Concept Name","value":"Mullerian_Adenosarcoma"},{"name":"Maps_To","value":"8933/3"},{"name":"Maps_To","value":"Adenosarcoma"},{"name":"Maps_To","value":"Mullerian adenosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001442"}]}}{"C40182":{"preferredName":"Uterine Corpus Carcinofibroma","code":"C40182","definitions":[{"definition":"An uncommon malignant neoplasm arising from the uterine corpus. It is characterized by the presence of a malignant epithelial component and a benign mesenchymal (usually fibrous) component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Carcinofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8934/3"},{"name":"Legacy Concept Name","value":"Uterine_Corpus_Adenocarcinofibroma"},{"name":"Maps_To","value":"8934/3"},{"name":"Maps_To","value":"Carcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1883485"}]}}{"C66772":{"preferredName":"Benign Stromal Tumor","code":"C66772","definitions":[{"definition":"A benign neoplasm composed of mesenchymal stromal cells without evidence of cellular atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Stromal Tumor","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8935/0"},{"name":"Legacy Concept Name","value":"Benign_Stromal_Tumor"},{"name":"Maps_To","value":"8935/0"},{"name":"Maps_To","value":"Stromal tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474833"}]}}{"C6781":{"preferredName":"Stromal Neoplasm","code":"C6781","definitions":[{"definition":"A benign or malignant mesenchymal neoplasm composed of stromal cells.  Representative examples include gastrointestinal stromal tumor, endometrial stromal sarcoma, and prostate stromal sarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that arises in the supporting connective tissue of an organ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stromal Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Stromal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8935/1"},{"name":"Legacy Concept Name","value":"Stromal_Neoplasm"},{"name":"Maps_To","value":"8935/1"},{"name":"Maps_To","value":"Stromal tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0879615"}]}}{"C6926":{"preferredName":"Stromal Sarcoma","code":"C6926","definitions":[{"definition":"A malignant neoplasm characterized by the presence of atypical mesenchymal-stromal cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm characterized by the presence of atypical mesenchymal-stromal cells. Representative examples include endometrial stromal sarcoma and prostate stromal sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stromal Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8935/3"},{"name":"Legacy Concept Name","value":"Stromal_Sarcoma"},{"name":"Maps_To","value":"8935/3"},{"name":"Maps_To","value":"Stromal sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370723"}]}}{"C53998":{"preferredName":"Benign Gastrointestinal Stromal Tumor","code":"C53998","definitions":[{"definition":"A benign neoplasm arising from specialized smooth muscle cells (i.e., interstitial cells of Cajal) in the tunica muscularis or myenteric plexus. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A gastrointestinal stromal tumor that is characterized by a maximum diameter equal or less than 5 cm (gastric localization), or equal or less than 2 cm (intestinal localization) and no more than 5 mitotic figures per 50 high power fields.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8936/0"},{"name":"Legacy Concept Name","value":"Probably_Benign_Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"8936/0"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, benign"},{"name":"Maps_To","value":"GIST, benign"},{"name":"NCI_META_CUI","value":"CL449186"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C54000":{"preferredName":"Gastrointestinal Stromal Tumor of Uncertain Malignant Potential","code":"C54000","definitions":[{"definition":"A gastrointestinal stromal tumor that is characterized by a maximum diameter greater than 5 cm and equal or less than 10 cm (gastric localization), or greater than 2 cm and equal or less than 5 cm (intestinal localization) and no more than 5 mitotic figures per 50 high power fields.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrointestinal Stromal Tumor of Uncertain Malignant Potential","termGroup":"HD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Stromal_Tumor_of_Uncertain_Malignant_Potential"},{"name":"Maps_To","value":"8936/1"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, uncertain malignant potential"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704399"}]}}{"C3868":{"preferredName":"Gastrointestinal Stromal Tumor","code":"C3868","definitions":[{"definition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","type":"DEFINITION","source":"NCI"},{"definition":"A type of tumor that usually begins in cells in the wall of the gastrointestinal tract. It can be benign or malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrointestinal Stromal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"GIST","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"8936/1"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"8936/1"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, NOS"},{"name":"Maps_To","value":"GIST, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3149028"}]}}{"C27940":{"preferredName":"Gastrointestinal Autonomic Nerve Tumor","code":"C27940","definitions":[{"definition":"A variant of gastrointestinal stromal tumor with ultrastructural features of neural differentiation.  It is composed of spindle or epithelioid neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrointestinal Autonomic Nerve Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"GANT","termGroup":"AB","termSource":"NCI"},{"termName":"Gastrointestinal Stromal Tumor with Neurogenic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Plexosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Autonomic_Nerve_Tumor"},{"name":"Maps_To","value":"8936/1"},{"name":"Maps_To","value":"GANT"},{"name":"Maps_To","value":"Gastrointestinal autonomic nerve tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2931518"}]}}{"C53999":{"preferredName":"Malignant Gastrointestinal Stromal Tumor","code":"C53999","definitions":[{"definition":"A gastrointestinal stromal tumor that is characterized by large size (diameter greater than 10 cm for gastric localization and greater than 5 cm for intestinal localization) or more than 5 mitotic figures per 50 high power fields.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from specialized smooth muscle cells (i.e., interstitial cells of Cajal) in the tunica muscularis or myenteric plexus. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8936/3"},{"name":"Legacy Concept Name","value":"Probably_Malignant_Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"8936/3"},{"name":"Maps_To","value":"Gastrointestinal stromal sarcoma"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor"},{"name":"Maps_To","value":"Gastrointestinal stromal tumor, malignant"},{"name":"Maps_To","value":"GIST, malignant"},{"name":"NCI_META_CUI","value":"CL497447"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6930":{"preferredName":"Mixed Neoplasm","code":"C6930","definitions":[{"definition":"A neoplasm composed of at least two distinct cellular populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8940/1"},{"name":"Legacy Concept Name","value":"Mixed_Neoplasm"},{"name":"Maps_To","value":"8940/0"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368354"}]}}{"C8602":{"preferredName":"Pleomorphic Adenoma","code":"C8602","definitions":[{"definition":"A benign neoplasm composed of epithelial and/or myoepithelial cells and a mesenchymal component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm characterized by the presence of benign epithelial and myoepithelial cells and a mesenchymal component that may contain mucoid, myxoid, cartilaginous, or osseous areas. It may be completely or partially encapsulated. It occurs in the parotid gland, submandibular gland, minor salivary glands in the oral cavity, upper respiratory tract, and nasal cavity and paranasal sinuses. It usually presents as a slow growing painless mass. Infrequently, patients may present with pain and facial palsy. It may recur after excision or transform to a malignant neoplasm (carcinoma ex pleomorphic adenoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Adenoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8940/0"},{"name":"Legacy Concept Name","value":"Pleomorphic_Adenoma"},{"name":"Maps_To","value":"8940/0"},{"name":"Maps_To","value":"Mixed tumor, salivary gland type, NOS"},{"name":"Maps_To","value":"Pleomorphic adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026277"}]}}{"C4474":{"preferredName":"Benign Mixed Tumor of the Skin","code":"C4474","definitions":[{"definition":"A rare, benign, slow-growing and painless neoplasm of sweat glands. It usually arises in the head and neck. It is characterized by the presence of a mesenchymal chondroid stroma, fibrosis, and epithelial structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Mixed Tumor of the Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Mixed Tumor of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mixed Tumor of Skin (Chondroid Syringoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mixed Tumor of the Skin (Chondroid Syringoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Chondroid Syringoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Tumor of the Skin (Chondroid Syringoma)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Mixed_Tumor_of_the_Skin_Chondroid_Syringoma"},{"name":"Maps_To","value":"8940/0"},{"name":"Maps_To","value":"Chondroid syringoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346026"}]}}{"C3729":{"preferredName":"Malignant Mixed Neoplasm","code":"C3729","definitions":[{"definition":"A malignant neoplasm composed of a carcinomatous epithelial component and a sarcomatous mesenchymal component. Representative examples include malignant mixed mesodermal (Mullerian) tumor of the female reproductive system and carcinosarcoma of the salivary gland and the lung.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of epithelial and/or myoepithelial cells and a mesenchymal component. A general term for which the transformed cell types have not been specified.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Mixed Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mixed Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8940/3"},{"name":"Legacy Concept Name","value":"Malignant_Mixed_Neoplasm"},{"name":"Maps_To","value":"8940/3"},{"name":"Maps_To","value":"Mixed tumor, malignant, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206625"}]}}{"C4397":{"preferredName":"Carcinoma ex Pleomorphic Adenoma","code":"C4397","definitions":[{"definition":"A carcinoma arising in a pre-existing pleomorphic adenoma. It most often occurs in the parotid gland and less often in the submandibular gland and minor salivary gland. Patients usually present with a history of a long-standing mass which recently had undergone rapid growth. The prognosis depends on the invasiveness of the malignant component. Patients with non-invasive or minimally invasive tumors usually have a good prognosis following surgical resection. Invasive tumors are usually aggressive and are associated with recurrences and metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoma ex Pleomorphic Adenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma in Pleomorphic Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"CXPA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8941/3"},{"name":"Legacy Concept Name","value":"Carcinoma_Ex_Pleomorphic_Adenoma"},{"name":"Maps_To","value":"8941/3"},{"name":"Maps_To","value":"Carcinoma ex pleomorphic adenoma"},{"name":"Maps_To","value":"Carcinoma in pleomorphic adenoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0344460"}]}}{"C3730":{"preferredName":"Mixed Mesodermal (Mullerian) Tumor","code":"C3730","definitions":[{"definition":"A group of tumors affecting the female reproductive system, characterized by the presence of epithelial and stromal elements. It includes the following clinicopathological entities: adenofibroma, adenomyoma, Mullerian adenosarcoma, and malignant mixed mesodermal (Mullerian) tumor.","type":"DEFINITION","source":"NCI"},{"definition":"A rare cancer of the uterus, ovary, or fallopian tubes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mixed Mesodermal (Mullerian) Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Mesodermal Mixed Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesodermal (Mullerian) Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesodermal (Müllerian) Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesodermal (Müllerian) Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mullerian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Müllerian Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8950/3"},{"name":"ICD-O-3_Code","value":"8951/3"},{"name":"Legacy Concept Name","value":"Mixed_Mesodermal_Mullerian_Tumor"},{"name":"Maps_To","value":"8950/3"},{"name":"Maps_To","value":"8951/3"},{"name":"Maps_To","value":"Mesodermal mixed tumor"},{"name":"Maps_To","value":"Mullerian mixed tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206627"}]}}{"C7504":{"preferredName":"Adult Cystic Nephroma","code":"C7504","definitions":[{"definition":"A localized, well-circumscribed multilocular tumor lined by hobnail epithelium. It was previously classified along with pediatric cystic nephroma, as a separate entity from mixed epithelial and stromal tumors. Now it is classified within the spectrum of the mixed epithelial and stromal tumor family. Most of these tumors are benign. (WHO 2016).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adult Cystic Nephroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8959/0"},{"name":"Legacy Concept Name","value":"Cystic_Nephroma"},{"name":"Maps_To","value":"8959/0"},{"name":"Maps_To","value":"Benign cystic nephroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266138"}]}}{"C6897":{"preferredName":"Cystic Partially Differentiated Kidney Nephroblastoma","code":"C6897","definitions":[{"definition":"A rare, cystic variant of Wilms tumor wholly comprising cysts in which their thin septa form the only solid portion of the tumor.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A variant of Wilms tumor of the kidney characterized by the presence of cystic spaces separated by septa.  The septa contain immature epithelial cells, immature stromal cells, and blastema cells.  Surgical resection is usually curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystic Partially Differentiated Kidney Nephroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Cystic Nephroma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Multilocular Cystic Nephroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8959/1"},{"name":"ICD-O-3_Code","value":"8959/3"},{"name":"Legacy Concept Name","value":"Cystic_Partially_Differentiated_Nephroblastoma"},{"name":"Maps_To","value":"8959/1"},{"name":"Maps_To","value":"8959/3"},{"name":"Maps_To","value":"Cystic partially differentiated nephroblastoma"},{"name":"Maps_To","value":"Malignant cystic nephroma"},{"name":"Maps_To","value":"Malignant multilocular cystic nephroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266139"}]}}{"C6569":{"preferredName":"Congenital Mesoblastic Nephroma","code":"C6569","definitions":[{"definition":"A congenital malignant neoplasm of the kidney characterized by the presence of fibroblastic cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A low grade childhood congenital malignant neoplasm arising from the kidney, which is characterized by the presence of fibroblastic cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A low grade childhood congenital malignant neoplasm arising from the kidney. It is characterized by the presence of fibroblastic cells. The majority of cases occur in the first year of life. Complete excision is usually associated with an excellent prognosis.","type":"DEFINITION","source":"NCI"},{"definition":"A type of kidney tumor that is usually found before birth by ultrasound or within the first 3 months of life. It contains fibroblastic cells (connective tissue cells), and may spread to the other kidney or to nearby tissue. Congenital mesoblastic nephroma is more common in males.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Congenital Mesoblastic Nephroma","termGroup":"PT","termSource":"NCI"},{"termName":"CMN","termGroup":"AB","termSource":"NCI"},{"termName":"Mesoblastic Nephroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8960/1"},{"name":"Legacy Concept Name","value":"Childhood_Congenital_Mesoblastic_Nephroma"},{"name":"Maps_To","value":"8960/1"},{"name":"Maps_To","value":"Mesoblastic nephroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332965"}]}}{"C40407":{"preferredName":"Kidney Wilms Tumor","code":"C40407","definitions":[{"definition":"A disease in which malignant (cancer) cells are found in the kidney, and may spread to the lungs, liver, or nearby lymph nodes. Wilms tumor usually occurs in children younger than 5 years old.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant embryonal neoplasm of the kidney.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An embryonal pediatric tumor of the kidney which may also be seen rarely in adults. The peak incidence of Wilms tumor is between the second and fifth year of life. Microscopically, it is composed of a mixture of cellular elements (blastemal, stromal, and epithelial). The most common sites of metastasis include the regional lymph nodes, lungs, and liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kidney Wilms Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Nephroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Wilms Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Wilms' Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Wilms Tumor of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Wilms' Tumor of the Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8960/3"},{"name":"Legacy Concept Name","value":"Renal_Wilms_Tumor"},{"name":"Maps_To","value":"8960/3"},{"name":"Maps_To","value":"Nephroblastoma, NOS"},{"name":"Maps_To","value":"Nephroma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027708"}]}}{"C3267":{"preferredName":"Wilms Tumor","code":"C3267","definitions":[{"definition":"A malignant neoplasm of embryonal origin arising within the kidney.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wilms Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Nephroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Wilms' Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Wilms_Tumor"},{"name":"Maps_To","value":"8960/3"},{"name":"Maps_To","value":"Nephroblastoma, NOS"},{"name":"Maps_To","value":"Wilms tumor"},{"name":"Maps_To","value":"Wilms Tumor"},{"name":"Maps_To","value":"Wilms tumor (WT)"},{"name":"NCI_META_CUI","value":"CL505178"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3808":{"preferredName":"Rhabdoid Tumor","code":"C3808","definitions":[{"definition":"A malignant tumor of either the central nervous system (CNS) or the kidney. Malignant rhabdoid tumors of the CNS often have an abnormality of chromosome 22. These tumors usually occur in children younger than 2 years.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive cancer of the central nervous system, kidney, or liver that occurs in very young children.\"","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant embryonal neoplasm usually occurring during childhood.  It is characterized by the presence of large cells with abundant cytoplasm, large eccentric nucleus, and a prominent nucleolus and it is associated with abnormalities of chromosome 22.  It can arise from the central nervous system, kidney, and the soft tissues.  The prognosis is poor.","type":"DEFINITION","source":"NCI"},{"definition":"Extremely aggressive malignancies that generally occur in infants and young children. The most common locations are the kidney and central nervous system (CNS), although they can also arise in most soft tissue sites. Approximately two-thirds of patients will present with advanced-stage disease. Rhabdoid tumors of the kidney tend to metastasize to the CNS and lungs. Rhabdoid tumors are associated with mutations of SMARCB1 (INI-1), a tumor suppressor gene.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Rhabdoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Rhabdoid Sarcoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8963/3"},{"name":"Legacy Concept Name","value":"Rhabdoid_Tumor"},{"name":"Maps_To","value":"8963/3"},{"name":"Maps_To","value":"Malignant rhabdoid tumor"},{"name":"Maps_To","value":"Rhabdoid sarcoma"},{"name":"Maps_To","value":"Rhabdoid tumor, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206743"}]}}{"C4264":{"preferredName":"Clear Cell Sarcoma of the Kidney","code":"C4264","definitions":[{"definition":"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. It metastasizes to lung, bone, brain and soft tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A rare primary renal tumor characterized by nests or cords of cells that are separated by regularly spaced fibrovascular septa, and which are known to metastasize to lung, bone, brain and soft tissue. It is associated with internal tandem duplications in the BCOR gene.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare type of kidney cancer, in which the inside of the cells look clear when viewed under a microscope. Clear cell sarcoma can spread from the kidney to other organs, most commonly the bone, but also including the lungs, brain, and soft tissues of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Sarcoma of the Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"CCSK","termGroup":"AB","termSource":"NCI"},{"termName":"Childhood Clear Cell Sarcoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Kidney Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Renal Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Sarcoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Kidney Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Renal Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Clear Cell Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8964/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Sarcoma_of_the_Kidney"},{"name":"Maps_To","value":"8964/3"},{"name":"Maps_To","value":"Clear cell sarcoma of kidney"},{"name":"Maps_To","value":"Clear cell sarcoma of the kidney (CCSK)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334488"}]}}{"C39812":{"preferredName":"Metanephric Adenofibroma","code":"C39812","definitions":[{"definition":"A benign, solitary, and partially cystic neoplasm arising from the kidney. It occurs in children and adults. Presenting symptoms include hematuria and polycythemia. It is characterized by the presence of epithelial nodules embedded in a stroma containing spindle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metanephric Adenofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Nephrogenic Adenofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8965/0"},{"name":"Legacy Concept Name","value":"Metanephric_Adenofibroma"},{"name":"Maps_To","value":"8965/0"},{"name":"Maps_To","value":"Nephrogenic adenofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266141"}]}}{"C5100":{"preferredName":"Renomedullary Interstitial Cell Tumor","code":"C5100","definitions":[{"definition":"A benign, asymptomatic kidney tumor arising from renomedullary interstitial cells. It is often found incidentally at the time of nephrectomy in adults. These tumors are either single or multiple and usually measure 1-10 mm in diameter. Microscopically the tumor cells are small, stellate, or spindled cells, embedded in a faintly basophilic stroma reminiscent of renal medullary stroma. (WHO 2016)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renomedullary Interstitial Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroma of Renal Medulla","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Hamartoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8966/0"},{"name":"Legacy Concept Name","value":"Renal_Fibroma"},{"name":"Maps_To","value":"8966/0"},{"name":"Maps_To","value":"Renomedullary interstitial cell tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335742"}]}}{"C66774":{"preferredName":"Ossifying Renal Tumor of Infancy","code":"C66774","definitions":[{"definition":"A benign neoplasm of the kidney occurring in infants. It develops as an intracalyceal mass and is characterized by the presence of osteoid formation, osteoblast-like cells, and spindle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ossifying Renal Tumor of Infancy","termGroup":"PT","termSource":"NCI"},{"termName":"ORTI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8967/0"},{"name":"Legacy Concept Name","value":"Ossifying_Renal_Tumor_of_Infancy"},{"name":"Maps_To","value":"8967/0"},{"name":"Maps_To","value":"Ossifying renal tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1882198"}]}}{"C7097":{"preferredName":"Mixed Epithelial and Mesenchymal Hepatoblastoma","code":"C7097","definitions":[{"definition":"A subtype of hepatoblastoma characterized by the presence of epithelial and mesenchymal components.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A subtype of hepatoblastoma characterized by the presence of epithelial and mesenchymal components.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Epithelial and Mesenchymal Hepatoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8970/3"},{"name":"Legacy Concept Name","value":"Mixed_Epithelial_and_Mesenchymal_Hepatoblastoma"},{"name":"Maps_To","value":"8970/3"},{"name":"Maps_To","value":"Hepatoblastoma, mixed epithelial-mesenchymal"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334784"}]}}{"C3728":{"preferredName":"Hepatoblastoma","code":"C3728","definitions":[{"definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant liver neoplasm composed of immature hepatocytic elements.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant liver tumor that arises from precursors of hepatocytes. It occurs almost exclusively in infants. The lungs are the most common site of metastasis.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of liver tumor that occurs in infants and children.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hepatoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"HBL","termGroup":"AB","termSource":"NCI"},{"termName":"Pediatric Embryonal Hepatoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Hepatoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8970/3"},{"name":"Legacy Concept Name","value":"Hepatoblastoma"},{"name":"Maps_To","value":"8970/3"},{"name":"Maps_To","value":"Embryonal hepatoma"},{"name":"Maps_To","value":"Hepatoblastoma"},{"name":"Maps_To","value":"Hepatoblastoma, NOS"},{"name":"Maps_To","value":"Malignant neoplasm: Hepatoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206624"}]}}{"C4265":{"preferredName":"Pancreatoblastoma","code":"C4265","definitions":[{"definition":"A rare malignant epithelial neoplasm arising from the pancreas. The vast majority of cases occur during childhood. It is characterized by acinar differentiation, the formation of squamoid corpuscles, and the formation of stromal bands. Patients may present with an abdominal mass. Symptoms include pain, weight loss, and diarrhea. It may metastasize to lymph nodes, liver, and distant anatomic sites. Children who do not have metastatic disease at the time of diagnosis usually have a favorable clinical outcome when treated with a combination of surgery and chemotherapy. However, children with metastatic disease at presentation or adult patients usually have a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8971/3"},{"name":"Legacy Concept Name","value":"Pancreatoblastoma"},{"name":"Maps_To","value":"8971/3"},{"name":"Maps_To","value":"Pancreatoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334489"}]}}{"C3732":{"preferredName":"Pulmonary Blastoma","code":"C3732","definitions":[{"definition":"A biphasic tumor that consists of fetal adenocarcinoma (typically low-grade) and primitive mesenchymal stroma. Foci of specific mesenchymal differentiation (osteosarcoma, chondrosarcoma, or rhabdomyosarcoma) may also be present, but are not required for the diagnosis. Most patients are smokers.  The prognosis is very poor. (WHO 2015)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Blastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Blastoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Blastoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Blastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pneumoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8972/3"},{"name":"Legacy Concept Name","value":"Pulmonary_Blastoma"},{"name":"Maps_To","value":"8972/3"},{"name":"Maps_To","value":"Pneumoblastoma"},{"name":"Maps_To","value":"Pulmonary blastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206629"}]}}{"C5669":{"preferredName":"Pleuropulmonary Blastoma","code":"C5669","definitions":[{"definition":"A malignant neoplasm affecting the lungs and/or the pleura. Pleuropulmonary blastoma is seen in children. Microscopically, the tumor may show features of chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, or undifferentiated sarcoma. In approximately 25% of patients there is a predisposition for other tumors. Heterozygous germline mutations in DICER1 gene have been identified in families harboring pleuropulmonary blastomas.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neoplasm affecting the lungs and/or the pleura. Pleuropulmonary blastoma is seen in children. Microscopically, the tumor may show features of chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, or undifferentiated sarcoma. In approximately 25% of patients with pleuropulmonary blastoma, there are other lesions or neoplasms that may affect patients or their families, including lung or kidney cysts, and ovarian or testicular neoplasms. Heterozygous germline mutations in DICER1 gene have been identified in families harboring pleuropulmonary blastomas.","type":"DEFINITION","source":"NCI"},{"definition":"A rare and very aggressive (fast-growing) cancer that forms in tissues of the lung and pleura (a thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity). Pleuropulmonary blastoma is most common in children.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pleuropulmonary Blastoma","termGroup":"PT","termSource":"NCI"},{"termName":"PPB","termGroup":"AB","termSource":"NCI"},{"termName":"Pulmonary Blastoma of Childhood","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8973/3"},{"name":"Legacy Concept Name","value":"Pleuropulmonary_Blastoma"},{"name":"Maps_To","value":"8973/3"},{"name":"Maps_To","value":"Pleuropulmonary blastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266144"}]}}{"C35837":{"preferredName":"Sialoblastoma","code":"C35837","definitions":[{"definition":"A rare, malignant primitive neoplasm that occurs in the salivary glands. Most tumors arise from the parotid gland, followed by the submandibular gland, and rarely the minor salivary glands. It is usually diagnosed during the neonatal period and presents with painless face swelling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Salivary Gland Sialoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8974/1"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Sialoblastoma"},{"name":"Maps_To","value":"8974/1"},{"name":"Maps_To","value":"Sialoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266145"}]}}{"C96830":{"preferredName":"Calcifying Nested Stromal-Epithelial Tumor","code":"C96830","definitions":[{"definition":"A rare malignant tumor that arises from the liver and occurs in children.  It is characterized by the presence of nested epithelioid and spindle cells.  Desmoplasia, calcifications, and bone formation may also be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcifying Nested Stromal-Epithelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Calcifying Nested Epithelial Stromal Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Nested Epithelial-Stromal Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Nested Stromal Epithelial Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Calcifying Nested Stromal-Epithelial Tumor of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"CNSET","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8975/1"},{"name":"Maps_To","value":"8975/1"},{"name":"Maps_To","value":"Calcifying fibrous tumor"},{"name":"Maps_To","value":"Calcifying nested epithelial stromal tumor"},{"name":"Maps_To","value":"Calcifying nested stromal-epithelial tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273067"}]}}{"C34448":{"preferredName":"Carcinosarcoma","code":"C34448","definitions":[{"definition":"A malignant neoplasm comprising a mixture of carcinomatous and sarcomatous elements.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant tumor that is a mixture of carcinoma (cancer of epithelial tissue, which is skin and tissue that lines or covers the internal organs) and sarcoma (cancer of connective tissue, such as bone, cartilage, and fat).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carcinosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8980/3"},{"name":"Legacy Concept Name","value":"Carcinosarcoma"},{"name":"Maps_To","value":"8980/3"},{"name":"Maps_To","value":"Carcinosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007140"}]}}{"C8975":{"preferredName":"Malignant Mixed Mesodermal (Mullerian) Tumor","code":"C8975","definitions":[{"definition":"A malignant neoplasm of the female reproductive tract (mostly uterus and ovaries) originating from the Mullerian ducts and composed of carcinomatous and sarcomatous elements.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare type of tumor that is a mixture of carcinoma and sarcoma cells. MMMT usually occurs in the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant tumor of the female reproductive system, affecting predominantly elderly menopausal women.  The endometrium and ovary are the most common sites of tumor origin.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mixed Mesodermal (Mullerian) Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mixed Mesodermal (Müllerian) Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Mesodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Mullerian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Müllerian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"MMMT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Mixed_Mesodermal_Mullerian_Tumor"},{"name":"Maps_To","value":"8981/3"},{"name":"Maps_To","value":"Carcinosarcoma, embryonal"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334603"}]}}{"C40392":{"preferredName":"Myoepithelial Tumor","code":"C40392","definitions":[{"definition":"A benign or malignant tumor characterized by the presence of cells that show myoepithelial differentiation. Based on its morphologic features, it is classified as benign or malignant. A representative example of benign myoepithelioma is benign salivary gland myoepithelioma. Representative examples of malignant myoepithelioma or myoepithelial carcinoma are malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myoepithelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Myoepithelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Myoepithelial Tumor of Soft Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Myoepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8982/0"},{"name":"ICD-O-3_Code","value":"8982/1"},{"name":"Legacy Concept Name","value":"Myoepithelial_Neoplasm"},{"name":"Maps_To","value":"8982/0"},{"name":"Maps_To","value":"Myoepithelial tumor"},{"name":"Maps_To","value":"Myoepithelioma"},{"name":"Maps_To","value":"Myoepithelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027070"}]}}{"C7442":{"preferredName":"Benign Myoepithelioma","code":"C7442","definitions":[{"definition":"A benign neoplasm composed of myoepithelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tumor with myoepithelial differentiation that lacks an infiltrative growth pattern and does not metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Myoepithelioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Myoepithelioma"},{"name":"Maps_To","value":"8982/0"},{"name":"Maps_To","value":"Myoepithelial adenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1947949"}]}}{"C7596":{"preferredName":"Malignant Myoepithelioma","code":"C7596","definitions":[{"definition":"A malignant neoplasm composed of myoepithelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An infiltrating malignant tumor characterized by the presence of atypical cells with myoepithelial differentiation. Representative examples include malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Myoepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Myoepithelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8982/3"},{"name":"Legacy Concept Name","value":"Myoepithelial_Carcinoma"},{"name":"Maps_To","value":"8982/3"},{"name":"Maps_To","value":"Malignant myoepithelioma"},{"name":"Maps_To","value":"Myoepithelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334699"}]}}{"C6899":{"preferredName":"Breast Adenomyoepithelioma","code":"C6899","definitions":[{"definition":"A usually benign tumor arising from the breast. It is characterized by the proliferation of cells with myoepithelial differentiation around spaces which are lined by epithelial cells. Rarely, the epithelial and/or myoepithelial cells may undergo malignant transformation. Cases with malignant transformation may follow an aggressive clinical course, including recurrences and local and distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Adenomyoepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomyoepithelioma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8983/0"},{"name":"Legacy Concept Name","value":"Adenomyoepithelioma"},{"name":"Maps_To","value":"8983/0"},{"name":"Maps_To","value":"Adenomyoepithelioma"},{"name":"Maps_To","value":"Adenomyoepithelioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266146"}]}}{"C5143":{"preferredName":"Malignant Breast Adenomyoepithelioma","code":"C5143","definitions":[{"definition":"An adenomyoepithelioma of the breast in which the epithelial, myoepithelial, or both components have undergone malignant transformation.  Such cases may follow an aggressive clinical course, including recurrences and local and distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Breast Adenomyoepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Adenomyoepithelioma with Malignant Change","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adenomyoepithelioma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adenomyoepithelioma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Breast_Adenomyoepithelioma"},{"name":"Maps_To","value":"8983/3"},{"name":"Maps_To","value":"Adenomyoepithelioma with carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839546"}]}}{"C4267":{"preferredName":"Benign Mesenchymoma","code":"C4267","definitions":[{"definition":"A benign soft-tissue neoplasm comprising two or more non-fibroblastic mesenchymal lines of differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A term describing a benign soft tissue tumor which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Mesenchymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8990/0"},{"name":"Legacy Concept Name","value":"Benign_Mesenchymoma"},{"name":"Maps_To","value":"8990/0"},{"name":"Maps_To","value":"Mesenchymoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334491"}]}}{"C3233":{"preferredName":"Mesenchymoma","code":"C3233","definitions":[{"definition":"A term describing a soft tissue tumor which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesenchymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8990/1"},{"name":"Legacy Concept Name","value":"Mesenchymoma"},{"name":"Maps_To","value":"8990/1"},{"name":"Maps_To","value":"Mesenchymoma, NOS"},{"name":"Maps_To","value":"Mixed mesenchymal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025464"}]}}{"C4268":{"preferredName":"Malignant Mesenchymoma","code":"C4268","definitions":[{"definition":"A malignant soft tissue neoplasm which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A term describing a malignant soft tissue tumor which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mesenchymoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8990/3"},{"name":"Legacy Concept Name","value":"Malignant_Mesenchymoma"},{"name":"Maps_To","value":"8990/3"},{"name":"Maps_To","value":"Mesenchymoma, malignant"},{"name":"Maps_To","value":"Mixed mesenchymal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334492"}]}}{"C27096":{"preferredName":"Liver Embryonal Sarcoma","code":"C27096","definitions":[{"definition":"An aggressive malignant mesenchymal neoplasm that arises from the liver and usually occurs in older children.  It is composed of immature spindle, stellate, polymorphous, and giant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liver Embryonal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonal Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Sarcoma (Undifferentiated Sarcoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Sarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"ESL","termGroup":"AB","termSource":"NCI"},{"termName":"UES","termGroup":"AB","termSource":"NCI"},{"termName":"Undifferentiated (Embryonal) Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated (Embryonal) Sarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8805/3"},{"name":"ICD-O-3_Code","value":"8991/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Embryonal_Sarcoma"},{"name":"Maps_To","value":"8991/3"},{"name":"Maps_To","value":"Embryonal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855073"}]}}{"C39954":{"preferredName":"Brenner Tumor","code":"C39954","definitions":[{"definition":"A tumor composed of solid and cystic nests of neoplastic urothelial-type cells in an abundant stromal component that is dense and fibroblastic in nature. It arises from the ovary and very rarely the paratesticular structures. It includes benign Brenner tumor, borderline Brenner tumor, and malignant Brenner tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brenner Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9000/0"},{"name":"Legacy Concept Name","value":"Brenner_Tumor"},{"name":"Maps_To","value":"9000/0"},{"name":"Maps_To","value":"Brenner tumor, NOS"},{"name":"NCI_META_CUI","value":"CL323981"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9459":{"preferredName":"Borderline Ovarian Brenner Tumor","code":"C9459","definitions":[{"definition":"A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of neoplastic atypical urothelial-type cells in a fibrotic stroma without evidence of invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Brenner Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Brenner Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Brenner Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Brenner Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Borderline Ovarian Transitional Cell Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Borderline Ovarian Transitional Cell Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Ovarian Brenner Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low Malignancy Potential Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Brenner Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferating Ovarian Brenner Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9000/1"},{"name":"Legacy Concept Name","value":"Borderline_Brenner_Tumor"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Transitional_Cell_Tumor"},{"name":"Maps_To","value":"9000/1"},{"name":"Maps_To","value":"Brenner tumor, borderline malignancy"},{"name":"Maps_To","value":"Brenner tumor, proliferating"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334494"}]}}{"C4270":{"preferredName":"Malignant Ovarian Brenner Tumor","code":"C4270","definitions":[{"definition":"A malignant neoplasm that arises from the ovary. It is characterized by the presence of an invasive malignant urothelial-type cellular component and nests of benign urothelial-type cells in a fibrotic stroma. When the neoplasm is confined to the ovary, the prognosis is good.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ovarian Brenner Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Brenner Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brenner Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ovarian Transitional Cell Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Ovarian Transitional Cell Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9000/3"},{"name":"Legacy Concept Name","value":"Malignant_Brenner_Tumor"},{"name":"Maps_To","value":"9000/3"},{"name":"Maps_To","value":"Brenner tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518237"}]}}{"C3744":{"preferredName":"Breast Fibroadenoma","code":"C3744","definitions":[{"definition":"A benign (not cancer) tumor that usually forms in the breast from both fibrous and glandular tissue. Fibroadenomas are the most common benign breast tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign neoplasm originating from glandular cells with a fibrous or fibroblastic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign tumor of the breast characterized by the presence of stromal and epithelial elements. It presents as a painless, solitary, slow growing, firm, and mobile mass. It is the most common benign breast lesion. It usually occurs in women of childbearing age. The majority of fibroadenomas do not recur after complete excision. A slightly increased risk of developing cancer within fibroadenomas or in the breast tissue of patients previously treated for fibroadenomas has been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9010/0"},{"name":"Legacy Concept Name","value":"Fibroadenoma"},{"name":"Maps_To","value":"9010/0"},{"name":"Maps_To","value":"Fibroadenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206650"}]}}{"C4271":{"preferredName":"Breast Intracanalicular Fibroadenoma","code":"C4271","definitions":[{"definition":"A morphologic variant of breast fibroadenoma without clinical significance. It is characterized by distortion and compression of the ducts by proliferating stromal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Intracanalicular Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Intracanalicular Breast Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracanalicular Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracanalicular Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Intracanalicular Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9011/0"},{"name":"Legacy Concept Name","value":"Intracanalicular_Fibroadenoma"},{"name":"Maps_To","value":"9011/0"},{"name":"Maps_To","value":"Intracanalicular fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334496"}]}}{"C4272":{"preferredName":"Breast Pericanalicular Fibroadenoma","code":"C4272","definitions":[{"definition":"A morphologic variant of breast fibroadenoma without clinical significance. It is characterized by circumferential proliferation of stromal cells around the ducts. This results in the formation of rounded ductal-epithelial structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Pericanalicular Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pericanalicular Breast Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pericanalicular Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pericanalicular Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Pericanalicular Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9012/0"},{"name":"Legacy Concept Name","value":"Pericanalicular_Fibroadenoma"},{"name":"Maps_To","value":"9012/0"},{"name":"Maps_To","value":"Pericanalicular fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334497"}]}}{"C8984":{"preferredName":"Female Reproductive System Adenofibroma","code":"C8984","definitions":[{"definition":"A benign or borderline neoplasm characterized by the presence of connective tissue stroma and epithelial structures. It occurs in the ovary, fallopian tube, uterine corpus, and cervix.","type":"DEFINITION","source":"NCI"},{"definition":"Benign mixed neoplasm comprised of epithelial/glandular and mesenchymal structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Female Reproductive System Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9013/0"},{"name":"Legacy Concept Name","value":"Adenofibroma"},{"name":"Maps_To","value":"9013/0"},{"name":"Maps_To","value":"Adenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001422"}]}}{"C8985":{"preferredName":"Cystadenofibroma","code":"C8985","definitions":[{"definition":"A benign or borderline neoplasm that arises from the ovaries and the fallopian tubes. It is characterized by the presence of cystic glandular structures and fibrous tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystadenofibroma"},{"name":"Maps_To","value":"9013/0"},{"name":"Maps_To","value":"Cystadenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334317"}]}}{"C8986":{"preferredName":"Papillary Adenofibroma","code":"C8986","definitions":[{"definition":"A biphasic polypoid neoplasm characterized by the presence of papillary projections that are lined by epithelial cells and fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Adenofibroma"},{"name":"Maps_To","value":"9013/0"},{"name":"Maps_To","value":"Papillary adenofibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377850"}]}}{"C67090":{"preferredName":"Serous Adenofibroma","code":"C67090","definitions":[{"definition":"A benign or borderline adenofibroma characterized by the presence of serous secretory cells and minute cystic spaces filled with watery fluid. A representative example is the ovarian serous adenofibroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9014/0"},{"name":"Legacy Concept Name","value":"Serous_Adenofibroma"},{"name":"Maps_To","value":"9014/0"},{"name":"Maps_To","value":"Serous adenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334498"}]}}{"C40028":{"preferredName":"Borderline Ovarian Serous Adenofibroma","code":"C40028","definitions":[{"definition":"A low malignant potential adenofibroma arising from the ovary. It is characterized by an atypical epithelial hyperplasia. The epithelial cells are of serous type. There is no evidence of stromal destructive invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Serous Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9014/1"},{"name":"Legacy Concept Name","value":"Borderline_Ovarian_Serous_Adenofibroma"},{"name":"Maps_To","value":"9014/1"},{"name":"Maps_To","value":"Serous adenofibroma of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266152"}]}}{"C67092":{"preferredName":"Ovarian Serous Adenocarcinofibroma","code":"C67092","definitions":[{"definition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells of serous type, forming glandular, papillary, and solid patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Serous Adenocarcinofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9014/3"},{"name":"Legacy Concept Name","value":"Ovarian_Serous_Adenocarcinofibroma"},{"name":"Maps_To","value":"9014/3"},{"name":"Maps_To","value":"Serous adenocarcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266153"}]}}{"C8979":{"preferredName":"Mucinous Cystadenofibroma","code":"C8979","definitions":[{"definition":"A benign neoplasm characterized by the presence of cystic structures lined by mucinous columnar epithelial cells in a fibrotic stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Cystadenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucinous_Cystadenofibroma"},{"name":"Maps_To","value":"9015/0"},{"name":"Maps_To","value":"Mucinous cystadenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377844"}]}}{"C8978":{"preferredName":"Mucinous Adenofibroma","code":"C8978","definitions":[{"definition":"A benign or borderline adenofibroma characterized by the presence of epithelial cells which contain intracytoplasmic mucin and a fibrotic stroma. A representative example is the ovarian mucinous adenofibroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Adenofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9015/0"},{"name":"Legacy Concept Name","value":"Mucinous_Adenofibroma"},{"name":"Maps_To","value":"9015/0"},{"name":"Maps_To","value":"Mucinous adenofibroma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334499"}]}}{"C66775":{"preferredName":"Borderline Ovarian Mucinous Adenofibroma","code":"C66775","definitions":[{"definition":"A low malignant potential adenofibroma of the ovary It is characterized by an atypical epithelial hyperplasia. The epithelial cells contain intracytoplasmic mucin. There is no evidence of stromal destructive invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Ovarian Mucinous Adenofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Mucinous Adenofibroma of Borderline Malignancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9015/1"},{"name":"Legacy Concept Name","value":"Mucinous_Adenofibroma_of_Borderline_Malignancy"},{"name":"Maps_To","value":"9015/1"},{"name":"Maps_To","value":"Mucinous adenofibroma of borderline malignancy"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266154"}]}}{"C40034":{"preferredName":"Ovarian Mucinous Adenocarcinofibroma","code":"C40034","definitions":[{"definition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells with intracytoplasmic mucin. Cystic spaces are also present which contain mucoid material.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Mucinous Adenocarcinofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Mucinous Malignant Adenofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9015/3"},{"name":"Legacy Concept Name","value":"Ovarian_Mucinous_Adenocarcinofibroma"},{"name":"Maps_To","value":"9015/3"},{"name":"Maps_To","value":"Mucinous adenocarcinofibroma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266155"}]}}{"C4273":{"preferredName":"Breast Giant Fibroadenoma","code":"C4273","definitions":[{"definition":"A breast fibroadenoma characterized by a very large size. This term has also been used as a synonym for juvenile fibroadenoma by some authors. The latter is characterized by epithelial hyperplasia and an increased stromal cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Giant Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Giant Breast Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9016/0"},{"name":"Legacy Concept Name","value":"Giant_Fibroadenoma"},{"name":"Maps_To","value":"9016/0"},{"name":"Maps_To","value":"Giant fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334500"}]}}{"C4274":{"preferredName":"Benign Phyllodes Tumor","code":"C4274","definitions":[{"definition":"A benign, circumscribed fibroepithelial neoplasm arising from the breast and rarely the prostate gland. It is characterized by the presence of epithelial structures which are arranged in clefts and by a hypercellular mesenchymal stroma which is organized in leaf-like structures. There is no evidence of cellular atypia or sarcomatous features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cystosarcoma Phyllodes","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9020/0"},{"name":"Legacy Concept Name","value":"Benign_Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/0"},{"name":"Maps_To","value":"Cystosarcoma phyllodes, benign"},{"name":"Maps_To","value":"Phyllodes tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334501"}]}}{"C2977":{"preferredName":"Phyllodes Tumor","code":"C2977","definitions":[{"definition":"A benign, borderline, or malignant fibroepithelial neoplasm arising from the breast and rarely the prostate gland.  It may recur following resection.  The recurrence rates are higher for borderline and malignant phyllodes tumors.  In borderline and malignant phyllodes tumors metastases to distant anatomic sites can occur.  The incidence of metastases is higher in malignant phyllodes tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A type of tumor found in breast or prostate tissue. It is often large and bulky and grows quickly. It may be benign (not cancer) or malignant (cancer) and may spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Cystosarcoma Phyllodes","termGroup":"SY","termSource":"NCI"},{"termName":"Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/1"},{"name":"Maps_To","value":"Cystosarcoma phyllodes, NOS"},{"name":"Maps_To","value":"Phyllodes tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010701"}]}}{"C7503":{"preferredName":"Borderline Phyllodes Tumor","code":"C7503","definitions":[{"definition":"A phyllodes tumor with morphologic characteristics which are intermediate between a benign and a malignant phyllodes tumor. The stromal sarcomatous changes are of low grade and are often reminiscent of low grade fibrosarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Borderline Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9020/1"},{"name":"Legacy Concept Name","value":"Borderline_Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/1"},{"name":"Maps_To","value":"Phyllodes tumor, borderline"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370913"}]}}{"C4275":{"preferredName":"Malignant Phyllodes Tumor","code":"C4275","definitions":[{"definition":"A phyllodes tumor with sarcomatous stroma. The sarcomatous component is usually of the fibrosarcomatous type. Liposarcomatous, chondrosarcomatous, osteosarcomatous, or rhabdomyosarcomatous differentiation may also occur in the stroma. It may recur and metastasize following surgical resection. The lung and skeleton are the anatomic sites most frequently involved by metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Phyllodes Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Cystosarcoma Phyllodes","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Phyllodes Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9020/3"},{"name":"Legacy Concept Name","value":"Malignant_Phyllodes_Tumor"},{"name":"Maps_To","value":"9020/3"},{"name":"Maps_To","value":"Cystosarcoma phyllodes, malignant"},{"name":"Maps_To","value":"Phyllodes tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0600066"}]}}{"C4276":{"preferredName":"Juvenile Breast Fibroadenoma","code":"C4276","definitions":[{"definition":"A breast fibroadenoma that usually occurs in young women. It is characterized by epithelial hyperplasia and an increased stromal cellularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Juvenile Breast Fibroadenoma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Juvenile Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Fibroadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Fibroadenoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Fibroadenoma of the Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9030/0"},{"name":"Legacy Concept Name","value":"Juvenile_Fibroadenoma"},{"name":"Maps_To","value":"9030/0"},{"name":"Maps_To","value":"Juvenile fibroadenoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346158"}]}}{"C3829":{"preferredName":"Benign Synovial Neoplasm","code":"C3829","definitions":[{"definition":"A benign neoplasm arising from the synovial membrane.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neoplasm arising from the synovial membrane.  Examples include the diffuse giant cell tumor of tendon sheath and localized giant cell tumor of tendon sheath.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Synovial Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neoplasm of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Neoplasm of the Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Synovial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Synovioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Tumor of the Synovium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9040/0"},{"name":"Legacy Concept Name","value":"Benign_Synovial_Neoplasm"},{"name":"Maps_To","value":"9040/0"},{"name":"Maps_To","value":"Synovioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221289"}]}}{"C3400":{"preferredName":"Synovial Sarcoma","code":"C3400","definitions":[{"definition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm that usually arises in the synovial membranes of the joints and the synovial cells of the tendons and bursae.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that develops in the synovial membrane of the joints.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"SS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9040/3"},{"name":"Legacy Concept Name","value":"Synovial_Sarcoma"},{"name":"Maps_To","value":"9040/3"},{"name":"Maps_To","value":"Synovial sarcoma, NOS"},{"name":"Maps_To","value":"Synovioma, malignant"},{"name":"Maps_To","value":"Synovioma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0039101"}]}}{"C4277":{"preferredName":"Spindle Cell Synovial Sarcoma","code":"C4277","definitions":[{"definition":"A synovial sarcoma characterized by the presence of a spindle cell component only.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Synovial Sarcoma with Spindle Cell Components","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9041/3"},{"name":"Legacy Concept Name","value":"Synovial_Sarcoma_with_Spindle_Cell_Components"},{"name":"Maps_To","value":"9041/3"},{"name":"Maps_To","value":"Synovial sarcoma, monophasic fibrous"},{"name":"Maps_To","value":"Synovial sarcoma, spindle cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334505"}]}}{"C4278":{"preferredName":"Epithelial Synovial Sarcoma","code":"C4278","definitions":[{"definition":"A synovial sarcoma characterized by the presence of an epithelial cell component only. The epithelial cells are arranged in glandular or papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelial Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Sarcoma of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Sarcoma of the Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Cell Sarcoma of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Cell Sarcoma of the Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Cell Synovial Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Synovial Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9042/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Synovial_Sarcoma"},{"name":"Maps_To","value":"9042/3"},{"name":"Maps_To","value":"Synovial sarcoma, epithelioid cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334506"}]}}{"C4279":{"preferredName":"Biphasic Synovial Sarcoma","code":"C4279","definitions":[{"definition":"A synovial sarcoma characterized by the presence of both an epithelial and a spindle cell component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biphasic Synovial Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Biphasic Sarcoma of Synovium","termGroup":"SY","termSource":"NCI"},{"termName":"Biphasic Sarcoma of the Synovium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9043/3"},{"name":"Legacy Concept Name","value":"Biphasic_Synovial_Sarcoma"},{"name":"Maps_To","value":"9043/3"},{"name":"Maps_To","value":"Synovial sarcoma, biphasic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334507"}]}}{"C3745":{"preferredName":"Clear Cell Sarcoma of Soft Tissue","code":"C3745","definitions":[{"definition":"A rare malignant neoplasm with melanocytic differentiation characterized by the presence of polygonal or spindle shaped clear cells. This sarcoma usually affects the tendons and aponeuroses and is associated with a poor prognosis due to recurrences and metastases.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that begins in a tendon (tough, fibrous, cord-like tissue that connects muscle to bone or to another structure). Clear cell sarcoma of soft tissue has certain markers that are also found on malignant melanoma (a type of skin cancer). It usually occurs in the leg or arm.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clear Cell Sarcoma of Soft Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Sarcoma of Soft Parts","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Sarcoma of Tendons and Aponeuroses","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma of Soft Parts","termGroup":"AQS","termSource":"NCI"},{"termName":"Melanoma of the Soft Parts","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9044/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Sarcoma_of_Soft_Parts"},{"name":"Maps_To","value":"9044/3"},{"name":"Maps_To","value":"Clear cell sarcoma, NOS"},{"name":"Maps_To","value":"Melanoma, malignant, of soft parts"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206651"}]}}{"C164205":{"preferredName":"Biphenotypic Sinonasal Sarcoma","code":"C164205","definitions":[{"definition":"A rare, slow-growing, low-grade soft tissue sarcoma arising from the sinonasal tract. It presents with non-specific obstructive nasal symptoms. Morphologically, it is an infiltrative, cellular spindle cell neoplasm. It is associated with rearrangement of the PAX3 gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biphenotypic Sinonasal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"BSNS","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Sinonasal Biphenotypic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9045/3"},{"name":"Maps_To","value":"Biphenotypic sinonasal sarcoma"},{"name":"NCI_META_CUI","value":"CL977505"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3762":{"preferredName":"Adenomatoid Tumor","code":"C3762","definitions":[{"definition":"A benign neoplasm arising from mesothelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well-circumscribed neoplasm arising from mesothelial cells. It is characterized by the formation of glandular and tubular patterns. It usually involves the paratesticular region, uterus, and fallopian tube. Rare cases involving the pleura, peritoneum, adrenal gland, and liver have also been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenomatoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Mesothelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9050/0"},{"name":"ICD-O-3_Code","value":"9052/0"},{"name":"ICD-O-3_Code","value":"9054/0"},{"name":"Legacy Concept Name","value":"Adenomatoid_Tumor"},{"name":"Maps_To","value":"9054/0"},{"name":"Maps_To","value":"Adenomatoid tumor, NOS"},{"name":"Maps_To","value":"Epithelioid mesothelioma, benign"},{"name":"Maps_To","value":"Mesothelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206675"}]}}{"C4456":{"preferredName":"Malignant Mesothelioma","code":"C4456","definitions":[{"definition":"A malignant neoplasm originating from mesothelial cells of the pleura or peritoneum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm that arises from mesothelial cells, usually in the pleura or peritoneum. It is associated with exposure to asbestos.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of cancer in which malignant cells are found in the sac lining the chest or abdomen. Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mesothelial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Mesothelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9050/3"},{"name":"Legacy Concept Name","value":"Malignant_Mesothelioma"},{"name":"Maps_To","value":"9050/3"},{"name":"Maps_To","value":"Mesothelioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0345967"}]}}{"C4457":{"preferredName":"Pleural Solitary Fibrous Tumor","code":"C4457","definitions":[{"definition":"A localized neoplasm of probable fibroblastic derivation, that arises from the pleura. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleural Solitary Fibrous Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroma of Pleura","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroma of the Pleura","termGroup":"SY","termSource":"NCI"},{"termName":"Localized Fibrous Mesothelioma of Pleura","termGroup":"AQS","termSource":"NCI"},{"termName":"Localized Fibrous Mesothelioma of the Pleura","termGroup":"AQS","termSource":"NCI"},{"termName":"Pleural Fibroma","termGroup":"SY","termSource":"NCI"},{"termName":"Pleural Submesothelial Fibroma","termGroup":"AQS","termSource":"NCI"},{"termName":"Solitary Fibrous Tumor of Pleura","termGroup":"SY","termSource":"NCI"},{"termName":"Solitary Fibrous Tumor of the Pleura","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleural_Fibroma"},{"name":"Maps_To","value":"9051/0"},{"name":"Maps_To","value":"Fibrous mesothelioma, benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334511"}]}}{"C6747":{"preferredName":"Desmoplastic Mesothelioma","code":"C6747","definitions":[{"definition":"A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of a dense collagenous tissue and atypical neoplastic cells. Sarcomatoid features, collagenous necrosis, and infiltration of muscle and adipose tissue may be present. It occurs in the pleura and less commonly in the peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Mesothelioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9051/3"},{"name":"Legacy Concept Name","value":"Malignant_Fibrous_Mesothelioma"},{"name":"Maps_To","value":"9051/3"},{"name":"Maps_To","value":"Desmoplastic mesothelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1270206"}]}}{"C45655":{"preferredName":"Sarcomatoid Mesothelioma","code":"C45655","definitions":[{"definition":"A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of spindle cells. Anaplastic morphologic features and multinucleated malignant cells may also be seen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sarcomatoid Mesothelioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sarcomatoid_Mesothelioma"},{"name":"Maps_To","value":"9051/3"},{"name":"Maps_To","value":"Fibrous mesothelioma, malignant"},{"name":"Maps_To","value":"Fibrous mesothelioma, NOS"},{"name":"Maps_To","value":"Sarcomatoid mesothelioma"},{"name":"Maps_To","value":"Spindled mesothelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334513"}]}}{"C7985":{"preferredName":"Epithelioid Mesothelioma","code":"C7985","definitions":[{"definition":"A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of cells with epithelioid morphology. The epithelioid cells usually have eosinophilic cytoplasm, bland nuclei, and form tubulopapillary, microglandular, or sheet-like patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelial Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9052/3"},{"name":"Legacy Concept Name","value":"Epithelial_Mesothelioma"},{"name":"Maps_To","value":"9052/3"},{"name":"Maps_To","value":"Epithelioid mesothelioma, malignant"},{"name":"Maps_To","value":"Epithelioid mesothelioma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862312"}]}}{"C4282":{"preferredName":"Biphasic Mesothelioma","code":"C4282","definitions":[{"definition":"A malignant mesothelioma characterized by the presence of epithelioid and sarcomatoid components, with each component representing at least 10% of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biphasic Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Biphasic Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9053/3"},{"name":"Legacy Concept Name","value":"Mixed_Mesothelioma"},{"name":"Maps_To","value":"9053/3"},{"name":"Maps_To","value":"Mesothelioma, biphasic, malignant"},{"name":"Maps_To","value":"Mesothelioma, biphasic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334515"}]}}{"C6536":{"preferredName":"Peritoneal Multicystic Mesothelioma","code":"C6536","definitions":[{"definition":"A mesothelial neoplasm that arises from the peritoneum and usually affects young to middle aged females. Grossly, it presents as a large multiloculated tumor mass, usually in the pelvic peritoneum. Histologically it is characterized by the presence of multiple cysts that are lined by one or more layers of mesothelial cells that do not show atypia. Patients usually present with abdominal or pelvic mass and pain. The clinical course is indolent. The tumor may reoccur, but transformation to malignant mesothelioma is rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneal Multicystic Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Multicystic Mesothelioma of Peritoneum","termGroup":"SY","termSource":"NCI"},{"termName":"Multicystic Mesothelioma of the Peritoneum","termGroup":"SY","termSource":"NCI"},{"termName":"Multilocular Peritoneal Inclusion Cyst","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Multicystic_Peritoneal_Mesothelioma"},{"name":"Maps_To","value":"9055/0"},{"name":"Maps_To","value":"Peritoneal inclusion cysts"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334818"}]}}{"C3765":{"preferredName":"Multicystic Mesothelioma","code":"C3765","definitions":[{"definition":"A mesothelial neoplasm that arises from the peritoneum and rarely the pleura. It is characterized by the presence of multiple cysts lined by flattened or cuboidal mesothelial cells. There is no evidence of significant cytologic atypia or increased mitotic activity. It may reoccur. Rare cases of transformation to malignant mesothelioma have been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multicystic Mesothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Cystic Mesothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Intermediate Mesothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9055/0"},{"name":"ICD-O-3_Code","value":"9055/1"},{"name":"Legacy Concept Name","value":"Cystic_Mesothelioma"},{"name":"Maps_To","value":"9055/0"},{"name":"Maps_To","value":"Cystic mesothelioma, NOS"},{"name":"Maps_To","value":"Multicystic mesothelioma, benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206680"}]}}{"C8106":{"preferredName":"Ovarian Dysgerminoma","code":"C8106","definitions":[{"definition":"A malignant germ cell neoplasm characterized by the presence of a monotonous primitive germ cell population, primarily in the ovary.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant germ cell tumor arising from the ovary.  Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei.  The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumor stage.","type":"DEFINITION","source":"NCI"},{"definition":"A seminomatous germ cell tumor originating in the ovary.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of tumor that begins in the type of cells that give rise to egg cells and is most often found in the ovaries. Dysgerminomas may also occur in other places in the body, including the central nervous system. They are the most common type of ovarian germ cell tumor and can spread to other parts of the body. They are most common in females who are younger than 20 years old.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ovarian Dysgerminoma","termGroup":"PT","termSource":"NCI"},{"termName":"Dysgerminoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Dysgerminoma of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Germ Cell Dysgerminoma of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Germ Cell Dysgerminoma of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Germ Cell Dysgerminoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9060/3"},{"name":"Legacy Concept Name","value":"Ovarian_Dysgerminoma"},{"name":"Maps_To","value":"9060/3"},{"name":"Maps_To","value":"Dysgerminoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346185"}]}}{"C9309":{"preferredName":"Seminoma","code":"C9309","definitions":[{"definition":"A germinomatous germ cell tumor originating in the testis.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant germ cell neoplasm of the testis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer of the testicles. Seminomas may spread to the lung, bone, liver, or brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Seminoma","termGroup":"PT","termSource":"NCI"},{"termName":"Seminoma, Pure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9061/3"},{"name":"Legacy Concept Name","value":"Seminoma"},{"name":"Maps_To","value":"9061/3"},{"name":"Maps_To","value":"Seminoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036631"}]}}{"C39920":{"preferredName":"Testicular Seminoma with High Mitotic Index","code":"C39920","definitions":[{"definition":"A seminoma of the testis characterized by increased cellular pleomorphism, high mitotic activity, and a non-prominent stromal lymphocytic infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Seminoma with High Mitotic Index","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Seminoma","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Seminoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9062/3"},{"name":"Legacy Concept Name","value":"Testicular_Seminoma_with_High_Mitotic_Index"},{"name":"Maps_To","value":"9062/3"},{"name":"Maps_To","value":"Seminoma with high mitotic index"},{"name":"Maps_To","value":"Seminoma, anaplastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334516"}]}}{"C39921":{"preferredName":"Testicular Spermatocytic Tumor","code":"C39921","definitions":[{"definition":"A testicular germ cell tumor derived from postpubertal-type germ cells. It is characterized by the presence of three cell types: round cells with eosinophilic cytoplasm, small cells with dark nucleus and a small amount of cytoplasm, and mono-or multinucleated giant cells. The neoplastic cells are not cohesive. There is an edematous stroma present; lymphocytic infiltrates are rarely seen. Most patients are older males.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Spermatocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Spermatocytic Seminoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Spermatocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Spermatocytic Seminoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9063/3"},{"name":"Legacy Concept Name","value":"Testicular_Spermatocytic_Seminoma"},{"name":"Maps_To","value":"9063/3"},{"name":"Maps_To","value":"Spermatocytic seminoma"},{"name":"Maps_To","value":"Spermatocytoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334517"}]}}{"C40345":{"preferredName":"Testicular Germ Cell Neoplasia In Situ","code":"C40345","definitions":[{"definition":"A non-invasive lesion of the testis, characterized by the presence of malignant large germ cells with abundant cytoplasm in the seminiferous tubules. It may be associated with undescended or atrophic testis and infertility. The vast majority of cases progress to invasive germ cell tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Germ Cell Neoplasia In Situ","termGroup":"PT","termSource":"NCI"},{"termName":"GCNIS","termGroup":"AB","termSource":"NCI"},{"termName":"Gonocytoma In Situ","termGroup":"SY","termSource":"NCI"},{"termName":"IGCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Testicular Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Intratubular Germ Cell Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Intratubular Germ Cell Neoplasia of the Unclassified Type","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Intratubular Germ Cell Neoplasia of Unclassified Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9064/2"},{"name":"Legacy Concept Name","value":"Testicular_Intratubular_Germ_Cell_Neoplasia_Unclassified"},{"name":"Maps_To","value":"9064/2"},{"name":"Maps_To","value":"Intratubular malignant germ cells"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1515286"}]}}{"C7009":{"preferredName":"Central Nervous System Germinoma","code":"C7009","definitions":[{"definition":"A germinomatous germ cell tumor arising in the central nervous system; it is histologically identical to the dysgerminoma and seminoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant germ cell tumor arising from the central nervous system.  It is composed of uniform cells resembling primitive germ cells.  These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm.  Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells.  (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Germinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Germinoma of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Germinoma of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Germinoma of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Germinoma of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9064/3"},{"name":"Legacy Concept Name","value":"Germinoma_of_the_Central_Nervous_System"},{"name":"Maps_To","value":"9064/3"},{"name":"Maps_To","value":"Germinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333813"}]}}{"C121619":{"preferredName":"Nongerminomatous Germ Cell Tumor","code":"C121619","definitions":[{"definition":"A germ cell tumor other than a pure germinoma. These tumors (choriocarcinoma, embryonal carcinoma, teratoma, yolk sac tumor, and mixed germ cell tumor) are histologically distinct from one another.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A term that refers to teratoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, or mixed forms of these tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nongerminomatous Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Nongerminomatous Germ Cell Tumor Including Central Nervous System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"9065/3"},{"name":"Maps_To","value":"Germ cell tumor, nonseminomatous"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266158"}]}}{"C3752":{"preferredName":"Embryonal Carcinoma","code":"C3752","definitions":[{"definition":"A non-seminomatous malignant germ cell neoplasm of the testis or ovary.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonal Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9070/3"},{"name":"Legacy Concept Name","value":"Embryonal_Carcinoma"},{"name":"Maps_To","value":"9070/3"},{"name":"Maps_To","value":"Embryonal adenocarcinoma"},{"name":"Maps_To","value":"Embryonal carcinoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206659"}]}}{"C3011":{"preferredName":"Yolk Sac Tumor","code":"C3011","definitions":[{"definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells and which produce an eosinophilic substance (alpha-fetoprotein).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yolk Sac Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Endodermal Sinus Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Endodermal Sinus Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Yolk Sac Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Yolk Sac Tumour Site Unspecified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9071/3"},{"name":"Legacy Concept Name","value":"Yolk_Sac_Tumor"},{"name":"Maps_To","value":"9071/3"},{"name":"Maps_To","value":"Embryonal carcinoma, infantile"},{"name":"Maps_To","value":"Endodermal sinus tumor"},{"name":"Maps_To","value":"Hepatoid yolk sac tumor"},{"name":"Maps_To","value":"Orchioblastoma"},{"name":"Maps_To","value":"Polyvesicular vitelline tumor"},{"name":"Maps_To","value":"Yolk sac tumor"},{"name":"Maps_To","value":"Yolk sac tumor, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4228805"}]}}{"C66776":{"preferredName":"Gonadal Polyembryoma","code":"C66776","definitions":[{"definition":"A rare malignant germ cell tumor arising from the testis and less often from the ovary. It is characterized by the presence of embryoid bodies which resemble early embryos.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadal Polyembryoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9072/3"},{"name":"Legacy Concept Name","value":"Gonadal_Polyembryoma"},{"name":"Maps_To","value":"9072/3"},{"name":"Maps_To","value":"Polyembryoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1880996"}]}}{"C3754":{"preferredName":"Gonadoblastoma","code":"C3754","definitions":[{"definition":"A mixed germ cell/sex cord-stromal tumor characterized by the presence of large germ cells that resemble seminoma cells and small cells that resemble Sertoli or granulosa cells. It occurs in the testis and the ovary, and is identified in children and adults. It is often associated with gonadal dysgenesis and abnormal karyotype.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A mixed germ cell/sex cord-stromal tumor characterized by the presence of large germ cells which resemble seminoma cells and small cells which resemble Sertoli or granulosa cells. It occurs in the testis and the ovary and is identified in children and adults. It is often associated with gonadal dysgenesis and abnormal karyotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9073/1"},{"name":"Legacy Concept Name","value":"Gonadoblastoma"},{"name":"Maps_To","value":"9073/1"},{"name":"Maps_To","value":"Gonadoblastoma"},{"name":"Maps_To","value":"Gonocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206661"}]}}{"C9012":{"preferredName":"Adult Cystic Teratoma","code":"C9012","synonyms":[{"termName":"Adult Cystic Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Cystic_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Adult cystic teratoma"},{"name":"NCI_META_CUI","value":"CL033098"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9013":{"preferredName":"Adult Teratoma","code":"C9013","synonyms":[{"termName":"Adult Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Adult teratoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368888"}]}}{"C9014":{"preferredName":"Cystic Teratoma","code":"C9014","synonyms":[{"termName":"Cystic Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystic_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Cystic teratoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368903"}]}}{"C67107":{"preferredName":"Benign Teratoma","code":"C67107","definitions":[{"definition":"A teratoma that contains only mature tissue elements (mature teratoma or grade 0 teratoma) or a limited amount of immature tissue elements (grade 1 teratoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Teratoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879828"}]}}{"C9015":{"preferredName":"Mature Teratoma","code":"C9015","definitions":[{"definition":"A teratoma which may be cystic; it is composed entirely of well differentiated, adult-type mature tissues, without evidence of fetal-type immature tissues (grade 0 teratoma).","type":"DEFINITION","source":"NCI"},{"definition":"A type of benign (not cancer) germ cell tumor (type of tumor that begins in the cells that give rise to sperm or eggs) that often contains several different types of tissue such as hair, muscle, and bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mature Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 0 Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9080/0"},{"name":"Legacy Concept Name","value":"Mature_Teratoma"},{"name":"Maps_To","value":"9080/0"},{"name":"Maps_To","value":"Mature teratoma"},{"name":"Maps_To","value":"Teratoma, benign"},{"name":"Maps_To","value":"Teratoma, differentiated"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368910"}]}}{"C3403":{"preferredName":"Teratoma","code":"C3403","definitions":[{"definition":"A non-germinomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as mature or immature. Mature teratomas are composed of well differentiated, adult-type tissues. Immature teratomas are composed of immature, fetal-type tissues.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as benign (grade 0 or 1), immature (grade 2), and malignant (grade 3). Grade 0 teratomas contain only mature elements; grade 1 teratomas have a limited degree of immaturity; grade 2 teratomas have a more extensive degree of immaturity; grade 3 teratomas are composed exclusively of immature tissues. The prognosis depends on patient age, tumor size and grade, and stage.","type":"DEFINITION","source":"NCI"},{"definition":"A type of germ cell tumor that may contain several different types of tissue, such as hair, muscle, and bone.  Teratomas occur most often in the ovaries in women, the testicles in men, and the tailbone in children.  Not all teratomas are malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Teratoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9080/1"},{"name":"Legacy Concept Name","value":"Teratoma"},{"name":"Maps_To","value":"9080/1"},{"name":"Maps_To","value":"Solid teratoma"},{"name":"Maps_To","value":"Teratoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0039538"}]}}{"C4287":{"preferredName":"Malignant Teratoma","code":"C4287","definitions":[{"definition":"A malignant germ-cell neoplasm derived from pluripotent cells and consisting of components from one or more of the three germ-cell layers.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A teratoma composed exclusively of immature tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 3 Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9082/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Immature_Teratoma"},{"name":"Maps_To","value":"9080/3"},{"name":"Maps_To","value":"9082/3"},{"name":"Maps_To","value":"Malignant teratoma, anaplastic"},{"name":"Maps_To","value":"Malignant teratoma, undifferentiated"},{"name":"Maps_To","value":"Teratoma, malignant, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334521"}]}}{"C3756":{"preferredName":"Mixed Embryonal Carcinoma and Teratoma","code":"C3756","definitions":[{"definition":"A germ cell tumor characterized by the presence of an embryonal carcinoma component and a teratoma component.","type":"DEFINITION","source":"NCI"},{"definition":"A type of germ cell cancer that usually forms in the testes (testicles).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mixed Embryonal Carcinoma and Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Teratocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9081/3"},{"name":"Legacy Concept Name","value":"Mixed_Embryonal_Carcinoma_and_Teratoma"},{"name":"Maps_To","value":"9081/3"},{"name":"Maps_To","value":"Mixed embryonal carcinoma and teratoma"},{"name":"Maps_To","value":"Teratocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206664"}]}}{"C4288":{"preferredName":"Intermediate Immature Teratoma","code":"C4288","definitions":[{"definition":"An immature teratoma characterized by the presence of an intermediate amount of undifferentiated tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermediate Immature Teratoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Intermediate Malignant Teratoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9083/3"},{"name":"Legacy Concept Name","value":"Intermediate_Immature_Teratoma"},{"name":"Maps_To","value":"9083/3"},{"name":"Maps_To","value":"Malignant teratoma, intermediate"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334522"}]}}{"C9011":{"preferredName":"Dermoid Cyst","code":"C9011","definitions":[{"definition":"A benign hamartomatous tumor that possesses various epidermal derivatives and is due to sequestration of skin along the lines of embryonic closure. In neonates, it is most commonly congenital and located in the subcutaneous tissues of the head, neck, or trunk.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A benign neoplasm comprised of a cyst, lined by mature epidermis-like tissue with dermal appendages.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A mature teratoma characterized by the presence of a cyst which is lined by mature tissue resembling the epidermis and the epidermal appendages. It occurs in the ovary, testis, and extragonadal sites including central nervous system and skin.","type":"DEFINITION","source":"NCI"},{"definition":"A type of benign (not cancer) germ cell tumor (type of tumor that begins in the cells that give rise to sperm or eggs) that often contains several different types of tissue such as hair, muscle, and bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dermoid Cyst","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cystic Teratoma","termGroup":"SY","termSource":"NCI"},{"termName":"Dermoid","termGroup":"SY","termSource":"NCI"},{"termName":"Dermoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mature Cystic Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9084/0"},{"name":"Legacy Concept Name","value":"Dermoid_Cyst"},{"name":"Maps_To","value":"9084/0"},{"name":"Maps_To","value":"Dermoid cyst, NOS"},{"name":"Maps_To","value":"Dermoid, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0011649"}]}}{"C4289":{"preferredName":"Teratoma with Somatic-Type Malignancy","code":"C4289","definitions":[{"definition":"A teratoma which is characterized by morphologic transformation to malignancy and an aggressive clinical course. The malignant component most often is sarcomatous or carcinomatous.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teratoma with Somatic-Type Malignancy","termGroup":"PT","termSource":"NCI"},{"termName":"Dermoid Cyst with Malignant Transformation","termGroup":"SY","termSource":"NCI"},{"termName":"Teratoma with Malignant Transformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9084/3"},{"name":"Legacy Concept Name","value":"Teratoma_with_Malignant_Transformation"},{"name":"Maps_To","value":"9084/3"},{"name":"Maps_To","value":"Dermoid cyst with malignant transformation"},{"name":"Maps_To","value":"Dermoid cyst with secondary tumor"},{"name":"Maps_To","value":"Teratoma with malignant transformation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334523"}]}}{"C9010":{"preferredName":"Mixed Teratoma and Seminoma","code":"C9010","synonyms":[{"termName":"Mixed Teratoma and Seminoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Teratoma_and_Seminoma"},{"name":"Maps_To","value":"9085/3"},{"name":"Maps_To","value":"Mixed teratoma and seminoma"},{"name":"NCI_META_CUI","value":"CL033096"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4290":{"preferredName":"Mixed Germ Cell Tumor","code":"C4290","definitions":[{"definition":"A malignant germ cell tumor characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Germ Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9085/3"},{"name":"Legacy Concept Name","value":"Mixed_Germ_Cell_Neoplasm"},{"name":"Maps_To","value":"9085/3"},{"name":"Maps_To","value":"Mixed germ cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334524"}]}}{"C45733":{"preferredName":"Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy","code":"C45733","definitions":[{"definition":"An extragonadal non-seminomatous malignant germ cell tumor that arises from the mediastinum and is associated with a hematologic malignancy.  The hematologic malignancies are clonally related to the malignant germ cell tumor and include acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, and mastocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy","termGroup":"PT","termSource":"NCI"},{"termName":"Germ Cell Tumor with Associated Hematological Malignancy","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mediastinal Germ Cell Tumor with Associated Hematological Malignancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mediastinal_Malignant_Germ_Cell_Tumor_with_Associated_Hematologic_Malignancy"},{"name":"Maps_To","value":"Germ cell tumor with associated hematological malignancy"},{"name":"Maps_To","value":"Germ cell tumors with associated hematological malignancy"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708955"}]}}{"C7468":{"preferredName":"Struma Ovarii","code":"C7468","definitions":[{"definition":"An ovarian mature teratoma characterized by the presence of aberrant thyroid tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Struma Ovarii","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9090/0"},{"name":"Legacy Concept Name","value":"Struma_Ovarii"},{"name":"Maps_To","value":"9090/0"},{"name":"Maps_To","value":"Struma ovarii, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0038478"}]}}{"C4291":{"preferredName":"Thyroid Carcinoma Arising in Struma Ovarii","code":"C4291","definitions":[{"definition":"A carcinoma with histological features identical to thyroid carcinoma, arising in ovarian mature teratoma with aberrant thyroid tissue (struma ovarii).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Carcinoma Arising in Struma Ovarii","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Struma Ovarii","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9090/3"},{"name":"Legacy Concept Name","value":"Malignant_Struma_Ovarii"},{"name":"Maps_To","value":"9090/3"},{"name":"Maps_To","value":"Struma ovarii, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334525"}]}}{"C4292":{"preferredName":"Strumal Carcinoid","code":"C4292","definitions":[{"definition":"An ovarian neoplasm characterized by the presence of aberrant thyroid tissue and a carcinoid tumor. A minority of patients develop symptoms of functioning thyroid tissue. The neuroendocrine carcinoid cells infiltrate the aberrant thyroid tissue and progressively replace the follicular lining cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Strumal Carcinoid","termGroup":"PT","termSource":"NCI"},{"termName":"Struma Ovarii and Carcinoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9091/1"},{"name":"Legacy Concept Name","value":"Strumal_Carcinoid_Neoplasm"},{"name":"Maps_To","value":"9091/1"},{"name":"Maps_To","value":"Struma ovarii and carcinoid"},{"name":"Maps_To","value":"Strumal carcinoid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334526"}]}}{"C3110":{"preferredName":"Hydatidiform Mole","code":"C3110","definitions":[{"definition":"A gestational trophoblastic disorder characterized by marked enlargement of the chorionic villi, hyperplasia of the villous trophoblastic cells and hydropic changes.","type":"DEFINITION","source":"NCI"},{"definition":"A placental disorder characterized by abnormal development with marked enlargement of the chorionic villi and hydropic changes which consist of hyperplasia of the villous trophoblastic cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A slow-growing tumor that develops from trophoblastic cells (cells that help an embryo attach to the uterus and help form the placenta) after fertilization of an egg by a sperm. A hydatidiform mole contains many cysts (sacs of fluid). It is usually benign (not cancer) but it may spread to nearby tissues (invasive mole). It may also become a malignant tumor called choriocarcinoma. Hydatidiform mole is the most common type of gestational trophoblastic tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Molar Pregnancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9100/0"},{"name":"Legacy Concept Name","value":"Hydatidiform_Mole"},{"name":"Maps_To","value":"9100/0"},{"name":"Maps_To","value":"Hydatid mole"},{"name":"Maps_To","value":"Hydatidiform mole, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0020217"}]}}{"C4871":{"preferredName":"Complete Hydatidiform Mole","code":"C4871","definitions":[{"definition":"A gestational trophoblastic disorder in which there is no embryo or normal placental tissue and the chorionic villi are hydropic.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A placental disorder where the majority of the chorionic villi are hydropic.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Complete Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Complete Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Complete Molar Pregnancy","termGroup":"SY","termSource":"NCI"},{"termName":"Complete Mole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Complete_Hydatidiform_Mole"},{"name":"Maps_To","value":"9100/0"},{"name":"Maps_To","value":"Complete hydatidiform mole"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0678213"}]}}{"C6985":{"preferredName":"Invasive Hydatidiform Mole","code":"C6985","definitions":[{"definition":"A complete hydatidiform mole or very rarely a partial mole that invades the myometrium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A complete hydatidiform mole or very rarely a partial mole that invades the myometrium.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of cancer that grows into the muscular wall of the uterus. It is formed after conception (fertilization of an egg by a sperm). It may spread to other parts of the body, such as the vagina, vulva, and lung.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Invasive Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Chorioadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Chorioadenoma Destruens","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Gestational Trophoblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Mole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9100/1"},{"name":"Legacy Concept Name","value":"Invasive_Hydatidiform_Mole"},{"name":"Maps_To","value":"9100/1"},{"name":"Maps_To","value":"Chorioadenoma"},{"name":"Maps_To","value":"Chorioadenoma destruens"},{"name":"Maps_To","value":"Invasive hydatidiform mole"},{"name":"Maps_To","value":"Invasive mole, NOS"},{"name":"Maps_To","value":"Malignant hydatidiform mole"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008493"}]}}{"C2948":{"preferredName":"Choriocarcinoma","code":"C2948","definitions":[{"definition":"A malignant neoplasm arising from placental trophoblast cells. They generally arise in the uterus.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant, fast-growing tumor that develops from trophoblastic cells (cells that help an embryo attach to the uterus and help form the placenta). Almost all choriocarcinomas form in the uterus after fertilization of an egg by a sperm, but a small number form in a testis or an ovary. Choriocarcinomas spread through the blood to other organs, especially the lungs. They are a type of gestational trophoblastic disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choriocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chorioepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9100/3"},{"name":"Legacy Concept Name","value":"Choriocarcinoma"},{"name":"Maps_To","value":"9100/3"},{"name":"Maps_To","value":"Choriocarcinoma, NOS"},{"name":"Maps_To","value":"Chorioepithelioma"},{"name":"Maps_To","value":"Chorionepithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008497"}]}}{"C66777":{"preferredName":"Choriocarcinoma Combined with Other Germ Cell Elements","code":"C66777","definitions":[{"definition":"A malignant mixed germ cell tumor characterized by the presence of a choriocarcinomatous component admixed with another germ cell component (e.g. embryonal carcinoma, teratoma, or seminoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choriocarcinoma Combined with Other Germ Cell Elements","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9101/3"},{"name":"Legacy Concept Name","value":"Choriocarcinoma_Combined_with_Other_Germ_Cell_Elements"},{"name":"Maps_To","value":"9101/3"},{"name":"Maps_To","value":"Choriocarcinoma combined with embryonal carcinoma"},{"name":"Maps_To","value":"Choriocarcinoma combined with other germ cell elements"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334527"}]}}{"C66778":{"preferredName":"Malignant Trophoblastic Teratoma","code":"C66778","definitions":[{"definition":"A malignant germ cell tumor which metastasizes widely and produces high levels of human chorionic gonadotropin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Trophoblastic Teratoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9102/3"},{"name":"Legacy Concept Name","value":"Malignant_Trophoblastic_Teratoma"},{"name":"Maps_To","value":"9102/3"},{"name":"Maps_To","value":"Malignant teratoma, trophoblastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334528"}]}}{"C4293":{"preferredName":"Partial Hydatidiform Mole","code":"C4293","definitions":[{"definition":"A gestational trophoblastic disorder characterized by the presence of an abnormal fetus and two populations of chorionic villi: one population which is unremarkable and a second one which shows hydropic changes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A placental disorder characterized by the presence of two populations of chorionic villi: one population which is of unremarkable development and a second one which shows hydropic changes.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Partial Hydatidiform Mole","termGroup":"PT","termSource":"NCI"},{"termName":"Incomplete Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Incomplete Hydatidiform Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Incomplete Molar Pregnancy","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Hydatid Mole","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Molar Pregnancy","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Mole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9103/0"},{"name":"Legacy Concept Name","value":"Partial_Hydatidiform_Mole"},{"name":"Maps_To","value":"9103/0"},{"name":"Maps_To","value":"Partial hydatidiform mole"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334529"}]}}{"C3757":{"preferredName":"Placental Site Trophoblastic Tumor","code":"C3757","definitions":[{"definition":"A rare gestational trophoblastic tumor characterized by the presence of a diffuse cellular infiltrate composed of intermediate trophoblasts and cytotrophoblasts and by the absense of a significant population of syncytiotrophoblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Placental Site Trophoblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Placental Site Gestational Trophoblastic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Placental-Site Gestational Trophoblastic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Placental-Site Gestational Trophoblastic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Placental-Site GTT","termGroup":"SY","termSource":"NCI"},{"termName":"PSTT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9104/1"},{"name":"Legacy Concept Name","value":"Placental-Site_Gestational_Trophoblastic_Tumor"},{"name":"Maps_To","value":"9104/1"},{"name":"Maps_To","value":"Placental site trophoblastic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206666"}]}}{"C4072":{"preferredName":"Mesonephric Adenocarcinoma","code":"C4072","definitions":[{"definition":"An adenocarcinoma of the cervix or the vagina that derives from Wolffian duct remnants and shows mesonephric differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesonephric Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mesonephroma","termGroup":"SY","termSource":"NCI"},{"termName":"Mesonephric Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"MNAC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9110/3"},{"name":"Legacy Concept Name","value":"Mesonephric_Adenocarcinoma"},{"name":"Maps_To","value":"9110/3"},{"name":"Maps_To","value":"Mesonephric adenocarcinoma"},{"name":"Maps_To","value":"Mesonephroma, malignant"},{"name":"Maps_To","value":"Wolffian duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025490"}]}}{"C3085":{"preferredName":"Hemangioma","code":"C3085","definitions":[{"definition":"A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.","type":"DEFINITION","source":"NCI"},{"definition":"A benign vascular neoplasm characterized by the formation of capillary-sized or cavernous vascular channels.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, vascular neoplasm characterized by the formation of capillary-sized vascular channels.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Hemangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9120/0"},{"name":"Legacy Concept Name","value":"Hemangioma"},{"name":"Maps_To","value":"9120/0"},{"name":"Maps_To","value":"Angioma, NOS"},{"name":"Maps_To","value":"Hemangioma"},{"name":"Maps_To","value":"Hemangioma unspecified site"},{"name":"Maps_To","value":"Hemangioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018916"}]}}{"C3088":{"preferredName":"Angiosarcoma","code":"C3088","definitions":[{"definition":"A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant vascular neoplasm arising from endothelial cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that begins in the cells that line blood vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Angiosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hemangiosarcoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Angioendothelioma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Hemangioendothelioma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9120/3"},{"name":"Legacy Concept Name","value":"Angiosarcoma"},{"name":"Maps_To","value":"9130/3"},{"name":"Maps_To","value":"Angiosarcoma"},{"name":"Maps_To","value":"Haemangiosarcoma"},{"name":"Maps_To","value":"Hemangioendothelial sarcoma"},{"name":"Maps_To","value":"Hemangioendothelioma, malignant"},{"name":"Maps_To","value":"Hemangiosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018923"}]}}{"C3086":{"preferredName":"Cavernous Hemangioma","code":"C3086","definitions":[{"definition":"A hemangioma characterized by the presence of cavernous vascular spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cavernous Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Cavernoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cavernous Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9121/0"},{"name":"Legacy Concept Name","value":"Cavernous_Hemangioma"},{"name":"Maps_To","value":"9121/0"},{"name":"Maps_To","value":"Cavernous hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018920"}]}}{"C4296":{"preferredName":"Venous Hemangioma","code":"C4296","definitions":[{"definition":"A hemangioma composed of veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venous Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Venous Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Venous Malformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9122/0"},{"name":"Legacy Concept Name","value":"Venous_Hemangioma"},{"name":"Maps_To","value":"9122/0"},{"name":"Maps_To","value":"Venous hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334532"}]}}{"C2882":{"preferredName":"Arteriovenous Malformation","code":"C2882","definitions":[{"definition":"A benign vascular lesion characterized by the presence of a complex network of communicating arterial and venous vascular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arteriovenous Malformation","termGroup":"PT","termSource":"NCI"},{"termName":"Arteriovenous Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Arteriovenous Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Arteriovenous Hemangioma/Malformation","termGroup":"SY","termSource":"NCI"},{"termName":"Arteriovenous Malformation","termGroup":"SY","termSource":"NCI"},{"termName":"Arteriovenous Malformation/Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"AVM","termGroup":"AB","termSource":"NCI"},{"termName":"AVM/H","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9123/0"},{"name":"Legacy Concept Name","value":"Arteriovenous_Malformation"},{"name":"Maps_To","value":"9123/0"},{"name":"Maps_To","value":"Arteriovenous hemangioma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0003857"}]}}{"C35479":{"preferredName":"Retinal Arteriovenous Malformation","code":"C35479","definitions":[{"definition":"A vascular malformation of the retina that consists of arteriovenous communications and shunts. It occurs as an isolated lesion or as a component of the Wyburn-Mason syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinal Arteriovenous Malformation","termGroup":"PT","termSource":"NCI"},{"termName":"Racemose Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Racemose Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Racemose Hemangioma of the Retina","termGroup":"SY","termSource":"NCI"},{"termName":"Retinal Arteriovenous Malformation/Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Retinal AVM","termGroup":"SY","termSource":"NCI"},{"termName":"Retinal AVM/H","termGroup":"SY","termSource":"NCI"},{"termName":"Retinal Racemose Hemangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retinal_Arteriovenous_Malformation"},{"name":"Maps_To","value":"9123/0"},{"name":"Maps_To","value":"Racemose hemangioma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0521570"}]}}{"C4438":{"preferredName":"Liver Angiosarcoma","code":"C4438","definitions":[{"definition":"A malignant vascular neoplasm arising from the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liver Angiosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiosarcoma of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Angiosarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangiosarcoma of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangiosarcoma of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Angiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Hemangiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Hemangiosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Angiosarcoma of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Angiosarcoma of the Liver","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9124/3"},{"name":"Legacy Concept Name","value":"Hepatic_Angiosarcoma"},{"name":"Maps_To","value":"9124/3"},{"name":"Maps_To","value":"Kupffer cell sarcoma"},{"name":"Maps_To","value":"Malignant neoplasm: Angiosarcoma of liver"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0345907"}]}}{"C4298":{"preferredName":"Epithelioid Hemangioma","code":"C4298","definitions":[{"definition":"A hemangioma characterized by the presence of epithelioid endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiolymphoid Hyperplasia with Eosinophilia","termGroup":"SY","termSource":"NCI"},{"termName":"Histiocytoid Hemangioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9125/0"},{"name":"Legacy Concept Name","value":"Epithelioid_Hemangioma"},{"name":"Maps_To","value":"9125/0"},{"name":"Maps_To","value":"Epithelioid hemangioma"},{"name":"Maps_To","value":"Histiocytoid hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368797"}]}}{"C66779":{"preferredName":"Benign Hemangioendothelioma","code":"C66779","definitions":[{"definition":"A benign vascular proliferation characterized by the presence of prominent endothelial cells and the formation of vascular channels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Hemangioendothelioma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9130/0"},{"name":"Legacy Concept Name","value":"Benign_Hemangioendothelioma"},{"name":"Maps_To","value":"9130/0"},{"name":"Maps_To","value":"Hemangioendothelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334536"}]}}{"C3084":{"preferredName":"Hemangioendothelioma","code":"C3084","definitions":[{"definition":"A vascular proliferation characterized by the presence of prominent endothelial cells and the formation of vascular channels. Hemangioendotheliomas may display borderline or low grade characteristics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioendothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9130/1"},{"name":"Legacy Concept Name","value":"Hemangioendothelioma"},{"name":"Maps_To","value":"9130/1"},{"name":"Maps_To","value":"Angioendothelioma"},{"name":"Maps_To","value":"Hemangioendothelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018915"}]}}{"C27510":{"preferredName":"Kaposiform Hemangioendothelioma","code":"C27510","definitions":[{"definition":"An intermediate, locally aggressive blood vessel neoplasm characterized by the presence of spindle endothelial cells, and formation of capillary-sized and slit-like vascular channels.  It is often associated with hemorrhage and hemosiderin deposition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kaposiform Hemangioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"KHE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kaposiform_Hemangioendothelioma"},{"name":"Maps_To","value":"9130/1"},{"name":"Maps_To","value":"Kaposiform hemangioendothelioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367420"}]}}{"C6645":{"preferredName":"Infantile Hemangioma","code":"C6645","definitions":[{"definition":"A hemangioma that is characterized by the proliferation of lobules of capillaries. It occurs in infants and children and may regress spontaneously.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infantile Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Cellular Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Infantile Hemangioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Capillary Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Strawberry Nevus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Infantile_Hemangioendothelioma"},{"name":"Maps_To","value":"9131/0"},{"name":"Maps_To","value":"Hemangioma simplex"},{"name":"Maps_To","value":"Infantile hemangioma"},{"name":"Maps_To","value":"Juvenile hemangioma"},{"name":"Maps_To","value":"Plexiform hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206733"}]}}{"C7457":{"preferredName":"Capillary Hemangioma","code":"C7457","definitions":[{"definition":"A common hemangioma characterized by the presence of capillary-sized vascular channels without prominent epithelioid endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capillary Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Capillary Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9131/0"},{"name":"Legacy Concept Name","value":"Capillary_Hemangioma"},{"name":"Maps_To","value":"9131/0"},{"name":"Maps_To","value":"Capillary hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2748741"}]}}{"C3699":{"preferredName":"Intramuscular Hemangioma","code":"C3699","definitions":[{"definition":"A hemangioma arising from skeletal muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramuscular Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Intramuscular Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9132/0"},{"name":"Legacy Concept Name","value":"Intramuscular_Hemangioma"},{"name":"Maps_To","value":"9132/0"},{"name":"Maps_To","value":"Intramuscular hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205789"}]}}{"C3800":{"preferredName":"Epithelioid Hemangioendothelioma","code":"C3800","definitions":[{"definition":"A low-grade malignant blood vessel neoplasm.  It is characterized by the presence of epithelioid endothelial cells.  The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Hemangioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Angioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelioid Angiosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9130/3"},{"name":"ICD-O-3_Code","value":"9133/1"},{"name":"ICD-O-3_Code","value":"9133/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Hemangioendothelioma"},{"name":"Maps_To","value":"9133/1"},{"name":"Maps_To","value":"9133/3"},{"name":"Maps_To","value":"Epithelioid hemangioendothelioma, malignant"},{"name":"Maps_To","value":"Epithelioid hemangioendothelioma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206732"}]}}{"C7526":{"preferredName":"Papillary Intralymphatic Angioendothelioma","code":"C7526","definitions":[{"definition":"A rare, intermediate and rarely metastasizing blood vessel neoplasm that most often affects the skin and soft tissue of the extremities and manifests as a slow-growing induration, nodule, or plaque. Rare cases have been described in the spleen, tongue, and testis as well. It is characterized by the presence of lymphatic-like vascular channels and papillary endothelial proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Intralymphatic Angioendothelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Dabska Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Endothelial Papillary Angioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Endovascular Angioendothelioma","termGroup":"SY","termSource":"NCI"},{"termName":"PILA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9135/1"},{"name":"Legacy Concept Name","value":"Endovascular_Papillary_Angioendothelioma"},{"name":"Maps_To","value":"9135/1"},{"name":"Maps_To","value":"Dabska tumor"},{"name":"Maps_To","value":"Endovascular papillary angioendothelioma"},{"name":"Maps_To","value":"Papillary intralymphatic angioendothelioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346087"}]}}{"C4754":{"preferredName":"Spindle Cell Hemangioma","code":"C4754","definitions":[{"definition":"A hemangioma characterized by the presence of spindle endothelial cells in the dermis with frequent extension in the subcutaneous tissue. It manifests with multiple asymptomatic bluish nodules and usually affects the distal extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"SCH","termGroup":"AB","termSource":"NCI"},{"termName":"Spindle -Cell Hemangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Spindle Cell Hemangioendothelioma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9136/0"},{"name":"ICD-O-3_Code","value":"9136/1"},{"name":"Legacy Concept Name","value":"Spindle_Cell_Hemangioma"},{"name":"Maps_To","value":"9136/1"},{"name":"Maps_To","value":"Spindle cell angioendothelioma"},{"name":"Maps_To","value":"Spindle cell hemangioendothelioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1304508"}]}}{"C53677":{"preferredName":"Intimal Sarcoma","code":"C53677","definitions":[{"definition":"A malignant neoplasm arising from the large blood vessels.  It is characterized by the presence of tumor cells that grow within the lumen of the blood vessels.  The intraluminal tumor growth may result in vascular obstruction and spread of tumor emboli to peripheral organs.  The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intimal Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intimal_Sarcoma"},{"name":"Maps_To","value":"9137/3"},{"name":"Maps_To","value":"Intimal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708550"}]}}{"C9087":{"preferredName":"Kaposi Sarcoma","code":"C9087","definitions":[{"definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer characterized by the abnormal growth of blood vessels that develop into skin lesions or occur internally.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Kaposi Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Kaposi's Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"KS","termGroup":"AB","termSource":"NCI"},{"termName":"Multiple Hemorrhagic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9140/3"},{"name":"Legacy Concept Name","value":"Kaposi_s_Sarcoma"},{"name":"Maps_To","value":"9140/3"},{"name":"Maps_To","value":"Kaposi Sarcoma"},{"name":"Maps_To","value":"Kaposi sarcoma"},{"name":"Maps_To","value":"Kaposi sarcoma of soft tissue"},{"name":"Maps_To","value":"Kaposi's sarcoma"},{"name":"Maps_To","value":"Kaposi's sarcoma of gastrointestinal sites"},{"name":"Maps_To","value":"Kaposi's sarcoma, gastrointestinal sites"},{"name":"Maps_To","value":"Multiple hemorrhagic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3552576"}]}}{"C4488":{"preferredName":"Angiokeratoma","code":"C4488","definitions":[{"definition":"A vascular lesion in the papillary dermis that results from ectasia of pre-existing vessels. It is associated with secondary proliferative changes in the overlying epidermis. It can present with widespread lesions or as a localized lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiokeratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiokeratoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Angiokeratoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Angiokeratoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Angiokeratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9141/0"},{"name":"Legacy Concept Name","value":"Angiokeratoma"},{"name":"Legacy Concept Name","value":"Skin_Angiokeratoma"},{"name":"Maps_To","value":"9141/0"},{"name":"Maps_To","value":"Angiokeratoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0002985"},{"name":"UMLS_CUI","value":"C0346075"}]}}{"C4299":{"preferredName":"Verrucous Venous Malformation","code":"C4299","definitions":[{"definition":"A rare skin vascular malformation characterized by the proliferation of numerous dilated and congested capillaries and venules in the papillary dermis. It is associated with overlying epidermal acanthosis, hyperkeratosis, parakeratosis, and papillomatosis. It most often affects the distal extremities and manifests with red-to-purple plaques.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verrucous Venous Malformation","termGroup":"PT","termSource":"NCI"},{"termName":"Verrucous Hemangioma","termGroup":"AQS","termSource":"NCI"},{"termName":"Verrucous Keratotic Hemangioma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9142/0"},{"name":"Legacy Concept Name","value":"Verrucous_Keratotic_Hemangioma"},{"name":"Maps_To","value":"9142/0"},{"name":"Maps_To","value":"Verrucous keratotic hemangioma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334540"}]}}{"C4300":{"preferredName":"Benign Hemangiopericytoma","code":"C4300","definitions":[{"definition":"A benign neoplasm originating from vascular pericytes (cells in the periphery of vessels).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A hemangiopericytoma without malignant morphologic or clinical characteristics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Hemangiopericytoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9150/0"},{"name":"Legacy Concept Name","value":"Benign_Hemangiopericytoma"},{"name":"Maps_To","value":"9150/0"},{"name":"Maps_To","value":"Hemangiopericytoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334541"}]}}{"C3087":{"preferredName":"Hemangiopericytoma","code":"C3087","definitions":[{"definition":"A type of cancer involving blood vessels and soft tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antiquated term that refers to benign or malignant mesenchymal neoplasms characterized by the presence of neoplastic spindle-shaped to round cells arranged around thin-walled branching vascular spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangiopericytoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9150/1"},{"name":"Legacy Concept Name","value":"Hemangiopericytoma"},{"name":"Maps_To","value":"9150/1"},{"name":"Maps_To","value":"Hemangiopericytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018922"}]}}{"C4301":{"preferredName":"Malignant Hemangiopericytoma","code":"C4301","definitions":[{"definition":"A malignant neoplasm originating from vascular pericytes (cells in the periphery of vessels).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An uncommon malignant neoplasm arising from pericytes.  Distinction between benign and malignant hemangiopericytoma may be difficult or even impossible on morphologic grounds alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Hemangiopericytoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Malignant Hemangiopericytoma NOS","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9150/3"},{"name":"Legacy Concept Name","value":"Malignant_Hemangiopericytoma"},{"name":"Maps_To","value":"9150/3"},{"name":"Maps_To","value":"Hemangiopericytoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334542"}]}}{"C27257":{"preferredName":"Cellular Angiofibroma","code":"C27257","definitions":[{"definition":"A benign mesenchymal neoplasm that usually arises in the superficial soft tissues of the vulva or inguinal and scrotal regions.  It is characterized by the presence of a cellular fibroblastic proliferation in an edematous to fibrous stroma containing numerous vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Angiofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cellular_Angiofibroma"},{"name":"Maps_To","value":"9160/0"},{"name":"Maps_To","value":"Cellular angiofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367534"}]}}{"C27256":{"preferredName":"Giant Cell Angiofibroma","code":"C27256","definitions":[{"definition":"A morphologic variant of angiofibroma characterized by the presence of multinucleated giant cells, collagenous or myxoid stroma, focal sclerotic areas, and angiectoid spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Angiofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Giant_Cell_Angiofibroma"},{"name":"Maps_To","value":"9160/0"},{"name":"Maps_To","value":"Giant cell angiofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367539"}]}}{"C3799":{"preferredName":"Angiofibroma","code":"C3799","definitions":[{"definition":"A benign, morphologic variant of fibroma characterized by the presence of numerous dilated vascular channels.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic variant of fibroma characterized by the presence of numerous dilated vascular channels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiofibromatous Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrous Papule","termGroup":"SY","termSource":"NCI"},{"termName":"Telangiectatic Fibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9160/0"},{"name":"Legacy Concept Name","value":"Angiofibroma"},{"name":"Maps_To","value":"9160/0"},{"name":"Maps_To","value":"Angiofibroma, NOS"},{"name":"Maps_To","value":"Juvenile angiofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206731"}]}}{"C4487":{"preferredName":"Tufted Hemangioma","code":"C4487","definitions":[{"definition":"A rare cutaneous hemangioma characterized by the presence of multiple scattered and tightly packed lobules of capillaries in the dermis and rarely the subcutaneous tissue. It usually affects infants and children and manifests with macules, papules, nodules, or plaques.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tufted Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioblastoma of Nakagawa","termGroup":"SY","termSource":"NCI"},{"termName":"TA","termGroup":"AB","termSource":"NCI"},{"termName":"Tufted Angioma","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Angioma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Angioma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Hemangioma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Hemangioma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Tufted Skin Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9161/0"},{"name":"Legacy Concept Name","value":"Tufted_Hemangioma"},{"name":"Maps_To","value":"9161/0"},{"name":"Maps_To","value":"Acquired tufted hemangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346073"}]}}{"C3801":{"preferredName":"Hemangioblastoma","code":"C3801","definitions":[{"definition":"A rare, slow-growing tumor of uncertain histogenesis. It affects the central nervous system and infrequently other sites. It is composed of stromal cells and abundant capillaries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangioblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Capillary Hemangioblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9161/1"},{"name":"Legacy Concept Name","value":"Hemangioblastoma"},{"name":"Maps_To","value":"9161/1"},{"name":"Maps_To","value":"Angioblastoma"},{"name":"Maps_To","value":"Haemangioblastoma"},{"name":"Maps_To","value":"Hemangioblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206734"}]}}{"C8965":{"preferredName":"Lymphangioma","code":"C8965","definitions":[{"definition":"A benign lesion composed of dilated lymphatic channels. Painless swelling is the usual clinical manifestation.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm arising from the lymphatics.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymphangioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9170/0"},{"name":"Legacy Concept Name","value":"Lymphangioma"},{"name":"Maps_To","value":"9170/0"},{"name":"Maps_To","value":"9171/0"},{"name":"Maps_To","value":"Capillary lymphangioma"},{"name":"Maps_To","value":"Lymphangioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024221"}]}}{"C3203":{"preferredName":"Acquired Progressive Lymphangioma","code":"C3203","definitions":[{"definition":"A lymphangioma characterized by the presence of collagen bundle formation.  It has an indolent clinical course and may be associated with skin plaques.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acquired Progressive Lymphangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangioendothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphangioendothelioma"},{"name":"Maps_To","value":"9170/0"},{"name":"Maps_To","value":"Lymphangioendothelioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024217"}]}}{"C3205":{"preferredName":"Lymphangiosarcoma","code":"C3205","definitions":[{"definition":"A malignant neoplasm arising from the endothelial cells of the lymphatic vessels.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from the endothelial cells of the lymphatic vessels.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that begins in the cells that line lymph vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphangiosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangioendothelial Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Lymphangioendothelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9170/3"},{"name":"Legacy Concept Name","value":"Lymphangiosarcoma"},{"name":"Maps_To","value":"9170/3"},{"name":"Maps_To","value":"Lymphangioendothelial sarcoma"},{"name":"Maps_To","value":"Lymphangioendothelioma, malignant"},{"name":"Maps_To","value":"Lymphangiosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024224"}]}}{"C53316":{"preferredName":"Cavernous Lymphangioma","code":"C53316","definitions":[{"definition":"A lymphangioma characterized by the presence of thin-walled cavernous lymphatic spaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cavernous Lymphangioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9172/0"},{"name":"Legacy Concept Name","value":"Cavernous_Lymphangioma"},{"name":"Maps_To","value":"9172/0"},{"name":"Maps_To","value":"Cavernous lymphangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205828"}]}}{"C3724":{"preferredName":"Cystic Hygroma","code":"C3724","definitions":[{"definition":"A congenital lymphatic malformation that usually arises from the neck and is characterized by cystic dilation of the lymphatic vessels.","type":"DEFINITION","source":"NCI"},{"definition":"A congenital lymphatic malformation usually arising from the neck and characterized by cystic dilation of the lymphatic vessels.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Cystic Hygroma","termGroup":"PT","termSource":"NCI"},{"termName":"Congenital Cystic Hygroma","termGroup":"SY","termSource":"NCI"},{"termName":"Cystic Lymphatic Malformation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9173/0"},{"name":"Legacy Concept Name","value":"Cystic_Lymphangioma"},{"name":"Maps_To","value":"9173/0"},{"name":"Maps_To","value":"Cystic hygroma"},{"name":"Maps_To","value":"Cystic lymphangioma"},{"name":"Maps_To","value":"Hygroma, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0206620"},{"name":"UMLS_CUI","value":"C3899506"}]}}{"C3204":{"preferredName":"Lymphangioleiomyoma","code":"C3204","definitions":[{"definition":"A neoplasm with perivascular epithelioid cell differentiation, often associated with tuberous sclerosis. It is characterized by the presence of smooth muscle and epithelioid cells and by the proliferation of lymphatic vessels. Sites of involvement include the lymph nodes, lung, mediastinum, and retroperitoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphangioleiomyoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangiomyoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9174/0"},{"name":"Legacy Concept Name","value":"Lymphangiomyoma"},{"name":"Maps_To","value":"9174/0"},{"name":"Maps_To","value":"Lymphangiomyoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024223"}]}}{"C3725":{"preferredName":"Lymphangioleiomyomatosis","code":"C3725","definitions":[{"definition":"A multifocal neoplasm with perivascular epithelioid cell differentiation affecting almost exclusively females of child-bearing age. It is characterized by the presence of smooth muscle and epithelioid cells and by the proliferation of lymphatic vessels. Sites of involvement include the lungs, mediastinum, and the retroperitoneum. It usually presents with chylous pleural effusion or ascites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphangioleiomyomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"LAM","termGroup":"AB","termSource":"NCI"},{"termName":"Lymphangiomyomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9174/1"},{"name":"Legacy Concept Name","value":"Lymphangiomyomatosis"},{"name":"Maps_To","value":"9174/1"},{"name":"Maps_To","value":"Lymphangioleiomyomatosis"},{"name":"Maps_To","value":"Lymphangiomyomatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751674"}]}}{"C66792":{"preferredName":"Hemolymphangioma","code":"C66792","definitions":[{"definition":"A hemorrhagic lymphatic lesion characterized by the presence of dilated lymphatic spaces, extravasation of red blood cells, hemosiderin deposition, and fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemolymphangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Lymphangioma with Hemorrhage","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9175/0"},{"name":"Legacy Concept Name","value":"Lymphangioma_with_Hemorrhage"},{"name":"Maps_To","value":"9175/0"},{"name":"Maps_To","value":"Hemolymphangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334544"}]}}{"C3296":{"preferredName":"Osteoma","code":"C3296","definitions":[{"definition":"A benign well-differentiated neoplasm of bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, well-circumscribed, bone-forming neoplasm predominantly composed of lamellar bone. It usually arises from the calvarial, facial, or jaw bones.  It is usually asymptomatic but it may cause local swelling or obstruction of the paranasal sinuses.  Asymptomatic cases have an indolent clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9180/0"},{"name":"Legacy Concept Name","value":"Osteoma"},{"name":"Maps_To","value":"9180/0"},{"name":"Maps_To","value":"Osteoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029440"}]}}{"C53953":{"preferredName":"Osteoblastic Osteosarcoma","code":"C53953","definitions":[{"definition":"A conventional osteosarcoma characterized by the predominance of osteoid matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoblastic Osteosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Osteoblastic_Osteosarcoma"},{"name":"Maps_To","value":"9180/3"},{"name":"Maps_To","value":"Osteoblastic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704328"}]}}{"C4021":{"preferredName":"Chondroblastic Osteosarcoma","code":"C4021","definitions":[{"definition":"An osteosarcoma characterised by the presence of atypical cartilage of variable cellularity.  It may or may not be associated with the presence of myxoid areas or focal bone formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroblastic Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chondroblastic Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9181/3"},{"name":"Legacy Concept Name","value":"Chondrosarcomatous_Osteosarcoma"},{"name":"Maps_To","value":"9180/3"},{"name":"Maps_To","value":"9181/3"},{"name":"Maps_To","value":"Chondroblastic osteosarcoma"},{"name":"Maps_To","value":"Osteochondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279603"}]}}{"C9145":{"preferredName":"Osteosarcoma","code":"C9145","definitions":[{"definition":"A cancer of the bone that usually affects the large bones of the arm or leg. It occurs most commonly in young people and affects more males than females.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm of connective tissue origin that produces bone or osteoid.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neoplasm usually arising from bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9180/3"},{"name":"Legacy Concept Name","value":"Osteosarcoma"},{"name":"Maps_To","value":"9180/3"},{"name":"Maps_To","value":"Osteogenic sarcoma, NOS"},{"name":"Maps_To","value":"Osteosarcoma"},{"name":"Maps_To","value":"Osteosarcoma (OS)"},{"name":"Maps_To","value":"Osteosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029463"}]}}{"C4020":{"preferredName":"Fibroblastic Osteosarcoma","code":"C4020","definitions":[{"definition":"A conventional osteosarcoma characterized by the presence of spindle shaped cells.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant fibrosarcoma characterized by pleomorphic cells intermixed with variable amounts of collagenous matrix.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fibroblastic Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblastic Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrosarcomatous Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibrosarcomatous Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9182/3"},{"name":"Legacy Concept Name","value":"Fibroblastic_Osteosarcoma"},{"name":"Maps_To","value":"9182/3"},{"name":"Maps_To","value":"Fibroblastic osteosarcoma"},{"name":"Maps_To","value":"Osteofibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279602"}]}}{"C3902":{"preferredName":"Telangiectatic Osteosarcoma","code":"C3902","definitions":[{"definition":"An osteosarcoma usually arising from the metaphysis of long bones. It is characterized by the presence of a cystic architecture with blood-filled spaces. The prognosis is similar to that of conventional osteosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telangiectatic Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Bone Aneurysm","termGroup":"SY","termSource":"NCI"},{"termName":"Telangiectatic Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9183/3"},{"name":"Legacy Concept Name","value":"Telangiectatic_Osteosarcoma"},{"name":"Maps_To","value":"9183/3"},{"name":"Maps_To","value":"Telangiectatic osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259782"}]}}{"C6469":{"preferredName":"Osteosarcoma Arising in Paget Disease of Bone","code":"C6469","definitions":[{"definition":"A sarcomatous transformation of pre-existing Paget disease of the bone. Osteosarcomas arising from Paget disease of the bone are high grade lesions and usually have a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteosarcoma Arising in Paget Disease of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Bone Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Osseous Paget's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Osteitis Deformans","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma Arising in Paget's Disease of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osteosarcoma in Paget Disease of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Paget Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Paget's Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9184/3"},{"name":"Legacy Concept Name","value":"Osteosarcoma_Arising_in_Paget_s_Disease_of_Bone"},{"name":"Maps_To","value":"9184/3"},{"name":"Maps_To","value":"Osteosarcoma in Paget disease of bone"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334546"}]}}{"C4023":{"preferredName":"Small Cell Osteosarcoma","code":"C4023","definitions":[{"definition":"An osteosarcoma usually arising from the metaphysis of long bones. It is characterized by the presence of small cells and osteoid production. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Small Cell Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Small Cell Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9185/3"},{"name":"Legacy Concept Name","value":"Small_Cell_Osteosarcoma"},{"name":"Maps_To","value":"9185/3"},{"name":"Maps_To","value":"Round cell osteosarcoma"},{"name":"Maps_To","value":"Small cell osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279622"}]}}{"C35870":{"preferredName":"Conventional Osteosarcoma","code":"C35870","definitions":[{"definition":"A high grade malignant bone-forming mesenchymal neoplasm producing osteoid. The tumor arises from the medullary portion of the bone. It affects the long bones and most commonly, the distal femur, proximal tibia, and proximal humerus. Pain with or without a palpable mass is the most common clinical presentation. It usually has an aggressive growth and may metastasize through the hematogenous route. The lung is the most frequent site of metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conventional Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Conventional Central Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"COS","termGroup":"AB","termSource":"NCI"},{"termName":"Intracortical Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intracortical Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9186/3"},{"name":"ICD-O-3_Code","value":"9195/3"},{"name":"Legacy Concept Name","value":"Conventional_Osteosarcoma"},{"name":"Maps_To","value":"9186/3"},{"name":"Maps_To","value":"9195/3"},{"name":"Maps_To","value":"Central osteosarcoma"},{"name":"Maps_To","value":"Central osteosarcoma, NOS"},{"name":"Maps_To","value":"Conventional central osteosarcoma"},{"name":"Maps_To","value":"Intracortical osteosarcoma"},{"name":"Maps_To","value":"Medullary osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266166"}]}}{"C6474":{"preferredName":"Low Grade Central Osteosarcoma","code":"C6474","definitions":[{"definition":"A low grade osteosarcoma arising from the medullary portion of the bone. It affects the long bones and is characterized by the presence of fibroblastic stroma and osteoid production. Pain and swelling are the usual sign and symptom. The prognosis is more favorable than conventional osteosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Central Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Intraosseous Well Differentiated Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraosseous Well-Differentiated Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intraosseous Well-Differentiated Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"LGCOS","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Intramedullary Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Intramedullary Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9187/3"},{"name":"Legacy Concept Name","value":"Low_Grade_Central_Osteosarcoma"},{"name":"Maps_To","value":"9187/3"},{"name":"Maps_To","value":"Intraosseous low grade osteosarcoma"},{"name":"Maps_To","value":"Intraosseous well differentiated osteosarcoma"},{"name":"Maps_To","value":"Low grade central osteosarcoma"},{"name":"Maps_To","value":"Low-grade central osteosarcoma"},{"name":"Maps_To","value":"Low-grade intramedullary osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266163"}]}}{"C3297":{"preferredName":"Osteoid Osteoma","code":"C3297","definitions":[{"definition":"A small, benign, bone-forming neoplasm that can arise from any bone but more frequently affects the long bones. The central portion of the neoplasm (nidus) contains differentiated osteoblasts which produce osteoid and sometimes bone. The lesion is usually surrounded by hypervascular sclerotic bone and has limited growth potential. Clinical signs and symptoms include pain and localized tenderness, at the site of the lesion. The pain may be intense but in the majority of cases it is completely alleviated by non-steroidal anti-inflammatory drugs. Prognosis is excellent and recurrences are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoid Osteoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9191/0"},{"name":"Legacy Concept Name","value":"Osteoid_Osteoma"},{"name":"Maps_To","value":"9191/0"},{"name":"Maps_To","value":"Osteoid osteoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029441"}]}}{"C8969":{"preferredName":"Parosteal Osteosarcoma","code":"C8969","definitions":[{"definition":"A low grade malignant bone-forming mesenchymal neoplasm arising from the surface of the bone. It usually affects the distal posterior femur, the proximal tibia, and proximal humerus. Painless swelling is the usual clinical sign. Most patients are young adults and the prognosis is usually excellent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parosteal Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Juxtacortical Osteosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Parosteal Osteogenic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9192/3"},{"name":"Legacy Concept Name","value":"Parosteal_Osteosarcoma"},{"name":"Maps_To","value":"9192/3"},{"name":"Maps_To","value":"Juxtacortical osteosarcoma"},{"name":"Maps_To","value":"Parosteal osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206642"}]}}{"C8970":{"preferredName":"Periosteal Osteosarcoma","code":"C8970","definitions":[{"definition":"An intermediate grade malignant bone-forming mesenchymal neoplasm with chondroblastic differentiation.  It arises from the surface of the bone and affects the diaphysis or diaphyseal- metaphyseal portion of the long bones.  A painless mass or swelling is the most common clinical sign.  It is associated with a better prognosis than conventional osteosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Chondroblastic Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9193/3"},{"name":"Legacy Concept Name","value":"Periosteal_Osteosarcoma"},{"name":"Maps_To","value":"9193/3"},{"name":"Maps_To","value":"Periosteal osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377843"}]}}{"C53958":{"preferredName":"High Grade Surface Osteosarcoma","code":"C53958","definitions":[{"definition":"A usually aggressive high grade malignant bone-forming mesenchymal neoplasm arising from the surface of the bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Surface Osteosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"High-Grade Surface Osteosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9194/3"},{"name":"Legacy Concept Name","value":"High_Grade_Surface_Osteosarcoma"},{"name":"Maps_To","value":"9194/3"},{"name":"Maps_To","value":"High grade surface osteosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266165"}]}}{"C3294":{"preferredName":"Osteoblastoma","code":"C3294","definitions":[{"definition":"A benign neoplasm of bone, characterized by the formation of osteoid tissue and large osteoblast-like cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare benign bone-forming neoplasm usually arising from the spine. It is a well-circumscribed lytic tumor that varies in size. The tumor is composed of woven bone trabeculae and shares similar histologic characteristics with the osteoid osteoma. Surgical curettage is the treatment of choice. The prognosis is excellent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Giant Osteoid Osteoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ossifying Giant Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9200/0"},{"name":"Legacy Concept Name","value":"Osteoblastoma"},{"name":"Maps_To","value":"9200/0"},{"name":"Maps_To","value":"Giant osteoid osteoma"},{"name":"Maps_To","value":"Osteoblastoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029417"}]}}{"C66796":{"preferredName":"Aggressive Osteoblastoma","code":"C66796","definitions":[{"definition":"An osteoblastoma characterized by the presence of prominent epithelioid osteoblasts and recurrences.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggressive Osteoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9200/1"},{"name":"Legacy Concept Name","value":"Aggressive_Osteoblastoma"},{"name":"Maps_To","value":"9200/1"},{"name":"Maps_To","value":"Aggressive osteoblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334547"}]}}{"C3295":{"preferredName":"Osteochondroma","code":"C3295","definitions":[{"definition":"A benign cartiliginous neoplasm arising from the metaphysis of bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A common, benign cartiliginous neoplasm arising from the metaphysis of bone. The tumor grows on the surface of the bone; it may be pedunculated or sessile. It is characterized by the presence of chondrocytes, a cartilage cap, and a fibrous perichondrium that extends to the periosteum of the bone. In some cases, there is deletion of 8q24.1 chromosome locus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osteochondroma","termGroup":"PT","termSource":"NCI"},{"termName":"Osteocartilaginous Exostosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9210/0"},{"name":"Legacy Concept Name","value":"Osteochondroma"},{"name":"Maps_To","value":"9210/0"},{"name":"Maps_To","value":"Cartilaginous exostosis"},{"name":"Maps_To","value":"Ecchondroma"},{"name":"Maps_To","value":"Osteocartilaginous exostosis"},{"name":"Maps_To","value":"Osteochondroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0029423"}]}}{"C53457":{"preferredName":"Multiple Osteochondromas","code":"C53457","definitions":[{"definition":"An autosomal dominant neoplastic chondrogenic process affecting multiple sites. It is caused by mutations in the EXT1 or EXT2 genes.  Grossly and microscopically, the lesions resemble an osteochondroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multiple Osteochondromas","termGroup":"PT","termSource":"NCI"},{"termName":"Osteochondromatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9210/1"},{"name":"Legacy Concept Name","value":"Multiple_Osteochondromas"},{"name":"Maps_To","value":"9210/1"},{"name":"Maps_To","value":"Ecchondrosis"},{"name":"Maps_To","value":"Osteochondromatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206641"}]}}{"C53459":{"preferredName":"Chondroma","code":"C53459","definitions":[{"definition":"A benign well circumscribed neoplasm of hyaline cartilage arising from bone or soft tissue. It is characterized by the presence of chondrocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A benign, well circumscribed neoplasm arising from the hyaline cartilage in soft tissue or bone. It is characterized by the presence of chondrocytes.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Chondroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9220/0"},{"name":"Legacy Concept Name","value":"Chondroma"},{"name":"Maps_To","value":"9220/0"},{"name":"Maps_To","value":"Chondroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0936248"}]}}{"C3007":{"preferredName":"Enchondroma","code":"C3007","definitions":[{"definition":"A benign (noncancerous) growth of cartilage in bones or in other areas where cartilage is not normally found.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A common benign hyaline cartilage neoplasm arising in the intramedullary bone.  It is characterized by the presence of chondrocytes, low mitotic activity, and in some cases, a nodular pattern and calcification. The small bones of the hands and feet are the most frequently affected sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enchondroma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Chondroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Enchondroma"},{"name":"Maps_To","value":"9220/0"},{"name":"Maps_To","value":"Enchondroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704356"}]}}{"C35259":{"preferredName":"Chondromatosis","code":"C35259","definitions":[{"definition":"A multifocal benign neoplasm arising from bone or soft tissue.  It is characterized by the presence of chondrocytes and is composed of hyaline cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondromatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9220/1"},{"name":"Legacy Concept Name","value":"Chondromatosis"},{"name":"Maps_To","value":"9220/1"},{"name":"Maps_To","value":"Chondromatosis, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206636"}]}}{"C2946":{"preferredName":"Chondrosarcoma","code":"C2946","definitions":[{"definition":"A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue.  It usually affects middle-aged to elderly adults.  The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant mesenchymal neoplasm arising from cartilage-forming tissues.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that forms in bone cartilage. It usually starts in the pelvis (between the hip bones), the shoulder, the ribs, or at the ends of the long bones of the arms and legs. A rare type of chondrosarcoma called extraskeletal chondrosarcoma does not form in bone cartilage. Instead, it forms in the soft tissues of the upper part of the arms and legs. Chondrosarcoma can occur at any age but is more common in people older than 40 years. It is a type of bone cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9220/3"},{"name":"Legacy Concept Name","value":"Chondrosarcoma"},{"name":"Maps_To","value":"9220/3"},{"name":"Maps_To","value":"Chondrosarcoma"},{"name":"Maps_To","value":"Chondrosarcoma, NOS"},{"name":"Maps_To","value":"Fibrochondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008479"}]}}{"C4302":{"preferredName":"Periosteal Chondroma","code":"C4302","definitions":[{"definition":"A benign neoplasm of bone surface composed of hyaline cartilage.  It arises beneath the periosteum and is characterized by the presence of chondrocytes, a lobulated growth pattern, and calcification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Chondroma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Chondroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9221/0"},{"name":"Legacy Concept Name","value":"Periosteal_Chondroma"},{"name":"Maps_To","value":"9221/0"},{"name":"Maps_To","value":"Juxtacortical chondroma"},{"name":"Maps_To","value":"Periosteal chondroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4076530"}]}}{"C7357":{"preferredName":"Periosteal Chondrosarcoma","code":"C7357","definitions":[{"definition":"A chondrosarcoma arising from the surface of bone. It is characterized by a lobulated growth pattern, high mitotic activity, myxoid stroma formation, and necrotic changes. It occurs in adults. Clinical presentation includes pain, and sometimes swelling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periosteal Chondrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Juxtacortical Chondrosarcoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9221/3"},{"name":"Legacy Concept Name","value":"Periosteal_Chondrosarcoma"},{"name":"Maps_To","value":"9221/3"},{"name":"Maps_To","value":"Juxtacortical chondrosarcoma"},{"name":"Maps_To","value":"Periosteal chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334549"}]}}{"C2945":{"preferredName":"Chondroblastoma","code":"C2945","definitions":[{"definition":"A benign, chondroid-producing, well-circumscribed, lytic neoplasm usually arising from the epiphysis of long bones.  It is characterized by the presence of chondroblasts, osteoclast-like giant cells, chondroid formation, calcification, and mitotic activity. In aggressive cases, there is rearrangement of the 8q21 chromosome band.  It occurs most frequently in children and young adults and rarely metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chondroblastoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9230/0"},{"name":"Legacy Concept Name","value":"Chondroblastoma"},{"name":"Maps_To","value":"9230/0"},{"name":"Maps_To","value":"Chondroblastoma, NOS"},{"name":"Maps_To","value":"Chondromatous giant cell tumor"},{"name":"Maps_To","value":"Codman tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008441"}]}}{"C66799":{"preferredName":"Metastasizing Chondroblastoma","code":"C66799","definitions":[{"definition":"A rare chondroblastoma that has metastasized to another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasizing Chondroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9230/3"},{"name":"Legacy Concept Name","value":"Malignant_Chondroblastoma"},{"name":"Maps_To","value":"9230/3"},{"name":"Maps_To","value":"Chondroblastoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334550"}]}}{"C27502":{"preferredName":"Extraskeletal Myxoid Chondrosarcoma","code":"C27502","definitions":[{"definition":"A rare malignant soft tissue neoplasm of uncertain differentiation, characterized by the presence of chondroblast-like cells in a myxoid stroma and a multinodular growth pattern.  The most common sites of involvement are the deep soft tissues of the extremities, particularly the thigh.  It usually presents as an enlarging soft tissue mass.  Patients may have long survivals, but local recurrences and metastases occur in approximately half of the cases.  The most common site of metastasis is the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraskeletal Myxoid Chondrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"EMC","termGroup":"AB","termSource":"NCI"},{"termName":"Extraosseous Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extraskeletal Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid Extraosseous Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myxoid Extraskeletal Chondrosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"NR4A3-Rearranged Myxoid Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9231/3"},{"name":"Legacy Concept Name","value":"Myxoid_Extraskeletal_Chondrosarcoma"},{"name":"Maps_To","value":"9231/3"},{"name":"Maps_To","value":"Myxoid chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334551"}]}}{"C3737":{"preferredName":"Mesenchymal Chondrosarcoma","code":"C3737","definitions":[{"definition":"A morphologic variant of chondrosarcoma arising from bone and soft tissue. It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling. The clinical course is aggressive, with local recurrences and distant metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesenchymal Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9240/3"},{"name":"Legacy Concept Name","value":"Mesenchymal_Chondrosarcoma"},{"name":"Maps_To","value":"9240/3"},{"name":"Maps_To","value":"Mesenchymal chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206637"}]}}{"C3830":{"preferredName":"Chondromyxoid Fibroma","code":"C3830","definitions":[{"definition":"An uncommon benign cartilaginous neoplasm arising from the bone. It is characterized by the presence of spindle-shaped or stellate chondrocytes, a lobulated growth pattern, myxoid stroma formation, and sometimes multinucleated giant cells. It has been associated with chromosomal rearrangement of 6q13 and 6q25 bands. The most common clinical symptom is mild, localized pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondromyxoid Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9241/0"},{"name":"Legacy Concept Name","value":"Chondromyxoid_Fibroma"},{"name":"Maps_To","value":"9241/0"},{"name":"Maps_To","value":"Chondromyxoid fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221290"}]}}{"C6475":{"preferredName":"Clear Cell Chondrosarcoma","code":"C6475","definitions":[{"definition":"A rare, usually low grade chondrosarcoma characterized by the presence of tumor cells with clear cytoplasm. It usually arises in the epiphyseal ends of long bones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9242/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Chondrosarcoma"},{"name":"Maps_To","value":"9242/3"},{"name":"Maps_To","value":"Clear cell chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266167"}]}}{"C6476":{"preferredName":"Dedifferentiated Chondrosarcoma","code":"C6476","definitions":[{"definition":"An aggressive morphologic variant of chondrosarcoma. It is composed of a low grade chondrosarcoma and a high grade non-cartilagenous sarcomatous component. Due to the aggressive nature of the disease, its prognosis is poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dedifferentiated Chondrosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9243/3"},{"name":"Legacy Concept Name","value":"Dedifferentiated_Chondrosarcoma"},{"name":"Maps_To","value":"9243/3"},{"name":"Maps_To","value":"Dedifferentiated chondrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862878"}]}}{"C121932":{"preferredName":"Giant Cell Tumor of Bone","code":"C121932","definitions":[{"definition":"A benign but locally aggressive tumor that arises from the bone and is composed of mononuclear cells admixed with macrophages and osteoclast-like giant cells.  It usually arises from the ends of long bones or the vertebrae.  Clinical presentation includes pain, edema, and decreased range of motion in the affected joint.","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of bone comprised of giant cells (osteoclast-like) and mononuclear cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Giant Cell Tumor of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"GCTB","termGroup":"AB","termSource":"NCI"},{"termName":"Giant Cell Tumor of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osteoclastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9250/1"},{"name":"Maps_To","value":"Giant cell tumor of bone, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206638"}]}}{"C4304":{"preferredName":"Malignancy in Giant Cell Tumor of Bone","code":"C4304","definitions":[{"definition":"A malignant neoplasm of bone comprised of osteoclast-like giant cells and mononuclear cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that arises from the bone.  It is characterized by the presence of an area of high grade sarcoma in an otherwise typical giant cell tumor (primary malignancy in giant cell tumor), or the presence of sarcoma in which the pre-existing giant cell tumor may or may not be apparent (secondary malignancy in giant cell tumor).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignancy in Giant Cell Tumor of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Dedifferentiated Giant Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Bone Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Sarcoma of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Sarcoma of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignancy in Giant Cell Tumor of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9250/3"},{"name":"Legacy Concept Name","value":"Malignant_Giant_Cell_Tumor_of_Bone"},{"name":"Maps_To","value":"9250/3"},{"name":"Maps_To","value":"Giant cell sarcoma of bone"},{"name":"Maps_To","value":"Giant cell tumor of bone, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334552"}]}}{"C8380":{"preferredName":"Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells","code":"C8380","definitions":[{"definition":"An undifferentiated pleomorphic sarcoma characterized by the presence of osteoclast-like giant cells and cellular pleomorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Giant Cell Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Giant Cell Malignant Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Giant Cell Neoplasm of Soft Parts","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of Soft Parts","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9251/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"9250/3"},{"name":"Maps_To","value":"9251/3"},{"name":"Maps_To","value":"Malignant giant cell tumor of soft parts"},{"name":"Maps_To","value":"Osteoblastoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334554"}]}}{"C49107":{"preferredName":"Giant Cell Tumor of Soft Tissue","code":"C49107","definitions":[{"definition":"A painless, well circumscribed tumor arising in soft tissue, usually of the upper and lower extremities. Morphologically, it is characterized by a multinodular growth pattern. The cellular infiltrate is composed of mononuclear round or oval cells and multinucleated osteoclast-like giant cells, in a rich vascular stroma.  It rarely metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Tumor of Soft Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"GCT-ST","termGroup":"AB","termSource":"NCI"},{"termName":"Giant Cell Tumor of Low Malignant Potential","termGroup":"AQS","termSource":"NCI"},{"termName":"Osteoclastoma of Soft Tissue","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9251/1"},{"name":"Legacy Concept Name","value":"Giant_Cell_Tumor_of_Soft_Tissue"},{"name":"Maps_To","value":"9251/1"},{"name":"Maps_To","value":"Giant cell tumor of soft parts, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334553"}]}}{"C3402":{"preferredName":"Tenosynovial Giant Cell Tumor","code":"C3402","definitions":[{"definition":"A tumor usually arising in the synovium of joints, bursa or tendon sheath. It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. According to the growth pattern, it is classified as localized or diffuse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tenosynovial Giant Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Fibrous Histiocytoma of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Neoplasm of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Neoplasm of Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Neoplasm of the Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Tumor of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Tumor of Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Giant Cell Tumor of the Tenosynovium","termGroup":"SY","termSource":"NCI"},{"termName":"Tendon Sheath Giant Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Tendon Sheath Giant Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tenosynovial Giant Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9252/0"},{"name":"Legacy Concept Name","value":"Giant_Cell_Tumor_of_Tendon_Sheath"},{"name":"Maps_To","value":"9252/0"},{"name":"Maps_To","value":"Fibrous histiocytoma of tendon sheath"},{"name":"Maps_To","value":"Giant cell tumor of tendon sheath"},{"name":"Maps_To","value":"Tenosynovial giant cell tumor"},{"name":"Maps_To","value":"Tenosynovial giant cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1318543"}]}}{"C6535":{"preferredName":"Malignant Tenosynovial Giant Cell Tumor","code":"C6535","definitions":[{"definition":"An uncommon malignant tumor arising from the tendon sheath. Morphologically, it is characterized by the presence of a cellular infiltrate reminiscent of a giant cell tumor with prominent malignant characteristics. Recurrent giant cell tumors with a sarcomatous dedifferentiation are included in this category as well.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Tenosynovial Giant Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Giant Cell Neoplasm of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Neoplasm of the Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Giant Cell Tumor of the Tendon Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tendon Sheath Giant Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tendon Sheath Giant Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9252/3"},{"name":"Legacy Concept Name","value":"Malignant_Giant_Cell_Tumor_of_Tendon_Sheath"},{"name":"Maps_To","value":"9252/3"},{"name":"Maps_To","value":"Giant cell tumor of tendon sheath, malignant"},{"name":"Maps_To","value":"Malignant tenosynovial giant cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266168"}]}}{"C4817":{"preferredName":"Ewing Sarcoma","code":"C4817","definitions":[{"definition":"A malignant neoplasm of the bone, or the soft tissue adjacent to bone, that is comprised of primitive neuroectodermal cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that forms in bone or soft tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ewing Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ES","termGroup":"SY","termSource":"NCI"},{"termName":"Ewing's Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ewing's Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9260/3"},{"name":"Legacy Concept Name","value":"Ewing_s_Sarcoma"},{"name":"Maps_To","value":"9260/3"},{"name":"Maps_To","value":"Ewing sarcoma"},{"name":"Maps_To","value":"Ewing Sarcoma"},{"name":"Maps_To","value":"Ewing tumor"},{"name":"Maps_To","value":"Ewing's sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0553580"}]}}{"C7644":{"preferredName":"Adamantinoma","code":"C7644","definitions":[{"definition":"A low grade malignant neoplasm arising from the long bones. The tibia is the most frequently affected bone site. Patients present with swelling which may or may not be associated with pain. Morphologically, it is characterized by a biphasic pattern consisting of an epithelial and an osteofibrous component. The vast majority of cases recur if they are not treated with radical surgery. In a minority of cases the tumor may metastasize to other anatomic sites including lymph nodes, lungs, liver, brain, and skeleton.","type":"DEFINITION","source":"NCI"},{"definition":"A low-grade malignant neoplasm composed of epithelial cells and a spindle cell osteo-fibrous proliferation.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adamantinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adamantinoma of Long Bones","termGroup":"SY","termSource":"NCI"},{"termName":"Extragnathic Adamantinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9261/3"},{"name":"Legacy Concept Name","value":"Adamantinoma"},{"name":"Maps_To","value":"9261/3"},{"name":"Maps_To","value":"Adamantinoma of long bones"},{"name":"Maps_To","value":"Adamantinoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334556"}]}}{"C8461":{"preferredName":"Tibial Adamantinoma","code":"C8461","definitions":[{"definition":"An adamantinoma arising from the tibia.  The tibia is the site which is more frequently involved by adamantinoma (80-90% of cases).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tibial Adamantinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tibial_Adamantinoma"},{"name":"Maps_To","value":"9261/3"},{"name":"Maps_To","value":"Tibial adamantinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1273017"}]}}{"C173820":{"preferredName":"Ossifying Fibroma","code":"C173820","definitions":[{"definition":"A benign fibro-osseous neoplasm affecting the jaws and the craniofacial skeleton. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ossifying Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ossifying Fibroma of the Jaws and Craniofacial Skeleton","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9262/0"},{"name":"Maps_To","value":"Fibro-osteoma"},{"name":"Maps_To","value":"Ossifying fibroma"},{"name":"NCI_META_CUI","value":"CL1407622"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4306":{"preferredName":"Benign Odontogenic Neoplasm","code":"C4306","definitions":[{"definition":"A benign neoplasm arising from tooth-forming tissues.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Representative examples include adenomatoid odontogenic tumor, calcifying cystic odontogenic tumor, and squamous odontogenic tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Odontogenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9270/0"},{"name":"Legacy Concept Name","value":"Benign_Odontogenic_Neoplasm"},{"name":"Maps_To","value":"9270/0"},{"name":"Maps_To","value":"Odontogenic tumor, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334557"}]}}{"C4812":{"preferredName":"Malignant Odontogenic Neoplasm","code":"C4812","definitions":[{"definition":"A malignant neoplasm of tooth origin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Symptoms include swelling, pain, bleeding, mobility of affected teeth, and oral mucosa ulcerations. It may metastasize to lymph nodes and distant anatomic sites early.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Odontogenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9270/3"},{"name":"ICD-O-3_Code","value":"9342/3"},{"name":"Legacy Concept Name","value":"Malignant_Odontogenic_Neoplasm"},{"name":"Maps_To","value":"9270/3"},{"name":"Maps_To","value":"Odontogenic tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334558"}]}}{"C7492":{"preferredName":"Ameloblastic Carcinoma","code":"C7492","definitions":[{"definition":"A malignant neoplasm arising from tooth-forming tissues with-enamel organ differentiation (but without enamel formation).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, cytologically malignant ameloblastoma that may metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"AC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ameloblastic_Carcinoma"},{"name":"Maps_To","value":"9270/3"},{"name":"Maps_To","value":"Ameloblastic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1314678"}]}}{"C54323":{"preferredName":"Dentinogenic Ghost Cell Tumor","code":"C54323","definitions":[{"definition":"A benign but locally infiltrating neoplasm arising from tooth-forming tissues. It is more often intraosseous and less frequently extraosseous and occurs in the jaw. It is characterized by the presence of ameloblastoma-like epithelium, connective tissue stroma, ghost cells, and dysplastic dentin. Wide local resection is recommended for intraosseous neoplasms and enucleation for extraosseous neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dentinogenic Ghost Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Calcifying Ghost Cell Odontogenic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Dentinoameloblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Dentinoma","termGroup":"SY","termSource":"NCI"},{"termName":"DGCT","termGroup":"AB","termSource":"NCI"},{"termName":"Odontogenic Ghost Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9302/0"},{"name":"Legacy Concept Name","value":"Dentinogenic_Ghost_Cell_Tumor"},{"name":"Maps_To","value":"9271/0"},{"name":"Maps_To","value":"9302/0"},{"name":"Maps_To","value":"Dentinogenic ghost cell tumor"},{"name":"Maps_To","value":"Dentinoma"},{"name":"Maps_To","value":"Odontogenic ghost cell tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704219"}]}}{"C66800":{"preferredName":"Ameloblastic Fibrodentinoma","code":"C66800","definitions":[{"definition":"A rare neoplasm arising from tooth-forming tissues. It usually arises from the posterior mandible. It is characterized by the presence of an epithelial component, fibromyxoid stroma, and dentin formation. It is treated with enucleation and curettage. Recurrences may occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibrodentinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9271/0"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibrodentinoma"},{"name":"Maps_To","value":"9271/0"},{"name":"Maps_To","value":"Ameloblastic fibrodentinoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0457520"}]}}{"C173927":{"preferredName":"Cemento-Osseous Dysplasia","code":"C173927","definitions":[{"definition":"A non-neoplastic fibro-osseous lesion of the tooth-bearing regions of the gnathic bones. It is characterized by a variably cellular fibrous stroma with areas of swirling and/or loose collagen. Within the stroma are mineralizing tissues consisting of osteoid, bone, and cementum-like material. As the lesions mature, they become increasingly calcified. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemento-Osseous Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Cemental Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Cementoma","termGroup":"SY","termSource":"NCI"},{"termName":"COD","termGroup":"AB","termSource":"NCI"},{"termName":"Osseous Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9272/0"},{"name":"Maps_To","value":"Cementoma, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334068"}]}}{"C4308":{"preferredName":"Cementoblastoma","code":"C4308","definitions":[{"definition":"A rare benign bone-forming neoplasm usually arising from the jaw. It is a well-circumscribed lytic tumor that varies in size. The cell of origin is the cementoblast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cementoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Cementoblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9273/0"},{"name":"Legacy Concept Name","value":"Benign_Cementoblastoma"},{"name":"Maps_To","value":"9273/0"},{"name":"Maps_To","value":"Cementoblastoma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007659"}]}}{"C8422":{"preferredName":"Cemento-Ossifying Fibroma","code":"C8422","definitions":[{"definition":"A benign fibrous neoplasm characterized by a mineralized component (woven bone, lamellar bone, or cementum-like material).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A well circumscribed lesion of the bone, most frequently arising from the posterior mandible. It is characterized by the presence of fibrous tissue and a mineralized component which may be woven bone, lamellar bone, or cementum-like material. Complete removal is recommended, since it continues to enlarge if left untreated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemento-Ossifying Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"COF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9262/0"},{"name":"ICD-O-3_Code","value":"9274/0"},{"name":"Legacy Concept Name","value":"Cementifying_Fibroma"},{"name":"Maps_To","value":"9274/0"},{"name":"Maps_To","value":"Cementifying fibroma"},{"name":"Maps_To","value":"Cemento-ossifying fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206640"}]}}{"C202219":{"preferredName":"Gigantiform Cementoma","code":"C202219","definitions":[{"definition":"An extremely rare, benign, rapidly progressing fibro-osseous lesion that arises from the jaws as a multifocal expansile growth in children or adolescents. It results in significant deformity, orbital distortion, and possible airway involvement. An autosomal dominant inheritance has been proposed. Histologically, it is characterized by the presence of immature bony trabeculae and cementum-like calcifications within a hypercellular fibroblastic stroma. It shares morphological features with florid cemento-osseous dysplasia, but in florid cemento-osseous dysplasia the degree of expansion is less prominent and patients are usually older.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gigantiform Cementoma","termGroup":"PT","termSource":"NCI"},{"termName":"Expansive Osseous Dysplasia","termGroup":"AQS","termSource":"NCI"},{"termName":"Familial Gigantiform Cementoma","termGroup":"SY","termSource":"NCI"},{"termName":"FGC","termGroup":"AB","termSource":"NCI"},{"termName":"Florid Osseous Dysplasia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9275/0"},{"name":"Maps_To","value":"Florid osseous dysplasia"},{"name":"Maps_To","value":"Gigantiform cementoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3495361"}]}}{"C3287":{"preferredName":"Odontoma","code":"C3287","definitions":[{"definition":"A benign neoplasm of tooth origin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing, and painless hamartomatous tumor occurring in tooth-bearing areas of the jaws. According to the presence or absence of tooth-like structures, it is classified as complex type or compound type. Odontoma of complex type is characterized by the presence of enamel and dentin and the absence of tooth-like structures. It is treated with local excision. If it is incompletely removed, it may recur. Odontoma of compound type is characterized by the presence of tooth-like structures. It is treated by local excision. Recurrences have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibro-Odontoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroodontoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9280/0"},{"name":"Legacy Concept Name","value":"Odontoma"},{"name":"Maps_To","value":"9280/0"},{"name":"Maps_To","value":"Odontoma, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0028882"}]}}{"C3711":{"preferredName":"Compound Odontoma","code":"C3711","definitions":[{"definition":"A benign, slow growing, and painless hamartomatous tumor occurring in tooth-bearing areas of the jaws. It usually affects children and adolescents. It is characterized by the presence of tooth-like structures. Treatment consists of local excision. Recurrences have not been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Compound Odontoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9281/0"},{"name":"Legacy Concept Name","value":"Compound_Odontoma"},{"name":"Maps_To","value":"9281/0"},{"name":"Maps_To","value":"Compound odontoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0205866"}]}}{"C4309":{"preferredName":"Complex Odontoma","code":"C4309","definitions":[{"definition":"A benign, slow growing, and painless hamartomatous tumor occurring in tooth-bearing areas of the jaws. It is one of the most common odontogenic tumors and it usually affects children, adolescents, and young adults. It is characterized by the presence of enamel and dentin and the absence of tooth-like structures. It is treated with local excision. If it is incompletely removed, it may recur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complex Odontoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9282/0"},{"name":"Legacy Concept Name","value":"Complex_Odontoma"},{"name":"Maps_To","value":"9282/0"},{"name":"Maps_To","value":"Complex odontoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0334563"}]}}{"C3710":{"preferredName":"Ameloblastic Fibro-Odontoma","code":"C3710","definitions":[{"definition":"A benign neoplasm arising from tooth-forming tissues with-enamel organ differentiation (but without enamel formation).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare benign neoplasm arising from tooth-forming tissues. It is characterized by the presence of a fibromyxoid stroma, epithelial component, dentin, and enamel. Recurrences are rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibro-Odontoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ameloblastic Fibroodontoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroameloblastic Odontoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9290/0"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibro-Odontoma"},{"name":"Maps_To","value":"9290/0"},{"name":"Maps_To","value":"Ameloblastic fibro-odontoma"},{"name":"Maps_To","value":"Fibroameloblastic odontoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205865"}]}}{"C173740":{"preferredName":"Ameloblastic Fibro-Odontosarcoma","code":"C173740","definitions":[{"definition":"An odontogenic sarcoma producing enamel/enameloid and dentin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibro-Odontosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ameloblastic Fibroodontosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9290/3"},{"name":"Maps_To","value":"9290/3"},{"name":"Maps_To","value":"Ameloblastic fibro-odontosarcoma"},{"name":"Maps_To","value":"Ameloblastic odontosarcoma"},{"name":"Maps_To","value":"Odontogenic fibrosarcoma"},{"name":"NCI_META_CUI","value":"CL1407559"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4310":{"preferredName":"Adenomatoid Odontogenic Tumor","code":"C4310","definitions":[{"definition":"A benign, slow growing neoplasm arising from tooth-forming tissues. The vast majority of cases are intraosseous and most often grow in the maxilla. It is characterized by the presence of odontogenic epithelium which is embedded in a connective tissue stroma. Local excision is curative and recurrences are very rare.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenomatoid Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomatoid Odontogenic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"AOT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9300/0"},{"name":"Legacy Concept Name","value":"Adenomatoid_Odontogenic_Tumor"},{"name":"Maps_To","value":"9300/0"},{"name":"Maps_To","value":"Adenoameloblastoma"},{"name":"Maps_To","value":"Adenomatoid odontogenic tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334565"}]}}{"C54319":{"preferredName":"Calcifying Cystic Odontogenic Tumor","code":"C54319","definitions":[{"definition":"A benign, intraosseous or extraosseous cystic neoplasm arising from tooth-forming tissues. It is characterized by the presence of a cyst lined by an ameloblastoma-like epithelium and ghost cells formation. The ghost cells may undergo calcification. It is treated with enucleation. Few recurrences have been reported for intraosseous neoplasms whereas no recurrences have been reported for extraosseous neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcifying Cystic Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Calcifying Odontogenic Cyst","termGroup":"SY","termSource":"NCI"},{"termName":"Gorlin Cyst","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9301/0"},{"name":"Legacy Concept Name","value":"Calcifying_Cystic_Odontogenic_Tumor"},{"name":"Maps_To","value":"9301/0"},{"name":"Maps_To","value":"Calcifying odontogenic cyst"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Finding"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206740"}]}}{"C4311":{"preferredName":"Ghost Cell Odontogenic Carcinoma","code":"C4311","definitions":[{"definition":"A carcinoma usually arising from the maxilla and less often the mandible.  Symptoms include swelling and paresthesia.  It is characterized by the presence of rounded islands of malignant epithelial cells in a fibrous stroma and the benign features of calcifying cystic odontogenic tumor.  The clinical course varies from slow growing and locally invasive to rapidly growing and highly aggressive with metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ghost Cell Odontogenic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"GCOC","termGroup":"AB","termSource":"NCI"},{"termName":"Odontogenic Ghost Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9302/3"},{"name":"Legacy Concept Name","value":"Odontogenic_Ghost_Cell_Neoplasm"},{"name":"Maps_To","value":"9302/3"},{"name":"Maps_To","value":"Ghost cell odontogenic carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334566"}]}}{"C4313":{"preferredName":"Ameloblastoma","code":"C4313","definitions":[{"definition":"The most common odontogenic tumor, arising from the epithelial component of the embryonic tooth and usually affecting the molar-ramus region of the mandible or maxilla.  Although most ameloblastomas are morphologically and clinically benign, they may cause extensive local destruction, recur, or metastasize.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9310/0"},{"name":"Legacy Concept Name","value":"Ameloblastoma"},{"name":"Maps_To","value":"9310/0"},{"name":"Maps_To","value":"Ameloblastoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002448"}]}}{"C54297":{"preferredName":"Metastasizing Ameloblastoma","code":"C54297","definitions":[{"definition":"A malignant odontogenic neoplasm arising from the epithelial component of the embryonic tooth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, well differentiated, cytologically benign ameloblastoma which paradoxically metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasizing Ameloblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Ameloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9310/3"},{"name":"Legacy Concept Name","value":"Metastasizing_Ameloblastoma"},{"name":"Maps_To","value":"9310/3"},{"name":"Maps_To","value":"Ameloblastoma, malignant"},{"name":"Maps_To","value":"Ameloblastoma, metastasizing"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334567"}]}}{"C54317":{"preferredName":"Odontoameloblastoma","code":"C54317","definitions":[{"definition":"A rare, locally aggressive neoplasm arising from tooth-forming tissues. It occurs in the mandible and maxilla. It is characterized by the presence of odontogenic epithelium and adjacent myxoid tissue, fibrous stroma, and mineralized dental tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Odontoma","termGroup":"AQS","termSource":"NCI"},{"termName":"OA","termGroup":"AB","termSource":"NCI"},{"termName":"Odontoameloblastoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Odontoblastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9311/0"},{"name":"Legacy Concept Name","value":"Odontoameloblastoma"},{"name":"Maps_To","value":"9311/0"},{"name":"Maps_To","value":"Odontoameloblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704220"}]}}{"C7112":{"preferredName":"Squamous Odontogenic Tumor","code":"C7112","definitions":[{"definition":"A rare, locally invasive neoplasm arising from tooth-forming tissues. It usually grows intraosseously in the mandible. The maxilla is less frequently involved. It is characterized by the presence of well differentiated squamous cells which form islands. Recurrences may rarely occur and probably are related to incomplete excision of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"SOT","termGroup":"AB","termSource":"NCI"},{"termName":"Squamous Odontogenic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9312/0"},{"name":"Legacy Concept Name","value":"Squamous_Odontogenic_Tumor"},{"name":"Maps_To","value":"9312/0"},{"name":"Maps_To","value":"Squamous odontogenic tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1458142"}]}}{"C7501":{"preferredName":"Odontogenic Myxoma","code":"C7501","definitions":[{"definition":"An intraosseous odontogenic neoplasm with good prognosis, arising from the mandible and less frequently from the maxilla. It is characterized by the presence of stellate cells and abundant myxoid stroma formation. Small tumors may be cured with enucleation. Complete excision may be required for larger tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Myxoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9320/0"},{"name":"Legacy Concept Name","value":"Odontogenic_Myxoma"},{"name":"Maps_To","value":"9320/0"},{"name":"Maps_To","value":"Odontogenic myxoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334569"}]}}{"C7452":{"preferredName":"Odontogenic Myxofibroma","code":"C7452","definitions":[{"definition":"An intraosseous odontogenic neoplasm with good prognosis, arising from the mandible and less frequently from the maxilla. It is characterized by the presence of stellate cells, myxoid stroma formation, and prominent collagen. Small tumors may be cured with enucleation. Complete excision may be required for larger tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Myxofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Odontogenic_Myxofibroma"},{"name":"Maps_To","value":"9320/0"},{"name":"Maps_To","value":"Odontogenic myxofibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377940"}]}}{"C4314":{"preferredName":"Odontogenic Fibroma","code":"C4314","definitions":[{"definition":"A benign intraosseous neoplasm arising from tooth-forming tissues in the mandible and maxilla, characterized by the presence of islands of odontogenic epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rare, benign neoplasm arising from tooth-forming tissues in the mandible and maxilla (central odontogenic fibroma); and rarely from extraosseous tissues, usually in the gingiva (peripheral odontogenic fibroma). It is characterized by the presence of odontogenic epithelium that is embedded in a fibrous stroma. Local enucleation of the tumor is curative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"OdF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9321/0"},{"name":"Legacy Concept Name","value":"Odontogenic_Fibroma"},{"name":"Maps_To","value":"9321/0"},{"name":"Maps_To","value":"Odontogenic fibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260966"}]}}{"C202077":{"preferredName":"Central Odontogenic Fibroma","code":"C202077","definitions":[{"definition":"An odontogenic fibroma that arises from tooth-forming tissues in the mandible and maxilla.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Odontogenic Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9321/0"},{"name":"Maps_To","value":"Central odontogenic fibroma"},{"name":"NCI_META_CUI","value":"CL1921478"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4315":{"preferredName":"Peripheral Odontogenic Fibroma","code":"C4315","definitions":[{"definition":"A rare, benign, extraosseous neoplasm arising from tooth-forming tissues. It usually presents as a slow growing exophytic mass in the gingiva. It is characterized by the presence of odontogenic epithelium that is embedded in a fibrous stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Odontogenic Fibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9322/0"},{"name":"Legacy Concept Name","value":"Peripheral_Odontogenic_Fibroma"},{"name":"Maps_To","value":"9322/0"},{"name":"Maps_To","value":"Peripheral odontogenic fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334571"}]}}{"C4316":{"preferredName":"Ameloblastic Fibroma","code":"C4316","definitions":[{"definition":"A rare neoplasm arising from tooth-forming tissues. It usually arises from the posterior mandible. It is characterized by the presence of an epithelial component and fibromyxoid stroma. It may recur and rarely shows malignant transformation to ameloblastic fibrosarcoma. It is treated with enucleation and curettage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibrodentinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9330/0"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibroma"},{"name":"Maps_To","value":"9330/0"},{"name":"Maps_To","value":"Ameloblastic fibroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334572"}]}}{"C4317":{"preferredName":"Ameloblastic Fibrosarcoma","code":"C4317","definitions":[{"definition":"A locally aggressive malignant neoplasm arising from odontogenic tissue. It occurs in the mandible and less often in the maxilla.  It is characterized by the presence of a malignant connective tissue component and a benign epithelial component.  The frequency of distal metastases is low.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"AFS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9330/3"},{"name":"Legacy Concept Name","value":"Ameloblastic_Fibrosarcoma"},{"name":"Maps_To","value":"9330/3"},{"name":"Maps_To","value":"Ameloblastic fibrosarcoma"},{"name":"Maps_To","value":"Ameloblastic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334573"}]}}{"C54301":{"preferredName":"Calcifying Epithelial Odontogenic Tumor","code":"C54301","definitions":[{"definition":"A slow growing, locally invasive neoplasm arising from tooth-forming tissues. It most often grows intraosseously in the mandible and less frequently in the maxilla. In a minority of cases it grows extraosseously in the gingiva. It is characterized by the presence of a fibrous stroma, epithelial cells with abundant eosinophilic cytoplasm, and amyloid material which is often calcified. Small tumors may be successfully treated with enucleation. Local resection is usually required for larger tumors. Recurrences have been reported in a minority of cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcifying Epithelial Odontogenic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"CEOT","termGroup":"AB","termSource":"NCI"},{"termName":"Pindborg Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9340/0"},{"name":"Legacy Concept Name","value":"Calcifying_Epithelial_Odontogenic_Tumor"},{"name":"Maps_To","value":"9340/0"},{"name":"Maps_To","value":"Calcifying epithelial odontogenic tumor"},{"name":"Maps_To","value":"Pindborg tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334574"}]}}{"C54300":{"preferredName":"Clear Cell Odontogenic Carcinoma","code":"C54300","definitions":[{"definition":"A usually aggressive malignant neoplasm arising from tooth-forming tissues. It more often affects older females and more frequently occurs in the mandible. It is characterized by the presence of malignant epithelial cells with clear cytoplasm and a fibrotic stroma formation. It may recur and metastasize. Metastases may occur in the lymph nodes, lungs, and bones. Treatment of choice is resection with clean margins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Odontogenic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell Ameloblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Odontogenic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9341/1"},{"name":"ICD-O-3_Code","value":"9341/3"},{"name":"Legacy Concept Name","value":"Clear_Cell_Odontogenic_Carcinoma"},{"name":"Maps_To","value":"9341/1"},{"name":"Maps_To","value":"9341/3"},{"name":"Maps_To","value":"Clear cell odontogenic carcinoma"},{"name":"Maps_To","value":"Clear cell odontogenic tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0475829"}]}}{"C173735":{"preferredName":"Odontogenic Carcinosarcoma","code":"C173735","definitions":[{"definition":"An extremely rare malignant mixed odontogenic neoplasm in which both the epithelial and the mesenchymal components are cytologically malignant. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Carcinosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ameloblastic Carcinosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Odontogenic Mixed Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"OCS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9342/3"},{"name":"Maps_To","value":"Odontogenic carcinosarcoma"},{"name":"Maps_To","value":"Odontogenic Carcinosarcoma"},{"name":"NCI_META_CUI","value":"CL1407549"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C2964":{"preferredName":"Craniopharyngioma","code":"C2964","definitions":[{"definition":"A benign brain tumor that may be considered malignant because it can damage the hypothalamus, the area of the brain that controls body temperature, hunger, and thirst.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A benign epithelial neoplasm of the sellar region, presumably derived from Rathke pouch epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A histologically benign, but locally destructive, partly cystic, epithelial tumor of the sellar region, derived from Rathke pouch epithelium.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Craniopharyngioma","termGroup":"PT","termSource":"NCI"},{"termName":"Craniopharyngioma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Craniopharyngioma (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke's Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Rathke's Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Rathke's Pouch","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9350/1"},{"name":"Legacy Concept Name","value":"Craniopharyngioma"},{"name":"Maps_To","value":"9350/1"},{"name":"Maps_To","value":"Craniopharyngioma"},{"name":"Maps_To","value":"Neoplasm of uncertain or unknown behaviour: Craniopharyngeal duct"},{"name":"Maps_To","value":"Rathke pouch tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0010276"}]}}{"C4726":{"preferredName":"Adamantinomatous Craniopharyngioma","code":"C4726","definitions":[{"definition":"A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adamantinomatous Craniopharyngioma","termGroup":"PT","termSource":"NCI"},{"termName":"ACP","termGroup":"AB","termSource":"NCI"},{"termName":"Adamantinous Craniopharyngioma","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Neoplasm of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Rathke's Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Rathke's Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Adamantinous Tumor of Rathke's Pouch","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9351/1"},{"name":"Legacy Concept Name","value":"Adamantinous_Craniopharyngioma"},{"name":"Maps_To","value":"9351/1"},{"name":"Maps_To","value":"Craniopharyngioma, adamantinomatous"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431129"}]}}{"C4725":{"preferredName":"Papillary Craniopharyngioma","code":"C4725","definitions":[{"definition":"A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Craniopharyngioma","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Neoplasm of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Rathke Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Rathke's Pouch Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Rathke's Pouch Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Tumor of Rathke's Pouch","termGroup":"SY","termSource":"NCI"},{"termName":"PCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9352/1"},{"name":"Legacy Concept Name","value":"Papillary_Craniopharyngioma"},{"name":"Maps_To","value":"9352/1"},{"name":"Maps_To","value":"Craniopharyngioma, papillary"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431128"}]}}{"C3328":{"preferredName":"Pineal Region Neoplasm","code":"C3328","definitions":[{"definition":"A benign or malignant neoplasm that affects the pineal region.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor arising in the pineal region, the majority of which are malignant germ cell tumors. A minority of pinealomas are benign, and comprise neoplastic cells that resemble normal pineocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of brain tumor that occurs in or around the pineal gland, a tiny organ near the center of the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pineal Region Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of Pineal Region","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Pineal Region","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Area Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Area Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Body Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Body Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Region Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pinealoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Pineal Region","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Pineal Area","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Pineal Region","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pineal_Region_Neoplasm"},{"name":"Maps_To","value":"9360/1"},{"name":"Maps_To","value":"Pinealoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1412004"}]}}{"C6966":{"preferredName":"Pineocytoma","code":"C6966","definitions":[{"definition":"A WHO grade 1 slow growing tumor, more frequently affecting young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes. It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the brain arising from the pineal gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing, pineal parenchymal tumor that more frequently affects young adults.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A slow growing type of brain tumor that occurs in or around the pineal gland, a tiny organ near the center of the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pineocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pineocytoma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Pineocytoma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9361/1"},{"name":"Legacy Concept Name","value":"Pineocytoma"},{"name":"Maps_To","value":"9361/1"},{"name":"Maps_To","value":"Pineocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0917890"}]}}{"C6967":{"preferredName":"Pineal Parenchymal Tumor of Intermediate Differentiation","code":"C6967","definitions":[{"definition":"A WHO grade 2 or 3 pineal parenchymal neoplasm of intermediate-grade malignancy, affecting all ages.  It is composed of diffuse sheets or large lobules of uniform cells with mild to moderate nuclear atypia and low to moderate level mitotic activity.  (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pineal Parenchymal Tumor of Intermediate Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"PPTID","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pineal_Parenchymal_Tumor_of_Intermediate_Differentiation"},{"name":"Maps_To","value":"9362/3"},{"name":"Maps_To","value":"Pineal parenchymal tumor of intermediate differentiation"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367859"}]}}{"C9344":{"preferredName":"Pineoblastoma","code":"C9344","definitions":[{"definition":"A fast growing type of brain tumor that occurs in or around the pineal gland, a tiny organ near the center of the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region of the brain.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region.  It usually occurs in children and it is characterized by the presence of small immature neuroepithelial cells.  It may follow an aggressive clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pineoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pineal Gland PNET","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Gland Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Gland Primitive Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal PNET","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pineal Primitive Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pineoblastoma (WHO Grade 4)","termGroup":"SY","termSource":"NCI"},{"termName":"Pineoblastoma (WHO Grade IV)","termGroup":"SY","termSource":"NCI"},{"termName":"PNET of Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"PNET of the Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Neoplasm of Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Neoplasm of the Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Tumor of Pineal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Tumor of the Pineal Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9362/3"},{"name":"Legacy Concept Name","value":"Pineoblastoma"},{"name":"Maps_To","value":"9362/3"},{"name":"Maps_To","value":"Pineoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205898"}]}}{"C3717":{"preferredName":"Melanotic Neuroectodermal Tumor","code":"C3717","definitions":[{"definition":"A rare neoplasm usually occurring in infants.  It is characterized by the presence of a mixture of melanin-containing epithelial cells and smaller neuroblast-like cells.  It may involve the skull and facial bones, or the epididymis.  It usually has a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanotic Neuroectodermal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Infantile Melanotic Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Neuroectodermal Tumor of Infancy","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Progonoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MNTI","termGroup":"AB","termSource":"NCI"},{"termName":"Pigmented Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Retinal Anlage Neoplasm","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9363/0"},{"name":"Legacy Concept Name","value":"Infantile_Melanotic_Neuroectodermal_Neoplasm"},{"name":"Maps_To","value":"9363/0"},{"name":"Maps_To","value":"Melanoameloblastoma"},{"name":"Maps_To","value":"Melanotic neuroectodermal tumor"},{"name":"Maps_To","value":"Melanotic progonoma"},{"name":"Maps_To","value":"Retinal anlage tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206094"}]}}{"C3716":{"preferredName":"Primitive Neuroectodermal Tumor","code":"C3716","definitions":[{"definition":"A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of cancers that develop from the same type of early cells, and share certain biochemical and genetic features. Some PNETs develop in the brain and central nervous system (CNS-PNET), and others develop in sites outside of the brain such as the limbs, pelvis, and chest wall (peripheral PNET).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primitive Neuroectodermal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"PNET","termGroup":"AB","termSource":"NCI"},{"termName":"Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9473/3"},{"name":"ICD-O-3_Code","value":"9503/3"},{"name":"Legacy Concept Name","value":"Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9364/3"},{"name":"Maps_To","value":"9473/3"},{"name":"Maps_To","value":"9503/3"},{"name":"Maps_To","value":"Neuroectodermal tumor, NOS"},{"name":"Maps_To","value":"Neuroepithelioma, NOS"},{"name":"Maps_To","value":"PNET, NOS"},{"name":"Maps_To","value":"Primitive neuroectodermal tumor, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206663"}]}}{"C9341":{"preferredName":"Peripheral Primitive Neuroectodermal Tumor","code":"C9341","definitions":[{"definition":"A small round cell tumor with neural differentiation arising from the soft tissues or bone.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that forms in bone or soft tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peripheral Primitive Neuroectodermal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Peripheral Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neuroectodermal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neuroepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral PNET","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Primitive Neuroectodermal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"pPNET","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9364/3"},{"name":"Legacy Concept Name","value":"Peripheral_Primitive_Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9364/3"},{"name":"Maps_To","value":"Peripheral neuroectodermal tumor"},{"name":"Maps_To","value":"Peripheral primitive neuroectodermal tumor, NOS"},{"name":"Maps_To","value":"PPNET"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3489398"}]}}{"C7542":{"preferredName":"Askin Tumor","code":"C7542","definitions":[{"definition":"A primitive neuroectodermal tumor (small round blue cell tumor) of the thorax which can involve the periosteum, thoracic wall and/or pleura though it spares the lung parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Askin Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Askin's Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neuroectodermal Tumor of Thoracopulmonary Region","termGroup":"SY","termSource":"NCI"},{"termName":"PNET of Thoracopulmonary Region","termGroup":"SY","termSource":"NCI"},{"termName":"Small Cell Tumor of Thoracopulmonary Region","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9365/3"},{"name":"Legacy Concept Name","value":"Askin_s_Tumor"},{"name":"Maps_To","value":"9365/3"},{"name":"Maps_To","value":"Askin tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0877849"}]}}{"C2947":{"preferredName":"Chordoma","code":"C2947","definitions":[{"definition":"A malignant bone neoplasm arising from the remnants of the fetal notochord.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant bone tumor arising from the remnants of the fetal notochord. Although it can occur at all ages, it is more frequently seen in middle-aged adults. The most frequent sites of involvement are the sacrococcygeal area, spheno-occipital area, and cervico-thoraco-lumbar spine. Chordomas tend to recur and may metastasize. The most common sites of metastasis are lung, bone, lymph nodes, and subcutaneous tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A type of bone cancer that usually starts in the lower spinal column or at the base of the skull.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chordoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9370/3"},{"name":"Legacy Concept Name","value":"Chordoma"},{"name":"Maps_To","value":"9370/3"},{"name":"Maps_To","value":"Chordoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0008487"}]}}{"C6902":{"preferredName":"Chondroid Chordoma","code":"C6902","definitions":[{"definition":"A slow-growing malignant bone tumor arising from the remnants of the notochord and occurring in the base of the skull. The tumor is characterized by a lobulated growth pattern, myxoid stroma formation, and the presence of physaliphorous cells and cartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chondroid Chordoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9371/3"},{"name":"Legacy Concept Name","value":"Chondroid_Chordoma"},{"name":"Maps_To","value":"9371/3"},{"name":"Maps_To","value":"Chondroid chordoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266173"}]}}{"C48876":{"preferredName":"Dedifferentiated Chordoma","code":"C48876","definitions":[{"definition":"A high-grade malignant bone tumor arising from the remnants of the notochord. It is characterized by a lobulated growth pattern, myxoid stroma formation, the presence of physaliphorous cells, and a sarcomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dedifferentiated Chordoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcomatoid Chordoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9372/3"},{"name":"Legacy Concept Name","value":"Dedifferentiated_Chordoma"},{"name":"Maps_To","value":"9372/3"},{"name":"Maps_To","value":"Dedifferentiated chordoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266174"}]}}{"C6581":{"preferredName":"Parachordoma","code":"C6581","definitions":[{"definition":"A rare, usually benign myoepithelial tumor characterized by the presence of epithelioid, often vacuolated neoplastic cells. Most patients present with painless swelling in the subcutaneous or subfascial soft tissues of the extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parachordoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9373/0"},{"name":"ICD-O-3_Code","value":"9373/1"},{"name":"Legacy Concept Name","value":"Parachordoma"},{"name":"Maps_To","value":"9373/0"},{"name":"Maps_To","value":"Parachordoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266175"}]}}{"C4822":{"preferredName":"Malignant Glioma","code":"C4822","definitions":[{"definition":"A grade 3 or grade 4 glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neuroglial neoplasm. The term can apply to several primary neoplasm of the brain and spinal cord, including astrocytoma and oligodendroglioma in addition to others.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"High Grade Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Glial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neuroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neuroglial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9380/3"},{"name":"Legacy Concept Name","value":"Malignant_Glioma"},{"name":"Maps_To","value":"9380/3"},{"name":"Maps_To","value":"Glioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0555198"}]}}{"C4318":{"preferredName":"Gliomatosis Cerebri","code":"C4318","definitions":[{"definition":"A diffuse glial tumor which infiltrates the brain extensively, involving more than two lobes. It is frequently bilateral and often extends to the infratentorial structures, even to the spinal cord. It is probably of astrocytic origin, although GFAP expression may be scant or absent. (Adapted from WHO.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gliomatosis Cerebri","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytosis cerebri","termGroup":"SY","termSource":"NCI"},{"termName":"Gliomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9381/3"},{"name":"Legacy Concept Name","value":"Gliomatosis_Cerebri"},{"name":"Maps_To","value":"9381/3"},{"name":"Maps_To","value":"Gliomatosis cerebri"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334576"}]}}{"C4050":{"preferredName":"Oligoastrocytoma","code":"C4050","definitions":[{"definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A benign neoplasm of the central nervous system with an astrocytic and oligodendrocytic component.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A brain tumor that forms from both oligodendrocytes and astrocytes, which are types of glial cells (cells that cover and protect nerve cells in the brain and spinal cord and help them work the way they should). An oligoastrocytoma is a type of mixed glioma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Oligoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Astrocytic-Oligodendroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Astrocytic-Oligodendroglial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Astrocytoma-Oligodendroglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Oligo-Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 2 Mixed Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Mixed Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Astrocytoma-Oligodendroglioma"},{"name":"Maps_To","value":"9382/3"},{"name":"Maps_To","value":"Oligoastrocytoma"},{"name":"Maps_To","value":"Oligoastrocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280793"}]}}{"C3903":{"preferredName":"Mixed Glioma","code":"C3903","definitions":[{"definition":"A brain tumor that forms from more than one type of brain cell, usually astrocytes and oligodendrocytes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm comprising two or more glial cell types (e.g., astrocytes, ependymal cells, oligodendrocytes).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tumor composed of two or more glial cell types (astrocytes, ependymal cells, and oligodendrocytes).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Glial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Neuroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Neuroglial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9382/3"},{"name":"Legacy Concept Name","value":"Mixed_Glioma"},{"name":"Maps_To","value":"9382/3"},{"name":"Maps_To","value":"Mixed glioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259783"}]}}{"C6959":{"preferredName":"Anaplastic Oligoastrocytoma","code":"C6959","definitions":[{"definition":"An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Oligoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Mixed Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Mixed Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Mixed Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anaplastic_Oligoastrocytoma"},{"name":"Maps_To","value":"9382/3"},{"name":"Maps_To","value":"Anaplastic oligoastrocytoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431108"}]}}{"C3795":{"preferredName":"Subependymoma","code":"C3795","definitions":[{"definition":"A benign neoplasm of the brain localized in the vicinity of a ventricular wall and is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic changes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subependymoma","termGroup":"PT","termSource":"NCI"},{"termName":"Subependymal Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Subependymal Glioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 1 Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 1 Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade I Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade I Ependymal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9383/1"},{"name":"Legacy Concept Name","value":"Subependymoma"},{"name":"Maps_To","value":"9383/1"},{"name":"Maps_To","value":"Mixed subependymoma-ependymoma"},{"name":"Maps_To","value":"Subependymal glioma"},{"name":"Maps_To","value":"Subependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206725"}]}}{"C3696":{"preferredName":"Subependymal Giant Cell Astrocytoma","code":"C3696","definitions":[{"definition":"A benign, slowly growing tumor (WHO grade I) typically arising in the wall of the lateral ventricles and composed of large ganglioid astrocytes. It is the most common CNS neoplasm in patients with tuberous sclerosis complex and typically occurs during the first two decades of life. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subependymal Giant Cell Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"SEGA","termGroup":"AB","termSource":"NCI"},{"termName":"Subependymal Giant Cell Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Subependymal Giant Cell Astrocytic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9384/1"},{"name":"Legacy Concept Name","value":"Subependymal_Giant_Cell_Astrocytoma"},{"name":"Maps_To","value":"9384/1"},{"name":"Maps_To","value":"Subependymal giant cell astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205768"}]}}{"C129309":{"preferredName":"Diffuse Midline Glioma, H3 K27M-Mutant","code":"C129309","definitions":[{"definition":"A diffuse midline glioma characterized by the presence of histone H3 K27M mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Midline Glioma, H3 K27M-Mutant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9385/3"},{"name":"Maps_To","value":"Diffuse midline glioma, H3 K27M-mutant"},{"name":"NCI_META_CUI","value":"CL512144"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3698":{"preferredName":"Choroid Plexus Papilloma","code":"C3698","definitions":[{"definition":"A benign neoplasm of the choroid plexus of the central nervous system.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, slow growing tumor which may cause symptoms by blocking cerebrospinal fluid pathways.  It is characterized by the presence of delicate fibrovascular connective tissue fronds covered by a single layer of epithelial cells.  Mitotic activity is extremely low.  Surgical resection is usually curative. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choroid Plexus Papilloma","termGroup":"PT","termSource":"NCI"},{"termName":"Papilloma of Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Papilloma of the Choroid Plexus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9390/0"},{"name":"Legacy Concept Name","value":"Choroid_Plexus_Papilloma"},{"name":"Maps_To","value":"9390/0"},{"name":"Maps_To","value":"Choroid plexus papilloma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4012134"}]}}{"C53686":{"preferredName":"Atypical Choroid Plexus Papilloma","code":"C53686","definitions":[{"definition":"A choroid plexus papilloma characterized by increased mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Choroid Plexus Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9390/1"},{"name":"Legacy Concept Name","value":"Atypical_Choroid_Plexus_Papilloma"},{"name":"Maps_To","value":"9390/1"},{"name":"Maps_To","value":"Atypical choroid plexus papilloma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266176"}]}}{"C4715":{"preferredName":"Choroid Plexus Carcinoma","code":"C4715","definitions":[{"definition":"A malignant neoplasm arising from the choroid plexus of the brain.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choroid Plexus Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Choroid Plexus Papilloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Cancer of Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Choroid Plexus","termGroup":"SY","termSource":"NCI"},{"termName":"Choroid Plexus Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9390/3"},{"name":"Legacy Concept Name","value":"Choroid_Plexus_Carcinoma"},{"name":"Maps_To","value":"9390/3"},{"name":"Maps_To","value":"Choroid plexus carcinoma"},{"name":"Maps_To","value":"Choroid plexus papilloma, anaplastic"},{"name":"Maps_To","value":"Choroid plexus papilloma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431109"}]}}{"C6903":{"preferredName":"Tanycytic Ependymoma","code":"C6903","definitions":[{"definition":"A variant of ependymoma, often found in the spinal cord, with tumor cells arranged in fascicles of variable width and cell density. Ependymal rosettes are generally absent, so this lesion must be distinguished from astrocytic neoplasms, but its EM characteristics are ependymal. (Adapted from WHO.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tanycytic Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tanycytic_Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"Tanycytic ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370500"}]}}{"C4713":{"preferredName":"Cellular Ependymoma","code":"C4713","definitions":[{"definition":"An ependymoma which shows conspicuous cellularity without a significant increase in mitotic rate. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cellular_Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"Cellular ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384403"}]}}{"C4714":{"preferredName":"Clear Cell Ependymoma","code":"C4714","definitions":[{"definition":"An ependymoma, often supratentorial in location, characterized by the presence of ependymal cells with a perinuclear halo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clear_Cell_Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"Clear cell ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384404"}]}}{"C3017":{"preferredName":"Ependymoma","code":"C3017","definitions":[{"definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from WHO"}]},{"definition":"A malignant neoplasm arising from ependymal cells that line the ventricles of the brain and the central canal of the spinal cord.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A type of brain tumor that begins in cells lining the spinal cord central canal (fluid-filled space down the center) or the ventricles (fluid-filled spaces of the brain). Ependymomas may also form in the choroid plexus (tissue in the ventricles that makes cerebrospinal fluid).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ependymoma","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Grade 2 Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 2 Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Ependymal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9391/3"},{"name":"Legacy Concept Name","value":"Ependymoma"},{"name":"Maps_To","value":"9391/3"},{"name":"Maps_To","value":"CNS, ependymoma"},{"name":"Maps_To","value":"Ependymoma"},{"name":"Maps_To","value":"Ependymoma, NOS"},{"name":"Maps_To","value":"Epithelial ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0014474"}]}}{"C4049":{"preferredName":"Anaplastic Ependymoma","code":"C4049","definitions":[{"definition":"A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Ependymoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Anaplastic Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Ependymoma with Anaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ependymoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Ependymoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Ependymal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Ependymal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Ependymal Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9392/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Ependymoma"},{"name":"Maps_To","value":"9392/3"},{"name":"Maps_To","value":"Ependymoma, anaplastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280788"}]}}{"C4915":{"preferredName":"Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","code":"C4915","definitions":[{"definition":"An aggressive embryonal tumor with multilayered rosettes characterized by the presence of amplification of the C19MC region on chromosome 19 (19q13.42).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonal Tumor with Abundant Neuropil and True Rosettes","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Tumor with Multilayered Rosettes","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonal Tumor with Multilayered Rosettes with C19MC Amplification","termGroup":"SY","termSource":"NCI"},{"termName":"Ependymoblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"ETMR, C19MC-Altered","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ependymoblastoma"},{"name":"Maps_To","value":"9392/3"},{"name":"Maps_To","value":"9478/3"},{"name":"Maps_To","value":"Embryonal tumor with multilayered rosettes C19MC-altered"},{"name":"Maps_To","value":"Embryonal tumor with multilayered rosettes with C19MC alteration"},{"name":"Maps_To","value":"Ependymoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0700367"}]}}{"C4319":{"preferredName":"Papillary Ependymoma","code":"C4319","definitions":[{"definition":"A rare variant of ependymoma characterized by well formed papillae. Tumor cell processes abutting capillaries are usually GFAP-positive. Differential diagnoses include choroid plexus papilloma, papillary meningioma and metastatic papillary carcinoma. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9393/3"},{"name":"Legacy Concept Name","value":"Papillary_Ependymoma"},{"name":"Maps_To","value":"9393/3"},{"name":"Maps_To","value":"Papillary ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334578"}]}}{"C3697":{"preferredName":"Myxopapillary Ependymoma","code":"C3697","definitions":[{"definition":"A benign neoplasm of ependymal origin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A slow growing, WHO grade I glioma which generally occurs in young adults.  It arises almost exclusively in the conus medullaris, cauda equina, and filum terminale of the spinal cord. It generally has a favorable prognosis and is characterized histologically by tumor cells arranged in a papillary manner around vascularized mucoid stromal cores. (Adapted from WHO).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myxopapillary Ependymoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9394/1"},{"name":"Legacy Concept Name","value":"Myxopapillary_Ependymoma"},{"name":"Maps_To","value":"9394/1"},{"name":"Maps_To","value":"Myxopapillary ependymoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205769"}]}}{"C92624":{"preferredName":"Papillary Tumor of the Pineal Region","code":"C92624","definitions":[{"definition":"A rare tumor that arises from the pineal region and affects adults.  It is characterized by the presence of neuroepithelial cells and a papillary architecture.  Electron microscopic studies suggest ependymal differentiation.  The clinical course is variable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Tumor of the Pineal Region","termGroup":"PT","termSource":"NCI"},{"termName":"PTPR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9395/3"},{"name":"Maps_To","value":"9395/3"},{"name":"Maps_To","value":"Papillary tumor of pineal region"},{"name":"Maps_To","value":"Papillary tumor of the pineal region"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985219"}]}}{"C129351":{"preferredName":"Supratentorial Ependymoma, ZFTA-RELA Fusion-Positive","code":"C129351","definitions":[{"definition":"A supratentorial ependymoma characterized by a gene fusion involving ZFTA and RELA genes. It accounts for the majority of supratentorial ependymomas in children. It has an unfavorable outcome when compared to other ependymoma subtypes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supratentorial Ependymoma, ZFTA-RELA Fusion-Positive","termGroup":"PT","termSource":"NCI"},{"termName":"Ependymoma, RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Ependymoma, ZFTA-RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Supratentorial Ependymoma, RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Supratentorial Ependymoma, ZFTA::RELA Fusion-Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9396/3"},{"name":"Maps_To","value":"Ependymoma, RELA fusion positive"},{"name":"Maps_To","value":"Ependymoma, RELA fusion-positive"},{"name":"NCI_META_CUI","value":"CL512399"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6958":{"preferredName":"Astrocytic Tumor","code":"C6958","definitions":[{"definition":"A glial tumor of the brain or spinal cord showing astrocytic differentiation.  It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and glioblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Astroglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Astrocytic_Tumor"},{"name":"Maps_To","value":"9400/3"},{"name":"Maps_To","value":"Astrocytic glioma"},{"name":"Maps_To","value":"Astroglioma"},{"name":"NCI_META_CUI","value":"CL357919"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7173":{"preferredName":"Diffuse Astrocytoma","code":"C7173","definitions":[{"definition":"A low-grade (WHO grade 2) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant astrocytic neoplasm characterized by a high degree of cellular differentiation, slow growth, and diffuse infiltration of neighboring brain structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Diffuse Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 2 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade II Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Astrocytoma"},{"name":"Maps_To","value":"9400/3"},{"name":"Maps_To","value":"Astrocytoma, low grade"},{"name":"Maps_To","value":"Cystic astrocytoma"},{"name":"Maps_To","value":"Diffuse astrocytoma"},{"name":"Maps_To","value":"Diffuse astrocytoma, low grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280785"}]}}{"C60781":{"preferredName":"Astrocytoma","code":"C60781","definitions":[{"definition":"A malignant neoplasm of the central nervous system that arises from astrocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor that begins in the brain or spinal cord in small, star-shaped cells called astrocytes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9400/3"},{"name":"Legacy Concept Name","value":"Astrocytoma"},{"name":"Maps_To","value":"9400/3"},{"name":"Maps_To","value":"Astrocytoma"},{"name":"Maps_To","value":"Astrocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0004114"}]}}{"C9477":{"preferredName":"Anaplastic Astrocytoma","code":"C9477","definitions":[{"definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 3 Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 3 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9401/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Astrocytoma"},{"name":"Maps_To","value":"9401/3"},{"name":"Maps_To","value":"Astrocytoma, anaplastic"},{"name":"Maps_To","value":"Astrocytoma, anaplastic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334579"}]}}{"C4320":{"preferredName":"Protoplasmic Astrocytoma","code":"C4320","definitions":[{"definition":"A rare variant of diffuse astrocytoma. It is predominantly composed of neoplastic astrocytes showing a small cell body with few, flaccid processes with a low content of glial filaments and scant GFAP expression. This lesion is not well defined and is considered by some authors as an occasional histopathological feature rather than a reproducibly identifiable variant. When occurring in children, this neoplasm may be difficult to separate from pilocytic juvenile astrocytoma. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protoplasmic Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9410/3"},{"name":"Legacy Concept Name","value":"Protoplasmic_Astrocytoma"},{"name":"Maps_To","value":"9410/3"},{"name":"Maps_To","value":"Protoplasmic astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334580"}]}}{"C4321":{"preferredName":"Gemistocytic Astrocytoma","code":"C4321","definitions":[{"definition":"A rare variant of diffuse astrocytoma. It is characterized by the presence of a conspicuous, though variable, fraction of gemistocytic neoplastic astrocytes. Gemistocytes are round to oval astrocytes with abundant, glassy, non-fibrillary cytoplasm which appears to displace the dark, angulated nucleus to the periphery of the cell. To make the diagnosis of gemistocytic astrocytoma, gemistocytes should amount to more than approximately 20% of all tumor cells. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemistocytic Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Gemistocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9411/3"},{"name":"Legacy Concept Name","value":"Gemistocytic_Astrocytoma"},{"name":"Maps_To","value":"9411/3"},{"name":"Maps_To","value":"Gemistocytic astrocytoma"},{"name":"Maps_To","value":"Gemistocytic astrocytoma, NOS"},{"name":"Maps_To","value":"Gemistocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334581"}]}}{"C9476":{"preferredName":"Desmoplastic Infantile Astrocytoma","code":"C9476","definitions":[{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, and which involves the superficial cerebral cortex and leptomeninges.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population consisting mainly of neoplastic astrocytes. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura. Although clinically it presents as large tumor, it generally has a good prognosis following surgical resection. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic Infantile Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Desmoplastic Astrocytoma of Infancy","termGroup":"SY","termSource":"NCI"},{"termName":"DIA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9412/1"},{"name":"Legacy Concept Name","value":"Desmoplastic_Infantile_Astrocytoma"},{"name":"Maps_To","value":"9412/1"},{"name":"Maps_To","value":"Desmoplastic infantile astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0457179"}]}}{"C4738":{"preferredName":"Desmoplastic Infantile Ganglioglioma","code":"C4738","definitions":[{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population of neoplastic astrocytes together with a variable neuronal component. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura. Although clinically it presents as a large tumor, it generally has a good prognosis following surgical resection. (Adapted from WHO)","type":"DEFINITION","source":"NCI"},{"definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Desmoplastic Infantile Ganglioglioma","termGroup":"PT","termSource":"NCI"},{"termName":"DIG","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Desmoplastic_Infantile_Ganglioglioma"},{"name":"Maps_To","value":"9412/1"},{"name":"Maps_To","value":"Desmoplastic infantile ganglioglioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321878"}]}}{"C9505":{"preferredName":"Dysembryoplastic Neuroepithelial Tumor","code":"C9505","definitions":[{"definition":"A glial-neuronal neoplasm located in the cortex. It occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dysembryoplastic Neuroepithelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"DNET","termGroup":"AQS","termSource":"NCI"},{"termName":"DNT","termGroup":"AB","termSource":"NCI"},{"termName":"Dysembryoplastic Neuroepithelial Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9413/0"},{"name":"Legacy Concept Name","value":"Dysembryoplastic_Neuroepithelial_Tumor"},{"name":"Maps_To","value":"9413/0"},{"name":"Maps_To","value":"Dysembryoplastic neuroepithelial tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266177"}]}}{"C4322":{"preferredName":"Fibrillary Astrocytoma","code":"C4322","definitions":[{"definition":"The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrillary Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9420/3"},{"name":"Legacy Concept Name","value":"Fibrillary_Astrocytoma"},{"name":"Maps_To","value":"9420/3"},{"name":"Maps_To","value":"Fibrillary astrocytoma"},{"name":"Maps_To","value":"Fibrous astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334582"}]}}{"C4047":{"preferredName":"Pilocytic Astrocytoma","code":"C4047","definitions":[{"definition":"A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilocytic Astrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Astrocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9421/1"},{"name":"Legacy Concept Name","value":"Pilocytic_Astrocytoma"},{"name":"Maps_To","value":"9421/1"},{"name":"Maps_To","value":"Pilocytic astrocytoma"},{"name":"Maps_To","value":"Piloid astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334583"}]}}{"C9022":{"preferredName":"Childhood Astrocytic Tumor","code":"C9022","definitions":[{"definition":"An astrocytic tumor appearing before the age of twenty one without designation of benign or malignant nor designated location.","type":"DEFINITION","source":"NCI"},{"definition":"An astrocytic tumor arising during childhood, without designation of benign or malignant, nor a designated location.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood Astrocytic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytic Tumors, Childhood","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Astrocytic Tumour","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Astrocytic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Astrocytic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Childhood_Astrocytic_Tumor"},{"name":"Maps_To","value":"9421/1"},{"name":"Maps_To","value":"Juvenile astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321865"}]}}{"C66801":{"preferredName":"Polar Spongioblastoma","code":"C66801","definitions":[{"definition":"A lesion characterized by the presence of neoplastic neuroepithelial cells with palisading nuclei. This lesion implies a morphologic growth pattern and it is not considered a clinicopathological entity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polar Spongioblastoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9423/3"},{"name":"Legacy Concept Name","value":"Polar_Spongioblastoma"},{"name":"Maps_To","value":"9423/3"},{"name":"Maps_To","value":"Polar spongioblastoma"},{"name":"Maps_To","value":"Spongioblastoma polare"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334589"}]}}{"C4323":{"preferredName":"Pleomorphic Xanthoastrocytoma","code":"C4323","definitions":[{"definition":"A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleomorphic Xanthoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pleomorphic Xantho-Astrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"PXA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9424/3"},{"name":"Legacy Concept Name","value":"Pleomorphic_Xanthoastrocytoma"},{"name":"Maps_To","value":"9424/3"},{"name":"Maps_To","value":"Pleomorphic xanthoastrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334586"}]}}{"C40315":{"preferredName":"Pilomyxoid Astrocytoma","code":"C40315","definitions":[{"definition":"An astrocytic tumor of uncertain relation to pilocytic astrocytoma.  It occurs predominantly in infants and young children.  It is characterized by a monomorphic architectural pattern, usually associated with the absence of Rosenthal fibers and eosinophilic granular bodies.  The clinical course is usually aggressive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilomyxoid Astrocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9425/3"},{"name":"Legacy Concept Name","value":"Pilomyxoid_Astrocytoma"},{"name":"Maps_To","value":"9425/3"},{"name":"Maps_To","value":"Pilomyxoid astrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1519086"}]}}{"C4324":{"preferredName":"Astroblastoma, MN1-Altered","code":"C4324","definitions":[{"definition":"A rare glial neoplasm characterized by structural rearrangements of the MN1 gene at chromosome band 22q12.1. It is usually found in the cerebral hemispheres of young adults and children and predominantly affects females. Morphologically, it consists of elongated glial cells with abundant eosinophilic cytoplasm and GFAP-positive processes, arranged perivascularly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astroblastoma, MN1-Altered","termGroup":"PT","termSource":"NCI"},{"termName":"Astroblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9430/3"},{"name":"Legacy Concept Name","value":"Astroblastoma"},{"name":"Maps_To","value":"9430/3"},{"name":"Maps_To","value":"Astroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334587"}]}}{"C92552":{"preferredName":"Angiocentric Glioma","code":"C92552","definitions":[{"definition":"A WHO grade 1, slow-growing brain neoplasm of children and young adults, associated with epilepsy.  Morphologically it is characterized by an angiocentric pattern, monomorphic cellular infiltrate, and ependymal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiocentric Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiocentric Glioma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Angiocentric Glioma (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Angiocentric Neuroepithelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Monomorphus Angiocentric Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9431/1"},{"name":"Maps_To","value":"9431/1"},{"name":"Maps_To","value":"Angiocentric glioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2363903"}]}}{"C94524":{"preferredName":"Pituicytoma","code":"C94524","definitions":[{"definition":"A benign neoplasm arising from the posterior lobe of the pituitary gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An extremely rare, WHO grade 1, circumscribed and slow-growing tumor that arises from the neurohypophysis or infundibulum and described in adults.  It is characterized by the presence of elongated, spindle-shaped neoplastic glial cells that form storiform patterns or interlacing fascicular arrangements.  Signs and symptoms include visual disturbances, headache, amenorrhea, and decreased libido.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pituicytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Pituicytoma (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Pituicytoma (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Posterior Pituitary Astrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9432/1"},{"name":"Maps_To","value":"9432/1"},{"name":"Maps_To","value":"Pituicytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2986550"}]}}{"C3058":{"preferredName":"Glioblastoma","code":"C3058","definitions":[{"definition":"A fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. GBM usually occurs in adults and affects the brain more often than the spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"GBM","termGroup":"AB","termSource":"NCI"},{"termName":"GBM (Glioblastoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Glioblastoma Multiforme","termGroup":"AQS","termSource":"NCI"},{"termName":"Spongioblastoma Multiforme","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Glioblastoma is not an astrocytoma. It is an astrocytic tumor. The latter includes astrocytomas and glioblastomas.  However, when an anaplastic astrocytoma progresses to grade IV tumor, it is called a glioblastoma."},{"name":"ICD-O-3_Code","value":"9440/3"},{"name":"Legacy Concept Name","value":"Glioblastoma"},{"name":"Maps_To","value":"01"},{"name":"Maps_To","value":"02"},{"name":"Maps_To","value":"03"},{"name":"Maps_To","value":"04"},{"name":"Maps_To","value":"10"},{"name":"Maps_To","value":"20"},{"name":"Maps_To","value":"62"},{"name":"Maps_To","value":"9440/3"},{"name":"Maps_To","value":"CNS, glioblastoma (GBM)"},{"name":"Maps_To","value":"Glioblastoma"},{"name":"Maps_To","value":"Glioblastoma multiforme"},{"name":"Maps_To","value":"Glioblastoma, NOS"},{"name":"Maps_To","value":"Spongioblastoma multiforme"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017636"}]}}{"C4325":{"preferredName":"Giant Cell Glioblastoma","code":"C4325","definitions":[{"definition":"A rare histological variant of glioblastoma with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network, and a high frequency of TP53 mutations. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giant Cell Glioblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9441/3"},{"name":"Legacy Concept Name","value":"Giant_Cell_Glioblastoma"},{"name":"Maps_To","value":"9441/3"},{"name":"Maps_To","value":"Giant cell glioblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334588"}]}}{"C5419":{"preferredName":"Gliofibroma","code":"C5419","definitions":[{"definition":"An astrocytic tumor affecting young people.  Morphologically, it is characterized by the presence of collagenous tissue surrounding neoplastic astrocytes.  In some cases the collagen is produced by the tumor cells (desmoplastic astrocytoma), whereas in others it is produced by mesenchymal cells (mixed glioma/fibroma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gliofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9442/1"},{"name":"Legacy Concept Name","value":"Gliofibroma"},{"name":"Maps_To","value":"9442/1"},{"name":"Maps_To","value":"Gliofibroma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266178"}]}}{"C3796":{"preferredName":"Gliosarcoma","code":"C3796","definitions":[{"definition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","type":"DEFINITION","source":"NCI"},{"definition":"A type of glioma (cancer of the brain that comes from glial, or supportive, cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gliosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Glioblastoma with a Sarcomatous Component","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9442/3"},{"name":"Legacy Concept Name","value":"Gliosarcoma"},{"name":"Maps_To","value":"9442/3"},{"name":"Maps_To","value":"Glioblastoma with sarcomatous component"},{"name":"Maps_To","value":"Gliosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206726"}]}}{"C5592":{"preferredName":"Chordoid Glioma","code":"C5592","definitions":[{"definition":"A rare, slow-growing neuroepithelial neoplasm of uncertain origin affecting adults. It is located in the third ventricle. It is characterized by the presence of epithelioid cells which express GFAP, and mucinous stroma which contains lymphoplasmacytic infiltrates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chordoid Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"Chordoid Glioma of 3rd Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the 3rd Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the Third Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the Third Ventricle (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of the Third Ventricle (WHO Grade II)","termGroup":"SY","termSource":"NCI"},{"termName":"Chordoid Glioma of Third Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Third Ventricle Chordoid Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9444/1"},{"name":"Legacy Concept Name","value":"Chordoid_Glioma"},{"name":"Maps_To","value":"9444/1"},{"name":"Maps_To","value":"Chordoid glioma"},{"name":"Maps_To","value":"Chordoid glioma of third ventricle"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1322252"}]}}{"C167335":{"preferredName":"Astrocytoma, IDH-Mutant, Grade 4","code":"C167335","definitions":[{"definition":"IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytoma, IDH-Mutant, Grade 4","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytoma, IDH-Mutant, Grade IV","termGroup":"SY","termSource":"NCI"},{"termName":"Glioblastoma, IDH-Mutant","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9445/3"},{"name":"Maps_To","value":"Glioblastoma, IDH-mutant"},{"name":"NCI_META_CUI","value":"CL972314"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129319":{"preferredName":"Oligodendroglioma, Not Otherwise Specified","code":"C129319","definitions":[{"definition":"A central nervous system tumor with morphological features of oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligodendroglioma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Oligodendroglioma, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9450/3"},{"name":"Maps_To","value":"Oligodendroglioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2732301"}]}}{"C4326":{"preferredName":"Anaplastic Oligodendroglioma","code":"C4326","definitions":[{"definition":"A WHO grade 3 oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Oligodendroglioma","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Oligodendroglioma","termGroup":"SY","termSource":"NCI"},{"termName":"Oligodendroglioma, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Oligodendroglioma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Oligodendroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade 3 Oligodendroglial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Oligodendroglial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Oligodendroglial Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9451/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Oligodendroglioma"},{"name":"Maps_To","value":"9451/3"},{"name":"Maps_To","value":"Oligodendroglioma, anaplastic"},{"name":"Maps_To","value":"Oligodendroglioma, anaplastic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334590"}]}}{"C66802":{"preferredName":"Oligodendroblastoma","code":"C66802","definitions":[{"definition":"An obsolete term referring to neoplasms arising from oligodendrocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligodendroblastoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9460/3"},{"name":"Legacy Concept Name","value":"Oligodendroblastoma"},{"name":"Maps_To","value":"9460/3"},{"name":"Maps_To","value":"Oligodendroblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0344461"}]}}{"C9497":{"preferredName":"Melanocytic Medulloblastoma","code":"C9497","definitions":[{"definition":"A rare malignant embryonal neoplasm characterized by the presence of small cells which resemble the cells of classic medulloblastoma and a minor population of melanin-forming neuroepithelial cells.  It usually has an unfavorable clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanocytic Medulloblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Medulloblastoma with Melanotic Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanotic_Medulloblastoma"},{"name":"Maps_To","value":"9470/3"},{"name":"Maps_To","value":"Melanotic medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275668"}]}}{"C5407":{"preferredName":"Medulloblastoma with Extensive Nodularity","code":"C5407","definitions":[{"definition":"A medulloblastoma characterized by nodularity and neuronal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma with Extensive Nodularity","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebellar Neuroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Medulloblastoma with Extensive Nodularity and Advanced Neuronal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9471/3"},{"name":"Legacy Concept Name","value":"Nodular_Medulloblastoma"},{"name":"Maps_To","value":"9471/3"},{"name":"Maps_To","value":"Medulloblastoma with extensive nodularity"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334970"}]}}{"C4956":{"preferredName":"Desmoplastic/Nodular Medulloblastoma","code":"C4956","definitions":[{"definition":"A medulloblastoma characterized by the presence of nodular, collagenous areas which do not contain reticulin, surrounded by hypercellular areas which contain an intercellular reticulin fiber network.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Desmoplastic/Nodular Medulloblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Desmoplastic Medulloblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Desmoplastic Nodular Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9471/3"},{"name":"Legacy Concept Name","value":"Desmoplastic_Medulloblastoma"},{"name":"Maps_To","value":"9471/3"},{"name":"Maps_To","value":"Circumscribed arachnoidal cerebellar sarcoma"},{"name":"Maps_To","value":"Desmoplastic medulloblastoma"},{"name":"Maps_To","value":"Desmoplastic nodular medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751291"}]}}{"C3706":{"preferredName":"Medullomyoblastoma","code":"C3706","definitions":[{"definition":"A rare malignant embryonal neoplasm arising from the cerebellum.  It is characterized by the morphologic features of a medulloblastoma and the presence of a striated muscle component.  Its clinical behavior is similar to medulloblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medullomyoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Medullomyoblastoma with Myogenic Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9472/3"},{"name":"Legacy Concept Name","value":"Medullomyoblastoma"},{"name":"Maps_To","value":"9472/3"},{"name":"Maps_To","value":"Medullomyoblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205833"}]}}{"C6968":{"preferredName":"Supratentorial Embryonal Tumor, Not Otherwise Specified","code":"C6968","definitions":[{"definition":"A central nervous system embryonal tumor, not otherwise specified arising from the supratentorial region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supratentorial Embryonal Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"CNS/Supratentorial PNET","termGroup":"AQS","termSource":"NCI"},{"termName":"Supratentorial Embryonal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Supratentorial PNET","termGroup":"AQS","termSource":"NCI"},{"termName":"Supratentorial Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supratentorial_Primitive_Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9473/3"},{"name":"Maps_To","value":"Supratentorial PNET"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336538"}]}}{"C5398":{"preferredName":"Central Nervous System Embryonal Tumor, Not Otherwise Specified","code":"C5398","definitions":[{"definition":"A term that refers to central nervous system embryonal tumors which are not fully characterized.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that arises from a particular type of cell within the brain or spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Central Nervous System Embryonal Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Embryonal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System PNET","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Primitive Neuroectodermal Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Primitive Neuroectodermal Tumor (WHO Grade IV)","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Primitive Neuroectodermal Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"CNS Embryonal Tumor, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Embryonal Tumor, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"CNS PNET","termGroup":"AB","termSource":"NCI"},{"termName":"CNS Primitive Neuroectodermal Neoplasm","termGroup":"AQS","termSource":"NCI"},{"termName":"CNS Primitive Neuroectodermal Tumor","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Primitive_Neuroectodermal_Tumor"},{"name":"Maps_To","value":"9473/3"},{"name":"Maps_To","value":"Central primitive neuroectodermal tumor, NOS"},{"name":"Maps_To","value":"CPNET"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3887678"}]}}{"C92625":{"preferredName":"Anaplastic Medulloblastoma","code":"C92625","definitions":[{"definition":"A medulloblastoma characterized by marked nuclear pleomorphism, and high mitotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9474/3"},{"name":"Maps_To","value":"9474/3"},{"name":"Maps_To","value":"Anaplastic medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985220"}]}}{"C6904":{"preferredName":"Large Cell Medulloblastoma","code":"C6904","definitions":[{"definition":"A medulloblastoma composed of large cells with prominent nucleoli and a larger amount of cytoplasm in contrast with the cells of the classic medulloblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Large Cell Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9474/3"},{"name":"Legacy Concept Name","value":"Large_Cell_Medulloblastoma"},{"name":"Maps_To","value":"9474/3"},{"name":"Maps_To","value":"Large cell medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266180"}]}}{"C129442":{"preferredName":"Medulloblastoma, SHH-Activated, TP53-Mutant","code":"C129442","definitions":[{"definition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the presence of TP53 mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, SHH-Activated, TP53-Mutant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9476/3"},{"name":"Maps_To","value":"Medulloblastoma, SHH-activated and TP53-mutant"},{"name":"NCI_META_CUI","value":"CL512715"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C186534":{"preferredName":"Embryonal Tumor with Multilayered Rosettes","code":"C186534","definitions":[{"definition":"A central nervous system embryonal tumor characterized by the presence of multilayered rosette formation and typically the presence of amplification of the C19MC region on chromosome 19 (19q13.42) or rarely a DICER1 mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonal Tumor with Multilayered Rosettes","termGroup":"PT","termSource":"NCI"},{"termName":"ETMR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9478/3"},{"name":"Maps_To","value":"Embryonal tumor with multilayered rosettes, NOS"},{"name":"NCI_META_CUI","value":"CL1778829"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C66803":{"preferredName":"Cerebellar Sarcoma","code":"C66803","definitions":[{"definition":"An obsolete term referring to desmoplastic medulloblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebellar Sarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9480/3"},{"name":"Legacy Concept Name","value":"Cerebellar_Sarcoma"},{"name":"Maps_To","value":"9480/3"},{"name":"Maps_To","value":"Cerebellar sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334592"}]}}{"C3049":{"preferredName":"Ganglioneuroma","code":"C3049","definitions":[{"definition":"A benign neoplasm characterized by the presence of ganglion cells and spindle cell proliferation, located primarily in the brain, ganglia, or adrenal medulla.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign neuroblastic tumor of the sympathetic nervous system that occurs in childhood. Ganglioneuroma typically arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. Common presenting features include a palpable abdominal mass, hepatomegaly, and a thoracic mass detected on routine chest X-ray.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioneuroma","termGroup":"PT","termSource":"NCI"},{"termName":"Ganglioneuroma (Schwannian Stroma-Dominant)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9490/0"},{"name":"Legacy Concept Name","value":"Ganglioneuroma"},{"name":"Maps_To","value":"9490/0"},{"name":"Maps_To","value":"Ganglioneuroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0017075"}]}}{"C3790":{"preferredName":"Ganglioneuroblastoma","code":"C3790","definitions":[{"definition":"A malignant neoplasm characterized by the presence of neuroblastic and ganglion cells and a stroma with Schwannian differentiation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume.  There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioneuroblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9490/3"},{"name":"Legacy Concept Name","value":"Ganglioneuroblastoma"},{"name":"Maps_To","value":"9490/3"},{"name":"Maps_To","value":"Ganglioneuroblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206718"}]}}{"C66804":{"preferredName":"Ganglioneuromatosis","code":"C66804","definitions":[{"definition":"Extensive and diffuse infiltration of tissues by ganglioneuroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioneuromatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9491/0"},{"name":"Legacy Concept Name","value":"Ganglioneuromatosis"},{"name":"Maps_To","value":"9491/0"},{"name":"Maps_To","value":"Ganglioneuromatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334595"}]}}{"C6934":{"preferredName":"Gangliocytoma","code":"C6934","definitions":[{"definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gangliocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9492/0"},{"name":"Legacy Concept Name","value":"Gangliocytoma"},{"name":"Maps_To","value":"9492/0"},{"name":"Maps_To","value":"Gangliocytoma"},{"name":"Maps_To","value":"Gangliocytoma, NOS"},{"name":"NCI_META_CUI","value":"CL378224"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8419":{"preferredName":"Dysplastic Cerebellar Gangliocytoma","code":"C8419","definitions":[{"definition":"A benign, WHO grade I cerebellar mass, which occurs in young adults and is composed of dysplastic ganglion cells.  It is the major CNS manifestation of Cowden disease, an autosomal dominant condition that causes a variety of hamartomas and neoplasms.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from WHO"}]}],"synonyms":[{"termName":"Dysplastic Cerebellar Gangliocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease)","termGroup":"SY","termSource":"NCI"},{"termName":"Dysplastic Gangliocytoma of Cerebellum","termGroup":"SY","termSource":"NCI"},{"termName":"Dysplastic Gangliocytoma of the Cerebellum","termGroup":"SY","termSource":"NCI"},{"termName":"Lhermitte-Duclos Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9493/0"},{"name":"Legacy Concept Name","value":"Dysplastic_Cerebellar_Gangliocytoma"},{"name":"Maps_To","value":"9493/0"},{"name":"Maps_To","value":"Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0391826"}]}}{"C3270":{"preferredName":"Neuroblastoma","code":"C3270","definitions":[{"definition":"A malignant neoplasm composed of neuroblastic cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm comprised of neuroblasts that commonly arises in or near the adrenal glands.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that arises in immature nerve cells and affects mostly infants and children.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Neuroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Neuroblastoma (Schwannian Stroma-Poor)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9500/3"},{"name":"Legacy Concept Name","value":"Neuroblastoma"},{"name":"Maps_To","value":"9500/3"},{"name":"Maps_To","value":"Central neuroblastoma"},{"name":"Maps_To","value":"Neuroblastoma"},{"name":"Maps_To","value":"Neuroblastoma (NBL)"},{"name":"Maps_To","value":"Neuroblastoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2751421"}]}}{"C66807":{"preferredName":"Ciliary Body Benign Medulloepithelioma","code":"C66807","definitions":[{"definition":"A rare, unilateral, benign embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body Benign Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Ciliary Body Medulloepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Intraocular Medulloepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9501/0"},{"name":"Legacy Concept Name","value":"Benign_Intraocular_Medulloepithelioma"},{"name":"Maps_To","value":"9501/0"},{"name":"Maps_To","value":"Medulloepithelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879808"}]}}{"C66808":{"preferredName":"Medulloepithelioma Not Otherwise Specified","code":"C66808","definitions":[{"definition":"A rare, unilateral, benign or malignant embryonic neoplasm typically presenting as a cilliary body mass during childhood. It is composed of medullary epithelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloepithelioma Not Otherwise Specified","termGroup":"AQ","termSource":"NCI"},{"termName":"Medulloepithelioma, NOS","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9501/3"},{"name":"Legacy Concept Name","value":"Medulloepithelioma_not_Otherwise_Specified"},{"name":"Maps_To","value":"9501/3"},{"name":"Maps_To","value":"Medulloepithelioma, NOS"},{"name":"NCI_META_CUI","value":"CL505197"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4327":{"preferredName":"Central Nervous System Medulloepithelioma","code":"C4327","definitions":[{"definition":"A rare malignant embryonal neoplasm of the central nervous system, occurring in children. It is characterized by the presence of neuroepithelial cells that form papillary, trabecular, or tubular structures.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare, usually aggressive malignant embryonal neoplasm of the central nervous system occurring in children. It is characterized by the presence of neuroepithelial cells which form papillary, trabecular, or tubular structures and absence of C19MC amplification. Symptoms include headache, nausea, and vomiting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Medulloepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Medulloepithelioma, Central Nervous System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Medulloepithelioma"},{"name":"Maps_To","value":"9501/3"},{"name":"Maps_To","value":"Diktyoma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334596"}]}}{"C66809":{"preferredName":"Ciliary Body Benign Teratoid Medulloepithelioma","code":"C66809","definitions":[{"definition":"A rare, unilateral, benign embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium and contains heterologous elements, particularly cartilage, skeletal muscle, and brain tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body Benign Teratoid Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Intraocular Teratoid Medulloepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9502/0"},{"name":"Legacy Concept Name","value":"Benign_Intraocular_Teratoid_Medulloepithelioma"},{"name":"Maps_To","value":"9502/0"},{"name":"Maps_To","value":"Teratoid medulloepithelioma, benign"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879809"}]}}{"C66810":{"preferredName":"Ciliary Body Teratoid Medulloepithelioma","code":"C66810","definitions":[{"definition":"A rare, unilateral, benign or malignant embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium and contains heterologous elements, particularly cartilage, skeletal muscle, and brain tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body Teratoid Medulloepithelioma","termGroup":"PT","termSource":"NCI"},{"termName":"Intraocular Teratoid Medulloepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9502/3"},{"name":"Legacy Concept Name","value":"Intraocular_Teratoid_Medulloepithelioma"},{"name":"Maps_To","value":"9502/3"},{"name":"Maps_To","value":"Teratoid medulloepithelioma"},{"name":"Maps_To","value":"Teratoid medulloepithelioma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1881244"}]}}{"C66811":{"preferredName":"Spongioneuroblastoma","code":"C66811","definitions":[{"definition":"A neuroectodermal tumor composed of neoplastic neural elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spongioneuroblastoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9504/3"},{"name":"Legacy Concept Name","value":"Spongioneuroblastoma"},{"name":"Maps_To","value":"9504/3"},{"name":"Maps_To","value":"Spongioneuroblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334598"}]}}{"C3788":{"preferredName":"Ganglioglioma","code":"C3788","definitions":[{"definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and neoplastic glial cells. Some gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III. Rare cases of newly diagnosed gangliogliomas with grade IV (glioblastoma) changes in the glial component have also been reported. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganglioglioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9505/1"},{"name":"Legacy Concept Name","value":"Ganglioglioma"},{"name":"Maps_To","value":"9505/1"},{"name":"Maps_To","value":"Ganglioglioma, NOS"},{"name":"Maps_To","value":"Glioneuroma"},{"name":"Maps_To","value":"Neuroastrocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206716"}]}}{"C4717":{"preferredName":"Anaplastic Ganglioglioma","code":"C4717","definitions":[{"definition":"A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Ganglioglioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9505/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Ganglioglioma"},{"name":"Maps_To","value":"9505/3"},{"name":"Maps_To","value":"Ganglioglioma, anaplastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431112"}]}}{"C92555":{"preferredName":"Extraventricular Neurocytoma","code":"C92555","definitions":[{"definition":"A WHO grade 2 neoplasm that arises from the brain parenchyma. Morphologically it is characterized by the presence of neoplastic uniform, round cells with neuronal differentiation. Unlike central neurocytoma, it does not involve the lateral ventricles. It usually affects young adults and has a favorable prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraventricular Neurocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Extraventricular Neurocytoma (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Extraventricular Neurocytoma (WHO Grade II)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9506/1"},{"name":"Maps_To","value":"9506/1"},{"name":"Maps_To","value":"Extraventricular neurocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985175"}]}}{"C6905":{"preferredName":"Cerebellar Liponeurocytoma","code":"C6905","definitions":[{"definition":"A rare, WHO grade II cerebellar neoplasm which shows consistent neuronal, variable astrocytic and focal lipomatous differentiation. It occurs in adults, has a low proliferative potential and usually has a favorable prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebellar Liponeurocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebellar Liponeurocytoma (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Cerebellar Liponeurocytoma (WHO Grade II)","termGroup":"SY","termSource":"NCI"},{"termName":"Lipomatous Medulloblastoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"0000/0"},{"name":"Legacy Concept Name","value":"Cerebellar_Liponeurocytoma"},{"name":"Maps_To","value":"9506/1"},{"name":"Maps_To","value":"Cerebellar liponeurocytoma"},{"name":"Maps_To","value":"Lipomatous medulloblastoma"},{"name":"Maps_To","value":"Medullocytoma"},{"name":"Maps_To","value":"Neurolipocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370507"}]}}{"C3791":{"preferredName":"Central Neurocytoma","code":"C3791","definitions":[{"definition":"An intraventricular neuronal neoplasm composed of uniform round cells with neuronal differentiation. It is typically located in the lateral ventricles in the region of the foramen of Monro. It generally affects young adults and has a favorable prognosis. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Neurocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Neurocytoma (WHO Grade 2)","termGroup":"SY","termSource":"NCI"},{"termName":"Central Neurocytoma (WHO Grade II)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9506/1"},{"name":"Legacy Concept Name","value":"Neurocytoma"},{"name":"Maps_To","value":"9506/1"},{"name":"Maps_To","value":"Central neurocytoma"},{"name":"Maps_To","value":"Neurocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206719"}]}}{"C4328":{"preferredName":"Pacinian Neurofibroma","code":"C4328","definitions":[{"definition":"A neurofibroma characterized by the presence of structures which resemble Vater-Pacini corpuscles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacinian Neurofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9507/0"},{"name":"Legacy Concept Name","value":"Pacinian_Neurofibroma"},{"name":"Maps_To","value":"9507/0"},{"name":"Maps_To","value":"Pacinian tumor"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334599"}]}}{"C6906":{"preferredName":"Atypical Teratoid/Rhabdoid Tumor","code":"C6906","definitions":[{"definition":"An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Teratoid/Rhabdoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"AT/RT","termGroup":"AB","termSource":"NCI"},{"termName":"ATRT","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Teratoid/Rhabdoid Tumor (WHO Grade 4)","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Teratoid/Rhabdoid Tumor (WHO Grade IV)","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brain Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brain Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Neoplasm of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Neoplasm of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Brain Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Brain Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Neoplasm of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Neoplasm of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Tumor of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Malignant Rhabdoid Tumor of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9508/3"},{"name":"Legacy Concept Name","value":"Atypical_Teratoid_Rhabdoid_Tumor"},{"name":"Maps_To","value":"9508/3"},{"name":"Maps_To","value":"Atypical teratoid/rhabdoid tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266184"}]}}{"C92554":{"preferredName":"Papillary Glioneuronal Tumor","code":"C92554","definitions":[{"definition":"A WHO grade 1, indolent and relatively circumscribed brain tumor.  Morphologically it is characterized by the presence of astrocytes that line vascular and hyalinized pseudopapillae.  In between the pseudopapillae aggregates of neurocytes, large neurons, and ganglioid cells are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Glioneuronal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Glioneuronal Tumor (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Papillary Glioneuronal Tumor (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"PGNT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9509/1"},{"name":"Maps_To","value":"9509/1"},{"name":"Maps_To","value":"Papillary glioneuronal tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2985174"}]}}{"C129431":{"preferredName":"Rosette-Forming Glioneuronal Tumor","code":"C129431","definitions":[{"definition":"A central nervous system neoplasm mostly occurring in the fourth ventricle region. It is characterized by the presence of neurocytes forming pseudorosettes and astrocytes which contain Rosenthal fibers. Cytologic atypia is minimal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosette-Forming Glioneuronal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"RGNT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9509/1"},{"name":"Maps_To","value":"Rosette-forming glioneuronal tumor"},{"name":"NCI_META_CUI","value":"CL497922"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C66812":{"preferredName":"Retinocytoma","code":"C66812","definitions":[{"definition":"A rare, unilateral or bilateral benign neoplasm that arises from the retina. There is an increased risk of malignant transformation to retinoblastoma; therefore, patients with a diagnosis of retinocytoma should be closely observed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Retinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9510/0"},{"name":"Legacy Concept Name","value":"Retinocytoma"},{"name":"Maps_To","value":"9510/0"},{"name":"Maps_To","value":"Retinocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346396"}]}}{"C7541":{"preferredName":"Retinoblastoma","code":"C7541","definitions":[{"definition":"A malignant neoplasm originating in the nuclear layer of the retina.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the retina (the light-sensitive layers of nerve tissue at the back of the eye). Retinoblastoma usually occurs in children younger than 5 years. It may be hereditary or nonhereditary (sporadic).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Retinoblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"RB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9510/3"},{"name":"Legacy Concept Name","value":"Retinoblastoma"},{"name":"Maps_To","value":"9510/3"},{"name":"Maps_To","value":"Retinoblastoma"},{"name":"Maps_To","value":"Retinoblastoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0035335"}]}}{"C66813":{"preferredName":"Differentiated Retinoblastoma","code":"C66813","definitions":[{"definition":"A retinoblastoma with well differentiated features. It often produces Flexner-Wintersteiner rosettes or Homer-Wright rosettes. In some cases the tumor cells form fleurettes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Differentiated Retinoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9511/3"},{"name":"Legacy Concept Name","value":"Differentiated_Retinoblastoma"},{"name":"Maps_To","value":"9511/3"},{"name":"Maps_To","value":"Retinoblastoma, differentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334600"}]}}{"C66814":{"preferredName":"Undifferentiated Retinoblastoma","code":"C66814","definitions":[{"definition":"A retinoblastoma composed of small, undifferentiated cells. It is often associated with necrotic changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Retinoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9512/3"},{"name":"Legacy Concept Name","value":"Undifferentiated_Retinoblastoma"},{"name":"Maps_To","value":"9512/3"},{"name":"Maps_To","value":"Retinoblastoma, undifferentiated"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334601"}]}}{"C66815":{"preferredName":"Diffuse Retinoblastoma","code":"C66815","definitions":[{"definition":"A retinoblastoma characterized by the absence of a distinct retinal mass and the presence of malignant cells diffusely infiltrating the retina. It is often confused with uveitis and endophthalmitis, resulting in delayed diagnosis of the malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Retinoblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9513/3"},{"name":"Legacy Concept Name","value":"Diffuse_Retinoblastoma"},{"name":"Maps_To","value":"9513/3"},{"name":"Maps_To","value":"Retinoblastoma, diffuse"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266185"}]}}{"C66816":{"preferredName":"Spontaneously Regressed Retinoblastoma","code":"C66816","definitions":[{"definition":"An archaic term that refers to benign, non-progressive retinal lesions in patients with mutation of the RB1 gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spontaneously Regressed Retinoblastoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Spontaneously Regressing Retinoblastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9514/1"},{"name":"Legacy Concept Name","value":"Spontaneously_Regressing_Retinoblastoma"},{"name":"Maps_To","value":"9514/1"},{"name":"Maps_To","value":"Retinoblastoma, spontaneously regressed"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266186"}]}}{"C67155":{"preferredName":"Olfactory Neurogenic Tumor","code":"C67155","definitions":[{"definition":"A rare, benign (olfactory neurocytoma) or malignant (olfactory neuroblastoma) neuroectodermal tumor originating from olfactory receptor cells in the nasal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Neurogenic Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9520/3"},{"name":"Legacy Concept Name","value":"Olfactory_Neurogenic_Tumor"},{"name":"Maps_To","value":"9520/3"},{"name":"Maps_To","value":"Olfactory neurogenic tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334602"}]}}{"C67156":{"preferredName":"Olfactory Neurocytoma","code":"C67156","definitions":[{"definition":"A rare benign neuroectodermal tumor originating from olfactory receptor cells in the nasal cavity. Microscopically, it is characterized by the absence of malignant characteristics and the absence of rosettes formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Neurocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9521/3"},{"name":"Legacy Concept Name","value":"Olfactory_Neurocytoma"},{"name":"Maps_To","value":"9521/3"},{"name":"Maps_To","value":"Olfactory neurocytoma"},{"name":"NCI_META_CUI","value":"CL031140"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3789":{"preferredName":"Olfactory Neuroblastoma","code":"C3789","definitions":[{"definition":"A rare neuroectodermal tumor originating from olfactory receptor cells in the nasal cavity or paranasal sinuses. Microscopically, it is characterized by neuroblastic differentiation with occasional formation of rosettes. If the tumor is not resected at an early stage, the prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Neuroblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"Esthesioneuroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Esthesioneuroepithelioma","termGroup":"SY","termSource":"NCI"},{"termName":"Olfactory Esthesioneuroblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Olfactory Neuroepithelioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9522/3"},{"name":"ICD-O-3_Code","value":"9523/3"},{"name":"Legacy Concept Name","value":"Olfactory_Neuroblastoma"},{"name":"Maps_To","value":"9522/3"},{"name":"Maps_To","value":"9523/3"},{"name":"Maps_To","value":"Esthesioneuroblastoma"},{"name":"Maps_To","value":"Esthesioneuroepithelioma"},{"name":"Maps_To","value":"Olfactory neuroblastoma"},{"name":"Maps_To","value":"Olfactory neuroepithelioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206717"}]}}{"C6907":{"preferredName":"Metaplastic Meningioma","code":"C6907","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of a prominent mesenchymal component. The mesenchymal component may be osseous, cartilaginous, myxoid, lipomatous, or a mixture of mesenchymal elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metaplastic Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Metaplastic_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Metaplastic meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384407"}]}}{"C4718":{"preferredName":"Secretory Meningioma","code":"C4718","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of epithelial differentiation and numerous intracellular PAS positive bodies that are rich in glycogen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secretory Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secretory_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Secretory meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384406"}]}}{"C4721":{"preferredName":"Microcystic Meningioma","code":"C4721","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of intercellular microcystic spaces that contain mucinous fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microcystic Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microcystic_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Microcystic meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384408"}]}}{"C4720":{"preferredName":"Lymphoplasmacyte-Rich Meningioma","code":"C4720","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of prominent chronic inflammatory infiltrates that predominate over the meningioma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoplasmacyte-Rich Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphoplasmacyte-Rich_Meningioma"},{"name":"Maps_To","value":"9530/0"},{"name":"Maps_To","value":"Lymphoplasmacyte-rich meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431119"}]}}{"C3707":{"preferredName":"Meningiomatosis","code":"C3707","definitions":[{"definition":"The presence of multiple meningiomas in the leptomeninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningiomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Meningiomas, Multiple","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9530/1"},{"name":"Legacy Concept Name","value":"Meningiomatosis"},{"name":"Maps_To","value":"9530/1"},{"name":"Maps_To","value":"Diffuse meningiomatosis"},{"name":"Maps_To","value":"Meningiomatosis, NOS"},{"name":"Maps_To","value":"Multiple meningiomas"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205834"}]}}{"C4051":{"preferredName":"Anaplastic (Malignant) Meningioma","code":"C4051","definitions":[{"definition":"A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","type":"DEFINITION","source":"NCI"},{"definition":"A rare, fast-growing tumor that forms in one of the inner layers of the meninges (thin layers of tissue that cover and protect the brain and spinal cord). Malignant meningioma often spreads to other areas of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anaplastic (Malignant) Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Meningioma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Meningioma","termGroup":"SY","termSource":"NCI"},{"termName":"Meningioma, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9530/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Malignant_Meningioma"},{"name":"Maps_To","value":"9530/3"},{"name":"Maps_To","value":"Meningioma, anaplastic"},{"name":"Maps_To","value":"Meningioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259785"}]}}{"C4073":{"preferredName":"Meningeal Sarcoma","code":"C4073","definitions":[{"definition":"A rare sarcoma arising from the meninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Meninges Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Meninges","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Meningeal_Sarcoma"},{"name":"Maps_To","value":"9530/3"},{"name":"Maps_To","value":"Meningeal sarcoma"},{"name":"Maps_To","value":"Meningothelial sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302327"}]}}{"C8312":{"preferredName":"Leptomeningeal Sarcoma","code":"C8312","definitions":[{"definition":"A malignant mesenchymal neoplasm arising from the leptomeninges.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sarcoma arising from the leptomeninges.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leptomeningeal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Sarcoma of Leptomeninges","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoma of the Leptomeninges","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Leptomeningeal_Sarcoma"},{"name":"Maps_To","value":"9530/3"},{"name":"Maps_To","value":"Leptomeningeal sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1384416"}]}}{"C4329":{"preferredName":"Meningothelial Meningioma","code":"C4329","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of tumor cells that form lobules. The tumor cells are generally uniform. Whorls and psammoma bodies are usually not present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningothelial Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Meningotheliomatous Meningioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9531/0"},{"name":"Legacy Concept Name","value":"Meningothelial_Meningioma"},{"name":"Maps_To","value":"9531/0"},{"name":"Maps_To","value":"Endotheliomatous meningioma"},{"name":"Maps_To","value":"Meningothelial meningioma"},{"name":"Maps_To","value":"Syncytial meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334605"}]}}{"C4330":{"preferredName":"Fibrous Meningioma","code":"C4330","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of spindle cells that form bundles in a collagen matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrous Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblastic Meningioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9532/0"},{"name":"Legacy Concept Name","value":"Fibrous_Meningioma"},{"name":"Maps_To","value":"9532/0"},{"name":"Maps_To","value":"Fibroblastic meningioma"},{"name":"Maps_To","value":"Fibrous meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334606"}]}}{"C4331":{"preferredName":"Psammomatous Meningioma","code":"C4331","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of psammoma bodies that predominate over the meningeal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Psammomatous Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9533/0"},{"name":"Legacy Concept Name","value":"Psammomatous_Meningioma"},{"name":"Maps_To","value":"9533/0"},{"name":"Maps_To","value":"Psammomatous meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334607"}]}}{"C4332":{"preferredName":"Angiomatous Meningioma","code":"C4332","definitions":[{"definition":"A WHO grade I meningioma characterized by the presence of small and medium sized vessels that predominate over the meningioma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiomatous Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9534/0"},{"name":"Legacy Concept Name","value":"Angiomatous_Meningioma"},{"name":"Maps_To","value":"9534/0"},{"name":"Maps_To","value":"Angiomatous meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334608"}]}}{"C66817":{"preferredName":"Hemangioblastic Meningioma","code":"C66817","definitions":[{"definition":"An obsolete term referring to hemangiopericytoma of the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemangioblastic Meningioma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9535/0"},{"name":"Legacy Concept Name","value":"Hemangioblastic_Meningioma"},{"name":"Maps_To","value":"9535/0"},{"name":"Maps_To","value":"Hemangioblastic meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334609"}]}}{"C4333":{"preferredName":"Transitional Meningioma","code":"C4333","definitions":[{"definition":"A WHO grade I meningioma characterized by the coexistence of meningothelial cells and fibrous architectural patterns.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transitional Meningioma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Meningioma","termGroup":"SY","termSource":"NCI"},{"termName":"Transitional (Mixed) Meningioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9537/0"},{"name":"Legacy Concept Name","value":"Transitional_Meningioma"},{"name":"Maps_To","value":"9537/0"},{"name":"Maps_To","value":"Mixed meningioma"},{"name":"Maps_To","value":"Transitional meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334611"}]}}{"C4722":{"preferredName":"Clear Cell Meningioma","code":"C4722","definitions":[{"definition":"A WHO grade II morphologic variant of meningioma characterized by the presence of clear glycogen-rich polygonal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clear Cell Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9538/1"},{"name":"Legacy Concept Name","value":"Clear_Cell_Meningioma"},{"name":"Maps_To","value":"9538/1"},{"name":"Maps_To","value":"Clear cell meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431121"}]}}{"C6908":{"preferredName":"Chordoid Meningioma","code":"C6908","definitions":[{"definition":"A WHO grade II, usually recurring meningioma characterized by the predominance of tissues that are histologically similar to chordoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chordoid Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chordoid_Meningioma"},{"name":"Maps_To","value":"9538/1"},{"name":"Maps_To","value":"Chordoid meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370510"}]}}{"C3904":{"preferredName":"Papillary Meningioma","code":"C3904","definitions":[{"definition":"A WHO grade III meningioma characterized by the predominance of a perivascular pseudopapillary pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9538/3"},{"name":"Legacy Concept Name","value":"Papillary_Meningioma"},{"name":"Maps_To","value":"9538/3"},{"name":"Maps_To","value":"Papillary meningioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3163622"}]}}{"C6909":{"preferredName":"Rhabdoid Meningioma","code":"C6909","definitions":[{"definition":"A WHO grade III meningioma characterized by the predominant presence of rhabdoid cells forming sheets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhabdoid Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rhabdoid_Meningioma"},{"name":"Maps_To","value":"9538/3"},{"name":"Maps_To","value":"Rhabdoid meningioma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0259786"}]}}{"C4723":{"preferredName":"Atypical Meningioma","code":"C4723","definitions":[{"definition":"A WHO grade II meningioma characterized by the presence of brain invasion and an increased mitotic activity, or at least three of the following morphologic features: small cells, high cellularity, prominent nucleoli, lack of architectural pattern, and necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Meningioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9539/1"},{"name":"Legacy Concept Name","value":"Atypical_Meningioma"},{"name":"Maps_To","value":"9539/1"},{"name":"Maps_To","value":"Atypical meningioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431122"}]}}{"C4334":{"preferredName":"Meningeal Sarcomatosis","code":"C4334","definitions":[{"definition":"A rare condition characterized by diffuse spread of sarcoma cells throughout the meninges. The neoplastic cells are derived from meningeal connective tissue. Clinically, this disorder may present as a fulminant pachymeningitis and/or encephalitis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Sarcomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Meninges Sarcomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatosis of Meninges","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatosis of the Meninges","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9539/3"},{"name":"Legacy Concept Name","value":"Meningeal_Sarcomatosis"},{"name":"Maps_To","value":"9539/3"},{"name":"Maps_To","value":"Meningeal sarcomatosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334612"}]}}{"C3272":{"preferredName":"Neurofibroma","code":"C3272","definitions":[{"definition":"A benign tumor that develops from the cells and tissues that cover nerves.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths, composed of perineurial-like fibroblasts and Schwann cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibroma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9540/0"},{"name":"Legacy Concept Name","value":"Neurofibroma"},{"name":"Maps_To","value":"9540/0"},{"name":"Maps_To","value":"Neurofibroma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027830"}]}}{"C6727":{"preferredName":"Neurofibromatosis","code":"C6727","definitions":[{"definition":"An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurofibromatosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9540/1"},{"name":"Legacy Concept Name","value":"Neurofibromatosis"},{"name":"Maps_To","value":"9540/1"},{"name":"Maps_To","value":"Multiple neurofibromatosis"},{"name":"Maps_To","value":"Neurofibromatosis (nonmalignant)"},{"name":"Maps_To","value":"Neurofibromatosis, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0162678"}]}}{"C3273":{"preferredName":"Neurofibromatosis Type 1","code":"C3273","definitions":[{"definition":"A rare genetic condition that causes brown spots and tumors on the skin, freckling in skin areas not exposed to the sun, tumors on the nerves, and developmental changes in the nervous system, muscles, bone, and skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant form of neurofibromatosis caused by mutation(s) in the NF1 gene, encoding neurofibromin. The clinical features of this condition may include smooth bordered areas of hyperpigmentation, known as cafe-au-lait spots, axillary freckling, Lisch nodules, short stature, cutaneous and subcutaneous tumors (neurofibromas), optic nerve gliomas, precocious puberty, and growth hormone excess.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The most common type of neurofibromatosis.  It is characterized clinically by cutaneous and subcutaneous tumors with patches of hyperpigmentation. The hyperpigmented skin areas, are present from birth and found anywhere on the body surface.  They can vary markedly in size and color.  The dark brown areas are called cafe-au-lait spots. The multiple cutaneous and subcutaneous tumors are nerve sheath tumors, called neurofibromas.  They can develop anywhere along the peripheral nerve fibers. Neurofibromas can become quite large, causing a major disfigurement, eroding bone, and compressing various peripheral nerve structures.  Type 1 neurofibromatosis has dominant inheritance, with a gene locus on the proximal long arm of chromosome 17.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurofibromatosis Type 1","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibromatosis 1","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral Neurofibromatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Von Recklinghausen Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Neurofibromatosis_Type_1"},{"name":"Maps_To","value":"9540/1"},{"name":"Maps_To","value":"Recklinghausen disease"},{"name":"Maps_To","value":"Von Recklinghausen disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0027831"}]}}{"C6561":{"preferredName":"Epithelioid Malignant Peripheral Nerve Sheath Tumor","code":"C6561","definitions":[{"definition":"A rare variant of malignant peripheral nerve sheath tumor composed predominantly or exclusively of epithelioid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Malignant Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid MPNST","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Neoplasm of Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Neoplasm of the Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Peripheral Nerve Sheath Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Tumor of Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Epithelioid Tumor of the Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epithelioid_Malignant_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"9540/3"},{"name":"Maps_To","value":"9542/3"},{"name":"Maps_To","value":"Epithelioid malignant peripheral nerve sheath tumor"},{"name":"Maps_To","value":"Epithelioid MPNST"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor, epithelioid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321427"}]}}{"C4748":{"preferredName":"Malignant Melanotic Peripheral Nerve Sheath Tumor","code":"C4748","definitions":[{"definition":"A rare variant of malignant peripheral nerve sheath tumor.  It is characterized by the presence of malignant cells that contain melanin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Melanotic Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Melanocytic Neoplasm of Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanocytic Neoplasm of the Peripheral Nerve Sheath","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanocytic Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanotic Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Melanotic Schwannian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytic MPNST","termGroup":"SY","termSource":"NCI"},{"termName":"MMNST","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Melanocytic_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"9540/3"},{"name":"Maps_To","value":"Melanotic MPNST"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0474847"}]}}{"C3798":{"preferredName":"Malignant Peripheral Nerve Sheath Tumor","code":"C3798","definitions":[{"definition":"A malignant neoplasm, originating from the sheaths of the peripheral nerve.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of soft tissue sarcoma that develops in cells that form a protective sheath (covering) around peripheral nerves, which are nerves that are outside of the central nervous system (brain and spinal cord).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neurilemmoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Peripheral Nerve Sheath Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Schwannoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MPNST","termGroup":"AB","termSource":"NCI"},{"termName":"Neurofibrosarcoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9540/3"},{"name":"ICD-O-3_Code","value":"9560/3"},{"name":"Legacy Concept Name","value":"Malignant_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"9540/3"},{"name":"Maps_To","value":"9560/3"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor, NOS"},{"name":"Maps_To","value":"Malignant schwannoma, NOS"},{"name":"Maps_To","value":"MPNST, NOS"},{"name":"Maps_To","value":"Neurilemoma, malignant"},{"name":"Maps_To","value":"Neurilemosarcoma"},{"name":"Maps_To","value":"Neurofibrosarcoma"},{"name":"Maps_To","value":"Neurogenic sarcoma"},{"name":"Maps_To","value":"Neurosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3279060"}]}}{"C66841":{"preferredName":"Melanotic Neurofibroma","code":"C66841","definitions":[{"definition":"A rare neurofibroma characterized by the presence of melanin-laden cells and the absence of atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanotic Neurofibroma","termGroup":"PT","termSource":"NCI"},{"termName":"Pigmented Neurofibroma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9541/0"},{"name":"Legacy Concept Name","value":"Melanotic_Neurofibroma"},{"name":"Maps_To","value":"9541/0"},{"name":"Maps_To","value":"Melanotic neurofibroma"},{"name":"NCI_META_CUI","value":"CL497402"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3797":{"preferredName":"Plexiform Neurofibroma","code":"C3797","definitions":[{"definition":"A nerve that has become thick and misshapen due to the abnormal growth of cells and tissues that cover the nerve.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plexiform Neurofibroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9550/0"},{"name":"Legacy Concept Name","value":"Plexiform_Neurofibroma"},{"name":"Maps_To","value":"9550/0"},{"name":"Maps_To","value":"Plexiform neurofibroma"},{"name":"Maps_To","value":"Plexiform neuroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3279070"}]}}{"C3276":{"preferredName":"Vestibular Schwannoma","code":"C3276","definitions":[{"definition":"A benign peripheral nerve sheath neoplasm that arises from the vestibular division of the vestibulocochlear nerve (eight cranial nerve) in the auditory canal or within the labyrinth. It is composed almost entirely of differentiated neoplastic Schwann cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vestibular Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Acoustic Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Acoustic Neuroma","termGroup":"SY","termSource":"NCI"},{"termName":"Acoustic Schwannoma","termGroup":"SY","termSource":"NCI"},{"termName":"Neurilemoma, Acoustic","termGroup":"SY","termSource":"NCI"},{"termName":"Neuroma, Acoustic","termGroup":"SY","termSource":"NCI"},{"termName":"Vestibular Neurilemmoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acoustic_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Acoustic neuroma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3549435"}]}}{"C3269":{"preferredName":"Schwannoma","code":"C3269","definitions":[{"definition":"A benign neoplasm of the peripheral nervous system composed of well-differentiated Schwann cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A benign, usually encapsulated slow growing tumor composed of Schwann cells.  It affects peripheral and cranial nerves.  It recurs infrequently and only rare cases associated with malignant transformation have been reported.","type":"DEFINITION","source":"NCI"},{"definition":"A tumor of the peripheral nervous system that arises in the nerve sheath (protective covering).  It is almost always benign, but rare malignant schwannomas have been reported.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Schwannoma","termGroup":"SY","termSource":"NCI"},{"termName":"Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Neurinoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Schwannoma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9560/0"},{"name":"Legacy Concept Name","value":"Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Neurilemoma, NOS"},{"name":"Maps_To","value":"Neurinoma"},{"name":"Maps_To","value":"Psammomatous schwannoma"},{"name":"Maps_To","value":"Schwannoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0027809"}]}}{"C4724":{"preferredName":"Cellular Schwannoma","code":"C4724","definitions":[{"definition":"A morphologic variant of schwannoma characterized by hypercellularity, Antoni A pattern, and the absence of well-formed Verocay bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellular Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cellular Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cellular Neurinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cellular_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Cellular schwannoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0431124"}]}}{"C6970":{"preferredName":"Melanotic Schwannoma","code":"C6970","definitions":[{"definition":"A rare circumscribed, non-encapsulated and grossly pigmented nerve sheath tumor. It is composed of cells with the immunophenotypic and electron microscopic features of Schwann cells which contain melanosomes and are positive for melanoma markers. It usually involves spinal nerve roots but may occur in other locations. It may be associated with PRKAR1A gene mutation and Carney complex. Malignant behavior has been reported in a significant number of patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanotic Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocytic Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytic Schwannoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Neurinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pigmented Schwannoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanocytic_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Melanotic schwannoma"},{"name":"Maps_To","value":"Pigmented schwannoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1306247"}]}}{"C6969":{"preferredName":"Plexiform Schwannoma","code":"C6969","definitions":[{"definition":"A schwannoma characterized by a plexiform or multinodular growth pattern.  It usually arises from the skin or subcutaneous tissues in the extremities, trunk, and head and neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plexiform Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Plexiform Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Plexiform Neurinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Plexiform_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Plexiform schwannoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370659"}]}}{"C6556":{"preferredName":"Ancient Schwannoma","code":"C6556","definitions":[{"definition":"A schwannoma that is characterized by degenerative changes such as hyalinization, hemorrhage, calcification and cystic change.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancient Schwannoma","termGroup":"PT","termSource":"NCI"},{"termName":"Ancient Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Degenerated Neurilemmoma","termGroup":"SY","termSource":"NCI"},{"termName":"Degenerated Schwannoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Degenerated_Schwannoma"},{"name":"Maps_To","value":"9560/0"},{"name":"Maps_To","value":"Ancient schwannoma"},{"name":"Maps_To","value":"Degenerated schwannoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1536561"}]}}{"C6557":{"preferredName":"Schwannomatosis","code":"C6557","definitions":[{"definition":"Rare genetic disorder caused by mutations in the SMARCB1 and LZTR1 genes. It is characterized by the presence of multiple Schwannomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Schwannomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Neurilemmomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Neurinomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9560/1"},{"name":"Legacy Concept Name","value":"Schwannomatosis"},{"name":"Maps_To","value":"9560/1"},{"name":"Maps_To","value":"Neurinomatosis"},{"name":"Maps_To","value":"Schwannomatosis"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335929"}]}}{"C4335":{"preferredName":"Malignant Triton Tumor","code":"C4335","definitions":[{"definition":"A malignant peripheral nerve sheath tumor which shows rhabdomyosarcomatous differentiation. More than half of the patients have neurofibromatosis type 1. The prognosis is usually poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Triton Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Peripheral Nerve Sheath Neoplasm with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Peripheral Nerve Sheath Tumor with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Peripheral Nerve Sheath with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"MPNST with Rhabdomyosarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9561/3"},{"name":"Legacy Concept Name","value":"Malignant_Triton_Tumor"},{"name":"Maps_To","value":"9561/3"},{"name":"Maps_To","value":"Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation"},{"name":"Maps_To","value":"Malignant schwannoma with rhabdomyoblastic differentiation"},{"name":"Maps_To","value":"MPNST with rhabdomyoblastic differentiation"},{"name":"Maps_To","value":"Triton tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334616"}]}}{"C7018":{"preferredName":"Nerve Sheath Myxoma","code":"C7018","definitions":[{"definition":"A benign neoplasm arising from nerve sheaths. It is characterized by the presence of a myxoid stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve Sheath Myxoma","termGroup":"PT","termSource":"NCI"},{"termName":"Neurothekeoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9562/0"},{"name":"Legacy Concept Name","value":"Neurothekeoma"},{"name":"Maps_To","value":"9562/0"},{"name":"Maps_To","value":"Nerve sheath myxoma"},{"name":"Maps_To","value":"Neurothekeoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206730"}]}}{"C3275":{"preferredName":"Neuroma","code":"C3275","definitions":[{"definition":"A tumor that arises in nerve cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor that grows from a nerve or is composed of nerve cells and nerve fibers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9570/0"},{"name":"Legacy Concept Name","value":"Neuroma"},{"name":"Maps_To","value":"9570/0"},{"name":"Maps_To","value":"Neuroma, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0027858"}]}}{"C6911":{"preferredName":"Intraneural Perineurioma","code":"C6911","definitions":[{"definition":"A WHO grade I perineurioma that arises within the endoneurium.  It is characterized by the formation of pseudo-onion bulbs by the proliferating perineural cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraneural Perineurioma","termGroup":"PT","termSource":"NCI"},{"termName":"Intraneural Perineurioma (WHO Grade I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraneural_Perineurioma"},{"name":"Maps_To","value":"9571/0"},{"name":"Maps_To","value":"Intraneural perineurioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370658"}]}}{"C6912":{"preferredName":"Soft Tissue Perineurioma","code":"C6912","definitions":[{"definition":"A perineurioma not associated with a nerve, arising from the soft tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soft Tissue Perineurioma","termGroup":"PT","termSource":"NCI"},{"termName":"Soft Tissue Perineurioma (WHO Grades I, II, or III)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Soft_Tissue_Perineurioma"},{"name":"Maps_To","value":"9571/0"},{"name":"Maps_To","value":"Soft tissue perineurioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1370657"}]}}{"C4973":{"preferredName":"Perineurioma","code":"C4973","definitions":[{"definition":"A rare benign tumor composed entirely of neoplastic perineurial cells. It may occur in the soft tissues, intraneurally or in mucosal sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perineurioma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9571/0"},{"name":"Legacy Concept Name","value":"Perineurioma"},{"name":"Maps_To","value":"9571/0"},{"name":"Maps_To","value":"Perineurioma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751691"}]}}{"C66845":{"preferredName":"Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation","code":"C66845","definitions":[{"definition":"A very rare malignant tumor with morphologic features similar to those of benign perineurioma of soft tissue along with hypercellularity, nuclear atypia, hyperchromasia, and a high mitotic rate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Perineurioma","termGroup":"SY","termSource":"NCI"},{"termName":"Perineurial Malignant Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9571/3"},{"name":"Legacy Concept Name","value":"Malignant_Peripheral_Nerve_Sheath_Tumor_with_Perineurial_Differentiation"},{"name":"Maps_To","value":"9571/3"},{"name":"Maps_To","value":"Perineural MPNST"},{"name":"Maps_To","value":"Perineurioma, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266188"}]}}{"C3474":{"preferredName":"Granular Cell Tumor","code":"C3474","definitions":[{"definition":"An unusual benign or malignant neoplasm characterized by the presence of neoplastic large polygonal cells with granular, eosinophilic cytoplasm which contains abundant lysosomes. It was originally thought to be a tumor originating from muscle cells and was named granular cell myoblastoma. Subsequent studies have suggested a derivation from Schwann cells. It affects females more often than males and it usually presents as a solitary mass. A minority of patients have multiple tumors. It can arise from many anatomic sites including the posterior pituitary gland, skin, oral cavity, esophagus, stomach, heart, mediastinum, and breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granular Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Abrikossoff Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Abrikossoff's Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Granular Cell Myoblastoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Granular Cell Nerve Sheath Tumor","termGroup":"AQS","termSource":"NCI"},{"termName":"Granular Cell Schwannoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9580/0"},{"name":"Legacy Concept Name","value":"Granular_Cell_Tumor"},{"name":"Maps_To","value":"9580/0"},{"name":"Maps_To","value":"Granular cell myoblastoma, NOS"},{"name":"Maps_To","value":"Granular cell tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0085167"}]}}{"C4336":{"preferredName":"Malignant Granular Cell Tumor","code":"C4336","definitions":[{"definition":"A malignant neoplasm, comprised of large cells with cytoplasmatic granules, occurring in various organs/tissues.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An uncommon granular cell tumor which may metastasize to other anatomic sites. Morphologic characteristics include the presence of spindling neoplastic cells, necrosis, extensive pleomorphism, prominent nucleoli, and increased mitiotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Granular Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Granular Cell Myoblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Granular Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9580/3"},{"name":"Legacy Concept Name","value":"Malignant_Granular_Cell_Tumor"},{"name":"Maps_To","value":"9580/3"},{"name":"Maps_To","value":"Granular cell myoblastoma, malignant"},{"name":"Maps_To","value":"Granular cell tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334618"}]}}{"C3750":{"preferredName":"Alveolar Soft Part Sarcoma","code":"C3750","definitions":[{"definition":"A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults the most common sites of involvement are the extremities, and in infants and children, the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain.","type":"DEFINITION","source":"NCI"},{"definition":"A soft tissue tumor that is most common in older children and teenagers. It begins in the soft supporting tissue that connects and surrounds the organs and other tissues. Alveolar soft part sarcoma usually occurs in the legs, but can also occur in the arms, hands, head, or neck. It can cause the growth of new blood vessels that help the tumor grow and spread.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alveolar Soft Part Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"ASPS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9581/3"},{"name":"Legacy Concept Name","value":"Alveolar_Soft_Part_Sarcoma"},{"name":"Maps_To","value":"9581/3"},{"name":"Maps_To","value":"Alveolar soft part sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206657"}]}}{"C7017":{"preferredName":"Granular Cell Tumor of the Sellar Region","code":"C7017","definitions":[{"definition":"A generally benign intrasellar and/or suprasellar mass arising from the neurohypophysis or infundibulum.  It is composed of nests of large cells with granular, eosinophilic cytoplasm due to abundant intracytoplasmic lysosomes. It generally has a slow progression and lacks invasive growth. (Adapted from WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granular Cell Tumor of the Sellar Region","termGroup":"PT","termSource":"NCI"},{"termName":"Granular Cell Tumor of Neurohypophysis","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Neurohypophysis","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Neurohypophysis (WHO Grade 1)","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Neurohypophysis (WHO Grade I)","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumor of the Posterior Pituitary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Cell Tumour of the Sellar Region/Granular Cell Pituicytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9582/0"},{"name":"Legacy Concept Name","value":"Granular_Cell_Tumor_of_the_Neurohypophysis"},{"name":"Maps_To","value":"9582/0"},{"name":"Maps_To","value":"Granular cell tumor of sellar region"},{"name":"Maps_To","value":"Granular cell tumor of the sellar region"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333873"}]}}{"C9301":{"preferredName":"Central Nervous System Lymphoma","code":"C9301","definitions":[{"definition":"A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the lymph tissue of the brain, spinal cord, meninges (outer covering of the brain), or eye (called ocular lymphoma).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Central Nervous System Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"CNS Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Lymphomas of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Lymphomas of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Central Nervous System Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary CNS Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Lymphoma"},{"name":"Maps_To","value":"9590/3"},{"name":"Maps_To","value":"Microglioma"},{"name":"Maps_To","value":"Primary central nervous system lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280803"}]}}{"C27258":{"preferredName":"Malignant Lymphoma, Non-Cleaved Cell Type","code":"C27258","synonyms":[{"termName":"Malignant Lymphoma, Non-Cleaved Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Non-Cleaved_Cell_Type"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Malignant lymphoma, non-cleaved cell, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1518190"}]}}{"C80308":{"preferredName":"Splenic B-Cell Lymphoma/Leukemia, Unclassifiable","code":"C80308","definitions":[{"definition":"A small B-cell clonal lymphoproliferative disorder of the spleen that does not fall into any of the other categories of mature B-cell neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic B-Cell Lymphoma/Leukemia, Unclassifiable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Splenic_B-Cell_Lymphoma_Leukemia_Unclassifiable"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Splenic B-cell lymphoma/leukemia, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699507"}]}}{"C27822":{"preferredName":"Diffuse Malignant Lymphoma","code":"C27822","definitions":[{"definition":"An antiquated term referring to non-Hodgkin lymphomas with a diffuse architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Malignant Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Malignant_Lymphoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Malignant lymphoma, diffuse, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334620"}]}}{"C27824":{"preferredName":"Reticulosarcoma","code":"C27824","definitions":[{"definition":"An antiquated term that refers to a non-Hodgkin lymphoma composed of diffuse infiltrates of large, often anaplastic lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reticulosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Reticulosarcoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Reticulosarcoma, NOS"},{"name":"Maps_To","value":"Reticulum cell sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024302"}]}}{"C26919":{"preferredName":"Lymphosarcoma","code":"C26919","definitions":[{"definition":"An antiquated term that refers to a non-Hodgkin lymphoma composed of small and medium sized lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"An obsolete term for a malignant tumor of lymphatic tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphosarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphosarcoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Lymphosarcoma, diffuse"},{"name":"Maps_To","value":"Lymphosarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3714542"}]}}{"C7401":{"preferredName":"Hairy Cell Leukemia Variant","code":"C7401","definitions":[{"definition":"An indolent chronic B-cell leukemia resembling classic hairy cell leukemia but shows variant cytologic, hematologic, and immunophenotypic features and is resistant to the conventional therapy applied to hairy cell leukemia.  Biologically, it is not related to hairy cell leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hairy Cell Leukemia Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Hairy Cell Leukemia-Variant","termGroup":"SY","termSource":"NCI"},{"termName":"HCL-V","termGroup":"AB","termSource":"NCI"},{"termName":"Prolymphocytic Variant of Hairy Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic B-Cell Lymphoma/Leukemia with Prominent Nucleoli","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Hairy_Cell_Leukemia_Variant"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"9940/3"},{"name":"Maps_To","value":"Hairy cell leukemia variant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349633"}]}}{"C80309":{"preferredName":"Splenic Diffuse Red Pulp Small B-Cell Lymphoma","code":"C80309","definitions":[{"definition":"An uncommon, indolent B-cell non-Hodgkin lymphoma composed of small B-lymphocytes involving the red pulp of the spleen, bone marrow, and peripheral blood.  Patients often have massive splenomegaly.  The peripheral blood examination reveals villous lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic Diffuse Red Pulp Small B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Splenic_Diffuse_Red_Pulp_Small_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Splenic diffuse red pulp small B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699508"}]}}{"C3211":{"preferredName":"Non-Hodgkin Lymphoma","code":"C3211","definitions":[{"definition":"A malignant neoplasm of the lymphatic system that is comprised of abnormal lymphocytes in the absence of Reed-Sternberg cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any of a large group of cancers of lymphocytes (white blood cells). NHLs can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of NHL. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and they can be formed from either B-cells or T-cells. B-cell NHLs include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell NHLs include mycosis fungoides, anaplastic large cell lymphoma, and precursor T-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or stem cell transplantation are usually B-cell NHLs. Prognosis and treatment depend on the stage and type of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"NHL","termGroup":"AB","termSource":"NCI"},{"termName":"Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Hodgkin's Lymphoma (NHL)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9591/3"},{"name":"Legacy Concept Name","value":"Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9591/3"},{"name":"Maps_To","value":"Large cell lymphoma"},{"name":"Maps_To","value":"Large cell lymphoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Large cell lymphoma involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Large cell lymphoma involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Large cell lymphoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Large cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Lymphosarcoma"},{"name":"Maps_To","value":"Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue"},{"name":"Maps_To","value":"Lymphosarcoma involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Lymphosarcoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Lymphosarcoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Malignant lymphoma, non-Hodgkin, NOS"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, NOS"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, unspecified"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Non-Hodgkin lymphoma, unspecified, unspecified site"},{"name":"Maps_To","value":"Non-Hodgkin's lymphoma"},{"name":"Maps_To","value":"Other and unspecified types of non-Hodgkin lymphoma"},{"name":"Maps_To","value":"Other named variants of lymphosarcoma and reticulosarcoma"},{"name":"Maps_To","value":"Other named variants of lymphosarcoma and reticulosarcoma, unspecified site"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Other specified types of non-Hodgkin lymphoma, unspecified site"},{"name":"Maps_To","value":"Reticulosarcoma"},{"name":"Maps_To","value":"Reticulosarcoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Reticulosarcoma involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Reticulosarcoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Reticulosarcoma, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024305"}]}}{"C38661":{"preferredName":"Composite Lymphoma","code":"C38661","definitions":[{"definition":"A rare form of lymphoma (cancer that begins in cells of the immune system) in which different types of lymphoma cells occur at the same time. The different lymphoma cells may form in the same tissue or organ or in many different tissues or organs. The composite lymphoma may contain different types of non-Hodgkin lymphoma cells or both Hodgkin and non-Hodgkin lymphoma cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Coexistence of Hodgkin and non-Hodgkin lymphoma in the same anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Composite Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9596/3"},{"name":"Legacy Concept Name","value":"Composite_Lymphoma"},{"name":"Maps_To","value":"9596/3"},{"name":"Maps_To","value":"Composite Hodgkin and non-Hodgkin lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0545080"}]}}{"C37869":{"preferredName":"Gray-Zone Lymphoma","code":"C37869","definitions":[{"definition":"A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classic Hodgkin lymphoma and diffuse large B-cell lymphoma.  This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classic Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gray-Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Gray Zone Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hodgkin-Like Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma with Hodgkin Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9596/3"},{"name":"Legacy Concept Name","value":"Gray_Zone_Lymphoma"},{"name":"Maps_To","value":"9596/3"},{"name":"Maps_To","value":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333878"}]}}{"C7217":{"preferredName":"Primary Cutaneous Follicle Center Lymphoma","code":"C7217","definitions":[{"definition":"A primary lymphoma of the skin composed of various numbers of small and large irregular neoplastic follicle center cells.  Its morphologic pattern can be nodular, diffuse, or nodular and diffuse.  It presents with solitary or grouped plaques and tumors, and it usually involves the scalp, forehead, or trunk.  It rarely involves the legs.  This type of cutaneous lymphoma tends to remain localized to the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Follicle Center Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Crosti's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Follicle Center Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous Follicle Centre Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PCFCL","termGroup":"AB","termSource":"NCI"},{"termName":"Reticulohistiocytoma of the Dorsum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9597/3"},{"name":"Legacy Concept Name","value":"Cutaneous_Follicle_Center_Lymphoma"},{"name":"Maps_To","value":"9597/3"},{"name":"Maps_To","value":"Primary cutaneous follicle center lymphoma"},{"name":"Maps_To","value":"Primary cutaneous follicle centre lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333171"}]}}{"C6913":{"preferredName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","code":"C6913","definitions":[{"definition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"LRCHL","termGroup":"AB","termSource":"NCI"},{"termName":"Lymphocyte Rich Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Rich Classical Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte Rich Classical Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Rich Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Rich Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte Rich Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Rich Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Rich Classical Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9651/3"},{"name":"Legacy Concept Name","value":"Lymphocyte_Rich_Classical_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9651/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, lymphocyte-rich"},{"name":"Maps_To","value":"Hodgkin disease, lymphocyte predominance, diffuse"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte-rich"},{"name":"Maps_To","value":"Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Lymphocyte-rich classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266194"}]}}{"C8590":{"preferredName":"Lymphocyte Predominant Type Hodgkin's Disease","code":"C8590","definitions":[{"definition":"An antiquated term that refers either to nodular lymphocyte predominant Hodgkin lymphoma or to lymphocyte-rich classical Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte Predominant Type Hodgkin's Disease","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocyte_Predominant_Type_Hodgkin_s_Disease"},{"name":"Maps_To","value":"9651/3"},{"name":"Maps_To","value":"Hodgkin disease, lymphocyte predominance, NOS"},{"name":"Maps_To","value":"Hodgkin disease, lymphocytic-histiocytic predominance"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0852444"}]}}{"C3517":{"preferredName":"Mixed Cellularity Classic Hodgkin Lymphoma","code":"C3517","definitions":[{"definition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Cellularity Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Disease Mixed Cellularity","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Lymphoma Mixed Cellularity","termGroup":"SY","termSource":"NCI"},{"termName":"MCCHL","termGroup":"AB","termSource":"NCI"},{"termName":"MCHL","termGroup":"AB","termSource":"NCI"},{"termName":"Mixed Cellularity Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cellularity Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Cellularity Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Mixed Cellularity Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9652/3"},{"name":"Legacy Concept Name","value":"Mixed_Cellularity_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9652/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, mixed cellularity, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, mixed cellularity, NOS"},{"name":"Maps_To","value":"Hodgkin's disease, mixed cellularity"},{"name":"Maps_To","value":"Hodgkin's disease, mixed cellularity, involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, mixed cellularity, involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mixed cellularity classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152266"}]}}{"C9283":{"preferredName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","code":"C9283","definitions":[{"definition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin Lymphoma Lymphocyte Depleted","termGroup":"SY","termSource":"NCI"},{"termName":"Hodgkin's Disease Lymphocyte Depletion","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Lymphoma Lymphocyte Depleted","termGroup":"SY","termSource":"NCI"},{"termName":"LDCHL","termGroup":"AB","termSource":"NCI"},{"termName":"LDHL","termGroup":"AB","termSource":"NCI"},{"termName":"Lymphocyte Depleted Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Depleted Classical Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Depleted Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Depleted Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte Depleted Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Depleted Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte-Depleted Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphocyte-Depleted Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9653/3"},{"name":"ICD-O-3_Code","value":"9662/3"},{"name":"Legacy Concept Name","value":"Lymphocyte_Depleted_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9653/3"},{"name":"Maps_To","value":"9654/3"},{"name":"Maps_To","value":"9655/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, lymphocyte depletion, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte depletion, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte depletion, reticular"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic depletion"},{"name":"Maps_To","value":"Hodgkin's sarcoma"},{"name":"Maps_To","value":"Hodgkin's sarcoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Lymphocyte depleted classical Hodgkin lymphoma"},{"name":"Maps_To","value":"Lymphocyte depleted classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152267"}]}}{"C7258":{"preferredName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","code":"C7258","definitions":[{"definition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of Hodgkin lymphoma, which is a cancer of the immune system. It is marked by the presence of a type of cell called a popcorn cell, which is different from the typical Reed-Sternberg cell found in classical Hodgkin lymphoma. This type of Hodgkin lymphoma may change into diffuse large B-cell lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"NLP-BCL","termGroup":"AB","termSource":"NCI"},{"termName":"NLPBL","termGroup":"AB","termSource":"NCI"},{"termName":"NLPHL","termGroup":"AB","termSource":"NCI"},{"termName":"Nodular Lymphocyte Predominant B-Cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Lymphocyte Predominant Hodgkin's Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9659/3"},{"name":"Legacy Concept Name","value":"Nodular_Lymphocyte_Predominant_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9659/3"},{"name":"Maps_To","value":"Hodgkin lymphoma, lymphocyte predominance, nodular"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular lymphocyte predominance"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular lymphocyte predominant"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin's disease, lymphocytic-histiocytic predominance, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334968"}]}}{"C26956":{"preferredName":"Hodgkin's Paragranuloma","code":"C26956","definitions":[{"definition":"An obsolete term that includes cases currently classified as nodular lymphocyte predominant Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin's Paragranuloma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Paragranuloma"},{"name":"Maps_To","value":"9659/3"},{"name":"Maps_To","value":"Hodgkin paragranuloma, nodular"},{"name":"Maps_To","value":"Hodgkin paragranuloma, NOS"},{"name":"Maps_To","value":"Hodgkin's paragranuloma"},{"name":"Maps_To","value":"Hodgkin's paragranuloma, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2239290"}]}}{"C6914":{"preferredName":"Hodgkin's Granuloma","code":"C6914","definitions":[{"definition":"An obsolete term that refers to cases of Hodgkin lymphoma excluding cases that were classified as Hodgkin's paragranuloma and Hodgkin's sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin Granuloma","termGroup":"AQS","termSource":"NCI"},{"termName":"Hodgkin's Granuloma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9661/3"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Granuloma"},{"name":"Maps_To","value":"9661/3"},{"name":"Maps_To","value":"Hodgkin granuloma"},{"name":"Maps_To","value":"Hodgkin's granuloma"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0334626"}]}}{"C164145":{"preferredName":"Hodgkin's Sarcoma","code":"C164145","definitions":[{"definition":"An obsolete term referring to a Hodgkin lymphoma that lacks inflammatory elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin's Sarcoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9662/3"},{"name":"Maps_To","value":"Hodgkin sarcoma"},{"name":"NCI_META_CUI","value":"CL977332"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3518":{"preferredName":"Nodular Sclerosis Classic Hodgkin Lymphoma","code":"C3518","definitions":[{"definition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Sclerosis Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Nodular Sclerosis","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin's Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"NSCHL","termGroup":"AB","termSource":"NCI"},{"termName":"NSHD","termGroup":"AQS","termSource":"NCI"},{"termName":"NSHL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9663/3"},{"name":"Legacy Concept Name","value":"Nodular_Sclerosis_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9663/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, NOS"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, NOS"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, NOS"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving intrathoracic lymph nodes"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Hodgkin's disease, nodular sclerosis, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Nodular sclerosis classical Hodgkin lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152268"}]}}{"C67171":{"preferredName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase","code":"C67171","definitions":[{"definition":"A nodular sclerosis Hodgkin lymphoma characterized by the presence of lacunar cells, nodular growth, and the absence of fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Disease Nodular Sclerosis, Cellular Phase","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Sclerosis Classical Hodgkin Lymphoma, Cellular Phase","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin Lymphoma, Cellular Phase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9664/3"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Cellular_Phase"},{"name":"Maps_To","value":"9664/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, cellular phase"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, cellular phase"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334627"}]}}{"C27270":{"preferredName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance","code":"C27270","synonyms":[{"termName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Lymphocyte_Predominance"},{"name":"Maps_To","value":"9665/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, lymphocyte predominance"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1264183"}]}}{"C27098":{"preferredName":"Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity","code":"C27098","synonyms":[{"termName":"Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Mixed_Cellularity"},{"name":"Maps_To","value":"9665/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, mixed cellularity"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334629"}]}}{"C7165":{"preferredName":"Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma","code":"C7165","definitions":[{"definition":"Nodular sclerosis Hodgkin lymphoma in which at least 75% of the tumor nodules contain scattered Reed-Sternberg cells. The background cellular infiltrate is lymphocytic, mixed, or fibrohistiocytic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Nodular Sclerosis Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Nodular Sclerosis Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 1 Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9665/3"},{"name":"Legacy Concept Name","value":"Grade_1_Nodular_Sclerosis_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9665/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, grade 1"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, grade 1"},{"name":"Maps_To","value":"Hodgkin lymphoma,nodular sclerosis,  grade 1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1521899"}]}}{"C27808":{"preferredName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion","code":"C27808","synonyms":[{"termName":"Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Lymphocyte_Depletion"},{"name":"Maps_To","value":"9667/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, lymphocyte depletion"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334630"}]}}{"C27807":{"preferredName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant","code":"C27807","synonyms":[{"termName":"Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Hodgkin's Disease, Nodular Sclerosis, Syncytial Variant","termGroup":"AQS","termSource":"NCI"},{"termName":"Nodular Sclerosis Classical Hodgkin Lymphoma, Syncytial Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Sclerosis Hodgkin Lymphoma, Syncytial Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Disease_Nodular_Sclerosis_Syncytial_Variant"},{"name":"Maps_To","value":"9667/3"},{"name":"Maps_To","value":"Hodgkin disease, nodular sclerosis, syncytial variant"},{"name":"NCI_META_CUI","value":"CL054962"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7166":{"preferredName":"Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma","code":"C7166","definitions":[{"definition":"Nodular sclerosis Hodgkin lymphoma in which at least 25% of the tumor nodules contain increased numbers of Reed-Sternberg cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Nodular Sclerosis Classical Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Nodular Sclerosis Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 2 Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Nodular Sclerosis Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9667/3"},{"name":"Legacy Concept Name","value":"Grade_2_Nodular_Sclerosis_Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9667/3"},{"name":"Maps_To","value":"Classical Hodgkin lymphoma, nodular sclerosis, grade 2"},{"name":"Maps_To","value":"Hodgkin lymphoma, nodular sclerosis, grade 2"},{"name":"NCI_META_CUI","value":"CL448834"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7540":{"preferredName":"Small Lymphocytic Lymphoma","code":"C7540","definitions":[{"definition":"A malignant neoplasm composed of small lymphocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of lymphoma in which too many immature lymphocytes (white blood cells) are found mostly in the lymph nodes. This causes the lymph nodes to become larger than normal. Sometimes cancer cells are found in the blood and bone marrow, and the disease is called chronic lymphocytic leukemia. The disease is most often seen in people older than 50 years. SLL is a type of non-Hodgkin Lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Small Lymphocytic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Small Lymphocytic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Well Differentiated Lymphocytic Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"SLL","termGroup":"AB","termSource":"NCI"},{"termName":"Small B-Cell Lymphocytic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9670/3"},{"name":"Legacy Concept Name","value":"Small_Lymphocytic_Lymphoma"},{"name":"Maps_To","value":"9670/3"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, diffuse, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, well differentiated, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, small B lymphocytic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, small cell diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, small cell, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, small lymphocytic, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, small lymphocytic, NOS"},{"name":"Maps_To","value":"Small cell B-cell lymphoma"},{"name":"Maps_To","value":"Small cell B-cell lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855095"}]}}{"C3212":{"preferredName":"Lymphoplasmacytic Lymphoma","code":"C3212","definitions":[{"definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of lymphocytes (B-cells), lymphoplasmacytoid cells, and plasma cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymphoplasmacytic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Immunocytoma, Lymphoplasmacytic Type","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphoplasmacytoid Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9671/3"},{"name":"ICD-O-3_Code","value":"9761/3"},{"name":"Legacy Concept Name","value":"Lymphoplasmacytic_Lymphoma_Waldenstrom_s_Macroglobulinemia"},{"name":"Maps_To","value":"9671/3"},{"name":"Maps_To","value":"Lymphoplasmacytic lymphoma"},{"name":"Maps_To","value":"Malignant lymphoma, lymphoplasmacytic"},{"name":"Maps_To","value":"Malignant lymphoma, lymphoplasmacytoid"},{"name":"Maps_To","value":"Malignant lymphoma, plasmacytoid"},{"name":"Maps_To","value":"Plasmacytic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334633"}]}}{"C3898":{"preferredName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","code":"C3898","definitions":[{"definition":"A type of cancer that arises in cells in mucosal tissue that are involved in antibody production.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Immunocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"MALToma","termGroup":"SY","termSource":"NCI"},{"termName":"Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9699/3"},{"name":"Legacy Concept Name","value":"Extranodal_Marginal_Zone_B-Cell_Lymphoma_of_Mucosa-Associated_Lymphoid_Tissue"},{"name":"Maps_To","value":"9671/3"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue"},{"name":"Maps_To","value":"Immunocytoma"},{"name":"Maps_To","value":"MALT lymphoma"},{"name":"Maps_To","value":"Marginal zone lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mucosal-associated lymphoid tissue lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0242647"}]}}{"C4339":{"preferredName":"Multifocal Lymphomatous Polyposis","code":"C4339","definitions":[{"definition":"A clinico-pathological entity reflecting the multiple polyps throughout the gastrointestinal tract created as a result of involvement by a non-Hodgkin lymphoma. Typically, mantle cell lymphomas involving the gastrointestinal tract give rise to multifocal lymphomatous polyposis. Importantly, other histologic subtypes of non-Hodgkin lymphoma can also produce this clinico-pathological entity.  (WHO, 2000)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multifocal Lymphomatous Polyposis","termGroup":"PT","termSource":"NCI"},{"termName":"Multiple Lymphomatous Polyposis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Multifocal_Lymphomatous_Polyposis"},{"name":"Maps_To","value":"9673/3"},{"name":"Maps_To","value":"Malignant lymphomatous polyposis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334638"}]}}{"C4337":{"preferredName":"Mantle Cell Lymphoma","code":"C4337","definitions":[{"definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma that usually occurs in middle-aged or older adults. It is marked by small- to medium-size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood, and gastrointestinal system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mantle Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Classical Mantle Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mantle Zone Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"MCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9673/3"},{"name":"Legacy Concept Name","value":"Mantle_Cell_Lymphoma"},{"name":"Maps_To","value":"9673/3"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"},{"name":"Maps_To","value":"Mantle cell lymphoma"},{"name":"Maps_To","value":"Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)"},{"name":"Maps_To","value":"Mantle cell lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mantle cell lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mantle cell lymphoma, unspecified site"},{"name":"Maps_To","value":"Mantle cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Mantle zone lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334634"}]}}{"C4338":{"preferredName":"Diffuse Centroblastic-Centrocytic Lymphoma","code":"C4338","synonyms":[{"termName":"CB/CC","termGroup":"AB","termSource":"NCI"},{"termName":"Diffuse Centroblastic-Centrocytic Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Centroblastic-Centrocytic_Lymphoma"},{"name":"Maps_To","value":"9675/3"},{"name":"Maps_To","value":"Malignant lymphoma, centroblasticcentrocytic, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, centroblasticcentrocytic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334637"}]}}{"C3463":{"preferredName":"Diffuse Mixed Cell Lymphoma","code":"C3463","definitions":[{"definition":"An antiquated term referring to non-Hodgkin lymphomas with a mixed cellular composition. This term applies to both B- and T- cell non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Mixed Cell Lymphoma","termGroup":"AQ","termSource":"NCI"},{"termName":"Diffuse Mixed Large and Small Cell Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9675/3"},{"name":"Legacy Concept Name","value":"Diffuse_Mixed_Cell_Lymphoma"},{"name":"Maps_To","value":"9675/3"},{"name":"Maps_To","value":"Malignant lymphoma, mixed cell type, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, mixed small and large cell, diffuse"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079757"}]}}{"C6915":{"preferredName":"Primary Effusion Lymphoma","code":"C6915","definitions":[{"definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","type":"DEFINITION","source":"NCI"},{"definition":"A rare, aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma marked by an abnormal build-up of fluids in a body cavity. It usually occurs together with a human herpesvirus in people who have weakened immune systems, such as in AIDS.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Effusion Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"PEL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9678/3"},{"name":"Legacy Concept Name","value":"Primary_Effusion_Lymphoma"},{"name":"Maps_To","value":"9678/3"},{"name":"Maps_To","value":"Primary effusion lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292753"}]}}{"C9280":{"preferredName":"Primary Mediastinal Large B-Cell Lymphoma","code":"C9280","definitions":[{"definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Mediastinal Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Diffuse Large Cell Lymphoma of Mediastinum","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Diffuse Large Cell Lymphoma of the Mediastinum","termGroup":"SY","termSource":"NCI"},{"termName":"Mediastinal (Thymic) Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mediastinal B-Cell Diffuse Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mediastinal Diffuse Large Cell Lymphoma with Sclerosis","termGroup":"AQS","termSource":"NCI"},{"termName":"PMBL","termGroup":"AB","termSource":"NCI"},{"termName":"PMLCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Mediastinal Clear Cell Lymphoma of B-Cell Type","termGroup":"AQS","termSource":"NCI"},{"termName":"Primary Mediastinal Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9679/3"},{"name":"Legacy Concept Name","value":"Mediastinal_Thymic_Large_B-Cell_Cell_Lymphoma"},{"name":"Maps_To","value":"9679/3"},{"name":"Maps_To","value":"Mediastinal (thymic) large B-cell lymphoma"},{"name":"Maps_To","value":"Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Mediastinal large B-cell lymphoma"},{"name":"Maps_To","value":"Thymic large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292754"}]}}{"C27099":{"preferredName":"Malignant Lymphoma, Histiocytic, Diffuse","code":"C27099","synonyms":[{"termName":"Malignant Lymphoma, Histiocytic, Diffuse","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Histiocytic_Diffuse"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, histiocytic, diffuse"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1521844"}]}}{"C4074":{"preferredName":"Centroblastic Lymphoma","code":"C4074","definitions":[{"definition":"A B-cell non-Hodgkin lymphoma composed of large noncleaved cells. This is a subtype of diffuse large B-cell non-Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Centroblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Centroblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Centroblastic_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, centroblastic, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, centroblastic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302329"}]}}{"C80289":{"preferredName":"Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation","code":"C80289","definitions":[{"definition":"A diffuse large B-cell lymphoma arising in body cavities or narrow spaces of long standing chronic inflammation.  The classic example is the pyothorax-associated lymphoma that arises in the pleural cavity of patients with a history of long standing pyothorax.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation","termGroup":"PT","termSource":"NCI"},{"termName":"DLBCL-CI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma_Associated_with_Chronic_Inflammation"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma associated with chronic inflammation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699776"}]}}{"C80281":{"preferredName":"EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","code":"C80281","definitions":[{"definition":"A diffuse large B-cell lymphoma originally described in patients older than 50 years, but it has been increasingly recognized in younger patients. Epstein-Barr virus is present in all cases. There is no known history of immunodeficiency or prior lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Age-Related EBV Positive B-Cell Lymphoproliferative Disorder","termGroup":"AQS","termSource":"NCI"},{"termName":"EBV Positive Diffuse Large B-Cell Lymphoma of the Elderly","termGroup":"AQS","termSource":"NCI"},{"termName":"EBV-Positive Diffuse Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"EBV-Positive DLBCL, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly","termGroup":"AQS","termSource":"NCI"},{"termName":"Epstein-Barr Virus Positive DLBCL, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Senile EBV-Associated B-Cell Lymphoproliferative Disorder","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Epstein-Barr_Virus_Positive_Diffuse_Large_B-Cell_Lymphoma_of_the_Elderly"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"EBV positive diffuse large B-cell lymphoma of the elderly"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2700007"}]}}{"C6916":{"preferredName":"Anaplastic Lymphoma","code":"C6916","definitions":[{"definition":"A diffuse large B-cell lymphoma variant characterized by the presence of large round, oval, or polygonal cells with bizarre pleomorphic nuclei resembling Hodgkin or Reed-Sternberg cells. It is unrelated to anaplastic large cell lymphoma which is a T-cell non-Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anaplastic_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Anaplastic large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321546"}]}}{"C80291":{"preferredName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","code":"C80291","definitions":[{"definition":"High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"BCLU","termGroup":"AB","termSource":"NCI"},{"termName":"HGBL, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"High Grade B-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade B-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade B-Cell Lymphoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"B-Cell_Lymphoma_Unclassifiable_with_Features_Intermediate_between_Diffuse_Large_B-Cell_Lymphoma_and_Burkitt_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698294"}]}}{"C9496":{"preferredName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","code":"C9496","definitions":[{"definition":"A large B-cell lymphoma characterized by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"T-Cell Rich/Histiocyte-Rich Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell/Histiocyte Rich Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"THRLBCL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"ICD-O-3_Code","value":"9688/3"},{"name":"Legacy Concept Name","value":"T-Cell_Histiocyte_Rich_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"9688/3"},{"name":"Maps_To","value":"Histiocyte-rich large B-cell lymphoma"},{"name":"Maps_To","value":"T-cell rich large B-cell lymphoma"},{"name":"Maps_To","value":"T-cell rich/histiocyte-rich large B-cell lymphoma"},{"name":"Maps_To","value":"T-cell/histiocyte rich large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321547"}]}}{"C4342":{"preferredName":"Intravascular Large B-Cell Lymphoma","code":"C4342","definitions":[{"definition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intravascular Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiotropic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Angiotropic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Intravascular B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"IVLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Malignant Angioendotheliomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9712/3"},{"name":"Legacy Concept Name","value":"Intravascular_Large_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"9712/3"},{"name":"Maps_To","value":"Angioendotheliomatosis"},{"name":"Maps_To","value":"Angiotropic lymphoma"},{"name":"Maps_To","value":"Intravascular B-cell lymphoma"},{"name":"Maps_To","value":"Intravascular large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334660"}]}}{"C80280":{"preferredName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","code":"C80280","definitions":[{"definition":"A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous. These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, diffuse, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699777"}]}}{"C27823":{"preferredName":"Malignant Lymphoma, Large Cell Type","code":"C27823","definitions":[{"definition":"An antiquated term that refers to a morphologic variant of non-Hodgkin lymphoma which is composed predominantly or exclusively of large neoplastic lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma, Large Cell Type","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Large_Cell_Type"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518189"}]}}{"C27265":{"preferredName":"Malignant Lymphoma, Large Cell, Cleaved","code":"C27265","definitions":[{"definition":"Antiquated term describing non-Hodgkin lymphomas that are usually diffuse and are composed of large cells with irregular nuclei, invisible nucleoli and a small amount of cytoplasm.  This morphologic category includes both mature B- and mature T-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma, Large Cell, Cleaved","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Large_Cell_Cleaved"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, cleaved, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, cleaved, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cleaved cell, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334641"}]}}{"C27266":{"preferredName":"Malignant Lymphoma, Non-Cleaved, Diffuse","code":"C27266","definitions":[{"definition":"Antiquated term for diffuse non-Hodgkin lymphomas composed of non-cleaved cells.  The vast majority of cases are mature B-cell lymphomas (Burkitts or diffuse large B-cell lymphomas).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma, Non-Cleaved, Diffuse","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Non-Cleaved_Diffuse"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, noncleaved, diffuse"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, noncleaved, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, noncleaved, diffuse, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, noncleaved, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334642"}]}}{"C8851":{"preferredName":"Diffuse Large B-Cell Lymphoma","code":"C8851","definitions":[{"definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually aggressive (fast-growing). It is the most common type of non-Hodgkin lymphoma, and is marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. Other symptoms include fever, night sweats, and weight loss. There are several subtypes of diffuse large B-cell lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"DLBCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9680/3"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma"},{"name":"Maps_To","value":"Diffuse Large B-Cell Lymphoma (DLBCL)"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Diffuse large B-cell lymphoma, unspecified site"},{"name":"Maps_To","value":"Malignant lymphoma, histiocytic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, cleaved and noncleaved"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, diffuse, NOS"},{"name":"Maps_To","value":"Non-follicular lymphoma"},{"name":"Maps_To","value":"Other non-follicular lymphoma, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079744"}]}}{"C3461":{"preferredName":"Immunoblastic Lymphoma","code":"C3461","definitions":[{"definition":"A diffuse large B-cell lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, a prominent nucleolus, and abundant cytoplasm.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of immunoblasts (large B cells).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Immunoblastic Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9684/3"},{"name":"Legacy Concept Name","value":"Immunoblastic_Lymphoma"},{"name":"Maps_To","value":"9684/3"},{"name":"Maps_To","value":"Immunoblastic sarcoma"},{"name":"Maps_To","value":"Malignant lymphoma, immunoblastic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, immunoblastic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079746"}]}}{"C6917":{"preferredName":"Atypical Burkitt/Burkitt-Like Lymphoma","code":"C6917","definitions":[{"definition":"A morphologic variant of Burkitt lymphoma characterized by marked nuclear pleomorphism, abundant apoptotic debris, and the presence of tangible body macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Burkitt/Burkitt-Like Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Burkitt's/Burkitt's-Like Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Burkitt's-like Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Burkitt-like Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Burkitt_s_Burkitt_s-Like_Lymphoma"},{"name":"Maps_To","value":"9687/3"},{"name":"Maps_To","value":"Burkitt-like lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1368771"}]}}{"C2912":{"preferredName":"Burkitt Lymphoma","code":"C2912","definitions":[{"definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma that occurs most often in children and young adults. The disease may affect the jaw, central nervous system, bowel, kidneys, ovaries, or other organs. There are three main types of Burkitt lymphoma (sporadic, endemic, and immunodeficiency related). Sporadic Burkitt lymphoma occurs throughout the world, and endemic Burkitt lymphoma occurs in Africa. Immunodeficiency-related Burkitt lymphoma is most often seen in AIDS patients.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Burkitt Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Burkitt's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Small Non-Cleaved Cell Lymphoma, Burkitt's Type","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9687/3"},{"name":"Legacy Concept Name","value":"Burkitt_s_Lymphoma"},{"name":"Maps_To","value":"9687/3"},{"name":"Maps_To","value":"Burkitt lymphoma"},{"name":"Maps_To","value":"Burkitt lymphoma, extranodal and solid organ sites"},{"name":"Maps_To","value":"Burkitt lymphoma, intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Burkitt lymphoma, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Burkitt lymphoma, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Burkitt lymphoma, NOS"},{"name":"Maps_To","value":"Burkitt lymphoma, NOS (Includes all variants)"},{"name":"Maps_To","value":"Burkitt lymphoma, unspecified site"},{"name":"Maps_To","value":"Burkitt tumor"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma involving lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Burkitt's tumor or lymphoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Malignant lymphoma, small noncleaved, Burkitt type"},{"name":"Maps_To","value":"Malignant lymphoma, undifferentiated, Burkitt type"},{"name":"Maps_To","value":"NHL, Burkitt lymphoma (BL)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0006413"}]}}{"C4663":{"preferredName":"Splenic Marginal Zone Lymphoma","code":"C4663","definitions":[{"definition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic Marginal Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Marginal Zone Lymphoma of Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Marginal Zone Lymphoma of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"SLVL","termGroup":"AB","termSource":"NCI"},{"termName":"SMZL","termGroup":"AB","termSource":"NCI"},{"termName":"Splenic Lymphoma with Circulating Villous Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Marginal Zone B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Marginal Zone B-Cell Lymphoma with Villous Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Marginal Zone Lymphoma with Villous Lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9689/3"},{"name":"Legacy Concept Name","value":"Splenic_Marginal_Zone_Lymphoma"},{"name":"Maps_To","value":"9689/3"},{"name":"Maps_To","value":"Splenic marginal zone B-cell lymphoma"},{"name":"Maps_To","value":"Splenic marginal zone lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349632"}]}}{"C3209":{"preferredName":"Follicular Lymphoma","code":"C3209","definitions":[{"definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","type":"DEFINITION","source":"NCI"},{"definition":"A neoplasm of lymphoid cells which has at least a partial follicular pattern.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually indolent (slow-growing). The tumor cells grow as groups to form nodules. There are several subtypes of follicular lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicle Center Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Non-Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9690/3"},{"name":"Legacy Concept Name","value":"Follicular_Lymphoma"},{"name":"Maps_To","value":"9690/3"},{"name":"Maps_To","value":"Follicular lymphoma"},{"name":"Maps_To","value":"Follicular lymphoma, NOS"},{"name":"Maps_To","value":"Follicular lymphoma, unspecified"},{"name":"Maps_To","value":"Follicular lymphoma, unspecified, unspecified site"},{"name":"Maps_To","value":"Malignant lymphoma, centroblasticcentrocytic, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, follicle center, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, follicle center, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, follicular, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, nodular, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, nodular, NOS"},{"name":"Maps_To","value":"Nodular lymphoma"},{"name":"Maps_To","value":"Nodular lymphoma involving intra-abdominal lymph nodes"},{"name":"Maps_To","value":"Nodular lymphoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Nodular lymphoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Nodular lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Other types of follicular lymphoma, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024301"}]}}{"C8968":{"preferredName":"Grade 2 Follicular Lymphoma","code":"C8968","definitions":[{"definition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of B-cell non-Hodgkin lymphoma (cancer of the lymphatic system) in which there are both small and large cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Grade 2 Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 2","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Mixed Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Mixed Lymphocytic-Histiocytic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Follicular Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II Follicular Mixed Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Mixed Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9691/3"},{"name":"Legacy Concept Name","value":"Grade_2_Follicular_Lymphoma"},{"name":"Maps_To","value":"9691/3"},{"name":"Maps_To","value":"Follicular lymphoma grade II, intrathoracic lymph nodes"},{"name":"Maps_To","value":"Follicular lymphoma grade II, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Follicular lymphoma, grade 2"},{"name":"Maps_To","value":"Malignant lymphoma, mixed cell type, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, mixed cell type, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, mixed lymphocytic-histiocytic, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, mixed small cleaved and large cell, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079758"}]}}{"C3465":{"preferredName":"Grade 1 Follicular Lymphoma","code":"C3465","definitions":[{"definition":"A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of non-Hodgkin lymphoma marked by enlarged lymph nodes and small cells that have cleaved (u-shaped) nuclei.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Grade 1 Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 1","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Small Cleaved Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Grade I Follicular Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I Follicular Small Cleaved Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Poorly Differentiated Nodular Lymphocytic Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9695/3"},{"name":"Legacy Concept Name","value":"Grade_1_Follicular_Lymphoma"},{"name":"Maps_To","value":"9695/3"},{"name":"Maps_To","value":"Follicular lymphoma grade I, unspecified site"},{"name":"Maps_To","value":"Follicular lymphoma, grade 1"},{"name":"Maps_To","value":"Follicular lymphoma, small cleaved cell"},{"name":"Maps_To","value":"Malignant lymphoma, lymphocytic, poorly differentiated, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, small cleaved cell, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079765"}]}}{"C3460":{"preferredName":"Grade 3 Follicular Lymphoma","code":"C3460","definitions":[{"definition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","type":"DEFINITION","source":"NCI"},{"definition":"A type of non-Hodgkin lymphoma marked by large cells and enlarged lymph nodes. Grade 3 follicular lymphoma is less common, and more aggressive than grades 1 or 2 follicular lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Grade 3 Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Lymphoma, Predominantly Large Cell","termGroup":"AQS","termSource":"NCI"},{"termName":"Grade III Follicular Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Follicular Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodular Histiocytic Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9698/3"},{"name":"Legacy Concept Name","value":"Grade_3_Follicular_Lymphoma"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Follicular lymphoma grade III, unspecified"},{"name":"Maps_To","value":"Follicular lymphoma, grade 3"},{"name":"Maps_To","value":"Malignant lymphoma, histiocytic, nodular"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, follicular, NOS"},{"name":"Maps_To","value":"Malignant lymphoma, large cell, noncleaved, follicular"},{"name":"Maps_To","value":"Malignant lymphoma, large cleaved cell, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079745"}]}}{"C7192":{"preferredName":"Grade 3b Follicular Lymphoma","code":"C7192","definitions":[{"definition":"A grade 3 follicular lymphoma composed of solid sheets of centroblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 3b Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"FLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Follicular Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 3b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9698/3"},{"name":"Legacy Concept Name","value":"Grade_3b_Follicular_Lymphoma"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Follicular lymphoma, grade 3B"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2853827"}]}}{"C7191":{"preferredName":"Grade 3a Follicular Lymphoma","code":"C7191","definitions":[{"definition":"A grade 3 follicular lymphoma in which centrocytes are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 3a Follicular Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Follicular Lymphoma Grade 3a","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Follicular Lymphoma Histologic Grade 3a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9698/3"},{"name":"Legacy Concept Name","value":"Grade_3a_Follicular_Lymphoma"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Follicular lymphoma grade IIIa, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Follicular lymphoma grade IIIa, unspecified site"},{"name":"Maps_To","value":"Follicular lymphoma, grade 3A"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333846"}]}}{"C8994":{"preferredName":"Malignant Lymphoma Centroblastic, Follicular","code":"C8994","definitions":[{"definition":"An antiquated term that refers to a follicular non-Hodgkin lymphoma composed predominantly of large B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymphoma Centroblastic, Follicular","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Centroblastic_Follicular"},{"name":"Maps_To","value":"9698/3"},{"name":"Maps_To","value":"Malignant lymphoma, centroblastic, follicular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862984"}]}}{"C7230":{"preferredName":"Primary Cutaneous Marginal Zone Lymphoproliferative Disorder","code":"C7230","definitions":[{"definition":"A B-cell lymphoproliferative disorder that arises from the skin. It was previously known as primary cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue. Two subtypes are recognized: heavy chain class-switched primary cutaneous marginal zone lymphoproliferative disorder and IgM-positive primary cutaneous marginal zone lymphoproliferative disorder. The majority of cases are class-switched and predominantly IgG-positive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Marginal Zone Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"C-MALT","termGroup":"AB","termSource":"NCI"},{"termName":"Cutaneous Immunocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Marginal Zone B Cell Lymphoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Marginal Zone B Cell Lymphoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"PCMZL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous Marginal Zone B Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"SALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cutaneous_Marginal_Zone_B_Cell_Lymphoma_of_Mucosa-Associated_Lymphoid_Tissue"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"SALT lymphoma"},{"name":"Maps_To","value":"Skin-associated lymphoid tissue lymphoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275321"}]}}{"C8863":{"preferredName":"Nodal Marginal Zone Lymphoma","code":"C8863","definitions":[{"definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodal Marginal Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Monocytoid B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Nodal Marginal Zone B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nodal_Marginal_Zone_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"Monocytoid B-cell lymphoma"},{"name":"Maps_To","value":"Nodal marginal zone lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855139"}]}}{"C4341":{"preferredName":"Marginal Zone Lymphoma","code":"C4341","definitions":[{"definition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","type":"DEFINITION","source":"NCI"},{"definition":"An indolent (slow-growing) type of B-cell non-Hodgkin lymphoma that begins forming in certain areas (the marginal zones) of lymph tissue. There are three types based on whether it forms in the spleen, lymph nodes, or other lymphoid tissue that contains a lot of B cells (a type of white blood cell).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Marginal Zone Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Marginal Zone B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"MZBCL","termGroup":"AB","termSource":"NCI"},{"termName":"MZL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9699/3"},{"name":"Legacy Concept Name","value":"Marginal_Zone_B-Cell_Lymphoma"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"Marginal zone B-cell lymphoma, NOS"},{"name":"Maps_To","value":"Marginal zone lymphoma"},{"name":"Maps_To","value":"Marginal zone lymphoma involving lymph nodes of inguinal region and lower limb"},{"name":"Maps_To","value":"Marginal zone lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367654"}]}}{"C5264":{"preferredName":"Lung Mucosa-Associated Lymphoid Tissue Lymphoma","code":"C5264","definitions":[{"definition":"An extranodal marginal zone lymphoma that arises from the lung.  It is characterized by the neoplastic proliferation of small B-lymphocytes, monocytoid cells and cells with plasma cell differentiation in the marginal zones of reactive lymphoid follicles.  The neoplastic cells infiltrate the interfollicular areas and the bronchial epithelium forming lymphoepithelial lesions.  The neoplasm is usually discovered as a mass in a chest x-ray in asymptomatic patients.  When symptoms occur, they include cough, dyspnea, hemoptysis, and chest pain.  If the lung lesions are resectable, surgery can result in prolonged remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"BALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"BALToma","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchial MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchus-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Lung MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary MALT Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bronchial_Mucosa-Associated_Lymphoid_Tissue_Lymphoma"},{"name":"Maps_To","value":"9699/3"},{"name":"Maps_To","value":"BALT lymphoma"},{"name":"Maps_To","value":"Bronchial-associated lymphoid tissue lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367652"}]}}{"C3246":{"preferredName":"Mycosis Fungoides","code":"C3246","definitions":[{"definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A type of non-Hodgkin's lymphoma that first appears on the skin and can spread to the lymph nodes or other organs such as the spleen, liver, or lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mycosis Fungoides","termGroup":"PT","termSource":"NCI"},{"termName":"MF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9700/3"},{"name":"Legacy Concept Name","value":"Mycosis_Fungoides"},{"name":"Maps_To","value":"9700/3"},{"name":"Maps_To","value":"Mycosis fungoides"},{"name":"Maps_To","value":"Mycosis fungoides involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Mycosis fungoides, unspecified site"},{"name":"Maps_To","value":"Mycosis fungoides, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026948"}]}}{"C35794":{"preferredName":"Pagetoid Reticulosis","code":"C35794","definitions":[{"definition":"A variant of mycosis fungoides, characterized by an exclusively intraepidermal atypical (cerebriform) lymphocytic infiltrate.  Patients present with a localized psoriasiform or hyperkeratotic patch or plaque, usually in the extremities.  Extracutaneous dissemination of the disease has never been reported.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pagetoid Reticulosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pagetoid_Reticulosis"},{"name":"Maps_To","value":"9700/3"},{"name":"Maps_To","value":"Pagetoid reticulosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1367970"}]}}{"C3366":{"preferredName":"Sezary Syndrome","code":"C3366","definitions":[{"definition":"A form of cutaneous T-cell lymphoma, a cancerous disease that affects the skin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sezary Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Sezary's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Sézary Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9701/3"},{"name":"Legacy Concept Name","value":"Sezary_Syndrome"},{"name":"Maps_To","value":"9701/3"},{"name":"Maps_To","value":"Sezary disease"},{"name":"Maps_To","value":"Sezary disease, unspecified site"},{"name":"Maps_To","value":"Sezary syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036920"}]}}{"C27352":{"preferredName":"Peripheral T-Cell Lymphoma, Large Cell","code":"C27352","synonyms":[{"termName":"Peripheral T-Cell Lymphoma, Large Cell","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peripheral_T-Cell_Lymphoma_Large_Cell"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, large cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1337079"}]}}{"C37194":{"preferredName":"Anaplastic Large Cell Lymphoma, ALK-Negative","code":"C37194","definitions":[{"definition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Large Cell Lymphoma, ALK-Negative","termGroup":"PT","termSource":"NCI"},{"termName":"ALCL, ALK-","termGroup":"AB","termSource":"NCI"},{"termName":"ALK-Negative Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9702/3"},{"name":"Legacy Concept Name","value":"ALK-Negative_Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK negative"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-negative"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332078"}]}}{"C4340":{"preferredName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","code":"C4340","definitions":[{"definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Mature T-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral T-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Peripheral T-Cell Lymphoma, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"PTCL, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"PTCL-NOS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Unspecified_Peripheral_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Mature T-cell lymphoma, NOS"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, NOS"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, not classified"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, not classified, unspecified site"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2853959"}]}}{"C3466":{"preferredName":"T-Cell Non-Hodgkin Lymphoma","code":"C3466","definitions":[{"definition":"A disease in which certain cells of the lymph system (called T lymphocytes) become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Hodgkin's T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell and NK-Cell Non-Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell and NK-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T-Cell_Non-Hodgkin_s_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"T-cell lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079772"}]}}{"C7205":{"preferredName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma, Not Otherwise Specified","code":"C7205","definitions":[{"definition":"A variant of peripheral T-cell lymphoma, not otherwise specified. It is characterized by the presence of neoplastic small lymphocytes infiltrating the lymph nodes in a diffuse and less frequently interfollicular pattern. There is an associated proliferation of epithelioid histiocytes forming confluent clusters.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Lennert Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lennert Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lennert's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lennert's Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioid Cell Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoepithelioid Variant Peripheral T-Cell Lymphoma, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphoepithelioid_Cell_Variant_Peripheral_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"Lennert lymphoma"},{"name":"Maps_To","value":"Lymphoepithelioid lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1621719"}]}}{"C7204":{"preferredName":"T-Zone Variant Peripheral T-Cell Lymphoma","code":"C7204","definitions":[{"definition":"An obsolete variant of peripheral T-cell lymphoma, not otherwise specified included in the 2008 WHO classification. These lymphomas usually have a T follicular helper (TFH) cell phenotype and have been moved to the category of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin in the 2017 WHO update. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Zone Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"T-Zone Variant Peripheral T-Cell Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"T-Zone_Variant_Peripheral_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9702/3"},{"name":"Maps_To","value":"T-zone lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334655"}]}}{"C7528":{"preferredName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","code":"C7528","definitions":[{"definition":"An aggressive (fast-growing) type of T-cell non-Hodgkin lymphoma marked by enlarged lymph nodes and hypergammaglobulinemia (increased antibodies in the blood). Other symptoms may include a skin rash, fever, weight loss, or night sweats.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","termGroup":"PT","termSource":"NCI"},{"termName":"AILD","termGroup":"AB","termSource":"NCI"},{"termName":"AITL","termGroup":"AB","termSource":"NCI"},{"termName":"Angioimmunoblastic Lymphadenopathy","termGroup":"AQS","termSource":"NCI"},{"termName":"Angioimmunoblastic Lymphadenopathy Type T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Angioimmunoblastic Lymphadenopathy with Dysproteinemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Angioimmunoblastic T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic Type (Angioimmunoblastic T-Cell Lymphoma)","termGroup":"SY","termSource":"NCI"},{"termName":"Nodal T-Follicular Helper Lymphoma, Angioimmunoblastic-Type","termGroup":"SY","termSource":"NCI"},{"termName":"nTFHL-AI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9705/3"},{"name":"ICD-O-3_Code","value":"9767/1"},{"name":"Legacy Concept Name","value":"Angioimmunoblastic_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9705/3"},{"name":"Maps_To","value":"9767/1"},{"name":"Maps_To","value":"Angioimmunoblastic lymphadenopathy"},{"name":"Maps_To","value":"Angioimmunoblastic lymphadenopathy (AIC)"},{"name":"Maps_To","value":"Angioimmunoblastic lymphadenopathy (AIL)"},{"name":"Maps_To","value":"Angioimmunoblastic lymphoma"},{"name":"Maps_To","value":"Angioimmunoblastic T-cell lymphoma"},{"name":"Maps_To","value":"Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0020981"}]}}{"C6918":{"preferredName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","code":"C6918","definitions":[{"definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"SPTCL","termGroup":"AB","termSource":"NCI"},{"termName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma (Alpha/Beta Type)","termGroup":"SY","termSource":"NCI"},{"termName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma, Alpha/Beta Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9708/3"},{"name":"Legacy Concept Name","value":"Subcutaneous_Panniculitis-Like_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9708/3"},{"name":"Maps_To","value":"Subcutaneous panniculitis-like T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522624"}]}}{"C7162":{"preferredName":"Primary Cutaneous Lymphoma","code":"C7162","synonyms":[{"termName":"Primary Cutaneous Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Skin Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cutaneous_Lymphoma"},{"name":"Maps_To","value":"9709/3"},{"name":"Maps_To","value":"Cutaneous lymphoma, NOS"},{"name":"NCI_META_CUI","value":"CL524081"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3467":{"preferredName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","code":"C3467","definitions":[{"definition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"Any of a group of T-cell non-Hodgkin lymphomas that begins in the skin as an itchy, red rash that can thicken or form a tumor. The most common types are mycosis fungoides and Sezary syndrome.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"CTCL","termGroup":"AB","termSource":"NCI"},{"termName":"Cutaneous T Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous T-Cell Non-Hodgkin Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cutaneous T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PCTCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin T-Cell Non-Hodgkin's Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Non-Hodgkin's Lymphoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Non-Hodgkin's Lymphoma of the Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9709/3"},{"name":"Legacy Concept Name","value":"Cutaneous_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9709/3"},{"name":"Maps_To","value":"Cutaneous T-cell lymphoma, NOS"},{"name":"Maps_To","value":"Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0079773"}]}}{"C45366":{"preferredName":"Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder","code":"C45366","definitions":[{"definition":"A primary cutaneous T-cell lymphoproliferative disorder composed of small to medium-sized CD4-positive, CD8-negative, and CD30-negative pleomorphic T-lymphocytes in the dermis. A small number of large pleomorphic T-lymphocytes, focal epidermotropism, and subcutaneous involvement may be seen. It usually presents with a solitary plaque or tumor on the face, neck, or upper trunk. The clinical behavior is almost always indolent, and most patients present with localized disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"PCSM-LPD","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous CD4-Positive Small or Medium T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Primary Cutaneous CD4-Positive Small/Medium-Sized Pleomorphic T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD4-Positive Small/Medium-Sized T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9709/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_CD4-Positive_Small_Medium-Sized_Pleomorphic_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9709/3"},{"name":"Maps_To","value":"Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder"},{"name":"Maps_To","value":"Primary cutaneous CD4-positive small/medium T-cell lymphoma"},{"name":"NCI_META_CUI","value":"CL524855"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C37193":{"preferredName":"Anaplastic Large Cell Lymphoma, ALK-Positive","code":"C37193","definitions":[{"definition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm. It is characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein. Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Large Cell Lymphoma, ALK-Positive","termGroup":"PT","termSource":"NCI"},{"termName":"ALCL, ALK+","termGroup":"AB","termSource":"NCI"},{"termName":"ALK-Positive Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"ALKoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9714/3"},{"name":"Legacy Concept Name","value":"ALK-Positive_Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9714/3"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK positive"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, ALK-positive, unspecified site"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332079"}]}}{"C3720":{"preferredName":"Anaplastic Large Cell Lymphoma","code":"C3720","definitions":[{"definition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of non-Hodgkin lymphoma that is usually of the T-cell type. The cancer cells express a marker called CD30 or Ki-1 on the surface, and may appear in the lymph nodes, skin, bones, soft tissues, lungs, or liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anaplastic Large Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"ALCL","termGroup":"AB","termSource":"NCI"},{"termName":"Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type","termGroup":"AQS","termSource":"NCI"},{"termName":"CD30 Positive Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Ki-1 Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Ki-1+ ALCL","termGroup":"AQS","termSource":"NCI"},{"termName":"Ki-1+ Anaplastic Large Cell Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9714/3"},{"name":"Legacy Concept Name","value":"Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9714/3"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma involving lymph nodes of head, face, and neck"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma involving lymph nodes of multiple sites"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, CD30+"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, NOS"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, T cell and Null cell type"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, T-cell and Null-cell type"},{"name":"Maps_To","value":"Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites"},{"name":"Maps_To","value":"Large cell (Ki-1+) lymphoma"},{"name":"Maps_To","value":"NHL, anaplastic large cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206180"}]}}{"C8459":{"preferredName":"Hepatosplenic T-Cell Lymphoma","code":"C8459","definitions":[{"definition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatosplenic T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatosplenic Gamma/Delta T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9716/3"},{"name":"Legacy Concept Name","value":"Hepatosplenic_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9716/3"},{"name":"Maps_To","value":"Hepatosplenic gamma-delta cell lymphoma"},{"name":"Maps_To","value":"Hepatosplenic T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522627"}]}}{"C150495":{"preferredName":"Intestinal T-Cell Lymphoma","code":"C150495","definitions":[{"definition":"A group of mature T-cell and NK-cell non-Hodgkin lymphomas that includes enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, and intestinal T-cell lymphoma, not otherwise specified. Most of these lymphomas arise from the small intestine and a minority from the large intestine or stomach.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intestinal T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9717/3"},{"name":"Maps_To","value":"Intestinal T-cell lymphoma"},{"name":"NCI_META_CUI","value":"CL552301"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4737":{"preferredName":"Enteropathy-Associated T-Cell Lymphoma","code":"C4737","definitions":[{"definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enteropathy-Associated T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"EATL","termGroup":"AB","termSource":"NCI"},{"termName":"Enteropathy Associated T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Enteropathy-Type T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9717/3"},{"name":"Legacy Concept Name","value":"Enteropathy-Type_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9717/3"},{"name":"Maps_To","value":"Enteropathy associated T-cell lymphoma"},{"name":"Maps_To","value":"Enteropathy type intestinal T-cell lymphoma"},{"name":"Maps_To","value":"Intestinal T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0456889"}]}}{"C3721":{"preferredName":"Lymphomatoid Papulosis","code":"C3721","definitions":[{"definition":"A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphomatoid Papulosis","termGroup":"PT","termSource":"NCI"},{"termName":"LyP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9718/1"},{"name":"Legacy Concept Name","value":"Lymphomatoid_Papulosis"},{"name":"Maps_To","value":"9718/3"},{"name":"Maps_To","value":"Lymphomatoid Papulosis"},{"name":"Maps_To","value":"Lymphomatoid papulosis"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206182"}]}}{"C6860":{"preferredName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","code":"C6860","definitions":[{"definition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"C-ALCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Anaplastic Large Cell Lymphoma of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Anaplastic Large Cell Lymphoma of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD30 Positive Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD30+ ALCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_Anaplastic_Large_Cell_Lymphoma"},{"name":"Maps_To","value":"9718/3"},{"name":"Maps_To","value":"Primary cutaneous anaplastic large cell lymphoma"},{"name":"Maps_To","value":"Primary cutaneous CD30+ large T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301362"}]}}{"C7195":{"preferredName":"Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","code":"C7195","definitions":[{"definition":"A spectrum of lymphoproliferative disorders characterized by CD30 (Ki-1)-positive cutaneous T-cell infiltrates. The two ends of the spectrum include lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9718/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_CD30-Positive_T-Cell_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9718/3"},{"name":"Maps_To","value":"Primary cutaneous CD30 positive T-cell lymphoproliferative disorder"},{"name":"Maps_To","value":"Primary cutaneous CD30+ T-cell lymphoproliferative disorder"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1371159"}]}}{"C68692":{"preferredName":"Childhood Nasal Type Extranodal NK/T-Cell Lymphoma","code":"C68692","definitions":[{"definition":"A nasal type extranodal NK/T-cell lymphoma occurring in childhood.","type":"DEFINITION","source":"NCI"},{"definition":"A nasal type of non-anaplastic peripheral NK/T cell lymphoma occurring during childhood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood Nasal Type Extranodal NK/T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Childhood_Nasal_Type_Extranodal_NK_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9719/3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879280"}]}}{"C4684":{"preferredName":"Nasal Type Extranodal NK/T-Cell Lymphoma","code":"C4684","definitions":[{"definition":"A malignant lymphoid neoplasm composed of EBV-positive NK/T cells arranged in an angiocentric pattern.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nasal Type Extranodal NK/T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Angiocentric T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extranodal NK/T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extranodal NK/T-Cell Lymphoma, Nasal Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9719/3"},{"name":"Legacy Concept Name","value":"Nasal_Type_Extranodal_NK_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9719/3"},{"name":"Maps_To","value":"Angiocentric T-cell lymphoma"},{"name":"Maps_To","value":"Extranodal NK/T-cell lymphoma, nasal type"},{"name":"Maps_To","value":"Malignant reticulosis, NOS"},{"name":"Maps_To","value":"NK/T-cell lymphoma, nasal and nasal type"},{"name":"Maps_To","value":"NK/T-cell lymphoma, nasal and nasal-type"},{"name":"Maps_To","value":"T/NK-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0392788"}]}}{"C80374":{"preferredName":"Systemic EBV-Positive T-Cell Lymphoma of Childhood","code":"C80374","definitions":[{"definition":"An aggressive and life-threatening, EBV-positive T-cell lymphoma affecting children.  It is more prevalent in Taiwan and Japan.  Clinically, it presents with acute onset of fever and generalized malaise, followed by hepatosplenomegaly and liver failure.  Morphologically it is characterized by the presence of infiltrating T-lymphocytes which are usually small and erythrophagocytosis.  Most patients have a fulminant clinical course.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive, life-threatening, EBV-positive T-cell lymphoproliferative disorder affecting children.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Systemic EBV-Positive T-Cell Lymphoma of Childhood","termGroup":"PT","termSource":"NCI"},{"termName":"Systemic EBV-Positive T-Cell Lymphoproliferative Disorder of Childhood","termGroup":"AQS","termSource":"NCI"},{"termName":"Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9724/3"},{"name":"Legacy Concept Name","value":"Systemic_EBV-Positive_T-Cell_Lymphoproliferative_Disease_of_Childhood"},{"name":"Maps_To","value":"9724/3"},{"name":"Maps_To","value":"Systemic EBV positive T-cell lymphoproliferative disease of childhood"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2699747"}]}}{"C45327":{"preferredName":"Hydroa Vacciniforme Lymphoproliferative Disorder","code":"C45327","definitions":[{"definition":"A rare, EBV-positive cutaneous T-cell lymphoproliferative disorder, composed of CD8 positive cytotoxic T-lymphocytes.  It affects children, almost exclusively in Latin America and Asia. Patients present with papulovesicular skin lesions, clinically resembling hydroa vacciniforme, in areas of sun-exposed skin.","type":"DEFINITION","source":"NCI"},{"definition":"In contrast to hydroa vacciniforme (HV), HV-like lymphoma is not induced by sun exposure and the lesions can occur in both sun-exposed and covered body areas. It affects children, almost exclusively in Latin America and Asia.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hydroa Vacciniforme Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"HV LPD","termGroup":"AB","termSource":"NCI"},{"termName":"HV-Like LPD","termGroup":"SY","termSource":"NCI"},{"termName":"HV-LPD","termGroup":"AB","termSource":"NCI"},{"termName":"Hydroa Vacciniforme-Like Cutaneous T-Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Hydroa Vacciniforme-Like Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Hydroa Vacciniforme-Like Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9725/3"},{"name":"Legacy Concept Name","value":"Hydroa_Vacciniforme-Like_Cutaneous_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9725/3"},{"name":"Maps_To","value":"Hydroa vacciniforme-like lymphoma"},{"name":"Maps_To","value":"Hydroa vacciniforme-like lymphoproliferative disorder"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1708397"}]}}{"C45340":{"preferredName":"Primary Cutaneous Gamma-Delta T-Cell Lymphoma","code":"C45340","definitions":[{"definition":"An aggressive cutaneous lymphoma of mature, activated gamma/delta T-lymphocytes.  It usually presents with disseminated plaques and nodules.  Involvement of mucosal sites is frequent.  However, involvement of lymph nodes, spleen, or bone marrow is uncommon.  Morphologically, there are three patterns of cutaneous involvement: epidermotropic, dermal, and subcutaneous.  Often, more than one pattern may co-exist in a single biopsy specimen, or may be present in different biopsy specimens from the same patient.  The lymphocytic infiltrate is composed of medium- to large-sized lymphocytes expressing CD56.  Most cases lack both CD4 and CD8, although CD8 may be present in some cases.  This group of lymphomas includes cases previously known as subcutaneous panniculitis-like T-cell lymphoma with a gamma/delta phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Gamma-Delta T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Gamma/Delta T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PCGD-TCL","termGroup":"AB","termSource":"NCI"},{"termName":"Peripheral Gamma-Delta T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9726/3"},{"name":"Legacy Concept Name","value":"Cutaneous_Gamma_Delta_T-Cell_Lymphoma"},{"name":"Maps_To","value":"9726/3"},{"name":"Maps_To","value":"Primary cutaneous gamma-delta T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707547"}]}}{"C27821":{"preferredName":"Malignant Lymphoma, Convoluted","code":"C27821","synonyms":[{"termName":"Malignant Lymphoma, Convoluted","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymphoma_Convoluted"},{"name":"Maps_To","value":"9727/3"},{"name":"Maps_To","value":"Malignant lymphoma, convoluted cell"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518186"}]}}{"C7203":{"preferredName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","code":"C7203","definitions":[{"definition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Agranular CD4+ CD56+ Hematodermic Neoplasm/Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Agranular CD4+ Natural Killer Cell Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Blastic Natural Killer Leukemia/Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Blastic NK Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Blastic NK-Cell Lymphoma","termGroup":"AQS","termSource":"NCI"},{"termName":"BPDCN","termGroup":"AB","termSource":"NCI"},{"termName":"CD4+/CD56+ Hematodermic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Monomorphic NK-Cell Lymphoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9727/3"},{"name":"Legacy Concept Name","value":"Blastic_NK-Cell_Lymphoma"},{"name":"Maps_To","value":"9727/3"},{"name":"Maps_To","value":"Blastic NK cell lymphoma"},{"name":"Maps_To","value":"Blastic plasmacytoid dendritic cell neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301363"}]}}{"C8868":{"preferredName":"B Lymphoblastic Lymphoma","code":"C8868","definitions":[{"definition":"An uncommon type of lymphoma.  It constitutes approximately 10% of cases of lymphoblastic lymphoma.  Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age.  The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes.  It has a high remission rate with a median survival of approximately 60 months.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor B-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9728/3"},{"name":"Legacy Concept Name","value":"Precursor_B_Lymphoblastic_Lymphoma"},{"name":"Maps_To","value":"9728/3"},{"name":"Maps_To","value":"Precursor B-cell lymphoblastic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292757"}]}}{"C6919":{"preferredName":"T Lymphoblastic Lymphoma","code":"C6919","definitions":[{"definition":"A type of non-Hodgkin lymphoma in which too many T-cell lymphoblasts (immature white blood cells) are found in the lymph nodes and spleen. It is most common in young men.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most frequent type of lymphoblastic lymphoma.  It comprises approximately 85-90% of cases.  It is more frequently seen in adolescent males.  It frequently presents with a mass lesion in the mediastinum.  Pleural effusions are common.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T Lymphoblastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Precursor T Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Cell Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Lymphoblastic Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9729/3"},{"name":"Legacy Concept Name","value":"Precursor_T_Lymphoblastic_Lymphoma"},{"name":"Maps_To","value":"9729/3"},{"name":"Maps_To","value":"Precursor T-cell lymphoblastic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292758"}]}}{"C6932":{"preferredName":"Solitary Plasmacytoma","code":"C6932","definitions":[{"definition":"A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Plasmacytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solitary_Plasmacytoma"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Solitary myeloma"},{"name":"Maps_To","value":"Solitary plasmacytoma"},{"name":"NCI_META_CUI","value":"CL018710"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7812":{"preferredName":"Solitary Plasmacytoma of Bone","code":"C7812","definitions":[{"definition":"A localized malignant neoplasm that arises in the bone. It is composed of clonal (malignant) plasma cells forming a tumor mass. The most commonly affected bones are the vertebrae, ribs, skull, pelvis, and femur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Plasmacytoma of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Solitary Plasmacytoma","termGroup":"SY","termSource":"NCI"},{"termName":"SPB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solitary_Osseous_Plasmacytoma"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Plasmacytoma of bone"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0272256"}]}}{"C9349":{"preferredName":"Plasmacytoma","code":"C9349","definitions":[{"definition":"A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.","type":"DEFINITION","source":"NCI"},{"definition":"A type of cancer that begins in plasma cells (white blood cells that produce antibodies). A plasmacytoma may turn into multiple myeloma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plasmacytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9731/3"},{"name":"Legacy Concept Name","value":"Plasmacytoma"},{"name":"Maps_To","value":"9731/3"},{"name":"Maps_To","value":"Plasmacytoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0032131"}]}}{"C3242":{"preferredName":"Multiple Myeloma","code":"C3242","definitions":[{"definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm of the bone marrow composed of plasma cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of cancer that begins in plasma cells (white blood cells that produce antibodies).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multiple Myeloma","termGroup":"PT","termSource":"NCI"},{"termName":"Multiple Myeloma/Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Cell Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Cell Myeloma/Multiple Myeloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9732/3"},{"name":"Legacy Concept Name","value":"Plasma_Cell_Myeloma"},{"name":"Maps_To","value":"9732/3"},{"name":"Maps_To","value":"Multiple Myeloma"},{"name":"Maps_To","value":"Multiple myeloma"},{"name":"Maps_To","value":"Multiple myeloma and immunoproliferative neoplasms"},{"name":"Maps_To","value":"Multiple myeloma not having achieved remission"},{"name":"Maps_To","value":"Multiple myeloma without mention of having achieved remission"},{"name":"Maps_To","value":"Myeloma, NOS"},{"name":"Maps_To","value":"Myelomatosis"},{"name":"Maps_To","value":"Plasma cell myeloma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026764"}]}}{"C3180":{"preferredName":"Plasma Cell Leukemia","code":"C3180","definitions":[{"definition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plasma Cell Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Plasmacytic","termGroup":"SY","termSource":"NCI"},{"termName":"PCL","termGroup":"AB","termSource":"NCI"},{"termName":"Plasmacytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9733/3"},{"name":"Legacy Concept Name","value":"Plasma_Cell_Leukemia"},{"name":"Maps_To","value":"9733/3"},{"name":"Maps_To","value":"Plasma cell leukemia"},{"name":"Maps_To","value":"Plasmacytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023484"}]}}{"C4002":{"preferredName":"Extraosseous Plasmacytoma","code":"C4002","definitions":[{"definition":"A localized malignant neoplasm arising in an extraosseous site. It is composed of clonal (malignant) plasma cells forming a tumor mass. It most frequently involves the oropharynx, nasopharynx, sinuses, and larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraosseous Plasmacytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Extramedullary Plasmacytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9734/3"},{"name":"Legacy Concept Name","value":"Extramedullary_Plasmacytoma"},{"name":"Maps_To","value":"9734/3"},{"name":"Maps_To","value":"Extraosseous plasmacytoma"},{"name":"Maps_To","value":"Plasmacytoma, extramedullary"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278619"}]}}{"C7224":{"preferredName":"Plasmablastic Lymphoma","code":"C7224","definitions":[{"definition":"An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells.  Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plasmablastic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"PBL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9684/3"},{"name":"ICD-O-3_Code","value":"9735/3"},{"name":"Legacy Concept Name","value":"Plasmablastic_Lymphoma"},{"name":"Maps_To","value":"9735/3"},{"name":"Maps_To","value":"Plasmablastic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472614"}]}}{"C7225":{"preferredName":"ALK-Positive Large B-Cell Lymphoma","code":"C7225","definitions":[{"definition":"A usually aggressive large B-cell lymphoma characterized by the presence of monomorphic immunoblast-like neoplastic B-lymphocytes in a sinusoidal growth pattern.  The neoplastic B-lymphocytes express the ALK kinase but they lack the 2;5 translocation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK-Positive Large B-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"ALK-DLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Diffuse Large B-Cell Lymphoma with Expression of Full-Length ALK","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Large B-Cell Lymphoma with Expression of Full-Length Anaplastic Lymphoma Kinase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9737/3"},{"name":"Legacy Concept Name","value":"Diffuse_Large_B-Cell_Lymphoma_with_Expression_of_Full-Length_ALK"},{"name":"Maps_To","value":"9737/3"},{"name":"Maps_To","value":"ALK positive large B-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333294"}]}}{"C27856":{"preferredName":"Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease","code":"C27856","definitions":[{"definition":"An aggressive diffuse large B-cell lymphoma occurring in patients with HHV8-positive multicentric Castleman disease. It is characterized by the presence of human herpesvirus 8-infected large B-lymphocytes that resemble plasmablasts. It is usually seen in patients with HIV infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease","termGroup":"AQ","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma Arising in HHV 8-Associated Multicentric Castleman Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma Arising in HHV8-Associated Multicentric Castleman Disease","termGroup":"AQS","termSource":"NCI"},{"termName":"Large B-Cell Lymphoma Arising in Human Herpes Virus 8-Associated Multicentric Castleman Disease","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9738/3"},{"name":"Legacy Concept Name","value":"Kaposi_s_Sarcoma-Associated_Human_Herpes_Virus_8_Positive_Extracavity_Lymphoma"},{"name":"Maps_To","value":"9738/3"},{"name":"Maps_To","value":"Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334319"}]}}{"C7138":{"preferredName":"Solitary Mastocytoma of the Skin","code":"C7138","definitions":[{"definition":"A benign, solitary, well-demarcated, yellow-brown or reddish-brown mast cell neoplasm that arises from the skin, most commonly in infants and children. The lesions are typically 2-5 cm in size, are characterized by infiltration of the dermis by neoplastic mast cells, and occasionally resolve spontaneously.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitary Mastocytoma of the Skin","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Solitary Mastocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Solitary Mastocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Solitary Mastocytoma of Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Solitary_Mastocytoma_of_the_Skin"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Solitary mastocytoma of skin"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0343115"}]}}{"C7137":{"preferredName":"Cutaneous Mastocytosis","code":"C7137","definitions":[{"definition":"Mastocytosis characterized by infiltration of the skin by mast cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cutaneous Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"CM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Cutaneous_Mastocytosis"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Cutaneous mastocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1136033"}]}}{"C9303":{"preferredName":"Mastocytoma","code":"C9303","definitions":[{"definition":"A growth or lump of mast cells (a type of white blood cell). Mast cell tumors can involve the skin, subcutaneous tissue, and muscle tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A localized tumor composed of sheets of mast cells without atypia. It includes the cutaneous mastocytoma which involves the dermis and subcutaneous tissue, and the extracutaneous mastocytoma. Most cases of extracutaneous mastocytoma have been reported in the lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mastocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Mastocytoma"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Mastocytoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024897"}]}}{"C7136":{"preferredName":"Extracutaneous Mastocytoma","code":"C7136","definitions":[{"definition":"A localized mast cell neoplasm involving extracutaneous sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extracutaneous Mastocytoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Extracutaneous_Mastocytoma"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Extracutaneous mastocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0272202"}]}}{"C3218":{"preferredName":"Diffuse Cutaneous Mastocytosis","code":"C3218","definitions":[{"definition":"A variant of cutaneous mastocytosis which is seen almost exclusively in children. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Cutaneous Mastocytosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Diffuse_Cutaneous_Mastocytosis"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Diffuse cutaneous mastocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024901"}]}}{"C3433":{"preferredName":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","code":"C3433","definitions":[{"definition":"The most frequent form of cutaneous mastocytosis.  In children, the lesions tend to be papular, and are characterized by aggregates of elongated or spindle-shaped mast cells which fill the papillary dermis and extend into the reticular dermis.  In adults, the lesions tend to have fewer mast cells compared to those in children.  The lesions are located most commonly on the trunk, but they can be seen on the extremities, head and neck. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"UP/MPCM","termGroup":"AB","termSource":"NCI"},{"termName":"Urticaria Pigmentosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9740/1"},{"name":"Legacy Concept Name","value":"Urticaria_Pigmentosa_Maculopapular_Cutaneous_Mastocytosis"},{"name":"Maps_To","value":"9740/1"},{"name":"Maps_To","value":"Urticaria pigmentosa"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0042111"}]}}{"C9348":{"preferredName":"Mast Cell Sarcoma","code":"C9348","definitions":[{"definition":"A rare malignant neoplasm characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"MCS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9740/3"},{"name":"Legacy Concept Name","value":"Mast_Cell_Sarcoma"},{"name":"Maps_To","value":"9740/3"},{"name":"Maps_To","value":"Malignant mast cell tumor"},{"name":"Maps_To","value":"Malignant mastocytoma"},{"name":"Maps_To","value":"Mast cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0036221"}]}}{"C9286":{"preferredName":"Indolent Systemic Mastocytosis","code":"C9286","definitions":[{"definition":"An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indolent Systemic Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"ISM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9741/1"},{"name":"Legacy Concept Name","value":"Indolent_Systemic_Mastocytosis"},{"name":"Maps_To","value":"9741/1"},{"name":"Maps_To","value":"Indolent systemic mastocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0272203"}]}}{"C9284":{"preferredName":"Systemic Mastocytosis with an Associated Myeloid Neoplasm","code":"C9284","definitions":[{"definition":"A disorder characterized by systemic infiltration of internal organs by aggregates of clonal mast cells and the presence of a clonal non-mast cell myeloid neoplasm (e.g., myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Systemic Mastocytosis with an Associated Myeloid Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"SM-AHN","termGroup":"AB","termSource":"NCI"},{"termName":"SM-AHNMD","termGroup":"AB","termSource":"NCI"},{"termName":"SM-AMN","termGroup":"AB","termSource":"NCI"},{"termName":"Systemic Mastocytosis with an Associated Hematologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Systemic Mastocytosis with an Associated Hematological Neoplasm (SM-AHN)","termGroup":"SY","termSource":"NCI"},{"termName":"Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9741/3"},{"name":"Legacy Concept Name","value":"Systemic_Mastocytosis_with_Associated_Clonal_Hematological_non-Mast-Cell_Lineage_Disease"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Systemic mastocytosis with AHNMD"},{"name":"Maps_To","value":"Systemic mastocytosis with associated hematological clonal non-mast cell disorder"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301365"}]}}{"C9235":{"preferredName":"Systemic Mastocytosis","code":"C9235","definitions":[{"definition":"A rare disease in which too many mast cells (a type of immune system cell) are found in the skin, bones, joints, lymph nodes, liver, spleen, and gastrointestinal tract. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Systemic Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Systemic Tissue Mast Cell Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Primary_Systemic_Mastocytosis"},{"name":"Legacy Concept Name","value":"Systemic_Mastocytosis"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Systemic tissue mast cell disease"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0221013"}]}}{"C9285":{"preferredName":"Aggressive Systemic Mastocytosis","code":"C9285","definitions":[{"definition":"An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggressive Systemic Mastocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Advanced Systemic Mastocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"ASM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9741/3"},{"name":"Legacy Concept Name","value":"Aggressive_Systemic_Mastocytosis"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Aggressive systemic mastocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1112486"}]}}{"C8991":{"preferredName":"Malignant Mastocytosis","code":"C8991","definitions":[{"definition":"A group of malignant mast cell disorders including aggressive systemic mastocytosis, mast cell leukemia, mast cell sarcoma, and systemic mastocytosis with an associated myeloid neoplasm. Individuals with advanced systemic mastocytosis have a reduced life expectancy, with median survival measured in months to years.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm composed of mast cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant Mastocytosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9741/3"},{"name":"Legacy Concept Name","value":"Malignant_Mastocytosis"},{"name":"Maps_To","value":"9741/3"},{"name":"Maps_To","value":"Malignant mast cell tumors"},{"name":"Maps_To","value":"Malignant mastocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1541840"}]}}{"C3169":{"preferredName":"Mast Cell Leukemia","code":"C3169","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from mast cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast Cell Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9742/3"},{"name":"Legacy Concept Name","value":"Mast_Cell_Leukemia"},{"name":"Maps_To","value":"9742/3"},{"name":"Maps_To","value":"Mast cell leukaemia"},{"name":"Maps_To","value":"Mast cell leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023461"}]}}{"C7202":{"preferredName":"Malignant Histiocytosis","code":"C7202","definitions":[{"definition":"An antiquated term referring to cases of systemic non-Hodgkin lymphomas which are composed of large, atypical neoplastic lymphoid cells and cases of hemophagocytic syndromes. In the past, cases of anaplastic large cells lymphoma were called malignant histiocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histiocytic Medullary Reticulosis","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Histiocytosis","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9750/3"},{"name":"Legacy Concept Name","value":"Malignant_Histiocytosis"},{"name":"Maps_To","value":"9750/3"},{"name":"Maps_To","value":"Histiocytic medullary reticulosis"},{"name":"Maps_To","value":"Malignant histiocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019623"}]}}{"C3107":{"preferredName":"Langerhans Cell Histiocytosis","code":"C3107","definitions":[{"definition":"A group of rare disorders in which too many Langerhans cells (a type of white blood cell) grow in certain tissues and organs including the bones, skin, and lungs, and damage them. Langerhans cell histiocytosis may also affect the pituitary gland (which makes hormones that control other glands and many body functions, especially growth). Langerhans cell histiocytosis is most common in children and young adults.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"Tissue infiltration by Langerhans cells (histiocytes). When infiltration involves the pituitary stalk or gland, presentation includes diabetes insipidus, which is sometimes accompanied by other pituitary dysfunction.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis","termGroup":"PT","termSource":"NCI"},{"termName":"Histiocytosis X","termGroup":"AQS","termSource":"NCI"},{"termName":"Langerhans Cell Granulomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"LCH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9751/1"},{"name":"ICD-O-3_Code","value":"9751/3"},{"name":"ICD-O-3_Code","value":"9752/1"},{"name":"ICD-O-3_Code","value":"9753/1"},{"name":"ICD-O-3_Code","value":"9754/3"},{"name":"Legacy Concept Name","value":"Langerhans_Cell_Histiocytosis"},{"name":"Maps_To","value":"9751/1"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Histiocytosis X, NOS"},{"name":"Maps_To","value":"Langerhans cell granulomatosis"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0019621"}]}}{"C3016":{"preferredName":"Eosinophilic Granuloma","code":"C3016","definitions":[{"definition":"A clinical variant of Langerhans cell histiocytosis characterized by unifocal involvement of a bone (most often), skin, or lung.  Patients are usually older children or adults usually presenting with a lytic bone lesion.  The etiology is unknown.  Morphologically, eosinophilic granuloma is characterized by the presence of Langerhans cells in a characteristic milieu which includes histiocytes, eosinophils, neutrophils, and small, mature lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A clinical variant of Langerhans cell histiocytosis that is characterized by unifocal involvement of a bone (most often), skin, or lung. Patients are usually older children or adults, often presenting with a lytic bone lesion of an unknown etiology. Morphologically, eosinophilic granuloma is characterized by the presence of Langerhans cells in a characteristic milieu that includes histiocytes, eosinophils, neutrophils, and small, mature lymphocytes.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Eosinophilic Granuloma","termGroup":"PT","termSource":"NCI"},{"termName":"Eosinophilic Xanthomatous Granuloma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9752/1"},{"name":"Legacy Concept Name","value":"Eosinophilic_Granuloma"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Eosinophilic granuloma"},{"name":"Maps_To","value":"Langerhans cell granulomatosis, unifocal"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0014461"}]}}{"C3160":{"preferredName":"Letterer-Siwe Disease","code":"C3160","definitions":[{"definition":"A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems including the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.","type":"DEFINITION","source":"NCI"},{"definition":"A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems that may include the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Letterer-Siwe Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9754/3"},{"name":"Legacy Concept Name","value":"Letterer-Siwe_Disease"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Letterer-Siwe disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023381"}]}}{"C6920":{"preferredName":"Hand-Schuller-Christian Disease","code":"C6920","definitions":[{"definition":"A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hand-Schuller-Christian Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9753/1"},{"name":"Legacy Concept Name","value":"Hand-Schuller-Christian_Disease"},{"name":"Maps_To","value":"9751/3"},{"name":"Maps_To","value":"Hand-Schuller-Christian disease"},{"name":"Maps_To","value":"Multifocal and unisystemic Langerhans-cell histiocytosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0268205"}]}}{"C27349":{"preferredName":"Histiocytic Sarcoma","code":"C27349","definitions":[{"definition":"A malignant neoplasm composed of cells resembling histiocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histiocytic Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9755/3"},{"name":"Legacy Concept Name","value":"Histiocytic_Sarcoma"},{"name":"Maps_To","value":"9755/3"},{"name":"Maps_To","value":"Histiocytic sarcoma"},{"name":"Maps_To","value":"Malignant histiocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334663"}]}}{"C6921":{"preferredName":"Langerhans Cell Sarcoma","code":"C6921","definitions":[{"definition":"A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features.  It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9756/3"},{"name":"Legacy Concept Name","value":"Langerhans_Cell_Sarcoma"},{"name":"Maps_To","value":"9756/3"},{"name":"Maps_To","value":"Langerhans cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260327"}]}}{"C9282":{"preferredName":"Interdigitating Dendritic Cell Sarcoma","code":"C9282","definitions":[{"definition":"A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells.  The clinical course is generally aggressive. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interdigitating Dendritic Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Interdigitating Cell Sarcoma/Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Interdigitating Dendritic Cell Sarcoma/Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9757/1"},{"name":"ICD-O-3_Code","value":"9757/3"},{"name":"Legacy Concept Name","value":"Interdigitating_Dendritic_Cell_Sarcoma"},{"name":"Maps_To","value":"9757/3"},{"name":"Maps_To","value":"Interdigitating cell sarcoma"},{"name":"Maps_To","value":"Interdigitating dendritic cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260326"}]}}{"C81767":{"preferredName":"Indeterminate Dendritic Cell Tumor","code":"C81767","definitions":[{"definition":"A very rare dendritic cell tumor composed of spindle to ovoid cells with a phenotype that is similar to the Langerhans cells.  Patients usually present with cutaneous papules, nodules, and plaques.  Systemic symptoms are usually absent.  The clinical course is variable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indeterminate Dendritic Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"IDCT","termGroup":"AB","termSource":"NCI"},{"termName":"Indeterminate Cell Histiocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Indeterminate Dendritic Cell Histiocytosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9757/3"},{"name":"Legacy Concept Name","value":"Indeterminate_Dendritic_Cell_Tumor"},{"name":"Maps_To","value":"9757/3"},{"name":"Maps_To","value":"Indeterminate dendritic cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825741"}]}}{"C9281":{"preferredName":"Follicular Dendritic Cell Sarcoma","code":"C9281","definitions":[{"definition":"A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Treatment options include complete surgical removal of the tumor with or without adjuvant chemotherapy or radiotherapy. Recurrences have been reported in up to half of the cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follicular Dendritic Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"FDCS","termGroup":"AB","termSource":"NCI"},{"termName":"Follicular Dendritic Cell Sarcoma/Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9758/1"},{"name":"ICD-O-3_Code","value":"9758/3"},{"name":"Legacy Concept Name","value":"Follicular_Dendritic_Cell_Sarcoma"},{"name":"Maps_To","value":"9758/3"},{"name":"Maps_To","value":"Follicular dendritic cell sarcoma"},{"name":"Maps_To","value":"Follicular dendritic cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1260325"}]}}{"C81758":{"preferredName":"Fibroblastic Reticular Cell Sarcoma","code":"C81758","definitions":[{"definition":"A very rare dendritic cell sarcoma affecting the lymph nodes, spleen, and soft tissues. Morphologically it is similar to the interdigitating dendritic cell sarcoma or follicular dendritic cell sarcoma. The tumor cells are positive for cytokeratin and CD68.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibroblastic Reticular Cell Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblastic Dendritic Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblastic Reticular Cell Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9759/3"},{"name":"Legacy Concept Name","value":"Fibroblastic_Reticular_Cell_Tumor"},{"name":"Maps_To","value":"9759/3"},{"name":"Maps_To","value":"Fibroblastic reticular cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825739"}]}}{"C3132":{"preferredName":"Alpha Heavy Chain Disease","code":"C3132","definitions":[{"definition":"A clonal disorder, also known as immunoproliferative small intestinal disease or Mediterranean lymphoma, characterized by the secretion of a defective alpha heavy chain. It predominantly affects young people in the Mediterranean region. It involves the small intestine, and patients usually present with malabsorption syndrome, abdominal pain, weight loss, and fever. There is extensive villous atrophy of the small intestinal mucosa, which is heavily infiltrated by small lymphocytes and plasma cells. The small intestinal morphologic changes are consistent with a mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha Heavy Chain Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoproliferative Small Intestinal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"IPSID","termGroup":"AB","termSource":"NCI"},{"termName":"Mediterranean Abdominal Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mediterranean Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9760/3"},{"name":"ICD-O-3_Code","value":"9764/3"},{"name":"Legacy Concept Name","value":"Alpha_Heavy_Chain_Disease"},{"name":"Maps_To","value":"9760/3"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"9764/3"},{"name":"Maps_To","value":"Alpha heavy chain disease"},{"name":"Maps_To","value":"Immunoproliferative disease, NOS"},{"name":"Maps_To","value":"Immunoproliferative small intestinal disease"},{"name":"Maps_To","value":"Mediterranean lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0021071"}]}}{"C80307":{"preferredName":"Waldenstrom Macroglobulinemia","code":"C80307","definitions":[{"definition":"An indolent (slow-growing) type of non-Hodgkin lymphoma marked by abnormal levels of IgM antibodies in the blood and an enlarged liver, spleen, or lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Waldenstrom Macroglobulinemia","termGroup":"PT","termSource":"NCI"},{"termName":"Waldenstrom's Macroglobulinemia","termGroup":"SY","termSource":"NCI"},{"termName":"Waldenström Macroglobulinemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Waldenstrom_Macroglobulinemia"},{"name":"Maps_To","value":"9761/3"},{"name":"Maps_To","value":"Waldenstrom macroglobulinemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024419"}]}}{"C3892":{"preferredName":"Mu Heavy Chain Disease","code":"C3892","definitions":[{"definition":"A clonal disorder characterized by the secretion of a mu heavy chain that lacks a variable region. Most patients present with slowly progressive chronic lymphocytic leukemia (CLL). In contrast to most cases of CLL, Mu heavy chain disease is associated with hepatosplenomegaly and absence of lymphadenopathy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mu Heavy Chain Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mu_Heavy_Chain_Disease"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"Mu heavy chain disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0242310"}]}}{"C3083":{"preferredName":"Gamma Heavy Chain Disease","code":"C3083","definitions":[{"definition":"A clonal disorder characterized by the secretion of a truncated gamma chain.  In most cases, it is associated with morphologic changes also seen in lymphoplasmacytic lymphomas, but the clinical course is typically more aggressive than in lymphoplasmacytic lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma Heavy Chain Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Franklin Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Franklin's Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gamma_Heavy_Chain_Disease"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"Franklin disease"},{"name":"Maps_To","value":"Gamma heavy chain disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018854"}]}}{"C3082":{"preferredName":"Heavy Chain Disease","code":"C3082","definitions":[{"definition":"A group of rare clonal disorders of immunoglobulin synthesis associated with B-cell proliferative disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heavy Chain Disease","termGroup":"PT","termSource":"NCI"},{"termName":"HCD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9762/3"},{"name":"Legacy Concept Name","value":"Heavy_Chain_Disease"},{"name":"Maps_To","value":"9762/3"},{"name":"Maps_To","value":"Heavy chain disease, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0018852"}]}}{"C3996":{"preferredName":"Monoclonal Gammopathy of Undetermined Significance","code":"C3996","definitions":[{"definition":"A benign condition in which there is a higher-than-normal level of a protein called M protein in the blood. Patients with MGUS are at an increased risk of developing cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Gammopathy of Undetermined Significance","termGroup":"PT","termSource":"NCI"},{"termName":"MGUS","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Gammopathy of Undetermined Significance (MGUS)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9765/1"},{"name":"Legacy Concept Name","value":"Monoclonal_Gammopathy_of_Undetermined_Significance"},{"name":"Maps_To","value":"9765/1"},{"name":"Maps_To","value":"MGUS"},{"name":"Maps_To","value":"Monoclonal gammopathy of undetermined significance"},{"name":"Maps_To","value":"Monoclonal gammopathy of undetermined significance, NOS"},{"name":"Maps_To","value":"Monoclonal gammopathy, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026470"}]}}{"C40970":{"preferredName":"Angiocentric Immunoproliferative Lesion","code":"C40970","definitions":[{"definition":"A neoplastic lymphoproliferative process characterized by an angiocentric arrangement of tumor cells and associated angiodestruction. It includes lymphomatoid granulomatosis which is a lymphoproliferative lesion derived from mature B-lymphocytes and cases of extranodal NK/T-cell lymphomas of nasal type.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiocentric Immunoproliferative Lesion","termGroup":"PT","termSource":"NCI"},{"termName":"AIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9766/1"},{"name":"Legacy Concept Name","value":"Angiocentric_Immunoproliferative_Lesion"},{"name":"Maps_To","value":"9766/1"},{"name":"Maps_To","value":"Angiocentric immunoproliferative lesion"},{"name":"NCI_META_CUI","value":"CL331771"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7930":{"preferredName":"Lymphomatoid Granulomatosis","code":"C7930","definitions":[{"definition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma.","type":"DEFINITION","source":"NCI"},{"definition":"Destructive growth of lymph cells, usually involving the lungs, skin, kidneys, and central nervous system. Grades I and II are not considered cancerous, but grade III is considered a lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lymphomatoid Granulomatosis","termGroup":"PT","termSource":"NCI"},{"termName":"LYG","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9766/1"},{"name":"Legacy Concept Name","value":"Lymphomatoid_Granulomatosis"},{"name":"Maps_To","value":"9766/1"},{"name":"Maps_To","value":"Lymphomatoid granulomatosis"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0024307"}]}}{"C4664":{"preferredName":"T-Cell Large Granular Lymphocyte Leukemia","code":"C4664","definitions":[{"definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, proliferative disease of blood cells which are large and granular, originating from lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of leukemia in which large T lymphocytes (a type of white blood cell) that contain granules (small particles) are found in the blood. It is a chronic disease that may last for a long time and get worse.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"T-Cell Large Granular Lymphocyte Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Large Cell Granular Lymphoid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Large Granular Lymphocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"LGLL","termGroup":"AB","termSource":"NCI"},{"termName":"T Gamma Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"T Large Granular Lymphocyte Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Gamma Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"T-Large Granular Lymphocyte Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9768/1"},{"name":"ICD-O-3_Code","value":"9831/1"},{"name":"ICD-O-3_Code","value":"9831/3"},{"name":"Legacy Concept Name","value":"T-Cell_Large_Granular_Lymphocyte_Leukemia"},{"name":"Maps_To","value":"9768/1"},{"name":"Maps_To","value":"9831/3"},{"name":"Maps_To","value":"T-cell large granular lymphocytic leukemia"},{"name":"Maps_To","value":"T-cell large granular lymphocytosis"},{"name":"Maps_To","value":"T-gamma lymphoproliferative disease"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1955861"}]}}{"C7727":{"preferredName":"Light Chain Deposition Disease","code":"C7727","definitions":[{"definition":"A condition in which plasma cells secrete immunoglobulin light chains of only one type, kappa or lambda. Light chain deposition disease is often associated with multiple myeloma or lymphoproliferative disease, but as many as 50% of patients have no evidence of neoplastic plasma cell proliferation. Light chains excreted in the urine are known as Bence Jones protein. Amyloidosis and severe renal failure occur more frequently than in multiple myeloma. Also known as Bence Jones myeloma. L-chain disease, L-chain myeloma, and LCDD.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Light Chain Deposition Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Bence Jones Myeloma","termGroup":"SY","termSource":"NCI"},{"termName":"Light Chain Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Light Chain Gammopathy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Light_Chain_Deposition_Disease"},{"name":"Maps_To","value":"9769/1"},{"name":"Maps_To","value":"Systemic light chain disease"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0238239"}]}}{"C7151":{"preferredName":"Monoclonal Immunoglobulin Deposition Disease","code":"C7151","definitions":[{"definition":"A mature B-cell neoplasm characterized by the deposition of immunoglobulin in tissues, resulting in impaired organ function. It includes the following entities: primary amyloidosis, heavy chain deposition disease, and light chain deposition disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Immunoglobulin Deposition Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin Deposition Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9769/1"},{"name":"Legacy Concept Name","value":"Monoclonal_Immunoglobulin_Deposition_Disease"},{"name":"Maps_To","value":"9769/1"},{"name":"Maps_To","value":"Immunoglobulin deposition disease"},{"name":"NCI_META_CUI","value":"CL357425"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3819":{"preferredName":"Primary Amyloidosis","code":"C3819","definitions":[{"definition":"Amyloidosis caused by monoclonal deposition of immunoglobulin light chain and, rarely, heavy chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Amyloidosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Amyloidosis"},{"name":"Maps_To","value":"9769/1"},{"name":"Maps_To","value":"Primary amyloidosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0268381"}]}}{"C4982":{"preferredName":"Aleukemic Leukemia","code":"C4982","definitions":[{"definition":"A leukemia characterized by the absence of leukemic cells in the peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aleukemic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aleukemic_Leukemia"},{"name":"Maps_To","value":"9800/3"},{"name":"Maps_To","value":"Aleukemic leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0877858"}]}}{"C3483":{"preferredName":"Chronic Leukemia","code":"C3483","definitions":[{"definition":"A slowly progressing cancer that starts in blood-forming tissues such as the bone marrow, and causes large numbers of white blood cells to be produced and enter the blood stream.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A slowly progressing leukemia characterized by a clonal (malignant) proliferation of maturing and mature myeloid cells or mature lymphocytes.  When the clonal cellular population is composed of myeloid cells, the process is called chronic myelogenous leukemia.  When the clonal cellular population is composed of lymphocytes, it is classified as chronic lymphocytic leukemia, hairy cell leukemia, or T-cell large granular lymphocyte leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chronic_Leukemia"},{"name":"Maps_To","value":"9800/3"},{"name":"Maps_To","value":"Chronic leukemia of unspecified cell type not having achieved remission"},{"name":"Maps_To","value":"Chronic leukemia of unspecified cell type without mention of having achieved remission"},{"name":"Maps_To","value":"Chronic leukemia, NOS"},{"name":"Maps_To","value":"Leukemia of unspecified cell type, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1279296"}]}}{"C9300":{"preferredName":"Acute Leukemia","code":"C9300","definitions":[{"definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","type":"DEFINITION","source":"NCI"},{"definition":"A rapidly progressing cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of white blood cells to be produced and enter the blood stream.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Acute Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9801/3"},{"name":"Legacy Concept Name","value":"Acute_Leukemia"},{"name":"Maps_To","value":"9801/3"},{"name":"Maps_To","value":"Acute leukaemia of unspecified cell type"},{"name":"Maps_To","value":"Acute leukemia of unspecified cell type not having achieved remission"},{"name":"Maps_To","value":"Acute leukemia of unspecified cell type without mention of having achieved remission"},{"name":"Maps_To","value":"Acute leukemia, NOS"},{"name":"Maps_To","value":"Blast cell leukemia"},{"name":"Maps_To","value":"Leukemia of unspecified cell type, acute"},{"name":"Maps_To","value":"Undifferentiated leukaemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0085669"}]}}{"C4673":{"preferredName":"Acute Biphenotypic Leukemia","code":"C4673","definitions":[{"definition":"An acute leukemia characterized by a single population of blasts that coexpress myeloid and lymphoid antigens.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Biphenotypic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9805/3"},{"name":"Legacy Concept Name","value":"Acute_Biphenotypic_Leukemia"},{"name":"Maps_To","value":"9805/3"},{"name":"Maps_To","value":"Acute biphenotypic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023464"}]}}{"C6923":{"preferredName":"Acute Bilineal Leukemia","code":"C6923","definitions":[{"definition":"An acute leukemia in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute leukemia of ambiguous lineage in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte).  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Bilineal Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Acute_Bilineal_Leukemia"},{"name":"Maps_To","value":"9805/3"},{"name":"Maps_To","value":"Acute bilineal leukemia"},{"name":"Maps_To","value":"Acute mixed lineage leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349680"}]}}{"C82192":{"preferredName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","code":"C82192","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR::ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(9;22)(q34;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed-Phenotype Acute Leukemia with BCR-ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed-Phenotype Acute Leukemia with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL with t(9;22)(q34.1;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL with t(9;22)(q34.1;q11.2); BCR::ABL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9806/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_with_t_9_22_q34_q11_2_BCR-ABL1"},{"name":"Maps_To","value":"9806/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826037"}]}}{"C82203":{"preferredName":"Mixed Phenotype Acute Leukemia with KMT2A Rearrangement","code":"C82203","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts carry a translocation between the KMT2A gene at 11q23.3 and another gene partner. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia with KMT2A Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(v;11q23); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia with t(v;11q23.3); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed-Phenotype Acute Leukemia with KMT2A Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL with t(v;11q23.3); KMT2A Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL, with t(v;11q23.3); KMT2A Rearranged","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9807/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_with_t_v_11q23_MLL_Rearranged"},{"name":"Maps_To","value":"9807/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826048"}]}}{"C82212":{"preferredName":"Mixed Phenotype Acute Leukemia, B/Myeloid","code":"C82212","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts express B-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia, B/Myeloid","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, B/Myeloid, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL, B/Myeloid, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9808/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_B_Myeloid_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9808/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia, B/myeloid, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472616"}]}}{"C82213":{"preferredName":"Mixed Phenotype Acute Leukemia, T/Myeloid","code":"C82213","definitions":[{"definition":"A rare mixed phenotype acute leukemia in which the blasts express T-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Phenotype Acute Leukemia, T/Myeloid","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, T/Myeloid, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"MPAL, T/Myeloid, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9809/3"},{"name":"Legacy Concept Name","value":"Mixed_Phenotype_Acute_Leukemia_T_Myeloid_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9809/3"},{"name":"Maps_To","value":"Mixed phenotype acute leukemia, T/myeloid, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826055"}]}}{"C80326":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","code":"C80326","definitions":[{"definition":"B-lymphoblastic leukemias/lymphomas characterized by the absence of recurrent genetic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9811/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_Not_Otherwise_Specified"},{"name":"Maps_To","value":"9811/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698310"}]}}{"C80331":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1","code":"C80331","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with BCR-ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR::ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with BCR-ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with BCR::ABL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34;q11.2); BCR-ABL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9812/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_9_22_q34_q11_2_BCR-ABL_1"},{"name":"Maps_To","value":"9812/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698317"}]}}{"C80332":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged","code":"C80332","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of an KMT2A related fusion protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with KMT2A Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with T(V;11Q23); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); MLL Rearranged","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with KMT2A Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); MLL Rearranged","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9813/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemi_Lymphoma_with_t_v_11q23_MLL_Rearranged"},{"name":"Maps_To","value":"9813/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698309"}]}}{"C80334":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","code":"C80334","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the TEL gene on chromosome 12 and the AML1 gene on chromosome 21, (p13.2;q22.1). It results in the production of the TEL-AML1 (ETV6-RUNX1) fusion protein. It has a favorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with ETV6::RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6::RUNX1","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with ETV6::RUNX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9814/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_12-21_p13_q22_TEL-AML1_ETV6-RUNX1"},{"name":"Maps_To","value":"9814/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698314"}]}}{"C80335":{"preferredName":"Hyperdiploid B Lymphoblastic Leukemia/Lymphoma","code":"C80335","definitions":[{"definition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It has a favorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperdiploid B Lymphoblastic Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9815/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_Hyperdiploidy"},{"name":"Maps_To","value":"9815/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with hyperdiploidy"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698311"}]}}{"C80344":{"preferredName":"Hyperdiploid B Acute Lymphoblastic Leukemia","code":"C80344","definitions":[{"definition":"A B-cell acute leukemia characterized by the presence of lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It is commonly seen in children and rarely in adults. It has a favorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperdiploid B Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"B Acute Lymphoblastic Leukemia with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Acute Lymphoblastic Leukemia with High Hyperdiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid ALL","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid B-Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Hyperdiploid B-Cell Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperdiploid_B_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9816/3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2697636"}]}}{"C80338":{"preferredName":"Hypodiploid B Lymphoblastic Leukemia/Lymphoma","code":"C80338","definitions":[{"definition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain less than 46 chromosomes. It has an unfavorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypodiploid B Lymphoblastic Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9816/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_Hypodiploidy"},{"name":"Maps_To","value":"9816/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698312"}]}}{"C80340":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH","code":"C80340","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the IL3 gene on chromosome 5 and the IGH locus on chromosome 14, (q31.1;q32.3). It results in eosinophilia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IGH-IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IGH::IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IL3-IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with IL3::IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3::IGH","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31;q32); IL3-IGH","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IGH-IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IGH::IL3 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IL3-IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with IL3::IGH Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31;q32); IL3-IGH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9817/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_5_14_q31_q32_IL3-IGH"},{"name":"Maps_To","value":"9817/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698316"}]}}{"C80341":{"preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1","code":"C80341","definitions":[{"definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1","termGroup":"PT","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3::PBX1","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with TCF3-PBX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B Lymphoblastic Leukemia/Lymphoma with TCF3::PBX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with TCF3-PBX1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphoblastic Leukemia/Lymphoma with TCF3::PBX1 Fusion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9818/3"},{"name":"Legacy Concept Name","value":"B_Lymphoblastic_Leukemia_Lymphoma_with_t_1_19_q23_p13_3_E2A-PBX1_TCF3-PBX1"},{"name":"Maps_To","value":"9818/3"},{"name":"Maps_To","value":"B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2698315"}]}}{"C7176":{"preferredName":"Aleukemic Chronic Lymphocytic Leukemia","code":"C7176","synonyms":[{"termName":"Aleukemic Chronic Lymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aleukemic Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aleukemic_Lymphocytic_Leukemia"},{"name":"Maps_To","value":"9820/3"},{"name":"Maps_To","value":"Aleukemic lymphocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3282876"}]}}{"C4343":{"preferredName":"Aleukemic Lymphoid Leukemia","code":"C4343","synonyms":[{"termName":"Aleukemic Lymphoid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aleukemic Lymphatic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Aleukemic Lymphogenous Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aleukemic_Lymphoid_Leukemia"},{"name":"Maps_To","value":"9820/3"},{"name":"Maps_To","value":"Aleukemic lymphatic leukemia"},{"name":"Maps_To","value":"Aleukemic lymphoid leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334667"}]}}{"C27911":{"preferredName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","code":"C27911","definitions":[{"definition":"An indolent (slow-growing) cancer in which immature lymphocytes (white blood cells) are found in the blood and bone marrow and/or in the lymph nodes. Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are the same disease, but in CLL cancer cells are found mostly in the blood and bone marrow. In SLL cancer cells are found mostly in the lymph nodes. Chronic lymphocytic leukemia/small lymphocytic lymphoma is a type of non-Hodgkin lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"CLL/SLL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9823/3"},{"name":"Legacy Concept Name","value":"Chronic_Lymphocytic_Leukemia_Small_Lymphocytic_Lymphoma"},{"name":"Maps_To","value":"9823/3"},{"name":"Maps_To","value":"B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma"},{"name":"Maps_To","value":"B-cell lymphocytic leukemia/small lymphocytic lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1302547"}]}}{"C3163":{"preferredName":"Chronic Lymphocytic Leukemia","code":"C3163","definitions":[{"definition":"An indolent (slow-growing) cancer in which too many immature lymphocytes (white blood cells) are found mostly in the blood and bone marrow. Sometimes, in later stages of the disease, cancer cells are found in the lymph nodes and the disease is called small lymphocytic lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Lymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"B Cell Chronic Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B Cell CLL","termGroup":"SY","termSource":"NCI"},{"termName":"B Cell Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Chronic Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Chronic Lymphoid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell CLL","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"BCLL","termGroup":"AB","termSource":"NCI"},{"termName":"Chronic B-Cell Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"CLL","termGroup":"AB","termSource":"NCI"},{"termName":"Hematopoeitic - Chronic Lymphocytic Leukemia (CLL)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chronic_Lymphocytic_Leukemia"},{"name":"Maps_To","value":"9823/3"},{"name":"Maps_To","value":"B-cell lymphocytic leukemia/small lymphocytic lymphoma"},{"name":"Maps_To","value":"Chronic lymphatic leukemia"},{"name":"Maps_To","value":"Chronic lymphocytic leukaemia of B-cell type"},{"name":"Maps_To","value":"Chronic lymphocytic leukemia"},{"name":"Maps_To","value":"Chronic lymphocytic leukemia of B-cell type not having achieved remission"},{"name":"Maps_To","value":"Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)"},{"name":"Maps_To","value":"Chronic lymphoid leukemia"},{"name":"Maps_To","value":"Chronic lymphoid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Lymphoid leukemia, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023434"}]}}{"C7400":{"preferredName":"Burkitt Leukemia","code":"C7400","definitions":[{"definition":"A rare, fast-growing type of leukemia (blood cancer) in which too many white blood cells called B lymphocytes form in the blood and bone marrow. It may start in the lymph nodes as Burkitt lymphoma and then spread to the blood and bone marrow, or it may start in the blood and bone marrow without involvement of the lymph nodes. Both Burkitt leukemia and Burkitt lymphoma have been linked to infection with the Epstein-Barr virus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burkitt Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Burkitt's Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Burkitt's Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB L3","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphoblastic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"L3 Acute Lymphoid Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9826/3"},{"name":"Legacy Concept Name","value":"Burkitt_s_Cell_Leukemia"},{"name":"Maps_To","value":"9826/3"},{"name":"Maps_To","value":"Acute leukemia, Burkitt type"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, mature B-cell type"},{"name":"Maps_To","value":"Burkitt cell leukemia"},{"name":"Maps_To","value":"FAB L3"},{"name":"Maps_To","value":"Mature B-cell leukemia Burkitt-type not having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023435"}]}}{"C8644":{"preferredName":"B Acute Lymphoblastic Leukemia","code":"C8644","definitions":[{"definition":"An acute lymphoblastic leukemia of B-lineage origin.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) type of leukemia (blood cancer) in which too many B-cell lymphoblasts (immature white blood cells) are found in the bone marrow and blood. It is the most common type of acute lymphoblastic leukemia (ALL).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute B Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute B-Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"B Cell Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"B Cell Precursor Type Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-ALL","termGroup":"AB","termSource":"NCI"},{"termName":"B-Cell Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"B-Cell ALL","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Precursor Type Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Type Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor B-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor B-Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9836/3"},{"name":"Legacy Concept Name","value":"Precursor_B_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9826/3"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"B-ALL"},{"name":"Maps_To","value":"Precursor B-cell lymphoblastic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4227542"}]}}{"C3184":{"preferredName":"Adult T-Cell Leukemia/Lymphoma","code":"C3184","definitions":[{"definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of T-cell non-Hodgkin lymphoma caused by the human T-cell leukemia virus type 1 (HTLV-1). It is marked by bone and skin lesions, high calcium levels, and enlarged lymph nodes, spleen, and liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Adult T-Cell Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adult T Cell Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Adult T-Cell Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"ATLL","termGroup":"SY","termSource":"NCI"},{"termName":"HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"HTLV-I Associated Adult T-Cell Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9827/3"},{"name":"Legacy Concept Name","value":"Adult_T-Cell_Lymphoma_Leukemia"},{"name":"Maps_To","value":"9827/3"},{"name":"Maps_To","value":"Adult T-cell leukemia"},{"name":"Maps_To","value":"Adult T-cell leukemia/lymphoma (HTLV-1 positive)"},{"name":"Maps_To","value":"Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)"},{"name":"Maps_To","value":"Adult T-cell lymphoma"},{"name":"Maps_To","value":"Adult T-cell lymphoma/leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023493"}]}}{"C39591":{"preferredName":"Chronic Lymphoproliferative Disorder of NK-Cells","code":"C39591","definitions":[{"definition":"A type of leukemia in which large natural killer (NK) cells (a type of white blood cell) that contain granules (small particles) are found in the blood. It is a chronic disease that may last for a long time and get worse.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An Epstein-Barr virus negative disorder with a chronic clinical course affecting predominantly adults and characterized by the proliferation of large granular lymphocytes with natural killer cell immunophenotype.  The T-cell receptor genes are not rearranged.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Lymphoproliferative Disorder of NK-Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic NK-Cell Lymphocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic NK-Large Granular Lymphocyte Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic NK-LGL Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"CLPD-NK","termGroup":"AB","termSource":"NCI"},{"termName":"Indolent Large Granular NK-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Indolent NK-Cell Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"NK Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Cell Large Granular Lymphocyte Lymphocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Large Granular Lymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Type Lymphoproliferative Disorder of Granular Lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Provisional_Concept"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9831/3"},{"name":"Legacy Concept Name","value":"Indolent_NK-Cell_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9831/3"},{"name":"Maps_To","value":"Chronic lymphoproliferative disorder of NK cells"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1512709"}]}}{"C3181":{"preferredName":"Prolymphocytic Leukemia","code":"C3181","definitions":[{"definition":"A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","type":"DEFINITION","source":"NCI"},{"definition":"A type of chronic lymphocytic leukemia (CLL) in which too many immature white blood cells (prolymphocytes) are found in the blood and bone marrow. PLL usually progresses more rapidly than classic CLL.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Prolymphocytic Leukemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9832/3"},{"name":"Legacy Concept Name","value":"Prolymphocytic_Leukemia"},{"name":"Maps_To","value":"9832/3"},{"name":"Maps_To","value":"Prolymphocytic leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023486"}]}}{"C4753":{"preferredName":"B-Cell Prolymphocytic Leukemia","code":"C4753","definitions":[{"definition":"A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen.  The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli.  The B-prolymphocytes must exceed 55% of lymphoid cells in the blood.  Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded.  The prognosis is poor.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Prolymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"B Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9833/3"},{"name":"Legacy Concept Name","value":"B-Cell_Prolymphocytic_Leukemia"},{"name":"Maps_To","value":"9833/3"},{"name":"Maps_To","value":"Prolymphocytic leukemia, B-cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0475801"}]}}{"C4752":{"preferredName":"T-Cell Prolymphocytic Leukemia","code":"C4752","definitions":[{"definition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Prolymphocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Prolymphocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9834/3"},{"name":"Legacy Concept Name","value":"T-Cell_Prolymphocytic_Leukemia"},{"name":"Maps_To","value":"9834/3"},{"name":"Maps_To","value":"Prolymphocytic leukemia, T-cell type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2363142"}]}}{"C27290":{"preferredName":"L1 Acute Lymphoblastic Leukemia","code":"C27290","definitions":[{"definition":"An acute lymphoblastic leukemia (current term: precursor lymphoblastic leukemia) of B-or T-cell origin which according to the FAB classification is characterized by the presence of more mature-appearing lymphoblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"L1 Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"L1_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9835/3"},{"name":"Maps_To","value":"FAB Ll"},{"name":"NCI_META_CUI","value":"CL033103"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27281":{"preferredName":"L2 Acute Lymphoblastic Leukemia","code":"C27281","definitions":[{"definition":"An antiquated term that refers to acute lymphoblastic leukemia with large and irregular lymphoblasts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAB L2","termGroup":"AQS","termSource":"NCI"},{"termName":"L2 Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"FAB_L2"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, L2 type, NOS"},{"name":"Maps_To","value":"FAB L2"},{"name":"NCI_META_CUI","value":"CL031627"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3167":{"preferredName":"Acute Lymphoblastic Leukemia","code":"C3167","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature lymphoid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rapidly progressive cancer of the blood and bone marrow consisting of the proliferation of lymphoblasts, which are immature, dysfunctional white blood cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) type of leukemia (blood cancer) in which too many lymphoblasts (immature white blood cells) are found in the blood and bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Lymphocytic Leukaemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphocytic Leukemias","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Lymphoid Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"ALL","termGroup":"AB","termSource":"NCI"},{"termName":"ALL - Acute Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9835/3"},{"name":"Legacy Concept Name","value":"Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9835/3"},{"name":"Maps_To","value":"Acute lymphatic leukemia"},{"name":"Maps_To","value":"Acute lymphoblastic leukaemia [ALL]"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia (ALL)"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia not having achieved remission"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, NOS"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia, precursor cell type"},{"name":"Maps_To","value":"Acute lymphoblastic leukemia-lymphoma, NOS"},{"name":"Maps_To","value":"Acute lymphocytic leukemia"},{"name":"Maps_To","value":"Acute lymphoid leukemia"},{"name":"Maps_To","value":"Acute lymphoid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Lymphoblastic leukemia, NOS"},{"name":"Maps_To","value":"Lymphoid leukemia, acute"},{"name":"Maps_To","value":"Precursor cell lymphoblastic leukemia, NOS"},{"name":"Maps_To","value":"Precursor cell lymphoblastic leukemia, not phenotyped"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3550748"}]}}{"C27797":{"preferredName":"Common Acute Lymphoblastic Leukemia","code":"C27797","synonyms":[{"termName":"Common Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Common_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"c-ALL"},{"name":"Maps_To","value":"Common ALL"},{"name":"Maps_To","value":"Common precursor B ALL"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0349637"}]}}{"C27799":{"preferredName":"Pre-Pre-B Acute Lymphoblastic Leukemia","code":"C27799","definitions":[{"definition":"Acute lymphoblastic leukemia of early B-lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Pre-B Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pre-Pre-B_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"Pre-pre-B ALL"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1514294"}]}}{"C27798":{"preferredName":"Pre-B Acute Lymphoblastic Leukemia","code":"C27798","definitions":[{"definition":"An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-B Acute Lymphoblastic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pre-B_Acute_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9836/3"},{"name":"Maps_To","value":"Pre-B ALL"},{"name":"Maps_To","value":"Pro-B ALL"},{"name":"NCI_META_CUI","value":"CL054934"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C27820":{"preferredName":"Mature T-ALL","code":"C27820","synonyms":[{"termName":"Mature T-ALL","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mature_T-ALL"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"Cortical T ALL"},{"name":"Maps_To","value":"Mature T ALL"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1521897"}]}}{"C27261":{"preferredName":"Pre T-ALL","code":"C27261","synonyms":[{"termName":"Pre T-ALL","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pre_T-ALL"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"Pre-T ALL"},{"name":"Maps_To","value":"Pro-T ALL"},{"name":"NCI_META_CUI","value":"CL301529"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8694":{"preferredName":"T Lymphoblastic Leukemia/Lymphoma","code":"C8694","definitions":[{"definition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T Lymphoblastic Leukemia/Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"Precursor T Lymphoblastic Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T Lymphoblastic Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Lymphoblastic Lymphoma/Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Lymphoblastic Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"T-Lymphoblastic Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9837/3"},{"name":"Legacy Concept Name","value":"Precursor_T_Lymphoblastic_Leukemia_Lymphoma"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"T lymphoblastic leukemia/lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301359"}]}}{"C3183":{"preferredName":"T Acute Lymphoblastic Leukemia","code":"C3183","definitions":[{"definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute lymphoblastic leukemia of T-lineage origin.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) type of leukemia (blood cancer) in which too many T-cell lymphoblasts (immature white blood cells) are found in the bone marrow and blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"T Acute Lymphoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute T Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute T-Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute T-Cell Lymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Precursor T-Cell Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Precursor T-Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-ALL","termGroup":"AB","termSource":"NCI"},{"termName":"T-Cell Acute Lymphoblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Type Acute Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9837/3"},{"name":"Legacy Concept Name","value":"Precursor_T_Lymphoblastic_Leukemia"},{"name":"Maps_To","value":"9837/3"},{"name":"Maps_To","value":"Precursor T-cell lymphoblastic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1961099"}]}}{"C7467":{"preferredName":"Pure Erythroid Leukemia","code":"C7467","definitions":[{"definition":"Acute erythroid leukemia characterized by the presence of immature erythroid cells in the bone marrow (at least 80% of the cellular component), without evidence of a significant myeloblastic cell population present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pure Erythroid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Erythremic Myelosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia M6b","termGroup":"SY","termSource":"NCI"},{"termName":"Di Guglielmo Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Di Guglielmo's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Erythremic Myelosis","termGroup":"SY","termSource":"NCI"},{"termName":"M6b","termGroup":"AB","termSource":"NCI"},{"termName":"PEL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pure_Erythroid_Leukemia"},{"name":"Maps_To","value":"9840/3"},{"name":"Maps_To","value":"Acute erythremic myelosis"},{"name":"Maps_To","value":"Di Guglielmo disease"},{"name":"Maps_To","value":"Erythremic myelosis, NOS"},{"name":"Maps_To","value":"M6B"},{"name":"NCI_META_CUI","value":"CL028054"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8923":{"preferredName":"Acute Erythroid Leukemia","code":"C8923","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature erythroid cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Erythroid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Erythroblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"AEL","termGroup":"AB","termSource":"NCI"},{"termName":"Erythroblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M6","termGroup":"AB","termSource":"NCI"},{"termName":"M6 Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9840/3"},{"name":"Legacy Concept Name","value":"Acute_Erythroid_Leukemia"},{"name":"Maps_To","value":"9840/3"},{"name":"Maps_To","value":"Acute erythremia"},{"name":"Maps_To","value":"Acute erythremia and erythroleukemia"},{"name":"Maps_To","value":"Acute erythremia and erythroleukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Acute erythroid leukaemia"},{"name":"Maps_To","value":"Acute erythroid leukemia"},{"name":"Maps_To","value":"Acute erythroid leukemia, not having achieved remission"},{"name":"Maps_To","value":"Acute myeloid leukemia, M6 type"},{"name":"Maps_To","value":"AML M6"},{"name":"Maps_To","value":"FAB M6"},{"name":"Maps_To","value":"M6"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023440"}]}}{"C34774":{"preferredName":"Chronic Monocytic Leukemia","code":"C34774","synonyms":[{"termName":"Chronic Monocytic Leukemia","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chronic_Monocytic_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"Chronic monocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023466"}]}}{"C3519":{"preferredName":"Atypical Chronic Myeloid Leukemia","code":"C3519","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Chronic Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"aCML","termGroup":"AB","termSource":"NCI"},{"termName":"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Chronic Myeloid Leukemia, BCR::ABL1 Negative","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical CML","termGroup":"SY","termSource":"NCI"},{"termName":"MDS/MPN-N","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Neutrophilia","termGroup":"SY","termSource":"NCI"},{"termName":"Subacute Granulocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Subacute Myelogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Subacute Myeloid Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9876/3"},{"name":"Legacy Concept Name","value":"Atypical_Chronic_Myeloid_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"9876/3"},{"name":"Maps_To","value":"Atypical chronic myeloid leukemia, BCR/ABL negative"},{"name":"Maps_To","value":"Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative"},{"name":"Maps_To","value":"Subacute granulocytic leukemia"},{"name":"Maps_To","value":"Subacute myelogenous leukemia"},{"name":"Maps_To","value":"Subacute myeloid leukemia"},{"name":"NCI_META_CUI","value":"CL1779346"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4563":{"preferredName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","code":"C4563","definitions":[{"definition":"A disease in which too many eosinophils (a type of white blood cell) are found in the bone marrow, blood, and other tissues. Chronic eosinophilic leukemia may stay the same for many years, or it may progress quickly to acute leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"CEL","termGroup":"AB","termSource":"NCI"},{"termName":"CEL, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Chronic Eosinophilic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Eosinophilic Leukemia, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Eosinophilic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9964/3"},{"name":"Legacy Concept Name","value":"Chronic_Eosinophilic_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"9964/3"},{"name":"Maps_To","value":"Chronic eosinophilic leukemia"},{"name":"Maps_To","value":"Chronic eosinophilic leukemia, NOS"},{"name":"Maps_To","value":"Eosinophilic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346421"}]}}{"C4861":{"preferredName":"Acute Monocytic Leukemia","code":"C4861","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature monocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Monocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Monocytic Leukemia (FAB M5b)","termGroup":"SY","termSource":"NCI"},{"termName":"Monocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9891/3"},{"name":"Legacy Concept Name","value":"Monocytic_Leukemia"},{"name":"Maps_To","value":"9860/3"},{"name":"Maps_To","value":"9891/3"},{"name":"Maps_To","value":"Acute monocytic leukemia"},{"name":"Maps_To","value":"Acute monocytic leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Monocytic leukaemia"},{"name":"Maps_To","value":"Monocytic leukaemia, unspecified"},{"name":"Maps_To","value":"Monocytic leukemia"},{"name":"Maps_To","value":"Monocytic leukemia, acute"},{"name":"Maps_To","value":"Monocytic leukemia, NOS"},{"name":"Maps_To","value":"Other monocytic leukemia"},{"name":"Maps_To","value":"Other monocytic leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Other monocytic leukemia, not having achieved remission"},{"name":"Maps_To","value":"Unspecified monocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023465"}]}}{"C27753":{"preferredName":"Acute Myeloid Leukemia, Not Otherwise Specified","code":"C27753","definitions":[{"definition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia Not Otherwise Categorized","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"AML, NOS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_not_Otherwise_Categorized"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"Acute myeloid leukemia, NOS"},{"name":"Maps_To","value":"Not Classified"},{"name":"NCI_META_CUI","value":"CL054841"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C82433":{"preferredName":"Acute Myeloid Leukemia with CEBPA Mutation","code":"C82433","definitions":[{"definition":"An acute myeloid leukemia (AML) with mutation of the CEBPA gene. It is usually associated with normal karyotype, and most cases meet the criteria for AML with or without maturation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with non-germline mutations of the CEBPA gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with CEBPA Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Mutated CEBPA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Non-Germline Mutated CEBPA","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Mutated CEBPA","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Familial Acute Myeloid Leukemia with Mutated CEBPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9861/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Mutated_CEBPA"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with mutated CEBPA"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826178"}]}}{"C82431":{"preferredName":"Acute Myeloid Leukemia with NPM1 Mutation","code":"C82431","definitions":[{"definition":"An acute myeloid leukemia (AML) with mutation of the nucleophosmin gene. It is usually associated with normal karyotype. It is seen in 8% of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with NPM1 Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Cytoplasmic Nucleophosmin","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Mutated NPM1","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Mutated NPM1","termGroup":"SY","termSource":"NCI"},{"termName":"NPMc+ AML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9861/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Mutated_NPM1"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with mutated NPM1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826177"}]}}{"C3171":{"preferredName":"Acute Myeloid Leukemia","code":"C3171","definitions":[{"definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","type":"DEFINITION","source":"NCI"},{"definition":"A rapidly progressive cancer of the blood and bone marrow consisting of the proliferation of abnormal myeloblasts, which are immature, dysfunctional white blood cells.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Acute Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemias","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Nonlymphocytic Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"AML","termGroup":"AB","termSource":"NCI"},{"termName":"AML - Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"ANLL","termGroup":"AB","termSource":"NCI"},{"termName":"Hematopoeitic - Acute Myleogenous Leukemia (AML)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9861/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia"},{"name":"Maps_To","value":"9861/3"},{"name":"Maps_To","value":"9872/3"},{"name":"Maps_To","value":"Acute granulocytic leukemia"},{"name":"Maps_To","value":"Acute myeloblastic leukaemia [AML]"},{"name":"Maps_To","value":"Acute myeloblastic leukemia"},{"name":"Maps_To","value":"Acute myeloblastic leukemia, not having achieved remission"},{"name":"Maps_To","value":"Acute myelocytic leukemia"},{"name":"Maps_To","value":"Acute myelogenous leukemia"},{"name":"Maps_To","value":"Acute myeloid leukemia"},{"name":"Maps_To","value":"Acute myeloid leukemia (AML)"},{"name":"Maps_To","value":"Acute myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Acute non-lymphocytic leukemia"},{"name":"Maps_To","value":"Myeloid leukemia, acute"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4015937"}]}}{"C3174":{"preferredName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","code":"C3174","definitions":[{"definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","type":"DEFINITION","source":"NCI"},{"definition":"A slowly progressing disease in which too many white blood cells are made in the bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","termGroup":"PT","termSource":"NCI"},{"termName":"BCR-ABL Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemia, BCR::ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myelogenous Leukemias","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia, BCR::ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"CML","termGroup":"AB","termSource":"NCI"},{"termName":"CML - Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoeitic - Chronic Myelocytic Leukemia (CML)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9863/3"},{"name":"ICD-O-3_Code","value":"9875/3"},{"name":"Legacy Concept Name","value":"Chronic_Myelogenous_Leukemia"},{"name":"Maps_To","value":"9863/3"},{"name":"Maps_To","value":"9875/3"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, NOS"},{"name":"Maps_To","value":"Chronic myelocytic leukemia, NOS"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, BCR-ABL positive"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, BCR/ABL positive"},{"name":"Maps_To","value":"Chronic myeloid leukaemia [CML], BCR/ABL-positive"},{"name":"Maps_To","value":"Chronic myeloid leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission"},{"name":"Maps_To","value":"Chronic myeloid leukemia, NOS"},{"name":"Maps_To","value":"Myeloid leukemia, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023473"}]}}{"C82423":{"preferredName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","code":"C82423","definitions":[{"definition":"An acute myeloid leukemia associated with t(6;9)(p22.3;q34), resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It is rare in children.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9) (p22.3;q34.1); DEK-NUP214 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9) (p22.3;q34.1); DEK::NUP214 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34); DEK-NUP214","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK::NUP214","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9865/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_6_9_p23_q34_DEK-NUP214"},{"name":"Maps_To","value":"9865/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826169"}]}}{"C3182":{"preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","code":"C3182","definitions":[{"definition":"Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), and it is treated differently than other types of AML because of its marked sensitivity to differentiating effects of all trans-retinoic acid. APL is characterized by a severe coagulopathy which may be present at diagnosis. APL occurs in 7 % of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","type":"DEFINITION","source":"NCI"},{"definition":"An aggressive (fast-growing) type of acute myeloid leukemia in which there are too many immature blood-forming cells in the blood and bone marrow. It is usually marked by an exchange of parts of chromosomes 15 and 17.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with PML-RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with PML::RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"AML with t(15;17)(q24.1;q21.2)","termGroup":"SY","termSource":"NCI"},{"termName":"APL","termGroup":"AB","termSource":"NCI"},{"termName":"APML","termGroup":"AB","termSource":"NCI"},{"termName":"APML - Acute promyelocytic leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M3","termGroup":"SY","termSource":"NCI"},{"termName":"Promyelocytic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9866/3"},{"name":"Legacy Concept Name","value":"Acute_Promyelocytic_Leukemia"},{"name":"Maps_To","value":"9866/3"},{"name":"Maps_To","value":"Acute myeloid leukemia, PML/RAR-alpha"},{"name":"Maps_To","value":"Acute promyelocytic leukaemia [PML]"},{"name":"Maps_To","value":"Acute promyelocytic leukaemia, PML-RAR-alpha"},{"name":"Maps_To","value":"Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)"},{"name":"Maps_To","value":"Acute promyelocytic leukemia, NOS"},{"name":"Maps_To","value":"Acute promyelocytic leukemia, t(15;17)(q22;q11-12)"},{"name":"Maps_To","value":"FAB M3 (includes all variants)"},{"name":"Maps_To","value":"M3"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023487"}]}}{"C7463":{"preferredName":"Acute Myelomonocytic Leukemia","code":"C7463","definitions":[{"definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myelomonocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M4 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelomonocytic Leukemia (FAB Type M4)","termGroup":"SY","termSource":"NCI"},{"termName":"AMML","termGroup":"AB","termSource":"NCI"},{"termName":"M4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9867/3"},{"name":"Legacy Concept Name","value":"Acute_Myelomonocytic_Leukemia"},{"name":"Maps_To","value":"9867/3"},{"name":"Maps_To","value":"Acute myelomonocytic leukaemia"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia, NOS"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia, not having achieved remission"},{"name":"Maps_To","value":"FAB M4"},{"name":"Maps_To","value":"M4"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023479"}]}}{"C82426":{"preferredName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","code":"C82426","definitions":[{"definition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia associated with inv(3)(q21q26.2) or t(3;3)(q21;q26.2), resulting in the expression of RPN1-EVI1 fusion protein. There have been rare cases in children that have been reported in the literature.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, EVI1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2::MECOM","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with MECOM Rearrangements","termGroup":"SY","termSource":"NCI"},{"termName":"AML with MECOM Rearrangements","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9869/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_inv_3_q2_q26_2_or_t_3_3_q21_q26_2_RPN1-EVI1"},{"name":"Maps_To","value":"9869/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3.3)(q21;q26.2); RPN1-EVI1"},{"name":"Maps_To","value":"Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1"},{"name":"Maps_To","value":"Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826172"}]}}{"C3164":{"preferredName":"Acute Basophilic Leukemia","code":"C3164","definitions":[{"definition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","type":"DEFINITION","source":"NCI"},{"definition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Basophilic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Basophilic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Leukemia Basophilic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9870/3"},{"name":"Legacy Concept Name","value":"Acute_Basophilic_Leukemia"},{"name":"Maps_To","value":"9870/3"},{"name":"Maps_To","value":"Acute basophilic leukaemia"},{"name":"Maps_To","value":"Acute basophilic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023437"}]}}{"C9020":{"preferredName":"Acute Myelomonocytic Leukemia with Abnormal Eosinophils","code":"C9020","definitions":[{"definition":"Acute myelomonocytic leukemia characterized by the presence of abnormal bone marrow eosinophils. It is associated with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22). It has a favorable prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myelomonocytic Leukemia with Abnormal Eosinophils","termGroup":"PT","termSource":"NCI"},{"termName":"AMML Eo","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M4Eo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Myelomonocytic_Leukemia_with_Abnormal_Eosinophils"},{"name":"Maps_To","value":"9871/3"},{"name":"Maps_To","value":"Acute myelomonocytic leukemia with abnormal eosinophils"},{"name":"Maps_To","value":"FAB M4Eo"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332156"}]}}{"C9287":{"preferredName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11","code":"C9287","definitions":[{"definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) or  t(16;16)(p13.1;q22), which results in the expression of the fusion protein CBFB-MYH11. This is seen in 7-9% of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the bone marrow.  This type of acute myeloid leukemia has a favorable prognosis.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Abnormal Marrow Eosinophils","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, CBF-beta/MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, CBFB-MYH11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9871/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Abnormal_Marrow_Eosinophils"},{"name":"Maps_To","value":"9871/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with abnormal marrow eosinophils"},{"name":"Maps_To","value":"Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)"},{"name":"Maps_To","value":"Acute myeloid leukemia, CBF-beta/MYH11"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522630"}]}}{"C8460":{"preferredName":"Acute Myeloid Leukemia with Minimal Differentiation","code":"C8460","definitions":[{"definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with Minimal Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia, Minimally Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Minimal Differentiation (MO)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, Minimally Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Acute Myelogenous Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M0 Myeloid Leukemia with Minimal Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9872/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_Minimally_Differentiated"},{"name":"Maps_To","value":"9872/3"},{"name":"Maps_To","value":"Acute myeloid leukemia, minimal differentiation"},{"name":"Maps_To","value":"FAB MO"},{"name":"Maps_To","value":"M0"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0522631"}]}}{"C3249":{"preferredName":"Acute Myeloid Leukemia without Maturation","code":"C3249","definitions":[{"definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of significant maturation in the neutrophilic lineage.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia without Maturation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M1 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia without Maturation (FAB M1)","termGroup":"SY","termSource":"NCI"},{"termName":"AML without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M1","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloblastic Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myelogenous Leukemia without Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M1 Acute Myeloid Leukemia without Maturation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9873/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_without_Maturation"},{"name":"Maps_To","value":"9873/3"},{"name":"Maps_To","value":"Acute myeloid leukemia without maturation"},{"name":"Maps_To","value":"FAB M1"},{"name":"Maps_To","value":"M1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0026998"}]}}{"C3250":{"preferredName":"Acute Myeloid Leukemia with Maturation","code":"C3250","definitions":[{"definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of significant maturation in the neutrophilic lineage.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with Maturation","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M2 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloblastic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelocytic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelogenous Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (AML-M2)","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M2","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloblastic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloblastic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myelocytic Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myelogenous Leukemia with Maturation","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"M2 Acute Myeloid Leukemia with Maturation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9874/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Maturation"},{"name":"Maps_To","value":"9874/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with maturation"},{"name":"Maps_To","value":"FAB M2, NOS"},{"name":"Maps_To","value":"M2"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1879321"}]}}{"C9128":{"preferredName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive","code":"C9128","definitions":[{"definition":"A chronic myeloid leukemia characterized by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia t(9;22) (q34;q11), BCR/ABL Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR::ABL1 Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Chromosome Positive Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Chromosome Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Chromosome Positive Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph' Positive Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Chromosome Positive Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Chromosome Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Chromosome Positive Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Ph1 Positive Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Granulocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive Chronic Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive CML","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Philadelphia Chromosome Positive, BCR::ABL1 Positive Chronic Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Philadelphia_Chromosome_Positive_Chronic_Myelogenous_Leukemia"},{"name":"Maps_To","value":"9875/3"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, BCR/ABL"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive"},{"name":"Maps_To","value":"Chronic granulocytic leukemia, t(9;22)(q34;q11)"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive"},{"name":"Maps_To","value":"Chronic myelogenous leukemia, t(9;22)(q34;q11)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292771"}]}}{"C7318":{"preferredName":"Acute Monoblastic and Monocytic Leukemia","code":"C7318","definitions":[{"definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Monoblastic and Monocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Monoblastic Leukemia and Acute Monocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia M5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9891/3"},{"name":"Legacy Concept Name","value":"Acute_Monoblastic_Leukemia_and_Acute_Monocytic_Leukemia"},{"name":"Maps_To","value":"9891/3"},{"name":"Maps_To","value":"Acute monoblastic and monocytic leukemia"},{"name":"Maps_To","value":"Acute monoblastic/monocytic leukaemia"},{"name":"Maps_To","value":"Acute monoblastic/monocytic leukemia, not having achieved remission"},{"name":"Maps_To","value":"FAB M5 (includes all variants)"},{"name":"Maps_To","value":"M5"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3831784"}]}}{"C7171":{"preferredName":"Acute Monoblastic Leukemia","code":"C7171","definitions":[{"definition":"An acute myeloid leukemia in which the monoblasts represent 80% or more of the total cellular population.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Monoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Monoblastic Leukemia (FAB M5a)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Monoblastic_Leukemia"},{"name":"Maps_To","value":"9891/3"},{"name":"Maps_To","value":"Acute monoblastic leukemia"},{"name":"Maps_To","value":"Monoblastic leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0457334"}]}}{"C9289":{"preferredName":"Acute Myeloid Leukemia with Multilineage Dysplasia","code":"C9289","definitions":[{"definition":"An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with Multilineage Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"AML with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"AML-MLD","termGroup":"AB","termSource":"NCI"},{"termName":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9895/3"},{"name":"Legacy Concept Name","value":"De_novo_Acute_Myeloid_Leukemia_with_Multilineage_Dysplasia"},{"name":"Maps_To","value":"9895/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with multilineage dysplasia"},{"name":"Maps_To","value":"Acute myeloid leukemia with multilineage dysplasia, not having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292773"}]}}{"C4037":{"preferredName":"Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome","code":"C4037","definitions":[{"definition":"An acute myeloid leukemia developing in patients with a prior history of myelodysplastic syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Multilineage Dysplasia following Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"AML/MDS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Multilineage_Dysplasia_following_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9895/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with prior myelodysplastic syndrome"},{"name":"Maps_To","value":"Acute myeloid leukemia without prior myelodysplastic syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321721"}]}}{"C7600":{"preferredName":"Acute Myeloid Leukemia, Myelodysplasia-Related","code":"C7600","definitions":[{"definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood and one of the following: a previous history of myelodysplastic syndrome; multilineage dysplasia; or myelodysplastic syndrome-related cytogenetic abnormalities.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia, Myelodysplasia-Related","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with Myelodysplasia-Related Changes","termGroup":"SY","termSource":"NCI"},{"termName":"AML with Myelodysplasia-Related Changes","termGroup":"SY","termSource":"NCI"},{"termName":"AML-MRC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9895/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_Multilineage_Dysplasia"},{"name":"Maps_To","value":"9895/3"},{"name":"Maps_To","value":"Acute myeloid leukemia with myelodysplasia-related changes"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825139"}]}}{"C9288":{"preferredName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","code":"C9288","definitions":[{"definition":"An acute myeloid leukemia (AML) associated with t(8;21)(q22;q22) resulting in RUNX1-RUNX1T1 fusion protein expression. This is seen in 12% of children with AML.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1::RUNX1T1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1::RUNX1T1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22;q22)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22;q22)(AML1(CBFa)/ETO)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, t(8;21)(q22;q22)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9896/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_8_21_q22_q22_AML1_CBFa_ETO"},{"name":"Maps_To","value":"9896/3"},{"name":"Maps_To","value":"Acute myeloid leukaemia, t(8;21)(q22;q22)"},{"name":"Maps_To","value":"Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1"},{"name":"Maps_To","value":"Acute myeloid leukemia, AML1(CBF-alpha)/ETO"},{"name":"Maps_To","value":"Acute myeloid leukemia, t(8;21)(q22;q22)"},{"name":"Maps_To","value":"FAB M2, AML1(CBF-alpha)/ETO"},{"name":"Maps_To","value":"FAB M2, t(8;21)(q22;q22)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292774"}]}}{"C174129":{"preferredName":"Acute Myeloid Leukemia with KMT2A Rearrangement","code":"C174129","definitions":[{"definition":"An acute myeloid leukemia characterized by rearrangement of the KMT2A gene. It affects infants, children and adults. It is usually associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with KMT2A Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with 11q23 Abnormalities","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with KMT2A/MLL Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with MLL Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with MLLr","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, MLL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"9897/3"},{"name":"Maps_To","value":"Acute myeloid leukaemia with 11q23-abnormality"},{"name":"Maps_To","value":"Acute myeloid leukemia with 11q23-abnormality not having achieved remission"},{"name":"Maps_To","value":"Acute myeloid leukemia, 11q23 abnormalities"},{"name":"Maps_To","value":"Acute myeloid leukemia, MLL"},{"name":"NCI_META_CUI","value":"CL1407773"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C82339":{"preferredName":"Transient Abnormal Myelopoiesis Associated with Down Syndrome","code":"C82339","definitions":[{"definition":"A myeloid proliferation occurring in newborns with Down syndrome.  It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.  The blasts display morphologic and immunophenotypic features of megakaryocytic lineage.  In the majority of patients the myeloid proliferation undergoes spontaneous remission.","type":"DEFINITION","source":"NCI"},{"definition":"A myeloid proliferation occurring in newborns with Down syndrome. It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations. The blasts display morphologic and immunophenotypic features of megakaryocytic lineage. In the majority of patients, the myeloid proliferation undergoes spontaneous remission.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"AML diagnosed within four years of a diagnosis of Transient Abnormal Myelopoiesis Associated with Down Syndrome (a myeloid proliferation occurring in newborns with Down syndrome). Transient Abnormal Myelopoiesis Associated with Down Syndrome is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]}],"synonyms":[{"termName":"Transient Abnormal Myelopoiesis Associated with Down Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"TAM","termGroup":"AB","termSource":"NCI"},{"termName":"Transient Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9898/1"},{"name":"Legacy Concept Name","value":"Transient_Abnormal_Myelopoiesis"},{"name":"Maps_To","value":"9898/1"},{"name":"Maps_To","value":"Transient abnormal myelopoiesis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1834582"}]}}{"C43223":{"preferredName":"Myeloid Leukemia Associated with Down Syndrome","code":"C43223","definitions":[{"definition":"Acute myeloid leukemia occurring in children with Down syndrome. During the first 3 years of life, it is usually the megakaryoblastic subtype, and is associated with GATA1 gene mutation. After age 4 this is no longer the case.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Acute myeloid leukemia or myelodysplastic syndrome occurring in children with Down syndrome.  The acute myeloid leukemia is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid Leukemia Associated with Down Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9898/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_Transient_Myeloproliferative_Disorder_in_Down_Syndrome"},{"name":"Maps_To","value":"9898/3"},{"name":"Maps_To","value":"Myeloid leukemia associated with Down Syndrome"},{"name":"Maps_To","value":"Myeloid leukemia associated with Down syndrome"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2825149"}]}}{"C3170":{"preferredName":"Acute Megakaryoblastic Leukemia","code":"C3170","definitions":[{"definition":"A progressive, proliferative disease of blood cells, originating from immature megakaryocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Megakaryoblastic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Acute M7 Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Megakaryoblastic Leukemia (FAB Type M7)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Megakaryocytic Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"FAB M7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9910/3"},{"name":"Legacy Concept Name","value":"Acute_Megakaryoblastic_Leukemia"},{"name":"Maps_To","value":"9910/3"},{"name":"Maps_To","value":"Acute megakaryoblastic leukaemia"},{"name":"Maps_To","value":"Acute megakaryoblastic leukemia"},{"name":"Maps_To","value":"Acute megakaryoblastic leukemia not having achieved remission"},{"name":"Maps_To","value":"FAB M7"},{"name":"Maps_To","value":"M7"},{"name":"Maps_To","value":"Megakaryocytic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023462"}]}}{"C82427":{"preferredName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","code":"C82427","definitions":[{"definition":"An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","type":"DEFINITION","source":"NCI"},{"definition":"An acute myeloid leukemia typically showing megakaryocytic maturation and associated with t(1;22)(p13;q13), resulting in the expression of RBM15-MKL1 fusion protein.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15- MRTFA","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15::MLK1 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15::MRTFA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9911/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_Megakaryoblastic_with_t_1_22_p13_q13_RBM15-MKL1"},{"name":"Maps_To","value":"9911/3"},{"name":"Maps_To","value":"Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826173"}]}}{"C27754":{"preferredName":"Alkylating Agent-Related Acute Myeloid Leukemia","code":"C27754","definitions":[{"definition":"Acute myeloid leukemia occurring as late complication of prior therapy with alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alkylating Agent-Related Acute Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Alkylating Agent Related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Alkylating Agent-Related AML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alkylating_Agent-Related_Acute_Myeloid_Leukemia"},{"name":"Maps_To","value":"9920/3"},{"name":"Maps_To","value":"Therapy-related acute myeloid leukemia, alkylating agent related"},{"name":"Maps_To","value":"Therapy-related acute myeloid leukemia, epipodophyllotoxin-related"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321724"}]}}{"C27912":{"preferredName":"Myeloid Neoplasm Post Cytotoxic Therapy","code":"C27912","definitions":[{"definition":"Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.","type":"DEFINITION","source":"NCI"},{"definition":"Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Myeloid Neoplasm Post Cytotoxic Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukaemias and Myelodysplastic Syndromes, Therapy-Related","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related AML and MDS","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related Myeloid Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9920/3"},{"name":"Legacy Concept Name","value":"Therapy-Related_Acute_Myeloid_Leukemia_and_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9920/3"},{"name":"Maps_To","value":"Therapy related myeloid neoplasm"},{"name":"Maps_To","value":"Therapy-related myeloid neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292776"}]}}{"C8252":{"preferredName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","code":"C8252","definitions":[{"definition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"t-AML","termGroup":"AB","termSource":"NCI"},{"termName":"Therapy-Related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment Related Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment Related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment Related AML","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment-Related Acute Myelogenous Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment-related Acute Myeloid Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment-Related AML","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9920/3"},{"name":"Legacy Concept Name","value":"Therapy-Related_Acute_Myeloid_Leukemia"},{"name":"Maps_To","value":"9920/3"},{"name":"Maps_To","value":"Therapy-related acute myeloid leukemia, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336735"}]}}{"C3520":{"preferredName":"Myeloid Sarcoma","code":"C3520","definitions":[{"definition":"A malignant neoplasm composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant, green-colored tumor of myeloid cells (a type of immature white blood cell). This tumor is usually associated with myelogenous leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A tumor mass composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone. (WHO, 2001)","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Myeloid Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Chloroma","termGroup":"SY","termSource":"NCI"},{"termName":"Extramedullary Myeloid Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Extramedullary Myeloid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9930/3"},{"name":"Legacy Concept Name","value":"Myeloid_Sarcoma"},{"name":"Maps_To","value":"9930/3"},{"name":"Maps_To","value":"Chloroma"},{"name":"Maps_To","value":"Myeloid sarcoma"},{"name":"Maps_To","value":"Myeloid sarcoma without mention of having achieved remission"},{"name":"Maps_To","value":"Myeloid sarcoma, not having achieved remission"},{"name":"NCI_META_CUI","value":"CL414320"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C35815":{"preferredName":"Granulocytic Sarcoma","code":"C35815","definitions":[{"definition":"A malignant neoplasm composed of myeloblasts, neutrophils and neutrophil precursors.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant, green-colored tumor of myeloid cells (a type of immature white blood cell). This tumor is usually associated with myelogenous leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tumor mass composed of myeloblasts, neutrophils and neutrophil precursors.  Granulocytic sarcoma is the most common type of myeloid sarcoma.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granulocytic Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Granulocytic_Sarcoma"},{"name":"Maps_To","value":"9930/3"},{"name":"Maps_To","value":"Granulocytic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152276"}]}}{"C4344":{"preferredName":"Acute Panmyelosis with Myelofibrosis","code":"C4344","definitions":[{"definition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Panmyelosis with Myelofibrosis","termGroup":"PT","termSource":"NCI"},{"termName":"Acute (Malignant) Myelofibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute (Malignant) Myelosclerosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelofibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myelosclerosis","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Panmyelosis","termGroup":"SY","termSource":"NCI"},{"termName":"APMF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9931/3"},{"name":"Legacy Concept Name","value":"Acute_Panmyelosis_with_Myelofibrosis"},{"name":"Maps_To","value":"9931/3"},{"name":"Maps_To","value":"Acute myelofibrosis"},{"name":"Maps_To","value":"Acute myelosclerosis, NOS"},{"name":"Maps_To","value":"Acute panmyelosis with myelofibrosis"},{"name":"Maps_To","value":"Acute panmyelosis, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334674"}]}}{"C7402":{"preferredName":"Hairy Cell Leukemia","code":"C7402","definitions":[{"definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A rare type of leukemia in which abnormal B-lymphocytes (a type of white blood cell) are present in the bone marrow, spleen, and peripheral blood. When viewed under a microscope, these cells appear to be covered with tiny hair-like projections.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hairy Cell Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"HCL","termGroup":"AB","termSource":"NCI"},{"termName":"Leukemic Reticuloendotheliosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9940/3"},{"name":"Legacy Concept Name","value":"Hairy_Cell_Leukemia"},{"name":"Maps_To","value":"9940/3"},{"name":"Maps_To","value":"Hairy cell leukemia"},{"name":"Maps_To","value":"Hairy cell leukemia, NOS"},{"name":"Maps_To","value":"Leukemic reticuloendotheliosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023443"}]}}{"C3178":{"preferredName":"Chronic Myelomonocytic Leukemia","code":"C3178","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","type":"DEFINITION","source":"NCI"},{"definition":"A slowly progressing type of myelodysplastic/myeloproliferative disease in which too many myelomonocytes (a type of white blood cell) are in the bone marrow, crowding out other normal blood cells, such as other white blood cells, red blood cells, and platelets.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chronic Myelomonocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"CMML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9945/3"},{"name":"Legacy Concept Name","value":"Chronic_Myelomonocytic_Leukemia"},{"name":"Maps_To","value":"9945/3"},{"name":"Maps_To","value":"Chronic monocytic leukemia without mention of having achieved remission"},{"name":"Maps_To","value":"Chronic myelomonocytic leukaemia"},{"name":"Maps_To","value":"Chronic myelomonocytic leukemia in transformation"},{"name":"Maps_To","value":"Chronic myelomonocytic leukemia not having achieved remission"},{"name":"Maps_To","value":"Chronic myelomonocytic leukemia, NOS"},{"name":"Maps_To","value":"Monocytic leukemia, chronic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023480"}]}}{"C9233":{"preferredName":"Juvenile Myelomonocytic Leukemia","code":"C9233","definitions":[{"definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","type":"DEFINITION","source":"NCI"},{"definition":"A myelodysplastic/myeloproliferative neoplasm of childhood that is principally characterized by proliferation of the granulocytic and monocytic lineages.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare form of childhood leukemia in which cancer cells often spread into tissues such as the skin, lung, and intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Juvenile Myelomonocytic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"JCML","termGroup":"AB","termSource":"NCI"},{"termName":"JMML","termGroup":"AB","termSource":"NCI"},{"termName":"Juvenile Chronic Myelogenous Leukemia","termGroup":"AQS","termSource":"NCI"},{"termName":"Juvenile Chronic Myeloid Leukemia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9946/3"},{"name":"Legacy Concept Name","value":"Juvenile_Myelomonocytic_Leukemia"},{"name":"Maps_To","value":"9946/3"},{"name":"Maps_To","value":"Juvenile chronic myelomonocytic leukemia"},{"name":"Maps_To","value":"Juvenile myelomonocytic leukemia"},{"name":"Maps_To","value":"Juvenile myelomonocytic leukemia, NOS"},{"name":"Maps_To","value":"Juvenile myelomonocytic leukemia, not having achieved remission"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0349639"}]}}{"C8647":{"preferredName":"Aggressive NK-Cell Leukemia","code":"C8647","definitions":[{"definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggressive NK-Cell Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aggressive NK-Cell Leukemia/Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Natural Killer Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"NK-Cell Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9948/3"},{"name":"Legacy Concept Name","value":"Aggressive_NK-Cell_Leukemia"},{"name":"Maps_To","value":"9948/3"},{"name":"Maps_To","value":"Aggressive NK-cell leukaemia"},{"name":"Maps_To","value":"Aggressive NK-cell leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292777"}]}}{"C3336":{"preferredName":"Polycythemia Vera","code":"C3336","definitions":[{"definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","type":"DEFINITION","source":"NCI"},{"definition":"A disease in which there are too many red blood cells in the bone marrow and blood, causing the blood to thicken. The number of white blood cells and platelets may also increase. The extra blood cells may collect in the spleen and cause it to become enlarged. They may also cause bleeding problems and make clots form in blood vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Polycythemia Vera","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Erythremia","termGroup":"AQS","termSource":"NCI"},{"termName":"Polycythemia Rubra Vera","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9950/3"},{"name":"Legacy Concept Name","value":"Polycythemia_Vera"},{"name":"Maps_To","value":"9950/3"},{"name":"Maps_To","value":"Polycythemia rubra vera"},{"name":"Maps_To","value":"Polycythemia vera"},{"name":"Maps_To","value":"Proliferative polycythemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0032463"}]}}{"C27350":{"preferredName":"Myeloproliferative Neoplasm, Not Otherwise Specified","code":"C27350","definitions":[{"definition":"This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloproliferative Neoplasm, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Disease, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Myeloproliferative Disorder, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"CMPD, U","termGroup":"AB","termSource":"NCI"},{"termName":"CMPD-U","termGroup":"AB","termSource":"NCI"},{"termName":"MPN, U","termGroup":"AB","termSource":"NCI"},{"termName":"MPN-NOS","termGroup":"AB","termSource":"NCI"},{"termName":"MPN-U","termGroup":"AB","termSource":"NCI"},{"termName":"Myeloproliferative Neoplasm, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloproliferative Neoplasm, Unclassifiable","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassifiable Chronic Myeloproliferative Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Unclassifiable Chronic Myeloproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9975/3"},{"name":"Legacy Concept Name","value":"Chronic_Myeloproliferative_Disease_Unclassifiable"},{"name":"Maps_To","value":"9960/3"},{"name":"Maps_To","value":"9975/3"},{"name":"Maps_To","value":"Chronic myeloproliferative disease, NOS"},{"name":"Maps_To","value":"Myeloproliferative disease, NOS"},{"name":"Maps_To","value":"Myeloproliferative neoplasm, NOS"},{"name":"Maps_To","value":"Myeloproliferative neoplasm, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333046"}]}}{"C2862":{"preferredName":"Primary Myelofibrosis","code":"C2862","definitions":[{"definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A progressive, chronic disease in which the bone marrow is replaced by fibrous tissue and blood is made in organs such as the liver and the spleen, instead of in the bone marrow. This disease is marked by an enlarged spleen and progressive anemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Primary Myelofibrosis","termGroup":"PT","termSource":"NCI"},{"termName":"Agnogenic Myeloid Metaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"AMM","termGroup":"AB","termSource":"NCI"},{"termName":"Idiopathic Bone Marrow Fibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Myelofibrosis","termGroup":"SY","termSource":"NCI"},{"termName":"Myelosclerosis with Myeloid Metaplasia","termGroup":"SY","termSource":"NCI"},{"termName":"PMF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9961/3"},{"name":"Legacy Concept Name","value":"Chronic_Idiopathic_Myelofibrosis"},{"name":"Maps_To","value":"9961/3"},{"name":"Maps_To","value":"Agnogenic myeloid metaplasia"},{"name":"Maps_To","value":"Megakaryocytic myelosclerosis"},{"name":"Maps_To","value":"Myelofibrosis with myeloid metaplasia"},{"name":"Maps_To","value":"Myelosclerosis with myeloid metaplasia"},{"name":"Maps_To","value":"Primary myelofibrosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0001815"}]}}{"C3407":{"preferredName":"Essential Thrombocythemia","code":"C3407","definitions":[{"definition":"A chronic condition that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and elevated risk for thrombosis and/or hemorrhage.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","type":"DEFINITION","source":"NCI"},{"definition":"An increased number of thrombocytes (platelets) in the blood, without a known cause.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Essential Thrombocythemia","termGroup":"PT","termSource":"NCI"},{"termName":"Essential Thrombocytemia","termGroup":"SY","termSource":"NCI"},{"termName":"Essential Thrombocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Thrombocythemia","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Thrombocythemia","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Thrombocytosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9962/3"},{"name":"Legacy Concept Name","value":"Essential_Thrombocythemia"},{"name":"Maps_To","value":"9962/3"},{"name":"Maps_To","value":"Essential (haemorrhagic) thrombocythaemia"},{"name":"Maps_To","value":"Essential hemorrhagic thrombocythaemia"},{"name":"Maps_To","value":"Essential thrombocythemia"},{"name":"Maps_To","value":"Idiopathic hemorrhagic thrombocythaemia"},{"name":"Maps_To","value":"Idiopathic thrombocythemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040028"}]}}{"C3179":{"preferredName":"Chronic Neutrophilic Leukemia","code":"C3179","definitions":[{"definition":"A disease in which too many neutrophils (a type of white blood cell) are found in the blood. The extra neutrophils may cause the spleen and liver to become enlarged. Chronic neutrophilic leukemia may stay the same for many years or it may progress quickly to acute leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Neutrophilic Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Neutrophilic Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9963/3"},{"name":"Legacy Concept Name","value":"Chronic_Neutrophilic_Leukemia"},{"name":"Maps_To","value":"9963/3"},{"name":"Maps_To","value":"Chronic neutrophilic leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0023481"}]}}{"C27038":{"preferredName":"Idiopathic Hypereosinophilic Syndrome","code":"C27038","definitions":[{"definition":"A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idiopathic Hypereosinophilic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Hyper Eosinophilic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hypereosinophilic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"iHES","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9964/3"},{"name":"Legacy Concept Name","value":"Hypereosinophilic_Syndrome"},{"name":"Maps_To","value":"9964/3"},{"name":"Maps_To","value":"Hypereosinophilic syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1540912"}]}}{"C84275":{"preferredName":"Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","code":"C84275","definitions":[{"definition":"Hematologic neoplasms characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts. Patients usually present with chronic eosinophilic leukemia, and less often with acute myeloid leukemia or T-lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"M/LN-eo with PDGFRA Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid Neoplasm with PDGFRA Rearrangement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9965/3"},{"name":"Maps_To","value":"9965/3"},{"name":"Maps_To","value":"Myeloid and lymphoid neoplasms with PDGFRA rearrangement"},{"name":"Maps_To","value":"Myeloid or lymphoid neoplasm with PDGFRA rearrangement"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2827360"}]}}{"C84276":{"preferredName":"Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","code":"C84276","definitions":[{"definition":"Myeloid and rarely lymphoid neoplasms characterized by the rearrangement of the PDGFRB gene, most often resulting in the formation of ETV6-PDGFRB fusion transcripts. Patients usually present with chronic myelomonocytic leukemia and less often with atypical chronic myeloid leukemia, or chronic eosinophilic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"M/LN-eo with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Neoplasms with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9966/3"},{"name":"Maps_To","value":"9966/3"},{"name":"Maps_To","value":"Myeloid neoplasms with PDGFRB rearrangement"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3472621"}]}}{"C84277":{"preferredName":"Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","code":"C84277","definitions":[{"definition":"Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"8p11 Myeloproliferative Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"8p11 Stem Cell Leukemia/Lymphoma Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"8p11 Stem Cell Lymphoma/Leukemia Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"8p11 Stem Cell Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"M/LN-eo with FGFR1 Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9967/3"},{"name":"Maps_To","value":"9967/3"},{"name":"Maps_To","value":"Myeloid and lymphoid neoplasms with FGFR1 abnormalities"},{"name":"Maps_To","value":"Myeloid or lymphoid neoplasm with FGFR1 abnormalities"},{"name":"NCI_META_CUI","value":"CL497893"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9308":{"preferredName":"Lymphoproliferative Disorder","code":"C9308","definitions":[{"definition":"A disease in which cells of the lymphatic system grow excessively. Lymphoproliferative disorders are often treated like cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9970/1"},{"name":"Legacy Concept Name","value":"Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9970/1"},{"name":"Maps_To","value":"Lymphoproliferative disease, NOS"},{"name":"Maps_To","value":"Lymphoproliferative disorder, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3554543"}]}}{"C4727":{"preferredName":"Post-Transplant Lymphoproliferative Disorder","code":"C4727","definitions":[{"definition":"A condition in which a group of B-cells grow out of control after an organ transplant in patients with weakened immune systems. This usually happens if the patient has also been infected with Epstein-Barr virus. Post-transplant lymphoproliferative disorder may progress to non-Hodgkin lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Abnormal proliferation of B lymphocytes as a complication of immunosuppression occurring after solid organ or allogenic stem cell transplantation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post-Transplant Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"PTLD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9971/1"},{"name":"Legacy Concept Name","value":"Post-Transplant_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9971/1"},{"name":"Maps_To","value":"Post transplant lymphoproliferative disorder"},{"name":"Maps_To","value":"Post transplant lymphoproliferative disorder, NOS"},{"name":"Maps_To","value":"Post-transplant lymphoproliferative disorder, NOS"},{"name":"Maps_To","value":"PTLD, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0432487"}]}}{"C7183":{"preferredName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","code":"C7183","definitions":[{"definition":"A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Polymorphic B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphic B-Cell Post-Transplant Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphic PTLD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9971/3"},{"name":"Legacy Concept Name","value":"Polymorphic_Post-Transplant_Lymphoproliferative_Disorder"},{"name":"Maps_To","value":"9971/3"},{"name":"Maps_To","value":"Polymorphic post transplant lymphoproliferative disorder"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301361"}]}}{"C2872":{"preferredName":"Refractory Anemia","code":"C2872","definitions":[{"definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Anemia","termGroup":"PT","termSource":"NCI"},{"termName":"Aregenerative Anemia","termGroup":"SY","termSource":"NCI"},{"termName":"RA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9980/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia"},{"name":"Maps_To","value":"9980/3"},{"name":"Maps_To","value":"Refractory anaemia, unspecified"},{"name":"Maps_To","value":"Refractory anemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002893"}]}}{"C4036":{"preferredName":"Myelodysplastic Syndrome with Ring Sideroblasts","code":"C4036","definitions":[{"definition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDS-RS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Ring Sideroblasts","termGroup":"AQ","termSource":"NCI"},{"termName":"Pure Sideroblastic Anemia","termGroup":"AQS","termSource":"NCI"},{"termName":"RARS","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with Ring Sideroblasts","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9982/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Ringed_Sideroblasts"},{"name":"Maps_To","value":"9982/3"},{"name":"Maps_To","value":"RARS"},{"name":"Maps_To","value":"Refractory anemia with ringed sideroblasts"},{"name":"Maps_To","value":"Refractory anemia with sideroblasts"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1264195"}]}}{"C82616":{"preferredName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","code":"C82616","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm characterized by marked thrombocytosis, anemia, erythroid lineage dysplasia, presence or absence of multilineage dysplasia, 15% or more ring sideroblasts, blasts less than 5% in bone marrow and less than 1% in peripheral blood, absence of BCR/ABL fusion, absence of SF3B1 mutation, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Essential Thrombocythemia with Ring Sideroblasts","termGroup":"SY","termSource":"NCI"},{"termName":"MDS/MPN with Ring Sideroblasts and Thrombocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"MDS/MPN-RS-T","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/MPN-RS-T, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, NOS","termGroup":"SY","termSource":"NCI"},{"termName":"RARS-T","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9982/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Ring_Sideroblasts_Associated_with_Marked_Thrombocytosis"},{"name":"Maps_To","value":"9982/3"},{"name":"Maps_To","value":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826330"}]}}{"C7506":{"preferredName":"Myelodysplastic Syndrome with Excess Blasts","code":"C7506","definitions":[{"definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome with Excess Blasts","termGroup":"PT","termSource":"NCI"},{"termName":"MDS-EB","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-EB-1","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB-1","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB1","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm with Increased Blasts","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Excess Blasts-1","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Increased Blasts","termGroup":"SY","termSource":"NCI"},{"termName":"RAEB","termGroup":"AB","termSource":"NCI"},{"termName":"RAEB I","termGroup":"SY","termSource":"NCI"},{"termName":"RAEB-I","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with an Excess of Blasts","termGroup":"SY","termSource":"NCI"},{"termName":"Refractory Anemia with Excess Blasts","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9983/3"},{"name":"Legacy Concept Name","value":"RAEB-1"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Excess_Blasts"},{"name":"Maps_To","value":"9983/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome with excess blasts"},{"name":"Maps_To","value":"RAEB"},{"name":"Maps_To","value":"RAEB I"},{"name":"Maps_To","value":"Refractory anaemia with excess of blasts"},{"name":"Maps_To","value":"Refractory anemia with excess blasts"},{"name":"Maps_To","value":"Refractory anemia with excess of blasts, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0002894"}]}}{"C27080":{"preferredName":"Refractory Anemia with Excess Blasts in Transformation","code":"C27080","definitions":[{"definition":"Refractory anemia with excess blasts in transformation (RAEB-T) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood.  The peripheral blood blast count ranges from 20% to 30%.  RAEB-T used to be a subcategory of myelodysplastic syndromes in the past.  Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes.  The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%.  The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments.  Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome).  A minority of cases are part of RAEB-2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAEB-T","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Anemia with Excess Blasts in Transformation","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9984/3"},{"name":"Legacy Concept Name","value":"Refractory_Anemia_with_Excess_Blasts_in_Transformation"},{"name":"Maps_To","value":"9984/3"},{"name":"Maps_To","value":"RAEB-T"},{"name":"Maps_To","value":"Refractory anemia with excess blasts in transformation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0280028"}]}}{"C8574":{"preferredName":"Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","code":"C8574","definitions":[{"definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"MDS, NOS with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-LB-MLD","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-MLD","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm with Low Blasts and Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Low Blasts and Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"RCMD","termGroup":"AB","termSource":"NCI"},{"termName":"Refractory Cytopenia with Multilineage Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9985/3"},{"name":"Legacy Concept Name","value":"Refractory_Cytopenia_with_Multilineage_Dysplasia"},{"name":"Maps_To","value":"9985/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome with multilineage dysplasia"},{"name":"Maps_To","value":"Refractory cytopenia with multilineage dysplasia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0796466"}]}}{"C82596":{"preferredName":"Refractory Cytopenia of Childhood","code":"C82596","definitions":[{"definition":"A myeloid disorder that occurs in childhood and is characterized by persistent cytopenia, dysplastic changes in at least two hematopoietic lineages or in 10% or more of cells in one hematopoietic lineage, less than 5% blasts in bone marrow, and less than 2% blasts in peripheral blood, absence of bone marrow fibrosis, and absence of history of prior cytotoxic chemotherapy or radiation therapy. In a subset of cases, somatic mutations or cytogenetic abnormalities can be identified. Other cases are the result of pre-existing disorders with germline mutations, including Fanconi anemia, Shwachman-Diamond syndrome, and dyskeratosis congenita.","type":"DEFINITION","source":"NCI"},{"definition":"The most common subtype of the myelodysplastic syndromes affecting children. It is characterized by persistent cytopenia with less than 5% blasts in the bone marrow and less than 2% blasts in the peripheral blood. Most cases are associated with a normal karyotype, however, when abnormal, monosomy 7 is the most frequently seen cytogenetic abnormality.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Refractory Cytopenia of Childhood","termGroup":"PT","termSource":"NCI"},{"termName":"RCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9985/3"},{"name":"Legacy Concept Name","value":"Refractory_Cytopenia_of_Childhood"},{"name":"Maps_To","value":"9985/3"},{"name":"Maps_To","value":"Refractory cytopenia of childhood"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826323"}]}}{"C6867":{"preferredName":"Myelodysplastic Syndrome with del(5q)","code":"C6867","definitions":[{"definition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","type":"DEFINITION","source":"NCI"},{"definition":"A rare disorder caused by loss of part of the long arm (Q arm) of human chromosome 5. This syndrome affects myeloid (bone marrow) cells, causing treatment-resistant anemia, and myelodysplastic syndromes that may lead to acute myelogenous leukemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Myelodysplastic Syndrome with del(5q)","termGroup":"PT","termSource":"NCI"},{"termName":"5q- Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-del(5q)","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Neoplasm with Low Blasts and 5q Deletion","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with 5q Deletion","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Isolated Del (5Q)","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Isolated del(5q)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9986/3"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Syndrome_Associated_with_Isolated_del_5q_Chromosome_Abnormality"},{"name":"Maps_To","value":"9986/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome with 5q deletion"},{"name":"Maps_To","value":"Myelodysplastic syndrome with 5q deletion (5q-) syndrome"},{"name":"Maps_To","value":"Myelodysplastic syndrome with isolated del (5q)"},{"name":"Maps_To","value":"Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292779"}]}}{"C7643":{"preferredName":"Alkylating Agent-Related Myelodysplastic Syndrome","code":"C7643","definitions":[{"definition":"A disorder seen following cancer chemotherapy. It is the most common cause of therapy-related myelodysplastic syndromes. It typically manifests several years after initiation of single or multi-agent chemotherapy with alkylators. Mutagenic potential of alkylating agents is believed to be age and cumulative dose-dependent. Deletions in chromosomes 5 and 7 are associated with susceptibility to this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course may progress to bone marrow failure or acute myeloid leukemia that is refractory to treatment. Prognosis is dismal with survivability usually less than one year.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alkylating Agent-Related Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Alkylating Agent Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alkylating_Agent-Related_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9987/3"},{"name":"Maps_To","value":"Therapy-related myelodysplastic syndrome, alkylating agent related"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332235"}]}}{"C7642":{"preferredName":"Epipodophyllotoxin-Related Myelodysplastic Syndrome","code":"C7642","definitions":[{"definition":"A disorder seen following cancer chemotherapy. It typically manifests a few years after initiation of epipodophyllotoxin chemotherapy. Mutagenic potential of these non-intercalating DNA topoisomerase II inhibitors is believed to be increased with concurrent use of asparaginase or granulocyte colony-stimulating factor. Balanced translocations involving chromosomal bands 11q23 and 21q22 are commonly associated with this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course usually progresses to acute myeloid leukemia though most epipodophyllotoxin-related leukemias do not have an antecedent myelodysplastic phase. Prognosis is dismal with survivability usually less than one year.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epipodophyllotoxin-Related Myelodysplastic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Epipodophyllotoxin Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epipodophyllotoxin-Related_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9987/3"},{"name":"Maps_To","value":"Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333418"}]}}{"C27722":{"preferredName":"Myelodysplastic Syndrome Post Cytotoxic Therapy","code":"C27722","definitions":[{"definition":"A myelodysplastic syndrome resulting from chemotherapy or radiation therapy for cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome Post Cytotoxic Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"MDS Post Cytotoxic Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-pCT","termGroup":"AB","termSource":"NCI"},{"termName":"t-MDS","termGroup":"AB","termSource":"NCI"},{"termName":"Therapy Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related MDS","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy-Related Myelodysplastic Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9987/3"},{"name":"Legacy Concept Name","value":"Therapy-Related_Myelodysplastic_Syndrome"},{"name":"Maps_To","value":"9987/3"},{"name":"Maps_To","value":"Therapy-related myelodysplastic syndrome, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1292780"}]}}{"C198589":{"preferredName":"Myelodysplastic Syndrome, Not Otherwise Specified","code":"C198589","definitions":[{"definition":"Myelodysplastic syndrome with low blasts characterized by the absence of defining genetic abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"MDS, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Low Blasts, Not Otherwise Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Ringed Sideroblasts","termGroup":"AQS","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"ICD-O-3_Code","value":"9989/3"},{"name":"Maps_To","value":"9989/3"},{"name":"Maps_To","value":"Myelodysplastic syndrome, NOS"},{"name":"NCI_META_CUI","value":"CL1905772"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C82593":{"preferredName":"Refractory Neutropenia","code":"C82593","definitions":[{"definition":"A myelodysplastic syndrome characterized by the presence of at least 10% dysplastic neutrophils in the bone marrow or the peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Neutropenia","termGroup":"PT","termSource":"NCI"},{"termName":"RN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9991/3"},{"name":"Legacy Concept Name","value":"Refractory_Neutropenia"},{"name":"Maps_To","value":"9991/3"},{"name":"Maps_To","value":"Refractory neutropenia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826320"}]}}{"C82594":{"preferredName":"Refractory Thrombocytopenia","code":"C82594","definitions":[{"definition":"A myelodysplastic syndrome characterized by the presence of at least 10% dysplastic megakaryocytes, found within at least 30 megakaryocytes examined in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Thrombocytopenia","termGroup":"PT","termSource":"NCI"},{"termName":"RT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9992/3"},{"name":"Legacy Concept Name","value":"Refractory_Thrombocytopenia"},{"name":"Maps_To","value":"9992/3"},{"name":"Maps_To","value":"Refractory thrombocytopenia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2826321"}]}}{"C164042":{"preferredName":"Ovarian Capsule Intact","code":"C164042","definitions":[{"definition":"A microscopy finding indicating that the ovarian capsule in a biopsy is intact.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Capsule Intact","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Capsule Intact"},{"name":"NCI_META_CUI","value":"CL977189"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164044":{"preferredName":"Ovarian Capsule Ruptured","code":"C164044","definitions":[{"definition":"A microscopy finding indicating that a portion of the ovarian capsule in a biopsy has ruptured.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Capsule Ruptured","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Capsule Ruptured"},{"name":"NCI_META_CUI","value":"CL977187"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164045":{"preferredName":"Ovarian Capsule Fragmented","code":"C164045","definitions":[{"definition":"A microscopy finding indicating that a portion of the ovarian capsule in a biopsy was fragmented.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Capsule Fragmented","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Capsule Fragmented"},{"name":"NCI_META_CUI","value":"CL977186"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25626":{"preferredName":"Present","code":"C25626","definitions":[{"definition":"Being or existing in a specified place or at the specified time.","type":"DEFINITION","source":"NCI"},{"definition":"Being or existing in a specified place or at the specified time. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Present","termGroup":"PT","termSource":"NCI"},{"termName":"Found","termGroup":"SY","termSource":"NCI"},{"termName":"In","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Present"},{"name":"Maps_To","value":"Present"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0150312"}]}}{"C48658":{"preferredName":"Indeterminate","code":"C48658","definitions":[{"definition":"Cannot distinguish between two or more possible values in the current context.","type":"DEFINITION","source":"NCI"},{"definition":"Cannot distinguish between two or more possible values in the current context. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Indeterminate","termGroup":"PT","termSource":"NCI"},{"termName":"Cannot Be Determined","termGroup":"SY","termSource":"NCI"},{"termName":"Inconclusive","termGroup":"SY","termSource":"NCI"},{"termName":"Unable to Determine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Indeterminate"},{"name":"Maps_To","value":"Indeterminant"},{"name":"Maps_To","value":"Indeterminate"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205258"}]}}{"C70430":{"preferredName":"Zero","code":"C70430","definitions":[{"definition":"A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zero","termGroup":"PT","termSource":"NCI"},{"termName":"0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Zero"},{"name":"Maps_To","value":"0"},{"name":"NCI_META_CUI","value":"CL938212"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C172224":{"preferredName":"One to Three Positive Lymph Nodes","code":"C172224","definitions":[{"definition":"An indication that cancer cells have been detected in one, two or three lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"One to Three Positive Lymph Nodes","termGroup":"PT","termSource":"NCI"},{"termName":"1-3 Lymph Nodes Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1-3"},{"name":"NCI_META_CUI","value":"CL1406306"},{"name":"Semantic_Type","value":"Finding"}]}}{"C172226":{"preferredName":"Four or More Positive Lymph Nodes","code":"C172226","definitions":[{"definition":"An indication that cancer cells have been detected in four or more lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Four or More Positive Lymph Nodes","termGroup":"PT","termSource":"NCI"},{"termName":"4 or More Lymph Nodes Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"4 or More"},{"name":"NCI_META_CUI","value":"CL1406327"},{"name":"Semantic_Type","value":"Finding"}]}}{"C8326":{"preferredName":"Cytologic Atypia","code":"C8326","definitions":[{"definition":"The presence of irregularly shaped or sized cells as compared to the cells that are normally present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytologic Atypia","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Cell Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cytologic_Atypia"},{"name":"Maps_To","value":"Atypical"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0333865"}]}}{"C14143":{"preferredName":"Malignant","code":"C14143","definitions":[{"definition":"Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Malignant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Malignant"},{"name":"Maps_To","value":"Malignant"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"Subsource","value":"IMT"},{"name":"UMLS_CUI","value":"C0205282"}]}}{"C25588":{"preferredName":"Non-Malignant","code":"C25588","definitions":[{"definition":"For neoplasms, a neoplastic process that, at the time of the pathologic diagnosis, does not show evidence of tissue infiltration and may or may not show evidence of atypical morphologic features (e.g., cellular atypia, formation of complex structures, cellular pseudostratification, and increased mitotic activity).  This term encompasses benign neoplastic processes, neoplastic processes with dysplastic features, and borderline processes.  The former do not metastasize and the latter two are associated with a future risk of stromal invasion and metastasis. For other conditions, a process that is not seriously resistant to treatment or dangerous to health.","type":"DEFINITION","source":"NCI"},{"definition":"Not cancerous. Nonmalignant tumors may grow larger but do not spread to other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Non-Malignant","termGroup":"PT","termSource":"NCI"},{"termName":"Non Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Nonmalignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Non-Malignant"},{"name":"Maps_To","value":"Non-Malignant"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1518371"}]}}{"C126862":{"preferredName":"Unsatisfactory","code":"C126862","definitions":[{"definition":"Failing to meet the quantitative or qualitative measures for the needs of a situation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unsatisfactory","termGroup":"PT","termSource":"NCI"},{"termName":"Inadequate","termGroup":"SY","termSource":"NCI"},{"termName":"Insufficient","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unsatisfactory"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0439856"}]}}{"C5530":{"preferredName":"Prostate Acinar Sarcomatoid Carcinoma","code":"C5530","definitions":[{"definition":"A rare acinar adenocarcinoma of the prostate gland with unfavorable prognosis. It is composed of both malignant glandular and sarcomatous components. The sarcomatous component contains a malignant spindle cell proliferation or specific mesenchymal elements including osteosarcoma, chondrosarcoma, and leiomyosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Acinar Sarcomatoid Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Prostate Carcinosarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Sarcomatoid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatoid Carcinoma of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcomatoid Carcinoma of the Prostate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Prostate_Sarcomatoid_Carcinoma"},{"name":"Maps_To","value":"Acinar adenocarcinoma, sarcomatoid"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335519"}]}}{"C9298":{"preferredName":"Acute Undifferentiated Leukemia","code":"C9298","definitions":[{"definition":"A rare acute leukemia in which the blasts do not express markers specific to myeloid or lymphoid lineage.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare acute leukemia of ambiguous lineage in which the blasts do not express markers specific to myeloid or lymphoid lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Undifferentiated Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Stem Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Stem Cell Acute Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Stem Cell Leukemia","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated Acute Leukemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Stem_Cell_Leukemia"},{"name":"Maps_To","value":"Acute leukemia, NOS"},{"name":"Maps_To","value":"Stem cell leukemia"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378511"}]}}{"C82403":{"preferredName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","code":"C82403","definitions":[{"definition":"An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3 (AF9)-KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-MLL","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::MLL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9897/3"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_9_11_p22_q23_MLLT3-MLL"},{"name":"Maps_To","value":"Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2919692"}]}}{"C9018":{"preferredName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","code":"C9018","definitions":[{"definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13q22)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with inv(16)(p13q22)(CBFb/MYH11)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, inv(16)(p13q22)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_inv_16_p13_q22"},{"name":"Maps_To","value":"Acute myeloid leukemia, inv(16)(p13;q22)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332154"}]}}{"C9019":{"preferredName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11","code":"C9019","definitions":[{"definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality t(16;16)(p13.1;q22) which results in the expression of the fusion protein CBFB-MYH11.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB::MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB::MYH11 Fusion","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia with t(16;16)(p13;q22)","termGroup":"SY","termSource":"NCI"},{"termName":"Acute Myeloid Leukemia, t(16;16)(p13;q22)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Myeloid_Leukemia_with_t_16_16_p13_q22"},{"name":"Maps_To","value":"Acute myeloid leukemia, t(16;16)(p 13;q 11)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332155"}]}}{"C127915":{"preferredName":"Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma","code":"C127915","definitions":[{"definition":"A carcinoma that arises from the cervix and is characterized by the presence of a cervical adenocarcinoma variant and a neuroendocrine carcinoma component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenocarcinoma admixed with neuroendocrine carcinoma"},{"name":"NCI_META_CUI","value":"CL509697"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C136717":{"preferredName":"Lung Mucinous Adenocarcinoma In Situ","code":"C136717","definitions":[{"definition":"A very rare lung adenocarcinoma in situ variant characterized by the presence of tall columnar cells with basal nuclei and abundant cytoplasmic mucin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Mucinous Adenocarcinoma In Situ","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenocarcinoma in situ of lung, mucinous"},{"name":"Maps_To","value":"Adenocarcinoma in situ, mucinous"},{"name":"NCI_META_CUI","value":"CL554698"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40017":{"preferredName":"Rete Ovarii Adenocarcinoma","code":"C40017","definitions":[{"definition":"An exceptionally rare adenocarcinoma that arises from the rete ovarii.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rete Ovarii Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rete_Ovarii_Adenocarcinoma"},{"name":"Maps_To","value":"9110/3"},{"name":"Maps_To","value":"Adenocarcinoma of rete ovarii"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3840223"}]}}{"C173739":{"preferredName":"Ameloblastic Fibrodentinosarcoma","code":"C173739","definitions":[{"definition":"An odontogenic sarcoma producing dentin/dentinoid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ameloblastic Fibrodentinosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ameloblastic fibrodentinosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334564"}]}}{"C129290":{"preferredName":"Astrocytoma, IDH-Mutant, Grade 3","code":"C129290","definitions":[{"definition":"IDH-mutant astrocytoma characterized by the presence of increased mitotic activity and anaplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytoma, IDH-Mutant, Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Astrocytoma, IDH-Mutant","termGroup":"SY","termSource":"NCI"},{"termName":"Astrocytoma, IDH-Mutant, Grade III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic astrocytoma, IDH-mutant"},{"name":"NCI_META_CUI","value":"CL512333"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129291":{"preferredName":"Anaplastic Astrocytoma, IDH-Wildtype","code":"C129291","definitions":[{"definition":"Anaplastic astrocytoma lacking mutations in IDH1 or IDH2 genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Astrocytoma, IDH-Wildtype","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic astrocytoma, IDH-wildtype"},{"name":"NCI_META_CUI","value":"CL512334"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129321":{"preferredName":"Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","code":"C129321","definitions":[{"definition":"An anaplastic oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted"},{"name":"NCI_META_CUI","value":"CL512337"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129327":{"preferredName":"Anaplastic Pleomorphic Xanthoastrocytoma","code":"C129327","definitions":[{"definition":"A WHO grade 3 pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade 2 pleomorphic xanthoastrocytoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaplastic Pleomorphic Xanthoastrocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"APX","termGroup":"AB","termSource":"NCI"},{"termName":"WHO Grade 3 Pleomorphic Xanthoastrocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"WHO Grade III Pleomorphic Xanthoastrocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaplastic pleomorphic xanthroastrocytoma"},{"name":"NCI_META_CUI","value":"CL512339"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C172804":{"preferredName":"Low Grade Biliary Intraepithelial Neoplasia","code":"C172804","definitions":[{"definition":"Biliary intraepithelial neoplasia characterized by the presence of low grade epithelial dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Biliary Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Low Grade BilIN","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Biliary Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade BilIN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary intraepithelial neoplasia, low grade"},{"name":"NCI_META_CUI","value":"CL497897"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C47847":{"preferredName":"Breast Carcinoma with Chondroid Metaplasia","code":"C47847","definitions":[{"definition":"An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Carcinoma with Chondroid Metaplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Carcinoma with Cartilaginous Metaplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Breast_Carcinoma_with_Chondroid_Metaplasia"},{"name":"Maps_To","value":"Carcinoma with chondroid differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707042"}]}}{"C47848":{"preferredName":"Breast Carcinoma with Osseous Metaplasia","code":"C47848","definitions":[{"definition":"An invasive breast carcinoma showing differentiation towards bone structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Carcinoma with Osseous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Breast_Carcinoma_with_Osseous_Metaplasia"},{"name":"Maps_To","value":"Carcinoma with osseous differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1711312"}]}}{"C4868":{"preferredName":"Placental Hemangioma","code":"C4868","definitions":[{"definition":"A hemangioma arising from the fetal blood vessels in the placental villi.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A hemangioma arising from the fetal blood vessels in the placental villi.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Placental Hemangioma","termGroup":"PT","termSource":"NCI"},{"termName":"Angioma of Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Angioma of the Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Chorangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Chorangioma of the Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Chorangioma Placentae","termGroup":"SY","termSource":"NCI"},{"termName":"Chorioangioma","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangioma of Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Hemangioma of the Placenta","termGroup":"SY","termSource":"NCI"},{"termName":"Placental Angioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Placental_Hemangioma"},{"name":"Maps_To","value":"Chorioangioma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0677608"}]}}{"C188314":{"preferredName":"Chronic Phase Primary Myelofibrosis","code":"C188314","definitions":[{"definition":"Primary myelofibrosis characterized by the presence of less than 10% blasts in the peripheral blood or bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Phase Primary Myelofibrosis","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Idiopathic Myelofibrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic idiopathic myelofibrosis"},{"name":"NCI_META_CUI","value":"CL1793031"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C191683":{"preferredName":"Invasive Clear Cell (Glycogen-Rich) Urothelial Carcinoma","code":"C191683","definitions":[{"definition":"An invasive urothelial carcinoma characterized by the presence of clear (glycogen-rich) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Clear Cell (Glycogen-Rich) Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Cell (Glycogen-Rich) Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Cell Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Clear Cell Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clear cell (glycogen-rich) urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1797870"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129501":{"preferredName":"Central Nervous System Embryonal Tumor with Rhabdoid Features","code":"C129501","definitions":[{"definition":"A central nervous system embryonal neoplasm characterized by the presence of histological features consistent with atypical teratoid/rhabdoid tumor and absence of mutations of the INI1 gene or SMARCA4 (BRG1) gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Embryonal Tumor with Rhabdoid Features","termGroup":"PT","termSource":"NCI"},{"termName":"CNS Embryonal Tumor with Rhabdoid Features","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS Embryonal tumor with rhabdoid features"},{"name":"Maps_To","value":"Embryonal tumor with rhabdoid features"},{"name":"NCI_META_CUI","value":"CL512681"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4139":{"preferredName":"Combined Carcinoid and Adenocarcinoma","code":"C4139","definitions":[{"definition":"A malignant epithelial neoplasm composed of a mixture of neuroendocrine cells with morphologic and immunohistochemical characteristics of carcinoid tumor and malignant glandular cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Carcinoid and Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Carcinoid Neoplasm and Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Carcinoid Tumor and Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Composite Carcinoid Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Combined_Carcinoid_and_Adenocarcinoma"},{"name":"Maps_To","value":"Combined carcinoid and adenocarcinoma"},{"name":"Maps_To","value":"Combined/mixed carcinoid and adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334302"}]}}{"C7267":{"preferredName":"Combined Lung Large Cell Neuroendocrine Carcinoma","code":"C7267","definitions":[{"definition":"A subtype of large cell neuroendocrine lung carcinoma characterized by the presence of large neuroendocrine cells in combination with adenocarcinoma, squamous cell carcinoma, giant cell carcinoma and/ or spindle cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Lung Large Cell Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Combined Large Cell Lung Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Large Cell Neuroendocrine Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Large Cell Neuroendocrine Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Combined Large Cell Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Combined Large Cell Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Combined_Large_Cell_Neuroendocrine_Carcinoma_of_the_Lung"},{"name":"Maps_To","value":"Combined large cell neuroendocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333122"}]}}{"C9379":{"preferredName":"Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma","code":"C9379","definitions":[{"definition":"A lung carcinoma characterized by a combination of small cell carcinoma and adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma and Small Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma and Small Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma and Small Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Combined Small Cell Lung Carcinoma and Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenocarcinoma_and_Small_Cell_Lung_Carcinoma"},{"name":"Maps_To","value":"Combined small cell-adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332165"}]}}{"C176005":{"preferredName":"Breast Ductal Carcinoma In Situ, Comedo Type","code":"C176005","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, Comedo Type","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Intraductal Comedo Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS - Comedo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8501/2"},{"name":"Maps_To","value":"Comedocarcinoma, noninfiltrating"},{"name":"Maps_To","value":"DCIS, comedo type"},{"name":"Maps_To","value":"Ductal carcinoma in situ, comedo type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334369"}]}}{"C27260":{"preferredName":"Dendritic Cell Tumor, Not Otherwise Specified","code":"C27260","definitions":[{"definition":"A dendritic cell neoplasm that does not fall into well-defined categories or shows hybrid features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendritic Cell Sarcoma, NOS","termGroup":"AQS","termSource":"NCI"},{"termName":"Dendritic Cell Tumor, Not Otherwise Specified","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Dendritic_Cell_Sarcoma_Not_Otherwise_Specified"},{"name":"Maps_To","value":"Dendritic cell sarcoma, NOS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301364"}]}}{"C37272":{"preferredName":"Vulvar Intraepithelial Neoplasia, HPV-Independent","code":"C37272","definitions":[{"definition":"HPV-negative vulvar squamous intraepithelial proliferation characterized by atypia of the basal and parabasal keratinocytes in an otherwise well-differentiated epithelium. Despite its subtle appearance, it has a high risk of malignant transformation. (WHO 2020)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vulvar Intraepithelial Neoplasia, HPV-Independent","termGroup":"PT","termSource":"NCI"},{"termName":"d-VIN","termGroup":"AB","termSource":"NCI"},{"termName":"Differentiated Vulvar Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"dVIN","termGroup":"AB","termSource":"NCI"},{"termName":"Simplex (Differentiated) Vulvar Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"SxVIN","termGroup":"AB","termSource":"NCI"},{"termName":"Vulvar Carcinoma In Situ of Simplex Type","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated (Simplex)","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated (Simplex) Type","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Differentiated Type","termGroup":"SY","termSource":"NCI"},{"termName":"Vulvar Intraepithelial Neoplasia, Simplex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Simplex_Differentiated_Type_of_Vulvar_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"Differentiated-type vulvar intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1335968"}]}}{"C129271":{"preferredName":"Astrocytoma, IDH-Mutant, Grade 2","code":"C129271","definitions":[{"definition":"IDH-mutant astrocytoma characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astrocytoma, IDH-Mutant, Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"Astrocytoma, IDH-Mutant, Grade II","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Astrocytoma, IDH-Mutant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse astrocytoma, IDH-mutant"},{"name":"NCI_META_CUI","value":"CL512140"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129274":{"preferredName":"Diffuse Astrocytoma, IDH-Wildtype","code":"C129274","definitions":[{"definition":"Diffuse astrocytoma lacking mutations in IDH1 or IDH2 genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Astrocytoma, IDH-Wildtype","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse astrocytoma, IDH-wildtype"},{"name":"NCI_META_CUI","value":"CL512141"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7364":{"preferredName":"Diffuse Intraductal Papillomatosis","code":"C7364","synonyms":[{"termName":"Diffuse Intraductal Papillomatosis","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Intraductal_Papillomatosis"},{"name":"Maps_To","value":"Diffuse intraductal papillomatosis"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1377912"}]}}{"C129424":{"preferredName":"Diffuse Leptomeningeal Glioneuronal Tumor","code":"C129424","definitions":[{"definition":"A relatively slow growing diffuse leptomeningeal neoplasm usually affecting children and adolescents. It is characterized by the presence of clear glial neoplastic cells reminiscent of oligodendroglioma. A neuronal component may be present. The prognosis is variable.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Leptomeningeal Glioneuronal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Disseminated Oligodendroglial-Like Leptomeningeal Tumor of Childhood","termGroup":"SY","termSource":"NCI"},{"termName":"DLGNT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse leptomeningeal glioneuronal tumor"},{"name":"NCI_META_CUI","value":"CL512526"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C5138":{"preferredName":"Breast Ductal Carcinoma In Situ, Cribriform Pattern","code":"C5138","definitions":[{"definition":"Breast ductal carcinoma in situ characterized by the presence of a cribriform architectural pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Ductal Carcinoma In Situ, Cribriform Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Ductal Carcinoma In Situ with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Ductal Carcinoma In Situ, Cribriform Type","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Intraductal Cribriform Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform DCIS of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform DCIS of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform Ductal Breast Carcinoma in situ","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform Ductal Carcinoma in situ of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cribriform Ductal Carcinoma in situ of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS of Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"DCIS of the Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ of Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Ductal Carcinoma in situ of the Breast with Cribriform Pattern","termGroup":"SY","termSource":"NCI"},{"termName":"Intraductal Cribriform Breast Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Infiltrating Cribriform Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Invasive Cribriform Ductal Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8201/2"},{"name":"Legacy Concept Name","value":"Intraductal_Cribriform_Breast_Adenocarcinoma"},{"name":"Maps_To","value":"Ductal carcinoma in situ, cribriform type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334248"}]}}{"C4286":{"preferredName":"Immature Teratoma","code":"C4286","definitions":[{"definition":"A rare type of malignant (cancer) germ cell tumor (type of tumor that begins in the cells that give rise to sperm or eggs) that often contains several different types of tissue such as hair, muscle, and bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A teratoma characterized by the presence of an extensive component of immature, fetal-type tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immature Teratoma","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Teratoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"ICD-O-3_Code","value":"9080/3"},{"name":"Legacy Concept Name","value":"Immature_Teratoma"},{"name":"Maps_To","value":"Embryonal teratoma"},{"name":"Maps_To","value":"Immature teratoma, malignant"},{"name":"Maps_To","value":"Immature teratoma, NOS"},{"name":"Maps_To","value":"Teratoblastoma, malignant"},{"name":"Maps_To","value":"Teratoma, malignant, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334520"}]}}{"C127907":{"preferredName":"Endocervical Adenocarcinoma, Usual-Type","code":"C127907","definitions":[{"definition":"A cervical adenocarcinoma in which 0-50% of malignant cells contain intracytoplasmic mucin. It is the most common subtype of cervical adenocarcinoma and represents 75% of all invasive cervical adenocarcinomas. The neoplastic epithelium shows a pseudostratified architecture and the malignant cells have enlarged, elongated, and hyperchromatic nuclei. Historically, usual-type cervical adenocarcinomas were termed \"endocervical-type\".","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endocervical Adenocarcinoma, Usual-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma, Endocervical Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Adenocarcinoma, Usual Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Adenocarcinoma, Usual-Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Endocervical Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Endocervical-Type","termGroup":"SY","termSource":"NCI"},{"termName":"Endocervical Adenocarcinoma, Usual Type","termGroup":"SY","termSource":"NCI"},{"termName":"UEA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8384/3"},{"name":"ICD-O-3_Code","value":"8482/3"},{"name":"Maps_To","value":"8384/3"},{"name":"Maps_To","value":"8482/3"},{"name":"Maps_To","value":"Adenocarcinoma, endocervical type"},{"name":"Maps_To","value":"Adenocarcinoma, endocervical type, NOS"},{"name":"Maps_To","value":"Endocervical adenocarcinoma usual type"},{"name":"Maps_To","value":"Mucinous adenocarcinoma, endocervical type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266079"}]}}{"C27846":{"preferredName":"Villoglandular Endometrial Endometrioid Adenocarcinoma","code":"C27846","definitions":[{"definition":"A primary endometrioid adenocarcinoma of the endometrium characterized by the presence of numerous finger-like villi lined by neoplastic columnar cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Villoglandular Endometrial Endometrioid Adenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Villoglandular_Uterine_Corpus_Endometrioid_Adenocarcinoma"},{"name":"Maps_To","value":"Endometrioid adenocarcinoma, villoglandular"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336962"}]}}{"C6290":{"preferredName":"Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation","code":"C6290","definitions":[{"definition":"An endometrioid adenocarcinoma of the endometrium showing squamous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocanthoma of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocanthoma of the Endometrium","termGroup":"AQS","termSource":"NCI"},{"termName":"Endometrial Adenoacanthoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrial_Adenosquamous_Carcinoma"},{"name":"Maps_To","value":"Endometrioid carcinoma with squamous differentiation"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279763"}]}}{"C66925":{"preferredName":"Enteroglucagonoma","code":"C66925","definitions":[{"definition":"An endocrine neoplasm producing glucagon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enteroglucagonoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8152/1"},{"name":"ICD-O-3_Code","value":"8157/1"},{"name":"Legacy Concept Name","value":"Enteroglucagonoma"},{"name":"Maps_To","value":"Enteroglucagonoma, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266016"}]}}{"C129293":{"preferredName":"Epithelioid Glioblastoma","code":"C129293","definitions":[{"definition":"An IDH-wildtype glioblastoma characterized by the presence of large epithelioid cells with abundant eosinophilic cytoplasm, vesicular chromatin, and prominent nucleoli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Glioblastoma","termGroup":"PT","termSource":"NCI"},{"termName":"E-GB","termGroup":"AB","termSource":"NCI"},{"termName":"E-GBM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epithelioid glioblastoma"},{"name":"NCI_META_CUI","value":"CL512400"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C3486":{"preferredName":"Epithelioid Cell Type Gastrointestinal Stromal Tumor","code":"C3486","definitions":[{"definition":"A benign or malignant gastrointestinal stromal tumor with epithelioid morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Cell Type Gastrointestinal Stromal Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelioid Cell Type GIST","termGroup":"SY","termSource":"NCI"},{"termName":"Leiomyoblastoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Stout's Leiomyoblastoma","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8891/0"},{"name":"Legacy Concept Name","value":"Epithelioid_Cell_Type_Gastrointestinal_Stromal_Tumor"},{"name":"Maps_To","value":"Epithelioid leiomyoma"},{"name":"Maps_To","value":"Leiomyoblastoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0086533"}]}}{"C7152":{"preferredName":"Erythroleukemia","code":"C7152","definitions":[{"definition":"Acute erythroid leukemia characterised by the presence of at least 50% erythroid precursors and at least 20% myeloblasts in the bone marrow.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer of the blood-forming tissues in which large numbers of immature, abnormal red blood cells are found in the blood and bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Erythroleukemia","termGroup":"PT","termSource":"NCI"},{"termName":"Erythroleukemia (Erythroid/Myeloid)","termGroup":"SY","termSource":"NCI"},{"termName":"Erythroleukemia, Erythroid/Myeloid","termGroup":"SY","termSource":"NCI"},{"termName":"M6a","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Erythroleukemia"},{"name":"Maps_To","value":"Erythroleukemia"},{"name":"Maps_To","value":"M6A"},{"name":"NCI_META_CUI","value":"CL432980"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C27426":{"preferredName":"High Grade Esophageal Squamous Intraepithelial Neoplasia","code":"C27426","definitions":[{"definition":"A lesion in which the architectural and cytologic abnormalities involve both the lower and the upper half of the esophageal squamous epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Esophageal Squamous Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Esophageal High-Grade Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Squamous Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Esophageal Squamous Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8077/2"},{"name":"Legacy Concept Name","value":"Esophageal_High-Grade_Squamous_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"Esophageal squamous intraepithelial neoplasia (dysplasia), high grade"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333451"}]}}{"C27547":{"preferredName":"Fibrosarcomatous Dermatofibrosarcoma Protuberans","code":"C27547","definitions":[{"definition":"A morphologic variant of dermatofibrosarcoma protuberans characterized by the presence of a fibrosarcomatous component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibrosarcomatous Dermatofibrosarcoma Protuberans","termGroup":"PT","termSource":"NCI"},{"termName":"Fibrosarcomatous DFSP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dedifferentiated_Dermatofibrosarcoma_Protuberans"},{"name":"Legacy Concept Name","value":"Fibrosarcomatous_Dermatofibrosarcoma_Protuberans"},{"name":"Maps_To","value":"Dermatofibrosarcoma protuberans, fibrosarcomatous"},{"name":"Maps_To","value":"Fibrosarcomatous dermatofibrosarcoma protuberans"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333264"},{"name":"UMLS_CUI","value":"C3665732"}]}}{"C6880":{"preferredName":"Glandular Papilloma","code":"C6880","synonyms":[{"termName":"Glandular Papilloma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glandular_Papilloma"},{"name":"Maps_To","value":"Glandular papilloma"},{"name":"Maps_To","value":"Papillary adenoma, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0205650"}]}}{"C39750":{"preferredName":"Glioblastoma, IDH-Wildtype","code":"C39750","definitions":[{"definition":"A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma, IDH-Wildtype","termGroup":"PT","termSource":"NCI"},{"termName":"Glioblastoma, IDH Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Glioblastoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Glioblastoma Multiforme","termGroup":"AQS","termSource":"NCI"},{"termName":"Primary Glioblastoma, IDH-Wildtype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Glioblastoma"},{"name":"Maps_To","value":"Glioblastoma, IDH wildtype"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1514422"}]}}{"C46068":{"preferredName":"Thyroid Gland Oncocytic Neoplasm","code":"C46068","definitions":[{"definition":"An adenoma or carcinoma arising from the follicular cells of the thyroid gland.  It is composed of large oncocytic cells with abundant granular eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"},{"definition":"An uncommon type of thyroid tumor that can be benign or malignant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Oncocytic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Hurthle Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hurthle Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle (Oncocytic) Cell Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Hurthle Cell Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Oncocytic_Neoplasm"},{"name":"Maps_To","value":"Hurthle cell tumor"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0949541"}]}}{"C96878":{"preferredName":"Gallbladder Intracholecystic Papillary (Tubular) Neoplasm with Intermediate Grade Intraepithelial Neoplasia","code":"C96878","definitions":[{"definition":"An intracholecystic papillary neoplasm that arises from the epithelium of the gallbladder. It is characterized by the presence of moderate epithelial atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gallbladder Intracholecystic Papillary (Tubular) Neoplasm with Intermediate Grade Intraepithelial Neoplasia","termGroup":"AQ","termSource":"NCI"},{"termName":"Gallbladder Papillary Neoplasm with Intermediate Grade Intraepithelial Neoplasia","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"Maps_To","value":"Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273094"}]}}{"C95506":{"preferredName":"Pancreatic Intraductal Tubulopapillary Neoplasm","code":"C95506","definitions":[{"definition":"An epithelial neoplasm that arises from the exocrine pancreas characterized by the formation of tubular structures, high grade dysplasia, and ductal differentiation. Grossly, it is characterized by the presence of intraductal nodular masses. Morphologically, there are nodules of tubular glands and occasional papillary structures growing in dilated ducts.  There is no significant mucin production. Signs and symptoms include epigastric pain, weight loss, vomiting, steatorrhea, and diabetes mellitus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Tubulopapillary Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"ITPN","termGroup":"AB","termSource":"NCI"},{"termName":"Pancreatic Intraductal Tubular Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic ITPN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8503/0"},{"name":"ICD-O-3_Code","value":"8503/2"},{"name":"Maps_To","value":"Intraductal tubulopapillary neoplasm"},{"name":"Neoplastic_Status","value":"Uncertain Malignant Potential"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2987189"}]}}{"C9480":{"preferredName":"Invasive Carcinoma","code":"C9480","definitions":[{"definition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Carcinoma"},{"name":"Maps_To","value":"Invasive carcinoma of no special type"},{"name":"Maps_To","value":"Invasive carcinoma, NST"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334274"}]}}{"C97049":{"preferredName":"Invasive Breast Lobular Carcinoma, Alveolar Variant","code":"C97049","definitions":[{"definition":"A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Alveolar Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Alveolar Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasive lobular carcinoma, alveolar type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273215"}]}}{"C97052":{"preferredName":"Invasive Breast Lobular Carcinoma, Solid Variant","code":"C97052","definitions":[{"definition":"A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Solid Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Solid Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasive lobular carcinoma, solid type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273217"}]}}{"C97053":{"preferredName":"Invasive Breast Lobular Carcinoma, Tubulolobular Variant","code":"C97053","definitions":[{"definition":"An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Tubulolobular Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Tubulolobular Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasive lobular carcinoma, tubulolobular variant"},{"name":"Maps_To","value":"Tubulolobular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273218"}]}}{"C9245":{"preferredName":"Invasive Breast Carcinoma","code":"C9245","definitions":[{"definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that has spread from where it started in the breast into surrounding, healthy tissue. Most invasive breast cancers start in the ducts (tubes that carry milk from the lobules to the nipple). Invasive breast cancer can spread to other parts of the body through the blood and lymph systems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Invasive Breast Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Infiltrating Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Breast Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Invasive Mammary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Invasive_Breast_Carcinoma"},{"name":"Maps_To","value":"61"},{"name":"Maps_To","value":"80"},{"name":"Maps_To","value":"Invasive mammary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0853879"}]}}{"C65184":{"preferredName":"Islet Cell Adenoma","code":"C65184","definitions":[{"definition":"A benign endocrine neoplasm arising from the pancreas. It is separated from the normal pancreatic tissues by a thin collagenous capsule. It may secrete a hormone (e.g. insulin, gastrin) or it may be non-functional.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Islet Cell Adenoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/0"},{"name":"Legacy Concept Name","value":"Islet_Cell_Adenoma"},{"name":"Maps_To","value":"Islet cell adenoma"},{"name":"Maps_To","value":"Nesidioblastoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0022134"}]}}{"C4375":{"preferredName":"Nesidioblastosis","code":"C4375","definitions":[{"definition":"A sporadic or inherited disorder characterized by the focal or diffuse proliferation of the cells of the islets of Langerhans in the pancreas. It results in hyperinsulinemia and hypoglycemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nesidioblastosis","termGroup":"PT","termSource":"NCI"},{"termName":"Islet Cell Adenomatosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Islet_Cell_Adenomatosis"},{"name":"Maps_To","value":"Islet cell adenomatosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0027773"}]}}{"C150703":{"preferredName":"Langerhans Cell Histiocytosis, Disseminated","code":"C150703","definitions":[{"definition":"Langerhans cell histiocytosis presenting with disseminated disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis, Disseminated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, disseminated"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, generalized"},{"name":"NCI_META_CUI","value":"CL480899"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C150701":{"preferredName":"Langerhans Cell Histiocytosis, Monostotic","code":"C150701","definitions":[{"definition":"Langerhans cell histiocytosis presenting as a solitary lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis, Monostotic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, mono-ostotic"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, unifocal"},{"name":"NCI_META_CUI","value":"CL552503"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C150702":{"preferredName":"Langerhans Cell Histiocytosis, Polyostotic","code":"C150702","definitions":[{"definition":"Langerhans cell histiocytosis presenting with multiple sites of involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Langerhans Cell Histiocytosis, Polyostotic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, multifocal"},{"name":"Maps_To","value":"Langerhans cell histiocytosis, poly-ostotic"},{"name":"NCI_META_CUI","value":"CL552504"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C123160":{"preferredName":"Lepidic Adenocarcinoma","code":"C123160","definitions":[{"definition":"A lung adenocarcinoma characterized by the presence of mildly and moderately differentiated adenocarcinoma cells across the alveolar walls with at least one focus of invasive carcinoma measuring more than 5 mm in greatest dimension.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lepidic Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lepidic Predominant Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lepidic Predominant Lung Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LPA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lepidic adenocarcinoma"},{"name":"Maps_To","value":"Lepidic predominant adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4049711"}]}}{"C191684":{"preferredName":"Invasive Lipid-Rich Urothelial Carcinoma","code":"C191684","definitions":[{"definition":"Invasive urothelial carcinoma characterized by the presence of lipid laden tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Lipid-Rich Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid-Rich Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid-rich urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1905265"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C9502":{"preferredName":"Myolipoma","code":"C9502","definitions":[{"definition":"A benign extrauterine tumor composed of mature adipocytes and smooth muscle cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myolipoma","termGroup":"PT","termSource":"NCI"},{"termName":"Extrauterine Lipoleiomyoma","termGroup":"SY","termSource":"NCI"},{"termName":"Myolipoma of Soft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myolipoma"},{"name":"Maps_To","value":"Lipoleiomyoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1096309"}]}}{"C176979":{"preferredName":"Lipoma-Like Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","code":"C176979","definitions":[{"definition":"An atypical lipomatous tumor/well differentiated liposarcoma composed of mature adipocytes in which, unlike in benign lipoma, substantial variation in cell size is appreciated alongside nuclear atypia in fat cells or stromal spindle cells. (WHO 2020)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipoma-Like Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Lipoma-Like ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Lipoma-Like Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Lipoma-Like Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipoma-like liposarcoma"},{"name":"NCI_META_CUI","value":"CL1642762"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40362":{"preferredName":"Low Grade Breast Adenosquamous Carcinoma","code":"C40362","definitions":[{"definition":"A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Breast Adenosquamous Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Infiltrating Breast Syringomatous Adenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Low Grade Adenosquamous Breast Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Low_Grade_Adenosquamous_Breast_Carcinoma"},{"name":"Maps_To","value":"Low grade adenosquamous carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518013"}]}}{"C62192":{"preferredName":"Salivary Gland Intraductal Carcinoma","code":"C62192","definitions":[{"definition":"A rare, low-grade adenocarcinoma that arises from the salivary glands.  It is characterized by the presence of cystic structures lined by ductal cells which are arranged in cribriform patterns.  Adjacent ducts show intraductal proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Gland Intraductal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Low Grade Salivary Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Gland Low Grade Cribriform Cystadenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Low_Grade_Cribriform_Cystadenocarcinoma"},{"name":"Maps_To","value":"Low grade cribriform cystadenocarcinoma (LGCCC)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1882972"}]}}{"C45202":{"preferredName":"Low Grade Fibromyxoid Sarcoma","code":"C45202","definitions":[{"definition":"A low-grade, late-metastasizing variant of fibrosarcoma characterized by alternating fibrous and myxoid areas and a whorling growth pattern.  The neoplastic cells have a spindle morphology, and lack hyperchromasia or significant nuclear atypia.  Approximately 40% of cases show the focal presence of collagen rosettes.  A t(7;16)(q33;p11) translocation has been identified in the majority of cases, associated with the presence of FUS-CREB3L2 fusion protein.  Rare cases carry the t(11;16)(p11;p11) translocation which is associated with the presence of the FUS-CREB3L1 fusion protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Fibromyxoid Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Low_Grade_Fibromyxoid_Sarcoma"},{"name":"Maps_To","value":"Low-grade fibromyxoid sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1275282"}]}}{"C8563":{"preferredName":"Undifferentiated High Grade Pleomorphic Sarcoma of Bone","code":"C8563","definitions":[{"definition":"A rare, high-grade pleomorphic malignant neoplasm arising from the bone.  It usually presents with pain which may or may not be associated with swelling in the affected area.  It is characterized by the presence of spindle-shaped cells, polygonal or epithelioid cells, multinucleated giant cells, and inflammatory cells.  The neoplastic cells exhibit nuclear pleomorphism and high mitotic activity.  It metastasizes frequently, most often in the lungs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated High Grade Pleomorphic Sarcoma of Bone","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Bone Fibrous Histiocytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibrous Histiocytoma of Bone","termGroup":"AQS","termSource":"NCI"},{"termName":"Malignant Fibrous Histiocytoma of the Bone","termGroup":"AQS","termSource":"NCI"},{"termName":"Undifferentiated High Grade Pleomorphic Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Undifferentiated High-Grade Pleomorphic Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Bone_Fibrous_Histiocytoma"},{"name":"Maps_To","value":"Malignant fibrous histiocytoma (MFH) of bone"},{"name":"Maps_To","value":"Undifferentiated high-grade pleomorphic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0740479"}]}}{"C6530":{"preferredName":"Malignant Pericytic Neoplasm","code":"C6530","definitions":[{"definition":"A malignant mesenchymal neoplasm arising from the perivascular cells of the connective and soft tissues.  It is characterized by the presence of pericytes that grow in a circumferential pattern around vessels, and cytologic atypia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Pericytic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Pericytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Perivascular Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Perivascular Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Perivascular_Neoplasm"},{"name":"Maps_To","value":"Malignant perivascular epithelial cell tumor"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1334611"}]}}{"C54039":{"preferredName":"Classic Medulloblastoma","code":"C54039","definitions":[{"definition":"A medulloblastoma composed of malignant cells with hyperchromatic nucleus and scanty cytoplasm.  Homer Wright rosettes may be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Classic Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Classic_Medulloblastoma"},{"name":"Maps_To","value":"Medulloblastoma, classic"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1707400"}]}}{"C129445":{"preferredName":"Medulloblastoma, Non-WNT/Non-SHH, Group 3","code":"C129445","definitions":[{"definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications may be present. TP53 mutations are absent. Patients in this group are usually young children. The overall survival is the worst among all the molecular groups.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Non-WNT/Non-SHH, Group 3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medulloblastoma, group 3"},{"name":"NCI_META_CUI","value":"CL512711"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129446":{"preferredName":"Medulloblastoma, Non-WNT/Non-SHH, Group 4","code":"C129446","definitions":[{"definition":"Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications are absent. TP53 mutations are absent. Chromosome 17 abnormalities may be present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, Non-WNT/Non-SHH, Group 4","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medulloblastoma, group 4"},{"name":"NCI_META_CUI","value":"CL512712"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129443":{"preferredName":"Medulloblastoma, SHH-Activated, TP53-Wildtype","code":"C129443","definitions":[{"definition":"Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the absence of TP53 mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medulloblastoma, SHH-Activated, TP53-Wildtype","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medulloblastoma, SHH-activated and TP53-wildtype"},{"name":"NCI_META_CUI","value":"CL512716"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C4230":{"preferredName":"Optic Disc Melanocytoma","code":"C4230","definitions":[{"definition":"A benign neoplastic melanocytic proliferation within or adjacent to the optic disk. It presents as a pigmented, intraocular tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Optic Disc Melanocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocytoma of Eyeball","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytoma of the Eyeball","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8726/0"},{"name":"Legacy Concept Name","value":"Melanocytoma_of_the_Eyeball"},{"name":"Maps_To","value":"Melanocytoma, eyeball"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2004458"}]}}{"C6910":{"preferredName":"Malignant Melanotic Psammomatous Peripheral Nerve Sheath Tumor","code":"C6910","definitions":[{"definition":"A malignant peripheral nerve sheath tumor characterized by the presence of malignant cells that contain melanin and formation of psammoma bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Melanotic Psammomatous Peripheral Nerve Sheath Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocytic Psammomatous Malignant Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Melanocytic Psammomatous MPNST","termGroup":"SY","termSource":"NCI"},{"termName":"Melanotic Psammomatous Malignant Peripheral Nerve Sheath Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanotic_Psammomatous_Malignant_Peripheral_Nerve_Sheath_Tumor"},{"name":"Maps_To","value":"Melanotic psammomatous MPNST"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1321709"}]}}{"C5317":{"preferredName":"Meningeal Melanoma","code":"C5317","definitions":[{"definition":"A melanoma that arises from leptomeningeal melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meningeal Melanoma","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Leptomeningeal Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma of Leptomeninges","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma of the Leptomeninges","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Central Nervous System Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Melanoma"},{"name":"Legacy Concept Name","value":"Leptomeningeal_Melanoma"},{"name":"Maps_To","value":"Meningeal melanoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332888"},{"name":"UMLS_CUI","value":"C1334386"}]}}{"C191685":{"preferredName":"Invasive Microcystic Urothelial Carcinoma","code":"C191685","definitions":[{"definition":"Invasive urothelial carcinoma characterized by microcysts formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Microcystic Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Microcystic Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microcystic urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1905264"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C154494":{"preferredName":"Renal Cell Carcinoma with MiT Translocations","code":"C154494","definitions":[{"definition":"A renal cell carcinoma usually seen in children or young adults. It is characterized by papillary, alveolar and nested growth patterns with clear and eosinophilic cells. The carcinomas range from microscopic lesions to clinically symptomatic tumors. It is associated with translocations/gene fusions involving members of the MiT family of transcription factors. There are two subtypes: TFE3-rearranged renal cell carcinoma [Xp11 translocation renal cell carcinoma] and TFEB-rearranged renal cell carcinoma [t(6;11) renal cell carcinoma].","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Cell Carcinoma with MiT Translocations","termGroup":"PT","termSource":"NCI"},{"termName":"MiT Family Translocation-Associated Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MiT family translocation renal cell carcinoma"},{"name":"NCI_META_CUI","value":"CL557969"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6879":{"preferredName":"Pancreatic Mixed Ductal Adenocarcinoma-Neuroendocrine Carcinoma","code":"C6879","definitions":[{"definition":"A carcinoma that arises from the pancreas and is composed of ductal adenocarcinoma and neuroendocrine carcinoma components in both the primary tumor and the metastatic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Mixed Ductal Adenocarcinoma-Neuroendocrine Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Ductal-Endocrine Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Ductal-Endocrine Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mixed Ductal Adenocarcinoma-NEC","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Mixed Ductal-Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Ductal-Endocrine_Carcinoma"},{"name":"Maps_To","value":"Mixed ductal-endocrine carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301048"}]}}{"C39912":{"preferredName":"Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified","code":"C39912","definitions":[{"definition":"A testicular mixed germ cell-sex cord-stromal tumor in which the neoplastic germ cells and the neoplastic sex cord-stromal cells do not form nests and are instead arranged in a diffuse pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Testicular_Mixed_Germ_Cell-Sex_Cord-Stromal_Tumor_Unclassified"},{"name":"Maps_To","value":"Mixed germ cell sex cord-stromal tumor, unclassified"},{"name":"NCI_META_CUI","value":"CL448662"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C8025":{"preferredName":"Malignant Mixed Tumor of the Salivary Gland","code":"C8025","definitions":[{"definition":"A malignant tumor arising from the salivary gland.  It includes carcinoma ex pleomorphic adenoma, a malignant epithelial tumor arising from a pre-existing pleomorphic adenoma and carcinosarcoma which is characterized by a mixture of malignant epithelial and sarcomatous elements.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Mixed Tumor of the Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Mixed Cell Type Neoplasm of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Cell Type Neoplasm of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Neoplasm of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Neoplasm of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Mixed Tumor of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Cell Type Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Cell Type Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Salivary Gland Mixed Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Neoplasm of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Neoplasm of the Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Salivary Gland Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Salivary Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Tumor of Salivary Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Mixed Malignant Tumor of the Salivary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Mixed_Tumor_of_the_Salivary_Gland"},{"name":"Maps_To","value":"Mixed tumor, malignant, NOS"},{"name":"Maps_To","value":"Mixed tumor, salivary gland type, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0344459"}]}}{"C121786":{"preferredName":"Mixed Tumor, Not Otherwise Specified","code":"C121786","definitions":[{"definition":"A benign myoepithelioma characterized by the presence of a minor ductal component.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Tumor, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"Mixed Tumor, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed tumor, NOS"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4049618"}]}}{"C127905":{"preferredName":"Cervical Mucinous Adenocarcinoma, Gastric Type","code":"C127905","definitions":[{"definition":"A cervical mucinous adenocarcinoma showing gastric differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Mucinous Adenocarcinoma, Gastric Type","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Mon Jul 19 15:28:50 EDT 2021 - See 'Human Papillomavirus-Independent Cervical Adenocarcinoma, Gastric-Type(C40206)'"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"OLD_PARENT","value":"C180848"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C40203":{"preferredName":"Cervical Mucinous Adenocarcinoma, Intestinal-Type","code":"C40203","definitions":[{"definition":"A cervical mucinous adenocarcinoma that resembles a large intestinal adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Mucinous Adenocarcinoma, Intestinal-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Intestinal Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Mucinous Adenocarcinoma, Intestinal Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cervical_Mucinous_Adenocarcinoma_Intestinal_Variant"},{"name":"Maps_To","value":"Mucinous carcinoma, intestinal type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516422"}]}}{"C39807":{"preferredName":"Mucinous Tubular and Spindle Cell Carcinoma of the Kidney","code":"C39807","definitions":[{"definition":"A low grade carcinoma of the kidney characterized by the presence of tubules which are separated by mucinous stroma. Often the tubular structures have a spindle cell appearance.  Patients are usually asymptomatic and occasionally they may present with hematuria or flank pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucinous Tubular and Spindle Cell Carcinoma of the Kidney","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"0000/0"},{"name":"Legacy Concept Name","value":"Mucinous_Tubular_and_Spindle_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Mucinous tubular and spindle cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1513719"}]}}{"C8648":{"preferredName":"Myelodysplastic Syndrome, Unclassifiable","code":"C8648","definitions":[{"definition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood; 2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDS, U","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-U","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome, Unclassifiable","termGroup":"AQ","termSource":"NCI"},{"termName":"Unclassifiable MDS","termGroup":"AQS","termSource":"NCI"},{"termName":"Unclassifiable Myelodysplastic Syndrome","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9989/3"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Syndrome_Unclassifiable"},{"name":"Maps_To","value":"Myelodysplastic syndrome, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0854809"}]}}{"C27780":{"preferredName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","code":"C27780","definitions":[{"definition":"A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"MDS/MPN, NOS","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/MPN, U","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/MPN-U","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic/Myeloproliferative Neoplasm, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myelodysplastic_Myeloproliferative_Disease_Unclassifiable"},{"name":"Maps_To","value":"Myelodysplastic and myeloproliferative disease, not elsewhere classified"},{"name":"Maps_To","value":"Myelodysplastic/myeloproliferative neoplasm, unclassifiable"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1328061"}]}}{"C27701":{"preferredName":"Secondary Myelofibrosis","code":"C27701","definitions":[{"definition":"Myelofibrosis that develops in patients with a history of hematologic malignancies or toxic injury to the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Myelofibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secondary_Myelofibrosis"},{"name":"Maps_To","value":"Myelofibrosis as a result of myeloproliferative disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0242006"}]}}{"C191687":{"preferredName":"Invasive Nested Urothelial Carcinoma","code":"C191687","definitions":[{"definition":"Invasive urothelial carcinoma characterized by a nested growth pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Nested Urothelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Nested Urothelial Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nested urothelial carcinoma"},{"name":"NCI_META_CUI","value":"CL1905262"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C155863":{"preferredName":"Poorly Differentiated Neuroendocrine Lesion","code":"C155863","definitions":[{"definition":"A neoplastic lesion with neuroendocrine differentiation and poorly differentiated histological features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Neuroendocrine Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neuroendocrine carcinoma, poorly differentiated"},{"name":"NCI_META_CUI","value":"CL562689"},{"name":"Semantic_Type","value":"Finding"}]}}{"C155861":{"preferredName":"Well Differentiated Neuroendocrine Lesion","code":"C155861","definitions":[{"definition":"A neoplastic lesion with neuroendocrine differentiation and well differentiated histological features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated Neuroendocrine Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neuroendocrine tumor, well differentiated"},{"name":"NCI_META_CUI","value":"CL562687"},{"name":"Semantic_Type","value":"Finding"}]}}{"C173720":{"preferredName":"Odontogenic Carcinoma","code":"C173720","definitions":[{"definition":"A carcinoma that arises from tooth-forming tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Odontogenic carcinoma"},{"name":"NCI_META_CUI","value":"CL1407572"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C173738":{"preferredName":"Odontogenic Sarcoma","code":"C173738","definitions":[{"definition":"A sarcoma that arises from tooth-forming tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odontogenic Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Odontogenic sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0542511"}]}}{"C129318":{"preferredName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","code":"C129318","definitions":[{"definition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted"},{"name":"NCI_META_CUI","value":"CL512489"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7072":{"preferredName":"Oncocytic Neoplasm","code":"C7072","definitions":[{"definition":"A benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm (oncocytes).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A usually benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.  Representative examples include oncocytic neoplasms of the thyroid gland, and kidney. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncocytic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Oncocytic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Oncocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oncocytic_Neoplasm"},{"name":"Maps_To","value":"Oncocytoma"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378050"}]}}{"C121774":{"preferredName":"Malignant Ossifying Fibromyxoid Tumor","code":"C121774","definitions":[{"definition":"An ossifying fibromyxoid tumor characterized by the presence of high grade nuclear features or increased cellularity and more than two mitotic figures per 50 HPFs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Ossifying Fibromyxoid Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ossifying fibromyxoid tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839955"}]}}{"C45837":{"preferredName":"Non-Functioning Pancreatic Neuroendocrine Tumor","code":"C45837","definitions":[{"definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the absence of a hormone-related clinical syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Functioning Pancreatic Neuroendocrine Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Inactive Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"NF-PanNET","termGroup":"AB","termSource":"NCI"},{"termName":"Non-Functional Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Functioning Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Functioning Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Functioning Well Differentiated Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Syndromic Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Syndromic Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonfunctional Pancreatic NET","termGroup":"SY","termSource":"NCI"},{"termName":"Nonfunctional Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonfunctioning Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonsyndromic Pancreatic Endocrine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Nonsyndromic Pancreatic Neuroendocrine Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/3"},{"name":"Legacy Concept Name","value":"Non-Functioning_Well_Differentiated_Pancreatic_Endocrine_Neoplasm"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, nonfunctioning"},{"name":"Maps_To","value":"Pancreatic neuroendocrine tumor, nonfunctioning"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839703"}]}}{"C45834":{"preferredName":"Pancreatic Neuroendocrine Microtumor","code":"C45834","definitions":[{"definition":"A non-functioning pancreatic neuroendocrine tumor measuring less than 0.5 cm in diameter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Neuroendocrine Microtumor","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Endocrine Microadenoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Neuroendocrine Microadenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8150/0"},{"name":"Legacy Concept Name","value":"Pancreatic_Endocrine_Microadenoma"},{"name":"Maps_To","value":"Pancreatic endocrine tumor, benign"},{"name":"Maps_To","value":"Pancreatic microadenoma"},{"name":"Maps_To","value":"Pancreatic neuroendocrine microadenoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709454"}]}}{"C4179":{"preferredName":"Papillary Cystic Neoplasm","code":"C4179","definitions":[{"definition":"A benign, malignant, or borderline epithelial neoplasm characterized by the presence of papillary mucinous, serous, or clear cell structures and cystic structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Cystic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Cystic Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Cystic_Neoplasm"},{"name":"Maps_To","value":"Papillary cystic tumor"},{"name":"Maps_To","value":"Solid and cystic tumor"},{"name":"Maps_To","value":"Solid and papillary epithelial neoplasm"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0334357"}]}}{"C173928":{"preferredName":"Periapical Cemento-Osseous Dysplasia","code":"C173928","definitions":[{"definition":"Cemento-osseous dysplasia affecting the apical areas of mandibular anterior teeth. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Periapical Cemento-Osseous Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"PCOD","termGroup":"AB","termSource":"NCI"},{"termName":"Periapical COD","termGroup":"SY","termSource":"NCI"},{"termName":"Periapical Osseous Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Periapical cemental dysplasia"},{"name":"Maps_To","value":"Periapical cemento-osseous dysplasia"},{"name":"NCI_META_CUI","value":"CL1407696"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C121789":{"preferredName":"Malignant Phosphaturic Mesenchymal Tumor","code":"C121789","definitions":[{"definition":"A phosphaturic mesenchymal tumor characterized by the presence of nuclear atypia, high mitotic activity, increased cellularity, marked pleomorphism, and necrosis. It usually develops in lesions that have recurred locally and metastasizes to other sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Phosphaturic Mesenchymal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phosphaturic mesenchymal tumor, malignant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3839061"}]}}{"C97051":{"preferredName":"Invasive Breast Lobular Carcinoma, Pleomorphic Variant","code":"C97051","definitions":[{"definition":"A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Breast Lobular Carcinoma, Pleomorphic Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Invasive Lobular Breast Carcinoma, Pleomorphic Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleomorphic lobular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273216"}]}}{"C45339":{"preferredName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","code":"C45339","definitions":[{"definition":"An aggressive, epidermotropic primary cutaneous T-cell lymphoma composed of small to medium-sized, or medium-sized to large, CD8-positive T-lymphocytes with pleomorphic or blastic nuclei. Epidermotropism is often pronounced, and angiocentricity and angioinvasion may be present. It manifests with localized or disseminated eruptive papules and nodules or tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"PCAETL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9709/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_Aggressive_Epidermotropic_CD8-Positive_T-Cell_Lymphoma"},{"name":"Maps_To","value":"Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709653"}]}}{"C45194":{"preferredName":"Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","code":"C45194","definitions":[{"definition":"An aggressive primary cutaneous B-cell lymphoma, usually involving the lower leg.  It is composed of a generally monotonous proliferation of immunoblasts, or less frequently centroblasts, with few admixed reactive cells.  This type of lymphoma occurs most often in elderly women who present with rapidly growing tumors, usually on one or both legs.  Dissemination to extracutaneous sites is frequent.  Treatment with combination chemotherapy is usually required.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","termGroup":"PT","termSource":"NCI"},{"termName":"Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Primary_Cutaneous_Diffuse_Large_B-Cell_Lymphoma_Leg_Type"},{"name":"Maps_To","value":"Primary cutaneous DLBCL, leg type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1709656"}]}}{"C71720":{"preferredName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","code":"C71720","definitions":[{"definition":"A diffuse large B-cell lymphoma arising from the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Diffuse Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Primary Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"CNS DLBCL","termGroup":"AB","termSource":"NCI"},{"termName":"CNS Primary Large B-Cell Lymphoma","termGroup":"SY","termSource":"NCI"},{"termName":"PCNS-LBCL","termGroup":"AB","termSource":"NCI"},{"termName":"Primary Diffuse Large B-Cell Lymphoma of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Primary DLBCL of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Large B-Cell Lymphoma of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Large B-Cell Lymphoma of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9680/3"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Diffuse_Large_B-Cell_Lymphoma"},{"name":"Maps_To","value":"Primary diffuse large B-cell lymphoma of the CNS"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2026186"}]}}{"C142825":{"preferredName":"Pulmonary Artery Intimal Sarcoma","code":"C142825","definitions":[{"definition":"A sarcoma arising from the arterial intima of pulmonary arteries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Artery Intimal Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Intimal Sarcoma of the Pulmonary Artery","termGroup":"SY","termSource":"NCI"},{"termName":"PAIS","termGroup":"AB","termSource":"NCI"},{"termName":"PAS","termGroup":"AB","termSource":"NCI"},{"termName":"PIS","termGroup":"AB","termSource":"NCI"},{"termName":"Pulmonary Artery Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pulmonary Intimal Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary artery intimal sarcoma"},{"name":"NCI_META_CUI","value":"CL540697"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C7168":{"preferredName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","code":"C7168","definitions":[{"definition":"A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","termGroup":"PT","termSource":"NCI"},{"termName":"MDS with Increased Blasts-2","termGroup":"SY","termSource":"NCI"},{"termName":"MDS-EB-2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-EB2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB-2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS-IB2","termGroup":"AB","termSource":"NCI"},{"termName":"MDS/AML","termGroup":"AB","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome with Excess Blasts-2","termGroup":"SY","termSource":"NCI"},{"termName":"RAEB-2","termGroup":"AB","termSource":"NCI"},{"termName":"RAEB-II","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"RAEB-2"},{"name":"Maps_To","value":"RAEB II"},{"name":"Maps_To","value":"Refractory anemia with excess of blasts 2"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1318551"}]}}{"C9385":{"preferredName":"Renal Cell Carcinoma","code":"C9385","definitions":[{"definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm arising from renal parenchyma.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant neoplasm arising from the renal parenchyma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"RCC","termGroup":"AB","termSource":"NCI"},{"termName":"Renal Cell Adenocarcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cell Carcinoma, Stage Unspecified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"8311/1"},{"name":"ICD-O-3_Code","value":"8312/3"},{"name":"Legacy Concept Name","value":"Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Renal cell adenocarcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1861854"}]}}{"C7572":{"preferredName":"Kidney Medullary Carcinoma","code":"C7572","definitions":[{"definition":"A type of renal carcinoma affecting mostly young African-Americans.  It is located in the medulla of the kidney, and follows an aggressive clinical course.  Most reported cases have shown metastatic disease at the time of diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kidney Medullary Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Renal Medullary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Medullary_Carcinoma"},{"name":"Maps_To","value":"Renal medullary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4049328"}]}}{"C5568":{"preferredName":"Skin Nodulo-Ulcerative Basal Cell Carcinoma","code":"C5568","definitions":[{"definition":"A type of basal cell carcinoma of the skin.  It appears as a flesh-colored papule with telangiectatic vessels on its surface.  It grows slowly; as it enlarges it becomes necrotic forming a central ulcer with raised borders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Nodulo-Ulcerative Basal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Nodulo-Ulcerative Basal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Rodent Ulcer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nodulo-Ulcerative_Basal_Cell_Carcinoma"},{"name":"Maps_To","value":"Rodent ulcer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0862887"}]}}{"C5904":{"preferredName":"Salivary Duct Carcinoma","code":"C5904","definitions":[{"definition":"An aggressive, high grade adenocarcinoma that arises from the salivary glands. It usually affects elderly males and presents as a rapidly enlarging mass. It metastasizes to regional lymph nodes and distant anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salivary Duct Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Salivary Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Salivary Duct","termGroup":"SY","termSource":"NCI"},{"termName":"High Grade Salivary Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SDC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salivary_Duct_Carcinoma"},{"name":"Maps_To","value":"Salivary duct carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301194"}]}}{"C49027":{"preferredName":"Sclerosing Epithelioid Fibrosarcoma","code":"C49027","definitions":[{"definition":"A well-circumscribed malignant fibroblastic neoplasm that usually arises from the soft tissue. It is characterized by the presence of nests of malignant epithelioid fibroblasts and sclerotic collagen stroma formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosing Epithelioid Fibrosarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"SEF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sclerosing_Epithelioid_Fibrosarcoma"},{"name":"Maps_To","value":"Sclerosing epithelioid fibrosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1710026"}]}}{"C121655":{"preferredName":"Sclerosing Rhabdomyosarcoma","code":"C121655","definitions":[{"definition":"An uncommon variant of rhabdomyosarcoma with sclerosing morphology.  It usually arises from the limbs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sclerosing Rhabdomyosarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sclerosing rhabdomyosarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4048700"}]}}{"C36310":{"preferredName":"Secondary Carcinoma","code":"C36310","definitions":[{"definition":"A carcinoma that arises from a pre-existing lower grade epithelial lesion, or as a result of a primary carcinoma that has spread to secondary sites, or due to a complication of a cancer treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Secondary_Carcinoma"},{"name":"Maps_To","value":"Secondary carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0085668"}]}}{"C40152":{"preferredName":"Serous Endometrial Intraepithelial Carcinoma","code":"C40152","definitions":[{"definition":"A precursor of endometrial serous adenocarcinoma characterized by the replacement of the normal endometrial cells by malignant glandular cells that resemble the malignant cells of invasive serous adenocarcinoma. The endometrial neoplastic process is non-invasive. It may coexist with invasive endometrial adenocarcinoma or can be associated with metastases outside the uterus, in the absence of invasive endometrial carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serous Endometrial Intraepithelial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"EIC","termGroup":"AB","termSource":"NCI"},{"termName":"Endometrial Intraepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Serous Carcinoma in Situ","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Serous Intraepithelial Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Endometrial Surface Serous Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SEIC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Endometrial_Serous_Intraepithelial_Carcinoma"},{"name":"Maps_To","value":"Serous endometrial intraepithelial carcinoma"},{"name":"Maps_To","value":"Serous intraepithelial carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516857"}]}}{"C40440":{"preferredName":"Ovarian Small Cell Carcinoma, Pulmonary-Type","code":"C40440","definitions":[{"definition":"An aggressive small cell neuroendocrine carcinoma that arises from the ovary.  Morphologically, it resembles the small cell carcinoma that arises from the lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Small Cell Carcinoma, Pulmonary-Type","termGroup":"PT","termSource":"NCI"},{"termName":"Ovarian Small Cell NEC","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Small Cell Neuroendocrine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Small_Cell_Carcinoma_Pulmonary_Type"},{"name":"Maps_To","value":"Small cell carcinoma pulmonary type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518737"}]}}{"C40439":{"preferredName":"Ovarian Small Cell Carcinoma, Hypercalcemic Type","code":"C40439","definitions":[{"definition":"An undifferentiated small cell carcinoma that arises from the ovary and is associated with hypercalcemia.  Electron microscopic studies show neurosecretory granules are either absent or, when present, are in small numbers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Small Cell Carcinoma, Hypercalcemic Type","termGroup":"PT","termSource":"NCI"},{"termName":"SCCOHT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Small_Cell_Carcinoma_Hypercalcemic_Type"},{"name":"Maps_To","value":"Small cell carcinoma, hypercalcemic type"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1518736"}]}}{"C3751":{"preferredName":"Smooth Muscle Neoplasm","code":"C3751","definitions":[{"definition":"A benign or malignant myomatous neoplasm arising from smooth muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smooth Muscle Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Neoplasm of Smooth Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm of the Smooth Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Smooth Muscle Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of Smooth Muscle","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor of the Smooth Muscle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Smooth_Muscle_Neoplasm"},{"name":"Maps_To","value":"Smooth muscle tumor, NOS"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206658"}]}}{"C129530":{"preferredName":"Central Nervous System Solitary Fibrous Tumor, Grade 1","code":"C129530","definitions":[{"definition":"A solitary fibrous tumor that arises from the central nervous system. It corresponds most often to the collagenous and low cellularity spindle cell tumor which was diagnosed as central nervous system solitary fibrous tumor in the past.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Solitary Fibrous Tumor, Grade 1","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor, Grade 1","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)"},{"name":"Maps_To","value":"Solitary fibrous tumor/Hemangiopericytoma, grade 1"},{"name":"NCI_META_CUI","value":"CL512613"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C129527":{"preferredName":"Central Nervous System Solitary Fibrous Tumor, Grade 3","code":"C129527","definitions":[{"definition":"A solitary fibrous tumor that arises from the central nervous system. It most often corresponds to the tumor previously diagnosed as anaplastic hemangiopericytoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Solitary Fibrous Tumor, Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Anaplastic Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Malignant Hemangiopericytoma","termGroup":"AQS","termSource":"NCI"},{"termName":"Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor, Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)"},{"name":"NCI_META_CUI","value":"CL512610"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C94537":{"preferredName":"Spindle Cell Oncocytoma","code":"C94537","definitions":[{"definition":"A very rare, WHO grade 1 neoplasm of the posterior pituitary. It is characterized by the presence of spindle cells with eosinophilic, granular cytoplasm forming fascicles.  Electron microscopic studies demonstrate the accumulation of intracytoplasmic mitochondria and lack of secretory granules.  Immunohistochemical studies are negative for pituitary hormones.  Patients may present with pituitary hypofunction, visual disturbances, headache, nausea and vomiting.  The clinical course is usually benign.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spindle Cell Oncocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Folliculo-Stellate Cell Tumor of the Pituitary","termGroup":"AQS","termSource":"NCI"},{"termName":"SCO","termGroup":"AB","termSource":"NCI"},{"termName":"Spindle Cell Oncocytoma of the Adenohypophysis","termGroup":"AQS","termSource":"NCI"},{"termName":"Spindle Cell Oncocytoma of the Adenohypophysis (WHO Grade 1)","termGroup":"AQS","termSource":"NCI"},{"termName":"Spindle Cell Oncocytoma/Oncocytic Pituicytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"8290/0"},{"name":"Legacy Concept Name","value":"Pituitary_Gland_Oncocytoma"},{"name":"Maps_To","value":"Spindle cell oncocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2986561"}]}}{"C40194":{"preferredName":"Cervical Squamotransitional Carcinoma","code":"C40194","definitions":[{"definition":"A human papillomavirus-related cervical squamous cell carcinoma characterized by the presence of papillary structures with fibrovascular cores. It is covered with multiple layers of atypical cells that resemble cervical intraepithelial neoplasia 3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Squamotransitional Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cervical_Squamotransitional_Carcinoma"},{"name":"Maps_To","value":"Squamotransitional cell carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516433"}]}}{"C176980":{"preferredName":"Superficial Atypical Lipomatous Tumor","code":"C176980","definitions":[{"definition":"A locally aggressive mesenchymal neoplasm of a superficial body structure that is characterized by the presence of an adipocytic proliferation exhibiting at least focal nuclear atypia in both adipocytes and stromal cells. Amplification of MDM2 and/or CDK4 is almost always present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Atypical Lipomatous Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Superficial ALT","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial ALT/WDLPS","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Atypical Lipomatous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Well Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Superficial Well-Differentiated Liposarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superficial well differentiated liposarcoma"},{"name":"Maps_To","value":"Well differentiated liposarcoma of superficial soft tissue"},{"name":"NCI_META_CUI","value":"CL1642763"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C6900":{"preferredName":"Epithelioid Trophoblastic Tumor","code":"C6900","definitions":[{"definition":"A gestational trophoblastic tumor characterized by the presence of a monomorphous cellular population of intermediate trophoblastic cells infiltrating in a nodular pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epithelioid Trophoblastic Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"ETT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"ICD-O-3_Code","value":"9105/3"},{"name":"Legacy Concept Name","value":"Epithelioid_Trophoblastic_Tumor"},{"name":"Maps_To","value":"9105/3"},{"name":"Maps_To","value":"Trophoblastic tumor, epithelioid"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266159"}]}}{"C35382":{"preferredName":"True Histiocytic Lymphoma","code":"C35382","definitions":[{"definition":"An antiquated term referring to large cell lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"An outdated term referring to non-Hodgkin lymphomas made up of large abnormal lymphoid cells. Histiocytic lymphomas include mature B-cell and T-cell non-Hodgkin lymphomas. Many tumors that were once called histiocytic lymphomas are now considered to be a type of large cell lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"True Histiocytic Lymphoma","termGroup":"AQ","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Obsolete_Concept"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"True_Histiocytic_Lymphoma"},{"name":"Maps_To","value":"True histiocytic lymphoma"},{"name":"NCI_META_CUI","value":"CL414775"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C126303":{"preferredName":"Tubulocystic Renal Cell Carcinoma","code":"C126303","definitions":[{"definition":"A rare, cytologically high grade carcinoma that arises from the renal parenchyma. It is characterized by the presence of prominently dilated cystic spaces in a bland, fibrotic stroma. The lining cells have large irregular nuclei with prominent nucleoli and abundant eosinophilic cytoplasm. Necrosis and mitotic figures are not present. It rarely metastasizes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulocystic Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"TcRCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tubulocystic renal cell carcinoma"},{"name":"NCI_META_CUI","value":"CL504875"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C121802":{"preferredName":"Undifferentiated Epithelioid Sarcoma","code":"C121802","definitions":[{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a malignant cellular infiltrate with epithelioid morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Epithelioid Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Undifferentiated epithelioid sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4053898"}]}}{"C121799":{"preferredName":"Undifferentiated Round Cell Sarcoma","code":"C121799","definitions":[{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of uniform round or ovoid malignant cells with a high nuclear to cytoplasmic ratio.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Round Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Undifferentiated round cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4048304"}]}}{"C121797":{"preferredName":"Undifferentiated Spindle Cell Sarcoma","code":"C121797","definitions":[{"definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a malignant spindle cell infiltrate with amphophilic or palely eosinophilic cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Undifferentiated Spindle Cell Sarcoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Undifferentiated spindle cell sarcoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C4048234"}]}}{"C8972":{"preferredName":"Uterine Corpus Undifferentiated Sarcoma","code":"C8972","definitions":[{"definition":"A rare, high grade sarcoma that arises from the endometrial stroma or myometrium without a specific type of differentiation. It was previously also known as high grade endometrial stromal sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. Undifferentiated uterine sarcoma has a worse prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uterine Corpus Undifferentiated Sarcoma","termGroup":"PT","termSource":"NCI"},{"termName":"Undifferentiated Uterine Sarcoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Corpus Undifferentiated Endometrial Sarcoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Undifferentiated_Uterine_Sarcoma"},{"name":"Maps_To","value":"Undifferentiated uterine sarcoma"},{"name":"NCI_META_CUI","value":"CL033042"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C39842":{"preferredName":"Urachal Carcinoma","code":"C39842","definitions":[{"definition":"A rare variant of carcinoma of the urachal remnant of bladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urachal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bladder Urachal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Urachal_Carcinoma"},{"name":"Maps_To","value":"Malignant neoplasm of urachus"},{"name":"Maps_To","value":"Urachal carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1511205"}]}}{"C191681":{"preferredName":"Invasive Urothelial Carcinoma with Squamous Differentiation","code":"C191681","definitions":[{"definition":"An invasive urothelial carcinoma that exhibits squamous differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Urothelial Carcinoma with Squamous Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Urothelial Carcinoma with Squamous Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urothelial carcinoma with squamous differentiation"},{"name":"NCI_META_CUI","value":"CL1905274"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C191682":{"preferredName":"Invasive Urothelial Carcinoma with Trophoblastic Differentiation","code":"C191682","definitions":[{"definition":"An invasive urothelial carcinoma characterized by the presence of trophoblastic differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Invasive Urothelial Carcinoma with Trophoblastic Differentiation","termGroup":"PT","termSource":"NCI"},{"termName":"Urothelial Carcinoma with Trophoblastic Differentiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urothelial carcinoma with trophoblastic differentiation"},{"name":"NCI_META_CUI","value":"CL1905273"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C89476":{"preferredName":"Stage 0 Vaginal Cancer AJCC v7","code":"C89476","definitions":[{"definition":"Abnormal cells are found in tissue lining the inside of the vagina (birth canal). These abnormal cells may become cancer and spread into nearby normal tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (preinvasive carcinoma). N0: No regional lymph node metastasis.  M0: No distant metastasis.  FIGO no longer includes stage 0. (AJCC 7th ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage 0 Vaginal Cancer AJCC v7","termGroup":"PT","termSource":"NCI"},{"termName":"Grade III Vaginal Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III Vaginal Intraepithelial Neoplasia AJCC v7","termGroup":"SY","termSource":"NCI"},{"termName":"Stage 0 Vaginal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Intraepithelial Neoplasia Grade 3","termGroup":"SY","termSource":"NCI"},{"termName":"Vaginal Intraepithelial Neoplasia Grade 3 AJCC v7","termGroup":"SY","termSource":"NCI"},{"termName":"VAIN 3","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN 3 AJCC v7","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN III","termGroup":"AB","termSource":"NCI"},{"termName":"VAIN III AJCC v7","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Maps_To","value":"VAIN III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3146269"}]}}{"C40208":{"preferredName":"Cervical Villoglandular Adenocarcinoma","code":"C40208","definitions":[{"definition":"A cervical adenocarcinoma characterized by the presence of a prominent villoglandular pattern.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cervical Villoglandular Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cervical Adenocarcinoma, Villoglandular Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Villoglandular Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cervical_Mucinous_Adenocarcinoma_Villoglandular_Variant"},{"name":"Maps_To","value":"Villoglandular carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1516425"}]}}{"C7635":{"preferredName":"Well Differentiated Papillary Mesothelial Tumor","code":"C7635","definitions":[{"definition":"A localized or multifocal mesothelial neoplasm arising from the peritoneum and less often the pleura and paratesticular region. Cases arising from the peritoneum predominantly occur in women. It is characterized by the formation of papillae, covered by a single layer of blunt mesothelial cells. Mitotic figures are not present. There is no evidence of severe cytologic atypia. It has a relatively favorable clinical outcome, compared to malignant mesothelioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated Papillary Mesothelial Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"WDPMT","termGroup":"AB","termSource":"NCI"},{"termName":"Well-Differentiated Mesothelial Papillary Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Mesothelial Papillary Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Mesothelial Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Neoplasm of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Neoplasm of the Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Tumor of Mesothelium","termGroup":"SY","termSource":"NCI"},{"termName":"Well-Differentiated Papillary Tumor of the Mesothelium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"ICD-O-3_Code","value":"9052/1"},{"name":"Legacy Concept Name","value":"Well-Differentiated_Papillary_Mesothelioma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1337012"}]}}{"C139012":{"preferredName":"Breast Implant-Associated Anaplastic Large Cell Lymphoma","code":"C139012","definitions":[{"definition":"A non-Hodgkin lymphoma which is associated with breast implants, and consists of large anaplastic cells. The WHO diagnostic criteria for BIA-ALCL includes positive expression of CD30 (CD30+) and negativity for anaplastic lymphoma kinase (ALK-).","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A rare anaplastic large cell lymphoma that develops in individuals with breast implants. It usually presents as an accumulation of seroma fluid between the implant and the surrounding fibrous capsule. The median interval from the time of the implant to the development of lymphoma is approximately 10 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breast Implant-Associated Anaplastic Large Cell Lymphoma","termGroup":"PT","termSource":"NCI"},{"termName":"BIA-ALCL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast implant-associated anaplastic large cell lymphoma"},{"name":"NCI_META_CUI","value":"CL526545"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"xRef","value":"IMDRF:E180102"}]}}{"C139021":{"preferredName":"Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","code":"C139021","definitions":[{"definition":"A clonal T-cell lymphoproliferative disorder that can involve the mucosa in all sites of the gastrointestinal tract, but is most common in the small intestine and colon. The lymphoid cells infiltrate the lamina propria but usually do not show invasion of the epithelium. The clinical course is indolent, but most patients do not respond to conventional chemotherapy. A subset of cases progress to a higher-grade T-cell lymphoma with spread beyond the gastrointestinal tract. (WHO 2017)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","termGroup":"PT","termSource":"NCI"},{"termName":"Indolent T-Cell Lymphoma of the Gastrointestinal Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","termGroup":"SY","termSource":"NCI"},{"termName":"ITLPD-GI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indolent T-cell lymphoproliferative disorder of gastrointestinal tract"},{"name":"NCI_META_CUI","value":"CL526526"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C185467":{"preferredName":"Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype","code":"C185467","definitions":[{"definition":"An aggressive, WHO grade 4 diffuse brain glioma usually affecting children, adolescents, or young adults. It is characterized by the absence of histone H3, IDH1, and IDH2 mutations. It includes the following subtypes, based on DNA methylation profiles: diffuse pediatric-type high grade glioma RTK1, diffuse pediatric-type high grade glioma RTK2, and diffuse pediatric-type high grade glioma MYCN.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse High Grade Glioma in Childhood, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse High-Grade Glioma in Childhood, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Glioblastoma, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric-Type Glioblastoma, H3-Wildtype","termGroup":"SY","termSource":"NCI"},{"termName":"pHGG, H3-Wildtype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diffuse Pediatric-type High Grade Glioma"},{"name":"NCI_META_CUI","value":"CL1773755"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C94764":{"preferredName":"Diffuse Intrinsic Pontine Glioma","code":"C94764","definitions":[{"definition":"A glioma that grows diffusely in the pons. It usually affects children and has a poor prognosis.","type":"DEFINITION","source":"NCI"},{"definition":"A type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord. Diffuse intrinsic pontine glioma usually occurs in children. It forms in the brain stem.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diffuse Intrinsic Pontine Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"DIPG","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Maps_To","value":"Diffuse intrinsic pontine glioma, H3 K27M-mutant"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2986658"}]}}{"C28085":{"preferredName":"Gleason Pattern 1","code":"C28085","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of a well circumscribed nodule of separate glands which are closely packed. There is no infiltration of the surrounding parenchyma. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 1","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_1"},{"name":"Maps_To","value":"Pattern 1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276439"}]}}{"C28086":{"preferredName":"Gleason Pattern 2","code":"C28086","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of glands that are more loosely arranged and less uniform compared to Gleason pattern 1. Minimal invasion of the surrounding parenchyma may be present. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 2","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_2"},{"name":"Maps_To","value":"Pattern 2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276440"}]}}{"C28087":{"preferredName":"Gleason Pattern 3","code":"C28087","definitions":[{"definition":"A pattern of prostate carcinoma characterized by the presence of glands that are infiltrative and vary in size and shape. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gleason Pattern 3","termGroup":"PT","termSource":"NCI"},{"termName":"Gleason Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gleason_Grade_3"},{"name":"Maps_To","value":"Pattern 3"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1276441"}]}}{"C139578":{"preferredName":"Stage R0","code":"C139578","definitions":[{"definition":"No detectable presence of residual tumor after treatment","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage R0","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage 0","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage R0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"R0"},{"name":"Maps_To","value":"Stage R0"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0475288"}]}}{"C139579":{"preferredName":"Stage R1","code":"C139579","definitions":[{"definition":"Presence of microscopic residual tumor after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage R1","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage 1","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage R1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"R1"},{"name":"Maps_To","value":"Stage R1"},{"name":"NCI_META_CUI","value":"CL526878"},{"name":"Semantic_Type","value":"Classification"}]}}{"C139580":{"preferredName":"Stage R2","code":"C139580","definitions":[{"definition":"Presence of macroscopic residual tumor after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage R2","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage 2","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage R2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"R2"},{"name":"Maps_To","value":"Stage R2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0475826"}]}}{"C139581":{"preferredName":"Stage RX","code":"C139581","definitions":[{"definition":"Presence of residual tumor after treatment cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stage RX","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor Stage RX","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage Unknown","termGroup":"SY","termSource":"NCI"},{"termName":"Residual Tumor Stage X","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RX"},{"name":"Maps_To","value":"Stage RX"},{"name":"Maps_To","value":"Unknown"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0475287"}]}}{"C12252":{"preferredName":"Abdominal Esophagus","code":"C12252","definitions":[{"definition":"Clinical esophageal segment composed of smooth muscle. It corresponds to the inferior part of the lower third topographic segment of the esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"Clinical esophageal segment composed of smooth muscle. It corresponds to the inferior part of the lower third topographic segment of the esophagus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Abdominal Esophagus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Abdominal_Esophagus"},{"name":"Maps_To","value":"Abdominal esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227190"}]}}{"C12697":{"preferredName":"Cochlear Nerve","code":"C12697","definitions":[{"definition":"The cochlear portion of cranial nerve VIII (the vestibulocochlear nerve), which transmits auditory sensory impulses to the cochlear nucleus in the brainstem.","type":"DEFINITION","source":"NCI"},{"definition":"The cochlear portion of the vestibulocochlear nerve, which transmits auditory sensory impulses to the cochlear nucleus in the brainstem.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cochlear Nerve","termGroup":"PT","termSource":"NCI"},{"termName":"Cochlear Root of Acoustic Nerve","termGroup":"SY","termSource":"NCI"},{"termName":"Cochlear Root of Eighth Cranial Nerve","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cochlear_Nerve"},{"name":"Maps_To","value":"Acoustic nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009201"}]}}{"C13011":{"preferredName":"Ampulla of Vater","code":"C13011","definitions":[{"definition":"A dilation of the duodenal papilla that is the opening of the juncture of the common bile duct and the main pancreatic duct.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"An enlargement of the ducts from the liver and pancreas at the point where they enter the small intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The junction of the common bile and main pancreatic ducts, which protrudes into the medial aspect of the descending duodenum at the major duodenal papilla.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The junction of the common bile and main pancreatic ducts, which protrudes into the medial aspect of the descending duodenum at the major duodenal papilla. The flow of bile and pancreatic juices into the duodenum through the Ampulla of Vater is controlled by the sphincter of Oddi.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ampulla of Vater","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatopancreatic Ampulla","termGroup":"SY","termSource":"NCI"},{"termName":"Vater's Ampulla","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ampulla_of_Vater"},{"name":"Maps_To","value":"Ampulla Of Vater"},{"name":"Maps_To","value":"Ampulla of Vater"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042425"},{"name":"xRef","value":"UBERON:0004913"}]}}{"C12375":{"preferredName":"Anal Canal","code":"C12375","definitions":[{"definition":"The terminal section of the alimentary canal, which extends from the anorectal junction and ends at the anal opening.","type":"DEFINITION","source":"NCI"},{"definition":"The terminal section of the alimentary canal, which extends from the anorectal junction and ends at the anal opening. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"excludes skin of anus and perianal skin C44.5","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Anal Canal","termGroup":"PT","termSource":"NCI"},{"termName":"Functional Anal Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Surgical Anal Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Anal_Canal"},{"name":"Maps_To","value":"Anal canal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227411"}]}}{"C32098":{"preferredName":"Anterior Mediastinum","code":"C32098","definitions":[{"definition":"The area between the lungs; it contains the thymus, some lymph nodes, and vessels and branches of the internal thoracic artery.","type":"DEFINITION","source":"NCI"},{"definition":"The area between the lungs; it contains the thymus, some lymph nodes, and vessels and branches of the internal thoracic artery. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The area in the front part of the chest between the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anterior Mediastinum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Mediastinum"},{"name":"Maps_To","value":"Anterior mediastinum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230148"}]}}{"C12238":{"preferredName":"Anterior Surface of the Epiglottis","code":"C12238","definitions":[{"definition":"The lingual or upper surface of the epiglottis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anterior Surface of the Epiglottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Surface_of_the_Epiglottis"},{"name":"Maps_To","value":"Anterior surface of epiglottis"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227160"}]}}{"C12334":{"preferredName":"Anterior Wall of the Bladder","code":"C12334","definitions":[{"definition":"The anterior aspect of the bladder wall.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anterior Wall of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Anterior Wall of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Wall_of_the_Bladder"},{"name":"Maps_To","value":"Anterior wall of bladder"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0559280"}]}}{"C12245":{"preferredName":"Anterior Wall of the Nasopharynx","code":"C12245","definitions":[{"definition":"The anterior aspect of the nasopharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anterior Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Anterior Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anterior_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Anterior wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225489"}]}}{"C43362":{"preferredName":"Anus","code":"C43362","definitions":[{"definition":"Orifice at the opposite end of an animal's digestive tract from the mouth. Its function is to expel feces, unwanted semi-solid matter produced during digestion, which, depending on the type of animal, may be one or more of: matter which the animal cannot digest, such as bones; food material after all the nutrients have been extracted, for example cellulose or lignin; ingested matter which would be toxic if it remained in the digestive tract; and dead or excess gut bacteria and other endosymbionts.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The distal orifice of the digestive tract located between the rectum and the external surface of the body, comprising glandular, transitional, and squamous epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.","type":"DEFINITION","source":"NCI"},{"definition":"The opening of the rectum to the outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Anus"},{"name":"Maps_To","value":"Anus"},{"name":"Maps_To","value":"Anus, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003461"},{"name":"xRef","value":"UBERON:0001245"}]}}{"C12380":{"preferredName":"Appendix","code":"C12380","definitions":[{"definition":"A blind-ended tube connected to the cecum, from which it develops embryologically.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A pouch-like tissue attached to the cecum, which may exist as a diverticulum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A small, fingerlike pouch that sticks out from the cecum (the first part of the large intestine near the end of the small intestine).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Appendix","termGroup":"PT","termSource":"NCI"},{"termName":"Vermiform Appendix","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vermiform_Appendix"},{"name":"Maps_To","value":"Appendix"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003617"},{"name":"xRef","value":"UBERON:0001154"}]}}{"C12265":{"preferredName":"Ascending Colon","code":"C12265","definitions":[{"definition":"Section of colon which is distal to the cecum and proximal to the transverse colon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ascending Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ascending_Colon"},{"name":"Maps_To","value":"Ascending colon"},{"name":"Maps_To","value":"Ascending Colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227375"},{"name":"xRef","value":"UBERON:0001156"}]}}{"C12673":{"preferredName":"Autonomic Nervous System","code":"C12673","definitions":[{"definition":"The autonomic nervous system is composed of neurons that are not under conscious control, and is comprised of two antagonistic components, the sympathetic and parasympathetic nervous systems. The autonomic nervous system regulates key functions including the activity of the cardiac (heart) muscle, smooth muscles (e.g. of the gut), and glands.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the nervous system of vertebrates that controls involuntary actions of the smooth muscles and heart and glands.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the nervous system that controls muscles of internal organs (such as the heart, blood vessels, lungs, stomach, and intestines) and glands (such as salivary glands and sweat glands). One part of the autonomic nervous system helps the body rest, relax, and digest food and another part helps a person fight or take flight in an emergency.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Autonomic Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"Autonomic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Autonomic_Nervous_System"},{"name":"Maps_To","value":"Autonomic Nervous System"},{"name":"Maps_To","value":"Autonomic nervous system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0004388"},{"name":"xRef","value":"UBERON:0002410"}]}}{"C12305":{"preferredName":"Axillary Tail of the Breast","code":"C12305","definitions":[{"definition":"The superolateral extension of the mammary gland into the axilla that consists of fibroadipose tissue, lymph nodes, and lymphatics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axillary Tail of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Axillary Process of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Axillary Tail of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Tail of Spence","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Axillary_Tail_of_the_Breast"},{"name":"Maps_To","value":"Axillary tail of breast"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0222611"}]}}{"C12678":{"preferredName":"Biliary Tract","code":"C12678","definitions":[{"definition":"The duct system that transports bile from its origination by hepatocytes in the liver to the small intestine. It is comprised of the common bile duct that connects the liver and gall bladder to the small intestine and the cystic duct that connects the gall bladder to the common bile duct. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organs and ducts that make and store bile (a fluid made by the liver that helps digest fat), and release it into the small intestine. The biliary tract includes the gallbladder and bile ducts inside and outside the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The system that transports bile from the hepatocytes in the liver to the small intestine. It is comprised of the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, and the gallbladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biliary Tract","termGroup":"PT","termSource":"NCI"},{"termName":"Bile Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary System","termGroup":"SY","termSource":"NCI"},{"termName":"Tract, Biliary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Biliary_Tract"},{"name":"Maps_To","value":"Biliary tract, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005423"},{"name":"xRef","value":"IMDRF:E11"}]}}{"C12336":{"preferredName":"Bladder Neck","code":"C12336","definitions":[{"definition":"The inferior portion of the urinary bladder which is formed as the walls of the bladder converge and become contiguous with the proximal urethra.","type":"DEFINITION","source":"NCI"},{"definition":"The inferior portion of the urinary bladder which is formed as the walls of the bladder converge and become contiguous with the proximal urethra. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bladder Neck","termGroup":"PT","termSource":"NCI"},{"termName":"Cervix Vesicae","termGroup":"SY","termSource":"NCI"},{"termName":"Neck of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Neck"},{"name":"Maps_To","value":"Bladder neck"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227716"}]}}{"C12434":{"preferredName":"Blood","code":"C12434","definitions":[{"definition":"A fluid that is composed of blood plasma and erythrocytes.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A liquid tissue with the primary function of transporting oxygen and carbon dioxide. It supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","type":"DEFINITION","source":"NCI"},{"definition":"A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Blood","termGroup":"PT","termSource":"NCI"},{"termName":"Reticuloendothelial System, Blood","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Blood"},{"name":"Maps_To","value":"Blood"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0005767"},{"name":"xRef","value":"UBERON:0000178"}]}}{"C12270":{"preferredName":"Body of the Pancreas","code":"C12270","definitions":[{"definition":"The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Body of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Body of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Body","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Body_of_the_Pancreas"},{"name":"Maps_To","value":"Body of pancreas"},{"name":"Maps_To","value":"Pancreas Body"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227582"}]}}{"C12325":{"preferredName":"Body of the Penis","code":"C12325","definitions":[{"definition":"The portion of the penis between the glans penis and the radix penis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the penis that extends from the site of attachment to the glans, and which is covered by skin. It is formed by the joining of the two proximal free parts of the corpora cavernosa and the related free part of the corpus spongiosum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Body of the Penis","termGroup":"PT","termSource":"NCI"},{"termName":"Body of Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Body_of_the_Penis"},{"name":"Maps_To","value":"Body of penis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227936"}]}}{"C12258":{"preferredName":"Body of Stomach","code":"C12258","definitions":[{"definition":"The main section of the digestive tube that connects the esophagus to the small intestine. The body proper excludes the upper and lower sections of the fundus and pyloric portion respectively.","type":"DEFINITION","source":"NCI"},{"definition":"The main section of the digestive tube that connects the esophagus to the small intestine. The body proper excludes the upper and lower sections of the fundus and pyloric portion respectively. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Body of Stomach","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Body_of_Stomach"},{"name":"Maps_To","value":"Body of stomach"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227230"}]}}{"C32223":{"preferredName":"Bone of the Extremity","code":"C32223","definitions":[{"definition":"A bone within a limb of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone of the Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Bone of Extremity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bone_of_the_Extremity"},{"name":"Maps_To","value":"Bone of limb, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0582791"}]}}{"C12441":{"preferredName":"Brain Stem","code":"C12441","definitions":[{"definition":"Stalk-like part of the brain that includes amongst its parts the medulla oblongata of the hindbrain and the tegmentum of the midbrain.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the brain that connects the cerebral hemispheres with the spinal cord. It consists of the mesencephalon, pons, and medulla oblongata. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the brain that is connected to the spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Three sections, the midbrain, pons and medulla oblongata, that are located at the base of the brain. The brain stem regulates the central nervous system, and is vital as a conduit for motor and sensory innervations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brain Stem","termGroup":"PT","termSource":"NCI"},{"termName":"Brainstem","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Brain_Stem"},{"name":"Maps_To","value":"Brain Stem"},{"name":"Maps_To","value":"Brain stem"},{"name":"Maps_To","value":"Brain, Brain stem"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006121"},{"name":"xRef","value":"UBERON:0002298"}]}}{"C104813":{"preferredName":"Branchial Cleft Remnant","code":"C104813","definitions":[{"definition":"A congenital defect in the neck that occurs during early embryonic development.  It is caused by developmental abnormalities of the pharyngeal arches and results in the development of a cyst or a fissure in the side of the neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Branchial Cleft Remnant","termGroup":"PT","termSource":"NCI"},{"termName":"Branchial Cleft","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Branchial cleft"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"UMLS_CUI","value":"C0079037"}]}}{"C12318":{"preferredName":"Broad Ligament","code":"C12318","definitions":[{"definition":"A broad fold of peritoneum that extends from the side of the uterus to the wall of the pelvis.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A wide fold of peritoneum that connects the uterus to the lateral walls and floor of the pelvis, and also attaches to the ovaries, fallopian tubes, ovarian ligaments, round ligament of the uterus, and ovarian and uterine arteries.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A wide fold of peritoneum that connects the uterus to the lateral walls and floor of the pelvis, and contains the ovaries, fallopian tubes, ovarian ligaments, round ligament of the uterus, and ovarian and uterine arteries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broad Ligament","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Ligament","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Broad_Ligament"},{"name":"Maps_To","value":"Broad Ligament"},{"name":"Maps_To","value":"Broad ligament"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006205"},{"name":"xRef","value":"UBERON:0012332"}]}}{"C12256":{"preferredName":"Gastric Cardia","code":"C12256","definitions":[{"definition":"The area around the esophagogastric mucosal junction where the esophageal mucosa transitions into the gastric mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the stomach attached to the esophagus. The cardia begins immediately distal to the z-line of the gastroesophageal junction, where the squamous epithelium of the esophagus gives way to the columnar epithelium of the gastrointestinal tract.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region of the stomach adjacent to the esophogastric junction.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gastric Cardia","termGroup":"PT","termSource":"NCI"},{"termName":"Cardia","termGroup":"SY","termSource":"NCI"},{"termName":"Cardia of the Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cardia"},{"name":"Maps_To","value":"Cardia"},{"name":"Maps_To","value":"Cardia, NOS"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0007144"},{"name":"xRef","value":"UBERON:0001162"}]}}{"C66852":{"preferredName":"Carotid Body","code":"C66852","definitions":[{"definition":"A cluster of cells that function as chemo-receptors, located at the bifurcation of the carotid artery. Its main purpose is to detect changes in the composition of arterial blood.","type":"DEFINITION","source":"NCI"},{"definition":"A cluster of cells that function as chemo-receptors, located near the bifurcation of the carotid artery.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A small epithelioid structure consisting of a small cluster of chemoreceptive and supporting cells located near the bifurcation of the common carotid artery that serves as a chemoreceptive organ that senses the pH, carbon dioxide, and oxygen concentrations in the blood and plays a crucial role in their homeostatic control.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Carotid Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Carotid_Body"},{"name":"Maps_To","value":"Carotid body"},{"name":"Maps_To","value":"Carotid Body"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007277"},{"name":"xRef","value":"UBERON:0001629"}]}}{"C12689":{"preferredName":"Cauda Equina","code":"C12689","definitions":[{"definition":"The collection of spinal nerve roots, arising from lumbar pairs two through five, sacral pairs one through five, and the coccygeal nerve, that branch off the conus medularis at the termination of the spinal cord, and float freely within the lumbar cistern before exiting the spinal column at the appropriate vertebra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cauda Equina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cauda_Equina"},{"name":"Maps_To","value":"Cauda equina"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007458"}]}}{"C12381":{"preferredName":"Cecum","code":"C12381","definitions":[{"definition":"A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from On-line Medical Dictionary"}]},{"definition":"A pouch in the digestive tract that connects the ileum with the ascending colon of the large intestine. It is separated from the ileum by the ileocecal valve, and is the beginning of the large intestine. It is also separated from the colon by the cecocolic junction.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A pouch that forms the first part of the large intestine. It connects the small intestine to the colon, which is part of the large intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pouch-like portion of the proximal large intestine opening into the colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cecum","termGroup":"PT","termSource":"NCI"},{"termName":"Cecal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cecum"},{"name":"Maps_To","value":"Cecum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007531"},{"name":"xRef","value":"UBERON:0001153"}]}}{"C12300":{"preferredName":"Central Portion of the Breast","code":"C12300","definitions":[{"definition":"The part of the breast which is in the center.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Portion of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Central Portion of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Central_Portion_of_the_Breast"},{"name":"Maps_To","value":"Central portion of breast"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0222595"}]}}{"C12445":{"preferredName":"Cerebellum","code":"C12445","definitions":[{"definition":"Brain structure derived from the anterior hindbrain, and perhaps including posterior midbrain. The cerebellum plays a role in somatic motor function, the control of muscle tone, and balance.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the brain in the back of the head between the cerebrum and the brain stem. The cerebellum controls balance for walking and standing, and other complex motor functions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the brain that extends from the brainstem through the cerebellar folia.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cerebellum","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebellar","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cerebellum"},{"name":"Maps_To","value":"Brain, Cerebellum, NOS"},{"name":"Maps_To","value":"Cerebellum"},{"name":"Maps_To","value":"Cerebellum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007765"},{"name":"xRef","value":"UBERON:0002037"}]}}{"C12349":{"preferredName":"Cerebral Meninges","code":"C12349","definitions":[{"definition":"The membranes that envelop and protect the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebral Meninges","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cerebral_Meninges"},{"name":"Maps_To","value":"Cerebral meninges"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228116"}]}}{"C12351":{"preferredName":"Cerebral Hemisphere","code":"C12351","definitions":[{"definition":"One of two bilateral, largely symmetrical organ subdivisions within the telencephalon which contain the cerebral cortex and cerebral white matter.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The largest part of the brain. It is divided into two hemispheres, or halves, called the cerebral hemispheres. Areas within the cerebrum control muscle functions and also control speech, thought, emotions, reading, writing, and learning.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the brain that controls muscle functions and also controls speech, thought, emotions, reading, writing, and learning. The right hemisphere controls the muscles on the left side of the body, and the left hemisphere controls the muscles on the right side of the body.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the brain comprising the frontal, parietal, temporal, and occipital lobes and extending through the thalamus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cerebral Hemisphere","termGroup":"PT","termSource":"NCI"},{"termName":"Brain Hemisphere","termGroup":"SY","termSource":"NCI"},{"termName":"Cerebral","termGroup":"AD","termSource":"NCI"},{"termName":"Cerebral Hemispheres","termGroup":"SY","termSource":"NCI"},{"termName":"Cerebrum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cerebral_Hemisphere"},{"name":"Maps_To","value":"Brain, Cerebrum"},{"name":"Maps_To","value":"Cerebrum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228174"},{"name":"xRef","value":"UBERON:0001869"}]}}{"C12250":{"preferredName":"Cervical Esophagus","code":"C12250","definitions":[{"definition":"Clinical esophageal segment composed of skeletal muscle. It corresponds to the superior part of the upper third topographic segment of the esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"Clinical esophageal segment composed of skeletal muscle. It corresponds to the superior part of the upper third topographic segment of the esophagus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cervical Esophagus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cervical_Esophagus"},{"name":"Maps_To","value":"Cervical esophagus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227186"}]}}{"C12505":{"preferredName":"Buccal Mucosa","code":"C12505","definitions":[{"definition":"The inner lining of the cheeks and lips.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The inner lining of the cheeks.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mucosal membranes located on the inside of the cheek, in the buccal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes located on the inside of the cheek, in the buccal cavity. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Buccal Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Buccal_Mucosa"},{"name":"Maps_To","value":"Buccal mucosa"},{"name":"Maps_To","value":"Buccal Mucosa"},{"name":"Maps_To","value":"Cheek mucosa"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C1578559"},{"name":"xRef","value":"UBERON:0006956"}]}}{"C12344":{"preferredName":"Choroid","code":"C12344","definitions":[{"definition":"A blood vessel-containing membrane of the eye that lies between the retina and the sclera.","type":"DEFINITION","source":"NCI"},{"definition":"A blood vessel-containing membrane of the eye that lies between the retina and the sclera. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thin layer of tissue that is part of the middle layer of the wall of the eye, between the sclera (white outer layer of the eye) and the retina (the inner layer of nerve tissue at the back of the eye). The choriod is filled with blood vessels that bring oxygen and nutrients to the eye.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Choroid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Choroid"},{"name":"Maps_To","value":"Choroid"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008520"}]}}{"C12345":{"preferredName":"Ciliary Body","code":"C12345","definitions":[{"definition":"A part of the middle layer of the wall of the eye. The ciliary body includes the ring-shaped muscle that changes the size of the pupil and the shape of the lens when the eye focuses. It also makes the fluid that fills the eye.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Circumferential tissue located behind the iris and composed of muscle and epithelium.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue located behind the iris and composed of muscle and epithelium. Its functions include the production of aqueous humor and changing the shape of the crystalline lens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciliary Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ciliary_Body"},{"name":"Maps_To","value":"Ciliary body"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008779"}]}}{"C12308":{"preferredName":"Clitoris","code":"C12308","definitions":[{"definition":"The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.","type":"DEFINITION","source":"NCI"},{"definition":"The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The small, erectile body located at the anterior end of the vulva.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Clitoris","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Clitoris"},{"name":"Maps_To","value":"Clitoris"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008984"},{"name":"xRef","value":"UBERON:0002411"}]}}{"C32072":{"preferredName":"Anal Transitional Zone","code":"C32072","definitions":[{"definition":"The middle segment of the anal canal between the colorectal and squamous zones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Transitional Zone","termGroup":"PT","termSource":"NCI"},{"termName":"Cloacogenic Zone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anal_Transitional_Zone"},{"name":"Maps_To","value":"Cloacogenic zone"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0443181"}]}}{"C12227":{"preferredName":"Commissure of the Lip","code":"C12227","definitions":[{"definition":"The junction of the upper and lower lips at the corner of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The junction of the upper and lower lips at the corner of the mouth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Commissure of the Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Commissure of Lip","termGroup":"SY","termSource":"NCI"},{"termName":"Labial Commissure (Mouth)","termGroup":"SY","termSource":"NCI"},{"termName":"Labial Junction","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Commissure_of_the_Lip"},{"name":"Maps_To","value":"Commissure of lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226924"}]}}{"C12341":{"preferredName":"Conjunctiva","code":"C12341","definitions":[{"definition":"A thin tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thin, transparent tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball).","type":"DEFINITION","source":"NCI"},{"definition":"The mucous membrane that lines the inner surface of the eyelids and the front of the eyeball.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Conjunctiva","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Conjunctiva"},{"name":"Maps_To","value":"Conjunctiva"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009758"},{"name":"xRef","value":"UBERON:0001811"}]}}{"C12342":{"preferredName":"Cornea","code":"C12342","definitions":[{"definition":"A dome-shaped, transparent, avascular tissue covering the front of the eye. It is composed of five layers: squamous epithelium, Bowman's membrane, stroma, Descemet's membrane, and endothelium. Refraction of light contributing to eye's focusing ability is its characteristic function. It contains unmyelinated nerve endings which are responsible for the high sensitivity of the tissue.","type":"DEFINITION","source":"NCI"},{"definition":"The transparent part of the eye that covers the iris and the pupil and allows light to enter the inside.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The transparent, avascular tissue covering the front of the eye and is continuous with the sclera.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cornea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cornea"},{"name":"Maps_To","value":"Cornea, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0010031"}]}}{"C12396":{"preferredName":"Adrenal Cortex","code":"C12396","definitions":[{"definition":"The outer part of the adrenal gland (a small organ on top of each kidney). The adrenal cortex makes androgen and corticosteroid hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The outer region of the adrenal gland consisting of the zona glomerulosa, the zona fasciculata, and the zona reticularis. The adrenal cortex produces and secretes mineralocorticoids, glucocorticoids, and adrenal androgens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Cortex of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Cortical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Cortex"},{"name":"Maps_To","value":"Cortex of adrenal gland"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0001613"}]}}{"C12700":{"preferredName":"Cranial Nerve","code":"C12700","definitions":[{"definition":"Any of the 12 paired nerves that originate in the brain stem.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the 12 paired nerves that originate in the brain stem. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Cranial nerves are nerves that emerge directly from the brain, in contrast to spinal nerves, which emerge from segments of the spinal cord.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Cranial Nerve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cranial_Nerve"},{"name":"Maps_To","value":"Cranial nerve, NOS"},{"name":"Maps_To","value":"Nerve(s) Cranial"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0010268"},{"name":"xRef","value":"UBERON:0001785"}]}}{"C12357":{"preferredName":"Craniopharyngeal Duct","code":"C12357","definitions":[{"definition":"The slender tubular part of the hypophysial diverticulum; the stalk of Rathke's pocket.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Craniopharyngeal Duct","termGroup":"PT","termSource":"NCI"},{"termName":"Bucconeural Duct","termGroup":"SY","termSource":"NCI"},{"termName":"Hypophysial Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Craniopharyngeal_Duct"},{"name":"Maps_To","value":"Craniopharyngeal duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229549"}]}}{"C12268":{"preferredName":"Descending Colon","code":"C12268","definitions":[{"definition":"The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the colon between the left colic flexure and the sigmoid colon at the pelvic brim; the portion of the descending colon lying in the left iliac fossa is sometimes called the iliac colon.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Descending Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Descending_Colon"},{"name":"Maps_To","value":"Descending Colon"},{"name":"Maps_To","value":"Descending colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227389"},{"name":"xRef","value":"UBERON:0001158"}]}}{"C12332":{"preferredName":"Dome of the Bladder","code":"C12332","definitions":[{"definition":"The upper, convex surface of the bladder.","type":"DEFINITION","source":"NCI"},{"definition":"The upper, convex surface of the bladder. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Dome of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Dome of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Surface of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Surface of the Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dome_of_the_Bladder"},{"name":"Maps_To","value":"Dome of bladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1288328"}]}}{"C12263":{"preferredName":"Duodenum","code":"C12263","definitions":[{"definition":"A jointed tube 25-30 cm long that connects the stomach to the jejunum.","type":"DEFINITION","source":"NCI"},{"definition":"The first part of the small intestine that connects to the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The first part of the small intestine. At the junction of the stomach and the duodenum the alimentary canal is inflected. The duodenum first goes anteriorly for a short distance, turns dorsally, and eventually caudally, thus it is a U-shaped structure with two horizontal sections (a ventral and a dorsal one).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the small intestine between the stomach and jejunum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Duodenum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Duodenum"},{"name":"Maps_To","value":"Duodenum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013303"},{"name":"xRef","value":"UBERON:0002114"}]}}{"C12309":{"preferredName":"Endocervix","code":"C12309","definitions":[{"definition":"The portion of the cervix which is lined by single columnar epithelium (mucosa).","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the cervix which is lined by single columnar epithelium (mucosa). (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endocervix","termGroup":"PT","termSource":"NCI"},{"termName":"Endocervical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endocervix"},{"name":"Maps_To","value":"Endocervix"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227837"}]}}{"C12704":{"preferredName":"Endocrine Gland","code":"C12704","definitions":[{"definition":"Ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.","type":"DEFINITION","source":"NCI"},{"definition":"Endocrine glands are glands of the endocrine system that secrete their products directly into the circulatory system rather than through a duct.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Endocrine Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Endocrine Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Endocrine_Gland"},{"name":"Maps_To","value":"Endocrine Gland"},{"name":"Maps_To","value":"Endocrine gland, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014133"},{"name":"xRef","value":"UBERON:0002368"}]}}{"C12313":{"preferredName":"Endometrium","code":"C12313","definitions":[{"definition":"The layer of tissue that lines the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mucous membrane comprising the inner layer of the uterine wall.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometrium","termGroup":"PT","termSource":"NCI"},{"termName":"Tunica Mucosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrium"},{"name":"Maps_To","value":"Endometrium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014180"}]}}{"C12328":{"preferredName":"Epididymis","code":"C12328","definitions":[{"definition":"A crescent-like structure located adjacent to the testis. It consists of a single highly coiled duct and is divided into 3 regions: caput (head), corpus (body) and cauda (tail).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A crescent-like structure located in the upper and posterior surfaces of the testis. It consists of the efferent ductules and the duct of the epididymis. It facilitates the maturation of sperm that is produced in the testis.","type":"DEFINITION","source":"NCI"},{"definition":"A narrow, tightly-coiled tube that is attached to each of the testicles (the male sex glands that produce sperm). Sperm cells (male reproductive cells) move from the testicles into the epididymis, where they finish maturing and are stored.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The elongated structure connected to the posterior surface of the testis that transports, stores, and matures spermatozoa between testis and vas deferens.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Epididymis","termGroup":"PT","termSource":"NCI"},{"termName":"Epididymal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Epididymis"},{"name":"Maps_To","value":"Epididymis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0014533"},{"name":"xRef","value":"UBERON:0001301"}]}}{"C12276":{"preferredName":"Ethmoid Sinus","code":"C12276","definitions":[{"definition":"A sinus of the meatuses of the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"A sinus of the meatuses of the nasal cavity. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). Ethmoid sinuses are found in the spongy ethmoid bone in the upper part of the nose between the eyes. They are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ethmoid Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Sinus, Ethmoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Ethmoid_Sinus"},{"name":"Maps_To","value":"Ethmoid sinus"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0015028"}]}}{"C12310":{"preferredName":"Ectocervix","code":"C12310","definitions":[{"definition":"Having to do with the part of the cervix that protrudes into the vagina and is lined with epithelial cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the cervix that extends into the vaginal vault, and is lined with stratified squamous epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ectocervix","termGroup":"PT","termSource":"NCI"},{"termName":"Exocervix","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ectocervix"},{"name":"Maps_To","value":"Exocervix"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227829"}]}}{"C12292":{"preferredName":"External Ear","code":"C12292","definitions":[{"definition":"The external part of the ear.","type":"DEFINITION","source":"NCI"},{"definition":"The external part of the ear. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Ear","termGroup":"PT","termSource":"NCI"},{"termName":"Auricle","termGroup":"SY","termSource":"NCI"},{"termName":"Ear, External","termGroup":"SY","termSource":"NCI"},{"termName":"Pinna","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"External_Ear"},{"name":"Maps_To","value":"Ear, Pinna (External)"},{"name":"Maps_To","value":"External ear"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013453"},{"name":"xRef","value":"UBERON:0001757"}]}}{"C12223":{"preferredName":"External Lip","code":"C12223","definitions":[{"definition":"One of two visible fleshy folds that surround the orifice of the mouth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"External Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"External_Lip"},{"name":"Maps_To","value":"External lip, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226926"}]}}{"C12222":{"preferredName":"External Lower Lip","code":"C12222","definitions":[{"definition":"The external surface of the lower lip.","type":"DEFINITION","source":"NCI"},{"definition":"The external surface of the lower lip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Lower Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"External_Lower_Lip"},{"name":"Maps_To","value":"External lower lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226942"}]}}{"C12221":{"preferredName":"External Upper Lip","code":"C12221","definitions":[{"definition":"The external surface of the upper lip.","type":"DEFINITION","source":"NCI"},{"definition":"The external surface of the upper lip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Upper Lip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"External_Upper_Lip"},{"name":"Maps_To","value":"External upper lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226936"}]}}{"C32573":{"preferredName":"Extrahepatic Bile Duct","code":"C32573","definitions":[{"definition":"The part of the common hepatic bile duct (tube that collects bile from the liver) that is outside the liver. This duct joins a duct from the gallbladder to form the common bile duct, which carries bile into the small intestine when food is being digested.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the biliary tract outside the liver; the common hepatic duct joins the cystic duct to form the common bile duct.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the biliary tract outside the liver; the common hepatic duct joins the cystic duct to form the common bile duct. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Extrahepatic Bile Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Extrahepatic_Bile_Duct"},{"name":"Maps_To","value":"Extrahepatic bile duct"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0206187"}]}}{"C12401":{"preferredName":"Eye","code":"C12401","definitions":[{"definition":"An organ that detects light.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Having to do with the eye.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The organ of sight or vision.","type":"DEFINITION","source":"NCI"},{"definition":"The sensory organ of vision.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Eye","termGroup":"PT","termSource":"NCI"},{"termName":"Eyeball","termGroup":"SY","termSource":"NCI"},{"termName":"Ocular","termGroup":"SY","termSource":"NCI"},{"termName":"Ophthalmic","termGroup":"AD","termSource":"NCI"},{"termName":"Optic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Eye"},{"name":"Maps_To","value":"Eye"},{"name":"Maps_To","value":"Eye, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015392"},{"name":"xRef","value":"IMDRF:E08"},{"name":"xRef","value":"UBERON:0000970"}]}}{"C12713":{"preferredName":"Eyelid","code":"C12713","definitions":[{"definition":"A thin membrane of skin with the purpose of covering and protecting an eye.","type":"DEFINITION","source":"NCI"},{"definition":"The section of skin, containing muscle and conjunctiva, that covers and protects the eye.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Eyelid","termGroup":"PT","termSource":"NCI"},{"termName":"Palpebra","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eyelid"},{"name":"Maps_To","value":"Eyelid"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015426"}]}}{"C12403":{"preferredName":"Fallopian Tube","code":"C12403","definitions":[{"definition":"A slender tube through which eggs pass from an ovary to the uterus. In the female reproductive tract, there is one ovary and one fallopian tube on each side of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Initial section of the oviduct through which the ova pass from the ovary to the uterus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.","type":"DEFINITION","source":"NCI"},{"definition":"The tube through which eggs pass from an ovary.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fallopian Tube","termGroup":"PT","termSource":"NCI"},{"termName":"Fallopian Tubes","termGroup":"SY","termSource":"NCI"},{"termName":"Oviduct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Fallopian_Tube"},{"name":"Maps_To","value":"Fallopian tube"},{"name":"Maps_To","value":"Fallopian Tube"},{"name":"Maps_To","value":"Fallopian Tube, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015560"},{"name":"xRef","value":"UBERON:0003889"}]}}{"C61600":{"preferredName":"Female Genitalia","code":"C61600","definitions":[{"definition":"Female internal and external organs of reproduction.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external female sexual organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Genitalia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Female_Genitalia"},{"name":"Maps_To","value":"Female genital tract, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017421"}]}}{"C12352":{"preferredName":"Frontal Lobe","code":"C12352","definitions":[{"definition":"Frontal lobe is the anterior-most of five lobes of the cerebral hemisphere. It is bounded by the central sulcus on its posterior border and by the longitudinal cerebral fissure on its medial border.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Frontal Lobe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Frontal_Lobe"},{"name":"Maps_To","value":"Brain, Frontal lobe"},{"name":"Maps_To","value":"Frontal Lobe"},{"name":"Maps_To","value":"Frontal lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016733"},{"name":"xRef","value":"UBERON:0016525"}]}}{"C12277":{"preferredName":"Frontal Sinus","code":"C12277","definitions":[{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). There are two, large frontal sinuses in the frontal bone, which forms the lower part of the forehead and reaches over the eye sockets and eyebrows. The frontal sinuses are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The paired, mucosal lined air spaces located above the orbit and communicating with the nasal passages.","type":"DEFINITION","source":"NCI"},{"definition":"The paired, mucosal lined air spaces located above the orbit and communicating with the nasal passages. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Frontal Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Sinus, Frontal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Frontal_Sinus"},{"name":"Maps_To","value":"Frontal sinus"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0016734"}]}}{"C12257":{"preferredName":"Fundus of the Stomach","code":"C12257","definitions":[{"definition":"The blind sac region of the glandular stomach.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fundus is the portion of the stomach that lies above the cardiac notch, and contains the fundic glands.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the stomach that lies above the cardiac notch. It allows for the accumulation of gases produced by chemical digestion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fundus of the Stomach","termGroup":"PT","termSource":"NCI"},{"termName":"Fundus of Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Fundus_of_the_Stomach"},{"name":"Maps_To","value":"Fundus of Stomach"},{"name":"Maps_To","value":"Fundus Of Stomach"},{"name":"Maps_To","value":"Fundus of stomach"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017129"},{"name":"xRef","value":"UBERON:0001160"}]}}{"C12315":{"preferredName":"Fundus Uteri","code":"C12315","definitions":[{"definition":"The upper, rounded portion of the uterus that is opposite from the cervix.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper, rounded portion of the uterus which is opposite from the cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fundus Uteri","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fundus_Uteri"},{"name":"Maps_To","value":"Fundus uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227817"}]}}{"C12259":{"preferredName":"Antrum Pylori","code":"C12259","definitions":[{"definition":"The initial part of the pyloric canal of the stomach. This site contains endocrine cells that produce gastrin and somatostatin.","type":"DEFINITION","source":"NCI"},{"definition":"The initial part of the pyloric canal of the stomach. This site contains endocrine cells that produce gastrin and somatostatin. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Antrum Pylori","termGroup":"PT","termSource":"NCI"},{"termName":"Gastric Antrum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antrum_Pylori"},{"name":"Maps_To","value":"Gastric antrum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0034193"}]}}{"C12324":{"preferredName":"Glans Penis","code":"C12324","definitions":[{"definition":"The most distal portion of the penis covered by the foreskin.","type":"DEFINITION","source":"NCI"},{"definition":"The most distal portion of the penis covered by the foreskin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The rounded, gland-like head of the penis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glans Penis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glans_Penis"},{"name":"Maps_To","value":"Glans penis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227948"}]}}{"C12724":{"preferredName":"Glottis","code":"C12724","definitions":[{"definition":"The middle part of the larynx; the area where the vocal cords are located.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The space in which the vocal cords are located.","type":"DEFINITION","source":"NCI"},{"definition":"The space in which the vocal cords are located. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The vocal apparatus of the larynx, which includes the vocal cords and the opening between them.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Glottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Glottis"},{"name":"Maps_To","value":"Glottis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017681"},{"name":"xRef","value":"UBERON:0002486"}]}}{"C12262":{"preferredName":"Greater Curvature of the Stomach","code":"C12262","definitions":[{"definition":"The lateral and inferior border of the stomach. Attached to it is the greater omentum.","type":"DEFINITION","source":"NCI"},{"definition":"The lateral and inferior border of the stomach. Attached to it is the greater omentum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"not classifiable to C16.0 to C16.4","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Greater Curvature of the Stomach","termGroup":"PT","termSource":"NCI"},{"termName":"Greater Curvature","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Greater_Curvature"},{"name":"Maps_To","value":"Greater curvature of stomach, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227223"}]}}{"C12230":{"preferredName":"Hard Palate","code":"C12230","definitions":[{"definition":"Anterior portion of the palate consisting of bone and mucous membranes [GO]. The hard palate is formed from bony processes of the maxilla, premaxilla and palatine bone.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bony anterior part of the roof of the mouth separating the nose from the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The front, bony part of the roof of the mouth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the roof of the mouth supported by bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hard Palate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hard_Palate"},{"name":"Maps_To","value":"Hard Palate"},{"name":"Maps_To","value":"Hard palate"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226901"},{"name":"xRef","value":"UBERON:0003216"}]}}{"C12269":{"preferredName":"Head of the Pancreas","code":"C12269","definitions":[{"definition":"That portion of the pancreas lying in the concavity of the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"That portion of the pancreas lying in the concavity of the duodenum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Head of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Head of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Head","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Head","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Head_of_the_Pancreas"},{"name":"Maps_To","value":"Head of pancreas"},{"name":"Maps_To","value":"Pancreas Head"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227579"}]}}{"C12909":{"preferredName":"Hematopoietic System","code":"C12909","definitions":[{"definition":"The bodily system of organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes, involved in the production of blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic System","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Hematologic","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Hematologic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hematopoietic_System"},{"name":"Maps_To","value":"Hematopoietic system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0018957"},{"name":"xRef","value":"IMDRF:E03"}]}}{"C12266":{"preferredName":"Hepatic Flexure","code":"C12266","definitions":[{"definition":"Hepatic (or the right colic) flexure is the sharp bend between the ascending and the transverse colon. The right colic flexure is adjacent to the liver, and is therefore also known as the hepatic flexure. Thus, the left colic flexure is also known as the splenic flexure (as it is close to the spleen). The hepatic flexure lies in the right upper quadrant of the abdomen in humans.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bend at the junction of the ascending and transverse colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bend of the colon at the juncture of its ascending and transverse portions.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Hepatic Flexure","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatic Flexure of Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatic Flexure of the Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Right Colic Flexure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hepatic_Flexure"},{"name":"Maps_To","value":"Ascending Colon Hepatic Flexure"},{"name":"Maps_To","value":"Hepatic Flexure"},{"name":"Maps_To","value":"Hepatic flexure of colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227385"},{"name":"xRef","value":"UBERON:0022277"}]}}{"C12387":{"preferredName":"Ileum","code":"C12387","definitions":[{"definition":"The final section of the small intestine.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the small intestine between the jejunum and large intestine.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the small intestine that extends from the jejunum to the colon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"excludes ileocecal valve C18.0","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Ileum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ileum"},{"name":"Maps_To","value":"Ileum"},{"name":"Maps_To","value":"Iliac"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020885"},{"name":"xRef","value":"UBERON:0002116"}]}}{"C12736":{"preferredName":"Intestine","code":"C12736","definitions":[{"definition":"The long, tube-shaped organ in the abdomen that completes the process of digestion. The intestine has two parts, the small intestine and the large intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The portion of the gastrointestinal tract between the stomach and the anus. It includes the small intestine and large intestine.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the gastrointestinal tract that includes the small and large intestines.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intestine","termGroup":"PT","termSource":"NCI"},{"termName":"Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Intestines","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Intestine"},{"name":"Maps_To","value":"Bowel"},{"name":"Maps_To","value":"Intestinal tract, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0021853"}]}}{"C12360":{"preferredName":"Intra-Abdominal Lymph Node","code":"C12360","definitions":[{"definition":"Any lymph node within the abdomen.","type":"DEFINITION","source":"NCI"},{"definition":"Any lymph node within the abdomen.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intra-Abdominal Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Intra-Abdominal Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intra-abdominal_Lymph_Node"},{"name":"Maps_To","value":"Intra-abdominal lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0588058"}]}}{"C12677":{"preferredName":"Intrahepatic Bile Duct","code":"C12677","definitions":[{"definition":"The bile ducts that pass through and drain bile from the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The bile ducts that pass through and drain bile from the liver. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bile ducts which are located within the liver. They include the small interlobular bile ducts, intrahepatic large bile ducts, and the intrahepatic portions of the left and right hepatic ducts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intrahepatic Bile Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intrahepatic_Bile_Duct"},{"name":"Maps_To","value":"Intrahepatic bile duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005401"}]}}{"C12359":{"preferredName":"Intrathoracic Lymph Node","code":"C12359","definitions":[{"definition":"Any lymph node within the thoracic cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Any lymph node within the thoracic cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intrathoracic Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Intra-Thoracic Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Intrathoracic Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intrathoracic_Lymph_Node"},{"name":"Maps_To","value":"Intrathoracic lymph nodes"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1517562"}]}}{"C12608":{"preferredName":"Islet of Langerhans","code":"C12608","definitions":[{"definition":"A specialized region of tissue located within the parenchyma of the pancreas that contains a mixed population of distinct endocrine cells, including beta, alpha, pancreatic polypeptide, delta, and epsilon cells, which respectively produce and secrete insulin, glucagon, pancreatic polypeptide, somatostatin, and ghrelin.","type":"DEFINITION","source":"NCI"},{"definition":"The pancreatic tissue that contains the islets of Langerhans. It is responsible for the production and secretions of the pancreatic hormones. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Islet of Langerhans","termGroup":"PT","termSource":"NCI"},{"termName":"Endocrine Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Islands of Langerhans","termGroup":"SY","termSource":"NCI"},{"termName":"Islet Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Islets of Langerhans","termGroup":"SY","termSource":"NCI"},{"termName":"Langerhans Islets","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Islets","termGroup":"SY","termSource":"NCI"},{"termName":"Pars Endocrina Pancreatis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Islet_of_Langerhans"},{"name":"Maps_To","value":"Islets of Langerhans"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0022131"}]}}{"C12312":{"preferredName":"Isthmus Uteri","code":"C12312","definitions":[{"definition":"An elongated constriction of the lower part of the uterus, located at the junction of the body of the uterus and the cervix, that is composed principally of smooth muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isthmus Uteri","termGroup":"PT","termSource":"NCI"},{"termName":"Isthmus of Uterus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isthmus_Uteri"},{"name":"Maps_To","value":"Isthmus uteri"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1288329"}]}}{"C12388":{"preferredName":"Jejunum","code":"C12388","definitions":[{"definition":"The portion of the small intestine between the duodenum and ileum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the small intestine that extends from the duodenum to the ileum.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the small intestine that extends from the duodenum to the ileum.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Jejunum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Jejunum"},{"name":"Maps_To","value":"Jejunum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022378"},{"name":"xRef","value":"UBERON:0002115"}]}}{"C12306":{"preferredName":"Labium Majus","code":"C12306","definitions":[{"definition":"One of the two longitudinal folds of skin that form the lateral boundary of the vulva.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the two longitudinal folds of skin that form the lateral boundary of the vulva. It extends from the mons pubis to the perineum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Labium Majus","termGroup":"PT","termSource":"NCI"},{"termName":"Labia Majora","termGroup":"SY","termSource":"NCI"},{"termName":"Labia Majus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Labium_Majus"},{"name":"Maps_To","value":"Labium majus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227760"}]}}{"C12307":{"preferredName":"Labium Minus","code":"C12307","definitions":[{"definition":"One of the two longitudinal folds of skin located between the labia majora.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the two longitudinal folds of skin located between the labia majora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Labium Minus","termGroup":"PT","termSource":"NCI"},{"termName":"Labia Minora","termGroup":"SY","termSource":"NCI"},{"termName":"Labia Minus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Labium_Minus"},{"name":"Maps_To","value":"Labium minus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227766"}]}}{"C12346":{"preferredName":"Lacrimal Gland","code":"C12346","definitions":[{"definition":"A gland that secretes tears. The lacrimal glands are found in the upper, outer part of each eye socket.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Paired, almond-shaped exocrine glands situated superior and posterior to each orbit of the eye that produce and secrete the watery serous component of tears.","type":"DEFINITION","source":"NCI"},{"definition":"The exocrine glands that produce the watery serous component of tears.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lacrimal glands are paired almond-shaped glands, located in or near the orbital region, that secrete the aqueous layer of the tear film.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Lacrimal Gland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lacrimal_Gland"},{"name":"Maps_To","value":"Lacrimal gland"},{"name":"Maps_To","value":"Lacrimal Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022907"},{"name":"xRef","value":"UBERON:0001817"}]}}{"C12281":{"preferredName":"Laryngeal Cartilage","code":"C12281","definitions":[{"definition":"The nine cartilages that comprise the skeleton of the larynx, including the single thyroid, epiglottic, and cricoid cartilages, and the paired arytenoid, corniculate, and cuneiform cartilages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laryngeal Cartilage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laryngeal_Cartilage"},{"name":"Maps_To","value":"Laryngeal cartilage"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0023050"}]}}{"C12333":{"preferredName":"Lateral Wall of the Bladder","code":"C12333","definitions":[{"definition":"The aspect of the bladder wall that is located on the side.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lateral Wall of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Wall of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lateral_Wall_of_the_Bladder"},{"name":"Maps_To","value":"Lateral wall of bladder"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0447583"}]}}{"C12244":{"preferredName":"Lateral Wall of the Nasopharynx","code":"C12244","definitions":[{"definition":"The aspect of the nasopharyngeal wall that is located on the side.  It contains the pharyngeal opening of the auditory tube.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lateral Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lateral_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Lateral wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0225486"}]}}{"C12239":{"preferredName":"Lateral Wall of the Oropharynx","code":"C12239","definitions":[{"definition":"The aspect of the oropharyngeal wall that is located on the side.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lateral Wall of the Oropharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Lateral Wall of Oropharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lateral_Wall_of_the_Oropharynx"},{"name":"Maps_To","value":"Lateral wall of oropharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227156"}]}}{"C12261":{"preferredName":"Lesser Curvature of the Stomach","code":"C12261","definitions":[{"definition":"The medial border of the stomach. It is concave in shape and extends from the cardiac orifice to the pyloric orifice.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The right border of the stomach.  It is concave in shape and extends from the cardiac orifice to the pyloric orifice.","type":"DEFINITION","source":"NCI"},{"definition":"not classifiable to C16.1 to C16.4","type":"ALT_DEFINITION","source":"ICDO3"}],"synonyms":[{"termName":"Lesser Curvature of the Stomach","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lesser_Curvature"},{"name":"Maps_To","value":"Lesser curvature of stomach, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227221"}]}}{"C32988":{"preferredName":"Lingual Tonsil","code":"C32988","definitions":[{"definition":"A tonsil in the mucosa at the root of the tongue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymphoid follicles on the dorsal surface in the posterior region of the tongue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lingual Tonsil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lingual_Tonsil"},{"name":"Maps_To","value":"Lingual tonsil"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229871"}]}}{"C54204":{"preferredName":"Lower Gingiva","code":"C54204","definitions":[{"definition":"The gingiva covering the mandibular alveolar bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower Gingiva","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Gums","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower_Gingiva"},{"name":"Maps_To","value":"Lower gum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227123"}]}}{"C12742":{"preferredName":"Lower Extremity","code":"C12742","definitions":[{"definition":"The limb that is composed of the hip, thigh, leg and foot.","type":"DEFINITION","source":"NCI"},{"definition":"The limb that is composed of the hip, thigh, leg and foot. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lower Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lower_Extremity"},{"name":"Maps_To","value":"Lower limb, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0023216"}]}}{"C12287":{"preferredName":"Lower Lobe of the Lung","code":"C12287","definitions":[{"definition":"The bottom most subdivision of either the right or left lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower Lobe of the Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Lower Lobe, Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Lower Lobe","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Lower_Lobe"},{"name":"Maps_To","value":"Lower lobe, lung"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225758"}]}}{"C12255":{"preferredName":"Lower Third of the Esophagus","code":"C12255","definitions":[{"definition":"The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type.","type":"DEFINITION","source":"NCI"},{"definition":"The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lower Third of the Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Third of Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Lower_Third_of_the_Esophagus"},{"name":"Maps_To","value":"Esophageal; Distal"},{"name":"Maps_To","value":"Esophagus, Lower Third"},{"name":"Maps_To","value":"Lower third of esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227191"},{"name":"xRef","value":"UBERON:0013473"}]}}{"C12302":{"preferredName":"Lower-Inner Quadrant of the Breast","code":"C12302","definitions":[{"definition":"The quarter of the breast which is inferior and medial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower-Inner Quadrant of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Lower-Inner Quadrant of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower-inner_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Lower-inner quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222597"}]}}{"C12304":{"preferredName":"Lower-Outer Quadrant of the Breast","code":"C12304","definitions":[{"definition":"The quarter of the breast which is inferior and lateral.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower-Outer Quadrant of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Lower-Outer Quadrant of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower-outer_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Lower-outer quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222599"}]}}{"C12358":{"preferredName":"Head and Neck Lymph Node","code":"C12358","definitions":[{"definition":"Lymph nodes found within the head and neck region of the body, which drain into the deep cervical nodes, either directly or indirectly. These include the occipital, mastoid, parotid, facial, retropharyngeal, submandibular, submental, lingual and cervical lymph nodes. Any lymph node located in the head or neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Head and Neck Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Node of Head, Face and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Nodes of Head, Face and Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Head_and_Neck_Lymph_Node"},{"name":"Maps_To","value":"Lymph nodes of head, face and neck"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1185605"}]}}{"C12362":{"preferredName":"Lymph Node of Inguinal Region or Leg","code":"C12362","definitions":[{"definition":"Any lymph node that is located in the inguinal region or in either leg.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymph Node of Inguinal Region or Leg","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Nodes of Inguinal Region or Leg","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymph_Node_of_Inguinal_Region_or_Leg"},{"name":"Maps_To","value":"Lymph nodes of inguinal region or leg"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1518054"}]}}{"C12284":{"preferredName":"Main Bronchus","code":"C12284","definitions":[{"definition":"The left and right main bronchi considered as a group.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Main Bronchus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Main_Bronchus"},{"name":"Maps_To","value":"Main bronchus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024496"}]}}{"C12999":{"preferredName":"Major Salivary Gland","code":"C12999","definitions":[{"definition":"One of the three larger salivary glands including the parotid, submandibular and sublingual glands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Major Salivary Gland","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Major_Salivary_Gland"},{"name":"Maps_To","value":"Major salivary gland, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0930553"}]}}{"C61599":{"preferredName":"Male Genitalia","code":"C61599","definitions":[{"definition":"Male internal and external organs of reproduction.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The external male sexual organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Male Genitalia","termGroup":"PT","termSource":"NCI"},{"termName":"Male Genital Organ","termGroup":"SY","termSource":"NCI"},{"termName":"Male Genital Organs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Male_Genitalia"},{"name":"Maps_To","value":"Male genital organs, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017422"}]}}{"C12290":{"preferredName":"Mandible","code":"C12290","definitions":[{"definition":"A dentary bone that is the only bone in one of the lateral halves of the lower jaw skeleton.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lower jaw bone holding the lower teeth.","type":"DEFINITION","source":"NCI"},{"definition":"The lower jaw bone holding the lower teeth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mandible","termGroup":"PT","termSource":"NCI"},{"termName":"Inferior Maxillary Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Lower Jaw","termGroup":"SY","termSource":"NCI"},{"termName":"Mandibular","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mandible"},{"name":"Maps_To","value":"Mandible"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024687"},{"name":"xRef","value":"UBERON:0001684"}]}}{"C12275":{"preferredName":"Maxillary Sinus","code":"C12275","definitions":[{"definition":"A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital.","type":"DEFINITION","source":"NCI"},{"definition":"A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). There are two large maxillary sinuses, one in each of the maxillary bones, which are in the cheek area next to the nose. The maxillary sinuses are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of the paired paranasal sinuses, located in the body of the maxilla, communicating with the middle meatus of the nasal cavity.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Maxillary Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Antrum Highmori","termGroup":"SY","termSource":"NCI"},{"termName":"Antrum of Highmore","termGroup":"SY","termSource":"NCI"},{"termName":"Antrum of Highmori","termGroup":"SY","termSource":"NCI"},{"termName":"Antrum, Maxillary","termGroup":"SY","termSource":"NCI"},{"termName":"Apertura Sinus Maxillaris","termGroup":"SY","termSource":"NCI"},{"termName":"Sinus, Maxillary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Maxillary_Sinus"},{"name":"Maps_To","value":"Maxillary sinus"},{"name":"Maps_To","value":"Sinus(es), Maxillary"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0024957"},{"name":"xRef","value":"UBERON:0001764"}]}}{"C12264":{"preferredName":"Meckel Diverticulum","code":"C12264","definitions":[{"definition":"A congenital pouch in the distal ileum. It may cause painless rectal bleeding and bowel obstruction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meckel Diverticulum","termGroup":"PT","termSource":"NCI"},{"termName":"Meckel's Diverticulum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Meckel_Diverticulum"},{"name":"Maps_To","value":"Meckel diverticulum"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0025037"}]}}{"C12397":{"preferredName":"Adrenal Medulla","code":"C12397","definitions":[{"definition":"The inner part of the adrenal gland (a small organ on top of each kidney). The adrenal medulla makes chemicals such as epinephrine (adrenaline) and norepinephrine (noradrenaline) which are involved in sending nerve signals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The inner region of the adrenal gland. The adrenal medulla produces, stores, and secretes epinephrine and norepinephrine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adrenal Medulla","termGroup":"PT","termSource":"NCI"},{"termName":"Medulla of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Medullary","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Medulla"},{"name":"Maps_To","value":"Medulla of adrenal gland"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0001629"}]}}{"C12274":{"preferredName":"Middle Ear","code":"C12274","definitions":[{"definition":"The part of the ear including the eardrum and ossicles.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the ear including the eardrum and ossicles. The middle ear leads to the inner ear.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Middle Ear","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Middle_Ear"},{"name":"Maps_To","value":"Middle ear"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013455"}]}}{"C12286":{"preferredName":"Middle Lobe of the Right Lung","code":"C12286","definitions":[{"definition":"The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure.","type":"DEFINITION","source":"NCI"},{"definition":"The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Middle Lobe of the Right Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Middle Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Middle Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Middle Lobe of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Right Middle Lobe, Lung","termGroup":"SY","termSource":"NCI"},{"termName":"RML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Only the right lung has a middle lobe."},{"name":"Legacy Concept Name","value":"Middle_Lobe_of_the_Right_Lung"},{"name":"Maps_To","value":"Middle lobe, lung"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225757"}]}}{"C12254":{"preferredName":"Middle Third of the Esophagus","code":"C12254","definitions":[{"definition":"The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Middle Third of the Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Middle Third of Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Middle_Third_of_the_Esophagus"},{"name":"Maps_To","value":"Esophageal; Mid"},{"name":"Maps_To","value":"Esophagus, Middle Third"},{"name":"Maps_To","value":"Middle third of esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227189"},{"name":"xRef","value":"UBERON:0013474"}]}}{"C12421":{"preferredName":"Oral Cavity","code":"C12421","definitions":[{"definition":"Anatomical cavity at the start of the digestive tract that that is enclosed by the mouth. The boundaries and contents vary depending on the species. In vertebrates, the boundaries are the oral opening, the cheeks, the palate and (if present) the palatoglossal arch - if this is not present then the mouth and pharynx form the oropharyngeal cavity. The buccal cavity contains the teeth, tongue and palate (when present).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Refers to the mouth. It includes the lips, the lining inside the cheeks and lips, the front two thirds of the tongue, the upper and lower gums, the floor of the mouth under the tongue, the bony roof of the mouth, and the small area behind the wisdom teeth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Relating to the buccal cavity of the mouth (the pouch located between the cheek and the gum) as the intended site of administration, where the pharmaceutical product is intended for a systemic action after passing through the buccal mucosa.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.","type":"DEFINITION","source":"NCI"},{"definition":"The cavity of the mouth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The proximal portion of the digestive tract, containing the oral cavity and bounded by the oral opening. In vertebrates, this extends to the pharynx and includes gums, lips, tongue and parts of the palate. Typically also includes the teeth, except where these occur elsewhere (e.g. pharyngeal jaws) or protrude from the mouth (tusks).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Oral Cavity","termGroup":"PT","termSource":"NCI"},{"termName":"Buccal Cavity","termGroup":"SY","termSource":"NCI"},{"termName":"Mouth","termGroup":"SY","termSource":"NCI"},{"termName":"Oral","termGroup":"AD","termSource":"NCI"},{"termName":"Orally","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Oral_Cavity"},{"name":"Maps_To","value":"Buccal Cavity"},{"name":"Maps_To","value":"Mouth"},{"name":"Maps_To","value":"Mouth, NOS"},{"name":"Maps_To","value":"Oral Cavity"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226896"},{"name":"xRef","value":"UBERON:0000165"},{"name":"xRef","value":"UBERON:0000167"}]}}{"C12226":{"preferredName":"Mucosa of the Lip","code":"C12226","definitions":[{"definition":"The inner lining of the lips.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lining of the fleshy folds surrounding the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","type":"DEFINITION","source":"NCI"},{"definition":"The lining of the fleshy folds surrounding the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mucosa of the Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Labial Mucosa","termGroup":"SY","termSource":"NCI"},{"termName":"Mucosa of Lip","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Hair Bearing Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"ICD-O3: excludes skin of lip C44.0"},{"name":"Legacy Concept Name","value":"Labial_Mucosa"},{"name":"Legacy Concept Name","value":"Mucosa_of_the_Lip"},{"name":"Maps_To","value":"Mucosa of lip, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0226927"}]}}{"C12225":{"preferredName":"Mucosa of the Lower Lip","code":"C12225","definitions":[{"definition":"The lining of the inferior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucosa of the Lower Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Mucosa of Lower Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucosa_of_the_Lower_Lip"},{"name":"Maps_To","value":"Mucosa of lower lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226939"}]}}{"C12224":{"preferredName":"Mucosa of the Upper Lip","code":"C12224","definitions":[{"definition":"The lining of the superior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucosa of the Upper Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Mucosa of Upper Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mucosa_of_the_Upper_Lip"},{"name":"Maps_To","value":"Mucosa of upper lip"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0226933"}]}}{"C12314":{"preferredName":"Myometrium","code":"C12314","definitions":[{"definition":"The muscular outer layer of the uterus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The smooth muscle lining the uterus.","type":"DEFINITION","source":"NCI"},{"definition":"The smooth muscle lining the uterus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Myometrium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myometrium"},{"name":"Maps_To","value":"Myometrium"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0027088"}]}}{"C12424":{"preferredName":"Nasal Cavity","code":"C12424","definitions":[{"definition":"An anatomical cavity that is part of the olfactory apparatus. This includes the space bounded anteriorly by the nares and posteriorly by the choanae, when these structures are present.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The proximal portion of the respiratory passages on either side of the nasal septum lying between the floor of the cranium and the roof of the mouth and extending from the face to the pharynx. The nasal cavity is lined with ciliated mucosa, extending from the nares to the pharynx.","type":"DEFINITION","source":"NCI"},{"definition":"The upper respiratory tract extending from the nares to the pharynx.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nasal Cavity","termGroup":"PT","termSource":"NCI"},{"termName":"Nasal Fossa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Nasal_Cavity"},{"name":"Legacy Concept Name","value":"Nasal_Cavity_and_Paranasal_Sinus"},{"name":"Maps_To","value":"Nasal cavity"},{"name":"Maps_To","value":"Nasal Cavity"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0027423"},{"name":"xRef","value":"UBERON:0001707"}]}}{"C12755":{"preferredName":"Nervous System","code":"C12755","definitions":[{"definition":"The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.","type":"DEFINITION","source":"NCI"},{"definition":"The organized network of nerve tissue in the body. It includes the central nervous system (the brain and spinal cord), the peripheral nervous system (nerves that extend from the spinal cord to the rest of the body), and other nerve tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nervous System","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Neurologic","termGroup":"SY","termSource":"NCI"},{"termName":"Neurologic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Neurologic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Neurologic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Nervous_System"},{"name":"Maps_To","value":"Nervous system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0027763"},{"name":"xRef","value":"IMDRF:E01"}]}}{"C12299":{"preferredName":"Nipple","code":"C12299","definitions":[{"definition":"In anatomy, the small raised area in the center of the breast through which milk can flow to the outside.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pigmented protuberance on the surface of the breast through which milk is drawn from the breast.","type":"DEFINITION","source":"NCI"},{"definition":"The protuberance in the skin where the ducts of the mammary gland open.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nipple","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nipple"},{"name":"Maps_To","value":"Nipple"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0028109"}]}}{"C12355":{"preferredName":"Occipital Lobe","code":"C12355","definitions":[{"definition":"One of the four regions of cortex in each cerebral hemisphere, located posterior to the temporal lobe and inferior to the parietal lobe.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the four regions of cortex in each cerebral hemisphere. It is located posterior to the temporal lobe and inferior to the parietal lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occipital Lobe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Occipital_Lobe"},{"name":"Maps_To","value":"Brain, Occipital lobe"},{"name":"Maps_To","value":"Occipital lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0028785"}]}}{"C12759":{"preferredName":"Olfactory Nerve","code":"C12759","definitions":[{"definition":"The first cranial nerve.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The first cranial nerve. It is the shortest cranial nerve and of paramount importance in the sense of smell. Its neurons are in the olfactory mucosa in the nasal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olfactory Nerve","termGroup":"PT","termSource":"NCI"},{"termName":"Cranial Nerve I","termGroup":"SY","termSource":"NCI"},{"termName":"First Cranial Nerve","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Olfactory_Nerve"},{"name":"Maps_To","value":"Olfactory nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0028938"}]}}{"C12761":{"preferredName":"Optic Nerve","code":"C12761","definitions":[{"definition":"A cranial nerve extending between the retina and optic chiasma, which innervates the eye.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The nerve that carries messages from the retina to the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The second cranial nerve.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Optic Nerve","termGroup":"PT","termSource":"NCI"},{"termName":"Second Cranial Nerve","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Optic_Nerve"},{"name":"Maps_To","value":"Optic nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0029130"}]}}{"C12347":{"preferredName":"Orbit","code":"C12347","definitions":[{"definition":"The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.","type":"DEFINITION","source":"NCI"},{"definition":"The bony cavity that contains the eye and its associated structures.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Orbit","termGroup":"PT","termSource":"NCI"},{"termName":"Eye Socket","termGroup":"SY","termSource":"NCI"},{"termName":"Ocular Orbit","termGroup":"SY","termSource":"NCI"},{"termName":"Orbital Cavity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Orbit"},{"name":"Maps_To","value":"Ocular orbits"},{"name":"Maps_To","value":"Ocular Orbits"},{"name":"Maps_To","value":"Orbit, NOS"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0029180"},{"name":"xRef","value":"UBERON:0001697"}]}}{"C147919":{"preferredName":"Ill-Defined Anatomic Site","code":"C147919","definitions":[{"definition":"An anatomic site that is not specified or defined well enough to associate with a specific site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ill-Defined Anatomic Site","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other ill-defined sites"},{"name":"NCI_META_CUI","value":"CL545798"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C12273":{"preferredName":"Other Specified Parts of Pancreas","code":"C12273","definitions":[{"definition":"Any component associated with the pancreas that is different from the one(s) previously specified or mentioned.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Specified Parts of Pancreas","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Other_Specified_Parts_of_Pancreas"},{"name":"Maps_To","value":"Other specified parts of pancreas"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1518669"}]}}{"C12272":{"preferredName":"Pancreatic Duct","code":"C12272","definitions":[{"definition":"A duct joining the pancreas to the common bile duct to supply pancreatic juices.","type":"DEFINITION","source":"NCI"},{"definition":"A duct that conveys pancreatic secretions from the pancreas to the duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Part of a system of ducts in the pancreas. Pancreatic juices containing enzymes are released into these ducts and flow into the small intestine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatic Duct","termGroup":"PT","termSource":"NCI"},{"termName":"Canal of Wirsung","termGroup":"SY","termSource":"NCI"},{"termName":"Main Pancreatic Duct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Duct"},{"name":"Maps_To","value":"Pancreas Duct"},{"name":"Maps_To","value":"Pancreatic duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030288"}]}}{"C158551":{"preferredName":"Neck of the Pancreas","code":"C158551","definitions":[{"definition":"The portion of the pancreas that is the junction of the head and body of the pancreas, and lies anterior to the aorta.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the pancreas that is the junction of the head and body of the pancreas; the portion of the pancreas that lies anterior to the aorta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neck of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreas Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic neck"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0447556"}]}}{"C12320":{"preferredName":"Parametrium","code":"C12320","definitions":[{"definition":"The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament.","type":"DEFINITION","source":"NCI"},{"definition":"The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Parametrium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Parametrium"},{"name":"Maps_To","value":"Parametrium"},{"name":"Maps_To","value":"Parametrium, Left"},{"name":"Maps_To","value":"Parametrium, NOS"},{"name":"Maps_To","value":"Parametrium, Right"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227822"}]}}{"C12765":{"preferredName":"Parathyroid Gland","code":"C12765","definitions":[{"definition":"Endocrine gland, usually in close proximity to the thyroid gland, that produces parathyroid hormone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parathyroid Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Parathyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Parathyroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"DesignNote","value":"Inadvertent removal of all parathyroid glands, as during thyroidectomy, produces tetany and death."},{"name":"Legacy Concept Name","value":"Parathyroid_Gland"},{"name":"Maps_To","value":"Parathyroid"},{"name":"Maps_To","value":"Parathyroid gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030518"},{"name":"xRef","value":"UBERON:0001132"}]}}{"C61122":{"preferredName":"Skene Gland","code":"C61122","definitions":[{"definition":"A gland located in the anterior wall of the vagina that drains into the urethra at the opening.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skene Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Paraurethral Skene Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Skene's Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skene_s_Gland"},{"name":"Maps_To","value":"Paraurethral gland"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227782"}]}}{"C12354":{"preferredName":"Parietal Lobe","code":"C12354","definitions":[{"definition":"One of the lobes of the cerebral hemisphere located superiorly to the occipital lobe and posteriorly to the frontal lobe. Cognition and visuospatial processing are its main function. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the lobes of the cerebral hemisphere located superiorly to the occipital lobe and posteriorly to the frontal lobe. Cognition and visuospatial processing are its main functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parietal Lobe","termGroup":"PT","termSource":"NCI"},{"termName":"Parietal Lobe of the Brain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Parietal_Lobe_of_the_Brain"},{"name":"Maps_To","value":"Brain, Parietal lobe"},{"name":"Maps_To","value":"Parietal lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030560"}]}}{"C12363":{"preferredName":"Pelvic Lymph Node","code":"C12363","definitions":[{"definition":"Any lymph node within the abdominal pelvic region.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Any lymph node within the abdominal pelvic region.","type":"DEFINITION","source":"NCI"},{"definition":"Any lymph node within the pelvic region. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pelvic Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Pelvic Lymph Nodes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pelvic_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Pelvic"},{"name":"Maps_To","value":"Pelvic Lymph Node(s)"},{"name":"Maps_To","value":"Pelvic lymph nodes"},{"name":"Maps_To","value":"Pelvis, NOS"},{"name":"NCI_META_CUI","value":"CL455365"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"xRef","value":"UBERON:0015876"}]}}{"C12425":{"preferredName":"Pharynx","code":"C12425","definitions":[{"definition":"A hollow tube that starts posterior to the mouth and nasal cavity and ends superior to the trachea and esophagus.","type":"DEFINITION","source":"NCI"},{"definition":"A passageway in the head and neck that includes the nasopharynx, oropharynx and laryngopharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The hollow tube inside the neck that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach). The pharynx is about 5 inches long, depending on body size.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pharynx is the part of the digestive system immediately posterior to the mouth.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pharynx","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pharynx"},{"name":"Maps_To","value":"Pharynx"},{"name":"Maps_To","value":"Pharynx, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0031354"},{"name":"xRef","value":"UBERON:0006562"}]}}{"C12398":{"preferredName":"Pineal Gland","code":"C12398","definitions":[{"definition":"A midline, cone like structure located in the dorso-caudal roof of the 3rd ventricle, attached by peduncles to the habenular and posterior commissures. The stalk contains nerve fibers, blood vessels, connective tissue and parenchymal cells (Paxinos, The Rat Central Nervous System, 2nd ed, pg 399).","type":"ALT_DEFINITION","source":"NCI"},{"definition":"A small endocrine gland in the brain, situated beneath the back part of the corpus callosum, that secretes melatonin.","type":"DEFINITION","source":"NCI"},{"definition":"A small endocrine gland that arises from the central posterior aspect of the diencephalon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tiny organ in the cerebrum that produces melatonin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pineal Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Pineal Body","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pineal_Gland"},{"name":"Maps_To","value":"Pineal"},{"name":"Maps_To","value":"Pineal gland"},{"name":"Maps_To","value":"Pineal Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0031939"},{"name":"xRef","value":"UBERON:0001905"}]}}{"C12399":{"preferredName":"Pituitary Gland","code":"C12399","definitions":[{"definition":"A small endocrine gland extending from the hypothalamus at the base of the brain.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An endocrine gland located ventral to the diencephalon and derived from mixed neuroectodermal and non neuroectodermal origin.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Pea-sized endocrine gland located at the base of the brain in the pituitary fossa. It produces and secretes hormones such as oxytocin and vasopressin, to regulate the activities of the hypothalamus.","type":"DEFINITION","source":"NCI"},{"definition":"The main endocrine gland. It produces hormones that control other glands and many body functions, especially growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pituitary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Hypophysis","termGroup":"SY","termSource":"NCI"},{"termName":"Hypophysis Cerebri","termGroup":"SY","termSource":"NCI"},{"termName":"Nervous System, Pituitary","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pituitary_Gland"},{"name":"Maps_To","value":"Pituitary gland"},{"name":"Maps_To","value":"Pituitary Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0032005"},{"name":"xRef","value":"UBERON:0000007"}]}}{"C54221":{"preferredName":"Postcricoid Region","code":"C54221","definitions":[{"definition":"The portion of the hypopharynx that is located posteriorly to the larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Postcricoid Region","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Hypopharyngeal Region","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lower_Hypopharyngeal_Region"},{"name":"Maps_To","value":"Postcricoid region"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0225516"}]}}{"C33368":{"preferredName":"Posterior Mediastinum","code":"C33368","definitions":[{"definition":"The part of the lower portion of the mediastinum that is located behind the pericardium.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the lower portion of the mediastinum that is located behind the pericardium. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Posterior Mediastinum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Mediastinum"},{"name":"Maps_To","value":"Posterior mediastinum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230150"}]}}{"C12335":{"preferredName":"Posterior Wall of the Bladder","code":"C12335","definitions":[{"definition":"The posterior aspect of the bladder wall.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Bladder","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Bladder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Bladder"},{"name":"Maps_To","value":"Posterior wall of bladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227701"}]}}{"C12249":{"preferredName":"Posterior Wall of the Hypopharynx","code":"C12249","definitions":[{"definition":"The region of the hypopharynx demarcated by a plane drawn at the level of the tip of the epiglottis to a plane at the inferior border of the cricoid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Hypopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Hypopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Hypopharynx"},{"name":"Maps_To","value":"Posterior wall of hypopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227174"}]}}{"C12243":{"preferredName":"Posterior Wall of the Nasopharynx","code":"C12243","definitions":[{"definition":"The dorsal portion of the nasopharyngeal cavity that contains the pharyngeal tonsil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Posterior wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0225484"}]}}{"C12240":{"preferredName":"Posterior Wall of the Oropharynx","code":"C12240","definitions":[{"definition":"The dorsal portion of the oropharyngeal cavity that is formed by the muscular pharyngeal wall comprising the superior and middle pharyngeal constrictor muscles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Posterior Wall of the Oropharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Posterior Wall of Oropharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Posterior_Wall_of_the_Oropharynx"},{"name":"Maps_To","value":"Posterior wall of oropharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227155"}]}}{"C12323":{"preferredName":"Prepuce","code":"C12323","definitions":[{"definition":"A covering fold of skin, often used alone to designate the preputium penis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"A fold of skin covering the end of the penis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Prepuce","termGroup":"PT","termSource":"NCI"},{"termName":"Preputium Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prepuce"},{"name":"Maps_To","value":"Prepuce"},{"name":"NCI_META_CUI","value":"CL415279"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C12260":{"preferredName":"Pylorus","code":"C12260","definitions":[{"definition":"The lower part of the stomach that connects to the duodenum.","type":"DEFINITION","source":"NCI"},{"definition":"The region of the stomach that connects to the duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The stomach tissue region surrounding and controlling the distal outlet of the stomach, which opens into the duodenum.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pylorus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pylorus"},{"name":"Maps_To","value":"Pylorus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0034196"},{"name":"xRef","value":"UBERON:0001166"}]}}{"C12780":{"preferredName":"Reticuloendothelial System","code":"C12780","definitions":[{"definition":"A widely distributed collection of both free and fixed macrophages derived from bone marrow precursor cells by way of monocytes; their substantial phagocytic activity is mediated by immunoglobulin and the serum complement system. In both connective and lymphoid tissue, they may occur as free and fixed macrophages; in the sinusoids of the liver, as Kupffer cells; in the lung, as alveolar macrophages; and in the nervous system, as microglia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reticuloendothelial System","termGroup":"PT","termSource":"NCI"},{"termName":"RE System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Reticuloendothelial_System"},{"name":"Maps_To","value":"Reticuloendothelial system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0035287"}]}}{"C12343":{"preferredName":"Retina","code":"C12343","definitions":[{"definition":"A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain.","type":"DEFINITION","source":"NCI"},{"definition":"A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The light-sensitive layers of nerve tissue at the back of the eye that receive images and sends them as electric signals through the optic nerve to the brain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The retina is the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Retina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Retina"},{"name":"Maps_To","value":"Retina"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0035298"},{"name":"xRef","value":"UBERON:0000966"}]}}{"C54223":{"preferredName":"Retromolar Trigone","code":"C54223","definitions":[{"definition":"A triangular-shaped area of mucosa located posterior the last mandibular molar tooth.","type":"DEFINITION","source":"NCI"},{"definition":"The small area behind the wisdom teeth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Retromolar Trigone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retromolar_Trigone"},{"name":"Maps_To","value":"Retromolar area"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0226920"}]}}{"C12319":{"preferredName":"Round Ligament","code":"C12319","definitions":[{"definition":"Any of the round ligaments including the round ligament of the liver and the round ligament of the uterus.","type":"DEFINITION","source":"NCI"},{"definition":"Band of fibrous tissue that anchors various organs in place.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Round Ligament","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Round_Ligament"},{"name":"Maps_To","value":"Round Ligament"},{"name":"Maps_To","value":"Round ligament"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3241921"}]}}{"C12785":{"preferredName":"Scrotum","code":"C12785","definitions":[{"definition":"In males, the external sac that contains the testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The external sac of skin that encloses the testes. It is an extension of the abdomen, and in placentals is located between the penis and anus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The musculocutaneous pouch that encloses the testicles.","type":"DEFINITION","source":"NCI"},{"definition":"The pouch that encloses the testicles.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Scrotum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Scrotum"},{"name":"Maps_To","value":"Scrotum"},{"name":"Maps_To","value":"Scrotum, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036471"},{"name":"xRef","value":"UBERON:0001300"}]}}{"C12384":{"preferredName":"Sigmoid Colon","code":"C12384","definitions":[{"definition":"The S-shaped section of the colon that connects to the rectum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The part of the large intestine that is closest to the rectum and anus. It forms a loop that averages about 40 cm. in length, and normally lies within the pelvis, but on account of its freedom of movement it is liable to be displaced into the abdominal cavity.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the colon that connects to the descending colon above and the rectum below.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The portion of the colon that connects to the descending colon above and the rectum below. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sigmoid Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sigmoid_Colon"},{"name":"Maps_To","value":"Sigmoid Colon"},{"name":"Maps_To","value":"Sigmoid colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227391"},{"name":"xRef","value":"UBERON:0001159"}]}}{"C12291":{"preferredName":"Skin of the Lip","code":"C12291","definitions":[{"definition":"The skin portion of the lip that contains hair.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The skin portion of the lip that contains hair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Lip","termGroup":"PT","termSource":"NCI"},{"termName":"Hair Bearing Lip","termGroup":"SY","termSource":"NCI"},{"termName":"Skin of Lip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Lip"},{"name":"Maps_To","value":"Skin of lip, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222101"}]}}{"C12297":{"preferredName":"Skin of the Lower Limb and Hip","code":"C12297","definitions":[{"definition":"The integumentary covering of the lower limb and hip region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Lower Limb and Hip","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Lower Limb and Hip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Lower_Limb_and_Hip"},{"name":"Maps_To","value":"Skin of lower limb and hip"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222268"}]}}{"C33561":{"preferredName":"Skin of the Face","code":"C33561","definitions":[{"definition":"The integumentary covering of the face.","type":"DEFINITION","source":"NCI"},{"definition":"The skin or integument that covers the face.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Skin of the Face","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Face"},{"name":"Maps_To","value":"Skin of other and unspecified parts of face"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222084"}]}}{"C12294":{"preferredName":"Skin of the Scalp and Neck","code":"C12294","definitions":[{"definition":"The integumentary covering of the scalp and neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Scalp and Neck","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Scalp and Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Scalp_and_Neck"},{"name":"Maps_To","value":"Skin of scalp and neck"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1522650"}]}}{"C12295":{"preferredName":"Skin of the Trunk","code":"C12295","definitions":[{"definition":"The integument that covers the trunk of the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The skin or integument surrounding the trunk of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Trunk","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Trunk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Trunk"},{"name":"Maps_To","value":"Skin of trunk"},{"name":"Maps_To","value":"Skin, trunk, local"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0205031"}]}}{"C12296":{"preferredName":"Skin of the Upper Limb and Shoulder","code":"C12296","definitions":[{"definition":"The integumentary covering of the upper limb and shoulder region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Upper Limb and Shoulder","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of Upper Limb and Shoulder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Skin_of_the_Upper_Limb_and_Shoulder"},{"name":"Maps_To","value":"Skin of upper limb and shoulder"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0222212"}]}}{"C12231":{"preferredName":"Soft Palate","code":"C12231","definitions":[{"definition":"The back, muscular (not bony) part of the roof of the mouth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The muscular extension of the hard palate which comprises the posterior of the oral cavity and the floor of the nasal cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The part of the roof of the mouth not supported by bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Soft Palate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Soft_Palate"},{"name":"Maps_To","value":"Soft palate, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0030219"}]}}{"C12329":{"preferredName":"Spermatic Cord","code":"C12329","definitions":[{"definition":"A cord-like structure in the male reproductive system that contains nerves, blood and lymph vessels, and the vas deferens (a coiled tube that carries sperm out of the testicle). It runs from the abdomen to the testicle, and connects to the testicle in the scrotum (external sac).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tube-like structure composed of the vas deferens and surrounding tissue layers, that runs from the abdomen to each of the testicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spermatic Cord","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spermatic_Cord"},{"name":"Maps_To","value":"Spermatic cord"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037855"}]}}{"C12278":{"preferredName":"Sphenoid Sinus","code":"C12278","definitions":[{"definition":"A type of paranasal sinus (a hollow space in the bones around the nose). There are two large sphenoid sinuses in the sphenoid bone, which is behind the nose between the eyes. The sphenoid sinuses are lined with cells that make mucus to keep the nose from drying out.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Either of the paired paranasal sinuses located in the anterior part of the body of the sphenoid bone, and communicating with the superior meatus of the nasal cavity on the same side.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of the paired paranasal sinuses, located in the anterior part of the body of the sphenoid bone and communicating with the superior meatus of the nasal cavity on the same side.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sphenoid Sinus","termGroup":"PT","termSource":"NCI"},{"termName":"Sinus, Sphenoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Sphenoid_Sinus"},{"name":"Maps_To","value":"Sphenoid sinus"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0037885"}]}}{"C12350":{"preferredName":"Spinal Meninges","code":"C12350","definitions":[{"definition":"Connective tissue membranes that surround and support the spinal cord and cauda equina. They are continuous with cranial meninges, which surround and support the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spinal Meninges","termGroup":"PT","termSource":"NCI"},{"termName":"Spinal Meninx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spinal_Meninges"},{"name":"Maps_To","value":"Spinal meninges"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037938"}]}}{"C12267":{"preferredName":"Splenic Flexure","code":"C12267","definitions":[{"definition":"The bend at the junction of the transverse and descending colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The bend at the junction of the transverse and descending colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The splenic (or left colic) flexure is a sharp bend between the transverse and the descending colon in the left upper quadrant of humans. The left colic flexure is near the spleen, and hence called the splenic flexure. There are two colic flexures in the transverse colon; the other being the hepatic flexure in the right upper quadrant.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Splenic Flexure","termGroup":"PT","termSource":"NCI"},{"termName":"Left Colic Flexure","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Flexure of Colon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Splenic_Flexure"},{"name":"Maps_To","value":"Splenic Flexure"},{"name":"Maps_To","value":"Splenic flexure of colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227387"},{"name":"xRef","value":"UBERON:0022276"}]}}{"C12280":{"preferredName":"Subglottis","code":"C12280","definitions":[{"definition":"The area of the larynx below the vocal cords down to the trachea.","type":"DEFINITION","source":"NCI"},{"definition":"The area of the larynx below the vocal cords down to the trachea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lower portion of the larynx, extending from just beneath the vocal cords down to the top of the trachea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lowest part of the larynx; the area from just below the vocal cords down to the top of the trachea.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Subglottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Subglottis"},{"name":"Maps_To","value":"Subglottis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0456475"},{"name":"xRef","value":"UBERON:0036068"}]}}{"C12234":{"preferredName":"Sublingual Salivary Gland","code":"C12234","definitions":[{"definition":"A salivary gland located under the tongue in the floor of the oral cavity.","type":"DEFINITION","source":"NCI"},{"definition":"The salivary gland located under the tongue in the floor of the oral cavity or adjacent to the submandibular salivary gland.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The small mucin-producing salivary glands in the floor of the mouth beneath the tongue, anterior to the submandibular gland.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Sublingual Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Sublingual Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sublingual_Salivary_Gland"},{"name":"Maps_To","value":"Sublingual Gland"},{"name":"Maps_To","value":"Sublingual gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0038553"},{"name":"xRef","value":"UBERON:0001832"}]}}{"C12233":{"preferredName":"Submandibular Salivary Gland","code":"C12233","definitions":[{"definition":"Either of the paired compound tubuloalveolar (aka tubuloacinar) major salivary glands composed of both serous and mucous secretory cells and situated beneath the mandible.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of major salivary glands located below the floor of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The salivary gland located adjacent to the mandible.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Submandibular Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Submandibular Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Submaxillary Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Submandibular_Gland"},{"name":"Maps_To","value":"Submandibular gland"},{"name":"Maps_To","value":"Submandibular Gland"},{"name":"NCI_META_CUI","value":"CL1773628"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"xRef","value":"UBERON:0001736"}]}}{"C12242":{"preferredName":"Superior Wall of the Nasopharynx","code":"C12242","definitions":[{"definition":"The roof of the nasopharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superior Wall of the Nasopharynx","termGroup":"PT","termSource":"NCI"},{"termName":"Nasopharyngeal Roof","termGroup":"SY","termSource":"NCI"},{"termName":"Roof of Nasopharynx","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Wall of Nasopharynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Superior_Wall_of_the_Nasopharynx"},{"name":"Maps_To","value":"Superior wall of nasopharynx"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225492"}]}}{"C12279":{"preferredName":"Supraglottis","code":"C12279","definitions":[{"definition":"The upper part of the larynx (voice box), including the epiglottis; the area above the vocal cords.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The upper part of the larynx, including the epiglottis; the area above the vocal cords.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper part of the larynx, including the epiglottis; the area above the vocal cords.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper part of the larynx, including the epiglottis; the area above the vocal cords.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supraglottis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Supraglottis"},{"name":"Maps_To","value":"Supraglottis"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225574"},{"name":"xRef","value":"UBERON:0036263"}]}}{"C12271":{"preferredName":"Tail of the Pancreas","code":"C12271","definitions":[{"definition":"The left extremity of the pancreas within the lienorenal ligament.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The left extremity of the pancreas within the lienorenal ligament. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tail of the Pancreas","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreas Tail","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Tail","termGroup":"SY","termSource":"NCI"},{"termName":"Tail of Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Tail_of_the_Pancreas"},{"name":"Maps_To","value":"Pancreas Tail"},{"name":"Maps_To","value":"Tail of pancreas"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227590"}]}}{"C12353":{"preferredName":"Temporal Lobe","code":"C12353","definitions":[{"definition":"One of the cerebral lobes. It is located inferior to the frontal and parietal lobes and anterior to the occipital lobe.","type":"DEFINITION","source":"NCI"},{"definition":"The second largest of the four cerebral lobes, the temporal lobe is approximately twenty two percent of the total neocortical volume. The temporal lobe can be divided into two main sections: first, the neocortex, comprising its lateral and inferolateral surfaces, and its standard cerebral cortex; and, second, the mesial temporal lobe, which is sometimes referred to as the limbic lobe, and includes the hippocampus, the amygdala, and the parahippocampal gyrus. Grossly, the lobe extends superiorly to the Sylvian fissure, and posteriorly to an imaginary line, the lateral parietotemporal line, which separates the temporal lobe from the inferior parietal lobule superiorly and the occipital lobe inferiorly. The middle cranial fossa forms its anterior and inferior boundaries.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Temporal Lobe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Temporal_Lobe"},{"name":"Maps_To","value":"Brain, Temporal lobe"},{"name":"Maps_To","value":"Temporal lobe"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0039485"}]}}{"C12251":{"preferredName":"Thoracic Esophagus","code":"C12251","definitions":[{"definition":"Clinical esophageal segment composed of smooth muscle. It includes the middle third topographic segment, as well as parts of the upper and lower thirds.","type":"DEFINITION","source":"NCI"},{"definition":"Clinical esophageal segment composed of smooth muscle. It includes the middle third topographic segment, as well as parts of the upper and lower thirds. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thoracic Esophagus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thoracic_Esophagus"},{"name":"Maps_To","value":"Thoracic esophagus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227188"}]}}{"C12799":{"preferredName":"Thorax","code":"C12799","definitions":[{"definition":"Subdivision of trunk proper, which is demarcated from the neck by the plane of the superior thoracic aperture and from the abdomen internally by the inferior surface of the diaphragm and externally by the costal margin and associated with the thoracic vertebral column and ribcage and from the back of the thorax by the external surface of the posterolateral part of the rib cage, the anterior surface of the thoracic vertebral column and the posterior axillary lines; together with the abdomen and the perineum, it constitutes the trunk proper.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The division of the body lying between the neck and the abdomen.","type":"DEFINITION","source":"NCI"},{"definition":"The division of the body lying between the neck and the abdomen. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thorax","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thorax"},{"name":"Maps_To","value":"Thorax"},{"name":"Maps_To","value":"Thorax, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0817096"},{"name":"xRef","value":"UBERON:0001443"}]}}{"C12422":{"preferredName":"Tongue","code":"C12422","definitions":[{"definition":"A muscular organ in the floor of the mouth.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The muscular organ in the mouth used in taste perception and food ingestion.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tongue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tongue"},{"name":"Maps_To","value":"Tongue"},{"name":"Maps_To","value":"Tongue, NOS"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040408"},{"name":"xRef","value":"UBERON:0001723"}]}}{"C33250":{"preferredName":"Palatine Tonsil","code":"C33250","definitions":[{"definition":"A tonsil in the mucosa of the glossopalatine arch of the oropharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Two masses of lymphatic tissue located one on either side of the oropharynx in the oropharyngeal isthmus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palatine Tonsil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palatine_Tonsil"},{"name":"Maps_To","value":"Tonsil, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0040421"}]}}{"C12235":{"preferredName":"Tonsillar Fossa","code":"C12235","definitions":[{"definition":"A triangular shaped space that lies on each side of the oropharynx and houses the palatine tonsils.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillar Fossa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillar_Fossa"},{"name":"Maps_To","value":"Tonsillar fossa"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0229881"}]}}{"C12236":{"preferredName":"Tonsillar Pillar","code":"C12236","definitions":[{"definition":"The anterior and posterior borders of the tonsillar fossa.  They are composed of muscle tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillar Pillar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillar_Pillar"},{"name":"Maps_To","value":"Tonsillar pillar"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0229872"}]}}{"C12385":{"preferredName":"Transverse Colon","code":"C12385","definitions":[{"definition":"The proximal-distal subdivision of colon that runs transversely across the upper part of the abdomen, from the right to the left colic flexure. Continuous with the descending colon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Transverse Colon","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Transverse_Colon"},{"name":"Maps_To","value":"Transverse colon"},{"name":"Maps_To","value":"Transverse Colon"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227386"},{"name":"xRef","value":"UBERON:0001157"}]}}{"C12331":{"preferredName":"Bladder Trigone","code":"C12331","definitions":[{"definition":"The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice.","type":"DEFINITION","source":"NCI"},{"definition":"The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bladder Trigone","termGroup":"PT","termSource":"NCI"},{"termName":"Trigone of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Bladder Trigone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Trigone"},{"name":"Maps_To","value":"Trigone of bladder"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0447586"}]}}{"C12326":{"preferredName":"Undescended Testes","code":"C12326","definitions":[{"definition":"A condition in which one or both testicles fail to move from the abdomen, where they develop before birth, into the scrotum. Undescended testicles may increase the risk for development of testicular cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The failure of one or both testes of a male fetus to descend from the abdomen into the scrotum during the late part of pregnancy. If not surgically corrected in early childhood, males may be at increased risk for testicular cancer later in life.","type":"DEFINITION","source":"NCI"},{"definition":"The persistent failure of one or both testes to descend into the scrotum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Undescended Testes","termGroup":"PT","termSource":"NCI"},{"termName":"Cryptorchidism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Undescended_Testis"},{"name":"Maps_To","value":"Undescended Testis"},{"name":"Maps_To","value":"Undescended testis"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3552639"}]}}{"C48322":{"preferredName":"Primary Site Unknown","code":"C48322","definitions":[{"definition":"Referring to the fact that the original site of growth of a metastatic cancer is unknown or uncertain.","type":"DEFINITION","source":"NCI"},{"definition":"Referring to the fact that the original site of growth of a metastatic cancer is unknown or uncertain. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Primary Site Unknown","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Site_Unknown"},{"name":"Maps_To","value":"Unknown primary site"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709668"}]}}{"C54205":{"preferredName":"Upper Gingiva","code":"C54205","definitions":[{"definition":"The gingiva covering the maxillary alveolar bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper Gingiva","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Gums","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Upper_Gingiva"},{"name":"Maps_To","value":"Upper Gum"},{"name":"Maps_To","value":"Upper gum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227121"}]}}{"C12671":{"preferredName":"Upper Extremity","code":"C12671","definitions":[{"definition":"The part of the forelimb extending from the shoulder to the autopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region of the body that extends distal to the scapulohumeral joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The region of the body that includes the arm, the forearm, and hand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Upper_Extremity"},{"name":"Maps_To","value":"Upper limb, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C1140618"},{"name":"xRef","value":"UBERON:0001460"}]}}{"C12285":{"preferredName":"Upper Lobe of the Lung","code":"C12285","definitions":[{"definition":"The lobe of the right lung that lies above the oblique and horizontal fissures and includes the apical, posterior and anterior bronchopulmonary segments; in the left lung, the lobe lies above the oblique fissure and contains the apicoposterior, anterior, superior lingular and inferior lingular segments.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"Biology-online.org"}]}],"synonyms":[{"termName":"Upper Lobe of the Lung","termGroup":"PT","termSource":"NCI"},{"termName":"Lung Upper Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Lobe, Lung","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Upper_Lobe"},{"name":"Maps_To","value":"Upper lobe, lung"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225756"}]}}{"C33839":{"preferredName":"Upper Respiratory System","code":"C33839","definitions":[{"definition":"The sinuses and those parts of the respiratory system above the trachea. It includes the nares, nasopharynx, oropharynx, larynx, vocal cords, glottis and upper trachea.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The sinuses and those parts of the respiratory system above the trachea. It includes the nares, nasopharynx, oropharynx, larynx, vocal cords, glottis and upper trachea.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper Respiratory System","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Airway","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Upper_Respiratory_System"},{"name":"Maps_To","value":"Upper respiratory tract, NOS"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1519817"}]}}{"C12253":{"preferredName":"Upper Third of the Esophagus","code":"C12253","definitions":[{"definition":"The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type.","type":"DEFINITION","source":"NCI"},{"definition":"The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Upper Third of the Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Upper Third of Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Upper_Third_of_the_Esophagus"},{"name":"Maps_To","value":"Esophageal; Proximal"},{"name":"Maps_To","value":"Esophagus, Upper Third"},{"name":"Maps_To","value":"Upper third of esophagus"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0227187"},{"name":"xRef","value":"UBERON:0013472"}]}}{"C12301":{"preferredName":"Upper-Inner Quadrant of the Breast","code":"C12301","definitions":[{"definition":"The quarter of the breast which is superior and medial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper-Inner Quadrant of the Breast","termGroup":"PT","termSource":"NCI"},{"termName":"Upper-Inner Quadrant of Breast","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Upper-inner_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Upper-inner quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222596"}]}}{"C12303":{"preferredName":"Upper-Outer Quadrant of the Breast","code":"C12303","definitions":[{"definition":"The quarter of the breast which is superior and lateral.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upper-Outer Quadrant of the Breast","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Upper-outer_Quadrant_of_the_Breast"},{"name":"Maps_To","value":"Upper-outer quadrant of breast"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0222598"}]}}{"C12338":{"preferredName":"Urachus","code":"C12338","definitions":[{"definition":"A cord of fibrous tissue that extends from the urinary bladder to the umbilicus. The urachus is a remnant of the fetal urinary canal.","type":"DEFINITION","source":"NCI"},{"definition":"A cord of fibrous tissue that extends from the urinary bladder to the umbilicus; the urachus is a remnant of the fetal urinary canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A fibrous cord that connects the urinary bladder to the umbilicus (navel).  The urachus is formed as the allantoic stalk during fetal development and lasts through life.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Urachus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urachus"},{"name":"Maps_To","value":"Urachus"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0041916"}]}}{"C12337":{"preferredName":"Ureteric Orifice","code":"C12337","definitions":[{"definition":"The opening of the ureter in the bladder that is situated at the lateral angle of the trigone.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The opening of the ureter in the bladder that is situated at the lateral angle of the trigone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ureteric Orifice","termGroup":"PT","termSource":"NCI"},{"termName":"Orifice of the Ureter","termGroup":"SY","termSource":"NCI"},{"termName":"Ureteral Opening","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ureteric_Orifice"},{"name":"Maps_To","value":"Ureteric orifice"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0447577"}]}}{"C12413":{"preferredName":"Urinary System","code":"C12413","definitions":[{"definition":"The organs involved in the creation and excretion of urine.","type":"DEFINITION","source":"NCI"},{"definition":"The organs involved in the creation and excretion of urine. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The organs that make urine and remove it from the body. The urinary tract is divided into two parts. The upper urinary tract includes the kidneys and ureters. The lower urinary tract includes the bladder and urethra. The kidneys remove waste and extra fluid from the blood to make urine. The urine flows from the kidneys through the ureters to the bladder. It is stored in the bladder until it leaves the body through the urethra.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Urinary System","termGroup":"PT","termSource":"NCI"},{"termName":"Body System, Renal/Urologic","termGroup":"SY","termSource":"NCI"},{"termName":"Organ System, Renal/Urologic","termGroup":"SY","termSource":"NCI"},{"termName":"Renal/Urologic Body System","termGroup":"SY","termSource":"NCI"},{"termName":"Renal/Urologic Organ System","termGroup":"SY","termSource":"NCI"},{"termName":"Urologic/Renal Body System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urinary_System"},{"name":"Maps_To","value":"Urinary system, NOS"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C1508753"},{"name":"xRef","value":"IMDRF:E13"}]}}{"C12232":{"preferredName":"Uvula","code":"C12232","definitions":[{"definition":"Conic projection from the posterior edge of the middle of the soft palate, composed of connective tissue containing a number of racemose glands, and some muscular fibers.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fleshy lobe that hangs at the back of the soft palate.","type":"DEFINITION","source":"NCI"},{"definition":"The fleshy lobe that is suspended from the back of the soft palate in the oral cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The soft flap of tissue that hangs down at the back of the mouth (at the edge of the soft palate).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Uvula","termGroup":"PT","termSource":"NCI"},{"termName":"Palatine Uvula","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Uvula"},{"name":"Maps_To","value":"Uvula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042173"},{"name":"xRef","value":"UBERON:0001734"}]}}{"C12237":{"preferredName":"Vallecula","code":"C12237","definitions":[{"definition":"A groove between the base of the tongue and the epiglottis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vallecula","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vallecula"},{"name":"Maps_To","value":"Vallecula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0227157"}]}}{"C12356":{"preferredName":"Brain Ventricle","code":"C12356","definitions":[{"definition":"The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Brain Ventricle","termGroup":"PT","termSource":"NCI"},{"termName":"Ventricle","termGroup":"SY","termSource":"NCI"},{"termName":"Ventricle of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Ventricle, Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Ventricles, Brain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Ventricle_Brain"},{"name":"Maps_To","value":"Brain, Ventricle, NOS"},{"name":"Maps_To","value":"Ventricle, NOS"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0007799"}]}}{"C12998":{"preferredName":"Vertebral Column","code":"C12998","definitions":[{"definition":"A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"Subdivision of skeletal system that consists of all the vertebra and associated skeletal elements and joints in the body.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bones, muscles, tendons, and other tissues that reach from the base of the skull to the tailbone. The spinal column encloses the spinal cord and the fluid surrounding the spinal cord.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The series of vertebrae and other tissues extending from the skull to the last tailbone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Vertebral Column","termGroup":"PT","termSource":"NCI"},{"termName":"Spinal Column","termGroup":"SY","termSource":"NCI"},{"termName":"Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vertebral_Column"},{"name":"Maps_To","value":"Spinal Column"},{"name":"Maps_To","value":"Spine"},{"name":"Maps_To","value":"Vertebral column"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037949"},{"name":"xRef","value":"UBERON:0001130"}]}}{"C165195":{"preferredName":"Vestibule of Mouth","code":"C165195","definitions":[{"definition":"The area inside the mouth between the cheek or lips, and the teeth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vestibule of Mouth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vestibule of mouth"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0226897"}]}}{"C73468":{"preferredName":"Waldeyer Ring","code":"C73468","definitions":[{"definition":"The ring of lymphoid tissue located in the pharynx, consisting of the pharyngeal, tubal, palatine, and lingual tonsils.","type":"DEFINITION","source":"NCI"},{"definition":"The ring of lymphoid tissue located in the pharynx, consisting of the pharyngeal, tubal, palatine, and lingual tonsils. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Waldeyer Ring","termGroup":"PT","termSource":"NCI"},{"termName":"Waldeyer Tonsillar Ring","termGroup":"SY","termSource":"NCI"},{"termName":"Waldeyer's Ring","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Waldeyers_Tonsillar_Ring"},{"name":"Maps_To","value":"Waldeyer ring"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0459892"}]}}{"C12443":{"preferredName":"Cerebral Cortex","code":"C12443","definitions":[{"definition":"The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers. It is responsible for memory, attention, consciousness and other higher levels of mental function.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers. It is responsible for memory, attention, consciousness and other higher levels of mental function.","type":"DEFINITION","source":"NCI"},{"definition":"The thin layer of gray matter on the surface of the cerebral hemisphere that develops from the telencephalon. It consists of the neocortex (6 layered cortex or isocortex), the hippocampal formation and the olfactory cortex.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Cerebral Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Cortex","termGroup":"SY","termSource":"NCI"},{"termName":"Cortical","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Cortex"},{"name":"Maps_To","value":"Cerebral Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007776"},{"name":"xRef","value":"UBERON:0000956"}]}}{"C158080":{"preferredName":"Deep Gray Matter","code":"C158080","definitions":[{"definition":"The gray matter that includes the basal ganglia and/or thalamus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Gray Matter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deep Gray (e.g. Basal Ganglia, Thalamus)"},{"name":"NCI_META_CUI","value":"CL937697"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C33892":{"preferredName":"White Matter","code":"C33892","definitions":[{"definition":"The nerve tissue forming the bulk of the deep parts of the brain and the superficial parts of the spinal cord. It is composed of nerve cell processes, i.e. extensions (axons), which connect various gray matter areas of the brain to each other and carry nerve impulses to and from the nerve cell bodies within the central nervous system (neurons). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The nerve tissue forming the bulk of the deep parts of the brain and the superficial parts of the spinal cord. It is composed of nerve cell processes, i.e. extensions (axons), which connect various grey matter areas of the brain to each other and carry nerve impulses to and from the nerve cell bodies within the central nervous system (neurons). Cerebral and spinal white matter does not contain dendrites. White matter is distinguished in that it is composed of axonal nerve fibers covered by a myelin sheath.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"White Matter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"White_Matter"},{"name":"Maps_To","value":"White Matter"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0682708"}]}}{"C38757":{"preferredName":"Negative Finding","code":"C38757","definitions":[{"definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","type":"DEFINITION","source":"NCI"},{"definition":"An indication of a negative finding for a test or assessment, such as for a disease, condition, analyte, or microorganism.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"COVID-19 test negative and no symptoms to suggest COVID-19","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]}],"synonyms":[{"termName":"Negative Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Negative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Negative_Finding"},{"name":"Maps_To","value":"Negative"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0205160"}]}}{"C160996":{"preferredName":"Transglottic Extension of Laryngeal Tumor","code":"C160996","definitions":[{"definition":"Extension of a laryngeal tumor beyond the glottic opening into the ventricles and vocal cords.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transglottic Extension of Laryngeal Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"NCI_META_CUI","value":"CL970016"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25253":{"preferredName":"Multifocal","code":"C25253","definitions":[{"definition":"Arising from, pertaining to, or having many locations.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Arising from, pertaining to, or having many locations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multifocal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Multifocal"},{"name":"Maps_To","value":"Multifocal"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205292"}]}}{"C47862":{"preferredName":"Unifocal","code":"C47862","definitions":[{"definition":"Arising from, pertaining to, or having a single location.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unifocal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unifocal"},{"name":"Maps_To","value":"Unifocal"},{"name":"NCI_META_CUI","value":"CL448715"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C28077":{"preferredName":"Grade 1","code":"C28077","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is well differentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 1","termGroup":"PT","termSource":"NCI"},{"termName":"G1","termGroup":"SY","termSource":"NCI"},{"termName":"Grade I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Grade_1"},{"name":"Maps_To","value":"G1"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0687695"}]}}{"C28078":{"preferredName":"Grade 2","code":"C28078","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is moderately differentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"G2","termGroup":"SY","termSource":"NCI"},{"termName":"Grade II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Grade_2"},{"name":"Maps_To","value":"G2"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1522446"}]}}{"C28079":{"preferredName":"Grade 3","code":"C28079","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is poorly differentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"G3","termGroup":"SY","termSource":"NCI"},{"termName":"Grade III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Grade_3"},{"name":"Maps_To","value":"G3"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0450094"}]}}{"C28082":{"preferredName":"Grade 4","code":"C28082","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that a cancerous lesion is undifferentiated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that a cancerous lesion is undifferentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade 4","termGroup":"PT","termSource":"NCI"},{"termName":"G4","termGroup":"SY","termSource":"NCI"},{"termName":"Grade IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Grade_4"},{"name":"Maps_To","value":"G4"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C0547054"}]}}{"C113730":{"preferredName":"Grade X","code":"C113730","definitions":[{"definition":"A morphologic qualifier by the American Joint Cancer Committee (AJCC) indicating that the grade of a cancerous lesion cannot be assessed.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade X","termGroup":"PT","termSource":"NCI"},{"termName":"Grade Cannot Be Assessed","termGroup":"SY","termSource":"NCI"},{"termName":"GX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GX"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3814800"}]}}{"C113729":{"preferredName":"Grade B","code":"C113729","definitions":[{"definition":"A morphologic qualifier indicating that a neoplasm is of borderline malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grade B","termGroup":"PT","termSource":"NCI"},{"termName":"Borderline Grade","termGroup":"SY","termSource":"NCI"},{"termName":"GB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GB"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3714906"}]}}{"C14158":{"preferredName":"High Grade","code":"C14158","definitions":[{"definition":"A term used to describe cells that look abnormal under a microscope. These cells are more likely to grow and spread quickly than cells in low-grade cancer or in growths that may become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"High_Grade"},{"name":"Maps_To","value":"High Grade"},{"name":"NCI_META_CUI","value":"CL378245"},{"name":"Semantic_Type","value":"Classification"}]}}{"C28083":{"preferredName":"Intermediate Grade","code":"C28083","definitions":[{"definition":"A term referring to the degree of differentiation of a malignant neoplasm and indicating that it is moderately differentiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermediate Grade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Intermediate_Grade"},{"name":"Maps_To","value":"Intermediate Grade"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1512863"}]}}{"C14161":{"preferredName":"Low Grade","code":"C14161","definitions":[{"definition":"A term used to describe cells that look nearly normal under a microscope. These cells are less likely to grow and spread more quickly than cells in high-grade cancer or in growths that may become cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Low_Grade"},{"name":"Maps_To","value":"Low Grade"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1282907"}]}}{"C155941":{"preferredName":"Tumor Regression Score 0","code":"C155941","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a complete response, defined as having no viable cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0"},{"name":"NCI_META_CUI","value":"CL562793"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C155942":{"preferredName":"Tumor Regression Score 1","code":"C155942","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a near complete response, defined as the presence of single cells or rare small groups of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1"},{"name":"NCI_META_CUI","value":"CL562794"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C155943":{"preferredName":"Tumor Regression Score 2","code":"C155943","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a partial response, defined as the presence of residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2"},{"name":"NCI_META_CUI","value":"CL562795"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C155944":{"preferredName":"Tumor Regression Score 3","code":"C155944","definitions":[{"definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates poor or no response, defined as extensive residual cancer with no evident tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Regression Score 3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3"},{"name":"NCI_META_CUI","value":"CL562817"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C44280":{"preferredName":"External","code":"C44280","definitions":[{"definition":"Happening or arising or located outside or beyond some limits, or especially, some surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"External","termGroup":"PT","termSource":"NCI"},{"termName":"Exogenous","termGroup":"AD","termSource":"NCI"},{"termName":"Externally","termGroup":"AD","termSource":"NCI"},{"termName":"Extramural","termGroup":"SY","termSource":"NCI"},{"termName":"Outside","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"External"},{"name":"Maps_To","value":"Extramural"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205101"}]}}{"C25234":{"preferredName":"Internal","code":"C25234","definitions":[{"definition":"Happening or arising or located within some limits, or especially, within some surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Internal","termGroup":"PT","termSource":"NCI"},{"termName":"Internally","termGroup":"AD","termSource":"NCI"},{"termName":"Intramural","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Internal"},{"name":"Maps_To","value":"Intramural"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205102"}]}}{"C43566":{"preferredName":"Gross","code":"C43566","definitions":[{"definition":"Visible to the naked eye.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gross","termGroup":"PT","termSource":"NCI"},{"termName":"Macroscopic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gross"},{"name":"Maps_To","value":"Macro"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0439806"}]}}{"C164046":{"preferredName":"Vascular Invasion Negative","code":"C164046","definitions":[{"definition":"An indication that signs of vascular invasion have not been found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Invasion Negative","termGroup":"PT","termSource":"NCI"},{"termName":"No Vascular Invasion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Vascular Invasion"},{"name":"NCI_META_CUI","value":"CL977185"},{"name":"Semantic_Type","value":"Finding"}]}}{"C66832":{"preferredName":"One","code":"C66832","definitions":[{"definition":"A textual representation of the numeral 1.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The smallest natural number and quantity it denotes: a single entity, unit, or object.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"One","termGroup":"PT","termSource":"NCI"},{"termName":"1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"One"},{"name":"Maps_To","value":"1"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205447"}]}}{"C66833":{"preferredName":"Two","code":"C66833","definitions":[{"definition":"A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Two","termGroup":"PT","termSource":"NCI"},{"termName":"2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Two"},{"name":"Maps_To","value":"2"},{"name":"NCI_META_CUI","value":"CL938172"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C66834":{"preferredName":"Three","code":"C66834","definitions":[{"definition":"A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Three","termGroup":"PT","termSource":"NCI"},{"termName":"3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Three"},{"name":"Maps_To","value":"3"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205449"}]}}{"C66835":{"preferredName":"Four","code":"C66835","definitions":[{"definition":"A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Four","termGroup":"PT","termSource":"NCI"},{"termName":"4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Four"},{"name":"Maps_To","value":"4"},{"name":"NCI_META_CUI","value":"CL938173"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C66836":{"preferredName":"Five","code":"C66836","definitions":[{"definition":"A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Five","termGroup":"PT","termSource":"NCI"},{"termName":"5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Five"},{"name":"Maps_To","value":"5"},{"name":"NCI_META_CUI","value":"CL938174"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C66837":{"preferredName":"Six","code":"C66837","definitions":[{"definition":"A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Six","termGroup":"PT","termSource":"NCI"},{"termName":"6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Six"},{"name":"Maps_To","value":"6"},{"name":"NCI_META_CUI","value":"CL1378607"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C66838":{"preferredName":"Seven","code":"C66838","definitions":[{"definition":"A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seven","termGroup":"PT","termSource":"NCI"},{"termName":"7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Seven"},{"name":"Maps_To","value":"7"},{"name":"NCI_META_CUI","value":"CL1407116"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C66839":{"preferredName":"Eight","code":"C66839","definitions":[{"definition":"A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eight","termGroup":"PT","termSource":"NCI"},{"termName":"8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eight"},{"name":"Maps_To","value":"8"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205454"}]}}{"C66840":{"preferredName":"Nine","code":"C66840","definitions":[{"definition":"A natural number greater than 8 and less than 10 and the quantity that it denotes: the sum of nine and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nine","termGroup":"PT","termSource":"NCI"},{"termName":"9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nine"},{"name":"Maps_To","value":"9"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205455"}]}}{"C62394":{"preferredName":"WHO Central Nervous System Grade 1","code":"C62394","definitions":[{"definition":"Describes central nervous system tumors that are generally low malignancy, non-infiltrative, and slow growing. Often they can be cured by surgery alone and there is a good chance of long term survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 1","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_I"},{"name":"Maps_To","value":"Grade I"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883546"}]}}{"C62395":{"preferredName":"WHO Central Nervous System Grade 2","code":"C62395","definitions":[{"definition":"Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 2","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_II"},{"name":"Maps_To","value":"Grade II"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883547"}]}}{"C62396":{"preferredName":"WHO Central Nervous System Grade 3","code":"C62396","definitions":[{"definition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 3","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_III"},{"name":"Maps_To","value":"Grade III"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883548"}]}}{"C62397":{"preferredName":"WHO Central Nervous System Grade 4","code":"C62397","definitions":[{"definition":"Describes central nervous system tumors that are generally highly malignant, show rapid and aggressive growth, widely infiltrative, and prone to necrosis. They often recur rapidly after treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WHO Central Nervous System Grade 4","termGroup":"PT","termSource":"NCI"},{"termName":"WHO Central Nervous System Grade IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WHO_CNS_Grade_IV"},{"name":"Maps_To","value":"Grade IV"},{"name":"Semantic_Type","value":"Classification"},{"name":"UMLS_CUI","value":"C1883549"}]}}{"C203250":{"preferredName":"Neuroendocrine Tumor G1","code":"C203250","definitions":[{"definition":"A well-differentiated, low-grade epithelial neoplasm with neuroendocrine differentiation. It arises from multiple sites, including the digestive system, lung, and head and neck.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Tumor G1","termGroup":"PT","termSource":"NCI"},{"termName":"NET G1","termGroup":"AB","termSource":"NCI"},{"termName":"Neuroendocrine Tumor Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Benign carcinoid tumor of unknown primary site"},{"name":"Maps_To","value":"Benign carcinoid tumor of unspecified site"},{"name":"Maps_To","value":"G1"},{"name":"Maps_To","value":"Other benign neuroendocrine tumors"},{"name":"NCI_META_CUI","value":"CL1921979"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C203251":{"preferredName":"Neuroendocrine Tumor G3","code":"C203251","definitions":[{"definition":"A well-differentiated, high-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Tumor G3","termGroup":"PT","termSource":"NCI"},{"termName":"NET G3","termGroup":"AB","termSource":"NCI"},{"termName":"Neuroendocrine Tumor Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"G3"},{"name":"NCI_META_CUI","value":"CL1921992"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C165216":{"preferredName":"Experiment Metadata","code":"C165216","definitions":[{"definition":"Supporting information that describes the experimental design in a study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Experiment Metadata","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Experiment Metadata"},{"name":"NCI_META_CUI","value":"CL978398"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C126383":{"preferredName":"Drinker","code":"C126383","definitions":[{"definition":"An individual who drinks at least once per week with regularity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Drinker","termGroup":"PT","termSource":"NCI"},{"termName":"Regular Drinker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Drinker"},{"name":"NCI_META_CUI","value":"CL504931"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C126384":{"preferredName":"Heavy Drinker","code":"C126384","definitions":[{"definition":"A man who drinks more than 14 standard drinks per week or a woman who drinks more than 7 standard drinks per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heavy Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heavy Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0337678"}]}}{"C126380":{"preferredName":"Lifelong Non-Drinker","code":"C126380","definitions":[{"definition":"An individual who does not drink at the present time and who claims that they have never been a drinker.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifelong Non-Drinker","termGroup":"PT","termSource":"NCI"},{"termName":"Teetotaller","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lifelong Non-Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0457801"}]}}{"C126379":{"preferredName":"Non-Drinker","code":"C126379","definitions":[{"definition":"An individual who does not drink at the present time. This is a heterogeneous group comprising both lifelong teetotallers and ex-drinkers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Drinker","termGroup":"PT","termSource":"NCI"},{"termName":"Abstainer","termGroup":"SY","termSource":"NCI"},{"termName":"Nondrinker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Drinker"},{"name":"NCI_META_CUI","value":"CL504930"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C126382":{"preferredName":"Occasional Drinker","code":"C126382","definitions":[{"definition":"An individual who drinks from time to time, but generally less than once per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occasional Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Occasional Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0556298"}]}}{"C156429":{"preferredName":"Social Drinker","code":"C156429","definitions":[{"definition":"An individual who generally only drinks at social events.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Social Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0337676"}]}}{"C66824":{"preferredName":"Beer","code":"C66824","definitions":[{"definition":"A carbonated alcoholic beverage made through the fermentation of sugars derived from malted grains; this beverage is usually flavored with hops but other herbs or fruit may be used to enhance its flavor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beer"},{"name":"Maps_To","value":"Beer"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C0004922"}]}}{"C66826":{"preferredName":"Liquor","code":"C66826","definitions":[{"definition":"An alcoholic beverage in which the initial fermentation mixture is distilled in order to concentrate the alcohol, generally resulting in a mixture that is at least 35% alcohol by volume.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liquor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liquor"},{"name":"Maps_To","value":"Liquor"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C0301611"}]}}{"C66822":{"preferredName":"Wine","code":"C66822","definitions":[{"definition":"An alcoholic beverage created from fermented juice of fresh grapes or of other fruit or plant products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"877011-55-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"13TE483N5I"},{"name":"Legacy Concept Name","value":"Wine"},{"name":"Maps_To","value":"Wine"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C0043188"}]}}{"C171137":{"preferredName":"Time of Exposure of Six Weeks or More","code":"C171137","definitions":[{"definition":"A response indicating that a subject was exposed to a potentially hazardous substance for six weeks or more.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time of Exposure of Six Weeks or More","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Six Weeks or More"},{"name":"NCI_META_CUI","value":"CL1405366"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C26659":{"preferredName":"Marijuana","code":"C26659","definitions":[{"definition":"Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The dried leaves and flowering tops of the Cannabis sativa plant, or an extract from the plant. Marijuana is being studied in the treatment of nausea and vomiting caused by chemotherapy or opiate drugs, such as morphine sulfate. Marijuana is also being studied in the treatment of pain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Marijuana","termGroup":"PT","termSource":"NCI"},{"termName":"Cannabis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FTS5RM302N"},{"name":"Legacy Concept Name","value":"Marijuana"},{"name":"Maps_To","value":"Marijuana"},{"name":"NCI_Drug_Dictionary_ID","value":"269131"},{"name":"NSC Number","value":"134452"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269131"},{"name":"PDQ_Open_Trial_Search_ID","value":"269131"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C0024808"}]}}{"C164057":{"preferredName":"Smoke Exposure","code":"C164057","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoke"},{"name":"Maps_To","value":"Smoke exposure, NOS"},{"name":"NCI_META_CUI","value":"CL977206"},{"name":"Semantic_Type","value":"Finding"}]}}{"C891":{"preferredName":"Tobacco","code":"C891","definitions":[{"definition":"A plant with leaves that have high levels of the addictive chemical nicotine. The leaves may be smoked (in cigarettes, cigars, and pipes), applied to the gums (as dipping and chewing tobacco), or inhaled (as snuff). Tobacco leaves also contain many cancer-causing chemicals, and tobacco use and exposure to secondhand tobacco smoke have been linked to many types of cancer and other diseases. The scientific name is Nicotiana tabacum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The dried cured leaves of the tobacco plant, Nicotiana tabacum, used for smoking, chewing, or snuff.  Tobacco contains nicotine, a stimulant, and other biologically active ingredients having carcinogenic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"8037-19-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YR2608RSU"},{"name":"Legacy Concept Name","value":"Tobacco"},{"name":"Maps_To","value":"Tobacco"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C0040329"}]}}{"C174115":{"preferredName":"Wood Dust Exposure","code":"C174115","definitions":[{"definition":"Environmental or occupational exposure to granular solids generated when timber is processed, such as when it is chipped, sawed, turned, drilled or sanded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wood Dust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood Dust"},{"name":"NCI_META_CUI","value":"CL1407785"},{"name":"Semantic_Type","value":"Finding"}]}}{"C61398":{"preferredName":"Radiation Exposure","code":"C61398","definitions":[{"definition":"Exposure to radioactive materials or ionizing radiation, whether by external irradiation, contact or contamination with radioactive material, or incorporation of radioactive materials, as in the case of certain diagnostic procedures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiation Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiation_Exposure"},{"name":"Maps_To","value":"Radiation"},{"name":"Semantic_Type","value":"Phenomenon or Process"},{"name":"UMLS_CUI","value":"C0015333"}]}}{"C55816":{"preferredName":"Asbestos Exposure","code":"C55816","definitions":[{"definition":"Inhalation of asbestos fibers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asbestos Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Asbestos_Exposure"},{"name":"Maps_To","value":"Asbestos"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0003948"}]}}{"C36290":{"preferredName":"Chemical Exposure","code":"C36290","definitions":[{"definition":"Contact with a chemical substance through touch, inhalation, or ingestion.","type":"DEFINITION","source":"NCI"},{"definition":"Contact with a chemical substance through touch, inhalation, or ingestion.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Chemical Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Chemical_Exposure"},{"name":"Maps_To","value":"Chemical"},{"name":"Maps_To","value":"Chemical Exposure, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0678803"},{"name":"Use_For","value":"Chemical Contamination"},{"name":"Use_For","value":"Contamination, Chemical"},{"name":"xRef","value":"IMDRF:E2003"}]}}{"C177573":{"preferredName":"Radon Exposure","code":"C177573","definitions":[{"definition":"Inhalation of radon gas which is found in rocks, soil and groundwater as a result of radioactive decay of uranium, thorium, or radium in the environment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radon Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radon"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0681792"}]}}{"C177575":{"preferredName":"Respirable Crystalline Silica Exposure","code":"C177575","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to respirable particles derived from industrial processing or breakdown of silica-containing materials such as sand, concrete, stone, mortar, bricks,  glass, pottery and ceramics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Respirable Crystalline Silica Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Respirable Crystalline Silica"},{"name":"NCI_META_CUI","value":"CL1643425"},{"name":"Semantic_Type","value":"Finding"}]}}{"C189768":{"preferredName":"Smokeless Tobacco Exposure","code":"C189768","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to any smokeless tobacco product.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokeless Tobacco Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smokeless Tobacco"},{"name":"NCI_META_CUI","value":"CL1798656"},{"name":"Semantic_Type","value":"Finding"}]}}{"C177574":{"preferredName":"Coal Dust Exposure","code":"C177574","definitions":[{"definition":"Environmental or occupational exposure to dust derived during the processing of coal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coal Dust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coal Dust"},{"name":"Maps_To","value":"Coal Gas, Coal Tar, Coal Tar Pitch, and Derivatives"},{"name":"NCI_META_CUI","value":"CL1643423"},{"name":"Semantic_Type","value":"Finding"}]}}{"C200417":{"preferredName":"Dust Exposure","code":"C200417","definitions":[{"definition":"Exposure to any type of airborne particulate matter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dust, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0239200"}]}}{"C67145":{"preferredName":"Current Every Day Smoker","code":"C67145","definitions":[{"definition":"Indicates a person who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes every day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Every Day Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Daily Smoker","termGroup":"SY","termSource":"NCI"},{"termName":"Every Day Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Current_Every_Day_Smoker"},{"name":"Maps_To","value":"Every day"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C3266136"}]}}{"C67146":{"preferredName":"Current Some Day Smoker","code":"C67146","definitions":[{"definition":"Indicates a person who has smoked at least 100 cigarettes in his or her lifetime, who smokes now, but does not smoke every day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Some Day Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Chipper","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Daily Smoker","termGroup":"SY","termSource":"NCI"},{"termName":"Occasional Smoker","termGroup":"SY","termSource":"NCI"},{"termName":"Some Day Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Current_Some_Day_Smoker"},{"name":"Maps_To","value":"Some days"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1880200"}]}}{"C164121":{"preferredName":"Time Between Waking and First Smoke - Within 5 Minutes","code":"C164121","definitions":[{"definition":"An indication that less than 5 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - Within 5 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Within 5 Minutes"},{"name":"NCI_META_CUI","value":"CL977379"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164124":{"preferredName":"Time Between Waking and First Smoke - Between 6 and 30 Minutes","code":"C164124","definitions":[{"definition":"An indication that between 6 and 30 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - Between 6 and 30 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6-30 Minutes"},{"name":"NCI_META_CUI","value":"CL977377"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164126":{"preferredName":"Time Between Waking and First Smoke - Between 31 and 60 Minutes","code":"C164126","definitions":[{"definition":"An indication that between 31 and 60 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - Between 31 and 60 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"31-60 Minutes"},{"name":"NCI_META_CUI","value":"CL977376"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164127":{"preferredName":"Time Between Waking and First Smoke - After 60 Minutes","code":"C164127","definitions":[{"definition":"An indication that more than 60 minutes passes between waking and smoking the first cigarette of the day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Time Between Waking and First Smoke - After 60 Minutes","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"After 60 Minutes"},{"name":"NCI_META_CUI","value":"CL977375"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C65108":{"preferredName":"Never Smoker","code":"C65108","definitions":[{"definition":"A person who has never smoked at the time of the interview or has smoked less than 100 cigarettes in their life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Never Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Never Smoked","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Never_Smoker"},{"name":"Maps_To","value":"Lifelong Non-Smoker"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0425293"}]}}{"C67147":{"preferredName":"Current Smoker","code":"C67147","definitions":[{"definition":"An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes. Includes daily smokers and non-daily smokers (also known as occasional smokers).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Smoker","termGroup":"PT","termSource":"NCI"},{"termName":"Smoker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Current_Smoker"},{"name":"Maps_To","value":"Current Smoker"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C3241966"}]}}{"C156828":{"preferredName":"Current Reformed Smoker, More than 15 Years","code":"C156828","definitions":[{"definition":"An individual who stopped smoking more than 15 years prior.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Reformed Smoker, More than 15 Years","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current Reformed Smoker for > 15 yrs"},{"name":"NCI_META_CUI","value":"CL935830"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C156829":{"preferredName":"Current Reformed Smoker Within Past 15 Years","code":"C156829","definitions":[{"definition":"An individual who stopped smoking within the past 15 years.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Reformed Smoker Within Past 15 Years","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current Reformed Smoker for < or = 15 yrs"},{"name":"NCI_META_CUI","value":"CL935827"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C156830":{"preferredName":"Current Reformed Smoker, Years Unknown","code":"C156830","definitions":[{"definition":"An individual who stopped smoking an unknown number of years prior.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Reformed Smoker, Years Unknown","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current Reformed Smoker, Duration Not Specified"},{"name":"NCI_META_CUI","value":"CL935828"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C164079":{"preferredName":"Smoking at Diagnosis","code":"C164079","definitions":[{"definition":"An indication that a person was a smoker at the time they received a pathologic diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoking at Diagnosis","termGroup":"PT","termSource":"NCI"},{"termName":"Smoker at Diagnosis","termGroup":"SY","termSource":"NCI"},{"termName":"Smoker at Time of Diagnosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoker at Diagnosis"},{"name":"NCI_META_CUI","value":"CL979291"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C163971":{"preferredName":"Smoking Status Not Documented","code":"C163971","definitions":[{"definition":"Indicates that a person's smoking status has not been recorded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoking Status Not Documented","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoking history not documented"},{"name":"NCI_META_CUI","value":"CL979297"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C164066":{"preferredName":"Accidental Building Fire Smoke Exposure","code":"C164066","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a building fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Building Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental building fire smoke"},{"name":"NCI_META_CUI","value":"CL977400"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164067":{"preferredName":"Accidental Grass Fire Smoke Exposure","code":"C164067","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a grass fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Grass Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental fire smoke, grass"},{"name":"NCI_META_CUI","value":"CL977399"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164059":{"preferredName":"Accidental Fire Smoke Exposure","code":"C164059","definitions":[{"definition":"Environmental exposure to airborne gases and particulates produced during a fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental fire smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977204"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164068":{"preferredName":"Accidental Forest Fire Smoke Exposure","code":"C164068","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a forest fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Forest Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental forest fire smoke"},{"name":"NCI_META_CUI","value":"CL977398"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164069":{"preferredName":"Accidental Vehicle Fire Smoke Exposure","code":"C164069","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during a vehicle fire that was not caused by deliberate human actions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Accidental Vehicle Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accidental vehicle fire smoke"},{"name":"NCI_META_CUI","value":"CL977397"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164072":{"preferredName":"Aircraft Smoke Exposure","code":"C164072","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when an aircraft is in operation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aircraft Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aircraft smoke"},{"name":"NCI_META_CUI","value":"CL977394"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164075":{"preferredName":"Burning Tree Smoke Exposure","code":"C164075","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when trees are undergoing combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Tree Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Burning tree smoke"},{"name":"NCI_META_CUI","value":"CL977392"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164060":{"preferredName":"Coal Smoke Exposure","code":"C164060","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when coal is rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coal Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coal smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977203"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164061":{"preferredName":"Cooking-Related Smoke Exposure","code":"C164061","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to vaporized materials produced when food products are being cooked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cooking-Related Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cooking-related smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977202"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164077":{"preferredName":"Electrical Fire Smoke Exposure","code":"C164077","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced during an electrical fire.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electrical Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrical fire smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977390"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164062":{"preferredName":"Electronic Cigarette Smoke Exposure","code":"C164062","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of an electronic cigarette.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electronic Cigarette Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"e-Cigarette Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electronic cigarette smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977201"},{"name":"Semantic_Type","value":"Finding"}]}}{"C17140":{"preferredName":"Passive Smoke Exposure","code":"C17140","definitions":[{"definition":"Exposure to tobacco smoke products among individuals who do not smoke. This can result from sharing space with a smoker or from placental transfer from mother to fetus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Passive Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Passive Smoking","termGroup":"SY","termSource":"NCI"},{"termName":"Smoking, Passive","termGroup":"SY","termSource":"NCI"},{"termName":"Smoking, Tobacco and Cancer-Passive Smoking","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Passive_Smoke_Exposure"},{"name":"Maps_To","value":"Environmental tobacco smoke"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0037370"}]}}{"C164081":{"preferredName":"Factory Smokestack Smoke Exposure","code":"C164081","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates emitted by a factory smokestack.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Factory Smokestack Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Factory Smokestack Emission Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Factory smokestack smoke"},{"name":"NCI_META_CUI","value":"CL977387"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164082":{"preferredName":"Field Burning Smoke Exposure","code":"C164082","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when trees, brush and grass in a field are burning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Field Burning Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Field burning smoke"},{"name":"NCI_META_CUI","value":"CL977415"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164058":{"preferredName":"Fire Smoke Exposure","code":"C164058","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when materials are rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fire smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977205"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164083":{"preferredName":"Furnace or Boiler Smoke Exposure","code":"C164083","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates emitted by a boiler or furnace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Furnace or Boiler Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Furnace or boiler smoke"},{"name":"NCI_META_CUI","value":"CL977414"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164084":{"preferredName":"Propane Smoke Exposue","code":"C164084","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when propane is rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Propane Smoke Exposue","termGroup":"PT","termSource":"NCI"},{"termName":"Burning Propane Smoke Exposue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gas burning smoke, propane"},{"name":"NCI_META_CUI","value":"CL977413"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164085":{"preferredName":"Grease Fire Smoke Exposure","code":"C164085","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced during a grease fire.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grease Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grease fire smoke"},{"name":"NCI_META_CUI","value":"CL977412"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164086":{"preferredName":"Grilling Smoke Exposure","code":"C164086","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates emitted by an indoor or outdoor grill used for cooking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grilling Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grilling smoke"},{"name":"NCI_META_CUI","value":"CL977411"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164087":{"preferredName":"Hashish Smoke Exposure","code":"C164087","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted product made from cannabis plant resin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hashish Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hashish smoke"},{"name":"NCI_META_CUI","value":"CL979270"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164088":{"preferredName":"Coal-Burining Indoor Stove or Fireplace Smoke Exposure","code":"C164088","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when coal is subjected to combustion in an indoor stove or fireplace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coal-Burining Indoor Stove or Fireplace Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Indoor Coal-Burining Stove or Fireplace Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indoor stove or fireplace smoke, coal burning"},{"name":"NCI_META_CUI","value":"CL977410"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164064":{"preferredName":"Indoor Stove or Fireplace Smoke Exposure","code":"C164064","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when materials are subjected to combustion in an indoor stove or fireplace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indoor Stove or Fireplace Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indoor stove or fireplace smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977199"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164089":{"preferredName":"Wood-Burning Indoor Stove or Fireplace Smoke Exposure","code":"C164089","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when wood is subjected to combustion in an indoor stove or fireplace.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wood-Burning Indoor Stove or Fireplace Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Indoor Wood-Burning Stove or Fireplace Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Indoor stove or fireplace smoke, wood burning"},{"name":"NCI_META_CUI","value":"CL977409"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164090":{"preferredName":"Machine Smoke Exposure","code":"C164090","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates through the direct or nearby use of a machine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Machine Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Machine smoke"},{"name":"NCI_META_CUI","value":"CL977408"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164091":{"preferredName":"Marijuana Smoke Exposure","code":"C164091","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted product made from the leaves and flowers of the cannabis plant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marijuana Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Marijuana smoke"},{"name":"NCI_META_CUI","value":"CL979280"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164092":{"preferredName":"No Smoke Exposure","code":"C164092","definitions":[{"definition":"An indication that a subject has no history of smoke exposure from any source.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Smoke Exposure"},{"name":"NCI_META_CUI","value":"CL977407"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164093":{"preferredName":"Kerosene Smoke Exposure","code":"C164093","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when kerosene is rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kerosene Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Burning Kerosene Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oil burning smoke, Kerosene"},{"name":"NCI_META_CUI","value":"CL977406"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164063":{"preferredName":"Burning Oil Smoke Exposure","code":"C164063","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when oils are rapidly oxidized via combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Oil Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Oil Burning Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oil burning smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977200"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164094":{"preferredName":"Recreational Fire Smoke Exposure","code":"C164094","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials (usually wood) are burned for recreational purposes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recreational Fire Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recreational fire smoke"},{"name":"NCI_META_CUI","value":"CL977405"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164095":{"preferredName":"Smokehouse Smoke Exposure","code":"C164095","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced during indoor smoke curing of food products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokehouse Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smokehouse smoke"},{"name":"NCI_META_CUI","value":"CL977404"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164097":{"preferredName":"Cigar Smoke Exposure","code":"C164097","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a cigar.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigar Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco smoke, cigar"},{"name":"NCI_META_CUI","value":"CL977402"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164098":{"preferredName":"Cigarette Smoke Exposure","code":"C164098","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a cigarette.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigarette Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco smoke, cigarette"},{"name":"NCI_META_CUI","value":"CL977371"},{"name":"Semantic_Type","value":"Finding"}]}}{"C44456":{"preferredName":"Tobacco Smoke Related Exposure","code":"C44456","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted tobacco product.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Smoke Related Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Tobacco Related Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tobacco_Related_Exposure"},{"name":"Maps_To","value":"Tobacco smoke, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1710429"}]}}{"C164099":{"preferredName":"Tobacco Pipe Smoke Exposure","code":"C164099","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a tobacco pipe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Pipe Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Pipe Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco smoke, pipe"},{"name":"NCI_META_CUI","value":"CL977370"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164100":{"preferredName":"Volcanic Smoke Exposure","code":"C164100","definitions":[{"definition":"Environmental exposure to airborne gases and particulates produced by a volcanic event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Volcanic Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Volcanic smoke"},{"name":"NCI_META_CUI","value":"CL977369"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164101":{"preferredName":"Burning Waste Smoke Exposure","code":"C164101","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when trash or waste is burned.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Waste Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Waste burning smoke"},{"name":"NCI_META_CUI","value":"CL977368"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164102":{"preferredName":"Wood-Burning Factory Smoke Exposure","code":"C164102","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when wood is burned in a factory setting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wood-Burning Factory Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood burning smoke, factory"},{"name":"NCI_META_CUI","value":"CL977367"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164065":{"preferredName":"Burning Wood Smoke Exposure","code":"C164065","definitions":[{"definition":"Environmental or occupational exposure to airborne gases and particulates produced when wood is subjected to combustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burning Wood Smoke Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Wood Burning Smoke Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood burning smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977401"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164104":{"preferredName":"Occupational Artificial Smoke Machine Smoke Exposure","code":"C164104","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a machine that produces artificial smoke.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Artificial Smoke Machine Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, artificial smoke machines"},{"name":"NCI_META_CUI","value":"CL977365"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164105":{"preferredName":"Occupational Fire Fighting Smoke Exposure","code":"C164105","definitions":[{"definition":"Occupational exposure to airborne gases and particulates while preventing, controlling or extinguishing fires.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Fire Fighting Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, fire fighting"},{"name":"NCI_META_CUI","value":"CL977364"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164106":{"preferredName":"Occupational Foundry Smoke Exposure","code":"C164106","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a foundry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Foundry Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, foundry"},{"name":"NCI_META_CUI","value":"CL977363"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164107":{"preferredName":"Occupational Generator Smoke Exposure","code":"C164107","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a power generator.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Generator Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, generators"},{"name":"NCI_META_CUI","value":"CL977362"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164115":{"preferredName":"Occupational Military Smoke Exposure","code":"C164115","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during a military posting or deployment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Military Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, military"},{"name":"NCI_META_CUI","value":"CL977385"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164103":{"preferredName":"Work-Related Smoke Exposure","code":"C164103","definitions":[{"definition":"Occupational exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Work-Related Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, NOS"},{"name":"NCI_META_CUI","value":"CL977366"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164116":{"preferredName":"Occupational Paint Baking Smoke Exposure","code":"C164116","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a paint oven.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Paint Baking Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, paint baking"},{"name":"NCI_META_CUI","value":"CL977384"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164118":{"preferredName":"Occupational Plastics Factory Smoke Exposure","code":"C164118","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the manufacturing of plastics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Plastics Factory Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, plastics factory"},{"name":"NCI_META_CUI","value":"CL977382"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164119":{"preferredName":"Occupational Plumbing Smoke Exposure","code":"C164119","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the installation of plumbing pipes and fixtures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Plumbing Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Work-related smoke, plumbing"},{"name":"NCI_META_CUI","value":"CL977381"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164120":{"preferredName":"Occupational Soldering/Welding Smoke Exposure","code":"C164120","definitions":[{"definition":"Occupational exposure to airborne gases and particulates during the operation of a soldering iron or welding machine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Soldering/Welding Smoke Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Occupational Soldering/Welding Smoke Exposure"},{"name":"Maps_To","value":"Work-related smoke, soldering/welding"},{"name":"NCI_META_CUI","value":"CL977380"},{"name":"Semantic_Type","value":"Finding"}]}}{"C1813":{"preferredName":"Cigar","code":"C1813","definitions":[{"definition":"A compact roll of tobacco leaves prepared for smoking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cigar"},{"name":"Maps_To","value":"Cigar"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C0678446"}]}}{"C1802":{"preferredName":"Cigarette","code":"C1802","definitions":[{"definition":"Finely cut tobacco encased in a wrapper of thin paper and rolled for smoking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cigarette","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cigarette"},{"name":"Maps_To","value":"Cigarette"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C0677453"}]}}{"C120482":{"preferredName":"Electronic Cigarette","code":"C120482","definitions":[{"definition":"A battery-powered electronic device designed to atomize a nicotine-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electronic Cigarette","termGroup":"PT","termSource":"NCI"},{"termName":"Electronic Nicotine Delivery System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electronic Cigarette"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C3849993"}]}}{"C86044":{"preferredName":"Pipe","code":"C86044","definitions":[{"definition":"A tube with a small bowl at one end, especially one used for smoking tobacco.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pipe","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pipe"},{"name":"Semantic_Type","value":"Manufactured Object"},{"name":"UMLS_CUI","value":"C2828033"}]}}{"C892":{"preferredName":"Smokeless Tobacco","code":"C892","definitions":[{"definition":"Tobacco that is not smoked but used in another form such as chewing tobacco or snuff.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokeless Tobacco","termGroup":"PT","termSource":"NCI"},{"termName":"Smoking, Tobacco and Cancer - Smokeless Tobacco","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Cancers of the oral cavity (mouth, lip, tongue) have been associated with the use of chewing tobacco as well as snuff. The tumors often arise at the site of placement of the tobacco. Smokeless tobacco was formally classified as a \"known human carcinogen\" by the US government in 2000. (MedicineNet.com)"},{"name":"Legacy Concept Name","value":"Smokeless_Tobacco"},{"name":"Maps_To","value":"Smokeless Tobacco"},{"name":"NCI_Drug_Dictionary_ID","value":"737707"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737707"},{"name":"PDQ_Open_Trial_Search_ID","value":"737707"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0040338"}]}}{"C166195":{"preferredName":"Adopted Brother","code":"C166195","definitions":[{"definition":"A male sibling who is legally adopted by one's biological parent or legal guardian.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Brother"},{"name":"NCI_META_CUI","value":"CL971457"},{"name":"Semantic_Type","value":"Human"}]}}{"C166131":{"preferredName":"Adopted Daughter","code":"C166131","definitions":[{"definition":"A female child in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Daughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Daughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337553"}]}}{"C166196":{"preferredName":"Adopted Sister","code":"C166196","definitions":[{"definition":"A female sibling who is legally adopted by one's biological parent or legal guardian.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Sister"},{"name":"NCI_META_CUI","value":"CL971456"},{"name":"Semantic_Type","value":"Human"}]}}{"C166132":{"preferredName":"Adopted Son","code":"C166132","definitions":[{"definition":"A male child in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adopted Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adopted Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337565"}]}}{"C166133":{"preferredName":"Adoptive Father","code":"C166133","definitions":[{"definition":"A male parent in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adoptive Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adoptive Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337495"}]}}{"C166134":{"preferredName":"Adoptive Mother","code":"C166134","definitions":[{"definition":"A female parent in the parent-child relationship established by a legal adoption proceeding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adoptive Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adoptive Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337487"}]}}{"C71405":{"preferredName":"Aunt","code":"C71405","definitions":[{"definition":"The sister of your father or mother; the wife of your uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aunt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aunt"},{"name":"Maps_To","value":"Aunt"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337576"}]}}{"C25289":{"preferredName":"Brother","code":"C25289","definitions":[{"definition":"A male sibling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brother"},{"name":"Maps_To","value":"Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337527"}]}}{"C71406":{"preferredName":"Brother-in-law","code":"C71406","definitions":[{"definition":"A brother by marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brother-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Brother-in-law"},{"name":"Maps_To","value":"Brother-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C1553711"}]}}{"C150886":{"preferredName":"Child Relation","code":"C150886","definitions":[{"definition":"A biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An individual's biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Child Relation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Child"},{"name":"NCI_META_CUI","value":"CL554545"},{"name":"Semantic_Type","value":"Human"}]}}{"C71410":{"preferredName":"Cousin","code":"C71410","definitions":[{"definition":"A child of your aunt or uncle or their descendents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cousin"},{"name":"Maps_To","value":"Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337580"}]}}{"C25165":{"preferredName":"Daughter","code":"C25165","definitions":[{"definition":"A female human offspring.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Daughter"},{"name":"Maps_To","value":"Daughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337552"}]}}{"C71401":{"preferredName":"Daughter-in-law","code":"C71401","definitions":[{"definition":"The wife of your son.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daughter-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Daughter-in-law"},{"name":"Maps_To","value":"Daughter-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C1553705"}]}}{"C53262":{"preferredName":"Domestic Partnership","code":"C53262","definitions":[{"definition":"Indicates a person who is a member of an unmarried couple, including same sex couples, living together in longstanding relationships, that are registered or unregistered.","type":"DEFINITION","source":"NCI"},{"definition":"Person declares that a domestic partnership relationship exists. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Domestic Partnership","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Domestic_Partnership"},{"name":"Maps_To","value":"Domestic Partner"},{"name":"Maps_To","value":"Domestic Partnership"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0683559"}]}}{"C25174":{"preferredName":"Father","code":"C25174","definitions":[{"definition":"A male parent.","type":"DEFINITION","source":"NCI"},{"definition":"A male parent.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Father"},{"name":"Maps_To","value":"Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0015671"}]}}{"C68640":{"preferredName":"Father-in-law","code":"C68640","definitions":[{"definition":"The father of your spouse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Father-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Father-in-law"},{"name":"Maps_To","value":"Father-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2349973"}]}}{"C165786":{"preferredName":"Female Cousin","code":"C165786","definitions":[{"definition":"A female child of one's aunt or uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Female Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337581"}]}}{"C166198":{"preferredName":"Female Sibling of Adopted Child","code":"C166198","definitions":[{"definition":"A female sibling of an adopted child. The said female is a biological or legal child of the parents who facilitated the adoption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Sibling of Adopted Child","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Female Sibling of Adopted Child"},{"name":"NCI_META_CUI","value":"CL971458"},{"name":"Semantic_Type","value":"Human"}]}}{"C71411":{"preferredName":"First Cousin","code":"C71411","definitions":[{"definition":"A child of your aunt or uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First_Cousin"},{"name":"Maps_To","value":"First Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337583"}]}}{"C71412":{"preferredName":"First Cousin Once Removed","code":"C71412","definitions":[{"definition":"A child of your first cousin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Cousin Once Removed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First_Cousin_Once_Removed"},{"name":"Maps_To","value":"First Cousin Once Removed"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2348676"}]}}{"C165788":{"preferredName":"Foster Brother","code":"C165788","definitions":[{"definition":"A male child being fostered by your parents or legal guardians.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337532"}]}}{"C165790":{"preferredName":"Foster Daughter","code":"C165790","definitions":[{"definition":"A female child you are fostering.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Daughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Daughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337556"}]}}{"C165792":{"preferredName":"Foster Father","code":"C165792","definitions":[{"definition":"A male foster parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337498"}]}}{"C165793":{"preferredName":"Foster Mother","code":"C165793","definitions":[{"definition":"A female foster parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337489"}]}}{"C165794":{"preferredName":"Foster Sister","code":"C165794","definitions":[{"definition":"A female child being fostered by your parents or legal guardians.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337519"}]}}{"C165795":{"preferredName":"Foster Son","code":"C165795","definitions":[{"definition":"A male child you are fostering.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foster Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foster Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337568"}]}}{"C165796":{"preferredName":"Fraternal Twin Brother","code":"C165796","definitions":[{"definition":"A male full sibling that developed from a separately fertilized ova during the same pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fraternal Twin Brother","termGroup":"PT","termSource":"NCI"},{"termName":"Dizygotic Twin Brother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fraternal Twin Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337536"}]}}{"C73428":{"preferredName":"Fraternal Twin","code":"C73428","definitions":[{"definition":"Either of the two offspring from separately fertilized ova during the same pregnancy.","type":"DEFINITION","source":"NCI"},{"definition":"Either of the two offspring resulting from two separately fertilized ovums during the same pregnancy.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fraternal Twin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fraternal_Twin"},{"name":"Maps_To","value":"Fraternal Twin Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0041429"}]}}{"C165797":{"preferredName":"Fraternal Twin Sister","code":"C165797","definitions":[{"definition":"A female full sibling that developed from a separately fertilized ova during the same pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fraternal Twin Sister","termGroup":"PT","termSource":"NCI"},{"termName":"Dizygotic Twin Sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fraternal Twin Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337523"}]}}{"C111201":{"preferredName":"Full Brother","code":"C111201","definitions":[{"definition":"A male who shares with his sibling the genetic makeup inherited from both of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A male who shares with his sibling the genetic makeup inherited from both of the biological parents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Full Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Full Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3830065"}]}}{"C111202":{"preferredName":"Full Sister","code":"C111202","definitions":[{"definition":"A female who shares with her sibling the genetic makeup inherited from both of the biological parents.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from both of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Full Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Full Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3827310"}]}}{"C165798":{"preferredName":"Great Nephew","code":"C165798","definitions":[{"definition":"A male child of one's niece or nephew.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Nephew","termGroup":"PT","termSource":"NCI"},{"termName":"Grand Nephew","termGroup":"SY","termSource":"NCI"},{"termName":"Grandnephew","termGroup":"SY","termSource":"NCI"},{"termName":"Great-Nephew","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grand Nephew"},{"name":"NCI_META_CUI","value":"CL979050"},{"name":"Semantic_Type","value":"Human"}]}}{"C165846":{"preferredName":"Great Niece","code":"C165846","definitions":[{"definition":"A female child of one's niece or nephew.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Niece","termGroup":"PT","termSource":"NCI"},{"termName":"Grand Niece","termGroup":"SY","termSource":"NCI"},{"termName":"Grandniece","termGroup":"SY","termSource":"NCI"},{"termName":"Great-Niece","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grand Niece"},{"name":"NCI_META_CUI","value":"CL979041"},{"name":"Semantic_Type","value":"Human"}]}}{"C71397":{"preferredName":"Grandchild","code":"C71397","definitions":[{"definition":"A child of your son or daughter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandchild","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandchild"},{"name":"Maps_To","value":"Grandchild"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337548"}]}}{"C71399":{"preferredName":"Granddaughter","code":"C71399","definitions":[{"definition":"A female grandchild.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granddaughter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Granddaughter"},{"name":"Maps_To","value":"Granddaughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337561"}]}}{"C71387":{"preferredName":"Grandfather","code":"C71387","definitions":[{"definition":"The father of your father or mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandfather"},{"name":"Maps_To","value":"Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337475"}]}}{"C71386":{"preferredName":"Grandmother","code":"C71386","definitions":[{"definition":"The mother of your father or mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandmother"},{"name":"Maps_To","value":"Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337474"}]}}{"C71385":{"preferredName":"Grandparent","code":"C71385","definitions":[{"definition":"A parent of your father or mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandparent"},{"name":"Maps_To","value":"Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337471"}]}}{"C71398":{"preferredName":"Grandson","code":"C71398","definitions":[{"definition":"A male grandchild.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grandson","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Grandson"},{"name":"Maps_To","value":"Grandson"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337573"}]}}{"C165847":{"preferredName":"Great Grandchild","code":"C165847","definitions":[{"definition":"A child of one's grandchild.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Grandchild","termGroup":"PT","termSource":"NCI"},{"termName":"Great-Grandchild","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Great Grandchild"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337549"}]}}{"C71402":{"preferredName":"Half Brother","code":"C71402","definitions":[{"definition":"A male sibling with whom you share a single parent.","type":"DEFINITION","source":"NCI"},{"definition":"A male who shares with his sibling the genetic makeup inherited from only one of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half Brother","termGroup":"PT","termSource":"NCI"},{"termName":"Half-brother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Half_Brother"},{"name":"Maps_To","value":"Half Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337531"}]}}{"C71391":{"preferredName":"Half Sibling","code":"C71391","definitions":[{"definition":"A person's brother or sister who has one parent in common.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A person's brother or sister with whom they share a genetic makeup inherited from one of their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sibling with whom you share a single parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Half Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Half Relation","termGroup":"SY","termSource":"NCI"},{"termName":"Half Relative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Half_Sibling"},{"name":"Maps_To","value":"Half Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337505"}]}}{"C71403":{"preferredName":"Half Sister","code":"C71403","definitions":[{"definition":"A female sibling with whom you share a single parent.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from only one of the biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half Sister","termGroup":"PT","termSource":"NCI"},{"termName":"Half-sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Half_Sister"},{"name":"Maps_To","value":"Half Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337518"}]}}{"C71588":{"preferredName":"Husband","code":"C71588","definitions":[{"definition":"A male partner in marriage.","type":"DEFINITION","source":"NCI"},{"definition":"A male partner in marriage. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Husband","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Husband"},{"name":"Maps_To","value":"Husband"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0242664"}]}}{"C165848":{"preferredName":"Identical Twin Brother","code":"C165848","definitions":[{"definition":"A male full sibling that developed from a shared ovum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Identical Twin Brother","termGroup":"PT","termSource":"NCI"},{"termName":"Monozygotic Twin Brother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Identical Twin Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337535"}]}}{"C73429":{"preferredName":"Identical Twin","code":"C73429","definitions":[{"definition":"Either of the two offspring resulting from a shared ovum.","type":"DEFINITION","source":"NCI"},{"definition":"Either of the two offspring resulting from a shared ovum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Identical Twin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Identical_Twin"},{"name":"Maps_To","value":"Identical Twin Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0041432"}]}}{"C165849":{"preferredName":"Identical Twin Sister","code":"C165849","definitions":[{"definition":"A female full sibling that developed from a shared ovum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Identical Twin Sister","termGroup":"PT","termSource":"NCI"},{"termName":"Monozygotic Twin Sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Identical Twin Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337522"}]}}{"C51828":{"preferredName":"Guardian","code":"C51828","definitions":[{"definition":"An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research.","type":"DEFINITION","source":"NCI"},{"definition":"An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Guardian","termGroup":"PT","termSource":"NCI"},{"termName":"Legal Guardian","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Guardian"},{"name":"Maps_To","value":"Legal Guardian"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C0023226"}]}}{"C165850":{"preferredName":"Male Cousin","code":"C165850","definitions":[{"definition":"A male child of one's aunt or uncle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Male Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Male Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337582"}]}}{"C166197":{"preferredName":"Male Sibling of Adopted Child","code":"C166197","definitions":[{"definition":"A male sibling of an adopted child. The said male is a biological or legal child of the parents who facilitated the adoption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Male Sibling of Adopted Child","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Male Sibling of Adopted Child"},{"name":"NCI_META_CUI","value":"CL971459"},{"name":"Semantic_Type","value":"Human"}]}}{"C96575":{"preferredName":"Biological Maternal Aunt","code":"C96575","definitions":[{"definition":"A female relative who is a sibling of the biological mother, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is a sibling of the biological mother, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Aunt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Aunt"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272872"}]}}{"C96576":{"preferredName":"Biological Maternal Cousin","code":"C96576","definitions":[{"definition":"A relative who is the offspring of a sibling of the biological mother and share a common ancestor.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A relative who is the offspring of a sibling of the biological mother and thus sharing a common ancestor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Maternal Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal First Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272873"}]}}{"C165851":{"preferredName":"Maternal First Cousin Once Removed","code":"C165851","definitions":[{"definition":"A child of one's first cousin who is related by lineage through the mother's side of the family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal First Cousin Once Removed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal First Cousin Once Removed"},{"name":"NCI_META_CUI","value":"CL979023"},{"name":"Semantic_Type","value":"Human"}]}}{"C96577":{"preferredName":"Biological Maternal Grandfather","code":"C96577","definitions":[{"definition":"A male relative who is the biological father of the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is the biological father of the biological mother. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272874"}]}}{"C96578":{"preferredName":"Biological Maternal Grandmother","code":"C96578","definitions":[{"definition":"A female relative who is the biological mother of the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is the biological mother of the biological mother. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272875"}]}}{"C111248":{"preferredName":"Maternal Biological Grandparent","code":"C111248","definitions":[{"definition":"A relative who is the biological parent of the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A relative who is the biological parent of the biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Maternal Biological Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3829175"}]}}{"C165853":{"preferredName":"Maternal Great Aunt","code":"C165853","definitions":[{"definition":"The aunt of one's mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Great Aunt","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Great-Aunt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Great Aunt"},{"name":"NCI_META_CUI","value":"CL979025"},{"name":"Semantic_Type","value":"Human"}]}}{"C166127":{"preferredName":"Maternal Great Grandparent","code":"C166127","definitions":[{"definition":"A parent of one's maternal grandparent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Great Grandparent","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Great-Grandparent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Great Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3242755"}]}}{"C165854":{"preferredName":"Maternal Great Uncle","code":"C165854","definitions":[{"definition":"The uncle of one's mother.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Great Uncle","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Great-Uncle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Great Uncle"},{"name":"NCI_META_CUI","value":"CL979020"},{"name":"Semantic_Type","value":"Human"}]}}{"C96656":{"preferredName":"Half-brother with Mother as Common Parent","code":"C96656","definitions":[{"definition":"A male sibling who shares the genetic makeup inherited from only the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A male who shares with his sibling the genetic makeup inherited from only the biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-brother with Mother as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Half Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272936"}]}}{"C166112":{"preferredName":"Maternal Half Sibling","code":"C166112","definitions":[{"definition":"A relative with whom you share a biological mother but you have different fathers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maternal Half Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Maternal Half-Sibling","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Half Sibling"},{"name":"NCI_META_CUI","value":"CL979209"},{"name":"Semantic_Type","value":"Human"}]}}{"C96658":{"preferredName":"Half-sister with Mother as Common Parent","code":"C96658","definitions":[{"definition":"A female sibling who shares the genetic makeup inherited from only the biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from only the biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-sister with Mother as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Half Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272938"}]}}{"C96579":{"preferredName":"Biological Maternal Uncle","code":"C96579","definitions":[{"definition":"A male relative who is a sibling of the biological mother, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is a sibling of the biological mother, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Maternal Uncle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maternal Uncle"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272876"}]}}{"C25189":{"preferredName":"Mother","code":"C25189","definitions":[{"definition":"A female parent.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A female parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mother"},{"name":"Maps_To","value":"Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0026591"}]}}{"C68639":{"preferredName":"Mother-in-law","code":"C68639","definitions":[{"definition":"The mother of your spouse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mother-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mother-in-law"},{"name":"Maps_To","value":"Mother-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2349972"}]}}{"C96570":{"preferredName":"Biological Brother","code":"C96570","definitions":[{"definition":"A male who shares with his sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A male who shares with his sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Brother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337528"}]}}{"C42708":{"preferredName":"Offspring","code":"C42708","definitions":[{"definition":"A first-generation, biological descendant of any age.","type":"DEFINITION","source":"NCI"},{"definition":"A son or daughter with genetic makeup inherited from the parent.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Offspring; the product of reproduction or replication.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Offspring","termGroup":"PT","termSource":"NCI"},{"termName":"Biological Child","termGroup":"SY","termSource":"NCI"},{"termName":"Children","termGroup":"SY","termSource":"NCI"},{"termName":"Human, Child","termGroup":"SY","termSource":"NCI"},{"termName":"Progeny","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Child_Offspring"},{"name":"Maps_To","value":"Biological Child"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0680063"}]}}{"C96572":{"preferredName":"Biological Father","code":"C96572","definitions":[{"definition":"A male who contributes to the genetic makeup of his offspring through the fertilization of an ovum by his sperm.","type":"DEFINITION","source":"NCI"},{"definition":"A male who contributes to the genetic makeup of his offspring through the fertilization of an ovum by his sperm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Father","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Father"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337494"}]}}{"C100805":{"preferredName":"Biological Grandchild","code":"C100805","definitions":[{"definition":"A biological child of an individual's biological child.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A biological child of an individual's biological child.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Grandchild","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandchild"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3639748"}]}}{"C96573":{"preferredName":"Biological Grandfather","code":"C96573","definitions":[{"definition":"A male relative who is the biological father of either the biological mother or the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is the biological father of either the biological mother or the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337477"}]}}{"C96574":{"preferredName":"Biological Grandmother","code":"C96574","definitions":[{"definition":"A female relative who is the biological mother of either the biological mother or the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is the biological mother of either the biological mother or the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337476"}]}}{"C100806":{"preferredName":"Biological Grandparent","code":"C100806","definitions":[{"definition":"A biological parent of the biological father or biological mother.","type":"DEFINITION","source":"NCI"},{"definition":"A biological parent of the biological father or biological mother.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337472"}]}}{"C96580":{"preferredName":"Biological Mother","code":"C96580","definitions":[{"definition":"A female who contributes to the genetic makeup of her offspring from the fertilization of her ovum.","type":"DEFINITION","source":"NCI"},{"definition":"A female who contributes to the genetic makeup of her offspring from the fertilization of her ovum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Mother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Mother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337486"}]}}{"C166114":{"preferredName":"Biological Parent","code":"C166114","definitions":[{"definition":"The male who supplied the sperm or the female who supplied the egg which resulted in one's conception.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Parent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337465"}]}}{"C100809":{"preferredName":"Biological Sibling","code":"C100809","definitions":[{"definition":"A person's brother or sister with whom they share a genetic makeup inherited from one or both of their shared biological parents.","type":"DEFINITION","source":"NCI"},{"definition":"A person's brother or sister with whom they share a genetic makeup inherited from their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Sibling","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337502"}]}}{"C96586":{"preferredName":"Biological Sister","code":"C96586","definitions":[{"definition":"A female who shares with her sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A female who shares with her sibling the genetic makeup inherited from one or both of their shared biological parents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337515"}]}}{"C150888":{"preferredName":"Biological Son","code":"C150888","definitions":[{"definition":"A male progeny with genetic makeup inherited from the parent.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A male progeny with genetic makeup inherited from the parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Natural Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337564"}]}}{"C71409":{"preferredName":"Nephew","code":"C71409","definitions":[{"definition":"A son of your brother or sister.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nephew","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nephew"},{"name":"Maps_To","value":"Nephew"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337579"}]}}{"C71408":{"preferredName":"Niece","code":"C71408","definitions":[{"definition":"A daughter of your brother or sister.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niece","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Niece"},{"name":"Maps_To","value":"Niece"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337578"}]}}{"C166115":{"preferredName":"Biological Niece","code":"C166115","definitions":[{"definition":"A daughter of one's biological sibling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Niece","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Niece Second Degree Relative"},{"name":"NCI_META_CUI","value":"CL979211"},{"name":"Semantic_Type","value":"Human"}]}}{"C42709":{"preferredName":"Parent","code":"C42709","definitions":[{"definition":"A mother or a father.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A mother or a father; an immediate progenitor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parent","termGroup":"PT","termSource":"NCI"},{"termName":"Parental","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Parent"},{"name":"Maps_To","value":"Parent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0030551"}]}}{"C96581":{"preferredName":"Biological Paternal Aunt","code":"C96581","definitions":[{"definition":"A female relative who is a sibling of the biological father, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is a sibling of the biological father, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Aunt","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Aunt"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272877"}]}}{"C96582":{"preferredName":"Biological Paternal Cousin","code":"C96582","definitions":[{"definition":"A relative who is the offspring of a sibling of the biological father and share a common ancestor.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A relative who is the offspring of a sibling of the biological father and thus sharing a common ancestor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biological Paternal Cousin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal First Cousin"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272878"}]}}{"C165852":{"preferredName":"Paternal First Cousin Once Removed","code":"C165852","definitions":[{"definition":"A child of one's first cousin who is related by lineage through the father's side of the family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal First Cousin Once Removed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal First Cousin Once Removed"},{"name":"NCI_META_CUI","value":"CL979024"},{"name":"Semantic_Type","value":"Human"}]}}{"C96583":{"preferredName":"Biological Paternal Grandfather","code":"C96583","definitions":[{"definition":"A male relative who is the biological father of the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is the biological father of the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Grandfather","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Grandfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272879"}]}}{"C96584":{"preferredName":"Biological Paternal Grandmother","code":"C96584","definitions":[{"definition":"A female relative who is the biological mother of the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A female relative who is the biological mother of the biological father. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Grandmother","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Grandmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272880"}]}}{"C111286":{"preferredName":"Paternal Biological Grandparent","code":"C111286","definitions":[{"definition":"A relative who is the biological parent of the biological father.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A relative who is the biological parent of the biological father.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Biological Grandparent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3828639"}]}}{"C165856":{"preferredName":"Paternal Great Aunt","code":"C165856","definitions":[{"definition":"The aunt of one's father.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Great Aunt","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Great-Aunt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Great Aunt"},{"name":"NCI_META_CUI","value":"CL979021"},{"name":"Semantic_Type","value":"Human"}]}}{"C166128":{"preferredName":"Paternal Great Grandparent","code":"C166128","definitions":[{"definition":"A parent of one's paternal grandparent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Great Grandparent","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Great-Grandparent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Great Grandparent"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3242758"}]}}{"C165857":{"preferredName":"Paternal Great Uncle","code":"C165857","definitions":[{"definition":"The uncle of one's father.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Great Uncle","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Great-Uncle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Great Uncle"},{"name":"NCI_META_CUI","value":"CL979022"},{"name":"Semantic_Type","value":"Human"}]}}{"C96655":{"preferredName":"Half-brother with Father as Common Parent","code":"C96655","definitions":[{"definition":"A male sibling who shares the genetic makeup inherited from only the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A male who shares with his sibling the genetic makeup inherited from only the biological father.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-brother with Father as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Half Brother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272935"}]}}{"C166113":{"preferredName":"Paternal Half Sibling","code":"C166113","definitions":[{"definition":"A relative with whom you share a biological father but you have different mothers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paternal Half Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Paternal Half-Sibling","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Half Sibling"},{"name":"NCI_META_CUI","value":"CL979210"},{"name":"Semantic_Type","value":"Human"}]}}{"C96657":{"preferredName":"Half-sister with Father as Common Parent","code":"C96657","definitions":[{"definition":"A female sibling who shares the genetic makeup inherited from only the biological father.","type":"DEFINITION","source":"NCI"},{"definition":"A female who shares with her sibling the genetic makeup inherited from only the biological father.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Half-sister with Father as Common Parent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Half Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272937"}]}}{"C96585":{"preferredName":"Biological Paternal Uncle","code":"C96585","definitions":[{"definition":"A male relative who is a sibling of the biological father, and who both share a common ancestor.","type":"DEFINITION","source":"NCI"},{"definition":"A male relative who is a sibling of the biological father, and who both share a common ancestor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Biological Paternal Uncle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paternal Uncle"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C3272881"}]}}{"C25204":{"preferredName":"Sibling","code":"C25204","definitions":[{"definition":"A person's brother or sister who has the same parents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A person's brother or sister.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A person's brother or sister.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sibling","termGroup":"PT","termSource":"NCI"},{"termName":"Sib","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sibling"},{"name":"Maps_To","value":"Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0037047"}]}}{"C25680":{"preferredName":"Sister","code":"C25680","definitions":[{"definition":"A female sibling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sister","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sister"},{"name":"Maps_To","value":"Sister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337514"}]}}{"C71407":{"preferredName":"Sister-in-law","code":"C71407","definitions":[{"definition":"A sister by marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sister-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sister-in-law"},{"name":"Maps_To","value":"Sister-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2350006"}]}}{"C25205":{"preferredName":"Son","code":"C25205","definitions":[{"definition":"A male human offspring.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Son","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Son"},{"name":"Maps_To","value":"Son"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0037683"}]}}{"C71400":{"preferredName":"Son-in-law","code":"C71400","definitions":[{"definition":"The husband of your daughter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Son-in-law","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Son-in-law"},{"name":"Maps_To","value":"Son-in-law"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2350007"}]}}{"C62649":{"preferredName":"Spouse","code":"C62649","definitions":[{"definition":"A person's partner in marriage.","type":"DEFINITION","source":"NCI"},{"definition":"A person's partner in marriage. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Spouse","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spouse"},{"name":"Maps_To","value":"Spouse"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0162409"}]}}{"C166117":{"preferredName":"Step Child","code":"C166117","definitions":[{"definition":"A child of one's spouse, acquired through marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Step Child","termGroup":"PT","termSource":"NCI"},{"termName":"Stepchild","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Step Child"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337542"}]}}{"C166118":{"preferredName":"Step Sibling","code":"C166118","definitions":[{"definition":"A child of one's step parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Step Sibling","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Step Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337504"}]}}{"C166119":{"preferredName":"Stepbrother","code":"C166119","definitions":[{"definition":"A male child of one's step parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepbrother","termGroup":"PT","termSource":"NCI"},{"termName":"Stepbrother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepbrother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337530"}]}}{"C166123":{"preferredName":"Stepdaughter","code":"C166123","definitions":[{"definition":"A female child of one's spouse, acquired through marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepdaughter","termGroup":"PT","termSource":"NCI"},{"termName":"Step Daughter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepdaughter"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337554"}]}}{"C154851":{"preferredName":"Step Father","code":"C154851","definitions":[{"definition":"A male that is related to a child or children through marriage to their biological parent.","type":"DEFINITION","source":"NCI"},{"definition":"A male who has acquired children through marriage.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Step Father","termGroup":"PT","termSource":"NCI"},{"termName":"Stepfather","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepfather"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337496"}]}}{"C132450":{"preferredName":"Stepmother","code":"C132450","definitions":[{"definition":"A female who has acquired children through marriage.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A female who is married to a spouse with children whom are not biologically related to her.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepmother","termGroup":"PT","termSource":"NCI"},{"termName":"Step Mother","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepmother"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337488"}]}}{"C166124":{"preferredName":"Stepsister","code":"C166124","definitions":[{"definition":"A female child of one's step parent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepsister","termGroup":"PT","termSource":"NCI"},{"termName":"Step Sister","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepsister"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337517"}]}}{"C166125":{"preferredName":"Stepson","code":"C166125","definitions":[{"definition":"A male child of one's spouse, acquired through marriage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stepson","termGroup":"PT","termSource":"NCI"},{"termName":"Step Son","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stepson"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337566"}]}}{"C73427":{"preferredName":"Twin","code":"C73427","definitions":[{"definition":"Either of two offspring born from the same pregnancy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from WordNet"}]},{"definition":"Either of two offspring born from the same pregnancy. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Twin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Twin"},{"name":"Maps_To","value":"Twin Sibling"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0041427"}]}}{"C71404":{"preferredName":"Uncle","code":"C71404","definitions":[{"definition":"The brother of your father or mother; the husband of your aunt.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uncle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uncle"},{"name":"Maps_To","value":"Uncle"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0337577"}]}}{"C25328":{"preferredName":"Unrelated","code":"C25328","definitions":[{"definition":"Not connected or associated e.g. by kinship.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unrelated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unrelated"},{"name":"Maps_To","value":"Unrelated"},{"name":"NCI_META_CUI","value":"CL448530"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C71413":{"preferredName":"Ward","code":"C71413","definitions":[{"definition":"A person who is under the protection or in the custody of another.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ward","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ward"},{"name":"Maps_To","value":"Ward"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C2355574"}]}}{"C71587":{"preferredName":"Wife","code":"C71587","definitions":[{"definition":"A female partner in marriage.","type":"DEFINITION","source":"NCI"},{"definition":"A female partner in marriage.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Wife","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Wife"},{"name":"Maps_To","value":"Wife"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C0242665"}]}}{"C21481":{"preferredName":"First Degree Relative","code":"C21481","definitions":[{"definition":"Any individual related biologically or legally to another individual and considered immediate family as in the case of a spouse, parent, sibling or child.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any relative who is one meiosis away from a particular individual in a family; a relative with whom one half of an individual's genes is shared (i.e., parent, sibling, offspring) (from Genetics Home Reference glossary)","type":"DEFINITION","source":"NCI"},{"definition":"The parents, siblings, or children of an individual.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"First Degree Relative","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First_Degree_Relative"},{"name":"Maps_To","value":"First Degree Relative, NOS"},{"name":"Semantic_Type","value":"Human"},{"name":"UMLS_CUI","value":"C1517194"}]}}{"C9338":{"preferredName":"Malignant Adrenal Gland Neoplasm","code":"C9338","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the adrenal gland.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the adrenal glands (two glands located just above the kidneys). The adrenal glands make hormones that control heart rate, blood pressure, and other important body functions. Adrenal cancer that starts in the outside layer of the adrenal gland is called adrenocortical carcinoma. Adrenal cancer that starts in the center of the adrenal gland is called malignant pheochromocytoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Adrenal Gland Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Adrenal Gland Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Adrenal Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Adrenal Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Adrenal Gland","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Adrenal_Gland_Neoplasm"},{"name":"Maps_To","value":"Adrenal Gland Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified part of left adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified part of right adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified part of unspecified adrenal gland"},{"name":"Maps_To","value":"Malignant neoplasm: Adrenal gland, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0750887"}]}}{"C4912":{"preferredName":"Bladder Carcinoma","code":"C4912","definitions":[{"definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the bladder (the organ that stores urine). Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the bladder). Other types include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). The cells that form squamous cell carcinoma and adenocarcinoma develop in the inner lining of the bladder as a result of chronic irritation and inflammation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bladder Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Bladder Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Urinary Bladder","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Bladder Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Bladder Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bladder_Carcinoma"},{"name":"Maps_To","value":"Bladder Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0699885"}]}}{"C116915":{"preferredName":"Liquid Tumor","code":"C116915","definitions":[{"definition":"A malignant tumor that originates from myeloid or lymphoid cells i.e., leukemias and lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liquid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3890429"}]}}{"C4016":{"preferredName":"Malignant Bone Neoplasm","code":"C4016","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","type":"DEFINITION","source":"NCI"},{"definition":"A solid malignant neoplasm that develops or arises in the bone.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Primary bone cancer is cancer that forms in cells of the bone. Some types of primary bone cancer are osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, and chondrosarcoma. Secondary bone cancer is cancer that spreads to the bone from another part of the body (such as the prostate, breast, or lung).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Bone Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Bone Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Osseous Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Osseous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Bone","termGroup":"SY","termSource":"NCI"},{"termName":"Osseous Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Malignant_Bone_Neoplasm"},{"name":"Maps_To","value":"Bone cancer"},{"name":"Maps_To","value":"Bone Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage of limbs"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage of other and unspecified sites"},{"name":"Maps_To","value":"Malignant neoplasm of bone and articular cartilage, site unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of bones of skull and face, except mandible"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of left lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of right lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of long bones of unspecified lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of pelvic bones, sacrum, and coccyx"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of left upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of right upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of unspecified upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of scapula and long bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of short bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm of short bones of unspecified upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of short bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified bones and articular cartilage of right limb"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb"},{"name":"Maps_To","value":"Malignant neoplasm of vertebral column, excluding sacrum and coccyx"},{"name":"Maps_To","value":"Malignant neoplasm: Bone and articular cartilage, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Bones of skull and face"},{"name":"Maps_To","value":"Malignant neoplasm: Long bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm: Pelvic bones, sacrum and coccyx"},{"name":"Maps_To","value":"Malignant neoplasm: Scapula and long bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm: Short bones of lower limb"},{"name":"Maps_To","value":"Malignant neoplasm: Short bones of upper limb"},{"name":"Maps_To","value":"Malignant neoplasm: Vertebral column"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279530"}]}}{"C3568":{"preferredName":"Malignant Brain Neoplasm","code":"C3568","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the brain.","type":"DEFINITION","source":"NCI"},{"definition":"An abnormal solid mass arising within the brain with histologic features suggesting the potential to metastasize.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Malignant Brain Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Brain Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Brain Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Brain Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Brain","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Brain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Malignant_Brain_Neoplasm"},{"name":"Maps_To","value":"Brain Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of brain"},{"name":"Maps_To","value":"Malignant neoplasm of brain, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of other parts of brain"},{"name":"Maps_To","value":"Malignant neoplasm: Brain, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Cerebral ventricle"},{"name":"Maps_To","value":"Malignant neoplasm: Overlapping lesion of brain"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0153633"}]}}{"C4872":{"preferredName":"Breast Carcinoma","code":"C4872","definitions":[{"definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant neoplasm that develops or arises in breast tissue.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A malignant neoplasm that develops or arises in breast tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Breast Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Mammary Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Breast_Carcinoma"},{"name":"Maps_To","value":"Breast cancer"},{"name":"Maps_To","value":"Breast Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0678222"},{"name":"xRef","value":"IMDRF:E180101"}]}}{"C9039":{"preferredName":"Cervical Carcinoma","code":"C9039","definitions":[{"definition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the cervix (the organ connecting the uterus and vagina). It is usually a slow-growing cancer that may not have symptoms but can be found with regular Pap tests (a procedure in which cells are scraped from the cervix and looked at under a microscope). Cervical cancer is almost always caused by human papillomavirus (HPV) infection.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cervical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Cervix Uteri","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Uterine Cervix","termGroup":"SY","termSource":"NCI"},{"termName":"Cervical Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Cervix Uteri Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cervix Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cervical_Carcinoma"},{"name":"Maps_To","value":"Cervical Cancer"},{"name":"Maps_To","value":"Cervical Cancer (all types)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0302592"}]}}{"C4627":{"preferredName":"Malignant Central Nervous System Neoplasm","code":"C4627","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Central Nervous System Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Central Nervous System Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Malignant Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"CNS Neoplasms, Malignant","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Central Nervous System Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant CNS Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant CNS Neoplasms","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant CNS Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of CNS","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Central Nervous System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the CNS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Central_Nervous_System_Neoplasm"},{"name":"Maps_To","value":"Brain and Nervous System"},{"name":"Maps_To","value":"CNS Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system"},{"name":"Maps_To","value":"Malignant neoplasm: Central nervous system, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0348374"}]}}{"C2955":{"preferredName":"Colorectal Carcinoma","code":"C2955","definitions":[{"definition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colorectal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Large Bowel","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Large Intestine","termGroup":"SY","termSource":"NCI"},{"termName":"Colorectal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"CRC","termGroup":"AB","termSource":"NCI"},{"termName":"Large Bowel Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Large Bowel Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Large Intestine Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Large Intestine Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colorectal_Carcinoma"},{"name":"Maps_To","value":"Colorectal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0009402"}]}}{"C3513":{"preferredName":"Esophageal Carcinoma","code":"C3513","definitions":[{"definition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues lining the esophagus (the muscular tube through which food passes from the throat to the stomach). Two types of esophageal cancer are squamous cell carcinoma (cancer that begins in flat cells lining the esophagus) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Esophageal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"ESCA","termGroup":"AB","termSource":"NCI"},{"termName":"Esophageal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Esophagus Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Esophageal_Carcinoma"},{"name":"Maps_To","value":"Esophageal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152018"}]}}{"C3844":{"preferredName":"Gallbladder Carcinoma","code":"C3844","definitions":[{"definition":"A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the gallbladder. The gallbladder is a pear-shaped organ below the liver that collects and stores bile (a fluid made by the liver to digest fat). Gallbladder cancer begins in the innermost layer of tissue and spreads through the outer layers as it grows.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gallbladder Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Gallbladder","termGroup":"SY","termSource":"NCI"},{"termName":"Gallbladder Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gallbladder_Carcinoma"},{"name":"Maps_To","value":"Gallbladder Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0235782"}]}}{"C4911":{"preferredName":"Gastric Carcinoma","code":"C4911","definitions":[{"definition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues lining the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastric Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Gastric Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Stomach Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Stomach Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastric_Carcinoma"},{"name":"Maps_To","value":"Gastric Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0699791"}]}}{"C4913":{"preferredName":"Malignant Female Reproductive System Neoplasm","code":"C4913","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the female reproductive system.  Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer of the female reproductive tract, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Female Reproductive System Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Female Reproductive Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Gynecologic Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Female Reproductive System Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Gynecologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Gynecologic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Female Reproductive System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Female Reproductive System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Female Reproductive System","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Female Reproductive System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Female_Reproductive_System_Neoplasm"},{"name":"Maps_To","value":"Gynecologic Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of female genital organ, site unspecified"},{"name":"Maps_To","value":"Malignant neoplasm of other and unspecified female genital organs"},{"name":"Maps_To","value":"Malignant neoplasm of ovary and other uterine adnexa"},{"name":"Maps_To","value":"Malignant neoplasm of uterine adnexa, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Female genital organ, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Other specified female genital organs"},{"name":"Maps_To","value":"Malignant neoplasm: Uterine adnexa, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0699889"}]}}{"C4013":{"preferredName":"Malignant Head and Neck Neoplasm","code":"C4013","definitions":[{"definition":"A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that arises in the head or neck region (in the nasal cavity, sinuses, lip, mouth, salivary glands, throat, or larynx [voice box]).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Head and Neck Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Head and Neck Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Head and Neck Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Head and Neck","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Head and Neck","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Head_and_Neck_Neoplasm"},{"name":"Maps_To","value":"Head and Neck Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of head, face, and neck"},{"name":"Maps_To","value":"Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses"},{"name":"Maps_To","value":"Malignant neoplasm of nasal cavity and middle ear"},{"name":"Maps_To","value":"Malignant neoplasm of other and ill-defined sites: Head, face and neck"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0278996"}]}}{"C27134":{"preferredName":"Hematopoietic and Lymphoid Cell Neoplasm","code":"C27134","definitions":[{"definition":"A cancer of the blood or bone marrow, such as leukemia or lymphoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant neoplasm composed of hemolymphoreticular cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A neoplasm that arises from hematopoietic and lymphoid cells. Representative examples include myeloproliferative neoplasms, myelodysplastic syndromes, leukemias, Hodgkin lymphomas, and non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic and Lymphoid Cell Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Hematologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematological Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic and Lymphoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Neoplasms Including Lymphomas","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Hematologic Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Hematopoietic Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Hematopoietic_Cell_Neoplasm"},{"name":"Maps_To","value":"Hematologic Cancer"},{"name":"Maps_To","value":"Malignant neoplasm of lymphoid, haematopoietic and related tissue, unspecified"},{"name":"Maps_To","value":"Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue"},{"name":"Maps_To","value":"Other lymphatic and hematopoietic tissues"},{"name":"Maps_To","value":"Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0376545"}]}}{"C9384":{"preferredName":"Kidney Carcinoma","code":"C9384","definitions":[{"definition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the kidneys. Kidney cancer includes renal cell carcinoma (cancer that forms in the lining of very small tubes in the kidney that filter the blood and remove waste products) and renal pelvis carcinoma (cancer that forms in the center of the kidney where urine collects). It also includes Wilms tumor, which is a type of kidney cancer that usually develops in children under the age of 5.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Kidney Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Carcinoma"},{"name":"Maps_To","value":"Kidney Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1378703"}]}}{"C4855":{"preferredName":"Laryngeal Carcinoma","code":"C4855","definitions":[{"definition":"Cancer that forms in tissues of the larynx (area of the throat that contains the vocal cords and is used for breathing, swallowing, and talking). Most laryngeal cancers are squamous cell carcinomas (cancer that begins in flat cells lining the larynx).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma that arises from the laryngeal epithelium. More than 90% of laryngeal carcinomas are squamous cell carcinomas. The remainder are adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas with neuroendocrine differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laryngeal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Larynx","termGroup":"SY","termSource":"NCI"},{"termName":"Laryngeal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Larynx Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laryngeal_Carcinoma"},{"name":"Maps_To","value":"Laryngeal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0595989"}]}}{"C7927":{"preferredName":"Liver Carcinoma","code":"C7927","definitions":[{"definition":"A carcinoma that arises from the hepatocytes or intrahepatic bile ducts.  The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"Primary liver cancer is cancer that forms in the tissues of the liver. Secondary liver cancer is cancer that spreads to the liver from another part of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Liver Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Liver and Intrahepatic Biliary Tract","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Bile Duct Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Bile Duct Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Biliary Tract Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Liver and Intrahepatic Biliary Tract Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Liver Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Liver Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liver_and_Intrahepatic_Biliary_Tract_Carcinoma"},{"name":"Maps_To","value":"Liver Cancer"},{"name":"Maps_To","value":"Malignant neoplasm: Other specified carcinomas of liver"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279000"}]}}{"C4878":{"preferredName":"Lung Carcinoma","code":"C4878","definitions":[{"definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the lung, usually in the cells lining air passages. The two main types are small cell lung cancer and non-small cell lung cancer. These types are diagnosed based on how the cells look under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lung Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Lung Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Carcinoma"},{"name":"Maps_To","value":"Lung Cancer"},{"name":"Maps_To","value":"Lung Cancer (all types)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0684249"}]}}{"C35812":{"preferredName":"Malignant Lymph Node Neoplasm","code":"C35812","definitions":[{"definition":"A primary or metastatic malignant tumor involving the lymph node.  Lymphomas and metastatic carcinomas are representative examples.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Lymph Node Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Node Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Lymph_Node_Neoplasm"},{"name":"Maps_To","value":"Lymph Node Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0948627"}]}}{"C7431":{"preferredName":"Malignant Ovarian Neoplasm","code":"C7431","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the ovary (one of a pair of female reproductive glands in which the ova, or eggs, are formed). Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Ovarian Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Ovarian Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Ovary","termGroup":"SY","termSource":"NCI"},{"termName":"Ovarian Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Ovarian_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm of left ovary"},{"name":"Maps_To","value":"Malignant neoplasm of ovary"},{"name":"Maps_To","value":"Malignant neoplasm of right ovary"},{"name":"Maps_To","value":"Malignant neoplasm of unspecified ovary"},{"name":"Maps_To","value":"Ovarian Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3810371"}]}}{"C3850":{"preferredName":"Pancreatic Carcinoma","code":"C3850","definitions":[{"definition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"A disease in which malignant (cancer) cells are found in the tissues of the pancreas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatic Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Exocrine Pancreas Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Carcinoma"},{"name":"Maps_To","value":"Pancreas Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0235974"}]}}{"C7708":{"preferredName":"Childhood Malignant Liver Neoplasm","code":"C7708","definitions":[{"definition":"A malignant neoplasm that affects the liver and occurs during childhood.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant tumor of the liver occurring during childhood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood Malignant Liver Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Childhood Cancer of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Cancer of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Liver Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Childhood Malignant Liver Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Cancer of Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Cancer of the Liver","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Liver Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Pediatric Malignant Liver Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Childhood_Liver_Cancer"},{"name":"Maps_To","value":"Pediatric Liver Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2945767"}]}}{"C4863":{"preferredName":"Prostate Carcinoma","code":"C4863","definitions":[{"definition":"Cancer that forms in tissues of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum). Prostate cancer usually occurs in older men.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Prostate_Carcinoma"},{"name":"Maps_To","value":"Prostate Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0600139"}]}}{"C9382":{"preferredName":"Rectal Carcinoma","code":"C9382","definitions":[{"definition":"A malignant epithelial neoplasm that arises from the rectum. The vast majority are adenocarcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the rectum (the last several inches of the large intestine closest to the anus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rectal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Rectum","termGroup":"SY","termSource":"NCI"},{"termName":"Rectal Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rectal_Carcinoma"},{"name":"Maps_To","value":"Rectal Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007113"}]}}{"C2920":{"preferredName":"Malignant Skin Neoplasm","code":"C2920","definitions":[{"definition":"A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissues of the skin. There are several types of skin cancer. Skin cancer that forms in melanocytes (skin cells that make pigment) is called melanoma. Skin cancer that forms in the lower part of the epidermis (the outer layer of the skin) is called basal cell carcinoma. Skin cancer that forms in squamous cells (flat cells that form the surface of the skin) is called squamous cell carcinoma. Skin cancer that forms in neuroendocrine cells (cells that release hormones in response to signals from the nervous system) is called neuroendocrine carcinoma of the skin. Most skin cancers form in older people on parts of the body exposed to the sun or in people who have weakened immune systems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Skin Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Neoplasm of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Skin Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Melanoma and Non-Melanoma Skin Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Cancer, Including Melanoma","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Neoplasm, Malignant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Skin_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm: Malignant neoplasm of skin, unspecified"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of ear and external auricular canal"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of eyelid, including canthus"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of lower limb, including hip"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of other and unspecified parts of face"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of scalp and neck"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of trunk"},{"name":"Maps_To","value":"Malignant neoplasm: Skin of upper limb, including shoulder"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of scalp and skin of neck"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of lower limb, including hip"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of other and unspecified parts of face"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of trunk, except scrotum"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin of upper limb, including shoulder"},{"name":"Maps_To","value":"Other and unspecified malignant neoplasm of skin, site unspecified"},{"name":"Maps_To","value":"Other malignant neoplasms of skin"},{"name":"Maps_To","value":"Other specified malignant neoplasm of overlapping sites of skin"},{"name":"Maps_To","value":"Other specified malignant neoplasm of scalp and skin of neck"},{"name":"Maps_To","value":"Other specified malignant neoplasm of skin, unspecified"},{"name":"Maps_To","value":"Skin Cancer"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of scalp and skin of neck"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of skin of unspecified part of face"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of skin, site unspecified"},{"name":"Maps_To","value":"Unspecified malignant neoplasm of skin, unspecified"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0007114"}]}}{"C3539":{"preferredName":"Malignant Splenic Neoplasm","code":"C3539","definitions":[{"definition":"A malignant neoplasm affecting the spleen. Representative examples include leukemias, lymphomas, and sarcomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Splenic Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Splenic Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Spleen","termGroup":"SY","termSource":"NCI"},{"termName":"Spleen Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Splenic Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Splenic_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm: Spleen"},{"name":"Maps_To","value":"Spleen Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0153470"}]}}{"C9063":{"preferredName":"Malignant Testicular Germ Cell Tumor","code":"C9063","definitions":[{"definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the testis (one of two egg-shaped glands inside the scrotum that make sperm and male hormones). Testicular cancer usually occurs in young or middle-aged men. Two main types of testicular cancer are seminomas (cancers that grow slowly and are sensitive to radiation therapy) and nonseminomas (different cell types that grow more quickly than seminomas).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Malignant Testicular Germ Cell Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"Malignant Germ Cell Neoplasm of Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Germ Cell Neoplasm of the Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Germ Cell Tumor of Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Germ Cell Tumor of the Testis","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Testicular Germ Cell Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Testicular Germ Cell Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malignant_Testicular_Germ_Cell_Tumor"},{"name":"Maps_To","value":"Testicular Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0855197"}]}}{"C35506":{"preferredName":"Throat Carcinoma","code":"C35506","definitions":[{"definition":"Cancer that forms in tissues of the pharynx (the hollow tube inside the neck that starts behind the nose and ends at the top of the windpipe and esophagus). Throat cancer includes cancer of the nasopharynx (the upper part of the throat behind the nose), the oropharynx (the middle part of the pharynx), and the hypopharynx (the bottom part of the pharynx). Cancer of the larynx (voice box) may also be included as a type of throat cancer. Most throat cancers are squamous cell carcinomas (cancer that begins in thin, flat cells that look like fish scales).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carcinoma, predominantly squamous cell, arising from epithelial cells of the larynx or pharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Throat Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Throat Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Throat_Cancer"},{"name":"Maps_To","value":"Throat Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0740339"}]}}{"C4815":{"preferredName":"Thyroid Gland Carcinoma","code":"C4815","definitions":[{"definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant tumor arising from the epithelial cells of the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Cancer that forms in the thyroid gland (an organ at the base of the throat that makes hormones that help control heart rate, blood pressure, body temperature, and weight). Four main types of thyroid cancer are papillary, follicular, medullary, and anaplastic thyroid cancer. The four types are based on how the cancer cells look under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thyroid Gland Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"THCA","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroid Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Gland Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Thyroid_Carcinoma"},{"name":"Maps_To","value":"Thyroid Cancer"},{"name":"Maps_To","value":"Thyroid cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0549473"}]}}{"C4824":{"preferredName":"Tongue Carcinoma","code":"C4824","definitions":[{"definition":"A malignant tumor arising from the epithelium that covers the tongue.  The vast majority of tongue carcinomas are moderately or poorly differentiated squamous cell carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that begins in the tongue. When the cancer begins in the front two-thirds of the tongue, it is considered to be a type of oral cavity cancer; when the cancer begins in the back third of the tongue, it is considered to be a type of oropharyngeal or throat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tongue Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Tongue Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tongue_Carcinoma"},{"name":"Maps_To","value":"Tongue Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0558353"}]}}{"C4825":{"preferredName":"Tonsillar Carcinoma","code":"C4825","definitions":[{"definition":"A carcinoma arising from the tonsilar epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillar Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Tonsil","termGroup":"SY","termSource":"NCI"},{"termName":"Tonsil Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Tonsil Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Tonsillar Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillar_Carcinoma"},{"name":"Maps_To","value":"Tonsillar Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0558355"}]}}{"C3552":{"preferredName":"Malignant Uterine Neoplasm","code":"C3552","definitions":[{"definition":"Cancer that forms in tissues of the uterus (the small, hollow, pear-shaped organ in a woman's pelvis in which a fetus develops). Two types of uterine cancer are endometrial cancer (cancer that begins in cells lining the uterus) and uterine sarcoma (a rare cancer that begins in muscle or other tissues in the uterus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Malignant Uterine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Neoplasm of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Tumor of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Uterine Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Malignant_Uterine_Neoplasm"},{"name":"Maps_To","value":"Malignant neoplasm of isthmus"},{"name":"Maps_To","value":"Malignant neoplasm of uterus, part unspecified"},{"name":"Maps_To","value":"Uterine Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0153567"}]}}{"C143253":{"preferredName":"Abdominal Distension, CTCAE","code":"C143253","definitions":[{"definition":"A disorder characterized by swelling of the abdomen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling of the abdomen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Abdominal Distension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal Distension"},{"name":"Maps_To","value":"Abdominal distension"},{"name":"NCI_META_CUI","value":"CL541634"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143254":{"preferredName":"Abdominal Infection, CTCAE","code":"C143254","definitions":[{"definition":"A disorder characterized by an infectious process involving the abdominal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the abdominal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Abdominal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal infection"},{"name":"Maps_To","value":"Abdominal Infection"},{"name":"NCI_META_CUI","value":"CL541635"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143255":{"preferredName":"Abdominal Pain, CTCAE","code":"C143255","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the abdominal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the abdominal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Abdominal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal pain"},{"name":"Maps_To","value":"Abdominal Pain"},{"name":"NCI_META_CUI","value":"CL541636"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143256":{"preferredName":"Abdominal Soft Tissue Necrosis, CTCAE","code":"C143256","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Abdominal Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal soft tissue necrosis"},{"name":"Maps_To","value":"Abdominal Soft Tissue Necrosis"},{"name":"NCI_META_CUI","value":"CL541637"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143257":{"preferredName":"Abducens Nerve Disorder, CTCAE","code":"C143257","definitions":[{"definition":"A disorder characterized by dysfunction of the abducens nerve (sixth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the abducens nerve (sixth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Abducens Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abducens nerve disorder"},{"name":"Maps_To","value":"Abducens Nerve Disorder"},{"name":"NCI_META_CUI","value":"CL541638"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143258":{"preferredName":"Accessory Nerve Disorder, CTCAE","code":"C143258","definitions":[{"definition":"A disorder characterized by dysfunction of the accessory nerve (eleventh cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the accessory nerve (eleventh cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Accessory Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Accessory nerve disorder"},{"name":"Maps_To","value":"Accessory Nerve Disorder"},{"name":"NCI_META_CUI","value":"CL541639"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143259":{"preferredName":"Acidosis, CTCAE","code":"C143259","definitions":[{"definition":"A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Acidosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acidosis"},{"name":"NCI_META_CUI","value":"CL541640"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143260":{"preferredName":"Acoustic Nerve Disorder NOS, CTCAE","code":"C143260","definitions":[{"definition":"A disorder characterized by dysfunction of the acoustic nerve (eighth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the acoustic nerve (eighth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Acoustic Nerve Disorder NOS, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acoustic nerve disorder NOS"},{"name":"Maps_To","value":"Acoustic Nerve Disorder NOS"},{"name":"NCI_META_CUI","value":"CL546042"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143261":{"preferredName":"Activated Partial Thromboplastin Time Prolonged, CTCAE","code":"C143261","definitions":[{"definition":"A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Activated Partial Thromboplastin Time Prolonged, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Activated partial thromboplastin time prolonged"},{"name":"Maps_To","value":"Activated Partial Thromboplastin Time Prolonged"},{"name":"NCI_META_CUI","value":"CL541628"},{"name":"Semantic_Type","value":"Finding"}]}}{"C53652":{"preferredName":"Acute Coronary Syndrome","code":"C53652","definitions":[{"definition":"A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Coronary Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acute_Coronary_Syndrome"},{"name":"Maps_To","value":"Acute Coronary Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0948089"}]}}{"C143262":{"preferredName":"Acute Kidney Injury, CTCAE","code":"C143262","definitions":[{"definition":"A disorder characterized by the acute loss of renal function (within 2 weeks) and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the acute loss of renal function (within 2 weeks) and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Acute Kidney Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acute kidney injury"},{"name":"Maps_To","value":"Acute Kidney Injury"},{"name":"NCI_META_CUI","value":"CL545954"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55748":{"preferredName":"Adrenal Insufficiency, CTCAE","code":"C55748","definitions":[{"definition":"A disorder characterized by the adrenal cortex not producing enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the adrenal cortex not producing enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Adrenal Insufficiency, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adrenal_Insufficiency_Adverse_Event"},{"name":"Maps_To","value":"Adrenal Insufficiency"},{"name":"Maps_To","value":"Adrenal insufficiency"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963059"}]}}{"C58020":{"preferredName":"Adult Respiratory Distress Syndrome, CTCAE","code":"C58020","definitions":[{"definition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Adult Respiratory Distress Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adult_Respiratory_Distress_Syndrome_Adverse_Event"},{"name":"Maps_To","value":"Adult respiratory distress syndrome"},{"name":"Maps_To","value":"Adult Respiratory Distress Syndrome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963227"}]}}{"C146777":{"preferredName":"Agitation, CTCAE 5.0","code":"C146777","definitions":[{"definition":"A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Agitation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agitation"},{"name":"NCI_META_CUI","value":"CL544784"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143266":{"preferredName":"Akathisia, CTCAE","code":"C143266","definitions":[{"definition":"A disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Akathisia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Akathisia"},{"name":"NCI_META_CUI","value":"CL541629"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143267":{"preferredName":"Alanine Aminotransferase Increased, CTCAE","code":"C143267","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Alanine Aminotransferase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alanine aminotransferase increased"},{"name":"Maps_To","value":"Alanine Aminotransferase Increased"},{"name":"NCI_META_CUI","value":"CL541630"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143268":{"preferredName":"Alcohol Intolerance, CTCAE","code":"C143268","definitions":[{"definition":"A disorder characterized by an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Alcohol Intolerance, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alcohol intolerance"},{"name":"Maps_To","value":"Alcohol Intolerance"},{"name":"NCI_META_CUI","value":"CL541631"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143269":{"preferredName":"Alkaline Phosphatase Increased, CTCAE","code":"C143269","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Alkaline Phosphatase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alkaline phosphatase increased"},{"name":"Maps_To","value":"Alkaline Phosphatase Increased"},{"name":"NCI_META_CUI","value":"CL546025"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143270":{"preferredName":"Alkalosis, CTCAE","code":"C143270","definitions":[{"definition":"A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Alkalosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alkalosis"},{"name":"NCI_META_CUI","value":"CL541632"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143271":{"preferredName":"Allergic Reaction, CTCAE","code":"C143271","definitions":[{"definition":"A disorder characterized by an adverse local or general response from exposure to an allergen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an adverse local or general response from exposure to an allergen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Allergic Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergic Reaction"},{"name":"Maps_To","value":"Allergic reaction"},{"name":"NCI_META_CUI","value":"CL541633"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143272":{"preferredName":"Allergic Rhinitis, CTCAE","code":"C143272","definitions":[{"definition":"A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Allergic Rhinitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergic Rhinitis"},{"name":"Maps_To","value":"Allergic rhinitis"},{"name":"NCI_META_CUI","value":"CL541718"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57898":{"preferredName":"Alopecia, CTCAE","code":"C57898","definitions":[{"definition":"A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Alopecia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alopecia_Adverse_Event"},{"name":"Maps_To","value":"Alopecia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559115"}]}}{"C143274":{"preferredName":"Amnesia, CTCAE","code":"C143274","definitions":[{"definition":"A disorder characterized by systematic and extensive loss of memory.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by systematic and extensive loss of memory.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Amnesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amnesia"},{"name":"NCI_META_CUI","value":"CL541719"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143275":{"preferredName":"Anal Fistula, CTCAE","code":"C143275","definitions":[{"definition":"A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Fistula"},{"name":"Maps_To","value":"Anal fistula"},{"name":"NCI_META_CUI","value":"CL546016"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143276":{"preferredName":"Anal Hemorrhage, CTCAE","code":"C143276","definitions":[{"definition":"A disorder characterized by bleeding from the anal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the anal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Hemorrhage"},{"name":"Maps_To","value":"Anal hemorrhage"},{"name":"NCI_META_CUI","value":"CL541720"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143277":{"preferredName":"Anal Mucositis, CTCAE","code":"C143277","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the anus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the anus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Mucositis"},{"name":"Maps_To","value":"Anal mucositis"},{"name":"NCI_META_CUI","value":"CL541721"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143278":{"preferredName":"Anal Necrosis, CTCAE","code":"C143278","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the anal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the anal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Necrosis"},{"name":"Maps_To","value":"Anal necrosis"},{"name":"NCI_META_CUI","value":"CL541722"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143279":{"preferredName":"Anal Pain, CTCAE","code":"C143279","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the anal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the anal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal Pain"},{"name":"Maps_To","value":"Anal pain"},{"name":"NCI_META_CUI","value":"CL541723"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143280":{"preferredName":"Anal Stenosis, CTCAE","code":"C143280","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the anal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the anal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal stenosis"},{"name":"Maps_To","value":"Anal Stenosis"},{"name":"NCI_META_CUI","value":"CL541724"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143281":{"preferredName":"Anal Ulcer, CTCAE","code":"C143281","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the anal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the anal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anal ulcer"},{"name":"Maps_To","value":"Anal Ulcer"},{"name":"NCI_META_CUI","value":"CL541712"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143282":{"preferredName":"Anaphylaxis, CTCAE","code":"C143282","definitions":[{"definition":"A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anaphylaxis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anaphylaxis"},{"name":"NCI_META_CUI","value":"CL546000"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143283":{"preferredName":"Anemia, CTCAE","code":"C143283","definitions":[{"definition":"A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anemia"},{"name":"NCI_META_CUI","value":"CL545972"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143284":{"preferredName":"Ankle Fracture, CTCAE","code":"C143284","definitions":[{"definition":"A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ankle Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ankle fracture"},{"name":"Maps_To","value":"Ankle Fracture"},{"name":"NCI_META_CUI","value":"CL541713"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143285":{"preferredName":"Anorectal Infection, CTCAE","code":"C143285","definitions":[{"definition":"A disorder characterized by an infectious process involving the anal area and the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the anal area and the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Anorectal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anorectal infection"},{"name":"Maps_To","value":"Anorectal Infection"},{"name":"NCI_META_CUI","value":"CL541714"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57118":{"preferredName":"Anorexia, CTCAE","code":"C57118","definitions":[{"definition":"A disorder characterized by a loss of appetite.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a loss of appetite.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anorexia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anorexia_Adverse_Event"},{"name":"Maps_To","value":"Anorexia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963063"}]}}{"C143287":{"preferredName":"Anorgasmia, CTCAE","code":"C143287","definitions":[{"definition":"A disorder characterized by an inability to achieve orgasm.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inability to achieve orgasm.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anorgasmia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anorgasmia"},{"name":"NCI_META_CUI","value":"CL541715"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146778":{"preferredName":"Anxiety, CTCAE 5.0","code":"C146778","definitions":[{"definition":"A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Anxiety, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anxiety"},{"name":"NCI_META_CUI","value":"CL544785"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143289":{"preferredName":"Aortic Injury, CTCAE","code":"C143289","definitions":[{"definition":"A finding of damage to the aorta.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the aorta.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Aortic Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aortic injury"},{"name":"Maps_To","value":"Aortic Injury"},{"name":"NCI_META_CUI","value":"CL541716"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143290":{"preferredName":"Aortic Valve Disease, CTCAE","code":"C143290","definitions":[{"definition":"A disorder characterized by a defect in aortic valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a defect in aortic valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Aortic Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aortic valve disease"},{"name":"Maps_To","value":"Aortic Valve Disease"},{"name":"NCI_META_CUI","value":"CL541717"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143291":{"preferredName":"Aphonia, CTCAE","code":"C143291","definitions":[{"definition":"A disorder characterized by the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Aphonia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aphonia"},{"name":"NCI_META_CUI","value":"CL541706"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55340":{"preferredName":"Apnea, CTCAE","code":"C55340","definitions":[{"definition":"A disorder characterized by cessation of breathing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by cessation of breathing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Apnea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Apnea_Adverse_Event"},{"name":"Maps_To","value":"Apnea"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963065"}]}}{"C143294":{"preferredName":"Appendicitis, CTCAE","code":"C143294","definitions":[{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Appendicitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Appendicitis"},{"name":"NCI_META_CUI","value":"CL545962"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143293":{"preferredName":"Appendicitis Perforated, CTCAE","code":"C143293","definitions":[{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Appendicitis Perforated, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Appendicitis perforated"},{"name":"Maps_To","value":"Appendicitis Perforated"},{"name":"NCI_META_CUI","value":"CL546033"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143295":{"preferredName":"Arachnoiditis, CTCAE","code":"C143295","definitions":[{"definition":"A disorder characterized by inflammation of the arachnoid membrane and adjacent subarachnoid space.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the arachnoid membrane and adjacent subarachnoid space.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Arachnoiditis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arachnoiditis"},{"name":"NCI_META_CUI","value":"CL541707"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143296":{"preferredName":"Arterial Injury, CTCAE","code":"C143296","definitions":[{"definition":"A finding of damage to an artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to an artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Arterial Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arterial injury"},{"name":"Maps_To","value":"Arterial Injury"},{"name":"NCI_META_CUI","value":"CL541708"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143297":{"preferredName":"Arteritis Infective, CTCAE","code":"C143297","definitions":[{"definition":"A disorder characterized by an infectious process involving an artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving an artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Arteritis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arteritis Infective"},{"name":"Maps_To","value":"Arteritis infective"},{"name":"NCI_META_CUI","value":"CL541709"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143298":{"preferredName":"Arthralgia, CTCAE","code":"C143298","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in a joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in a joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Arthralgia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arthralgia"},{"name":"NCI_META_CUI","value":"CL541710"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143299":{"preferredName":"Arthritis, CTCAE","code":"C143299","definitions":[{"definition":"A disorder characterized by inflammation involving a joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation involving a joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Arthritis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arthritis"},{"name":"NCI_META_CUI","value":"CL541711"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143300":{"preferredName":"Ascites, CTCAE","code":"C143300","definitions":[{"definition":"A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ascites, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ascites"},{"name":"NCI_META_CUI","value":"CL541698"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143301":{"preferredName":"Aspartate Aminotransferase Increased, CTCAE","code":"C143301","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Aspartate Aminotransferase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aspartate aminotransferase increased"},{"name":"Maps_To","value":"Aspartate Aminotransferase Increased"},{"name":"NCI_META_CUI","value":"CL541699"},{"name":"Semantic_Type","value":"Finding"}]}}{"C28245":{"preferredName":"Aspiration, CTCAE","code":"C28245","definitions":[{"definition":"A disorder characterized by inhalation of solids or liquids into the lungs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inhalation of solids or liquids into the lungs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"The entry of foreign material past the trachea, and into the lower respiratory tract.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Aspiration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Inhalation"},{"name":"Maps_To","value":"Aspiration"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963221"},{"name":"xRef","value":"IMDRF:E0704"}]}}{"C146731":{"preferredName":"Asystole, CTCAE 5.0","code":"C146731","definitions":[{"definition":"A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Asystole, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Asystole"},{"name":"NCI_META_CUI","value":"CL544694"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146737":{"preferredName":"Ataxia, CTCAE 5.0","code":"C146737","definitions":[{"definition":"A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ataxia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ataxia"},{"name":"NCI_META_CUI","value":"CL545970"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58022":{"preferredName":"Atelectasis, CTCAE","code":"C58022","definitions":[{"definition":"A disorder characterized by the collapse of part or the entire lung.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the collapse of part or the entire lung.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atelectasis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atelectasis_Adverse_Event"},{"name":"Maps_To","value":"Atelectasis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962948"}]}}{"C54767":{"preferredName":"Atrial Fibrillation, CTCAE","code":"C54767","definitions":[{"definition":"A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atrial Fibrillation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atrial_Fibrillation_Adverse_Event"},{"name":"Maps_To","value":"Atrial fibrillation"},{"name":"Maps_To","value":"Atrial Fibrillation"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963067"}]}}{"C54768":{"preferredName":"Atrial Flutter, CTCAE","code":"C54768","definitions":[{"definition":"A disorder characterized by a dysrhythmia with organized rhythmic atrial contractions with a rate of 200-300 beats per minute. The rhythm disturbance originates in the atria.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with organized rhythmic atrial contractions with a rate of 200-300 beats per minute. The rhythm disturbance originates in the atria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atrial Flutter, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atrial_Flutter_Adverse_Event"},{"name":"Maps_To","value":"Atrial flutter"},{"name":"Maps_To","value":"Atrial Flutter"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963068"}]}}{"C143308":{"preferredName":"Atrioventricular Block Complete, CTCAE","code":"C143308","definitions":[{"definition":"A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atrioventricular Block Complete, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Atrioventricular block complete"},{"name":"Maps_To","value":"Atrioventricular Block Complete"},{"name":"NCI_META_CUI","value":"CL541700"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143309":{"preferredName":"Atrioventricular Block First Degree, CTCAE","code":"C143309","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval greater than 200 milliseconds.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval greater than 200 milliseconds.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Atrioventricular Block First Degree, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Atrioventricular block first degree"},{"name":"Maps_To","value":"Atrioventricular Block First Degree"},{"name":"NCI_META_CUI","value":"CL541701"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143310":{"preferredName":"Autoimmune Disorder, CTCAE","code":"C143310","definitions":[{"definition":"A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Autoimmune Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autoimmune disorder"},{"name":"Maps_To","value":"Autoimmune Disorder"},{"name":"NCI_META_CUI","value":"CL541702"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143311":{"preferredName":"Avascular Necrosis, CTCAE","code":"C143311","definitions":[{"definition":"A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Avascular Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Avascular necrosis"},{"name":"Maps_To","value":"Avascular Necrosis"},{"name":"NCI_META_CUI","value":"CL541703"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143312":{"preferredName":"Azoospermia, CTCAE","code":"C143312","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate complete absence of spermatozoa in the semen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate complete absence of spermatozoa in the semen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Azoospermia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Azoospermia"},{"name":"NCI_META_CUI","value":"CL541704"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146739":{"preferredName":"Back Pain, CTCAE 5.0","code":"C146739","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the back region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the back region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Back Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Back Pain"},{"name":"Maps_To","value":"Back pain"},{"name":"NCI_META_CUI","value":"CL544687"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143314":{"preferredName":"Bile Duct Stenosis, CTCAE","code":"C143314","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the bile duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the bile duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bile Duct Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bile Duct Stenosis"},{"name":"Maps_To","value":"Bile duct stenosis"},{"name":"NCI_META_CUI","value":"CL541705"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143315":{"preferredName":"Biliary Anastomotic Leak, CTCAE","code":"C143315","definitions":[{"definition":"A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Biliary Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary anastomotic leak"},{"name":"Maps_To","value":"Biliary Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL541691"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143316":{"preferredName":"Biliary Fistula, CTCAE","code":"C143316","definitions":[{"definition":"A disorder characterized by an abnormal communication between the bile ducts and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the bile ducts and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Biliary Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary Fistula"},{"name":"Maps_To","value":"Biliary fistula"},{"name":"NCI_META_CUI","value":"CL541692"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143317":{"preferredName":"Biliary Tract Infection, CTCAE","code":"C143317","definitions":[{"definition":"A disorder characterized by an infectious process involving the biliary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the biliary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Biliary Tract Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biliary tract infection"},{"name":"Maps_To","value":"Biliary Tract Infection"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0920156"}]}}{"C143318":{"preferredName":"Bladder Anastomotic Leak, CTCAE","code":"C143318","definitions":[{"definition":"A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bladder Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bladder Anastomotic Leak"},{"name":"Maps_To","value":"Bladder anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541693"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143319":{"preferredName":"Bladder Infection, CTCAE","code":"C143319","definitions":[{"definition":"A disorder characterized by an infectious process involving the bladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the bladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bladder Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bladder infection"},{"name":"Maps_To","value":"Bladder Infection"},{"name":"NCI_META_CUI","value":"CL541694"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146707":{"preferredName":"Bladder Perforation, CTCAE 5.0","code":"C146707","definitions":[{"definition":"A disorder characterized by a rupture in the bladder wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the bladder wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bladder Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bladder Perforation"},{"name":"Maps_To","value":"Bladder perforation"},{"name":"NCI_META_CUI","value":"CL544718"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146698":{"preferredName":"Bladder Spasm, CTCAE 5.0","code":"C146698","definitions":[{"definition":"A disorder characterized by a sudden and involuntary contraction of the bladder wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sudden and involuntary contraction of the bladder wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bladder Spasm, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Bladder spasm"},{"name":"Maps_To","value":"Bladder Spasm"},{"name":"NCI_META_CUI","value":"CL544725"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143322":{"preferredName":"Bloating, CTCAE","code":"C143322","definitions":[{"definition":"A disorder characterized by subject-reported feeling of uncomfortable fullness of the abdomen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by subject-reported feeling of uncomfortable fullness of the abdomen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bloating, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bloating"},{"name":"NCI_META_CUI","value":"CL541695"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143323":{"preferredName":"Blood and Lymphatic System Disorders - Other, Specify, CTCAE","code":"C143323","synonyms":[{"termName":"Blood and Lymphatic System Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood and Lymphatic System Disorders - Other"},{"name":"Maps_To","value":"Blood and lymphatic system disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541696"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143324":{"preferredName":"Blood Antidiuretic Hormone Abnormal, CTCAE","code":"C143324","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Blood Antidiuretic Hormone Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood antidiuretic hormone abnormal"},{"name":"Maps_To","value":"Blood Antidiuretic Hormone Abnormal"},{"name":"NCI_META_CUI","value":"CL541697"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143325":{"preferredName":"Blood Bilirubin Increased, CTCAE","code":"C143325","definitions":[{"definition":"A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Blood Bilirubin Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood bilirubin increased"},{"name":"Maps_To","value":"Blood Bilirubin Increased"},{"name":"NCI_META_CUI","value":"CL541683"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143326":{"preferredName":"Blood Corticotrophin Decreased, CTCAE","code":"C143326","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Blood Corticotrophin Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood corticotrophin decreased"},{"name":"Maps_To","value":"Blood Corticotrophin Decreased"},{"name":"NCI_META_CUI","value":"CL541684"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143327":{"preferredName":"Blood Gonadotrophin Abnormal, CTCAE","code":"C143327","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Blood Gonadotrophin Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood gonadotrophin abnormal"},{"name":"Maps_To","value":"Blood Gonadotrophin Abnormal"},{"name":"NCI_META_CUI","value":"CL541685"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143328":{"preferredName":"Blood Prolactin Abnormal, CTCAE","code":"C143328","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Blood Prolactin Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blood prolactin abnormal"},{"name":"Maps_To","value":"Blood Prolactin Abnormal"},{"name":"NCI_META_CUI","value":"CL541686"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55906":{"preferredName":"Blurred Vision, CTCAE","code":"C55906","definitions":[{"definition":"A disorder characterized by visual perception of unclear or fuzzy images.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by visual perception of unclear or fuzzy images.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Blurred Vision, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blurred_Vision_Adverse_Event"},{"name":"Maps_To","value":"Blurred vision"},{"name":"Maps_To","value":"Blurred Vision"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1557375"}]}}{"C143330":{"preferredName":"Body Odor, CTCAE","code":"C143330","definitions":[{"definition":"A disorder characterized by an abnormal body smell resulting from the growth of bacteria on the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal body smell resulting from the growth of bacteria on the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Body Odor, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Body odor"},{"name":"Maps_To","value":"Body Odor"},{"name":"NCI_META_CUI","value":"CL541687"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143331":{"preferredName":"Bone Infection, CTCAE","code":"C143331","definitions":[{"definition":"A disorder characterized by an infectious process involving the bones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the bones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bone Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone infection"},{"name":"Maps_To","value":"Bone Infection"},{"name":"NCI_META_CUI","value":"CL541688"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143332":{"preferredName":"Bone Marrow Hypocellular, CTCAE","code":"C143332","definitions":[{"definition":"A disorder characterized by the inability of the bone marrow to produce hematopoietic elements.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the inability of the bone marrow to produce hematopoietic elements.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bone Marrow Hypocellular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone marrow hypocellular"},{"name":"Maps_To","value":"Bone Marrow Hypocellular"},{"name":"NCI_META_CUI","value":"CL541689"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146741":{"preferredName":"Bone Pain, CTCAE 5.0","code":"C146741","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the bones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the bones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bone Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone Pain"},{"name":"Maps_To","value":"Bone pain"},{"name":"NCI_META_CUI","value":"CL544689"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146754":{"preferredName":"Brachial Plexopathy, CTCAE 5.0","code":"C146754","definitions":[{"definition":"A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Brachial Plexopathy, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Brachial Plexopathy"},{"name":"Maps_To","value":"Brachial plexopathy"},{"name":"NCI_META_CUI","value":"CL544805"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143335":{"preferredName":"Breast Atrophy, CTCAE","code":"C143335","definitions":[{"definition":"A disorder characterized by underdevelopment of the breast.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by underdevelopment of the breast.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Breast Atrophy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast atrophy"},{"name":"Maps_To","value":"Breast Atrophy"},{"name":"NCI_META_CUI","value":"CL541690"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143336":{"preferredName":"Breast Infection, CTCAE","code":"C143336","definitions":[{"definition":"A disorder characterized by an infectious process involving the breast.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the breast.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Breast Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast infection"},{"name":"Maps_To","value":"Breast Infection"},{"name":"NCI_META_CUI","value":"CL552409"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146742":{"preferredName":"Breast Pain, CTCAE 5.0","code":"C146742","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the breast region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the breast region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Breast Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Breast Pain"},{"name":"Maps_To","value":"Breast pain"},{"name":"NCI_META_CUI","value":"CL545910"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143338":{"preferredName":"Bronchial Fistula, CTCAE","code":"C143338","definitions":[{"definition":"A disorder characterized by an abnormal communication between the bronchus and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the bronchus and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchial Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial fistula"},{"name":"Maps_To","value":"Bronchial Fistula"},{"name":"NCI_META_CUI","value":"CL541677"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143339":{"preferredName":"Bronchial Infection, CTCAE","code":"C143339","definitions":[{"definition":"A disorder characterized by an infectious process involving the bronchi.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the bronchi.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bronchial Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial infection"},{"name":"Maps_To","value":"Bronchial Infection"},{"name":"NCI_META_CUI","value":"CL546040"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143340":{"preferredName":"Bronchial Obstruction, CTCAE","code":"C143340","definitions":[{"definition":"A disorder characterized by blockage of a bronchus passage, most often by bronchial secretions and exudates.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of a bronchus passage, most often by bronchial secretions and exudates.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchial Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial obstruction"},{"name":"Maps_To","value":"Bronchial Obstruction"},{"name":"NCI_META_CUI","value":"CL541678"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143341":{"preferredName":"Bronchial Stricture, CTCAE","code":"C143341","definitions":[{"definition":"A disorder characterized by a narrowing of the bronchial tube.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the bronchial tube.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bronchial Stricture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchial stricture"},{"name":"Maps_To","value":"Bronchial Stricture"},{"name":"NCI_META_CUI","value":"CL541679"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143342":{"preferredName":"Bronchopleural Fistula, CTCAE","code":"C143342","definitions":[{"definition":"A disorder characterized by an abnormal communication between a bronchus and the pleural cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between a bronchus and the pleural cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bronchopleural Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchopleural fistula"},{"name":"Maps_To","value":"Bronchopleural Fistula"},{"name":"NCI_META_CUI","value":"CL541680"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143343":{"preferredName":"Bronchopulmonary Hemorrhage, CTCAE","code":"C143343","definitions":[{"definition":"A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchopulmonary Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchopulmonary hemorrhage"},{"name":"Maps_To","value":"Bronchopulmonary Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541681"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143344":{"preferredName":"Bronchospasm, CTCAE","code":"C143344","definitions":[{"definition":"A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bronchospasm, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bronchospasm"},{"name":"NCI_META_CUI","value":"CL541682"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143345":{"preferredName":"Bruising, CTCAE","code":"C143345","definitions":[{"definition":"A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Bruising, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bruising"},{"name":"NCI_META_CUI","value":"CL541669"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143346":{"preferredName":"Bullous Dermatitis, CTCAE","code":"C143346","definitions":[{"definition":"A disorder characterized by inflammation of the skin characterized by the presence of bullae which are filled with fluid.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the skin characterized by the presence of bullae which are filled with fluid.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Bullous Dermatitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bullous dermatitis"},{"name":"Maps_To","value":"Bullous Dermatitis"},{"name":"NCI_META_CUI","value":"CL541670"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57900":{"preferredName":"Burn, CTCAE","code":"C57900","definitions":[{"definition":"A finding of impaired integrity to the anatomic site of an adverse thermal reaction. Burns can be caused by exposure to chemicals, direct heat, electricity, flames and radiation. The extent of damage depends on the length and intensity of exposure and time until provision of treatment.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of impaired integrity to the anatomic site of an adverse thermal reaction. Burns can be caused by exposure to chemicals, direct heat, electricity, flames and radiation. The extent of damage depends on the length and intensity of exposure and time until provision of treatment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Burn, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Burn_Adverse_Event"},{"name":"Maps_To","value":"Burn"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962979"}]}}{"C146744":{"preferredName":"Buttock Pain, CTCAE 5.0","code":"C146744","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the buttocks.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the buttocks.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Buttock Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buttock Pain"},{"name":"Maps_To","value":"Buttock pain"},{"name":"NCI_META_CUI","value":"CL544691"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143349":{"preferredName":"Capillary Leak Syndrome, CTCAE","code":"C143349","definitions":[{"definition":"A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Capillary Leak Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Capillary leak syndrome"},{"name":"Maps_To","value":"Capillary Leak Syndrome"},{"name":"NCI_META_CUI","value":"CL541671"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143350":{"preferredName":"Carbon Monoxide Diffusing Capacity Decreased, CTCAE","code":"C143350","definitions":[{"definition":"A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Carbon Monoxide Diffusing Capacity Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Carbon monoxide diffusing capacity decreased"},{"name":"Maps_To","value":"Carbon Monoxide Diffusing Capacity Decreased"},{"name":"NCI_META_CUI","value":"CL541672"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143351":{"preferredName":"Cardiac Arrest, CTCAE","code":"C143351","definitions":[{"definition":"A disorder characterized by cessation of the pumping function of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by cessation of the pumping function of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cardiac Arrest, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac arrest"},{"name":"Maps_To","value":"Cardiac Arrest"},{"name":"NCI_META_CUI","value":"CL541673"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143352":{"preferredName":"Cardiac Disorders - Other, Specify, CTCAE","code":"C143352","synonyms":[{"termName":"Cardiac Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac Disorders - Other"},{"name":"Maps_To","value":"Cardiac disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541674"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143353":{"preferredName":"Cardiac Troponin I Increased, CTCAE","code":"C143353","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin I in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin I in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cardiac Troponin I Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac troponin I increased"},{"name":"Maps_To","value":"Cardiac Troponin I Increased"},{"name":"NCI_META_CUI","value":"CL541675"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143354":{"preferredName":"Cardiac Troponin T Increased, CTCAE","code":"C143354","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin T in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate increased levels of cardiac troponin T in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cardiac Troponin T Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cardiac troponin T increased"},{"name":"Maps_To","value":"Cardiac Troponin T Increased"},{"name":"NCI_META_CUI","value":"CL541676"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146674":{"preferredName":"Cataract, CTCAE 5.0","code":"C146674","definitions":[{"definition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cataract, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cataract"},{"name":"NCI_META_CUI","value":"CL545895"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143356":{"preferredName":"Catheter Related Infection, CTCAE","code":"C143356","definitions":[{"definition":"A disorder characterized by an infectious process that arises secondary to catheter use.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process that arises secondary to catheter use.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Catheter Related Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Catheter related infection"},{"name":"Maps_To","value":"Catheter Related Infection"},{"name":"NCI_META_CUI","value":"CL541776"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143357":{"preferredName":"CD4 Lymphocytes Decreased, CTCAE","code":"C143357","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"CD4 Lymphocytes Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD4 lymphocytes decreased"},{"name":"Maps_To","value":"CD4 Lymphocytes Decreased"},{"name":"NCI_META_CUI","value":"CL541777"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143358":{"preferredName":"Cecal Hemorrhage, CTCAE","code":"C143358","definitions":[{"definition":"A disorder characterized by bleeding from the cecum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the cecum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cecal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cecal hemorrhage"},{"name":"Maps_To","value":"Cecal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541778"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143359":{"preferredName":"Cecal Infection, CTCAE","code":"C143359","definitions":[{"definition":"A disorder characterized by an infectious process involving the cecum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the cecum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cecal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cecal infection"},{"name":"Maps_To","value":"Cecal Infection"},{"name":"NCI_META_CUI","value":"CL541779"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143360":{"preferredName":"Central Nervous System Necrosis, CTCAE","code":"C143360","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the brain and/or spinal cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the brain and/or spinal cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Central Nervous System Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Central nervous system necrosis"},{"name":"Maps_To","value":"Central Nervous System Necrosis"},{"name":"NCI_META_CUI","value":"CL541780"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143361":{"preferredName":"Cerebrospinal Fluid Leakage, CTCAE","code":"C143361","definitions":[{"definition":"A disorder characterized by loss of cerebrospinal fluid into the surrounding tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by loss of cerebrospinal fluid into the surrounding tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cerebrospinal Fluid Leakage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cerebrospinal fluid leakage"},{"name":"Maps_To","value":"Cerebrospinal Fluid Leakage"},{"name":"NCI_META_CUI","value":"CL541781"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143362":{"preferredName":"Cervicitis Infection, CTCAE","code":"C143362","definitions":[{"definition":"A disorder characterized by an infectious process involving the uterine cervix.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the uterine cervix.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cervicitis Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cervicitis infection"},{"name":"Maps_To","value":"Cervicitis Infection"},{"name":"NCI_META_CUI","value":"CL541782"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57901":{"preferredName":"Cheilitis, CTCAE","code":"C57901","definitions":[{"definition":"A disorder characterized by inflammation of the lip.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the lip.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cheilitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cheilitis_Adverse_Event"},{"name":"Maps_To","value":"Cheilitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962954"}]}}{"C143364":{"preferredName":"Chest Pain - Cardiac, CTCAE","code":"C143364","definitions":[{"definition":"A disorder characterized by substernal discomfort due to insufficient myocardial oxygenation e.g., angina pectoris.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by substernal discomfort due to insufficient myocardial oxygenation e.g., angina pectoris.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Chest Pain - Cardiac, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chest pain - cardiac"},{"name":"Maps_To","value":"Chest Pain - Cardiac"},{"name":"NCI_META_CUI","value":"CL545961"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146743":{"preferredName":"Chest Wall Pain, CTCAE 5.0","code":"C146743","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the chest wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the chest wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Chest Wall Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chest Wall Pain"},{"name":"Maps_To","value":"Chest wall pain"},{"name":"NCI_META_CUI","value":"CL544690"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143366":{"preferredName":"Chills, CTCAE","code":"C143366","definitions":[{"definition":"A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Chills, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chills"},{"name":"NCI_META_CUI","value":"CL541769"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146788":{"preferredName":"Cholecystitis, CTCAE 5.0","code":"C146788","definitions":[{"definition":"A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cholecystitis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cholecystitis"},{"name":"NCI_META_CUI","value":"CL544777"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143368":{"preferredName":"Cholesterol High, CTCAE","code":"C143368","definitions":[{"definition":"A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cholesterol High, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cholesterol high"},{"name":"Maps_To","value":"Cholesterol High"},{"name":"NCI_META_CUI","value":"CL545969"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143369":{"preferredName":"Chronic Kidney Disease, CTCAE","code":"C143369","definitions":[{"definition":"A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Chronic Kidney Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic kidney disease"},{"name":"Maps_To","value":"Chronic Kidney Disease"},{"name":"NCI_META_CUI","value":"CL541770"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58027":{"preferredName":"Chylothorax, CTCAE","code":"C58027","definitions":[{"definition":"A disorder characterized by milky pleural effusion (abnormal collection of fluid) resulting from accumulation of lymph fluid in the pleural cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by milky pleural effusion (abnormal collection of fluid) resulting from accumulation of lymph fluid in the pleural cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Chylothorax, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chylothorax_Adverse_Event"},{"name":"Maps_To","value":"Chylothorax"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962974"}]}}{"C146746":{"preferredName":"Cognitive Disturbance, CTCAE 5.0","code":"C146746","definitions":[{"definition":"A disorder characterized by a conspicuous change in cognitive function.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a conspicuous change in cognitive function.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cognitive Disturbance, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cognitive Disturbance"},{"name":"Maps_To","value":"Cognitive disturbance"},{"name":"NCI_META_CUI","value":"CL544693"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57134":{"preferredName":"Colitis, CTCAE","code":"C57134","definitions":[{"definition":"A disorder characterized by inflammation of the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Colitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colitis_Adverse_Event"},{"name":"Maps_To","value":"Colitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963084"}]}}{"C143373":{"preferredName":"Colonic Fistula, CTCAE","code":"C143373","definitions":[{"definition":"A disorder characterized by an abnormal communication between the large intestine and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the large intestine and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Colonic Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic fistula"},{"name":"Maps_To","value":"Colonic Fistula"},{"name":"NCI_META_CUI","value":"CL541771"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143374":{"preferredName":"Colonic Hemorrhage, CTCAE","code":"C143374","definitions":[{"definition":"A disorder characterized by bleeding from the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Colonic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic hemorrhage"},{"name":"Maps_To","value":"Colonic Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541772"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143375":{"preferredName":"Colonic Obstruction, CTCAE","code":"C143375","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Colonic Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic obstruction"},{"name":"Maps_To","value":"Colonic Obstruction"},{"name":"NCI_META_CUI","value":"CL541773"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143376":{"preferredName":"Colonic Perforation, CTCAE","code":"C143376","definitions":[{"definition":"A disorder characterized by a rupture in the colonic wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the colonic wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Colonic Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic perforation"},{"name":"Maps_To","value":"Colonic Perforation"},{"name":"NCI_META_CUI","value":"CL541774"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143377":{"preferredName":"Colonic Stenosis, CTCAE","code":"C143377","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Colonic Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic stenosis"},{"name":"Maps_To","value":"Colonic Stenosis"},{"name":"NCI_META_CUI","value":"CL541775"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143378":{"preferredName":"Colonic Ulcer, CTCAE","code":"C143378","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the colon.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the colon.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Colonic Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonic ulcer"},{"name":"Maps_To","value":"Colonic Ulcer"},{"name":"NCI_META_CUI","value":"CL541761"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143379":{"preferredName":"Concentration Impairment, CTCAE","code":"C143379","definitions":[{"definition":"A disorder characterized by a deterioration in the ability to concentrate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a deterioration in the ability to concentrate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Concentration Impairment, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Concentration impairment"},{"name":"Maps_To","value":"Concentration Impairment"},{"name":"NCI_META_CUI","value":"CL541762"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143380":{"preferredName":"Conduction Disorder, CTCAE","code":"C143380","definitions":[{"definition":"A disorder characterized by pathological irregularities in the cardiac conduction system.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by pathological irregularities in the cardiac conduction system.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Conduction Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conduction disorder"},{"name":"Maps_To","value":"Conduction Disorder"},{"name":"NCI_META_CUI","value":"CL541763"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146785":{"preferredName":"Confusion, CTCAE 5.0","code":"C146785","definitions":[{"definition":"A disorder characterized by a lack of clear and orderly thought and behavior.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a lack of clear and orderly thought and behavior.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Confusion, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Confusion"},{"name":"NCI_META_CUI","value":"CL544775"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143382":{"preferredName":"Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","code":"C143382","synonyms":[{"termName":"Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Congenital, Familial and Genetic Disorders - Other"},{"name":"Maps_To","value":"Congenital, familial and genetic disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541764"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143384":{"preferredName":"Conjunctivitis, CTCAE","code":"C143384","definitions":[{"definition":"A disorder characterized by inflammation, swelling and redness to the conjunctiva of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation, swelling and redness to the conjunctiva of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Conjunctivitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conjunctivitis"},{"name":"NCI_META_CUI","value":"CL541766"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143383":{"preferredName":"Conjunctivitis Infective, CTCAE","code":"C143383","definitions":[{"definition":"A disorder characterized by an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Conjunctivitis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conjunctivitis infective"},{"name":"Maps_To","value":"Conjunctivitis Infective"},{"name":"NCI_META_CUI","value":"CL541765"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57141":{"preferredName":"Constipation, CTCAE","code":"C57141","definitions":[{"definition":"A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Constipation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Constipation_Adverse_Event"},{"name":"Maps_To","value":"Constipation"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963087"}]}}{"C78246":{"preferredName":"Constrictive Pericarditis","code":"C78246","definitions":[{"definition":"A disorder characterized by a thickened and fibrotic pericardial sac; these fibrotic changes impede normal myocardial function by restricting myocardial muscle action.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A heart disorder in which the pericardial sac becomes thickened and fibrotic, tightening the myocardium and impeding the normal myocardial function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Constrictive Pericarditis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Constrictive_Pericarditis"},{"name":"Maps_To","value":"Constrictive Pericarditis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0031048"}]}}{"C143386":{"preferredName":"Corneal Infection, CTCAE","code":"C143386","definitions":[{"definition":"A disorder characterized by an infectious process involving the cornea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the cornea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Corneal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Corneal infection"},{"name":"Maps_To","value":"Corneal Infection"},{"name":"NCI_META_CUI","value":"CL541767"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143387":{"preferredName":"Corneal Ulcer, CTCAE","code":"C143387","definitions":[{"definition":"A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Corneal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Corneal ulcer"},{"name":"Maps_To","value":"Corneal Ulcer"},{"name":"NCI_META_CUI","value":"CL541768"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58028":{"preferredName":"Cough, CTCAE","code":"C58028","definitions":[{"definition":"A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cough, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cough_Adverse_Event"},{"name":"Maps_To","value":"Cough"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1961131"}]}}{"C143389":{"preferredName":"CPK Increased, CTCAE","code":"C143389","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"CPK Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CPK increased"},{"name":"Maps_To","value":"CPK Increased"},{"name":"NCI_META_CUI","value":"CL541755"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143390":{"preferredName":"Cranial Nerve Infection, CTCAE","code":"C143390","definitions":[{"definition":"A disorder characterized by an infectious process involving a cranial nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a cranial nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cranial Nerve Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cranial nerve infection"},{"name":"Maps_To","value":"Cranial Nerve Infection"},{"name":"NCI_META_CUI","value":"CL541756"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143391":{"preferredName":"Creatinine Increased, CTCAE","code":"C143391","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Creatinine Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Creatinine increased"},{"name":"Maps_To","value":"Creatinine Increased"},{"name":"NCI_META_CUI","value":"CL546003"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143392":{"preferredName":"Cushingoid, CTCAE","code":"C143392","definitions":[{"definition":"A disorder characterized by signs and symptoms that resemble Cushing's disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by signs and symptoms that resemble Cushing's disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Cushingoid, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cushingoid"},{"name":"NCI_META_CUI","value":"CL541757"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143393":{"preferredName":"Cystitis Noninfective, CTCAE","code":"C143393","definitions":[{"definition":"A disorder characterized by inflammation of the bladder which is not caused by an infection of the urinary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the bladder which is not caused by an infection of the urinary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cystitis Noninfective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Cystitis noninfective"},{"name":"Maps_To","value":"Cystitis Noninfective"},{"name":"NCI_META_CUI","value":"CL541758"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143394":{"preferredName":"Cytokine Release Syndrome, CTCAE","code":"C143394","definitions":[{"definition":"A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Cytokine Release Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytokine release syndrome"},{"name":"Maps_To","value":"Cytokine Release Syndrome"},{"name":"NCI_META_CUI","value":"CL541759"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143395":{"preferredName":"Death Neonatal, CTCAE","code":"C143395","definitions":[{"definition":"Newborn death occurring during the first 28 days after birth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"Newborn death occurring during the first 28 days after birth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Death Neonatal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death neonatal"},{"name":"Maps_To","value":"Death Neonatal"},{"name":"NCI_META_CUI","value":"CL541760"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143396":{"preferredName":"Death NOS, CTCAE","code":"C143396","definitions":[{"definition":"Death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"Death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Death NOS, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death NOS"},{"name":"NCI_META_CUI","value":"CL550658"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57787":{"preferredName":"Dehydration, CTCAE","code":"C57787","definitions":[{"definition":"A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dehydration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dehydration_Adverse_Event"},{"name":"Maps_To","value":"Dehydration"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963090"}]}}{"C143398":{"preferredName":"Delayed Orgasm, CTCAE","code":"C143398","definitions":[{"definition":"A disorder characterized by sexual dysfunction characterized by a delay in climax.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by sexual dysfunction characterized by a delay in climax.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Delayed Orgasm, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Delayed orgasm"},{"name":"Maps_To","value":"Delayed Orgasm"},{"name":"NCI_META_CUI","value":"CL541748"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55742":{"preferredName":"Delayed Puberty, CTCAE","code":"C55742","definitions":[{"definition":"A disorder characterized by unusually late sexual maturity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by unusually late sexual maturity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Delayed Puberty, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Delayed_Puberty_Adverse_Event"},{"name":"Maps_To","value":"Delayed Puberty"},{"name":"Maps_To","value":"Delayed puberty"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1883716"}]}}{"C143400":{"preferredName":"Delirium, CTCAE","code":"C143400","definitions":[{"definition":"A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Delirium, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Delirium"},{"name":"NCI_META_CUI","value":"CL541749"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143401":{"preferredName":"Delusions, CTCAE","code":"C143401","definitions":[{"definition":"A disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Delusions, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Delusions"},{"name":"NCI_META_CUI","value":"CL541750"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143402":{"preferredName":"Dental Caries, CTCAE","code":"C143402","definitions":[{"definition":"A disorder characterized by the decay of a tooth, in which it becomes softened, discolored and/or porous.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the decay of a tooth, in which it becomes softened, discolored and/or porous.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dental Caries, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dental caries"},{"name":"Maps_To","value":"Dental Caries"},{"name":"NCI_META_CUI","value":"CL541751"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143403":{"preferredName":"Depressed Level of Consciousness, CTCAE","code":"C143403","definitions":[{"definition":"A disorder characterized by a decrease in ability to perceive and respond.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a decrease in ability to perceive and respond.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Depressed Level of Consciousness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Depressed level of consciousness"},{"name":"Maps_To","value":"Depressed Level of Consciousness"},{"name":"NCI_META_CUI","value":"CL541752"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55447":{"preferredName":"Depression, CTCAE","code":"C55447","definitions":[{"definition":"A disorder characterized by melancholic feelings of grief or unhappiness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by melancholic feelings of grief or unhappiness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Depression, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Depression_Adverse_Event"},{"name":"Maps_To","value":"Depression"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1999266"}]}}{"C143405":{"preferredName":"Dermatitis Radiation, CTCAE","code":"C143405","definitions":[{"definition":"A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dermatitis Radiation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dermatitis radiation"},{"name":"Maps_To","value":"Dermatitis Radiation"},{"name":"NCI_META_CUI","value":"CL541753"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143406":{"preferredName":"Device Related Infection, CTCAE","code":"C143406","definitions":[{"definition":"A disorder characterized by an infectious process involving the use of a medical device.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the use of a medical device.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Device Related Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Device related infection"},{"name":"Maps_To","value":"Device Related Infection"},{"name":"NCI_META_CUI","value":"CL541754"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57788":{"preferredName":"Diarrhea, CTCAE","code":"C57788","definitions":[{"definition":"A disorder characterized by an increase in frequency and/or loose or watery bowel movements.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in frequency and/or loose or watery bowel movements.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Diarrhea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Diarrhea_Adverse_Event"},{"name":"Maps_To","value":"Diarrhea"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963091"}]}}{"C55273":{"preferredName":"Disseminated Intravascular Coagulation, CTCAE","code":"C55273","definitions":[{"definition":"A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the risk of hemorrhage as the body is depleted of platelets and coagulation factors.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the risk of hemorrhage as the body is depleted of platelets and coagulation factors.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Disseminated Intravascular Coagulation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Disseminated_Intravascular_Coagulation_Adverse_Event"},{"name":"Maps_To","value":"Disseminated Intravascular Coagulation"},{"name":"Maps_To","value":"Disseminated intravascular coagulation"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963092"}]}}{"C146747":{"preferredName":"Dizziness, CTCAE 5.0","code":"C146747","definitions":[{"definition":"A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dizziness, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dizziness"},{"name":"NCI_META_CUI","value":"CL544801"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143410":{"preferredName":"Dry Eye, CTCAE","code":"C143410","definitions":[{"definition":"A disorder characterized by dryness of the cornea and conjunctiva.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dryness of the cornea and conjunctiva.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dry Eye, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dry eye"},{"name":"Maps_To","value":"Dry Eye"},{"name":"NCI_META_CUI","value":"CL545897"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143411":{"preferredName":"Dry Mouth, CTCAE","code":"C143411","definitions":[{"definition":"A disorder characterized by reduced salivary flow in the oral cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by reduced salivary flow in the oral cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dry Mouth, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dry Mouth"},{"name":"Maps_To","value":"Dry mouth"},{"name":"NCI_META_CUI","value":"CL541740"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57996":{"preferredName":"Dry Skin, CTCAE","code":"C57996","definitions":[{"definition":"A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dry Skin, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dry_Skin_Adverse_Event"},{"name":"Maps_To","value":"Dry Skin"},{"name":"Maps_To","value":"Dry skin"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963094"}]}}{"C57789":{"preferredName":"Duodenal Fistula, CTCAE","code":"C57789","definitions":[{"definition":"A disorder characterized by an abnormal communication between the duodenum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the duodenum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Duodenum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Duodenal fistula"},{"name":"Maps_To","value":"Duodenal Fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962984"}]}}{"C143414":{"preferredName":"Duodenal Hemorrhage, CTCAE","code":"C143414","definitions":[{"definition":"A disorder characterized by bleeding from the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal hemorrhage"},{"name":"Maps_To","value":"Duodenal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541741"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143415":{"preferredName":"Duodenal Infection, CTCAE","code":"C143415","definitions":[{"definition":"A disorder characterized by an infectious process involving the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Duodenal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal infection"},{"name":"Maps_To","value":"Duodenal Infection"},{"name":"NCI_META_CUI","value":"CL541742"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143416":{"preferredName":"Duodenal Obstruction, CTCAE","code":"C143416","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of stomach contents through the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of stomach contents through the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal obstruction"},{"name":"Maps_To","value":"Duodenal Obstruction"},{"name":"NCI_META_CUI","value":"CL541743"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143417":{"preferredName":"Duodenal Perforation, CTCAE","code":"C143417","definitions":[{"definition":"A disorder characterized by a rupture in the duodenal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the duodenal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal perforation"},{"name":"Maps_To","value":"Duodenal Perforation"},{"name":"NCI_META_CUI","value":"CL541744"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143418":{"preferredName":"Duodenal Stenosis, CTCAE","code":"C143418","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the duodenum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the duodenum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal stenosis"},{"name":"Maps_To","value":"Duodenal Stenosis"},{"name":"NCI_META_CUI","value":"CL541745"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143419":{"preferredName":"Duodenal Ulcer, CTCAE","code":"C143419","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the duodenal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the duodenal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Duodenal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Duodenal ulcer"},{"name":"Maps_To","value":"Duodenal Ulcer"},{"name":"NCI_META_CUI","value":"CL541746"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143420":{"preferredName":"Dysarthria, CTCAE","code":"C143420","definitions":[{"definition":"A disorder characterized by slow and slurred speech resulting from an inability to coordinate the muscles used in speech.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by slow and slurred speech resulting from an inability to coordinate the muscles used in speech.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysarthria, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysarthria"},{"name":"NCI_META_CUI","value":"CL541747"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143421":{"preferredName":"Dysesthesia, CTCAE","code":"C143421","definitions":[{"definition":"A disorder characterized by distortion of sensory perception, resulting in an abnormal and unpleasant sensation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by distortion of sensory perception, resulting in an abnormal and unpleasant sensation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dysesthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysesthesia"},{"name":"NCI_META_CUI","value":"CL541733"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143422":{"preferredName":"Dysgeusia, CTCAE","code":"C143422","definitions":[{"definition":"A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dysgeusia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysgeusia"},{"name":"NCI_META_CUI","value":"CL541734"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143423":{"preferredName":"Dysmenorrhea, CTCAE","code":"C143423","definitions":[{"definition":"A disorder characterized by abnormally painful abdominal cramps during menses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormally painful abdominal cramps during menses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysmenorrhea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysmenorrhea"},{"name":"NCI_META_CUI","value":"CL541735"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143424":{"preferredName":"Dyspareunia, CTCAE","code":"C143424","definitions":[{"definition":"A disorder characterized by painful or difficult coitus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by painful or difficult coitus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dyspareunia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dyspareunia"},{"name":"NCI_META_CUI","value":"CL545960"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143425":{"preferredName":"Dyspepsia, CTCAE","code":"C143425","definitions":[{"definition":"A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dyspepsia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dyspepsia"},{"name":"NCI_META_CUI","value":"CL541736"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57795":{"preferredName":"Dysphagia, CTCAE","code":"C57795","definitions":[{"definition":"A disorder characterized by difficulty in swallowing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by difficulty in swallowing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Dysphagia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dysphagia_Adverse_Event"},{"name":"Maps_To","value":"Dysphagia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560331"}]}}{"C143427":{"preferredName":"Dysphasia, CTCAE","code":"C143427","definitions":[{"definition":"A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dysphasia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dysphasia"},{"name":"NCI_META_CUI","value":"CL541737"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58185":{"preferredName":"Dyspnea, CTCAE","code":"C58185","definitions":[{"definition":"A disorder characterized by an uncomfortable sensation of difficulty breathing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable sensation of difficulty breathing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Dyspnea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dyspnea_Adverse_Event"},{"name":"Maps_To","value":"Dyspnea"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963100"}]}}{"C143429":{"preferredName":"Ear and Labyrinth Disorders - Other, Specify, CTCAE","code":"C143429","synonyms":[{"termName":"Ear and Labyrinth Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ear and Labyrinth Disorders - Other"},{"name":"Maps_To","value":"Ear and labyrinth disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541738"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143430":{"preferredName":"Ear Pain, CTCAE","code":"C143430","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the ear.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the ear.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ear Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ear pain"},{"name":"Maps_To","value":"Ear Pain"},{"name":"NCI_META_CUI","value":"CL541739"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143431":{"preferredName":"Edema Cerebral, CTCAE","code":"C143431","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Edema Cerebral, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema cerebral"},{"name":"Maps_To","value":"Edema Cerebral"},{"name":"NCI_META_CUI","value":"CL541725"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143432":{"preferredName":"Edema Face, CTCAE","code":"C143432","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Edema Face, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema Face"},{"name":"Maps_To","value":"Edema face"},{"name":"NCI_META_CUI","value":"CL541726"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143433":{"preferredName":"Edema Limbs, CTCAE","code":"C143433","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Edema Limbs, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema limbs"},{"name":"Maps_To","value":"Edema Limbs"},{"name":"NCI_META_CUI","value":"CL541727"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143434":{"preferredName":"Edema Trunk, CTCAE","code":"C143434","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Edema Trunk, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Edema trunk"},{"name":"Maps_To","value":"Edema Trunk"},{"name":"NCI_META_CUI","value":"CL541728"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143435":{"preferredName":"Ejaculation Disorder, CTCAE","code":"C143435","definitions":[{"definition":"A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ejaculation Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Ejaculation disorder"},{"name":"Maps_To","value":"Ejaculation Disorder"},{"name":"NCI_META_CUI","value":"CL541729"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143436":{"preferredName":"Ejection Fraction Decreased, CTCAE","code":"C143436","definitions":[{"definition":"The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ejection Fraction Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ejection fraction decreased"},{"name":"Maps_To","value":"Ejection Fraction Decreased"},{"name":"NCI_META_CUI","value":"CL541730"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143437":{"preferredName":"Electrocardiogram QT Corrected Interval Prolonged, CTCAE","code":"C143437","definitions":[{"definition":"A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Electrocardiogram QT Corrected Interval Prolonged, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrocardiogram QT corrected interval prolonged"},{"name":"Maps_To","value":"Electrocardiogram QT Corrected Interval Prolonged"},{"name":"NCI_META_CUI","value":"CL541731"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143438":{"preferredName":"Encephalitis Infection, CTCAE","code":"C143438","definitions":[{"definition":"A disorder characterized by an infectious process involving the brain tissue.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the brain tissue.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Encephalitis Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encephalitis infection"},{"name":"Maps_To","value":"Encephalitis Infection"},{"name":"NCI_META_CUI","value":"CL541732"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143439":{"preferredName":"Encephalomyelitis Infection, CTCAE","code":"C143439","definitions":[{"definition":"A disorder characterized by an infectious process involving the brain and spinal cord tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the brain and spinal cord tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Encephalomyelitis Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encephalomyelitis infection"},{"name":"Maps_To","value":"Encephalomyelitis Infection"},{"name":"NCI_META_CUI","value":"CL541836"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146699":{"preferredName":"Encephalopathy, CTCAE 5.0","code":"C146699","definitions":[{"definition":"A disorder characterized by a pathologic process involving the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a pathologic process involving the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Encephalopathy, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encephalopathy"},{"name":"NCI_META_CUI","value":"CL544726"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143441":{"preferredName":"Endocarditis Infective, CTCAE","code":"C143441","definitions":[{"definition":"A disorder characterized by an infectious process involving the endocardial layer of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the endocardial layer of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Endocarditis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endocarditis infective"},{"name":"Maps_To","value":"Endocarditis Infective"},{"name":"NCI_META_CUI","value":"CL541837"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143442":{"preferredName":"Endocrine Disorders - Other, Specify, CTCAE","code":"C143442","synonyms":[{"termName":"Endocrine Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endocrine Disorders - Other"},{"name":"Maps_To","value":"Endocrine disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL546037"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143443":{"preferredName":"Endophthalmitis, CTCAE","code":"C143443","definitions":[{"definition":"A disorder characterized by an infectious process involving the internal structures of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the internal structures of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Endophthalmitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endophthalmitis"},{"name":"NCI_META_CUI","value":"CL541838"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143445":{"preferredName":"Enterocolitis, CTCAE","code":"C143445","definitions":[{"definition":"A disorder characterized by inflammation of the small and large intestines.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the small and large intestines.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Enterocolitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterocolitis"},{"name":"NCI_META_CUI","value":"CL541840"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143444":{"preferredName":"Enterocolitis Infectious, CTCAE","code":"C143444","definitions":[{"definition":"A disorder characterized by an infectious process involving the small and large intestines.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the small and large intestines.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Enterocolitis Infectious, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterocolitis Infectious"},{"name":"Maps_To","value":"Enterocolitis infectious"},{"name":"NCI_META_CUI","value":"CL541839"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143446":{"preferredName":"Enterovesical Fistula, CTCAE","code":"C143446","definitions":[{"definition":"A disorder characterized by an abnormal communication between the urinary bladder and the intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the urinary bladder and the intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Enterovesical Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterovesical Fistula"},{"name":"Maps_To","value":"Enterovesical fistula"},{"name":"NCI_META_CUI","value":"CL541841"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143447":{"preferredName":"Epistaxis, CTCAE","code":"C143447","definitions":[{"definition":"A disorder characterized by bleeding from the nose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the nose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Epistaxis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epistaxis"},{"name":"NCI_META_CUI","value":"CL541842"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55615":{"preferredName":"Erectile Dysfunction, CTCAE","code":"C55615","definitions":[{"definition":"A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Erectile Dysfunction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Erectile_Dysfunction_Adverse_Event"},{"name":"Maps_To","value":"Erectile Dysfunction"},{"name":"Maps_To","value":"Erectile dysfunction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1961100"}]}}{"C143449":{"preferredName":"Erythema Multiforme, CTCAE","code":"C143449","definitions":[{"definition":"A disorder characterized by target lesions (a pink-red ring around a pale center).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by target lesions (a pink-red ring around a pale center).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Erythema Multiforme, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Erythema Multiforme"},{"name":"Maps_To","value":"Erythema multiforme"},{"name":"NCI_META_CUI","value":"CL541829"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143450":{"preferredName":"Erythroderma, CTCAE","code":"C143450","definitions":[{"definition":"A disorder characterized by generalized inflammatory erythema and exfoliation. The inflammatory process involves > 90% of the body surface area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by generalized inflammatory erythema and exfoliation. The inflammatory process involves > 90% of the body surface area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Erythroderma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Erythroderma"},{"name":"NCI_META_CUI","value":"CL540990"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143451":{"preferredName":"Esophageal Anastomotic Leak, CTCAE","code":"C143451","definitions":[{"definition":"A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Anastomotic Leak"},{"name":"Maps_To","value":"Esophageal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541830"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57798":{"preferredName":"Esophageal Fistula, CTCAE","code":"C57798","definitions":[{"definition":"A disorder characterized by an abnormal communication between the esophagus and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the esophagus and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Esophagus_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Esophageal fistula"},{"name":"Maps_To","value":"Esophageal Fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963104"}]}}{"C143453":{"preferredName":"Esophageal Hemorrhage, CTCAE","code":"C143453","definitions":[{"definition":"A disorder characterized by bleeding from the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Hemorrhage"},{"name":"Maps_To","value":"Esophageal hemorrhage"},{"name":"NCI_META_CUI","value":"CL541831"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143454":{"preferredName":"Esophageal Infection, CTCAE","code":"C143454","definitions":[{"definition":"A disorder characterized by an infectious process involving the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophageal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Infection"},{"name":"Maps_To","value":"Esophageal infection"},{"name":"NCI_META_CUI","value":"CL541832"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143455":{"preferredName":"Esophageal Necrosis, CTCAE","code":"C143455","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the esophageal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the esophageal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Necrosis"},{"name":"Maps_To","value":"Esophageal necrosis"},{"name":"NCI_META_CUI","value":"CL541833"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143456":{"preferredName":"Esophageal Obstruction, CTCAE","code":"C143456","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents in the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the contents in the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Obstruction"},{"name":"Maps_To","value":"Esophageal obstruction"},{"name":"NCI_META_CUI","value":"CL541834"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143457":{"preferredName":"Esophageal Pain, CTCAE","code":"C143457","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the esophageal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the esophageal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophageal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Pain"},{"name":"Maps_To","value":"Esophageal pain"},{"name":"NCI_META_CUI","value":"CL541835"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143458":{"preferredName":"Esophageal Perforation, CTCAE","code":"C143458","definitions":[{"definition":"A disorder characterized by a rupture in the wall of the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the wall of the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophageal Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Perforation"},{"name":"Maps_To","value":"Esophageal perforation"},{"name":"NCI_META_CUI","value":"CL541821"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143459":{"preferredName":"Esophageal Stenosis, CTCAE","code":"C143459","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the esophagus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the esophagus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Stenosis"},{"name":"Maps_To","value":"Esophageal stenosis"},{"name":"NCI_META_CUI","value":"CL541822"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143460":{"preferredName":"Esophageal Ulcer, CTCAE","code":"C143460","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the esophageal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the esophageal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Ulcer"},{"name":"Maps_To","value":"Esophageal ulcer"},{"name":"NCI_META_CUI","value":"CL541823"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146710":{"preferredName":"Esophageal Varices Hemorrhage, CTCAE 5.0","code":"C146710","definitions":[{"definition":"A disorder characterized by bleeding from esophageal varices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from esophageal varices.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Esophageal Varices Hemorrhage, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Varices Hemorrhage"},{"name":"Maps_To","value":"Esophageal varices hemorrhage"},{"name":"NCI_META_CUI","value":"CL544721"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57797":{"preferredName":"Esophagitis, CTCAE","code":"C57797","definitions":[{"definition":"A disorder characterized by inflammation of the esophageal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the esophageal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Esophagitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Esophagitis_Adverse_Event"},{"name":"Maps_To","value":"Esophagitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963106"}]}}{"C146748":{"preferredName":"Euphoria, CTCAE 5.0","code":"C146748","definitions":[{"definition":"A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Euphoria, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Euphoria"},{"name":"NCI_META_CUI","value":"CL550637"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146749":{"preferredName":"Exostosis, CTCAE 5.0","code":"C146749","definitions":[{"definition":"A disorder characterized by non-neoplastic overgrowth of bone.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by non-neoplastic overgrowth of bone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Exostosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Exostosis"},{"name":"NCI_META_CUI","value":"CL544802"},{"name":"Semantic_Type","value":"Finding"}]}}{"C79601":{"preferredName":"Otitis Externa","code":"C79601","definitions":[{"definition":"A disorder characterized by inflammation, swelling and redness to the outer ear and ear canal.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the outer ear and/or ear canal.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Otitis Externa","termGroup":"PT","termSource":"NCI"},{"termName":"External Ear Inflammation","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammation of External Auditory Canal","termGroup":"SY","termSource":"NCI"},{"termName":"Inflammation of the External Auditory Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"External_Ear_Inflammation"},{"name":"Maps_To","value":"External Ear Inflammation"},{"name":"Maps_To","value":"Otitis externa"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0029878"}]}}{"C146745":{"preferredName":"External Ear Pain, CTCAE 5.0","code":"C146745","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the external ear region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the external ear region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"External Ear Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"External Ear Pain"},{"name":"Maps_To","value":"External ear pain"},{"name":"NCI_META_CUI","value":"CL544692"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143466":{"preferredName":"Extraocular Muscle Paresis, CTCAE","code":"C143466","definitions":[{"definition":"A disorder characterized by incomplete paralysis of an extraocular muscle.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by incomplete paralysis of an extraocular muscle.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Extraocular Muscle Paresis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extraocular Muscle Paresis"},{"name":"Maps_To","value":"Extraocular muscle paresis"},{"name":"NCI_META_CUI","value":"CL541824"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143467":{"preferredName":"Extrapyramidal Disorder, CTCAE","code":"C143467","definitions":[{"definition":"A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Extrapyramidal Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extrapyramidal Disorder"},{"name":"Maps_To","value":"Extrapyramidal disorder"},{"name":"NCI_META_CUI","value":"CL541825"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143468":{"preferredName":"Eye Disorders - Other, Specify, CTCAE","code":"C143468","synonyms":[{"termName":"Eye Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eye Disorders - Other"},{"name":"Maps_To","value":"Eye disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541826"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143469":{"preferredName":"Eye Infection, CTCAE","code":"C143469","definitions":[{"definition":"A disorder characterized by an infectious process involving the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Eye Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eye Infection"},{"name":"Maps_To","value":"Eye infection"},{"name":"NCI_META_CUI","value":"CL541827"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146751":{"preferredName":"Eye Pain, CTCAE 5.0","code":"C146751","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Eye Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eye Pain"},{"name":"Maps_To","value":"Eye pain"},{"name":"NCI_META_CUI","value":"CL544803"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143471":{"preferredName":"Eyelid Function Disorder, CTCAE","code":"C143471","definitions":[{"definition":"A disorder characterized by impaired eyelid function.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by impaired eyelid function.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Eyelid Function Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eyelid Function Disorder"},{"name":"Maps_To","value":"Eyelid function disorder"},{"name":"NCI_META_CUI","value":"CL541828"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143472":{"preferredName":"Facial Muscle Weakness, CTCAE","code":"C143472","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the facial muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the facial muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Facial Muscle Weakness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Facial Muscle Weakness"},{"name":"Maps_To","value":"Facial muscle weakness"},{"name":"NCI_META_CUI","value":"CL541814"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143473":{"preferredName":"Facial Nerve Disorder, CTCAE","code":"C143473","definitions":[{"definition":"A disorder characterized by dysfunction of the facial nerve (seventh cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the facial nerve (seventh cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Facial Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Facial Nerve Disorder"},{"name":"Maps_To","value":"Facial nerve disorder"},{"name":"NCI_META_CUI","value":"CL541815"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143474":{"preferredName":"Facial Pain, CTCAE","code":"C143474","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the face.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the face.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Facial Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Facial Pain"},{"name":"Maps_To","value":"Facial pain"},{"name":"NCI_META_CUI","value":"CL541816"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143475":{"preferredName":"Fall, CTCAE","code":"C143475","definitions":[{"definition":"A finding of sudden movement downward, usually resulting in injury.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of sudden movement downward, usually resulting in injury.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fall, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fall"},{"name":"NCI_META_CUI","value":"CL546052"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143476":{"preferredName":"Fallopian Tube Anastomotic Leak, CTCAE","code":"C143476","definitions":[{"definition":"A finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fallopian Tube Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fallopian Tube Anastomotic Leak"},{"name":"Maps_To","value":"Fallopian tube anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541817"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146752":{"preferredName":"Fallopian Tube Obstruction, CTCAE 5.0","code":"C146752","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fallopian Tube Obstruction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fallopian Tube Obstruction"},{"name":"Maps_To","value":"Fallopian tube obstruction"},{"name":"NCI_META_CUI","value":"CL544804"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146714":{"preferredName":"Fallopian Tube Perforation, CTCAE 5.0","code":"C146714","definitions":[{"definition":"A disorder characterized by a rupture of the fallopian tube wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture of the fallopian tube wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fallopian Tube Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fallopian Tube Perforation"},{"name":"Maps_To","value":"Fallopian tube perforation"},{"name":"NCI_META_CUI","value":"CL544709"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78295":{"preferredName":"Fallopian Tube Stenosis","code":"C78295","definitions":[{"definition":"A disorder characterized by a narrowing of the fallopian tube lumen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Narrowing of the lumen of the fallopian tube.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fallopian Tube Stenosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fallopian_Tube_Stenosis"},{"name":"Maps_To","value":"Fallopian Tube Stenosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0459524"}]}}{"C143479":{"preferredName":"Fat Atrophy, CTCAE","code":"C143479","definitions":[{"definition":"A disorder characterized by shrinking of adipose tissue.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by shrinking of adipose tissue.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fat Atrophy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fat Atrophy"},{"name":"Maps_To","value":"Fat atrophy"},{"name":"NCI_META_CUI","value":"CL541818"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146753":{"preferredName":"Fatigue, CTCAE 5.0","code":"C146753","definitions":[{"definition":"A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fatigue, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Fatigue"},{"name":"NCI_META_CUI","value":"CL550640"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143481":{"preferredName":"Febrile Neutropenia, CTCAE","code":"C143481","definitions":[{"definition":"A disorder characterized by an ANC <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an ANC <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Febrile Neutropenia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Febrile Neutropenia"},{"name":"Maps_To","value":"Febrile neutropenia"},{"name":"NCI_META_CUI","value":"CL541819"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143482":{"preferredName":"Fecal Incontinence, CTCAE","code":"C143482","definitions":[{"definition":"A disorder characterized by inability to control the escape of stool from the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inability to control the escape of stool from the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fecal Incontinence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Fecal Incontinence"},{"name":"Maps_To","value":"Fecal incontinence"},{"name":"NCI_META_CUI","value":"CL541820"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78298":{"preferredName":"Female Genital Tract Fistula","code":"C78298","definitions":[{"definition":"A disorder characterized by an abnormal communication between a female reproductive system organ and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An abnormal communication between a female reproductive system organ and another organ or cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Female Genital Tract Fistula","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Female_Genital_Tract_Fistula"},{"name":"Maps_To","value":"Female Genital Tract Fistula"},{"name":"Semantic_Type","value":"Anatomical Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0269131"}]}}{"C143483":{"preferredName":"Feminization Acquired, CTCAE","code":"C143483","definitions":[{"definition":"A disorder characterized by the development of secondary female sex characteristics in males due to extrinsic factors.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the development of secondary female sex characteristics in males due to extrinsic factors.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Feminization Acquired, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Feminization Acquired"},{"name":"Maps_To","value":"Feminization acquired"},{"name":"NCI_META_CUI","value":"CL541807"},{"name":"Semantic_Type","value":"Finding"}]}}{"C50620":{"preferredName":"Intrauterine Fetal Death","code":"C50620","definitions":[{"definition":"A disorder characterized by death in utero; failure of the product of conception to show evidence of respiration, heartbeat, or definite movement of a voluntary muscle after expulsion from the uterus, without possibility of resuscitation.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Death in utero; failure of the product of conception to show evidence of respiration, heart beat, or definite movement of a voluntary muscle after expulsion from the uterus, with no possibility of resuscitation.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Death of a conceptus that occurred inside the uterus.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Death of a fetus after 10 weeks gestation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Death of a fetus after 10 weeks gestation.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Intrauterine Fetal Death","termGroup":"PT","termSource":"NCI"},{"termName":"Fetal Death","termGroup":"SY","termSource":"NCI"},{"termName":"Fetal Demise","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Intrauterine_Fetal_Death"},{"name":"Maps_To","value":"Fetal Death"},{"name":"Maps_To","value":"Fetal death"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0015927"},{"name":"xRef","value":"IMDRF:F0201"}]}}{"C143484":{"preferredName":"Fetal Growth Retardation, CTCAE","code":"C143484","definitions":[{"definition":"A disorder characterized by inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fetal Growth Retardation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fetal Growth Retardation"},{"name":"Maps_To","value":"Fetal growth retardation"},{"name":"NCI_META_CUI","value":"CL546012"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143485":{"preferredName":"Fever, CTCAE","code":"C143485","definitions":[{"definition":"A disorder characterized by elevation of the body's temperature above the upper limit of normal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by elevation of the body's temperature above the upper limit of normal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Fever, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fever"},{"name":"NCI_META_CUI","value":"CL541808"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143486":{"preferredName":"Fibrinogen Decreased, CTCAE","code":"C143486","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fibrinogen Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fibrinogen Decreased"},{"name":"Maps_To","value":"Fibrinogen decreased"},{"name":"NCI_META_CUI","value":"CL541809"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143487":{"preferredName":"Fibrosis Deep Connective Tissue, CTCAE","code":"C143487","definitions":[{"definition":"A disorder characterized by fibrotic degeneration of the deep connective tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by fibrotic degeneration of the deep connective tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fibrosis Deep Connective Tissue, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fibrosis Deep Connective Tissue"},{"name":"Maps_To","value":"Fibrosis deep connective tissue"},{"name":"NCI_META_CUI","value":"CL541810"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143488":{"preferredName":"Flank Pain, CTCAE","code":"C143488","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Flank Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flank Pain"},{"name":"Maps_To","value":"Flank pain"},{"name":"NCI_META_CUI","value":"CL541811"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143489":{"preferredName":"Flashing Lights, CTCAE","code":"C143489","definitions":[{"definition":"A disorder characterized by a sudden or brief burst of light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sudden or brief burst of light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Flashing Lights, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flashing Lights"},{"name":"Maps_To","value":"Flashing lights"},{"name":"NCI_META_CUI","value":"CL541812"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57807":{"preferredName":"Flatulence, CTCAE","code":"C57807","definitions":[{"definition":"A disorder characterized by a discharge of excessive gas from the lower GI tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a discharge of excessive gas from the lower GI tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Flatulence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Flatulence_Adverse_Event"},{"name":"Maps_To","value":"Flatulence"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962956"}]}}{"C143491":{"preferredName":"Floaters, CTCAE","code":"C143491","definitions":[{"definition":"A disorder characterized by an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Floaters, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Floaters"},{"name":"NCI_META_CUI","value":"CL541813"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143492":{"preferredName":"Flu Like Symptoms, CTCAE","code":"C143492","definitions":[{"definition":"A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry cough.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry cough.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Flu Like Symptoms, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flu Like Symptoms"},{"name":"Maps_To","value":"Flu like symptoms"},{"name":"NCI_META_CUI","value":"CL541799"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146643":{"preferredName":"Flushing, CTCAE 5.0","code":"C146643","definitions":[{"definition":"A disorder characterized by episodic reddening of the skin, especially face, neck, or chest.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by episodic reddening of the skin, especially face, neck, or chest.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Flushing, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flushing"},{"name":"NCI_META_CUI","value":"CL545971"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143494":{"preferredName":"Forced Expiratory Volume Decreased, CTCAE","code":"C143494","definitions":[{"definition":"A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Forced Expiratory Volume Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Forced Expiratory Volume Decreased"},{"name":"Maps_To","value":"Forced expiratory volume decreased"},{"name":"NCI_META_CUI","value":"CL541800"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58382":{"preferredName":"Fracture, CTCAE","code":"C58382","definitions":[{"definition":"A finding of traumatic injury to the bone in which the continuity of the bone is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of traumatic injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fracture_Adverse_Event"},{"name":"Maps_To","value":"Fracture"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963113"}]}}{"C143496":{"preferredName":"Gait Disturbance, CTCAE","code":"C143496","definitions":[{"definition":"A disorder characterized by walking difficulties.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by walking difficulties.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gait Disturbance, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gait Disturbance"},{"name":"Maps_To","value":"Gait disturbance"},{"name":"NCI_META_CUI","value":"CL541801"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57808":{"preferredName":"Gallbladder Fistula, CTCAE","code":"C57808","definitions":[{"definition":"A disorder characterized by an abnormal communication between the gallbladder and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the gallbladder and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gallbladder_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Gallbladder fistula"},{"name":"Maps_To","value":"Gallbladder Fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963110"}]}}{"C143497":{"preferredName":"Gallbladder Infection, CTCAE","code":"C143497","definitions":[{"definition":"A disorder characterized by an infectious process involving the gallbladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the gallbladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gallbladder Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder Infection"},{"name":"Maps_To","value":"Gallbladder infection"},{"name":"NCI_META_CUI","value":"CL541802"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146735":{"preferredName":"Gallbladder Necrosis, CTCAE 5.0","code":"C146735","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the gallbladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the gallbladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gallbladder Necrosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder Necrosis"},{"name":"Maps_To","value":"Gallbladder necrosis"},{"name":"NCI_META_CUI","value":"CL544698"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57810":{"preferredName":"Gallbladder Obstruction, CTCAE","code":"C57810","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents of the gallbladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents of the gallbladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gallbladder_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Gallbladder obstruction"},{"name":"Maps_To","value":"Gallbladder Obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1964021"}]}}{"C146755":{"preferredName":"Gallbladder Pain, CTCAE 5.0","code":"C146755","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the gallbladder region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the gallbladder region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder Pain"},{"name":"Maps_To","value":"Gallbladder pain"},{"name":"NCI_META_CUI","value":"CL544793"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146708":{"preferredName":"Gallbladder Perforation, CTCAE 5.0","code":"C146708","definitions":[{"definition":"A disorder characterized by a rupture in the gallbladder wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the gallbladder wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gallbladder Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gallbladder Perforation"},{"name":"Maps_To","value":"Gallbladder perforation"},{"name":"NCI_META_CUI","value":"CL544719"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143498":{"preferredName":"Gastric Anastomotic Leak, CTCAE","code":"C143498","definitions":[{"definition":"A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Anastomotic Leak"},{"name":"Maps_To","value":"Gastric anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541803"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143499":{"preferredName":"Gastric Fistula, CTCAE","code":"C143499","definitions":[{"definition":"A disorder characterized by an abnormal communication between the stomach and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the stomach and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Fistula"},{"name":"Maps_To","value":"Gastric fistula"},{"name":"NCI_META_CUI","value":"CL541804"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143500":{"preferredName":"Gastric Hemorrhage, CTCAE","code":"C143500","definitions":[{"definition":"A disorder characterized by bleeding from the gastric wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the gastric wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastric Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Hemorrhage"},{"name":"Maps_To","value":"Gastric hemorrhage"},{"name":"NCI_META_CUI","value":"CL541805"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143501":{"preferredName":"Gastric Necrosis, CTCAE","code":"C143501","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the gastric wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the gastric wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Necrosis"},{"name":"Maps_To","value":"Gastric necrosis"},{"name":"NCI_META_CUI","value":"CL541806"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143502":{"preferredName":"Gastric Perforation, CTCAE","code":"C143502","definitions":[{"definition":"A disorder characterized by a rupture in the stomach wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the stomach wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Perforation"},{"name":"Maps_To","value":"Gastric perforation"},{"name":"NCI_META_CUI","value":"CL541791"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143503":{"preferredName":"Gastric Stenosis, CTCAE","code":"C143503","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastric Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Stenosis"},{"name":"Maps_To","value":"Gastric stenosis"},{"name":"NCI_META_CUI","value":"CL541792"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143504":{"preferredName":"Gastric Ulcer, CTCAE","code":"C143504","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastric Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastric Ulcer"},{"name":"Maps_To","value":"Gastric ulcer"},{"name":"NCI_META_CUI","value":"CL541793"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57812":{"preferredName":"Gastritis, CTCAE","code":"C57812","definitions":[{"definition":"A disorder characterized by inflammation of the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastritis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastritis_Adverse_Event"},{"name":"Maps_To","value":"Gastritis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560435"}]}}{"C143506":{"preferredName":"Gastroesophageal Reflux Disease, CTCAE","code":"C143506","definitions":[{"definition":"A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastroesophageal Reflux Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastroesophageal Reflux Disease"},{"name":"Maps_To","value":"Gastroesophageal reflux disease"},{"name":"NCI_META_CUI","value":"CL541794"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143507":{"preferredName":"Gastrointestinal Anastomotic Leak, CTCAE","code":"C143507","definitions":[{"definition":"A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastrointestinal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Anastomotic Leak"},{"name":"Maps_To","value":"Gastrointestinal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541795"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143508":{"preferredName":"Gastrointestinal Disorders - Other, Specify, CTCAE","code":"C143508","synonyms":[{"termName":"Gastrointestinal Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Disorders - Other"},{"name":"Maps_To","value":"Gastrointestinal disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541796"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146637":{"preferredName":"Gastrointestinal Fistula, CTCAE 5.0","code":"C146637","definitions":[{"definition":"A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastrointestinal Fistula, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal fistula"},{"name":"Maps_To","value":"Gastrointestinal Fistula"},{"name":"NCI_META_CUI","value":"CL544669"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143510":{"preferredName":"Gastrointestinal Pain, CTCAE","code":"C143510","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastrointestinal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Pain"},{"name":"Maps_To","value":"Gastrointestinal pain"},{"name":"NCI_META_CUI","value":"CL541797"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143511":{"preferredName":"Gastrointestinal Stoma Necrosis, CTCAE","code":"C143511","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the gastrointestinal tract stoma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the gastrointestinal tract stoma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gastrointestinal Stoma Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastrointestinal Stoma Necrosis"},{"name":"Maps_To","value":"Gastrointestinal stoma necrosis"},{"name":"NCI_META_CUI","value":"CL541798"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143512":{"preferredName":"Gastroparesis, CTCAE","code":"C143512","definitions":[{"definition":"A disorder characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gastroparesis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gastroparesis"},{"name":"NCI_META_CUI","value":"CL541783"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143513":{"preferredName":"General Disorders and Administration Site Conditions - Other, Specify, CTCAE","code":"C143513","synonyms":[{"termName":"General Disorders and Administration Site Conditions - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"General Disorders and Administration Site Conditions - Other"},{"name":"Maps_To","value":"General disorders and administration site conditions - Other, specify"},{"name":"NCI_META_CUI","value":"CL541784"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143514":{"preferredName":"Generalized Muscle Weakness, CTCAE","code":"C143514","definitions":[{"definition":"A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Generalized Muscle Weakness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Generalized Muscle Weakness"},{"name":"Maps_To","value":"Generalized muscle weakness"},{"name":"NCI_META_CUI","value":"CL541785"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143515":{"preferredName":"Genital Edema, CTCAE","code":"C143515","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the genitals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the genitals.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Genital Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genital Edema"},{"name":"Maps_To","value":"Genital edema"},{"name":"NCI_META_CUI","value":"CL541786"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143516":{"preferredName":"GGT Increased, CTCAE","code":"C143516","definitions":[{"definition":"A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"GGT Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GGT Increased"},{"name":"Maps_To","value":"GGT increased"},{"name":"NCI_META_CUI","value":"CL541787"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146626":{"preferredName":"Gingival Pain, CTCAE","code":"C146626","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the gingival region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the gingival region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gingival Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gingival pain"},{"name":"Maps_To","value":"Gingival Pain"},{"name":"NCI_META_CUI","value":"CL544673"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55842":{"preferredName":"Glaucoma, CTCAE","code":"C55842","definitions":[{"definition":"A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Glaucoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glaucoma_Adverse_Event"},{"name":"Maps_To","value":"Glaucoma"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962986"}]}}{"C143518":{"preferredName":"Glossopharyngeal Nerve Disorder, CTCAE","code":"C143518","definitions":[{"definition":"A disorder characterized by dysfunction of the glossopharyngeal nerve (ninth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the glossopharyngeal nerve (ninth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Glossopharyngeal Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glossopharyngeal Nerve Disorder"},{"name":"Maps_To","value":"Glossopharyngeal nerve disorder"},{"name":"NCI_META_CUI","value":"CL541788"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143519":{"preferredName":"Glucose Intolerance, CTCAE","code":"C143519","definitions":[{"definition":"A disorder characterized by an inability to properly metabolize glucose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an inability to properly metabolize glucose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Glucose Intolerance, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glucose Intolerance"},{"name":"Maps_To","value":"Glucose intolerance"},{"name":"NCI_META_CUI","value":"CL541789"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143520":{"preferredName":"Growth Accelerated, CTCAE","code":"C143520","definitions":[{"definition":"A disorder characterized by greater growth than expected for age.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by greater growth than expected for age.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Growth Accelerated, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Growth Accelerated"},{"name":"Maps_To","value":"Growth accelerated"},{"name":"NCI_META_CUI","value":"CL541790"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143521":{"preferredName":"Growth Hormone Abnormal, CTCAE","code":"C143521","definitions":[{"definition":"A finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Growth Hormone Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Growth Hormone Abnormal"},{"name":"Maps_To","value":"Growth hormone abnormal"},{"name":"NCI_META_CUI","value":"CL541895"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143522":{"preferredName":"Growth Suppression, CTCAE","code":"C143522","definitions":[{"definition":"A disorder characterized by stature that is smaller than normal as expected for age.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by stature that is smaller than normal as expected for age.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Growth Suppression, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Growth Suppression"},{"name":"Maps_To","value":"Growth suppression"},{"name":"NCI_META_CUI","value":"CL541896"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143523":{"preferredName":"Gum Infection, CTCAE","code":"C143523","definitions":[{"definition":"A disorder characterized by an infectious process involving the gums.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the gums.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Gum Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gum Infection"},{"name":"Maps_To","value":"Gum infection"},{"name":"NCI_META_CUI","value":"CL541897"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146685":{"preferredName":"Gynecomastia, CTCAE 5.0","code":"C146685","definitions":[{"definition":"A disorder characterized by excessive development of the breasts in males.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive development of the breasts in males.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Gynecomastia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Gynecomastia"},{"name":"NCI_META_CUI","value":"CL544743"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143525":{"preferredName":"Hallucinations, CTCAE","code":"C143525","definitions":[{"definition":"A disorder characterized by a false sensory perception in the absence of an external stimulus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a false sensory perception in the absence of an external stimulus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hallucinations, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hallucinations"},{"name":"NCI_META_CUI","value":"CL541898"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143526":{"preferredName":"Haptoglobin Decreased, CTCAE","code":"C143526","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Haptoglobin Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Haptoglobin Decreased"},{"name":"Maps_To","value":"Haptoglobin decreased"},{"name":"NCI_META_CUI","value":"CL541899"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58383":{"preferredName":"Head Soft Tissue Necrosis, CTCAE","code":"C58383","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the head.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the head.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Head Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Head_Soft_Tissue_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Head Soft Tissue Necrosis"},{"name":"Maps_To","value":"Head soft tissue necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963121"}]}}{"C143527":{"preferredName":"Headache, CTCAE","code":"C143527","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Headache, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Headache"},{"name":"NCI_META_CUI","value":"CL541900"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143528":{"preferredName":"Hearing Impaired, CTCAE","code":"C143528","definitions":[{"definition":"A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hearing Impaired, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hearing Impaired"},{"name":"Maps_To","value":"Hearing impaired"},{"name":"NCI_META_CUI","value":"CL545983"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143529":{"preferredName":"Heart Failure, CTCAE","code":"C143529","definitions":[{"definition":"A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Heart Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heart Failure"},{"name":"Maps_To","value":"Heart failure"},{"name":"NCI_META_CUI","value":"CL541901"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56539":{"preferredName":"Hematoma, CTCAE","code":"C56539","definitions":[{"definition":"A disorder characterized by a localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hematoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hematoma_Adverse_Event"},{"name":"Maps_To","value":"Hematoma"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962958"}]}}{"C143531":{"preferredName":"Hematosalpinx, CTCAE","code":"C143531","definitions":[{"definition":"A disorder characterized by the presence of blood in a fallopian tube.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the presence of blood in a fallopian tube.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hematosalpinx, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hematosalpinx"},{"name":"NCI_META_CUI","value":"CL541887"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143532":{"preferredName":"Hematuria, CTCAE","code":"C143532","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate blood in the urine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate blood in the urine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hematuria, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Hematuria"},{"name":"NCI_META_CUI","value":"CL541888"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143533":{"preferredName":"Hemoglobin Increased, CTCAE","code":"C143533","definitions":[{"definition":"A finding based on laboratory test results that indicate increased levels of hemoglobin above normal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate increased levels of hemoglobin above normal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemoglobin Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemoglobin Increased"},{"name":"Maps_To","value":"Hemoglobin increased"},{"name":"NCI_META_CUI","value":"CL541889"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146768":{"preferredName":"Hemoglobinuria, CTCAE 5.0","code":"C146768","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hemoglobinuria, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemoglobinuria"},{"name":"NCI_META_CUI","value":"CL544790"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55992":{"preferredName":"Hemolysis, CTCAE","code":"C55992","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate widespread erythrocyte cell membrane destruction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate widespread erythrocyte cell membrane destruction.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemolysis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemolysis_Adverse_Event"},{"name":"Maps_To","value":"Hemolysis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560209"}]}}{"C143536":{"preferredName":"Hemolytic Uremic Syndrome, CTCAE","code":"C143536","definitions":[{"definition":"A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemolytic Uremic Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemolytic Uremic Syndrome"},{"name":"Maps_To","value":"Hemolytic uremic syndrome"},{"name":"NCI_META_CUI","value":"CL541890"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143537":{"preferredName":"Hemorrhoidal Hemorrhage, CTCAE","code":"C143537","definitions":[{"definition":"A disorder characterized by bleeding from the hemorrhoids.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the hemorrhoids.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hemorrhoidal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hemorrhoidal Hemorrhage"},{"name":"Maps_To","value":"Hemorrhoidal hemorrhage"},{"name":"NCI_META_CUI","value":"CL541891"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146738":{"preferredName":"Hemorrhoids, CTCAE 5.0","code":"C146738","definitions":[{"definition":"A disorder characterized by the presence of dilated veins in the rectum and surrounding area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the presence of dilated veins in the rectum and surrounding area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hemorrhoids, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Hemorrhoids"},{"name":"NCI_META_CUI","value":"CL544700"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143539":{"preferredName":"Hepatic Failure, CTCAE","code":"C143539","definitions":[{"definition":"A disorder characterized by the inability of the liver to metabolize chemicals in the body. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, alkaline phosphatase, aminotransferase, and/or prolongation of prothrombin time (INR.) Drug-induced liever injury (DILI) as defined by Hy's Law.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the inability of the liver to metabolize chemicals in the body. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, alkaline phosphatase, aminotransferase, and/or prolongation of prothrombin time (INR.) Drug-induced liever injury (DILI) as defined by Hy's Law.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hepatic Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic Failure"},{"name":"Maps_To","value":"Hepatic failure"},{"name":"NCI_META_CUI","value":"CL541892"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143540":{"preferredName":"Hepatic Hemorrhage, CTCAE","code":"C143540","definitions":[{"definition":"A disorder characterized by bleeding from the liver.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the liver.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hepatic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic hemorrhage"},{"name":"Maps_To","value":"Hepatic Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541893"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143541":{"preferredName":"Hepatic Infection, CTCAE","code":"C143541","definitions":[{"definition":"A disorder characterized by an infectious process involving the liver.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the liver.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hepatic Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic infection"},{"name":"Maps_To","value":"Hepatic Infection"},{"name":"NCI_META_CUI","value":"CL541894"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146736":{"preferredName":"Hepatic Necrosis, CTCAE 5.0","code":"C146736","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the hepatic parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the hepatic parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hepatic Necrosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic Necrosis"},{"name":"Maps_To","value":"Hepatic necrosis"},{"name":"NCI_META_CUI","value":"CL544699"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143542":{"preferredName":"Hepatic Pain, CTCAE","code":"C143542","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the liver region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the liver region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hepatic Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatic pain"},{"name":"Maps_To","value":"Hepatic Pain"},{"name":"NCI_META_CUI","value":"CL541880"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143543":{"preferredName":"Hepatitis Viral, CTCAE","code":"C143543","definitions":[{"definition":"A disorder characterized by a viral pathologic process involving the liver parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a viral pathologic process involving the liver parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hepatitis Viral, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatitis viral"},{"name":"Maps_To","value":"Hepatitis Viral"},{"name":"NCI_META_CUI","value":"CL541881"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143544":{"preferredName":"Hepatobiliary Disorders - Other, Specify, CTCAE","code":"C143544","synonyms":[{"termName":"Hepatobiliary Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatobiliary Disorders - Other"},{"name":"Maps_To","value":"Hepatobiliary disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541882"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143545":{"preferredName":"Hiccups, CTCAE","code":"C143545","definitions":[{"definition":"A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hiccups, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hiccups"},{"name":"NCI_META_CUI","value":"CL541883"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143546":{"preferredName":"Hip Fracture, CTCAE","code":"C143546","definitions":[{"definition":"A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hip Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hip fracture"},{"name":"Maps_To","value":"Hip Fracture"},{"name":"NCI_META_CUI","value":"CL541884"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143547":{"preferredName":"Hirsutism, CTCAE","code":"C143547","definitions":[{"definition":"A disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hirsutism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hirsutism"},{"name":"NCI_META_CUI","value":"CL541885"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143548":{"preferredName":"Hoarseness, CTCAE","code":"C143548","definitions":[{"definition":"A disorder characterized by harsh and raspy voice arising from or spreading to the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by harsh and raspy voice arising from or spreading to the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hoarseness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hoarseness"},{"name":"NCI_META_CUI","value":"CL541886"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143549":{"preferredName":"Hot Flashes, CTCAE","code":"C143549","definitions":[{"definition":"A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hot Flashes, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Hot Flashes"},{"name":"Maps_To","value":"Hot flashes"},{"name":"NCI_META_CUI","value":"CL545907"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55401":{"preferredName":"Hydrocephalus, CTCAE","code":"C55401","definitions":[{"definition":"A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hydrocephalus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hydrocephalus_Adverse_Event"},{"name":"Maps_To","value":"Hydrocephalus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963137"}]}}{"C143551":{"preferredName":"Hypercalcemia, CTCAE","code":"C143551","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypercalcemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypercalcemia"},{"name":"NCI_META_CUI","value":"CL541874"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143552":{"preferredName":"Hyperglycemia, CTCAE","code":"C143552","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperglycemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperglycemia"},{"name":"NCI_META_CUI","value":"CL541875"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143553":{"preferredName":"Hyperhidrosis, CTCAE","code":"C143553","definitions":[{"definition":"A disorder characterized by excessive sweating.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excessive sweating.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperhidrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperhidrosis"},{"name":"NCI_META_CUI","value":"CL541876"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143554":{"preferredName":"Hyperkalemia, CTCAE","code":"C143554","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperkalemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperkalemia"},{"name":"NCI_META_CUI","value":"CL541877"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143555":{"preferredName":"Hypermagnesemia, CTCAE","code":"C143555","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypermagnesemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypermagnesemia"},{"name":"NCI_META_CUI","value":"CL546021"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143556":{"preferredName":"Hypernatremia, CTCAE","code":"C143556","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypernatremia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypernatremia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0020488"}]}}{"C143557":{"preferredName":"Hyperparathyroidism, CTCAE","code":"C143557","definitions":[{"definition":"A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hyperparathyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperparathyroidism"},{"name":"NCI_META_CUI","value":"CL541878"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143558":{"preferredName":"Hypersomnia, CTCAE","code":"C143558","definitions":[{"definition":"A disorder characterized by characterized by excessive sleepiness during the daytime.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by characterized by excessive sleepiness during the daytime.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypersomnia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypersomnia"},{"name":"NCI_META_CUI","value":"CL541879"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55060":{"preferredName":"Hypertension, CTCAE","code":"C55060","definitions":[{"definition":"A disorder characterized by a pathological increase in blood pressure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a pathological increase in blood pressure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypertension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypertension_Adverse_Event"},{"name":"Maps_To","value":"Hypertension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963138"}]}}{"C143560":{"preferredName":"Hyperthyroidism, CTCAE","code":"C143560","definitions":[{"definition":"A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyperthyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperthyroidism"},{"name":"NCI_META_CUI","value":"CL541866"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143561":{"preferredName":"Hypertrichosis, CTCAE","code":"C143561","definitions":[{"definition":"A disorder characterized by hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypertrichosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypertrichosis"},{"name":"NCI_META_CUI","value":"CL541867"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143562":{"preferredName":"Hypertriglyceridemia, CTCAE","code":"C143562","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypertriglyceridemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypertriglyceridemia"},{"name":"NCI_META_CUI","value":"CL541868"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143563":{"preferredName":"Hyperuricemia, CTCAE","code":"C143563","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hyperuricemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyperuricemia"},{"name":"NCI_META_CUI","value":"CL541869"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143564":{"preferredName":"Hypoalbuminemia, CTCAE","code":"C143564","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoalbuminemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoalbuminemia"},{"name":"NCI_META_CUI","value":"CL541870"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143565":{"preferredName":"Hypocalcemia, CTCAE","code":"C143565","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypocalcemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypocalcemia"},{"name":"NCI_META_CUI","value":"CL541871"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143566":{"preferredName":"Hypoglossal Nerve Disorder, CTCAE","code":"C143566","definitions":[{"definition":"A disorder characterized by dysfunction of the hypoglossal nerve (twelfth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the hypoglossal nerve (twelfth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoglossal Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoglossal Nerve Disorder"},{"name":"Maps_To","value":"Hypoglossal nerve disorder"},{"name":"NCI_META_CUI","value":"CL541872"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143567":{"preferredName":"Hypoglycemia, CTCAE","code":"C143567","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypoglycemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoglycemia"},{"name":"NCI_META_CUI","value":"CL541873"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143568":{"preferredName":"Hypohidrosis, CTCAE","code":"C143568","definitions":[{"definition":"A disorder characterized by reduced sweating.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by reduced sweating.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypohidrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypohidrosis"},{"name":"NCI_META_CUI","value":"CL541859"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143569":{"preferredName":"Hypokalemia, CTCAE","code":"C143569","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypokalemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypokalemia"},{"name":"NCI_META_CUI","value":"CL541860"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143570":{"preferredName":"Hypomagnesemia, CTCAE","code":"C143570","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypomagnesemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypomagnesemia"},{"name":"NCI_META_CUI","value":"CL541861"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143571":{"preferredName":"Hyponatremia, CTCAE","code":"C143571","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hyponatremia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hyponatremia"},{"name":"NCI_META_CUI","value":"CL541862"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143572":{"preferredName":"Hypoparathyroidism, CTCAE","code":"C143572","definitions":[{"definition":"A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoparathyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoparathyroidism"},{"name":"NCI_META_CUI","value":"CL541863"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143573":{"preferredName":"Hypophosphatemia, CTCAE","code":"C143573","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypophosphatemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypophosphatemia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0595888"}]}}{"C55061":{"preferredName":"Hypotension, CTCAE","code":"C55061","definitions":[{"definition":"A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypotension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypotension_Adverse_Event"},{"name":"Maps_To","value":"Hypotension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3163620"}]}}{"C55332":{"preferredName":"Hypothermia, CTCAE","code":"C55332","definitions":[{"definition":"A disorder characterized by an abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypothermia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypothermia_Adverse_Event"},{"name":"Maps_To","value":"Hypothermia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963170"}]}}{"C143576":{"preferredName":"Hypothyroidism, CTCAE","code":"C143576","definitions":[{"definition":"A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Hypothyroidism, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypothyroidism"},{"name":"NCI_META_CUI","value":"CL541864"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58188":{"preferredName":"Hypoxia, CTCAE","code":"C58188","definitions":[{"definition":"A disorder characterized by a decrease in the level of oxygen in the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in the level of oxygen in the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Hypoxia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypoxia_Adverse_Event"},{"name":"Maps_To","value":"Hypoxia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963140"}]}}{"C57821":{"preferredName":"Ileal Fistula, CTCAE","code":"C57821","definitions":[{"definition":"A disorder characterized by an abnormal communication between the ileum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the ileum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ileal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Ileal fistula"},{"name":"Maps_To","value":"Ileal Fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1397399"}]}}{"C56542":{"preferredName":"Ileal Hemorrhage, CTCAE","code":"C56542","definitions":[{"definition":"A disorder characterized by bleeding from the ileal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the ileal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Ileal Hemorrhage"},{"name":"Maps_To","value":"Ileal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963142"}]}}{"C57823":{"preferredName":"Ileal Obstruction, CTCAE","code":"C57823","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the ileum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the ileum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ileal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Ileal Obstruction"},{"name":"Maps_To","value":"Ileal obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1400387"}]}}{"C146633":{"preferredName":"Ileal Perforation, CTCAE 5.0","code":"C146633","definitions":[{"definition":"A disorder characterized by a rupture in the ileal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the ileal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ileal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ileal perforation"},{"name":"Maps_To","value":"Ileal Perforation"},{"name":"NCI_META_CUI","value":"CL544665"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143578":{"preferredName":"Ileal Stenosis, CTCAE","code":"C143578","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the ileum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the lumen of the ileum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ileal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ileal stenosis"},{"name":"Maps_To","value":"Ileal Stenosis"},{"name":"NCI_META_CUI","value":"CL541865"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57826":{"preferredName":"Ileal Ulcer, CTCAE","code":"C57826","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the ileum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the ileum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ileal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileum_Ulcer_Adverse_Event"},{"name":"Maps_To","value":"Ileal ulcer"},{"name":"Maps_To","value":"Ileal Ulcer"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963143"}]}}{"C57814":{"preferredName":"Ileus, CTCAE","code":"C57814","definitions":[{"definition":"A disorder characterized by failure of the ileum to transport intestinal contents.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by failure of the ileum to transport intestinal contents.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ileus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal_Ileus_Adverse_Event"},{"name":"Maps_To","value":"Ileus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560456"}]}}{"C143580":{"preferredName":"Immune System Disorders - Other, Specify, CTCAE","code":"C143580","synonyms":[{"termName":"Immune System Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immune System Disorders - Other"},{"name":"Maps_To","value":"Immune system disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL541851"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143581":{"preferredName":"Infections and Infestations - Other, Specify, CTCAE","code":"C143581","synonyms":[{"termName":"Infections and Infestations - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infections and Infestations - Other"},{"name":"Maps_To","value":"Infections and infestations - Other, specify"},{"name":"NCI_META_CUI","value":"CL541852"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143582":{"preferredName":"Infective Myositis, CTCAE","code":"C143582","definitions":[{"definition":"A disorder characterized by an infectious process involving the skeletal muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the skeletal muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Infective Myositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infective myositis"},{"name":"Maps_To","value":"Infective Myositis"},{"name":"NCI_META_CUI","value":"CL541853"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143583":{"preferredName":"Infusion Related Reaction, CTCAE","code":"C143583","definitions":[{"definition":"A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Infusion Related Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infusion related reaction"},{"name":"Maps_To","value":"Infusion Related Reaction"},{"name":"NCI_META_CUI","value":"CL541854"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143584":{"preferredName":"Infusion Site Extravasation, CTCAE","code":"C143584","definitions":[{"definition":"A disorder characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms may include induration, erythema, swelling, burning sensation and marked discomfort at the infusion site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms may include induration, erythema, swelling, burning sensation and marked discomfort at the infusion site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Infusion Site Extravasation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Infusion site extravasation"},{"name":"Maps_To","value":"Infusion Site Extravasation"},{"name":"NCI_META_CUI","value":"CL541855"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143585":{"preferredName":"Injection Site Reaction, CTCAE","code":"C143585","definitions":[{"definition":"A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Injection Site Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injection site reaction"},{"name":"Maps_To","value":"Injection Site Reaction"},{"name":"NCI_META_CUI","value":"CL541856"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143586":{"preferredName":"Injury To Carotid Artery, CTCAE","code":"C143586","definitions":[{"definition":"A finding of damage to the carotid artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the carotid artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Injury To Carotid Artery, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury to carotid artery"},{"name":"Maps_To","value":"Injury to Carotid Artery"},{"name":"NCI_META_CUI","value":"CL541857"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56735":{"preferredName":"Injury To Inferior Vena Cava, CTCAE","code":"C56735","definitions":[{"definition":"A finding of damage to the inferior vena cava.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the inferior vena cava.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Injury To Inferior Vena Cava, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inferior_Vena_Cava_Vein_Injury_Adverse_Event"},{"name":"Maps_To","value":"Injury to Inferior Vena Cava"},{"name":"Maps_To","value":"Injury to inferior vena cava"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559031"}]}}{"C143587":{"preferredName":"Injury To Jugular Vein, CTCAE","code":"C143587","definitions":[{"definition":"A finding of damage to the jugular vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the jugular vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Injury To Jugular Vein, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury to jugular vein"},{"name":"Maps_To","value":"Injury to Jugular Vein"},{"name":"NCI_META_CUI","value":"CL541858"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143588":{"preferredName":"Injury To Superior Vena Cava, CTCAE","code":"C143588","definitions":[{"definition":"A finding of damage to the superior vena cava.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the superior vena cava.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Injury To Superior Vena Cava, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury to superior vena cava"},{"name":"Maps_To","value":"Injury to Superior Vena Cava"},{"name":"NCI_META_CUI","value":"CL541843"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143589":{"preferredName":"Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","code":"C143589","synonyms":[{"termName":"Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injury, Poisoning and Procedural Complications - Other"},{"name":"Maps_To","value":"Injury, poisoning and procedural complications - Other, specify"},{"name":"NCI_META_CUI","value":"CL541844"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143590":{"preferredName":"INR Increased, CTCAE","code":"C143590","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time to a control sample in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time to a control sample in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"INR Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"INR increased"},{"name":"Maps_To","value":"INR Increased"},{"name":"NCI_META_CUI","value":"CL541845"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146771":{"preferredName":"Insomnia, CTCAE 5.0","code":"C146771","definitions":[{"definition":"A disorder characterized by difficulty in falling asleep and/or remaining asleep.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by difficulty in falling asleep and/or remaining asleep.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Insomnia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Insomnia"},{"name":"NCI_META_CUI","value":"CL544779"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143592":{"preferredName":"Intestinal Stoma Leak, CTCAE","code":"C143592","definitions":[{"definition":"A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intestinal Stoma Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intestinal stoma leak"},{"name":"Maps_To","value":"Intestinal Stoma Leak"},{"name":"NCI_META_CUI","value":"CL541846"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143593":{"preferredName":"Intestinal Stoma Obstruction, CTCAE","code":"C143593","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents of the intestinal stoma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents of the intestinal stoma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intestinal Stoma Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intestinal stoma obstruction"},{"name":"Maps_To","value":"Intestinal Stoma Obstruction"},{"name":"NCI_META_CUI","value":"CL541847"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143594":{"preferredName":"Intestinal Stoma Site Bleeding, CTCAE","code":"C143594","definitions":[{"definition":"A disorder characterized by bleeding from the intestinal stoma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the intestinal stoma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intestinal Stoma Site Bleeding, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intestinal stoma site bleeding"},{"name":"Maps_To","value":"Intestinal Stoma Site Bleeding"},{"name":"NCI_META_CUI","value":"CL541848"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143595":{"preferredName":"Intra-Abdominal Hemorrhage, CTCAE","code":"C143595","definitions":[{"definition":"A disorder characterized by bleeding in the abdominal cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding in the abdominal cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intra-Abdominal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intra-abdominal hemorrhage"},{"name":"Maps_To","value":"Intra-Abdominal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541849"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143596":{"preferredName":"Intracranial Hemorrhage, CTCAE","code":"C143596","definitions":[{"definition":"A disorder characterized by bleeding from the cranium.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the cranium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intracranial Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intracranial hemorrhage"},{"name":"Maps_To","value":"Intracranial Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541850"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143597":{"preferredName":"Intraoperative Arterial Injury, CTCAE","code":"C143597","definitions":[{"definition":"A finding of damage to an artery during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to an artery during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Arterial Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative arterial injury"},{"name":"Maps_To","value":"Intraoperative Arterial Injury"},{"name":"NCI_META_CUI","value":"CL541956"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143598":{"preferredName":"Intraoperative Breast Injury, CTCAE","code":"C143598","definitions":[{"definition":"A finding of damage to the breast parenchyma during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the breast parenchyma during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Breast Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative breast injury"},{"name":"Maps_To","value":"Intraoperative Breast Injury"},{"name":"NCI_META_CUI","value":"CL541957"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143599":{"preferredName":"Intraoperative Cardiac Injury, CTCAE","code":"C143599","definitions":[{"definition":"A finding of damage to the heart during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the heart during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Cardiac Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative cardiac injury"},{"name":"Maps_To","value":"Intraoperative Cardiac Injury"},{"name":"NCI_META_CUI","value":"CL541958"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143600":{"preferredName":"Intraoperative Ear Injury, CTCAE","code":"C143600","definitions":[{"definition":"A finding of damage to the ear during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the ear during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Ear Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative ear injury"},{"name":"Maps_To","value":"Intraoperative Ear Injury"},{"name":"NCI_META_CUI","value":"CL541959"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143601":{"preferredName":"Intraoperative Endocrine Injury, CTCAE","code":"C143601","definitions":[{"definition":"A finding of damage to the endocrine gland during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the endocrine gland during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Endocrine Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative endocrine injury"},{"name":"Maps_To","value":"Intraoperative Endocrine Injury"},{"name":"NCI_META_CUI","value":"CL541960"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143602":{"preferredName":"Intraoperative Gastrointestinal Injury, CTCAE","code":"C143602","definitions":[{"definition":"A finding of damage to the gastrointestinal system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the gastrointestinal system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Gastrointestinal Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative gastrointestinal injury"},{"name":"Maps_To","value":"Intraoperative Gastrointestinal Injury"},{"name":"NCI_META_CUI","value":"CL541961"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143603":{"preferredName":"Intraoperative Head and Neck Injury, CTCAE","code":"C143603","definitions":[{"definition":"A finding of damage to the head and neck during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the head and neck during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Head and Neck Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative head and neck injury"},{"name":"Maps_To","value":"Intraoperative Head and Neck Injury"},{"name":"NCI_META_CUI","value":"CL541962"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143604":{"preferredName":"Intraoperative Hemorrhage, CTCAE","code":"C143604","definitions":[{"definition":"A finding of uncontrolled bleeding during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of uncontrolled bleeding during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative hemorrhage"},{"name":"Maps_To","value":"Intraoperative Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541963"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143605":{"preferredName":"Intraoperative Hepatobiliary Injury, CTCAE","code":"C143605","definitions":[{"definition":"A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Hepatobiliary Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative hepatobiliary injury"},{"name":"Maps_To","value":"Intraoperative Hepatobiliary Injury"},{"name":"NCI_META_CUI","value":"CL541948"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143606":{"preferredName":"Intraoperative Musculoskeletal Injury, CTCAE","code":"C143606","definitions":[{"definition":"A finding of damage to the musculoskeletal system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the musculoskeletal system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Musculoskeletal Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative musculoskeletal injury"},{"name":"Maps_To","value":"Intraoperative Musculoskeletal Injury"},{"name":"NCI_META_CUI","value":"CL541949"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143607":{"preferredName":"Intraoperative Neurological Injury, CTCAE","code":"C143607","definitions":[{"definition":"A finding of damage to the nervous system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the nervous system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Neurological Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative neurological injury"},{"name":"Maps_To","value":"Intraoperative Neurological Injury"},{"name":"NCI_META_CUI","value":"CL541950"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143608":{"preferredName":"Intraoperative Ocular Injury, CTCAE","code":"C143608","definitions":[{"definition":"A finding of damage to the eye during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the eye during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Ocular Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative ocular injury"},{"name":"Maps_To","value":"Intraoperative Ocular Injury"},{"name":"NCI_META_CUI","value":"CL541951"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143609":{"preferredName":"Intraoperative Renal Injury, CTCAE","code":"C143609","definitions":[{"definition":"A finding of damage to the kidney during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the kidney during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Renal Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative renal injury"},{"name":"Maps_To","value":"Intraoperative Renal Injury"},{"name":"NCI_META_CUI","value":"CL541952"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143610":{"preferredName":"Intraoperative Reproductive Tract Injury, CTCAE","code":"C143610","definitions":[{"definition":"A finding of damage to the reproductive organs during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the reproductive organs during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Reproductive Tract Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative reproductive tract injury"},{"name":"Maps_To","value":"Intraoperative Reproductive Tract Injury"},{"name":"NCI_META_CUI","value":"CL541953"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143611":{"preferredName":"Intraoperative Respiratory Injury, CTCAE","code":"C143611","definitions":[{"definition":"A finding of damage to the respiratory system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to the respiratory system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Respiratory Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative respiratory injury"},{"name":"Maps_To","value":"Intraoperative Respiratory Injury"},{"name":"NCI_META_CUI","value":"CL541954"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78389":{"preferredName":"Intraoperative Skin Injury","code":"C78389","definitions":[{"definition":"A finding of damage to the skin during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Damage to the skin during a surgical procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraoperative Skin Injury","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraoperative_Skin_Injury"},{"name":"Maps_To","value":"Intraoperative Skin Injury"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1558746"}]}}{"C143612":{"preferredName":"Intraoperative Splenic Injury, CTCAE","code":"C143612","definitions":[{"definition":"A finding of damage to the spleen during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the spleen during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Splenic Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative splenic injury"},{"name":"Maps_To","value":"Intraoperative Splenic Injury"},{"name":"NCI_META_CUI","value":"CL541955"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143613":{"preferredName":"Intraoperative Urinary Injury, CTCAE","code":"C143613","definitions":[{"definition":"A finding of damage to the urinary system during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of damage to the urinary system during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Intraoperative Urinary Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative urinary injury"},{"name":"Maps_To","value":"Intraoperative Urinary Injury"},{"name":"NCI_META_CUI","value":"CL541940"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143614":{"preferredName":"Intraoperative Venous Injury, CTCAE","code":"C143614","definitions":[{"definition":"A finding of damage to a vein during a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to a vein during a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Intraoperative Venous Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intraoperative venous injury"},{"name":"Maps_To","value":"Intraoperative Venous Injury"},{"name":"NCI_META_CUI","value":"CL541941"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143615":{"preferredName":"Investigations - Other, Specify, CTCAE","code":"C143615","synonyms":[{"termName":"Investigations - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Investigations - Other"},{"name":"Maps_To","value":"Investigations - Other, specify"},{"name":"NCI_META_CUI","value":"CL541942"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55993":{"preferredName":"Iron Overload, CTCAE","code":"C55993","definitions":[{"definition":"A disorder characterized by accumulation of iron in the tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by accumulation of iron in the tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Iron Overload, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iron_Overload_Adverse_Event"},{"name":"Maps_To","value":"Iron Overload"},{"name":"Maps_To","value":"Iron overload"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963148"}]}}{"C143617":{"preferredName":"Irregular Menstruation, CTCAE","code":"C143617","definitions":[{"definition":"A disorder characterized by a change in cycle or duration of menses from baseline.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a change in cycle or duration of menses from baseline.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Irregular Menstruation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irregular menstruation"},{"name":"Maps_To","value":"Irregular Menstruation"},{"name":"NCI_META_CUI","value":"CL541943"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143618":{"preferredName":"Irritability, CTCAE","code":"C143618","definitions":[{"definition":"A disorder characterized by an abnormal responsiveness to stimuli or physiological arousal; may be in response to pain, fright, a drug, an emotional situation or a medical condition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal responsiveness to stimuli or physiological arousal; may be in response to pain, fright, a drug, an emotional situation or a medical condition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Irritability, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irritability"},{"name":"NCI_META_CUI","value":"CL541944"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143619":{"preferredName":"Ischemia Cerebrovascular, CTCAE","code":"C143619","definitions":[{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ischemia Cerebrovascular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ischemia cerebrovascular"},{"name":"Maps_To","value":"Ischemia Cerebrovascular"},{"name":"NCI_META_CUI","value":"CL541945"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143235":{"preferredName":"Trochlear Nerve Disorder, CTCAE","code":"C143235","definitions":[{"definition":"A disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Trochlear Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IVth Nerve Disorder"},{"name":"Maps_To","value":"Trochlear nerve disorder"},{"name":"NCI_META_CUI","value":"CL545921"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57827":{"preferredName":"Jejunal Fistula, CTCAE","code":"C57827","definitions":[{"definition":"A disorder characterized by an abnormal communication between the jejunum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the jejunum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Jejunal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Jejunal Fistula"},{"name":"Maps_To","value":"Jejunal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963149"}]}}{"C56543":{"preferredName":"Jejunal Hemorrhage, CTCAE","code":"C56543","definitions":[{"definition":"A disorder characterized by bleeding from the jejunal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the jejunal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Jejunal Hemorrhage"},{"name":"Maps_To","value":"Jejunal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963150"}]}}{"C57829":{"preferredName":"Jejunal Obstruction, CTCAE","code":"C57829","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the jejunum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the jejunum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Jejunal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Jejunal obstruction"},{"name":"Maps_To","value":"Jejunal Obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1401336"}]}}{"C143622":{"preferredName":"Jejunal Perforation, CTCAE","code":"C143622","definitions":[{"definition":"A disorder characterized by a rupture in the jejunal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the jejunal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Jejunal perforation"},{"name":"Maps_To","value":"Jejunal Perforation"},{"name":"NCI_META_CUI","value":"CL541946"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143623":{"preferredName":"Jejunal Stenosis, CTCAE","code":"C143623","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the jejunum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the jejunum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Jejunal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Jejunal stenosis"},{"name":"Maps_To","value":"Jejunal Stenosis"},{"name":"NCI_META_CUI","value":"CL541947"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57832":{"preferredName":"Jejunal Ulcer, CTCAE","code":"C57832","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the jejunum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the jejunum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Jejunal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jejunum_Ulcer_Adverse_Event"},{"name":"Maps_To","value":"Jejunal ulcer"},{"name":"Maps_To","value":"Jejunal Ulcer"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963151"}]}}{"C146760":{"preferredName":"Joint Effusion, CTCAE 5.0","code":"C146760","definitions":[{"definition":"A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Joint Effusion, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint Effusion"},{"name":"Maps_To","value":"Joint effusion"},{"name":"NCI_META_CUI","value":"CL544798"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143626":{"preferredName":"Joint Infection, CTCAE","code":"C143626","definitions":[{"definition":"A disorder characterized by an infectious process involving a joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Joint Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint infection"},{"name":"Maps_To","value":"Joint Infection"},{"name":"NCI_META_CUI","value":"CL541933"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143629":{"preferredName":"Joint Range of Motion Decreased, CTCAE","code":"C143629","definitions":[{"definition":"A disorder characterized by a decrease in joint flexibility of any joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in joint flexibility of any joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Joint Range of Motion Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint range of motion decreased"},{"name":"Maps_To","value":"Joint Range of Motion Decreased"},{"name":"NCI_META_CUI","value":"CL541936"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143627":{"preferredName":"Joint Range of Motion Decreased Cervical Spine, CTCAE","code":"C143627","definitions":[{"definition":"A disorder characterized by a decrease in flexibility of a cervical spine joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in flexibility of a cervical spine joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Joint Range of Motion Decreased Cervical Spine, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint range of motion decreased cervical spine"},{"name":"Maps_To","value":"Joint Range of Motion Decreased Cervical Spine"},{"name":"NCI_META_CUI","value":"CL541934"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143628":{"preferredName":"Joint Range of Motion Decreased Lumbar Spine, CTCAE","code":"C143628","definitions":[{"definition":"A disorder characterized by a decrease in flexibility of a lumbar spine joint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in flexibility of a lumbar spine joint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Joint Range of Motion Decreased Lumbar Spine, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint range of motion decreased lumbar spine"},{"name":"Maps_To","value":"Joint Range of Motion Decreased Lumbar Spine"},{"name":"NCI_META_CUI","value":"CL541935"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55847":{"preferredName":"Keratitis, CTCAE","code":"C55847","definitions":[{"definition":"A disorder characterized by inflammation to the cornea of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation to the cornea of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Keratitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Keratitis_Adverse_Event"},{"name":"Maps_To","value":"Keratitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1557321"}]}}{"C143631":{"preferredName":"Kidney Anastomotic Leak, CTCAE","code":"C143631","definitions":[{"definition":"A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Kidney Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney anastomotic leak"},{"name":"Maps_To","value":"Kidney Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL541937"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143632":{"preferredName":"Kidney Infection, CTCAE","code":"C143632","definitions":[{"definition":"A disorder characterized by an infectious process involving the kidney.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Kidney Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney infection"},{"name":"Maps_To","value":"Kidney Infection"},{"name":"NCI_META_CUI","value":"CL546047"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143633":{"preferredName":"Kyphosis, CTCAE","code":"C143633","definitions":[{"definition":"A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Kyphosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kyphosis"},{"name":"NCI_META_CUI","value":"CL541938"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143634":{"preferredName":"Lactation Disorder, CTCAE","code":"C143634","definitions":[{"definition":"A disorder characterized by disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lactation Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lactation disorder"},{"name":"Maps_To","value":"Lactation Disorder"},{"name":"NCI_META_CUI","value":"CL541939"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143635":{"preferredName":"Large Intestinal Anastomotic Leak, CTCAE","code":"C143635","definitions":[{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Large Intestinal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Large intestinal anastomotic leak"},{"name":"Maps_To","value":"Large Intestinal Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL541925"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143636":{"preferredName":"Laryngeal Edema, CTCAE","code":"C143636","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid in the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Laryngeal Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal edema"},{"name":"Maps_To","value":"Laryngeal Edema"},{"name":"NCI_META_CUI","value":"CL541926"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58190":{"preferredName":"Laryngeal Fistula, CTCAE","code":"C58190","definitions":[{"definition":"A disorder characterized by an abnormal communication between the larynx and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the larynx and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Larynx_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Laryngeal Fistula"},{"name":"Maps_To","value":"Laryngeal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1397408"}]}}{"C56545":{"preferredName":"Laryngeal Hemorrhage, CTCAE","code":"C56545","definitions":[{"definition":"A disorder characterized by bleeding from the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Larynx_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Laryngeal Hemorrhage"},{"name":"Maps_To","value":"Laryngeal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1881362"}]}}{"C143637":{"preferredName":"Laryngeal Inflammation, CTCAE","code":"C143637","definitions":[{"definition":"A disorder characterized by an inflammation involving the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an inflammation involving the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Laryngeal Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal inflammation"},{"name":"Maps_To","value":"Laryngeal Inflammation"},{"name":"NCI_META_CUI","value":"CL541927"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143638":{"preferredName":"Laryngeal Mucositis, CTCAE","code":"C143638","definitions":[{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal mucositis"},{"name":"Maps_To","value":"Laryngeal Mucositis"},{"name":"NCI_META_CUI","value":"CL541928"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143639":{"preferredName":"Laryngeal Obstruction, CTCAE","code":"C143639","definitions":[{"definition":"A disorder characterized by blockage of the laryngeal airway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the laryngeal airway.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal obstruction"},{"name":"Maps_To","value":"Laryngeal Obstruction"},{"name":"NCI_META_CUI","value":"CL541929"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143640":{"preferredName":"Laryngeal Stenosis, CTCAE","code":"C143640","definitions":[{"definition":"A disorder characterized by a narrowing of the laryngeal airway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the laryngeal airway.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngeal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngeal stenosis"},{"name":"Maps_To","value":"Laryngeal Stenosis"},{"name":"NCI_META_CUI","value":"CL541930"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143641":{"preferredName":"Laryngitis, CTCAE","code":"C143641","definitions":[{"definition":"A disorder characterized by an inflammatory process involving the larynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an inflammatory process involving the larynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Laryngitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngitis"},{"name":"NCI_META_CUI","value":"CL541931"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143642":{"preferredName":"Laryngopharyngeal Dysesthesia, CTCAE","code":"C143642","definitions":[{"definition":"A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Laryngopharyngeal Dysesthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngopharyngeal dysesthesia"},{"name":"Maps_To","value":"Laryngopharyngeal Dysesthesia"},{"name":"NCI_META_CUI","value":"CL541932"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143643":{"preferredName":"Laryngospasm, CTCAE","code":"C143643","definitions":[{"definition":"A disorder characterized by paroxysmal spasmodic muscular contraction of the vocal cords.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by paroxysmal spasmodic muscular contraction of the vocal cords.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Laryngospasm, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngospasm"},{"name":"NCI_META_CUI","value":"CL541917"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146719":{"preferredName":"Left Ventricular Systolic Dysfunction, CTCAE 5.0","code":"C146719","definitions":[{"definition":"A disorder characterized by failure of the left ventricle to produce adequate output.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by failure of the left ventricle to produce adequate output.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Left Ventricular Systolic Dysfunction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Left Ventricular Systolic Dysfunction"},{"name":"Maps_To","value":"Left ventricular systolic dysfunction"},{"name":"NCI_META_CUI","value":"CL544713"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143645":{"preferredName":"Lethargy, CTCAE","code":"C143645","definitions":[{"definition":"A disorder characterized by a decrease in consciousness characterized by mental and physical inertness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a decrease in consciousness characterized by mental and physical inertness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lethargy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lethargy"},{"name":"NCI_META_CUI","value":"CL541918"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143646":{"preferredName":"Leukemia Secondary To Oncology Chemotherapy, CTCAE","code":"C143646","definitions":[{"definition":"A disorder characterized by leukemia arising as a result of the mutagenic effect of chemotherapy agents.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by leukemia arising as a result of the mutagenic effect of chemotherapy agents.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Leukemia Secondary To Oncology Chemotherapy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leukemia secondary to oncology chemotherapy"},{"name":"Maps_To","value":"Leukemia Secondary to Oncology Chemotherapy"},{"name":"NCI_META_CUI","value":"CL541919"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143647":{"preferredName":"Leukocytosis, CTCAE","code":"C143647","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an increased number of white blood cells in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by laboratory test results that indicate an increased number of white blood cells in the blood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Leukocytosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leukocytosis"},{"name":"NCI_META_CUI","value":"CL541920"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143648":{"preferredName":"Leukoencephalopathy, CTCAE","code":"C143648","definitions":[{"definition":"A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Leukoencephalopathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leukoencephalopathy"},{"name":"NCI_META_CUI","value":"CL541921"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143649":{"preferredName":"Libido Decreased, CTCAE","code":"C143649","definitions":[{"definition":"A disorder characterized by a decrease in sexual desire.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in sexual desire.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Libido Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Libido decreased"},{"name":"Maps_To","value":"Libido Decreased"},{"name":"NCI_META_CUI","value":"CL541922"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143650":{"preferredName":"Libido Increased, CTCAE","code":"C143650","definitions":[{"definition":"A disorder characterized by an increase in sexual desire.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in sexual desire.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Libido Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Libido increased"},{"name":"Maps_To","value":"Libido Increased"},{"name":"NCI_META_CUI","value":"CL541923"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143651":{"preferredName":"Lip Infection, CTCAE","code":"C143651","definitions":[{"definition":"A disorder characterized by an infectious process involving the lips.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the lips.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lip Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lip infection"},{"name":"Maps_To","value":"Lip Infection"},{"name":"NCI_META_CUI","value":"CL541924"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146761":{"preferredName":"Lip Pain, CTCAE 5.0","code":"C146761","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort of the lip.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort of the lip.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lip Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lip Pain"},{"name":"Maps_To","value":"Lip pain"},{"name":"NCI_META_CUI","value":"CL544799"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143652":{"preferredName":"Lipase Increased, CTCAE","code":"C143652","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lipase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipase increased"},{"name":"Maps_To","value":"Lipase Increased"},{"name":"NCI_META_CUI","value":"CL541910"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143653":{"preferredName":"Lipohypertrophy, CTCAE","code":"C143653","definitions":[{"definition":"A disorder characterized by hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lipohypertrophy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipohypertrophy"},{"name":"NCI_META_CUI","value":"CL541911"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143654":{"preferredName":"Localized Edema, CTCAE","code":"C143654","definitions":[{"definition":"A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Localized Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Localized edema"},{"name":"Maps_To","value":"Localized Edema"},{"name":"NCI_META_CUI","value":"CL541912"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143655":{"preferredName":"Lordosis, CTCAE","code":"C143655","definitions":[{"definition":"A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lordosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lordosis"},{"name":"NCI_META_CUI","value":"CL545982"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143656":{"preferredName":"Lower Gastrointestinal Hemorrhage, CTCAE","code":"C143656","definitions":[{"definition":"A disorder characterized by bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lower Gastrointestinal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lower gastrointestinal hemorrhage"},{"name":"Maps_To","value":"Lower Gastrointestinal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL541913"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143657":{"preferredName":"Lung Infection, CTCAE","code":"C143657","definitions":[{"definition":"A disorder characterized by an infectious process involving the lungs, including pneumonia.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the lungs, including pneumonia.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lung Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lung infection"},{"name":"Maps_To","value":"Lung Infection"},{"name":"NCI_META_CUI","value":"CL541914"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143658":{"preferredName":"Lymph Gland Infection, CTCAE","code":"C143658","definitions":[{"definition":"A disorder characterized by an infectious process involving the lymph nodes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the lymph nodes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lymph Gland Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph gland infection"},{"name":"Maps_To","value":"Lymph Gland Infection"},{"name":"NCI_META_CUI","value":"CL541915"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143659":{"preferredName":"Lymph Leakage, CTCAE","code":"C143659","definitions":[{"definition":"A disorder characterized by the loss of lymph fluid into the surrounding tissue or body cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the loss of lymph fluid into the surrounding tissue or body cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lymph Leakage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph leakage"},{"name":"Maps_To","value":"Lymph Leakage"},{"name":"NCI_META_CUI","value":"CL541916"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146773":{"preferredName":"Lymph Node Pain, CTCAE 5.0","code":"C146773","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in a lymph node.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in a lymph node.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lymph Node Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node Pain"},{"name":"Maps_To","value":"Lymph node pain"},{"name":"NCI_META_CUI","value":"CL544781"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143660":{"preferredName":"Lymphedema, CTCAE","code":"C143660","definitions":[{"definition":"A disorder characterized by excessive fluid collection in tissues that causes swelling.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excessive fluid collection in tissues that causes swelling.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lymphedema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphedema"},{"name":"NCI_META_CUI","value":"CL541902"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55705":{"preferredName":"Lymphocele, CTCAE","code":"C55705","definitions":[{"definition":"A disorder characterized by a cystic lesion containing lymph.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a cystic lesion containing lymph.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Lymphocele, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocele_Adverse_Event"},{"name":"Maps_To","value":"Lymphocele"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963162"}]}}{"C143662":{"preferredName":"Lymphocyte Count Decreased, CTCAE","code":"C143662","definitions":[{"definition":"A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lymphocyte Count Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphocyte count decreased"},{"name":"Maps_To","value":"Lymphocyte Count Decreased"},{"name":"NCI_META_CUI","value":"CL541903"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143663":{"preferredName":"Lymphocyte Count Increased, CTCAE","code":"C143663","definitions":[{"definition":"A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Lymphocyte Count Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphocyte count increased"},{"name":"Maps_To","value":"Lymphocyte Count Increased"},{"name":"NCI_META_CUI","value":"CL541904"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57838":{"preferredName":"Malabsorption, CTCAE","code":"C57838","definitions":[{"definition":"A disorder characterized by inadequate absorption of nutrients in the small intestine. Symptoms include abdominal marked discomfort, bloating and diarrhea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inadequate absorption of nutrients in the small intestine. Symptoms include abdominal marked discomfort, bloating and diarrhea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Malabsorption, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Malabsorption_Adverse_Event"},{"name":"Maps_To","value":"Malabsorption"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963165"}]}}{"C143665":{"preferredName":"Malaise, CTCAE","code":"C143665","definitions":[{"definition":"A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Malaise, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Malaise"},{"name":"NCI_META_CUI","value":"CL541905"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143666":{"preferredName":"Mania, CTCAE","code":"C143666","definitions":[{"definition":"A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Mania, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mania"},{"name":"NCI_META_CUI","value":"CL541906"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56549":{"preferredName":"Mediastinal Hemorrhage, CTCAE","code":"C56549","definitions":[{"definition":"A disorder characterized by bleeding from the mediastinum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the mediastinum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mediastinal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mediastinum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Mediastinal hemorrhage"},{"name":"Maps_To","value":"Mediastinal Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560796"}]}}{"C143667":{"preferredName":"Mediastinal Infection, CTCAE","code":"C143667","definitions":[{"definition":"A disorder characterized by an infectious process involving the mediastinum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the mediastinum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Mediastinal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mediastinal infection"},{"name":"Maps_To","value":"Mediastinal Infection"},{"name":"NCI_META_CUI","value":"CL541907"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146763":{"preferredName":"Memory Impairment, CTCAE 5.0","code":"C146763","definitions":[{"definition":"A disorder characterized by a deterioration in memory function.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a deterioration in memory function.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Memory Impairment, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Memory Impairment"},{"name":"Maps_To","value":"Memory impairment"},{"name":"NCI_META_CUI","value":"CL544787"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143669":{"preferredName":"Meningismus, CTCAE","code":"C143669","definitions":[{"definition":"A disorder characterized by neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Meningismus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Meningismus"},{"name":"NCI_META_CUI","value":"CL541908"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143670":{"preferredName":"Meningitis, CTCAE","code":"C143670","definitions":[{"definition":"A disorder characterized by acute inflammation of the meninges of the brain and/or spinal cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by acute inflammation of the meninges of the brain and/or spinal cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Meningitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Meningitis"},{"name":"NCI_META_CUI","value":"CL541909"},{"name":"Semantic_Type","value":"Finding"}]}}{"C3231":{"preferredName":"Menopause","code":"C3231","definitions":[{"definition":"A disorder characterized by the permanent cessation of menses, usually defined by 12 consecutive months of amenorrhea in a woman over 45 years of age.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"The permanent cessation of menses, usually defined by 6 to 12 months of amenorrhea in a woman over 45 years of age.","type":"DEFINITION","source":"NCI"},{"definition":"The time of life when a woman's ovaries stop producing hormones and menstrual periods stop. Natural menopause usually occurs around age 50. A woman is said to be in menopause when she hasn't had a period for 12 months in a row. Symptoms of menopause include hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Menopause","termGroup":"PT","termSource":"NCI"},{"termName":"Menopausal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Menopause"},{"name":"Maps_To","value":"Menopause"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0025320"}]}}{"C143671":{"preferredName":"Menorrhagia, CTCAE","code":"C143671","definitions":[{"definition":"A disorder characterized by abnormally heavy vaginal bleeding during menses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormally heavy vaginal bleeding during menses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Menorrhagia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Menorrhagia"},{"name":"NCI_META_CUI","value":"CL542013"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143672":{"preferredName":"Metabolism and Nutrition Disorders - Other, Specify, CTCAE","code":"C143672","synonyms":[{"termName":"Metabolism and Nutrition Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metabolism and Nutrition Disorders - Other"},{"name":"Maps_To","value":"Metabolism and nutrition disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542014"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143673":{"preferredName":"Middle Ear Inflammation, CTCAE","code":"C143673","definitions":[{"definition":"A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Middle Ear Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Middle ear inflammation"},{"name":"Maps_To","value":"Middle Ear Inflammation"},{"name":"NCI_META_CUI","value":"CL542015"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143674":{"preferredName":"Mitral Valve Disease, CTCAE","code":"C143674","definitions":[{"definition":"A disorder characterized by a defect in mitral valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a defect in mitral valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Mitral Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitral valve disease"},{"name":"Maps_To","value":"Mitral Valve Disease"},{"name":"NCI_META_CUI","value":"CL542016"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54772":{"preferredName":"Mobitz (Type) II Atrioventricular Block, CTCAE","code":"C54772","definitions":[{"definition":"A disorder characterized by a dysrhythmia with relatively constant PR interval prior to the block of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with relatively constant PR interval prior to the block of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mobitz (Type) II Atrioventricular Block, CTCAE","termGroup":"PT","termSource":"NCI"},{"termName":"AV Block Second Degree Mobitz Type II Adverse Event","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AV_Block_Second_Degree_Mobitz_Type_II_Adverse_Event"},{"name":"Maps_To","value":"Mobitz (Type) II Atrioventricular Block"},{"name":"Maps_To","value":"Mobitz (type) II atrioventricular block"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1964030"}]}}{"C54771":{"preferredName":"Mobitz Type I, CTCAE","code":"C54771","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a progressively lengthening PR interval prior to the blocking of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a progressively lengthening PR interval prior to the blocking of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mobitz Type I, CTCAE","termGroup":"PT","termSource":"NCI"},{"termName":"AV Block Second Degree Möbitz Type I Adverse Event","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AV_Block_Second_Degree_Mobitz_Type_I_Adverse_Event"},{"name":"Maps_To","value":"Mobitz type I"},{"name":"Maps_To","value":"Mobitz Type I"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560266"}]}}{"C143677":{"preferredName":"Movements Involuntary, CTCAE","code":"C143677","definitions":[{"definition":"A disorder characterized by uncontrolled and purposeless movements.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by uncontrolled and purposeless movements.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Movements Involuntary, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Movements involuntary"},{"name":"Maps_To","value":"Movements Involuntary"},{"name":"NCI_META_CUI","value":"CL545900"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143678":{"preferredName":"Mucosal Infection, CTCAE","code":"C143678","definitions":[{"definition":"A disorder characterized by an infectious process involving a mucosal surface.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving a mucosal surface.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mucosal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mucosal infection"},{"name":"Maps_To","value":"Mucosal Infection"},{"name":"NCI_META_CUI","value":"CL542017"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143679":{"preferredName":"Mucositis Oral, CTCAE","code":"C143679","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the oral mucosal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by ulceration or inflammation of the oral mucosal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Mucositis Oral, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mucositis oral"},{"name":"Maps_To","value":"Mucositis Oral"},{"name":"NCI_META_CUI","value":"CL542018"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143680":{"preferredName":"Multi-Organ Failure, CTCAE","code":"C143680","definitions":[{"definition":"A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Multi-Organ Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-organ failure"},{"name":"Maps_To","value":"Multi-Organ Failure"},{"name":"NCI_META_CUI","value":"CL542019"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143681":{"preferredName":"Muscle Weakness Left-Sided, CTCAE","code":"C143681","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the muscles on the left side of the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the muscles on the left side of the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Muscle Weakness Left-Sided, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle weakness left-sided"},{"name":"Maps_To","value":"Muscle Weakness Left-Sided"},{"name":"NCI_META_CUI","value":"CL542005"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143682":{"preferredName":"Muscle Weakness Lower Limb, CTCAE","code":"C143682","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the lower limb muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the lower limb muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Muscle Weakness Lower Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Lower Limb"},{"name":"Maps_To","value":"Muscle weakness lower limb"},{"name":"NCI_META_CUI","value":"CL542006"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143683":{"preferredName":"Muscle Weakness Right-Sided, CTCAE","code":"C143683","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the muscles on the right side of the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a reduction in the strength of the muscles on the right side of the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Muscle Weakness Right-Sided, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Right-Sided"},{"name":"Maps_To","value":"Muscle weakness right-sided"},{"name":"NCI_META_CUI","value":"CL542007"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143684":{"preferredName":"Muscle Weakness Trunk, CTCAE","code":"C143684","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the trunk muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the trunk muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Muscle Weakness Trunk, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Trunk"},{"name":"Maps_To","value":"Muscle weakness trunk"},{"name":"NCI_META_CUI","value":"CL542008"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143685":{"preferredName":"Muscle Weakness Upper Limb, CTCAE","code":"C143685","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the upper limb muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the upper limb muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Muscle Weakness Upper Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscle Weakness Upper Limb"},{"name":"Maps_To","value":"Muscle weakness upper limb"},{"name":"NCI_META_CUI","value":"CL542009"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143686":{"preferredName":"Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","code":"C143686","synonyms":[{"termName":"Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Musculoskeletal and connective tissue disorder - Other, specify"},{"name":"Maps_To","value":"Musculoskeletal and Connective Tissue Disorders - Other"},{"name":"NCI_META_CUI","value":"CL542010"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143687":{"preferredName":"Musculoskeletal Deformity, CTCAE","code":"C143687","definitions":[{"definition":"A disorder characterized by a malformation of the musculoskeletal system.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a malformation of the musculoskeletal system.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Musculoskeletal Deformity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Musculoskeletal Deformity"},{"name":"Maps_To","value":"Musculoskeletal deformity"},{"name":"NCI_META_CUI","value":"CL542011"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143688":{"preferredName":"Myalgia, CTCAE","code":"C143688","definitions":[{"definition":"A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Myalgia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myalgia"},{"name":"NCI_META_CUI","value":"CL542012"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55459":{"preferredName":"Myelitis, CTCAE","code":"C55459","definitions":[{"definition":"A disorder characterized by inflammation involving the spinal cord. Symptoms include weakness, paresthesia, sensory loss, marked discomfort and incontinence.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving the spinal cord. Symptoms include weakness, paresthesia, sensory loss, marked discomfort and incontinence.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Myelitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myelitis_Adverse_Event"},{"name":"Maps_To","value":"Myelitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963178"}]}}{"C143690":{"preferredName":"Myelodysplastic Syndrome, CTCAE","code":"C143690","definitions":[{"definition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Myelodysplastic Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myelodysplastic Syndrome"},{"name":"Maps_To","value":"Myelodysplastic syndrome"},{"name":"NCI_META_CUI","value":"CL541998"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143691":{"preferredName":"Myocardial Infarction, CTCAE","code":"C143691","definitions":[{"definition":"A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Myocardial Infarction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myocardial Infarction"},{"name":"Maps_To","value":"Myocardial infarction"},{"name":"NCI_META_CUI","value":"CL546005"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146695":{"preferredName":"Myocarditis, CTCAE 5.0","code":"C146695","definitions":[{"definition":"A disorder characterized by inflammation of the muscle tissue of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the muscle tissue of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Myocarditis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myocarditis"},{"name":"NCI_META_CUI","value":"CL544737"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146787":{"preferredName":"Myositis, CTCAE 5.0","code":"C146787","definitions":[{"definition":"A disorder characterized by inflammation involving the skeletal muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation involving the skeletal muscles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Myositis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Myositis"},{"name":"NCI_META_CUI","value":"CL544776"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143694":{"preferredName":"Nail Discoloration, CTCAE","code":"C143694","definitions":[{"definition":"A disorder characterized by a change in the color of the nail plate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a change in the color of the nail plate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Nail Discoloration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Discoloration"},{"name":"Maps_To","value":"Nail discoloration"},{"name":"NCI_META_CUI","value":"CL541999"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143695":{"preferredName":"Nail Infection, CTCAE","code":"C143695","definitions":[{"definition":"A disorder characterized by an infectious process involving the nail.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the nail.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nail Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Infection"},{"name":"Maps_To","value":"Nail infection"},{"name":"NCI_META_CUI","value":"CL542000"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143696":{"preferredName":"Nail Loss, CTCAE","code":"C143696","definitions":[{"definition":"A disorder characterized by loss of all or a portion of the nail.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by loss of all or a portion of the nail.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Nail Loss, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Loss"},{"name":"Maps_To","value":"Nail loss"},{"name":"NCI_META_CUI","value":"CL542001"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143697":{"preferredName":"Nail Ridging, CTCAE","code":"C143697","definitions":[{"definition":"A disorder characterized by vertical or horizontal ridges on the nails.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by vertical or horizontal ridges on the nails.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Nail Ridging, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nail Ridging"},{"name":"Maps_To","value":"Nail ridging"},{"name":"NCI_META_CUI","value":"CL542002"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143698":{"preferredName":"Nasal Congestion, CTCAE","code":"C143698","definitions":[{"definition":"A disorder characterized by obstruction of the nasal passage due to mucosal edema.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by obstruction of the nasal passage due to mucosal edema.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Nasal Congestion, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nasal Congestion"},{"name":"Maps_To","value":"Nasal congestion"},{"name":"NCI_META_CUI","value":"CL542003"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146764":{"preferredName":"Nausea, CTCAE 5.0","code":"C146764","definitions":[{"definition":"A disorder characterized by a queasy sensation and/or the urge to vomit.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a queasy sensation and/or the urge to vomit.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nausea, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nausea"},{"name":"NCI_META_CUI","value":"CL550642"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143700":{"preferredName":"Neck Edema, CTCAE","code":"C143700","definitions":[{"definition":"A disorder characterized by swelling due to an accumulation of excessive fluid in the neck.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by swelling due to an accumulation of excessive fluid in the neck.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Neck Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neck Edema"},{"name":"Maps_To","value":"Neck edema"},{"name":"NCI_META_CUI","value":"CL542004"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146766":{"preferredName":"Neck Pain, CTCAE 5.0","code":"C146766","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the neck area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the neck area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Neck Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neck Pain"},{"name":"Maps_To","value":"Neck pain"},{"name":"NCI_META_CUI","value":"CL544789"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58394":{"preferredName":"Neck Soft Tissue Necrosis, CTCAE","code":"C58394","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the neck.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the neck.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Neck Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neck_Soft_Tissue_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Neck Soft Tissue Necrosis"},{"name":"Maps_To","value":"Neck soft tissue necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963181"}]}}{"C143701":{"preferredName":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","code":"C143701","synonyms":[{"termName":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other"},{"name":"Maps_To","value":"Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify"},{"name":"NCI_META_CUI","value":"CL541991"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143702":{"preferredName":"Nervous System Disorders - Other, Specify, CTCAE","code":"C143702","synonyms":[{"termName":"Nervous System Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nervous System Disorders - Other"},{"name":"Maps_To","value":"Nervous system disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL546038"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143703":{"preferredName":"Neuralgia, CTCAE","code":"C143703","definitions":[{"definition":"A disorder characterized by intense painful sensation along a nerve or group of nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by intense painful sensation along a nerve or group of nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Neuralgia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neuralgia"},{"name":"NCI_META_CUI","value":"CL541992"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143704":{"preferredName":"Neutrophil Count Decreased, CTCAE","code":"C143704","definitions":[{"definition":"A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Neutrophil Count Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neutrophil Count Decreased"},{"name":"Maps_To","value":"Neutrophil count decreased"},{"name":"NCI_META_CUI","value":"CL541993"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143705":{"preferredName":"Night Blindness, CTCAE","code":"C143705","definitions":[{"definition":"A disorder characterized by an inability to see clearly in dim light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an inability to see clearly in dim light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Night Blindness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Night Blindness"},{"name":"Maps_To","value":"Night blindness"},{"name":"NCI_META_CUI","value":"CL541994"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143706":{"preferredName":"Nipple Deformity, CTCAE","code":"C143706","definitions":[{"definition":"A disorder characterized by a malformation of the nipple.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a malformation of the nipple.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nipple Deformity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nipple Deformity"},{"name":"Maps_To","value":"Nipple deformity"},{"name":"NCI_META_CUI","value":"CL541995"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143707":{"preferredName":"Non-Cardiac Chest Pain, CTCAE","code":"C143707","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the chest unrelated to a heart disorder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the chest unrelated to a heart disorder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Non-Cardiac Chest Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Cardiac Chest Pain"},{"name":"Maps_To","value":"Non-cardiac chest pain"},{"name":"NCI_META_CUI","value":"CL541996"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146775":{"preferredName":"Nystagmus, CTCAE 5.0","code":"C146775","definitions":[{"definition":"A disorder characterized by involuntary movements of the eyeballs.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by involuntary movements of the eyeballs.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Nystagmus, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nystagmus"},{"name":"NCI_META_CUI","value":"CL544783"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55334":{"preferredName":"Obesity, CTCAE","code":"C55334","definitions":[{"definition":"A disorder characterized by having a high amount of body fat.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by having a high amount of body fat.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Obesity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Obesity_Adverse_Event"},{"name":"Maps_To","value":"Obesity"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963185"}]}}{"C143710":{"preferredName":"Obstruction Gastric, CTCAE","code":"C143710","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents in the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the contents in the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Obstruction Gastric, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Obstruction Gastric"},{"name":"Maps_To","value":"Obstruction gastric"},{"name":"NCI_META_CUI","value":"CL541997"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143711":{"preferredName":"Oculomotor Nerve Disorder, CTCAE","code":"C143711","definitions":[{"definition":"A disorder characterized by dysfunction of the oculomotor nerve (third cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the oculomotor nerve (third cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Oculomotor Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oculomotor Nerve Disorder"},{"name":"Maps_To","value":"Oculomotor nerve disorder"},{"name":"NCI_META_CUI","value":"CL541984"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143712":{"preferredName":"Olfactory Nerve Disorder, CTCAE","code":"C143712","definitions":[{"definition":"A disorder characterized by dysfunction of the olfactory nerve (first cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the olfactory nerve (first cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Olfactory Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Olfactory Nerve Disorder"},{"name":"Maps_To","value":"Olfactory nerve disorder"},{"name":"NCI_META_CUI","value":"CL541985"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143713":{"preferredName":"Oligospermia, CTCAE","code":"C143713","definitions":[{"definition":"A disorder characterized by a decrease in the number of spermatozoa in the semen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease in the number of spermatozoa in the semen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Oligospermia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oligospermia"},{"name":"NCI_META_CUI","value":"CL541986"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143714":{"preferredName":"Optic Nerve Disorder, CTCAE","code":"C143714","definitions":[{"definition":"A disorder characterized by involvement of the optic nerve (second cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by involvement of the optic nerve (second cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Optic Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Optic Nerve Disorder"},{"name":"Maps_To","value":"Optic nerve disorder"},{"name":"NCI_META_CUI","value":"CL545955"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143715":{"preferredName":"Oral Cavity Fistula, CTCAE","code":"C143715","definitions":[{"definition":"A disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Oral Cavity Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Cavity Fistula"},{"name":"Maps_To","value":"Oral cavity fistula"},{"name":"NCI_META_CUI","value":"CL541987"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143716":{"preferredName":"Oral Dysesthesia, CTCAE","code":"C143716","definitions":[{"definition":"A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Oral Dysesthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Dysesthesia"},{"name":"Maps_To","value":"Oral dysesthesia"},{"name":"NCI_META_CUI","value":"CL541988"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56551":{"preferredName":"Oral Hemorrhage, CTCAE","code":"C56551","definitions":[{"definition":"A disorder characterized by bleeding from the mouth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the mouth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Oral Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Cavity_Adverse_Event_Hemorrhage"},{"name":"Maps_To","value":"Oral hemorrhage"},{"name":"Maps_To","value":"Oral Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560644"}]}}{"C146627":{"preferredName":"Oral Pain, CTCAE 5.0","code":"C146627","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Oral Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Pain"},{"name":"Maps_To","value":"Oral pain"},{"name":"NCI_META_CUI","value":"CL544674"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143717":{"preferredName":"Osteonecrosis of Jaw, CTCAE","code":"C143717","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the bone of the mandible.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the bone of the mandible.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Osteonecrosis of Jaw, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Osteonecrosis of Jaw"},{"name":"Maps_To","value":"Osteonecrosis of jaw"},{"name":"NCI_META_CUI","value":"CL541989"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146767":{"preferredName":"Osteoporosis, CTCAE 5.0","code":"C146767","definitions":[{"definition":"A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Osteoporosis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Osteoporosis"},{"name":"NCI_META_CUI","value":"CL545899"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143719":{"preferredName":"Otitis Externa, CTCAE","code":"C143719","definitions":[{"definition":"A disorder characterized by an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer's ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer's ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Otitis Externa, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Otitis Externa"},{"name":"Maps_To","value":"Otitis externa"},{"name":"NCI_META_CUI","value":"CL541990"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143720":{"preferredName":"Otitis Media, CTCAE","code":"C143720","definitions":[{"definition":"A disorder characterized by an infectious process involving the middle ear.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the middle ear.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Otitis Media, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Otitis Media"},{"name":"Maps_To","value":"Otitis media"},{"name":"NCI_META_CUI","value":"CL541977"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56553":{"preferredName":"Ovarian Hemorrhage, CTCAE","code":"C56553","definitions":[{"definition":"A disorder characterized by bleeding from the ovary.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the ovary.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ovarian Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovary_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Ovarian hemorrhage"},{"name":"Maps_To","value":"Ovarian Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963125"}]}}{"C143721":{"preferredName":"Ovarian Infection, CTCAE","code":"C143721","definitions":[{"definition":"A disorder characterized by an infectious process involving the ovary.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the ovary.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ovarian Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Infection"},{"name":"Maps_To","value":"Ovarian infection"},{"name":"NCI_META_CUI","value":"CL541978"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143722":{"preferredName":"Ovarian Rupture, CTCAE","code":"C143722","definitions":[{"definition":"A disorder characterized by tearing or disruption of the ovarian tissue.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by tearing or disruption of the ovarian tissue.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ovarian Rupture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Rupture"},{"name":"Maps_To","value":"Ovarian rupture"},{"name":"NCI_META_CUI","value":"CL541979"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146769":{"preferredName":"Ovulation Pain, CTCAE 5.0","code":"C146769","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ovulation Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovulation Pain"},{"name":"Maps_To","value":"Ovulation pain"},{"name":"NCI_META_CUI","value":"CL544791"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143725":{"preferredName":"Pain, CTCAE","code":"C143725","definitions":[{"definition":"A disorder characterized by the sensation of marked discomfort, distress or agony.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the sensation of marked discomfort, distress or agony.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pain"},{"name":"NCI_META_CUI","value":"CL550641"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143723":{"preferredName":"Pain In Extremity, CTCAE","code":"C143723","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pain In Extremity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pain in Extremity"},{"name":"Maps_To","value":"Pain in extremity"},{"name":"NCI_META_CUI","value":"CL541980"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143724":{"preferredName":"Pain of Skin, CTCAE","code":"C143724","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pain of Skin, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pain of Skin"},{"name":"Maps_To","value":"Pain of skin"},{"name":"NCI_META_CUI","value":"CL541981"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143726":{"preferredName":"Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE","code":"C143726","definitions":[{"definition":"A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Also known as Hand-Foot Syndrome.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Also known as Hand-Foot Syndrome.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Palmar-Plantar Erythrodysesthesia Syndrome"},{"name":"Maps_To","value":"Palmar-plantar erythrodysesthesia syndrome"},{"name":"NCI_META_CUI","value":"CL541982"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54935":{"preferredName":"Palpitations, CTCAE","code":"C54935","definitions":[{"definition":"A disorder characterized by an unpleasant sensation of irregular and/or forceful beating of the heart.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an unpleasant sensation of irregular and/or forceful beating of the heart.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Palpitations, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Palpitations_Adverse_Event"},{"name":"Maps_To","value":"Palpitations"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3160712"}]}}{"C143728":{"preferredName":"Pancreas Infection, CTCAE","code":"C143728","definitions":[{"definition":"A disorder characterized by an infectious process involving the pancreas.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreas Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreas Infection"},{"name":"Maps_To","value":"Pancreas infection"},{"name":"NCI_META_CUI","value":"CL541983"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143729":{"preferredName":"Pancreatic Anastomotic Leak, CTCAE","code":"C143729","definitions":[{"definition":"A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Anastomotic Leak"},{"name":"Maps_To","value":"Pancreatic anastomotic leak"},{"name":"NCI_META_CUI","value":"CL541970"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143730":{"preferredName":"Pancreatic Duct Stenosis, CTCAE","code":"C143730","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the pancreatic duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the pancreatic duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Duct Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Duct Stenosis"},{"name":"Maps_To","value":"Pancreatic duct stenosis"},{"name":"NCI_META_CUI","value":"CL541971"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143731":{"preferredName":"Pancreatic Enzymes Decreased, CTCAE","code":"C143731","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Enzymes Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Enzymes Decreased"},{"name":"Maps_To","value":"Pancreatic enzymes decreased"},{"name":"NCI_META_CUI","value":"CL541972"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57845":{"preferredName":"Pancreatic Fistula, CTCAE","code":"C57845","definitions":[{"definition":"A disorder characterized by an abnormal communication between the pancreas and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the pancreas and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreas_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Pancreatic Fistula"},{"name":"Maps_To","value":"Pancreatic fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963197"}]}}{"C56554":{"preferredName":"Pancreatic Hemorrhage, CTCAE","code":"C56554","definitions":[{"definition":"A disorder characterized by bleeding from the pancreas.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pancreatic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreas_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Pancreatic hemorrhage"},{"name":"Maps_To","value":"Pancreatic Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963128"}]}}{"C143732":{"preferredName":"Pancreatic Necrosis, CTCAE","code":"C143732","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the pancreas.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pancreatic Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatic Necrosis"},{"name":"Maps_To","value":"Pancreatic necrosis"},{"name":"NCI_META_CUI","value":"CL541973"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146789":{"preferredName":"Pancreatitis, CTCAE 5.0","code":"C146789","definitions":[{"definition":"A disorder characterized by inflammation of the pancreas with no documented pancreas infection.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the pancreas with no documented pancreas infection.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pancreatitis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pancreatitis"},{"name":"NCI_META_CUI","value":"CL544778"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143734":{"preferredName":"Papilledema, CTCAE","code":"C143734","definitions":[{"definition":"A disorder characterized by swelling around the optic disc.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling around the optic disc.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Papilledema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Papilledema"},{"name":"NCI_META_CUI","value":"CL541974"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143735":{"preferredName":"Papulopustular Rash, CTCAE","code":"C143735","definitions":[{"definition":"A disorder characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Papulopustular Rash, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Papulopustular Rash"},{"name":"Maps_To","value":"Papulopustular rash"},{"name":"NCI_META_CUI","value":"CL541975"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143736":{"preferredName":"Paresthesia, CTCAE","code":"C143736","definitions":[{"definition":"A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Paresthesia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paresthesia"},{"name":"NCI_META_CUI","value":"CL541976"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143737":{"preferredName":"Paronychia, CTCAE","code":"C143737","definitions":[{"definition":"A disorder characterized by an infectious process involving the soft tissues around the nail.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the soft tissues around the nail.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Paronychia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paronychia"},{"name":"NCI_META_CUI","value":"CL545950"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143738":{"preferredName":"Paroxysmal Atrial Tachycardia, CTCAE","code":"C143738","definitions":[{"definition":"A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Paroxysmal Atrial Tachycardia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paroxysmal Atrial Tachycardia"},{"name":"Maps_To","value":"Paroxysmal atrial tachycardia"},{"name":"NCI_META_CUI","value":"CL541964"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143739":{"preferredName":"Pelvic Floor Muscle Weakness, CTCAE","code":"C143739","definitions":[{"definition":"A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pelvic Floor Muscle Weakness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic Floor Muscle Weakness"},{"name":"Maps_To","value":"Pelvic floor muscle weakness"},{"name":"NCI_META_CUI","value":"CL541965"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143740":{"preferredName":"Pelvic Infection, CTCAE","code":"C143740","definitions":[{"definition":"A disorder characterized by an infectious process involving the pelvic cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the pelvic cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pelvic Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic Infection"},{"name":"Maps_To","value":"Pelvic infection"},{"name":"NCI_META_CUI","value":"CL546035"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146679":{"preferredName":"Pelvic Pain, CTCAE 5.0","code":"C146679","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the pelvis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the pelvis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pelvic Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic pain"},{"name":"Maps_To","value":"Pelvic Pain"},{"name":"NCI_META_CUI","value":"CL545999"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58399":{"preferredName":"Pelvic Soft Tissue Necrosis, CTCAE","code":"C58399","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pelvic Soft Tissue Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pelvic_Soft_Tissue_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Pelvic Soft Tissue Necrosis"},{"name":"Maps_To","value":"Pelvic soft tissue necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962964"}]}}{"C143741":{"preferredName":"Penile Infection, CTCAE","code":"C143741","definitions":[{"definition":"A disorder characterized by an infectious process involving the penis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the penis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Penile Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Penile Infection"},{"name":"Maps_To","value":"Penile infection"},{"name":"NCI_META_CUI","value":"CL541966"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146680":{"preferredName":"Penile Pain, CTCAE 5.0","code":"C146680","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the penis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the penis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Penile Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Penile pain"},{"name":"Maps_To","value":"Penile Pain"},{"name":"NCI_META_CUI","value":"CL544633"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143742":{"preferredName":"Perforation Bile Duct, CTCAE","code":"C143742","definitions":[{"definition":"A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Perforation Bile Duct, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perforation Bile Duct"},{"name":"Maps_To","value":"Perforation bile duct"},{"name":"NCI_META_CUI","value":"CL541967"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143743":{"preferredName":"Pericardial Effusion, CTCAE","code":"C143743","definitions":[{"definition":"A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pericardial Effusion, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pericardial Effusion"},{"name":"Maps_To","value":"Pericardial effusion"},{"name":"NCI_META_CUI","value":"CL545996"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143744":{"preferredName":"Pericardial Tamponade, CTCAE","code":"C143744","definitions":[{"definition":"A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pericardial Tamponade, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pericardial Tamponade"},{"name":"Maps_To","value":"Pericardial tamponade"},{"name":"NCI_META_CUI","value":"CL541968"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55067":{"preferredName":"Pericarditis, CTCAE","code":"C55067","definitions":[{"definition":"A disorder characterized by irritation to the layers of the pericardium (the protective sac around the heart).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by irritation to the layers of the pericardium (the protective sac around the heart).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pericarditis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pericarditis_Adverse_Event"},{"name":"Maps_To","value":"Pericarditis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963211"}]}}{"C146681":{"preferredName":"Perineal Pain, CTCAE 5.0","code":"C146681","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Perineal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perineal pain"},{"name":"Maps_To","value":"Perineal Pain"},{"name":"NCI_META_CUI","value":"CL544634"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57849":{"preferredName":"Periodontal Disease, CTCAE","code":"C57849","definitions":[{"definition":"A disorder in the gingival tissue around the teeth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder in the gingival tissue around the teeth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Periodontal Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Periodontal_Disease_Adverse_Event"},{"name":"Maps_To","value":"Periodontal disease"},{"name":"Maps_To","value":"Periodontal Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559300"}]}}{"C143747":{"preferredName":"Periorbital Edema, CTCAE","code":"C143747","definitions":[{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Periorbital Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Periorbital Edema"},{"name":"Maps_To","value":"Periorbital edema"},{"name":"NCI_META_CUI","value":"CL541969"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143748":{"preferredName":"Periorbital Infection, CTCAE","code":"C143748","definitions":[{"definition":"A disorder characterized by an infectious process involving the orbit of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the orbit of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Periorbital Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Periorbital Infection"},{"name":"Maps_To","value":"Periorbital infection"},{"name":"NCI_META_CUI","value":"CL542071"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143749":{"preferredName":"Peripheral Ischemia, CTCAE","code":"C143749","definitions":[{"definition":"A disorder characterized by impaired circulation to an extremity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by impaired circulation to an extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Peripheral Ischemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Ischemia"},{"name":"Maps_To","value":"Peripheral ischemia"},{"name":"NCI_META_CUI","value":"CL542072"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143750":{"preferredName":"Peripheral Motor Neuropathy, CTCAE","code":"C143750","definitions":[{"definition":"A disorder characterized by damage or dysfunction of the peripheral motor nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by damage or dysfunction of the peripheral motor nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Peripheral Motor Neuropathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Motor Neuropathy"},{"name":"Maps_To","value":"Peripheral motor neuropathy"},{"name":"NCI_META_CUI","value":"CL542073"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143751":{"preferredName":"Peripheral Nerve Infection, CTCAE","code":"C143751","definitions":[{"definition":"A disorder characterized by an infectious process involving the peripheral nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the peripheral nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Peripheral Nerve Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Nerve Infection"},{"name":"Maps_To","value":"Peripheral nerve infection"},{"name":"NCI_META_CUI","value":"CL542074"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143752":{"preferredName":"Peripheral Sensory Neuropathy, CTCAE","code":"C143752","definitions":[{"definition":"A disorder characterized by damage or dysfunction of the peripheral sensory nerves.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by damage or dysfunction of the peripheral sensory nerves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Peripheral Sensory Neuropathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Sensory Neuropathy"},{"name":"Maps_To","value":"Peripheral sensory neuropathy"},{"name":"NCI_META_CUI","value":"CL542075"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143753":{"preferredName":"Peritoneal Infection, CTCAE","code":"C143753","definitions":[{"definition":"A disorder characterized by an infectious process involving the peritoneum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the peritoneum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Peritoneal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peritoneal Infection"},{"name":"Maps_To","value":"Peritoneal infection"},{"name":"NCI_META_CUI","value":"CL542076"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57850":{"preferredName":"Peritoneal Necrosis, CTCAE","code":"C57850","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the peritoneum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the peritoneum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Peritoneal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peritoneal_Cavity_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Peritoneal necrosis"},{"name":"Maps_To","value":"Peritoneal Necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556514"}]}}{"C143754":{"preferredName":"Personality Change, CTCAE","code":"C143754","definitions":[{"definition":"A disorder characterized by a conspicuous change in a person's behavior and thinking.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a conspicuous change in a person's behavior and thinking.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Personality Change, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personality Change"},{"name":"Maps_To","value":"Personality change"},{"name":"NCI_META_CUI","value":"CL542077"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146682":{"preferredName":"Phantom Pain, CTCAE 5.0","code":"C146682","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Phantom Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phantom Pain"},{"name":"Maps_To","value":"Phantom pain"},{"name":"NCI_META_CUI","value":"CL544740"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143755":{"preferredName":"Pharyngeal Anastomotic Leak, CTCAE","code":"C143755","definitions":[{"definition":"A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngeal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngeal Anastomotic Leak"},{"name":"Maps_To","value":"Pharyngeal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL542078"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57851":{"preferredName":"Pharyngeal Fistula, CTCAE","code":"C57851","definitions":[{"definition":"A disorder characterized by an abnormal communication between the pharynx and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the pharynx and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngeal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pharynx_GI_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Pharyngeal fistula"},{"name":"Maps_To","value":"Pharyngeal Fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560407"}]}}{"C56557":{"preferredName":"Pharyngeal Hemorrhage, CTCAE","code":"C56557","definitions":[{"definition":"A disorder characterized by bleeding from the pharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the pharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngeal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pharynx_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Pharyngeal Hemorrhage"},{"name":"Maps_To","value":"Pharyngeal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560807"}]}}{"C143756":{"preferredName":"Pharyngeal Mucositis, CTCAE","code":"C143756","definitions":[{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the pharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by ulceration or inflammation involving the mucous membrane of the pharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngeal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngeal Mucositis"},{"name":"Maps_To","value":"Pharyngeal mucositis"},{"name":"NCI_META_CUI","value":"CL542065"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57855":{"preferredName":"Pharyngeal Necrosis, CTCAE","code":"C57855","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the pharynx.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the pharynx.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngeal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pharynx_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Pharyngeal Necrosis"},{"name":"Maps_To","value":"Pharyngeal necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1397204"}]}}{"C143757":{"preferredName":"Pharyngeal Stenosis, CTCAE","code":"C143757","definitions":[{"definition":"A disorder characterized by a narrowing of the pharyngeal airway.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a narrowing of the pharyngeal airway.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pharyngeal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngeal Stenosis"},{"name":"Maps_To","value":"Pharyngeal stenosis"},{"name":"NCI_META_CUI","value":"CL542066"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143758":{"preferredName":"Pharyngitis, CTCAE","code":"C143758","definitions":[{"definition":"A disorder characterized by inflammation of the throat.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the throat.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngitis"},{"name":"NCI_META_CUI","value":"CL542067"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143759":{"preferredName":"Pharyngolaryngeal Pain, CTCAE","code":"C143759","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the pharyngolaryngeal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the pharyngolaryngeal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pharyngolaryngeal Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharyngolaryngeal Pain"},{"name":"Maps_To","value":"Pharyngolaryngeal pain"},{"name":"NCI_META_CUI","value":"CL542068"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143761":{"preferredName":"Phlebitis, CTCAE","code":"C143761","definitions":[{"definition":"A disorder characterized by inflammation of the wall of a vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation of the wall of a vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Phlebitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phlebitis"},{"name":"NCI_META_CUI","value":"CL542070"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143760":{"preferredName":"Phlebitis Infective, CTCAE","code":"C143760","definitions":[{"definition":"A disorder characterized by an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Phlebitis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phlebitis Infective"},{"name":"Maps_To","value":"Phlebitis infective"},{"name":"NCI_META_CUI","value":"CL542069"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146770":{"preferredName":"Photophobia, CTCAE 5.0","code":"C146770","definitions":[{"definition":"A disorder characterized by fear and avoidance of light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by fear and avoidance of light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Photophobia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Photophobia"},{"name":"NCI_META_CUI","value":"CL544792"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58005":{"preferredName":"Photosensitivity, CTCAE","code":"C58005","definitions":[{"definition":"A disorder characterized by an increase in sensitivity of the skin to light.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in sensitivity of the skin to light.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Photosensitivity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Photosensitivity_Adverse_Event"},{"name":"Maps_To","value":"Photosensitivity"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2362621"}]}}{"C143764":{"preferredName":"Platelet Count Decreased, CTCAE","code":"C143764","definitions":[{"definition":"A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Platelet Count Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Platelet Count Decreased"},{"name":"Maps_To","value":"Platelet count decreased"},{"name":"NCI_META_CUI","value":"CL545991"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143765":{"preferredName":"Pleural Effusion, CTCAE","code":"C143765","definitions":[{"definition":"A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pleural Effusion, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleural Effusion"},{"name":"Maps_To","value":"Pleural effusion"},{"name":"NCI_META_CUI","value":"CL545973"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56558":{"preferredName":"Pleural Hemorrhage, CTCAE","code":"C56558","definitions":[{"definition":"A disorder characterized by bleeding from the pleural cavity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the pleural cavity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pleural Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleura_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Pleural Hemorrhage"},{"name":"Maps_To","value":"Pleural hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556619"}]}}{"C143766":{"preferredName":"Pleural Infection, CTCAE","code":"C143766","definitions":[{"definition":"A disorder characterized by an infectious process involving the pleura.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the pleura.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pleural Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleural Infection"},{"name":"Maps_To","value":"Pleural infection"},{"name":"NCI_META_CUI","value":"CL542057"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146663":{"preferredName":"Pleuritic Pain, CTCAE 5.0","code":"C146663","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the pleura.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the pleura.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pleuritic Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleuritic pain"},{"name":"Maps_To","value":"Pleuritic Pain"},{"name":"NCI_META_CUI","value":"CL544647"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143767":{"preferredName":"Pneumonitis, CTCAE","code":"C143767","definitions":[{"definition":"A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pneumonitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pneumonitis"},{"name":"NCI_META_CUI","value":"CL542058"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58201":{"preferredName":"Pneumothorax, CTCAE","code":"C58201","definitions":[{"definition":"A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the lung.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the lung.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pneumothorax, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pneumothorax_Adverse_Event"},{"name":"Maps_To","value":"Pneumothorax"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963215"}]}}{"C143769":{"preferredName":"Portal Hypertension, CTCAE","code":"C143769","definitions":[{"definition":"A disorder characterized by an increase in blood pressure in the portal venous system.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in blood pressure in the portal venous system.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Portal Hypertension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Portal Hypertension"},{"name":"Maps_To","value":"Portal hypertension"},{"name":"NCI_META_CUI","value":"CL542059"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143770":{"preferredName":"Portal Vein Thrombosis, CTCAE","code":"C143770","definitions":[{"definition":"A disorder characterized by the formation of a thrombus (blood clot) in the portal vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the formation of a thrombus (blood clot) in the portal vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Portal Vein Thrombosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Portal Vein Thrombosis"},{"name":"Maps_To","value":"Portal vein thrombosis"},{"name":"NCI_META_CUI","value":"CL542060"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143771":{"preferredName":"Postnasal Drip, CTCAE","code":"C143771","definitions":[{"definition":"A disorder characterized by excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Postnasal Drip, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Postnasal Drip"},{"name":"Maps_To","value":"Postnasal drip"},{"name":"NCI_META_CUI","value":"CL542061"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143772":{"preferredName":"Postoperative Hemorrhage, CTCAE","code":"C143772","definitions":[{"definition":"A disorder characterized by bleeding occurring after a surgical procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding occurring after a surgical procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Postoperative Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Postoperative Hemorrhage"},{"name":"Maps_To","value":"Postoperative hemorrhage"},{"name":"NCI_META_CUI","value":"CL542062"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143773":{"preferredName":"Postoperative Thoracic Procedure Complication, CTCAE","code":"C143773","definitions":[{"definition":"A finding of a previously undocumented problem that occurs after a thoracic procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of a previously undocumented problem that occurs after a thoracic procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Postoperative Thoracic Procedure Complication, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Postoperative Thoracic Procedure Complication"},{"name":"Maps_To","value":"Postoperative thoracic procedure complication"},{"name":"NCI_META_CUI","value":"CL542063"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146645":{"preferredName":"Precocious Puberty, CTCAE 5.0","code":"C146645","definitions":[{"definition":"A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Precocious Puberty, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Precocious Puberty"},{"name":"Maps_To","value":"Precocious puberty"},{"name":"NCI_META_CUI","value":"CL544661"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143775":{"preferredName":"Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","code":"C143775","synonyms":[{"termName":"Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pregnancy, Puerperium and Perinatal Conditions - Other"},{"name":"Maps_To","value":"Pregnancy, puerperium and perinatal conditions - Other, specify"},{"name":"NCI_META_CUI","value":"CL542064"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143776":{"preferredName":"Premature Delivery, CTCAE","code":"C143776","definitions":[{"definition":"A disorder characterized by delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Premature Delivery, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Premature Delivery"},{"name":"Maps_To","value":"Premature delivery"},{"name":"NCI_META_CUI","value":"CL542049"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143777":{"preferredName":"Premature Menopause, CTCAE","code":"C143777","definitions":[{"definition":"A disorder characterized by premature ovarian failure. Symptoms may include hot flashes, night sweats, mood swings, and a decrease in sex drive. Laboratory findings include elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH.)","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by premature ovarian failure. Symptoms may include hot flashes, night sweats, mood swings, and a decrease in sex drive. Laboratory findings include elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH.)","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Premature Menopause, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Premature Menopause"},{"name":"Maps_To","value":"Premature menopause"},{"name":"NCI_META_CUI","value":"CL542050"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143778":{"preferredName":"Presyncope, CTCAE","code":"C143778","definitions":[{"definition":"A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Presyncope, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Presyncope"},{"name":"NCI_META_CUI","value":"CL542051"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57857":{"preferredName":"Proctitis, CTCAE","code":"C57857","definitions":[{"definition":"A disorder characterized by inflammation of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Proctitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Proctitis_Adverse_Event"},{"name":"Maps_To","value":"Proctitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963216"}]}}{"C143780":{"preferredName":"Productive Cough, CTCAE","code":"C143780","definitions":[{"definition":"A disorder characterized by expectorated secretions upon coughing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by expectorated secretions upon coughing.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Productive Cough, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Productive Cough"},{"name":"Maps_To","value":"Productive cough"},{"name":"NCI_META_CUI","value":"CL542052"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143781":{"preferredName":"Prolapse of Intestinal Stoma, CTCAE","code":"C143781","definitions":[{"definition":"A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Prolapse of Intestinal Stoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prolapse of Intestinal Stoma"},{"name":"Maps_To","value":"Prolapse of intestinal stoma"},{"name":"NCI_META_CUI","value":"CL542053"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143782":{"preferredName":"Prolapse of Urostomy, CTCAE","code":"C143782","definitions":[{"definition":"A finding of displacement of the urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of displacement of the urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Prolapse of Urostomy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prolapse of Urostomy"},{"name":"Maps_To","value":"Prolapse of urostomy"},{"name":"NCI_META_CUI","value":"CL542054"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143783":{"preferredName":"Prostate Infection, CTCAE","code":"C143783","definitions":[{"definition":"A disorder characterized by an infectious process involving the prostate gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the prostate gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Prostate Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostate Infection"},{"name":"Maps_To","value":"Prostate infection"},{"name":"NCI_META_CUI","value":"CL542055"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56552":{"preferredName":"Prostatic Hemorrhage, CTCAE","code":"C56552","definitions":[{"definition":"A disorder characterized by bleeding from the prostate gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the prostate gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Prostatic Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prostate_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Prostatic Hemorrhage"},{"name":"Maps_To","value":"Prostatic hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963129"}]}}{"C143784":{"preferredName":"Prostatic Obstruction, CTCAE","code":"C143784","definitions":[{"definition":"A disorder characterized by compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Prostatic Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostatic Obstruction"},{"name":"Maps_To","value":"Prostatic obstruction"},{"name":"NCI_META_CUI","value":"CL542056"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146664":{"preferredName":"Prostatic Pain, CTCAE 5.0","code":"C146664","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the prostate gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the prostate gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Prostatic Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostatic Pain"},{"name":"Maps_To","value":"Prostatic pain"},{"name":"NCI_META_CUI","value":"CL544648"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146758":{"preferredName":"Proteinuria, CTCAE 5.0","code":"C146758","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Proteinuria, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Proteinuria"},{"name":"NCI_META_CUI","value":"CL544796"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58006":{"preferredName":"Pruritus, CTCAE","code":"C58006","definitions":[{"definition":"A disorder characterized by an intense itching sensation.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an intense itching sensation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pruritus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pruritus_Adverse_Event"},{"name":"Maps_To","value":"Pruritus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559138"}]}}{"C143787":{"preferredName":"Psychiatric Disorders - Other, Specify, CTCAE","code":"C143787","synonyms":[{"termName":"Psychiatric Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Psychiatric Disorders - Other"},{"name":"Maps_To","value":"Psychiatric disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542043"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143788":{"preferredName":"Psychosis, CTCAE","code":"C143788","definitions":[{"definition":"A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Psychosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Psychosis"},{"name":"NCI_META_CUI","value":"CL545977"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143789":{"preferredName":"Pulmonary Edema, CTCAE","code":"C143789","definitions":[{"definition":"A disorder characterized by accumulation of fluid in the lung tissues that causes a disturbance of the gas exchange that may lead to respiratory failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by accumulation of fluid in the lung tissues that causes a disturbance of the gas exchange that may lead to respiratory failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pulmonary Edema, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Edema"},{"name":"Maps_To","value":"Pulmonary edema"},{"name":"NCI_META_CUI","value":"CL542044"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143790":{"preferredName":"Pulmonary Fibrosis, CTCAE","code":"C143790","definitions":[{"definition":"A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pulmonary Fibrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Fibrosis"},{"name":"Maps_To","value":"Pulmonary fibrosis"},{"name":"NCI_META_CUI","value":"CL542045"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143791":{"preferredName":"Pulmonary Fistula, CTCAE","code":"C143791","definitions":[{"definition":"A disorder characterized by an abnormal communication between the lung and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the lung and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pulmonary Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Fistula"},{"name":"Maps_To","value":"Pulmonary fistula"},{"name":"NCI_META_CUI","value":"CL542046"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55068":{"preferredName":"Pulmonary Hypertension, CTCAE","code":"C55068","definitions":[{"definition":"A disorder characterized by an increase in pressure within the pulmonary circulation due to lung or heart disorder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an increase in pressure within the pulmonary circulation due to lung or heart disorder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Pulmonary Hypertension, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pulmonary_Hypertension_Adverse_Event"},{"name":"Maps_To","value":"Pulmonary hypertension"},{"name":"Maps_To","value":"Pulmonary Hypertension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963220"}]}}{"C143793":{"preferredName":"Pulmonary Valve Disease, CTCAE","code":"C143793","definitions":[{"definition":"A disorder characterized by a defect in pulmonary valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a defect in pulmonary valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pulmonary Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pulmonary Valve Disease"},{"name":"Maps_To","value":"Pulmonary valve disease"},{"name":"NCI_META_CUI","value":"CL542047"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143794":{"preferredName":"Purpura, CTCAE","code":"C143794","definitions":[{"definition":"A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Purpura, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Purpura"},{"name":"NCI_META_CUI","value":"CL545981"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143795":{"preferredName":"Pyramidal Tract Syndrome, CTCAE","code":"C143795","definitions":[{"definition":"A disorder characterized by dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Pyramidal Tract Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pyramidal Tract Syndrome"},{"name":"Maps_To","value":"Pyramidal tract syndrome"},{"name":"NCI_META_CUI","value":"CL542048"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143796":{"preferredName":"Radiation Recall Reaction (Dermatologic), CTCAE","code":"C143796","definitions":[{"definition":"A finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Radiation Recall Reaction (Dermatologic), CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation Recall Reaction (Dermatologic)"},{"name":"Maps_To","value":"Radiation recall reaction (dermatologic)"},{"name":"NCI_META_CUI","value":"CL542036"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143797":{"preferredName":"Radiculitis, CTCAE","code":"C143797","definitions":[{"definition":"A disorder characterized by inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Radiculitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiculitis"},{"name":"NCI_META_CUI","value":"CL542037"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143798":{"preferredName":"Rash Acneiform, CTCAE","code":"C143798","definitions":[{"definition":"A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rash Acneiform, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rash Acneiform"},{"name":"Maps_To","value":"Rash acneiform"},{"name":"NCI_META_CUI","value":"CL542038"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143799":{"preferredName":"Rash Maculo-Papular, CTCAE","code":"C143799","definitions":[{"definition":"A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rash Maculo-Papular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rash Maculo-Papular"},{"name":"Maps_To","value":"Rash maculo-papular"},{"name":"NCI_META_CUI","value":"CL542039"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143800":{"preferredName":"Rash Pustular, CTCAE","code":"C143800","definitions":[{"definition":"A disorder characterized by a circumscribed and elevated skin lesion filled with pus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed and elevated skin lesion filled with pus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rash Pustular, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rash Pustular"},{"name":"Maps_To","value":"Rash pustular"},{"name":"NCI_META_CUI","value":"CL542040"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143801":{"preferredName":"Rectal Anastomotic Leak, CTCAE","code":"C143801","definitions":[{"definition":"A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rectal Anastomotic Leak"},{"name":"Maps_To","value":"Rectal anastomotic leak"},{"name":"NCI_META_CUI","value":"CL546006"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57859":{"preferredName":"Rectal Fistula, CTCAE","code":"C57859","definitions":[{"definition":"A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rectal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Rectum_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Rectal fistula"},{"name":"Maps_To","value":"Rectal Fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963224"}]}}{"C56560":{"preferredName":"Rectal Hemorrhage, CTCAE","code":"C56560","definitions":[{"definition":"A disorder characterized by bleeding from the rectal wall and discharged from the anus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the rectal wall and discharged from the anus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Rectum_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Rectal hemorrhage"},{"name":"Maps_To","value":"Rectal Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962965"}]}}{"C143802":{"preferredName":"Rectal Mucositis, CTCAE","code":"C143802","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal Mucositis"},{"name":"Maps_To","value":"Rectal mucositis"},{"name":"NCI_META_CUI","value":"CL542041"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57863":{"preferredName":"Rectal Necrosis, CTCAE","code":"C57863","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the rectal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the rectal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Necrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rectum_Necrosis_Adverse_Event"},{"name":"Maps_To","value":"Rectal necrosis"},{"name":"Maps_To","value":"Rectal Necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556521"}]}}{"C57864":{"preferredName":"Rectal Obstruction, CTCAE","code":"C57864","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents in the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rectum_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Rectal Obstruction"},{"name":"Maps_To","value":"Rectal obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1406054"}]}}{"C146631":{"preferredName":"Rectal Pain, CTCAE 5.0","code":"C146631","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the rectal region.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the rectal region.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal pain"},{"name":"Maps_To","value":"Rectal Pain"},{"name":"NCI_META_CUI","value":"CL544677"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146634":{"preferredName":"Rectal Perforation, CTCAE 5.0","code":"C146634","definitions":[{"definition":"A disorder characterized by a rupture in the rectal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the rectal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal Perforation"},{"name":"Maps_To","value":"Rectal perforation"},{"name":"NCI_META_CUI","value":"CL544666"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143803":{"preferredName":"Rectal Stenosis, CTCAE","code":"C143803","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Rectal Stenosis"},{"name":"Maps_To","value":"Rectal stenosis"},{"name":"NCI_META_CUI","value":"CL542042"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57867":{"preferredName":"Rectal Ulcer, CTCAE","code":"C57867","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the rectum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the rectum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Rectal Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Rectum_Ulcer_Adverse_Event"},{"name":"Maps_To","value":"Rectal Ulcer"},{"name":"Maps_To","value":"Rectal ulcer"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963258"}]}}{"C143804":{"preferredName":"Recurrent Laryngeal Nerve Palsy, CTCAE","code":"C143804","definitions":[{"definition":"A disorder characterized by paralysis of the recurrent laryngeal nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by paralysis of the recurrent laryngeal nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Recurrent Laryngeal Nerve Palsy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrent Laryngeal Nerve Palsy"},{"name":"Maps_To","value":"Recurrent laryngeal nerve palsy"},{"name":"NCI_META_CUI","value":"CL542028"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143805":{"preferredName":"Renal and Urinary Disorders - Other, Specify, CTCAE","code":"C143805","synonyms":[{"termName":"Renal and Urinary Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal and Urinary Disorders - Other"},{"name":"Maps_To","value":"Renal and urinary disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542029"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143806":{"preferredName":"Renal Calculi, CTCAE","code":"C143806","definitions":[{"definition":"A disorder characterized by the formation of crystals/kidney stones in the pelvis of the kidney.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the formation of crystals/kidney stones in the pelvis of the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Renal Calculi, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Calculi"},{"name":"Maps_To","value":"Renal calculi"},{"name":"NCI_META_CUI","value":"CL542030"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143807":{"preferredName":"Renal Colic, CTCAE","code":"C143807","definitions":[{"definition":"A disorder characterized by paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of crystals/kidney stones.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of crystals/kidney stones.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Renal Colic, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Colic"},{"name":"Maps_To","value":"Renal colic"},{"name":"NCI_META_CUI","value":"CL542031"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56544":{"preferredName":"Renal Hemorrhage, CTCAE","code":"C56544","definitions":[{"definition":"A disorder characterized by bleeding from the kidney.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Renal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kidney_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Renal Hemorrhage"},{"name":"Maps_To","value":"Renal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963127"}]}}{"C143808":{"preferredName":"Reproductive System and Breast Disorders - Other, Specify, CTCAE","code":"C143808","synonyms":[{"termName":"Reproductive System and Breast Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Reproductive System and Breast Disorders - Other"},{"name":"Maps_To","value":"Reproductive system and breast disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542032"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143809":{"preferredName":"Respiratory Failure, CTCAE","code":"C143809","definitions":[{"definition":"A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of carbon dioxide.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of carbon dioxide.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Respiratory Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Respiratory Failure"},{"name":"Maps_To","value":"Respiratory failure"},{"name":"NCI_META_CUI","value":"CL542033"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143810":{"preferredName":"Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","code":"C143810","synonyms":[{"termName":"Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Respiratory, Thoracic and Mediastinal Disorders - Other"},{"name":"Maps_To","value":"Respiratory, thoracic and mediastinal disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542034"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143811":{"preferredName":"Restlessness, CTCAE","code":"C143811","definitions":[{"definition":"A disorder characterized by an inability to rest, relax or be still.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inability to rest, relax or be still.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Restlessness, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Restlessness"},{"name":"NCI_META_CUI","value":"CL542035"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55069":{"preferredName":"Restrictive Cardiomyopathy, CTCAE","code":"C55069","definitions":[{"definition":"A disorder characterized by an inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and loses its flexibility.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and loses its flexibility.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Restrictive Cardiomyopathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Restrictive_Cardiomyopathy_Adverse_Event"},{"name":"Maps_To","value":"Restrictive cardiomyopathy"},{"name":"Maps_To","value":"Restrictive Cardiomyopathy"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963079"}]}}{"C146729":{"preferredName":"Retinal Detachment, CTCAE 5.0","code":"C146729","definitions":[{"definition":"A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Retinal Detachment, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retinal Detachment"},{"name":"Maps_To","value":"Retinal detachment"},{"name":"NCI_META_CUI","value":"CL544707"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143814":{"preferredName":"Retinal Tear, CTCAE","code":"C143814","definitions":[{"definition":"A disorder characterized by a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Retinal Tear, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retinal Tear"},{"name":"Maps_To","value":"Retinal tear"},{"name":"NCI_META_CUI","value":"CL542020"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143815":{"preferredName":"Retinal Vascular Disorder, CTCAE","code":"C143815","definitions":[{"definition":"A disorder characterized by pathological retinal blood vessels that adversely affects vision.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by pathological retinal blood vessels that adversely affects vision.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Retinal Vascular Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retinal Vascular Disorder"},{"name":"Maps_To","value":"Retinal vascular disorder"},{"name":"NCI_META_CUI","value":"CL542021"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56635":{"preferredName":"Retinoic Acid Syndrome, CTCAE","code":"C56635","definitions":[{"definition":"A disorder characterized by weight gain, dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans retinoic acid.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by weight gain, dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans retinoic acid.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Retinoic Acid Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retinoic_Acid_Syndrome_Adverse_Event"},{"name":"Maps_To","value":"Retinoic Acid Syndrome"},{"name":"Maps_To","value":"Retinoic acid syndrome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962967"}]}}{"C55891":{"preferredName":"Retinopathy, CTCAE","code":"C55891","definitions":[{"definition":"A disorder involving the retina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder involving the retina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Retinopathy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retinopathy_Adverse_Event"},{"name":"Maps_To","value":"Retinopathy"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1962966"}]}}{"C146632":{"preferredName":"Retroperitoneal Hemorrhage, CTCAE 5.0","code":"C146632","definitions":[{"definition":"A disorder characterized by bleeding from the retroperitoneal area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the retroperitoneal area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Retroperitoneal Hemorrhage, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retroperitoneal hemorrhage"},{"name":"Maps_To","value":"Retroperitoneal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL544678"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143818":{"preferredName":"Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","code":"C143818","definitions":[{"definition":"A disorder characterized by headaches, mental status changes, visual disturbances, and/or seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition. Also known as posterior reversible encephalopathy syndrome (PRES).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by headaches, mental status changes, visual disturbances, and/or seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition. Also known as posterior reversible encephalopathy syndrome (PRES).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Reversible Posterior Leukoencephalopathy Syndrome"},{"name":"Maps_To","value":"Reversible posterior leukoencephalopathy syndrome"},{"name":"NCI_META_CUI","value":"CL542022"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143819":{"preferredName":"Rhinitis Infective, CTCAE","code":"C143819","definitions":[{"definition":"A disorder characterized by an infectious process involving the nasal mucosal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the nasal mucosal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Rhinitis Infective, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rhinitis Infective"},{"name":"Maps_To","value":"Rhinitis infective"},{"name":"NCI_META_CUI","value":"CL542023"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55070":{"preferredName":"Right Ventricular Dysfunction, CTCAE","code":"C55070","definitions":[{"definition":"A disorder characterized by impairment of right ventricular function associated with low ejection fraction and a decrease in motility of the right ventricular wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by impairment of right ventricular function associated with low ejection fraction and a decrease in motility of the right ventricular wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Right Ventricular Dysfunction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Ventricular_Dysfunction_Adverse_Event"},{"name":"Maps_To","value":"Right Ventricular Dysfunction"},{"name":"Maps_To","value":"Right ventricular dysfunction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556315"}]}}{"C143821":{"preferredName":"Salivary Duct Inflammation, CTCAE","code":"C143821","definitions":[{"definition":"A disorder characterized by inflammation of the salivary duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation of the salivary duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Salivary Duct Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Salivary Duct Inflammation"},{"name":"Maps_To","value":"Salivary duct inflammation"},{"name":"NCI_META_CUI","value":"CL542024"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57868":{"preferredName":"Salivary Gland Fistula, CTCAE","code":"C57868","definitions":[{"definition":"A disorder characterized by an abnormal communication between a salivary gland and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between a salivary gland and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Salivary Gland Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salivary_Gland_Fistula"},{"name":"Maps_To","value":"Salivary Gland Fistula"},{"name":"Maps_To","value":"Salivary gland fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2700637"}]}}{"C143822":{"preferredName":"Salivary Gland Infection, CTCAE","code":"C143822","definitions":[{"definition":"A disorder characterized by an infectious process involving the salivary gland.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the salivary gland.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Salivary Gland Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Salivary Gland Infection"},{"name":"Maps_To","value":"Salivary gland infection"},{"name":"NCI_META_CUI","value":"CL542025"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146772":{"preferredName":"Scalp Pain, CTCAE 5.0","code":"C146772","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Scalp Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scalp Pain"},{"name":"Maps_To","value":"Scalp pain"},{"name":"NCI_META_CUI","value":"CL544780"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143823":{"preferredName":"Scleral Disorder, CTCAE","code":"C143823","definitions":[{"definition":"A disorder characterized by involvement of the sclera of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by involvement of the sclera of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Scleral Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scleral Disorder"},{"name":"Maps_To","value":"Scleral disorder"},{"name":"NCI_META_CUI","value":"CL542026"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143824":{"preferredName":"Scoliosis, CTCAE","code":"C143824","definitions":[{"definition":"A disorder characterized by a malformed, lateral curvature of the spine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a malformed, lateral curvature of the spine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Scoliosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scoliosis"},{"name":"NCI_META_CUI","value":"CL542027"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143825":{"preferredName":"Scrotal Infection, CTCAE","code":"C143825","definitions":[{"definition":"A disorder characterized by an infectious process involving the scrotum.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the scrotum.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Scrotal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scrotal Infection"},{"name":"Maps_To","value":"Scrotal infection"},{"name":"NCI_META_CUI","value":"CL542131"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146665":{"preferredName":"Scrotal Pain, CTCAE 5.0","code":"C146665","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the scrotal area.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the scrotal area.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Scrotal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Scrotal pain"},{"name":"Maps_To","value":"Scrotal Pain"},{"name":"NCI_META_CUI","value":"CL544649"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146700":{"preferredName":"Seizure, CTCAE 5.0","code":"C146700","definitions":[{"definition":"A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Seizure, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Seizure"},{"name":"NCI_META_CUI","value":"CL544727"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143827":{"preferredName":"Sepsis, CTCAE","code":"C143827","definitions":[{"definition":"A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sepsis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sepsis"},{"name":"NCI_META_CUI","value":"CL545911"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58401":{"preferredName":"Seroma, CTCAE","code":"C58401","definitions":[{"definition":"A finding of tumor-like collection of serum in the tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of tumor-like collection of serum in the tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Seroma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Seroma_Adverse_Event"},{"name":"Maps_To","value":"Seroma"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963233"}]}}{"C143829":{"preferredName":"Serum Amylase Increased, CTCAE","code":"C143829","definitions":[{"definition":"A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Serum Amylase Increased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Amylase Increased"},{"name":"Maps_To","value":"Serum amylase increased"},{"name":"NCI_META_CUI","value":"CL542132"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146642":{"preferredName":"Serum Sickness, CTCAE 5.0","code":"C146642","definitions":[{"definition":"A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Serum Sickness, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum sickness"},{"name":"Maps_To","value":"Serum Sickness"},{"name":"NCI_META_CUI","value":"CL544659"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54938":{"preferredName":"Sick Sinus Syndrome, CTCAE","code":"C54938","definitions":[{"definition":"A disorder characterized by a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by syncope, fatigue and dizziness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by syncope, fatigue and dizziness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sick Sinus Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sick_Sinus_Syndrome_Adverse_Event"},{"name":"Maps_To","value":"Sick sinus syndrome"},{"name":"Maps_To","value":"Sick Sinus Syndrome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963235"}]}}{"C54940":{"preferredName":"Sinus Bradycardia, CTCAE","code":"C54940","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sinus Bradycardia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sinus_Bradycardia_Adverse_Event"},{"name":"Maps_To","value":"Sinus Bradycardia"},{"name":"Maps_To","value":"Sinus bradycardia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963175"}]}}{"C143831":{"preferredName":"Sinus Disorder, CTCAE","code":"C143831","definitions":[{"definition":"A disorder characterized by involvement of the paranasal sinuses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by involvement of the paranasal sinuses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sinus Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinus Disorder"},{"name":"Maps_To","value":"Sinus disorder"},{"name":"NCI_META_CUI","value":"CL542133"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146783":{"preferredName":"Sinus Pain, CTCAE 5.0","code":"C146783","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sinus Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinus pain"},{"name":"Maps_To","value":"Sinus Pain"},{"name":"NCI_META_CUI","value":"CL544774"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146759":{"preferredName":"Sinus Tachycardia, CTCAE 5.0","code":"C146759","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sinus Tachycardia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinus Tachycardia"},{"name":"Maps_To","value":"Sinus tachycardia"},{"name":"NCI_META_CUI","value":"CL544797"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143832":{"preferredName":"Sinusitis, CTCAE","code":"C143832","definitions":[{"definition":"A disorder characterized by an infectious process involving the mucous membranes of the paranasal sinuses.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the mucous membranes of the paranasal sinuses.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sinusitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sinusitis"},{"name":"NCI_META_CUI","value":"CL542134"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143833":{"preferredName":"Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","code":"C143833","synonyms":[{"termName":"Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin and Subcutaneous Tissue Disorders - Other"},{"name":"Maps_To","value":"Skin and subcutaneous tissue disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL546009"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146644":{"preferredName":"Skin Atrophy, CTCAE 5.0","code":"C146644","definitions":[{"definition":"A disorder characterized by the degeneration and thinning of the epidermis and dermis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the degeneration and thinning of the epidermis and dermis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Skin Atrophy, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin atrophy"},{"name":"Maps_To","value":"Skin Atrophy"},{"name":"NCI_META_CUI","value":"CL544660"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143835":{"preferredName":"Skin Hyperpigmentation, CTCAE","code":"C143835","definitions":[{"definition":"A disorder characterized by darkening of the skin due to excessive melanin deposition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by darkening of the skin due to excessive melanin deposition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Skin Hyperpigmentation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin Hyperpigmentation"},{"name":"Maps_To","value":"Skin hyperpigmentation"},{"name":"NCI_META_CUI","value":"CL542135"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143836":{"preferredName":"Skin Hypopigmentation, CTCAE","code":"C143836","definitions":[{"definition":"A disorder characterized by loss of skin pigment (e.g., vitiligo).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by loss of skin pigment (e.g., vitiligo).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Skin Hypopigmentation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin Hypopigmentation"},{"name":"Maps_To","value":"Skin hypopigmentation"},{"name":"NCI_META_CUI","value":"CL542136"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143837":{"preferredName":"Skin Induration, CTCAE","code":"C143837","definitions":[{"definition":"A disorder characterized by an area of hardness in the skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an area of hardness in the skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Skin Induration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin Induration"},{"name":"Maps_To","value":"Skin induration"},{"name":"NCI_META_CUI","value":"CL542125"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143838":{"preferredName":"Skin Infection, CTCAE","code":"C143838","definitions":[{"definition":"A disorder characterized by an infectious process involving the skin such as cellulitis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the skin such as cellulitis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Skin Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin infection"},{"name":"Maps_To","value":"Skin Infection"},{"name":"NCI_META_CUI","value":"CL545896"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143839":{"preferredName":"Skin Ulceration, CTCAE","code":"C143839","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the skin.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the skin.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Skin Ulceration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin ulceration"},{"name":"Maps_To","value":"Skin Ulceration"},{"name":"NCI_META_CUI","value":"CL542126"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143840":{"preferredName":"Sleep Apnea, CTCAE","code":"C143840","definitions":[{"definition":"A disorder characterized by cessation of breathing for short periods during sleep.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by cessation of breathing for short periods during sleep.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sleep Apnea, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sleep apnea"},{"name":"Maps_To","value":"Sleep Apnea"},{"name":"NCI_META_CUI","value":"CL545901"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143841":{"preferredName":"Small Intestinal Anastomotic Leak, CTCAE","code":"C143841","definitions":[{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Small Intestinal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small intestinal anastomotic leak"},{"name":"Maps_To","value":"Small Intestinal Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542127"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143842":{"preferredName":"Small Intestinal Mucositis, CTCAE","code":"C143842","definitions":[{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by ulceration or inflammation of the mucous membrane of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Small Intestinal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small intestinal mucositis"},{"name":"Maps_To","value":"Small Intestinal Mucositis"},{"name":"NCI_META_CUI","value":"CL542128"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143843":{"preferredName":"Small Intestinal Obstruction, CTCAE","code":"C143843","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the intestinal contents of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Small Intestinal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestinal Obstruction"},{"name":"Maps_To","value":"Small intestinal obstruction"},{"name":"NCI_META_CUI","value":"CL542129"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146635":{"preferredName":"Small Intestinal Perforation, CTCAE 5.0","code":"C146635","definitions":[{"definition":"A disorder characterized by a rupture in the small intestine wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the small intestine wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Small Intestinal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small intestinal perforation"},{"name":"Maps_To","value":"Small Intestinal Perforation"},{"name":"NCI_META_CUI","value":"CL544667"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143844":{"preferredName":"Small Intestinal Stenosis, CTCAE","code":"C143844","definitions":[{"definition":"A disorder characterized by a narrowing of the lumen of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the lumen of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Small Intestinal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestinal Stenosis"},{"name":"Maps_To","value":"Small intestinal stenosis"},{"name":"NCI_META_CUI","value":"CL542130"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143845":{"preferredName":"Small Intestine Infection, CTCAE","code":"C143845","definitions":[{"definition":"A disorder characterized by an infectious process involving the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Small Intestine Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestine Infection"},{"name":"Maps_To","value":"Small intestine infection"},{"name":"NCI_META_CUI","value":"CL542117"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143846":{"preferredName":"Small Intestine Ulcer, CTCAE","code":"C143846","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the small intestine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the small intestine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Small Intestine Ulcer, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Small Intestine Ulcer"},{"name":"Maps_To","value":"Small intestine ulcer"},{"name":"NCI_META_CUI","value":"CL542118"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143847":{"preferredName":"Sneezing, CTCAE","code":"C143847","definitions":[{"definition":"A disorder characterized by the involuntary expulsion of air from the nose.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the involuntary expulsion of air from the nose.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Sneezing, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sneezing"},{"name":"NCI_META_CUI","value":"CL542119"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143848":{"preferredName":"Social Circumstances - Other, Specify, CTCAE","code":"C143848","synonyms":[{"termName":"Social Circumstances - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social Circumstances - Other"},{"name":"Maps_To","value":"Social circumstances - Other, specify"},{"name":"NCI_META_CUI","value":"CL542120"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143849":{"preferredName":"Soft Tissue Infection, CTCAE","code":"C143849","definitions":[{"definition":"A disorder characterized by an infectious process involving soft tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving soft tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Soft Tissue Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Soft Tissue Infection"},{"name":"Maps_To","value":"Soft tissue infection"},{"name":"NCI_META_CUI","value":"CL542121"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143850":{"preferredName":"Soft Tissue Necrosis Lower Limb, CTCAE","code":"C143850","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Soft Tissue Necrosis Lower Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Soft Tissue Necrosis Lower Limb"},{"name":"Maps_To","value":"Soft tissue necrosis lower limb"},{"name":"NCI_META_CUI","value":"CL542122"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143851":{"preferredName":"Soft Tissue Necrosis Upper Limb, CTCAE","code":"C143851","definitions":[{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Soft Tissue Necrosis Upper Limb, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Soft tissue necrosis upper limb"},{"name":"Maps_To","value":"Soft Tissue Necrosis Upper Limb"},{"name":"NCI_META_CUI","value":"CL542123"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143852":{"preferredName":"Somnolence, CTCAE","code":"C143852","definitions":[{"definition":"A disorder characterized by characterized by excessive sleepiness and drowsiness.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by characterized by excessive sleepiness and drowsiness.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Somnolence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Somnolence"},{"name":"NCI_META_CUI","value":"CL542124"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143853":{"preferredName":"Sore Throat, CTCAE","code":"C143853","definitions":[{"definition":"A disorder characterized by marked discomfort in the throat","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by marked discomfort in the throat","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sore Throat, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sore throat"},{"name":"Maps_To","value":"Sore Throat"},{"name":"NCI_META_CUI","value":"CL542109"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143854":{"preferredName":"Spasticity, CTCAE","code":"C143854","definitions":[{"definition":"A disorder characterized by increased involuntary muscle tone that affects the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by increased involuntary muscle tone that affects the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Spasticity, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spasticity"},{"name":"NCI_META_CUI","value":"CL542110"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143855":{"preferredName":"Spermatic Cord Anastomotic Leak, CTCAE","code":"C143855","definitions":[{"definition":"A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Spermatic Cord Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spermatic cord anastomotic leak"},{"name":"Maps_To","value":"Spermatic Cord Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542111"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56563":{"preferredName":"Spermatic Cord Hemorrhage, CTCAE","code":"C56563","definitions":[{"definition":"A disorder characterized by bleeding from the spermatic cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the spermatic cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Spermatic Cord Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spermatic_Cord_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Spermatic Cord Hemorrhage"},{"name":"Maps_To","value":"Spermatic cord hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963130"}]}}{"C146757":{"preferredName":"Spermatic Cord Obstruction, CTCAE 5.0","code":"C146757","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of the contents of the spermatic cord.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of the contents of the spermatic cord.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Spermatic Cord Obstruction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spermatic Cord Obstruction"},{"name":"Maps_To","value":"Spermatic cord obstruction"},{"name":"NCI_META_CUI","value":"CL544795"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143856":{"preferredName":"Spinal Fracture, CTCAE","code":"C143856","definitions":[{"definition":"A finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Spinal Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spinal fracture"},{"name":"Maps_To","value":"Spinal Fracture"},{"name":"NCI_META_CUI","value":"CL542112"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35823":{"preferredName":"Splenic Disorder","code":"C35823","definitions":[{"definition":"A disorder of the spleen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A non-neoplastic or neoplastic disorder affecting the spleen. Examples include infection, hemangioma, lymphoma, leukemia and angiosarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splenic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Spleen Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Splenic_Disorder"},{"name":"Maps_To","value":"Other diseases of spleen"},{"name":"Maps_To","value":"Spleen Disorder"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0037997"}]}}{"C143857":{"preferredName":"Splenic Infection, CTCAE","code":"C143857","definitions":[{"definition":"A disorder characterized by an infectious process involving the spleen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the spleen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Splenic Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Splenic infection"},{"name":"Maps_To","value":"Splenic Infection"},{"name":"NCI_META_CUI","value":"CL542113"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143858":{"preferredName":"Stenosis of Gastrointestinal Stoma, CTCAE","code":"C143858","definitions":[{"definition":"A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stenosis of Gastrointestinal Stoma, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stenosis of gastrointestinal stoma"},{"name":"Maps_To","value":"Stenosis of Gastrointestinal Stoma"},{"name":"NCI_META_CUI","value":"CL542114"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143859":{"preferredName":"Stevens-Johnson Syndrome, CTCAE","code":"C143859","definitions":[{"definition":"A disorder characterized by less than 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by less than 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Stevens-Johnson Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stevens-Johnson syndrome"},{"name":"Maps_To","value":"Stevens-Johnson Syndrome"},{"name":"NCI_META_CUI","value":"CL542115"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143860":{"preferredName":"Stoma Site Infection, CTCAE","code":"C143860","definitions":[{"definition":"A disorder characterized by an infectious process involving a stoma (surgically created opening on the surface of the body).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving a stoma (surgically created opening on the surface of the body).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Stoma Site Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stoma site infection"},{"name":"Maps_To","value":"Stoma Site Infection"},{"name":"NCI_META_CUI","value":"CL542116"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146774":{"preferredName":"Stomach Pain, CTCAE 5.0","code":"C146774","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the stomach.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation of marked discomfort in the stomach.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stomach Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stomach Pain"},{"name":"Maps_To","value":"Stomach pain"},{"name":"NCI_META_CUI","value":"CL544782"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146694":{"preferredName":"Stomal Ulcer, CTCAE 5.0","code":"C146694","definitions":[{"definition":"A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stomal Ulcer, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stomal Ulcer"},{"name":"Maps_To","value":"Stomal ulcer"},{"name":"NCI_META_CUI","value":"CL544736"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143861":{"preferredName":"Stridor, CTCAE","code":"C143861","definitions":[{"definition":"A disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Stridor, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stridor"},{"name":"NCI_META_CUI","value":"CL542102"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143862":{"preferredName":"Stroke, CTCAE","code":"C143862","definitions":[{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Stroke, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stroke"},{"name":"NCI_META_CUI","value":"CL542103"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143863":{"preferredName":"Sudden Death NOS, CTCAE","code":"C143863","definitions":[{"definition":"An unexpected death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"An unexpected death that cannot be attributed to a CTCAE term associated with Grade 5.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Sudden Death NOS, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sudden death NOS"},{"name":"Maps_To","value":"Sudden Death NOS"},{"name":"NCI_META_CUI","value":"CL542104"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143864":{"preferredName":"Suicidal Ideation, CTCAE","code":"C143864","definitions":[{"definition":"A disorder characterized by thoughts of taking one's own life.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by thoughts of taking one's own life.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Suicidal Ideation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Suicidal ideation"},{"name":"Maps_To","value":"Suicidal Ideation"},{"name":"NCI_META_CUI","value":"CL545963"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143865":{"preferredName":"Suicide Attempt, CTCAE","code":"C143865","definitions":[{"definition":"A disorder characterized by self-inflicted harm in an attempt to end one's own life.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by self-inflicted harm in an attempt to end one's own life.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Suicide Attempt, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Suicide attempt"},{"name":"Maps_To","value":"Suicide Attempt"},{"name":"NCI_META_CUI","value":"CL542105"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143866":{"preferredName":"Superficial Soft Tissue Fibrosis, CTCAE","code":"C143866","definitions":[{"definition":"A disorder characterized by fibrotic degeneration of the superficial soft tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by fibrotic degeneration of the superficial soft tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Superficial Soft Tissue Fibrosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superficial soft tissue fibrosis"},{"name":"Maps_To","value":"Superficial Soft Tissue Fibrosis"},{"name":"NCI_META_CUI","value":"CL542106"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143867":{"preferredName":"Superficial Thrombophlebitis, CTCAE","code":"C143867","definitions":[{"definition":"A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Superficial Thrombophlebitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superficial thrombophlebitis"},{"name":"Maps_To","value":"Superficial Thrombophlebitis"},{"name":"NCI_META_CUI","value":"CL542107"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143868":{"preferredName":"Superior Vena Cava Syndrome, CTCAE","code":"C143868","definitions":[{"definition":"A disorder characterized by obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Superior Vena Cava Syndrome, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Superior vena cava syndrome"},{"name":"Maps_To","value":"Superior Vena Cava Syndrome"},{"name":"NCI_META_CUI","value":"CL542108"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54945":{"preferredName":"Supraventricular Tachycardia, CTCAE","code":"C54945","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Supraventricular Tachycardia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supraventricular_Tachycardia_Adverse_Event"},{"name":"Maps_To","value":"Supraventricular Tachycardia"},{"name":"Maps_To","value":"Supraventricular tachycardia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963244"}]}}{"C143869":{"preferredName":"Surgical and Medical Procedures - Other, Specify, CTCAE","code":"C143869","synonyms":[{"termName":"Surgical and Medical Procedures - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgical and Medical Procedures - Other"},{"name":"Maps_To","value":"Surgical and medical procedures - Other, specify"},{"name":"NCI_META_CUI","value":"CL542094"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146750":{"preferredName":"Syncope, CTCAE 5.0","code":"C146750","definitions":[{"definition":"A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Syncope, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Syncope"},{"name":"NCI_META_CUI","value":"CL545953"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146740":{"preferredName":"Telangiectasia, CTCAE 5.0","code":"C146740","definitions":[{"definition":"A disorder characterized by local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Telangiectasia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Telangiectasia"},{"name":"NCI_META_CUI","value":"CL544688"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143872":{"preferredName":"Testicular Disorder, CTCAE","code":"C143872","definitions":[{"definition":"A disorder characterized by abnormal function or appearance of the testis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by abnormal function or appearance of the testis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Testicular Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Testicular disorder"},{"name":"Maps_To","value":"Testicular Disorder"},{"name":"NCI_META_CUI","value":"CL542095"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56566":{"preferredName":"Testicular Hemorrhage, CTCAE","code":"C56566","definitions":[{"definition":"A disorder characterized by bleeding from the testis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the testis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Testicular Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Testes_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Testicular Hemorrhage"},{"name":"Maps_To","value":"Testicular hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963131"}]}}{"C146666":{"preferredName":"Testicular Pain, CTCAE 5.0","code":"C146666","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the testis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the testis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Testicular Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Testicular Pain"},{"name":"Maps_To","value":"Testicular pain"},{"name":"NCI_META_CUI","value":"CL544635"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143873":{"preferredName":"Thromboembolic Event, CTCAE","code":"C143873","definitions":[{"definition":"A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Thromboembolic Event, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thromboembolic event"},{"name":"Maps_To","value":"Thromboembolic Event"},{"name":"NCI_META_CUI","value":"CL542096"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143874":{"preferredName":"Thrombotic Thrombocytopenic Purpura, CTCAE","code":"C143874","definitions":[{"definition":"A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Thrombotic Thrombocytopenic Purpura, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thrombotic thrombocytopenic purpura"},{"name":"Maps_To","value":"Thrombotic Thrombocytopenic Purpura"},{"name":"NCI_META_CUI","value":"CL542097"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146690":{"preferredName":"Tinnitus, CTCAE 5.0","code":"C146690","definitions":[{"definition":"A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tinnitus, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tinnitus"},{"name":"NCI_META_CUI","value":"CL545922"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143876":{"preferredName":"Tooth Development Disorder, CTCAE","code":"C143876","definitions":[{"definition":"A disorder characterized by a pathological process of the teeth occurring during tooth development.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a pathological process of the teeth occurring during tooth development.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tooth Development Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tooth development disorder"},{"name":"Maps_To","value":"Tooth Development Disorder"},{"name":"NCI_META_CUI","value":"CL542098"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143877":{"preferredName":"Tooth Discoloration, CTCAE","code":"C143877","definitions":[{"definition":"A disorder characterized by a change in tooth hue or tint.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a change in tooth hue or tint.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tooth Discoloration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tooth discoloration"},{"name":"Maps_To","value":"Tooth Discoloration"},{"name":"NCI_META_CUI","value":"CL542099"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143878":{"preferredName":"Tooth Infection, CTCAE","code":"C143878","definitions":[{"definition":"A disorder characterized by an infectious process involving a tooth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving a tooth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tooth Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tooth infection"},{"name":"Maps_To","value":"Tooth Infection"},{"name":"NCI_META_CUI","value":"CL542100"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143879":{"preferredName":"Toothache, CTCAE","code":"C143879","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the tooth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the tooth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Toothache, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Toothache"},{"name":"NCI_META_CUI","value":"CL542101"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143880":{"preferredName":"Toxic Epidermal Necrolysis, CTCAE","code":"C143880","definitions":[{"definition":"A disorder characterized by greater than 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by greater than 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Toxic Epidermal Necrolysis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Toxic epidermal necrolysis"},{"name":"Maps_To","value":"Toxic Epidermal Necrolysis"},{"name":"NCI_META_CUI","value":"CL542087"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58205":{"preferredName":"Tracheal Fistula, CTCAE","code":"C58205","definitions":[{"definition":"A disorder characterized by an abnormal communication between the trachea and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the trachea and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tracheal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trachea_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Tracheal Fistula"},{"name":"Maps_To","value":"Tracheal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963251"}]}}{"C56567":{"preferredName":"Tracheal Hemorrhage, CTCAE","code":"C56567","definitions":[{"definition":"A disorder characterized by bleeding from the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tracheal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trachea_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Tracheal Hemorrhage"},{"name":"Maps_To","value":"Tracheal hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556636"}]}}{"C143881":{"preferredName":"Tracheal Mucositis, CTCAE","code":"C143881","definitions":[{"definition":"A disorder characterized by an inflammation or ulceration involving the mucous membrane of the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an inflammation or ulceration involving the mucous membrane of the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tracheal Mucositis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheal mucositis"},{"name":"Maps_To","value":"Tracheal Mucositis"},{"name":"NCI_META_CUI","value":"CL542088"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143882":{"preferredName":"Tracheal Obstruction, CTCAE","code":"C143882","definitions":[{"definition":"A disorder characterized by blockage of the lumen of the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the lumen of the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tracheal Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheal obstruction"},{"name":"Maps_To","value":"Tracheal Obstruction"},{"name":"NCI_META_CUI","value":"CL542089"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143883":{"preferredName":"Tracheal Stenosis, CTCAE","code":"C143883","definitions":[{"definition":"A disorder characterized by a narrowing of the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tracheal Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheal stenosis"},{"name":"Maps_To","value":"Tracheal Stenosis"},{"name":"NCI_META_CUI","value":"CL542090"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143884":{"preferredName":"Tracheitis, CTCAE","code":"C143884","definitions":[{"definition":"A disorder characterized by an infectious process involving the trachea.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the trachea.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tracheitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheitis"},{"name":"NCI_META_CUI","value":"CL542091"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143885":{"preferredName":"Tracheostomy Site Bleeding, CTCAE","code":"C143885","definitions":[{"definition":"A disorder characterized by bleeding from the tracheostomy site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the tracheostomy site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tracheostomy Site Bleeding, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tracheostomy site bleeding"},{"name":"Maps_To","value":"Tracheostomy Site Bleeding"},{"name":"NCI_META_CUI","value":"CL542092"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143886":{"preferredName":"Transient Ischemic Attacks, CTCAE","code":"C143886","definitions":[{"definition":"A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Transient Ischemic Attacks, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transient ischemic attacks"},{"name":"Maps_To","value":"Transient Ischemic Attacks"},{"name":"NCI_META_CUI","value":"CL545979"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143887":{"preferredName":"Treatment Related Secondary Malignancy, CTCAE","code":"C143887","definitions":[{"definition":"A disorder characterized by development of a malignancy most probably as a result of treatment for a previously existing malignancy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by development of a malignancy most probably as a result of treatment for a previously existing malignancy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Treatment Related Secondary Malignancy, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treatment related secondary malignancy"},{"name":"Maps_To","value":"Treatment Related Secondary Malignancy"},{"name":"NCI_META_CUI","value":"CL542093"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146780":{"preferredName":"Tremor, CTCAE 5.0","code":"C146780","definitions":[{"definition":"A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Tremor, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tremor"},{"name":"NCI_META_CUI","value":"CL544772"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143889":{"preferredName":"Tricuspid Valve Disease, CTCAE","code":"C143889","definitions":[{"definition":"A disorder characterized by a defect in tricuspid valve function or structure.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a defect in tricuspid valve function or structure.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tricuspid Valve Disease, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tricuspid valve disease"},{"name":"Maps_To","value":"Tricuspid Valve Disease"},{"name":"NCI_META_CUI","value":"CL542079"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143890":{"preferredName":"Trigeminal Nerve Disorder, CTCAE","code":"C143890","definitions":[{"definition":"A disorder characterized by dysfunction of the trigeminal nerve (fifth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the trigeminal nerve (fifth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Trigeminal Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trigeminal nerve disorder"},{"name":"Maps_To","value":"Trigeminal Nerve Disorder"},{"name":"NCI_META_CUI","value":"CL542080"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58404":{"preferredName":"Trismus, CTCAE","code":"C58404","definitions":[{"definition":"A disorder characterized by lack of ability to open the mouth fully due to a decrease in the range of motion of the muscles of mastication.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by lack of ability to open the mouth fully due to a decrease in the range of motion of the muscles of mastication.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Trismus, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trismus_Adverse_Event"},{"name":"Maps_To","value":"Trismus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1561266"}]}}{"C146688":{"preferredName":"Tumor Lysis Syndrome, CTCAE 5.0","code":"C146688","definitions":[{"definition":"A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tumor Lysis Syndrome, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor lysis syndrome"},{"name":"Maps_To","value":"Tumor Lysis Syndrome"},{"name":"NCI_META_CUI","value":"CL544746"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146782":{"preferredName":"Tumor Pain, CTCAE 5.0","code":"C146782","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Tumor Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor Pain"},{"name":"Maps_To","value":"Tumor pain"},{"name":"NCI_META_CUI","value":"CL544773"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146730":{"preferredName":"Typhlitis, CTCAE 5.0","code":"C146730","definitions":[{"definition":"A disorder characterized by necrotizing enterocolitis in neutropenic patients.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by necrotizing enterocolitis in neutropenic patients.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Typhlitis, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Typhlitis"},{"name":"NCI_META_CUI","value":"CL544708"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143894":{"preferredName":"Unequal Limb Length, CTCAE","code":"C143894","definitions":[{"definition":"A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Unequal Limb Length, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unequal limb length"},{"name":"Maps_To","value":"Unequal Limb Length"},{"name":"NCI_META_CUI","value":"CL542081"},{"name":"Semantic_Type","value":"Finding"}]}}{"C79801":{"preferredName":"Unintended Pregnancy","code":"C79801","definitions":[{"definition":"A disorder characterized by an unexpected pregnancy at the time of conception.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A pregnancy that was not desired or was timed incorrectly at the time that the conception occurred.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unintended Pregnancy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unintended_Pregnancy"},{"name":"Maps_To","value":"Unintended Pregnancy"},{"name":"Semantic_Type","value":"Organism Function"},{"name":"UMLS_CUI","value":"C0041747"}]}}{"C143895":{"preferredName":"Upper Gastrointestinal Hemorrhage, CTCAE","code":"C143895","definitions":[{"definition":"A disorder characterized by bleeding from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Upper Gastrointestinal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Upper gastrointestinal hemorrhage"},{"name":"Maps_To","value":"Upper Gastrointestinal Hemorrhage"},{"name":"NCI_META_CUI","value":"CL542082"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143896":{"preferredName":"Upper Respiratory Infection, CTCAE","code":"C143896","definitions":[{"definition":"A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Upper Respiratory Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Upper respiratory infection"},{"name":"Maps_To","value":"Upper Respiratory Infection"},{"name":"NCI_META_CUI","value":"CL542083"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143897":{"preferredName":"Ureteric Anastomotic Leak, CTCAE","code":"C143897","definitions":[{"definition":"A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ureteric Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ureteric anastomotic leak"},{"name":"Maps_To","value":"Ureteric Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542084"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143898":{"preferredName":"Urethral Anastomotic Leak, CTCAE","code":"C143898","definitions":[{"definition":"A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urethral Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urethral anastomotic leak"},{"name":"Maps_To","value":"Urethral Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542085"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143899":{"preferredName":"Urethral Infection, CTCAE","code":"C143899","definitions":[{"definition":"A disorder characterized by an infectious process involving the urethra.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the urethra.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urethral Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urethral infection"},{"name":"Maps_To","value":"Urethral Infection"},{"name":"NCI_META_CUI","value":"CL542086"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143900":{"preferredName":"Urinary Fistula, CTCAE","code":"C143900","definitions":[{"definition":"A disorder characterized by an abnormal communication between any part of the urinary system and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between any part of the urinary system and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urinary Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary fistula"},{"name":"Maps_To","value":"Urinary Fistula"},{"name":"NCI_META_CUI","value":"CL542190"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143901":{"preferredName":"Urinary Frequency, CTCAE","code":"C143901","definitions":[{"definition":"A disorder characterized by urination at short intervals.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by urination at short intervals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Frequency, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary frequency"},{"name":"Maps_To","value":"Urinary Frequency"},{"name":"NCI_META_CUI","value":"CL542191"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146786":{"preferredName":"Urinary Incontinence, CTCAE 5.0","code":"C146786","definitions":[{"definition":"A disorder characterized by inability to control the flow of urine from the bladder.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inability to control the flow of urine from the bladder.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urinary Incontinence, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary incontinence"},{"name":"Maps_To","value":"Urinary Incontinence"},{"name":"NCI_META_CUI","value":"CL550644"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57097":{"preferredName":"Urinary Retention, CTCAE","code":"C57097","definitions":[{"definition":"A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Retention, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Urinary_Retention_Adverse_Event"},{"name":"Maps_To","value":"Urinary retention"},{"name":"Maps_To","value":"Urinary Retention"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1558141"}]}}{"C143904":{"preferredName":"Urinary Tract Infection, CTCAE","code":"C143904","definitions":[{"definition":"A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urinary Tract Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urinary tract infection"},{"name":"Maps_To","value":"Urinary Tract Infection"},{"name":"NCI_META_CUI","value":"CL545980"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143905":{"preferredName":"Urinary Tract Obstruction, CTCAE","code":"C143905","definitions":[{"definition":"A disorder characterized by blockage of the normal flow of contents of the urinary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the normal flow of contents of the urinary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urinary Tract Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary tract obstruction"},{"name":"Maps_To","value":"Urinary Tract Obstruction"},{"name":"NCI_META_CUI","value":"CL542192"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143906":{"preferredName":"Urinary Tract Pain, CTCAE","code":"C143906","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the urinary tract.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the urinary tract.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urinary Tract Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary tract pain"},{"name":"Maps_To","value":"Urinary Tract Pain"},{"name":"NCI_META_CUI","value":"CL542193"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143907":{"preferredName":"Urinary Urgency, CTCAE","code":"C143907","definitions":[{"definition":"A disorder characterized by a sudden compelling urge to urinate.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sudden compelling urge to urinate.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urinary Urgency, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Urinary urgency"},{"name":"Maps_To","value":"Urinary Urgency"},{"name":"NCI_META_CUI","value":"CL542194"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143908":{"preferredName":"Urine Discoloration, CTCAE","code":"C143908","definitions":[{"definition":"A disorder characterized by a change in the color of the urine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a change in the color of the urine.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urine Discoloration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urine discoloration"},{"name":"Maps_To","value":"Urine Discoloration"},{"name":"NCI_META_CUI","value":"CL542195"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143909":{"preferredName":"Urine Output Decreased, CTCAE","code":"C143909","definitions":[{"definition":"A finding based on test results that indicate urine production is less relative to previous output.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on test results that indicate urine production is less relative to previous output.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urine Output Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urine output decreased"},{"name":"Maps_To","value":"Urine Output Decreased"},{"name":"NCI_META_CUI","value":"CL542196"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143910":{"preferredName":"Urostomy Leak, CTCAE","code":"C143910","definitions":[{"definition":"A finding of leakage of contents from a urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage of contents from a urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urostomy Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy leak"},{"name":"Maps_To","value":"Urostomy Leak"},{"name":"NCI_META_CUI","value":"CL542183"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143911":{"preferredName":"Urostomy Obstruction, CTCAE","code":"C143911","definitions":[{"definition":"A disorder characterized by blockage of the urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of the urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urostomy Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy obstruction"},{"name":"Maps_To","value":"Urostomy Obstruction"},{"name":"NCI_META_CUI","value":"CL542184"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143912":{"preferredName":"Urostomy Site Bleeding, CTCAE","code":"C143912","definitions":[{"definition":"A disorder characterized by bleeding from the urostomy site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the urostomy site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urostomy Site Bleeding, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy site bleeding"},{"name":"Maps_To","value":"Urostomy Site Bleeding"},{"name":"NCI_META_CUI","value":"CL542185"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143913":{"preferredName":"Urostomy Stenosis, CTCAE","code":"C143913","definitions":[{"definition":"A finding of narrowing of the opening of a urostomy.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of narrowing of the opening of a urostomy.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Urostomy Stenosis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urostomy stenosis"},{"name":"Maps_To","value":"Urostomy Stenosis"},{"name":"NCI_META_CUI","value":"CL542186"},{"name":"Semantic_Type","value":"Finding"}]}}{"C58019":{"preferredName":"Urticaria, CTCAE","code":"C58019","definitions":[{"definition":"A disorder characterized by an itchy skin eruption characterized by wheals with pale interiors and well-defined red margins.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an itchy skin eruption characterized by wheals with pale interiors and well-defined red margins.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Urticaria, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Urticaria_Adverse_Reaction"},{"name":"Maps_To","value":"Urticaria"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559188"}]}}{"C143915":{"preferredName":"Uterine Anastomotic Leak, CTCAE","code":"C143915","definitions":[{"definition":"A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine anastomotic leak"},{"name":"Maps_To","value":"Uterine Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542187"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143916":{"preferredName":"Uterine Fistula, CTCAE","code":"C143916","definitions":[{"definition":"A disorder characterized by an abnormal communication between the uterus and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an abnormal communication between the uterus and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine fistula"},{"name":"Maps_To","value":"Uterine Fistula"},{"name":"NCI_META_CUI","value":"CL542188"},{"name":"Semantic_Type","value":"Finding"}]}}{"C56572":{"preferredName":"Uterine Hemorrhage, CTCAE","code":"C56572","definitions":[{"definition":"A disorder characterized by bleeding from the uterus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by bleeding from the uterus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Uterine Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterus_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Uterine Hemorrhage"},{"name":"Maps_To","value":"Uterine hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1560757"}]}}{"C143917":{"preferredName":"Uterine Infection, CTCAE","code":"C143917","definitions":[{"definition":"A disorder characterized by an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine infection"},{"name":"Maps_To","value":"Uterine Infection"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0042136"}]}}{"C143918":{"preferredName":"Uterine Obstruction, CTCAE","code":"C143918","definitions":[{"definition":"A disorder characterized by blockage of the uterine outlet.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by blockage of the uterine outlet.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Uterine Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine obstruction"},{"name":"Maps_To","value":"Uterine Obstruction"},{"name":"NCI_META_CUI","value":"CL542189"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146683":{"preferredName":"Uterine Pain, CTCAE 5.0","code":"C146683","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the uterus.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the uterus.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine pain"},{"name":"Maps_To","value":"Uterine Pain"},{"name":"NCI_META_CUI","value":"CL544741"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143919":{"preferredName":"Uterine Perforation, CTCAE","code":"C143919","definitions":[{"definition":"A disorder characterized by a rupture in the uterine wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a rupture in the uterine wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Uterine Perforation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uterine perforation"},{"name":"Maps_To","value":"Uterine Perforation"},{"name":"NCI_META_CUI","value":"CL542175"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55901":{"preferredName":"Uveitis, CTCAE","code":"C55901","definitions":[{"definition":"A disorder characterized by inflammation to the uvea of the eye.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inflammation to the uvea of the eye.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Uveitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uveitis_Adverse_Event"},{"name":"Maps_To","value":"Uveitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963266"}]}}{"C143921":{"preferredName":"Vaginal Anastomotic Leak, CTCAE","code":"C143921","definitions":[{"definition":"A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal anastomotic leak"},{"name":"Maps_To","value":"Vaginal Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542176"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143922":{"preferredName":"Vaginal Discharge, CTCAE","code":"C143922","definitions":[{"definition":"A disorder characterized by vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Discharge, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal discharge"},{"name":"Maps_To","value":"Vaginal Discharge"},{"name":"NCI_META_CUI","value":"CL542177"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146687":{"preferredName":"Vaginal Dryness, CTCAE 5.0","code":"C146687","definitions":[{"definition":"A disorder characterized by an uncomfortable feeling of itching and burning in the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by an uncomfortable feeling of itching and burning in the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Dryness, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal dryness"},{"name":"Maps_To","value":"Vaginal Dryness"},{"name":"NCI_META_CUI","value":"CL544745"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57104":{"preferredName":"Vaginal Fistula, CTCAE","code":"C57104","definitions":[{"definition":"A disorder characterized by an abnormal communication between the vagina and another organ or anatomic site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an abnormal communication between the vagina and another organ or anatomic site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Fistula, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vagina_Fistula_Adverse_Event"},{"name":"Maps_To","value":"Vaginal Fistula"},{"name":"Maps_To","value":"Vaginal fistula"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963267"}]}}{"C56573":{"preferredName":"Vaginal Hemorrhage, CTCAE","code":"C56573","definitions":[{"definition":"A disorder characterized by bleeding from the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding from the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Hemorrhage, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vagina_Hemorrhage_Adverse_Event"},{"name":"Maps_To","value":"Vaginal hemorrhage"},{"name":"Maps_To","value":"Vaginal Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2911646"}]}}{"C143924":{"preferredName":"Vaginal Infection, CTCAE","code":"C143924","definitions":[{"definition":"A disorder characterized by an infectious process involving the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal infection"},{"name":"Maps_To","value":"Vaginal Infection"},{"name":"NCI_META_CUI","value":"CL542178"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143925":{"preferredName":"Vaginal Inflammation, CTCAE","code":"C143925","definitions":[{"definition":"A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Inflammation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal inflammation"},{"name":"Maps_To","value":"Vaginal Inflammation"},{"name":"NCI_META_CUI","value":"CL542179"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146696":{"preferredName":"Vaginal Obstruction, CTCAE 5.0","code":"C146696","definitions":[{"definition":"A disorder characterized by blockage of vaginal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by blockage of vaginal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Obstruction, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal obstruction"},{"name":"Maps_To","value":"Vaginal Obstruction"},{"name":"NCI_META_CUI","value":"CL544738"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146684":{"preferredName":"Vaginal Pain, CTCAE 5.0","code":"C146684","definitions":[{"definition":"A disorder characterized by a sensation of marked discomfort in the vagina.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sensation of marked discomfort in the vagina.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Pain, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal Pain"},{"name":"Maps_To","value":"Vaginal pain"},{"name":"NCI_META_CUI","value":"CL544742"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146697":{"preferredName":"Vaginal Perforation, CTCAE 5.0","code":"C146697","definitions":[{"definition":"A disorder characterized by a rupture in the vaginal wall.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a rupture in the vaginal wall.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vaginal Perforation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal perforation"},{"name":"Maps_To","value":"Vaginal Perforation"},{"name":"NCI_META_CUI","value":"CL544739"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143926":{"preferredName":"Vaginal Stricture, CTCAE","code":"C143926","definitions":[{"definition":"A disorder characterized by a narrowing of the vaginal canal.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a narrowing of the vaginal canal.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vaginal Stricture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaginal stricture"},{"name":"Maps_To","value":"Vaginal Stricture"},{"name":"NCI_META_CUI","value":"CL542180"},{"name":"Semantic_Type","value":"Finding"}]}}{"C78703":{"preferredName":"Vaginismus","code":"C78703","definitions":[{"definition":"A disorder characterized by involuntary spasms of the pelvic floor muscles, resulting in pathologic tightness of the vaginal wall during penetration such as during sexual intercourse.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Tightness of the vaginal wall during vaginal penetration including sexual intercourse. It is caused by involuntary spasm of the pelvic floor muscles, and results in painful intercourse or failure to have intercourse. It may due to psychological conditions, trauma in the vaginal area, or vaginal infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vaginismus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vaginismus"},{"name":"Maps_To","value":"Vaginismus"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2004487"}]}}{"C143927":{"preferredName":"Vagus Nerve Disorder, CTCAE","code":"C143927","definitions":[{"definition":"A disorder characterized by dysfunction of the vagus nerve (tenth cranial nerve).","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by dysfunction of the vagus nerve (tenth cranial nerve).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vagus Nerve Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vagus nerve disorder"},{"name":"Maps_To","value":"Vagus Nerve Disorder"},{"name":"NCI_META_CUI","value":"CL542181"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143928":{"preferredName":"Vas Deferens Anastomotic Leak, CTCAE","code":"C143928","definitions":[{"definition":"A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vas Deferens Anastomotic Leak, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vas deferens anastomotic leak"},{"name":"Maps_To","value":"Vas Deferens Anastomotic Leak"},{"name":"NCI_META_CUI","value":"CL542182"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143929":{"preferredName":"Vascular Access Complication, CTCAE","code":"C143929","definitions":[{"definition":"A finding of a previously undocumented problem related to the vascular access site.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of a previously undocumented problem related to the vascular access site.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vascular Access Complication, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vascular access complication"},{"name":"Maps_To","value":"Vascular Access Complication"},{"name":"NCI_META_CUI","value":"CL542169"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143930":{"preferredName":"Vascular Disorders - Other, Specify, CTCAE","code":"C143930","synonyms":[{"termName":"Vascular Disorders - Other, Specify, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vascular Disorders - Other"},{"name":"Maps_To","value":"Vascular disorders - Other, specify"},{"name":"NCI_META_CUI","value":"CL542170"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54741":{"preferredName":"Vasculitis, CTCAE","code":"C54741","definitions":[{"definition":"A disorder characterized by inflammation involving the wall of a vessel.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by inflammation involving the wall of a vessel.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vasculitis, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vasculitis_Adverse_Event"},{"name":"Maps_To","value":"Vasculitis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963274"}]}}{"C143932":{"preferredName":"Vasovagal Reaction, CTCAE","code":"C143932","definitions":[{"definition":"A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vasovagal Reaction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vasovagal reaction"},{"name":"Maps_To","value":"Vasovagal Reaction"},{"name":"NCI_META_CUI","value":"CL542171"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143933":{"preferredName":"Venous Injury, CTCAE","code":"C143933","definitions":[{"definition":"A finding of damage to a vein.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding of damage to a vein.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Venous Injury, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Venous injury"},{"name":"Maps_To","value":"Venous Injury"},{"name":"NCI_META_CUI","value":"CL542172"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146629":{"preferredName":"Ventricular Arrhythmia, CTCAE 5.0","code":"C146629","definitions":[{"definition":"A disorder characterized by a dysrhythmia that originates in the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a dysrhythmia that originates in the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Ventricular Arrhythmia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ventricular Arrhythmia"},{"name":"Maps_To","value":"Ventricular arrhythmia"},{"name":"NCI_META_CUI","value":"CL544675"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146732":{"preferredName":"Ventricular Fibrillation, CTCAE 5.0","code":"C146732","definitions":[{"definition":"A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ventricular Fibrillation, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ventricular Fibrillation"},{"name":"Maps_To","value":"Ventricular fibrillation"},{"name":"NCI_META_CUI","value":"CL544695"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146733":{"preferredName":"Ventricular Tachycardia, CTCAE 5.0","code":"C146733","definitions":[{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Ventricular Tachycardia, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ventricular Tachycardia"},{"name":"Maps_To","value":"Ventricular tachycardia"},{"name":"NCI_META_CUI","value":"CL544696"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143935":{"preferredName":"Vertigo, CTCAE","code":"C143935","definitions":[{"definition":"A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo).","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo).","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vertigo, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vertigo"},{"name":"NCI_META_CUI","value":"CL546001"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143936":{"preferredName":"Vestibular Disorder, CTCAE","code":"C143936","definitions":[{"definition":"A disorder characterized by dizziness, imbalance, nausea, and vision problems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by dizziness, imbalance, nausea, and vision problems.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vestibular Disorder, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vestibular disorder"},{"name":"Maps_To","value":"Vestibular Disorder"},{"name":"NCI_META_CUI","value":"CL545965"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143937":{"preferredName":"Virilization, CTCAE","code":"C143937","definitions":[{"definition":"A disorder characterized by inappropriate masculinization occurring in a female or prepubertal male.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by inappropriate masculinization occurring in a female or prepubertal male.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Virilization, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Virilization"},{"name":"NCI_META_CUI","value":"CL542173"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143938":{"preferredName":"Visceral Arterial Ischemia, CTCAE","code":"C143938","definitions":[{"definition":"A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Visceral Arterial Ischemia, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Visceral arterial ischemia"},{"name":"Maps_To","value":"Visceral Arterial Ischemia"},{"name":"NCI_META_CUI","value":"CL542174"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143939":{"preferredName":"Vital Capacity Abnormal, CTCAE","code":"C143939","definitions":[{"definition":"A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vital Capacity Abnormal, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vital capacity abnormal"},{"name":"Maps_To","value":"Vital Capacity Abnormal"},{"name":"NCI_META_CUI","value":"CL542161"},{"name":"Semantic_Type","value":"Finding"}]}}{"C146677":{"preferredName":"Vitreous Hemorrhage, CTCAE 5.0","code":"C146677","definitions":[{"definition":"A disorder characterized by bleeding into the vitreous humor.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by bleeding into the vitreous humor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Vitreous Hemorrhage, CTCAE 5.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vitreous hemorrhage"},{"name":"Maps_To","value":"Vitreous Hemorrhage"},{"name":"NCI_META_CUI","value":"CL544631"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143941":{"preferredName":"Voice Alteration, CTCAE","code":"C143941","definitions":[{"definition":"A disorder characterized by a change in the sound and/or speed of the voice.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a change in the sound and/or speed of the voice.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Voice Alteration, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Voice alteration"},{"name":"Maps_To","value":"Voice Alteration"},{"name":"NCI_META_CUI","value":"CL542162"},{"name":"Semantic_Type","value":"Finding"}]}}{"C57896":{"preferredName":"Vomiting, CTCAE","code":"C57896","definitions":[{"definition":"A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vomiting, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vomiting_Adverse_Event"},{"name":"Maps_To","value":"Vomiting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963281"}]}}{"C143943":{"preferredName":"Vulval Infection, CTCAE","code":"C143943","definitions":[{"definition":"A disorder characterized by an infectious process involving the vulva.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the vulva.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Vulval Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vulval infection"},{"name":"Maps_To","value":"Vulval Infection"},{"name":"NCI_META_CUI","value":"CL542163"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143944":{"preferredName":"Watering Eyes, CTCAE","code":"C143944","definitions":[{"definition":"A disorder characterized by excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Watering Eyes, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Watering eyes"},{"name":"Maps_To","value":"Watering Eyes"},{"name":"NCI_META_CUI","value":"CL542164"},{"name":"Semantic_Type","value":"Finding"}]}}{"C55338":{"preferredName":"Weight Gain, CTCAE","code":"C55338","definitions":[{"definition":"A finding characterized by an unexpected or abnormal increase in overall body weight; for pediatrics, greater than the baseline growth curve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding characterized by an unexpected or abnormal increase in overall body weight; for pediatrics, greater than the baseline growth curve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Weight Gain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Weight_Gain_Adverse_Event"},{"name":"Maps_To","value":"Weight gain"},{"name":"Maps_To","value":"Weight Gain"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2911647"}]}}{"C55339":{"preferredName":"Weight Loss, CTCAE","code":"C55339","definitions":[{"definition":"A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Weight Loss, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Weight_Loss_Adverse_Event"},{"name":"Maps_To","value":"Weight loss"},{"name":"Maps_To","value":"Weight Loss"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2911645"}]}}{"C143947":{"preferredName":"Wheezing, CTCAE","code":"C143947","definitions":[{"definition":"A disorder characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A disorder characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Wheezing, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wheezing"},{"name":"NCI_META_CUI","value":"CL542165"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143948":{"preferredName":"White Blood Cell Decreased, CTCAE","code":"C143948","definitions":[{"definition":"A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"White Blood Cell Decreased, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"White blood cell decreased"},{"name":"Maps_To","value":"White Blood Cell Decreased"},{"name":"NCI_META_CUI","value":"CL542166"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35132":{"preferredName":"Wolff-Parkinson-White Syndrome","code":"C35132","definitions":[{"definition":"A cardiac conduction disorder characterized by an electrocardiographic finding of ventricular pre-excitation, which is a short PR interval and a long QRS interval with a delta wave. Most individuals are asymptomatic; however they can experience periods of palpitations, shortness of breath or syncope during tachycardic episodes.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by the presence of an accessory conductive pathway between the atria and the ventricles that causes premature ventricular activation.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An electrocardiographic finding of ventricular pre-excitation. The syndrome is characterized by a short PR interval and a long QRS interval with a delta wave.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Wolff-Parkinson-White Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Wolff-Parkinson-White_Syndrome"},{"name":"Maps_To","value":"Wolff-Parkinson-White Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227386"}]}}{"C143949":{"preferredName":"Wound Complication, CTCAE","code":"C143949","definitions":[{"definition":"A finding of development of a new problem at the site of an existing wound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of development of a new problem at the site of an existing wound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Wound Complication, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wound complication"},{"name":"Maps_To","value":"Wound Complication"},{"name":"NCI_META_CUI","value":"CL542167"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143950":{"preferredName":"Wound Dehiscence, CTCAE","code":"C143950","definitions":[{"definition":"A finding of separation of the approximated margins of a surgical wound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of separation of the approximated margins of a surgical wound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Wound Dehiscence, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wound dehiscence"},{"name":"Maps_To","value":"Wound Dehiscence"},{"name":"NCI_META_CUI","value":"CL542168"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143951":{"preferredName":"Wound Infection, CTCAE","code":"C143951","definitions":[{"definition":"A disorder characterized by an infectious process involving the wound.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]},{"definition":"A disorder characterized by an infectious process involving the wound.","type":"ALT_DEFINITION","source":"CTCAE 5.0"}],"synonyms":[{"termName":"Wound Infection, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wound infection"},{"name":"Maps_To","value":"Wound Infection"},{"name":"NCI_META_CUI","value":"CL542153"},{"name":"Semantic_Type","value":"Finding"}]}}{"C143952":{"preferredName":"Wrist Fracture, CTCAE","code":"C143952","definitions":[{"definition":"A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.","type":"ALT_DEFINITION","source":"CTCAE 5.0"},{"definition":"A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"CTCAE 5.0"}]}],"synonyms":[{"termName":"Wrist Fracture, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wrist fracture"},{"name":"Maps_To","value":"Wrist Fracture"},{"name":"NCI_META_CUI","value":"CL542154"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54986":{"preferredName":"Cardiac Ischemia or Infarction, CTCAE","code":"C54986","synonyms":[{"termName":"Cardiac Ischemia or Infarction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cardiac_Ischemia_or_Infarction_Adverse_Event"},{"name":"Maps_To","value":"Cardiac Ischemia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1556254"}]}}{"C55159":{"preferredName":"Glomerular Filtration Rate, CTCAE","code":"C55159","synonyms":[{"termName":"Glomerular Filtration Rate, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glomerular_Filtration_Rate_Adverse_Event"},{"name":"Maps_To","value":"Glomerular Filtration Rate Decreased"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1561549"}]}}{"C56095":{"preferredName":"Joint Pain, CTCAE","code":"C56095","synonyms":[{"termName":"Joint Pain, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Joint_Pain_Adverse_Event"},{"name":"Maps_To","value":"Joint Pain"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963066"}]}}{"C58010":{"preferredName":"Rash Desquamation, CTCAE","code":"C58010","synonyms":[{"termName":"Rash Desquamation, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Rash_Desquamation_Adverse_Event"},{"name":"Maps_To","value":"Rash/Desquamation"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1559142"}]}}{"C57074":{"preferredName":"Renal Failure, CTCAE","code":"C57074","synonyms":[{"termName":"Renal Failure, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Failure_Adverse_Event"},{"name":"Maps_To","value":"Renal Failure"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963154"}]}}{"C57086":{"preferredName":"Ureter Obstruction, CTCAE","code":"C57086","synonyms":[{"termName":"Ureter Obstruction, CTCAE","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ureter_Obstruction_Adverse_Event"},{"name":"Maps_To","value":"Ureteral Obstruction"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1963260"}]}}{"C41338":{"preferredName":"Mild Adverse Event","code":"C41338","definitions":[{"definition":"A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mild Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 1 Mild Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Mild_Adverse_Event"},{"name":"Maps_To","value":"Grade 1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1513302"}]}}{"C41339":{"preferredName":"Moderate Adverse Event","code":"C41339","definitions":[{"definition":"A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderate Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 2 Moderate Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Moderate_Adverse_Event"},{"name":"Maps_To","value":"Grade 2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1513374"}]}}{"C41340":{"preferredName":"Severe Adverse Event","code":"C41340","definitions":[{"definition":"A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Severe Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Grade 3 Severe Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Severe_Adverse_Event"},{"name":"Maps_To","value":"Grade 3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1519275"}]}}{"C84266":{"preferredName":"Life Threatening Adverse Event","code":"C84266","definitions":[{"definition":"An adverse event that has life-threatening consequences; for which urgent intervention is indicated; that puts the patient at risk of death at the time of the event if immediate intervention is not undertaken.","type":"DEFINITION","source":"NCI"},{"definition":"Any adverse drug experience that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred (i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death). [FDA 21 CFR 312.32; ICH-E2A]","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Life Threatening Adverse Event","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Grade 4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1517874"}]}}{"C48275":{"preferredName":"Death Related to Adverse Event","code":"C48275","definitions":[{"definition":"The termination of life as a result of an adverse event. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The termination of life associated with an adverse event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Death Related to Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Fatal","termGroup":"SY","termSource":"NCI"},{"termName":"Grade 5 Death Related to Adverse Event","termGroup":"SY","termSource":"NCI"},{"termName":"Standard Toxicity Grade 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Death_Related_to_Adverse_Event"},{"name":"Maps_To","value":"Grade 5"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1705232"}]}}{"C26711":{"preferredName":"Candidiasis","code":"C26711","definitions":[{"definition":"A condition in which Candida albicans, a type of yeast, grows out of control in moist skin areas of the body. It is usually a result of a weakened immune system, but can be a side effect of chemotherapy or treatment with antibiotics. Thrush usually affects the mouth (oral thrush); however, rarely, it spreads throughout the entire body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An infection that is caused by one of many species of the genus Candida.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Infection with the organism Candida.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Candidiasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Candidiasis"},{"name":"Maps_To","value":"Candidiasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0006840"}]}}{"C84642":{"preferredName":"Coccidioidomycosis","code":"C84642","definitions":[{"definition":"A fungal infection caused by Coccidioides immitis. Affected individuals usually have mild flu-like symptoms. However, pneumonia and systemic involvement with the formation of abscesses may develop as complications of the disease.","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by Coccidioides immitis, which typically manifests as a flu-like illness, although pneumonia and systemic infection can occur.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Coccidioidomycosis","termGroup":"PT","termSource":"NCI"},{"termName":"Valley Fever","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Coccidioidomycosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009186"}]}}{"C2967":{"preferredName":"Cryptococcosis","code":"C2967","definitions":[{"definition":"An acute or chronic, localized or disseminated infection by Cryptococcus neoformans.  Sites of involvement include the lungs, central nervous system and meninges, skin, and visceral organs.--2004","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by Cryptococcus neoformans, and in some geographic areas by Cryptococcus gattii, which can be either acute or chronic, and either localized or disseminated; it typically involves the lungs, though disseminated disease can occur.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Cryptococcosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cryptococcosis"},{"name":"Maps_To","value":"Cryptococcosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0010414"}]}}{"C174107":{"preferredName":"Chronic Intestinal Cryptosporidiosis","code":"C174107","definitions":[{"definition":"A chronic infection caused by Cryptosporidium parvum or hominis that manifests as enteritis. It usually occurs in immunocompromised patients including persons with AIDS, transplant recipients, patients receiving cytotoxic chemotherapy, and patients with hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Intestinal Cryptosporidiosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cryptosporidiosis, Chronic Intestinal"},{"name":"NCI_META_CUI","value":"CL1407753"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C53649":{"preferredName":"Cytomegaloviral Infection","code":"C53649","definitions":[{"definition":"A herpesvirus infection caused by Cytomegalovirus. Healthy individuals generally do not produce symptoms. However, the infection may be life-threatening in affected immunocompromised patients. The virus may cause retinitis, esophagitis, gastritis, and colitis. Morphologically, it is characterized by the presence of intranuclear inclusion bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytomegaloviral Infection","termGroup":"PT","termSource":"NCI"},{"termName":"CMV Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Cytomegalovirus Infection","termGroup":"SY","termSource":"NCI"},{"termName":"HCMV Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cytomegaloviral_Infection"},{"name":"Maps_To","value":"Cytomegaloviral disease"},{"name":"Maps_To","value":"Cytomegaloviral disease, unspecified"},{"name":"Maps_To","value":"Cytomegalovirus"},{"name":"Maps_To","value":"Cytomegalovirus (CMV)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0010823"}]}}{"C26920":{"preferredName":"Encephalopathy","code":"C26920","definitions":[{"definition":"A disorder characterized by a pathologic process involving the brain.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A disorder of the brain that can be caused by disease, injury, drugs, or chemicals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A functional and/or structural disorder of the brain caused by diseases (e.g. liver disease, kidney disease), medications, chemicals, and injuries.","type":"DEFINITION","source":"NCI"},{"definition":"A functional and/or structural disorder of the brain that is acquired or congenital and characterised by mental and neurological symptoms.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Diffuse disease of the brain that alters function and/or structure of the brain and is characterized by an altered mental state.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Encephalopathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Encephalopathy"},{"name":"Maps_To","value":"Encephalopathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4013377"},{"name":"xRef","value":"IMDRF:E0115"}]}}{"C155871":{"preferredName":"Herpes Simplex Virus Infection","code":"C155871","definitions":[{"definition":"An infection that is caused by herpes simplex virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Herpes Simplex Virus Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HSV Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Herpes"},{"name":"Maps_To","value":"Herpes Simplex Virus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019340"}]}}{"C77201":{"preferredName":"Histoplasmosis","code":"C77201","definitions":[{"definition":"A disease caused by the fungus Histoplasma capsulatum. It primarily affects the lungs but can also occur as a disseminated disease that affects additional organs. The acute respiratory disease has symptoms similar to those of a cold or flu and it usually resolves without treatment in healthy individuals. The disseminated form is generally fatal if untreated.","type":"DEFINITION","source":"NCI"},{"definition":"An often self-limited infection that is caused by Histoplasma capsulatum, which typically manifests as a flu-like illness, but severe disseminated disease can occur.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Histoplasmosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Histoplasmosis"},{"name":"Maps_To","value":"Histoplasmosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0677640"}]}}{"C4076":{"preferredName":"Isosporiasis","code":"C4076","definitions":[{"definition":"A protozoan infection that is caused by Cystoisospora belli (formerly known as Isospora belli), which is most commonly acquired from contaminated food or water, and which is characterized by watery diarrhea and abdominal pain.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An intestinal infection with Isospora belli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isosporiasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Isosporiasis"},{"name":"Maps_To","value":"Isosporiasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0311386"}]}}{"C36197":{"preferredName":"Mycobacterium Avium Infection","code":"C36197","definitions":[{"definition":"An infection that is caused by Mycobacterium avium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium Avium Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mycobacterium_Avium_Infection"},{"name":"Maps_To","value":"Mycobacterium avium Complex"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026916"}]}}{"C128377":{"preferredName":"Tuberculosis Infection","code":"C128377","definitions":[{"definition":"The asymptomatic presence of Mycobacterium tuberculosis in the body, which is determined by a positive result to a tuberculin skin test or interferon-gamma release assay.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The asymptomatic presence of Mycobacterium tuberculosis in the body, which is determined by a positive result to a tuberculin skin test or interferon-gamma release assay.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuberculosis Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Mycobacterium tuberculosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1609538"}]}}{"C26831":{"preferredName":"Mycobacterial Infection","code":"C26831","definitions":[{"definition":"Infection due to organisms from the genus Mycobacteria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterial Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Mycobacterium Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mycobacterial_Infection"},{"name":"Maps_To","value":"Mycobacterium, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026918"}]}}{"C171147":{"preferredName":"Nocardiosis","code":"C171147","definitions":[{"definition":"A bacterial infection caused by members of the gram-positive bacilli genus Nocardia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nocardiosis","termGroup":"PT","termSource":"NCI"},{"termName":"Nocardial Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nocardiosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0028242"}]}}{"C3334":{"preferredName":"Pneumocystis Pneumonia","code":"C3334","definitions":[{"definition":"A severe, progressive pneumonia caused by Pneumocystis jirovecii, which is usually seen in immunologically compromised individuals.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months.  Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pneumocystis Pneumonia","termGroup":"PT","termSource":"NCI"},{"termName":"PCP","termGroup":"AB","termSource":"NCI"},{"termName":"PJP","termGroup":"AB","termSource":"NCI"},{"termName":"Pneumocystis","termGroup":"SY","termSource":"NCI"},{"termName":"Pneumocystis carinii Pneumonia","termGroup":"AQS","termSource":"NCI"},{"termName":"Pneumocystis jirovecii Pneumonia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pneumocystis_Carinii_Pneumonia"},{"name":"Maps_To","value":"Pneumocystis Pneumonia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1535939"}]}}{"C3333":{"preferredName":"Pneumonia","code":"C3333","definitions":[{"definition":"A condition resulting from infection in one or both lungs.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A severe inflammation of the lungs in which the alveoli (tiny air sacs) are filled with fluid. This may cause a decrease in the amount of oxygen that blood can absorb from air breathed into the lung. Pneumonia is usually caused by infection but may also be caused by radiation therapy, allergy, or irritation of lung tissue by inhaled substances. It may involve part or all of the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An acute and/or chronic inflammation focally or diffusely affecting the lung parenchyma.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pneumonia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pneumonia"},{"name":"Maps_To","value":"Pneumonia"},{"name":"Maps_To","value":"Pneumonia, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0032285"},{"name":"xRef","value":"IMDRF:E0733"}]}}{"C26815":{"preferredName":"Progressive Multifocal Leukoencephalopathy","code":"C26815","definitions":[{"definition":"A demyelinating central nervous system disease caused by reactivation of the polyomavirus JC, which results in a lytic infection of oligodendrocytes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A progressive demyelination within the central nervous system associated with reactivation of a latent JC virus infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progressive Multifocal Leukoencephalopathy","termGroup":"PT","termSource":"NCI"},{"termName":"PML","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Progressive_Multifocal_Leukoencephalopathy"},{"name":"Maps_To","value":"Progressive Multifocal Leukoencephalopathy"},{"name":"Maps_To","value":"Progressive multifocal leukoencephalopathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0023524"}]}}{"C171146":{"preferredName":"Salmonella Septicemia","code":"C171146","definitions":[{"definition":"Sepsis due to the presence of Salmonella bacteria in the bloodstream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salmonella Septicemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Salmonella Septicemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3163971"}]}}{"C3418":{"preferredName":"Toxoplasmosis","code":"C3418","definitions":[{"definition":"A parasitic disease contracted by the ingestion or fetal transmission of toxoplasma gondii.","type":"DEFINITION","source":"NCI"},{"definition":"A protozoan infection that is acquired by the ingestion or maternal-to-fetal transmission of Toxoplasma gondii.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Toxoplasmosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Toxoplasmosis"},{"name":"Maps_To","value":"Toxoplasmosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0040558"}]}}{"C171148":{"preferredName":"Wasting Syndrome","code":"C171148","definitions":[{"definition":"Pathologic loss of more than 10% of body weight concurrent with 30 or more days of either diarrhea or weakness and fever.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wasting Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wasting Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0043046"}]}}{"C3093":{"preferredName":"Hemophilia","code":"C3093","definitions":[{"definition":"A coagulation disorder characterized by the partial or complete absence of factor VIII or IX activity in the blood.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A deficiency or abnormality of a blood coagulation factor characterized by the tendency to hemorrhage. Hemophilia is typically a hereditary disorder but, rarely, may be acquired. Inherited coagulation factor-deficient hemophilias include hemophilia A or classic hemophilia (hereditary factor VIII deficiency) hemophilia B or Christmas disease (hereditary factor IX deficiency), and hemophilia C (hereditary factor XI deficiency). Factor VIII inhibitors may occur spontaneously as autoantibodies, resulting in acquired hemophilia known as acquired factor VIII deficiency. Approximately 10% of patients with acquired hemophilia have an underlying malignancy.","type":"DEFINITION","source":"NCI"},{"definition":"Group of hereditary disorders in which affected individuals fail to make enough of certain proteins needed to form blood clots.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hemophilia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hemophilia"},{"name":"Maps_To","value":"Hemophiliac"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0684275"}]}}{"C154862":{"preferredName":"Heterosexual Contact","code":"C154862","definitions":[{"definition":"Sexual contact with a member of the opposite sex.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Sexual contact with someone of the opposite sex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heterosexual Contact","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heterosexual Contact"},{"name":"NCI_META_CUI","value":"CL555675"},{"name":"Semantic_Type","value":"Individual Behavior"}]}}{"C154863":{"preferredName":"Homosexual Contact","code":"C154863","definitions":[{"definition":"Sexual contact with a member of the same sex.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Sexual contact with someone of the same sex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Homosexual Contact","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Homosexual Contact"},{"name":"NCI_META_CUI","value":"CL555676"},{"name":"Semantic_Type","value":"Individual Behavior"}]}}{"C84367":{"preferredName":"Intravenous Drug User","code":"C84367","definitions":[{"definition":"A person who injects recreational drugs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intravenous Drug User","termGroup":"PT","termSource":"NCI"},{"termName":"IDU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intravenous Drug User"},{"name":"Semantic_Type","value":"Population Group"},{"name":"UMLS_CUI","value":"C0242566"}]}}{"C159672":{"preferredName":"Risk Factor History Negative","code":"C159672","definitions":[{"definition":"The determination that an individual's risk factor history is negative.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Risk Factor History Negative","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"None"},{"name":"NCI_META_CUI","value":"CL552484"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C171149":{"preferredName":"Transfusion Recipient","code":"C171149","definitions":[{"definition":"A person who receives a direct injection of whole blood or blood products derived from a blood donor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transfusion Recipient","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transfusion Recipient"},{"name":"NCI_META_CUI","value":"CL1405383"},{"name":"Semantic_Type","value":"Human"}]}}{"C26808":{"preferredName":"Acute Renal Failure","code":"C26808","definitions":[{"definition":"A disorder characterized by the acute loss of renal function and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Deterioration of renal function, occurring within a time frame of hours to weeks, that results in failure to maintain normal fluid, electrolyte, waste products, and/or acid-base balance.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Sudden and sustained deterioration of the kidney function characterized by decreased glomerular filtration rate, increased serum creatinine or oliguria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Renal Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Kidney Injury","termGroup":"SY","termSource":"NCI"},{"termName":"AKI","termGroup":"AB","termSource":"NCI"},{"termName":"ARF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Renal_Failure"},{"name":"Maps_To","value":"Acute kidney injury"},{"name":"Maps_To","value":"Acute Renal Failure"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0022660"}]}}{"C26691":{"preferredName":"Adrenocortical Insufficiency","code":"C26691","definitions":[{"definition":"A disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison's disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency).","type":"DEFINITION","source":"NCI"},{"definition":"Subnormal concentration of cortisol, with or without mineralocorticoid insufficiency.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Adrenocortical Insufficiency","termGroup":"PT","termSource":"NCI"},{"termName":"Adrenal Cortical Insufficiency","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Gland Insufficiency","termGroup":"SY","termSource":"NCI"},{"termName":"Adrenal Insufficiency","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Adrenal_Gland_Insufficiency"},{"name":"Maps_To","value":"Adrenal insufficiency"},{"name":"Maps_To","value":"Adrenocortical Insufficiency"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4012286"}]}}{"C114476":{"preferredName":"Allergic Reaction","code":"C114476","definitions":[{"definition":"A disorder characterized by an adverse local or general response from exposure to an allergen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A hypersensitive immune reaction to a substance that normally is harmless or would not cause an immune response in most people. An allergic response may cause harmful symptoms such as itching or inflammation or tissue injury.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A hypersensitivity reaction triggered by exposure to a previously encountered foreign substance to which the individual has formed antibodies.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allergic Reaction","termGroup":"PT","termSource":"NCI"},{"termName":"Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Allergic reaction"},{"name":"Maps_To","value":"Allergies"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1527304"}]}}{"C84397":{"preferredName":"Alpha-1 Antitrypsin Deficiency","code":"C84397","definitions":[{"definition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-1 Antitrypsin Deficiency","termGroup":"PT","termSource":"NCI"},{"termName":"A-1ATD","termGroup":"AB","termSource":"NCI"},{"termName":"A1AD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Alpha-1 Antitrypsin"},{"name":"Maps_To","value":"Alpha-1 Antitrypsin Deficiency"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0221757"}]}}{"C2869":{"preferredName":"Anemia","code":"C2869","definitions":[{"definition":"A condition in which the number of red blood cells is below normal.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by an reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally low level of hemoglobin in the blood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Anemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Anemia"},{"name":"Maps_To","value":"Anemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229468"},{"name":"xRef","value":"IMDRF:E0301"}]}}{"C26696":{"preferredName":"Anxiety","code":"C26696","definitions":[{"definition":"An emotional state characterized by excessive worried thoughts that may be accompanied by restlessness, tension, tachycardia, increased blood pressure, and/or dyspnea.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","type":"DEFINITION","source":"NCI"},{"definition":"Apprehension or uneasiness which may be accompanied by restlessness, tension, tachycardia, and dyspnea.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Feelings of fear, dread, and uneasiness that may occur as a reaction to stress. A person with anxiety may sweat, feel restless and tense, and have a rapid heart beat. Extreme anxiety that happens often over time may be a sign of an anxiety disorder.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anxiety","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Anxiety"},{"name":"Maps_To","value":"Anxiety"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C4228281"},{"name":"xRef","value":"IMDRF:E020201"}]}}{"C2881":{"preferredName":"Arrhythmia","code":"C2881","definitions":[{"definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","type":"DEFINITION","source":"NCI"},{"definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Arrhythmia","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiac Arrhythmia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Arrhythmia"},{"name":"Maps_To","value":"Arrhythmia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3275765"},{"name":"xRef","value":"IMDRF:E0601"}]}}{"C2883":{"preferredName":"Arthritis","code":"C2883","definitions":[{"definition":"A disease that causes inflammation and pain in the joints.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by inflammation involving a joint.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An inflammatory process affecting a joint.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the joint tissues of any etiology. Signs and symptoms may include pain, swelling, warmth, guarding, limited range of motion or overlying erythema.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Arthritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Arthritis"},{"name":"Maps_To","value":"Arthritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014799"},{"name":"xRef","value":"IMDRF:E1602"}]}}{"C28397":{"preferredName":"Asthma","code":"C28397","definitions":[{"definition":"A chronic disease in which the bronchial airways in the lungs become narrowed and swollen, making it difficult to breathe. Symptoms include wheezing, coughing, tightness in the chest, shortness of breath, and rapid breathing. An attack may be brought on by pet hair, dust, smoke, pollen, mold, exercise, cold air, or stress.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A chronic respiratory disease caused by obstruction of the bronchi and small airways, and characterized by wheezing and shortness of breath.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asthma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Asthma"},{"name":"Maps_To","value":"Asthma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229310"},{"name":"xRef","value":"IMDRF:E0706"}]}}{"C2887":{"preferredName":"Ataxia Telangiectasia Syndrome","code":"C2887","definitions":[{"definition":"A rare, inherited, progressive, degenerative disease of childhood that causes loss of muscle control, a weakened immune system, and an increased risk of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ataxia Telangiectasia Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Ataxia Telangiectasia","termGroup":"SY","termSource":"NCI"},{"termName":"Ataxia-Telangiectasia Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Louis-Bar Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ataxia_Telangiectasia_Syndrome"},{"name":"Maps_To","value":"Ataxia-telangiectasia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004135"}]}}{"C50466":{"preferredName":"Atrial Fibrillation","code":"C50466","definitions":[{"definition":"A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A disorder characterized by an electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregular ventricular response. (CDISC)","type":"DEFINITION","source":"NCI"},{"definition":"An irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atrial.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Atrial Fibrillation","termGroup":"PT","termSource":"NCI"},{"termName":"AF","termGroup":"AB","termSource":"NCI"},{"termName":"AFib","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Atrial_Fibrillation"},{"name":"Maps_To","value":"Atrial fibrillation"},{"name":"Maps_To","value":"Atrial Fibrillation"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4015486"},{"name":"xRef","value":"IMDRF:E060102"}]}}{"C37864":{"preferredName":"Autoimmune Lymphoproliferative Syndrome","code":"C37864","definitions":[{"definition":"An autoimmune hematologic disorder characterized by autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatomegaly and splenomegaly. Patients are at an increased risk of developing Hodgkin and non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autoimmune Lymphoproliferative Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"ALPS","termGroup":"AB","termSource":"NCI"},{"termName":"Canale-Smith Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Autoimmune_Lymphoproliferative_Syndrome"},{"name":"Maps_To","value":"Autoimmune Lymphoproliferative Syndrome (ALPS)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1328840"}]}}{"C118385":{"preferredName":"Avascular Necrosis","code":"C118385","definitions":[{"definition":"Tissue death resulting from an interruption to the blood supply.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Tissue death resulting from an interruption to the blood supply.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avascular Necrosis","termGroup":"PT","termSource":"NCI"},{"termName":"AVN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Avascular necrosis"},{"name":"Maps_To","value":"Avascular Necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3538978"}]}}{"C86172":{"preferredName":"Bacteroides fragilis","code":"C86172","definitions":[{"definition":"A species of obligately anaerobic, Gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is nonmotile, non-spore forming, indole positive, produces hydrogen sulfide, does not reduce nitrate, hydrolyzes esculin and starch, does not ferment trehalose, melezitose or arabinose, and is penicillin resistant. B. fragilis is commensal and part of the normal human gastrointestinal tract flora, but may become pathogenic in other body regions.","type":"DEFINITION","source":"NCI"},{"definition":"Any bacterial organism that can be assigned to the species Bacteroides fragilis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Bacteroides fragilis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bacteroides fragilis"},{"name":"NCBI_Taxon_ID","value":"817"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"UMLS_CUI","value":"C0004663"}]}}{"C2891":{"preferredName":"Barrett Esophagus","code":"C2891","definitions":[{"definition":"A condition in which the cells lining the lower part of the esophagus have changed or been replaced with abnormal cells that could lead to cancer of the esophagus. The backing up of stomach contents (reflux) may irritate the esophagus and, over time, cause Barrett's esophagus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Esophageal lesion lined with columnar metaplastic epithelium which is flat or villiform. Barrett epithelium is characterized by two different types of cells: goblet cells and columnar cells. The symptomatology of Barrett esophagus is that of gastro-esophageal reflux. It is the precursor of most esophageal adenocarcinomas.  (WHO)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Barrett Esophagus","termGroup":"PT","termSource":"NCI"},{"termName":"Barrett's Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"BE","termGroup":"AB","termSource":"NCI"},{"termName":"CELLO","termGroup":"AB","termSource":"NCI"},{"termName":"CLE","termGroup":"AB","termSource":"NCI"},{"termName":"Columnar Epithelial-Lined Lower Esophagus","termGroup":"SY","termSource":"NCI"},{"termName":"Columnar-Lined Esophagus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Barrett_s_Esophagus"},{"name":"Maps_To","value":"Barrett oesophagus"},{"name":"Maps_To","value":"Barrett's Esophagus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004763"}]}}{"C34415":{"preferredName":"Beckwith-Wiedemann Syndrome","code":"C34415","definitions":[{"definition":"A complex syndrome resulting from various genetic and epigenetic anomalies of the 11p15.5 chromosomal region, leading to dysregulated expression of imprinted genes. Specific genes involved include CDKN1C, H19, IGF2, and KCNQ1OT1. One of the key genetic anomalies is an imbalance between the paternally expressed IGF2 growth enhancer gene and the maternally expressed H19 growth suppressor gene, leading to fetal and postnatal overgrowth. The condition is typically characterized by macrosomia, macroglossia, umbilical hernia or more severe abdominal wall anomalies such as omphalocele, ear lobe indentations, and hypoglycemia associated with hyperinsulinemia due to pancreatic islet cell hyperplasia. Patients with this syndrome have an increased risk for development of embryonal tumors (particularly Wilms tumor and hepatoblastoma) and adrenal cortex carcinoma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A genetic syndrome caused by abnormalities in chromosome 11. It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia. Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, rhabdomyosarcoma) and adrenal cortex carcinomas.","type":"DEFINITION","source":"NCI"},{"definition":"A rare, overgrowth disorder in which babies are large at birth and may develop low blood sugar. Other common symptoms are a large tongue, large internal organs, and defects of the abdominal wall near the navel. Beckwith-Wiedemann syndrome increases the risk of developing certain cancers, especially Wilms tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Beckwith-Wiedemann Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Beckwith-Wiedemann_Syndrome"},{"name":"Maps_To","value":"Beckwith-Wiedemann"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004903"}]}}{"C34416":{"preferredName":"Behcet Syndrome","code":"C34416","definitions":[{"definition":"A rare chronic inflammatory disorder of unknown etiology. It is characterized by the development of ulcers in the mouth and genital region and uveitis. Other signs and symptoms include arthritis, deep vein thrombosis and superficial thrombophlebitis.","type":"DEFINITION","source":"NCI"},{"definition":"A systemic vasculitis affecting both arteries and veins which manifests primarily as recurrent oral and genital ulceration, uveitis, characteristic rash, and arthritis. It may also cause central nervous system disease, gastrointestinal inflammation or ulceration, or thrombophlebitis.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Behcet Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Behcet's Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Behçet Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Behcet_s_Syndrome"},{"name":"Maps_To","value":"Behcet's Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004943"}]}}{"C2899":{"preferredName":"Biliary System Disorder","code":"C2899","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biliary System Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Biliary Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Biliary Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Biliary_Tract_Disorder"},{"name":"Maps_To","value":"Biliary Disorder"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3275124"}]}}{"C27083":{"preferredName":"Blood Clot","code":"C27083","definitions":[{"definition":"A mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aggregation of blood factors, primarily platelets and fibrin with entrapment of cellular elements, frequently causing vascular obstruction at the point of its formation.","type":"DEFINITION","source":"NCI"},{"definition":"An aggregation of platelets and fibrin within the cardiovascular system.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An intravascular aggregation of blood components, primarily platelets and fibrin with entrapment of cellular elements, which is attached to the vessel wall.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The formation of a blood clot in the lumen of a vessel or heart chamber","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The formation of a blood clot in the lumen of a vessel or heart chamber.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Blood Clot","termGroup":"PT","termSource":"NCI"},{"termName":"Thrombus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Blood_Clot"},{"name":"Maps_To","value":"Blood Clots"},{"name":"Maps_To","value":"Clot blood"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0087086"},{"name":"xRef","value":"IMDRF:E0514"}]}}{"C3046":{"preferredName":"Fracture","code":"C3046","definitions":[{"definition":"A finding of traumatic injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A traumatic injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A traumatic injury to the bone in which the continuity of the bone is broken.","type":"DEFINITION","source":"NCI"},{"definition":"A traumatic or pathological injury to the bone in which the continuity of the bone is broken.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Localized disruption of bone or tooth structure resulting in partial or complete discontinuity. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fracture","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Fracture","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Fracture"},{"name":"Maps_To","value":"Bone Fracture(s)"},{"name":"Maps_To","value":"Fracture"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3808973"},{"name":"xRef","value":"IMDRF:E1603"}]}}{"C2911":{"preferredName":"Bronchitis","code":"C2911","definitions":[{"definition":"A disorder characterized by an infectious process involving the bronchi.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An acute or chronic inflammatory process affecting the bronchi.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An acute or chronic inflammatory process affecting the bronchi.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation (swelling and reddening) of the bronchi.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Inflammation of the bronchi.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Bronchitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Bronchitis"},{"name":"Maps_To","value":"Bronchitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0006277"},{"name":"xRef","value":"IMDRF:E0708"}]}}{"C333":{"preferredName":"Calcium Channel Blocker","code":"C333","definitions":[{"definition":"A pharmaceutical agent that inhibits the movement of calcium across through calcium channels in the cell membrane, preventing or decreasing the amount of calcium able to enter the cell. These drugs are used for their chronotropic, antihypertensive and vasodilatory effects.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A pharmaceutical agent that inhibits the movement of calcium across through calcium channels in the cell membrane, preventing or decreasing the amount of calcium able to enter the cell. These drugs are used for their chronotropic, antihypertensive and vasodilatory effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcium Channel Blocker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:38215"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Calcium_Channel_Blocker"},{"name":"Maps_To","value":"Calcium Channel Blockers"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0006684"}]}}{"C26713":{"preferredName":"Cataract","code":"C26713","definitions":[{"definition":"A condition in which the lens of the eye becomes cloudy. Symptoms include blurred, cloudy, or double vision; sensitivity to light; and difficulty seeing at night. Without treatment, cataracts can cause blindness. There are many different types and causes of cataracts. They may occur in people of all ages, but are most common in the elderly.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Opacity of the crystalline lens.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cataract","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Cataract"},{"name":"Maps_To","value":"Cataract"},{"name":"Maps_To","value":"Cataracts"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0086543"},{"name":"xRef","value":"IMDRF:E0802"}]}}{"C26714":{"preferredName":"Celiac Disease","code":"C26714","definitions":[{"definition":"A digestive disease that is caused by an immune response to a protein called gluten, which is found in wheat, rye, barley, and oats. Celiac disease damages the lining of the small intestine and interferes with the absorption of nutrients from food. A person with celiac disease may become malnourished no matter how much food is consumed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Celiac Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Celiac Sprue","termGroup":"SY","termSource":"NCI"},{"termName":"Gluten-Induced Enteropathy","termGroup":"SY","termSource":"NCI"},{"termName":"Non Tropical Sprue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Celiac_Disease"},{"name":"Maps_To","value":"Celiac Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007570"}]}}{"C2938":{"preferredName":"Cerebrovascular Disorder","code":"C2938","definitions":[{"definition":"A disorder resulting from inadequate blood flow in the vessels that supply the brain. Representative examples include cerebrovascular ischemia, cerebral embolism, and cerebral infarction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerebrovascular Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebrovascular Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cerebrovascular_Disorder"},{"name":"Maps_To","value":"Cerebrovascular Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007820"}]}}{"C34463":{"preferredName":"Chlamydial Infection","code":"C34463","definitions":[{"definition":"An infection that is caused by Chlamydia trachomatis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlamydial Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chlamydial_Infection"},{"name":"Maps_To","value":"Chlamydia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0008149"}]}}{"C122822":{"preferredName":"Cholelithiasis","code":"C122822","definitions":[{"definition":"The presence of calculi in the gallbladder.","type":"DEFINITION","source":"NCI"},{"definition":"The presence of calculi in the gallbladder.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Cholelithiasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Cholelithiasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3806112"}]}}{"C9438":{"preferredName":"Chronic Renal Failure","code":"C9438","definitions":[{"definition":"Impairment of the renal function due to chronic kidney damage.","type":"DEFINITION","source":"NCI"},{"definition":"Impairment of the renal function due to chronic kidney damage.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Chronic Renal Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"CRF - Chronic Renal Failure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Chronic_Renal_Failure"},{"name":"Maps_To","value":"Chronic renal failure"},{"name":"Maps_To","value":"Chronic Renal Failure"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3810486"}]}}{"C174112":{"preferredName":"Chronic Systemic Steroid Use","code":"C174112","definitions":[{"definition":"An indication that the subject has been using a systemic steroid at the prescribed dose for a long period of time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Systemic Steroid Use","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic Systemic Steroid Use"},{"name":"NCI_META_CUI","value":"CL1407748"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C2951":{"preferredName":"Cirrhosis","code":"C2951","definitions":[{"definition":"A chronic degenerative disease of the liver characterized by parenchymal nodularity and fibrosis.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","type":"DEFINITION","source":"NCI"},{"definition":"A type of chronic, progressive liver disease in which liver cells are replaced by scar tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cirrhosis","termGroup":"PT","termSource":"NCI"},{"termName":"Liver Cirrhosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cirrhosis"},{"name":"Maps_To","value":"Cirrhosis"},{"name":"Maps_To","value":"Cirrhosis of liver"},{"name":"Maps_To","value":"Cirrhosis, Unknown Etiology"},{"name":"Maps_To","value":"Liver Cirrhosis (Liver Disease)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4228437"}]}}{"C2954":{"preferredName":"Colon Polyp","code":"C2954","definitions":[{"definition":"A polypoid lesion that arises from the colon and protrudes into the lumen.  This group includes adenomatous polyps, serrated polyps, and hamartomatous polyps.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormal growths of tissue in the lining of the bowel.  Polyps are a risk factor for colon cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colon Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Colonic Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of the Colon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colon_Polyp"},{"name":"Maps_To","value":"Colon Polyps"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009376"}]}}{"C26725":{"preferredName":"Common Variable Immunodeficiency","code":"C26725","definitions":[{"definition":"A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally low level of functional immunoglobulins in the blood that is not associated with a primary immunodeficiency.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Common Variable Immunodeficiency","termGroup":"PT","termSource":"NCI"},{"termName":"Acquired Agammaglobulinemia","termGroup":"SY","termSource":"NCI"},{"termName":"Secondary Hypogammaglobulinemia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Common_Variable_Immunodeficiency"},{"name":"Maps_To","value":"Common variable immune deficiency (CVID)"},{"name":"Maps_To","value":"Common Variable Immunodeficiency"},{"name":"Maps_To","value":"Secondary acquired hypogammaglobulinaemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009447"}]}}{"C3080":{"preferredName":"Congestive Heart Failure","code":"C3080","definitions":[{"definition":"Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.","type":"DEFINITION","source":"NCI"},{"definition":"Inability of the heart to pump blood adequately to fill tissue metabolic requirements or the ability to do so only at an elevated filling pressure.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Weakness of the heart muscle that leads to a buildup of fluid in body tissues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Congestive Heart Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiac Failure Congestive","termGroup":"SY","termSource":"NCI"},{"termName":"CHF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Congestive_Heart_Failure"},{"name":"Maps_To","value":"Congestive Heart Failure (CHF)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3551869"},{"name":"xRef","value":"IMDRF:E0611"}]}}{"C26729":{"preferredName":"Connective Tissue Disorder","code":"C26729","definitions":[{"definition":"A disorder characterized by abnormalities in one or more of the elements of the connective tissues, typically associated with genetic defects.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A non-neoplastic or neoplastic disorder that affects the connective tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A non-neoplastic or neoplastic disorder that affects the connective tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Connective Tissue Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Connective Tissue Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Connective Tissue Diseases","termGroup":"SY","termSource":"NCI"},{"termName":"Connective Tissue Disorders","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Connective_Tissue_Disorder"},{"name":"Maps_To","value":"Connective Tissue Disorder"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009782"},{"name":"xRef","value":"IMDRF:E1604"}]}}{"C3199":{"preferredName":"Chronic Obstructive Pulmonary Disease","code":"C3199","definitions":[{"definition":"A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","type":"DEFINITION","source":"NCI"},{"definition":"A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A type of lung disease marked by permanent damage to tissues in the lungs, making it hard to breathe. Chronic obstructive pulmonary disease includes chronic bronchitis, in which the bronchi (large air passages) are inflamed and scarred, and emphysema, in which the alveoli (tiny air sacs) are damaged. It develops over many years and is usually caused by cigarette smoking.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chronic Obstructive Pulmonary Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Obstructive Airways Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Obstructive Lung Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Obstructive Pulmonary Disease (COPD)","termGroup":"SY","termSource":"NCI"},{"termName":"COLD","termGroup":"AB","termSource":"NCI"},{"termName":"COPD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Chronic_Obstructive_Airways_Disease"},{"name":"Maps_To","value":"COPD"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0024117"},{"name":"xRef","value":"IMDRF:E0711"}]}}{"C26732":{"preferredName":"Coronary Artery Disease","code":"C26732","definitions":[{"definition":"Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coronary Artery Disease","termGroup":"PT","termSource":"NCI"},{"termName":"CAD","termGroup":"AB","termSource":"NCI"},{"termName":"Coronary Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Coronary_Disease"},{"name":"Maps_To","value":"Coronary Artery Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3549709"}]}}{"C2965":{"preferredName":"Crohn Disease","code":"C2965","definitions":[{"definition":"A chronic, transmural inflammation that can affect any location along the gastrointestinal tract.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A condition in which the gastrointestinal tract is inflamed over a long period of time. Crohn disease usually affects the small intestine and colon. Symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. Crohn disease increases the risk of colorectal cancer and small intestine cancer. It is a type of inflammatory bowel disease (IBD).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A condition in which the gastrointestinal tract is inflamed over a long period of time. Regional enteritis usually affects the small intestine and colon. Symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. Regional enteritis increases the risk of colorectal cancer and small intestine cancer. It is a type of inflammatory bowel disease (IBD).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crohn Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Crohn's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Regional Enteritis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Crohn_s_Disease"},{"name":"Maps_To","value":"Crohn's disease"},{"name":"Maps_To","value":"Crohn's Disease"},{"name":"Maps_To","value":"Other Crohn disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3553281"}]}}{"C62586":{"preferredName":"Cryptogenic Organizing Pneumonia","code":"C62586","definitions":[{"definition":"A form of organizing pneumonia with a non-infectious etiology. Excessive proliferation of granulation tissue occurs in alveolar ducts and alveoli and primarily causes injury to alveolar walls, but bronchioles may be affected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptogenic Organizing Pneumonia","termGroup":"PT","termSource":"NCI"},{"termName":"BOOP","termGroup":"AB","termSource":"NCI"},{"termName":"Bronchiolitis Obliterans Organizing Pneumonia","termGroup":"SY","termSource":"NCI"},{"termName":"COP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cryptogenic_Organizing_Pneumonia"},{"name":"Maps_To","value":"Cryptogenic Organizing Pneumonia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0242770"}]}}{"C174113":{"preferredName":"Cryptococcal Meningitis","code":"C174113","definitions":[{"definition":"A blood borne fungal infection of the membranes surrounding the brain and spinal column (meninges) caused by Cryptococcus, usually C. neoformans or C. gattii. It usually occurs in immunocompromised patients including persons with AIDS, transplant recipients, patients receiving cytotoxic chemotherapy, and patients with hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptococcal Meningitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cryptococcal Meningitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085436"}]}}{"C49343":{"preferredName":"Deep Vein Thrombosis","code":"C49343","definitions":[{"definition":"A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Formation of a blood clot within a deep vein.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The formation of a blood clot in a deep vein of the leg or lower pelvis. Symptoms may include pain, swelling, warmth, and redness in the affected area.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Thrombosis formation within deep veins during acute COVID-19","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]}],"synonyms":[{"termName":"Deep Vein Thrombosis","termGroup":"PT","termSource":"NCI"},{"termName":"DVT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Deep_Vein_Thrombosis"},{"name":"Maps_To","value":"Deep vein thrombosis"},{"name":"Maps_To","value":"Deep Vein Thrombosis / Thromboembolism"},{"name":"Maps_To","value":"DVT/PE"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0149871"}]}}{"C28195":{"preferredName":"Thromboembolism","code":"C28195","definitions":[{"definition":"A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.","type":"DEFINITION","source":"NCI"},{"definition":"Occlusion of the lumen of a vessel by a thrombus.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Thromboembolism","termGroup":"PT","termSource":"NCI"},{"termName":"Thromboembolic Event","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Thromboembolism"},{"name":"Maps_To","value":"Deep Vein Thrombosis / Thromboembolism"},{"name":"Maps_To","value":"Thromboembolism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3550383"},{"name":"xRef","value":"IMDRF:E050304"}]}}{"C84668":{"preferredName":"Denys-Drash Syndrome","code":"C84668","definitions":[{"definition":"A Wilms tumor 1 gene syndrome caused by various point mutation(s) affecting the zinc finger(s) of the Wilms tumor protein. This syndrome is characterized by congenital nephropathy (diffuse mesangial sclerosis), gonadal dysgenesis resulting in atypical genital and reproductive tract development in male infants, and high risk for development of Wilms tumor, an embryonal neoplasm defined by the presence of epithelial, mesenchymal, and blastema components.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare congenital syndrome caused by mutations in the WT1 gene. It is characterized by the presence of congenital nephropathy (diffuse mesangial sclerosis), Wilms tumor, and intersex disorders.","type":"DEFINITION","source":"NCI"},{"definition":"A rare disorder that causes kidney failure before age 3, abnormal development of the sexual organs, and, in most cases, Wilms tumor (a type of kidney cancer). Children with Denys-Drash syndrome are also at high risk of some other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Denys-Drash Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"DDS","termGroup":"AB","termSource":"NCI"},{"termName":"Denys Drash Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Denys-Drash Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0950121"}]}}{"C2982":{"preferredName":"Depression","code":"C2982","definitions":[{"definition":"A condition marked by ongoing feelings of sadness, despair, loss of energy, diminished interest/pleasure and difficulty dealing with normal daily life.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A disorder characterized by melancholic feelings of grief or unhappiness.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A melancholy feeling of sadness and despair.","type":"DEFINITION","source":"NCI"},{"definition":"A mental condition marked by ongoing feelings of sadness, despair, loss of energy, and difficulty dealing with normal daily life. Other symptoms of depression include feelings of worthlessness and hopelessness, loss of pleasure in activities, changes in eating or sleeping habits, and thoughts of death or suicide. Depression can affect anyone, and can be successfully treated. Depression affects 15-25% of cancer patients.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Depression","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Depression"},{"name":"Maps_To","value":"Depression"},{"name":"Semantic_Type","value":"Mental or Behavioral Dysfunction"},{"name":"UMLS_CUI","value":"C3277399"},{"name":"xRef","value":"IMDRF:E020202"}]}}{"C2985":{"preferredName":"Diabetes Mellitus","code":"C2985","definitions":[{"definition":"A disease in which the body does not control the amount of glucose (a type of sugar) in the blood and the kidneys make a large amount of urine. This disease occurs when the body does not make enough insulin or does not use it the way it should.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A metabolic condition, characterized by hyperglycemia, caused by insufficient secretion of insulin by the pancreas and/or decreased insulin action in target tissues.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetes Mellitus","termGroup":"PT","termSource":"NCI"},{"termName":"Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"DM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Diabetes_Mellitus"},{"name":"Maps_To","value":"Diabetes"},{"name":"Maps_To","value":"Diabetes, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4013416"}]}}{"C26747":{"preferredName":"Type 2 Diabetes Mellitus","code":"C26747","definitions":[{"definition":"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.","type":"DEFINITION","source":"NCI"},{"definition":"Diabetes mellitus caused by decreased insulin action in target tissues and insufficient production of insulin by pancreatic beta cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Type 2 Diabetes Mellitus","termGroup":"PT","termSource":"NCI"},{"termName":"Adult-Onset Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Diabetes, Type 2","termGroup":"SY","termSource":"NCI"},{"termName":"NIDDM","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Insulin Dependent Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Insulin Dependent Diabetes Mellitus","termGroup":"SY","termSource":"NCI"},{"termName":"T2DM - Type 2 Diabetes mellitus","termGroup":"SY","termSource":"NCI"},{"termName":"Type 2 Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type 2 Diabetes Mellitus Non-Insulin Dependent","termGroup":"SY","termSource":"NCI"},{"termName":"Type II Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type II Diabetes Mellitus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Non-Insulin_Dependent_Diabetes_Mellitus"},{"name":"Maps_To","value":"Diabetes, Type II"},{"name":"Maps_To","value":"Type II diabetes mellitus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0011860"}]}}{"C26748":{"preferredName":"Diabetic Neuropathy","code":"C26748","definitions":[{"definition":"A chronic, pathological complication associated with diabetes mellitus, where nerve damages are incurred due to diabetic microvascular injury involving small blood vessels that supply these nerves, resulting in peripheral and/or autonomic nerve dysfunction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetic Neuropathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diabetic_Neuropathy"},{"name":"Maps_To","value":"Diabetic Neuropathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0011882"}]}}{"C184754":{"preferredName":"Diabetes Is Controlled by Diet","code":"C184754","definitions":[{"definition":"An indication that a subject with diabetes is able to control symptoms by modifying their diet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetes Is Controlled by Diet","termGroup":"PT","termSource":"NCI"},{"termName":"Diet Controlled Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Diet-Controlled Diabetes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diet Controlled Diabetes"},{"name":"NCI_META_CUI","value":"CL1773079"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C26752":{"preferredName":"Diverticulitis","code":"C26752","definitions":[{"definition":"An infection that develops in the diverticula of the intestinal tract. Signs and symptoms include abdominal pain, fever, and leukocytosis.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of one or more pouches or sacs that bulge out from the wall of a hollow organ, such as the colon. Symptoms include muscle spasms and cramps in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diverticulitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diverticulitis"},{"name":"Maps_To","value":"Diverticulitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0012813"}]}}{"C50713":{"preferredName":"Pulmonary Embolism","code":"C50713","definitions":[{"definition":"The obstruction of blood flow by an embolus within the pulmonary circulation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung, during acute COVID-19","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Embolism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pulmonary_Embolism"},{"name":"Maps_To","value":"DVT/PE"},{"name":"Maps_To","value":"Pulmonary embolism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3552763"},{"name":"xRef","value":"IMDRF:E050303"}]}}{"C80385":{"preferredName":"Dyslipidemia","code":"C80385","definitions":[{"definition":"A lipoprotein metabolism disorder characterized by decreased levels of high-density lipoproteins, or elevated levels of plasma cholesterol, low-density lipoproteins and/or triglycerides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dyslipidemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dyslipidemia"},{"name":"Maps_To","value":"Dyslipidemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C4229397"}]}}{"C3001":{"preferredName":"Eczema","code":"C3001","definitions":[{"definition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A group of conditions in which the skin becomes inflamed, forms blisters, and becomes crusty, thick, and scaly. Eczema causes burning and itching, and may occur over a long period of time. Atopic dermatitis is the most common type of eczema.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Eczema","termGroup":"PT","termSource":"NCI"},{"termName":"Atopic Dermatitis","termGroup":"SY","termSource":"NCI"},{"termName":"Eczematous Dermatitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Eczema"},{"name":"Maps_To","value":"Eczema"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227545"},{"name":"xRef","value":"IMDRF:E172004"}]}}{"C3020":{"preferredName":"Seizure Disorder","code":"C3020","definitions":[{"definition":"A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.","type":"DEFINITION","source":"NCI"},{"definition":"A group of disorders marked by problems in the normal functioning of the brain.  These problems can produce seizures, unusual body movements, a loss of consciousness or changes in consciousness, as well as mental problems or problems with the senses.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A neurological disorder characterized by recurring seizures.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Epilepsy caused or apparently caused by device. Do not use when epilepsy is a pre-existing condition.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Seizure Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Epilepsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Epilepsy"},{"name":"Maps_To","value":"Epilepsy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3810329"},{"name":"xRef","value":"IMDRF:E010903"}]}}{"C38759":{"preferredName":"EBV Infection","code":"C38759","definitions":[{"definition":"An infection that is caused by Epstein-Barr virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Epstein-Barr Virus Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Epstein-Barr_Virus_Infection"},{"name":"Maps_To","value":"Epstein-Barr Virus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0149678"}]}}{"C62505":{"preferredName":"Fanconi Anemia","code":"C62505","definitions":[{"definition":"A chromosomal instability syndrome that is the most common form of inherited aplastic anemia. It is inherited as an autosomal recessive or X-linked disorder. In addition to bone marrow failure, it is associated with skeletal abnormalities and increased incidence of the development of malignancy. Multiple genes are responsible for Fanconi anemia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A rare inherited disorder in which the bone marrow does not make blood cells. It is usually diagnosed in children between 2 and 15 years old. Symptoms include frequent infections, easy bleeding, and extreme tiredness. People with Fanconi anemia may have a small skeleton and brown spots on the skin. They also have an increased risk of developing certain types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fanconi Anemia","termGroup":"PT","termSource":"NCI"},{"termName":"Fanconi's Anemia","termGroup":"SY","termSource":"NCI"},{"termName":"Pancytopenia, Congenital","termGroup":"SY","termSource":"NCI"},{"termName":"Panmyelopathy, Fanconi","termGroup":"SY","termSource":"NCI"},{"termName":"Primary Erythroid Hypoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Fanconi_Anemia"},{"name":"Maps_To","value":"Fanconi Anemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0015625"}]}}{"C3044":{"preferredName":"Fibrosis","code":"C3044","definitions":[{"definition":"Increase in collagen and low numbers of fibrocytes.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The formation of fibrous tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The formation of fibrous tissue.","type":"DEFINITION","source":"NCI"},{"definition":"The growth of fibrous tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Fibrosis"},{"name":"Maps_To","value":"Fibrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3550476"},{"name":"xRef","value":"IMDRF:E2313"}]}}{"C26781":{"preferredName":"Gastroesophageal Reflux Disease","code":"C26781","definitions":[{"definition":"A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Reflux of stomach contents with symptoms and/or complications from the reflux act.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Gastroesophageal Reflux Disease","termGroup":"PT","termSource":"NCI"},{"termName":"GERD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Gastroesophageal_Reflux_Disease"},{"name":"Maps_To","value":"Gastro-oesophageal reflux disease with oesophagitis"},{"name":"Maps_To","value":"Gastroesophageal reflux disease"},{"name":"Maps_To","value":"Gastroesophageal Reflux Disease"},{"name":"Maps_To","value":"GERD"},{"name":"Maps_To","value":"Reflux Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229251"}]}}{"C26782":{"preferredName":"Glaucoma","code":"C26782","definitions":[{"definition":"A condition in which there is a build-up of fluid in the eye, which presses on the retina and the optic nerve. The retina is the layer of nerve tissue inside the eye that senses light and sends images along the optic nerve to the brain. Glaucoma can damage the optic nerve and cause loss of vision or blindness.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.","type":"DEFINITION","source":"NCI"},{"definition":"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Optic nerve damage secondary to increased intraocular pressure.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Glaucoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Glaucoma"},{"name":"Maps_To","value":"Glaucoma"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4228099"},{"name":"xRef","value":"IMDRF:E0822"}]}}{"C61272":{"preferredName":"Glycogen Storage Disease","code":"C61272","definitions":[{"definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glycogen Storage Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Glycogen_Storage_Disease"},{"name":"Maps_To","value":"Glycogen Storage Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0017919"}]}}{"C26786":{"preferredName":"Gonadal Disorder","code":"C26786","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that affects the testis or the ovary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadal Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Gonadal Disorders","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Gonadal_Disorder"},{"name":"Maps_To","value":"Gonadal Dysfunction"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018050"}]}}{"C2892":{"preferredName":"Nevoid Basal Cell Carcinoma Syndrome","code":"C2892","definitions":[{"definition":"A genetic condition that causes unusual facial features and disorders of the skin, bones, nervous system, eyes, and endocrine glands. People with this syndrome have a higher risk of basal cell carcinoma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH and SUFU gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nevoid Basal Cell Carcinoma Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Basal Cell Nevus Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Gorlin Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Gorlin-Goltz Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Basal Cell Carcinomas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Basal_Cell_Nevus_Syndrome"},{"name":"Maps_To","value":"Gorlin Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0004779"}]}}{"C34650":{"preferredName":"Gout","code":"C34650","definitions":[{"definition":"A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.","type":"DEFINITION","source":"NCI"},{"definition":"A condition marked by increased levels of uric acid in the blood, joints, and tissue. The buildup of uric acid in the joints and tissues causes arthritis and inflammation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gout","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gout"},{"name":"Maps_To","value":"Gout"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018099"}]}}{"C39293":{"preferredName":"Helicobacter Pylori Infection","code":"C39293","definitions":[{"definition":"A bacterial infection of the stomach, caused by Helicobacter pylori.  It is associated with the development of peptic ulcer and mucosa-associated lymphoid tissue lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Helicobacter Pylori Infection","termGroup":"PT","termSource":"NCI"},{"termName":"H. pylori Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Helicobacter_Pylori_Infection"},{"name":"Maps_To","value":"H. pylori Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0850666"}]}}{"C27191":{"preferredName":"Hashimoto Thyroiditis","code":"C27191","definitions":[{"definition":"An autoimmune condition of the thyroid gland (a gland located beneath the larynx). It is caused by the formation of antibodies that attack the thyroid gland and it usually causes hypothyroidism (too little thyroid hormone). Symptoms include fatigue, weight gain, constipation, dry skin, depression, and the inability to exercise. It is more common in females and can run in families.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.","type":"DEFINITION","source":"NCI"},{"definition":"An autoimmune disorder characterized by inflammation and lymphocytic infiltration of the thyroid gland, sometimes associated with reduced thyroid function.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hashimoto Thyroiditis","termGroup":"PT","termSource":"NCI"},{"termName":"Autoimmune Thyroiditis","termGroup":"SY","termSource":"NCI"},{"termName":"Chronic Lymphocytic Thyroiditis","termGroup":"SY","termSource":"NCI"},{"termName":"Hashimoto Thyroiditis","termGroup":"SY","termSource":"NCI"},{"termName":"Hashimoto's Thyroiditis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hashimoto_s_Thyroiditis"},{"name":"Maps_To","value":"Hashimoto's disease"},{"name":"Maps_To","value":"Hashimoto's Thyroiditis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0677607"}]}}{"C3079":{"preferredName":"Heart Disorder","code":"C3079","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.","type":"DEFINITION","source":"NCI"},{"definition":"The report describes a non-specific problem with the heart. Note: Please use \"Appropriate Term / Code Not Available\" if the report describes a specific problem but the relevant term does not exist.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Heart Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Heart Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Heart_Disease"},{"name":"Maps_To","value":"Heart Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018799"},{"name":"xRef","value":"IMDRF:E0623"}]}}{"C88541":{"preferredName":"Hemihypertrophy","code":"C88541","definitions":[{"definition":"A condition in which one side of the body or a part of one side is larger than the other. Children with hemihypertrophy have an increased risk of developing certain types of cancer, including Wilms tumor (a childhood kidney cancer) and liver cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A finding indicating the presence of greater than normal asymmetry between the right and left sides of the body. The asymmetry may be manifested in the entire side or part of it.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemihypertrophy","termGroup":"PT","termSource":"NCI"},{"termName":"Hemihyperplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Hemihypertrophy"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0332890"}]}}{"C114666":{"preferredName":"Hemorrhagic Cystitis","code":"C114666","definitions":[{"definition":"Inflammation of the bladder resulting in bloody urine.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the bladder resulting in bloody urine.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hemorrhagic Cystitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Hemorrhagic Cystitis"},{"name":"Maps_To","value":"Hemorrhagic cystitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085692"}]}}{"C3095":{"preferredName":"Hepatitis","code":"C3095","definitions":[{"definition":"Disease of the liver causing inflammation. Symptoms include an enlarged liver, fever, nausea, vomiting, abdominal pain, and dark urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Inflammation of the liver.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Hepatitis"},{"name":"Maps_To","value":"Hepatitis"},{"name":"Maps_To","value":"Hepatitis, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3806111"},{"name":"xRef","value":"IMDRF:E1102"}]}}{"C3096":{"preferredName":"Hepatitis A Infection","code":"C3096","definitions":[{"definition":"Acute inflammation of the liver caused by the hepatitis A virus. It is highly contagious and usually contracted through close contact with an infected individual or their feces, contaminated food or water.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis A Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Hepatitis A","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hepatitis_A"},{"name":"Maps_To","value":"Hepatitis A Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019159"}]}}{"C3097":{"preferredName":"Hepatitis B Infection","code":"C3097","definitions":[{"definition":"A viral infection caused by the hepatitis B virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatitis B","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis B Virus infection","termGroup":"SY","termSource":"NCI"},{"termName":"Viral Hepatitis B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hepatitis_B"},{"name":"Maps_To","value":"Hepatitis B Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019163"}]}}{"C3098":{"preferredName":"Hepatitis C Infection","code":"C3098","definitions":[{"definition":"A viral infection caused by the hepatitis C virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis C Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HCV Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C Virus Infection","termGroup":"SY","termSource":"NCI"},{"termName":"NANBH","termGroup":"AQS","termSource":"NCI"},{"termName":"Non-A, Non-B Hepatitis","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatitis_C"},{"name":"Maps_To","value":"Hepatitis C Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019196"}]}}{"C82978":{"preferredName":"Chronic Hepatitis","code":"C82978","definitions":[{"definition":"An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Hepatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Chronic_Hepatitis"},{"name":"Maps_To","value":"Chronic Hepatitis"},{"name":"Maps_To","value":"Hepatitis, Chronic"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019189"}]}}{"C120083":{"preferredName":"Hereditary Nonpolyposis Colorectal Cancer Syndrome","code":"C120083","definitions":[{"definition":"An inherited disorder in which affected individuals have a higher-than-normal chance of developing colorectal cancer and certain other types of cancer, often before the age of 50.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inherited syndrome characterized by the development of several cancers, particularly colon and rectal cancers.  It includes Lynch syndrome which is associated with germline mutations in DNA mismatch-repair genes and familial colorectal cancer type X which is characterized by the absence of germline mutations in DNA mismatch-repair genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Nonpolyposis Colorectal Cancer Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Nonpolyposis Colorectal Cancer Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Nonpolyposis Colorectal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"HNPCC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hereditary Non-polyposis Colon Cancer"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0009405"}]}}{"C96768":{"preferredName":"High Grade Liver Dysplastic Nodule","code":"C96768","definitions":[{"definition":"A hepatic dysplastic nodule characterized by the presence of high grade atypical cellular changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Liver Dysplastic Nodule","termGroup":"PT","termSource":"NCI"},{"termName":"HGDN","termGroup":"AB","termSource":"NCI"},{"termName":"High Grade Hepatic Dysplastic Nodule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"High Grade Liver Dysplastic Nodule"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273016"}]}}{"C2851":{"preferredName":"Acquired Immunodeficiency Syndrome","code":"C2851","definitions":[{"definition":"A chronic, potentially life threatening condition that is caused by human immunodeficiency virus (HIV) infection, and is characterized by increased susceptibility to opportunistic infections, certain cancers and neurologic disorders.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disease caused by human immunodeficiency virus (HIV). People with acquired immunodeficiency syndrome are at an increased risk for developing certain cancers and for infections that usually occur only in individuals with a weak immune system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acquired Immunodeficiency Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Acquired Immune Deficiency","termGroup":"SY","termSource":"NCI"},{"termName":"AIDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"AIDS"},{"name":"Maps_To","value":"Acquired immune deficiency syndrome"},{"name":"Maps_To","value":"HIV / AIDS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0001175"}]}}{"C27851":{"preferredName":"Human Papillomavirus Infection","code":"C27851","definitions":[{"definition":"An infectious process caused by a human papillomavirus. This infection can cause abnormal tissue growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HPV","termGroup":"SY","termSource":"NCI"},{"termName":"HPV Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papilloma_Virus_Infection"},{"name":"Maps_To","value":"Human Papillomavirus Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0343641"}]}}{"C75545":{"preferredName":"Hemolytic Uremic Syndrome","code":"C75545","definitions":[{"definition":"A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.","type":"DEFINITION","source":"NCI"},{"definition":"Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hemolytic Uremic Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hemolytic_Uremic_Syndrome"},{"name":"Maps_To","value":"Hemolytic-uremic syndrome"},{"name":"Maps_To","value":"HUS/TTP"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3808621"}]}}{"C78797":{"preferredName":"Thrombotic Thrombocytopenic Purpura","code":"C78797","definitions":[{"definition":"A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.","type":"DEFINITION","source":"NCI"},{"definition":"A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.","type":"ALT_DEFINITION","source":"CTCAE"}],"synonyms":[{"termName":"Thrombotic Thrombocytopenic Purpura","termGroup":"PT","termSource":"NCI"},{"termName":"Moschowitz Disease","termGroup":"SY","termSource":"NCI"},{"termName":"TTP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Thrombotic_Thrombocytopenic_Purpura"},{"name":"Maps_To","value":"HUS/TTP"},{"name":"Maps_To","value":"Thrombotic thrombocytopenic purpura"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0034155"}]}}{"C3112":{"preferredName":"Hypercalcemia","code":"C3112","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium in blood.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high concentration of calcium in the peripheral blood.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally high level of calcium in the blood.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Higher than normal levels of calcium in the blood. Some types of cancer increase the risk of hypercalcemia.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Higher than normal levels of calcium in the circulating blood.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Hypercalcemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hypercalcemia"},{"name":"Maps_To","value":"Hypercalcemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0020437"},{"name":"xRef","value":"IMDRF:E120203"}]}}{"C37967":{"preferredName":"Hypercholesterolemia","code":"C37967","definitions":[{"definition":"A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A laboratory test result indicating an increased amount of cholesterol in the blood.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally high level of cholesterol in the blood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hypercholesterolemia","termGroup":"PT","termSource":"NCI"},{"termName":"High Cholesterol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hypercholesterolemia"},{"name":"Maps_To","value":"Hypercholesterolemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C1522133"}]}}{"C26797":{"preferredName":"Hyperglycemia","code":"C26797","definitions":[{"definition":"A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high level of glucose in the blood.","type":"DEFINITION","source":"NCI"},{"definition":"Abnormally high level of glucose in the blood.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Higher than normal amount of glucose (a type of sugar) in the blood. Hyperglycemia can be a sign of diabetes or other conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Plasma glucose concentration above the reference range.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hyperglycemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Hyperglycemia"},{"name":"Maps_To","value":"Hyperglycemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C4015534"},{"name":"xRef","value":"IMDRF:E1205"}]}}{"C34707":{"preferredName":"Hyperlipidemia","code":"C34707","definitions":[{"definition":"Elevated levels of lipids in the blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperlipidemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperlipidemia"},{"name":"Maps_To","value":"Hyperlipidemia"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0020473"}]}}{"C3117":{"preferredName":"Hypertension","code":"C3117","definitions":[{"definition":"A blood pressure of 140/90 or higher. High blood pressure usually has no symptoms. It can harm the arteries and cause an increase in the risk of stroke, heart attack, kidney failure, and blindness.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by a pathological increase in blood pressure; a repeatedly elevation in the blood pressure exceeding 140 over 90 mm Hg.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high blood pressure.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Blood pressure that is abnormally high.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Blood pressure that is abnormally high.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypertension","termGroup":"PT","termSource":"NCI"},{"termName":"High Blood Pressure","termGroup":"SY","termSource":"NCI"},{"termName":"HTN","termGroup":"AB","termSource":"NCI"},{"termName":"Vascular Hypertensive Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Hypertension"},{"name":"Maps_To","value":"Hypertension"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4014808"},{"name":"xRef","value":"IMDRF:E2320"}]}}{"C40341":{"preferredName":"Hypospadias","code":"C40341","definitions":[{"definition":"A birth defect in which the opening of the urethra (the tube through which urine leaves the body) is not in its normal place. In males with hypospadias, the urethra opens on the underside of the penis or between the anus and the scrotum. In females with hypospadias, it opens into the vagina. Hypospadias is much more common in males than in females, and can be corrected by surgery. Children with hypospadias have an increased risk of developing Wilms tumor (a type of kidney cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A congenital abnormality in which the external urethral orifice is on the underside of the penis. In a minority of cases it is associated with other genitourinary abnormalities.","type":"DEFINITION","source":"NCI"},{"definition":"A congenital condition in which the urethra fails to develop properly, and the opening of the urethra is located on the ventrum of the penis, scrotum, or perineum.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Urethra opening on the underside of the penis or on the perineum. (Makris S, Solomon HM, Clark R, Shiota K, Barbellion S, Buschmann J, Ema M, Fujiwara M, Grote K, Hazelden KP, Hew KW, Horimoto M, Ooshima Y, Parkinson M, Wise LD. Terminology of developmental abnormalities in common laboratory mammals (Version 2). Part B. Birth Defects Res B Dev Reprod Toxicol. 2009 Aug;86(4):227-327.)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hypospadias","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hypospadias"},{"name":"Maps_To","value":"Hypospadias"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231490"}]}}{"C26800":{"preferredName":"Hypothyroidism","code":"C26800","definitions":[{"definition":"A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally low levels of thyroid hormone.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Abnormally low levels of thyroid hormone.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Reduced secretion of thyroid hormone(s) by the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Too little thyroid hormone. Symptoms include weight gain, constipation, dry skin, and sensitivity to the cold.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hypothyroidism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hypothyroidism"},{"name":"Maps_To","value":"Hypothyroidism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4229471"},{"name":"xRef","value":"IMDRF:E1212"}]}}{"C3138":{"preferredName":"Inflammatory Bowel Disease","code":"C3138","definitions":[{"definition":"A general term that refers to the inflammation of the colon and rectum. Inflammatory bowel disease includes ulcerative colitis and Crohn's disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.","type":"DEFINITION","source":"NCI"},{"definition":"Chronic inflammatory process affecting the gastrointestinal tract; primarily ulcerative colitis and Crohn's disease.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Inflammatory Bowel Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Autoimmune Bowel Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"IBD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Inflammatory_Bowel_Disease"},{"name":"Maps_To","value":"Inflammatory bowel disease"},{"name":"Maps_To","value":"Inflammatory Bowel Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227559"}]}}{"C184766":{"preferredName":"Diabetes Is Controlled by Insulin","code":"C184766","definitions":[{"definition":"An indication that a subject with diabetes is able to control symptoms using insulin-based therapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diabetes Is Controlled by Insulin","termGroup":"PT","termSource":"NCI"},{"termName":"Insulin Controlled Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin-Controlled Diabetes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Insulin Controlled Diabetes"},{"name":"NCI_META_CUI","value":"CL1773083"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C3353":{"preferredName":"Acute Respiratory Distress Syndrome","code":"C3353","definitions":[{"definition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Respiratory Distress Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Adult RDS","termGroup":"SY","termSource":"NCI"},{"termName":"Adult Respiratory Distress Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"ARDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Adult_Respiratory_Distress_Syndrome"},{"name":"Maps_To","value":"Interstitial Pneumontis or ARDS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035222"},{"name":"xRef","value":"IMDRF:E0701"}]}}{"C27006":{"preferredName":"Interstitial Pneumonia","code":"C27006","definitions":[{"definition":"Inflammation of interstitial lung tissue, usually associated with infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interstitial Pneumonia","termGroup":"PT","termSource":"NCI"},{"termName":"Interstitial Pneumonitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Interstitial_Pneumonitis"},{"name":"Maps_To","value":"Interstitial Pneumontis or ARDS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014800"}]}}{"C38342":{"preferredName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm","code":"C38342","definitions":[{"definition":"A usually slow-growing epithelial neoplasm with ductal differentiation that arises from the exocrine pancreas and grows mostly within the pancreatic ducts. Grossly, it is characterized by the presence of intraductal masses. Morphologically, there is proliferation of mucin-producing cells within the pancreatic ducts, intraductal accumulation of mucin, and a papillary growth pattern. It may be associated with the presence of an invasive carcinoma. It usually occurs in older patients. Signs and symptoms include epigastric pain, weight loss, jaundice, chronic pancreatitis, and diabetes mellitus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatic Intraductal Papillary-Mucinous Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Pancreatic Intraductal Papillary-Mucinous Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreatic IPMN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatic_Intraductal_Papillary-Mucinous_Neoplasm"},{"name":"Maps_To","value":"Intraductal Papillary Mucinous Neoplasm"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1266071"}]}}{"C78393":{"preferredName":"Iron Overload","code":"C78393","definitions":[{"definition":"A condition in which the body takes up and stores more iron than it needs. The extra iron is stored in the liver, heart, and pancreas, which may cause liver disease, heart problems, organ failure, and cancer. It may also cause bronze skin, diabetes, pain in the joints and abdomen, tiredness, and impotence. Iron overload may be inherited, or it may be caused by blood transfusions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by accumulation of iron in the tissues.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Abnormally high level of iron in the tissues.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Accumulation of iron in the tissues. It may be a manifestation of an inherited disorder (e.g., hemochromatosis) or acquired (in patients with repeated blood transfusions). Symptoms include hepatomegaly, arthritis, diabetes mellitus, and bronzed skin. If untreated it has a progressive course and may lead to death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iron Overload","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Iron_Overload"},{"name":"Maps_To","value":"Iron Overload"},{"name":"Maps_To","value":"Iron overload"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3806118"}]}}{"C50625":{"preferredName":"Ischemic Heart Disease","code":"C50625","definitions":[{"definition":"A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ischemic Heart Disease","termGroup":"PT","termSource":"NCI"},{"termName":"IHD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Ischemic_Heart_Disease"},{"name":"Maps_To","value":"Ischemic Heart Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0151744"},{"name":"xRef","value":"IMDRF:E0612"}]}}{"C3446":{"preferredName":"Primary Immune Thrombocytopenia","code":"C3446","definitions":[{"definition":"A condition in which platelets (blood cells that cause blood clots to form) are destroyed by the immune system. The low platelet count causes easy bruising and bleeding, which may be seen as purple areas in the skin, mucous membranes, and outer linings of organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).","type":"DEFINITION","source":"NCI"},{"definition":"Disorder characterized by abnormally low level of circulating platelets, usually with normal hemoglobin/red blood cell and white blood cell levels, and thought to be secondary to autoimmune destruction.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Primary Immune Thrombocytopenia","termGroup":"PT","termSource":"NCI"},{"termName":"Idiopathic Thrombocytopenia","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Thrombocytopenia Purpura","termGroup":"SY","termSource":"NCI"},{"termName":"Idiopathic Thrombocytopenic Purpura","termGroup":"SY","termSource":"NCI"},{"termName":"ITP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Idiopathic_Thrombocytopenic_Purpura"},{"name":"Maps_To","value":"Idiopathic thrombocytopenic purpura"},{"name":"Maps_To","value":"ITP"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0920163"}]}}{"C131579":{"preferredName":"Joint Replacement","code":"C131579","definitions":[{"definition":"A surgical procedure to replace part, or all structures, of a joint with an orthopedic prosthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Joint Replacement","termGroup":"PT","termSource":"NCI"},{"termName":"Joint Replacement Surgery","termGroup":"SY","termSource":"NCI"},{"termName":"Replacement Arthroplasty","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Joint Replacement"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0185317"}]}}{"C3476":{"preferredName":"Li-Fraumeni Syndrome","code":"C3476","definitions":[{"definition":"A rare, inherited predisposition to multiple cancers, caused by an alteration in the p53 tumor suppressor gene.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Li-Fraumeni Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Li-Fraumeni Familial Cancer Susceptibility Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Li-Fraumeni Syndrome, TP53-Associated","termGroup":"SY","termSource":"NCI"},{"termName":"TP53-Associated Li-Fraumeni Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Li-Fraumeni_Syndrome"},{"name":"Maps_To","value":"Li-Fraumeni Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085390"}]}}{"C184773":{"preferredName":"Personal History of Liver Toxicity due to Non-Infectious Cause","code":"C184773","definitions":[{"definition":"An indication that a subject a has a history that includes symptoms of liver toxicity that is not due to an infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Liver Toxicity due to Non-Infectious Cause","termGroup":"PT","termSource":"NCI"},{"termName":"History of Liver Toxicity due to Non-Infectious Cause","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liver Toxicity (Non-Infectious)"},{"name":"NCI_META_CUI","value":"CL1773090"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C96770":{"preferredName":"Low Grade Liver Dysplastic Nodule","code":"C96770","definitions":[{"definition":"A hepatic dysplastic nodule characterized by the presence of low grade atypical cellular changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Liver Dysplastic Nodule","termGroup":"PT","termSource":"NCI"},{"termName":"LGDN","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Hepatic Dysplastic Nodule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Grade Liver Dysplastic Nodule"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3273018"}]}}{"C27153":{"preferredName":"Lupus Erythematosus","code":"C27153","definitions":[{"definition":"A chronic inflammatory connective tissue disease marked by skin rashes, joint pain and swelling, inflammation of the kidneys, inflammation of the fibrous tissue surrounding the heart (i.e., the pericardium), as well as other problems. Not all affected individuals display all of these problems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.","type":"DEFINITION","source":"NCI"},{"definition":"An umbrella term referring to disease entities such as cutaneous, subacute cutaneous, discoid and systemic lupus erythematosus.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Lupus Erythematosus","termGroup":"PT","termSource":"NCI"},{"termName":"Lupus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Lupus_Erythematosus"},{"name":"Maps_To","value":"Lupus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0409974"}]}}{"C174114":{"preferredName":"Lymphocytic Meningitis","code":"C174114","definitions":[{"definition":"Meningitis in which lymphocytes predominate in the cerebrospinal fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocytic Meningitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphocytic Meningitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0024266"}]}}{"C8494":{"preferredName":"Lynch Syndrome","code":"C8494","definitions":[{"definition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lynch Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Non-Polyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2)","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Colorectal Endometrial Cancer Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Defective Mismatch Repair Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Non-Polyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2)","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Nonpolyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hereditary_Non-Polyposis_Colon_Cancer"},{"name":"Maps_To","value":"Lynch Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1333990"}]}}{"C27314":{"preferredName":"Mycobacterium Avium Complex Lymphadenitis","code":"C27314","definitions":[{"definition":"Lymph node infection by Mycobacterium avium or Mycobacterium intracellulare. It most often affects children and usually presents with cervical lymph node enlargement. It generally follows a benign clinical course.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium Avium Complex Lymphadenitis","termGroup":"PT","termSource":"NCI"},{"termName":"MAC Lymphadenitis","termGroup":"SY","termSource":"NCI"},{"termName":"MAI Lymphadenitis","termGroup":"SY","termSource":"NCI"},{"termName":"Mycobacterium Avium Intracellulare Lymphadenitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mycobacterium_Avium_Complex_Lymphadenitis"},{"name":"Maps_To","value":"MAI"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0858195"}]}}{"C34797":{"preferredName":"Malaria","code":"C34797","definitions":[{"definition":"A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.","type":"DEFINITION","source":"NCI"},{"definition":"Plasmodium parasite infection, characterized by fever, flu-like symptoms, anemia, and jaundice, that may be transmitted through infected mosquito bites, blood transfusion, organ transplant, contaminated needles or syringes, or before or during birth.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Malaria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Malaria"},{"name":"Maps_To","value":"Malaria"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0024530"}]}}{"C84442":{"preferredName":"Metabolic Syndrome","code":"C84442","definitions":[{"definition":"A combination of medical conditions that when present, increase the risk of heart attack, stroke, and diabetes mellitus. It includes the following medical conditions: increased blood pressure, central obesity, dyslipidemia, impaired glucose tolerance, and insulin resistance.","type":"DEFINITION","source":"NCI"},{"definition":"A condition is marked by extra fat around the abdomen, high levels of blood glucose (sugar) when not eating, high levels of triglycerides (a type of fat) in the blood, low levels of high-density lipoproteins (a type of protein that carries fats) in the blood, and high blood pressure. People with metabolic syndrome are at increased risk of diabetes mellitus and diseases of the heart and blood vessels.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Metabolic Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Cardiometabolic Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Metabolic Syndrome X","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metabolic Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0524620"}]}}{"C60989":{"preferredName":"Myasthenia Gravis","code":"C60989","definitions":[{"definition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","type":"DEFINITION","source":"NCI"},{"definition":"A disease in which antibodies made by a person's immune system prevent certain nerve-muscle interactions. It causes weakness in the arms and legs, vision problems, and drooping eyelids or head. It may also cause paralysis and problems with swallowing, talking, climbing stairs, lifting things, and getting up from a sitting position. The muscle weakness gets worse during activity, and improves after periods of rest.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Myasthenia Gravis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Myasthenia_Gravis"},{"name":"Maps_To","value":"Myasthenia Gravis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0026896"}]}}{"C27996":{"preferredName":"Myocardial Infarction","code":"C27996","definitions":[{"definition":"A condition which occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","type":"DEFINITION","source":"NCI"},{"definition":"Necrosis of the myocardium, as a result of interruption of the blood supply to the area.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Myocardial Infarction","termGroup":"PT","termSource":"NCI"},{"termName":"Heart Attack","termGroup":"SY","termSource":"NCI"},{"termName":"MI","termGroup":"SY","termSource":"NCI"},{"termName":"Myocardial Infarct","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Myocardial_Infarction"},{"name":"Maps_To","value":"Myocardial infarction"},{"name":"Maps_To","value":"Myocardial Infarction"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3280935"},{"name":"xRef","value":"IMDRF:E061202"}]}}{"C3809":{"preferredName":"Neuroendocrine Neoplasm","code":"C3809","definitions":[{"definition":"A tumor that forms from cells that release hormones in response to a signal from the nervous system. Some examples of neuroendocrine tumors are carcinoid tumors, islet cell tumors, medullary thyroid carcinomas, pheochromocytomas, and neuroendocrine carcinomas of the skin (Merkel cell cancer). These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuroendocrine Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"NEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Neuroendocrine_Neoplasm"},{"name":"Maps_To","value":"Neuroendocrine Tumor"},{"name":"Maps_To","value":"Neuroendocrine tumors"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0206754"}]}}{"C84445":{"preferredName":"Nonalcoholic Steatohepatitis","code":"C84445","definitions":[{"definition":"Fatty replacement and damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonalcoholic Steatohepatitis","termGroup":"PT","termSource":"NCI"},{"termName":"NASH - Nonalcoholic Steatohepatitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Maps_To","value":"Nonalcoholic Steatohepatitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3241937"}]}}{"C3283":{"preferredName":"Obesity","code":"C3283","definitions":[{"definition":"A condition marked by an abnormally high, unhealthy amount of body fat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by having a high amount of body fat.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obesity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Obesity"},{"name":"Maps_To","value":"Obesity"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C3809449"}]}}{"C15289":{"preferredName":"Organ Transplantation","code":"C15289","definitions":[{"definition":"The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient's damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Organ Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical, Transplantation, Organ","termGroup":"SY","termSource":"NCI"},{"termName":"Organ Donation","termGroup":"SY","termSource":"NCI"},{"termName":"Organ Donation Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"organ grafting","termGroup":"SY","termSource":"NCI"},{"termName":"Organ Transplants","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Organ_Transplantation"},{"name":"Maps_To","value":"Organ transplant (site)"},{"name":"Maps_To","value":"Organ Transplantation"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0029216"}]}}{"C3293":{"preferredName":"Osteoarthritis","code":"C3293","definitions":[{"definition":"A disease process characterized by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. (INHAND)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A noninflammatory degenerative joint disease occurring chiefly in older persons, characterised by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. It is accompanied by pain and stiffness, particularly after prolonged activity.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Osteoarthritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Osteoarthritis"},{"name":"Maps_To","value":"Osteoarthritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0029408"}]}}{"C3298":{"preferredName":"Osteoporosis","code":"C3298","definitions":[{"definition":"A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).","type":"DEFINITION","source":"NCI"},{"definition":"A condition that is marked by a decrease in bone mass and density, causing bones to become fragile.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Reduced bone mineral density due to decreased number and thickness of bone trabeculae and decreased cortical thickness, associated with increased risk of skeletal fractures. A clinical diagnosis of osteoporosis in childhood requires either a finding of one or more otherwise unexplained vertebral compression fractures, or the presence of bone mineral density Z-score less than or equal to 2.0 accompanied by one or more of the following: 1) at least two long bone fractures by age 10 years; 2) at least three long bone fractures up to age 19 years.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Osteoporosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Osteoporosis"},{"name":"Maps_To","value":"Osteoporosis or Osteopenia"},{"name":"Maps_To","value":"Osteoporosis, unspecified"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014080"}]}}{"C50910":{"preferredName":"Osteopenia","code":"C50910","definitions":[{"definition":"A condition in which there is a lower-than-normal bone mass or bone mineral density (the amount of bone mineral contained in a certain amount of bone). Osteopenia is a less severe form of bone loss than osteoporosis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Decreased calcification or density of bone tissue.","type":"DEFINITION","source":"NCI"},{"definition":"Decreased calcification or density of bone tissue.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Osteopenia","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Loss","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Osteopenia"},{"name":"Maps_To","value":"Osteoporosis or Osteopenia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4227764"},{"name":"xRef","value":"IMDRF:E1629"}]}}{"C184782":{"preferredName":"Personal History of Other Cancer Within 5 Years","code":"C184782","definitions":[{"definition":"An individual history of a cancer, other than those listed, within 5 years of the current cancer diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Cancer Within 5 Years","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Cancer Within 5 Years","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Cancer Within 5 Years"},{"name":"NCI_META_CUI","value":"CL1773099"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184785":{"preferredName":"Personal History of Other Nonmalignant Systemic Disease","code":"C184785","definitions":[{"definition":"An individual history of a nonmalignant systemic disease, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Nonmalignant Systemic Disease","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Nonmalignant Systemic Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Nonmalignant Systemic Disease"},{"name":"NCI_META_CUI","value":"CL1773108"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184786":{"preferredName":"Personal History of Other Pulmonary Complications","code":"C184786","definitions":[{"definition":"An individual history of a pulmonary complication, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Pulmonary Complications","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Pulmonary Complications","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Pulmonary Complications"},{"name":"NCI_META_CUI","value":"CL1773109"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C3303":{"preferredName":"Pain","code":"C3303","definitions":[{"definition":"A disorder characterized by the sensation of marked discomfort, distress or agony.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A feeling of distress, suffering, or agony, caused by stimulation of specialized nerve endings.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"An unpleasant sensation associated with real or perceived physical or mental trauma.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An unpleasant sensory and emotional experience that is associated with actual or potential tissue damage or described in such terms.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pain"},{"name":"Maps_To","value":"Pain"},{"name":"Maps_To","value":"Pain (Various)"},{"name":"Maps_To","value":"Pain, not elsewhere classified"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C0030193"},{"name":"Use_For","value":"Soreness"},{"name":"xRef","value":"IMDRF:E2330"}]}}{"C3306":{"preferredName":"Pancreatitis","code":"C3306","definitions":[{"definition":"A disorder characterized by inflammation of the pancreas.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Inflammation of the pancreas.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammation of the pancreas.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Inflammation of the pancreas.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the pancreas. Chronic pancreatitis may cause diabetes and problems with digestion. Pain is the primary symptom.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pancreatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pancreatitis"},{"name":"Maps_To","value":"Pancreatitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4011703"},{"name":"xRef","value":"IMDRF:E1021"}]}}{"C3318":{"preferredName":"Peptic Ulcer","code":"C3318","definitions":[{"definition":"A break in the lining of the lower part of the esophagus, the stomach, or the upper part of the small intestine. Peptic ulcers form when cells on the surface of the lining become inflamed and die. They are usually caused by Helicobacter pylori bacteria and by certain medicines, such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Peptic ulcers may be linked to cancer and other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.","type":"DEFINITION","source":"NCI"},{"definition":"A mucosal injury that occurs in the stomach or duodenum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Peptic Ulcer","termGroup":"PT","termSource":"NCI"},{"termName":"Peptic Ulcer Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Peptic_Ulcer"},{"name":"Maps_To","value":"Peptic ulcer"},{"name":"Maps_To","value":"Peptic Ulcer (Ulcer)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4012822"}]}}{"C119734":{"preferredName":"Peripheral Neuropathy","code":"C119734","definitions":[{"definition":"A disorder affecting one or more peripheral nerves. It is manifested with pain, tingling, numbness, and/ or muscle weakness. Causes may include physical injury, toxic substances, viral infection and systemic illness.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.","type":"DEFINITION","source":"NCI"},{"definition":"A nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Neuropathy may be caused by physical injury, infection, toxic substances, disease (such as cancer, diabetes, kidney failure, or malnutrition), or drugs, including anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peripheral Neuropathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Peripheral Neuropathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3277001"}]}}{"C35136":{"preferredName":"Peripheral Vascular Disorder","code":"C35136","definitions":[{"definition":"Any disorder affecting blood flow through the veins or arteries outside of the heart.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Vascular Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Peripheral Vascular Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Peripheral_Vascular_Disorder"},{"name":"Maps_To","value":"Peripheral Vascular Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0085096"}]}}{"C3324":{"preferredName":"Peutz-Jeghers Syndrome","code":"C3324","definitions":[{"definition":"A genetic disorder in which polyps form in the intestine and dark spots appear on the mouth and fingers. Having Peutz-Jeghers syndrome increases the risk of developing gastrointestinal and many other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peutz-Jeghers Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Jeghers-Peutz Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Peutz's Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"PJS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peutz-Jeghers_Syndrome"},{"name":"Maps_To","value":"Peutz-Jeghers Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0031269"}]}}{"C26862":{"preferredName":"Polycystic Ovary Syndrome","code":"C26862","definitions":[{"definition":"A condition marked by infertility, enlarged ovaries, menstrual problems, high levels of male hormones, excess hair on the face and body, acne, and obesity. Women with PCOS have an increased risk of diabetes, high blood pressure, heart disease, and endometrial cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A condition of unknown or heterogenous genetic etiology that is characterized by hyperandrogenism and ovarian dysfunction, though the clinical features of the condition may differ between teenage girls and adult women. For teenage girls, the characteristic features generally manifest as persistent, otherwise unexplained hyperandrogenism and reduced or absent ovulation with associated menstrual irregularity, as determined by age- and pubertal stage-appropriate criteria. Additional clinical manifestations include some or all of the following: obesity, insulin resistance/hyperinsulinemia or frank type 2 diabetes mellitus, acanthosis nigricans, hirsutism, and polycystic ovary on ultrasound.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder that manifests as multiple cysts on the ovaries. It results in hormonal imbalances and leads to irregular and abnormal menstrual periods, excess growth of hair, acne eruptions and obesity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polycystic Ovary Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Polycystic Ovarian Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Stein-Leventhal Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Stein-Leventhal_Syndrome"},{"name":"Maps_To","value":"Polycystic Ovarian Syndrome (PCOS)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1835381"}]}}{"C124295":{"preferredName":"Pregnant","code":"C124295","definitions":[{"definition":"Observed to be or have been pregnant or positive for a pregnancy test.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Observed to be or have been pregnant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pregnant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pregnancy in Patient or Partner"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0549206"}]}}{"C4828":{"preferredName":"Primary Sclerosing Cholangitis","code":"C4828","definitions":[{"definition":"A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Sclerosing Cholangitis","termGroup":"PT","termSource":"NCI"},{"termName":"PSC","termGroup":"AB","termSource":"NCI"},{"termName":"Sclerosing Cholangitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Sclerosing_Cholangitis"},{"name":"Maps_To","value":"Primary Sclerosing Cholangitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0566602"}]}}{"C3346":{"preferredName":"Psoriasis","code":"C3346","definitions":[{"definition":"A chronic disease of the skin marked by red patches covered with white scales.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Psoriasis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Psoriasis"},{"name":"Maps_To","value":"Psoriasis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231128"}]}}{"C26869":{"preferredName":"Pulmonary Fibrosis","code":"C26869","definitions":[{"definition":"A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A interstitial lung disease characterized by the replacement of lung tissue with connective tissue.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Fibrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Pulmonary_Fibrosis"},{"name":"Maps_To","value":"Pulmonary Fibrosis"},{"name":"Maps_To","value":"Pulmonary fibrosis"},{"name":"Maps_To","value":"Pulmonary interstitial fibrosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4013574"}]}}{"C78578":{"preferredName":"Pulmonary Hemorrhage","code":"C78578","definitions":[{"definition":"Bleeding from the lung parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulmonary Hemorrhage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pulmonary_Hemorrhage"},{"name":"Maps_To","value":"Pulmonary Hemorrhage"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0151701"}]}}{"C15248":{"preferredName":"Hemodialysis","code":"C15248","definitions":[{"definition":"A therapeutic procedure involving the extracorporeal removal of harmful waste and fluids from the blood using a dialysis machine. Following dialysis, the blood is returned to the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A therapeutic procedure used in patients with kidney failure.  It involves the extracorporeal removal of harmful wastes and fluids from the blood using a dialysis machine.  Following the dialysis, the blood is returned to the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemodialysis","termGroup":"PT","termSource":"NCI"},{"termName":"Artificial Kidney Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Extracorporeal Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Dialysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemodialysis"},{"name":"Maps_To","value":"Renal Dialysis"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0019004"}]}}{"C184791":{"preferredName":"Personal History of Renal Failure Requiring Dialysis","code":"C184791","definitions":[{"definition":"An indication that a subject a history of renal failure that required treatment with dialysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Renal Failure Requiring Dialysis","termGroup":"PT","termSource":"NCI"},{"termName":"History of Renal Failure Requiring Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"History of Renal Failure that Required Dialysis","termGroup":"SY","termSource":"NCI"},{"termName":"Personal History of Renal Failure that Required Dialysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Renal Failure (Requiring Dialysis)"},{"name":"NCI_META_CUI","value":"CL1772993"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C4376":{"preferredName":"Renal Failure","code":"C4376","definitions":[{"definition":"A condition in which the kidneys stop working and are not able to remove waste and extra water from the blood or keep body chemicals in balance. Acute or severe renal failure happens suddenly (for example, after an injury) and may be treated and cured. Chronic renal failure develops over many years, may be caused by conditions like high blood pressure or diabetes, and cannot be cured. Chronic renal failure may lead to total and long-lasting renal failure, called end-stage renal disease (ESRD). A person in ESRD needs dialysis (the process of cleaning the blood by passing it through a membrane or filter) or a kidney transplant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood resulting in uremia and electrolyte imbalances.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Failure","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Failure","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Insufficiency","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Renal_Failure"},{"name":"Maps_To","value":"Renal failure"},{"name":"Maps_To","value":"Renal Insufficiency"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1862666"},{"name":"xRef","value":"IMDRF:E130501"}]}}{"C2884":{"preferredName":"Rheumatoid Arthritis","code":"C2884","definitions":[{"definition":"A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A chronic, inflammatory condition manifesting primarily as a symmetric, erosive, polyarthritis that spares the axial skeleton and is typically associated with rheumatoid factor and anti-citrullinated protein antibodies.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.","type":"DEFINITION","source":"NCI"},{"definition":"An autoimmune disease that causes pain, swelling, and stiffness in the joints, and may cause severe joint damage, loss of function, and disability. The disease may last from months to a lifetime, and symptoms may improve and worsen over time.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rheumatoid Arthritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Rheumatoid_Arthritis"},{"name":"Maps_To","value":"Rheumatoid Arthritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0003873"},{"name":"xRef","value":"IMDRF:E160201"}]}}{"C27204":{"preferredName":"Rheumatologic Disorder","code":"C27204","definitions":[{"definition":"A group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A term previously used to describe chronic diseases of the connective tissue (e.g., rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis), but now is thought to be more appropriate for diseases associated with defects in collagen, which is a component of the connective tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An umbrella term used to encompass disorders characterized by autoimmunity, autoinflammatory processes, joint or connective tissue inflammation or degeneration.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rheumatologic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Collagen Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Musculoskeletal Pain Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Rheumatism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Rheumatologic_Disorder"},{"name":"Maps_To","value":"Rheumatologic Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035435"}]}}{"C75466":{"preferredName":"Rubinstein-Taybi Syndrome","code":"C75466","definitions":[{"definition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene. It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes. Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rubinstein-Taybi Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Rubinstein_Taybi_Syndrome"},{"name":"Maps_To","value":"Rubinstein-Taybi Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035934"}]}}{"C34995":{"preferredName":"Sarcoidosis","code":"C34995","definitions":[{"definition":"An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.","type":"DEFINITION","source":"NCI"},{"definition":"An inflammatory disease marked by the formation of granulomas (small nodules of immune cells) in the lungs, lymph nodes, and other organs. Sarcoidosis may be acute and go away by itself, or it may be chronic and progressive.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inflammatory disorder characterized by the formation of non-necrotizing granulomas often associated with multi-nucleated giant cells within affected organs. Virtually all organs may be affected; however, it often affects the lungs, lymph nodes, liver, synovium, skin, heart, and uveal tract.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sarcoidosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Sarcoidosis"},{"name":"Maps_To","value":"Sarcoidosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4227551"}]}}{"C71079":{"preferredName":"Herpes Zoster","code":"C71079","definitions":[{"definition":"A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.","type":"DEFINITION","source":"NCI"},{"definition":"Varicella zoster virus infection that is caused by the reactivation of virus, which can be latent within dorsal root ganglia; zoster is characterized by vesicular lesions clustered unilaterally in a dermatomal distribution of one or more adjacent sensory nerves. Neuralgic pain can occur and can be severe.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Herpes Zoster","termGroup":"PT","termSource":"NCI"},{"termName":"Shingles","termGroup":"SY","termSource":"NCI"},{"termName":"Zoster","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Herpes_Zoster"},{"name":"Maps_To","value":"Herpes Zoster"},{"name":"Maps_To","value":"Shingles"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019360"}]}}{"C26883":{"preferredName":"Sjogren Syndrome","code":"C26883","definitions":[{"definition":"An autoimmune disease that affects the tear glands and salivary glands, and may affect glands in the stomach, pancreas, and intestines. The disease causes dry eyes and mouth, and may cause dryness in the nose, throat, air passages, skin, and vagina. It may also cause inflammation in the joints, muscles, and skin; pneumonia; tingling in the fingers and toes; and fatigue. It often occurs with rheumatoid arthritis or other connective tissue diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","type":"DEFINITION","source":"NCI"},{"definition":"Autoimmune epithelial inflammation often affecting the salivary and lacrimal glands (causing dry mouth and dry eyes) with potential extraglandular manifestations. In children, it most commonly presents with recurrent parotitis. It may occur alone (primary) or in association with another autoimmune disease (secondary).","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sjogren Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Sjogren's Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Sjögren Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Sjogren_s_Syndrome"},{"name":"Maps_To","value":"Sjogren's Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1527336"}]}}{"C26884":{"preferredName":"Sleep Apnea","code":"C26884","definitions":[{"definition":"A disorder characterized by cessation of breathing for short periods during sleep.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A sleep disorder that is marked by pauses in breathing of 10 seconds or more during sleep, and causes unrestful sleep. Symptoms include loud or abnormal snoring, daytime sleepiness, irritability, and depression.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Cessation of breathing for short periods during sleep. It is classified as obstructive, central, or mixed obstructive-central. It can occur at any age but it is more frequent in people over forty. Risk factors include male sex and obesity.","type":"DEFINITION","source":"NCI"},{"definition":"The cessation of breathing for periods of time during sleep.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Sleep Apnea","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Sleep_Apnea"},{"name":"Maps_To","value":"Sleep apnea"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C3279848"}]}}{"C17934":{"preferredName":"Tobacco Smoking","code":"C17934","definitions":[{"definition":"The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Smoking","termGroup":"PT","termSource":"NCI"},{"termName":"Smoking","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tobacco_Smoking"},{"name":"Maps_To","value":"Tobacco, Smoking"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0453996"}]}}{"C122576":{"preferredName":"Staphylococcus aureus Infection","code":"C122576","definitions":[{"definition":"An infectious process in which the bacteria Staphylococcus aureus is present.","type":"DEFINITION","source":"NCI"},{"definition":"An infectious process in which the bacteria Staphylococcus aureus is present.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Staphylococcus aureus Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Staphylococcus aureus"},{"name":"Maps_To","value":"Staphylococcus aureus infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1318973"}]}}{"C36185":{"preferredName":"Steatosis","code":"C36185","definitions":[{"definition":"Acumulation of adipose tissue in intracytoplasmic or extracellular spaces.","type":"DEFINITION","source":"NCI"},{"definition":"Increased lipid within the cytoplasm of cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Steatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Fatty Change","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fatty_Change"},{"name":"Maps_To","value":"Steatosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1849982"}]}}{"C3390":{"preferredName":"Stroke","code":"C3390","definitions":[{"definition":"A disorder characterized by a sudden loss of sensory function due to an intracranial vascular event.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","type":"DEFINITION","source":"NCI"},{"definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"An acute episode of focal or global neurological dysfunction caused by presumed brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction but with insufficient information to allow categorization as ischemic or hemorrhagic.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An episode of acute neurological dysfunction presumed to be caused by ischemia or hemorrhage, persisting greater than or equal to 24 h or until death but without sufficient evidence to be classified as one of the above","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Brain tissue necrosis due to a disturbance in the blood flow or hemorrhage.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"In medicine, a loss of blood flow to part of the brain, which damages brain tissue. Strokes are caused by blood clots and broken blood vessels in the brain. Symptoms include dizziness, numbness, weakness on one side of the body, and problems with talking, writing, or understanding language. The risk of stroke is increased by high blood pressure, older age, smoking, diabetes, high cholesterol, heart disease, atherosclerosis (a build-up of fatty material and plaque inside the coronary arteries), and a family history of stroke.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stroke","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebrovascular Accident","termGroup":"SY","termSource":"NCI"},{"termName":"CVA","termGroup":"AB","termSource":"NCI"},{"termName":"Stroke Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Cerebrovascular_Accident"},{"name":"Maps_To","value":"Cerebrovascular accident"},{"name":"Maps_To","value":"Stroke"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3554760"},{"name":"xRef","value":"IMDRF:E0133"}]}}{"C35055":{"preferredName":"Syphilis","code":"C35055","definitions":[{"definition":"A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by the spirochete Treponema pallidum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Syphilis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Syphilis"},{"name":"Maps_To","value":"Syphilis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0039128"}]}}{"C50781":{"preferredName":"Transient Ischemic Attack","code":"C50781","definitions":[{"definition":"A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"DEFINITION","source":"NCI"},{"definition":"A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A brief episode of neurological dysfunction, caused by focal brain or retinal ischemia without imaging evidence of acute infarction","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A transient episode of cerebral dysfunction of vascular origin with no persistent neurological deficit.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Transient Ischemic Attack","termGroup":"PT","termSource":"NCI"},{"termName":"TIA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Transient_Ischemic_Attack"},{"name":"Maps_To","value":"Transient Ischemic Attack"},{"name":"Maps_To","value":"Transient ischemic attacks"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007787"},{"name":"xRef","value":"IMDRF:E0137"}]}}{"C85197":{"preferredName":"Treponemal Infection","code":"C85197","definitions":[{"definition":"A sexually transmitted infection caused by the Gram-negative spirochete Treponema pallidum. It is manifested as syphilis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treponemal Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treponema pallidum"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0040843"}]}}{"C3423":{"preferredName":"Tuberculosis","code":"C3423","definitions":[{"definition":"A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use.","type":"DEFINITION","source":"NCI"},{"definition":"A disease caused by Mycobacterium tuberculosis infection that is characterized by the growth of nodules in body tissues, most commonly the lungs, and may be transmitted through droplets from the throat or lungs of individuals with the active respiratory disease.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Tuberculosis","termGroup":"PT","termSource":"NCI"},{"termName":"TB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Tuberculosis"},{"name":"Maps_To","value":"Tuberculosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0041296"}]}}{"C3938":{"preferredName":"Turcot Syndrome","code":"C3938","definitions":[{"definition":"An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Turcot Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Turcot_Syndrome"},{"name":"Maps_To","value":"Turcot Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0265325"}]}}{"C98640":{"preferredName":"Tyrosinemia","code":"C98640","definitions":[{"definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tyrosinemia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0268483"}]}}{"C2952":{"preferredName":"Ulcerative Colitis","code":"C2952","definitions":[{"definition":"A chronic inflammatory disease affecting the mucosal surface of the colon and rectum.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","type":"DEFINITION","source":"NCI"},{"definition":"Chronic inflammation of the colon that produces ulcers in its lining.  This condition is marked by abdominal pain, cramps, and loose discharges of pus, blood, and mucus from the bowel.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ulcerative Colitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Ulcerative_Colitis"},{"name":"Maps_To","value":"Ulcerative colitis"},{"name":"Maps_To","value":"Ulcerative Colitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3553962"}]}}{"C3718":{"preferredName":"WAGR Syndrome","code":"C3718","definitions":[{"definition":"A rare, genetic disorder that is present at birth and has two or more of the following symptoms: Wilms tumor (a type of kidney cancer); little or no iris (the colored part of the eye); defects in the sexual organs and urinary tract (the organs that make urine and pass it from the body); and below average mental ability. This syndrome occurs when part of chromosome 11 is missing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A syndrome characterized by a predisposition for Wilms tumor, aniridia, genitourinary anomalies, and developmental delay. This is a contiguous gene syndrome due to deletion in the vicinity of chromosome 11p13 in a region containing the WT1 and PAX6 genes.","type":"DEFINITION","source":"NCI"},{"definition":"A syndrome characterized by a predisposition for Wilms tumor, aniridia, genitourinary anomalies, and developmental delay. This is a contiguous gene syndrome due to deletion in the vicinity of chromosome 11p13 in a region containing the WT1 and PAX6 genes.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"WAGR Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Wilms_Tumor-Aniridia-Genitourinary_Anomalies-Mental_Retardation_Syndrome"},{"name":"Maps_To","value":"Wagr Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0206115"}]}}{"C3037":{"preferredName":"Chronic Fatigue Syndrome","code":"C3037","definitions":[{"definition":"A condition lasting for more than 6 months in which a person feels tired most of the time and may have trouble concentrating and carrying out daily activities. Other symptoms include sore throat, fever, muscle weakness, headache, and joint pain.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A syndrome of unknown etiology. Chronic fatigue syndrome (CFS) is a clinical diagnosis characterized by an unexplained persistent or relapsing chronic fatigue that is of at least six months' duration, is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction of previous levels of occupational, educational, social, or personal activities. Common concurrent symptoms of at least six months duration include impairment of memory or concentration, diffuse pain, sore throat, tender lymph nodes, headaches of a new type, pattern, or severity, and nonrestorative sleep. The etiology of CFS may be viral or immunologic. Neurasthenia and fibromyalgia may represent related disorders. Also known as myalgic encephalomyelitis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Fatigue Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Myalgic Encephalomyelitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Chronic_Fatigue_Syndrome"},{"name":"Maps_To","value":"Chronic Fatigue Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0015674"}]}}{"C162188":{"preferredName":"Clonal Hematopoiesis","code":"C162188","definitions":[{"definition":"Cellular proliferation of hematopoietic cells where a substantial proportion of the cells is derived from a single hematopoietic stem cell lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clonal Hematopoiesis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clonal Hematopoiesis"},{"name":"NCI_META_CUI","value":"CL970785"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C87497":{"preferredName":"Fibromyalgia","code":"C87497","definitions":[{"definition":"A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.","type":"DEFINITION","source":"NCI"},{"definition":"Chronic, diffuse, non-inflammatory musculoskeletal pain disorder with characteristic tender points of neck, back, shoulders, hips, arms and legs, and associated with fatigue and sleep disturbance. Other symptoms may include headaches, abdominal discomfort, and depression/anxiety. It may also be associated with a primary rheumatic disorder.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Fibromyalgia","termGroup":"PT","termSource":"NCI"},{"termName":"Fibromyalgia Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Fibromyalgia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0016053"}]}}{"C26780":{"preferredName":"Gastritis","code":"C26780","definitions":[{"definition":"A disorder characterized by inflammation of the stomach.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Inflammation of the lining of the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Inflammation of the stomach.","type":"DEFINITION","source":"NCI"},{"definition":"Inflammation of the stomach.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Inflammation of the stomach.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Gastritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Gastritis"},{"name":"Maps_To","value":"Gastritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0017152"},{"name":"xRef","value":"IMDRF:E1012"}]}}{"C179424":{"preferredName":"Abnormal Glucose Level Finding","code":"C179424","definitions":[{"definition":"A finding that either fasting or postprandial blood glucose levels are above or below the normal thresholds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abnormal Glucose Level Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Abnormal Glucose Level","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abnormal Glucose Level"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0522083"}]}}{"C26744":{"preferredName":"Dermatomyositis","code":"C26744","definitions":[{"definition":"Inflammation of the skin and muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dermatomyositis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Dermatomyositis"},{"name":"Maps_To","value":"Dermatomyosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3278909"}]}}{"C96407":{"preferredName":"Varicella Zoster Infection","code":"C96407","definitions":[{"definition":"A highly contagious viral infection caused by the varicella zoster virus. Clinically, it may be manifested as shingles or chicken pox.","type":"DEFINITION","source":"NCI"},{"definition":"A highly contagious viral infection that is caused by the varicella zoster virus; it clinically manifests as either shingles or chicken pox.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Varicella Zoster Infection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Varicella Zoster Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0586989"}]}}{"C188353":{"preferredName":"Staphylococcal Osteomyelitis","code":"C188353","definitions":[{"definition":"Osteomyelitis resulting from an infection with Staphylococcus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staphylococcal Osteomyelitis","termGroup":"PT","termSource":"NCI"},{"termName":"Staph Osteomyelitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Infectious osteomyelitis usually results from an infection with Staphylococcus aureus."},{"name":"Maps_To","value":"Staph Osteomyelitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1535985"}]}}{"C27582":{"preferredName":"Central Nervous System Infectious Disorder","code":"C27582","definitions":[{"definition":"An infectious process that affects the brain and/or spinal cord. Representative examples include encephalitis, poliomyelitis, arachnoiditis, and meningitis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Nervous System Infectious Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Central Nervous System Infectious Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Central_Nervous_System_Infectious_Disorder"},{"name":"Maps_To","value":"CNS Infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0007684"}]}}{"C159717":{"preferredName":"EBV-Related Lymphoproliferative Disorder","code":"C159717","definitions":[{"definition":"A lymphoproliferative disorder associated with Epstein-Barr virus. This category includes, but is not limited to, Burkitt lymphoma, classic Hodgkin lymphoma, and lymphomas arising in immunocompromised individuals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBV-Related Lymphoproliferative Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Epstein-Barr Virus-Associated Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Epstein-Barr Virus-Related Lymphoproliferative Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EBV Lymphoproliferation"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C2363744"}]}}{"C115248":{"preferredName":"Methicillin-Resistant Staphylococcus aureus Infection","code":"C115248","definitions":[{"definition":"A bacterial infection that is caused by Staphylococcus aureus and is resistant to methicillin treatment.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A bacterial infection that is caused by Staphylococcus aureus that is not susceptible to methicillin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methicillin-Resistant Staphylococcus aureus Infection","termGroup":"PT","termSource":"NCI"},{"termName":"MRSA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Methicillin-Resistant Staphylococcus aureus (MRSA)"},{"name":"Maps_To","value":"Methicillin-resistant Staphylococcus aureus infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0343401"}]}}{"C27566":{"preferredName":"Non-Neoplastic Thyroid Gland Disorder","code":"C27566","definitions":[{"definition":"A non-neoplastic disorder that affects the thyroid gland.  Representative examples include hyperthyroidism, hypothyroidism, thyroiditis, and thyroid gland abscess.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Neoplastic Thyroid Gland Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Non-Neoplastic_Thyroid_Gland_Disorder"},{"name":"Maps_To","value":"Thyroid Disease, Non-Cancer"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1335047"}]}}{"C50791":{"preferredName":"Urinary Tract Infection","code":"C50791","definitions":[{"definition":"A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.","type":"DEFINITION","source":"NCI"},{"definition":"A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An infection of the kidneys, ureters, bladder and/or urethra.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An inflammatory process affecting any part of the urinary tract, most commonly the bladder or the urethra.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Urinary Tract Infection","termGroup":"PT","termSource":"NCI"},{"termName":"UTI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Urinary_Tract_Infection"},{"name":"Maps_To","value":"Urinary Tract Infection"},{"name":"Maps_To","value":"Urinary tract infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0042029"},{"name":"xRef","value":"IMDRF:E1310"}]}}{"C16681":{"preferredName":"Histology","code":"C16681","definitions":[{"definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","type":"DEFINITION","source":"NCI"},{"definition":"The study of tissues and cells under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Histology","termGroup":"PT","termSource":"NCI"},{"termName":"Microanatomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Histology"},{"name":"Maps_To","value":"Histology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0019638"}]}}{"C18189":{"preferredName":"Pathology","code":"C18189","definitions":[{"definition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pathology","termGroup":"PT","termSource":"NCI"},{"termName":"Pathological","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pathology"},{"name":"Maps_To","value":"Pathology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0030664"}]}}{"C19187":{"preferredName":"Diagnostic Radiology","code":"C19187","definitions":[{"definition":"The branch of radiology concerned with the use of ionizing or nonionizing radiation for diagnostic purposes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diagnostic Radiology","termGroup":"PT","termSource":"NCI"},{"termName":"Diagnostic Radiology (Ionizing and Nonionizing)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diagnostic_Radiology_Ionizing_and_Nonionizing"},{"name":"Maps_To","value":"Radiology"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"},{"name":"UMLS_CUI","value":"C1511880"}]}}{"C139651":{"preferredName":"Alpha-glucosidase Inhibitor","code":"C139651","definitions":[{"definition":"Any agent that inhibits the enzyme alpha-glucosidase located in the intestines. This prevents the breakdown of complex carbohydrates to glucose and other monosaccharides, which results in decreased intestinal absorption of monosaccharides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-glucosidase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"AGI","termGroup":"AB","termSource":"NCI"},{"termName":"AGIs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alpha-Glucosidase Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C2267008"}]}}{"C98234":{"preferredName":"Biguanide Antidiabetic Agent","code":"C98234","definitions":[{"definition":"Any antidiabetic agent with the biguanide base structure or phenformin derivatives with antihyperglycemic activity. Biguanide antidiabetic agents activate AMP-activated protein kinase (AMPK) resulting in decreased glucose production in the liver, increased peripheral glucose uptake and improved utilization of glucose. Biguanide-based antidiabetic agents do not cause hypoglycemia. In addition, biguanide antidiabetics decrease absorption of glucose from the gastrointestinal tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biguanide Antidiabetic Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biguanide"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273895"}]}}{"C15383":{"preferredName":"Special Diet Therapy","code":"C15383","definitions":[{"definition":"A form of therapy which includes dietary approaches and special diets that are applied as alternative therapies for risk factors or chronic disease in general.","type":"DEFINITION","source":"NCI"},{"definition":"A form of therapy which includes dietary approaches and special diets.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Special Diet Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Special Diet Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Special_Diet_Therapy"},{"name":"Maps_To","value":"Diet"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1519433"}]}}{"C179441":{"preferredName":"Injected Insulin Diabetes Therapy","code":"C179441","definitions":[{"definition":"The use of injected forms of insulin to treat diabetes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Injected Insulin Diabetes Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Injected Insulin","termGroup":"SY","termSource":"NCI"},{"termName":"Injected Insulin Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic Insulin Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Injected Insulin"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0199782"}]}}{"C581":{"preferredName":"Therapeutic Insulin","code":"C581","definitions":[{"definition":"A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Insulin","termGroup":"PT","termSource":"NCI"},{"termName":"Insulin","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Insulin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11061-68-0"},{"name":"CAS_Registry","value":"9004-10-8"},{"name":"CHEBI_ID","value":"CHEBI:5931"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Insulin"},{"name":"Maps_To","value":"Insulin"},{"name":"NCI_Drug_Dictionary_ID","value":"43345"},{"name":"NSC Number","value":"88206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43345"},{"name":"PDQ_Open_Trial_Search_ID","value":"43345"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1579433"}]}}{"C179448":{"preferredName":"Oral Hypoglycemic Diabetes Therapy","code":"C179448","definitions":[{"definition":"The use of oral hypoglycemic agents to treat diabetes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Hypoglycemic Diabetes Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Oral Hypoglycemic Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic Oral Hypoglycemic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Hypoglycemic"},{"name":"NCI_META_CUI","value":"CL1662299"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C97936":{"preferredName":"Sulfonylurea Antidiabetic Agent","code":"C97936","definitions":[{"definition":"Sulfonamide urea derivatives with antihyperglycemic activity. Sulphonylurea antidiabetic agents bind to sulfonylurea receptor type 1 (SUR1), the subunit of ATP-sensitive inwardly-rectifier potassium (IKATP) channels on the membranes of pancreatic beta cells, thereby blocking the inward current flow (influx) of positively charged K+ ions into the cell. This results in tonic membrane depolarization, and induces a calcium ion influx through voltage-sensitive calcium channels; increased intracellular calcium ion levels trigger exocytosis of insulin-containing granules. This eventually induces secretion of insulin. The IKATP channels found in pancreatic islets are complexes of four IKATP 6.2 and four SUR1 subunits. In addition, some sulfonylureas of larger molecular size may increase the sensitivity of peripheral tissues to insulin mediated through peroxisome proliferator-activated receptor gamma (PPARgamma).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulfonylurea Antidiabetic Agent","termGroup":"PT","termSource":"NCI"},{"termName":"Sulphonylurea Antidiabetic Agent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sulfonylurea"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273710"}]}}{"C98241":{"preferredName":"Thiazolidinedione Antidiabetic Agent","code":"C98241","definitions":[{"definition":"Any antidiabetic agent with the glitazone (thiazolidinedione) base structure with antihyperglycemic activity. Glitazone antidiabetic agents selectively bind to and stimulate the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma. This results in the selective transcription of a number of insulin-sensitive genes involved in glucose metabolism. This eventually enhances insulin sensitivity, reduces insulin resistance and decreases hepatic gluconeogenesis. PPARs function as transcription factors that regulate expressions of genes involved in cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), as well as tumorigenesis; PPARgamma is expressed at high levels in adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thiazolidinedione Antidiabetic Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thiazolidinedione"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273907"}]}}{"C83887":{"preferredName":"Linagliptin","code":"C83887","definitions":[{"definition":"A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linagliptin","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-8-(3-Amino-Piperidin-1-yl)-7-but-2-ynyl-3-Methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"8-((3R)-3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-3,7-Dihydro-1H-Purine-2,6-Dione","termGroup":"SN","termSource":"NCI"},{"termName":"BI 1356 BS","termGroup":"CN","termSource":"NCI"},{"termName":"BI-1356","termGroup":"CN","termSource":"NCI"},{"termName":"Tradjenta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diabetes Mellitus Type II"},{"name":"CAS_Registry","value":"668270-12-0"},{"name":"Chemical_Formula","value":"C25H28N8O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3X29ZEJ4R2"},{"name":"Maps_To","value":"Linagliptin"},{"name":"NCI_Drug_Dictionary_ID","value":"793591"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793591"},{"name":"PDQ_Open_Trial_Search_ID","value":"793591"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2746078"}]}}{"C165196":{"preferredName":"Biochemical Evidence of Disease","code":"C165196","definitions":[{"definition":"An indication that biochemical markers of a disease are present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biochemical Evidence of Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BED-Biochemical Evidence of Disease"},{"name":"Maps_To","value":"Biochemical"},{"name":"NCI_META_CUI","value":"CL978408"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165205":{"preferredName":"Persistent Distant Metastasis","code":"C165205","definitions":[{"definition":"An indication that distant metastases have remained despite treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Persistent Distant Metastasis","termGroup":"PT","termSource":"NCI"},{"termName":"Persistent Distant Metastases","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PDM-Persistent Distant Metastasis"},{"name":"NCI_META_CUI","value":"CL978417"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188367":{"preferredName":"Persistent Locoregional Disease","code":"C188367","definitions":[{"definition":"A disease that persists locally and/or regionally in regards to the site of origin despite treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Persistent Locoregional Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Persistent Local and/or Regional Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Persistent Local-Regional Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PLD-Persistent Locoregional Disease"},{"name":"NCI_META_CUI","value":"CL1793605"},{"name":"Semantic_Type","value":"Finding"}]}}{"C105722":{"preferredName":"ECOG Performance Status 0","code":"C105722","definitions":[{"definition":"Fully active, able to carry on all pre-disease performance without restriction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 0","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 0","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"0"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830346"}]}}{"C105723":{"preferredName":"ECOG Performance Status 1","code":"C105723","definitions":[{"definition":"Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 1","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"1"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830345"}]}}{"C105725":{"preferredName":"ECOG Performance Status 2","code":"C105725","definitions":[{"definition":"Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 2","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"2"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830344"}]}}{"C105726":{"preferredName":"ECOG Performance Status 3","code":"C105726","definitions":[{"definition":"Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 3","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"3"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830343"}]}}{"C105727":{"preferredName":"ECOG Performance Status 4","code":"C105727","definitions":[{"definition":"Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 4","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"4"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830342"}]}}{"C105728":{"preferredName":"ECOG Performance Status 5","code":"C105728","definitions":[{"definition":"Dead.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECOG Performance Status 5","termGroup":"PT","termSource":"NCI"},{"termName":"ECOG 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"5"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3830341"}]}}{"C158780":{"preferredName":"Biopsy with Histologic Confirmation","code":"C158780","definitions":[{"definition":"A biopsy with microscopic confirmation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biopsy with Histologic Confirmation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biopsy with Histologic Confirmation"},{"name":"Maps_To","value":"Histologic Confirmation"},{"name":"NCI_META_CUI","value":"CL950682"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C158782":{"preferredName":"Convincing Image Source","code":"C158782","definitions":[{"definition":"Radiologic evidence that supports a diagnosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Convincing Image Source","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Convincing Image Source"},{"name":"NCI_META_CUI","value":"CL950684"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C83119":{"preferredName":"Physical Examination Finding","code":"C83119","definitions":[{"definition":"The result of an evaluation of the body and its functions using visual inspection, palpation, percussion, or auscultation that is performed to determine the presence, absence, or degree of a condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Physical Examination Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Physical Exam Finding","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Exam Result","termGroup":"SY","termSource":"NCI"},{"termName":"Physical Examination Result","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Physical_Exam_Result"},{"name":"Maps_To","value":"Physical Examination"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2826729"}]}}{"C150123":{"preferredName":"Biomarker Positive Malignant Neoplasm","code":"C150123","definitions":[{"definition":"A finding indicating the presence of a biomarker in a tumor sample from a patient with a malignant neoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biomarker Positive Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Biomarker Positive Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Positive Biomarker in Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Positive Biomarker in Malignant Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Positive Biomarker(s)"},{"name":"NCI_META_CUI","value":"CL551925"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C179455":{"preferredName":"Progestin Only Hormonal Contraception","code":"C179455","definitions":[{"definition":"A hormonal contraceptive that utilizes progestin (synthetic progesterone) to prevent implantation and pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progestin Only Hormonal Contraception","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progestin"},{"name":"NCI_META_CUI","value":"CL1662307"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C179456":{"preferredName":"Combination Estrogen/Progestin Hormonal Contraception","code":"C179456","definitions":[{"definition":"A hormonal contraceptive that utilizes a combination of estrogen and progestin (synthetic progesterone) to prevent ovulation and pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combination Estrogen/Progestin Hormonal Contraception","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progestin and Estrogen"},{"name":"NCI_META_CUI","value":"CL1662306"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C160671":{"preferredName":"Current Hormonal Contraceptive User","code":"C160671","definitions":[{"definition":"The individual is a current user of hormonal contraceptives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Current Hormonal Contraceptive User","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Current User"},{"name":"NCI_META_CUI","value":"CL969602"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C160672":{"preferredName":"Former Hormonal Contraceptive User","code":"C160672","definitions":[{"definition":"The individual is a former user of hormonal contraceptives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Former Hormonal Contraceptive User","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Former User"},{"name":"NCI_META_CUI","value":"CL969601"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C160673":{"preferredName":"Never Used Hormonal Contraceptives","code":"C160673","definitions":[{"definition":"The individual has never used of hormonal contraceptives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Never Used Hormonal Contraceptives","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Never Used"},{"name":"NCI_META_CUI","value":"CL969600"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C179434":{"preferredName":"Estrogen Only Hormone Replacement Therapy","code":"C179434","definitions":[{"definition":"The use of estrogen in postmenopausal women or to women who have had their ovaries surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogen Only Hormone Replacement Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Estrogen only"},{"name":"NCI_META_CUI","value":"CL1662210"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C179452":{"preferredName":"Estrogen/Progesterone Hormone Replacement Therapy","code":"C179452","definitions":[{"definition":"A combination of estrogen and progesterone given to postmenopausal women or to women who have had their ovaries surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogen/Progesterone Hormone Replacement Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progesterone and Estrogen"},{"name":"NCI_META_CUI","value":"CL1662310"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C179453":{"preferredName":"Progesterone Only Hormone Replacement Therapy","code":"C179453","definitions":[{"definition":"Progesterone given to postmenopausal women or to women who have had their ovaries surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progesterone Only Hormone Replacement Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progesterone only"},{"name":"NCI_META_CUI","value":"CL1662305"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C14338":{"preferredName":"Human Papillomavirus-16","code":"C14338","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-16 (HPV16) has been directly linked to cervical cancer and is significantly associated with invasiveness. Progression from low- to high-grade neoplasia is often associated with the integration of the HPV16 genome into the host chromosome.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 16 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-16","termGroup":"PT","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus 16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus Subtype 16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus Subtype HPV16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Human Papillomavirus-16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Subtype HPV-16","termGroup":"SY","termSource":"NCI"},{"termName":"High-Risk Subtype HPV16","termGroup":"SY","termSource":"NCI"},{"termName":"HPV Genotype 16","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-16","termGroup":"AB","termSource":"NCI"},{"termName":"HPV16","termGroup":"AB","termSource":"NCI"},{"termName":"hrHPV-16","termGroup":"SY","termSource":"NCI"},{"termName":"hrHPV16","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 16","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Genotype 16","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 16","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus-16"},{"name":"Maps_To","value":"HPV16"},{"name":"NCBI_Taxon_ID","value":"333760"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0999806"}]}}{"C14377":{"preferredName":"Human Papillomavirus-18","code":"C14377","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-18 (HPV18) has been directly linked to cervical cancer and plays a role in the pathogenesis of the disease. The virus integrates its DNA at specific chromosomal locations, such as 8q24 and 12q15. The use of molecular markers for HPV18 infection may allow the identification of patients with early stage cervical cancer and those at high risk for disease recurrence.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 18 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-18","termGroup":"PT","termSource":"NCI"},{"termName":"HPV Genotype 18","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-18","termGroup":"AB","termSource":"NCI"},{"termName":"HPV18","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Genotype 18","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 18","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus-18"},{"name":"Maps_To","value":"HPV18"},{"name":"NCBI_Taxon_ID","value":"333761"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0999807"}]}}{"C102995":{"preferredName":"Human Papillomavirus-26","code":"C102995","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-26 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-26","termGroup":"PT","termSource":"NCI"},{"termName":"Alphapapillomavirus 5","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-26","termGroup":"SY","termSource":"NCI"},{"termName":"HPV26","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 26","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"26"},{"name":"NCBI_Taxon_ID","value":"333762"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1645198"}]}}{"C102904":{"preferredName":"Human Papillomavirus-31","code":"C102904","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-31 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 31 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-31","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-31","termGroup":"SY","termSource":"NCI"},{"termName":"HPV31","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 31","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV31"},{"name":"NCBI_Taxon_ID","value":"10585"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C2936597"}]}}{"C102996":{"preferredName":"Human Papillomavirus-33","code":"C102996","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-33 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 33 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-33","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-33","termGroup":"SY","termSource":"NCI"},{"termName":"HPV33","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV33"},{"name":"NCBI_Taxon_ID","value":"10586"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641011"}]}}{"C102997":{"preferredName":"Human Papillomavirus-35","code":"C102997","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-35 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 35 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-35","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-35","termGroup":"SY","termSource":"NCI"},{"termName":"HPV35","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 35","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV35"},{"name":"NCBI_Taxon_ID","value":"10587"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641012"}]}}{"C102998":{"preferredName":"Human Papillomavirus-39","code":"C102998","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-39 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 39 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-39","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-39","termGroup":"SY","termSource":"NCI"},{"termName":"HPV39","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 39","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV39"},{"name":"NCBI_Taxon_ID","value":"10588"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641013"}]}}{"C102999":{"preferredName":"Human Papillomavirus-45","code":"C102999","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-45 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 45 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-45","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-45","termGroup":"SY","termSource":"NCI"},{"termName":"HPV45","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 45","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV45"},{"name":"NCBI_Taxon_ID","value":"10593"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641014"}]}}{"C103000":{"preferredName":"Human Papillomavirus-51","code":"C103000","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-51 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 51 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-51","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-51","termGroup":"SY","termSource":"NCI"},{"termName":"HPV51","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 51","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV51"},{"name":"NCBI_Taxon_ID","value":"10595"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641015"}]}}{"C103001":{"preferredName":"Human Papillomavirus-52","code":"C103001","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-52 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 52 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-52","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-52","termGroup":"SY","termSource":"NCI"},{"termName":"HPV52","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 52","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV52"},{"name":"NCBI_Taxon_ID","value":"10618"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641016"}]}}{"C103002":{"preferredName":"Human Papillomavirus-53","code":"C103002","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-53 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 53 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-53","termGroup":"PT","termSource":"NCI"},{"termName":"Alphapapillomavirus 6","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-53","termGroup":"SY","termSource":"NCI"},{"termName":"HPV53","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 53","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"53"},{"name":"NCBI_Taxon_ID","value":"333765"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1629153"}]}}{"C103003":{"preferredName":"Human Papillomavirus-56","code":"C103003","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-56 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 56 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-56","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-56","termGroup":"SY","termSource":"NCI"},{"termName":"HPV56","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 56","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV56"},{"name":"NCBI_Taxon_ID","value":"10596"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641017"}]}}{"C103004":{"preferredName":"Human Papillomavirus-58","code":"C103004","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-58 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 58 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-58","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-58","termGroup":"SY","termSource":"NCI"},{"termName":"HPV58","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 58","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV58"},{"name":"NCBI_Taxon_ID","value":"10598"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641018"}]}}{"C103005":{"preferredName":"Human Papillomavirus-59","code":"C103005","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-59 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 59 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-59","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-59","termGroup":"SY","termSource":"NCI"},{"termName":"HPV59","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 59","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV59"},{"name":"NCBI_Taxon_ID","value":"37115"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641019"}]}}{"C156054":{"preferredName":"Human Papillomavirus-63","code":"C156054","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-63 may be associated with a risk for cervical cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-63","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-63","termGroup":"SY","termSource":"NCI"},{"termName":"HPV63","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus 63","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus-63","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 63","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"63"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1628029"}]}}{"C103006":{"preferredName":"Human Papillomavirus-66","code":"C103006","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-66 is associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 66 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-66","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-66","termGroup":"SY","termSource":"NCI"},{"termName":"HPV66","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 66","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV66"},{"name":"NCBI_Taxon_ID","value":"37119"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641020"}]}}{"C103007":{"preferredName":"Human Papillomavirus-68","code":"C103007","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-68 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 68 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-68","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-68","termGroup":"SY","termSource":"NCI"},{"termName":"HPV68","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 68","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV68"},{"name":"NCBI_Taxon_ID","value":"45240"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641021"}]}}{"C156055":{"preferredName":"Human Papillomavirus-70","code":"C156055","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-70 may be associated with a high risk for cervical cancer.","type":"DEFINITION","source":"NCI"},{"definition":"Any viral organism that can be assigned to the Human papillomavirus virus type 70 serotype.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Human Papillomavirus-70","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-70","termGroup":"SY","termSource":"NCI"},{"termName":"HPV70","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus 70","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papilloma Virus-70","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 70","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"70"},{"name":"NCBI_Taxon_ID","value":"39457"},{"name":"NCI_META_CUI","value":"CL562899"},{"name":"Semantic_Type","value":"Virus"}]}}{"C103008":{"preferredName":"Human Papillomavirus-73","code":"C103008","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-73 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-73","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-73","termGroup":"SY","termSource":"NCI"},{"termName":"HPV73","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 73","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV73"},{"name":"NCBI_Taxon_ID","value":"51033"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641022"}]}}{"C103009":{"preferredName":"Human Papillomavirus-82","code":"C103009","definitions":[{"definition":"A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-82 may be associated with a high risk for cervical intraepithelial neoplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus-82","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-82","termGroup":"SY","termSource":"NCI"},{"termName":"HPV82","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Type 82","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"82"},{"name":"NCBI_Taxon_ID","value":"129724"},{"name":"PubMedID_Primary_Reference","value":"16949995"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C3641023"}]}}{"C179443":{"preferredName":"Macroscopically Positive Parametrial Margin","code":"C179443","definitions":[{"definition":"The presence of macroscopically visible residual tumor in surgical margins in the parametrial region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macroscopically Positive Parametrial Margin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Macroscopic Parametrium"},{"name":"NCI_META_CUI","value":"CL1662302"},{"name":"Semantic_Type","value":"Finding"}]}}{"C179445":{"preferredName":"Microscopically Positive Parametrial Margin","code":"C179445","definitions":[{"definition":"The presence of microscopically visible residual tumor in surgical margins in the parametrial region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microscopically Positive Parametrial Margin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microscopic Parametrium"},{"name":"NCI_META_CUI","value":"CL1662298"},{"name":"Semantic_Type","value":"Finding"}]}}{"C48621":{"preferredName":"Negative Surgical Margin","code":"C48621","definitions":[{"definition":"Indicates the absence of tumor cells at the edge of a surgically excised specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Negative Surgical Margin","termGroup":"PT","termSource":"NCI"},{"termName":"Clear Margin","termGroup":"SY","termSource":"NCI"},{"termName":"Clear Surgical Margin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Negative_Surgical_Margin"},{"name":"Maps_To","value":"None"},{"name":"Maps_To","value":"Uninvolved"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709157"}]}}{"C15256":{"preferredName":"Hysterectomy","code":"C15256","definitions":[{"definition":"A surgical procedure to remove the uterine body (partial hysterectomy) or the uterine body and cervix (total hysterectomy).","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove the uterus and, sometimes, the cervix. When the uterus and the cervix are removed, it is called a total hysterectomy. When only the uterus is removed, it is called a partial hysterectomy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hysterectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hysterectomy"},{"name":"Maps_To","value":"Hysterectomy NOS"},{"name":"Maps_To","value":"Hysterectomy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0020699"}]}}{"C141477":{"preferredName":"Not Performed","code":"C141477","definitions":[{"definition":"An indicator that specifies that an activity did not occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Not Performed","termGroup":"PT","termSource":"NCI"},{"termName":"Not Performed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Not performed"},{"name":"Maps_To","value":"Not Performed"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0445106"}]}}{"C94470":{"preferredName":"Radical Hysterectomy","code":"C94470","definitions":[{"definition":"Surgery to remove the uterus, cervix, and part of the vagina. The ovaries, fallopian tubes, and nearby lymph nodes may also be removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of the uterus and surrounding structures, including bilateral pelvic lymph nodes, the parametrium, and the upper one-third to one-half of the vagina.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Hysterectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radical Hysterectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2987682"}]}}{"C15701":{"preferredName":"Total Hysterectomy","code":"C15701","definitions":[{"definition":"A surgical procedure to remove the uterine body and cervix. -- 2004","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove the entire uterus, including the cervix.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Total Hysterectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Hysterectomy"},{"name":"Maps_To","value":"Full Hysterectomy"},{"name":"Maps_To","value":"Simple Hysterectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0677962"}]}}{"C38758":{"preferredName":"Positive Finding","code":"C38758","definitions":[{"definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","type":"DEFINITION","source":"NCI"},{"definition":"A test result that shows a person has what was tested for. (https://mrctcenter.org/glossaryterm/positive-test-result/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"An indication of an affirmative finding for a test or assessment, such as for a disease, condition, analyte, or microorganism.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Positive Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Positive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Positive_Finding"},{"name":"Maps_To","value":"Positive"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1446409"}]}}{"C162575":{"preferredName":"99mTc Bone Scintography","code":"C162575","definitions":[{"definition":"An imaging modality that reflects alterations in the metabolic activity of bone through the use of radiopharmaceutical agents, commonly technetium-99m-labeled methylene diphosphonate (MDP).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"99mTc Bone Scintography","termGroup":"PT","termSource":"NCI"},{"termName":"99mTc Bone Scintiscan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"99mTc Bone Scintigraphy"},{"name":"NCI_META_CUI","value":"CL971093"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C17204":{"preferredName":"Computed Tomography","code":"C17204","definitions":[{"definition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","type":"DEFINITION","source":"NCI"},{"definition":"A series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A way to take pictures of the inside of a person's body using a type of radiation and a computer. (https://mrctcenter.org/glossaryterm/computerized-tomography-ct-scan/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"An imaging technique for examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Computed Tomography","termGroup":"PT","termSource":"NCI"},{"termName":"CAT","termGroup":"AB","termSource":"NCI"},{"termName":"CAT Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Computerized Axial Tomography","termGroup":"SY","termSource":"NCI"},{"termName":"Computerized Tomography","termGroup":"SY","termSource":"NCI"},{"termName":"CT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Computed_Tomography"},{"name":"Maps_To","value":"CT Scan"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0040405"}]}}{"C16809":{"preferredName":"Magnetic Resonance Imaging","code":"C16809","definitions":[{"definition":"A procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and diseased tissue. NMRI makes better images of organs and soft tissue than other scanning techniques, such as computed tomography (CT) or x-ray. NMRI is especially useful for imaging the brain, the spine, the soft tissue of joints, and the inside of bones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A way to take pictures of the inside of a person's body with a machine that uses strong magnets and radio waves. (https://mrctcenter.org/glossaryterm/magnetic-resonance-imaging-mri/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Magnetic Resonance Imaging","termGroup":"PT","termSource":"NCI"},{"termName":"Magnetic Resonance Imaging Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","termGroup":"SY","termSource":"NCI"},{"termName":"MR Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"MRI","termGroup":"AB","termSource":"NCI"},{"termName":"MRI Scan","termGroup":"SY","termSource":"NCI"},{"termName":"NMR Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"NMRI","termGroup":"AB","termSource":"NCI"},{"termName":"Nuclear Magnetic Resonance Imaging","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Magnetic_Resonance_Imaging"},{"name":"Maps_To","value":"MRI"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0024485"}]}}{"C17007":{"preferredName":"Positron Emission Tomography","code":"C17007","definitions":[{"definition":"A procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is used. Because cancer cells often use more glucose than normal cells, the pictures can be used to find cancer cells in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","type":"DEFINITION","source":"NCI"},{"definition":"An imaging technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance. A scanner reveals the tissue location of the metabolically-active substance administered.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Positron Emission Tomography","termGroup":"PT","termSource":"NCI"},{"termName":"Medical Imaging, Positron Emission Tomography","termGroup":"SY","termSource":"NCI"},{"termName":"PET","termGroup":"SY","termSource":"NCI"},{"termName":"PET Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Positron Emission Tomography Scan","termGroup":"SY","termSource":"NCI"},{"termName":"Positron-Emission Tomography","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Positron_Emission_Tomography"},{"name":"Maps_To","value":"PET"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0032743"}]}}{"C17230":{"preferredName":"Ultrasound Imaging","code":"C17230","definitions":[{"definition":"A procedure in which high-energy sound waves are bounced off internal tissues or organs and make echoes. The echo patterns are shown on the screen of an ultrasound machine, forming a picture of body tissues called a sonogram.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The use of high-frequency sound waves to generate images of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ultrasound Imaging","termGroup":"PT","termSource":"NCI"},{"termName":"2-Dimensional Grayscale Ultrasound Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"2-Dimensional Ultrasound Imaging","termGroup":"SY","termSource":"NCI"},{"termName":"2D-US","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasonography","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasound","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasound Test","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasound, Medical","termGroup":"SY","termSource":"NCI"},{"termName":"US","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Ultrasound_Imaging"},{"name":"Maps_To","value":"Ultrasound"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0041618"}]}}{"C17646":{"preferredName":"Bone Scan","code":"C17646","definitions":[{"definition":"A nuclear imaging method used to evaluate pathological bone metabolism.","type":"DEFINITION","source":"NCI"},{"definition":"A technique to create images of bones on a computer screen or on film. A small amount of radioactive material is injected into a blood vessel and travels through the bloodstream; it collects in the bones and is detected by a scanner.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bone Scan","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Scintigraphy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Bone_Scan"},{"name":"Maps_To","value":"Bone Scan, NOS"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0203668"}]}}{"C15577":{"preferredName":"Anti-Tumor Necrosis Factor Therapy","code":"C15577","definitions":[{"definition":"Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Tumor Necrosis Factor Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"anti-TNF therapy","termGroup":"SY","termSource":"NCI"},{"termName":"anti-TNF-alpha therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-Tumor_Necrosis_Factor_Therapy"},{"name":"Maps_To","value":"Anti-TNF Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0281481"}]}}{"C290":{"preferredName":"Azathioprine","code":"C290","definitions":[{"definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azathioprine","termGroup":"PT","termSource":"NCI"},{"termName":"6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine","termGroup":"SN","termSource":"NCI"},{"termName":"AZA","termGroup":"AB","termSource":"NCI"},{"termName":"AZTP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"446-86-6"},{"name":"CHEBI_ID","value":"CHEBI:2948"},{"name":"Chemical_Formula","value":"C9H7N7O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MRK240IY2L"},{"name":"Legacy Concept Name","value":"Azathioprine"},{"name":"Maps_To","value":"Azathioprine"},{"name":"NSC Number","value":"39084"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004482"}]}}{"C405":{"preferredName":"Cyclophosphamide","code":"C405","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclophosphamide","termGroup":"PT","termSource":"NCI"},{"termName":"1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-[bis(b-chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane-2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-[di(chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane 2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Asta B 518","termGroup":"CN","termSource":"NCI"},{"termName":"B 518","termGroup":"CN","termSource":"NCI"},{"termName":"B-518","termGroup":"CN","termSource":"NCI"},{"termName":"B518","termGroup":"CN","termSource":"NCI"},{"termName":"bis(2-chloroethyl)phosphamide cyclic propanolamide ester monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Carloxan","termGroup":"FB","termSource":"NCI"},{"termName":"Ciclofosfamida","termGroup":"SY","termSource":"NCI"},{"termName":"Ciclofosfamide","termGroup":"SY","termSource":"NCI"},{"termName":"Cicloxal","termGroup":"FB","termSource":"NCI"},{"termName":"Clafen","termGroup":"SY","termSource":"NCI"},{"termName":"Claphene","termGroup":"SY","termSource":"NCI"},{"termName":"CP monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"CTX","termGroup":"AB","termSource":"NCI"},{"termName":"CYCLO-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Cycloblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Cycloblastine","termGroup":"FB","termSource":"NCI"},{"termName":"Cyclophospham","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphamid monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphamide Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphamidum","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphan","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclophosphanum","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclostin","termGroup":"FB","termSource":"NCI"},{"termName":"Cyclostine","termGroup":"FB","termSource":"NCI"},{"termName":"Cytophosphan","termGroup":"FB","termSource":"NCI"},{"termName":"Cytophosphane","termGroup":"SY","termSource":"NCI"},{"termName":"Fosfaseron","termGroup":"FB","termSource":"NCI"},{"termName":"Genoxal","termGroup":"FB","termSource":"NCI"},{"termName":"Genuxal","termGroup":"FB","termSource":"NCI"},{"termName":"Ledoxina","termGroup":"FB","termSource":"NCI"},{"termName":"Mitoxan","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)phosphorodiamidic acid intramolecular ester monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(b-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Neosar","termGroup":"AQS","termSource":"NCI"},{"termName":"Revimmune","termGroup":"SY","termSource":"NCI"},{"termName":"Syklofosfamid","termGroup":"SY","termSource":"NCI"},{"termName":"WR 138719","termGroup":"CN","termSource":"NCI"},{"termName":"WR- 138719","termGroup":"CN","termSource":"NCI"},{"termName":"WR-138719","termGroup":"CN","termSource":"NCI"},{"termName":"WR138719","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Leukemias; Lupus nephritis; Lymphoma; Multiple myeloma; Neuroblastoma; Nephrotic syndrome; Ovarian cancer; Retinoblastoma; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia"},{"name":"CAS_Registry","value":"6055-19-2"},{"name":"CHEBI_ID","value":"CHEBI:4026"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O2P.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"8N3DW7272P"},{"name":"Legacy Concept Name","value":"Cyclophosphamide"},{"name":"Maps_To","value":"Cyclophosphamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39748"},{"name":"NSC Number","value":"26271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39748"},{"name":"PDQ_Open_Trial_Search_ID","value":"39748"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010583"}]}}{"C642":{"preferredName":"Methotrexate","code":"C642","definitions":[{"definition":"A drug used to treat some types of cancer, rheumatoid arthritis, and severe skin conditions, such as psoriasis. Amethopterin stops cells from making DNA and may kill cancer cells. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-10-methylfolic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Abitrexate","termGroup":"BR","termSource":"NCI"},{"termName":"Alpha-Methopterin","termGroup":"SY","termSource":"NCI"},{"termName":"Amethopterin","termGroup":"BR","termSource":"NCI"},{"termName":"Brimexate","termGroup":"FB","termSource":"NCI"},{"termName":"CL-14377","termGroup":"CN","termSource":"NCI"},{"termName":"Emtexate","termGroup":"FB","termSource":"NCI"},{"termName":"Emthexat","termGroup":"FB","termSource":"NCI"},{"termName":"Emthexate","termGroup":"FB","termSource":"NCI"},{"termName":"Farmitrexat","termGroup":"FB","termSource":"NCI"},{"termName":"Fauldexato","termGroup":"FB","termSource":"NCI"},{"termName":"Folex","termGroup":"BR","termSource":"NCI"},{"termName":"Folex PFS","termGroup":"BR","termSource":"NCI"},{"termName":"Lantarel","termGroup":"FB","termSource":"NCI"},{"termName":"Ledertrexate","termGroup":"FB","termSource":"NCI"},{"termName":"Lumexon","termGroup":"FB","termSource":"NCI"},{"termName":"Maxtrex","termGroup":"FB","termSource":"NCI"},{"termName":"Medsatrexate","termGroup":"FB","termSource":"NCI"},{"termName":"Metex","termGroup":"FB","termSource":"NCI"},{"termName":"Methoblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Methotrexate LPF","termGroup":"BR","termSource":"NCI"},{"termName":"Methotrexate Methylaminopterin","termGroup":"SY","termSource":"NCI"},{"termName":"Methotrexatum","termGroup":"SY","termSource":"NCI"},{"termName":"Metotrexato","termGroup":"SY","termSource":"NCI"},{"termName":"Metrotex","termGroup":"FB","termSource":"NCI"},{"termName":"Mexate","termGroup":"BR","termSource":"NCI"},{"termName":"Mexate-AQ","termGroup":"BR","termSource":"NCI"},{"termName":"MTX","termGroup":"AB","termSource":"NCI"},{"termName":"N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Novatrex","termGroup":"FB","termSource":"NCI"},{"termName":"Rheumatrex","termGroup":"BR","termSource":"NCI"},{"termName":"Texate","termGroup":"FB","termSource":"NCI"},{"termName":"Tremetex","termGroup":"FB","termSource":"NCI"},{"termName":"Trexeron","termGroup":"FB","termSource":"NCI"},{"termName":"Trixilem","termGroup":"FB","termSource":"NCI"},{"termName":"WR-19039","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Abortion; Bladder cancer; Breast cancer; Carcinomatous; meningitis; Chorioadenoma destruens; Crohn's disease; Ectopic pregnancy; Esophageal cancer; Gestational choriocarcinoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Graft versus host disease-prophylaxis; Head/neck cancer; Hydatidiform mole; Leukemia; meningeal; Lymphomas; Acute Lymphoblastic Leukemia; Burkitt's; Lung cancer; Mycosis fungoides; Osteosarcoma; Psoriasis; Rheumatoid arthritis; Wegener's granulomatosis"},{"name":"CAS_Registry","value":"59-05-2"},{"name":"CHEBI_ID","value":"CHEBI:44185"},{"name":"Chemical_Formula","value":"C20H22N8O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"YL5FZ2Y5U1"},{"name":"Legacy Concept Name","value":"Methotrexate"},{"name":"Maps_To","value":"Methotrexate"},{"name":"NCI_Drug_Dictionary_ID","value":"41719"},{"name":"NSC Number","value":"740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41719"},{"name":"PDQ_Open_Trial_Search_ID","value":"41719"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025677"}]}}{"C105720":{"preferredName":"Karnofsky Performance Status 0","code":"C105720","definitions":[{"definition":"Dead.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Equivalent to ECOG 5"},{"name":"Maps_To","value":"0"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829432"}]}}{"C105718":{"preferredName":"Karnofsky Performance Status 10","code":"C105718","definitions":[{"definition":"Moribund; fatal processes progressing rapidly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 10","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"10"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829430"}]}}{"C105716":{"preferredName":"Karnofsky Performance Status 20","code":"C105716","definitions":[{"definition":"Very sick; hospitalization necessary; active support treatment is necessary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 20","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 4"},{"name":"Maps_To","value":"20"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829429"}]}}{"C105715":{"preferredName":"Karnofsky Performance Status 30","code":"C105715","definitions":[{"definition":"Severely disabled; hospitalization is indicated, although death not imminent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 30","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 3"},{"name":"Maps_To","value":"30"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829428"}]}}{"C105714":{"preferredName":"Karnofsky Performance Status 40","code":"C105714","definitions":[{"definition":"Disabled; requires special care and assistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 40","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 3"},{"name":"Maps_To","value":"40"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829427"}]}}{"C105713":{"preferredName":"Karnofsky Performance Status 50","code":"C105713","definitions":[{"definition":"Requires considerable assistance and frequent medical care.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 50","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 2"},{"name":"Maps_To","value":"50"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829426"}]}}{"C105712":{"preferredName":"Karnofsky Performance Status 60","code":"C105712","definitions":[{"definition":"Requires occasional assistance, but is able to care for most personal needs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 60","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 2"},{"name":"Maps_To","value":"60"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829425"}]}}{"C105711":{"preferredName":"Karnofsky Performance Status 70","code":"C105711","definitions":[{"definition":"Cares for self; unable to carry on normal activity or do active work.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 70","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 1"},{"name":"Maps_To","value":"70"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829424"}]}}{"C105710":{"preferredName":"Karnofsky Performance Status 80","code":"C105710","definitions":[{"definition":"Normal activity with effort; some sign or symptoms of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 80","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 1"},{"name":"Maps_To","value":"80"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829423"}]}}{"C105709":{"preferredName":"Karnofsky Performance Status 90","code":"C105709","definitions":[{"definition":"Able to carry on normal activity; minor signs or symptoms of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 90","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 0"},{"name":"Maps_To","value":"90"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829422"}]}}{"C105707":{"preferredName":"Karnofsky Performance Status 100","code":"C105707","definitions":[{"definition":"Normal; no complaints; no evidence of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karnofsky Performance Status 100","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Roughly equivalent to ECOG 0"},{"name":"Maps_To","value":"100"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3829431"}]}}{"C15491":{"preferredName":"Premenopausal","code":"C15491","definitions":[{"definition":"Having to do with the time before menopause. Menopause (\"change of life\") is the time of life when a woman's menstrual periods stop permanently.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Prior to menopause.","type":"DEFINITION","source":"NCI"},{"definition":"The period of time before perimenopause.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Premenopausal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Premenopausal"},{"name":"Maps_To","value":"Premenopausal"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0279752"}]}}{"C15692":{"preferredName":"Perimenopausal","code":"C15692","definitions":[{"definition":"Describes the time in a woman's life as she approaches menopause. This is usually three to five years before menopause and is often marked by irregular menstrual periods and many of the symptoms of menopause, including hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.","type":"DEFINITION","source":"NCI"},{"definition":"Describes the time in a woman's life when menstrual periods become irregular as she approaches menopause. This is usually three to five years before menopause and is often marked by many of the symptoms of menopause, including hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The 10 or so years immediately prior to menopause when the subject experiences symptoms of menopause.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Perimenopausal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Perimenopausal"},{"name":"Maps_To","value":"Perimenopausal"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3839366"}]}}{"C15421":{"preferredName":"Postmenopausal","code":"C15421","definitions":[{"definition":"After menopause.","type":"DEFINITION","source":"NCI"},{"definition":"Having to do with the time after menopause. Menopause (\"change of life\") is the time in a woman's life when menstrual periods stop permanently.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The period of time after menopause.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Postmenopausal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Postmenopausal"},{"name":"Maps_To","value":"Postmenopausal"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C0232970"}]}}{"C34945":{"preferredName":"Ectopic Pregnancy","code":"C34945","definitions":[{"definition":"A condition in which a fertilized egg grows outside of the uterus, usually in one of the fallopian tubes. Symptoms include sharp pain on one side of the abdomen and bleeding from the vagina.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pregnancy that implants in a location other than the uterine endometrium.","type":"ALT_DEFINITION","source":"GAIA"},{"definition":"An abnormal pregnancy in which the conception is implanted outside the endometrial cavity.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An abnormal pregnancy in which the conception is implanted outside the endometrial cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Pregnancy condition that happens when there is a developing fetus or embryo outside the uterus.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Ectopic Pregnancy","termGroup":"PT","termSource":"NCI"},{"termName":"Extrauterine Pregnancy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Ectopic_Pregnancy"},{"name":"Maps_To","value":"Ectopic Pregnancy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0032987"},{"name":"xRef","value":"IMDRF:E1506"}]}}{"C50613":{"preferredName":"Induced Abortion Finding","code":"C50613","definitions":[{"definition":"Abortion brought on intentionally.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Abortion brought on intentionally.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Induced Abortion Finding","termGroup":"PT","termSource":"NCI"},{"termName":"Induced Abortion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Induced_Abortion"},{"name":"Maps_To","value":"Induced Abortion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1704300"},{"name":"xRef","value":"IMDRF:E150103"}]}}{"C114091":{"preferredName":"Live Birth","code":"C114091","definitions":[{"definition":"An infant delivered, that breathes/shows any evidence of life (e.g. beating heart, pulsation of umbilical cord) or definite movement of voluntary muscles.","type":"ALT_DEFINITION","source":"GAIA"},{"definition":"The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Live Birth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Live Birth"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0481667"}]}}{"C34336":{"preferredName":"Spontaneous Abortion","code":"C34336","definitions":[{"definition":"Early pregnancy loss.","type":"ALT_DEFINITION","source":"GAIA"},{"definition":"Fetal loss at less than 20 weeks of gestation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Fetal loss at less than 20 weeks of gestation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Spontaneous expulsion of a human fetus before it is viable.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Spontaneous Abortion","termGroup":"PT","termSource":"NCI"},{"termName":"Miscarriage","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Spontaneous_Abortion"},{"name":"Maps_To","value":"Miscarriage"},{"name":"Maps_To","value":"Spontaneous abortion"},{"name":"Maps_To","value":"Spontaneous Abortion"},{"name":"NCI_META_CUI","value":"CL793064"},{"name":"Semantic_Type","value":"Finding"},{"name":"xRef","value":"IMDRF:E150105"}]}}{"C49151":{"preferredName":"Stillbirth","code":"C49151","definitions":[{"definition":"A fetus of at least 20 weeks gestation, or of a birth weight of 350 grams or greater when the gestational age is not known, with no signs of life at the time of delivery, with Apgar scores of 0 at 1 and 5 minutes.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A fetus of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, that is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Foetal death occurring before birth after a selected, pre-defined duration of gestation. The death of the foetus could have occurred before the onset of labor (antepartum) or at the time of delivery (intrapartum). For all levels of diagnostic certainty, the definition of stillbirth is defined by the two following criteria: First, determination of absence of signs of life in the foetus or newborn; Second, determination of foetal/newborn gestational age through maternal information or through foetal/newborn evaluation.","type":"ALT_DEFINITION","source":"GAIA"}],"synonyms":[{"termName":"Stillbirth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GAIA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Stillbirth"},{"name":"Maps_To","value":"Stillbirth"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0595939"}]}}{"C16450":{"preferredName":"Colonoscopy","code":"C16450","definitions":[{"definition":"Endoscopic examination of the luminal surface of the colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Endoscopic examination of the luminal surface of the colon.","type":"DEFINITION","source":"NCI"},{"definition":"Examination of the inside of the colon using a colonoscope, inserted into the rectum. A colonoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colonoscopy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colonoscopy"},{"name":"Maps_To","value":"Colonoscopy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0009378"}]}}{"C16546":{"preferredName":"Endoscopic Procedure","code":"C16546","definitions":[{"definition":"A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A procedure that uses an endoscope to examine the inside of the body. An endoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An examination of the body using an endoscope.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endoscopic Procedure","termGroup":"PT","termSource":"NCI"},{"termName":"Endoscopic","termGroup":"AD","termSource":"NCI"},{"termName":"Endoscopic Examination","termGroup":"SY","termSource":"NCI"},{"termName":"Endoscopy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endoscopy"},{"name":"Maps_To","value":"Endoscopy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0014245"}]}}{"C55073":{"preferredName":"Recurrent Disease, Distant Site","code":"C55073","definitions":[{"definition":"Recurrence of symptoms of a disease, at a site different and away from the original site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recurrent Disease, Distant Site","termGroup":"PT","termSource":"NCI"},{"termName":"Relapse, Distant Site","termGroup":"SY","termSource":"NCI"},{"termName":"Relapsed Disease, Distant Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Recurrent_Disease_Distal_Site"},{"name":"Maps_To","value":"Distant"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1882917"}]}}{"C36162":{"preferredName":"Localized Disease","code":"C36162","definitions":[{"definition":"A disease that is confined to a specific organ or tissue and has not spread to other anatomic sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Localized Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Localized_Disease"},{"name":"Maps_To","value":"Local"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0277565"}]}}{"C41844":{"preferredName":"Regional Disease","code":"C41844","definitions":[{"definition":"A disease or condition that extends beyond the site and spreads into adjacent tissues and regional lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regional Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Regional_Disease"},{"name":"Maps_To","value":"Regional"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1514819"}]}}{"C25388":{"preferredName":"Local-Regional","code":"C25388","definitions":[{"definition":"Of or belonging to both a local and regional area of the body.","type":"DEFINITION","source":"NCI"},{"definition":"Of or belonging to either a local and/or regional area of the body in relation to a point of origin.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Local-Regional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Local-Regional"},{"name":"Maps_To","value":"Locoregional"},{"name":"Maps_To","value":"Locoregional Site"},{"name":"Semantic_Type","value":"Spatial Concept"},{"name":"UMLS_CUI","value":"C0205276"}]}}{"C29633":{"preferredName":"Antacid Preparation","code":"C29633","definitions":[{"definition":"Natural or synthetic compounds or mixtures, Antiacid Preparations such as sodium bicarbonate, sodium citrate, and phosphate salts act as proton acceptors, neutralizing the acidity of a biologic environment (skin, gastric content, urine, etc.) and raising the pH. These agents are used topically or systemically for management of metabolic acidosis, improved muscle contraction, and hyper-acidic conditions (preventing, counteracting, or neutralizing stomach acidity). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antacid Preparation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antacid_Preparation"},{"name":"Maps_To","value":"Antacids"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0003138"}]}}{"C29702":{"preferredName":"Histamine-2 Receptor Antagonist","code":"C29702","definitions":[{"definition":"A pharmaceutical agent that blocks the binding of histamine to the type II histamine receptor, and is often used to decrease gastric acid production and to treat urticaria.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any agent that competitively binds to and blocks the histamine H2 receptors found in the stomach, heart, uterus, on vascular smooth muscle and in the central nervous system (CNS). Of particular clinical relevance is the blockage of H2 receptors found on the parietal cells of the stomach, which prevents gastric acid secretion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histamine-2 Receptor Antagonist","termGroup":"PT","termSource":"NCI"},{"termName":"H2 Antagonist","termGroup":"SY","termSource":"NCI"},{"termName":"H2 Blocker","termGroup":"SY","termSource":"NCI"},{"termName":"H2 Receptor Antagonist","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:37961"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Histamine-2_Receptor_Antagonist"},{"name":"Maps_To","value":"H2 Blockers"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0019593"}]}}{"C165200":{"preferredName":"Medically Treated Reflux","code":"C165200","definitions":[{"definition":"An indication that a subject has used or is using medication to treat gastrointestinal reflux.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medically Treated Reflux","termGroup":"PT","termSource":"NCI"},{"termName":"Reflux Medically Treated","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medically Treated"},{"name":"NCI_META_CUI","value":"CL978412"},{"name":"Semantic_Type","value":"Finding"}]}}{"C29723":{"preferredName":"Proton Pump Inhibitor","code":"C29723","definitions":[{"definition":"A pharmaceutical agent that inhibits the transport of hydrogen ions, in exchange for potassium ions, into the gastric lumen and results in an inhibition of gastric acid secretion. These drugs are used for their anti-ulcer activity.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any one of the substituted benzimidazole compounds with anti-ulcer activity. A proton pump inhibitor is orally administered in the neutrally charged, inactive form and, upon entering the acidic environment of the parietal cell, gets protonated and converted into its active form. The active form will covalently and irreversibly bind to the proton pump, the H+/K+-ATPase, located on the surface of parietal cells. This leads to an inhibition of the transport of hydrogen ions, in exchange for potassium ions, into the gastric lumen and results in an inhibition of gastric acid secretion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proton Pump Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"PPI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:49200"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Proton_Pump_Inhibitor"},{"name":"Maps_To","value":"Proton Pump Inhibitors"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0358591"}]}}{"C15329":{"preferredName":"Surgical Procedure","code":"C15329","definitions":[{"definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","type":"DEFINITION","source":"NCI"},{"definition":"A procedure to remove or repair a part of the body or to find out whether disease is present. An operation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One or more surgical procedures, including percutaneous or minimally invasive procedures, were required, or an existing procedure changed.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Surgical Procedure","termGroup":"PT","termSource":"NCI"},{"termName":"Operation","termGroup":"SY","termSource":"NCI"},{"termName":"Surgery","termGroup":"SY","termSource":"NCI"},{"termName":"Surgical","termGroup":"AD","termSource":"NCI"},{"termName":"Surgical Interventions","termGroup":"SY","termSource":"NCI"},{"termName":"Surgical Procedures","termGroup":"SY","termSource":"NCI"},{"termName":"Surgically","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Surgical_Procedure"},{"name":"Maps_To","value":"Surgery, NOS"},{"name":"Maps_To","value":"Surgically Treated"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0543467"},{"name":"xRef","value":"IMDRF:F19"}]}}{"C120861":{"preferredName":"Adenosis","code":"C120861","definitions":[{"definition":"Any disease or disorder of a gland, characterized by abnormal development or enlargement of the gland.","type":"DEFINITION","source":"NCI"},{"definition":"The presence of small collections of epithelial cells with or without microlumens in the stroma adjacent to ducts or acini in glandular tissues.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Adenosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosis (Atypical Adenomatous Hyperplasia)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334050"}]}}{"C5665":{"preferredName":"Atypical Adenomatous Lung Hyperplasia","code":"C5665","definitions":[{"definition":"A preinvasive lesion in the lung. It is characterized by the presence of a small, localized proliferation of mildly to moderately atypical type II pneumocytes and/or Clara cells lining alveolar walls and sometimes respiratory bronchioles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Adenomatous Lung Hyperplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Atypical Adenomatous Hyperplasia of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Adenomatous Hyperplasia of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Alveolar Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchioloalveolar Cell Adenoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Adenomatous_Lung_Hyperplasia"},{"name":"Maps_To","value":"Adenosis (Atypical Adenomatous Hyperplasia)"},{"name":"Maps_To","value":"Atypical adenomatous hyperplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1332345"}]}}{"C16273":{"preferredName":"Alcohol Consumption","code":"C16273","definitions":[{"definition":"Consumption of liquids containing ethanol, including the behaviors associated with drinking the alcohol.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alcohol Consumption","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alcohol_Consumption"},{"name":"Maps_To","value":"Alcohol Consumption"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0001948"}]}}{"C34783":{"preferredName":"Alcoholic Liver Disease","code":"C34783","definitions":[{"definition":"A disorder caused by damage to the liver parenchyma due to alcohol consumption. It may present with an acute onset or follow a chronic course, leading to cirrhosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alcoholic Liver Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Alcoholic_Liver_Disease"},{"name":"Maps_To","value":"Alcoholic Liver Disease"},{"name":"Maps_To","value":"Alcoholic liver disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0023896"}]}}{"C172303":{"preferredName":"Animal Allergy","code":"C172303","definitions":[{"definition":"An allergic reaction triggered by exposure to animal-associated allergens, includes allergenic factors in venom, saliva and dander.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Animal Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Animal, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0700360"}]}}{"C172307":{"preferredName":"Venomous Ant Bite Allergy","code":"C172307","definitions":[{"definition":"An allergic reaction triggered by exposure to ant venom, usually as a result of being bitten by a fire ant (Solenopsis spp.).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venomous Ant Bite Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Ant Bite Allergy","termGroup":"SY","termSource":"NCI"},{"termName":"Ant Sting Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Ant"},{"name":"NCI_META_CUI","value":"CL1406169"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172308":{"preferredName":"Bee Venom Allergy","code":"C172308","definitions":[{"definition":"An allergic reaction triggered by being exposed to bee venom following a bee sting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bee Venom Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Bee Sting Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Bee"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1828283"}]}}{"C172310":{"preferredName":"Cat Allergy","code":"C172310","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens expressed by cats, includes allergenic factors found in feline saliva and dander.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cat Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Cat"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0339805"}]}}{"C175520":{"preferredName":"Dairy or Lactose Intolerance Allergy","code":"C175520","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in foods containing lactose or other dairy components.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dairy or Lactose Intolerance Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Dairy or Lactose"},{"name":"NCI_META_CUI","value":"CL1412861"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172311":{"preferredName":"Dog Allergy","code":"C172311","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens expressed by dogs, includes allergenic factors found in canine saliva and dander.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dog Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Dog"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0740913"}]}}{"C172313":{"preferredName":"Egg Allergy","code":"C172313","definitions":[{"definition":"An allergic reaction triggered by exposure to foodborne allergens found in eggs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Egg Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Egg"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0559469"}]}}{"C172304":{"preferredName":"Food Allergy","code":"C172304","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in food; exposure can occur through the skin, respiratory tract or digestive tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Food Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Foodborne Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Food, NOS"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C3280920"}]}}{"C172316":{"preferredName":"Fruit Allergy","code":"C172316","definitions":[{"definition":"An allergic reaction triggered by exposure to foodborne allergens found in fruit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fruit Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Fruit"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0685901"}]}}{"C172317":{"preferredName":"Meat Allergy","code":"C172317","definitions":[{"definition":"An allergic reaction triggered by exposure to foodborne allergens found in meat.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Meat Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Meat"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0859949"}]}}{"C172306":{"preferredName":"Mold or Dust Allergy","code":"C172306","definitions":[{"definition":"An allergic reaction triggered by exposure to airborne allergens expressed by dust mites or molds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mold or Dust Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Mold or Dust"},{"name":"NCI_META_CUI","value":"CL1406170"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C175521":{"preferredName":"Nut Allergy","code":"C175521","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in nuts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nut Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Nuts"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0577620"}]}}{"C175522":{"preferredName":"Processed Food Allergy","code":"C175522","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in processed foods.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Processed Food Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Processed Foods"},{"name":"NCI_META_CUI","value":"CL1412863"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172320":{"preferredName":"Shellfish Allergy","code":"C172320","definitions":[{"definition":"An allergic reaction triggered by exposure to allergens found in foods containing molluscs, crustaceans or echinoderms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shellfish Allergy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Seafood"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0577625"}]}}{"C172321":{"preferredName":"Wasp Venom Allergy","code":"C172321","definitions":[{"definition":"An allergic reaction triggered by being exposed to wasp venom following a wasp sting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wasp Venom Allergy","termGroup":"PT","termSource":"NCI"},{"termName":"Wasp Sting Allergy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allergy, Wasp"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1827129"}]}}{"C156076":{"preferredName":"Autoimmune Atrophic Chronic Gastritis","code":"C156076","definitions":[{"definition":"Chronic atrophic gastritis that is caused by autoimmune destruction of parietal cells in the stomach resulting in hypochlorhydria and decreased production of intrinsic factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autoimmune Atrophic Chronic Gastritis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autoimmune Atrophic Chronic Gastritis"},{"name":"Maps_To","value":"Autoimmune atrophic chronic gastritis"},{"name":"NCI_META_CUI","value":"CL562911"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C172639":{"preferredName":"BAP1 Tumor Predisposition Syndrome","code":"C172639","definitions":[{"definition":"A syndrome caused by germline mutations in the BAP1 gene. It is inherited in an autosomal dominant pattern. Individuals carrying heterozygous BAP1 mutations have an increased risk of developing various tumor types, most commonly BAP1-inactivated nevi/melanocytomas of the skin, uveal and cutaneous melanomas, peritoneal and pleural mesotheliomas, clear cell renal cell carcinoma, and basal cell carcinoma. (WHO 2018)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BAP1 Tumor Predisposition Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"BAP1-TPDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BAP1 Tumor Predisposition Syndrome"},{"name":"NCI_META_CUI","value":"CL558268"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C2897":{"preferredName":"Benign Prostatic Hyperplasia","code":"C2897","definitions":[{"definition":"A benign (noncancerous) condition in which an overgrowth of prostate tissue pushes against the urethra and the bladder, blocking the flow of urine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benign Prostatic Hyperplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Hyperplasia of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Hyperplasia of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Prostate Hyperplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Prostatic Hyperplasia - BPH","termGroup":"SY","termSource":"NCI"},{"termName":"Benign Prostatic Hypertrophy","termGroup":"SY","termSource":"NCI"},{"termName":"BPH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benign_Prostatic_Hyperplasia"},{"name":"Maps_To","value":"Benign Prostatic Hyperplasia"},{"name":"Maps_To","value":"Nodular Prostatic Hyperplasia"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0005001"}]}}{"C28244":{"preferredName":"Birt-Hogg-Dube Syndrome","code":"C28244","definitions":[{"definition":"A rare genetic syndrome with an autosomal dominant pattern of inheritance. It is caused by a mutation in the FLCN gene which encodes the protein folliculin. Clinical signs include multiple benign growths of the skin and lungs that begin to manifest in the second or third decade of life. The clinical course is characterized by the progressive growth of new and existing neoplasms. In those with mutations in both copies of FLCN, the kidneys may also be affected by the growth of benign or malignant neoplasms.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited condition in which benign tumors develop in hair follicles on the head, chest, back, and arms.  People who have this disorder may be at increased risk of developing colon or kidney cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Birt-Hogg-Dube Syndrome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Birt-Hogg-Dube_Syndrome"},{"name":"Maps_To","value":"Birt-Hogg-Dube Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0346010"}]}}{"C172230":{"preferredName":"Family History of BRCA Mutation","code":"C172230","definitions":[{"definition":"An indication that a variant in a BRCA family gene has been identified in a family member of a subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Family History of BRCA Mutation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRCA Family History"},{"name":"NCI_META_CUI","value":"CL1406124"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C171138":{"preferredName":"Bacterial Colonization","code":"C171138","definitions":[{"definition":"The detection of bacteria in or on an anatomic site, medical device or biospecimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bacterial Colonization","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colonization, Bacterial"},{"name":"Maps_To","value":"Colonization; bacterial"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2747813"}]}}{"C82980":{"preferredName":"Fungal Colonization","code":"C82980","definitions":[{"definition":"Collection of fungal organisms in an anatomic site or medical device.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fungal Colonization","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fungal_Colonization"},{"name":"Maps_To","value":"Colonization, Fungal"},{"name":"Maps_To","value":"Colonization; fungal"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2826606"}]}}{"C3076":{"preferredName":"Cowden Syndrome","code":"C3076","definitions":[{"definition":"An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.","type":"DEFINITION","source":"NCI"},{"definition":"An inherited disorder marked by the formation of many noncancerous growths called hamartomas. These growths occur in the skin, breast, thyroid, colon, intestines, and inside of the mouth. Patients with Cowden syndrome are at increased risk of certain types of cancer, including breast and thyroid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cowden Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Cowden Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Cowden's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Ruvalcaba-Myhre-Smith Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cowden_Syndrome"},{"name":"Maps_To","value":"Cowden Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018553"}]}}{"C2978":{"preferredName":"Cyst","code":"C2978","definitions":[{"definition":"A sac or capsule in the body. It may be filled with fluid or other material.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.","type":"DEFINITION","source":"NCI"},{"definition":"A sac-like closed pocket of tissue that may be empty or may be filled with fluid, gas, semisolid, or amorphous material. It typically has an outer epithelial-lined capsule.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cyst","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Cyst"},{"name":"Maps_To","value":"Cyst(s)"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0010709"}]}}{"C2986":{"preferredName":"Type 1 Diabetes Mellitus","code":"C2986","definitions":[{"definition":"A chronic condition characterized by minimal or absent production of insulin by the pancreas.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Diabetes mellitus caused by cell-mediated autoimmune destruction of pancreatic beta cells.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Type 1 Diabetes Mellitus","termGroup":"PT","termSource":"NCI"},{"termName":"IDDM","termGroup":"AB","termSource":"NCI"},{"termName":"Insulin Dependent Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin Dependent Diabetes Mellitus","termGroup":"SY","termSource":"NCI"},{"termName":"Juvenile Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type 1 Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type I Diabetes","termGroup":"SY","termSource":"NCI"},{"termName":"Type I Diabetes Mellitus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Insulin_Dependent_Diabetes_Mellitus"},{"name":"Maps_To","value":"Diabetes, Type I"},{"name":"Maps_To","value":"Type I diabetes mellitus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0011854"}]}}{"C15222":{"preferredName":"Diet","code":"C15222","definitions":[{"definition":"The customary allowance of food and drink taken by a person or an animal from day to day, particularly one especially planned to meet specific requirements of the individual, including or excluding certain items of food; a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health.","type":"DEFINITION","source":"NCI"},{"definition":"The things a person eats and drinks.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diet","termGroup":"PT","termSource":"NCI"},{"termName":"Dietary","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diet"},{"name":"Maps_To","value":"Diet"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0012155"}]}}{"C3014":{"preferredName":"Endometriosis","code":"C3014","definitions":[{"definition":"A benign condition in which tissue that looks like endometrial tissue grows in abnormal places in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Presence of endometrial tissue outside of endometrium and myometrium, consisting of both endometrial glands and stroma.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endometriosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometriosis"},{"name":"Maps_To","value":"Endometriosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0014175"}]}}{"C179646":{"preferredName":"Endosalpingiosis","code":"C179646","definitions":[{"definition":"A rare condition characterized by the replacement of the epithelium of an organ which is not related to fallopian tube with ectopic fallopian tube-type ciliated epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endosalpingiosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endosalpingiosis"},{"name":"NCI_META_CUI","value":"CL1662418"},{"name":"Semantic_Type","value":"Finding"}]}}{"C8366":{"preferredName":"Intraepithelial Neoplasia","code":"C8366","definitions":[{"definition":"A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Epithelial Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"Intraepithelial Neoplasm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"Epithelial"},{"name":"Maps_To","value":"Epithelial dysplasia"},{"name":"Maps_To","value":"Epithelial Dysplasia"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0878500"}]}}{"C3954":{"preferredName":"Gastric Polyp","code":"C3954","definitions":[{"definition":"A polyp that arises from the stomach.  This category includes neoplastic polyps (intestinal-type adenomatous polyps, gastric-type adenomas, and fundic gland polyps), and non-neoplastic polyps (hyperplastic polyps and hamartomatous polyps).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastric Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Gastric Polyposa","termGroup":"SY","termSource":"NCI"},{"termName":"Gastric Polyposis","termGroup":"SY","termSource":"NCI"},{"termName":"Polyps of Stomach","termGroup":"SY","termSource":"NCI"},{"termName":"Polyps of the Stomach","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastric_Polyp"},{"name":"Maps_To","value":"Gastric Polyp(s)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0236048"}]}}{"C84729":{"preferredName":"Gilbert Syndrome","code":"C84729","definitions":[{"definition":"An autosomal recessive inherited disorder characterized by unconjugated hyperbilirubinemia, resulting in harmless intermittent jaundice.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gilbert Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Gilbert Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gilbert's Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0017551"}]}}{"C35605":{"preferredName":"Glomerular Vascular Disorder","code":"C35605","definitions":[{"definition":"A disorder that is caused by pathologic changes in the glomerular vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glomerular Vascular Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glomerular_Vascular_Disorder"},{"name":"Maps_To","value":"Glomerular Disease"},{"name":"Maps_To","value":"Glomerular disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0852683"}]}}{"C92188":{"preferredName":"Seasonal Allergic Rhinitis","code":"C92188","definitions":[{"definition":"Allergic rhinitis caused by outdoor allergens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seasonal Allergic Rhinitis","termGroup":"PT","termSource":"NCI"},{"termName":"Hay Fever","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hay Fever"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018621"}]}}{"C27121":{"preferredName":"Helicobacter Pylori-Associated Gastritis","code":"C27121","definitions":[{"definition":"Inflammation of the stomach that is associated with Helicobacter Pylori.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Helicobacter Pylori-Associated Gastritis","termGroup":"PT","termSource":"NCI"},{"termName":"Helicobacter Gastritis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Helicobacter_Pylori-Associated_Gastritis"},{"name":"Maps_To","value":"Helicobacter Pylori-Associated Gastritis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0343378"}]}}{"C26323":{"preferredName":"Hematopoietic and Lymphoid Cell Disorder","code":"C26323","definitions":[{"definition":"A non-neoplastic or neoplastic disorder that arises from the hematopoietic and lymphoid cells. Representative examples include disorders that affect the synthesis of hemoglobin, coagulation disorders, leukemias, and lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic and Lymphoid Cell Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic and Lymphocytic Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic and Lymphoid Cell Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematologic Disorder","termGroup":"SY","termSource":"NCI"},{"termName":"Hematological Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hematologic_Disorder"},{"name":"Maps_To","value":"Disease of blood and blood-forming organs, unspecified"},{"name":"Maps_To","value":"Hematologic Disorder, NOS"},{"name":"Maps_To","value":"Other diseases of blood and blood-forming organs"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018939"}]}}{"C82892":{"preferredName":"Hemochromatosis","code":"C82892","definitions":[{"definition":"A condition in which the body takes up and stores more iron than it needs. The extra iron is stored in the liver, heart, and pancreas, which may cause liver disease, heart problems, organ failure, and cancer. It may also cause bronze skin, diabetes, pain in the joints and abdomen, tiredness, and impotence. Hemochromatosis may be inherited, or it may be caused by blood transfusions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Accumulation of iron in internal organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemochromatosis","termGroup":"PT","termSource":"NCI"},{"termName":"Hemosiderosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemosiderosis"},{"name":"Maps_To","value":"Hemochromatosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1849984"}]}}{"C79596":{"preferredName":"Hepatic Encephalopathy","code":"C79596","definitions":[{"definition":"A constellation of signs and symptoms characterized by changes in personality, consciousness, and reflexes, resulting from neuropsychiatric abnormalities secondary to liver failure without evidence of other brain disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatic Encephalopathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatic_Encephalopathy"},{"name":"Maps_To","value":"Hepatic Encephalopathy"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019151"}]}}{"C4503":{"preferredName":"Hereditary Breast Carcinoma","code":"C4503","definitions":[{"definition":"Breast carcinoma that has developed in relatives of patients with history of breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Breast Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Breast Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Cancer of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Familial Cancer of the Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Breast Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Breast_Carcinoma"},{"name":"Maps_To","value":"Hereditary Breast Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0346153"}]}}{"C8960":{"preferredName":"Hereditary Kidney Oncocytoma","code":"C8960","definitions":[{"definition":"An inherited condition characterized by the development of kidney oncocytomas which are often bilateral and multifocal.  This condition may be connected to Birt-Hogg-Dube syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Kidney Oncocytoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Renal Oncocytoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Renal Oncocytoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Familial_Renal_Oncocytoma"},{"name":"Maps_To","value":"Hereditary Kidney Oncocytoma"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0879606"}]}}{"C36102":{"preferredName":"Hereditary Ovarian Carcinoma","code":"C36102","definitions":[{"definition":"Ovarian carcinoma that has developed in relatives of patients that have a history of ovarian carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Ovarian Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Ovarian Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Ovarian_Carcinoma"},{"name":"Maps_To","value":"Hereditary Ovarian Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1333992"}]}}{"C9222":{"preferredName":"Hereditary Papillary Renal Cell Carcinoma","code":"C9222","definitions":[{"definition":"A familial carcinoma inherited in an autosomal dominant trait.  It is characterized by the development of multiple, bilateral papillary renal cell carcinomas.  The carcinomas range from microscopic lesions to clinically symptomatic tumors.  It is associated with activating mutations of the MET oncogene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Papillary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Renal Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Kidney Papillary Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Papillary Carcinoma of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Papillary Carcinoma of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Papillary Renal Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Renal_Papillary_Carcinoma"},{"name":"Maps_To","value":"Hereditary Papillary Renal Cell Carcinoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0879257"}]}}{"C103817":{"preferredName":"Hereditary Prostate Carcinoma","code":"C103817","definitions":[{"definition":"Prostate carcinoma that has developed in relatives of patients with a history of prostate carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Prostate Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hereditary Prostate Cancer"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C2931456"}]}}{"C39789":{"preferredName":"Hereditary Renal Cell Carcinoma","code":"C39789","definitions":[{"definition":"Renal cell carcinoma that has developed in relatives of patients with history of renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Familial Renal Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hereditary_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Hereditary Renal Cell Carcinoma"},{"name":"NCI_META_CUI","value":"CL412456"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C5541":{"preferredName":"High Grade Prostatic Intraepithelial Neoplasia","code":"C5541","definitions":[{"definition":"Prostatic intraepithelial neoplasia characterized by the presence of morphologically malignant cells lining the acini and ducts.  The malignant cells are enlarged, contain prominent nucleoli, and have increased nuclear/cytoplasmic ratio.  The malignant cells may grow within the ducts and acini in four architectural patterns: flat, tufting, micropapillary, and cribriform.  The presence of high grade prostatic intraepithelial neoplasia in needle biopsy is a risk factor for the subsequent detection of carcinoma on repeat biopsy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High Grade Prostatic Intraepithelial Neoplasia","termGroup":"PT","termSource":"NCI"},{"termName":"HGPIN","termGroup":"AB","termSource":"NCI"},{"termName":"High-Grade Intraepithelial Neoplasia of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Intraepithelial Neoplasia of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade PIN","termGroup":"SY","termSource":"NCI"},{"termName":"High-Grade Prostatic Intraepithelial Neoplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"High-Grade_Prostatic_Intraepithelial_Neoplasia"},{"name":"Maps_To","value":"High-grade Prostatic Intraepithelial Neoplasia (PIN)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1168327"}]}}{"C3108":{"preferredName":"HIV Infection","code":"C3108","definitions":[{"definition":"An infection caused by the human immunodeficiency virus.","type":"DEFINITION","source":"NCI"},{"definition":"Infection caused by the human immunodeficiency virus.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"HIV Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Human Immunodeficiency Virus Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"HIV_Infection"},{"name":"Maps_To","value":"HIV"},{"name":"Maps_To","value":"HIV infection"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019693"}]}}{"C3137":{"preferredName":"Inflammation","code":"C3137","definitions":[{"definition":"A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","type":"DEFINITION","source":"NCI"},{"definition":"A localized physical condition in which part of the body becomes reddened, swollen, or hot and often painful.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"A response to an injury or abnormal stimuli characterized by inflammatory cell infiltration and varying degrees of vascular and tissue reactions (hyperemia, edema, fibrin, and/or fibrosis).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Redness, swelling, pain, and/or a feeling of heat in an area of the body. This is a protective reaction to injury, disease, or irritation of the tissues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Inflammation","termGroup":"PT","termSource":"NCI"},{"termName":"Inflammatory Finding","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Inflammation"},{"name":"Maps_To","value":"Inflammation"},{"name":"Maps_To","value":"Inflammation, Hyperkeratosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0021368"},{"name":"xRef","value":"IMDRF:E2326"}]}}{"C35541":{"preferredName":"Hyperkeratosis","code":"C35541","definitions":[{"definition":"A condition marked by thickening of the outer layer of the skin, which is made of keratin (a tough, protective protein). It can result from normal use (corns, calluses), chronic inflammation (eczema), or genetic disorders (X-linked ichthyosis, ichthyosis vulgaris).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Hypertrophy of the outermost layer of the epidermis. It may be caused by physical or chemical irritants, irradiation, infection, or neoplastic processes.","type":"DEFINITION","source":"NCI"},{"definition":"Thickening of the outermost layer of stratified squamous epithelium.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hyperkeratosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperkeratosis"},{"name":"Maps_To","value":"Hyperkeratosis"},{"name":"Maps_To","value":"Inflammation, Hyperkeratosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3809745"}]}}{"C8360":{"preferredName":"Intestinal Metaplasia","code":"C8360","definitions":[{"definition":"A morphologic finding indicating the replacement of epithelial tissue outside the intestines by intestinal-type epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intestinal Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intestinal_Metaplasia"},{"name":"Maps_To","value":"Intestinal Metaplasia"},{"name":"Maps_To","value":"Intestinal metaplasia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334037"}]}}{"C38766":{"preferredName":"Lymphocytic Thyroiditis","code":"C38766","definitions":[{"definition":"An inflammatory disorder that affects the thyroid gland.  It is characterized by the infiltration of the thyroid parenchyma by lymphocytes.  It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocytic Thyroiditis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocytic_Thyroiditis"},{"name":"Maps_To","value":"Lymphocytic Thyroiditis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0920350"}]}}{"C84444":{"preferredName":"Nonalcoholic Fatty Liver Disease","code":"C84444","definitions":[{"definition":"A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonalcoholic Fatty Liver Disease","termGroup":"PT","termSource":"NCI"},{"termName":"NAFLD - Nonalcoholic Fatty Liver Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nonalcoholic Fatty Liver Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0400966"}]}}{"C389":{"preferredName":"Oral Contraceptive","code":"C389","definitions":[{"definition":"An agent taken orally to prevent conception.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Contraceptive","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:49325"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Contraceptive"},{"name":"Maps_To","value":"Oral Contraceptives"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0009905"}]}}{"C164213":{"preferredName":"Recurrent Pyogenic Cholangitis","code":"C164213","definitions":[{"definition":"A recurrent form of cholangitis that is characterized by intrabiliary pigment stone formation, biliary tree stricture and obstruction, and recurrent bouts of cholangitis. There is an association with biliary parasitosis, but evidence supporting these infections in the pathogenesis of recurrent pyogenic cholangitis is inconclusive. The most common causes of death are sepsis, liver failure, or complications from cirrhosis. Patients are also at increased risk of cholangiocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recurrent Pyogenic Cholangitis","termGroup":"PT","termSource":"NCI"},{"termName":"Cholangiohepatitis","termGroup":"SY","termSource":"NCI"},{"termName":"RPC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrent Pyogenic Cholangitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0267921"}]}}{"C26882":{"preferredName":"Sialadenitis","code":"C26882","definitions":[{"definition":"An acute or chronic inflammatory process affecting a salivary gland. Signs and symptoms include pain and tenderness in the affected area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialadenitis","termGroup":"PT","termSource":"NCI"},{"termName":"Sialoadenitis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sialoadenitis"},{"name":"Maps_To","value":"Sialadenitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0037023"}]}}{"C3237":{"preferredName":"Squamous Metaplasia","code":"C3237","definitions":[{"definition":"A morphologic finding indicating the transformation of glandular or transitional epithelial cells to, usually, mature squamous epithelial cells.  Representative examples include squamous metaplasia of bronchial epithelium, cervix, urinary bladder, and prostate gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Metaplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Squamous_Metaplasia"},{"name":"Maps_To","value":"Squamous Metaplasia"},{"name":"Maps_To","value":"Squamous metaplasia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0025570"}]}}{"C156464":{"preferredName":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","code":"C156464","definitions":[{"definition":"A very rare renal cell carcinoma that usually affects young adults. It is characterized by mutations in one of the four subunits of the SDH complex (SDHA, SDHB, SDHC, or SDHD gene). Most frequently, the mutations occur in the SDHB subunit. It has a relatively good prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"SDH Deficient Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SDH-Deficient Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"SDH-RCC","termGroup":"AB","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Renal Cell Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Succinate Dehydrogenase-Deficient Renal Cell Carcinoma"},{"name":"NCI_META_CUI","value":"CL563184"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"}]}}{"C113681":{"preferredName":"Skin Tattoo","code":"C113681","definitions":[{"definition":"A permanent mark created by the insertion of pigment below the skin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin Tattoo","termGroup":"PT","termSource":"NCI"},{"termName":"Tattoo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tattoo"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1366940"}]}}{"C18059":{"preferredName":"Tobacco Use","code":"C18059","definitions":[{"definition":"Use of tobacco in any form, e.g., smoking, chewing or sniffing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobacco Use","termGroup":"PT","termSource":"NCI"},{"termName":"Tobacco Consumption","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tobacco_Use"},{"name":"Maps_To","value":"Tobacco use"},{"name":"Maps_To","value":"Tobacco, NOS"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0543414"}]}}{"C137998":{"preferredName":"Smokeless Tobacco Use","code":"C137998","definitions":[{"definition":"Use of smokeless tobacco in any form, e.g., chewing or sniffing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smokeless Tobacco Use","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tobacco, Smokeless"},{"name":"NCI_META_CUI","value":"CL525032"},{"name":"Semantic_Type","value":"Individual Behavior"}]}}{"C3424":{"preferredName":"Tuberous Sclerosis","code":"C3424","definitions":[{"definition":"A genetic disorder in which benign (not cancer) tumors form in the kidneys, brain, eyes, heart, lungs, and skin. This disease can cause seizures, mental disabilities, and different types of skin lesions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Hereditary disease characterized by seizures, intracerebral tumors, cardiac tumors, developmental delay, and skin and ocular lesions.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuberous Sclerosis","termGroup":"PT","termSource":"NCI"},{"termName":"Bourneville's Disease","termGroup":"SY","termSource":"NCI"},{"termName":"TSC","termGroup":"AB","termSource":"NCI"},{"termName":"Tuberous Sclerosis Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Tuberous_Sclerosis"},{"name":"Maps_To","value":"Tuberous Sclerosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0041341"}]}}{"C123036":{"preferredName":"Tubulointerstitial Disease","code":"C123036","definitions":[{"definition":"Disease affecting the renal tubules and interstitium of the kidney.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Disease affecting the renal tubules and interstitium of the kidney.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Tubulointerstitial Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Tubulointerstitial Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0041349"}]}}{"C171150":{"preferredName":"Tumor-Associated Lymphocytosis","code":"C171150","definitions":[{"definition":"Non-neoplastic lymphocytosis associated with the presence of a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor-Associated Lymphocytosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor-associated Lymphoid Proliferation"},{"name":"Maps_To","value":"Tumor-associated lymphoid proliferation"},{"name":"NCI_META_CUI","value":"CL1405382"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35117":{"preferredName":"Vascular Disorder","code":"C35117","definitions":[{"definition":"A non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels. Examples include vasculitis, thrombophlebitis, arteriosclerosis, lymphedema, hemangioma, and angiosarcoma.","type":"DEFINITION","source":"NCI"},{"definition":"The report describes a non-specific problem with the vascular system. Note: Please use \"Appropriate Term / Code Not Available\" if the report describes a specific problem but the relevant term does not exist.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]}],"synonyms":[{"termName":"Vascular Disorder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Vascular_Disorder"},{"name":"Maps_To","value":"Vascular Disease"},{"name":"Maps_To","value":"Vascular disorders of intestine"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0042373"},{"name":"xRef","value":"IMDRF:E0518"}]}}{"C3105":{"preferredName":"Von Hippel Lindau Syndrome","code":"C3105","definitions":[{"definition":"A rare inherited disorder in which blood vessels grow abnormally in the eyes, brain, spinal cord, adrenal glands, or other parts of the body. People with von Hippel-Lindau syndrome have a higher risk of developing some types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autosomal dominant multiple neoplasia syndrome caused by germline mutations of the VHL gene, encoding the protein von Hippel-Lindau tumor suppressor (pVHL). The condition is characterized by development of capillary hemangioblastomas of the central nervous system and retina, clear cell renal carcinoma, pheochromocytoma, pancreatic tumors, and inner ear tumors (endolymphatic sac tumors).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Von Hippel Lindau Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Cerebroretinal Angiomatosis","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Syndrome","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Syndrome (VHL)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Von_Hippel-Lindau_Syndrome"},{"name":"Maps_To","value":"Von Hippel-Lindau Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019562"}]}}{"C80078":{"preferredName":"Chronic Kidney Disease","code":"C80078","definitions":[{"definition":"A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Kidney Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Chronic Renal Disease","termGroup":"SY","termSource":"NCI"},{"termName":"CKD - Chronic Kidney Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Chronic_Kidney_Disease"},{"name":"Maps_To","value":"Chronic kidney disease"},{"name":"Maps_To","value":"Chronic Kidney Disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1561643"}]}}{"C34594":{"preferredName":"Escherichia coli Infection","code":"C34594","definitions":[{"definition":"Infection with the organism Escherichia Coli.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Escherichia coli Infection","termGroup":"PT","termSource":"NCI"},{"termName":"E coli Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Escherichia_Coli_Infection"},{"name":"Maps_To","value":"Escherichia coli"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0014836"}]}}{"C39594":{"preferredName":"Skin Rash","code":"C39594","definitions":[{"definition":"An eruption in the skin which affects its appearance and/or texture.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An eruption in the skin which effects its appearance and/or texture.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Any change in the skin that affects its appearance or texture. A rash may be localized to one part of the body or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked, or blistered, swell, and may be painful.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.","type":"DEFINITION","source":"NCI"},{"definition":"Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked, or blistered, swell and may be painful.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Skin Rash","termGroup":"PT","termSource":"NCI"},{"termName":"Cutaneous Eruption","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Skin_Rash"},{"name":"Maps_To","value":"Rash"},{"name":"Maps_To","value":"Skin Rash"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4227880"},{"name":"xRef","value":"IMDRF:E1714"}]}}{"C6996":{"preferredName":"Uterine Corpus Adenomyosis","code":"C6996","definitions":[{"definition":"The growth of endometrial tissue inside the muscular wall of the uterine corpus. Clinical manifestations include pain, dysmenorrhea, and menorrhagia.","type":"DEFINITION","source":"NCI"},{"definition":"The growth of endometrial tissue inside the muscular wall of the uterus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Uterine Corpus Adenomyosis","termGroup":"PT","termSource":"NCI"},{"termName":"Adenomyosis","termGroup":"SY","termSource":"NCI"},{"termName":"Adenomyosis of the Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Adenomyosis of Uterus","termGroup":"SY","termSource":"NCI"},{"termName":"Uterine Adenomyosis","termGroup":"SY","termSource":"NCI"},{"termName":"Uterus Corpus Adenomyosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Uterine_Adenomyosis"},{"name":"Maps_To","value":"Adenomyosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0341858"}]}}{"C128829":{"preferredName":"HHV6 Infection","code":"C128829","definitions":[{"definition":"An infection that is caused by human herpesvirus-6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HHV6 Infection","termGroup":"PT","termSource":"NCI"},{"termName":"HHV-6 Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Human Herpes Virus-6 Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Human Herpesvirus-6 Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Human Herpesvirus-6 (HHV-6)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0854530"}]}}{"C39291":{"preferredName":"HHV8 Infection","code":"C39291","definitions":[{"definition":"An infectious process caused by the human herpesvirus 8. This infection is associated with Kaposi sarcoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HHV8 Infection","termGroup":"PT","termSource":"NCI"},{"termName":"Human Herpesvirus 8 Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Herpes_Virus_8_Infection"},{"name":"Maps_To","value":"Human Herpesvirus-8 (HHV-8)"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1512508"}]}}{"C94719":{"preferredName":"Acetate","code":"C94719","definitions":[{"definition":"A form of acetic acid (an acid found in vinegar).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Salt or ester form of acetic acid. Acetate is the most common building block for biosynthesis, such as fatty acids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acetate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71-50-1"},{"name":"CHEBI_ID","value":"CHEBI:30089"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"569DQM74SC"},{"name":"Maps_To","value":"Acetate"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0000975"}]}}{"C74002":{"preferredName":"Fluciclovine F18","code":"C74002","definitions":[{"definition":"A radiotracer containing a synthetic amino acid analogue of L-leucine radiolabeled with fluorine F 18 with potential diagnostic imaging use. Similar to most amino acids, fluciclovine F18 appears to enter cells through the energy-independent L-type amino acid transporter (LAT) system. As an amino acid analogue, this agent is preferentially accumulated by tumor cells due to their increased metabolic needs; however, unlike naturally occurring amino acids, this non-natural amino acid-analogue radiotracer is not metabolized. Accordingly, fluciclovine F18 accumulates in tumor cells and can potentially be used to image tumors using positron emission tomography (PET).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluciclovine F18","termGroup":"PT","termSource":"NCI"},{"termName":"(18F)Fluciclovine","termGroup":"SY","termSource":"NCI"},{"termName":"(18F)GE-148","termGroup":"CN","termSource":"NCI"},{"termName":"(1R,3R)-1-Amino-3(18f)fluorocyclobutane-1-carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"18F-Fluciclovine","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]FACBC","termGroup":"AB","termSource":"NCI"},{"termName":"Anti-(18f)FABC","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-[18F] FACBC","termGroup":"AB","termSource":"NCI"},{"termName":"Axumin","termGroup":"BR","termSource":"NCI"},{"termName":"Fluciclovine (18F)","termGroup":"SY","termSource":"NCI"},{"termName":"GE-148 (18F)","termGroup":"CN","termSource":"NCI"},{"termName":"GE-148 F-18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222727-39-1"},{"name":"Chemical_Formula","value":"C5H8FNO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"38R1Q0L1ZE"},{"name":"Legacy Concept Name","value":"Anti-1-Amino-3-Fluorocyclobutane-1-Carboxylic_Acid"},{"name":"Maps_To","value":"Axumin"},{"name":"NCI_Drug_Dictionary_ID","value":"581382"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581382"},{"name":"PDQ_Open_Trial_Search_ID","value":"581382"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311253"}]}}{"C61674":{"preferredName":"Choline","code":"C61674","definitions":[{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Choline helps cells make membranes, make a neurotransmitter (a chemical that helps nerve cells communicate with other cells), and remove fat from the liver. It is found in whole milk, beef liver, eggs, soy foods, and peanuts. Choline is water-soluble (can dissolve in water) and must be taken in every day. Not enough choline can cause diseases of the heart and blood vessels and damage to the liver. A form of choline is being studied in the treatment of some types of cancer and to reduce pain and fever. Choline is also being studied together with vitamin B12 in the prevention and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Water-soluble vitamin that is a precursor for acetylcholine, phospholipids, and the methyl donor betaine. (DRI)","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Choline","termGroup":"PT","termSource":"NCI"},{"termName":"(2-Hydroxyethyl)trimethylammonium","termGroup":"SN","termSource":"NCI"},{"termName":"2-hydroxyethyl-trimethyl-ammonium","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin J","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62-49-7"},{"name":"CHEBI_ID","value":"CHEBI:15354"},{"name":"Chemical_Formula","value":"C5H14NO"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N91BDP6H0X"},{"name":"INFOODS","value":"CHOLN"},{"name":"Legacy Concept Name","value":"Choline"},{"name":"Maps_To","value":"Choline"},{"name":"Micronutrient","value":"Y"},{"name":"Nutrient","value":"Y"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"Tolerable_Level","value":"Y"},{"name":"UMLS_CUI","value":"C0008405"},{"name":"Unit","value":"mcg"},{"name":"US_Recommended_Intake","value":"Y"},{"name":"USDA_ID","value":"421"}]}}{"C17796":{"preferredName":"Glutamate Carboxypeptidase 2","code":"C17796","definitions":[{"definition":"Glutamate carboxypeptidase 2 (750 aa, ~84 kDa) is encoded by the human FOLH1 gene. This protein plays a role in the mediation of folate metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glutamate Carboxypeptidase 2","termGroup":"PT","termSource":"NCI"},{"termName":"Cell Growth-Inhibiting Gene 27 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.4.17.21","termGroup":"SY","termSource":"NCI"},{"termName":"FGCP","termGroup":"SY","termSource":"NCI"},{"termName":"Folate Hydrolase 1","termGroup":"SY","termSource":"NCI"},{"termName":"FOLH1","termGroup":"SY","termSource":"NCI"},{"termName":"Folylpoly-Gamma-Glutamate Carboxypeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"GCP2","termGroup":"SY","termSource":"NCI"},{"termName":"GCPII","termGroup":"SY","termSource":"NCI"},{"termName":"Glutamate Carboxypeptidase II","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane Glutamate Carboxypeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"mGCP","termGroup":"SY","termSource":"NCI"},{"termName":"N-Acetylated-Alpha-Linked Acidic Dipeptidase I","termGroup":"SY","termSource":"NCI"},{"termName":"NAALADase I","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate-Specific Membrane Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"PSM","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA","termGroup":"AB","termSource":"NCI"},{"termName":"Pteroylpoly-Gamma-Glutamate Carboxypeptidase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Folate_Hydrolase-1"},{"name":"Maps_To","value":"PSMA"},{"name":"OMIM_Number","value":"600934"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"Q04609"},{"name":"UMLS_CUI","value":"C1310550"}]}}{"C832":{"preferredName":"Sodium Fluoride","code":"C832","definitions":[{"definition":"An inorganic salt of fluoride used topically or in municipal water fluoridation systems to prevent dental caries.  Fluoride appears to bind to calcium ions in the hydroxyapatite of surface tooth enamel, preventing corrosion of tooth enamel by acids. This agent may also inhibit acid production by commensal oral bacteria. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Fluoride","termGroup":"PT","termSource":"NCI"},{"termName":"NaF","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7681-49-4"},{"name":"CHEBI_ID","value":"CHEBI:28741"},{"name":"Chemical_Formula","value":"F.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8ZYQ1474W7"},{"name":"Legacy Concept Name","value":"Sodium_Fluoride"},{"name":"Maps_To","value":"Sodium Fluoride"},{"name":"NCI_Drug_Dictionary_ID","value":"39598"},{"name":"NSC Number","value":"77385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39598"},{"name":"PDQ_Open_Trial_Search_ID","value":"39598"},{"name":"Semantic_Type","value":"Biomedical or Dental Material"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0037508"}]}}{"C96660":{"preferredName":"Hepatitis B Virus Core Antibody Measurement","code":"C96660","definitions":[{"definition":"The determination of the amount of Hepatitis B virus core antibody present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B Virus Core Antibody Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"HBV Core Antibody Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HBV Core Antibody"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3272940"}]}}{"C103404":{"preferredName":"Hepatitis B DNA Measurement","code":"C103404","definitions":[{"definition":"A measurement of the Hepatitis B virus DNA in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of hepatitis B virus DNA in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B DNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatitis B Virus DNA Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HBV DNA"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3641250"}]}}{"C117108":{"preferredName":"HBV Genotype Assay","code":"C117108","definitions":[{"definition":"An assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HBV Genotype Assay","termGroup":"PT","termSource":"NCI"},{"termName":"HBV Genotype Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"HBV Genotyping","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis B Virus Genotype Assay","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HBV Genotype"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3899000"}]}}{"C74711":{"preferredName":"Hepatitis B Surface Antibody Measurement","code":"C74711","definitions":[{"definition":"The determination of the surface antibody reaction of a sample to the Hepatitis B virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis B Surface Antibody Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"HBV Surface Antibody Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatitis_B_Surface_Antibody_Measurement"},{"name":"Maps_To","value":"HBV Surface Antibody"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201478"}]}}{"C117109":{"preferredName":"HCV Genotype Assay","code":"C117109","definitions":[{"definition":"An assay for determining the genotype(s) of hepatitis C virus (HCV) in plasma or serum from HCV-infected individuals. Six major genotypes are recognized and they vary in their response to treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HCV Genotype Assay","termGroup":"PT","termSource":"NCI"},{"termName":"HCV Genotype Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"HCV Genotyping","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C Virus Genotype Assay","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HCV Genotype"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C1533728"}]}}{"C64850":{"preferredName":"Hepatitis B Virus Surface Antigen Measurement","code":"C64850","definitions":[{"definition":"A determination of the presence of hepatitis B virus surface antigen.","type":"DEFINITION","source":"NCI"},{"definition":"A measurement of the surface antigen reaction of a biological specimen to the Hepatitis B virus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hepatitis B Virus Surface Antigen Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatitis_B_Virus_Surface_Antigen_Measurement"},{"name":"Maps_To","value":"Hepatitis B Surface Antigen"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201477"}]}}{"C92535":{"preferredName":"Hepatitis C Antibody Measurement","code":"C92535","definitions":[{"definition":"A quantitative measurement of the antibody reaction of a biological specimen to the Hepatitis C virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis C Antibody Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatitis C Antibody"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201487"}]}}{"C142330":{"preferredName":"Hepatitis C Virus RNA Measurement","code":"C142330","definitions":[{"definition":"A measurement of the Hepatitis C virus RNA in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of hepatitis C virus RNA present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hepatitis C Virus RNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatitis C RNA","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatitis C RNA Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hepatitis C Virus RNA"},{"name":"NCI_META_CUI","value":"CL540367"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C26149":{"preferredName":"B-Cell Lymphoma 6 Protein","code":"C26149","definitions":[{"definition":"B-cell lymphoma 6 protein (706 aa, ~79 kDa) is encoded by the human BCL6 gene. This protein is involved in transcriptional repression, apoptosis regulation and cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Lymphoma 6 Protein","termGroup":"PT","termSource":"NCI"},{"termName":"B-cell CLL/Lymphoma-6","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Lymphoma 5 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-5","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-6","termGroup":"SY","termSource":"NCI"},{"termName":"BCL5","termGroup":"SY","termSource":"NCI"},{"termName":"BCL6","termGroup":"SY","termSource":"NCI"},{"termName":"BCL6 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Cys-His2 Zinc Finger Transcription Factor","termGroup":"SY","termSource":"NCI"},{"termName":"LAZ-3 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"LAZ3","termGroup":"SY","termSource":"NCI"},{"termName":"Protein LAZ-3","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger and BTB Domain-Containing Protein 27","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger Protein 51","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF51","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"B-Cell Lymphoma 6 Protein is a zinc finger transcription factor containing an N-terminal POZ domain. It acts as a sequence-specific repressor of transcription and its activity is dependent upon DNA-binding and on the N-terminal region containing the POZ motif. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. Target genes have roles in B-cell activation, B-cell differentiation, inflammation, and cell cycle control. Expression of BCL6 in some B-cells early in the antigen response may skew them toward a germinal center fate, away from a plasma cell fate. The BCL6 gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. (from OMIM, and LocusLink)"},{"name":"Legacy Concept Name","value":"B-Cell_Lymphoma-6_Protein"},{"name":"Maps_To","value":"BCL6"},{"name":"OMIM_Number","value":"109565"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P41182"},{"name":"UMLS_CUI","value":"C1448774"}]}}{"C325":{"preferredName":"CA-125 Antigen","code":"C325","definitions":[{"definition":"A substance that may be found in high amounts in the blood of patients with certain types of cancer, including ovarian cancer. CA-125 levels may also help monitor how well cancer treatments are working or if cancer has come back.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CA-125 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"CA-125","termGroup":"SY","termSource":"NCI"},{"termName":"CA125","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Antigen 125","termGroup":"SY","termSource":"NCI"},{"termName":"Carbohydrate Antigen 125","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Monitoring levels in patients with Ovarian Cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"45047SF2ZS"},{"name":"Legacy Concept Name","value":"CA-125_Antigen"},{"name":"Maps_To","value":"CA-125"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0006610"}]}}{"C327":{"preferredName":"CA19-9 Antigen","code":"C327","definitions":[{"definition":"CA 19-9 is a fucosylated glycosphingolipid carbohydrate antigen that is soluble and is adsorbed to erythrocytes and to many adenocarcinomas of the digestive tract, especially pancreatic tumors. By structure CA 19-9 is related to the Lewis blood group antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CA19-9 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"CA-19-9","termGroup":"SY","termSource":"NCI"},{"termName":"CA19-9","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Antigen 19-9","termGroup":"SY","termSource":"NCI"},{"termName":"Carbohydrate Antigen 19-9","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl Le(a) Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl LeA","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl LewisA","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl-Lewis A","termGroup":"SY","termSource":"NCI"},{"termName":"Sialylated Lewis (a) Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Sialylated Lewis a Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"SLeA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:61793"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZEJ6FM4UJK"},{"name":"Legacy Concept Name","value":"CA19-9_Antigen"},{"name":"Maps_To","value":"CA19-9"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0006613"}]}}{"C17988":{"preferredName":"G1/S-Specific Cyclin-D1","code":"C17988","definitions":[{"definition":"G1/S-specific cyclin-D1 (295 aa, ~34 kDa) is encoded by the human CCND1 gene. This protein is involved in the regulation of the G1/S transition of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"G1/S-Specific Cyclin-D1","termGroup":"PT","termSource":"NCI"},{"termName":"BCL-1 Oncogene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL1","termGroup":"SY","termSource":"NCI"},{"termName":"CCND1","termGroup":"SY","termSource":"NCI"},{"termName":"CCND1a","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D1a","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-D1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-D1a","termGroup":"SY","termSource":"NCI"},{"termName":"D11S287E","termGroup":"SY","termSource":"NCI"},{"termName":"G1/S-Specific Cyclin D1","termGroup":"SY","termSource":"NCI"},{"termName":"G1/S-Specific Cyclin D1a","termGroup":"SY","termSource":"NCI"},{"termName":"G1/S-Specific Cyclin-D1a","termGroup":"SY","termSource":"NCI"},{"termName":"PRAD1","termGroup":"SY","termSource":"NCI"},{"termName":"PRAD1 Oncogene","termGroup":"SY","termSource":"NCI"},{"termName":"U21B31","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Essential for control of the G1/S transition, cyclin D1 interacts with CDK4 and CDK6 to form a serine/threonine kinase holoenzyme and imparts substrate specificity to the complex.  RB regulates cyclin D1 gene expression.  Cyclin D1 expression may identify Barrett's esophagus patients at high risk for esophageal carcinoma; risk of progression to adenocarcinoma exhibits an odds ratio of 6.85.  The BCL1 and PRAD1 oncogenes involve cyclin D1 gene translocations.  (J Natl Cancer Inst 2000. 92:1282 & 1316, SWISS-PROT, OMIM)"},{"name":"Legacy Concept Name","value":"Cyclin-D1"},{"name":"Maps_To","value":"CCND1"},{"name":"OMIM_Number","value":"168461"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P24385"},{"name":"UMLS_CUI","value":"C1741716"}]}}{"C16836":{"preferredName":"Neprilysin","code":"C16836","definitions":[{"definition":"Neprilysin (750 aa, ~86 kDa) is encoded by the human MME gene. This protein is involved in the metabolism of biologically active peptides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neprilysin","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD10","termGroup":"SY","termSource":"NCI"},{"termName":"Atriopeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"CALLA","termGroup":"SY","termSource":"NCI"},{"termName":"CD10 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Common Acute Lymphoblastic Leukemia Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Common ALL Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.4.24.11","termGroup":"SY","termSource":"NCI"},{"termName":"Enkephalinase","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane Metalloendopeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"MME","termGroup":"SY","termSource":"NCI"},{"termName":"NEP","termGroup":"SY","termSource":"NCI"},{"termName":"Neutral Endopeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"SFE","termGroup":"SY","termSource":"NCI"},{"termName":"Skin Fibroblast Elastase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Membrane Metalloendopeptidase is a zinc-binding type II transmembrane glycoprotein that preferentially cleaves Gly-Phe bonds of peptides at the N side of hydrophobic residues and inactivates several peptide hormones, including insulin, glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin, as well as casein, hemoglobin, and other proteins and polypeptides. An important cell surface marker of human acute lymphocytic leukemia, MME is present on pre-B leukemic cells, which represent 85% of cases of ALL."},{"name":"Legacy Concept Name","value":"Membrane_Metalloendopeptidase"},{"name":"Maps_To","value":"CD10"},{"name":"OMIM_Number","value":"120520"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P08473"},{"name":"UMLS_CUI","value":"C0025250"}]}}{"C17328":{"preferredName":"Mast/Stem Cell Growth Factor Receptor Kit","code":"C17328","definitions":[{"definition":"A protein on the surface of some cells that binds to biologic substance called stem cell factor (SCF). SCF causes certain types of blood cells to grow. The stem cell factor receptor is found at high levels or in a changed form on some types of cancer cells. This may cause these cells to grow rapidly when SCF is present. The stem cell factor receptor is a type of receptor tyrosine kinase.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Mast/stem cell growth factor receptor Kit (976 aa, ~110 kDa) is encoded by the human KIT gene. This protein is involved in cell survival, tyrosine phosphorylation and ligand-mediated signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mast/Stem Cell Growth Factor Receptor Kit","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD117","termGroup":"SY","termSource":"NCI"},{"termName":"C-KIT","termGroup":"SY","termSource":"NCI"},{"termName":"CD117 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"EC 2.7.10.1","termGroup":"SY","termSource":"NCI"},{"termName":"KIT","termGroup":"SY","termSource":"NCI"},{"termName":"Mast Cell Growth Factor Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"p145 c-kit","termGroup":"SY","termSource":"NCI"},{"termName":"PBT","termGroup":"SY","termSource":"NCI"},{"termName":"Piebald Trait Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Proto-Oncogene c-Kit","termGroup":"SY","termSource":"NCI"},{"termName":"Proto-Oncogene Tyrosine-Protein Kinase Kit","termGroup":"SY","termSource":"NCI"},{"termName":"SCF Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"SCFR","termGroup":"SY","termSource":"NCI"},{"termName":"SCFR","termGroup":"AB","termSource":"NCI"},{"termName":"Stem Cell Factor Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Tyrosine-Protein Kinase Kit","termGroup":"SY","termSource":"NCI"},{"termName":"v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stem_Cell_Factor_Receptor"},{"name":"Maps_To","value":"CD117"},{"name":"NCI_META_CUI","value":"CL964236"},{"name":"OMIM_Number","value":"164920"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P10721"}]}}{"C96914":{"preferredName":"Syndecan-1","code":"C96914","definitions":[{"definition":"Syndecan-1 (310 aa, ~32 kDa) is encoded by the human SDC1 gene. This protein is involved in the mediation of cell adhesion, signaling and cytoskeletal organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Syndecan-1","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD138","termGroup":"SY","termSource":"NCI"},{"termName":"CD138","termGroup":"SY","termSource":"NCI"},{"termName":"CD138 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"SDC1","termGroup":"SY","termSource":"NCI"},{"termName":"SYND1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD138"},{"name":"OMIM_Number","value":"186355"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P18827"},{"name":"UMLS_CUI","value":"C0753253"}]}}{"C17488":{"preferredName":"Monocyte Differentiation Antigen CD14","code":"C17488","definitions":[{"definition":"Monocyte differentiation antigen CD14 (375 aa, ~40 kDa) is encoded by the human CD14 gene. This protein plays a role in the innate immune response to lipopolysaccharide exposure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monocyte Differentiation Antigen CD14","termGroup":"PT","termSource":"NCI"},{"termName":"CD14","termGroup":"SY","termSource":"NCI"},{"termName":"CD14 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lipopolysaccharide Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Cell-Specific Leucine-Rich Glycoprotein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CD14_Antigen"},{"name":"Maps_To","value":"CD14"},{"name":"NCI_META_CUI","value":"CL1375183"},{"name":"OMIM_Number","value":"158120"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P08571"}]}}{"C96898":{"preferredName":"CD15 Antigen","code":"C96898","definitions":[{"definition":"A carbohydrate molecule found on the surface of neutrophils, eosinophils and monocytes. It is involved in neutrophil chemotaxis and phagocytosis. Expression of this antigen is associated with Hodgkin disease, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD15 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"3-Fucosyl-N-Acetyl-Lactosamine","termGroup":"SY","termSource":"NCI"},{"termName":"Lewis X","termGroup":"SY","termSource":"NCI"},{"termName":"LewisX Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"LeX","termGroup":"SY","termSource":"NCI"},{"termName":"SSEA-1","termGroup":"SY","termSource":"NCI"},{"termName":"Stage-Specific Embryonic Antigen 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD15"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0080188"}]}}{"C38894":{"preferredName":"B-Lymphocyte Antigen CD19","code":"C38894","definitions":[{"definition":"B-lymphocyte antigen CD19 (556 aa, ~61 kDa) is encoded by the human CD19 gene. This protein is involved in enhancing B-cell receptor-dependent signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Lymphocyte Antigen CD19","termGroup":"PT","termSource":"NCI"},{"termName":"B-Lymphocyte Surface Antigen B4","termGroup":"SY","termSource":"NCI"},{"termName":"B4","termGroup":"SY","termSource":"NCI"},{"termName":"CD19","termGroup":"SY","termSource":"NCI"},{"termName":"Differentiation Antigen CD19","termGroup":"SY","termSource":"NCI"},{"termName":"Leu-12","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Surface Antigen Leu-12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"When B-lymphocyte antigen CD19 complexes with the B-cell receptor, the threshold for antigen receptor-dependent stimulation of B lymphocyte proliferation is decreased. Additionally, CD19 functions as an adapter protein for Src family kinase amplification, which is crucial for antigen receptor-induced signal transduction."},{"name":"Legacy Concept Name","value":"CD19_Antigen"},{"name":"Maps_To","value":"CD19"},{"name":"NCI_META_CUI","value":"CL599759"},{"name":"OMIM_Number","value":"107265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P15391"}]}}{"C38896":{"preferredName":"B-Lymphocyte Antigen CD20","code":"C38896","definitions":[{"definition":"B-lymphocyte antigen CD20 (297 aa, ~33 kDa) is encoded by the human MS4A1 gene. This protein plays a role in both the activation and proliferation of B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Lymphocyte Antigen CD20","termGroup":"PT","termSource":"NCI"},{"termName":"B-Lymphocyte Surface Antigen B1","termGroup":"SY","termSource":"NCI"},{"termName":"B1","termGroup":"SY","termSource":"NCI"},{"termName":"Bp35","termGroup":"SY","termSource":"NCI"},{"termName":"CD20 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD20 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Leu-16","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane-Spanning 4-Domains Subfamily A Member 1","termGroup":"SY","termSource":"NCI"},{"termName":"MS4A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Expressed during B-cell ontogeny (early pre-B-cell to plasma cell) by human CD20 Gene (MS4A Family), 297-aa 33-kDa CD20 Antigen is a phosphorylated cell surface integral membrane protein shown to participate in B-cell proliferation, development, and differentiation into plasma cells. MS4A family proteins share structural similarity, sequence homology, and unique expression patterns among hematopoietic cells and nonlymphoid tissues. MS4A proteins contain 4 highly conserved transmembrane domains, flanked by N- and C-terminal cytoplasmic regions. CD20 may be involved in regulation of B-cell activation and may be regulated by protein kinases."},{"name":"Legacy Concept Name","value":"CD20_Antigen"},{"name":"Maps_To","value":"CD20"},{"name":"Maps_To","value":"FMC-7"},{"name":"OMIM_Number","value":"112210"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P11836"},{"name":"UMLS_CUI","value":"C0054946"}]}}{"C17279":{"preferredName":"B-Cell Receptor CD22","code":"C17279","definitions":[{"definition":"B-cell receptor CD22 (847 aa, ~95 kDa) is encoded by the human CD22 gene. This protein is involved in B-cell/B-cell interactions and downstream signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Receptor CD22","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Antigen CD22","termGroup":"SY","termSource":"NCI"},{"termName":"B-Lymphocyte Cell Adhesion Molecule","termGroup":"SY","termSource":"NCI"},{"termName":"BL-CAM","termGroup":"SY","termSource":"NCI"},{"termName":"CD22 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lyb8","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Ig-Like Lectin 2","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Immunoglobulin-Like Lectin 2","termGroup":"SY","termSource":"NCI"},{"termName":"Siglec-2","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Surface Antigen Leu-14","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The CD22 gene is expressed in pro-B cells as a cytoplasmic protein and later as a cell surface protein, persisting until they differentiate into plasma cells. CD22 antigen is a glycoprotein heterodimer with two subunits from separate precursor molecules that arise by differential RNA processing of the same gene. The larger subunit is composed of an extracellular portion of seven Ig domains and a smaller subunit of five Ig domains. Structurally related to MAG, NCAM, and CEA, CD22 participates in adhesion between B-cells and other cell types. Conserved ITIM motifs in inhibitory receptors are sites for phosphorylation by a SRC kinase and dephosphorylation by tyrosine phosphatase SHP1 or inositol phosphatase SHIP, transducing signals to distinct pathways. CD22 ITIMs interact with SHP1 and oppose activation mediated by the B-cell receptor. CD22 is a negative regulator of antigen receptor signaling."},{"name":"Legacy Concept Name","value":"CD22_Antigen"},{"name":"Maps_To","value":"CD22"},{"name":"OMIM_Number","value":"107266"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P20273"},{"name":"UMLS_CUI","value":"C1505685"}]}}{"C96902":{"preferredName":"Low Affinity Immunoglobulin Epsilon Fc Receptor","code":"C96902","definitions":[{"definition":"Low affinity immunoglobulin epsilon Fc receptor (321 aa, ~36 kDa) is encoded by the human FCER2 gene. This protein is involved in B cell differentiation and IgE production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Affinity Immunoglobulin Epsilon Fc Receptor","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD23","termGroup":"SY","termSource":"NCI"},{"termName":"BLAST-2","termGroup":"SY","termSource":"NCI"},{"termName":"C-Type Lectin Domain Family 4 Member J","termGroup":"SY","termSource":"NCI"},{"termName":"CD23 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Fc-Epsilon-RII","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin E-Binding Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte IgE Receptor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD23"},{"name":"OMIM_Number","value":"151445"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P06734"},{"name":"UMLS_CUI","value":"C2744538"}]}}{"C17073":{"preferredName":"Interleukin-2 Receptor Subunit Alpha","code":"C17073","definitions":[{"definition":"Interleukin-2 receptor subunit alpha (272 aa, ~31 kDa) is encoded by the human IL2RA gene. This protein plays a role in interleukin-2-dependent signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-2 Receptor Subunit Alpha","termGroup":"PT","termSource":"NCI"},{"termName":"CD25","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2 Receptor Subunit Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2-RA","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2R","termGroup":"SY","termSource":"NCI"},{"termName":"IL-2R Subunit Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"IL2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"IL2-RA","termGroup":"SY","termSource":"NCI"},{"termName":"IL2R","termGroup":"SY","termSource":"NCI"},{"termName":"IL2RA","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 2 Receptor, Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-2 Receptor Alpha Chain","termGroup":"SY","termSource":"NCI"},{"termName":"Low Affinity Interleukin 2 Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"p55","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Growth Factor Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"TAC Antigen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolysis. (LocusLink)"},{"name":"Legacy Concept Name","value":"Interleukin-2_Receptor_Alpha"},{"name":"Maps_To","value":"CD25"},{"name":"OMIM_Number","value":"147730"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P01589"},{"name":"UMLS_CUI","value":"C1700887"}]}}{"C38897":{"preferredName":"CD3 Complex","code":"C38897","definitions":[{"definition":"A protein complex comprised of one T-cell surface glycoprotein CD3 delta chain (CD3D), one T-cell surface glycoprotein CD3 gamma chain (CD3G) and two T-cell surface glycoprotein CD3 epsilon chains (CD3E). CD3D, CD3G and CD3E are transmembrane proteins with one extracellular immunoglobulin domain and one intracellular ITAM domain. The CD3 complex is a T-cell co-receptor that noncovalently associates with either the disulfide bound heterodimeric alpha/beta T-cell receptor (TCR) or gamma/delta TCR and two copies of the accessory protein, T-cell surface glycoprotein CD3 zeta chain (CD247), which is a transmembrane protein with three ITAM domains. The TCR moiety of the TCR-CD3 complex binds to MHC and processed antigens on antigen presenting cells, which triggers phosphorylation of and cellular propagation of the signal by CD247 and the CD3 complex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD3 Complex","termGroup":"PT","termSource":"NCI"},{"termName":"CD3","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Surface Glycoprotein CD3","termGroup":"SY","termSource":"NCI"},{"termName":"T3 Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CD3_Complex"},{"name":"Maps_To","value":"CD3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0108779"}]}}{"C38906":{"preferredName":"Tumor Necrosis Factor Receptor Superfamily Member 8","code":"C38906","definitions":[{"definition":"Tumor necrosis factor receptor superfamily member 8 (595 aa, ~ 64 kDa) is encoded by the human TNFRSF8 gene. This protein is involved in ligand-mediated signal transduction, the positive regulation of apoptosis and the inhibition of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Necrosis Factor Receptor Superfamily Member 8","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD30","termGroup":"SY","termSource":"NCI"},{"termName":"CD30 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD30L Receptor","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokine Receptor CD30","termGroup":"SY","termSource":"NCI"},{"termName":"Ki-1 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Activation Antigen CD30","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoid Activation Antigen CD30","termGroup":"SY","termSource":"NCI"},{"termName":"TNF Receptor 8","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Tumor necrosis factor receptor superfamily member 8 is a receptor for TNFSF8/CD30L and interacts with the TRAF1, TRAF2, TRAF3, and TRAF5. (UniProt)"},{"name":"Legacy Concept Name","value":"TNF_Receptor-8"},{"name":"Maps_To","value":"CD30"},{"name":"OMIM_Number","value":"153243"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Receptor"},{"name":"Swiss_Prot","value":"P28908"},{"name":"UMLS_CUI","value":"C0054950"}]}}{"C97246":{"preferredName":"Myeloid Cell Surface Antigen CD33","code":"C97246","definitions":[{"definition":"Myeloid cell surface antigen CD33 (364 aa, ~40 kDa) is encoded by the human CD33 gene. This protein is involved in the mediation of cell adhesion and the regulation of cell-cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloid Cell Surface Antigen CD33","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD33","termGroup":"SY","termSource":"NCI"},{"termName":"CD33 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"gp67","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Differentiation Antigen CD33","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Ig-Like Lectin 3","termGroup":"SY","termSource":"NCI"},{"termName":"Sialic Acid-Binding Immunoglobulin-Like Lectin 3","termGroup":"SY","termSource":"NCI"},{"termName":"Siglec-3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD33"},{"name":"OMIM_Number","value":"159590"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P20138"},{"name":"UMLS_CUI","value":"C3491277"}]}}{"C17280":{"preferredName":"Hematopoietic Progenitor Cell Antigen CD34","code":"C17280","definitions":[{"definition":"Hematopoietic progenitor cell antigen CD34 (385 aa, ~41 kDa) is encoded by the human CD34 gene. This protein plays a role in cell-cell adhesion and may have a role in leukocyte migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic Progenitor Cell Antigen CD34","termGroup":"PT","termSource":"NCI"},{"termName":"CD34","termGroup":"SY","termSource":"NCI"},{"termName":"gp105-120","termGroup":"SY","termSource":"NCI"},{"termName":"HPCA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"A protein found on the surface of some bone marrow and blood cells. Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow."},{"name":"Legacy Concept Name","value":"CD34_Antigen"},{"name":"Maps_To","value":"CD34"},{"name":"OMIM_Number","value":"142230"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P28906"},{"name":"UMLS_CUI","value":"C0054953"}]}}{"C17282":{"preferredName":"Receptor-Type Tyrosine-Protein Phosphatase C","code":"C17282","definitions":[{"definition":"Receptor-type tyrosine-protein phosphatase C (1304 aa, ~147 kDa) is encoded by the human PTPRC gene. This protein plays a role in protein dephosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Receptor-Type Tyrosine-Protein Phosphatase C","termGroup":"PT","termSource":"NCI"},{"termName":"CD45 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD45RABC","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.1.3.48","termGroup":"SY","termSource":"NCI"},{"termName":"L-CA","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Common Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRC","termGroup":"SY","termSource":"NCI"},{"termName":"Receptor-Type Tyrosine-Protein Phosphatase C Isoform 1","termGroup":"SY","termSource":"NCI"},{"termName":"T200","termGroup":"SY","termSource":"NCI"},{"termName":"T200 Glycoprotein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Protein_Tyrosine_Phosphatase_Receptor_Type-C"},{"name":"Maps_To","value":"CD45"},{"name":"OMIM_Number","value":"151460"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P08575"},{"name":"UMLS_CUI","value":"C1870006"}]}}{"C73124":{"preferredName":"T-Cell Surface Glycoprotein CD5","code":"C73124","definitions":[{"definition":"T-cell surface glycoprotein CD5 (495 aa, ~54 kDa) is encoded by the human CD5 gene. This protein may be involved in regulating the proliferation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Surface Glycoprotein CD5","termGroup":"PT","termSource":"NCI"},{"termName":"CD5 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Antigen CD5","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Antigen T1/Leu-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"T-cell surface glycoprotein CD5 is a membrane bound glycoprotein expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies that specifically bind to CD5 can enhance T-cell receptor-mediated T-cell activation. This protein can bind to CD72 antigen. (Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)"},{"name":"Legacy Concept Name","value":"T-Cell_Surface_Glycoprotein_CD5"},{"name":"Maps_To","value":"CD5"},{"name":"OMIM_Number","value":"153340"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P06127"},{"name":"UMLS_CUI","value":"C0054964"}]}}{"C25276":{"preferredName":"Neural Cell Adhesion Molecule 1","code":"C25276","definitions":[{"definition":"Neural cell adhesion molecule 1 (761 aa, ~84 kDa) is encoded by the human NCAM1 gene. This protein is involved in the mediation of neuron-neuron adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neural Cell Adhesion Molecule 1","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen MSK39 Identified By Monoclonal Antibody 5.1H11","termGroup":"SY","termSource":"NCI"},{"termName":"CD56 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"N-CAM-1","termGroup":"SY","termSource":"NCI"},{"termName":"NCAM","termGroup":"AB","termSource":"NCI"},{"termName":"NCAM-1","termGroup":"SY","termSource":"NCI"},{"termName":"NCAM1","termGroup":"SY","termSource":"NCI"},{"termName":"Neural Cell Adhesion Molecule","termGroup":"SY","termSource":"NCI"},{"termName":"NKH-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Neural Cell Adhesion Molecule is a membrane-bound glycoprotein member of the Ig superfamily that binds to a variety of other cell adhesion proteins involved in diverse contact-mediated interactions.  NCAM appears on early embryonic cells and is important in the formation of cell collectives at sites of morphogenesis.  Later it is found on differentiated neurons, astrocytes, oligodendrocytes, and myotubes and mediates neuronal adhesion, guidance, and differentiation.  NCAM plays a role in cell-cell and cell-matrix adhesion through homophilic and heterophilic binding.  The invertebrate cell adhesion molecules fasciclin II (grasshoppers and Drosophila) and apCAM (Aplysia) are related to NCAM and can mediate homophilic cell aggregation.  Four main isoforms exist, including CD56, but many variants result from alternative splicing and post-translational modifications."},{"name":"Legacy Concept Name","value":"Neural_Cell_Adhesion_Molecule"},{"name":"Maps_To","value":"CD56"},{"name":"OMIM_Number","value":"116930"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P13591"},{"name":"UMLS_CUI","value":"C1999531"}]}}{"C38935":{"preferredName":"T-Cell Antigen CD7","code":"C38935","definitions":[{"definition":"T-cell antigen CD7 (240 aa, ~25 kDa) is encoded by the human CD7 gene. This protein plays a role in the development and function of lymphoid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Antigen CD7","termGroup":"PT","termSource":"NCI"},{"termName":"CD7 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"GP40","termGroup":"SY","termSource":"NCI"},{"termName":"Leu-9","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Leukemia Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"TP41","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Expressed in thymocytes and mature T cells by human CD7 Gene (Immunoglobulin Superfamily), 240-aa 25-kDa (precursor) T-Cell Antigen CD7 is a cell surface type I transmembrane glycoprotein that interacts with SECTM1, contains an Ig-like domain, and is essential in T-cell interactions and in T-cell/B-cell interaction during early lymphoid development. One of the earliest antigens on cells of the T-lymphocyte lineage, CD7 is the most reliable clinical marker of T-cell acute lymphocytic leukemia."},{"name":"Legacy Concept Name","value":"T-Cell_Antigen_CD7"},{"name":"Maps_To","value":"CD7"},{"name":"OMIM_Number","value":"186820"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P09564"},{"name":"UMLS_CUI","value":"C0054968"}]}}{"C97423":{"preferredName":"B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain","code":"C97423","definitions":[{"definition":"B-cell antigen receptor complex-associated protein alpha chain (226 aa, ~25 kDa) is encoded by the human CD79A gene. This protein is involved in the modulation of signaling in and proliferation of B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD79a","termGroup":"SY","termSource":"NCI"},{"termName":"CD79a","termGroup":"SY","termSource":"NCI"},{"termName":"CD79a Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Ig-Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"MB-1 Membrane Glycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Membrane-Bound Immunoglobulin-Associated Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Surface IgM-Associated Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD79A"},{"name":"OMIM_Number","value":"112205"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P11912"},{"name":"UMLS_CUI","value":"C1506239"}]}}{"C16384":{"preferredName":"Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5","code":"C16384","definitions":[{"definition":"Carcinoembryonic antigen-related cell adhesion molecule 5 (702 aa, ~77 kDa) is encoded by the human CEACAM5 gene. This protein is involved in cell-cell adhesion, apotosis regulation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoembryonic Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD66e Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CEA","termGroup":"SY","termSource":"NCI"},{"termName":"CEACAM5","termGroup":"SY","termSource":"NCI"},{"termName":"Meconium Antigen 100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CD66E_Antigen"},{"name":"Maps_To","value":"CEA"},{"name":"OMIM_Number","value":"114890"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P06731"},{"name":"UMLS_CUI","value":"C2352715"}]}}{"C16692":{"preferredName":"HLA-DR Antigen","code":"C16692","definitions":[{"definition":"Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-DR Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-DR","termGroup":"SY","termSource":"NCI"},{"termName":"Human Leukocyte Antigen - DR Isotype","termGroup":"SY","termSource":"NCI"},{"termName":"Human Leukocyte Antigen-DR Isotype","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HLA-DR_Antigen"},{"name":"Maps_To","value":"HLA-DR"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0019764"}]}}{"C20887":{"preferredName":"Mesothelin","code":"C20887","definitions":[{"definition":"A protein found on the surface of certain types of normal cells and cancer cells. Mesothelin may help these cells stick together and send signals. A higher-than-normal amount of mesothelin is found on some cancer cells, including mesothelioma, pancreatic cancer, and ovarian cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Mesothelin (630 aa, ~69 kDa) is encoded by the human MSLN gene. This protein may play a role in cellular adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesothelin","termGroup":"PT","termSource":"NCI"},{"termName":"CAK1 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"MSLN","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Pro-Megakaryocyte-Potentiating Factor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"An antibody that reacts with ovarian cancers and mesotheliomas was used to isolate a cell surface antigen named mesothelin. Although the function of mesothelin is unknown, it may play a role in cellular adhesion and is present on mesothelium, mesotheliomas, and ovarian cancers. Three transcript variants have been described for this gene and their protein products were initially named megakaryocyte potentiating factor (MPF), mesothelin, and the soluble member(s) of the mesothelin/MPF family. The protein isoform named MPF is a cytokine with megakaryocyte potentiating activity. The soluble member encoded by the third splice variant is detected in ovarian carcinoma; the full length sequence of the third variant has not been described. (LocusLink)"},{"name":"Legacy Concept Name","value":"Mesothelin"},{"name":"Maps_To","value":"Mesothelin"},{"name":"OMIM_Number","value":"601051"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q13421"},{"name":"UMLS_CUI","value":"C1429990"}]}}{"C62216":{"preferredName":"Gamma-Enolase","code":"C62216","definitions":[{"definition":"Gamma-enolase (434 aa, ~47 kDa) is encoded by the human ENO2 gene. This protein is involved in glycolysis, neurotrophy and neuroprotection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma-Enolase","termGroup":"PT","termSource":"NCI"},{"termName":"2-Phospho-D-Glycerate Hydro-Lyase","termGroup":"SY","termSource":"NCI"},{"termName":"EC 4.2.1.11","termGroup":"SY","termSource":"NCI"},{"termName":"ENO2","termGroup":"SY","termSource":"NCI"},{"termName":"Enolase 2","termGroup":"SY","termSource":"NCI"},{"termName":"Neural Enolase","termGroup":"SY","termSource":"NCI"},{"termName":"Neuron-Specific Enolase","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphopyruvate Hydratase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Gamma-enolase is expressed specifically in neurons."},{"name":"DesignNote","value":"Gamma-enolase protein levels are significantly elevated in brain tumors and Creutzfeld-Jacob disease. Cardiovascular accidents and cerebral trauma also cause dramatic increases in levels of this protein."},{"name":"Legacy Concept Name","value":"Gamma-Enolase"},{"name":"Maps_To","value":"NSE"},{"name":"OMIM_Number","value":"131360"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P09104"},{"name":"UMLS_CUI","value":"C1880904"}]}}{"C17525":{"preferredName":"Prostate-Specific Antigen","code":"C17525","definitions":[{"definition":"A protein made by the prostate gland and found in the blood. Prostate-specific antigen blood levels may be higher than normal in men who have prostate cancer, benign prostatic hyperplasia (BPH), or infection or inflammation of the prostate gland.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate-Specific Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen, Prostate-Specific","termGroup":"SY","termSource":"NCI"},{"termName":"EC 3.4.21.77","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-Seminoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Kallikrein-3","termGroup":"SY","termSource":"NCI"},{"termName":"KLK3","termGroup":"SY","termSource":"NCI"},{"termName":"P-30 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Specific Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Specific Antigen Preproprotein","termGroup":"SY","termSource":"NCI"},{"termName":"PSA","termGroup":"AB","termSource":"NCI"},{"termName":"Semenogelase","termGroup":"SY","termSource":"NCI"},{"termName":"Seminin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The serum level of PSA is used in diagnosis and monitoring of prostatic carcinoma, benign prostate hyperplasia, or infection or inflammation of the prostate."},{"name":"Legacy Concept Name","value":"Prostate-Specific_Antigen"},{"name":"Maps_To","value":"Prostate-Specific Antigen (PSA)"},{"name":"OMIM_Number","value":"176820"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Swiss_Prot","value":"P07288"},{"name":"UMLS_CUI","value":"C0138741"}]}}{"C120660":{"preferredName":"Squamous Cell Carcinoma Antigen Measurement","code":"C120660","definitions":[{"definition":"A measurement of the squamous cell carcinoma antigen in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the squamous cell carcinoma antigen present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squamous Cell Carcinoma Antigen Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Serpin B3/B4 Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Squamous Cell Carcinoma Antigen (SCCA)"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C4049934"}]}}{"C17675":{"preferredName":"Antigen KI-67","code":"C17675","definitions":[{"definition":"Antigen KI-67 protein (3256 aa, ~359 kDa) is encoded by the human MKI67 gene. This protein is required for cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antigen KI-67","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen Identified by Monoclonal Antibody Ki-67","termGroup":"SY","termSource":"NCI"},{"termName":"Ki-67 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"KIA","termGroup":"SY","termSource":"NCI"},{"termName":"MIB-1","termGroup":"SY","termSource":"NCI"},{"termName":"MKI67","termGroup":"SY","termSource":"NCI"},{"termName":"MKI67 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Proliferation-Related Ki-67 Antigen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Antigen KI-67 protein expression occurs during late G1, S, G2, and M phases of the cell cycle, while in cells in G0 phase the protein cannot be detected. The protein is located in the perinucleolar region during G1 phase. In the later phases it is detected throughout the nuclear interior, predominantly in the nuclear matrix. In mitosis, it is present on all chromosomes. (SwissProt)"},{"name":"DesignNote","value":"Detection of Antigen KI-67 is used to locate proliferating cells in neoplastic diseases. (OMIM)"},{"name":"Legacy Concept Name","value":"Proliferation-Related-Ki-67_Antigen"},{"name":"Maps_To","value":"Ki67"},{"name":"NCI_META_CUI","value":"CL963711"},{"name":"OMIM_Number","value":"176741"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Swiss_Prot","value":"P46013"}]}}{"C184770":{"preferredName":"Surface Immunoglobulin Light Chain Kappa","code":"C184770","definitions":[{"definition":"Immunoglobulin kappa proteins expressed on the extracellular surface of the plasma membrane","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surface Immunoglobulin Light Chain Kappa","termGroup":"PT","termSource":"NCI"},{"termName":"Surface Ig Kappa","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Kappa","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Kappa Light Chain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kappa, Surface"},{"name":"NCI_META_CUI","value":"CL1773095"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C184771":{"preferredName":"Surface Immunoglobulin Light Chain Lambda","code":"C184771","definitions":[{"definition":"Immunoglobulin lambda proteins expressed on the extracellular surface of the plasma membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surface Immunoglobulin Light Chain Lambda","termGroup":"PT","termSource":"NCI"},{"termName":"Surface Ig Lambda","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Lambda","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Lambda Light Chain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lambda, Surface"},{"name":"NCI_META_CUI","value":"CL1773092"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C1269":{"preferredName":"TAG-72 Antigen","code":"C1269","definitions":[{"definition":"A protein/sugar complex found on the surface of many cancer cells, including breast, colon, and pancreatic cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Tumor-associated oncofetal glycoprotein 72 (TAG-72) is a high molecular weight (220-400 kD) complex expressed by a wide variety of human adenocarcinomas. This antigen is expressed by a majority of invasive ductal breast carcinomas, and most colon, pancreatic, gastric, esophageal, lung (non-small cell), ovarian and endometrial adenocarcinomas, and on normal secretory endometrium, but not on other normal tissues. It is not expressed by leukemias, lymphomas, sarcomas, mesotheliomas, melanomas or benign tumors. The monoclonal antibodies against TAG-72 have been widely employed for the immunohistochemical analysis of adenocarcinomas as well as for radioimmunoscintigraphy and radioimmunoguided surgery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAG-72 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"Antitumor-Associated Glycoprotein 72","termGroup":"SY","termSource":"NCI"},{"termName":"CA 72-4","termGroup":"SY","termSource":"NCI"},{"termName":"CA-72-4","termGroup":"SY","termSource":"NCI"},{"termName":"CA72-4","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer Antigen 72-4","termGroup":"SY","termSource":"NCI"},{"termName":"TAG-72","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TAG-72_Antigen"},{"name":"Maps_To","value":"TAG-72"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0077505"}]}}{"C172121":{"preferredName":"Cytoplasmic Immunoglobulin","code":"C172121","definitions":[{"definition":"Immunoglobulins found within intact cells. The proportion of cells expressing cytoplasmic immunoglobulin can be a diagnostic criterion in B-cell lymphoproliferative disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytoplasmic Immunoglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"cIg","termGroup":"SY","termSource":"NCI"},{"termName":"Cytoplasmic Ig","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunoglobulin, Cytoplasmic"},{"name":"NCI_META_CUI","value":"CL1406231"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C573":{"preferredName":"Surface Immunoglobulin","code":"C573","definitions":[{"definition":"Immunoglobulin containing a transmembrane region and expressed on the plasma membrane of a B cell.  Contrast with secreted Ig which has no transmembrane region but which can still be bound to the cell surface via Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surface Immunoglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"sIg","termGroup":"SY","termSource":"NCI"},{"termName":"Surface Ig","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Surface_Immunoglobulin"},{"name":"Maps_To","value":"Immunoglobulin, Surface"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0034789"}]}}{"C101153":{"preferredName":"Leukosialin","code":"C101153","definitions":[{"definition":"Leukosialin (400 aa, ~40 kDa) is encoded by the human SPN gene. This protein is involved in immune cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leukosialin","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen CD43","termGroup":"SY","termSource":"NCI"},{"termName":"CD43","termGroup":"SY","termSource":"NCI"},{"termName":"CD43 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Galactoglycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"GALGP","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Large Sialoglycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Sialoglycoprotein","termGroup":"SY","termSource":"NCI"},{"termName":"Sialophorin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD43"},{"name":"OMIM_Number","value":"182160"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P16150"},{"name":"UMLS_CUI","value":"C1434437"}]}}{"C84507":{"preferredName":"Buffy Coat","code":"C84507","definitions":[{"definition":"The middle fraction of an anticoagulated blood specimen following separation by centrifugation. It contains most of the white blood cells and platelets.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The middle layer of an anticoagulated blood specimen following separation by centrifugation. It contains most of the white blood cells and platelets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buffy Coat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buffy Coat"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0443089"}]}}{"C12374":{"preferredName":"Connective Tissue","code":"C12374","definitions":[{"definition":"Supporting tissue that surrounds other tissues and organs. Specialized connective tissue includes bone, cartilage, blood, and fat.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Supporting tissue that surrounds other tissues and organs. Specialized connective tissue includes bone, cartilage, blood, and fat.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The supporting or framework tissue of the animal body, formed of fibrous and ground substance with more or less numerous cells of various kinds; it is derived from the mesenchyme, and this in turn from the mesoderm; the varieties of connective tissue are: areolar or loose; adipose; dense, regular or irregular, white fibrous; elastic; mucous; and lymphoid tissue; cartilage; and bone; the blood and lymph may be regarded as connective tissues the ground substance of which is a liquid.","type":"DEFINITION","source":"NCI"},{"definition":"The supporting or framework tissue of the body, formed of fibrous and ground substance with a variety of cell types. The varieties of connective tissue are: areolar or loose; adipose; dense, regular or irregular, white fibrous; elastic; mucous; lymphoid tissue; cartilage; bone.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Connective Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Connective_Tissue"},{"name":"Maps_To","value":"Connective Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0009780"},{"name":"xRef","value":"UBERON:0002384"}]}}{"C13398":{"preferredName":"Embryonic Fluid","code":"C13398","definitions":[{"definition":"Fluids surrounding or related to an embryo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonic Fluid","termGroup":"PT","termSource":"NCI"},{"termName":"Embryonic Fluids","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonic Tissue, Fluids, Secretions","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Embryonic_Fluid"},{"name":"Maps_To","value":"Embryonic Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C1516820"}]}}{"C12950":{"preferredName":"Embryonic Tissue","code":"C12950","definitions":[{"definition":"Tissue that is formed during the embryonic stage of life of an organism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embryonic Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Embryonic_Tissue"},{"name":"Maps_To","value":"Embryonic Tissue"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0920502"}]}}{"C13234":{"preferredName":"Feces","code":"C13234","definitions":[{"definition":"The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.","type":"DEFINITION","source":"NCI"},{"definition":"The material discharged from the bowel during defecation. It consists of undigested food, intestinal mucus, epithelial cells, and bacteria. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The material in a bowel movement. Feces is made up of undigested food, bacteria, mucus, and cells from the lining of the intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Feces","termGroup":"PT","termSource":"NCI"},{"termName":"Fecal","termGroup":"AD","termSource":"NCI"},{"termName":"Gastrointestinal Tract, Feces","termGroup":"SY","termSource":"NCI"},{"termName":"Stool","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Feces"},{"name":"Maps_To","value":"Feces"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0015733"}]}}{"C12530":{"preferredName":"Granulocyte","code":"C12530","definitions":[{"definition":"A type of immune cell that has granules (small particles) with enzymes that are released during infections, allergic reactions, and asthma. Neutrophils, eosinophils, and basophils are granulocytes. A granulocyte is a type of white blood cell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of leukocyte containing a nucleus and cytoplasmic granules. Granulocytes are subdivided according to the staining properties of their granules into eosinophils, basophils, and neutrophils.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of leukocyte with a multilobed nucleus and cytoplasmic granules. The unique morphology of the nucleus has led to their also being known as polymorphonuclear leukocytes (PMLs or PMNs). Granulocytes are subdivided according to the staining properties of their granules into eosinophils (red with acidic dye), basophils (blue with basic dye), and neutrophils (not amenable to staining with either acidic or basic dyes).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Granulocyte","termGroup":"PT","termSource":"NCI"},{"termName":"Granular Leukocyte","termGroup":"SY","termSource":"NCI"},{"termName":"Granular Leukocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Granulocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Granulocytic","termGroup":"AD","termSource":"NCI"},{"termName":"Granulocytic Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphonuclear Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Polymorphonuclear Leukocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Granulocyte"},{"name":"Maps_To","value":"Granulocyte"},{"name":"Maps_To","value":"Granulocytes"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0018183"}]}}{"C18009":{"preferredName":"Tumor Tissue Sample","code":"C18009","definitions":[{"definition":"A tumor sample, or entire tumor that is removed for examination.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue sample that contains an abnormal cellular infiltrate forming a solid mass. The abnormal cellular component can be benign or malignant. Tumor samples are obtained for microscopic examination and/or molecular analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Tissue Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Tumor Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Tumor_Tissue"},{"name":"Maps_To","value":"Involved Tissue, NOS"},{"name":"Maps_To","value":"Tumor"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0475358"}]}}{"C12435":{"preferredName":"Muscle Tissue","code":"C12435","definitions":[{"definition":"Tissue responsible for body and internal organ movement. Muscle tissue is composed of specialized contractile cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue responsible for the body movements and the shape and size changes of internal organs.  Muscle tissue is composed of specialized contractile cells.  There are two types of muscle tissue recognized: striated and smooth muscle.  The striated muscle tissue is further subdivided into skeletal, visceral striated, and cardiac muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Muscle Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Muscle_Tissue"},{"name":"Maps_To","value":"Muscle Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C2328219"}]}}{"C13052":{"preferredName":"Nerve Tissue","code":"C13052","definitions":[{"definition":"The tissue that generates and conducts electrical signals in the body.  It contains the neurons.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Nervous Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nervous_Tissue"},{"name":"Maps_To","value":"Nerve Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0027757"}]}}{"C77612":{"preferredName":"Peritoneal Fluid","code":"C77612","definitions":[{"definition":"A liquid that is made in the abdominal cavity to lubricate the surface of the tissue that lines the abdominal wall and pelvic cavity and covers most of the organs in the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid within the peritoneal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The small amount of fluid that is generated in the abdominal cavity to lubricate the peritoneum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneal Fluid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peritoneal_Fluid"},{"name":"Maps_To","value":"Peritoneal Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0003964"}]}}{"C13356":{"preferredName":"Plasma","code":"C13356","definitions":[{"definition":"Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.","type":"DEFINITION","source":"NCI"},{"definition":"The clear, yellowish, fluid part of the blood that carries the blood cells. The proteins that form blood clots are in plasma.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid (acellular) portion of the circulating blood with retained clotting components.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Plasma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Plasma"},{"name":"Maps_To","value":"Plasma"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0032105"}]}}{"C77613":{"preferredName":"Pleural Fluid","code":"C77613","definitions":[{"definition":"The fluid that is ordinarily present in the pleural space. It allows for normal movement of the lungs during respiration.","type":"DEFINITION","source":"NCI"},{"definition":"The fluid within the pleural cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pleural Fluid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Pleural_Fluid"},{"name":"Maps_To","value":"Pleural Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0225778"}]}}{"C13275":{"preferredName":"Saliva","code":"C13275","definitions":[{"definition":"A clear liquid secreted by the salivary glands.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The watery fluid in the mouth made by the salivary glands. Saliva moistens food to help digestion and it helps protect the mouth against infections.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The watery fluid in the mouth made by the salivary glands. Saliva moistens food to help digestion and it helps protect the mouth against infections.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saliva","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Saliva","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Saliva"},{"name":"Maps_To","value":"Saliva"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0036087"}]}}{"C13325":{"preferredName":"Serum","code":"C13325","definitions":[{"definition":"The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins.","type":"DEFINITION","source":"NCI"},{"definition":"The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Serum","termGroup":"PT","termSource":"NCI"},{"termName":"Sera","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Serum"},{"name":"Maps_To","value":"Serum"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0229671"}]}}{"C12801":{"preferredName":"Tissue","code":"C12801","definitions":[{"definition":"A group or layer of cells that work together to perform a specific function.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.","type":"DEFINITION","source":"NCI"},{"definition":"An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Normal Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Tissues","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Tissue"},{"name":"Maps_To","value":"Tissue, NOS"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0040300"}]}}{"C162623":{"preferredName":"Normal Tissue Sample","code":"C162623","definitions":[{"definition":"Tissue sample with cellular composition and architectural patterns expected for the particular anatomic site in which it belongs. There is no evidence of abnormal cellular infiltrates or tumor mass formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Normal Tissue Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Normal Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Normal Tissue Segment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uninvolved Tissue, NOS"},{"name":"NCI_META_CUI","value":"CL971063"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C13283":{"preferredName":"Urine","code":"C13283","definitions":[{"definition":"Fluid containing water and waste products. Urine is made by the kidneys, stored in the bladder, and leaves the body through the urethra.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The fluid produced by the kidneys.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fluid that is excreted by the kidneys.  It is stored in the bladder and discharged through the urethra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urine","termGroup":"PT","termSource":"NCI"},{"termName":"Urinary System, Urine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Urine"},{"name":"Maps_To","value":"Urine"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0042036"}]}}{"C13204":{"preferredName":"Human Chromosome 1","code":"C13204","definitions":[{"definition":"The designation for each member of the largest human autosomal chromosome pair. Chromosome 1 spans about 247 million nucleotide base pairs and represents about 8% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 1","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_1"},{"name":"Maps_To","value":"chr1"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008651"}]}}{"C13215":{"preferredName":"Human Chromosome 2","code":"C13215","definitions":[{"definition":"The designation for each member of the second largest human autosomal chromosome pair. Chromosome 2 spans more than 237 million base pairs and represents almost 8% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 2","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_2"},{"name":"Maps_To","value":"chr2"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008662"}]}}{"C13219":{"preferredName":"Human Chromosome 3","code":"C13219","definitions":[{"definition":"The designation for each member of the third largest human autosomal chromosome pair. Chromosome 3 spans almost 200 million base pairs and represents about 6.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 3","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_3"},{"name":"Maps_To","value":"chr3"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008666"}]}}{"C13220":{"preferredName":"Human Chromosome 4","code":"C13220","definitions":[{"definition":"The designation for each member of the fourth largest human autosomal chromosome pair. Chromosome 4 spans more than 186 million base pairs and represents between 6 and 6.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 4","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_4"},{"name":"Maps_To","value":"chr4"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008667"}]}}{"C13221":{"preferredName":"Human Chromosome 5","code":"C13221","definitions":[{"definition":"The designation for each member of the fifth largest human autosomal chromosome pair. Chromosome 5 spans about 181 million base pairs and represents almost 6% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 5","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_5"},{"name":"Maps_To","value":"chr5"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008668"}]}}{"C13222":{"preferredName":"Human Chromosome 6","code":"C13222","definitions":[{"definition":"The designation for each member of the sixth largest human autosomal chromosome pair. Chromosome 6 spans more than 170 million base pairs and represents between 5.5 and 6% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 6","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_6"},{"name":"Maps_To","value":"chr6"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008669"}]}}{"C13223":{"preferredName":"Human Chromosome 7","code":"C13223","definitions":[{"definition":"The designation for each member of the seventh largest human autosomal chromosome pair. Chromosome 7 spans more than 158 million base pairs and represents between 5 and 5.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 7","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_7"},{"name":"Maps_To","value":"chr7"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008670"}]}}{"C13224":{"preferredName":"Human Chromosome 8","code":"C13224","definitions":[{"definition":"The designation for each member of the eighth largest human autosomal chromosome pair. Chromosome 8 spans about 145 million base pairs and represents between 4.5 and 5.0% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 8","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_8"},{"name":"Maps_To","value":"chr8"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008671"}]}}{"C13225":{"preferredName":"Human Chromosome 9","code":"C13225","definitions":[{"definition":"The designation for each member of the ninth largest human autosomal chromosome pair. Chromosome 9 spans about 145 million base pairs of nucleic acids and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 9","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_9"},{"name":"Maps_To","value":"chr9"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008672"}]}}{"C13205":{"preferredName":"Human Chromosome 10","code":"C13205","definitions":[{"definition":"The designation for each member of the tenth largest human autosomal chromosome pair. Chromosome 10 spans about 135 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 10","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_10"},{"name":"Maps_To","value":"chr10"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008652"}]}}{"C13206":{"preferredName":"Human Chromosome 11","code":"C13206","definitions":[{"definition":"The designation for each member of the eleventh largest human autosomal chromosome pair. Chromosome 11 spans about 134.5 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 11","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_11"},{"name":"Maps_To","value":"chr11"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008653"}]}}{"C13207":{"preferredName":"Human Chromosome 12","code":"C13207","definitions":[{"definition":"The designation for each member of the twelfth largest human autosomal chromosome pair. Chromosome 12 spans about 143 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 12","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_12"},{"name":"Maps_To","value":"chr12"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008654"}]}}{"C13208":{"preferredName":"Human Chromosome 13","code":"C13208","definitions":[{"definition":"The designation for each member of the thirteenth largest human autosomal chromosome pair. Chromosome 13 spans about 113 million base pairs and represents between 3.5 and 4% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 13","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_13"},{"name":"Maps_To","value":"chr13"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008655"}]}}{"C13209":{"preferredName":"Human Chromosome 14","code":"C13209","definitions":[{"definition":"The designation for each member of the fourteenth largest human autosomal chromosome pair. Chromosome 14 spans about 105 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 14","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 14","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_14"},{"name":"Maps_To","value":"chr14"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008656"}]}}{"C13210":{"preferredName":"Human Chromosome 15","code":"C13210","definitions":[{"definition":"The designation for each member of the fifteenth largest human autosomal chromosome pair. Chromosome 15 spans about 106 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 15","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_15"},{"name":"Maps_To","value":"chr15"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008657"}]}}{"C13211":{"preferredName":"Human Chromosome 16","code":"C13211","definitions":[{"definition":"The designation for each member of the sixteenth largest human autosomal chromosome pair. Chromosome 16 spans about 90 million base pairs and represents just under 3% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 16","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 16","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_16"},{"name":"Maps_To","value":"chr16"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008658"}]}}{"C13212":{"preferredName":"Human Chromosome 17","code":"C13212","definitions":[{"definition":"The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 17","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 17","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_17"},{"name":"Maps_To","value":"chr17"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008659"}]}}{"C13213":{"preferredName":"Human Chromosome 18","code":"C13213","definitions":[{"definition":"The designation for each member of the eighteenth largest human autosomal chromosome pair. Chromosome 18 spans about 76 million base pairs and represents about 2.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 18","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 18","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_18"},{"name":"Maps_To","value":"chr18"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008660"}]}}{"C13214":{"preferredName":"Human Chromosome 19","code":"C13214","definitions":[{"definition":"The designation for each member of the nineteenth largest human autosomal chromosome pair. Chromosome 19 spans more than 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 19","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_19"},{"name":"Maps_To","value":"chr19"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008661"}]}}{"C13216":{"preferredName":"Human Chromosome 20","code":"C13216","definitions":[{"definition":"The designation for each member of the third smallest human autosomal chromosome pair. Chromosome 20 spans around 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 20","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_20"},{"name":"Maps_To","value":"chr20"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008663"}]}}{"C13217":{"preferredName":"Human Chromosome 21","code":"C13217","definitions":[{"definition":"The designation for each member of the second smallest human autosomal chromosome pair. Chromosome 21 spans around 47 million nucleotides and represents about 1.5% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 21","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 21","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_21"},{"name":"Maps_To","value":"chr21"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008664"}]}}{"C13218":{"preferredName":"Human Chromosome 22","code":"C13218","definitions":[{"definition":"The designation for each member of the smallest human autosomal chromosome pair. Chromosome 22 spans about 49 million base pairs and represents between 1.5 and 2% of the total DNA in normal diploid cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 22","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome 22","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_22"},{"name":"Maps_To","value":"chr22"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0008665"}]}}{"C33542":{"preferredName":"Human Chromosome 23","code":"C33542","definitions":[{"definition":"The X or Y chromosome in human beings that determines the sex of an individual. Females have two X chromosomes in diploid cells; males have an X and a Y chromosome. The sex chromosomes comprise the 23rd chromosome pair in a human karyotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome 23","termGroup":"PT","termSource":"NCI"},{"termName":"Chr23","termGroup":"SY","termSource":"NCI"},{"termName":"Human Sex Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"Sex Chromosome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sex_Chromosome"},{"name":"Maps_To","value":"chr23"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0036869"}]}}{"C28512":{"preferredName":"Mitochondrial DNA","code":"C28512","definitions":[{"definition":"Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitochondrial DNA","termGroup":"PT","termSource":"NCI"},{"termName":"Mitochondrial Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"mtDNA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mitochondrial_DNA"},{"name":"Maps_To","value":"chrM"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0012929"}]}}{"C13285":{"preferredName":"Human Chromosome X","code":"C13285","definitions":[{"definition":"The larger of the two human sex chromosomes. It is usually present singly in males and doubly in females.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome X","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome X","termGroup":"SY","termSource":"NCI"},{"termName":"Human X Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"X Chromosome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_X"},{"name":"Maps_To","value":"chrX"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0043292"}]}}{"C13286":{"preferredName":"Human Chromosome Y","code":"C13286","definitions":[{"definition":"The smaller of the two human sex chromosome. Its presence usually determines the development of a fetus as male, while its absence usually determines the development of a fetus as female.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Chromosome Y","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Y","termGroup":"SY","termSource":"NCI"},{"termName":"Human Y Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"Y Chromosome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chromosome_Y"},{"name":"Maps_To","value":"chrY"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0043381"}]}}{"C41179":{"preferredName":"Monoclonal Cellular Population Present","code":"C41179","definitions":[{"definition":"A finding indicating that a monoclonal population of cells were detected in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Cellular Population Present","termGroup":"PT","termSource":"NCI"},{"termName":"Clonal Cellular Population Present","termGroup":"SY","termSource":"NCI"},{"termName":"Monotypic Cell Population Present","termGroup":"SY","termSource":"NCI"},{"termName":"Monotypic Cells Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clonal_Cellular_Population_Present"},{"name":"Maps_To","value":"Clonal"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C1516667"}]}}{"C172229":{"preferredName":"Nonclonal Cellular Population Present","code":"C172229","definitions":[{"definition":"An indication that the cells in a sample did not arise from a single progenitor cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonclonal Cellular Population Present","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Clonal Cellular Population Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-clonal"},{"name":"NCI_META_CUI","value":"CL1406096"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C143031":{"preferredName":"A1CF Gene","code":"C143031","definitions":[{"definition":"This gene is involved in the deamination of APOB mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"A1CF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"A1CF","termGroup":"SY","termSource":"NCI"},{"termName":"APOBEC1 Complementation Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24086"},{"name":"Maps_To","value":"A1CF"},{"name":"NCI_META_CUI","value":"CL541489"},{"name":"OMIM_Number","value":"618199"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24824":{"preferredName":"ABI1 Gene","code":"C24824","definitions":[{"definition":"This gene plays a role in signal transduction and negative regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABI1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ABI1","termGroup":"SY","termSource":"NCI"},{"termName":"ABL Interactor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11320"},{"name":"Legacy Concept Name","value":"SSH3BP1_Gene"},{"name":"Maps_To","value":"ABI1"},{"name":"OMIM_Number","value":"603050"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335864"}]}}{"C17346":{"preferredName":"ABL1 Gene","code":"C17346","definitions":[{"definition":"This gene is involved in cell adhesion, differentiation, division and stress response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ABL","termGroup":"SY","termSource":"NCI"},{"termName":"ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ABL1","termGroup":"SY","termSource":"NCI"},{"termName":"v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:76"},{"name":"Legacy Concept Name","value":"ABL1_Gene"},{"name":"Maps_To","value":"ABL1"},{"name":"OMIM_Number","value":"189980"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412097"}]}}{"C18451":{"preferredName":"ABL2 Gene","code":"C18451","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ABL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:77"},{"name":"Legacy Concept Name","value":"ABL2_Gene"},{"name":"Maps_To","value":"ABL2"},{"name":"OMIM_Number","value":"164690"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812381"}]}}{"C91369":{"preferredName":"ACKR3 Gene","code":"C91369","definitions":[{"definition":"This gene is involved in the regulation of chemokine signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACKR3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACKR3","termGroup":"SY","termSource":"NCI"},{"termName":"Atypical Chemokine Receptor 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CXCR7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23692"},{"name":"Maps_To","value":"ACKR3"},{"name":"OMIM_Number","value":"610376"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1835886"}]}}{"C97365":{"preferredName":"ACSL3 Gene","code":"C97365","definitions":[{"definition":"This gene is involved in lipid biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACSL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACSL3","termGroup":"SY","termSource":"NCI"},{"termName":"Acyl-CoA Synthetase Long-Chain Family Member 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3570"},{"name":"Maps_To","value":"ACSL3"},{"name":"OMIM_Number","value":"602371"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414519"}]}}{"C97519":{"preferredName":"ACSL6 Gene","code":"C97519","definitions":[{"definition":"This gene is involved in the biosynthesis of lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACSL6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACSL6","termGroup":"SY","termSource":"NCI"},{"termName":"Acyl-CoA Synthetase Long-Chain Family Member 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16496"},{"name":"Maps_To","value":"ACSL6"},{"name":"OMIM_Number","value":"604443"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424328"}]}}{"C21267":{"preferredName":"ACVR1 Gene","code":"C21267","definitions":[{"definition":"This gene plays a role in the transforming growth factor-beta signal transduction pathway through serine/threonine specificity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACVR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Activin A Receptor Type 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ACVR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:171"},{"name":"Legacy Concept Name","value":"ACVR1_Gene"},{"name":"Maps_To","value":"ACVR1"},{"name":"OMIM_Number","value":"102576"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332012"}]}}{"C21271":{"preferredName":"ACVR2A Gene","code":"C21271","definitions":[{"definition":"This gene plays a role in the transforming growth factor-beta signal transduction pathway through constitutive kinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACVR2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Activin A Receptor, Type II Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ACVR2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:173"},{"name":"Legacy Concept Name","value":"ACVR2_Gene"},{"name":"Maps_To","value":"ACVR2A"},{"name":"OMIM_Number","value":"102581"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1706636"}]}}{"C24602":{"preferredName":"AFF1 Gene","code":"C24602","definitions":[{"definition":"This gene is involved in the regulation of transcription elongation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF4","termGroup":"SY","termSource":"NCI"},{"termName":"AF4/FMR2 Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFF1","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7135"},{"name":"Legacy Concept Name","value":"MLLT2_Gene"},{"name":"Maps_To","value":"AFF1"},{"name":"OMIM_Number","value":"159557"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826604"}]}}{"C24538":{"preferredName":"AFF3 Gene","code":"C24538","definitions":[{"definition":"This gene is involved in transcriptional activation and is purported to play roles in lymphoid development and oncogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF4/FMR2 Family, Member 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6473"},{"name":"Legacy Concept Name","value":"LAF4_Gene"},{"name":"Maps_To","value":"AFF3"},{"name":"OMIM_Number","value":"601464"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1708616"}]}}{"C21385":{"preferredName":"AFF4 Gene","code":"C21385","definitions":[{"definition":"This gene plays a regulatory role in transcription and is involved in male germ cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF4/FMR2 Family Member 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFF4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17869"},{"name":"Legacy Concept Name","value":"AF5Q31_Gene"},{"name":"Maps_To","value":"AFF4"},{"name":"OMIM_Number","value":"604417"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1706652"}]}}{"C21305":{"preferredName":"AKAP9 Gene","code":"C21305","definitions":[{"definition":"This gene plays a role in signal transduction and modulates synaptic transmission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKAP9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"A-Kinase Anchor Protein 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKAP9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:379"},{"name":"Legacy Concept Name","value":"AKAP9_Gene"},{"name":"Maps_To","value":"AKAP9"},{"name":"OMIM_Number","value":"604001"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332072"}]}}{"C18350":{"preferredName":"AKT1 Gene","code":"C18350","definitions":[{"definition":"This gene is involved in signal transduction and negative regulation of apoptosis. It also plays a role in glucose transport, glycogen synthesis, protein synthesis and neuronal survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Serine/Threonine Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:391"},{"name":"Legacy Concept Name","value":"AKT1_Gene"},{"name":"Maps_To","value":"AKT1"},{"name":"OMIM_Number","value":"164730"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812228"}]}}{"C18352":{"preferredName":"AKT2 Gene","code":"C18352","definitions":[{"definition":"This gene plays a role in glucose homeostasis and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Serine/Threonine Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKT2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:392"},{"name":"Legacy Concept Name","value":"AKT2_Gene"},{"name":"Maps_To","value":"AKT2"},{"name":"OMIM_Number","value":"164731"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812230"}]}}{"C20937":{"preferredName":"AKT3 Gene","code":"C20937","definitions":[{"definition":"This gene is involved in signal transduction and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Serine/Threonine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AKT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:393"},{"name":"Legacy Concept Name","value":"AKT3_Gene"},{"name":"Maps_To","value":"AKT3"},{"name":"OMIM_Number","value":"611223"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332074"}]}}{"C84921":{"preferredName":"ALDH2 Gene","code":"C84921","definitions":[{"definition":"This gene plays a role in intermediary metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALDH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Aldehyde Dehydrogenase 2 Family Member Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ALDH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:404"},{"name":"Maps_To","value":"ALDH2"},{"name":"OMIM_Number","value":"100650"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412335"}]}}{"C38184":{"preferredName":"ALK Gene","code":"C38184","definitions":[{"definition":"This gene is involved in brain development and neuronal specificity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ALK","termGroup":"SY","termSource":"NCI"},{"termName":"ALK Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:427"},{"name":"Legacy Concept Name","value":"ALK_Gene"},{"name":"Maps_To","value":"ALK"},{"name":"OMIM_Number","value":"105590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332080"}]}}{"C68718":{"preferredName":"AMER1 Gene","code":"C68718","definitions":[{"definition":"This gene may play a role in kidney development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AMER1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AMER1","termGroup":"SY","termSource":"NCI"},{"termName":"APC Membrane Recruitment Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAM123B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26837"},{"name":"Legacy Concept Name","value":"FAM123B_Gene"},{"name":"Maps_To","value":"AMER1"},{"name":"OMIM_Number","value":"300647"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825263"}]}}{"C84301":{"preferredName":"ANK1 Gene","code":"C84301","definitions":[{"definition":"This gene plays a role in red blood cell morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ANK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ANK1","termGroup":"SY","termSource":"NCI"},{"termName":"Ankyrin 1, Erythrocytic Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:492"},{"name":"Maps_To","value":"ANK1"},{"name":"OMIM_Number","value":"612641"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412402"}]}}{"C17567":{"preferredName":"APC Gene","code":"C17567","definitions":[{"definition":"This gene plays a role in signal transduction. It is involved in both adhesion and migration of cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"APC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"APC","termGroup":"SY","termSource":"NCI"},{"termName":"APC Regulator of WNT Signaling Pathway Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:583"},{"name":"Legacy Concept Name","value":"APC_Gene"},{"name":"Maps_To","value":"APC"},{"name":"OMIM_Number","value":"611731"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0162832"}]}}{"C117001":{"preferredName":"APOBEC3B Gene","code":"C117001","definitions":[{"definition":"This gene plays a role in viral DNA cytosine deamination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"APOBEC3B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"APOBEC3B","termGroup":"SY","termSource":"NCI"},{"termName":"Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17352"},{"name":"Maps_To","value":"APOBEC3B"},{"name":"OMIM_Number","value":"607110"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424925"}]}}{"C28539":{"preferredName":"AR Gene","code":"C28539","definitions":[{"definition":"This gene plays a role in the transcriptional activation of androgen responsive genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor (Dihydrotestosterone Receptor; Testicular Feminization; Spinal and Bulbar Muscular Atrophy; Kennedy Disease) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:644"},{"name":"Legacy Concept Name","value":"AR_Gene"},{"name":"Maps_To","value":"AR"},{"name":"OMIM_Number","value":"313700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367578"}]}}{"C18354":{"preferredName":"ARAF Gene","code":"C18354","definitions":[{"definition":"This gene plays a role in signal transduction and the cellular response to mitogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARAF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"A-Raf Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ARAF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:646"},{"name":"Legacy Concept Name","value":"ARAF1_Gene"},{"name":"Maps_To","value":"ARAF"},{"name":"OMIM_Number","value":"311010"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538917"}]}}{"C97504":{"preferredName":"ARHGAP26 Gene","code":"C97504","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARHGAP26 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARHGAP26","termGroup":"SY","termSource":"NCI"},{"termName":"Rho GTPase Activating Protein 26 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17073"},{"name":"Maps_To","value":"ARHGAP26"},{"name":"OMIM_Number","value":"605370"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538925"}]}}{"C97279":{"preferredName":"ARHGAP5 Gene","code":"C97279","definitions":[{"definition":"This gene is involved in the regulation of GTPase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARHGAP5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARHGAP5","termGroup":"SY","termSource":"NCI"},{"termName":"Rho GTPase Activating Protein 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:675"},{"name":"Maps_To","value":"ARHGAP5"},{"name":"OMIM_Number","value":"602680"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412522"}]}}{"C97436":{"preferredName":"ARHGEF12 Gene","code":"C97436","definitions":[{"definition":"This gene plays a role in both G-protein coupled receptor- and Rho-mediated signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARHGEF12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARHGEF12","termGroup":"SY","termSource":"NCI"},{"termName":"Rho Guanine Nucleotide Exchange Factor (GEF) 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14193"},{"name":"Maps_To","value":"ARHGEF12"},{"name":"OMIM_Number","value":"604763"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422475"}]}}{"C92530":{"preferredName":"ARID1A Gene","code":"C92530","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARID1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARID1A","termGroup":"SY","termSource":"NCI"},{"termName":"AT Rich Interactive Domain 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11110"},{"name":"Maps_To","value":"ARID1A"},{"name":"OMIM_Number","value":"603024"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420251"}]}}{"C102520":{"preferredName":"ARID1B Gene","code":"C102520","definitions":[{"definition":"This gene plays a role in both chromatin remodeling and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARID1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARID1B","termGroup":"SY","termSource":"NCI"},{"termName":"AT-Rich Interactive Domain 1B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18040"},{"name":"Maps_To","value":"ARID1B"},{"name":"OMIM_Number","value":"614556"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425260"}]}}{"C101088":{"preferredName":"ARID2 Gene","code":"C101088","definitions":[{"definition":"This gene is involved in both transcriptional regulation and chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARID2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARID2","termGroup":"SY","termSource":"NCI"},{"termName":"AT-Rich Interactive Domain 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18037"},{"name":"Maps_To","value":"ARID2"},{"name":"OMIM_Number","value":"609539"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425257"}]}}{"C26373":{"preferredName":"ARNT Gene","code":"C26373","definitions":[{"definition":"This gene is involved in xenobiotic metabolism and receptor-ligand mediated interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARNT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ARNT","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Nuclear Translocator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:700"},{"name":"Legacy Concept Name","value":"ARNT_Gene"},{"name":"Maps_To","value":"ARNT"},{"name":"OMIM_Number","value":"126110"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332116"}]}}{"C70991":{"preferredName":"ASPSCR1 Gene","code":"C70991","definitions":[{"definition":"This gene is involved in the modulation of blood glucose levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASPSCR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ASPSCR1","termGroup":"SY","termSource":"NCI"},{"termName":"ASPSCR1 Tether for SLC2A4, UBX Domain Containing Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13825"},{"name":"Legacy Concept Name","value":"ASPSCR1_Gene"},{"name":"Maps_To","value":"ASPSCR1"},{"name":"OMIM_Number","value":"606236"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422219"}]}}{"C97320":{"preferredName":"ASXL1 Gene","code":"C97320","definitions":[{"definition":"This gene may be involved in both transcriptional regulation and chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASXL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ASXL Transcriptional Regulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ASXL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18318"},{"name":"Maps_To","value":"ASXL1"},{"name":"OMIM_Number","value":"612990"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425445"}]}}{"C116296":{"preferredName":"ASXL2 Gene","code":"C116296","definitions":[{"definition":"This gene plays a role in both chromatin modification and the positive regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASXL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Additional Sex Combs Like 2 (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ASXL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23805"},{"name":"Maps_To","value":"ASXL2"},{"name":"OMIM_Number","value":"612991"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428272"}]}}{"C92177":{"preferredName":"ATF1 Gene","code":"C92177","definitions":[{"definition":"This gene is involved in the modulation of transcription of genes with promoters containing a cAMP response element.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Activating Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ATF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:783"},{"name":"Maps_To","value":"ATF1"},{"name":"OMIM_Number","value":"123803"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412615"}]}}{"C97400":{"preferredName":"ATIC Gene","code":"C97400","definitions":[{"definition":"This gene plays a role in purine biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATIC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP Cyclohydrolase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ATIC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:794"},{"name":"Maps_To","value":"ATIC"},{"name":"OMIM_Number","value":"601731"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412625"}]}}{"C18583":{"preferredName":"ATM Gene","code":"C18583","definitions":[{"definition":"This gene is involved in apoptosis, DNA repair and cell cycle regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATM","termGroup":"SY","termSource":"NCI"},{"termName":"ATM Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:795"},{"name":"Legacy Concept Name","value":"ATM_Gene"},{"name":"Maps_To","value":"ATM"},{"name":"OMIM_Number","value":"607585"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919524"}]}}{"C113762":{"preferredName":"ATP1A1 Gene","code":"C113762","definitions":[{"definition":"This gene is involved in both ion transport and ATP metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATP1A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATP1A1","termGroup":"SY","termSource":"NCI"},{"termName":"ATPase Na+/K+ Transporting Subunit Alpha 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:799"},{"name":"Maps_To","value":"ATP1A1"},{"name":"OMIM_Number","value":"182310"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412628"}]}}{"C113765":{"preferredName":"ATP2B3 Gene","code":"C113765","definitions":[{"definition":"This gene plays a role in ATP-dependent calcium transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATP2B3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATP2B3","termGroup":"SY","termSource":"NCI"},{"termName":"ATPase Plasma Membrane Ca2+ Transporting 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:816"},{"name":"Maps_To","value":"ATP2B3"},{"name":"OMIM_Number","value":"300014"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412642"}]}}{"C20560":{"preferredName":"ATR Gene","code":"C20560","definitions":[{"definition":"This gene is involved in cell cycle checkpoints and DNA recombination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATR","termGroup":"SY","termSource":"NCI"},{"termName":"ATR Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:882"},{"name":"Legacy Concept Name","value":"ATR_Gene"},{"name":"Maps_To","value":"ATR"},{"name":"OMIM_Number","value":"601215"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332120"}]}}{"C74976":{"preferredName":"ATRX Gene","code":"C74976","definitions":[{"definition":"This gene plays a role in the regulation of both chromatin remodeling and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATRX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ATRX","termGroup":"SY","termSource":"NCI"},{"termName":"ATRX, Chromatin Remodeler Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:886"},{"name":"Legacy Concept Name","value":"ATRX_Gene"},{"name":"Maps_To","value":"ATRX"},{"name":"OMIM_Number","value":"300032"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412697"}]}}{"C19969":{"preferredName":"AXIN1 Gene","code":"C19969","definitions":[{"definition":"This gene plays a role in signal transduction and is involved in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXIN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Axin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AXIN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:903"},{"name":"Legacy Concept Name","value":"AXIN1_Gene"},{"name":"Maps_To","value":"AXIN1"},{"name":"OMIM_Number","value":"603816"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332125"}]}}{"C20763":{"preferredName":"AXIN2 Gene","code":"C20763","definitions":[{"definition":"This gene is involved in signal transduction and plays a role in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXIN2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Axin 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AXIN2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:904"},{"name":"Legacy Concept Name","value":"AXIN2_Gene"},{"name":"Maps_To","value":"AXIN2"},{"name":"OMIM_Number","value":"604025"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332126"}]}}{"C62660":{"preferredName":"B2M Gene","code":"C62660","definitions":[{"definition":"This gene plays a role in immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B2M Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B2M","termGroup":"SY","termSource":"NCI"},{"termName":"Beta-2-Microglobulin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:914"},{"name":"Legacy Concept Name","value":"B2M_Gene"},{"name":"Maps_To","value":"B2M"},{"name":"OMIM_Number","value":"109700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412709"}]}}{"C20766":{"preferredName":"BAP1 Gene","code":"C20766","definitions":[{"definition":"This gene is involved in cellular growth regulation and is purported to have tumor suppression activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BAP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAP1","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA1 Associated Protein-1 (Ubiquitin Carboxy-Terminal Hydrolase) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:950"},{"name":"Legacy Concept Name","value":"BAP1_Gene"},{"name":"Maps_To","value":"BAP1"},{"name":"OMIM_Number","value":"603089"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332380"}]}}{"C20715":{"preferredName":"BARD1 Gene","code":"C20715","definitions":[{"definition":"This gene plays a role in cellular response and is susceptible to oncogenic mutations in breast and ovarian cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BARD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BARD1","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA1 Associated RING Domain 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:952"},{"name":"Legacy Concept Name","value":"BARD1_Gene"},{"name":"Maps_To","value":"BARD1"},{"name":"OMIM_Number","value":"601593"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332381"}]}}{"C24259":{"preferredName":"BCL10 Gene","code":"C24259","definitions":[{"definition":"This gene is involved in the promotion of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 10 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:989"},{"name":"Legacy Concept Name","value":"BCL10_Gene"},{"name":"Maps_To","value":"BCL10"},{"name":"OMIM_Number","value":"603517"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367449"}]}}{"C97394":{"preferredName":"BCL11A Gene","code":"C97394","definitions":[{"definition":"This gene is involved in both the modulation of cell shape and lymphopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL11A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAF Chromatin Remodeling Complex Subunit BCL11A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL11A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13221"},{"name":"Maps_To","value":"BCL11A"},{"name":"OMIM_Number","value":"606557"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421886"}]}}{"C91855":{"preferredName":"BCL11B Gene","code":"C91855","definitions":[{"definition":"This gene may play a role in tumor suppression, signaling and T cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL11B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAF Chromatin Remodeling Complex Subunit BCL11B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL11B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13222"},{"name":"Maps_To","value":"BCL11B"},{"name":"OMIM_Number","value":"606558"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421887"}]}}{"C17963":{"preferredName":"BCL2 Gene","code":"C17963","definitions":[{"definition":"A protein that helps control whether a cell lives or dies by blocking a type of cell death called apoptosis. The gene for BCL2 is found on chromosome 18, and transfer of the BCL2 gene to a different chromosome is seen in many B-cell leukemias and lymphomas. This causes the BCL2 protein to be made in larger amounts, which may keep cancer cells from dying.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in apoptotic regulation. Overexpression of this gene promotes the pathogenesis of B-Cell lymphomas, due to anti-apoptotic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL2","termGroup":"SY","termSource":"NCI"},{"termName":"BCL2, Apoptosis Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:990"},{"name":"Legacy Concept Name","value":"BCL2_Gene"},{"name":"Maps_To","value":"BCL2"},{"name":"OMIM_Number","value":"151430"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0376515"}]}}{"C114743":{"preferredName":"BCL2L12 Gene","code":"C114743","definitions":[{"definition":"This gene is involved in the regulation of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL2L12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL2-Like 12 (Proline Rich) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL2L12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13787"},{"name":"Maps_To","value":"BCL2L12"},{"name":"OMIM_Number","value":"610837"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422195"}]}}{"C18360":{"preferredName":"BCL3 Gene","code":"C18360","definitions":[{"definition":"This gene is involved in transcriptional co-activation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL3","termGroup":"SY","termSource":"NCI"},{"termName":"BCL3 Transcription Coactivator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:998"},{"name":"Legacy Concept Name","value":"BCL3_Gene"},{"name":"Maps_To","value":"BCL3"},{"name":"OMIM_Number","value":"109560"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812238"}]}}{"C24260":{"preferredName":"BCL6 Gene","code":"C24260","definitions":[{"definition":"This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1001"},{"name":"Legacy Concept Name","value":"BCL6_Gene"},{"name":"Maps_To","value":"BCL6"},{"name":"OMIM_Number","value":"109565"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332399"}]}}{"C24261":{"preferredName":"BCL7A Gene","code":"C24261","definitions":[{"definition":"This gene may play a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL7A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BAF Chromatin Remodeling Complex Subunit BCL7A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL7A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1004"},{"name":"Legacy Concept Name","value":"BCL7A_Gene"},{"name":"Maps_To","value":"BCL7A"},{"name":"OMIM_Number","value":"601406"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332400"}]}}{"C24262":{"preferredName":"BCL9 Gene","code":"C24262","definitions":[{"definition":"This gene plays a role in signal transduction and is involved in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL9","termGroup":"SY","termSource":"NCI"},{"termName":"BCL9 Transcription Coactivator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1008"},{"name":"Legacy Concept Name","value":"BCL9_Gene"},{"name":"Maps_To","value":"BCL9"},{"name":"OMIM_Number","value":"602597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332402"}]}}{"C132328":{"preferredName":"BCL9L Gene","code":"C132328","definitions":[{"definition":"This gene plays a role in the coactivation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL9L Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell CLL/Lymphoma 9-Like Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCL9L","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23688"},{"name":"Maps_To","value":"BCL9L"},{"name":"OMIM_Number","value":"609004"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428193"}]}}{"C115994":{"preferredName":"BCLAF1 Gene","code":"C115994","definitions":[{"definition":"Human BCLAF1 wild-type allele is located within 6q22-q23 and is approximately 33 kb in length. This allele, which encodes Bcl-2-associated transcription factor 1 protein, plays a role in both apoptosis promotion and the repression of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCLAF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL2-Associated Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCLAF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16863"},{"name":"Maps_To","value":"BCLAF1"},{"name":"OMIM_Number","value":"612588"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424602"}]}}{"C101091":{"preferredName":"BCOR Gene","code":"C101091","definitions":[{"definition":"This gene plays a role in the repression of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCOR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL6 Corepressor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCOR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20893"},{"name":"Maps_To","value":"BCOR"},{"name":"OMIM_Number","value":"300485"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427193"}]}}{"C131268":{"preferredName":"BCORL1 Gene","code":"C131268","definitions":[{"definition":"This gene plays a role in the inhibition of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCORL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCL6 Corepressor-Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BCORL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25657"},{"name":"Maps_To","value":"BCORL1"},{"name":"OMIM_Number","value":"300688"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538320"}]}}{"C18455":{"preferredName":"BCR Gene","code":"C18455","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BCR","termGroup":"SY","termSource":"NCI"},{"termName":"BCR, RhoGEF and GTPase Activating Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1014"},{"name":"Legacy Concept Name","value":"BCR_Gene"},{"name":"Maps_To","value":"BCR"},{"name":"OMIM_Number","value":"151410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812385"}]}}{"C20356":{"preferredName":"BIRC3 Gene","code":"C20356","definitions":[{"definition":"This anti-apoptotic gene regulates apoptotic activity. BIRC3 gene promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BIRC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Baculoviral IAP Repeat Containing 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BIRC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:591"},{"name":"Legacy Concept Name","value":"BIRC3_Gene"},{"name":"Maps_To","value":"BIRC3"},{"name":"OMIM_Number","value":"601721"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332415"}]}}{"C20352":{"preferredName":"BIRC6 Gene","code":"C20352","definitions":[{"definition":"This gene regulates the apoptotic program via signal transduction in the ubiquitination pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BIRC6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Baculoviral IAP Repeat-Containing 6 (Apollon) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BIRC6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13516"},{"name":"Legacy Concept Name","value":"BIRC6_Gene"},{"name":"Maps_To","value":"BIRC6"},{"name":"OMIM_Number","value":"605638"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332417"}]}}{"C20805":{"preferredName":"BLM Gene","code":"C20805","definitions":[{"definition":"This gene plays a role in DNA unwinding and recombination-mediated telomere lengthening.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BLM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BLM","termGroup":"SY","termSource":"NCI"},{"termName":"Bloom Syndrome Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1058"},{"name":"Legacy Concept Name","value":"BLM_Gene"},{"name":"Maps_To","value":"BLM"},{"name":"OMIM_Number","value":"604610"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337098"}]}}{"C21353":{"preferredName":"BMP5 Gene","code":"C21353","definitions":[{"definition":"This gene plays a role in the regulation of mesenchymal differentiation. It is involved in cartilage and bone formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMP5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BMP5","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Morphogenetic Protein 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1072"},{"name":"Legacy Concept Name","value":"BMP5_Gene"},{"name":"Maps_To","value":"BMP5"},{"name":"OMIM_Number","value":"112265"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332426"}]}}{"C21366":{"preferredName":"BMPR1A Gene","code":"C21366","definitions":[{"definition":"This gene plays a role in the bone morphogenetic protein signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMPR1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BMPR1A","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Morphogenetic Protein Receptor Type 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1076"},{"name":"Legacy Concept Name","value":"BMPR1A_Gene"},{"name":"Maps_To","value":"BMPR1A"},{"name":"OMIM_Number","value":"601299"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332430"}]}}{"C18363":{"preferredName":"BRAF Gene","code":"C18363","definitions":[{"definition":"A gene that makes a protein called B-RAF, which is involved in sending signals in cells and in cell growth. This gene may be mutated (changed) in many types of cancer, which causes a change in the B-RAF protein. This can increase the growth and spread of cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in cell organization/biogenesis and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"B-Raf Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BRAF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1097"},{"name":"Legacy Concept Name","value":"BRAF_Gene"},{"name":"Maps_To","value":"BRAF"},{"name":"OMIM_Number","value":"164757"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812241"}]}}{"C17965":{"preferredName":"BRCA1 Gene","code":"C17965","definitions":[{"definition":"This gene plays a role in cell cycle control, regulation of transcription and the maintenance of genomic stability. It is also involved in the inhibition of mammary cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRCA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRCA1","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA1, DNA Repair Associated Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer 1, Early Onset Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1100"},{"name":"Legacy Concept Name","value":"BRCA1_Gene"},{"name":"Maps_To","value":"BRCA1"},{"name":"OMIM_Number","value":"113705"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0376571"}]}}{"C18120":{"preferredName":"BRCA2 Gene","code":"C18120","definitions":[{"definition":"A gene on chromosome 13 that normally helps to suppress cell growth. A person who inherits an altered version of the BRCA2 gene has a higher risk of getting breast, ovarian, or prostate cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in cell cycle control, DNA repair and the maintenance of genomic stability. It also plays a role in the proliferation of embryonic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRCA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRCA2","termGroup":"SY","termSource":"NCI"},{"termName":"BRCA2, DNA Repair Associated Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Breast Cancer 2, Early Onset Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1101"},{"name":"Legacy Concept Name","value":"BRCA2_Gene"},{"name":"Maps_To","value":"BRCA2"},{"name":"OMIM_Number","value":"600185"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0598034"}]}}{"C97397":{"preferredName":"BRD3 Gene","code":"C97397","definitions":[{"definition":"This gene may play a role in both histone acetylation and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRD3","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain Containing 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1104"},{"name":"Maps_To","value":"BRD3"},{"name":"OMIM_Number","value":"601541"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412821"}]}}{"C92702":{"preferredName":"BRD4 Gene","code":"C92702","definitions":[{"definition":"This gene plays a role in mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRD4","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain Containing 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13575"},{"name":"Maps_To","value":"BRD4"},{"name":"OMIM_Number","value":"608749"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422073"}]}}{"C63526":{"preferredName":"BRIP1 Gene","code":"C63526","definitions":[{"definition":"This gene is involved in DNA double-strand break repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRCA1 Interacting Protein C-Terminal Helicase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BRIP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20473"},{"name":"Legacy Concept Name","value":"BRIP1_Gene"},{"name":"Maps_To","value":"BRIP1"},{"name":"OMIM_Number","value":"605882"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426958"}]}}{"C80101":{"preferredName":"BTG1 Gene","code":"C80101","definitions":[{"definition":"This gene is involved in the regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BTG Anti-Proliferation Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BTG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1130"},{"name":"Legacy Concept Name","value":"BTG1_Gene"},{"name":"Maps_To","value":"BTG1"},{"name":"OMIM_Number","value":"109580"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1439347"}]}}{"C75013":{"preferredName":"BTK Gene","code":"C75013","definitions":[{"definition":"This gene is involved in both signaling and B-cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BTK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1133"},{"name":"Legacy Concept Name","value":"BTK_Gene"},{"name":"Maps_To","value":"BTK"},{"name":"OMIM_Number","value":"300300"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412841"}]}}{"C95592":{"preferredName":"BUB1B Gene","code":"C95592","definitions":[{"definition":"This gene is involved in mitotic progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BUB1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BUB1 Mitotic Checkpoint Serine/Threonine Kinase B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BUB1B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1149"},{"name":"Maps_To","value":"BUB1B"},{"name":"OMIM_Number","value":"602860"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412854"}]}}{"C98096":{"preferredName":"PIERCE2 Gene","code":"C98096","definitions":[{"definition":"This gene may play a role in microtubule structure and ciliary motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIERCE2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C15orf65","termGroup":"SY","termSource":"NCI"},{"termName":"FLJ27352","termGroup":"SY","termSource":"NCI"},{"termName":"PIERCE2","termGroup":"SY","termSource":"NCI"},{"termName":"Piercer of Microtubule Wall 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:44654"},{"name":"Maps_To","value":"C15orf65"},{"name":"OMIM_Number","value":"619669"},{"name":"PubMedID_Primary_Reference","value":"34715025"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C3273816"}]}}{"C113769":{"preferredName":"CACNA1D Gene","code":"C113769","definitions":[{"definition":"This gene is involved in voltage-dependent calcium transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CACNA1D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CACNA1D","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Voltage-Gated Channel Subunit Alpha1 D Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1391"},{"name":"Maps_To","value":"CACNA1D"},{"name":"OMIM_Number","value":"114206"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413058"}]}}{"C95313":{"preferredName":"CALR Gene","code":"C95313","definitions":[{"definition":"This gene plays a role in calcium binding and protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CALR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CALR","termGroup":"SY","termSource":"NCI"},{"termName":"Calreticulin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1455"},{"name":"Maps_To","value":"CALR"},{"name":"OMIM_Number","value":"109091"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413096"}]}}{"C101440":{"preferredName":"CAMTA1 Gene","code":"C101440","definitions":[{"definition":"This gene is involved in both DNA binding and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAMTA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Calmodulin Binding Transcription Activator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CAMTA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18806"},{"name":"Maps_To","value":"CAMTA1"},{"name":"OMIM_Number","value":"611501"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425790"}]}}{"C97375":{"preferredName":"CANT1 Gene","code":"C97375","definitions":[{"definition":"This gene plays a role in both nucleotide hydrolysis and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CANT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Calcium Activated Nucleotidase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CANT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19721"},{"name":"Maps_To","value":"CANT1"},{"name":"OMIM_Number","value":"613165"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538435"}]}}{"C60668":{"preferredName":"CARD11 Gene","code":"C60668","definitions":[{"definition":"This gene plays a role in apoptotic regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CARD11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CARD11","termGroup":"SY","termSource":"NCI"},{"termName":"Caspase Recruitment Domain Family Member 11 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16393"},{"name":"Legacy Concept Name","value":"CARD11_Gene"},{"name":"Maps_To","value":"CARD11"},{"name":"OMIM_Number","value":"607210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424244"}]}}{"C97369":{"preferredName":"CARS1 Gene","code":"C97369","definitions":[{"definition":"This gene is involved in transfer RNA metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CARS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CARS","termGroup":"SY","termSource":"NCI"},{"termName":"CARS1","termGroup":"SY","termSource":"NCI"},{"termName":"Cysteinyl-tRNA Synthetase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1493"},{"name":"Maps_To","value":"CARS"},{"name":"OMIM_Number","value":"123859"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413126"}]}}{"C26623":{"preferredName":"CASP8 Gene","code":"C26623","definitions":[{"definition":"This gene is involved in apoptosis, immune cell homeostasis, lymphocyte activation and immunoprotection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CASP8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CASP8","termGroup":"SY","termSource":"NCI"},{"termName":"Caspase 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1509"},{"name":"Legacy Concept Name","value":"CASP8_Gene"},{"name":"Maps_To","value":"CASP8"},{"name":"OMIM_Number","value":"601763"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332667"}]}}{"C97445":{"preferredName":"CBFA2T3 Gene","code":"C97445","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBFA2T3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CBFA2T3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1537"},{"name":"Maps_To","value":"CBFA2T3"},{"name":"OMIM_Number","value":"603870"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413149"}]}}{"C18584":{"preferredName":"CBFB Gene","code":"C18584","definitions":[{"definition":"This gene is involved in hematopoiesis and osteogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBFB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBFB","termGroup":"SY","termSource":"NCI"},{"termName":"Core-Binding Factor Subunit Beta Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1539"},{"name":"Legacy Concept Name","value":"CBFB_Gene"},{"name":"Maps_To","value":"CBFB"},{"name":"OMIM_Number","value":"121360"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332671"}]}}{"C18364":{"preferredName":"CBL Gene","code":"C18364","definitions":[{"definition":"This gene plays a role in signal transduction and the regulation of protein degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBL","termGroup":"SY","termSource":"NCI"},{"termName":"Cbl Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1541"},{"name":"Legacy Concept Name","value":"CBL_Gene"},{"name":"Maps_To","value":"CBL"},{"name":"OMIM_Number","value":"165360"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812242"}]}}{"C21589":{"preferredName":"CBLB Gene","code":"C21589","definitions":[{"definition":"This gene plays a role in the regulation of T cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBLB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cbl Proto-Oncogene B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CBLB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1542"},{"name":"Legacy Concept Name","value":"CBLB_Gene"},{"name":"Maps_To","value":"CBLB"},{"name":"OMIM_Number","value":"604491"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332672"}]}}{"C97439":{"preferredName":"CBLC Gene","code":"C97439","definitions":[{"definition":"This gene is involved in both ubiquitination and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBLC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cbl Proto-Oncogene C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CBLC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15961"},{"name":"Maps_To","value":"CBLC"},{"name":"OMIM_Number","value":"608453"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423865"}]}}{"C18376":{"preferredName":"CCDC6 Gene","code":"C18376","definitions":[{"definition":"This gene may play a role in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCDC6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCDC6","termGroup":"SY","termSource":"NCI"},{"termName":"Coiled-Coil Domain Containing 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18782"},{"name":"Legacy Concept Name","value":"D10S170"},{"name":"Maps_To","value":"CCDC6"},{"name":"OMIM_Number","value":"601985"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425774"}]}}{"C97372":{"preferredName":"CCNB1IP1 Gene","code":"C97372","definitions":[{"definition":"This gene plays a role in both ubiquitination and cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCNB1IP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCNB1IP1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin B1 Interacting Protein 1, E3 Ubiquitin Protein Ligase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19437"},{"name":"Maps_To","value":"CCNB1IP1"},{"name":"OMIM_Number","value":"608249"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426243"}]}}{"C105393":{"preferredName":"CCNC Gene","code":"C105393","definitions":[{"definition":"This gene plays a role in the modulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCNC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCNC","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1581"},{"name":"Maps_To","value":"CCNC"},{"name":"OMIM_Number","value":"123838"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413171"}]}}{"C18021":{"preferredName":"CCND1 Gene","code":"C18021","definitions":[{"definition":"This gene plays a role in the regulation of mitotic events.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCND1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCND1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1582"},{"name":"Legacy Concept Name","value":"CCND1_Gene"},{"name":"Maps_To","value":"CCND1"},{"name":"OMIM_Number","value":"168461"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413172"}]}}{"C39596":{"preferredName":"CCND2 Gene","code":"C39596","definitions":[{"definition":"This gene is involved in the regulation of the G1/S phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCND2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCND2","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Gene_Encodes_Product","value":"Cyclin-D2"},{"name":"HGNC_ID","value":"HGNC:1583"},{"name":"Legacy Concept Name","value":"CCND2_Gene"},{"name":"Maps_To","value":"CCND2"},{"name":"OMIM_Number","value":"123833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413173"}]}}{"C97381":{"preferredName":"CCND3 Gene","code":"C97381","definitions":[{"definition":"This gene is involved in cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCND3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCND3","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin D3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1585"},{"name":"Maps_To","value":"CCND3"},{"name":"OMIM_Number","value":"123834"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413175"}]}}{"C21412":{"preferredName":"CCNE1 Gene","code":"C21412","definitions":[{"definition":"This gene regulates the G1/S phase of the cell cycle by cyclin expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCNE1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCNE1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin E1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1589"},{"name":"Legacy Concept Name","value":"CCNE1_Gene"},{"name":"Maps_To","value":"CCNE1"},{"name":"OMIM_Number","value":"123837"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332697"}]}}{"C129065":{"preferredName":"CCR4 Gene","code":"C129065","definitions":[{"definition":"This gene is involved in chemokine-dependent G protein-coupled receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C-C Motif Chemokine Receptor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CCR4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1605"},{"name":"Maps_To","value":"CCR4"},{"name":"OMIM_Number","value":"604836"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413190"}]}}{"C104128":{"preferredName":"CCR7 Gene","code":"C104128","definitions":[{"definition":"This gene plays a role in immune function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCR7","termGroup":"SY","termSource":"NCI"},{"termName":"Chemokine (C-C motif) Receptor 7 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1608"},{"name":"Maps_To","value":"CCR7"},{"name":"OMIM_Number","value":"600242"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413191"}]}}{"C21568":{"preferredName":"CD209 Gene","code":"C21568","definitions":[{"definition":"This gene plays a role in the regulation of host defense responses and mediates pathogen-binding properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD209 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD209","termGroup":"SY","termSource":"NCI"},{"termName":"CD209 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1641"},{"name":"Legacy Concept Name","value":"CD209_Gene"},{"name":"Maps_To","value":"CD209"},{"name":"OMIM_Number","value":"604672"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332707"}]}}{"C96022":{"preferredName":"CD274 Gene","code":"C96022","definitions":[{"definition":"This gene is involved in T cell activation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD274 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD274","termGroup":"SY","termSource":"NCI"},{"termName":"CD274 Molecule Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PD-L1","termGroup":"SY","termSource":"NCI"},{"termName":"PDL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17635"},{"name":"Maps_To","value":"CD274"},{"name":"OMIM_Number","value":"605402"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1540292"}]}}{"C21291":{"preferredName":"CD28 Gene","code":"C21291","definitions":[{"definition":"This gene plays several roles in cellular functions specific to the T-cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD28 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD28","termGroup":"SY","termSource":"NCI"},{"termName":"CD28 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1653"},{"name":"Legacy Concept Name","value":"CD28_Gene"},{"name":"Maps_To","value":"CD28"},{"name":"OMIM_Number","value":"186760"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332709"}]}}{"C97418":{"preferredName":"CD74 Gene","code":"C97418","definitions":[{"definition":"This gene plays a role in antigen processing and presentation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD74 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD74","termGroup":"SY","termSource":"NCI"},{"termName":"CD74 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1697"},{"name":"Maps_To","value":"CD74"},{"name":"OMIM_Number","value":"142790"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413237"}]}}{"C97421":{"preferredName":"CD79A Gene","code":"C97421","definitions":[{"definition":"This gene is involved in B-cell signaling and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD79A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD79A","termGroup":"SY","termSource":"NCI"},{"termName":"CD79a Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1698"},{"name":"Maps_To","value":"CD79A"},{"name":"OMIM_Number","value":"112205"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413238"}]}}{"C97424":{"preferredName":"CD79B Gene","code":"C97424","definitions":[{"definition":"This gene plays a role in signaling in B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD79B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD79B","termGroup":"SY","termSource":"NCI"},{"termName":"CD79b Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1699"},{"name":"Maps_To","value":"CD79B"},{"name":"OMIM_Number","value":"147245"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413239"}]}}{"C102939":{"preferredName":"CD99 Gene","code":"C102939","definitions":[{"definition":"This gene plays a role in the cell adhesion process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD99 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD99","termGroup":"SY","termSource":"NCI"},{"termName":"CD99 Molecule Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7082"},{"name":"Maps_To","value":"CD99"},{"name":"OMIM_Number","value":"313470"},{"name":"OMIM_Number","value":"450000"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417157"}]}}{"C43569":{"preferredName":"CDC73 Gene","code":"C43569","definitions":[{"definition":"This gene is involved in transcription and may play a role in cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC73 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDC73","termGroup":"SY","termSource":"NCI"},{"termName":"Cell Division Cycle 73 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16783"},{"name":"Legacy Concept Name","value":"HRPT2_Gene"},{"name":"Maps_To","value":"CDC73"},{"name":"OMIM_Number","value":"607393"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1708291"}]}}{"C18249":{"preferredName":"CDH1 Gene","code":"C18249","definitions":[{"definition":"This gene plays a role in cell-cell adhesion and loss of function contributes to the progression of many carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1748"},{"name":"Legacy Concept Name","value":"CDH1_Gene"},{"name":"Maps_To","value":"CDH1"},{"name":"OMIM_Number","value":"192090"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694872"}]}}{"C143093":{"preferredName":"CDH10 Gene","code":"C143093","definitions":[{"definition":"This gene plays a role in the modulation of neuronal cell shape and cell-cell adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 10 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1749"},{"name":"Maps_To","value":"CDH10"},{"name":"NCI_META_CUI","value":"CL541550"},{"name":"OMIM_Number","value":"604555"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97427":{"preferredName":"CDH11 Gene","code":"C97427","definitions":[{"definition":"This gene is involved in the adherens junction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1750"},{"name":"Maps_To","value":"CDH11"},{"name":"OMIM_Number","value":"600023"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413269"}]}}{"C143096":{"preferredName":"CDH17 Gene","code":"C143096","definitions":[{"definition":"This gene is involved in cell-cell adhesion and intestinal proton-dependent peptide transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDH17 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cadherin 17 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDH17","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1756"},{"name":"Maps_To","value":"CDH17"},{"name":"NCI_META_CUI","value":"CL541553"},{"name":"OMIM_Number","value":"603017"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C101095":{"preferredName":"CDK12 Gene","code":"C101095","definitions":[{"definition":"This gene is involved in protein phosphorylation, RNA splicing and transcription elongation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDK12","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24224"},{"name":"Maps_To","value":"CDK12"},{"name":"OMIM_Number","value":"615514"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824794"}]}}{"C18250":{"preferredName":"CDK4 Gene","code":"C18250","definitions":[{"definition":"This gene is involved in G1 stage cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDK4","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1773"},{"name":"Legacy Concept Name","value":"CDK4_Gene"},{"name":"Maps_To","value":"CDK4"},{"name":"OMIM_Number","value":"123829"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694873"}]}}{"C97384":{"preferredName":"CDK6 Gene","code":"C97384","definitions":[{"definition":"This gene plays a role in the progression of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDK6","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1777"},{"name":"Maps_To","value":"CDK6"},{"name":"OMIM_Number","value":"603368"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413287"}]}}{"C17782":{"preferredName":"CDKN1A Gene","code":"C17782","definitions":[{"definition":"This gene is a regulator of cell cycle progression at the G1 phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN1A","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1784"},{"name":"Legacy Concept Name","value":"CDKN1A_Gene"},{"name":"Maps_To","value":"CDKN1A"},{"name":"OMIM_Number","value":"116899"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0249197"}]}}{"C20060":{"preferredName":"CDKN1B Gene","code":"C20060","definitions":[{"definition":"This gene is involved in cell cycle regulation and cyclin regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN1B","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor 1B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1785"},{"name":"Legacy Concept Name","value":"CDKN1B_Gene"},{"name":"Maps_To","value":"CDKN1B"},{"name":"OMIM_Number","value":"600778"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332737"}]}}{"C18022":{"preferredName":"CDKN2A Gene","code":"C18022","definitions":[{"definition":"This gene functions as a tumor suppressor and transcriptional regulator.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN2A","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor 2A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1787"},{"name":"Legacy Concept Name","value":"CDKN2A_Gene"},{"name":"Maps_To","value":"CDKN2A"},{"name":"OMIM_Number","value":"600160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0525037"}]}}{"C24288":{"preferredName":"CDKN2C Gene","code":"C24288","definitions":[{"definition":"This gene is involved in cell cycle inhibition and regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDKN2C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CDKN2C","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor 2C (p18, Inhibits CDK4) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1789"},{"name":"Legacy Concept Name","value":"CDKN2C_Gene"},{"name":"Maps_To","value":"CDKN2C"},{"name":"OMIM_Number","value":"603369"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332738"}]}}{"C24292":{"preferredName":"CDX2 Gene","code":"C24292","definitions":[{"definition":"This gene plays a role in transcriptional initiation, embryonic axial elongation and patterning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Caudal Type Homeobox 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CDX2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1806"},{"name":"Legacy Concept Name","value":"CDX2_Gene"},{"name":"Maps_To","value":"CDX2"},{"name":"OMIM_Number","value":"600297"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332743"}]}}{"C39598":{"preferredName":"CEBPA Gene","code":"C39598","definitions":[{"definition":"This gene plays a role in body weight homeostasis and cellular proliferation. Mutations in the gene are associated with acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEBPA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCAAT Enhancer Binding Protein Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEBPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1833"},{"name":"Legacy Concept Name","value":"CEBPA_Gene"},{"name":"Maps_To","value":"CEBPA"},{"name":"OMIM_Number","value":"116897"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413322"}]}}{"C122887":{"preferredName":"CEP89 Gene","code":"C122887","definitions":[{"definition":"This gene is involved in cilia formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP89 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 89kDa Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP89","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25907"},{"name":"Maps_To","value":"CEP89"},{"name":"OMIM_Number","value":"615470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824650"}]}}{"C97403":{"preferredName":"CHCHD7 Gene","code":"C97403","definitions":[{"definition":"This gene may be involved in stature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHCHD7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHCHD7","termGroup":"SY","termSource":"NCI"},{"termName":"Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 7 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28314"},{"name":"Maps_To","value":"CHCHD7"},{"name":"OMIM_Number","value":"611238"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428688"}]}}{"C75307":{"preferredName":"CHD2 Gene","code":"C75307","definitions":[{"definition":"This gene may be involved in the regulation of both gene expression and chromatin modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHD2","termGroup":"SY","termSource":"NCI"},{"termName":"Chromodomain Helicase DNA Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1917"},{"name":"Legacy Concept Name","value":"CHD2_Gene"},{"name":"Maps_To","value":"CHD2"},{"name":"OMIM_Number","value":"602119"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413381"}]}}{"C128251":{"preferredName":"CHD4 Gene","code":"C128251","definitions":[{"definition":"This gene is involved in ATP-dependent chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHD4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHD4","termGroup":"SY","termSource":"NCI"},{"termName":"Chromodomain Helicase DNA Binding Protein 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1919"},{"name":"Maps_To","value":"CHD4"},{"name":"OMIM_Number","value":"603277"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413383"}]}}{"C40965":{"preferredName":"CHEK2 Gene","code":"C40965","definitions":[{"definition":"This gene plays a role in cell survival and the negative regulation of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHEK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Checkpoint Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CHEK2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16627"},{"name":"Legacy Concept Name","value":"CHEK2_Gene"},{"name":"Maps_To","value":"CHEK2"},{"name":"OMIM_Number","value":"604373"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424448"}]}}{"C97406":{"preferredName":"CHIC2 Gene","code":"C97406","definitions":[{"definition":"This gene may play a role in vesicular transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHIC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHIC2","termGroup":"SY","termSource":"NCI"},{"termName":"Cysteine Rich Hydrophobic Domain 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1935"},{"name":"Maps_To","value":"CHIC2"},{"name":"OMIM_Number","value":"604332"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413390"}]}}{"C143061":{"preferredName":"CHST11 Gene","code":"C143061","definitions":[{"definition":"This gene plays a role in the metabolism of chondroitin sulfate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHST11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Carbohydrate Sulfotransferase 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CHST11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17422"},{"name":"Maps_To","value":"CHST11"},{"name":"OMIM_Number","value":"610128"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424960"}]}}{"C97912":{"preferredName":"CIC Gene","code":"C97912","definitions":[{"definition":"This gene is involved in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CIC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Capicua Transcriptional Repressor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CIC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14214"},{"name":"Maps_To","value":"CIC"},{"name":"OMIM_Number","value":"612082"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422489"}]}}{"C96013":{"preferredName":"CIITA Gene","code":"C96013","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CIITA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CIITA","termGroup":"SY","termSource":"NCI"},{"termName":"Class II Major Histocompatibility Complex Transactivator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7067"},{"name":"Maps_To","value":"CIITA"},{"name":"OMIM_Number","value":"600005"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824738"}]}}{"C84464":{"preferredName":"CLIP1 Gene","code":"C84464","definitions":[{"definition":"This gene plays a role in both endocytosis and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CAP-GLY Domain Containing Linker Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLIP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10461"},{"name":"Maps_To","value":"CLIP1"},{"name":"OMIM_Number","value":"179838"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824746"}]}}{"C97528":{"preferredName":"CLP1 Gene","code":"C97528","definitions":[{"definition":"This gene plays a role in RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cleavage Factor Polyadenylation Kinase Subunit 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16999"},{"name":"Maps_To","value":"CLP1"},{"name":"OMIM_Number","value":"608757"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824753"}]}}{"C97412":{"preferredName":"CLTC Gene","code":"C97412","definitions":[{"definition":"This gene plays a role in both the formation of cellular vesicles and receptor-mediated endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLTC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Clathrin Heavy Chain Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLTC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2092"},{"name":"Maps_To","value":"CLTC"},{"name":"OMIM_Number","value":"118955"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413512"}]}}{"C97415":{"preferredName":"CLTCL1 Gene","code":"C97415","definitions":[{"definition":"This gene is involved in both receptor-mediated endocytosis and vesicle formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CLTCL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Clathrin Heavy Chain Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CLTCL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2093"},{"name":"Maps_To","value":"CLTCL1"},{"name":"OMIM_Number","value":"601273"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413513"}]}}{"C143056":{"preferredName":"CNBD1 Gene","code":"C143056","definitions":[{"definition":"This gene is involved in cyclic nucleotide binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNBD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CNBD1","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclic Nucleotide Binding Domain Containing 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26663"},{"name":"Maps_To","value":"CNBD1"},{"name":"NCI_META_CUI","value":"CL541468"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97888":{"preferredName":"CNBP Gene","code":"C97888","definitions":[{"definition":"This gene is involved in sterol-mediated transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNBP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCHC-Type Zinc Finger, Nucleic Acid Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CNBP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13164"},{"name":"Maps_To","value":"CNBP"},{"name":"OMIM_Number","value":"116955"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824763"}]}}{"C107658":{"preferredName":"CNOT3 Gene","code":"C107658","definitions":[{"definition":"This gene is involved in mRNA degradation, miRNA-mediated repression, translational regulation and general transcription regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNOT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCR4-NOT Transcription Complex, Subunit 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CNOT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7879"},{"name":"Maps_To","value":"CNOT3"},{"name":"OMIM_Number","value":"604910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417765"}]}}{"C73461":{"preferredName":"CNTNAP2 Gene","code":"C73461","definitions":[{"definition":"This gene may be involved in axonal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNTNAP2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CNTNAP2","termGroup":"SY","termSource":"NCI"},{"termName":"Contactin Associated Protein-Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13830"},{"name":"Legacy Concept Name","value":"CNTNAP2_Gene"},{"name":"Maps_To","value":"CNTNAP2"},{"name":"OMIM_Number","value":"604569"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422223"}]}}{"C97891":{"preferredName":"CNTRL Gene","code":"C97891","definitions":[{"definition":"This gene plays a role in cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CNTRL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centriolin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CNTRL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1858"},{"name":"Maps_To","value":"CNTRL"},{"name":"OMIM_Number","value":"605496"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824717"}]}}{"C29949":{"preferredName":"COL1A1 Gene","code":"C29949","definitions":[{"definition":"This gene plays an important structural role in cartilage and mutations in the gene are associated with osteogenesis imperfecta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COL1A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COL1A1","termGroup":"SY","termSource":"NCI"},{"termName":"Collagen Type I Alpha 1 Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2197"},{"name":"Legacy Concept Name","value":"COL1A1_Gene"},{"name":"Maps_To","value":"COL1A1"},{"name":"OMIM_Number","value":"120150"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332772"}]}}{"C75315":{"preferredName":"COL2A1 Gene","code":"C75315","definitions":[{"definition":"This gene plays a role in both skeletal development and cartilage structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COL2A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COL2A1","termGroup":"SY","termSource":"NCI"},{"termName":"Collagen, Type II, Alpha 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2200"},{"name":"Legacy Concept Name","value":"COL2A1_Gene"},{"name":"Maps_To","value":"COL2A1"},{"name":"OMIM_Number","value":"120140"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413580"}]}}{"C143052":{"preferredName":"COL3A1 Gene","code":"C143052","definitions":[{"definition":"This gene plays a role in collagen formation in connective tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COL3A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COL3A1","termGroup":"SY","termSource":"NCI"},{"termName":"Collagen Type III Alpha 1 Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2201"},{"name":"Maps_To","value":"COL3A1"},{"name":"OMIM_Number","value":"120180"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413581"}]}}{"C24308":{"preferredName":"COX6C Gene","code":"C24308","definitions":[{"definition":"This gene is involved in mitochondrial respiration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"COX6C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COX6C","termGroup":"SY","termSource":"NCI"},{"termName":"Cytochrome C Oxidase Subunit VIC Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2285"},{"name":"Legacy Concept Name","value":"COX6C_Gene"},{"name":"Maps_To","value":"COX6C"},{"name":"OMIM_Number","value":"124090"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332776"}]}}{"C38536":{"preferredName":"CREB1 Gene","code":"C38536","definitions":[{"definition":"This gene is involved in transcriptional regulation and its activity is modulated in response to hormonal stimulation from the cAMP pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"cAMP Responsive Element Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2345"},{"name":"Legacy Concept Name","value":"CREB1_Gene"},{"name":"Maps_To","value":"CREB1"},{"name":"OMIM_Number","value":"123810"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413702"}]}}{"C95477":{"preferredName":"CREB3L1 Gene","code":"C95477","definitions":[{"definition":"This gene plays a role in transcriptional regulation in response to cellular stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREB3L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"cAMP Responsive Element Binding Protein 3-Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREB3L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18856"},{"name":"Maps_To","value":"CREB3L1"},{"name":"OMIM_Number","value":"616215"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425827"}]}}{"C95480":{"preferredName":"CREB3L2 Gene","code":"C95480","definitions":[{"definition":"This gene is involved in the response to cellular stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREB3L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"cAMP Responsive Element Binding Protein 3-Like 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREB3L2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23720"},{"name":"Maps_To","value":"CREB3L2"},{"name":"OMIM_Number","value":"608834"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428221"}]}}{"C26568":{"preferredName":"CREBBP Gene","code":"C26568","definitions":[{"definition":"This gene plays a role in transcriptional regulation and in NF-kappa B signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CREBBP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CREB Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CREBBP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2348"},{"name":"Legacy Concept Name","value":"CREBBP_Gene"},{"name":"Maps_To","value":"CREBBP"},{"name":"OMIM_Number","value":"600140"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337090"}]}}{"C97430":{"preferredName":"CRLF2 Gene","code":"C97430","definitions":[{"definition":"This gene is involved in cytokine binding and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRLF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CRLF2","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokine Receptor Like Factor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14281"},{"name":"Maps_To","value":"CRLF2"},{"name":"OMIM_Number","value":"300357"},{"name":"OMIM_Number","value":"400023"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422539"}]}}{"C143049":{"preferredName":"CRNKL1 Gene","code":"C143049","definitions":[{"definition":"This gene is involved in RNA binding and pre-mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRNKL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CRNKL1","termGroup":"SY","termSource":"NCI"},{"termName":"Crooked Neck Pre-mRNA Splicing Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15762"},{"name":"Maps_To","value":"CRNKL1"},{"name":"NCI_META_CUI","value":"CL541477"},{"name":"OMIM_Number","value":"610952"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C95449":{"preferredName":"CRTC1 Gene","code":"C95449","definitions":[{"definition":"This gene plays a role in the positive regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRTC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CREB Regulated Transcription Coactivator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CRTC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16062"},{"name":"Maps_To","value":"CRTC1"},{"name":"OMIM_Number","value":"607536"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824798"}]}}{"C95276":{"preferredName":"CRTC3 Gene","code":"C95276","definitions":[{"definition":"This gene is involved in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CRTC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CREB Regulated Transcription Coactivator 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CRTC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26148"},{"name":"Maps_To","value":"CRTC3"},{"name":"OMIM_Number","value":"608986"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824800"}]}}{"C18516":{"preferredName":"CSF1R Gene","code":"C18516","definitions":[{"definition":"This gene is essential for the regulation of the production, differentiation, and function of macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSF1R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Colony Stimulating Factor 1 Receptor, Formerly McDonough Feline Sarcoma Viral (v-fms) Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CSF1R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2433"},{"name":"Legacy Concept Name","value":"CSF1R_Gene"},{"name":"Maps_To","value":"CSF1R"},{"name":"OMIM_Number","value":"164770"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879468"}]}}{"C24313":{"preferredName":"CSF3R Gene","code":"C24313","definitions":[{"definition":"This gene plays an inhibitory role in cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSF3R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Colony Stimulating Factor 3 Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CSF3R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2439"},{"name":"Legacy Concept Name","value":"CSF3R_Gene"},{"name":"Maps_To","value":"CSF3R"},{"name":"OMIM_Number","value":"138971"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332792"}]}}{"C143042":{"preferredName":"CSMD3 Gene","code":"C143042","definitions":[{"definition":"This gene plays a role in neuronal development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSMD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CSMD3","termGroup":"SY","termSource":"NCI"},{"termName":"CUB and Sushi Multiple Domains 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19291"},{"name":"Maps_To","value":"CSMD3"},{"name":"NCI_META_CUI","value":"CL541470"},{"name":"OMIM_Number","value":"608399"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C73679":{"preferredName":"CTCF Gene","code":"C73679","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTCF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CCCTC-Binding Factor (Zinc Finger Protein) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTCF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13723"},{"name":"Legacy Concept Name","value":"CTCF_Gene"},{"name":"Maps_To","value":"CTCF"},{"name":"OMIM_Number","value":"604167"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422163"}]}}{"C143115":{"preferredName":"CTNNA2 Gene","code":"C143115","definitions":[{"definition":"This gene is involved in cell-cell adhesion and cellular differentiation in the nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNNA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin Alpha 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNNA2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2510"},{"name":"Maps_To","value":"CTNNA2"},{"name":"NCI_META_CUI","value":"CL541524"},{"name":"OMIM_Number","value":"114025"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C20987":{"preferredName":"CTNNB1 Gene","code":"C20987","definitions":[{"definition":"This gene is involved in signal transduction and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNNB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin Beta 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNNB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2514"},{"name":"Legacy Concept Name","value":"CTNNB1_Gene"},{"name":"Maps_To","value":"CTNNB1"},{"name":"OMIM_Number","value":"116806"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332803"}]}}{"C79770":{"preferredName":"CTNND1 Gene","code":"C79770","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNND1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin (Cadherin-Associated Protein), Delta 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNND1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2515"},{"name":"Legacy Concept Name","value":"CTNND1_Gene"},{"name":"Maps_To","value":"CTNND1"},{"name":"OMIM_Number","value":"601045"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413800"}]}}{"C82941":{"preferredName":"CTNND2 Gene","code":"C82941","definitions":[{"definition":"This gene is involved in the regulation of both transcription and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTNND2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Catenin (Cadherin-Associated Protein), Delta 2 (Neural Plakophilin-Related Arm-Repeat Protein) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTNND2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2516"},{"name":"Legacy Concept Name","value":"CTNND2_Gene"},{"name":"Maps_To","value":"CTNND2"},{"name":"OMIM_Number","value":"604275"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413801"}]}}{"C24323":{"preferredName":"CUL3 Gene","code":"C24323","definitions":[{"definition":"This gene plays a role in protein degradation and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CUL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CUL3","termGroup":"SY","termSource":"NCI"},{"termName":"Cullin 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2553"},{"name":"Legacy Concept Name","value":"CUL3_Gene"},{"name":"Maps_To","value":"CUL3"},{"name":"OMIM_Number","value":"603136"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332811"}]}}{"C95578":{"preferredName":"CUX1 Gene","code":"C95578","definitions":[{"definition":"This gene is involved in both transcriptional regulation and Golgi vesicle transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CUX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Cut-Like Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CUX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The CUX gene has two significantly different protein products with divergent molecular functions. The two proteins are the result of alternative splicing. (UniProt)"},{"name":"HGNC_ID","value":"HGNC:2557"},{"name":"Maps_To","value":"CUX1"},{"name":"OMIM_Number","value":"116896"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413827"}]}}{"C24327":{"preferredName":"CXCR4 Gene","code":"C24327","definitions":[{"definition":"This gene is involved in the mediation of viral entry into cells and cellular migration and chemotaxis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Chemokine (C-X-C Motif) Receptor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CXCR4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2561"},{"name":"Legacy Concept Name","value":"CXCR4_Gene"},{"name":"Maps_To","value":"CXCR4"},{"name":"OMIM_Number","value":"162643"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332823"}]}}{"C92678":{"preferredName":"CYLD Gene","code":"C92678","definitions":[{"definition":"This gene is involved in protein deubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYLD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CYLD","termGroup":"SY","termSource":"NCI"},{"termName":"CYLD Lysine 63 Deubiquitinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2584"},{"name":"Maps_To","value":"CYLD"},{"name":"OMIM_Number","value":"605018"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413850"}]}}{"C46071":{"preferredName":"CYP2C8 Gene","code":"C46071","definitions":[{"definition":"This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP2C8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CYP2C8","termGroup":"SY","termSource":"NCI"},{"termName":"Cytochrome P450, Family 2, Subfamily C, Polypeptide 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2622"},{"name":"Legacy Concept Name","value":"CYP2C8_Gene"},{"name":"Maps_To","value":"CYP2C8"},{"name":"OMIM_Number","value":"601129"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413873"}]}}{"C143039":{"preferredName":"CYSLTR2 Gene","code":"C143039","definitions":[{"definition":"This gene is involved in cysteinyl leukotriene binding and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYSLTR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CYSLTR2","termGroup":"SY","termSource":"NCI"},{"termName":"Cysteinyl Leukotriene Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18274"},{"name":"Maps_To","value":"CYSLTR2"},{"name":"NCI_META_CUI","value":"CL541483"},{"name":"OMIM_Number","value":"605666"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24330":{"preferredName":"DAXX Gene","code":"C24330","definitions":[{"definition":"This gene plays a role in signal transduction, regulation of transcription and enhancement of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DAXX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DAXX","termGroup":"SY","termSource":"NCI"},{"termName":"Death-Domain Associated Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2681"},{"name":"Legacy Concept Name","value":"DAXX_Gene"},{"name":"Maps_To","value":"DAXX"},{"name":"OMIM_Number","value":"603186"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333203"}]}}{"C143036":{"preferredName":"DCAF12L2 Gene","code":"C143036","definitions":[{"definition":"This gene may play a role in protein complex formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DCAF12L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DCAF12L2","termGroup":"SY","termSource":"NCI"},{"termName":"DDB1 and CUL4 Associated Factor 12 Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:32950"},{"name":"Maps_To","value":"DCAF12L2"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823822"}]}}{"C17358":{"preferredName":"DCC Gene","code":"C17358","definitions":[{"definition":"This gene plays a role in the regulation of several processes that determine neuronal cell morphology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DCC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DCC","termGroup":"SY","termSource":"NCI"},{"termName":"Deleted in Colorectal Carcinoma Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2701"},{"name":"Legacy Concept Name","value":"DCC_Gene"},{"name":"Maps_To","value":"DCC"},{"name":"OMIM_Number","value":"120470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0079414"}]}}{"C122875":{"preferredName":"DCTN1 Gene","code":"C122875","definitions":[{"definition":"This gene is involved in the modulation of retrograde transport of cytoplasmic organelles and vesicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DCTN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DCTN1","termGroup":"SY","termSource":"NCI"},{"termName":"Dynactin 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2711"},{"name":"Maps_To","value":"DCTN1"},{"name":"OMIM_Number","value":"601143"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413935"}]}}{"C93075":{"preferredName":"DDB2 Gene","code":"C93075","definitions":[{"definition":"This gene plays a role in DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Damage-Specific DNA Binding Protein 2, 48kDa Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DDB2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2718"},{"name":"Maps_To","value":"DDB2"},{"name":"OMIM_Number","value":"600811"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413942"}]}}{"C92539":{"preferredName":"DDIT3 Gene","code":"C92539","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDIT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHOP","termGroup":"SY","termSource":"NCI"},{"termName":"DDIT3","termGroup":"SY","termSource":"NCI"},{"termName":"DNA Damage Inducible Transcript 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2726"},{"name":"Maps_To","value":"DDIT3"},{"name":"OMIM_Number","value":"126337"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413947"}]}}{"C24333":{"preferredName":"DDR2 Gene","code":"C24333","definitions":[{"definition":"This gene plays a role in extracellular matrix communication processes and receptor-mediated signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDR2","termGroup":"SY","termSource":"NCI"},{"termName":"Discoidin Domain Receptor Family Member 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2731"},{"name":"Legacy Concept Name","value":"DDR2_Gene"},{"name":"Maps_To","value":"DDR2"},{"name":"OMIM_Number","value":"191311"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333207"}]}}{"C97457":{"preferredName":"DDX10 Gene","code":"C97457","definitions":[{"definition":"This gene plays a role in both RNA metabolism and ATP hydrolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX10","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 10 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2735"},{"name":"Maps_To","value":"DDX10"},{"name":"OMIM_Number","value":"601235"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413952"}]}}{"C101565":{"preferredName":"DDX3X Gene","code":"C101565","definitions":[{"definition":"This gene is involved in RNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX3X Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX3X","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 3 X-Linked Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2745"},{"name":"Maps_To","value":"DDX3X"},{"name":"OMIM_Number","value":"300160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413962"}]}}{"C97460":{"preferredName":"DDX5 Gene","code":"C97460","definitions":[{"definition":"This gene is involved in the mediation of RNA metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX5","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2746"},{"name":"Maps_To","value":"DDX5"},{"name":"OMIM_Number","value":"180630"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413963"}]}}{"C18378":{"preferredName":"DDX6 Gene","code":"C18378","definitions":[{"definition":"This gene plays a role in the translation of mRNA encoded by genes involved in cell proliferation and malignant transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DDX6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DDX6","termGroup":"SY","termSource":"NCI"},{"termName":"DEAD-Box Helicase 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2747"},{"name":"Legacy Concept Name","value":"DDX6_Gene"},{"name":"Maps_To","value":"DDX6"},{"name":"OMIM_Number","value":"600326"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812257"}]}}{"C24339":{"preferredName":"DEK Gene","code":"C24339","definitions":[{"definition":"This gene is involved in RNA processing and regulation of chromatin organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DEK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DEK","termGroup":"SY","termSource":"NCI"},{"termName":"DEK Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2768"},{"name":"Legacy Concept Name","value":"DEK_Gene"},{"name":"Maps_To","value":"DEK"},{"name":"OMIM_Number","value":"125264"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333214"}]}}{"C92663":{"preferredName":"DGCR8 Gene","code":"C92663","definitions":[{"definition":"This gene plays a role in microRNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DGCR8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DGCR8","termGroup":"SY","termSource":"NCI"},{"termName":"DGCR8 Microprocessor Complex Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2847"},{"name":"Maps_To","value":"DGCR8"},{"name":"OMIM_Number","value":"609030"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414028"}]}}{"C25956":{"preferredName":"DICER1 Gene","code":"C25956","definitions":[{"definition":"This gene is involved in the RNA interference pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DICER1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Dicer 1, Ribonuclease III Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DICER1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17098"},{"name":"Legacy Concept Name","value":"DICER1_Gene"},{"name":"Maps_To","value":"DICER1"},{"name":"OMIM_Number","value":"606241"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333218"}]}}{"C122560":{"preferredName":"DNAJB1 Gene","code":"C122560","definitions":[{"definition":"This gene plays a role in the regulation of protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNAJB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DnaJ (Hsp40) Homolog, Subfamily B, Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DNAJB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5270"},{"name":"Maps_To","value":"DNAJB1"},{"name":"OMIM_Number","value":"604572"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415791"}]}}{"C102796":{"preferredName":"DNM2 Gene","code":"C102796","definitions":[{"definition":"This gene plays a role in both GTP hydrolysis and microtubule organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNM2","termGroup":"SY","termSource":"NCI"},{"termName":"Dynamin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2974"},{"name":"Maps_To","value":"DNM2"},{"name":"OMIM_Number","value":"602378"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414120"}]}}{"C73652":{"preferredName":"DNMT3A Gene","code":"C73652","definitions":[{"definition":"This gene is involved in epigenetic modification of DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNMT3A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Methyltransferase 3 Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DNMT3A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2978"},{"name":"Legacy Concept Name","value":"DNMT3A_Gene"},{"name":"Maps_To","value":"DNMT3A"},{"name":"OMIM_Number","value":"602769"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414123"}]}}{"C25955":{"preferredName":"DROSHA Gene","code":"C25955","definitions":[{"definition":"This gene plays a role in the processing of microRNA in the nucleus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DROSHA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DROSHA","termGroup":"SY","termSource":"NCI"},{"termName":"Drosha Ribonuclease III Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RNASEN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17904"},{"name":"Legacy Concept Name","value":"Rnase-III_Gene"},{"name":"Maps_To","value":"DROSHA"},{"name":"OMIM_Number","value":"608828"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1709966"}]}}{"C124048":{"preferredName":"DUX4L1 Gene","code":"C124048","definitions":[{"definition":"Human DUX4L1 gene is located in the vicinity of 4q35 and is approximately 2 kb in length. The product is a processed pseudogene that produces an RNA transcript, but does not encode a protein product. This gene is within a D4Z4 repeat array; contraction of this macrosatellite repeat is associated with facioscapulohumeral muscular dystrophy (FSHD).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DUX4L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Double Homeobox 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Double Homeobox 4 Like 1 (Pseudogene) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Double Homeobox 4 Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DUX10","termGroup":"SY","termSource":"NCI"},{"termName":"DUX4L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The DUX4L1 gene is located within a D4Z4 repeat array in the subtelomeric region of chromosome 4q. (EntrezGene)"},{"name":"EntrezGene_ID","value":"22947"},{"name":"GenBank_Accession_Number","value":"D38024"},{"name":"HGNC_ID","value":"HGNC:3082"},{"name":"Maps_To","value":"DUX4L1"},{"name":"NCI_META_CUI","value":"CL498402"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C80023":{"preferredName":"EBF1 Gene","code":"C80023","definitions":[{"definition":"This gene plays a role in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Early B-Cell Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EBF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3126"},{"name":"Legacy Concept Name","value":"EBF1_Gene"},{"name":"Maps_To","value":"EBF1"},{"name":"OMIM_Number","value":"164343"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825022"}]}}{"C101452":{"preferredName":"ECT2L Gene","code":"C101452","definitions":[{"definition":"This gene may be involved in guanine nucleotide exchange.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ECT2L Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ECT2L","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Cell Transforming Sequence 2 Oncogene-Like Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:21118"},{"name":"Maps_To","value":"ECT2L"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427334"}]}}{"C101721":{"preferredName":"EED Gene","code":"C101721","definitions":[{"definition":"This gene plays a role in the negative regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EED Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EED","termGroup":"SY","termSource":"NCI"},{"termName":"Embryonic Ectoderm Development Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3188"},{"name":"Maps_To","value":"EED"},{"name":"OMIM_Number","value":"605984"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414269"}]}}{"C17757":{"preferredName":"EGFR Gene","code":"C17757","definitions":[{"definition":"This gene is involved in the epidermal growth factor signal transduction pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EGFR","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermal Growth Factor Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3236"},{"name":"Legacy Concept Name","value":"EGFR_Gene"},{"name":"Maps_To","value":"EGFR"},{"name":"OMIM_Number","value":"131550"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414313"}]}}{"C131315":{"preferredName":"EIF1AX Gene","code":"C131315","definitions":[{"definition":"This gene is involved in translation initiation and efficiency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EIF1AX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EIF1AX","termGroup":"SY","termSource":"NCI"},{"termName":"Eukaryotic Translation Initiation Factor 1A X-Linked Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3250"},{"name":"Maps_To","value":"EIF1AX"},{"name":"OMIM_Number","value":"300186"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539339"}]}}{"C18347":{"preferredName":"EIF3E Gene","code":"C18347","definitions":[{"definition":"This gene is involved in the initiation and regulation of protein translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EIF3E Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EIF3E","termGroup":"SY","termSource":"NCI"},{"termName":"Eukaryotic Translation Initiation Factor 3, Subunit E Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3277"},{"name":"Legacy Concept Name","value":"EIF3S6_Gene"},{"name":"Maps_To","value":"EIF3E"},{"name":"OMIM_Number","value":"602210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812224"}]}}{"C97467":{"preferredName":"EIF4A2 Gene","code":"C97467","definitions":[{"definition":"This gene is involved in translation initiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EIF4A2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EIF4A2","termGroup":"SY","termSource":"NCI"},{"termName":"Eukaryotic Translation Initiation Factor 4A2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3284"},{"name":"Maps_To","value":"EIF4A2"},{"name":"OMIM_Number","value":"601102"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414349"}]}}{"C20899":{"preferredName":"ELF3 Gene","code":"C20899","definitions":[{"definition":"This gene is involved in the regulation of both transcription and epithelial cell differentiation. It also plays a role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E74-Like Factor 3 (ETS Domain Transcription Factor, Epithelial-Specific) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ELF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3318"},{"name":"Legacy Concept Name","value":"ELF3_Gene"},{"name":"Maps_To","value":"ELF3"},{"name":"OMIM_Number","value":"602191"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366763"}]}}{"C97470":{"preferredName":"ELF4 Gene","code":"C97470","definitions":[{"definition":"This gene plays a role in both DNA binding and transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E74 Like ETS Transcription Factor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ELF4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3319"},{"name":"Maps_To","value":"ELF4"},{"name":"OMIM_Number","value":"300775"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414377"}]}}{"C97476":{"preferredName":"ELK4 Gene","code":"C97476","definitions":[{"definition":"This gene is involved in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELK4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ELK4","termGroup":"SY","termSource":"NCI"},{"termName":"ELK4, ETS-Domain Protein (SRF Accessory Protein 1) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3326"},{"name":"Maps_To","value":"ELK4"},{"name":"OMIM_Number","value":"600246"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414381"}]}}{"C97516":{"preferredName":"ELL Gene","code":"C97516","definitions":[{"definition":"This gene is involved in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ELL","termGroup":"SY","termSource":"NCI"},{"termName":"Elongation Factor RNA Polymerase II Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23114"},{"name":"Maps_To","value":"ELL"},{"name":"OMIM_Number","value":"600284"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427925"}]}}{"C75333":{"preferredName":"ELN Gene","code":"C75333","definitions":[{"definition":"This gene is involved in the structure of the extracellular matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ELN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Elastin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ELN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3327"},{"name":"Legacy Concept Name","value":"ELN_Gene"},{"name":"Maps_To","value":"ELN"},{"name":"OMIM_Number","value":"130160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414382"}]}}{"C71003":{"preferredName":"EML4 Gene","code":"C71003","definitions":[{"definition":"This gene may play a role in cytoskeletal assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EML4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Echinoderm Microtubule Associated Protein Like 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EML4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1316"},{"name":"Legacy Concept Name","value":"EML4_Gene"},{"name":"Maps_To","value":"EML4"},{"name":"OMIM_Number","value":"607442"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412993"}]}}{"C26569":{"preferredName":"EP300 Gene","code":"C26569","definitions":[{"definition":"This gene plays a role in DNA repair and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP300 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E1A Binding Protein p300 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EP300","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3373"},{"name":"Legacy Concept Name","value":"EP300_Gene"},{"name":"Maps_To","value":"EP300"},{"name":"OMIM_Number","value":"602700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333336"}]}}{"C104303":{"preferredName":"EPAS1 Gene","code":"C104303","definitions":[{"definition":"This gene plays a role in the cellular response to hypoxia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPAS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Endothelial PAS Domain Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPAS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3374"},{"name":"Maps_To","value":"EPAS1"},{"name":"OMIM_Number","value":"603349"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414421"}]}}{"C18384":{"preferredName":"EPHA3 Gene","code":"C18384","definitions":[{"definition":"This gene is involved in receptor tyrosine kinase signal transduction and plays a role in lymphoid function and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPHA3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EPH Receptor A3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPHA3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3387"},{"name":"Legacy Concept Name","value":"EPHA3_Gene"},{"name":"Maps_To","value":"EPHA3"},{"name":"OMIM_Number","value":"179611"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812263"}]}}{"C111841":{"preferredName":"EPHA7 Gene","code":"C111841","definitions":[{"definition":"This gene plays a role in mediation of developmental processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPHA7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EPH Receptor A7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPHA7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3390"},{"name":"Maps_To","value":"EPHA7"},{"name":"OMIM_Number","value":"602190"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414430"}]}}{"C24369":{"preferredName":"EPS15 Gene","code":"C24369","definitions":[{"definition":"This gene plays a role in signal transduction and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPS15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermal Growth Factor Receptor Pathway Substrate 15 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EPS15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3419"},{"name":"Legacy Concept Name","value":"EPS15_Gene"},{"name":"Maps_To","value":"EPS15"},{"name":"OMIM_Number","value":"600051"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333343"}]}}{"C17756":{"preferredName":"ERBB2 Gene","code":"C17756","definitions":[{"definition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERBB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Erb-b2 Receptor Tyrosine Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERBB2","termGroup":"SY","termSource":"NCI"},{"termName":"HER2","termGroup":"SY","termSource":"NCI"},{"termName":"HER2/Neu","termGroup":"SY","termSource":"NCI"},{"termName":"NEU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3430"},{"name":"Legacy Concept Name","value":"ERBB2_Gene"},{"name":"Maps_To","value":"ERBB2"},{"name":"OMIM_Number","value":"164870"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0242957"}]}}{"C18386":{"preferredName":"ERBB3 Gene","code":"C18386","definitions":[{"definition":"This gene is involved in signal transduction pathways that result in cellular proliferation or differentiation. The gene has also been associated with numerous cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERBB3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Erb-B2 Receptor Tyrosine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERBB3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3431"},{"name":"Legacy Concept Name","value":"ERBB3_Gene"},{"name":"Maps_To","value":"ERBB3"},{"name":"OMIM_Number","value":"190151"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812265"}]}}{"C18388":{"preferredName":"ERBB4 Gene","code":"C18388","definitions":[{"definition":"This gene is involved in neuronal development and plays a role in receptor tyrosine kinase signal transduction that regulates cellular proliferation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERBB4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Erb-B2 Receptor Tyrosine Kinase 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERBB4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3432"},{"name":"Legacy Concept Name","value":"ERBB4_Gene"},{"name":"Maps_To","value":"ERBB4"},{"name":"OMIM_Number","value":"600543"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812267"}]}}{"C97499":{"preferredName":"ERC1 Gene","code":"C97499","definitions":[{"definition":"This gene plays a role in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ELKS/RAB6-Interacting/CAST Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17072"},{"name":"Maps_To","value":"ERC1"},{"name":"OMIM_Number","value":"607127"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825059"}]}}{"C20555":{"preferredName":"ERCC2 Gene","code":"C20555","definitions":[{"definition":"This gene is involved in nucleotide excision repair and corrects sensitivity to UV radiation and defective nucleotide excision repair in xeroderma pigmentosum cells of complementation group D.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3434"},{"name":"Legacy Concept Name","value":"ERCC2_Gene"},{"name":"Maps_To","value":"ERCC2"},{"name":"OMIM_Number","value":"126340"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333356"}]}}{"C20556":{"preferredName":"ERCC3 Gene","code":"C20556","definitions":[{"definition":"This gene is involved in DNA excision repair and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3435"},{"name":"Legacy Concept Name","value":"ERCC3_Gene"},{"name":"Maps_To","value":"ERCC3"},{"name":"OMIM_Number","value":"133510"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333357"}]}}{"C20558":{"preferredName":"ERCC4 Gene","code":"C20558","definitions":[{"definition":"This gene is involved in nucleotide excision repair and is involved in the correction of defective nucleotide excision repair in xeroderma pigmentosum cells of complementation group F.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 4, Endonuclease Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3436"},{"name":"Legacy Concept Name","value":"ERCC4_Gene"},{"name":"Maps_To","value":"ERCC4"},{"name":"OMIM_Number","value":"133520"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333358"}]}}{"C20557":{"preferredName":"ERCC5 Gene","code":"C20557","definitions":[{"definition":"This gene plays a role in the nucleotide base excision repair of UV-induced DNA damage and mutations of the gene cause Cockayne syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERCC5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERCC Excision Repair 5, Endonuclease Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ERCC5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3437"},{"name":"Legacy Concept Name","value":"ERCC5_Gene"},{"name":"Maps_To","value":"ERCC5"},{"name":"OMIM_Number","value":"133530"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333359"}]}}{"C18139":{"preferredName":"ERG Gene","code":"C18139","definitions":[{"definition":"This gene plays a regulatory role in transcription, cellular maintenance and hematopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ERG","termGroup":"SY","termSource":"NCI"},{"termName":"ETS Transcription Factor ERG Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3446"},{"name":"Legacy Concept Name","value":"ERG_Gene"},{"name":"Maps_To","value":"ERG"},{"name":"OMIM_Number","value":"165080"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0599295"}]}}{"C38349":{"preferredName":"ESR1 Gene","code":"C38349","definitions":[{"definition":"This gene is involved in ligand-activated transcriptional activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ESR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ER","termGroup":"SY","termSource":"NCI"},{"termName":"ESR1","termGroup":"SY","termSource":"NCI"},{"termName":"Estrogen Receptor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3467"},{"name":"Legacy Concept Name","value":"ESR1_Gene"},{"name":"Maps_To","value":"ESR1"},{"name":"OMIM_Number","value":"133430"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414461"}]}}{"C122823":{"preferredName":"ETNK1 Gene","code":"C122823","definitions":[{"definition":"This gene plays a role in phospholipid biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETNK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ethanolamine Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETNK1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24649"},{"name":"Maps_To","value":"ETNK1"},{"name":"OMIM_Number","value":"609858"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539368"}]}}{"C24377":{"preferredName":"ETV1 Gene","code":"C24377","definitions":[{"definition":"This gene is involved in transcriptional activation and spinal cord development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ETS Variant Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3490"},{"name":"Legacy Concept Name","value":"ETV1_Gene"},{"name":"Maps_To","value":"ETV1"},{"name":"OMIM_Number","value":"600541"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333361"}]}}{"C24378":{"preferredName":"ETV4 Gene","code":"C24378","definitions":[{"definition":"This gene plays a regulatory role in transcription and in matrix metalloproteinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E1AF","termGroup":"SY","termSource":"NCI"},{"termName":"ETS Variant Transcription Factor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3493"},{"name":"Legacy Concept Name","value":"ETV4_Gene"},{"name":"Maps_To","value":"ETV4"},{"name":"OMIM_Number","value":"600711"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333362"}]}}{"C97479":{"preferredName":"ETV5 Gene","code":"C97479","definitions":[{"definition":"This gene plays a role in the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ets Variant Transcription Factor 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3494"},{"name":"Maps_To","value":"ETV5"},{"name":"OMIM_Number","value":"601600"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414477"}]}}{"C18312":{"preferredName":"ETV6 Gene","code":"C18312","definitions":[{"definition":"This gene plays a regulatory role in transcription and in matrix metalloproteinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ETV6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ETS Variant Transcription Factor 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ETV6","termGroup":"SY","termSource":"NCI"},{"termName":"TEL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3495"},{"name":"Legacy Concept Name","value":"ETV6_Gene"},{"name":"Maps_To","value":"ETV6"},{"name":"OMIM_Number","value":"600618"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0796520"}]}}{"C18322":{"preferredName":"EWSR1 Gene","code":"C18322","definitions":[{"definition":"This gene may play a role in post-transcriptional regulation; however the function remains to be elucidated. Mutations in the gene result in Ewing sarcoma and other tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EWSR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ewing Sarcoma Breakpoint Region 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EWS RNA-Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EWSR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3508"},{"name":"Legacy Concept Name","value":"EWSR1_Gene"},{"name":"Maps_To","value":"EWSR1"},{"name":"OMIM_Number","value":"133450"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0808901"}]}}{"C18251":{"preferredName":"EXT1 Gene","code":"C18251","definitions":[{"definition":"This gene plays a role in heparin/heparin sulfate biosynthesis, axon guidance and biogenesis/cell organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EXT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Exostosin Glycosyltransferase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EXT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3512"},{"name":"Legacy Concept Name","value":"EXT1_Gene"},{"name":"Maps_To","value":"EXT1"},{"name":"OMIM_Number","value":"608177"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694878"}]}}{"C18252":{"preferredName":"EXT2 Gene","code":"C18252","definitions":[{"definition":"This gene is involved in the heparin/heparin sulfate biosynthesis, cell organization/biogenesis and development of the cytoskeleton in chondrocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EXT2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Exostosin Glycosyltransferase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EXT2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3513"},{"name":"Legacy Concept Name","value":"EXT2_Gene"},{"name":"Maps_To","value":"EXT2"},{"name":"OMIM_Number","value":"608210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694879"}]}}{"C21327":{"preferredName":"EZH2 Gene","code":"C21327","definitions":[{"definition":"This gene plays a role in chromatin remodeling and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"EZH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3527"},{"name":"Legacy Concept Name","value":"EZH2_Gene"},{"name":"Maps_To","value":"EZH2"},{"name":"OMIM_Number","value":"601573"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333368"}]}}{"C68722":{"preferredName":"EZR Gene","code":"C68722","definitions":[{"definition":"This gene plays a role in cellular structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EZR","termGroup":"SY","termSource":"NCI"},{"termName":"Ezrin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12691"},{"name":"Legacy Concept Name","value":"VIL2_Gene"},{"name":"Maps_To","value":"EZR"},{"name":"OMIM_Number","value":"123900"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421450"}]}}{"C106340":{"preferredName":"FAM131B Gene","code":"C106340","definitions":[{"definition":"This gene has not been characterized.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAM131B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM131B","termGroup":"SY","termSource":"NCI"},{"termName":"Family with Sequence Similarity 131 Member B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22202"},{"name":"Maps_To","value":"FAM131B"},{"name":"OMIM_Number","value":"619282"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2239421"}]}}{"C143112":{"preferredName":"FAM135B Gene","code":"C143112","definitions":[{"definition":"This gene may play a role in the metabolism of lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAM135B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM135B","termGroup":"SY","termSource":"NCI"},{"termName":"Family with Sequence Similarity 135 Member B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28029"},{"name":"Maps_To","value":"FAM135B"},{"name":"NCI_META_CUI","value":"CL541537"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C96316":{"preferredName":"TENT5C Gene","code":"C96316","definitions":[{"definition":"This gene is involved in polyadenylation of RNA and mRNA stability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TENT5C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM46C","termGroup":"SY","termSource":"NCI"},{"termName":"TENT5C","termGroup":"SY","termSource":"NCI"},{"termName":"Terminal Nucleotidyltransferase 5C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24712"},{"name":"Maps_To","value":"FAM46C"},{"name":"OMIM_Number","value":"613952"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539445"}]}}{"C143109":{"preferredName":"FAM47C Gene","code":"C143109","definitions":[{"definition":"This gene has no known function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAM47C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM47C","termGroup":"SY","termSource":"NCI"},{"termName":"Family with Sequence Similarity 47 Member C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25301"},{"name":"Maps_To","value":"FAM47C"},{"name":"NCI_META_CUI","value":"CL541534"},{"name":"OMIM_Number","value":"301067"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C85995":{"preferredName":"FANCA Gene","code":"C85995","definitions":[{"definition":"This gene may be involved in the mediation of DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3582"},{"name":"Maps_To","value":"FANCA"},{"name":"OMIM_Number","value":"607139"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414527"}]}}{"C86025":{"preferredName":"FANCC Gene","code":"C86025","definitions":[{"definition":"This gene may play a role in DNA cross-link repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3584"},{"name":"Maps_To","value":"FANCC"},{"name":"OMIM_Number","value":"613899"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414529"}]}}{"C86549":{"preferredName":"FANCD2 Gene","code":"C86549","definitions":[{"definition":"This gene is involved in the regulation of meiosis, DNA repair and the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group D2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCD2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3585"},{"name":"Maps_To","value":"FANCD2"},{"name":"OMIM_Number","value":"613984"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414530"}]}}{"C86551":{"preferredName":"FANCE Gene","code":"C86551","definitions":[{"definition":"This gene plays a role in the regulation of both DNA repair and protein localization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group E Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3586"},{"name":"Maps_To","value":"FANCE"},{"name":"OMIM_Number","value":"613976"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414531"}]}}{"C86553":{"preferredName":"FANCF Gene","code":"C86553","definitions":[{"definition":"This gene may be involved in the regulation of DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group F Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3587"},{"name":"Maps_To","value":"FANCF"},{"name":"OMIM_Number","value":"613897"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414532"}]}}{"C24385":{"preferredName":"FANCG Gene","code":"C24385","definitions":[{"definition":"This gene is involved in the maintenance of genomic integrity and nuclear signal transduction. Allelic variants of the gene are involved in Fanconi syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FANCG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FA Complementation Group G Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FANCG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3588"},{"name":"Legacy Concept Name","value":"FANCG_Gene"},{"name":"Maps_To","value":"FANCG"},{"name":"OMIM_Number","value":"602956"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333532"}]}}{"C21555":{"preferredName":"FAS Gene","code":"C21555","definitions":[{"definition":"This gene is involved in the mediation of cellular surface receptors and apoptotic signals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAS","termGroup":"SY","termSource":"NCI"},{"termName":"Fas Cell Surface Death Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11920"},{"name":"Legacy Concept Name","value":"TNFRSF6_Gene"},{"name":"Maps_To","value":"FAS"},{"name":"OMIM_Number","value":"134637"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539477"}]}}{"C18397":{"preferredName":"FAT1 Gene","code":"C18397","definitions":[{"definition":"This gene is involved in both cellular polarization and cell-cell adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAT","termGroup":"SY","termSource":"NCI"},{"termName":"FAT Atypical Cadherin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAT1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3595"},{"name":"Legacy Concept Name","value":"FAT_Gene"},{"name":"Maps_To","value":"FAT1"},{"name":"OMIM_Number","value":"600976"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812278"}]}}{"C143133":{"preferredName":"FAT3 Gene","code":"C143133","definitions":[{"definition":"This gene is involved in cell adhesion and neurite development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAT Atypical Cadherin 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23112"},{"name":"Maps_To","value":"FAT3"},{"name":"NCI_META_CUI","value":"CL541510"},{"name":"OMIM_Number","value":"612483"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C128254":{"preferredName":"FAT4 Gene","code":"C128254","definitions":[{"definition":"This gene plays a role in planar cell polarity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAT4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAT Atypical Cadherin 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FAT4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23109"},{"name":"Maps_To","value":"FAT4"},{"name":"OMIM_Number","value":"612411"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427920"}]}}{"C143130":{"preferredName":"FBLN2 Gene","code":"C143130","definitions":[{"definition":"This gene plays a role in protein-protein interactions in the extracellular matrix.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FBLN2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FBLN2","termGroup":"SY","termSource":"NCI"},{"termName":"Fibulin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3601"},{"name":"Maps_To","value":"FBLN2"},{"name":"NCI_META_CUI","value":"CL541507"},{"name":"OMIM_Number","value":"135821"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C101104":{"preferredName":"FBXO11 Gene","code":"C101104","definitions":[{"definition":"This gene plays a role in the recognition of proteins to be ubiquitinylated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FBXO11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"F-Box Protein 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FBXO11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13590"},{"name":"Maps_To","value":"FBXO11"},{"name":"OMIM_Number","value":"607871"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422085"}]}}{"C20786":{"preferredName":"FBXW7 Gene","code":"C20786","definitions":[{"definition":"This gene is involved in ubiquitin-dependent proteolysis and regulation of the G1-S cell cycle checkpoint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FBXW7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"F-Box and WD Repeat Domain Containing 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FBXW7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16712"},{"name":"Legacy Concept Name","value":"FBXW7_Gene"},{"name":"Maps_To","value":"FBXW7"},{"name":"OMIM_Number","value":"606278"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333533"}]}}{"C38554":{"preferredName":"FCGR2B Gene","code":"C38554","definitions":[{"definition":"This gene plays a role in the inhibition of immune functions and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FCGR2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Fc Gamma Receptor IIB Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FCGR2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3618"},{"name":"Legacy Concept Name","value":"FCGR2B_Gene"},{"name":"Maps_To","value":"FCGR2B"},{"name":"OMIM_Number","value":"604590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414554"}]}}{"C97592":{"preferredName":"FCRL4 Gene","code":"C97592","definitions":[{"definition":"This gene may be involved in B cell receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FCRL4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Fc Receptor-Like 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FCRL4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18507"},{"name":"Maps_To","value":"FCRL4"},{"name":"OMIM_Number","value":"605876"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539514"}]}}{"C98120":{"preferredName":"FEN1 Gene","code":"C98120","definitions":[{"definition":"This gene is involved in DNA replication and repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FEN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FEN1","termGroup":"SY","termSource":"NCI"},{"termName":"Flap Structure-Specific Endonuclease 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3650"},{"name":"Maps_To","value":"FEN1"},{"name":"OMIM_Number","value":"600393"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414583"}]}}{"C45497":{"preferredName":"FES Gene","code":"C45497","definitions":[{"definition":"This gene is involved in hematopoiesis and the maintenance of cellular transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FES Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Feline Sarcoma Oncogene Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FES","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3657"},{"name":"Legacy Concept Name","value":"FES_Gene"},{"name":"Maps_To","value":"FES"},{"name":"OMIM_Number","value":"190030"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414588"}]}}{"C97482":{"preferredName":"FEV Gene","code":"C97482","definitions":[{"definition":"This gene may play a role in transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FEV Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FEV","termGroup":"SY","termSource":"NCI"},{"termName":"FEV Transcription Factor, ETS Family Member Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18562"},{"name":"Maps_To","value":"FEV"},{"name":"OMIM_Number","value":"607150"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425602"}]}}{"C19929":{"preferredName":"FGFR1 Gene","code":"C19929","definitions":[{"definition":"This gene plays a role in mitogenesis and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR1","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 1 (FMS-Related Tyrosine Kinase 2, Pfeiffer Syndrome) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3688"},{"name":"Legacy Concept Name","value":"FGFR1_Gene"},{"name":"Maps_To","value":"FGFR1"},{"name":"OMIM_Number","value":"136350"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919509"}]}}{"C24401":{"preferredName":"CEP43 Gene","code":"C24401","definitions":[{"definition":"This gene is involved in the regulation of cell shape, polarity and motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP43 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 43 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP43","termGroup":"SY","termSource":"NCI"},{"termName":"FGFR1OP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17012"},{"name":"Legacy Concept Name","value":"FGFR1OP_Gene"},{"name":"Maps_To","value":"FGFR1OP"},{"name":"OMIM_Number","value":"605392"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333541"}]}}{"C19931":{"preferredName":"FGFR2 Gene","code":"C19931","definitions":[{"definition":"This gene plays a role in mitogenesis and differentiation and mutations in the gene are associated with craniosynostotic syndromes and bone malformations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR2","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3689"},{"name":"Legacy Concept Name","value":"FGFR2_Gene"},{"name":"Maps_To","value":"FGFR2"},{"name":"OMIM_Number","value":"176943"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333542"}]}}{"C24393":{"preferredName":"FGFR3 Gene","code":"C24393","definitions":[{"definition":"This gene plays a role in bone development and maintenance and mutations in the gene are associated with craniosynostosis and several types of skeletal dysplasia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR3","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3690"},{"name":"Legacy Concept Name","value":"FGFR3_Gene"},{"name":"Maps_To","value":"FGFR3"},{"name":"OMIM_Number","value":"134934"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333543"}]}}{"C20743":{"preferredName":"FGFR4 Gene","code":"C20743","definitions":[{"definition":"This gene plays a role in mitogenesis and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR4","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3691"},{"name":"Legacy Concept Name","value":"FGFR4_Gene"},{"name":"Maps_To","value":"FGFR4"},{"name":"OMIM_Number","value":"134935"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333544"}]}}{"C95268":{"preferredName":"FH Gene","code":"C95268","definitions":[{"definition":"This gene plays a role in the Krebs cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FH Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FH","termGroup":"SY","termSource":"NCI"},{"termName":"Fumarate Hydratase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3700"},{"name":"Maps_To","value":"FH"},{"name":"OMIM_Number","value":"136850"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366530"}]}}{"C18524":{"preferredName":"FHIT Gene","code":"C18524","definitions":[{"definition":"This gene is involved in nucleotide metabolism and cell cycle control.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FHIT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FHIT","termGroup":"SY","termSource":"NCI"},{"termName":"Fragile Histidine Triad Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3701"},{"name":"Legacy Concept Name","value":"FHIT_Gene"},{"name":"Maps_To","value":"FHIT"},{"name":"OMIM_Number","value":"601153"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919457"}]}}{"C97454":{"preferredName":"FIP1L1 Gene","code":"C97454","definitions":[{"definition":"This gene is involved in mRNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FIP1L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FIP1 Like 1 (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FIP1L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19124"},{"name":"Maps_To","value":"FIP1L1"},{"name":"OMIM_Number","value":"607686"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426030"}]}}{"C143127":{"preferredName":"FKBP9 Gene","code":"C143127","definitions":[{"definition":"This gene is involved in chaperone-mediated protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FKBP9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FK506 Binding Protein 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FKBP9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3725"},{"name":"Maps_To","value":"FKBP9"},{"name":"NCI_META_CUI","value":"CL541520"},{"name":"OMIM_Number","value":"616257"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C63514":{"preferredName":"FLCN Gene","code":"C63514","definitions":[{"definition":"This gene may play a role in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLCN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLCN","termGroup":"SY","termSource":"NCI"},{"termName":"Folliculin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:27310"},{"name":"Legacy Concept Name","value":"FLCN_Gene"},{"name":"Maps_To","value":"FLCN"},{"name":"OMIM_Number","value":"607273"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539518"}]}}{"C18321":{"preferredName":"FLI1 Gene","code":"C18321","definitions":[{"definition":"This gene plays a role in transcriptional activation and has been implicated in the pathogenesis of neuroepithelioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLI1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLI1","termGroup":"SY","termSource":"NCI"},{"termName":"Friend Leukemia Virus Integration 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3749"},{"name":"Legacy Concept Name","value":"FLI1_Gene"},{"name":"Maps_To","value":"FLI1"},{"name":"OMIM_Number","value":"193067"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1860424"}]}}{"C113585":{"preferredName":"FLNA Gene","code":"C113585","definitions":[{"definition":"This gene is involved in remodeling of the cytoskeleton.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLNA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Filamin A, Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FLNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3754"},{"name":"Maps_To","value":"FLNA"},{"name":"OMIM_Number","value":"300017"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414635"}]}}{"C24399":{"preferredName":"FLT3 Gene","code":"C24399","definitions":[{"definition":"This gene plays a role in hematopoiesis and may function as a growth factor receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3","termGroup":"SY","termSource":"NCI"},{"termName":"FMS-Related Tyrosine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3765"},{"name":"Legacy Concept Name","value":"FLT3_Gene"},{"name":"Maps_To","value":"FLT3"},{"name":"OMIM_Number","value":"136351"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333568"}]}}{"C24400":{"preferredName":"FLT4 Gene","code":"C24400","definitions":[{"definition":"This gene plays an essential role in the development of embryonic cardiovasculature and lymphatic vessel formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FLT4","termGroup":"SY","termSource":"NCI"},{"termName":"FMS Related Tyrosine Kinase 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3767"},{"name":"Legacy Concept Name","value":"FLT4_Gene"},{"name":"Maps_To","value":"FLT4"},{"name":"OMIM_Number","value":"136352"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333569"}]}}{"C97540":{"preferredName":"FNBP1 Gene","code":"C97540","definitions":[{"definition":"This gene plays a role in endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FNBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FNBP1","termGroup":"SY","termSource":"NCI"},{"termName":"Formin Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17069"},{"name":"Maps_To","value":"FNBP1"},{"name":"OMIM_Number","value":"606191"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424722"}]}}{"C101646":{"preferredName":"FOXA1 Gene","code":"C101646","definitions":[{"definition":"This gene plays a role in the modulation of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box A1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5021"},{"name":"Maps_To","value":"FOXA1"},{"name":"OMIM_Number","value":"602294"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415626"}]}}{"C75472":{"preferredName":"FOXL2 Gene","code":"C75472","definitions":[{"definition":"This gene plays a role in ovarian function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box L2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1092"},{"name":"Legacy Concept Name","value":"FOXL2_Gene"},{"name":"Maps_To","value":"FOXL2"},{"name":"OMIM_Number","value":"605597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412815"}]}}{"C24402":{"preferredName":"FOXO1 Gene","code":"C24402","definitions":[{"definition":"This gene is involved in transcriptional regulation and may play a role in myogenic growth and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXO1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box O1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXO1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3819"},{"name":"Legacy Concept Name","value":"FOXO1A_Gene"},{"name":"Maps_To","value":"FOXO1"},{"name":"OMIM_Number","value":"136533"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333572"}]}}{"C28519":{"preferredName":"FOXO3 Gene","code":"C28519","definitions":[{"definition":"This gene is involved in transcriptional regulation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXO3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box O3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXO3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3821"},{"name":"Legacy Concept Name","value":"FOXO3A_Gene"},{"name":"Maps_To","value":"FOXO3"},{"name":"OMIM_Number","value":"602681"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333573"}]}}{"C24606":{"preferredName":"FOXO4 Gene","code":"C24606","definitions":[{"definition":"This gene plays a role in smooth muscle cell differentiation, cellular growth, cell cycle regulation and tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXO4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box O4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXO4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7139"},{"name":"Legacy Concept Name","value":"MLLT7_Gene"},{"name":"Maps_To","value":"FOXO4"},{"name":"OMIM_Number","value":"300033"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334518"}]}}{"C97549":{"preferredName":"FOXP1 Gene","code":"C97549","definitions":[{"definition":"This gene is involved in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box P1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3823"},{"name":"Maps_To","value":"FOXP1"},{"name":"OMIM_Number","value":"605515"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414688"}]}}{"C143124":{"preferredName":"FOXR1 Gene","code":"C143124","definitions":[{"definition":"This gene plays a role in DNA binding and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FOXR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Forkhead Box R1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FOXR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29980"},{"name":"Maps_To","value":"FOXR1"},{"name":"NCI_META_CUI","value":"CL541517"},{"name":"OMIM_Number","value":"615755"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24408":{"preferredName":"FSTL3 Gene","code":"C24408","definitions":[{"definition":"This gene plays a role in a variety of processes including transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FSTL3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Follistatin-Like 3 (Secreted Glycoprotein) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FSTL3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3973"},{"name":"Legacy Concept Name","value":"FSTL3_Gene"},{"name":"Maps_To","value":"FSTL3"},{"name":"OMIM_Number","value":"605343"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333581"}]}}{"C99614":{"preferredName":"FUBP1 Gene","code":"C99614","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FUBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Far Upstream Element (FUSE) Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FUBP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4004"},{"name":"Maps_To","value":"FUBP1"},{"name":"OMIM_Number","value":"603444"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414855"}]}}{"C91852":{"preferredName":"FUS Gene","code":"C91852","definitions":[{"definition":"This gene is involved in gene expression, genomic integrity and RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FUS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FUS","termGroup":"SY","termSource":"NCI"},{"termName":"FUS RNA Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TLS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4010"},{"name":"Maps_To","value":"FUS"},{"name":"OMIM_Number","value":"137070"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414860"}]}}{"C97562":{"preferredName":"GAS7 Gene","code":"C97562","definitions":[{"definition":"This gene may play a role in neuronal development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GAS7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GAS7","termGroup":"SY","termSource":"NCI"},{"termName":"Growth Arrest Specific 7 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4169"},{"name":"Maps_To","value":"GAS7"},{"name":"OMIM_Number","value":"603127"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414992"}]}}{"C28575":{"preferredName":"GATA1 Gene","code":"C28575","definitions":[{"definition":"This gene is involved in erythropoiesis and transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GATA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GATA Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GATA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4170"},{"name":"Legacy Concept Name","value":"GATA1_Gene"},{"name":"Maps_To","value":"GATA1"},{"name":"OMIM_Number","value":"305371"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333663"}]}}{"C97552":{"preferredName":"GATA2 Gene","code":"C97552","definitions":[{"definition":"This gene is involved in both DNA binding and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GATA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GATA Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GATA2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4171"},{"name":"Maps_To","value":"GATA2"},{"name":"OMIM_Number","value":"137295"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414993"}]}}{"C75492":{"preferredName":"GATA3 Gene","code":"C75492","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GATA3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GATA Binding Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GATA3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4172"},{"name":"Legacy Concept Name","value":"GATA3_Gene"},{"name":"Maps_To","value":"GATA3"},{"name":"OMIM_Number","value":"131320"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414994"}]}}{"C24432":{"preferredName":"GLI1 Gene","code":"C24432","definitions":[{"definition":"This gene plays a regulatory role in transcription and embryonic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GLI1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GLI Family Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GLI1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4317"},{"name":"Legacy Concept Name","value":"GLI_Gene"},{"name":"Maps_To","value":"GLI1"},{"name":"OMIM_Number","value":"165220"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812304"}]}}{"C97522":{"preferredName":"GMPS Gene","code":"C97522","definitions":[{"definition":"This gene plays a role in nucleotide biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GMPS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GMPS","termGroup":"SY","termSource":"NCI"},{"termName":"Guanine Monphosphate Synthetase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4378"},{"name":"Maps_To","value":"GMPS"},{"name":"OMIM_Number","value":"600358"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415137"}]}}{"C89717":{"preferredName":"GNA11 Gene","code":"C89717","definitions":[{"definition":"This gene is involved in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GNA11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"G Protein Subunit Alpha 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GNA11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4379"},{"name":"Maps_To","value":"GNA11"},{"name":"OMIM_Number","value":"139313"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415138"}]}}{"C38316":{"preferredName":"GNAQ Gene","code":"C38316","definitions":[{"definition":"This gene plays a role in signal transduction and is involved in calcium signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GNAQ Gene","termGroup":"PT","termSource":"NCI"},{"termName":"G Protein Subunit Alpha q Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GNAQ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4390"},{"name":"Legacy Concept Name","value":"GNAQ_Gene"},{"name":"Maps_To","value":"GNAQ"},{"name":"OMIM_Number","value":"600998"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333685"}]}}{"C38317":{"preferredName":"GNAS Gene","code":"C38317","definitions":[{"definition":"This gene plays a role in signal transduction and is associated with pituitary tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GNAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GNAS","termGroup":"SY","termSource":"NCI"},{"termName":"GNAS Complex Locus Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GNAS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4392"},{"name":"Legacy Concept Name","value":"GNAS_Gene"},{"name":"Maps_To","value":"GNAS"},{"name":"OMIM_Number","value":"139320"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366550"}]}}{"C97543":{"preferredName":"GOLGA5 Gene","code":"C97543","definitions":[{"definition":"This gene is involved in Golgi maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GOLGA5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GOLGA5","termGroup":"SY","termSource":"NCI"},{"termName":"Golgin A5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4428"},{"name":"Maps_To","value":"GOLGA5"},{"name":"OMIM_Number","value":"606918"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415177"}]}}{"C97546":{"preferredName":"GOPC Gene","code":"C97546","definitions":[{"definition":"This gene plays a role in protein transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GOPC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Golgi-Associated PDZ and Coiled-Coil Motif Containing Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GOPC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17643"},{"name":"Maps_To","value":"GOPC"},{"name":"OMIM_Number","value":"606845"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425021"}]}}{"C88173":{"preferredName":"GPC3 Gene","code":"C88173","definitions":[{"definition":"This gene is involved in heparin sulfate binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GPC3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Glypican 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GPC3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4451"},{"name":"Maps_To","value":"GPC3"},{"name":"OMIM_Number","value":"300037"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415195"}]}}{"C97525":{"preferredName":"GPHN Gene","code":"C97525","definitions":[{"definition":"This gene is involved in vitamin metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GPHN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Gephyrin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GPHN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15465"},{"name":"Maps_To","value":"GPHN"},{"name":"OMIM_Number","value":"603930"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423507"}]}}{"C98146":{"preferredName":"GRIN2A Gene","code":"C98146","definitions":[{"definition":"This gene is involved in the regulation of ion transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GRIN2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GRIN2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4585"},{"name":"Maps_To","value":"GRIN2A"},{"name":"OMIM_Number","value":"138253"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415299"}]}}{"C114529":{"preferredName":"GRM3 Gene","code":"C114529","definitions":[{"definition":"This gene is involved in ligand-depending signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GRM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Glutamate Receptor, Metabotropic 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GRM3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4595"},{"name":"Maps_To","value":"GRM3"},{"name":"OMIM_Number","value":"601115"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415307"}]}}{"C101443":{"preferredName":"H3-3A Gene","code":"C101443","definitions":[{"definition":"This gene is involved in chromatin structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H3-3A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H3-3A","termGroup":"SY","termSource":"NCI"},{"termName":"H3.3 Histone A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H3F3A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4764"},{"name":"Maps_To","value":"H3F3A"},{"name":"OMIM_Number","value":"601128"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415427"}]}}{"C113760":{"preferredName":"H3-3B Gene","code":"C113760","definitions":[{"definition":"This gene plays a role in nucleosome assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H3-3B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H3-3B","termGroup":"SY","termSource":"NCI"},{"termName":"H3.3 Histone B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H3F3B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4765"},{"name":"Maps_To","value":"H3F3B"},{"name":"OMIM_Number","value":"601058"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415428"}]}}{"C97534":{"preferredName":"HERPUD1 Gene","code":"C97534","definitions":[{"definition":"This gene is involved in the response to endoplasmic reticulum stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HERPUD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HERPUD1","termGroup":"SY","termSource":"NCI"},{"termName":"Homocysteine Inducible ER Protein with Ubiquitin Like Domain 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13744"},{"name":"Maps_To","value":"HERPUD1"},{"name":"OMIM_Number","value":"608070"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422179"}]}}{"C101107":{"preferredName":"HEY1 Gene","code":"C101107","definitions":[{"definition":"This gene is involved in both transcription factor binding and transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HEY1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Hes Related Family BHLH Transcription Factor With YRPW Motif 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HEY1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4880"},{"name":"Maps_To","value":"HEY1"},{"name":"OMIM_Number","value":"602953"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415524"}]}}{"C26372":{"preferredName":"HIF1A Gene","code":"C26372","definitions":[{"definition":"This gene plays a role in cardiovascular development and systemic oxygen homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIF1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HIF1A","termGroup":"SY","termSource":"NCI"},{"termName":"Hypoxia-Inducible Factor 1, Alpha Subunit (Basic Helix-Loop-Helix Transcription Factor) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4910"},{"name":"Legacy Concept Name","value":"HIF1A_Gene"},{"name":"Maps_To","value":"HIF1A"},{"name":"OMIM_Number","value":"603348"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333897"}]}}{"C97537":{"preferredName":"HIP1 Gene","code":"C97537","definitions":[{"definition":"This gene plays a role in both vesicle coat formation and endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HIP1","termGroup":"SY","termSource":"NCI"},{"termName":"Huntingtin Interacting Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4913"},{"name":"Maps_To","value":"HIP1"},{"name":"OMIM_Number","value":"601767"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415546"}]}}{"C101732":{"preferredName":"H3C2 Gene","code":"C101732","definitions":[{"definition":"This gene is involved in chromatin structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H3C2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H3 Clustered Histone 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H3C2","termGroup":"SY","termSource":"NCI"},{"termName":"HIST1H3B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4776"},{"name":"Maps_To","value":"HIST1H3B"},{"name":"OMIM_Number","value":"602819"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415439"}]}}{"C68734":{"preferredName":"H4C9 Gene","code":"C68734","definitions":[{"definition":"This gene plays a role in nucleosomal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H4C9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"H4 Clustered Histone 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"H4C9","termGroup":"SY","termSource":"NCI"},{"termName":"HIST1H4I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4793"},{"name":"Legacy Concept Name","value":"HIST1H4I_Gene"},{"name":"Maps_To","value":"HIST1H4I"},{"name":"OMIM_Number","value":"602833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415453"}]}}{"C28585":{"preferredName":"HLA-A Gene","code":"C28585","definitions":[{"definition":"This gene is involved in immune responses and histocompatibility processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-A","termGroup":"SY","termSource":"NCI"},{"termName":"Major Histocompatibility Complex, Class I, A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4931"},{"name":"Legacy Concept Name","value":"HLA-A_Gene"},{"name":"Maps_To","value":"HLA-A"},{"name":"OMIM_Number","value":"142800"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333899"}]}}{"C97556":{"preferredName":"HLF Gene","code":"C97556","definitions":[{"definition":"This gene is involved in both transcriptional regulation and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HLF","termGroup":"SY","termSource":"NCI"},{"termName":"HLF Transcription Factor, PAR BZIP Family Member Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4977"},{"name":"Maps_To","value":"HLF"},{"name":"OMIM_Number","value":"142385"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415594"}]}}{"C20576":{"preferredName":"HMGA1 Gene","code":"C20576","definitions":[{"definition":"This gene plays a role in a number of cellular processes including apoptosis, chromatin organization and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High Mobility Group AT-Hook 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5010"},{"name":"Legacy Concept Name","value":"HMGA1_Gene"},{"name":"Maps_To","value":"HMGA1"},{"name":"OMIM_Number","value":"600701"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333903"}]}}{"C20577":{"preferredName":"HMGA2 Gene","code":"C20577","definitions":[{"definition":"This gene is involved in chromatin organization and regulation of gene transcription. It also plays a role in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High Mobility Group AT-Hook 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGA2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5009"},{"name":"Legacy Concept Name","value":"HMGA2_Gene"},{"name":"Maps_To","value":"HMGA2"},{"name":"OMIM_Number","value":"600698"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333906"}]}}{"C98093":{"preferredName":"HMGN2P46 Gene","code":"C98093","definitions":[{"definition":"This gene may be involved in prostate functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGN2P46 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 46 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGN2P46","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26817"},{"name":"Maps_To","value":"HMGN2P46"},{"name":"OMIM_Number","value":"611314"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428626"}]}}{"C97825":{"preferredName":"HNF1A Gene","code":"C97825","definitions":[{"definition":"This gene plays a role in both DNA binding and transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HNF1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HNF1 Homeobox A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HNF1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11621"},{"name":"Maps_To","value":"HNF1A"},{"name":"OMIM_Number","value":"142410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420631"}]}}{"C97496":{"preferredName":"HNRNPA2B1 Gene","code":"C97496","definitions":[{"definition":"This gene is involved in RNA processing and transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HNRNPA2B1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heterogeneous Nuclear Ribonucleoprotein A2/B1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HNRNPA2B1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5033"},{"name":"Maps_To","value":"HNRNPA2B1"},{"name":"OMIM_Number","value":"600124"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415636"}]}}{"C97493":{"preferredName":"HOOK3 Gene","code":"C97493","definitions":[{"definition":"This gene plays a role in endocytosis and Golgi maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOOK3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Hook Homolog 3 (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOOK3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23576"},{"name":"Maps_To","value":"HOOK3"},{"name":"OMIM_Number","value":"607825"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428139"}]}}{"C97568":{"preferredName":"HOXA11 Gene","code":"C97568","definitions":[{"definition":"This gene is involved in embryologic pattern formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXA11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox A11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXA11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5101"},{"name":"Maps_To","value":"HOXA11"},{"name":"OMIM_Number","value":"142958"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415654"}]}}{"C97571":{"preferredName":"HOXA13 Gene","code":"C97571","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXA13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox A13 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXA13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5102"},{"name":"Maps_To","value":"HOXA13"},{"name":"OMIM_Number","value":"142959"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415655"}]}}{"C24474":{"preferredName":"HOXA9 Gene","code":"C24474","definitions":[{"definition":"This gene plays a role in transcriptional regulation, morphogenesis and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXA9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox A9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXA9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5109"},{"name":"Legacy Concept Name","value":"HOXA9_Gene"},{"name":"Maps_To","value":"HOXA9"},{"name":"OMIM_Number","value":"142956"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333922"}]}}{"C162630":{"preferredName":"HOXB1 Gene","code":"C162630","definitions":[{"definition":"This gene is involved in the development of anterior embryonic structures and facial nerves.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox B1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5111"},{"name":"Maps_To","value":"HOXB1"},{"name":"OMIM_Number","value":"142968"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415663"}]}}{"C97574":{"preferredName":"HOXC11 Gene","code":"C97574","definitions":[{"definition":"This gene is involved in embryological development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXC11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox C11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXC11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5123"},{"name":"Maps_To","value":"HOXC11"},{"name":"OMIM_Number","value":"605559"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415675"}]}}{"C97577":{"preferredName":"HOXC13 Gene","code":"C97577","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXC13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox C13 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXC13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5125"},{"name":"Maps_To","value":"HOXC13"},{"name":"OMIM_Number","value":"142976"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415677"}]}}{"C97580":{"preferredName":"HOXD11 Gene","code":"C97580","definitions":[{"definition":"This gene is involved in limb morphogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXD11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox D11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXD11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5134"},{"name":"Maps_To","value":"HOXD11"},{"name":"OMIM_Number","value":"142986"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415685"}]}}{"C97583":{"preferredName":"HOXD13 Gene","code":"C97583","definitions":[{"definition":"This gene plays a role in the development of limbs and appendages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HOXD13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Homeobox D13 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HOXD13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5136"},{"name":"Maps_To","value":"HOXD13"},{"name":"OMIM_Number","value":"142989"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415687"}]}}{"C17060":{"preferredName":"HRAS Gene","code":"C17060","definitions":[{"definition":"A gene that may cause cancer when it is mutated (changed). The Hras gene makes the HRAS protein, which is involved in cell signaling pathways, cell growth, and apoptosis (cell death). Agents that block the actions of the mutated Hras gene or its protein in cancer cells may stop the growth of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene plays a role in signal transduction and cellular communication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HRAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HRAS","termGroup":"SY","termSource":"NCI"},{"termName":"HRas Proto-Oncogene, GTPase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5173"},{"name":"Legacy Concept Name","value":"HRAS_Gene"},{"name":"Maps_To","value":"HRAS"},{"name":"OMIM_Number","value":"190020"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0079471"}]}}{"C97586":{"preferredName":"HSP90AA1 Gene","code":"C97586","definitions":[{"definition":"This gene is involved in both protein folding and nitric oxide metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HSP90AA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Alpha Family Class A Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90AA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5253"},{"name":"Maps_To","value":"HSP90AA1"},{"name":"OMIM_Number","value":"140571"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825534"}]}}{"C97589":{"preferredName":"HSP90AB1 Gene","code":"C97589","definitions":[{"definition":"This gene plays a role in both interferon signaling and protein folding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HSP90AB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90kDa Alpha (Cytosolic), Class B Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90AB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5258"},{"name":"Maps_To","value":"HSP90AB1"},{"name":"OMIM_Number","value":"140572"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825540"}]}}{"C102968":{"preferredName":"ID3 Gene","code":"C102968","definitions":[{"definition":"This gene plays a role in transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ID3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ID3","termGroup":"SY","termSource":"NCI"},{"termName":"Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5362"},{"name":"Maps_To","value":"ID3"},{"name":"OMIM_Number","value":"600277"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415856"}]}}{"C77215":{"preferredName":"IDH1 Gene","code":"C77215","definitions":[{"definition":"This gene plays a role in carbohydrate metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IDH1","termGroup":"SY","termSource":"NCI"},{"termName":"Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5382"},{"name":"Legacy Concept Name","value":"IDH1_Gene"},{"name":"Maps_To","value":"IDH1"},{"name":"OMIM_Number","value":"147700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415876"}]}}{"C84948":{"preferredName":"IDH2 Gene","code":"C84948","definitions":[{"definition":"This gene plays a role in intermediary metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IDH2","termGroup":"SY","termSource":"NCI"},{"termName":"Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5383"},{"name":"Maps_To","value":"IDH2"},{"name":"OMIM_Number","value":"147650"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415877"}]}}{"C26422":{"preferredName":"Immunoglobulin Heavy Locus","code":"C26422","definitions":[{"definition":"This region represents the germline organization of the immunoglobulin heavy chain locus. The locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Heavy Locus","termGroup":"PT","termSource":"NCI"},{"termName":"IGH","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Heavy Chain Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Heavy Chain Locus","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Heavy Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"3492"},{"name":"GenBank_Accession_Number","value":"NG_001019"},{"name":"Gene_Encodes_Product","value":"Immunoglobulin Heavy Chain"},{"name":"HGNC_ID","value":"HGNC:5477"},{"name":"Legacy Concept Name","value":"Immunoglobulin_Heavy_Locus"},{"name":"Maps_To","value":"IGH"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0017351"}]}}{"C26425":{"preferredName":"Immunoglobulin Kappa Locus","code":"C26425","definitions":[{"definition":"This region represents the germline organization of the kappa light chain locus. The locus includes V (variable), J (joining), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a single V segment with a J segment; the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Kappa Locus","termGroup":"PT","termSource":"NCI"},{"termName":"IGK","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Kappa Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Kappa Light Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"50802"},{"name":"GenBank_Accession_Number","value":"NG_000833"},{"name":"Gene_Encodes_Product","value":"Immunoglobulin Light Chain, Kappa"},{"name":"HGNC_ID","value":"HGNC:5715"},{"name":"Legacy Concept Name","value":"Immunoglobulin_Kappa_Locus"},{"name":"Maps_To","value":"IGK"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366332"}]}}{"C171139":{"preferredName":"IGKC Gene","code":"C171139","definitions":[{"definition":"This gene plays a role in the structure of immunoglobulin light chains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGKC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IGKC","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Kappa Constant Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5716"},{"name":"Maps_To","value":"IGKC"},{"name":"OMIM_Number","value":"147200"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416163"}]}}{"C26423":{"preferredName":"Immunoglobulin Lambda Locus","code":"C26423","definitions":[{"definition":"This region represents the germline organization of the lambda light chain locus. The locus includes V (variable), J (joining), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a single V segment with a J segment; the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Lambda Locus","termGroup":"PT","termSource":"NCI"},{"termName":"IGL","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Lambda Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Lambda Light Chain Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"3535"},{"name":"GenBank_Accession_Number","value":"NG_000002"},{"name":"Gene_Encodes_Product","value":"Immunoglobulin Light Chain, Lambda"},{"name":"HGNC_ID","value":"HGNC:5853"},{"name":"Legacy Concept Name","value":"Immunoglobulin_Lambda_Locus"},{"name":"Maps_To","value":"IGL"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0314619"}]}}{"C96383":{"preferredName":"IKBKB Gene","code":"C96383","definitions":[{"definition":"This gene is involved in protein phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IKBKB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IKBKB","termGroup":"SY","termSource":"NCI"},{"termName":"Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5960"},{"name":"Maps_To","value":"IKBKB"},{"name":"OMIM_Number","value":"603258"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1442489"}]}}{"C68730":{"preferredName":"IKZF1 Gene","code":"C68730","definitions":[{"definition":"This gene is involved in B-cell and T-cell maturation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IKZF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ikaros","termGroup":"SY","termSource":"NCI"},{"termName":"IKAROS Family Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"IKZF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13176"},{"name":"Legacy Concept Name","value":"IKZF1_Gene"},{"name":"Maps_To","value":"IKZF1"},{"name":"OMIM_Number","value":"603023"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825588"}]}}{"C24498":{"preferredName":"IL2 Gene","code":"C24498","definitions":[{"definition":"This gene is involved in growth and lymphokine regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL2","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6001"},{"name":"Legacy Concept Name","value":"IL2_Gene"},{"name":"Maps_To","value":"IL2"},{"name":"OMIM_Number","value":"147680"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879590"}]}}{"C68736":{"preferredName":"IL21R Gene","code":"C68736","definitions":[{"definition":"This gene is involved in cytokine recognition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL21R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL21R","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 21 Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6006"},{"name":"Legacy Concept Name","value":"IL21R_Gene"},{"name":"Maps_To","value":"IL21R"},{"name":"OMIM_Number","value":"605383"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416407"}]}}{"C24505":{"preferredName":"IL6ST Gene","code":"C24505","definitions":[{"definition":"This gene plays a role in signal transduction and is putatively involved in embryonic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL6ST Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL6ST","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 6 Signal Transducer Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6021"},{"name":"Legacy Concept Name","value":"IL6ST_Gene"},{"name":"Maps_To","value":"IL6ST"},{"name":"OMIM_Number","value":"600694"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1325331"}]}}{"C24506":{"preferredName":"IL7R Gene","code":"C24506","definitions":[{"definition":"This gene is involved in the regulation of lymphopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL7R Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL7R","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin 7 Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6024"},{"name":"Legacy Concept Name","value":"IL7R_Gene"},{"name":"Maps_To","value":"IL7R"},{"name":"OMIM_Number","value":"146661"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334123"}]}}{"C18430":{"preferredName":"IRF4 Gene","code":"C18430","definitions":[{"definition":"This gene is involved in the regulation of B-cell differentiation and proliferation. It also plays a role in mediating the proliferation of mitogen-stimulated T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IRF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Interferon Regulatory Factor 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"IRF4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6119"},{"name":"Legacy Concept Name","value":"IRF4_Gene"},{"name":"Maps_To","value":"IRF4"},{"name":"OMIM_Number","value":"601900"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812314"}]}}{"C24524":{"preferredName":"IRS4 Gene","code":"C24524","definitions":[{"definition":"This gene plays a role in signal transduction and ligand binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IRS4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Insulin Receptor Substrate 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"IRS4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6128"},{"name":"Legacy Concept Name","value":"IRS4_Gene"},{"name":"Maps_To","value":"IRS4"},{"name":"OMIM_Number","value":"603510"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334142"}]}}{"C116411":{"preferredName":"ISX Gene","code":"C116411","definitions":[{"definition":"This gene is involved in gene expression regulation in the intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Intestine-Specific Homeobox Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ISX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28084"},{"name":"Maps_To","value":"ISX"},{"name":"OMIM_Number","value":"612019"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825625"}]}}{"C53661":{"preferredName":"ITGAV Gene","code":"C53661","definitions":[{"definition":"This gene plays a role in cell communication and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ITGAV Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Integrin, Alpha V Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ITGAV","termGroup":"SY","termSource":"NCI"},{"termName":"VTNR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6150"},{"name":"Legacy Concept Name","value":"ITGAV_Gene"},{"name":"Maps_To","value":"ITGAV"},{"name":"OMIM_Number","value":"193210"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416494"}]}}{"C24526":{"preferredName":"ITK Gene","code":"C24526","definitions":[{"definition":"This gene is involved in the differentiation and proliferation of T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ITK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"IL2-Inducible T-Cell Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ITK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6171"},{"name":"Legacy Concept Name","value":"ITK_Gene"},{"name":"Maps_To","value":"ITK"},{"name":"OMIM_Number","value":"186973"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367389"}]}}{"C24528":{"preferredName":"JAK1 Gene","code":"C24528","definitions":[{"definition":"This gene plays a role in non-receptor tyrosine protein kinase-mediated signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAK1","termGroup":"SY","termSource":"NCI"},{"termName":"Janus Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6190"},{"name":"Legacy Concept Name","value":"JAK1_Gene"},{"name":"Maps_To","value":"JAK1"},{"name":"OMIM_Number","value":"147795"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334290"}]}}{"C24529":{"preferredName":"JAK2 Gene","code":"C24529","definitions":[{"definition":"This gene is involved in erythropoiesis and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAK2","termGroup":"SY","termSource":"NCI"},{"termName":"Janus Kinase 2 (A Protein Tyrosine Kinase) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6192"},{"name":"Legacy Concept Name","value":"JAK2_Gene"},{"name":"Maps_To","value":"JAK2"},{"name":"OMIM_Number","value":"147796"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334291"}]}}{"C24530":{"preferredName":"JAK3 Gene","code":"C24530","definitions":[{"definition":"This gene plays a role in signal transduction and non-receptor tyrosine protein kinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAK3","termGroup":"SY","termSource":"NCI"},{"termName":"Janus Kinase 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6193"},{"name":"Legacy Concept Name","value":"JAK3_Gene"},{"name":"Maps_To","value":"JAK3"},{"name":"OMIM_Number","value":"600173"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334292"}]}}{"C73542":{"preferredName":"JAZF1 Gene","code":"C73542","definitions":[{"definition":"This gene may be involved in transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAZF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JAZF Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"JAZF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28917"},{"name":"Legacy Concept Name","value":"JAZF1_Gene"},{"name":"Maps_To","value":"JAZF1"},{"name":"OMIM_Number","value":"606246"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825635"}]}}{"C19531":{"preferredName":"JUN Gene","code":"C19531","definitions":[{"definition":"This gene plays a critical role in transcriptional regulation and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JUN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JUN","termGroup":"SY","termSource":"NCI"},{"termName":"Jun Proto-oncogene, AP-1 Transcription Factor Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6204"},{"name":"Legacy Concept Name","value":"JUN_Gene"},{"name":"Maps_To","value":"JUN"},{"name":"OMIM_Number","value":"165160"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0162508"}]}}{"C71429":{"preferredName":"KAT6A Gene","code":"C71429","definitions":[{"definition":"This gene is involved in both histone acetylation and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KAT6A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KAT6A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Acetyltransferase 6A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MOZ","termGroup":"SY","termSource":"NCI"},{"termName":"MYST3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13013"},{"name":"Legacy Concept Name","value":"MYST3_Gene"},{"name":"Maps_To","value":"KAT6A"},{"name":"OMIM_Number","value":"601408"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421709"}]}}{"C71431":{"preferredName":"KAT6B Gene","code":"C71431","definitions":[{"definition":"This gene plays a role in both transcription and histone acetylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KAT6B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"K(Lysine) Acetyltransferase 6B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KAT6B","termGroup":"SY","termSource":"NCI"},{"termName":"MYST4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17582"},{"name":"Legacy Concept Name","value":"MYST4_Gene"},{"name":"Maps_To","value":"KAT6B"},{"name":"OMIM_Number","value":"605880"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425003"}]}}{"C73660":{"preferredName":"KAT7 Gene","code":"C73660","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression through histone acetylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KAT7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"K(Lysine) Acetyltransferase 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KAT7","termGroup":"SY","termSource":"NCI"},{"termName":"MYST2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17016"},{"name":"Legacy Concept Name","value":"MYST2_Gene"},{"name":"Maps_To","value":"KAT7"},{"name":"OMIM_Number","value":"609880"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424687"}]}}{"C95838":{"preferredName":"KCNJ5 Gene","code":"C95838","definitions":[{"definition":"This gene is involved in ion transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KCNJ5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KCNJ5","termGroup":"SY","termSource":"NCI"},{"termName":"Potassium Voltage-Gated Channel Subfamily J Member 5 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6266"},{"name":"Maps_To","value":"KCNJ5"},{"name":"OMIM_Number","value":"600734"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416587"}]}}{"C97595":{"preferredName":"KDM5A Gene","code":"C97595","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDM5A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JARID1A","termGroup":"SY","termSource":"NCI"},{"termName":"KDM5A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine (K)-Specific Demethylase 5A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9886"},{"name":"Maps_To","value":"KDM5A"},{"name":"OMIM_Number","value":"180202"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419288"}]}}{"C97598":{"preferredName":"KDM5C Gene","code":"C97598","definitions":[{"definition":"This gene is involved in histone modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDM5C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KDM5C","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine (K)-Specific Demethylase 5C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11114"},{"name":"Maps_To","value":"KDM5C"},{"name":"OMIM_Number","value":"314690"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539790"}]}}{"C96334":{"preferredName":"KDM6A Gene","code":"C96334","definitions":[{"definition":"This gene is involved in the modulation of histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDM6A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KDM6A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Demethylase 6A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12637"},{"name":"Maps_To","value":"KDM6A"},{"name":"OMIM_Number","value":"300128"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421414"}]}}{"C24532":{"preferredName":"KDR Gene","code":"C24532","definitions":[{"definition":"This gene plays a role in angiogenesis and vascular regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KDR","termGroup":"SY","termSource":"NCI"},{"termName":"Kinase Insert Domain Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6307"},{"name":"Legacy Concept Name","value":"KDR_Gene"},{"name":"Maps_To","value":"KDR"},{"name":"OMIM_Number","value":"191306"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334306"}]}}{"C24410":{"preferredName":"KDSR Gene","code":"C24410","definitions":[{"definition":"This gene plays a role in glycosphingolipid metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KDSR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"3-Ketodihydrosphingosine Reductase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FVT1","termGroup":"SY","termSource":"NCI"},{"termName":"KDSR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4021"},{"name":"Legacy Concept Name","value":"FVT1_Gene"},{"name":"Maps_To","value":"KDSR"},{"name":"OMIM_Number","value":"136440"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333583"}]}}{"C112105":{"preferredName":"KEAP1 Gene","code":"C112105","definitions":[{"definition":"This gene is involved in ubiquitin-mediated protein degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KEAP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KEAP1","termGroup":"SY","termSource":"NCI"},{"termName":"Kelch-Like ECH-Associated Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23177"},{"name":"Maps_To","value":"KEAP1"},{"name":"OMIM_Number","value":"606016"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427969"}]}}{"C98017":{"preferredName":"KIAA1549 Gene","code":"C98017","definitions":[{"definition":"This gene may play a role in brain functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KIAA1549 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIAA1549","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22219"},{"name":"Maps_To","value":"KIAA1549"},{"name":"OMIM_Number","value":"613344"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2681629"}]}}{"C101425":{"preferredName":"KIF5B Gene","code":"C101425","definitions":[{"definition":"This gene is involved in the transport of vesicles along microtubules.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KIF5B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIF5B","termGroup":"SY","termSource":"NCI"},{"termName":"Kinesin Family Member 5B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6324"},{"name":"Maps_To","value":"KIF5B"},{"name":"OMIM_Number","value":"602809"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416639"}]}}{"C18609":{"preferredName":"KIT Gene","code":"C18609","definitions":[{"definition":"This gene plays a role in cellular hematopoiesis and differentiations. Mutations in the gene are associated with several diseases, including acute myelogenous leukemia, gastrointestinal tumors, and mast cell disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KIT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIT","termGroup":"SY","termSource":"NCI"},{"termName":"V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6342"},{"name":"Legacy Concept Name","value":"C-KIT_Gene"},{"name":"Maps_To","value":"KIT"},{"name":"OMIM_Number","value":"164920"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416655"}]}}{"C73449":{"preferredName":"KLF4 Gene","code":"C73449","definitions":[{"definition":"This gene plays a role in gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KLF4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KLF4","termGroup":"SY","termSource":"NCI"},{"termName":"Kruppel Like Factor 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6348"},{"name":"Legacy Concept Name","value":"KLF4_Gene"},{"name":"Maps_To","value":"KLF4"},{"name":"OMIM_Number","value":"602253"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416660"}]}}{"C97448":{"preferredName":"KLF6 Gene","code":"C97448","definitions":[{"definition":"This gene plays a role in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KLF6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KLF6","termGroup":"SY","termSource":"NCI"},{"termName":"Kruppel-Like Factor 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2235"},{"name":"Maps_To","value":"KLF6"},{"name":"OMIM_Number","value":"602053"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537486"}]}}{"C26584":{"preferredName":"KLK2 Gene","code":"C26584","definitions":[{"definition":"This gene plays a role in proteolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KLK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Kallikrein 2, Prostatic Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KLK2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6363"},{"name":"Legacy Concept Name","value":"KLK2_Gene"},{"name":"Maps_To","value":"KLK2"},{"name":"OMIM_Number","value":"147960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334308"}]}}{"C18585":{"preferredName":"KMT2A Gene","code":"C18585","definitions":[{"definition":"This gene is involved in transcriptional regulation and alterations in the gene are associated with acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KMT2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KMT2A","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Methyltransferase 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MLL","termGroup":"SY","termSource":"NCI"},{"termName":"MLL Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7132"},{"name":"Legacy Concept Name","value":"MLL_Gene"},{"name":"Maps_To","value":"KMT2A"},{"name":"OMIM_Number","value":"159555"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919528"}]}}{"C93091":{"preferredName":"KMT2C Gene","code":"C93091","definitions":[{"definition":"This gene plays a role in both methylation and transcriptional regulation","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KMT2C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KMT2C","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Specific Methyltransferase 2C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MLL3","termGroup":"SY","termSource":"NCI"},{"termName":"MLL3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13726"},{"name":"Maps_To","value":"KMT2C"},{"name":"OMIM_Number","value":"606833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422165"}]}}{"C24600":{"preferredName":"KMT2D Gene","code":"C24600","definitions":[{"definition":"This gene plays a role in co-activation of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KMT2D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KMT2D","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine Methyltransferase 2D Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MLL2","termGroup":"SY","termSource":"NCI"},{"termName":"MLL2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7133"},{"name":"Legacy Concept Name","value":"MLL2_Gene"},{"name":"Maps_To","value":"KMT2D"},{"name":"OMIM_Number","value":"602113"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334512"}]}}{"C97378":{"preferredName":"KNL1 Gene","code":"C97378","definitions":[{"definition":"This gene is involved in both signaling and chromosome alignment in mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KNL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CASC5","termGroup":"SY","termSource":"NCI"},{"termName":"Kinetochore Scaffold 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KNL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24054"},{"name":"Maps_To","value":"KNL1"},{"name":"OMIM_Number","value":"609173"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539063"}]}}{"C119652":{"preferredName":"KNSTRN Gene","code":"C119652","definitions":[{"definition":"This gene plays a role in both mitotic spindle formation and chromosome segregation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KNSTRN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Kinetochore-Localized Astrin/SPAG5 Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KNSTRN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30767"},{"name":"Maps_To","value":"KNSTRN"},{"name":"OMIM_Number","value":"614718"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539051"}]}}{"C25785":{"preferredName":"KRAS Gene","code":"C25785","definitions":[{"definition":"A gene that may cause cancer when it is mutated (changed). The Kras gene makes the KRAS protein, which is involved in cell signaling pathways, cell growth, and apoptosis (cell death). Agents that block the activity of the mutated Kras gene or its protein may stop the growth of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"This gene is involved in signal transduction and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KRAS","termGroup":"SY","termSource":"NCI"},{"termName":"KRas Proto-Oncogene, GTPase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6407"},{"name":"Legacy Concept Name","value":"KRAS2_Gene"},{"name":"Maps_To","value":"KRAS"},{"name":"OMIM_Number","value":"190070"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537502"}]}}{"C96457":{"preferredName":"KRT20 Gene","code":"C96457","definitions":[{"definition":"This gene plays a role in the formation of intestinal epithelia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRT20 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Keratin 20 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KRT20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20412"},{"name":"Maps_To","value":"KRT20"},{"name":"OMIM_Number","value":"608218"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426926"}]}}{"C96444":{"preferredName":"KRT7 Gene","code":"C96444","definitions":[{"definition":"This gene plays a role in DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRT7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Keratin 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KRT7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6445"},{"name":"Maps_To","value":"KRT7"},{"name":"OMIM_Number","value":"148059"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416745"}]}}{"C97601":{"preferredName":"KTN1 Gene","code":"C97601","definitions":[{"definition":"This gene plays a role in kinesin function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KTN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Kinectin 1 (Kinesin Receptor) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"KTN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6467"},{"name":"Maps_To","value":"KTN1"},{"name":"OMIM_Number","value":"600381"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416766"}]}}{"C143064":{"preferredName":"LARP4B Gene","code":"C143064","definitions":[{"definition":"This gene is involved in RNA metabolism and translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LARP4B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"La Ribonucleoprotein Domain Family Member 4B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LARP4B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28987"},{"name":"Maps_To","value":"LARP4B"},{"name":"NCI_META_CUI","value":"CL541460"},{"name":"OMIM_Number","value":"616513"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97604":{"preferredName":"LASP1 Gene","code":"C97604","definitions":[{"definition":"This gene is involved in actin-dependent ion transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LASP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LASP1","termGroup":"SY","termSource":"NCI"},{"termName":"LIM and SH3 Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6513"},{"name":"Maps_To","value":"LASP1"},{"name":"OMIM_Number","value":"602920"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416800"}]}}{"C18541":{"preferredName":"LCK Gene","code":"C18541","definitions":[{"definition":"This gene is involved in signal transduction and the development/function of T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LCK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LCK","termGroup":"SY","termSource":"NCI"},{"termName":"LCK Proto-Oncogene, Src Family Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6524"},{"name":"Legacy Concept Name","value":"LCK_Gene"},{"name":"Maps_To","value":"LCK"},{"name":"OMIM_Number","value":"153390"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919477"}]}}{"C21294":{"preferredName":"LCP1 Gene","code":"C21294","definitions":[{"definition":"This gene plays a role in cytoskeletal remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LCP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LCP1","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Cytosolic Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6528"},{"name":"Legacy Concept Name","value":"LCP1_Gene"},{"name":"Maps_To","value":"LCP1"},{"name":"OMIM_Number","value":"153430"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334332"}]}}{"C80032":{"preferredName":"LEF1 Gene","code":"C80032","definitions":[{"definition":"This gene plays a role in both signal transduction and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LEF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LEF1","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoid Enhancer-Binding Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6551"},{"name":"Legacy Concept Name","value":"LEF1_Gene"},{"name":"Maps_To","value":"LEF1"},{"name":"OMIM_Number","value":"153245"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1384617"}]}}{"C97607":{"preferredName":"LHFPL6 Gene","code":"C97607","definitions":[{"definition":"This gene may play a role in cell adhesion or cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LHFPL6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LHFP","termGroup":"SY","termSource":"NCI"},{"termName":"LHFPL Tetraspan Subfamily Member 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LHFPL6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6586"},{"name":"Maps_To","value":"LHFP"},{"name":"OMIM_Number","value":"606710"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416844"}]}}{"C24552":{"preferredName":"LIFR Gene","code":"C24552","definitions":[{"definition":"This gene plays a critical role in cell fate and proliferation in both embryonic and adult cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LIFR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Inhibitory Factor Receptor Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LIFR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6597"},{"name":"Legacy Concept Name","value":"LIFR_Gene"},{"name":"Maps_To","value":"LIFR"},{"name":"OMIM_Number","value":"151443"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334339"}]}}{"C61148":{"preferredName":"LMNA Gene","code":"C61148","definitions":[{"definition":"This gene is involved in the architecture of nuclear membrane construction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMNA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Lamin A/C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LMNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6636"},{"name":"Legacy Concept Name","value":"LMNA_Gene"},{"name":"Maps_To","value":"LMNA"},{"name":"OMIM_Number","value":"150330"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416877"}]}}{"C91263":{"preferredName":"LMO1 Gene","code":"C91263","definitions":[{"definition":"This gene is involved in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMO1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LIM Domain Only 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LMO1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6641"},{"name":"Maps_To","value":"LMO1"},{"name":"OMIM_Number","value":"186921"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416881"}]}}{"C17973":{"preferredName":"LMO2 Gene","code":"C17973","definitions":[{"definition":"This gene plays a crucial role in hematopoietic development and is involved in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMO2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LIM Domain Only 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LMO2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6642"},{"name":"Legacy Concept Name","value":"LMO2_Gene"},{"name":"Maps_To","value":"LMO2"},{"name":"OMIM_Number","value":"180385"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0380093"}]}}{"C97610":{"preferredName":"LPP Gene","code":"C97610","definitions":[{"definition":"This gene may be involved in cell shape and cell motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LPP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LIM Domain Containing Preferred Translocation Partner in Lipoma Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LPP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6679"},{"name":"Maps_To","value":"LPP"},{"name":"OMIM_Number","value":"600700"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416904"}]}}{"C101446":{"preferredName":"LRIG3 Gene","code":"C101446","definitions":[{"definition":"This gene may be involved in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRIG3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Leucine-Rich Repeats and Immunoglobulin-Like Domains 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LRIG3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30991"},{"name":"Maps_To","value":"LRIG3"},{"name":"OMIM_Number","value":"608870"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537590"}]}}{"C111830":{"preferredName":"LRP1B Gene","code":"C111830","definitions":[{"definition":"This gene plays a role in low density lipoprotein metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRP1B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Low Density Lipoprotein Receptor-Related Protein 1B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LRP1B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6693"},{"name":"Maps_To","value":"LRP1B"},{"name":"OMIM_Number","value":"608766"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416913"}]}}{"C122884":{"preferredName":"LSM14A Gene","code":"C122884","definitions":[{"definition":"This gene plays a role in the storage of mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LSM14A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LSM14A","termGroup":"SY","termSource":"NCI"},{"termName":"LSM14A, SCD6 Homolog A (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24489"},{"name":"Maps_To","value":"LSM14A"},{"name":"OMIM_Number","value":"610677"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825913"}]}}{"C24564":{"preferredName":"LYL1 Gene","code":"C24564","definitions":[{"definition":"This gene plays a role in transcriptional regulation and is involved in the pathogenesis of acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LYL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LYL1","termGroup":"SY","termSource":"NCI"},{"termName":"LYL1 Basic Helix-Loop-Helix Family Member Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6734"},{"name":"Legacy Concept Name","value":"LYL1_Gene"},{"name":"Maps_To","value":"LYL1"},{"name":"OMIM_Number","value":"151440"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334354"}]}}{"C128257":{"preferredName":"LZTR1 Gene","code":"C128257","definitions":[{"definition":"This gene may be involved in Golgi stabilization, embryogenesis or transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LZTR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Leucine Zipper Like Transcription Regulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"LZTR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6742"},{"name":"Maps_To","value":"LZTR1"},{"name":"OMIM_Number","value":"600574"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416947"}]}}{"C18417":{"preferredName":"MAF Gene","code":"C18417","definitions":[{"definition":"This gene plays a role in transcriptional regulation and cellular differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAF","termGroup":"SY","termSource":"NCI"},{"termName":"MAF bZIP Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6776"},{"name":"Legacy Concept Name","value":"MAF_Gene"},{"name":"Maps_To","value":"MAF"},{"name":"OMIM_Number","value":"177075"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919481"}]}}{"C97671":{"preferredName":"MAFB Gene","code":"C97671","definitions":[{"definition":"This gene plays a role in both hematopoiesis and transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAFB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAF bZIP Transcription Factor B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MAFB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6408"},{"name":"Maps_To","value":"MAFB"},{"name":"OMIM_Number","value":"608968"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416710"}]}}{"C92696":{"preferredName":"MALAT1 Gene","code":"C92696","definitions":[{"definition":"This gene may play a role in carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MALAT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MALAT1","termGroup":"SY","termSource":"NCI"},{"termName":"Metastasis Associated Lung Adenocarcinoma Transcript 1 (Non-Protein Coding) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29665"},{"name":"Maps_To","value":"MALAT1"},{"name":"OMIM_Number","value":"607924"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537647"}]}}{"C60671":{"preferredName":"MALT1 Gene","code":"C60671","definitions":[{"definition":"This gene plays a role in signal transduction and in the pathology of mucosa-associated lymphoid tissue lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MALT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MALT1","termGroup":"SY","termSource":"NCI"},{"termName":"MALT1 Paracaspase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6819"},{"name":"Legacy Concept Name","value":"MALT1_Gene"},{"name":"Maps_To","value":"MALT1"},{"name":"OMIM_Number","value":"604860"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416991"}]}}{"C95456":{"preferredName":"MAML2 Gene","code":"C95456","definitions":[{"definition":"This gene plays a role in transcriptional regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAML2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAML2","termGroup":"SY","termSource":"NCI"},{"termName":"Mastermind Like Transcriptional Coactivator 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16259"},{"name":"Maps_To","value":"MAML2"},{"name":"OMIM_Number","value":"607537"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424132"}]}}{"C117094":{"preferredName":"MAML3 Gene","code":"C117094","definitions":[{"definition":"This gene plays a role in both transcriptional activation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAML3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAML3","termGroup":"SY","termSource":"NCI"},{"termName":"Mastermind Like Transcriptional Coactivator 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16272"},{"name":"Maps_To","value":"MAML3"},{"name":"OMIM_Number","value":"608991"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424142"}]}}{"C21222":{"preferredName":"MAP2K1 Gene","code":"C21222","definitions":[{"definition":"This gene plays a role in signal transduction and regulation of transcription. It is also involved in cell differentiation, growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP2K1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K1","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6840"},{"name":"Legacy Concept Name","value":"MAP2K1_Gene"},{"name":"Maps_To","value":"MAP2K1"},{"name":"OMIM_Number","value":"176872"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334474"}]}}{"C106606":{"preferredName":"MAP2K2 Gene","code":"C106606","definitions":[{"definition":"This gene plays a role in both protein phosphorylation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP2K2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K2","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6842"},{"name":"Maps_To","value":"MAP2K2"},{"name":"OMIM_Number","value":"601263"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1456385"}]}}{"C97674":{"preferredName":"MAP2K4 Gene","code":"C97674","definitions":[{"definition":"This gene is involved in MAPK signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP2K4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K4","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6844"},{"name":"Maps_To","value":"MAP2K4"},{"name":"OMIM_Number","value":"601335"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417008"}]}}{"C24572":{"preferredName":"MAP3K1 Gene","code":"C24572","definitions":[{"definition":"This gene plays a role in mediating cellular responses to growth factors, metabolic stimuli and mitogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP3K1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP3K1","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6848"},{"name":"Legacy Concept Name","value":"MAP3K1_Gene"},{"name":"Maps_To","value":"MAP3K1"},{"name":"OMIM_Number","value":"600982"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367675"}]}}{"C102523":{"preferredName":"MAP3K13 Gene","code":"C102523","definitions":[{"definition":"This gene is involved in both protein phosphorylation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAP3K13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAP3K13","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase Kinase Kinase 13 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6852"},{"name":"Maps_To","value":"MAP3K13"},{"name":"OMIM_Number","value":"604915"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417012"}]}}{"C21227":{"preferredName":"MAPK1 Gene","code":"C21227","definitions":[{"definition":"This gene plays a role in signal transduction and positive regulation of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAPK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAPK1","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogen-Activated Protein Kinase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6871"},{"name":"Legacy Concept Name","value":"MAPK1_Gene"},{"name":"Maps_To","value":"MAPK1"},{"name":"OMIM_Number","value":"176948"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366882"}]}}{"C18576":{"preferredName":"MAX Gene","code":"C18576","definitions":[{"definition":"This gene is involved in transcriptional regulation and plays a role in the mediation of DNA-protein interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAX Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MAX","termGroup":"SY","termSource":"NCI"},{"termName":"MYC Associated Factor X Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6913"},{"name":"Legacy Concept Name","value":"MAX_Gene"},{"name":"Maps_To","value":"MAX"},{"name":"OMIM_Number","value":"154950"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919516"}]}}{"C132170":{"preferredName":"MB21D2 Gene","code":"C132170","definitions":[{"definition":"This gene plays a role in protein-protein interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MB21D2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mab-21 Domain Containing 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MB21D2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30438"},{"name":"Maps_To","value":"MB21D2"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C3147784"}]}}{"C18345":{"preferredName":"MDM2 Gene","code":"C18345","definitions":[{"definition":"This gene plays a role in several cellular processes related to cellular viability; including the cell cycle and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MDM2","termGroup":"SY","termSource":"NCI"},{"termName":"MDM2 Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6973"},{"name":"Legacy Concept Name","value":"MDM2_Gene"},{"name":"Maps_To","value":"MDM2"},{"name":"OMIM_Number","value":"164785"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812222"}]}}{"C88218":{"preferredName":"MDM4 Gene","code":"C88218","definitions":[{"definition":"This gene plays a role in both cell cycle arrest and the inhibition of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MDM4","termGroup":"SY","termSource":"NCI"},{"termName":"MDM4, p53 Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6974"},{"name":"Maps_To","value":"MDM4"},{"name":"OMIM_Number","value":"602704"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417089"}]}}{"C97615":{"preferredName":"MDS2 Gene","code":"C97615","definitions":[{"definition":"This gene plays a role in myelodysplastic syndrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MDS2","termGroup":"SY","termSource":"NCI"},{"termName":"Myelodysplastic Syndrome 2 Translocation Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29633"},{"name":"Maps_To","value":"MDS2"},{"name":"OMIM_Number","value":"607305"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825956"}]}}{"C18392":{"preferredName":"MECOM Gene","code":"C18392","definitions":[{"definition":"This gene plays a role in transcriptional regulation, histone methylation and leukemogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MECOM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EVI1","termGroup":"SY","termSource":"NCI"},{"termName":"MDS1 and EVI1 Complex Locus Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MECOM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3498"},{"name":"Legacy Concept Name","value":"EVI1_Gene"},{"name":"Maps_To","value":"MECOM"},{"name":"OMIM_Number","value":"165215"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812271"}]}}{"C98210":{"preferredName":"MED12 Gene","code":"C98210","definitions":[{"definition":"This gene plays a role in the regulation of RNA polymerase II-dependent transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MED12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MED12","termGroup":"SY","termSource":"NCI"},{"termName":"Mediator Complex Subunit 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11957"},{"name":"Maps_To","value":"MED12"},{"name":"OMIM_Number","value":"300188"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537677"}]}}{"C18254":{"preferredName":"MEN1 Gene","code":"C18254","definitions":[{"definition":"This gene is involved in transcriptional regulation and has tumor suppressor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MEN1","termGroup":"SY","termSource":"NCI"},{"termName":"Menin 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7010"},{"name":"Legacy Concept Name","value":"MEN1_Gene"},{"name":"Maps_To","value":"MEN1"},{"name":"OMIM_Number","value":"131100"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694884"}]}}{"C18325":{"preferredName":"MET Gene","code":"C18325","definitions":[{"definition":"This gene plays a regulatory role in the modulation of cell-surface receptors and hepatocyte growth factor interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MET","termGroup":"SY","termSource":"NCI"},{"termName":"MET Proto-Oncogene, Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7029"},{"name":"Legacy Concept Name","value":"C-MET_Gene"},{"name":"Maps_To","value":"MET"},{"name":"OMIM_Number","value":"164860"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417123"}]}}{"C21232":{"preferredName":"MGMT Gene","code":"C21232","definitions":[{"definition":"This gene is involved in DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MGMT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MGMT","termGroup":"SY","termSource":"NCI"},{"termName":"O-6-Methylguanine-DNA Methyltransferase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7059"},{"name":"Legacy Concept Name","value":"MGMT_Gene"},{"name":"Maps_To","value":"MGMT"},{"name":"OMIM_Number","value":"156569"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334505"}]}}{"C104651":{"preferredName":"MIB1 Gene","code":"C104651","definitions":[{"definition":"This gene is involved in both ubiquitination and cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MIB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MIB1","termGroup":"SY","termSource":"NCI"},{"termName":"Mindbomb E3 Ubiquitin Protein Ligase 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:21086"},{"name":"Maps_To","value":"MIB1"},{"name":"OMIM_Number","value":"608677"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1537692"}]}}{"C70584":{"preferredName":"MITF Gene","code":"C70584","definitions":[{"definition":"This gene is involved in transcriptional promotion in melanocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MITF Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Melanocyte Inducing Transcription Factor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MITF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7105"},{"name":"Legacy Concept Name","value":"MITF_Gene"},{"name":"Maps_To","value":"MITF"},{"name":"OMIM_Number","value":"156845"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417172"}]}}{"C97296":{"preferredName":"MRTFA Gene","code":"C97296","definitions":[{"definition":"This gene is involved in transcriptional modulation and muscle cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MRTFA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MKL1","termGroup":"SY","termSource":"NCI"},{"termName":"MRTFA","termGroup":"SY","termSource":"NCI"},{"termName":"Myocardin Related Transcription Factor A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14334"},{"name":"Maps_To","value":"MKL1"},{"name":"OMIM_Number","value":"606078"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422572"}]}}{"C97650":{"preferredName":"MLF1 Gene","code":"C97650","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MLF1","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Leukemia Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7125"},{"name":"Maps_To","value":"MLF1"},{"name":"OMIM_Number","value":"601402"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417188"}]}}{"C18482":{"preferredName":"MLH1 Gene","code":"C18482","definitions":[{"definition":"This gene plays a role in DNA mismatch repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MLH1","termGroup":"SY","termSource":"NCI"},{"termName":"MutL Homolog 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7127"},{"name":"Legacy Concept Name","value":"MLH1_Gene"},{"name":"Maps_To","value":"MLH1"},{"name":"OMIM_Number","value":"120436"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879389"}]}}{"C18590":{"preferredName":"PMS1 Gene","code":"C18590","definitions":[{"definition":"This gene is involved in mismatch repair and mutations in the gene result in hereditary non-polyposis colon cancer 3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PMS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MLH2","termGroup":"SY","termSource":"NCI"},{"termName":"PMS1","termGroup":"SY","termSource":"NCI"},{"termName":"PMS1 Postmeiotic Segregation Increased 1 (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9121"},{"name":"Legacy Concept Name","value":"PMS1_Gene"},{"name":"Maps_To","value":"MLH2"},{"name":"Maps_To","value":"PMS1"},{"name":"OMIM_Number","value":"600258"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879390"}]}}{"C24601":{"preferredName":"MLLT1 Gene","code":"C24601","definitions":[{"definition":"This gene is involved in transcriptional regulation as part of the transcription elongation factor complex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ENL","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT1","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT1, Super Elongation Complex Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7134"},{"name":"Legacy Concept Name","value":"MLLT1_Gene"},{"name":"Maps_To","value":"MLLT1"},{"name":"OMIM_Number","value":"159556"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334513"}]}}{"C84461":{"preferredName":"MLLT10 Gene","code":"C84461","definitions":[{"definition":"This gene may be involved in transcriptional regulation through the modulation of histone methyltransferase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF10","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT10","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16063"},{"name":"Maps_To","value":"MLLT10"},{"name":"OMIM_Number","value":"602409"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423947"}]}}{"C97387":{"preferredName":"MLLT11 Gene","code":"C97387","definitions":[{"definition":"This gene is involved in mitochondrial functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF1Q","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT11","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila); Translocated to, 11 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16997"},{"name":"Maps_To","value":"MLLT11"},{"name":"OMIM_Number","value":"604684"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826257"}]}}{"C24603":{"preferredName":"MLLT3 Gene","code":"C24603","definitions":[{"definition":"This gene plays a role in transcriptional regulation and translocations in the gene are associated with leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF9","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT3","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT3 Super Elongation Complex Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7136"},{"name":"Legacy Concept Name","value":"MLLT3_Gene"},{"name":"Maps_To","value":"MLLT3"},{"name":"OMIM_Number","value":"159558"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334515"}]}}{"C24604":{"preferredName":"AFDN Gene","code":"C24604","definitions":[{"definition":"This gene is involved in cell adhesion and cytoskeletal modeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AFDN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF6","termGroup":"SY","termSource":"NCI"},{"termName":"Afadin, Adherens Junction Formation Factor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"AFDN","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7137"},{"name":"Legacy Concept Name","value":"MLLT4_Gene"},{"name":"Maps_To","value":"MLLT4"},{"name":"OMIM_Number","value":"159559"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334516"}]}}{"C24605":{"preferredName":"MLLT6 Gene","code":"C24605","definitions":[{"definition":"This gene is involved in transcriptional regulation and aberrations in the gene are associated with acute leukemias due to chromosomal translocations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MLLT6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AF17","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT6","termGroup":"SY","termSource":"NCI"},{"termName":"MLLT6, PHD Finger Containing Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7138"},{"name":"Legacy Concept Name","value":"MLLT6_Gene"},{"name":"Maps_To","value":"MLLT6"},{"name":"OMIM_Number","value":"600328"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334517"}]}}{"C97618":{"preferredName":"MN1 Gene","code":"C97618","definitions":[{"definition":"This gene is involved in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MN1","termGroup":"SY","termSource":"NCI"},{"termName":"MN1 Proto-Oncogene, Transcriptional Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7180"},{"name":"Maps_To","value":"MN1"},{"name":"OMIM_Number","value":"156100"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417217"}]}}{"C97559":{"preferredName":"MNX1 Gene","code":"C97559","definitions":[{"definition":"This gene plays a role in both the regulation of transcription and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MNX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"HLXB9","termGroup":"SY","termSource":"NCI"},{"termName":"MNX1","termGroup":"SY","termSource":"NCI"},{"termName":"Motor Neuron and Pancreas Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:4979"},{"name":"Maps_To","value":"MNX1"},{"name":"OMIM_Number","value":"142994"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415596"}]}}{"C18411":{"preferredName":"MPL Gene","code":"C18411","definitions":[{"definition":"This gene plays a regulatory role in megakaryocytopoiesis and platelet formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MPL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MPL","termGroup":"SY","termSource":"NCI"},{"termName":"MPL Proto-Oncogene, Thrombopoietin Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7217"},{"name":"Legacy Concept Name","value":"MPL_Gene"},{"name":"Maps_To","value":"MPL"},{"name":"OMIM_Number","value":"159530"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812295"}]}}{"C18481":{"preferredName":"MSH2 Gene","code":"C18481","definitions":[{"definition":"This gene plays a role in DNA mismatch repair mutations in the gene result in hereditary nonpolyposis colorectal cancer-1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MSH2","termGroup":"SY","termSource":"NCI"},{"termName":"MutS Homolog 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7325"},{"name":"Legacy Concept Name","value":"MSH2_Gene"},{"name":"Maps_To","value":"MSH2"},{"name":"OMIM_Number","value":"609309"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879290"}]}}{"C19195":{"preferredName":"MSH6 Gene","code":"C19195","definitions":[{"definition":"This gene is involved in mismatch repair and plays a role in several cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSH6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MSH6","termGroup":"SY","termSource":"NCI"},{"termName":"MutS Homolog 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7329"},{"name":"Legacy Concept Name","value":"MSH6_Gene"},{"name":"Maps_To","value":"MSH6"},{"name":"OMIM_Number","value":"600678"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879393"}]}}{"C91356":{"preferredName":"MSI2 Gene","code":"C91356","definitions":[{"definition":"This gene is involved in translational regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSI2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MSI2","termGroup":"SY","termSource":"NCI"},{"termName":"Musashi RNA Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18585"},{"name":"Maps_To","value":"MSI2"},{"name":"OMIM_Number","value":"607897"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425623"}]}}{"C97621":{"preferredName":"MSN Gene","code":"C97621","definitions":[{"definition":"This gene plays a role in both cell adhesion and cytoskeleton modeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MSN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Moesin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MSN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7373"},{"name":"Maps_To","value":"MSN"},{"name":"OMIM_Number","value":"309845"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417371"}]}}{"C24617":{"preferredName":"MTCP1 Gene","code":"C24617","definitions":[{"definition":"This gene plays a role in the proliferation of T cells and is involved in cell cycle regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MTCP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mature T-Cell Proliferation 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MTCP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7423"},{"name":"Legacy Concept Name","value":"MTCP1_Gene"},{"name":"Maps_To","value":"MTCP1"},{"name":"OMIM_Number","value":"300116"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334535"}]}}{"C38928":{"preferredName":"MTOR Gene","code":"C38928","definitions":[{"definition":"This gene plays a role in apoptosis, cell growth, differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MTOR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mechanistic Target of Rapamycin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MTOR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:3942"},{"name":"Legacy Concept Name","value":"FRAP1_Gene"},{"name":"Maps_To","value":"MTOR"},{"name":"OMIM_Number","value":"601231"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1414805"}]}}{"C38939":{"preferredName":"MUC1 Gene","code":"C38939","definitions":[{"definition":"This gene plays a role in cellular signal transduction and is used as a biomarker for breast cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MUC1","termGroup":"SY","termSource":"NCI"},{"termName":"Mucin 1, Cell Surface Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7508"},{"name":"Legacy Concept Name","value":"MUC1_Gene"},{"name":"Maps_To","value":"MUC1"},{"name":"OMIM_Number","value":"158340"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417490"}]}}{"C71018":{"preferredName":"MUC16 Gene","code":"C71018","definitions":[{"definition":"This gene is involved in both cellular adhesion and the maintenance of mucosal surfaces.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC16 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MUC16","termGroup":"SY","termSource":"NCI"},{"termName":"Mucin 16, Cell Surface Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15582"},{"name":"Legacy Concept Name","value":"MUC16_Gene"},{"name":"Maps_To","value":"MUC16"},{"name":"OMIM_Number","value":"606154"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423594"}]}}{"C128854":{"preferredName":"MUC4 Gene","code":"C128854","definitions":[{"definition":"This gene is involved in both cell adhesion and receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MUC4","termGroup":"SY","termSource":"NCI"},{"termName":"Mucin 4, Cell Surface Associated Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7514"},{"name":"Maps_To","value":"MUC4"},{"name":"OMIM_Number","value":"158372"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417496"}]}}{"C61056":{"preferredName":"MUTYH Gene","code":"C61056","definitions":[{"definition":"This gene plays a role in the repair of oxidative DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUTYH Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MutY DNA Glycosylase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MUTYH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7527"},{"name":"Legacy Concept Name","value":"MUTYH_Gene"},{"name":"Maps_To","value":"MUTYH"},{"name":"OMIM_Number","value":"604933"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417505"}]}}{"C28569":{"preferredName":"MYB Gene","code":"C28569","definitions":[{"definition":"This gene plays a role in hematopoietic cell proliferation and development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYB","termGroup":"SY","termSource":"NCI"},{"termName":"MYB Proto-Oncogene, Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7545"},{"name":"Legacy Concept Name","value":"MYB_Gene"},{"name":"Maps_To","value":"MYB"},{"name":"OMIM_Number","value":"189990"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0751994"}]}}{"C16887":{"preferredName":"MYC Gene","code":"C16887","definitions":[{"definition":"This gene plays a role in cell cycle progression and apoptosis. Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYC","termGroup":"SY","termSource":"NCI"},{"termName":"v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7553"},{"name":"Legacy Concept Name","value":"MYC_Gene"},{"name":"Maps_To","value":"MYC"},{"name":"OMIM_Number","value":"190080"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0086661"}]}}{"C18407":{"preferredName":"MYCL Gene","code":"C18407","definitions":[{"definition":"This gene is involved in transcriptional regulation and is frequently amplified in small-cell lung cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYCL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LMYC","termGroup":"SY","termSource":"NCI"},{"termName":"MYCL","termGroup":"SY","termSource":"NCI"},{"termName":"MYCL Proto-Oncogene, bHLH Transcription Factor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"MYCL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7555"},{"name":"Legacy Concept Name","value":"LMYC_Gene"},{"name":"Maps_To","value":"MYCL"},{"name":"OMIM_Number","value":"164850"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812289"}]}}{"C18405":{"preferredName":"MYCN Gene","code":"C18405","definitions":[{"definition":"This gene is involved in transcriptional regulation and amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYCN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYCN","termGroup":"SY","termSource":"NCI"},{"termName":"MYCN Proto-Oncogene, bHLH Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7559"},{"name":"Legacy Concept Name","value":"NMYC_Gene"},{"name":"Maps_To","value":"MYCN"},{"name":"NCI_META_CUI","value":"CL414356"},{"name":"OMIM_Number","value":"164840"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C90089":{"preferredName":"MYD88 Gene","code":"C90089","definitions":[{"definition":"This gene is involved in the modulation of proinflammatory gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYD88 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYD88","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Differentiation Primary Response 88 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7562"},{"name":"Maps_To","value":"MYD88"},{"name":"OMIM_Number","value":"602170"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417530"}]}}{"C29957":{"preferredName":"MYH11 Gene","code":"C29957","definitions":[{"definition":"This gene plays a regulatory role in muscle contraction and the required ATP hydrolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYH11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYH11","termGroup":"SY","termSource":"NCI"},{"termName":"Myosin Heavy Chain 11 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7569"},{"name":"Legacy Concept Name","value":"MYH11_Gene"},{"name":"Maps_To","value":"MYH11"},{"name":"OMIM_Number","value":"160745"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334538"}]}}{"C97646":{"preferredName":"MYH9 Gene","code":"C97646","definitions":[{"definition":"This gene is involved in both cytoskeleton modeling and cytokinesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYH9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYH9","termGroup":"SY","termSource":"NCI"},{"termName":"Myosin Heavy Chain 9 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7579"},{"name":"Maps_To","value":"MYH9"},{"name":"OMIM_Number","value":"160775"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417544"}]}}{"C122881":{"preferredName":"MYO5A Gene","code":"C122881","definitions":[{"definition":"This gene is involved in vesicle transport along actin filaments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYO5A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYO5A","termGroup":"SY","termSource":"NCI"},{"termName":"Myosin VA (Heavy Chain 12, Myoxin) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7602"},{"name":"Maps_To","value":"MYO5A"},{"name":"OMIM_Number","value":"160777"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417565"}]}}{"C93113":{"preferredName":"MYOD1 Gene","code":"C93113","definitions":[{"definition":"This gene plays a role in DNA binding and myogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYOD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MYOD1","termGroup":"SY","termSource":"NCI"},{"termName":"Myogenic Differentiation 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7611"},{"name":"Maps_To","value":"MYOD1"},{"name":"OMIM_Number","value":"159970"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417574"}]}}{"C122903":{"preferredName":"NAB2 Gene","code":"C122903","definitions":[{"definition":"This gene plays a role in the repression of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NAB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NAB2","termGroup":"SY","termSource":"NCI"},{"termName":"NGFI-A Binding Protein 2 (EGR1 Binding Protein 2) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7627"},{"name":"Maps_To","value":"NAB2"},{"name":"OMIM_Number","value":"602381"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417589"}]}}{"C97653":{"preferredName":"NACA Gene","code":"C97653","definitions":[{"definition":"This gene plays a role in protein sorting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NACA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NACA","termGroup":"SY","termSource":"NCI"},{"termName":"Nascent Polypeptide Associated Complex Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7629"},{"name":"Maps_To","value":"NACA"},{"name":"OMIM_Number","value":"601234"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417590"}]}}{"C143075":{"preferredName":"NBEA Gene","code":"C143075","definitions":[{"definition":"This gene plays a role in membrane-targeting of protein kinase A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NBEA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NBEA","termGroup":"SY","termSource":"NCI"},{"termName":"Neurobeachin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7648"},{"name":"Maps_To","value":"NBEA"},{"name":"NCI_META_CUI","value":"CL541563"},{"name":"OMIM_Number","value":"604889"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C21178":{"preferredName":"NBN Gene","code":"C21178","definitions":[{"definition":"This gene plays a role in DNA repair and cell cycle checkpoints.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NBN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NBN","termGroup":"SY","termSource":"NCI"},{"termName":"Nibrin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7652"},{"name":"Legacy Concept Name","value":"NBS1_Gene"},{"name":"Maps_To","value":"NBN"},{"name":"OMIM_Number","value":"602667"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334862"}]}}{"C97433":{"preferredName":"NCKIPSD Gene","code":"C97433","definitions":[{"definition":"This gene plays a role in stress fiber formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCKIPSD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCK Interacting Protein with SH3 Domain Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NCKIPSD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15486"},{"name":"Maps_To","value":"NCKIPSD"},{"name":"OMIM_Number","value":"606671"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423524"}]}}{"C20695":{"preferredName":"NCOA1 Gene","code":"C20695","definitions":[{"definition":"This gene plays a role in regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOA1","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Coactivator 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7668"},{"name":"Legacy Concept Name","value":"NCOA1_Gene"},{"name":"Maps_To","value":"NCOA1"},{"name":"OMIM_Number","value":"602691"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334866"}]}}{"C20697":{"preferredName":"NCOA2 Gene","code":"C20697","definitions":[{"definition":"This gene is involved in regulation of transcription. It also plays a role in myogenic differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOA2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOA2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Coactivator 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7669"},{"name":"Legacy Concept Name","value":"NCOA2_Gene"},{"name":"Maps_To","value":"NCOA2"},{"name":"OMIM_Number","value":"601993"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334867"}]}}{"C18381":{"preferredName":"NCOA4 Gene","code":"C18381","definitions":[{"definition":"This gene is involved in the transcriptional activation of target genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOA4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOA4","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Coactivator 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7671"},{"name":"Legacy Concept Name","value":"NCOA4_Gene"},{"name":"Maps_To","value":"NCOA4"},{"name":"OMIM_Number","value":"601984"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812260"}]}}{"C28640":{"preferredName":"NCOR1 Gene","code":"C28640","definitions":[{"definition":"This gene is involved in chromatin remodeling and repression of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOR1","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Co-Repressor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7672"},{"name":"Legacy Concept Name","value":"NCOR1_Gene"},{"name":"Maps_To","value":"NCOR1"},{"name":"OMIM_Number","value":"600849"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334870"}]}}{"C28633":{"preferredName":"NCOR2 Gene","code":"C28633","definitions":[{"definition":"This gene plays a role in repression of transcription. It is also involved in chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NCOR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NCOR2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Co-Repressor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7673"},{"name":"Legacy Concept Name","value":"NCOR2_Gene"},{"name":"Maps_To","value":"NCOR2"},{"name":"OMIM_Number","value":"600848"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334871"}]}}{"C24625":{"preferredName":"NDRG1 Gene","code":"C24625","definitions":[{"definition":"This gene plays a role in cellular stress responses. It is also involved in both cell growth and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NDRG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"N-myc Downstream Regulated Gene 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NDRG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7679"},{"name":"Legacy Concept Name","value":"NDRG1_Gene"},{"name":"Maps_To","value":"NDRG1"},{"name":"OMIM_Number","value":"605262"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334873"}]}}{"C17424":{"preferredName":"NF1 Gene","code":"C17424","definitions":[{"definition":"This gene plays a role in signal transduction and cytoskeletal remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibromin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7765"},{"name":"Legacy Concept Name","value":"NF1_Gene"},{"name":"Maps_To","value":"NF1"},{"name":"OMIM_Number","value":"162200"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0085113"}]}}{"C17425":{"preferredName":"NF2 Gene","code":"C17425","definitions":[{"definition":"This gene plays a role in cell adhesion and cytoskeletal remodeling. It is also involved in suppression of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurofibromin 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NF2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7773"},{"name":"Legacy Concept Name","value":"NF2_Gene"},{"name":"Maps_To","value":"NF2"},{"name":"OMIM_Number","value":"607379"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0085114"}]}}{"C93138":{"preferredName":"NFATC2 Gene","code":"C93138","definitions":[{"definition":"This gene is involved in cytokine gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFATC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFATC2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor of Activated T Cells 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7776"},{"name":"Maps_To","value":"NFATC2"},{"name":"OMIM_Number","value":"600490"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417695"}]}}{"C54237":{"preferredName":"NFE2L2 Gene","code":"C54237","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFE2L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFE2L2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor (Erythroid-Derived 2)-Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7782"},{"name":"Legacy Concept Name","value":"NFE2L2_Gene"},{"name":"Maps_To","value":"NFE2L2"},{"name":"OMIM_Number","value":"600492"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417701"}]}}{"C38401":{"preferredName":"NFIB Gene","code":"C38401","definitions":[{"definition":"This gene plays a role in transcriptional regulation and mediates DNA-binding interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFIB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFIB","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor I/B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7785"},{"name":"Legacy Concept Name","value":"NFIB_Gene"},{"name":"Maps_To","value":"NFIB"},{"name":"OMIM_Number","value":"600728"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417704"}]}}{"C18404":{"preferredName":"NFKB2 Gene","code":"C18404","definitions":[{"definition":"This gene plays a role in transcriptional regulation, signal transduction and inflammatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFKB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFKB2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Factor Kappa B Subunit 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7795"},{"name":"Legacy Concept Name","value":"NFKB2_Gene"},{"name":"Maps_To","value":"NFKB2"},{"name":"OMIM_Number","value":"164012"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812286"}]}}{"C38396":{"preferredName":"NFKBIE Gene","code":"C38396","definitions":[{"definition":"This gene plays a role in signal transduction and regulation of transcription. It is involved in the immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NFKBIE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NFKB Inhibitor Epsilon Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NFKBIE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7799"},{"name":"Legacy Concept Name","value":"NFKBIE_Gene"},{"name":"Maps_To","value":"NFKBIE"},{"name":"OMIM_Number","value":"604548"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417710"}]}}{"C97668":{"preferredName":"NIN Gene","code":"C97668","definitions":[{"definition":"This gene is involved in the localization of the centrosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NIN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NIN","termGroup":"SY","termSource":"NCI"},{"termName":"Ninein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14906"},{"name":"Maps_To","value":"NIN"},{"name":"NCI_META_CUI","value":"CL505189"},{"name":"OMIM_Number","value":"608684"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C73443":{"preferredName":"NKX2-1 Gene","code":"C73443","definitions":[{"definition":"This gene plays a role in thyroid gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NKX2-1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NK2 Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NKX2-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11825"},{"name":"Legacy Concept Name","value":"NKX2-1_Gene"},{"name":"Maps_To","value":"NKX2-1"},{"name":"OMIM_Number","value":"600635"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1384616"}]}}{"C71419":{"preferredName":"NONO Gene","code":"C71419","definitions":[{"definition":"This gene may play a role in both transcriptional regulation and nuclear RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NONO Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Non-POU Domain Containing, Octamer-Binding Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NONO","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7871"},{"name":"Legacy Concept Name","value":"NONO_Gene"},{"name":"Maps_To","value":"NONO"},{"name":"OMIM_Number","value":"300084"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417758"}]}}{"C24636":{"preferredName":"NOTCH1 Gene","code":"C24636","definitions":[{"definition":"This gene is involved in intercellular signal transduction that plays a key role in development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NOTCH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Notch 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NOTCH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7881"},{"name":"Legacy Concept Name","value":"NOTCH1_Gene"},{"name":"Maps_To","value":"NOTCH1"},{"name":"OMIM_Number","value":"190198"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334889"}]}}{"C97677":{"preferredName":"NOTCH2 Gene","code":"C97677","definitions":[{"definition":"This gene plays a role in cell-cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NOTCH2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Notch 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NOTCH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7882"},{"name":"Maps_To","value":"NOTCH2"},{"name":"OMIM_Number","value":"600275"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417767"}]}}{"C21185":{"preferredName":"NPM1 Gene","code":"C21185","definitions":[{"definition":"This gene is involved in the regulation of ribosomal assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NPM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NPM1","termGroup":"SY","termSource":"NCI"},{"termName":"Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7910"},{"name":"Legacy Concept Name","value":"NPM1_Gene"},{"name":"Maps_To","value":"NPM1"},{"name":"OMIM_Number","value":"164040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334894"}]}}{"C96007":{"preferredName":"NR4A3 Gene","code":"C96007","definitions":[{"definition":"This gene is involved in nuclear receptor-dependent modulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NR4A3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NR4A3","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Subfamily 4 Group A Member 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7982"},{"name":"Maps_To","value":"NR4A3"},{"name":"OMIM_Number","value":"600542"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417837"}]}}{"C25786":{"preferredName":"NRAS Gene","code":"C25786","definitions":[{"definition":"This gene plays a role in signal transduction and cell cycle regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NRAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neuroblastoma RAS Viral Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NRAS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7989"},{"name":"Legacy Concept Name","value":"NRAS_Gene"},{"name":"Maps_To","value":"NRAS"},{"name":"OMIM_Number","value":"164790"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0809246"}]}}{"C20174":{"preferredName":"NRG1 Gene","code":"C20174","definitions":[{"definition":"This gene plays a role in cellular differentiation, growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NRG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neuregulin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NRG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7997"},{"name":"Legacy Concept Name","value":"NRG1_Gene"},{"name":"Maps_To","value":"NRG1"},{"name":"OMIM_Number","value":"142445"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367656"}]}}{"C75876":{"preferredName":"NSD1 Gene","code":"C75876","definitions":[{"definition":"This gene is involved in the mediation of histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NSD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NSD1","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Binding SET Domain Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14234"},{"name":"Legacy Concept Name","value":"NSD1_Gene"},{"name":"Maps_To","value":"NSD1"},{"name":"OMIM_Number","value":"606681"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422496"}]}}{"C21416":{"preferredName":"NSD2 Gene","code":"C21416","definitions":[{"definition":"This gene plays a role in histone-lysine methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NSD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NSD2","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Binding SET Domain Protein 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WHSC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12766"},{"name":"Legacy Concept Name","value":"WHSC1_Gene"},{"name":"Maps_To","value":"NSD2"},{"name":"OMIM_Number","value":"602952"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421505"}]}}{"C96341":{"preferredName":"NSD3 Gene","code":"C96341","definitions":[{"definition":"This gene is involved in histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NSD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"NSD3","termGroup":"SY","termSource":"NCI"},{"termName":"Nuclear Receptor Binding SET Domain Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WHSC1L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12767"},{"name":"Maps_To","value":"NSD3"},{"name":"OMIM_Number","value":"607083"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421506"}]}}{"C104587":{"preferredName":"NT5C2 Gene","code":"C104587","definitions":[{"definition":"This gene plays a role in purine metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NT5C2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"5'-Nucleotidase, Cytosolic II Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NT5C2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8022"},{"name":"Maps_To","value":"NT5C2"},{"name":"OMIM_Number","value":"600417"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417862"}]}}{"C106190":{"preferredName":"NTHL1 Gene","code":"C106190","definitions":[{"definition":"This gene plays a role in nucleotide-excision DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NTHL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nth Like DNA Glycosylase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NTHL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8028"},{"name":"Maps_To","value":"NTHL1"},{"name":"OMIM_Number","value":"602656"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417867"}]}}{"C18551":{"preferredName":"NTRK1 Gene","code":"C18551","definitions":[{"definition":"This gene is involved in cellular differentiation and neurotrophic functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NTRK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurotrophic Receptor Tyrosine Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NTRK1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8031"},{"name":"Legacy Concept Name","value":"NTRK1_Gene"},{"name":"Maps_To","value":"NTRK1"},{"name":"OMIM_Number","value":"191315"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919487"}]}}{"C24647":{"preferredName":"NTRK3 Gene","code":"C24647","definitions":[{"definition":"This gene plays a role in neuronal development and cellular differentiation. Mutations in the gene are associated with medulloblastomas, secretory breast carcinomas and other cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NTRK3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Neurotrophic Receptor Tyrosine Kinase 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NTRK3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8033"},{"name":"Legacy Concept Name","value":"NTRK3_Gene"},{"name":"Maps_To","value":"NTRK3"},{"name":"OMIM_Number","value":"191316"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334910"}]}}{"C24648":{"preferredName":"NUMA1 Gene","code":"C24648","definitions":[{"definition":"This gene plays an essential role in normal mitosis. It is also involved in cell organization/biogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUMA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nuclear Mitotic Apparatus Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUMA1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8059"},{"name":"Legacy Concept Name","value":"NUMA1_Gene"},{"name":"Maps_To","value":"NUMA1"},{"name":"OMIM_Number","value":"164009"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334911"}]}}{"C24649":{"preferredName":"NUP214 Gene","code":"C24649","definitions":[{"definition":"This gene plays a critical role in nuclear transport and docking regulation. Alterations in the gene have been associated with several cancers and leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUP214 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleoporin 214 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUP214","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8064"},{"name":"Legacy Concept Name","value":"NUP214_Gene"},{"name":"Maps_To","value":"NUP214"},{"name":"OMIM_Number","value":"114350"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334912"}]}}{"C20820":{"preferredName":"NUP98 Gene","code":"C20820","definitions":[{"definition":"This gene plays a role in transport and is frequently overexpressed in prostate cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUP98 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleoporin 98 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUP98","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8068"},{"name":"Legacy Concept Name","value":"NUP98_Gene"},{"name":"Maps_To","value":"NUP98"},{"name":"OMIM_Number","value":"601021"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334913"}]}}{"C92705":{"preferredName":"NUTM1 Gene","code":"C92705","definitions":[{"definition":"This gene may be involved in testicular function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUTM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C15orf55","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Midline Carcinoma Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUTM1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29919"},{"name":"Maps_To","value":"NUTM1"},{"name":"OMIM_Number","value":"608963"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1837033"}]}}{"C101098":{"preferredName":"NUTM2A Gene","code":"C101098","definitions":[{"definition":"This gene has an unknown function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUTM2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM22A","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Family Member 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUTM2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23438"},{"name":"Maps_To","value":"NUTM2A"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C3541493"}]}}{"C101101":{"preferredName":"NUTM2B Gene","code":"C101101","definitions":[{"definition":"The function of this gene is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NUTM2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FAM22B","termGroup":"SY","termSource":"NCI"},{"termName":"NUT Family Member 2B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"NUTM2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23445"},{"name":"Maps_To","value":"NUTM2B"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539399"}]}}{"C68575":{"preferredName":"OLIG2 Gene","code":"C68575","definitions":[{"definition":"This gene is involved in transcriptional regulation and oligodendrocyte and motor neuron differentiation. This gene may play a role in the development of brain tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OLIG2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"OLIG2","termGroup":"SY","termSource":"NCI"},{"termName":"Oligodendrocyte Lineage Transcription Factor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9398"},{"name":"Legacy Concept Name","value":"OLIG2_Gene"},{"name":"Maps_To","value":"OLIG2"},{"name":"OMIM_Number","value":"606386"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418915"}]}}{"C97680":{"preferredName":"OMD Gene","code":"C97680","definitions":[{"definition":"This gene is involved in cell adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OMD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"OMD","termGroup":"SY","termSource":"NCI"},{"termName":"Osteomodulin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8134"},{"name":"Maps_To","value":"OMD"},{"name":"OMIM_Number","value":"618926"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417948"}]}}{"C97683":{"preferredName":"P2RY8 Gene","code":"C97683","definitions":[{"definition":"This gene plays a role in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P2RY8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"P2RY8","termGroup":"SY","termSource":"NCI"},{"termName":"P2Y Receptor Family Member 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15524"},{"name":"Maps_To","value":"P2RY8"},{"name":"OMIM_Number","value":"300525"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423554"}]}}{"C143072":{"preferredName":"PABPC1 Gene","code":"C143072","definitions":[{"definition":"This gene is involved in binding to poly(A)RNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PABPC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PABPC1","termGroup":"SY","termSource":"NCI"},{"termName":"Poly(A) Binding Protein Cytoplasmic 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8554"},{"name":"Maps_To","value":"PABPC1"},{"name":"NCI_META_CUI","value":"CL541452"},{"name":"OMIM_Number","value":"604679"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97894":{"preferredName":"PAFAH1B2 Gene","code":"C97894","definitions":[{"definition":"This gene is involved in lipid metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAFAH1B2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PAFAH1B2","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet Activating Factor Acetylhydrolase 1b Catalytic Subunit 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8575"},{"name":"Maps_To","value":"PAFAH1B2"},{"name":"OMIM_Number","value":"602508"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418246"}]}}{"C84945":{"preferredName":"PALB2 Gene","code":"C84945","definitions":[{"definition":"This gene may play a role in the repair of DNA damage that is resolved by recombination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PALB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PALB2","termGroup":"SY","termSource":"NCI"},{"termName":"Partner and Localizer of BRCA2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26144"},{"name":"Maps_To","value":"PALB2"},{"name":"OMIM_Number","value":"610355"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1835898"}]}}{"C97876":{"preferredName":"PATZ1 Gene","code":"C97876","definitions":[{"definition":"This gene is involved in both transcriptional regulation and the modulation of cellular tumor antigen p53-dependent cellular processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PATZ1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PATZ1","termGroup":"SY","termSource":"NCI"},{"termName":"POZ (BTB) and AT Hook Containing Zinc Finger 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF278","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13071"},{"name":"Maps_To","value":"PATZ1"},{"name":"OMIM_Number","value":"605165"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826545"}]}}{"C24658":{"preferredName":"PAX3 Gene","code":"C24658","definitions":[{"definition":"This gene plays a role in the transcriptional activation of target genes. It is involved in melanogenesis, neurogenesis and skeletal muscle development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box Gene 3 (Waardenburg Syndrome 1) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8617"},{"name":"Legacy Concept Name","value":"PAX3_Gene"},{"name":"Maps_To","value":"PAX3"},{"name":"OMIM_Number","value":"606597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335192"}]}}{"C24659":{"preferredName":"PAX5 Gene","code":"C24659","definitions":[{"definition":"This gene is involved in the transcriptional regulation of target genes. It plays a role in B-cell differentiation, neural development and spermatogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8619"},{"name":"Legacy Concept Name","value":"PAX5_Gene"},{"name":"Maps_To","value":"PAX5"},{"name":"OMIM_Number","value":"167414"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335193"}]}}{"C24660":{"preferredName":"PAX7 Gene","code":"C24660","definitions":[{"definition":"This gene plays a role in the transcriptional regulation of target genes. It is involved in pattern formation during embryogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8621"},{"name":"Legacy Concept Name","value":"PAX7_Gene"},{"name":"Maps_To","value":"PAX7"},{"name":"OMIM_Number","value":"167410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335194"}]}}{"C97687":{"preferredName":"PAX8 Gene","code":"C97687","definitions":[{"definition":"This gene is involved in thyroid development and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAX8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Box 8 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PAX8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8622"},{"name":"Maps_To","value":"PAX8"},{"name":"OMIM_Number","value":"167415"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418277"}]}}{"C95438":{"preferredName":"PBRM1 Gene","code":"C95438","definitions":[{"definition":"This gene plays a role in chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PBRM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PBRM1","termGroup":"SY","termSource":"NCI"},{"termName":"Polybromo 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30064"},{"name":"Maps_To","value":"PBRM1"},{"name":"OMIM_Number","value":"606083"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1853685"}]}}{"C97317":{"preferredName":"PBX1 Gene","code":"C97317","definitions":[{"definition":"This gene plays a role in the modulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PBX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PBX1","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-B-Cell Leukemia Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8632"},{"name":"Maps_To","value":"PBX1"},{"name":"OMIM_Number","value":"176310"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418285"}]}}{"C95865":{"preferredName":"PCBP1 Gene","code":"C95865","definitions":[{"definition":"This gene plays a role in RNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PCBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PCBP1","termGroup":"SY","termSource":"NCI"},{"termName":"Poly(rC)-Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8647"},{"name":"Maps_To","value":"PCBP1"},{"name":"OMIM_Number","value":"601209"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418297"}]}}{"C97900":{"preferredName":"PCM1 Gene","code":"C97900","definitions":[{"definition":"This gene is involved in centrosome formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PCM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PCM1","termGroup":"SY","termSource":"NCI"},{"termName":"Pericentriolar Material 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8727"},{"name":"Maps_To","value":"PCM1"},{"name":"OMIM_Number","value":"600299"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418374"}]}}{"C45437":{"preferredName":"PDCD1LG2 Gene","code":"C45437","definitions":[{"definition":"This gene plays a role in the regulation of T-cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDCD1LG2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDCD1LG2","termGroup":"SY","termSource":"NCI"},{"termName":"Programmed Cell Death 1 Ligand 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18731"},{"name":"Legacy Concept Name","value":"PDCD1LG2_Gene"},{"name":"Maps_To","value":"PDCD1LG2"},{"name":"OMIM_Number","value":"605723"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425745"}]}}{"C97718":{"preferredName":"PDE4DIP Gene","code":"C97718","definitions":[{"definition":"This gene plays a role in protein complex localization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDE4DIP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDE4DIP","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphodiesterase 4D Interacting Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15580"},{"name":"Maps_To","value":"PDE4DIP"},{"name":"OMIM_Number","value":"608117"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423592"}]}}{"C18278":{"preferredName":"PDGFB Gene","code":"C18278","definitions":[{"definition":"This gene is involved in cellular growth and proliferation. It is also plays a role in intercellular signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDGFB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDGFB","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet Derived Growth Factor Subunit B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8800"},{"name":"Legacy Concept Name","value":"PDGFB_Gene"},{"name":"Maps_To","value":"PDGFB"},{"name":"OMIM_Number","value":"190040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0751995"}]}}{"C24666":{"preferredName":"PDGFRA Gene","code":"C24666","definitions":[{"definition":"This gene plays a role in mitogenic activities affecting mesenchymal cells and is involved in receptor tyrosine kinase signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDGFRA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDGFRA","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet-Derived Growth Factor Receptor, Alpha Polypeptide Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8803"},{"name":"Legacy Concept Name","value":"PDGFRA_Gene"},{"name":"Maps_To","value":"PDGFRA"},{"name":"OMIM_Number","value":"173490"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335201"}]}}{"C24667":{"preferredName":"PDGFRB Gene","code":"C24667","definitions":[{"definition":"This gene plays a role in mitogenic activities affecting mesenchymal cells and a translocation in the gene results in chronic myelomonocytic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDGFRB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDGFRB","termGroup":"SY","termSource":"NCI"},{"termName":"Platelet-Derived Growth Factor Receptor, Beta Polypeptide Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8804"},{"name":"Legacy Concept Name","value":"PDGFRB_Gene"},{"name":"Maps_To","value":"PDGFRB"},{"name":"OMIM_Number","value":"173410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335202"}]}}{"C97721":{"preferredName":"PER1 Gene","code":"C97721","definitions":[{"definition":"This gene is involved in circadian rhythm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PER1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PER1","termGroup":"SY","termSource":"NCI"},{"termName":"Period Circadian Regulator 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8845"},{"name":"Maps_To","value":"PER1"},{"name":"OMIM_Number","value":"602260"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418464"}]}}{"C28656":{"preferredName":"PGR Gene","code":"C28656","definitions":[{"definition":"This gene plays a role in the signal transduction processes that are involved in pregnancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PGR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PGR","termGroup":"SY","termSource":"NCI"},{"termName":"PR","termGroup":"SY","termSource":"NCI"},{"termName":"Progesterone Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8910"},{"name":"Legacy Concept Name","value":"PGR_Gene"},{"name":"Maps_To","value":"PGR"},{"name":"OMIM_Number","value":"607311"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366500"}]}}{"C101449":{"preferredName":"PHF6 Gene","code":"C101449","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PHF6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PHD Finger Protein 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PHF6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18145"},{"name":"Maps_To","value":"PHF6"},{"name":"OMIM_Number","value":"300414"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425343"}]}}{"C97724":{"preferredName":"PHOX2B Gene","code":"C97724","definitions":[{"definition":"This gene plays a role in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PHOX2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired-Like Homeobox 2b Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PHOX2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9143"},{"name":"Maps_To","value":"PHOX2B"},{"name":"OMIM_Number","value":"603851"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418697"}]}}{"C84434":{"preferredName":"PICALM Gene","code":"C84434","definitions":[{"definition":"This gene plays a role in receptor mediated endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PICALM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol Binding Clathrin Assembly Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PICALM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15514"},{"name":"Maps_To","value":"PICALM"},{"name":"OMIM_Number","value":"603025"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423544"}]}}{"C21220":{"preferredName":"PIK3CA Gene","code":"C21220","definitions":[{"definition":"This gene is involved in second messenger signaling, apoptosis, cell growth and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIK3CA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIK3CA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8975"},{"name":"Legacy Concept Name","value":"PIK3CA_Gene"},{"name":"Maps_To","value":"PIK3CA"},{"name":"OMIM_Number","value":"171834"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335212"}]}}{"C24672":{"preferredName":"PIK3CB Gene","code":"C24672","definitions":[{"definition":"This gene is involved in phosphorylation of phosphatidylinositol derivatives, apoptosis, cell growth and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIK3CB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIK3CB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8976"},{"name":"Legacy Concept Name","value":"PIK3CB_Gene"},{"name":"Maps_To","value":"PIK3CB"},{"name":"OMIM_Number","value":"602925"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335213"}]}}{"C97733":{"preferredName":"PIK3R1 Gene","code":"C97733","definitions":[{"definition":"This gene is involved in phosphoinositol signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIK3R1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIK3R1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8979"},{"name":"Maps_To","value":"PIK3R1"},{"name":"OMIM_Number","value":"171833"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418576"}]}}{"C18337":{"preferredName":"PIM1 Gene","code":"C18337","definitions":[{"definition":"This gene is involved in apoptosis, cell cycle regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Pim-1 Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIM1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8986"},{"name":"Legacy Concept Name","value":"PIM1_Gene"},{"name":"Maps_To","value":"PIM1"},{"name":"OMIM_Number","value":"164960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812214"}]}}{"C71423":{"preferredName":"PLAG1 Gene","code":"C71423","definitions":[{"definition":"This gene is involved in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PLAG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PLAG1","termGroup":"SY","termSource":"NCI"},{"termName":"PLAG1 Zinc Finger Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9045"},{"name":"Legacy Concept Name","value":"PLAG1_Gene"},{"name":"Maps_To","value":"PLAG1"},{"name":"OMIM_Number","value":"603026"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418629"}]}}{"C104821":{"preferredName":"PLCG1 Gene","code":"C104821","definitions":[{"definition":"This gene is involved in both intracellular signaling and second messenger production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PLCG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phospholipase C, Gamma 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PLCG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9065"},{"name":"Maps_To","value":"PLCG1"},{"name":"OMIM_Number","value":"172420"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418640"}]}}{"C24686":{"preferredName":"PML Gene","code":"C24686","definitions":[{"definition":"This gene plays a role in tumor suppression and is involved in the regulation of p53 in response to oncogenic signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PML Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PML","termGroup":"SY","termSource":"NCI"},{"termName":"PML Nuclear Body Scaffold Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9113"},{"name":"Legacy Concept Name","value":"PML_Gene"},{"name":"Maps_To","value":"PML"},{"name":"OMIM_Number","value":"102578"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366903"}]}}{"C18591":{"preferredName":"PMS2 Gene","code":"C18591","definitions":[{"definition":"This gene is involved in mismatch repair and mutations in the gene result in hereditary non-polyposis colon cancer 4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PMS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PMS2","termGroup":"SY","termSource":"NCI"},{"termName":"PMS2 Postmeiotic Segregation Increased 2 (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9122"},{"name":"Legacy Concept Name","value":"PMS2_Gene"},{"name":"Maps_To","value":"PMS2"},{"name":"OMIM_Number","value":"600259"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0879391"}]}}{"C106224":{"preferredName":"POLD1 Gene","code":"C106224","definitions":[{"definition":"This gene is involved in DNA replication and proofreading.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Delta 1, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLD1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9175"},{"name":"Maps_To","value":"POLD1"},{"name":"OMIM_Number","value":"174761"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418727"}]}}{"C106232":{"preferredName":"POLE Gene","code":"C106232","definitions":[{"definition":"This gene is involved in both DNA replication and DNA base-excision repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Epsilon, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9177"},{"name":"Maps_To","value":"POLE"},{"name":"OMIM_Number","value":"174761"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418729"}]}}{"C143069":{"preferredName":"POLG Gene","code":"C143069","definitions":[{"definition":"This gene plays a role in the replication of mitochondrial DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Gamma, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9179"},{"name":"Maps_To","value":"POLG"},{"name":"OMIM_Number","value":"174763"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418731"}]}}{"C131801":{"preferredName":"POLQ Gene","code":"C131801","definitions":[{"definition":"This gene is involved in DNA synthesis and repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POLQ Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Polymerase Theta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POLQ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9186"},{"name":"Maps_To","value":"POLQ"},{"name":"OMIM_Number","value":"604419"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418738"}]}}{"C107655":{"preferredName":"POT1 Gene","code":"C107655","definitions":[{"definition":"This gene plays a role in the regulation of telomere length.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"POT1","termGroup":"SY","termSource":"NCI"},{"termName":"Protection of Telomeres Protein 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17284"},{"name":"Maps_To","value":"POT1"},{"name":"OMIM_Number","value":"606478"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538704"}]}}{"C97730":{"preferredName":"POU2AF1 Gene","code":"C97730","definitions":[{"definition":"This gene is involved in both humoral immunity and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POU2AF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"POU Class 2 Associating Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POU2AF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9211"},{"name":"Maps_To","value":"POU2AF1"},{"name":"OMIM_Number","value":"601206"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418760"}]}}{"C61140":{"preferredName":"POU5F1 Gene","code":"C61140","definitions":[{"definition":"This gene plays a role in early mammalian development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"POU5F1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"POU Class 5 Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"POU5F1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9221"},{"name":"Legacy Concept Name","value":"POU5F1_Gene"},{"name":"Maps_To","value":"POU5F1"},{"name":"OMIM_Number","value":"164177"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418768"}]}}{"C24689":{"preferredName":"PPARG Gene","code":"C24689","definitions":[{"definition":"This gene plays a regulatory role in adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPARG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Peroxisome Proliferator-Activated Receptor Gamma Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PPARG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9236"},{"name":"Legacy Concept Name","value":"PPARG_Gene"},{"name":"Maps_To","value":"PPARG"},{"name":"OMIM_Number","value":"601487"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335238"}]}}{"C101494":{"preferredName":"PPFIBP1 Gene","code":"C101494","definitions":[{"definition":"This gene plays a role in protein-protein interactions and cell-matrix adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPFIBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPFIBP1","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9249"},{"name":"Maps_To","value":"PPFIBP1"},{"name":"OMIM_Number","value":"603141"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418789"}]}}{"C88179":{"preferredName":"PPM1D Gene","code":"C88179","definitions":[{"definition":"This gene plays a role in the modulation of cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPM1D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPM1D","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Phosphatase 1D Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9277"},{"name":"Maps_To","value":"PPM1D"},{"name":"OMIM_Number","value":"605100"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418816"}]}}{"C92536":{"preferredName":"PPP2R1A Gene","code":"C92536","definitions":[{"definition":"This gene plays a role in the regulation of cell growth and division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPP2R1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPP2R1A","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Phosphatase 2 Scaffold Subunit Aalpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9302"},{"name":"Maps_To","value":"PPP2R1A"},{"name":"OMIM_Number","value":"605983"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418837"}]}}{"C102901":{"preferredName":"PPP6C Gene","code":"C102901","definitions":[{"definition":"This gene plays a role in both protein dephosphorylation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPP6C Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PPP6C","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Phosphatase 6, Catalytic Subunit Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9323"},{"name":"Maps_To","value":"PPP6C"},{"name":"OMIM_Number","value":"612725"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418853"}]}}{"C70994":{"preferredName":"PRCC Gene","code":"C70994","definitions":[{"definition":"This gene may be involved in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRCC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Renal Cell Carcinoma (Translocation-Associated) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRCC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9343"},{"name":"Legacy Concept Name","value":"PRCC_Gene"},{"name":"Maps_To","value":"PRCC"},{"name":"OMIM_Number","value":"179755"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418872"}]}}{"C24692":{"preferredName":"PRDM1 Gene","code":"C24692","definitions":[{"definition":"This gene is involved in repression of transcription. It plays a role in the formation of pre-plasma memory B cells and immunoglobulin-secreting plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRDM1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PR/SET Domain 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRDM1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9346"},{"name":"Legacy Concept Name","value":"PRDM1_Gene"},{"name":"Maps_To","value":"PRDM1"},{"name":"OMIM_Number","value":"603423"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335253"}]}}{"C97736":{"preferredName":"PRDM16 Gene","code":"C97736","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRDM16 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PR/SET Domain 16 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRDM16","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14000"},{"name":"Maps_To","value":"PRDM16"},{"name":"OMIM_Number","value":"605557"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422337"}]}}{"C143121":{"preferredName":"PRDM2 Gene","code":"C143121","definitions":[{"definition":"This gene is involved in both methylation of histone H3 and transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRDM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PR/SET Domain 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRDM2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9347"},{"name":"Maps_To","value":"PRDM2"},{"name":"OMIM_Number","value":"601196"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418875"}]}}{"C102517":{"preferredName":"PREX2 Gene","code":"C102517","definitions":[{"definition":"This gene is involved in guanine nucleotide exchange activity that regulates the GTPase activity of Rac family proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PREX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac Exchange Factor 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PREX2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22950"},{"name":"Maps_To","value":"PREX2"},{"name":"OMIM_Number","value":"612139"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427805"}]}}{"C97739":{"preferredName":"PRF1 Gene","code":"C97739","definitions":[{"definition":"This gene is involved in cytolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Perforin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9360"},{"name":"Maps_To","value":"PRF1"},{"name":"OMIM_Number","value":"170280"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418887"}]}}{"C38409":{"preferredName":"PRKACA Gene","code":"C38409","definitions":[{"definition":"This gene is involved in the regulation of diverse cell processes including cell growth, proliferation, differentiation and motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRKACA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PRKACA","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase cAMP-Activated Catalytic Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9380"},{"name":"Legacy Concept Name","value":"PRKACA_Gene"},{"name":"Maps_To","value":"PRKACA"},{"name":"OMIM_Number","value":"601639"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418901"}]}}{"C97742":{"preferredName":"PRKAR1A Gene","code":"C97742","definitions":[{"definition":"This gene plays a role in the regulation of protein kinase A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRKAR1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PRKAR1A","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9388"},{"name":"Maps_To","value":"PRKAR1A"},{"name":"OMIM_Number","value":"188830"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418907"}]}}{"C39597":{"preferredName":"PRKCB Gene","code":"C39597","definitions":[{"definition":"This gene is involved in diverse cell processes such as apoptosis, B cell activation and endothelial cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRKCB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PRKCB","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase C, Beta Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9395"},{"name":"Legacy Concept Name","value":"PRKCB1_Gene"},{"name":"Maps_To","value":"PRKCB"},{"name":"OMIM_Number","value":"176970"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418913"}]}}{"C143090":{"preferredName":"PRPF40B Gene","code":"C143090","definitions":[{"definition":"This gene may be involved in mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRPF40B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Pre-mRNA Processing Factor 40 Homolog B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRPF40B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25031"},{"name":"Maps_To","value":"PRPF40B"},{"name":"NCI_META_CUI","value":"CL541547"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C98030":{"preferredName":"PRRX1 Gene","code":"C98030","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and muscle cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRRX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Paired Related Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PRRX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9142"},{"name":"Maps_To","value":"PRRX1"},{"name":"OMIM_Number","value":"167420"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418696"}]}}{"C20676":{"preferredName":"PSIP1 Gene","code":"C20676","definitions":[{"definition":"This gene is involved in regulation of transcription. It also plays a role in mediation of pre-mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSIP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PC4 and SFRS1 Interacting Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PSIP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9527"},{"name":"Legacy Concept Name","value":"PSIP1_Gene"},{"name":"Maps_To","value":"PSIP1"},{"name":"OMIM_Number","value":"603620"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335268"}]}}{"C18255":{"preferredName":"PTCH1 Gene","code":"C18255","definitions":[{"definition":"This gene is involved in tumor suppression and mutations in this gene have been associated with several cancers and cancer related diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTCH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Patched 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTCH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9585"},{"name":"Legacy Concept Name","value":"PTCH_Gene"},{"name":"Maps_To","value":"PTCH1"},{"name":"OMIM_Number","value":"601309"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826732"}]}}{"C18256":{"preferredName":"PTEN Gene","code":"C18256","definitions":[{"definition":"This gene plays a role in signal transduction and apoptosis. It is also involved in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTEN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatase and Tensin Homolog Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTEN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9588"},{"name":"Legacy Concept Name","value":"PTEN_Gene"},{"name":"Maps_To","value":"PTEN"},{"name":"OMIM_Number","value":"601728"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694888"}]}}{"C24701":{"preferredName":"PTK6 Gene","code":"C24701","definitions":[{"definition":"This gene plays a role in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTK6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PTK6","termGroup":"SY","termSource":"NCI"},{"termName":"PTK6 Protein Tyrosine Kinase 6 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9617"},{"name":"Legacy Concept Name","value":"PTK6_Gene"},{"name":"Maps_To","value":"PTK6"},{"name":"OMIM_Number","value":"602004"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335274"}]}}{"C26337":{"preferredName":"PTPN11 Gene","code":"C26337","definitions":[{"definition":"This gene plays a role in the regulation of cell signaling. It is involved in cell migration, metabolic control, mitogenic activation and gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPN11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPN11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9644"},{"name":"Legacy Concept Name","value":"PTPN11_Gene"},{"name":"Maps_To","value":"PTPN11"},{"name":"OMIM_Number","value":"176876"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335280"}]}}{"C104212":{"preferredName":"PTPN13 Gene","code":"C104212","definitions":[{"definition":"This gene is involved in both protein dephosphorylation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPN13 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Non-Receptor Type 13 (APO-1/CD95 (Fas)-Associated Phosphatase) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPN13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9646"},{"name":"Maps_To","value":"PTPN13"},{"name":"OMIM_Number","value":"600267"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419096"}]}}{"C24708":{"preferredName":"PTPN6 Gene","code":"C24708","definitions":[{"definition":"This gene plays a role in the regulation of multiple signaling pathways in hematopoietic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPN6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Non-Receptor Type 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPN6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9658"},{"name":"Legacy Concept Name","value":"PTPN6_Gene"},{"name":"Maps_To","value":"PTPN6"},{"name":"OMIM_Number","value":"176883"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335283"}]}}{"C122909":{"preferredName":"PTPRB Gene","code":"C122909","definitions":[{"definition":"This gene is involved in dephosphorylation of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type, B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9665"},{"name":"Maps_To","value":"PTPRB"},{"name":"OMIM_Number","value":"176882"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419112"}]}}{"C24711":{"preferredName":"PTPRC Gene","code":"C24711","definitions":[{"definition":"This gene plays a role in suppression of cytokine receptor signaling and the regulation of signal transduction in lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CD45","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9666"},{"name":"Legacy Concept Name","value":"PTPRC_Gene"},{"name":"Maps_To","value":"PTPRC"},{"name":"OMIM_Number","value":"151460"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335285"}]}}{"C106113":{"preferredName":"PTPRK Gene","code":"C106113","definitions":[{"definition":"This gene is involved in receptor signaling, cell-cell contact and cell migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type, K Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9674"},{"name":"Maps_To","value":"PTPRK"},{"name":"OMIM_Number","value":"602545"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419117"}]}}{"C24716":{"preferredName":"PTPRT Gene","code":"C24716","definitions":[{"definition":"This gene plays a role in the control of motor axon guidance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTPRT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase, Receptor Type, T Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTPRT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9682"},{"name":"Legacy Concept Name","value":"PTPRT_Gene"},{"name":"Maps_To","value":"PTPRT"},{"name":"OMIM_Number","value":"608712"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335289"}]}}{"C122890":{"preferredName":"PWWP2A Gene","code":"C122890","definitions":[{"definition":"This gene may play a role in protein-protein or protein-DNA interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PWWP2A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PWWP Domain Containing 2A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PWWP2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29406"},{"name":"Maps_To","value":"PWWP2A"},{"name":"OMIM_Number","value":"617823"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2239866"}]}}{"C111937":{"preferredName":"QKI Gene","code":"C111937","definitions":[{"definition":"This gene is involved in both the biosynthesis and maintenance of mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"QKI Gene","termGroup":"PT","termSource":"NCI"},{"termName":"QKI","termGroup":"SY","termSource":"NCI"},{"termName":"QKI, KH Domain Containing, RNA Binding Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:21100"},{"name":"Maps_To","value":"QKI"},{"name":"OMIM_Number","value":"609590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427319"}]}}{"C97751":{"preferredName":"RABEP1 Gene","code":"C97751","definitions":[{"definition":"This gene is involved in the regulation of both GTPase activity and endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RABEP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Rabaptin, RAB GTPase Binding Effector Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RABEP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17677"},{"name":"Maps_To","value":"RABEP1"},{"name":"OMIM_Number","value":"603616"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425034"}]}}{"C99663":{"preferredName":"RAC1 Gene","code":"C99663","definitions":[{"definition":"This gene is involved in both cell motility and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAC1","termGroup":"SY","termSource":"NCI"},{"termName":"Ras-Related C3 Botulinum Toxin Substrate 1 (Rho Family, Small GTP Binding Protein Rac1) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9801"},{"name":"Maps_To","value":"RAC1"},{"name":"OMIM_Number","value":"602048"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419227"}]}}{"C93082":{"preferredName":"RAD21 Gene","code":"C93082","definitions":[{"definition":"This gene is involved in chromosomal cohesion, DNA repair and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAD21 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAD21","termGroup":"SY","termSource":"NCI"},{"termName":"RAD21 Cohesin Complex Component Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9811"},{"name":"Maps_To","value":"RAD21"},{"name":"OMIM_Number","value":"606462"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419235"}]}}{"C90145":{"preferredName":"RAD51B Gene","code":"C90145","definitions":[{"definition":"This gene plays a role in the mediation of homologous recombinational repair of DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAD51B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAD51 Paralog B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RAD51B","termGroup":"SY","termSource":"NCI"},{"termName":"RAD51L1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9822"},{"name":"Maps_To","value":"RAD51B"},{"name":"OMIM_Number","value":"602948"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419241"}]}}{"C18338":{"preferredName":"RAF1 Gene","code":"C18338","definitions":[{"definition":"This gene is involved in cell growth, proliferation, differentiation and migration. It also plays a role in apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAF1","termGroup":"SY","termSource":"NCI"},{"termName":"v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9829"},{"name":"Legacy Concept Name","value":"RAF1_Gene"},{"name":"Maps_To","value":"RAF1"},{"name":"OMIM_Number","value":"164760"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812215"}]}}{"C24721":{"preferredName":"RALGDS Gene","code":"C24721","definitions":[{"definition":"This gene plays a role in signal transduction and cytoskeletal remodeling. It is also involved in regulation of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RALGDS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAL Guanine Nucleotide Dissociation Stimulator Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RALGDS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9842"},{"name":"Legacy Concept Name","value":"RALGDS_Gene"},{"name":"Maps_To","value":"RALGDS"},{"name":"OMIM_Number","value":"601619"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335588"}]}}{"C114452":{"preferredName":"RANBP2 Gene","code":"C114452","definitions":[{"definition":"This gene is involved in both SUMOylation and nuclear transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RANBP2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAN Binding Protein 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RANBP2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9848"},{"name":"Maps_To","value":"RANBP2"},{"name":"OMIM_Number","value":"601181"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419259"}]}}{"C97758":{"preferredName":"RAP1GDS1 Gene","code":"C97758","definitions":[{"definition":"This gene is involved in guanine nucleotide exchange.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAP1GDS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Rap1 GTPase-GDP Dissociation Stimulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RAP1GDS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9859"},{"name":"Maps_To","value":"RAP1GDS1"},{"name":"OMIM_Number","value":"179502"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419268"}]}}{"C21571":{"preferredName":"RARA Gene","code":"C21571","definitions":[{"definition":"This gene plays a role in transcription and retinoic acid receptor signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RARA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RARA","termGroup":"SY","termSource":"NCI"},{"termName":"Retinoic Acid Receptor Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9864"},{"name":"Legacy Concept Name","value":"RARA_Gene"},{"name":"Maps_To","value":"RARA"},{"name":"OMIM_Number","value":"180240"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366536"}]}}{"C17360":{"preferredName":"RB1 Gene","code":"C17360","definitions":[{"definition":"This gene is involved in the regulation of cell differentiation, growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RB Transcriptional Corepressor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9884"},{"name":"Legacy Concept Name","value":"RB1_Gene"},{"name":"Maps_To","value":"RB1"},{"name":"OMIM_Number","value":"614041"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694889"}]}}{"C115382":{"preferredName":"RBM10 Gene","code":"C115382","definitions":[{"definition":"This gene is involved in RNA binding and processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RBM10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RBM10","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Binding Motif Protein 10 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9896"},{"name":"Maps_To","value":"RBM10"},{"name":"OMIM_Number","value":"300080"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419296"}]}}{"C97293":{"preferredName":"RBM15 Gene","code":"C97293","definitions":[{"definition":"This gene plays a role in RNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RBM15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RBM15","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Binding Motif Protein 15 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14959"},{"name":"Maps_To","value":"RBM15"},{"name":"OMIM_Number","value":"606077"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423088"}]}}{"C26492":{"preferredName":"RECQL4 Gene","code":"C26492","definitions":[{"definition":"This gene is involved in the initiation of DNA replication and sister-chromatid cohesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RECQL4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RecQ Like Helicase 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RECQL4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9949"},{"name":"Legacy Concept Name","value":"RECQL4_Gene"},{"name":"Maps_To","value":"RECQL4"},{"name":"OMIM_Number","value":"603780"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335607"}]}}{"C17084":{"preferredName":"REL Gene","code":"C17084","definitions":[{"definition":"This gene is involved in transcriptional regulation and signal transduction through the nuclear factor kappa B NFKB signal transduction pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"REL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"REL","termGroup":"SY","termSource":"NCI"},{"termName":"v-REL Avian Reticuloendotheliosis Viral Oncogene Homolog Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9954"},{"name":"Legacy Concept Name","value":"REL_Gene"},{"name":"Maps_To","value":"REL"},{"name":"OMIM_Number","value":"164910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0035018"}]}}{"C18257":{"preferredName":"RET Gene","code":"C18257","definitions":[{"definition":"This gene plays an essential role in neural crest development, cellular growth and differentiation. Mutations in the gene are associated with a variety of neoplasias and carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RET Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RET","termGroup":"SY","termSource":"NCI"},{"termName":"RET Proto-Oncogene (Multiple Endocrine Neoplasia and Medullary Thyroid Carcinoma 1, Hirschsprung Disease) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9967"},{"name":"Legacy Concept Name","value":"RET_Gene"},{"name":"Maps_To","value":"RET"},{"name":"OMIM_Number","value":"164761"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694890"}]}}{"C143082":{"preferredName":"RGPD3 Gene","code":"C143082","definitions":[{"definition":"This gene may play a role in the localization of the GTPase Ran.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RGPD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RANBP2-Like and GRIP Domain Containing 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RGPD3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:32416"},{"name":"Maps_To","value":"RGPD3"},{"name":"NCI_META_CUI","value":"CL541555"},{"name":"OMIM_Number","value":"612706"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C143118":{"preferredName":"RGS7 Gene","code":"C143118","definitions":[{"definition":"This gene plays a role in the inhibition of both G protein-coupled receptor signaling and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RGS7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Regulator of G Protein Signaling 7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RGS7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10003"},{"name":"Maps_To","value":"RGS7"},{"name":"OMIM_Number","value":"602517"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419377"}]}}{"C18356":{"preferredName":"RHOA Gene","code":"C18356","definitions":[{"definition":"This gene plays a role in signal transduction. It is involved in several cellular functions including cell differentiation and cytoskeletal remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RHOA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAS Homolog Family Member A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RHOA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:667"},{"name":"Legacy Concept Name","value":"ARHA_Gene"},{"name":"Maps_To","value":"RHOA"},{"name":"OMIM_Number","value":"165390"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812234"}]}}{"C21320":{"preferredName":"RHOH Gene","code":"C21320","definitions":[{"definition":"This gene plays a role in signal transduction in hematopoietic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RHOH Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RAS Homolog Family Member H Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RHOH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:686"},{"name":"Legacy Concept Name","value":"ARHH_Gene"},{"name":"Maps_To","value":"RHOH"},{"name":"OMIM_Number","value":"602037"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332112"}]}}{"C96027":{"preferredName":"RMI2 Gene","code":"C96027","definitions":[{"definition":"This gene is involved in DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RMI2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RecQ Mediated Genome Instability 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RMI2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28349"},{"name":"Maps_To","value":"RMI2"},{"name":"OMIM_Number","value":"612426"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824428"}]}}{"C97390":{"preferredName":"RNF213 Gene","code":"C97390","definitions":[{"definition":"This gene may be involved in ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RNF213 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ring Finger Protein 213 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RNF213","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14539"},{"name":"Maps_To","value":"RNF213"},{"name":"OMIM_Number","value":"613768"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422738"}]}}{"C107649":{"preferredName":"RNF43 Gene","code":"C107649","definitions":[{"definition":"This gene is involved in both protein ubiquitination and the Wnt signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RNF43 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ring Finger Protein 43 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RNF43","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18505"},{"name":"Maps_To","value":"RNF43"},{"name":"OMIM_Number","value":"612482"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425565"}]}}{"C126774":{"preferredName":"ROBO2 Gene","code":"C126774","definitions":[{"definition":"This gene plays a role in ligand binding, axon guidance and cell migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ROBO2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ROBO2","termGroup":"SY","termSource":"NCI"},{"termName":"Roundabout Guidance Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10250"},{"name":"Maps_To","value":"ROBO2"},{"name":"OMIM_Number","value":"602431"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419597"}]}}{"C18399":{"preferredName":"ROS1 Gene","code":"C18399","definitions":[{"definition":"This gene plays a role in receptor tyrosine phosphorylation signal transduction, and is thought to play a role in cellular growth or differentiation, but an exact function has not been substantiated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ROS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ROS1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10261"},{"name":"Legacy Concept Name","value":"ROS1_Gene"},{"name":"Maps_To","value":"ROS1"},{"name":"NCI_META_CUI","value":"CL414355"},{"name":"OMIM_Number","value":"165020"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C24748":{"preferredName":"RPL10 Gene","code":"C24748","definitions":[{"definition":"This gene plays a role in protein biosynthesis. It is also involved in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPL10 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein L10 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPL10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10298"},{"name":"Legacy Concept Name","value":"RPL10_Gene"},{"name":"Maps_To","value":"RPL10"},{"name":"OMIM_Number","value":"312173"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335635"}]}}{"C97761":{"preferredName":"RPL22 Gene","code":"C97761","definitions":[{"definition":"This gene is involved in translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPL22 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein L22 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPL22","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10315"},{"name":"Maps_To","value":"RPL22"},{"name":"OMIM_Number","value":"180474"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419639"}]}}{"C107652":{"preferredName":"RPL5 Gene","code":"C107652","definitions":[{"definition":"This gene plays a role in ribosome assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPL5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein L5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPL5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10360"},{"name":"Maps_To","value":"RPL5"},{"name":"OMIM_Number","value":"603634"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419683"}]}}{"C97290":{"preferredName":"RPN1 Gene","code":"C97290","definitions":[{"definition":"This gene plays a role in post-translational protein modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribophorin I Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10381"},{"name":"Maps_To","value":"RPN1"},{"name":"OMIM_Number","value":"180470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419697"}]}}{"C106067":{"preferredName":"RSPO2 Gene","code":"C106067","definitions":[{"definition":"This gene plays a role in both Wnt signaling and embryonic morphogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RSPO2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"R-Spondin 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RSPO2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28583"},{"name":"Maps_To","value":"RSPO2"},{"name":"OMIM_Number","value":"610575"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826945"}]}}{"C24397":{"preferredName":"RSPO3 Gene","code":"C24397","definitions":[{"definition":"This gene is thought to be involved in transport; however, a function has yet to be elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RSPO3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"R-Spondin 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RSPO3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20866"},{"name":"Legacy Concept Name","value":"THSD2_Gene"},{"name":"Maps_To","value":"RSPO3"},{"name":"OMIM_Number","value":"610574"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1704989"}]}}{"C18579":{"preferredName":"RUNX1 Gene","code":"C18579","definitions":[{"definition":"This gene plays a role in transcriptional regulation and cytogenetic aberrations are associated with several leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RUNX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AML1","termGroup":"SY","termSource":"NCI"},{"termName":"Runt-Related Transcription Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RUNX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10471"},{"name":"Legacy Concept Name","value":"RUNX1_Gene"},{"name":"Maps_To","value":"RUNX1"},{"name":"OMIM_Number","value":"151385"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335654"}]}}{"C28570":{"preferredName":"RUNX1T1 Gene","code":"C28570","definitions":[{"definition":"This gene plays a role in transcriptional regulation and hematopoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RUNX1T1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RUNX1 Partner Transcriptional Co-Repressor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RUNX1T1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1535"},{"name":"Legacy Concept Name","value":"CBFA2T1_Gene"},{"name":"Maps_To","value":"RUNX1T1"},{"name":"OMIM_Number","value":"133435"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539715"}]}}{"C143078":{"preferredName":"S100A7 Gene","code":"C143078","definitions":[{"definition":"This gene is involved in both calcium binding and antimicrobial activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"S100A7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"S100 Calcium Binding Protein A7 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"S100A7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10497"},{"name":"Maps_To","value":"S100A7"},{"name":"NCI_META_CUI","value":"CL541566"},{"name":"OMIM_Number","value":"600353"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C112905":{"preferredName":"SALL4 Gene","code":"C112905","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and stem cell maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SALL4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SALL4","termGroup":"SY","termSource":"NCI"},{"termName":"Spalt Like Transcription Factor 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15924"},{"name":"Maps_To","value":"SALL4"},{"name":"OMIM_Number","value":"607343"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423836"}]}}{"C97767":{"preferredName":"SBDS Gene","code":"C97767","definitions":[{"definition":"This gene plays a role in ribosome formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SBDS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SBDS","termGroup":"SY","termSource":"NCI"},{"termName":"SBDS Ribosome Maturation Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19440"},{"name":"Maps_To","value":"SBDS"},{"name":"OMIM_Number","value":"607444"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426244"}]}}{"C101431":{"preferredName":"SDC4 Gene","code":"C101431","definitions":[{"definition":"This gene is involved in cell-matrix interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDC4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDC4","termGroup":"SY","termSource":"NCI"},{"termName":"Syndecan 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10661"},{"name":"Maps_To","value":"SDC4"},{"name":"OMIM_Number","value":"600017"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419894"}]}}{"C103873":{"preferredName":"SDHA Gene","code":"C103873","definitions":[{"definition":"This gene is involved in the mitochondrial respiratory chain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHA","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10680"},{"name":"Maps_To","value":"SDHA"},{"name":"OMIM_Number","value":"600857"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419906"}]}}{"C97770":{"preferredName":"SDHAF2 Gene","code":"C97770","definitions":[{"definition":"This gene is involved in the electron transport chain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHAF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHAF2","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Assembly Factor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26034"},{"name":"Maps_To","value":"SDHAF2"},{"name":"OMIM_Number","value":"613019"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2240298"}]}}{"C97773":{"preferredName":"SDHB Gene","code":"C97773","definitions":[{"definition":"This gene plays a role in electron transport in the mitochondria.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHB","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Iron Sulfur Subunit B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10681"},{"name":"Maps_To","value":"SDHB"},{"name":"OMIM_Number","value":"185470"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419907"}]}}{"C97776":{"preferredName":"SDHC Gene","code":"C97776","definitions":[{"definition":"This gene is involved in mitochondrial electron transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHC","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Subunit C Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10682"},{"name":"Maps_To","value":"SDHC"},{"name":"OMIM_Number","value":"602413"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419908"}]}}{"C97779":{"preferredName":"SDHD Gene","code":"C97779","definitions":[{"definition":"This gene plays a role in the localization of succinate dehydrogenase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDHD Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SDHD","termGroup":"SY","termSource":"NCI"},{"termName":"Succinate Dehydrogenase Complex Subunit D Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10683"},{"name":"Maps_To","value":"SDHD"},{"name":"OMIM_Number","value":"602690"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419909"}]}}{"C97727":{"preferredName":"SEPTIN5 Gene","code":"C97727","definitions":[{"definition":"This gene plays a role in cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SEPTIN5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SEPT5","termGroup":"SY","termSource":"NCI"},{"termName":"Septin 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SEPTIN5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9164"},{"name":"Maps_To","value":"SEPT5"},{"name":"OMIM_Number","value":"602724"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539748"}]}}{"C97782":{"preferredName":"SEPTIN6 Gene","code":"C97782","definitions":[{"definition":"This gene is involved in both cytokinesis and the organization of the actin cytoskeleton.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SEPTIN6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SEPT6","termGroup":"SY","termSource":"NCI"},{"termName":"Septin 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SEPTIN6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15848"},{"name":"Maps_To","value":"SEPT6"},{"name":"OMIM_Number","value":"300683"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423771"}]}}{"C97897":{"preferredName":"SEPTIN9 Gene","code":"C97897","definitions":[{"definition":"This gene plays a role in actin filament dynamics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SEPTIN9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SEPT9","termGroup":"SY","termSource":"NCI"},{"termName":"Septin 9 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SEPTIN9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7323"},{"name":"Maps_To","value":"SEPT9"},{"name":"OMIM_Number","value":"604061"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539750"}]}}{"C24801":{"preferredName":"SET Gene","code":"C24801","definitions":[{"definition":"This gene is involved in apoptosis, biogenesis, DNA replication and nuclear organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SET Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET","termGroup":"SY","termSource":"NCI"},{"termName":"SET Nuclear Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10760"},{"name":"Legacy Concept Name","value":"SET_Gene"},{"name":"Maps_To","value":"SET"},{"name":"OMIM_Number","value":"600960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1366517"}]}}{"C106635":{"preferredName":"SETBP1 Gene","code":"C106635","definitions":[{"definition":"This gene may be involved in the modulation of protein SET activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SETBP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET Binding Protein 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SETBP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15573"},{"name":"Maps_To","value":"SETBP1"},{"name":"OMIM_Number","value":"611060"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423585"}]}}{"C73662":{"preferredName":"SETD2 Gene","code":"C73662","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression through histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SETD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET Domain Containing 2, Histone Lysine Methyltransferase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SETD2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18420"},{"name":"Legacy Concept Name","value":"SETD2_Gene"},{"name":"Maps_To","value":"SETD2"},{"name":"OMIM_Number","value":"612778"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822686"}]}}{"C98284":{"preferredName":"SF3B1 Gene","code":"C98284","definitions":[{"definition":"This gene is involved in mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SF3B1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SF3B1","termGroup":"SY","termSource":"NCI"},{"termName":"Splicing Factor 3b Subunit 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10768"},{"name":"Maps_To","value":"SF3B1"},{"name":"OMIM_Number","value":"605590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419980"}]}}{"C71417":{"preferredName":"SFPQ Gene","code":"C71417","definitions":[{"definition":"This gene may be involved in both transcriptional regulation and nuclear RNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SFPQ Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SFPQ","termGroup":"SY","termSource":"NCI"},{"termName":"Splicing Factor Proline/Glutamine-Rich (Polypyrimidine Tract Binding Protein Associated) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10774"},{"name":"Legacy Concept Name","value":"SFPQ_Gene"},{"name":"Maps_To","value":"SFPQ"},{"name":"OMIM_Number","value":"605199"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419984"}]}}{"C24804":{"preferredName":"SFRP4 Gene","code":"C24804","definitions":[{"definition":"This gene plays a role in signal transduction, apoptosis and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SFRP4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Secreted Frizzled Related Protein 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SFRP4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10778"},{"name":"Legacy Concept Name","value":"SFRP4_Gene"},{"name":"Maps_To","value":"SFRP4"},{"name":"OMIM_Number","value":"606570"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335814"}]}}{"C101559":{"preferredName":"SGK1 Gene","code":"C101559","definitions":[{"definition":"This gene plays a role in both protein phosphorylation and cellular stress response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SGK1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serum/Glucocorticoid Regulated Kinase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SGK1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10810"},{"name":"Maps_To","value":"SGK1"},{"name":"OMIM_Number","value":"602958"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420010"}]}}{"C102802":{"preferredName":"SH2B3 Gene","code":"C102802","definitions":[{"definition":"This gene plays a role in T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SH2B3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SH2B Adaptor Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SH2B3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29605"},{"name":"Maps_To","value":"SH2B3"},{"name":"OMIM_Number","value":"605093"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822705"}]}}{"C97788":{"preferredName":"SH3GL1 Gene","code":"C97788","definitions":[{"definition":"This gene may be involved in endocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SH3GL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SH3-Domain GRB2-Like 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SH3GL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10830"},{"name":"Maps_To","value":"SH3GL1"},{"name":"OMIM_Number","value":"601768"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420025"}]}}{"C122906":{"preferredName":"SHTN1 Gene","code":"C122906","definitions":[{"definition":"This gene is involved in neuronal polarization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHTN1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"KIAA1598","termGroup":"SY","termSource":"NCI"},{"termName":"Shootin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SHTN1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29319"},{"name":"Maps_To","value":"SHTN1"},{"name":"OMIM_Number","value":"611171"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428834"}]}}{"C24710":{"preferredName":"SIRPA Gene","code":"C24710","definitions":[{"definition":"This gene is involved in cellular signal transduction and tyrosine kinase-coupled signaling processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIRPA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal Regulatory Protein Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9662"},{"name":"Legacy Concept Name","value":"PTPNS1_Gene"},{"name":"Maps_To","value":"SIRPA"},{"name":"OMIM_Number","value":"602461"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822726"}]}}{"C69184":{"preferredName":"SKI Gene","code":"C69184","definitions":[{"definition":"This gene is involved in transcriptional regulation and is involved in cellular signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SKI Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SKI","termGroup":"SY","termSource":"NCI"},{"termName":"SKI Proto-Oncogene Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10896"},{"name":"Legacy Concept Name","value":"SKI_Gene"},{"name":"Maps_To","value":"SKI"},{"name":"OMIM_Number","value":"164780"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812379"}]}}{"C101434":{"preferredName":"SLC34A2 Gene","code":"C101434","definitions":[{"definition":"This gene plays a role in phosphate transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SLC34A2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLC34A2","termGroup":"SY","termSource":"NCI"},{"termName":"Solute Carrier Family 34 Member 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11020"},{"name":"Maps_To","value":"SLC34A2"},{"name":"OMIM_Number","value":"604217"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420186"}]}}{"C97791":{"preferredName":"SLC45A3 Gene","code":"C97791","definitions":[{"definition":"This gene plays a role in transmembrane transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SLC45A3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLC45A3","termGroup":"SY","termSource":"NCI"},{"termName":"Solute Carrier Family 45, Member 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:8642"},{"name":"Maps_To","value":"SLC45A3"},{"name":"OMIM_Number","value":"605097"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1418294"}]}}{"C24566":{"preferredName":"SMAD2 Gene","code":"C24566","definitions":[{"definition":"This gene plays a role in signal transduction and repression of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAD2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMAD, Mothers Against DPP Homolog 2 (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SMAD2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6768"},{"name":"Legacy Concept Name","value":"MADH2_Gene"},{"name":"Maps_To","value":"SMAD2"},{"name":"OMIM_Number","value":"601366"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1334468"}]}}{"C18504":{"preferredName":"SMAD3 Gene","code":"C18504","definitions":[{"definition":"This gene is involved in signal transduction and apoptosis. It also plays a role in the regulation of both steroid synthesis and T-cell response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAD3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Mothers Against Decapentaplegic Homolog 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SMAD3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6769"},{"name":"Legacy Concept Name","value":"MADH3_Gene"},{"name":"Maps_To","value":"SMAD3"},{"name":"OMIM_Number","value":"603109"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919432"}]}}{"C18258":{"preferredName":"SMAD4 Gene","code":"C18258","definitions":[{"definition":"This gene plays a role in signal transduction and transcriptional activation. It is also involved in suppression of angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAD4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMAD Family Member 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SMAD4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6770"},{"name":"Legacy Concept Name","value":"MADH4_Gene"},{"name":"Maps_To","value":"SMAD4"},{"name":"OMIM_Number","value":"600993"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694891"}]}}{"C19878":{"preferredName":"SMARCA4 Gene","code":"C19878","definitions":[{"definition":"This gene plays a role in chromatin remodeling, cell cycle control and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCA4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCA4","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11100"},{"name":"Legacy Concept Name","value":"SMARCA4_Gene"},{"name":"Maps_To","value":"SMARCA4"},{"name":"OMIM_Number","value":"603254"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335843"}]}}{"C18394":{"preferredName":"SMARCB1 Gene","code":"C18394","definitions":[{"definition":"This gene plays a role in chromatin remodeling and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCB1","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11103"},{"name":"Legacy Concept Name","value":"SMARCB1_Gene"},{"name":"Maps_To","value":"SMARCB1"},{"name":"OMIM_Number","value":"601607"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812273"}]}}{"C19875":{"preferredName":"SMARCD1 Gene","code":"C19875","definitions":[{"definition":"This gene plays a role in chromatin remodeling and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCD1","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily D, Member 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11106"},{"name":"Legacy Concept Name","value":"SMARCD1_Gene"},{"name":"Maps_To","value":"SMARCD1"},{"name":"OMIM_Number","value":"601735"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335847"}]}}{"C19874":{"preferredName":"SMARCE1 Gene","code":"C19874","definitions":[{"definition":"This gene is involved in chromatin remodeling and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMARCE1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMARCE1","termGroup":"SY","termSource":"NCI"},{"termName":"SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily E, Member 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11109"},{"name":"Legacy Concept Name","value":"SMARCE1_Gene"},{"name":"Maps_To","value":"SMARCE1"},{"name":"OMIM_Number","value":"603111"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335850"}]}}{"C75406":{"preferredName":"SMC1A Gene","code":"C75406","definitions":[{"definition":"This gene is involved in maintenance of sister chromatid cohesion during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMC1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMC1A","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Maintenance of Chromosomes 1A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11111"},{"name":"Legacy Concept Name","value":"SMC1A_Gene"},{"name":"Maps_To","value":"SMC1A"},{"name":"OMIM_Number","value":"300040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822777"}]}}{"C24817":{"preferredName":"SMO Gene","code":"C24817","definitions":[{"definition":"This gene plays a role in G protein-coupled receptor signal transduction and sonic hedgehog pathway activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMO Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SMO","termGroup":"SY","termSource":"NCI"},{"termName":"Smoothened, Frizzled Class Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11119"},{"name":"Legacy Concept Name","value":"SMO_Gene"},{"name":"Maps_To","value":"SMO"},{"name":"OMIM_Number","value":"601500"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1364142"}]}}{"C96331":{"preferredName":"SND1 Gene","code":"C96331","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and RNA interference.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SND1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SND1","termGroup":"SY","termSource":"NCI"},{"termName":"Staphylococcal Nuclease and Tudor Domain Containing 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30646"},{"name":"Maps_To","value":"SND1"},{"name":"OMIM_Number","value":"602181"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822796"}]}}{"C97764":{"preferredName":"SNX29 Gene","code":"C97764","definitions":[{"definition":"This gene may be involved in signal transduction or lipid binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SNX29 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"RUNDC2A","termGroup":"SY","termSource":"NCI"},{"termName":"SNX29","termGroup":"SY","termSource":"NCI"},{"termName":"Sorting Nexin 29 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30542"},{"name":"Maps_To","value":"SNX29"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2680432"}]}}{"C97794":{"preferredName":"SOCS1 Gene","code":"C97794","definitions":[{"definition":"This gene is involved in the attenuation of cytokine signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SOCS1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SOCS1","termGroup":"SY","termSource":"NCI"},{"termName":"Suppressor of Cytokine Signaling 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19383"},{"name":"Maps_To","value":"SOCS1"},{"name":"OMIM_Number","value":"603597"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426208"}]}}{"C61136":{"preferredName":"SOX2 Gene","code":"C61136","definitions":[{"definition":"This gene is involved in embryonic development and in the determination of cell fate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SOX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SOX2","termGroup":"SY","termSource":"NCI"},{"termName":"SRY (Sex Determining Region Y)-Box 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11195"},{"name":"Legacy Concept Name","value":"SOX2_Gene"},{"name":"Maps_To","value":"SOX2"},{"name":"OMIM_Number","value":"184429"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420322"}]}}{"C97531":{"preferredName":"SPECC1 Gene","code":"C97531","definitions":[{"definition":"This gene may be involved in nuclear structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SPECC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SPECC1","termGroup":"SY","termSource":"NCI"},{"termName":"Sperm Antigen with Calponin Homology and Coiled-Coil Domains 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:30615"},{"name":"Maps_To","value":"SPECC1"},{"name":"OMIM_Number","value":"608793"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823096"}]}}{"C115310":{"preferredName":"SPEN Gene","code":"C115310","definitions":[{"definition":"This gene plays a role in hormone-mediated transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SPEN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SPEN","termGroup":"SY","termSource":"NCI"},{"termName":"Spen Family Transcriptional Repressor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17575"},{"name":"Maps_To","value":"SPEN"},{"name":"OMIM_Number","value":"613484"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539835"}]}}{"C102534":{"preferredName":"SPOP Gene","code":"C102534","definitions":[{"definition":"This gene is involved in protein ubiquitination, which often leads to proteasomal degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SPOP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Speckle Type BTB/POZ Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SPOP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11254"},{"name":"Maps_To","value":"SPOP"},{"name":"OMIM_Number","value":"602650"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420368"}]}}{"C19917":{"preferredName":"SRC Gene","code":"C19917","definitions":[{"definition":"This gene is involved in apoptosis, hormonogenesis, focal adhesion and the formation of intercellular junctions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SRC","termGroup":"SY","termSource":"NCI"},{"termName":"SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11283"},{"name":"Legacy Concept Name","value":"SRC_Gene"},{"name":"Maps_To","value":"SRC"},{"name":"NCI_META_CUI","value":"CL448326"},{"name":"OMIM_Number","value":"190090"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97797":{"preferredName":"SRGAP3 Gene","code":"C97797","definitions":[{"definition":"This gene plays a role in GTPase-mediated signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRGAP3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLIT-ROBO Rho GTPase Activating Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SRGAP3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19744"},{"name":"Maps_To","value":"SRGAP3"},{"name":"OMIM_Number","value":"606525"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539848"}]}}{"C101110":{"preferredName":"SRSF2 Gene","code":"C101110","definitions":[{"definition":"This gene plays a role in RNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRSF2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serine and Arginine Rich Splicing Factor 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SRSF2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10783"},{"name":"Maps_To","value":"SRSF2"},{"name":"OMIM_Number","value":"600813"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419992"}]}}{"C97785":{"preferredName":"SRSF3 Gene","code":"C97785","definitions":[{"definition":"This gene plays a role in RNA splicing and export.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SRSF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serine/Arginine-Rich Splicing Factor 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SRSF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10785"},{"name":"Maps_To","value":"SRSF3"},{"name":"OMIM_Number","value":"603364"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419994"}]}}{"C97800":{"preferredName":"SS18 Gene","code":"C97800","definitions":[{"definition":"This gene is involved in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SS18 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SS18","termGroup":"SY","termSource":"NCI"},{"termName":"SS18 Subunit of BAF Chromatin Remodeling Complex Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11340"},{"name":"Maps_To","value":"SS18"},{"name":"OMIM_Number","value":"600192"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420439"}]}}{"C97803":{"preferredName":"SS18L1 Gene","code":"C97803","definitions":[{"definition":"This gene plays a role in the positive regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SS18L1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SS18L1","termGroup":"SY","termSource":"NCI"},{"termName":"Synovial Sarcoma Translocation Gene on Chromosome 18-Like 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15592"},{"name":"Maps_To","value":"SS18L1"},{"name":"OMIM_Number","value":"606472"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423601"}]}}{"C97806":{"preferredName":"SSX1 Gene","code":"C97806","definitions":[{"definition":"This gene may be involved in the regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SSX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SSX Family Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SSX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11335"},{"name":"Maps_To","value":"SSX1"},{"name":"OMIM_Number","value":"312820"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420434"}]}}{"C97809":{"preferredName":"SSX2 Gene","code":"C97809","definitions":[{"definition":"This gene may play a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SSX2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SSX Family Member 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SSX2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11336"},{"name":"Maps_To","value":"SSX2"},{"name":"OMIM_Number","value":"300192"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420435"}]}}{"C97814":{"preferredName":"SSX4 Gene","code":"C97814","definitions":[{"definition":"This gene may be involved in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SSX4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SSX Family Member 4 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SSX4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11338"},{"name":"Maps_To","value":"SSX4"},{"name":"OMIM_Number","value":"300326"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420437"}]}}{"C131224":{"preferredName":"STAG1 Gene","code":"C131224","definitions":[{"definition":"This gene plays a role in sister chromatid binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAG1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"STAG1","termGroup":"SY","termSource":"NCI"},{"termName":"Stromal Antigen 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11354"},{"name":"Maps_To","value":"STAG1"},{"name":"OMIM_Number","value":"604358"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420448"}]}}{"C101346":{"preferredName":"STAG2 Gene","code":"C101346","definitions":[{"definition":"This gene is involved in cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAG2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"STAG2","termGroup":"SY","termSource":"NCI"},{"termName":"STAG2 Cohesin Complex Component Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11355"},{"name":"Maps_To","value":"STAG2"},{"name":"OMIM_Number","value":"300826"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420449"}]}}{"C24833":{"preferredName":"STAT3 Gene","code":"C24833","definitions":[{"definition":"This gene plays a role in signal transduction and activation of transcription. It is involved in regulation of both apoptosis and cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal Transducer and Activator of Transcription 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STAT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11364"},{"name":"Legacy Concept Name","value":"STAT3_Gene"},{"name":"Maps_To","value":"STAT3"},{"name":"OMIM_Number","value":"102582"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367307"}]}}{"C28667":{"preferredName":"STAT5B Gene","code":"C28667","definitions":[{"definition":"This gene is involved in signal transduction and activation of transcription. It plays a role in the immune response via stimulation of T-cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT5B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal Transducer and Activator of Transcription 5B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STAT5B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11367"},{"name":"Legacy Concept Name","value":"STAT5B_Gene"},{"name":"Maps_To","value":"STAT5B"},{"name":"OMIM_Number","value":"604260"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335876"}]}}{"C24835":{"preferredName":"STAT6 Gene","code":"C24835","definitions":[{"definition":"This gene plays a role in signal transduction and activation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Signal Transducer and Activator of Transcription 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STAT6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11368"},{"name":"Legacy Concept Name","value":"STAT6_Gene"},{"name":"Maps_To","value":"STAT6"},{"name":"OMIM_Number","value":"601512"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1832224"}]}}{"C101126":{"preferredName":"STIL Gene","code":"C101126","definitions":[{"definition":"This gene plays a role in both cellular proliferation and embryonic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STIL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"STIL","termGroup":"SY","termSource":"NCI"},{"termName":"STIL Centriolar Assembly Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10879"},{"name":"Maps_To","value":"STIL"},{"name":"OMIM_Number","value":"181590"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420065"}]}}{"C18253":{"preferredName":"STK11 Gene","code":"C18253","definitions":[{"definition":"This gene plays a role in cell cycle regulation. It is also putatively involved in glucose production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STK11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"LKB1","termGroup":"SY","termSource":"NCI"},{"termName":"Serine/Threonine Kinase 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STK11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11389"},{"name":"Legacy Concept Name","value":"STK11_Gene"},{"name":"Maps_To","value":"STK11"},{"name":"OMIM_Number","value":"602216"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694883"}]}}{"C107661":{"preferredName":"STRN Gene","code":"C107661","definitions":[{"definition":"This gene may play a role in cell scaffolding or calcium signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STRN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Striatin, Calmodulin Binding Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"STRN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11424"},{"name":"Maps_To","value":"STRN"},{"name":"OMIM_Number","value":"614765"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420489"}]}}{"C97819":{"preferredName":"SUFU Gene","code":"C97819","definitions":[{"definition":"This gene plays a role in the regulation of both transcription and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SUFU Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SUFU","termGroup":"SY","termSource":"NCI"},{"termName":"SUFU Negative Regulator uf Hedgehog Signaling Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16466"},{"name":"Maps_To","value":"SUFU"},{"name":"OMIM_Number","value":"607035"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424302"}]}}{"C73545":{"preferredName":"SUZ12 Gene","code":"C73545","definitions":[{"definition":"This gene plays a role in embryonic development and histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SUZ12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Suppressor of Zeste 12 Homolog (Drosophila) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SUZ12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17101"},{"name":"Legacy Concept Name","value":"SUZ12_Gene"},{"name":"Maps_To","value":"SUZ12"},{"name":"OMIM_Number","value":"606245"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539902"}]}}{"C26536":{"preferredName":"SYK Gene","code":"C26536","definitions":[{"definition":"This gene plays a role in receptor tyrosine phosphorylation signal transduction, phagocytosis, endothelial cell growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SYK Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Spleen Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SYK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11491"},{"name":"Legacy Concept Name","value":"SYK_Gene"},{"name":"Maps_To","value":"SYK"},{"name":"OMIM_Number","value":"600085"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335892"}]}}{"C95994":{"preferredName":"TAF15 Gene","code":"C95994","definitions":[{"definition":"This gene plays a role in transcriptional initiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAF15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TAF15","termGroup":"SY","termSource":"NCI"},{"termName":"TATA-Box Binding Protein Associated Factor 15 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11547"},{"name":"Maps_To","value":"TAF15"},{"name":"OMIM_Number","value":"601574"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420573"}]}}{"C18301":{"preferredName":"TAL1 Gene","code":"C18301","definitions":[{"definition":"This gene plays a role in regulation of transcription and cell organization. It is involved in both embryonic hematopoiesis and adult erythropoiesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAL1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"T-Cell Acute Lymphocytic Leukemia 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TAL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11556"},{"name":"Legacy Concept Name","value":"TAL1_Gene"},{"name":"Maps_To","value":"TAL1"},{"name":"OMIM_Number","value":"187040"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0796355"}]}}{"C24843":{"preferredName":"TAL2 Gene","code":"C24843","definitions":[{"definition":"This gene is involved in transcriptional regulation. It plays a role in T-cell acute lymphocytic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAL2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TAL bHLH Transcription Factor 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TAL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11557"},{"name":"Legacy Concept Name","value":"TAL2_Gene"},{"name":"Maps_To","value":"TAL2"},{"name":"OMIM_Number","value":"186855"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336574"}]}}{"C80116":{"preferredName":"TBL1XR1 Gene","code":"C80116","definitions":[{"definition":"This gene is involved in transcriptional activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TBL1XR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TBL1X Receptor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TBL1XR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29529"},{"name":"Legacy Concept Name","value":"TBL1XR1_Gene"},{"name":"Maps_To","value":"TBL1XR1"},{"name":"OMIM_Number","value":"608628"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539940"}]}}{"C101638":{"preferredName":"TBX3 Gene","code":"C101638","definitions":[{"definition":"This gene is involved in both transcriptional repression and limb development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TBX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"T-Box 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TBX3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11602"},{"name":"Maps_To","value":"TBX3"},{"name":"OMIM_Number","value":"601621"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420613"}]}}{"C97822":{"preferredName":"TCEA1 Gene","code":"C97822","definitions":[{"definition":"This gene is involved in transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCEA1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCEA1","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Elongation Factor A (SII), 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11612"},{"name":"Maps_To","value":"TCEA1"},{"name":"OMIM_Number","value":"601425"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420622"}]}}{"C97828":{"preferredName":"TCF12 Gene","code":"C97828","definitions":[{"definition":"This gene is involved in both transcriptional regulation and tissue differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCF12 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCF12","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor 12 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11623"},{"name":"Maps_To","value":"TCF12"},{"name":"OMIM_Number","value":"600480"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420632"}]}}{"C24846":{"preferredName":"TCF3 Gene","code":"C24846","definitions":[{"definition":"This gene plays a role in regulation of transcription. It is involved in the control of tissue-specific cell fate during embryogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"E2A","termGroup":"SY","termSource":"NCI"},{"termName":"TCF3","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11633"},{"name":"Legacy Concept Name","value":"TCF3_Gene"},{"name":"Maps_To","value":"TCF3"},{"name":"OMIM_Number","value":"147141"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336596"}]}}{"C24847":{"preferredName":"TCF7L2 Gene","code":"C24847","definitions":[{"definition":"This gene plays a role in signal transduction and regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCF7L2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCF7L2","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor 7 Like 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11641"},{"name":"Legacy Concept Name","value":"TCF7L2_Gene"},{"name":"Maps_To","value":"TCF7L2"},{"name":"OMIM_Number","value":"602228"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420644"}]}}{"C92699":{"preferredName":"TCL1A Gene","code":"C92699","definitions":[{"definition":"This gene is involved in signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCL1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCL1 Family AKT Coactivator A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCL1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11648"},{"name":"Maps_To","value":"TCL1A"},{"name":"OMIM_Number","value":"186960"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420650"}]}}{"C24850":{"preferredName":"TEC Gene","code":"C24850","definitions":[{"definition":"This gene is involved in signal transduction and regulation of immune function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TEC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TEC","termGroup":"SY","termSource":"NCI"},{"termName":"Tec Protein Tyrosine Kinase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11719"},{"name":"Legacy Concept Name","value":"TEC_Gene"},{"name":"Maps_To","value":"TEC"},{"name":"OMIM_Number","value":"600583"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336601"}]}}{"C18173":{"preferredName":"TERT Gene","code":"C18173","definitions":[{"definition":"This gene is involved in cell cycle regulation and telomere maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TERT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Telomerase Reverse Transcriptase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TERT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11730"},{"name":"Legacy Concept Name","value":"TERT_Gene"},{"name":"Maps_To","value":"TERT"},{"name":"OMIM_Number","value":"187270"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367342"}]}}{"C95423":{"preferredName":"TET1 Gene","code":"C95423","definitions":[{"definition":"This gene is involved in the regulation of DNA methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TET1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tet Methylcytosine Dioxygenase 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TET1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29484"},{"name":"Maps_To","value":"TET1"},{"name":"OMIM_Number","value":"607790"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428863"}]}}{"C95252":{"preferredName":"TET2 Gene","code":"C95252","definitions":[{"definition":"This gene is involved in oxidation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TET2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tet Methylcytosine Dioxygenase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TET2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25941"},{"name":"Maps_To","value":"TET2"},{"name":"OMIM_Number","value":"612839"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825692"}]}}{"C24854":{"preferredName":"TFE3 Gene","code":"C24854","definitions":[{"definition":"This gene plays a role in transcriptional activation. It is involved in melanogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFE3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFE3","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor Binding to IGHM Enhancer 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11752"},{"name":"Legacy Concept Name","value":"TFE3_Gene"},{"name":"Maps_To","value":"TFE3"},{"name":"OMIM_Number","value":"314310"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336608"}]}}{"C94761":{"preferredName":"TFEB Gene","code":"C94761","definitions":[{"definition":"This gene plays a role in transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFEB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFEB","termGroup":"SY","termSource":"NCI"},{"termName":"Transcription Factor EB Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11753"},{"name":"Maps_To","value":"TFEB"},{"name":"OMIM_Number","value":"600744"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420699"}]}}{"C97834":{"preferredName":"TFG Gene","code":"C97834","definitions":[{"definition":"This gene is involved in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFG Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFG","termGroup":"SY","termSource":"NCI"},{"termName":"Trafficking from ER to Golgi Regulator Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11758"},{"name":"Maps_To","value":"TFG"},{"name":"OMIM_Number","value":"602498"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420703"}]}}{"C97837":{"preferredName":"TFPT Gene","code":"C97837","definitions":[{"definition":"This gene plays a role in the regulation of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFPT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TCF3 Fusion Partner Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TFPT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13630"},{"name":"Maps_To","value":"TFPT"},{"name":"OMIM_Number","value":"609519"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422118"}]}}{"C38517":{"preferredName":"TFRC Gene","code":"C38517","definitions":[{"definition":"This gene plays a regulatory role in receptor-mediated endocytosis and iron metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TFRC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TFRC","termGroup":"SY","termSource":"NCI"},{"termName":"Transferrin Receptor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11763"},{"name":"Legacy Concept Name","value":"TFRC_Gene"},{"name":"Maps_To","value":"TFRC"},{"name":"OMIM_Number","value":"190010"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420708"}]}}{"C18592":{"preferredName":"TGFBR2 Gene","code":"C18592","definitions":[{"definition":"This gene plays a role in cellular proliferation and mitogenic responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGFBR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TGFBR2","termGroup":"SY","termSource":"NCI"},{"termName":"Transforming Growth Factor, Beta Receptor II (70/80kDa) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11773"},{"name":"Legacy Concept Name","value":"TGFBR2_Gene"},{"name":"Maps_To","value":"TGFBR2"},{"name":"OMIM_Number","value":"190182"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0919538"}]}}{"C97840":{"preferredName":"THRAP3 Gene","code":"C97840","definitions":[{"definition":"This gene is involved in the activation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"THRAP3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"THRAP3","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Hormone Receptor Associated Protein 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:22964"},{"name":"Maps_To","value":"THRAP3"},{"name":"OMIM_Number","value":"603809"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1427817"}]}}{"C18608":{"preferredName":"TLX1 Gene","code":"C18608","definitions":[{"definition":"This gene plays a role in transcriptional regulation and organogenesis. Translocations in the gene are associated with acute T-cell leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLX1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Leukemia Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TLX1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5056"},{"name":"Legacy Concept Name","value":"HOX11_Gene"},{"name":"Maps_To","value":"TLX1"},{"name":"OMIM_Number","value":"186770"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0920270"}]}}{"C98099":{"preferredName":"TLX3 Gene","code":"C98099","definitions":[{"definition":"This gene may be involved in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Leukemia Homeobox 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TLX3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13532"},{"name":"Maps_To","value":"TLX3"},{"name":"OMIM_Number","value":"604640"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422043"}]}}{"C95303":{"preferredName":"TMEM127 Gene","code":"C95303","definitions":[{"definition":"This gene may play a role in signaling and protein trafficking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TMEM127 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TMEM127","termGroup":"SY","termSource":"NCI"},{"termName":"Transmembrane Protein 127 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26038"},{"name":"Maps_To","value":"TMEM127"},{"name":"OMIM_Number","value":"613403"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823386"}]}}{"C24871":{"preferredName":"TMPRSS2 Gene","code":"C24871","definitions":[{"definition":"This gene plays a role in the activation of pathway signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TMPRSS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TMPRSS2","termGroup":"SY","termSource":"NCI"},{"termName":"Transmembrane Serine Protease 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11876"},{"name":"Legacy Concept Name","value":"TMPRSS2_Gene"},{"name":"Maps_To","value":"TMPRSS2"},{"name":"OMIM_Number","value":"602060"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336641"}]}}{"C21091":{"preferredName":"TNC Gene","code":"C21091","definitions":[{"definition":"This gene is involved in cell adhesion, differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tenascin C Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TNC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5318"},{"name":"Legacy Concept Name","value":"TNC_Gene"},{"name":"Maps_To","value":"TNC"},{"name":"OMIM_Number","value":"187380"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336642"}]}}{"C84928":{"preferredName":"TNFAIP3 Gene","code":"C84928","definitions":[{"definition":"This gene may play a role in the regulation of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNFAIP3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNF Alpha Induced Protein 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TNFAIP3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11896"},{"name":"Maps_To","value":"TNFAIP3"},{"name":"OMIM_Number","value":"191163"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420799"}]}}{"C97843":{"preferredName":"TNFRSF14 Gene","code":"C97843","definitions":[{"definition":"This gene plays a role in receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNFRSF14 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNFRSF14","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Necrosis Factor Receptor Superfamily, Member 14 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11912"},{"name":"Maps_To","value":"TNFRSF14"},{"name":"OMIM_Number","value":"602746"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420808"}]}}{"C97846":{"preferredName":"TNFRSF17 Gene","code":"C97846","definitions":[{"definition":"This gene is involved in the modulation of cytokine signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TNFRSF17 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNFRSF17","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Necrosis Factor Receptor Superfamily, Member 17 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11913"},{"name":"Maps_To","value":"TNFRSF17"},{"name":"OMIM_Number","value":"109545"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420809"}]}}{"C26591":{"preferredName":"TOP1 Gene","code":"C26591","definitions":[{"definition":"This gene is involved in the regulation of both DNA topology and transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TOP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Topoisomerase I Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TOP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11986"},{"name":"Legacy Concept Name","value":"TOP1_Gene"},{"name":"Maps_To","value":"TOP1"},{"name":"OMIM_Number","value":"126420"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336656"}]}}{"C17359":{"preferredName":"TP53 Gene","code":"C17359","definitions":[{"definition":"This gene plays a critical role in cell cycle regulation and has tumor suppressor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TP53 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TP53","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Protein P53 (Li-Fraumeni Syndrome) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11998"},{"name":"Legacy Concept Name","value":"TP53_Gene"},{"name":"Maps_To","value":"TP53"},{"name":"OMIM_Number","value":"191170"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0079419"}]}}{"C91791":{"preferredName":"TP63 Gene","code":"C91791","definitions":[{"definition":"This gene plays a role in both transcriptional regulation and limb development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TP63 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TP63","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Protein p63 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15979"},{"name":"Maps_To","value":"TP63"},{"name":"OMIM_Number","value":"603273"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1422009"}]}}{"C97849":{"preferredName":"TPM3 Gene","code":"C97849","definitions":[{"definition":"This gene plays a role in muscle contraction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TPM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TPM3","termGroup":"SY","termSource":"NCI"},{"termName":"Tropomyosin 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12012"},{"name":"Maps_To","value":"TPM3"},{"name":"OMIM_Number","value":"191030"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420874"}]}}{"C97852":{"preferredName":"TPM4 Gene","code":"C97852","definitions":[{"definition":"This gene is involved in smooth muscle cell contraction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TPM4 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TPM4","termGroup":"SY","termSource":"NCI"},{"termName":"Tropomyosin 4 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12013"},{"name":"Maps_To","value":"TPM4"},{"name":"OMIM_Number","value":"600317"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420875"}]}}{"C97855":{"preferredName":"TPR Gene","code":"C97855","definitions":[{"definition":"This gene plays a role in both nuclear transport and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TPR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TPR","termGroup":"SY","termSource":"NCI"},{"termName":"Translocated Promoter Region, Nuclear Basket Protein Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12017"},{"name":"Maps_To","value":"TPR"},{"name":"OMIM_Number","value":"189940"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420877"}]}}{"C26419":{"preferredName":"T-Cell Receptor Alpha Locus","code":"C26419","definitions":[{"definition":"This region represents the germline organization of the T cell receptor alpha locus. The alpha locus includes V (variable), J (joining), and C (constant) segments. During T cell development, the alpha chain is synthesized by a recombination event at the DNA level joining a V segment with a J segment. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Receptor Alpha Locus","termGroup":"PT","termSource":"NCI"},{"termName":"T-Cell Receptor Alpha Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCRA","termGroup":"SY","termSource":"NCI"},{"termName":"TRA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"6955"},{"name":"GenBank_Accession_Number","value":"NG_001332"},{"name":"Gene_Encodes_Product","value":"T-Cell Receptor Alpha Chain"},{"name":"HGNC_ID","value":"HGNC:12027"},{"name":"Legacy Concept Name","value":"T-Cell_Receptor_Alpha_Locus"},{"name":"Maps_To","value":"TRA"},{"name":"OMIM_Number","value":"186880"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0524890"}]}}{"C107646":{"preferredName":"TRAF7 Gene","code":"C107646","definitions":[{"definition":"This gene is involved in both MAPK signaling and protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRAF7 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TNF Receptor-Associated Factor 7, E3 Ubiquitin Protein Ligase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TRAF7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20456"},{"name":"Maps_To","value":"TRAF7"},{"name":"OMIM_Number","value":"606692"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1540047"}]}}{"C26418":{"preferredName":"T-Cell Receptor Beta Locus","code":"C26418","definitions":[{"definition":"This region represents the germline organization of the T cell receptor beta locus. The beta locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During T cell development, the beta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase.  Chromosomal abnormalities involving the T-cell receptor beta locus have been associated with T-cell lymphomas. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Receptor Beta Locus","termGroup":"PT","termSource":"NCI"},{"termName":"T-Cell Receptor Beta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCRB","termGroup":"SY","termSource":"NCI"},{"termName":"TRB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"6957"},{"name":"GenBank_Accession_Number","value":"U66059"},{"name":"Gene_Encodes_Product","value":"T-Cell Receptor Beta Chain"},{"name":"HGNC_ID","value":"HGNC:12155"},{"name":"Legacy Concept Name","value":"T-Cell_Receptor_Beta_Locus"},{"name":"Maps_To","value":"TRB"},{"name":"OMIM_Number","value":"186930"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0524891"}]}}{"C26420":{"preferredName":"T-Cell Receptor Delta Locus","code":"C26420","definitions":[{"definition":"This region represents the germline organization of the T cell receptordelta locus. The delta locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During T cell development, the delta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. (from LocusLink)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"T-Cell Receptor Delta Locus","termGroup":"PT","termSource":"NCI"},{"termName":"T Cell Receptor Delta Locus","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Receptor Delta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TCRD","termGroup":"SY","termSource":"NCI"},{"termName":"TRD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"EntrezGene_ID","value":"6964"},{"name":"GenBank_Accession_Number","value":"M21624"},{"name":"Gene_Encodes_Product","value":"T-Cell Receptor Delta Chain"},{"name":"HGNC_ID","value":"HGNC:12252"},{"name":"Legacy Concept Name","value":"T-Cell_Receptor_Delta_Locus"},{"name":"Maps_To","value":"TRD"},{"name":"OMIM_Number","value":"186810"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0524893"}]}}{"C95280":{"preferredName":"TRIM24 Gene","code":"C95280","definitions":[{"definition":"This gene plays a role in hormone-dependent gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIM24 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TRIM24","termGroup":"SY","termSource":"NCI"},{"termName":"Tripartite Motif-Containing 24 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11812"},{"name":"Maps_To","value":"TRIM24"},{"name":"OMIM_Number","value":"603406"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823488"}]}}{"C24733":{"preferredName":"TRIM27 Gene","code":"C24733","definitions":[{"definition":"This gene is involved in the differentiation of male germ cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIM27 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TRIM27","termGroup":"SY","termSource":"NCI"},{"termName":"Tripartite Motif-Containing 27 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9975"},{"name":"Legacy Concept Name","value":"RFP_Gene"},{"name":"Maps_To","value":"TRIM27"},{"name":"OMIM_Number","value":"602165"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823489"}]}}{"C97858":{"preferredName":"TRIM33 Gene","code":"C97858","definitions":[{"definition":"This gene is involved in the mediation of protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIM33 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TRIM33","termGroup":"SY","termSource":"NCI"},{"termName":"Tripartite Motif Containing 33 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16290"},{"name":"Maps_To","value":"TRIM33"},{"name":"OMIM_Number","value":"605769"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1424158"}]}}{"C97861":{"preferredName":"TRIP11 Gene","code":"C97861","definitions":[{"definition":"This gene plays a role in thyroid receptor binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRIP11 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Thyroid Hormone Receptor Interactor 11 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TRIP11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12305"},{"name":"Maps_To","value":"TRIP11"},{"name":"OMIM_Number","value":"604505"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421146"}]}}{"C24880":{"preferredName":"TRRAP Gene","code":"C24880","definitions":[{"definition":"This gene is involved in DNA repair and regulation of mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRRAP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Transformation/Transcription Domain-Associated Protein Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TRRAP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12347"},{"name":"Legacy Concept Name","value":"TRRAP_Gene"},{"name":"Maps_To","value":"TRRAP"},{"name":"OMIM_Number","value":"603015"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336677"}]}}{"C18259":{"preferredName":"TSC1 Gene","code":"C18259","definitions":[{"definition":"This gene is involved in cell cycle regulation and the loss of cellular adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSC1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TSC1","termGroup":"SY","termSource":"NCI"},{"termName":"Tuberous Sclerosis 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12362"},{"name":"Legacy Concept Name","value":"TSC1_Gene"},{"name":"Maps_To","value":"TSC1"},{"name":"OMIM_Number","value":"605284"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694894"}]}}{"C18260":{"preferredName":"TSC2 Gene","code":"C18260","definitions":[{"definition":"This gene plays a role in signal transduction and cell cycle control. It is involved in cell adhesion, differentiation, growth and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSC2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TSC2","termGroup":"SY","termSource":"NCI"},{"termName":"Tuberous Sclerosis 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12363"},{"name":"Legacy Concept Name","value":"TSC2_Gene"},{"name":"Maps_To","value":"TSC2"},{"name":"OMIM_Number","value":"191092"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694895"}]}}{"C24881":{"preferredName":"TSHR Gene","code":"C24881","definitions":[{"definition":"This gene plays an important role in the regulation of thyroid cell metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSHR Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Thyroid Stimulating Hormone Receptor Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TSHR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12373"},{"name":"Legacy Concept Name","value":"TSHR_Gene"},{"name":"Maps_To","value":"TSHR"},{"name":"OMIM_Number","value":"603372"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336679"}]}}{"C101113":{"preferredName":"U2AF1 Gene","code":"C101113","definitions":[{"definition":"This gene is involved in the splicing of mRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"U2AF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"U2 Small Nuclear RNA Auxiliary Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"U2AF1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12453"},{"name":"Maps_To","value":"U2AF1"},{"name":"OMIM_Number","value":"191317"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421254"}]}}{"C111928":{"preferredName":"UBR5 Gene","code":"C111928","definitions":[{"definition":"This gene plays a role in protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"UBR5 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ubiquitin Protein Ligase E3 Component N-Recognin 5 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"UBR5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16806"},{"name":"Maps_To","value":"UBR5"},{"name":"OMIM_Number","value":"608413"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825027"}]}}{"C24892":{"preferredName":"USP6 Gene","code":"C24892","definitions":[{"definition":"This gene is involved in the regulation of cellular ubiquitination. It also plays a role in promoting the recycling of endocytic vesicles to the plasma membrane.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"USP6 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ubiquitin Specific Peptidase 6 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"USP6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12629"},{"name":"Legacy Concept Name","value":"USP6_Gene"},{"name":"Maps_To","value":"USP6"},{"name":"OMIM_Number","value":"604334"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421407"}]}}{"C24893":{"preferredName":"USP8 Gene","code":"C24893","definitions":[{"definition":"This gene plays a role in ubiquitin-dependent proteolysis and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"USP8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ubiquitin Specific Protease 8 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"USP8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12631"},{"name":"Legacy Concept Name","value":"USP8_Gene"},{"name":"Maps_To","value":"USP8"},{"name":"OMIM_Number","value":"603158"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336848"}]}}{"C18365":{"preferredName":"VAV1 Gene","code":"C18365","definitions":[{"definition":"This gene plays a role in signal transduction. It is involved in the development and activation of both B cells and T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VAV1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Vav Guanine Nucleotide Exchange Factor 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"VAV1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12657"},{"name":"Legacy Concept Name","value":"VAV1_Gene"},{"name":"Maps_To","value":"VAV1"},{"name":"OMIM_Number","value":"164875"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336926"}]}}{"C18261":{"preferredName":"VHL Gene","code":"C18261","definitions":[{"definition":"This gene is involved in transcriptional repression and protein degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VHL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"VHL","termGroup":"SY","termSource":"NCI"},{"termName":"Von Hippel-Lindau Tumor Suppressor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12687"},{"name":"Legacy Concept Name","value":"VHL_Gene"},{"name":"Maps_To","value":"VHL"},{"name":"OMIM_Number","value":"608537"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694897"}]}}{"C99462":{"preferredName":"VTI1A Gene","code":"C99462","definitions":[{"definition":"This gene is involved in vesicular transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VTI1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Vesicle Transport through Interaction with t-SNAREs Homolog 1A (Yeast) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"VTI1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:17792"},{"name":"Maps_To","value":"VTI1A"},{"name":"OMIM_Number","value":"614316"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425079"}]}}{"C43236":{"preferredName":"WAS Gene","code":"C43236","definitions":[{"definition":"This gene is involved in signal transduction and plays a role in cell communication and organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WAS Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WAS","termGroup":"SY","termSource":"NCI"},{"termName":"WASP Actin Nucleation Promoting Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12731"},{"name":"Legacy Concept Name","value":"WAS_Gene"},{"name":"Maps_To","value":"WAS"},{"name":"OMIM_Number","value":"300392"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421478"}]}}{"C101428":{"preferredName":"WDCP Gene","code":"C101428","definitions":[{"definition":"This gene plays a role in binding to tyrosine-protein kinase HCK.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WDCP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"C2orf44","termGroup":"SY","termSource":"NCI"},{"termName":"WD Repeat and Coiled Coil Containing Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WDCP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26157"},{"name":"Maps_To","value":"WDCP"},{"name":"OMIM_Number","value":"616234"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824110"}]}}{"C97867":{"preferredName":"WIF1 Gene","code":"C97867","definitions":[{"definition":"This gene plays a role in Wnt protein-dependent signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WIF1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WIF1","termGroup":"SY","termSource":"NCI"},{"termName":"WNT Inhibitory Factor 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18081"},{"name":"Maps_To","value":"WIF1"},{"name":"OMIM_Number","value":"605186"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1425289"}]}}{"C143106":{"preferredName":"WNK2 Gene","code":"C143106","definitions":[{"definition":"This gene plays a role in electrolyte homeostasis, cell signaling, cell survival, and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WNK2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WNK Lysine Deficient Protein Kinase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WNK2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14542"},{"name":"Maps_To","value":"WNK2"},{"name":"NCI_META_CUI","value":"CL541531"},{"name":"OMIM_Number","value":"606249"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C20070":{"preferredName":"WRN Gene","code":"C20070","definitions":[{"definition":"This gene is involved in DNA repair and the unwinding of DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WRN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Werner Syndrome Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WRN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12791"},{"name":"Legacy Concept Name","value":"WRN_Gene"},{"name":"Maps_To","value":"WRN"},{"name":"OMIM_Number","value":"604611"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337007"}]}}{"C18262":{"preferredName":"WT1 Gene","code":"C18262","definitions":[{"definition":"This gene plays a role in regulation of transcription. It is involved in the control of both cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WT1","termGroup":"SY","termSource":"NCI"},{"termName":"WT1 Transcription Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12796"},{"name":"Legacy Concept Name","value":"WT1_Gene"},{"name":"Maps_To","value":"WT1"},{"name":"OMIM_Number","value":"607102"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0694898"}]}}{"C24844":{"preferredName":"WWTR1 Gene","code":"C24844","definitions":[{"definition":"This gene is involved in regulation of transcription. It is involved in fetal/neonatal cardiac and muscle development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WWTR1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"WW Domain Containing Transcription Regulator 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"WWTR1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24042"},{"name":"Legacy Concept Name","value":"TAZ_Gene"},{"name":"Maps_To","value":"WWTR1"},{"name":"OMIM_Number","value":"607392"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538117"}]}}{"C20361":{"preferredName":"XPA Gene","code":"C20361","definitions":[{"definition":"This gene facilitates DNA binding in repair processes and is associated with the disease xeroderma pigmentosum complementation group A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XPA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Xeroderma Pigmentosum, Complementation Group A Gene","termGroup":"SY","termSource":"NCI"},{"termName":"XPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12814"},{"name":"Legacy Concept Name","value":"XPA_Gene"},{"name":"Maps_To","value":"XPA"},{"name":"OMIM_Number","value":"611153"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1337030"}]}}{"C97870":{"preferredName":"XPC Gene","code":"C97870","definitions":[{"definition":"This gene is involved in nucleotide excision repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XPC Gene","termGroup":"PT","termSource":"NCI"},{"termName":"XPC","termGroup":"SY","termSource":"NCI"},{"termName":"XPC Complex Subunit, DNA Damage Recognition and Repair Factor Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12816"},{"name":"Maps_To","value":"XPC"},{"name":"OMIM_Number","value":"613208"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421540"}]}}{"C99484":{"preferredName":"XPO1 Gene","code":"C99484","definitions":[{"definition":"This gene plays a role in the regulation of nuclear export.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XPO1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Exportin 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"XPO1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12825"},{"name":"Maps_To","value":"XPO1"},{"name":"OMIM_Number","value":"602559"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421544"}]}}{"C101116":{"preferredName":"YWHAE Gene","code":"C101116","definitions":[{"definition":"This gene plays a role in signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"YWHAE Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Epsilon Polypeptide Gene","termGroup":"SY","termSource":"NCI"},{"termName":"YWHAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12851"},{"name":"Maps_To","value":"YWHAE"},{"name":"OMIM_Number","value":"605066"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421560"}]}}{"C28635":{"preferredName":"ZBTB16 Gene","code":"C28635","definitions":[{"definition":"This gene plays a role in apoptosis and regulation of transcription. It is also involved in cell organization/biogenesis and megakaryocytic development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZBTB16 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZBTB16","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger and BTB Domain Containing 16 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12930"},{"name":"Legacy Concept Name","value":"ZNF145_Gene"},{"name":"Maps_To","value":"ZBTB16"},{"name":"OMIM_Number","value":"176797"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538149"}]}}{"C122878":{"preferredName":"ZCCHC8 Gene","code":"C122878","definitions":[{"definition":"This gene plays a role in RNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZCCHC8 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZCCHC8","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger CCHC-Type Containing 8 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25265"},{"name":"Maps_To","value":"ZCCHC8"},{"name":"OMIM_Number","value":"616381"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428463"}]}}{"C105605":{"preferredName":"ZEB1 Gene","code":"C105605","definitions":[{"definition":"This gene is involved in the transcriptional repression of interleukin 2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZEB1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZEB1","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger E-Box Binding Homeobox 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11642"},{"name":"Maps_To","value":"ZEB1"},{"name":"OMIM_Number","value":"189909"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420645"}]}}{"C115424":{"preferredName":"ZFHX3 Gene","code":"C115424","definitions":[{"definition":"This gene is involved in myoblast and neuronal differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZFHX3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZFHX3","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger Homeobox 3 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:777"},{"name":"Maps_To","value":"ZFHX3"},{"name":"OMIM_Number","value":"104155"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412611"}]}}{"C101617":{"preferredName":"ZMYM3 Gene","code":"C101617","definitions":[{"definition":"This gene is involved in chromatin modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZMYM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger, MYM-Type 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZMYM3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:13054"},{"name":"Maps_To","value":"ZMYM3"},{"name":"OMIM_Number","value":"300061"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823959"}]}}{"C97873":{"preferredName":"ZMYM2 Gene","code":"C97873","definitions":[{"definition":"This gene plays a role in transcriptional modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZMYM2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger MYM-Type Containing 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZMYM2","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF198","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12989"},{"name":"Maps_To","value":"ZNF198"},{"name":"OMIM_Number","value":"602221"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1823958"}]}}{"C97879":{"preferredName":"ZNF331 Gene","code":"C97879","definitions":[{"definition":"This gene plays a role in transcriptional regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF331 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 331 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF331","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15489"},{"name":"Maps_To","value":"ZNF331"},{"name":"OMIM_Number","value":"606043"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423527"}]}}{"C97882":{"preferredName":"ZNF384 Gene","code":"C97882","definitions":[{"definition":"This gene is involved in both transcriptional regulation and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF384 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 384 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF384","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11955"},{"name":"Maps_To","value":"ZNF384"},{"name":"OMIM_Number","value":"609951"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420834"}]}}{"C143100":{"preferredName":"ZNF429 Gene","code":"C143100","definitions":[{"definition":"This gene may play a role in the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF429 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 429 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF429","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20817"},{"name":"Maps_To","value":"ZNF429"},{"name":"NCI_META_CUI","value":"CL541541"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C106358":{"preferredName":"ZNF444 Gene","code":"C106358","definitions":[{"definition":"This gene is involved in LDL metabolism, transcriptional regulation and DNA binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF444 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 444 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF444","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:16052"},{"name":"Maps_To","value":"ZNF444"},{"name":"OMIM_Number","value":"607874"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423940"}]}}{"C143103":{"preferredName":"ZNF479 Gene","code":"C143103","definitions":[{"definition":"This gene may play a role in the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF479 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 479 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF479","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23258"},{"name":"Maps_To","value":"ZNF479"},{"name":"NCI_META_CUI","value":"CL541544"},{"name":"OMIM_Number","value":"617444"},{"name":"Semantic_Type","value":"Gene or Genome"}]}}{"C97885":{"preferredName":"ZNF521 Gene","code":"C97885","definitions":[{"definition":"This gene plays a role in both the positive and negative regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNF521 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger Protein 521 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNF521","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24605"},{"name":"Maps_To","value":"ZNF521"},{"name":"OMIM_Number","value":"610974"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428393"}]}}{"C118319":{"preferredName":"ZNRF3 Gene","code":"C118319","definitions":[{"definition":"This gene is involved in protein ubiquitination and Wnt pathway inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZNRF3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc and Ring Finger 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZNRF3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:18126"},{"name":"Maps_To","value":"ZNRF3"},{"name":"OMIM_Number","value":"612062"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538251"}]}}{"C101120":{"preferredName":"ZRSR2 Gene","code":"C101120","definitions":[{"definition":"This gene is involved in mRNA processing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZRSR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"ZRSR2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:23019"},{"name":"Maps_To","value":"ZRSR2"},{"name":"OMIM_Number","value":"300028"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824082"}]}}{"C21167":{"preferredName":"CHGA Gene","code":"C21167","definitions":[{"definition":"This gene plays a role in the modulation of the neuroendocrine system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHGA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CHGA","termGroup":"SY","termSource":"NCI"},{"termName":"Chromogranin A Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1929"},{"name":"Legacy Concept Name","value":"CHGA_Gene"},{"name":"Maps_To","value":"CHGA"},{"name":"OMIM_Number","value":"118910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1332754"}]}}{"C101144":{"preferredName":"SYP Gene","code":"C101144","definitions":[{"definition":"This gene is involved in vesicle targeting and synaptic plasticity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SYP Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Synaptophysin Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SYP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11506"},{"name":"Maps_To","value":"SYP"},{"name":"OMIM_Number","value":"313475"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1420554"}]}}{"C181091":{"preferredName":"AQP1 Gene","code":"C181091","definitions":[{"definition":"This gene plays a role in transmembrane transport of water.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AQP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"AQP1","termGroup":"SY","termSource":"NCI"},{"termName":"Aquaporin 1 (Colton Blood Group) Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:633"},{"name":"Maps_To","value":"AQP1"},{"name":"OMIM_Number","value":"107776"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412491"}]}}{"C123856":{"preferredName":"CALB2 Gene","code":"C123856","definitions":[{"definition":"This gene is involved in calcium ion homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CALB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CALB2","termGroup":"SY","termSource":"NCI"},{"termName":"Calbindin 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1435"},{"name":"Maps_To","value":"CALB2"},{"name":"OMIM_Number","value":"114051"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413081"}]}}{"C26556":{"preferredName":"DNTT Gene","code":"C26556","definitions":[{"definition":"This gene is involved in DNA synthesis. It also plays a role in the generation of antigen diversity in pre-B and pre-T lymphocytes during early differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNTT Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Deoxynucleotidyltransferase, Terminal Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DNTT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2983"},{"name":"Legacy Concept Name","value":"DNTT_Gene"},{"name":"Maps_To","value":"DNTT"},{"name":"OMIM_Number","value":"187410"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333243"}]}}{"C18421":{"preferredName":"EPCAM Gene","code":"C18421","definitions":[{"definition":"This gene is involved in calcium-independent cellular adhesion and in the regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EPCAM Gene","termGroup":"PT","termSource":"NCI"},{"termName":"EPCAM","termGroup":"SY","termSource":"NCI"},{"termName":"Epithelial Cell Adhesion Molecule Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TACSTD1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CCPS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11529"},{"name":"Legacy Concept Name","value":"TACSTD1_Gene"},{"name":"Maps_To","value":"EPCAM"},{"name":"OMIM_Number","value":"185535"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C0812305"}]}}{"C106015":{"preferredName":"SERPINA9 Gene","code":"C106015","definitions":[{"definition":"This gene is involved in trypsin activity regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SERPINA9 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Serpin Family A Member 9","termGroup":"SY","termSource":"NCI"},{"termName":"SERPINA9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:15995"},{"name":"Maps_To","value":"GCET1"},{"name":"OMIM_Number","value":"615677"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423895"}]}}{"C104785":{"preferredName":"PDPN Gene","code":"C104785","definitions":[{"definition":"This gene plays a role in cell shape.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDPN Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PDPN","termGroup":"SY","termSource":"NCI"},{"termName":"Podoplanin Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29602"},{"name":"Maps_To","value":"PDPN"},{"name":"OMIM_Number","value":"608863"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826560"}]}}{"C26598":{"preferredName":"PTGS2 Gene","code":"C26598","definitions":[{"definition":"This gene is involved in mitogenesis, inflammation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTGS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"COX2","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin-Endoperoxide Synthase 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTGS2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9605"},{"name":"Legacy Concept Name","value":"PTGS2_Gene"},{"name":"Maps_To","value":"PTGS2"},{"name":"OMIM_Number","value":"600262"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1367485"}]}}{"C24863":{"preferredName":"TLR2 Gene","code":"C24863","definitions":[{"definition":"This gene plays a role in pathogen recognition and mediates the host response to gram-positive bacteria and yeast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"TLR2","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-Like Receptor 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11848"},{"name":"Legacy Concept Name","value":"TLR2_Gene"},{"name":"Maps_To","value":"TLR2"},{"name":"OMIM_Number","value":"603028"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336634"}]}}{"C103885":{"preferredName":"ACACA Gene","code":"C103885","definitions":[{"definition":"This gene plays a role in the synthesis of long-chain fatty acids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ACACA Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ACACA","termGroup":"SY","termSource":"NCI"},{"termName":"Acetyl-CoA Carboxylase Alpha Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:84"},{"name":"Maps_To","value":"ACACA"},{"name":"OMIM_Number","value":"200350"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412104"}]}}{"C185736":{"preferredName":"BRD1 Gene","code":"C185736","definitions":[{"definition":"This gene is involved in the localization of histone acetyltransferase complexes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BRD1","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain Containing 1 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1102"},{"name":"Maps_To","value":"BRD1"},{"name":"OMIM_Number","value":"604589"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1412820"}]}}{"C126629":{"preferredName":"BTBD18 Gene","code":"C126629","definitions":[{"definition":"This gene may be involved in protein ubiquitination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTBD18 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"BTB Domain Containing 18 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"BTBD18","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:37214"},{"name":"Maps_To","value":"BTBD18"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2828831"}]}}{"C104928":{"preferredName":"CBFA2T2 Gene","code":"C104928","definitions":[{"definition":"This gene may be involved in tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBFA2T2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CBFA2T2","termGroup":"SY","termSource":"NCI"},{"termName":"Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:1536"},{"name":"Maps_To","value":"CBFA2T2"},{"name":"OMIM_Number","value":"603672"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413148"}]}}{"C200372":{"preferredName":"CEP164 Gene","code":"C200372","definitions":[{"definition":"This gene is involved in the formation of cilium basal bodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP164 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 164 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP164","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29182"},{"name":"Maps_To","value":"CEP164"},{"name":"OMIM_Number","value":"614848"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1824720"}]}}{"C126611":{"preferredName":"CEP170B Gene","code":"C126611","definitions":[{"definition":"This gene may be involved in microtubule organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEP170B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Centrosomal Protein 170B Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CEP170B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:20362"},{"name":"Maps_To","value":"CEP170B"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1426896"}]}}{"C200378":{"preferredName":"CTDP1 Gene","code":"C200378","definitions":[{"definition":"This gene plays a role in the dephosphorylation of the C-terminal domain (CTD) of RNA polymerase II subunit A (POLR2A).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CTDP1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"CTD Phosphatase Subunit 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"CTDP1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:2498"},{"name":"Maps_To","value":"CTDP1"},{"name":"OMIM_Number","value":"604927"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1413790"}]}}{"C73677":{"preferredName":"DOT1L Gene","code":"C73677","definitions":[{"definition":"This gene is involved in epigenetic control of gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DOT1L Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DOT1-like, Histone H3 Methyltransferase (S. cerevisiae) Gene","termGroup":"SY","termSource":"NCI"},{"termName":"DOT1L","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:24948"},{"name":"Legacy Concept Name","value":"DOT1L_Gene"},{"name":"Maps_To","value":"DOT1L"},{"name":"OMIM_Number","value":"607375"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428431"}]}}{"C126623":{"preferredName":"FRYL Gene","code":"C126623","definitions":[{"definition":"This gene is involved in the regulation of cell shape and polarity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FRYL Gene","termGroup":"PT","termSource":"NCI"},{"termName":"FRY-Like Gene","termGroup":"SY","termSource":"NCI"},{"termName":"FRYL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29127"},{"name":"Maps_To","value":"FRYL"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1825320"}]}}{"C105900":{"preferredName":"GLIS2 Gene","code":"C105900","definitions":[{"definition":"This gene is involved in transcriptional regulation and signaling pathway modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GLIS2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"GLIS Family Zinc Finger 2 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"GLIS2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29450"},{"name":"Maps_To","value":"GLIS2"},{"name":"OMIM_Number","value":"608539"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1539573"}]}}{"C20580":{"preferredName":"HMGB3 Gene","code":"C20580","definitions":[{"definition":"This gene plays a role in development and the regulation of gene transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMGB3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"High-Mobility Group Box 3 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HMGB3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5004"},{"name":"Legacy Concept Name","value":"HMGB3_Gene"},{"name":"Maps_To","value":"HMGB3"},{"name":"OMIM_Number","value":"300193"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1333910"}]}}{"C200386":{"preferredName":"HNRNPH1 Gene","code":"C200386","definitions":[{"definition":"This gene is involved in the regulation of alternative pre-mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HNRNPH1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Heterogeneous Nuclear Ribonucleoprotein H1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"HNRNPH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:5041"},{"name":"Maps_To","value":"HNRNPH1"},{"name":"OMIM_Number","value":"601035"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1415642"}]}}{"C125258":{"preferredName":"INO80D Gene","code":"C125258","definitions":[{"definition":"This gene plays a role in ATP-dependent chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INO80D Gene","termGroup":"PT","termSource":"NCI"},{"termName":"INO80 Complex Subunit D Gene","termGroup":"SY","termSource":"NCI"},{"termName":"INO80D","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:25997"},{"name":"Maps_To","value":"INO80D"},{"name":"OMIM_Number","value":"619207"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C2681613"}]}}{"C200399":{"preferredName":"JARID2 Gene","code":"C200399","definitions":[{"definition":"This gene plays a role in transcriptional repression and the regulation of Polycomb repressive complex 2 (PRC2)-mediated histone methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JARID2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"JARID2","termGroup":"SY","termSource":"NCI"},{"termName":"Jumonji and AT-Rich Interaction Domain Containing 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:6196"},{"name":"Maps_To","value":"JARID2"},{"name":"OMIM_Number","value":"601594"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1416528"}]}}{"C98035":{"preferredName":"PHF23 Gene","code":"C98035","definitions":[{"definition":"This gene may be involved in chromatin remodeling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PHF23 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"PHD Finger Protein 23 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PHF23","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:28428"},{"name":"Maps_To","value":"PHF23"},{"name":"OMIM_Number","value":"612910"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1826581"}]}}{"C178143":{"preferredName":"PIM3 Gene","code":"C178143","definitions":[{"definition":"This gene is involved in serine/threonine kinase activity that inhibits apoptosis, promotes cell survival and regulates protein translation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM3 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Pim-3 Proto-Oncogene, Serine/Threonine Kinase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PIM3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:19310"},{"name":"Maps_To","value":"PIM3"},{"name":"OMIM_Number","value":"610580"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1538648"}]}}{"C24704":{"preferredName":"PTP4A1 Gene","code":"C24704","definitions":[{"definition":"This gene is involved in liver cell growth and the cellular response to mitogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PTP4A1 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Phosphatase Type IVA, Member 1 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"PTP4A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:9634"},{"name":"Legacy Concept Name","value":"PTP4A1_Gene"},{"name":"Maps_To","value":"PTP4A1"},{"name":"OMIM_Number","value":"601585"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335279"}]}}{"C200404":{"preferredName":"RPS15 Gene","code":"C200404","definitions":[{"definition":"This gene is involved in the maturation and nuclear export of the 40S ribosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RPS15 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"Ribosomal Protein S15 Gene","termGroup":"SY","termSource":"NCI"},{"termName":"RPS15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:10388"},{"name":"Legacy Concept Name","value":"RPL10_Gene"},{"name":"Maps_To","value":"RPS15"},{"name":"OMIM_Number","value":"180535"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1419704"}]}}{"C200408":{"preferredName":"SETD1A Gene","code":"C200408","definitions":[{"definition":"This gene plays a role in the transfer of one to three methyl groups to the lysine at amino acid residue 4 of histone H3 (H3K4).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SETD1A Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SET Domain Containing 1A, Histone Lysine Methyltransferase Gene","termGroup":"SY","termSource":"NCI"},{"termName":"SETD1A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:29010"},{"name":"Legacy Concept Name","value":"SETD2_Gene"},{"name":"Maps_To","value":"SETD1A"},{"name":"OMIM_Number","value":"611052"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1822684"}]}}{"C200414":{"preferredName":"SLC66A2 Gene","code":"C200414","definitions":[{"definition":"This gene may be involved in retrograde transport and phospholipid translocation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SLC66A2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"SLC66A2","termGroup":"SY","termSource":"NCI"},{"termName":"Solute Carrier Family 66 Member 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:26188"},{"name":"Maps_To","value":"SLC66A2 (aka PQLC1)"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1428559"}]}}{"C26593":{"preferredName":"TOP2B Gene","code":"C26593","definitions":[{"definition":"This gene is involved in chromosome recombination, DNA replication and the regulation of DNA topology during transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TOP2B Gene","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Topoisomerase II Beta Gene","termGroup":"SY","termSource":"NCI"},{"termName":"TOP2B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:11990"},{"name":"Legacy Concept Name","value":"TOP2B_Gene"},{"name":"Maps_To","value":"TOP2B"},{"name":"OMIM_Number","value":"126431"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1336658"}]}}{"C38431":{"preferredName":"UBB Gene","code":"C38431","definitions":[{"definition":"This gene is involved in ubiquitin-dependent proteolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"UBB Gene","termGroup":"PT","termSource":"NCI"},{"termName":"UBB","termGroup":"SY","termSource":"NCI"},{"termName":"Ubiquitin B Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:12463"},{"name":"Legacy Concept Name","value":"UBB_Gene"},{"name":"Maps_To","value":"UBB"},{"name":"OMIM_Number","value":"191339"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1421262"}]}}{"C75441":{"preferredName":"ZEB2 Gene","code":"C75441","definitions":[{"definition":"This gene is involved in regulation of transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ZEB2 Gene","termGroup":"PT","termSource":"NCI"},{"termName":"ZEB2","termGroup":"SY","termSource":"NCI"},{"termName":"Zinc Finger E-Box Binding Homeobox 2 Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:14881"},{"name":"Legacy Concept Name","value":"ZEB2_Gene"},{"name":"Maps_To","value":"ZEB2"},{"name":"OMIM_Number","value":"605802"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1423021"}]}}{"C91742":{"preferredName":"MPO Gene","code":"C91742","definitions":[{"definition":"This gene is involved in the modulation of neutrophil microbicidal activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MPO Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MPO","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloperoxidase Gene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"HGNC_ID","value":"HGNC:7218"},{"name":"Maps_To","value":"MPO"},{"name":"OMIM_Number","value":"606989"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1417245"}]}}{"C25784":{"preferredName":"RAS Family Gene","code":"C25784","definitions":[{"definition":"A family of genes that encode structurally similar small GTPases involved in a variety of signal transduction pathways. Mutation of genes in this family is associated with cancer.","type":"DEFINITION","source":"NCI"},{"definition":"A family of genes that may cause cancer when they are mutated (changed). They make proteins that are involved in cell signaling pathways, cell growth, and apoptosis (cell death). Agents that block the actions of a mutated ras gene or its protein may stop the growth of cancer. Members of the ras gene family include Kras, Hras, and Nras.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"RAS Family Gene","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"RAS_Family_Gene"},{"name":"Maps_To","value":"RAS, NOS"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"UMLS_CUI","value":"C1335597"}]}}{"C16683":{"preferredName":"Histone H1","code":"C16683","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H1. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. Histones are basic nuclear proteins responsible for the nucleosome structure of eukaryotic chromatin. Repeating nucleosome units contain two molecules each of core Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H1"},{"name":"Maps_To","value":"H1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0019644"}]}}{"C16684":{"preferredName":"Histone H2A","code":"C16684","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H2A. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Slightly lysine rich histone.  One of four histones assembled into a nucleosomal core octamer.  Various posttranslationally modified forms and variants exist.  Combines with histone H2B in a heterodimer; two H2A/H2B dimers are incorporated in the nucleosomal octamer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A","termGroup":"PT","termSource":"NCI"},{"termName":"H2A","termGroup":"SY","termSource":"NCI"},{"termName":"HIST1H2A","termGroup":"SY","termSource":"NCI"},{"termName":"Histone 2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H2A"},{"name":"Maps_To","value":"H2A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0019646"}]}}{"C17460":{"preferredName":"Histone H2B","code":"C17460","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H2B. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H2B is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H2B"},{"name":"Maps_To","value":"H2B"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0086411"}]}}{"C16685":{"preferredName":"Histone H3","code":"C16685","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H3. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H3 is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Histone-H3"},{"name":"Maps_To","value":"H3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0019647"}]}}{"C16686":{"preferredName":"Histone H4","code":"C16686","definitions":[{"definition":"An antigen in the core histone family and a subunit of the nucleosome complex, with a designation of H4. It can be considered as an autoantigen and is commonly associated with the autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H4 (103 aa, ~11 kDa) is encoded by the human H4C1, H4C2, H4C3, H4C4, H4C5, H4C6, H4C6, H4C8, H4C9, H4C11, H4C12, H4C13, H4C14, H4C15, H4-16 genes. This protein plays a role in nucleating the formation of high order chromatin structures as a part of nucleosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H4","termGroup":"PT","termSource":"NCI"},{"termName":"HIST1H4","termGroup":"SY","termSource":"NCI"},{"termName":"Histone 1, H4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Histone H4 is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. The nucleosome interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures."},{"name":"DesignNote","value":"Histone H4 is encoded for by a cluster of genes that are clustered in the vicinity of 6p21.33 and all have the same SwissProt identifier."},{"name":"Legacy Concept Name","value":"Histone-H4"},{"name":"Maps_To","value":"H4"},{"name":"OMIM_Number","value":"602830"},{"name":"OMIM_Number","value":"602833"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P62805"},{"name":"UMLS_CUI","value":"C0019648"}]}}{"C152974":{"preferredName":"Histone H3-Like Centromeric Protein A","code":"C152974","definitions":[{"definition":"An antigen of the centromere protein encoded by the CENPA gene, with a designation of A. It can be considered as an autoantigen and is commonly associated with the autoimmune disease CREST syndrome.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Histone H3-like centromeric protein A (140 aa, ~16 kDa) is encoded by the human CENPA gene. This protein plays a role in cell cycle progression, cell division and centromeric nucleosome assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3-Like Centromeric Protein A","termGroup":"PT","termSource":"NCI"},{"termName":"CENP-A","termGroup":"SY","termSource":"NCI"},{"termName":"CENPA","termGroup":"SY","termSource":"NCI"},{"termName":"Centromere Autoantigen A","termGroup":"SY","termSource":"NCI"},{"termName":"Centromere Protein A","termGroup":"SY","termSource":"NCI"},{"termName":"Centromere-Specific Histone","termGroup":"SY","termSource":"NCI"},{"termName":"Centromeric Protein A","termGroup":"SY","termSource":"NCI"},{"termName":"Histone cenH3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CENP-A"},{"name":"NCI_META_CUI","value":"CL554177"},{"name":"OMIM_Number","value":"117139"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P49450"}]}}{"C154613":{"preferredName":"Histone H2A-Bbd","code":"C154613","definitions":[{"definition":"A variant form of histone H2A found in chromatin structures that are transcriptionally active.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A-Bbd","termGroup":"PT","termSource":"NCI"},{"termName":"H2A Barr Body Deficient","termGroup":"SY","termSource":"NCI"},{"termName":"H2A Barr Body-Deficient","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.B","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Bbd","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A-Bbd"},{"name":"NCI_META_CUI","value":"CL555506"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C19432":{"preferredName":"Histone H2AX","code":"C19432","definitions":[{"definition":"Histone H2AX (143 aa, ~15 kDa) is encoded by the human H2AX gene. This protein plays a role in nucleosome formation and V(D)J recombination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2AX","termGroup":"PT","termSource":"NCI"},{"termName":"H2A Histone Family, Member X","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.X","termGroup":"SY","termSource":"NCI"},{"termName":"H2A/X","termGroup":"SY","termSource":"NCI"},{"termName":"H2AFX","termGroup":"SY","termSource":"NCI"},{"termName":"H2AX","termGroup":"SY","termSource":"NCI"},{"termName":"H2AX Histone","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.X","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Histone H2AX is a variant histone H2A that replaces conventional H2A proteins."},{"name":"Legacy Concept Name","value":"Histone-H2AX"},{"name":"Maps_To","value":"H2A.X"},{"name":"OMIM_Number","value":"601772"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P16104"},{"name":"UMLS_CUI","value":"C1172465"}]}}{"C126766":{"preferredName":"Histone H2A.Z","code":"C126766","definitions":[{"definition":"Histone H2A.Z (128 aa, ~14 kDa) is encoded by the human H2AZ1 gene. This protein is involved in nucleosome and heterochromatin formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A.Z","termGroup":"PT","termSource":"NCI"},{"termName":"H2A.Z-1","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.1","termGroup":"SY","termSource":"NCI"},{"termName":"H2A/z","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ Histone","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A.Z"},{"name":"Maps_To","value":"H2A.Z.1"},{"name":"NCI_META_CUI","value":"CL507981"},{"name":"OMIM_Number","value":"142763"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P0C0S5"}]}}{"C162832":{"preferredName":"Histone H2A.V","code":"C162832","definitions":[{"definition":"Histone H2A.V (128 aa, ~14 kDa) is encoded by the human H2AZ2 gene. This protein is involved in nucleosome formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A.V","termGroup":"PT","termSource":"NCI"},{"termName":"H2A.F/Z","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z-2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z-2.1","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.2.1","termGroup":"SY","termSource":"NCI"},{"termName":"H2AFV","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.F/Z","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.V Isoform 1","termGroup":"SY","termSource":"NCI"},{"termName":"Purine-Rich Binding Element Protein B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A.Z.2"},{"name":"NCI_META_CUI","value":"CL973150"},{"name":"OMIM_Number","value":"620128"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q71UI9"}]}}{"C162834":{"preferredName":"Histone H2A.V Isoform 2","code":"C162834","definitions":[{"definition":"Histone H2A.V isoform 2 (114 aa, ~12 kDa) is encoded by the human H2AZ2 gene. This protein plays a role in nucleosome stability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H2A.V Isoform 2","termGroup":"PT","termSource":"NCI"},{"termName":"H2A.Z-2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A.Z.2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2AZ2","termGroup":"SY","termSource":"NCI"},{"termName":"Z.2.2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H2A.Z.2.2"},{"name":"NCI_META_CUI","value":"CL973148"},{"name":"OMIM_Number","value":"620128"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q71UI9"}]}}{"C101734":{"preferredName":"Histone H3.1","code":"C101734","definitions":[{"definition":"Histone H3.1 (136 aa, ~15 kDa) is encoded by the human H3C1, H3C2, H3C3, H3C4, H3C6, H3C7, H3C8, H3C10, H3C11 and H3C12 genes. This protein plays a role in the formation of chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.1","termGroup":"PT","termSource":"NCI"},{"termName":"Histone H3/a","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/b","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/c","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/d","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/f","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/h","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/i","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/j","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/k","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/l","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.1"},{"name":"OMIM_Number","value":"602810"},{"name":"OMIM_Number","value":"602811"},{"name":"OMIM_Number","value":"602812"},{"name":"OMIM_Number","value":"602813"},{"name":"OMIM_Number","value":"602814"},{"name":"OMIM_Number","value":"602815"},{"name":"OMIM_Number","value":"602816"},{"name":"OMIM_Number","value":"602817"},{"name":"OMIM_Number","value":"602818"},{"name":"OMIM_Number","value":"602819"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P68431"},{"name":"UMLS_CUI","value":"C3640207"}]}}{"C148067":{"preferredName":"Histone H3.2","code":"C148067","definitions":[{"definition":"Histone H3.2 (136 aa, ~15 kDa) is encoded by the human H3C13, H3C14 and H3C15 genes. This protein plays a role in nucleosome remodeling and chromosomal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.2","termGroup":"PT","termSource":"NCI"},{"termName":"Histone H3/m","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3/o","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.2"},{"name":"NCI_META_CUI","value":"CL545807"},{"name":"OMIM_Number","value":"142780"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q71DI3"}]}}{"C101445":{"preferredName":"Histone H3.3","code":"C101445","definitions":[{"definition":"Histone H3.3 (136 aa, ~15 kDa) is encoded by both the human H3-3A and H3-3B genes. This protein plays a role in chromosomal structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.3","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.3"},{"name":"OMIM_Number","value":"601058"},{"name":"OMIM_Number","value":"601128"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P84243"},{"name":"UMLS_CUI","value":"C0086412"}]}}{"C154668":{"preferredName":"Histone H3.3C","code":"C154668","definitions":[{"definition":"Histone H3.3C (135 aa, ~15 kDa) is encoded by the human H3-5 gene. This protein is involved in the modulation of DNA accessibility to the transcriptional machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.3C","termGroup":"PT","termSource":"NCI"},{"termName":"H3-5","termGroup":"SY","termSource":"NCI"},{"termName":"H3.3C","termGroup":"SY","termSource":"NCI"},{"termName":"H3.5","termGroup":"SY","termSource":"NCI"},{"termName":"H3F3C","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.5"},{"name":"NCI_META_CUI","value":"CL555444"},{"name":"OMIM_Number","value":"616134"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q6NXT2"}]}}{"C188199":{"preferredName":"Histone H3.X","code":"C188199","definitions":[{"definition":"Histone H3.X (147 aa, ~16 kDa) is encoded by the human H3Y2 gene. This protein may be involved in both transcriptional regulation and the formation of higher order chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.X","termGroup":"PT","termSource":"NCI"},{"termName":"H3.X","termGroup":"SY","termSource":"NCI"},{"termName":"H3.Y.2","termGroup":"SY","termSource":"NCI"},{"termName":"H3Y2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y.2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3.X"},{"name":"NCI_META_CUI","value":"CL1793117"},{"name":"PubMedID_Primary_Reference","value":"20819935"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P0DPK5"}]}}{"C155738":{"preferredName":"Histone H3.Y","code":"C155738","definitions":[{"definition":"Histone H3.Y (136 aa, ~15 kDa) is encoded by the human H3Y1 gene. This protein may be involved in both the positive regulation of transcription and the formation of higher order chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.Y","termGroup":"PT","termSource":"NCI"},{"termName":"H3.Y","termGroup":"SY","termSource":"NCI"},{"termName":"H3.Y.1","termGroup":"SY","termSource":"NCI"},{"termName":"H3Y1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.y","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y.1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.Y1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Histone H3.Y protein has been deposited in RefSeq with accession number NP_001342187."},{"name":"Maps_To","value":"H3.Y"},{"name":"NCI_META_CUI","value":"CL556224"},{"name":"PubMedID_Primary_Reference","value":"20819935"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"P0DPK2"}]}}{"C154671":{"preferredName":"Histone H3.1t","code":"C154671","definitions":[{"definition":"Histone H3.1t (136 aa, ~16 kDa) is encoded by the human H3-4 gene. This protein is involved in formation of higher order chromatin structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3.1t","termGroup":"PT","termSource":"NCI"},{"termName":"H3-4","termGroup":"SY","termSource":"NCI"},{"termName":"H3.4","termGroup":"SY","termSource":"NCI"},{"termName":"H3/g","termGroup":"SY","termSource":"NCI"},{"termName":"H3/t","termGroup":"SY","termSource":"NCI"},{"termName":"H3t","termGroup":"SY","termSource":"NCI"},{"termName":"HIST3H3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3.4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3t (H3.4)"},{"name":"NCI_META_CUI","value":"CL555447"},{"name":"OMIM_Number","value":"602820"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q16695"}]}}{"C95407":{"preferredName":"Core Histone Macro-H2A","code":"C95407","definitions":[{"definition":"A histone protein that is comprised of a histone H2A domain, which allows interaction with the nucleosome, and a macro domain, which may bind to ADP-ribose. This protein can substitute for histone H2A in the nucleosomal complex and plays a role in transcriptional repression and X chromosome inactivation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Core Histone Macro-H2A","termGroup":"PT","termSource":"NCI"},{"termName":"Histone MacroH2A","termGroup":"SY","termSource":"NCI"},{"termName":"MacroH2A","termGroup":"SY","termSource":"NCI"},{"termName":"mH2A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mH2A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0908130"}]}}{"C113624":{"preferredName":"Core Histone Macro-H2A.1","code":"C113624","definitions":[{"definition":"Core histone macro-H2A.1 (372 aa, ~40 kDa) is encoded by the human MACROH2A1 gene. This protein plays a role in chromatin modification.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Core Histone Macro-H2A.1","termGroup":"PT","termSource":"NCI"},{"termName":"H2A/y","termGroup":"SY","termSource":"NCI"},{"termName":"H2A1.1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H2A.Y","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A1.1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A1.2","termGroup":"SY","termSource":"NCI"},{"termName":"MACROH2A1","termGroup":"SY","termSource":"NCI"},{"termName":"MACROH2A1.1","termGroup":"SY","termSource":"NCI"},{"termName":"Medulloblastoma Antigen MU-MB-50.205","termGroup":"SY","termSource":"NCI"},{"termName":"mH2A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mH2A.1"},{"name":"OMIM_Number","value":"610054"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"O75367"},{"name":"UMLS_CUI","value":"C3814450"}]}}{"C154659":{"preferredName":"Core Histone Macro-H2A.2","code":"C154659","definitions":[{"definition":"Core histone macro-H2A.2 (372 aa, ~40 kDa) is encoded by the human MACROH2A2 gene. This protein plays a role in nucleosome formation and transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Core Histone Macro-H2A.2","termGroup":"PT","termSource":"NCI"},{"termName":"Core Histone MacroH2A2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2A2.2","termGroup":"SY","termSource":"NCI"},{"termName":"H2AFY2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone MacroH2A2","termGroup":"SY","termSource":"NCI"},{"termName":"MACROH2A2","termGroup":"SY","termSource":"NCI"},{"termName":"mH2A2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mH2A.2"},{"name":"NCI_META_CUI","value":"CL555437"},{"name":"OMIM_Number","value":"616141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Swiss_Prot","value":"Q9P0M6"}]}}{"C112217":{"preferredName":"5-Hydroxyindoleacetic Acid Measurement","code":"C112217","definitions":[{"definition":"A measurement of 5-hydroxyindoleacetic acid in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of 5-hydroxyindoleacetic acid present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5-Hydroxyindoleacetic Acid Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5-Hydroxyindoleacetic Acid"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0523708"}]}}{"C63321":{"preferredName":"Absolute Neutrophil Count","code":"C63321","definitions":[{"definition":"A measurement of the neutrophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Absolute Neutrophil Count","termGroup":"PT","termSource":"NCI"},{"termName":"ANC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Absolute_Neutrophil_Count"},{"name":"Maps_To","value":"Absolute Neutrophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0948762"}]}}{"C64431":{"preferredName":"Albumin Measurement","code":"C64431","definitions":[{"definition":"A measurement of the albumin protein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of albumin present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Albumin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Albumin_Measurement"},{"name":"Maps_To","value":"Albumin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201838"}]}}{"C74732":{"preferredName":"Alpha-fetoprotein Measurement","code":"C74732","definitions":[{"definition":"A measurement of the alpha fetoprotein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of alpha-fetoprotein present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-fetoprotein Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Alpha-fetoprotein_Measurement"},{"name":"Maps_To","value":"Alpha Fetoprotein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201539"}]}}{"C171142":{"preferredName":"B-Cell Genotyping Assay","code":"C171142","definitions":[{"definition":"The determination of the genomic DNA sequences in a subject's B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Cell Genotyping Assay","termGroup":"PT","termSource":"NCI"},{"termName":"B-Cell Genotyping","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"B-cell genotyping"},{"name":"NCI_META_CUI","value":"CL1405363"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C64470":{"preferredName":"Absolute Basophil Count","code":"C64470","definitions":[{"definition":"A measurement of the basophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Absolute Basophil Count","termGroup":"PT","termSource":"NCI"},{"termName":"Total Basophil Count","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Basophil_Count"},{"name":"Maps_To","value":"Basophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200641"}]}}{"C81980":{"preferredName":"Beta-2 Microglobulin Measurement","code":"C81980","definitions":[{"definition":"A measurement of the beta-2 microglobulin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of beta-2 microglobulin present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-2 Microglobulin Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Beta 2 Microglobulin Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beta-2_Microglobulin_Measurement"},{"name":"Maps_To","value":"Beta 2 Microglobulin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201910"}]}}{"C61019":{"preferredName":"Blood Urea Nitrogen Measurement","code":"C61019","definitions":[{"definition":"A quantitative measurement of the amount of urea nitrogen present in a serum sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Urea Nitrogen Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"BUN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blood_Urea_Nitrogen_Measurement"},{"name":"Maps_To","value":"Blood Urea Nitrogen"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0005845"}]}}{"C64548":{"preferredName":"C-Reactive Protein Measurement","code":"C64548","definitions":[{"definition":"A measurement of the C reactive protein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of C-reactive protein present in a sample.","type":"DEFINITION","source":"NCI"},{"definition":"A quantitative measurement of the amount of CRP, an inflammatory marker, in the blood, expressed as milligrams per liter.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"C-Reactive Protein Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"C-Reactive_Protein_Measurement"},{"name":"Maps_To","value":"C-Reactive Protein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201657"}]}}{"C64488":{"preferredName":"Calcium Measurement","code":"C64488","definitions":[{"definition":"A measurement of the calcium in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of calcium present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcium Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Calcium_Measurement"},{"name":"Maps_To","value":"Calcium"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201925"}]}}{"C111153":{"preferredName":"Cellularity Measurement","code":"C111153","definitions":[{"definition":"A measurement of the degree, quality or condition of cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of degree, quality or condition of cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cellularity Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Cellularity Index","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cellularity"},{"name":"NCI_META_CUI","value":"CL453628"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C122108":{"preferredName":"Chromogranin A Measurement","code":"C122108","definitions":[{"definition":"A measurement of the chromogranin A in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of chromogranin A present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromogranin A Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"CgA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"CHGA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Chromogranin-A Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Parathyroid Secretory Protein 1 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Pituitary Secretory Protein I Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"SP-I Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chromogranin A"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1295114"}]}}{"C174116":{"preferredName":"Chromogranin B Measurement","code":"C174116","definitions":[{"definition":"The determination of the amount of chromogranin B present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromogranin B Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"CgB Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"CHGB Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Chromogranin-B Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Secretogranin I Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Secretogranin-1 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"SgI Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chromogranin B"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1531661"}]}}{"C96593":{"preferredName":"Circulating Tumor Cell Count","code":"C96593","definitions":[{"definition":"A measurement of the circulating tumor cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of circulating tumor cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Circulating Tumor Cell Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Circulating Tumor Cells"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3272887"}]}}{"C64547":{"preferredName":"Creatinine Measurement","code":"C64547","definitions":[{"definition":"A measurement of the creatinine in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of creatinine present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Creatinine Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Cr","termGroup":"SY","termSource":"NCI"},{"termName":"Creatinine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Creatinine_Measurement"},{"name":"Maps_To","value":"Creatinine"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201975"}]}}{"C64550":{"preferredName":"Eosinophil Count","code":"C64550","definitions":[{"definition":"A measurement of the eosinophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of eosinophils in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eosinophil Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Eosinophil_Count"},{"name":"Maps_To","value":"Eosinophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200638"}]}}{"C171143":{"preferredName":"Epstein-Barr Virus Test","code":"C171143","definitions":[{"definition":"Any microbiologic test or molecular assay used to detect the presence of Epstein-Barr virus in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epstein-Barr Virus Test","termGroup":"PT","termSource":"NCI"},{"termName":"EBV Assay","termGroup":"SY","termSource":"NCI"},{"termName":"EBV Test","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epstein-Barr Virus"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0851107"}]}}{"C116205":{"preferredName":"Neuron Specific Enolase Measurement","code":"C116205","definitions":[{"definition":"A measurement of the neuron specific enolase in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of neuron specific enolase present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neuron Specific Enolase Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"ENO2 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Enolase 2 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-Enolase Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Neuron-Specific Enolase Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"NSE Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gamma-Enolase"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202144"}]}}{"C105585":{"preferredName":"Glucose Measurement","code":"C105585","definitions":[{"definition":"A measurement of the glucose in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of glucose present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glucose Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Glucose"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0337438"}]}}{"C64796":{"preferredName":"Hematocrit Measurement","code":"C64796","definitions":[{"definition":"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.","type":"DEFINITION","source":"NCI"},{"definition":"The percentage of a whole blood specimen that is composed of red blood cells (erythrocytes).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hematocrit Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hematocrit"},{"name":"Maps_To","value":"Hematocrit"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0018935"}]}}{"C64848":{"preferredName":"Hemoglobin Measurement","code":"C64848","definitions":[{"definition":"A measurement of the total erythrocyte associated hemoglobin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of hemoglobin present in a biospecimen.","type":"DEFINITION","source":"NCI"},{"definition":"Concentration of hemoglobin in the peripheral blood stream, expressed as grams per deciliter.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Hemoglobin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hemoglobin_Measurement"},{"name":"Maps_To","value":"Hemoglobin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0518015"}]}}{"C171144":{"preferredName":"Human Papillomavirus E6/E7 Protein Measurement","code":"C171144","definitions":[{"definition":"The determination of the amount of the human papillomavirus transforming proteins E6 and E7 present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus E6/E7 Protein Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"E6/E7 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-E6/E7 Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV-E6/E7"},{"name":"NCI_META_CUI","value":"CL1405385"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C147128":{"preferredName":"Choriogonadotropin Measurement","code":"C147128","definitions":[{"definition":"A measurement of the total choriogonadotropin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of choriogonadotropin present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choriogonadotropin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Human Chorionic Gonadotropin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1295113"}]}}{"C171145":{"preferredName":"Human Papillomavirus Test","code":"C171145","definitions":[{"definition":"Any microbiologic test or molecular assay used to detect the presence of a human papillomavirus in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus Test","termGroup":"PT","termSource":"NCI"},{"termName":"HPV Assay","termGroup":"SY","termSource":"NCI"},{"termName":"HPV Test","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Human Papillomavirus"},{"name":"NCI_META_CUI","value":"CL1405384"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C81969":{"preferredName":"Immunoglobulin A Measurement","code":"C81969","definitions":[{"definition":"A measurement of the total immunoglobulin A in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin A present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin A Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Immunoglobulin_A_Measurement"},{"name":"Maps_To","value":"Immunoglobulin A"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202083"}]}}{"C81971":{"preferredName":"Immunoglobulin G Measurement","code":"C81971","definitions":[{"definition":"A measurement of the total immunoglobulin G in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin G present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin G Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Immunoglobulin_G_Measurement"},{"name":"Maps_To","value":"Immunoglobulin G"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202087"}]}}{"C81972":{"preferredName":"Immunoglobulin M Measurement","code":"C81972","definitions":[{"definition":"A measurement of the total immunoglobulin M in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin M present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin M Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Immunoglobulin_M_Measurement"},{"name":"Maps_To","value":"Immunoglobulin M"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202084"}]}}{"C64855":{"preferredName":"Lactate Dehydrogenase Measurement","code":"C64855","definitions":[{"definition":"A measurement of the lactate dehydrogenase in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of lactate dehydrogenase present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lactate Dehydrogenase Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"LDH Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lactate_Dehydrogenase_Measurement"},{"name":"Maps_To","value":"Lactate Dehydrogenase"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202113"}]}}{"C51948":{"preferredName":"Leukocyte Count","code":"C51948","definitions":[{"definition":"A measurement of the leukocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A test to determine the number of leukocytes in a biospecimen.","type":"DEFINITION","source":"NCI"},{"definition":"Concentration of leukocytes in the peripheral blood stream, expressed as WBCs per milliliter of whole blood.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Leukocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Leukocyte_Count"},{"name":"Maps_To","value":"Leukocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0023508"}]}}{"C74790":{"preferredName":"Luteinizing Hormone Measurement","code":"C74790","definitions":[{"definition":"A measurement of the luteinizing hormone in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of luteinizing hormone present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luteinizing Hormone Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Luteinizing_Hormone_Measurement"},{"name":"Maps_To","value":"Luteinizing Hormone"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202123"}]}}{"C102278":{"preferredName":"Lymphoblast Count","code":"C102278","definitions":[{"definition":"A measurement of the lymphoblasts (immature cells that differentiate to form lymphocytes) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of lymphoblasts (immature cells that differentiate to form lymphocytes) present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoblast Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphoblasts"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1167770"}]}}{"C51949":{"preferredName":"Lymphocyte Count","code":"C51949","definitions":[{"definition":"A measurement of the lymphocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of lymphocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lymphocyte_Count"},{"name":"Maps_To","value":"Lymphocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200635"}]}}{"C92291":{"preferredName":"Monoclonal Protein Measurement","code":"C92291","definitions":[{"definition":"A measurement of homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of monoclonal protein present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Protein Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"M Protein Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M Protein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0443737"}]}}{"C74615":{"preferredName":"Metamyelocyte Count","code":"C74615","definitions":[{"definition":"A measurement of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of metamyelocytes present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metamyelocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Metamyelocyte_Count"},{"name":"Maps_To","value":"Metamyelocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0455285"}]}}{"C74632":{"preferredName":"Myeloblast Count","code":"C74632","definitions":[{"definition":"A measurement of the myeloblast cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of myeloblast cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myeloblast Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myeloblast_Count"},{"name":"Maps_To","value":"Myeloblasts"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0580952"}]}}{"C74662":{"preferredName":"Myelocyte Count","code":"C74662","definitions":[{"definition":"A measurement of the myelocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of myelocyte cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myelocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Myelocyte_Count"},{"name":"Maps_To","value":"Myelocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0455284"}]}}{"C64830":{"preferredName":"Neutrophil Band Form Count","code":"C64830","definitions":[{"definition":"A measurement of the banded neutrophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of band neutrophils in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neutrophil Band Form Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neutrophil_Band_Form_Count"},{"name":"Maps_To","value":"Neutrophil Bands"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0369738"}]}}{"C51951":{"preferredName":"Platelet Count","code":"C51951","definitions":[{"definition":"A measurement of the platelets (non-nucleated thrombocytes) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of platelets in a biospecimen.","type":"DEFINITION","source":"NCI"},{"definition":"The determination of the number of platelets in a blood sample, usually expressed as platelets per milliliter of whole blood.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Platelet Count","termGroup":"PT","termSource":"NCI"},{"termName":"Anucleated Thrombocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Platelet_Count"},{"name":"Maps_To","value":"Platelets"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0032181"}]}}{"C74620":{"preferredName":"Prolymphocyte Count","code":"C74620","definitions":[{"definition":"A measurement of the prolymphocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of prolymphocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prolymphocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prolymphocyte_Count"},{"name":"Maps_To","value":"Prolymphocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2698885"}]}}{"C74621":{"preferredName":"Promonocyte Count","code":"C74621","definitions":[{"definition":"A measurement of the promonocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of promonocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Promonocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Promonocyte_Count"},{"name":"Maps_To","value":"Promonocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2698887"}]}}{"C74622":{"preferredName":"Promyelocyte Count","code":"C74622","definitions":[{"definition":"A measurement of the promyelocytes (immature myelocytes) in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of promyelocytes present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Promyelocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Promyelocyte_Count"},{"name":"Maps_To","value":"Promyelocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0455279"}]}}{"C81997":{"preferredName":"Segmented Neutrophil Count","code":"C81997","definitions":[{"definition":"A measurement of the segmented neutrophils in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of segmented neutrophils present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Segmented Neutrophil Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Segmented_Neutrophil_Count"},{"name":"Maps_To","value":"Segmented Neutrophil"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1168341"}]}}{"C98730":{"preferredName":"Free Kappa Light Chain Measurement","code":"C98730","definitions":[{"definition":"A measurement of the free kappa light chain in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of free kappa light chain present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Free Kappa Light Chain Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Free Immunoglobulin Light Chain, Kappa"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3274397"}]}}{"C98732":{"preferredName":"Free Lambda Light Chain Measurement","code":"C98732","definitions":[{"definition":"A measurement of the free lambda light chain in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of free lambda light chain present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Free Lambda Light Chain Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Free Immunoglobulin Light Chain, Lambda"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3274399"}]}}{"C147376":{"preferredName":"Immunoglobulin Light Chain Measurement","code":"C147376","definitions":[{"definition":"A measurement of the total immunoglobulin (kappa and lambda) light chains in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of immunoglobulin light chain present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Light Chain Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Free Immunoglobulin Light Chain, NOS"},{"name":"NCI_META_CUI","value":"CL545281"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C74793":{"preferredName":"Total Testosterone Measurement","code":"C74793","definitions":[{"definition":"A measurement of the total (free and bound) testosterone in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of free and bound testosterone present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Testosterone Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Testosterone_Measurement"},{"name":"Maps_To","value":"Testosterone"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0202227"}]}}{"C38037":{"preferredName":"Total Bilirubin Measurement","code":"C38037","definitions":[{"definition":"A measurement of the total bilirubin in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Bilirubin Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Total_Bilirubin"},{"name":"Maps_To","value":"Total Bilirubin"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0201913"}]}}{"C64858":{"preferredName":"Total Protein Measurement","code":"C64858","definitions":[{"definition":"A measurement of the total protein in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A quantitative measurement of the amount of total protein present in a sample.","type":"DEFINITION","source":"NCI"},{"definition":"Test to determine total protein concentration in the product.","type":"ALT_DEFINITION","source":"PQCMC"}],"synonyms":[{"termName":"Total Protein Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Protein_Measurement"},{"name":"Maps_To","value":"Total Protein"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0555903"}]}}{"C178240":{"preferredName":"BG8 IHC Staining Method","code":"C178240","definitions":[{"definition":"An immunohistochemical technique utilizing the mouse monoclonal antibody BG8, which is directed against the type 2 fucosylated antigen Lewis Y (LeY). BG8 specifically binds to LeY, a blood group Lewis carbohydrate determinant expressed on certain glycolipids and glycoproteins. In healthy subjects, LeY is expressed in low levels by a few types of epithelial cells; however, it is aberrantly expressed in high levels in many carcinomas. This method is use in the detection of certain tumors, such as carcinomas of the breast, lung, and colon. Additionally, it may distinguish neoplasms derived from mesothelium from other epithelial-derived neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BG8 IHC Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Anti-Lewis Y BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Anti-Lewis-Y BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LeY BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody BG8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"BG-8 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"BG8 Antibody Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"BG8 Staining Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BG8"},{"name":"NCI_META_CUI","value":"CL1647890"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C96592":{"preferredName":"Circulating Endothelial Cell Count","code":"C96592","definitions":[{"definition":"A measurement of the circulating endothelial cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of circulating endothelial cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Circulating Endothelial Cell Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Circulating Endothelial Cells"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3272886"}]}}{"C103871":{"preferredName":"Dopamine-Secreting","code":"C103871","definitions":[{"definition":"A finding indicating that an excess amount of dopamine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dopamine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Dopamine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dopamine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641670"}]}}{"C103869":{"preferredName":"Epinephrine-Secreting","code":"C103869","definitions":[{"definition":"A finding indicating that an excess amount of epinephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epinephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Epinephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epinephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641668"}]}}{"C103870":{"preferredName":"Metanephrine-Secreting","code":"C103870","definitions":[{"definition":"A finding indicating that an excess amount of metanephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metanephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Metanephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metanephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641669"}]}}{"C103872":{"preferredName":"Methoxytyramine-Secreting","code":"C103872","definitions":[{"definition":"A finding indicating that an excess amount of methoxytyramine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxytyramine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Methoxytyramine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methoxytyramine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641671"}]}}{"C36318":{"preferredName":"Microsatellite Instability","code":"C36318","definitions":[{"definition":"A change that occurs in the DNA of certain cells (such as tumor cells) in which the number of repeats of microsatellites (short, repeated sequences of DNA) is different than the number of repeats that was in the DNA when it was inherited. The cause of microsatellite instability may be a defect in the ability to repair mistakes made when DNA is copied in the cell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Genomic instability associated with the presence of hypermutability in specific genetic marker regions resulting from defective DNA mismatch repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microsatellite Instability","termGroup":"PT","termSource":"NCI"},{"termName":"Microsatellite Instability Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Microsatellite Instability Present","termGroup":"SY","termSource":"NCI"},{"termName":"MSI","termGroup":"AB","termSource":"NCI"},{"termName":"MSI Positive","termGroup":"SY","termSource":"NCI"},{"termName":"MSI Present","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Microsatellites are stretches of DNA in which a short motif (usually one to five nucleotides long) is repeated several times. Instability of these regions is initiated when mutations in genes that repair damaged DNA cause these regions to get longer or shorter. Hereditary colon cancer syndrome is associated with mutations in the DNA mismatch repair genes, which may result in alterations in the nucleotide sequence."},{"name":"Legacy Concept Name","value":"Microsatellite_Instability"},{"name":"Maps_To","value":"MSI"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0920269"}]}}{"C103867":{"preferredName":"Norepinephrine-Secreting","code":"C103867","definitions":[{"definition":"A finding indicating that an excess amount of norepinephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Norepinephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Norepinephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Norepinephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641666"}]}}{"C103868":{"preferredName":"Normetanephrine-Secreting","code":"C103868","definitions":[{"definition":"A finding indicating that an excess amount of normetanephrine is secreted by a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Normetanephrine-Secreting","termGroup":"PT","termSource":"NCI"},{"termName":"Normetanephrine Secreting","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Normetanephrine-Secreting"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641667"}]}}{"C106505":{"preferredName":"Cancer Antigen 72-4 Measurement","code":"C106505","definitions":[{"definition":"A measurement of the cancer antigen 72-4 in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of the cancer antigen 72-4 present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Antigen 72-4 Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"TAG-72","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Associated Antigen 72 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor-Associated Antigen TAG-72 Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor-Associated Glycoprotein 72 Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TAG-72"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2732693"}]}}{"C122859":{"preferredName":"Cytokeratin-5 Staining Method","code":"C122859","definitions":[{"definition":"An immunohistochemical technique used to detect the presence of cytokeratin-5 in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytokeratin-5 Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"CK5 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokeratin 5 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Keratin, Type II Cytoskeletal 5 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"KRT5 Staining Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytokeratin 5"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C4053759"}]}}{"C122858":{"preferredName":"Cytokeratin-6 Staining Method","code":"C122858","definitions":[{"definition":"An immunohistochemical technique used to detect the presence of cytokeratin-6 in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytokeratin-6 Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"CK6 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Cytokeratin 6 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Keratin, Type II Cytoskeletal 6 Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"KRT6 Staining Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytokeratin 6"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C4055167"}]}}{"C184798":{"preferredName":"Serum Mesothelin Measurement","code":"C184798","definitions":[{"definition":"A quantitative measurement of the amount of mesothelin present in a sample of serum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serum Mesothelin Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Serum MSLN Measurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Serum Mesothelin"},{"name":"NCI_META_CUI","value":"CL1772988"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C74611":{"preferredName":"Erythrocyte Sedimentation Rate Measurement","code":"C74611","definitions":[{"definition":"A quantitative measurement of the distance that red blood cells settle in one hour in a sample of unclotted blood. Used in the evaluation of systemic inflammation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A quantitative measurement of the distance that red blood cells travel in 1 hour in a sample of unclotted blood.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"A quantitative measurement of the distance that red blood cells travel in one hour in a sample of unclotted blood.","type":"DEFINITION","source":"NCI"},{"definition":"The distance (e.g. millimeters) that red blood cells settle in unclotted blood over a specified unit of time (e.g. one hour).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The distance red blood cells travel in one hour in a sample of blood as they settle to the bottom of a test tube. The sedimentation rate is increased in inflammation, infection, cancer, rheumatic diseases, and diseases of the blood and bone marrow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Erythrocyte Sedimentation Rate Measurement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Erythrocyte_Sedimentation_Rate_Measurement"},{"name":"Maps_To","value":"Erythrocyte Sedimentation Rate"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1176468"}]}}{"C62656":{"preferredName":"Prothrombin Time","code":"C62656","definitions":[{"definition":"A blood clotting measurement that evaluates the extrinsic pathway of coagulation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A measurement of the clotting time of plasma recalcified in the presence of excess tissue thromboplastin; it is a measure of the extrinsic pathway of coagulation. It is used to determine the clotting tendency of blood, in the measure of warfarin dosage, liver damage and vitamin K status. Factors measured are fibrinogen, prothrombin, and factors V, VII, and X.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prothrombin Time","termGroup":"PT","termSource":"NCI"},{"termName":"Prothrombin Time Test","termGroup":"SY","termSource":"NCI"},{"termName":"PT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Prothrombin_Time_Test"},{"name":"Maps_To","value":"Prothrombin Time"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0033707"}]}}{"C74605":{"preferredName":"Blast Count","code":"C74605","definitions":[{"definition":"A measurement of the blast cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of blast cells present in a biospecimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blast Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Blast_Count"},{"name":"Maps_To","value":"Blast Count"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0523113"}]}}{"C168918":{"preferredName":"Number of Cells in Metaphase during Karyotyping","code":"C168918","definitions":[{"definition":"The number of cells in metaphase during karyotype analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Number of Cells in Metaphase during Karyotyping","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Metaphase Nucleus Count"},{"name":"NCI_META_CUI","value":"CL1378987"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C185298":{"preferredName":"Measurable Residual Disease Assessment","code":"C185298","definitions":[{"definition":"An examination for minimal residual disease status.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Measurable Residual Disease Assessment","termGroup":"PT","termSource":"NCI"},{"termName":"Minimal Residual Disease Assessment","termGroup":"SY","termSource":"NCI"},{"termName":"MRD Assessment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Minimal Residual Disease"},{"name":"NCI_META_CUI","value":"CL1773389"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C64823":{"preferredName":"Monocyte Count","code":"C64823","definitions":[{"definition":"A measurement of the monocytes in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the number of monocytes in a blood sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monocyte Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Monocyte_Count"},{"name":"Maps_To","value":"Monocytes"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0200637"}]}}{"C111124":{"preferredName":"Abnormal Cell Count","code":"C111124","definitions":[{"definition":"A measurement of the abnormal cells in a biological specimen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The determination of the amount of abnormal cells present in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abnormal Cell Count","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abnormal Cells"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C3811057"}]}}{"C18084":{"preferredName":"Comparative Genomic Hybridization","code":"C18084","definitions":[{"definition":"Comparative genomic hybridization (CGH) is a technique that allows the detection of losses and gains in DNA copy number across the entire genome without prior knowledge of specific chromosomal abnormalities.  Comparative genomic hybridization utilizes the hybridization of differentially labeled tumor and reference DNA to generate a map of DNA copy number changes in tumor genomes. Comparative genomic hybridization is an ideal tool for analyzing chromosomal imbalances in archived tumor material and for examining possible correlations between these findings and tumor phenotypes. (from Ried et al. J Mol Med 1997 75:801-14)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Comparative Genomic Hybridization","termGroup":"PT","termSource":"NCI"},{"termName":"CGH","termGroup":"AB","termSource":"NCI"},{"termName":"Comparative Genome Hybridization","termGroup":"SY","termSource":"NCI"},{"termName":"Comparative Genomic Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Comparative_Genomic_Analysis"},{"name":"Maps_To","value":"Comparative Genomic Hybridization"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0796358"}]}}{"C18280":{"preferredName":"Cytogenetic Analysis","code":"C18280","definitions":[{"definition":"An assessment by microscopic analysis of chromosomal and subchromosomal structure and function.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytogenetic Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Cytogenetic Techniques","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cytogenetic_Analysis"},{"name":"Maps_To","value":"Cytogenetics, NOS"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0752095"}]}}{"C17563":{"preferredName":"Fluorescence In Situ Hybridization","code":"C17563","definitions":[{"definition":"A laboratory technique used to look at genes or chromosomes in cells and tissues. Pieces of DNA that contain a fluorescent dye are made in the laboratory and added to cells or tissues on a glass slide. When these pieces of DNA bind to specific genes or areas of chromosomes on the slide, they light up when viewed under a microscope with a special light.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from Online Medical Dictionary and NHGRI Glossary"}]}],"synonyms":[{"termName":"Fluorescence In Situ Hybridization","termGroup":"PT","termSource":"NCI"},{"termName":"FISH","termGroup":"AB","termSource":"NCI"},{"termName":"Fluorescence in situ Hybridization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Fluorescence_in_situ_Hybridization"},{"name":"Maps_To","value":"FISH"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C0162789"}]}}{"C16585":{"preferredName":"Flow Cytometry","code":"C16585","definitions":[{"definition":"A method of measuring the number of cells in a sample, the percentage of live cells in a sample, and certain characteristics of cells, such as size, shape, and the presence of tumor markers on the cell surface. The cells are stained with a light-sensitive dye, placed in a fluid, and passed in a stream before a laser or other type of light. The measurements are based on how the light-sensitive dye reacts to the light.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.","type":"DEFINITION","source":"NCI"},{"definition":"A technique for counting, examining or sorting microscopic particles in which the particles are placed in a fluid (with or without light-sensitive dye) and passed through a beam of light.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Flow Cytometry","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Flow_Cytometry"},{"name":"Maps_To","value":"Flow Cytometry"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0016263"}]}}{"C23020":{"preferredName":"Immunohistochemistry Staining Method","code":"C23020","definitions":[{"definition":"A technique used to identify specific molecules in different kinds of tissue. The tissue is treated with antibodies that bind the specific molecule. These are made visible under a microscope by using a color reaction, a radioisotope, colloidal gold, or a fluorescent dye. Immunohistochemistry is used to help diagnose diseases, such as cancer, and to detect the presence of microorganisms. It is also used in basic research to understand how cells grow and differentiate (become more specialized).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","type":"DEFINITION","source":"NCI"},{"definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Immunohistochemistry Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"Cell/Tissue, Immunohistochemistry","termGroup":"SY","termSource":"NCI"},{"termName":"IHC","termGroup":"AB","termSource":"NCI"},{"termName":"Immunohistochemistry","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Immunohistochemistry_Staining_Method"},{"name":"Maps_To","value":"IHC"},{"name":"Maps_To","value":"Immunohistochemistry (IHC)"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0021044"}]}}{"C142337":{"preferredName":"Immunofluorescent Staining Method","code":"C142337","definitions":[{"definition":"A microscopy staining method that utilizes immunofluorescent markers for use with histological applications of preserved cells.","type":"DEFINITION","source":"NCI"},{"definition":"A microscopy staining method that utilizes immunofluorescent markers for use with histological applications of preserved cells.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Immunofluorescent Staining Method","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunofluorescence"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1318793"}]}}{"C17562":{"preferredName":"In Situ Hybridization","code":"C17562","definitions":[{"definition":"Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues.","type":"DEFINITION","source":"NCI"},{"definition":"Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"In Situ Hybridization","termGroup":"PT","termSource":"NCI"},{"termName":"Genetics, in situ Hybridization","termGroup":"SY","termSource":"NCI"},{"termName":"in situ Hybridization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"in_situ_Hybridization"},{"name":"Maps_To","value":"ISH"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C0162788"}]}}{"C16768":{"preferredName":"Karyotyping","code":"C16768","definitions":[{"definition":"The assessment of the chromosomal morphology and number in somatic cells of an individual.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]},{"definition":"The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell sample.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Karyotyping","termGroup":"PT","termSource":"NCI"},{"termName":"Genetics, Karyotyping","termGroup":"SY","termSource":"NCI"},{"termName":"Karotype Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Karyotyping"},{"name":"Maps_To","value":"Karyotype"},{"name":"Semantic_Type","value":"Occupational Activity"},{"name":"UMLS_CUI","value":"C0022526"}]}}{"C18477":{"preferredName":"Microarray Analysis","code":"C18477","definitions":[{"definition":"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).","type":"DEFINITION","source":"NCI"},{"definition":"Information about all messenger RNAs that are made in various cell types. A gene expression profile may be used to find and diagnose a disease or condition and to see how well the body responds to treatment. Gene expression profiles may be used in personalized medicine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Microarray Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Expression Profiling","termGroup":"SY","termSource":"NCI"},{"termName":"Microarray Analysis","termGroup":"SY","termSource":"NCI"},{"termName":"Microarray Technology","termGroup":"SY","termSource":"NCI"},{"termName":"Microarray-Based Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microarray_Analysis"},{"name":"Maps_To","value":"Microarray"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1449575"}]}}{"C63331":{"preferredName":"Microsatellite Instability Analysis","code":"C63331","definitions":[{"definition":"A laboratory procedure to detect microsatellite instability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microsatellite Instability Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"MSI Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Microsatellite_Instability_Analysis"},{"name":"Maps_To","value":"Microsatellite Analysis"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1881824"}]}}{"C165224":{"preferredName":"Nuclear Staining Method","code":"C165224","definitions":[{"definition":"A microscopy staining method that uses a dye or a contrast agent that specifically binds to chromosomal material and/or nucleoproteins, which permits visualization of a cellular nucleus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nuclear Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"Nuclear Staining","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nuclear Staining"},{"name":"NCI_META_CUI","value":"CL978405"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C17003":{"preferredName":"Polymerase Chain Reaction","code":"C17003","definitions":[{"definition":"A laboratory method used to make many copies of a specific DNA sequence.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.","type":"DEFINITION","source":"NCI"},{"definition":"A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase. This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Polymerase Chain Reaction","termGroup":"PT","termSource":"NCI"},{"termName":"PCR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Polymerase_Chain_Reaction"},{"name":"Maps_To","value":"PCR"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0032520"}]}}{"C124261":{"preferredName":"Whole Transcriptome Sequencing","code":"C124261","definitions":[{"definition":"A procedure that can determine the nucleotide sequence for all of the RNA transcripts in an individual.","type":"DEFINITION","source":"NCI"},{"definition":"An RNA sequencing technique in which all of the RNA transcripts of an individual's genome are sequenced.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Whole Transcriptome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"RNA Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"RNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Total RNA Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Total RNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Transcriptome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Whole-Transcriptome Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"RNA Sequencing"},{"name":"Maps_To","value":"RNA-Seq"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C4086963"}]}}{"C18136":{"preferredName":"Reverse Transcriptase-Polymerase Chain Reaction","code":"C18136","definitions":[{"definition":"A laboratory procedure in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase.","type":"DEFINITION","source":"NCI"},{"definition":"A molecular biology technique used to recreate and amplify complementary DNA (cDNA) from total RNA or messenger RNA (mRNA), using reverse transcriptase and DNA polymerase.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Reverse Transcriptase-Polymerase Chain Reaction","termGroup":"PT","termSource":"NCI"},{"termName":"RT-PCR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"RT-PCR"},{"name":"Maps_To","value":"RT-PCR"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C0599161"}]}}{"C17565":{"preferredName":"Sequence Analysis","code":"C17565","definitions":[{"definition":"The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sequence Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sequence_Analysis"},{"name":"Maps_To","value":"Sequencing, NOS"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0162801"}]}}{"C16356":{"preferredName":"Southern Blotting","code":"C16356","definitions":[{"definition":"A technique for the detection of specific DNA fragments that have been separated by polyacrylamide-gel electrophoresis, transferred to a nitrocellulose or other type of paper or nylon membrane, and detected by hybridization and visualization with a labeled probe.","type":"DEFINITION","source":"NCI"},{"definition":"Electrophoresis-based technique used in genetic testing to detect large deletions in DNA that can be missed by PCR-based genetic testing methods.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Southern Blotting","termGroup":"PT","termSource":"NCI"},{"termName":"Blotting, Southern","termGroup":"SY","termSource":"NCI"},{"termName":"Southern Blot","termGroup":"SY","termSource":"NCI"},{"termName":"Southern Blot Hybridization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blotting_Southern"},{"name":"Maps_To","value":"Southern Blotting"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0005862"}]}}{"C130177":{"preferredName":"Next Generation Targeted Sequencing","code":"C130177","definitions":[{"definition":"A technique that determines the nucleotide sequence of a pre-specified region of DNA or RNA by using primers that are specific for that region.","type":"DEFINITION","source":"NCI"},{"definition":"A type of next generation sequencing in which specific genes or portions of genes are targeted for sequencing using amplicon-based workflow.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Next Generation Targeted Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Targeted NGS","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Targeted Sequencing"},{"name":"NCI_META_CUI","value":"CL514064"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C101294":{"preferredName":"Whole Genome Sequencing","code":"C101294","definitions":[{"definition":"A DNA sequencing technique in which the entirety of the individual's genome is sequenced.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A procedure that can determine the DNA sequence for nearly the entire genome of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Whole Genome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"WGS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"WGS"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3640076"}]}}{"C101295":{"preferredName":"Whole Exome Sequencing","code":"C101295","definitions":[{"definition":"A DNA sequencing technique in which all of the exons of an individual's genome are sequenced.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A procedure that can determine the DNA sequence for all of the exons in an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Whole Exome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Exome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"WES","termGroup":"SY","termSource":"NCI"},{"termName":"Whole-Exome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"WXS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"WXS"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3640077"}]}}{"C16853":{"preferredName":"Microscopy","code":"C16853","definitions":[{"definition":"The application of microscope magnification to the study of materials that cannot be properly seen by the unaided eye. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The use of various technologies to resolve the structure or features of objects too small or fine to naturally be seen by eye.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microscopy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Microscopy"},{"name":"Maps_To","value":"Microscopy, NOS"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0026018"}]}}{"C181250":{"preferredName":"Immunophenotyping Assay","code":"C181250","definitions":[{"definition":"A type of immunoassay that examines the markers or antigens associated with the cell surface, nucleus, or cytoplasm.","type":"DEFINITION","source":"NCI"},{"definition":"An assay type that examines the types of markers or antigens associated with the cell surface, nucleus, or cytoplasm.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Immunophenotyping Assay","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunophenotyping, NOS"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C0079611"}]}}{"C63433":{"preferredName":"3' Untranslated Region Mutation","code":"C63433","definitions":[{"definition":"Any mutation in a gene occurring in the 3' end which contains sequences which may regulate the transcription or translation of the message. 3' UTR mutations are found only outside of open reading frames.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"3' Untranslated Region Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"3 Prime UTR Variant","termGroup":"SY","termSource":"NCI"},{"termName":"3' UTR Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_3_Untranslated_Region_Mutation"},{"name":"Maps_To","value":"3 Prime UTR Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883634"}]}}{"C63432":{"preferredName":"5' Untranslated Region Mutation","code":"C63432","definitions":[{"definition":"Any mutation in a gene occurring in the 5' end which contains sequences which may regulate the transcription or translation of the message. 5' UTR mutations are found only outside of open-reading frames.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5' Untranslated Region Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"5 Prime UTR Variant","termGroup":"SY","termSource":"NCI"},{"termName":"5' UTR Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_5_Untranslated_Region_Mutation"},{"name":"Maps_To","value":"5 Prime UTR Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883645"}]}}{"C148639":{"preferredName":"Exon Mutation","code":"C148639","definitions":[{"definition":"A change in the nucleotide sequence of an exon in a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exon Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Coding Region Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Coding Sequence Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coding Sequence Variant"},{"name":"Maps_To","value":"Exon Variant"},{"name":"NCI_META_CUI","value":"CL551156"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C63431":{"preferredName":"3' Flank Mutation","code":"C63431","definitions":[{"definition":"Any gene mutation that occurs in the sequences downstream from a coding region of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"3' Flank Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Downstream Gene Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"This term itself is applied primarily to polycistronic RNAs, in which any downstream mutation is considered a 3' flank mutation with respect to the upstream open reading frame."},{"name":"Legacy Concept Name","value":"_3_Flank_Mutation"},{"name":"Maps_To","value":"Downstream Gene Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883632"}]}}{"C148640":{"preferredName":"Elongation Mutation","code":"C148640","definitions":[{"definition":"The mutation of either a splice site or stop codon that leads to an extended transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elongation Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Feature Elongation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Feature Elongation"},{"name":"NCI_META_CUI","value":"CL551155"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148641":{"preferredName":"Truncation Mutation","code":"C148641","definitions":[{"definition":"The mutation of either a splice site or stop codon that leads to a truncated transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Truncation Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Feature Truncation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Feature Truncation"},{"name":"NCI_META_CUI","value":"CL551266"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C17354":{"preferredName":"Frameshift Mutation","code":"C17354","definitions":[{"definition":"A mutation occurring within the protein-coding region of a gene which results in a shift in the reading frame of the encoded protein. Frameshift mutations often result in the premature truncation of a gene product.","type":"DEFINITION","source":"NCI"},{"definition":"An insertion or deletion involving a number of base pairs that is not a multiple of three, which consequently disrupts the triplet reading frame of a DNA sequence. Such mutations usually lead to the creation of a premature termination (stop) codon, and result in a truncated (shorter-than-normal) protein product.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Frameshift Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Frameshift","termGroup":"SY","termSource":"NCI"},{"termName":"Frameshift Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Frameshift Variant","termGroup":"SY","termSource":"NCI"},{"termName":"fs","termGroup":"AB","termSource":"NCI"},{"termName":"Mutation, Frameshift","termGroup":"SY","termSource":"NCI"},{"termName":"Reading Frame Shift Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Frameshift_Mutation"},{"name":"Maps_To","value":"Frameshift Mutation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0079380"}]}}{"C179438":{"preferredName":"Incomplete Terminal Codon Variant","code":"C179438","definitions":[{"definition":"A change in the nucleotide sequence of at least one base of the final codon of a incompletely annotated transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Incomplete Terminal Codon Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Incomplete Terminal Codon Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Incomplete Terminal Codon Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Incomplete Terminal Codon Variant"},{"name":"NCI_META_CUI","value":"CL1662206"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C165225":{"preferredName":"Inframe Deletion","code":"C165225","definitions":[{"definition":"A loss of three consecutive nucleotides (one codon) or multiple codons in a gene that encodes for a protein where one or more canonical amino acids are deleted but does not result in a frameshift mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inframe Deletion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inframe Deletion"},{"name":"NCI_META_CUI","value":"CL978406"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C165226":{"preferredName":"Inframe Insertion","code":"C165226","definitions":[{"definition":"A gain of three consecutive nucleotides (one codon) or multiple codons in a gene that encodes for a protein where one or more non-wildtype amino acids are inserted but does not result in a frameshift mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inframe Insertion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inframe Insertion"},{"name":"NCI_META_CUI","value":"CL978407"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148642":{"preferredName":"Intergenic Mutation","code":"C148642","definitions":[{"definition":"A change in the nucleotide sequence of a region between gene loci.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intergenic Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Intergenic Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intergenic Variant"},{"name":"NCI_META_CUI","value":"CL551265"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C63429":{"preferredName":"Intronic Mutation","code":"C63429","definitions":[{"definition":"Any mutation within an intron, including the sequences that comprise the intron boundary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intronic Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Intron Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Intron Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intronic_Mutation"},{"name":"Maps_To","value":"Intron Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1881250"}]}}{"C165227":{"preferredName":"Mature miRNA Variant","code":"C165227","definitions":[{"definition":"A ribonucleotide variation in the sequence of a fully processed microRNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mature miRNA Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Mature MicroRNA Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mature miRNA Variant"},{"name":"NCI_META_CUI","value":"CL978379"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C18133":{"preferredName":"Missense Mutation","code":"C18133","definitions":[{"definition":"A point mutation occurring within the protein-coding region of a gene, and which codes for a different amino acid than expected.","type":"DEFINITION","source":"NCI"},{"definition":"A single base pair substitution that alters the genetic code in a way that produces an amino acid that is different from the usual amino acid at that position. Some missense mutations will alter the function of the protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Missense Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Exon Non-Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonic Non-Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Missense Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Missense Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Mutation, Missense","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Substitution Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Missense_Mutation"},{"name":"Legacy Concept Name","value":"Missense_Mutation_Abnormality"},{"name":"Maps_To","value":"Missense Variant"},{"name":"Maps_To","value":"Protein Altering Variant"},{"name":"Maps_To","value":"Substitution"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0599155"}]}}{"C148643":{"preferredName":"Non-Sense Mediated Decay Mutation","code":"C148643","definitions":[{"definition":"A mutation occurring in a sequence that regulates non-sense mediated mRNA decay.","type":"DEFINITION","source":"NCI"},{"definition":"A transcript with a premature stop codon considered likely to be subjected to targeted degradation. (Ensembl)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Non-Sense Mediated Decay Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"NMD Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"NMD Transcript Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NMD Transcript Variant"},{"name":"NCI_META_CUI","value":"CL551268"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148645":{"preferredName":"Non-Coding Gene Exon Mutation","code":"C148645","definitions":[{"definition":"A change in the nucleotide sequence of an exon in a non-coding gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Coding Gene Exon Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Coding Transcript Exon Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Noncoding Gene Exon Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Untranslated Gene Exon Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Coding Gene Exon Mutation"},{"name":"NCI_META_CUI","value":"CL551262"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148644":{"preferredName":"Non-Coding Gene Mutation","code":"C148644","definitions":[{"definition":"A change in the nucleotide sequence of a non-coding gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Coding Gene Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Coding Transcript Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Noncoding Gene Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Untranslated Gene Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Coding Gene Mutation"},{"name":"NCI_META_CUI","value":"CL551267"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C62198":{"preferredName":"Nonsense Mutation","code":"C62198","definitions":[{"definition":"A mutation that alters the genetic code in a way that causes the premature termination of a protein. The altered protein may be partially or completely inactivated, resulting in a change or loss of protein function.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A point mutation occurring within the protein-coding region of a gene, and which codes for a stop that can truncate the protein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonsense Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Premature Termination Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Premature Termination Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Stop Gain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nonsense_Mutation"},{"name":"Maps_To","value":"Nonsense"},{"name":"Maps_To","value":"Stop Gain"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0544885"}]}}{"C148647":{"preferredName":"Regulatory Region Deletion","code":"C148647","definitions":[{"definition":"A deletion mutation where the deleted sequence includes a regulatory region for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regulatory Region Deletion","termGroup":"PT","termSource":"NCI"},{"termName":"Regulatory Region Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regulatory Region Ablation"},{"name":"NCI_META_CUI","value":"CL551264"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148648":{"preferredName":"Regulatory Region Amplification","code":"C148648","definitions":[{"definition":"An increase in the copy number of a region containing a regulatory sequence for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regulatory Region Amplification","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regulatory Region Amplification"},{"name":"NCI_META_CUI","value":"CL551263"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148646":{"preferredName":"Regulatory Region Mutation","code":"C148646","definitions":[{"definition":"A change in the nucleotide sequence of a regulatory region for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regulatory Region Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Regulatory Region Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regulatory Region Variant"},{"name":"NCI_META_CUI","value":"CL551261"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C45389":{"preferredName":"Acceptor Splice Site SNP","code":"C45389","definitions":[{"definition":"A heritable single nucleotide polymorphism located at the acceptor splice site in certain allelic variants of eukaryotic genes. These sites are located in genes at intron to exon junctions at the 3' end of the intron.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acceptor Splice Site SNP","termGroup":"PT","termSource":"NCI"},{"termName":"Intronic, Acceptor Splice Site SNP","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Acceptor Point Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Acceptor Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Acceptor_Splice_Site_SNP"},{"name":"Maps_To","value":"Splice Acceptor Variant"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C1706692"}]}}{"C45390":{"preferredName":"Donor Splice Site SNP","code":"C45390","definitions":[{"definition":"An inherited single base change at a donor splice site in a genomic DNA sequence that results in an allelic variant of the wild-type gene. Donor splice sites are located at exon to intron junctions at the 5' end of the intron.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Donor Splice Site SNP","termGroup":"PT","termSource":"NCI"},{"termName":"Intronic, Donor Splice Site SNP","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Donor Point Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Donor Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Donor_Splice_Site_SNP"},{"name":"Maps_To","value":"Splice Donor Variant"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C1707808"}]}}{"C19798":{"preferredName":"Splice-Site Mutation","code":"C19798","definitions":[{"definition":"Any mutation that occurs within the discrete sequences comprising the 5' or 3' splice sites of a gene that has a spliced message. Splice-site mutation may result in a deletion or insertion of extraneous amino acids in the gene product or a change in the reading frame of the spliced message.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splice-Site Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Splice Region Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Splice-Juction Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Splice-Site Mutation Abnormality","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Splice-Site_Mutation"},{"name":"Maps_To","value":"Splice"},{"name":"Maps_To","value":"Splice Region Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1519478"}]}}{"C148649":{"preferredName":"Start Lost Mutation","code":"C148649","definitions":[{"definition":"A mutation occurring within the start codon of a gene that results in a sequence that no longer encodes a start codon. This can result in a gene deletion or gene transcription may start from an alternative start site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Start Lost Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Start Lost","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Start Lost"},{"name":"NCI_META_CUI","value":"CL551258"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148650":{"preferredName":"Nonstop Mutation","code":"C148650","definitions":[{"definition":"A mutation occurring within the stop codon of a gene that results in a sequence that no longer encodes a stop codon and results in the transcription of non-coding regions downstream of the gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonstop Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Read-Through Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Stop Lost","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extension"},{"name":"Maps_To","value":"Stop Lost"},{"name":"NCI_META_CUI","value":"CL551257"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148651":{"preferredName":"Silent Stop Codon Mutation","code":"C148651","definitions":[{"definition":"A mutation occurring within the stop codon of a gene, which still encodes a stop codon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silent Stop Codon Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Stop Retained Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stop Retained Variant"},{"name":"NCI_META_CUI","value":"CL551260"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C20629":{"preferredName":"Silent Mutation","code":"C20629","definitions":[{"definition":"A point mutation occurring within the protein-coding region of a gene, and which codes for the same amino acid as expected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silent Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Exon Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonic Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Mutation, Silent","termGroup":"SY","termSource":"NCI"},{"termName":"Synonymous Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Synonymous Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Silent_Mutation"},{"name":"Maps_To","value":"Synonymous Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1519323"}]}}{"C148652":{"preferredName":"Transcription Factor Binding Site Mutation","code":"C148652","definitions":[{"definition":"A change in the nucleotide sequence of a transcription factor binding site for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcription Factor Binding Site Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"TF Binding Site Variant","termGroup":"SY","termSource":"NCI"},{"termName":"TFBS Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TF Binding Site Variant"},{"name":"NCI_META_CUI","value":"CL551259"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148653":{"preferredName":"Transcription Factor Binding Site Deletion Mutation","code":"C148653","definitions":[{"definition":"A deletion mutation where the deleted sequence includes a transcription factor binding site for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcription Factor Binding Site Deletion Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"TFBS Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TFBS Ablation"},{"name":"NCI_META_CUI","value":"CL551256"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C148654":{"preferredName":"Transcription Factor Binding Site Amplification","code":"C148654","definitions":[{"definition":"An increase in the copy number of a region containing a transcription factor binding site for a gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcription Factor Binding Site Amplification","termGroup":"PT","termSource":"NCI"},{"termName":"TFBS Amplification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TFBS Amplification"},{"name":"NCI_META_CUI","value":"CL551255"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C16606":{"preferredName":"Gene Deletion","code":"C16606","definitions":[{"definition":"A deletion that results in the loss of a DNA segment encompassing an entire gene sequence.","type":"DEFINITION","source":"NCI"},{"definition":"The loss of all or a part of a gene. There may also be a change in the RNA and protein made from that gene. Certain gene deletions are found in cancer and in other genetic diseases and abnormalities.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gene Deletion","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Deletion Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Transcript Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Deletion"},{"name":"Maps_To","value":"Transcript Ablation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0017260"}]}}{"C45581":{"preferredName":"Gene Amplification Abnormality","code":"C45581","definitions":[{"definition":"An increase in the copy number of a particular gene. This type of abnormality can be either inherited or somatic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Amplification Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Amplification","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Amplification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Amplification_Abnormality"},{"name":"Maps_To","value":"Amplification"},{"name":"Maps_To","value":"Gene Amplification Abnormality"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705759"}]}}{"C63430":{"preferredName":"5' Flank Mutation","code":"C63430","definitions":[{"definition":"Any gene mutation that occurs in the sequences upstream from a coding region of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5' Flank Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Upstream Gene Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"This term is applied primarily to polycistronic RNAs, in which any upstream mutation is considered a 5' flank mutation with respect to the downstream open reading frame."},{"name":"Legacy Concept Name","value":"_5_Flank_Mutation"},{"name":"Maps_To","value":"Upstream Gene Variant"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1883643"}]}}{"C168802":{"preferredName":"Variant Benign","code":"C168802","definitions":[{"definition":"A genetic variant that is known to not contribute to the development of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Variant Benign","termGroup":"PT","termSource":"NCI"},{"termName":"Benign Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Benign"},{"name":"NCI_META_CUI","value":"CL1378700"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C168801":{"preferredName":"Variant Likely Benign","code":"C168801","definitions":[{"definition":"A genetic variant that is not expected to contribute to the development of a disease, but the scientific evidence may be insufficient to prove this conclusively.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Variant Likely Benign","termGroup":"PT","termSource":"NCI"},{"termName":"Likely Benign Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Likely Benign"},{"name":"NCI_META_CUI","value":"CL1379136"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C168800":{"preferredName":"Likely Pathogenic Variant","code":"C168800","definitions":[{"definition":"A genetic variant that is known to have a high likelihood (greater than 90% certainty) to contribute to the development of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Likely Pathogenic Variant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Likely Pathogenic"},{"name":"NCI_META_CUI","value":"CL1379135"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C168799":{"preferredName":"Pathogenic Variant","code":"C168799","definitions":[{"definition":"A genetic variant that is known to directly contribute to the development of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pathogenic Variant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pathogenic"},{"name":"NCI_META_CUI","value":"CL1379138"},{"name":"Semantic_Type","value":"Nucleotide Sequence"}]}}{"C94187":{"preferredName":"Variant of Unknown Significance","code":"C94187","definitions":[{"definition":"A variation in a genetic sequence whose association with disease risk is unknown.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Variant of Unknown Significance","termGroup":"PT","termSource":"NCI"},{"termName":"Uncertain Significance","termGroup":"SY","termSource":"NCI"},{"termName":"Variant of Undetermined Significance","termGroup":"SY","termSource":"NCI"},{"termName":"VUS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uncertain Significance"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C2986382"}]}}{"C2873":{"preferredName":"Aneuploidy","code":"C2873","definitions":[{"definition":"A chromosomal abnormality in which there is an addition or loss of chromosomes within a set (e.g., 23 + 22 or 23 + 24).","type":"DEFINITION","source":"NCI"},{"definition":"The occurrence of one or more extra or missing chromosomes leading to an unbalanced chromosome complement, or any chromosome number that is not an exact multiple of the haploid number (which is 46).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aneuploidy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aneuploidy"},{"name":"Maps_To","value":"Aneuploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0002938"}]}}{"C118941":{"preferredName":"Diploidy","code":"C118941","definitions":[{"definition":"Having two sets of homologous chromosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diploidy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diploid"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0012568"}]}}{"C80336":{"preferredName":"Hyperdiploidy","code":"C80336","definitions":[{"definition":"A chromosomal abnormality in which the chromosomal number is greater than the normal diploid number.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperdiploidy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hyperdiploidy"},{"name":"Maps_To","value":"Hyperdiploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1305143"}]}}{"C80337":{"preferredName":"Hypodiploidy","code":"C80337","definitions":[{"definition":"A chromosomal abnormality in which the chromosomal number is less than the normal diploid number.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypodiploidy","termGroup":"PT","termSource":"NCI"},{"termName":"Hypodiploid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypodiploidy"},{"name":"Maps_To","value":"Hypodiploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0333691"}]}}{"C165228":{"preferredName":"Near Diploidy","code":"C165228","definitions":[{"definition":"A chromosomal abnormality in which the total chromosome number is slightly more (hyperdiploid) or slightly less (hypodiploid) than the normal diploid number.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Near Diploidy","termGroup":"PT","termSource":"NCI"},{"termName":"Near Diploid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Near Diploid"},{"name":"NCI_META_CUI","value":"CL978380"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C28450":{"preferredName":"Tetraploidy","code":"C28450","definitions":[{"definition":"A numerical chromosomal abnormality characterized by the presence of four complete sets of chromosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetraploidy","termGroup":"PT","termSource":"NCI"},{"termName":"Tetraploid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tetraploidy"},{"name":"Maps_To","value":"Tetraploid"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0333694"}]}}{"C25966":{"preferredName":"MicroRNA","code":"C25966","definitions":[{"definition":"A sequence of single-stranded RNA which is typically 20-25 nucleotides in length and may regulate the expression of other genes. miRNAs are transcribed from DNA, but are not translated into proteins.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sequence of single-stranded RNA, that is 20-25 nucleotides in length, which is transcribed from DNA but is not translated into a protein. This nucleic acid may regulate the transcription or translation of other genes.","type":"DEFINITION","source":"NCI"},{"definition":"A type of RNA found in cells and in blood. MicroRNAs are smaller than many other types of RNA and can bind to messenger RNAs (mRNAs) to block them from making proteins. MicroRNAs are being studied in the diagnosis and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"MicroRNA","termGroup":"PT","termSource":"NCI"},{"termName":"Micro RNA","termGroup":"SY","termSource":"NCI"},{"termName":"micro-RNA","termGroup":"SY","termSource":"NCI"},{"termName":"MIR","termGroup":"SY","termSource":"NCI"},{"termName":"MIRN","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA","termGroup":"SY","termSource":"NCI"},{"termName":"Small Temporal RNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MicroRNA"},{"name":"Maps_To","value":"miRNA"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C1101610"}]}}{"C813":{"preferredName":"Messenger RNA","code":"C813","definitions":[{"definition":"A class of RNA molecule containing protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein.","type":"DEFINITION","source":"NCI"},{"definition":"A class of RNA molecule containing protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A representation of a member of the class of RNA molecules that contains protein-coding information in its nucleotide sequence.   EXAMPLE(S): Homo sapiens BRCA1 transcript variant 1 mRNA, GenBank identifier NM_007294.3, is available at http://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3  OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"A type of RNA found in cells. Messenger RNA molecules carry the genetic information needed to make proteins. They carry the information from the DNA in the nucleus of the cell to the cytoplasm where the proteins are made.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Messenger RNA","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:33699"},{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail."},{"name":"Legacy Concept Name","value":"Messenger_RNA"},{"name":"Maps_To","value":"mRNA"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0035696"}]}}{"C17021":{"preferredName":"Protein","code":"C17021","definitions":[{"definition":"A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.","type":"DEFINITION","source":"NCI"},{"definition":"A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.","type":"ALT_DEFINITION","source":"PQCMC","qualifiers":[{"type":"attribution","value":"NCI"}]},{"definition":"A molecule made up of amino acids that are needed for the body to function properly. Proteins are the basis of body structures such as skin and hair and of substances such as enzymes, cytokines, and antibodies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A representation of an organic macromolecule in public resources (e.g., UniProt or NCBI RefSeq) composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons.  Comment Requested:  In interest of re-using existing standards, should the above definition of Protein be replaced by the following from the NLM -- :  A molecule made up of amino acids that are needed for the body to function properly. Proteins are the basis of body structures such as skin and hair and of substances such as enzymes, cytokines, and antibodies. [Source: http://ghr.nlm.nih.gov/glossary=protein]  EXAMPLE(S): A protein record from UniProt Knowledgebase: http://www.uniprot.org/uniprot/P38398   OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"}],"synonyms":[{"termName":"Protein","termGroup":"PT","termSource":"NCI"},{"termName":"Proteins","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:36080"},{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Protein"},{"name":"Maps_To","value":"Protein"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0033684"}]}}{"C26683":{"preferredName":"Abnormal Laboratory Test Result","code":"C26683","definitions":[{"definition":"A laboratory test result that falls outside of the normal, acceptable range.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abnormal Laboratory Test Result","termGroup":"PT","termSource":"NCI"},{"termName":"Abnormal Lab Test Result","termGroup":"SY","termSource":"NCI"},{"termName":"Abnormal Laboratory Test","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Abnormal_Laboratory_Test"},{"name":"Maps_To","value":"Abnormal, NOS"},{"name":"Semantic_Type","value":"Laboratory or Test Result"},{"name":"UMLS_CUI","value":"C0438215"}]}}{"C49142":{"preferredName":"Copy Number","code":"C49142","definitions":[{"definition":"The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Copy Number","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Copy_Number"},{"name":"Maps_To","value":"Copy Number Reported"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1707513"}]}}{"C165233":{"preferredName":"Expression Negative","code":"C165233","definitions":[{"definition":"An indication that expression of a gene, RNA species or protein is not detected in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Expression Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Absent","termGroup":"SY","termSource":"NCI"},{"termName":"Loss of Expression","termGroup":"SY","termSource":"NCI"},{"termName":"Negative","termGroup":"SY","termSource":"NCI"},{"termName":"Not Expressed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Loss of Expression"},{"name":"NCI_META_CUI","value":"CL978385"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C14165":{"preferredName":"Normal","code":"C14165","definitions":[{"definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","type":"DEFINITION","source":"NCI"},{"definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Normal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Normal"},{"name":"Maps_To","value":"Normal"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1550457"}]}}{"C177693":{"preferredName":"Elevated Expression","code":"C177693","definitions":[{"definition":"An indication that the expression of a gene, transcript or protein is higher than a previous value or a normal range of values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elevated Expression","termGroup":"PT","termSource":"NCI"},{"termName":"High Expression","termGroup":"SY","termSource":"NCI"},{"termName":"Overexpression","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Overexpressed"},{"name":"NCI_META_CUI","value":"CL930180"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C165229":{"preferredName":"Test Value Reported Indicator","code":"C165229","definitions":[{"definition":"An indication as to whether a test value has been reported or recorded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Test Value Reported Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Test Value Reported","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Test Value Reported"},{"name":"NCI_META_CUI","value":"CL978381"},{"name":"Semantic_Type","value":"Finding"}]}}{"C30103":{"preferredName":"Stable","code":"C30103","definitions":[{"definition":"Subject to little fluctuation; showing little if any change.","type":"DEFINITION","source":"NCI"},{"definition":"Subject to little fluctuation; showing little if any change. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Stable","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Stable"},{"name":"Maps_To","value":"Stable"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205360"}]}}{"C177682":{"preferredName":"Gene Amplification Positive","code":"C177682","definitions":[{"definition":"An indication that amplification of one or more genes of interest was detected in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Amplification Positive","termGroup":"PT","termSource":"NCI"},{"termName":"Amplification Detected","termGroup":"SY","termSource":"NCI"},{"termName":"Amplification Positive","termGroup":"SY","termSource":"NCI"},{"termName":"Amplified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amplified"},{"name":"NCI_META_CUI","value":"CL1643457"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C202274":{"preferredName":"Mitotic Count Reported Indicator","code":"C202274","definitions":[{"definition":"An indication that a mitotic count was reported for a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitotic Count Reported Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Mitotic Count Reported","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitotic Count Reported"},{"name":"NCI_META_CUI","value":"CL1921238"},{"name":"Semantic_Type","value":"Finding"}]}}{"C202275":{"preferredName":"Staining Intensity Value Reported Indicator","code":"C202275","definitions":[{"definition":"An indication that a staining intensity value was reported for a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity Value Reported Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Staining Intensity Value Reported","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Staining Intensity Value Reported"},{"name":"NCI_META_CUI","value":"CL1921239"},{"name":"Semantic_Type","value":"Finding"}]}}{"C17666":{"preferredName":"Germline Variation","code":"C17666","definitions":[{"definition":"A gene change in the body's reproductive cells (egg or sperm) that becomes incorporated into the DNA of every cell in the body of offspring; germline mutations are passed on from parents to offspring.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any inheritable variation in the DNA that is transmitted to the progeny with some frequency.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any mutation that appears in the gametes and which will therefore be transmitted to the progeny with some frequency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Germline Variation","termGroup":"PT","termSource":"NCI"},{"termName":"Germline Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Germline Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Germline Variant","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Germline_Mutation"},{"name":"Maps_To","value":"Germline"},{"name":"Maps_To","value":"Simple Germline Variation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0206530"}]}}{"C18060":{"preferredName":"Somatic Variation","code":"C18060","definitions":[{"definition":"An alteration in DNA that occurs after conception. Somatic mutations can occur in any of the cells of the body except the germ cells (sperm and egg) and therefore are not passed on to children. These alterations can (but do not always) cause cancer or other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any mutation with an origin in cells that are not destined to become gametes. As a consequence, such mutations are not transmitted to progeny, though they will be transmitted during any mitosis within the individual. Somatic mutations may contribute to a broad variety of pathologies including cancer.","type":"DEFINITION","source":"NCI"},{"definition":"Any non-inheritable variation in the DNA that is not transmitted to the progeny but will be maintained during any mitosis within the individual.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Somatic Variation","termGroup":"PT","termSource":"NCI"},{"termName":"Somatic Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Mutation Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Somatic_Mutation"},{"name":"Maps_To","value":"Somatic"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0544886"}]}}{"C16277":{"preferredName":"Allele","code":"C16277","definitions":[{"definition":"Mutually exclusive alternative forms of the same gene occupying the same locus on homologous chromosomes, differing in nucleotide sequence and governing the same biochemical and developmental process.","type":"DEFINITION","source":"NCI"},{"definition":"One of two or more DNA sequences occurring at a particular gene locus. Typically one allele (normal DNA sequence) is common, and other alleles (mutations) are rare.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Allele","termGroup":"PT","termSource":"NCI"},{"termName":"Alleles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Two or more genes are said to be alleles if they occupy the same DNA sequence at a locus on homologous chromosomes."},{"name":"Legacy Concept Name","value":"Allele"},{"name":"Maps_To","value":"Alleles"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0002085"}]}}{"C62582":{"preferredName":"Chimerism","code":"C62582","definitions":[{"definition":"The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chimerism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chimerism"},{"name":"Maps_To","value":"Chimerism"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0333678"}]}}{"C165230":{"preferredName":"Conversion Mutation","code":"C165230","definitions":[{"definition":"A rearrangement where nonreciprocal transfer of genetic information between two sites in the genome lead to the deletion of one sequence and the duplication of the transferred sequence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conversion Mutation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Conversion"},{"name":"NCI_META_CUI","value":"CL978382"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C19296":{"preferredName":"Deletion Mutation","code":"C19296","definitions":[{"definition":"Absence of a segment of DNA; may be as small as a single base or as large as a whole chromosome.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any rearrangement to the genomic content that results in the loss of one or more nucleotides of DNA. Deletions are generally irreversible rearrangements. They may alter the reading frame of a gene, or may result in loss of large chromosomal regions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deletion Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"del","termGroup":"AB","termSource":"NCI"},{"termName":"Deletion","termGroup":"SY","termSource":"NCI"},{"termName":"Deletion Abnormality","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Deletion_Mutation"},{"name":"Legacy Concept Name","value":"Gene_Deletion_Abnormality"},{"name":"Maps_To","value":"Deletion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1511760"}]}}{"C171175":{"preferredName":"Delins Mutation","code":"C171175","definitions":[{"definition":"A change in a nucleotide sequence where nucleotides in a reference sequence are replaced by other nucleotides and which is not a substitution, inversion or conversion.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution"}]}],"synonyms":[{"termName":"Delins Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Deletion-Insertion","termGroup":"SY","termSource":"NCI"},{"termName":"Deletion-Insertion Variant","termGroup":"SY","termSource":"NCI"},{"termName":"delins","termGroup":"SY","termSource":"NCI"},{"termName":"delins Variant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deletion-Insertion"},{"name":"NCI_META_CUI","value":"CL1405386"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C45582":{"preferredName":"Gene Duplication Abnormality","code":"C45582","definitions":[{"definition":"Generation of an extra copy of a particular gene in the genome. A gene duplication abnormality may occur by gene amplification, random breakage and reunion, retrotransposition or unequal crossing-over at meiosis. A gene duplication abnormality can be either heritable or somatic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Duplication Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Duplication","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Duplication","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Duplication_Abnormality"},{"name":"Maps_To","value":"Duplication"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705960"}]}}{"C37956":{"preferredName":"Gain","code":"C37956","definitions":[{"definition":"Gain; to increase or the amount of increase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gain","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gain"},{"name":"Maps_To","value":"Gain"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1517378"}]}}{"C20102":{"preferredName":"Hypermethylation","code":"C20102","definitions":[{"definition":"Hypermethylation appears to be a controlled, epigenetic, heritable, and aberrant DNA methylation reaction on gene promoter regions and CpG islands associated with loss of (e.g., tumor-suppressor) gene function in diverse cellular pathways through transcriptional silencing by the formation of transcriptionally repressive chromatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypermethylation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hypermethylation"},{"name":"Maps_To","value":"Hypermethylation"},{"name":"Semantic_Type","value":"Phenomenon or Process"},{"name":"UMLS_CUI","value":"C1512554"}]}}{"C19295":{"preferredName":"Insertion Mutation","code":"C19295","definitions":[{"definition":"Any rearrangement to the genomic content that adds one or more extra nucleotides into the DNA. Insertions may be reversible, particulary if caused by transposable elements. They may alter the reading frame of a gene, or may cause large scale additions of genomic DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Insertion Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"ins","termGroup":"AB","termSource":"NCI"},{"termName":"Insertion","termGroup":"SY","termSource":"NCI"},{"termName":"Insertion Mutation Abnormality","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Insertion_Mutation"},{"name":"Maps_To","value":"Insertion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1512796"}]}}{"C45589":{"preferredName":"Inversion Mutation Abnormality","code":"C45589","definitions":[{"definition":"A structural change in genomic DNA where the 5' to 3' order of a nucleotide sequence is completely reversed to the 3' to 5' order relative to its adjacent sequences. This inversion is termed either pericentric, if it includes the centromere of a chromosome, or pancentric, if it excludes the centromere. An inversion mutation abnormality may be heritable or occur somatically.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inversion Mutation Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"inv","termGroup":"AB","termSource":"NCI"},{"termName":"Inversion","termGroup":"SY","termSource":"NCI"},{"termName":"Inversion Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Inversion_Mutation_Abnormality"},{"name":"Maps_To","value":"Inversion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705687"}]}}{"C25559":{"preferredName":"Loss","code":"C25559","definitions":[{"definition":"A gradual decline in amount or activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Loss","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Loss"},{"name":"Maps_To","value":"Loss"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1517945"}]}}{"C16848":{"preferredName":"Methylation","code":"C16848","definitions":[{"definition":"A chemical reaction in which a small molecule called a methyl group is added to other molecules. Methylation of proteins or nucleic acids may affect how they act in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The covalent chemical or biochemical addition of a methyl group(s) to a compound. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methylation"},{"name":"Maps_To","value":"Methylation"},{"name":"Semantic_Type","value":"Phenomenon or Process"},{"name":"UMLS_CUI","value":"C0025723"}]}}{"C92976":{"preferredName":"Mosaicism","code":"C92976","definitions":[{"definition":"The occurrence of 2 or more cell lines with different genetic or chromosomal make-up, within a single individual or tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The presence of more than one genetically distinct cell line in germ and/or somatic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mosaicism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mosaicism"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0026578"}]}}{"C165231":{"preferredName":"Partial DNA Methylation","code":"C165231","definitions":[{"definition":"An indication that 10-90% of the CpG islands in a gene or gene promoter have detectable methylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial DNA Methylation","termGroup":"PT","termSource":"NCI"},{"termName":"Partial Methylation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Partial Methylation"},{"name":"NCI_META_CUI","value":"CL978383"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C36541":{"preferredName":"Chromosomal Rearrangement","code":"C36541","definitions":[{"definition":"Any change in the structure of one or more chromosomes.","type":"DEFINITION","source":"NCI"},{"definition":"Any process affecting a DNA sequence that results in the gain, loss or exchange of DNA between chromosomes and/or autonomous replicons.","type":"ALT_DEFINITION","source":"PCDC","qualifiers":[{"type":"attribution","value":"AML"}]}],"synonyms":[{"termName":"Chromosomal Rearrangement","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosomal Rearrangements","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Chromosomal Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Chromosome Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Structural Chromosome Anomalies","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Chromosomal_Rearrangement"},{"name":"Maps_To","value":"Rearrangement"},{"name":"Maps_To","value":"Structural Rearrangement"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515001"}]}}{"C13298":{"preferredName":"Repetitive Sequence","code":"C13298","definitions":[{"definition":"Nucleotide sequences present in multiple copies in the genome. There are several types of repeated sequences. Interspersed (or dispersed) DNA repeats (Interspersed Repetitive Sequences) are copies of transposable elements interspersed throughout the genome.  Flanking (or terminal) repeats (Terminal Repeat Sequences) are sequences that are repeated on both ends of a sequence, for example, the long terminal repeats (LTRs) on retroviruses. Direct terminal repeats are in the same direction and inverted terminal repeats are opposite to each other in direction. Tandem repeats (Tandem Repeat Sequences) are repeated copies which lie adjacent to each other. These can also be direct or inverted. The ribosomal RNA and transfer RNA genes belong to the class of middle repetitive DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Repetitive Sequence","termGroup":"PT","termSource":"NCI"},{"termName":"Repeated Sequence","termGroup":"SY","termSource":"NCI"},{"termName":"Repetitive Element","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Repetitive_Sequence"},{"name":"Maps_To","value":"Repeated Sequences"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C0086908"}]}}{"C3420":{"preferredName":"Chromosomal Translocation","code":"C3420","definitions":[{"definition":"A genetic exchange where a piece of one chromosome is transferred to another chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromosomal Translocation","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Translocation","termGroup":"SY","termSource":"NCI"},{"termName":"t","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Chromosomal_Translocation"},{"name":"Maps_To","value":"Translocation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0040715"}]}}{"C45584":{"preferredName":"Gene Fusion Abnormality","code":"C45584","definitions":[{"definition":"Fusion of two genes or segments of genes that were previously separated prior to a mutation abnormality such as translocation. A gene fusion abnormality results in the formation of a new genetic unit that typically exhibits altered functional characteristics. This type of mutation abnormality can be either heritable or occur somatically.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Fusion Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Fusion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gene_Fusion_Abnormality"},{"name":"Maps_To","value":"Fusion"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705736"}]}}{"C17004":{"preferredName":"Genetic Polymorphism","code":"C17004","definitions":[{"definition":"A common change in the genetic code in DNA. Polymorphisms can have a harmful effect, a good effect, or no effect. Some polymorphisms have been shown to increase the risk of certain types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The regular and simultaneous occurrence of alternative nucleotide sequences at equivalent locations of the genetic material among individuals of a single interbreeding population that are not maintained by recurrent mutation. Polymorphisms may range in size from single nucleotide to large nucleotide sequence variation visible at the chromosomal level.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genetic Polymorphism","termGroup":"PT","termSource":"NCI"},{"termName":"Polymorphism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Genetic_Polymorphism"},{"name":"Maps_To","value":"Genetic Polymorphism"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C0032529"}]}}{"C198980":{"preferredName":"Internal Tandem Duplication Mutation","code":"C198980","definitions":[{"definition":"The duplication of adjacent coding regions or whole exon sequences that are reinserted in-frame within the gene of origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Internal Tandem Duplication Mutation","termGroup":"PT","termSource":"NCI"},{"termName":"Internal Tandem Duplication","termGroup":"SY","termSource":"NCI"},{"termName":"ITD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Internal Tandem Duplication"},{"name":"NCI_META_CUI","value":"CL1907624"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C45576":{"preferredName":"Mutation Abnormality","code":"C45576","definitions":[{"definition":"Any change in the DNA of a cell. Mutations may be caused by mistakes during cell division, or they may be caused by exposure to DNA-damaging agents in the environment. Mutations can be harmful, beneficial, or have no effect. If they occur in cells that make eggs or sperm, they can be inherited; if mutations occur in other types of cells, they are not inherited. Certain mutations may lead to cancer or other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutation Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Genetic Alteration","termGroup":"SY","termSource":"NCI"},{"termName":"Genetic Change","termGroup":"SY","termSource":"NCI"},{"termName":"Mutated","termGroup":"AD","termSource":"NCI"},{"termName":"Mutation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Mutation_Abnormality"},{"name":"Maps_To","value":"Mutation, NOS"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1705285"}]}}{"C64346":{"preferredName":"Hemizygosity","code":"C64346","definitions":[{"definition":"Having only one copy of a particular gene or genetic region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemizygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Hemizygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemizygous"},{"name":"Maps_To","value":"Hemizygous"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1881036"}]}}{"C45825":{"preferredName":"Heterozygosity","code":"C45825","definitions":[{"definition":"Having two different allelic forms of a gene, one inherited from each parent, on each of the two homologous chromosomes.","type":"DEFINITION","source":"NCI"},{"definition":"Occurs when the two alleles at a particular gene locus are different. A heterozygous genotype may include one normal allele and one mutation, or two different mutations. The latter is called a compound heterozygote.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Heterozygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Heterozygote","termGroup":"SY","termSource":"NCI"},{"termName":"Heterozygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Heterozygous"},{"name":"Maps_To","value":"Heterozygous"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0019425"}]}}{"C45826":{"preferredName":"Homozygosity","code":"C45826","definitions":[{"definition":"Having two identical allelic forms of a gene, one inherited from each parent, on each of the two homologous chromosomes.","type":"DEFINITION","source":"NCI"},{"definition":"Occurs when both alleles at a particular gene locus are the same. A person may be homozygous for the normal allele or for a mutation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Homozygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Homozygote","termGroup":"SY","termSource":"NCI"},{"termName":"Homozygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Homozygous"},{"name":"Maps_To","value":"Homozygous"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0019904"}]}}{"C148063":{"preferredName":"Nullizygosity","code":"C148063","definitions":[{"definition":"Having no copies, or nonfunctional copies, of a particular gene or genetic region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nullizygosity","termGroup":"PT","termSource":"NCI"},{"termName":"Homozygous Null","termGroup":"SY","termSource":"NCI"},{"termName":"Nullizygous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nullizygous"},{"name":"NCI_META_CUI","value":"CL545804"},{"name":"Semantic_Type","value":"Functional Concept"}]}}{"C8362":{"preferredName":"Mild Dysplasia","code":"C8362","definitions":[{"definition":"A morphologic finding indicating the presence of mild cellular atypia associated with mild architectural changes in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mild Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mild_Dysplasia"},{"name":"Maps_To","value":"Mild"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334046"}]}}{"C8363":{"preferredName":"Moderate Dysplasia","code":"C8363","definitions":[{"definition":"A morphologic finding indicating the presence of moderate cellular atypia associated with moderate architectural changes in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderate Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Moderate_Dysplasia"},{"name":"Maps_To","value":"Moderate"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334047"}]}}{"C8364":{"preferredName":"Severe Dysplasia","code":"C8364","definitions":[{"definition":"A morphologic finding indicating the presence of severe cellular atypia associated with severe architectural changes in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Severe Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Severe_Dysplasia"},{"name":"Maps_To","value":"Severe"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0334048"}]}}{"C174120":{"preferredName":"Esophageal Columnar Dysplasia","code":"C174120","definitions":[{"definition":"A morphologic finding the replacement of the normal lower esophagus squamous epithelium with columnar epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esophageal Columnar Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Columnar Epithelial Dysplasia","termGroup":"SY","termSource":"NCI"},{"termName":"ECD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Esophageal Columnar Dysplasia"},{"name":"Maps_To","value":"Esophageal Mucosa Columnar Dysplasia"},{"name":"NCI_META_CUI","value":"CL1407784"},{"name":"Semantic_Type","value":"Finding"}]}}{"C161017":{"preferredName":"Keratinizing Dysplasia","code":"C161017","definitions":[{"definition":"Epithelial dysplasia in which the dysplastic changes, although limited to the lower basal zone, are so severe, that there is a high probability of progression to invasive carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Keratinizing Dysplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Keratinizing"},{"name":"NCI_META_CUI","value":"CL969991"},{"name":"Semantic_Type","value":"Finding"}]}}{"C161016":{"preferredName":"Non-Keratinizing Dysplasia","code":"C161016","definitions":[{"definition":"Intraepithelial proliferation of dysplastic epithelial cells not associated with keratin formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Keratinizing Dysplasia","termGroup":"PT","termSource":"NCI"},{"termName":"Nonkeratinizing Dysplasia","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nonkeratinizing"},{"name":"NCI_META_CUI","value":"CL969992"},{"name":"Semantic_Type","value":"Finding"}]}}{"C27296":{"preferredName":"Positive Lymph Node","code":"C27296","definitions":[{"definition":"Cancer that has spread to the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The presence of metastatic cancer cells in a lymph node.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Positive Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Positive_Lymph_Node"},{"name":"Maps_To","value":"Positive"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0746319"}]}}{"C36174":{"preferredName":"Negative Lymph Node","code":"C36174","definitions":[{"definition":"A clinical finding that a lymph node is free from cancer spread.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that has not spread to the lymph nodes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Negative Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Negative_Lymph_Node"},{"name":"Maps_To","value":"Negative"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0678034"}]}}{"C48620":{"preferredName":"Positive Surgical Margin","code":"C48620","definitions":[{"definition":"Indicates the presence of tumor cells at the edge of a surgically excised specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Positive Surgical Margin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Positive_Surgical_Margin"},{"name":"Maps_To","value":"Involved"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709603"}]}}{"C179432":{"preferredName":"Cohesive Pattern","code":"C179432","definitions":[{"definition":"A microscopic finding that the cells in the sample are tightly adhered to one another and distributed uniformly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cohesive Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Cohesive Architectural Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cohesive"},{"name":"NCI_META_CUI","value":"CL1662208"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35920":{"preferredName":"Cribriform Pattern","code":"C35920","definitions":[{"definition":"A morphologic finding indicating the presence of sheets of malignant epithelial cells punctuated by gland-like spaces in a tissue sample.","type":"DEFINITION","source":"NCI"},{"definition":"Formation of epithelial pseudoglandular structures with lumens.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cribriform Pattern","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cribriform_Pattern"},{"name":"Maps_To","value":"Cribiform"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1333163"}]}}{"C36181":{"preferredName":"Micropapillary Growth Pattern","code":"C36181","definitions":[{"definition":"A morphologic finding indicating the presence of a growth pattern dominated by the presence of small papillary structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micropapillary Growth Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Micropapillary Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Micropapillary_Pattern"},{"name":"Maps_To","value":"Micropapillary"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1334756"}]}}{"C179447":{"preferredName":"Non-Cohesive Pattern","code":"C179447","definitions":[{"definition":"A microscopic finding where the cells in a sample are arranged, singly or in small clusters, demonstrate loose adhesion with one another and may not be distributed uniformly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Cohesive Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Non-Cohesive Architectural Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-cohesive"},{"name":"NCI_META_CUI","value":"CL1662300"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35911":{"preferredName":"Papillary Growth Pattern","code":"C35911","definitions":[{"definition":"A morphologic finding indicating the presence of a cellular infiltrate with papillary growth in a tissue sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Papillary Growth Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Papillary Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Papillary_Pattern"},{"name":"Maps_To","value":"Papillary, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1335326"}]}}{"C36182":{"preferredName":"Solid Growth Pattern","code":"C36182","definitions":[{"definition":"A microscopic finding indicating that the neoplastic cells are arranged in solid sheets in a tumor sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Growth Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Solid_Pattern"},{"name":"Maps_To","value":"Solid"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1336028"}]}}{"C35925":{"preferredName":"Tubular Pattern","code":"C35925","definitions":[{"definition":"A morphological appearance characteristic of neoplasms which arise from the glandular or ductal (or both) epithelium, consisting of glandular or ductal neoplastic proliferations forming small tubules with a lumen lined by neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubular Pattern","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tubular_Pattern"},{"name":"Maps_To","value":"Tubular"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1336833"}]}}{"C28277":{"preferredName":"Pathology Report","code":"C28277","definitions":[{"definition":"A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.","type":"DEFINITION","source":"NCI"},{"definition":"The description of cells and tissues made by a pathologist based on microscopic evidence, and sometimes used to make a diagnosis of a disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pathology Report","termGroup":"PT","termSource":"NCI"},{"termName":"Histology Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Pathology_Report"},{"name":"Maps_To","value":"Pathology Report"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0807321"}]}}{"C63805":{"preferredName":"Portable Document Format","code":"C63805","definitions":[{"definition":"An open file format created and controlled by Adobe Systems, for representing two-dimensional documents in a device independent and resolution independent fixed-layout document format. Each PDF file encapsulates a complete description of a 2D document that includes the text, fonts, images, and 2D vector graphics that compose the document. PDF files do not encode information that is specific to the application software, hardware, or operating system used to create or view the document. This feature ensures that a valid PDF will render exactly the same regardless of its origin or destination (but depending on font availability when fonts are not encapsulated in the file).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Portable Document Format","termGroup":"PT","termSource":"NCI"},{"termName":"pdf","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Portable_Document_Format"},{"name":"Maps_To","value":"PDF"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1554990"}]}}{"C120024":{"preferredName":"Histone H3 Methyl Lys4","code":"C120024","definitions":[{"definition":"A form of histone H3 where the lysine residue at position 4 has been post-translationally modified with a single methyl group. This modification may be a marker for transcriptionally active genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Methyl Lys4","termGroup":"PT","termSource":"NCI"},{"termName":"H3K4me1","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Methyl Lysine 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K4me1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C3896986"}]}}{"C107153":{"preferredName":"Histone H3 Trimethyl Lys4","code":"C107153","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 4 is trimethylated. This modification may be a marker for areas of active gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys4","termGroup":"PT","termSource":"NCI"},{"termName":"H3K4me3","termGroup":"SY","termSource":"NCI"},{"termName":"H3K4me3 Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K4me3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C3829683"}]}}{"C174109":{"preferredName":"Histone H3 Trimethyl Lys9","code":"C174109","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 9 is trimethylated. This modification is associated with heterochromatin formation and plays a role in embryonic stem cell lineage commitment and maintenance of lineage fidelity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys9","termGroup":"PT","termSource":"NCI"},{"termName":"H3K9me3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K9me3"},{"name":"NCI_META_CUI","value":"CL1407747"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C174110":{"preferredName":"Histone H3 Trimethyl Lys28","code":"C174110","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 28 is trimethylated. This modification is associated with formation of heterochromatin and polycomb repressive complex 1 (PRC1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys28","termGroup":"PT","termSource":"NCI"},{"termName":"H3K27me3","termGroup":"SY","termSource":"NCI"},{"termName":"H3K28me3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 28","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Even though the literature refers to lysine 27 methylation or amino acid variation/mutation, RefSeq indicates that the lysine is located at amino acid position 28 in histone H3. (see https://link.springer.com/article/10.1007/s00401-018-1867-2)"},{"name":"Maps_To","value":"H3K27me3"},{"name":"NCI_META_CUI","value":"CL1407746"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C142872":{"preferredName":"Histone H3 Trimethyl Lys36","code":"C142872","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 36 is trimethylated. This modification may be involved in defining exon boundaries; it also may be a marker for genes targeted for transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Trimethyl Lys36","termGroup":"PT","termSource":"NCI"},{"termName":"H3K36me3","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Trimethyl Lysine 36","termGroup":"SY","termSource":"NCI"},{"termName":"Trimethylated Histone H3 at Lysine 36","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H3K36me3"},{"name":"NCI_META_CUI","value":"CL540739"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C120023":{"preferredName":"Histone H3 Acetyl Lys28","code":"C120023","definitions":[{"definition":"A post-translationally modified form of histone H3 where the lysine residue at position 28 is acetylated. This modification may be a marker for transcriptional enhancement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone H3 Acetyl Lys28","termGroup":"PT","termSource":"NCI"},{"termName":"H3K27ac","termGroup":"SY","termSource":"NCI"},{"termName":"H3K28ac","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Acetyl Lys27","termGroup":"SY","termSource":"NCI"},{"termName":"Histone H3 Acetyl Lysine 28","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Even though the literature refers to lysine 27 methylation or amino acid variation/mutation, RefSeq indicates that the lysine is located at amino acid position 28 in histone H3. (see https://link.springer.com/article/10.1007/s00401-018-1867-2)"},{"name":"Maps_To","value":"H3K27ac"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C3898882"}]}}{"C156442":{"preferredName":"Control Analyte","code":"C156442","definitions":[{"definition":"A biospecimen that is used as a comparator for an experimental sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Control Analyte","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"00"},{"name":"Maps_To","value":"Control Analyte"},{"name":"Maps_To","value":"Input Control"},{"name":"NCI_META_CUI","value":"CL563180"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C163987":{"preferredName":"Affinity Enriched Genomic Library","code":"C163987","definitions":[{"definition":"A genomic library where the sample has been subjected to enrichment via binding to a target protein or oligonucleotide prior to molecular analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Affinity Enriched Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Affinity Enrichment"},{"name":"NCI_META_CUI","value":"CL977266"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163986":{"preferredName":"Hybrid Selected Genomic Library","code":"C163986","definitions":[{"definition":"A genomic library where the sample has been subjected to enrichment via nucleic acid hybridization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hybrid Selected Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hybrid Selection"},{"name":"NCI_META_CUI","value":"CL977267"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163991":{"preferredName":"miRNA Size Fractionated Genomic Library","code":"C163991","definitions":[{"definition":"A RNA library that has been fractionated by size exclusion methods to enrich for microRNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"miRNA Size Fractionated Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"miRNA Size Fractionation"},{"name":"NCI_META_CUI","value":"CL977262"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163988":{"preferredName":"Poly-A Enriched Genomic Library","code":"C163988","definitions":[{"definition":"A genomic library where the sample has been subjected to enrichment via binding to immobilized poly-T oligonucleotides, which will preferentially isolate polyadenylated (poly-A) RNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly-A Enriched Genomic Library","termGroup":"PT","termSource":"NCI"},{"termName":"Poly(A) Enriched Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"Poly(A) Selected Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-A Selected Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-T Enriched Genomic Library","termGroup":"SY","termSource":"NCI"},{"termName":"PolyA Selected Genomic Library","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Poly-T Enrichment"},{"name":"NCI_META_CUI","value":"CL977265"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163989":{"preferredName":"Randomly Selected Genomic Library","code":"C163989","definitions":[{"definition":"A genomic library constructed to generate random DNA fragments by subjecting a genomic sample to either amplification using random primers or fragmentation via exposure to restriction enzymes or shear stress. The fragments can then be cloned or sequenced directly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Randomly Selected Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Random"},{"name":"NCI_META_CUI","value":"CL977264"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C163990":{"preferredName":"rRNA Depleted Genomic Library","code":"C163990","definitions":[{"definition":"A genomic library where the sample has been subjected to a ribosomal RNA depletion step before it is amplified.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"rRNA Depleted Genomic Library","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"rRNA Depletion"},{"name":"NCI_META_CUI","value":"CL977263"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C150427":{"preferredName":"Unstranded Library Sequencing","code":"C150427","definitions":[{"definition":"Non-directional sequencing, where the reads can map from either the transcript strand or its complement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unstranded Library Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Unstranded","termGroup":"SY","termSource":"NCI"},{"termName":"Unstranded Library","termGroup":"SY","termSource":"NCI"},{"termName":"Unstranded Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unstranded"},{"name":"NCI_META_CUI","value":"CL552241"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C150428":{"preferredName":"First-strand Library Sequencing","code":"C150428","definitions":[{"definition":"Directional sequencing, where the first read (or the only read in case of single end reads) is from the complement strand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First-strand Library Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"First-strand","termGroup":"SY","termSource":"NCI"},{"termName":"First-strand Library","termGroup":"SY","termSource":"NCI"},{"termName":"First-strand Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First_Stranded"},{"name":"NCI_META_CUI","value":"CL552240"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C150426":{"preferredName":"Second-strand Library Sequencing","code":"C150426","definitions":[{"definition":"Directional sequencing, where the first read of the read pair (or in case of single end reads, the only read) is from the transcript strand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Second-strand Library Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Second-strand","termGroup":"SY","termSource":"NCI"},{"termName":"Second-strand Library","termGroup":"SY","termSource":"NCI"},{"termName":"Second-strand Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Second_Stranded"},{"name":"NCI_META_CUI","value":"CL552130"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C156056":{"preferredName":"ATAC-Seq","code":"C156056","definitions":[{"definition":"A molecular genetic technique that isolates and sequences chromosomal regions that are rich in open chromatin. First, nuclei are harvested from a cellular sample. Then a hyperactive Tn5 transposase is added to the nuclei where it excises non-nucleosomal DNA strands and ligates co-administered high-throughput sequencing adapters (tagmentation).  The tagged DNA fragments are isolated, amplified by PCR and sequenced. The number of reads for specific region of DNA correlate with increased chromatin accessibility and this method can identify regions of transcription factor and nucleosome binding.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATAC-Seq","termGroup":"PT","termSource":"NCI"},{"termName":"Assay for Transposase Accessible Chromatin with High-Throughput Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Assay for Transposase-Accessible Chromatin Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Assay for Transposase-Accessible Chromatin Using Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ATAC-Seq"},{"name":"NCI_META_CUI","value":"CL562893"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C106054":{"preferredName":"Bisulfite Sequencing","code":"C106054","definitions":[{"definition":"A DNA sequencing technique that can differentiate cytosine from 5-methylcytosine in a DNA sample. First, a denatured DNA sample is treated with bisulfite which converts non-methylated cytosine to uracil. Next, the sample is amplified using a PCR method that does not discriminate between non-methylated and methylated sequences. The amplified DNA is subjected to nucleotide sequencing. The resulting sequence is compared to an identical control sample of DNA that was not treated with bisulfite. Unmethylated cytosines will be displayed as cytosines in the control sample and as thymines in the bisulfite-treated sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisulfite Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Bisulfite-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Bisulphite Conversion Followed by Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"BS-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"DNA Methylation Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl-C-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Methylation Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"MethylC-Seq","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Bisulfite-Seq"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3829113"}]}}{"C106049":{"preferredName":"ChIP-Seq","code":"C106049","definitions":[{"definition":"A molecular genetic technique that combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing to map the binding sites of DNA-associated proteins in a sample of cells. First, crosslinked protein-DNA complexes are isolated using ChIP. Next, the crosslinks are broken, the proteins are removed and the purified DNA is modified with adaptor oligonucleotides to facilitate massively parallel DNA sequencing. Following sequencing, the DNA sequences that are obtained can be mapped to their genomic locations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ChIP-Seq","termGroup":"PT","termSource":"NCI"},{"termName":"ChIP-Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Chromatin Immunoprecipitation Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ChIP-Seq"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"},{"name":"UMLS_CUI","value":"C3831111"}]}}{"C156057":{"preferredName":"MicroRNA Sequencing","code":"C156057","definitions":[{"definition":"A next-generation or massively parallel high-throughput DNA sequencing-based procedure that can identify and quantify the microRNA sequences present in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MicroRNA Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"MicroRNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA-Seq","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"miRNA-Seq"},{"name":"NCI_META_CUI","value":"CL562894"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C171152":{"preferredName":"Single Cell RNA Sequencing","code":"C171152","definitions":[{"definition":"A procedure that can determine the nucleotide sequence for all of the RNA transcripts in an amplified nucleotide sample that was derived from a single cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Single Cell RNA Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"scRNA-Seq","termGroup":"AB","termSource":"NCI"},{"termName":"Single Cell RNA-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Single Cell Transcriptome Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"scRNA-Seq"},{"name":"NCI_META_CUI","value":"CL1405380"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179435":{"preferredName":"HiChIP","code":"C179435","definitions":[{"definition":"A method that combines chromosome conformation capture, proximity ligation and chromatin immunoprecipitation to isolate DNA from a biospecimen, create a genomic library and analyze 3D chromatin organization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HiChIP","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HiChIP"},{"name":"NCI_META_CUI","value":"CL1662209"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179442":{"preferredName":"N6-Methyladenine RNA Analysis","code":"C179442","definitions":[{"definition":"An assay that quantitates the amount and identifies the location of N6-methyladenine modifications within an RNA sequence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N6-Methyladenine RNA Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"m6A RNA Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"m6A RNA Methylation"},{"name":"NCI_META_CUI","value":"CL1662303"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179458":{"preferredName":"Single Cell ATAC-Seq","code":"C179458","definitions":[{"definition":"A molecular genetic technique where DNA is isolated from single cell (sc) samples and amplified to create a genomic library. Then the library is subjected to ATAC-seq, which isolates and sequences regions rich in open chromatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Single Cell ATAC-Seq","termGroup":"PT","termSource":"NCI"},{"termName":"scATAC-Seq","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"scATAC-Seq"},{"name":"NCI_META_CUI","value":"CL1662285"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C188371":{"preferredName":"N6-Methyladenine RNA Immunoprecipitation-Sequencing","code":"C188371","definitions":[{"definition":"A method used to sequence N6-methyladenine (m6A)-modified RNA. Briefly, an RNA sample is subjected to immunoprecipitation using an antibody that specifically enriches m6A RNA, the m6A enriched RNA is reverse-transcribed to produce the complimentary DNA (cDNA) strand and the cDNA is subjected to sequencing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N6-Methyladenine RNA Immunoprecipitation-Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"m6A MeRIP-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"m6A-Methylated RNA Immunoprecipitation-Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"m6A-seq","termGroup":"SY","termSource":"NCI"},{"termName":"MeRIP-Seq","termGroup":"SY","termSource":"NCI"},{"termName":"Methylated RNA Immunoprecipitation-Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"m6A MeRIP-Seq"},{"name":"NCI_META_CUI","value":"CL1793642"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146815":{"preferredName":"Complete Genomics Sequencing","code":"C146815","definitions":[{"definition":"A next-generation DNA sequencing service offered by Complete Genomics. Unamplified human genomic DNA is sheared into 500bp fragments and then amplified to create DNA nano-balls (DNBs). The DNBs are arrayed on a substrate and their sequence is determined by Combinatorial Probe-Anchor Ligation (cPAL) sequencing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complete Genomics Sequencing","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Complete Genomics"},{"name":"NCI_META_CUI","value":"CL544862"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146817":{"preferredName":"Illumina Sequencing","code":"C146817","definitions":[{"definition":"A proprietary next-generation DNA sequencing system from Solexa that uses reversible terminator nucleotides. The genomic DNA to be sequenced is fragmented and ligated to adapter molecules on both ends to construct an Illumina-specific adapter library. PCR amplification of the DNA fragments is then performed using the adapter sequence as primer. Sequencing is carried out by repeated cycles of adding reversible fluorescent-labelled nucleotide and incorporation of the nucleotides to the complementary strand. The fluorescence of the incorporated nucleotides is detected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Illumina Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Illumina Sequencing Technology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Illumina"},{"name":"NCI_META_CUI","value":"CL544864"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C125894":{"preferredName":"Ion Semiconductor Sequencing","code":"C125894","definitions":[{"definition":"A method of DNA sequencing based on the detection of hydrogen ions that are released during synthesis of a complementary strand polymerized on a template strand. This technology differs from other sequencing technologies in that no modified nucleotides or optics are used. It claims to be simpler, faster, and more cost effective and scalable than any other technology available.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ion Semiconductor Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Ion Torrent Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Ion Torrent Sequencing Technology","termGroup":"SY","termSource":"NCI"},{"termName":"pH-Mediated Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Semiconductor Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Silicon Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ion Torrent"},{"name":"NCI_META_CUI","value":"CL504544"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146809":{"preferredName":"454 Sequencing","code":"C146809","definitions":[{"definition":"A proprietary next-generation DNA sequencing system from 454 Life Sciences that used large-scale parallel pyrosequencing. The system relied on fixing nebulized and adapter-ligated DNA fragments to small DNA-capture beads in a water-in-oil emulsion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"454 Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"454 Sequencing Technology","termGroup":"SY","termSource":"NCI"},{"termName":"LS 454 Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LS454"},{"name":"NCI_META_CUI","value":"CL544750"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146819":{"preferredName":"SMRT Sequencing","code":"C146819","definitions":[{"definition":"A proprietary third-generation DNA sequencing system from Pacific Biosciences that uses zero-mode waveguides (ZMWs) and phospholinked nucleotides. A single DNA polymerase enzyme is affixed at the bottom of a ZMW structure with a single molecule of DNA as a template. A fluorescent tag is cleaved off with each base addition and is detected to create the sequence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMRT Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Single Molecule, Real-Time Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"SMRT Sequencing Technology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PacBio"},{"name":"NCI_META_CUI","value":"CL544866"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C146811":{"preferredName":"ABI SOLiD Sequencing","code":"C146811","definitions":[{"definition":"A proprietary next-generation DNA sequencing system from Applied Biosystems that utilizes DNA ligase. DNA fragments attached to beads are clonally amplified and ligated to fluorescently labeled \"interrogation probes\". Ligation frees the fluor, which is detected and identifies the specific probe. The marker of the attached probe is then removed and a 5'-phosphate group is regenerated. Multiple cycles of ligation, detection, and cleavage are performed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ABI SOLiD Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Sequencing of Oligonucleotides by Ligation/Detection","termGroup":"SY","termSource":"NCI"},{"termName":"SOLiD Sequencing Technology","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SOLiD"},{"name":"NCI_META_CUI","value":"CL544752"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C172256":{"preferredName":"Root Directory","code":"C172256","definitions":[{"definition":"The top-most directory in a hierarchical file system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Root Directory","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"root"},{"name":"NCI_META_CUI","value":"CL1406129"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C165214":{"preferredName":"Run Metadata","code":"C165214","definitions":[{"definition":"Supporting information that describes the nucleic acid sequencing run(s) in a study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Run Metadata","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Run Metadata"},{"name":"NCI_META_CUI","value":"CL978396"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C77608":{"preferredName":"Abdominal Wall","code":"C77608","definitions":[{"definition":"The tissue that surrounds the organs present in the abdominal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles.","type":"DEFINITION","source":"NCI"},{"definition":"The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Abdominal Wall","termGroup":"PT","termSource":"NCI"},{"termName":"wall of abdomen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Abdominal_Wall"},{"name":"Maps_To","value":"Abdominal Wall"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0836916"},{"name":"xRef","value":"UBERON:0003697"}]}}{"C32042":{"preferredName":"Acetabulum","code":"C32042","definitions":[{"definition":"The acetabulum is a concave surface of the pelvis. The head of the femur meets with the pelvis at the acetabulum, forming the hip joint. There are three bones of the os coxae (hip bone) that come together to form the acetabulum. Contributing a little more than two-fifths of the structure is the ischium, which provides lower and side boundaries to the acetabulum. The ilium forms the upper boundary, providing a little less than two-fifths of the structure of the acetabulum. The rest is formed by the pubis, near the midline. It is bounded by a prominent uneven rim, which is thick and strong above, and serves for the attachment of the acetabular labrum, which reduces its opening, and deepens the surface for formation of the hip joint. At the lower part of the acetabulum is the acetabular notch, which is continuous with a circular depression, the acetabular fossa, at the bottom of the cavity of the acetabulum. The rest of the acetabulum is formed by a curved, crescent-moon shaped surface, the lunate surface, where the joint is made with the head of the femur. Its counterpart in the pectoral girdle is the glenoid fossa.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Two cup shaped areas, one each on the lateral side of the lower pelvis that house the head of the femur to form the ball and socket joint of the hip.","type":"DEFINITION","source":"NCI"},{"definition":"Two cup shaped areas, one each on the lateral side of the lower pelvis that house the head of the femur to form the ball and socket joint of the hip. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Acetabulum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Acetabulum"},{"name":"Maps_To","value":"Acetabulum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0000962"},{"name":"xRef","value":"UBERON:0001269"}]}}{"C33318":{"preferredName":"Pharyngeal Tonsil","code":"C33318","definitions":[{"definition":"A fold of lymphatic tissue covered by ciliated epithelium at the very back of the nose, in the roof of the nasopharynx.","type":"DEFINITION","source":"NCI"},{"definition":"A tonsil in the mucosa of the nasopharynx.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The lymph tissue in the roof and posterior wall of the nasopharynx.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Pharyngeal Tonsil","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pharyngeal_Tonsil"},{"name":"Maps_To","value":"Adenoid"},{"name":"Maps_To","value":"Tonsil (Pharyngeal)"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0001428"},{"name":"xRef","value":"UBERON:0001732"}]}}{"C12472":{"preferredName":"Adipose Tissue","code":"C12472","definitions":[{"definition":"A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers.","type":"DEFINITION","source":"NCI"},{"definition":"Connective tissue consisting primarily of adipocytes (fat cells) and supporting structural matrix.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Portion of connective tissue composed of adipocytes enmeshed in areolar tissue.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Adipose Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Body Fat","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Adipose_Tissue"},{"name":"Maps_To","value":"Adipose"},{"name":"NCI_META_CUI","value":"CL1773619"},{"name":"Semantic_Type","value":"Tissue"},{"name":"xRef","value":"UBERON:0001013"}]}}{"C89749":{"preferredName":"Alveolar Ridge","code":"C89749","definitions":[{"definition":"The thickened bony structures in the mandible and maxilla that contain the sockets of the teeth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The thickened bony structures in the mandible and maxilla that contain the sockets of the teeth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alveolar Ridge","termGroup":"PT","termSource":"NCI"},{"termName":"Alveolar Margin","termGroup":"SY","termSource":"NCI"},{"termName":"Alveolar Process","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Alveolar Ridge"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0447411"},{"name":"xRef","value":"UBERON:0004103"}]}}{"C13188":{"preferredName":"Amniotic Fluid","code":"C13188","definitions":[{"definition":"Amniotic fluid is a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. The composition of the fluid changes over the course of gestation. Initially, amniotic fluid is similar to maternal plasma, mainly water with electrolytes. As the fetus develops, proteins, carbohydrates, lipids, phospholipids originating from the lungs, fetal cells, and urea are deposited in the fluid.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fluid within the amniotic cavity which surrounds and protects the developing embryo. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The fluid within the amniotic cavity which surrounds and protects the developing embryo. It is initially produced by the amnion and then later by the lungs and kidneys. The amount at term normally varies from 500 to 2000 ml.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amniotic Fluid","termGroup":"PT","termSource":"NCI"},{"termName":"Aqua Amnii","termGroup":"SY","termSource":"NCI"},{"termName":"Liquor Amnii","termGroup":"SY","termSource":"NCI"},{"termName":"Waters (Amniotic Fluid)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Amniotic_Fluid"},{"name":"Maps_To","value":"Amniotic Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0002638"},{"name":"xRef","value":"UBERON:0000173"}]}}{"C165177":{"preferredName":"Anal Sphincter","code":"C165177","definitions":[{"definition":"A sphincter muscle that is part of the anal region.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The internal and external muscles surrounding the anus that maintain continence.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The internal and external muscles surrounding the anus that maintain continence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anal Sphincter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Anal Sphincter"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0002760"},{"name":"xRef","value":"UBERON:0004916"}]}}{"C32078":{"preferredName":"Ankle Joint","code":"C32078","definitions":[{"definition":"A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus.","type":"DEFINITION","source":"NCI"},{"definition":"A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A joint that connects the hindlimb autopod and zeugopod skeletons.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Ankle Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Ankle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ankle_Joint"},{"name":"Maps_To","value":"Ankle"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0003087"},{"name":"xRef","value":"UBERON:0001488"}]}}{"C129464":{"preferredName":"Anorectal","code":"C129464","definitions":[{"definition":"Pertaining to the anus and rectum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anorectal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anorectum"},{"name":"NCI_META_CUI","value":"CL018341"},{"name":"Semantic_Type","value":"Spatial Concept"}]}}{"C103238":{"preferredName":"Antecubital Fossa","code":"C103238","definitions":[{"definition":"A triangular space on the anterior side of the elbow joint. Three main veins of the arm, the brachial artery, the medial nerve and the tendon of the biceps muscle pass through this space.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A triangular space on the anterior side of the elbow joint. Three main veins of the arm, the brachial artery, the medial nerve and the tendon of the biceps pass through this space.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antecubital Fossa","termGroup":"PT","termSource":"NCI"},{"termName":"Cubital Fossa","termGroup":"SY","termSource":"NCI"},{"termName":"Elbow Pit","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antecubital Fossa"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0446523"}]}}{"C97102":{"preferredName":"Antrum","code":"C97102","definitions":[{"definition":"A chamber formation in an organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antrum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antrum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1549092"}]}}{"C12669":{"preferredName":"Aorta","code":"C12669","definitions":[{"definition":"The largest artery in the body. It carries oxygen-rich blood away from the heart to vessels that reach the rest of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The main trunk of the systemic arterial system that carries blood from the heart to all the organs and other structures of the body, bringing oxygenated blood to all parts of the body in the systemic circulation.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The major arterial trunk that carries oxygenated blood from the left ventricle into the ascending aorta behind the heart, the aortic arch, through the thorax as the descending aorta and through the abdomen as the abdominal aorta; it bifurcates into the left and right common iliac arteries.","type":"DEFINITION","source":"NCI"},{"definition":"The major artery of the body; it arises from the left ventricle of the heart and terminally bifurcates into the common iliac arteries.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Aorta","termGroup":"PT","termSource":"NCI"},{"termName":"Aortic","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Aorta"},{"name":"Maps_To","value":"Aorta"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003483"},{"name":"xRef","value":"UBERON:0000947"}]}}{"C97112":{"preferredName":"Aortic Body","code":"C97112","definitions":[{"definition":"A small mass that is located in the inferior surface of the aortic arch. It functions as a peripheral chemoreceptor and is composed of glomus cells.","type":"DEFINITION","source":"NCI"},{"definition":"A small mass that is located on the inferior surface of the aortic arch. It functions as a peripheral chemoreceptor and is composed of glomus cells.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of several small clusters of chemoreceptors, baroreceptors, and supporting cells located along the aortic arch.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Aortic Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Aortic Body"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1510461"},{"name":"xRef","value":"UBERON:0034971"}]}}{"C13190":{"preferredName":"Aqueous Humor","code":"C13190","definitions":[{"definition":"A thick watery refractive medium that fills the space between the lens and the cornea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The watery fluid which is present in the anterior and posterior chambers of the eye.","type":"DEFINITION","source":"NCI"},{"definition":"The watery fluid which is present in the anterior and posterior chambers of the eye. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Aqueous Humor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Aqueous_Humor"},{"name":"Maps_To","value":"Aqueous Fluid"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0003662"},{"name":"xRef","value":"UBERON:0001796"}]}}{"C32141":{"preferredName":"Arm","code":"C32141","definitions":[{"definition":"The portion of the upper extremity between the shoulder and the elbow.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Arm"},{"name":"Maps_To","value":"Arm"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0446516"},{"name":"xRef","value":"UBERON:0004250"}]}}{"C12372":{"preferredName":"Artery","code":"C12372","definitions":[{"definition":"A blood vessel that carries blood away from the heart.","type":"DEFINITION","source":"NCI"},{"definition":"A blood vessel that carries blood away from the heart. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A blood vessel that carries blood from the heart to tissues and organs in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An epithelial tube or tree of tubes that transports blood away from the heart.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Artery","termGroup":"PT","termSource":"NCI"},{"termName":"Arterial","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Artery"},{"name":"Maps_To","value":"Artery"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0003842"},{"name":"xRef","value":"UBERON:0001637"}]}}{"C12498":{"preferredName":"External Acoustic Meatus","code":"C12498","definitions":[{"definition":"A part of the ear canal that is external to the ear drum.","type":"DEFINITION","source":"NCI"},{"definition":"A tube running from the outer ear to the middle ear. The human ear canal extends from the pinna to the eardrum and is about 26 mm in length and 7 mm in diameter.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A tubular structure that runs from the outer ear to the tympanic membrane.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"External Acoustic Meatus","termGroup":"PT","termSource":"NCI"},{"termName":"External Auditory Canal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"External_Acoustic_Meatus"},{"name":"Maps_To","value":"Auditory Canal"},{"name":"Maps_To","value":"Ear Canal"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013444"},{"name":"xRef","value":"UBERON:0001352"}]}}{"C12674":{"preferredName":"Axilla","code":"C12674","definitions":[{"definition":"The axilla is the area directly under the joint where the forelimb connects to the shoulder.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The underarm or armpit.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The underside concavity where the arm and the shoulder are joined.","type":"DEFINITION","source":"NCI"},{"definition":"The underside concavity where the arm and the shoulder are joined. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Axilla","termGroup":"PT","termSource":"NCI"},{"termName":"Armpit","termGroup":"SY","termSource":"NCI"},{"termName":"Underarm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Axilla"},{"name":"Maps_To","value":"Axilla"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C4018906"},{"name":"xRef","value":"UBERON:0009472"}]}}{"C13062":{"preferredName":"Back","code":"C13062","definitions":[{"definition":"A major subdivision of an organism that is the entire part of the organism dorsal to a horizontal plane and bounded on one side by the same transverse plane. In vertebrares this includes the vertebral column.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The dorsal area between the base of the neck and the sacrum.","type":"DEFINITION","source":"NCI"},{"definition":"The dorsal area between the base of the neck and the sacrum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Back","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Back"},{"name":"Maps_To","value":"Back"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0817745"},{"name":"xRef","value":"UBERON:0001137"}]}}{"C12376":{"preferredName":"Bile Duct","code":"C12376","definitions":[{"definition":"A tube through which bile passes in and out of the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any of the ducts conveying bile between the liver and the intestine, including hepatic, cystic, and common bile duct.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any of the ducts conveying bile between the liver and the intestine, including hepatic, cystic, and common bile duct.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the ducts that form the biliary tree, carrying bile from the liver to the small intestine.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Bile Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bile_Duct"},{"name":"Maps_To","value":"Bile Duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005400"},{"name":"xRef","value":"UBERON:0002394"}]}}{"C12679":{"preferredName":"Blood Vessel","code":"C12679","definitions":[{"definition":"A tube through which the blood circulates in the body.  Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tubular structure through which the blood circulates in the body. Blood vessels constitute a network composed of arteries, arterioles, capillaries, venules, and veins.","type":"DEFINITION","source":"NCI"},{"definition":"A tubular structure through which the blood circulates in the body. Blood vessels constitute a network composed of arteries, arterioles, capillaries, venules, and veins. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A vessel through which blood circulates in the body.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Blood Vessel","termGroup":"PT","termSource":"NCI"},{"termName":"Vessel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Blood_Vessel"},{"name":"Maps_To","value":"Blood Vessel"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0005847"},{"name":"xRef","value":"UBERON:0001981"}]}}{"C12684":{"preferredName":"Bronchiole","code":"C12684","definitions":[{"definition":"A tiny branch of air tubes in the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The conducting airway of the lungs found terminal to the bronchi; these structures contain neither cartilage nor mucous-secreting glands; the epithelium of the bronchioles becomes thinner with each branching.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The smallest subdivisions of the bronchial tree, which are both acartilagenous and aglandular.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The smallest subdivisions of the bronchial tree, which are both acartilagenous and aglandular.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bronchiole","termGroup":"PT","termSource":"NCI"},{"termName":"Bronchioles","termGroup":"SY","termSource":"NCI"},{"termName":"Bronchiolus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Bronchiole"},{"name":"Maps_To","value":"Bronchiole"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0006270"},{"name":"xRef","value":"UBERON:0002186"}]}}{"C32575":{"preferredName":"Eyebrow","code":"C32575","definitions":[{"definition":"The arched strip of hair on the bony ridge above each eye socket.","type":"DEFINITION","source":"NCI"},{"definition":"The arched strip of hairs (supercilia) on the brow ridge (supercilium) above each eye socket.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Eyebrow","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Eyebrow"},{"name":"Maps_To","value":"Brow"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0015420"}]}}{"C89806":{"preferredName":"Buttock","code":"C89806","definitions":[{"definition":"A zone of soft tissue located on the posterior of the lateral side of the pelvic region corresponding to the gluteal muscles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Either of the fleshy mounds in the rear pelvic area of the human body formed by the gluteal muscles.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of the fleshy mounds in the rear pelvic area of the human body formed by the gluteal muscles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buttock","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Buttock"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0006497"},{"name":"xRef","value":"UBERON:0013691"}]}}{"C93027":{"preferredName":"Calf","code":"C93027","definitions":[{"definition":"The posterior aspect of the lower extremity that extends from the knee to the foot.","type":"DEFINITION","source":"NCI"},{"definition":"The posterior aspect of the lower extremity that extends from the knee to the foot. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Calf","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Calf"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0230445"}]}}{"C12685":{"preferredName":"Capillary","code":"C12685","definitions":[{"definition":"A tiny vessel that can be either a blood capillary or a lymphatic capillary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capillary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Capillary"},{"name":"Maps_To","value":"Capillary"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0935624"}]}}{"C25264":{"preferredName":"Carina","code":"C25264","definitions":[{"definition":"A cartilaginous ridge within the trachea that runs anteroposteriorly between the two primary bronchi at the site of the tracheal bifurcation at the lower end of the trachea.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A ridge at the base of the trachea (windpipe) that separates the openings of the right and left main bronchi (the large air passages that lead from the trachea to the lungs)","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A ridge at the bifurcation of the trachea where the primary bronchi meet.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A ridge or ridge-like structure.  In humans it usually refers to the trachea.  The carina of trachea is part of the lowest tracheal cartilage which is placed between the orifices of the two bronchi.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carina","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Carina"},{"name":"Maps_To","value":"Carina"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0225594"},{"name":"xRef","value":"UBERON:0006679"}]}}{"C12687":{"preferredName":"Common Carotid Artery","code":"C12687","definitions":[{"definition":"A major artery that carries blood from the heart to the head. There is a carotid artery on each side of the neck, and each one splits into two branches. The interior branch carries blood to the brain and eyes, and the exterior branch carries blood to the face, tongue, and outside parts of the head.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An artery of the mediastinum and neck; in general it arises as a primary or secondary branch of the aortic arch and branches into the internal and external carotid arteries.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of two arteries that supply oxygenated blood to the head and neck; the left common carotid branches from the aorta and the right common carotid from the innominate (brachiocephalic artery).","type":"DEFINITION","source":"NCI"},{"definition":"The artery of the neck that arises from the aortic arch and terminates in the external and internal carotid arteries whose pulse can be palpated just medial to the sternocleidomastoid muscle.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Common Carotid Artery","termGroup":"PT","termSource":"NCI"},{"termName":"Carotid Artery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Carotid_Artery"},{"name":"Legacy Concept Name","value":"Common_Carotid_Artery"},{"name":"Maps_To","value":"Carotid Artery"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0007272"}]}}{"C12373":{"preferredName":"Cartilage","code":"C12373","definitions":[{"definition":"A tough, flexible tissue that lines joints and gives structure to the nose, ears, larynx, and other parts of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of connective tissue composed of chondrocytes and an extracellular matrix composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cartilage","termGroup":"PT","termSource":"NCI"},{"termName":"Cartilagenous","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cartilage"},{"name":"Maps_To","value":"Cartilage"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0007301"}]}}{"C16403":{"preferredName":"Cell Line","code":"C16403","definitions":[{"definition":"A defined cell population established from serial passage of cells in culture.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]},{"definition":"An established cell culture that has the potential to propagate indefinitely. [Source: <http://www.solvobiotech.com/support/glossary?/Literature/glossary.html>]  EXAMPLE(S): human HeLa cells, mouse fibroblast 3T3 cells  OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"Cells of a single type (human, animal, or plant) that have been adapted to grow continuously in the laboratory and are used in research.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cell Line","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Cell_Line"},{"name":"Maps_To","value":"Cell-Line"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0007600"}]}}{"C69313":{"preferredName":"Cervical Spine","code":"C69313","definitions":[{"definition":"The set of vertebrae immediately caudal to the skull.","type":"DEFINITION","source":"NCI"},{"definition":"The set of vertebrae immediately caudal to the skull.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Cervical Spine","termGroup":"PT","termSource":"NCI"},{"termName":"C Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Cervical_Spine"},{"name":"Maps_To","value":"Cervical Spine"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0728985"}]}}{"C25389":{"preferredName":"Chest","code":"C25389","definitions":[{"definition":"The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction.","type":"DEFINITION","source":"NCI"},{"definition":"The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Chest","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Chest"},{"name":"Maps_To","value":"Chest"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C1527391"}]}}{"C62484":{"preferredName":"Chest Wall","code":"C62484","definitions":[{"definition":"Subdivision of thorax which includes all structures from the skin to the costal pleura. Examples: There is only one chest wall.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The muscles, bones, and joints that make up the area of the body between the neck and the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.","type":"DEFINITION","source":"NCI"},{"definition":"The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Chest Wall","termGroup":"PT","termSource":"NCI"},{"termName":"Thoracic Wall","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Chest_Wall"},{"name":"Maps_To","value":"Chest Wall"},{"name":"Maps_To","value":"Chest wall"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0205076"},{"name":"xRef","value":"UBERON:0016435"}]}}{"C81169":{"preferredName":"Mentum","code":"C81169","definitions":[{"definition":"A subdivision of the face that is the anteriormost part of the lower jaw region.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The part of the face below the lower lip and including the protruding part of the lower jaw.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the face below the lower lip and including the protruding part of the lower jaw.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mentum","termGroup":"PT","termSource":"NCI"},{"termName":"Chin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mentum"},{"name":"Maps_To","value":"Chin"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008114"},{"name":"xRef","value":"UBERON:0008199"}]}}{"C12695":{"preferredName":"Clavicle","code":"C12695","definitions":[{"definition":"One of a pair of bones at the base of the front of the neck. The clavicles connect the breastbone to the shoulder blades.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of a pair of bones linking the scapula and the sternum. The clavicle is part of the pectoral girdle.","type":"DEFINITION","source":"NCI"},{"definition":"The paired bone that is situated between the sternum and the shoulder.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Clavicle","termGroup":"PT","termSource":"NCI"},{"termName":"Collar Bone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Clavicle"},{"name":"Maps_To","value":"Clavicle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0008913"},{"name":"xRef","value":"UBERON:0001105"}]}}{"C164003":{"preferredName":"Colonic Mucosa","code":"C164003","definitions":[{"definition":"Mucosa that is part of a colon. The mucosa of the colon is lined by a simple columnar epithelium with a thin brush border and numerous goblet cells.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The mucosal membranes that line the inner surface of the colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The mucus membrane lining the inner surface of the colon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colonic Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Colon - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227349"},{"name":"xRef","value":"UBERON:0000317"}]}}{"C12698":{"preferredName":"Common Bile Duct","code":"C12698","definitions":[{"definition":"A duct that conveys bile from the convergence of the cystic and hepatic duct to the duodenum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A tube that carries bile from the liver and the gallbladder through the pancreas and into the duodenum (the upper part of the small intestine). It is formed where the ducts from the liver and gallbladder are joined. It is part of the biliary duct system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Bile ducts are passageways that carry bile. Two major bile ducts come together into a \"trunk\"-the common bile duct which empties into the upper part of the small intestine (the part next to the stomach).","type":"DEFINITION","source":"NCI"},{"definition":"The part of the biliary tree formed by the union of the cystic duct and the common hepatic duct.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Common Bile Duct","termGroup":"PT","termSource":"NCI"},{"termName":"Ductus Communis Choledochus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Common_Bile_Duct"},{"name":"Maps_To","value":"Common Duct"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0009437"},{"name":"xRef","value":"UBERON:0001174"}]}}{"C25478":{"preferredName":"Dermal","code":"C25478","definitions":[{"definition":"Of or relating to or located in the dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Of or relating to or located in the dermis. When used in the context of clinical observations, dermal may also include findings related to other components of the skin.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Dermal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dermal"},{"name":"Maps_To","value":"Dermal"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0221928"}]}}{"C12702":{"preferredName":"Diaphragm","code":"C12702","definitions":[{"definition":"A musculotendinous sheet separating the thoracic cavity from the abdominal cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A thin musculomembranous barrier that separates the abdominal and thoracic cavities. Often used for breathing control.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Fibromuscular tissue that separates the thoracic from the abdominal cavity. It increases the volume of the thoracic cavity through contractions, thus facilitating respiration.","type":"DEFINITION","source":"NCI"},{"definition":"The thin muscle below the lungs and heart that separates the chest from the abdomen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diaphragm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Diaphragm"},{"name":"Maps_To","value":"Diaphragm"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0011980"},{"name":"xRef","value":"UBERON:0001103"}]}}{"C12394":{"preferredName":"Ear","code":"C12394","definitions":[{"definition":"A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance.","type":"DEFINITION","source":"NCI"},{"definition":"A sensory organ that contains auditory and vestibular apparatuses.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Ear","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ear"},{"name":"Maps_To","value":"Ear"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013443"},{"name":"xRef","value":"IMDRF:E09"},{"name":"xRef","value":"UBERON:0001690"}]}}{"C3003":{"preferredName":"Effusion","code":"C3003","definitions":[{"definition":"A collection of fluid in a body cavity, which may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A collection of fluid in a body cavity, which may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung).","type":"DEFINITION","source":"NCI"},{"definition":"Abnormal collection of fluid in a body cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An abnormal collection of fluid in hollow spaces or between tissues of the body. For example, a pleural effusion is a collection of fluid between the two layers of membrane covering the lungs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Effusion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Effusion"},{"name":"Maps_To","value":"Effusion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0013687"}]}}{"C32497":{"preferredName":"Elbow Joint","code":"C32497","definitions":[{"definition":"A joint involving the humerus, radius and ulna bones.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of hinge joint located between the forearm and upper arm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elbow Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Elbow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Elbow_Joint"},{"name":"Maps_To","value":"Elbow"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0013770"},{"name":"xRef","value":"UBERON:0001461"}]}}{"C41449":{"preferredName":"Epidural Spinal Canal Space","code":"C41449","definitions":[{"definition":"Having to do with the space between the wall of the spinal canal and the covering of the spinal cord. An epidural injection is given into this space.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Space between the dura mater and the walls of the vertebral canal.","type":"DEFINITION","source":"NCI"},{"definition":"The body space between the dura mater and the walls of the vertebral canal.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The outermost part of the spinal canal. It is the space within the canal (formed by the surrounding vertebrae) lying outside the dura mater.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Epidural Spinal Canal Space","termGroup":"PT","termSource":"NCI"},{"termName":"Epidural Space","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Epidural_Spinal_Canal_Space"},{"name":"Maps_To","value":"Epidural Space"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0014537"},{"name":"xRef","value":"UBERON:0003691"}]}}{"C32668":{"preferredName":"Gastroesophageal Junction","code":"C32668","definitions":[{"definition":"The anatomical location where the esophagus joins to the stomach.","type":"DEFINITION","source":"NCI"},{"definition":"The anatomical location where the esophagus joins to the stomach. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The junction between the esophagus and the stomach epithelium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The place where the esophagus is connected to the stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gastroesophageal Junction","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gastroesophageal_Junction"},{"name":"Maps_To","value":"Esophagogastric Junction"},{"name":"Maps_To","value":"Gastroesophageal Junction"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0014871"},{"name":"xRef","value":"UBERON:0007650"}]}}{"C32538":{"preferredName":"Esophageal Mucosa","code":"C32538","definitions":[{"definition":"A mucosa that is part of a esophagus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lining of the esophagus. It is composed of non-keratinized stratified squamous epithelium, lamina propria, and muscularis mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes that line the inner surface of the esophagus.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Esophageal Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Esophageal_Mucosa"},{"name":"Maps_To","value":"Esophagus - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227176"},{"name":"xRef","value":"UBERON:0002469"}]}}{"C12715":{"preferredName":"Femoral Artery","code":"C12715","definitions":[{"definition":"An artery of the thigh; in general it arises from the external iliac artery distal to the inguinal ligment and continues as the popliteal artery.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An artery that starts within the inguinal region and extends to the lower extremities.","type":"DEFINITION","source":"NCI"},{"definition":"The artery of the groin that supplies the lower extremity, including the anterior and anteromedial surfaces of the thigh, whose pulse is palpable below the inguinal ligament, midway between the anterior superior iliac spine and the symphysis pubis.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"The femoral artery is a large artery in the muscles of the thigh. It is a continuation of external iliac artery where it enters the femoral triangle at the mid inguinal point behind the inguinal ligament. It leaves femoral triangle through apex beneath the sartorius muscle. It enters the popliteal fossa by passing through the 5th osseo-aponeurotic (adductor hiatus) opening of adductor magnus where it becomes the Popliteal Artery.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Femoral Artery","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Femoral_Artery"},{"name":"Maps_To","value":"Femoral Artery"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015801"},{"name":"xRef","value":"UBERON:0002060"}]}}{"C12716":{"preferredName":"Femoral Vein","code":"C12716","definitions":[{"definition":"A vein of the thigh; in general it arises from the popliteal vein and drains into the external iliac vein.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A vein that starts within the inguinal region and extends to the lower extremities.","type":"DEFINITION","source":"NCI"},{"definition":"In the human body, the femoral vein is a blood vessel that accompanies the femoral artery in the femoral sheath. It begins at the adductor canal (also known as Hunter's canal) and is a continuation of the popliteal vein. It ends at the inferior margin of the inguinal ligament, where it becomes the external iliac vein.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Femoral Vein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Femoral_Vein"},{"name":"Maps_To","value":"Femoral Vein"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015809"},{"name":"xRef","value":"UBERON:0001361"}]}}{"C12717":{"preferredName":"Femur","code":"C12717","definitions":[{"definition":"Endochondral long bone connecting the pelvic girdle with posterior zeugopodium skeleton.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bone positioned between the pelvis and the femorotibial joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper leg bone positioned between the pelvis and the knee.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Femur","termGroup":"PT","termSource":"NCI"},{"termName":"Femoral","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Femur"},{"name":"Maps_To","value":"Femur"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0015811"},{"name":"xRef","value":"UBERON:0000981"}]}}{"C12482":{"preferredName":"Fibroblast","code":"C12482","definitions":[{"definition":"A connective tissue cell that makes and secretes collagen proteins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A connective tissue cell that secretes collagen, a component of the extracellular matrix.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Fibroblast","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblasts","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fibroblast"},{"name":"Maps_To","value":"Fibroblasts"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0016030"}]}}{"C12718":{"preferredName":"Fibula","code":"C12718","definitions":[{"definition":"The long bone that is lateral to the tibia.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The major postaxial endochondral bone in the posterior zeugopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The small, lateral calf bone extending from the knee to the ankle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fibula","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Fibula"},{"name":"Maps_To","value":"Fibula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016068"},{"name":"xRef","value":"UBERON:0001446"}]}}{"C32608":{"preferredName":"Finger","code":"C32608","definitions":[{"definition":"A digit that is part of a manus (hand).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Any of the digits of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the digits of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Finger","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Finger"},{"name":"Maps_To","value":"Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0016129"},{"name":"xRef","value":"UBERON:0002389"}]}}{"C25278":{"preferredName":"Fluid","code":"C25278","definitions":[{"definition":"A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that flows smoothly and takes the shape of its container. Liquids and gases are fluids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fluid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fluid"},{"name":"Maps_To","value":"Fluid"},{"name":"Semantic_Type","value":"Substance"},{"name":"UMLS_CUI","value":"C1704353"}]}}{"C32622":{"preferredName":"Foot","code":"C32622","definitions":[{"definition":"Distal portion of the hind limb, including tarsal region, metatarsal region and digits.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The entire structure distal to the ankle joint/tarsus, which includes the metatarsus and digit(s).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The structure found below the ankle joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foot","termGroup":"PT","termSource":"NCI"},{"termName":"Pedal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Foot"},{"name":"Maps_To","value":"Foot"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0016504"},{"name":"xRef","value":"UBERON:0002387"}]}}{"C32628":{"preferredName":"Forearm","code":"C32628","definitions":[{"definition":"The structure on the upper limb, between the elbow and the wrist.","type":"DEFINITION","source":"NCI"},{"definition":"The structure on the upper limb, between the elbow and the wrist. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Forearm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Forearm"},{"name":"Maps_To","value":"Forearm"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0016536"}]}}{"C89803":{"preferredName":"Forehead","code":"C89803","definitions":[{"definition":"In human anatomy, the forehead is the fore part of the head. It is, formally, an area of the head bounded by three features, two of the skull and one of the scalp. The top of the forehead is marked by the hairline, the edge of the area where hair on the scalp grows. The bottom of the forehead is marked by the supraorbital ridge, the bone feature of the skull above the eyes. The two sides of the forehead are marked by the temporal ridge, a bone feature that links the supraorbital ridge to the coronal suture line and beyond.","type":"ALT_DEFINITION","source":"NCI"},{"definition":"The part of the face between the eyebrows and the normal hairline.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the face between the eyebrows and the normal hairline.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Forehead","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Forehead"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0016540"},{"name":"xRef","value":"UBERON:0008200"}]}}{"C33049":{"preferredName":"Male Prepuce","code":"C33049","definitions":[{"definition":"A fold of skin covering the tip of the penis.","type":"DEFINITION","source":"NCI"},{"definition":"A fold of skin covering the tip of the penis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A retractable double-layered fold of skin and mucous membrane that covers the glans penis and protects the urinary meatus when the penis is not erect.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The loose skin that covers the head of the penis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Male Prepuce","termGroup":"PT","termSource":"NCI"},{"termName":"Foreskin","termGroup":"SY","termSource":"NCI"},{"termName":"Preputium Penis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Male_Prepuce"},{"name":"Maps_To","value":"Foreskin"},{"name":"Maps_To","value":"Prepuce"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227952"},{"name":"xRef","value":"UBERON:0001332"}]}}{"C177766":{"preferredName":"Frontal Lobe Cortex","code":"C177766","definitions":[{"definition":"Anterior portion of the neocortex, lying anterior to the central sulcus in humans. It is bounded by the parietal cortex posteriorly and the temporal cortex laterally.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The grey matter, or outermost layer of the frontal lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Frontal Lobe Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Frontal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Frontal Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228196"},{"name":"xRef","value":"UBERON:0001870"}]}}{"C12719":{"preferredName":"Ganglion","code":"C12719","definitions":[{"definition":"A biological tissue mass, most commonly a mass of nerve cell bodies.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS).","type":"DEFINITION","source":"NCI"},{"definition":"A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS). (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"is a macroscopic organ component of one or more nerves, which primarily consists of cell bodies of neurons located outside the central nervous system; together with nerve fibers, it constitutes a nerve or a nerve plexus. Example(s): spinal ganglion, trigeminal ganglion, superior cervical ganglion, celiac ganglion, inferior hypogastric (pelvic) ganglion.","type":"ALT_DEFINITION","source":"UWDA142"}],"synonyms":[{"termName":"Ganglion","termGroup":"PT","termSource":"NCI"},{"termName":"Ganglia","termGroup":"SY","termSource":"NCI"},{"termName":"Ganglionic","termGroup":"AD","termSource":"NCI"},{"termName":"Neural Ganglion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ganglion"},{"name":"Maps_To","value":"Ganglia"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0017067"},{"name":"xRef","value":"UBERON:0000045"}]}}{"C32712":{"preferredName":"Hand","code":"C32712","definitions":[{"definition":"Distal segment of the fore limb, including carpal region, metacarpal region and digits.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits.","type":"DEFINITION","source":"NCI"},{"definition":"The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand"},{"name":"Maps_To","value":"Hand"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0018563"},{"name":"xRef","value":"UBERON:0002398"}]}}{"C12418":{"preferredName":"Head and Neck","code":"C12418","definitions":[{"definition":"For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.","type":"DEFINITION","source":"NCI"},{"definition":"The area of the body comprising the skull, facial bones and the cervical vertebrae, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature, soft tissue and lymph nodes draining these areas.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Head and Neck","termGroup":"PT","termSource":"NCI"},{"termName":"H and N","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Head_and_Neck"},{"name":"Maps_To","value":"Head & Neck"},{"name":"Maps_To","value":"Head and Neck"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0460004"},{"name":"xRef","value":"UBERON:0000033"},{"name":"xRef","value":"UBERON:0000974"}]}}{"C13308":{"preferredName":"Hepatic","code":"C13308","definitions":[{"definition":"Pertaining to, affecting, or associated with the liver.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to the liver.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hepatic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hepatic"},{"name":"Maps_To","value":"Hepatic"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205054"}]}}{"C32730":{"preferredName":"Hepatic Duct","code":"C32730","definitions":[{"definition":"Any of the three ducts associated with the liver including the right hepatic duct, left hepatic duct and common hepatic duct.","type":"DEFINITION","source":"NCI"},{"definition":"Any portion of the ducts that carry bile from the liver to the common bile duct. This may include both intrahepatic components (parts of left and right hepatic ducts) and extrahepatic components (common hepatic duct, plus hilar portion).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Hepatic Duct","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hepatic_Duct"},{"name":"Maps_To","value":"Hepatic Duct"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0917710"},{"name":"xRef","value":"UBERON:0005171"}]}}{"C32736":{"preferredName":"Hepatic Vein","code":"C32736","definitions":[{"definition":"The blood vessels that drain blood from the central veins of the liver into the inferior vena cava.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The blood vessels that drain blood from the central veins of the liver into the inferior vena cava.","type":"DEFINITION","source":"NCI"},{"definition":"Vein that carries blood away from the liver.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Hepatic Vein","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hepatic_Vein"},{"name":"Maps_To","value":"Hepatic Vein"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0019155"},{"name":"xRef","value":"UBERON:0001143"}]}}{"C64193":{"preferredName":"Hip","code":"C64193","definitions":[{"definition":"The hip region is located lateral to the gluteal region (i.e. the buttock), inferior to the iliac crest, and overlying the greater trochanter of the thigh bone. In adults, three of the bones of the pelvis have fused into the hip bone which forms part of the hip region. The hip joint, scientifically referred to as the acetabulofemoral joint (art. coxae), is the joint between the femur and acetabulum of the pelvis and its primary function is to support the weight of the body in both static (e.g. standing) and dynamic (e.g. walking or running) postures.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The lateral prominence of the pelvis from the waist to the thigh.","type":"DEFINITION","source":"NCI"},{"definition":"The lateral prominence of the pelvis from the waist to the thigh. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hip","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hip"},{"name":"Maps_To","value":"Hip"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0019552"},{"name":"xRef","value":"UBERON:0001464"}]}}{"C12444":{"preferredName":"Hippocampus","code":"C12444","definitions":[{"definition":"A curved gray matter structure of the cerebrum that is part of the limbic system.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A curved gray matter structure of the temporal lobe lying on the floor of the lateral ventricle of the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hippocampus","termGroup":"PT","termSource":"NCI"},{"termName":"Hippocampal","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Hippocampus"},{"name":"Maps_To","value":"Hippocampus"},{"name":"NCI_META_CUI","value":"CL554606"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"}]}}{"C12731":{"preferredName":"Humerus","code":"C12731","definitions":[{"definition":"Paired endochondral long bone that extends between the pectoral girdle and the skeletal parts of the forelimb.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bone between the scapulohumeral and humeroulnar joints.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper arm bone between the shoulder and elbow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Humerus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Humerus"},{"name":"Maps_To","value":"Humerus"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020164"},{"name":"xRef","value":"UBERON:0000976"}]}}{"C32765":{"preferredName":"Ilium","code":"C32765","definitions":[{"definition":"Paired endochondral bone that is the dorsal-most of the pelvic bones, offering attachment areas for gluteal muscles on its main surface.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The broad, dorsal, upper, and widest of the three principal bones composing either half of the pelvis.","type":"DEFINITION","source":"NCI"},{"definition":"The broad, dorsal, upper, and widest of the three principal bones composing either half of the pelvis. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ilium","termGroup":"PT","termSource":"NCI"},{"termName":"Iliac","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ilium"},{"name":"Maps_To","value":"Ilium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020889"},{"name":"xRef","value":"UBERON:0001273"}]}}{"C52835":{"preferredName":"Hand Digit 2","code":"C52835","definitions":[{"definition":"2nd digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The second finger from the radial side of the hand, next to the thumb.","type":"DEFINITION","source":"NCI"},{"definition":"The second finger from the radial side of the hand, next to the thumb. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 2","termGroup":"PT","termSource":"NCI"},{"termName":"Index Finger","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_2"},{"name":"Maps_To","value":"Index Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230388"},{"name":"xRef","value":"UBERON:0003622"}]}}{"C32884":{"preferredName":"Ischium","code":"C32884","definitions":[{"definition":"Endochondral bone that is paired, forming the posterior part of the pelvis, articulating with the pubis and ilium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The most posterior and ventral bone making up the pelvis.","type":"DEFINITION","source":"NCI"},{"definition":"The most posterior and ventral bone making up the pelvis. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ischium","termGroup":"PT","termSource":"NCI"},{"termName":"Hip","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ischium"},{"name":"Maps_To","value":"Ischium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022122"},{"name":"xRef","value":"UBERON:0001274"}]}}{"C32885":{"preferredName":"Islet Cell","code":"C32885","definitions":[{"definition":"A pancreatic cell that produces and secretes hormones such as insulin and glucagon.","type":"DEFINITION","source":"NCI"},{"definition":"A pancreatic cell that produces hormones (e.g., insulin and glucagon) that are secreted into the bloodstream. These hormones help control the level of glucose (sugar) in the blood.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Islet Cell","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Islet_Cell"},{"name":"Maps_To","value":"Islet Cells"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C1522529"}]}}{"C48821":{"preferredName":"Jaw Bone","code":"C48821","definitions":[{"definition":"Subdivision of skeleton which includes upper and lower jaw skeletons.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bones of the skull that frame the mouth and serve to open it; the bones that hold the teeth.","type":"DEFINITION","source":"NCI"},{"definition":"The structures of the skull that frame the mouth.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Jaw Bone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Jaw"},{"name":"Maps_To","value":"Jaw"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0022359"},{"name":"xRef","value":"UBERON:0001708"}]}}{"C13044":{"preferredName":"Joint","code":"C13044","definitions":[{"definition":"Anatomical cluster that consists of two or more adjacent skeletal structures, which may be interconnected by various types of tissue.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"In medicine, the place where two or more bones are connected. Examples include the shoulder, elbow, knee, and jaw.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The connection point between two bones or skeletal elements. The joint may be fixed or movable.","type":"DEFINITION","source":"NCI"},{"definition":"The connection point between two bones or skeletal elements. The joint may be fixed or movable. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"is an organ that constitutes an anatomical junction; it consists of two or more adjacent bones, parts of which are interconnected by organ parts that consist of various types of connective tissue. Together with other joints and bones, a joint constitutes the skeletal system. Example(s): pubic symphysis, knee joint, temporomandibular joint.","type":"ALT_DEFINITION","source":"UWDA142"}],"synonyms":[{"termName":"Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Articular","termGroup":"AD","termSource":"NCI"},{"termName":"Articulation","termGroup":"SY","termSource":"NCI"},{"termName":"Joints","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Joint"},{"name":"Maps_To","value":"Joint"},{"name":"Semantic_Type","value":"Body Space or Junction"},{"name":"UMLS_CUI","value":"C0022417"},{"name":"xRef","value":"UBERON:0000982"}]}}{"C32898":{"preferredName":"Knee Joint","code":"C32898","definitions":[{"definition":"A joint connecting the lower part of the femur with the upper part of the tibia. The lower part of the femur and the upper part of the tibia are attached to each other by ligaments. Other structures of the knee joint include the upper part of the fibula, located below and parallel to the tibia, and the patella which moves as the knee bends.","type":"DEFINITION","source":"NCI"},{"definition":"A segment of the hindlimb that corresponds to the joint connecting a hindlimb stylopod and zeugopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The joint connecting the lower part of the femur with the upper part of the tibia.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Knee Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Knee","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Knee_Joint"},{"name":"Maps_To","value":"Knee"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0022745"},{"name":"xRef","value":"UBERON:0001465"}]}}{"C12379":{"preferredName":"Large Intestine","code":"C12379","definitions":[{"definition":"A muscular tube that extends from the end of the small intestine to the anus.","type":"DEFINITION","source":"NCI"},{"definition":"A subdivision of the digestive tract that connects the small intestine to the cloaca or anus. Lacks or has few villi.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The avillous section of the intestine composed of crypts and extending from the terminal small intestine to the external orifice.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The long, tube-like organ that is connected to the small intestine at one end and the anus at the other. The large intestine has four parts: cecum, colon, rectum, and anal canal. Partly digested food moves through the cecum into the colon, where water and some nutrients and electrolytes are removed. The remaining material, solid waste called stool, moves through the colon, is stored in the rectum, and leaves the body through the anal canal and anus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Large Intestine","termGroup":"PT","termSource":"NCI"},{"termName":"Large Bowel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Large_Intestine"},{"name":"Maps_To","value":"Large Bowel"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0021851"},{"name":"xRef","value":"UBERON:0000059"}]}}{"C32974":{"preferredName":"Leg","code":"C32974","definitions":[{"definition":"The portion of the hindlimb that contains both the stylopod and zeugopod.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The portion of the lower extremity between the knee and the ankle.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The portion of the lower extremity between the knee and the ankle. For clinical purposes this term is also used to refer to the whole inferior limb.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leg","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Leg"},{"name":"Maps_To","value":"Leg"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1140621"},{"name":"xRef","value":"UBERON:0000978"}]}}{"C32979":{"preferredName":"Leptomeninges","code":"C32979","definitions":[{"definition":"Having to do with the two innermost meninges (thin layers of tissue that cover and protect the brain and spinal cord).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Pia mater or arachnoid mater.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater.","type":"DEFINITION","source":"NCI"},{"definition":"The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Leptomeninges","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Leptomeninges"},{"name":"Maps_To","value":"Leptomeninges"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0228126"},{"name":"xRef","value":"UBERON:0000391"}]}}{"C13046":{"preferredName":"Ligament","code":"C13046","definitions":[{"definition":"Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint.","type":"DEFINITION","source":"NCI"},{"definition":"Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Dense regular connective tissue connecting two or more adjacent skeletal elements or supporting an organ.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Ligament","termGroup":"PT","termSource":"NCI"},{"termName":"Ligaments","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Ligament"},{"name":"Maps_To","value":"Ligament"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0023685"},{"name":"xRef","value":"UBERON:0000211"}]}}{"C69314":{"preferredName":"Lumbar Spine","code":"C69314","definitions":[{"definition":"The vertebrae located below the thoracic and above the sacral vertebrae.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Those vertebrae between the ribs and the pelvis, L1-L5 in man.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lumbar Spine","termGroup":"PT","termSource":"NCI"},{"termName":"L Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lumbar_Spine"},{"name":"Maps_To","value":"Lumbar Spine"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C3887615"}]}}{"C106042":{"preferredName":"Distant Lymph Node","code":"C106042","definitions":[{"definition":"A lymph node located distant to the anatomic site of interest.","type":"DEFINITION","source":"NCI"},{"definition":"Lymph node(s) that is distant to the anatomic region of interest.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Distant Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Nodes"},{"name":"Maps_To","value":"Lymph Node(s) Distant"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3830456"}]}}{"C32853":{"preferredName":"Internal Mammary Lymph Node","code":"C32853","definitions":[{"definition":"Any of the lymph nodes of the breast located under the ribcage, near the sternum.","type":"DEFINITION","source":"NCI"},{"definition":"Any of the lymph nodes of the breast located under the ribcage, near the sternum.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Lymph node(s) in or adjacent to the mammary gland.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Internal Mammary Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Internal_Mammary_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Internal Mammary"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0444440"},{"name":"xRef","value":"UBERON:0035219"}]}}{"C137678":{"preferredName":"Intramammary Lymph Node","code":"C137678","definitions":[{"definition":"Any of the lymph nodes located within the breast parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramammary Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Intramammary Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node(s) Mammary"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2732830"}]}}{"C89780":{"preferredName":"Scalene Lymph Node","code":"C89780","definitions":[{"definition":"A lymph node located in proximity to any of the scalene muscles.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in proximity to any of the scalene muscles.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Scalene Lymph Node","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymph Node(s) Scalene"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229744"}]}}{"C63705":{"preferredName":"Infraclavicular Lymph Node","code":"C63705","definitions":[{"definition":"A lymph node located in the area below the clavicle.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A lymph node located in the area below the clavicle.","type":"DEFINITION","source":"NCI"},{"definition":"A lymph node located in the area below the clavicle. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Infraclavicular Lymph Node","termGroup":"PT","termSource":"NCI"},{"termName":"Deltopectoral Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Deltopectoral Node","termGroup":"SY","termSource":"NCI"},{"termName":"Infraclavicular Node","termGroup":"SY","termSource":"NCI"},{"termName":"Subclavicular Lymph Node","termGroup":"SY","termSource":"NCI"},{"termName":"Subclavicular Node","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Infraclavicular_Lymph_Node"},{"name":"Maps_To","value":"Lymph Node(s) Subclavicular"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0229743"},{"name":"xRef","value":"UBERON:0035162"}]}}{"C26470":{"preferredName":"Maxilla","code":"C26470","definitions":[{"definition":"The bone which normally forms the lateral upper jaw in osteichthyans, including tetrapods.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The upper jaw bone holding the upper teeth.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The upper jawbone in vertebrates; it is fused to the cranium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maxilla","termGroup":"PT","termSource":"NCI"},{"termName":"Maxillary","termGroup":"AD","termSource":"NCI"},{"termName":"Upper Jaw","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Maxilla"},{"name":"Maps_To","value":"Maxilla"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0024947"},{"name":"xRef","value":"UBERON:0002397"}]}}{"C164004":{"preferredName":"Mediastinal Soft Tissue","code":"C164004","definitions":[{"definition":"Any non-hardened or non-calcified tissue found in the mediastinum.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue of the mediastinum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mediastinal Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mediastinal soft tissue"},{"name":"Maps_To","value":"Mediastinal Soft Tissue"},{"name":"NCI_META_CUI","value":"CL977224"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C33103":{"preferredName":"Mesentery","code":"C33103","definitions":[{"definition":"A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines.","type":"DEFINITION","source":"NCI"},{"definition":"A double layer of peritoneum that attaches to the wall of the abdominal cavity and supports the small intestines.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Anatomical organ component composed of a double layer of serous membrane that suspends a viscus from the body wall or connects adjacent viscera and in doing so conveys blood vessels, lymphatics and nerves to and from the viscera. Examples: greater omentum, broad ligament of uterus, sigmoid mesocolon.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The peritoneal membrane that attaches the intestines to the abdominal wall near the back.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mesentery","termGroup":"PT","termSource":"NCI"},{"termName":"Mesenteric Membrane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mesentery"},{"name":"Maps_To","value":"Mesentery"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0025474"},{"name":"xRef","value":"UBERON:0002095"}]}}{"C33105":{"preferredName":"Mesothelium","code":"C33105","definitions":[{"definition":"A simple layer of cells, derived from the mesoderm that lines the coelom or body cavity of the embryo. In the adult, it covers all true serous membranes (peritoneum, pericardium, pleura).","type":"DEFINITION","source":"NCI"},{"definition":"A simple layer of cells, derived from the mesoderm, that covers the serous membranes including the peritoneum, pericardium, and pleura.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Simple squamous epithelium of mesodermal origin which lines serous membranes. Examples: mesothelium of pleura, mesothelium of peritoneum[FMA]. Wikipedia: The mesothelium is a membrane that forms the lining of several body cavities: the pleura (thoracal cavity), peritoneum (abdominal cavity including the mesentery) and pericardium (heart sac). Mesothelial tissue also surrounds the male internal reproductive organs (the tunica vaginalis testis) and covers the internal reproductive organs of women (the tunica serosa uteri).","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Mesothelium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Mesothelium"},{"name":"Maps_To","value":"Mesothelium"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0086610"},{"name":"xRef","value":"UBERON:0001136"}]}}{"C52836":{"preferredName":"Hand Digit 3","code":"C52836","definitions":[{"definition":"The middle or third finger from the radial side of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"The middle or third finger from the radial side of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 3","termGroup":"PT","termSource":"NCI"},{"termName":"Middle Finger","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hand_Digit_3"},{"name":"Maps_To","value":"Middle Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230393"}]}}{"C13258":{"preferredName":"Mitochondrion","code":"C13258","definitions":[{"definition":"Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Mitochondria contain distinctive ribosomes, transfer RNAs, amino acyl t-RNA synthetases, and elongation and termination factors. Mitochondria depend upon genes within the nucleus for many essential messenger RNAs. Mitochondria consist of two sets of membranes, a smooth continuous outer coat and an inner membrane arranged in tubules or more often in folds that form platelike double membranes (cristae). Mitochondria are the principal energy source of the cell and contains the cytochrome enzymes of terminal electron transport and the enzymes of the citric acid cycle, fatty acid oxidation, and oxidative phosphorylation. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP.","type":"DEFINITION","source":"NCI"},{"definition":"Small structures in a cell that are found in the cytoplasm (fluid that surrounds the cell nucleus). Mitochondria make most of the energy for the cell and have their own genetic material that is different from the genetic material found in the nucleus. Many diseases are caused by mutations (changes) in the DNA of mitochondria. Mitochondria are cell organelles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mitochondrion","termGroup":"PT","termSource":"NCI"},{"termName":"Mitochondria","termGroup":"SY","termSource":"NCI"},{"termName":"Mitochondrial","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mitochondrion"},{"name":"Maps_To","value":"Mitochondria"},{"name":"Semantic_Type","value":"Cell Component"},{"name":"UMLS_CUI","value":"C0026237"}]}}{"C13056":{"preferredName":"Muscle","code":"C13056","definitions":[{"definition":"A fibrous soft tissue with the ability to contract to produce force and motion.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One of the contractile organs of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Muscle","termGroup":"PT","termSource":"NCI"},{"termName":"Muscular","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Muscle"},{"name":"Maps_To","value":"Muscle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0026845"}]}}{"C33156":{"preferredName":"Nail","code":"C33156","definitions":[{"definition":"A horn-like keratin structure covering the dorsal aspect of the terminal phalanges of fingers and toes.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The cutaneous plate on the dorsal surface of the distal end of a finger or toe.","type":"DEFINITION","source":"NCI"},{"definition":"The cutaneous plate on the dorsal surface of the distal end of a finger or toe. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nail","termGroup":"PT","termSource":"NCI"},{"termName":"Nail Apparatus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Nail"},{"name":"Maps_To","value":"Nails"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0027342"},{"name":"xRef","value":"UBERON:0001705"}]}}{"C164006":{"preferredName":"Nasal Soft Tissue","code":"C164006","definitions":[{"definition":"Any non-hardened or non-calcified tissue found in the nose.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue of the nose.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nasal Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nasal Soft Tissue"},{"name":"Maps_To","value":"Nasal soft tissue"},{"name":"NCI_META_CUI","value":"CL977222"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C12466":{"preferredName":"Nerve","code":"C12466","definitions":[{"definition":"A bundle of fibers that receives and sends messages between the body and the brain. The messages are sent by chemical and electrical changes in the cells that make up the nerves.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A bundle of neuronal fibers that transmits electrochemical impulses encoding sensory and motor information from one body part to another.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Part of the peripheral nervous system composed of bundles of nerve fibers running to various organs and tissues of the body using chemical and electrical signals to transmit sensory and motor information from one body part to another.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nerve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nerve"},{"name":"Maps_To","value":"Nerve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0027740"}]}}{"C177767":{"preferredName":"Occipital Lobe Cortex","code":"C177767","definitions":[{"definition":"The grey matter, or outermost layer of the occipital lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occipital Lobe Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Occipital Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Occipital Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228221"},{"name":"xRef","value":"UBERON:0016540"}]}}{"C77637":{"preferredName":"Oral Mucosa","code":"C77637","definitions":[{"definition":"A mucous membrane that lines the mouth.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Moist tissue lining the oral cavity, containing mucous secreting glands.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes that line the oral cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Oral Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Oral_Mucosa"},{"name":"Maps_To","value":"Oral Cavity - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0026639"},{"name":"xRef","value":"UBERON:0003729"}]}}{"C97925":{"preferredName":"Para-Spinal Ganglion","code":"C97925","definitions":[{"definition":"A cluster of neuronal cell bodies and their dendrites located just ventral and lateral to the spinal cord that give rise to the sympathetic nervous system.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A sympathetic ganglion located adjacent to the spinal column.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Para-Spinal Ganglion","termGroup":"PT","termSource":"NCI"},{"termName":"Bilaterally Symmetric Sympathetic Chain Ganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Paraspinal Ganglion","termGroup":"SY","termSource":"NCI"},{"termName":"Paravertebral Ganglion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paraspinal Ganglion"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228973"}]}}{"C33282":{"preferredName":"Patella","code":"C33282","definitions":[{"definition":"A large sesamoid bone found in the distal femur/proximal tibial region of the hindlimb of tetrapods. The patella is the attachment site for proximal hindlimb tendons.","type":"ALT_DEFINITION","source":"NCI"},{"definition":"A small bone in front of the femorotibial joint that articulates with the femur.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A small flat triangular bone in front of the knee that articulates with the femur and protects the knee joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patella","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Patella"},{"name":"Maps_To","value":"Patella"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0030647"},{"name":"xRef","value":"UBERON:0002446"}]}}{"C13005":{"preferredName":"Pericardium","code":"C13005","definitions":[{"definition":"A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.","type":"DEFINITION","source":"NCI"},{"definition":"The combination of pericardial sac (a double-walled sac containing the heart and the roots of the great vessels) plus fibrous pericardium.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The membrane surrounding the heart and roots of the vessels at the base of the heart.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pericardium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Pericardium"},{"name":"Maps_To","value":"Pericardium"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0031050"},{"name":"xRef","value":"UBERON:0002407"}]}}{"C164007":{"preferredName":"Periorbital Soft Tissue","code":"C164007","definitions":[{"definition":"Any non-hardened or non-calcified tissue found in the periorbital area.","type":"DEFINITION","source":"NCI"},{"definition":"The soft tissue of the peri-orbital region.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Periorbital Soft Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peri-orbital soft tissue"},{"name":"Maps_To","value":"Periorbital Soft Tissue"},{"name":"NCI_META_CUI","value":"CL977221"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C103222":{"preferredName":"Popliteal Fossa","code":"C103222","definitions":[{"definition":"A depression on the ventral side of the femur, at the knee joint, between the condyles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A diamond-shaped depression located in the back of the knee joint bounded by the medial and lateral heads of the gastrocnemius muscle, the semimembranosus muscle, and the biceps femoris.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A diamond-shaped depression located in the back of the knee joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Popliteal Fossa","termGroup":"PT","termSource":"NCI"},{"termName":"Popliteal Fossa Structure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Popliteal Fossa"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230436"},{"name":"xRef","value":"UBERON:0013069"}]}}{"C54155":{"preferredName":"Retro-Orbital Region","code":"C54155","definitions":[{"definition":"The area behind the orbit of the eye.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The area of the body behind the orbit of the eye.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retro-Orbital Region","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retro-Orbital_Region"},{"name":"Maps_To","value":"Retro-Orbital Region"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0230065"}]}}{"C12782":{"preferredName":"Rib","code":"C12782","definitions":[{"definition":"An intersegmental rod-shaped bone that forms in the peritoneal membrane and attach to the vertebral parapophyses.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs.","type":"DEFINITION","source":"NCI"},{"definition":"Any one of the paired bones, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Rib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Rib"},{"name":"Maps_To","value":"Rib"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0035561"},{"name":"xRef","value":"UBERON:0002228"}]}}{"C52837":{"preferredName":"Hand Digit 4","code":"C52837","definitions":[{"definition":"4th digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fourth finger from the radial side of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"The fourth finger from the radial side of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 4","termGroup":"PT","termSource":"NCI"},{"termName":"Ring Finger","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_4"},{"name":"Maps_To","value":"Ring Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230398"},{"name":"xRef","value":"UBERON:0003624"}]}}{"C33508":{"preferredName":"Sacrum","code":"C33508","definitions":[{"definition":"A collection of sacral vertebrae in the sacral region that are fused and part of the bony pelvis.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The large, triangle-shaped bone in the lower spine that forms part of the pelvis. It is made of 5 fused bones of the spine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx.","type":"DEFINITION","source":"NCI"},{"definition":"The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sacrum","termGroup":"PT","termSource":"NCI"},{"termName":"Sacral","termGroup":"AD","termSource":"NCI"},{"termName":"Sacral Region","termGroup":"SY","termSource":"NCI"},{"termName":"Sacral Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sacrum"},{"name":"Maps_To","value":"Sacrum"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C3669209"},{"name":"xRef","value":"UBERON:0005473"}]}}{"C12426":{"preferredName":"Salivary Gland","code":"C12426","definitions":[{"definition":"A gland in the mouth that produces saliva.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity.","type":"DEFINITION","source":"NCI"},{"definition":"Any number of exocrine glands that secrete saliva into the oral cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Salivary Gland","termGroup":"PT","termSource":"NCI"},{"termName":"Head and Neck, Salivary Glands","termGroup":"SY","termSource":"NCI"},{"termName":"Salivary Glands","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"ICDO3: excludes minor salivary gland, NOS C06.9"},{"name":"Legacy Concept Name","value":"Salivary_Gland"},{"name":"Maps_To","value":"Salivary gland"},{"name":"Maps_To","value":"Salivary Gland"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036098"}]}}{"C12783":{"preferredName":"Scapula","code":"C12783","definitions":[{"definition":"A bone that articulates with the humerus and is part of the scapulohumeral joint.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Endochondral bone that is dorsoventrally compressed and provides attachment site for muscles of the pectoral appendage.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of a pair of triangular bones at the back of the shoulder. The scapula connects the collarbone with the upper arm bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The flat triangle-shaped bone that connects the humerus with the clavicle in the back of the shoulder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scapula","termGroup":"PT","termSource":"NCI"},{"termName":"Shoulder Blade","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Scapula"},{"name":"Maps_To","value":"Scapula"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036277"},{"name":"xRef","value":"UBERON:0006849"}]}}{"C52810":{"preferredName":"Sciatic Nerve","code":"C52810","definitions":[{"definition":"A large nerve that supplies nearly the whole of the skin of the leg, the muscles of the back of the thigh, and those of the leg and foot. It begins in the lower back and runs through the buttock and down the lower limb.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"A nerve arising from the merge of the lumbar and sacral rami in the pelvis and dividing into the common peroneal and tibial nerves, and which innervates the muscles of the thigh.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The long nerve that is formed by the merging of the ventral rami of the L4, L5, and S1 in the pelvis and passes down the lower limb where it divides into the common peroneal and tibial nerves.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sciatic Nerve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sciatic_Nerve"},{"name":"Maps_To","value":"Sciatic Nerve"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0036394"},{"name":"xRef","value":"UBERON:0001322"}]}}{"C12787":{"preferredName":"Seminal Vesicle","code":"C12787","definitions":[{"definition":"A gland that helps produce semen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mammalian male reproductive accessory gland located adjacent to the urinary bladder and proximal to the prostate.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Either of a pair of glandular pouches that lie one on either side of the male reproductive tract posterolateral to the urinary bladder and in the human male secrete a sugar- and protein-containing fluid into the ejaculatory duct.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus deferens to form the ejaculatory duct.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seminal Vesicle","termGroup":"PT","termSource":"NCI"},{"termName":"Seminal Sacs","termGroup":"SY","termSource":"NCI"},{"termName":"Seminal Vesicles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Seminal_Vesicle"},{"name":"Maps_To","value":"Seminal Vesicle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0036628"},{"name":"xRef","value":"UBERON:0000998"}]}}{"C25203":{"preferredName":"Shoulder","code":"C25203","definitions":[{"definition":"A subdivision of the pectoral complex consisting of the structures in the region of the shoulder joint (which connects the humerus, scapula and clavicle).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The region of the body between the neck and the upper arm.","type":"DEFINITION","source":"NCI"},{"definition":"The region of the body between the neck and the upper arm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Shoulder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Shoulder"},{"name":"Maps_To","value":"Shoulder"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0037004"},{"name":"xRef","value":"UBERON:0001467"}]}}{"C33556":{"preferredName":"Sinus","code":"C33556","definitions":[{"definition":"A cavity, space, or channel in the body. Examples include hollow spaces in the bones at the front of the skull, and channels for blood and lymph. Sinuses may also be found in the heart, brain, and other organs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recess, cavity, or channel.","type":"DEFINITION","source":"NCI"},{"definition":"A recess, cavity, or channel. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sinus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sinus"},{"name":"Maps_To","value":"Sinus"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1305231"}]}}{"C13050":{"preferredName":"Skeletal Muscle Tissue","code":"C13050","definitions":[{"definition":"Muscle tissue that consists primarily of skeletal muscle fibers.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Striated muscles that are under voluntary control of the organism.  They are connected at either or both ends to a bone and are utilized for locomotion and other movements.","type":"DEFINITION","source":"NCI"},{"definition":"Voluntary, striated muscle tissue predominantly associated with the skeleton.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Skeletal Muscle Tissue","termGroup":"PT","termSource":"NCI"},{"termName":"Skeletal Muscle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Skeletal_Muscle_Tissue"},{"name":"Maps_To","value":"Skeletal Muscle"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0242692"},{"name":"xRef","value":"UBERON:0001134"}]}}{"C12789":{"preferredName":"Skull","code":"C12789","definitions":[{"definition":"Anatomical structure that is part of the head consisting entirely of cranium and mandible.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The bones that form the head, made up of the bones of the braincase and face.","type":"DEFINITION","source":"NCI"},{"definition":"The bones that form the head, made up of the bones of the braincase and face. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Skull","termGroup":"PT","termSource":"NCI"},{"termName":"Cranium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Skull"},{"name":"Maps_To","value":"Skull"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0037303"},{"name":"xRef","value":"UBERON:0003128"}]}}{"C33568":{"preferredName":"Small Intestinal Mucosa","code":"C33568","definitions":[{"definition":"A mucosa that is part of a small intestine.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Mucosa arranged into two fundamental structures - villi and crypts of Lieberkuhn. Villi are projections into the lumen of the small intestine, covered with simple columnar epithelium. Crypts of Lieberkuhn are moat-like invaginations of the epithelium around the villi that extend through the lamina propria down to the muscularis mucosae. Lymphocytes often invade the epithelium or form solitary lymphoid nodules in the lamina propria. Lymph nodules may form longitudinal aggregations of 30-50 nodules in the lamina propria of the ileum. These large aggregations are called Peyer's patches. The muscularis mucosae has two layers and extends into the intestinal villi, where the smooth muscle cells form a longitudinal bundle in the centre of the villi. The small intestinal mucosa secretes gastrin, somatostatin, cholecystokinin and secretin.","type":"DEFINITION","source":"NCI"},{"definition":"The mucosal membranes that line the inner surface of the small intestine.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Small Intestinal Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Small_Intestinal_Mucosa"},{"name":"Maps_To","value":"Small Bowel - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0227261"},{"name":"xRef","value":"UBERON:0001204"}]}}{"C52838":{"preferredName":"Hand Digit 5","code":"C52838","definitions":[{"definition":"5th digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The fifth and smallest finger from the radial side of the hand.","type":"DEFINITION","source":"NCI"},{"definition":"The fifth and smallest finger from the radial side of the hand. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 5","termGroup":"PT","termSource":"NCI"},{"termName":"Little Finger","termGroup":"SY","termSource":"NCI"},{"termName":"Pinkie","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_5"},{"name":"Maps_To","value":"Small Finger"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230403"},{"name":"xRef","value":"UBERON:0003625"}]}}{"C12793":{"preferredName":"Sternum","code":"C12793","definitions":[{"definition":"A midventral endochondral skeletal element which represents the origin site of the pectoral muscles.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The long flat bone that forms the center front of the chest wall. The sternum is attached to the collarbone and the first seven ribs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The long, flat bone connecting with the cartilages of the first seven ribs and the clavicle.","type":"DEFINITION","source":"NCI"},{"definition":"The long, flat bone or sternebrae connecting with the cartilage of some ribs.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sternum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Sternum"},{"name":"Maps_To","value":"Sternum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0038293"},{"name":"xRef","value":"UBERON:0000975"}]}}{"C32656":{"preferredName":"Gastric Mucosa","code":"C32656","definitions":[{"definition":"The mucosal layer that lines the stomach.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The mucosal membranes that line the inner surface of the stomach.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The mucus membrane lining the inner surface of the stomach.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastric Mucosa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Gastric_Mucosa"},{"name":"Maps_To","value":"Stomach - Mucosa Only"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0017136"},{"name":"xRef","value":"UBERON:0001199"}]}}{"C33645":{"preferredName":"Subcutis","code":"C33645","definitions":[{"definition":"Adipose and connective tissue located deep to the dermis.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subcutis","termGroup":"PT","termSource":"NCI"},{"termName":"Subcutaneous Adipose Tissue","termGroup":"SY","termSource":"NCI"},{"termName":"Subcutaneous Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Subcutis"},{"name":"Maps_To","value":"Subcutaneous Tissue"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0278403"}]}}{"C12473":{"preferredName":"Synovial Membrane","code":"C12473","definitions":[{"definition":"A layer of connective tissue that lines the cavities of joints, tendon sheaths, and bursae (fluid-filled sacs between tendons and bones). The synovial membrane makes synovial fluid, which has a lubricating function.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Soft tissue that lines the non-cartilaginous surfaces within joints with cavities (synovial joints).","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The connective tissue and synoviocytes that line the inner surface of the joint capsule.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The inner layer of the connective tissue that seals the joint.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synovial Membrane","termGroup":"PT","termSource":"NCI"},{"termName":"Synovium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Synovial_Membrane"},{"name":"Maps_To","value":"Synovium"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0039099"},{"name":"xRef","value":"UBERON:0002018"}]}}{"C177768":{"preferredName":"Temporal Lobe Cortex","code":"C177768","definitions":[{"definition":"Gray matter of the temporal region of the neocortex, located in the temporal lobe in gyrencephalic animals.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The grey matter, or outermost layer of the temporal lobe.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temporal Lobe Cortex","termGroup":"PT","termSource":"NCI"},{"termName":"Temporal Cortex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Maps_To","value":"Temporal Cortex"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0228235"},{"name":"xRef","value":"UBERON:0016538"}]}}{"C13045":{"preferredName":"Tendon","code":"C13045","definitions":[{"definition":"A band of fibrous connective tissue that joins bone to muscle.","type":"DEFINITION","source":"NCI"},{"definition":"A band of fibrous connective tissue that joins bone to muscle. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Dense regular connective tissue that connects muscle to bone.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Tough, fibrous, cord-like tissue that connects muscle to bone or another structure, such as an eyeball. Tendons help the bone or structure to move.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tendon","termGroup":"PT","termSource":"NCI"},{"termName":"Tendons","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tendon"},{"name":"Maps_To","value":"Tendon"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0039508"},{"name":"xRef","value":"UBERON:0000043"}]}}{"C33763":{"preferredName":"Thigh","code":"C33763","definitions":[{"definition":"A part of the lower limb, located between hip and knee.","type":"DEFINITION","source":"NCI"},{"definition":"A part of the lower limb, located between hip and knee. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The part of the hindlimb between pelvis and the knee, corresponding to the femur.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Thigh","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thigh"},{"name":"Maps_To","value":"Thigh"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0039866"},{"name":"xRef","value":"UBERON:0000376"}]}}{"C69315":{"preferredName":"Thoracic Spine","code":"C69315","definitions":[{"definition":"That part of the spine comprising the thoracic vertebrae.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The vertebrae of the thoracic spine, numbered one through twelve in humans.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The vertebrae of the thoracic spine, numbered one through twelve in man.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thoracic Spine","termGroup":"PT","termSource":"NCI"},{"termName":"T Spine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Thoracic_Spine"},{"name":"Maps_To","value":"Thoracic Spine"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0581269"},{"name":"xRef","value":"UBERON:0006073"}]}}{"C54272":{"preferredName":"Throat","code":"C54272","definitions":[{"definition":"In anatomy, the throat is the anterior part of the neck, in front of the vertebral column. It consists of the pharynx and larynx. An important feature of the throat is the epiglottis, a flap which separates the esophagus from the trachea and prevents inhalation of food or drink. The throat contains various blood vessels, various pharyngeal muscles, the trachea (windpipe) and the esophagus. The hyoid bone and the clavicle are the only bones located in the throat of mammals. It is sometimes considered a synonym for fauces.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The hollow tube inside the neck that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach). The throat is about 5 inches long, depending on body size.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The narrow passage from the mouth to the cavity at the back of the mouth.","type":"DEFINITION","source":"NCI"},{"definition":"The narrow passage from the mouth to the cavity at the back of the mouth. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Throat","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Throat"},{"name":"Maps_To","value":"Throat"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230069"},{"name":"xRef","value":"UBERON:0000341"}]}}{"C52834":{"preferredName":"Hand Digit 1","code":"C52834","definitions":[{"definition":"1st (preaxial) digit of the manus.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The thick and short hand digit which is next to the index finger in humans.","type":"DEFINITION","source":"NCI"},{"definition":"The thick and short hand digit which is next to the index finger in humans. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Hand Digit 1","termGroup":"PT","termSource":"NCI"},{"termName":"Thumb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Hand_Digit_1"},{"name":"Maps_To","value":"Thumb"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0040067"},{"name":"xRef","value":"UBERON:0001463"}]}}{"C12800":{"preferredName":"Tibia","code":"C12800","definitions":[{"definition":"A bone located between the femur and the tarsus, being part of the lower leg.","type":"DEFINITION","source":"NCI"},{"definition":"The larger of two bones between the knee and ankle.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The long bone that is medial to the fibula.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The major preaxial endochondral bone in the posterior zeugopod.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Tibia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Tibia"},{"name":"Maps_To","value":"Tibia"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0040184"},{"name":"xRef","value":"UBERON:0000979"}]}}{"C12961":{"preferredName":"Trachea and Bronchus","code":"C12961","definitions":[{"definition":"Trachea -The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi. Bronchi-The larger air passages of the lungs arising from the terminal bifurcation of the trachea.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trachea and Bronchus","termGroup":"PT","termSource":"NCI"},{"termName":"Respiratory System, Trachea, Bronchus","termGroup":"SY","termSource":"NCI"},{"termName":"Trachea, Bronchus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trachea_and_Bronchus"},{"name":"Maps_To","value":"Trachea / Major Bronchi"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0302191"}]}}{"C33816":{"preferredName":"Trunk","code":"C33816","definitions":[{"definition":"Organism subdivision which is the part of the body posterior to the cervical region (or head, when cervical region not present) and anterior to the caudal region. Includes the sacrum when present.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"The body excluding the head and neck and limbs.","type":"DEFINITION","source":"NCI"},{"definition":"The body excluding the head, neck and appendages.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Trunk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Trunk"},{"name":"Maps_To","value":"Trunk"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0460005"},{"name":"xRef","value":"UBERON:0002100"}]}}{"C34320":{"preferredName":"Umbilical Cord","code":"C34320","definitions":[{"definition":"Extraembryonic structure that connects the fetus to the placenta.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Extraembryonic structure that connects the fetus to the placenta. It contains two arteries and one vein.","type":"DEFINITION","source":"NCI"},{"definition":"The connecting cord from the developing embryo to the placenta.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Umbilical Cord","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Umbilical_Cord"},{"name":"Maps_To","value":"Umbilical Cord"},{"name":"Semantic_Type","value":"Embryonic Structure"},{"name":"UMLS_CUI","value":"C0041633"},{"name":"xRef","value":"UBERON:0002331"}]}}{"C191741":{"preferredName":"Urinary Tract","code":"C191741","definitions":[{"definition":"The parts of the urinary system that discharge urine. These include the renal pelvis, ureter, bladder, and urethra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urinary Tract","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Urinary system, NOS"},{"name":"Maps_To","value":"Urinary Tract"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042027"}]}}{"C12813":{"preferredName":"Vas Deferens","code":"C12813","definitions":[{"definition":"A coiled tube that carries the sperm out of the testes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A duct carrying spermatozoa from the epididymides to the urethra.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A secretory duct that transports sperm from the testis. In mammals this is a continuation of the epididymis and ends in the prostatic urethra where it terminates to form ejaculatory duct.","type":"ALT_DEFINITION","source":"UBERON"},{"definition":"Duct carrying spermatozoa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vas Deferens","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vas_Deferens"},{"name":"Maps_To","value":"Vas Deferens"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042360"},{"name":"xRef","value":"UBERON:0001000"}]}}{"C12814":{"preferredName":"Vein","code":"C12814","definitions":[{"definition":"A blood vessel that carries blood to the heart from tissues and organs in the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A blood vessel that carries blood toward the heart.","type":"DEFINITION","source":"NCI"},{"definition":"A blood vessel that carries blood towards the heart.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any of the tubular branching vessels that carry blood from the capillaries toward the heart.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Vein","termGroup":"PT","termSource":"NCI"},{"termName":"Venous","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Vein"},{"name":"Maps_To","value":"Vein"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042449"},{"name":"xRef","value":"UBERON:0001638"}]}}{"C25291":{"preferredName":"Venous","code":"C25291","definitions":[{"definition":"Of, or pertaining to, or contained in, or performing the function of the veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Venous"},{"name":"Maps_To","value":"Venous"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0348013"}]}}{"C12933":{"preferredName":"Vertebra","code":"C12933","definitions":[{"definition":"Any of thirty-three ring-shaped structures that form the vertebral column which surrounds and protects the spinal cord. Each vertebra consists of a bony body with its superior and inferior articular surfaces covered by hyaline cartilage. The body includes the centrum anteriorly and vertebral arch posteriorly. The articular surfaces of the vertebrae are connected by a fibrocartilaginous intervertebral disc.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vertebra","termGroup":"PT","termSource":"NCI"},{"termName":"Vertebrae","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vertebra"},{"name":"Maps_To","value":"Vertebra"},{"name":"Maps_To","value":"Vertebrae"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0549207"}]}}{"C12529":{"preferredName":"Leukocyte","code":"C12529","definitions":[{"definition":"A type of immune cell. Most leukocytes are made in the bone marrow and are found in the blood and lymph tissue. Leukocytes help the body fight infections and other diseases. Granulocytes, monocytes, and lymphocytes are leukocytes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Blood cells that are devoid of hemoglobin, capable of ameboid motion and phagocytosis, and act as the principal components of the immune system.","type":"DEFINITION","source":"NCI"},{"definition":"Blood cells that are devoid of hemoglobin, capable of amoeboid motion and phagocytosis, and act as the principal components of the immune system.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Leukocyte","termGroup":"PT","termSource":"NCI"},{"termName":"Leukocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Reticuloendothelial System, Leukocytes","termGroup":"SY","termSource":"NCI"},{"termName":"WBCs","termGroup":"SY","termSource":"NCI"},{"termName":"White Blood Cell","termGroup":"SY","termSource":"NCI"},{"termName":"White Blood Cells","termGroup":"SY","termSource":"NCI"},{"termName":"White Blood Corpuscle","termGroup":"AQS","termSource":"NCI"},{"termName":"White Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Leukocyte"},{"name":"Maps_To","value":"White Blood Cells"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0023516"}]}}{"C33894":{"preferredName":"Wrist Joint","code":"C33894","definitions":[{"definition":"A joint between the distal end of the radius and the proximal row of carpal bones.","type":"DEFINITION","source":"NCI"},{"definition":"A joint between the distal end of the radius and the proximal row of carpal bones. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A joint connecting the forelimb zeugopod skeleton with the carpal skeleton.","type":"ALT_DEFINITION","source":"UBERON"}],"synonyms":[{"termName":"Wrist Joint","termGroup":"PT","termSource":"NCI"},{"termName":"Carpal","termGroup":"AD","termSource":"NCI"},{"termName":"Radiocarpal Joint","termGroup":"SY","termSource":"NCI"},{"termName":"Wrist","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UBERON"},{"name":"Legacy Concept Name","value":"Wrist_Joint"},{"name":"Maps_To","value":"Wrist"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1322271"},{"name":"xRef","value":"UBERON:0001491"}]}}{"C172257":{"preferredName":"Conditionally Reprogrammed Cells","code":"C172257","definitions":[{"definition":"A cellular sample derived from epithelial cells isolated from a tissue sample that were rapidly expanded in a monolayer culture in the presence of irradiated mouse cells and a Rho kinase (ROCK) inhibitor. Under these conditions the cells are reprogrammed to be more stem-like but the reprogramming is conditional. When the cells are transferred to cultures that mimic in vivo environments they become differentiated and can form structures that resemble the tissue from which they were derived.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conditionally Reprogrammed Cells","termGroup":"PT","termSource":"NCI"},{"termName":"2D Classical Conditionally Reprogrammed Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Classical Conditionally Reprogrammed Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Classical CRC","termGroup":"SY","termSource":"NCI"},{"termName":"CRC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2D Classical Conditionally Reprogrammed Cells"},{"name":"NCI_META_CUI","value":"CL1406128"},{"name":"PubMedID_Primary_Reference","value":"23169653"},{"name":"Semantic_Type","value":"Cell"}]}}{"C172258":{"preferredName":"Modified Conditionally Reprogrammed Cells","code":"C172258","definitions":[{"definition":"A conditionally reprogrammed cell sample comprised of non-epithelial cells isolated from a tissue sample that were rapidly expanded in monolayer culture under various cell type-specific culture conditions to promote the rapid proliferation of the cell type of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Conditionally Reprogrammed Cells","termGroup":"PT","termSource":"NCI"},{"termName":"2D Modified Conditionally Reprogrammed Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Modified CRC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2D Modified Conditionally Reprogrammed Cells"},{"name":"NCI_META_CUI","value":"CL1406127"},{"name":"PubMedID_Primary_Reference","value":"26907527"},{"name":"Semantic_Type","value":"Cell"}]}}{"C172260":{"preferredName":"Air-Liquid Interface Organoid","code":"C172260","definitions":[{"definition":"An organoid grown in vitro where a portion of the cultured cells or tissue is in contact with the medium and another portion is exposed to air. This technique promotes the growth of three dimensional mass resembling a layered tissue or organ, such as the pseudostratified columnar epithelium normally found in the lung and other organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Air-Liquid Interface Organoid","termGroup":"PT","termSource":"NCI"},{"termName":"3D Air-Liquid Interface Organoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3D Air-Liquid Interface Organoid"},{"name":"NCI_META_CUI","value":"CL1406126"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172261":{"preferredName":"Neurosphere","code":"C172261","definitions":[{"definition":"A spherical organoid comprised of neural progenitor cells grown in suspension culture in the presence of a combination of growth factors that promote the proliferation neural stem cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurosphere","termGroup":"PT","termSource":"NCI"},{"termName":"3D Neurosphere","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3D Neurosphere"},{"name":"NCI_META_CUI","value":"CL1406125"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172259":{"preferredName":"Organoid","code":"C172259","definitions":[{"definition":"A three dimensional mass comprised of a cultured cell or tissue sample that resembles an in vivo tissue or organ. Organoids are grown in vitro from a combination of cells or tissue fragments cultured in medium containing a variety of biochemical factors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Organoid","termGroup":"PT","termSource":"NCI"},{"termName":"3D Organoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3D Organoid"},{"name":"PubMedID_Primary_Reference","value":"26907527"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0029250"}]}}{"C20216":{"preferredName":"Adherent Culture","code":"C20216","definitions":[{"definition":"A type of culture in which cells grow as a monolayer that is attached to the culture substrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adherent Culture","termGroup":"PT","termSource":"NCI"},{"termName":"Monolayer culture","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adherent_Culture"},{"name":"Maps_To","value":"Adherent Cell Line"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1510803"}]}}{"C164009":{"preferredName":"Bone Marrow Sample","code":"C164009","definitions":[{"definition":"A biological sample containing components collected from bone marrow of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Marrow Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Bone Marrow Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Bone Marrow Components NOS"},{"name":"Maps_To","value":"Bone Marrow NOS"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0438737"},{"name":"xRef","value":"UBERON:0002371"}]}}{"C172264":{"preferredName":"Buccal Cell Sample","code":"C172264","definitions":[{"definition":"A sample comprised of cells collected from the inside of a subject's cheek.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buccal Cell Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buccal Cells"},{"name":"NCI_META_CUI","value":"CL365909"},{"name":"Semantic_Type","value":"Cell"}]}}{"C12508":{"preferredName":"Cell","code":"C12508","definitions":[{"definition":"The individual unit that makes up all of the tissues of the body. All living things are made up of one or more cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell","termGroup":"PT","termSource":"NCI"},{"termName":"Cell Type","termGroup":"SY","termSource":"NCI"},{"termName":"Cell Types","termGroup":"DN","termSource":"NCI"},{"termName":"Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Cellular","termGroup":"AD","termSource":"NCI"},{"termName":"Normal Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Cell"},{"name":"Maps_To","value":"Cell"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C3282337"}]}}{"C156445":{"preferredName":"Derived Cell Line","code":"C156445","definitions":[{"definition":"A biospecimen generated by in vitro culturing of a single cell isolated from a tissue of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Derived Cell Line","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Derived Cell Line"},{"name":"Maps_To","value":"Derived Cell Lines and Sorted Cells"},{"name":"NCI_META_CUI","value":"CL563176"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164010":{"preferredName":"Bone Marrow-Derived Fibroblasts","code":"C164010","definitions":[{"definition":"A biological sample containing fibroblasts isolated from the bone marrow of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Marrow-Derived Fibroblasts","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fibroblasts from Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977219"},{"name":"Semantic_Type","value":"Cell"}]}}{"C19315":{"preferredName":"Primary Cell Culture","code":"C19315","definitions":[{"definition":"The cells taken from a tissue source, and their progeny, grown in culture before subdivision and transfer to a sub culture.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Primary Cell Culture","termGroup":"PT","termSource":"NCI"},{"termName":"Culturing, in vitro Vertebrate, Primary","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Cell_Culture"},{"name":"Maps_To","value":"Human Original Cells"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1449562"}]}}{"C20217":{"preferredName":"Suspension Culture","code":"C20217","definitions":[{"definition":"A type of culture in which cells, or aggregates of cells, multiply while suspended in liquid medium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suspension Culture","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Suspension_Culture"},{"name":"Maps_To","value":"Liquid Suspension Cell Line"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1515100"}]}}{"C12535":{"preferredName":"Lymphocyte","code":"C12535","definitions":[{"definition":"A type of immune cell that is made in the bone marrow and is found in the blood and in lymph tissue. The two main types of lymphocytes are B lymphocytes and T lymphocytes. B lymphocytes make antibodies, and T lymphocytes help kill tumor cells and help control immune responses. A lymphocyte is a type of white blood cell.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphocyte","termGroup":"PT","termSource":"NCI"},{"termName":"Lymph Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphocyte"},{"name":"Maps_To","value":"Lymphocytes"},{"name":"Semantic_Type","value":"Cell"},{"name":"UMLS_CUI","value":"C0024264"}]}}{"C164011":{"preferredName":"Bone Marrow-Derived Mononuclear Cells","code":"C164011","definitions":[{"definition":"A biological sample containing mononuclear cells isolated from the bone marrow of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bone Marrow-Derived Mononuclear Cells","termGroup":"PT","termSource":"NCI"},{"termName":"BM-MNC","termGroup":"SY","termSource":"NCI"},{"termName":"Bone Marrow-Derived Unselected Mononuclear Cell","termGroup":"SY","termSource":"NCI"},{"termName":"Non-Selected Mononuclear Cell","termGroup":"SY","termSource":"NCI"},{"termName":"tMNC","termGroup":"SY","termSource":"NCI"},{"termName":"Total Mononuclear Cell Population","termGroup":"SY","termSource":"NCI"},{"termName":"Unselected Mononuclear Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mononuclear Cells from Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977218"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"Semantic_Type","value":"Cell"}]}}{"C41067":{"preferredName":"Whole Blood","code":"C41067","definitions":[{"definition":"Blood that has not been separated into its various components; blood that has not been modified except for the addition of an anticoagulant.","type":"DEFINITION","source":"NCI"},{"definition":"Blood that has not been separated into its various components; blood that has not been modified except for the addition of an anticoagulant. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Whole Blood","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Whole_Blood"},{"name":"Maps_To","value":"Peripheral Whole Blood"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0370231"}]}}{"C3331":{"preferredName":"Pleural Effusion","code":"C3331","definitions":[{"definition":"A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An abnormal collection of fluid between the thin layers of tissue (pleura) lining the lung and the wall of the chest cavity.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An accumulation of fluid in the pleural cavity.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive HF, pleural and lung tumors, connective tissue disorders, and trauma","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive HF, pleural and lung tumors, connective tissue disorders, and trauma.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pleural Effusion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Pleural_Effusion"},{"name":"Maps_To","value":"Pleural Effusion"},{"name":"Maps_To","value":"Pleural effusion"},{"name":"Maps_To","value":"Unspecified pleural effusion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0032227"},{"name":"xRef","value":"IMDRF:E0731"}]}}{"C164014":{"preferredName":"Solid Tissue Specimen","code":"C164014","definitions":[{"definition":"A biological sample containing components collected from non-liquid tissue of an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solid Tissue Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Solid Tissue Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solid Tissue"},{"name":"NCI_META_CUI","value":"CL977215"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C126974":{"preferredName":"Sorted Cells","code":"C126974","definitions":[{"definition":"Cells separated and collected from a heterogeneous population based on physical, phenotypic, biochemical, and/or molecular properties, regardless of technique.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorted Cells","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Derived Cell Lines and Sorted Cells"},{"name":"Maps_To","value":"Sorted Cells"},{"name":"NCI_META_CUI","value":"CL508211"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C13278":{"preferredName":"Sputum","code":"C13278","definitions":[{"definition":"Material containing mucus, cellular debris, microorganisms and sometimes blood or pus.  It is ejected through the mouth from the lungs, bronchi, and trachea.","type":"DEFINITION","source":"NCI"},{"definition":"Material containing mucus, cellular debris, microorganisms and sometimes blood or pus. It is ejected through the mouth from the lungs, bronchi, and trachea. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sputum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Sputum"},{"name":"Maps_To","value":"Sputum"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0038056"}]}}{"C84513":{"preferredName":"Whole Bone Marrow","code":"C84513","definitions":[{"definition":"Bone marrow sample containing a mixture of different types of stem cells, including hematopoietic stem cells, mesenchymal stem cells, and multipotent progenitor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Whole Bone Marrow","termGroup":"PT","termSource":"NCI"},{"termName":"WBM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Whole Bone Marrow"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C2827482"}]}}{"C174118":{"preferredName":"Mixed Adherent Cells in Suspension","code":"C174118","definitions":[{"definition":"A sample comprised of a mixture of cells or clumps of cells, which may have been isolated from normal or tumor tissues, that are maintained in a suspension culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Adherent Cells in Suspension","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed Adherent Suspension"},{"name":"NCI_META_CUI","value":"CL1407783"},{"name":"Semantic_Type","value":"Cell"}]}}{"C25408":{"preferredName":"Adjacent","code":"C25408","definitions":[{"definition":"Next to or adjoining.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adjacent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Adjacent"},{"name":"Maps_To","value":"Adjacent (< or = 2cm)"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205117"}]}}{"C25237":{"preferredName":"Distal","code":"C25237","definitions":[{"definition":"In medicine, refers to a part of the body that is farther away from the center of the body than another part. For example, the fingers are distal to the shoulder. The opposite is proximal.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline of the body.","type":"DEFINITION","source":"NCI"},{"definition":"Situated farthest from a point of reference.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Distal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Distal"},{"name":"Maps_To","value":"Distal (>2cm)"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205108"}]}}{"C91826":{"preferredName":"Abdominoperineal Resection","code":"C91826","definitions":[{"definition":"A therapeutic surgical procedure in which the anus, rectum, part of the sigmoid colon, and the regional lymph nodes are removed through abdominal and perineal incisions.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove the anus, the rectum, and part of the sigmoid colon through an incision made in the abdomen. The end of the intestine is attached to an opening in the surface of the abdomen and body waste is collected in a disposable bag outside of the body. This opening is called a colostomy. Lymph nodes that contain cancer may also be removed during this operation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Abdominoperineal Resection","termGroup":"PT","termSource":"NCI"},{"termName":"APR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdomino-perineal Resection of Rectum"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2004459"}]}}{"C113716":{"preferredName":"Low Anterior Resection","code":"C113716","definitions":[{"definition":"Resection of the rectum for cancer through an incision in the lower abdomen.","type":"DEFINITION","source":"NCI"},{"definition":"Resection of the rectum through an incision in the lower abdomen.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Low Anterior Resection","termGroup":"PT","termSource":"NCI"},{"termName":"LAR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anterior Resection of Rectum"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3814448"}]}}{"C159342":{"preferredName":"Ascites Drainage","code":"C159342","definitions":[{"definition":"The systematic withdrawal of ascitic fluid  from the abdominal cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ascites Drainage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ascites Drainage"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0405789"}]}}{"C13347":{"preferredName":"Aspirate","code":"C13347","definitions":[{"definition":"Fluid withdrawn from a body cavity, cyst, or tumor. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Fluid withdrawn from a body cavity, organ, cyst, or tumor.","type":"DEFINITION","source":"NCI"},{"definition":"Fluid withdrawn from a lump, often a cyst, or a nipple.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aspirate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aspirate"},{"name":"Maps_To","value":"Aspirate"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0370199"}]}}{"C172322":{"preferredName":"Buccal Mucosal Resection","code":"C172322","definitions":[{"definition":"Surgical removal of the mucosal lining of the inside of the cheek through the mouth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buccal Mucosal Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Buccal Mucosal Resection"},{"name":"NCI_META_CUI","value":"CL1406180"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15217":{"preferredName":"Cystectomy","code":"C15217","definitions":[{"definition":"Surgery to remove all or part of the bladder (the organ that holds urine) or to remove a cyst (a sac or capsule in the body).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of the urinary bladder; or the surgical removal of a cyst..","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cystectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cystectomy"},{"name":"Maps_To","value":"Cystectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0010651"}]}}{"C161002":{"preferredName":"Deep Parotidectomy","code":"C161002","definitions":[{"definition":"Surgical removal of part or all of the deep lobe of the parotid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Parotidectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deep Parotidectomy"},{"name":"NCI_META_CUI","value":"CL969979"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165178":{"preferredName":"Endorectal Tumor Resection","code":"C165178","definitions":[{"definition":"The use of an endoscope to guide the surgical removal of tumor and any surrounding tissue located inside the rectum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endorectal Tumor Resection","termGroup":"PT","termSource":"NCI"},{"termName":"Endorectal Endoscopic Tumor Resection","termGroup":"SY","termSource":"NCI"},{"termName":"Endorectal Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endo Rectal Tumor Resection"},{"name":"NCI_META_CUI","value":"CL978442"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C160999":{"preferredName":"Endolaryngeal Excision","code":"C160999","definitions":[{"definition":"Surgical excision performed through the mouth and glottic opening.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endolaryngeal Excision","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endolaryngeal Excision"},{"name":"NCI_META_CUI","value":"CL969981"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15389":{"preferredName":"Endoscopic Biopsy","code":"C15389","definitions":[{"definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis. In the case of an endoscopic biopsy, an endoscope is used to obtain the sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endoscopic Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Endoscopy and Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endoscopic_Biopsy"},{"name":"Maps_To","value":"Endoscopic Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0184980"}]}}{"C103242":{"preferredName":"Endoscopic Mucosal Resection","code":"C103242","definitions":[{"definition":"An endoscopic procedure that visualizes a part of the gastrointestinal tract to first identify and demarcate superficial mucosal lesions, then to guide a submucosal injection to the site to lift the lesion and finally to aid in the removal of the lesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endoscopic Mucosal Resection","termGroup":"PT","termSource":"NCI"},{"termName":"EMR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Endoscopic Mucosal Resection (EMR)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1700928"}]}}{"C51604":{"preferredName":"Glossectomy","code":"C51604","definitions":[{"definition":"Surgery involving partial or complete excision of the tongue.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of all or part of the tongue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glossectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Excision of Tongue","termGroup":"SY","termSource":"NCI"},{"termName":"Resection of Tongue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glossectomy"},{"name":"Maps_To","value":"Glossectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0017673"}]}}{"C131672":{"preferredName":"Gross Total Resection","code":"C131672","definitions":[{"definition":"Surgical removal of an entire visible lesion, with no obvious lesion detected on post-operative evaluation; microscopic residual disease may be present.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of an entire visible lesion, with no obvious lesion detected on post-operative evaluation; microscopic residual disease may be present.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Gross Total Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Gross Total Resection"},{"name":"NCI_META_CUI","value":"CL514299"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165179":{"preferredName":"Hand Assisted Laparoscopic Radical Nephrectomy","code":"C165179","definitions":[{"definition":"A radical nephrectomy procedure performed using hand assisted laparoscopy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hand Assisted Laparoscopic Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hand Assisted Laparoscopic Radical Nephrectomy"},{"name":"NCI_META_CUI","value":"CL978423"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165180":{"preferredName":"Laparoscopic Biopsy","code":"C165180","definitions":[{"definition":"A biospy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0198536"}]}}{"C165181":{"preferredName":"Laparoscopic Partial Nephrectomy","code":"C165181","definitions":[{"definition":"A partial nephrectomy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Partial Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Partial Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1144661"}]}}{"C165182":{"preferredName":"Laparoscopic Radical Nephrectomy","code":"C165182","definitions":[{"definition":"A radical nephrectomy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Radical Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2584683"}]}}{"C165183":{"preferredName":"Laparoscopic Radical Prostatectomy with Robotics","code":"C165183","definitions":[{"definition":"A radical prostatectomy procedure performed with the aid of a robotic laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Radical Prostatectomy with Robotics","termGroup":"PT","termSource":"NCI"},{"termName":"RARP","termGroup":"SY","termSource":"NCI"},{"termName":"Robot-assisted Radical Prostatectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Radical Prostatectomy with Robotics"},{"name":"NCI_META_CUI","value":"CL978424"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165184":{"preferredName":"Laparoscopic Radical Prostatectomy","code":"C165184","definitions":[{"definition":"A radical prostatectomy procedure performed with the aid of a laparoscope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laparoscopic Radical Prostatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laparoscopic Radical Prostatectomy without Robotics"},{"name":"NCI_META_CUI","value":"CL978425"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C150660":{"preferredName":"Laryngopharyngectomy","code":"C150660","definitions":[{"definition":"Surgery involving the complete or partial excision of the larynx and pharynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laryngopharyngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Laryngopharyngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189242"}]}}{"C51624":{"preferredName":"Left Colectomy","code":"C51624","definitions":[{"definition":"Surgical removal of the left part of the colon.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the left portion of the colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Left Colectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Left Hemicolectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Left_Colectomy"},{"name":"Maps_To","value":"Left Hemicolectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192865"}]}}{"C135727":{"preferredName":"Liquid Biopsy","code":"C135727","definitions":[{"definition":"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liquid Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Liquid Biopsy","termGroup":"SY","termSource":"NCI"},{"termName":"Plasma Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Liquid Biopsy"},{"name":"NCI_META_CUI","value":"CL523042"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C15272":{"preferredName":"Lobectomy","code":"C15272","definitions":[{"definition":"Surgery to remove a whole lobe (section) of an organ (such as the lungs, liver, brain, or thyroid gland).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a lobe of an organ.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of a lobe of an organ.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lobectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Lobectomy"},{"name":"Maps_To","value":"Lobectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0023928"}]}}{"C15755":{"preferredName":"Lumpectomy","code":"C15755","definitions":[{"definition":"Surgery to remove abnormal tissue or cancer from the breast and a small amount of normal tissue around it. It is a type of breast-sparing surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a discrete mass.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The surgical removal of a discrete mass.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lumpectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Lumpectomy of Breast","termGroup":"SY","termSource":"NCI"},{"termName":"Partial Mastectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lumpectomy"},{"name":"Maps_To","value":"Lumpectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0851238"}]}}{"C15275":{"preferredName":"Lymphadenectomy","code":"C15275","definitions":[{"definition":"A surgical procedure in which the lymph nodes are removed and a sample of tissue is checked under a microscope for signs of cancer. For a regional lymphadenectomy, some of the lymph nodes in the tumor area are removed; for a radical lymphadenectomy, most or all of the lymph nodes in the tumor area are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of lymph nodes, usually done to assess the spread of cancer.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the lymph node(s).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Lymphadenectomy","termGroup":"PT","termSource":"NCI"},{"termName":"excision of the lymph node","termGroup":"SY","termSource":"NCI"},{"termName":"Lymph Node Dissection","termGroup":"SY","termSource":"NCI"},{"termName":"lymph node excision","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Lymphadenectomy"},{"name":"Maps_To","value":"Lymph Node Dissection"},{"name":"Maps_To","value":"Lymphadenectomy"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0024203"}]}}{"C51664":{"preferredName":"Mandibulectomy","code":"C51664","definitions":[{"definition":"Surgery to remove part or all of the mandible.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mandibulectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Excision of Mandible","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mandibulectomy"},{"name":"Maps_To","value":"Mandibulectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0185566"}]}}{"C51656":{"preferredName":"Maxillectomy","code":"C51656","definitions":[{"definition":"Surgery to remove part or all of the maxilla.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maxillectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Maxillectomy"},{"name":"Maps_To","value":"Maxillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0407722"}]}}{"C94461":{"preferredName":"Metastasectomy","code":"C94461","definitions":[{"definition":"Surgery to remove one or more metastases (tumors formed from cells that have spread from the primary tumor). When all metastases are removed, it is called a complete metastasectomy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of metastases.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The surgical removal of metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastasectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Metastasectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2363923"}]}}{"C15278":{"preferredName":"Modified Radical Mastectomy","code":"C15278","definitions":[{"definition":"Surgery for breast cancer in which the breast, most or all of the lymph nodes under the arm, and the lining over the chest muscles are removed. Sometimes the surgeon also removes part of the chest wall muscles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of one or both breasts, including the areola, nipple, and the majority of the axillary lymph nodes, but sparing the pectoralis major muscle.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The surgical removal of one or both breasts, including the areola, nipple, and the majority of the axillary lymph nodes, but sparing the pectoralis major muscle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Radical Mastectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Mastectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Modified_Radical_Mastectomy"},{"name":"Maps_To","value":"Modified Radical Mastectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0024883"}]}}{"C15190":{"preferredName":"Needle Biopsy","code":"C15190","definitions":[{"definition":"The removal of a tissue sample using a needle, for microscopic examination.","type":"DEFINITION","source":"NCI"},{"definition":"The removal of tissue or fluid with a needle for examination under a microscope. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Needle Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Aspiration Biopsy","termGroup":"SY","termSource":"NCI"},{"termName":"Puncture Biopsy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Needle_Biopsy"},{"name":"Maps_To","value":"Needle Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0005560"}]}}{"C51787":{"preferredName":"Omentectomy","code":"C51787","definitions":[{"definition":"Partial or complete resection of the omentum.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove part or all of the omentum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Omentectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Epiploectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Resection of Omentum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Omentectomy"},{"name":"Maps_To","value":"Omentectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0812449"}]}}{"C15291":{"preferredName":"Oophorectomy","code":"C15291","definitions":[{"definition":"Partial or complete removal of one or both of the ovaries.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove one or both ovaries.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Oophorectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Female Castration","termGroup":"SY","termSource":"NCI"},{"termName":"Ovariectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oophorectomy"},{"name":"Maps_To","value":"Oophorectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0029936"}]}}{"C15214":{"preferredName":"Craniotomy","code":"C15214","definitions":[{"definition":"An operation in which an opening is made in the skull.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical creation of an opening of the skull.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Craniotomy","termGroup":"PT","termSource":"NCI"},{"termName":"incision of the skull","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Craniotomy"},{"name":"Maps_To","value":"Open Craniotomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0010280"}]}}{"C165186":{"preferredName":"Open Partial Nephrectomy","code":"C165186","definitions":[{"definition":"A partial nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Partial Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Open Partial Nephrectomy"},{"name":"NCI_META_CUI","value":"CL978427"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165187":{"preferredName":"Open Radical Nephrectomy","code":"C165187","definitions":[{"definition":"A radical nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Open Radical Nephrectomy"},{"name":"NCI_META_CUI","value":"CL978428"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C165188":{"preferredName":"Open Radical Prostatectomy","code":"C165188","definitions":[{"definition":"A radical prostatectomy procedure performed using a long incision for visualization and the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Radical Prostatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Open Radical Prostatectomy"},{"name":"NCI_META_CUI","value":"CL978429"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15288":{"preferredName":"Orchiectomy","code":"C15288","definitions":[{"definition":"Surgery to remove one or both testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of one or both testicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orchiectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Castration","termGroup":"SY","termSource":"NCI"},{"termName":"Male Castration","termGroup":"SY","termSource":"NCI"},{"termName":"Male Gonadectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Orchiectomy"},{"name":"Maps_To","value":"Orchiectomy"},{"name":"Maps_To","value":"Testis Removed"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0029189"}]}}{"C184787":{"preferredName":"Biospecimen Collection by Other Surgical Resection Method","code":"C184787","definitions":[{"definition":"The use of an unspecified or other surgical resection procedure for biospecimen collection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biospecimen Collection by Other Surgical Resection Method","termGroup":"PT","termSource":"NCI"},{"termName":"Sample Collection by Other Surgical Resection Method","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Surgical Resection Method"},{"name":"NCI_META_CUI","value":"CL1773107"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C160997":{"preferredName":"Palatectomy","code":"C160997","definitions":[{"definition":"Surgical removal of part or all of the palate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Palatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1737220"}]}}{"C103239":{"preferredName":"Total Proctocolectomy","code":"C103239","definitions":[{"definition":"Surgical removal of the entire colon, anus, and rectum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Proctocolectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Pan-Procto Colectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-Proctocolectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Panproctocolectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-Procto Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0842176"}]}}{"C15294":{"preferredName":"Pancreatectomy","code":"C15294","definitions":[{"definition":"Surgery to remove all or part of the pancreas. In a total pancreatectomy, part of the stomach, part of the small intestine, the common bile duct, gallbladder, spleen, and nearby lymph nodes also are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of part or all of the pancreas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancreatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Excision of the Pancreas","termGroup":"SY","termSource":"NCI"},{"termName":"Pancreas Excision","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancreatectomy"},{"name":"Maps_To","value":"Pancreatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0030279"}]}}{"C15310":{"preferredName":"Paracentesis","code":"C15310","definitions":[{"definition":"A procedure in which a thin needle or tube is put into the abdomen to remove fluid from the peritoneal cavity (the space within the abdomen that contains the intestines, the stomach, and the liver).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The removal of excess fluid via needle puncture from any body cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paracentesis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paracentesis"},{"name":"Maps_To","value":"Paracentesis"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C0034115"}]}}{"C51490":{"preferredName":"Parotidectomy","code":"C51490","definitions":[{"definition":"Surgery involving complete or partial excision of the parotid gland.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove all or part of the parotid gland (a large salivary gland located in front of and just below the ear). In a radical parotidectomy, the entire gland is removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Parotidectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Parotidectomy"},{"name":"Maps_To","value":"Parotidectomy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193317"}]}}{"C15394":{"preferredName":"Partial Hepatectomy","code":"C15394","definitions":[{"definition":"Partial removal of the liver","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Hepatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"partial excision of liver","termGroup":"SY","termSource":"NCI"},{"termName":"subtotal hepatectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Partial_Hepatectomy"},{"name":"Maps_To","value":"Partial Hepatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193398"}]}}{"C94240":{"preferredName":"Partial Laryngectomy","code":"C94240","definitions":[{"definition":"An operation to remove part of the larynx (voice box).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Partial Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Partial Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189234"}]}}{"C51657":{"preferredName":"Partial Maxillectomy","code":"C51657","definitions":[{"definition":"Surgery to remove part of the maxilla.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Maxillectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Partial_Maxillectomy"},{"name":"Maps_To","value":"Partial Maxillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0407589"}]}}{"C51928":{"preferredName":"Partial Nephrectomy","code":"C51928","definitions":[{"definition":"Surgery to remove part of one kidney or a kidney tumor, but not an entire kidney.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of a portion of a kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Nephrectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Nephron Sparing Surgery","termGroup":"SY","termSource":"NCI"},{"termName":"NSS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Partial_Nephrectomy"},{"name":"Maps_To","value":"Partial Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194086"}]}}{"C159340":{"preferredName":"Peritoneal Lavage","code":"C159340","definitions":[{"definition":"A minimally invasive procedure that permits sampling of peritoneal fluid for cytopathologic analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritoneal Lavage","termGroup":"PT","termSource":"NCI"},{"termName":"Peritoneal Washing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peritoneal Lavage"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0031148"}]}}{"C15305":{"preferredName":"Pneumonectomy","code":"C15305","definitions":[{"definition":"Surgery to remove all of one lung.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The excision of part or all of a lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pneumonectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Pneumonectomy"},{"name":"Maps_To","value":"Pneumonectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0032284"}]}}{"C28743":{"preferredName":"Punch Biopsy","code":"C28743","definitions":[{"definition":"A type of biopsy in which a disk of tissue is removed using a punch device.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Removal of a disk of skin tissue, for microscopic examination, using a punch.","type":"DEFINITION","source":"NCI"},{"definition":"Removal of a small disk-shaped sample of tissue using a sharp, hollow device. The tissue is then examined under a microscope.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Punch Biopsy","termGroup":"PT","termSource":"NCI"},{"termName":"Punch Biopsy of Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Punch_Biopsy"},{"name":"Maps_To","value":"Punch Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0191321"}]}}{"C172324":{"preferredName":"Total Maxillectomy","code":"C172324","definitions":[{"definition":"Surgical removal of the entire maxilla, hard palate and orbital floor on one side of the face.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Maxillectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Radical Maxillectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radical Maxillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0407611"}]}}{"C51778":{"preferredName":"Radical Nephrectomy","code":"C51778","definitions":[{"definition":"Surgery to remove an entire kidney, nearby adrenal gland and lymph nodes, and other surrounding tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a kidney, the adrenal gland, adjacent lymph nodes, and other surrounding tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radical_Nephrectomy"},{"name":"Maps_To","value":"Radical Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0401181"}]}}{"C15399":{"preferredName":"Radical Prostatectomy","code":"C15399","definitions":[{"definition":"Surgery to remove the entire prostate. The two types of radical prostatectomy are retropubic prostatectomy (surgery through an incision in the wall of the abdomen) and perineal prostatectomy (surgery through an incision between the scrotum and the anus).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The surgical removal of all of the prostate as well as some surrounding tissue, including lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Prostatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Prostatovesiculectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radical_Prostatectomy"},{"name":"Maps_To","value":"Radical prostatectomy"},{"name":"Maps_To","value":"Radical Prostatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194810"}]}}{"C51623":{"preferredName":"Right Colectomy","code":"C51623","definitions":[{"definition":"Surgical removal of the right part of the colon.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the right portion of the colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Right Colectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Right Hemicolectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Colectomy"},{"name":"Maps_To","value":"Right Hemicolectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192861"}]}}{"C51605":{"preferredName":"Salpingectomy","code":"C51605","definitions":[{"definition":"Surgery to remove part or all of the fallopian tube(s).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salpingectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Tubal Excision","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salpingectomy"},{"name":"Maps_To","value":"Salpingectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0041271"}]}}{"C15323":{"preferredName":"Salpingo-Oophorectomy","code":"C15323","definitions":[{"definition":"Surgical removal of the fallopian tube(s) and ovary(ies).","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the fallopian tubes and ovaries.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Salpingo-Oophorectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salpingo-Oophorectomy"},{"name":"Maps_To","value":"Salpingo-Oophorectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0036132"}]}}{"C91838":{"preferredName":"Sigmoidectomy","code":"C91838","definitions":[{"definition":"A surgical procedure involving the partial or complete resection of the sigmoid colon.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the sigmoid colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Sigmoidectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Sigmoid Colectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sigmoid Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0810152"}]}}{"C15281":{"preferredName":"Total Mastectomy","code":"C15281","definitions":[{"definition":"A surgical procedure involving the removal of the entire breast tissue, nipple and a portion of the overlying skin, while leaving the axillary contents intact.","type":"DEFINITION","source":"NCI"},{"definition":"Removal of the breast.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Total Mastectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Simple Mastectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Mastectomy"},{"name":"Maps_To","value":"Simple Mastectomy"},{"name":"Maps_To","value":"Total Mastectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0024886"}]}}{"C172325":{"preferredName":"Subtotal Prostatectomy","code":"C172325","definitions":[{"definition":"Surgical removal of part of the prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subtotal Prostatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Simple Prostatectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subtotal Prostatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194809"}]}}{"C131680":{"preferredName":"Partial Resection","code":"C131680","definitions":[{"definition":"Surgical removal of a part of a lesion; some portion of the lesion is detectable on post-operative evaluation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Surgical removal of a part of a lesion; some portion of the lesion is detectable on post-operative evaluation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partial Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Subtotal Resection"},{"name":"NCI_META_CUI","value":"CL514546"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C51910":{"preferredName":"Superficial Parotidectomy","code":"C51910","definitions":[{"definition":"Surgery involving excision of the superficial portion of the parotid gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Parotidectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Superficial_Parotidectomy"},{"name":"Maps_To","value":"Superficial Parotidectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0554011"}]}}{"C126397":{"preferredName":"Supracervical Hysterectomy","code":"C126397","definitions":[{"definition":"A hysterectomy that removes the uterus and leaves the cervix in place.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supracervical Hysterectomy","termGroup":"PT","termSource":"NCI"},{"termName":"SCH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Supracervical Hysterectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1270948"}]}}{"C91839":{"preferredName":"Supracricoid Laryngectomy","code":"C91839","definitions":[{"definition":"A conservation laryngeal surgery involving the resection of the true and false vocal cords, both paraglottic spaces, and the thyroid cartilage. In some cases the preepiglottic space and the epiglottis are also removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supracricoid Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Supracricoid Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2984588"}]}}{"C51889":{"preferredName":"Supraglottic Laryngectomy","code":"C51889","definitions":[{"definition":"An operation to remove the supraglottis, which is part of the larynx (voice box) above the vocal cords.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of the portion of the larynx superior to the true vocal cords.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supraglottic Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supraglottic_Laryngectomy"},{"name":"Maps_To","value":"Supraglottic Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189240"}]}}{"C163997":{"preferredName":"Thoracoscopic Biopsy","code":"C163997","definitions":[{"definition":"The use of a thoracoscope to obtain a biopsy from the pleural cavity and/or thoracic cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thoracoscopic Biopsy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thoracoscopic Biopsy"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0198373"}]}}{"C51679":{"preferredName":"Tonsillectomy","code":"C51679","definitions":[{"definition":"Surgical removal of the tonsils.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Surgical removal of the tonsils.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tonsillectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tonsillectomy"},{"name":"Maps_To","value":"Tonsillectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040423"}]}}{"C51924":{"preferredName":"Total Colectomy","code":"C51924","definitions":[{"definition":"Surgical removal of the entire colon.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the entire colon.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Total Colectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Complete Excisioin of Colon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Colectomy"},{"name":"Maps_To","value":"Total Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192871"}]}}{"C51781":{"preferredName":"Total Hepatectomy","code":"C51781","definitions":[{"definition":"Surgical removal of the entire liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Hepatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Hepatectomy"},{"name":"Maps_To","value":"Total Hepatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040507"}]}}{"C51771":{"preferredName":"Total Laryngectomy","code":"C51771","definitions":[{"definition":"An operation to remove all of the larynx (voice box).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgery to completely remove the larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Laryngectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Laryngectomy"},{"name":"Maps_To","value":"Total Laryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189231"}]}}{"C51632":{"preferredName":"Total Nephrectomy","code":"C51632","synonyms":[{"termName":"Total Nephrectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Nephrectomy"},{"name":"Maps_To","value":"Total Nephrectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0176996"}]}}{"C91840":{"preferredName":"Transoral Laser Microsurgery","code":"C91840","definitions":[{"definition":"A minimally invasive procedure in which a surgeon performs tumor resection through the mouth using a microscope for visualization and a CO2 laser for incisions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transoral Laser Microsurgery","termGroup":"PT","termSource":"NCI"},{"termName":"TLM","termGroup":"SY","termSource":"NCI"},{"termName":"Transoral Laser Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transoral Laser Excision"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2984589"}]}}{"C15342":{"preferredName":"Transplantation","code":"C15342","definitions":[{"definition":"A surgical procedure in which tissue or an organ is transferred from one area of a person's body to another area, or from one person (the donor) to another person (the recipient).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Grafting","termGroup":"SY","termSource":"NCI"},{"termName":"Grafting Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Surgery, Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"Transplant Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Transplantation Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transplantation"},{"name":"Maps_To","value":"Transplant"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040732"}]}}{"C116651":{"preferredName":"Transurethral Resection of Bladder Tumor","code":"C116651","definitions":[{"definition":"A surgical procedure in which a resectoscope is passed through the urethra into the bladder to diagnose and remove all or part of a bladder tumor.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A surgical procedure used to treat bladder tumors, during which a resectoscope is passed through the urethra and into the bladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transurethral Resection of Bladder Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"TURBT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transurethral resection (TURBT)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0401496"}]}}{"C15343":{"preferredName":"Transurethral Prostatic Resection","code":"C15343","definitions":[{"definition":"Prostate tissue removal via a cystoscope.","type":"DEFINITION","source":"NCI"},{"definition":"Surgery to remove tissue from the prostate using an instrument inserted through the urethra.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Transurethral Prostatic Resection","termGroup":"PT","termSource":"NCI"},{"termName":"Prostate Transurethral Resection","termGroup":"SY","termSource":"NCI"},{"termName":"Transurethral Prostatectomy","termGroup":"SY","termSource":"NCI"},{"termName":"Transurethral Resection of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Transurethral Resection of the Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"TURP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Transurethral_Prostatic_Resection"},{"name":"Maps_To","value":"Transurethral Resection (TURP)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040771"}]}}{"C51612":{"preferredName":"Transverse Colectomy","code":"C51612","definitions":[{"definition":"Surgical removal of the transverse colon.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Surgical removal of the transverse colon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transverse Colectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transverse_Colectomy"},{"name":"Maps_To","value":"Transverse Colectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0192863"}]}}{"C164212":{"preferredName":"Tumor Resection","code":"C164212","definitions":[{"definition":"A surgical procedure in which cancerous tissue is surgically removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Resection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor Resection"},{"name":"NCI_META_CUI","value":"CL936686"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C51906":{"preferredName":"Hemilaryngectomy","code":"C51906","definitions":[{"definition":"An operation to remove one side of the larynx (voicebox).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgery to remove one half of the larynx.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemilaryngectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Vertical Partial Laryngectomy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hemilaryngectomy"},{"name":"Maps_To","value":"Vertical Hemilaryngectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189233"}]}}{"C51690":{"preferredName":"Wedge Excision","code":"C51690","definitions":[{"definition":"Surgery to remove a triangle-shaped slice of tissue. It may be used to remove a tumor and a small amount of normal tissue around it.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of a triangular wedge shaped section of tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wedge Excision","termGroup":"PT","termSource":"NCI"},{"termName":"Wedge Resection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Wedge_Excision"},{"name":"Maps_To","value":"Wedge Resection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0184909"}]}}{"C15356":{"preferredName":"Whipple Procedure","code":"C15356","definitions":[{"definition":"A type of surgery used to treat pancreatic cancer. The head of the pancreas, the duodenum, a portion of the stomach, and other nearby tissues are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of part of the pancreas, duodenum, and distal part of the bile duct.  Sometimes, the lower portion of the stomach and the gallbladder are also removed.  This procedure is performed for pancreatic, ampullary, duodenal and distal bile duct cancers.","type":"DEFINITION","source":"NCI"},{"definition":"Surgical removal of the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct. (Mayo Clinic)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Whipple Procedure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Whipple_procedure"},{"name":"Maps_To","value":"Whipple"},{"name":"Maps_To","value":"Whipple Procedure"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0085162"}]}}{"C16475":{"preferredName":"Cryopreservation","code":"C16475","definitions":[{"definition":"Preservation of cells, tissues, organs, or embryos by storage at low temperatures.","type":"DEFINITION","source":"NCI"},{"definition":"Storage at very low temperature, usually in liquid nitrogen or the vapor phase of liquid nitrogen.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"eManu"}]},{"definition":"The process of cooling and storing cells, tissues, or organs at very low or freezing temperatures to save them for future use.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cryopreservation","termGroup":"PT","termSource":"NCI"},{"termName":"Cryopreserved","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cryopreservation"},{"name":"Maps_To","value":"Cryopreserved"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0010405"}]}}{"C143028":{"preferredName":"Formalin-Fixed Paraffin-Embedded","code":"C143028","definitions":[{"definition":"Refers to a process where a sample is preserved with formalin and then embedded into a paraffin block for sectioning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"FFPE"},{"name":"NCI_META_CUI","value":"CL541488"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C84517":{"preferredName":"Fresh Specimen","code":"C84517","definitions":[{"definition":"A specimen that is analyzed in the state that it was collected.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Tissue which has not been exposed to a fixative solution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fresh Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Fresh","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fresh"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C2827486"}]}}{"C70717":{"preferredName":"Frozen Specimen","code":"C70717","definitions":[{"definition":"A specimen that has been subjected to and immobilized by severe cold.","type":"DEFINITION","source":"NCI"},{"definition":"A specimen that has been subjected to and immobilized by severe cold. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Frozen Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Frozen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Frozen_Specimen"},{"name":"Maps_To","value":"Frozen"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1548793"}]}}{"C63523":{"preferredName":"Optimal Cutting Temperature Compound","code":"C63523","definitions":[{"definition":"A solution of water soluble glycols and resins that provide a specimen support matrix for cryostat sectioning at temperatures of -10 degrees C and below.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Optimal Cutting Temperature Compound","termGroup":"PT","termSource":"NCI"},{"termName":"OCT","termGroup":"AB","termSource":"NCI"},{"termName":"Tissue-Tek OCT","termGroup":"SY","termSource":"NCI"},{"termName":"Tissue-Tek Optimal Cutting Temperature Compound","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Optimal_Cutting_Temperature_Compound"},{"name":"Maps_To","value":"OCT"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C1882161"}]}}{"C63521":{"preferredName":"Quick Freeze","code":"C63521","definitions":[{"definition":"To freeze rapidly so as to preserve structure and prevent ice crystal formation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"To freeze rapidly so as to preserve structure and prevent ice crystal formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quick Freeze","termGroup":"PT","termSource":"NCI"},{"termName":"Flash Freeze","termGroup":"SY","termSource":"NCI"},{"termName":"Flash Frozen","termGroup":"AD","termSource":"NCI"},{"termName":"Quick Frozen","termGroup":"AD","termSource":"NCI"},{"termName":"Snap Freeze","termGroup":"SY","termSource":"NCI"},{"termName":"Snap Frozen","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Quick_Freeze"},{"name":"Maps_To","value":"Snap Frozen"},{"name":"Semantic_Type","value":"Activity"},{"name":"UMLS_CUI","value":"C1882516"}]}}{"C61742":{"preferredName":"Edetic Acid","code":"C61742","definitions":[{"definition":"The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"EDTA","termGroup":"AB","termSource":"NCI"},{"termName":"Ethylenediaminetetraacetic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60-00-4"},{"name":"CHEBI_ID","value":"CHEBI:4735"},{"name":"Chemical_Formula","value":"C10H16N2O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9G34HU7RV0"},{"name":"Legacy Concept Name","value":"Edetic_Acid"},{"name":"Maps_To","value":"EDTA"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0013618"}]}}{"C156441":{"preferredName":"Sample Derived from New Primary","code":"C156441","definitions":[{"definition":"A biospecimen derived from a new primary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sample Derived from New Primary","termGroup":"PT","termSource":"NCI"},{"termName":"New Primary Tumor Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Sample Derived from New Primary Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"05"},{"name":"Maps_To","value":"Additional - New Primary"},{"name":"NCI_META_CUI","value":"CL563179"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C156440":{"preferredName":"Metastatic Tumor Sample","code":"C156440","definitions":[{"definition":"A biospecimen derived from a metastatic tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metastatic Tumor Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Metastatic Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"06"},{"name":"Maps_To","value":"07"},{"name":"Maps_To","value":"Additional Metastatic"},{"name":"Maps_To","value":"Metastatic"},{"name":"NCI_META_CUI","value":"CL563178"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C164015":{"preferredName":"Blood Cancer-Derived Bone Marrow Specimen","code":"C164015","definitions":[{"definition":"A bone marrow specimen collected from a subject that has been diagnosed with a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Bone Marrow Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Bone Marrow Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"09"},{"name":"Maps_To","value":"Blood Derived Cancer - Bone Marrow"},{"name":"Maps_To","value":"Primary Blood Derived Cancer - Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977214"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164017":{"preferredName":"Blood Cancer-Derived Bone Marrow Specimen, Post-Treatment","code":"C164017","definitions":[{"definition":"A bone marrow specimen collected from a subject after receiving treatment for a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Bone Marrow Specimen, Post-Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Bone Marrow Sample, Post-Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"04"},{"name":"Maps_To","value":"Blood Derived Cancer - Bone Marrow, Post-treatment"},{"name":"Maps_To","value":"Recurrent Blood Derived Cancer - Bone Marrow"},{"name":"NCI_META_CUI","value":"CL977241"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164030":{"preferredName":"Blood Cancer-Derived Blood Specimen","code":"C164030","definitions":[{"definition":"A whole blood specimen collected from a subject that has been diagnosed with a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Blood Specimen","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Blood Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Sample","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Specimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"03"},{"name":"Maps_To","value":"Blood Derived Cancer - Peripheral Blood"},{"name":"Maps_To","value":"Primary Blood Derived Cancer - Peripheral Blood"},{"name":"NCI_META_CUI","value":"CL977229"},{"name":"Semantic_Type","value":"Cell"}]}}{"C164031":{"preferredName":"Blood Cancer-Derived Blood Specimen, Post-Treatment","code":"C164031","definitions":[{"definition":"A whole blood specimen collected from a subject after receiving treatment for a liquid tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blood Cancer-Derived Blood Specimen, Post-Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Blood Cancer-Derived Blood Sample, Post-Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Sample, Post-Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Blood Cancer-Derived Peripheral Blood Specimen, Post-Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"40"},{"name":"Maps_To","value":"Blood Derived Cancer - Peripheral Blood, Post-treatment"},{"name":"Maps_To","value":"Recurrent Blood Derived Cancer - Peripheral Blood, Post Treatment"},{"name":"NCI_META_CUI","value":"CL977228"},{"name":"Semantic_Type","value":"Cell"}]}}{"C156443":{"preferredName":"Cell Line-Derived Xenograft","code":"C156443","definitions":[{"definition":"A biospecimen derived from the culturing of a derived cell line in a non-human organism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell Line-Derived Xenograft","termGroup":"PT","termSource":"NCI"},{"termName":"CDX","termGroup":"AB","termSource":"NCI"},{"termName":"Cell Line Derived Xenograft Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"61"},{"name":"Maps_To","value":"Cell Line Derived Xenograft Tissue"},{"name":"NCI_META_CUI","value":"CL563174"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C184757":{"preferredName":"Expanded Next Generation Cancer Model","code":"C184757","definitions":[{"definition":"A next generation cancer model that has been expanded using tissue culture or other methods.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Expanded Next Generation Cancer Model","termGroup":"PT","termSource":"NCI"},{"termName":"Expanded NGCM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Expanded Next Generation Cancer Model"},{"name":"NCI_META_CUI","value":"CL1773074"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C172267":{"preferredName":"Formalin-Fixed Paraffin-Embedded Tissue Sample from Recurrent Disease","code":"C172267","definitions":[{"definition":"A formalin-fixed, paraffin-embedded sample derived from tissue isolated from a subject with recurrent disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded Tissue Sample from Recurrent Disease","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE Recurrent Disease Tissue","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE Recurrent"},{"name":"NCI_META_CUI","value":"CL1406148"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172268":{"preferredName":"Formalin-Fixed Paraffin-Embedded Tissue Scroll","code":"C172268","definitions":[{"definition":"A formalin-fixed, paraffin-embedded tissue sample that has been cut on a microtome so that it rolls up on itself.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formalin-Fixed Paraffin-Embedded Tissue Scroll","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE Scroll","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FFPE Scroll"},{"name":"NCI_META_CUI","value":"CL1406147"},{"name":"Semantic_Type","value":"Tissue"}]}}{"C172293":{"preferredName":"Original Tumor Cell Sample","code":"C172293","definitions":[{"definition":"A sample comprised of cells that were isolated from a tumor and have not been cultured or expanded.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Original Tumor Cell Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Original Tumor Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"08"},{"name":"Maps_To","value":"Human Tumor Original Cells"},{"name":"NCI_META_CUI","value":"CL1406152"},{"name":"Semantic_Type","value":"Cell"}]}}{"C36118":{"preferredName":"In Situ Lesion","code":"C36118","synonyms":[{"termName":"In Situ Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"In_Situ_Lesion"},{"name":"Maps_To","value":"In Situ Neoplasms"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1334167"}]}}{"C13049":{"preferredName":"Lymphoid Tissue","code":"C13049","definitions":[{"definition":"Tissue characterized by the presence of large numbers of lymphocytes in different stages of transformation. Connective tissue cells including fibroblasts and macrophages may be present. Lymphoid tissue is framed by a network of reticular fibers and may be diffuse, or densely aggregated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoid Tissue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lymphoid_Tissue"},{"name":"Maps_To","value":"Lymphoid"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0024296"}]}}{"C172295":{"preferredName":"Next Generation Cancer Model","code":"C172295","definitions":[{"definition":"An approach to cancer modeling that utilizes clinical data as well as the genomic and transcriptomic profiles of the parent tumor, metastases, if present, and case-matched normal tissues from individual patients.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"RFA-CA-19-055"}]}],"synonyms":[{"termName":"Next Generation Cancer Model","termGroup":"PT","termSource":"NCI"},{"termName":"NGCM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Next Generation Cancer Model"},{"name":"NCI_META_CUI","value":"CL1406176"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C156444":{"preferredName":"Post Neoadjuvant Therapy Sample","code":"C156444","definitions":[{"definition":"A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post Neoadjuvant Therapy Sample","termGroup":"PT","termSource":"NCI"},{"termName":"Post Neo-adjuvant Therapy Sample","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post neo-adjuvant therapy"},{"name":"NCI_META_CUI","value":"CL563175"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C12932":{"preferredName":"Xenograft","code":"C12932","definitions":[{"definition":"Cells, tissues, or organs from a donor that are transplanted into a recipient of another species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xenograft","termGroup":"PT","termSource":"NCI"},{"termName":"Heterograft","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Xenograft"},{"name":"Maps_To","value":"Xenograft"},{"name":"Semantic_Type","value":"Biomedical or Dental Material"},{"name":"UMLS_CUI","value":"C0522537"}]}}{"C174119":{"preferredName":"Saliva Sample","code":"C174119","definitions":[{"definition":"A small volume of saliva removed for testing or storage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saliva Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Maps_To","value":"Saliva"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C1608524"}]}}{"C172296":{"preferredName":"Biospecimen on a Slide","code":"C172296","definitions":[{"definition":"The deposition of a biospecimen onto a slide prior to analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biospecimen on a Slide","termGroup":"PT","termSource":"NCI"},{"termName":"Sample on a Slide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Slides"},{"name":"NCI_META_CUI","value":"CL1406175"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C164033":{"preferredName":"Tumor-Adjacent Normal Post Neoadjuvant Therapy Sample","code":"C164033","definitions":[{"definition":"A specimen derived from a tumor-adjacent normal tissue specimen that was collected from the subject after treatment with a neoadjuvant therapeutic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor-Adjacent Normal Post Neoadjuvant Therapy Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tumor Adjacent Normal - Post Neo-adjuvant Therapy"},{"name":"NCI_META_CUI","value":"CL977197"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C184781":{"preferredName":"Next Generation Cancer Model Expanded Under Non-Conforming Conditions","code":"C184781","definitions":[{"definition":"A next generation cancer model that has been expanded using unconventional culturing methods.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Next Generation Cancer Model Expanded Under Non-Conforming Conditions","termGroup":"PT","termSource":"NCI"},{"termName":"NGCM Expanded Under Non-Conforming Conditions","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Next Generation Cancer Model Expanded Under Non-Conforming Conditions"},{"name":"NCI_META_CUI","value":"CL1773098"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C172297":{"preferredName":"Prospective Tissue Collection","code":"C172297","definitions":[{"definition":"A process by which a tissue sample is collected from a subject prior to treatment or enrollment in a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prospective Tissue Collection","termGroup":"PT","termSource":"NCI"},{"termName":"Prospective Collection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prospective"},{"name":"NCI_META_CUI","value":"CL1406174"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C172298":{"preferredName":"Retrospective Tissue Collection","code":"C172298","definitions":[{"definition":"A process by which a tissue sample is collected from a subject following treatment or participation in a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retrospective Tissue Collection","termGroup":"PT","termSource":"NCI"},{"termName":"Retrospective Collection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retrospective"},{"name":"NCI_META_CUI","value":"CL1406173"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C25401":{"preferredName":"Abnormal","code":"C25401","definitions":[{"definition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.","type":"DEFINITION","source":"NCI"},{"definition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Not normal. An abnormal lesion or growth may be cancer, premalignant (likely to become cancer), or benign (not cancer).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Abnormal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Abnormal"},{"name":"Maps_To","value":"Abnormal"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205161"}]}}{"C119010":{"preferredName":"Peritumoral","code":"C119010","definitions":[{"definition":"Located in tissues surrounding a tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peritumoral","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peritumoral"},{"name":"Semantic_Type","value":"Spatial Concept"},{"name":"UMLS_CUI","value":"C3897941"}]}}{"C7464":{"preferredName":"Acute Leukemia of Ambiguous Lineage","code":"C7464","definitions":[{"definition":"A rare subtype of acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid, or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. These subtypes account for less than 4% of cases of acute leukemia.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acute Leukemia of Ambiguous Lineage","termGroup":"PT","termSource":"NCI"},{"termName":"Acute Leukemia of Indeterminate Lineage","termGroup":"SY","termSource":"NCI"},{"termName":"ALAL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Acute_Leukemia_of_Ambiguous_Lineage"},{"name":"Maps_To","value":"Acute Leukemia of Ambiguous Lineage (ALAL)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1301357"}]}}{"C9291":{"preferredName":"Anal Carcinoma","code":"C9291","definitions":[{"definition":"A carcinoma that arises from the anus. Anal carcinomas include the anal canal and perianal area (anal margin) carcinomas. Perianal carcinomas are staged separately as skin carcinomas in AJCC v6 and v7 editions. The AJCC v8 edition staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin).","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in tissues of the anus. The anus is the opening of the rectum (last part of the large intestine) to the outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anal Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Anal Cancer","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Cancer of the Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of Anus","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Anus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anal_Carcinoma"},{"name":"Maps_To","value":"Anal Cancer (all types)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279637"}]}}{"C132067":{"preferredName":"Low Grade Glioma","code":"C132067","definitions":[{"definition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low Grade Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"LGG","termGroup":"AB","termSource":"NCI"},{"termName":"Low Grade Glial Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Grade Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS, low grade glioma (LGG)"},{"name":"Neoplastic_Status","value":"Undetermined"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1997217"}]}}{"C3222":{"preferredName":"Medulloblastoma","code":"C3222","definitions":[{"definition":"A malignant brain tumor that begins in the lower part of the brain and that can spread to the spine or to other parts of the body. Medulloblastomas are a type of primitive neuroectodermal tumor (PNET).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","type":"DEFINITION","source":"NCI"},{"definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A rapidly progressive cancer of the brain that originates in the cerebellum.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Medulloblastoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"ICD-O-3_Code","value":"9470/3"},{"name":"Legacy Concept Name","value":"Medulloblastoma"},{"name":"Maps_To","value":"CNS, medulloblastoma"},{"name":"Maps_To","value":"Medulloblastoma"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0025149"}]}}{"C184750":{"preferredName":"Personal History of Other Central Nervous System Tumor","code":"C184750","definitions":[{"definition":"An individual history of a cancer occurring in the central nervous system, other than those listed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Other Central Nervous System Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"History of Other Central Nervous System Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Other Central Nervous System Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS, other"},{"name":"NCI_META_CUI","value":"CL1773067"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184751":{"preferredName":"Personal History of Central Nervous System Rhabdoid Tumor","code":"C184751","definitions":[{"definition":"An individual history of a rhabdoid tumor occurring in the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Central Nervous System Rhabdoid Tumor","termGroup":"PT","termSource":"NCI"},{"termName":"History of Central Nervous System Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNS, rhabdoid tumor"},{"name":"NCI_META_CUI","value":"CL1773080"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184765":{"preferredName":"Personal History of Acute Myeloid Leukemia with Induction Failure","code":"C184765","definitions":[{"definition":"An individual history of acute myeloid leukemia and induction failure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Acute Myeloid Leukemia with Induction Failure","termGroup":"PT","termSource":"NCI"},{"termName":"History of Acute Myeloid Leukemia with Induction Failure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Induction Failure AML (AML-IF)"},{"name":"NCI_META_CUI","value":"CL1773082"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C166238":{"preferredName":"Non-Tumor Tissue Area","code":"C166238","definitions":[{"definition":"The area within a sample that is represented by non-tumor tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Tumor Tissue Area","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"Non cancerous tissue"},{"name":"NCI_META_CUI","value":"CL971284"},{"name":"Semantic_Type","value":"Spatial Concept"}]}}{"C8715":{"preferredName":"Rhabdoid Tumor of the Kidney","code":"C8715","definitions":[{"definition":"A rhabdoid tumor that arises from the kidney.  It occurs in children and it is associated with abnormalities of chromosome 22. It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  The prognosis is poor.","type":"DEFINITION","source":"NCI"},{"definition":"A rhabdoid tumor that arises in the kidney.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Rhabdoid Tumor of the Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Malignant Rhabdoid Tumor of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"MRTK","termGroup":"AB","termSource":"NCI"},{"termName":"Renal Rhabdoid Neoplasm","termGroup":"SY","termSource":"NCI"},{"termName":"Renal Rhabdoid Tumor","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Neoplasm of the Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumor of the Kidney (RTK)","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumour of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Rhabdoid Tumour of the Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Rhabdoid_Tumour_of_the_Kidney"},{"name":"Maps_To","value":"Rhabdoid tumor (kidney) (RT)"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0854917"}]}}{"C7978":{"preferredName":"Ovarian Serous Cystadenocarcinoma","code":"C7978","definitions":[{"definition":"A malignant serous cystic epithelial neoplasm arising from the ovary.  It is characterized by the presence of glandular, papillary, or solid structures.  Psammoma bodies may be present.  In well differentiated cases the malignant epithelial cells resemble the cells of fallopian tube epithelium.  In poorly differentiated cases the malignant epithelial cells show anaplastic features.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Serous Cystadenocarcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovarian_Serous_Cystadenocarcinoma"},{"name":"Maps_To","value":"15"},{"name":"Maps_To","value":"21"},{"name":"Maps_To","value":"40"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0279663"}]}}{"C4349":{"preferredName":"Colon Adenocarcinoma","code":"C4349","definitions":[{"definition":"An adenocarcinoma arising from the colon.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, colonic adenocarcinomas are divided into well, moderately, and poorly differentiated.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colon Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Colon","termGroup":"SY","termSource":"NCI"},{"termName":"Colonic Adenocarcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colon_Adenocarcinoma"},{"name":"Maps_To","value":"30"},{"name":"Maps_To","value":"41"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0338106"}]}}{"C3512":{"preferredName":"Lung Adenocarcinoma","code":"C3512","definitions":[{"definition":"A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Adenocarcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Adenocarcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Adenocarcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"LUAD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lung_Adenocarcinoma"},{"name":"Maps_To","value":"52"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0152013"}]}}{"C3493":{"preferredName":"Lung Squamous Cell Carcinoma","code":"C3493","definitions":[{"definition":"A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Squamous Cell Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermoid Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Epidermoid Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"},{"termName":"LSCC","termGroup":"AB","termSource":"NCI"},{"termName":"LUSC","termGroup":"AB","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma of Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Carcinoma of the Lung","termGroup":"SY","termSource":"NCI"},{"termName":"Squamous Cell Lung Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Squamous_Cell_Lung_Carcinoma"},{"name":"Maps_To","value":"60"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0149782"}]}}{"C7558":{"preferredName":"Endometrial Carcinoma","code":"C7558","definitions":[{"definition":"A malignant epithelial neoplasm arising from the lining of the uterine body cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","type":"DEFINITION","source":"NCI"},{"definition":"Cancer that forms in the tissue lining the uterus (the small, hollow, pear-shaped organ in a woman's pelvis in which a fetus develops). Most endometrial cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Endometrial Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"Carcinoma of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Carcinoma of the Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"UCEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrial_Carcinoma"},{"name":"Maps_To","value":"81"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0476089"}]}}{"C19594":{"preferredName":"Not Otherwise Specified","code":"C19594","definitions":[{"definition":"Not characterized in any other way.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Not Otherwise Specified","termGroup":"PT","termSource":"NCI"},{"termName":"NOS","termGroup":"AB","termSource":"NCI"},{"termName":"Not Specified","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Not_Otherwise_Specified"},{"name":"Maps_To","value":"NOS"},{"name":"Maps_To","value":"Not Otherwise Specified"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1518425"}]}}{"C165212":{"preferredName":"Cell Culture Image","code":"C165212","definitions":[{"definition":"Any image of cells grown or manipulated in a tissue culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell Culture Image","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cell Culture Image"},{"name":"NCI_META_CUI","value":"CL978394"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C165215":{"preferredName":"Slide Image","code":"C165215","definitions":[{"definition":"Any image of cells or tissue sections on a slide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Slide Image","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Slide Image"},{"name":"NCI_META_CUI","value":"CL978397"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C171154":{"preferredName":"Tissue Microarray Image","code":"C171154","definitions":[{"definition":"Any image of clinical tissue specimens within a tissue microarray.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tissue Microarray Image","termGroup":"PT","termSource":"NCI"},{"termName":"TMA Image","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tissue Microarray Image"},{"name":"NCI_META_CUI","value":"CL1405378"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C48230":{"preferredName":"JPEG","code":"C48230","definitions":[{"definition":"A file compression format mostly used for color and greyscale photographs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JPEG","termGroup":"PT","termSource":"NCI"},{"termName":"Joint Photographic Experts Group Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"JPEG"},{"name":"Maps_To","value":"JPEG"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1708584"}]}}{"C172214":{"preferredName":"Spectral View Settings Format","code":"C172214","definitions":[{"definition":"An electronic file format based on TIFF that is used for storing multiple high-resolution images in a single electronic file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spectral View Settings Format","termGroup":"PT","termSource":"NCI"},{"termName":"Spectral View Settings","termGroup":"SY","termSource":"NCI"},{"termName":"SVS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SVS"},{"name":"NCI_META_CUI","value":"CL1406108"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C70631":{"preferredName":"TIFF","code":"C70631","definitions":[{"definition":"A bitmap graphics file format utilizing tagged fields.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TIFF","termGroup":"PT","termSource":"NCI"},{"termName":"Tagged Image File Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TIFF"},{"name":"Maps_To","value":"TIFF"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2348636"}]}}{"C184768":{"preferredName":"JPEG 2000 Format","code":"C184768","definitions":[{"definition":"A discrete wavelet transform (DWT)-based compression standard electronic file format for storing video images.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JPEG 2000 Format","termGroup":"PT","termSource":"NCI"},{"termName":"Joint Photographic Experts Group 2000 Format","termGroup":"SY","termSource":"NCI"},{"termName":"JP2","termGroup":"SY","termSource":"NCI"},{"termName":"JPEG 2000","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JPEG 2000"},{"name":"NCI_META_CUI","value":"CL1773097"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C16396":{"preferredName":"Cell Culture","code":"C16396","definitions":[{"definition":"Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. [Source: Medical Subject Headings]  EXAMPLE(S):  OTHER NAME(S):  NOTE(S):","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"Controlled cell proliferation in flasks, fermentors or other devices under defined growth conditions.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"eManu"}]},{"definition":"General term referring to the maintenance of cell strains or lines in the laboratory.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"On-line Medical Dictionary"}]}],"synonyms":[{"termName":"Cell Culture","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cell_Culture"},{"name":"Maps_To","value":"Cell Culture"},{"name":"NCI_META_CUI","value":"CL473433"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C165218":{"preferredName":"Diagnostic Slide","code":"C165218","definitions":[{"definition":"A slide on which a biospecimen has been mounted in order to perform a microscopy-based diagnostic test.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diagnostic Slide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diagnostic Slide"},{"name":"NCI_META_CUI","value":"CL365977"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C165223":{"preferredName":"Tissue Slide","code":"C165223","definitions":[{"definition":"A slide on which a tissue section has been mounted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tissue Slide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tissue Slide"},{"name":"NCI_META_CUI","value":"CL978404"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C23011":{"preferredName":"Hematoxylin and Eosin Staining Method","code":"C23011","definitions":[{"definition":"A microscopy staining method that utilizes two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematoxylin and Eosin Staining Method","termGroup":"PT","termSource":"NCI"},{"termName":"H and E","termGroup":"SY","termSource":"NCI"},{"termName":"H and E Staining","termGroup":"SY","termSource":"NCI"},{"termName":"H and E Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"H&E","termGroup":"SY","termSource":"NCI"},{"termName":"H&E Staining","termGroup":"SY","termSource":"NCI"},{"termName":"H&E Staining Method","termGroup":"SY","termSource":"NCI"},{"termName":"Hematoxylin and Eosin","termGroup":"SY","termSource":"NCI"},{"termName":"Hematoxylin and Eosin Staining","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hematoxylin_and_Eosin_Staining_Method"},{"name":"Maps_To","value":"Haemotoxylin and Eosin (H&E)"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C0523207"}]}}{"C164052":{"preferredName":"Aligned Sequence Read","code":"C164052","definitions":[{"definition":"The determination of the order of a set of sequenced nucleic acid fragments via alignment to a reference genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Sequence Read","termGroup":"PT","termSource":"NCI"},{"termName":"Aligned Read","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aligned Reads"},{"name":"NCI_META_CUI","value":"CL977210"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C153249":{"preferredName":"Binary Alignment Map","code":"C153249","definitions":[{"definition":"A binary representation of a sequence alignment map (SAM), a compact and indexable representation of nucleotide sequence alignments, compressed by the BGZF (Blocked GNU Zip Format) library.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Binary Alignment Map","termGroup":"PT","termSource":"NCI"},{"termName":"BAM","termGroup":"SY","termSource":"NCI"},{"termName":"Binary Alignment/Map","termGroup":"SY","termSource":"NCI"},{"termName":"Binary Sequence Alignment Map","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BAM"},{"name":"NCI_META_CUI","value":"CL554575"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C165220":{"preferredName":"Low-Pass Whole Genome Sequencing","code":"C165220","definitions":[{"definition":"A form of whole genome sequencing where the sequencing read depth falls between 0.1 and 30 times.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low-Pass Whole Genome Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Low Pass WGS","termGroup":"SY","termSource":"NCI"},{"termName":"Low Pass Whole Genome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Pass WGS","termGroup":"SY","termSource":"NCI"},{"termName":"Low-Pass Whole-Genome Sequencing","termGroup":"SY","termSource":"NCI"},{"termName":"LP WGS","termGroup":"AB","termSource":"NCI"},{"termName":"LP-WGS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Low Pass WGS"},{"name":"NCI_META_CUI","value":"CL978401"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C94411":{"preferredName":"Genomic Profile","code":"C94411","definitions":[{"definition":"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Genomic Profile","termGroup":"PT","termSource":"NCI"},{"termName":"Genome Profile","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Profiling","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Test","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Testing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genomic Profiling"},{"name":"Maps_To","value":"submitted_genomic_profile"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2986505"}]}}{"C171155":{"preferredName":"Combined Nucleotide Variation Profile","code":"C171155","definitions":[{"definition":"A genomic profile that includes all of the genome variants and/or polymorphisms detected during nucleotide sequencing of one or more samples derived from an individual subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combined Nucleotide Variation Profile","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Combined Nucleotide Variation"},{"name":"NCI_META_CUI","value":"CL1405377"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184758":{"preferredName":"FoundationOne Report","code":"C184758","definitions":[{"definition":"A document provided by FoundationOne listing the sequence variants, genetic aberrations and tumor biomarker-related findings detected in a solid or liquid tumor sample subjected to their proprietary companion diagnostic (CDx) testing. The report also may contain select clinical data related to the findings.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FoundationOne Report","termGroup":"PT","termSource":"NCI"},{"termName":"FoundationOne CDx Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FoundationOne Report"},{"name":"NCI_META_CUI","value":"CL1773075"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184760":{"preferredName":"GENIE Report","code":"C184760","definitions":[{"definition":"A document that reports the sequence variants, genetic aberrations and tumor biomarker-related findings detected in a tumor sample and compares the findings to data stored the Genomics Evidence Neoplasia Information Exchange (GENIE) registry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GENIE Report","termGroup":"PT","termSource":"NCI"},{"termName":"Genomics Evidence Neoplasia Information Exchange Report","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GENIE Report"},{"name":"NCI_META_CUI","value":"CL1773089"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184794":{"preferredName":"Raw CpG Island Variation Data","code":"C184794","definitions":[{"definition":"CpG island sequence variation data that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw CpG Island Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw CGI Variant Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw CGI Variation Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw CpG Island Variant Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw CGI Variant"},{"name":"NCI_META_CUI","value":"CL1772992"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C172215":{"preferredName":"Mutation Annotation Format","code":"C172215","definitions":[{"definition":"A tab-delimited text file containing mutation information aggregated from variant call files (VCF) across a project, trial or study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutation Annotation Format","termGroup":"PT","termSource":"NCI"},{"termName":"MAF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"MAF"},{"name":"NCI_META_CUI","value":"CL1406107"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172216":{"preferredName":"Variant Call File Format","code":"C172216","definitions":[{"definition":"A text-based electronic file used for storing gene sequence variation data. The first text section is composed of a header containing the metadata and keywords used in the file. This is followed by the body of the file which is tab-separated into eight mandatory data columns for each sample. Additionally, the body of the file can include an unlimited number of optional columns to record other sample-related data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Variant Call File Format","termGroup":"PT","termSource":"NCI"},{"termName":"Variant Call File","termGroup":"SY","termSource":"NCI"},{"termName":"VCF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Maps_To","value":"VCF"},{"name":"NCI_META_CUI","value":"CL1406106"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C45967":{"preferredName":"Extensible Markup Language","code":"C45967","definitions":[{"definition":"A general-purpose markup language for creating special-purpose markup languages. It is capable of describing many different kinds of data. Its primary purpose is to facilitate the sharing of data across different systems, particularly systems connected via the Internet.","type":"DEFINITION","source":"NCI"},{"definition":"A set of rules for encoding documents and data in a format that is both human readable and machine readable. [After Study Data Technical Conformance Guide, Technical Specifications Document, March 2019; After W3C Extensible Markup Language (XML)] See also eXtensible markup language (XML) data element, Define-XML.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Extensible Markup Language","termGroup":"PT","termSource":"NCI"},{"termName":"XML","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Extensible_Markup_Language"},{"name":"Maps_To","value":"XML"},{"name":"Semantic_Type","value":"Language"},{"name":"UMLS_CUI","value":"C1707981"}]}}{"C63328":{"preferredName":"DNA Methylation Analysis","code":"C63328","definitions":[{"definition":"The analysis of the methylated deoxyribonucleotides present in the genome in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Methylation Analysis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DNA_Methylation_Analysis"},{"name":"Maps_To","value":"DNA Methylation"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1880239"}]}}{"C164051":{"preferredName":"Methylation Beta Value","code":"C164051","definitions":[{"definition":"An estimate for the level of DNA methylation in a set of replicate samples that is calculated as the ratio of average signal intensities for methylated alleles divided by the average signal intensities of methylated alleles (M) plus unmethylated alleles (U) plus an offset factor (a), such that beta (b) equals M/(M+U+a). Beta values must fall between zero and one.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylation Beta Value","termGroup":"PT","termSource":"NCI"},{"termName":"Beta Value","termGroup":"SY","termSource":"NCI"},{"termName":"DNA Methylation Beta Value","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methylation Beta Value"},{"name":"NCI_META_CUI","value":"CL977211"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C85873":{"preferredName":"Plain Text Data Format","code":"C85873","definitions":[{"definition":"A data format consisting of readable textual material maintained as a sequential file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plain Text Data Format","termGroup":"PT","termSource":"NCI"},{"termName":"TXT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TXT"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2828004"}]}}{"C165222":{"preferredName":"DNA Methylation Array","code":"C165222","definitions":[{"definition":"The use of a high-throughput microarray where all of the known CpG islands either in a single specimen or all of the known promoter sequences of a specimen or a population group are coupled to beads or microwells to determine which are methylated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Methylation Array","termGroup":"PT","termSource":"NCI"},{"termName":"Methylation Array","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methylation Array"},{"name":"NCI_META_CUI","value":"CL978403"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C200431":{"preferredName":"Illumina Infinium Methylation BeadChip System","code":"C200431","definitions":[{"definition":"A platform that leverages bisulfite conversion with proprietary high-throughput silica beads on a chip microarray libraries, sequencing technology and sequence analysis tools developed by Illumina to analyze genome- and epigenome-wide DNA methylation at single nucleotide resolution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Illumina Infinium Methylation BeadChip System","termGroup":"PT","termSource":"NCI"},{"termName":"Illumina Infinium Methylation BeadChip Assay System","termGroup":"SY","termSource":"NCI"},{"termName":"Illumina Methylation","termGroup":"SY","termSource":"NCI"},{"termName":"Illumina Methylation Assay System","termGroup":"SY","termSource":"NCI"},{"termName":"Infinium Methylation BeadChip System","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Illumina Human Methylation 27"},{"name":"Maps_To","value":"Illumina Human Methylation 450"},{"name":"Maps_To","value":"Illumina Methylation Epic"},{"name":"Maps_To","value":"Illumina Methylation Epic v2"},{"name":"NCI_META_CUI","value":"CL1907432"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C40207":{"preferredName":"Copy Number Polymorphism","code":"C40207","definitions":[{"definition":"Refers to the genetic trait involving the number of copies of a particular gene present in the genome of an individual. Genetic variants, including insertions, deletions, and duplications of segments of DNA, are also collectively referred to as copy number variants. Copy number variants account for a significant proportion of the genetic variation between individuals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Variation in the number of copies of a particular sequence within the genetic material of an individual. Large-scale copy number polymorphisms are common and widely distributed in the human genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copy Number Polymorphism","termGroup":"PT","termSource":"NCI"},{"termName":"CNA","termGroup":"AB","termSource":"NCI"},{"termName":"CNP","termGroup":"AB","termSource":"NCI"},{"termName":"CNV","termGroup":"AB","termSource":"NCI"},{"termName":"Copy Number Alteration","termGroup":"SY","termSource":"NCI"},{"termName":"Copy Number Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Copy_Number_Polymorphism"},{"name":"Maps_To","value":"Copy Number Variation"},{"name":"Semantic_Type","value":"Nucleotide Sequence"},{"name":"UMLS_CUI","value":"C1511518"}]}}{"C165213":{"preferredName":"Copy Number Estimate","code":"C165213","definitions":[{"definition":"An estimation on the number of copies of a nucleic acid sequence of interest found in a sample using an algorithm that is based on the length and average mass of the sequence of interest and/or involves the normalization of a set of results gathered from similar samples or duplicate runs of a single sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copy Number Estimate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Copy Number Estimate"},{"name":"NCI_META_CUI","value":"CL978395"},{"name":"Semantic_Type","value":"Research Activity"}]}}{"C165219":{"preferredName":"Genotyping Array","code":"C165219","definitions":[{"definition":"The application of microarray technology to the determination of the nucleotide sequence of the genetic material of an individual.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genotyping Array","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genotyping Array"},{"name":"NCI_META_CUI","value":"CL978400"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C164053":{"preferredName":"Unaligned Sequence Read","code":"C164053","definitions":[{"definition":"A set of sequenced nucleic acid fragments that have not been aligned to each other or to a reference sequence or genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unaligned Sequence Read","termGroup":"PT","termSource":"NCI"},{"termName":"Unaligned Read","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unaligned Reads"},{"name":"NCI_META_CUI","value":"CL977209"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C153250":{"preferredName":"FASTQ Format","code":"C153250","definitions":[{"definition":"A text-based format for storing a biological sequence that encodes the nucleotide calls as well as their quality scores. It is an extension of the FASTA format.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FASTQ Format","termGroup":"PT","termSource":"NCI"},{"termName":"FASTQ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FASTQ"},{"name":"NCI_META_CUI","value":"CL554479"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C172301":{"preferredName":"Read Pair 1","code":"C172301","definitions":[{"definition":"The read direction identified as number 1 in a paired-end nucleotide sequencing reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Read Pair 1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"R1"},{"name":"NCI_META_CUI","value":"CL1406307"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C172302":{"preferredName":"Read Pair 2","code":"C172302","definitions":[{"definition":"The read direction identified as number 2 in a paired-end nucleotide sequencing reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Read Pair 2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"R2"},{"name":"NCI_META_CUI","value":"CL1406328"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C156813":{"preferredName":"Initial Diagnosis","code":"C156813","definitions":[{"definition":"The first diagnosis of the disease.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The first diagnosis of the individual's condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Initial Diagnosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Adulthood"},{"name":"Maps_To","value":"Initial Diagnosis"},{"name":"NCI_META_CUI","value":"CL935841"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C35571":{"preferredName":"Progressive Disease","code":"C35571","definitions":[{"definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","type":"DEFINITION","source":"NCI"},{"definition":"A disease process that is increasing in extent or severity. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Progressive Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Progressive_Disease"},{"name":"Maps_To","value":"PD-Progressive Disease"},{"name":"Maps_To","value":"Progressive Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1335499"}]}}{"C38155":{"preferredName":"Recurrent Disease","code":"C38155","definitions":[{"definition":"The return of a disease after a period of remission.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"The return of a disease after a period of remission.","type":"DEFINITION","source":"NCI"},{"definition":"The return of a disease after a period of remission.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The return of a disease after a period of remission.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"The return of a disease or the signs and symptoms of a disease after a period of improvement.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recurrent Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Relapse","termGroup":"SY","termSource":"NCI"},{"termName":"Relapse, Site Not Specified","termGroup":"SY","termSource":"NCI"},{"termName":"Relapsed Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Recurrent_Disease"},{"name":"Maps_To","value":"Recurrence"},{"name":"Maps_To","value":"Recurrent Disease"},{"name":"Maps_To","value":"Relapse"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0277556"}]}}{"C4809":{"preferredName":"Residual Disease","code":"C4809","definitions":[{"definition":"Cancer cells that remain after attempts to remove the cancer have been made.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Tumor cells that remain in the body following cancer treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Residual Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Residual Tumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Residual_Disease"},{"name":"Maps_To","value":"Residual Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0543478"}]}}{"C90169":{"preferredName":"Persistent Disease","code":"C90169","definitions":[{"definition":"A disease that does not go to remission despite treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Persistent Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Persistent Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2983415"}]}}{"C39752":{"preferredName":"Refractory Disease","code":"C39752","definitions":[{"definition":"A disease that is not responsive to treatment.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disease that resists treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refractory Disease","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Refractory_Disease"},{"name":"Maps_To","value":"Refractory Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1514815"}]}}{"C41331":{"preferredName":"Adverse Event","code":"C41331","definitions":[{"definition":"An unexpected medical problem that happens during treatment with a drug or other therapy. Adverse effects do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any health problem that happens during the study. (https://mrctcenter.org/glossaryterm/adverse-event/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"},{"definition":"Any unfavorable and unintended sign, symptom, disease, or other medical occurrence with a temporal association with the use of a medical product, procedure or other therapy, or in conjunction with a research study, regardless of causal relationship.   EXAMPLE(S): death, back pain, headache, pulmonary embolism, heart attack  OTHER NAME(S):  NOTE(S): The BRIDG SCC has a GForge Tracker Issue (#31893) indicating a need to validate the requirement that every AdverseEvent be described by a SafetyReportVersion.","type":"ALT_DEFINITION","source":"BRIDG 5.3"},{"definition":"Any unfavorable and unintended sign, symptom, disease, or other medical occurrence with a temporal association with the use of a medical product, procedure or other therapy, or in conjunction with a research study, regardless of causal relationship. EXAMPLE(S): death, back pain, headache, pulmonary embolism, heart attack","type":"ALT_DEFINITION","source":"BRIDG 3.0.3"},{"definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","type":"DEFINITION","source":"NCI"},{"definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. NOTE: For further information, see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. [Modified from ICH E2A] Synonyms: side effect, adverse experience. See also serious adverse event, serious adverse experience. (CDISC glossary)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. an adverse event (AE) can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. NOTE: For further information, see the ICH Guideline for Clinical safety Data Management: Definitions and standards for expedited Reporting. [After ICH E2A] See also serious adverse event, serious adverse experience.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"}],"synonyms":[{"termName":"Adverse Event","termGroup":"PT","termSource":"NCI"},{"termName":"Adverse Experience","termGroup":"SY","termSource":"NCI"},{"termName":"AE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Adverse_Event"},{"name":"Maps_To","value":"Adverse Event"},{"name":"Maps_To","value":"Adverse Event/Complications"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0877248"}]}}{"C82568":{"preferredName":"Study Medication Completed","code":"C82568","definitions":[{"definition":"An indication or description that the planned amount of medication was taken by the subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Study Medication Completed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Study_Medication_Completed"},{"name":"Maps_To","value":"Course of Therapy Completed"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C2826299"}]}}{"C49634":{"preferredName":"Withdrawal by Subject","code":"C49634","definitions":[{"definition":"An indication that a study participant has removed themself from the study or from one or more segments of the study.","type":"DEFINITION","source":"NCI"},{"definition":"The subject-initiated act of discontinuing participation in a clinical study. NOTE: Withdrawal can range from the subject's complete withdrawal from study procedures and follow-up activities, to the subject's withdrawal from study-related interventions. [After Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues, September 21, 2010] See also discontinuation.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"The subject-initiated act of discontinuing participation in the study as a whole or one or more aspects of the study (e.g., a study period or use of biospecimens).","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"To stop being a participant in a study. (https://mrctcenter.org/glossaryterm/withdraw/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Withdrawal by Subject","termGroup":"PT","termSource":"NCI"},{"termName":"Subject Dropped Out","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Withdrawal_by_Subject"},{"name":"Maps_To","value":"Withdrawal by Subject"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C1710677"}]}}{"C13041":{"preferredName":"Body","code":"C13041","definitions":[{"definition":"The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces.","type":"DEFINITION","source":"NCI"},{"definition":"The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Body"},{"name":"Maps_To","value":"Body, total"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C1268086"}]}}{"C179433":{"preferredName":"Distant Site Receiving Treatment","code":"C179433","definitions":[{"definition":"The anatomic site that is located away from the primary disease site and is the target of a medical intervention.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Distant Site Receiving Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Treatment of Distant Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Distant Site"},{"name":"NCI_META_CUI","value":"CL1662207"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C165193":{"preferredName":"Epitrochlear Region","code":"C165193","definitions":[{"definition":"The inner surface of the upper arm adjacent to the elbow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epitrochlear Region","termGroup":"PT","termSource":"NCI"},{"termName":"Epitrochlear","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epitrochlear"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0450279"}]}}{"C13359":{"preferredName":"Gastrointestinal","code":"C13359","definitions":[{"definition":"Pertaining to the stomach and intestines.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to the stomach and intestines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Relating to the stomach or duodenum as the intended site of administration, where direct administration is achieved using an appropriate device.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Gastrointestinal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrointestinal"},{"name":"Maps_To","value":"Gastrointestinal, Intestine"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0521362"}]}}{"C25350":{"preferredName":"Genitourinary","code":"C25350","definitions":[{"definition":"Of or related to the genital and urinary organs or their functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genitourinary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Genitourinary"},{"name":"Maps_To","value":"Genitourinary, NOS"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C3887515"}]}}{"C25724":{"preferredName":"Hilar","code":"C25724","definitions":[{"definition":"Refers to the area associated with the hilum.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to the area associated with the hilum. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Refers to the area where nerves and blood vessels attach to an organ.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hilar","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hilar"},{"name":"Maps_To","value":"Hilar"},{"name":"NCI_META_CUI","value":"CL053209"},{"name":"Semantic_Type","value":"Spatial Concept"}]}}{"C13066":{"preferredName":"Ileocecal Valve","code":"C13066","definitions":[{"definition":"The valve between the ileum of the small intestine and the cecum of the large intestine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ileocecal Valve","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ileocecal_Valve"},{"name":"Maps_To","value":"Ileocecal Valve"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0020880"}]}}{"C12507":{"preferredName":"Mantle Field","code":"C12507","definitions":[{"definition":"A type of extended radiation field that includes lymph node areas in the neck, chest, and axilla.","type":"DEFINITION","source":"NCI"},{"definition":"The area of the neck, chest, and lymph nodes in the armpit that are exposed to radiation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mantle Field","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mantle_Field"},{"name":"Maps_To","value":"Mantle"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C1512986"}]}}{"C43200":{"preferredName":"Pouch","code":"C43200","definitions":[{"definition":"A flexible container used to protect or hold one or more doses of a drug product (e.g. a pouch into which oral contraceptive blister packs are inserted, and an overwrap pouch for large volume parenterals).","type":"ALT_DEFINITION","source":"PQCMC"},{"definition":"A flexible container used to protect or hold one or more doses of a drug product (e.g. a pouch into which oral contraceptive blister packs are inserted, and an overwrap pouch for large volume parenterals).","type":"DEFINITION","source":"NCI"},{"definition":"Item of packaging intended for use as an intermediate or outer container, intended to contain one or more medicinal product(s); it is made of a flexible material and may be for single use or be re-usable, and may be fitted with a closure system. Bags and sachets are excluded.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Pouch","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Package Type (C-DRG-00907)"},{"name":"Legacy Concept Name","value":"Drug_Pouch"},{"name":"Maps_To","value":"Pouch"},{"name":"NCI_META_CUI","value":"CL333395"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C179450":{"preferredName":"Primary Tumor Field","code":"C179450","definitions":[{"definition":"The anatomic site(s) surrounding and including a primary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Tumor Field","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Primary Tumor Field"},{"name":"NCI_META_CUI","value":"CL1662308"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C179451":{"preferredName":"Primary Tumor Site","code":"C179451","definitions":[{"definition":"The anatomic location of a primary tumor.","type":"DEFINITION","source":"NCI"},{"definition":"The anatomical location of the primary tumor site of disease.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Primary Tumor Site","termGroup":"PT","termSource":"NCI"},{"termName":"Anatomic Site of Primary Tumor Origin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Primary tumor site"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0475447"}]}}{"C90348":{"preferredName":"Prostate Bed","code":"C90348","definitions":[{"definition":"The anatomical space just below the bladder within which the prostate is situated.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The cavity just below the bladder where the prostate gland is located.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Bed","termGroup":"PT","termSource":"NCI"},{"termName":"Prostate Fossa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prostate Bed"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2983573"}]}}{"C179457":{"preferredName":"Regional Site Receiving Treatment","code":"C179457","definitions":[{"definition":"The anatomic site that is located near the primary disease site and is targeted by a medical intervention.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regional Site Receiving Treatment","termGroup":"PT","termSource":"NCI"},{"termName":"Treatment of Regional Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Regional Site"},{"name":"NCI_META_CUI","value":"CL1662286"},{"name":"Semantic_Type","value":"Body Location or Region"}]}}{"C164047":{"preferredName":"Skin of the Lower Extremity","code":"C164047","definitions":[{"definition":"The integument that covers the lower limb.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The integumentary covering of the lower extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Lower Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Lower Extremity Skin","termGroup":"SY","termSource":"NCI"},{"termName":"Skin of the Lower Limb","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin, lower extremity, local"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C1266887"}]}}{"C164048":{"preferredName":"Skin of the Upper Extremity","code":"C164048","definitions":[{"definition":"The integument that covers the upper limb.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The integumentary covering of the upper extremities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Skin of the Upper Extremity","termGroup":"PT","termSource":"NCI"},{"termName":"Skin of the Upper Limb","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Extremity Skin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Skin, upper extremity, local"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0205032"}]}}{"C64693":{"preferredName":"Centigray","code":"C64693","definitions":[{"definition":"The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Centigray","termGroup":"PT","termSource":"NCI"},{"termName":"cGy","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Centigray"},{"name":"Maps_To","value":"cGy"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0556645"}]}}{"C18063":{"preferredName":"Gray","code":"C18063","definitions":[{"definition":"A SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gray","termGroup":"PT","termSource":"NCI"},{"termName":"Gy","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gray"},{"name":"Maps_To","value":"Gy"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0556636"}]}}{"C28253":{"preferredName":"Milligram","code":"C28253","definitions":[{"definition":"A measure of weight.  A milligram is approximately 450,000 times smaller than a pound and 28,000 times smaller than an ounce.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass equal to one thousandth (1E-3) of a gram.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram","termGroup":"PT","termSource":"NCI"},{"termName":"mg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Milligram"},{"name":"Maps_To","value":"mg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439210"}]}}{"C64774":{"preferredName":"Area Under Curve","code":"C64774","definitions":[{"definition":"The area between the x-axis and the curve given by the integrand, equal to the definite integral of a function. For the purpose of pharmacokinetic measurements, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in tissue, blood, or other body fluid against time.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The area between the x-axis and the curve given by the integrand. It is equal to the definite integral of a function. In the field of pharmacokinetics, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in plasma against time. AUC is usually given for the time interval zero to infinity, and other time intervals are indicated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Area Under Curve","termGroup":"PT","termSource":"NCI"},{"termName":"AUC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Area_under_Curve"},{"name":"Maps_To","value":"AUC"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0376690"}]}}{"C67372":{"preferredName":"Gram per 24 Hours","code":"C67372","definitions":[{"definition":"A metric mass flow rate unit equal to the rate at which mass of matter of one gram crosses a given surface or/and is transferred over a period of twenty four hours.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass flow rate equal to one gram per day.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gram per 24 Hours","termGroup":"PT","termSource":"NCI"},{"termName":"g/24h","termGroup":"AB","termSource":"NCI"},{"termName":"g/d","termGroup":"AB","termSource":"NCI"},{"termName":"Gram/24 Hours","termGroup":"SY","termSource":"NCI"},{"termName":"gram/day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_24_Hours"},{"name":"Maps_To","value":"g/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439417"}]}}{"C67282":{"preferredName":"Gram per Square Meter","code":"C67282","definitions":[{"definition":"A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of area density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gram per Square Meter","termGroup":"PT","termSource":"NCI"},{"termName":"g/m2","termGroup":"AB","termSource":"NCI"},{"termName":"Gram per Meter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"Gram/Square Meter","termGroup":"SY","termSource":"NCI"},{"termName":"gsm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_Square_Meter"},{"name":"Maps_To","value":"g/m2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1300564"}]}}{"C67379":{"preferredName":"International Unit per Kilogram","code":"C67379","definitions":[{"definition":"A unit of measure of a quantity of substance per unit mass, expressed as the quantity of substance in International Units, divided by the mass of the substance in kilograms. It is also used as a dose calculation unit expressed in International Units of biological activity per one kilogram of body mass.","type":"DEFINITION","source":"NCI"},{"definition":"An arbitrary unit of substance content expressed in international units of biological activity per one kilogram of mass of the system. It is also used as a dose calculation unit expressed in international units of biological activity per one kilogram of body mass.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"International Unit per Kilogram","termGroup":"PT","termSource":"NCI"},{"termName":"[iU]/kg","termGroup":"AB","termSource":"NCI"},{"termName":"International Unit/Kilogram","termGroup":"SY","termSource":"NCI"},{"termName":"iU/kg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"International_Unit_per_Kilogram"},{"name":"Maps_To","value":"IU/kg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439463"}]}}{"C67380":{"preferredName":"International Unit per Milligram","code":"C67380","definitions":[{"definition":"A unit of measure of quantity of substance per unit mass, expressed in terms of International Units per milligram. (CDISC)","type":"DEFINITION","source":"NCI"},{"definition":"A unit of measure of quantity of substance per unit mass, expressed in terms of international units per milligram.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"International Unit per Milligram","termGroup":"PT","termSource":"NCI"},{"termName":"[iU]/mg","termGroup":"AB","termSource":"NCI"},{"termName":"International Unit/Milligram","termGroup":"SY","termSource":"NCI"},{"termName":"iU/mg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"International_Unit_per_Milligram"},{"name":"Maps_To","value":"IU/mg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1319632"}]}}{"C48511":{"preferredName":"Millicurie","code":"C48511","definitions":[{"definition":"A unit of radioactivity equal to one thousandth of a Curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.(NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of radioactivity equal to one thousandth of a curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Millicurie","termGroup":"PT","termSource":"NCI"},{"termName":"mCi","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Millicurie"},{"name":"Maps_To","value":"mCi"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0560005"}]}}{"C48512":{"preferredName":"Milliequivalent","code":"C48512","definitions":[{"definition":"A unit of relative amount of a substance equal to one thousandth of an equivalent weight.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of relative amount of a substance equal to one thousandth of an equivalent weight.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milliequivalent","termGroup":"PT","termSource":"NCI"},{"termName":"mEq","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Milliequivalent"},{"name":"Maps_To","value":"mEq"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439152"}]}}{"C67399":{"preferredName":"Milligram per 24 Hours","code":"C67399","definitions":[{"definition":"A unit of mass flow rate equal to one milligram per day.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milligram per 24 Hours","termGroup":"PT","termSource":"NCI"},{"termName":"mg/24h","termGroup":"AB","termSource":"NCI"},{"termName":"mg/d","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_24_Hours"},{"name":"Maps_To","value":"mg/24 hr"},{"name":"Maps_To","value":"mg/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439422"}]}}{"C67015":{"preferredName":"Milligram per Deciliter","code":"C67015","definitions":[{"definition":"A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Deciliter","termGroup":"PT","termSource":"NCI"},{"termName":"mg/dL","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram/Deciliter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Deciliter"},{"name":"Maps_To","value":"mg/dL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439269"}]}}{"C67401":{"preferredName":"Milligram per Kilogram","code":"C67401","definitions":[{"definition":"A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.","type":"DEFINITION","source":"NCI"},{"definition":"Milligrams (weight), divided by kilograms (weight) or nanograms (weight) per milligrams (weight).","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Kilogram","termGroup":"PT","termSource":"NCI"},{"termName":"ag/pg","termGroup":"AB","termSource":"NCI"},{"termName":"Attogram per Picogram","termGroup":"SY","termSource":"NCI"},{"termName":"Femtogram per Nanogram","termGroup":"SY","termSource":"NCI"},{"termName":"fg/ng","termGroup":"AB","termSource":"NCI"},{"termName":"mcg/g","termGroup":"AB","termSource":"NCI"},{"termName":"mg/kg","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Gram","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/Kilogram","termGroup":"SY","termSource":"NCI"},{"termName":"Nanogram per Milligram","termGroup":"SY","termSource":"NCI"},{"termName":"ng/mg","termGroup":"AB","termSource":"NCI"},{"termName":"pg/mcg","termGroup":"AB","termSource":"NCI"},{"termName":"pg/ug","termGroup":"AB","termSource":"NCI"},{"termName":"Picogram per Microgram","termGroup":"SY","termSource":"NCI"},{"termName":"ug/g","termGroup":"AB","termSource":"NCI"},{"termName":"yg/ag","termGroup":"AB","termSource":"NCI"},{"termName":"Yoctogram per Attogram","termGroup":"SY","termSource":"NCI"},{"termName":"Zeptogram per Femtogram","termGroup":"SY","termSource":"NCI"},{"termName":"zg/fg","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Kilogram"},{"name":"Maps_To","value":"mg/kg"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439272"}]}}{"C66976":{"preferredName":"Milligram per Kilogram per Day","code":"C66976","definitions":[{"definition":"A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours.","type":"DEFINITION","source":"NCI"},{"definition":"A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Kilogram per Day","termGroup":"PT","termSource":"NCI"},{"termName":"mg/kg/d","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Kilogram per 24 Hours","termGroup":"SY","termSource":"NCI"},{"termName":"milligram/kilogram/day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Milligram_per_Kilogram_per_Day"},{"name":"Maps_To","value":"mg/kg/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C3665414"}]}}{"C67402":{"preferredName":"Milligram per Square Meter","code":"C67402","definitions":[{"definition":"A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of area density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Square Meter","termGroup":"PT","termSource":"NCI"},{"termName":"mg/m2","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Meter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/Square Meter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Square_Meter"},{"name":"Maps_To","value":"mg/m2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1319266"}]}}{"C66974":{"preferredName":"Milligram per Square Meter per Day","code":"C66974","definitions":[{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours.","type":"DEFINITION","source":"NCI"},{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Square Meter per Day","termGroup":"PT","termSource":"NCI"},{"termName":"mg/m2/d","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram per Square Meter per 24 Hours","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/meter2/day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Milligram_per_Square_Meter_per_Day"},{"name":"Maps_To","value":"mg/m2/day"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1532575"}]}}{"C88148":{"preferredName":"Milligram per Square Meter per Week","code":"C88148","definitions":[{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milligram per Square Meter per Week","termGroup":"PT","termSource":"NCI"},{"termName":"mg/m2/week","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram/meter2/week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mg/m2/wk"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C2981713"}]}}{"C42576":{"preferredName":"Kilogram per Cubic Meter","code":"C42576","definitions":[{"definition":"A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of concentration or mass density equal to one milligram of substance per milliliter of solution or one gram of substance per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kilogram per Cubic Meter","termGroup":"PT","termSource":"NCI"},{"termName":"g/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"g/L","termGroup":"AB","termSource":"NCI"},{"termName":"Gram per Cubic Decimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Gram per Liter","termGroup":"SY","termSource":"NCI"},{"termName":"kg/m3","termGroup":"AB","termSource":"NCI"},{"termName":"Kilogram/Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"mg/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"ug/uL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Kilogram_per_Cubic_Meter"},{"name":"Maps_To","value":"g/L"},{"name":"Maps_To","value":"mg/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439294"}]}}{"C67404":{"preferredName":"Milligram per Week","code":"C67404","definitions":[{"definition":"A dose administration rate unit equal to the rate at which one thousandth of a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass flow rate equal to one milligram per week or a dose administration rate unit equal to the rate at which a milligram of a product is delivered or administered over the time period of one week.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milligram per Week","termGroup":"PT","termSource":"NCI"},{"termName":"mg/wk","termGroup":"AB","termSource":"NCI"},{"termName":"Milligram/Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milligram_per_Week"},{"name":"Maps_To","value":"mg/wk"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1881833"}]}}{"C67316":{"preferredName":"Milliinternational Unit","code":"C67316","definitions":[{"definition":"A unit equal to one-thousandth of an international unit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milliinternational Unit","termGroup":"PT","termSource":"NCI"},{"termName":"m[iU]","termGroup":"AB","termSource":"NCI"},{"termName":"Milli-International Unit","termGroup":"SY","termSource":"NCI"},{"termName":"miU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Milliinternational_Unit"},{"name":"Maps_To","value":"mIU"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439455"}]}}{"C28254":{"preferredName":"Milliliter","code":"C28254","definitions":[{"definition":"A measure of volume in the metric system. One thousand ccs equal one liter.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of volume equal to one thousandth (1E-3) of a liter.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"cc","termGroup":"AB","termSource":"NCI"},{"termName":"cm3","termGroup":"AB","termSource":"NCI"},{"termName":"cu cm","termGroup":"AB","termSource":"NCI"},{"termName":"Cubic Centimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"mL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Milliliter"},{"name":"Maps_To","value":"mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439242"}]}}{"C48152":{"preferredName":"Microgram","code":"C48152","definitions":[{"definition":"A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass equal to one millionth (1E-6) of a gram.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"One millionth of a gram.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Microgram","termGroup":"PT","termSource":"NCI"},{"termName":"mcg","termGroup":"AB","termSource":"NCI"},{"termName":"ug","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Microgram"},{"name":"Maps_To","value":"ug"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439211"}]}}{"C67312":{"preferredName":"Microgram per Square Meter","code":"C67312","definitions":[{"definition":"A dose calculation unit expressed in microgram(s) per square meter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A metric unit of areal density equal to approximately 2.94935E-8 ounce per square yard. Also used as a dose calculation unit.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microgram per Square Meter","termGroup":"PT","termSource":"NCI"},{"termName":"mcg/m2","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Meter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"Microgram/Square Meter","termGroup":"SY","termSource":"NCI"},{"termName":"ug/m2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Microgram_per_Square_Meter"},{"name":"Maps_To","value":"ug/m2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1319267"}]}}{"C48552":{"preferredName":"Wafer Dosing Unit","code":"C48552","definitions":[{"definition":"A dosing measurement based on the wafer unit.(NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A dosing unit equal to the amount of active ingredient(s) contained in a wafer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wafer Dosing Unit","termGroup":"PT","termSource":"NCI"},{"termName":"Wafer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Wafer_Dosing_Unit"},{"name":"Maps_To","value":"Wafer"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1706425"}]}}{"C156234":{"preferredName":"Complete Tumor Cell Necrosis","code":"C156234","definitions":[{"definition":"A morphologic finding indicating the presence of tumor cell necrosis involving the entire neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Complete Tumor Cell Necrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Complete Necrosis (No Viable Tumor)"},{"name":"NCI_META_CUI","value":"CL562940"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156235":{"preferredName":"Incomplete Tumor Cell Necrosis","code":"C156235","definitions":[{"definition":"A morphologic finding indicating the presence of focal or diffuse tumor cell necrosis involving part of the neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are still present.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Incomplete Tumor Cell Necrosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Incomplete Necrosis (Viable Tumor Present)"},{"name":"NCI_META_CUI","value":"CL562941"},{"name":"Semantic_Type","value":"Finding"}]}}{"C168971":{"preferredName":"Necrosis Negative","code":"C168971","definitions":[{"definition":"An indication that signs of necrosis were not found in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necrosis Negative","termGroup":"PT","termSource":"NCI"},{"termName":"Negative for Necrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Necrosis"},{"name":"NCI_META_CUI","value":"CL1379139"},{"name":"Semantic_Type","value":"Finding"}]}}{"C164134":{"preferredName":"No Effect","code":"C164134","definitions":[{"definition":"A subjective response indicating that something has or had no effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Effect","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Known Treatment Effect"},{"name":"NCI_META_CUI","value":"CL978353"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C64510":{"preferredName":"Every Hour","code":"C64510","definitions":[{"definition":"Every hour.","type":"DEFINITION","source":"NCI"},{"definition":"Every hour. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Every Hour","termGroup":"PT","termSource":"NCI"},{"termName":"Hourly","termGroup":"SY","termSource":"NCI"},{"termName":"QH","termGroup":"AB","termSource":"NCI"},{"termName":"quaque hora","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Every_Hour"},{"name":"Maps_To","value":"Every Hour"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0558292"}]}}{"C98849":{"preferredName":"Five Times Daily","code":"C98849","definitions":[{"definition":"Five times per day.","type":"DEFINITION","source":"NCI"},{"definition":"Five times per day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Five Times Daily","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Five Times Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0585292"}]}}{"C64530":{"preferredName":"Four Times Daily","code":"C64530","definitions":[{"definition":"Four times per day.","type":"DEFINITION","source":"NCI"},{"definition":"Four times per day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Four Times Daily","termGroup":"PT","termSource":"NCI"},{"termName":"Four times a day","termGroup":"SY","termSource":"NCI"},{"termName":"QID","termGroup":"AB","termSource":"NCI"},{"termName":"quarter in die","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Four_Times_Daily"},{"name":"Maps_To","value":"Four Times Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0585291"}]}}{"C64527":{"preferredName":"Three Times Daily","code":"C64527","definitions":[{"definition":"Three times per day.","type":"DEFINITION","source":"NCI"},{"definition":"Three times per day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Three Times Daily","termGroup":"PT","termSource":"NCI"},{"termName":"ter in die","termGroup":"SY","termSource":"NCI"},{"termName":"Three times a day","termGroup":"SY","termSource":"NCI"},{"termName":"TID","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Three_Times_Daily"},{"name":"Maps_To","value":"Three Times Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0556984"}]}}{"C64496":{"preferredName":"Twice Daily","code":"C64496","definitions":[{"definition":"Two times per day, at unspecified times.","type":"DEFINITION","source":"NCI"},{"definition":"Two times per day, at unspecified times. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Twice Daily","termGroup":"PT","termSource":"NCI"},{"termName":"BID","termGroup":"SY","termSource":"NCI"},{"termName":"bis in die","termGroup":"SY","termSource":"NCI"},{"termName":"Twice a day","termGroup":"SY","termSource":"NCI"},{"termName":"Two Times per Day","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Twice_Daily"},{"name":"Maps_To","value":"Twice Daily"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0585361"}]}}{"C64515":{"preferredName":"Every Twenty-Four Hours","code":"C64515","definitions":[{"definition":"Every twenty-four hours.","type":"DEFINITION","source":"NCI"},{"definition":"Every twenty-four hours. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Every Twenty-Four Hours","termGroup":"PT","termSource":"NCI"},{"termName":"Every 24 hours","termGroup":"SY","termSource":"NCI"},{"termName":"Q24H","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Every_Twenty-Four_Hours"},{"name":"Maps_To","value":"Every 24 Hours"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C1275548"}]}}{"C64525":{"preferredName":"Every Other Day","code":"C64525","definitions":[{"definition":"Every other day.","type":"DEFINITION","source":"NCI"},{"definition":"Every other day. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Every Other Day","termGroup":"PT","termSource":"NCI"},{"termName":"Every Two Days","termGroup":"SY","termSource":"NCI"},{"termName":"q.a.d.","termGroup":"AB","termSource":"NCI"},{"termName":"Q2D","termGroup":"SY","termSource":"NCI"},{"termName":"QOD","termGroup":"AB","termSource":"NCI"},{"termName":"Quoque Alternis Die","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Every_Other_Day"},{"name":"Maps_To","value":"Every Other Day"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0558287"}]}}{"C64497":{"preferredName":"Twice Weekly","code":"C64497","definitions":[{"definition":"Two times per week.","type":"DEFINITION","source":"NCI"},{"definition":"Two times per week. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Twice Weekly","termGroup":"PT","termSource":"NCI"},{"termName":"BIS","termGroup":"SY","termSource":"NCI"},{"termName":"Twice a week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Twice_Weekly"},{"name":"Maps_To","value":"Twice Weekly"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0556985"}]}}{"C64526":{"preferredName":"Once Weekly","code":"C64526","definitions":[{"definition":"One time per week.","type":"DEFINITION","source":"NCI"},{"definition":"One time per week. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Once Weekly","termGroup":"PT","termSource":"NCI"},{"termName":"Once a week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Once_Weekly"},{"name":"Maps_To","value":"Once Weekly"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0558293"}]}}{"C25722":{"preferredName":"Adjuvant Generic","code":"C25722","definitions":[{"definition":"Serving to aid or contribute; auxiliary.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"Merriam-Webster OnLine"}]}],"synonyms":[{"termName":"Adjuvant Generic","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adjuvant_CADSR"},{"name":"Maps_To","value":"Adjuvant"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1522673"}]}}{"C15481":{"preferredName":"Antiandrogen Therapy","code":"C15481","definitions":[{"definition":"A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment with drugs used to block production or interfere with the action of male sex hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Antiandrogen Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"ADT","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Deprivation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Deprivation Therapy (ADT)","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-androgen Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-androgen Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Antiandrogen Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Hormone Deprivation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Hormone-Deprivation Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antiandrogen_Therapy"},{"name":"Maps_To","value":"Androgen Deprivation Therapy (ADT)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0279492"}]}}{"C15971":{"preferredName":"Cancer Control","code":"C15971","definitions":[{"definition":"Integrated program having an objective of reducing risk, incidence, and mortality from cancer and to enhancing the quality of life for cancer survivors. Realized through an orderly sequence of measures from genetic, epidemiologic, behavioral, social, applied, and surveillance cancer research to the development and implementation of effective interventions, and monitor and analysis of cancer trends in all segments of the population.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Control","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Control Science","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cancer_Control"},{"name":"Maps_To","value":"Cancer Control"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C1516188"}]}}{"C62220":{"preferredName":"Cure","code":"C62220","definitions":[{"definition":"Any action or response that serves to eliminate disease and prevent recurrence.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Serving or tending to restore health; a remedy.","type":"DEFINITION","source":"NCI"},{"definition":"To heal or restore health; a treatment to restore health.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cure","termGroup":"PT","termSource":"NCI"},{"termName":"Curative","termGroup":"AD","termSource":"NCI"},{"termName":"Cured","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Cure"},{"name":"Maps_To","value":"Cure"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1880198"}]}}{"C15688":{"preferredName":"Maintenance Therapy","code":"C15688","definitions":[{"definition":"Continuation of treatment for an extended period of time to prevent relapse.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Maintenance Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Maintenance_Therapy"},{"name":"Maps_To","value":"Maintenance Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0677908"}]}}{"C15665":{"preferredName":"Neoadjuvant Therapy","code":"C15665","definitions":[{"definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Neoadjuvant Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Induction Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Neoadjuvant","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Adjuvant Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Preoperative Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Neoadjuvant_Therapy"},{"name":"Maps_To","value":"Neoadjuvant"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0600558"}]}}{"C15843":{"preferredName":"Preventive Intervention","code":"C15843","definitions":[{"definition":"Any action or response to modify or stop the development of a disease.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Practices or interventions used to help people stay healthy and avoid disease. NOTE: Involves limiting the chances of illness, injuries, or reduced health status from occurring (primary prevention) and, when diseases occur, supporting people to manage them as effectively as possible in order to prevent progression or recurrence (secondary prevention). Prevention is achieved by applying vaccines, behavioral changes, life style changes, improved nutrition, etc. [After Prevention is better than cure, UK Department of Health and Social Care, Nov 5th 2018. After Primary, secondary and tertiary prevention, Institute for Work & Health, Toronto April 2015]","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Preventive Intervention","termGroup":"PT","termSource":"NCI"},{"termName":"Prevention","termGroup":"SY","termSource":"NCI"},{"termName":"Prevention Measures","termGroup":"SY","termSource":"NCI"},{"termName":"Prophylaxis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Preventive_Intervention"},{"name":"Maps_To","value":"Prevention"},{"name":"NCI_META_CUI","value":"CL000755"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15679":{"preferredName":"Consolidation Therapy","code":"C15679","definitions":[{"definition":"Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Consolidation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Post Remission Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Postremission Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Consolidation_Therapy"},{"name":"Maps_To","value":"Consolidation Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1511484"}]}}{"C45792":{"preferredName":"First-Line Therapy","code":"C45792","definitions":[{"definition":"Initial treatment used to reduce a cancer. First-line therapy is followed by other treatments, such as chemotherapy, radiation therapy, and hormone therapy to get rid of cancer that remains.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The preferred standard treatment for a particular condition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First-Line Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"First Line Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"First Line Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"First-Line Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"First-Line_Therapy"},{"name":"Maps_To","value":"First-Line Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1708063"}]}}{"C158876":{"preferredName":"Induction Therapy","code":"C158876","definitions":[{"definition":"The first choice of treatment for a particular type of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Induction Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Induction"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0857127"}]}}{"C137812":{"preferredName":"Radiation Boost","code":"C137812","definitions":[{"definition":"One or more extra radiation treatments targeted at the tumor bed, given after the regular sessions of radiation are complete.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiation Boost","termGroup":"PT","termSource":"NCI"},{"termName":"Boost Radiation","termGroup":"SY","termSource":"NCI"},{"termName":"Boost Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Boost Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation Therapy Boost","termGroup":"SY","termSource":"NCI"},{"termName":"Radiotherapy Boost","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Radiation Boost"},{"name":"NCI_META_CUI","value":"CL524908"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C40413":{"preferredName":"No Evidence of Disease","code":"C40413","definitions":[{"definition":"An absence of detectable disease.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Diagnostic tests fail to detect presence of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"No Evidence of Disease","termGroup":"PT","termSource":"NCI"},{"termName":"NED","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"No_Evidence_of_Disease"},{"name":"Maps_To","value":"No Measurable Disease"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1518340"}]}}{"C165209":{"preferredName":"Treatment Ongoing","code":"C165209","definitions":[{"definition":"An indication that a subject is still undergoing therapy to prevent, mitigate or cure a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treatment Ongoing","termGroup":"PT","termSource":"NCI"},{"termName":"Ongoing Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treatment Ongoing"},{"name":"NCI_META_CUI","value":"CL978421"},{"name":"Semantic_Type","value":"Finding"}]}}{"C105741":{"preferredName":"Treatment Terminated Due to Toxicity","code":"C105741","definitions":[{"definition":"Indicates that the patient terminated the treatment due to toxicity related to the treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treatment Terminated Due to Toxicity","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Treatment Stopped Due to Toxicity"},{"name":"Semantic_Type","value":"Clinical Attribute"},{"name":"UMLS_CUI","value":"C3827777"}]}}{"C198983":{"preferredName":"Tumor Markers Normalized","code":"C198983","definitions":[{"definition":"The levels of expression of tumor markers has decreased to non-disease levels due to therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Markers Normalized","termGroup":"PT","termSource":"NCI"},{"termName":"Normalization of Tumor Markers","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Marker Normalization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Normalization of Tumor Markers"},{"name":"NCI_META_CUI","value":"CL1906415"},{"name":"Semantic_Type","value":"Finding"}]}}{"C15215":{"preferredName":"Cryosurgery","code":"C15215","definitions":[{"definition":"A procedure in which tissue is frozen to destroy abnormal cells. Liquid nitrogen or liquid carbon dioxide is used to freeze the tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Removal, separation, detachment, extirpation or eradication of a body part, pathway or function by freezing. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The use of extreme cold to damage or destroy a body part, pathway, or function. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryosurgery","termGroup":"PT","termSource":"NCI"},{"termName":"Cryoablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cryosurgery"},{"name":"Maps_To","value":"Ablation, Cryo"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0010408"}]}}{"C67444":{"preferredName":"Ethanol Ablation Therapy","code":"C67444","definitions":[{"definition":"An injection of ethanol (alcohol) through the skin directly into a tumor to kill cancer cells. Ultrasound or a CT scan is used to guide the needle into the tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ethanol Ablation Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ethanol_Ablation_Therapy"},{"name":"Maps_To","value":"Ablation, Ethanol Injection"},{"name":"Maps_To","value":"Ethanol Injection Ablation"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1880568"}]}}{"C116643":{"preferredName":"Microwave Ablation","code":"C116643","definitions":[{"definition":"A treatment modality that uses directed electromagnetic waves within the microwave spectrum to heat the targeted tissue for the purpose of causing tissue necrosis within solid tissue tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microwave Ablation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ablation, Microwave"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3854551"}]}}{"C20985":{"preferredName":"Ablation Therapy","code":"C20985","definitions":[{"definition":"In medicine, the removal or destruction of a body part or tissue or its function. Ablation may be performed by surgery, hormones, drugs, radiofrequency, heat, or other methods.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Removal, separation, detachment, extirpation or eradication of a body part, pathway or function by surgery, chemical destruction, morbid process, or noxious substance. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by surgery, chemical destruction, morbid process, or noxious substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ablation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Ablation","termGroup":"SY","termSource":"NCI"},{"termName":"Local Ablation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Local Ablative Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ablation"},{"name":"Maps_To","value":"Ablation or Embolization, NOS"},{"name":"Maps_To","value":"Ablation, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0547070"}]}}{"C15666":{"preferredName":"Radiofrequency Ablation","code":"C15666","definitions":[{"definition":"A procedure that uses radio waves to heat and destroy abnormal cells. The radio waves travel through electrodes (small devices that carry electricity). Radiofrequency ablation may be used to treat cancer and other conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A therapeutic procedure to kill tissue using radiowaves to generate heat. The procedure is performed by the insertion of an electrode into a target tissue. Electrical energy delivered to the electrode heats and destroys the tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiofrequency Ablation","termGroup":"PT","termSource":"NCI"},{"termName":"Radiofrequency Interstitial Ablation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiofrequency_Interstitial_Ablation"},{"name":"Maps_To","value":"Ablation, Radiofrequency"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0850292"}]}}{"C15696":{"preferredName":"Radiosurgery","code":"C15696","definitions":[{"definition":"A surgical procedure to treat cancer cells that use high energy beams.","type":"DEFINITION","source":"NCI"},{"definition":"A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radiosurgery","termGroup":"PT","termSource":"NCI"},{"termName":"Radiation Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiation_Surgery"},{"name":"Maps_To","value":"Ablation, Radiosurgical"},{"name":"NCI_META_CUI","value":"CL031853"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15747":{"preferredName":"Supportive Care","code":"C15747","definitions":[{"definition":"Any action or process to maximize comfort, minimize side effects, or mitigate against a decline in the participant's health or function. (clinicaltrials.gov)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Supportive care is that which helps the patient and their family to cope with cancer and treatment of it from pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing illness or death and into bereavement. It helps the patient to maximize the benefits of treatment and to live as well as possible with the effects of the disease. Supportive therapy may provide a patient with friendship, encouragement, practical advice such as access to community resources or how to develop a more active social life, vocational counseling, suggestions for minimizing friction with family members, and, above all, hope that the life of the patient may be improved. In all situations, supportive therapy involves the teaching of such life skills as managing medication, learning to socialize, handling finances, and getting a job.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supportive Care","termGroup":"PT","termSource":"NCI"},{"termName":"Supportive Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Symptom Management","termGroup":"SY","termSource":"NCI"},{"termName":"Therapy, Supportive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supportive_Care"},{"name":"Maps_To","value":"Ancillary Treatment"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0344211"}]}}{"C64172":{"preferredName":"Anticonvulsant Therapy","code":"C64172","definitions":[{"definition":"Drug treatment to prevent, stop, or reduce the severity of seizures or convulsions, commonly used in cases of epilepsy or other seizure disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anticonvulsant Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Antiseizure Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anticonvulsant_Therapy"},{"name":"Maps_To","value":"Antiseizure Treatment"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0521306"}]}}{"C443":{"preferredName":"Biphosphonate","code":"C443","definitions":[{"definition":"A drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Biphosphonate","termGroup":"PT","termSource":"NCI"},{"termName":"Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Diphosphonates","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Biphosphonate"},{"name":"Maps_To","value":"Bisphosphonate Therapy"},{"name":"Semantic_Type","value":"Chemical Viewed Structurally"},{"name":"UMLS_CUI","value":"C0012544"}]}}{"C70840":{"preferredName":"Blinded Clinical Study","code":"C70840","definitions":[{"definition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","type":"DEFINITION","source":"NCI"},{"definition":"A study in which the subject, the investigator, or anyone assessing the outcome is unaware of the treatment assignment(s). NOTE: Blinding is used to reduce the potential for bias. [Modified ICH E6 Glossary] See also blinding/masking, double-blind study, single-blind study, triple-blind study; contrast with open-label or unblinded study.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"A type of study in which the patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given. The opposite of a blinded study is an open label study.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Blinded Clinical Study","termGroup":"PT","termSource":"NCI"},{"termName":"Blind Clinical Study","termGroup":"SY","termSource":"NCI"},{"termName":"Blinded Clinical Trial","termGroup":"SY","termSource":"NCI"},{"termName":"Masked Clinical Study","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Blinded_Clinical_Study"},{"name":"Maps_To","value":"Blinded Study, Treatment Unknown"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C2347038"}]}}{"C15651":{"preferredName":"High-Dose Rate Brachytherapy","code":"C15651","definitions":[{"definition":"A type of brachytherapy that targets a cancerous tissue with high doses of radiation through the use of inserted temporary implants.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Internal radiation treatment that targets a cancerous tissue with accurate, high doses of radiation through the use of inserted temporary implants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High-Dose Rate Brachytherapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"High-Dose_Rate_Brachytherapy"},{"name":"Maps_To","value":"Brachytherapy, High Dose"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0454270"}]}}{"C85254":{"preferredName":"Low-Dose Rate Brachytherapy","code":"C85254","definitions":[{"definition":"A type of brachytherapy that targets a cancerous tissue with low doses of radiation through the use of inserted temporary or permanent implants.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Internal radiation treatment that targets a cancerous tissue with low doses of radiation through the use of inserted temporary or permanent implants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Low-Dose Rate Brachytherapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Brachytherapy, Low Dose"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0454271"}]}}{"C15195":{"preferredName":"Brachytherapy","code":"C15195","definitions":[{"definition":"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.","type":"DEFINITION","source":"NCI"},{"definition":"A type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brachytherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Internal Radiation","termGroup":"SY","termSource":"NCI"},{"termName":"Internal Radiation Brachytherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Internal Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation Brachytherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Radiation_Brachytherapy"},{"name":"Maps_To","value":"Brachytherapy, NOS"},{"name":"Maps_To","value":"Internal Radiation"},{"name":"Maps_To","value":"Radiation, Internal"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0006098"}]}}{"C15752":{"preferredName":"Chemoembolization","code":"C15752","definitions":[{"definition":"A procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This permits a higher concentration of drug to be in contact with the tumor for a longer period of time.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A procedure that introduces chemotherapy to blood vessels adjacent to a tumor, for the purpose of both treating the tumor and interrupt blood flow to the tumor, which serves both to trap the chemotherapeutic agent at the tumor and to decrease the amount of nutrients flowing to the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chemoembolization","termGroup":"PT","termSource":"NCI"},{"termName":"Chemotherapy Embolization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chemoembolization"},{"name":"Maps_To","value":"Chemoembolization"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0796679"}]}}{"C15533":{"preferredName":"Chemoprotection","code":"C15533","definitions":[{"definition":"The use of drugs to protect normal tissue from damage by cancer therapy agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chemoprotection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chemoprotection"},{"name":"Maps_To","value":"Chemoprotectant"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0280959"}]}}{"C15632":{"preferredName":"Chemotherapy","code":"C15632","definitions":[{"definition":"Non-systemic chemotherapy treatment (e.g., intra-peritoneal, intra-cavitary, intra-thecal), or chemotherapy not described by Chemotherapy Single Agent Systemic or Multi-Agent Systemic.","type":"ALT_DEFINITION","source":"CTEP"},{"definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment with anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chemotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Chemo","termGroup":"SY","termSource":"NCI"},{"termName":"Chemotherapy, Cancer, General","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity."},{"name":"Legacy Concept Name","value":"Chemotherapy"},{"name":"Maps_To","value":"Chemotherapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0392920"}]}}{"C141342":{"preferredName":"Concurrent Chemoradiation","code":"C141342","definitions":[{"definition":"Treatment in which radiation therapy is administered at the same time as chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Concurrent Chemoradiation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Maps_To","value":"Concurrent Chemoradiation"},{"name":"NCI_META_CUI","value":"CL539462"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15230":{"preferredName":"Embolization Therapy","code":"C15230","definitions":[{"definition":"A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells.","type":"DEFINITION","source":"NCI"},{"definition":"The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Embolization Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"therapy, embolization","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Embolization_Therapy"},{"name":"Maps_To","value":"Ablation or Embolization, NOS"},{"name":"Maps_To","value":"Embolization"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0013931"}]}}{"C15751":{"preferredName":"External Beam Radiation Therapy","code":"C15751","definitions":[{"definition":"A type of radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of radiation therapy that uses a machine to aim high-energy rays at the cancer from outside of the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"External Beam Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Definitive Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"EBRT","termGroup":"SY","termSource":"NCI"},{"termName":"External Beam Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"External Beam RT","termGroup":"SY","termSource":"NCI"},{"termName":"External Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Teletherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Teletherapy Radiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"External_Beam_Radiation"},{"name":"Maps_To","value":"External Beam Radiation"},{"name":"Maps_To","value":"Radiation, External Beam"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0419095"}]}}{"C15445":{"preferredName":"Hormone Therapy","code":"C15445","definitions":[{"definition":"Cancer therapy, which incorporates hormonal manipulation (e.g., tamoxifen, androgen deprivation).","type":"ALT_DEFINITION","source":"CTEP"},{"definition":"Treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body's natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hormone Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Chemotherapy-Hormones/Steroids","termGroup":"SY","termSource":"NCI"},{"termName":"Hormonal Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"DesignNote","value":"The concept covers but is not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration."},{"name":"DesignNote","value":"The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy."},{"name":"Legacy Concept Name","value":"Hormone_Therapy"},{"name":"Maps_To","value":"Hormone Therapy"},{"name":"Maps_To","value":"Hormones"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0279025"}]}}{"C198584":{"preferredName":"Iodine I 131 Radiation Therapy","code":"C198584","definitions":[{"definition":"Radiation Therapy that uses iodine I-131. It is typically used to treat thyroid conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"I-131 Radiation Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"I-131 Radiation Therapy"},{"name":"NCI_META_CUI","value":"CL1905765"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15262":{"preferredName":"Immunotherapy","code":"C15262","definitions":[{"definition":"A therapy designed to induce changes in a patient's immune status.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Immunotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Immunologically Directed Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"The concept encompasses various treatment modalities including active and passive immunization, treatment with immunopotentiators, immunosuppressants and nonspecific systemic immunostimulators and adjuvants, desensitization to any allergens, bone marrow transplantation, thymus implantation."},{"name":"Legacy Concept Name","value":"Immunotherapy"},{"name":"Maps_To","value":"Immunotherapy (Including Vaccines)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0021083"}]}}{"C15393":{"preferredName":"Isolated Chemotherapeutic Limb Perfusion","code":"C15393","definitions":[{"definition":"A procedure used to deliver anticancer drugs directly to an arm or leg but not to the rest of the body. The flow of blood to and from the limb is temporarily stopped with a tourniquet (a tight band around the limb). Catheters (small, flexible tubes) attached to a pump are put into an artery and a vein in the limb so that blood can be circulated through the pump into the limb. Anticancer drugs are injected into the catheters. Wrapping the limb in a heated blanket or warming the drugs or blood may help the drugs work better.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Isolated Chemotherapeutic Limb Perfusion","termGroup":"PT","termSource":"NCI"},{"termName":"Limb Perfusion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Limb_Perfusion"},{"name":"Maps_To","value":"Isolated Limb Perfusion (ILP)"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0396670"}]}}{"C15986":{"preferredName":"Pharmacotherapy","code":"C15986","definitions":[{"definition":"Treatment of disease through the use of drugs.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment with any substance, other than food, that is used to prevent, diagnose, treat, or relieve symptoms of a disease or abnormal condition.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pharmacotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"Drug Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Pharmacological Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Pharmacological Treatments","termGroup":"SY","termSource":"NCI"},{"termName":"Treatment With Medication","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Pharmacological_Treatment"},{"name":"Maps_To","value":"Pharmaceutical Therapy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0013216"}]}}{"C66899":{"preferredName":"Pleurodesis","code":"C66899","definitions":[{"definition":"A medical procedure that uses chemicals or drugs to cause inflammation and adhesion between the layers of the pleura (a thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity). This prevents the buildup of fluid in the pleural cavity. It is used as a treatment for severe pleural effusion.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae.","type":"DEFINITION","source":"NCI"},{"definition":"A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Pleurodesis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pleurodesis"},{"name":"Maps_To","value":"Pleurodesis"},{"name":"Maps_To","value":"Pleurodesis, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0189557"}]}}{"C15313":{"preferredName":"Radiation Therapy","code":"C15313","definitions":[{"definition":"Patient required additional radiation therapy.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that travels in the blood to tissues throughout the body.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","type":"DEFINITION","source":"NCI"},{"definition":"Use of targeted or whole body radiation to treat a disease.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"Irradiate","termGroup":"SY","termSource":"NCI"},{"termName":"Irradiated","termGroup":"SY","termSource":"NCI"},{"termName":"Irradiation","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation","termGroup":"SY","termSource":"NCI"},{"termName":"Radiotherapeutics","termGroup":"SY","termSource":"NCI"},{"termName":"Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"RT","termGroup":"AB","termSource":"NCI"},{"termName":"Therapy, Radiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Radiation_Therapy"},{"name":"Maps_To","value":"Radiation Therapy, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1522449"},{"name":"xRef","value":"IMDRF:F2305"}]}}{"C165189":{"preferredName":"Conventional Radiotherapy","code":"C165189","definitions":[{"definition":"A course of radiotherapy where minimal imaging support (i.e. X-rays films) is used to determine the positioning of radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conventional Radiotherapy","termGroup":"PT","termSource":"NCI"},{"termName":"2-Dimensional Conventional Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"2D Conventional Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"2D Radiotherapy","termGroup":"SY","termSource":"NCI"},{"termName":"2D-RT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Radiation, 2D Conventional"},{"name":"NCI_META_CUI","value":"CL978430"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C16035":{"preferredName":"3-Dimensional Conformal Radiation Therapy","code":"C16035","definitions":[{"definition":"A procedure that uses a computer to create a 3-dimensional picture of the tumor. This allows doctors to give the highest possible dose of radiation to the tumor, while sparing the normal tissue as much as possible.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"from Varian Oncology web site"}]},{"definition":"A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"3-Dimensional Conformal Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"3D-CRT","termGroup":"AB","termSource":"NCI"},{"termName":"Conformal Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation Conformal Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Three-Dimensional_Conformal_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, 3D Conformal"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0600521"}]}}{"C165192":{"preferredName":"Combination Radiotherapy","code":"C165192","definitions":[{"definition":"Simultaneous or consecutive use of radiotherapy and one or more non-radiation based treatment modalities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combination Radiotherapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation, Combination"},{"name":"NCI_META_CUI","value":"CL978433"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C95484":{"preferredName":"CyberKnife","code":"C95484","definitions":[{"definition":"A proprietary, robotic radiosurgery system designed to deliver precise beams of high dose radiation to tumors with extreme accuracy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CyberKnife","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation, Cyberknife"},{"name":"NCI_META_CUI","value":"CL449164"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C66891":{"preferredName":"Interstitial Radiation Therapy","code":"C66891","definitions":[{"definition":"A type of brachytherapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue. (Cancer.gov)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interstitial Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Implant Radiation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Interstitial_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, Implants"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1881237"}]}}{"C16135":{"preferredName":"Intensity-Modulated Radiation Therapy","code":"C16135","definitions":[{"definition":"A type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.","type":"DEFINITION","source":"NCI"},{"definition":"An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Intensity-Modulated Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"IMRT","termGroup":"AB","termSource":"NCI"},{"termName":"Intensity Modulated RT","termGroup":"SY","termSource":"NCI"},{"termName":"Intensity-Modulated Radiotherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Intensity-Modulated_Radiotherapy"},{"name":"Maps_To","value":"Radiation, Intensity-Modulated Radiotherapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1512814"}]}}{"C66897":{"preferredName":"Proton Beam Radiation Therapy","code":"C66897","definitions":[{"definition":"A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A type of radiation therapy that uses streams of protons (tiny particles with a positive charge) that come from a special machine. This type of radiation kills tumor cells but does not damage nearby tissues. It is used to treat cancers in the head and neck and in organs such as the brain, eye, lung, spine, and prostate. Proton beam radiation is different from x-ray radiation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Proton Beam Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"PBRT","termGroup":"SY","termSource":"NCI"},{"termName":"Proton Radiation Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Proton_Beam_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, Proton Beam"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0436226"}]}}{"C15470":{"preferredName":"Isotope Therapy","code":"C15470","definitions":[{"definition":"Treatment of a disease by means of exposure of the target to radioisotopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isotope Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Radioactive Isotope Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Radioisotope Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"therapy, isotope, radioactive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isotope_Therapy"},{"name":"Maps_To","value":"Radiation, Radioisotope"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0203608"}]}}{"C15382":{"preferredName":"Gamma Knife","code":"C15382","definitions":[{"definition":"A treatment using gamma rays, a type of high-energy radiation that can be tightly focused on small tumors or other lesions in the head or neck, so very little normal tissue receives radiation. The gamma rays are aimed at the tumor from many different angles at once, and deliver a large dose of radiation exactly to the tumor in one treatment session. This procedure is a type of stereotactic radiosurgery. Gamma Knife therapy is not a knife and is not surgery. Gamma Knife is a registered trademark of Elekta Instruments, Inc.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gamma Knife","termGroup":"PT","termSource":"NCI"},{"termName":"Gamma Knife Radiosurgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gamma_Knife"},{"name":"Maps_To","value":"Radiation, Stereotactic/Gamma Knife/SRS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0086330"}]}}{"C92991":{"preferredName":"Systemic Radiation Therapy","code":"C92991","definitions":[{"definition":"A type of radiation therapy in which a radioactive substance, such radioactive iodine or a radioactively labeled monoclonal antibody, is swallowed or injected into the body and travels through the blood, locating and killing tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation therapy in which radioactive drugs are administered orally or through an injection then circulate through the blood and collect in tumor sites where they kill cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Systemic Radiation Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiation, Systemic"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2985381"}]}}{"C157968":{"preferredName":"Radioactive Iodine Therapy","code":"C157968","definitions":[{"definition":"The use of radioactive iodine to treat disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radioactive Iodine Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radioactive Iodine Therapy"},{"name":"NCI_META_CUI","value":"CL1407114"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C93340":{"preferredName":"Radioembolization","code":"C93340","definitions":[{"definition":"A combination therapy for cancer treatment that couples radiation therapy and embolization through the introduction of radioactive microspheres directly into vessels supplying the tumor, allowing for the delivery of high dose radiation without irradiating healthy tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A type of radiation therapy used to treat liver cancer that is advanced or has come back. Tiny beads that hold the radioisotope yttrium Y 90 are injected into the hepatic artery (the main blood vessel that carries blood to the liver). The beads collect in the tumor and the yttrium Y 90 gives off radiation. This destroys the blood vessels that the tumor needs to grow and kills the cancer cells. Radioembolization is a type of selective internal radiation therapy (SIRT).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radioembolization","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radioembolization"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2985560"}]}}{"C798":{"preferredName":"Radiosensitizing Agent","code":"C798","definitions":[{"definition":"An agent that makes tumor cells more sensitive to radiation therapy.","type":"DEFINITION","source":"NCI"},{"definition":"Drugs that make tumor cells more sensitive to radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radiosensitizing Agent","termGroup":"PT","termSource":"NCI"},{"termName":"Radiation Sensitizers","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation-Sensitizing Agents","termGroup":"SY","termSource":"NCI"},{"termName":"Radiation-Sensitizing Drugs","termGroup":"SY","termSource":"NCI"},{"termName":"Radiosensitizers","termGroup":"SY","termSource":"NCI"},{"termName":"Radiosensitizing Drugs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiosensitizing_Agent"},{"name":"Maps_To","value":"Radiosensitizing Agent"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0034541"}]}}{"C46089":{"preferredName":"Allogeneic Hematopoietic Stem Cell Transplantation","code":"C46089","definitions":[{"definition":"A clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.","type":"DEFINITION","source":"NCI"},{"definition":"A procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. This is often a sister or brother, but could be an unrelated donor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Allogeneic Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Hematopoietic Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"HSC","termGroup":"AB","termSource":"NCI"},{"termName":"HSCT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Allogeneic_Hematopoietic_Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, Allogeneic"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2242529"}]}}{"C16039":{"preferredName":"Autologous Hematopoietic Stem Cell Transplantation","code":"C16039","definitions":[{"definition":"A procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Stem cell transfer or transplantation in which the patient is their own donor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"AHSCT","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Hematopoietic Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Autologous_Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, Autologous"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1831743"}]}}{"C116466":{"preferredName":"Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation","code":"C116466","definitions":[{"definition":"Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from autologous hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"auto-auto HCT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Transplantation, Double Autologous"},{"name":"NCI_META_CUI","value":"CL388423"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C138187":{"preferredName":"Haploidentical Hematopoietic Cell Transplantation","code":"C138187","definitions":[{"definition":"A clinical treatment in which hematopoietic stem cells are transferred from a HLA half-matched donor to a recipient.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Haploidentical Hematopoietic Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Haploidentical Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-Haploidentical Hematopoietic Cell Transplantation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Transplantation, Haploidentical"},{"name":"Maps_To","value":"Transplant from live related donor"},{"name":"NCI_META_CUI","value":"CL525718"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C62714":{"preferredName":"Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","code":"C62714","definitions":[{"definition":"A modification of the standard method of allogeneic hematopoietic stem cell transplantation developed to allow for the therapy to be extended to a patient population that is unable to tolerate treatment with the conventional procedure due to its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"Nonmyeloablative Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"NST","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NCCN"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Nonmyeloablative_Allogeneic_Hematopoietic_Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, Non-Myeloablative"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1831742"}]}}{"C15431":{"preferredName":"Hematopoietic Cell Transplantation","code":"C15431","definitions":[{"definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells from a donor to a recipient.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hematopoietic Cell Transplantation","termGroup":"PT","termSource":"NCI"},{"termName":"HCT","termGroup":"AB","termSource":"NCI"},{"termName":"Hematopoietic Stem Cell Infusion","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietic Stem Cell Transplantation","termGroup":"SY","termSource":"NCI"},{"termName":"HSCT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Stem_Cell_Transplantation"},{"name":"Maps_To","value":"Stem Cell Transplantation, NOS"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0472699"}]}}{"C93196":{"preferredName":"Syngeneic Stem Cell Transplantation","code":"C93196","definitions":[{"definition":"A procedure in which a patient receives blood-forming stem cells (cells from which all blood cells develop) donated by his or her healthy identical twin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Syngeneic Stem Cell Transplantation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Transplantation, Syngenic"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2985487"}]}}{"C165194":{"preferredName":"Stem Cell Therapy","code":"C165194","definitions":[{"definition":"A treatment modality that leverages stem cells to prevent or treat disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stem Cell Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Stem Cell Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stem Cell Treatment"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0872278"}]}}{"C15358":{"preferredName":"Stereotactic Radiosurgery","code":"C15358","definitions":[{"definition":"A non-surgical procedure that was developed to deliver one or several maximum dose targeted radiation treatments for cancers in the brain or spine.","type":"DEFINITION","source":"NCI"},{"definition":"A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Stereotactic Radiosurgery","termGroup":"PT","termSource":"NCI"},{"termName":"Stereotactic External Beam Irradiation","termGroup":"SY","termSource":"NCI"},{"termName":"Stereotactic Radiation Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Stereotactic Radiotherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Stereotaxic_Radiosurgery"},{"name":"Maps_To","value":"Stereotactic Radiosurgery"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0085203"}]}}{"C15370":{"preferredName":"Steroid Therapy","code":"C15370","definitions":[{"definition":"The use of exogenous steroids for the treatment of any disease or disorder.","type":"DEFINITION","source":"NCI"},{"definition":"Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Steroid Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Steroid_Therapy"},{"name":"Maps_To","value":"Steroid Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0149783"}]}}{"C76243":{"preferredName":"Targeted Molecular Therapy","code":"C76243","definitions":[{"definition":"Cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread.","type":"DEFINITION","source":"NCI"},{"definition":"In cancer treatment, substances that kill cancer cells by targeting key molecules involved in cancer cell growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Targeted Molecular Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Targeted_Molecular_Therapy"},{"name":"Maps_To","value":"Targeted Molecular Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2699893"}]}}{"C62726":{"preferredName":"Hypofractionated Radiation Therapy","code":"C62726","definitions":[{"definition":"Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypofractionated Radiation Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Hypofractionated Radiotherapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Hypofractionated_Radiation_Therapy"},{"name":"Maps_To","value":"Radiation, Hypofractionated"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1831786"}]}}{"C152055":{"preferredName":"Direct Mixed Photon and Electron Field","code":"C152055","definitions":[{"definition":"A radiation therapy technique where external photon and electron beams are used to deliver treatment of superficial and deep-seated malignancies, respectively, while sparing underlying organs at risk.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Direct Mixed Photon and Electron Field","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Radiation, Mixed Photon Beam"},{"name":"NCI_META_CUI","value":"CL553390"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C104914":{"preferredName":"Photon Beam Radiation Therapy","code":"C104914","definitions":[{"definition":"A type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator (linac). The radiation dose is delivered at the surface of the body and goes into the tumor and through the body. Photon beam radiation therapy is different from proton beam therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Radiation therapy using photon beam.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Photon Beam Radiation Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Radiation, Photon Beam"},{"name":"NCI_META_CUI","value":"CL445995"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C178422":{"preferredName":"Talc Poudrage","code":"C178422","definitions":[{"definition":"A surgical procedure in which talc is insufflated into the pleural space during thoracoscopy to promote the adhesion of the visceral and parietal layers of the pleura as a treatment for recurring pleural effusion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talc Poudrage","termGroup":"PT","termSource":"NCI"},{"termName":"Talc Pleurodesis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pleurodesis, Talc"},{"name":"NCI_META_CUI","value":"CL1648595"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C162449":{"preferredName":"Peptide Receptor Radionuclide Therapy","code":"C162449","definitions":[{"definition":"Treatment with a radioactive substance that is linked to a peptide receptor so that it will attach to a specific cell type when injected into the body. It is currently being used to treat neuroendocrine tumors, using octreotide as the targeting peptide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptide Receptor Radionuclide Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"PRRT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peptide Receptor Radionuclide Therapy (PRRT)"},{"name":"NCI_META_CUI","value":"CL970990"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C51647":{"preferredName":"Distal Pancreatectomy","code":"C51647","definitions":[{"definition":"Removal of the body and tail of the pancreas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of the distal part of the pancreas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Distal Pancreatectomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Distal_Pancreatectomy"},{"name":"Maps_To","value":"Distal Pancreatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0176940"}]}}{"C172727":{"preferredName":"Minimally Invasive Surgery","code":"C172727","definitions":[{"definition":"Surgery that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. It also minimizes the risk of post-surgical complications, including less risk of infection, and is expected to reduce recovery time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Minimally Invasive Surgery","termGroup":"PT","termSource":"NCI"},{"termName":"Minimally-Invasive Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgery, Minimally Invasive"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0282624"}]}}{"C126391":{"preferredName":"Open Surgical Procedure","code":"C126391","definitions":[{"definition":"Traditional surgery using a long incision for visualization and for the insertion of instruments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Open Surgical Procedure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Surgery, Open"},{"name":"NCI_META_CUI","value":"CL504936"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C15340":{"preferredName":"Total Pancreatectomy","code":"C15340","definitions":[{"definition":"Surgery to remove the entire pancreas. Part of the stomach, part of the small intestine, the common bile duct, gallbladder, spleen, and nearby lymph nodes also are removed.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Surgical removal of the entire pancreas.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Surgical removal of the entire pancreas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Total Pancreatectomy","termGroup":"PT","termSource":"NCI"},{"termName":"Total Excision of the Pancreas","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Total_Pancreatectomy"},{"name":"Maps_To","value":"Total Pancreatectomy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0040511"}]}}{"C957":{"preferredName":"10-Deacetyltaxol","code":"C957","definitions":[{"definition":"An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"10-Deacetyltaxol","termGroup":"PT","termSource":"NCI"},{"termName":"10-Deacetylpaclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"78432-77-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B77R96LJLK"},{"name":"Legacy Concept Name","value":"_10-Deacetyltaxol"},{"name":"Maps_To","value":"10-Deacetyltaxol"},{"name":"NSC Number","value":"656201"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044663"}]}}{"C49172":{"preferredName":"11C Topotecan","code":"C49172","definitions":[{"definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata radiolabeled with carbon 11 (11C) with antineoplastic and radiotracer properties. During the S phase of the cell cycle, topotecan inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Quantitation of 11C topotecan accumulated in tumor tissues by positron emission tomography (PET) may help predict responses to topotecan therapy.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of certain types of cancer, including ovarian cancer and lung cancer. 11C topotecan is a radioactive form of the anticancer drug topotecan. It builds up in tumor tissues and is detected by positron emission tomography (PET). It may be used to help determine whether treatment with topotecan will work. It is a type of topoisomerase I inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"11C Topotecan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_11C_Topotecan"},{"name":"Maps_To","value":"11C Topotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"454314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454314"},{"name":"PDQ_Open_Trial_Search_ID","value":"454314"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1711433"}]}}{"C28781":{"preferredName":"11D10 AluGel Anti-Idiotype Monoclonal Antibody","code":"C28781","definitions":[{"definition":"A monoclonal anti-idiotype antibody adsorbed to aluminum hydroxide gel (AluGel) with potential antineoplastic activity.  11D10 AluGel anti-idiotype monoclonal antibody mimics the human milk fat globule (HMFG) antigen found in breast and other cancers.  Vaccination with 11D10 AluGel anti-idiotype monoclonal antibody may induce a host antibody response against tumor cells positive for the HMFG antigen. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"11D10 AluGel Anti-Idiotype Monoclonal Antibody","termGroup":"PT","termSource":"NCI"},{"termName":"TriAb","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_11D10_AluGel_Anti-Idiotype_Monoclonal_Antibody"},{"name":"Maps_To","value":"11D10 AluGel Anti-Idiotype Monoclonal Antibody"},{"name":"NSC Number","value":"719681"},{"name":"NSC Number","value":"724593"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1520305"}]}}{"C41441":{"preferredName":"12-Allyldeoxoartemisinin","code":"C41441","definitions":[{"definition":"A semi-synthetic analogue of Artemisinin - a sesquiterpene lactone extracted from the dry leaves of Artemisia Annua (sweet wormwood) used as anti-malaria agent. Limited data is available on Artemisinin antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"12-Allyldeoxoartemisinin","termGroup":"PT","termSource":"NCI"},{"termName":"12-Allyldeoxoartemisinin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_12-Allyldeoxoartemisinin"},{"name":"Maps_To","value":"12-Allyldeoxoartemisinin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0294412"}]}}{"C2494":{"preferredName":"13-Deoxydoxorubicin","code":"C2494","definitions":[{"definition":"An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  13-Deoxydoxorubicin intercalates DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent was designed to be a non-cardiotoxic anthracycline antibiotic.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics. It is an anthracycline.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"13-Deoxydoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"GPX-100","termGroup":"CN","termSource":"NCI"},{"termName":"GPX100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"628290-43-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1S9VO1DQG5"},{"name":"Legacy Concept Name","value":"GPX-100"},{"name":"Maps_To","value":"13-Deoxydoxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"43222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43222"},{"name":"PDQ_Open_Trial_Search_ID","value":"43222"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796383"}]}}{"C62553":{"preferredName":"14C BMS-275183","code":"C62553","definitions":[{"definition":"An orally bioavailable taxane compound, a C-4 methyl carbonate analogue of paclitaxel, labeled with radioactive carbon 14, with potential antineoplastic and radioimaging activities. BMS-275183 binds to tubulin and as a result inhibits microtubule disassembly or assembly. This leads to cell cycle arrest at the G2/M phase, thereby resulting in an inhibition of cell division and ultimately cell death. BMS-275183 may be useful for treating multi-drug resistant tumors as it does not appear to be a substrate for P-glycoprotein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"14C BMS-275183","termGroup":"PT","termSource":"NCI"},{"termName":"[14C] BMS-275183","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_14C_BMS-275183"},{"name":"Maps_To","value":"14C BMS-275183"},{"name":"NCI_Drug_Dictionary_ID","value":"487486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487486"},{"name":"PDQ_Open_Trial_Search_ID","value":"487486"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831856"}]}}{"C133224":{"preferredName":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521","code":"C133224","definitions":[{"definition":"A selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17bHSD5, aldo-keto reductase 1C3; AKR1C3), with potential antineoplastic activity. Upon administration, ASP9521 selectively binds to and inhibits the activity of 17bHSD5. This prevents the conversion of the adrenal androgens dehydroepiandrosterone and androstenedione into 5-androstenediol and testosterone. By blocking testosterone production, ASP9521 may inhibit the growth of testosterone-dependent cancers such as castration-resistant prostate cancer (CRPC). 17bHSD5, expressed both in normal prostate tissue and in prostate cancer (PC), plays a crucial role in persistent production of androgens despite castration; its expression is associated with increased malignancy of PC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521","termGroup":"PT","termSource":"NCI"},{"termName":"(4-(2-Hydroxy-2-methylpropyl)piperidin-1-yl)(5-methoxy-1H-indol-2-yl)methanone","termGroup":"SN","termSource":"NCI"},{"termName":"17bHSD5 Inhibitor ASP9521","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 9521","termGroup":"CN","termSource":"NCI"},{"termName":"ASP9521","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1126084-37-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AA79G37CPR"},{"name":"Maps_To","value":"17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521"},{"name":"NCI_Drug_Dictionary_ID","value":"700558"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700558"},{"name":"PDQ_Open_Trial_Search_ID","value":"700558"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045761"}]}}{"C116618":{"preferredName":"2-Deoxy-D-glucose","code":"C116618","definitions":[{"definition":"A non-metabolizable glucose analog in which the hydroxyl group at position 2 of glucose is replaced by hydrogen, with potential glycolysis inhibiting and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration of 2-deoxy-D-glucose (2-DG), this agent competes with glucose for uptake by proliferating cells, such as tumor cells. 2-DG inhibits the first step of glycolysis and therefore prevents cellular energy production, which may result in decreased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Deoxy-D-glucose","termGroup":"PT","termSource":"NCI"},{"termName":"2-DG","termGroup":"AB","termSource":"NCI"},{"termName":"Deoxyglucose","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154-17-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9G2MP84A8W"},{"name":"Maps_To","value":"2-Deoxy-D-glucose"},{"name":"NCI_Drug_Dictionary_ID","value":"409701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"409701"},{"name":"PDQ_Open_Trial_Search_ID","value":"409701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011501"}]}}{"C1165":{"preferredName":"2-Ethylhydrazide","code":"C1165","definitions":[{"definition":"A podophyllic acid derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, 2-ethylhydrazide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Ethylhydrazide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_2-Ethylhydrazide"},{"name":"Maps_To","value":"2-Ethylhydrazide"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066615"}]}}{"C29794":{"preferredName":"2-Fluoroadenine","code":"C29794","definitions":[{"definition":"A fluorinated heterocyclic 2-ring compound. 2-fluoroadenine is the base moiety for many carbocyclic and acyclic nucleoside analogues, which may be used in antineoplastic studies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Fluoroadenine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Purin-6-amine, 2-fluoro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"2-Fad","termGroup":"AB","termSource":"NCI"},{"termName":"2-Fluoro-1H-purin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"Adenine, 2-fluoro-","termGroup":"SY","termSource":"NCI"},{"termName":"BRN 0610958","termGroup":"CN","termSource":"NCI"},{"termName":"Purine, 6-amino-2-fluoro-","termGroup":"SN","termSource":"NCI"},{"termName":"SRI 774","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"700-49-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2C8H3H4EBG"},{"name":"Legacy Concept Name","value":"_2-Fluoroadenine"},{"name":"Maps_To","value":"2-Fluoroadenine"},{"name":"NSC Number","value":"27364"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0046110"}]}}{"C131289":{"preferredName":"2-Fluorofucose","code":"C131289","definitions":[{"definition":"An orally bioavailable fluorinated analog of fucose that is a protein fucosylation inhibitor, with potential antineoplastic and immunomodulating activities. Upon administration, 2-fluorofucose (2-FF) mimics fucose and is converted to guanosine diphosphate (GDP)-2FF, which prevents the formation of the fucosylation substrate GDP-fucose, and the incorporation of fucose into glycoproteins by fucosyltransferase. As fucosylation of glycoproteins plays a key role in many biological processes, such as protein function, receptor binding, cell signaling and cellular adhesion, and is essential for tumor progression, blocking fucosylation decreases tumor cell growth. In addition, blocking fucosylation of monoclonal antibodies generates fucose-deficient antibodies that exert enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Fluorofucose","termGroup":"PT","termSource":"NCI"},{"termName":"2-FF Containing SGN-2FF","termGroup":"SY","termSource":"NCI"},{"termName":"2FF-containing SGN-2FF","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-2FF","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70763-62-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W39886N0ZG"},{"name":"Maps_To","value":"2-Fluorofucose-containing SGN-2FF"},{"name":"NCI_Drug_Dictionary_ID","value":"785540"},{"name":"NCI_META_CUI","value":"CL514470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785540"},{"name":"PDQ_Open_Trial_Search_ID","value":"785540"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120474":{"preferredName":"2-Hydroxyestradiol","code":"C120474","definitions":[{"definition":"A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 2 by the CYP450 enzymes 1A1/1A2. Theoretically, 2-hydroxyestradiol (2-OHE2) is able to undergo redox cycling, which generates active radicals and induces DNA damage; however, this estradiol metabolite is very unstable in vivo and is quickly inactivated by catechol-O-methyltransferase (COMT)-mediated O-methylation and converted to 2-methoxyestradiol (2-MeE2). 2-MeE2 exerts antineoplastic activities through its estrogen receptor antagonistic effect and the induction of apoptosis in susceptible cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Hydroxyestradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17beta)-Estra-1,3,5(10)-Triene-2,3,17-Triol","termGroup":"SY","termSource":"NCI"},{"termName":"2-Hydroxy-17beta-Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"2-Hydroxyestradiol-17beta","termGroup":"SY","termSource":"NCI"},{"termName":"2-OH-E2","termGroup":"AB","termSource":"NCI"},{"termName":"2-OH-Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"2-OHE2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-05-0"},{"name":"CHEBI_ID","value":"CHEBI:28744"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AYU2L67YUU"},{"name":"Maps_To","value":"2-Hydroxyestradiol"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046196"}]}}{"C63947":{"preferredName":"2-Hydroxyestrone","code":"C63947","definitions":[{"definition":"A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 2 by cytochrome P450 (CYP) enzymes, including CYP1A1 and 1A2, with potential anticarcinogenic activity. The mechanism of action for the antitumor activity of 2-hydroxyestrone is not known but this metabolic product has minimal estrogenic activity compared to the parent compound and other estrone metabolites. Additionally, O-methylation of this compound produces 2-methoxyestradiol (2-MeOE2), which is a potent inhibitor of both cell proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Hydroxyestrone","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5(10)-Estratrien-2,3-diol-17-one","termGroup":"SN","termSource":"NCI"},{"termName":"2-OHE(1)","termGroup":"SY","termSource":"NCI"},{"termName":"2-OHE1","termGroup":"SY","termSource":"NCI"},{"termName":"Catecholestrone","termGroup":"SY","termSource":"NCI"},{"termName":"Estra-1,3,5(1)-Trien-17-One, 2,3-Dihydroxy-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-06-1"},{"name":"CHEBI_ID","value":"CHEBI:1156"},{"name":"Chemical_Formula","value":"C18H22O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UQS3A06ILY"},{"name":"Legacy Concept Name","value":"_2-Hydroxyestrone"},{"name":"Maps_To","value":"2-Hydroxyestrone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046200"}]}}{"C85482":{"preferredName":"2-Hydroxyflutamide Depot","code":"C85482","definitions":[{"definition":"A depot formulation containing a bioresorbable, controlled-release, calcium sulphate-based paste of the nonsteroidal antiandrogen 2-hydroxyflutamide (2-HOF) with potential antineoplastic activity. Upon injection into the tumor site in the prostate, 2-hydroxyflutamide depot slowly releases 2-HOF, which competitively binds to androgen receptors (ARs), blocking the binding of dihydrotestosterone (DHT). This may inhibit androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest and decreased cellular proliferation. In addition, 2-HOF inhibits nuclear uptake of androgen in androgen-responsive tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Hydroxyflutamide Depot","termGroup":"PT","termSource":"NCI"},{"termName":"2-Hydroxyflutamide Controlled-Release Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"Liproca","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2-Hydroxyflutamide Depot"},{"name":"NCI_Drug_Dictionary_ID","value":"648122"},{"name":"NCI_META_CUI","value":"CL412370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648122"},{"name":"PDQ_Open_Trial_Search_ID","value":"648122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105401":{"preferredName":"Idroxioleic Acid","code":"C105401","definitions":[{"definition":"An orally bioavailable, synthetic analog of the fatty acid oleic acid, with potential antitumor activity. Upon administration,idroxioleic acid activates sphingomyelin synthase (SMS), thereby increasing the concentration of sphingomyelin (SM) and diacylglycerol (DAG) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signaling and the aberrant activity of signaling pathways in certain tumor cells, including the Ras/MAPK and PI3K/AKt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idroxioleic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2-Hydroxyoleic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"2-OHOA","termGroup":"CN","termSource":"NCI"},{"termName":"2OHOA","termGroup":"CN","termSource":"NCI"},{"termName":"LAM 561","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-561","termGroup":"CN","termSource":"NCI"},{"termName":"LAM561","termGroup":"CN","termSource":"NCI"},{"termName":"Minerval","termGroup":"FB","termSource":"NCI"},{"termName":"NFX88","termGroup":"CN","termSource":"NCI"},{"termName":"SML-0256","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56472-29-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OSV3KVO1BT"},{"name":"Maps_To","value":"2-Hydroxyoleic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"746793"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746793"},{"name":"PDQ_Open_Trial_Search_ID","value":"746793"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566317"}]}}{"C965":{"preferredName":"2-Methoxyestradiol","code":"C965","definitions":[{"definition":"2ME2. A drug derived from estrogen that belongs to the family of drugs called angiogenesis inhibitors.  It prevents the formation of new blood vessels that tumors need in order to grow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable estradiol metabolite with potential antineoplastic activity.  2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis.  This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Methoxyestradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol","termGroup":"SN","termSource":"NCI"},{"termName":"2-MeE2","termGroup":"AB","termSource":"NCI"},{"termName":"2-MeOE2","termGroup":"AB","termSource":"NCI"},{"termName":"2-Methoxy Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"2ME2","termGroup":"AB","termSource":"NCI"},{"termName":"Panzem","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-07-2"},{"name":"CHEBI_ID","value":"CHEBI:28955"},{"name":"Chemical_Formula","value":"C19H26O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6I2QW73SR5"},{"name":"Legacy Concept Name","value":"_2-Methoxyestradiol"},{"name":"Maps_To","value":"2-Methoxyestradiol"},{"name":"NCI_Drug_Dictionary_ID","value":"38472"},{"name":"NSC Number","value":"659853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38472"},{"name":"PDQ_Open_Trial_Search_ID","value":"38472"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046319"}]}}{"C62603":{"preferredName":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion","code":"C62603","definitions":[{"definition":"An orally bioavailable liquid formulation containing the small molecule 2-methoxyestradiol with potential antineoplastic activity. 2-Methoxyestradiol, a naturally occurring estradiol metabolite, exerts its antitumor effect by inhibiting endothelial cells as well as tumor cells through multiple mechanisms. This agent binds to tubulin and disrupts microtubule formation, thereby preventing mitosis and subsequent cellular proliferation. In addition, 2-methoxyestradiol induces caspase activation, resulting in cell cycle arrest in G2 phase and apoptosis in due course. This agent also down-regulates hypoxia inducible factor-one alpha (HIF-1a). The nanocrystal colloidal dispersion increases the absorption of 2-methoxyestradiol, thereby improving its bioavailability, which results in enhanced drug plasma levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion","termGroup":"PT","termSource":"NCI"},{"termName":"Panzem NCD","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_2-Methoxyestradiol_Nanocrystal_Colloidal_Dispersion"},{"name":"Maps_To","value":"2-Methoxyestradiol Nanocrystal Colloidal Dispersion"},{"name":"NCI_Drug_Dictionary_ID","value":"488412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488412"},{"name":"PDQ_Open_Trial_Search_ID","value":"488412"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831865"}]}}{"C120472":{"preferredName":"2-Methoxyestrone","code":"C120472","definitions":[{"definition":"A metabolite formed during the methylation of 2-hydroxyestrone (2-OHE1) by catechol-O-methyltransferase (COMT), with potential anticarcinogenic and minimal estrogen activities. The mechanism of action for the antitumor activity of 2-methoxyestrone (2-OMeE1) is not known. A high 2-methoxyestrone (2-OMeE1)/2-OHE1 ratio indicates higher methylation efficiency and correlates with a lower cancer risk.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2-Methoxyestrone","termGroup":"PT","termSource":"NCI"},{"termName":"2-MeE1","termGroup":"AB","termSource":"NCI"},{"termName":"2-MeOE1","termGroup":"AB","termSource":"NCI"},{"termName":"2-OMeE1","termGroup":"AB","termSource":"NCI"},{"termName":"3-Hydroxy-2-Methoxyestra-1,3,5(10)-Trien-17-One","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"362-08-3"},{"name":"CHEBI_ID","value":"CHEBI:1189"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SJ5857RRL3"},{"name":"Maps_To","value":"2-Methoxyestrone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046322"}]}}{"C99130":{"preferredName":"Dociparstat sodium","code":"C99130","definitions":[{"definition":"A heparin derivative in which the 2-O and 3-O sulfate groups of heparin are removed and that lacks anticoagulant activity, with potential anti-inflammatory, immodulatory and antineoplastic activities. Upon administration, dociparstat sodium binds to both chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) and CXC chemokine receptor 4 (CXCR4). This prevents the interaction of CXCL12 with CXCR4, blocks CXCR4 activation, and may result in decreased proliferation and migration in CXCR4-overexpressing tumor cells. In addition, inhibition of CXCL12/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into the blood.  In addition, dociparstat sodium prevents the interaction of the receptor for advanced glycation end-products (RAGE) with its ligands, including advanced glycation end-products (AGEs), Mac-1(CD11b/CD18), the nuclear pro-inflammatory protein high mobility group box protein-1 (HMGB-1), carboxymethyl lysine-bovine serum albumin (CML-BSA) and members of the S100 calgranulin family. In addition, this agent inhibits the enzymes heparanase, cathepsin G, and human leukocyte elastase, which are involved in inflammation and metastasis. Altogether, this may inhibit tumor cell invasiveness and metastasis. Dociparstat sodium also binds to platelet factor 4 (PF4 or CXCL4) and may prevent PF4's inhibitory effect on platelet production. This may increase platelet production. Unlike heparin, this agent does not induce heparin-induced thrombocytopenia (HIT). RAGE, a receptor belonging to the immunoglobulin superfamily, plays a key role in inflammation and is overexpressed in a variety of cancers. CXCR4 is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family that plays an important role in chemotaxis, chemoresistance and angiogenesis, and is upregulated in several tumor cell types. The interaction between CXCL12/CXCR4 induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dociparstat sodium","termGroup":"PT","termSource":"NCI"},{"termName":"2,3-o-Desulfated Heparin (12000 da)","termGroup":"SN","termSource":"NCI"},{"termName":"CX 01","termGroup":"CN","termSource":"NCI"},{"termName":"CX-01","termGroup":"CN","termSource":"NCI"},{"termName":"CX01","termGroup":"CN","termSource":"NCI"},{"termName":"O-desulfated Heparin","termGroup":"SY","termSource":"NCI"},{"termName":"ODSH","termGroup":"AB","termSource":"NCI"},{"termName":"PGX-100","termGroup":"CN","termSource":"NCI"},{"termName":"PGX-ODSH","termGroup":"SY","termSource":"NCI"},{"termName":"PGX100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"177021-00-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O75889WF4"},{"name":"Maps_To","value":"2-O, 3-O Desulfated Heparin"},{"name":"Maps_To","value":"Dociparstat sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"715907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715907"},{"name":"PDQ_Open_Trial_Search_ID","value":"715907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0915548"}]}}{"C29796":{"preferredName":"2,6-Diaminopurine","code":"C29796","definitions":[{"definition":"One of a number of organic compounds that share a similar purine structure and possess antiviral and antitumor properties. 2,6-Diaminopurine nucleosides are versatile synthetic precursors for specific N-6 modifications of antiviral and antitumor agents. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2,6-Diaminopurine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Purine-2,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"9h-purine-2,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"DAP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1904-98-9"},{"name":"CHEBI_ID","value":"CHEBI:38001"},{"name":"Chemical_Formula","value":"C5H6N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49P95BAU4Z"},{"name":"Legacy Concept Name","value":"_2_6-Diaminopurine"},{"name":"Maps_To","value":"2,6-Diaminopurine"},{"name":"NSC Number","value":"743"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"UMLS_CUI","value":"C0045587"}]}}{"C126754":{"preferredName":"2,6-Dimethoxyquinone","code":"C126754","definitions":[{"definition":"A methoxy-substituted benzoquinone and bioactive compound found in fermented wheat germ extracts, with potential antineoplastic and immune-enhancing activity. 2,6-Dimethoxyquinone (2,6-DMBQ) inhibits anaerobic glycolysis thereby preventing cellular metabolism and inducing apoptosis. As cancer cells use the anaerobic glycolysis pathway to metabolize glucose and cancer cells proliferate at an increased rate as compared to normal, healthy cells, this agent is specifically cytotoxic towards cancer cells. In addition, 2,6-DMBQ exerts immune-enhancing effects by increasing natural killer (NK) cell and T-cell activity against cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"2,6-Dimethoxyquinone","termGroup":"PT","termSource":"NCI"},{"termName":"2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy-","termGroup":"SY","termSource":"NCI"},{"termName":"2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Dimethoxy-1,4-Benzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-Dimethoxy-p-Benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Dimethoxy-p-Quinone","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-Dimethoxybenzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-Dimethoxycyclohexa-2,5-Diene-1,4-Dione","termGroup":"SY","termSource":"NCI"},{"termName":"2,6-DMBQ","termGroup":"AB","termSource":"NCI"},{"termName":"p-Benzoquinone, 2,6-Dimethoxy-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"530-55-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z701W789S"},{"name":"Maps_To","value":"2,6-Dimethoxyquinone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0045611"}]}}{"C80036":{"preferredName":"2'-F-ara-deoxyuridine","code":"C80036","definitions":[{"definition":"A deoxyuridine prodrug with potential antineoplastic activity. Upon cellular uptake, 2'-F-ara-deoxyuridine (FAU) is phosphorylated by thymidine kinase to FAU monophosphate and subsequently methylated in the 5'-position by thymidylate synthase (TS) to its activated form, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) 5-methyluracil monophosphate (FMAUMP). FMAUMP is incorporated into DNA leading to an inhibition of DNA synthesis and so cell growth. The catalytic activity of TS is critical to activation of FAU and subsequent incorporation into DNA. FAU may be beneficial in the case of tumors with high TS activity that are resistant to TS inhibitors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of advanced solid tumors and lymphomas. It blocks the growth of cells and may cause cancer cells to die. It is a type of uracil analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"2'-F-ara-deoxyuridine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) Uracil","termGroup":"SN","termSource":"NCI"},{"termName":"FAU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69123-94-0"},{"name":"Chemical_Formula","value":"C9H11FN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K7386OMP29"},{"name":"Legacy Concept Name","value":"_2-F-ara-deoxyuridine"},{"name":"Maps_To","value":"2'-F-ara-deoxyuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"616102"},{"name":"NCI_META_CUI","value":"CL388502"},{"name":"PDQ_Closed_Trial_Search_ID","value":"616102"},{"name":"PDQ_Open_Trial_Search_ID","value":"616102"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29475":{"preferredName":"3'-C-ethynylcytidine","code":"C29475","definitions":[{"definition":"A synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"3'-C-ethynylcytidine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine","termGroup":"SN","termSource":"NCI"},{"termName":"3'-C-ethynylcytidine","termGroup":"SY","termSource":"NCI"},{"termName":"ECdy","termGroup":"AB","termSource":"NCI"},{"termName":"ECyd","termGroup":"AB","termSource":"NCI"},{"termName":"TAS-106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"180300-43-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y3O05I09ZK"},{"name":"Legacy Concept Name","value":"TAS-106"},{"name":"Maps_To","value":"3'-C-ethynylcytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"614024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614024"},{"name":"PDQ_Open_Trial_Search_ID","value":"614024"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0533115"}]}}{"C977":{"preferredName":"4-Nitroestrone 3-Methyl Ether","code":"C977","definitions":[{"definition":"A synthetic derivative of estradiol. 4-nitroestrone 3-methyl ether inhibits estrogen sulfotransferase (EST), a progesterone-induced secretory endometrial enzyme which affects estrogen receptor levels.  This agent has been shown to be an effective growth inhibitor of some chemically induced animal mammary tumors. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"4-Nitroestrone 3-Methyl Ether","termGroup":"PT","termSource":"NCI"},{"termName":"3-Methoxy-4-nitro-estra-1,3,5(10)-trien-17-one","termGroup":"SY","termSource":"NCI"},{"termName":"4-Nitroestrone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"14846-62-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G484L3U0O2"},{"name":"Legacy Concept Name","value":"_4-Nitroestrone_3-Methyl_Ether"},{"name":"Maps_To","value":"4-Nitroestrone 3-Methyl Ether"},{"name":"NCI_Drug_Dictionary_ID","value":"39339"},{"name":"NSC Number","value":"321803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39339"},{"name":"PDQ_Open_Trial_Search_ID","value":"39339"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048573"}]}}{"C121828":{"preferredName":"4-Thio-2-deoxycytidine","code":"C121828","definitions":[{"definition":"An orally bioavailable 4-thio modified 2-deoxycytidine analog, with potential antineoplastic activity. Upon administration of 4-thio-2-deoxycytidine (TdCyd), this cytidine analog gets incorporated into DNA during replication and inhibits the activity of DNA methyltransferase 1 (DNMT1), which blocks DNA hypermethylation. This results in DNMT1 depletion, hypomethylation of DNA, and the reactivation of tumor suppressor genes that were silenced by hypermethylation; this results in antitumor activity and an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"4-Thio-2-deoxycytidine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Thio-2'-deoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"T-dCyd","termGroup":"AB","termSource":"NCI"},{"termName":"TdCyd","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134111-30-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L76O0M313F"},{"name":"Maps_To","value":"4-Thio-2-deoxycytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"771603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771603"},{"name":"PDQ_Open_Trial_Search_ID","value":"771603"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0647434"}]}}{"C971":{"preferredName":"4'-Iodo-4'-Deoxydoxorubicin","code":"C971","definitions":[{"definition":"A substance that is being studied as a treatment for cancer, and for primary systemic amyloidosis (a disease in which proteins are deposited in specific organs). It belongs to the family of drugs called anthracycline analogues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An iodinated doxorubicin analogue with antiamyloid activity. 4'-Iodo-4'-deoxydoxorubicin (IDOX) binds with high affinity to five types of natural amyloid fibrils including immunoglobulin light chains, amyloid A, transthyretin (methionine-30 variant), beta-protein (Alzheimer), and beta2-microglobulin. This agent may inhibit fibril growth, increasing the solubility of amyloid tissue deposits and facilitating their clearance. IDOX has also been shown to insulin amyloid fibrillogenesis in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"4'-Iodo-4'-Deoxydoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxy-4'-Iododoxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"IDOX","termGroup":"AB","termSource":"NCI"},{"termName":"Iodo-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Iododoxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83997-75-5"},{"name":"CHEBI_ID","value":"CHEBI:47897"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65JH75I9JX"},{"name":"Legacy Concept Name","value":"_4_Iodo-4_Deoxydoxorubicin"},{"name":"Maps_To","value":"4'-Iodo-4'-Deoxydoxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"41162"},{"name":"NSC Number","value":"378901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41162"},{"name":"PDQ_Open_Trial_Search_ID","value":"41162"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0047758"}]}}{"C153479":{"preferredName":"5-Aza-4'-thio-2'-deoxycytidine","code":"C153479","definitions":[{"definition":"An orally bioavailable, nucleoside analog and DNA methyltransferase I (DNMT1) inhibitor, with potential DNA hypomethylating and antineoplastic activities. Upon administration, 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) gets incorporated into DNA, where it binds to the active site of DNMT1, a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. The formation of covalent DNMT1-DNA complexes inhibits DNMT1, prevents DNA methylation of CpG sites, causes CpG demethylation, and results in the re-expression and re-activation of silenced tumor suppressor genes. This inhibits tumor cell proliferation. DNMT1, overactivated in tumor cells, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5-Aza-4'-thio-2'-deoxycytidine","termGroup":"PT","termSource":"NCI"},{"termName":"5-Aza-4-thio-2-deoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"5-Aza-TdCyd","termGroup":"AB","termSource":"NCI"},{"termName":"Aza-TdC","termGroup":"AB","termSource":"NCI"},{"termName":"Aza-TdCyd","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"169514-76-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U2PTN0RZF6"},{"name":"Maps_To","value":"5-Aza-4'-thio-2'-deoxycytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"794175"},{"name":"NCI_META_CUI","value":"CL554978"},{"name":"NSC Number","value":"777586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794175"},{"name":"PDQ_Open_Trial_Search_ID","value":"794175"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62785":{"preferredName":"5-Fluoro-2-Deoxycytidine","code":"C62785","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It may prevent the growth of tumors by stopping cancer cells from dividing and by killing them. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"5-Fluoro-2-Deoxycytidine","termGroup":"PT","termSource":"NCI"},{"termName":"Cytidine, 2'-deoxy-5-fluoro-","termGroup":"SN","termSource":"NCI"},{"termName":"FdCyd","termGroup":"AB","termSource":"NCI"},{"termName":"Ro 5-1090","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10356-76-0"},{"name":"Chemical_Formula","value":"C9H12FN3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KUA4693H5W"},{"name":"Legacy Concept Name","value":"_5-Fluoro-2-Deoxycytidine"},{"name":"Maps_To","value":"5-Fluoro-2-Deoxycytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"509184"},{"name":"NSC Number","value":"48006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"509184"},{"name":"PDQ_Open_Trial_Search_ID","value":"509184"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049174"}]}}{"C113787":{"preferredName":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158","code":"C113787","definitions":[{"definition":"An inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. PFKFB3, an enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, is highly expressed and active in human cancer cells; it plays a key role in increasing both glycolytic flux in and proliferation of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158","termGroup":"PT","termSource":"NCI"},{"termName":"ACT-PFK-158","termGroup":"CN","termSource":"NCI"},{"termName":"PFK-158","termGroup":"CN","termSource":"NCI"},{"termName":"PFKFB3 Inhibitor PFK-158","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158"},{"name":"NCI_Drug_Dictionary_ID","value":"757225"},{"name":"NCI_META_CUI","value":"CL471768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757225"},{"name":"PDQ_Open_Trial_Search_ID","value":"757225"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1611":{"preferredName":"7-Cyanoquinocarcinol","code":"C1611","definitions":[{"definition":"A semisynthetic analogue of the Streptomyces melanovinaceus-derived tetracyclic antitumor antibiotic quinocarmycin with potential antineoplastic activity. Quinocarmycin belongs to the naphthyridinomycin/saframycin class of antitumor antibiotics. These antibiotics appear to act through DNA alkylation.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics. It is an anthracycline.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"7-Cyanoquinocarcinol","termGroup":"PT","termSource":"NCI"},{"termName":"DX 52-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96251-59-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"64T9QZ8N2Y"},{"name":"Legacy Concept Name","value":"_7-Cyanoquinocarcinol"},{"name":"Maps_To","value":"7-Cyanoquinocarcinol"},{"name":"NCI_Drug_Dictionary_ID","value":"42444"},{"name":"NSC Number","value":"607097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42444"},{"name":"PDQ_Open_Trial_Search_ID","value":"42444"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0294165"}]}}{"C61618":{"preferredName":"7-Ethyl-10-Hydroxycamptothecin","code":"C61618","synonyms":[{"termName":"7-Ethyl-10-Hydroxycamptothecin","termGroup":"PT","termSource":"NCI"},{"termName":"7-Ethyl-10-hydroxy-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"SN 38","termGroup":"CN","termSource":"NCI"},{"termName":"SN-38","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86639-52-3"},{"name":"Chemical_Formula","value":"C22H20N2O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0H43101T0J"},{"name":"Legacy Concept Name","value":"_7-Ethyl-10-Hydroxycamptothecin"},{"name":"Maps_To","value":"7-Ethyl-10-Hydroxycamptothecin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0142710"}]}}{"C1271":{"preferredName":"7-Hydroxystaurosporine","code":"C1271","definitions":[{"definition":"A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called staurosporine analogues.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"7-Hydroxystaurosporine","termGroup":"PT","termSource":"NCI"},{"termName":"7-Hydroxy-staurosporine","termGroup":"SN","termSource":"NCI"},{"termName":"8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo[a, g]cyclonona[cde] Trinden-1-one, 2,3,9,10,11, 12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)","termGroup":"SN","termSource":"NCI"},{"termName":"UCN-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112953-11-4"},{"name":"Chemical_Formula","value":"C28H26N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BU5H4V94A"},{"name":"Legacy Concept Name","value":"_7-Hydroxystaurosporine"},{"name":"Maps_To","value":"7-Hydroxystaurosporine"},{"name":"NCI_Drug_Dictionary_ID","value":"42305"},{"name":"NSC Number","value":"638850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42305"},{"name":"PDQ_Open_Trial_Search_ID","value":"42305"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077681"}]}}{"C28788":{"preferredName":"8-Azaguanine","code":"C28788","definitions":[{"definition":"A purine analogue with potential antineoplastic activity.  8-Azaguanine interferes with the modification of transfer ribonucleic acid (tRNA) by competing with guanine for incorporation into tRNA catalyzed by the enzyme tRNA-guanine ribosyltransferase (tRNA-guanine transglycosylase).  Altered guanine modification of tRNA has been implicated in cellular differentiation and neoplastic transformation.  8-Azaguanine also inhibits the formation of 43S and 80S initiation complexes, thereby interfering with initiation of translation and inhibiting protein synthesis.  This agent inhibits tumor cell growth and stimulates cell differentiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"8-Azaguanine","termGroup":"PT","termSource":"NCI"},{"termName":"5-Amino-1,4-dihydro-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-1H-v-triazolo(d)pyrimidin-7-ol","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-7-hydroxy-1H-v-triazolo(d)pyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"8 AG","termGroup":"AB","termSource":"NCI"},{"termName":"Guanazolo","termGroup":"SY","termSource":"NCI"},{"termName":"Pathocidin","termGroup":"SY","termSource":"NCI"},{"termName":"SF-337","termGroup":"CN","termSource":"NCI"},{"termName":"SK 1150","termGroup":"CN","termSource":"NCI"},{"termName":"Triazologuanine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134-58-7"},{"name":"CHEBI_ID","value":"CHEBI:63486"},{"name":"Chemical_Formula","value":"C4H4N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q150359I72"},{"name":"Legacy Concept Name","value":"_8-Azaguanine"},{"name":"Maps_To","value":"8-Azaguanine"},{"name":"NSC Number","value":"223526"},{"name":"NSC Number","value":"749"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004476"}]}}{"C28789":{"preferredName":"9-Ethyl 6-Mercaptopurine","code":"C28789","definitions":[{"definition":"A synthetic alkyl derivative prodrug of the antineoplastic agent 6-mercaptopurine (6-MP).  In vivo, 9-ethyl 6-mercaptopurine appears to be converted to 6-MP, which substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"9-Ethyl 6-Mercaptopurine","termGroup":"PT","termSource":"NCI"},{"termName":"9-Ethyl 6-MP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5427-20-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_9-Ethyl_6-Mercaptopurine"},{"name":"Maps_To","value":"9-Ethyl 6-Mercaptopurine"},{"name":"NSC Number","value":"14575"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0626019"}]}}{"C28793":{"preferredName":"9H-Purine-6Thio-98D","code":"C28793","definitions":[{"definition":"An antimetabolite analogue of purine with antineoplastic and immuno-suppressant properties.  9H-Purine-6Thio-98D substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. In vivo, this agent, also known as 6MP-arabinoside, may occur as a metabolite of the antineoplastic agent mercaptopurine. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"9H-Purine-6Thio-98D","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_9H-Purine-6Thio-98D"},{"name":"Maps_To","value":"9H-Purine-6Thio-98D"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515473"}]}}{"C26449":{"preferredName":"Abagovomab","code":"C26449","definitions":[{"definition":"A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abagovomab","termGroup":"PT","termSource":"NCI"},{"termName":"Monoclonal Antibody ACA125 Anti-Idiotype Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"VaccinOvar","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"792921-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3YK0326U7X"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_ACA125_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Abagovomab"},{"name":"NCI_Drug_Dictionary_ID","value":"299488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299488"},{"name":"PDQ_Open_Trial_Search_ID","value":"299488"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832044"}]}}{"C2015":{"preferredName":"Abarelix","code":"C2015","definitions":[{"definition":"A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone.  As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abarelix","termGroup":"PT","termSource":"NCI"},{"termName":"Plenaxis","termGroup":"SY","termSource":"NCI"},{"termName":"PPI-149","termGroup":"CN","termSource":"NCI"},{"termName":"R-3827","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prostate Cancer"},{"name":"CAS_Registry","value":"183552-38-7"},{"name":"CHEBI_ID","value":"CHEBI:337298"},{"name":"Chemical_Formula","value":"C72H95ClN14O14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"W486SJ5824"},{"name":"Legacy Concept Name","value":"Abarelix"},{"name":"Maps_To","value":"Abarelix"},{"name":"NCI_Drug_Dictionary_ID","value":"415570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415570"},{"name":"PDQ_Open_Trial_Search_ID","value":"415570"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1174732"}]}}{"C97660":{"preferredName":"Abemaciclib","code":"C97660","definitions":[{"definition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abemaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)","termGroup":"SN","termSource":"NCI"},{"termName":"LY 2835219","termGroup":"CN","termSource":"NCI"},{"termName":"LY-2835219","termGroup":"CN","termSource":"NCI"},{"termName":"LY2835219","termGroup":"CN","termSource":"NCI"},{"termName":"Verzenio","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer"},{"name":"CAS_Registry","value":"1231929-97-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"60UAB198HK"},{"name":"Maps_To","value":"Abemaciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"706364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706364"},{"name":"PDQ_Open_Trial_Search_ID","value":"706364"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852841"}]}}{"C162507":{"preferredName":"Abemaciclib Mesylate","code":"C162507","definitions":[{"definition":"The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abemaciclib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"LY-2835219 methanesulfonate","termGroup":"CN","termSource":"NCI"},{"termName":"LY-2835219 Methanesulfonate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1231930-82-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KKT462Q807"},{"name":"Maps_To","value":"Abemaciclib Mesylate"},{"name":"NCI_META_CUI","value":"CL970947"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68920":{"preferredName":"Abexinostat","code":"C68920","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abexinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-benzofurancarboxamide, 3-((dimethylamino)methyl)-n-(2-(4-((hydroxyamino)carbonyl)phenoxy)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)-1-benzofuran-2-carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"CRA-024781","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC Inhibitor PCI-24781","termGroup":"SY","termSource":"NCI"},{"termName":"PCI 24781","termGroup":"CN","termSource":"NCI"},{"termName":"PCI-24781","termGroup":"CN","termSource":"NCI"},{"termName":"PCI24781","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"783355-60-2"},{"name":"Chemical_Formula","value":"C21H23N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IYO470654U"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_CRA-024781"},{"name":"Maps_To","value":"Abexinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"553625"},{"name":"PDQ_Closed_Trial_Search_ID","value":"553625"},{"name":"PDQ_Open_Trial_Search_ID","value":"553625"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537177"}]}}{"C160889":{"preferredName":"Abexinostat Tosylate","code":"C160889","definitions":[{"definition":"The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abexinostat Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrolo(2,3-C)pyridine-2-carboxamide, N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl)-6,7-dihydro-6-methyl-7-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"PCI-24781 Tosylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138861-99-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AOH3JC92C0"},{"name":"Maps_To","value":"Abexinostat Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"553625"},{"name":"NCI_META_CUI","value":"CL969910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"553625"},{"name":"PDQ_Open_Trial_Search_ID","value":"553625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77333":{"preferredName":"Abiraterone","code":"C77333","definitions":[{"definition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abiraterone","termGroup":"PT","termSource":"NCI"},{"termName":"17-(3-Pyridyl)androsta-5,16-dien-3beta-ol","termGroup":"SN","termSource":"NCI"},{"termName":"CB 7598","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154229-19-3"},{"name":"Chemical_Formula","value":"C24H31NO"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"G819A456D0"},{"name":"Legacy Concept Name","value":"Abiraterone"},{"name":"Maps_To","value":"Abiraterone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0754011"}]}}{"C68845":{"preferredName":"Abiraterone Acetate","code":"C68845","definitions":[{"definition":"A substance being studied in the treatment of prostate cancer and breast cancer. It blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of cancer cells that need androgens to grow. It is a type of anti-androgen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abiraterone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"17-(3-Pyridyl)-5,16-androstadien-3beta-acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-","termGroup":"SN","termSource":"NCI"},{"termName":"BR9004","termGroup":"CN","termSource":"NCI"},{"termName":"BR9004-1","termGroup":"CN","termSource":"NCI"},{"termName":"CB 7630","termGroup":"CN","termSource":"NCI"},{"termName":"CB-7630","termGroup":"CN","termSource":"NCI"},{"termName":"CB7630","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-212082","termGroup":"CN","termSource":"NCI"},{"termName":"Yonsa","termGroup":"BR","termSource":"NCI"},{"termName":"Zytiga","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Castration-resistant prostate cancer"},{"name":"CAS_Registry","value":"154229-18-2"},{"name":"Chemical_Formula","value":"C26H33NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EM5OCB9YJ6"},{"name":"Legacy Concept Name","value":"Abiraterone_Acetate"},{"name":"Maps_To","value":"Abiraterone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"552704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"552704"},{"name":"PDQ_Open_Trial_Search_ID","value":"552704"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607886"}]}}{"C82422":{"preferredName":"Abituzumab","code":"C82422","definitions":[{"definition":"A humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities. Abituzumab, a chimeric antibody which includes the antigen binding sites of the anti-integrin mouse antibody 17E6, binds to and inhibits the activity of alphaVbeta3 integrin (vitronectin receptor); this may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alphavbeta3-expressing tumor cells. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is expressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 525797","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1105038-73-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"724QD330RD"},{"name":"Legacy Concept Name","value":"Anti-alphaVbeta3_Monoclonal_Antibody_EMD_525797"},{"name":"Maps_To","value":"Abituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"638087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638087"},{"name":"PDQ_Open_Trial_Search_ID","value":"638087"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830088"}]}}{"C99901":{"preferredName":"Acai Berry Juice","code":"C99901","definitions":[{"definition":"A juice product obtained from the fruit of the acai palm tree (Euterpe oleracea) with anti-inflammatory, antioxidant and potential chemopreventive activities. Besides high amounts of vitamins, minerals and fatty acids, acai berry is rich in phytonutrients such as anthocyanins and flavones which are potent scavengers of reactive oxygen species. The fruit also contains high amounts of the flavone velutin which exhibits potent anti-inflammatory properties. Velutin is able to inhibit the degradation of the inhibitor of nuclear factor kappa-B (NF-kB), thereby blocking the activation of NF-kB, as well as inhibiting phosphorylation of mitogen-activated protein kinase p38 and JNK. Inhibition of these processes results in suppression of the production of proinflammatory cytokines, such as tumor necrosis factor alpha and interleukin 6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acai Berry Juice","termGroup":"PT","termSource":"NCI"},{"termName":"Acai Juice","termGroup":"SY","termSource":"NCI"},{"termName":"Açai Berry Juice","termGroup":"SY","termSource":"NCI"},{"termName":"Açai Juice","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6JR5T80U0G"},{"name":"Maps_To","value":"Acai Berry Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"724700"},{"name":"NCI_META_CUI","value":"CL433602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724700"},{"name":"PDQ_Open_Trial_Search_ID","value":"724700"},{"name":"Semantic_Type","value":"Food"}]}}{"C113442":{"preferredName":"Acalabrutinib","code":"C113442","definitions":[{"definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acalabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"ACP 196","termGroup":"CN","termSource":"NCI"},{"termName":"ACP-196","termGroup":"CN","termSource":"NCI"},{"termName":"ACP196","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-","termGroup":"SN","termSource":"NCI"},{"termName":"Bruton Tyrosine Kinase Inhibitor ACP-196","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy; with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"CAS_Registry","value":"1420477-60-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I42748ELQW"},{"name":"Maps_To","value":"Acalabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"756623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756623"},{"name":"PDQ_Open_Trial_Search_ID","value":"756623"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4078312"}]}}{"C103277":{"preferredName":"Acalisib","code":"C103277","definitions":[{"definition":"An inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. Acalisib inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acalisib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Fluoro-3-phenyl-2-((1S)-1-(7H-purin-6-ylamino)ethyl)quinazolin-4(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"CAL-120","termGroup":"CN","termSource":"NCI"},{"termName":"GS-9820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"870281-34-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OVW60IDW1D"},{"name":"Maps_To","value":"Acalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"741949"},{"name":"NCI_META_CUI","value":"CL438128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741949"},{"name":"PDQ_Open_Trial_Search_ID","value":"741949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C984":{"preferredName":"Aceglatone","code":"C984","definitions":[{"definition":"A derivative of D-glucaro-1, 4-lactone with chemopreventive and anti-tumor activities. One of the key processes in which human body eliminates toxic chemicals as well as hormones (such as estrogen) is by glucuronidation. When beta-glucuronidase deconjugates these glucuronides, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Thereby, aceglatone may suppress the developments of hormone-dependent cancers mediated through beta-glucuronidase inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aceglatone","termGroup":"PT","termSource":"NCI"},{"termName":"Glucaron","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"642-83-1"},{"name":"Chemical_Formula","value":"C10H10O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"347Q3OOJ13"},{"name":"Legacy Concept Name","value":"Aceglatone"},{"name":"Maps_To","value":"Aceglatone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050406"}]}}{"C200":{"preferredName":"Acetylcysteine","code":"C200","definitions":[{"definition":"A drug usually used to reduce the thickness of mucus and ease its removal. It is also used to reverse the toxicity of high doses of acetaminophen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acetylcysteine","termGroup":"PT","termSource":"NCI"},{"termName":"Acetadote","termGroup":"BR","termSource":"NCI"},{"termName":"Airbron","termGroup":"FB","termSource":"NCI"},{"termName":"Broncholysin","termGroup":"FB","termSource":"NCI"},{"termName":"Brunac","termGroup":"FB","termSource":"NCI"},{"termName":"Fabrol","termGroup":"FB","termSource":"NCI"},{"termName":"Fluatox","termGroup":"FB","termSource":"NCI"},{"termName":"Fluimucetin","termGroup":"FB","termSource":"NCI"},{"termName":"Fluimucil","termGroup":"FB","termSource":"NCI"},{"termName":"Fluprowit","termGroup":"FB","termSource":"NCI"},{"termName":"L-Alpha-acetamido-beta-mercaptopropionic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Muco Sanigen","termGroup":"FB","termSource":"NCI"},{"termName":"Mucocedyl","termGroup":"FB","termSource":"NCI"},{"termName":"Mucolator","termGroup":"FB","termSource":"NCI"},{"termName":"Mucolyticum","termGroup":"FB","termSource":"NCI"},{"termName":"Mucomyst","termGroup":"BR","termSource":"NCI"},{"termName":"Mucosolvin","termGroup":"FB","termSource":"NCI"},{"termName":"Mucret","termGroup":"FB","termSource":"NCI"},{"termName":"N-Acetyl Cysteine","termGroup":"SY","termSource":"NCI"},{"termName":"N-acetyl-3-mercaptoalanine","termGroup":"SY","termSource":"NCI"},{"termName":"N-acetyl-L-cysteine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Acetylcysteine","termGroup":"SY","termSource":"NCI"},{"termName":"NAC","termGroup":"AB","termSource":"NCI"},{"termName":"Neo-Fluimucil","termGroup":"FB","termSource":"NCI"},{"termName":"Parvolex","termGroup":"FB","termSource":"NCI"},{"termName":"Respaire","termGroup":"FB","termSource":"NCI"},{"termName":"Tixair","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acetaminophen Overdose"},{"name":"CAS_Registry","value":"616-91-1"},{"name":"CHEBI_ID","value":"CHEBI:28939"},{"name":"Chemical_Formula","value":"C5H9NO3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WYQ7N0BPYC"},{"name":"Legacy Concept Name","value":"Acetylcysteine"},{"name":"Maps_To","value":"Acetylcysteine"},{"name":"NCI_Drug_Dictionary_ID","value":"39130"},{"name":"NSC Number","value":"111180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39130"},{"name":"PDQ_Open_Trial_Search_ID","value":"39130"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001047"}]}}{"C985":{"preferredName":"Acitretin","code":"C985","definitions":[{"definition":"A substance that is used in the prevention of cancer and in the treatment of psoriasis. It belongs to the family of drugs called retinoids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acitretin","termGroup":"PT","termSource":"NCI"},{"termName":"(All-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Etretin","termGroup":"SY","termSource":"NCI"},{"termName":"Neotigason","termGroup":"FB","termSource":"NCI"},{"termName":"Ro 10-1670","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-10-1670","termGroup":"CN","termSource":"NCI"},{"termName":"Soriatane","termGroup":"BR","termSource":"NCI"},{"termName":"Trimethylmethoxyphenyl-retinoic acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Psoriasis; cutaneous T-cell lymphoma"},{"name":"CAS_Registry","value":"55079-83-9"},{"name":"CHEBI_ID","value":"CHEBI:50173"},{"name":"Chemical_Formula","value":"C21H26O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LCH760E9T7"},{"name":"Legacy Concept Name","value":"Acitretin"},{"name":"Maps_To","value":"Acitretin"},{"name":"NCI_Drug_Dictionary_ID","value":"43244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43244"},{"name":"PDQ_Open_Trial_Search_ID","value":"43244"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050559"}]}}{"C986":{"preferredName":"Acivicin","code":"C986","definitions":[{"definition":"A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acivicin","termGroup":"PT","termSource":"NCI"},{"termName":"(S-(R*,R*))-4,5-Dihydro-alpha-amino-3-chloro-5-isoxazoleacetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AT-125","termGroup":"CN","termSource":"NCI"},{"termName":"U-42126","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42228-92-2"},{"name":"Chemical_Formula","value":"C5H7ClN2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O0X60K76I6"},{"name":"Legacy Concept Name","value":"Acivicin"},{"name":"Maps_To","value":"Acivicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39132"},{"name":"NSC Number","value":"163501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39132"},{"name":"PDQ_Open_Trial_Search_ID","value":"39132"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050560"}]}}{"C1861":{"preferredName":"Aclacinomycin B","code":"C1861","definitions":[{"definition":"An antineoplastic oligosaccharide anthracycline antibiotic isolated from the bacterium Streptomyces galilaeus.  Aclacinomycin B intercalates into DNA and inhibits both the topoisomerase I and II enzymes, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aclacinomycin B","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexapyranosyl)oxy)-, methyl ester,(1R-(1-alpha,2-beta,4-beta))-","termGroup":"SN","termSource":"NCI"},{"termName":"Aclarubicin B","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic MA 144B1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57596-79-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P8EJD9HI5K"},{"name":"Legacy Concept Name","value":"Aclacinomycin_B"},{"name":"Maps_To","value":"Aclacinomycin B"},{"name":"NSC Number","value":"208735"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0889093"}]}}{"C202":{"preferredName":"Aclarubicin","code":"C202","definitions":[{"definition":"An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aclarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacenecarboxylic acid methyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1alpha,2beta,4beta))-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Aclacinomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Aclacinomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"Aclacinomycin-A","termGroup":"SY","termSource":"NCI"},{"termName":"ACM-A","termGroup":"AB","termSource":"NCI"},{"termName":"Antibiotic MA144-A1","termGroup":"SY","termSource":"NCI"},{"termName":"MA144-A1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57576-44-0"},{"name":"Chemical_Formula","value":"C42H53NO15"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"74KXF8I502"},{"name":"Legacy Concept Name","value":"Aclarubicin"},{"name":"Maps_To","value":"Aclarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39131"},{"name":"NSC Number","value":"208734"},{"name":"NSC Number","value":"240619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39131"},{"name":"PDQ_Open_Trial_Search_ID","value":"39131"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001143"}]}}{"C988":{"preferredName":"Acodazole","code":"C988","definitions":[{"definition":"A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acodazole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-imidazo[4,5-f]quinoline, acetamide deriv","termGroup":"SN","termSource":"NCI"},{"termName":"acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"79152-85-5"},{"name":"Chemical_Formula","value":"C20H19N5O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8M28A9O41G"},{"name":"Legacy Concept Name","value":"Acodazole"},{"name":"Maps_To","value":"Acodazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39786"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39786"},{"name":"PDQ_Open_Trial_Search_ID","value":"39786"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050565"}]}}{"C71627":{"preferredName":"Acodazole Hydrochloride","code":"C71627","definitions":[{"definition":"The hydrochloride salt of acodazole, a synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acodazole Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-, monohydrochloride (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55435-65-9"},{"name":"Chemical_Formula","value":"C20H19N5O.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6D7W9EAH22"},{"name":"Legacy Concept Name","value":"Acodazole_Hydrochloride"},{"name":"Maps_To","value":"Acodazole Hydrochloride"},{"name":"NSC Number","value":"305884"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0970589"}]}}{"C65213":{"preferredName":"Acolbifene Hydrochloride","code":"C65213","definitions":[{"definition":"A substance being studied in the prevention of breast cancer in women at high risk of breast cancer. Acolbifene hydrochloride binds to estrogen receptors in the body and blocks the effects of estrogen in the breast. It is a type of selective estrogen receptor modulator (SERM).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of acolbifene, a fourth-generation estrogen receptor modulator (SERM) with potential lipid lowering and antineoplastic activity. Acolbifene specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. Acolbifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the effects of estrogen in these tissues. This may inhibit tumor cell proliferation in ER-positive tumor cells. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acolbifene Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"252555-01-4"},{"name":"Chemical_Formula","value":"C29H31NO4.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KXC7811DBY"},{"name":"Legacy Concept Name","value":"Acolbifene_Hydrochloride"},{"name":"Maps_To","value":"Acolbifene Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"636416"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636416"},{"name":"PDQ_Open_Trial_Search_ID","value":"636416"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879543"}]}}{"C203":{"preferredName":"Acridine","code":"C203","definitions":[{"definition":"A polycyclic aromatic dye with antineoplastic, antimicrobial and imaging activities. Acridine and its derivatives intercalate within DNA and RNA by forming hydrogen-bonds and stacking between base pairs resulting in DNA crosslinks and strand breaks. In addition, acridine and its derivatives are a potent inhibitor of topoisomerase II enzyme. This results in the inhibition of DNA and RNA synthesis, predominantly occurring during S phase of the cell cycle and ultimately leads to cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acridine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"260-94-6"},{"name":"CHEBI_ID","value":"CHEBI:36420"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42NI1P5Q1X"},{"name":"Legacy Concept Name","value":"Acridine"},{"name":"Maps_To","value":"Acridine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001186"}]}}{"C2203":{"preferredName":"Acridine Carboxamide","code":"C2203","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tricyclic acridine-based (or carboxamide-based) drug with dual topoisomerase inhibitor and potential antineoplastic activities. Acridine carboxamide inhibits both topoisomerases I and II and intercalates into DNA, resulting in DNA damage, the disruption of DNA repair and replication, the inhibition of RNA and protein synthesis, and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acridine Carboxamide","termGroup":"PT","termSource":"NCI"},{"termName":"DACA","termGroup":"AB","termSource":"NCI"},{"termName":"N-(2-(Dimehtylamino)ethyl)acridine-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"SN 22995","termGroup":"CN","termSource":"NCI"},{"termName":"XR5000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89459-25-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0N3V8R4E13"},{"name":"Legacy Concept Name","value":"Acridine_Carboxamide"},{"name":"Maps_To","value":"Acridine Carboxamide"},{"name":"NCI_Drug_Dictionary_ID","value":"37776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37776"},{"name":"PDQ_Open_Trial_Search_ID","value":"37776"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919282"}]}}{"C75297":{"preferredName":"Acronine","code":"C75297","definitions":[{"definition":"A natural alkaloid with an acridine structure isolated from the bark of the plant Acronychia baueri (Australian scrub ash) with antineoplastic properties.  Acronycine appears to alkylate DNA and interfere with DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acronine","termGroup":"PT","termSource":"NCI"},{"termName":"Acronycine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7008-42-6"},{"name":"CHEBI_ID","value":"CHEBI:2437"},{"name":"Chemical_Formula","value":"C20H19NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QE0G097358"},{"name":"Legacy Concept Name","value":"Acronine"},{"name":"Maps_To","value":"Acronine"},{"name":"NSC Number","value":"403169"},{"name":"PubMedID_Primary_Reference","value":"11996885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0001210"}]}}{"C82414":{"preferredName":"Actinium Ac 225 Lintuzumab","code":"C82414","definitions":[{"definition":"A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinium Ac 225 Lintuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"225Ac-HuM195","termGroup":"SY","termSource":"NCI"},{"termName":"Actimab-A","termGroup":"BR","termSource":"NCI"},{"termName":"Actinium (225Ac) Lintuzumab Satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-33 AC-225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2209911-94-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"V860J30J9N"},{"name":"Legacy Concept Name","value":"Actinium_Ac_225_Lintuzumab"},{"name":"Maps_To","value":"Actinium Ac 225 Lintuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"637163"},{"name":"NCI_META_CUI","value":"CL408677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637163"},{"name":"PDQ_Open_Trial_Search_ID","value":"637163"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158815":{"preferredName":"Actinium Ac 225-FPI-1434","code":"C158815","definitions":[{"definition":"A radioconjugate consisting of veligrotug, a humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-1R) linked, via a bifunctional chelate, to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-FPI-1434, the veligrotug moiety targets and binds to IGF-1R expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to IGF-1R-expressing tumor cells. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinium Ac 225-FPI-1434","termGroup":"PT","termSource":"NCI"},{"termName":"225Ac-FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"[225Ac]-FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"[Ac-225]-FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac 225-FPI-1397-FPI-1175","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac 225-labeled FPI-1434","termGroup":"SY","termSource":"NCI"},{"termName":"FPI 1434","termGroup":"CN","termSource":"NCI"},{"termName":"FPI-1434","termGroup":"CN","termSource":"NCI"},{"termName":"FPI1434","termGroup":"CN","termSource":"NCI"},{"termName":"FPX 01","termGroup":"CN","termSource":"NCI"},{"termName":"FPX-01","termGroup":"CN","termSource":"NCI"},{"termName":"FPX01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Actinium_Ac_225_Lintuzumab"},{"name":"Maps_To","value":"Actinium Ac 225-FPI-1434"},{"name":"NCI_Drug_Dictionary_ID","value":"797340"},{"name":"NCI_META_CUI","value":"CL950887"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797340"},{"name":"PDQ_Open_Trial_Search_ID","value":"797340"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153159":{"preferredName":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","code":"C153159","definitions":[{"definition":"A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac-225 anti-PSMA monoclonal antibody J591 binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","termGroup":"PT","termSource":"NCI"},{"termName":"225Ac-J591","termGroup":"AB","termSource":"NCI"},{"termName":"Ac 225 MOAB J591","termGroup":"AB","termSource":"NCI"},{"termName":"Ac 225 Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac-225 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"},{"termName":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591"},{"name":"NCI_Drug_Dictionary_ID","value":"793676"},{"name":"NCI_META_CUI","value":"CL554298"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793676"},{"name":"PDQ_Open_Trial_Search_ID","value":"793676"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95198":{"preferredName":"Actinomycin C2","code":"C95198","definitions":[{"definition":"A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C2 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms including, intercalating into the minor groove of DNA and interfering with the function of topoisomerase II. In addition, actinomycin C2 appears to block the interaction between the SH2 domain of growth factor receptor-bound protein-2 (GRB2) and the Src homology 2 domain containing transforming protein 1 adaptor protein SHC, which plays a key role in the Ras signaling pathway thereby halting cellular differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinomycin C2","termGroup":"PT","termSource":"NCI"},{"termName":"Actinomycin D, 2a-D-Alloisoleucine-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2612-14-8"},{"name":"Chemical_Formula","value":"C63H88N12O16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"719U3YSA1F"},{"name":"Maps_To","value":"Actinomycin C2"},{"name":"NSC Number","value":"87221"},{"name":"PubMedID_Primary_Reference","value":"10888331"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762401"}]}}{"C99564":{"preferredName":"Actinomycin C3","code":"C99564","definitions":[{"definition":"A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C3 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms such as intercalating into the minor groove of DNA and interfering with the function of topoisomerase II.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinomycin C3","termGroup":"PT","termSource":"NCI"},{"termName":"2104-L-I","termGroup":"CN","termSource":"NCI"},{"termName":"Actinomycin AY1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin I3","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin VII","termGroup":"SY","termSource":"NCI"},{"termName":"Aurathin-A3","termGroup":"SY","termSource":"NCI"},{"termName":"AY 3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6156-47-4"},{"name":"Chemical_Formula","value":"C64H90N12O16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Z5DS38J6F"},{"name":"Maps_To","value":"Actinomycin C3"},{"name":"PubMedID_Primary_Reference","value":"10888331"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0604201"}]}}{"C2844":{"preferredName":"Actinomycin F1","code":"C2844","definitions":[{"definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Actinomycin F1 intercalates into the minor groove of DNA and binds to topoisomerase II, leading to the inhibition of DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Actinomycin F1","termGroup":"PT","termSource":"NCI"},{"termName":"Actinomycin KS4","termGroup":"SY","termSource":"NCI"},{"termName":"KS4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402-44-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D8HJS52NSZ"},{"name":"Legacy Concept Name","value":"Actinomycin_F1"},{"name":"Maps_To","value":"Actinomycin F1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515876"}]}}{"C118625":{"preferredName":"Activin Type 2B Receptor Fc Fusion Protein STM 434","code":"C118625","definitions":[{"definition":"A soluble fusion protein containing the extracellular domain of the activin receptor type 2B (ACVR2B or ActRIIB) fused to a human Fc domain, with potential antineoplastic activity. Upon intravenous administration, STM 434 selectively binds to the growth factor activin A, thereby preventing its binding to and the activation of endogenous ActRIIB. This prevents activin A/ActRIIB-mediated signaling and inhibits the proliferation of activin A-overexpressing tumor cells. Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, is overexpressed in a variety of cancers and plays a key role in promoting cancer cell proliferation, migration, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Activin Type 2B Receptor Fc Fusion Protein STM 434","termGroup":"PT","termSource":"NCI"},{"termName":"Activin Inhibitor STM 434","termGroup":"SY","termSource":"NCI"},{"termName":"STM 434","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2055761-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7G4D2B5AC8"},{"name":"Maps_To","value":"Activin Type 2B Receptor Fc Fusion Protein STM 434"},{"name":"NCI_Drug_Dictionary_ID","value":"765514"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765514"},{"name":"PDQ_Open_Trial_Search_ID","value":"765514"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896763"}]}}{"C151941":{"preferredName":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968","code":"C151941","definitions":[{"definition":"A prodrug of an acyclic nucleoside phosphonate, with potential anti-viral and antineoplastic activities. Upon administration, acyclic nucleoside phosphonate prodrug ABI-1968 is taken up by viral-infected cells and converted to its active metabolite. The metabolite is incorporated into DNA chains by DNA polymerases, which results in the termination of DNA synthesis, inhibits viral replication and induces apoptosis and inhibits the proliferation of susceptible virally-infected tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968","termGroup":"PT","termSource":"NCI"},{"termName":"ABI-1968","termGroup":"CN","termSource":"NCI"},{"termName":"ABI1968","termGroup":"CN","termSource":"NCI"},{"termName":"HTI 1968","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Acyclic Nucleoside Phosphonate Prodrug ABI-1968"},{"name":"NCI_Drug_Dictionary_ID","value":"793142"},{"name":"NCI_META_CUI","value":"CL553169"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793142"},{"name":"PDQ_Open_Trial_Search_ID","value":"793142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143953":{"preferredName":"Ad-RTS-hIL-12","code":"C143953","definitions":[{"definition":"An inducible adenoviral vector encoding human pro-inflammatory cytokine interleukin-12 (IL-12; IL12), which is under the transcriptional control of the RheoSwitch Therapeutic System (RTS) (Ad-RTS-hIL-12), with potential immunomodulating and antineoplastic activities. RTS consists of two fusion proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). Upon intratumoral administration of Ad-RTS-hIL-12, given in combination with the proprietary, diacylhydrazine-based activator ligand veledimex (INXN-1001), veledimex binds specifically to the EcR part of the RTS and stabilizes heterodimerization between the two fusion proteins, forming an active transcription factor, which induces the transcription of IL-12 under the control of an inducible promoter containing Gal4-binding sites. The expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL)-mediated responses against tumor cells, which may result in immune-mediated tumor cell lysis and inhibition of tumor cell proliferation. In the presence of veledimex, the protein heterodimer changes to a stable conformation and can bind to the inducible promoter, while without veledimex the two fusion proteins form unstable heterodimers; this allows the controlled, regulated intratumoral expression of the IL-12 gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ad-RTS-hIL-12","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoviral- RheoSwitch Therapeutic System-Human Interleukin 12","termGroup":"SY","termSource":"NCI"},{"termName":"INXN 2001","termGroup":"CN","termSource":"NCI"},{"termName":"INXN-2001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ad-RTS-hIL-12"},{"name":"NCI_Drug_Dictionary_ID","value":"792151"},{"name":"NCI_META_CUI","value":"CL542155"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792151"},{"name":"PDQ_Open_Trial_Search_ID","value":"792151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99766":{"preferredName":"Adagloxad Simolenin","code":"C99766","definitions":[{"definition":"A carbohydrate-based immunostimulant comprised of the Globo H hexasaccharide 1 (Globo H) epitope linked to the immunostimulant carrier protein keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration of adagloxad simolenin, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. Globo H is a tumor associated antigen (TAA) commonly found on a variety of tumor cells including breast cancer cells. KLH improves antigenic immune recognition and T-cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adagloxad Simolenin","termGroup":"PT","termSource":"NCI"},{"termName":"OBI 822","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-822","termGroup":"CN","termSource":"NCI"},{"termName":"OBI822","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1458687-85-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UCG949AA7Z"},{"name":"Maps_To","value":"Adagloxad Simolenin"},{"name":"NCI_Drug_Dictionary_ID","value":"724401"},{"name":"NCI_META_CUI","value":"CL433491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724401"},{"name":"PDQ_Open_Trial_Search_ID","value":"724401"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91725":{"preferredName":"Adavosertib","code":"C91725","definitions":[{"definition":"A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adavosertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 1775","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-1775","termGroup":"CN","termSource":"NCI"},{"termName":"AZD1775","termGroup":"CN","termSource":"NCI"},{"termName":"MK 1775","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1775","termGroup":"CN","termSource":"NCI"},{"termName":"MK1775","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"955365-80-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K2T6HJX3I3"},{"name":"Maps_To","value":"Adavosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"594147"},{"name":"NCI_META_CUI","value":"CL791432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594147"},{"name":"PDQ_Open_Trial_Search_ID","value":"594147"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82358":{"preferredName":"Adecatumumab","code":"C82358","definitions":[{"definition":"A recombinant human IgG1 monoclonal antibody (MoAb) directed against the tumor associated antigen (TAA) epithelial cell adhesion molecule (EpCAM) with potential antitumor activity. Adecatumumab binds to EpCAM, which may result in antibody-dependent cellular cytotoxicity (ADCC) directed against EpCAM-expressing tumor cells. EpCAM (CD326), a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells; for some cancers, overexpression has been correlated with decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adecatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EpCAM Monoclonal Antibody MT201","termGroup":"SY","termSource":"NCI"},{"termName":"MT201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"503605-66-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"000705ZASD"},{"name":"Legacy Concept Name","value":"Adecatumumab"},{"name":"Maps_To","value":"Adecatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"640250"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640250"},{"name":"PDQ_Open_Trial_Search_ID","value":"640250"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1741817"}]}}{"C148039":{"preferredName":"Imaradenant","code":"C148039","definitions":[{"definition":"An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, imaradenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imaradenant","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR Antagonist AZD4635","termGroup":"SY","termSource":"NCI"},{"termName":"Adenosine A2A Receptor Antagonist AZD4635","termGroup":"SY","termSource":"NCI"},{"termName":"AZD-4635","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4635","termGroup":"CN","termSource":"NCI"},{"termName":"HTL-1071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1321514-06-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"770140J08A"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist AZD4635"},{"name":"Maps_To","value":"Imaradenant"},{"name":"NCI_Drug_Dictionary_ID","value":"794358"},{"name":"NCI_META_CUI","value":"CL545814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794358"},{"name":"PDQ_Open_Trial_Search_ID","value":"794358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142374":{"preferredName":"Adenosine A2A Receptor Antagonist NIR178","code":"C142374","definitions":[{"definition":"An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist NIR178 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2A Receptor Antagonist NIR178","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR Antagonist NIR178","termGroup":"SY","termSource":"NCI"},{"termName":"NIR 178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist NIR178"},{"name":"NCI_Drug_Dictionary_ID","value":"793151"},{"name":"NCI_META_CUI","value":"CL540321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793151"},{"name":"PDQ_Open_Trial_Search_ID","value":"793151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157489":{"preferredName":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999","code":"C157489","definitions":[{"definition":"An orally bioavailable inhibitor of both the adenosine A2A receptor (A2AR; ADORA2A) and phosphodiesterase 10A (PDE-10A), with potential immunomodulating and antineoplastic activities. Upon administration, A2A/PDE-10A inhibitor PBF-999 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression. In addition, PBF-999 binds to and inhibits the activity of PDE-10A, thereby preventing the degradation of cyclic guanosine monophosphate (cGMP) and activates cGMP/cGMP-dependent protein kinase G (PKG) signaling. This induces beta-catenin degradation and thereby prevents the translocation of beta-catenin into the nucleus, and the beta-catenin-mediated induction of transcription of survival proteins, such as cyclin D1 and survivin. It also suppresses RAS/RAF/mitogen-activated protein kinase (MAPK) signaling. This induces apoptosis and inhibits the growth of tumor cells in which PDE-10A is overexpressed. PDE-10A is a cGMP-degrading PDE isozyme that is highly expressed in the brain and overexpressed in certain types of tumor cells. Elevation of intracellular cGMP is known to inhibit tumor proliferation and induce apoptosis. cGMP levels are low in cancer cells resulting from the overexpression PDE-10A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999","termGroup":"PT","termSource":"NCI"},{"termName":"A2A/PDE-10A Inhibitor PBF-999","termGroup":"SY","termSource":"NCI"},{"termName":"PBF 999","termGroup":"CN","termSource":"NCI"},{"termName":"PBF-999","termGroup":"CN","termSource":"NCI"},{"termName":"PBF999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620909-95-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DY6W3NQA36"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999"},{"name":"NCI_Drug_Dictionary_ID","value":"796763"},{"name":"NCI_META_CUI","value":"CL937074"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796763"},{"name":"PDQ_Open_Trial_Search_ID","value":"796763"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159564":{"preferredName":"Etrumadenant","code":"C159564","definitions":[{"definition":"An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon administration, etrumadenant competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T-lymphocytes. The binding of AB928 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etrumadenant","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR/A2BR Antagonist AB928","termGroup":"SY","termSource":"NCI"},{"termName":"AB 928","termGroup":"CN","termSource":"NCI"},{"termName":"AB-928","termGroup":"CN","termSource":"NCI"},{"termName":"AB928","termGroup":"CN","termSource":"NCI"},{"termName":"Adenosine A2A/A2B Receptor Antagonist AB928","termGroup":"SY","termSource":"NCI"},{"termName":"Dual A2AR/A2BR Antagonist AB928","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2239273-34-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W0ZE0NT8IF"},{"name":"Maps_To","value":"Adenosine A2A/A2B Receptor Antagonist AB928"},{"name":"NCI_Drug_Dictionary_ID","value":"797798"},{"name":"NCI_META_CUI","value":"CL951401"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797798"},{"name":"PDQ_Open_Trial_Search_ID","value":"797798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148435":{"preferredName":"Adenosine A2B Receptor Antagonist PBF-1129","code":"C148435","definitions":[{"definition":"An orally bioavailable antagonist of the immunomodulatory checkpoint molecule adenosine A2B receptor (A2BR; ADORA2B), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, A2BR antagonist PBF-1129 competes with adenosine for binding to A2BR expressed on various cancer cell types and numerous immune cells, such as dendritic cells (DCs), mast cells, macrophages and lymphocytes. This inhibits A2BR activity and prevents adenosine/A2BR-mediated signaling. The inhibition of A2BR in cancer cells prevents activation of downstream oncogenic pathways, which leads to an inhibition of cell proliferation and metastasis. A2BR inhibition also prevents the release of various growth factors, cytokines and chemokines, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin-2 (Ang2) from immune cells, which may abrogate the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activate the immune system to exert anti-tumor immune responses against cancer cells leading to tumor cell killing. In addition, under non-cancerous inflammatory conditions, inhibition of A2BR leads to reduced activation and proliferation of various immune cells, which results in decreased pro-inflammatory cytokine production and may prevent inflammation. A2BR, a G protein-coupled signaling receptor, is expressed on the cell surfaces of numerous immune cells and is often overexpressed on a variety of cancer cell types; it plays a key role in their proliferation, progression and metastasis. Adenosine is overproduced under inflammatory conditions and plays a key role in pro-inflammatory actions. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation. The pro- and anti-inflammatory effects of adenosine and A2BR are cell type-specific and dependent on the extracellular microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2B Receptor Antagonist PBF-1129","termGroup":"PT","termSource":"NCI"},{"termName":"A2BR Antagonist PBF-1129","termGroup":"SY","termSource":"NCI"},{"termName":"PBF 1129","termGroup":"CN","termSource":"NCI"},{"termName":"PBF-1129","termGroup":"CN","termSource":"NCI"},{"termName":"PBF1129","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosine A2B Receptor Antagonist PBF-1129"},{"name":"NCI_Drug_Dictionary_ID","value":"793680"},{"name":"NCI_META_CUI","value":"CL550982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793680"},{"name":"PDQ_Open_Trial_Search_ID","value":"793680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106242":{"preferredName":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","code":"C106242","definitions":[{"definition":"A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","termGroup":"PT","termSource":"NCI"},{"termName":"Adenovector-transduced AP1903-inducible iMC-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","termGroup":"SY","termSource":"NCI"},{"termName":"BPX-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201"},{"name":"NCI_Drug_Dictionary_ID","value":"748904"},{"name":"NCI_META_CUI","value":"CL447413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748904"},{"name":"PDQ_Open_Trial_Search_ID","value":"748904"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143034":{"preferredName":"Adenoviral Brachyury Vaccine ETBX-051","code":"C143034","definitions":[{"definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Brachyury Vaccine ETBX-051","termGroup":"PT","termSource":"NCI"},{"termName":"ETBX 051","termGroup":"CN","termSource":"NCI"},{"termName":"ETBX-051","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2171537-82-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BPG11IF0HW"},{"name":"Maps_To","value":"Adenoviral Brachyury Vaccine ETBX-051"},{"name":"NCI_Drug_Dictionary_ID","value":"791863"},{"name":"NCI_META_CUI","value":"CL541478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791863"},{"name":"PDQ_Open_Trial_Search_ID","value":"791863"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156015":{"preferredName":"Adenoviral Cancer Vaccine PF-06936308","code":"C156015","definitions":[{"definition":"A cancer vaccine composed of a replication-defective E1-deleted adenovirus vector based on chimpanzee adenovirus serotype 68 (AdC68) expressing three not yet disclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral cancer vaccine PF-06936308, the adenovirus infects cells and expresses the TAAs. In turn, the TAAs activate the immune system to produce a cytotoxic T-lymphocyte (CTL) response against cells expressing the TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Cancer Vaccine PF-06936308","termGroup":"PT","termSource":"NCI"},{"termName":"PF 06936308","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06936308","termGroup":"CN","termSource":"NCI"},{"termName":"PF06936308","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Cancer Vaccine PF-06936308"},{"name":"NCI_Drug_Dictionary_ID","value":"795350"},{"name":"NCI_META_CUI","value":"CL562758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795350"},{"name":"PDQ_Open_Trial_Search_ID","value":"795350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143035":{"preferredName":"Adenoviral MUC1 Vaccine ETBX-061","code":"C143035","definitions":[{"definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral MUC1 Vaccine ETBX-061","termGroup":"PT","termSource":"NCI"},{"termName":"ETBX 061","termGroup":"CN","termSource":"NCI"},{"termName":"ETBX-061","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2171550-29-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"17K7SN702N"},{"name":"Maps_To","value":"Adenoviral MUC1 Vaccine ETBX-061"},{"name":"NCI_Drug_Dictionary_ID","value":"791864"},{"name":"NCI_META_CUI","value":"CL541479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791864"},{"name":"PDQ_Open_Trial_Search_ID","value":"791864"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148142":{"preferredName":"Adenoviral PSA Vaccine ETBX-071","code":"C148142","definitions":[{"definition":"A cancer vaccine composed of a genetically engineered, replication-deficient adenovirus carrying the gene encoding human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral-PSA vaccine ETBX-071, the adenovirus infects cells and expresses PSA. In turn, PSA activates the immune system and induces a cytotoxic T-lymphocyte (CTL) response against PSA-expressing tumor cells. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral PSA Vaccine ETBX-071","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoviral PSA Prostate Cancer Vaccine ETBX-071","termGroup":"SY","termSource":"NCI"},{"termName":"ETBX-071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68TF9SDE9N"},{"name":"Maps_To","value":"Adenoviral PSA Vaccine ETBX-071"},{"name":"NCI_Drug_Dictionary_ID","value":"795436"},{"name":"NCI_META_CUI","value":"CL550802"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795436"},{"name":"PDQ_Open_Trial_Search_ID","value":"795436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C101789":{"preferredName":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001","code":"C101789","definitions":[{"definition":"Autologous dendritic cells tranduced with a replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-3001) in combination with the proprietary orally bioavailable, small molecule activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer INXN-1001. Upon intratumoral injection of INXN-3001 and subsequent oral administration of activator ligand, INXN-1001 is able to induce expression of IL-12 in INXN-3001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells, inducing the secretion of interferon-gamma and inducing a cytotoxic T lymphocyte response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. As INXN-1001 regulates both the timing and the levels of IL-12 expression, IL-12 toxicity can be reduced.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001","termGroup":"PT","termSource":"NCI"},{"termName":"DC-RTS-IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"INXN-3001/1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"733561"},{"name":"NCI_META_CUI","value":"CL435907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733561"},{"name":"PDQ_Open_Trial_Search_ID","value":"733561"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162805":{"preferredName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","code":"C162805","definitions":[{"definition":"An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","termGroup":"PT","termSource":"NCI"},{"termName":"GAd-209-FSP","termGroup":"CN","termSource":"NCI"},{"termName":"GAd20-209-FSP","termGroup":"CN","termSource":"NCI"},{"termName":"Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP"},{"name":"NCI_Drug_Dictionary_ID","value":"799098"},{"name":"NCI_META_CUI","value":"CL973183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799098"},{"name":"PDQ_Open_Trial_Search_ID","value":"799098"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156925":{"preferredName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901","code":"C156925","definitions":[{"definition":"A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral-TSNA priming vaccine GRT-C901, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901","termGroup":"PT","termSource":"NCI"},{"termName":"Adenoviral TSNA Priming Vaccine GRT-C901","termGroup":"SY","termSource":"NCI"},{"termName":"GRT C901","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-C901","termGroup":"CN","termSource":"NCI"},{"termName":"GRTC901","termGroup":"CN","termSource":"NCI"},{"termName":"Priming Cancer Vaccine GRT-C901","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901"},{"name":"NCI_Drug_Dictionary_ID","value":"796478"},{"name":"NCI_META_CUI","value":"CL935908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796478"},{"name":"PDQ_Open_Trial_Search_ID","value":"796478"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131825":{"preferredName":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3","code":"C131825","definitions":[{"definition":"A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3","termGroup":"PT","termSource":"NCI"},{"termName":"M-VM3","termGroup":"CN","termSource":"NCI"},{"termName":"Mobilan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3"},{"name":"NCI_Drug_Dictionary_ID","value":"786108"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786108"},{"name":"PDQ_Open_Trial_Search_ID","value":"786108"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1177020"}]}}{"C97959":{"preferredName":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001","code":"C97959","definitions":[{"definition":"A replication incompetent adenovirus encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-2001) in combination with the proprietary activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer. Upon intratumoral administration of INXN-2001 and oral administration of INXN-1001, INXN-1001 is able to induce expression of IL-12 from INXN-2001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001","termGroup":"PT","termSource":"NCI"},{"termName":"Ad-RTS-IL-12 Plus AL","termGroup":"SY","termSource":"NCI"},{"termName":"INXN-2001/1001","termGroup":"CN","termSource":"NCI"},{"termName":"ZIN ATI-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"710508"},{"name":"NCI_META_CUI","value":"CL430563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710508"},{"name":"PDQ_Open_Trial_Search_ID","value":"710508"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C76115":{"preferredName":"Aderbasib","code":"C76115","definitions":[{"definition":"An orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase 'sheddase' activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. The metalloproteinase domains of ADAMs cleave cell surface proteins at extracellular sites proximal to the cell membrane, releasing or \"shedding\" soluble protein etcodomains from the cell surface; the disintegrin domains of these multifunctional proteins interact with various components of the extracellular matrix (ECM). ADAM10 processes particular epithelial growth factor receptor (EGFR) ligands and appears to regulate Notch signaling through the cleavage of Notch and its related ligand delta-like ligand-1 (Dll-1). ADAM17 (also known as Tumor necrosis factor-Converting Enzyme or TACE) is involved in processing tumor necrosis factor (TNF) from its membrane bound precursor to its soluble circulating form and in processing ligands for the epidermal growth factor receptor (EGFR) family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aderbasib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Azaspiro(2.5)octane-5-carboxylic Acid, 7-((Hydroxyamino)carbonyl)-6-((4-phenyl-1-piperazinyl)carbonyl)-, Methyl Ester, (6S,7S)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB007839","termGroup":"CN","termSource":"NCI"},{"termName":"INCB7839","termGroup":"CN","termSource":"NCI"},{"termName":"Methyl (6S,7S)-7-(Hhydroxyamino)carbonyl)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2.5)octane-5-carboxylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"791828-58-5"},{"name":"Chemical_Formula","value":"C21H28N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9YL6NEJ3G"},{"name":"Legacy Concept Name","value":"Aderbasib"},{"name":"Legacy Concept Name","value":"Sheddase_Inhibitor_INCB007839"},{"name":"Maps_To","value":"Aderbasib"},{"name":"NCI_Drug_Dictionary_ID","value":"633945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633945"},{"name":"PDQ_Open_Trial_Search_ID","value":"633945"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700364"}]}}{"C53399":{"preferredName":"ADH-1","code":"C53399","definitions":[{"definition":"A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ADH-1","termGroup":"PT","termSource":"NCI"},{"termName":"Exherin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"229971-81-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B058ME29VU"},{"name":"Legacy Concept Name","value":"ADH-1"},{"name":"Maps_To","value":"ADH-1"},{"name":"NCI_Drug_Dictionary_ID","value":"462569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462569"},{"name":"PDQ_Open_Trial_Search_ID","value":"462569"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706644"}]}}{"C91719":{"preferredName":"AE37 Peptide/GM-CSF Vaccine","code":"C91719","definitions":[{"definition":"A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AE37 Peptide/GM-CSF Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"AE-37 Peptide/GM-CSF Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AE37 Peptide/GM-CSF Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"564693"},{"name":"NCI_META_CUI","value":"CL376182"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564693"},{"name":"PDQ_Open_Trial_Search_ID","value":"564693"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48369":{"preferredName":"Multikinase Inhibitor AEE788","code":"C48369","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multikinase Inhibitor AEE788","termGroup":"PT","termSource":"NCI"},{"termName":"AEE-788","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"497839-62-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F9JLR95I3I"},{"name":"Legacy Concept Name","value":"AEE788"},{"name":"Maps_To","value":"AEE788"},{"name":"Maps_To","value":"Multikinase Inhibitor AEE788"},{"name":"NCI_Drug_Dictionary_ID","value":"371727"},{"name":"PDQ_Closed_Trial_Search_ID","value":"371727"},{"name":"PDQ_Open_Trial_Search_ID","value":"371727"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506057"}]}}{"C153133":{"preferredName":"Aerosol Gemcitabine","code":"C153133","definitions":[{"definition":"An aerosol inhalation formulation containing gemcitabine (GCB), a broad-spectrum antimetabolite and deoxycytidine analogue, with potential antineoplastic activity. Upon inhalation via a nebulizer, GCB is converted intracellularly by deoxycytidine kinase to its active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase (RNR), thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in DNA strand termination and the induction of apoptosis of lung tumor cells. GCB administration directly into the lungs via aerosol yields higher concentrations of GCB locally than can be achieved by systemic GCB administration, potentially reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aerosol Gemcitabine","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized GCB","termGroup":"SY","termSource":"NCI"},{"termName":"Aerosolized Gemcitabine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aerosol Gemcitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"793934"},{"name":"NCI_META_CUI","value":"CL554390"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793934"},{"name":"PDQ_Open_Trial_Search_ID","value":"793934"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101794":{"preferredName":"Aerosolized Aldesleukin","code":"C101794","definitions":[{"definition":"An aerosol formulation of aldesleukin, a recombinant form of interleukin-2 (IL-2), with potential immunostimulating activity. Upon IL-2 inhalation, this cytokine activates lymphokine-activated killer cells and natural killer cells, and induces expression of cytotoxic cytokines, such as interferon-gamma and transforming growth factor-beta. This may eventually halt tumor cell growth. Localized administration of IL-2 may decrease toxicity and increase efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aerosolized Aldesleukin","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized Recombinant IL-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aerosolized Aldesleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"733682"},{"name":"NCI_META_CUI","value":"CL435912"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733682"},{"name":"PDQ_Open_Trial_Search_ID","value":"733682"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C61071":{"preferredName":"Aerosolized Liposomal Rubitecan","code":"C61071","definitions":[{"definition":"An aerosolized liposomal preparation of rubitecan, a water-insoluble derivative of camptothecin with potential antineoplastic activity. Rubitecan (or 9-nitro-20 (S)-camptothecin) and its active metabolite 9-aminocamptothecin (9-AC) selectively stabilize topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. This agent is formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 micrometer mass median aerodynamic diameter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aerosolized Liposomal Rubitecan","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized liposomal 9-nitro-20(S)-camptothecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aerosolized_Liposomal_9-Nitrocamptothecin"},{"name":"Maps_To","value":"Aerosolized Liposomal Rubitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"473242"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473242"},{"name":"PDQ_Open_Trial_Search_ID","value":"473242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831773"}]}}{"C66940":{"preferredName":"Afatinib","code":"C66940","definitions":[{"definition":"An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afatinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide","termGroup":"SN","termSource":"NCI"},{"termName":"BIBW 2992","termGroup":"CN","termSource":"NCI"},{"termName":"BIBW-2992","termGroup":"CN","termSource":"NCI"},{"termName":"BIBW2992","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850140-72-6"},{"name":"CHEBI_ID","value":"CHEBI:61390"},{"name":"Chemical_Formula","value":"C24H25ClFN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"41UD74L59M"},{"name":"Legacy Concept Name","value":"BIBW_2992"},{"name":"Maps_To","value":"Afatinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987648"}]}}{"C97273":{"preferredName":"Afatinib Dimaleate","code":"C97273","definitions":[{"definition":"The dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afatinib Dimaleate","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate)","termGroup":"SY","termSource":"NCI"},{"termName":"2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2E)-, (2Z)-2-Butenedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"BIBW 2992MA2","termGroup":"CN","termSource":"NCI"},{"termName":"BIBW2992 MA2","termGroup":"CN","termSource":"NCI"},{"termName":"Gilotrif","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations"},{"name":"CAS_Registry","value":"850140-73-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V1T5K7RZ0B"},{"name":"Maps_To","value":"Afatinib Dimaleate"},{"name":"NCI_Drug_Dictionary_ID","value":"537572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537572"},{"name":"PDQ_Open_Trial_Search_ID","value":"537572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879772"}]}}{"C975":{"preferredName":"Afimoxifene","code":"C975","definitions":[{"definition":"A form of the drug tamoxifen that is made by the body after taking tamoxifen. It can also be made in the laboratory, and may help decrease breast density. A topical form of 4-hydroxytamoxifen is being studied in breast cancer screening.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afimoxifene","termGroup":"PT","termSource":"NCI"},{"termName":"4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hydroxy-Tamoxifen","termGroup":"SY","termSource":"NCI"},{"termName":"4-Hydroxytamoxifen","termGroup":"SY","termSource":"NCI"},{"termName":"4-OHT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68047-06-3"},{"name":"CAS_Registry","value":"68392-35-8"},{"name":"CHEBI_ID","value":"CHEBI:44616"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"17197F0KYM"},{"name":"Legacy Concept Name","value":"_4-Hydroxy-Tamoxifen"},{"name":"Maps_To","value":"Afimoxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"371709"},{"name":"PDQ_Closed_Trial_Search_ID","value":"371709"},{"name":"PDQ_Open_Trial_Search_ID","value":"371709"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347999"}]}}{"C82390":{"preferredName":"Afuresertib","code":"C82390","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afuresertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Thiophenecarboxamide, N-((1S)-2-amino-1-((3-fluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"GSK 2110183","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-2110183","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2110183","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1047644-62-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8739X25QI3"},{"name":"Legacy Concept Name","value":"Oral_Akt_Inhibitor_GSK2110183"},{"name":"Maps_To","value":"Afuresertib"},{"name":"NCI_Drug_Dictionary_ID","value":"642287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642287"},{"name":"PDQ_Open_Trial_Search_ID","value":"642287"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853882"}]}}{"C28580":{"preferredName":"Agatolimod Sodium","code":"C28580","definitions":[{"definition":"A substance that is being studied in the treatment of some types of cancer. It belongs to the family of drugs called biological response modifiers.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. Agatolimod selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agatolimod Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"(3'-5')d(P-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T) Tricosasodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"CpG 7909","termGroup":"CN","termSource":"NCI"},{"termName":"PF 3512676","termGroup":"CN","termSource":"NCI"},{"termName":"PF-3512676","termGroup":"CN","termSource":"NCI"},{"termName":"PF3512676","termGroup":"CN","termSource":"NCI"},{"termName":"ProMune","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"541547-35-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I4Z5C8FM6H"},{"name":"Legacy Concept Name","value":"CpG_7909"},{"name":"Maps_To","value":"Agatolimod Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"38660"},{"name":"NSC Number","value":"731581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38660"},{"name":"PDQ_Open_Trial_Search_ID","value":"38660"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1436331"}]}}{"C107245":{"preferredName":"Agerafenib","code":"C107245","definitions":[{"definition":"An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agerafenib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"AC013773","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-32496","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188910-76-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78I4VEX88N"},{"name":"Maps_To","value":"Agerafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"750855"},{"name":"NCI_META_CUI","value":"CL550786"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750855"},{"name":"PDQ_Open_Trial_Search_ID","value":"750855"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73996":{"preferredName":"Aglatimagene Besadenovec","code":"C73996","definitions":[{"definition":"An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aglatimagene Besadenovec","termGroup":"PT","termSource":"NCI"},{"termName":"ADV-tk","termGroup":"AB","termSource":"NCI"},{"termName":"CAN 2409","termGroup":"CN","termSource":"NCI"},{"termName":"CAN-2409","termGroup":"CN","termSource":"NCI"},{"termName":"CAN2409","termGroup":"CN","termSource":"NCI"},{"termName":"GliAtak","termGroup":"BR","termSource":"NCI"},{"termName":"ProstAtak","termGroup":"BR","termSource":"NCI"},{"termName":"Virafir","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1621271-62-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Z72SSS34W"},{"name":"Legacy Concept Name","value":"Adenoviral_Vector_Encoding_HSV_Thymidine_Kinase"},{"name":"Maps_To","value":"Aglatimagene Besadenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"581584"},{"name":"NCI_META_CUI","value":"CL383459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581584"},{"name":"PDQ_Open_Trial_Search_ID","value":"581584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121538":{"preferredName":"Mitazalimab","code":"C121538","definitions":[{"definition":"A human immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, mitazalimab binds to CD40 on antigen-presenting dendritic cells, which leads to the activation and proliferation of effector and memory T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC). This eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitazalimab","termGroup":"PT","termSource":"NCI"},{"termName":"ADC 1013","termGroup":"CN","termSource":"NCI"},{"termName":"ADC-1013","termGroup":"CN","termSource":"NCI"},{"termName":"ADC1013","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ 7107","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64457107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2055640-86-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q9J81E7VFM"},{"name":"Maps_To","value":"Agonistic Anti-CD40 Monoclonal Antibody ADC-1013"},{"name":"Maps_To","value":"Mitazalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"770043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770043"},{"name":"PDQ_Open_Trial_Search_ID","value":"770043"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053684"}]}}{"C129967":{"preferredName":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949","code":"C129967","definitions":[{"definition":"An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, agonistic anti-OX40 monoclonal antibody INCAGN01949 selectively binds to and activates OX40 on activated T-cells, thereby potentiating T-cell receptor (TCR) signaling. OX40 activation inhibits regulatory T-cell (Treg)-mediated suppression of effector T-cells, induces the proliferation of memory and effector T-lymphocytes and modulates cytokine production. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. In addition, the IgG1 Fc region of INCAGN01949 binds to and co-engages with the IgG Fc-gamma receptor III (FcgammaRIII; CD16) expressed by immune effector cells; thus, binding activates FcgammaRIII-mediated signaling and facilitates the selective depletion of intratumoral Tregs, thereby further enhancing the cytotoxic T-lymphocyte (CTL)-mediated tumor cell response. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells; OX40 stimulation abrogates the immunosuppressive tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Agonist Antibody INCAGN01949","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-OX40 Monoclonal Antibody INCAGN0194","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 1949","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN-1949","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN1949","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody INCAGN01949","termGroup":"SY","termSource":"NCI"},{"termName":"NCAGN01949","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949"},{"name":"NCI_Drug_Dictionary_ID","value":"785256"},{"name":"NCI_META_CUI","value":"CL512862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785256"},{"name":"PDQ_Open_Trial_Search_ID","value":"785256"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C117293":{"preferredName":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469","code":"C117293","definitions":[{"definition":"An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-OX40 monoclonal antibody MEDI6469 selectively binds to and activates OX40. OX40 activation induces proliferation of effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469","termGroup":"PT","termSource":"NCI"},{"termName":"Agonistic Anti-CD134 Monoclonal Antibody MEDI6469","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI6469","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1715924-11-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AKV2GM43DD"},{"name":"Maps_To","value":"Agonistic Anti-OX40 Monoclonal Antibody MEDI6469"},{"name":"NCI_Drug_Dictionary_ID","value":"763664"},{"name":"NCI_META_CUI","value":"CL474118"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763664"},{"name":"PDQ_Open_Trial_Search_ID","value":"763664"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156414":{"preferredName":"AKR1C3-activated Prodrug AST-3424","code":"C156414","definitions":[{"definition":"A small-molecule nitro-benzene, aldo-keto reductase 1C3 (AKR1C3)-activated prodrug of N,N'-bisethylenephosphoramidate, a DNA bis-alkylating agent, with potential antineoplastic activity. Upon intravenous administration, AKR1C3-activated prodrug AST-3424 is converted to its active form by AKR1C3, which is upregulated in certain tumor cell types while not expressed in normal healthy cells. The active metabolite selectively binds to and alkylates DNA in AKR1C3-overexpressing tumor cells, resulting in DNA base pair mismatching, interstrand crosslinking and inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. As the expression of AKR1C3 is restricted to tumors, AST-3424 is selectively converted to its active metabolite in tumor cells only while its conversion in normal, healthy tissue is absent; this allows for an increased cytotoxic effect of the alkylating agent in tumor cells while decreasing its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKR1C3-activated Prodrug AST-3424","termGroup":"PT","termSource":"NCI"},{"termName":"AKR1C3-activated Prodrug OBI-3424","termGroup":"SY","termSource":"NCI"},{"termName":"AKR1C3-activated Prodrug TH-3424","termGroup":"SY","termSource":"NCI"},{"termName":"Aldo-keto Reductase 1c3-activated Prodrug OBI-3424","termGroup":"SY","termSource":"NCI"},{"termName":"OBI 3424","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-3424","termGroup":"CN","termSource":"NCI"},{"termName":"OBI3424","termGroup":"CN","termSource":"NCI"},{"termName":"TH 3424","termGroup":"CN","termSource":"NCI"},{"termName":"TH-3424","termGroup":"CN","termSource":"NCI"},{"termName":"TH3424","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097713-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X6SH5T8H76"},{"name":"Maps_To","value":"AKR1C3-activated Prodrug OBI-3424"},{"name":"NCI_Drug_Dictionary_ID","value":"795700"},{"name":"NCI_META_CUI","value":"CL563114"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795700"},{"name":"PDQ_Open_Trial_Search_ID","value":"795700"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111575":{"preferredName":"AKT 1/2 Inhibitor BAY1125976","code":"C111575","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) isoforms 1 and 2 (AKT1/2) with potential antineoplastic activity. AKT1/2 inhibitor BAY1125976 selectively binds to and inhibits the phosphorylation and activity of AKT1/2 in a non-ATP competitive manner, which may result in the inhibition of the phosphatidylinositol 3 (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. This may lead to both the reduction of cell proliferation and the induction of cell apoptosis in AKT-overexpressing tumor cells. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AKT 1/2 Inhibitor BAY1125976","termGroup":"PT","termSource":"NCI"},{"termName":"BAY1125976","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402608-02-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL7A1UM87X"},{"name":"Maps_To","value":"AKT 1/2 Inhibitor BAY1125976"},{"name":"NCI_Drug_Dictionary_ID","value":"752318"},{"name":"NCI_META_CUI","value":"CL453983"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752318"},{"name":"PDQ_Open_Trial_Search_ID","value":"752318"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99172":{"preferredName":"Miransertib","code":"C99172","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Miransertib binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. This may lead to the reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miransertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinamine, 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo(4,5-b)pyridin-2-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"ARQ 092","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10490","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313881-70-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T1DQI1B52Y"},{"name":"Maps_To","value":"AKT Inhibitor ARQ 092"},{"name":"Maps_To","value":"Miransertib"},{"name":"NCI_Drug_Dictionary_ID","value":"717768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717768"},{"name":"PDQ_Open_Trial_Search_ID","value":"717768"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274586"}]}}{"C95737":{"preferredName":"Akt Inhibitor LY2780301","code":"C95737","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor LY2780301 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway, thereby leading to inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Akt Inhibitor LY2780301","termGroup":"PT","termSource":"NCI"},{"termName":"LY2780301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Akt Inhibitor LY2780301"},{"name":"NCI_Drug_Dictionary_ID","value":"673505"},{"name":"NCI_META_CUI","value":"CL421578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673505"},{"name":"PDQ_Open_Trial_Search_ID","value":"673505"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90581":{"preferredName":"Akt Inhibitor MK2206","code":"C90581","definitions":[{"definition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Akt Inhibitor MK2206","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MK 2206","termGroup":"CN","termSource":"NCI"},{"termName":"MK-2206","termGroup":"CN","termSource":"NCI"},{"termName":"MK2206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032349-93-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"51HZG6MP1K"},{"name":"Maps_To","value":"Akt Inhibitor MK2206"},{"name":"NCI_Drug_Dictionary_ID","value":"596332"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596332"},{"name":"PDQ_Open_Trial_Search_ID","value":"596332"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933427"}]}}{"C85448":{"preferredName":"Akt Inhibitor SR13668","code":"C85448","definitions":[{"definition":"An orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities. Akt inhibitor SR13668 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation, and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Akt Inhibitor SR13668","termGroup":"PT","termSource":"NCI"},{"termName":"SRI13668","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Akt Inhibitor SR13668"},{"name":"NCI_Drug_Dictionary_ID","value":"642606"},{"name":"NCI_META_CUI","value":"CL412317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642606"},{"name":"PDQ_Open_Trial_Search_ID","value":"642606"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113792":{"preferredName":"Dordaviprone","code":"C113792","definitions":[{"definition":"A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dordaviprone","termGroup":"PT","termSource":"NCI"},{"termName":"Akt/ERK Inhibitor ONC201","termGroup":"SY","termSource":"NCI"},{"termName":"ONC201","termGroup":"CN","termSource":"NCI"},{"termName":"TIC10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616632-77-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9U35A31JAI"},{"name":"Maps_To","value":"Akt/ERK Inhibitor ONC201"},{"name":"NCI_Drug_Dictionary_ID","value":"757339"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757339"},{"name":"PDQ_Open_Trial_Search_ID","value":"757339"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3710983"}]}}{"C61438":{"preferredName":"Alacizumab Pegol","code":"C61438","definitions":[{"definition":"A pegylated, cross-linked, humanized divalent-Fab' antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab' antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alacizumab Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"CDP-791","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934216-54-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL9780F883"},{"name":"Legacy Concept Name","value":"Pegylated_Anti-GRF_Antibody_Fragment"},{"name":"Maps_To","value":"Alacizumab Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"472077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"472077"},{"name":"PDQ_Open_Trial_Search_ID","value":"472077"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831765"}]}}{"C994":{"preferredName":"Alanosine","code":"C994","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities. L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency. The clinical use of this agent may be limited by its toxicity profile. MTAP is a key enzyme in the adenine and methionine salvage pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alanosine","termGroup":"PT","termSource":"NCI"},{"termName":"3-(Hydroxynitrosoamino)-L-alanine","termGroup":"SN","termSource":"NCI"},{"termName":"Alanosine","termGroup":"SY","termSource":"NCI"},{"termName":"L-2-Amino-3-(hydroxynitrosoamino)propionic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"L-2-Amino-3-[(N-nitroso)hydroxylamino]propionic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"L-Alanosine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Alanosine Sodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5854-93-3"},{"name":"Chemical_Formula","value":"C3H7N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2CNI71214Y"},{"name":"Legacy Concept Name","value":"L-Alanosine"},{"name":"Maps_To","value":"Alanosine"},{"name":"NCI_Drug_Dictionary_ID","value":"39138"},{"name":"NSC Number","value":"529469"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39138"},{"name":"PDQ_Open_Trial_Search_ID","value":"39138"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051066"}]}}{"C131607":{"preferredName":"Albumin-binding Cisplatin Prodrug BTP-114","code":"C131607","definitions":[{"definition":"A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity.  Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Albumin-binding Cisplatin Prodrug BTP-114","termGroup":"PT","termSource":"NCI"},{"termName":"Albumin-conjugating Platinum-prodrug BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"BTP 114","termGroup":"CN","termSource":"NCI"},{"termName":"BTP-114","termGroup":"CN","termSource":"NCI"},{"termName":"Cisplatin Prodrug BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatin/Maleimide-based Complex BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum-Prodrug BTP-114","termGroup":"SY","termSource":"NCI"},{"termName":"Prodrug BTP 114","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Albumin-binding Cisplatin Prodrug BTP-114"},{"name":"NCI_Drug_Dictionary_ID","value":"786268"},{"name":"NCI_META_CUI","value":"CL514482"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786268"},{"name":"PDQ_Open_Trial_Search_ID","value":"786268"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1498":{"preferredName":"Aldesleukin","code":"C1498","definitions":[{"definition":"A drug used to treat some types of cancer. It is a form of interleukin-2, a cytokine made by leukocytes (white blood cells), that is made in the laboratory. Aldesleukin increases the activity and growth of white blood cells called T lymphocytes and B lymphocytes. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aldesleukin","termGroup":"PT","termSource":"NCI"},{"termName":"125-L-Serine-2-133-interleukin 2","termGroup":"SY","termSource":"NCI"},{"termName":"Proleukin","termGroup":"BR","termSource":"NCI"},{"termName":"r-serHuIL-2","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Human IL-2","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Interleukin-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110942-02-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M89N0Q7EQR"},{"name":"Legacy Concept Name","value":"Aldesleukin"},{"name":"Maps_To","value":"Aldesleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"39756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39756"},{"name":"PDQ_Open_Trial_Search_ID","value":"39756"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0218986"}]}}{"C68921":{"preferredName":"Aldoxorubicin","code":"C68921","definitions":[{"definition":"A 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, aldoxorubicin binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hypervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aldoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"DOXO-EMCH","termGroup":"AB","termSource":"NCI"},{"termName":"Doxorubicin-EMCH","termGroup":"SY","termSource":"NCI"},{"termName":"INNO-206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1361644-26-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C28MV4IM0B"},{"name":"Legacy Concept Name","value":"Doxorubicin_Prodrug_INNO-206"},{"name":"Maps_To","value":"Aldoxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"552648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"552648"},{"name":"PDQ_Open_Trial_Search_ID","value":"552648"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3495619"}]}}{"C101790":{"preferredName":"Alectinib","code":"C101790","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alectinib","termGroup":"PT","termSource":"NCI"},{"termName":"5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"AF 802","termGroup":"CN","termSource":"NCI"},{"termName":"AF-802","termGroup":"CN","termSource":"NCI"},{"termName":"AF802","termGroup":"CN","termSource":"NCI"},{"termName":"Alecensa","termGroup":"BR","termSource":"NCI"},{"termName":"Alecensa","termGroup":"FB","termSource":"NCI"},{"termName":"ALK Inhibitor RO5424802","termGroup":"SY","termSource":"NCI"},{"termName":"CH 5424802","termGroup":"CN","termSource":"NCI"},{"termName":"CH-5424802","termGroup":"CN","termSource":"NCI"},{"termName":"CH5424802","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7853","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7853","termGroup":"CN","termSource":"NCI"},{"termName":"RG7853","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5424802","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5424802","termGroup":"CN","termSource":"NCI"},{"termName":"RO5424802","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1256580-46-7"},{"name":"CHEBI_ID","value":"CHEBI:62268"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LIJ4CT1Z3Y"},{"name":"Maps_To","value":"Alectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"733572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733572"},{"name":"PDQ_Open_Trial_Search_ID","value":"733572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853921"}]}}{"C65220":{"preferredName":"Alefacept","code":"C65220","definitions":[{"definition":"A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Alefacept is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alefacept","termGroup":"PT","termSource":"NCI"},{"termName":"Amevive","termGroup":"BR","termSource":"NCI"},{"termName":"LFA3TIP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222535-22-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ELK3V90G6C"},{"name":"Legacy Concept Name","value":"Alefacept"},{"name":"Maps_To","value":"Alefacept"},{"name":"NCI_Drug_Dictionary_ID","value":"531798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531798"},{"name":"PDQ_Open_Trial_Search_ID","value":"531798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0962603"}]}}{"C1681":{"preferredName":"Alemtuzumab","code":"C1681","definitions":[{"definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alemtuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Campath","termGroup":"BR","termSource":"NCI"},{"termName":"Campath-1H","termGroup":"BR","termSource":"NCI"},{"termName":"LDP 03","termGroup":"CN","termSource":"NCI"},{"termName":"LDP-03","termGroup":"CN","termSource":"NCI"},{"termName":"LDP03","termGroup":"CN","termSource":"NCI"},{"termName":"Lemtrada","termGroup":"BR","termSource":"NCI"},{"termName":"MabCampath","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Lymphocytic Leukemia (CLL)"},{"name":"CAS_Registry","value":"216503-57-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3A189DH42V"},{"name":"Legacy Concept Name","value":"Alemtuzumab"},{"name":"Maps_To","value":"Alemtuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"37783"},{"name":"NSC Number","value":"715969"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37783"},{"name":"PDQ_Open_Trial_Search_ID","value":"37783"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0383429"}]}}{"C77370":{"preferredName":"Alestramustine","code":"C77370","definitions":[{"definition":"The l-alanine ester form of estramustine, a combination of the nitrogen mustard normustine coupled via a carbamate to estradiol, with antineoplastic activity. Upon conversion of alestramustine to estramustine, estramustine binds to microtubule-associated proteins (MAPs) and beta tubulin, thereby interfering with microtubule dynamics and leading to microtubule disassembly and cell cycle arrest. Due to the estrogen moiety, this agent is able to selectively bind to and be taken up by estrogen receptor-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alestramustine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"139402-18-9"},{"name":"Chemical_Formula","value":"C26H36Cl2N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81U8A51CHK"},{"name":"Legacy Concept Name","value":"Alestramustine"},{"name":"Maps_To","value":"Alestramustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697985"}]}}{"C133719":{"preferredName":"Alflutinib Mesylate","code":"C133719","definitions":[{"definition":"The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alflutinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"ASK 120067","termGroup":"CN","termSource":"NCI"},{"termName":"ASK-120067","termGroup":"CN","termSource":"NCI"},{"termName":"ASK120067","termGroup":"CN","termSource":"NCI"},{"termName":"AST 2818 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"AST2818 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Furmonertinib Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Ivesa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2130958-55-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q09ZKD19V0"},{"name":"Maps_To","value":"Alflutinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"788215"},{"name":"NCI_META_CUI","value":"CL520357"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788215"},{"name":"PDQ_Open_Trial_Search_ID","value":"788215"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61082":{"preferredName":"Algenpantucel-L","code":"C61082","definitions":[{"definition":"A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Algenpantucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha (1,3) Galactosyltransferase Tumor Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Alpha-1,3-Galactosyltransferase-expressing Allogeneic Pancreatic Tumor Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HAPa","termGroup":"CN","termSource":"NCI"},{"termName":"Hyperacute Pancreatic Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HyperAcute-Pancreas Immunotherapy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I6HAD3HP89"},{"name":"Legacy Concept Name","value":"Alpha-Gal_Pancreatic_Cancer_Vaccine"},{"name":"Maps_To","value":"Algenpantucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"475734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"475734"},{"name":"PDQ_Open_Trial_Search_ID","value":"475734"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831790"}]}}{"C71717":{"preferredName":"Alisertib","code":"C71717","definitions":[{"definition":"A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alisertib","termGroup":"PT","termSource":"NCI"},{"termName":"Aurora A Kinase Inhibitor MLN8237","termGroup":"SY","termSource":"NCI"},{"termName":"Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"MLN 8237","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-8237","termGroup":"CN","termSource":"NCI"},{"termName":"MLN8237","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1028486-01-2"},{"name":"Chemical_Formula","value":"C27H20ClFN4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T66ES73M18"},{"name":"Legacy Concept Name","value":"Aurora_A_Kinase_Inhibitor_MLN8237"},{"name":"Maps_To","value":"Alisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"561286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561286"},{"name":"PDQ_Open_Trial_Search_ID","value":"561286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346875"}]}}{"C1574":{"preferredName":"Alitretinoin","code":"C1574","definitions":[{"definition":"A drug being studied for cancer prevention.  It belongs to the family of drugs called retinoids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alitretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"9-cis Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"9-cis-RA","termGroup":"AB","termSource":"NCI"},{"termName":"9-cis-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"9-cRA","termGroup":"AB","termSource":"NCI"},{"termName":"ALRT 1057","termGroup":"CN","termSource":"NCI"},{"termName":"ALRT-1057","termGroup":"CN","termSource":"NCI"},{"termName":"ALRT1057","termGroup":"CN","termSource":"NCI"},{"termName":"LGD 1057","termGroup":"CN","termSource":"NCI"},{"termName":"LGD-1057","termGroup":"CN","termSource":"NCI"},{"termName":"LGD1057","termGroup":"CN","termSource":"NCI"},{"termName":"Panretin","termGroup":"BR","termSource":"NCI"},{"termName":"Panretyn","termGroup":"FB","termSource":"NCI"},{"termName":"Panrexin","termGroup":"FB","termSource":"NCI"},{"termName":"Retinoicacid-9-cis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi sarcoma"},{"name":"CAS_Registry","value":"5300-03-8"},{"name":"CHEBI_ID","value":"CHEBI:50648"},{"name":"Chemical_Formula","value":"C20H28O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1UA8E65KDZ"},{"name":"Legacy Concept Name","value":"Alitretinoin"},{"name":"Maps_To","value":"Alitretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"42147"},{"name":"NSC Number","value":"659772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42147"},{"name":"PDQ_Open_Trial_Search_ID","value":"42147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281666"}]}}{"C141136":{"preferredName":"ALK Inhibitor","code":"C141136","definitions":[{"definition":"Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Anaplastic Lymphoma Kinase Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK Inhibitor"},{"name":"NCI_META_CUI","value":"CL539186"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"}]}}{"C116727":{"preferredName":"ALK Inhibitor ASP3026","code":"C116727","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ASP3026 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor ASP3026","termGroup":"PT","termSource":"NCI"},{"termName":"ASP-3026","termGroup":"CN","termSource":"NCI"},{"termName":"ASP3026","termGroup":"CN","termSource":"NCI"},{"termName":"N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1097917-15-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HP4L6MXF10"},{"name":"Maps_To","value":"ALK Inhibitor ASP3026"},{"name":"NCI_Drug_Dictionary_ID","value":"694592"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694592"},{"name":"PDQ_Open_Trial_Search_ID","value":"694592"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896911"}]}}{"C148533":{"preferredName":"ALK Inhibitor PLB 1003","code":"C148533","definitions":[{"definition":"An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, PLB1003 selectively binds to and inhibits wild-type ALK, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor PLB 1003","termGroup":"PT","termSource":"NCI"},{"termName":"PLB 1003","termGroup":"CN","termSource":"NCI"},{"termName":"PLB-1003","termGroup":"CN","termSource":"NCI"},{"termName":"PLB1003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK Inhibitor PLB 1003"},{"name":"NCI_Drug_Dictionary_ID","value":"792707"},{"name":"NCI_META_CUI","value":"CL551132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792707"},{"name":"PDQ_Open_Trial_Search_ID","value":"792707"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154279":{"preferredName":"Iruplinalkib","code":"C154279","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, iruplinalkib binds to and inhibits ALK tyrosine kinase, ALK fusion proteins, ALK point mutation variants ALK L1196M, ALK C1156Y, and EGFR L858R/T790M. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iruplinalkib","termGroup":"PT","termSource":"NCI"},{"termName":"ALK Inhibitor WX-0593","termGroup":"SY","termSource":"NCI"},{"termName":"FL 006","termGroup":"CN","termSource":"NCI"},{"termName":"FL-006","termGroup":"CN","termSource":"NCI"},{"termName":"FL006","termGroup":"CN","termSource":"NCI"},{"termName":"WX 0593","termGroup":"CN","termSource":"NCI"},{"termName":"WX-0593","termGroup":"CN","termSource":"NCI"},{"termName":"WX0593","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1854943-32-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z5F65W1YAZ"},{"name":"Maps_To","value":"ALK Inhibitor WX-0593"},{"name":"NCI_Drug_Dictionary_ID","value":"794180"},{"name":"NCI_META_CUI","value":"CL555276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794180"},{"name":"PDQ_Open_Trial_Search_ID","value":"794180"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156729":{"preferredName":"Itacnosertib","code":"C156729","definitions":[{"definition":"An orally bioavailable inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2; ACRV1), with potential antineoplastic activity. Upon oral administration,itacnosertib targets, binds to and inhibits the activity of ALK-2. This prevents ALK-2-mediated signaling and inhibits cell growth in ALK-2-overexpressing tumor cells. In addition, in cancer and inflammatory conditions, ALK-2 is upregulated in response to increased signaling of pro-inflammatory cytokines, especially interleukin-6 (IL-6), and enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of iron homeostasis. Blocking ALK-2-mediated pathways in inflammation and cancer leads to a decrease of hepcidin expression and restores plasma iron levels, thereby preventing low serum iron levels and anemia of chronic disease (ACD). ALK-2, a serine/threonine receptor kinase, is constitutively activated due to activating mutations or upregulated upstream signaling pathways in inflammatory conditions and certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itacnosertib","termGroup":"PT","termSource":"NCI"},{"termName":"ACVR1 Inhibitor TP-0184","termGroup":"SY","termSource":"NCI"},{"termName":"ALK-2 Inhibitor TP-0184","termGroup":"SY","termSource":"NCI"},{"termName":"ALK2 Inhibitor TP-0184","termGroup":"SY","termSource":"NCI"},{"termName":"TP 0184","termGroup":"CN","termSource":"NCI"},{"termName":"TP-0184","termGroup":"CN","termSource":"NCI"},{"termName":"TP0184","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1628870-27-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22Z53X5LHF"},{"name":"Maps_To","value":"ALK-2 Inhibitor TP-0184"},{"name":"NCI_Drug_Dictionary_ID","value":"795585"},{"name":"NCI_META_CUI","value":"CL935854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795585"},{"name":"PDQ_Open_Trial_Search_ID","value":"795585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111685":{"preferredName":"ALK-FAK Inhibitor CEP-37440","code":"C111685","definitions":[{"definition":"An orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK-FAK Inhibitor CEP-37440","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-37440","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1391712-60-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3MNS8782H"},{"name":"Maps_To","value":"ALK-FAK Inhibitor CEP-37440"},{"name":"NCI_Drug_Dictionary_ID","value":"752740"},{"name":"NCI_META_CUI","value":"CL454076"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752740"},{"name":"PDQ_Open_Trial_Search_ID","value":"752740"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148513":{"preferredName":"ALK/c-Met Inhibitor TQ-B3139","code":"C148513","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK/c-Met Inhibitor TQ-B3139","termGroup":"PT","termSource":"NCI"},{"termName":"TQ B3139","termGroup":"CN","termSource":"NCI"},{"termName":"TQ-B3139","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK/c-Met Inhibitor TQ-B3139"},{"name":"NCI_Drug_Dictionary_ID","value":"792652"},{"name":"NCI_META_CUI","value":"CL551150"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792652"},{"name":"PDQ_Open_Trial_Search_ID","value":"792652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126648":{"preferredName":"ALK/FAK/Pyk2 Inhibitor CT-707","code":"C126648","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, ALK/FAK/Pyk2 inhibitor CT-707 selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK/FAK/Pyk2 Inhibitor CT-707","termGroup":"PT","termSource":"NCI"},{"termName":"CT 707","termGroup":"CN","termSource":"NCI"},{"termName":"CT-707","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK/FAK/Pyk2 Inhibitor CT-707"},{"name":"NCI_Drug_Dictionary_ID","value":"779790"},{"name":"NCI_META_CUI","value":"CL503764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779790"},{"name":"PDQ_Open_Trial_Search_ID","value":"779790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114287":{"preferredName":"ALK/TRK Inhibitor TSR-011","code":"C114287","definitions":[{"definition":"An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK/TRK Inhibitor TSR-011","termGroup":"PT","termSource":"NCI"},{"termName":"TSR-011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ALK/TRK Inhibitor TSR-011"},{"name":"NCI_Drug_Dictionary_ID","value":"757983"},{"name":"NCI_META_CUI","value":"CL471796"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757983"},{"name":"PDQ_Open_Trial_Search_ID","value":"757983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165556":{"preferredName":"Alkotinib","code":"C165556","definitions":[{"definition":"An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, alkotinib binds to and inhibits the wild-type, point mutations and fusion proteins of ALK and ROS1. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of proliferation in tumor cells which these kinases are overexpressed, rearranged or mutated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alkotinib","termGroup":"PT","termSource":"NCI"},{"termName":"ZG 0418","termGroup":"CN","termSource":"NCI"},{"termName":"ZG-0418","termGroup":"CN","termSource":"NCI"},{"termName":"ZG0418","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alkotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"799671"},{"name":"NCI_META_CUI","value":"CL978663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799671"},{"name":"PDQ_Open_Trial_Search_ID","value":"799671"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123911":{"preferredName":"Allodepleted T Cell Immunotherapeutic ATIR101","code":"C123911","definitions":[{"definition":"A cell-based immunotherapeutic product containing T-lymphocyte-enriched leukocytes that are devoid of alloreactive T-lymphocytes, that can potentially be used to restore lymphocyte levels after stem cell transplantations and are derived from partially matched (haploidentical) family donors for blood cancer patients who do not have a matching stem cell donor available. Host alloreactive T-cells, which can cause graft-versus-host disease (GVHD), are eliminated from the donor lymphocytes ex vivo using photodynamic therapy. After allogeneic hematopoietic stem cell transplantation (HSCT), allodepleted T cell immunotherapeutic ATIR101 is administered. This maintains a T-cell-mediated immune response against tumor cells and the donor T-cells can prevent opportunistic infections. ATIR101 does not cause severe, acute GVHD. In addition, administration of ATIR101 eliminates the need for immunosuppressants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allodepleted T Cell Immunotherapeutic ATIR101","termGroup":"PT","termSource":"NCI"},{"termName":"Allodepleted T-cell ImmunotheRapeutics","termGroup":"BR","termSource":"NCI"},{"termName":"ATIR101","termGroup":"CN","termSource":"NCI"},{"termName":"Theralux-ATIR","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allodepleted T Cell Immunotherapeutic ATIR101"},{"name":"NCI_Drug_Dictionary_ID","value":"775836"},{"name":"NCI_META_CUI","value":"CL498275"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775836"},{"name":"PDQ_Open_Trial_Search_ID","value":"775836"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158558":{"preferredName":"Azercabtagene Zapreleucel","code":"C158558","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azercabtagene Zapreleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19-CAR T-cells PBCAR0191","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19-CAR T-lymphocytes PBCAR0191","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19-CAR Allogeneic T-cells PBCAR0191","termGroup":"SY","termSource":"NCI"},{"termName":"PBCAR0191","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PFZ3AP93TA"},{"name":"Maps_To","value":"Allogeneic Anti-CD19-CAR T-cells PBCAR0191"},{"name":"NCI_Drug_Dictionary_ID","value":"797475"},{"name":"NCI_META_CUI","value":"CL938005"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797475"},{"name":"PDQ_Open_Trial_Search_ID","value":"797475"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137863":{"preferredName":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100","code":"C137863","definitions":[{"definition":"A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells derived from a related but not completely matched human leukocyte antigen (HLA)-haploidentical donor that is seropositive for cytomegalovirus (CMV+), with potential cytolytic and antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+). The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15 (IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta) to generate the adaptive, CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100 ex vivo. Upon infusion of the allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100, these cells selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression of the memory-like activating receptor NKG2C and the maturation marker CD57 in the isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57 both enhances the effector function of NK cells and stimulates CD16-dependent signaling. Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor induces preferential expansion of CD57+ NK cells that exhibit enhanced interferon (IFN)-gamma production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100","termGroup":"PT","termSource":"NCI"},{"termName":"Adaptive Memory Natural Killer Cells FATE-NK100","termGroup":"SY","termSource":"NCI"},{"termName":"Adaptive Memory NKs Cells FATE-NK100","termGroup":"SY","termSource":"NCI"},{"termName":"Adaptive NKs Cells FATE-NK100","termGroup":"SY","termSource":"NCI"},{"termName":"FATE NK100","termGroup":"CN","termSource":"NCI"},{"termName":"FATE-NK100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100"},{"name":"NCI_Drug_Dictionary_ID","value":"790374"},{"name":"NCI_META_CUI","value":"CL524941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790374"},{"name":"PDQ_Open_Trial_Search_ID","value":"790374"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119759":{"preferredName":"Allogeneic Cellular Vaccine 1650-G","code":"C119759","definitions":[{"definition":"A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Cellular Vaccine 1650-G","termGroup":"PT","termSource":"NCI"},{"termName":"1650-G","termGroup":"CN","termSource":"NCI"},{"termName":"1650-G Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"1650G","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Cellular Vaccine 1650-G"},{"name":"NCI_Drug_Dictionary_ID","value":"810695"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896934"}]}}{"C146711":{"preferredName":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","code":"C146711","definitions":[{"definition":"A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","termGroup":"PT","termSource":"NCI"},{"termName":"Breast Cancer Vaccine SV-BR-1-GM","termGroup":"SY","termSource":"NCI"},{"termName":"Bria-IMT","termGroup":"BR","termSource":"NCI"},{"termName":"GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM","termGroup":"SY","termSource":"NCI"},{"termName":"SV-BR-1 Breast Cancer Cell Line Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"SV-BR-1-GM","termGroup":"CN","termSource":"NCI"},{"termName":"SV-BR-1-GM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM"},{"name":"NCI_Drug_Dictionary_ID","value":"792158"},{"name":"NCI_META_CUI","value":"CL544722"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792158"},{"name":"PDQ_Open_Trial_Search_ID","value":"792158"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C2525":{"preferredName":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine","code":"C2525","definitions":[{"definition":"An allogeneic whole cell vaccine expressing human granulocyte macrophage-colony stimulating factor (GM-CSF) with potential antineoplastic activity. Tumor cells from prostate cancer patients are harvested and then genetically modified to secrete GM-CSF, an immune stimulatory growth factor that plays a key role in stimulating the body's immune responses against tumor cells. Because the vaccine is derived from allogenic cells, it has demonstrated a favorable side effect profile than other approaches of delivering long-lasting GM-CSF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic GM-CSF Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Prostate Cancer Vaccine, GM- CSF Gene Transduced","termGroup":"SY","termSource":"NCI"},{"termName":"Allogenic Prostate GVAX","termGroup":"SY","termSource":"NCI"},{"termName":"GM-CSF Gene Transduced Allogeneic Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Allogeneic Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Allogenic Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"GVAX Prostate Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Cancer Vaccine, GM-CSF Gene Transduced","termGroup":"SY","termSource":"NCI"},{"termName":"Prostate Cancer Vaccine, GVAX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GVAX_Prostate_Cancer_Vaccine"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43459"},{"name":"PDQ_Open_Trial_Search_ID","value":"43459"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796615"}]}}{"C98282":{"preferredName":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine","code":"C98282","definitions":[{"definition":"An allogeneic cancer vaccine composed of lethally irradiated whole melanoma cancer cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the body's immune system against tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"GVAX Melanoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"712484"},{"name":"NCI_META_CUI","value":"CL432401"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712484"},{"name":"PDQ_Open_Trial_Search_ID","value":"712484"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101892":{"preferredName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo","code":"C101892","definitions":[{"definition":"An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo","termGroup":"PT","termSource":"NCI"},{"termName":"PANC 10.05 pcDNA-1/GM-Neo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo"},{"name":"NCI_Drug_Dictionary_ID","value":"734024"},{"name":"NCI_META_CUI","value":"CL436275"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734024"},{"name":"PDQ_Open_Trial_Search_ID","value":"734024"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101891":{"preferredName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo","code":"C101891","definitions":[{"definition":"An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo","termGroup":"PT","termSource":"NCI"},{"termName":"PANC 6.03 pcDNA-1/GM-Neo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo"},{"name":"NCI_Drug_Dictionary_ID","value":"734023"},{"name":"NCI_META_CUI","value":"CL436274"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734023"},{"name":"PDQ_Open_Trial_Search_ID","value":"734023"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90577":{"preferredName":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2","code":"C90577","definitions":[{"definition":"A preparation of glucocorticoid receptor (GR) negative, allogeneic cytotoxic T-lymphocytes (CTLs) expressing a membrane-tethered interleukin 13 (IL13) cytokine chimeric T-cell antigen receptor (zetakine), with potential antineoplastic activity. Upon transfection of donor T-lymphocytes with a plasmid encoding a fusion protein of the IL13-zetakine and the selection-suicide expression enzyme HyTK, these modified CTLs are expanded and introduced into a patient with glioblastoma multiforme (GBM). This agent specifically targets IL13 receptor alpha2, a glioma-restricted cell-surface epitope; the CTLs exert their cytolytic effect thereby killing IL13Ra2-expressing glioma cells. In addition, IL13-zetakine redirected CTLs induce production of certain cytokines. Furthermore, due to the fact that these CTLs are GR negative, they can be used concomitantly with glucocorticoid therapy. The IL13-zetakine consists of an extracellular IL-13 E13Y mutein-human IgG4 hinge-Fc chimera fused to human cytoplasmic CD3-zeta via the transmembrane domain of human CD4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2","termGroup":"PT","termSource":"NCI"},{"termName":"GRm13Z40-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2"},{"name":"NCI_Drug_Dictionary_ID","value":"668180"},{"name":"NCI_META_CUI","value":"CL416270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"668180"},{"name":"PDQ_Open_Trial_Search_ID","value":"668180"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103862":{"preferredName":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470","code":"C103862","definitions":[{"definition":"An allogeneic cancer vaccine composed of a mixture of lethally irradiated whole melanoma cancer cells obtained from four different melanoma cell lines, with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic irradiated melanoma cell vaccine may stimulate the body's immune system to exert a cytotoxic T-lymphocyte response and antibody-dependent cellular cytotoxicity (ADCC) against the melanoma cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470","termGroup":"PT","termSource":"NCI"},{"termName":"CSF 470 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CSF470 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Irradiated Melanoma Cell Vaccine CSF470"},{"name":"NCI_Drug_Dictionary_ID","value":"743369"},{"name":"NCI_META_CUI","value":"CL438340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743369"},{"name":"PDQ_Open_Trial_Search_ID","value":"743369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78862":{"preferredName":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307","code":"C78862","definitions":[{"definition":"A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic LMI Melanoma Vaccine LP2307","termGroup":"SY","termSource":"NCI"},{"termName":"LP2307","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Allogeneic_Large_Multivalent_Immunogen_Melanoma_Vaccine_LP2307"},{"name":"Maps_To","value":"Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307"},{"name":"NCI_Drug_Dictionary_ID","value":"602166"},{"name":"NCI_META_CUI","value":"CL387595"},{"name":"PDQ_Closed_Trial_Search_ID","value":"602166"},{"name":"PDQ_Open_Trial_Search_ID","value":"602166"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78861":{"preferredName":"Allogeneic Melanoma Vaccine AGI-101H","code":"C78861","definitions":[{"definition":"A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Melanoma Vaccine AGI-101H","termGroup":"PT","termSource":"NCI"},{"termName":"AGI-101H","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Allogeneic_Melanoma_Vaccine_AGI-101H"},{"name":"Maps_To","value":"Allogeneic Melanoma Vaccine AGI-101H"},{"name":"NCI_Drug_Dictionary_ID","value":"601981"},{"name":"NCI_META_CUI","value":"CL387596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601981"},{"name":"PDQ_Open_Trial_Search_ID","value":"601981"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94209":{"preferredName":"Allogeneic Natural Killer Cell Line MG4101","code":"C94209","definitions":[{"definition":"A population of allogeneic, cytotoxic natural killer (NK) cells with potential antitumor activity. Allogeneic natural killer cell line MG4101 is derived from cells of a normal, healthy donor upon leukapheresis and activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Natural Killer Cell Line MG4101","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic NK Cell Line MG4101","termGroup":"SY","termSource":"NCI"},{"termName":"MG4101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WX2ZW10GHO"},{"name":"Maps_To","value":"Allogeneic Natural Killer Cell Line MG4101"},{"name":"NCI_Drug_Dictionary_ID","value":"686754"},{"name":"NCI_META_CUI","value":"CL426022"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686754"},{"name":"PDQ_Open_Trial_Search_ID","value":"686754"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117231":{"preferredName":"Allogeneic Natural Killer Cell Line NK-92","code":"C117231","definitions":[{"definition":"A proprietary, human cytotoxic cell line composed of allogeneic, activated, interleukin-2 (IL-2) dependent-natural killer cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma, with potential antineoplastic activity. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells. Upon infusion of the allogeneic NK cell line NK-92, the NKs recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in cancer cell lysis and apoptosis. In addition, NK-92 cells express high affinity Fc receptors, which bind to therapeutic antibodies; therefore, this agent can enhance antibody dependent cellular cytotoxicity (ADCC) of co-administered therapeutic antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Natural Killer Cell Line NK-92","termGroup":"PT","termSource":"NCI"},{"termName":"haNK","termGroup":"BR","termSource":"NCI"},{"termName":"NK-92","termGroup":"CN","termSource":"NCI"},{"termName":"NK-92 Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y0EW4890B4"},{"name":"Maps_To","value":"Allogeneic Natural Killer Cell Line NK-92"},{"name":"NCI_Drug_Dictionary_ID","value":"763083"},{"name":"NCI_META_CUI","value":"CL474099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763083"},{"name":"PDQ_Open_Trial_Search_ID","value":"763083"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95213":{"preferredName":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601","code":"C95213","definitions":[{"definition":"A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601","termGroup":"PT","termSource":"NCI"},{"termName":"IL-7/GM-CSF/CD80/CD154-encoding Synthetic dSLIM-30L1 Allogeneic Renal Cell Carcinoma Vaccine MGN1601","termGroup":"SY","termSource":"NCI"},{"termName":"MGN1601","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Renal Cell Carcinoma Vaccine MGN1601"},{"name":"NCI_Drug_Dictionary_ID","value":"692088"},{"name":"NCI_META_CUI","value":"CL426701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"692088"},{"name":"PDQ_Open_Trial_Search_ID","value":"692088"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1649":{"preferredName":"Allovectin-7","code":"C1649","definitions":[{"definition":"A substance that is being studied as a gene therapy agent for the treatment of cancer.  It increases the ability of the immune system to recognize cancer cells and kill them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Allovectin-7","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2M DNA Lipid Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2M Plasmid DNA/DMRIE/DOPE Lipid Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2M Plasmid DNA/Lipid Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HLA-B7/Beta2Microglobulin DNA-Liposome Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Allovectin-7"},{"name":"Maps_To","value":"Allovectin-7"},{"name":"NCI_Drug_Dictionary_ID","value":"42356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42356"},{"name":"PDQ_Open_Trial_Search_ID","value":"42356"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338269"}]}}{"C81667":{"preferredName":"Almurtide","code":"C81667","definitions":[{"definition":"A synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Almurtide","termGroup":"PT","termSource":"NCI"},{"termName":"2-Acetamido-3-O-((((1S)-1-(((1R)-1-carbamoyl-3- carboxypropyl)carbamoyl)ethyl)carbamoyl)methyl)-2-deoxy-D- glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"Cgp-11637","termGroup":"CN","termSource":"NCI"},{"termName":"N-Acetyl-nor-muramyl-L-alanyl-D-isoglutamine","termGroup":"SY","termSource":"NCI"},{"termName":"nor-MDP","termGroup":"SY","termSource":"NCI"},{"termName":"norMDP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"61136-12-7"},{"name":"Chemical_Formula","value":"C18H30N4O11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1DCO35D4OR"},{"name":"Legacy Concept Name","value":"Almurtide"},{"name":"Maps_To","value":"Almurtide"},{"name":"NCI_Drug_Dictionary_ID","value":"702874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"702874"},{"name":"PDQ_Open_Trial_Search_ID","value":"702874"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0130664"}]}}{"C94214":{"preferredName":"Alpelisib","code":"C94214","definitions":[{"definition":"An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpelisib","termGroup":"PT","termSource":"NCI"},{"termName":"BYL 719","termGroup":"CN","termSource":"NCI"},{"termName":"BYL-719","termGroup":"CN","termSource":"NCI"},{"termName":"BYL719","termGroup":"CN","termSource":"NCI"},{"termName":"Phosphoinositide 3-kinase Inhibitor BYL719","termGroup":"SY","termSource":"NCI"},{"termName":"Piqray","termGroup":"BR","termSource":"NCI"},{"termName":"VIJOICE","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"f adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CARelated Overgrowth Spectrum (PROS) who require systemic therapy."},{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer"},{"name":"CAS_Registry","value":"1217486-61-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"08W5N2C97Q"},{"name":"Maps_To","value":"Alpelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"687431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687431"},{"name":"PDQ_Open_Trial_Search_ID","value":"687431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986399"}]}}{"C1720":{"preferredName":"Alpha Galactosylceramide","code":"C1720","definitions":[{"definition":"A drug being studied in the treatment of cancer. It is a biological response modifier that belongs to the family of drugs called glycosphingolipids or agelasphins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A potent alpha galactosylceramide modified from marine-sponge that stimulates the immune system to exhibit antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha Galactosylceramide","termGroup":"PT","termSource":"NCI"},{"termName":"a-GalCer","termGroup":"AB","termSource":"NCI"},{"termName":"KRN-7000","termGroup":"CN","termSource":"NCI"},{"termName":"KRN7000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"158021-47-7"},{"name":"CHEBI_ID","value":"CHEBI:466659"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WX671898JF"},{"name":"Legacy Concept Name","value":"KRN7000"},{"name":"Maps_To","value":"Alpha Galactosylceramide"},{"name":"NCI_Drug_Dictionary_ID","value":"43562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43562"},{"name":"PDQ_Open_Trial_Search_ID","value":"43562"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0534775"}]}}{"C52185":{"preferredName":"Alpha V Beta 1 Inhibitor ATN-161","code":"C52185","definitions":[{"definition":"A small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for integrin alpha5beta1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. Integrin alpha5beta1 is expressed on endothelial cells and plays a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. ATN-161 may prevent the spread of tumor cells and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Alpha V Beta 1 Inhibitor ATN-161","termGroup":"PT","termSource":"NCI"},{"termName":"ATN-161","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"262438-43-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XW0H5LE42K"},{"name":"Legacy Concept Name","value":"ATN-161"},{"name":"Maps_To","value":"Alpha V Beta 1 Inhibitor ATN-161"},{"name":"NCI_Drug_Dictionary_ID","value":"459774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459774"},{"name":"PDQ_Open_Trial_Search_ID","value":"459774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706674"}]}}{"C120550":{"preferredName":"Idetrexed","code":"C120550","definitions":[{"definition":"An alpha-folate receptor (aFR)-mediated inhibitor of thymidylate synthase (TS), with potential antineoplastic activity. Upon intravenous infusion, idetrexed selectively targets and binds to aFR-expressing tumor cells. Upon uptake by aFR, this agent binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits both DNA synthesis and cell division, and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division. aFR, a cell-surface receptor glycoprotein, is overexpressed on various tumor cell types, but is minimally expressed by normal, healthy tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idetrexed","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801","termGroup":"SY","termSource":"NCI"},{"termName":"BGC 945","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-gamma-glutamyl-d-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ONX 0801","termGroup":"CN","termSource":"NCI"},{"termName":"ONX-0801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501332-69-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q718FS1C7X"},{"name":"Maps_To","value":"alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801"},{"name":"Maps_To","value":"Idetrexed"},{"name":"NCI_Drug_Dictionary_ID","value":"769152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769152"},{"name":"PDQ_Open_Trial_Search_ID","value":"769152"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1612758"}]}}{"C165548":{"preferredName":"Alpha-Gal AGI-134","code":"C165548","definitions":[{"definition":"A synthetic alpha Gal (aGal) molecule, with potential immunomodulating and antineoplastic activities. Upon intratumoral injection of aGal AGI-134, aGal coats the cancer cell membranes and triggers an anti-aGal antibody-mediated immune response leading to an initial complement-dependent and antibody-dependent cellular cytotoxicity (ADCC). This cytotoxicity causes release from tumor cells and subsequent uptake of released tumor-associated antigens (TAAs) by antigen-presenting cells (APCs). This may activate a systemic immune response against the TAAs and may eradicate cancer cells. aGal is a cell-surface carbohydrate antigen not expressed by humans while being expressed by all other mammals and bacteria. Anti-aGal antibodies are continuously and abundantly produced by humans due to exposure to aGal present on intestinal bacteria in the digestive system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-Gal AGI-134","termGroup":"PT","termSource":"NCI"},{"termName":"aGal AGI-134","termGroup":"SY","termSource":"NCI"},{"termName":"AGI 134","termGroup":"CN","termSource":"NCI"},{"termName":"AGI-134","termGroup":"CN","termSource":"NCI"},{"termName":"AGI134","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-alpha Gal Immunotherapeutic AGI-134","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1821461-84-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OE0L4ZX3I8"},{"name":"Maps_To","value":"Alpha-Gal AGI-134"},{"name":"NCI_Drug_Dictionary_ID","value":"799503"},{"name":"NCI_META_CUI","value":"CL978678"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799503"},{"name":"PDQ_Open_Trial_Search_ID","value":"799503"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159497":{"preferredName":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H","code":"C159497","definitions":[{"definition":"A synthetic proteolipid complex comprised of the alpha-1 domain of alpha-lactalbumin (lactose synthase B protein) and oleic acid, with potential antineoplastic activity. Upon intravesical instillation, alpha1H selectively accumulates in the nuclei of tumor cells and binds to histones H3, H4, and H2B. By binding to histones, alpha1H disrupts chromatin assembly and interferes with intact chromatin, thereby preventing tumor cell transcription and replication. Additionally, alpha1H inhibits the phosphorylation of multiple kinases involved in cancer-associated pathways including the Ras/Raf/ERK, PI3K/AKT, p38 MAPK and JNK signaling pathways. This may inhibit tumor cell proliferation and induce apoptosis in tumor cells that are driven by the dysregulation of certain kinases and oncogenic GTPases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha 1H","termGroup":"CN","termSource":"NCI"},{"termName":"Alpha-1H","termGroup":"CN","termSource":"NCI"},{"termName":"Alpha-lactalbumin-derived Synthetic Proteolipid Complex Alpha1H","termGroup":"SY","termSource":"NCI"},{"termName":"Alpha1H","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H"},{"name":"NCI_Drug_Dictionary_ID","value":"797495"},{"name":"NCI_META_CUI","value":"CL951455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797495"},{"name":"PDQ_Open_Trial_Search_ID","value":"797495"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28795":{"preferredName":"Alpha-Thioguanine Deoxyriboside","code":"C28795","definitions":[{"definition":"A purine analog with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-Thioguanine Deoxyriboside","termGroup":"PT","termSource":"NCI"},{"termName":"6H-Purine-6-thione, 2-amino-9-(2-deoxy-alpha-D-erythro-pentofuranosyl)-1,9-dihydro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"9H-Purine-6-thiol, 2-amino-9-(2-deoxy-alpha-D-erythro-pentofuranosyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"A-TGDR","termGroup":"AB","termSource":"NCI"},{"termName":"alpha-2'-Deoxy-6-thioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-2'-Deoxythioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-Thiodeoxyguanosine","termGroup":"SY","termSource":"NCI"},{"termName":"Thioguanine 9-alpha-D-2'-deoxyriboside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2133-81-5"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alpha-Thioguanine_Deoxyriboside"},{"name":"Maps_To","value":"Alpha-Thioguanine Deoxyriboside"},{"name":"NSC Number","value":"71851"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051299"}]}}{"C117234":{"preferredName":"Alpha-tocopheryloxyacetic Acid","code":"C117234","definitions":[{"definition":"An orally bioavailable vitamin E derivative with potential antineoplastic and immunostimulating activities. Upon administration, alpha-tocopheryloxyacetic acid (alpha-TEA) induces tumor autophagy; the autophagosomes formed, which carry tumor associated antigens (TAAs), allow for increased cross-presentation of TAAs by professional antigen-presenting cells (APCs). This activates a T cell-mediated T helper type 1 (TH1) response, generates a cytotoxic T-lymphocyte (CTL) response against cancer cells, and reduces the frequency of regulatory T-cell (Treg) differentiation. In addition, alpha-TEA modulates the release of various cytokines and chemokines and induces tumor cell apoptosis. Altogether, this results in decreased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha-tocopheryloxyacetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2,5,7,8-Tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) Acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"a-TEA","termGroup":"AB","termSource":"NCI"},{"termName":"alpha-TEA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"261929-52-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JW7FJR3ZLY"},{"name":"Maps_To","value":"Alpha-tocopheryloxyacetic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"763148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763148"},{"name":"PDQ_Open_Trial_Search_ID","value":"763148"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1455006"}]}}{"C118290":{"preferredName":"Altiratinib","code":"C118290","definitions":[{"definition":"An orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Altiratinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"DCC-2701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1345847-93-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T678746713"},{"name":"Maps_To","value":"Altiratinib"},{"name":"NCI_Drug_Dictionary_ID","value":"764368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764368"},{"name":"PDQ_Open_Trial_Search_ID","value":"764368"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896881"}]}}{"C544":{"preferredName":"Altretamine","code":"C544","definitions":[{"definition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Altretamine","termGroup":"PT","termSource":"NCI"},{"termName":"2,4,6-tris(dimethylamino)-s-triazine","termGroup":"SN","termSource":"NCI"},{"termName":"ENT-50852","termGroup":"CN","termSource":"NCI"},{"termName":"Hemel","termGroup":"SY","termSource":"NCI"},{"termName":"Hexalen","termGroup":"BR","termSource":"NCI"},{"termName":"Hexaloids","termGroup":"SY","termSource":"NCI"},{"termName":"Hexamethylamine","termGroup":"SY","termSource":"NCI"},{"termName":"Hexamethylmelamine","termGroup":"SY","termSource":"NCI"},{"termName":"Hexastat","termGroup":"FB","termSource":"NCI"},{"termName":"Hexinawas","termGroup":"FB","termSource":"NCI"},{"termName":"HMM","termGroup":"AB","termSource":"NCI"},{"termName":"HXM","termGroup":"AB","termSource":"NCI"},{"termName":"N,n,n',N\"N\"-hexamethyl-1,3,5,-triazine-2,4,6,-triamine","termGroup":"SN","termSource":"NCI"},{"termName":"N,N,N',N',N\",N\"-hexamethyl-1,3,5-triazine-2,4,6-triamine","termGroup":"SN","termSource":"NCI"},{"termName":"RB-1515","termGroup":"CN","termSource":"NCI"},{"termName":"WR-95704","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"645-05-6"},{"name":"CHEBI_ID","value":"CHEBI:24564"},{"name":"Chemical_Formula","value":"C9H18N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q8BIH59O7H"},{"name":"Legacy Concept Name","value":"Altretamine"},{"name":"Maps_To","value":"Altretamine"},{"name":"NCI_Drug_Dictionary_ID","value":"39475"},{"name":"NSC Number","value":"13875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39475"},{"name":"PDQ_Open_Trial_Search_ID","value":"39475"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0019453"}]}}{"C38142":{"preferredName":"Alvespimycin","code":"C38142","definitions":[{"definition":"17-DMAG. A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called geldanamycin analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvespimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"17-DMAG","termGroup":"AB","termSource":"NCI"},{"termName":"Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"467214-20-6"},{"name":"Chemical_Formula","value":"C32H48N4O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"001L2FE0M3"},{"name":"Legacy Concept Name","value":"_17-Dimethylaminoethylamino_17-Demethoxygeldanamycin"},{"name":"Maps_To","value":"Alvespimycin"},{"name":"NSC Number","value":"707545"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527262"}]}}{"C76665":{"preferredName":"Alvespimycin Hydrochloride","code":"C76665","definitions":[{"definition":"The hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvespimycin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"17-DMAG HCl","termGroup":"AB","termSource":"NCI"},{"termName":"BMS-826476","termGroup":"CN","termSource":"NCI"},{"termName":"Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-, Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"KOS-1022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"467214-21-7"},{"name":"Chemical_Formula","value":"C32H48N4O8.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"612K359T69"},{"name":"Legacy Concept Name","value":"Alvespimycin_Hydrochloride"},{"name":"Maps_To","value":"Alvespimycin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"378203"},{"name":"PDQ_Closed_Trial_Search_ID","value":"378203"},{"name":"PDQ_Open_Trial_Search_ID","value":"378203"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350808"}]}}{"C74940":{"preferredName":"Alvocidib","code":"C74940","definitions":[{"definition":"The free base form of a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvocidib","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"Alvocidib Freebase","termGroup":"SY","termSource":"NCI"},{"termName":"Flavopiridol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"146426-40-6"},{"name":"Chemical_Formula","value":"C21H20ClNO5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"45AD6X575G"},{"name":"Legacy Concept Name","value":"Alvocidib_Freebase"},{"name":"Maps_To","value":"Alvocidib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0174903"}]}}{"C1571":{"preferredName":"Alvocidib Hydrochloride","code":"C1571","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It stops cells from dividing and may kill cancer cells. It is a type of cyclin-dependent kinase (CDK) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvocidib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Flavopiridol Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"HL-275","termGroup":"CN","termSource":"NCI"},{"termName":"HMR 1275","termGroup":"CN","termSource":"NCI"},{"termName":"HMR-1275","termGroup":"CN","termSource":"NCI"},{"termName":"HMR1275","termGroup":"CN","termSource":"NCI"},{"termName":"L 868275","termGroup":"CN","termSource":"NCI"},{"termName":"L-86-8275","termGroup":"CN","termSource":"NCI"},{"termName":"L-868275","termGroup":"CN","termSource":"NCI"},{"termName":"L868275","termGroup":"CN","termSource":"NCI"},{"termName":"MDL 107,826A","termGroup":"CN","termSource":"NCI"},{"termName":"MDL-107826A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"131740-09-5"},{"name":"Chemical_Formula","value":"C21H20ClNO5.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D48MS3A6N9"},{"name":"Legacy Concept Name","value":"Flavopiridol"},{"name":"Maps_To","value":"Alvocidib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42068"},{"name":"NSC Number","value":"649890"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42068"},{"name":"PDQ_Open_Trial_Search_ID","value":"42068"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281603"}]}}{"C165555":{"preferredName":"Alvocidib Prodrug TP-1287","code":"C165555","definitions":[{"definition":"An orally bioavailable, highly soluble phosphate prodrug of alvocidib, a potent inhibitor of cyclin-dependent kinase-9 (CDK9), with potential antineoplastic activity. Upon administration of the phosphate prodrug TP-1287, the prodrug is enzymatically cleaved at the tumor site and the active moiety alvocidib is released. Alvocidib targets and binds to CDK9, thereby reducing the expression of CDK9 target genes such as the anti-apoptotic protein MCL-1, and inducing G1 cell cycle arrest and apoptosis in CDK9-overexpressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alvocidib Prodrug TP-1287","termGroup":"PT","termSource":"NCI"},{"termName":"Alvocidib Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Alvocidib Phosphate TP-1287","termGroup":"SY","termSource":"NCI"},{"termName":"TP 1287","termGroup":"CN","termSource":"NCI"},{"termName":"TP-1287","termGroup":"CN","termSource":"NCI"},{"termName":"TP1287","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2044686-42-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7MPP85IIJ3"},{"name":"Maps_To","value":"Alvocidib Prodrug TP-1287"},{"name":"NCI_Drug_Dictionary_ID","value":"799663"},{"name":"NCI_META_CUI","value":"CL978685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799663"},{"name":"PDQ_Open_Trial_Search_ID","value":"799663"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62483":{"preferredName":"Amatuximab","code":"C62483","definitions":[{"definition":"A chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed on many epithelial-derived cancer cells. Upon binding to the mesothelin antigen, amatuximab triggers an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing cells, resulting in cell lysis.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Amatuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Mesothelin Monoclonal Antibody MORAb-009","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(mesothelin) (Human-Mouse Monoclonal MORAb-009 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-009 Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb-009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"931402-35-6"},{"name":"Chemical_Formula","value":"C6394H9870N1694O2024S46"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6HP0354G04"},{"name":"Legacy Concept Name","value":"Anti-Mesothelin_Monoclonal_Antibody"},{"name":"Maps_To","value":"Amatuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"489384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489384"},{"name":"PDQ_Open_Trial_Search_ID","value":"489384"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3179481"}]}}{"C73320":{"preferredName":"Ambamustine","code":"C73320","definitions":[{"definition":"A tripeptidic nitrogen mustard compound and bifunctional alkylating agent with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ambamustine","termGroup":"PT","termSource":"NCI"},{"termName":"N-(3-(m-(Bis(2-chloroethyl)amino)phenyl)-N-(3-(p-fluorophenyl)-L-alanyl)-L-alanyl)-L-methionine, Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"PTT-119","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85754-59-2"},{"name":"Chemical_Formula","value":"C29H39Cl2FN4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IB1H345F24"},{"name":"Legacy Concept Name","value":"Ambamustine"},{"name":"Maps_To","value":"Ambamustine"},{"name":"PubMedID_Primary_Reference","value":"10683068"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244456"}]}}{"C72627":{"preferredName":"Ambazone","code":"C72627","definitions":[{"definition":"An antiseptic agent with potential antibacterial and antileukemic activity. Although the exact mechanism of action remains to be fully elucidated, ambazone appears to interfere with the membrane-bound nucleotide system by increasing the intracellular concentration of cAMP in leukemia cells and macrophages, which potentially contributes to this agent's antineoplastic activity. Furthermore, this agent's affinity for various cellular targets, i.e. membranes, nucleic acids and proteins, may contribute to the overall antibacterial effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ambazone","termGroup":"PT","termSource":"NCI"},{"termName":"Faringosept","termGroup":"BR","termSource":"NCI"},{"termName":"p-Benzoquinone Amidinohydrazone Thiosemicarbazone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6011-12-7"},{"name":"Chemical_Formula","value":"C8H11N7S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BYK4592A3Q"},{"name":"Legacy Concept Name","value":"Ambazone"},{"name":"Maps_To","value":"Ambazone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043983"}]}}{"C148521":{"preferredName":"Amblyomin-X","code":"C148521","definitions":[{"definition":"A recombinant form of a toxic protein derived from the salivary glands of the Amblyomma cajennense tick that inhibits Factor Xa and induces apoptosis, with potential antithrombotic and antineoplastic activities.  Upon administration, amblyomin-X promotes endoplasmic reticulum (ER) stress, mitochondrial dysfunction, cytochrome-c release, poly(ADP-ribose) polymerase (PARP) cleavage, and activation of caspase. Additionally, this agent selectively induces apoptosis in tumor cells. It also affects endothelial cell functions, such as adhesion, and may inhibit angiogenesis. Amblyomin-X targets and binds to factor Xa, inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. As cancer is associated with thrombosis, amblyomin-X could potentially exert its antineoplastic and antithrombotic effects in the cancer patient at the same time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amblyomin-X","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amblyomin-X"},{"name":"NCI_Drug_Dictionary_ID","value":"792680"},{"name":"NCI_META_CUI","value":"CL551143"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792680"},{"name":"PDQ_Open_Trial_Search_ID","value":"792680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104745":{"preferredName":"Amcasertib","code":"C104745","definitions":[{"definition":"An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, amcasertib targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amcasertib","termGroup":"PT","termSource":"NCI"},{"termName":"BBI503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1129403-56-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GLY8ABW25V"},{"name":"Maps_To","value":"Amcasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"746133"},{"name":"NCI_META_CUI","value":"CL445816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746133"},{"name":"PDQ_Open_Trial_Search_ID","value":"746133"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1342":{"preferredName":"Ametantrone","code":"C1342","definitions":[{"definition":"A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ametantrone","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-bis[[2-[(2-Hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64862-96-0"},{"name":"Chemical_Formula","value":"C22H28N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PNT6041ST1"},{"name":"Legacy Concept Name","value":"Ametantrone"},{"name":"Maps_To","value":"Ametantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"39147"},{"name":"NSC Number","value":"196473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39147"},{"name":"PDQ_Open_Trial_Search_ID","value":"39147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0102923"}]}}{"C488":{"preferredName":"Amifostine","code":"C488","definitions":[{"definition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amifostine","termGroup":"PT","termSource":"NCI"},{"termName":"2-[(3-Aminopropyl)amino]ethanethiol Dihydrogen Phosphate Ester Trihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Amifostine Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Aminopropylaminoethylthiophosphoric Acid Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"APAETP","termGroup":"AB","termSource":"NCI"},{"termName":"Cytofos","termGroup":"FB","termSource":"NCI"},{"termName":"Ethiofos","termGroup":"SY","termSource":"NCI"},{"termName":"Ethyol","termGroup":"BR","termSource":"NCI"},{"termName":"Gammaphos","termGroup":"SY","termSource":"NCI"},{"termName":"S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid Trihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"S-2-(3-Aminopropylamino)ethylphosphorothioic Acid Trihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"WR-2721","termGroup":"CN","termSource":"NCI"},{"termName":"WR2721","termGroup":"CN","termSource":"NCI"},{"termName":"YM-08310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cisplatin-induced nephrotoxicity; Radiation-induced mucositis and xerostomia"},{"name":"CAS_Registry","value":"112901-68-5"},{"name":"Chemical_Formula","value":"C5H15N2O3PS.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"M487QF2F4V"},{"name":"Legacy Concept Name","value":"Amifostine"},{"name":"Maps_To","value":"Amifostine"},{"name":"NCI_Drug_Dictionary_ID","value":"39741"},{"name":"NSC Number","value":"296961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39741"},{"name":"PDQ_Open_Trial_Search_ID","value":"39741"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015020"}]}}{"C15509":{"preferredName":"Amino Acid Injection","code":"C15509","definitions":[{"definition":"A concentrated dietary supplement for injection containing the essential amino acids leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine and tryptophan as well as the non-essential amino acids alanine, arginine, glycine, proline, serine and tyrosine, with potential anabolic and anti-catabolic activities. Upon dilution and intravenous infusion of the amino acid nutritional supplement, the amino acids serve as protein building blocks, promote protein synthesis in muscle cells and prevent protein breakdown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amino Acid Injection","termGroup":"PT","termSource":"NCI"},{"termName":"RenAmin","termGroup":"BR","termSource":"NCI"},{"termName":"Travasol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Amino_Acid_Injection"},{"name":"Maps_To","value":"Amino Acid Injection"},{"name":"NCI_Drug_Dictionary_ID","value":"757081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757081"},{"name":"PDQ_Open_Trial_Search_ID","value":"757081"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0076943"}]}}{"C1488":{"preferredName":"Aminocamptothecin","code":"C1488","definitions":[{"definition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aminocamptothecin","termGroup":"PT","termSource":"NCI"},{"termName":"9-AC","termGroup":"AB","termSource":"NCI"},{"termName":"9-amino-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"9-amino-20-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"9-amino-camptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"9-amino-CPT","termGroup":"SY","termSource":"NCI"},{"termName":"9-aminocamptothecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86639-63-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5MB77ICE2Q"},{"name":"Legacy Concept Name","value":"Aminocamptothecin"},{"name":"Maps_To","value":"Aminocamptothecin"},{"name":"NCI_Drug_Dictionary_ID","value":"41792"},{"name":"NSC Number","value":"603071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41792"},{"name":"PDQ_Open_Trial_Search_ID","value":"41792"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0214192"}]}}{"C2452":{"preferredName":"Aminocamptothecin Colloidal Dispersion","code":"C2452","definitions":[{"definition":"A colloidal dispersion formulation of 9-Aminocamptothecin, a water-insoluble camptothecin derivative. Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages. Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aminocamptothecin Colloidal Dispersion","termGroup":"PT","termSource":"NCI"},{"termName":"9-aminocamptothecin colloidal dispersion","termGroup":"SY","termSource":"NCI"},{"termName":"9AC colloidal dispersion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aminocamptothecin_Colloidal_Dispersion"},{"name":"Maps_To","value":"Aminocamptothecin Colloidal Dispersion"},{"name":"NCI_Drug_Dictionary_ID","value":"42874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42874"},{"name":"PDQ_Open_Trial_Search_ID","value":"42874"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677807"}]}}{"C48370":{"preferredName":"Aminoflavone Prodrug AFP464","code":"C48370","definitions":[{"definition":"A substance being studied in the treatment of cancer. AFP464 kills cancer cells or stops them from dividing. It is a type of aminoflavone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic lysyl prodrug of the amino-substituted flavone derivate aminoflavone with antiproliferative and antineoplastic activities. AFP464 is rapidly converted to aminoflavone in plasma. Aminoflavone activates the aryl hydrocarbon receptor (AhR) signaling pathway leading to an increase in cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1A2 (CYP1A2) expression and, to a lesser extent, an increase in cytochrome P450 1B1 (CYP1B1) expression. Subsequently, aminoflavone is metabolized to toxic metabolites by the cytochromome P450 enzymes that it induces; these toxic metabolites covalently bind to DNA, resulting in the phosphorylation of p53, the induction of the p53 downstream target p21Waf1/Cip1, and apoptosis. Pulmonary toxicity may be dose-limiting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aminoflavone Prodrug AFP464","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"468719-53-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"73JNH95XPX"},{"name":"Legacy Concept Name","value":"AFP464"},{"name":"Maps_To","value":"Aminoflavone Prodrug AFP464"},{"name":"NCI_Drug_Dictionary_ID","value":"453584"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453584"},{"name":"PDQ_Open_Trial_Search_ID","value":"453584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706653"}]}}{"C235":{"preferredName":"Aminopterin","code":"C235","definitions":[{"definition":"A synthetic derivative of pterins with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Aminopterin","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-PGA","termGroup":"SY","termSource":"NCI"},{"termName":"4-Aminofolic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"4-Aminopteroyl-glutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"4-Aminopteroylglutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Aminopteroylglutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"APGA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54-62-6"},{"name":"CHEBI_ID","value":"CHEBI:22526"},{"name":"Chemical_Formula","value":"C19H20N8O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JYB41CTM2Q"},{"name":"Legacy Concept Name","value":"Aminopterin"},{"name":"Maps_To","value":"Aminopterin"},{"name":"NCI_Drug_Dictionary_ID","value":"39141"},{"name":"NSC Number","value":"739"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39141"},{"name":"PDQ_Open_Trial_Search_ID","value":"39141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002583"}]}}{"C74554":{"preferredName":"Aminopterin Sodium","code":"C74554","definitions":[{"definition":"The sodium salt of a pterin derivative with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aminopterin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Aminopterin Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Sodium Aminopterin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58602-66-7"},{"name":"Chemical_Formula","value":"C19H18N8O5.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FZU1QI13O9"},{"name":"Legacy Concept Name","value":"Aminopterin_Sodium"},{"name":"Maps_To","value":"Aminopterin Sodium"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282048"}]}}{"C90592":{"preferredName":"Amolimogene Bepiplasmid","code":"C90592","definitions":[{"definition":"A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amolimogene Bepiplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"Amolimogene","termGroup":"SY","termSource":"NCI"},{"termName":"Bacterially Derived DNA and Microparticles Made of Poly(D,L-lactide-co-glydolide)","termGroup":"SY","termSource":"NCI"},{"termName":"DNA (synthetic Plasmid p3kDRalphaHPV16-18)","termGroup":"SY","termSource":"NCI"},{"termName":"ZYC101a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"870524-46-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B5KCA0GAK"},{"name":"Maps_To","value":"Amolimogene Bepiplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"561721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561721"},{"name":"PDQ_Open_Trial_Search_ID","value":"561721"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1435422"}]}}{"C61306":{"preferredName":"Amonafide L-Malate","code":"C61306","definitions":[{"definition":"The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amonafide L-Malate","termGroup":"PT","termSource":"NCI"},{"termName":"5-amino-2-[2-(dimethylamino)ethyl]-1H-benz[de]isoquinoline-1,3(2H)-dione (2S)-2-ydroxybutanedioate","termGroup":"SN","termSource":"NCI"},{"termName":"AS1413","termGroup":"CN","termSource":"NCI"},{"termName":"Butanedioic Acid, 2-hydroxy-, (2S)-, compd. with 5-amino-2-(2-(dimethylamino)ethyl)-1h-benz[de]isoquinoline-1,3(2h)-dione (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"XAN-02","termGroup":"CN","termSource":"NCI"},{"termName":"Xanafide","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of secondary acute myeloid leukemia"},{"name":"CAS_Registry","value":"618863-54-0"},{"name":"Chemical_Formula","value":"C16H17N3O2.C4H6O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LI06Q37TEG"},{"name":"Legacy Concept Name","value":"Amonafide_L-Malate"},{"name":"Maps_To","value":"Amonafide L-Malate"},{"name":"NCI_Drug_Dictionary_ID","value":"485171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485171"},{"name":"PDQ_Open_Trial_Search_ID","value":"485171"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879697"}]}}{"C80089":{"preferredName":"Amrubicin","code":"C80089","definitions":[{"definition":"A substance being studied in the treatment of lung cancer. It is a type of anthracycline analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amrubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110267-81-7"},{"name":"Chemical_Formula","value":"C25H25NO9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"93N13LB4Z2"},{"name":"Legacy Concept Name","value":"Amrubicin"},{"name":"Maps_To","value":"Amrubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"813335"},{"name":"NCI_META_CUI","value":"CL405282"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C47948":{"preferredName":"Amrubicin Hydrochloride","code":"C47948","definitions":[{"definition":"The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amrubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Amrubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Calsed","termGroup":"FB","termSource":"NCI"},{"termName":"SM 5887","termGroup":"CN","termSource":"NCI"},{"termName":"SM-5887","termGroup":"CN","termSource":"NCI"},{"termName":"SM5887","termGroup":"CN","termSource":"NCI"},{"termName":"SMP-5887","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110311-30-3"},{"name":"Chemical_Formula","value":"C25H25NO9.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EUL6MP8FZW"},{"name":"Legacy Concept Name","value":"Amrubicin_Hydrochloride"},{"name":"Maps_To","value":"Amrubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"443682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"443682"},{"name":"PDQ_Open_Trial_Search_ID","value":"443682"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762659"}]}}{"C240":{"preferredName":"Amsacrine","code":"C240","definitions":[{"definition":"An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amsacrine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-(9-Acridinylamino)methane-sulfon-m-anisidide","termGroup":"SN","termSource":"NCI"},{"termName":"Acridinyl Anisidide","termGroup":"SY","termSource":"NCI"},{"termName":"Amekrin","termGroup":"FB","termSource":"NCI"},{"termName":"AMSA","termGroup":"AB","termSource":"NCI"},{"termName":"Amsa P-D","termGroup":"BR","termSource":"NCI"},{"termName":"Amsidine","termGroup":"FB","termSource":"NCI"},{"termName":"Amsidyl","termGroup":"FB","termSource":"NCI"},{"termName":"Cain's Acridine","termGroup":"SY","termSource":"NCI"},{"termName":"CI 880","termGroup":"CN","termSource":"NCI"},{"termName":"CI-880","termGroup":"CN","termSource":"NCI"},{"termName":"CI880","termGroup":"CN","termSource":"NCI"},{"termName":"Lamasine","termGroup":"FB","termSource":"NCI"},{"termName":"m-AMSA","termGroup":"AB","termSource":"NCI"},{"termName":"N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"SN-11841","termGroup":"CN","termSource":"NCI"},{"termName":"SN-21429","termGroup":"CN","termSource":"NCI"},{"termName":"SN11841","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51264-14-3"},{"name":"CHEBI_ID","value":"CHEBI:2687"},{"name":"Chemical_Formula","value":"C21H19N3O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"00DPD30SOY"},{"name":"Legacy Concept Name","value":"Amsacrine"},{"name":"Maps_To","value":"Amsacrine"},{"name":"NCI_Drug_Dictionary_ID","value":"39142"},{"name":"NSC Number","value":"249992"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39142"},{"name":"PDQ_Open_Trial_Search_ID","value":"39142"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0591085"}]}}{"C96771":{"preferredName":"Amsacrine Lactate","code":"C96771","definitions":[{"definition":"The lactate form of amsacrine, an aminoacridine analog and topoisomerase II inhibitor, with antineoplastic activity. Although the exact relationship between DNA binding and its activity has yet to be fully elucidated, amsacrine intercalates DNA through its acridine moiety, and its nonintercalative headgroup impedes topoisomerase II activity, augmenting enzyme-mediated DNA cleavage and resulting in DNA double-strand breaks. This ultimately induces programmed cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amsacrine Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"m-AMSA lactate","termGroup":"SY","termSource":"NCI"},{"termName":"Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-, compd. with Lactic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide compd. with Lactic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80277-11-8"},{"name":"Chemical_Formula","value":"C21H19N3O3S.C3H6O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"959PWE0Q2E"},{"name":"Maps_To","value":"Amsacrine Lactate"},{"name":"NSC Number","value":"141549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1271552"}]}}{"C38684":{"preferredName":"Amsilarotene","code":"C38684","definitions":[{"definition":"A retinobenzoic acid with potential antineoplastic activity. Amsilarotene inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest.  This agent also causes a cytotoxic decline in cyclin A and thymidylate synthase expression.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called synthetic retinoids and angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Amsilarotene","termGroup":"PT","termSource":"NCI"},{"termName":"TAC 101","termGroup":"CN","termSource":"NCI"},{"termName":"TAC-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125973-56-0"},{"name":"Chemical_Formula","value":"C20H27NO3Si2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1418F39MH"},{"name":"Legacy Concept Name","value":"TAC-101"},{"name":"Maps_To","value":"Amsilarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"350384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350384"},{"name":"PDQ_Open_Trial_Search_ID","value":"350384"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0675838"}]}}{"C75926":{"preferredName":"Amustaline","code":"C75926","definitions":[{"definition":"A quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amustaline","termGroup":"PT","termSource":"NCI"},{"termName":"(N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate","termGroup":"SN","termSource":"NCI"},{"termName":"S-303","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220180-88-1"},{"name":"Chemical_Formula","value":"C22H25Cl2N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25571657UW"},{"name":"Legacy Concept Name","value":"Amustaline"},{"name":"Maps_To","value":"Amustaline"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1667749"}]}}{"C75035":{"preferredName":"Amustaline Dihydrochloride","code":"C75035","definitions":[{"definition":"The hydrochloride salt form of amustaline, a quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amustaline Dihydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"210584-54-6"},{"name":"Chemical_Formula","value":"C22H25Cl2N3O2.2ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C5MKX7XOYA"},{"name":"Legacy Concept Name","value":"Amustaline_Dihydrochloride"},{"name":"Maps_To","value":"Amustaline Dihydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698106"}]}}{"C71750":{"preferredName":"Amuvatinib","code":"C71750","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks the action of certain enzymes involved in cell growth and the repair of DNA damaged by some anticancer drugs. It is a type of tyrosine kinase inhibitor and a type of recombinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amuvatinib","termGroup":"PT","termSource":"NCI"},{"termName":"HPK56","termGroup":"CN","termSource":"NCI"},{"termName":"MP470","termGroup":"CN","termSource":"NCI"},{"termName":"Receptor Tyrosine Kinase Inhibitor MP470","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850879-09-3"},{"name":"Chemical_Formula","value":"C23H21N5O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SO9S6QZB4R"},{"name":"Legacy Concept Name","value":"Receptor_Tyrosine_Kinase_Inhibitor_MP470"},{"name":"Maps_To","value":"Amuvatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"559320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"559320"},{"name":"PDQ_Open_Trial_Search_ID","value":"559320"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1958331"}]}}{"C95776":{"preferredName":"Amuvatinib Hydrochloride","code":"C95776","definitions":[{"definition":"The hydrochloride salt of an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amuvatinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazinecarbothioamide, N-(1,3-Benzodioxol-5-Ylmethyl)-4-Benzofuro(3,2-D)Pyrimidin-4-Yl-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"HPK56 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"MP-470 HCI","termGroup":"SY","termSource":"NCI"},{"termName":"MP470 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"N-(1,3-Benzodioxol-5-Ylmethyl)-4-(Benzofuro(3,2-D)Pyrimidin-4-Yl)Piperazine-1- Carbothioamide Monohydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1055986-67-8"},{"name":"Chemical_Formula","value":"C23H21N5O3S.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14L8O2K12B"},{"name":"Maps_To","value":"Amuvatinib Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987416"}]}}{"C38717":{"preferredName":"Anakinra","code":"C38717","definitions":[{"definition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is used to treat rheumatoid arthritis, and is being studied in the treatment of cancer. Anakinra blocks the action of interleukin 1 (IL-1). It is a type of interleukin receptor antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anakinra","termGroup":"PT","termSource":"NCI"},{"termName":"Kineret","termGroup":"BR","termSource":"NCI"},{"termName":"rIL-1ra","termGroup":"AB","termSource":"NCI"},{"termName":"rIL1RN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Rheumatoid arthritis"},{"name":"CAS_Registry","value":"143090-92-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9013DUQ28K"},{"name":"Legacy Concept Name","value":"Anakinra"},{"name":"Maps_To","value":"Anakinra"},{"name":"NCI_Drug_Dictionary_ID","value":"43007"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43007"},{"name":"PDQ_Open_Trial_Search_ID","value":"43007"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245109"}]}}{"C1607":{"preferredName":"Anastrozole","code":"C1607","definitions":[{"definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is used to decrease estrogen production and suppress the growth of tumors that need estrogen to grow. It is a type of nonsteroidal aromatase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anastrozole","termGroup":"PT","termSource":"NCI"},{"termName":"2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"Anastrazole","termGroup":"SY","termSource":"NCI"},{"termName":"Arimidex","termGroup":"BR","termSource":"NCI"},{"termName":"ICI-D1033","termGroup":"CN","termSource":"NCI"},{"termName":"ZD-1033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hormone Receptor-Positive Early Breast cancer"},{"name":"CAS_Registry","value":"120511-73-1"},{"name":"CHEBI_ID","value":"CHEBI:2704"},{"name":"Chemical_Formula","value":"C17H19N5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2Z07MYW1AZ"},{"name":"Legacy Concept Name","value":"Anastrozole"},{"name":"Maps_To","value":"Anastrozole"},{"name":"NCI_Drug_Dictionary_ID","value":"42540"},{"name":"NSC Number","value":"719344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42540"},{"name":"PDQ_Open_Trial_Search_ID","value":"42540"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0290883"}]}}{"C950":{"preferredName":"Anaxirone","code":"C950","definitions":[{"definition":"A synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anaxirone","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-triglycidylurazol","termGroup":"SN","termSource":"NCI"},{"termName":"TGU","termGroup":"AB","termSource":"NCI"},{"termName":"Triglycidylurazol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"77658-97-0"},{"name":"Chemical_Formula","value":"C11H15N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"36R61Y789T"},{"name":"Legacy Concept Name","value":"Anaxirone"},{"name":"Maps_To","value":"Anaxirone"},{"name":"NCI_Drug_Dictionary_ID","value":"39194"},{"name":"NSC Number","value":"332488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39194"},{"name":"PDQ_Open_Trial_Search_ID","value":"39194"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043767"}]}}{"C80636":{"preferredName":"Ancitabine","code":"C80636","definitions":[{"definition":"A cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine, which is converted to the active triphosphate form and competes with deoxycytidine triphosphate for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA and RNA polymerases, resulting in a decrease in cell growth. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancitabine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31698-14-3"},{"name":"Chemical_Formula","value":"C9H11N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DO2D32W0VC"},{"name":"Legacy Concept Name","value":"Ancitabine"},{"name":"Maps_To","value":"Ancitabine"},{"name":"NCI_META_CUI","value":"CL406826"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C403":{"preferredName":"Ancitabine Hydrochloride","code":"C403","definitions":[{"definition":"The hydrochloride salt of a cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine. Subsequently, cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. Cytarabine agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancitabine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"6H-furo(2',3':4,5)oxazolo(3,2-a)pyrimidine-2-methanol,2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-,(2R(2alpha,3beta,3a beta,9a beta))","termGroup":"SN","termSource":"NCI"},{"termName":"Ancid","termGroup":"FB","termSource":"NCI"},{"termName":"Ancytabine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"CycloCMP Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclocytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclocytidine HCL","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclocytidine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"U-33, 624A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10212-25-6"},{"name":"Chemical_Formula","value":"C9H11N3O4.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3T6920M469"},{"name":"Legacy Concept Name","value":"Ancitabine_Hydrochloride"},{"name":"Maps_To","value":"Ancitabine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39199"},{"name":"NSC Number","value":"145668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39199"},{"name":"PDQ_Open_Trial_Search_ID","value":"39199"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010557"}]}}{"C98290":{"preferredName":"Androgen Antagonist APC-100","code":"C98290","definitions":[{"definition":"An orally available, vitamin E derivative and androgen receptor (AR) antagonist with potential anti-oxidant, chemopreventative and antineoplastic activity. APC-100 binds to ARs in target tissues thereby inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. By inhibiting the formation of the complex between androgen activated AR- and the AP1 transcription factor JunD, the expression of androgen-responsive genes are blocked. One of such gene is spermidine/spermine N1-acetyl transferase gene (SSAT) that is responsible for the breakdown of polyamines, which are produced in high levels by prostatic epithelial cells, into reactive oxygen species (ROS) that cause cellular damage. APC-100 may ultimately lead to an inhibition of growth in both AR-dependent and AR-independent prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Antagonist APC-100","termGroup":"PT","termSource":"NCI"},{"termName":"APC-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"950-99-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7G73627R36"},{"name":"Maps_To","value":"Androgen Antagonist APC-100"},{"name":"NCI_Drug_Dictionary_ID","value":"712831"},{"name":"NCI_META_CUI","value":"CL432408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712831"},{"name":"PDQ_Open_Trial_Search_ID","value":"712831"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148520":{"preferredName":"Androgen Receptor Antagonist BAY 1161116","code":"C148520","definitions":[{"definition":"An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist BAY 1161116 specifically binds to AR, inhibits AR activation, and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antagonist BAY 1161116","termGroup":"PT","termSource":"NCI"},{"termName":"AR Antagonist BAY 1161116","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1161116","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1161116","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1161116","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Antagonist BAY 1161116"},{"name":"NCI_Drug_Dictionary_ID","value":"792679"},{"name":"NCI_META_CUI","value":"CL551148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792679"},{"name":"PDQ_Open_Trial_Search_ID","value":"792679"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175852":{"preferredName":"Rezvilutamide","code":"C175852","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, rezvilutamide competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells. ARs are overexpressed in prostate cancer and play a key role in prostate cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rezvilutamide","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Antagonist SHR3680","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 3680","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-3680","termGroup":"CN","termSource":"NCI"},{"termName":"SHR3680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1572045-62-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"70FJN2AW22"},{"name":"Maps_To","value":"Androgen Receptor Antagonist SHR3680"},{"name":"NCI_Drug_Dictionary_ID","value":"779621"},{"name":"NCI_META_CUI","value":"CL1413047"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137818":{"preferredName":"Androgen Receptor Antagonist TAS3681","code":"C137818","definitions":[{"definition":"An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antagonist TAS3681","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Inhibitor TAS3681","termGroup":"SY","termSource":"NCI"},{"termName":"AR Antagonist TAS3681","termGroup":"SY","termSource":"NCI"},{"termName":"TAS 3681","termGroup":"CN","termSource":"NCI"},{"termName":"TAS3681","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Antagonist TAS3681"},{"name":"NCI_Drug_Dictionary_ID","value":"789958"},{"name":"NCI_META_CUI","value":"CL524893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789958"},{"name":"PDQ_Open_Trial_Search_ID","value":"789958"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131874":{"preferredName":"Androgen Receptor Antagonist TRC253","code":"C131874","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antagonist TRC253","termGroup":"PT","termSource":"NCI"},{"termName":"AR Antagonist TRC253","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63576253","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63576253","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63576253","termGroup":"CN","termSource":"NCI"},{"termName":"TRC 253","termGroup":"CN","termSource":"NCI"},{"termName":"TRC-253","termGroup":"CN","termSource":"NCI"},{"termName":"TRC253","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GNG9GQ9Y27"},{"name":"Maps_To","value":"Androgen Receptor Antagonist TRC253"},{"name":"NCI_Drug_Dictionary_ID","value":"786539"},{"name":"NCI_META_CUI","value":"CL520350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786539"},{"name":"PDQ_Open_Trial_Search_ID","value":"786539"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116326":{"preferredName":"Androgen Receptor Antisense Oligonucleotide AZD5312","code":"C116326","definitions":[{"definition":"An antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon intravenous administration, AZD5312 hybridizes with AR mRNA, which blocks translation of the AR protein. This both inhibits AR-induced tumor cell growth and promotes apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antisense Oligonucleotide AZD5312","termGroup":"PT","termSource":"NCI"},{"termName":"AZD5312","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-ARRx","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-AZ1Rx","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S31QX1Q6J"},{"name":"Maps_To","value":"Androgen Receptor Antisense Oligonucleotide AZD5312"},{"name":"NCI_Drug_Dictionary_ID","value":"761561"},{"name":"NCI_META_CUI","value":"CL473660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761561"},{"name":"PDQ_Open_Trial_Search_ID","value":"761561"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96742":{"preferredName":"Androgen Receptor Antisense Oligonucleotide EZN-4176","code":"C96742","definitions":[{"definition":"A locked nucleic acid (LNA)-based antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon administration, EZN-4176 is hybridized and releases the complementary sequences of AR mRNA, thereby blocking translation of the AR protein and inhibiting AR-induced tumor cell growth and promoting tumor cell apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival. LNAs contain a methylene bridge linking 2'-oxygen and 4'-carbon of ribose sugar rings, thereby increasing their thermal stability and decreasing degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Antisense Oligonucleotide EZN-4176","termGroup":"PT","termSource":"NCI"},{"termName":"EZN-4176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Antisense Oligonucleotide EZN-4176"},{"name":"NCI_Drug_Dictionary_ID","value":"699628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699628"},{"name":"PDQ_Open_Trial_Search_ID","value":"699628"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273001"}]}}{"C160788":{"preferredName":"Bavdegalutamide","code":"C160788","definitions":[{"definition":"An orally available selective androgen receptor (AR)-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Bavdegalutamide is composed of an AR ligand attached to an E3 ligase recognition moiety. Upon oral administration, bavdegalutamide targets and binds to the AR ligand binding domain. E3 ligase is recruited to the AR by the E3 ligase recognition moiety and the AR target protein is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome. This prevents the expression of AR target genes and halts AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. In addition, the degradation of the AR protein releases the ARV-110 is released and can bind to additional AR target proteins. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bavdegalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Degrader ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"Androgen Receptor PROTAC Degrader ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"AR PROTAC ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"AR-targeted PROTAC Protein Degrader ARV-110","termGroup":"SY","termSource":"NCI"},{"termName":"ARV 110","termGroup":"CN","termSource":"NCI"},{"termName":"ARV-110","termGroup":"CN","termSource":"NCI"},{"termName":"ARV110","termGroup":"CN","termSource":"NCI"},{"termName":"PROTAC Degrader ARV-110","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222112-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H6NYM0V650"},{"name":"Maps_To","value":"Androgen Receptor Degrader ARV-110"},{"name":"NCI_Drug_Dictionary_ID","value":"798419"},{"name":"NCI_META_CUI","value":"CL969773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798419"},{"name":"PDQ_Open_Trial_Search_ID","value":"798419"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116726":{"preferredName":"Androgen Receptor Downregulator AZD3514","code":"C116726","definitions":[{"definition":"An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514 binds to the AR ligand binding domain and inhibits the binding of androgen, thereby preventing androgen-dependent AR signaling. AZD3514 also causes downregulation of AR expression, which further prevents AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. AR plays a key role in the proliferation of castration-resistant prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Downregulator AZD3514","termGroup":"PT","termSource":"NCI"},{"termName":"AZD3514","termGroup":"CN","termSource":"NCI"},{"termName":"SARD AZD3514","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Downregulator AZD3514"},{"name":"NCI_Drug_Dictionary_ID","value":"682100"},{"name":"NCI_Drug_Dictionary_ID","value":"810703"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682100"},{"name":"PDQ_Open_Trial_Search_ID","value":"682100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3712375"}]}}{"C121777":{"preferredName":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118","code":"C121777","definitions":[{"definition":"A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118","termGroup":"PT","termSource":"NCI"},{"termName":"AR LBD-encoding Plasmid DNA Vaccine MVI-118","termGroup":"SY","termSource":"NCI"},{"termName":"MVI-118","termGroup":"CN","termSource":"NCI"},{"termName":"pTVG-AR","termGroup":"AB","termSource":"NCI"},{"termName":"pTVG-AR Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118"},{"name":"NCI_Drug_Dictionary_ID","value":"771098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771098"},{"name":"PDQ_Open_Trial_Search_ID","value":"771098"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053487"}]}}{"C61637":{"preferredName":"Andrographolide","code":"C61637","definitions":[{"definition":"A labdane diterpenoid that is produced by the Andrographis paniculata plant, which has a broad range of therapeutic applications including anti-inflammatory and anti-platelet aggregation activities and potential antineoplastic properties. Since andrographolide has multiple therapeutic activities there are several proposed mechanisms of action for this agent. The anti-inflammatory effects of this agent appear to be related to the inhibition of nitric oxide (NO) production by macrophages. This agent may activate the NO/cyclic GMP pathway and inhibit both the phospholipase C gamma 2 (PLC gamma2)/protein kinase C (PKC) and PI3K/AKT-MAPK signaling pathways in activated platelets to inhibit platelet aggregation. In activated platelets, these three signaling pathways are downstream of integrin activation mediated by collagen binding and influence the association of fibrinogen with its receptors. Additionally, andrographolide may exert its anti-cancer activity through the induction of cell cycle arrest at G0/G1 phase and the stimulation of lymphocyte proliferation and activation. These processes could result in decreased proliferation of and increased immunocytotoxicity against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Andrographolide","termGroup":"PT","termSource":"NCI"},{"termName":"(1R-(1-alpha(E(S)),4a-beta,5alpha,6alpha,8a-alpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone","termGroup":"SY","termSource":"NCI"},{"termName":"(3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one","termGroup":"SY","termSource":"NCI"},{"termName":"(3E,4S)-4-hydroxy-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]ethylidene}dihydrofuran-2(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"2(3H)-Furanone, 3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-, (1R-(1-alpha(E(S*)),4a-beta,5-alpha,6-alpha,8a-alpha))-","termGroup":"SN","termSource":"NCI"},{"termName":"3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone","termGroup":"SY","termSource":"NCI"},{"termName":"Andrographis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5508-58-7"},{"name":"CHEBI_ID","value":"CHEBI:65408"},{"name":"Chemical_Formula","value":"C20H30O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"410105JHGR"},{"name":"Legacy Concept Name","value":"Andrographolide"},{"name":"Maps_To","value":"Andrographolide"},{"name":"NCI_Drug_Dictionary_ID","value":"755596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755596"},{"name":"PDQ_Open_Trial_Search_ID","value":"755596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051821"}]}}{"C78831":{"preferredName":"Androstane Steroid HE3235","code":"C78831","definitions":[{"definition":"An orally bioavailable adrenal steroid analogue with potential antineoplastic activity. Androstane steroid HE3235 appears to bind the androgen receptor (AR), down-regulating anti-apoptotic genes, such as Bcl-2, while increasing the expression of pro-apoptotic genes, such as caspases. In vitro and in vivo studies indicate that this agent inhibits androstenediol-dependent LNCaP cell tumor growth. In addition, HE3235 may potentiate chemotherapeutic agents by down-regulating ABCG2, the gene encoding the multi-drug resistant (MDR) protein MDR2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androstane Steroid HE3235","termGroup":"PT","termSource":"NCI"},{"termName":"17Alpha-ethynyl-5alpha-androstane-3alpha, 17Beta-diol","termGroup":"SN","termSource":"NCI"},{"termName":"APOPTONE","termGroup":"BR","termSource":"NCI"},{"termName":"HE3235","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183387-50-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"891O182ZP5"},{"name":"Legacy Concept Name","value":"Adrenal_Steroid_Analogue_HE3235"},{"name":"Maps_To","value":"Androstane Steroid HE3235"},{"name":"NCI_Drug_Dictionary_ID","value":"601983"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601983"},{"name":"PDQ_Open_Trial_Search_ID","value":"601983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2715313"}]}}{"C98293":{"preferredName":"Anetumab Ravtansine","code":"C98293","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of anetumab ravtansine targets and binds to the tumor associated antigen mesothelin; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anetumab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 94-9343","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1375258-01-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M170940PMI"},{"name":"Maps_To","value":"Anetumab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"712853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712853"},{"name":"PDQ_Open_Trial_Search_ID","value":"712853"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045305"}]}}{"C88301":{"preferredName":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241","code":"C88301","definitions":[{"definition":"A fusion protein containing angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF) derived peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic aldolase monoclonal antibody, with potential antiangiogenic and antineoplastic activities. The Ang2/VEGF peptide moieties of Ang2/VEGF-binding peptides-antibody fusion protein CVX-241 bind to Ang2 and VEGF receptors, which may inhibit tumor angiogenesis and tumor cell proliferation. The proprietary humanized catalytic IgG1 monoclonal aldolase antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the Ang2 and VEGFR peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. This agent possesses an enhanced half-life compared to the naked peptides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241","termGroup":"PT","termSource":"NCI"},{"termName":"CVX-241","termGroup":"CN","termSource":"NCI"},{"termName":"PF-05057459","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415642-63-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3RM68C5CTG"},{"name":"Maps_To","value":"Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241"},{"name":"NCI_Drug_Dictionary_ID","value":"659158"},{"name":"NCI_META_CUI","value":"CL413555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659158"},{"name":"PDQ_Open_Trial_Search_ID","value":"659158"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71539":{"preferredName":"Ofranergene Obadenovec","code":"C71539","definitions":[{"definition":"A non-replicating adenovirus 5 (Ad-5, El-deleted) encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin-1 (PPE-1) promoter, with potential anti-angiogenic activity. Upon the administration of ofranergene obadenovec, the modified murine PPE-1 promoter is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature.  Subsequently, the Fas-c pro-apoptotic transgene, containing the human tumor necrosis factor (TNF) receptor 1 (TNFR-1/p55) and the signaling domain of Fas, is expressed in angiogenic endothelial cells.  Fas-mediated apoptosis is activated via binding of the TNFR-1 receptor with TNF-alpha, which is more abundant in the tumor microenvironment (TME), enhancing specificity and limiting systemic toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ofranergene Obadenovec","termGroup":"PT","termSource":"NCI"},{"termName":"GT-111","termGroup":"CN","termSource":"NCI"},{"termName":"VB-111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1476737-24-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Q5PRH05GI"},{"name":"Legacy Concept Name","value":"GT-111"},{"name":"Maps_To","value":"Angiogenesis Inhibitor GT-111"},{"name":"Maps_To","value":"Ofranergene Obadenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"580988"},{"name":"NCI_META_CUI","value":"CL378317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580988"},{"name":"PDQ_Open_Trial_Search_ID","value":"580988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82413":{"preferredName":"Angiogenesis Inhibitor JI-101","code":"C82413","definitions":[{"definition":"An orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Angiogenesis inhibitor JI-101 binds to and inhibits VEGFR2, PDGFRb and EphB4, which may inhibit tumor angiogenesis and, so, cellular proliferation in tumor cells overexpressing VEGFR2, PDGFRb and EphB4. The receptor tyrosine kinases VEGFR2, PDGFRb and EphB4 may be overexpressed in a number of different cancer cell types and may play crucial roles in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiogenesis Inhibitor JI-101","termGroup":"PT","termSource":"NCI"},{"termName":"JI-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"900573-88-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"980M4N37DH"},{"name":"Legacy Concept Name","value":"Oral_Angiogenesis_Inhibitor_JI-101"},{"name":"Maps_To","value":"Angiogenesis Inhibitor JI-101"},{"name":"NCI_Drug_Dictionary_ID","value":"637113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637113"},{"name":"PDQ_Open_Trial_Search_ID","value":"637113"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830086"}]}}{"C95202":{"preferredName":"Pixatimod","code":"C95202","definitions":[{"definition":"A synthetic sugar modified heparan sulfate mimetic and agonist of toll-like receptor 9 (TLR9), with potential immunostimulating, antineoplastic and anti-viral activities. Upon administration, pixatimod binds to and activates TLR9 expressed by dendritic cells (DCs) and B-cells. This initiates cytokine release from DCs and activates innate immune signaling pathways, and leads to the activation of natural killer (NK) cells to destroy tumor cells. The combination of pixatimod with certain checkpoint inhibitors may enhance the activation of cytotoxic T-lymphocytes to further kill tumor cells. In addition, pixatimod inhibits the cleavage of heparan sulfate from cell surface proteoglycan by heparanase (HPSE) and inhibits the infiltration of tumor-associated macrophages (TAMs). TLR9, a member of the TLR family, plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pixatimod","termGroup":"PT","termSource":"NCI"},{"termName":"PG545","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1144617-49-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"66QR34C83N"},{"name":"Maps_To","value":"Angiogenesis/Heparanase Inhibitor PG545"},{"name":"Maps_To","value":"Pixatimod"},{"name":"NCI_Drug_Dictionary_ID","value":"690742"},{"name":"NCI_META_CUI","value":"CL426692"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690742"},{"name":"PDQ_Open_Trial_Search_ID","value":"690742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116625":{"preferredName":"Angiopoietin-2-specific Fusion Protein PF-04856884","code":"C116625","definitions":[{"definition":"A humanized monoclonal antibody fused to two peptides that bind to angiopoietin 2 (Ang2; ANGPT2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous administration, Ang2-targeting PF-04856884 CovX body specifically binds to Ang2 and prevents the binding of Ang2 to its receptor Tie2 expressed on endothelial cells. This inhibits Tie2-mediated signaling, prevents angiogenesis and inhibits tumor cell proliferation.  Ang2, a proangiogenic cytokine and ligand for the Tie2 receptor, plays a key role in the regulation of tumor angiogenesis and tumor cell proliferation; its expression is upregulated by tumor endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Angiopoietin-2-specific Fusion Protein PF-04856884","termGroup":"PT","termSource":"NCI"},{"termName":"CVX-060","termGroup":"CN","termSource":"NCI"},{"termName":"PF-04856884","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415649-10-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78LXD26OX3"},{"name":"Maps_To","value":"Angiopoietin-2-specific Fusion Protein PF-04856884"},{"name":"NCI_Drug_Dictionary_ID","value":"687982"},{"name":"NCI_META_CUI","value":"CL433732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687982"},{"name":"PDQ_Open_Trial_Search_ID","value":"687982"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2526":{"preferredName":"Anhydrovinblastine","code":"C2526","definitions":[{"definition":"A semisynthetic derivative of the vinca alkaloid vinblastine, with potential antineoplastic activity. Like vinblastine, anhydrovinblastine targets and binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and causing tumor cell cycle arrest in the M phase.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Anhydrovinblastine","termGroup":"PT","termSource":"NCI"},{"termName":"AVLB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38390-45-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5B622U08B3"},{"name":"Legacy Concept Name","value":"Anhydrovinblastine"},{"name":"Maps_To","value":"Anhydrovinblastine"},{"name":"NCI_Drug_Dictionary_ID","value":"43460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43460"},{"name":"PDQ_Open_Trial_Search_ID","value":"43460"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796616"}]}}{"C249":{"preferredName":"Aniline Mustard","code":"C249","definitions":[{"definition":"An alkylating mustard with antineoplastic activity. Aniline mustard forms covalent linkages with nucleophilic centers, resulting in depurination, base miscoding and strand scission, and crosslinking of DNA strands, all of which contribute to its cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aniline Mustard","termGroup":"PT","termSource":"NCI"},{"termName":"A 14489","termGroup":"CN","termSource":"NCI"},{"termName":"Benzenamine, N, N-bis(2-chloroethyl)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"beta, beta'-dichlorodiethylaniline","termGroup":"SN","termSource":"NCI"},{"termName":"CB 1074","termGroup":"CN","termSource":"NCI"},{"termName":"Lymphochin","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocin","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoquin","termGroup":"SY","termSource":"NCI"},{"termName":"mesylerythrol","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)aniline","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)benzenamine","termGroup":"SN","termSource":"NCI"},{"termName":"phenylbis[2-chloroethylamine]","termGroup":"SN","termSource":"NCI"},{"termName":"SK 592","termGroup":"CN","termSource":"NCI"},{"termName":"TL 476","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"553-27-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CUJ6745Z9J"},{"name":"Legacy Concept Name","value":"Aniline_Mustard"},{"name":"Maps_To","value":"Aniline Mustard"},{"name":"NCI_Drug_Dictionary_ID","value":"39146"},{"name":"NSC Number","value":"18429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39146"},{"name":"PDQ_Open_Trial_Search_ID","value":"39146"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1142666"}]}}{"C106428":{"preferredName":"Catequentinib Hydrochloride","code":"C106428","definitions":[{"definition":"The hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Catequentinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"ALTN HCl","termGroup":"AB","termSource":"NCI"},{"termName":"Anlotinib Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"Fukewei","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1360460-82-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A3749M6582"},{"name":"Maps_To","value":"Anlotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"749736"},{"name":"NCI_META_CUI","value":"CL447782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749736"},{"name":"PDQ_Open_Trial_Search_ID","value":"749736"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2632":{"preferredName":"Annamycin","code":"C2632","definitions":[{"definition":"A lipophilic, anthracycline antineoplastic antibiotic. Annamycin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as inhibiting RNA and protein synthesis.  This agent appears to not be a substrate for the p-glycoprotein associated multidrug-resistance (MDR) transporter; therefore, overcoming the resistance pattern seen with other anthracycline compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annamycin","termGroup":"PT","termSource":"NCI"},{"termName":"2'-iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-l-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92689-49-1"},{"name":"Chemical_Formula","value":"C26H25IO11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SNU299M83Q"},{"name":"Legacy Concept Name","value":"Annamycin"},{"name":"Maps_To","value":"Annamycin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0214529"}]}}{"C25838":{"preferredName":"Annamycin Liposomal","code":"C25838","definitions":[{"definition":"A liposome-encapsulated form of the semi-synthetic doxorubicin analogue annamycin with antineoplastic activity. Annamycin intercalates into DNA and inhibits topoisomerase II, resulting in the inhibition of DNA replication and repair and RNA and protein synthesis. This agent circumvents multidrug-resistance (MDR) transporters, including P-glycoprotein (P-gp). Liposomal annamycin is less toxic and shows improved antitumor activity compared to annamycin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annamycin Liposomal","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Annamycin_Liposomal"},{"name":"Maps_To","value":"Annamycin Liposomal"},{"name":"NCI_Drug_Dictionary_ID","value":"38230"},{"name":"NSC Number","value":"700363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38230"},{"name":"PDQ_Open_Trial_Search_ID","value":"38230"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0935796"}]}}{"C118972":{"preferredName":"Annonaceous Acetogenins","code":"C118972","definitions":[{"definition":"A family of naturally occurring polyketides that consist of C32 or C34 long chain fatty acids and combined with a propan-2-ol unit at C-2 to form a gamma-lactone, which are isolated from various species of the plant family Annonaceae, with potential antineoplastic and antimicrobial activity. Annonaceous acetogenins bind to the ubiquinone catalytic site(s) within the mitochondrial NADH:ubiquinone oxidoreductase (complex I), and block the electron transport chain in mitochondria. In addition, the acetogenins bind to and block the activity of ubiquinone-linked NADH oxidase, an enzyme overexpressed in the plasma membranes of cancer cells. This inhibits adenosine triphosphate (ATP) production, decreases intracellular ATP levels, and induces tumor cell apoptosis. Compared to normal cells, cancer cells have higher ATP demands. The Annonaceous acetogenins also inhibit microbial glucose dehydrogenase 6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annonaceous Acetogenins","termGroup":"PT","termSource":"NCI"},{"termName":"Acetogenins","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Annonaceous Acetogenins"},{"name":"NCI_Drug_Dictionary_ID","value":"766482"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766482"},{"name":"PDQ_Open_Trial_Search_ID","value":"766482"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1955902"}]}}{"C97710":{"preferredName":"Ansamitomicin P-3","code":"C97710","definitions":[{"definition":"An ansamacrolide and maytansine analogue originally isolated from the Ethiopian shrub Maytenus serrata with antineoplastic activity. Ansamitomicin P-3 binds to tubulin at the maytansine-binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ansamitomicin P-3","termGroup":"PT","termSource":"NCI"},{"termName":"Maytansine, 3-o-de(2-(acetylmethylamino)-1-oxopropyl)-3-o-(1-oxobutyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66547-09-9"},{"name":"Chemical_Formula","value":"C32H43ClN2O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7SUK7876BG"},{"name":"Maps_To","value":"Ansamitomicin P-3"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0952781"}]}}{"C252":{"preferredName":"Anthramycin","code":"C252","definitions":[{"definition":"A pyrrolo(1,4)benzodiazepine antineoplastic antibiotic isolated from the bacterium Streptomyces refuineus var. thermotolerans.  Anthramycin binds covalently to guanine in the minor groove of DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anthramycin","termGroup":"PT","termSource":"NCI"},{"termName":"3-(5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-1h-pyrrolo(2,1-c)(1,4)benzodiazepin-2-yl)-2-propenamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4803-27-4"},{"name":"Chemical_Formula","value":"C16H17N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0WZD9Y66WN"},{"name":"Legacy Concept Name","value":"Anthramycin"},{"name":"Maps_To","value":"Anthramycin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0003167"}]}}{"C2706":{"preferredName":"Anthrapyrazole","code":"C2706","definitions":[{"definition":"An antineoplastic antibiotic that intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Anthrapyrazoles may also block cell cycle division.  In the presence of electron donors, some anthrapyrazole antibiotics cause single-strand breaks in DNA via photosensitization by visible light.  These agents are less cardiotoxic than doxorubicin. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anthrapyrazole","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra[1, 9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-acetate (salt) hydrobromide(10:5:21)","termGroup":"SN","termSource":"NCI"},{"termName":"Anthra[1,9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-, acetate (salt) hydrobromide(10:5:21)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91440-30-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anthrapyrazole"},{"name":"Maps_To","value":"Anthrapyrazole"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0051960"}]}}{"C117735":{"preferredName":"Anti c-KIT Antibody-drug Conjugate LOP628","code":"C117735","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) and conjugated, via a non-cleavable linker, to the cytotoxic agent maytansine, with potential antineoplastic activity. The monoclonal antibody moiety of anti c-KIT ADC LOP628 targets and binds to the cell surface antigen c-Kit. After antibody-antigen interaction followed by internalization, the maytansine moiety binds to tubulin, inhibits microtubule assembly, and induces microtubule disassembly. This leads to a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing c-Kit. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti c-KIT Antibody-drug Conjugate LOP628","termGroup":"PT","termSource":"NCI"},{"termName":"Anti c-KIT ADC LOP628","termGroup":"SY","termSource":"NCI"},{"termName":"LOP628","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti c-KIT Antibody-drug Conjugate LOP628"},{"name":"NCI_Drug_Dictionary_ID","value":"764075"},{"name":"NCI_META_CUI","value":"CL474131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764075"},{"name":"PDQ_Open_Trial_Search_ID","value":"764075"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107388":{"preferredName":"Anti-5T4 Antibody-Drug Conjugate PF-06263507","code":"C107388","definitions":[{"definition":"An antibody-drug conjugate composed of an antibody directed against 5T4 and conjugated, via the stable linker maleimidocaproyl (mc), to the microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration, the antibody moiety of PF-06263507 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-5T4 Antibody-Drug Conjugate PF-06263507","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06263507","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7U0JSO7FH"},{"name":"Maps_To","value":"Anti-5T4 Antibody-Drug Conjugate PF-06263507"},{"name":"NCI_Drug_Dictionary_ID","value":"751006"},{"name":"NCI_META_CUI","value":"CL449599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751006"},{"name":"PDQ_Open_Trial_Search_ID","value":"751006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90583":{"preferredName":"Anti-A33 Monoclonal Antibody KRN330","code":"C90583","definitions":[{"definition":"A recombinant fully human monoclonal antibody directed against the human A33 antigen, with potential immunomodulatory and antineoplastic activity. Anti-A33 monoclonal antibody KRN330 recognizes and binds to the human A33 antigen, which may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against A33-positive colorectal cancers. A33 antigen, a 43 kDa transmembrane glycoprotein of the immunoglobulin superfamily, is highly and homogenously expressed in 95% of colorectal cancer cancers with only restricted expression in normal colonic mucosa and small bowel epithelia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-A33 Monoclonal Antibody KRN330","termGroup":"PT","termSource":"NCI"},{"termName":"KRN330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A64J777I28"},{"name":"Maps_To","value":"Anti-A33 Monoclonal Antibody KRN330"},{"name":"NCI_Drug_Dictionary_ID","value":"584603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"584603"},{"name":"PDQ_Open_Trial_Search_ID","value":"584603"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983782"}]}}{"C85478":{"preferredName":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412","code":"C85478","definitions":[{"definition":"A monoclonal antibody directed against the human alpha5beta1 integrin with potential antiangiogenic and antineoplastic activities. Anti-alpha5beta1 integrin monoclonal antibody PF-04605412 selectively binds to alpha5beta1 integrin, preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alpha5beta1-expressing tumor cells. Alpha5beta1 integrin, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-alpha5beta1 Integrin Monoclonal Antibody PF-04605412","termGroup":"SY","termSource":"NCI"},{"termName":"PF-04605412","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CFN88ESH2J"},{"name":"Maps_To","value":"Anti-A5B1 Integrin Monoclonal Antibody PF-04605412"},{"name":"NCI_Drug_Dictionary_ID","value":"647821"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647821"},{"name":"PDQ_Open_Trial_Search_ID","value":"647821"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830142"}]}}{"C129715":{"preferredName":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087","code":"C129715","definitions":[{"definition":"Autologous T-lymphocytes that are genetically modified and transfected with a viral vector expressing the ACTR gene, a proprietary gene encoding for an antibody-coupled T-cell receptor (ATCR), with potential antineoplastic activity. The ACTR contains the extracellular Fc receptor CD16 domain, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-immunostimulatory signaling domain 4-1BB, normally expressed on T-cells, and linked to the intracellular CD3 zeta domain (CD3z), which is needed for TCR signaling. Upon reintroduction into the patient and co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, this induces the activation of the ACTR087 cells and destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; b) targeting and killing adjacent tumor cells that are not bound to the antibody; c) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it enhances the survival and persistence of T-lymphocytes. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087","termGroup":"PT","termSource":"NCI"},{"termName":"ACTR-087","termGroup":"CN","termSource":"NCI"},{"termName":"ACTR087","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-ACTR Viral Vector-transduced Autologous T-lymphocytes ACTR087","termGroup":"SY","termSource":"NCI"},{"termName":"CD16-41BB-CD3zeta ACTR Autologous T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Virally-delivered Antibody-coupled TCR ACTR087","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087"},{"name":"NCI_Drug_Dictionary_ID","value":"784523"},{"name":"NCI_META_CUI","value":"CL512898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784523"},{"name":"PDQ_Open_Trial_Search_ID","value":"784523"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133818":{"preferredName":"Anti-AG7 Antibody Drug Conjugate AbGn-107","code":"C133818","definitions":[{"definition":"An antibody drug conjugate (ADC) composed of a monoclonal antibody that targets the tumor-associated antigen (TAA) AG7 and is linked, through a hydrophilic, self-immolative linker, to a proprietary cytotoxic payload, with potential antineoplastic activity. Upon administration of AbGn-107 the antibody moiety targets and binds to the AG7 antigen expressed on a variety of cancer cells. Upon binding and internalization, the linker is cleaved and the payload is released, binds to tubulin, inhibits tubulin polymerization and kills the AG7-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AG7 Antibody Drug Conjugate AbGn-107","termGroup":"PT","termSource":"NCI"},{"termName":"Ab1-18Hr1","termGroup":"CN","termSource":"NCI"},{"termName":"AbGn-107","termGroup":"CN","termSource":"NCI"},{"termName":"AbGn107","termGroup":"CN","termSource":"NCI"},{"termName":"ADC AbGn-107","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-AG7 ADC AbGn-107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-AG7 Antibody Drug Conjugate AbGn-107"},{"name":"NCI_Drug_Dictionary_ID","value":"789018"},{"name":"NCI_META_CUI","value":"CL521740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789018"},{"name":"PDQ_Open_Trial_Search_ID","value":"789018"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82685":{"preferredName":"Anti-AGS-16 Monoclonal Antibody AGS-16M18","code":"C82685","definitions":[{"definition":"A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-16 with potential antineoplastic activity. Anti-AGS-16 monoclonal antibody AGS-16M18 selectively binds to AGS-16, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells expressing AGS-16. While normally expressed at low levels in the proximal tubules of the kidney, AGS-16 has been found to be overexpressed in more than 95% of kidney and 40% of liver neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AGS-16 Monoclonal Antibody AGS-16M18","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-16M18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-AGS-16_Monoclonal_Antibody_AGS-16M18"},{"name":"Maps_To","value":"Anti-AGS-16 Monoclonal Antibody AGS-16M18"},{"name":"NCI_Drug_Dictionary_ID","value":"633313"},{"name":"NCI_META_CUI","value":"CL388472"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633313"},{"name":"PDQ_Open_Trial_Search_ID","value":"633313"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C92590":{"preferredName":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME","code":"C92590","definitions":[{"definition":"An antibody drug conjugate (ADC) containing the fully human IgG2k monoclonal antibody targeting an epitope of SLC44A4 (AGS-5) linked, via a valine-citrulline (vc) maleimidocaproyl (mc) linker, to the antimicrotubulin drug monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of ASG-5ME selectively binds to AGS-5. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. SLC44A4, potentially a sodium-dependent transmembrane transport protein, is overexpressed on more than 80 percent of samples derived from patients with pancreatic, prostate and gastric cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME","termGroup":"PT","termSource":"NCI"},{"termName":"ASG-5ME","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME"},{"name":"NCI_Drug_Dictionary_ID","value":"682506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682506"},{"name":"PDQ_Open_Trial_Search_ID","value":"682506"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3696055"}]}}{"C82686":{"preferredName":"Anti-AGS-8 Monoclonal Antibody AGS-8M4","code":"C82686","definitions":[{"definition":"A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-8 with potential antineoplastic activity. Anti-AGS-8 monoclonal antibody AGS-8M4 selectively binds to AGS-8, triggering complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in tumor cells expressing AGS-8. While normally expressed at low levels in the heart in response to ischemia, AGS-8 has been found to be expressed in more than 70% of ovarian neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-AGS-8 Monoclonal Antibody AGS-8M4","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-8M4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-AGS-8_Monoclonal_Antibody_AGS-8M4"},{"name":"Maps_To","value":"Anti-AGS-8 Monoclonal Antibody AGS-8M4"},{"name":"NCI_Drug_Dictionary_ID","value":"633505"},{"name":"NCI_META_CUI","value":"CL388473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633505"},{"name":"PDQ_Open_Trial_Search_ID","value":"633505"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C164668":{"preferredName":"Etentamig","code":"C164668","definitions":[{"definition":"A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities.  Upon administration, etentamig binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to low-activating CD3 preferentially activates effector over regulatory T-cells and stimulates minimum cytokine release.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etentamig","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 383","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-383","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV383","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA x aCD3 T-BsAb TNB-383B","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA x aCD3 T-cell Engaging Bispecific Antibody TNB-383B","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA x CD3 T-cell Engaging Bispecific Antibody ABBV-383","termGroup":"SY","termSource":"NCI"},{"termName":"TNB 383B","termGroup":"CN","termSource":"NCI"},{"termName":"TNB-383B","termGroup":"CN","termSource":"NCI"},{"termName":"TNB383B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2490552-52-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CO86AOP337"},{"name":"Maps_To","value":"Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B"},{"name":"NCI_Drug_Dictionary_ID","value":"799707"},{"name":"NCI_META_CUI","value":"CL977826"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799707"},{"name":"PDQ_Open_Trial_Search_ID","value":"799707"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116865":{"preferredName":"Anti-alpha5beta1 Integrin Antibody MINT1526A","code":"C116865","definitions":[{"definition":"An antibody directed against the human alpha5beta1 integrin (a5b1) with potential antiangiogenic and antineoplastic activities. Anti-a5b1 antibody MINT1526A selectively binds to a5b1, thereby preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in a5b1-expressing tumor cells. a5b1, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in both endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-alpha5beta1 Integrin Antibody MINT1526A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-a5b1 Antibody MINT1526A","termGroup":"SY","termSource":"NCI"},{"termName":"MINT1526A","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7594","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H6BAM62K4Q"},{"name":"Maps_To","value":"Anti-alpha5beta1 Integrin Antibody MINT1526A"},{"name":"NCI_Drug_Dictionary_ID","value":"675425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675425"},{"name":"PDQ_Open_Trial_Search_ID","value":"675425"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053617"}]}}{"C95704":{"preferredName":"Anti-ANG2 Monoclonal Antibody MEDI-3617","code":"C95704","definitions":[{"definition":"A fully human IgG1 monoclonal antibody against angiopoietin 2 (ANG2), with potential antiangiogenic activity. Anti-ANG2 monoclonal antibody MEDI-3617 binds to Ang2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), thereby resulting in the disruption of vascular remodeling. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ANG2 Monoclonal Antibody MEDI-3617","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ANG2 MoAb MEDI-3617","termGroup":"AB","termSource":"NCI"},{"termName":"MEDI-3617","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415642-51-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6RH6DL8R4L"},{"name":"Maps_To","value":"Anti-ANG2 Monoclonal Antibody MEDI-3617"},{"name":"NCI_Drug_Dictionary_ID","value":"690474"},{"name":"NCI_META_CUI","value":"CL428170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690474"},{"name":"PDQ_Open_Trial_Search_ID","value":"690474"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116627":{"preferredName":"Anti-angiopoietin Monoclonal Antibody AMG 780","code":"C116627","definitions":[{"definition":"An immunoglobulin (Ig) G2 monoclonal antibody targeting the proangiogenic cytokines angiopoietin 1 (Ang1) and 2 (Ang2), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-angiopoietin monoclonal antibody AMG 780 binds to Ang1 and Ang2. This prevents the binding of the angiopoietin ligands to their receptor Tie2 (TEK), an endothelial cell-specific receptor tyrosine kinase. This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-angiopoietin Monoclonal Antibody AMG 780","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 780","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2473627-81-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C55H82K3JJ"},{"name":"Maps_To","value":"Anti-angiopoietin Monoclonal Antibody AMG 780"},{"name":"NCI_Drug_Dictionary_ID","value":"675243"},{"name":"NCI_META_CUI","value":"CL421599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675243"},{"name":"PDQ_Open_Trial_Search_ID","value":"675243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142822":{"preferredName":"Zigakibart","code":"C142822","definitions":[{"definition":"A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, zigakibart binds to APRIL and inhibits its binding to both of its receptors, B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and transmembrane activator and CAML Interactor (TACI; tumor necrosis factor receptor superfamily member 13B; TNFRSF13B). This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, zigakibart may reduce APRIL-induced drug resistance which occurs in some tumors. APRIL, an extracellular protein and member of the tumor necrosis factor ligand superfamily (TNFSF), is expressed by bone marrow plasma cells and myeloid cells, and overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and colorectal carcinoma. APRIL induces immune suppression and tumor progression through the activation of BCMA- and TACI-dependent signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zigakibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody BION-1301","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-APRIL Monoclonal Antibody BION-1301","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TNFSF13 Monoclonal Antibody BION-1301","termGroup":"SY","termSource":"NCI"},{"termName":"BION-1301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2642175-46-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WM18Z62RTI"},{"name":"Maps_To","value":"Anti-APRIL Monoclonal Antibody BION-1301"},{"name":"NCI_Drug_Dictionary_ID","value":"791698"},{"name":"NCI_META_CUI","value":"CL540711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791698"},{"name":"PDQ_Open_Trial_Search_ID","value":"791698"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156017":{"preferredName":"Batiraxcept","code":"C156017","definitions":[{"definition":"A soluble fusion protein comprised of the extracellular domain of the receptor tyrosine kinase (RTK) AXL (UFO) fused to a human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic activity. Upon administration, batiraxcept selectively binds to growth arrest-specific protein 6 (GAS6), the endogenous ligand for AXL. This may inhibit GAS6/AXL-mediated signaling, which plays a key role in tumor cell proliferation, survival, invasion and metastasis, as well as immune evasion and resistance to other anticancer agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of RTKs, is overexpressed by many tumor cell types and its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Batiraxcept","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-AXL Fusion Protein AVB-S6-500","termGroup":"SY","termSource":"NCI"},{"termName":"AVB S6 500","termGroup":"CN","termSource":"NCI"},{"termName":"AVB-500","termGroup":"CN","termSource":"NCI"},{"termName":"AVB-S6-500","termGroup":"CN","termSource":"NCI"},{"termName":"AVBS6500","termGroup":"CN","termSource":"NCI"},{"termName":"AXL Fc Fusion Protein AVB-S6-500","termGroup":"SY","termSource":"NCI"},{"termName":"RUGA-S6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2268717-61-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6840JH4EB"},{"name":"Maps_To","value":"Anti-AXL Fusion Protein AVB-S6-500"},{"name":"NCI_Drug_Dictionary_ID","value":"795349"},{"name":"NCI_META_CUI","value":"CL562760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795349"},{"name":"PDQ_Open_Trial_Search_ID","value":"795349"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160890":{"preferredName":"Anti-AXL/PBD Antibody-drug Conjugate ADCT-601","code":"C160890","synonyms":[{"termName":"Anti-AXL/PBD Antibody-drug Conjugate ADCT-601","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Jun 15 12:19:15 EDT 2022 - See 'Mipasetamab Uzoptirine(C175823)'"},{"name":"OLD_PARENT","value":"C129823"},{"name":"OLD_PARENT","value":"C1512"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122924":{"preferredName":"Anti-B7-H3 Antibody DS-5573a","code":"C122924","definitions":[{"definition":"An antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-B7-H3 antibody DS-5573a binds to the cell surface antigen B7-H3, thereby blocking B7-H3-mediated signaling. This abrogates the inhibitory effect on T-cell activation and may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-B7-H3 Antibody DS-5573a","termGroup":"PT","termSource":"NCI"},{"termName":"DS-5573a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-B7-H3 Antibody DS-5573a"},{"name":"NCI_Drug_Dictionary_ID","value":"763154"},{"name":"NCI_META_CUI","value":"CL474104"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763154"},{"name":"PDQ_Open_Trial_Search_ID","value":"763154"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155967":{"preferredName":"Alsevalimab","code":"C155967","definitions":[{"definition":"A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alsevalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B7-H4 Monoclonal Antibody FPA150","termGroup":"SY","termSource":"NCI"},{"termName":"FPA 150","termGroup":"CN","termSource":"NCI"},{"termName":"FPA-150","termGroup":"CN","termSource":"NCI"},{"termName":"FPA150","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254029-91-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U8LYN0Y118"},{"name":"Maps_To","value":"Alsevalimab"},{"name":"Maps_To","value":"Anti-B7-H4 Monoclonal Antibody FPA150"},{"name":"NCI_Drug_Dictionary_ID","value":"795105"},{"name":"NCI_META_CUI","value":"CL562720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795105"},{"name":"PDQ_Open_Trial_Search_ID","value":"795105"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159495":{"preferredName":"Vobramitamab Duocarmazine","code":"C159495","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of vobamitamab, an anti-B7-homolog 3 (B7-H3, CD276) humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody, conjugated to the cleavable linker-duocarmycin payload duocarmazine (valine-citrulline-seco duocarmycin hydroxybenzamide azaindole; vc-seco-DUBA), with potential antineoplastic activity. Upon administration of vobramitamab duocarmazine, vobramitamab specifically targets and binds to the cell surface antigen B7-H3, leading to internalization of the ADC by B7-H3-expressing tumor cells. The vc linker is cleaved inside the tumor cell by proteases, thereby releasing the duocarmycin payload. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vobramitamab Duocarmazine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B7H3 ADC","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-B7H3 Antibody-drug Conjugate MGC018","termGroup":"SY","termSource":"NCI"},{"termName":"MG-C018","termGroup":"CN","termSource":"NCI"},{"termName":"MGC 018","termGroup":"CN","termSource":"NCI"},{"termName":"MGC018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2490556-51-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ZK3D69DQJ"},{"name":"Maps_To","value":"Anti-B7H3 Antibody-drug Conjugate MGC018"},{"name":"NCI_Drug_Dictionary_ID","value":"797520"},{"name":"NCI_META_CUI","value":"CL951453"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797520"},{"name":"PDQ_Open_Trial_Search_ID","value":"797520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148176":{"preferredName":"Anti-BCMA Antibody SEA-BCMA","code":"C148176","definitions":[{"definition":"A humanized, afucosylated monoclonal antibody created using the proprietary, sugar-engineered antibody (SEA) platform and directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), with potential immunoadjuvant activity. Upon administration, the anti-BCMA antibody SEA-BCMA targets and binds to BCMA expressed on tumor cells.  When administered with antibody-coupled T-cell receptor (ACTR)-expressing T-cells, the ACTR-expressing T-cells bind, with high affinity, to the anti-BCMA antibody SEA-BCMA. This activates the ACTR T-cells and the T-cells induce specific cytotoxic T-lymphocyte (CTL)-mediated cytotoxicity toward BCMA-expressing tumor cells. BCMA, a cell surface protein and member of the tumor necrosis factor (TNF) receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA Antibody SEA-BCMA","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA Afucosylated Monoclonal Antibody SEA-BCMA","termGroup":"SY","termSource":"NCI"},{"termName":"SEA-BCMA","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2115084-53-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3C28VJ95EV"},{"name":"Maps_To","value":"Anti-BCMA Antibody SEA-BCMA"},{"name":"NCI_Drug_Dictionary_ID","value":"793894"},{"name":"NCI_META_CUI","value":"CL550772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793894"},{"name":"PDQ_Open_Trial_Search_ID","value":"793894"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162528":{"preferredName":"Anti-BCMA Antibody-drug Conjugate AMG 224","code":"C162528","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of an anti-human B-cell maturation antigen (BCMA) immunoglobulin G1 (IgG1) antibody conjugated via the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC), to the cytotoxic maytansine-derivative, DM1, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AMG 224 selectively binds to BCMA expressed on the surface of tumor cells. Upon internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of tumor cells that express BCMA. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF)and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA Antibody-drug Conjugate AMG 224","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 224","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-224","termGroup":"CN","termSource":"NCI"},{"termName":"AMG224","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y69B45U0TK"},{"name":"Maps_To","value":"Anti-BCMA Antibody-drug Conjugate AMG 224"},{"name":"NCI_META_CUI","value":"CL971104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114299":{"preferredName":"Belantamab Mafodotin","code":"C114299","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belantamab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"Belantamab Mafodotin-blmf","termGroup":"SY","termSource":"NCI"},{"termName":"Blenrep","termGroup":"BR","termSource":"NCI"},{"termName":"GSK 2857916","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-2857916","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2857916","termGroup":"CN","termSource":"NCI"},{"termName":"J6M0-mcMMAF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent."},{"name":"CAS_Registry","value":"2050232-20-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DB1041CXDG"},{"name":"Maps_To","value":"Anti-BCMA Antibody-drug Conjugate GSK2857916"},{"name":"Maps_To","value":"Belantamab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"758317"},{"name":"NCI_META_CUI","value":"CL471808"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758317"},{"name":"PDQ_Open_Trial_Search_ID","value":"758317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159652":{"preferredName":"Pacanalotamab","code":"C159652","definitions":[{"definition":"A short half-life bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pacanalotamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacanalotamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 420","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-420","termGroup":"CN","termSource":"NCI"},{"termName":"AMG420","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 BiTE AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 BiTE Antibody AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"BI 836909","termGroup":"CN","termSource":"NCI"},{"termName":"BI-836909","termGroup":"CN","termSource":"NCI"},{"termName":"BI836909","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 420","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 420","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2251756-52-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"102VUR9WQE"},{"name":"Maps_To","value":"Anti-BCMA/CD3 BiTE Antibody AMG 420"},{"name":"NCI_Drug_Dictionary_ID","value":"801291"},{"name":"NCI_META_CUI","value":"CL951538"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801291"},{"name":"PDQ_Open_Trial_Search_ID","value":"801291"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147028":{"preferredName":"Pavurutamab","code":"C147028","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pavurutamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pavurutamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 701","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-701","termGroup":"CN","termSource":"NCI"},{"termName":"AMG701","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 BiTE AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 BiTE Antibody AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 701","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 701","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2250292-39-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GLR3JG8TZU"},{"name":"Maps_To","value":"Anti-BCMA/CD3 BiTE Antibody AMG 701"},{"name":"NCI_Drug_Dictionary_ID","value":"792377"},{"name":"NCI_META_CUI","value":"CL545027"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792377"},{"name":"PDQ_Open_Trial_Search_ID","value":"792377"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158504":{"preferredName":"Linvoseltamab","code":"C158504","definitions":[{"definition":"A human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFvs): one directed again the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the CD3 antigen expressed on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linvoseltamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 BiTE REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 BiTE Antibody REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific BCMA x CD3 T-cell Engaging Antibody REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody REGN5458","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5458","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5458","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5458","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2408319-25-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M3CPC50MZS"},{"name":"Maps_To","value":"Anti-BCMA/CD3 BiTE Antibody REGN5458"},{"name":"NCI_Drug_Dictionary_ID","value":"797141"},{"name":"NCI_META_CUI","value":"CL938057"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797141"},{"name":"PDQ_Open_Trial_Search_ID","value":"797141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C150127":{"preferredName":"Anti-BCMA/PBD ADC MEDI2228","code":"C150127","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a fully human monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) that is site-specifically conjugated, via a protease-cleavable linker, to a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-BCMA/PBD ADC MEDI2228, the antibody moiety targets the cell surface antigen BCMA expressed on certain cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA/PBD ADC MEDI2228","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA ADC MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/PBD MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate MEDI2228","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 2228","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-2228","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI2228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YQ4C0NDW44"},{"name":"Maps_To","value":"Anti-BCMA/PBD ADC MEDI2228"},{"name":"NCI_Drug_Dictionary_ID","value":"795378"},{"name":"NCI_META_CUI","value":"CL551921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795378"},{"name":"PDQ_Open_Trial_Search_ID","value":"795378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98295":{"preferredName":"Anti-c-fms Monoclonal Antibody AMG 820","code":"C98295","definitions":[{"definition":"A fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (or CSFR1), with potential antineoplastic activity. Upon administration, anti-c-fms monoclonal antibody AMG 820 binds to and blocks c-fms, thereby blocking CSF-1 binding to its receptor and suppressing CSF-1-induced c-fms signaling. This results in the suppression of recruitment and activation of tumor associated macrophages (TAM) within the tumor microenvironment. This eventually leads to a decrease in tumor growth. c-fms, a transmembrane protein belonging to the tyrosine kinase family, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation and regulation of cell proliferation. The presence of TAM is correlated with tumor proliferation, invasion and a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-fms Monoclonal Antibody AMG 820","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2243120-07-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SZ3778HS3S"},{"name":"Maps_To","value":"Anti-c-fms Monoclonal Antibody AMG 820"},{"name":"NCI_Drug_Dictionary_ID","value":"713961"},{"name":"NCI_META_CUI","value":"CL432413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713961"},{"name":"PDQ_Open_Trial_Search_ID","value":"713961"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125620":{"preferredName":"Anti-c-KIT Monoclonal Antibody CDX 0158","code":"C125620","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. Upon administration, the anti-c-KIT monoclonal antibody CDX 0158 binds to and inhibits the activation of the cell surface antigen c-Kit. This leads to an inhibition of the activation of c-KIT-mediated signal transduction pathways and inhibits cell proliferation in cancer cells expressing c-Kit. In mast cells, inhibition of c-KIT and c-KIT-mediated signaling prevents mast cell activation, degranulation and subsequent cytokine release. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in various cell types, including certain cancer cells and mast cells; it plays a key role in the regulation of cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-KIT Monoclonal Antibody CDX 0158","termGroup":"PT","termSource":"NCI"},{"termName":"CDX 0158","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-0158","termGroup":"CN","termSource":"NCI"},{"termName":"CDX0158","termGroup":"CN","termSource":"NCI"},{"termName":"KTN 0158","termGroup":"CN","termSource":"NCI"},{"termName":"KTN-0158","termGroup":"CN","termSource":"NCI"},{"termName":"KTN0158","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DF2O3JG5D2"},{"name":"Maps_To","value":"Anti-c-KIT Monoclonal Antibody CDX 0158"},{"name":"NCI_Drug_Dictionary_ID","value":"777970"},{"name":"NCI_META_CUI","value":"CL504322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777970"},{"name":"PDQ_Open_Trial_Search_ID","value":"777970"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146667":{"preferredName":"Anti-c-Met Antibody-drug Conjugate HTI-1066","code":"C146667","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of HTI-1066 targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the c-Met-expressing cancer cells, through an as of yet unknown mechanism of action. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Antibody-drug Conjugate HTI-1066","termGroup":"PT","termSource":"NCI"},{"termName":"ADC HTI-1066","termGroup":"SY","termSource":"NCI"},{"termName":"HTI 1066","termGroup":"CN","termSource":"NCI"},{"termName":"HTI-1066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Antibody-drug Conjugate HTI-1066"},{"name":"NCI_Drug_Dictionary_ID","value":"792156"},{"name":"NCI_META_CUI","value":"CL544636"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792156"},{"name":"PDQ_Open_Trial_Search_ID","value":"792156"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158513":{"preferredName":"Anti-c-Met Antibody-drug Conjugate TR1801","code":"C158513","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a non-agonizing anti-c-Met humanized monoclonal antibody that is linked in a site-specific manner to a pyrrolobenzodiazepine dimer (PBD) toxin, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety targets and binds to the c-Met protein, which is overexpressed in certain tumor types. Upon antibody/antigen binding and internalization, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of tumor cell DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of c-Met-expressing cells. c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Antibody-drug Conjugate TR1801","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-c-Met ADC TR1801","termGroup":"SY","termSource":"NCI"},{"termName":"MT 8633","termGroup":"CN","termSource":"NCI"},{"termName":"MT-8633","termGroup":"CN","termSource":"NCI"},{"termName":"TR 1801","termGroup":"CN","termSource":"NCI"},{"termName":"TR-1801","termGroup":"CN","termSource":"NCI"},{"termName":"TR1801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Antibody-drug Conjugate TR1801"},{"name":"NCI_Drug_Dictionary_ID","value":"797392"},{"name":"NCI_META_CUI","value":"CL938047"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797392"},{"name":"PDQ_Open_Trial_Search_ID","value":"797392"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C106262":{"preferredName":"Telisotuzumab","code":"C106262","definitions":[{"definition":"An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telisotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-700","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-c-Met Monoclonal Antibody ABT-700","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1781223-80-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R15ZW356HN"},{"name":"Maps_To","value":"Anti-c-Met Monoclonal Antibody ABT-700"},{"name":"Maps_To","value":"Telisotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"717765"},{"name":"NCI_META_CUI","value":"CL433934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717765"},{"name":"PDQ_Open_Trial_Search_ID","value":"717765"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113802":{"preferredName":"Anti-c-Met Monoclonal Antibody ARGX-111","code":"C113802","definitions":[{"definition":"A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and blocks both ligand-dependent and -independent activation of c-Met-mediated signaling pathways. In addition, this agent enhances antibody dependent cellular cytotoxicity (ADCC). This leads to a reduction in cell proliferation of c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors. Compared to other c-Met targeting monoclonal antibodies, ARGX-111 shows increased antibody circulation time, enhanced tissue distribution and increased efficacy. ARGX-111 is obtained through active immunization with C-met antigen in Camelids and utilizes the Camelid V-domains fused with human antibody backbones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Monoclonal Antibody ARGX-111","termGroup":"PT","termSource":"NCI"},{"termName":"ARGX-111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Monoclonal Antibody ARGX-111"},{"name":"NCI_Drug_Dictionary_ID","value":"757660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757660"},{"name":"PDQ_Open_Trial_Search_ID","value":"757660"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3827162"}]}}{"C95732":{"preferredName":"Emibetuzumab","code":"C95732","definitions":[{"definition":"A humanized IgG4 monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-MET) with potential antineoplastic activity. Emibetuzumab binds to c-MET, thereby preventing the binding of HGF to its receptor c-Met and subsequent activation of the HGF/c-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emibetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-c-MET Monoclonal Antibody LY2875358","termGroup":"SY","termSource":"NCI"},{"termName":"LA-480","termGroup":"CN","termSource":"NCI"},{"termName":"LY2875358","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1365287-97-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MO4K3GDN1I"},{"name":"Maps_To","value":"Anti-c-MET Monoclonal Antibody LY2875358"},{"name":"Maps_To","value":"Emibetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"694952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694952"},{"name":"PDQ_Open_Trial_Search_ID","value":"694952"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987383"}]}}{"C119619":{"preferredName":"Anti-C-met Monoclonal Antibody SAIT301","code":"C119619","definitions":[{"definition":"A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Anti-c-Met monoclonal antibody SAIT301 binds to c-Met, thereby preventing both binding of its ligand, HGF, and the subsequent activation of the HGF/c-Met signaling pathway. In addition, SAIT301 induces c-MET internalization and subsequent degradation, which further inhibits c-Met-mediated signaling. This leads to a reduction in the proliferation of c-Met-expressing cancer cells. c-Met, a proto-oncogene receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in various tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-C-met Monoclonal Antibody SAIT301","termGroup":"PT","termSource":"NCI"},{"termName":"SAIT301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-C-met Monoclonal Antibody SAIT301"},{"name":"NCI_Drug_Dictionary_ID","value":"766799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766799"},{"name":"PDQ_Open_Trial_Search_ID","value":"766799"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3896772"}]}}{"C116070":{"preferredName":"Lupartumab Amadotin","code":"C116070","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody against a structural homolog of the urokinase-type plasminogen activator receptor (uPAR) and tumor-associated antigen, C4.4a, and conjugated with a cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, lupartumab amadotin targets and binds to C4.4a-expressing tumor cells. Upon binding and cell entry, the cytotoxic agent kills the tumor cell. C4.4a, a glycolipid-anchored membrane protein and a member of the Ly-6 family, is overexpressed by a variety of cancer cell types whereas it is minimally expressed on healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lupartumab Amadotin","termGroup":"PT","termSource":"NCI"},{"termName":"BAY112-9980","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1129980","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1640972-00-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"21970JMA97"},{"name":"Maps_To","value":"Anti-C4.4a Antibody-Drug Conjugate BAY1129980"},{"name":"Maps_To","value":"Lupartumab Amadotin"},{"name":"NCI_Drug_Dictionary_ID","value":"761118"},{"name":"NCI_META_CUI","value":"CL473489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761118"},{"name":"PDQ_Open_Trial_Search_ID","value":"761118"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163020":{"preferredName":"Avdoralimab","code":"C163020","definitions":[{"definition":"A human monoclonal antibody targeting the C5a receptor (C5aR), with potential immunomodulating activity.  Upon administration, avdoralimab specifically targets, binds to and blocks C5aR expressed on subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils. This prevents the binding of its ligand C5a to C5aR and prevents the C5aR-mediated activation and accumulation of these cells in the tumor microenvironment (TME), and abrogates the secretion of inflammatory and angiogenic factors by these cells. This results in the activation of T- and natural killer (NK) cells, the induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSCs and neutrophils in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avdoralimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-C5aR-215","termGroup":"SY","termSource":"NCI"},{"termName":"IPH 5401","termGroup":"CN","termSource":"NCI"},{"termName":"IPH-5401","termGroup":"CN","termSource":"NCI"},{"termName":"IPH5401","termGroup":"CN","termSource":"NCI"},{"termName":"NN 8210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226393-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DW4CE8MKS9"},{"name":"Maps_To","value":"Anti-C5aR Monoclonal Antibody IPH5401"},{"name":"Maps_To","value":"Avdoralimab"},{"name":"NCI_Drug_Dictionary_ID","value":"798695"},{"name":"NCI_META_CUI","value":"CL973370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798695"},{"name":"PDQ_Open_Trial_Search_ID","value":"798695"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125900":{"preferredName":"Anti-CA19-9 Monoclonal Antibody 5B1","code":"C125900","definitions":[{"definition":"A human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, monoclonal antibody 5B1 binds to CA19-9 and kills CA19-9-expressing tumor cells, possibly through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CA19-9 Monoclonal Antibody 5B1","termGroup":"PT","termSource":"NCI"},{"termName":"5B1","termGroup":"CN","termSource":"NCI"},{"termName":"HuMab 5B1","termGroup":"SY","termSource":"NCI"},{"termName":"HuMab-5B1","termGroup":"SY","termSource":"NCI"},{"termName":"MVT-5873","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2101410-19-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KEX1QY18OH"},{"name":"Maps_To","value":"Anti-CA19-9 Monoclonal Antibody 5B1"},{"name":"NCI_Drug_Dictionary_ID","value":"778807"},{"name":"NCI_META_CUI","value":"CL504549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778807"},{"name":"PDQ_Open_Trial_Search_ID","value":"778807"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95764":{"preferredName":"Anti-CA6-DM4 Immunoconjugate SAR566658","code":"C95764","definitions":[{"definition":"An immunoconjugate consisting of a humanized monoclonal antibody against the tumor-associated sialoglycotope CA6 (huDS6) conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-CA6 monoclonal antibody moiety of SAR566658 targets and binds to the cell surface antigen CA6. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CA6-expressing tumor cells. The CA6 epitope is found on a variety of solid tumors, including breast, ovarian, cervical, lung and pancreatic tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CA6-DM4 Immunoconjugate SAR566658","termGroup":"PT","termSource":"NCI"},{"termName":"huDs6-DM4","termGroup":"AB","termSource":"NCI"},{"termName":"SAR-566658","termGroup":"CN","termSource":"NCI"},{"termName":"SAR566658","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UFB8CT84JS"},{"name":"Maps_To","value":"Anti-CA6-DM4 Immunoconjugate SAR566658"},{"name":"NCI_Drug_Dictionary_ID","value":"681584"},{"name":"NCI_META_CUI","value":"CL421654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681584"},{"name":"PDQ_Open_Trial_Search_ID","value":"681584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121231":{"preferredName":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1","code":"C121231","definitions":[{"definition":"A humanized version of the immunoglobulin (Ig) G1 monoclonal antibody Mik-Beta-1 (Hu-Mik-Beta-1) directed against CD122, the beta-subunit shared by the interleukin-2 (IL-2) and IL-15 receptor (IL-2/IL-15Rbeta). Upon intravenous infusion, Hu-Mik-Beta-1 binds to CD122 expressed on certain tumor cells. This blocks the binding of the inflammatory cytokines IL-2 and IL-15 to IL-2R and IL-15R, respectively, and prevents IL-2/IL-2R- and IL-15/IL-15R-mediated signaling. This may inhibit the proliferation of CD122-expressing tumor cells. In addition, blocking CD122 on T-lymphocytes prevents the over-activation of T-lymphocytes in various T-cell mediated autoimmune diseases, which is predominantly mediated by IL-15/IL-15R signaling. CD122, involved in both IL-2 and IL-15 signaling, is overexpressed on certain cancer cells, such as those found in T-cell large granular lymphocyte (T-LGL) leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1","termGroup":"PT","termSource":"NCI"},{"termName":"Hu-Mik-Beta-1","termGroup":"SY","termSource":"NCI"},{"termName":"Hu-Mik-beta1","termGroup":"SY","termSource":"NCI"},{"termName":"Hu-Mikb1","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Mik-beta-1","termGroup":"SY","termSource":"NCI"},{"termName":"HuMikBeta1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1"},{"name":"NCI_Drug_Dictionary_ID","value":"810708"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055462"}]}}{"C184834":{"preferredName":"Pivekimab Sunirine","code":"C184834","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pivekimab Sunirine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD123 ADC IMGN632","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate IMGN632","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-targeted ADC IMGN632","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN 632","termGroup":"CN","termSource":"NCI"},{"termName":"IMGN-632","termGroup":"CN","termSource":"NCI"},{"termName":"IMGN632","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417174-95-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L15LO3W1XX"},{"name":"Maps_To","value":"Anti-CD123 ADC IMGN632"},{"name":"NCI_Drug_Dictionary_ID","value":"792150"},{"name":"NCI_META_CUI","value":"CL541645"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91093":{"preferredName":"Anti-CD123 Monoclonal Antibody CSL360","code":"C91093","definitions":[{"definition":"A chimeric IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain) with potential antineoplastic activity. Derived from mouse monoclonal antibody 7G3, anti-CD123 monoclonal antibody CSL360 binds to and neutralizes CD123 which is upregulated on leukemic stem cells (LSC) in acute myeloid leukemia (AML). This may inhibit IL-3-dependent signalling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123 Monoclonal Antibody CSL360","termGroup":"PT","termSource":"NCI"},{"termName":"CSL360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123 Monoclonal Antibody CSL360"},{"name":"NCI_Drug_Dictionary_ID","value":"529287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529287"},{"name":"PDQ_Open_Trial_Search_ID","value":"529287"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832015"}]}}{"C123380":{"preferredName":"Anti-CD123 Monoclonal Antibody KHK2823","code":"C123380","definitions":[{"definition":"A fully human monoclonal antibody against CD123 (interleukin-3 receptor alpha chain) with potential antineoplastic activity. Anti-CD123 monoclonal antibody KHK2823 binds to and neutralizes CD123, which is upregulated on leukemic stem cells (LSC) found in myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This agent may inhibit IL-3-dependent signaling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123 Monoclonal Antibody KHK2823","termGroup":"PT","termSource":"NCI"},{"termName":"KHK2823","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123 Monoclonal Antibody KHK2823"},{"name":"NCI_Drug_Dictionary_ID","value":"762775"},{"name":"NCI_META_CUI","value":"CL474096"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762775"},{"name":"PDQ_Open_Trial_Search_ID","value":"762775"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127120":{"preferredName":"Vibecotamab","code":"C127120","definitions":[{"definition":"An anti-CD123/anti-CD3 bispecific monoclonal antibody, in which most of the naturally-occurring Fc domain is maintained, with potential immunostimulatory and antineoplastic activities. Vibecotamab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of vibecotamab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell mediated tumor cell killing through its binding to the Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vibecotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD123/Anti-CD3 Bispecific Antibody XmAb14045","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb14045","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138442-13-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JD56EJA59S"},{"name":"Maps_To","value":"Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404"},{"name":"Maps_To","value":"Vibecotamab"},{"name":"NCI_Drug_Dictionary_ID","value":"780966"},{"name":"NCI_META_CUI","value":"CL507910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780966"},{"name":"PDQ_Open_Trial_Search_ID","value":"780966"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129457":{"preferredName":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A","code":"C129457","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an anti-CD123 humanized monoclonal antibody conjugated, via a stable maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD123 ADC SGN-CD123A, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD123-overexpressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers, including myeloid leukemia, and increased expression of CD123 on leukemic stem cells is associated with poor prognosis. Cysteine engineering of the monoclonal antibody (EC-mAb) allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123 ADC SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123-PBD ADC SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate SGN-CD123A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD123A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD123A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"89ATB9I3D2"},{"name":"Maps_To","value":"Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A"},{"name":"NCI_Drug_Dictionary_ID","value":"784132"},{"name":"NCI_META_CUI","value":"CL512667"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784132"},{"name":"PDQ_Open_Trial_Search_ID","value":"784132"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157257":{"preferredName":"Anti-CD123/CD3 Bispecific Antibody APVO436","code":"C157257","definitions":[{"definition":"An immunoglobulin Fc-modified bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3 bispecific monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD123/CD3 monoclonal antibody APVO436 simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody. Compared to some other CD123 x CD3 targeting bispecific antibodies, APVO436 causes less cytokine release upon T-cell stimulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123/CD3 Bispecific Antibody APVO436","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD123 x Anti-CD3 Bispecific Antibody APVO436","termGroup":"SY","termSource":"NCI"},{"termName":"APVO 436","termGroup":"CN","termSource":"NCI"},{"termName":"APVO-436","termGroup":"CN","termSource":"NCI"},{"termName":"APVO436","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Anti-CD123 x Anti-CD3 Antibody APVO436","termGroup":"SY","termSource":"NCI"},{"termName":"CD123 x CD3 Targeting Bispecific Antibody APVO436","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DNP8BBW84R"},{"name":"Maps_To","value":"Anti-CD123/CD3 Bispecific Antibody APVO436"},{"name":"NCI_Drug_Dictionary_ID","value":"796808"},{"name":"NCI_META_CUI","value":"CL936868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796808"},{"name":"PDQ_Open_Trial_Search_ID","value":"796808"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128486":{"preferredName":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178","code":"C128486","definitions":[{"definition":"A humanized anti-CD123/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-CD123/CD3 bispecific antibody JNJ-63709178 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of JNJ-63709178, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of cancers; its expression is low or absent in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178","termGroup":"PT","termSource":"NCI"},{"termName":"Humanized CD123 x CD3 DuoBody JNJ-63709178","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ-63709178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123/CD3 Bispecific Antibody JNJ-63709178"},{"name":"NCI_Drug_Dictionary_ID","value":"782366"},{"name":"NCI_META_CUI","value":"CL507949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782366"},{"name":"PDQ_Open_Trial_Search_ID","value":"782366"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160348":{"preferredName":"Anti-CD123/CD3 BiTE Antibody SAR440234","code":"C160348","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody comprised of a humanized Fc-silenced immunoglobulin G1 (IgG1) backbone and two single-chain variable fragments (scFvs): one directed against the CD3 antigen expressed on T-lymphocytes and another directed against the alpha-chain of the interleukin-3 receptor (IL-3RA; CD123), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, anti-CD123/CD3 BiTE antibody SAR440234 binds to both CD3 expressed on T-cells and CD123 expressed on tumor cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CD123-expressing tumor cells, leading to enhanced CTL-mediated elimination of CD123-expressing tumor cells. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD123/CD3 BiTE Antibody SAR440234","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody SAR440234","termGroup":"SY","termSource":"NCI"},{"termName":"CD123xCD3 Bispecific T-cell Engager SAR440234","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 440234","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-440234","termGroup":"CN","termSource":"NCI"},{"termName":"SAR440234","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD123/CD3 BiTE Antibody SAR440234"},{"name":"NCI_Drug_Dictionary_ID","value":"798327"},{"name":"NCI_META_CUI","value":"CL969414"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798327"},{"name":"PDQ_Open_Trial_Search_ID","value":"798327"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C160715":{"preferredName":"Anti-CD137 Agonistic Monoclonal Antibody ADG106","code":"C160715","definitions":[{"definition":"A human agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating activity. Upon administration, anti-CD137 agonistic monoclonal antibody ADG106 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD137 Agonistic Monoclonal Antibody ADG106","termGroup":"PT","termSource":"NCI"},{"termName":"4-1BB-directed Agonistic Monoclonal Antibody ADG106","termGroup":"SY","termSource":"NCI"},{"termName":"ADG 106","termGroup":"SY","termSource":"NCI"},{"termName":"ADG-106","termGroup":"CN","termSource":"NCI"},{"termName":"ADG106","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody ADG106","termGroup":"SY","termSource":"NCI"},{"termName":"CD137-directed Agonistic Monoclonal Antibody ADG106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I4QM8E7Y2R"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody ADG106"},{"name":"NCI_Drug_Dictionary_ID","value":"797894"},{"name":"NCI_META_CUI","value":"CL969811"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797894"},{"name":"PDQ_Open_Trial_Search_ID","value":"797894"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162039":{"preferredName":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471","code":"C162039","definitions":[{"definition":"A fully human immunoglobulin G4 (IgG4) agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody CTX-471 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody CTX-471","termGroup":"SY","termSource":"NCI"},{"termName":"CTX 471","termGroup":"CN","termSource":"NCI"},{"termName":"CTX-471","termGroup":"CN","termSource":"NCI"},{"termName":"CTX471","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody CTX-471"},{"name":"NCI_Drug_Dictionary_ID","value":"798594"},{"name":"NCI_META_CUI","value":"CL970637"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798594"},{"name":"PDQ_Open_Trial_Search_ID","value":"798594"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C120317":{"preferredName":"Anti-CD157 Monoclonal Antibody MEN1112","code":"C120317","definitions":[{"definition":"A humanized, Fc engineered, de-fucosylated monoclonal immunoglobulin G1 (IgG1) antibody directed against the bone marrow stromal cell antigen 1 (BST1/CD157), with potential antineoplastic activity. Upon intravenous infusion, anti-CD157 monoclonal antibody MEN1112 specifically binds to and induces an antibody dependent cell cytotoxic (ADCC) response against CD157-expressing tumor cells. CD157, also known as ADP-ribosyl cyclase 2, is a glycosyl-phosphatidylinositol (GPI)-anchored transmembrane protein belonging to the ADP-ribosyl-cyclase family and is overexpressed on certain cancer cell types. Fc-optimization of MEN1112, which involves the removal of fucose residues from its Fc domain, allows for enhanced Fc-gamma receptor binding on effector cells, such as natural killer (NK) cells, and further enhances tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD157 Monoclonal Antibody MEN1112","termGroup":"PT","termSource":"NCI"},{"termName":"MEN1112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD157 Monoclonal Antibody MEN1112"},{"name":"NCI_Drug_Dictionary_ID","value":"768862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768862"},{"name":"PDQ_Open_Trial_Search_ID","value":"768862"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3896815"}]}}{"C134697":{"preferredName":"Praluzatamab Ravtansine","code":"C134697","definitions":[{"definition":"A probody drug conjugate (PDC) composed of a recombinant antibody targeting the tumor-associated antigen (TAA) CD166, which is masked by a cleavable masking peptide, and conjugated to the cytotoxic agent maytansinoid DM4, with potential antineoplastic activity. Upon administration of praluzatamab ravtansine and migration to the tumor microenvironment (TME), the cleavable masking peptide, which prevent anti-CD166 antibody binding to the CD166 expressed on both normal cells and tumor cells, is proteolytically cleaved by tumor-associated proteases that are specifically present in the TME. This enables the anti-CD166 antibody moiety of CX-2009 to selectively bind to, be internalized by, and deliver DM4 into CD166-expressing tumor cells. Following internalization, DM4 is released, binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD166-expressing tumor cells. The masking peptide prevents binding of the anti-CD166 antibody to CD166 in normal tissues, thereby minimizing toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Praluzatamab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC CX-2009","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD166-DM4 CX-2009","termGroup":"SY","termSource":"NCI"},{"termName":"CX-2009","termGroup":"CN","termSource":"NCI"},{"termName":"PDC CX-2009","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2145115-85-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RD2I59M9FC"},{"name":"Maps_To","value":"Anti-CD166 Probody-drug Conjugate CX-2009"},{"name":"Maps_To","value":"Praluzatamab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"789027"},{"name":"NCI_META_CUI","value":"CL522231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789027"},{"name":"PDQ_Open_Trial_Search_ID","value":"789027"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126377":{"preferredName":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B","code":"C126377","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody (hBU12ec) with engineered cysteines (EC-mAb) conjugated, via a maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer (SGD-1882), with potential antineoplastic activity. Upon administration of anti-CD19 ADC SGN-CD19B, the antibody moiety targets the cell surface antigen CD19, which is found on B-cell-derived cancers. Upon antibody/antigen binding, internalization and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, is expressed on B-cell-derived cancers. The cysteine engineering of the EC-mAb allows for a site-specific and stable conjugation of PBD to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD19B","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD19B","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD19B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 Antibody-drug Conjugate SGN-CD19B"},{"name":"NCI_Drug_Dictionary_ID","value":"779706"},{"name":"NCI_META_CUI","value":"CL504928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779706"},{"name":"PDQ_Open_Trial_Search_ID","value":"779706"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105805":{"preferredName":"Anti-CD19 Monoclonal Antibody DI-B4","code":"C105805","definitions":[{"definition":"A low-fucosylated, humanized, IgG1 isotype, monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody DI-B4 binds to CD19, which may result in a strong antibody-dependent cellular cytotoxicity (ADCC) directed at CD19-expressing B-cells but with minimal complement dependent cytotoxicity. DI-B4 contains low levels of fucose, which contributes to its enhanced ADCC activity. CD19 is a B-cell specific membrane antigen that is widely expressed during B-cell development and in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Monoclonal Antibody DI-B4","termGroup":"PT","termSource":"NCI"},{"termName":"anti-CD19 MoAb DI-B4","termGroup":"SY","termSource":"NCI"},{"termName":"DI-B4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody DI-B4"},{"name":"NCI_Drug_Dictionary_ID","value":"747738"},{"name":"NCI_META_CUI","value":"CL447157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747738"},{"name":"PDQ_Open_Trial_Search_ID","value":"747738"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74003":{"preferredName":"Anti-CD19 Monoclonal Antibody MDX-1342","code":"C74003","definitions":[{"definition":"A fully human anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential antineoplastic activity. Anti-CD19 monoclonal antibody MDX-1342 binds to CD19, depleting and eliminating CD19-expressing B-cells. CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Monoclonal Antibody MDX-1342","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-1342","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD19_Monoclonal_Antibody_MDX-1342"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody MDX-1342"},{"name":"NCI_Drug_Dictionary_ID","value":"586439"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586439"},{"name":"PDQ_Open_Trial_Search_ID","value":"586439"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346795"}]}}{"C88283":{"preferredName":"Inebilizumab","code":"C88283","definitions":[{"definition":"A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inebilizumab","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI-551","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1299440-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"74T7185BMM"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody MEDI-551"},{"name":"Maps_To","value":"Inebilizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"656851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656851"},{"name":"PDQ_Open_Trial_Search_ID","value":"656851"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981806"}]}}{"C95768":{"preferredName":"Tafasitamab","code":"C95768","definitions":[{"definition":"An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tafasitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Monjuvi","termGroup":"BR","termSource":"NCI"},{"termName":"MOR 00208","termGroup":"CN","termSource":"NCI"},{"termName":"MOR 208","termGroup":"CN","termSource":"NCI"},{"termName":"MOR-00208","termGroup":"CN","termSource":"NCI"},{"termName":"MOR-208","termGroup":"CN","termSource":"NCI"},{"termName":"MOR00208","termGroup":"CN","termSource":"NCI"},{"termName":"MOR208","termGroup":"CN","termSource":"NCI"},{"termName":"Tafasitamab-cxix","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb-5574","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb5574","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"},{"name":"CAS_Registry","value":"1422527-84-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"QQA9MLH692"},{"name":"Maps_To","value":"Anti-CD19 Monoclonal Antibody XmAb5574"},{"name":"Maps_To","value":"Tafasitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"682091"},{"name":"NCI_META_CUI","value":"CL421662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682091"},{"name":"PDQ_Open_Trial_Search_ID","value":"682091"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71009":{"preferredName":"Coltuximab Ravtansine","code":"C71009","definitions":[{"definition":"An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Coltuximab ravtansine targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coltuximab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19-DM4 Immunoconjugate SAR3419","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 3419","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-3419","termGroup":"CN","termSource":"NCI"},{"termName":"SAR3419","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1269764-99-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MRS84YT9L2"},{"name":"Legacy Concept Name","value":"Anti-CD19-DM4_Conjugate"},{"name":"Maps_To","value":"Anti-CD19-DM4 Immunoconjugate SAR3419"},{"name":"Maps_To","value":"Coltuximab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"574048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574048"},{"name":"PDQ_Open_Trial_Search_ID","value":"574048"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346794"}]}}{"C82375":{"preferredName":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL","code":"C82375","definitions":[{"definition":"A substance being studied in the treatment of some types of B-cell cancer. It contains an antibody linked to a toxic substance. The antibody binds to proteins called CD19 and CD22 on the surface of B cells, and the toxic substance kills the cells. It is a type of bispecific ligand-directed toxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunotoxin consisting of two scFv ligands recognizing human CD19 and CD22 linked to the first 389 amino acids of diphtheria toxin (DT), DT 390, with potential antineoplastic activity. The VH and VL regions of anti-CD22 (sFv) and anti-CD19 are reversed and linked by an aggregration stabilizing linker (ARL) consisting of a 20 amino acid segment of human muscle aldolase (hma) and an Xho1-compatible restriction site; the CDR3 region of the VH of anti-CD22 sFv is mutated to enhance its affinity. The anti-CD19 and anti CD-22 portions of the immunotoxin specifically bind to CD19 and CD22 receptors on tumor B cells. Upon internalization, DT catalyzes ADP ribosylation of elongation factor 2 (EF-2) which may result in the irreversible inhibition of protein synthesis and cell death in CD19- and CD22-expressing tumor cells. CD19 and CD22 are transmembrane proteins upregulated on malignant B cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/CD22 BLT DT2219ARL","termGroup":"SY","termSource":"NCI"},{"termName":"DT2219ARL","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD19_Anti-CD22_Bispecific_Immunotoxin_DT2219ARL"},{"name":"Maps_To","value":"Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL"},{"name":"NCI_Drug_Dictionary_ID","value":"641179"},{"name":"NCI_META_CUI","value":"CL408648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641179"},{"name":"PDQ_Open_Trial_Search_ID","value":"641179"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C153215":{"preferredName":"Anti-CD19/CD3 BiTE Antibody AMG 562","code":"C153215","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 BiTE antibody AMG 562 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/CD3 BiTE Antibody AMG 562","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 562","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-562","termGroup":"CN","termSource":"NCI"},{"termName":"AMG562","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 562","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 562","termGroup":"SY","termSource":"NCI"},{"termName":"CD19/CD3-directed Bispecific T-cell Engager Antibody AMG 562","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19/CD3 BiTE Antibody AMG 562"},{"name":"NCI_Drug_Dictionary_ID","value":"794049"},{"name":"NCI_META_CUI","value":"CL554338"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794049"},{"name":"PDQ_Open_Trial_Search_ID","value":"794049"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C115101":{"preferredName":"Anti-CD19/CD3 Tetravalent Antibody AFM11","code":"C115101","definitions":[{"definition":"An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/CD3 Tetravalent Antibody AFM11","termGroup":"PT","termSource":"NCI"},{"termName":"AFM11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"250245-29-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UGA95385P3"},{"name":"Maps_To","value":"Anti-CD19/CD3 Tetravalent Antibody AFM11"},{"name":"NCI_Drug_Dictionary_ID","value":"759829"},{"name":"NCI_META_CUI","value":"CL472632"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759829"},{"name":"PDQ_Open_Trial_Search_ID","value":"759829"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155899":{"preferredName":"Anti-CD20 Monoclonal Antibody B001","code":"C155899","definitions":[{"definition":"A recombinant humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Upon intravenous administration, anti-CD20 monoclonal antibody B001 specifically binds to CD20 on the surfaces of B-cells. Although the exact mechanisms through which B001 exert its effects have not been elucidated, B001 may induce a B-cell directed cell-mediated immune response against CD20-expressing B-cells and/or prevent CD20-medaited signaling. This induces tumor cell apoptosis and inhibits proliferation. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development and which is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody B001","termGroup":"PT","termSource":"NCI"},{"termName":"B 001","termGroup":"CN","termSource":"NCI"},{"termName":"B001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody B001"},{"name":"NCI_Drug_Dictionary_ID","value":"794877"},{"name":"NCI_META_CUI","value":"CL562774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794877"},{"name":"PDQ_Open_Trial_Search_ID","value":"794877"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90590":{"preferredName":"Anti-CD20 Monoclonal Antibody PRO131921","code":"C90590","definitions":[{"definition":"A third-generation, humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody PRO131921 specifically binds to the B cell-specific cell surface antigen CD20. This may result in the induction of a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B cells during most stages of B cell development and which is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody PRO131921","termGroup":"PT","termSource":"NCI"},{"termName":"PRO131921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody PRO131921"},{"name":"NCI_Drug_Dictionary_ID","value":"543157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543157"},{"name":"PDQ_Open_Trial_Search_ID","value":"543157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934873"}]}}{"C122680":{"preferredName":"Ripertamab","code":"C122680","definitions":[{"definition":"A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ripertamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody SCT400","termGroup":"SY","termSource":"NCI"},{"termName":"SCT400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249927-04-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"URS0374MIV"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody SCT400"},{"name":"NCI_Drug_Dictionary_ID","value":"772859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772859"},{"name":"PDQ_Open_Trial_Search_ID","value":"772859"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053591"}]}}{"C94206":{"preferredName":"Anti-CD20 Monoclonal Antibody TL011","code":"C94206","definitions":[{"definition":"A monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody TL011 specifically binds to the B cell-specific cell surface antigen CD20 antigen (MS4A1; membrane-spanning 4-domains, subfamily A, member 1), thereby potentially triggering an immune response against CD20-positive B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody TL011","termGroup":"PT","termSource":"NCI"},{"termName":"TL011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody TL011"},{"name":"NCI_Drug_Dictionary_ID","value":"686495"},{"name":"NCI_META_CUI","value":"CL426019"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686495"},{"name":"PDQ_Open_Trial_Search_ID","value":"686495"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123915":{"preferredName":"Eramkafusp Alfa","code":"C123915","definitions":[{"definition":"A humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20 and fused to the recombinant cytokine, interferon-alpha (IFN-a), with potential antineoplastic and immunomodulating activities. Upon administration of eramkafusp alfa, the antibody moiety specifically targets and binds to CD20. In turn, the IFN-a moiety binds to the IFN receptor, and activates IFN-mediated signal transduction, which induces the transcription and translation of genes whose protein products mediate anticancer effects. This results in the induction of both G2 cell cycle arrest and apoptosis in CD20-expressing tumor cells. In addition, IGN002 causes the induction of complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eramkafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody-IFN-a Fusion Protein IGN002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002","termGroup":"SY","termSource":"NCI"},{"termName":"IGN002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2388499-82-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N7FO1V18PR"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002"},{"name":"NCI_Drug_Dictionary_ID","value":"775840"},{"name":"NCI_META_CUI","value":"CL498279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775840"},{"name":"PDQ_Open_Trial_Search_ID","value":"775840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120546":{"preferredName":"Anti-CD20-engineered Toxin Body MT-3724","code":"C120546","definitions":[{"definition":"An engineered toxin body (ETB) composed of the single-chain variable fragment (ScFv) from an antibody targeting CD20 that is linked to a modified form of the ribosome-inactivating alpha subunit of Shiga-like toxin 1 (Shiga-like Toxin-1 A or SLT-1A), with antineoplastic activity. Upon administration, the ScFv moiety of anti-CD20-engineered toxin body MT-3724 targets and binds to the CD20 antigen expressed on tumor cells. Upon internalization, the SLT-1A moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and eventually leads to apoptosis of CD20-expressing tumor cells. CD20, a B-cell specific transmembrane protein and tumor-associated antigen (TAA), is expressed during most stages of B-cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20-engineered Toxin Body MT-3724","termGroup":"PT","termSource":"NCI"},{"termName":"MT-3724","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R23ZRN6GWR"},{"name":"Maps_To","value":"Anti-CD20-engineered Toxin Body MT-3724"},{"name":"NCI_Drug_Dictionary_ID","value":"769207"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769207"},{"name":"PDQ_Open_Trial_Search_ID","value":"769207"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053580"}]}}{"C165166":{"preferredName":"Imvotamab","code":"C165166","definitions":[{"definition":"An engineered immunoglobulin M (IgM) bispecific antibody, with potential antineoplastic activity. Imvotamab contains ten high affinity binding domains for the tumor-associated antigen (TAA) CD20, and one binding domain for CD3, a T-cell surface antigen. Upon administration, imvotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Additionally, imvotamab induces complement-dependent cytotoxicity (CDC) to a greater extent than anti-CD20/anti-CD3 IgG bispecific antibodies, thereby further enhancing the killing CD20-expressing tumor cells. The extra binding units of imvotamab may bind cancer cells that express relatively low amounts of CD20. Also, compared to IgG format bispecific T-cell engaging antibodies, imvotamab appears to induce less cytokine release, which may reduce the risk of cytokine release syndrome (CRS). CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imvotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific CD20xCD3 IgM Antibody IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific IgM Antibody IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"IGM 2323","termGroup":"CN","termSource":"NCI"},{"termName":"IgM Pentamer IGM2323","termGroup":"SY","termSource":"NCI"},{"termName":"IGM-2323","termGroup":"CN","termSource":"NCI"},{"termName":"IGM2323","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2573121-53-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3HG38I0T1"},{"name":"Maps_To","value":"Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323"},{"name":"NCI_Drug_Dictionary_ID","value":"799710"},{"name":"NCI_META_CUI","value":"CL978274"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799710"},{"name":"PDQ_Open_Trial_Search_ID","value":"799710"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119615":{"preferredName":"Odronextamab","code":"C119615","definitions":[{"definition":"A bispecific, human monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody REGN1979 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, odronextamab binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odronextamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979","termGroup":"SY","termSource":"NCI"},{"termName":"REGN1979","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11035","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801338-64-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8R5CM46UIO"},{"name":"Maps_To","value":"Anti-CD20/CD3 Monoclonal Antibody REGN1979"},{"name":"Maps_To","value":"Odronextamab"},{"name":"NCI_Drug_Dictionary_ID","value":"766653"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766653"},{"name":"PDQ_Open_Trial_Search_ID","value":"766653"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896743"}]}}{"C130050":{"preferredName":"Plamotamab","code":"C130050","definitions":[{"definition":"A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic activity. Plamotamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, plamotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell-mediated tumor cell killing because the agent is able to bind to Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plamotamab","termGroup":"PT","termSource":"NCI"},{"termName":"XmAb13676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138442-31-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5ENX424FNF"},{"name":"Maps_To","value":"Anti-CD20/CD3 Monoclonal Antibody XmAb13676"},{"name":"Maps_To","value":"Plamotamab"},{"name":"NCI_Drug_Dictionary_ID","value":"785610"},{"name":"NCI_META_CUI","value":"CL514016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785610"},{"name":"PDQ_Open_Trial_Search_ID","value":"785610"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156882":{"preferredName":"Anti-CD22 ADC TRPH-222","code":"C156882","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an anti-CD22 humanized monoclonal antibody site-specifically conjugated to, via formylglycine (FG) residues and a protease insensitive 4AP linker, a cytotoxic microtubule-targeting maytansinoid payload, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TRPH-222 binds to B-cell-specific CD22 receptors and is rapidly internalized, thereby delivering the payload intracellularly. Upon proteolytic cleavage, the maytansinoid payload binds to tubulin, disrupting microtubule assembly/disassembly dynamics, inhibiting both cell division and tumor cell proliferation. CD22, a cell surface sialoglycoprotein, is expressed on mature B-cells and on most malignant B-cells. The site specific and stable conjugation to the payload allows for a higher drug-to-antibody ratio (DAR) and an enhanced therapeutic index.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD22 ADC TRPH-222","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD22 Antibody-drug Conjugate TRPH-222","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD22-4AP ADC TRPH-222","termGroup":"SY","termSource":"NCI"},{"termName":"CAT-02-106","termGroup":"CN","termSource":"NCI"},{"termName":"TRPH 222","termGroup":"CN","termSource":"NCI"},{"termName":"TRPH-222","termGroup":"CN","termSource":"NCI"},{"termName":"TRPH222","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"00NT1ETN9K"},{"name":"Maps_To","value":"Anti-CD22 ADC TRPH-222"},{"name":"NCI_Drug_Dictionary_ID","value":"796465"},{"name":"NCI_META_CUI","value":"CL935995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796465"},{"name":"PDQ_Open_Trial_Search_ID","value":"796465"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104167":{"preferredName":"Pinatuzumab Vedotin","code":"C104167","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of MCDT2219A, a humanized IgG1 anti-CD22 monoclonal antibody covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of pinatuzumab vedotin binds to B cell-specific CD22 receptors and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pinatuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DCDT2980S","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate DCDT2980S","termGroup":"SY","termSource":"NCI"},{"termName":"DCDT2980S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313706-14-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6KA1906BLC"},{"name":"Maps_To","value":"Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S"},{"name":"Maps_To","value":"Pinatuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"686534"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686534"},{"name":"PDQ_Open_Trial_Search_ID","value":"686534"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641731"}]}}{"C121949":{"preferredName":"Camidanlumab Tesirine","code":"C121949","definitions":[{"definition":"An immunoconjugate consisting of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha or CD25) and conjugated, via a cleavable linker, to a synthetic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer that targets DNA minor grooves, with potential antineoplastic activity. The monoclonal antibody portion of the anti-CD25 antibody-drug conjugate (ADC) ADCT-301 specifically binds to the cell surface antigen CD25. This causes the internalization of ADCT-301 and the subsequent release of the cytotoxic PBD moiety. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD25-overexpressing tumor cells. CD25, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on certain cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camidanlumab Tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-301","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT-301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1853239-04-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LYJ1AEJ9YH"},{"name":"Maps_To","value":"Anti-CD25-PBD Antibody-drug Conjugate ADCT-301"},{"name":"Maps_To","value":"Camidanlumab Tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"771992"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771992"},{"name":"PDQ_Open_Trial_Search_ID","value":"771992"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053683"}]}}{"C150677":{"preferredName":"Anti-CD26 Monoclonal Antibody YS110","code":"C150677","definitions":[{"definition":"A humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells. YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD26 Monoclonal Antibody YS110","termGroup":"PT","termSource":"NCI"},{"termName":"YS110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD26 Monoclonal Antibody YS110"},{"name":"NCI_Drug_Dictionary_ID","value":"793089"},{"name":"NCI_META_CUI","value":"CL552568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793089"},{"name":"PDQ_Open_Trial_Search_ID","value":"793089"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C106266":{"preferredName":"Anti-CD27L Antibody-Drug Conjugate AMG 172","code":"C106266","definitions":[{"definition":"An immunoconjugate consisting of a human IgG1 monoclonal antibody directed against CD27L conjugated, via a non-cleavable linker, to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to CD27L on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of cancer cells that express CD27L. CD27L, a type II transmembrane protein and member of the tumor necrosis factor family, is a co-stimulatory molecule constitutively expressed on a subset of activated T-cells, B-cells, and dendritic cells, which is overexpressed in certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD27L Antibody-Drug Conjugate AMG 172","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 172","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-172","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6M586T6SD"},{"name":"Maps_To","value":"Anti-CD27L Antibody-Drug Conjugate AMG 172"},{"name":"NCI_Drug_Dictionary_ID","value":"721679"},{"name":"NCI_META_CUI","value":"CL433957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721679"},{"name":"PDQ_Open_Trial_Search_ID","value":"721679"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74004":{"preferredName":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)","code":"C74004","definitions":[{"definition":"A bivalent recombinant fusion protein immunotoxin derived from the anti-CD3 monoclonal antibody UCHT1 with potential antineoplastic activity. Anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1) consists of 1-390 amino acid residues of chain A diphtheria toxin (DT) joined via a spacer to the Fv fragment of UCHT1, which is connected to a second UCHT1 Fv fragment via a disulfide bond (hence the \"bisFv\" designation); the addition of the second Fv fragment overcomes the steric hindrance of immunotoxin binding due to the large N-terminal DT domain. Once inside target T cells, the DT moiety catalyzes the transfer of the ADP-ribose moiety of NAD to diphthamide, a posttranslationally modified histidine residue found in elongation factor 2 (EF-2); inactivation of EF-2, disruption of polypeptide chain elongation, and cell death ensue. CD3 is a complex of five cell-surface polypeptides associated with the T cell receptor (TCR) complex.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)","termGroup":"PT","termSource":"NCI"},{"termName":"A-dmDT390-bisFv(UCHT1)","termGroup":"AB","termSource":"NCI"},{"termName":"Resimmune","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1470038-56-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P7MQ9ZOQ82"},{"name":"Legacy Concept Name","value":"Anti-CD3_Immunotoxin_A-dmDT390-bisFv_UCHT1"},{"name":"Maps_To","value":"Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)"},{"name":"NCI_Drug_Dictionary_ID","value":"588895"},{"name":"NCI_META_CUI","value":"CL383887"},{"name":"PDQ_Closed_Trial_Search_ID","value":"588895"},{"name":"PDQ_Open_Trial_Search_ID","value":"588895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136823":{"preferredName":"Teclistamab","code":"C136823","definitions":[{"definition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teclistamab","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 64007957","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64007957","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ64007957","termGroup":"CN","termSource":"NCI"},{"termName":"Teclistamab-cqyv","termGroup":"SY","termSource":"NCI"},{"termName":"Tecvayli","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2119595-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"54534MX6Z9"},{"name":"Maps_To","value":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957"},{"name":"Maps_To","value":"Teclistamab"},{"name":"NCI_Drug_Dictionary_ID","value":"789710"},{"name":"NCI_META_CUI","value":"CL524654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789710"},{"name":"PDQ_Open_Trial_Search_ID","value":"789710"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146860":{"preferredName":"Elranatamab","code":"C146860","definitions":[{"definition":"A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elranatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA x CD3 Bispecific Antibody PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-CD3 Bispecific Ab PF-06863135","termGroup":"SY","termSource":"NCI"},{"termName":"Elranatamab-bcmm","termGroup":"SY","termSource":"NCI"},{"termName":"Elrexfio","termGroup":"BR","termSource":"NCI"},{"termName":"PF 06863135","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06863135","termGroup":"CN","termSource":"NCI"},{"termName":"PF06863135","termGroup":"CN","termSource":"NCI"},{"termName":"RN 613","termGroup":"CN","termSource":"NCI"},{"termName":"RN-613","termGroup":"CN","termSource":"NCI"},{"termName":"RN613","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adults with relapsed or refractory multiple myeloma."},{"name":"CAS_Registry","value":"2408850-14-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"L0HR9A577V"},{"name":"Maps_To","value":"Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135"},{"name":"NCI_Drug_Dictionary_ID","value":"792267"},{"name":"NCI_META_CUI","value":"CL544825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792267"},{"name":"PDQ_Open_Trial_Search_ID","value":"792267"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95760":{"preferredName":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05","code":"C95760","definitions":[{"definition":"A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. FBTA05 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human CD20, a tumor-associated antigen that is exclusively expressed on B cells during most stages of B cell development and often overexpressed in B-cell malignancies. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). FBTA05 brings T cells, CD20-expressing tumor B-cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells. Fc-mediated binding of APCs in the tricellular complex potentiates CD20 antigen presentation to T cells and the activation of anti-tumor cytotoxic T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05","termGroup":"PT","termSource":"NCI"},{"termName":"FBTA05","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05"},{"name":"NCI_Drug_Dictionary_ID","value":"675323"},{"name":"NCI_META_CUI","value":"CL421602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675323"},{"name":"PDQ_Open_Trial_Search_ID","value":"675323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171840":{"preferredName":"Talquetamab","code":"C171840","definitions":[{"definition":"A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talquetamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"GPRC5D x CD3 Bispecific Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"GPRC5D x CD3 DuoBody Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"GPRC5D/CD3 DuoBody Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 64407564","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64407564","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ64407564","termGroup":"CN","termSource":"NCI"},{"termName":"Talquetamab-tgvs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226212-40-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4W3KFI3TN3"},{"name":"Maps_To","value":"Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564"},{"name":"NCI_Drug_Dictionary_ID","value":"792477"},{"name":"NCI_META_CUI","value":"CL545429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792477"},{"name":"PDQ_Open_Trial_Search_ID","value":"792477"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163022":{"preferredName":"Epcoritamab","code":"C163022","definitions":[{"definition":"A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epcoritamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20/CD3 Bispecific Antibody GEN3013","termGroup":"SY","termSource":"NCI"},{"termName":"DuoBody-CD3xCD20","termGroup":"SY","termSource":"NCI"},{"termName":"Epcoritamab-bysp","termGroup":"SY","termSource":"NCI"},{"termName":"Epkinly","termGroup":"BR","termSource":"NCI"},{"termName":"GEN 3013","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-3013","termGroup":"CN","termSource":"NCI"},{"termName":"GEN3013","termGroup":"CN","termSource":"NCI"},{"termName":"Tepkinly","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2134641-34-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D6OMY2L0WA"},{"name":"Maps_To","value":"Anti-CD3/CD20 Bispecific Antibody GEN3013"},{"name":"Maps_To","value":"Epcoritamab"},{"name":"NCI_Drug_Dictionary_ID","value":"798973"},{"name":"NCI_META_CUI","value":"CL973375"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798973"},{"name":"PDQ_Open_Trial_Search_ID","value":"798973"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153147":{"preferredName":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424","code":"C153147","definitions":[{"definition":"A humanized, bispecific monoclonal antibody (BsAb) targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody AMG 424 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 424","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-424","termGroup":"CN","termSource":"NCI"},{"termName":"AMG424","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD3 x Anti-CD38 Bispecific Monoclonal Antibody AMG 424","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD3/Anti-CD38 Bispecific Monoclonal Antibody AMG 424","termGroup":"SY","termSource":"NCI"},{"termName":"CD3xCD38 BsAb AMG 424","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424"},{"name":"NCI_Drug_Dictionary_ID","value":"793935"},{"name":"NCI_META_CUI","value":"CL554400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793935"},{"name":"PDQ_Open_Trial_Search_ID","value":"793935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77886":{"preferredName":"Anti-CD30 Monoclonal Antibody MDX-1401","code":"C77886","definitions":[{"definition":"A fully human, second-generation, nonfucosylated monoclonal antibody directed against the cell surface receptor CD30 with potential immunomodulating and antineoplastic activities. Anti-CD30 monoclonal antibody MDX-1401 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Compared to conventional antibodies, deletion of fucose molecules on the antibody backbone, as is done in MDX-1401, may result in an increased affinity for Fc receptors and an enhanced antibody-dependent cellular cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD30 Monoclonal Antibody MDX-1401","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-1401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD30_Monoclonal_Antibody_MDX-1401"},{"name":"Maps_To","value":"Anti-CD30 Monoclonal Antibody MDX-1401"},{"name":"NCI_Drug_Dictionary_ID","value":"592962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592962"},{"name":"PDQ_Open_Trial_Search_ID","value":"592962"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2703085"}]}}{"C74005":{"preferredName":"Anti-CD30 Monoclonal Antibody XmAb2513","code":"C74005","definitions":[{"definition":"A humanized monoclonal antibody directed against the cell surface receptor CD30 with potential immunotherapeutic activity. Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD30 Monoclonal Antibody XmAb2513","termGroup":"PT","termSource":"NCI"},{"termName":"XmAb2513","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33VWC847G8"},{"name":"Legacy Concept Name","value":"Anti-CD30_Monoclonal_Antibody_XmAb2513"},{"name":"Maps_To","value":"Anti-CD30 Monoclonal Antibody XmAb2513"},{"name":"NCI_Drug_Dictionary_ID","value":"589299"},{"name":"NCI_META_CUI","value":"CL383523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589299"},{"name":"PDQ_Open_Trial_Search_ID","value":"589299"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94219":{"preferredName":"Acimtamig","code":"C94219","definitions":[{"definition":"A tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, acimtamig binds to the CD16A expressed on natural killer (NK) cells with two of its binding sites and to CD30 on CD30-expressing tumor cells with the other two binding sites, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation, antibody-dependent cellular cytotoxicity (ADCC) and eventually tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is overexpressed in hematologic malignancies; CD16A is specifically expressed on the surface of NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acimtamig","termGroup":"PT","termSource":"NCI"},{"termName":"AFM13","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD30/CD16A Monoclonal Antibody AFM13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2738880-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ND470TT8Y3"},{"name":"Maps_To","value":"Anti-CD30/CD16A Monoclonal Antibody AFM13"},{"name":"NCI_Drug_Dictionary_ID","value":"687622"},{"name":"NCI_META_CUI","value":"CL426032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687622"},{"name":"PDQ_Open_Trial_Search_ID","value":"687622"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156458":{"preferredName":"Anti-CD32B Monoclonal Antibody BI-1206","code":"C156458","definitions":[{"definition":"A fully human monoclonal antibody targeting the Fc gamma receptor IIB (FcgRIIB; CD32B) with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, anti-CD32B monoclonal antibody BI-1206 selectively binds to CD32B, a receptor expressed on the surface of B-cells. This prevents CD32B-mediated internalization of anti-CD20 monoclonal antibodies, such as rituximab, which abrogates tumor cell resistance caused by CD32B-mediated monoclonal antibody internalization and degradation of CD32B-expressing B-cells. By blocking CD32B, BI-1206 may recover and enhance the activity of rituximab and other anti CD20 monoclonal antibodies. In addition, BI-1206 itself activates the immune system to exert an immune-mediated tumor cell death of B-cells. CD32B, an inhibitory member of the FcgammaR family, is implicated in immune cell desensitization and tumor cell resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD32B Monoclonal Antibody BI-1206","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-hFcgammaRIIB mAb BI-1206","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-hFcgRIIB Monoclonal Antibody BI-1206","termGroup":"SY","termSource":"NCI"},{"termName":"BI 1206","termGroup":"CN","termSource":"NCI"},{"termName":"BI-1206","termGroup":"CN","termSource":"NCI"},{"termName":"BI1206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"24S6PA0WXW"},{"name":"Maps_To","value":"Anti-CD32B Monoclonal Antibody BI-1206"},{"name":"NCI_Drug_Dictionary_ID","value":"795804"},{"name":"NCI_META_CUI","value":"CL563195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795804"},{"name":"PDQ_Open_Trial_Search_ID","value":"795804"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125717":{"preferredName":"Anti-CD33 Antibody-drug Conjugate IMGN779","code":"C125717","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody Z4681A conjugated, via a cleavable disulfide linker, to the cytotoxic DNA alkylating agent DGN462, which is an indolino-benzodiazepine dimer containing a mono-imine moiety, with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DGN462 conjugate IMGN779 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DGN462 moiety is released, and covalently binds to and alkylates DNA, thereby causing cell cycle arrest, apoptosis and inhibition of cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33 Antibody-drug Conjugate IMGN779","termGroup":"PT","termSource":"NCI"},{"termName":"ADC IMGN779","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33 ADC IMGN779","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN779","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YE6R3UY9IV"},{"name":"Maps_To","value":"Anti-CD33 Antibody-drug Conjugate IMGN779"},{"name":"NCI_Drug_Dictionary_ID","value":"778810"},{"name":"NCI_META_CUI","value":"CL504373"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778810"},{"name":"PDQ_Open_Trial_Search_ID","value":"778810"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135632":{"preferredName":"Vixtimotamab","code":"C135632","definitions":[{"definition":"An anti-CD33/anti-CD3 bispecific tetravalent antibody, with potential immunostimulatory and antineoplastic activities. Anti-CD33/CD3 tetravalent bispecific monoclonal antibody AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of a variety of tumor cell types. Upon infusion of vixtimotamab, this bispecific antibody binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed by a variety of cancers, including the majority of acute myeloid leukemias (AMLs), and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vixtimotamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMV 564","termGroup":"CN","termSource":"NCI"},{"termName":"AMV-564","termGroup":"CN","termSource":"NCI"},{"termName":"AMV564","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564","termGroup":"SY","termSource":"NCI"},{"termName":"CD33 x CD3 Tandem Diabody AMV-56","termGroup":"SY","termSource":"NCI"},{"termName":"CD33/CD3 TandAbs AMV564","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO-3953","termGroup":"CN","termSource":"NCI"},{"termName":"T652","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2243775-32-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56FUB33G5M"},{"name":"Maps_To","value":"Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564"},{"name":"NCI_Drug_Dictionary_ID","value":"789017"},{"name":"NCI_META_CUI","value":"CL522987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789017"},{"name":"PDQ_Open_Trial_Search_ID","value":"789017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116737":{"preferredName":"Anti-CD33 Monoclonal Antibody BI 836858","code":"C116737","definitions":[{"definition":"An engineered, fully human, immunoglobulin (Ig) G1 anti-CD33 monoclonal antibody, with potential antineoplastic activity. Upon administration, anti-CD33 monoclonal antibody BI 836858 induces an antibody-dependent cellular cytotoxicity (ADCC) against CD33-expressing tumor cells, leading to cell death. CD33, a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells, is overexpressed on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33 Monoclonal Antibody BI 836858","termGroup":"PT","termSource":"NCI"},{"termName":"BI 836858","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2206770-25-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JA7I0QFJ17"},{"name":"Maps_To","value":"Anti-CD33 Monoclonal Antibody BI 836858"},{"name":"NCI_Drug_Dictionary_ID","value":"737148"},{"name":"NCI_META_CUI","value":"CL446627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737148"},{"name":"PDQ_Open_Trial_Search_ID","value":"737148"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71523":{"preferredName":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633","code":"C71523","definitions":[{"definition":"An immunoconjugate consisting of the humanized monoclonal antibody huMy9-6 conjugated to the cytotoxic maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DM4 conjugate AVE9633 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DM4 moiety is released, binds tubulin, and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of cell division and cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells as well as on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD33-DM4_Conjugate"},{"name":"Maps_To","value":"Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633"},{"name":"NCI_Drug_Dictionary_ID","value":"575732"},{"name":"NCI_META_CUI","value":"CL378287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575732"},{"name":"PDQ_Open_Trial_Search_ID","value":"575732"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155970":{"preferredName":"Anti-CD33/CD3 Bispecific Antibody GEM 333","code":"C155970","definitions":[{"definition":"A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration of anti-CD33/CD3 bispecific antibody GEM 333, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33/CD3 Bispecific Antibody GEM 333","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD33 Bispecific Antibody GEM 333","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33/Anti-CD3 Bispecific Antibody GEM 333","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33/CD3 Antibody GEM 333","termGroup":"SY","termSource":"NCI"},{"termName":"GEM 333","termGroup":"CN","termSource":"NCI"},{"termName":"GEM-333","termGroup":"CN","termSource":"NCI"},{"termName":"GEM333","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD33/CD3 Bispecific Antibody GEM 333"},{"name":"NCI_Drug_Dictionary_ID","value":"795023"},{"name":"NCI_META_CUI","value":"CL562715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795023"},{"name":"PDQ_Open_Trial_Search_ID","value":"795023"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162296":{"preferredName":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244","code":"C162296","definitions":[{"definition":"A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD33/CD3 bispecific antibody JNJ-67571244 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen expressed on certain tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in CTL-mediated killing of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 67571244","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-67571244","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ67571244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD33/CD3 Bispecific Antibody JNJ-67571244"},{"name":"NCI_Drug_Dictionary_ID","value":"798705"},{"name":"NCI_META_CUI","value":"CL970869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798705"},{"name":"PDQ_Open_Trial_Search_ID","value":"798705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123332":{"preferredName":"Eluvixtamab","code":"C123332","definitions":[{"definition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eluvixtamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 330","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-330","termGroup":"CN","termSource":"NCI"},{"termName":"AMG330","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD33/CD3 BiTE Antibody AMG 330","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 330","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 330","termGroup":"SY","termSource":"NCI"},{"termName":"CD33/CD3-directed Bispecific T-cell Engager Antibody AMG 330","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1679391-73-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6Z4B5PJ4OP"},{"name":"Maps_To","value":"Anti-CD33/CD3 BiTE Antibody AMG 330"},{"name":"NCI_Drug_Dictionary_ID","value":"775135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775135"},{"name":"PDQ_Open_Trial_Search_ID","value":"775135"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3851031"}]}}{"C175778":{"preferredName":"Emerfetamab","code":"C175778","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emerfetamab binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emerfetamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 673","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-673","termGroup":"CN","termSource":"NCI"},{"termName":"AMG673","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD33 x Anti-CD3 BiTE AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD33/CD3 BiTE Antibody AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 673","termGroup":"SY","termSource":"NCI"},{"termName":"CD33/CD3-directed Bispecific T-cell Engager Antibody AMG 673","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2250261-27-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HOG226RYH1"},{"name":"Maps_To","value":"Anti-CD33/CD3 BiTE Antibody AMG 673"},{"name":"NCI_Drug_Dictionary_ID","value":"792374"},{"name":"NCI_META_CUI","value":"CL545041"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131174":{"preferredName":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A","code":"C131174","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an engineered cysteine humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) that is conjugated to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD352 ADC SGN-CD352A, the antibody moiety targets the cell surface antigen CD352. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD352-overexpressing tumor cells. CD352, a tumor-associated antigen (TAA), is overexpressed on a variety of cancers. Cysteine engineering of the monoclonal antibody allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"PBD Dimer ADC SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"PBD-based Anti-CD352 ADC SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"PBD-based Anti-CD352 Antibody-drug Conjugate SGN-CD352A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-CD352A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZX1I49XP7L"},{"name":"Maps_To","value":"Anti-CD352 Antibody-drug Conjugate SGN-CD352A"},{"name":"NCI_Drug_Dictionary_ID","value":"785477"},{"name":"NCI_META_CUI","value":"CL513495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785477"},{"name":"PDQ_Open_Trial_Search_ID","value":"785477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C100101":{"preferredName":"Naratuximab Emtansine","code":"C100101","definitions":[{"definition":"An immunoconjugate that consists of a humanized IgG1 antibody K7153A against the cell-surface antigen CD37 and covalently linked via the uncleavable, maleimide-derived thioether-based linker SMCC to the maytansinoid DM1, with potential pro-apoptotic and cytotoxic activities. Upon administration of naratuximab emtansine, the antibody moiety of IMGN529 binds to CD37 on tumor B-cells and induces an antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and eventually causing cell death in CD37-positive B-cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies. Compared to reducible, cleavable linkers, the non-reducible SMCC linker shows increased stability in plasma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naratuximab Emtansine","termGroup":"PT","termSource":"NCI"},{"termName":"IMGN529","termGroup":"CN","termSource":"NCI"},{"termName":"MP 529","termGroup":"CN","termSource":"NCI"},{"termName":"MP-529","termGroup":"CN","termSource":"NCI"},{"termName":"MP529","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1607824-64-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WE1X5A83B9"},{"name":"Maps_To","value":"Anti-CD37 Antibody-Drug Conjugate IMGN529"},{"name":"Maps_To","value":"Naratuximab Emtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"727107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"727107"},{"name":"PDQ_Open_Trial_Search_ID","value":"727107"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3639093"}]}}{"C119700":{"preferredName":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E","code":"C119700","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of AGS67C, a human anti-CD37 monoclonal antibody covalently linked, via reduced cysteines and a protease cleavable linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AGS67E binds to CD37 antigens on tumor B-cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E","termGroup":"PT","termSource":"NCI"},{"termName":"AGS67E","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD37 MMAE ADC AGS67E","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD37 MMAE Antibody-drug Conjugate AGS67E"},{"name":"NCI_Drug_Dictionary_ID","value":"762606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762606"},{"name":"PDQ_Open_Trial_Search_ID","value":"762606"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896733"}]}}{"C122833":{"preferredName":"Anti-CD37 Monoclonal Antibody BI 836826","code":"C122833","definitions":[{"definition":"An Fc-engineered, chimeric immunoglobulin (Ig) G1 monoclonal antibody against the tumor-associated antigen (TAA) CD37, with potential antineoplastic activity. Upon administration, the anti-CD37 monoclonal antibody BI 836826 both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. BI 836826 is Fc-engineered to improve ADCC activity and enhance affinity for the receptor Fc-gamma-RIIIa, which is expressed on human natural killer (NK) cells. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD37 Monoclonal Antibody BI 836826","termGroup":"PT","termSource":"NCI"},{"termName":"BI 836826","termGroup":"CN","termSource":"NCI"},{"termName":"MAb 37.1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LB090AB8DB"},{"name":"Maps_To","value":"Anti-CD37 Monoclonal Antibody BI 836826"},{"name":"NCI_Drug_Dictionary_ID","value":"695895"},{"name":"NCI_META_CUI","value":"CL433789"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695895"},{"name":"PDQ_Open_Trial_Search_ID","value":"695895"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97954":{"preferredName":"Felzartamab","code":"C97954","definitions":[{"definition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Felzartamab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Felzartamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38 Monoclonal Antibody MOR03087","termGroup":"SY","termSource":"NCI"},{"termName":"MOR03087","termGroup":"CN","termSource":"NCI"},{"termName":"MOR202","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2197112-39-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3O9FA4XC02"},{"name":"Maps_To","value":"Anti-CD38 Monoclonal Antibody MOR03087"},{"name":"Maps_To","value":"Felzartamab"},{"name":"NCI_Drug_Dictionary_ID","value":"710408"},{"name":"NCI_META_CUI","value":"CL430560"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710408"},{"name":"PDQ_Open_Trial_Search_ID","value":"710408"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148078":{"preferredName":"Mezagitamab","code":"C148078","definitions":[{"definition":"A human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. Mezagitamab specifically binds to CD38 that is expressed on human plasmablasts, plasma cells, NK cells and activated T- and B-cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), cell lysis and depletion of CD38-expressing cells. Additionally, TAK-079 does not induce CD38-dependent signaling and does not promote cytokine activation in peripheral blood mononuclear cells (PMBCs). CD38, a type II transmembrane glycoprotein, is overexpressed on cells associated with autoimmune diseases and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mezagitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38 MAb TAK-079","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 079","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-079","termGroup":"CN","termSource":"NCI"},{"termName":"TAK079","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2227490-52-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0XMR8L9LOL"},{"name":"Maps_To","value":"Anti-CD38 Monoclonal Antibody TAK-079"},{"name":"Maps_To","value":"Mezagitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"795705"},{"name":"NCI_META_CUI","value":"CL545882"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795705"},{"name":"PDQ_Open_Trial_Search_ID","value":"795705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C140427":{"preferredName":"Modakafusp Alfa","code":"C140427","definitions":[{"definition":"A proprietary preparation composed of an immunoglobulin G4 (IgG4) directed against the cell surface glycoprotein CD-38 (CD38) that is fused to an attenuated form of human interferon alpha (IFN alpha; IFNa), with potential immunomodulating and antineoplastic activities. Upon administration, modakafusp alfa specifically targets and binds to CD38 on CD38-positive tumor cells. In turn, the IFNa moiety binds to cell-surface IFN receptors, and activates IFN-mediated signal transduction pathways, which results in the transcription and translation of genes whose products may cause antiproliferative effects in CD38-positive tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modakafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38-targeted IgG4-attenuated IFNa TAK-573","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-targeted IgG4 Fused with Attenuated IFNa","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-573","termGroup":"CN","termSource":"NCI"},{"termName":"TEV-48573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254522-19-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TN8CEX4UT2"},{"name":"Maps_To","value":"Anti-CD38-targeted IgG4-attenuated IFNa TAK-573"},{"name":"Maps_To","value":"Modakafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"791259"},{"name":"NCI_META_CUI","value":"CL538488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791259"},{"name":"PDQ_Open_Trial_Search_ID","value":"791259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147563":{"preferredName":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342","code":"C147563","definitions":[{"definition":"A humanized, bispecific monoclonal antibody (BsAb) against human CD3, a T-cell surface antigen, and the human cell surface glycoprotein CD38, a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD38/anti-CD3 bispecific monoclonal antibody GBR 1342 binds to both CD3 on T-cells and CD38 expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis. GBR 1342 uses the proprietary bispecific engagement by antibodies based on the T-cell receptor (BEAT) platform.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD38 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38/Anti-CD3 Bispecific Monoclonal Antibody GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"BEAT GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"CD38xCD3 BsAb GBR 1342","termGroup":"SY","termSource":"NCI"},{"termName":"GBR 1342","termGroup":"CN","termSource":"NCI"},{"termName":"GBR-1342","termGroup":"CN","termSource":"NCI"},{"termName":"GBR1342","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7H3Q0M9END"},{"name":"Maps_To","value":"Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342"},{"name":"NCI_Drug_Dictionary_ID","value":"792483"},{"name":"NCI_META_CUI","value":"CL545397"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792483"},{"name":"PDQ_Open_Trial_Search_ID","value":"792483"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162693":{"preferredName":"Anti-CD39 Monoclonal Antibody TTX-030","code":"C162693","definitions":[{"definition":"A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody TTX-030 specifically binds to the CD39 antigen, which may inhibit both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may promote the stimulation of dendritic and other myeloid-derived cells that are necessary for both innate and adaptive immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD39 Monoclonal Antibody TTX-030","termGroup":"PT","termSource":"NCI"},{"termName":"TTX 030","termGroup":"CN","termSource":"NCI"},{"termName":"TTX-030","termGroup":"CN","termSource":"NCI"},{"termName":"TTX030","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD39 Monoclonal Antibody TTX-030"},{"name":"NCI_Drug_Dictionary_ID","value":"798967"},{"name":"NCI_META_CUI","value":"CL973084"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798967"},{"name":"PDQ_Open_Trial_Search_ID","value":"798967"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139553":{"preferredName":"Giloralimab","code":"C139553","definitions":[{"definition":"An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, giloralimab binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giloralimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-927","termGroup":"CN","termSource":"NCI"},{"termName":"Agonistic Anti-CD40 Monoclonal Antibody ABBV-927","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Agonist Monoclonal Antibody ABBV-927","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Monoclonal Antibody ABBV-927","termGroup":"SY","termSource":"NCI"},{"termName":"PR-1614645","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226292-20-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6C58X3BFH"},{"name":"Maps_To","value":"Anti-CD40 Agonist Monoclonal Antibody ABBV-927"},{"name":"Maps_To","value":"Giloralimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791105"},{"name":"NCI_META_CUI","value":"CL526913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791105"},{"name":"PDQ_Open_Trial_Search_ID","value":"791105"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150558":{"preferredName":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","code":"C150558","definitions":[{"definition":"A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","termGroup":"PT","termSource":"NCI"},{"termName":"Agonist CD40 Antibody CDX-1140","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Agonistic Monoclonal Antibody CDX-1140","termGroup":"SY","termSource":"NCI"},{"termName":"CDX 1140","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-1140","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OWK8BG0FO6"},{"name":"Maps_To","value":"Anti-CD40 Agonist Monoclonal Antibody CDX-1140"},{"name":"NCI_Drug_Dictionary_ID","value":"793440"},{"name":"NCI_META_CUI","value":"CL552359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793440"},{"name":"PDQ_Open_Trial_Search_ID","value":"793440"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101366":{"preferredName":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4","code":"C101366","definitions":[{"definition":"An IgG1 chimeric monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-CD40 monoclonal antibody Chi Lob 7/4 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent binds to the CD40 antigen present on the surfaces of some solid tumor cells, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) eventually resulting in decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and many solid tumors, mediating both indirect tumor cell death through the activation of the immune system and direct tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4","termGroup":"PT","termSource":"NCI"},{"termName":"Chi Lob 7/4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD40 Monoclonal Antibody Chi Lob 7/4"},{"name":"NCI_Drug_Dictionary_ID","value":"729807"},{"name":"NCI_META_CUI","value":"CL435546"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729807"},{"name":"PDQ_Open_Trial_Search_ID","value":"729807"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121217":{"preferredName":"Cifurtilimab","code":"C121217","definitions":[{"definition":"A proprietary, non-fucosylated monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, cifurtilimab binds to CD40 on a variety of immune cell types, triggering both cellular proliferation and activation of antigen-presenting cells (APCs), which activates B-cells and T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC), and eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system. The non-fucosylated antibody shows increased efficacy as compared to its fucosylated counterpart.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cifurtilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD40 Monoclonal Antibody SEA-CD40","termGroup":"SY","termSource":"NCI"},{"termName":"SEA CD40","termGroup":"CN","termSource":"NCI"},{"termName":"SEA-CD40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BY4DOG9SMH"},{"name":"Maps_To","value":"Anti-CD40 Monoclonal Antibody SEA-CD40"},{"name":"NCI_Drug_Dictionary_ID","value":"769820"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769820"},{"name":"PDQ_Open_Trial_Search_ID","value":"769820"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053590"}]}}{"C132681":{"preferredName":"Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428","code":"C132681","definitions":[{"definition":"A bispecific antibody directed against both the cell-surface receptor CD40 and the tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunostimulatory and antineoplastic activities. Upon administration of anti-CD40/anti-MSLN bispecific antibody ABBV-428, the anti-MSLN moiety targets and binds to MSLN expressed on tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells in the tumor microenvironment (TME) and induces CD40-dependent signaling pathways, which triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B-lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 428","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-428","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD40 x Anti-mesothelin Bispecific Antibody ABBV-428","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40/Anti-MSLN Bispecific Antibody ABBV-428","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428"},{"name":"NCI_Drug_Dictionary_ID","value":"787098"},{"name":"NCI_META_CUI","value":"CL520571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787098"},{"name":"PDQ_Open_Trial_Search_ID","value":"787098"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120140":{"preferredName":"Letolizumab","code":"C120140","definitions":[{"definition":"A dimeric fusion protein composed of the C-terminus of the domain antibody (dAb) BMS2h-572-633 targeting the CD40 ligand (CD40L or CD154) linked to a modified Fc fragment of immunoglobulin G1 (IgG1), with potential immunomodulatory activity. Upon intravenous administration, the peptide moiety of letolizumab specifically targets and binds to CD40L expressed on T-lymphocytes. This prevents the binding of CD40L to its cognate receptor CD40 expressed on B-lymphocytes, macrophages, and dendritic cells (DCs). This prevents T-cell mediated proliferation and differentiation of B-cells, and prevents the production of antibodies. By inhibiting both the production of anti-glycoprotein (GP) IIb/IIIa antibodies by B-cells and GPIIb/IIIa-dependent T-cell proliferation, letolizumab may prevent platelet destruction and may increase platelet counts in idiopathic thrombocytopenic purpura (ITP). The direct binding of letolizumab to CD40L on platelets further prevents CD40L/CD40-mediated destruction by macrophages and DCs in ITP. The modified Fc domain prevents the binding of letolizumab to the Fc receptor FcgammaRIIA on platelets, thereby preventing FcgammaRIIA-dependent platelet activation and anti-CD40L-induced thromboembolism. CD40L, a transmembrane protein of the tumor necrosis factor (TNF) superfamily, is primarily expressed on activated T-cells, but is also expressed on eosinophils, basophils, natural killer (NK) cells, mast cells, platelets and activated endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986004","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986004","termGroup":"CN","termSource":"NCI"},{"termName":"Fc-Fusion Protein BMS986004","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1450981-87-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"449MIE2SD6"},{"name":"Maps_To","value":"Anti-CD40L Fc-Fusion Protein BMS-986004"},{"name":"Maps_To","value":"Letolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"773819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"773819"},{"name":"PDQ_Open_Trial_Search_ID","value":"773819"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896896"}]}}{"C116881":{"preferredName":"Anti-CD44 Monoclonal Antibody RO5429083","code":"C116881","definitions":[{"definition":"A recombinant, humanized monoclonal antibody targeting the cancer stem cell (CSC) antigen CD44, with potential immunomodulating and antineoplastic activities. Upon administration, RO5429083 binds to the constant region of the extracellular domain of CD44, thereby preventing the activation of various CD44-mediated signal transduction pathways. This may lead to a reduction in the proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in tumor cell proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD44 Monoclonal Antibody RO5429083","termGroup":"PT","termSource":"NCI"},{"termName":"RG 7356","termGroup":"CN","termSource":"NCI"},{"termName":"RO5429083","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0T69CA5LQA"},{"name":"Maps_To","value":"Anti-CD44 Monoclonal Antibody RO5429083"},{"name":"NCI_Drug_Dictionary_ID","value":"701281"},{"name":"NCI_META_CUI","value":"CL433841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701281"},{"name":"PDQ_Open_Trial_Search_ID","value":"701281"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74009":{"preferredName":"Anti-CD45 Monoclonal Antibody AHN-12","code":"C74009","definitions":[{"definition":"A high affinity IgG1 monoclonal antibody with potential immunotherapeutic activity. Anti-CD45 monoclonal antibody AHN-12 recognizes CD45, a transmembrane protein tyrosine phosphatase that is expressed on the surface of normal and malignant hematopoietic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD45 Monoclonal Antibody AHN-12","termGroup":"PT","termSource":"NCI"},{"termName":"AHN-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD45_Monoclonal_Antibody_AHN-12"},{"name":"Maps_To","value":"Anti-CD45 Monoclonal Antibody AHN-12"},{"name":"NCI_Drug_Dictionary_ID","value":"587980"},{"name":"NCI_META_CUI","value":"CL383504"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587980"},{"name":"PDQ_Open_Trial_Search_ID","value":"587980"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156416":{"preferredName":"Anti-CD46 Antibody-drug Conjugate FOR46","code":"C156416","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and conjugated to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon administration, anti-CD46 ADC FOR46 specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. Upon binding and internalization, the cytotoxic payload kills the CD46-expressing tumor cells. The conformational epitope of CD46 is highly expressed in multiple tumor cell types while minimally expressed or absent in normal, healthy tissues.  FOR46 does not interfere with other CD46-mediated pathways that naturally occur in normal, healthy tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD46 Antibody-drug Conjugate FOR46","termGroup":"PT","termSource":"NCI"},{"termName":"ADC FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD46 ADC FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"CD46-ADC FOR46","termGroup":"SY","termSource":"NCI"},{"termName":"FOR 46","termGroup":"CN","termSource":"NCI"},{"termName":"FOR-46","termGroup":"CN","termSource":"NCI"},{"termName":"FOR46","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD46 Antibody-drug Conjugate FOR46"},{"name":"NCI_Drug_Dictionary_ID","value":"795803"},{"name":"NCI_META_CUI","value":"CL563108"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795803"},{"name":"PDQ_Open_Trial_Search_ID","value":"795803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159600":{"preferredName":"Anti-CD47 Monoclonal Antibody AO-176","code":"C159600","definitions":[{"definition":"A humanized immunoglobulin G2 (IgG2) monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody AO-176 preferentially binds to CD47 on tumor cells because it exhibits enhanced binding at the acidic pH found in the tumor microenvironment (TME). This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. In addition, AO-176 induces immunogenic cell death (ICD) and releases damage-associated molecular patterns (DAMPs) from tumor cells, thereby further stimulating immune responses. AO-176 is also able to induce direct cytotoxic cell death by a cell autonomous mechanism. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody AO-176","termGroup":"PT","termSource":"NCI"},{"termName":"AO 176","termGroup":"CN","termSource":"NCI"},{"termName":"AO-176","termGroup":"CN","termSource":"NCI"},{"termName":"AO176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody AO-176"},{"name":"NCI_Drug_Dictionary_ID","value":"797803"},{"name":"NCI_META_CUI","value":"CL951599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797803"},{"name":"PDQ_Open_Trial_Search_ID","value":"797803"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C121211":{"preferredName":"Anti-CD47 Monoclonal Antibody CC-90002","code":"C121211","definitions":[{"definition":"A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody CC-90002","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Mab CC-90002","termGroup":"SY","termSource":"NCI"},{"termName":"CC 90002","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody CC-90002"},{"name":"NCI_Drug_Dictionary_ID","value":"769566"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769566"},{"name":"PDQ_Open_Trial_Search_ID","value":"769566"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053657"}]}}{"C117730":{"preferredName":"Magrolimab","code":"C117730","definitions":[{"definition":"A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, magrolimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Magrolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Hu5F9-G4","termGroup":"CN","termSource":"NCI"},{"termName":"ONO 7913","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-7913","termGroup":"CN","termSource":"NCI"},{"termName":"ONO7913","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169232-81-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"90YIEHRFJ9"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody Hu5F9-G4"},{"name":"Maps_To","value":"Magrolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"763907"},{"name":"NCI_META_CUI","value":"CL474125"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763907"},{"name":"PDQ_Open_Trial_Search_ID","value":"763907"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157385":{"preferredName":"Letaplimab","code":"C157385","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, letaplimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letaplimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Monoclonal Antibody IBI188","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 188","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-188","termGroup":"CN","termSource":"NCI"},{"termName":"IBI188","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2283356-07-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BDN84I1TFE"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody IBI188"},{"name":"NCI_Drug_Dictionary_ID","value":"797112"},{"name":"NCI_META_CUI","value":"CL936985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797112"},{"name":"PDQ_Open_Trial_Search_ID","value":"797112"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160202":{"preferredName":"Anti-CD47 Monoclonal Antibody SHR-1603","code":"C160202","definitions":[{"definition":"A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SHR-1603 preferentially binds to CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody SHR-1603","termGroup":"PT","termSource":"NCI"},{"termName":"SHR 1603","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1603","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1603","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody SHR-1603"},{"name":"NCI_Drug_Dictionary_ID","value":"797797"},{"name":"NCI_META_CUI","value":"CL969337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797797"},{"name":"PDQ_Open_Trial_Search_ID","value":"797797"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C155976":{"preferredName":"Urabrelimab","code":"C155976","definitions":[{"definition":"A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, urabrelimab selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urabrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Monoclonal Antibody SRF231","termGroup":"SY","termSource":"NCI"},{"termName":"SRF 231","termGroup":"CN","termSource":"NCI"},{"termName":"SRF-231","termGroup":"CN","termSource":"NCI"},{"termName":"SRF231","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249722-58-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6284A5K8N"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody SRF231"},{"name":"Maps_To","value":"Urabrelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795110"},{"name":"NCI_META_CUI","value":"CL562712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795110"},{"name":"PDQ_Open_Trial_Search_ID","value":"795110"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163977":{"preferredName":"Lemzoparlimab","code":"C163977","definitions":[{"definition":"A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, lemzoparlimab preferentially binds to a unique epitope of CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. TJC4, compared to other anti-CD47 monoclonal antibodies, is designed to minimize inherent binding to normal red blood cells (RBCs), which may results in a more advantageous hematologic safety profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lemzoparlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47 Monoclonal Antibody TJC4","termGroup":"SY","termSource":"NCI"},{"termName":"TJ 011133","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-011133","termGroup":"CN","termSource":"NCI"},{"termName":"TJ011133","termGroup":"CN","termSource":"NCI"},{"termName":"TJC4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2377483-71-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0H2XLR2IKW"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody TJC4"},{"name":"NCI_Drug_Dictionary_ID","value":"801670"},{"name":"NCI_META_CUI","value":"CL977248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801670"},{"name":"PDQ_Open_Trial_Search_ID","value":"801670"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148103":{"preferredName":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A","code":"C148103","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody targeting the cell surface antigen CD48 that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary next-generation PEGylated glucuronide linker, with potential antineoplastic activity. Following intravenous administration, the antibody moiety of anti-CD48 ADC SGN-CD48A binds to CD48 on the surface of tumor cells. Following internalization of the ADC, the MMAE binds to tubulin and inhibits microtubule polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in CD48-expressing tumor cells. CD48, a member of the signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, is involved in T-cell activation and leukocyte trafficking. Additionally, CD48 is expressed on the surface of multiple myeloma cells at significantly higher levels than it is expressed on normal lymphocytes and monocytes. The linkage system in SGN-CD48A improves stability, reduces off-target uptake, and enables conjugation of larger numbers of MMAE/antibody than other systems, resulting in increased specificity against CD48-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD48 ADC SGN-CD48A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD48A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD48A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD48A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A"},{"name":"NCI_Drug_Dictionary_ID","value":"794392"},{"name":"NCI_META_CUI","value":"CL545862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794392"},{"name":"PDQ_Open_Trial_Search_ID","value":"794392"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160787":{"preferredName":"Anti-CD52 Monoclonal Antibody ALLO-647","code":"C160787","definitions":[{"definition":"A monoclonal antibody directed against the cell surface glycoprotein CD52 (CAMPATH-1 antigen; Cambridge pathology 1 antigen), with potential immunodepleting activity. Upon administration, anti-CD52 monoclonal antibody ALLO-647 selectively targets and binds to CD52, thereby triggering a host immune response that results in the lysis of CD52-positive lymphocytes. This leads to immunodepletion and may prevent graft-versus-host disease (GvHD). CD52 is a glycoprotein expressed on the surface of many immune cells, including essentially all B- and T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD52 Monoclonal Antibody ALLO-647","termGroup":"PT","termSource":"NCI"},{"termName":"ALLO 647","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-647","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO647","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD52 Monoclonal Antibody ALLO-647"},{"name":"NCI_Drug_Dictionary_ID","value":"798418"},{"name":"NCI_META_CUI","value":"CL969759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798418"},{"name":"PDQ_Open_Trial_Search_ID","value":"798418"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C84855":{"preferredName":"Anti-CD70 Antibody-Drug Conjugate MDX-1203","code":"C84855","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to a prodrug of a CC-1065 (rachelmycin) analogue via a stable peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate MDX-1203 selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the prodrug moiety is released and activated and binds to double-stranded B-DNA within the minor groove, thereby alkylating the -3 position of adenine, which may result in the inhibition of cellular proliferation of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The antitumor antibiotic CC-1065, a DNA minor-groove-binding alkylating agent, was originally isolated from the bacterium Streptomyces zelensis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 Antibody-Drug Conjugate MDX-1203","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 ADC MDX-1203","termGroup":"SY","termSource":"NCI"},{"termName":"MDX-1203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD70 Antibody-Drug Conjugate MDX-1203"},{"name":"NCI_Drug_Dictionary_ID","value":"651385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651385"},{"name":"PDQ_Open_Trial_Search_ID","value":"651385"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827532"}]}}{"C117732":{"preferredName":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A","code":"C117732","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing an engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70 molecule, conjugated to the synthetic, cytotoxic, DNA minor-groove crosslinking agent, pyrrolobenzodiazepine (PBD) dimer, via a stable, protease-cleavable, peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate SGN-CD70A selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the PBD dimer moiety is released and covalently binds, through its imine moieties, to the N2 positions of guanines on opposite strands of DNA. This induces DNA double strand breaks and inhibits DNA replication, which lead to the inhibition of cell growth of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The cysteine moiety of the EC-mAb allows for the stable conjugation of the PBD to the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A","termGroup":"PT","termSource":"NCI"},{"termName":"SGN-CD70A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1447736-02-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YFZ7N482WG"},{"name":"Maps_To","value":"Anti-CD70 Antibody-drug Conjugate SGN-CD70A"},{"name":"NCI_Drug_Dictionary_ID","value":"763909"},{"name":"NCI_META_CUI","value":"CL474127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763909"},{"name":"PDQ_Open_Trial_Search_ID","value":"763909"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162699":{"preferredName":"Anti-CD70 CAR-expressing T Lymphocytes","code":"C162699","definitions":[{"definition":"A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 CAR-expressing T Lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 CAR-expressing T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD70 CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD70 CAR T-lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD70 CAR-expressing T Lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"810124"},{"name":"NCI_META_CUI","value":"CL973102"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78187":{"preferredName":"Anti-CD70 Monoclonal Antibody MDX-1411","code":"C78187","definitions":[{"definition":"A glycoengineered, fully human IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Anti-CD70 fully human monoclonal antibody MDX-1411 selectivity binds to the extracellular domain of CD70, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on renal cell carcinoma (RCC) cells among other cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD70 Monoclonal Antibody MDX-1411","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-1411","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CD70_Fully_Human_Monoclonal_Antibody_MDX-1411"},{"name":"Maps_To","value":"Anti-CD70 Monoclonal Antibody MDX-1411"},{"name":"NCI_Drug_Dictionary_ID","value":"594769"},{"name":"NCI_META_CUI","value":"CL383579"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594769"},{"name":"PDQ_Open_Trial_Search_ID","value":"594769"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153287":{"preferredName":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029","code":"C153287","definitions":[{"definition":"A probody-drug conjugate (PDC) composed of a monoclonal antibody directed against the transferrin receptor 1 (TFR1;TRP1; CD71), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, and conjugated, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of the anti-CD71/vcMMAE PDC CX-2029, the anti-CD71 moiety is unable to bind to CD71 antigen, which is highly expressed on both tumor and healthy dividing cells, until the masking peptide that is attached to the anti-CD71 probody is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Local protease-mediated removal of the linker and masking peptide enables specific binding of the unmasked anti-CD71 moiety to CD71 expressed on tumor cells. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of CD71-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. CD71, a transmembrane glycoprotein, is a highly expressed protein present in a number of solid and hematologic cancers, but is also expressed on normal, healthy tissues. The peptide masking of CX-2029 minimizes binding of the anti-CD71 antibody moiety to normal, healthy cells and may minimize systemic toxicity, when compared to other anti-CD71 antibody-drug conjugates (ADCs). Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD71 Probody/vcMMAE Drug Conjugate CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody Prodrug-drug Conjugate CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"CD71-directed PDC CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"CD71-Directed Probody Therapeutic CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"CX 2029","termGroup":"CN","termSource":"NCI"},{"termName":"CX-2029","termGroup":"CN","termSource":"NCI"},{"termName":"CX2029","termGroup":"CN","termSource":"NCI"},{"termName":"PBC CX-2029","termGroup":"SY","termSource":"NCI"},{"termName":"PDC-targeting CD71 CX-2029","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029"},{"name":"NCI_Drug_Dictionary_ID","value":"794073"},{"name":"NCI_META_CUI","value":"CL554515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794073"},{"name":"PDQ_Open_Trial_Search_ID","value":"794073"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132266":{"preferredName":"Anti-CD73 Monoclonal Antibody BMS-986179","code":"C132266","definitions":[{"definition":"A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody BMS-986179 targets and binds to CD73, leading to clustering and internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD73 Monoclonal Antibody BMS-986179","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986179","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7PO9B4VQ1U"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody BMS-986179"},{"name":"NCI_Drug_Dictionary_ID","value":"783651"},{"name":"NCI_META_CUI","value":"CL520363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783651"},{"name":"PDQ_Open_Trial_Search_ID","value":"783651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156061":{"preferredName":"Mupadolimab","code":"C156061","definitions":[{"definition":"A type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, mupadolimab targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mupadolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD73 Monoclonal Antibody CPI-006","termGroup":"SY","termSource":"NCI"},{"termName":"CPI 006","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-006","termGroup":"CN","termSource":"NCI"},{"termName":"CPI006","termGroup":"CN","termSource":"NCI"},{"termName":"CPX-006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2451856-97-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23ET6940RM"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody CPI-006"},{"name":"NCI_Drug_Dictionary_ID","value":"795397"},{"name":"NCI_META_CUI","value":"CL562920"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795397"},{"name":"PDQ_Open_Trial_Search_ID","value":"795397"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C158132":{"preferredName":"Anti-CD73 Monoclonal Antibody NZV930","code":"C158132","definitions":[{"definition":"A fully human monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-CD73 monoclonal antibody NZV930 targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated in many cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD73 Monoclonal Antibody NZV930","termGroup":"PT","termSource":"NCI"},{"termName":"NZV 930","termGroup":"CN","termSource":"NCI"},{"termName":"NZV-930","termGroup":"CN","termSource":"NCI"},{"termName":"NZV930","termGroup":"CN","termSource":"NCI"},{"termName":"SRF 373","termGroup":"CN","termSource":"NCI"},{"termName":"SRF-373","termGroup":"SY","termSource":"NCI"},{"termName":"SRF373","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2M0F9Q9SZ2"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody NZV930"},{"name":"NCI_Drug_Dictionary_ID","value":"797358"},{"name":"NCI_META_CUI","value":"CL937671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797358"},{"name":"PDQ_Open_Trial_Search_ID","value":"797358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159168":{"preferredName":"Uliledlimab","code":"C159168","definitions":[{"definition":"A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, uliledlimab targets and binds to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uliledlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD73 Monoclonal Antibody TJ4309","termGroup":"SY","termSource":"NCI"},{"termName":"TJ 004309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ 4309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-004309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-4309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ004309","termGroup":"CN","termSource":"NCI"},{"termName":"TJ4309","termGroup":"CN","termSource":"NCI"},{"termName":"TJD5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2378407-27-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3OX1DBR75G"},{"name":"Maps_To","value":"Anti-CD73 Monoclonal Antibody TJ4309"},{"name":"NCI_Drug_Dictionary_ID","value":"797647"},{"name":"NCI_META_CUI","value":"CL951040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797647"},{"name":"PDQ_Open_Trial_Search_ID","value":"797647"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148066":{"preferredName":"Anti-CD74 Antibody-drug Conjugate STRO-001","code":"C148066","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. The antibody moiety of anti-CD74 ADC STRO-001 targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD74 Antibody-drug Conjugate STRO-001","termGroup":"PT","termSource":"NCI"},{"termName":"ADC STRO-001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD74 ADC STRO-001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD74 Antibody-drug Conjugate BN301","termGroup":"SY","termSource":"NCI"},{"termName":"BN 301","termGroup":"CN","termSource":"NCI"},{"termName":"BN-301","termGroup":"CN","termSource":"NCI"},{"termName":"BN301","termGroup":"CN","termSource":"NCI"},{"termName":"SP7675","termGroup":"CN","termSource":"NCI"},{"termName":"STRO-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0D8BWL78LD"},{"name":"Maps_To","value":"Anti-CD74 Antibody-drug Conjugate STRO-001"},{"name":"NCI_Drug_Dictionary_ID","value":"795302"},{"name":"NCI_META_CUI","value":"CL545806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795302"},{"name":"PDQ_Open_Trial_Search_ID","value":"795302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113659":{"preferredName":"Anti-CD98 Monoclonal Antibody IGN523","code":"C113659","definitions":[{"definition":"A humanized, monoclonal antibody targeting the CD98 (gp125) antigen, with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, IGN523 binds to CD98 expressed on the tumor cell surface and elicits both natural killer (NK)-cell mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity towards CD98-expressing tumor cells. In addition, IGN523 inhibits essential amino acid uptake by rapidly proliferating tumor cells. CD98, a type II transmembrane glycoprotein, is involved in both integrin signaling and amino acid transport processes; it is overexpressed in certain cancer cells and plays a key role in the proliferation, survival and metastasis of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD98 Monoclonal Antibody IGN523","termGroup":"PT","termSource":"NCI"},{"termName":"IGN523","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2206820-08-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7OI79TB6KN"},{"name":"Maps_To","value":"Anti-CD98 Monoclonal Antibody IGN523"},{"name":"NCI_Drug_Dictionary_ID","value":"757070"},{"name":"NCI_META_CUI","value":"CL458372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757070"},{"name":"PDQ_Open_Trial_Search_ID","value":"757070"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131439":{"preferredName":"Anti-CDH6 Antibody-drug Conjugate HKT288","code":"C131439","definitions":[{"definition":"An immunoconjugate consisting of a human monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated to a maytansine-based cytotoxic agent, with potential antineoplastic activity. The monoclonal antibody moiety of HKT288 targets and binds to CDH6 located on tumor cell surfaces. After internalization, the maytansine moiety binds to tubulin, which disrupts microtubule assembly/disassembly dynamics and inhibits both division and proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CDH6 Antibody-drug Conjugate HKT288","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CDH6 ADC HKT288","termGroup":"SY","termSource":"NCI"},{"termName":"HKT 288","termGroup":"CN","termSource":"NCI"},{"termName":"HKT-288","termGroup":"CN","termSource":"NCI"},{"termName":"HKT288","termGroup":"CN","termSource":"NCI"},{"termName":"Maytansine-based ADC HKT-288","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"94ZE6ON35F"},{"name":"Maps_To","value":"Anti-CDH6 Antibody-drug Conjugate HKT288"},{"name":"NCI_Drug_Dictionary_ID","value":"786265"},{"name":"NCI_META_CUI","value":"CL514241"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786265"},{"name":"PDQ_Open_Trial_Search_ID","value":"786265"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95728":{"preferredName":"Anti-CEA BiTE Monoclonal Antibody AMG211","code":"C95728","definitions":[{"definition":"A recombinant, proprietary bispecific T-cell engagers (BiTE) antibody directed against human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Anti-CEA BiTE monoclonal antibody AMG211 possesses two antigen-recognition sites, one for CEA and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings CEA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CEA-expressing cells. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEA BiTE Monoclonal Antibody AMG211","termGroup":"PT","termSource":"NCI"},{"termName":"AMG211","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-565","termGroup":"CN","termSource":"NCI"},{"termName":"MT111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CEA BiTE Monoclonal Antibody AMG211"},{"name":"NCI_Drug_Dictionary_ID","value":"694640"},{"name":"NCI_META_CUI","value":"CL428189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694640"},{"name":"PDQ_Open_Trial_Search_ID","value":"694640"},{"name":"PubMedID_Primary_Reference","value":"19342971"},{"name":"PubMedID_Primary_Reference","value":"19953093"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68927":{"preferredName":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody","code":"C68927","definitions":[{"definition":"A bispecific monoclonal antibody (BsMAb) consisting of the Fab fragment of an anti-CEA monoclonal antibody (F6) coupled to the Fab fragment of an anti-DTPA-In monoclonal antibody (734) with potential radioimmunotherapeutic activity. In a two-step pretargeted radioimmunotherapeutic approach, this BsMAb, localizing to CEA-expressing tumor cells via the F6 Fab fragment, is introduced into patient first, followed by injection of indium 131-radiolabeled DTPA, which is recognized by the 734 Fab fragment of the BsMAb. Accordingly, a potentially lethal dose of indium 131 is delivered specifically to CEA-expressing tumor cells while minimizing radiotoxicity to normal tissues. CEA (carcinoembryonic antigen) is a tumor antigen overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. DTPA (diethylenetriaminepentaacetic acid) is a bivalent hapten.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody","termGroup":"PT","termSource":"NCI"},{"termName":"F6-734 BsMAb","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CEA_Anti-DTPA-In_F6-734_Bispecific_Antibody"},{"name":"Maps_To","value":"Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody"},{"name":"NCI_Drug_Dictionary_ID","value":"549681"},{"name":"NCI_META_CUI","value":"CL374415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"549681"},{"name":"PDQ_Open_Trial_Search_ID","value":"549681"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82355":{"preferredName":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2","code":"C82355","definitions":[{"definition":"A tri-Fab bispecific monoclonal antibody (BiMoAb) divalent for the carcinoembryonic antigen (CEA) and monovalent for histamine-succinyl-glycine (HSG) peptide-hapten. Anti-CEA/anti-HSG bispecific monoclonal antibody TF2 binds to the tumor associated antigen (TAA) CEA on CEA-expressing tumor cells. Subsequently, an HSG peptide-hapten carrying a radionuclide is administered, binding to the anti-HSG binding fragment on the BiMoAb. Depending on the characteristics of the radionuclide used, CEA-expressing tumor cells may then be radioimaged and/or treated radioimmunotherapeutically.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CEA x Anti-Histamine-Succinyl-Glycine Bispecific Monoclonal Antibody TF2","termGroup":"SY","termSource":"NCI"},{"termName":"TF2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-CEA_Anti-HSG_Bispecific_Monoclonal_Antibody_TF2"},{"name":"Maps_To","value":"Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2"},{"name":"NCI_Drug_Dictionary_ID","value":"639754"},{"name":"NCI_META_CUI","value":"CL408839"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639754"},{"name":"PDQ_Open_Trial_Search_ID","value":"639754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C120305":{"preferredName":"Anti-CEACAM1 Monoclonal Antibody CM-24","code":"C120305","definitions":[{"definition":"A humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting the anti-carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1; CD66a), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CEACAM1 monoclonal antibody CM-24, this agent binds to CEACAM1 on cancer cells and certain immune cells. This blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. This enhances the activation of cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells and increases CTL- and NK-mediated killing of CEACAM1-overexpressing cancer cells. CEACAM1, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its overexpression is correlated with both immunosuppression and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEACAM1 Monoclonal Antibody CM-24","termGroup":"PT","termSource":"NCI"},{"termName":"CM-24","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1783801-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JTP97OR4LL"},{"name":"Maps_To","value":"Anti-CEACAM1 Monoclonal Antibody CM-24"},{"name":"NCI_Drug_Dictionary_ID","value":"768651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768651"},{"name":"PDQ_Open_Trial_Search_ID","value":"768651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896886"}]}}{"C117229":{"preferredName":"Tusamitamab Ravtansine","code":"C117229","definitions":[{"definition":"An immunoconjugate consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to a cytotoxic agent, with potential antineoplastic activity. Upon administration of tusamitamab ravtansine the antibody moiety targets CEACAM5 on tumor cells. Upon antibody/antigen binding and internalization, the immunoconjugate releases the cytotoxic agent, which results in tumor cell death. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tusamitamab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SAR408701","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CEACAM5 Antibody-Drug Conjugate SAR408701","termGroup":"SY","termSource":"NCI"},{"termName":"SAR408701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254086-60-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DSS3BE2ZXN"},{"name":"Maps_To","value":"Anti-CEACAM5 Antibody-Drug Conjugate SAR408701"},{"name":"NCI_Drug_Dictionary_ID","value":"762948"},{"name":"NCI_META_CUI","value":"CL474097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762948"},{"name":"PDQ_Open_Trial_Search_ID","value":"762948"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120068":{"preferredName":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47","code":"C120068","definitions":[{"definition":"A lyophilized formulation of DOS47, an immunoconjugate composed of AFAIKL2, a recombinant camelid single-domain antibody which recognizes carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), and the enzyme urease derived from the plant Canavalia ensiformis (Jack bean), with potential antineoplastic activity. Upon intravenous administration, the AFAIKL2 antibody fragment moiety of L-DOS47 specifically targets and binds to CEACAM6 expressed on certain tumor cells. In turn, the urease moiety of L-DOS47 catalyzes the hydrolysis of urea into ammonia, which is further hydrolyzed to produce hydroxyl ions, and causes a locally increased concentration of the toxic waste product ammonia, which under normal conditions is converted into the nontoxic substance urea via the urea cycle. This increases the pH of the tumor microenvironment and alkalinizes the highly acidic environment that is needed for cancer cell survival and proliferation. In addition, the ammonia diffuses into cancer cells and exerts a cytotoxic effect. Altogether, this leads to cell death of CEACAM6-expressing cancer cells. The naturally-occurring enzyme urease catalyzes the hydrolysis of urea into ammonia and carbon dioxide. CEACAM6, a tumor-associated antigen and CEA family member, is overexpressed in a variety of tumor cells and plays a key role in tumor initiation, progression, metastasis and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47","termGroup":"PT","termSource":"NCI"},{"termName":"L-DOS47","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"95E1ZQM329"},{"name":"Maps_To","value":"Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47"},{"name":"NCI_Drug_Dictionary_ID","value":"768359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768359"},{"name":"PDQ_Open_Trial_Search_ID","value":"768359"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896827"}]}}{"C171841":{"preferredName":"Tinurilimab","code":"C171841","definitions":[{"definition":"A humanized monoclonal antibody directed against the immune checkpoint regulator carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,tinurilimab targets, binds to and blocks the activity of CEACAM6 expressed on various tumor and immune cells, including T-cells. Blocking CEACAM6 signaling abrogates effector T-cell inhibition, activates antigen-specific T-lymphocytes, increases secretion of T-cell cytokines and effector molecules, and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated immune suppression. Elevated CEACAM6 expression is associated with advanced tumor stages and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinurilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CEACAM6 Antibody BAY1834942","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1834942","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1834942","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1834942","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226224-30-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"227KIR246G"},{"name":"Maps_To","value":"Anti-CEACAM6 Antibody BAY1834942"},{"name":"NCI_Drug_Dictionary_ID","value":"797774"},{"name":"NCI_META_CUI","value":"CL951555"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114286":{"preferredName":"Anti-CLDN6 Monoclonal Antibody ASP1650","code":"C114286","definitions":[{"definition":"A monoclonal antibody directed against the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN6 monoclonal antibody ASP1650 binds to CLDN-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (ADCC) and a complement-dependent cytotoxicity (CDC) mediated immune response against CLDN-6-expressing tumor cells. This may inhibit tumor cell growth. CLDN-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CLDN6 Monoclonal Antibody ASP1650","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Claudin 6 Monoclonal Antibody ASP1650","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 1650","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1650","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1650","termGroup":"CN","termSource":"NCI"},{"termName":"IMAB027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CLDN6 Monoclonal Antibody ASP1650"},{"name":"NCI_Drug_Dictionary_ID","value":"757981"},{"name":"NCI_META_CUI","value":"CL471794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757981"},{"name":"PDQ_Open_Trial_Search_ID","value":"757981"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148141":{"preferredName":"Tepoditamab","code":"C148141","definitions":[{"definition":"An immunoglobulin G1 (IgG1) bispecific human monoclonal antibody against human CD3, a T-cell surface antigen, and human C-type lectin domain family 12 member A (CLEC12A), a tumor-associated antigen (TAA) overexpressed on certain tumor cells, with potential antineoplastic activity. Upon administration, tepoditamab binds to both CD3 on T-cells and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor cells and leukemic stem cells (LSCs). This results in the cross-linking of T-cells with tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CLEC12A-expressing tumor cells. CLEC12A, a myeloid differentiation antigen and member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including hematopoietic stem cells (HSCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tepoditamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CLEC12A x CD3 Bispecific Antibody MCLA117","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CLEC12A/Anti-CD3 Bispecific Antibody MCLA117","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody MCLA-117","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Bispecific, Anti-(C-type lectin CLEC12A and CD3 Antigen) (Human Monoclonal MCLA-117 Gamma1-chain), Disulfide with Human Monoclonal MCLA-117 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MCLA 117","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA-117","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA117","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2044679-53-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LK0H7J2V3C"},{"name":"Maps_To","value":"Anti-CLEC12A/CD3 Bispecific Antibody MCLA117"},{"name":"Maps_To","value":"Tepoditamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792475"},{"name":"NCI_META_CUI","value":"CL550807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792475"},{"name":"PDQ_Open_Trial_Search_ID","value":"792475"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159536":{"preferredName":"Bexmarilimab","code":"C159536","definitions":[{"definition":"A monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1), with potential immunomodulatory and antineoplastic activities. Upon administration, bexmarilimab targets and binds to CLEVER-1 that is expressed on tumor endothelial cells. This prevents the recruitment, infiltration and attachment of tumor-associated macrophages (TAMs) at the tumor site. By preventing the binding of TAMs to tumor cells, the infiltration of activated T-regulatory cells (Tregs) to the tumor and the TAM-mediated immune suppression is abrogated, leading to the polarization of TAM from the immunosuppressive M2 macrophages to the anti-inflammatory and immunostimulatory M1 macrophages. This leads to the activation of the immune system, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response and inhibition of tumor cell growth and metastasis. CLEVER-1 is an endothelial cell surface molecule involved in immune suppression, cancer growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bexmarilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-stabilin-1 Monoclonal Antibody FP-1305","termGroup":"SY","termSource":"NCI"},{"termName":"Clevegen","termGroup":"FB","termSource":"NCI"},{"termName":"FP 1305","termGroup":"CN","termSource":"NCI"},{"termName":"FP-1305","termGroup":"CN","termSource":"NCI"},{"termName":"FP1305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2259301-27-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SA0O2AK3LA"},{"name":"Maps_To","value":"Anti-CLEVER-1 Monoclonal Antibody FP-1305"},{"name":"Maps_To","value":"Bexmarilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"797468"},{"name":"NCI_META_CUI","value":"CL951430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797468"},{"name":"PDQ_Open_Trial_Search_ID","value":"797468"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131301":{"preferredName":"Anti-CSF1 Monoclonal Antibody PD-0360324","code":"C131301","definitions":[{"definition":"A humanized immunoglobulin (Ig) G2 monoclonal antibody (mAb) directed against the cytokine colony stimulating factor 1 (CSF1; CSF-1; macrophage colony-stimulating factor; M-CSF), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CSF1 monoclonal antibody PD-0360324 targets, binds to and neutralizes CSF1. This prevents the binding of CSF1 to its receptor CSF1R (CD115; M-CSFR), which is expressed on various immune cells, such as monocytes and macrophages. This prevents CSF1R activation and CSF1R-mediated signaling in these cells; this inhibits monocyte differentiation, blocks the activity of macrophages, and reduces their production of inflammatory mediators, which reduces inflammation. By blocking the activity and proliferation of CSF1R-dependent tumor-associated macrophages (TAMs) in the tumor microenvironment, PD-0360324 reduces TAM-mediated immune suppression, decreases regulatory T-cells (Tregs), re-activates the immune system, and improves anti-tumor cell responses mediated by increasing infiltration by cytotoxic T-cells. TAMs play key roles in immune suppression, and tumor cell proliferation and survival. CSF-1 plays a key role in the regulation of the proliferation, differentiation and survival of monocytes and macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CSF1 Monoclonal Antibody PD-0360324","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-M-CSF mAb PD-0360324","termGroup":"SY","termSource":"NCI"},{"termName":"PD 0360324","termGroup":"CN","termSource":"NCI"},{"termName":"PD 360324","termGroup":"CN","termSource":"NCI"},{"termName":"PD-0360324","termGroup":"CN","termSource":"NCI"},{"termName":"PD-360,324","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1822383-05-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EF7PK2TQ0U"},{"name":"Maps_To","value":"Anti-CSF1 Monoclonal Antibody PD-0360324"},{"name":"NCI_Drug_Dictionary_ID","value":"785869"},{"name":"NCI_META_CUI","value":"CL514242"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785869"},{"name":"PDQ_Open_Trial_Search_ID","value":"785869"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96801":{"preferredName":"Anti-CSF1R Monoclonal Antibody IMC-CS4","code":"C96801","definitions":[{"definition":"A monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. CSF1R monoclonal antibody IMC-CS4 binds to CSF1R which may trigger antitumoral antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells overexpressing CSF1R. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (Cluster of Differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1); this receptor is overexpressed or mutated in certain tumor cell types and plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CSF1R Monoclonal Antibody IMC-CS4","termGroup":"PT","termSource":"NCI"},{"termName":"IMC-CS4","termGroup":"CN","termSource":"NCI"},{"termName":"LY3022855","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CSF1R Monoclonal Antibody IMC-CS4"},{"name":"NCI_Drug_Dictionary_ID","value":"710355"},{"name":"NCI_META_CUI","value":"CL429408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710355"},{"name":"PDQ_Open_Trial_Search_ID","value":"710355"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155813":{"preferredName":"Axatilimab","code":"C155813","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R), with potential antineoplastic activity. Upon intravenous administration, axatilimab binds to the ligand binding domain of CSF-1R, preventing binding and consequent activation by its natural ligands, IL-34 and colony-stimulating factor 1 (CSF-1). Inhibition of CSF-1R activation may disrupt the activity of tumor-associated macrophages (TAMs), which promote initiation and metastasis of tumor cells, inhibit T-cell responses, and stimulate tumor angiogenesis and disease progression. CSF-1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and cluster of differentiation 115 (CD115), is a tyrosine-protein kinase that plays an essential role in the regulation, proliferation, survival and differentiation of tissue macrophages as well as TAMs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axatilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-M-CSFR Monoclonal Antibody SNDX-6352","termGroup":"SY","termSource":"NCI"},{"termName":"SNDX 6352","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX-6352","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX6352","termGroup":"CN","termSource":"NCI"},{"termName":"UCB6352","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2155851-88-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R96Z451BMC"},{"name":"Maps_To","value":"Anti-CSF1R Monoclonal Antibody SNDX-6352"},{"name":"Maps_To","value":"Axatilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"794081"},{"name":"NCI_META_CUI","value":"CL556346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794081"},{"name":"PDQ_Open_Trial_Search_ID","value":"794081"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92577":{"preferredName":"Pamrevlumab","code":"C92577","definitions":[{"definition":"A human monoclonal antibody targeting connective tissue growth factor (CTGF) with potential anti-fibrotic and antineoplastic activities. Pamrevlumab binds to CTGF thereby preventing the binding of the ligand to the receptor and subsequent receptor activation. As CTGF enhances the production of collagen and fibronectin, FG-319 may prevent and reverse fibrosis. In addition, FG-3019 may prevent tumor cell proliferation in CTGF-expressing tumor cells. CTGF, a member of the CCN family (CTGF, CYR61/CEF and NOV), is expressed in a variety of tumor cell types and is involved in processes such as cell proliferation, cell migration, cell adhesion, differentiation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamrevlumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Connective Tissue Growth Factor Monoclonal Antibody FG-3019","termGroup":"SY","termSource":"NCI"},{"termName":"FG-3019","termGroup":"CN","termSource":"NCI"},{"termName":"FG3019","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946415-13-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QS5F6VTS0O"},{"name":"Maps_To","value":"Anti-CTGF Monoclonal Antibody FG-3019"},{"name":"Maps_To","value":"Pamrevlumab"},{"name":"NCI_Drug_Dictionary_ID","value":"683932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683932"},{"name":"PDQ_Open_Trial_Search_ID","value":"683932"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985186"}]}}{"C162505":{"preferredName":"Anti-CTLA-4 Monoclonal Antibody ADU-1604","code":"C162505","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADU-1604 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4 Monoclonal Antibody ADU-1604","termGroup":"PT","termSource":"NCI"},{"termName":"ADU 1604","termGroup":"CN","termSource":"NCI"},{"termName":"ADU-1604","termGroup":"CN","termSource":"NCI"},{"termName":"ADU1604","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody ADU-1604"},{"name":"NCI_Drug_Dictionary_ID","value":"798657"},{"name":"NCI_META_CUI","value":"CL970933"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798657"},{"name":"PDQ_Open_Trial_Search_ID","value":"798657"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158557":{"preferredName":"Botensilimab","code":"C158557","definitions":[{"definition":"An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody  botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botensilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 1181","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-1181","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1181","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody AGEN1181","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2408310-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z5YC3ME5N"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody AGEN1181"},{"name":"NCI_Drug_Dictionary_ID","value":"797474"},{"name":"NCI_META_CUI","value":"CL938004"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797474"},{"name":"PDQ_Open_Trial_Search_ID","value":"797474"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156734":{"preferredName":"Nurulimab","code":"C156734","definitions":[{"definition":"A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nurulimab targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nurulimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody BCD-145","termGroup":"SY","termSource":"NCI"},{"termName":"BCD 145","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-145","termGroup":"CN","termSource":"NCI"},{"termName":"BCD145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2168561-20-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"894KSI08XK"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody BCD-145"},{"name":"Maps_To","value":"Nurulimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795594"},{"name":"NCI_META_CUI","value":"CL935901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795594"},{"name":"PDQ_Open_Trial_Search_ID","value":"795594"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150679":{"preferredName":"Quavonlimab","code":"C150679","definitions":[{"definition":"A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, quavonlimab targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quavonlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody MK-1308","termGroup":"SY","termSource":"NCI"},{"termName":"MK 1308","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1308","termGroup":"CN","termSource":"NCI"},{"termName":"MK1308","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254059-25-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GG0AN49Y59"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody MK-1308"},{"name":"NCI_Drug_Dictionary_ID","value":"793094"},{"name":"NCI_META_CUI","value":"CL552570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793094"},{"name":"PDQ_Open_Trial_Search_ID","value":"793094"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159764":{"preferredName":"Anti-CTLA-4 Monoclonal Antibody REGN4659","code":"C159764","definitions":[{"definition":"A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4 Monoclonal Antibody REGN4659","termGroup":"PT","termSource":"NCI"},{"termName":"REGN 4659","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-4659","termGroup":"CN","termSource":"NCI"},{"termName":"REGN4659","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6CGQ1X5Y6V"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody REGN4659"},{"name":"NCI_Drug_Dictionary_ID","value":"797920"},{"name":"NCI_META_CUI","value":"CL951623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797920"},{"name":"PDQ_Open_Trial_Search_ID","value":"797920"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159530":{"preferredName":"Pavunalimab","code":"C159530","definitions":[{"definition":"An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pavunalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4/Anti-LAG-3 Bispecific Monoclonal Antibody XmAb22841","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841","termGroup":"SY","termSource":"NCI"},{"termName":"CTLA-4 x LAG-3 Bispecific Antibody XmAb22841","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb 22841","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb-22841","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb22841","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2329669-78-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3PT70X17VS"},{"name":"Maps_To","value":"Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841"},{"name":"NCI_Drug_Dictionary_ID","value":"797814"},{"name":"NCI_META_CUI","value":"CL951426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797814"},{"name":"PDQ_Open_Trial_Search_ID","value":"797814"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157494":{"preferredName":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","code":"C157494","definitions":[{"definition":"A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","termGroup":"PT","termSource":"NCI"},{"termName":"ADC 1015","termGroup":"SY","termSource":"NCI"},{"termName":"ADC-1015","termGroup":"CN","termSource":"NCI"},{"termName":"ADC1015","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR 1015","termGroup":"SY","termSource":"NCI"},{"termName":"ATOR-1015","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR1015","termGroup":"CN","termSource":"NCI"},{"termName":"CTLA-4 x OX40 Bispecific Antibody ATOR-1015","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015"},{"name":"NCI_Drug_Dictionary_ID","value":"796793"},{"name":"NCI_META_CUI","value":"CL937070"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796793"},{"name":"PDQ_Open_Trial_Search_ID","value":"796793"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135633":{"preferredName":"Anti-CTLA4 Monoclonal Antibody BMS-986218","code":"C135633","definitions":[{"definition":"A Fc-modified monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 monoclonal antibody BMS-986218 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. Removal of the fucose sugar units from the antibody's Fc region, enhances its activity and decreases the toxicity of BMS-986218.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA4 Monoclonal Antibody BMS-986218","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986218","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986218","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody BMS-986218","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA4 Monoclonal Antibody BMS-986218"},{"name":"NCI_Drug_Dictionary_ID","value":"789026"},{"name":"NCI_META_CUI","value":"CL522988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789026"},{"name":"PDQ_Open_Trial_Search_ID","value":"789026"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C131572":{"preferredName":"Anti-CXCR4 Monoclonal Antibody PF-06747143","code":"C131572","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) against C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, anti-CXCR4 mAb PF-06747143 binds to CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation. This results in decreased proliferation and migration of CXCR4-expressing tumor cells. In addition, PF-06747143 promotes cell death through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is upregulated in several tumor cell types and plays an important role in cancer cell proliferation, survival, and chemotaxis, and in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CXCR4 Monoclonal Antibody PF-06747143","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CXCR4 IgG1 Antibody PF-06747143","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06747143","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06747143","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7TS9C20ZWA"},{"name":"Maps_To","value":"Anti-CXCR4 Monoclonal Antibody PF-06747143"},{"name":"NCI_Drug_Dictionary_ID","value":"786269"},{"name":"NCI_META_CUI","value":"CL514243"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786269"},{"name":"PDQ_Open_Trial_Search_ID","value":"786269"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71749":{"preferredName":"Anti-Denatured Collagen Monoclonal Antibody TRC093","code":"C71749","definitions":[{"definition":"A humanized, affinity-matured IgG1k antibody directed against denatured collagens (I-IV) with potential antiangiogenic and antineoplastic activities. Anti-denatured collagen recombinant monoclonal antibody TRC093 binds to multiple epitopes on denatured collagens, inhibiting proteolytic collagen-mediated signaling in the extracellular matrix (ECM) that is important to tumor angiogenesis, tumor growth, and metastasis. The epitopes on denatured collagen bound by this antibody are considered cryptic because, in vivo, they are accessible only on the subendothelial basement membrane of tumors or in normal tissues undergoing neovascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Denatured Collagen Monoclonal Antibody TRC093","termGroup":"PT","termSource":"NCI"},{"termName":"D93","termGroup":"CN","termSource":"NCI"},{"termName":"MT293","termGroup":"CN","termSource":"NCI"},{"termName":"TRC093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Humanized_IgG1k_Monoclonal_Antibody_TRC093"},{"name":"Maps_To","value":"Anti-Denatured Collagen Monoclonal Antibody TRC093"},{"name":"NCI_Drug_Dictionary_ID","value":"560174"},{"name":"NCI_META_CUI","value":"CL376136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560174"},{"name":"PDQ_Open_Trial_Search_ID","value":"560174"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C99123":{"preferredName":"Sirexatamab","code":"C99123","definitions":[{"definition":"A humanized monoclonal antibody directed against the WNT antagonist dickkopf homolog 1 (DKK1), with potential anti-osteolytic activity. Upon administration, sirexatamab binds to and inhibits DKK1, thereby restoring signaling through the WNT pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1, overexpressed by certain cancer cells, is an inhibitor of the WNT signaling pathway and prevents the mediated formation of bone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirexatamab","termGroup":"PT","termSource":"NCI"},{"termName":"DKK1-Neutralizing Monoclonal Antibody DKN-01","termGroup":"SY","termSource":"NCI"},{"termName":"DKN-01","termGroup":"CN","termSource":"NCI"},{"termName":"LY2812176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2414962-49-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RM898LZ4SI"},{"name":"Maps_To","value":"Anti-DKK-1 Monoclonal Antibody LY2812176"},{"name":"Maps_To","value":"DKK1-Neutralizing Monoclonal Antibody DKN-01"},{"name":"NCI_Drug_Dictionary_ID","value":"715663"},{"name":"NCI_META_CUI","value":"CL432944"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715663"},{"name":"PDQ_Open_Trial_Search_ID","value":"715663"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80040":{"preferredName":"Anti-DKK1 Monoclonal Antibody BHQ880","code":"C80040","definitions":[{"definition":"A humanized monoclonal antibody directed against Wnt antagonist Dickkopf-1 (DKK1) with potential anti-osteolytic activity. Anti-DKK1 monoclonal antibody BHQ880 binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1 is a potent Wnt signaling pathway antagonist.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DKK1 Monoclonal Antibody BHQ880","termGroup":"PT","termSource":"NCI"},{"termName":"BHQ 880","termGroup":"CN","termSource":"NCI"},{"termName":"BHQ-880","termGroup":"CN","termSource":"NCI"},{"termName":"BHQ880","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IS3ESI44W5"},{"name":"Legacy Concept Name","value":"Anti-DKK1_Monoclonal_Antibody_BHQ880"},{"name":"Maps_To","value":"Anti-DKK1 Monoclonal Antibody BHQ880"},{"name":"NCI_Drug_Dictionary_ID","value":"614254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614254"},{"name":"PDQ_Open_Trial_Search_ID","value":"614254"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703201"}]}}{"C147027":{"preferredName":"Anti-DLL3/CD3 BiTE Antibody AMG 757","code":"C147027","synonyms":[{"termName":"Anti-DLL3/CD3 BiTE Antibody AMG 757","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed May 04 11:36:45 EDT 2022 - See 'Tarlatamab(C175858)'"},{"name":"OLD_PARENT","value":"C20401"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C101521":{"preferredName":"Anti-DLL4 Monoclonal Antibody MEDI0639","code":"C101521","definitions":[{"definition":"An immunoglobulin G1 lambda monoclonal antibody directed against the Notch ligand delta-like 4 (DLL4) with potential antineoplastic activity. Anti-DLL4 monoclonal antibody MEDI0639 specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may block tumor angiogenesis and eventually the inhibition of tumor cell growth. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DLL4 Monoclonal Antibody MEDI0639","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI0639","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LPT9GX4OUB"},{"name":"Maps_To","value":"Anti-DLL4 Monoclonal Antibody MEDI0639"},{"name":"NCI_Drug_Dictionary_ID","value":"732226"},{"name":"NCI_META_CUI","value":"CL435778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732226"},{"name":"PDQ_Open_Trial_Search_ID","value":"732226"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119620":{"preferredName":"Navicixizumab","code":"C119620","definitions":[{"definition":"A bispecific monoclonal antibody directed against both the Notch ligand delta-like 4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors, and inhibits Notch-mediated signaling and gene transcription, which may both block tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling and further inhibits the growth and maintenance of tumor blood vessels. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navicixizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G2-kappa, Anti-(Homo sapiens DLL4(delta-like 4)) and Anti-(Homo sapiens VEGFA (Vascular Endothelial Growth Factor A,VEGF-a, VEGF)), Humanized and Chimeric Monoclonal Antibody, Bispecific","termGroup":"SN","termSource":"NCI"},{"termName":"OMP 305B83","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-305B83","termGroup":"CN","termSource":"NCI"},{"termName":"OMP305B83","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638338-43-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1W14T9L25W"},{"name":"Maps_To","value":"Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83"},{"name":"Maps_To","value":"Navicixizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"766887"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766887"},{"name":"PDQ_Open_Trial_Search_ID","value":"766887"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896797"}]}}{"C78826":{"preferredName":"Anti-DR5 Agonist Monoclonal Antibody TRA-8","code":"C78826","definitions":[{"definition":"An agonist mouse monoclonal antibody directed against TRAIL death receptor type 5 (DR5) with potential antineoplastic activity. Anti-DR5 agonist monoclonal antibody TRA-8 binds DR5, which may induce apoptosis in DR5-expressing tumor cells. DR5 is a tumor cell surface ligand that crosslinks with death receptor type 4 (DR4) when bound by TRAIL [Tumor necrosis (TNF)-related apoptosis-inducing ligand], triggering apoptosis via a death receptor signaling pathway. The apoptotic activity of this antibody may not require DR4/DR5 crosslinking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DR5 Agonist Monoclonal Antibody TRA-8","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-death Receptor 5 Agonist Monoclonal Antibody TRA-8","termGroup":"SY","termSource":"NCI"},{"termName":"TRA-8","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-DR5_Agonist_Monoclonal_Antibody_TRA-8"},{"name":"Maps_To","value":"Anti-DR5 Agonist Monoclonal Antibody TRA-8"},{"name":"NCI_Drug_Dictionary_ID","value":"601797"},{"name":"NCI_META_CUI","value":"CL387674"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601797"},{"name":"PDQ_Open_Trial_Search_ID","value":"601797"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121158":{"preferredName":"Anti-DR5 Agonistic Antibody DS-8273a","code":"C121158","definitions":[{"definition":"An agonistic monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2, with potential pro-apoptotic and antitumor activities. Upon administration, anti-DR5 agonistic antibody DS-8273a mimics the natural receptor ligand TRAIL and binds to DR5. This activates DR5 and leads to the activation of the death receptor signal pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily, is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-DR5 Agonistic Antibody DS-8273a","termGroup":"PT","termSource":"NCI"},{"termName":"DS 8273","termGroup":"CN","termSource":"NCI"},{"termName":"DS-8273a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2107396-50-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G674PEN33T"},{"name":"Maps_To","value":"Anti-DR5 Agonistic Antibody DS-8273a"},{"name":"NCI_Drug_Dictionary_ID","value":"758683"},{"name":"NCI_META_CUI","value":"CL471819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758683"},{"name":"PDQ_Open_Trial_Search_ID","value":"758683"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157062":{"preferredName":"Ozekibart","code":"C157062","definitions":[{"definition":"A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, ozekibart specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ozekibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-DR5 Agonistic Monoclonal Antibody INBRX-109","termGroup":"SY","termSource":"NCI"},{"termName":"INBRX 109","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX-109","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX109","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2539847-03-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R0GA5221D4"},{"name":"Maps_To","value":"Anti-DR5 Agonistic Monoclonal Antibody INBRX-109"},{"name":"NCI_Drug_Dictionary_ID","value":"796494"},{"name":"NCI_META_CUI","value":"CL936041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796494"},{"name":"PDQ_Open_Trial_Search_ID","value":"796494"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155876":{"preferredName":"Anti-EGFR Monoclonal Antibody CPGJ 602","code":"C155876","definitions":[{"definition":"A recombinant, human-mouse chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, anti-EGFR monoclonal antibody CPGJ 602 targets and binds to EGFR, which prevents receptor dimerization and activation. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody CPGJ 602","termGroup":"PT","termSource":"NCI"},{"termName":"CPGJ 602","termGroup":"CN","termSource":"NCI"},{"termName":"CPGJ-602","termGroup":"CN","termSource":"NCI"},{"termName":"CPGJ602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody CPGJ 602"},{"name":"NCI_Drug_Dictionary_ID","value":"794677"},{"name":"NCI_META_CUI","value":"CL562684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794677"},{"name":"PDQ_Open_Trial_Search_ID","value":"794677"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C2714":{"preferredName":"Anti-EGFR Monoclonal Antibody EMD 55900","code":"C2714","definitions":[{"definition":"A murine monoclonal antibody targeting the epidermal growth factor receptor (EGFR) exhibiting anti-tumor activity. EMD 55900 antibody binds to the extracellular domain of EGFR close to the EGF binding domain and does not induce any tyrosine kinase activity on its own. As a result, EMD 55900 binding inhibits receptor activation by natural ligands thereby interrupting activation of downstream signaling cascade, required for tumor cell growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody EMD 55900","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 55 900","termGroup":"CN","termSource":"NCI"},{"termName":"EMD 55900","termGroup":"CN","termSource":"NCI"},{"termName":"Mab 425","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody 425","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EMD_55900"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody EMD 55900"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1512123"}]}}{"C120316":{"preferredName":"Anti-EGFR Monoclonal Antibody GC1118","code":"C120316","definitions":[{"definition":"A recombinant, human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, GC1118 binds to and blocks the ligand binding site of EGFR, which prevents receptor dimerization and activation. This may lead to an inhibition of both EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody GC1118","termGroup":"PT","termSource":"NCI"},{"termName":"GC1118","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody GC1118"},{"name":"NCI_Drug_Dictionary_ID","value":"768860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768860"},{"name":"PDQ_Open_Trial_Search_ID","value":"768860"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C3896855"}]}}{"C94221":{"preferredName":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX","code":"C94221","definitions":[{"definition":"A glycoengineered form of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Anti-EGFR monoclonal antibody GT-MAB 5.2-GEX specifically binds to the extracellular domain of EGFR, thereby potentially inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells, eventually leading to tumor cell apoptosis and an inhibition of tumor cell growth. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, is overexpressed on the cell surfaces of various solid tumors. This antibody has a specific glycosylation profile that may enhance its ADCC response against EGFR-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX","termGroup":"PT","termSource":"NCI"},{"termName":"CetuGEX","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX"},{"name":"NCI_Drug_Dictionary_ID","value":"687632"},{"name":"NCI_META_CUI","value":"CL426034"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687632"},{"name":"PDQ_Open_Trial_Search_ID","value":"687632"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163981":{"preferredName":"Pimurutamab","code":"C163981","definitions":[{"definition":"A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimurutamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR Monoclonal Antibody HLX-07","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab Biobetter HLX07","termGroup":"SY","termSource":"NCI"},{"termName":"HLX 07","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-07","termGroup":"CN","termSource":"NCI"},{"termName":"HLX07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2251771-76-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5V1Y8T4RB6"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody HLX-07"},{"name":"Maps_To","value":"Pimurutamab"},{"name":"NCI_Drug_Dictionary_ID","value":"799130"},{"name":"NCI_META_CUI","value":"CL977244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799130"},{"name":"PDQ_Open_Trial_Search_ID","value":"799130"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99899":{"preferredName":"Anti-EGFR Monoclonal Antibody Mixture MM-151","code":"C99899","definitions":[{"definition":"An oligoclonal therapeutic composed of three fully human monoclonal antibodies targeting epidermal growth factor receptor (EGFR or ErbB1), with potential antineoplastic activity. Upon administration of MM-151, the three antibodies bind to distinct, non-overlapping epitopes of EGFR, thereby preventing the binding of a full range of both high and low affinity EGFR ligands and inhibiting EGFR-ERK-mediated signaling. This eventually inhibits tumor cell proliferation in EGFR-overexpressing tumor cells. Furthermore, multi antibody-antigen bindings cause crosslinking of EGFR and downregulate receptor signalings that are mediated via heterodimerization of EGFR with other members of the EGFR family. EGFR, a receptor tyrosine kinase overexpressed in a variety of cancer cell types, is a key regulator of cancer cell proliferation, apoptosis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody Mixture MM-151","termGroup":"PT","termSource":"NCI"},{"termName":"MM-151","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody Mixture MM-151"},{"name":"NCI_Drug_Dictionary_ID","value":"724591"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724591"},{"name":"PDQ_Open_Trial_Search_ID","value":"724591"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3275035"}]}}{"C78838":{"preferredName":"Imgatuzumab","code":"C78838","definitions":[{"definition":"A glycoengineered monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Imgatuzumab binds to the extracellular domain of EGFR, preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition of downstream ERK and JNK signaling pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imgatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epidermal Growth Factor Receptor Monoclonal Antibody RO5083945","termGroup":"SY","termSource":"NCI"},{"termName":"GA-201","termGroup":"CN","termSource":"NCI"},{"termName":"GA201","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7160","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7160","termGroup":"CN","termSource":"NCI"},{"termName":"RG7160","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"959963-46-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V77J4WJF9Z"},{"name":"Legacy Concept Name","value":"Anti-EGFR_Monoclonal_Antibody_RO5083945"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody RO5083945"},{"name":"Maps_To","value":"Imgatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"609889"},{"name":"NCI_META_CUI","value":"CL387675"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609889"},{"name":"PDQ_Open_Trial_Search_ID","value":"609889"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117726":{"preferredName":"Anti-EGFR Monoclonal Antibody SCT200","code":"C117726","definitions":[{"definition":"A recombinant monoclonal antibody against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SCT200 targets EGFR, prevents the activation and subsequent dimerization of this receptor and inhibits both EGFR-mediated signal transduction and cellular proliferation of EGFR-expressing tumor cells. In addition, SCT200 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the cell surfaces of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody SCT200","termGroup":"PT","termSource":"NCI"},{"termName":"SCT200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody SCT200"},{"name":"NCI_Drug_Dictionary_ID","value":"763740"},{"name":"NCI_META_CUI","value":"CL474121"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763740"},{"name":"PDQ_Open_Trial_Search_ID","value":"763740"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C121550":{"preferredName":"Anti-EGFR Monoclonal Antibody SYN004","code":"C121550","definitions":[{"definition":"A glyco-engineered monoclonal antibody directed against the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SYN004 binds to the extracellular domain of EGFR, which prevents ligand binding and the subsequent activation and dimerization of the receptor. This inhibits the activation of EGFR-mediated signaling pathways and inhibits EGFR-dependent tumor cell proliferation. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR Monoclonal Antibody SYN004","termGroup":"PT","termSource":"NCI"},{"termName":"SYN004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR Monoclonal Antibody SYN004"},{"name":"NCI_Drug_Dictionary_ID","value":"770314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770314"},{"name":"PDQ_Open_Trial_Search_ID","value":"770314"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053588"}]}}{"C111906":{"preferredName":"Laprituximab Emtansine","code":"C111906","definitions":[{"definition":"A targeted antibody payload (TAP)-based immunoconjugate consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of laprituximab emtansine binds to and inhibits EGFR on tumor cell surfaces. Inhibition of EGFR prevents EGFR-mediated signaling and may inhibit tumor cell proliferation. After internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival. Linkage of the antibody and drug, through a nonreducible linker, appears to contribute to the improved efficacy and reduced toxicity of this antibody-drug conjugate (ADC) compared to similar ADCs constructed with reducible linkers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laprituximab Emtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR-SMCC-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN289","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622327-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7J0LQD86OG"},{"name":"Maps_To","value":"Anti-EGFR TAP Antibody-drug Conjugate IMGN289"},{"name":"Maps_To","value":"Laprituximab Emtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"753683"},{"name":"NCI_META_CUI","value":"CL454236"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753683"},{"name":"PDQ_Open_Trial_Search_ID","value":"753683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158085":{"preferredName":"Bafisontamab","code":"C158085","definitions":[{"definition":"A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR;; cMet; c-Met), with potential antineoplastic activity. Upon administration, bafisontamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In bafisontamab, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bafisontamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-cMET/EGFR Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/Anti-c-Met Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/c-Met Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody EMB-01","termGroup":"SY","termSource":"NCI"},{"termName":"EMB 01","termGroup":"CN","termSource":"NCI"},{"termName":"EMB-01","termGroup":"CN","termSource":"NCI"},{"termName":"EMB01","termGroup":"CN","termSource":"NCI"},{"termName":"FIT-013a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2437210-79-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G86X5QQ7M5"},{"name":"Maps_To","value":"Anti-EGFR/c-Met Bispecific Antibody EMB-01"},{"name":"NCI_Drug_Dictionary_ID","value":"797352"},{"name":"NCI_META_CUI","value":"CL937694"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797352"},{"name":"PDQ_Open_Trial_Search_ID","value":"797352"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124993":{"preferredName":"Amivantamab","code":"C124993","definitions":[{"definition":"A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amivantamab","termGroup":"PT","termSource":"NCI"},{"termName":"Amivantamab-vmjw","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO-4424","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ 61186372","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-611","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-61186372","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ61186372","termGroup":"CN","termSource":"NCI"},{"termName":"Rybrevant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations"},{"name":"CAS_Registry","value":"2171511-58-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0JSR7Z0NB6"},{"name":"Maps_To","value":"Amivantamab"},{"name":"Maps_To","value":"Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372"},{"name":"NCI_Drug_Dictionary_ID","value":"777269"},{"name":"NCI_META_CUI","value":"CL503840"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777269"},{"name":"PDQ_Open_Trial_Search_ID","value":"777269"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148507":{"preferredName":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100","code":"C148507","definitions":[{"definition":"A targeted antibody drug conjugate (ADC) consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AVID100 binds to  EGFR on tumor cell surfaces. Following receptor internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AVID100","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate AVID100","termGroup":"SY","termSource":"NCI"},{"termName":"AVID100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91PZ0ZWR8S"},{"name":"Maps_To","value":"Anti-EGFR/DM1 Antibody-drug Conjugate AVID100"},{"name":"NCI_Drug_Dictionary_ID","value":"792639"},{"name":"NCI_META_CUI","value":"CL551039"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792639"},{"name":"PDQ_Open_Trial_Search_ID","value":"792639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131175":{"preferredName":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013","code":"C131175","definitions":[{"definition":"An antibody mixture composed of six humanized, immunoglobulin G1 (IgG1) monoclonal antibodies directed against three members of the human epidermal growth factor receptor (EGFR; HER) family: EGFR (HER1; ErbB1), HER2 (ErbB2) and HER3 (ErbB3), with potential antineoplastic activity. Upon administration of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013, the six antibodies bind to non-overlapping epitopes on EGFR, HER2 and HER3, which prevents both ligand binding and receptor activation, and induce simultaneous down-modulation of EGFR, HER2 and HER3.  This inhibits the activation of HER-dependent signaling pathways and HER-dependent tumor cell proliferation. Overexpression of the HER family plays a key role in many cancers; targeting multiple HER family members simultaneously may increase therapeutic efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013","termGroup":"PT","termSource":"NCI"},{"termName":"pan-HER Antibody Mixture Sym013","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-HER mAb Mixture Sym013","termGroup":"SY","termSource":"NCI"},{"termName":"Sym-013","termGroup":"CN","termSource":"NCI"},{"termName":"Sym013","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013"},{"name":"NCI_Drug_Dictionary_ID","value":"785503"},{"name":"NCI_META_CUI","value":"CL513501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785503"},{"name":"PDQ_Open_Trial_Search_ID","value":"785503"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150590":{"preferredName":"Serclutamab Talirine","code":"C150590","definitions":[{"definition":"A antibody drug conjugate (ADC) consisting of serclutamab, an affinity-matured humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to a talirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration of serclutamab talirine, the serclutamab moiety targets and binds to EGFR on tumor cell surfaces. Following receptor internalization and lysosome-mediated cleavage, talirine is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase (RTK) that is overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serclutamab Talirine","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 321","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-321","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV321","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-321","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/PBD ADC ABBV-321","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2140174-56-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7W0O278T12"},{"name":"Maps_To","value":"Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321"},{"name":"Maps_To","value":"Serclutamab Talirine"},{"name":"NCI_Drug_Dictionary_ID","value":"793472"},{"name":"NCI_META_CUI","value":"CL552328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793472"},{"name":"PDQ_Open_Trial_Search_ID","value":"793472"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99222":{"preferredName":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595","code":"C99222","definitions":[{"definition":"An immunoconjugate consisting of a human monoclonal antibody directed against the deletion-mutant of epidermal growth factor receptor, EGFRvIII, conjugated via a non-cleavable linker to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to EGFRvIII on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that express the EGFRvIII mutant. EGFRvIII, a deletion mutation of exons 2-7 in the epidermal growth factor receptor gene, is overexpressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 595","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-EGFRvIII-DM1 Immunoconjugate AMG 595","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFRvIII Antibody Drug Conjugate AMG 595"},{"name":"NCI_Drug_Dictionary_ID","value":"718917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"718917"},{"name":"PDQ_Open_Trial_Search_ID","value":"718917"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274618"}]}}{"C88307":{"preferredName":"Anti-EGFRvIII Immunotoxin MR1-1","code":"C88307","definitions":[{"definition":"A recombinant immunotoxin consisting of single-chain variable domain fragment antibody directed against the tumor-specific antigen EGFRvIII (MR1scFv) fused to domains II and III of the Pseudomonas exotoxin (PE38KDEL), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-EGFRvIII immunotoxin MR1-1 binds to EGFRvIII; upon internalization, the exotoxin portion inhibits protein synthesis, resulting in a reduction in tumor cell proliferation of EGFRvIII- expressing tumor cells. EGFRvIII, a type III in-frame deletion mutation of the epidermal growth factor receptor (EGFR) gene, is expressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma. Compared to intact IgG antibodies, single-chain antibodies such as MR1scFv are smaller and may penetrate tumors better. Pseudomonas exotoxin PE38KDEL was modified to remove the natural cell binding domain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFRvIII Immunotoxin MR1-1","termGroup":"PT","termSource":"NCI"},{"termName":"MR1-1","termGroup":"CN","termSource":"NCI"},{"termName":"MR1-1KDEL","termGroup":"SY","termSource":"NCI"},{"termName":"MR1scFvPE38KDEL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFRvIII Immunotoxin MR1-1"},{"name":"NCI_Drug_Dictionary_ID","value":"659598"},{"name":"NCI_META_CUI","value":"CL413562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659598"},{"name":"PDQ_Open_Trial_Search_ID","value":"659598"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146824":{"preferredName":"Etevritamab","code":"C146824","definitions":[{"definition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one that is directed against a tumor-associated antigen (TAA), the epidermal growth factor receptor (EGFR) deletion-mutant form, EGFR variant III (EGFRvIII), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of etevritamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and EGFRvIII found on EGFRvIII-expressing tumor cells. This activates and crosslinks CTLs with EGFRvIII-expressing tumor cells, which results in the CTL-mediated cell death of EGFRvIII-expressing tumor cells. EGFRvIII, a mutation in the EGFR gene where exons 2-7 have been deleted, is overexpressed by a variety of cancers, but is absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etevritamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 596","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-596","termGroup":"CN","termSource":"NCI"},{"termName":"AMG596","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-EGFRvIII x Anti-CD3 Bi-specific T-cell Engager AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFRvIII/CD3 BiTE Antibody AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific BITE Antibody AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 596","termGroup":"SY","termSource":"NCI"},{"termName":"EGFRvIII specific BiTE Antibody AMG 596","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2329692-74-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WR4J8FV2SM"},{"name":"Maps_To","value":"Anti-EGFRvIII/CD3 BiTE Antibody AMG 596"},{"name":"NCI_Drug_Dictionary_ID","value":"792074"},{"name":"NCI_META_CUI","value":"CL544854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792074"},{"name":"PDQ_Open_Trial_Search_ID","value":"792074"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90551":{"preferredName":"Anti-EGP-2 Immunotoxin MOC31-PE","code":"C90551","definitions":[{"definition":"An immunotoxin consisting of a monoclonal antibody directed against epithelial glycoprotein-2 (EP-2, or epithelial cell adhesion molecule (EpCAM)) conjugated to the bacterial toxin Pseudomonas exotoxin A (PE) with potential antineoplastic activity. Upon administration of anti-EGP-2 immunotoxin MOC31-PE, the monoclonal antibody moiety targets and binds to EP-2. Upon internalization, the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in EP-2-expressing cells. EP-2, a tumor-associated antigen, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGP-2 Immunotoxin MOC31-PE","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epithelial Glycoprotein-2 Immunotoxin MOC31-PE","termGroup":"SY","termSource":"NCI"},{"termName":"MOC31-PE","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGP-2 Immunotoxin MOC31-PE"},{"name":"NCI_Drug_Dictionary_ID","value":"666058"},{"name":"NCI_META_CUI","value":"CL416235"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666058"},{"name":"PDQ_Open_Trial_Search_ID","value":"666058"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102980":{"preferredName":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F","code":"C102980","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity. Upon intravenous administration of ADC AGS-16C3F, the monoclonal antibody moiety of this conjugate selectively binds to ENPP3 then is internalized and undergoes proteolytic cleavage to release MMAF. MMAF binds to and inhibits tubulin polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 has been found to be overexpressed in renal neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AGS-16C3F","termGroup":"AB","termSource":"NCI"},{"termName":"AGS-16C3F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VC1D38AGN9"},{"name":"Maps_To","value":"Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F"},{"name":"NCI_Drug_Dictionary_ID","value":"739766"},{"name":"NCI_META_CUI","value":"CL437217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739766"},{"name":"PDQ_Open_Trial_Search_ID","value":"739766"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116626":{"preferredName":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F","code":"C116626","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a human immunoglobulin (Ig) G2k monoclonal antibody (AGS-16C) directed against the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3, NPP3, B10, PDNP3 CD203c, or PD-IBETA ), conjugated, via the non-cleavable maleimidocaproyl (mc) linker, to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-ENPP3/MMAF ADC AGS-16M8F, the monoclonal antibody moiety selectively binds to ENPP3 expressed on tumor cells; upon internalization, the ADC is degraded by lysosomal proteases and MMAF is released. In turn, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 is overexpressed in most renal neoplasms and some liver cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AGS-16M8F","termGroup":"SY","termSource":"NCI"},{"termName":"AGS 16M8F","termGroup":"CN","termSource":"NCI"},{"termName":"AGS-16M8F","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-ENPP3 ADC AGS-16M8F","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ENPP3/MMAF ADC AGS-16M8F","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F"},{"name":"NCI_Drug_Dictionary_ID","value":"673092"},{"name":"NCI_META_CUI","value":"CL421575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673092"},{"name":"PDQ_Open_Trial_Search_ID","value":"673092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133022":{"preferredName":"Anti-Ep-CAM Monoclonal Antibody ING-1","code":"C133022","definitions":[{"definition":"An engineered monoclonal antibody (MAb) directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326), with potential antitumor activity. Upon administration, anti-Ep-CAM monoclonal antibody ING-1 binds to Ep-CAM, which may result in a cytotoxic T-lymphocyte (CTL)-mediated immune response against Ep-CAM-expressing tumor cells. Ep-CAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Ep-CAM Monoclonal Antibody ING-1","termGroup":"PT","termSource":"NCI"},{"termName":"ING 1","termGroup":"CN","termSource":"NCI"},{"termName":"ING-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Ep-CAM Monoclonal Antibody ING-1"},{"name":"NCI_Drug_Dictionary_ID","value":"357603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357603"},{"name":"PDQ_Open_Trial_Search_ID","value":"357603"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328238"}]}}{"C136981":{"preferredName":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310","code":"C136981","definitions":[{"definition":"A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's efficacy while lowering its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EphA2 Antibody-targeted Nanoliposome MM-310","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EphA2 Docetaxel-based Nanoliposome MM-310","termGroup":"SY","termSource":"NCI"},{"termName":"EphA2-targeted Docetaxel Nanoliposome MM-310","termGroup":"SY","termSource":"NCI"},{"termName":"MM 310","termGroup":"CN","termSource":"NCI"},{"termName":"MM-310","termGroup":"CN","termSource":"NCI"},{"termName":"MM310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310"},{"name":"NCI_Drug_Dictionary_ID","value":"789748"},{"name":"NCI_META_CUI","value":"CL524774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789748"},{"name":"PDQ_Open_Trial_Search_ID","value":"789748"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118447":{"preferredName":"Anti-EphA2 Monoclonal Antibody DS-8895a","code":"C118447","definitions":[{"definition":"A monoclonal antibody directed against the ephrin receptor A2 (EphA2), with potential antineoplastic activity. Upon administration, anti-EphA2 monoclonal antibody DS-8895a selectively binds to cells expressing the EphA2 receptor. This blocks EphA2 activation and EphA2-mediated signaling. In addition, DS-8895a may activate an immune response against EphA2-expressing tumor cells. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EphA2 Monoclonal Antibody DS-8895a","termGroup":"PT","termSource":"NCI"},{"termName":"DS-8895a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EphA2 Monoclonal Antibody DS-8895a"},{"name":"NCI_Drug_Dictionary_ID","value":"756010"},{"name":"NCI_META_CUI","value":"CL471759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756010"},{"name":"PDQ_Open_Trial_Search_ID","value":"756010"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79836":{"preferredName":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","code":"C79836","definitions":[{"definition":"An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti-EphA2 monoclonal antibody-MMAF immunoconjugate MEDI-547 is generated by conjugating the fully human IgG1 anti-EphA2 monoclonal antibody (1C1) to the small-molecule microtubule inhibitor monomethyl auristatin phenylalanine (MMAF) via the stable linker maleimidocaproyl (mc) (1C1-mcMMAF). The monoclonal antibody moiety of this agent selectively binds to cells expressing the EphA2 receptor. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","termGroup":"PT","termSource":"NCI"},{"termName":"1C1-mcMMAF","termGroup":"AB","termSource":"NCI"},{"termName":"Medi-547","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D21E6RU881"},{"name":"Legacy Concept Name","value":"Anti-EphA2_Monoclonal_Antibody-MMAF_Immunoconjugate_MEDI-547"},{"name":"Maps_To","value":"Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547"},{"name":"NCI_Drug_Dictionary_ID","value":"629927"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629927"},{"name":"PDQ_Open_Trial_Search_ID","value":"629927"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703178"}]}}{"C85486":{"preferredName":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111","code":"C85486","definitions":[{"definition":"A bispecific monoclonal antibody directed against the human epidermal growth factor receptors ErbB2 (Her2) and ErbB3 (Her3) with potential antineoplastic activity. The anti-ErB2 targeting arm of anti-ErbB2/anti-ErbB3 bispecific monoclonal antibody MM-111 binds to ErbB2 on tumor cells with high affinity while the anti-Erb3 therapeutic arm binds to ErbB3, which may result in the inhibition of cellular proliferation and differentiation in ErbB2-overexpressing tumor cells via inhibition of ErbB3-dependent signal transduction pathways. ErbB2 and ErB3 are members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and are frequently overexpressed in solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111","termGroup":"PT","termSource":"NCI"},{"termName":"MM-111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1361108-53-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6IJ4CQY76O"},{"name":"Maps_To","value":"Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111"},{"name":"NCI_Drug_Dictionary_ID","value":"647542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647542"},{"name":"PDQ_Open_Trial_Search_ID","value":"647542"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830144"}]}}{"C158746":{"preferredName":"Barecetamab","code":"C158746","definitions":[{"definition":"A fully human antibody directed against the receptor tyrosine-protein kinase erbB-3 (ErbB3; HER3) with potential antineoplastic activity. Upon intravenous administration, barecetamab targets and binds to domain 3 and weakly interacts with domain 1 of ErbB3. This prevents heregulin (HRG) binding and blocks dimerization of ErbB3, thereby inactivating ErbB3 downstream signaling. ISU104 may also elicit the internalization of ErbB3 from the plasma membrane and downregulate ErbB3 expression. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Barecetamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ErbB3 Antibody ISU104","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER3 Antibody ISU104","termGroup":"SY","termSource":"NCI"},{"termName":"ISU 104","termGroup":"CN","termSource":"NCI"},{"termName":"ISU-104","termGroup":"SY","termSource":"NCI"},{"termName":"ISU104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2275727-74-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M9SE4M9U1V"},{"name":"Maps_To","value":"Anti-ErbB3 Antibody ISU104"},{"name":"NCI_Drug_Dictionary_ID","value":"797411"},{"name":"NCI_META_CUI","value":"CL950712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797411"},{"name":"PDQ_Open_Trial_Search_ID","value":"797411"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102535":{"preferredName":"Anti-ErbB3 Monoclonal Antibody AV-203","code":"C102535","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) directed against the human receptor tyrosine-protein kinase ErbB-3 (HER3) with potential antineoplastic activity. Anti-ErbB3 MoAb AV-203 binds to and inhibits both ligand neuregulin-1 (NRG-1)-dependent and ligand-independent ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and may lead to inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family, is frequently overexpressed in solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB3 Monoclonal Antibody AV-203","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ErbB3 MoAb AV-203","termGroup":"SY","termSource":"NCI"},{"termName":"AV 203","termGroup":"CN","termSource":"NCI"},{"termName":"AV-203","termGroup":"CN","termSource":"NCI"},{"termName":"AV203","termGroup":"CN","termSource":"NCI"},{"termName":"CAN-017","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353581-77-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"841P9W25WA"},{"name":"Maps_To","value":"Anti-ErbB3 Monoclonal Antibody AV-203"},{"name":"NCI_Drug_Dictionary_ID","value":"734410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734410"},{"name":"PDQ_Open_Trial_Search_ID","value":"734410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640798"}]}}{"C113333":{"preferredName":"Anti-ErbB3 Monoclonal Antibody CDX-3379","code":"C113333","definitions":[{"definition":"A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (HER3), with potential antineoplastic activity. Upon administration, the anti-ErbB3 monoclonal antibody CDX-3379 targets and binds to a unique epitope on ErbB3, thereby preventing ErbB3 phosphorylation and both ligand-dependent and ligand-independent ErbB3 signaling. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB3 Monoclonal Antibody CDX-3379","termGroup":"PT","termSource":"NCI"},{"termName":"CDX 3379","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-3379","termGroup":"CN","termSource":"NCI"},{"termName":"CDX3379","termGroup":"CN","termSource":"NCI"},{"termName":"KTN 3379","termGroup":"CN","termSource":"NCI"},{"termName":"KTN-3379","termGroup":"CN","termSource":"NCI"},{"termName":"KTN3379","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2070921-00-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"00X6I56YXR"},{"name":"Maps_To","value":"Anti-ErbB3 Monoclonal Antibody CDX-3379"},{"name":"NCI_Drug_Dictionary_ID","value":"756069"},{"name":"NCI_META_CUI","value":"CL458161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756069"},{"name":"PDQ_Open_Trial_Search_ID","value":"756069"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103859":{"preferredName":"Anti-ErbB3 Monoclonal Antibody REGN1400","code":"C103859","definitions":[{"definition":"A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Upon administration, anti-ErbB3 monoclonal antibody REGN1400 binds to ErbB3 and prevents neuregulin 1 ligand binding to ErbB3, which may result in an inhibition of ErbB3-dependent phosphatidylinositol-3 kinase (PI3K)/Akt signaling. This eventually leads to the inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ErbB3 Monoclonal Antibody REGN1400","termGroup":"PT","termSource":"NCI"},{"termName":"REGN 1400","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-1400","termGroup":"CN","termSource":"NCI"},{"termName":"REGN1400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443016-81-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"93F274N35Z"},{"name":"Maps_To","value":"Anti-ErbB3 Monoclonal Antibody REGN1400"},{"name":"NCI_Drug_Dictionary_ID","value":"743118"},{"name":"NCI_META_CUI","value":"CL438337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743118"},{"name":"PDQ_Open_Trial_Search_ID","value":"743118"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103863":{"preferredName":"Istiratumab","code":"C103863","definitions":[{"definition":"A bispecific monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) and the human insulin-like growth factor-1 receptor (IGF-1R), with potential antineoplastic activity. The anti-IGF-1R targeting arm of Istiratumab binds to IGF-1R on tumor cells thereby preventing the binding of the natural ligands IGF-1, 2 and heregulin (HRG) to IGF-1R; the anti-ErbB3 therapeutic arm prevents the binding of neuregulin (NRG) to ErbB3. This prevents the activation of the PI3K/AKT signal transduction pathway and may result in both the induction of apoptosis and a decrease in cellular proliferation in IGF-1R and ErbB3-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, and ErB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Istiratumab","termGroup":"PT","termSource":"NCI"},{"termName":"MM-005","termGroup":"CN","termSource":"NCI"},{"termName":"MM-141","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1509928-04-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XLR461MD3M"},{"name":"Maps_To","value":"Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141"},{"name":"Maps_To","value":"Istiratumab"},{"name":"NCI_Drug_Dictionary_ID","value":"743370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743370"},{"name":"PDQ_Open_Trial_Search_ID","value":"743370"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641662"}]}}{"C116742":{"preferredName":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A","code":"C116742","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody against anti-endothelin B receptor (ETBR) and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DEDN6526A binds to ETBR-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. ETBR, a G-protein coupled receptor that can activate RAF/MEK signaling, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DEDN6526A","termGroup":"SY","termSource":"NCI"},{"termName":"DEDN6526A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A"},{"name":"NCI_Drug_Dictionary_ID","value":"724717"},{"name":"NCI_META_CUI","value":"CL433966"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724717"},{"name":"PDQ_Open_Trial_Search_ID","value":"724717"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129383":{"preferredName":"Simlukafusp Alfa","code":"C129383","definitions":[{"definition":"A recombinant fusion protein comprised of a human monoclonal antibody directed against fibroblast activation protein-alpha (FAP) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of simlukafusp alfa, the monoclonal antibody moiety recognizes and binds to FAP, thereby concentrating IL-2 in FAP-expressing tumor tissue. Subsequently, the IL-2 moiety of this fusion protein may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. FAP is a cell surface protein that is expressed on a wide variety of cancer cells. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simlukafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"aFAP-IL2v RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FAP/Interleukin-2 Fusion Protein RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"FAP-IL2v FP RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"FAP-IL2v RO6874281","termGroup":"SY","termSource":"NCI"},{"termName":"RG 7461","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7461","termGroup":"CN","termSource":"NCI"},{"termName":"RG7461","termGroup":"CN","termSource":"NCI"},{"termName":"RO 6874281","termGroup":"CN","termSource":"NCI"},{"termName":"RO-6874281","termGroup":"CN","termSource":"NCI"},{"termName":"RO6874281","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1776942-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FL08SGO9XA"},{"name":"Maps_To","value":"Anti-FAP/Interleukin-2 Fusion Protein RO6874281"},{"name":"Maps_To","value":"Simlukafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"783990"},{"name":"NCI_META_CUI","value":"CL512652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783990"},{"name":"PDQ_Open_Trial_Search_ID","value":"783990"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139549":{"preferredName":"Cevostamab","code":"C139549","definitions":[{"definition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevostamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FCRH5/CD3 BiTE Antibody BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FCRH5/CD3 TDB BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"BFCR4350A","termGroup":"CN","termSource":"NCI"},{"termName":"Cevostamab","termGroup":"SY","termSource":"NCI"},{"termName":"FCRH5/CD3 T Cell Dependent Bispecific Antibody BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"FCRH5/CD3 TDB Antibody BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A","termGroup":"SY","termSource":"NCI"},{"termName":"RO7187797","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249888-53-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P86BHN01VE"},{"name":"Maps_To","value":"Anti-FCRH5/CD3 BiTE Antibody BFCR4350A"},{"name":"Maps_To","value":"Cevostamab"},{"name":"NCI_Drug_Dictionary_ID","value":"791048"},{"name":"NCI_META_CUI","value":"CL526909"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791048"},{"name":"PDQ_Open_Trial_Search_ID","value":"791048"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107683":{"preferredName":"Aprutumab","code":"C107683","definitions":[{"definition":"An antibody against the fibroblast growth factor receptor type 2 (FGFR2), with potential antineoplastic activity. Upon administration, aprutumab binds to and inhibits FGFR2, which may result in the inhibition of both FGFR2 phosphorylation and FGFR2-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2, upregulated in many tumor cell types, is a receptor tyrosine kinase, which is essential to tumor cellular proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aprutumab","termGroup":"PT","termSource":"NCI"},{"termName":"AGC-2500","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1179470","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1179470","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1634620-63-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GK8781218Z"},{"name":"Maps_To","value":"Anti-FGFR2 Antibody BAY1179470"},{"name":"Maps_To","value":"Aprutumab"},{"name":"NCI_Drug_Dictionary_ID","value":"751593"},{"name":"NCI_META_CUI","value":"CL451871"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751593"},{"name":"PDQ_Open_Trial_Search_ID","value":"751593"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123829":{"preferredName":"Anti-FGFR3 Antibody-drug Conjugate LY3076226","code":"C123829","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody against the fibroblast growth factor receptor type 3 (FGFR3) that is conjugated to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the antibody moiety of anti-FGFR3 ADC LY3076226 binds to FGFR3. Upon internalization, the cytotoxic moiety causes cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FGFR3 Antibody-drug Conjugate LY3076226","termGroup":"PT","termSource":"NCI"},{"termName":"ADC LY3076226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FGFR3 ADC LY3076226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-fibroblast Growth Factor Receptor 3 Antibody-Drug Conjugate LY3076226","termGroup":"SY","termSource":"NCI"},{"termName":"LY3076226","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GP2L3N7FIM"},{"name":"Maps_To","value":"Anti-FGFR3 Antibody-drug Conjugate LY3076226"},{"name":"NCI_Drug_Dictionary_ID","value":"775899"},{"name":"NCI_META_CUI","value":"CL498222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775899"},{"name":"PDQ_Open_Trial_Search_ID","value":"775899"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126334":{"preferredName":"Anti-FGFR4 Monoclonal Antibody U3-1784","code":"C126334","definitions":[{"definition":"A human monoclonal antibody against human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, U3-1784 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FGFR4 Monoclonal Antibody U3-1784","termGroup":"PT","termSource":"NCI"},{"termName":"U3 1784","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1784","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-FGFR4 Monoclonal Antibody U3-1784"},{"name":"NCI_Drug_Dictionary_ID","value":"779617"},{"name":"NCI_META_CUI","value":"CL504900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779617"},{"name":"PDQ_Open_Trial_Search_ID","value":"779617"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129937":{"preferredName":"Anti-FLT3 Antibody-drug Conjugate AGS62P1","code":"C129937","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the extracellular domain of receptor-type tyrosine-protein kinase FLT3 (FLT-3; FMS-like tyrosine kinase 3; CD135; fetal-liver kinase 2; FLK2) and conjugated, via an oxime linker and the site-directed non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to a microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon administration of ADC AGS62P1, the antibody moiety targets and binds to FLT3. Upon antibody/antigen binding and internalization, the microtubule-targeting agent binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody, through pAcF, improves the biophysical properties of AGS62P1, increases payload distribution and stability, and optimizes its efficacy. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage, acute lymphoblastic leukemias and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FLT3 Antibody-drug Conjugate AGS62P1","termGroup":"PT","termSource":"NCI"},{"termName":"ADC AGS62P1","termGroup":"SY","termSource":"NCI"},{"termName":"AGS62P1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37I4D4Q7S2"},{"name":"Maps_To","value":"Anti-FLT3 Antibody-drug Conjugate AGS62P1"},{"name":"NCI_Drug_Dictionary_ID","value":"785317"},{"name":"NCI_META_CUI","value":"CL513016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785317"},{"name":"PDQ_Open_Trial_Search_ID","value":"785317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129376":{"preferredName":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM","code":"C129376","definitions":[{"definition":"A human, Fc-optimized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135), with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody 4G8-SDIEM blocks FLT3 ligand binding to FLT3 and subsequent phosphorylation of FLT3, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may lead to the inhibition of cellular proliferation and decreased survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM","termGroup":"PT","termSource":"NCI"},{"termName":"4G8-SDIEM","termGroup":"CN","termSource":"NCI"},{"termName":"FLYSYN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-FLT3 Monoclonal Antibody 4G8-SDIEM"},{"name":"NCI_Drug_Dictionary_ID","value":"783748"},{"name":"NCI_META_CUI","value":"CL512340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783748"},{"name":"PDQ_Open_Trial_Search_ID","value":"783748"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85453":{"preferredName":"Anti-FLT3 Monoclonal Antibody IMC-EB10","code":"C85453","definitions":[{"definition":"A fully human, IgG1 monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135) with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody IMC-EB10 blocks FLT3 ligand binding to FLT3 and subsequent FLT3 phosphorylation, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may result in the inhibition of cellular proliferation and survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-FLT3 Monoclonal Antibody IMC-EB10","termGroup":"PT","termSource":"NCI"},{"termName":"IMC-EB10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-FLT3 Monoclonal Antibody IMC-EB10"},{"name":"NCI_Drug_Dictionary_ID","value":"642753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642753"},{"name":"PDQ_Open_Trial_Search_ID","value":"642753"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830134"}]}}{"C156399":{"preferredName":"Emirodatamab","code":"C156399","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emirodatamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emirodatamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 427","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-427","termGroup":"CN","termSource":"NCI"},{"termName":"AMG427","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-FLT3 x Anti-CD3 BiTE AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FLT3/CD3 BiTE Antibody AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 427","termGroup":"SY","termSource":"NCI"},{"termName":"FLT3/CD3-directed Bispecific T-cell Engager Antibody AMG 427","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2449199-61-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P9I9Z3MF7Z"},{"name":"Maps_To","value":"Anti-FLT3/CD3 BiTE Antibody AMG 427"},{"name":"NCI_Drug_Dictionary_ID","value":"795695"},{"name":"NCI_META_CUI","value":"CL563094"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795695"},{"name":"PDQ_Open_Trial_Search_ID","value":"795695"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158067":{"preferredName":"Luveltamab Tazevibulin","code":"C158067","definitions":[{"definition":"An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luveltamab Tazevibulin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FolRa ADC STRO-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FolRalpha ADC STRO-002","termGroup":"SY","termSource":"NCI"},{"termName":"STRO 002","termGroup":"CN","termSource":"NCI"},{"termName":"STRO-002","termGroup":"CN","termSource":"NCI"},{"termName":"STRO002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2493327-62-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XDE2GOF1JT"},{"name":"Maps_To","value":"Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002"},{"name":"NCI_Drug_Dictionary_ID","value":"797174"},{"name":"NCI_META_CUI","value":"CL937710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797174"},{"name":"PDQ_Open_Trial_Search_ID","value":"797174"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118443":{"preferredName":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012","code":"C118443","definitions":[{"definition":"A monoclonal antibody directed against the ganglioside fucosyl-GM1, with potential antineoplastic and immunomodulating activities. Upon administration, anti-fucosyl-GM1 monoclonal antibody BMS-986012 binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1894272-37-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q8PK97HY9B"},{"name":"Maps_To","value":"Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012"},{"name":"NCI_Drug_Dictionary_ID","value":"764995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764995"},{"name":"PDQ_Open_Trial_Search_ID","value":"764995"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896899"}]}}{"C79795":{"preferredName":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962","code":"C79795","definitions":[{"definition":"A humanized anti-ganglioside GM2 (GM2) monoclonal antibody with potential antineoplastic and immunomodulating activities. Upon administration, anti-ganglioside GM2 monoclonal antibody BIW-8962 may activate an antibody dependent cellular cytotoxicity (ADCC) against GM2-expressing tumor cells. GM2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells, such as multiple myeloma (MM) cells and neuroblastoma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GM2 Monoclonal Antibody BIW-8962","termGroup":"SY","termSource":"NCI"},{"termName":"BIW-8962","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-Ganglioside_GM2_Monoclonal_Antibody_BIW-896"},{"name":"Maps_To","value":"Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962"},{"name":"NCI_Drug_Dictionary_ID","value":"618862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"618862"},{"name":"PDQ_Open_Trial_Search_ID","value":"618862"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2703163"}]}}{"C101524":{"preferredName":"Indusatumab Vedotin","code":"C101524","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a monoclonal antibody directed against guanylyl cyclase C (GCC or GUCY2C) conjugated to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. The monoclonal antibody moiety of indusatumab vedotin selectively binds to GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, but is also overexpressed on the surface of gastrointestinal cancers. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis in GCC-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indusatumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"MLN0264","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1514889-12-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3F0FR4W3H8"},{"name":"Maps_To","value":"Anti-GCC Antibody-Drug Conjugate MLN0264"},{"name":"Maps_To","value":"Indusatumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"732254"},{"name":"NCI_META_CUI","value":"CL435781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732254"},{"name":"PDQ_Open_Trial_Search_ID","value":"732254"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156707":{"preferredName":"Anti-GCC Antibody-Drug Conjugate TAK-164","code":"C156707","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of a full-length, fully-human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C), conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (IGN-P1), with potential antineoplastic activity. Upon intravenous administration of TAK-164, the antibody moiety selectively binds to GCC-expressing cells. Upon antibody/antigen binding and internalization, the cytotoxic DGN549 payload is released and binds to guanine residues on opposing strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of GCC-expressing cells. GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, is overexpressed on the surface of certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GCC Antibody-Drug Conjugate TAK-164","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GCC ADC TAK-164","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 164","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-164","termGroup":"CN","termSource":"NCI"},{"termName":"TAK164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QCA97P3GSS"},{"name":"Maps_To","value":"Anti-GCC Antibody-Drug Conjugate TAK-164"},{"name":"NCI_Drug_Dictionary_ID","value":"795729"},{"name":"NCI_META_CUI","value":"CL935871"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795729"},{"name":"PDQ_Open_Trial_Search_ID","value":"795729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158436":{"preferredName":"Nivatrotamab","code":"C158436","definitions":[{"definition":"A bispecific antibody comprised of a humanized anti-CD3 OKT3 (huOKT3) single chain variable fragment (scFv), linked to the carboxyl end of a humanized anti-GD2 3F8 (hu3F8) immunoglobulin G1 (IgG1) light chain, with potential antineoplastic activity. Upon intravenous administration, nivatrotamab binds to CD3 on T-cells and disialoganglioside GD2 expressed on certain tumor cells, thereby cross-linking T-cells with GD2-expressing tumor cells. This promotes a selective cytotoxic T-lymphocyte (CTL) response against GD2-expressing cells. The Fc region of the anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific antibody has two amino acid substitutions, N297A and K322A, which may prevent cytokine release syndrome and other unwanted side effects including complement-mediated pain. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells and is required for signal transduction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nivatrotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"hu3F8 x huOKT3 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"hu3F8-BsAb","termGroup":"AB","termSource":"NCI"},{"termName":"Humanized 3F8 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-GD2 x Anti-CD3 Bispecific Antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2278244-14-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8RV18E4A94"},{"name":"Maps_To","value":"Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody"},{"name":"NCI_Drug_Dictionary_ID","value":"804949"},{"name":"NCI_META_CUI","value":"CL937882"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80042":{"preferredName":"Anti-GD2 Monoclonal Antibody hu14.18K322A","code":"C80042","definitions":[{"definition":"A monoclonal antibody directed against human glycosphingolipid GD2 with potential antineoplastic activity. Upon binding to the GD2 antigen, anti-GD2 monoclonal antibody hu14.18K322A triggers a host immune response against GD2-expressing tumor cells, which may result in tumor cell death. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GD2 Monoclonal Antibody hu14.18K322A","termGroup":"PT","termSource":"NCI"},{"termName":"hu14.18K322A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-GD2_Monoclonal_Antibody_hu14_18K322A"},{"name":"Maps_To","value":"Anti-GD2 Monoclonal Antibody hu14.18K322A"},{"name":"NCI_Drug_Dictionary_ID","value":"614666"},{"name":"NCI_META_CUI","value":"CL388377"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614666"},{"name":"PDQ_Open_Trial_Search_ID","value":"614666"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C91383":{"preferredName":"Anti-GD2 Monoclonal Antibody MORAb-028","code":"C91383","definitions":[{"definition":"A human IgM monoclonal antibody directed against disialoganglioside GD2 with potential immunomodulating activity. Upon administration, anti-GD2 monoclonal antibody MORAb-028 may stimulate the immune system to exert a complement-mediated cytotoxic response against GD2-expressing tumor cells. The glycosphingolipid GD2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GD2 Monoclonal Antibody MORAb-028","termGroup":"PT","termSource":"NCI"},{"termName":"MORAb-028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GD2 Monoclonal Antibody MORAb-028"},{"name":"NCI_Drug_Dictionary_ID","value":"673996"},{"name":"NCI_META_CUI","value":"CL421587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673996"},{"name":"PDQ_Open_Trial_Search_ID","value":"673996"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136426":{"preferredName":"Anti-GD3 Antibody-drug Conjugate PF-06688992","code":"C136426","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells, and linked to an as of yet not fully elucidated chemotherapeutic agent, with potential antineoplastic activity. Upon administration of the ADC PF-06688992, the antibody moiety targets and binds to GD3 expressed on melanoma cells. Upon internalization, the chemotherapeutic agent specifically kills the GD3-positive cells. GD3 represents a major surface marker on most human melanoma cells and is not expressed on most other types of normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GD3 Antibody-drug Conjugate PF-06688992","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GD3 ADC PF-06688992","termGroup":"SY","termSource":"NCI"},{"termName":"GD3 ADC PF-06688992","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06688992","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06688992","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249791-21-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X6L6R3CFT8"},{"name":"Maps_To","value":"Anti-GD3 Antibody-drug Conjugate PF-06688992"},{"name":"NCI_Drug_Dictionary_ID","value":"789230"},{"name":"NCI_META_CUI","value":"CL523729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789230"},{"name":"PDQ_Open_Trial_Search_ID","value":"789230"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159411":{"preferredName":"Anti-GITR Agonistic Monoclonal Antibody ASP1951","code":"C159411","definitions":[{"definition":"A human, high-affinity, tetravalent monospecific agonistic monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357), with potential immune checkpoint modulating activity. Upon administration, anti-GITR agonistic monoclonal antibody ASP1951 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-lymphocytes. This induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs), which may promote the elimination of tumor cells. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Agonistic Monoclonal Antibody ASP1951","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GITR Agonistic Monoclonal Antibody PTZ-522","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 1951","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1951","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1951","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ 522","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ-522","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ522","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6WFM86G7J"},{"name":"Maps_To","value":"Anti-GITR Agonistic Monoclonal Antibody ASP1951"},{"name":"NCI_Drug_Dictionary_ID","value":"797644"},{"name":"NCI_META_CUI","value":"CL951269"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797644"},{"name":"PDQ_Open_Trial_Search_ID","value":"797644"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132267":{"preferredName":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156","code":"C132267","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody BMS-986156 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GITR MoAb BMS-986156","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986156","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986156","termGroup":"CN","termSource":"NCI"},{"termName":"GITR Agonist BMS-986156","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF18 Agonist BMS-986156","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V0XQ564M2L"},{"name":"Maps_To","value":"Anti-GITR Agonistic Monoclonal Antibody BMS-986156"},{"name":"NCI_Drug_Dictionary_ID","value":"780443"},{"name":"NCI_META_CUI","value":"CL507899"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780443"},{"name":"PDQ_Open_Trial_Search_ID","value":"780443"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126643":{"preferredName":"Ragifilimab","code":"C126643","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody, with potential immune checkpoint modulating activity. Ragifilimab binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ragifilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GITR Agonistic Monoclonal Antibody INCAGN01876","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 01876","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN 1876","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN-1876","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN01876","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2207590-51-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O440IW9NHN"},{"name":"Maps_To","value":"Anti-GITR Agonistic Monoclonal Antibody INCAGN01876"},{"name":"Maps_To","value":"Ragifilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"779746"},{"name":"NCI_META_CUI","value":"CL503760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779746"},{"name":"PDQ_Open_Trial_Search_ID","value":"779746"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128028":{"preferredName":"Anti-GITR Monoclonal Antibody GWN 323","code":"C128028","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody GWN 323 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Monoclonal Antibody GWN 323","termGroup":"PT","termSource":"NCI"},{"termName":"GWN 323","termGroup":"CN","termSource":"NCI"},{"termName":"GWN323","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WYJ05POC5C"},{"name":"Maps_To","value":"Anti-GITR Monoclonal Antibody GWN 323"},{"name":"NCI_Drug_Dictionary_ID","value":"781243"},{"name":"NCI_META_CUI","value":"CL507922"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781243"},{"name":"PDQ_Open_Trial_Search_ID","value":"781243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116065":{"preferredName":"Anti-GITR Monoclonal Antibody MK-4166","code":"C116065","definitions":[{"definition":"An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody (MoAb) with potential immunomodulating activity. Anti-GITR monoclonal antibody MK-4166 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system and induces both the activation and proliferation of tumor-antigen-specific T effector cells, and suppresses the function of activated T regulatory cells. This leads to tumor cell eradication. Also, this agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including regulatory T-cells, effector T-cells, B-cells, and natural killer (NK) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GITR Monoclonal Antibody MK-4166","termGroup":"PT","termSource":"NCI"},{"termName":"MK-4166","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GITR Monoclonal Antibody MK-4166"},{"name":"NCI_Drug_Dictionary_ID","value":"760889"},{"name":"NCI_META_CUI","value":"CL473484"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760889"},{"name":"PDQ_Open_Trial_Search_ID","value":"760889"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153261":{"preferredName":"Anti-Globo H Monoclonal Antibody OBI-888","code":"C153261","definitions":[{"definition":"A monoclonal antibody targeting the hexasaccharide glycosphingolipid antigen Globo H with potential immunostimulating, anti-angiogenic and antineoplastic activities. Upon infusion, anti-Globo H monoclonal antibody OBI-888 may induce tumor cell destruction via the activation of antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), and may reduce immunosuppression. Globo H is a tumor-associated antigen (TAA) expressed on the surface of various types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Globo H Monoclonal Antibody OBI-888","termGroup":"PT","termSource":"NCI"},{"termName":"OBI 888","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-888","termGroup":"CN","termSource":"NCI"},{"termName":"OBI888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2227156-40-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JI5TBH62QP"},{"name":"Maps_To","value":"Anti-Globo H Monoclonal Antibody OBI-888"},{"name":"NCI_Drug_Dictionary_ID","value":"794060"},{"name":"NCI_META_CUI","value":"CL554489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794060"},{"name":"PDQ_Open_Trial_Search_ID","value":"794060"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129936":{"preferredName":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974","code":"C129936","definitions":[{"definition":"An anti-glypican 3 (GPC3; GPC-3)/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-GPC3/CD3 bispecific antibody ERY974 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for GPC3, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of ERY974, this bispecific antibody simultaneously binds to both CD3-expressing and GPC3-expressing cells, thereby crosslinking GPC3-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and an oncofetal antigen protein, is overexpressed in a variety of cancers; it plays a role in cell division and growth regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GPC3/CD3 BiAb ERY974","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GPC3/CD3 Bispecific Antibody ERY974","termGroup":"SY","termSource":"NCI"},{"termName":"ERY974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PGF2HXQ0D3"},{"name":"Maps_To","value":"Anti-Glypican 3/CD3 Bispecific Antibody ERY974"},{"name":"NCI_Drug_Dictionary_ID","value":"785257"},{"name":"NCI_META_CUI","value":"CL512901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785257"},{"name":"PDQ_Open_Trial_Search_ID","value":"785257"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85464":{"preferredName":"Anti-GnRH Vaccine PEP223","code":"C85464","definitions":[{"definition":"A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GnRH Vaccine PEP223","termGroup":"PT","termSource":"NCI"},{"termName":"PEP223","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GnRH Vaccine PEP223"},{"name":"NCI_Drug_Dictionary_ID","value":"643767"},{"name":"NCI_META_CUI","value":"CL412337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643767"},{"name":"PDQ_Open_Trial_Search_ID","value":"643767"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118442":{"preferredName":"Anti-gpA33/CD3 Monoclonal Antibody MGD007","code":"C118442","definitions":[{"definition":"An anti-glycoprotein A33 (gpA33)/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-gpA33/CD3 monoclonal antibody MGD007 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for gpA33, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of MGD007, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and gpA33-expressing cancer cells, thereby crosslinking cytotoxic T-lymphocytes (CTLs) to gpA33-expressing tumor cells. This may result in CTL-mediated cell lysis of the crosslinked tumor cells. The gpA33 antigen, a member of the immunoglobulin superfamily, is expressed in certain malignancies, including colon and gastrointestinal cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-gpA33/CD3 Monoclonal Antibody MGD007","termGroup":"PT","termSource":"NCI"},{"termName":"Humanized gpA33 x CD3 DART (TM) Protein MGD007","termGroup":"SY","termSource":"NCI"},{"termName":"MGD007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OZ8N9U6CEH"},{"name":"Maps_To","value":"Anti-gpA33/CD3 Monoclonal Antibody MGD007"},{"name":"NCI_Drug_Dictionary_ID","value":"764994"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764994"},{"name":"PDQ_Open_Trial_Search_ID","value":"764994"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896811"}]}}{"C103857":{"preferredName":"Anti-GRP78 Monoclonal Antibody PAT-SM6","code":"C103857","definitions":[{"definition":"A IgM monoclonal antibody (MoAb) against 78-kDa glucose-regulated protein (GRP78; also called BiP or HSPA5), with potential proapoptotic and antineoplastic activities. Upon intravenous administration of the anti-GRP78 monoclonal antibody PAT-SM6, the MoAb strongly binds to GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking the GRP78-induced suppression of apoptotic pathways. This eventually leads to the induction of tumor cell apoptosis and a reduction in tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types; its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GRP78 Monoclonal Antibody PAT-SM6","termGroup":"PT","termSource":"NCI"},{"termName":"PAT-SM6","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GRP78 Monoclonal Antibody PAT-SM6"},{"name":"NCI_Drug_Dictionary_ID","value":"743101"},{"name":"NCI_META_CUI","value":"CL438335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743101"},{"name":"PDQ_Open_Trial_Search_ID","value":"743101"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C131295":{"preferredName":"Anti-HA Epitope Monoclonal Antibody MEDI8852","code":"C131295","definitions":[{"definition":"A human immunoglobulin (Ig) G1 kappa monoclonal antibody (mAb) targeting a unique epitope in the stalk of the influenza A hemagglutinin (HA) protein, with broad influenza A virus neutralization activity. MEDI8852 was derived from an antibody isolated from human memory B-cells from patients previously infected with influenza caused by type A strains that was further optimized to increase neutralization potential. Upon infusion, MEDI8852 targets and binds to a region within the stalk of the HA protein that is highly conserved amongst all influenza A virus subtypes. This neutralizes and prevents essential steps of the viral lifecycle, thereby blocking infectivity of all influenza A virus subtypes. HA, a glycoprotein found on the surface of the influenza virus, plays a key role in viral attachment and cell entry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HA Epitope Monoclonal Antibody MEDI8852","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Influenza A Hemagglutinin Epitope mAb MEDI8852","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 8852","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-8852","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI8852","termGroup":"CN","termSource":"NCI"},{"termName":"pan-Influenza A mAb MEDI8852","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OZS4TXB9VO"},{"name":"Maps_To","value":"Anti-HA Epitope Monoclonal Antibody MEDI8852"},{"name":"NCI_Drug_Dictionary_ID","value":"785886"},{"name":"NCI_META_CUI","value":"CL514244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785886"},{"name":"PDQ_Open_Trial_Search_ID","value":"785886"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95721":{"preferredName":"Anti-HB-EGF Monoclonal Antibody KHK2866","code":"C95721","definitions":[{"definition":"A proprietary fucose-free monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HB-EGF Monoclonal Antibody KHK2866 binds to HBEGF, thereby blocking its binding to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation. The fucose-free monoclonal antibodies enhance antigen dependent cellular cytotoxicity (ADCC), and increase binding affinity to the Fc Receptor to overcome genetic polymorphism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HB-EGF Monoclonal Antibody KHK2866","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HB-EGF MoAb KHK2866","termGroup":"SY","termSource":"NCI"},{"termName":"KHK2866","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1832713-21-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"111EN0IJ7C"},{"name":"Maps_To","value":"Anti-HB-EGF Monoclonal Antibody KHK2866"},{"name":"NCI_Drug_Dictionary_ID","value":"694265"},{"name":"NCI_META_CUI","value":"CL428183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694265"},{"name":"PDQ_Open_Trial_Search_ID","value":"694265"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95736":{"preferredName":"Anti-HBEGF Monoclonal Antibody U3-1565","code":"C95736","definitions":[{"definition":"A humanized monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HBEGF monoclonal antibody U3-1565 binds to HBEGF and blocks the binding of HBEGF to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HBEGF Monoclonal Antibody U3-1565","termGroup":"PT","termSource":"NCI"},{"termName":"U3-1565","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HBEGF Monoclonal Antibody U3-1565"},{"name":"NCI_Drug_Dictionary_ID","value":"695315"},{"name":"NCI_META_CUI","value":"CL428196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695315"},{"name":"PDQ_Open_Trial_Search_ID","value":"695315"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116630":{"preferredName":"Anti-hepcidin Monoclonal Antibody LY2787106","code":"C116630","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) targeting the peptide hormone hepcidin, with potential anti-anemic activity. Upon intravenous administration, anti-hepcidin MoAb LY2787106 binds to hepcidin and prevents it from binding to the iron exporting protein ferroportin, which is expressed on both the basolateral surface of gastrointestinal (GI) enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export, thus increasing iron export from macrophages and iron absorption by enterocytes. This normalizes plasma iron levels, increases erythropoiesis and may inhibit anemia. Hepcidin, produced in hepatocytes, plays a key role in the homeostasis of systemic iron; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-hepcidin Monoclonal Antibody LY2787106","termGroup":"PT","termSource":"NCI"},{"termName":"LY2787106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q87RWM02HX"},{"name":"Maps_To","value":"Anti-hepcidin Monoclonal Antibody LY2787106"},{"name":"NCI_Drug_Dictionary_ID","value":"687185"},{"name":"NCI_META_CUI","value":"CL433725"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687185"},{"name":"PDQ_Open_Trial_Search_ID","value":"687185"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162577":{"preferredName":"Anbenitamab","code":"C162577","definitions":[{"definition":"An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anbenitamab simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2 heterodimerization and prevents the activation of HER-2 signaling pathways. By binding to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anbenitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER-2 Bispecific Antibody KN026","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Heterodimeric Antibody KN026","termGroup":"SY","termSource":"NCI"},{"termName":"HER2 Bispecific Antibody KN026","termGroup":"SY","termSource":"NCI"},{"termName":"KN 026","termGroup":"CN","termSource":"NCI"},{"termName":"KN-026","termGroup":"CN","termSource":"NCI"},{"termName":"KN026","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2367012-88-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RHS90QRF9E"},{"name":"Maps_To","value":"Anti-HER-2 Bispecific Antibody KN026"},{"name":"NCI_Drug_Dictionary_ID","value":"798820"},{"name":"NCI_META_CUI","value":"CL971091"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798820"},{"name":"PDQ_Open_Trial_Search_ID","value":"798820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128799":{"preferredName":"Trastuzumab Deruxtecan","code":"C128799","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"DS-8201","termGroup":"CN","termSource":"NCI"},{"termName":"DS-8201a","termGroup":"CN","termSource":"NCI"},{"termName":"Enhertu","termGroup":"BR","termSource":"NCI"},{"termName":"Fam-trastuzumab Deruxtecan-nxki","termGroup":"SY","termSource":"NCI"},{"termName":"T-DXd","termGroup":"SY","termSource":"NCI"},{"termName":"WHO 10516","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH ) breast cancer; unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations."},{"name":"CAS_Registry","value":"1826843-81-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5384HK7574"},{"name":"Maps_To","value":"Anti-HER2 ADC DS-8201a"},{"name":"Maps_To","value":"Trastuzumab Deruxtecan"},{"name":"NCI_Drug_Dictionary_ID","value":"783025"},{"name":"NCI_META_CUI","value":"CL509598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783025"},{"name":"PDQ_Open_Trial_Search_ID","value":"783025"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156480":{"preferredName":"Trastuzumab Botidotin","code":"C156480","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated, via a cleavable linker, to the microtubule inhibitor and auristatin derivative duostatin-5 (Duo-5), with potential antineoplastic activity. Upon administration of trastuzumab botidotin, the trastuzumab moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, duo-5 binds to tubulin and inhibits its polymerization, which results in cell cycle arrest and induces tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Botidotin","termGroup":"PT","termSource":"NCI"},{"termName":"A 166","termGroup":"CN","termSource":"NCI"},{"termName":"A-166","termGroup":"CN","termSource":"NCI"},{"termName":"A166","termGroup":"CN","termSource":"NCI"},{"termName":"ADC A166","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC A166","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Antibody-drug Conjugate A166","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2699055-12-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6HUZ008AZX"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate A166"},{"name":"NCI_Drug_Dictionary_ID","value":"795827"},{"name":"NCI_META_CUI","value":"CL935677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795827"},{"name":"PDQ_Open_Trial_Search_ID","value":"795827"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123917":{"preferredName":"Anvatabart Opadotin","code":"C123917","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMAF) analog and potent microtubule inhibitor opadotin, with potential antineoplastic activity. Upon administration of anvatabart opadotin, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, opadotin binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of anvatabart opadotin, increases payload stability and optimizes its efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anvatabart Opadotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ARX788","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC ARX788","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Antibody-drug Conjugate ARX788","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788","termGroup":"SY","termSource":"NCI"},{"termName":"ARX788","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2636710-07-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B2KH16FA7H"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate ARX788"},{"name":"NCI_Drug_Dictionary_ID","value":"775851"},{"name":"NCI_META_CUI","value":"CL498281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775851"},{"name":"PDQ_Open_Trial_Search_ID","value":"775851"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126355":{"preferredName":"Anti-HER2 Antibody-drug Conjugate MEDI4276","code":"C126355","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a bispecific antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2; ERBB2) comprised of the single-chain variable fragment (scFv) of the anti- HER2 monoclonal antibody trastuzumab, which binds to domain IV of HER2, fused to the heavy chains of the anti-HER2 monoclonal antibody 39S, which binds to domain II of HER2, and conjugated, via a cleavable linker, to the cytotoxic anti-microtubule agent tubulysin, with potential antineoplastic activity. Upon administration of ADC MEDI4276, the anti-HER2 bispecific antibody specifically targets and binds to HER2 on the surface of certain cancer cells. Upon binding, crosslinking and internalization of antibody-HER2 complexes occurs and MEDI4276 is transported to the lysosome where the linker is cleaved, thereby delivering tubulysin inside HER2-expressing cancer cells. Tubulysin binds to tubulin and inhibits microtubule polymerization, which blocks cell division. This results in G2/M phase arrest, tumor cell apoptosis, and decreased proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Antibody-drug Conjugate MEDI4276","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MEDI4276","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-4276","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI4276","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAM3L34SEW"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate MEDI4276"},{"name":"NCI_Drug_Dictionary_ID","value":"780016"},{"name":"NCI_META_CUI","value":"CL504915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780016"},{"name":"PDQ_Open_Trial_Search_ID","value":"780016"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130011":{"preferredName":"Anti-HER2 Antibody-drug Conjugate RC48","code":"C130011","synonyms":[{"termName":"Anti-HER2 Antibody-drug Conjugate RC48","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Feb 02 11:54:11 EST 2022 - See 'Disitamab Vedotin(C169918)'"},{"name":"OLD_PARENT","value":"C155712"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130010":{"preferredName":"Zanidatamab","code":"C130010","definitions":[{"definition":"An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, with potential immunomodulating and antineoplastic activities. Upon administration, zanidatamab targets and binds to the two distinct HER2 domains on the tumor cell surface. This results in dual HER2 signal blockade, HER2 clustering, receptor internalization and downregulation. This also induces a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. Antibody-dependent cellular phagocytosis (ADCP) is also induced and further stimulates the immune system to kill HER2-overexpressing tumor cells. The HER2 receptor internalization also further inhibits HER2 activation, HER2-mediated signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanidatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2/HER2 Bispecific Antibody ZW25","termGroup":"SY","termSource":"NCI"},{"termName":"HER2 x HER2 Bispecific Antibody ZW25","termGroup":"SY","termSource":"NCI"},{"termName":"ZW-25","termGroup":"CN","termSource":"NCI"},{"termName":"ZW25","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169946-15-8"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z20OC92TDI"},{"name":"Maps_To","value":"Anti-HER2 Bi-specific Monoclonal Antibody ZW25"},{"name":"Maps_To","value":"Zanidatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"784826"},{"name":"NCI_META_CUI","value":"CL514017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784826"},{"name":"PDQ_Open_Trial_Search_ID","value":"784826"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162115":{"preferredName":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49","code":"C162115","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a bispecific monoclonal antibody (ZW25) directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2, receptor tyrosine-protein kinase erbB-2) linked to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon intravenous administration, anti-HER2 bispecific ADC ZW49 targets and binds to HER2 expressed on tumor cells. Following receptor internalization, the cytotoxic payload is released and induces tumor cell death through an as of yet unknown mechanism of action. Additionally, binding of HER2 may inhibit HER2 activation, HER2 signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ZW49","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Bispecific ADC ZW49","termGroup":"SY","termSource":"NCI"},{"termName":"ZW-49","termGroup":"CN","termSource":"NCI"},{"termName":"ZW49","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Bispecific Antibody-drug Conjugate ZW49"},{"name":"NCI_Drug_Dictionary_ID","value":"798595"},{"name":"NCI_META_CUI","value":"CL970593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798595"},{"name":"PDQ_Open_Trial_Search_ID","value":"798595"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160349":{"preferredName":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395","code":"C160349","definitions":[{"definition":"An immune stimulator-antibody conjugate (ISAC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a not yet disclosed immune stimulator, with potential antineoplastic and immunostimulating activities. Upon administration of the anti-HER2 immune stimulator-antibody conjugate NJH395, the antibody moiety targets and binds to HER2 expressed on tumor cells. Upon antibody/antigen binding, the immune-stimulating moiety may, through an as of yet undisclosed mechanism, enhance the immune-mediated killing of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed in many cancer types and plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 ISAC NJH395","termGroup":"SY","termSource":"NCI"},{"termName":"NJH 395","termGroup":"CN","termSource":"NCI"},{"termName":"NJH-395","termGroup":"CN","termSource":"NCI"},{"termName":"NJH395","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"301EY96MDU"},{"name":"Maps_To","value":"Anti-HER2 Immune Stimulator-antibody Conjugate NJH395"},{"name":"NCI_Drug_Dictionary_ID","value":"798283"},{"name":"NCI_META_CUI","value":"CL969413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798283"},{"name":"PDQ_Open_Trial_Search_ID","value":"798283"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1647":{"preferredName":"Trastuzumab","code":"C1647","definitions":[{"definition":"A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type of HER2 receptor antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 980","termGroup":"CN","termSource":"NCI"},{"termName":"ALT02","termGroup":"CN","termSource":"NCI"},{"termName":"Biceltis","termGroup":"FB","termSource":"NCI"},{"termName":"CANMab","termGroup":"FB","termSource":"NCI"},{"termName":"CT-P06","termGroup":"CN","termSource":"NCI"},{"termName":"CT-P6","termGroup":"CN","termSource":"NCI"},{"termName":"Herceptin","termGroup":"BR","termSource":"NCI"},{"termName":"Herceptin Biosimilar PF-05280014","termGroup":"SY","termSource":"NCI"},{"termName":"Herceptin Trastuzumab Biosimilar PF-05280014","termGroup":"SY","termSource":"NCI"},{"termName":"Hercessi","termGroup":"BR","termSource":"NCI"},{"termName":"Herclon","termGroup":"FB","termSource":"NCI"},{"termName":"Hertraz","termGroup":"FB","termSource":"NCI"},{"termName":"Herwenda","termGroup":"FB","termSource":"NCI"},{"termName":"Herzuma","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Kanjinti","termGroup":"BR","termSource":"NCI"},{"termName":"Ogivri","termGroup":"BR","termSource":"NCI"},{"termName":"Ontruzant","termGroup":"BR","termSource":"NCI"},{"termName":"PF-05280014","termGroup":"CN","termSource":"NCI"},{"termName":"QL 1701","termGroup":"CN","termSource":"NCI"},{"termName":"QL-1701","termGroup":"CN","termSource":"NCI"},{"termName":"QL1701","termGroup":"CN","termSource":"NCI"},{"termName":"rhuMAb HER2","termGroup":"AB","termSource":"NCI"},{"termName":"RO0452317","termGroup":"CN","termSource":"NCI"},{"termName":"SB3","termGroup":"CN","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar ABP 980","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar ALT02","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar CT-P6","termGroup":"SY","termSource":"NCI"},{"termName":"trastuzumab biosimilar EG12014","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar HLX02","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar PF-05280014","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar QL1701","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar SB3","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Biosimilar SIBP-01","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-anns","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-dkst","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-dttb","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-pkrb","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-qyyp","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-strf","termGroup":"SY","termSource":"NCI"},{"termName":"Trazimera","termGroup":"BR","termSource":"NCI"},{"termName":"Zercepac","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer overexpressing HER2 protein; Pancreatic cancer overexpressing p185HER2"},{"name":"CAS_Registry","value":"180288-69-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"P188ANX8CK"},{"name":"Legacy Concept Name","value":"Trastuzumab"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody CT-P6"},{"name":"Maps_To","value":"Trastuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42265"},{"name":"NSC Number","value":"688097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42265"},{"name":"PDQ_Open_Trial_Search_ID","value":"42265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0728747"}]}}{"C142890":{"preferredName":"Cinrebafusp Alfa","code":"C142890","definitions":[{"definition":"A bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin with potential immunostimulatory and antineoplastic activities. Upon administration of cinrebafusp alfa, CD137 clustering is promoted by bridging CD137-positive T-cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. CD137 is a costimulatory immunoreceptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). Anticalins are synthetic antigen-binding proteins derived from lipocalins. Structurally dissimilar to antibodies, anticalins are able to bind to smaller antigens and exhibit improved tissue penetration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinrebafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 Monoclonal Antibody/Anti-CD137 Anticalin Bispecific Fusion Protein PRS-343","termGroup":"SY","termSource":"NCI"},{"termName":"PRS-343","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2218515-90-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"21Z359Z1CV"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody/Anti-CD137 Anticalin Bispecific Fusion Protein PRS-343"},{"name":"Maps_To","value":"Cinrebafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"791831"},{"name":"NCI_META_CUI","value":"CL541381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791831"},{"name":"PDQ_Open_Trial_Search_ID","value":"791831"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141420":{"preferredName":"Anti-HER2-vc0101 ADC PF-06804103","code":"C141420","definitions":[{"definition":"A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2-vc0101 ADC PF-06804103","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2-vcAur0101 ADC PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NG-HER2 ADC PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NG-Her2-vc0101 ADC PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate PF-06804103","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06804103","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06804103","termGroup":"CN","termSource":"NCI"},{"termName":"PF06804103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2-vc0101 ADC PF-06804103"},{"name":"NCI_Drug_Dictionary_ID","value":"791410"},{"name":"NCI_META_CUI","value":"CL539508"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791410"},{"name":"PDQ_Open_Trial_Search_ID","value":"791410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156705":{"preferredName":"Runimotamab","code":"C156705","definitions":[{"definition":"An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Runimotamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody RG 6194","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody 4017A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A","termGroup":"SY","termSource":"NCI"},{"termName":"BTRC 4017A","termGroup":"CN","termSource":"NCI"},{"termName":"BTRC-4017A","termGroup":"SY","termSource":"NCI"},{"termName":"BTRC4017A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 6194","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6194","termGroup":"CN","termSource":"NCI"},{"termName":"RG6194","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2361325-98-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F8Z9VSZ0K1"},{"name":"Maps_To","value":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A"},{"name":"NCI_Drug_Dictionary_ID","value":"795725"},{"name":"NCI_META_CUI","value":"CL935873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795725"},{"name":"PDQ_Open_Trial_Search_ID","value":"795725"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142889":{"preferredName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","code":"C142889","definitions":[{"definition":"An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 bispecific monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-HER2/Anti-CD3 bispecific monoclonal antibody GBR 1302 possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of GBR 1302, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","termGroup":"SY","termSource":"NCI"},{"termName":"GBR 1302","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HA8VPA83AE"},{"name":"Maps_To","value":"Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302"},{"name":"NCI_Drug_Dictionary_ID","value":"791830"},{"name":"NCI_META_CUI","value":"CL541380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791830"},{"name":"PDQ_Open_Trial_Search_ID","value":"791830"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C152948":{"preferredName":"Zenocutuzumab","code":"C152948","definitions":[{"definition":"A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zenocutuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 x Anti-HER3 Bispecific Monoclonal Antibody MCLA-128","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128","termGroup":"SY","termSource":"NCI"},{"termName":"MCLA 128","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA-128","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA128","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1969309-56-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AE72RB1W1X"},{"name":"Maps_To","value":"Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128"},{"name":"NCI_Drug_Dictionary_ID","value":"794043"},{"name":"NCI_META_CUI","value":"CL554279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794043"},{"name":"PDQ_Open_Trial_Search_ID","value":"794043"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132112":{"preferredName":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522","code":"C132112","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed against the human epidermal growth factor receptor 2 (ERBB2; HER2), conjugated, via a proprietary biodegradable, hydrophilic polymer backbone and various linkers, to proprietary auristatin-derived payload molecules (about 15 per antibody), with potential antineoplastic activity. Upon administration of anti-HER2/auristatin payload ADC XMT-1522, the antibody moiety targets and binds to a unique epitope in the extracellular domain (ECD) of HER2. Upon internalization, cleavage and release of the cytotoxic molecules, the auristatin-derived molecules bind to tubulin and inhibit its polymerization, which results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells. The attachment of multiple auristatin molecules to the backbone enables XMT-1522 to effectively kill tumors that express relatively low amounts of the HER2 protein; therefore, this agent shows increased therapeutic potential in tumors with low HER2 expression compared to other anti-HER2 antibody-based therapies. The polymer-based proprietary platform optimizes delivery of the cytotoxic drug payload and improves drug solubility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522","termGroup":"PT","termSource":"NCI"},{"termName":"ADC XMT-1522","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC XMT-1522","termGroup":"SY","termSource":"NCI"},{"termName":"XMT-1522","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522"},{"name":"NCI_Drug_Dictionary_ID","value":"786937"},{"name":"NCI_META_CUI","value":"CL520319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786937"},{"name":"PDQ_Open_Trial_Search_ID","value":"786937"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155940":{"preferredName":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A","code":"C155940","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) linked to a DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA), with potential antineoplastic activity. Upon intravenous administration of ADC DHES0815A, the monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD-MA moiety is released. In turn, the imine groups of the PBD-MA moiety bind to and crosslink specific sites of DNA, resulting in DNA strand breaks, cell cycle arrest, and cell death in HER2 expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DHES0815A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/PBD-MA ADC DHES0815A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/PBD-Monoamide ADC DHES0815A","termGroup":"SY","termSource":"NCI"},{"termName":"DHES0815A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1E55T9OY5I"},{"name":"Maps_To","value":"Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A"},{"name":"NCI_Drug_Dictionary_ID","value":"795265"},{"name":"NCI_META_CUI","value":"CL562792"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795265"},{"name":"PDQ_Open_Trial_Search_ID","value":"795265"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136987":{"preferredName":"Patritumab Deruxtecan","code":"C136987","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patritumab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER3 Antibody-drug Conjugate U3 1402","termGroup":"SY","termSource":"NCI"},{"termName":"U3 1402","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1402","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1402a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2227102-46-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3XPI7EG4W8"},{"name":"Maps_To","value":"Anti-HER3 Antibody-drug Conjugate U3 1402"},{"name":"Maps_To","value":"Patritumab Deruxtecan"},{"name":"NCI_Drug_Dictionary_ID","value":"789807"},{"name":"NCI_META_CUI","value":"CL524745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789807"},{"name":"PDQ_Open_Trial_Search_ID","value":"789807"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111997":{"preferredName":"Anti-HER3 Monoclonal Antibody GSK2849330","code":"C111997","definitions":[{"definition":"A monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3) with potential antineoplastic activity. Anti-HER3 monoclonal antibody GSK2849330 binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER3 Monoclonal Antibody GSK2849330","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2849330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER3 Monoclonal Antibody GSK2849330"},{"name":"NCI_Drug_Dictionary_ID","value":"754219"},{"name":"NCI_META_CUI","value":"CL454286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754219"},{"name":"PDQ_Open_Trial_Search_ID","value":"754219"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C81939":{"preferredName":"Anti-HGF Monoclonal Antibody TAK-701","code":"C81939","definitions":[{"definition":"A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody TAK-701 binds to the soluble ligand HGF, preventing HGF binding to and activation of the HGF receptor c-Met and so the activation of the c-Met signaling pathway; this may result in the induction of cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HGF Monoclonal Antibody TAK-701","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HGF MoAb TAK-701","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-HGF_Monoclonal_Antibody_TAK-701"},{"name":"Maps_To","value":"Anti-HGF Monoclonal Antibody TAK-701"},{"name":"NCI_Drug_Dictionary_ID","value":"637760"},{"name":"NCI_META_CUI","value":"CL407463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637760"},{"name":"PDQ_Open_Trial_Search_ID","value":"637760"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68930":{"preferredName":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","code":"C68930","definitions":[{"definition":"A synthetic antisense oligodeoxynucleotide (AS ODN) targeting hypoxia-inducible factor-1alpha (HIF-1alpha) with potential antineoplastic activity. Anti-HIF-1alpha LNA antisense oligonucleotide EZN-2968 hybridizes with HIF-1alpha mRNA and blocks t HIF-1 alpha protein expression, which may result in the inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1alpha, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","termGroup":"PT","termSource":"NCI"},{"termName":"anti-HIF-1alpha LNA AS-ODN","termGroup":"SY","termSource":"NCI"},{"termName":"EZN-2968","termGroup":"CN","termSource":"NCI"},{"termName":"RO7070179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-HIF-1alpha_LNA_Antisense_Oligonucleotide_EZN-2968"},{"name":"Maps_To","value":"Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968"},{"name":"NCI_Drug_Dictionary_ID","value":"549337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"549337"},{"name":"PDQ_Open_Trial_Search_ID","value":"549337"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607869"}]}}{"C165547":{"preferredName":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1","code":"C165547","definitions":[{"definition":"A gene transfer construct composed of a self-inactivating (SIN) lentiviral vector (LV) expressing a short hairpin RNA (shRNA) that targets the human C-C chemokine receptor type 5 (CCR5) mRNA (sh5) and expressing the HIV entry inhibitor C46, with potential anti-human immunodeficiency virus (HIV) type 1 (HIV-1) activity. Upon transduction of the anti-HIV-1 LVsh5/C46 Cal-1 in specified blood cell populations, such as peripheral blood mononuclear cells (PBMCs), hematopoietic stem/progenitor cells (HSPCs) and CD4+ T-lymphocytes, the cells express shCCR5 and C46. shCCR5 targets and binds to CCR5 mRNA, which inhibits the expression of CCR5 and prevents binding of the virus to the cellular CCR5 co-receptor. The cell surface expression of the cell membrane-anchored C46  peptide blocks HIV-1 fusion to the cellular membrane. The removal of CCR5 from and the production of C46 in the bone marrow and white blood cells, make the transduced cells resistant to and protect them from HIV-1 entry, infection and replication. HIV-resistant HSPCs could provide long-term protection against latent HIV infection and against HIV-associated cancers. C46 is a membrane-anchored 46-amino acid sequence found in HIV-1 gp41. CCR5 is a HIV-1 co-receptor that mediates HIV attachment and cell entry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HIV-1 Lentiviral Vector sh5/C46","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HIV-1 LV-expressing sh5/C46 Cal-1","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HIV-1 LVsh5/C46","termGroup":"SY","termSource":"NCI"},{"termName":"Cal-1","termGroup":"CN","termSource":"NCI"},{"termName":"Cal-1 Vector","termGroup":"SY","termSource":"NCI"},{"termName":"LVsh5/C46","termGroup":"SY","termSource":"NCI"},{"termName":"LVsh5/C46 Vector","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1"},{"name":"NCI_Drug_Dictionary_ID","value":"799502"},{"name":"NCI_META_CUI","value":"CL978677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799502"},{"name":"PDQ_Open_Trial_Search_ID","value":"799502"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103860":{"preferredName":"Anti-HLA-DR Monoclonal Antibody IMMU-114","code":"C103860","definitions":[{"definition":"A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration, anti-HLA-DR monoclonal antibody IMMU-114 binds to HLA-DR on HLA-DR-expressing tumor cells and, although the exact mechanism has yet to be fully elucidated, appears to induce hyperactivation of ERK- and JNK-dependent mitogen activated protein kinase signaling pathways. This may lead to mitochondrial membrane depolarization and reactive oxygen species (ROS) generation. This eventually leads to an induction of tumor cell apoptosis and a reduction in tumor cell proliferation. IMMU-14 may be beneficial in the treatment of graft versus host disease (GVHD) as it appears to suppress T-lymphocyte proliferation and natural killer (NK) cell activation. As the Fc region of the orgnial IgG1 MoAb was replaced with the IgG4 isotype, IMMU-114 does not induce a complement cytotoxicity (CDC) or an antibody-dependent cell-mediated cytotoxicity (ADCC). HLA-DR, a MHC class II molecule, is found on various b-cell hematologic malignancies and in autoimmune diseases as well as on normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HLA-DR Monoclonal Antibody IMMU-114","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HLA-DR MoAb L243","termGroup":"SY","termSource":"NCI"},{"termName":"hL243gamma4P","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HLA-DR Monoclonal Antibody IMMU-114"},{"name":"NCI_Drug_Dictionary_ID","value":"743255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743255"},{"name":"PDQ_Open_Trial_Search_ID","value":"743255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3530137"}]}}{"C129694":{"preferredName":"Anti-human GITR Monoclonal Antibody AMG 228","code":"C129694","definitions":[{"definition":"An agonistic anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor receptor superfamily, member 18; TNFRSF18; GITR; CD357) humanized monoclonal antibody, with potential immune checkpoint modulating activity. Anti-human GITR monoclonal antibody AMG 228 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teffs), and suppresses the function of activated T regulatory cells (Tregs). This leads to immune-mediated tumor cell eradication though a cytotoxic T-lymphocyte (CTL) response. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-human GITR Monoclonal Antibody AMG 228","termGroup":"PT","termSource":"NCI"},{"termName":"Agonistic GITR Antibody AMG 228","termGroup":"SY","termSource":"NCI"},{"termName":"AMG 228","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-228","termGroup":"CN","termSource":"NCI"},{"termName":"AMG228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-human GITR Monoclonal Antibody AMG 228"},{"name":"NCI_META_CUI","value":"CL512894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95023":{"preferredName":"Anti-human GITR Monoclonal Antibody TRX518","code":"C95023","definitions":[{"definition":"A humanized, Fc disabled anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody (MoAb) with immunomodulating activity. Anti-human GITR MoAb TRX518 blocks the interaction of GITR, found on multiple types of T cells, with its ligand, thereby inducing both the activation of tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. This agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-human GITR Monoclonal Antibody TRX518","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-huGITR MoAb TRX518","termGroup":"SY","termSource":"NCI"},{"termName":"TRX518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-human GITR Monoclonal Antibody TRX518"},{"name":"NCI_Drug_Dictionary_ID","value":"689549"},{"name":"NCI_META_CUI","value":"CL426557"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689549"},{"name":"PDQ_Open_Trial_Search_ID","value":"689549"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88327":{"preferredName":"Bersanlimab","code":"C88327","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bersanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"BI-505","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1987854-08-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MP3N1L4OR6"},{"name":"Maps_To","value":"Anti-ICAM-1 Monoclonal Antibody BI-505"},{"name":"Maps_To","value":"Bersanlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"661398"},{"name":"NCI_META_CUI","value":"CL413589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661398"},{"name":"PDQ_Open_Trial_Search_ID","value":"661398"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126804":{"preferredName":"Feladilimab","code":"C126804","definitions":[{"definition":"An agonistic antibody for the inducible T-cell co-stimulator (ICOS; CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, feladilimab targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This stimulates ICOS-positive T-cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Feladilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS Agonist Antibody GSK3359609","termGroup":"SY","termSource":"NCI"},{"termName":"GSK3359609","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2252518-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OUP4QB2A3R"},{"name":"Maps_To","value":"Anti-ICOS Agonist Antibody GSK3359609"},{"name":"Maps_To","value":"Feladilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"780433"},{"name":"NCI_META_CUI","value":"CL507897"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780433"},{"name":"PDQ_Open_Trial_Search_ID","value":"780433"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146762":{"preferredName":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226","code":"C146762","definitions":[{"definition":"An agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS BMS-986226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-inducible T-cell Co-stimulator BMS-986226","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986226","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986226","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986226","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ICOS Agonist Monoclonal Antibody BMS-986226"},{"name":"NCI_Drug_Dictionary_ID","value":"792161"},{"name":"NCI_META_CUI","value":"CL544800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792161"},{"name":"PDQ_Open_Trial_Search_ID","value":"792161"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C162521":{"preferredName":"Alomfilimab","code":"C162521","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, alomfilimab selectively binds to dimeric ICOS expressed on certain T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Additionally, KY1044 may eliminate ICOS-positive T-cells via antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alomfilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS Monoclonal Antibody KY1044","termGroup":"SY","termSource":"NCI"},{"termName":"KY 1044","termGroup":"CN","termSource":"NCI"},{"termName":"KY-1044","termGroup":"CN","termSource":"NCI"},{"termName":"KY1044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2378692-24-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D2OPG50FF7"},{"name":"Maps_To","value":"Anti-ICOS Monoclonal Antibody KY1044"},{"name":"NCI_Drug_Dictionary_ID","value":"798819"},{"name":"NCI_META_CUI","value":"CL970948"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798819"},{"name":"PDQ_Open_Trial_Search_ID","value":"798819"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123267":{"preferredName":"Anti-ICOS Monoclonal Antibody MEDI-570","code":"C123267","definitions":[{"definition":"An Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-ICOS MoAb MEDI-570 targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Fc optimization enhances antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ICOS Monoclonal Antibody MEDI-570","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI-570","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2179209-59-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G9F0G3YL28"},{"name":"Maps_To","value":"Anti-ICOS Monoclonal Antibody MEDI-570"},{"name":"NCI_Drug_Dictionary_ID","value":"774809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774809"},{"name":"PDQ_Open_Trial_Search_ID","value":"774809"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053619"}]}}{"C79798":{"preferredName":"Veligrotug","code":"C79798","definitions":[{"definition":"A humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) with potential antineoplastic activity. Veligrotug specifically binds to and blocks membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signal transduction, which may result in the induction of apoptosis and a decrease in cellular proliferation. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Veligrotug","termGroup":"PT","termSource":"NCI"},{"termName":"anti-CD122 monoclonal antibody AVE1642","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IGF-1R Monoclonal Antibody AVE1642","termGroup":"SY","termSource":"NCI"},{"termName":"AVE-1642","termGroup":"CN","termSource":"NCI"},{"termName":"AVE1642","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1242567-05-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z9U2SS9ZC8"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Monoclonal_Antibody_AVE1642"},{"name":"Maps_To","value":"Anti-IGF-1R Monoclonal Antibody AVE1642"},{"name":"NCI_Drug_Dictionary_ID","value":"619043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"619043"},{"name":"PDQ_Open_Trial_Search_ID","value":"619043"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703165"}]}}{"C71530":{"preferredName":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022","code":"C71530","definitions":[{"definition":"A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R recombinant monoclonal antibody BIIB022 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1242567-19-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y60655Y65T"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Recombinant_Monoclonal_Antibody_BIIB022"},{"name":"Maps_To","value":"Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022"},{"name":"NCI_Drug_Dictionary_ID","value":"579227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579227"},{"name":"PDQ_Open_Trial_Search_ID","value":"579227"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346816"}]}}{"C95708":{"preferredName":"Bermekimab","code":"C95708","definitions":[{"definition":"A human immunoglobulin (Ig) G1 monoclonal antibody directed against interleukin-1 alpha (IL-1a) and derived from human B-lymphocytes that were obtained from a natural human immune response against IL-1a, with potential antineoplastic, anti-inflammatory, anti-cachectic and anti-angiogenic activities. Upon administration, bermekimab targets, binds to and neutralizes IL-1a thereby preventing IL-1a activity. This prevents IL-1a-mediated inflammation, tumorigenesis and angiogenesis. In addition, bermekimab may abrogate IL-1a-mediated cachexia and stimulate metabolic activity in the central nervous system (CNS). IL-1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bermekimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-1 alpha Monoclonal Antibody MABp1","termGroup":"SY","termSource":"NCI"},{"termName":"CA-18C3","termGroup":"CN","termSource":"NCI"},{"termName":"CV 18C3","termGroup":"CN","termSource":"NCI"},{"termName":"CV-18C3","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-77474462","termGroup":"CN","termSource":"NCI"},{"termName":"MABp1","termGroup":"AB","termSource":"NCI"},{"termName":"MABp1","termGroup":"CN","termSource":"NCI"},{"termName":"RA 18C3","termGroup":"CN","termSource":"NCI"},{"termName":"RA-18C3","termGroup":"CN","termSource":"NCI"},{"termName":"Xilonix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401965-15-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N6SVN735GY"},{"name":"Maps_To","value":"Anti-IL-1 alpha Monoclonal Antibody MABp1"},{"name":"Maps_To","value":"Bermekimab"},{"name":"NCI_Drug_Dictionary_ID","value":"661044"},{"name":"NCI_Drug_Dictionary_ID","value":"691526"},{"name":"NCI_META_CUI","value":"CL428173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691526"},{"name":"PDQ_Open_Trial_Search_ID","value":"691526"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C87767":{"preferredName":"Lebrikizumab","code":"C87767","definitions":[{"definition":"A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lebrikizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-13 Humanized Monoclonal Antibody TNX-650","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Interleukin 13) (Human-Mouse Monoclonal MILR1444a Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal MILR1444a Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MILR1444A","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody TNX-650","termGroup":"SY","termSource":"NCI"},{"termName":"PRO301444","termGroup":"CN","termSource":"NCI"},{"termName":"TNX-650","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"953400-68-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U9JLP7V031"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_TNX-650"},{"name":"Maps_To","value":"Anti-IL-13 Humanized Monoclonal Antibody TNX-650"},{"name":"NCI_Drug_Dictionary_ID","value":"539362"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981360"}]}}{"C126841":{"preferredName":"Ordesekimab","code":"C126841","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human pro-inflammatory cytokine interleukin-15 (IL-15), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, ordesekimab binds to and neutralizes IL-15, thereby preventing IL-15-mediated pro-inflammatory signaling. By inhibiting IL-15-mediated immune responses, ordesekimab decreases natural killer (NK) cell activation and proliferation, reduces T-cell infiltration, increases T-cell apoptosis, and may prevent the growth of IL-15-driven cancer cells. IL-15 plays a key role in inflammation and is associated with a variety of autoimmune and inflammatory disorders as well as with cell proliferation in certain cancer types, such as T-cell lymphomas. IL-15 is required for the proliferation of certain T-cells and NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ordesekimab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 714","termGroup":"CN","termSource":"NCI"},{"termName":"AMG714","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-IL-15 Monoclonal Antibody AMG 714","termGroup":"SY","termSource":"NCI"},{"termName":"HuMab-IL15 AMG 714","termGroup":"SY","termSource":"NCI"},{"termName":"HUMAX-IL 15","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2394931-19-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EJ48MR05C3"},{"name":"Maps_To","value":"Anti-IL-15 Monoclonal Antibody AMG 714"},{"name":"NCI_Drug_Dictionary_ID","value":"781143"},{"name":"NCI_META_CUI","value":"CL507916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781143"},{"name":"PDQ_Open_Trial_Search_ID","value":"781143"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124227":{"preferredName":"Adakitug","code":"C124227","definitions":[{"definition":"A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, adakitug directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, BMS-986253 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adakitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-8 Monoclonal Antibody BMS-986253","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986253","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986253","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986253","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-IL-8","termGroup":"SY","termSource":"NCI"},{"termName":"HuMax-IL8","termGroup":"SY","termSource":"NCI"},{"termName":"MDX 018","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231258-73-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N0YWS8X3S9"},{"name":"Maps_To","value":"Anti-IL-8 Monoclonal Antibody BMS-986253"},{"name":"Maps_To","value":"Anti-IL-8 Monoclonal Antibody HuMax-IL8"},{"name":"NCI_Drug_Dictionary_ID","value":"777250"},{"name":"NCI_META_CUI","value":"CL502607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777250"},{"name":"PDQ_Open_Trial_Search_ID","value":"777250"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156490":{"preferredName":"Bapotulimab","code":"C156490","definitions":[{"definition":"A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bapotulimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ILDR2 Inhibitor BAY1905254","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ILDR2 Monoclonal Antibody BAY 1905254","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-immunoglobulin-like Domain Containing Receptor 2 MoAb BAY1905254","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1905254","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1905254","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1905254","termGroup":"CN","termSource":"NCI"},{"termName":"ILDR2 Function-blocking Antibody BAY1905254","termGroup":"SY","termSource":"NCI"},{"termName":"Immune Checkpoint Inhibitor BAY1905254","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2359413-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I92BM16NTD"},{"name":"Maps_To","value":"Anti-ILDR2 Monoclonal Antibody BAY 1905254"},{"name":"NCI_Drug_Dictionary_ID","value":"795831"},{"name":"NCI_META_CUI","value":"CL935671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795831"},{"name":"PDQ_Open_Trial_Search_ID","value":"795831"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160204":{"preferredName":"Anti-ILT4 Monoclonal Antibody MK-4830","code":"C160204","definitions":[{"definition":"A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ILT4 Monoclonal Antibody MK-4830","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-leukocyte Immunoglobulin-like Receptor 2 Monoclonal Antibody MK-4830","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LIR2 Monoclonal Antibody MK-4830","termGroup":"SY","termSource":"NCI"},{"termName":"MK 4830","termGroup":"CN","termSource":"NCI"},{"termName":"MK-4830","termGroup":"CN","termSource":"NCI"},{"termName":"MK4830","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ILT4 Monoclonal Antibody MK-4830"},{"name":"NCI_Drug_Dictionary_ID","value":"797844"},{"name":"NCI_META_CUI","value":"CL969335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797844"},{"name":"PDQ_Open_Trial_Search_ID","value":"797844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78839":{"preferredName":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388","code":"C78839","definitions":[{"definition":"An immunoconjugate consisting of an anti-integrin monoclonal antibody covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Integrin-targeted immunoconjugate IMGN388 binds to tumor cell surface integrins; upon internalization, the DM4 moiety is released from the immunoconjugate, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in inhibition of cell division and cell growth of integrin-expressing tumor cells. Integrins, a class of transmembrane cell surface receptors, link the extracellular matrix (ECM) to intracellular signaling pathways that control cell proliferation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388","termGroup":"PT","termSource":"NCI"},{"termName":"IMGN388","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-Integrin_Immunotoxin_IMGN388"},{"name":"Maps_To","value":"Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388"},{"name":"NCI_Drug_Dictionary_ID","value":"609890"},{"name":"NCI_META_CUI","value":"CL387679"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609890"},{"name":"PDQ_Open_Trial_Search_ID","value":"609890"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78464":{"preferredName":"Anti-KIR Monoclonal Antibody IPH 2101","code":"C78464","definitions":[{"definition":"A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody IPH 2101 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-KIR Monoclonal Antibody IPH 2101","termGroup":"PT","termSource":"NCI"},{"termName":"1-7F9","termGroup":"CN","termSource":"NCI"},{"termName":"IPH 2101","termGroup":"CN","termSource":"NCI"},{"termName":"IPH-2101","termGroup":"CN","termSource":"NCI"},{"termName":"IPH2101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000676-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5Q686XLG8L"},{"name":"Legacy Concept Name","value":"Anti-KIR_Monoclonal_Antibody_1-7F9"},{"name":"Maps_To","value":"Anti-KIR Monoclonal Antibody IPH 2101"},{"name":"NCI_Drug_Dictionary_ID","value":"599832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599832"},{"name":"PDQ_Open_Trial_Search_ID","value":"599832"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703118"}]}}{"C82391":{"preferredName":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02","code":"C82391","definitions":[{"definition":"A lipid nanoparticle formulation containing two small interfering RNAs (siRNAs) for kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF) with potential antitumor activity. Upon intravenous administration, the siRNAs in KSP/VEGF siRNAs ALN-VSP02ALN bind to both KSP and VEGF messenger RNAs (mRNAs), preventing translation of KSP and VEGF proteins; this may result in growth inhibition of tumor cells that overexpress KSP and VEGF. VEGF and KSP are upregulated in many tumor cells and play an important role in tumor proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02","termGroup":"PT","termSource":"NCI"},{"termName":"ALN-VSP02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Anti-KSP_Anti-VEGF_siRNAs_ALN-VSP02"},{"name":"Maps_To","value":"Anti-KSP/Anti-VEGF siRNAs ALN-VSP02"},{"name":"NCI_Drug_Dictionary_ID","value":"642288"},{"name":"NCI_META_CUI","value":"CL408662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642288"},{"name":"PDQ_Open_Trial_Search_ID","value":"642288"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157127":{"preferredName":"Tuparstobart","code":"C157127","definitions":[{"definition":"A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, tuparstobart targets and binds to human LAG-3 on tumor-infiltrating  lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both proliferation and activation of T-cells. Its expression on  TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuparstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody INCAGN02385","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody INCAGN02385","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 02385","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN 2385","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN02385","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN2385","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649466-03-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z0A08C63DF"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody INCAGN02385"},{"name":"NCI_Drug_Dictionary_ID","value":"796980"},{"name":"NCI_META_CUI","value":"CL936810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796980"},{"name":"PDQ_Open_Trial_Search_ID","value":"796980"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122683":{"preferredName":"Ieramilimab","code":"C122683","definitions":[{"definition":"A humanized monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, Ieramilimab binds to LAG-3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF) and expressed on various immune cells, negatively regulates cellular proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ieramilimab","termGroup":"PT","termSource":"NCI"},{"termName":"IMP-701","termGroup":"CN","termSource":"NCI"},{"termName":"LAG 525","termGroup":"CN","termSource":"NCI"},{"termName":"LAG525","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2137049-37-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OI8P0SFD4R"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody LAG525"},{"name":"Maps_To","value":"Ieramilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"772952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772952"},{"name":"PDQ_Open_Trial_Search_ID","value":"772952"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053626"}]}}{"C132339":{"preferredName":"Fianlimab","code":"C132339","definitions":[{"definition":"A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fianlimab binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks LAG-3 binding to tumor cells expressing major histocompatibility complex (MHC) class II molecules. This may activate antigen-specific T-lymphocytes and enhance cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells; its expression on TILs is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fianlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 MoAb REGN3767","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 3767","termGroup":"CN","termSource":"NCI"},{"termName":"REGN3767","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11182","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2126132-98-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OX5LRQ5H6K"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody REGN3767"},{"name":"Maps_To","value":"Fianlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"787595"},{"name":"NCI_META_CUI","value":"CL520574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787595"},{"name":"PDQ_Open_Trial_Search_ID","value":"787595"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150734":{"preferredName":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118","code":"C150734","definitions":[{"definition":"A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118","termGroup":"PT","termSource":"NCI"},{"termName":"FS118","termGroup":"CN","termSource":"NCI"},{"termName":"LAG-3/PD-L1 Bispecific Antibody FS118","termGroup":"SY","termSource":"NCI"},{"termName":"LAG-3/PD-L1 Mab2 FS118","termGroup":"SY","termSource":"NCI"},{"termName":"Mab2 FS118","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LAG-3/PD-L1 Bispecific Antibody FS118"},{"name":"NCI_Drug_Dictionary_ID","value":"793522"},{"name":"NCI_META_CUI","value":"CL552521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793522"},{"name":"PDQ_Open_Trial_Search_ID","value":"793522"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150403":{"preferredName":"Miptenalimab","code":"C150403","definitions":[{"definition":"A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miptenalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody BI 754111","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody BI 754111","termGroup":"SY","termSource":"NCI"},{"termName":"BI 754111","termGroup":"CN","termSource":"NCI"},{"termName":"BI-754111","termGroup":"CN","termSource":"NCI"},{"termName":"BI754111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2245092-03-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NVCTROPV3P"},{"name":"Maps_To","value":"Anti-LAG3 Monoclonal Antibody BI 754111"},{"name":"Maps_To","value":"Miptenalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"792749"},{"name":"NCI_META_CUI","value":"CL552148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792749"},{"name":"PDQ_Open_Trial_Search_ID","value":"792749"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142077":{"preferredName":"Favezelimab","code":"C142077","definitions":[{"definition":"A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Favezelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody MK-4280","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody MK-4280","termGroup":"SY","termSource":"NCI"},{"termName":"MK 4280","termGroup":"CN","termSource":"NCI"},{"termName":"MK-4280","termGroup":"CN","termSource":"NCI"},{"termName":"MK4280","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231068-83-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H1396W7D1H"},{"name":"Maps_To","value":"Anti-LAG3 Monoclonal Antibody MK-4280"},{"name":"Maps_To","value":"Favezelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791433"},{"name":"NCI_META_CUI","value":"CL540133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791433"},{"name":"PDQ_Open_Trial_Search_ID","value":"791433"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142978":{"preferredName":"Encelimab","code":"C142978","definitions":[{"definition":"A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,encelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody TSR-033","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG3 Monoclonal Antibody TSR-033","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody TSR-033","termGroup":"SY","termSource":"NCI"},{"termName":"TSR 033","termGroup":"CN","termSource":"NCI"},{"termName":"TSR-033","termGroup":"CN","termSource":"NCI"},{"termName":"TSR033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2173096-82-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N151VZIIPD"},{"name":"Maps_To","value":"Anti-LAG3 Monoclonal Antibody TSR-033"},{"name":"Maps_To","value":"Encelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791832"},{"name":"NCI_META_CUI","value":"CL541410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791832"},{"name":"PDQ_Open_Trial_Search_ID","value":"791832"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126275":{"preferredName":"Anti-LAMP1 Antibody-drug Conjugate SAR428926","code":"C126275","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) conjugated, via the disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-LAMP1 ADC SAR428926, the anti-LAMP1 monoclonal antibody moiety targets and binds to the cell surface antigen LAMP1. After antibody-antigen interaction and internalization, the SPDB linker is selectively cleaved by proteases in the cytosol and the DM4 moiety is released. DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting both cell division and cell growth of LAMP1-expressing tumor cells. LAMP1, overexpressed on a variety of cancer cells, plays a key role in cell-cell adhesion and migration. The SPDB linker is resistant to cleavage in the bloodstream, which may increase stability and reduce toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LAMP1 Antibody-drug Conjugate SAR428926","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SAR428926","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAMP1 ADC SAR428926","termGroup":"SY","termSource":"NCI"},{"termName":"SAR428926","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LAMP1 Antibody-drug Conjugate SAR428926"},{"name":"NCI_Drug_Dictionary_ID","value":"779304"},{"name":"NCI_META_CUI","value":"CL504852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779304"},{"name":"PDQ_Open_Trial_Search_ID","value":"779304"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126794":{"preferredName":"Anti-LGR5 Monoclonal Antibody BNC101","code":"C126794","definitions":[{"definition":"A humanized monoclonal antibody targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, the anti-LGR5 humanized monoclonal antibody BNC101 targets and binds to LGR5, thereby inhibiting LRG5-mediated signal transduction pathways. This prevents proliferation of LRG5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LGR5 Monoclonal Antibody BNC101","termGroup":"PT","termSource":"NCI"},{"termName":"BNC-101","termGroup":"CN","termSource":"NCI"},{"termName":"BNC101","termGroup":"CN","termSource":"NCI"},{"termName":"ET-101","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LGR5 Monoclonal Antibody BNC101"},{"name":"NCI_Drug_Dictionary_ID","value":"780067"},{"name":"NCI_META_CUI","value":"CL507886"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780067"},{"name":"PDQ_Open_Trial_Search_ID","value":"780067"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156176":{"preferredName":"Falbikitug","code":"C156176","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, falbikitug binds to LIF and inhibits LIF signaling by blocking the recruitment of glycoprotein 130 (gp130) to the LIF-LIF receptor (LIFR)-gp130 signaling complex. This inhibits signal transducer and activator of transcription 3 (STAT3) signaling and inhibits tumor cell growth. In addition, the inhibition of LIF signaling abrogates the immunosuppressive tumor microenvironment (TME) by decreasing immunosuppressive M2 macrophages and allows for the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. LIF, a member of the interleukin-6 (IL-6) family of cytokines, is involved in many physiological and pathological processes and plays an important role in both creating the TME and promoting the activity of cancer-initiating cells (CICs). LIF is overexpressed in many tumor cell types and its expression correlates with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Falbikitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LIF Monoclonal Antibody MSC-1","termGroup":"SY","termSource":"NCI"},{"termName":"AZD 0171","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-0171","termGroup":"CN","termSource":"NCI"},{"termName":"AZD0171","termGroup":"CN","termSource":"NCI"},{"termName":"MSC 1","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-1","termGroup":"CN","termSource":"NCI"},{"termName":"MSC1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2740565-02-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E4JL3K3CI6"},{"name":"Maps_To","value":"Anti-LIF Monoclonal Antibody MSC-1"},{"name":"NCI_Drug_Dictionary_ID","value":"795377"},{"name":"NCI_META_CUI","value":"CL563028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795377"},{"name":"PDQ_Open_Trial_Search_ID","value":"795377"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C112001":{"preferredName":"Ladiratuzumab Vedotin","code":"C112001","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in ladiratuzumab vedotin is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ladiratuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"SGN-LIV1A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1629760-29-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VM4G5D1A60"},{"name":"Maps_To","value":"Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A"},{"name":"Maps_To","value":"Ladiratuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"754237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754237"},{"name":"PDQ_Open_Trial_Search_ID","value":"754237"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827076"}]}}{"C116745":{"preferredName":"Anti-Ly6E Antibody-Drug Conjugate RG 7841","code":"C116745","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) and linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of RG 7841 targets and binds to Ly6E expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills, through an as of yet unknown mechanism of action, the Ly6E-expressing cancer cells. Ly6E, an interferon (IFN)-inducible glycosylphosphatidylinositol (GPI)-linked cell membrane protein, is expressed on a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Ly6E Antibody-Drug Conjugate RG 7841","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DLYE5953A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LY6E-VCMMAE","termGroup":"SY","termSource":"NCI"},{"termName":"DLYE5953A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7841","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7841","termGroup":"CN","termSource":"NCI"},{"termName":"RG7841","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ONS92I2A7F"},{"name":"Maps_To","value":"Anti-Ly6E Antibody-Drug Conjugate RG 7841"},{"name":"NCI_Drug_Dictionary_ID","value":"759448"},{"name":"NCI_META_CUI","value":"CL473919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759448"},{"name":"PDQ_Open_Trial_Search_ID","value":"759448"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162462":{"preferredName":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C","code":"C162462","definitions":[{"definition":"A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon intravenous administration of IMC-C103C, the TCR moiety of this agent targets and binds to MAGE-A4 on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C","termGroup":"PT","termSource":"NCI"},{"termName":"IMC C103C","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-C103C","termGroup":"CN","termSource":"NCI"},{"termName":"IMCC103C","termGroup":"CN","termSource":"NCI"},{"termName":"ImmTAC IMC-C103C","termGroup":"SY","termSource":"NCI"},{"termName":"ImmTAC Molecule IMC-C103C","termGroup":"SY","termSource":"NCI"},{"termName":"Immune Mobilizing Monoclonal TCR Against Cancer IMC-C103C","termGroup":"SY","termSource":"NCI"},{"termName":"T-cell Redirecting Bi-specific Biologic IMC-C103C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C"},{"name":"NCI_Drug_Dictionary_ID","value":"801761"},{"name":"NCI_META_CUI","value":"CL970956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801761"},{"name":"PDQ_Open_Trial_Search_ID","value":"801761"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91092":{"preferredName":"Anti-Melanin Monoclonal Antibody PTI-6D2","code":"C91092","definitions":[{"definition":"A monoclonal antibody (MoAb) against extracellular melanin with tumor targeting activity. Anti-melanin monoclonal antibody PTI-6D2 binds to extracellular melanin, a melanocyte pigment which is released during tumor cell turnover from dead melanoma tumor cells, while avoiding the binding of melanin in normal, healthy tissue because of melanin's normal intracellular location. Upon labeling with the beta-emitting radioisotope rhenium Re 188 (PTI-188), this MoAb may target multiple melanoma (MM) cells, thereby delivering a cytotoxic dose of radiation specifically to the targeted tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Melanin Monoclonal Antibody PTI-6D2","termGroup":"PT","termSource":"NCI"},{"termName":"PTI-6D2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Melanin Monoclonal Antibody PTI-6D2"},{"name":"NCI_Drug_Dictionary_ID","value":"529286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529286"},{"name":"PDQ_Open_Trial_Search_ID","value":"529286"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832013"}]}}{"C120303":{"preferredName":"Anti-mesothelin Antibody-drug Conjugate BMS-986148","code":"C120303","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to an as of yet undisclosed cytotoxic drug, with potential antineoplastic activity. The monoclonal antibody moiety of anti-mesothelin ADC BMS-986148 targets and binds to the tumor associated antigen mesothelin. Upon internalization, the cytotoxic agent kills or prevents cellular proliferation of mesothelin-expressing tumor cells through an as of yet undescribed mechanism of action. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-mesothelin Antibody-drug Conjugate BMS-986148","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986148","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-mesothelin Antibody-drug Conjugate BMS-986148"},{"name":"NCI_Drug_Dictionary_ID","value":"768587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768587"},{"name":"PDQ_Open_Trial_Search_ID","value":"768587"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896897"}]}}{"C121653":{"preferredName":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100","code":"C121653","definitions":[{"definition":"An anti-mesothelin (MSLN) recombinant cytolytic fusion protein (cFP) composed of a humanized Fab fragment of anti-MSLN monoclonal antibody SS1 linked to a truncated and de-immunized 24 kDa fragment of the Pseudomonas exotoxin (PE) (PE24), with potential antineoplastic activity. Upon intravenous administration of anti-MSLN-PE24 cFP LMB-100, the anti-MSLN moiety targets and binds to MSLN-expressing tumor cells. Upon binding and internalization through endocytosis, the toxin moiety ADP-ribosylates and inactivates eukaryotic elongation factor 2 (eEF2), preventing the elongation step of protein synthesis and leading to both an inhibition of protein synthesis and an induction of MSLN-expressing tumor cell apoptosis. MSLN, a tumor-associated antigen overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation and migration. The engineered PE24 portion of LMB-100 does contain the targeting domain and furin cleavage site, which are needed for cytotoxicity, but most of the translocation domain II is deleted and the catalytic domain III contains point mutations, which result in the deletion and silencing of most T- and B-cell epitopes; therefore, the immunogenicity and toxicity is reduced compared to non-engineered PE toxin, which allows for the administration of larger doses of LMB-100.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-MSLN-PE24 cFP LMB-100","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-100","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7787","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7787","termGroup":"CN","termSource":"NCI"},{"termName":"RG7787","termGroup":"CN","termSource":"NCI"},{"termName":"RO 6927005","termGroup":"CN","termSource":"NCI"},{"termName":"RO6927005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1841500-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D6AT024T4P"},{"name":"Maps_To","value":"Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100"},{"name":"NCI_Drug_Dictionary_ID","value":"767396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767396"},{"name":"PDQ_Open_Trial_Search_ID","value":"767396"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4044528"}]}}{"C116746":{"preferredName":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A","code":"C116746","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of MMOT0530A, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface glycoprotein mesothelin (MSLN), and covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DMOT4039A binds to MSLN-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. MSLN, a tumor-associated antigen (TAA), is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A","termGroup":"PT","termSource":"NCI"},{"termName":"DMOT-4039A","termGroup":"CN","termSource":"NCI"},{"termName":"DMOT4039A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7600","termGroup":"CN","termSource":"NCI"},{"termName":"RG7600","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A"},{"name":"NCI_Drug_Dictionary_ID","value":"717527"},{"name":"NCI_META_CUI","value":"CL433928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717527"},{"name":"PDQ_Open_Trial_Search_ID","value":"717527"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127906":{"preferredName":"Anti-Met Monoclonal Antibody Mixture Sym015","code":"C127906","definitions":[{"definition":"A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the extracellular domain of the human hepatocyte growth factor receptor (MET; HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-MET monoclonal antibody mixture Sym015 targets and binds to the extracellular domain of MET, thereby preventing the binding of its ligand, hepatocyte growth factor (HGF). This may prevent activation of the receptor and MET-mediated signal transduction pathways. This inhibits MET-dependent tumor cell proliferation. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Met Monoclonal Antibody Mixture Sym015","termGroup":"PT","termSource":"NCI"},{"termName":"Hu9006-Hu9338","termGroup":"SY","termSource":"NCI"},{"termName":"Hu9006/Hu9338","termGroup":"SY","termSource":"NCI"},{"termName":"Sym 015","termGroup":"CN","termSource":"NCI"},{"termName":"Sym-015","termGroup":"CN","termSource":"NCI"},{"termName":"Sym015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Met Monoclonal Antibody Mixture Sym015"},{"name":"NCI_Drug_Dictionary_ID","value":"781406"},{"name":"NCI_META_CUI","value":"CL507929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781406"},{"name":"PDQ_Open_Trial_Search_ID","value":"781406"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118281":{"preferredName":"Anti-Met/EGFR Monoclonal Antibody LY3164530","code":"C118281","definitions":[{"definition":"A monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) and human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-Met/EGFR MoAb LY3164530 targets and prevents the activation of EGFR and c-Met. This leads to a downstream inhibition of EGFR/c-Met-mediated signal transduction pathways, and prevents cellular proliferation in tumor cells overexpressing EGFR and c-Met. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surface of various solid tumor cell types. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Met/EGFR Monoclonal Antibody LY3164530","termGroup":"PT","termSource":"NCI"},{"termName":"LY3164530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2069210-01-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K85WE44TZ7"},{"name":"Maps_To","value":"Anti-Met/EGFR Monoclonal Antibody LY3164530"},{"name":"NCI_Drug_Dictionary_ID","value":"764231"},{"name":"NCI_META_CUI","value":"CL474133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764231"},{"name":"PDQ_Open_Trial_Search_ID","value":"764231"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105803":{"preferredName":"Andecaliximab","code":"C105803","definitions":[{"definition":"A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential antineoplastic activity. Upon administration, andecaliximab binds to MMP-9 and inhibits its enzymatic activity. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in the degradation of collagens and proteoglycans; increased activity of MMP-9 has been associated with increased invasion and metastasis of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Andecaliximab","termGroup":"PT","termSource":"NCI"},{"termName":"GS-5745","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1518996-49-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"571045EIM4"},{"name":"Maps_To","value":"Andecaliximab"},{"name":"Maps_To","value":"Anti-MMP-9 Monoclonal Antibody GS-5745"},{"name":"NCI_Drug_Dictionary_ID","value":"747683"},{"name":"NCI_META_CUI","value":"CL447155"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747683"},{"name":"PDQ_Open_Trial_Search_ID","value":"747683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118362":{"preferredName":"Anti-MUC1 Monoclonal Antibody BTH1704","code":"C118362","definitions":[{"definition":"A monoclonal antibody against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, anti-MUC1 monoclonal antibody BTH1704 targets and binds to MUC1 expressed on the surface of tumor cells, which can potentially activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-MUC1 Monoclonal Antibody BTH1704","termGroup":"PT","termSource":"NCI"},{"termName":"BTH1704","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-MUC1 Monoclonal Antibody BTH1704"},{"name":"NCI_Drug_Dictionary_ID","value":"764610"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764610"},{"name":"PDQ_Open_Trial_Search_ID","value":"764610"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896895"}]}}{"C153129":{"preferredName":"Ubamatamab","code":"C153129","definitions":[{"definition":"A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen that is part of the T cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ubamatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-MUC16 x Anti-CD3 REGN4018","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-MUC16/CD3 Bispecific Antibody REGN4018","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 4018","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-4018","termGroup":"CN","termSource":"NCI"},{"termName":"REGN4018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305629-50-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6BUL1G4D60"},{"name":"Maps_To","value":"Anti-MUC16/CD3 Bispecific Antibody REGN4018"},{"name":"Maps_To","value":"Anti-MUC16/CD3 BiTE Antibody REGN4018"},{"name":"NCI_Drug_Dictionary_ID","value":"793937"},{"name":"NCI_META_CUI","value":"CL554386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793937"},{"name":"PDQ_Open_Trial_Search_ID","value":"793937"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147031":{"preferredName":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A","code":"C147031","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human mucin 16 (MUC16; cancer antigen 125; CA125; FLJ14303) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-MUC16/MMAE ADC DMUC4064A binds to MUC16 located on the tumor cell surface. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. MUC16, a member of the mucin family glycoproteins, is overexpressed in a variety of tumor cells and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DMUC4064A","termGroup":"SY","termSource":"NCI"},{"termName":"DMUC4064A","termGroup":"CN","termSource":"NCI"},{"termName":"RG7882","termGroup":"CN","termSource":"NCI"},{"termName":"THIOMAB-drug Conjugate DMUC4064A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D5STG0624V"},{"name":"Maps_To","value":"Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A"},{"name":"NCI_Drug_Dictionary_ID","value":"792380"},{"name":"NCI_META_CUI","value":"CL545030"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792380"},{"name":"PDQ_Open_Trial_Search_ID","value":"792380"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78840":{"preferredName":"Indatuximab Ravtansine","code":"C78840","definitions":[{"definition":"An immunoconjugate consisting of a monoclonal antibody directed against syndecan-1 (CD138) covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Upon administration, indatuximab ravtansine binds to syndecan-1-expressing tumor cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of syndecan-1-expressing tumor cells. Syndecan-1, a type 1 transmembrane proteoglycan and tumor-associated antigen (TAA), is overexpressed in a variety of cancer cells and plays a key role in the regulation of cell growth, differentiation, and adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indatuximab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","termGroup":"SY","termSource":"NCI"},{"termName":"BT-062","termGroup":"CN","termSource":"NCI"},{"termName":"BT062","termGroup":"CN","termSource":"NCI"},{"termName":"Maytansinoid-Conjugated Anti-Myeloma Monoclonal Antibody BT062","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1238517-16-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XGL4M23834"},{"name":"Legacy Concept Name","value":"Maytansinoid-Conjugated_Anti-Myeloma_Monoclonal_Antibody_BT062"},{"name":"Maps_To","value":"Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062"},{"name":"Maps_To","value":"Indatuximab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"609930"},{"name":"NCI_META_CUI","value":"CL387726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609930"},{"name":"PDQ_Open_Trial_Search_ID","value":"609930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99640":{"preferredName":"Landogrozumab","code":"C99640","definitions":[{"definition":"A monoclonal antibody against myostatin (MSTN) with potential anti-cachexia activity. Upon administration,  landogrozumab binds to and neutralizes the MSTN protein, thereby blocking the MSTN signalling pathway. This may help decrease muscle protein breakdown and muscle weakness and may attenuate cancer cachexia. MSTN, a member of the transforming growth factor-beta (TGF-beta) superfamily, is a negative regulator of muscle growth and development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Landogrozumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-myostatin Monoclonal Antibody LY2495655","termGroup":"SY","termSource":"NCI"},{"termName":"LY2495655","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1391726-30-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B1792M902R"},{"name":"Maps_To","value":"Anti-myostatin Monoclonal Antibody LY2495655"},{"name":"Maps_To","value":"Landogrozumab"},{"name":"NCI_Drug_Dictionary_ID","value":"722359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"722359"},{"name":"PDQ_Open_Trial_Search_ID","value":"722359"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274844"}]}}{"C147578":{"preferredName":"Upinitatug","code":"C147578","definitions":[{"definition":"A proprietary humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), with potential antineoplastic activity. Upon administration of upinitatug, the antibody targets and binds to NaPi2b expressed on tumor cells. Although the tumor cell killing effects of upinitatug are not established, this binding may induce an antibody-dependent cellular cytotoxicity (ADCC)-mediated immune response against NaPi2b-expressing tumor cells, and/or may inhibit NaPi2b-mediated sodium and phosphate ion cotransport activity and ion-dependent tumor cell signaling. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of tumor cells. It plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upinitatug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-NaPi2b MoAb XMT-1535","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b Monoclonal Antibody XMT-1535","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb XMT-1535","termGroup":"SY","termSource":"NCI"},{"termName":"Upifitamab","termGroup":"SY","termSource":"NCI"},{"termName":"XMT 1535","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1535","termGroup":"CN","termSource":"NCI"},{"termName":"XMT1535","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254118-43-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15OY7NA275"},{"name":"Maps_To","value":"Anti-NaPi2b Monoclonal Antibody XMT-1535"},{"name":"Maps_To","value":"Upifitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792494"},{"name":"NCI_META_CUI","value":"CL545380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792494"},{"name":"PDQ_Open_Trial_Search_ID","value":"792494"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114500":{"preferredName":"Enfortumab Vedotin","code":"C114500","definitions":[{"definition":"An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enfortumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"AGS 22ME","termGroup":"CN","termSource":"NCI"},{"termName":"AGS-22M6E","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-Nectin 4 ADC ASG-22CE","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E","termGroup":"SY","termSource":"NCI"},{"termName":"ASG 22CE","termGroup":"CN","termSource":"NCI"},{"termName":"ASG-22CE","termGroup":"CN","termSource":"NCI"},{"termName":"ASG22CE","termGroup":"CN","termSource":"NCI"},{"termName":"Enfortumab Vedotin-ejfv","termGroup":"SY","termSource":"NCI"},{"termName":"Padcev","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting."},{"name":"CAS_Registry","value":"1346452-25-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DLE8519RWM"},{"name":"Maps_To","value":"Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E"},{"name":"Maps_To","value":"Enfortumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"759429"},{"name":"NCI_META_CUI","value":"CL472325"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759429"},{"name":"PDQ_Open_Trial_Search_ID","value":"759429"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91728":{"preferredName":"Vesencumab","code":"C91728","definitions":[{"definition":"A human IgG1 monoclonal antibody directed against neuropilin-1 (NRP1), with potential antiangiogenic and antineoplastic activities. Upon intravenous administration, vesencumab specifically targets and binds to NRP1; the antibody-NRP1 complex prevents the subsequent coupling of NRP1 to VEGFR2, thereby potentially inhibiting VEGF-mediated signaling and potentially preventing angiogenesis. In combination with other anti-VEGF therapies, vesencumab may enhance their anti-angiogenic effect. NRP1 is a membrane-bound co-receptor normally expressed by endothelial cells and overexpressed by certain tumor cells, and plays a role in angiogenesis, cell survival, migration, and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vesencumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin GL, Anti-(Human Neuropilin 1) (Human Monoclonal MNRP1685a Heavy Chain), Disulfide with Human Monoclonal MNRP1685a Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MNRP-1685A","termGroup":"CN","termSource":"NCI"},{"termName":"MNRP1685A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1205533-60-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7SF22186WT"},{"name":"Maps_To","value":"Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A"},{"name":"Maps_To","value":"Vesencumab"},{"name":"NCI_Drug_Dictionary_ID","value":"614996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614996"},{"name":"PDQ_Open_Trial_Search_ID","value":"614996"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984519"}]}}{"C124647":{"preferredName":"Anti-nf-P2X7 Antibody Ointment BIL-010t","code":"C124647","definitions":[{"definition":"An ointment formulation composed of a purified sheep immunoglobulin G (IgG) antibody against the non-functional form of the purinergic P2X7 receptor (nf-P2X7), with potential antineoplastic activity. Upon topical application of the anti-nf-P2X7 antibody ointment BIL-010t, the antibody binds to nf-P2X7 and inhibits its antiapoptotic activity. This may induce apoptosis and inhibit the growth of nf-P2X7-overexpressing cancer cells. P2X7, an ATP-gated cation-selective channel, plays a role in the induction of apoptosis; nf-P2X7, is upregulated in a variety of cancer cell types while not expressed on normal, healthy cells and is unable to form a large transmembrane, apoptotic pore upon exposure to ATP and prevents apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-nf-P2X7 Antibody Ointment BIL-010t","termGroup":"PT","termSource":"NCI"},{"termName":"BIL-010t","termGroup":"CN","termSource":"NCI"},{"termName":"BSCT 10 % Ointment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-nf-P2X7 Antibody Ointment BIL-010t"},{"name":"NCI_Drug_Dictionary_ID","value":"776771"},{"name":"NCI_META_CUI","value":"CL502879"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776771"},{"name":"PDQ_Open_Trial_Search_ID","value":"776771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91721":{"preferredName":"Anti-Nucleolin Aptamer AS1411","code":"C91721","definitions":[{"definition":"A 26-base guanine-rich oligodeoxynucleotide aptamer with potential apoptotic induction activity. Upon administration, anti-nucleolin aptamer AS1411 targets and binds to nucleolin, a nucleolar phosphoprotein which is overexpressed on the surface of certain cancer cells. Via binding to cell surface nucleolin, AS1411 is internalized and may prevent nucleolin from binding to and stabilizing mRNA of the anti-apoptotic BCL2, thereby destabilizing BCL2 mRNA, leading to a reduction in BCL2 protein synthesis. This may lead to the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Nucleolin Aptamer AS1411","termGroup":"PT","termSource":"NCI"},{"termName":"AS1411","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Nucleolin Aptamer AS1411"},{"name":"NCI_Drug_Dictionary_ID","value":"565948"},{"name":"PDQ_Closed_Trial_Search_ID","value":"565948"},{"name":"PDQ_Open_Trial_Search_ID","value":"565948"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1744513"}]}}{"C116847":{"preferredName":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A","code":"C116847","definitions":[{"definition":"An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A","termGroup":"PT","termSource":"NCI"},{"termName":"CTAG1A ASCI","termGroup":"SY","termSource":"NCI"},{"termName":"GSK-2241658A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2241658A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2241658A Antigen-Specific Cancer Immunotherapeutic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A"},{"name":"NCI_Drug_Dictionary_ID","value":"686918"},{"name":"NCI_META_CUI","value":"CL433722"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686918"},{"name":"PDQ_Open_Trial_Search_ID","value":"686918"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153130":{"preferredName":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso","code":"C153130","definitions":[{"definition":"A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and/or LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T-cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and/or LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific NY-ESO-1- and LAGE-1A-specific TCR/Anti-CD3","termGroup":"SY","termSource":"NCI"},{"termName":"HLA- A*0201-Restricted NY-ESO-1- and LAGE-1A-specific Soluble TCR/Anti-CD3 Bispecific Molecule","termGroup":"SY","termSource":"NCI"},{"termName":"IMCnyeso","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C416JC9CX0"},{"name":"Maps_To","value":"Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso"},{"name":"NCI_Drug_Dictionary_ID","value":"793936"},{"name":"NCI_META_CUI","value":"CL554387"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793936"},{"name":"PDQ_Open_Trial_Search_ID","value":"793936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118368":{"preferredName":"Anti-OFA Immunotherapeutic BB-MPI-03","code":"C118368","definitions":[{"definition":"A cancer vaccine composed of 3 different cytotoxic T-cell epitopes derived from the tumor-associated antigen oncofetal antigen (OFA), with potential immunostimulating and antineoplastic activities. Upon intradermal administration, anti-OFA immunotherapeutic vaccine BB-MPI-03 activates the immune system to elicit a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing OFA. OFA, also called immature laminin receptor protein (iLRP), is expressed in fetal tissues and is overexpressed in various cancers; its expression is correlated with cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OFA Immunotherapeutic BB-MPI-03","termGroup":"PT","termSource":"NCI"},{"termName":"BB-MPI-03","termGroup":"CN","termSource":"NCI"},{"termName":"BBMPI03","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-OFA Immunotherapeutic BB-MPI-03"},{"name":"NCI_Drug_Dictionary_ID","value":"764767"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764767"},{"name":"PDQ_Open_Trial_Search_ID","value":"764767"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896736"}]}}{"C161864":{"preferredName":"Revdofilimab","code":"C161864","definitions":[{"definition":"An agonistic humanized IgG1 monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, revdofilimab selectively binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Revdofilimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 368","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-368","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV368","termGroup":"CN","termSource":"NCI"},{"termName":"Agonistic Anti-OX40 Monoclonal Antibody ABBV-368","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-OX40 Agonist Monoclonal Antibody ABBV-368","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-OX40 Agonistic Monoclonal Antibody ABBV-368","termGroup":"SY","termSource":"NCI"},{"termName":"PR1628103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230138-89-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2Y83Y2ORD3"},{"name":"Maps_To","value":"Anti-OX40 Agonist Monoclonal Antibody ABBV-368"},{"name":"Maps_To","value":"Revdofilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"792559"},{"name":"NCI_META_CUI","value":"CL970355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792559"},{"name":"PDQ_Open_Trial_Search_ID","value":"792559"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121927":{"preferredName":"Ivuxolimab","code":"C121927","definitions":[{"definition":"An agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, ivuxolimab selectively binds to and activates OX40; which induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivuxolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Agonist Monoclonal Antibody PF-04518600","termGroup":"SY","termSource":"NCI"},{"termName":"PF-04518600","termGroup":"CN","termSource":"NCI"},{"termName":"PF-8600","termGroup":"CN","termSource":"NCI"},{"termName":"PF04518600","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2128729-41-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"APS3IS9D6W"},{"name":"Maps_To","value":"Anti-OX40 Agonist Monoclonal Antibody PF-04518600"},{"name":"Maps_To","value":"Ivuxolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"767326"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767326"},{"name":"PDQ_Open_Trial_Search_ID","value":"767326"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053606"}]}}{"C128026":{"preferredName":"Anti-OX40 Antibody BMS 986178","code":"C128026","definitions":[{"definition":"An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 monoclonal antibody BMS 986178 selectively binds to and activates the OX40 receptor, by mimicking the action of the endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor family (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OX40 Antibody BMS 986178","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986178","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P9XVH8H2HF"},{"name":"Maps_To","value":"Anti-OX40 Antibody BMS 986178"},{"name":"NCI_Drug_Dictionary_ID","value":"781172"},{"name":"NCI_META_CUI","value":"CL507919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781172"},{"name":"PDQ_Open_Trial_Search_ID","value":"781172"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124783":{"preferredName":"Anti-OX40 Monoclonal Antibody GSK3174998","code":"C124783","definitions":[{"definition":"An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-OX40 monoclonal antibody GSK3174998 selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OX40 Monoclonal Antibody GSK3174998","termGroup":"PT","termSource":"NCI"},{"termName":"GSK3174998","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2089398-68-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CT69TVL1KE"},{"name":"Maps_To","value":"Anti-OX40 Monoclonal Antibody GSK3174998"},{"name":"NCI_META_CUI","value":"CL503015"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158507":{"preferredName":"Cudarolimab","code":"C158507","definitions":[{"definition":"An agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4; TNFRSF4; CD134; OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cudarolimab selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cudarolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Monoclonal Antibody IBI101","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 101","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-101","termGroup":"CN","termSource":"NCI"},{"termName":"IBI101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2244739-29-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DT958C4NWR"},{"name":"Maps_To","value":"Anti-OX40 Monoclonal Antibody IBI101"},{"name":"NCI_Drug_Dictionary_ID","value":"797150"},{"name":"NCI_META_CUI","value":"CL938052"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797150"},{"name":"PDQ_Open_Trial_Search_ID","value":"797150"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124058":{"preferredName":"Sasanlimab","code":"C124058","definitions":[{"definition":"An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sasanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 PF-06801591","termGroup":"SY","termSource":"NCI"},{"termName":"PF-06801591","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11161","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2206792-50-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LZZ0IC2EWP"},{"name":"Maps_To","value":"Anti-PD-1 Checkpoint Inhibitor PF-06801591"},{"name":"Maps_To","value":"Sasanlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"776395"},{"name":"NCI_META_CUI","value":"CL502495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776395"},{"name":"PDQ_Open_Trial_Search_ID","value":"776395"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97039":{"preferredName":"Anti-PD-1 Fusion Protein AMP-224","code":"C97039","definitions":[{"definition":"A recombinant B7-DC Fc-fusion protein composed of the extracellular domain of the PD-1 ligand programmed cell death ligand 2 (PD-L2, B7-DC) and the Fc region of human immunoglobulin (Ig) G1, with potential immune checkpoint inhibitory and antineoplastic activities. Anti-PD-1 fusion protein AMP-224 specifically binds to PD-1 on chronically stimulated T-cells and reduces their proliferation. This may restore immune function and may result in the activation of cytotoxic T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein of Ig superfamily and inhibitor receptor expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. AMP-224 does not bind normal activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Fusion Protein AMP-224","termGroup":"PT","termSource":"NCI"},{"termName":"AMP-224","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422184-00-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SKF3JJJ5QA"},{"name":"Maps_To","value":"Anti-PD-1 Fusion Protein AMP-224"},{"name":"NCI_Drug_Dictionary_ID","value":"700595"},{"name":"NCI_META_CUI","value":"CL429646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700595"},{"name":"PDQ_Open_Trial_Search_ID","value":"700595"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155879":{"preferredName":"Penpulimab","code":"C155879","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, penpulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penpulimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 105","termGroup":"CN","termSource":"NCI"},{"termName":"AK-105","termGroup":"CN","termSource":"NCI"},{"termName":"AK105","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody AK105","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2350298-92-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IBS1BZ4E4I"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody AK105"},{"name":"NCI_Drug_Dictionary_ID","value":"794779"},{"name":"NCI_META_CUI","value":"CL562705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794779"},{"name":"PDQ_Open_Trial_Search_ID","value":"794779"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161597":{"preferredName":"Zeluvalimab","code":"C161597","definitions":[{"definition":"A human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zeluvalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zeluvalimab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 404","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-404","termGroup":"CN","termSource":"NCI"},{"termName":"AMG404","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody AMG 404","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2315361-37-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DX474PAV6P"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody AMG 404"},{"name":"NCI_Drug_Dictionary_ID","value":"798431"},{"name":"NCI_META_CUI","value":"CL970132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798431"},{"name":"PDQ_Open_Trial_Search_ID","value":"798431"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162871":{"preferredName":"Anti-PD-1 Monoclonal Antibody BAT1306","code":"C162871","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1306 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody BAT1306","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1 Monoclonal Antibody BAT1306","termGroup":"SY","termSource":"NCI"},{"termName":"BAT 1306","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-1306","termGroup":"CN","termSource":"NCI"},{"termName":"BAT1306","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody BAT1306"},{"name":"NCI_Drug_Dictionary_ID","value":"798913"},{"name":"NCI_META_CUI","value":"CL973356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798913"},{"name":"PDQ_Open_Trial_Search_ID","value":"798913"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148155":{"preferredName":"Prolgolimab","code":"C148155","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, prolgolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prolgolimab","termGroup":"PT","termSource":"NCI"},{"termName":"BCD 100","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-100","termGroup":"CN","termSource":"NCI"},{"termName":"BCD100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2093956-19-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W05CP6IT8R"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody BCD-100"},{"name":"Maps_To","value":"Prolgolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"792520"},{"name":"NCI_META_CUI","value":"CL1382578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792520"},{"name":"PDQ_Open_Trial_Search_ID","value":"792520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132252":{"preferredName":"Ezabenlimab","code":"C132252","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, ezabenlimab selectively binds to and blocks the activation of PD-1, an immunoglobulin (Ig) superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and T-cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ezabenlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody BI 754091","termGroup":"SY","termSource":"NCI"},{"termName":"BI 754091","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2249882-54-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5V1UI86573"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody BI 754091"},{"name":"Maps_To","value":"Ezabenlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"787036"},{"name":"NCI_META_CUI","value":"CL520361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787036"},{"name":"PDQ_Open_Trial_Search_ID","value":"787036"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156726":{"preferredName":"Nofazinlimab","code":"C156726","definitions":[{"definition":"A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nofazinlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nofazinlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody CS1003","termGroup":"SY","termSource":"NCI"},{"termName":"CS 1003","termGroup":"CN","termSource":"NCI"},{"termName":"CS-1003","termGroup":"CN","termSource":"NCI"},{"termName":"CS1003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2377845-98-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42T48Q7A6O"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody CS1003"},{"name":"NCI_Drug_Dictionary_ID","value":"795581"},{"name":"NCI_META_CUI","value":"CL935855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795581"},{"name":"PDQ_Open_Trial_Search_ID","value":"795581"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162636":{"preferredName":"Rulonilimab","code":"C162636","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,rulonilimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rulonilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody F520","termGroup":"SY","termSource":"NCI"},{"termName":"F 520","termGroup":"CN","termSource":"NCI"},{"termName":"F520","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417124-95-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KQA6N2NT4Z"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody F520"},{"name":"NCI_Drug_Dictionary_ID","value":"798724"},{"name":"NCI_META_CUI","value":"CL971026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798724"},{"name":"PDQ_Open_Trial_Search_ID","value":"798724"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159549":{"preferredName":"Zimberelimab","code":"C159549","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zimberelimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zimberelimab","termGroup":"PT","termSource":"NCI"},{"termName":"AB 122","termGroup":"CN","termSource":"NCI"},{"termName":"AB-122","termGroup":"CN","termSource":"NCI"},{"termName":"AB122","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody GLS-010","termGroup":"SY","termSource":"NCI"},{"termName":"GLS 010","termGroup":"CN","termSource":"NCI"},{"termName":"GLS-010","termGroup":"CN","termSource":"NCI"},{"termName":"GLS010","termGroup":"CN","termSource":"NCI"},{"termName":"Sepalizumab","termGroup":"SY","termSource":"NCI"},{"termName":"WBP 3055","termGroup":"CN","termSource":"NCI"},{"termName":"WBP-3055","termGroup":"CN","termSource":"NCI"},{"termName":"WBP3055","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2259860-24-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ZBL7O904IL"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody GLS-010"},{"name":"NCI_Drug_Dictionary_ID","value":"797805"},{"name":"NCI_META_CUI","value":"CL951387"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797805"},{"name":"PDQ_Open_Trial_Search_ID","value":"797805"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156738":{"preferredName":"Serplulimab","code":"C156738","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serplulimab","termGroup":"PT","termSource":"NCI"},{"termName":"HLX 10","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-10","termGroup":"CN","termSource":"NCI"},{"termName":"HLX10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231029-82-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"S3GQZ2K36V"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody HLX10"},{"name":"Maps_To","value":"Serplulimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795682"},{"name":"NCI_META_CUI","value":"CL935905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795682"},{"name":"PDQ_Open_Trial_Search_ID","value":"795682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160717":{"preferredName":"Pucotenlimab","code":"C160717","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pucotenlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pucotenlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody HX008","termGroup":"SY","termSource":"NCI"},{"termName":"HX 008","termGroup":"CN","termSource":"NCI"},{"termName":"HX-008","termGroup":"CN","termSource":"NCI"},{"termName":"HX008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2403647-03-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CGA81G3KR5"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody HX008"},{"name":"NCI_Drug_Dictionary_ID","value":"797959"},{"name":"NCI_META_CUI","value":"CL969824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797959"},{"name":"PDQ_Open_Trial_Search_ID","value":"797959"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157485":{"preferredName":"Pimivalimab","code":"C157485","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pimivalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimivalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody JTX-4014","termGroup":"SY","termSource":"NCI"},{"termName":"JTX 4014","termGroup":"CN","termSource":"NCI"},{"termName":"JTX-4014","termGroup":"CN","termSource":"NCI"},{"termName":"JTX4014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2293951-22-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MA05AF40UO"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody JTX-4014"},{"name":"NCI_Drug_Dictionary_ID","value":"796722"},{"name":"NCI_META_CUI","value":"CL937077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796722"},{"name":"PDQ_Open_Trial_Search_ID","value":"796722"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153149":{"preferredName":"Lipustobart","code":"C153149","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, lipustobart binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways, leading to the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells that negatively regulates T-cell activation and effector function when activated by its ligands. PD-1 plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipustobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody LZM009","termGroup":"SY","termSource":"NCI"},{"termName":"LZM 009","termGroup":"CN","termSource":"NCI"},{"termName":"LZM-009","termGroup":"CN","termSource":"NCI"},{"termName":"LZM009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2639481-06-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H6KN31H3XF"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody LZM009"},{"name":"NCI_Drug_Dictionary_ID","value":"793463"},{"name":"NCI_META_CUI","value":"CL554402"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793463"},{"name":"PDQ_Open_Trial_Search_ID","value":"793463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113332":{"preferredName":"Anti-PD-1 Monoclonal Antibody MEDI0680","code":"C113332","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MEDI0680 binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody MEDI0680","termGroup":"PT","termSource":"NCI"},{"termName":"AMP-514","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI0680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody MEDI0680"},{"name":"NCI_Drug_Dictionary_ID","value":"756047"},{"name":"NCI_META_CUI","value":"CL458160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756047"},{"name":"PDQ_Open_Trial_Search_ID","value":"756047"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C142168":{"preferredName":"Retifanlimab","code":"C142168","definitions":[{"definition":"A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retifanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"INCMGA 0012","termGroup":"CN","termSource":"NCI"},{"termName":"INCMGA-0012","termGroup":"CN","termSource":"NCI"},{"termName":"INCMGA00012","termGroup":"CN","termSource":"NCI"},{"termName":"INCMGA0012","termGroup":"CN","termSource":"NCI"},{"termName":"MGA 012","termGroup":"CN","termSource":"NCI"},{"termName":"MGA-012","termGroup":"CN","termSource":"NCI"},{"termName":"MGA012","termGroup":"CN","termSource":"NCI"},{"termName":"Retifanlimab-dlwr","termGroup":"SY","termSource":"NCI"},{"termName":"Zynyz","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)."},{"name":"CAS_Registry","value":"2226345-85-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2Y3T5IF01Z"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody MGA012"},{"name":"Maps_To","value":"Retifanlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791453"},{"name":"NCI_META_CUI","value":"CL540160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791453"},{"name":"PDQ_Open_Trial_Search_ID","value":"791453"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142865":{"preferredName":"Anti-PD-1 Monoclonal Antibody Sym021","code":"C142865","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 , PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody Sym021 binds to and inhibits PD-1 activation and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF), is expressed on T-cells and functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2). Activated PD-1 plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody Sym021","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1 Monoclonal Antibody Sym021","termGroup":"SY","termSource":"NCI"},{"termName":"Sym021","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2233593-42-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K45ZNW8WU9"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody Sym021"},{"name":"NCI_Drug_Dictionary_ID","value":"791807"},{"name":"NCI_META_CUI","value":"CL540754"},{"name":"PDQ_Open_Trial_Search_ID","value":"791807"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126799":{"preferredName":"Dostarlimab","code":"C126799","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dostarlimab","termGroup":"PT","termSource":"NCI"},{"termName":"ANB011","termGroup":"CN","termSource":"NCI"},{"termName":"Dostarlimab-gxly","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Jemperli","termGroup":"BR","termSource":"NCI"},{"termName":"TSR 042","termGroup":"CN","termSource":"NCI"},{"termName":"TSR-042","termGroup":"CN","termSource":"NCI"},{"termName":"TSR042","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer"},{"name":"CAS_Registry","value":"2022215-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"P0GVQ9A4S5"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody TSR-042"},{"name":"Maps_To","value":"Dostarlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"780223"},{"name":"NCI_META_CUI","value":"CL1676862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780223"},{"name":"PDQ_Open_Trial_Search_ID","value":"780223"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158505":{"preferredName":"Lorigerlimab","code":"C158505","definitions":[{"definition":"A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lorigerlimab","termGroup":"PT","termSource":"NCI"},{"termName":"AEX-1344","termGroup":"CN","termSource":"NCI"},{"termName":"AEX1344","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-CTLA4 DART Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific DART Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"D-1 x CTLA4 DART Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"Dual-affinity Retargeting Protein MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"MGD 019","termGroup":"CN","termSource":"NCI"},{"termName":"MGD-019","termGroup":"SY","termSource":"NCI"},{"termName":"MGD019","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 x CTLA4 Bispecific DART Molecule MGD019","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA4 DART Protein MGD019","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416595-46-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JM802R57SA"},{"name":"Maps_To","value":"Anti-PD-1/Anti-CTLA4 DART Protein MGD019"},{"name":"NCI_Drug_Dictionary_ID","value":"797142"},{"name":"NCI_META_CUI","value":"CL938054"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797142"},{"name":"PDQ_Open_Trial_Search_ID","value":"797142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143957":{"preferredName":"Tebotelimab","code":"C143957","definitions":[{"definition":"An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T-cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tebotelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-LAG-3 DART Protein MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific DART Protein MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"Dual-affinity Retargeting Protein MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"MGD 013","termGroup":"CN","termSource":"NCI"},{"termName":"MGD-013","termGroup":"CN","termSource":"NCI"},{"termName":"MGD013","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 x LAG-3 Bispecific DART Molecule MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x LAG-3 DART Molecule MGD013","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x LAG-3 DART Protein MGD013","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2245725-04-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L62556GPXB"},{"name":"Maps_To","value":"Anti-PD-1/Anti-LAG-3 DART Protein MGD013"},{"name":"NCI_Drug_Dictionary_ID","value":"792154"},{"name":"NCI_META_CUI","value":"CL542159"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792154"},{"name":"PDQ_Open_Trial_Search_ID","value":"792154"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160605":{"preferredName":"Reozalimab","code":"C160605","definitions":[{"definition":"A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reozalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/PD-L1 Bispecific Antibody LY3434172","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody LY3434172","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3434172","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3434172","termGroup":"CN","termSource":"NCI"},{"termName":"LY3434172","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1LO2LQW7QG"},{"name":"Maps_To","value":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172"},{"name":"NCI_Drug_Dictionary_ID","value":"801671"},{"name":"NCI_META_CUI","value":"CL969662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801671"},{"name":"PDQ_Open_Trial_Search_ID","value":"801671"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C153379":{"preferredName":"Cadonilimab","code":"C153379","definitions":[{"definition":"A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cadonilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 104","termGroup":"CN","termSource":"NCI"},{"termName":"AK-104","termGroup":"CN","termSource":"NCI"},{"termName":"AK104","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 x CTLA-4 Bispecific Antibody AK104","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/CTLA-4 Bispecific Antibody AK104","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD1/Anti-CTLA4 Bispecific Antibody AK104","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA-4 Dual Checkpoint Inhibitor AK104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2394841-59-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6FYG1DS4NW"},{"name":"Maps_To","value":"Anti-PD-1/CTLA-4 Bispecific Antibody AK104"},{"name":"NCI_Drug_Dictionary_ID","value":"793930"},{"name":"NCI_META_CUI","value":"CL554535"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793930"},{"name":"PDQ_Open_Trial_Search_ID","value":"793930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160714":{"preferredName":"Lomvastomig","code":"C160714","definitions":[{"definition":"A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lomvastomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 x TIM-3 Bispecific Antibody RO7121661","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-TIM-3 Bispecific Antibody RO7121661","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/TIM-3 Bispecific Antibody RO7121661","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7121661","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7121661","termGroup":"SY","termSource":"NCI"},{"termName":"RO7121661","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9GAH9VG7IP"},{"name":"Maps_To","value":"Anti-PD-1/TIM-3 Bispecific Antibody RO7121661"},{"name":"NCI_Drug_Dictionary_ID","value":"797892"},{"name":"NCI_META_CUI","value":"CL969812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797892"},{"name":"PDQ_Open_Trial_Search_ID","value":"797892"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163992":{"preferredName":"Tagitanlimab","code":"C163992","definitions":[{"definition":"A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tagitanlimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tagitanlimab","termGroup":"PT","termSource":"NCI"},{"termName":"A 167","termGroup":"CN","termSource":"NCI"},{"termName":"A-167","termGroup":"CN","termSource":"NCI"},{"termName":"A167","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody A167","termGroup":"SY","termSource":"NCI"},{"termName":"KL A167","termGroup":"CN","termSource":"NCI"},{"termName":"KL-A167","termGroup":"CN","termSource":"NCI"},{"termName":"KLA167","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417649-97-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GUY458P83P"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody A167"},{"name":"NCI_Drug_Dictionary_ID","value":"799136"},{"name":"NCI_META_CUI","value":"CL977261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799136"},{"name":"PDQ_Open_Trial_Search_ID","value":"799136"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156741":{"preferredName":"Manelimab","code":"C156741","definitions":[{"definition":"A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, manelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Manelimab","termGroup":"PT","termSource":"NCI"},{"termName":"BCD 135","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-135","termGroup":"CN","termSource":"NCI"},{"termName":"BCD135","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2168561-26-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U3OZ7HX207"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody BCD-135"},{"name":"Maps_To","value":"Manelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795701"},{"name":"NCI_META_CUI","value":"CL935904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795701"},{"name":"PDQ_Open_Trial_Search_ID","value":"795701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155654":{"preferredName":"Garivulimab","code":"C155654","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, garivulimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333 blocks the interaction between PD-L1 and its other receptor, the immunostimulatory molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling and inhibits the induction of PD-L1-induced apoptosis of activated CD8+ T-cells and increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Garivulimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody BGB-A333","termGroup":"SY","termSource":"NCI"},{"termName":"BGB A333","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A333","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA333","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2342597-81-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CSJ7UEQ4D9"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody BGB-A333"},{"name":"NCI_Drug_Dictionary_ID","value":"794412"},{"name":"NCI_META_CUI","value":"CL556266"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794412"},{"name":"PDQ_Open_Trial_Search_ID","value":"794412"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156692":{"preferredName":"Benmelstobart","code":"C156692","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, benmelstobart specifically targets and binds to PD-L1, preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benmelstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody CBT-502","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody TQB2450","termGroup":"SY","termSource":"NCI"},{"termName":"APL502","termGroup":"CN","termSource":"NCI"},{"termName":"CBT 502","termGroup":"CN","termSource":"NCI"},{"termName":"CBT-502","termGroup":"CN","termSource":"NCI"},{"termName":"CBT502","termGroup":"CN","termSource":"NCI"},{"termName":"TQB 2450","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-2450","termGroup":"CN","termSource":"NCI"},{"termName":"TQB2450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2303884-58-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B25CF42QKP"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody CBT-502"},{"name":"NCI_Drug_Dictionary_ID","value":"795708"},{"name":"NCI_META_CUI","value":"CL935711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795708"},{"name":"PDQ_Open_Trial_Search_ID","value":"795708"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151947":{"preferredName":"Cosibelimab","code":"C151947","definitions":[{"definition":"An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cosibelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody TG-1501","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDL1 Monoclonal Antibody TG-1501","termGroup":"SY","termSource":"NCI"},{"termName":"CK 301","termGroup":"CN","termSource":"NCI"},{"termName":"CK-301","termGroup":"CN","termSource":"NCI"},{"termName":"TG 1501","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1501","termGroup":"CN","termSource":"NCI"},{"termName":"TG1501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2216751-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PNW7GBB44P"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody CK-301"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody TG-1501"},{"name":"Maps_To","value":"Cosibelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"793157"},{"name":"NCI_META_CUI","value":"CL937684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793157"},{"name":"PDQ_Open_Trial_Search_ID","value":"793157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154550":{"preferredName":"Sugemalimab","code":"C154550","definitions":[{"definition":"A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sugemalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody CS1001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody WBP 3155","termGroup":"SY","termSource":"NCI"},{"termName":"Cejemly","termGroup":"FB","termSource":"NCI"},{"termName":"CS 1001","termGroup":"SY","termSource":"NCI"},{"termName":"CS-1001","termGroup":"CN","termSource":"NCI"},{"termName":"CS1001","termGroup":"CN","termSource":"NCI"},{"termName":"WBP 315","termGroup":"CN","termSource":"NCI"},{"termName":"WBP-315","termGroup":"CN","termSource":"NCI"},{"termName":"WBP315","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2256084-03-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"90IQR2I6TR"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody CS1001"},{"name":"Maps_To","value":"Sugemalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"794350"},{"name":"NCI_META_CUI","value":"CL555350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794350"},{"name":"PDQ_Open_Trial_Search_ID","value":"794350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131537":{"preferredName":"Anti-PD-L1 Monoclonal Antibody FAZ053","code":"C131537","definitions":[{"definition":"A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1), with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody FAZ053 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated anti-tumor immune response and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody FAZ053","termGroup":"PT","termSource":"NCI"},{"termName":"FAZ 053","termGroup":"CN","termSource":"NCI"},{"termName":"FAZ-053","termGroup":"CN","termSource":"NCI"},{"termName":"FAZ053","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V6W1OW12H2"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody FAZ053"},{"name":"NCI_Drug_Dictionary_ID","value":"786263"},{"name":"NCI_META_CUI","value":"CL514246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786263"},{"name":"PDQ_Open_Trial_Search_ID","value":"786263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159538":{"preferredName":"Anti-PD-L1 Monoclonal Antibody GR1405","code":"C159538","definitions":[{"definition":"A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody GR1405 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody GR1405","termGroup":"PT","termSource":"NCI"},{"termName":"GR 1405","termGroup":"CN","termSource":"NCI"},{"termName":"GR-1405","termGroup":"CN","termSource":"NCI"},{"termName":"GR1405","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody GR1405"},{"name":"NCI_Drug_Dictionary_ID","value":"797479"},{"name":"NCI_META_CUI","value":"CL951376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797479"},{"name":"PDQ_Open_Trial_Search_ID","value":"797479"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165270":{"preferredName":"Opucolimab","code":"C165270","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, opucolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opucolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody HLX20","termGroup":"SY","termSource":"NCI"},{"termName":"HLX 20","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-20","termGroup":"CN","termSource":"NCI"},{"termName":"HLX20","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1-targeting Monoclonal Antibody HLX20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2251771-79-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"20ZE3P16HV"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody HLX20"},{"name":"Maps_To","value":"Opucolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"799415"},{"name":"NCI_META_CUI","value":"CL978537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799415"},{"name":"PDQ_Open_Trial_Search_ID","value":"799415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128138":{"preferredName":"Lodapolimab","code":"C128138","definitions":[{"definition":"A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lodapolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Checkpoint Antibody LY3300054","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody LY3300054","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Programmed Cell Death Ligand 1 Checkpoint Antibody LY3300054","termGroup":"SY","termSource":"NCI"},{"termName":"LY3300054","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11185","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2118349-31-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NR4MAD6PPB"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody LY3300054"},{"name":"Maps_To","value":"Lodapolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"782062"},{"name":"NCI_META_CUI","value":"CL507936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782062"},{"name":"PDQ_Open_Trial_Search_ID","value":"782062"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78852":{"preferredName":"Anti-PD-L1 Monoclonal Antibody MDX-1105","code":"C78852","definitions":[{"definition":"A fully human monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody MDX-1105","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 936559","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-1105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TLZ6R6973Z"},{"name":"Legacy Concept Name","value":"Anti-PD-L1_Monoclonal_Antibody_MDX-1105"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody MDX-1105"},{"name":"NCI_Drug_Dictionary_ID","value":"612730"},{"name":"NCI_META_CUI","value":"CL387680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612730"},{"name":"PDQ_Open_Trial_Search_ID","value":"612730"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155931":{"preferredName":"Betifisolimab","code":"C155931","definitions":[{"definition":"A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Betifisolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody MSB2311","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDL1 Monoclonal Antibody MSB2311","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-PD-L1 Monoclonal Antibody MSB2311","termGroup":"SY","termSource":"NCI"},{"termName":"MSB 2311","termGroup":"CN","termSource":"NCI"},{"termName":"MSB-2311","termGroup":"CN","termSource":"NCI"},{"termName":"MSB2311","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460539-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7XRB4BO26"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody MSB2311"},{"name":"NCI_Drug_Dictionary_ID","value":"795264"},{"name":"NCI_META_CUI","value":"CL562806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795264"},{"name":"PDQ_Open_Trial_Search_ID","value":"795264"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148535":{"preferredName":"Adebrelimab","code":"C148535","definitions":[{"definition":"An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adebrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"HTI 1088","termGroup":"CN","termSource":"NCI"},{"termName":"HTI-1088","termGroup":"CN","termSource":"NCI"},{"termName":"HTI1088","termGroup":"CN","termSource":"NCI"},{"termName":"SHR 1316","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1316","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1316","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2247114-85-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1XBY50W1OX"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody SHR-1316"},{"name":"NCI_Drug_Dictionary_ID","value":"792709"},{"name":"NCI_META_CUI","value":"CL551134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792709"},{"name":"PDQ_Open_Trial_Search_ID","value":"792709"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162504":{"preferredName":"Socazolimab","code":"C162504","definitions":[{"definition":"A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, socazolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Socazolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody ZKAB001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDL1 Monoclonal Antibody ZKAB001","termGroup":"SY","termSource":"NCI"},{"termName":"STI A1014","termGroup":"CN","termSource":"NCI"},{"termName":"STI-A1014","termGroup":"CN","termSource":"NCI"},{"termName":"STIA1014","termGroup":"CN","termSource":"NCI"},{"termName":"ZKAB 001","termGroup":"CN","termSource":"NCI"},{"termName":"ZKAB-001","termGroup":"CN","termSource":"NCI"},{"termName":"ZKAB001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305043-30-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82P4S8Q3FB"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody ZKAB001"},{"name":"NCI_Drug_Dictionary_ID","value":"798649"},{"name":"NCI_META_CUI","value":"CL970934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798649"},{"name":"PDQ_Open_Trial_Search_ID","value":"798649"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C159978":{"preferredName":"Enristomig","code":"C159978","definitions":[{"definition":"A recombinant, humanized, bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, enristomig simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, enristomig acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, Ienristomig prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enristomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1/CD137 Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"},{"termName":"ES 101","termGroup":"CN","termSource":"NCI"},{"termName":"ES-101","termGroup":"CN","termSource":"NCI"},{"termName":"ES101","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX 105","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX-105","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX105","termGroup":"CN","termSource":"NCI"},{"termName":"PDL1 x 4-1BB Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"},{"termName":"PDL1 x CD137 Bispecific Antibody INBRX-105","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2539845-73-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3CX9U8V1CV"},{"name":"Maps_To","value":"Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105"},{"name":"NCI_Drug_Dictionary_ID","value":"797967"},{"name":"NCI_META_CUI","value":"CL969077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797967"},{"name":"PDQ_Open_Trial_Search_ID","value":"797967"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160772":{"preferredName":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","code":"C160772","definitions":[{"definition":"A full-length, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/CD137 bispecific antibody MCLA-145 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, MCLA-145 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, MCLA-145 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1/4-1BB Bispecific Antibody MCLA-145","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-L1/Anti-CD137 Bispecific Antibody MCLA-145","termGroup":"SY","termSource":"NCI"},{"termName":"MCLA 145","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA-145","termGroup":"CN","termSource":"NCI"},{"termName":"MCLA145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1/CD137 Bispecific Antibody MCLA-145"},{"name":"NCI_Drug_Dictionary_ID","value":"798414"},{"name":"NCI_META_CUI","value":"CL969758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798414"},{"name":"PDQ_Open_Trial_Search_ID","value":"798414"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157058":{"preferredName":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","code":"C157058","definitions":[{"definition":"A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3415244","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3415244","termGroup":"SY","termSource":"NCI"},{"termName":"LY3415244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"603H2FWG4N"},{"name":"Maps_To","value":"Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244"},{"name":"NCI_Drug_Dictionary_ID","value":"796576"},{"name":"NCI_META_CUI","value":"CL936018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796576"},{"name":"PDQ_Open_Trial_Search_ID","value":"796576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136465":{"preferredName":"Balstilimab","code":"C136465","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balstilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 2034","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-2034","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN2034","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230167-06-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Q2QT5M7EO"},{"name":"Maps_To","value":"Anti-PD1 Monoclonal Antibody AGEN2034"},{"name":"Maps_To","value":"Balstilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"789509"},{"name":"NCI_META_CUI","value":"CL523768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789509"},{"name":"PDQ_Open_Trial_Search_ID","value":"789509"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150463":{"preferredName":"Vudalimab","code":"C150463","definitions":[{"definition":"A Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vudalimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T-lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with XmAb20717 may enhance T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vudalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-CTLA-4 XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD1/CTLA4 Bispecific Antibody XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA-4 Bispecific Antibody XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 x CTLA-4 Dual Checkpoint Inhibitor XmAb20717","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb 20717","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb20717","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2329669-72-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4I9I5X3Z6N"},{"name":"Maps_To","value":"Anti-PD1/CTLA4 Bispecific Antibody XmAb20717"},{"name":"NCI_Drug_Dictionary_ID","value":"793410"},{"name":"NCI_META_CUI","value":"CL552206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793410"},{"name":"PDQ_Open_Trial_Search_ID","value":"793410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78486":{"preferredName":"Anti-PLGF Monoclonal Antibody TB-403","code":"C78486","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the placenta growth factor (PGF), with potential anti-angiogenic and antineoplastic activities. Anti-PGF monoclonal antibody TB-403 binds to both PGF-1 and -2, thereby inhibiting the binding of PGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and subsequent VEGFR-1 phosphorylation. This may result in the inhibition of tumor angiogenesis and tumor cell proliferation. PGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PLGF Monoclonal Antibody TB-403","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PGF Monoclonal Antibody RO5323441","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Placental Growth Factor Monoclonal Antibody TB-403","termGroup":"SY","termSource":"NCI"},{"termName":"RG7334","termGroup":"CN","termSource":"NCI"},{"termName":"RO5323441","termGroup":"CN","termSource":"NCI"},{"termName":"TB-403","termGroup":"CN","termSource":"NCI"},{"termName":"THR 317","termGroup":"CN","termSource":"NCI"},{"termName":"THR-317","termGroup":"CN","termSource":"NCI"},{"termName":"THR317","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46MVG4H2LF"},{"name":"Legacy Concept Name","value":"Anti-PLGF_Monoclonal_Antibody_TB-403"},{"name":"Maps_To","value":"Anti-PGF Monoclonal Antibody RO5323441"},{"name":"Maps_To","value":"Anti-PLGF Monoclonal Antibody TB-403"},{"name":"NCI_Drug_Dictionary_ID","value":"601058"},{"name":"NCI_META_CUI","value":"CL387523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601058"},{"name":"PDQ_Open_Trial_Search_ID","value":"601058"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84847":{"preferredName":"Anti-PKN3 siRNA Atu027","code":"C84847","definitions":[{"definition":"A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and fusiogenic lipids with potential antineoplastic activity. Upon administration, catiogenic and fusiogenic lipids promote anti-PKN3 siRNA Atu02 uptake by tumor cells; the siRNAs moieties are subsequently released once inside the cell. The siRNAs bind to PKN3 mRNAs, which may result in the inhibition of translation and expression of the PKN3 protein and, so, growth inhibition of tumor cells that overexpress PKN3. The protein kinase C-related molecule PKN3, downstream in the phosphoinositide-3-kinase (PI3K) signaling pathway, is upregulated in many tumor cells and plays an important role in invasive cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PKN3 siRNA Atu027","termGroup":"PT","termSource":"NCI"},{"termName":"Atu027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415935-22-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IFJ2SAK127"},{"name":"Maps_To","value":"Anti-PKN3 siRNA Atu027"},{"name":"NCI_Drug_Dictionary_ID","value":"650831"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650831"},{"name":"PDQ_Open_Trial_Search_ID","value":"650831"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827525"}]}}{"C123924":{"preferredName":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4","code":"C123924","definitions":[{"definition":"A T-cell receptor (TCR)-like monoclonal antibody against PR1, a 9 amino-acid (VLQELNVTV) human leukocyte antigen (HLA)-A2-restricted leukemia-associated antigen (LAA) derived from the myeloid leukemia-associated antigens proteinase 3 (P3) and neutrophil elastase (NE), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PR1/HLA-A2 monoclonal antibody Hu8F4 selectively binds to a combined epitope of the PR1/HLA-A2 complex expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSC), and prevents PR1/HLA-A2-mediated signaling. This induces complement-dependent cytotoxicity (CDC), to a lesser extent, antibody-dependent cell-mediated cytotoxicity (ADCC), and CDC/ADCC-independent cytolysis of myeloid leukemia cells. This results in a reduction of cellular proliferation in PR1/HLA-A2-overexpressing leukemic cells. PR1 in combination with the HLA-A2 molecule is highly expressed on AML blasts and LSCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4","termGroup":"PT","termSource":"NCI"},{"termName":"Hu8F4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NL06848HBQ"},{"name":"Maps_To","value":"Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4"},{"name":"NCI_Drug_Dictionary_ID","value":"775929"},{"name":"NCI_META_CUI","value":"CL498288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775929"},{"name":"PDQ_Open_Trial_Search_ID","value":"775929"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116848":{"preferredName":"Anti-PRAME Immunotherapeutic GSK2302032A","code":"C116848","definitions":[{"definition":"An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PRAME Immunotherapeutic GSK2302032A","termGroup":"PT","termSource":"NCI"},{"termName":"GSK-2302032A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2302032A","termGroup":"CN","termSource":"NCI"},{"termName":"PRAME ASCI","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PRAME Immunotherapeutic GSK2302032A"},{"name":"NCI_Drug_Dictionary_ID","value":"681985"},{"name":"NCI_META_CUI","value":"CL421661"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681985"},{"name":"PDQ_Open_Trial_Search_ID","value":"681985"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151931":{"preferredName":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab","code":"C151931","definitions":[{"definition":"A humanized monoclonal antibody against  phosphatase of regenerating liver 3 (PRL-3; PTP4A3), with potential immunomodulating and antineoplastic activities. Upon administration, anti-PRL-3 monoclonal antibody PRL3-zumab targets, binds to and blocks PRL-3 expressed on tumor cells. Although the exact mechanism of action through which this antibody kills tumor cells has yet to be fully elucidated, PRL3-zumab binds to PRL-3. This prevents PRL-3-mediated signaling in, inhibits the proliferation of and induces apoptosis in PRL-3-expressing tumor cells. PRL-3, a member of the PRL family of protein tyrosine kinases, is upregulated in a variety of tumor cells. Its expression is associated with increased invasiveness, higher metastatic potential, increased tumor cell survival and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab","termGroup":"PT","termSource":"NCI"},{"termName":"PRL3 Zumab","termGroup":"SY","termSource":"NCI"},{"termName":"PRL3-zumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PRL-3 Monoclonal Antibody PRL3-zumab"},{"name":"NCI_Drug_Dictionary_ID","value":"793124"},{"name":"NCI_META_CUI","value":"CL553270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793124"},{"name":"PDQ_Open_Trial_Search_ID","value":"793124"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C96744":{"preferredName":"Anti-prolactin Receptor Antibody LFA102","code":"C96744","definitions":[{"definition":"A neutralizing antibody against the prolactin receptor (PRLR) with potential antineoplastic activity. Upon administration, anti-prolactin receptor antibody LFA102 binds to PRLR and prevents the binding of the peptide hormone prolactin (PRL) to its receptor. This binding induces an antibody-dependent cellular cytotoxicity (ADCC) and may eventually prevent tumor cell proliferation in PRLR-positive cancer cells. PRLR/PRL signaling pathway is frequently overexpressed in breast and prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-prolactin Receptor Antibody LFA102","termGroup":"PT","termSource":"NCI"},{"termName":"LFA102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-prolactin Receptor Antibody LFA102"},{"name":"NCI_Drug_Dictionary_ID","value":"699731"},{"name":"NCI_META_CUI","value":"CL429368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699731"},{"name":"PDQ_Open_Trial_Search_ID","value":"699731"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71157":{"preferredName":"Anti-PSCA Monoclonal Antibody AGS-1C4D4","code":"C71157","definitions":[{"definition":"An IgG1k fully human monoclonal antibody directed against the human prostate stem cell antigen (PSCA) with potential antineoplastic activity. Anti-PSCA fully human monoclonal antibody MK4721 selectively targets and binds to PSCA, triggering complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in tumor cells expressing PSCA. PSCA is a glycosyl-phosphatidylinositol (GPI)-linked cell surface antigen found in cancers of the bladder, pancreas, and prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSCA Monoclonal Antibody AGS-1C4D4","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-1C4D4","termGroup":"CN","termSource":"NCI"},{"termName":"MK4721","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0505LPC7O"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_MK4721"},{"name":"Maps_To","value":"Anti-PSCA Monoclonal Antibody AGS-1C4D4"},{"name":"NCI_Drug_Dictionary_ID","value":"570981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570981"},{"name":"PDQ_Open_Trial_Search_ID","value":"570981"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347292"}]}}{"C113439":{"preferredName":"PSMA-targeting Fluorescent Imaging Agent MDX1201-A488","code":"C113439","definitions":[{"definition":"A recombinant, human monoclonal antibody targeting an extracellular epitope of human prostate specific membrane antigen (PSMA) that is conjugated with A488, a photostable fluorescent dye with a high quantum yield, with potential imaging activity. Upon intravenous administration of PSMA-targeting fluorescent imaging agent MDX1201-A488, the MDX1201 moiety targets PSMA expressed on cancer cells. Subsequently, the A488 moiety can then be visualized by fluorescence-based imaging and the amount of PSMA-expressing tumor cells can be assessed. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA-targeting Fluorescent Imaging Agent MDX1201-A488","termGroup":"PT","termSource":"NCI"},{"termName":"MDX1201-A488","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA Monoclonal Antibody MDX1201-A488"},{"name":"NCI_Drug_Dictionary_ID","value":"756416"},{"name":"NCI_META_CUI","value":"CL458233"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756416"},{"name":"PDQ_Open_Trial_Search_ID","value":"756416"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26660":{"preferredName":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704","code":"C26660","definitions":[{"definition":"A substance that is being studied in the treatment of prostate cancer. It belongs to the family of drugs called antibody drug conjugates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate that consists of a humanized monoclonal antibody (MLN591), directed against prostate-specific membrane antigen linked to a maytansinoid (DM1). The monoclonal antibody moiety of MLN2704 binds to tumor cells expressing prostate-specific membrane antigen; MLN274 is then internalized into the tumor cell where the DM1 maytansinoid moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704","termGroup":"PT","termSource":"NCI"},{"termName":"MLN591DM1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MLN2704"},{"name":"Maps_To","value":"Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704"},{"name":"NCI_Drug_Dictionary_ID","value":"299464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299464"},{"name":"PDQ_Open_Trial_Search_ID","value":"299464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327945"}]}}{"C95707":{"preferredName":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate","code":"C95707","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody directed against prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  The monoclonal antibody moiety of this conjugate selectively binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA Monoclonal Antibody-Monomethylauristatin E Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PSMA-MMAE-ADC","termGroup":"AB","termSource":"NCI"},{"termName":"Prostate-specific Membrane Antigen Antibody-Drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA ADC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA Monoclonal Antibody-MMAE Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"709281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709281"},{"name":"PDQ_Open_Trial_Search_ID","value":"709281"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987347"}]}}{"C162936":{"preferredName":"Nezastomig","code":"C162936","definitions":[{"definition":"A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of nezastomig this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nezastomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA/Anti-CD28 Bispecific Antibody REGN5678","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PSMA/CD28 Bispecific Antibody REGN5678","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PSMAxCD28 Antibody REGN5678","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5678","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5678","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5678","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2657613-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M355PGI1TG"},{"name":"Maps_To","value":"Anti-PSMA/CD28 Bispecific Antibody REGN5678"},{"name":"NCI_Drug_Dictionary_ID","value":"799093"},{"name":"NCI_META_CUI","value":"CL973295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799093"},{"name":"PDQ_Open_Trial_Search_ID","value":"799093"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163976":{"preferredName":"Voxalatamab","code":"C163976","definitions":[{"definition":"An immunoglobulin G4 (IgG4) bispecific antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, voxalatamab simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Voxalatamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63898081","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63898081","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-8081","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63898081","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2411871-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O257GFG7G0"},{"name":"Maps_To","value":"Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081"},{"name":"NCI_Drug_Dictionary_ID","value":"801628"},{"name":"NCI_META_CUI","value":"CL977249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801628"},{"name":"PDQ_Open_Trial_Search_ID","value":"801628"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118626":{"preferredName":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414","code":"C118626","definitions":[{"definition":"An anti-prostate specific membrane antigen (PSMA)/anti-CD3 bispecific humanized monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Anti-PSMA/CD3 monoclonal antibody MOR209/ES414 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for PSMA, a tumor-associated antigen (TAA) overexpressed on the surface of prostate tumor cells. Upon intravenous administration of MOR209/ES414, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and PSMA-expressing cancer cells, thereby crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in CTL-mediated cancer cell lysis of prostate cancer cells expressing PSMA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414","termGroup":"PT","termSource":"NCI"},{"termName":"MOR209/ES414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414"},{"name":"NCI_Drug_Dictionary_ID","value":"765517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765517"},{"name":"PDQ_Open_Trial_Search_ID","value":"765517"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896808"}]}}{"C140552":{"preferredName":"Anti-PSMA/PBD ADC MEDI3726","code":"C140552","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an engineered version of anti-human prostate-specific membrane antigen (PSMA) monoclonal antibody J591 conjugated, via a valine-alanine dipeptide linker, to tesirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-PSMA/PBD ADC MEDI3726, the antibody moiety targets the cell surface antigen PSMA, which is found on prostate cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage of the dipeptide linker, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of PSMA-overexpressing tumor cells. PSMA is overexpressed by prostate cancers; its expression is associated with poor prognosis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA/PBD ADC MEDI3726","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MEDI3726","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT 401","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT-401","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT401","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI 3726","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-3726","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI3726","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SA4H7K0SW2"},{"name":"Maps_To","value":"Anti-PSMA/PBD ADC MEDI3726"},{"name":"NCI_Drug_Dictionary_ID","value":"791113"},{"name":"NCI_META_CUI","value":"CL538618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791113"},{"name":"PDQ_Open_Trial_Search_ID","value":"791113"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123828":{"preferredName":"Cofetuzumab Pelidotin","code":"C123828","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cofetuzumab Pelidotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC PF-06647020","termGroup":"SY","termSource":"NCI"},{"termName":"ADC PF-7020","termGroup":"SY","termSource":"NCI"},{"termName":"h6M24-vc0101","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human protein tyrosine kinase 7) (humanized Mus musculus clone hu24 gamma-chain), Disulfide with humanized Mus musculus clone hu24 kappa-chain, Dimer, Thioether with N-(((4-((N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl)amino)phenyl)methoxy)carbonyl)-2-methylalanyl-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(2-thiazolyl)ethyl)amino)propyl)-1-pyrrolidinyl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide","termGroup":"SN","termSource":"NCI"},{"termName":"PF 06647020","termGroup":"CN","termSource":"NCI"},{"termName":"PF 7020","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06647020","termGroup":"CN","termSource":"NCI"},{"termName":"PF-7020","termGroup":"CN","termSource":"NCI"},{"termName":"PF06647020","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1869937-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"249EAP69MT"},{"name":"Maps_To","value":"Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020"},{"name":"Maps_To","value":"Cofetuzumab Pelidotin"},{"name":"NCI_Drug_Dictionary_ID","value":"764236"},{"name":"NCI_META_CUI","value":"CL474137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764236"},{"name":"PDQ_Open_Trial_Search_ID","value":"764236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156791":{"preferredName":"Anti-PVRIG Monoclonal Antibody COM701","code":"C156791","definitions":[{"definition":"A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody COM701 targets and binds to PVRIG expressed on cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG, abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PVRIG Monoclonal Antibody COM701","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-poliovirus Receptor-related Immunoglobulin COM701","termGroup":"SY","termSource":"NCI"},{"termName":"COM 701","termGroup":"CN","termSource":"NCI"},{"termName":"COM-701","termGroup":"CN","termSource":"NCI"},{"termName":"COM701","termGroup":"CN","termSource":"NCI"},{"termName":"PVRIG Inhibitor COM701","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253186-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IAY02XUV7L"},{"name":"Maps_To","value":"Anti-PVRIG Monoclonal Antibody COM701"},{"name":"NCI_Drug_Dictionary_ID","value":"796463"},{"name":"NCI_META_CUI","value":"CL935797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796463"},{"name":"PDQ_Open_Trial_Search_ID","value":"796463"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157772":{"preferredName":"Zilovertamab Vedotin","code":"C157772","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zilovertamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ROR1 ADC VLS-101","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate VLS-101","termGroup":"SY","termSource":"NCI"},{"termName":"MK-2140","termGroup":"CN","termSource":"NCI"},{"termName":"VLS 101","termGroup":"CN","termSource":"NCI"},{"termName":"VLS-101","termGroup":"CN","termSource":"NCI"},{"termName":"VLS101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2376463-48-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IZY9ZSI6FI"},{"name":"Maps_To","value":"Anti-ROR1 ADC VLS-101"},{"name":"NCI_Drug_Dictionary_ID","value":"797160"},{"name":"NCI_META_CUI","value":"CL937381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797160"},{"name":"PDQ_Open_Trial_Search_ID","value":"797160"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157061":{"preferredName":"Anti-S15 Monoclonal Antibody NC318","code":"C157061","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting sialic acid binding Ig-like lectin 15 (Siglec-15; SIGLEC15; S15), a member of the sialic acid-binding immunoglobulin type lectins, with potential antineoplastic and immunomodulatory activities. Upon administration, anti-S15 monoclonal antibody NC318 targets and binds to S15 on the surface of tumor-associated macrophages (TAMs) and certain tumor cells. Binding to S15 may disrupt TAM-mediated activities such as promotion of tumor initiation and metastasis of tumor cells, inhibition of T-cell responses, and stimulation of tumor angiogenesis and disease progression. S15, a highly conserved type 1 cell surface protein, normally involved in osteoclast differentiation and bone remodeling, may play a role in the survival and differentiation of TAMs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-S15 Monoclonal Antibody NC318","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-S15 mAb NC318","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Siglec-15 Monoclonal Antibody NC318","termGroup":"SY","termSource":"NCI"},{"termName":"NC 318","termGroup":"CN","termSource":"NCI"},{"termName":"NC-318","termGroup":"CN","termSource":"NCI"},{"termName":"NC318","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-S15 Monoclonal Antibody NC318"},{"name":"NCI_Drug_Dictionary_ID","value":"796496"},{"name":"NCI_META_CUI","value":"CL936043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796496"},{"name":"PDQ_Open_Trial_Search_ID","value":"796496"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121778":{"preferredName":"Sotevtamab","code":"C121778","definitions":[{"definition":"A humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential antineoplastic and anti-metastatic activities. Upon administration, sotevtamab specifically binds to tumor-associated sCLU and inhibits its activity. This inhibits both the sCLU-mediated signal transduction pathways and epithelial-to-mesenchymal transition (EMT), which leads to the inhibition of tumor cell migration and invasion. In addition, sotevtamab enhances chemo-sensitivity. sCLU, a heterodimeric disulfide-linked glycoprotein overexpressed by various types of cancer cells, contributes to proliferation and survival of cancer cells, and stimulates tumor cell EMT.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotevtamab","termGroup":"PT","termSource":"NCI"},{"termName":"AB-16B5","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-sCLU Monoclonal Antibody AB-16B5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2411526-47-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YQ3YJK67AF"},{"name":"Maps_To","value":"Anti-sCLU Monoclonal Antibody AB-16B5"},{"name":"NCI_Drug_Dictionary_ID","value":"771181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771181"},{"name":"PDQ_Open_Trial_Search_ID","value":"771181"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053577"}]}}{"C157501":{"preferredName":"Anzurstobart","code":"C157501","definitions":[{"definition":"An immunoglobulin G1 (IgG1) monoclonal antibody targeting signal-regulatory protein alpha (SIRPa; CD172a) with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anzurstobart targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47/SIRPa-mediated signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anzurstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-SIRPa Monoclonal Antibody CC-95251","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986351","termGroup":"CN","termSource":"NCI"},{"termName":"CC 95251","termGroup":"CN","termSource":"NCI"},{"termName":"CC-95251","termGroup":"CN","termSource":"NCI"},{"termName":"CC95251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2543693-10-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"61FKP5V847"},{"name":"Maps_To","value":"Anti-SIRPa Monoclonal Antibody CC-95251"},{"name":"NCI_Drug_Dictionary_ID","value":"796792"},{"name":"NCI_META_CUI","value":"CL937061"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796792"},{"name":"PDQ_Open_Trial_Search_ID","value":"796792"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C152370":{"preferredName":"Sirtratumab Vedotin","code":"C152370","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of sirtratumab, a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of sirtratumab vedotin binds to SLITRK6 expressed on tumor cells, which facilitates both the internalization of the ADC and the intracellular delivery of MMAE. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.  SLITRK6, a member of the Slitrk family of leucine-rich repeat (LRR) neuronal transmembrane proteins, is minimally expressed in normal tissue but overexpressed in a variety of cancers, including bladder cancer, some forms of lung cancer, breast cancer and glioblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirtratumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-15E","termGroup":"CN","termSource":"NCI"},{"termName":"AGS15E","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-SLITRK6 ADC AGS15E","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-SLITRK6 Antibody-drug Conjugate AGS15E","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E","termGroup":"SY","termSource":"NCI"},{"termName":"ASG-15ME","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1824663-83-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E58B6OP5QG"},{"name":"Maps_To","value":"Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E"},{"name":"NCI_Drug_Dictionary_ID","value":"754120"},{"name":"NCI_META_CUI","value":"CL553574"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28880":{"preferredName":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218","code":"C28880","definitions":[{"definition":"An immunoglobulin derived from the single-chain antigen-binding domain (sFv) of the monoclonal antibody CC-49 with potential antineoplastic activity.  The parent monoclonal antibody CC-49 binds to the tumor-associated glycoprotein TAG-72 with high affinity, recognizing many tumor cell types that express TAG-72. Because of its single-chain structure, CC-49/218 sFv may exhibit a longer half-life than the parent monoclonal antibody CC-49; 218 represents the linker sequence that helps reduce aggregation and proteolysis of this agent.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Single-chain Fv construct of CC49 monoclonal antibody containing a linker sequence 218 that targets tumor-associated glycoprotein (TAG)-72"},{"name":"Legacy Concept Name","value":"CC49-218_sFv"},{"name":"Maps_To","value":"Anti-TAG-72 Monoclonal Antibody scFV CC-49/218"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1511412"}]}}{"C96430":{"preferredName":"Anti-TF Monoclonal Antibody ALT-836","code":"C96430","definitions":[{"definition":"A recombinant human-mouse chimeric monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody ALT-836 binds to TF or the TF-Factor VIIa (FVIIa) complex preventing binding and activation of Factor X (FX) and Factor IX (FIX). This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and procoagulant, is overexpressed in many tumor cell types, and is correlated with metastasis, angiogenesis, tumor growth and tumor-associated thrombosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TF Monoclonal Antibody ALT-836","termGroup":"PT","termSource":"NCI"},{"termName":"ALT-836","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-TF MoAb ALT-836","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TF Monoclonal Antibody ALT-836"},{"name":"NCI_Drug_Dictionary_ID","value":"698353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698353"},{"name":"PDQ_Open_Trial_Search_ID","value":"698353"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272773"}]}}{"C132250":{"preferredName":"Nisevokitug","code":"C132250","definitions":[{"definition":"A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Upon administration, nisevokitug targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nisevokitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TGF-beta Monoclonal Antibody NIS793","termGroup":"SY","termSource":"NCI"},{"termName":"NIS793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649854-92-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W2OR26S7UE"},{"name":"Maps_To","value":"Anti-TGF-beta Monoclonal Antibody NIS793"},{"name":"NCI_Drug_Dictionary_ID","value":"786999"},{"name":"NCI_META_CUI","value":"CL520460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786999"},{"name":"PDQ_Open_Trial_Search_ID","value":"786999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146862":{"preferredName":"Anti-TGF-beta Monoclonal Antibody SAR-439459","code":"C146862","definitions":[{"definition":"A monoclonal antibody (mAb) directed against human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-TGF-beta monoclonal antibody SAR-439459 specifically targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGF-beta is overactivated. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a variety of cancer cell types, is involved in cancer cell proliferation and migration, and in tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TGF-beta Monoclonal Antibody SAR-439459","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TGFb SAR-439459","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-transforming Growth Factor-beta mAb SAR439459","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 439459","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-439459","termGroup":"CN","termSource":"NCI"},{"termName":"SAR439459","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7EFI23P78R"},{"name":"Maps_To","value":"Anti-TGF-beta Monoclonal Antibody SAR-439459"},{"name":"NCI_Drug_Dictionary_ID","value":"792270"},{"name":"NCI_META_CUI","value":"CL544827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792270"},{"name":"PDQ_Open_Trial_Search_ID","value":"792270"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102853":{"preferredName":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1","code":"C102853","definitions":[{"definition":"A monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. Anti-TGF-beta RII monoclonal antibody IMC-TR1 specifically targets and binds to TGF-beta R11, thereby preventing the activation of TGF-beta RII-mediated signaling pathways. TGF-beta RII is mutated in a number of cancer cell types and is involved in cancer cell proliferation and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1","termGroup":"PT","termSource":"NCI"},{"termName":"IMC-TR1","termGroup":"CN","termSource":"NCI"},{"termName":"LY3022859","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TGF-beta RII Monoclonal Antibody IMC-TR1"},{"name":"NCI_Drug_Dictionary_ID","value":"737617"},{"name":"NCI_META_CUI","value":"CL437134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737617"},{"name":"PDQ_Open_Trial_Search_ID","value":"737617"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162875":{"preferredName":"Domvanalimab","code":"C162875","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, domvanalimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Domvanalimab","termGroup":"PT","termSource":"NCI"},{"termName":"AB 154","termGroup":"CN","termSource":"NCI"},{"termName":"AB-154","termGroup":"CN","termSource":"NCI"},{"termName":"AB154","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-TIGIT Monoclonal Antibody AB154","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2368219-35-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"45X7OU8C4J"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody AB154"},{"name":"NCI_Drug_Dictionary_ID","value":"798948"},{"name":"NCI_META_CUI","value":"CL973360"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798948"},{"name":"PDQ_Open_Trial_Search_ID","value":"798948"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131907":{"preferredName":"Renvistobart","code":"C131907","definitions":[{"definition":"A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, renvistobart binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renvistobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIGIT Monoclonal Antibody BMS-986207","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2725062-35-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81J55YFQ16"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody BMS-986207"},{"name":"NCI_Drug_Dictionary_ID","value":"786363"},{"name":"NCI_META_CUI","value":"CL520364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786363"},{"name":"PDQ_Open_Trial_Search_ID","value":"786363"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142821":{"preferredName":"Etigilimab","code":"C142821","definitions":[{"definition":"A monoclonal antibody targeting the human co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, etigilimab binds to TIGIT expressed on various immune cells, including T-cells, and prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8-positive T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etigilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIGIT OMP-313M32","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Receptor TIGIT(T-cell Immunoreceptor with Ig and iTIM Domains)) (Humanized Mouse Monoclonal OMP-313M32 Gamma1-chain), Disulfide with Humanized Mouse Monoclonal OMP-313M32 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"OMP 313M32","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-313M32","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10742","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2044984-83-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FC1ZF28VIT"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody OMP-313M32"},{"name":"Maps_To","value":"Etigilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791697"},{"name":"NCI_META_CUI","value":"CL540712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791697"},{"name":"PDQ_Open_Trial_Search_ID","value":"791697"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148042":{"preferredName":"Anti-TIM-3 Antibody BMS-986258","code":"C148042","definitions":[{"definition":"An antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Following administration, anti-TIM-3 antibody BMS-986258 binds to TIM-3 that is expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which together result in decreased tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM-3 Antibody BMS-986258","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM3 Antibody BMS-986258","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986258","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P339Q7RL7K"},{"name":"Maps_To","value":"Anti-TIM-3 Antibody BMS-986258"},{"name":"NCI_Drug_Dictionary_ID","value":"795721"},{"name":"NCI_META_CUI","value":"CL545803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795721"},{"name":"PDQ_Open_Trial_Search_ID","value":"795721"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157242":{"preferredName":"Surzebiclimab","code":"C157242","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, surzebiclimab binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surzebiclimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM-3 Monoclonal Antibody BGB-A425","termGroup":"SY","termSource":"NCI"},{"termName":"BGB A425","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A425","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA425","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2342597-90-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53YMC3A1CU"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody BGB-A425"},{"name":"NCI_Drug_Dictionary_ID","value":"796770"},{"name":"NCI_META_CUI","value":"CL936885"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796770"},{"name":"PDQ_Open_Trial_Search_ID","value":"796770"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162625":{"preferredName":"Verzistobart","code":"C162625","definitions":[{"definition":"A fully human Fc-engineered immunoglobulin G1 kappa (IgG1kappa) antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, verzistobart forms a high-affinity interaction with TIM-3 expressed on certain T-cells, thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. Additionally, INCAGN02390 elicits TIM-3 receptor internalization, potentially preventing interactions with other ligands.TIM-3, a transmembrane protein and immune checkpoint receptor expressed on certain lymphocytes, including tumor infiltrating lymphocytes (TILs), is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verzistobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM-3 Monoclonal Antibody INCAGN02390","termGroup":"SY","termSource":"NCI"},{"termName":"INCAGN 02390","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN-02390","termGroup":"CN","termSource":"NCI"},{"termName":"INCAGN02390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649466-18-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KAC8QY6TMN"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody INCAGN02390"},{"name":"NCI_Drug_Dictionary_ID","value":"798754"},{"name":"NCI_META_CUI","value":"CL971021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798754"},{"name":"PDQ_Open_Trial_Search_ID","value":"798754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124850":{"preferredName":"Sabatolimab","code":"C124850","definitions":[{"definition":"An inhibitor of the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sabatolimab binds to TIM-3 expressed on certain immune cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis resulting in a reduction in tumor growth. TIM-3, a transmembrane protein expressed on certain T-cells, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sabatolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM-3 Monoclonal Antibody MBG453","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TIM3 Checkpoint Inhibitor MBG453","termGroup":"SY","termSource":"NCI"},{"termName":"MBG 453","termGroup":"CN","termSource":"NCI"},{"termName":"MBG453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2252262-24-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3L7R886Y06"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody MBG453"},{"name":"Maps_To","value":"Sabatolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"777759"},{"name":"NCI_META_CUI","value":"CL503065"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777759"},{"name":"PDQ_Open_Trial_Search_ID","value":"777759"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150560":{"preferredName":"Anti-TIM-3 Monoclonal Antibody Sym023","code":"C150560","definitions":[{"definition":"A recombinant, fully human monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody Sym023 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM-3 Monoclonal Antibody Sym023","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM3 Monoclonal Antibody Sym023","termGroup":"SY","termSource":"NCI"},{"termName":"Sym 023","termGroup":"CN","termSource":"NCI"},{"termName":"Sym-023","termGroup":"CN","termSource":"NCI"},{"termName":"Sym023","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9GEU9XHE20"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody Sym023"},{"name":"NCI_Drug_Dictionary_ID","value":"793443"},{"name":"NCI_META_CUI","value":"CL552361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793443"},{"name":"PDQ_Open_Trial_Search_ID","value":"793443"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128627":{"preferredName":"Cobolimab","code":"C128627","definitions":[{"definition":"A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cobolimab binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cobolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIM3 Checkpoint Inhibitor TSR-022","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TIM3 Monoclonal Antibody TSR-022","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Hepatitis A Virus Cellular Receptor 2 (havcr2)) (Humanized Clone ABT2 Gamma4-chain), Disulfide with Humanized Clone ABT2 Kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"TSR-022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2022215-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3K5H4TX2KP"},{"name":"Maps_To","value":"Anti-TIM-3 Monoclonal Antibody TSR-022"},{"name":"Maps_To","value":"Cobolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"782940"},{"name":"NCI_META_CUI","value":"CL509686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782940"},{"name":"PDQ_Open_Trial_Search_ID","value":"782940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137820":{"preferredName":"Anti-TIM3 Monoclonal Antibody LY3321367","code":"C137820","definitions":[{"definition":"A monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody LY3321367 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM3 Monoclonal Antibody LY3321367","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3321367","termGroup":"CN","termSource":"NCI"},{"termName":"LY3321367","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2U7U2OB839"},{"name":"Maps_To","value":"Anti-TIM3 Monoclonal Antibody LY3321367"},{"name":"NCI_Drug_Dictionary_ID","value":"789989"},{"name":"NCI_META_CUI","value":"CL524891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789989"},{"name":"PDQ_Open_Trial_Search_ID","value":"789989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104291":{"preferredName":"Anti-Tissue Factor Monoclonal Antibody MORAb-066","code":"C104291","definitions":[{"definition":"A humanized monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody MORAb-066 binds to TF and prevents Factor VIIa (FVIIa) from binding, thereby interfering with the activation of Factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor endothelial cells; its expression is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Tissue Factor Monoclonal Antibody MORAb-066","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TF Monoclonal Antibody MORAb-066","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb-066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Tissue Factor Monoclonal Antibody MORAb-066"},{"name":"NCI_Drug_Dictionary_ID","value":"745031"},{"name":"NCI_META_CUI","value":"CL445626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745031"},{"name":"PDQ_Open_Trial_Search_ID","value":"745031"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C151967":{"preferredName":"Datopotamab Deruxtecan","code":"C151967","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) conjugated, via an enzymatically cleavable tetrapeptide-based  linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the datopotamab deruxtecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Datopotamab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DS-1062a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a","termGroup":"SY","termSource":"NCI"},{"termName":"Dato-DXd","termGroup":"SY","termSource":"NCI"},{"termName":"DS-1062","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1062a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2238831-60-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GD2OWY1DTK"},{"name":"Maps_To","value":"Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a"},{"name":"NCI_Drug_Dictionary_ID","value":"793720"},{"name":"NCI_META_CUI","value":"CL553190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793720"},{"name":"PDQ_Open_Trial_Search_ID","value":"793720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97337":{"preferredName":"Anti-TWEAK Monoclonal Antibody RG7212","code":"C97337","definitions":[{"definition":"A humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. Anti-TWEAK monoclonal antibody RG7212 binds to TWEAK and prevents the binding of TWEAK to its receptor, FGF-inducible molecule 14 (Fn14), thereby blocking the TWEAK/Fn14 signaling. This may prevent tumor cell proliferation, invasion, migration and angiogenesis. TWEAK has pleiotropic effects, mediating proinflammatory and pro-angiogenic activity as well as stimulation of invasion, migration, and survival mediated via its receptor Fn14; Fn14 is expressed at relatively low levels in normal tissues, but is elevated in tumor cells and locally in injured and diseased tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TWEAK Monoclonal Antibody RG7212","termGroup":"PT","termSource":"NCI"},{"termName":"RG 7212","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7212","termGroup":"CN","termSource":"NCI"},{"termName":"RG7212","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5458640","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5458640","termGroup":"CN","termSource":"NCI"},{"termName":"RO5458640","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TWEAK Monoclonal Antibody RG7212"},{"name":"NCI_Drug_Dictionary_ID","value":"703243"},{"name":"NCI_META_CUI","value":"CL429827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703243"},{"name":"PDQ_Open_Trial_Search_ID","value":"703243"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91376":{"preferredName":"Anti-VEGF Anticalin PRS-050-PEG40","code":"C91376","definitions":[{"definition":"A pegylated, proprietary lipocalin that targets human vascular endothelial growth factor (VEGF), with potential antineoplastic activity. Pegylated anti-VEGF anticalin PRS-050 specifically targets and binds to VEGF receptor 2 (VEGFR2 or KDR), thereby preventing its activity. This may inhibit angiogenesis and eventually reduce tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF Anticalin PRS-050-PEG40","termGroup":"PT","termSource":"NCI"},{"termName":"PRS-050-PEG40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGF Anticalin PRS-050-PEG40"},{"name":"NCI_Drug_Dictionary_ID","value":"675538"},{"name":"NCI_META_CUI","value":"CL421607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675538"},{"name":"PDQ_Open_Trial_Search_ID","value":"675538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156139":{"preferredName":"Anti-VEGF Monoclonal Antibody hPV19","code":"C156139","definitions":[{"definition":"A humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-VEGF monoclonal antibody hPV19 targets and binds to VEGFR at a unique binding site and inhibits VEGF binding to its receptors, VEGFR1 and VEGFR2, thereby preventing VEGF/VEGFR-mediated signaling. This prevents the growth and maintenance of tumor blood vessels. This decreases nutrient supply to tumor cells, resulting in tumor cell death. Increased VEGF/VEGFR signaling is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF Monoclonal Antibody hPV19","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGF MAb hPV19","termGroup":"SY","termSource":"NCI"},{"termName":"hPV 19","termGroup":"CN","termSource":"NCI"},{"termName":"hPV-19","termGroup":"CN","termSource":"NCI"},{"termName":"hPV19","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb hPV19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGF Monoclonal Antibody hPV19"},{"name":"NCI_Drug_Dictionary_ID","value":"795278"},{"name":"NCI_META_CUI","value":"CL562852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795278"},{"name":"PDQ_Open_Trial_Search_ID","value":"795278"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126644":{"preferredName":"Anti-VEGF/ANG2 Nanobody BI 836880","code":"C126644","definitions":[{"definition":"A nanobody directed against angiopoietin-2 (Ang2; ANGPT2)- and vascular endothelial growth factor (VEGF)-derived peptides, with potential antiangiogenic and antineoplastic activities. Anti-VEGF/ANG2 nanobody BI 836880 binds to Ang2 and VEGF and inhibits receptor binding; this prevents Ang2- and VEGF-mediated signaling and inhibits both tumor angiogenesis and tumor cell proliferation. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. The nanobody is based on functional fragments of single-chain antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF/ANG2 Nanobody BI 836880","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGF/ANG2 BI 836880","termGroup":"SY","termSource":"NCI"},{"termName":"BI 836880","termGroup":"CN","termSource":"NCI"},{"termName":"Bi-specific Anti-VEGF/Ang2 Nanobody BI 836880","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254603-60-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IS7N1X9TSW"},{"name":"Maps_To","value":"Anti-VEGF/ANG2 Nanobody BI 836880"},{"name":"NCI_Drug_Dictionary_ID","value":"779752"},{"name":"NCI_META_CUI","value":"CL503761"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779752"},{"name":"PDQ_Open_Trial_Search_ID","value":"779752"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162872":{"preferredName":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T","code":"C162872","definitions":[{"definition":"A recombinant, human immunoglobulin Fc fusion protein targeting both the transforming growth factor (TGF) beta 1 (TGF-beta 1; TGFb1) and the vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration of anti-VEGF/TGF-beta 1 fusion protein HB-002T, the fusion protein specifically and selectively targets, binds to and neutralizes both TGF-beta 1 and VEGF. This prevents TGFb1- and VEGF-mediated signaling and abrogates VEGF/VEGFR-induced angiogenesis and TGFb1-mediated induction of VEGF, which further inhibits angiogenesis. It also inhibits TGFb1-mediated immunosuppression, thereby enhancing anti-tumor immunity in the tumor microenvironment (TME) and promoting a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T","termGroup":"PT","termSource":"NCI"},{"termName":"HB 002T","termGroup":"CN","termSource":"NCI"},{"termName":"HB-002T","termGroup":"CN","termSource":"NCI"},{"termName":"HB002.1T","termGroup":"CN","termSource":"NCI"},{"termName":"HB002T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T"},{"name":"NCI_Drug_Dictionary_ID","value":"798914"},{"name":"NCI_META_CUI","value":"CL973357"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798914"},{"name":"PDQ_Open_Trial_Search_ID","value":"798914"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99765":{"preferredName":"Anti-VEGFC Monoclonal Antibody VGX-100","code":"C99765","definitions":[{"definition":"A fully human monoclonal antibody directed against the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity. Anti-VEGFC monoclonal antibody VGX-100 specifically binds to and inhibits VEGFC protein, thereby preventing its binding to VEGFR3 (FLT4) or VEGFR2 (KDR or FLK1). This may prevent VEGFC-mediated signaling and may lead to the inhibition of vascular and lymphatic endothelial cell proliferation. The inhibition of tumor angiogenesis and lymphangiogenesis may eventually decrease tumor cell proliferation and prevent metastasis. VEGFC is overexpressed in a variety of cancer cells, and is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGFC Monoclonal Antibody VGX-100","termGroup":"PT","termSource":"NCI"},{"termName":"VEGF-C mAb VGX-100","termGroup":"SY","termSource":"NCI"},{"termName":"VGX-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RJ12A315RN"},{"name":"Maps_To","value":"Anti-VEGFC Monoclonal Antibody VGX-100"},{"name":"NCI_Drug_Dictionary_ID","value":"724066"},{"name":"NCI_META_CUI","value":"CL433490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724066"},{"name":"PDQ_Open_Trial_Search_ID","value":"724066"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156172":{"preferredName":"Vulinacimab","code":"C156172","definitions":[{"definition":"A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vulinacimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR2 Monoclonal Antibody HLX06","termGroup":"SY","termSource":"NCI"},{"termName":"HLX 06","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-06","termGroup":"CN","termSource":"NCI"},{"termName":"HLX06","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2250342-36-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SA09JNQ24D"},{"name":"Maps_To","value":"Anti-VEGFR2 Monoclonal Antibody HLX06"},{"name":"Maps_To","value":"Vulinacimab"},{"name":"NCI_Drug_Dictionary_ID","value":"795367"},{"name":"NCI_META_CUI","value":"CL563001"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795367"},{"name":"PDQ_Open_Trial_Search_ID","value":"795367"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95734":{"preferredName":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5","code":"C95734","definitions":[{"definition":"A fully-human monoclonal antibody directed against human vascular endothelial growth factor receptor 3 (VEGFR-3; Flt-4) with antiangiogenic activity. Anti-VEGFR-3 monoclonal antibody IMC-3C5 specifically binds to and inhibits VEGFR-3, which may result in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-3 plays a critical role in the embryonic vascular system development but is restricted postnatally to endothelial cells of lymphatic vessels and found to be expressed in many solid and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR3 MoAb IMC-3C5","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-3C5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGFR3 Monoclonal Antibody IMC-3C5"},{"name":"NCI_Drug_Dictionary_ID","value":"695064"},{"name":"NCI_META_CUI","value":"CL428195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695064"},{"name":"PDQ_Open_Trial_Search_ID","value":"695064"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127124":{"preferredName":"Onvatilimab","code":"C127124","definitions":[{"definition":"A human monoclonal antibody against the protein V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative checkpoint regulatory and antineoplastic activities. Upon administration, onvatilimab targets and binds to VISTA. This inhibits VISTA signaling, abrogates the VISTA-induced suppression of T-lymphocyte-mediated immune responses, enhances cytotoxic T-cell responses against tumor cells and inhibits tumor cell growth. VISTA, mainly expressed on hematopoietic cells, plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onvatilimab","termGroup":"PT","termSource":"NCI"},{"termName":"CI 8993","termGroup":"CN","termSource":"NCI"},{"termName":"CI-8993","termGroup":"CN","termSource":"NCI"},{"termName":"CI8993","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Protein Vista (v-domain Immunoglobulin Suppressor of T Cell Activation)) (Human Clone JNJ 61610588 gamma1-chain), Disulfide with Human Clone JNJ","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 61610588","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-61610588","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10758","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1969313-51-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1UI8F5IIZ4"},{"name":"Maps_To","value":"Anti-VISTA Monoclonal Antibody JNJ 61610588"},{"name":"Maps_To","value":"Onvatilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"780996"},{"name":"NCI_META_CUI","value":"CL507914"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99761":{"preferredName":"Antiangiogenic Drug Combination TL-118","code":"C99761","definitions":[{"definition":"A proprietary, oral suspension containing a combination of agents comprised of a nonsteroidal anti-inflammatory agent, an alkylating agent, a histamine H2 antagonist and a sulfonamide with potential anti-angiogenic and antineoplastic activities. Antiangiogenic drug combination TL-118 is administrated as a specific dosing regimen and may result in a synergistic effect and reduce angiogenesis and inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antiangiogenic Drug Combination TL-118","termGroup":"PT","termSource":"NCI"},{"termName":"Hamsa-1","termGroup":"FB","termSource":"NCI"},{"termName":"TL-118","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antiangiogenic Drug Combination TL-118"},{"name":"NCI_Drug_Dictionary_ID","value":"723650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"723650"},{"name":"PDQ_Open_Trial_Search_ID","value":"723650"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274907"}]}}{"C161599":{"preferredName":"Anti-SEZ6 Antibody-drug Conjugate ABBV-011","code":"C161599","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against seizure protein 6 homolog (SEZ6) linked to the cytotoxic antitumor antibiotic calicheamicin, with potential antineoplastic activity. Upon administration of anti-SEZ6 ADC ABBV-011, the monoclonal antibody moiety targets and binds to SEZ6 expressed on tumor cells. Upon binding and internalization, calicheamicin is released. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in apoptosis of SEZ6-expressing tumor cells. SEZ6, overexpressed in certain cancers while minimally expressed in normal tissues, plays a role in cell-cell recognition and in neuronal membrane signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-SEZ6 Antibody-drug Conjugate ABBV-011","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 011","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-011","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV011","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-SEZ6 ADC ABBV-011","termGroup":"SY","termSource":"NCI"},{"termName":"SC 011","termGroup":"CN","termSource":"NCI"},{"termName":"SC-011","termGroup":"CN","termSource":"NCI"},{"termName":"SC011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-011"},{"name":"NCI_Drug_Dictionary_ID","value":"798433"},{"name":"NCI_META_CUI","value":"CL970130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798433"},{"name":"PDQ_Open_Trial_Search_ID","value":"798433"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124134":{"preferredName":"Samrotamab Vedotin","code":"C124134","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of samrotamab vedotin, the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts (CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily, is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor stroma and on tumor cells in certain tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samrotamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-085","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-085","termGroup":"SY","termSource":"NCI"},{"termName":"PR-1498487 PAB-MMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2052649-42-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SY5HF6N5MB"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-085"},{"name":"Maps_To","value":"Samrotamab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"776647"},{"name":"NCI_META_CUI","value":"CL502530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776647"},{"name":"PDQ_Open_Trial_Search_ID","value":"776647"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157279":{"preferredName":"Mirzotamab Clezutoclax","code":"C157279","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity. Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirzotamab Clezutoclax","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 155","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-155","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV155","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-155","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate ABBV-155","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2229859-12-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TY49T0B03B"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-155"},{"name":"Maps_To","value":"Mirzotamab Clezutoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"796806"},{"name":"NCI_META_CUI","value":"CL937020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796806"},{"name":"PDQ_Open_Trial_Search_ID","value":"796806"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137991":{"preferredName":"Rolinsatamab Talirine","code":"C137991","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against the prolactin receptor (PRLR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration of rolinsatamab talirine, rolinsatamab targets and binds to PRLR expressed on tumor cells. Upon binding and internalization, talirine is released and kills the PRLR-expressing tumor cells, through an as of yet unknown mechanism of action. PRLR, a tumor-associated antigen (TAA), is overexpressed by a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rolinsatamab Talirine","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 176","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-176","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV176","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-176","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095467-44-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25TA76U16O"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-176"},{"name":"Maps_To","value":"Rolinsatamab Talirine"},{"name":"NCI_Drug_Dictionary_ID","value":"790299"},{"name":"NCI_META_CUI","value":"CL525031"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790299"},{"name":"PDQ_Open_Trial_Search_ID","value":"790299"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122816":{"preferredName":"Azintuxizumab Vedotin","code":"C122816","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody targeting CS1 (SLAMF7/CD319) that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a cathepsin-cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of azintuxizumab vedotin binds to CS1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CS1-expressing tumor cells.  CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is expressed with high levels and prevalence on multiple myeloma (MM) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azintuxizumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-838","termGroup":"CN","termSource":"NCI"},{"termName":"ADC ABBV-838","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1826819-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6XQ9TM3U2G"},{"name":"Maps_To","value":"Antibody-drug Conjugate ABBV-838"},{"name":"Maps_To","value":"Azintuxizumab Vedotin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053688"}]}}{"C147577":{"preferredName":"Upinitatug Rilsodotin","code":"C147577","definitions":[{"definition":"A proprietary antibody-drug conjugate (ADC) composed of upinitatug , a proprietary, humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), site-specifically linked, via a protease cleavable linker, to the proprietary cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upinitatug rilsodotin is produced via the proprietary dolaflexin ADC conjugation platform, which promotes the conjugation of between 10 and 15 AF-HPA payload molecules to each XMT-1535 antibody. Upon administration of upinitatug rilsodotin, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Upon binding, internalization by endosomes/lysosomes, and enzymatic cleavage, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upinitatug Rilsodotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC XMT-1536","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b ADC XMT-1536","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b/Auristatin F-HPA ADC XMT-1536","termGroup":"SY","termSource":"NCI"},{"termName":"Upifitamab Rilsodotin","termGroup":"SY","termSource":"NCI"},{"termName":"XMT 1536","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1536","termGroup":"CN","termSource":"NCI"},{"termName":"XMT1536","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2254119-00-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E8US1SQ3B5"},{"name":"Maps_To","value":"Antibody-drug Conjugate ADC XMT-1536"},{"name":"NCI_Drug_Dictionary_ID","value":"792493"},{"name":"NCI_META_CUI","value":"CL545394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792493"},{"name":"PDQ_Open_Trial_Search_ID","value":"792493"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129401":{"preferredName":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014","code":"C129401","definitions":[{"definition":"A monoclonal antibody-drug conjugate (ADC) comprised of human immunoglobulin G1 (IgG1) clone CR014, which targets the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1; HAVCR1), that is linked, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of ADC anti-TIM-1-vcMMAE CDX-014, the monoclonal antibody moiety targets and binds to TIM-1. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of TIM-1-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. TIM-1 is upregulated in a variety of cancer cell types while only minimally expressed in healthy tissue. The linkage system in CDX-014 is highly stable in plasma, resulting in increased specificity and cytotoxic efficacy towards TIM-1-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014","termGroup":"PT","termSource":"NCI"},{"termName":"ADC Anti-TIM-1-vcMMAE CDX-014","termGroup":"SY","termSource":"NCI"},{"termName":"ADC CDX-014","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate CDX-014","termGroup":"SY","termSource":"NCI"},{"termName":"CDX-014","termGroup":"CN","termSource":"NCI"},{"termName":"CR014-vc-MMAE","termGroup":"SY","termSource":"NCI"},{"termName":"CR014-vcMMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GJV1PP34M2"},{"name":"Maps_To","value":"Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014"},{"name":"NCI_Drug_Dictionary_ID","value":"783989"},{"name":"NCI_META_CUI","value":"CL512670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783989"},{"name":"PDQ_Open_Trial_Search_ID","value":"783989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106256":{"preferredName":"Antibody-Drug Conjugate DFRF4539A","code":"C106256","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against a specific myeloma antigen and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DFRF4539A selectively binds to a specific protein expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-Drug Conjugate DFRF4539A","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DFRF4539A","termGroup":"SY","termSource":"NCI"},{"termName":"DFRF4539A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-Drug Conjugate DFRF4539A"},{"name":"NCI_Drug_Dictionary_ID","value":"710969"},{"name":"NCI_META_CUI","value":"CL433882"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710969"},{"name":"PDQ_Open_Trial_Search_ID","value":"710969"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137821":{"preferredName":"Anti-ASCT2 Antibody-drug Conjugate MEDI7247","code":"C137821","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody against neutral amino acid transporter B(0) (ASCT2; SLC1A5) that is site-specifically conjugated, via a protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-ASCT2 ADC MEDI7247, the antibody moiety targets and binds to ASCT2 expressed on cancer cells. Upon antibody/antigen binding, internalization and linker cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of ASCT2-overexpressing tumor cells. ASCT2, a neutral amino acid transporter that mediates the uptake of glutamine, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ASCT2 Antibody-drug Conjugate MEDI7247","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ASCT2 ADC MEDI7247","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ASCT2/PBD ADC MEDI7247","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 7247","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI7247","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XZ66R08EI3"},{"name":"Maps_To","value":"Antibody-drug Conjugate MEDI7247"},{"name":"NCI_Drug_Dictionary_ID","value":"789996"},{"name":"NCI_META_CUI","value":"CL524897"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789996"},{"name":"PDQ_Open_Trial_Search_ID","value":"789996"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118572":{"preferredName":"Antibody-drug Conjugate PF-06647263","code":"C118572","synonyms":[{"termName":"Antibody-drug Conjugate PF-06647263","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06647263","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate PF-06647263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896742"}]}}{"C118570":{"preferredName":"Antibody-drug Conjugate PF-06664178","code":"C118570","synonyms":[{"termName":"Antibody-drug Conjugate PF-06664178","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06664178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate PF-06664178"},{"name":"NCI_META_CUI","value":"CL474086"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123284":{"preferredName":"Antibody-drug Conjugate SC-002","code":"C123284","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an as of yet publicly unknown monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-002 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-002","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-002","termGroup":"SY","termSource":"NCI"},{"termName":"SC-002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-002"},{"name":"NCI_Drug_Dictionary_ID","value":"774849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774849"},{"name":"PDQ_Open_Trial_Search_ID","value":"774849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0967624"}]}}{"C124133":{"preferredName":"Tamrintamab Pamozirine","code":"C124133","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against dipeptidase 3 (DPEP3) conjugated, via a plasma-stable valine-alanine dipeptide linker, to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of tamrintamab pamozirine targets DPEP3 expressed on tumor cells. Upon binding and internalization, the cytotoxic, DNA cross-linking PBD moiety is released. This inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DPEP3-expressing tumor cells. DPEP3, a membrane-bound glycoprotein, is overexpressed in some ovarian cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamrintamab Pamozirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-003","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1(226-serine), Anti-(Human Dipeptidase 3)(Human-mus musculus Monoclonal sc34.28SS1 Gamma1-chain), Compd. with Human-mus musculus Monoclonal sc34.28SS1 Kappa-chain, Dimer, Bis(thioether) with N-(6-(3-mercapto-2, 5-dioxo-1-pyrrolidinyl)-1","termGroup":"SY","termSource":"NCI"},{"termName":"SC 003","termGroup":"CN","termSource":"NCI"},{"termName":"SC-003","termGroup":"CN","termSource":"NCI"},{"termName":"SC003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2148334-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GM0RU5SU0E"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-003"},{"name":"Maps_To","value":"Tamrintamab Pamozirine"},{"name":"NCI_Drug_Dictionary_ID","value":"776646"},{"name":"NCI_META_CUI","value":"CL502529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776646"},{"name":"PDQ_Open_Trial_Search_ID","value":"776646"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136807":{"preferredName":"Antibody-drug Conjugate SC-004","code":"C136807","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-004 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-004","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-004","termGroup":"SY","termSource":"NCI"},{"termName":"SC 004","termGroup":"CN","termSource":"NCI"},{"termName":"SC-004","termGroup":"CN","termSource":"NCI"},{"termName":"SC004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EBA1W201ZY"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-004"},{"name":"NCI_Drug_Dictionary_ID","value":"789553"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789553"},{"name":"PDQ_Open_Trial_Search_ID","value":"789553"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0967625"}]}}{"C154558":{"preferredName":"Antibody-drug Conjugate SC-005","code":"C154558","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-005 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-005","termGroup":"PT","termSource":"NCI"},{"termName":"SC 005","termGroup":"SY","termSource":"NCI"},{"termName":"SC 005","termGroup":"CN","termSource":"NCI"},{"termName":"SC-005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BT8F8AD6WO"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-005"},{"name":"NCI_Drug_Dictionary_ID","value":"794353"},{"name":"NCI_META_CUI","value":"CL555355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794353"},{"name":"PDQ_Open_Trial_Search_ID","value":"794353"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136779":{"preferredName":"Antibody-drug Conjugate SC-006","code":"C136779","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-006 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-006","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-006","termGroup":"SY","termSource":"NCI"},{"termName":"SC 006","termGroup":"CN","termSource":"NCI"},{"termName":"SC-006","termGroup":"CN","termSource":"NCI"},{"termName":"SC006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"293BGU7HL8"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-006"},{"name":"NCI_Drug_Dictionary_ID","value":"789538"},{"name":"NCI_META_CUI","value":"CL524579"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789538"},{"name":"PDQ_Open_Trial_Search_ID","value":"789538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147029":{"preferredName":"Antibody-drug Conjugate SC-007","code":"C147029","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an undisclosed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-007 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antibody-drug Conjugate SC-007","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SC-007","termGroup":"SY","termSource":"NCI"},{"termName":"SC-007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4NP0CFH7QL"},{"name":"Maps_To","value":"Antibody-drug Conjugate SC-007"},{"name":"NCI_Drug_Dictionary_ID","value":"792378"},{"name":"NCI_META_CUI","value":"CL545028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792378"},{"name":"PDQ_Open_Trial_Search_ID","value":"792378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90562":{"preferredName":"Asunercept","code":"C90562","definitions":[{"definition":"A human, soluble fusion protein consisting of the extracellular domain of the CD95 receptor fused to the Fc-domain of the human IgG antibody, with potential antineoplastic activity. Upon administration, asunercept binds to the CD95 ligand (CD95L) and blocks the binding of CD95L to the CD95 receptor. In tumor cells, blockage of CD95L-mediated signaling pathways may prevent cell migration and invasive cell growth; in healthy cells, blockage of CD95L-mediated signaling pathways may prevent apoptosis and may protect cell damage. Activation of the CD95 receptor plays an important role in the initiation of apoptosis in healthy cells or the invasive growth of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asunercept","termGroup":"PT","termSource":"NCI"},{"termName":"APG-101","termGroup":"CN","termSource":"NCI"},{"termName":"APG101","termGroup":"CN","termSource":"NCI"},{"termName":"Apocept","termGroup":"BR","termSource":"NCI"},{"termName":"CAN-008","termGroup":"CN","termSource":"NCI"},{"termName":"CAN008","termGroup":"CN","termSource":"NCI"},{"termName":"CD95-Fc Fusion Protein CAN008","termGroup":"SY","termSource":"NCI"},{"termName":"Fas-Fc Fusion Protein CAN008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1450882-18-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F333OQQ9UV"},{"name":"Maps_To","value":"Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008"},{"name":"Maps_To","value":"Asunercept"},{"name":"NCI_Drug_Dictionary_ID","value":"666905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666905"},{"name":"PDQ_Open_Trial_Search_ID","value":"666905"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983762"}]}}{"C165256":{"preferredName":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV","code":"C165256","definitions":[{"definition":"A preparation of antigen presenting cells (APCs) specific for human papillomavirus (HPV) type 16 E6 and E7 proteins, with potential immunomodulating and antineoplastic activities. Autologous peripheral blood mononuclear cells (PBMCs) were ex vivo manipulated, using a technique involving membrane disruption to get the HPV16 E6 and E7 proteins into the cells; the resulting APCs present the antigens in a major histocompatibility type I (MHC-I) manner.  Upon administration of the APCs-expressing HPV16 E6/E7 SQZ-PBMC-HPV, these cells activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing HPV16 E6 and E7.  HPV16 E6 and E7 play an important role in the development of certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV","termGroup":"PT","termSource":"NCI"},{"termName":"APCs Expressing HPV16 E6/E7 SQZ-PBMC-HPV","termGroup":"SY","termSource":"NCI"},{"termName":"SQZ PBMC HPV","termGroup":"CN","termSource":"NCI"},{"termName":"SQZ-PBMC-HPV","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV"},{"name":"NCI_Drug_Dictionary_ID","value":"799743"},{"name":"NCI_META_CUI","value":"CL978557"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799743"},{"name":"PDQ_Open_Trial_Search_ID","value":"799743"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125690":{"preferredName":"Antimetabolite FF-10502","code":"C125690","definitions":[{"definition":"An antimetabolite with potential antineoplastic activity. Upon administration, FF-10502 is able to enter the nucleus where it inhibits DNA polymerases, thereby preventing DNA synthesis and halting tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antimetabolite FF-10502","termGroup":"PT","termSource":"NCI"},{"termName":"FF-10502","termGroup":"CN","termSource":"NCI"},{"termName":"FF-10502-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antimetabolite FF-10502"},{"name":"NCI_Drug_Dictionary_ID","value":"778592"},{"name":"NCI_META_CUI","value":"CL504366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778592"},{"name":"PDQ_Open_Trial_Search_ID","value":"778592"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124051":{"preferredName":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus","code":"C124051","definitions":[{"definition":"A combination agent containing racemetyrosine, methoxsalen, phenytoin and sirolimus, with potential antineoplastic activity. Upon administration of racemetyrosine/methoxsalen/phenytoin/sirolimus SM-88, racemetyrosine, being a dysfunctional and modified form of the non-essential amino acid tyrosine, is specifically taken up by cancer cells through the transporter L-amino acid transferase-1 (LAT1; CD98). As a tyrosine derivative and faulty amino acid protein building block, racemetyrosine prevents protein synthesis in cancer cells. Specifically, this prevents mucin-1 (MUC1) protein synthesis. MUC1 is highly overexpressed by most cancer cells and regulates the increased reactive oxygen species (ROS) in cancer cells created from the altered metabolism that cancer cells utilize, by upregulating key antioxidant defenses and preventing ROS-mediated apoptosis. In the absence of MUC1, ROS levels are increased, leading to an increase in oxidative stress, and induction of apoptosis. Also, being a protective transmembrane protein, MUC1 is part of the protective layer on the outside of cancer cells and plays a key role in shielding the cancer cell from the immune system. The loss of MUC1 compromises the cell membrane, thereby making the cancer cell more vulnerable to be recognized and attacked by the immune system. Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, increases the cancer cells' need for tyrosine uptake and increases the uptake of racemetyrosine by LAT1. Phenytoin stimulates the release of reactive lipid species by the liver which accumulate in the tumor microenvironment (TME) and are taken up by cancer cells, thereby further increasing ROS within the cancer cell and increasing oxidative-related apoptosis. Mehoxsalen promotes toxic electron transfer and increases melanin, increases oxidative reactions and production of ROS. This further stimulates oxidative stress-mediated apoptosis. Normal cells do not regularly take up certain non-essential amino acids, such as tyrosine, but readily convert phenylalanine to tyrosine, so normal healthy cells are not expected to consume racemetyrosine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus","termGroup":"PT","termSource":"NCI"},{"termName":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus Combination","termGroup":"SY","termSource":"NCI"},{"termName":"SM-88 Used with Methoxsalen/Phenytoin/Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"SM-88 Used with MPS","termGroup":"SY","termSource":"NCI"},{"termName":"SM-88/Methoxsalen/Phenytoin/Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Tyrosine Isomers/Phenytoin/Methoxsalen/Sirolimus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antineoplastic Agent Combination SM-88"},{"name":"Maps_To","value":"Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88"},{"name":"NCI_Drug_Dictionary_ID","value":"776184"},{"name":"NCI_META_CUI","value":"CL498405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776184"},{"name":"PDQ_Open_Trial_Search_ID","value":"776184"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1663":{"preferredName":"Antineoplastic Vaccine","code":"C1663","definitions":[{"definition":"A type of vaccine that is usually made from a patient's own tumor cells or from substances taken from tumor cells. A cancer vaccine may help the immune system kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A type of vaccine that prevents or treats cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplastic Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Neoplasm Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Tumor Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antineoplastic_Vaccine"},{"name":"Maps_To","value":"Antineoplastic Vaccine"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0376659"}]}}{"C2100":{"preferredName":"Antineoplastic Vaccine GV-1301","code":"C2100","definitions":[{"definition":"Antineoplastic vaccine being developed against liver cancer. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplastic Vaccine GV-1301","termGroup":"PT","termSource":"NCI"},{"termName":"GV-1301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GV-1301"},{"name":"Maps_To","value":"Antineoplastic Vaccine GV-1301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517372"}]}}{"C1004":{"preferredName":"Antineoplaston A10","code":"C1004","definitions":[{"definition":"A piperidinedione antineoplaston with potential antineoplastic activity.  Antineoplaston A10 was originally isolated from human urine but is now synthetically derived.  This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis.  Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplaston A10","termGroup":"PT","termSource":"NCI"},{"termName":"3-Phenylacetylamino-2, 6-piperidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"A10","termGroup":"AB","termSource":"NCI"},{"termName":"Atengenal","termGroup":"SY","termSource":"NCI"},{"termName":"Benzeneacetamide, N-(2,6-dioxo-3-piperidinyl)-, (S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91531-30-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16VY3TM7ZO"},{"name":"Legacy Concept Name","value":"Antineoplaston_A10"},{"name":"Maps_To","value":"Antineoplaston A10"},{"name":"NCI_Drug_Dictionary_ID","value":"41984"},{"name":"NSC Number","value":"377381"},{"name":"NSC Number","value":"619130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41984"},{"name":"PDQ_Open_Trial_Search_ID","value":"41984"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052080"}]}}{"C1613":{"preferredName":"Antineoplaston AS2-1","code":"C1613","definitions":[{"definition":"A 4:1 mixture of phenylacetate and phenylacetylgluatmine, degradation products of the antineoplaston agent A10.  Antineoplaston AS2-1 inhibits the incorporation of L-glutamine into tumor-cell proteins, leading to cell cycle arrest in the G1 phase and inhibition of mitosis.  This agent may also inhibit RAS oncogene expression and activate tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antineoplaston AS2-1","termGroup":"PT","termSource":"NCI"},{"termName":"AS2-1","termGroup":"AB","termSource":"NCI"},{"termName":"Astugenal","termGroup":"SY","termSource":"NCI"},{"termName":"L-Glutamine, N2-(phenylacetyl)-, Monosodium Salt, Mixture with Sodium Benzeneacetate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"104624-98-8"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Antineoplaston_AS2-1"},{"name":"Maps_To","value":"Antineoplaston AS2-1"},{"name":"NCI_Drug_Dictionary_ID","value":"41985"},{"name":"NSC Number","value":"620261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41985"},{"name":"PDQ_Open_Trial_Search_ID","value":"41985"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0294295"}]}}{"C26652":{"preferredName":"Antisense Oligonucleotide GTI-2040","code":"C26652","definitions":[{"definition":"A 20-mer antisense oligonucleotide complementary to a coding region in the mRNA of the R2 small subunit component of human ribonucleotide reductase.  GTI-2040 decreases mRNA and protein levels of R2 in vitro and may inhibit tumor cell proliferation in human tumors in vivo. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It blocks the production of a protein called ribonucleotide reductase, which helps cells make DNA. This may kill cancer cells that need ribonucleotide reductase to grow. It may also make cells more sensitive to anticancer drugs. It is a type of antisense oligonucleotide, and a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Antisense Oligonucleotide GTI-2040","termGroup":"PT","termSource":"NCI"},{"termName":"GTI-2040","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"236391-66-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5WY0FWR2CF"},{"name":"Legacy Concept Name","value":"GTI-2040"},{"name":"Maps_To","value":"Antisense Oligonucleotide GTI-2040"},{"name":"NCI_Drug_Dictionary_ID","value":"301635"},{"name":"NSC Number","value":"722929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301635"},{"name":"PDQ_Open_Trial_Search_ID","value":"301635"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1142995"}]}}{"C156694":{"preferredName":"Antitumor B Key Active Component-alpha","code":"C156694","definitions":[{"definition":"An orally available concentrated preparation of antitumor B (ATB, Zeng Sheng Ping), a Chinese herbal formula comprised of Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera, with potential antineoplastic activity. Upon administration, antitumor B key active component-alpha (ATB-KAC-alpha) may, through a not yet fully elucidated mechanism, inhibit tumorigenesis and prevent the development of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antitumor B Key Active Component-alpha","termGroup":"PT","termSource":"NCI"},{"termName":"Antitumor B KAC-a","termGroup":"SY","termSource":"NCI"},{"termName":"C156694","termGroup":"SY","termSource":"NCI"},{"termName":"Chinese Herbal Mixture Antitumor B KAC-a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antitumor B Key Active Component-alpha"},{"name":"NCI_Drug_Dictionary_ID","value":"795710"},{"name":"NCI_META_CUI","value":"CL935709"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795710"},{"name":"PDQ_Open_Trial_Search_ID","value":"795710"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95731":{"preferredName":"Antrodia cinnamomea Supplement","code":"C95731","definitions":[{"definition":"A dietary supplement containing extract from the medicinal fungus Antrodia cinnamomea with potential antiangiogenic, hepatoprotective and antioxidant activities. The components in Antrodia cinnamomea supplement are rather complex, however, rich in triterpenoids, polysaccharides, nucleosides (adenosine) nucleic acids, superoxide dismutase, other small molecular weight proteins and steroid like compounds. Neutral sugars in this supplement show inhibitory activity on endothelial tube formation, while maleimide and maleic anhydride derivative components in the extract, such as antrodin B and antrodin C and their metabolites, exhibit significant cytotoxic effects on tumor cells and hepatitis C virus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antrodia cinnamomea Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antrodia cinnamomea Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"694951"},{"name":"NCI_META_CUI","value":"CL428192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694951"},{"name":"PDQ_Open_Trial_Search_ID","value":"694951"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119701":{"preferredName":"Antroquinonol Capsule","code":"C119701","definitions":[{"definition":"An orally available capsule containing antroquinonol, a farnesylated quinone derivative isolated from the mycelium of Antrodia camphorata, with potential antineoplastic activity. Upon oral administration, antroquinonol binds to and inhibits protein prenylation mediated by the enzymes farnesyltransferase (FTase) and geranylgeranyltransferase 1 (GGTase-1). This prevents both post-translational prenylation and signaling activity of a number of Ras superfamily proteins, such as Ras and Rho. This results in the inhibition of downstream signaling, such as the PI3K/mTOR signaling pathway, and induces apoptosis in susceptible tumor cells. Ras superfamily proteins are overexpressed in numerous cancer cell types, and play a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antroquinonol Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Hocena","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1010081-09-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AX9P92T7JZ"},{"name":"Maps_To","value":"Antroquinonol Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"674922"},{"name":"NCI_META_CUI","value":"CL421596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674922"},{"name":"PDQ_Open_Trial_Search_ID","value":"674922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92574":{"preferredName":"Apalutamide","code":"C92574","definitions":[{"definition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"ARN 509","termGroup":"CN","termSource":"NCI"},{"termName":"ARN-509","termGroup":"CN","termSource":"NCI"},{"termName":"ARN509","termGroup":"CN","termSource":"NCI"},{"termName":"Erleada","termGroup":"BR","termSource":"NCI"},{"termName":"JNJ 56021927","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-56021927","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-metastatic castration-resistant prostate cancer"},{"name":"CAS_Registry","value":"956104-40-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"4T36H88UA7"},{"name":"Maps_To","value":"Apalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"683082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683082"},{"name":"PDQ_Open_Trial_Search_ID","value":"683082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985183"}]}}{"C71740":{"preferredName":"Apatorsen","code":"C71740","definitions":[{"definition":"A second-generation antisense oligonucleotide targeting heat shock protein 27 (Hsp27) with potential antitumor and chemosensitizing activities. Apatorsen suppresses tumor cell expression of Hsp27, which may induce tumor cell apoptosis and enhance tumor cell sensitivity to cytotoxic agents. Hsp27, a chaperone belonging to the small heat shock protein (sHsp) group of proteins, is a cytoprotective protein that supports cell survival under conditions of stress; it has been found to be over-expressed in a variety of human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apatorsen","termGroup":"PT","termSource":"NCI"},{"termName":"ISIS 306053","termGroup":"CN","termSource":"NCI"},{"termName":"OGX-427","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1002331-21-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IFJ6X26JW6"},{"name":"Legacy Concept Name","value":"Hsp27_Antisense_Oligonucleotide_OGX-427"},{"name":"Maps_To","value":"Apatorsen"},{"name":"NCI_Drug_Dictionary_ID","value":"559200"},{"name":"PDQ_Closed_Trial_Search_ID","value":"559200"},{"name":"PDQ_Open_Trial_Search_ID","value":"559200"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348994"}]}}{"C1087":{"preferredName":"Apaziquone","code":"C1087","definitions":[{"definition":"An indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is converted to active metabolites in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. The active metabolites alkylate DNA, resulting in apoptotic cell death. This agent displays selectivity activity towards both hypoxic solid tumors, which exhibits higher expression of cytochrome P450 reductase, and well-oxygenated malignant cells that overexpress the bioreductive enzyme NQO1 (NAD(P)H: quinone oxidoreductase). Apaziquone may selectively sensitize hypoxic tumor cells to radiocytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apaziquone","termGroup":"PT","termSource":"NCI"},{"termName":"3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-en-alpha-ol","termGroup":"SN","termSource":"NCI"},{"termName":"E O9","termGroup":"SY","termSource":"NCI"},{"termName":"EO9","termGroup":"CN","termSource":"NCI"},{"termName":"Eoquin","termGroup":"BR","termSource":"NCI"},{"termName":"Neoquin","termGroup":"BR","termSource":"NCI"},{"termName":"Qapzola","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114560-48-4"},{"name":"Chemical_Formula","value":"C15H16N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H464ZO600O"},{"name":"Legacy Concept Name","value":"EO9"},{"name":"Maps_To","value":"Apaziquone"},{"name":"NCI_Drug_Dictionary_ID","value":"42095"},{"name":"NSC Number","value":"382456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42095"},{"name":"PDQ_Open_Trial_Search_ID","value":"42095"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0095568"}]}}{"C48640":{"preferredName":"APC8015F","code":"C48640","definitions":[{"definition":"A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.","type":"DEFINITION","source":"NCI"},{"definition":"A vaccine made from immune system cells taken from a patient with prostate cancer and frozen for future use. The cells are treated in the laboratory with a growth factor attached to a protein called prostatic-acid phosphatase (PAP), which is found on prostate cancer cells. When APC8015F is injected into the patient, it may cause T cells (a type of white blood cell) to kill tumor cells that have PAP on them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"APC8015F","termGroup":"PT","termSource":"NCI"},{"termName":"APC 8015F","termGroup":"CN","termSource":"NCI"},{"termName":"APC8015F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"APC8015F"},{"name":"Maps_To","value":"APC8015F"},{"name":"NCI_Drug_Dictionary_ID","value":"385490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385490"},{"name":"PDQ_Open_Trial_Search_ID","value":"385490"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541593"}]}}{"C150216":{"preferredName":"APE1/Ref-1 Redox Inhibitor APX3330","code":"C150216","definitions":[{"definition":"An orally bioavailable inhibitor of apurinic/apyrimidinic endonuclease 1/reduction-oxidation (redox) effector factor-1 (APE1/Ref-1; APEX1), with potential anti-angiogenic and antineoplastic activities. Upon administration, the APE1/Ref-1 Inhibitor APX3330 selectively targets and binds to APE1/Ref-1. This inhibits the redox-dependent signaling activity of APE1/Ref-1, by preventing the reduction and activation of numerous APE1/Ref-1-dependent oncogenic transcription factors (TFs), such as nuclear factor kappa B (NF-kB), AP-1, STAT3, p53, NRF2 and HIF-1alpha, that are involved in signaling, cell proliferation, tumor progression and survival of cancer cells. Therefore, this agent inhibits the activation of multiple TF-mediated signaling pathways and inhibits tumor cell proliferation and survival.  APE1/Ref-1, a multifunctional protein overexpressed in many cancer cell types, plays a key role as a redox regulator of transcription factor activation and in base excision repair upon DNA damage. It drives cancer cell proliferation, migration, drug resistance, angiogenesis and inflammation and its expression level correlates with increased tumor aggressiveness and decreased patient survival. APX3330 specifically blocks the redox activity of APE1/Ref-1 and does not affect its ability to act as a DNA repair endonuclease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"APE1/Ref-1 Redox Inhibitor APX3330","termGroup":"PT","termSource":"NCI"},{"termName":"[(2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-undecanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"APE1/Ref-1 Inhibitor APX3330","termGroup":"SY","termSource":"NCI"},{"termName":"APX 3330","termGroup":"CN","termSource":"NCI"},{"termName":"APX-3330","termGroup":"CN","termSource":"NCI"},{"termName":"APX3330","termGroup":"CN","termSource":"NCI"},{"termName":"E 3330","termGroup":"CN","termSource":"NCI"},{"termName":"E3330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"136164-66-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"11267UI968"},{"name":"Maps_To","value":"APE1/Ref-1 Redox Inhibitor APX3330"},{"name":"NCI_Drug_Dictionary_ID","value":"794415"},{"name":"NCI_META_CUI","value":"CL551955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794415"},{"name":"PDQ_Open_Trial_Search_ID","value":"794415"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28802":{"preferredName":"Aphidicoline Glycinate","code":"C28802","definitions":[{"definition":"A tetracyclic diterpene antibiotic isolated from the fungus Cephalosporium aphidicola and other fungal species with potential antineoplastic activity.  Aphidicoline glycinate blocks the cell cycle at early S-phase by specifically inhibiting DNA polymerases in eukaryotic cells, induces apoptosis, and stops the growth of eukaryotic cells and certain viruses by selectively inhibiting DNA polymerase II or viral-induced DNA polymerases. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aphidicoline Glycinate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aphidicoline_Glycinate"},{"name":"Maps_To","value":"Aphidicoline Glycinate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516035"}]}}{"C126661":{"preferredName":"Apilimod Dimesylate Capsule","code":"C126661","definitions":[{"definition":"A capsule containing the dimesylate salt form of apilimod, an inhibitor of the class III PI kinase phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), with potential antineoplastic and immunomodulatory activities. Upon oral administration of apilimod dimesylate capsule, apilimod selectively binds to and inhibits PIKfyve. The inhibition leads to disruption of PIKfyve-mediated signal transduction pathways and eventually inhibits tumor cell growth in PIKfyve-overexpressing tumor cells. Also, PIKfyve inhibition by apilimod inhibits the toll-like receptor (TLR)-induced production of various cytokines, including interleukin-12 (IL-12) and IL-23, thereby preventing IL-12/IL-23-mediated immune responses. PIKfyve, a lipid kinase dysregulated in various tumor types, plays a key role in TLR signaling and tumor cell migration, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apilimod Dimesylate Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"LAM 002A","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-002A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Apilimod Dimesylate Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"780441"},{"name":"NCI_META_CUI","value":"CL503772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780441"},{"name":"PDQ_Open_Trial_Search_ID","value":"780441"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91731":{"preferredName":"Apitolisib","code":"C91731","definitions":[{"definition":"An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Apitolisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apitolisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 0980","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0980","termGroup":"CN","termSource":"NCI"},{"termName":"GNE 390","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7422","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032754-93-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1C854K1MIJ"},{"name":"Maps_To","value":"Apitolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"639518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639518"},{"name":"PDQ_Open_Trial_Search_ID","value":"639518"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984520"}]}}{"C2228":{"preferredName":"Apolizumab","code":"C2228","definitions":[{"definition":"A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of hematologic (blood) cancers. Apolizumab binds to a protein called ID10, which is found on the surface of some types of immune cells and cancer cells. It may help the immune system kill cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Apolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"1D10 Anti-lymphoma Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MAbHu1D10","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Hu1D10","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal antibody 1D10","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody Hu1D10","termGroup":"SY","termSource":"NCI"},{"termName":"Remitogen","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"267227-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G88KCP51RE"},{"name":"Legacy Concept Name","value":"Apolizumab"},{"name":"Maps_To","value":"Apolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38451"},{"name":"NSC Number","value":"704867"},{"name":"NSC Number","value":"710066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38451"},{"name":"PDQ_Open_Trial_Search_ID","value":"38451"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122758"}]}}{"C71693":{"preferredName":"Apomab","code":"C71693","definitions":[{"definition":"A fully human monoclonal antibody directed against human death receptor 5 (DR5; TRAIL-R2; TNFRSF10B) with potential pro-apoptotic and antineoplastic activities. Mimicking the natural ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand), apomab binds to DR5, which may directly activate the extrinsic apoptosis pathway and indirectly induce the intrinsic apoptosis pathway in tumor cells. DR5 is a cell surface receptor of the TNF-receptor superfamily and is expressed in a broad range of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apomab","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1108170-71-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"703KLX5LXZ"},{"name":"Legacy Concept Name","value":"Apomab"},{"name":"Maps_To","value":"Apomab"},{"name":"NCI_Drug_Dictionary_ID","value":"555507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"555507"},{"name":"PDQ_Open_Trial_Search_ID","value":"555507"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346838"}]}}{"C1873":{"preferredName":"Apomine","code":"C1873","definitions":[{"definition":"A 1,1-bisphosphonate ester with potential antineoplastic and hypocholesterolemic activities. SR-45023A binds to hydroxyapatite crystals in the bone matrix where it inhibits enzymatic activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for the formation of mevalonate, the precursor of cholesterol. Consequently, shortage of mevalonate impedes the synthesis of downstream isoprenoids that are essential for protein prenylation. This leads to the loss of activity of proteins involved in osteoclast function and cellular proliferation, such as Ras and Rho, leading to an inhibition of cellular proliferation, and induction of osteoclasts apoptosis. In addition, SR-45023A activates the farnesoid X activated receptor (FXR), a member of the nuclear hormone superfamily implicated in cholesterol metabolism and bile acid transport and may play a role in this agent's antineoplastic effect.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called bisphosphonates. It affects cancer cell receptors governing cell growth and cell death.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Apomine","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl) Ester","termGroup":"SN","termSource":"NCI"},{"termName":"SKF 99085","termGroup":"CN","termSource":"NCI"},{"termName":"SR-45023A","termGroup":"CN","termSource":"NCI"},{"termName":"Tetraisopropyl-2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethylidene-1,1-diphosphonate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"126411-13-0"},{"name":"Chemical_Formula","value":"C28H52O7P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JQ95208805"},{"name":"Legacy Concept Name","value":"SR-45023A"},{"name":"Maps_To","value":"Apomine"},{"name":"NCI_Drug_Dictionary_ID","value":"43447"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43447"},{"name":"PDQ_Open_Trial_Search_ID","value":"43447"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0766100"}]}}{"C69134":{"preferredName":"Apoptosis Inducer BZL101","code":"C69134","definitions":[{"definition":"An orally active aqueous extract derived from the plant Scutellaria barbata with potential antineoplastic activity. Sparing normal cells, apoptosis inducer BZL101 specifically facilitates translocation of the protein apoptosis-inducing factor (AIF) from the mitochondrial membrane into the nucleus in tumor cells, thereby causing tumor cell-specific chromatin condensation and DNA degradation followed by the induction of caspase-independent apoptosis. AIF is both a mitochondrial intermembrane flavoprotein with oxidoreductase activity and a caspase-independent death effector that, similar to cytochrome c, is released from mitochondria early in the apoptotic process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apoptosis Inducer BZL101","termGroup":"PT","termSource":"NCI"},{"termName":"BZL101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J52LXC6DTW"},{"name":"Legacy Concept Name","value":"Apoptosis_Inducer_BZL101"},{"name":"Maps_To","value":"Apoptosis Inducer BZL101"},{"name":"NCI_Drug_Dictionary_ID","value":"543519"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543519"},{"name":"PDQ_Open_Trial_Search_ID","value":"543519"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1999759"}]}}{"C70984":{"preferredName":"Apoptosis Inducer GCS-100","code":"C70984","definitions":[{"definition":"A galectin-binding polysaccharide derived from citrus pectin with potential antineoplastic activity. Apoptosis inducer GCS-100 binds to the carbohydrate-binding domain of the lectin galectin-3, which may result in apoptosis mediated through mitochondria/caspase activation cascades; this agent may overcome tumor growth mediated through anti-apoptotic protein Bcl-2, heat-shock protein 27 (Hsp27), and nuclear factor-kappa B (NF-kB). Galectin-3, a chimeric molecule consisting of both carbohydrate recognition and collagen-like domains, interacts with a variety of carbohydrate and protein ligands to form pentamers with unique crosslinking abilities; this lectin also exhibits anti-apoptotic properties, perhaps, in part, through the regulation of intracellular signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apoptosis Inducer GCS-100","termGroup":"PT","termSource":"NCI"},{"termName":"GCS-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3HO3IZ2ILX"},{"name":"Legacy Concept Name","value":"Apoptosis_Inducer_GCS-100"},{"name":"Maps_To","value":"Apoptosis Inducer GCS-100"},{"name":"NCI_Drug_Dictionary_ID","value":"567705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"567705"},{"name":"PDQ_Open_Trial_Search_ID","value":"567705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1690444"}]}}{"C64781":{"preferredName":"Apoptosis Inducer MPC-2130","code":"C64781","definitions":[{"definition":"A broad-acting, apoptosis-inducing, small molecule with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, apoptosis inducer MPC-2130 exhibits proapoptotic activities in tumor cells, including membrane phosphatidylserine externalization, release of cytochrome C from mitochondria, caspase activation, cell condensation, and DNA fragmentation. In addition, because this agent is not a substrate for several types of multidrug resistance (MDR) ABC superfamily transporters, such as P-glycoprotein 1 (MDR-1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1/ABCG2), it may be useful in treating MDR tumors that express these particular MDR efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apoptosis Inducer MPC-2130","termGroup":"PT","termSource":"NCI"},{"termName":"MPC-2130","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MPC-2130"},{"name":"Maps_To","value":"Apoptosis Inducer MPC-2130"},{"name":"NCI_Drug_Dictionary_ID","value":"526178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526178"},{"name":"PDQ_Open_Trial_Search_ID","value":"526178"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881499"}]}}{"C74021":{"preferredName":"Apricoxib","code":"C74021","definitions":[{"definition":"An orally bioavailable nonsteroidal anti-inflammatory agent (NSAID) with potential antiangiogenic and antineoplastic activities. Apricoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. Apricoxib-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apricoxib","termGroup":"PT","termSource":"NCI"},{"termName":"COX-2 Inhibitor TG01","termGroup":"SY","termSource":"NCI"},{"termName":"CS-706","termGroup":"CN","termSource":"NCI"},{"termName":"R-109339","termGroup":"CN","termSource":"NCI"},{"termName":"TG01","termGroup":"CN","termSource":"NCI"},{"termName":"TP2001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197904-84-0"},{"name":"Chemical_Formula","value":"C19H20N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5X5HB3VZ3Z"},{"name":"Legacy Concept Name","value":"COX-2_Inhibitor_TG01"},{"name":"Maps_To","value":"Apricoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"594363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594363"},{"name":"PDQ_Open_Trial_Search_ID","value":"594363"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1737955"}]}}{"C121212":{"preferredName":"Aprutumab Ixadotin","code":"C121212","definitions":[{"definition":"An antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated to an as of yet unidentified toxin, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2. Upon binding, the toxin selectively induces cell death, through an as of yet undisclosed mechanism of action, in FGFR2-expressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays an essential role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aprutumab Ixadotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BAY1187982","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1187982","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1187982","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1708947-48-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DDD2AB5TWK"},{"name":"Maps_To","value":"Aprutumab Ixadotin"},{"name":"NCI_Drug_Dictionary_ID","value":"769589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769589"},{"name":"PDQ_Open_Trial_Search_ID","value":"769589"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053667"}]}}{"C62522":{"preferredName":"AR Antagonist BMS-641988","code":"C62522","definitions":[{"definition":"An androgen receptor (AR) antagonist with potential antineoplastic and anti-androgenic activities. BMS-641988 binds to the androgen receptor in target tissues, thereby preventing androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This may inhibit androgen-dependent gene expression, subsequently leading to an inhibition of cell growth and apoptosis in AR-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AR Antagonist BMS-641988","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-641988","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1093276-09-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W17M53Y8IM"},{"name":"Legacy Concept Name","value":"BMS-641988"},{"name":"Maps_To","value":"AR Antagonist BMS-641988"},{"name":"NCI_Drug_Dictionary_ID","value":"489385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489385"},{"name":"PDQ_Open_Trial_Search_ID","value":"489385"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831892"}]}}{"C1879":{"preferredName":"Arabinoxylan Compound MGN3","code":"C1879","definitions":[{"definition":"An arabinoxylane polysaccharide composed of the hemicellulose-Beta extract of rice bran, treated with enzymes from Shiitake mushrooms, that exerts antitumor and antiviral activity by increasing the level of natural killer cells activation. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arabinoxylan Compound MGN3","termGroup":"PT","termSource":"NCI"},{"termName":"Arabinoxylan Compound","termGroup":"SY","termSource":"NCI"},{"termName":"Biobran","termGroup":"FB","termSource":"NCI"},{"termName":"MGN3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"204866-62-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MGN3"},{"name":"Maps_To","value":"Arabinoxylan Compound MGN3"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0963824"}]}}{"C162540":{"preferredName":"Aranose","code":"C162540","definitions":[{"definition":"A nitrosourea derivative with potential antineoplastic activity. Upon administration, aranose alkylates and crosslinks DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aranose","termGroup":"PT","termSource":"NCI"},{"termName":"3-(alpha-L-Arabinopyranosyl)-1-methyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Aranoza","termGroup":"SY","termSource":"NCI"},{"termName":"CRC 0510375","termGroup":"CN","termSource":"NCI"},{"termName":"CRC-0510375","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"167396-23-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7149VX7891"},{"name":"Maps_To","value":"Aranose"},{"name":"NCI_META_CUI","value":"CL971124"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161803":{"preferredName":"ARC Fusion Protein SL-279252","code":"C161803","definitions":[{"definition":"An agonist redirected checkpoint (ARC) fusion protein consisting of the extracellular domains of human programmed cell death 1 (PD-1; PDCD1; CD279) and tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 ligand; OX40L; CD252), linked by a central Fc domain (PD1-Fc-OX40L), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, ARC fusion protein SL-279252 simultaneously binds to both tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40) and PD-1 expressed on T-lymphocytes. Stimulation of OX40 may promote cytokine production and induce proliferation of memory and effector T-lymphocytes against tumor cells, while PD-1 binding disrupts PD-1 signaling and may restore immune function through the activation of T-cells. This may enhance the immune-mediated elimination of tumor cells more effectively than PD-1 blockade or OX40-agonism alone. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ARC Fusion Protein SL-279252","termGroup":"PT","termSource":"NCI"},{"termName":"Agonist Redirected Checkpoint Fusion Protein SL-279252","termGroup":"SY","termSource":"NCI"},{"termName":"PD1-Fc-OX40L ARC Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"SL 279252","termGroup":"CN","termSource":"NCI"},{"termName":"SL-279252","termGroup":"CN","termSource":"NCI"},{"termName":"SL279252","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ARC Fusion Protein SL-279252"},{"name":"NCI_Drug_Dictionary_ID","value":"798455"},{"name":"NCI_META_CUI","value":"CL970428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798455"},{"name":"PDQ_Open_Trial_Search_ID","value":"798455"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88335":{"preferredName":"Archexin","code":"C88335","definitions":[{"definition":"A 20-mer antisense oligodeoxynucleotide (ODN) against the proto-oncogene Akt with potential antineoplastic activity. Akt-1 antisense oligonucleotide RX-0201 binds to Akt-1 mRNA, inhibiting translation of the transcript; suppression of Akt-1 expression may result in the inhibition of cellular proliferation and the induction of apoptosis in tumor cells that overexpress Akt-1. Akt-1 is a serine-threonine protein kinase that stimulates proliferation and inhibits apoptosis of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Archexin","termGroup":"PT","termSource":"NCI"},{"termName":"Akt-1 Antisense Oligonucleotide RX-0201","termGroup":"SY","termSource":"NCI"},{"termName":"RX-0201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Chemical_Formula","value":"C194H228N70O103P19S19"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4TEW51C830"},{"name":"Maps_To","value":"Archexin"},{"name":"NCI_Drug_Dictionary_ID","value":"662321"},{"name":"NCI_META_CUI","value":"CL413599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662321"},{"name":"PDQ_Open_Trial_Search_ID","value":"662321"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1494":{"preferredName":"Arcitumomab","code":"C1494","definitions":[{"definition":"A murine IgG monoclonal Fab' fragment antibody directed against carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cell types. For tumors that overexpress CEA, technetium-99m labeled arcitumomab may be used as an adjunct diagnostic imaging tool to obtain prognostic information following resection and to monitor for recurrent disease. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arcitumomab","termGroup":"PT","termSource":"NCI"},{"termName":"CEA-Scan","termGroup":"BR","termSource":"NCI"},{"termName":"IMMU-4","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G 1 (mouse monoclonal IMMU-4 Fab' fragment gamma-chain anti-human antigen CEA), disulfide with mouse Monoclonal IMMU-4 Light Chain","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colorectal carcinoma and medullary thyroid carcinoma detection"},{"name":"CAS_Registry","value":"154361-48-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"79T6JRG308"},{"name":"Legacy Concept Name","value":"Arcitumomab"},{"name":"Maps_To","value":"Arcitumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"42612"},{"name":"NCI_META_CUI","value":"CL938206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42612"},{"name":"PDQ_Open_Trial_Search_ID","value":"42612"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157079":{"preferredName":"Arfolitixorin","code":"C157079","definitions":[{"definition":"The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect against certain antimetabolite-associated adverse effects, such as those seen with high-dose (HD) methotrexate. Upon administration of arfolitixorin, 5,10-methylenetetrahydrofolate (MTHF) is a reduced folate substrate for the enzyme thymidylate synthase (TS) and stabilizes, upon co-administration of 5-FU, the covalent binding of the 5-FU metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), instead of deoxyuridine monophosphate (dUMP), to its target enzyme TS, which results in an inhibition of TS. This inhibits the synthesis of deoxythymidine monophosphate (dTMP) and leads to the depletion of thymidine triphosphate (TTP), which is a necessary constituent of DNA. This inhibits DNA synthesis, which leads to an inhibition of cellular proliferation and induces tumor cell death. As MTHF is able to stabilize and strengthen the ternary complex, co-administration of arfolitixorin enhances the inhibition of DNA synthesis and increases the cytotoxic effect of 5-FU. As MTHF is the active form of folate and the active metabolite of LV and l-LV, arfolitixorin does not need to be converted to an active metabolite to become activated. In DNA synthesis, a ternary complex is formed between the reduced folate substrate MTHF, the TS enzyme and dUMP in order to convert dUMP to the DNA building block dTMP, which is necessary for DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arfolitixorin","termGroup":"PT","termSource":"NCI"},{"termName":"(6R)-5,10-Methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"6R-5,10-methyleneTHF","termGroup":"SY","termSource":"NCI"},{"termName":"6R-5-10-Methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"6R-methylene THF","termGroup":"SY","termSource":"NCI"},{"termName":"6R-MTHF","termGroup":"AB","termSource":"NCI"},{"termName":"[6R] 5,10-methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"[6R]-5,10-methylene-tetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"Methylenetetrahydrofolic Acid, L-(+)-","termGroup":"SY","termSource":"NCI"},{"termName":"Modufolin","termGroup":"BR","termSource":"NCI"},{"termName":"Rescufolin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31690-11-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z8R4A37V9Q"},{"name":"Maps_To","value":"Arfolitixorin"},{"name":"NCI_Drug_Dictionary_ID","value":"796585"},{"name":"NCI_META_CUI","value":"CL936794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796585"},{"name":"PDQ_Open_Trial_Search_ID","value":"796585"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142866":{"preferredName":"Numidargistat","code":"C142866","definitions":[{"definition":"An orally available inhibitor of arginase, a manganese-dependent enzyme that hydrolyzes the amino acid arginine to form ornithine and urea, with potential immunomodulating and antineoplastic activities. Upon administration, numidargistat inhibits the breakdown of arginine by arginase, which is produced by myeloid cells, and restores arginine levels. This allows arginine to stimulate the synthesis of nitric oxide and the secretion of pro-inflammatory cytokines and chemokines, which induces the proliferation and activation of T-cells. Therefore, this agent may prevent the immunosuppressive effects of tumor-infiltrating myeloid cells and promote lymphocyte-mediated immune responses against tumor cells. Arginase is produced by neutrophils, macrophages and myeloid-derived suppressor cells (MDSC) and plays a role in inflammation-associated immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Numidargistat","termGroup":"PT","termSource":"NCI"},{"termName":"Arginase Inhibitor INCB001158","termGroup":"SY","termSource":"NCI"},{"termName":"CB-1158","termGroup":"CN","termSource":"NCI"},{"termName":"CB1158","termGroup":"CN","termSource":"NCI"},{"termName":"INCB001158","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095732-06-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IFD73D535A"},{"name":"Maps_To","value":"Arginase Inhibitor INCB001158"},{"name":"Maps_To","value":"Numidargistat"},{"name":"NCI_Drug_Dictionary_ID","value":"791808"},{"name":"NCI_META_CUI","value":"CL540753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791808"},{"name":"PDQ_Open_Trial_Search_ID","value":"791808"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2570":{"preferredName":"Arginine Butyrate","code":"C2570","definitions":[{"definition":"A compound composed of the short chain fatty acid (SCFA) butyrate combined with the amino acid arginine, with potential Epstein-Barr virus thymidine kinase gene (EBV-TK)-inducing activity. Upon administration, arginine butyrate induces the expression of thymidine kinase (TK). This activates a co-administered antiviral, such as ganciclovir, and results in the destruction of EBV-infected cancer cells. In addition, butyrate inhibits histone deacetylase (HDAC), which results in hyperacetylation of histones H3 and H4. Acetylated histones have a reduced affinity for chromatin; this reduced histone-chromatin affinity may allow chromosomal unfolding, potentially enhancing the expression of genes related to tumor cell growth arrest and apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Arginine Butyrate","termGroup":"PT","termSource":"NCI"},{"termName":"HQK-1004","termGroup":"CN","termSource":"NCI"},{"termName":"L-Arginine, Butanoate (3:4)","termGroup":"SY","termSource":"NCI"},{"termName":"SCFA HQK-1004","termGroup":"AB","termSource":"NCI"},{"termName":"Short Chain Fatty Acid HQK-1004","termGroup":"SY","termSource":"NCI"},{"termName":"VX-105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80407-72-3"},{"name":"Chemical_Formula","value":"3C6H14N4O2.4C4H8O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IK8S1P79MU"},{"name":"Legacy Concept Name","value":"Arginine_Butyrate"},{"name":"Maps_To","value":"Arginine Butyrate"},{"name":"Maps_To","value":"Short Chain Fatty Acid HQK-1004"},{"name":"NCI_Drug_Dictionary_ID","value":"42492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42492"},{"name":"PDQ_Open_Trial_Search_ID","value":"42492"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052329"}]}}{"C74013":{"preferredName":"Arnebia Indigo Jade Pearl Topical Cream","code":"C74013","definitions":[{"definition":"A proprietary multiherbal topical cream based on Chinese herbal medicine with potential antineoplastic, antiviral, antibacterial and immunostimulatory activities. Arnebia Indigo Jade Pearl topical cream contains 12 ingredients including 9 herbs infused in sesame oil, with an additional three powdered ingredients and beeswax added to the infused oil to create the salve. The purported mechanism(s) of action is unclear due to the complexity of the herbal mixture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arnebia Indigo Jade Pearl Topical Cream","termGroup":"PT","termSource":"NCI"},{"termName":"AIJP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Arnebia_Indigo_Jade_Pearl_Topical_Cream"},{"name":"Maps_To","value":"Arnebia Indigo Jade Pearl Topical Cream"},{"name":"NCI_Drug_Dictionary_ID","value":"589518"},{"name":"NCI_META_CUI","value":"CL383530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589518"},{"name":"PDQ_Open_Trial_Search_ID","value":"589518"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1005":{"preferredName":"Arsenic Trioxide","code":"C1005","definitions":[{"definition":"A drug used to treat acute promyelocytic leukemia (APL) that has not gotten better or that has come back after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arsenic Trioxide","termGroup":"PT","termSource":"NCI"},{"termName":"Arsenic (III) Oxide","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenic Sesquioxide","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenous Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenous Acid Anhydride","termGroup":"SY","termSource":"NCI"},{"termName":"Arsenous Oxide","termGroup":"SY","termSource":"NCI"},{"termName":"ATO","termGroup":"AB","termSource":"NCI"},{"termName":"Trisenox","termGroup":"BR","termSource":"NCI"},{"termName":"White Arsenic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Myelodysplastic syndrome; multiple myeloma; chronic myeloid leukemia; acute myelocytic leukemia"},{"name":"CAS_Registry","value":"1327-53-3"},{"name":"CHEBI_ID","value":"CHEBI:30621"},{"name":"Chemical_Formula","value":"As2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"S7V92P67HO"},{"name":"Legacy Concept Name","value":"Arsenic_Trioxide"},{"name":"Maps_To","value":"Arsenic Trioxide"},{"name":"NCI_Drug_Dictionary_ID","value":"43067"},{"name":"NSC Number","value":"706363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43067"},{"name":"PDQ_Open_Trial_Search_ID","value":"43067"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052416"}]}}{"C133720":{"preferredName":"Arsenic Trioxide Capsule Formulation ORH 2014","code":"C133720","definitions":[{"definition":"An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells, including tumor cells. In addition, As2O3 causes damage to and induces degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein, and inhibits the activity of the enzyme thioredoxin reductase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arsenic Trioxide Capsule Formulation ORH 2014","termGroup":"PT","termSource":"NCI"},{"termName":"Arsenic Trioxide Formulation ORH 2014","termGroup":"SY","termSource":"NCI"},{"termName":"As2O3 Formulation ORH 2014","termGroup":"SY","termSource":"NCI"},{"termName":"Oral Arsenic Trioxide Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"ORH 2014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arsenic Trioxide Capsule Formulation ORH 2014"},{"name":"NCI_Drug_Dictionary_ID","value":"788312"},{"name":"NCI_META_CUI","value":"CL520496"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788312"},{"name":"PDQ_Open_Trial_Search_ID","value":"788312"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118504":{"preferredName":"Artemether Sublingual Spray","code":"C118504","definitions":[{"definition":"A sublingual spray containing artemether, a semisynthetic derivative of artemisinin, an endoperoxide extracted from the Chinese herb qinghaosu (Artemisia annua or annual wormwood), with antiparasitic and potential antineoplastic activity. Upon sublingual application of the spray, artemether exerts its antineoplastic activity through as of yet not fully elucidated mechanism(s) of action. This agent binds to heme molecules inside cells, thereby inducing reactive oxygen species (ROS)-mediated damage which selectively kills cancer cells. In addition, artemether appears to target and modulate the expression of various proteins involved in cancer cell proliferation, angiogenesis, invasion and metastasis. Also, this agent depletes T regulatory cells, and modulates the production of inflammatory cytokines, such as interleukin-4 and interferon-gamma. Altogether, this inhibits tumor cell proliferation. The sublingual spray allows faster absorption of a higher percentage of the artemether dose, when compared to the oral form, as it avoids first pass metabolism; this results in an increased efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artemether Sublingual Spray","termGroup":"PT","termSource":"NCI"},{"termName":"LON002","termGroup":"CN","termSource":"NCI"},{"termName":"Sublingual Artemether Spray","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Artemether Sublingual Spray"},{"name":"NCI_Drug_Dictionary_ID","value":"765719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765719"},{"name":"PDQ_Open_Trial_Search_ID","value":"765719"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3900015"}]}}{"C60769":{"preferredName":"Artemisinin Dimer","code":"C60769","definitions":[{"definition":"A sesquiterpene lactone peroxide and dimerized plant product derived from Artemisia annua L with anti-malarial, anti-proliferative and anti-angiogenic effects. Artemisinin contains an endoperoxide moiety which forms free radicals when it reacts with iron. The resultant carbon-based radical can lead to cellular damage and cell death by reacting with cellular macromolecules such as proteins and membrane lipids. Malaria parasites contain large amounts of heme-iron, a product from the digestion of hemoglobin. However, recently it has been suggested that activation of artemisinin inside the parasite is by ferrous iron. Furthermore, due to their rapid rate of division, cancer cells require and uptake a large amount of iron to proliferate, therefore they are more susceptible to the cytotoxic effect of artemisinin than non-cancerous cells. The dimer configuration has been shown to increase compound stability and reduce general toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artemisinin Dimer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Artemisinin_Dimer"},{"name":"Maps_To","value":"Artemisinin Dimer"},{"name":"NSC Number","value":"724910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879739"}]}}{"C73005":{"preferredName":"Artesunate","code":"C73005","definitions":[{"definition":"A water-soluble, semi-synthetic derivative of the sesquiterpine lactone artemisinin with anti-malarial, anti-schistosomiasis, antiviral, and potential anti-neoplastic activities. Upon hydrolysis of artesunate's active endoperoxide bridge moiety by liberated heme in parasite-infected red blood cells, reactive oxygen species and carbon-centered radicals form, which have been shown to damage and kill parasitic organisms. Additionally, in vitro studies demonstrate that this agent induces DNA breakage in a dose-dependent manner. Artesunate has also been shown to stimulate cell differentiation, arrest the cell cycle in the G1 and G2/M phases, inhibit cell proliferation, and induce apoptosis through mitochondrial and caspase signaling pathways. Artemisinin is isolated from the plant Artemisia annua.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artesunate","termGroup":"PT","termSource":"NCI"},{"termName":"4-oxo-4-{[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy}butanoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"WR 256283","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88495-63-0"},{"name":"CHEBI_ID","value":"CHEBI:63918"},{"name":"Chemical_Formula","value":"C19H28O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"60W3249T9M"},{"name":"Legacy Concept Name","value":"Artesunate"},{"name":"Maps_To","value":"Artesunate"},{"name":"NCI_Drug_Dictionary_ID","value":"617258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617258"},{"name":"PDQ_Open_Trial_Search_ID","value":"617258"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052432"}]}}{"C131020":{"preferredName":"Arugula Seed Powder","code":"C131020","definitions":[{"definition":"A dietary supplement containing an extract powder derived from the seeds of the cruciferous vegetable arugula (Eruca sativa), with potential chemopreventive and antioxidant activities. Arugula seed powder contains numerous vitamins and minerals, and is rich in phytonutrients, such as sulforaphane and indole-3-carbinol. Although the exact mechanism of action through which arugula seed powder may exert its anti-tumor effect has yet to be fully elucidated, the effects of this powder on cancer cells may be attributable to the antioxidant and pro-apoptotic activities of the phytonutrients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arugula Seed Powder","termGroup":"PT","termSource":"NCI"},{"termName":"Eruca sativa Seed Powder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arugula Seed Powder"},{"name":"NCI_Drug_Dictionary_ID","value":"785258"},{"name":"NCI_META_CUI","value":"CL513823"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785258"},{"name":"PDQ_Open_Trial_Search_ID","value":"785258"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164317":{"preferredName":"Aryl Hydrocarbon Receptor Antagonist BAY2416964","code":"C164317","definitions":[{"definition":"An orally available formulation containing a small molecule antagonist of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76) with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR antagonist BAY2416964 specifically binds to AhR, inhibits AhR activation, and prevents AhR-mediated signaling. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, has important roles in regulating immunity and cellular differentiation. AhR can exhibit both pro-oncogenic and tumor suppressor-like functions depending on the tumor type; therefore, its expression may serve as a negative or positive prognostic factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aryl Hydrocarbon Receptor Antagonist BAY2416964","termGroup":"PT","termSource":"NCI"},{"termName":"AhR Antagonist BAY2416964","termGroup":"SY","termSource":"NCI"},{"termName":"AhR Inhibitor BAY2416964","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Inhibitor BAY2416964","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2416964","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2416964","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2416964","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aryl Hydrocarbon Receptor Antagonist BAY2416964"},{"name":"NCI_Drug_Dictionary_ID","value":"799706"},{"name":"NCI_META_CUI","value":"CL977437"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799706"},{"name":"PDQ_Open_Trial_Search_ID","value":"799706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1346":{"preferredName":"Asaley","code":"C1346","definitions":[{"definition":"An L-leucine derivative of melphalan with antineoplastic activity. Asaley alkylates and crosslinks DNA, resulting in disruption of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asaley","termGroup":"PT","termSource":"NCI"},{"termName":"Asalex","termGroup":"SY","termSource":"NCI"},{"termName":"ethyl ester of N-acetyl-DL-sarcolysyl-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"L-leucine, N-[N-acetyl-4-[bis(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"L-leucine, N-[N-acetyl-4-[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethylester","termGroup":"SN","termSource":"NCI"},{"termName":"leucine, N-[N-acetyl-3-[p-[bis(2-chloroethyl)amino]phenyl]-DL-alanyl]-, ethyl ester, L- (8CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Asaley"},{"name":"Maps_To","value":"Asaley"},{"name":"NCI_Drug_Dictionary_ID","value":"39151"},{"name":"NSC Number","value":"167780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39151"},{"name":"PDQ_Open_Trial_Search_ID","value":"39151"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064791"}]}}{"C114494":{"preferredName":"Asciminib","code":"C114494","definitions":[{"definition":"An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asciminib","termGroup":"PT","termSource":"NCI"},{"termName":"ABL 001","termGroup":"CN","termSource":"NCI"},{"termName":"ABL-001","termGroup":"CN","termSource":"NCI"},{"termName":"ABL001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1492952-76-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"L1F3R18W77"},{"name":"Maps_To","value":"Asciminib"},{"name":"NCI_META_CUI","value":"CL472320"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91073":{"preferredName":"Ascrinvacumab","code":"C91073","definitions":[{"definition":"A fully human, IgG2 monoclonal antibody directed against activin-like receptor kinase 1 (ALK-1) with potential antineoplastic activity. Ascrinvacumab binds to and neutralizes ALK-1. This may disrupt tumor endothelial cell function and inhibit tumor angiogenesis, eventually leading to an inhibition of tumor cell proliferation. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ascrinvacumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Activin Receptor-like Kinase 1 Monoclonal Antibody PF-03446962","termGroup":"SY","termSource":"NCI"},{"termName":"PF-03446962","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1463459-96-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"716FQ5REVO"},{"name":"Maps_To","value":"Ascrinvacumab"},{"name":"NCI_Drug_Dictionary_ID","value":"580797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580797"},{"name":"PDQ_Open_Trial_Search_ID","value":"580797"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984015"}]}}{"C77883":{"preferredName":"Ashwagandha Root Powder Extract","code":"C77883","definitions":[{"definition":"A dietary supplement containing an extract powder derived from the root of the ashwagandha shrub with potential antineoplastic, antioxidant, immunostimulating and anti-angiogenic activities. Ashwagandha root powder extract contains numerous alkaloids, including withanine as the primary alkaloid, and steroidal lactone withanolides. The withanolides in this agent may suppress nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene expression, potentiating apoptosis and inhibiting tumor cell invasion. Cultivated in India and North America, ashwagandha (Withania somnifera Dunal or Indian ginseng) belongs to the Solanaceae (nightshade) family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ashwagandha Root Powder Extract","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ashwagandha_Root_Powder_Extract"},{"name":"Maps_To","value":"Ashwagandha Root Powder Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"598859"},{"name":"NCI_META_CUI","value":"CL387179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598859"},{"name":"PDQ_Open_Trial_Search_ID","value":"598859"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122720":{"preferredName":"ASP4132","code":"C122720","definitions":[{"definition":"A molecule with potential antineoplastic activity. Upon oral administration, ASP4132 affects oxidative phosphorylation in mitochondria of metabolically-active tumor cells, which reduces both energy production and tumor cell proliferation. Mitochondrial oxidative phosphorylation is hyperactivated in tumor cells and plays a key role in the promotion of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ASP4132","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ASP4132"},{"name":"NCI_Drug_Dictionary_ID","value":"770100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770100"},{"name":"PDQ_Open_Trial_Search_ID","value":"770100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055601"}]}}{"C286":{"preferredName":"Asparaginase","code":"C286","definitions":[{"definition":"A drug that is used to treat acute lymphoblastic leukemia (ALL) and is being studied in the treatment of some other types of cancer. It is an enzyme taken from the bacterium Escherichia coli (E. coli). It breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asparaginase","termGroup":"PT","termSource":"NCI"},{"termName":"ASP-1","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase II","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase-E.Coli","termGroup":"SY","termSource":"NCI"},{"termName":"Colaspase","termGroup":"SY","termSource":"NCI"},{"termName":"Elspar","termGroup":"BR","termSource":"NCI"},{"termName":"Kidrolase","termGroup":"FB","termSource":"NCI"},{"termName":"L-Asnase","termGroup":"BR","termSource":"NCI"},{"termName":"L-ASP","termGroup":"AB","termSource":"NCI"},{"termName":"L-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"L-Asparagine Amidohydrolase","termGroup":"SY","termSource":"NCI"},{"termName":"Laspar","termGroup":"FB","termSource":"NCI"},{"termName":"Lcf-ASP","termGroup":"AB","termSource":"NCI"},{"termName":"Leucogen","termGroup":"FB","termSource":"NCI"},{"termName":"Leunase","termGroup":"FB","termSource":"NCI"},{"termName":"MK-965","termGroup":"CN","termSource":"NCI"},{"termName":"Paronal","termGroup":"FB","termSource":"NCI"},{"termName":"Re-82-TAD-15","termGroup":"CN","termSource":"NCI"},{"termName":"Serasa","termGroup":"FB","termSource":"NCI"},{"termName":"Spectrila","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute non-lymphocytic leukemia"},{"name":"CAS_Registry","value":"9015-68-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G4FQ3CKY5R"},{"name":"Legacy Concept Name","value":"Asparaginase"},{"name":"Maps_To","value":"Asparaginase"},{"name":"NCI_Drug_Dictionary_ID","value":"41146"},{"name":"NSC Number","value":"109229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41146"},{"name":"PDQ_Open_Trial_Search_ID","value":"41146"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0003993"}]}}{"C64260":{"preferredName":"Asparaginase Erwinia chrysanthemi","code":"C64260","definitions":[{"definition":"A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asparaginase Erwinia chrysanthemi","termGroup":"PT","termSource":"NCI"},{"termName":"Asparaginase Erwinia chrysanthemi (Recombinant)-rywn","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase Erwinia chrysanthemi, Recombinant-rywn","termGroup":"SY","termSource":"NCI"},{"termName":"Asparaginase Erwinia chrysanthemi-rywn","termGroup":"SY","termSource":"NCI"},{"termName":"Crisantaspase","termGroup":"SY","termSource":"NCI"},{"termName":"Crisantaspase Biobetter JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Crisantaspasum","termGroup":"SY","termSource":"NCI"},{"termName":"Enrylaze","termGroup":"FB","termSource":"NCI"},{"termName":"Erwinase","termGroup":"FB","termSource":"NCI"},{"termName":"Erwinaze","termGroup":"BR","termSource":"NCI"},{"termName":"JZP 458","termGroup":"CN","termSource":"NCI"},{"termName":"JZP-458","termGroup":"CN","termSource":"NCI"},{"termName":"JZP458","termGroup":"CN","termSource":"NCI"},{"termName":"PF743","termGroup":"CN","termSource":"NCI"},{"termName":"RC-P JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Asparaginase erwinia chrysanthemi JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Crisantaspase JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Erwinia asparaginase JZP-458","termGroup":"SY","termSource":"NCI"},{"termName":"Rylaze","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute non-lymphocytic leukemia"},{"name":"CAS_Registry","value":"9015-68-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D733ET3F9O"},{"name":"Legacy Concept Name","value":"Asparaginase-Erwinia"},{"name":"Maps_To","value":"Asparaginase Erwinia chrysanthemi"},{"name":"Maps_To","value":"Recombinant Erwinia asparaginase JZP-458"},{"name":"NCI_Drug_Dictionary_ID","value":"601044"},{"name":"NSC Number","value":"106977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601044"},{"name":"PDQ_Open_Trial_Search_ID","value":"601044"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771210"}]}}{"C165280":{"preferredName":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10","code":"C165280","definitions":[{"definition":"A radioimmunoconjugate composed of the anti-CD38 monoclonal antibody (MoAb) OKT10-B10 labeled with the alpha-emitting radionuclide astatine (At) 211 (211At), with potential antineoplastic activity. Upon administration of astatine At 211 anti-CD38 MoAb OKT10-B10, the MoAb moiety targets and binds to CD38-expressing tumor cells, thereby delivering a cytotoxic dose of alpha radiation directly to the CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein and tumor-associated antigen (TAA), is present on various immune cells and in hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10","termGroup":"PT","termSource":"NCI"},{"termName":"211At-OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"[211At]OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 Anti-CD38 MoAb OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine-211-OKT10-B10","termGroup":"SY","termSource":"NCI"},{"termName":"At211-OKT10-B10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10"},{"name":"NCI_Drug_Dictionary_ID","value":"799762"},{"name":"NCI_META_CUI","value":"CL978515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799762"},{"name":"PDQ_Open_Trial_Search_ID","value":"799762"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133190":{"preferredName":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","code":"C133190","definitions":[{"definition":"A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MAb) BC8 where the lysine side groups have been conjugated with decaborate (closo-decaborate; B10) and labeled with astatine (At) 211, with potential immunotherapeutic activity. Astatine At 211 anti-CD45 monoclonal antibody BC8-B10 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of alpha radiation. Additionally, the radiolabel can be leveraged to assay the biodistribution and/or pharmacokinetics (absorption, distribution, metabolism and excretion) for this agent. The use of B10 rather than other labeling methods increases the therapeutic efficacy while decreasing the toxicity of the radioconjugate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","termGroup":"PT","termSource":"NCI"},{"termName":"Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 MAb BC8-B10","termGroup":"SY","termSource":"NCI"},{"termName":"At 211 Anti-CD45 Monoclonal Antibody BC8-B10","termGroup":"SY","termSource":"NCI"},{"termName":"At 211 MAb BC8-B10","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3BVH1ZF9JX"},{"name":"Maps_To","value":"Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10"},{"name":"NCI_Drug_Dictionary_ID","value":"789457"},{"name":"NCI_META_CUI","value":"CL520581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789457"},{"name":"PDQ_Open_Trial_Search_ID","value":"789457"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78478":{"preferredName":"Astuprotimut-R","code":"C78478","definitions":[{"definition":"A cancer vaccine consisting of a recombinant form of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with potential immunostimulatory and antineoplastic activities. Upon administration, astuprotimut-R may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen (TAA) originally discovered in melanoma cells, is expressed by various tumor types. The proprietary immunostimulating adjuvant in this agent is composed of a specific combination of immunostimulating compounds selected to increase the anti-tumor immune response to MAGE-A3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Astuprotimut-R","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1203486A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK1572932A","termGroup":"CN","termSource":"NCI"},{"termName":"Immunotherapeutic GSK1572932A","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant MAGE-A3 ASCI GSK1203486A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"949885-73-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"50I23C5UOR"},{"name":"Legacy Concept Name","value":"Recombinant_MAGE-A3_Antigen-Specific_Cancer_Immunotherapeutic_GSK1203486A"},{"name":"Maps_To","value":"Astuprotimut-R"},{"name":"Maps_To","value":"Immunotherapeutic GSK1572932A"},{"name":"NCI_Drug_Dictionary_ID","value":"600553"},{"name":"NCI_META_CUI","value":"CL414862"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600553"},{"name":"PDQ_Open_Trial_Search_ID","value":"600553"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91758":{"preferredName":"Asulacrine","code":"C91758","definitions":[{"definition":"An amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asulacrine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Acridinecarboxamide,9-((2-methoxy-4-((methylsulfonyl)amino)phenyl)amino)-N,5-dimethyl","termGroup":"SN","termSource":"NCI"},{"termName":"Amsalog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80841-47-0"},{"name":"Chemical_Formula","value":"C24H24N4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S8P50T62B6"},{"name":"Legacy Concept Name","value":"CI-921"},{"name":"Maps_To","value":"Asulacrine"},{"name":"NSC Number","value":"343499"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1765331"}]}}{"C1050":{"preferredName":"Asulacrine Isethionate","code":"C1050","definitions":[{"definition":"The isethionate salt of an amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Asulacrine Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"9-(2-Methoxy-4-(methylsulfonylamino)phenylamino)-N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"CI-921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80841-48-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"649R3P169I"},{"name":"Legacy Concept Name","value":"CI-921"},{"name":"Maps_To","value":"Asulacrine Isethionate"},{"name":"NCI_Drug_Dictionary_ID","value":"38943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38943"},{"name":"PDQ_Open_Trial_Search_ID","value":"38943"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0130561"}]}}{"C2490":{"preferredName":"At 211 Monoclonal Antibody 81C6","code":"C2490","definitions":[{"definition":"A radioimmunoconjugate of a human-murine chimeric IgG2 monoclonal antibody (MoAb) 81C6 labeled with an alpha-emitting radionuclide Astatine 211 (At-211), with imaging and radioimmunotherapeutic properties. MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), which is up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for At-211 results in the targeted imaging and/or destruction of cells expressing tenascin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"At 211 Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"Astatine 211 Conjugated 81C6 Anti-Tenascin Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 MOAB 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine At 211 Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Astatine-211 Labelled Anti-Tenascin Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"At_211_Monoclonal_Antibody_81C6"},{"name":"Maps_To","value":"At 211 Monoclonal Antibody 81C6"},{"name":"NCI_Drug_Dictionary_ID","value":"43148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43148"},{"name":"PDQ_Open_Trial_Search_ID","value":"43148"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796331"}]}}{"C1224":{"preferredName":"Atamestane","code":"C1224","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. Atamestane blocks the production of the hormone estrogen in the body. It belongs to the family of drugs called antiestrogens.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic steroidal substance with antineoplastic activity.  Atamestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atamestane","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96301-34-7"},{"name":"Chemical_Formula","value":"C20H26O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"62GA3K28B6"},{"name":"Legacy Concept Name","value":"Atamestane"},{"name":"Maps_To","value":"Atamestane"},{"name":"NCI_Drug_Dictionary_ID","value":"38195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38195"},{"name":"PDQ_Open_Trial_Search_ID","value":"38195"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074442"}]}}{"C106250":{"preferredName":"Atezolizumab","code":"C106250","definitions":[{"definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atezolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"MPDL 3280A","termGroup":"CN","termSource":"NCI"},{"termName":"MPDL 328OA","termGroup":"SY","termSource":"NCI"},{"termName":"MPDL-3280A","termGroup":"CN","termSource":"NCI"},{"termName":"MPDL3280A","termGroup":"CN","termSource":"NCI"},{"termName":"MPDL328OA","termGroup":"SY","termSource":"NCI"},{"termName":"RG 7446","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7446","termGroup":"CN","termSource":"NCI"},{"termName":"RG7446","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5541267","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5541267","termGroup":"CN","termSource":"NCI"},{"termName":"RO5541267","termGroup":"CN","termSource":"NCI"},{"termName":"Tecentriq","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC); locally advanced or metastatic urothelial carcinoma; extensive-stage small cell lung cancer (ES-SCLC)"},{"name":"Accepted_Therapeutic_Use_For","value":"the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%]), with no EGFR or ALK genomic tumor aberrations."},{"name":"CAS_Registry","value":"1380723-44-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"52CMI0WC3Y"},{"name":"Maps_To","value":"Atezolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"702758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"702758"},{"name":"PDQ_Open_Trial_Search_ID","value":"702758"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827082"}]}}{"C52184":{"preferredName":"Atiprimod","code":"C52184","definitions":[{"definition":"A substance being studied in the treatment of certain multiple myelomas and other advanced cancers. SK&F106615 may block the growth of tumors and may prevent the growth of new blood vessels that tumors need to grow. SK&F106615 is a type of signal transduction inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic properties. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atiprimod","termGroup":"PT","termSource":"NCI"},{"termName":"Azaspirane SK&F106615","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine","termGroup":"SN","termSource":"NCI"},{"termName":"SK&F106615","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123018-47-3"},{"name":"Chemical_Formula","value":"C22H44N2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MG7D3QD743"},{"name":"Legacy Concept Name","value":"Atiprimod"},{"name":"Maps_To","value":"Atiprimod"},{"name":"NCI_Drug_Dictionary_ID","value":"382134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"382134"},{"name":"PDQ_Open_Trial_Search_ID","value":"382134"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1579206"}]}}{"C76969":{"preferredName":"Atiprimod Dihydrochloride","code":"C76969","definitions":[{"definition":"The dihydrochloride salt form of atiprimod, an orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and anti-angiogenic activities. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and AKT, blocking the signaling pathways of interleukin-6, vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. This results in the inhibition of cell proliferation, induction of cell cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atiprimod Dihydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130065-61-1"},{"name":"Chemical_Formula","value":"C22H44N2.2ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O12I24570R"},{"name":"Legacy Concept Name","value":"Atiprimod_Dihydrochloride"},{"name":"Maps_To","value":"Atiprimod Dihydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698190"}]}}{"C76970":{"preferredName":"Atiprimod Dimaleate","code":"C76970","definitions":[{"definition":"The dimaleate salt form of atiprimod, an orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic activities. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and AKT, blocking the signaling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. This results in the inhibition of cell proliferation, induction of cell cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atiprimod Dimaleate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183063-72-1"},{"name":"Chemical_Formula","value":"C22H44N2.2C4H4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YNU265SSR3"},{"name":"Legacy Concept Name","value":"Atiprimod_Dimaleate"},{"name":"Maps_To","value":"Atiprimod Dimaleate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698191"}]}}{"C138076":{"preferredName":"ATM Inhibitor M 3541","code":"C138076","definitions":[{"definition":"An orally bioavailable inhibitor of ataxia telangiectasia mutated kinase (ATM), with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, M 3541 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, M 3541 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Inhibitor M 3541","termGroup":"PT","termSource":"NCI"},{"termName":"Ataxia Telangiectasia Mutated Kinase Inhibitor M 3541","termGroup":"SY","termSource":"NCI"},{"termName":"M 3541","termGroup":"CN","termSource":"NCI"},{"termName":"M3541","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ATM Inhibitor M 3541"},{"name":"NCI_Drug_Dictionary_ID","value":"790665"},{"name":"NCI_META_CUI","value":"CL525064"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790665"},{"name":"PDQ_Open_Trial_Search_ID","value":"790665"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124648":{"preferredName":"ATM Kinase Inhibitor AZD0156","code":"C124648","definitions":[{"definition":"An orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, AZD0156 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, AZD0156 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Kinase Inhibitor AZD0156","termGroup":"PT","termSource":"NCI"},{"termName":"AZD0156","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1821428-35-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P5T0XWC07Z"},{"name":"Maps_To","value":"ATM Kinase Inhibitor AZD0156"},{"name":"NCI_Drug_Dictionary_ID","value":"776772"},{"name":"NCI_META_CUI","value":"CL502880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776772"},{"name":"PDQ_Open_Trial_Search_ID","value":"776772"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150167":{"preferredName":"ATM Kinase Inhibitor AZD1390","code":"C150167","definitions":[{"definition":"An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death in ATM-overexpressing tumor cells. AZD1390 hypersensitizes tumors to chemo/radiotherapy. In addition, AZD1390 is able to cross the blood-brain barrier (BBB). ATM, a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family of protein kinases, is upregulated in a variety of cancer cell types. It is activated in response to DNA double-strand breaks (DSB) and plays a key role in DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ATM Kinase Inhibitor AZD1390","termGroup":"PT","termSource":"NCI"},{"termName":"7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-1390","termGroup":"CN","termSource":"NCI"},{"termName":"AZD1390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2089288-03-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CI43QFE22O"},{"name":"Maps_To","value":"ATM Kinase Inhibitor AZD1390"},{"name":"NCI_Drug_Dictionary_ID","value":"804166"},{"name":"NCI_META_CUI","value":"CL552001"},{"name":"PDQ_Closed_Trial_Search_ID","value":"804166"},{"name":"PDQ_Open_Trial_Search_ID","value":"804166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28837":{"preferredName":"Atorvastatin Calcium","code":"C28837","definitions":[{"definition":"A drug used to lower the amount of cholesterol in the blood and to prevent stroke, heart attack, and angina (chest pain). It is also being studied in the prevention and treatment of some types of cancer and other conditions. Atorvastatin calcium blocks an enzyme that helps make cholesterol in the body. It also causes an increase in the breakdown of cholesterol. It is a type of HMG-CoA reductase inhibitor and a type of statin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atorvastatin Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"CI-981","termGroup":"CN","termSource":"NCI"},{"termName":"Lipitor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134523-03-8"},{"name":"CAS_Registry","value":"344423-98-9"},{"name":"CHEBI_ID","value":"CHEBI:2911"},{"name":"Chemical_Formula","value":"2C33H34FN2O5.Ca.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48A5M73Z4Q"},{"name":"Legacy Concept Name","value":"Atorvastatin"},{"name":"Maps_To","value":"Atorvastatin Calcium"},{"name":"NCI_Drug_Dictionary_ID","value":"460239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"460239"},{"name":"PDQ_Open_Trial_Search_ID","value":"460239"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286650"}]}}{"C78676":{"preferredName":"Atorvastatin Sodium","code":"C78676","definitions":[{"definition":"The sodium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atorvastatin Sodium","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134523-01-6"},{"name":"Chemical_Formula","value":"C33H34FN2O5.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DN43058TIV"},{"name":"Legacy Concept Name","value":"Atorvastatin_Sodium"},{"name":"Maps_To","value":"Atorvastatin Sodium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698196"}]}}{"C146807":{"preferredName":"Elimusertib","code":"C146807","definitions":[{"definition":"An orally available ataxia telangiectasia and Rad3-related (ATR)-specific kinase inhibitor, with potential antineoplastic activity. Upon oral administration, elimusertib selectively binds to and inhibits the activity of ATR, which prevents ATR-mediated signaling. This inhibits DNA damage checkpoint activation, disrupts DNA damage repair and induces apoptosis in ATR-overexpressing tumor cells. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elimusertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATR Inhibitor BAY1895344","termGroup":"SY","termSource":"NCI"},{"termName":"ATR Kinase Inhibitor BAY1895344","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1895344","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1895344","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1895344","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1876467-74-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7N13IK9LNH"},{"name":"Maps_To","value":"ATR Kinase Inhibitor BAY1895344"},{"name":"NCI_Drug_Dictionary_ID","value":"792166"},{"name":"NCI_META_CUI","value":"CL544748"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792166"},{"name":"PDQ_Open_Trial_Search_ID","value":"792166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116355":{"preferredName":"Berzosertib","code":"C116355","definitions":[{"definition":"An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. Upon administration, berzosertib selectively binds to and inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Berzosertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"M 6620","termGroup":"CN","termSource":"NCI"},{"termName":"M6620","termGroup":"CN","termSource":"NCI"},{"termName":"VX 970","termGroup":"CN","termSource":"NCI"},{"termName":"VX-970","termGroup":"CN","termSource":"NCI"},{"termName":"VX970","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1232416-25-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L423PRV3V3"},{"name":"Maps_To","value":"ATR Kinase Inhibitor M6620"},{"name":"Maps_To","value":"Berzosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"761970"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761970"},{"name":"PDQ_Open_Trial_Search_ID","value":"761970"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896746"}]}}{"C129693":{"preferredName":"Gartisertib","code":"C129693","definitions":[{"definition":"An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration,gartisertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gartisertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATR Kinase Inhibitor VX-803","termGroup":"SY","termSource":"NCI"},{"termName":"M 4344","termGroup":"CN","termSource":"NCI"},{"termName":"M-4344","termGroup":"CN","termSource":"NCI"},{"termName":"M4344","termGroup":"CN","termSource":"NCI"},{"termName":"VX 803","termGroup":"CN","termSource":"NCI"},{"termName":"VX-803","termGroup":"CN","termSource":"NCI"},{"termName":"VX803","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1613191-99-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7OM98IUD1O"},{"name":"Maps_To","value":"ATR Kinase Inhibitor VX-803"},{"name":"NCI_Drug_Dictionary_ID","value":"802157"},{"name":"NCI_META_CUI","value":"CL507788"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802157"},{"name":"PDQ_Open_Trial_Search_ID","value":"802157"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1779":{"preferredName":"Atrasentan Hydrochloride","code":"C1779","definitions":[{"definition":"The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity.  As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atrasentan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-A 127722","termGroup":"CN","termSource":"NCI"},{"termName":"(2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ABT-627","termGroup":"CN","termSource":"NCI"},{"termName":"Xinlay","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195733-43-8"},{"name":"Chemical_Formula","value":"C29H38N2O6.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E4G31X93ZA"},{"name":"Legacy Concept Name","value":"Atrasentan"},{"name":"Maps_To","value":"Atrasentan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38333"},{"name":"NSC Number","value":"720763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38333"},{"name":"PDQ_Open_Trial_Search_ID","value":"38333"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0387926"}]}}{"C62409":{"preferredName":"Attenuated Listeria monocytogenes ANZ-100","code":"C62409","definitions":[{"definition":"A live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, attenuated Listeria monocytogenes ANZ-100 may accumulate in and infect liver cells where it may activate a potent innate immune response and an adaptive immune response involving the by recruitment and activation of T lymphocytes. This agent may potentiate the immune response to vaccines against various liver neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Attenuated Listeria monocytogenes ANZ-100","termGroup":"PT","termSource":"NCI"},{"termName":"ANZ 100","termGroup":"CN","termSource":"NCI"},{"termName":"ANZ-100","termGroup":"CN","termSource":"NCI"},{"termName":"ANZ100","termGroup":"CN","termSource":"NCI"},{"termName":"CRS-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7UKM1TA46L"},{"name":"Legacy Concept Name","value":"CRS-100"},{"name":"Maps_To","value":"Attenuated Listeria monocytogenes CRS-100"},{"name":"NCI_Drug_Dictionary_ID","value":"487160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487160"},{"name":"PDQ_Open_Trial_Search_ID","value":"487160"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"UMLS_CUI","value":"C1831855"}]}}{"C74595":{"preferredName":"Axalimogene Filolisbac","code":"C74595","definitions":[{"definition":"A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axalimogene Filolisbac","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS11-001","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS11-001 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Attenuated Live Listeria Encoding HPV 16 E7 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Attenuated Live Listeria Encoding Human Papilloma Virus 16 E7 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Lm-LLO-E7","termGroup":"SY","termSource":"NCI"},{"termName":"Lovaxin-C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1587258-09-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NY7PTD1862"},{"name":"Legacy Concept Name","value":"Attenuated_Live_Listeria_Encoding_HPV_16_E7_Vaccine"},{"name":"Maps_To","value":"Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001"},{"name":"Maps_To","value":"Axalimogene Filolisbac"},{"name":"NCI_Drug_Dictionary_ID","value":"673240"},{"name":"NCI_META_CUI","value":"CL384120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673240"},{"name":"PDQ_Open_Trial_Search_ID","value":"673240"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C65242":{"preferredName":"Auranofin","code":"C65242","definitions":[{"definition":"An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Auranofin","termGroup":"PT","termSource":"NCI"},{"termName":"Ridaura","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"34031-32-8"},{"name":"CHEBI_ID","value":"CHEBI:2922"},{"name":"Chemical_Formula","value":"C20H34AuO9PS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3H04W2810V"},{"name":"Legacy Concept Name","value":"Auranofin"},{"name":"Maps_To","value":"Auranofin"},{"name":"NCI_Drug_Dictionary_ID","value":"710355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710355"},{"name":"PDQ_Open_Trial_Search_ID","value":"710355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699923"}]}}{"C148501":{"preferredName":"Aurora A Kinase Inhibitor LY3295668","code":"C148501","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor LY3295668","termGroup":"PT","termSource":"NCI"},{"termName":"AK 01","termGroup":"CN","termSource":"NCI"},{"termName":"AK-01","termGroup":"CN","termSource":"NCI"},{"termName":"LY 3295668","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3295668","termGroup":"CN","termSource":"NCI"},{"termName":"LY3295668","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1919888-06-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1WX8O5XV4R"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor LY3295668"},{"name":"NCI_Drug_Dictionary_ID","value":"792635"},{"name":"NCI_META_CUI","value":"CL551041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792635"},{"name":"PDQ_Open_Trial_Search_ID","value":"792635"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165238":{"preferredName":"Aurora A Kinase Inhibitor LY3295668 Erbumine","code":"C165238","definitions":[{"definition":"The tert-butylamine salt form of LY3295668, an orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor LY3295668 Erbumine","termGroup":"PT","termSource":"NCI"},{"termName":"AK-01 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"Aurora Kinase A Inhibitor LY3295668 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3295668 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"LY-3295668 Erbumine","termGroup":"SY","termSource":"NCI"},{"termName":"LY3295668 Erbumine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor LY3295668 Erbumine"},{"name":"NCI_Drug_Dictionary_ID","value":"792635"},{"name":"NCI_META_CUI","value":"CL978388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792635"},{"name":"PDQ_Open_Trial_Search_ID","value":"792635"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90585":{"preferredName":"Aurora A Kinase Inhibitor MK5108","code":"C90585","definitions":[{"definition":"An orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A, with potential antimitotic and antineoplastic activity. Aurora A kinase inhibitor MK5108 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and eventually inhibition of cell division, proliferation and an induction of apoptosis in cells overexpressing Aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aurora kinases are overexpressed in a wide variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor MK5108","termGroup":"PT","termSource":"NCI"},{"termName":"MK 5108","termGroup":"CN","termSource":"NCI"},{"termName":"MK-5108","termGroup":"CN","termSource":"NCI"},{"termName":"MK5108","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1010085-13-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H8J407531S"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor MK5108"},{"name":"NCI_Drug_Dictionary_ID","value":"575529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575529"},{"name":"PDQ_Open_Trial_Search_ID","value":"575529"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2932550"}]}}{"C116068":{"preferredName":"Aurora A Kinase Inhibitor VIC-1911","code":"C116068","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon intravenous administration, aurora A kinase inhibitor VIC-1911 binds to and inhibits aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis; it plays an essential role in the regulation of spindle assembly. Aurora kinase A is overexpressed in a wide variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase Inhibitor VIC-1911","termGroup":"PT","termSource":"NCI"},{"termName":"Aurora A Kinase Inhibitor TAS-119","termGroup":"SY","termSource":"NCI"},{"termName":"TAS-119","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-2104","termGroup":"CN","termSource":"NCI"},{"termName":"VIC 1911","termGroup":"CN","termSource":"NCI"},{"termName":"VIC-1911","termGroup":"CN","termSource":"NCI"},{"termName":"VIC1911","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora A Kinase Inhibitor TAS-119"},{"name":"NCI_Drug_Dictionary_ID","value":"760907"},{"name":"NCI_META_CUI","value":"CL473487"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760907"},{"name":"PDQ_Open_Trial_Search_ID","value":"760907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78190":{"preferredName":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076","code":"C78190","definitions":[{"definition":"An orally bioavailable synthetic small molecule with potential antiangiogenic and antineoplastic activities. Aurora A kinase/tyrosine kinase inhibitor ENMD-2076 selectively binds to and inhibits non-specified tyrosine kinases and Aurora kinases (AKs). The inhibition of AKs may result in the inhibition of cell division and proliferation and may induce apoptosis in tumor cells that overexpress AKs; antiangiogenic activity is related to the inhibition of angiogenic tyrosine kinases. AKs are serine-threonine kinases that play an essential role in mitotic checkpoint control during mitosis and are important regulators of cell division and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076","termGroup":"PT","termSource":"NCI"},{"termName":"ENMD-2076","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453868-32-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KXQ762CQTH"},{"name":"Legacy Concept Name","value":"Aurora_A_Kinase_Tyrosine_Kinase_Inhibitor_ENMD-2076"},{"name":"Maps_To","value":"Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076"},{"name":"NCI_Drug_Dictionary_ID","value":"594863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594863"},{"name":"PDQ_Open_Trial_Search_ID","value":"594863"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703108"}]}}{"C82674":{"preferredName":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901","code":"C82674","definitions":[{"definition":"A small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B kinase inhibitor TAK-901 binds to and inhibits the activity of Aurora B, which may result in a decrease in the proliferation of tumor cells that overexpress Aurora B. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere; the segregation of sister chromatids to each daughter cell; and the separation of daughter cells during cytokinesis. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901","termGroup":"PT","termSource":"NCI"},{"termName":"TAK-901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934541-31-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DM9UIR23R7"},{"name":"Legacy Concept Name","value":"Aurora_B_Serine_Threonine_Kinase_Inhibitor_TAK-901"},{"name":"Maps_To","value":"Aurora B Serine/Threonine Kinase Inhibitor TAK-901"},{"name":"NCI_Drug_Dictionary_ID","value":"632219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632219"},{"name":"PDQ_Open_Trial_Search_ID","value":"632219"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2826371"}]}}{"C91081":{"preferredName":"Aurora B/C Kinase Inhibitor GSK1070916A","code":"C91081","definitions":[{"definition":"An ATP-competitive inhibitor of the serine/threonine kinases Aurora B and C with potential antineoplastic activity. Aurora B/C kinase inhibitor GSK1070916A binds to and inhibits the activity of Aurora B and C, which may result in inhibition of cellular division and a decrease in the proliferation of tumor cells that overexpress the Aurora kinases B and C. Aurora kinases play essential roles in mitotic checkpoint control during mitosis, and are overexpressed by a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora B/C Kinase Inhibitor GSK1070916A","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1070916A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora B/C Kinase Inhibitor GSK1070916A"},{"name":"NCI_Drug_Dictionary_ID","value":"670668"},{"name":"NCI_META_CUI","value":"CL416287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670668"},{"name":"PDQ_Open_Trial_Search_ID","value":"670668"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162532":{"preferredName":"Tinengotinib","code":"C162532","definitions":[{"definition":"An orally available small molecule inhibitor of Aurora kinases (AKs) A and B, Janus kinases (JAKs), fibroblast growth factor receptors (FGFRs) and vascular endothelial growth factor receptors (VEGFRs), with potential antineoplastic and immunomodulatory activities. Upon oral administration, tinengotinib selectively binds to and inhibits AKs A and B, which inhibit cell division in tumor cells that overexpress AKs. Tinengotinib also targets JAKs that are involved in cytokine signaling and inflammation, and FGFRs and VEGFRs, which  are overexpressed in the microenvironment (TME) and contribute to neovascularization, tumor growth and metastasis.  These kinases are overexpressed by a wide variety of cancer cell types and drive tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinengotinib","termGroup":"PT","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor TT-00420","termGroup":"SY","termSource":"NCI"},{"termName":"Multi-target Kinase Inhibitor TT-00420","termGroup":"SY","termSource":"NCI"},{"termName":"Multiple Kinase Inhibitor TT-00420","termGroup":"SY","termSource":"NCI"},{"termName":"TT 00420","termGroup":"CN","termSource":"NCI"},{"termName":"TT-00420","termGroup":"CN","termSource":"NCI"},{"termName":"TT00420","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230490-29-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WZ9TJ0L9Y8"},{"name":"Maps_To","value":"Aurora kinase A/B inhibitor TT-00420"},{"name":"NCI_Drug_Dictionary_ID","value":"798739"},{"name":"NCI_META_CUI","value":"CL971116"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798739"},{"name":"PDQ_Open_Trial_Search_ID","value":"798739"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82349":{"preferredName":"Aurora Kinase Inhibitor AMG 900","code":"C82349","definitions":[{"definition":"A small-molecule inhibitor of Aurora kinases A, B and C with potential antineoplastic activity. Aurora kinase inhibitor AMG 900 selectively binds to and inhibits the activities of Aurora kinases A, B and C, which may result in inhibition of cellular division and proliferation in tumor cells that overexpress these kinases. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis and are overexpressed by a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor AMG 900","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 900","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945595-80-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9R2G075611"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_Inhibitor_AMG_900"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor AMG 900"},{"name":"NCI_Drug_Dictionary_ID","value":"639524"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639524"},{"name":"PDQ_Open_Trial_Search_ID","value":"639524"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830045"}]}}{"C74014":{"preferredName":"Aurora Kinase Inhibitor BI 811283","code":"C74014","definitions":[{"definition":"A small molecule inhibitor of the serine/threonine protein kinase Aurora kinase with potential antineoplastic activity. Aurora kinase inhibitor BI 811283 binds to and inhibits Aurora kinases, resulting in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor BI 811283","termGroup":"PT","termSource":"NCI"},{"termName":"BI 811283","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_Inhibitor_BI_811283"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor BI 811283"},{"name":"NCI_Drug_Dictionary_ID","value":"590640"},{"name":"NCI_META_CUI","value":"CL383543"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590640"},{"name":"PDQ_Open_Trial_Search_ID","value":"590640"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61075":{"preferredName":"Aurora Kinase Inhibitor MLN8054","code":"C61075","definitions":[{"definition":"An orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Auora kinase inhibitor MLN8054 binds to and inhibits Aurora kinase A, resulting in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A localizes in mitosis to the spindle poles and to spindle microtubules and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor MLN8054","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic Acid, 4-((9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"MLN 8054","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-8054","termGroup":"CN","termSource":"NCI"},{"termName":"MLN8054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"869363-13-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BX854EHD63"},{"name":"Legacy Concept Name","value":"MLN8054"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor MLN8054"},{"name":"NCI_Drug_Dictionary_ID","value":"473901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473901"},{"name":"PDQ_Open_Trial_Search_ID","value":"473901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831780"}]}}{"C66946":{"preferredName":"Aurora Kinase Inhibitor PF-03814735","code":"C66946","definitions":[{"definition":"An aurora kinase inhibitor with potential antineoplastic activity. PF-03814735 binds to and inhibits aurora kinases, serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of aurora kinases may result in an inhibition of cellular division and proliferation in tumor cells that overexpress aurora kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor PF-03814735","termGroup":"PT","termSource":"NCI"},{"termName":"PF-03814735","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"942487-16-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6V5T4O5758"},{"name":"Legacy Concept Name","value":"PF-03814735"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor PF-03814735"},{"name":"NCI_Drug_Dictionary_ID","value":"536035"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536035"},{"name":"PDQ_Open_Trial_Search_ID","value":"536035"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882256"}]}}{"C70655":{"preferredName":"Aurora Kinase Inhibitor SNS-314","code":"C70655","definitions":[{"definition":"A synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively binds to and inhibits AKs A and B, which may result in the inhibition of cellular division and proliferation in tumor cells that overexpress AKs. AKs are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor SNS-314","termGroup":"PT","termSource":"NCI"},{"termName":"SNS-314","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1057249-41-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"802IFJ0Z8X"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_Inhibitor_SNS-314"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor SNS-314"},{"name":"NCI_Drug_Dictionary_ID","value":"570599"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570599"},{"name":"PDQ_Open_Trial_Search_ID","value":"570599"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346877"}]}}{"C84846":{"preferredName":"Aurora Kinase Inhibitor TTP607","code":"C84846","definitions":[{"definition":"A small-molecule pan-Aurora kinase inhibitor with potential antineoplastic activity. Aurora kinase inhibitor TTP607 selectively binds to and inhibits Aurora kinases A, B and C, which may result in the disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cellular division and proliferation in Aurora kinase-overexpressing tumor cells. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase Inhibitor TTP607","termGroup":"PT","termSource":"NCI"},{"termName":"TTP607","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aurora Kinase Inhibitor TTP607"},{"name":"NCI_Drug_Dictionary_ID","value":"650689"},{"name":"NCI_META_CUI","value":"CL412399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650689"},{"name":"PDQ_Open_Trial_Search_ID","value":"650689"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70983":{"preferredName":"Aurora Kinase/VEGFR2 Inhibitor CYC116","code":"C70983","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It blocks certain enzymes involved in cell division and may kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of protein kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule multi-kinase inhibitor with antineoplastic activity. Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis. Aurora kinases are serine/threonine protein kinases that are only expressed in actively dividing cells and are critical in division or mitosis. VEGFR2 is a receptor tyrosine kinase that appears to account for most of the mitogenic and chemotactic effects of vascular endothelial growth factor (VEGF) on adult endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aurora Kinase/VEGFR2 Inhibitor CYC116","termGroup":"PT","termSource":"NCI"},{"termName":"CYC116","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Aurora_Kinase_VEGFR2_Inhibitor_CYC116"},{"name":"Maps_To","value":"Aurora Kinase/VEGFR2 Inhibitor CYC116"},{"name":"NCI_Drug_Dictionary_ID","value":"566443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"566443"},{"name":"PDQ_Open_Trial_Search_ID","value":"566443"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346878"}]}}{"C139730":{"preferredName":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707","code":"C139730","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified, using proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, to express a chimeric protein containing, at least, the extracellular Fc receptor domain of CD16, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-stimulatory signaling domain of CD28, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient with co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, the autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707 bind to the antibody, become activated and induce the destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; c) targeting and killing adjacent tumor cells that are not bound to the antibody; d) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. Compared to other T-cell products, ACTR-based products do not target a specific TAA and can potentially be used in a variety of tumors because targeting is based on the specificity of the co-administered antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707","termGroup":"PT","termSource":"NCI"},{"termName":"ACTR707","termGroup":"AB","termSource":"NCI"},{"termName":"ACTR707 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ACTR707 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707"},{"name":"NCI_Drug_Dictionary_ID","value":"791109"},{"name":"NCI_META_CUI","value":"CL537915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791109"},{"name":"PDQ_Open_Trial_Search_ID","value":"791109"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155883":{"preferredName":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585","code":"C155883","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused, via an as of yet unknown linker, to the co-stimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA CAR transduced T-cells KITE-585 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. The CD28 co-stimulatory domain optimizes T-cell expansion and function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Genetically Modified Anti-BCMA CAR-T Cells KITE-585","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified Anti-BCMA CAR-transduced T-cells KITE-585","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cells KITE-585","termGroup":"SY","termSource":"NCI"},{"termName":"KITE 585","termGroup":"CN","termSource":"NCI"},{"termName":"KITE-585","termGroup":"CN","termSource":"NCI"},{"termName":"KITE585","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA CAR-transduced T-cells KITE-585"},{"name":"NCI_Drug_Dictionary_ID","value":"794792"},{"name":"NCI_META_CUI","value":"CL562701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794792"},{"name":"PDQ_Open_Trial_Search_ID","value":"794792"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142864":{"preferredName":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101","code":"C142864","definitions":[{"definition":"A preparation consisting of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac) containing an undisclosed selection gene and encoding both an unidentified human-derived safety switch and a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing Tscm P-BCMA-101 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than agents based on antibody-derived single chain variable fragments (scFv), and this agent may exhibit increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can induce the rapid attenuation or elimination of P-BCMA-101. BCMA, a tumor-specific antigen and a member of the tumor necrosis factor receptor superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13) and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA Centyrin-based Chimeric Antigen Receptor-expressing Tscm","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous P-BCMA-101 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous P-BCMA-101 CAR-T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous P-BCMA-101 CARTyrin-T cells","termGroup":"SY","termSource":"NCI"},{"termName":"P-BCMA-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101"},{"name":"NCI_Drug_Dictionary_ID","value":"791806"},{"name":"NCI_META_CUI","value":"CL540755"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791806"},{"name":"PDQ_Open_Trial_Search_ID","value":"791806"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147523":{"preferredName":"Orvacabtagene Autoleucel","code":"C147523","definitions":[{"definition":"A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orvacabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA CAR-T Cells JCARH 125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA 41BBz CAR-T Cell JCARH-125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA-specific CAR-T Cells JCARH125","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA-specific CAR4-1BB-CD3zeta-expressing CD4+/CD8+ T Lymphocytes JCARH 125","termGroup":"SY","termSource":"NCI"},{"termName":"JCARH 125","termGroup":"CN","termSource":"NCI"},{"termName":"JCARH-125","termGroup":"CN","termSource":"NCI"},{"termName":"JCARH125","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K8RW1TW3EM"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125"},{"name":"Maps_To","value":"Orvacabtagene Autoleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"792482"},{"name":"NCI_META_CUI","value":"CL545333"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792482"},{"name":"PDQ_Open_Trial_Search_ID","value":"792482"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C140310":{"preferredName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217","code":"C140310","definitions":[{"definition":"A preparation of autologous memory T-lymphocytes transduced, ex vivo, with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-B-cell maturation antigen (BCMA) single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137) and a CD3-zeta T-cell activation domain, with potential immunostimulating and antineoplastic activities. Upon intravenous administration back into the patient, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing memory T-lymphocytes bb21217 are directed to, and induce selective toxicity in, BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival. BCMA is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-Cells bb21217","termGroup":"SY","termSource":"NCI"},{"termName":"BB 21217","termGroup":"CN","termSource":"NCI"},{"termName":"bb-21217","termGroup":"CN","termSource":"NCI"},{"termName":"bb21217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217"},{"name":"NCI_Drug_Dictionary_ID","value":"791258"},{"name":"NCI_META_CUI","value":"CL538477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791258"},{"name":"PDQ_Open_Trial_Search_ID","value":"791258"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165507":{"preferredName":"Zevorcabtagene Autoleucel","code":"C165507","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a humanized single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, zevorcabtagene autoleucel specifically recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zevorcabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA-CAR-41BB-CD3zeta-expressing T-cells CT053","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA Car-T (CT053)","termGroup":"SY","termSource":"NCI"},{"termName":"CAR-BCMA T-cells CT053","termGroup":"SY","termSource":"NCI"},{"termName":"CT 053","termGroup":"CN","termSource":"NCI"},{"termName":"CT-053","termGroup":"CN","termSource":"NCI"},{"termName":"CT053","termGroup":"CN","termSource":"NCI"},{"termName":"CT053 CAR-BCMA T","termGroup":"SY","termSource":"NCI"},{"termName":"CT053 CAR-BCMA T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GMV2GFP3G2"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053"},{"name":"NCI_Drug_Dictionary_ID","value":"799961"},{"name":"NCI_META_CUI","value":"CL978697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799961"},{"name":"PDQ_Open_Trial_Search_ID","value":"799961"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142807":{"preferredName":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143","code":"C142807","definitions":[{"definition":"A preparation of ex vivo expanded autologous CD8+ and CD4+ T-cells that have been genetically modified to express a chimeric antigen receptor (CAR) specific for human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR CD4+/CD8+ Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-BCMA-CAR-expressing CD8+ and CD4+ T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA CAR-CD4+/CD8+ T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-specific CAR-expressing CD4+/CD8+ T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"FCARH143","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143"},{"name":"NCI_Drug_Dictionary_ID","value":"794992"},{"name":"NCI_META_CUI","value":"CL540710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794992"},{"name":"PDQ_Open_Trial_Search_ID","value":"794992"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155888":{"preferredName":"Autologous Anti-CD19 CAR T-cells IM19","code":"C155888","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells IM19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR T-cells IM19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells IM19","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-specific CAR-T Cells IM19","termGroup":"SY","termSource":"NCI"},{"termName":"IM19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR T-cells IM19"},{"name":"NCI_Drug_Dictionary_ID","value":"794869"},{"name":"NCI_META_CUI","value":"CL562698"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794869"},{"name":"PDQ_Open_Trial_Search_ID","value":"794869"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156271":{"preferredName":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19","code":"C156271","definitions":[{"definition":"Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a humanized single chain variable fragment (scFv) of anti-CD19 coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta) and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon re-introduction into the patient, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, resulting in tumor cell lysis. CD19 (cluster of differentiation 19) is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the co-stimulatory signaling domains increases human T-cell function, expansion, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 CAR-T Cells huCART19","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 Humanized scFv TCRz-41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells huCART19","termGroup":"SY","termSource":"NCI"},{"termName":"CTL119","termGroup":"CN","termSource":"NCI"},{"termName":"CTL119 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"huCART19 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"huCART19 T-lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19"},{"name":"NCI_Drug_Dictionary_ID","value":"795543"},{"name":"NCI_META_CUI","value":"CL562996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795543"},{"name":"PDQ_Open_Trial_Search_ID","value":"795543"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162856":{"preferredName":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002","code":"C162856","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD28 T-cells ET019002 target, bind to, and induce selective toxicity in CD19-expressing B-cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 Autologous CAR T-cells ET019002","termGroup":"SY","termSource":"NCI"},{"termName":"ET019002-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-CD28 T-cells ET019002"},{"name":"NCI_Drug_Dictionary_ID","value":"798902"},{"name":"NCI_Drug_Dictionary_ID","value":"813320"},{"name":"NCI_META_CUI","value":"CL973342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798902"},{"name":"PDQ_Open_Trial_Search_ID","value":"798902"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153118":{"preferredName":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01","code":"C153118","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domains of 4-1BB (CD137) and the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01 target, bind to, and induce selective toxicity in CD19-expressing B cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD19-specific CAR-T cells PZ01","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PZ01 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"PZ01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01"},{"name":"NCI_Drug_Dictionary_ID","value":"793588"},{"name":"NCI_META_CUI","value":"CL554376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793588"},{"name":"PDQ_Open_Trial_Search_ID","value":"793588"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158604":{"preferredName":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901","code":"C158604","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T-lymphocytes CLIC-1901 bind to and induce selective toxicity against CD19-expressing tumor cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CLIC-1901 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CLIC 1901","termGroup":"CN","termSource":"NCI"},{"termName":"CLIC-1901","termGroup":"CN","termSource":"NCI"},{"termName":"CLIC1901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901"},{"name":"NCI_Drug_Dictionary_ID","value":"797095"},{"name":"NCI_META_CUI","value":"CL938077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797095"},{"name":"PDQ_Open_Trial_Search_ID","value":"797095"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142887":{"preferredName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19","code":"C142887","definitions":[{"definition":"A proprietary preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells SJCAR19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells SJCAR19","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CART Cells SJCAR19","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-specific CAR-T Cells SJCAR19","termGroup":"SY","termSource":"NCI"},{"termName":"SJCAR19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19"},{"name":"NCI_Drug_Dictionary_ID","value":"791828"},{"name":"NCI_META_CUI","value":"CL541378"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791828"},{"name":"PDQ_Open_Trial_Search_ID","value":"791828"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148030":{"preferredName":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1","code":"C148030","definitions":[{"definition":"Autologous human peripheral blood T-lymphocytes transduced with a lentivirus encoding a proprietary expression construct composed of a T-cell receptor (TCR)-like human antibody, which is synthesized by a proprietary phage display platform, targeting peptides derived from the tumor-associated antigen (TAA) CD19 that are presented in the context of major histocompatibility complex (MHC) molecules, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the autologous anti-CD19 TCR T-cells ET190L1 target and bind to tumor cells expressing CD19 peptide/MHC complexes. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. CD19, cluster of differentiation antigen 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. ET190L1 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells; however, ET190L1 is less likely to stimulate cytokine release syndrome (CRS) and does not cause CAR T-cell-triggered neurotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1","termGroup":"PT","termSource":"NCI"},{"termName":"ET 190","termGroup":"CN","termSource":"NCI"},{"termName":"ET190","termGroup":"CN","termSource":"NCI"},{"termName":"ET190L1","termGroup":"CN","termSource":"NCI"},{"termName":"ET190L1-ARTEMIS (TM)","termGroup":"SY","termSource":"NCI"},{"termName":"ET190L1-ARTEMIS (TM) T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 T-cell Receptor T cells ET190L1"},{"name":"NCI_Drug_Dictionary_ID","value":"794393"},{"name":"NCI_META_CUI","value":"CL545822"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794393"},{"name":"PDQ_Open_Trial_Search_ID","value":"794393"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162620":{"preferredName":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3","code":"C162620","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a bicistronic retroviral vector encoding both an anti-CD19 chimeric antigen receptor (CAR) fused to OX40 co-stimulatory domain and an anti-CD22 CAR linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), optimized with a novel pentameric spacer derived from the collagen oligomeric matrix protein (COMP), with potential antineoplastic activity. Upon administration, the autologous anti-CD19/CD22 CAR T-cells AUTO3 bind to and induce selective toxicity in tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/CD22 CAR Autologous T-lymphocytes AUTO3","termGroup":"SY","termSource":"NCI"},{"termName":"AUTO 3","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO-3","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19/CD22 CAR T-cells AUTO3"},{"name":"NCI_Drug_Dictionary_ID","value":"798924"},{"name":"NCI_META_CUI","value":"CL971066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798924"},{"name":"PDQ_Open_Trial_Search_ID","value":"798924"},{"name":"Semantic_Type","value":"Cell"}]}}{"C126639":{"preferredName":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014","code":"C126639","definitions":[{"definition":"A defined preparation of CD4+ and CD8+ central memory (CM) autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domains of CD28, 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+CM T-lymphocytes JCAR014 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ CM T-lymphocytes JCAR014","termGroup":"SY","termSource":"NCI"},{"termName":"JCAR014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014"},{"name":"NCI_Drug_Dictionary_ID","value":"780444"},{"name":"NCI_META_CUI","value":"CL505072"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780444"},{"name":"PDQ_Open_Trial_Search_ID","value":"780444"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156251":{"preferredName":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s","code":"C156251","definitions":[{"definition":"Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD22 human single chain variable fragment (scFv) and linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD22 CAR-4-1BB-TCRz -transduced T-lymphocytes CART22-65s express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD22 CAR T-Cells CART22-65s","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD22 scFv CAR 4-1BB-TCRz-expressing T-lymphocytes CART22-65s","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CART22-65s Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CART22-65s T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CART22-65s-expressing T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CART22-65s","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s"},{"name":"NCI_Drug_Dictionary_ID","value":"795556"},{"name":"NCI_META_CUI","value":"CL562955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795556"},{"name":"PDQ_Open_Trial_Search_ID","value":"795556"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162260":{"preferredName":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202","code":"C162260","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) antibody synthesized by a proprietary phage display platform, targeting the immunogenetic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) complexed with human leukocyte antigen (HLA)-A*02 (HLA-A*02/AFP), with potential antineoplastic and immunomodulatory activities. Upon administration, the autologous anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202 specifically recognize and selectively bind to AFP peptides presented by HLA-A*02. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of AFP-expressing tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202","termGroup":"PT","termSource":"NCI"},{"termName":"ET 140202","termGroup":"CN","termSource":"NCI"},{"termName":"ET-140202","termGroup":"CN","termSource":"NCI"},{"termName":"ET140202","termGroup":"CN","termSource":"NCI"},{"termName":"ET140202 Autologous T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202"},{"name":"NCI_Drug_Dictionary_ID","value":"798638"},{"name":"NCI_META_CUI","value":"CL970721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798638"},{"name":"PDQ_Open_Trial_Search_ID","value":"798638"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155884":{"preferredName":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1","code":"C155884","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for an immunogenic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) epitope, AFP158-166, complexed with human leukocyte antigen (HLA)-A*02:01 (HLA-A*0201/AFP), fused to the co-stimulatory domains of CD28 and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-HLA-A*0201/AFP CAR T-cells ET1402L1 specifically recognize and selectively bind to the AFP158-166 peptide presented by HLA-A*0201. Upon binding to the AFP-MHC complex, the T-cells release cytokines and induce selective toxicity in HLA-A*0201/AFP-positive tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous AFP-CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous AFP-CAR-transduced T-cells ET1402L1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ET1402L1-CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ET1402L1-CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cells Transduced with ET1402L1-CAR","termGroup":"SY","termSource":"NCI"},{"termName":"ET1402L1-CAR T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1"},{"name":"NCI_Drug_Dictionary_ID","value":"794793"},{"name":"NCI_META_CUI","value":"CL562702"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794793"},{"name":"PDQ_Open_Trial_Search_ID","value":"794793"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121379":{"preferredName":"Letetresgene Autoleucel","code":"C121379","definitions":[{"definition":"Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letetresgene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1a GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794","termGroup":"SY","termSource":"NCI"},{"termName":"NY-ESO-1c259 T Cells GSK3377794","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B5ME4ZU4BS"},{"name":"Maps_To","value":"Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794"},{"name":"Maps_To","value":"Letetresgene Autoleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"786186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786186"},{"name":"PDQ_Open_Trial_Search_ID","value":"786186"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055426"}]}}{"C154276":{"preferredName":"Autologous AXL-targeted CAR T-cells CCT301-38","code":"C154276","definitions":[{"definition":"A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous AXL-targeted CAR T-cells CCT301-38","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-AXL CAR T Cells CCT30138","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR T-cells Targeting AXL CCT301-38","termGroup":"SY","termSource":"NCI"},{"termName":"CCT301 38","termGroup":"CN","termSource":"NCI"},{"termName":"CCT301-38","termGroup":"CN","termSource":"NCI"},{"termName":"CCT30138 CAR T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous AXL-targeted CAR T-cells CCT301-38"},{"name":"NCI_Drug_Dictionary_ID","value":"794160"},{"name":"NCI_META_CUI","value":"CL555277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794160"},{"name":"PDQ_Open_Trial_Search_ID","value":"794160"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156153":{"preferredName":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B","code":"C156153","definitions":[{"definition":"An autologous vaccine composed of the antigen presenting cells (APCs) B-lymphocytes and monocytes presenting the tumor-associated antigen (TAA) human epidermal growth factor receptor type 2 (HER2/neu; HER-2; EGFR2; ErbB2). Upon administration of the autologous B-cell- and monocyte-presenting HER2/neu antigen vaccine BVAC-B, the APCs may stimulate the immune system to mount a HER2/neu-specific cytotoxic T-lymphocyte (CTL) immune response as well as a natural killer (NK) cell, and antibody-mediated immune response against HER-2/neu-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed by a variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B","termGroup":"PT","termSource":"NCI"},{"termName":"BVAC B","termGroup":"CN","termSource":"NCI"},{"termName":"BVAC-B","termGroup":"CN","termSource":"NCI"},{"termName":"BVACB","termGroup":"CN","termSource":"NCI"},{"termName":"HER2/neu-specific Autologous B-cell/Monocyte Vaccine BVAC-B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B"},{"name":"NCI_Drug_Dictionary_ID","value":"795331"},{"name":"NCI_META_CUI","value":"CL562872"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795331"},{"name":"PDQ_Open_Trial_Search_ID","value":"795331"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162506":{"preferredName":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M","code":"C162506","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T-cells LCAR-B4822M specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous LCAR-B4822M CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-specific CAR-expressing T-lymphocytes LCAR-B4822M","termGroup":"SY","termSource":"NCI"},{"termName":"LCAR B4822M","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B4822M","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B4822M CAR-T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"LCAR-B4822M-02 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"LCARB4822M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous BCMA-targeted CAR T Cells LCAR-B4822M"},{"name":"NCI_Drug_Dictionary_ID","value":"798658"},{"name":"NCI_META_CUI","value":"CL970932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798658"},{"name":"PDQ_Open_Trial_Search_ID","value":"798658"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148498":{"preferredName":"Ciltacabtagene Autoleucel","code":"C148498","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciltacabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA CAR-T Cells JNJ-68284528","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Bi-epitope CAR T-cells JNJ-68284528","termGroup":"SY","termSource":"NCI"},{"termName":"CARVYKTI","termGroup":"BR","termSource":"NCI"},{"termName":"Cilta-cel","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 68284528","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-68284528","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ68284528","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR B38M","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B38M","termGroup":"CN","termSource":"NCI"},{"termName":"LCAR-B38M-transduced CAR-T Cells JNJ-68284528","termGroup":"SY","termSource":"NCI"},{"termName":"LCARB38M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"the treatment of adult patients with relapsed or refractory multiple myeloma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0L1F17908Q"},{"name":"Maps_To","value":"Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528"},{"name":"Maps_To","value":"Ciltacabtagene Autoleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"792630"},{"name":"NCI_META_CUI","value":"CL551044"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792630"},{"name":"PDQ_Open_Trial_Search_ID","value":"792630"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103865":{"preferredName":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001","code":"C103865","definitions":[{"definition":"A cell-based product containing autologous bone marrow derived CD34 positive and C-X-C chemokine receptor type 4 (CXCR4) positive stem cells with potential antiapoptotic and proangiogenic activities. Upon intracoronary infusion after a myocardial infarction (MI), autologous bone marrow-derived CD34/CXCR4-positive stem cells may preserve cardiac muscle cells and prevent apoptosis; thus improving myocardial perfusion. CD34/CXCR4-positive stem cells are naturally mobilized upon cell injury through signaling by hypoxia inducing factor (HIF), which is secreted in response to hypoxia. In turn, HIF induces the synthesis of stromal-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) which mobilize CD34/CXCR4 positive stem cells; CXCR4 is the receptor for stromal-derived factor 1 (SDF-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001","termGroup":"PT","termSource":"NCI"},{"termName":"AMR-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001"},{"name":"NCI_Drug_Dictionary_ID","value":"743421"},{"name":"NCI_META_CUI","value":"CL438343"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743421"},{"name":"PDQ_Open_Trial_Search_ID","value":"743421"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158533":{"preferredName":"Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005","code":"C158533","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the unshed portion of the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-MUC16 CAR-mbIL15-safety switch T-cells PRGN-3005 into the patient, the T-cells target and bind to MUC16-expressing tumor cells, thereby inducing selective toxicity in MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed on a variety of cancer cell types. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-MUC16 CAR-T Cells PRGN-3005","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T Cells PRGN 3005","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PRGN-3005 UltraCAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"PRGN 3005","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN-3005","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN-3005 UltraCAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"PRGN3005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005"},{"name":"NCI_Drug_Dictionary_ID","value":"798316"},{"name":"NCI_META_CUI","value":"CL937966"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798316"},{"name":"PDQ_Open_Trial_Search_ID","value":"798316"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160847":{"preferredName":"Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006","code":"C160847","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD33, a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-CD33 CAR-mbIL15-safety switch T-cells PRGN-3006 into the patient, the T-cells target and bind to CD33-expressing tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD33 CAR-T Cells PRGN-3006","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T Cells PRGN 3006","termGroup":"SY","termSource":"NCI"},{"termName":"PRGN 3006","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN-3006","termGroup":"CN","termSource":"NCI"},{"termName":"PRGN3006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006"},{"name":"NCI_Drug_Dictionary_ID","value":"798420"},{"name":"NCI_META_CUI","value":"CL969928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798420"},{"name":"PDQ_Open_Trial_Search_ID","value":"798420"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148526":{"preferredName":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123","code":"C148526","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD123 (interleukin-3 receptor alpha chain or IL3RA) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD123-4SCAR-expressing T-cells 4SCAR123 are directed to and induce selective toxicity in CD123-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD123-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR123","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR123 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123 CAR-T Cells 4SCAR123","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD123-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR123","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD123-4SCAR-expressing T-cells 4SCAR123"},{"name":"NCI_Drug_Dictionary_ID","value":"792687"},{"name":"NCI_META_CUI","value":"CL551139"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792687"},{"name":"PDQ_Open_Trial_Search_ID","value":"792687"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155878":{"preferredName":"Relmacabtagene Autoleucel","code":"C155878","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relmacabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR T-cells JWCAR029","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-targeted CAR T Cells JWCAR029","termGroup":"SY","termSource":"NCI"},{"termName":"JWCAR 029","termGroup":"CN","termSource":"NCI"},{"termName":"JWCAR-029","termGroup":"CN","termSource":"NCI"},{"termName":"JWCAR029","termGroup":"CN","termSource":"NCI"},{"termName":"Relma-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K5CXA4X5U8"},{"name":"Maps_To","value":"Autologous CD19-targeted CAR T Cells JWCAR029"},{"name":"NCI_Drug_Dictionary_ID","value":"794777"},{"name":"NCI_META_CUI","value":"CL562704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794777"},{"name":"PDQ_Open_Trial_Search_ID","value":"794777"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148525":{"preferredName":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20","code":"C148525","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD20 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD20-4SCAR-expressing T-cells 4SCAR20 are directed to and induce selective toxicity in CD20-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD20-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR20","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR20 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20 CAR-T Cells 4SCAR20","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR20","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD20-4SCAR-expressing T-cells 4SCAR20"},{"name":"NCI_Drug_Dictionary_ID","value":"792686"},{"name":"NCI_META_CUI","value":"CL551140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792686"},{"name":"PDQ_Open_Trial_Search_ID","value":"792686"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148524":{"preferredName":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22","code":"C148524","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD22 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD22-4SCAR-expressing T-cells 4SCAR22 are directed to and induce selective toxicity in CD22-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD22-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR22","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR22 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD22 CAR-T Cells 4SCAR22","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD22-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR22","termGroup":"SY","termSource":"NCI"},{"termName":"CD22-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD22-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD22-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD22-4SCAR-expressing T-cells 4SCAR22"},{"name":"NCI_Drug_Dictionary_ID","value":"792685"},{"name":"NCI_META_CUI","value":"CL551144"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792685"},{"name":"PDQ_Open_Trial_Search_ID","value":"792685"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148523":{"preferredName":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38","code":"C148523","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD38 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD38-4SCAR-expressing T-cells 4SCAR38 are directed to and induce selective toxicity in CD38-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38","termGroup":"PT","termSource":"NCI"},{"termName":"4S-CD38-CAR-T Cell","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR38","termGroup":"CN","termSource":"NCI"},{"termName":"4SCAR38 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38 CAR-T Cells 4SCAR38","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR38","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-4SCAR-expressing T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-specific 4th Generation Chimeric Antigen Receptor-modified T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD38-4SCAR-expressing T-cells 4SCAR38"},{"name":"NCI_Drug_Dictionary_ID","value":"792684"},{"name":"NCI_META_CUI","value":"CL551145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792684"},{"name":"PDQ_Open_Trial_Search_ID","value":"792684"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158091":{"preferredName":"Autologous Deep IL-15 Primed T-cells TRQ15-01","code":"C158091","definitions":[{"definition":"A preparation of genetically modified, multi-antigen-directed autologous T-lymphocytes, that have particles, consisting of multiple chemically crosslinked human cytokine interleukin-15 (IL-15)/IL-15 receptor alpha (IL-15Ra)/Fc heterodimers, attached to their surface, with potential immunostimulating and antineoplastic activities. TRQ15-01 is made from monocyte-derived dendritic cells (moDCs) that are pulsed with peptides from multiple tumor-associated antigens (TAAs) to expand cytotoxic T-lymphocytes (CTLs) that are subsequently loaded with IL-15 particles. Upon administration of the autologous deep IL-15 primed T-cells, the IL-15/IL-15Ra fusion proteins are slowly released in vivo from the T-cells in a controlled manner and induce autocrine cytokine stimulation of the administered T-cells, thereby increasing T-cell division of the administered T-cells. The expanded T-cells target, bind to and kill tumor cells. This increases tumor cell growth inhibition by T-cells. IL-15 is a pro-survival, inflammatory cytokine and causes sustained T-cell expansion and enhanced anti-tumor activity. Compared to systemically delivered IL-15, IL-15 attached to the T-cells greatly increases target CD8 T-cell concentrations in the tumor, without significant systemic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Deep IL-15 Primed T-cells TRQ15-01","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15 Loaded Autologous T-lymphocytes TRQ15-01","termGroup":"SY","termSource":"NCI"},{"termName":"TRQ15-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Deep IL-15 Primed T-cells TRQ15-01"},{"name":"NCI_Drug_Dictionary_ID","value":"797353"},{"name":"NCI_META_CUI","value":"CL937688"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797353"},{"name":"PDQ_Open_Trial_Search_ID","value":"797353"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121856":{"preferredName":"Autologous Dendritic Cell Vaccine ACT2001","code":"C121856","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Dendritic Cell Vaccine ACT2001","termGroup":"PT","termSource":"NCI"},{"termName":"ACT2001","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous DC Vaccine ACT2001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Dendritic Cell Vaccine ACT2001"},{"name":"NCI_Drug_Dictionary_ID","value":"771721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771721"},{"name":"PDQ_Open_Trial_Search_ID","value":"771721"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053686"}]}}{"C123928":{"preferredName":"Audencel","code":"C123928","definitions":[{"definition":"A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of audencel, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Audencel","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous DC-based Immunotherapeutic AV0113","termGroup":"SY","termSource":"NCI"},{"termName":"AV0113","termGroup":"CN","termSource":"NCI"},{"termName":"AV0113 DC-CIT","termGroup":"SY","termSource":"NCI"},{"termName":"AV0113 Dendritic Cell Cancer Immunotherapeutic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H2CDQ1PWN7"},{"name":"Maps_To","value":"Audencel"},{"name":"Maps_To","value":"Autologous Dendritic Cell-based Immunotherapeutic AV0113"},{"name":"NCI_Drug_Dictionary_ID","value":"775935"},{"name":"NCI_META_CUI","value":"CL498291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775935"},{"name":"PDQ_Open_Trial_Search_ID","value":"775935"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150698":{"preferredName":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa","code":"C150698","definitions":[{"definition":"A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-folate receptor alpha (FRa; folate receptor 1; FOLR1) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa are directed to and induce selective toxicity in FRa-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. FRa is overexpressed in various tumor cell types, and is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa","termGroup":"PT","termSource":"NCI"},{"termName":"4SCAR-FRa","termGroup":"AB","termSource":"NCI"},{"termName":"Autologous 4S-FRa-CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-FRa-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR-FRa","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric Antigen Receptor T Cells 4SCAR-FRa","termGroup":"SY","termSource":"NCI"},{"termName":"FRa-specific 4th Generation CART Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa"},{"name":"NCI_Drug_Dictionary_ID","value":"793118"},{"name":"NCI_META_CUI","value":"CL552500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793118"},{"name":"PDQ_Open_Trial_Search_ID","value":"793118"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162804":{"preferredName":"Uzatresgene Autoleucel","code":"C162804","definitions":[{"definition":"Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, uzatresgene autoleucel bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T-cells into CD8+ cytotoxic T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uzatresgene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"ADP-A2M4CD8","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified Melanoma Antigen A4 CD8alpha T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous MAGE-A4 C1032 TCR-modified CD8alpha T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TCR-transduced MAGE-A4 C1032 CD8alpha T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4 SPEAR CD8alpha T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4-specific TCR gene-transduced C1032 CD8alpha T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"SPEAR T-cell ADP-A2M4CD8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7VY54Y73ZG"},{"name":"Maps_To","value":"Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"799099"},{"name":"NCI_META_CUI","value":"CL973182"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799099"},{"name":"PDQ_Open_Trial_Search_ID","value":"799099"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175738":{"preferredName":"Afamitresgene Autoleucel","code":"C175738","definitions":[{"definition":"A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afamitresgene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"ADP-A2M4","termGroup":"CN","termSource":"NCI"},{"termName":"Afami-cel","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified MAGE-A4 C1032 T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Genetically-modified MAGE-A4 C1032 T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4 SPEAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A4C1032T","termGroup":"SY","termSource":"NCI"},{"termName":"SPEAR T-cell ADP-A2M4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CUY18BJ7BP"},{"name":"Maps_To","value":"Autologous Genetically-modified MAGE-A4 C1032 T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"790617"},{"name":"NCI_META_CUI","value":"CL1413156"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C37448":{"preferredName":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858","code":"C37448","definitions":[{"definition":"A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes.  HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858","termGroup":"PT","termSource":"NCI"},{"termName":"AG-858","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Autologous_Heat-Shock_Protein_70_Peptide_Vaccine"},{"name":"Maps_To","value":"Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858"},{"name":"NCI_Drug_Dictionary_ID","value":"334949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"334949"},{"name":"PDQ_Open_Trial_Search_ID","value":"334949"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328058"}]}}{"C159977":{"preferredName":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439","code":"C159977","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted human papillomavirus type 16 isoform E7 protein (HPV16 E7) with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous HPV16 E7-specific HLA-A*02:01-restricted T-lymphocytes KITE-439 target and bind HPV16 E7-expressing tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 E7 antigen. HPV16 E7, a cell surface glycoprotein and tumor-associated antigen (TAA), is overexpressed in various HPV-mediated cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E7 T-cell Receptor Engineered T-cells KITE-439","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Autologous T-lymphocytes KITE-439","termGroup":"SY","termSource":"NCI"},{"termName":"KITE 439","termGroup":"CN","termSource":"NCI"},{"termName":"KITE-439","termGroup":"CN","termSource":"NCI"},{"termName":"KITE439","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439"},{"name":"NCI_Drug_Dictionary_ID","value":"797966"},{"name":"NCI_META_CUI","value":"CL969078"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797966"},{"name":"PDQ_Open_Trial_Search_ID","value":"797966"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162627":{"preferredName":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001","code":"C162627","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A02:01/24:02/11:01-restricted Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Upon administration, the autologous LMP1/LMP2/EBNA1-specific, HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001 recognize and bind to HLA-presented EBV peptides, which may promote cell death and inhibit the growth of tumor cells expressing LMP1, LMP2 or EBNA1. LMP1, LMP2, and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous EBV-specific TCR T-cells YT-E001","termGroup":"SY","termSource":"NCI"},{"termName":"YT E001","termGroup":"CN","termSource":"NCI"},{"termName":"YT-E001","termGroup":"CN","termSource":"NCI"},{"termName":"YTE001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001"},{"name":"NCI_Drug_Dictionary_ID","value":"798763"},{"name":"NCI_META_CUI","value":"CL971019"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798763"},{"name":"PDQ_Open_Trial_Search_ID","value":"798763"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135534":{"preferredName":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718","code":"C135534","definitions":[{"definition":"Human autologous T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-MAGE-A3/A6 TCR-transduced T Cells KITE-718","termGroup":"SY","termSource":"NCI"},{"termName":"KITE 718","termGroup":"CN","termSource":"NCI"},{"termName":"KITE-718","termGroup":"CN","termSource":"NCI"},{"termName":"MAGE-A3/A6 T Cell Receptor Engineered T-Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3/A6 T-Cell Receptor Engineered T-Cells KITE-718","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3/A6 TCR Engineered T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"MAGEA3/A6-targeted TCR-transduced T-Cells KITE-718","termGroup":"SY","termSource":"NCI"},{"termName":"TCR-transduced Autologous T-Cells KITE-718","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718"},{"name":"NCI_Drug_Dictionary_ID","value":"788966"},{"name":"NCI_META_CUI","value":"CL522896"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788966"},{"name":"PDQ_Open_Trial_Search_ID","value":"788966"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156382":{"preferredName":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","code":"C156382","definitions":[{"definition":"A preparation of autologous CD4+ and CD62L-expressing CD8+ T-cells transduced with a third generation lentiviral vector (LV) to express the high affinity T-cell receptor (TCR) A2 -MCC1, specific for the human leukocyte antigen (HLA)-A02-restricted Merkel cell polyomavirus (MCPyV; MCV) viral oncoprotein, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD8+ and CD4+ T-cells FH-MCVA2TCR selectively bind to the KLLEIAPNC epitope (KLL epitope) within the MCPyV viral oncoprotein. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the MCPyV viral oncoprotein. Additionally, tumor-specific HLA-A02-restricted CD4+ cells promote class I-restricted CD8+ proliferation, survival and effector functions by producing interleukin (IL)-2 and facilitating the activation of dendritic cells (DCs). MCPyV viral oncoprotein is highly expressed in Merkel cell carcinoma (MCC) caused by MCPyV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1","termGroup":"SY","termSource":"NCI"},{"termName":"FH-MCVA2TCR","termGroup":"CN","termSource":"NCI"},{"termName":"FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR"},{"name":"NCI_Drug_Dictionary_ID","value":"795693"},{"name":"NCI_META_CUI","value":"CL563078"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795693"},{"name":"PDQ_Open_Trial_Search_ID","value":"795693"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113803":{"preferredName":"Autologous Mesenchymal Stem Cells Apceth_101","code":"C113803","definitions":[{"definition":"Human autologous mesenchymal stem cells (MSCs) harvested from the bone marrow of a patient and genetically modified with a self-inactivating retroviral vector expressing the suicide gene herpes simplex virus thymidine kinase (HSV-TK), that can be used to activate synthetic acyclic guanosine analogues when co-administered. Upon intravenous administration of autologous mesenchymal stem cells apceth_101, the cells are actively recruited to the tumor stroma, differentiate into more mature mesenchymal cells, and become part of the tumor microenvironment. When a synthetic acyclic guanosine analogue, such as ganciclovir, is co-administered, the HSV-TK within the HSV-TK-transduced MSCs will monophosphorylate this prodrug. Subsequently the monophosphate form is further converted to the diphosphate form and then to its active triphosphate form by cellular kinases. The active form of ganciclovir kills the HSV-TK-transduced MSCs and leads to a bystander effect, which eliminates neighboring cancer cells. Therefore, synthetic acyclic guanosine analogues are activated only at the tumor site, which increases their local efficacy and reduces systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Mesenchymal Stem Cells Apceth_101","termGroup":"PT","termSource":"NCI"},{"termName":"Agenmestencel-T","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous MSC_Apceth_101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Mesenchymal Stem Cells Apceth_101"},{"name":"NCI_Drug_Dictionary_ID","value":"757685"},{"name":"NCI_META_CUI","value":"CL471784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757685"},{"name":"PDQ_Open_Trial_Search_ID","value":"757685"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155775":{"preferredName":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","code":"C155775","definitions":[{"definition":"Autologous peripheral blood mononuclear cells (PBMCs) transfected with anti-mesothelin chimeric antigen receptor (CAR) mRNA, with potential antineoplastic activity. Upon intraperitoneal (IP) administration, the autologous mesothelin-specific human mRNA CAR-transfected PBMCs MCY-M11 recognize, bind to, phagocytose and directly kill cancer cells expressing mesothelin. In addition, MCY-M11 stimulates the immune system to induce a cytotoxic T-lymphocyte response against the mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-mesothelin mRNA-transfected Autologous PBMCs MCY-M11","termGroup":"SY","termSource":"NCI"},{"termName":"MCY-M11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ER09HM7LIR"},{"name":"Maps_To","value":"Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11"},{"name":"NCI_Drug_Dictionary_ID","value":"794988"},{"name":"NCI_META_CUI","value":"CL556250"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794988"},{"name":"PDQ_Open_Trial_Search_ID","value":"794988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121536":{"preferredName":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01","code":"C121536","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified and transduced with a retroviral vector to express a chimeric antigen receptor (CAR) encoding full-length human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) fused to the CD3zeta cytoplasmic signaling domain and containing the naturally-expressed adaptor molecule DNAX-activating protein of 10 kDa (DAP10), with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR-CD3zeta-DAP10-expressing T-lymphocytes CYAD-01 specifically recognize and bind to tumor cells expressing NKG2D ligands. This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-01 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The CD3zeta signaling domain and DAP10 provide co-stimulatory signaling upon ligand binding, enhance the secretion of pro-inflammatory cytokines in response to binding to NKG2D ligand-expressing tumor cells and enhances T-cell cytotoxicity. DAP10 also associates with and stabilizes NKG2D, which facilitates expression of the NKG2D-CAR-CD3zeta construct at the cell surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CAR NKG2D","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T NKG2D","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T NKR-2","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CM-CS1 T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-cells CYAD-01","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKR 2 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKR-2 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CM CS-1","termGroup":"CN","termSource":"NCI"},{"termName":"CM-CS-1","termGroup":"CN","termSource":"NCI"},{"termName":"CM-CS1","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD-01","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD-101","termGroup":"CN","termSource":"NCI"},{"termName":"NKR 2","termGroup":"CN","termSource":"NCI"},{"termName":"NKR-2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01"},{"name":"NCI_Drug_Dictionary_ID","value":"788734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788734"},{"name":"PDQ_Open_Trial_Search_ID","value":"788734"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055424"}]}}{"C82361":{"preferredName":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101","code":"C82361","definitions":[{"definition":"A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered; AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA.  This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101","termGroup":"PT","termSource":"NCI"},{"termName":"BP-GMAX-CD1","termGroup":"SY","termSource":"NCI"},{"termName":"BPX-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"iCD40_Receptor_Pulsed_Autologous_Dendritic_Cell_Vaccine_BP-GMAX-CD1"},{"name":"Maps_To","value":"Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101"},{"name":"NCI_Drug_Dictionary_ID","value":"640422"},{"name":"NCI_META_CUI","value":"CL408640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640422"},{"name":"PDQ_Open_Trial_Search_ID","value":"640422"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128031":{"preferredName":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601","code":"C128031","definitions":[{"definition":"A preparation of autologous T-lymphocytes expressing a chimeric antigen receptor (CAR) consisting of an anti-human prostate stem cell antigen (PSCA) scFv (single chain variable fragment) coupled to the zeta chain of the T-cell receptor (TCRzeta) and a drug-induced co-stimulatory molecule, composed of an inducible, chimeric MyD88/CD40 (inducible MC; iMC) co-stimulatory domain, in which both the MyD88 and CD40 lack their extracellular domains, with potential antineoplastic activity. Upon administration of BPX-601, the T-cells target and bind to PSCA-expressing cancer cells. Upon subsequent administration of the chemical inducer of dimerization (CID) agent rimiducid, this agent targets and binds to the drug binding domain, which leads to iMC expression, activation of both CD40- and MyD88-mediated signal transduction pathways, and an induction of selective cytotoxicity in, and eradication of PSCA-expressing cancer cells. iMC activation by rimiducid increases T-cell survival and anti-tumor activity of the administered T-cells, compared to T-cells without the drug iMC activation-switch. As these T-cells are engineered to only be fully activated by binding to both antigen and rimiducid, T-cell proliferation, activity and toxicity can be controlled by adjusting the dose of rimiducid, thereby preventing uncontrolled T-cell activation which increases the safety of the administered T-cells. PSCA is a glycosylphosphatidylinositol (GPI)-anchored cell surface antigen overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous PSCA-specific CAR T Cells BPX-601","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PSCA-Specific Chimeric Antigen Receptor Engineered T Cells BPX-601","termGroup":"SY","termSource":"NCI"},{"termName":"BPX-601","termGroup":"CN","termSource":"NCI"},{"termName":"GoCART BPX-601","termGroup":"SY","termSource":"NCI"},{"termName":"iMC/PSCA-zeta CAR BPX-601","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601"},{"name":"NCI_Drug_Dictionary_ID","value":"781278"},{"name":"NCI_META_CUI","value":"CL507925"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781278"},{"name":"PDQ_Open_Trial_Search_ID","value":"781278"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154277":{"preferredName":"Autologous ROR2-targeted CAR T-cells CCT301-59","code":"C154277","definitions":[{"definition":"A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, CCT301-59 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of ROR2-expressing tumor cells. ROR2 is involved in Wnt signal transduction and is involved in tumorigenesis and progression. ROR2 expression is upregulated in certain tumor types and high levels of ROR2 expression often correlates with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous ROR2-targeted CAR T-cells CCT301-59","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-ROR2 CAR T Cells CCT301-59","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR T-cells Targeting ROR2 CCT301-59","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CCT301-59 CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CCT301 59","termGroup":"CN","termSource":"NCI"},{"termName":"CCT301-59","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous ROR2-targeted CAR T-cells CCT301-59"},{"name":"NCI_Drug_Dictionary_ID","value":"794161"},{"name":"NCI_META_CUI","value":"CL555278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794161"},{"name":"PDQ_Open_Trial_Search_ID","value":"794161"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154285":{"preferredName":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1","code":"C154285","definitions":[{"definition":"A preparation of autologous dendritic cells (DCs) loaded with immunogenic tumor-associated antigens (TAAs) derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TAAs-loaded Autologous DCs AV-GBM-1","termGroup":"SY","termSource":"NCI"},{"termName":"AV GBM 1","termGroup":"CN","termSource":"NCI"},{"termName":"AV-GBM-1","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen-loaded Autologous Dendritic Cells AV-GBM-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1"},{"name":"NCI_Drug_Dictionary_ID","value":"794138"},{"name":"NCI_META_CUI","value":"CL555286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794138"},{"name":"PDQ_Open_Trial_Search_ID","value":"794138"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146779":{"preferredName":"Autologous TCR-engineered T-cells IMA201","code":"C146779","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for an as of yet not identified tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA201 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TCR-engineered T-cells IMA201","termGroup":"PT","termSource":"NCI"},{"termName":"ACTengine IMA201","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cell Receptor-engineered T-cells IMA201","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TCR-engineered T-cells IMA201","termGroup":"SY","termSource":"NCI"},{"termName":"IMA 201","termGroup":"CN","termSource":"NCI"},{"termName":"IMA-201","termGroup":"CN","termSource":"NCI"},{"termName":"IMA201","termGroup":"CN","termSource":"NCI"},{"termName":"IMA201 Autologous T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"IMA201 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCR-engineered T-cells IMA201"},{"name":"NCI_Drug_Dictionary_ID","value":"792163"},{"name":"NCI_META_CUI","value":"CL544786"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792163"},{"name":"PDQ_Open_Trial_Search_ID","value":"792163"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153218":{"preferredName":"Autologous TCR-engineered T-cells IMA202","code":"C153218","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) targeting patient-specific tumor associated antigens (TAAs), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA202 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TCR-engineered T-cells IMA202","termGroup":"PT","termSource":"NCI"},{"termName":"ACTengine IMA202","termGroup":"SY","termSource":"NCI"},{"termName":"IMA 202","termGroup":"CN","termSource":"NCI"},{"termName":"IMA-202","termGroup":"CN","termSource":"NCI"},{"termName":"IMA202","termGroup":"CN","termSource":"NCI"},{"termName":"IMA202 T-cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"IMA202 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCR-engineered T-cells IMA202"},{"name":"NCI_Drug_Dictionary_ID","value":"794052"},{"name":"NCI_META_CUI","value":"CL554340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794052"},{"name":"PDQ_Open_Trial_Search_ID","value":"794052"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161831":{"preferredName":"Autologous PRAME-targeting TCR-engineered T-cells IMA203","code":"C161831","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous PRAME-targeting TCR-engineered T-cells IMA203 specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous PRAME-targeting TCR-engineered T-cells IMA203","termGroup":"PT","termSource":"NCI"},{"termName":"ACTengine IMA203","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous T-cell Receptor-engineered T-cells IMA203","termGroup":"SY","termSource":"NCI"},{"termName":"IMA 203","termGroup":"CN","termSource":"NCI"},{"termName":"IMA-203","termGroup":"CN","termSource":"NCI"},{"termName":"IMA203","termGroup":"CN","termSource":"NCI"},{"termName":"IMA203 Autologous T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"IMA203 T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCR-engineered T-cells IMA203"},{"name":"NCI_Drug_Dictionary_ID","value":"798429"},{"name":"NCI_META_CUI","value":"CL970385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798429"},{"name":"PDQ_Open_Trial_Search_ID","value":"798429"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120552":{"preferredName":"Lifileucel","code":"C120552","definitions":[{"definition":"A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifileucel","termGroup":"PT","termSource":"NCI"},{"termName":"Amtagvi","termGroup":"BR","termSource":"NCI"},{"termName":"Autologous TIL LN-144","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tumor Infiltrating Lymphocytes LN-144","termGroup":"SY","termSource":"NCI"},{"termName":"Contego","termGroup":"AQS","termSource":"NCI"},{"termName":"LN 144","termGroup":"CN","termSource":"NCI"},{"termName":"LN-144","termGroup":"CN","termSource":"NCI"},{"termName":"LN144","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2306267-74-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R0835E18NH"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes LN-144"},{"name":"Maps_To","value":"Lifileucel"},{"name":"NCI_Drug_Dictionary_ID","value":"769186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769186"},{"name":"PDQ_Open_Trial_Search_ID","value":"769186"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053624"}]}}{"C135634":{"preferredName":"Autologous Tumor Infiltrating Lymphocytes LN-145","code":"C135634","definitions":[{"definition":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tumor Infiltrating Lymphocytes LN-145","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous TILs LN-145","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tumor-infiltrating Lymphocytes LN-145","termGroup":"SY","termSource":"NCI"},{"termName":"LN-145","termGroup":"CN","termSource":"NCI"},{"termName":"LN145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes LN-145"},{"name":"NCI_Drug_Dictionary_ID","value":"789043"},{"name":"NCI_META_CUI","value":"CL522989"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789043"},{"name":"PDQ_Open_Trial_Search_ID","value":"789043"},{"name":"Semantic_Type","value":"Cell"}]}}{"C153312":{"preferredName":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL","code":"C153312","definitions":[{"definition":"A preparation of autologous tumor infiltrating lymphocytes (TILs) with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, then cultured and expanded in vitro in the presence of interleukin-2 (IL-2) and an agonistic anti-4-1BB (CD137) antibody. Upon infusion of the autologous expanded TILs back into the patient, the cells specifically recognize, target, and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL","termGroup":"PT","termSource":"NCI"},{"termName":"MDA Autologous TILs","termGroup":"SY","termSource":"NCI"},{"termName":"MDA Autologous Tumor Infiltrating Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"MDA-TILs","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL"},{"name":"NCI_Drug_Dictionary_ID","value":"794072"},{"name":"NCI_META_CUI","value":"CL554425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794072"},{"name":"PDQ_Open_Trial_Search_ID","value":"794072"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160786":{"preferredName":"Avadomide","code":"C160786","definitions":[{"definition":"A novel, small molecule cereblon-modulating agent with potential antineoplastic, antiangiogenic and immunomodulatory activities. Upon oral administration, avadomide binds to and modulates cereblon to promote recruitment of the hematopoietic transcription factors Aiolos and Ikaros to the Cullin-4 RING E3 ubiquitin ligase complex. This binding results in the ubiquitination and rapid proteasomal degradation of Aiolos and Ikaros and the derepression of interferon (IFN)-stimulated genes, including DDX58 and IRF7, leading to apoptosis of certain tumor cells. Additionally, Aiolos degredation leads to derepression of the IL2 gene, thereby enhancing interleukin-2 production, costimulation of T-lymphocytes and IL-2-induced T-cell proliferation. Avadomide may also promote the activation of natural killer (NK) cells, potentially enhancing tumor cell killing. Aiolos and Ikaros are transcriptional repressors known to play an important role in normal B- and T-cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avadomide","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CC 122","termGroup":"CN","termSource":"NCI"},{"termName":"CC-122","termGroup":"CN","termSource":"NCI"},{"termName":"CC122","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1015474-32-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"28DZS29F59"},{"name":"Maps_To","value":"Avadomide"},{"name":"NCI_Drug_Dictionary_ID","value":"798417"},{"name":"NCI_META_CUI","value":"CL969760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798417"},{"name":"PDQ_Open_Trial_Search_ID","value":"798417"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97956":{"preferredName":"Avadomide Hydrochloride","code":"C97956","definitions":[{"definition":"The hydrochloride salt form of avadomide, a novel, small molecule, cereblon-modulating agent with potential antineoplastic, antiangiogenic and immunomodulatory activities. Upon oral administration, avadomide binds to and modulates cereblon to promote recruitment of the hematopoietic transcription factors Aiolos and Ikaros to the Cullin-4 RING E3 ubiquitin ligase complex. This binding results in the ubiquitination and rapid proteasomal degradation of Aiolos and Ikaros and the derepression of interferon (IFN)-stimulated genes, including DDX58 and IRF7, leading to apoptosis of certain tumor cells. Additionally, Aiolos degredation leads to derepression of the IL2 gene, thereby enhancing interleukin-2 production, costimulation of T-lymphocytes and IL-2-induced T-cell proliferation. Avadomide may also promote the activation of natural killer (NK) cells, potentially enhancing tumor cell killing. Aiolos and Ikaros are transcriptional repressors known to play an important role in normal B- and T-cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avadomide Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Piperidinedione, 3-(5-Amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CC-122 Hydrochloride","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1398053-45-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6CX4AEX3KR"},{"name":"Maps_To","value":"Avadomide Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"710428"},{"name":"NCI_META_CUI","value":"CL430562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710428"},{"name":"PDQ_Open_Trial_Search_ID","value":"710428"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123827":{"preferredName":"Avapritinib","code":"C123827","definitions":[{"definition":"An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avapritinib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine","termGroup":"SY","termSource":"NCI"},{"termName":"AYVAKIT","termGroup":"BR","termSource":"NCI"},{"termName":"Ayvakyt","termGroup":"FB","termSource":"NCI"},{"termName":"BLU 285","termGroup":"CN","termSource":"NCI"},{"termName":"BLU-285","termGroup":"CN","termSource":"NCI"},{"termName":"BLU285","termGroup":"CN","termSource":"NCI"},{"termName":"CS3007","termGroup":"CN","termSource":"NCI"},{"termName":"PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of Adults with Unresectable or Metastatic Gastrointestinal Stromal Tumor Harboring a Platelet-derived Growth Factor Receptor Alpha Exon 18 Mutation"},{"name":"CAS_Registry","value":"1703793-34-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"513P80B4YJ"},{"name":"Maps_To","value":"Avapritinib"},{"name":"NCI_Drug_Dictionary_ID","value":"775630"},{"name":"NCI_META_CUI","value":"CL498221"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775630"},{"name":"PDQ_Open_Trial_Search_ID","value":"775630"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116870":{"preferredName":"Avelumab","code":"C116870","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avelumab","termGroup":"PT","termSource":"NCI"},{"termName":"Bavencio","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"MSB 0010718C","termGroup":"CN","termSource":"NCI"},{"termName":"MSB-0010718C","termGroup":"CN","termSource":"NCI"},{"termName":"MSB0010718C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma (MCC); advanced renal cell carcinoma (RCC)."},{"name":"CAS_Registry","value":"1537032-82-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"KXG2PJ551I"},{"name":"Maps_To","value":"Avelumab"},{"name":"NCI_Drug_Dictionary_ID","value":"745752"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745752"},{"name":"PDQ_Open_Trial_Search_ID","value":"745752"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055417"}]}}{"C118671":{"preferredName":"Abivertinib Maleate Anhydrous","code":"C118671","definitions":[{"definition":"The maleate salt form of abivertinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abivertinib Maleate Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"AC0010 Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"AC0010 Maleate Dihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"AC0010MA","termGroup":"CN","termSource":"NCI"},{"termName":"Avitinib Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"STI-5656","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1557268-88-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0447KM2XTD"},{"name":"Maps_To","value":"Avitinib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"765931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765931"},{"name":"PDQ_Open_Trial_Search_ID","value":"765931"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053687"}]}}{"C120309":{"preferredName":"Axicabtagene Ciloleucel","code":"C120309","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axicabtagene Ciloleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Axi-cel","termGroup":"SY","termSource":"NCI"},{"termName":"Axicel","termGroup":"SY","termSource":"NCI"},{"termName":"KTE C19","termGroup":"CN","termSource":"NCI"},{"termName":"KTE-C19","termGroup":"CN","termSource":"NCI"},{"termName":"KTE-C19 CAR","termGroup":"SY","termSource":"NCI"},{"termName":"KTEC19","termGroup":"CN","termSource":"NCI"},{"termName":"Yescarta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy; for adult patients with large B-cell lymphoma (LBCL)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U2I8T43Y7R"},{"name":"Maps_To","value":"Axicabtagene Ciloleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"768723"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768723"},{"name":"PDQ_Open_Trial_Search_ID","value":"768723"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896829"}]}}{"C38718":{"preferredName":"Axitinib","code":"C38718","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and protein tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axitinib","termGroup":"PT","termSource":"NCI"},{"termName":"AG 013736","termGroup":"CN","termSource":"NCI"},{"termName":"AG-013736","termGroup":"CN","termSource":"NCI"},{"termName":"AG013736","termGroup":"CN","termSource":"NCI"},{"termName":"Inlyta","termGroup":"BR","termSource":"NCI"},{"termName":"N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"319460-85-0"},{"name":"Chemical_Formula","value":"C22H18N4OS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"C9LVQ0YUXG"},{"name":"Legacy Concept Name","value":"AG-013736"},{"name":"Maps_To","value":"Axitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"352181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352181"},{"name":"PDQ_Open_Trial_Search_ID","value":"352181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1700874"}]}}{"C152976":{"preferredName":"AXL Inhibitor DS-1205c","code":"C152976","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, DS-1205c targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways and inhibits tumor cell proliferation and migration. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types. It plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL Inhibitor DS-1205c","termGroup":"PT","termSource":"NCI"},{"termName":"DS 1205c","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1205c","termGroup":"CN","termSource":"NCI"},{"termName":"DS1205c","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL Inhibitor DS-1205c"},{"name":"NCI_Drug_Dictionary_ID","value":"793863"},{"name":"NCI_META_CUI","value":"CL554179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793863"},{"name":"PDQ_Open_Trial_Search_ID","value":"793863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132025":{"preferredName":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M","code":"C132025","definitions":[{"definition":"An orally available inhibitor of the AXL receptor tyrosine kinase (AXL; UFO) and the receptor tyrosine kinase c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Upon administration, AXL receptor tyrosine kinase/cMET inhibitor BPI-9016M, binds to both AXL and cMet, thereby disrupting both AXL- and c-Met-mediated signaling pathways. Altogether, this agent inhibits growth in AXL and cMet-overexpressing tumor cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, and cMet, both overexpressed by many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M","termGroup":"PT","termSource":"NCI"},{"termName":"AXL/cMET Inhibitor BPI-9016M","termGroup":"SY","termSource":"NCI"},{"termName":"BPI 9016","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-9016","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-9016M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M"},{"name":"NCI_Drug_Dictionary_ID","value":"786576"},{"name":"NCI_META_CUI","value":"CL520367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786576"},{"name":"PDQ_Open_Trial_Search_ID","value":"786576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153122":{"preferredName":"Axl/Mer Inhibitor INCB081776","code":"C153122","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, INCB081776 targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axl/Mer Inhibitor INCB081776","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 081776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 81776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-081776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-81776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB081776","termGroup":"CN","termSource":"NCI"},{"termName":"INCB81776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Axl/Mer Inhibitor INCB081776"},{"name":"Maps_To","value":"Axl/Mer Inhibitor INCB081776"},{"name":"NCI_Drug_Dictionary_ID","value":"793938"},{"name":"NCI_META_CUI","value":"CL554380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793938"},{"name":"PDQ_Open_Trial_Search_ID","value":"793938"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C288":{"preferredName":"Azacitidine","code":"C288","definitions":[{"definition":"A drug that is used to treat myelodysplastic syndromes and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azacitidine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-AC","termGroup":"AB","termSource":"NCI"},{"termName":"5-Aza-cytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Azacitidine","termGroup":"SY","termSource":"NCI"},{"termName":"5-Azacytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-AZC","termGroup":"AB","termSource":"NCI"},{"termName":"Azacytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Ladakamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Mylosar","termGroup":"SY","termSource":"NCI"},{"termName":"U-18496","termGroup":"CN","termSource":"NCI"},{"termName":"Vidaza","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Myelodysplastic Syndrome; acute myeloid leukemia"},{"name":"CAS_Registry","value":"320-67-2"},{"name":"CHEBI_ID","value":"CHEBI:2038"},{"name":"Chemical_Formula","value":"C8H12N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M801H13NRU"},{"name":"Legacy Concept Name","value":"Azacitidine"},{"name":"Maps_To","value":"Azacitidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39153"},{"name":"NSC Number","value":"102816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39153"},{"name":"PDQ_Open_Trial_Search_ID","value":"39153"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004475"}]}}{"C1007":{"preferredName":"Azapicyl","code":"C1007","definitions":[{"definition":"A hydrazine compound that has been investigated for antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azapicyl","termGroup":"PT","termSource":"NCI"},{"termName":"1-acetyl-2-picolinoylhydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"2-acetylhydrazide-2-pyridinecarboxylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"P-2292","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17433-31-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"186TH42ZNH"},{"name":"Legacy Concept Name","value":"Azapicyl"},{"name":"Maps_To","value":"Azapicyl"},{"name":"NCI_Drug_Dictionary_ID","value":"39154"},{"name":"NSC Number","value":"68626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39154"},{"name":"PDQ_Open_Trial_Search_ID","value":"39154"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052754"}]}}{"C1008":{"preferredName":"Azaribine","code":"C1008","definitions":[{"definition":"The triacetate salt of azauridine, a synthetic triazine nucleoside derivative possessing antineoplastic and anti-psoriatic activity. After metabolism to 6-azauridine-5-prime monophosphate, 6-Azauridine inhibits de novo pyrimidine biosynthesis and its 5-prime triphosphate metabolite gets incorporated into RNA, thereby preventing RNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azaribine","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-Triazine-3,5(2H,4H)-dione, 2-Beta-D-ribofuranosyl-","termGroup":"SN","termSource":"NCI"},{"termName":"2',3',4'-azauridine triacetate","termGroup":"SN","termSource":"NCI"},{"termName":"2-(2,3,5-Tri-O-acetyl-beta-D-ribofuranosyl)-as-triazine-3,5(2H,4H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"6-Azauridine Triacetate","termGroup":"SY","termSource":"NCI"},{"termName":"Azauridine Triacetate","termGroup":"SY","termSource":"NCI"},{"termName":"Triacetyl 6-azuridine","termGroup":"SN","termSource":"NCI"},{"termName":"Triazure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169-64-4"},{"name":"Chemical_Formula","value":"C14H17N3O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K1U80DO9EB"},{"name":"Legacy Concept Name","value":"Azauridine_Triacetate"},{"name":"Maps_To","value":"Azaribine"},{"name":"NCI_Drug_Dictionary_ID","value":"39155"},{"name":"NSC Number","value":"67239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39155"},{"name":"PDQ_Open_Trial_Search_ID","value":"39155"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052757"}]}}{"C289":{"preferredName":"Azaserine","code":"C289","definitions":[{"definition":"A naturally occurring serine derivative diazo compound with antineoplastic properties, Azaserine functions as a purine antagonist and glutamine analogue (glutamine amidotransferase inhibitor) that competitively inhibits pathways in which glutamine is metabolized. An antibiotic and antitumor agent, Azaserine is used in clinical studies as a potential antineoplastic agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azaserine","termGroup":"PT","termSource":"NCI"},{"termName":"AZS","termGroup":"AB","termSource":"NCI"},{"termName":"CL-337","termGroup":"CN","termSource":"NCI"},{"termName":"CN-15757","termGroup":"CN","termSource":"NCI"},{"termName":"Diazoacetate (Ester) L-Serine","termGroup":"SY","termSource":"NCI"},{"termName":"Diazoacetic Acid Ester with Serine","termGroup":"SY","termSource":"NCI"},{"termName":"Diazoacetylserine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Azaserine","termGroup":"SN","termSource":"NCI"},{"termName":"L-diazoacetate (ester) serine","termGroup":"SN","termSource":"NCI"},{"termName":"L-serine diazoacetate (ester)","termGroup":"SN","termSource":"NCI"},{"termName":"O-diazoacetyl-L-serine","termGroup":"SN","termSource":"NCI"},{"termName":"P-165","termGroup":"CN","termSource":"NCI"},{"termName":"Serine Diazoacetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"115-02-6"},{"name":"Chemical_Formula","value":"C5H7N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"87299V3Q9W"},{"name":"Legacy Concept Name","value":"Azaserine"},{"name":"Maps_To","value":"Azaserine"},{"name":"NCI_Drug_Dictionary_ID","value":"39156"},{"name":"NSC Number","value":"742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39156"},{"name":"PDQ_Open_Trial_Search_ID","value":"39156"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004480"}]}}{"C1347":{"preferredName":"Azimexon","code":"C1347","definitions":[{"definition":"Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azimexon","termGroup":"PT","termSource":"NCI"},{"termName":"2-Aziridinecarboxamide, 1-[1-(2-cyano-1-aziridinyl)-1-methylethyl]","termGroup":"SN","termSource":"NCI"},{"termName":"2-Cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane","termGroup":"SN","termSource":"NCI"},{"termName":"AZ","termGroup":"AB","termSource":"NCI"},{"termName":"Azimexone","termGroup":"SY","termSource":"NCI"},{"termName":"BM 12.531","termGroup":"CN","termSource":"NCI"},{"termName":"BM12531","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64118-86-1"},{"name":"Chemical_Formula","value":"C9H14N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4NJ842U6BZ"},{"name":"Legacy Concept Name","value":"Azimexon"},{"name":"Maps_To","value":"Azimexon"},{"name":"NCI_Drug_Dictionary_ID","value":"39159"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39159"},{"name":"PDQ_Open_Trial_Search_ID","value":"39159"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0104835"}]}}{"C29404":{"preferredName":"Aziridinylbenzoquinone RH1","code":"C29404","definitions":[{"definition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aziridinylbenzoquinone RH1","termGroup":"PT","termSource":"NCI"},{"termName":"2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"RH1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"RH1"},{"name":"Maps_To","value":"Aziridinylbenzoquinone RH1"},{"name":"NCI_Drug_Dictionary_ID","value":"580840"},{"name":"NSC Number","value":"697726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580840"},{"name":"PDQ_Open_Trial_Search_ID","value":"580840"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0764431"}]}}{"C28803":{"preferredName":"Azotomycin","code":"C28803","definitions":[{"definition":"An antineoplastic-antibiotic diazo analog of L-glutamine isolated from the bacterium Streptomyces ambofaciens.  Azotomycin inhibits glutamine-dependent enzymes involved in purine and pyrimidine biosynthesis, resulting in inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azotomycin","termGroup":"PT","termSource":"NCI"},{"termName":"A 10270B","termGroup":"CN","termSource":"NCI"},{"termName":"Diazomycin B","termGroup":"SY","termSource":"NCI"},{"termName":"Duazomycin B","termGroup":"SY","termSource":"NCI"},{"termName":"L-Norleucine, 6-diazo-N-(6-diazo-N-L-gamma-glutamyl-5-oxo-L-norleucyl)-5-oxo- (8CI 9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7644-67-9"},{"name":"Chemical_Formula","value":"C17H23N7O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6TQY580E8M"},{"name":"Legacy Concept Name","value":"Azotomycin"},{"name":"Maps_To","value":"Azotomycin"},{"name":"NSC Number","value":"56654"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052821"}]}}{"C85480":{"preferredName":"Azurin:50-77 Cell Penetrating Peptide p28","code":"C85480","definitions":[{"definition":"A water-soluble, amphipathic, 28 amino acid (amino acids 50-77), 2.9 kD fragment peptide (p28) derived from the protein azurin with potential antineoplastic and antiangiogenic activities. Although the mechanism has yet to be fully elucidated, the preferential cellular uptake of azurin-derived cell-penetrating peptide p28 by tumor cells and endothelial cells is likely via caveolae-mediated endocytosis; the C-terminal 18 amino acid residues (50-67) appear to be responsible for this preferential uptake. After cell entry, the first 12 amino acid residues interact with tumor suppressor p53 and form a p28:p53 complex, which may result in a reduction of proteasomal degradation of p53, increased p53 levels, and p53-mediated cell cycle inhibition and apoptosis. Azurin is a cupredoxin secreted by the bacterium Pseudomonas aeruginosa. Cell penetrating peptides (CPPs) are cationic and/or amphipathic peptides, typically less than 30 amino acids in length, that can penetrate cell membranes easily and may transport molecular cargo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azurin:50-77 Cell Penetrating Peptide p28","termGroup":"PT","termSource":"NCI"},{"termName":"Azurin-Derived Cell Penetrating Peptide p28","termGroup":"SY","termSource":"NCI"},{"termName":"Azurin:50-77 CPP p28","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897026-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H4QZU9L323"},{"name":"Maps_To","value":"Azurin:50-77 Cell Penetrating Peptide p28"},{"name":"NCI_Drug_Dictionary_ID","value":"647827"},{"name":"NCI_META_CUI","value":"CL412365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647827"},{"name":"PDQ_Open_Trial_Search_ID","value":"647827"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61311":{"preferredName":"B-Raf/VEGFR-2 Inhibitor RAF265","code":"C61311","definitions":[{"definition":"A substance being studied in the treatment of melanoma. CHIR-265 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It is a type of Raf kinase inhibitor and angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"B-Raf/VEGFR-2 Inhibitor RAF265","termGroup":"PT","termSource":"NCI"},{"termName":"CHIR-265","termGroup":"CN","termSource":"NCI"},{"termName":"RAF 265","termGroup":"CN","termSource":"NCI"},{"termName":"RAF-265","termGroup":"CN","termSource":"NCI"},{"termName":"RAF265","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"927880-90-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8O434L3768"},{"name":"Legacy Concept Name","value":"CHIR-265"},{"name":"Maps_To","value":"B-Raf/VEGFR-2 Inhibitor RAF265"},{"name":"NCI_Drug_Dictionary_ID","value":"484456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"484456"},{"name":"PDQ_Open_Trial_Search_ID","value":"484456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831810"}]}}{"C155974":{"preferredName":"Babaodan Capsule","code":"C155974","definitions":[{"definition":"An orally available mixed powder of traditional Chinese medicine containing eight constituents including natural calculus bovis, snake gall, antelope horn, pearl, musk, radix notoginseng, and other as of yet not disclosed ingredients, with potential antifibrotic, immunomodulatory, and antineoplastic activities. Upon oral administration, babaodan may ameliorate substance-induced liver injury and fibrosis, and inhibit lipopolysaccharide (LPS)-induced hepatic stellate cell (HSC) activation and proliferation through toll-like receptor 4 (TLR4)/nuclear factor-kappa B and TLR4/extracellular-signal-regulated kinase (ERK) pathways. Babaodan may, through an as of yet not elucidated mechanism, enhance the efficacy of chemotherapeutic drugs and may inhibit the occurrence and development of certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Babaodan Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Babao Dan","termGroup":"SY","termSource":"NCI"},{"termName":"BBD","termGroup":"AB","termSource":"NCI"},{"termName":"BD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Babaodan Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"795030"},{"name":"NCI_META_CUI","value":"CL562711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795030"},{"name":"PDQ_Open_Trial_Search_ID","value":"795030"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77694":{"preferredName":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen","code":"C77694","synonyms":[{"termName":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin Live Antigen, B","termGroup":"SY","termSource":"NCI"},{"termName":"Immucyst","termGroup":"BR","termSource":"NCI"},{"termName":"Mycobacterium bovis BCG Substrain Connaught","termGroup":"SY","termSource":"NCI"},{"termName":"Mycobax","termGroup":"BR","termSource":"NCI"},{"termName":"TheraCys","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5H5854UBMZ"},{"name":"Legacy Concept Name","value":"Bacillus_Calmette-Guerin_Live_Antigen_B"},{"name":"Maps_To","value":"Bacillus Calmette-Guerin Substrain Connaught Live Antigen"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0255289"}]}}{"C28850":{"preferredName":"Bactobolin","code":"C28850","definitions":[{"definition":"A 3-dichloromethylactinobolin antineoplastic antibiotic isolated from various Pseudomonas bacterial species.  BN-183 induces apoptosis via a caspase-dependent pathway.  This agent also has immunomodulatory properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bactobolin","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Bactobolin","termGroup":"SY","termSource":"NCI"},{"termName":"2-Amino-N-[3-(dichloromethyl)-3,4,4a,5,6,7- hexahydro-5,6,8-trihydroxy-3-methyl-1-oxo-1H-2- benzopyran-4-yl], Propanamide","termGroup":"SN","termSource":"NCI"},{"termName":"Antibiotic BN 183B","termGroup":"SY","termSource":"NCI"},{"termName":"BN 183B","termGroup":"CN","termSource":"NCI"},{"termName":"Y 12278","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72615-20-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EOF7S67HS2"},{"name":"Legacy Concept Name","value":"Bactobolin"},{"name":"Maps_To","value":"Bactobolin"},{"name":"NSC Number","value":"325014"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052913"}]}}{"C62516":{"preferredName":"Bafetinib","code":"C62516","definitions":[{"definition":"An orally active 2-phenylaminopyrimidine derivative with potential antineoplastic activity. INNO-406 specifically binds to and inhibits the Bcr/Abl fusion protein tyrosine kinase, an abnormal enzyme produced by Philadelphia chromosomal translocation associated with chronic myeloid leukemia (CML). Furthermore, this agent also inhibits the Src-family member Lyn tyrosine kinase, upregulated in imatinib-resistant CML cells and in a variety of solid cancer cell types. The inhibitory effect of INNO-406 on these specific tyrosine kinases decreases cellular proliferation and induces apoptosis. A high percentage of CML patients are refractory to imatinib, which sometimes results from point mutations occurring in the kinase domain of the Bcr/Abl fusion product. Due to its dual inhibitory activity, INNO-406 has been shown to overcome this particular drug resistance and to be a potent and effective agent in the treatment of imatinib-resistant CML.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bafetinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CNS-9","termGroup":"CN","termSource":"NCI"},{"termName":"Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor INNO-406","termGroup":"SY","termSource":"NCI"},{"termName":"INNO-406","termGroup":"CN","termSource":"NCI"},{"termName":"NS-187","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"859212-16-1"},{"name":"Chemical_Formula","value":"C30H31F3N8O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NVW4Z03I9B"},{"name":"Legacy Concept Name","value":"INNO-406"},{"name":"Maps_To","value":"Bafetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"500041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500041"},{"name":"PDQ_Open_Trial_Search_ID","value":"500041"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607225"}]}}{"C91094":{"preferredName":"Balixafortide","code":"C91094","definitions":[{"definition":"An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Balixafortide binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Balixafortide","termGroup":"PT","termSource":"NCI"},{"termName":"Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his Cyclic (2->9)-disulfide","termGroup":"SY","termSource":"NCI"},{"termName":"POL6326","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1051366-32-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PRC974M49B"},{"name":"Maps_To","value":"Balixafortide"},{"name":"NCI_Drug_Dictionary_ID","value":"672350"},{"name":"NCI_META_CUI","value":"CL421480"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672350"},{"name":"PDQ_Open_Trial_Search_ID","value":"672350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129374":{"preferredName":"Baltaleucel-T","code":"C129374","definitions":[{"definition":"A preparation of autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (CTLs), which have specific reactivity to the EBV antigens, latent membrane proteins (LMP) 1 (LMP1) and 2 (LMP2), EBV nuclear antigen (EBNA) and BamHI-A rightward frame-1 (BARF1), with potential immunomodulating and antineoplastic activities. Upon administration, baltaleucel-T targets and binds to EBV-expressing cancer cells specifically expressing the targeted antigens. This may kill LMP1/LMP2/EBNA/BARF1-expressing EBV-associated cancer cells. LMP1, LMP2, EBNA and BARF1 are tumor-associated antigens (TAAs) that are specifically associated with EBV infection, and play key roles in the proliferation of a variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Baltaleucel-T","termGroup":"PT","termSource":"NCI"},{"termName":"Baltaleucel T","termGroup":"SY","termSource":"NCI"},{"termName":"CMD-003","termGroup":"CN","termSource":"NCI"},{"termName":"Epstein Barr Virus-specific LMP1/LMP2/EBNABARF1-targeting Autologous Cytotoxic T-lymphocytes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F9670LP52I"},{"name":"Maps_To","value":"Baltaleucel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"783439"},{"name":"NCI_META_CUI","value":"CL512344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783439"},{"name":"PDQ_Open_Trial_Search_ID","value":"783439"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79528":{"preferredName":"Banoxantrone","code":"C79528","definitions":[{"definition":"A bioreductive, alkylaminoanthraquinone prodrug with antineoplastic activity. Under hypoxic conditions, often seen in solid tumors, banoxantrone (AQ4N) is converted and activated by cytochrome P450 enzymes, which are upregulated in certain tumors, to the cytotoxic DNA-binding agent AQ4. Banoxantrone intercalates into and crosslinks DNA, and inhibits topoisomerase II. This results in an inhibition of DNA replication and repair in tumor cells. Combined with conventional therapeutic agents, both oxygenic and hypoxic regions of tumors can be targeted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Banoxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Anthracenedione, 1,4-bis((2-(dimethylamino)ethyl)amino)-5,8-dihydroxy-, N,N'-dioxide","termGroup":"SN","termSource":"NCI"},{"termName":"AQ 4N","termGroup":"CN","termSource":"NCI"},{"termName":"Aq4N","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"136470-65-0"},{"name":"Chemical_Formula","value":"C22H28N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W5H7E45YT3"},{"name":"Legacy Concept Name","value":"Banoxantrone"},{"name":"Maps_To","value":"Banoxantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"393464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"393464"},{"name":"PDQ_Open_Trial_Search_ID","value":"393464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299316"}]}}{"C62502":{"preferredName":"Barasertib","code":"C62502","definitions":[{"definition":"An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity. Upon administration and rapid conversion from the prodrug form in plasma, AZD1152-HQPA specifically binds to and inhibits Aurora kinase B, which results in the disruption of spindle checkpoint functions and chromosome alignment and, so, the disruption of chromosome segregation and cytokinesis. Consequently, cell division and cell proliferation are inhibited and apoptosis is induced in Aurora kinase B-overexpressing tumor cells. Aurora kinase B, a serine/threonine protein kinase that functions in the attachment of the mitotic spindle to the centromere, is overexpressed in a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Barasertib","termGroup":"PT","termSource":"NCI"},{"termName":"1h-pyrazole-3-acetamide, 5-((7-(3-(ethyl(2-(phosphonooxy)ethyl)amino)propoxy)-4-quinazolinyl)amino)-n-(3-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Aurora Kinase Inhibitor AZD1152","termGroup":"SY","termSource":"NCI"},{"termName":"AZD 1152","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-1152","termGroup":"CN","termSource":"NCI"},{"termName":"AZD1152","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"722543-31-9"},{"name":"Chemical_Formula","value":"C26H31FN7O6P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"16XC2U7W8N"},{"name":"Legacy Concept Name","value":"AZD1152"},{"name":"Maps_To","value":"Barasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"496937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496937"},{"name":"PDQ_Open_Trial_Search_ID","value":"496937"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831923"}]}}{"C48382":{"preferredName":"Bardoxolone","code":"C48382","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. CDDO may block enzymes involved in inflammation and cancer growth. It is a type of antineoplastic plant product.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bardoxolone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"CDDO","termGroup":"AB","termSource":"NCI"},{"termName":"Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-","termGroup":"SN","termSource":"NCI"},{"termName":"RTA 401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Antineoplastic and anti-inflammatory"},{"name":"CAS_Registry","value":"218600-44-3"},{"name":"Chemical_Formula","value":"C31H41NO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7HT68L8941"},{"name":"Legacy Concept Name","value":"CDDO"},{"name":"Maps_To","value":"Bardoxolone"},{"name":"NCI_Drug_Dictionary_ID","value":"453589"},{"name":"NSC Number","value":"711193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453589"},{"name":"PDQ_Open_Trial_Search_ID","value":"453589"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762434"}]}}{"C98250":{"preferredName":"Bardoxolone Methyl","code":"C98250","definitions":[{"definition":"The methyl ester form of bardoxolone, a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bardoxolone Methyl","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate","termGroup":"SN","termSource":"NCI"},{"termName":"2-cyano-3,12-dioxoolean-1,9-dien-28-oic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"CDDO Methyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"CDDO-Me","termGroup":"AB","termSource":"NCI"},{"termName":"RTA 402","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"218600-53-4"},{"name":"Chemical_Formula","value":"C32H43NO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CEG1Q6OGU1"},{"name":"Maps_To","value":"Bardoxolone Methyl"},{"name":"NSC Number","value":"713200"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1100924"}]}}{"C127012":{"preferredName":"Baricitinib","code":"C127012","definitions":[{"definition":"An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Baricitinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 028050","termGroup":"CN","termSource":"NCI"},{"termName":"INCB028050","termGroup":"CN","termSource":"NCI"},{"termName":"LY 3009104","termGroup":"CN","termSource":"NCI"},{"termName":"LY3009104","termGroup":"CN","termSource":"NCI"},{"termName":"Olumiant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Emergency Use Authorization (EUA): for the treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)."},{"name":"CAS_Registry","value":"1187594-09-7"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ISP4442I3Y"},{"name":"Maps_To","value":"Baricitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"781527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781527"},{"name":"PDQ_Open_Trial_Search_ID","value":"781527"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4044947"}]}}{"C72716":{"preferredName":"Batabulin","code":"C72716","definitions":[{"definition":"A synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to beta tubulin, resulting in a disruption of microtubule polymerization, collapse of the cytoskeleton, cell cycle arrest, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called mitotic inhibitors. It inhibits the growth of cancer cells by preventing cell division.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Batabulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195533-53-0"},{"name":"Chemical_Formula","value":"C13H7F6NO3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T4NP8G3K6Q"},{"name":"Legacy Concept Name","value":"Batabulin"},{"name":"Maps_To","value":"Batabulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0767920"}]}}{"C1835":{"preferredName":"Batabulin Sodium","code":"C1835","definitions":[{"definition":"The sodium salt form of batabulin, a synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Batabulin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-1-methoxy-4-(pentafluorophenyl-sulfonamido)benzene, Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"T138067 Sodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195533-98-3"},{"name":"Chemical_Formula","value":"C13H6F6NO3S.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G04B77F772"},{"name":"Legacy Concept Name","value":"T138067"},{"name":"Maps_To","value":"Batabulin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43107"},{"name":"PDQ_Open_Trial_Search_ID","value":"43107"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0767921"}]}}{"C1529":{"preferredName":"Batimastat","code":"C1529","definitions":[{"definition":"A synthetic hydroxamate with potential antineoplastic activity.  Batimastat binds covalently to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Batimastat is a matrix metalloproteinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Batimastat","termGroup":"PT","termSource":"NCI"},{"termName":"(2R,3S)-N{4}-Hydroxy-N{1}-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide","termGroup":"SN","termSource":"NCI"},{"termName":"[4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide","termGroup":"SN","termSource":"NCI"},{"termName":"[4-(N-Hydroxyamino)-2R-isobutyl-3S-(thiophen-2-ylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide","termGroup":"SN","termSource":"NCI"},{"termName":"BB-94","termGroup":"CN","termSource":"NCI"},{"termName":"BB94","termGroup":"CN","termSource":"NCI"},{"termName":"Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130370-60-4"},{"name":"Chemical_Formula","value":"C23H31N3O4S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK349F52C9"},{"name":"Legacy Concept Name","value":"Batimastat"},{"name":"Maps_To","value":"Batimastat"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0215791"}]}}{"C49088":{"preferredName":"Bavituximab","code":"C49088","definitions":[{"definition":"A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bavituximab","termGroup":"PT","termSource":"NCI"},{"termName":"Chimeric Anti-Phosphotidylserine Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"PGN 401","termGroup":"CN","termSource":"NCI"},{"termName":"PGN-401","termGroup":"CN","termSource":"NCI"},{"termName":"PGN401","termGroup":"CN","termSource":"NCI"},{"termName":"Tarvacin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"648904-28-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q16CT95N25"},{"name":"Legacy Concept Name","value":"Chimeric_Anti-Phosphotidylserine_Monoclonal_Antibody"},{"name":"Maps_To","value":"Bavituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"450954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"450954"},{"name":"PDQ_Open_Trial_Search_ID","value":"450954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707382"}]}}{"C73598":{"preferredName":"Bazedoxifene","code":"C73598","definitions":[{"definition":"An indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration, bazedoxifene specifically binds to estrogen receptors in responsive tissues, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it either promotes or suppresses the transcription of estrogen-regulated genes. Bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues. Bazedoxifene functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bazedoxifene","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"TSE-424","termGroup":"SY","termSource":"NCI"},{"termName":"WAY 140424","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198481-32-2"},{"name":"Chemical_Formula","value":"C30H34N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q16TT9C5BK"},{"name":"Legacy Concept Name","value":"Bazedoxifene"},{"name":"Maps_To","value":"Bazedoxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"772911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772911"},{"name":"PDQ_Open_Trial_Search_ID","value":"772911"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346970"}]}}{"C107685":{"preferredName":"BC-819 Plasmid/Polyethylenimine Complex","code":"C107685","definitions":[{"definition":"A plasmid DNA encoding for the A fragment of Diphtheria Toxin (DTA) under the control of the H19 gene promoter (BC-819 or DTA-H19) and mixed with the transfectant polyethylenimine (PEI), with potential antineoplastic activity. Upon administration, the PEI moiety enhances the entry of the agent into rapidly dividing cells. Upon cell entry, activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells. H19, an oncofetal, regulatory RNA, is overexpressed in certain cancer cells while its expression in normal cells is minimal or absent; it plays a key role in cancer progression, angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BC-819 Plasmid/Polyethylenimine Complex","termGroup":"PT","termSource":"NCI"},{"termName":"BC-819/PEI","termGroup":"AB","termSource":"NCI"},{"termName":"DTA-H19/PEI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BC-819 Plasmid/Polyethylenimine Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"751613"},{"name":"NCI_META_CUI","value":"CL451873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751613"},{"name":"PDQ_Open_Trial_Search_ID","value":"751613"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83496":{"preferredName":"BCG Solution","code":"C83496","definitions":[{"definition":"A form of biological therapy for superficial (not invasive) bladder cancer. The solution is made from a weakened form of the bacterium Mycobacterium bovis (bacillus Calmette-Guerin) that does not cause disease but stimulates the body's immune system. A catheter is used to place the BCG solution into the bladder where it is held for about two hours.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A solution containing an attenuated, live culture preparation of the Bacillus Calmette Guerin (BCG) strain of Mycobacterium bovis with potential immunostimulating activity. Although the precise mechanism of action is unknown, upon intravesical administration, attenuated, live BCG bacteria in the solution come into direct contact with the bladder wall, inciting an antitumor granulomatous inflammatory reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCG Solution","termGroup":"PT","termSource":"NCI"},{"termName":"Bacillus Calmette Guerin Solution","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin Solution","termGroup":"SY","termSource":"NCI"},{"termName":"TICE BCG Solution","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BCG Solution"},{"name":"NCI_Drug_Dictionary_ID","value":"632465"},{"name":"NCI_META_CUI","value":"CL388460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632465"},{"name":"PDQ_Open_Trial_Search_ID","value":"632465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126694":{"preferredName":"BCG Tokyo-172 Strain Solution","code":"C126694","definitions":[{"definition":"A solution containing an attenuated, live culture preparation of the bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis obtained from the Pasteur Institute in 1924, with potential immunostimulating and antineoplastic activities. Although the precise mechanism of action is unknown, upon intravesical instillation through a catheter, the attenuated, live BCG bacteria in the BCG Tokyo-172 strain solution come into direct contact with the bladder wall and elicits a local, multifaceted immune response against the BCG antigens, which kills the bladder cancer cells. Previous vaccination with a systemic BCG vaccine may enhance the immune system's response against the BCG antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCG Tokyo-172 Strain Solution","termGroup":"PT","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin Tokyo-172 Strain Solution","termGroup":"SY","termSource":"NCI"},{"termName":"Immunobladder","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"267H8I71ZT"},{"name":"Maps_To","value":"BCG Tokyo-172 Strain Solution"},{"name":"NCI_Drug_Dictionary_ID","value":"788251"},{"name":"NCI_META_CUI","value":"CL508158"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788251"},{"name":"PDQ_Open_Trial_Search_ID","value":"788251"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C298":{"preferredName":"BCG Vaccine","code":"C298","definitions":[{"definition":"A tuberculosis vaccine containing bacillus Calmette-Guérin, a live attenuated strain of Mycobacterium bovis. There are many different strains of BCG vaccine, all of which were originally derived from one strain, but which now have very different properties.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","type":"DEFINITION","source":"NCI"},{"definition":"A weakened form of the bacterium Mycobacterium bovis (bacillus Calmette-Guerin) that does not cause disease. BCG is used in a solution to stimulate the immune system in the treatment of bladder cancer and as a vaccine to prevent tuberculosis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"BCG Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Bacille Calmette Guerin","termGroup":"SY","termSource":"NCI"},{"termName":"Bacille Calmette-Guerin Live","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillius Calmette-Guerin Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillus Calmette Guerin Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Bacillus Calmette-Guerin","termGroup":"SY","termSource":"NCI"},{"termName":"BCG","termGroup":"SY","termSource":"NCI"},{"termName":"BCG (Pasteur)","termGroup":"SY","termSource":"NCI"},{"termName":"BCG Tice","termGroup":"SY","termSource":"NCI"},{"termName":"Cultivo BCG","termGroup":"FB","termSource":"NCI"},{"termName":"Imovax BCG","termGroup":"FB","termSource":"NCI"},{"termName":"Live Intravesical BCG","termGroup":"SY","termSource":"NCI"},{"termName":"Monovax","termGroup":"FB","termSource":"NCI"},{"termName":"Mycobacterium bovis (Strain BCG)","termGroup":"SY","termSource":"NCI"},{"termName":"Oncotice","termGroup":"FB","termSource":"NCI"},{"termName":"Pacis","termGroup":"FB","termSource":"NCI"},{"termName":"Pastimmun","termGroup":"FB","termSource":"NCI"},{"termName":"TICE BCG","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Tuberculosis, immunization"},{"name":"Accepted_Therapeutic_Use_For","value":"Immunoadjuvant in Vaccine Therapy"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"BCG_Vaccine"},{"name":"Maps_To","value":"BCG Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43028"},{"name":"NSC Number","value":"116328"},{"name":"NSC Number","value":"116341"},{"name":"NSC Number","value":"614389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43028"},{"name":"PDQ_Open_Trial_Search_ID","value":"43028"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3257574"}]}}{"C156249":{"preferredName":"Lisaftoclax","code":"C156249","definitions":[{"definition":"An orally bioavailable and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lisaftoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lisaftoclax","termGroup":"PT","termSource":"NCI"},{"termName":"APG 2575","termGroup":"CN","termSource":"NCI"},{"termName":"APG-2575","termGroup":"CN","termSource":"NCI"},{"termName":"APG2575","termGroup":"CN","termSource":"NCI"},{"termName":"Bcl-2 Inhibitor APG 2575","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2180923-05-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OSL3FEZ1IF"},{"name":"Maps_To","value":"Bcl-2 Inhibitor APG 2575"},{"name":"NCI_Drug_Dictionary_ID","value":"795558"},{"name":"NCI_META_CUI","value":"CL562961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795558"},{"name":"PDQ_Open_Trial_Search_ID","value":"795558"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125603":{"preferredName":"Bcl-2 Inhibitor BCL201","code":"C125603","definitions":[{"definition":"A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bcl-2 Inhibitor BCL201","termGroup":"PT","termSource":"NCI"},{"termName":"BCL-201","termGroup":"CN","termSource":"NCI"},{"termName":"BCL201","termGroup":"CN","termSource":"NCI"},{"termName":"S-55746","termGroup":"CN","termSource":"NCI"},{"termName":"S55746","termGroup":"CN","termSource":"NCI"},{"termName":"Servier 1","termGroup":"CN","termSource":"NCI"},{"termName":"Servier-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448584-12-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W93257I68I"},{"name":"Maps_To","value":"Bcl-2 Inhibitor BCL201"},{"name":"NCI_Drug_Dictionary_ID","value":"778922"},{"name":"NCI_META_CUI","value":"CL504308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778922"},{"name":"PDQ_Open_Trial_Search_ID","value":"778922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158510":{"preferredName":"BCL2 Inhibitor VOB560","code":"C158510","definitions":[{"definition":"An inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon intravenous administration, Bcl-2 inhibitor VOB560 binds to and inhibits the activity of Bcl-2, thereby restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancer types and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCL2 Inhibitor VOB560","termGroup":"PT","termSource":"NCI"},{"termName":"Bcl-2 Inhibitor S65487","termGroup":"SY","termSource":"NCI"},{"termName":"S 65487","termGroup":"CN","termSource":"NCI"},{"termName":"S-65487","termGroup":"CN","termSource":"NCI"},{"termName":"S65487","termGroup":"CN","termSource":"NCI"},{"termName":"VOB 560","termGroup":"CN","termSource":"NCI"},{"termName":"VOB-560","termGroup":"CN","termSource":"NCI"},{"termName":"VOB560","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bcl-2 Inhibitor S65487"},{"name":"NCI_Drug_Dictionary_ID","value":"797175"},{"name":"NCI_META_CUI","value":"CL938051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797175"},{"name":"PDQ_Open_Trial_Search_ID","value":"797175"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28860":{"preferredName":"Bcl-Xs Adenovirus Vaccine","code":"C28860","definitions":[{"definition":"A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity.  Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected.  Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bcl-Xs Adenovirus Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bcl-Xs_Adenovirus_Vaccine"},{"name":"Maps_To","value":"Bcl-Xs Adenovirus Vaccine"},{"name":"NSC Number","value":"689513"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1511078"}]}}{"C175740":{"preferredName":"Alnuctamab","code":"C175740","definitions":[{"definition":"A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alnuctamab","termGroup":"PT","termSource":"NCI"},{"termName":"ALNUC","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 Bispecific Antibody CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA x CD3 T Cell Engaging Antibody CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA x CD3 T-cell Engaging Antibody CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3 T-cell Bi-specific Antibody CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3-directed Bispecific T-cell Engager Antibody CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"BCMAxCD3 BiTE Antibody CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"BCMAxCD3 TCB CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"Bi-specific Antibody CC-93269","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 986349","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986349","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986349","termGroup":"CN","termSource":"NCI"},{"termName":"CC 93269","termGroup":"CN","termSource":"NCI"},{"termName":"CC-93269","termGroup":"CN","termSource":"NCI"},{"termName":"CC93269","termGroup":"CN","termSource":"NCI"},{"termName":"EM901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2296827-07-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7OSV6M6T4D"},{"name":"Maps_To","value":"BCMA x CD3 T-cell Engaging Antibody CC-93269"},{"name":"NCI_Drug_Dictionary_ID","value":"795389"},{"name":"NCI_META_CUI","value":"CL1413154"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174748":{"preferredName":"Vodobatinib","code":"C174748","definitions":[{"definition":"An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vodobatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Methyl-3-quinolin-3-ylethynylbenzoic Acid N'-(2-chloro-6-methylbenzoyl) Hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"Bcr-Abl Kinase Inhibitor K0706","termGroup":"SY","termSource":"NCI"},{"termName":"K-0706","termGroup":"CN","termSource":"NCI"},{"termName":"K0706","termGroup":"CN","termSource":"NCI"},{"termName":"SCO-088","termGroup":"CN","termSource":"NCI"},{"termName":"SUN K706","termGroup":"CN","termSource":"NCI"},{"termName":"SUN-K0706","termGroup":"CN","termSource":"NCI"},{"termName":"SUN-K706","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11506","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1388803-90-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N8Q12KU2SW"},{"name":"Maps_To","value":"Bcr-Abl Kinase Inhibitor K0706"},{"name":"NCI_Drug_Dictionary_ID","value":"787015"},{"name":"NCI_META_CUI","value":"CL520597"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787015"},{"name":"PDQ_Open_Trial_Search_ID","value":"787015"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130033":{"preferredName":"Vamotinib","code":"C130033","definitions":[{"definition":"An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor, with potential antineoplastic activity. Designed to overcome resistance of tumor cells to second generation Bcr-Abl inhibitors, vamotinib targets and binds to the Bcr-Abl fusion oncoprotein, including those fusion proteins with the 'gatekeeper' resistance mutation T315I, an amino acid substitution at position 315 in Bcr-Abl from a threonine (T) to an isoleucine (I). This inhibits Bcr-Abl-mediated proliferation of, and enhances apoptosis in, Philadelphia chromosome-positive (Ph+) hematologic malignancies. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by leukemia cells that contain the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vamotinib","termGroup":"PT","termSource":"NCI"},{"termName":"Bcr-Abl Inhibitor PF-114","termGroup":"SY","termSource":"NCI"},{"termName":"Bcr-Abl Kinase Inhibitor PF-114","termGroup":"SY","termSource":"NCI"},{"termName":"PF-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1416241-23-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I8C3R768IZ"},{"name":"Maps_To","value":"Bcr-Abl Kinase Inhibitor PF-114"},{"name":"NCI_Drug_Dictionary_ID","value":"784962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784962"},{"name":"PDQ_Open_Trial_Search_ID","value":"784962"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4043268"}]}}{"C165549":{"preferredName":"Olverembatinib","code":"C165549","definitions":[{"definition":"An orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity. Upon administration,olverembatinib targets, binds to and inhibits the kinase activities of Bcr-Abl, AKT, c-Kit and ERK. This inhibits their mediated signaling pathways and inhibits proliferation of tumor cells in which these kinases are overexpressed and/or mutated. Bcr-Abl, c-Kit, AKT and ERK play key roles in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olverembatinib","termGroup":"PT","termSource":"NCI"},{"termName":"BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351","termGroup":"SY","termSource":"NCI"},{"termName":"GZD-824","termGroup":"CN","termSource":"NCI"},{"termName":"HQP 1351","termGroup":"CN","termSource":"NCI"},{"termName":"HQP-1351","termGroup":"CN","termSource":"NCI"},{"termName":"HQP1351","termGroup":"CN","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor HQP1351","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1257628-77-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"KV1M7Q3CBP"},{"name":"Maps_To","value":"BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351"},{"name":"NCI_Drug_Dictionary_ID","value":"799639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799639"},{"name":"PDQ_Open_Trial_Search_ID","value":"799639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659765"}]}}{"C1011":{"preferredName":"Beauvericin","code":"C1011","definitions":[{"definition":"A cyclic hexadepsipeptide antibiotic and mycotoxin isolated from the fungus Beauveria bassiana and various Fusarium fungal species.  As a potassium-specific ionophore, beauvericin A increases intracellular calcium concentrations and triggers DNA fragmentation and apoptosis through a calcium dependent caspase 3-sensitive pathway.  This agent has been studied as a potential antineoplastic agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beauvericin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26048-05-5"},{"name":"CHEBI_ID","value":"CHEBI:3000"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"26S048LS2R"},{"name":"Legacy Concept Name","value":"Beauvericin"},{"name":"Maps_To","value":"Beauvericin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053065"}]}}{"C1620":{"preferredName":"Becatecarin","code":"C1620","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called antitumor antibiotics and topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic diethylaminoethyl analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin.  Becatecarin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Becatecarin","termGroup":"PT","termSource":"NCI"},{"termName":"5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-181176","termGroup":"CN","termSource":"NCI"},{"termName":"BMY-27557-14","termGroup":"CN","termSource":"NCI"},{"termName":"DEAE-Rebeccamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Rebeccamycin Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"Rebeccamycin Analogue, Tartrate Salt","termGroup":"SY","termSource":"NCI"},{"termName":"XL119","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"119673-08-4"},{"name":"Chemical_Formula","value":"C33H34Cl2N4O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A60X6MBU6G"},{"name":"Legacy Concept Name","value":"Rebeccamycin_Analogue"},{"name":"Maps_To","value":"Becatecarin"},{"name":"NCI_Drug_Dictionary_ID","value":"42257"},{"name":"NSC Number","value":"655649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42257"},{"name":"PDQ_Open_Trial_Search_ID","value":"42257"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0936065"}]}}{"C73438":{"preferredName":"Belagenpumatucel-L","code":"C73438","definitions":[{"definition":"A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belagenpumatucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Lucanix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Belagenpumatucel-L"},{"name":"Maps_To","value":"Belagenpumatucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"590662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590662"},{"name":"PDQ_Open_Trial_Search_ID","value":"590662"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1739687"}]}}{"C91385":{"preferredName":"Belimumab","code":"C91385","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Benlysta","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(Human Cytokine BAFF) (Human Monoclonal LymphoStat-B Heavy Chain), Disulfide with Human Monoclonal LymphoStat-B lambda-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"LymphoStat-B","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Systemic Lupus Erythematosus"},{"name":"CAS_Registry","value":"356547-88-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"73B0K5S26A"},{"name":"Maps_To","value":"Belimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"680522"},{"name":"PDQ_Closed_Trial_Search_ID","value":"680522"},{"name":"PDQ_Open_Trial_Search_ID","value":"680522"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723401"}]}}{"C48812":{"preferredName":"Belinostat","code":"C48812","definitions":[{"definition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Belinostat blocks enzymes needed for cell division and may kill cancer cells. It also prevents the growth of blood vessels needed for tumors to grow and may make tumor cells more sensitive to other anticancer drugs. It is a type of histone deacetylase (HDAC) inhibitor, a type of angiogenesis inhibitor, and a type of chemosensitizer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Belinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Beleodaq","termGroup":"BR","termSource":"NCI"},{"termName":"PXD 101","termGroup":"CN","termSource":"NCI"},{"termName":"PXD-101","termGroup":"CN","termSource":"NCI"},{"termName":"PXD101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory peripheral T-cell lymphoma (PTCL)"},{"name":"CAS_Registry","value":"414864-00-9"},{"name":"CHEBI_ID","value":"CHEBI:61076"},{"name":"Chemical_Formula","value":"C15H14N2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F4H96P17NZ"},{"name":"Legacy Concept Name","value":"PXD101"},{"name":"Maps_To","value":"Belinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"454583"},{"name":"NSC Number","value":"726630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454583"},{"name":"PDQ_Open_Trial_Search_ID","value":"454583"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1948068"}]}}{"C66954":{"preferredName":"Belotecan Hydrochloride","code":"C66954","definitions":[{"definition":"A substance being studied in the treatment of small cell lung cancer and other types of cancer. It blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of camptothecin analog and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the semi-synthetic camptothecin analogue belotecan with potential antitumor activity. Belotecan binds to and inhibits the activity of topoisomerase I, stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Topoisomerase I is an enzyme that mediates reversible single-strand breaks in DNA during DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"CKD602 HCl","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"213819-48-8"},{"name":"Chemical_Formula","value":"C25H27N3O4.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01DZ4127G7"},{"name":"Legacy Concept Name","value":"Belotecan_Hydrochloride"},{"name":"Maps_To","value":"Belotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"537355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537355"},{"name":"PDQ_Open_Trial_Search_ID","value":"537355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762739"}]}}{"C120040":{"preferredName":"Bemarituzumab","code":"C120040","definitions":[{"definition":"A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration, bemarituzumab specifically binds to and inhibits FGFR2b on tumor cell surfaces, which prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing tumor cells. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bemarituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"FPA144","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1952272-74-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RJW23BQ0KW"},{"name":"Maps_To","value":"Bemarituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"767461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767461"},{"name":"PDQ_Open_Trial_Search_ID","value":"767461"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896858"}]}}{"C121854":{"preferredName":"Bemcentinib","code":"C121854","definitions":[{"definition":"An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration, bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, bemcentinib enhances chemo-sensitivity. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bemcentinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-Dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"AXL Inhibitor BGB324","termGroup":"SY","termSource":"NCI"},{"termName":"BGB 324","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-324","termGroup":"CN","termSource":"NCI"},{"termName":"BGB324","termGroup":"CN","termSource":"NCI"},{"termName":"R-428","termGroup":"CN","termSource":"NCI"},{"termName":"R428","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10631","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1037624-75-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0ICW2LX8AS"},{"name":"Maps_To","value":"Bemcentinib"},{"name":"NCI_Drug_Dictionary_ID","value":"771720"},{"name":"NCI_META_CUI","value":"CL777354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771720"},{"name":"PDQ_Open_Trial_Search_ID","value":"771720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131019":{"preferredName":"Bempegaldesleukin","code":"C131019","definitions":[{"definition":"A recombinant form of the endogenous cytokine interleukin-2 (IL-2) conjugated to six releasable polyethylene glycol (PEG) chains, with potential immunostimulating activity. Upon administration of bempegaldesleukin, the IL-2 moiety binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells primarily causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells. PEG conjugation prevents IL-2 binding to the IL2Ralpha subunit (IL2Ra) because signaling through IL2Ra activates CD4-positive regulatory, immunosuppressive T-cells (Tregs), which would suppress tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bempegaldesleukin","termGroup":"PT","termSource":"NCI"},{"termName":"Aldesleukin Prodrug NKTR-214","termGroup":"SY","termSource":"NCI"},{"termName":"NKTR-214","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1939126-74-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BNO1JG5MZC"},{"name":"Maps_To","value":"Bempegaldesleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"785056"},{"name":"NCI_META_CUI","value":"CL513468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785056"},{"name":"PDQ_Open_Trial_Search_ID","value":"785056"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73231":{"preferredName":"Benaxibine","code":"C73231","definitions":[{"definition":"A cyclophosphamide synergizer with antineoplastic, antidiabetic, antihypertensive and immunopotentiating activity. Benaxibine is active against integrin alph-4 precursor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benaxibine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Aminobenzoic acid-N-xyloside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"27661-27-4"},{"name":"Chemical_Formula","value":"C12H15NO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6EEL176LGY"},{"name":"Legacy Concept Name","value":"Benaxibine"},{"name":"Maps_To","value":"Benaxibine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048028"}]}}{"C73261":{"preferredName":"Bendamustine","code":"C73261","definitions":[{"definition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat chronic lymphocytic leukemia (CLL), to treat slow-growing B-cell non-Hodgkin lymphoma (NHL) that has gotten worse within 6 months of treatment with other anticancer drugs, and is being studied in the treatment of other types of cancer. Bendamustine may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bendamustine","termGroup":"PT","termSource":"NCI"},{"termName":"5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"SDX 105","termGroup":"CN","termSource":"NCI"},{"termName":"SDX-105","termGroup":"CN","termSource":"NCI"},{"termName":"SDX105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Lymphocytic Leukemia, Indolent B-cell non-Hodgkin Lymphoma"},{"name":"CAS_Registry","value":"16506-27-7"},{"name":"Chemical_Formula","value":"C16H21Cl2N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"9266D9P3PQ"},{"name":"Legacy Concept Name","value":"Bendamustine"},{"name":"Maps_To","value":"Bendamustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0525079"}]}}{"C61565":{"preferredName":"Bendamustine Hydrochloride","code":"C61565","definitions":[{"definition":"A drug used to treat chronic lymphocytic leukemia (CLL). It is also used to treat slow-growing B-cell non-Hodgkin lymphoma (NHL) that has gotten worse within 6 months of treatment with other anticancer drugs.It is being studied in the treatment of other types of cancer. Bendamustine hydrochloride may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bendamustine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-Benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Belrapzo","termGroup":"BR","termSource":"NCI"},{"termName":"Bendamustin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Bendeka","termGroup":"BR","termSource":"NCI"},{"termName":"CEP 18083","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-18083","termGroup":"CN","termSource":"NCI"},{"termName":"CEP18083","termGroup":"CN","termSource":"NCI"},{"termName":"Cytostasan Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Levact","termGroup":"FB","termSource":"NCI"},{"termName":"Ribomustin","termGroup":"FB","termSource":"NCI"},{"termName":"SyB L-0501","termGroup":"CN","termSource":"NCI"},{"termName":"Treakisym","termGroup":"FB","termSource":"NCI"},{"termName":"Treanda","termGroup":"BR","termSource":"NCI"},{"termName":"VIVIMUSTA","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia"},{"name":"CAS_Registry","value":"3543-75-7"},{"name":"Chemical_Formula","value":"C16H21Cl2N3O2.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"981Y8SX18M"},{"name":"Legacy Concept Name","value":"Bendamustine_Hydrochloride"},{"name":"Maps_To","value":"Bendamustine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"350251"},{"name":"NSC Number","value":"138783"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350251"},{"name":"PDQ_Open_Trial_Search_ID","value":"350251"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0772139"}]}}{"C124053":{"preferredName":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107","code":"C124053","definitions":[{"definition":"A nanoparticle-based formulation containing the alkyl ester of bendamustine, a bifunctional mechlorethamine derivative, encapsulated in human serum albumin (HSA), with potential alkylating and antineoplastic activities. Upon administration of the alkyl ester bendamustine-containing nanoparticle formulation RXDX-107, the nanoparticle formulation permits high concentrations of the alkyl ester of bendamustine be localized at the tumor site. The modified bendamustine alkylates and crosslinks macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-40125","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX 107","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1456608-94-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22C7JIO84O"},{"name":"Maps_To","value":"Bendamustine-containing Nanoparticle-based Formulation RXDX-107"},{"name":"NCI_Drug_Dictionary_ID","value":"776266"},{"name":"NCI_META_CUI","value":"CL498407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776266"},{"name":"PDQ_Open_Trial_Search_ID","value":"776266"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107164":{"preferredName":"Benzaldehyde Dimethane Sulfonate","code":"C107164","definitions":[{"definition":"A dimethane sulfonate derivative and alkylating agent with a structure similar to other alkylating agents such as chlorambucil, busulfan and melphalan, with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, benzaldehyde dimethane sulfonate alkylates DNA, which results in DNA double strand breaks, inhibition of DNA replication, cell cycle arrest and cell death. In addition, this agent is metabolized by the enzyme aldehyde dehydrogenase (ALDH) into the active carboxylic acid metabolite benzoic acid dimethane sulfonate (BA), which further contributes to its alkylating activity. Unlike other alkylating agents, benzaldehyde dimethane sulfonate has demonstrated antitumor activity in renal cell carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benzaldehyde Dimethane Sulfonate","termGroup":"PT","termSource":"NCI"},{"termName":"BEN","termGroup":"AB","termSource":"NCI"},{"termName":"DMS612","termGroup":"CN","termSource":"NCI"},{"termName":"NSC 281612","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56967-08-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96B0BRI1JU"},{"name":"Maps_To","value":"Benzaldehyde Dimethane Sulfonate"},{"name":"NCI_Drug_Dictionary_ID","value":"750365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750365"},{"name":"PDQ_Open_Trial_Search_ID","value":"750365"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661349"}]}}{"C2618":{"preferredName":"Benzoylphenylurea","code":"C2618","definitions":[{"definition":"A low molecular weight agent with antineoplastic activity. Benzoylphenylurea binds to the colchicine binding site on tubulin, thereby blocking tubulin polymerization and disrupting mitotic function.  This agent also inhibits DNA polymerase, and has been shown to arrest leukemia cells in the G1-S transition phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of antitubulin agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Benzoylphenylurea","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-(aminocarbonyl)-N-phenyl-","termGroup":"SY","termSource":"NCI"},{"termName":"BPU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1195179-46-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M10I9SO6RR"},{"name":"Legacy Concept Name","value":"Benzoylphenylurea"},{"name":"Maps_To","value":"Benzoylphenylurea"},{"name":"NCI_Drug_Dictionary_ID","value":"38213"},{"name":"NSC Number","value":"639829"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38213"},{"name":"PDQ_Open_Trial_Search_ID","value":"38213"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935907"}]}}{"C87331":{"preferredName":"Berberine Chloride","code":"C87331","definitions":[{"definition":"The orally bioavailable, hydrochloride salt form of berberine, a quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation.  In addition, berberine modulates lipid and glucose metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Berberine Chloride","termGroup":"PT","termSource":"NCI"},{"termName":"5,6-Dihydro-9,10-Dimethoxybenzo(G)-1,3-Benzodioxolo(5,6-A)Quinolizinium Chloride","termGroup":"SN","termSource":"NCI"},{"termName":"Berberine Chloride Dihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Berberine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Berberinum Chloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"633-65-8"},{"name":"Chemical_Formula","value":"C20H18NO4.Cl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UOT4O1BYV8"},{"name":"Maps_To","value":"Berberine Chloride"},{"name":"NCI_Drug_Dictionary_ID","value":"764359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764359"},{"name":"PDQ_Open_Trial_Search_ID","value":"764359"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0873019"}]}}{"C61568":{"preferredName":"Berubicin Hydrochloride","code":"C61568","definitions":[{"definition":"A substance being studied in the treatment of adult brain tumors. RTA 744 crosses the blood-brain barrier and blocks an enzyme needed for cancer growth. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the anthracycline derivative berubicin with potential antineoplastic activity. Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. Unlike other anthracycline derivatives, this agent crosses the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Berubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,10S)-10-((3-amino-4-O-benzyl-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)- 6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"RTA 744","termGroup":"CN","termSource":"NCI"},{"termName":"WP744","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"293736-67-1"},{"name":"Chemical_Formula","value":"C34H35NO11.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BA3X03948"},{"name":"Legacy Concept Name","value":"RTA_744"},{"name":"Maps_To","value":"Berubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"491929"},{"name":"NCI_META_CUI","value":"CL364772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"491929"},{"name":"PDQ_Open_Trial_Search_ID","value":"491929"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126805":{"preferredName":"BET Bromodomain Inhibitor ZEN-3694","code":"C126805","definitions":[{"definition":"An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ZEN-3694 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Bromodomain Inhibitor ZEN-3694","termGroup":"PT","termSource":"NCI"},{"termName":"BETi ZEN-3694","termGroup":"SY","termSource":"NCI"},{"termName":"ZEN 3694","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN-3694","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN003694","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1643947-30-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O28XHZ9UQ4"},{"name":"Maps_To","value":"BET Bromodomain Inhibitor ZEN-3694"},{"name":"NCI_Drug_Dictionary_ID","value":"780442"},{"name":"NCI_META_CUI","value":"CL507898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780442"},{"name":"PDQ_Open_Trial_Search_ID","value":"780442"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148415":{"preferredName":"BET Inhibitor ABBV-744","code":"C148415","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ABBV-744 preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor ABBV-744","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 744","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-744","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV744","termGroup":"CN","termSource":"NCI"},{"termName":"BD2-selective BET Inhibitor ABBV-744","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2138861-99-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9MX546E2SF"},{"name":"Maps_To","value":"BET Inhibitor ABBV-744"},{"name":"NCI_Drug_Dictionary_ID","value":"794664"},{"name":"NCI_META_CUI","value":"CL550999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794664"},{"name":"PDQ_Open_Trial_Search_ID","value":"794664"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121213":{"preferredName":"BET Inhibitor BAY1238097","code":"C121213","definitions":[{"definition":"An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BAY1238097 binds to the acetylated lysine recognition motifs on the BRD of BET proteins, thereby preventing the interaction between BET proteins and histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes. This leads to an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor BAY1238097","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1238097","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1238097","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1238097","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1564268-08-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M9ALI41OQR"},{"name":"Maps_To","value":"BET Inhibitor BAY1238097"},{"name":"NCI_Drug_Dictionary_ID","value":"769590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769590"},{"name":"PDQ_Open_Trial_Search_ID","value":"769590"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053666"}]}}{"C160257":{"preferredName":"Amredobresib","code":"C160257","definitions":[{"definition":"An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity. Upon oral administration, amredobresib binds to bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) as well as bromodomain testis-specific protein (BRDT), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, including Myc and other transcriptional regulators. Preventing the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amredobresib","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,4-Triazolo(4,3-a)pyrazin-8-amine, N,3-dimethyl-6-(6-(4-methyl-1-piperazinyl)-1-(phenylmethyl)-1hbenzimidazol-2-yl)","termGroup":"SN","termSource":"NCI"},{"termName":"6-(1-Benzyl-6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl)-N,3-dimethyl-(1,2,4)triazolo(4,3-a)pyrazin-8-amine","termGroup":"SN","termSource":"NCI"},{"termName":"BET inhibitor BI 894999","termGroup":"SY","termSource":"NCI"},{"termName":"BI 894999","termGroup":"CN","termSource":"NCI"},{"termName":"BI-894999","termGroup":"CN","termSource":"NCI"},{"termName":"BI894999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610044-98-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6XR3O34V2"},{"name":"Maps_To","value":"BET inhibitor BI 894999"},{"name":"NCI_META_CUI","value":"CL969271"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121849":{"preferredName":"Ezobresib","code":"C121849","definitions":[{"definition":"An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, ezobresib binds to the acetyl-lysine binding site in the BRD of BET proteins, thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes, resulting in an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ezobresib","termGroup":"PT","termSource":"NCI"},{"termName":"BET Inhibitor BMS-986158","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986158","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1800340-40-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X8BW0MQ5PI"},{"name":"Maps_To","value":"BET Inhibitor BMS-986158"},{"name":"NCI_Drug_Dictionary_ID","value":"771520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771520"},{"name":"PDQ_Open_Trial_Search_ID","value":"771520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053659"}]}}{"C151951":{"preferredName":"Trotabresib","code":"C151951","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trotabresib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl)-2-methylisoquinolin-1-one","termGroup":"SY","termSource":"NCI"},{"termName":"BET Inhibitor CC-90010","termGroup":"SY","termSource":"NCI"},{"termName":"CC 90010","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90010","termGroup":"CN","termSource":"NCI"},{"termName":"CC90010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1706738-98-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K424WH3WU0"},{"name":"Maps_To","value":"BET Inhibitor CC-90010"},{"name":"NCI_Drug_Dictionary_ID","value":"793170"},{"name":"NCI_META_CUI","value":"CL553179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793170"},{"name":"PDQ_Open_Trial_Search_ID","value":"793170"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111901":{"preferredName":"Pelabresib Anhydrous","code":"C111901","definitions":[{"definition":"The anhydrous form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of two bromodomains at the N-terminus, the BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelabresib Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"BET Inhibitor CPI-0610","termGroup":"SY","termSource":"NCI"},{"termName":"CPI-0610 Anhydrous","termGroup":"SY","termSource":"NCI"},{"termName":"CPI-232","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-267232","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1380087-89-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U4017GUQ06"},{"name":"Maps_To","value":"BET Inhibitor CPI-0610"},{"name":"Maps_To","value":"Pelabresib"},{"name":"NCI_Drug_Dictionary_ID","value":"753680"},{"name":"NCI_META_CUI","value":"CL454233"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753680"},{"name":"PDQ_Open_Trial_Search_ID","value":"753680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123733":{"preferredName":"BET Inhibitor FT-1101","code":"C123733","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor FT-1101","termGroup":"PT","termSource":"NCI"},{"termName":"CC 95775","termGroup":"CN","termSource":"NCI"},{"termName":"CC-95775","termGroup":"CN","termSource":"NCI"},{"termName":"CC95775","termGroup":"CN","termSource":"NCI"},{"termName":"FT-1101","termGroup":"CN","termSource":"NCI"},{"termName":"FT1101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET Inhibitor FT-1101"},{"name":"NCI_Drug_Dictionary_ID","value":"775905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775905"},{"name":"PDQ_Open_Trial_Search_ID","value":"775905"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053643"}]}}{"C126640":{"preferredName":"Alobresib","code":"C126640","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, alobresib binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alobresib","termGroup":"PT","termSource":"NCI"},{"termName":"(2-Cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1hbenzimidazol-4-yl)(dipyridin-2-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"GS 5829","termGroup":"CN","termSource":"NCI"},{"termName":"GS-5829","termGroup":"CN","termSource":"NCI"},{"termName":"GS5829","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637771-14-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3QBL0BLP3D"},{"name":"Maps_To","value":"Alobresib"},{"name":"Maps_To","value":"BET Inhibitor GS-5829"},{"name":"NCI_Drug_Dictionary_ID","value":"770347"},{"name":"NCI_META_CUI","value":"CL505073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770347"},{"name":"PDQ_Open_Trial_Search_ID","value":"770347"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125391":{"preferredName":"BET Inhibitor GSK2820151","code":"C125391","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor GSK2820151 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor GSK2820151","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 2820151","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2820151","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET Inhibitor GSK2820151"},{"name":"NCI_Drug_Dictionary_ID","value":"778693"},{"name":"NCI_META_CUI","value":"CL504160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778693"},{"name":"PDQ_Open_Trial_Search_ID","value":"778693"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121948":{"preferredName":"BET Inhibitor INCB054329","code":"C121948","definitions":[{"definition":"An inhibitor of the Bromodomain and Extra-Terminal (BET) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor INCB054329 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor INCB054329","termGroup":"PT","termSource":"NCI"},{"termName":"INCB054329","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET Inhibitor INCB054329"},{"name":"NCI_Drug_Dictionary_ID","value":"771984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771984"},{"name":"PDQ_Open_Trial_Search_ID","value":"771984"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053634"}]}}{"C128622":{"preferredName":"BET Inhibitor INCB057643","code":"C128622","definitions":[{"definition":"An inhibitor of the Bromodomain (BRD) and Extra-Terminal (BET) family of BRD-containing proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor INCB057643 binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, such as c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. BET proteins are transcriptional regulators that are overexpressed in certain tumor cells and play an important role in cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor INCB057643","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 057643","termGroup":"CN","termSource":"NCI"},{"termName":"INCB057643","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1820889-23-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"87TZD0JEBS"},{"name":"Maps_To","value":"BET Inhibitor INCB057643"},{"name":"NCI_Drug_Dictionary_ID","value":"780220"},{"name":"NCI_META_CUI","value":"CL507893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780220"},{"name":"PDQ_Open_Trial_Search_ID","value":"780220"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C112500":{"preferredName":"BET Inhibitor RO6870810","code":"C112500","definitions":[{"definition":"A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor RO6870810 binds to the acetylated lysine recognition motifs found in the bromodomain of BET proteins, which prevents the interaction between BET proteins and acetylated histones. This interaction disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET Inhibitor RO6870810","termGroup":"PT","termSource":"NCI"},{"termName":"Bromodomain and Extra-Terminal Protein Inhibitor RO6870810","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6146","termGroup":"CN","termSource":"NCI"},{"termName":"RG6146","termGroup":"CN","termSource":"NCI"},{"termName":"RO6870810","termGroup":"CN","termSource":"NCI"},{"termName":"TEN 010","termGroup":"CN","termSource":"NCI"},{"termName":"TEN-010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1349719-98-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TA3QN7788D"},{"name":"Maps_To","value":"BET Inhibitor RO6870810"},{"name":"NCI_Drug_Dictionary_ID","value":"755021"},{"name":"NCI_META_CUI","value":"CL454674"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755021"},{"name":"PDQ_Open_Trial_Search_ID","value":"755021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148138":{"preferredName":"BET-bromodomain Inhibitor ODM-207","code":"C148138","definitions":[{"definition":"An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ODM-207 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression of oncogenic drivers that are important for cell proliferation and survival. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that bind to acetylated lysine residues in histones and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BET-bromodomain Inhibitor ODM-207","termGroup":"PT","termSource":"NCI"},{"termName":"BET Inhibitor ODM-207","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodomain and Extraterminal Domain Protein Inhibitor ODM-207","termGroup":"SY","termSource":"NCI"},{"termName":"ODM 207","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-207","termGroup":"CN","termSource":"NCI"},{"termName":"ODM207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BET-bromodomain Inhibitor ODM-207"},{"name":"NCI_Drug_Dictionary_ID","value":"792467"},{"name":"NCI_META_CUI","value":"CL550806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792467"},{"name":"PDQ_Open_Trial_Search_ID","value":"792467"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2605":{"preferredName":"Beta Alethine","code":"C2605","definitions":[{"definition":"A disulfide agent that stimulates T and B-cell functions and exhibits anti-tumor and immunostimulant activity. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to a family of chemicals called disulfides.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Beta Alethine","termGroup":"PT","termSource":"NCI"},{"termName":"Alethine","termGroup":"SY","termSource":"NCI"},{"termName":"Beta-alanyl-cysteamine Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"BetaLT","termGroup":"BR","termSource":"NCI"},{"termName":"Betathine","termGroup":"BR","termSource":"NCI"},{"termName":"N,N'-(Dithiodiethylene)bis(3-aminopropionamide)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"646-08-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LY583605Y8"},{"name":"Legacy Concept Name","value":"Beta_Alethine"},{"name":"Maps_To","value":"Beta Alethine"},{"name":"NCI_Drug_Dictionary_ID","value":"38126"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38126"},{"name":"PDQ_Open_Trial_Search_ID","value":"38126"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0290021"}]}}{"C1016":{"preferredName":"Beta-Carotene","code":"C1016","definitions":[{"definition":"A naturally-occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities.  As an anti-oxidant, beta carotene inhibits free-radical damage to DNA.  This agent also induces cell differentiation and apoptosis of some tumor cell types, particularly in early stages of tumorigenesis, and enhances immune system activity by stimulating the release of natural killer cells, lymphocytes, and monocytes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance found in yellow and orange fruits and vegetables and in dark green, leafy vegetables. The body can make vitamin A from beta carotene. Beta carotene is being studied in the prevention of some types of cancer. It is a type of antioxidant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Carotenoid consisting of a cyclic structure on each end with additional double bonds at the number 5 and 5' carbon atoms of the cyclic structures.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Beta-Carotene","termGroup":"PT","termSource":"NCI"},{"termName":"Beta Carotene","termGroup":"SY","termSource":"NCI"},{"termName":"Beta-carotene","termGroup":"SY","termSource":"NCI"},{"termName":"Lumitene","termGroup":"BR","termSource":"NCI"},{"termName":"Solatene","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dietary supplement; prevention of photosensitivity reactions in patients with erythropoietic protoporphyria; polymorphous light eruption; chemoprevention for cardiovascular disease and cancer"},{"name":"CAS_Registry","value":"7235-40-7"},{"name":"CHEBI_ID","value":"CHEBI:17579"},{"name":"Chemical_Formula","value":"C40H56"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01YAE03M7J"},{"name":"INFOODS","value":"CARTB"},{"name":"Legacy Concept Name","value":"Beta_Carotene"},{"name":"Maps_To","value":"Beta-Carotene"},{"name":"NCI_Drug_Dictionary_ID","value":"40992"},{"name":"NSC Number","value":"62794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40992"},{"name":"PDQ_Open_Trial_Search_ID","value":"40992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"UMLS_CUI","value":"C0053396"},{"name":"Unit","value":"mcg"},{"name":"USDA_ID","value":"321"}]}}{"C103177":{"preferredName":"Beta-elemene","code":"C103177","definitions":[{"definition":"One of the isomers of elemene, a lipid soluble sesquiterpene and the active component isolated from the Chinese medicinal herb Rhizoma zedoariae with potential antineoplastic and chemopreventive activities. Although the exact mechanism of action through which beta-elemene exerts its effect has yet to be fully elucidated, this agent appears to induce apoptosis through different mechanisms of action and induces cell cycle arrest at different stages based on the tumor cell type involved. Beta-elemene may sensitize cancer cells to other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-elemene","termGroup":"PT","termSource":"NCI"},{"termName":"(1alpha,2beta,4beta)-1-Methyl-2,4-bis(methylvinyl)-1- vinylcyclohexane","termGroup":"SN","termSource":"NCI"},{"termName":"(1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Beta-elemene"},{"name":"NCI_Drug_Dictionary_ID","value":"740161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740161"},{"name":"PDQ_Open_Trial_Search_ID","value":"740161"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1101268"}]}}{"C2678":{"preferredName":"Beta-Glucan","code":"C2678","definitions":[{"definition":"A polysaccharide isolated from the cell walls of bacteria, plants, and fungi with immunostimulant and antineoplastic activities. In a solubilized form, beta-glucan binds to a lectin site within complement receptor 3 (CR3) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to complement 3 (iC3b)-coated tumors. Thus, the attachment of beta-glucan to CR3 of circulating leukocytes simulates leukocytes to kill iC3b-coated tumor cells in the same way as they kill iC3b-coated yeast. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance found in bacteria, plants, and certain foods, such as baker's yeast, cereal grains, and mushrooms. It is a type of polysaccharide that is made of a string of glucose (sugar) molecules joined together. Beta-glucan may stimulate the immune system and help kill cancer cells. It is being studied in the treatment of cancer. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Beta-Glucan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:28793"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beta-Glucan"},{"name":"Maps_To","value":"Beta-Glucan"},{"name":"NCI_Drug_Dictionary_ID","value":"38642"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38642"},{"name":"PDQ_Open_Trial_Search_ID","value":"38642"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134651"}]}}{"C82657":{"preferredName":"Beta-Glucan MM-10-001","code":"C82657","definitions":[{"definition":"A powder formulation containing a triple helix beta-glucan, isolated from the cell walls of the shiitake mushroom (Lentinula edodes), with potential immunostimulating activity. The beta-glucan in beta-glucan MM-10-001 binds to a lectin site within the complement receptor 3 (CR3 or iC3b receptor) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to iC3b-opsonized tumor cells. iC3b is the proteolyticly inactive product of the complement cleavage fragment C3b.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-Glucan MM-10-001","termGroup":"PT","termSource":"NCI"},{"termName":"MM-10-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Beta-Glucan_MM-10-001"},{"name":"Maps_To","value":"Beta-Glucan MM-10-001"},{"name":"NCI_Drug_Dictionary_ID","value":"636186"},{"name":"NCI_META_CUI","value":"CL388490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636186"},{"name":"PDQ_Open_Trial_Search_ID","value":"636186"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99146":{"preferredName":"Beta-lapachone Prodrug ARQ 761","code":"C99146","definitions":[{"definition":"A synthetic, soluble prodrug of beta-lapachone, a poorly soluble, ortho-naphthoquinone with potential antineoplastic and radiosensitizing activity. ARQ 761 is converted to beta-lapachone (b-lap) in vivo. When b-lap is activated by NAD(P)H:quinone oxidoreductase-1 (NQO1) this agent creates a futile oxidoreduction, generating highly reactive oxygen species (ROS) that results in DNA damage. The activation of b-lap also causes hyperactivation of poly (ADP-ribose) polymerase-1 (PARP-1), an enzyme that facilitates DNA repair, accompanied by rapid depletion of NAD+/ATP nucleotide levels. As a result, a caspase-independent and endoplasmic reticulum (ER) stress-induced mu-calpain-mediated cell death occurs in NQO1-overexpressing tumor cells. In addition, b-lap induces expression of the checkpoints activator E2F transcription factor 1 (E2F1) and thereby activates the E2F1-mediated checkpoint pathway that directly triggers apoptosis. As ARQ 761 is soluble and requires less solvent, this formulation may cause less hemolytic anemia associated with administration of the synthetic b-lap ARQ 501.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-lapachone Prodrug ARQ 761","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 761","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Beta-lapachone Prodrug ARQ 761"},{"name":"NCI_Drug_Dictionary_ID","value":"715599"},{"name":"NCI_META_CUI","value":"CL432960"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715599"},{"name":"PDQ_Open_Trial_Search_ID","value":"715599"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1350":{"preferredName":"Beta-Thioguanine Deoxyriboside","code":"C1350","definitions":[{"definition":"A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication.  This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo.  Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beta-Thioguanine Deoxyriboside","termGroup":"PT","termSource":"NCI"},{"termName":"1,9-dihydro-6H-purine-6-thione, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"2'-deoxythioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"2'-desoxy-6-thioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"6-Mercaptoguaninedeoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"9H-purine-6-thiol, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl) monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"B-TGDR","termGroup":"AB","termSource":"NCI"},{"termName":"Beta Thioguanine Deoxyriboside","termGroup":"SY","termSource":"NCI"},{"termName":"beta-2'-deoxy-6-thioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"beta-2'-deoxythioguanosine","termGroup":"SN","termSource":"NCI"},{"termName":"beta-2'-deoxythiol guanosine","termGroup":"SN","termSource":"NCI"},{"termName":"BTG","termGroup":"AB","termSource":"NCI"},{"termName":"thioguanine 9-beta-D-2'-deoxyriboside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64039-27-6"},{"name":"CAS_Registry","value":"789-61-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KR0RFB46DF"},{"name":"Legacy Concept Name","value":"Beta-Thioguanine_Deoxyriboside"},{"name":"Maps_To","value":"Beta-Thioguanine Deoxyriboside"},{"name":"NCI_Drug_Dictionary_ID","value":"39711"},{"name":"NSC Number","value":"71261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39711"},{"name":"PDQ_Open_Trial_Search_ID","value":"39711"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053376"}]}}{"C38126":{"preferredName":"Betulinic Acid","code":"C38126","definitions":[{"definition":"A pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial apogenic factors, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Betulinic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(3beta)-3-Hydroxy-lup-20(29)-en-28-oic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ALS-357","termGroup":"CN","termSource":"NCI"},{"termName":"Mairin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"472-15-1"},{"name":"Chemical_Formula","value":"C30H48O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4G6A18707N"},{"name":"Legacy Concept Name","value":"Betulinic_Acid"},{"name":"Maps_To","value":"Betulinic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"496932"},{"name":"NSC Number","value":"113090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496932"},{"name":"PDQ_Open_Trial_Search_ID","value":"496932"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053530"}]}}{"C2039":{"preferredName":"Bevacizumab","code":"C2039","definitions":[{"definition":"A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bevacizumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 215","termGroup":"CN","termSource":"NCI"},{"termName":"ABP-215","termGroup":"CN","termSource":"NCI"},{"termName":"ABP215","termGroup":"CN","termSource":"NCI"},{"termName":"Alymsys","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-VEGF Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VEGF Monoclonal Antibody SIBP04","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VEGF rhuMAb","termGroup":"SY","termSource":"NCI"},{"termName":"Avastin","termGroup":"BR","termSource":"NCI"},{"termName":"Aybintio","termGroup":"FB","termSource":"NCI"},{"termName":"BAT 1706","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-1706","termGroup":"CN","termSource":"NCI"},{"termName":"BAT1706","termGroup":"CN","termSource":"NCI"},{"termName":"BAT1706 Biosimilar","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab awwb","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar ABP 215","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar BAT1706","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar BEVZ92","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar BI 695502","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar CBT 124","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar CT-P16","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar FKB238","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar GB-222","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar HD204","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar HLX04","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar IBI305","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar LY01008","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar MIL60","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar Mvasi","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar MYL-1402O","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar QL 1101","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar QL1101","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar RPH-001","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar SCT501","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab Biosimilar Zirabev","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab-adcd","termGroup":"SY","termSource":"NCI"},{"termName":"Bevacizumab-maly","termGroup":"SY","termSource":"NCI"},{"termName":"BP102","termGroup":"CN","termSource":"NCI"},{"termName":"BP102 Biosimilar","termGroup":"SY","termSource":"NCI"},{"termName":"CT P16","termGroup":"CN","termSource":"NCI"},{"termName":"CT-P16","termGroup":"CN","termSource":"NCI"},{"termName":"CTP16","termGroup":"CN","termSource":"NCI"},{"termName":"Equidacent","termGroup":"FB","termSource":"NCI"},{"termName":"HD204","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Mvasi","termGroup":"BR","termSource":"NCI"},{"termName":"MYL-1402O","termGroup":"CN","termSource":"NCI"},{"termName":"Onbevzi","termGroup":"FB","termSource":"NCI"},{"termName":"QL1101","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Humanized Anti-VEGF Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"rhuMab-VEGF","termGroup":"AB","termSource":"NCI"},{"termName":"SCT501","termGroup":"CN","termSource":"NCI"},{"termName":"SIBP 04","termGroup":"CN","termSource":"NCI"},{"termName":"SIBP-04","termGroup":"CN","termSource":"NCI"},{"termName":"SIBP04","termGroup":"CN","termSource":"NCI"},{"termName":"Vegzelma","termGroup":"BR","termSource":"NCI"},{"termName":"Zirabev","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic Colorectal Cancer, Non-small Cell Lung Cancer, glioblastoma; Metastatic Renal Cell Carcinoma; persistent, recurrent or metastatic cervical cancer; epithelial ovarian, fallopian tube, or primary peritoneal cancer"},{"name":"CAS_Registry","value":"216974-75-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2S9ZZM9Q9V"},{"name":"Legacy Concept Name","value":"Bevacizumab"},{"name":"Maps_To","value":"Bevacizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"43234"},{"name":"NSC Number","value":"704865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43234"},{"name":"PDQ_Open_Trial_Search_ID","value":"43234"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796392"}]}}{"C1635":{"preferredName":"Bexarotene","code":"C1635","definitions":[{"definition":"A drug used to treat skin problems caused by cutaneous T-cell lymphoma that have not gotten better after other treatment. It is also being studied in the treatment of other types of cancer. Bexarotene is a type of retinoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bexarotene","termGroup":"PT","termSource":"NCI"},{"termName":"3-methyl TTNEB","termGroup":"SY","termSource":"NCI"},{"termName":"4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LGD 1069","termGroup":"CN","termSource":"NCI"},{"termName":"LGD-1069","termGroup":"CN","termSource":"NCI"},{"termName":"LGD1069","termGroup":"CN","termSource":"NCI"},{"termName":"Targretin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Oral or topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)."},{"name":"CAS_Registry","value":"153559-49-0"},{"name":"CHEBI_ID","value":"CHEBI:50859"},{"name":"Chemical_Formula","value":"C24H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A61RXM4375"},{"name":"Legacy Concept Name","value":"Bexarotene"},{"name":"Maps_To","value":"Bexarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"42117"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42117"},{"name":"PDQ_Open_Trial_Search_ID","value":"42117"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0765273"}]}}{"C131905":{"preferredName":"BF-200 Gel Formulation","code":"C131905","definitions":[{"definition":"A topical nanoemulsion-based gel formulation containing 5-aminolevulinic acid (ALA), a metabolic precursor of the photosensitizer protoporphyrin IX, with a potential application for enhanced photodynamic therapy (PDT) for various precancerous and malignant skin lesions. After topical administration of a thick layer of the ALA-based BF-200 gel formulation to the affected area, ALA penetrates the skin and is intracellularly converted to protoporphyrin IX (PpIX). Exposure of PpIX to the proper excitation wavelength of light generates singlet oxygen molecules, resulting in a local cytotoxic effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BF-200 Gel Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"BF-200","termGroup":"CN","termSource":"NCI"},{"termName":"BF-200 ALA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BF-200 Gel Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"786308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786308"},{"name":"PDQ_Open_Trial_Search_ID","value":"786308"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490787"}]}}{"C114384":{"preferredName":"BH3 Mimetic ABT-737","code":"C114384","definitions":[{"definition":"An orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic activities. ABT-737 binds to the hydrophobic groove of multiple members of the anti-apoptotic Bcl-2 protein family, including Bcl-2, Bcl-xl and Bcl-w. This inhibits the activity of these pro-survival proteins and restores apoptotic processes in tumor cells, via activation of Bak/Bax-mediated apoptosis. The pro-survival Bcl-2 proteins are overexpressed in many cancers and play important roles in the regulation of apoptosis. Their expression is associated with increased drug resistance and tumor cell survival. ABT-737 does not inhibit the pro-survival proteins Mcl-1, Bcl-B, Bfl-1 (A1); therefore, tumors that overexpress these Bcl-2 family proteins are resistant to ABT-737.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BH3 Mimetic ABT-737","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-737","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 4-(4-((4'-Chloro(1,1'-biphenyl)-2-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"852808-04-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z5NFR173NV"},{"name":"Maps_To","value":"BH3 Mimetic ABT-737"},{"name":"NCI_Drug_Dictionary_ID","value":"758552"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758552"},{"name":"PDQ_Open_Trial_Search_ID","value":"758552"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1570187"}]}}{"C425":{"preferredName":"Dianhydrogalactitol","code":"C425","definitions":[{"definition":"A bifunctional hexitol derivative with potential antineoplastic activity. Dianhydrogalactitol alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in disruption of DNA function and cell cycle arrest. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dianhydrogalactitol","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,5,6 dianhydrogalactitol","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:5, 6-diepoxydulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:5,6 dianhydrogalactitol","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:5,6-dianhydrodulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"Bi-functional Alkylating Agent VAL-083","termGroup":"SY","termSource":"NCI"},{"termName":"DAG","termGroup":"AB","termSource":"NCI"},{"termName":"dianhydrodulcitol","termGroup":"SY","termSource":"NCI"},{"termName":"diepoxydulcitol","termGroup":"SY","termSource":"NCI"},{"termName":"diepoxygalactitol","termGroup":"SY","termSource":"NCI"},{"termName":"dulcitol diepoxide","termGroup":"SY","termSource":"NCI"},{"termName":"Galactitol","termGroup":"SY","termSource":"NCI"},{"termName":"galactitol, 1,2:5,6-dianhydro- (8CI 9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"VAL-083","termGroup":"CN","termSource":"NCI"},{"termName":"VAL083","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23261-20-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4S465RYF7M"},{"name":"Legacy Concept Name","value":"Dianhydrogalactitol"},{"name":"Maps_To","value":"Bi-functional Alkylating Agent VAL-083"},{"name":"Maps_To","value":"Dianhydrogalactitol"},{"name":"NCI_Drug_Dictionary_ID","value":"39215"},{"name":"NSC Number","value":"132313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39215"},{"name":"PDQ_Open_Trial_Search_ID","value":"39215"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011967"}]}}{"C1599":{"preferredName":"Bicalutamide","code":"C1599","definitions":[{"definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antiandrogens.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bicalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline","termGroup":"SN","termSource":"NCI"},{"termName":"Casodex","termGroup":"BR","termSource":"NCI"},{"termName":"Cassotide","termGroup":"FB","termSource":"NCI"},{"termName":"Cosudex","termGroup":"FB","termSource":"NCI"},{"termName":"ICI 176,334","termGroup":"CN","termSource":"NCI"},{"termName":"ICI 176334","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide","termGroup":"SN","termSource":"NCI"},{"termName":"Utamide","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic prostate cancer"},{"name":"CAS_Registry","value":"90357-06-5"},{"name":"CHEBI_ID","value":"CHEBI:3090"},{"name":"Chemical_Formula","value":"C18H14F4N2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"A0Z3NAU9DP"},{"name":"Legacy Concept Name","value":"Bicalutamide"},{"name":"Maps_To","value":"Bicalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"41298"},{"name":"NSC Number","value":"722665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41298"},{"name":"PDQ_Open_Trial_Search_ID","value":"41298"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0285590"}]}}{"C111898":{"preferredName":"Bimiralisib","code":"C111898","definitions":[{"definition":"An orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Bimiralisib inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy. As mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase. By inhibiting mTOR to a lesser extent than PI3K, PQR309 does not interfere with the mTOR-mediated negative feedback loop on PI3K signaling. Blocking the negative feedback loop would potentially increase PI3K signaling and decrease therapeutic efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bimiralisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinamine, 5-(4,6-Di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"PQR-309","termGroup":"CN","termSource":"NCI"},{"termName":"PQR309","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1225037-39-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Z3QHB00LB"},{"name":"Maps_To","value":"Bimiralisib"},{"name":"NCI_Drug_Dictionary_ID","value":"753407"},{"name":"NCI_META_CUI","value":"CL454230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753407"},{"name":"PDQ_Open_Trial_Search_ID","value":"753407"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C589":{"preferredName":"Binetrakin","code":"C589","definitions":[{"definition":"A recombinant agent chemically identical to or similar to the endogenous cytokine interleukin-4 (IL-4). Produced primarily by activated T-cells, IL-4 binds to and activates its cell-surface receptor, stimulating the proliferation and differentiation of activated B-cells and enhancing their ability to present antigens to T-cells. As a potential immunotherapeutic agent, binetrakin also augments the effects of other cytokines on dendritic cells (DC), cytotoxic T lymphocytes (CTL), and tumor-infiltrating lymphocytes (TIL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Binetrakin","termGroup":"PT","termSource":"NCI"},{"termName":"B Cell Proliferating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Stimulatory Factor 1","termGroup":"SY","termSource":"NCI"},{"termName":"BCGF","termGroup":"AB","termSource":"NCI"},{"termName":"BCSF 1","termGroup":"AB","termSource":"NCI"},{"termName":"IL-4","termGroup":"AB","termSource":"NCI"},{"termName":"Interleukin 4 (Human) 129","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4","termGroup":"SY","termSource":"NCI"},{"termName":"Mast Cell Growth Factor-2","termGroup":"SY","termSource":"NCI"},{"termName":"MCGF 2","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Human IL-4","termGroup":"SY","termSource":"NCI"},{"termName":"RHIL-4","termGroup":"AB","termSource":"NCI"},{"termName":"SCH 93400","termGroup":"CN","termSource":"NCI"},{"termName":"T-Cell Growth Factor 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"207137-56-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"751635Z921"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-4"},{"name":"Maps_To","value":"Binetrakin"},{"name":"NCI_Drug_Dictionary_ID","value":"39324"},{"name":"NSC Number","value":"618085"},{"name":"NSC Number","value":"620211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39324"},{"name":"PDQ_Open_Trial_Search_ID","value":"39324"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522540"}]}}{"C84865":{"preferredName":"Binimetinib","code":"C84865","definitions":[{"definition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Binimetinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY 162","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY 438162","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-162","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-438162","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY162","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY438162","termGroup":"CN","termSource":"NCI"},{"termName":"MEK 162","termGroup":"CN","termSource":"NCI"},{"termName":"MEK-162","termGroup":"CN","termSource":"NCI"},{"termName":"MEK162","termGroup":"CN","termSource":"NCI"},{"termName":"Mektovi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation"},{"name":"CAS_Registry","value":"606143-89-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"181R97MR71"},{"name":"Maps_To","value":"Binimetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"653635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653635"},{"name":"PDQ_Open_Trial_Search_ID","value":"653635"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830125"}]}}{"C124229":{"preferredName":"Bintrafusp Alfa","code":"C124229","definitions":[{"definition":"A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bintrafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PDL1/TGFb Trap MSB0011359C","termGroup":"SY","termSource":"NCI"},{"termName":"M7824","termGroup":"SY","termSource":"NCI"},{"termName":"MSB0011359C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1918149-01-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NW9K8C1JN3"},{"name":"Maps_To","value":"Bintrafusp Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"795582"},{"name":"NCI_META_CUI","value":"CL502609"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795582"},{"name":"PDQ_Open_Trial_Search_ID","value":"795582"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103298":{"preferredName":"Birabresib","code":"C103298","definitions":[{"definition":"A synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity. Upon administration, birabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, including c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, the BET proteins BRD2, BRD3, BRD4 are transcriptional regulators that play an important role in cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Birabresib","termGroup":"PT","termSource":"NCI"},{"termName":"6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6S)-","termGroup":"SN","termSource":"NCI"},{"termName":"BRD 2/3/4 Inhibitor OTX015","termGroup":"SY","termSource":"NCI"},{"termName":"MK-8628","termGroup":"CN","termSource":"NCI"},{"termName":"OTX015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"202590-98-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X40LKS49S3"},{"name":"Maps_To","value":"Birabresib"},{"name":"NCI_Drug_Dictionary_ID","value":"742152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742152"},{"name":"PDQ_Open_Trial_Search_ID","value":"742152"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641185"}]}}{"C88295":{"preferredName":"Birinapant","code":"C88295","definitions":[{"definition":"A synthetic small molecule that is both a peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity. As a SMAC mimetic and IAP antagonist, birinapant selectively binds to and inhibits the activity of IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 (cIAP1) and 2 (cIAP2), with a greater effect on cIAP1 than cIAP2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells and inactivate the nuclear factor-kappa B (NF-kB)-mediated survival pathway. IAPs are overexpressed by many cancer cell types. They are able to suppress apoptosis by binding to, via their baculoviral lAP repeat (BIR) domains, and inhibiting active caspases-3, -7 and -9. IAP overexpression promotes both cancer cell survival and chemotherapy resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Birinapant","termGroup":"PT","termSource":"NCI"},{"termName":"Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-,(2S,2'S)-","termGroup":"SN","termSource":"NCI"},{"termName":"TL32711","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260251-31-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6O4Z07B57R"},{"name":"Maps_To","value":"Birinapant"},{"name":"NCI_Drug_Dictionary_ID","value":"657946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"657946"},{"name":"PDQ_Open_Trial_Search_ID","value":"657946"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658709"}]}}{"C62514":{"preferredName":"Tiomolibdate Choline","code":"C62514","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may prevent the growth of new blood vessels that tumors need to grow. ATN-224 also blocks enzymes that cells need to divide and grow, and it may kill cancer cells. It is a type of antiangiogenesis agent and a type of superoxide dismutase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active second generation tetrathiomolybdate analog with anti-angiogenic and antineoplastic activities. Tiomolibdate choline selectively chelates the copper ion in superoxide dismutase 1 (SOD1) in endothelial cells, thereby depleting SOD1 of copper and inhibiting its activity. Inhibition of SOD1 interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis, including those mediated by ERK1/2 and FAK and Src kinases. This results in an inhibition of cell proliferation and angiogenesis as well as induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tiomolibdate Choline","termGroup":"PT","termSource":"NCI"},{"termName":"ALXN-1840","termGroup":"CN","termSource":"NCI"},{"termName":"ATN 224","termGroup":"CN","termSource":"NCI"},{"termName":"ATN-224","termGroup":"CN","termSource":"NCI"},{"termName":"Bis(choline)tetrathiomolybdate","termGroup":"SY","termSource":"NCI"},{"termName":"Ethanaminium, 2-Hydroxy-N,N,N-Trimethyl-, (T-4)-Tetrathioxomolybdate(2-) (2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"SOD1 Inhibitor ATN-224","termGroup":"SY","termSource":"NCI"},{"termName":"WTX-101","termGroup":"CN","termSource":"NCI"},{"termName":"WTX101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"649749-10-0"},{"name":"Chemical_Formula","value":"2C5H14NO.MoS4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FD57A79R4P"},{"name":"Legacy Concept Name","value":"ATN-224"},{"name":"Maps_To","value":"Bis(choline)tetrathiomolybdate"},{"name":"Maps_To","value":"Tiomolibdate Choline"},{"name":"NCI_Drug_Dictionary_ID","value":"500040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500040"},{"name":"PDQ_Open_Trial_Search_ID","value":"500040"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831930"}]}}{"C1019":{"preferredName":"Bisantrene","code":"C1019","definitions":[{"definition":"An anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication.  This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisantrene","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxakdehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]","termGroup":"SN","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxaldehyde Bis(2-imidazolin-2-yl)hydrazone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"78186-34-2"},{"name":"Chemical_Formula","value":"C22H22N8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39C34M111K"},{"name":"Legacy Concept Name","value":"Bisantrene"},{"name":"Maps_To","value":"Bisantrene"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053776"}]}}{"C77218":{"preferredName":"Bisantrene Hydrochloride","code":"C77218","definitions":[{"definition":"The hydrochloride salt of an anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the helical structure of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisantrene Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"9,10,Anthracenedicarboxaldehyde Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxakdehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"9,10-Anthracenedicarboxaldehyde Bis(2-imidazolin-2-yl)hydrazone Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Bisantrene Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"CL-216942","termGroup":"CN","termSource":"NCI"},{"termName":"Orange Crush","termGroup":"SY","termSource":"NCI"},{"termName":"Zantrene","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71439-68-4"},{"name":"Chemical_Formula","value":"C22H22N8.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"74GNV897RO"},{"name":"Legacy Concept Name","value":"Bisantrene_Hydrochloride"},{"name":"Maps_To","value":"Bisantrene Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39136"},{"name":"PDQ_Open_Trial_Search_ID","value":"39136"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0955176"}]}}{"C73611":{"preferredName":"Bisnafide","code":"C73611","definitions":[{"definition":"A bis-naphthalimide compound with anticancer activity. Bisnafide selectively intercalates guanine-cytosine (GC) rich regions of DNA, thereby interfering with DNA replication machinery and activity of topoisomerase II. As a result, this agent causes potent cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisnafide","termGroup":"PT","termSource":"NCI"},{"termName":"DMP 840","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144849-63-8"},{"name":"Chemical_Formula","value":"C32H28N6O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"62H4W26906"},{"name":"Legacy Concept Name","value":"Bisnafide"},{"name":"Maps_To","value":"Bisnafide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0250021"}]}}{"C73307":{"preferredName":"Bisnafide Dimesylate","code":"C73307","definitions":[{"definition":"The dimesylate salt form of bisnafide, a bis-naphthalimide compound with anticancer activity. Bisnafide selectively intercalates guanine-cytosine (GC) rich regions of DNA, thereby interfering with DNA replication machinery and activity of topoisomerase II. As a result, this agent causes potent cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisnafide Dimesylate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145124-30-7"},{"name":"Chemical_Formula","value":"C32H28N6O8.2CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J30IBO0LMA"},{"name":"Legacy Concept Name","value":"Bisnafide_Dimesylate"},{"name":"Maps_To","value":"Bisnafide Dimesylate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347031"}]}}{"C2399":{"preferredName":"Bispecific Antibody 2B1","code":"C2399","definitions":[{"definition":"A monoclonal antibody with potential antineoplastic activity.  Specific for both the immunoglobulin G (IgG) receptor CD16 and c-erbB-2, bispecific antibody 2B1 may enhance cellular immune responses against c-erbB-2-positive cells, resulting in increased tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody 2B1","termGroup":"PT","termSource":"NCI"},{"termName":"2B1","termGroup":"SY","termSource":"NCI"},{"termName":"2B1 Antibody, Bispecific","termGroup":"SY","termSource":"NCI"},{"termName":"2B1 Bispecific MAb","termGroup":"SY","termSource":"NCI"},{"termName":"2B1 Bispecific Murine MAb","termGroup":"SY","termSource":"NCI"},{"termName":"bsAb 2B1","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb 2B1 Bispecific","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bispecific_Antibody_2B1"},{"name":"Maps_To","value":"Bispecific Antibody 2B1"},{"name":"NCI_Drug_Dictionary_ID","value":"42286"},{"name":"NSC Number","value":"673928"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42286"},{"name":"PDQ_Open_Trial_Search_ID","value":"42286"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338223"}]}}{"C1578":{"preferredName":"Bispecific Antibody MDX-H210","code":"C1578","definitions":[{"definition":"A humanized bivalent antibody directed against both cytotoxic effector cells expressing Fc gamma receptor type I (Fc gammaRI, or CD64) and HER2/neu-overexpressing tumor cells with potential antineoplastic activity. Bispecific antibody MDX-H210 was constructed by chemically linking Fab' fragments of the anti-HER2/neu-specific monoclonal antibody 520C9 and the Fab' fragments of the anti-Fc gammaRI-specific monoclonal antibody H22. This agent selectively binds to both HER2/neu-expressing tumor cells and Fc gammaRI-expressing cytotoxic effector cells, which may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis of HER2/neu-expressing tumor cells. While HER2/neu is overexpressed in a variety of epithelial malignancies, expression of Fc gammaRI is primarily found in cytotoxic immune cells, including monocytes, macrophages, and cytokine-activated polymorphonuclear (PMN) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody MDX-H210","termGroup":"PT","termSource":"NCI"},{"termName":"520C9x22 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"520C9xH22 Bispecific Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody, Bispecific 520C9xH22","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody 520C9 x H22","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody MDXH210","termGroup":"SY","termSource":"NCI"},{"termName":"BsAb 520C9x22","termGroup":"SY","termSource":"NCI"},{"termName":"BsAb 520C9xH22","termGroup":"SY","termSource":"NCI"},{"termName":"MDX-210","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-H210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bispecific_Antibody_520C9XH22"},{"name":"Maps_To","value":"Bispecific Antibody MDX-H210"},{"name":"NCI_Drug_Dictionary_ID","value":"42227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42227"},{"name":"PDQ_Open_Trial_Search_ID","value":"42227"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281736"}]}}{"C2207":{"preferredName":"Bispecific Antibody MDX447","code":"C2207","definitions":[{"definition":"An antibody with potential antineoplastic activity. Specific for both the high-affinity immunoglobulin G (IgG) receptor CD64 and epidermal growth factor receptor (EGFR), bispecific antibody MDX447 may enhance cellular immune responses against EGFR positive cells, resulting in increased tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody MDX447","termGroup":"PT","termSource":"NCI"},{"termName":"BsAb MDX447","termGroup":"SY","termSource":"NCI"},{"termName":"EMD 82633","termGroup":"CN","termSource":"NCI"},{"termName":"MDX 447","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-447","termGroup":"CN","termSource":"NCI"},{"termName":"MDX447","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bispecific_Antibody_MDX447"},{"name":"Maps_To","value":"Bispecific Antibody MDX447"},{"name":"NCI_Drug_Dictionary_ID","value":"37952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37952"},{"name":"PDQ_Open_Trial_Search_ID","value":"37952"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879492"}]}}{"C163996":{"preferredName":"Bisthianostat","code":"C163996","definitions":[{"definition":"An orally bioavailable pan-inhibitor of human histone deacetylase (HDAC), with potential antineoplastic activity. Upon administration, bisthianostat selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes. This prevents cell division, induces cell cycle arrest and apoptosis. This may inhibit the proliferation of susceptible tumor cells. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bisthianostat","termGroup":"PT","termSource":"NCI"},{"termName":"CF367","termGroup":"CN","termSource":"NCI"},{"termName":"CFH367 C","termGroup":"CN","termSource":"NCI"},{"termName":"CFH367-C","termGroup":"CN","termSource":"NCI"},{"termName":"CFH367C","termGroup":"CN","termSource":"NCI"},{"termName":"PY-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bisthianostat"},{"name":"NCI_Drug_Dictionary_ID","value":"799197"},{"name":"NCI_META_CUI","value":"CL977258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799197"},{"name":"PDQ_Open_Trial_Search_ID","value":"799197"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151943":{"preferredName":"Bivalent BRD4 Inhibitor AZD5153","code":"C151943","definitions":[{"definition":"An orally bioavailable bivalent inhibitor of  bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor AZD5153 selectively binds to the acetylated lysine recognition motifs in two bromodomains in the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dysregulates expression of target genes, which leads to the downregulation of the expression of certain growth-promoting genes, induces apoptosis and inhibits the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bivalent BRD4 Inhibitor AZD5153","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-4-(2-(4-(1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 5153","termGroup":"CN","termSource":"NCI"},{"termName":"AZD5153","termGroup":"CN","termSource":"NCI"},{"termName":"BET Inhibitor AZD5153","termGroup":"SY","termSource":"NCI"},{"termName":"Bivalent BET Bromodomain Inhibitor AZD5153","termGroup":"SY","termSource":"NCI"},{"termName":"BRD4/BET Bromodomain Antagonist AZD5153","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1869912-39-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C7C7U6YEAO"},{"name":"Maps_To","value":"Bivalent BRD4 Inhibitor AZD5153"},{"name":"NCI_Drug_Dictionary_ID","value":"793144"},{"name":"NCI_META_CUI","value":"CL553171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793144"},{"name":"PDQ_Open_Trial_Search_ID","value":"793144"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1472":{"preferredName":"Bizelesin","code":"C1472","definitions":[{"definition":"A synthetic cyclopropylpyrroloindole antineoplastic antibiotic.  Bizelesin binds to the minor groove of DNA and induces interstrand cross-linking of DNA, thereby inhibiting DNA replication and RNA synthesis.  Bizelesin also enhances p53 and p21 induction and triggers G2/M cell-cycle arrest, resulting in cell senescence without apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents. It is also an antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bizelesin","termGroup":"PT","termSource":"NCI"},{"termName":"Benzo(1,2-b:4,3-b')dipyrrol-4-ol, 6,6'-(carbonylbis(imino-1H-indole-5,2-diylcarbonyl))bis(8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (S-(R*,R*)))-","termGroup":"SN","termSource":"NCI"},{"termName":"U-77779","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129655-21-6"},{"name":"Chemical_Formula","value":"C43H36Cl2N8O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0O9OBI87E"},{"name":"Legacy Concept Name","value":"Bizelesin"},{"name":"Maps_To","value":"Bizelesin"},{"name":"NCI_Drug_Dictionary_ID","value":"42688"},{"name":"NSC Number","value":"615291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42688"},{"name":"PDQ_Open_Trial_Search_ID","value":"42688"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0209891"}]}}{"C1842":{"preferredName":"BL22 Immunotoxin","code":"C1842","definitions":[{"definition":"A bacterial toxic substance linked to an antibody that attaches to cancer cells and kills them. It belongs to the family of drugs called bacterial immunotoxins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity.  BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells.  The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BL22 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD22 Recombinant Immunotoxin BL22","termGroup":"SY","termSource":"NCI"},{"termName":"BL22","termGroup":"SY","termSource":"NCI"},{"termName":"BL22 Immunotoxin [RFB4(dsFv)-PE38]","termGroup":"SY","termSource":"NCI"},{"termName":"CAT 3888","termGroup":"CN","termSource":"NCI"},{"termName":"CAT-3888","termGroup":"CN","termSource":"NCI"},{"termName":"CAT3888","termGroup":"CN","termSource":"NCI"},{"termName":"GCR 3888","termGroup":"CN","termSource":"NCI"},{"termName":"GCR-3888","termGroup":"CN","termSource":"NCI"},{"termName":"GCR3888","termGroup":"CN","termSource":"NCI"},{"termName":"Immunotoxin BL22","termGroup":"SY","termSource":"NCI"},{"termName":"RFB4(dsFv)-PE38 Immunotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"BL22_Immunotoxin"},{"name":"Maps_To","value":"BL22 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43322"},{"name":"NSC Number","value":"691237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43322"},{"name":"PDQ_Open_Trial_Search_ID","value":"43322"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796473"}]}}{"C26647":{"preferredName":"Black Cohosh","code":"C26647","definitions":[{"definition":"A triterpene-containing herb isolated from the roots and rhizomes of the plant Cimicifuga racemosa (also known as Actaea racemosa). While the mechanism of action of black cohosh is not completely understood, it appears to act as a selective estrogen receptor modulator.  In vitro, this preparation has been shown to induce cell cycle arrest and caspase-dependent apoptosis of estrogen-sensitive breast cancer cells. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An eastern North American perennial herb. A substance obtained from the root of the plant has been used in some cultures to treat a number of medical problems. It is being studied in the treatment of hot flashes and other symptoms of menopause. The scientific name is Cimicifuga racemosa.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Black Cohosh","termGroup":"PT","termSource":"NCI"},{"termName":"Actaea racemosa Root","termGroup":"SY","termSource":"NCI"},{"termName":"Cimicifuga racemosa Root","termGroup":"SY","termSource":"NCI"},{"termName":"Cimicifugae racemosae Rhizoma","termGroup":"SY","termSource":"NCI"},{"termName":"Fariy Candle Root","termGroup":"SY","termSource":"NCI"},{"termName":"Remifemin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K73E24S6X9"},{"name":"Legacy Concept Name","value":"Black_Cohosh"},{"name":"Maps_To","value":"Black Cohosh"},{"name":"NCI_Drug_Dictionary_ID","value":"302635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"302635"},{"name":"PDQ_Open_Trial_Search_ID","value":"302635"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C0771967"}]}}{"C122398":{"preferredName":"Black Raspberry Nectar","code":"C122398","definitions":[{"definition":"A concentrated fruit juice containing black raspberries, with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, anthocyanidins, and flavonoids. Upon oral administration, the phytochemicals in the black raspberry nectar inhibit the activation of several signal transduction pathways involved in carcinogenesis and the expression of downstream target genes that are upregulated in a variety of cancer cell types. In addition, the phytochemicals in black raspberry may protect the oral microbiome and may enhance the bacterial defense against pathogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Black Raspberry Nectar","termGroup":"PT","termSource":"NCI"},{"termName":"BRB Nectar","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Black Raspberry Nectar"},{"name":"NCI_Drug_Dictionary_ID","value":"772463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772463"},{"name":"PDQ_Open_Trial_Search_ID","value":"772463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055378"}]}}{"C313":{"preferredName":"Bleomycin","code":"C313","definitions":[{"definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It comes from the bacterium Streptomyces verticillus. Bleomycin damages DNA and may kill rapidly growing cancer cells. It is a type of antineoplastic antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bleomycin","termGroup":"PT","termSource":"NCI"},{"termName":"BLEO","termGroup":"AB","termSource":"NCI"},{"termName":"BLM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11056-06-7"},{"name":"CHEBI_ID","value":"CHEBI:3139"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"40S1VHN69B"},{"name":"Legacy Concept Name","value":"Bleomycin"},{"name":"Maps_To","value":"Bleomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"813324"},{"name":"NSC Number","value":"125066"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005740"}]}}{"C311":{"preferredName":"Bleomycin A2","code":"C311","definitions":[{"definition":"The primary bleomycin species in bleomycin sulfate, a mixture of the sulfate salts of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Bleomycin A2 forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bleomycin A2","termGroup":"PT","termSource":"NCI"},{"termName":"N1-(3-(Dimethylsulfonio)propyl)bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"Pingyangmycin A2","termGroup":"SY","termSource":"NCI"},{"termName":"Zhengguangmycin A2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11116-31-7"},{"name":"CHEBI_ID","value":"CHEBI:3139"},{"name":"Chemical_Formula","value":"C55H84N17O21S3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"13M89UEA7W"},{"name":"Legacy Concept Name","value":"Bleomycin_A2"},{"name":"Maps_To","value":"Bleomycin A2"},{"name":"NSC Number","value":"146842"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005736"}]}}{"C81672":{"preferredName":"Bleomycin B2","code":"C81672","definitions":[{"definition":"One of the primary bleomycin species in bleomycin sulfate, a mixture of the sulfate salts of glycopeptide bleomycin A2 and B2 isolated from Streptomyces verticillus with potential antineoplastic activity. Bleomycin B2 forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bleomycin B2","termGroup":"PT","termSource":"NCI"},{"termName":"Bleomycinamide, N1-(4-((aminoiminomethyl)amino)butyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Dehydrophleomycin D1","termGroup":"SY","termSource":"NCI"},{"termName":"N1-(4-((Aminoiminomethyl)amino)butyl)bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"Phleomycin D2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9060-10-0"},{"name":"CHEBI_ID","value":"CHEBI:28641"},{"name":"Chemical_Formula","value":"C55H84N20O21S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M62KK37O40"},{"name":"Legacy Concept Name","value":"Bleomycin_B2"},{"name":"Maps_To","value":"Bleomycin B2"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005738"}]}}{"C312":{"preferredName":"Bleomycin Sulfate","code":"C312","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It comes from the bacterium Streptomyces verticillus. Blenoxane that damages DNA and may kill cancer cells. It is a type of antineoplastic antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin sulfate forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bleomycin Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"Blanoxan","termGroup":"FB","termSource":"NCI"},{"termName":"BleMomycine","termGroup":"BR","termSource":"NCI"},{"termName":"Blenoxane","termGroup":"AQS","termSource":"NCI"},{"termName":"Bleo-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Bleo-S","termGroup":"FB","termSource":"NCI"},{"termName":"Bleocin","termGroup":"FB","termSource":"NCI"},{"termName":"Bleolem","termGroup":"FB","termSource":"NCI"},{"termName":"Bleomycin Sulfas","termGroup":"SY","termSource":"NCI"},{"termName":"Bleomycin Sulphate","termGroup":"SY","termSource":"NCI"},{"termName":"Bleomycini Sulfas","termGroup":"SY","termSource":"NCI"},{"termName":"Blexane","termGroup":"SY","termSource":"NCI"},{"termName":"Oil Bleo","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Squamous cell carcinomas of the head and neck; penis; cervix and vulva; Hodgkins and; non-Hodgkins lymphoma; testicular embryonal cell and ovarian carcinoma; chorio- and teratocarcinoma; malignant pleural effusion; melanoma; sarcoma; ovary germ cell tumor"},{"name":"CAS_Registry","value":"9041-93-4"},{"name":"CHEBI_ID","value":"CHEBI:34582"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7DP3NTV15T"},{"name":"Legacy Concept Name","value":"Bleomycin_Sulphate"},{"name":"Maps_To","value":"Bleomycin Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"39139"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39139"},{"name":"PDQ_Open_Trial_Search_ID","value":"39139"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0005739"}]}}{"C62528":{"preferredName":"Blinatumomab","code":"C62528","definitions":[{"definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blinatumomab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 103","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-103","termGroup":"CN","termSource":"NCI"},{"termName":"AMG103","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103","termGroup":"SY","termSource":"NCI"},{"termName":"Blincyto","termGroup":"BR","termSource":"NCI"},{"termName":"MEDI 538","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-538","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI538","termGroup":"CN","termSource":"NCI"},{"termName":"MT 103","termGroup":"CN","termSource":"NCI"},{"termName":"MT-103","termGroup":"CN","termSource":"NCI"},{"termName":"MT103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)"},{"name":"CAS_Registry","value":"853426-35-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4FR53SIF3A"},{"name":"Legacy Concept Name","value":"Anti-CD19_Anti-CD3_Bispecific_Monoclonal_Antibody"},{"name":"Maps_To","value":"Blinatumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"487684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487684"},{"name":"PDQ_Open_Trial_Search_ID","value":"487684"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853839"}]}}{"C98108":{"preferredName":"Blueberry Powder Supplement","code":"C98108","definitions":[{"definition":"An orally available, dietary supplement consisting of lyophilized blueberry powder, with antioxidant and potential chemopreventive and chemosensitizing activity. In addition to vitamins and minerals, blueberries are rich in phytonutrients, such as proanthocyanidins, anthocyanins (e.g. malvidin, delphinidin, pelargonidin, cyanidin, petunidin, and peonidin), hydroxycinnamic acids, hydroxybenzoic acids, pterostilbene, resveratrol, and flavonols (e.g. kaempferol, quercetin and myricetin). Although the exact mechanism of action through which blueberries may exert their anti-tumor effect has yet to be fully elucidated, the effects of blueberry powder on cancer cells may be attributable to the phytonutrient's antioxidant and pro-apoptotic activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Blueberry Powder Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blueberry Powder Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"710970"},{"name":"NCI_META_CUI","value":"CL430627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710970"},{"name":"PDQ_Open_Trial_Search_ID","value":"710970"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121645":{"preferredName":"Unesbulin","code":"C121645","definitions":[{"definition":"An orally active inhibitor of the polycomb ring finger oncogene BMI1 (B-cell-specific Moloney murine leukemia virus integration site 1), with potential antineoplastic activity. Upon oral administration, unesbulin targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1 leading to its degradation. This inhibits BMI1-mediated signal transduction pathways and results in a reduction of proliferation of BMI1-expressing tumor cells.  BMI1, a key protein in the polycomb repressive complex 1 (PRC1), is overexpressed in certain tumor cell types, and plays a key role in CSC survival, proliferation and resistance to chemotherapeutics; its expression is associated with increased tumor aggressiveness and a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unesbulin","termGroup":"PT","termSource":"NCI"},{"termName":"Polycomb Ring Finger Oncogene Inhibitor PTC596","termGroup":"SY","termSource":"NCI"},{"termName":"PTC596","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610964-64-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z4HZ70S62Q"},{"name":"Maps_To","value":"BMI1 Inhibitor PTC596"},{"name":"NCI_Drug_Dictionary_ID","value":"770799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770799"},{"name":"PDQ_Open_Trial_Search_ID","value":"770799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053603"}]}}{"C1843":{"preferredName":"BMS-184476","code":"C1843","definitions":[{"definition":"A 7-methylthiomethyl ether derivative of paclitaxel with antineoplastic activity.  BMS-184476 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"BMS-184476","termGroup":"PT","termSource":"NCI"},{"termName":"7-O-[(Methylthio)methyl]paclitaxel","termGroup":"SN","termSource":"NCI"},{"termName":"beta-(Benzoylamino)-a-hydroxybenzenepropanoic Acid (aR,bS)-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-[(methylthio)methoxy]-5-oxo-7,11-methano-1H","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-184476","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160237-25-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3811W2NBZ8"},{"name":"Legacy Concept Name","value":"BMS-184476"},{"name":"Maps_To","value":"BMS-184476"},{"name":"NCI_Drug_Dictionary_ID","value":"43331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43331"},{"name":"PDQ_Open_Trial_Search_ID","value":"43331"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796479"}]}}{"C1859":{"preferredName":"BMS-188797","code":"C1859","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called taxane analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analog of paclitaxel with antineoplastic activity.  BMS-188797 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMS-188797","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-188797","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"427896-23-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0HG7S0S581"},{"name":"Legacy Concept Name","value":"BMS-188797"},{"name":"Maps_To","value":"BMS-188797"},{"name":"NCI_Drug_Dictionary_ID","value":"37942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37942"},{"name":"PDQ_Open_Trial_Search_ID","value":"37942"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879485"}]}}{"C1856":{"preferredName":"BMS-214662","code":"C1856","definitions":[{"definition":"A nonsedating benzodiazepine derivative with potential antineoplastic activity. Farnesyltransferase inhibitor BMS-214662 inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. This agent may reverse the malignant phenotype of H-Ras-transformed cells and has been shown to be active against tumor cells with and without Ras mutations.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"BMS-214662","termGroup":"PT","termSource":"NCI"},{"termName":"7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-Benzodiazepine","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-214662","termGroup":"CN","termSource":"NCI"},{"termName":"FTI BMS 214662","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195987-41-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L2U9GFD244"},{"name":"Legacy Concept Name","value":"BMS214662"},{"name":"Maps_To","value":"BMS-214662"},{"name":"NCI_Drug_Dictionary_ID","value":"37852"},{"name":"NSC Number","value":"710086"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37852"},{"name":"PDQ_Open_Trial_Search_ID","value":"37852"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1306120"}]}}{"C62639":{"preferredName":"BMS-275183","code":"C62639","definitions":[{"definition":"An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin and stabilizes microtubules, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and an induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BMS-275183","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"355113-98-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UQC681JJIV"},{"name":"Legacy Concept Name","value":"BMS-275183"},{"name":"Maps_To","value":"BMS-275183"},{"name":"NCI_Drug_Dictionary_ID","value":"415311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415311"},{"name":"PDQ_Open_Trial_Search_ID","value":"415311"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1098058"}]}}{"C102878":{"preferredName":"Boanmycin Hydrochloride","code":"C102878","definitions":[{"definition":"The hydrochloride salt form of boanmycin (aka bleomycin A6), a component of the antibiotic bleomycin produced by Streptomyces species, with potential antineoplastic activity. Upon administration, boanmycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals. This causes single- and double-stranded DNA breaks which eventually leads to cell death. Compared to bleomycin, boanmycin appears to have a more favorable toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Boanmycin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BAM HCl","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K4QGS58U92"},{"name":"Maps_To","value":"Boanmycin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"738501"},{"name":"NCI_META_CUI","value":"CL437181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738501"},{"name":"PDQ_Open_Trial_Search_ID","value":"738501"},{"name":"Semantic_Type","value":"Antibiotic"}]}}{"C2405":{"preferredName":"Boronophenylalanine-Fructose Complex","code":"C2405","definitions":[{"definition":"A boronated phenylalanine complexed with fructose to increase its solubility. When exposed to neutron irradiation, boronophenylalanine absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A substance used in a type of radiation therapy called boron neutron capture therapy. BPA-F is injected into a vein, and becomes concentrated in tumor cells. The patient then receives radiation treatment with atomic particles called neutrons. The neutrons react with the boron in BPA-F, producing radioactive particles that kill the tumor cells without harming normal cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Boronophenylalanine-Fructose Complex","termGroup":"PT","termSource":"NCI"},{"termName":"p-Boronophenylalanine-Fructose Complex","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Boronophenylalanine-Fructose_Complex"},{"name":"Maps_To","value":"Boronophenylalanine-Fructose Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"42404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42404"},{"name":"PDQ_Open_Trial_Search_ID","value":"42404"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0289335"}]}}{"C1851":{"preferredName":"Bortezomib","code":"C1851","definitions":[{"definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bortezomib","termGroup":"PT","termSource":"NCI"},{"termName":"[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LDP 341","termGroup":"CN","termSource":"NCI"},{"termName":"LDP-341","termGroup":"CN","termSource":"NCI"},{"termName":"LDP341","termGroup":"CN","termSource":"NCI"},{"termName":"MLN 341","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-341","termGroup":"CN","termSource":"NCI"},{"termName":"MLN341","termGroup":"CN","termSource":"NCI"},{"termName":"PS 341","termGroup":"CN","termSource":"NCI"},{"termName":"PS-341","termGroup":"CN","termSource":"NCI"},{"termName":"PS341","termGroup":"CN","termSource":"NCI"},{"termName":"Velcade","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Multiple Myeloma; Advanced Thyroid Cancer"},{"name":"CAS_Registry","value":"179324-69-7"},{"name":"CHEBI_ID","value":"CHEBI:52717"},{"name":"Chemical_Formula","value":"C19H25BN4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"69G8BD63PP"},{"name":"Legacy Concept Name","value":"Bortezomib"},{"name":"Maps_To","value":"Bortezomib"},{"name":"NCI_Drug_Dictionary_ID","value":"43560"},{"name":"NSC Number","value":"681239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43560"},{"name":"PDQ_Open_Trial_Search_ID","value":"43560"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1176309"}]}}{"C60809":{"preferredName":"Bosutinib","code":"C60809","definitions":[{"definition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bosutinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"4-Anilino-3-quinolinecarbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"4-Anilinobenzo(g)quinoline-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"SKI 606","termGroup":"CN","termSource":"NCI"},{"termName":"SKI-606","termGroup":"CN","termSource":"NCI"},{"termName":"SKI606","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"380843-75-4"},{"name":"CHEBI_ID","value":"CHEBI:39112"},{"name":"Chemical_Formula","value":"C26H29Cl2N5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5018V4AEZ0"},{"name":"Legacy Concept Name","value":"Bosutinib"},{"name":"Maps_To","value":"Bosutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"467222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467222"},{"name":"PDQ_Open_Trial_Search_ID","value":"467222"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831731"}]}}{"C154440":{"preferredName":"Bosutinib Monohydrate","code":"C154440","definitions":[{"definition":"The monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bosutinib Monohydrate","termGroup":"PT","termSource":"NCI"},{"termName":"3-Quinolinecarbonitrile, 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, Hydrate (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"Bosulif","termGroup":"SY","termSource":"NCI"},{"termName":"SKI-606 Monohydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"918639-08-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"844ZJE6I55"},{"name":"Maps_To","value":"Bosutinib Monohydrate"},{"name":"NCI_META_CUI","value":"CL555365"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153419":{"preferredName":"Botanical Agent BEL-X-HG","code":"C153419","definitions":[{"definition":"An orally available botanically-based agent with potential antineoplastic activity. Upon oral administration, the components in BEL-X-HG may exert cytotoxic effects against cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botanical Agent BEL-X-HG","termGroup":"PT","termSource":"NCI"},{"termName":"BEL X HG","termGroup":"CN","termSource":"NCI"},{"termName":"BEL-X-HG","termGroup":"CN","termSource":"NCI"},{"termName":"BELXHG","termGroup":"CN","termSource":"NCI"},{"termName":"Botanical Agent BEL X HG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Botanical Agent BEL-X-HG"},{"name":"NCI_Drug_Dictionary_ID","value":"793949"},{"name":"NCI_META_CUI","value":"CL554859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793949"},{"name":"PDQ_Open_Trial_Search_ID","value":"793949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129711":{"preferredName":"Botanical Agent LEAC-102","code":"C129711","definitions":[{"definition":"A botanical-based formulation derived from the Taiwanese mushroom Antrodia cinnamomea, with potential antineoplastic activity, Upon administration, the components in LEAC-102 may exert cytotoxic effects against cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Botanical Agent LEAC-102","termGroup":"PT","termSource":"NCI"},{"termName":"LEAC 102","termGroup":"CN","termSource":"NCI"},{"termName":"LEAC-102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3796H63LII"},{"name":"Maps_To","value":"Botanical Agent LEAC-102"},{"name":"NCI_Drug_Dictionary_ID","value":"784382"},{"name":"NCI_META_CUI","value":"CL512955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784382"},{"name":"PDQ_Open_Trial_Search_ID","value":"784382"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2418":{"preferredName":"Bovine Cartilage","code":"C2418","definitions":[{"definition":"Cartilage extracted from various parts of a cow and is proposed to stimulate the immune system and inhibit tumor cell growth.  It was used in the 1950s and 60s to enhance wound healing. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bovine Cartilage","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bovine_Cartilage"},{"name":"Maps_To","value":"Bovine Cartilage"},{"name":"NCI_Drug_Dictionary_ID","value":"42603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42603"},{"name":"PDQ_Open_Trial_Search_ID","value":"42603"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0106940"}]}}{"C129717":{"preferredName":"Vebreltinib","code":"C129717","definitions":[{"definition":"An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vebreltinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(1-Cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine","termGroup":"SY","termSource":"NCI"},{"termName":"APL-101","termGroup":"CN","termSource":"NCI"},{"termName":"APL101","termGroup":"CN","termSource":"NCI"},{"termName":"Bozitinib","termGroup":"SY","termSource":"NCI"},{"termName":"CBI-3103","termGroup":"CN","termSource":"NCI"},{"termName":"CBT-101","termGroup":"CN","termSource":"NCI"},{"termName":"PLB-1001","termGroup":"CN","termSource":"NCI"},{"termName":"PLB1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1440964-89-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2WZP8A9VFN"},{"name":"Maps_To","value":"Bozitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"784709"},{"name":"NCI_META_CUI","value":"CL512997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784709"},{"name":"PDQ_Open_Trial_Search_ID","value":"784709"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107387":{"preferredName":"BP-Cx1-Platinum Complex BP-C1","code":"C107387","definitions":[{"definition":"A combination agent composed of the benzo-poly-carbonic-acid polymer BP-Cx1 chelated to platinum with potential antineoplastic activity. Upon intramuscular injection, the polymer moiety of BP-Cx1-Platinum Complex BP-C1 (BP-C1) alters the permeability of the cell membranes, which allows for increased penetration of platinum into tumor cells. In turn, platinum binds to nucleophilic groups such as GC-rich sites in DNA and induces intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. In addition, the BP-Cx1 ligand is able to stimulate the innate immune system and upregulates a variety of cytokines including interferon, tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), and various interleukins (ILs) such as IL-6 and IL-25. In comparison to cisplatin and other platinum-based compounds, treatment with BP-C1 allows for less platinum administration, which reduces platinum-associated systemic toxicity and side effects, and enhances the safety profile while maintaining or improving its efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BP-Cx1-Platinum Complex BP-C1","termGroup":"PT","termSource":"NCI"},{"termName":"BP-C1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BP-Cx1-Platinum Complex BP-C1"},{"name":"NCI_Drug_Dictionary_ID","value":"751002"},{"name":"NCI_META_CUI","value":"CL449598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751002"},{"name":"PDQ_Open_Trial_Search_ID","value":"751002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1617":{"preferredName":"BR96-Doxorubicin Immunoconjugate","code":"C1617","definitions":[{"definition":"An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin.  The antibody moiety of BMS-182248-1 binds to Lewis Y, a cell surface antigen expressed on many solid tumor types.  Thus, the doxorubicin conjugate is targeted specifically to Lewis Y-expressing tumor cells, where it intercalates with DNA, thereby inhibiting DNA replication and repair, RNA synthesis and protein synthesis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BR96-Doxorubicin Immunoconjugate","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-182248-01","termGroup":"CN","termSource":"NCI"},{"termName":"BR96-DOX","termGroup":"AB","termSource":"NCI"},{"termName":"BR96-DOX immunoconjugate","termGroup":"SY","termSource":"NCI"},{"termName":"BR96-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"BR96-Doxorubicin Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"cBR96-Doxorubicin Immunoconjugate","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-15","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"BR96-Doxorubicin_Immunoconjugate"},{"name":"Maps_To","value":"BR96-Doxorubicin Immunoconjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"38477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38477"},{"name":"PDQ_Open_Trial_Search_ID","value":"38477"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0295525"}]}}{"C106267":{"preferredName":"Brachyury-expressing Yeast Vaccine GI-6301","code":"C106267","definitions":[{"definition":"A cancer vaccine composed of a heat-killed, recombinant form of the yeast Saccharomyces cerevisiae that is genetically modified to express the transcription factor brachyury protein, with potential antineoplastic activity. Upon subcutaneous administration, the brachyury-expressing yeast vaccine GI-6301 is recognized by dendritic cells, processed, and presented by Class I and II MHC molecules on the dendritic cell surface. This elicits a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response. This process kills brachyury-expressing tumor cells. Brachyury is overexpressed in a variety of tumor types and plays an important role in cancer progression and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brachyury-expressing Yeast Vaccine GI-6301","termGroup":"PT","termSource":"NCI"},{"termName":"GI-6301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B0L24T8TB7"},{"name":"Maps_To","value":"Brachyury-expressing Yeast Vaccine GI-6301"},{"name":"NCI_Drug_Dictionary_ID","value":"724520"},{"name":"NCI_META_CUI","value":"CL433965"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724520"},{"name":"PDQ_Open_Trial_Search_ID","value":"724520"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155322":{"preferredName":"BRAF Inhibitor","code":"C155322","definitions":[{"definition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"B-RAF Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF Inhibitor"},{"name":"NCI_META_CUI","value":"CL556869"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94224":{"preferredName":"BRAF Inhibitor ARQ 736","code":"C94224","definitions":[{"definition":"An orally bioavailable, highly soluble phosphate prodrug of B-raf (BRAF) protein kinase with potential antineoplastic activity. BRAF inhibitor ARQ 736 is converted into its active form ARQ 680 in the presence of phosphatases. In turn, ARQ 680 selectively binds to and inhibits the activity of oncogenic B-raf, which may inhibit the proliferation of tumor cells expressing mutated B-raf gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. The valine to glutamic acid substitution at residue 600 (V600E) accounts for about 90% of BRAF gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF Inhibitor ARQ 736","termGroup":"PT","termSource":"NCI"},{"termName":"AQ 736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228237-57-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2H4S74Y8U"},{"name":"Maps_To","value":"BRAF Inhibitor ARQ 736"},{"name":"NCI_Drug_Dictionary_ID","value":"688029"},{"name":"NCI_META_CUI","value":"CL433988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688029"},{"name":"PDQ_Open_Trial_Search_ID","value":"688029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113330":{"preferredName":"Plixorafenib","code":"C113330","definitions":[{"definition":"An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, plixorafenib selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plixorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"BRAF Inhibitor FORE8394","termGroup":"SY","termSource":"NCI"},{"termName":"BRAF Inhibitor PLX8394","termGroup":"SY","termSource":"NCI"},{"termName":"FORE 8394","termGroup":"CN","termSource":"NCI"},{"termName":"FORE-8394","termGroup":"CN","termSource":"NCI"},{"termName":"FORE8394","termGroup":"CN","termSource":"NCI"},{"termName":"PL -8394","termGroup":"CN","termSource":"NCI"},{"termName":"PLX8394","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1393466-87-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J2L7Z273SG"},{"name":"Maps_To","value":"BRAF Inhibitor PLX8394"},{"name":"NCI_Drug_Dictionary_ID","value":"756043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756043"},{"name":"PDQ_Open_Trial_Search_ID","value":"756043"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827086"}]}}{"C92591":{"preferredName":"BRAF(V600E) Kinase Inhibitor RO5212054","code":"C92591","definitions":[{"definition":"An orally available small-molecule inhibitor of mutant (V600E) v-raf murine sarcoma viral oncogene homolog B1 (BRAF) with potential antineoplastic activity. BRAF(V600E) kinase inhibitor RO5212054 selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. The valine to glutamic acid substitution at residue 600 accounts for about 90% of BRAF gene mutations; the oncogenic product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF(V600E) Kinase Inhibitor RO5212054","termGroup":"PT","termSource":"NCI"},{"termName":"B-Raf Inhibitor RO5212054","termGroup":"SY","termSource":"NCI"},{"termName":"PLX3603","termGroup":"CN","termSource":"NCI"},{"termName":"RO5212054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF(V600E) Kinase Inhibitor RO5212054"},{"name":"NCI_Drug_Dictionary_ID","value":"680347"},{"name":"NCI_META_CUI","value":"CL421616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"680347"},{"name":"PDQ_Open_Trial_Search_ID","value":"680347"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124995":{"preferredName":"Lifirafenib","code":"C124995","definitions":[{"definition":"An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifirafenib","termGroup":"PT","termSource":"NCI"},{"termName":"Begeine-283","termGroup":"SY","termSource":"NCI"},{"termName":"BGB 283","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-283","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446090-79-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8762XZS5ZF"},{"name":"Maps_To","value":"BRAF/EGFR Inhibitor BGB-283"},{"name":"Maps_To","value":"Lifirafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"777271"},{"name":"NCI_META_CUI","value":"CL503841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777271"},{"name":"PDQ_Open_Trial_Search_ID","value":"777271"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C134967":{"preferredName":"BRAFV600/PI3K Inhibitor ASN003","code":"C134967","definitions":[{"definition":"A selective inhibitor of mutated forms of B-RAF kinase at amino acid position 600 (BRAFV600), including BRAFV600E, the alpha, delta and, to a lesser extent, beta isoforms of phosphatidylinositide 3-kinase (PI3K), including mutated forms of PI3KCA, which encodes the p110-alpha catalytic subunit of the class I PI3K, and the phosphatase and tensin homologs (PTEN) with loss-of-function mutation, with potential antineoplastic activity. Upon administration of ASN003, this agent selectively targets, binds to and inhibits the activity of BRAFV600 mutants as well as mutated isoforms of PI3K. This inhibits signaling through B-RAF- and PI3K/mechanistic target of rapamycin (mTOR)-mediated pathways and inhibits cellular proliferation in tumor cells with BRAFV600 mutations, those expressing PI3K and/or those driven by PTEN. Dysregulation of the B-RAF- and PI3K-mediated pathways is frequently seen in a variety of tumors and results in increased tumor cell growth and survival. Dual targeting of both pathways may increase efficacy and anti-tumor potential compared to the targeting of just one pathway by a selective B-RAF inhibitor or selective PI3K pathway inhibitor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAFV600/PI3K Inhibitor ASN003","termGroup":"PT","termSource":"NCI"},{"termName":"ASN 003","termGroup":"CN","termSource":"NCI"},{"termName":"ASN-003","termGroup":"CN","termSource":"NCI"},{"termName":"ASN003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAFV600/PI3K Inhibitor ASN003"},{"name":"NCI_Drug_Dictionary_ID","value":"789080"},{"name":"NCI_META_CUI","value":"CL522477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789080"},{"name":"PDQ_Open_Trial_Search_ID","value":"789080"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146825":{"preferredName":"BRD4 Inhibitor PLX2853","code":"C146825","definitions":[{"definition":"An orally bioavailable inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor PLX2853 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dyregulates gene expression. This may lead to the downregulation of the expression of certain growth-promoting genes, which may induce apoptosis and inhibit the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD4 Inhibitor PLX2853","termGroup":"PT","termSource":"NCI"},{"termName":"PLX 2853","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-2853","termGroup":"CN","termSource":"NCI"},{"termName":"PLX2853","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRD4 Inhibitor PLX2853"},{"name":"NCI_Drug_Dictionary_ID","value":"792077"},{"name":"NCI_META_CUI","value":"CL544855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792077"},{"name":"PDQ_Open_Trial_Search_ID","value":"792077"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125739":{"preferredName":"BRD4 Inhibitor PLX51107","code":"C125739","definitions":[{"definition":"An inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon administration, the BRD4 inhibitor PLX51107 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRD4 Inhibitor PLX51107","termGroup":"PT","termSource":"NCI"},{"termName":"PLX 51107","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-51107","termGroup":"CN","termSource":"NCI"},{"termName":"PLX51107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1627929-55-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W758F1L9ND"},{"name":"Maps_To","value":"BRD4 Inhibitor PLX51107"},{"name":"NCI_Drug_Dictionary_ID","value":"779000"},{"name":"NCI_META_CUI","value":"CL504394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779000"},{"name":"PDQ_Open_Trial_Search_ID","value":"779000"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28855":{"preferredName":"Breflate","code":"C28855","definitions":[{"definition":"A water soluble analogue of the antineoplastic agent brefeldin A (BFA). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Breflate","termGroup":"PT","termSource":"NCI"},{"termName":"13-(N,N-Dimethylglycyl)brefeldin A","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"174305-65-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Y1QP4AO5M"},{"name":"Legacy Concept Name","value":"Breflate"},{"name":"Maps_To","value":"Breflate"},{"name":"NSC Number","value":"656202"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0760968"}]}}{"C2007":{"preferredName":"Brentuximab","code":"C2007","definitions":[{"definition":"A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brentuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD30 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"CAC-10","termGroup":"CN","termSource":"NCI"},{"termName":"CAC10","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody SGN-30","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-30","termGroup":"CN","termSource":"NCI"},{"termName":"SGN30","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"775303-41-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C67ORA155P"},{"name":"Legacy Concept Name","value":"SGN-30"},{"name":"Maps_To","value":"Brentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"357600"},{"name":"NSC Number","value":"731636"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357600"},{"name":"PDQ_Open_Trial_Search_ID","value":"357600"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328236"}]}}{"C66944":{"preferredName":"Brentuximab Vedotin","code":"C66944","definitions":[{"definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brentuximab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-35","termGroup":"CN","termSource":"NCI"},{"termName":"Adcetris","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-CD30 Antibody-Drug Conjugate SGN-35","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD30 Monoclonal Antibody-MMAE SGN-35","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35","termGroup":"SY","termSource":"NCI"},{"termName":"cAC10-vcMMAE","termGroup":"AB","termSource":"NCI"},{"termName":"SGN 35","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-35","termGroup":"CN","termSource":"NCI"},{"termName":"SGN35","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hodgkin lymphoma (HL); anaplastic large cell lymphoma (ALCL); other CD30-expressing peripheral T-cell lymphomas"},{"name":"CAS_Registry","value":"914088-09-8"},{"name":"Chemical_Formula","value":"C68H106N11O15S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7XL5ISS668"},{"name":"Legacy Concept Name","value":"SGN-35"},{"name":"Maps_To","value":"Brentuximab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"530758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530758"},{"name":"PDQ_Open_Trial_Search_ID","value":"530758"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2932409"}]}}{"C1560":{"preferredName":"Brequinar","code":"C1560","definitions":[{"definition":"A synthetic quinolinecarboxylic acid analogue with antineoplastic properties.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brequinar","termGroup":"PT","termSource":"NCI"},{"termName":"6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Bipenquinate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96187-53-0"},{"name":"Chemical_Formula","value":"C23H15F2NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5XL19F49H6"},{"name":"Legacy Concept Name","value":"Brequinar"},{"name":"Maps_To","value":"Brequinar"},{"name":"NCI_Drug_Dictionary_ID","value":"40886"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40886"},{"name":"PDQ_Open_Trial_Search_ID","value":"40886"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280509"}]}}{"C1078":{"preferredName":"Brequinar Sodium","code":"C1078","definitions":[{"definition":"The sodium salt form of Brequinar.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brequinar Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"DUP-785","termGroup":"CN","termSource":"NCI"},{"termName":"DUP785","termGroup":"CN","termSource":"NCI"},{"termName":"Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96201-88-6"},{"name":"Chemical_Formula","value":"C23H14F2NO2.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49EEF6HRUS"},{"name":"Legacy Concept Name","value":"Brequinar_Sodium"},{"name":"Maps_To","value":"Brequinar Sodium"},{"name":"NSC Number","value":"368390"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058809"}]}}{"C90541":{"preferredName":"Briciclib Sodium","code":"C90541","definitions":[{"definition":"A benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, briciclib is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Briciclib Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methoxy-5-(((2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)phenyl Disodium Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"ON 013105","termGroup":"CN","termSource":"NCI"},{"termName":"Phenol, 2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)-, 1-(Dihydrogen Phosphate), Sodium Salt (1:2)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"865784-01-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7C9N0VM8NR"},{"name":"Maps_To","value":"Briciclib Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"664346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"664346"},{"name":"PDQ_Open_Trial_Search_ID","value":"664346"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983737"}]}}{"C98831":{"preferredName":"Brigatinib","code":"C98831","definitions":[{"definition":"An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brigatinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone","termGroup":"SN","termSource":"NCI"},{"termName":"5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"Alunbrig","termGroup":"BR","termSource":"NCI"},{"termName":"AP 26113","termGroup":"CN","termSource":"NCI"},{"termName":"AP-26113","termGroup":"CN","termSource":"NCI"},{"termName":"AP26113","termGroup":"CN","termSource":"NCI"},{"termName":"Biganib","termGroup":"FB","termSource":"NCI"},{"termName":"Briganix","termGroup":"FB","termSource":"NCI"},{"termName":"Trepmac","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1197953-54-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HYW8DB273J"},{"name":"Maps_To","value":"Brigatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"714373"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714373"},{"name":"PDQ_Open_Trial_Search_ID","value":"714373"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274459"}]}}{"C106235":{"preferredName":"Brilanestrant","code":"C106235","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brilanestrant","termGroup":"PT","termSource":"NCI"},{"termName":"ARN-810","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0810","termGroup":"CN","termSource":"NCI"},{"termName":"RO7056118","termGroup":"CN","termSource":"NCI"},{"termName":"SERD ARN-810","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1365888-06-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9MM2R1A06R"},{"name":"Maps_To","value":"Brilanestrant"},{"name":"NCI_Drug_Dictionary_ID","value":"748900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748900"},{"name":"PDQ_Open_Trial_Search_ID","value":"748900"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827161"}]}}{"C158723":{"preferredName":"Brimonidine Tartrate Nanoemulsion OCU-300","code":"C158723","definitions":[{"definition":"An ophthalmic nanoemulsion consisting of the tartrate salt form of brimonidine, an imidazole derivative and selective alpha-2 adrenergic receptor agonist, with potential anti-inflammatory and vasoconstrictive activities. Upon ophthalmic instillation, brimonidine tartrate nanoemulsion OCU-300 reduces intraocular pressure by promoting the outflow and decreasing the production of aqueous humor and may reduce ocular erythema through direct vasoconstriction. Additionally, brimonidine may disrupt leukocyte extravasation into the ocular tissue, inhibit nociception and reduce inflammation associated with ocular graft-versus-host disease (oGvHD). The nanoemulsion formulation may enhance distribution of brimonidine to target tissues, thereby allowing more of the active drug to reach underlying ocular tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brimonidine Tartrate Nanoemulsion OCU-300","termGroup":"PT","termSource":"NCI"},{"termName":"OCU 300","termGroup":"CN","termSource":"NCI"},{"termName":"OCU-300","termGroup":"CN","termSource":"NCI"},{"termName":"OCU300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Brimonidine Tartrate Nanoemulsion OCU-300"},{"name":"NCI_Drug_Dictionary_ID","value":"797485"},{"name":"NCI_META_CUI","value":"CL950750"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797485"},{"name":"PDQ_Open_Trial_Search_ID","value":"797485"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67040":{"preferredName":"Brivanib","code":"C67040","definitions":[{"definition":"A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. BMS-540215 specifically targets and binds strongly to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Brivanib may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brivanib","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-540215","termGroup":"CN","termSource":"NCI"},{"termName":"VEGFR2 Inhibitor BMS-540215","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"649735-46-6"},{"name":"Chemical_Formula","value":"C19H19FN4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DDU33B674I"},{"name":"Legacy Concept Name","value":"BMS-540215"},{"name":"Maps_To","value":"Brivanib"},{"name":"NCI_Drug_Dictionary_ID","value":"539377"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539377"},{"name":"PDQ_Open_Trial_Search_ID","value":"539377"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700604"}]}}{"C53397":{"preferredName":"Brivanib Alaninate","code":"C53397","definitions":[{"definition":"A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brivanib Alaninate","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 582664","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-582664","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"649735-63-7"},{"name":"Chemical_Formula","value":"C22H24FN5O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U2Y5OFN795"},{"name":"Legacy Concept Name","value":"BMS-582664"},{"name":"Maps_To","value":"Brivanib Alaninate"},{"name":"NCI_Drug_Dictionary_ID","value":"462556"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462556"},{"name":"PDQ_Open_Trial_Search_ID","value":"462556"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1701190"}]}}{"C67088":{"preferredName":"Brivudine","code":"C67088","definitions":[{"definition":"A substance that is being studied in the treatment of infections caused by herpesvirus, including herpes-zoster (shingles). It belongs to the family of drugs called antivirals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A uridine derivative and nucleoside analog with pro-apoptotic and chemosensitizing properties. In vitro, bromovinyl-deoxyuridine (BVDU) has been shown to downregulate the multifunctional DNA repair enzyme APEX nuclease 1, resulting in the inhibition of DNA repair and the induction of apoptosis. In addition, this agent may inhibit the expression of STAT3 (signal transducer and activator of transcription 3), which may result in the downregulation of vascular endothelial growth factor (VEGF). BVDU has also been found to inhibit the upregulation of chemoresistance genes (Mdr1 and DHFR) during chemotherapy. Overall, the gene expression changes associated with BVDU treatment result in the decrease or prevention of chemoresistance. In addition, this agent has been shown to enhance the cytolytic activity of NK-92 natural killer cells towards a pancreatic cancer cell line in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brivudine","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-5-(2-Bromovinyl)-deoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"Bromovinyl-Deoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"BVDU","termGroup":"AB","termSource":"NCI"},{"termName":"Helpin","termGroup":"BR","termSource":"NCI"},{"termName":"RP101","termGroup":"CN","termSource":"NCI"},{"termName":"Trans-5-(2-Bromovinyl)-2'-deoxyuridine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69304-47-8"},{"name":"Chemical_Formula","value":"C11H13BrN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2M3055079H"},{"name":"Legacy Concept Name","value":"Brivudine"},{"name":"Maps_To","value":"Brivudine"},{"name":"NCI_Drug_Dictionary_ID","value":"577369"},{"name":"NSC Number","value":"633770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577369"},{"name":"PDQ_Open_Trial_Search_ID","value":"577369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0163272"}]}}{"C1882":{"preferredName":"Brivudine Phosphoramidate","code":"C1882","definitions":[{"definition":"A small molecule phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) with potential antineoplastic activity. Selectively active against tumor cells expressing high levels of thymidylate synthase (TS), brivudine is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites. As key enzyme in the de novo synthesis of dTMP, TS is an enzyme critical to DNA biosynthesis and is overexpressed in many solid tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied for its ability to make cancer cells respond to drugs to which they have become resistant. It is a type of nucleoside analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Brivudine Phosphoramidate","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-5-(2-Bromovinyl)-2'-deoxy-5'-uridyl Phenyl L-methoxyalaninylphosphoramidate","termGroup":"SN","termSource":"NCI"},{"termName":"BVdU Phosphoramidate","termGroup":"SY","termSource":"NCI"},{"termName":"BVDU Prodrug","termGroup":"SY","termSource":"NCI"},{"termName":"NB101.1","termGroup":"CN","termSource":"NCI"},{"termName":"NB1011","termGroup":"CN","termSource":"NCI"},{"termName":"Thymectacin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"232925-18-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ZRZ4TSW3F"},{"name":"Legacy Concept Name","value":"NB1011"},{"name":"Maps_To","value":"Brivudine Phosphoramidate"},{"name":"NCI_Drug_Dictionary_ID","value":"38549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38549"},{"name":"PDQ_Open_Trial_Search_ID","value":"38549"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0964443"}]}}{"C70598":{"preferredName":"Broad-Spectrum Human Papillomavirus Vaccine V505","code":"C70598","definitions":[{"definition":"A non-infectious recombinant cancer vaccine prepared from the human papillomavirus (HPV) with potential immunoprophylactic activity. Vaccination with broad-spectrum human papillomavirus vaccine V505 may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte (CTL) responses against HPV-infected cells. HPV infection, the cause of genital warts, is a risk factor for the development of cancers of the cervix, vagina, vulva, anus, and penis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broad-Spectrum Human Papillomavirus Vaccine V505","termGroup":"PT","termSource":"NCI"},{"termName":"V505","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Broad-Spectrum_Human_Papillomavirus_Vaccine_V505"},{"name":"Maps_To","value":"Broad-Spectrum Human Papillomavirus Vaccine V505"},{"name":"NCI_Drug_Dictionary_ID","value":"570766"},{"name":"NCI_META_CUI","value":"CL375942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570766"},{"name":"PDQ_Open_Trial_Search_ID","value":"570766"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C128293":{"preferredName":"Broccoli Sprout/Broccoli Seed Extract Supplement","code":"C128293","definitions":[{"definition":"A tablet-based nutritional supplement composed of a mixture of sprout and seed extracts of the cruciferous vegetable broccoli, with potential chemopreventive and antioxidant activities. Broccoli sprout/broccoli seed extract contains a high amount of both the glycosinolate glucoraphanin and the enzyme myrosinase, which catalyzes the production of glucoraphanin to sulforaphane. Upon administration of the broccoli sprout/broccoli seed extract, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs promote the transcription of antioxidant and detoxifying enzymes, particularly glutathione-S-transferase and NAD(P)H dehydrogenase [quinone] 1 (NAD(P)H:quinone oxidoreductase; NQO1), resulting in the detoxification of highly reactive carcinogens. This accelerates the elimination of carcinogens, may protect against cellular damage, and prevents cancer formation. AREs are cis-acting regulatory enhancer elements found in the 5' flanking region of many phase II detoxification enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broccoli Sprout/Broccoli Seed Extract Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Avmacol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Broccoli Sprout/Broccoli Seed Extract Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"782181"},{"name":"NCI_META_CUI","value":"CL507940"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782181"},{"name":"PDQ_Open_Trial_Search_ID","value":"782181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73259":{"preferredName":"Bromacrylide","code":"C73259","definitions":[{"definition":"A propenamide-based agent with antineoplastic activity. Bromacrylide has been shown to decrease tumor growth in animal models, but is accompanied with severe toxicity, including severe bone marrow suppression and weight loss.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bromacrylide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4213-51-8"},{"name":"Chemical_Formula","value":"C7H11BrN2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"173648DEO8"},{"name":"Legacy Concept Name","value":"Bromacrylide"},{"name":"Maps_To","value":"Bromacrylide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347213"}]}}{"C72089":{"preferredName":"Bromebric Acid","code":"C72089","definitions":[{"definition":"A derivative of bromoacrylic acid with cytostatic and antineoplastic activity. Bromebric acid appears to inhibit purine synthesis, oxidative phosphorylation and DNA synthesis. This agent inhibits tumor cell growth and causes cell cycle arrest. This agent may also have some use in the phrophylaxis of migraine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bromebric Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-3-p-Anisoyl-3-bromoacrylic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5711-40-0"},{"name":"Chemical_Formula","value":"C11H9BrO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FGE8818GWA"},{"name":"Legacy Concept Name","value":"Bromebric_Acid"},{"name":"Maps_To","value":"Bromebric Acid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054091"}]}}{"C317":{"preferredName":"Bromocriptine Mesylate","code":"C317","definitions":[{"definition":"The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine selectively binds to and activates postsynaptic dopamine D2 receptors in the corpus striatum of the central nervous system (CNS). Activation of these D2 receptors activate inhibitory G-proteins, which inhibit adenylyl cyclase, preventing signal transduction mediated via cAMP and resulting in the inhibition of neurotransmission and an antidyskinetic effect. This agent also stimulates dopamine D2 receptors in the anterior pituitary gland, which results in the inhibition of prolactin secretion and lactation and may inhibit the proliferation of prolactin-dependent breast cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bromocriptine Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-","termGroup":"SN","termSource":"NCI"},{"termName":"Parlodel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Parlodel treatment is indicated in patients with prolactin-secreting adenomas."},{"name":"CAS_Registry","value":"22260-51-1"},{"name":"CHEBI_ID","value":"CHEBI:3182"},{"name":"Chemical_Formula","value":"C32H40BrN5O5.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FFP983J3OD"},{"name":"Legacy Concept Name","value":"Bromocriptine"},{"name":"Maps_To","value":"Bromocriptine Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"39165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39165"},{"name":"PDQ_Open_Trial_Search_ID","value":"39165"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546852"}]}}{"C103274":{"preferredName":"Brontictuzumab","code":"C103274","definitions":[{"definition":"A humanized monoclonal antibody directed against the Notch-1 receptor with potential antineoplastic activity. Upon administration, brontictuzumab binds to Notch-1 on the cell surface, thereby inhibiting Notch-mediated signaling and tumor cell proliferation. Notch 1, a type 1 transmembrane protein belonging to the Notch family, functions as a receptor for membrane bound ligands and has various roles during development; dysregulated Notch signaling is associated with increased cell growth and chemoresistance in cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brontictuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G2-lambda, Anti-(homo Sapiens Notch1 (Notch 1, Translocation-associated Notch-1, TAN-1,Tan1)), Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"OMP-52M51","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1447814-75-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UNY2TQA40E"},{"name":"Maps_To","value":"Brontictuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"741867"},{"name":"NCI_META_CUI","value":"CL438125"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741867"},{"name":"PDQ_Open_Trial_Search_ID","value":"741867"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128040":{"preferredName":"Brostacillin Hydrochloride","code":"C128040","definitions":[{"definition":"A substance being studied in the treatment of cancer. Brostallicin hydrochloride binds to DNA and may kill cancer cells. It may also help other drugs kill cancer cells. It is a type of DNA minor groove binding agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of brostacillin, a synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brostacillin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide) Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"PNU-166196 Hydrochloride","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203258-38-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1DKC476797"},{"name":"Maps_To","value":"Brostacillin Hydrochloride"},{"name":"NCI_META_CUI","value":"CL509004"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1889":{"preferredName":"Brostallicin","code":"C1889","definitions":[{"definition":"A synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brostallicin","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide)","termGroup":"SN","termSource":"NCI"},{"termName":"PNU-166196","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203258-60-0"},{"name":"Chemical_Formula","value":"C30H35BrN12O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RPC6R41K4I"},{"name":"Legacy Concept Name","value":"Brostallicin"},{"name":"Maps_To","value":"Brostallicin"},{"name":"NCI_Drug_Dictionary_ID","value":"590644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590644"},{"name":"PDQ_Open_Trial_Search_ID","value":"590644"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122890"}]}}{"C318":{"preferredName":"Broxuridine","code":"C318","definitions":[{"definition":"A drug that makes cancer cells more sensitive to radiation and is also used as a diagnostic agent to determine how fast cancer cells grow.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A halogenated thymidine analogue with potential antineoplastic and radiosensitizing activities. Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and the inhibition of cell proliferation. As a radiosensitizer, this agent is associated with the inhibition of repair of radiation-induced DNA double-strand breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Broxuridine","termGroup":"PT","termSource":"NCI"},{"termName":"5-BrdU","termGroup":"AB","termSource":"NCI"},{"termName":"5-Bromo-2'-deoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Bromodeoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Bromouracil Deoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"5-Bromouracil-2-deoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"BrdU","termGroup":"AB","termSource":"NCI"},{"termName":"Bromo Deoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Bromodeoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Bromouracil Deoxyriboside","termGroup":"SY","termSource":"NCI"},{"termName":"Bromouridine","termGroup":"SY","termSource":"NCI"},{"termName":"Broxine","termGroup":"BR","termSource":"NCI"},{"termName":"Neomark","termGroup":"BR","termSource":"NCI"},{"termName":"Neomark-BU","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59-14-3"},{"name":"CHEBI_ID","value":"CHEBI:472552"},{"name":"Chemical_Formula","value":"C9H11BrN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G34N38R2N1"},{"name":"Legacy Concept Name","value":"Bromodeoxyuridine"},{"name":"Maps_To","value":"Broxuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39168"},{"name":"NSC Number","value":"38297"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39168"},{"name":"PDQ_Open_Trial_Search_ID","value":"39168"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006233"}]}}{"C1765":{"preferredName":"Bruceanol A","code":"C1765","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol A","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-(benzoyloxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101391-06-4"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_A"},{"name":"Maps_To","value":"Bruceanol A"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0626930"}]}}{"C1764":{"preferredName":"Bruceanol B","code":"C1764","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol B","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-15-((1-oxopentyl)oxy)-, Methyl Ester, (1beta,11beta,12alpha,15beta)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101391-05-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_B"},{"name":"Maps_To","value":"Bruceanol B"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0626928"}]}}{"C1768":{"preferredName":"Bruceanol C","code":"C1768","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol C","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-((4-(acetyloxy)-3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114586-21-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_C"},{"name":"Maps_To","value":"Bruceanol C"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0634036"}]}}{"C1535":{"preferredName":"Bruceanol D","code":"C1535","definitions":[{"definition":"A quassinoid phytochemical isolated form the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol D","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152645-84-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_D"},{"name":"Maps_To","value":"Bruceanol D"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0252924"}]}}{"C1536":{"preferredName":"Bruceanol E","code":"C1536","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol E","termGroup":"PT","termSource":"NCI"},{"termName":"Picrasan-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152645-85-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_E"},{"name":"Maps_To","value":"Bruceanol E"},{"name":"NSC Number","value":"368672"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0252925"}]}}{"C1537":{"preferredName":"Bruceanol F","code":"C1537","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol F","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-2-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-2,11,12-trihydroxy-1,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101910-72-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_F"},{"name":"Maps_To","value":"Bruceanol F"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0252926"}]}}{"C1694":{"preferredName":"Bruceanol G","code":"C1694","definitions":[{"definition":"A natural quassinoid agent extracted from Brucea antidysenterica with potential antineoplastic activity that is cytotoxic to certain cancer cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol G","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"168301-20-0"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_G"},{"name":"Maps_To","value":"Bruceanol G"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391118"}]}}{"C1695":{"preferredName":"Bruceanol H","code":"C1695","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceanol H","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"168569-27-5"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Bruceanol_H"},{"name":"Maps_To","value":"Bruceanol H"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391119"}]}}{"C1025":{"preferredName":"Bruceantin","code":"C1025","definitions":[{"definition":"A triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica.  Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis.  Bruceantin also has antiamoebic and antimalarial activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bruceantin","termGroup":"PT","termSource":"NCI"},{"termName":"2H-3, 11c-(Epoxymethano)phenanthro[10,1-bc]pyran, Picras-3-en-21-oic Acid Derivative","termGroup":"SN","termSource":"NCI"},{"termName":"[11Beta,12alpha,15beta(E)]-15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxopicras-3-en-21-oic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Picras-3-en-21-oic Acid, 15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11, 12-trihydroxy-2,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E))","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41451-75-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3NW88DI4T"},{"name":"Legacy Concept Name","value":"Bruceantin"},{"name":"Maps_To","value":"Bruceantin"},{"name":"NCI_Drug_Dictionary_ID","value":"39169"},{"name":"NSC Number","value":"165563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39169"},{"name":"PDQ_Open_Trial_Search_ID","value":"39169"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0054160"}]}}{"C1026":{"preferredName":"Bryostatin 1","code":"C1026","definitions":[{"definition":"A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity.  Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer and certain brain conditions such as Alzheimer disease and stroke. It binds to an enzyme involved in cell growth and it may help anticancer drugs work better. Bryostatin 1 comes from a marine organism. It is a type of protein kinase C modulator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bryostatin 1","termGroup":"PT","termSource":"NCI"},{"termName":"B705008K112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83314-01-6"},{"name":"Chemical_Formula","value":"C47H68O17"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37O2X55Y9E"},{"name":"Legacy Concept Name","value":"Bryostatin-1"},{"name":"Maps_To","value":"Bryostatin 1"},{"name":"NCI_Drug_Dictionary_ID","value":"41959"},{"name":"NSC Number","value":"339555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41959"},{"name":"PDQ_Open_Trial_Search_ID","value":"41959"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054173"}]}}{"C138066":{"preferredName":"Nemtabrutinib","code":"C138066","definitions":[{"definition":"An orally available reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, nemtabrutinib non-covalently binds to and inhibits the activity of both the wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, nemtabrutinib does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemtabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 531","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ-531","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ531","termGroup":"CN","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor ARQ 531","termGroup":"SY","termSource":"NCI"},{"termName":"BTK Inhibitor ARQ 531","termGroup":"SY","termSource":"NCI"},{"termName":"MK-1026","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095393-15-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JTZ51LIXN4"},{"name":"Maps_To","value":"BTK Inhibitor ARQ 531"},{"name":"NCI_Drug_Dictionary_ID","value":"790667"},{"name":"NCI_META_CUI","value":"CL525087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790667"},{"name":"PDQ_Open_Trial_Search_ID","value":"790667"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C138164":{"preferredName":"BTK Inhibitor CT-1530","code":"C138164","definitions":[{"definition":"An inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, CT-1530 binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor CT-1530","termGroup":"PT","termSource":"NCI"},{"termName":"CT 1530","termGroup":"CN","termSource":"NCI"},{"termName":"CT-1530","termGroup":"CN","termSource":"NCI"},{"termName":"CT1530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor CT-1530"},{"name":"NCI_Drug_Dictionary_ID","value":"790538"},{"name":"NCI_META_CUI","value":"CL525731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790538"},{"name":"PDQ_Open_Trial_Search_ID","value":"790538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130001":{"preferredName":"BTK Inhibitor DTRMWXHS-12","code":"C130001","definitions":[{"definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, DTRMWXHS-12 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor DTRMWXHS-12","termGroup":"PT","termSource":"NCI"},{"termName":"DTRMWXHS 12","termGroup":"CN","termSource":"NCI"},{"termName":"DTRMWXHS-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor DTRMWXHS-12"},{"name":"NCI_Drug_Dictionary_ID","value":"784823"},{"name":"NCI_META_CUI","value":"CL513821"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784823"},{"name":"PDQ_Open_Trial_Search_ID","value":"784823"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156173":{"preferredName":"Orelabrutinib","code":"C156173","definitions":[{"definition":"A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orelabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"BTK Inhibitor ICP-022","termGroup":"SY","termSource":"NCI"},{"termName":"ICP 022","termGroup":"CN","termSource":"NCI"},{"termName":"ICP-022","termGroup":"CN","termSource":"NCI"},{"termName":"ICP022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1655504-04-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WJA5UO9E10"},{"name":"Maps_To","value":"BTK Inhibitor ICP-022"},{"name":"Maps_To","value":"Orelabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"795368"},{"name":"NCI_META_CUI","value":"CL563002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795368"},{"name":"PDQ_Open_Trial_Search_ID","value":"795368"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158617":{"preferredName":"Pirtobrutinib","code":"C158617","definitions":[{"definition":"An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirtobrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"BTK Inhibitor LOXO-305","termGroup":"SY","termSource":"NCI"},{"termName":"Jaypirca","termGroup":"BR","termSource":"NCI"},{"termName":"LOXO 305","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO-305","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO305","termGroup":"CN","termSource":"NCI"},{"termName":"LY3527727","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory mantle cell lymphoma (MCL)"},{"name":"CAS_Registry","value":"2101700-15-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JNA39I7ZVB"},{"name":"Maps_To","value":"BTK Inhibitor LOXO-305"},{"name":"NCI_Drug_Dictionary_ID","value":"797383"},{"name":"NCI_META_CUI","value":"CL950650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797383"},{"name":"PDQ_Open_Trial_Search_ID","value":"797383"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129710":{"preferredName":"BTK Inhibitor TL-895","code":"C129710","definitions":[{"definition":"An orally bioavailable, selective inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor TL-895 targets and covalently binds to BTK, thereby preventing its activity. This leads to an inhibition of B cell receptor (BCR) signaling and inhibits cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor TL-895","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor M7583","termGroup":"SY","termSource":"NCI"},{"termName":"M 7583","termGroup":"CN","termSource":"NCI"},{"termName":"M-7583","termGroup":"CN","termSource":"NCI"},{"termName":"M7583","termGroup":"CN","termSource":"NCI"},{"termName":"TL 895","termGroup":"CN","termSource":"NCI"},{"termName":"TL-895","termGroup":"CN","termSource":"NCI"},{"termName":"TL895","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor M7583"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor TL-895"},{"name":"NCI_Drug_Dictionary_ID","value":"784381"},{"name":"NCI_META_CUI","value":"CL512935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175775":{"preferredName":"Edralbrutinib","code":"C175775","definitions":[{"definition":"An orally available irreversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, edralbrutinib covalently binds to and irreversibly inhibits BTK activity, thereby preventing the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This may inhibit the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edralbrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"BTK inhibitor TG-1701","termGroup":"SY","termSource":"NCI"},{"termName":"EBI 1459","termGroup":"CN","termSource":"NCI"},{"termName":"EBI-1459","termGroup":"CN","termSource":"NCI"},{"termName":"EBI1459","termGroup":"CN","termSource":"NCI"},{"termName":"SHR 1459","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1459","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1459","termGroup":"CN","termSource":"NCI"},{"termName":"TG 1701","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1701","termGroup":"CN","termSource":"NCI"},{"termName":"TG1701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858206-58-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SG5I5QTR4E"},{"name":"Maps_To","value":"BTK inhibitor TG-1701"},{"name":"NCI_Drug_Dictionary_ID","value":"798666"},{"name":"NCI_META_CUI","value":"CL970969"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137682":{"preferredName":"Budigalimab","code":"C137682","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody ABBV-181 targets and binds to PD-1, thereby blocking its binding to the PD-1 ligand, programmed cell death-1 ligand 1 (PD-L1), and preventing the activation of PD-1/PD-L1 downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs). PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Budigalimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 181","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-181","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV181","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098225-93-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6VDO4TY3OO"},{"name":"Maps_To","value":"Budigalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"790298"},{"name":"NCI_META_CUI","value":"CL524834"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790298"},{"name":"PDQ_Open_Trial_Search_ID","value":"790298"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C81555":{"preferredName":"Budotitane","code":"C81555","definitions":[{"definition":"A titanium metal complex, coordinated with asymmetric beta-diketonate ligands, with antineoplastic activity. Although the exact mechanism of action remains to be elucidated, budotitane potentially binds either to macromolecules via coordinative covalent bonds, or via intercalation between nucleic acids strands by the aromatic ring of the beta-diketonate. In addition, this agent appears to cause cardiac arrhythmias and is toxic to the liver and kidneys at higher doses. The development of budotitane was halted due to the rapid loss of its labile groups under physiological conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Budotitane","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85969-07-9"},{"name":"Chemical_Formula","value":"2C10H9O2.2C2H5O.Ti"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DV05VZD83V"},{"name":"Legacy Concept Name","value":"Budotitane"},{"name":"Maps_To","value":"Budotitane"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057922"}]}}{"C107555":{"preferredName":"Bufalin","code":"C107555","definitions":[{"definition":"An active ingredient and one of the glycosides in the traditional Chinese medicine ChanSu; it is also a bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans, with potential cardiotonic and antineoplastic activity. Although the mechanism of action of bufalin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and can induce apoptosis in cancer cell lines through the activation of the transcription factor AP-1 via a mitogen activated protein kinase (MAPK) pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bufalin","termGroup":"PT","termSource":"NCI"},{"termName":"3,14-Dihydroxy-Bufa-20,22-Dienolide","termGroup":"SN","termSource":"NCI"},{"termName":"3-Beta,14-Dihydroxy-5-Beta-Bufa-20,22-Dienolide","termGroup":"SY","termSource":"NCI"},{"termName":"3beta,14beta-Dihydroxy-5beta-Bufa-20,22-Dienolide","termGroup":"SY","termSource":"NCI"},{"termName":"5-Beta-Bufa-20,22-Dienolide, 3-Beta,14-Dihydroxy-","termGroup":"SN","termSource":"NCI"},{"termName":"5beta-Bufa-20,22-Dienolide, 3beta,14-Dihydroxy- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3-Beta,5-Beta)- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3beta,5beta)- (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"465-21-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U549S98QLW"},{"name":"Maps_To","value":"Bufalin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054205"}]}}{"C90565":{"preferredName":"Buparlisib","code":"C90565","definitions":[{"definition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buparlisib","termGroup":"PT","termSource":"NCI"},{"termName":"AN 2025","termGroup":"CN","termSource":"NCI"},{"termName":"AN-2025","termGroup":"CN","termSource":"NCI"},{"termName":"AN2025","termGroup":"CN","termSource":"NCI"},{"termName":"BKM 120","termGroup":"CN","termSource":"NCI"},{"termName":"BKM-120","termGroup":"CN","termSource":"NCI"},{"termName":"BKM120","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor BKM120","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"944396-07-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0ZM2Z182GD"},{"name":"Maps_To","value":"Buparlisib"},{"name":"NCI_Drug_Dictionary_ID","value":"667281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"667281"},{"name":"PDQ_Open_Trial_Search_ID","value":"667281"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3886769"}]}}{"C88323":{"preferredName":"Burixafor","code":"C88323","definitions":[{"definition":"An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation; this may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burixafor","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphonic Acid, p-(2-(4-(6-Amino-2-(((trans-4-(((3-(cyclohexylamino)propyl)amino)methyl)cyclohexyl)methyl)amino)-4-pyrimidinyl)-1-piperazinyl)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"TG-0054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1191448-17-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2G17Y0Q20G"},{"name":"Maps_To","value":"Burixafor"},{"name":"NCI_Drug_Dictionary_ID","value":"813325"},{"name":"NCI_META_CUI","value":"CL413584"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130049":{"preferredName":"Burixafor Hydrobromide","code":"C130049","definitions":[{"definition":"The hydrobromide salt form of burixafor, an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with hematopoietic stem cell (HSC)-mobilization and chemosensitizing activities. Upon administration, burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into the peripheral circulation. Additionally, burixafor-mediated mobilization of disseminated tumor cells (DTCs) from the bone marrow into the blood may make these metastatic tumor cells more susceptible to the actions of chemotherapeutic agents. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burixafor Hydrobromide","termGroup":"PT","termSource":"NCI"},{"termName":"Burixafor HBr","termGroup":"SY","termSource":"NCI"},{"termName":"TG-0054 HBr","termGroup":"SY","termSource":"NCI"},{"termName":"TG-0054 Hydrobromide","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Burixafor Hydrobromide"},{"name":"NCI_Drug_Dictionary_ID","value":"661023"},{"name":"NCI_META_CUI","value":"CL513400"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119744":{"preferredName":"Burosumab","code":"C119744","definitions":[{"definition":"An orally bioavailable recombinant human immunoglobulin G1 monoclonal antibody directed against human fibroblast growth factor 23 (FGF23), that can be used to increase serum phosphate levels. Upon subcutaneous administration, burosumab binds to and inhibits FGF23, thereby interfering with FGF23 signaling. This increases tubular phosphate reabsorption, decreases excretion of phosphate, and increases serum phosphate levels, resulting in enhanced bone mineralization. FGF23, a member of the fibroblast growth factor (FGF) family produced by osteocytes, plays a key role in hypophosphatemic rickets/osteomalacia, such as X-linked hypophosphatemia (XLH) and tumor-induced rickets/osteomalacia. Increased FGF23 levels lead to decreased expression of the sodium-phosphate co-transporters in the proximal tubules, reduced renal phosphate reabsorption, increased excretion by the kidneys, and low serum phosphate concentration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Burosumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-FGF23 IgG1 Monoclonal Antibody KRN23","termGroup":"SY","termSource":"NCI"},{"termName":"Burosumab-TWZA","termGroup":"SY","termSource":"NCI"},{"termName":"Crysvita","termGroup":"BR","termSource":"NCI"},{"termName":"KRN23","termGroup":"CN","termSource":"NCI"},{"termName":"UX023","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610833-03-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G9WJT6RD29"},{"name":"Maps_To","value":"Burosumab"},{"name":"NCI_Drug_Dictionary_ID","value":"767123"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767123"},{"name":"PDQ_Open_Trial_Search_ID","value":"767123"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896830"}]}}{"C320":{"preferredName":"Buserelin","code":"C320","definitions":[{"definition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called gonadotropin-releasing hormones. In prostate cancer therapy, buserelin blocks the production of testosterone in the testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Buserelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)","termGroup":"SN","termSource":"NCI"},{"termName":"BSRL","termGroup":"AB","termSource":"NCI"},{"termName":"Busereline","termGroup":"SY","termSource":"NCI"},{"termName":"Etilamide","termGroup":"BR","termSource":"NCI"},{"termName":"HOE 766","termGroup":"CN","termSource":"NCI"},{"termName":"HOE-766","termGroup":"CN","termSource":"NCI"},{"termName":"HOE766","termGroup":"CN","termSource":"NCI"},{"termName":"ICI 123215","termGroup":"CN","termSource":"NCI"},{"termName":"ICI-123215","termGroup":"CN","termSource":"NCI"},{"termName":"ICI123215","termGroup":"CN","termSource":"NCI"},{"termName":"S74 6766","termGroup":"CN","termSource":"NCI"},{"termName":"S74-6766","termGroup":"CN","termSource":"NCI"},{"termName":"S746766","termGroup":"CN","termSource":"NCI"},{"termName":"Tiloryth","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Contraception, female; Endometriosis; Infertility; in vitro fertilization; Polycystic ovary syndrome; Prostate cancer; Uterine leiomyoma"},{"name":"CAS_Registry","value":"57982-77-1"},{"name":"Chemical_Formula","value":"C60H86N16O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PXW8U3YXDV"},{"name":"Legacy Concept Name","value":"Buserelin"},{"name":"Maps_To","value":"Buserelin"},{"name":"NCI_Drug_Dictionary_ID","value":"39170"},{"name":"NSC Number","value":"725176"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39170"},{"name":"PDQ_Open_Trial_Search_ID","value":"39170"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006456"}]}}{"C160712":{"preferredName":"Bushen Culuan Decoction","code":"C160712","definitions":[{"definition":"A traditional Chinese medicine (TCM) decoction containing a mixture of ten Chinese herbs including Tusizi, Yinyanghuo, Xianmao, Xuduan, Gouqizi, Nvzhenzi, Zelan, Shengpuhuang, Xiangfu and Chuanshanlong, with potential to induce ovulation. Upon oral administration, Bushen Culuan decoction may, through a not yet fully elucidated mechanism, depress follicle-stimulating hormone (FSH) levels, elevate anti-Mullerian hormone (AMH) levels, and increase the number of antral follicle counts (AFCs), thereby promoting ovulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bushen Culuan Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"Bushen Culuan TCM Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"Bushen Culuan Traditional Chinese Medicine Decoction","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bushen Culuan Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"797882"},{"name":"NCI_META_CUI","value":"CL969814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797882"},{"name":"PDQ_Open_Trial_Search_ID","value":"797882"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151930":{"preferredName":"Bushen-Jianpi Decoction","code":"C151930","definitions":[{"definition":"A traditional Chinese medicine (TCM) that is used for Yin deficiency of the liver, kidney and spleen, with potential immunomodulating and antineoplastic activities. Bushen-Jianpi decoction (BSJPD; BJD) consists of various herbs, including, but not limited to, Radix Codonopsis (Dang Shen), Fructus Lycii (the fruit of Chinese wolfberry), Rhizoma Atractylodis Macrocephalae (Baishu; Bai Zhu), Fructus Ligustri Lucidi, Cuscuta chinensis (Chinese dodder) seed, and Psoralea corylifolia Linn. As a TCM, Bushen-Jianpi is used as an antineoplastic agent as it is thought to invigorate the spleen and tonify the kidney, which presumably prevents or treats a variety of cancers. Upon administration of Bushen-Jianpi decoction, the ingredients in the decoction may affect signaling pathways involved in carcinogenesis and enhance the immune system by increasing the levels of numerous cytokines and a variety of immune cells, such as cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs) and macrophages. It may also reduce the expression of various proteins involved in tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bushen-Jianpi Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"BJD","termGroup":"AB","termSource":"NCI"},{"termName":"BJHD","termGroup":"AB","termSource":"NCI"},{"termName":"BSJPD","termGroup":"AB","termSource":"NCI"},{"termName":"Jianpi Bushen","termGroup":"SY","termSource":"NCI"},{"termName":"Jianpi Bushen Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"JPBS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bushen-Jianpi Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"793123"},{"name":"NCI_META_CUI","value":"CL553269"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793123"},{"name":"PDQ_Open_Trial_Search_ID","value":"793123"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C321":{"preferredName":"Busulfan","code":"C321","definitions":[{"definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Busulfan","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-Bis(methanesulfonoxy)butane","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Bitanediol Dimethanesulfonate Esters","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Butanediol Dimethylsulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Di(methanesulfonyloxy)butane","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Di(methylsulfonyloxy)butane","termGroup":"SN","termSource":"NCI"},{"termName":"BUS","termGroup":"AB","termSource":"NCI"},{"termName":"Busilvex","termGroup":"FB","termSource":"NCI"},{"termName":"Bussulfam","termGroup":"SY","termSource":"NCI"},{"termName":"Busulfanum","termGroup":"SY","termSource":"NCI"},{"termName":"Busulfex","termGroup":"BR","termSource":"NCI"},{"termName":"Busulphan","termGroup":"SY","termSource":"NCI"},{"termName":"CB-2041","termGroup":"CN","termSource":"NCI"},{"termName":"Glyzophrol","termGroup":"SY","termSource":"NCI"},{"termName":"GT-41","termGroup":"CN","termSource":"NCI"},{"termName":"Joacamine","termGroup":"SY","termSource":"NCI"},{"termName":"Methanesulfonic Acid Tetramethylene Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Mielucin","termGroup":"FB","termSource":"NCI"},{"termName":"Misulban","termGroup":"FB","termSource":"NCI"},{"termName":"Misulfan","termGroup":"SY","termSource":"NCI"},{"termName":"Mitosan","termGroup":"FB","termSource":"NCI"},{"termName":"Myeleukon","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloleukon","termGroup":"SY","termSource":"NCI"},{"termName":"Myelosan","termGroup":"SY","termSource":"NCI"},{"termName":"Mylecytan","termGroup":"SY","termSource":"NCI"},{"termName":"Myleran","termGroup":"BR","termSource":"NCI"},{"termName":"Sulfabutin","termGroup":"SY","termSource":"NCI"},{"termName":"Tetramethylene Bis(methanesulfonate)","termGroup":"SY","termSource":"NCI"},{"termName":"WR-19508","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bone marrow disorders; chronic myelogenous leukemia; palliative; neoadjuvant to allogeneic hematopoietic progenitor cell transplantation; neoplastic meningitis; primary brain malignancies"},{"name":"CAS_Registry","value":"55-98-1"},{"name":"CHEBI_ID","value":"CHEBI:28901"},{"name":"Chemical_Formula","value":"C6H14O6S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"G1LN9045DK"},{"name":"Legacy Concept Name","value":"Busulfan"},{"name":"Maps_To","value":"Busulfan"},{"name":"NCI_Drug_Dictionary_ID","value":"41947"},{"name":"NSC Number","value":"750"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41947"},{"name":"PDQ_Open_Trial_Search_ID","value":"41947"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006463"}]}}{"C1029":{"preferredName":"Buthionine Sulfoximine","code":"C1029","definitions":[{"definition":"A drug that may help prevent resistance to some anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Buthionine Sulfoximine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino-4-(S-butylsulfonimidoyl) Butanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BSO","termGroup":"AB","termSource":"NCI"},{"termName":"Butanoic Acid, 2-Amino-4-(S-butylsulfonimidoyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Buthionine Sulphoximine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Buthionine Sulfoximine","termGroup":"SY","termSource":"NCI"},{"termName":"S-(3-Amino-3-carboxypropyl)-S-butylsulfoximine","termGroup":"SN","termSource":"NCI"},{"termName":"S-(n-Butyl)homocysteine Sulfoximine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83730-53-4"},{"name":"Chemical_Formula","value":"C8H18N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EEY8DZS103"},{"name":"Legacy Concept Name","value":"Buthionine_Sulfoximine"},{"name":"Maps_To","value":"Buthionine Sulfoximine"},{"name":"NCI_Drug_Dictionary_ID","value":"39123"},{"name":"NSC Number","value":"326231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39123"},{"name":"PDQ_Open_Trial_Search_ID","value":"39123"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054252"}]}}{"C131491":{"preferredName":"BXQ-350 Nanovesicle Formulation","code":"C131491","definitions":[{"definition":"A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BXQ-350 Nanovesicle Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"BXQ-350","termGroup":"CN","termSource":"NCI"},{"termName":"SapC-DOPS Nanovesicles","termGroup":"SY","termSource":"NCI"},{"termName":"Saposin C-Dioleoylphosphatidylserine Complexes","termGroup":"SY","termSource":"NCI"},{"termName":"Saposin C-Dioleoylphosphatidylserine Nanovesicles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2N62LTC861"},{"name":"Maps_To","value":"BXQ-350 Nanovesicle Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"785725"},{"name":"NCI_META_CUI","value":"CL514261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785725"},{"name":"PDQ_Open_Trial_Search_ID","value":"785725"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121647":{"preferredName":"Bezuclastinib","code":"C121647","definitions":[{"definition":"An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bezuclastinib","termGroup":"PT","termSource":"NCI"},{"termName":"c-Kit Inhibitor PLX9486","termGroup":"SY","termSource":"NCI"},{"termName":"CGT 9486","termGroup":"CN","termSource":"NCI"},{"termName":"CGT-9486","termGroup":"CN","termSource":"NCI"},{"termName":"CGT9486","termGroup":"CN","termSource":"NCI"},{"termName":"PLX9486","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616385-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ROQ545LAG"},{"name":"Maps_To","value":"c-Kit Inhibitor PLX9486"},{"name":"NCI_Drug_Dictionary_ID","value":"770823"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770823"},{"name":"PDQ_Open_Trial_Search_ID","value":"770823"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053605"}]}}{"C129314":{"preferredName":"c-Met Inhibitor AL2846","code":"C129314","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration AL2846 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor AL2846","termGroup":"PT","termSource":"NCI"},{"termName":"AL 2846","termGroup":"CN","termSource":"NCI"},{"termName":"AL-2846","termGroup":"CN","termSource":"NCI"},{"termName":"AL2846","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor AL2846"},{"name":"NCI_Drug_Dictionary_ID","value":"783249"},{"name":"NCI_META_CUI","value":"CL512253"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783249"},{"name":"PDQ_Open_Trial_Search_ID","value":"783249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82677":{"preferredName":"c-Met Inhibitor AMG 208","code":"C82677","definitions":[{"definition":"A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity, which may result in cell growth inhibition in tumors that overexpress c-Met. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase, plays an important role in epithelial cell proliferation and has been shown to be overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor AMG 208","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1002304-34-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2SR66P7VM"},{"name":"Legacy Concept Name","value":"c-Met_Inhibitor_AMG_208"},{"name":"Maps_To","value":"c-Met Inhibitor AMG 208"},{"name":"NCI_Drug_Dictionary_ID","value":"632625"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632625"},{"name":"PDQ_Open_Trial_Search_ID","value":"632625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830208"}]}}{"C95203":{"preferredName":"c-Met Inhibitor AMG 337","code":"C95203","definitions":[{"definition":"An orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-Met, thereby disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor AMG 337","termGroup":"PT","termSource":"NCI"},{"termName":"1,6-Naphthyridin-5(6H)-one, 6-((1R)-1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo(4,3-a)pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"AMG 337","termGroup":"CN","termSource":"NCI"},{"termName":"AMG337","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1173699-31-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"08WG8S0L8D"},{"name":"Maps_To","value":"c-Met Inhibitor AMG 337"},{"name":"NCI_Drug_Dictionary_ID","value":"690935"},{"name":"NCI_META_CUI","value":"CL426693"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690935"},{"name":"PDQ_Open_Trial_Search_ID","value":"690935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128895":{"preferredName":"c-Met Inhibitor HS-10241","code":"C128895","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor HS-10241","termGroup":"PT","termSource":"NCI"},{"termName":"HS-10241","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor HS-10241"},{"name":"NCI_Drug_Dictionary_ID","value":"782607"},{"name":"NCI_META_CUI","value":"CL512254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782607"},{"name":"PDQ_Open_Trial_Search_ID","value":"782607"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77893":{"preferredName":"c-Met Inhibitor JNJ-38877605","code":"C77893","definitions":[{"definition":"An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor JNJ-38877605","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-38877605","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943540-75-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15UDG410PN"},{"name":"Legacy Concept Name","value":"c-Met_Inhibitor_JNJ-38877605"},{"name":"Maps_To","value":"c-Met Inhibitor JNJ-38877605"},{"name":"NCI_Drug_Dictionary_ID","value":"594157"},{"name":"NCI_META_CUI","value":"CL383572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594157"},{"name":"PDQ_Open_Trial_Search_ID","value":"594157"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90591":{"preferredName":"c-Met Inhibitor MK2461","code":"C90591","definitions":[{"definition":"A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor MK2461 preferentially inhibits activated c-Met in an ATP-competitive manner, thereby inhibiting its tyrosine kinase activity, which may inhibit c-Met signaling and result in cell growth inhibition in tumors that overexpress c-Met. c-Met, encoding the hepatocyte growth factor receptor (HGFR) tyrosine kinase, plays an important role in tumor cell proliferation and has been shown to be overexpressed or mutated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor MK2461","termGroup":"PT","termSource":"NCI"},{"termName":"MK2461","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor MK2461"},{"name":"NCI_Drug_Dictionary_ID","value":"560555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560555"},{"name":"PDQ_Open_Trial_Search_ID","value":"560555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983789"}]}}{"C116866":{"preferredName":"c-Met Inhibitor MK8033","code":"C116866","definitions":[{"definition":"An orally bioavailable inhibitor of c-Met, with potential antineoplastic activity. Upon administration, c-Met inhibitor MK8033 binds to and inhibits the autophosphorylation of the c-Met protein, which disrupts c-Met signal transduction pathways and may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. In addition, MK8033 inhibits Ron (receptor originated from nantes, MST1R). c-Met protein, which is encoded by the proto-oncogene MET, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis. Ron, a member of the Met family of cell surface receptor tyrosine kinases, is also overexpressed on certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor MK8033","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"MK 8033","termGroup":"CN","termSource":"NCI"},{"termName":"MK-8033","termGroup":"CN","termSource":"NCI"},{"termName":"MK8033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1196681-38-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"350H6PBQ5Q"},{"name":"Maps_To","value":"c-Met Inhibitor MK8033"},{"name":"NCI_Drug_Dictionary_ID","value":"580991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580991"},{"name":"PDQ_Open_Trial_Search_ID","value":"580991"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659325"}]}}{"C88314":{"preferredName":"Tepotinib","code":"C88314","definitions":[{"definition":"An orally bioavailable inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR), is the product of the proto-oncogene c-Met and is overexpressed or mutated in many tumor cell types; this protein plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tepotinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzonitrile, 3-(1,6-Dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"c-Met Inhibitor MSC2156119J","termGroup":"SY","termSource":"NCI"},{"termName":"EMD 1214063","termGroup":"CN","termSource":"NCI"},{"termName":"EMD-1214063","termGroup":"CN","termSource":"NCI"},{"termName":"EMD1214063","termGroup":"CN","termSource":"NCI"},{"termName":"MSC 2156119","termGroup":"CN","termSource":"NCI"},{"termName":"MSC 2156119J","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-2156119","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-2156119J","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2156119","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2156119J","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1100598-32-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1IJV77EI07"},{"name":"Maps_To","value":"c-Met Inhibitor MSC2156119J"},{"name":"Maps_To","value":"Tepotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"749525"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658472"}]}}{"C1541":{"preferredName":"C-myb Antisense Oligonucleotide G4460","code":"C1541","definitions":[{"definition":"A 24-base phosphorothiolate antisense oligodeoxynucleotide (ODN) for the proto-oncogene c-myb with potential antineoplastic activity. C-myb antisense oligonucleotide G4460 binds to codon sequences 2 to 9 of c-myb mRNA, inhibiting translation of the transcript. Suppression of c-myb expression with this agent may result in the restoration of normal differentiation pathways, increased antiproliferative effects, and the induction of apoptosis in early progenitor hematopoietic cells and in tumor cells that overexpress c-myb. Tumor-cell overexpression of c-myb blocks differentiation, promotes proliferation, and inhibits apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"C-myb Antisense Oligonucleotide G4460","termGroup":"PT","termSource":"NCI"},{"termName":"c-MYB Antisense","termGroup":"SY","termSource":"NCI"},{"termName":"c-MYB Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"c-Myb Antisense OND","termGroup":"SY","termSource":"NCI"},{"termName":"c-Myb LR-3001","termGroup":"SY","termSource":"NCI"},{"termName":"G4460","termGroup":"CN","termSource":"NCI"},{"termName":"INX-3001","termGroup":"CN","termSource":"NCI"},{"termName":"LR-3001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LR-3001"},{"name":"Maps_To","value":"C-myb Antisense Oligonucleotide G4460"},{"name":"NCI_Drug_Dictionary_ID","value":"43388"},{"name":"NSC Number","value":"710296"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43388"},{"name":"PDQ_Open_Trial_Search_ID","value":"43388"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253788"}]}}{"C2721":{"preferredName":"c-raf Antisense Oligonucleotide ISIS 5132","code":"C2721","definitions":[{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA.  ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo.  Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-raf Antisense Oligonucleotide ISIS 5132","termGroup":"PT","termSource":"NCI"},{"termName":"c-RAF Antisense","termGroup":"SY","termSource":"NCI"},{"termName":"CGP 69846A","termGroup":"CN","termSource":"NCI"},{"termName":"CGP69846A","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS 5132","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS 5132/CGP69846A","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS-5132","termGroup":"CN","termSource":"NCI"},{"termName":"RAF-IK Antisense ODN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"177075-18-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48IAF3FDP3"},{"name":"Legacy Concept Name","value":"ISIS_5132"},{"name":"Maps_To","value":"c-raf Antisense Oligonucleotide ISIS 5132"},{"name":"NCI_Drug_Dictionary_ID","value":"42994"},{"name":"NSC Number","value":"719336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42994"},{"name":"PDQ_Open_Trial_Search_ID","value":"42994"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0389883"}]}}{"C88264":{"preferredName":"C-VISA BikDD:Liposome","code":"C88264","definitions":[{"definition":"A formulation composed of DOTAP:cholesterol liposome nanoparticles complexed with the plasmid C-VISA BiKDD, with potential antineoplastic activity. C-VISA BikDD: liposome consists of a pancreatic-cancer-specific expression vector VISA (VP16-GAL4-WPRE integrated systemic amplifier) and a pancreatic-cancer-specific promoter CCKAR (cholecystokinin type A receptor) (CCKAR-VISA or C-VISA) which drives expression of the gene BikDD, a mutant form of the potent proapoptotic gene Bik (Bcl-2 interacting killer). Upon administration and transduction into pancreatic tumor cells, expression of BikDD by C-VISA BikDD:liposome may induce pancreatic tumor cell apoptosis and suppress pancreatic tumor cell proliferation. BikDD binds with greater affinity to anti-apoptotic proteins bcl-2, bcl-xl, bcl-w and Mcl-1 and is more potent than wild-type Bik. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at molar ratio of 1:1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"C-VISA BikDD:Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"C-VISA BikDD Plasmid: DOTAP:Cholesterol Liposome-Based Nanoparticle","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"C-VISA BikDD:Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"654631"},{"name":"NCI_META_CUI","value":"CL412442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654631"},{"name":"PDQ_Open_Trial_Search_ID","value":"654631"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155812":{"preferredName":"Ozuriftamab Vedotin","code":"C155812","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Upon administration of ozuriftamab vedotin, the anti-ROR2 antibody becomes activated through an as of yet not fully elucidated process, only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells and not in the microenvironment of normal, healthy tissues. Upon binding to ROR2-expressing cancer cells and internalization, the cytotoxic agent kills the cancer cells. ROR2, highly expressed during embryonic development while only minimally expressed on certain normal, healthy cells, is involved in Wnt signal transduction and is overexpressed on certain cancer cells. It plays a key role in cancer cell proliferation, migration and invasion. High levels of ROR2 expression often correlates with poor prognosis. The CAB antibody allows for efficient binding to ROR2-expressing cancer cells only, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy ROR2-expressing cells under normal conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ozuriftamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ROR2 CAB ADC","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"BA 3021","termGroup":"CN","termSource":"NCI"},{"termName":"BA3021","termGroup":"CN","termSource":"NCI"},{"termName":"CAB Anti-ROR2 ADC BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"CAB-ROR2-ADC","termGroup":"SY","termSource":"NCI"},{"termName":"CAB-ROR2-ADC BA3021","termGroup":"SY","termSource":"NCI"},{"termName":"Conditionally Active Biologic Anti-ROR2 Antibody-drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"ROR2-targeted ADC BA3021","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460400-11-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BPM6YN0KLI"},{"name":"Maps_To","value":"CAB-ROR2-ADC BA3021"},{"name":"NCI_Drug_Dictionary_ID","value":"794991"},{"name":"NCI_META_CUI","value":"CL556342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794991"},{"name":"PDQ_Open_Trial_Search_ID","value":"794991"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66937":{"preferredName":"Cabazitaxel","code":"C66937","definitions":[{"definition":"A drug used with prednisone to treat hormone-resistant prostate cancer that has spread and that had been treated with docetaxel. It is also being studied in the treatment of other types of cancer. Cabazitaxel blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabazitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]","termGroup":"SN","termSource":"NCI"},{"termName":"Jevtana","termGroup":"BR","termSource":"NCI"},{"termName":"RPR 116258A","termGroup":"CN","termSource":"NCI"},{"termName":"RPR-116258A","termGroup":"CN","termSource":"NCI"},{"termName":"RPR116258A","termGroup":"CN","termSource":"NCI"},{"termName":"Taxoid XRP6258","termGroup":"SY","termSource":"NCI"},{"termName":"TXD 258","termGroup":"CN","termSource":"NCI"},{"termName":"TXD-258","termGroup":"CN","termSource":"NCI"},{"termName":"TXD258","termGroup":"CN","termSource":"NCI"},{"termName":"XRP 6258","termGroup":"CN","termSource":"NCI"},{"termName":"XRP-6258","termGroup":"CN","termSource":"NCI"},{"termName":"XRP6258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic hormone-refractory prostate cancer"},{"name":"CAS_Registry","value":"183133-96-2"},{"name":"CHEBI_ID","value":"CHEBI:63584"},{"name":"Chemical_Formula","value":"C45H57NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"51F690397J"},{"name":"Legacy Concept Name","value":"XRP6258"},{"name":"Maps_To","value":"Cabazitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"534131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"534131"},{"name":"PDQ_Open_Trial_Search_ID","value":"534131"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830183"}]}}{"C123831":{"preferredName":"Cabiralizumab","code":"C123831","definitions":[{"definition":"A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks bone destruction. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabiralizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CSF1R FPA008","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986227","termGroup":"CN","termSource":"NCI"},{"termName":"FPA 008","termGroup":"CN","termSource":"NCI"},{"termName":"FPA-008","termGroup":"CN","termSource":"NCI"},{"termName":"FPA008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1613144-80-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5FJL6W0640"},{"name":"Maps_To","value":"Cabiralizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"775874"},{"name":"NCI_META_CUI","value":"CL498224"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775874"},{"name":"PDQ_Open_Trial_Search_ID","value":"775874"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52200":{"preferredName":"Cabozantinib","code":"C52200","definitions":[{"definition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabozantinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849217-68-1"},{"name":"Chemical_Formula","value":"C28H24FN3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"1C39JW444G"},{"name":"Legacy Concept Name","value":"XL184"},{"name":"Maps_To","value":"Cabozantinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3181682"}]}}{"C97938":{"preferredName":"Cabozantinib S-malate","code":"C97938","definitions":[{"definition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cabozantinib S-malate","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-907351","termGroup":"CN","termSource":"NCI"},{"termName":"Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Cabometyx","termGroup":"BR","termSource":"NCI"},{"termName":"Cometriq","termGroup":"BR","termSource":"NCI"},{"termName":"XL 184","termGroup":"CN","termSource":"NCI"},{"termName":"XL-184","termGroup":"CN","termSource":"NCI"},{"termName":"XL184","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced renal cell carcinoma (RCC); hepatocellular carcinoma (HCC)"},{"name":"CAS_Registry","value":"1140909-48-3"},{"name":"Chemical_Formula","value":"C28H24FN3O5.C4H6O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DR7ST46X58"},{"name":"Maps_To","value":"Cabozantinib S-malate"},{"name":"NCI_Drug_Dictionary_ID","value":"461103"},{"name":"PDQ_Closed_Trial_Search_ID","value":"461103"},{"name":"PDQ_Open_Trial_Search_ID","value":"461103"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3468008"}]}}{"C1032":{"preferredName":"Cactinomycin","code":"C1032","definitions":[{"definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Cactinomycin binds to DNA by intercalating between guanine and cytosine, forming stable antibiotic-DNA complexes that inhibit RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cactinomycin","termGroup":"PT","termSource":"NCI"},{"termName":"Actinomycin C","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"8052-16-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0OCC969V50"},{"name":"Legacy Concept Name","value":"Cactinomycin"},{"name":"Maps_To","value":"Cactinomycin"},{"name":"NSC Number","value":"18268"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054404"}]}}{"C63756":{"preferredName":"Caffeic Acid Phenethyl Ester","code":"C63756","definitions":[{"definition":"The phenethyl alcohol ester of caffeic acid and a bioactive component of honeybee hive propolis, with antineoplastic, cytoprotective and immunomodulating activities. Upon administration, caffeic acid phenethyl ester (CAPE) inhibits the activation of nuclear transcription factor NF-kappa B and may suppress p70S6K and Akt-driven signaling pathways. In addition, CAPE inhibits PDGF-induced proliferation of vascular smooth muscle cells through the activation of p38 mitogen-activated protein kinase (MAPK) and hypoxia-inducible factor (HIF)-1alpha and subsequent induction of heme oxygenase-1 (HO-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Caffeic Acid Phenethyl Ester","termGroup":"PT","termSource":"NCI"},{"termName":"2-Phenylethyl 3-(3,4-dihydroxyphenyl)-2-propenoate","termGroup":"SN","termSource":"NCI"},{"termName":"3-(3,4-Dihydroxyphenyl)-2-propenoic Acid, 2-Phenylethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"CAPE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"104594-70-9"},{"name":"Chemical_Formula","value":"C17H16O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G960R9S5SK"},{"name":"Legacy Concept Name","value":"Caffeic_Acid_Phenethyl_Ester"},{"name":"Maps_To","value":"Caffeic Acid Phenethyl Ester"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054434"}]}}{"C117731":{"preferredName":"CAIX Inhibitor DTP348","code":"C117731","definitions":[{"definition":"An orally bioavailable, nitroimidazole-based sulfamide, carbonic anhydrase IX (CAIX) inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor DTP348 inhibits tumor-associated CAIX, a hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents the acidification of the tumor's extracellular microenvironment and decreases the intracellular pH. This results in increased cell death in CAIX-expressing, hypoxic tumors. In addition, DTP348, through its nitroimidazole moiety, is able to sensitize hypoxic tumor cells to irradiation. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAIX Inhibitor DTP348","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide","termGroup":"SN","termSource":"NCI"},{"termName":"DTP348","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1383370-92-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2HB46A9CNM"},{"name":"Maps_To","value":"CAIX Inhibitor DTP348"},{"name":"NCI_Drug_Dictionary_ID","value":"763908"},{"name":"NCI_META_CUI","value":"CL474126"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763908"},{"name":"PDQ_Open_Trial_Search_ID","value":"763908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117728":{"preferredName":"CAIX Inhibitor SLC-0111","code":"C117728","definitions":[{"definition":"A sulfonamide carbonic anhydrase inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor SLC-0111 inhibits tumor-associated carbonic anhydrase IX (CAIX), an hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents both the acidification of the tumor's extracellular microenvironment and cytoplasmic alkalization. This increases cell death in CAIX-expressing, hypoxic tumors. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion; it is also involved in resistance to both chemo- and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAIX Inhibitor SLC-0111","termGroup":"PT","termSource":"NCI"},{"termName":"SLC-0111","termGroup":"CN","termSource":"NCI"},{"termName":"U-104","termGroup":"CN","termSource":"NCI"},{"termName":"U104","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"178606-66-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ANM9DBL9JT"},{"name":"Maps_To","value":"CAIX Inhibitor SLC-0111"},{"name":"NCI_Drug_Dictionary_ID","value":"763832"},{"name":"NCI_META_CUI","value":"CL474123"},{"name":"NSC Number","value":"213841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763832"},{"name":"PDQ_Open_Trial_Search_ID","value":"763832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78198":{"preferredName":"Calaspargase Pegol","code":"C78198","definitions":[{"definition":"A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the anticancer drug PEG-asparaginase that stays in the body longer. EZN-2285 is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol, L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calaspargase Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl)","termGroup":"SY","termSource":"NCI"},{"termName":"Asparlas","termGroup":"BR","termSource":"NCI"},{"termName":"Calaspargase Pegol","termGroup":"SY","termSource":"NCI"},{"termName":"Calaspargase Pegol-mknl","termGroup":"SY","termSource":"NCI"},{"termName":"EZN-2285","termGroup":"CN","termSource":"NCI"},{"termName":"SC-PEG E. Coli L-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute lymphoblastic leukemia (ALL)"},{"name":"CAS_Registry","value":"941577-06-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T9FVH03HMZ"},{"name":"Legacy Concept Name","value":"Succinimidyl_Carbonate_Monomethoxypolyethylene_Glycol_E_Coli_L-Asparaginase"},{"name":"Maps_To","value":"Calaspargase Pegol-mknl"},{"name":"NCI_Drug_Dictionary_ID","value":"595298"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595298"},{"name":"PDQ_Open_Trial_Search_ID","value":"595298"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699709"}]}}{"C330":{"preferredName":"Calcitriol","code":"C330","definitions":[{"definition":"A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active form of vitamin D. Calcitriol is formed in the kidneys or made in the laboratory. It is used as a drug to increase calcium levels in the body in order to treat skeletal and tissue-related calcium deficiencies caused by kidney or thyroid disorders.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Calcitriol","termGroup":"PT","termSource":"NCI"},{"termName":"(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol","termGroup":"SN","termSource":"NCI"},{"termName":"1,25(OH)2-D3","termGroup":"AB","termSource":"NCI"},{"termName":"1,25-DHCC","termGroup":"SY","termSource":"NCI"},{"termName":"1,25-Dihydroxycholecalciferol","termGroup":"SY","termSource":"NCI"},{"termName":"1,25-Dihydroxycholecaliferol","termGroup":"SY","termSource":"NCI"},{"termName":"Calcijex","termGroup":"BR","termSource":"NCI"},{"termName":"Rocaltrol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hyperparathyroidism; Hypocalcemia"},{"name":"CAS_Registry","value":"32222-06-3"},{"name":"CHEBI_ID","value":"CHEBI:17823"},{"name":"Chemical_Formula","value":"C27H44O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FXC9231JVH"},{"name":"Legacy Concept Name","value":"Calcitriol"},{"name":"Maps_To","value":"Calcitriol"},{"name":"NCI_Drug_Dictionary_ID","value":"41919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41919"},{"name":"PDQ_Open_Trial_Search_ID","value":"41919"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006674"}]}}{"C136828":{"preferredName":"Calcium Release-activated Channels Inhibitor RP4010","code":"C136828","definitions":[{"definition":"A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential antineoplastic activity. Upon administration, RP4010 binds to and inhibits CRACs, thereby preventing the transport of extracellular Ca2+ into the cell and inhibiting the subsequent activation of Ca2+-mediated signaling and transcription of target genes. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), play key roles in calcium homeostasis and are over-activated in a number of cancer cell types. Aberrant activation of CRACs leads to increased cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcium Release-activated Channels Inhibitor RP4010","termGroup":"PT","termSource":"NCI"},{"termName":"CRAC Inhibitor RP4010","termGroup":"SY","termSource":"NCI"},{"termName":"RP 4010","termGroup":"CN","termSource":"NCI"},{"termName":"RP-4010","termGroup":"CN","termSource":"NCI"},{"termName":"RP4010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Calcium Release-activated Channels Inhibitor RP4010"},{"name":"NCI_Drug_Dictionary_ID","value":"790238"},{"name":"NCI_META_CUI","value":"CL524660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790238"},{"name":"PDQ_Open_Trial_Search_ID","value":"790238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C335":{"preferredName":"Calcium Saccharate","code":"C335","definitions":[{"definition":"The calcium salt form of glucaric acid, a natural substance found in many fruits and vegetables, with potential anti-cancer property. One of the key processes in which the human body eliminates toxic chemicals as well as hormones (such as estrogen) is by attaching glucuronic acid to them in the liver and then excreting the complex in the bile. When beta-glucuronidase breaks the bond, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Therefore, supplementing calcium glucarate may suppress the developments of hormone-dependent cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calcium Saccharate","termGroup":"PT","termSource":"NCI"},{"termName":"2,3,4,5-tetrahydroxy-1,6- dioxido-hexane-1,6-dione, Calcium","termGroup":"SN","termSource":"NCI"},{"termName":"Antacidin","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium D-Glucarate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium D-Saccharate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Glucarate","termGroup":"SY","termSource":"NCI"},{"termName":"CGT","termGroup":"AB","termSource":"NCI"},{"termName":"Saccharated Lime","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5793-89-5"},{"name":"Chemical_Formula","value":"C6H8O8.Ca.4H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6AP9J91K4V"},{"name":"Legacy Concept Name","value":"Calcium_Glucarate"},{"name":"Maps_To","value":"Calcium Saccharate"},{"name":"NCI_Drug_Dictionary_ID","value":"41803"},{"name":"NSC Number","value":"122011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41803"},{"name":"PDQ_Open_Trial_Search_ID","value":"41803"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771997"}]}}{"C121642":{"preferredName":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule","code":"C121642","definitions":[{"definition":"An orally available traditional Chinese medicine (TCM)-based capsule formulation containing Calculus bovis, the dried gallstones of cattle, Moschus, also referred to as deer musk, the resin Olibanum and the resin Myrrha, with potential antineoplastic and chemopreventive activities. Although the exact mechanisms of action through which the active ingredients in the Calculus bovis/Moschus/Olibanum/Myrrha capsule elicit their effects have yet to be fully elucidated, they may, upon intake, exert their antineoplastic activity through modulation of the immune system, inhibition of tumor cell proliferation and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Wangbang Pharmaceutical Xihuang Capsule","termGroup":"SY","termSource":"NCI"},{"termName":"XHP","termGroup":"AB","termSource":"NCI"},{"termName":"Xihuang Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Calculus bovis/Moschus/Olibanum/Myrrha Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"770710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770710"},{"name":"PDQ_Open_Trial_Search_ID","value":"770710"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053490"}]}}{"C1035":{"preferredName":"Calicheamicin Gamma 1I","code":"C1035","definitions":[{"definition":"An oligosaccharide enediyne antitumor antibiotic isolated from Micromonospora echinospora ssp. Calichensis.  Calicheamicin Gamma 1I binds to the minor groove of DNA, resulting in site-specific double-strand breaks and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Calicheamicin Gamma 1I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Calicheamicin_Gamma_1I"},{"name":"Maps_To","value":"Calicheamicin Gamma 1I"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0054506"}]}}{"C338":{"preferredName":"Camptothecin","code":"C338","definitions":[{"definition":"An alkaloid isolated from the Chinese tree Camptotheca acuminata, with antineoplastic activity.  During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Camptothecin","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-Camptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"(S)-4-ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolozino[1,2-b]quinoline-3,14(4H,12H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Pyrano[3',3'.6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4hydroxy-(S)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"20-(S)-camptothecine","termGroup":"SY","termSource":"NCI"},{"termName":"21, 22-secocamptothecin-21-oic acid lactone","termGroup":"SN","termSource":"NCI"},{"termName":"camptothecine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7689-03-4"},{"name":"CHEBI_ID","value":"CHEBI:27656"},{"name":"Chemical_Formula","value":"C20H16N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XT3Z54Z28A"},{"name":"Legacy Concept Name","value":"Camptothecin"},{"name":"Maps_To","value":"Camptothecin"},{"name":"NCI_Drug_Dictionary_ID","value":"39173"},{"name":"NSC Number","value":"94600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39173"},{"name":"PDQ_Open_Trial_Search_ID","value":"39173"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006812"}]}}{"C80047":{"preferredName":"Camptothecin Analogue TLC388","code":"C80047","definitions":[{"definition":"A synthetic analogue of camptothecin with potential antineoplastic and radio-sensitizing activities. Camptothecin analogue TLC388 selectively stabilizes topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Topoisomerase I relaxes negative super-coiled DNA during replication and transcription. This agent has been chemically modified to enhance the potency and stability of camptothecin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camptothecin Analogue TLC388","termGroup":"PT","termSource":"NCI"},{"termName":"Lipotecan","termGroup":"BR","termSource":"NCI"},{"termName":"TLC388","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1432468-79-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D47234N30N"},{"name":"Legacy Concept Name","value":"Camptothecin_Analogue_TLC388"},{"name":"Maps_To","value":"Camptothecin Analogue TLC388"},{"name":"NCI_Drug_Dictionary_ID","value":"615096"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615096"},{"name":"PDQ_Open_Trial_Search_ID","value":"615096"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703206"}]}}{"C1886":{"preferredName":"Afeletecan Hydrochloride","code":"C1886","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called camptothecins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of afeletecan, a water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. Afeletecan stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Afeletecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 38-3441","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 56-3722","termGroup":"CN","termSource":"NCI"},{"termName":"BAY56-3722","termGroup":"CN","termSource":"NCI"},{"termName":"Camptothecin Glycoconjugate BAY 38-3441","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"215604-74-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DTJ7VPW43J"},{"name":"Legacy Concept Name","value":"BAY_56-3722"},{"name":"Maps_To","value":"Camptothecin Glycoconjugate BAY 38-3441"},{"name":"NCI_Drug_Dictionary_ID","value":"38705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38705"},{"name":"PDQ_Open_Trial_Search_ID","value":"38705"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1101785"}]}}{"C2344":{"preferredName":"Camptothecin Sodium","code":"C2344","definitions":[{"definition":"The sodium salt of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, with antineoplastic activity.  During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The sodium salt of camptothecin is more water-soluble than the parent molecule. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camptothecin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Camptothecin Sodium Salt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"25387-67-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3L6CT9UWOM"},{"name":"Legacy Concept Name","value":"Camptothecin_Sodium"},{"name":"Maps_To","value":"Camptothecin Sodium"},{"name":"NSC Number","value":"100880"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516156"}]}}{"C84857":{"preferredName":"Camptothecin-20(S)-O-Propionate Hydrate","code":"C84857","definitions":[{"definition":"The hydrated, crystalline propionate ester (attached in position C-20) prodrug of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, with potential antineoplastic activity. Upon entry into cells, camptothecin-20(S)-O-propionate is hydrolyzed by esterases into the active form camptothecin. Camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery, thus inhibiting DNA replication and triggering apoptotic cell death. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active, S-configured lactone structure to an inactive carboxylate form. The ester chain in the vicinity of the S-configured lactone moiety, a key determinant for the chemotherapeutic efficacy of the camptothecins, inhibits protein binding, rendering this agent resistant to hydrolysis and prolonging its half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camptothecin-20(S)-O-Propionate Hydrate","termGroup":"PT","termSource":"NCI"},{"termName":"CZ48","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Camptothecin-20(S)-O-Propionate Hydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"651549"},{"name":"NCI_META_CUI","value":"CL412415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651549"},{"name":"PDQ_Open_Trial_Search_ID","value":"651549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123816":{"preferredName":"Camrelizumab","code":"C123816","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camrelizumab","termGroup":"PT","termSource":"NCI"},{"termName":"AiRuiKa","termGroup":"FB","termSource":"NCI"},{"termName":"AiRuiKa (TM)","termGroup":"SY","termSource":"NCI"},{"termName":"Carrelizumab","termGroup":"SY","termSource":"NCI"},{"termName":"Carrizumab","termGroup":"SY","termSource":"NCI"},{"termName":"Erica","termGroup":"FB","termSource":"NCI"},{"termName":"HR 301210","termGroup":"CN","termSource":"NCI"},{"termName":"HR-301210","termGroup":"CN","termSource":"NCI"},{"termName":"HR301210","termGroup":"CN","termSource":"NCI"},{"termName":"SHR 1210","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1210","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1798286-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"73096E137E"},{"name":"Maps_To","value":"Camrelizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"775449"},{"name":"NCI_META_CUI","value":"CL498210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775449"},{"name":"PDQ_Open_Trial_Search_ID","value":"775449"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78863":{"preferredName":"Camsirubicin","code":"C78863","definitions":[{"definition":"A synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Camsirubicin intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camsirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"5-Imino-13-deoxydoxoubicin","termGroup":"SN","termSource":"NCI"},{"termName":"GPX-150","termGroup":"CN","termSource":"NCI"},{"termName":"GPX150","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"236095-26-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VI79RD8VNN"},{"name":"Legacy Concept Name","value":"Anthracycline_Analogue_GPX-150"},{"name":"Maps_To","value":"Camsirubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"601485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601485"},{"name":"PDQ_Open_Trial_Search_ID","value":"601485"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698125"}]}}{"C1775":{"preferredName":"Cancell","code":"C1775","definitions":[{"definition":"A liquid that has been promoted as a treatment for a wide range of diseases, including cancer. The ingredients thought to be in Cancell have been tested, and none of them has been shown to be effective in treating any form of cancer. Cancell is not available in the United States.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Cancell (Entelev or Cantron), is a liquid that has been produced in various forms, principally by two manufacturers, since the late 1930s.  The exact composition of Cancell/Entelev is unknown, but the U.S. Food and Drug Administration (FDA) has listed the components as inositol, nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, and catechol.  NCI studies determined that the mixture lacked substantial antitumor activity. (from CancerNet)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancell","termGroup":"PT","termSource":"NCI"},{"termName":"Entelev","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cancell"},{"name":"Maps_To","value":"Cancell"},{"name":"NCI_Drug_Dictionary_ID","value":"257610"},{"name":"NSC Number","value":"637907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257610"},{"name":"PDQ_Open_Trial_Search_ID","value":"257610"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0656937"}]}}{"C121776":{"preferredName":"Cancer Peptide Vaccine S-588410","code":"C121776","definitions":[{"definition":"A cancer peptide vaccine containing five human leukocyte antigen (HLA)-A*2402-restricted epitope peptides derived from as of yet not disclosed oncoantigens, with potential immunostimulating and antineoplastic activities. Upon administration of the cancer peptide vaccine S-588410, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Peptide Vaccine S-588410","termGroup":"PT","termSource":"NCI"},{"termName":"S-588410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cancer Peptide Vaccine S-588410"},{"name":"NCI_Drug_Dictionary_ID","value":"770997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770997"},{"name":"PDQ_Open_Trial_Search_ID","value":"770997"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053593"}]}}{"C88318":{"preferredName":"Canerpaturev","code":"C88318","definitions":[{"definition":"A non-engineered, naturally oncolytic, replication-competent spontaneous herpes simplex virus (HSV) type I mutant variant. Upon intratumoral injection, canerpaturev transfects, replicates in, and lyses rapidly dividing cells such as tumor cells. In addition, this agent may increase host immune responses that may kill non-infected tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canerpaturev","termGroup":"PT","termSource":"NCI"},{"termName":"Herpes Simplex Virus Type 1 HF10","termGroup":"SY","termSource":"NCI"},{"termName":"HF10","termGroup":"CN","termSource":"NCI"},{"termName":"HSV1 HF10","termGroup":"SY","termSource":"NCI"},{"termName":"Msc 2","termGroup":"SY","termSource":"NCI"},{"termName":"TBI-1401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1662666-66-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3F5D10T4M"},{"name":"Maps_To","value":"Canerpaturev"},{"name":"NCI_Drug_Dictionary_ID","value":"660850"},{"name":"NCI_META_CUI","value":"CL413628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660850"},{"name":"PDQ_Open_Trial_Search_ID","value":"660850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1880":{"preferredName":"Canertinib Dihydrochloride","code":"C1880","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. Canertinib blocks the action of proteins called epidermal growth factor receptors, and may cause cancer cells to die. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canertinib Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"CI-1033","termGroup":"CN","termSource":"NCI"},{"termName":"N-[-4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"PD-0183805-002B","termGroup":"CN","termSource":"NCI"},{"termName":"PD183805","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"289499-45-2"},{"name":"Chemical_Formula","value":"C24H25ClFN5O3.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ICJ93X8X90"},{"name":"Legacy Concept Name","value":"CI-1033"},{"name":"Maps_To","value":"Canertinib Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38403"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38403"},{"name":"PDQ_Open_Trial_Search_ID","value":"38403"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707132"}]}}{"C83581":{"preferredName":"Canfosfamide","code":"C83581","definitions":[{"definition":"A modified glutathione analogue and nitrogen mustard prodrug, with potential antineoplastic activity. Canfosfamide is selectively activated by glutathione S-transferase P1-1 into an alkylating metabolite that forms covalent linkages with nucleophilic centers in tumor cell DNA, which may induce a cellular stress response and cytotoxicity, and decrease tumor cell proliferation. Glutathione S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canfosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-L-gamma-Glutamyl-3-((2-((bis(bis(2-chloroethyl)amino)phosphinyl)oxy)ethyl)sulfonyl)-L-alanyl-2-phenylglycine","termGroup":"SN","termSource":"NCI"},{"termName":"Ter 286","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"158382-37-7"},{"name":"Chemical_Formula","value":"C26H40Cl4N5O10PS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1RS284BFUI"},{"name":"Maps_To","value":"Canfosfamide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664315"}]}}{"C2641":{"preferredName":"Canfosfamide Hydrochloride","code":"C2641","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called glutathione analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a modified glutathione analogue with potential antineoplastic activity. Canfosfamide is selectively activated by glutathione S-transferase P1-1 into an alkylating metabolite that forms covalent linkages with nucleophilic centers in tumor cell DNA, which may induce a cellular stress response and cytotoxicity, and decrease tumor proliferation. S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canfosfamide Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Telcyta","termGroup":"BR","termSource":"NCI"},{"termName":"TLK286","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"439943-59-6"},{"name":"Chemical_Formula","value":"C26H40Cl4N5O10PS.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1LI341K7NQ"},{"name":"Legacy Concept Name","value":"TLK286"},{"name":"Maps_To","value":"Canfosfamide Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38367"},{"name":"PDQ_Open_Trial_Search_ID","value":"38367"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1258106"}]}}{"C118452":{"preferredName":"Cannabidiol","code":"C118452","definitions":[{"definition":"A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor 1. CBD stimulates endoplasmic reticulum (ER) stress and inhibits AKT/mTOR signaling, thereby activating autophagy and promoting apoptosis. In addition, CBD enhances the generation of reactive oxygen species (ROS), which further enhances apoptosis. This agent also upregulates the expression of intercellular adhesion molecule 1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) and decreases the expression of inhibitor of DNA binding 1 (ID-1). This inhibits cancer cell invasiveness and metastasis. CBD may also activate the transient receptor potential vanilloid type 2 (TRPV2), which may increase the uptake of various cytotoxic agents in cancer cells. The analgesic effect of CBD is mediated through the binding of this agent to and activation of CB1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cannabidiol","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-","termGroup":"SN","termSource":"NCI"},{"termName":"CBD","termGroup":"AB","termSource":"NCI"},{"termName":"CBD Oil","termGroup":"SY","termSource":"NCI"},{"termName":"Epidiolex","termGroup":"BR","termSource":"NCI"},{"termName":"GWP42003-P","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13956-29-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19GBJ60SN5"},{"name":"Maps_To","value":"Cannabidiol"},{"name":"NCI_Drug_Dictionary_ID","value":"765192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765192"},{"name":"PDQ_Open_Trial_Search_ID","value":"765192"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006863"}]}}{"C159719":{"preferredName":"Cantrixil","code":"C159719","definitions":[{"definition":"A cyclodextrin-encapsulated, third generation super-benzopyran (SBP) compound with potential antineoplastic activity. Upon intraperitoneal (IP) administration, cantrixil enhances the activation and expression of c-Jun, downregulates phosphorylated extracellular signal-regulated kinase (p-ERK) and induces activation of caspase-3, -7 and -9, thereby inducing tumor cell apoptosis. c-Jun, an activator protein-1 (AP-1) transcription factor component, is involved in a wide range of cellular processes including cell cycle progression, differentiation, cell transformation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cantrixil","termGroup":"PT","termSource":"NCI"},{"termName":"cis-4-(para-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan","termGroup":"SN","termSource":"NCI"},{"termName":"TRX E 002 1","termGroup":"CN","termSource":"NCI"},{"termName":"TRX-E-002-1","termGroup":"CN","termSource":"NCI"},{"termName":"TRXE0021","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1803036-93-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5DVS457HEG"},{"name":"Maps_To","value":"Cantrixil"},{"name":"NCI_Drug_Dictionary_ID","value":"797919"},{"name":"NCI_META_CUI","value":"CL951687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797919"},{"name":"PDQ_Open_Trial_Search_ID","value":"797919"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61576":{"preferredName":"Cantuzumab Ravtansine","code":"C61576","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It is made by linking the monoclonal antibody huC242 to a toxic substance called maytansinoid DM4. The monoclonal antibody binds to the surfaces of cancer cells and the maytansinoid DM4 enters the cells and blocks their growth. It is a type of immunotoxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated to a derivative of the cytotoxic agent maytansine, DM4, with potential antitumor activity. Cantuzumab ravtansine is generated from MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. As a result, this agent prevents cell division and reduces cell growth of cancer cells that express CA242.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cantuzumab Ravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"HuC242-DM4","termGroup":"AB","termSource":"NCI"},{"termName":"IMGN242","termGroup":"CN","termSource":"NCI"},{"termName":"Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"868747-45-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RNQ8JQ4R9P"},{"name":"Legacy Concept Name","value":"HuC242-DM4"},{"name":"Maps_To","value":"Cantuzumab Ravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"492706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492706"},{"name":"PDQ_Open_Trial_Search_ID","value":"492706"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831909"}]}}{"C1794":{"preferredName":"Capecitabine","code":"C1794","definitions":[{"definition":"A drug used to treat stage III colon cancer in patients who had surgery to remove the cancer. It is also used to treat metastatic breast cancer that has not improved after treatment with certain other anticancer drugs. Xeloda is being studied in the treatment of other types of cancer. It is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills tumor cells. Xeloda is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capecitabine","termGroup":"PT","termSource":"NCI"},{"termName":"5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine","termGroup":"SN","termSource":"NCI"},{"termName":"Ro 09-1978/000","termGroup":"CN","termSource":"NCI"},{"termName":"Xeloda","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Colorectal cancer, Stage III colon cancer"},{"name":"CAS_Registry","value":"154361-50-9"},{"name":"CHEBI_ID","value":"CHEBI:31348"},{"name":"Chemical_Formula","value":"C15H22FN3O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6804DJ8Z9U"},{"name":"Legacy Concept Name","value":"Capecitabine"},{"name":"Maps_To","value":"Capecitabine"},{"name":"Maps_To","value":"Xeloda"},{"name":"NCI_Drug_Dictionary_ID","value":"42852"},{"name":"NSC Number","value":"712807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42852"},{"name":"PDQ_Open_Trial_Search_ID","value":"42852"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0671970"}]}}{"C99629":{"preferredName":"Capecitabine Rapidly Disintegrating Tablet","code":"C99629","definitions":[{"definition":"A rapidly disintegrating film-coated tablet composed of the fluoropyrimidine carbamate antimetabolite capecitabine with antineoplastic activity. As a prodrug, capecitabine is converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by hepatic carboxylesterase and then to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase and is eventually activated by thymidine phosphorylase to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine triphosphate production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Capecitabine rapidly disintegrating tablet (RDT) contains the water insoluble, disintegrating agent crospovidone which very rapidly disperses and swells in water making this RDT easier to swallow than the traditional capecitabine tablet.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capecitabine Rapidly Disintegrating Tablet","termGroup":"PT","termSource":"NCI"},{"termName":"Capecitabine RDT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Capecitabine Rapidly Disintegrating Tablet"},{"name":"NCI_Drug_Dictionary_ID","value":"721986"},{"name":"NCI_META_CUI","value":"CL433297"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721986"},{"name":"PDQ_Open_Trial_Search_ID","value":"721986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102564":{"preferredName":"Capivasertib","code":"C102564","definitions":[{"definition":"A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capivasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 5363","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-5363","termGroup":"CN","termSource":"NCI"},{"termName":"AZD5363","termGroup":"CN","termSource":"NCI"},{"termName":"Truqap","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations"},{"name":"CAS_Registry","value":"1143532-39-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WFR23M21IE"},{"name":"Maps_To","value":"Capivasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"688304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688304"},{"name":"PDQ_Open_Trial_Search_ID","value":"688304"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3502775"}]}}{"C90564":{"preferredName":"Capmatinib","code":"C90564","definitions":[{"definition":"An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Capmatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"INC 280","termGroup":"CN","termSource":"NCI"},{"termName":"INC-280","termGroup":"CN","termSource":"NCI"},{"termName":"INC280","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 28060","termGroup":"CN","termSource":"NCI"},{"termName":"INCB028060","termGroup":"CN","termSource":"NCI"},{"termName":"INCB28060","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1029712-80-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"TY34L4F9OZ"},{"name":"Maps_To","value":"Capmatinib"},{"name":"NCI_META_CUI","value":"CL416248"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C340":{"preferredName":"Captopril","code":"C340","definitions":[{"definition":"A drug used to treat high blood pressure that is also being studied in the prevention of side effects caused by radiation therapy used in the treatment of cancer. It belongs to the family of drugs called ACE inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity. Captopril competitively inhibits angiotensin converting enzyme (ACE), thereby decreasing levels of angiotensin II, increasing plasma renin activity, and decreasing aldosterone secretion.  This agent may also inhibit tumor angiogenesis by inhibiting endothelial cell matrix metalloproteinases (MMPs) and endothelial cell migration. Captopril may also exhibit antineoplastic activity independent of effects on tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Captopril","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline","termGroup":"SN","termSource":"NCI"},{"termName":"Capoten","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypertension; Heart failure; Left ventricular dysfunction; Diabetic nephropathy"},{"name":"CAS_Registry","value":"62571-86-2"},{"name":"CHEBI_ID","value":"CHEBI:3380"},{"name":"Chemical_Formula","value":"C9H15NO3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9G64RSX1XD"},{"name":"Legacy Concept Name","value":"Captopril"},{"name":"Maps_To","value":"Captopril"},{"name":"NCI_Drug_Dictionary_ID","value":"37824"},{"name":"NSC Number","value":"719847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37824"},{"name":"PDQ_Open_Trial_Search_ID","value":"37824"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006938"}]}}{"C150586":{"preferredName":"CAR T-Cells AMG 119","code":"C150586","definitions":[{"definition":"A preparation of T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of the CAR T-cells AMG 119, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CAR T-Cells AMG 119","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 119","termGroup":"CN","termSource":"NCI"},{"termName":"AMG 119 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"AMG-119","termGroup":"CN","termSource":"NCI"},{"termName":"AMG119","termGroup":"CN","termSource":"NCI"},{"termName":"CAR-T Cells AMG 119","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CAR T-Cells AMG 119"},{"name":"NCI_Drug_Dictionary_ID","value":"793448"},{"name":"NCI_META_CUI","value":"CL552332"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793448"},{"name":"PDQ_Open_Trial_Search_ID","value":"793448"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1037":{"preferredName":"Caracemide","code":"C1037","definitions":[{"definition":"An agent derived from acetohydroxamic acid with potential antineoplastic activity.  Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase.  In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Caracemide","termGroup":"PT","termSource":"NCI"},{"termName":"Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81424-67-1"},{"name":"Chemical_Formula","value":"C6H11N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H74F6J185A"},{"name":"Legacy Concept Name","value":"Caracemide"},{"name":"Maps_To","value":"Caracemide"},{"name":"NCI_Drug_Dictionary_ID","value":"39751"},{"name":"NSC Number","value":"253272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39751"},{"name":"PDQ_Open_Trial_Search_ID","value":"39751"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054633"}]}}{"C1154":{"preferredName":"Carbendazim","code":"C1154","definitions":[{"definition":"A broad-spectrum benzimidazole antifungal with potential antimitotic and antineoplastic activities. Although the exact mechanism of action is unclear, carbendazim appears to binds to an unspecified site on tubulin and suppresses microtubule assembly dynamic. This results in cell cycle arrest at the G2/M phase and an induction of apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antifungal agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carbendazim","termGroup":"PT","termSource":"NCI"},{"termName":"1H-benzimidazol-2-ylcarbamic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"2-(Methoxycarbonylamino)benzimidazole","termGroup":"SN","termSource":"NCI"},{"termName":"2-Benzimidazolecarcamic Acid Methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"BAS-3460","termGroup":"CN","termSource":"NCI"},{"termName":"BAS-67054","termGroup":"CN","termSource":"NCI"},{"termName":"Bavistin","termGroup":"FB","termSource":"NCI"},{"termName":"BCM","termGroup":"AB","termSource":"NCI"},{"termName":"BMC","termGroup":"AB","termSource":"NCI"},{"termName":"Carbendazole","termGroup":"SY","termSource":"NCI"},{"termName":"CTR-6669","termGroup":"CN","termSource":"NCI"},{"termName":"Derosal","termGroup":"FB","termSource":"NCI"},{"termName":"FB642","termGroup":"CN","termSource":"NCI"},{"termName":"HOE-17411","termGroup":"CN","termSource":"NCI"},{"termName":"MBC","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl 2-Benzimidazolecarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl Benzimidazol-2-ylcarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-1H-benzimidazol-2-yl Carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-2-benzimidazole Carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-2-benzimidazolecarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Methyl-alpha-benzimidazole Carbamate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10605-21-7"},{"name":"Chemical_Formula","value":"C9H9N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H75J14AA89"},{"name":"Legacy Concept Name","value":"Carbendazim"},{"name":"Maps_To","value":"Carbendazim"},{"name":"NCI_Drug_Dictionary_ID","value":"43319"},{"name":"NSC Number","value":"109874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43319"},{"name":"PDQ_Open_Trial_Search_ID","value":"43319"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065839"}]}}{"C1356":{"preferredName":"Carbetimer","code":"C1356","definitions":[{"definition":"Carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride.  It has demonstrated antitumor activity against several animal models.  It has calcium chelation activity but seems to inhibit growth of sensitive cells by disrupting nucleoside uptake and metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carbetimer","termGroup":"PT","termSource":"NCI"},{"termName":"carbethimer","termGroup":"SY","termSource":"NCI"},{"termName":"carboxyaminidate","termGroup":"SY","termSource":"NCI"},{"termName":"N-137","termGroup":"CN","termSource":"NCI"},{"termName":"NED-137","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"82230-03-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A678KM0M0N"},{"name":"Legacy Concept Name","value":"Carbetimer"},{"name":"Maps_To","value":"Carbetimer"},{"name":"NCI_Drug_Dictionary_ID","value":"40089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40089"},{"name":"PDQ_Open_Trial_Search_ID","value":"40089"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0108454"}]}}{"C1038":{"preferredName":"Carbogen","code":"C1038","definitions":[{"definition":"An inhalant consisting of hyperoxic gas (95%-98% oxygen and 2%-5% carbon dioxide) with radiosensitizing properties.  Inhaled carbogen reduces diffusion-limited tumor hypoxia, increasing tumor radiosensitivity due to the increased availability of molecular oxygen for cytotoxic radiation-induced oxygen free radical production. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An inhalant of oxygen and carbon dioxide that increases the sensitivity of tumor cells to the effects of radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carbogen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"inhalation therapy to produce vasodilation."},{"name":"CAS_Registry","value":"8063-77-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FJQ44KPA4J"},{"name":"Legacy Concept Name","value":"Carbogen"},{"name":"Maps_To","value":"Carbogen"},{"name":"NCI_Drug_Dictionary_ID","value":"42043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42043"},{"name":"PDQ_Open_Trial_Search_ID","value":"42043"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054692"}]}}{"C1282":{"preferredName":"Carboplatin","code":"C1282","definitions":[{"definition":"A drug that is used to treat advanced ovarian cancer that has never been treated or symptoms of ovarian cancer that has come back after treatment with other anticancer drugs. It is also used with other drugs to treat advanced, metastatic, or recurrent non-small cell lung cancer and is being studied in the treatment of other types of cancer. Paraplatin is a form of the anticancer drug cisplatin and causes fewer side effects in patients. It attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum","termGroup":"SN","termSource":"NCI"},{"termName":"1,1-cyclobutanedicarboxylic acid platinum complex","termGroup":"SN","termSource":"NCI"},{"termName":"Blastocarb","termGroup":"FB","termSource":"NCI"},{"termName":"Carboplat","termGroup":"FB","termSource":"NCI"},{"termName":"Carboplatin Hexal","termGroup":"SY","termSource":"NCI"},{"termName":"Carboplatino","termGroup":"SY","termSource":"NCI"},{"termName":"Carboplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Carbosin","termGroup":"FB","termSource":"NCI"},{"termName":"Carbosol","termGroup":"FB","termSource":"NCI"},{"termName":"Carbotec","termGroup":"FB","termSource":"NCI"},{"termName":"CBDCA","termGroup":"AB","termSource":"NCI"},{"termName":"cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"cis-diammine(cyclobutanedicarboxylato)platinum II","termGroup":"SN","termSource":"NCI"},{"termName":"Displata","termGroup":"FB","termSource":"NCI"},{"termName":"Ercar","termGroup":"FB","termSource":"NCI"},{"termName":"JM-8","termGroup":"CN","termSource":"NCI"},{"termName":"JM8","termGroup":"CN","termSource":"NCI"},{"termName":"Nealorin","termGroup":"FB","termSource":"NCI"},{"termName":"Novoplatinum","termGroup":"FB","termSource":"NCI"},{"termName":"Paraplat","termGroup":"AQS","termSource":"NCI"},{"termName":"Paraplatin","termGroup":"AQS","termSource":"NCI"},{"termName":"Paraplatin AQ","termGroup":"FB","termSource":"NCI"},{"termName":"Paraplatine","termGroup":"FB","termSource":"NCI"},{"termName":"platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)","termGroup":"SN","termSource":"NCI"},{"termName":"Platinwas","termGroup":"FB","termSource":"NCI"},{"termName":"Ribocarbo","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Osteogenic sarcoma; CNS and germ cell tumors; ovarian; lung; head and neck; endometrial; esophageal; bladder; breast; cervical cancer."},{"name":"CAS_Registry","value":"41575-94-4"},{"name":"CHEBI_ID","value":"CHEBI:31355"},{"name":"Chemical_Formula","value":"C6H6O4.Pt.2H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"BG3F62OND5"},{"name":"Legacy Concept Name","value":"Carboplatin"},{"name":"Maps_To","value":"Carboplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39176"},{"name":"NSC Number","value":"201345"},{"name":"NSC Number","value":"241240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39176"},{"name":"PDQ_Open_Trial_Search_ID","value":"39176"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079083"}]}}{"C342":{"preferredName":"Carboquone","code":"C342","definitions":[{"definition":"An aziridinylbenzoquinone-based alkylating agent with potential antineoplastic activity. The alkylating group in carboquone becomes activated upon reduction of quinone to the hydroquinone form. This eventually results in the alkylation and crosslinking of DNA, thereby inhibiting DNA replication followed by an induction of apoptosis. In addition, reactive oxygen species may form during redox cycling which may contribute to this agent's cytotoxic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboquone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"24279-91-2"},{"name":"Chemical_Formula","value":"C15H19N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1CB0HBT12C"},{"name":"Legacy Concept Name","value":"Carboquone"},{"name":"Maps_To","value":"Carboquone"},{"name":"NSC Number","value":"662"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0006971"}]}}{"C1141":{"preferredName":"Carboxyamidotriazole","code":"C1141","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active agent with potential antineoplastic activity.  Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis.  This agent may also inhibit tumor cell growth, invasion and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyamidotriazole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4(4-chlorobenzoyl)phenyl)methyl)","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1H-1,2,3-triazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CAI","termGroup":"AB","termSource":"NCI"},{"termName":"Carboxyamido-triazole","termGroup":"SY","termSource":"NCI"},{"termName":"Carboxyaminoimidazole","termGroup":"SY","termSource":"NCI"},{"termName":"L651582","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99519-84-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6ST3ZF52WB"},{"name":"Legacy Concept Name","value":"Carboxyamidotriazole"},{"name":"Maps_To","value":"Carboxyamidotriazole"},{"name":"NCI_Drug_Dictionary_ID","value":"41613"},{"name":"NSC Number","value":"609974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41613"},{"name":"PDQ_Open_Trial_Search_ID","value":"41613"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064494"}]}}{"C91090":{"preferredName":"Carboxyamidotriazole Orotate","code":"C91090","definitions":[{"definition":"The orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable small molecule with potential antiangiogenic and antiproliferative activities. Carboxyamidotriazole binds to and inhibits non-voltage-operated calcium channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores, resulting in the disruption of calcium channel-mediated signal transduction. CAI inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling. This may inhibit endothelial proliferation, tumor cell growth, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyamidotriazole Orotate","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3-Carboxyamido-triazole Orotate","termGroup":"SN","termSource":"NCI"},{"termName":"CTO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"187739-60-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"776C212QQH"},{"name":"Maps_To","value":"Carboxyamidotriazole Orotate"},{"name":"NCI_Drug_Dictionary_ID","value":"671851"},{"name":"NCI_META_CUI","value":"CL421478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671851"},{"name":"PDQ_Open_Trial_Search_ID","value":"671851"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1169":{"preferredName":"Carboxyphenyl Retinamide","code":"C1169","definitions":[{"definition":"A synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Carboxyphenyl retinamide induces cell differentiation and inhibits tumor cell growth and carcinogenesis.  This agent may also induce cell cycle arrest in the G1 phase in some cancer cell types. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyphenyl Retinamide","termGroup":"PT","termSource":"NCI"},{"termName":"4-carboxyphenyl retinamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-(4-carboxyphenyl)retinamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74193-17-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carboxyphenyl_Retinamide"},{"name":"Maps_To","value":"Carboxyphenyl Retinamide"},{"name":"NCI_Drug_Dictionary_ID","value":"42559"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42559"},{"name":"PDQ_Open_Trial_Search_ID","value":"42559"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0067533"}]}}{"C52196":{"preferredName":"Carfilzomib","code":"C52196","definitions":[{"definition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carfilzomib","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide","termGroup":"SN","termSource":"NCI"},{"termName":"Carfilnat","termGroup":"FB","termSource":"NCI"},{"termName":"CFZ","termGroup":"AB","termSource":"NCI"},{"termName":"Kyprolis","termGroup":"BR","termSource":"NCI"},{"termName":"PR 171","termGroup":"CN","termSource":"NCI"},{"termName":"PR-171","termGroup":"CN","termSource":"NCI"},{"termName":"PR171","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed multiple myeloma (MM)"},{"name":"CAS_Registry","value":"868540-17-4"},{"name":"Chemical_Formula","value":"C40H57N5O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"72X6E3J5AR"},{"name":"Legacy Concept Name","value":"PR-171"},{"name":"Maps_To","value":"Carfilzomib"},{"name":"NCI_Drug_Dictionary_ID","value":"459751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459751"},{"name":"PDQ_Open_Trial_Search_ID","value":"459751"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709429"}]}}{"C80048":{"preferredName":"Caricotamide/Tretazicar","code":"C80048","definitions":[{"definition":"A combination therapy consisting of the prodrug tretazicar and the enzyme co-substrate caricotamide with potential antineoplastic activity. In the presence of separately and simultaneously administered caricotamide, tretazicar is converted to the short-lived cytotoxic DNA cross-linking agent dinitrobenzamide by NAD(P)H quinine oxidoreductase 2 (NQO2), resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be elevated in certain cancers such as hepatocellular carcinoma (HCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Caricotamide/Tretazicar","termGroup":"PT","termSource":"NCI"},{"termName":"EP-0152R/CB1954","termGroup":"CN","termSource":"NCI"},{"termName":"Prolarix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Caricotamide_Tretazicar"},{"name":"Maps_To","value":"Caricotamide/Tretazicar"},{"name":"NCI_Drug_Dictionary_ID","value":"615142"},{"name":"NCI_META_CUI","value":"CL388385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615142"},{"name":"PDQ_Open_Trial_Search_ID","value":"615142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71010":{"preferredName":"Carlumab","code":"C71010","definitions":[{"definition":"A human IgG1 kappa monoclonal antibody directed against human CC chemokine ligand 2 (CCL2) with potential antineoplastic activity. Carlumab binds to and inhibits CLL2, which may result in inhibition of angiogenesis and, so, tumor cell proliferation. Endothelium-derived CLL2 (monocyte chemoattractant protein; MCP1) is a member of the beta-chemokine family, can stimulate monocyte/macrophage migration and smooth muscle cell (SMC) proliferation, and plays a role in angiogenesis and tumor cell migration; CCL2 induction of angiogenesis may involve the upregulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression which, in turn, induces vascular endothelial growth factor-A (VEGF-A) gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carlumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-human Small-inducible Cytokine A2 Monoclonal Antibody CNTO 888","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO 888","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human monocyte chemoattractant protein-1) (human monoclonal CNTO888 gamma 1-chain), disulfide with human monoclonal CNTO888 kappa-chain, dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915404-94-3"},{"name":"Chemical_Formula","value":"C6442H9966N1706O2018S40"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6TC1BB2EV9"},{"name":"Legacy Concept Name","value":"Anti-CCL2_Human_Monoclonal_Antibody_CNTO_888"},{"name":"Maps_To","value":"Carlumab"},{"name":"NCI_Drug_Dictionary_ID","value":"573742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573742"},{"name":"PDQ_Open_Trial_Search_ID","value":"573742"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537194"}]}}{"C955":{"preferredName":"Carmofur","code":"C955","definitions":[{"definition":"An antimetabolite (pyrimidine analogue) antineoplastic derivative of 5-fluorouracil. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmofur","termGroup":"PT","termSource":"NCI"},{"termName":"1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo-","termGroup":"SN","termSource":"NCI"},{"termName":"1-Hexylcarbamoyl-5-Fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"HCFU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"61422-45-5"},{"name":"Chemical_Formula","value":"C11H16FN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HA82M3RAB2"},{"name":"Legacy Concept Name","value":"Carmofur"},{"name":"Maps_To","value":"Carmofur"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044401"}]}}{"C349":{"preferredName":"Carmustine","code":"C349","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Bis(2-chloroethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"1,3-Bis(beta-chloroethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"BCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Becenum","termGroup":"BR","termSource":"NCI"},{"termName":"Becenun","termGroup":"FB","termSource":"NCI"},{"termName":"BiCNU","termGroup":"BR","termSource":"NCI"},{"termName":"Bis(chloroethyl) Nitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"Bis-Chloronitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"Carmubris","termGroup":"BR","termSource":"NCI"},{"termName":"Carmustin","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustinum","termGroup":"FB","termSource":"NCI"},{"termName":"FDA 0345","termGroup":"CN","termSource":"NCI"},{"termName":"N,N'-bis(2-chloroethyl)-N-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Nitrourean","termGroup":"FB","termSource":"NCI"},{"termName":"Nitrumon","termGroup":"FB","termSource":"NCI"},{"termName":"NSC 409962","termGroup":"CN","termSource":"NCI"},{"termName":"NSC409962","termGroup":"CN","termSource":"NCI"},{"termName":"SK 27702","termGroup":"CN","termSource":"NCI"},{"termName":"SRI 1720","termGroup":"CN","termSource":"NCI"},{"termName":"WR 139021","termGroup":"CN","termSource":"NCI"},{"termName":"WR-139021","termGroup":"CN","termSource":"NCI"},{"termName":"WR139021","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Brain tumors; colon cancer; lung cancer; lymphomas; Hodgkins and Non-Hodgkins; melanoma; multiple myeloma; mycosis fungoides"},{"name":"CAS_Registry","value":"154-93-8"},{"name":"CHEBI_ID","value":"CHEBI:3423"},{"name":"Chemical_Formula","value":"C5H9Cl2N3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"U68WG3173Y"},{"name":"Legacy Concept Name","value":"Carmustine"},{"name":"Maps_To","value":"Carmustine"},{"name":"NCI_Drug_Dictionary_ID","value":"43027"},{"name":"NSC Number","value":"409962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43027"},{"name":"PDQ_Open_Trial_Search_ID","value":"43027"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0007257"}]}}{"C2487":{"preferredName":"Carmustine Implant","code":"C2487","definitions":[{"definition":"A biodegradable wafer that is used to deliver the anticancer drug carmustine directly into a brain tumor site after the tumor has been removed by surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine Implant","termGroup":"PT","termSource":"NCI"},{"termName":"BCNU Wafer","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustine Copolymer","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustine Wafer","termGroup":"SY","termSource":"NCI"},{"termName":"Carmustine Wafers","termGroup":"SY","termSource":"NCI"},{"termName":"Gliadel","termGroup":"BR","termSource":"NCI"},{"termName":"Gliadel Wafer","termGroup":"BR","termSource":"NCI"},{"termName":"Gliadel Wafer","termGroup":"SY","termSource":"NCI"},{"termName":"Gliadel Wafers","termGroup":"BR","termSource":"NCI"},{"termName":"NPC 08","termGroup":"CN","termSource":"NCI"},{"termName":"NPC08","termGroup":"CN","termSource":"NCI"},{"termName":"Polifeprosan 20 with Carmustine Implant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant glioma, adjuvant to surgery and radiation; Recurrent glioblastoma multiforme, adjuvant to surgery"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Polifeprosan_20_with_Carmustine_Implant"},{"name":"Maps_To","value":"Carmustine Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"43142"},{"name":"NCI_META_CUI","value":"CL381677"},{"name":"NSC Number","value":"714372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43142"},{"name":"PDQ_Open_Trial_Search_ID","value":"43142"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2602":{"preferredName":"Carmustine in Ethanol","code":"C2602","definitions":[{"definition":"A formulation containing carmustine dissolved in ethanol for intra-tumoral administration that allows carmustine to enter both aqueous and lipid compartments of the target tissue. As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect. Carmustine is highly lipophilic and crosses the blood-brain barrier readily.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine in Ethanol","termGroup":"PT","termSource":"NCI"},{"termName":"DTI-015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Carmustine_in_Ethanol"},{"name":"Maps_To","value":"Carmustine in Ethanol"},{"name":"NCI_Drug_Dictionary_ID","value":"38104"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38104"},{"name":"PDQ_Open_Trial_Search_ID","value":"38104"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935694"}]}}{"C102847":{"preferredName":"Carmustine Sustained-Release Implant Wafer","code":"C102847","definitions":[{"definition":"A sustained release (SR) implant wafer containing the lipophilic nitrosourea carmustine (BCNU) with antineoplastic activity. Upon intracranial administration of the implant wafer and subsequent release of BCNU from the wafer, this agent alkylates and cross-links DNA during all phases of the cell cycle, resulting in the disruption of DNA function, cell cycle arrest, and apoptosis. This wafer contains the biodegradable copolymer PLGA (poly(lactide-co-glycolide) as the major drug delivery vehicle which is slowly degraded into water and carbon dioxide thereby continously releasing BCNU over approximately 3-4 weeks. Compared to systemic administration of BCNU alone, this local SR formulation is able to maintain higher drug concentrations locally over a longer period of time while minimizing exposure to other tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carmustine Sustained-Release Implant Wafer","termGroup":"PT","termSource":"NCI"},{"termName":"CASANT Wafer","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Carmustine Sustained-Release Implant Wafer"},{"name":"NCI_Drug_Dictionary_ID","value":"737196"},{"name":"NCI_META_CUI","value":"CL437131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737196"},{"name":"PDQ_Open_Trial_Search_ID","value":"737196"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74010":{"preferredName":"Carotuximab","code":"C74010","definitions":[{"definition":"A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Carotuximab binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carotuximab","termGroup":"PT","termSource":"NCI"},{"termName":"TRC 105","termGroup":"CN","termSource":"NCI"},{"termName":"TRC-105","termGroup":"CN","termSource":"NCI"},{"termName":"TRC105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268714-50-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YB2EWE6139"},{"name":"Legacy Concept Name","value":"Anti-Endoglin_Chimeric_Monoclonal_Antibody_TRC105"},{"name":"Maps_To","value":"Carotuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"584952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"584952"},{"name":"PDQ_Open_Trial_Search_ID","value":"584952"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346810"}]}}{"C352":{"preferredName":"Carubicin","code":"C352","definitions":[{"definition":"An anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata. Carubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S,3S)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,10,12-tetrahydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"(8S-cis)-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"4-O-demethyldaunorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetra-hydroxy-(8S-cis)-(8CI 9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetra-hydroxy-,(8S-cis)-(8CI)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Carminomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Carminomycin I","termGroup":"SY","termSource":"NCI"},{"termName":"CMM","termGroup":"AB","termSource":"NCI"},{"termName":"Demethyldaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Karminomitsin","termGroup":"SY","termSource":"NCI"},{"termName":"Karminomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50935-04-1"},{"name":"Chemical_Formula","value":"C26H27NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E7437K3983"},{"name":"Legacy Concept Name","value":"Carubicin"},{"name":"Maps_To","value":"Carubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39175"},{"name":"NSC Number","value":"180024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39175"},{"name":"PDQ_Open_Trial_Search_ID","value":"39175"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0007308"}]}}{"C1582":{"preferredName":"Carubicin Hydrochloride","code":"C1582","definitions":[{"definition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic carubicin.  Carubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carubicin Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52794-97-5"},{"name":"Chemical_Formula","value":"C26H27NO10.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4V3R166MB3"},{"name":"Legacy Concept Name","value":"Carubicin_Hydrochloride"},{"name":"Maps_To","value":"Carubicin Hydrochloride"},{"name":"NSC Number","value":"275649"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282089"}]}}{"C1441":{"preferredName":"Carzelesin","code":"C1441","definitions":[{"definition":"A cyclopropylpyrroloindole prodrug analogue and DNA minor groove binding agent, with antineoplastic activity.  After hydrolysis, the cyclopropyl group of carzelesin alkylates N3-adenine in a sequence-selective fashion. This results in tumor growth inhibition.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Carzelesin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Benzofurancarboxamide, N-(2-((1-(chloromethyl)-1,6-dihydro-8-methyl-5-(((phenylamino)carbonyl)oxy)benzo(1,2-b:4,3-b')dipyrrol-3(2H)-yl)carbonyl)-1H-indol-5-yl)-6-(diethylamino)-, (S)-","termGroup":"SN","termSource":"NCI"},{"termName":"U-80244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"119813-10-4"},{"name":"Chemical_Formula","value":"C41H37ClN6O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"668UF07O1P"},{"name":"Legacy Concept Name","value":"Carzelesin"},{"name":"Maps_To","value":"Carzelesin"},{"name":"NCI_Drug_Dictionary_ID","value":"42571"},{"name":"NSC Number","value":"619029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42571"},{"name":"PDQ_Open_Trial_Search_ID","value":"42571"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0172048"}]}}{"C1040":{"preferredName":"Carzinophilin","code":"C1040","definitions":[{"definition":"An ethylenimine antineoplastic antibiotic isolated from the bacterium Streptomyces sahachiroi.  Carzinophilin forms interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carzinophilin","termGroup":"PT","termSource":"NCI"},{"termName":"Cardinophillin","termGroup":"SY","termSource":"NCI"},{"termName":"Cardinophyllin","termGroup":"SY","termSource":"NCI"},{"termName":"Carzinophyllin","termGroup":"SY","termSource":"NCI"},{"termName":"CZP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1403-28-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"051R55X44C"},{"name":"Legacy Concept Name","value":"Carzinophilin"},{"name":"Maps_To","value":"Carzinophilin"},{"name":"NSC Number","value":"20088"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054841"}]}}{"C118292":{"preferredName":"Ropocamptide","code":"C118292","definitions":[{"definition":"A synthetic form of a human antimicrobial peptide (37 amino acids), belonging to the cathelicidin family, with antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities. Upon intratumoral injection of the ropocamptide, this peptide increases p53 expression, and induces phosphatidylserine externalization, DNA fragmentation, cell cycle arrest and caspase-independent apoptosis-inducing factor (AIF)/ endonuclease G (EndoG)-mediated apoptotic cell death in susceptible cancer cells. This suppresses tumor cell proliferation.  LL-37, a protein secreted by bone marrow cells, circulating leukocytes, and various epithelial tissues, plays a crucial role in the innate host immune defense via the regulation of leukocyte chemotaxis and cytokine production; it also promotes wound healing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ropocamptide","termGroup":"PT","termSource":"NCI"},{"termName":"Antimicrobial Peptide, Human LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES","termGroup":"SY","termSource":"NCI"},{"termName":"Cathelicidin LL-37","termGroup":"SY","termSource":"NCI"},{"termName":"LL-37","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154947-66-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3DD771JO2H"},{"name":"Maps_To","value":"Cathelicidin LL-37"},{"name":"Maps_To","value":"Ropocamptide"},{"name":"NCI_Drug_Dictionary_ID","value":"764409"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764409"},{"name":"PDQ_Open_Trial_Search_ID","value":"764409"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391752"}]}}{"C69130":{"preferredName":"Cationic Liposome-Encapsulated Paclitaxel","code":"C69130","definitions":[{"definition":"A cationic liposome preparation of paclitaxel with antineoplastic activity. Paclitaxel, the active ingredient in cationic liposome-encapsulated paclitaxel, binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis and cellular proliferation, and apoptosis. Cationic liposome encapsulation of paclitaxel allows the delivery of high doses of paclitaxel to target tissues while minimizing systemic toxicity. Tumor endothelial cells may preferentially bind and internalize cationic liposomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cationic Liposome-Encapsulated Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"EndoTAG-1","termGroup":"FB","termSource":"NCI"},{"termName":"LipoPac","termGroup":"FB","termSource":"NCI"},{"termName":"MBT-0206","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cationic_Liposome-Encapsulated_Paclitaxel"},{"name":"Maps_To","value":"Cationic Liposome-Encapsulated Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"543136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543136"},{"name":"PDQ_Open_Trial_Search_ID","value":"543136"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1722887"}]}}{"C62445":{"preferredName":"Catumaxomab","code":"C62445","definitions":[{"definition":"A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Catumaxomab","termGroup":"PT","termSource":"NCI"},{"termName":"Removab","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"509077-98-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M2HPV837HO"},{"name":"Legacy Concept Name","value":"Catumaxomab"},{"name":"Maps_To","value":"Catumaxomab"},{"name":"NCI_Drug_Dictionary_ID","value":"487002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487002"},{"name":"PDQ_Open_Trial_Search_ID","value":"487002"},{"name":"PubMedID_Primary_Reference","value":"17622246"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831854"}]}}{"C95894":{"preferredName":"Foscenvivint","code":"C95894","definitions":[{"definition":"A potent, specific inhibitor of the canonical Wnt signaling pathway in cancer stem cells with potential antineoplastic activity. Foscenvivint specifically inhibits the recruiting of beta-catenin with its coactivator CBP (the binding protein of the cAMP response element-binding protein CREB); together with other transcription factors beta-catenin/CBP binds to WRE (Wnt-responsive element) and activates transcription of a wide range of target genes of Wnt/beta-catenin signaling. Blocking the interaction of CBP and beta-catenin by this agent prevents gene expression of many proteins necessary for growth, thereby potentially suppressing cancer cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foscenvivint","termGroup":"PT","termSource":"NCI"},{"termName":"CBP/beta-catenin Antagonist PRI-724","termGroup":"SY","termSource":"NCI"},{"termName":"PRI-724","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422253-38-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43Y934BBZ6"},{"name":"Maps_To","value":"CBP/beta-catenin Antagonist PRI-724"},{"name":"NCI_Drug_Dictionary_ID","value":"696436"},{"name":"NCI_META_CUI","value":"CL428291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696436"},{"name":"PDQ_Open_Trial_Search_ID","value":"696436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153376":{"preferredName":"CBP/beta-catenin Modulator E7386","code":"C153376","definitions":[{"definition":"An orally bioavailable, specific inhibitor of the canonical Wnt/beta-catenin signaling pathway, with potential antineoplastic activity. Upon oral administration, CBP/beta-catenin modulator E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CBP/beta-catenin Modulator E7386","termGroup":"PT","termSource":"NCI"},{"termName":"E 7386","termGroup":"CN","termSource":"NCI"},{"termName":"E-7386","termGroup":"CN","termSource":"NCI"},{"termName":"E7386","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1799824-08-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I0DX1FG55Y"},{"name":"Maps_To","value":"CBP/beta-catenin Modulator E7386"},{"name":"NCI_Drug_Dictionary_ID","value":"793902"},{"name":"NCI_META_CUI","value":"CL554532"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793902"},{"name":"PDQ_Open_Trial_Search_ID","value":"793902"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120302":{"preferredName":"CCR2 Antagonist CCX872-B","code":"C120302","definitions":[{"definition":"An orally available human C-C chemokine receptor type 2 (CCR2) antagonist, with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist CCX872-B specifically binds to CCR2 and prevents the binding its cognate endothelium-derived chemokine ligand CCL2 (monocyte chemoattractant protein-1 or MCP1). This may result in the inhibition of both CCR2 activation and CCR2-mediated signal transduction, which may inhibit inflammatory processes, angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, and stimulates their migration and infiltration; it plays a key role in inflammation. CCR2 is overexpressed in certain cancer cell types, where it is involved in angiogenesis, tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR2 Antagonist CCX872-B","termGroup":"PT","termSource":"NCI"},{"termName":"CCX872-B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CCR2 Antagonist CCX872-B"},{"name":"NCI_Drug_Dictionary_ID","value":"768571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768571"},{"name":"PDQ_Open_Trial_Search_ID","value":"768571"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896888"}]}}{"C97507":{"preferredName":"CCR2 Antagonist PF-04136309","code":"C97507","definitions":[{"definition":"An orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR2 Antagonist PF-04136309","termGroup":"PT","termSource":"NCI"},{"termName":"PF-04136309","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1341224-83-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3M2595V4KT"},{"name":"Maps_To","value":"CCR2 Antagonist PF-04136309"},{"name":"NCI_Drug_Dictionary_ID","value":"703421"},{"name":"NCI_META_CUI","value":"CL430252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703421"},{"name":"PDQ_Open_Trial_Search_ID","value":"703421"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139550":{"preferredName":"CCR2/CCR5 Antagonist BMS-813160","code":"C139550","definitions":[{"definition":"An antagonist of both human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating and antineoplastic activities. Upon administration, CCR2/CCR5 antagonist BMS-813160 specifically binds and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages, and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune disease. CCR2 and CCR5 are overexpressed in certain cancer cell types, and are also involved in angiogenesis, and in tumor cell migration, proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CCR2/CCR5 Antagonist BMS-813160","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-[(1S,2R,4R)-4-isopropyl(methyl)amino)-2-propylcyclohexyl]-3-(6(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-813160","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1286279-29-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"83U7957287"},{"name":"Maps_To","value":"CCR2/CCR5 Antagonist BMS-813160"},{"name":"NCI_Drug_Dictionary_ID","value":"791102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791102"},{"name":"PDQ_Open_Trial_Search_ID","value":"791102"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490973"}]}}{"C157240":{"preferredName":"Tivumecirnon","code":"C157240","definitions":[{"definition":"An orally available, small molecule antagonist of C-C chemokine receptor type 4 (CCR4) with potential immunomodulatory and antineoplastic activities. Upon oral administration, tivumecirnon inhibits the binding of CCR4 to its signaling molecules, thereby blocking the recruitment of regulatory T-cells (Tregs) to the tumor microenvironment (TME). This may abrogate the immunosuppressive effects of Tregs and promote an effective anti-tumor immune response. CCR4, a chemokine receptor normally expressed on circulating and tissue-resident T-cells, is highly expressed on circulating Tregs and is associated with poor prognosis in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tivumecirnon","termGroup":"PT","termSource":"NCI"},{"termName":"CCR4 Inhibitor FLX475","termGroup":"SY","termSource":"NCI"},{"termName":"FLX 475","termGroup":"CN","termSource":"NCI"},{"termName":"FLX-475","termGroup":"CN","termSource":"NCI"},{"termName":"FLX475","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2174938-78-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1T69T65FJ"},{"name":"Maps_To","value":"CCR4 Inhibitor FLX475"},{"name":"NCI_Drug_Dictionary_ID","value":"796771"},{"name":"NCI_META_CUI","value":"CL936884"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796771"},{"name":"PDQ_Open_Trial_Search_ID","value":"796771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129596":{"preferredName":"CD4-specific Telomerase Peptide Vaccine UCPVax","code":"C129596","definitions":[{"definition":"A therapeutic peptide vaccine containing the human telomerase reverse transcriptase catalytic subunit (hTERT)-derived universal cancer peptides 2 (UCP2) and 4 (UCP4), and combined with the immunoadjuvant Montanide ISA 51 VG, with potential immunostimulating and antineoplastic activities. Vaccination with the CD4-specific telomerase peptide vaccine UCPVax activates the immune system to mount a T-helper 1 (TH1) CD4-positive T-lymphocyte immune response against and ultimately killing telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD4-specific Telomerase Peptide Vaccine UCPVax","termGroup":"PT","termSource":"NCI"},{"termName":"UCP2/UCP4 CD4-specific Telomerase Peptide Vaccine UCPVax","termGroup":"SY","termSource":"NCI"},{"termName":"UCPVax","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD4-specific Telomerase Peptide Vaccine UCPVax"},{"name":"NCI_Drug_Dictionary_ID","value":"783988"},{"name":"NCI_META_CUI","value":"CL512660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783988"},{"name":"PDQ_Open_Trial_Search_ID","value":"783988"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119740":{"preferredName":"Selicrelumab","code":"C119740","definitions":[{"definition":"A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selicrelumab","termGroup":"PT","termSource":"NCI"},{"termName":"CD40 Agonist Monoclonal Antibody CP-870,893","termGroup":"SY","termSource":"NCI"},{"termName":"CP-870,893","termGroup":"CN","termSource":"NCI"},{"termName":"RO7009789","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622140-49-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0O39RGI33V"},{"name":"Legacy Concept Name","value":"Anti-CD40_Monoclonal_Antibody_CP-870_893"},{"name":"Maps_To","value":"CD40 Agonist Monoclonal Antibody CP-870,893"},{"name":"Maps_To","value":"Selicrelumab"},{"name":"NCI_Drug_Dictionary_ID","value":"588974"},{"name":"NCI_Drug_Dictionary_ID","value":"767014"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767014"},{"name":"PDQ_Open_Trial_Search_ID","value":"767014"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896775"}]}}{"C123734":{"preferredName":"Sotigalimab","code":"C123734","definitions":[{"definition":"A humanized monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Similar to the endogenous CD40 ligand (CD40L or CD154), sotigalimab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Sotigalimab also binds to and activates CD40 present on the surfaces of some solid tumor cells, leading to apoptosis and decreased tumor growth. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it mediates both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotigalimab","termGroup":"PT","termSource":"NCI"},{"termName":"APX 005","termGroup":"CN","termSource":"NCI"},{"termName":"APX 005M","termGroup":"CN","termSource":"NCI"},{"termName":"APX-005M","termGroup":"CN","termSource":"NCI"},{"termName":"APX005M","termGroup":"CN","termSource":"NCI"},{"termName":"CD40 Agonistic Monoclonal Antibody APX005M","termGroup":"SY","termSource":"NCI"},{"termName":"EPI-0050","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305607-45-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JEA93WJ5DG"},{"name":"Maps_To","value":"CD40 Agonistic Monoclonal Antibody APX005M"},{"name":"Maps_To","value":"Sotigalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"775520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775520"},{"name":"PDQ_Open_Trial_Search_ID","value":"775520"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053581"}]}}{"C142813":{"preferredName":"CD44 Targeted Agent SPL-108","code":"C142813","definitions":[{"definition":"A proprietary agent that targets the cancer stem cell (CSC) antigen CD44, with potential antineoplastic activity. Although the mechanism of action has not been elucidated, following subcutaneous administration, CD44 targeted agent SPL-108 binds to CD44 and prevents the activation of various CD44-mediated signal transduction pathways, which may lead to reduced proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in the proliferation, migration and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD44 Targeted Agent SPL-108","termGroup":"PT","termSource":"NCI"},{"termName":"SPL 108","termGroup":"CN","termSource":"NCI"},{"termName":"SPL-108","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD44 Targeted Agent SPL-108"},{"name":"NCI_Drug_Dictionary_ID","value":"789749"},{"name":"NCI_META_CUI","value":"CL540705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789749"},{"name":"PDQ_Open_Trial_Search_ID","value":"789749"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132851":{"preferredName":"Evorpacept","code":"C132851","definitions":[{"definition":"A variant of signal regulatory protein alpha (SIRPa) that antagonizes the human cell surface antigen CD47, with potential phagocytosis-inducing, immunostimulating and antineoplastic activities. Upon administration, evorpacept binds to CD47 expressed on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of the pro-phagocytic signal calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evorpacept","termGroup":"PT","termSource":"NCI"},{"termName":"ALX 148","termGroup":"CN","termSource":"NCI"},{"termName":"ALX-148","termGroup":"CN","termSource":"NCI"},{"termName":"ALX148","termGroup":"CN","termSource":"NCI"},{"termName":"CD47 Antagonist ALX148","termGroup":"SY","termSource":"NCI"},{"termName":"CD47/SIRPa-blocking Agent ALX148","termGroup":"SY","termSource":"NCI"},{"termName":"LGGL-ALX-148","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa Variant ALX148","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2484949-51-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X7K762X1IJ"},{"name":"Maps_To","value":"CD47 Antagonist ALX148"},{"name":"NCI_Drug_Dictionary_ID","value":"787529"},{"name":"NCI_META_CUI","value":"CL519706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787529"},{"name":"PDQ_Open_Trial_Search_ID","value":"787529"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126641":{"preferredName":"Simurosertib","code":"C126641","definitions":[{"definition":"An orally bioavailable inhibitor of cell division cycle 7 (cell division cycle 7-related protein kinase; CDC7), with potential antineoplastic activity. Upon administration, simurosertib binds to and inhibits CDC7; this prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis. This inhibits cell growth in CDC7-overexpressing tumor cells. CDC7, a serine/threonine kinase and cell division cycle protein, is overexpressed in a variety of cancers and plays a key role in the activation of DNA replication and the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simurosertib","termGroup":"PT","termSource":"NCI"},{"termName":"Cell Division Cycle 7 Inhibitor TAK-931","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 931","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-931","termGroup":"CN","termSource":"NCI"},{"termName":"Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-Azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1330782-76-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LST350G3XU"},{"name":"Maps_To","value":"CDC7 Inhibitor TAK-931"},{"name":"Maps_To","value":"Simurosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"779700"},{"name":"NCI_META_CUI","value":"CL505074"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779700"},{"name":"PDQ_Open_Trial_Search_ID","value":"779700"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82418":{"preferredName":"CDC7 Kinase Inhibitor BMS-863233","code":"C82418","definitions":[{"definition":"An orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC7 Kinase Inhibitor BMS-863233","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-863233","termGroup":"CN","termSource":"NCI"},{"termName":"Cell Division Cycle 7 Homolog Kinase Inhibitor BMS-863233","termGroup":"SY","termSource":"NCI"},{"termName":"XL-413","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1169558-38-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8QK62S7492"},{"name":"Legacy Concept Name","value":"CDC7_Kinase_Inhibitor_BMS-863233"},{"name":"Maps_To","value":"CDC7 Kinase Inhibitor BMS-863233"},{"name":"NCI_Drug_Dictionary_ID","value":"637599"},{"name":"NCI_META_CUI","value":"CL408681"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637599"},{"name":"PDQ_Open_Trial_Search_ID","value":"637599"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148509":{"preferredName":"CDC7 Kinase Inhibitor LY3143921 Hydrate","code":"C148509","definitions":[{"definition":"The hydrated form of an orally bioavailable inhibitor of cell division cycle 7 (CDC7) kinase, with potential antineoplastic activity. Upon administration of CDC7 kinase inhibitor LY3143921 hydrate, LY3143921 targets, binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 plays a key role in DNA replication by binding to and  phosphorylating serine (Ser)-40 and 53 of MCM2 (minichromosome maintenance complex component 2), which is required for the initiation of DNA replication. Although expressed at low levels in healthy, normal cells, CDC7 is expressed at much higher levels in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC7 Kinase Inhibitor LY3143921 Hydrate","termGroup":"PT","termSource":"NCI"},{"termName":"LY-3143921 Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"LY3143921 Hydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDC7 Kinase Inhibitor LY3143921 Hydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"792646"},{"name":"NCI_META_CUI","value":"CL551033"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792646"},{"name":"PDQ_Open_Trial_Search_ID","value":"792646"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88316":{"preferredName":"CDC7 Kinase Inhibitor NMS-1116354","code":"C88316","definitions":[{"definition":"An orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor NMS-1116354 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 initiates DNA replication by phosphorylating MCM2 (minichromosome maintenance complex component 2) at Ser40 and Ser53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDC7 Kinase Inhibitor NMS-1116354","termGroup":"PT","termSource":"NCI"},{"termName":"NMS-1116354","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDC7 Kinase Inhibitor NMS-1116354"},{"name":"NCI_Drug_Dictionary_ID","value":"660731"},{"name":"NCI_META_CUI","value":"CL413571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660731"},{"name":"PDQ_Open_Trial_Search_ID","value":"660731"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64761":{"preferredName":"CDK Inhibitor AT7519","code":"C64761","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. AT7519M blocks enzymes needed for cells to divide. It is a type of cyclin-dependent kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK Inhibitor AT7519","termGroup":"PT","termSource":"NCI"},{"termName":"AT7519","termGroup":"CN","termSource":"NCI"},{"termName":"AT7519M","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor AT7519M","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"844442-38-2"},{"name":"Chemical_Formula","value":"C16H17Cl2N5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X1BF92PW9T"},{"name":"Legacy Concept Name","value":"AT7519M"},{"name":"Maps_To","value":"CDK Inhibitor AT7519"},{"name":"NCI_Drug_Dictionary_ID","value":"513177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513177"},{"name":"PDQ_Open_Trial_Search_ID","value":"513177"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879520"}]}}{"C64544":{"preferredName":"CDK Inhibitor R547","code":"C64544","definitions":[{"definition":"An orally bioavailable diaminopyrimidine compound and a cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and are frequently overexpressed in cancerous cells. R547 selectively binds to and inhibits CDKs, especially CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1. The inhibition of CDKs results in cell cycle arrest, inhibition of tumor cell proliferation, and induction of apoptosis. By inhibiting CDK activity, R547 also reduces phosphorylation of the retinoblastoma (Rb) protein, thereby preventing activation of transcription factor E2F and leading to further suppression of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK Inhibitor R547","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor R547","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinase Inhibitor R547","termGroup":"SY","termSource":"NCI"},{"termName":"R 547","termGroup":"CN","termSource":"NCI"},{"termName":"R547","termGroup":"CN","termSource":"NCI"},{"termName":"RO 4584820","termGroup":"CN","termSource":"NCI"},{"termName":"RO-4584820","termGroup":"CN","termSource":"NCI"},{"termName":"RO4584820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"741713-40-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T61871RKRI"},{"name":"Legacy Concept Name","value":"R547"},{"name":"Maps_To","value":"CDK Inhibitor R547"},{"name":"NCI_Drug_Dictionary_ID","value":"529189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529189"},{"name":"PDQ_Open_Trial_Search_ID","value":"529189"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832011"}]}}{"C62523":{"preferredName":"CDK Inhibitor SNS-032","code":"C62523","definitions":[{"definition":"A small aminothiazole molecule and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. SNS-032 binds to and prevents the phosphorylation of cyclin-dependent kinases, especially CDK2, 7, and 9 that regulate cell cycle progression. Inhibition of CDKs leads to cell cycle arrest and induces apoptosis. As a result, this agent causes cytotoxicity and prevents further tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK Inhibitor SNS-032","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-387032","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-032","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"345627-80-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9979I93686"},{"name":"Legacy Concept Name","value":"SNS-032"},{"name":"Maps_To","value":"CDK Inhibitor SNS-032"},{"name":"NCI_Drug_Dictionary_ID","value":"488948"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488948"},{"name":"PDQ_Open_Trial_Search_ID","value":"488948"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451099"}]}}{"C105851":{"preferredName":"Zotiraciclib Citrate","code":"C105851","definitions":[{"definition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zotiraciclib Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"20-Oxa-5,7,14,27-tetraazatetracyclo(19.3.1.12,6.18,12)heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-Methyl-, 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"SB1317 Citrate","termGroup":"SY","termSource":"NCI"},{"termName":"TG02 Citrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204918-73-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3VF50SU4RZ"},{"name":"Maps_To","value":"CDK/JAK2/FLT3 Inhibitor TG02 Citrate"},{"name":"Maps_To","value":"Zotiraciclib Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"686272"},{"name":"NCI_META_CUI","value":"CL447179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686272"},{"name":"PDQ_Open_Trial_Search_ID","value":"686272"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163985":{"preferredName":"Avotaciclib","code":"C163985","definitions":[{"definition":"An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Avotaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"BEY 1107","termGroup":"CN","termSource":"NCI"},{"termName":"BEY-1107","termGroup":"CN","termSource":"NCI"},{"termName":"BEY-A","termGroup":"CN","termSource":"NCI"},{"termName":"BEY1107","termGroup":"CN","termSource":"NCI"},{"termName":"BEY1107G","termGroup":"CN","termSource":"NCI"},{"termName":"BEY1107P","termGroup":"CN","termSource":"NCI"},{"termName":"CDK1 Inhibitor BEY1107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1983983-41-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z6BYC0F36E"},{"name":"Maps_To","value":"CDK1 Inhibitor BEY1107"},{"name":"NCI_Drug_Dictionary_ID","value":"799135"},{"name":"NCI_META_CUI","value":"CL977268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799135"},{"name":"PDQ_Open_Trial_Search_ID","value":"799135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52182":{"preferredName":"CDK1/2/4 Inhibitor AG-024322","code":"C52182","definitions":[{"definition":"A cyclin-dependent kinase (CDK) inhibitor with antineoplastic activity. AG-024322 selectively inhibits cyclin-dependent kinases (particularly CDK1,2 and 4), enzymes that regulate cell cycle progression. Inhibition of CDK may result in cell cycle arrest, induction of apoptosis, and inhibition of DNA replication and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK1/2/4 Inhibitor AG-024322","termGroup":"PT","termSource":"NCI"},{"termName":"AG-024322","termGroup":"CN","termSource":"NCI"},{"termName":"AG-24322","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"837364-57-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"926F8X7TNO"},{"name":"Legacy Concept Name","value":"AG-024322"},{"name":"Maps_To","value":"CDK1/2/4 Inhibitor AG-024322"},{"name":"NCI_Drug_Dictionary_ID","value":"459491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459491"},{"name":"PDQ_Open_Trial_Search_ID","value":"459491"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706655"}]}}{"C155956":{"preferredName":"CDK2/4/6/FLT3 Inhibitor FN-1501","code":"C155956","definitions":[{"definition":"A small molecule multi-kinase inhibitor of cyclin-dependent kinase (CDK) subtypes 2 (CDK2), 4 (CDK4), and 6 (CDK6) and FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon intravenous administration, CDK2/4/6/FLT3 inhibitor FN-1501 binds to and inhibits CDK2, CDK4, and CDK6, as well as FLT3. This may induce apoptosis and inhibit tumor cell proliferation in cancer cells that overexpress these kinases. CDKs are serine/threonine kinases that assist in cell cycle regulation and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in many cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK2/4/6/FLT3 Inhibitor FN-1501","termGroup":"PT","termSource":"NCI"},{"termName":"4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CDK/FLT3 Inhibitor FN-1501","termGroup":"SY","termSource":"NCI"},{"termName":"FN 1501","termGroup":"CN","termSource":"NCI"},{"termName":"FN-1501","termGroup":"CN","termSource":"NCI"},{"termName":"FN1501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429515-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6MC966B505"},{"name":"Maps_To","value":"CDK2/4/6/FLT3 Inhibitor FN-1501"},{"name":"NCI_Drug_Dictionary_ID","value":"795267"},{"name":"NCI_META_CUI","value":"CL562813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795267"},{"name":"PDQ_Open_Trial_Search_ID","value":"795267"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123902":{"preferredName":"Fadraciclib","code":"C123902","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fadraciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CYC065","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1070790-89-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YET2XNU791"},{"name":"Maps_To","value":"CDK2/5/9 Inhibitor CYC065"},{"name":"Maps_To","value":"Fadraciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"775991"},{"name":"NCI_META_CUI","value":"CL498266"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775991"},{"name":"PDQ_Open_Trial_Search_ID","value":"775991"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80049":{"preferredName":"CDK4 Inhibitor P1446A-05","code":"C80049","definitions":[{"definition":"A protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with potential antineoplastic activity. CDK4 inhibitor P1446A-05 specifically inhibits CDK4-mediated G1-S phase transition, arresting cell cycling and inhibiting cancer cell growth. The serine/threonine kinase CDK4 is found in a complex with D-type G1 cyclins and is the first kinase to become activated upon mitogenic stimulation, releasing cells from a quiescent stage into the G1/S growth cycling stage; CDK-cyclin complexes have been shown to phosphorylate the retinoblastoma (Rb) transcription factor in early G1, displacing histone deacetylase (HDAC) and blocking transcriptional repression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4 Inhibitor P1446A-05","termGroup":"PT","termSource":"NCI"},{"termName":"P1446A-05","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CDK4_Serine_Threonine_Kinase_Inhibitor_P1446A-05"},{"name":"Maps_To","value":"CDK4 Inhibitor P1446A-05"},{"name":"NCI_Drug_Dictionary_ID","value":"618682"},{"name":"NCI_META_CUI","value":"CL388407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"618682"},{"name":"PDQ_Open_Trial_Search_ID","value":"618682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116938":{"preferredName":"CDK4/6 Inhibition","code":"C116938","definitions":[{"definition":"Inhibition of cyclin-dependent kinases 4 and 6 pathway activity to prevent proliferation of cancer cells and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibition","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin-Dependent Kinases 4 and 6 Inhibition","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C3899807"}]}}{"C157481":{"preferredName":"CDK4/6 Inhibitor BPI-16350","code":"C157481","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor BPI-16350 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor BPI-16350","termGroup":"PT","termSource":"NCI"},{"termName":"BPI 16350","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-16350","termGroup":"CN","termSource":"NCI"},{"termName":"BPI16350","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor BPI-16350"},{"name":"NCI_Drug_Dictionary_ID","value":"796716"},{"name":"NCI_META_CUI","value":"CL937081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796716"},{"name":"PDQ_Open_Trial_Search_ID","value":"796716"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165199":{"preferredName":"CDK4/6 Inhibitor FCN-437","code":"C165199","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor FCN-437 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1/S transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play key roles in the regulation of both cell cycle progression from the G1-phase into the S-phase and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor FCN-437","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin-dependent Kinase 4/6 Inhibitor FCN-437","termGroup":"SY","termSource":"NCI"},{"termName":"FCN 437","termGroup":"CN","termSource":"NCI"},{"termName":"FCN-437","termGroup":"CN","termSource":"NCI"},{"termName":"FCN-437c","termGroup":"SY","termSource":"NCI"},{"termName":"FCN437","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor FCN-437"},{"name":"NCI_Drug_Dictionary_ID","value":"799711"},{"name":"NCI_META_CUI","value":"CL978411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799711"},{"name":"PDQ_Open_Trial_Search_ID","value":"799711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C138165":{"preferredName":"Lerociclib","code":"C138165","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lerociclib","termGroup":"PT","termSource":"NCI"},{"termName":"7',8'-Dihydro-2'-((5-(4-(1-methylethyl)-1-piperazinyl)-2-pyridinyl)amino)spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one","termGroup":"SY","termSource":"NCI"},{"termName":"CDK4/6 Inhibitor G1T38","termGroup":"SY","termSource":"NCI"},{"termName":"G1T38","termGroup":"CN","termSource":"NCI"},{"termName":"G1T38 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"GB 491","termGroup":"CN","termSource":"NCI"},{"termName":"GB-491","termGroup":"CN","termSource":"NCI"},{"termName":"GB491","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1628256-23-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WBH8AY6ENB"},{"name":"Maps_To","value":"CDK4/6 Inhibitor G1T38"},{"name":"Maps_To","value":"Lerociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"790539"},{"name":"NCI_META_CUI","value":"CL525730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790539"},{"name":"PDQ_Open_Trial_Search_ID","value":"790539"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125899":{"preferredName":"Dalpiciclib","code":"C125899","definitions":[{"definition":"A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dalpiciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK4/6 Inhibitor SHR6390","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 6390","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-6390","termGroup":"CN","termSource":"NCI"},{"termName":"SHR6390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637781-04-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5ZHA5P4PFX"},{"name":"Maps_To","value":"CDK4/6 Inhibitor SHR6390"},{"name":"NCI_Drug_Dictionary_ID","value":"778742"},{"name":"NCI_META_CUI","value":"CL504548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778742"},{"name":"PDQ_Open_Trial_Search_ID","value":"778742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155652":{"preferredName":"Samuraciclib","code":"C155652","definitions":[{"definition":"An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samuraciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK7 Inhibitor CT7001","termGroup":"SY","termSource":"NCI"},{"termName":"CT 7001","termGroup":"CN","termSource":"NCI"},{"termName":"CT-7001","termGroup":"CN","termSource":"NCI"},{"termName":"CT7001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1805833-75-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46D4HS9ODA"},{"name":"Maps_To","value":"CDK7 Inhibitor CT7001"},{"name":"Maps_To","value":"Samuraciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"794642"},{"name":"NCI_META_CUI","value":"CL556268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794642"},{"name":"PDQ_Open_Trial_Search_ID","value":"794642"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139552":{"preferredName":"Mevociclib","code":"C139552","definitions":[{"definition":"A selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon administration, SY-1365 binds to and inhibits CDK7, thereby inhibiting CDK7-mediated signal transduction pathways. This inhibits cell growth of CDK7-overexpressing tumor cells. CDK7, a serine/threonine kinase, plays a key role in cell proliferation; CDK7 is overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mevociclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK7 Inhibitor SY-1365","termGroup":"SY","termSource":"NCI"},{"termName":"SY-1365","termGroup":"CN","termSource":"NCI"},{"termName":"SY1365","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1816989-16-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"704LW082GI"},{"name":"Maps_To","value":"CDK7 Inhibitor SY-1365"},{"name":"Maps_To","value":"Mevociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"791104"},{"name":"NCI_META_CUI","value":"CL526907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791104"},{"name":"PDQ_Open_Trial_Search_ID","value":"791104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153377":{"preferredName":"CDK9 Inhibitor AZD4573","code":"C153377","definitions":[{"definition":"A selective, short-acting inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon intravenous administration, AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. This induces cell cycle arrest and apoptosis, and leads to a reduction in tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA polymerase II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK9 Inhibitor AZD4573","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 4573","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-4573","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2057509-72-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E5XSP3X68B"},{"name":"Maps_To","value":"CDK9 Inhibitor AZD4573"},{"name":"NCI_Drug_Dictionary_ID","value":"793903"},{"name":"NCI_META_CUI","value":"CL554533"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793903"},{"name":"PDQ_Open_Trial_Search_ID","value":"793903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131129":{"preferredName":"CEA-MUC-1-TRICOM Vaccine CV301","code":"C131129","definitions":[{"definition":"A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEA-MUC-1-TRICOM Vaccine CV301","termGroup":"PT","termSource":"NCI"},{"termName":"CV-301","termGroup":"CN","termSource":"NCI"},{"termName":"CV301","termGroup":"CN","termSource":"NCI"},{"termName":"CV301-V/F","termGroup":"CN","termSource":"NCI"},{"termName":"CVAC-301","termGroup":"CN","termSource":"NCI"},{"termName":"MVA-BN/Fowlpox-CEA-MUC-1-TRICOM Vaccine CV301","termGroup":"SY","termSource":"NCI"},{"termName":"PANVAC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEA-MUC-1-TRICOM Vaccine CV301"},{"name":"NCI_Drug_Dictionary_ID","value":"787798"},{"name":"NCI_META_CUI","value":"CL513447"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787798"},{"name":"PDQ_Open_Trial_Search_ID","value":"787798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159892":{"preferredName":"CEA-targeting Agent RG6123","code":"C159892","definitions":[{"definition":"An agent targeting the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, CEA-targeting agent RG6123 targets and binds to human CEA that is specifically expressed on certain tumor cells. This may, through an as of yet not elucidated mechanism of action, kill CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEA-targeting Agent RG6123","termGroup":"PT","termSource":"NCI"},{"termName":"RG 6123","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6123","termGroup":"CN","termSource":"NCI"},{"termName":"RG6123","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7172508","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7172508","termGroup":"CN","termSource":"NCI"},{"termName":"RO7172508","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEA-targeting Agent RG6123"},{"name":"NCI_Drug_Dictionary_ID","value":"797964"},{"name":"NCI_META_CUI","value":"CL968916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797964"},{"name":"PDQ_Open_Trial_Search_ID","value":"797964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126800":{"preferredName":"CEBPA-targeting saRNA MTL-CEBPA Liposome","code":"C126800","definitions":[{"definition":"A lipid-based nanoparticle formulation composed of liposomes encapsulating a small oligonucleotide encoding a small activating RNA (saRNA) targeting the CCAAT enhancer binding protein alpha (CEBPA; C/EBP-a) gene, with potential antineoplastic activity. Although the exact mechanism of action through which saRNAs exert their effect(s) is still largely being investigated, it appears that, upon administration, the CEBPA-targeting saRNA MTL-CEBPA liposome targets and binds to a specific DNA regulatory target region, most likely the promoter region, for the CEBPA gene. This restores CEBPA gene transcription, and increases both CEBPA mRNA levels and protein expression. This in turn activates the expression of tumor suppressor genes and may halt proliferation of susceptible tumor cells. Specifically, upregulation of CEBPA in liver cells abrogates liver cancer cell proliferation, thereby prevents liver failure and normalizes liver function. CEBPA, a transcription factor that plays a key role in the regulation of the expression of genes with many functions, including those involved in cellular proliferation, metastasis and normal hepatocyte function, is found in many tissues, including liver cells, adipose tissue and myeloid cells. CEBPA is downregulated in certain types of cancer cells, such as liver cancer cells. saRNA is a short, double-stranded RNA that is structurally related to siRNAs; saRNA is most likely to bind to a target site on the promoter of the CEBPA gene and upregulates its gene expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CEBPA-targeting saRNA MTL-CEBPA Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"MTL-501","termGroup":"CN","termSource":"NCI"},{"termName":"MTL-CEBPA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEBPA-targeting saRNA MTL-CEBPA Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"780224"},{"name":"NCI_META_CUI","value":"CL507895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780224"},{"name":"PDQ_Open_Trial_Search_ID","value":"780224"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164146":{"preferredName":"Cedazuridine","code":"C164146","definitions":[{"definition":"An orally available synthetic nucleoside analog derived from tetrahydrouridine (THU) and cytidine deaminase inhibitor (CDAi), that can potentially be used to prevent the breakdown of cytidines. Upon oral administration, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. Given in combination with a cytidine, such as the antineoplastic hypomethylating agent decitabine, it specifically prevents its breakdown and increases its bioavailability and efficacy. In addition, this allows for lower doses of decitabine to be administered, which results in decreased decitabine-associated GI toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cedazuridine","termGroup":"PT","termSource":"NCI"},{"termName":"(4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine","termGroup":"SY","termSource":"NCI"},{"termName":"CDA Inhibitor E7727","termGroup":"SY","termSource":"NCI"},{"termName":"E7727","termGroup":"CN","termSource":"NCI"},{"termName":"Uridine, 2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydro-, (4R)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1141397-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39IS23Q1EW"},{"name":"Maps_To","value":"Cedazuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"799445"},{"name":"NCI_META_CUI","value":"CL977331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799445"},{"name":"PDQ_Open_Trial_Search_ID","value":"799445"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C115102":{"preferredName":"Decitabine and Cedazuridine","code":"C115102","definitions":[{"definition":"An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Decitabine and Cedazuridine","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 727","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX-727","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX727","termGroup":"CN","termSource":"NCI"},{"termName":"C-DEC","termGroup":"SY","termSource":"NCI"},{"termName":"CDA Inhibitor E7727/Decitabine Combination Agent ASTX727","termGroup":"SY","termSource":"NCI"},{"termName":"Cedazuridine/Decitabine Combination Agent ASTX727","termGroup":"SY","termSource":"NCI"},{"termName":"Cedazuridine/Decitabine Tablet","termGroup":"SY","termSource":"NCI"},{"termName":"DEC-C","termGroup":"SY","termSource":"NCI"},{"termName":"Inaqovi","termGroup":"FB","termSource":"NCI"},{"termName":"Inqovi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with myelodysplastic syndromes (MDS)"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Cedazuridine/Decitabine Combination Agent ASTX727"},{"name":"Maps_To","value":"Decitabine and Cedazuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"759831"},{"name":"NCI_META_CUI","value":"CL472633"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759831"},{"name":"PDQ_Open_Trial_Search_ID","value":"759831"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78081":{"preferredName":"Cedefingol","code":"C78081","definitions":[{"definition":"A derivative of sphingosine, with potential antineoplastic activity. As a sphingosine derivative, cedefingol appears to inhibit protein kinase C (PKC), a kinase that plays an important role in tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cedefingol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"35301-24-7"},{"name":"Chemical_Formula","value":"C20H41NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81HH79X39W"},{"name":"Legacy Concept Name","value":"Cedefingol"},{"name":"Maps_To","value":"Cedefingol"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699130"}]}}{"C80867":{"preferredName":"Cediranib","code":"C80867","definitions":[{"definition":"An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cediranib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline","termGroup":"SN","termSource":"NCI"},{"termName":"AZ-D2171","termGroup":"CN","termSource":"NCI"},{"termName":"AZD 2171","termGroup":"CN","termSource":"NCI"},{"termName":"AZD2171","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"288383-20-0"},{"name":"Chemical_Formula","value":"C25H27FN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NQU9IPY4K9"},{"name":"Legacy Concept Name","value":"Cediranib"},{"name":"Maps_To","value":"Cediranib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1698364"}]}}{"C48379":{"preferredName":"Cediranib Maleate","code":"C48379","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. Cediranib maleate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cediranib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"AZD2171 Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"Recentin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857036-77-2"},{"name":"Chemical_Formula","value":"C25H27FN4O3.C4H4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68AYS9A614"},{"name":"Legacy Concept Name","value":"AZD2171"},{"name":"Maps_To","value":"Cediranib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"425596"},{"name":"NSC Number","value":"732208"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425596"},{"name":"PDQ_Open_Trial_Search_ID","value":"425596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541530"}]}}{"C1728":{"preferredName":"Celecoxib","code":"C1728","definitions":[{"definition":"A drug that reduces pain. Celecoxib belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is being studied in the prevention of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Celecoxib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"Celebrex","termGroup":"BR","termSource":"NCI"},{"termName":"Elyxyb","termGroup":"FB","termSource":"NCI"},{"termName":"Onsenal","termGroup":"FB","termSource":"NCI"},{"termName":"SC-58635","termGroup":"CN","termSource":"NCI"},{"termName":"YM 177","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute pain; Familial adenomatous polyposis; Primary dysmenorrhea; Osteoarthritis; Rheumatoid arthritis"},{"name":"CAS_Registry","value":"169590-42-5"},{"name":"CHEBI_ID","value":"CHEBI:41423"},{"name":"Chemical_Formula","value":"C17H14F3N3O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JCX84Q7J1L"},{"name":"Legacy Concept Name","value":"Celecoxib"},{"name":"Maps_To","value":"Celecoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"43023"},{"name":"NSC Number","value":"719627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43023"},{"name":"PDQ_Open_Trial_Search_ID","value":"43023"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0538927"}]}}{"C67075":{"preferredName":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83","code":"C67075","definitions":[{"definition":"A proprietary agent with potential antineoplastic activity. IC83 appears to target cell cycle checkpoint/DNA repair enzymes, which are involved in the recognition and repair of damaged DNA and are overexpressed in many types of cancer cells. Inhibition of cell cycle checkpoint/DNA repair enzymes may enhance the cytotoxicity of DNA damaging agents and dissipate tumor cell resistance to chemotherapy and radiation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83","termGroup":"PT","termSource":"NCI"},{"termName":"IC83","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"IC83"},{"name":"Maps_To","value":"Cell Cycle Checkpoint/DNA Repair Antagonist IC83"},{"name":"NCI_Drug_Dictionary_ID","value":"536220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536220"},{"name":"PDQ_Open_Trial_Search_ID","value":"536220"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881108"}]}}{"C75875":{"preferredName":"Cemadotin","code":"C75875","definitions":[{"definition":"A synthetic dolastatin 15 analogue with potential antineoplastic activity.  Cemadotin suppresses spindle microtubule dynamics by binding to tubulin, thereby blocking mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemadotin","termGroup":"PT","termSource":"NCI"},{"termName":"LU-103793","termGroup":"CN","termSource":"NCI"},{"termName":"LU103793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"159776-69-9"},{"name":"Chemical_Formula","value":"C35H56N6O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SQ8M7ZSFV"},{"name":"Legacy Concept Name","value":"Cemadotin_Base"},{"name":"Maps_To","value":"Cemadotin"},{"name":"NSC Number","value":"D-669356"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0754175"}]}}{"C1634":{"preferredName":"Cemadotin Hydrochloride","code":"C1634","definitions":[{"definition":"An anticancer drug that reduces the risk of tumor cell growth and reproduction.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of cemadotin, a synthetic dolastatin 15 analogue with potential antineoplastic activity.  Cemadotin suppresses spindle microtubule dynamics by binding to tubulin, thereby blocking mitosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemadotin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Cemadotin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"LU-103793","termGroup":"CN","termSource":"NCI"},{"termName":"LU103793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"172837-41-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"CCR recorded NSC-D-669356"},{"name":"FDA_UNII_Code","value":"4LJQ1IXS6C"},{"name":"Legacy Concept Name","value":"Cemadotin"},{"name":"Maps_To","value":"Cemadotin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42651"},{"name":"NSC Number","value":"D-669356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42651"},{"name":"PDQ_Open_Trial_Search_ID","value":"42651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299746"}]}}{"C121540":{"preferredName":"Cemiplimab","code":"C121540","definitions":[{"definition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemiplimab","termGroup":"PT","termSource":"NCI"},{"termName":"Cemiplimab RWLC","termGroup":"SY","termSource":"NCI"},{"termName":"Cemiplimab-rwlc","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Libtayo","termGroup":"BR","termSource":"NCI"},{"termName":"REGN 2810","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-2810","termGroup":"CN","termSource":"NCI"},{"termName":"REGN2810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC"},{"name":"CAS_Registry","value":"1801342-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6QVL057INT"},{"name":"Maps_To","value":"Cemiplimab"},{"name":"NCI_Drug_Dictionary_ID","value":"770083"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770083"},{"name":"PDQ_Open_Trial_Search_ID","value":"770083"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053601"}]}}{"C37454":{"preferredName":"Cenersen","code":"C37454","definitions":[{"definition":"A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cenersen","termGroup":"PT","termSource":"NCI"},{"termName":"Aezea","termGroup":"BR","termSource":"NCI"},{"termName":"EL625","termGroup":"CN","termSource":"NCI"},{"termName":"OL(1)p53","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"415168-49-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K6KJ8AZ05F"},{"name":"Legacy Concept Name","value":"EL625"},{"name":"Maps_To","value":"Cenersen"},{"name":"NCI_Drug_Dictionary_ID","value":"354249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354249"},{"name":"PDQ_Open_Trial_Search_ID","value":"354249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700610"}]}}{"C64540":{"preferredName":"Cenisertib","code":"C64540","definitions":[{"definition":"A water-soluble, synthetic small molecule with potential antineoplastic activity. Cenisertib selectively binds to and inhibits aurora kinases (AKs), a family of serine-threonine kinases which are important regulators of cell division and proliferation, and which are overexpressed in certain types of cancer. Inhibition of aurora kinases inhibits cell division and proliferation and induces apoptosis in tumor cells overexpressing AKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cenisertib","termGroup":"PT","termSource":"NCI"},{"termName":"AS703569","termGroup":"CN","termSource":"NCI"},{"termName":"Aurora Kinase Inhibitor AS703569","termGroup":"SY","termSource":"NCI"},{"termName":"R763","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871357-89-0"},{"name":"Chemical_Formula","value":"C24H30FN7O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5277GPA358"},{"name":"Legacy Concept Name","value":"R763"},{"name":"Maps_To","value":"Cenisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"522734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"522734"},{"name":"PDQ_Open_Trial_Search_ID","value":"522734"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853900"}]}}{"C91080":{"preferredName":"CENP-E Inhibitor GSK-923295A","code":"C91080","definitions":[{"definition":"A small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), with potential antineoplastic activity. Upon administration, GSK-923295A binds to and inhibits CENP-E, thereby preventing cell division, inducing cell cycle arrest, and ultimately leading to an inhibition of cell proliferation. CENP-E, a kinetochore-associated mitotic kinesin, plays an essential role in chromosome movement during mitosis and regulates cell-cycle transition from metaphase to anaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CENP-E Inhibitor GSK-923295A","termGroup":"PT","termSource":"NCI"},{"termName":"Centromere-Associated Protein E Inhibitor GSK-923295","termGroup":"SY","termSource":"NCI"},{"termName":"GSK 923295","termGroup":"CN","termSource":"NCI"},{"termName":"GSK 923295A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-923295","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-923295A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK923295","termGroup":"CN","termSource":"NCI"},{"termName":"GSK923295A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1088965-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"072702W9QD"},{"name":"Maps_To","value":"CENP-E Inhibitor GSK-923295"},{"name":"NCI_Drug_Dictionary_ID","value":"562003"},{"name":"NCI_META_CUI","value":"CL376164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"562003"},{"name":"PDQ_Open_Trial_Search_ID","value":"562003"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111993":{"preferredName":"Ceralasertib","code":"C111993","definitions":[{"definition":"An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceralasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD6738","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1352226-88-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"85RE35306Z"},{"name":"Maps_To","value":"Ceralasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"754022"},{"name":"NCI_META_CUI","value":"CL454282"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754022"},{"name":"PDQ_Open_Trial_Search_ID","value":"754022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131434":{"preferredName":"Ceramide Nanoliposome","code":"C131434","definitions":[{"definition":"A lipid-based nanoparticle formulation composed of the apoptosis-inducing sphingolipid ceramide encapsulated within nanoliposomes, with potential apoptotic and antineoplastic activities. Upon administration, ceramide nanoliposomes accumulate in the tumor environment, due to the unique properties of the tumor vasculature, and easily enter tumor cells. This delivers ceramide inside the tumor cells, where ceramide induces apoptosis. Although the process is not completely understood, ceramide-dependent apoptosis most likely results from the downregulation of nutrient transporter proteins, which prevents cellular access to extracellular nutrients and causes tumor cell starvation. This selectively destroys tumor cells. Ceramide alone is insoluble and has a very short half-life; therefore, the nanoliposome formulation increases its solubility and half-life. Ceramide plays a key role in the regulation of autophagy, apoptosis, survival and proliferation. Serving as a tumor suppressor lipid, the expression of ceramide is inversely correlated with tumor cell growth, survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceramide Nanoliposome","termGroup":"PT","termSource":"NCI"},{"termName":"CNL","termGroup":"AB","termSource":"NCI"},{"termName":"KN 001","termGroup":"CN","termSource":"NCI"},{"termName":"KN-001","termGroup":"CN","termSource":"NCI"},{"termName":"KN-01","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoliposomal Ceramide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ceramide Nanoliposome"},{"name":"NCI_Drug_Dictionary_ID","value":"786010"},{"name":"NCI_META_CUI","value":"CL514701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786010"},{"name":"PDQ_Open_Trial_Search_ID","value":"786010"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113173":{"preferredName":"Cerdulatinib","code":"C113173","definitions":[{"definition":"An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cerdulatinib","termGroup":"PT","termSource":"NCI"},{"termName":"PRT-062070","termGroup":"CN","termSource":"NCI"},{"termName":"PRT062070","termGroup":"CN","termSource":"NCI"},{"termName":"Syk/JAK Inhibitor PRT062070","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1198300-79-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D1LXQ45S1O"},{"name":"Maps_To","value":"Cerdulatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"755483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755483"},{"name":"PDQ_Open_Trial_Search_ID","value":"755483"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827083"}]}}{"C146660":{"preferredName":"Mezigdomide","code":"C146660","definitions":[{"definition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mezigdomide","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986348","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986348","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986348","termGroup":"CN","termSource":"NCI"},{"termName":"CC 92480","termGroup":"CN","termSource":"NCI"},{"termName":"CC-92480","termGroup":"CN","termSource":"NCI"},{"termName":"CC92480","termGroup":"CN","termSource":"NCI"},{"termName":"CELMoD CC-92480","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ligase Modulation Drug CC-92480","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon Modulator CC-92480","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2259648-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LA88IH4O02"},{"name":"Maps_To","value":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480"},{"name":"NCI_Drug_Dictionary_ID","value":"792155"},{"name":"NCI_META_CUI","value":"CL544644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792155"},{"name":"PDQ_Open_Trial_Search_ID","value":"792155"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131177":{"preferredName":"Eragidomide","code":"C131177","definitions":[{"definition":"A modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, eragidomide specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex. This leads to the ubiquitination of certain substrate proteins and induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcriptional repressors in T-cells. This reduces the levels of these transcription factors, and modulates the activity of the immune system, which may include the activation of T-lymphocytes. In addition, this downregulates the expression of other proteins, including interferon regulatory factor 4 (IRF4) and c-myc, which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eragidomide","termGroup":"PT","termSource":"NCI"},{"termName":"CC 90009","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90009","termGroup":"CN","termSource":"NCI"},{"termName":"Cereblon Modulator CC-90009","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1860875-51-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R76M2Z6366"},{"name":"Maps_To","value":"Cereblon Modulator CC-90009"},{"name":"NCI_Drug_Dictionary_ID","value":"785499"},{"name":"NCI_META_CUI","value":"CL514037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785499"},{"name":"PDQ_Open_Trial_Search_ID","value":"785499"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141459":{"preferredName":"Cergutuzumab Amunaleukin","code":"C141459","definitions":[{"definition":"A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of cergutuzumab amunaleukin, the cergutuzumab moiety recognizes and binds to CEA, thereby specifically targeting IL-2v to CEA-expressing tumor tissue. Subsequently, the IL-2v moiety stimulates a local immune response, which activates both natural killer (NK) cells and cytotoxic T-cells, and eventually leads to tumor cell killing. CEA is a cell surface protein that is expressed on a wide variety of cancer cells. The mutations found in IL-2v inhibit its binding to IL-2 receptor-alpha (CD25, IL2Ra), which prevents the activation of regulatory T-cells (Tregs); however, IL-2v is able to bind to and induce signaling through IL-2Rbetagamma, which allows the preferential expansion of NK cells and CD8-positive T-cells. The Fc domain of cergutuzumab is modified to prevent Fc-gamma binding and downstream effector functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cergutuzumab Amunaleukin","termGroup":"PT","termSource":"NCI"},{"termName":"CEA-IL-2variant","termGroup":"SY","termSource":"NCI"},{"termName":"CEA-IL2v","termGroup":"SY","termSource":"NCI"},{"termName":"RG-7813","termGroup":"CN","termSource":"NCI"},{"termName":"RG7813","termGroup":"CN","termSource":"NCI"},{"termName":"RO-6895882","termGroup":"CN","termSource":"NCI"},{"termName":"RO6895882","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1509916-03-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48FCG62C25"},{"name":"Maps_To","value":"Cergutuzumab Amunaleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"791420"},{"name":"NCI_META_CUI","value":"CL539489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791420"},{"name":"PDQ_Open_Trial_Search_ID","value":"791420"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C115112":{"preferredName":"Ceritinib","code":"C115112","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ceritinib","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"LDK 378","termGroup":"CN","termSource":"NCI"},{"termName":"LDK-378","termGroup":"CN","termSource":"NCI"},{"termName":"LDK378","termGroup":"CN","termSource":"NCI"},{"termName":"Zykadia","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive"},{"name":"CAS_Registry","value":"1032900-25-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K418KG2GET"},{"name":"Maps_To","value":"Ceritinib"},{"name":"NCI_Drug_Dictionary_ID","value":"694589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694589"},{"name":"PDQ_Open_Trial_Search_ID","value":"694589"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3818721"}]}}{"C28882":{"preferredName":"Cesalin","code":"C28882","definitions":[{"definition":"An antineoplastic protein isolated from the seeds of the plant Caesalpinia gilliesii with antineoplastic activity.  Cesalin intercalates into and crosslinks DNA and inhibits the incorporation of the nucleotides uridine and thymidine into DNA, thereby inhibiting DNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cesalin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cesalin"},{"name":"Maps_To","value":"Cesalin"},{"name":"NSC Number","value":"110435"},{"name":"NSC Number","value":"264879"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055132"}]}}{"C147521":{"preferredName":"cEt KRAS Antisense Oligonucleotide AZD4785","code":"C147521","definitions":[{"definition":"A proprietary formulation composed of a high affinity antisense oligonucleotide (ASO) that contains 2'-4' constrained ethyl residues (cEt) and targets KRAS (K-RAS) transcripts, with potential antineoplastic activity. Upon intravenous administration, cEt KRAS antisense oligonucleotide AZD4785 targets and binds, with high affinity, to a unique genetic sequence within KRAS messenger RNA (mRNA), thereby inhibiting translation of KRAS protein, including forms containing activating mutations. Inhibition of KRAS protein synthesis prevents KRAS-dependent signaling and inhibits the proliferation of KRAS-driven tumor cells. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cEt KRAS Antisense Oligonucleotide AZD4785","termGroup":"PT","termSource":"NCI"},{"termName":"ASO AZD4785","termGroup":"SY","termSource":"NCI"},{"termName":"AZD 4785","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-4785","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4785","termGroup":"CN","termSource":"NCI"},{"termName":"cEt KRAS ASO AZD4785","termGroup":"SY","termSource":"NCI"},{"termName":"Generation 2.5 Drug AZD4785","termGroup":"SY","termSource":"NCI"},{"termName":"IONIS-KRAS-2.5Rx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D43WWD6RDZ"},{"name":"Maps_To","value":"cEt KRAS Antisense Oligonucleotide AZD4785"},{"name":"NCI_Drug_Dictionary_ID","value":"792660"},{"name":"NCI_META_CUI","value":"CL545331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792660"},{"name":"PDQ_Open_Trial_Search_ID","value":"792660"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129448":{"preferredName":"Cetrelimab","code":"C129448","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 protein (PD-1, PCDC-1), with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 63723283","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63723283","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63723283","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10757","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2050478-92-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LYK98WP91F"},{"name":"Maps_To","value":"Cetrelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"784126"},{"name":"NCI_META_CUI","value":"CL512668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784126"},{"name":"PDQ_Open_Trial_Search_ID","value":"784126"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1723":{"preferredName":"Cetuximab","code":"C1723","definitions":[{"definition":"A monoclonal antibody used to treat certain types of head and neck cancer, and colorectal cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Erbitux binds to the epidermal growth factor receptor (EGFR), which is found on the surface of some types of cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetuximab","termGroup":"PT","termSource":"NCI"},{"termName":"C 225","termGroup":"CN","termSource":"NCI"},{"termName":"C-225","termGroup":"CN","termSource":"NCI"},{"termName":"C225","termGroup":"CN","termSource":"NCI"},{"termName":"Cetuximab Biosimilar CDP-1","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab Biosimilar CMAB009","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab Biosimilar KL 140","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric Anti-EGFR Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric MoAb C225","termGroup":"AB","termSource":"NCI"},{"termName":"Chimeric Monoclonal Antibody C225","termGroup":"SY","termSource":"NCI"},{"termName":"Erbitux","termGroup":"BR","termSource":"NCI"},{"termName":"IMC-C225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced colorectal cancer; Head and neck cancer"},{"name":"CAS_Registry","value":"205923-56-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PQX0D8J21J"},{"name":"Legacy Concept Name","value":"Cetuximab"},{"name":"Maps_To","value":"Cetuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"42384"},{"name":"NSC Number","value":"714692"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42384"},{"name":"PDQ_Open_Trial_Search_ID","value":"42384"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0995188"}]}}{"C121850":{"preferredName":"Cetuximab Sarotalocan Sodium","code":"C121850","definitions":[{"definition":"The sodium salt form of cetuximab sarotalocan, which consists of a chemical conjugate composed of the dye IR700 linked to cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon injection of cetuximab sarotalocan sodium, the cetuximab moiety targets and binds to EGFR-expressing tumor cells, resulting in the internalization of the conjugate. Upon localized application of near-infrared (NIR) light, the IR700 dye becomes activated, disrupts the cell membrane and selectively kills the EGFR-expressing tumor cells. EGFR, a tyrosine kinase receptor, is overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetuximab Sarotalocan Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"ASP 1929","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1929","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1929","termGroup":"CN","termSource":"NCI"},{"termName":"Cet-IR700","termGroup":"SY","termSource":"NCI"},{"termName":"Cetuximab-IR700 Conjugate RM-1929","termGroup":"SY","termSource":"NCI"},{"termName":"RM-1929","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2166339-33-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MG94W1I5XW"},{"name":"Maps_To","value":"Cetuximab Sarotalocan"},{"name":"Maps_To","value":"Cetuximab-IR700 Conjugate RM-1929"},{"name":"NCI_Drug_Dictionary_ID","value":"771602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771602"},{"name":"PDQ_Open_Trial_Search_ID","value":"771602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053596"}]}}{"C158083":{"preferredName":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide","code":"C158083","definitions":[{"definition":"A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide","termGroup":"PT","termSource":"NCI"},{"termName":"Cetuximab-loaded Polymeric Nanoparticles Decorated With Octreotide","termGroup":"SY","termSource":"NCI"},{"termName":"Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Octreotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)"},{"name":"NCI_Drug_Dictionary_ID","value":"797050"},{"name":"NCI_META_CUI","value":"CL937696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797050"},{"name":"PDQ_Open_Trial_Search_ID","value":"797050"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C77064":{"preferredName":"Cevipabulin","code":"C77064","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevipabulin","termGroup":"PT","termSource":"NCI"},{"termName":"Cevipabulinum","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 237","termGroup":"SY","termSource":"NCI"},{"termName":"Tubulin Binding Agent TTI-237","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849550-05-6"},{"name":"Chemical_Formula","value":"C18H18ClF5N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P14M0DWS2J"},{"name":"Legacy Concept Name","value":"Cevipabulin"},{"name":"Legacy Concept Name","value":"TTI-237"},{"name":"Maps_To","value":"Cevipabulin"},{"name":"Maps_To","value":"Tubulin Binding Agent TTI-237"},{"name":"NCI_Drug_Dictionary_ID","value":"432958"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699167"}]}}{"C73815":{"preferredName":"Cevipabulin Fumarate","code":"C73815","definitions":[{"definition":"The fumarate salt of cevipabulin, a synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth., a small, water soluble, synthetic tubulin-binding agent with potential antineoplastic activity.  Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and may reduce cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevipabulin Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, (2E)-2-butenedioate (1:1), dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"TTI-237","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849550-69-2"},{"name":"Chemical_Formula","value":"C18H18ClF5N6O.C4H4O4.2H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q380BYV049"},{"name":"Legacy Concept Name","value":"Cevipabulin_Fumarate"},{"name":"Maps_To","value":"Cevipabulin Fumarate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347606"}]}}{"C96746":{"preferredName":"Cevipabulin Succinate","code":"C96746","definitions":[{"definition":"The succinate salt form of cevipabulin, a synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin binds at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. This stabilizes tubulin and prevents microtubule disassembly. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cevipabulin Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"5-chloro-6-(2,6-difluoro-4-(3-(methylamino)propoxy)phenyl)-N-((1S)-2,2,2-trifluoro-1-methylethyl)(1,2,4)triazolo(1,5-a)pyrimidin-7-amine succinate dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"TTI-237 Succinate Dihydrate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"852954-81-5"},{"name":"Chemical_Formula","value":"C18H18ClF5N6O.C4H6O4.2H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8XI0CX98LY"},{"name":"Maps_To","value":"Cevipabulin Succinate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273003"}]}}{"C96227":{"preferredName":"cFMS Tyrosine Kinase Inhibitor ARRY-382","code":"C96227","definitions":[{"definition":"A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; cFMS) with potential antineoplastic activity. cFMS tyrosine kinase inhibitor ARRY-382 binds to and inhibits the activity of cFMS. By preventing colony-stimulating factor-1 (CSF-1)-cFMS signaling, this agent may inhibit tumor cell proliferation in cFMS-overexpressing tumor cells. cFMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation and regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cFMS Tyrosine Kinase Inhibitor ARRY-382","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-382","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"cFMS Tyrosine Kinase Inhibitor ARRY-382"},{"name":"NCI_Drug_Dictionary_ID","value":"697525"},{"name":"NCI_META_CUI","value":"CL429011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697525"},{"name":"PDQ_Open_Trial_Search_ID","value":"697525"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1767":{"preferredName":"Chaparrin","code":"C1767","definitions":[{"definition":"A quassinoid phytochemical isolated from Simaba cedron and other plant species with potential antineoplastic activity.  Chaparrin is a mixture of compounds that includes flavonoids, antioxidants, and nordihydroguaiaretic acid (NDGA).  NDGA is an antioxidant and lipoxygenase inhibitor that promotes cell differentiation, induces G1 phase cell-cycle arrest, and causes apoptosis in certain cancer cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chaparrin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4616-50-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YX31WC5SRV"},{"name":"Legacy Concept Name","value":"Chaparrin"},{"name":"Maps_To","value":"Chaparrin"},{"name":"NSC Number","value":"132794"},{"name":"NSC Number","value":"79404"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0630780"}]}}{"C1046":{"preferredName":"Chaparrinone","code":"C1046","definitions":[{"definition":"A quassinoid phytochemical isolated from Ailanthus integrifolia sp. calycina and other plant species with potential antineoplastic activity.  Chaparrinone inhibits protein synthesis, has antimalarial properties, and is cytotoxic to some tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chaparrinone","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-ene-2,16-dione, 11,20-epoxy-1,11,12-trihydroxy-, (1beta,11beta,12alpha)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"22611-34-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chaparrinone"},{"name":"Maps_To","value":"Chaparrinone"},{"name":"NSC Number","value":"288754"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055268"}]}}{"C66961":{"preferredName":"Checkpoint Kinase Inhibitor AZD7762","code":"C66961","definitions":[{"definition":"A synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis. This agent may enhance the cytotoxicity of DNA-damaging agents. Chks are protein kinases that regulate either G1/S or G2/M transitions in the cell cycle. In the presence of DNA damage or incomplete DNA replication, Chks become activated and initiate cell cycle arrest to allow DNA repair or the completion of DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Checkpoint Kinase Inhibitor AZD7762","termGroup":"PT","termSource":"NCI"},{"termName":"AZD7762","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"860352-01-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5D822Y3L1H"},{"name":"Legacy Concept Name","value":"AZD7762"},{"name":"Maps_To","value":"Checkpoint Kinase Inhibitor AZD7762"},{"name":"NCI_Drug_Dictionary_ID","value":"530784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530784"},{"name":"PDQ_Open_Trial_Search_ID","value":"530784"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832037"}]}}{"C61102":{"preferredName":"Checkpoint Kinase Inhibitor XL844","code":"C61102","definitions":[{"definition":"A synthetic small-molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antineoplastic activity. XL844 binds to and inhibits Chks 1 and 2, resulting in inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumor cell apoptosis. This agent also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), important mediators of tumor angiogenesis and lymphogenesis, respectively. In the presence of extensive damage or absence of timely repair, these checkpoint-signaling pathways may also trigger a pathway that effects apoptosis. Normal functions of Chks involve the initiation of cell-cycle arrest and the up-regulation of transcription genes involved with DNA excision repair and dNTP synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Checkpoint Kinase Inhibitor XL844","termGroup":"PT","termSource":"NCI"},{"termName":"Chk Inhibitor XL844","termGroup":"SY","termSource":"NCI"},{"termName":"XL844","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XL844"},{"name":"Maps_To","value":"Checkpoint Kinase Inhibitor XL844"},{"name":"NCI_Drug_Dictionary_ID","value":"469731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"469731"},{"name":"PDQ_Open_Trial_Search_ID","value":"469731"},{"name":"PubMedID_Primary_Reference","value":"20024691"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831757"}]}}{"C115970":{"preferredName":"Ibcasertib","code":"C115970","definitions":[{"definition":"An orally available, small molecule inhibitor of select serine-threonine kinases, including aurora kinase B (aurora B), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-KIT), and platelet-derived growth factor receptors (PDGFRs), with potential antineoplastic activity. Upon oral administration, ibcasertib binds to and inhibits the activity of aurora B, VEGFRs, c-kit and PDGFRs, which may result in a decrease in the proliferation of tumor cells that overexpress these kinases. These kinases are overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibcasertib","termGroup":"PT","termSource":"NCI"},{"termName":"Chiauranib","termGroup":"SY","termSource":"NCI"},{"termName":"CS2164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256349-48-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F40IRN5981"},{"name":"Maps_To","value":"Chiauranib"},{"name":"NCI_Drug_Dictionary_ID","value":"760526"},{"name":"NCI_META_CUI","value":"CL473304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760526"},{"name":"PDQ_Open_Trial_Search_ID","value":"760526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156351":{"preferredName":"Chimeric Monoclonal Antibody 81C6","code":"C156351","definitions":[{"definition":"A chimeric, murine-human monoclonal antibody directed against the tumor-associated antigen (TAA) tenascin (hexabrachion) that may, when conjugated with a radioisotope, be useful in radiotherapy or radioimaging. Tenascin, an extracellular matrix glycoprotein is upregulated in certain pathological conditions such as infection, inflammation and tumor growth, and is highly expressed in the tumor microenvironment in some malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chimeric Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"ch81c6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chimeric Monoclonal Antibody 81C6"},{"name":"NCI_META_CUI","value":"CL563141"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C119741":{"preferredName":"ChiNing Decoction","code":"C119741","definitions":[{"definition":"A decoction of Liang Ge San, a traditional Chinese herbal medicine, with potential anti-inflammatory and anti-stomatitis activities. Although the complete mechanism of action through which the ChiNing decoction works has yet to be fully elucidated, upon oral administration, the active ingredients may inhibit the inflammatory response, possibly by reducing the levels of pro-inflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNFa), in the saliva. This may protect the oral mucosa against these inflammatory mediators, and may reduce and relieve radiation-induced stomatitis and the associated pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ChiNing Decoction","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ChiNing Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"767025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767025"},{"name":"PDQ_Open_Trial_Search_ID","value":"767025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899687"}]}}{"C129580":{"preferredName":"Chk1 Inhibitor SRA737","code":"C129580","definitions":[{"definition":"An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor SRA737 selectively binds to chk1, thereby preventing chk1 activity and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. SRA737 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an adenosine triphosphate (ATP)-dependent serine/threonine kinase overexpressed in a variety of cancer cell types, mediates cell cycle checkpoint control and is essential for DNA repair; it plays a key role in resistance to chemotherapeutic agents by repairing DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chk1 Inhibitor SRA737","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"CCT245737","termGroup":"CN","termSource":"NCI"},{"termName":"Checkpoint Kinase 1 Inhibitor CCT245737","termGroup":"SY","termSource":"NCI"},{"termName":"Chk1 Inhibitor CCT245737","termGroup":"SY","termSource":"NCI"},{"termName":"PNT-737","termGroup":"CN","termSource":"NCI"},{"termName":"SRA 737","termGroup":"CN","termSource":"NCI"},{"termName":"SRA-737","termGroup":"CN","termSource":"NCI"},{"termName":"SRA737","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1489389-18-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QB6LNL4NF6"},{"name":"Maps_To","value":"Chk1 Inhibitor CCT245737"},{"name":"NCI_Drug_Dictionary_ID","value":"783792"},{"name":"NCI_META_CUI","value":"CL512598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783792"},{"name":"PDQ_Open_Trial_Search_ID","value":"783792"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116756":{"preferredName":"Chk1 Inhibitor GDC-0425","code":"C116756","definitions":[{"definition":"An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor GDC-0425 selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. GDC-0425 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an ATP-dependent serine/threonine kinase, mediates cell cycle checkpoint control, is essential for DNA repair, and plays a key role in resistance to chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chk1 Inhibitor GDC-0425","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0425","termGroup":"CN","termSource":"NCI"},{"termName":"RG7602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1627539-18-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4N173XZ7SX"},{"name":"Maps_To","value":"Chk1 Inhibitor GDC-0425"},{"name":"NCI_Drug_Dictionary_ID","value":"701310"},{"name":"NCI_META_CUI","value":"CL433842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701310"},{"name":"PDQ_Open_Trial_Search_ID","value":"701310"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116845":{"preferredName":"Chk1 Inhibitor GDC-0575","code":"C116845","definitions":[{"definition":"A small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity. Chk1 inhibitor GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis. Therefore, Chk1 inhibition may sensitize tumor cells to the DNA-damaging effects of certain chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that phosphorylates cdc25 phosphatases in response to DNA damage. This results in both inhibitory tyrosine phosphorylation of cyclin-dependent kinase (CDK)-cyclin complexes and cell cycle arrest, which facilitates DNA damage repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chk1 Inhibitor GDC-0575","termGroup":"PT","termSource":"NCI"},{"termName":"Checkpoint Kinase 1 Inhibitor GDC-0575","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0575","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chk1 Inhibitor GDC-0575"},{"name":"NCI_Drug_Dictionary_ID","value":"730054"},{"name":"NCI_META_CUI","value":"CL446611"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730054"},{"name":"PDQ_Open_Trial_Search_ID","value":"730054"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79867":{"preferredName":"CHK1 Inhibitor MK-8776","code":"C79867","definitions":[{"definition":"An agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities. Chk1 inhibitor MK-8776 specifically binds to and inhibits Chk1, which may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases to undergo DNA repair prior to entry into mitosis; tumor cells may thus be sensitized to the DNA-damaging effects of ionizing radiation and alkylating chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that in response to DNA damage phosphorylates cdc25 phosphatases, resulting in inhibitory tyrosine phosphorylation of CDK-cyclin complexes and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHK1 Inhibitor MK-8776","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-6-Bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine","termGroup":"SN","termSource":"NCI"},{"termName":"MK8776","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900776","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-900776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"891494-63-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K2ZSF0992C"},{"name":"Legacy Concept Name","value":"CHK1_Inhibitor_SCH_900776"},{"name":"Maps_To","value":"CHK1 Inhibitor MK-8776"},{"name":"NCI_Drug_Dictionary_ID","value":"624396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"624396"},{"name":"PDQ_Open_Trial_Search_ID","value":"624396"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703183"}]}}{"C68820":{"preferredName":"CHK1 Inhibitor PF-477736","code":"C68820","definitions":[{"definition":"A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHK1 Inhibitor PF-477736","termGroup":"PT","termSource":"NCI"},{"termName":"PF-00477736","termGroup":"CN","termSource":"NCI"},{"termName":"PF-477736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"952021-60-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XO23PGZ0SM"},{"name":"Legacy Concept Name","value":"CHK1_Inhibitor_PF-477736"},{"name":"Maps_To","value":"CHK1 Inhibitor PF-477736"},{"name":"NCI_Drug_Dictionary_ID","value":"539740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539740"},{"name":"PDQ_Open_Trial_Search_ID","value":"539740"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4049082"}]}}{"C362":{"preferredName":"Chlorambucil","code":"C362","definitions":[{"definition":"A drug used to treat several types of leukemias and lymphomas. It blocks cell growth by damaging the cell's DNA and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorambucil","termGroup":"PT","termSource":"NCI"},{"termName":"4-[bis(2-chloroethyl)amino]benzenebutanoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"Alti-chlorambucil","termGroup":"FB","termSource":"NCI"},{"termName":"Ambochlorin","termGroup":"SY","termSource":"NCI"},{"termName":"Amboclorin","termGroup":"SY","termSource":"NCI"},{"termName":"aminochlorambucil","termGroup":"SY","termSource":"NCI"},{"termName":"benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)","termGroup":"SN","termSource":"NCI"},{"termName":"CB-1348","termGroup":"CN","termSource":"NCI"},{"termName":"CHL","termGroup":"AB","termSource":"NCI"},{"termName":"Chlorambucilum","termGroup":"SY","termSource":"NCI"},{"termName":"Chloraminophen","termGroup":"SY","termSource":"NCI"},{"termName":"Chloraminophene","termGroup":"FB","termSource":"NCI"},{"termName":"Chlorbutin","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorbutine","termGroup":"SY","termSource":"NCI"},{"termName":"chlorbutinum","termGroup":"SY","termSource":"NCI"},{"termName":"chloroambucil","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorobutin","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorobutine","termGroup":"SY","termSource":"NCI"},{"termName":"Ecloril","termGroup":"SY","termSource":"NCI"},{"termName":"Elcoril","termGroup":"SY","termSource":"NCI"},{"termName":"gamma-(p-bis(2-chloroethyl)aminophenyl)butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"Leukeran","termGroup":"BR","termSource":"NCI"},{"termName":"Leukersan","termGroup":"SY","termSource":"NCI"},{"termName":"Leukoran","termGroup":"SY","termSource":"NCI"},{"termName":"Linfolizin","termGroup":"SY","termSource":"NCI"},{"termName":"Lympholysin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"p-(N, N-di-2-chloroethyl)aminophenyl butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"p-N, N-di-(beta-chloroethyl)aminophenyl butyric acid","termGroup":"SN","termSource":"NCI"},{"termName":"phenylbutyric acid nitrogen mustard","termGroup":"SY","termSource":"NCI"},{"termName":"WR-139013","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia, Hodgkin lymphoma, and certain types of non-Hodgkin lymphoma."},{"name":"CAS_Registry","value":"305-03-3"},{"name":"CHEBI_ID","value":"CHEBI:28830"},{"name":"Chemical_Formula","value":"C14H19Cl2NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"18D0SL7309"},{"name":"Legacy Concept Name","value":"Chlorambucil"},{"name":"Maps_To","value":"Chlorambucil"},{"name":"NCI_Drug_Dictionary_ID","value":"43113"},{"name":"NSC Number","value":"3088"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43113"},{"name":"PDQ_Open_Trial_Search_ID","value":"43113"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008163"}]}}{"C2085":{"preferredName":"Chlorodihydropyrimidine","code":"C2085","definitions":[{"definition":"A pyrimidine derivative with antitumor activity. Chlorodihydropyrimidine competitively and reversibly inhibits dihydropyrimidine dehydrogenase, a rate-limiting enzyme in the catabolism of fluoropyrimidines thereby blocking the degradation of the fluoropyrimidines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorodihydropyrimidine","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chlorodihydropyrimidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Chlorodihydropyrimidine"},{"name":"Maps_To","value":"Chlorodihydropyrimidine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516486"}]}}{"C61671":{"preferredName":"Chloroquine","code":"C61671","definitions":[{"definition":"A 4-aminoquinoline with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the mechanism is not well understood, chloroquine is shown to inhibit the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. This agent may also interfere with the biosynthesis of nucleic acids. Chloroquine's potential chemosensitizing and radiosensitizing activities in cancer may be related to its inhibition of autophagy, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chloroquine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54-05-7"},{"name":"CHEBI_ID","value":"CHEBI:3638"},{"name":"Chemical_Formula","value":"C18H26ClN3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"886U3H6UFF"},{"name":"Legacy Concept Name","value":"Chloroquine"},{"name":"Maps_To","value":"Chloroquine"},{"name":"NCI_Drug_Dictionary_ID","value":"654729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654729"},{"name":"PDQ_Open_Trial_Search_ID","value":"654729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008269"}]}}{"C982":{"preferredName":"Chloroquinoxaline Sulfonamide","code":"C982","definitions":[{"definition":"A chlorinated heterocyclic sulfanilamide with potential antineoplastic activity and potential immunosuppressive activity.  Chloroquinoxaline sulfonamide poisons topoisomerase II alpha and topoisomerase II beta, thereby causing double-stranded breaks in DNA, accumulation of unrepaired DNA, and apoptosis.  This agent also exhibits lymphotoxicity by inhibiting lymphocyte activation in a cell cycle-specific manner. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chloroquinoxaline Sulfonamide","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, 4-amino-N-(5-chloro-2-quinoxalinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"chlorosulfaquinoxaline","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorsulfaquinoxaline","termGroup":"SY","termSource":"NCI"},{"termName":"CQS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97919-22-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O0408QB48D"},{"name":"Legacy Concept Name","value":"Chloroquinoxaline_Sulfonamide"},{"name":"Maps_To","value":"Chloroquinoxaline Sulfonamide"},{"name":"NCI_Drug_Dictionary_ID","value":"41055"},{"name":"NSC Number","value":"339004"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41055"},{"name":"PDQ_Open_Trial_Search_ID","value":"41055"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049111"}]}}{"C94723":{"preferredName":"Chlorotoxin","code":"C94723","definitions":[{"definition":"A neurotoxin with potential anticancer property. Chlorotoxin (CTX) is a 36-amino acid peptide found in the venom of the deathstalker scorpion, and a chloride channel blocker. This toxin binds preferentially to glioma cells via the transmembrane endopeptidase matrix metalloproteinase-2 (MMP-2), and thereby prevents the spread of tumor cells. MMP-2 is specifically up-regulated in gliomas and related cancers, but is not normally expressed in brain.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the diagnosis and treatment of glioma (a type of brain cancer) and other types of cancer. It binds to cancer cells in the brain and peripheral nervous system and may keep them from spreading. Chlorotoxin comes from the venom of a type of scorpion. A form of chlorotoxin made in the laboratory is called TM-601. Chlorotoxin is a type of neurotoxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Chlorotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"TM-601","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"163515-35-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"06UV5RFW57"},{"name":"Maps_To","value":"Chlorotoxin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Biologically Active Substance"},{"name":"UMLS_CUI","value":"C0293227"}]}}{"C1049":{"preferredName":"Chlorozotocin","code":"C1049","definitions":[{"definition":"A glucose-linked chloroethylnitrosourea with potential antineoplastic activity.  Chlorozotocin alkylates DNA and proteins, induces the formation of interstrand DNA and DNA-protein crosslinks, and causes DNA strand breakage, thereby damaging DNA and resulting in cell death.  This agent has been shown to exhibit antitumor and immunomodulatory effects in cell lines and animal models.  Chlorozotocin is a mutagen and is less myelotoxic than other nitrosoureas. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorozotocin","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-chloroethyl)-1-nitroso-3-(D-glucos-2-yl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"2-[3-(2-chloroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"2-[[[(2-chloroethyl)nitrosamino]carbonyl]amino]-2-deoxy-D-glucose","termGroup":"SN","termSource":"NCI"},{"termName":"Chlorozotocyna","termGroup":"SY","termSource":"NCI"},{"termName":"CHLZ","termGroup":"AB","termSource":"NCI"},{"termName":"CZT","termGroup":"AB","termSource":"NCI"},{"termName":"D-glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy","termGroup":"SN","termSource":"NCI"},{"termName":"D-glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"DCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Dome","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54749-90-5"},{"name":"Chemical_Formula","value":"C9H16ClN3O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3053LTY75Z"},{"name":"Legacy Concept Name","value":"Chlorozotocin"},{"name":"Maps_To","value":"Chlorozotocin"},{"name":"NCI_Drug_Dictionary_ID","value":"39182"},{"name":"NSC Number","value":"178248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39182"},{"name":"PDQ_Open_Trial_Search_ID","value":"39182"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055465"}]}}{"C94213":{"preferredName":"Choline Kinase Alpha Inhibitor TCD-717","code":"C94213","definitions":[{"definition":"A small-molecule inhibitor of choline kinase alpha (CHKA), with potential antineoplastic activity. TCD-717 targets and binds to CHKA, an enzyme that plays a key role in the synthesis of phosphatidylcholine, the major phospholipid in eukaryotic cell membranes. Blockade of this enzyme induces cells to activate a different route for phospholipid production which causes a toxic effect and eventually leads to cell destruction. CHKA, overexpressed in human cancer cells while only minimally expressed in normal cells, appears to play a significant role in cellular proliferation, evasion of apoptosis, increased cell motility and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Choline Kinase Alpha Inhibitor TCD-717","termGroup":"PT","termSource":"NCI"},{"termName":"CHKA Inhibitor TCD-717","termGroup":"SY","termSource":"NCI"},{"termName":"RSM-932A","termGroup":"CN","termSource":"NCI"},{"termName":"TCD-717","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850993-73-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KC1UXA6R4Z"},{"name":"Maps_To","value":"Choline Kinase Alpha Inhibitor TCD-717"},{"name":"NCI_Drug_Dictionary_ID","value":"687183"},{"name":"NCI_META_CUI","value":"CL426026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687183"},{"name":"PDQ_Open_Trial_Search_ID","value":"687183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62598":{"preferredName":"CHP-NY-ESO-1 Peptide Vaccine IMF-001","code":"C62598","definitions":[{"definition":"A peptide cancer vaccine containing nanoparticles of cholesteryl hydrophobized pullulan (CHP) complexed with the cancer-testis antigen NY-ESO-1 protein, with potential immunostimulating and antineoplastic activities.  Upon administration, CHP-NY-ESO-1 peptide vaccine IMF-001 may stimulate the host immune system to mount a humoral and cytotoxic T-cell response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water. NY-ESO-1, an antigen found in normal testis, is upregulated in various cancers, including bladder, breast, hepatocellular, melanoma, and prostate cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CHP-NY-ESO-1 Peptide Vaccine IMF-001","termGroup":"PT","termSource":"NCI"},{"termName":"Cholesteryl Pullulan-NY-ESO-1 Vaccine IMF-001","termGroup":"SY","termSource":"NCI"},{"termName":"IMF-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CHP-NY-ESO-1_Peptide_Vaccine"},{"name":"Maps_To","value":"CHP-NY-ESO-1 Peptide Vaccine IMF-001"},{"name":"NCI_Drug_Dictionary_ID","value":"489132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489132"},{"name":"PDQ_Open_Trial_Search_ID","value":"489132"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831881"}]}}{"C895":{"preferredName":"Chromomycin A3","code":"C895","definitions":[{"definition":"A glycosidic antineoplastic antibiotic isolated from the bacterium Streptomyces griseus.  Chromomycin A3 reversibly binds to guanine-cytosine (G-C) base pairs in the minor groove of DNA, thereby inhibiting RNA synthesis.  This agent is used as a fluorescent chromosome dye. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromomycin A3","termGroup":"PT","termSource":"NCI"},{"termName":"3B-O-(4-O-Acetyl-2,6-dideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-7-methylolivomycin D","termGroup":"SN","termSource":"NCI"},{"termName":"Antibiotic 69895 A","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic B 599","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic from Streptomyces griseus","termGroup":"SY","termSource":"NCI"},{"termName":"Olivomycin D, 3B-O-(4-O-Acetyl-2, 6-dideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-7-methyl- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Toyomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7059-24-7"},{"name":"CHEBI_ID","value":"CHEBI:34638"},{"name":"Chemical_Formula","value":"C57H82O26"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DVW027E7NL"},{"name":"Legacy Concept Name","value":"Chromomycin_A3"},{"name":"Maps_To","value":"Chromomycin A3"},{"name":"NCI_Drug_Dictionary_ID","value":"39184"},{"name":"NSC Number","value":"58514"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39184"},{"name":"PDQ_Open_Trial_Search_ID","value":"39184"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040563"}]}}{"C1828":{"preferredName":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement","code":"C1828","definitions":[{"definition":"A mixture of eight herbs that has been sold as a dietary supplement and promoted as a way to keep the prostate healthy and to treat prostate cancer. PC-SPES has been studied in the treatment of prostate cancer, but has been taken off the market in the U.S. because of safety concerns.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An herbal mixture with potential antineoplastic effects. PC-SPES, an herbal supplement containing extracts from 8 herbs including Chrysanthemum morifolium, Ganoderma lucidum (a root fungus), Glycyrrhiza glabra (Spanish liquorice), Isatis indigotica, Panax pseudoginseng, Rabdosia rubescens, Scutellaria baicalensis, and Serona repens (saw palmetto), with potential antineoplastic and antiproliferative effects, specifically in prostate cancer cells. Its exact pharmacology is not fully understood due to the complexity of the herbal mixture and may involve multiple metabolic pathways. Exposure to PC-SPES in vitro has resulted in a decreased expression of genes encoding cell cycle regulatory proteins as well as an upregulation of genes that modulate apoptosis in both androgen-dependent and androgen-independent cells. The PC in the acronym PC-SPES stands for Prostate Cancer, while SPES is the Latin word for hope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"374933-93-4"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PC-SPES"},{"name":"Maps_To","value":"Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"404383"},{"name":"PDQ_Closed_Trial_Search_ID","value":"404383"},{"name":"PDQ_Open_Trial_Search_ID","value":"404383"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0756934"}]}}{"C120097":{"preferredName":"Cibisatamab","code":"C120097","definitions":[{"definition":"An anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific monoclonal antibody with potential antineoplastic activity. Cibisatamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CEA, a tumor-associated antigen that is specifically expressed on certain tumor cells. Upon intravenous administration, cibisatamab binds to both T-cells and CEA-expressing tumor cells, which cross-links the T-cells with the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cibisatamab","termGroup":"PT","termSource":"NCI"},{"termName":"RG-7802","termGroup":"CN","termSource":"NCI"},{"termName":"RG7802","termGroup":"CN","termSource":"NCI"},{"termName":"RO6958688","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10636","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1855925-27-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAM5J1ATF2"},{"name":"Maps_To","value":"Cibisatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"767685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767685"},{"name":"PDQ_Open_Trial_Search_ID","value":"767685"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896776"}]}}{"C175786":{"preferredName":"Fosciclopirox","code":"C175786","definitions":[{"definition":"A phosphoryloxymethyl (POM) ester-based prodrug of ciclopirox (CPX), a synthetic, broad-spectrum antifungal agent with antibacterial, anti-inflammatory and potential antineoplastic activities. Upon intravenous administration of fosciclopirox, the POM moiety is cleaved off by phosphatases and the active metabolite CPX is released. Although its exact anticancer mechanism is not yet fully elucidated, CPX has been shown to inhibit tumor cell proliferation, induce apoptosis, and reduce tumor cell mobility in certain cancer types. CPX inhibits Notch1 activation and inhibits the Notch1-mediated signaling pathway, which is upregulated in many cancer cell types. This inhibits Notch downstream target proteins, inhibits the expression of gamma-secretase complex proteins, and prevents proliferation in susceptible cancer cells. CPX inhibits the iron-containing enzymes, catalase and peroxidase, which facilitate the decomposition of hydrogen peroxide, a reactive oxygen species (ROS) involved in oxidative stress. CPX also inhibits the iron-dependent enzyme ribonucleotide reductase, which is essential in DNA synthesis. CPX downregulates protein expression of cyclin D1 and cyclin E1, as well as their enzymatic counterparts cyclin-dependent kinases 4 and 2 (CDK4 and CDK2), which may inhibit tumor cell proliferation by slowing cell cycle progression from G1/G0 to S phase. Further, CPX may induce apoptosis by downregulating the expression of anti-apoptotic proteins, Bcl-xL and survivin, and increasing cleavage of Bcl-2. Additionally, CPX may inhibit tumor cell proliferation, survival and motility by inhibiting the phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), two downstream effector molecules of the mammalian target of rapamycin complex 1 (mTORC1). The CPX-POM prodrug improves the solubility of CPX and increases systemic efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosciclopirox","termGroup":"PT","termSource":"NCI"},{"termName":"Ciclopirox Prodrug","termGroup":"SY","termSource":"NCI"},{"termName":"Ciclopirox Prodrug CPX-POM","termGroup":"SY","termSource":"NCI"},{"termName":"Ciclopirox-POM","termGroup":"SY","termSource":"NCI"},{"termName":"CPX POM","termGroup":"CN","termSource":"NCI"},{"termName":"CPX-POM","termGroup":"CN","termSource":"NCI"},{"termName":"CPXPOM","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1380539-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G8FR269QPQ"},{"name":"Maps_To","value":"Ciclopirox Prodrug CPX-POM"},{"name":"NCI_Drug_Dictionary_ID","value":"794795"},{"name":"NCI_META_CUI","value":"CL562696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794795"},{"name":"PDQ_Open_Trial_Search_ID","value":"794795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118451":{"preferredName":"Cidan Herbal Capsule","code":"C118451","definitions":[{"definition":"A capsule-based formulation containing artificial bezoar, Strychni pulveratum (strychnos powder), camphol alcohol (borneol or borneo camphor) and extracts from Zedoary rhizome (Rhizoma curcumae), Pseudobulbus cremastrae seu pleiones (dried pseudobulb of Cremastra appendiculata), Yatantzu (seed of Brucca javanica), beehive, Bombyx mori (Bombyx batryticatus or silkworm), Danshen (dried root of Salvia miltiorrhiza or red sage root), Radix astragali, and Angelica, with potential antineoplastic activity. Upon oral administration of the cidan herbal capsule, the active ingredients in the plant extracts may induce tumor cell apoptosis and reduce tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cidan Herbal Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Zedoary rhizome/Pseudobulbus cremastrae seu pleiones/Yatantzu/Strychni pulveratum/Beehive/Artificial Bezoar/Bombyx mori/Danshen Root/Radix astragali/Angelica/Camphol Alcohol Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cidan Herbal Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"765191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765191"},{"name":"PDQ_Open_Trial_Search_ID","value":"765191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899625"}]}}{"C125659":{"preferredName":"Ciforadenant","code":"C125659","definitions":[{"definition":"A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration, ciforadenant binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor-released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine-induced immunosuppression in the tumor microenvironment. This may stimulate anti-tumor immune responses, resulting in tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ciforadenant","termGroup":"PT","termSource":"NCI"},{"termName":"3H-1,2,3-Triazolo(4,5-d)pyrimidin-5-amine, 7-(5-Methyl-2-furanyl)-3-((6-((((3S)-tetrahydro-3-furanyl)oxy)methyl)-2-pyridinyl)methyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Adenosine-A2A Receptor-Targeting Agent CPI-444","termGroup":"SY","termSource":"NCI"},{"termName":"CPI-444","termGroup":"CN","termSource":"NCI"},{"termName":"V81444","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1202402-40-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8KFO2187CP"},{"name":"Maps_To","value":"Ciforadenant"},{"name":"NCI_Drug_Dictionary_ID","value":"778585"},{"name":"NCI_META_CUI","value":"CL504345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778585"},{"name":"PDQ_Open_Trial_Search_ID","value":"778585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1834":{"preferredName":"Cilengitide","code":"C1834","definitions":[{"definition":"A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity.  Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as an anticancer and antiangiogenesis drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cilengitide","termGroup":"PT","termSource":"NCI"},{"termName":"cyclo(L-arginylglycyl-L-a-aspartyl-D-phenylalanyl-N-methyl-L-valyl)","termGroup":"SN","termSource":"NCI"},{"termName":"EMD 121974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"188968-51-6"},{"name":"Chemical_Formula","value":"C27H40N8O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4EDF46E4GI"},{"name":"Legacy Concept Name","value":"Cilengitide"},{"name":"Maps_To","value":"Cilengitide"},{"name":"NCI_Drug_Dictionary_ID","value":"37844"},{"name":"NSC Number","value":"707544"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37844"},{"name":"PDQ_Open_Trial_Search_ID","value":"37844"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0971473"}]}}{"C374":{"preferredName":"Cimetidine","code":"C374","definitions":[{"definition":"A drug usually used to treat stomach ulcers and heartburn. It is also commonly used in a regimen to prevent allergic reactions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cimetidine","termGroup":"PT","termSource":"NCI"},{"termName":"Guanidine, N''-Cyano-N-Methyl-N'-(2-(((5-Methyl-1H-Imidazol-4-yl)Methyl)Thio)Ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-Cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine","termGroup":"SN","termSource":"NCI"},{"termName":"Tagamet","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastrointestinal conditions; allergic reaction prevention; immune modulation"},{"name":"CAS_Registry","value":"51481-61-9"},{"name":"CHEBI_ID","value":"CHEBI:3699"},{"name":"Chemical_Formula","value":"C10H16N6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"80061L1WGD"},{"name":"Legacy Concept Name","value":"Cimetidine"},{"name":"Maps_To","value":"Cimetidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39185"},{"name":"NSC Number","value":"335308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39185"},{"name":"PDQ_Open_Trial_Search_ID","value":"39185"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008783"}]}}{"C47450":{"preferredName":"Cinacalcet Hydrochloride","code":"C47450","definitions":[{"definition":"The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels; PTH appears to raise PSA levels and may increase prostate cancer cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinacalcet Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthalenemethanamine, a-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-,(aR)-, Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Mimpara","termGroup":"FB","termSource":"NCI"},{"termName":"Sensipar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"364782-34-3"},{"name":"CHEBI_ID","value":"CHEBI:48391"},{"name":"Chemical_Formula","value":"C22H22F3N.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1K860WSG25"},{"name":"Legacy Concept Name","value":"Cinacalcet_Hydrochloride"},{"name":"Maps_To","value":"Cinacalcet Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"662071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662071"},{"name":"PDQ_Open_Trial_Search_ID","value":"662071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1260199"}]}}{"C95021":{"preferredName":"Cinobufagin","code":"C95021","definitions":[{"definition":"A bufadienolide compound extracted from the dried venom secreted by the parotid glands of toads and one of the glycosides in the traditional Chinese medicine ChanSu, with potential antineoplastic activity. Although the mechanism of action of cinobufagin is still under investigation, it has been found to suppress cancer cell proliferation and cause apoptosis in cancer cells via a sequence of apoptotic modulators that include mitochondrial Bax and cytosolic chromosome c, and caspases 3, 8, and 9. Possible upstream mediators of cinobufagin-induced apoptosis include Fas and p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinobufagin","termGroup":"PT","termSource":"NCI"},{"termName":"Cinobufacini","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"470-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T9PSN4R8IR"},{"name":"Maps_To","value":"Cinobufagin"},{"name":"NCI_Drug_Dictionary_ID","value":"689412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689412"},{"name":"PDQ_Open_Trial_Search_ID","value":"689412"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055767"}]}}{"C151929":{"preferredName":"Cinobufotalin","code":"C151929","definitions":[{"definition":"A bufadienolide isolated from toad venom and utilized in traditional Chinese medicine (TCM) for its cardiotonic, diuretic and hemostatic effects, with potential cytotoxic and antineoplastic activities. Upon administration and although the exact mechanism of action(s) (MoAs) through which this agent exerts its effects have yet to be fully discovered, cinobufotalin causes DNA fragmentation, decreases mitochondrial membrane potential (MMP), increases intracellular calcium (Ca2+) ion concentrations and reactive oxygen species (ROS) production, upregulates Fas protein and activates cytochrome C, various caspases, Bid and Bax. This causes cell cycle arrest, induces apoptosis and inhibits tumor cell growth and survival. In addition, cinobufotalin inhibits the activity of sphingosine kinase 1 (SphK1) and induces pro-apoptotic ceramide production, which further promotes tumor cell apoptosis. Cinobufotalin also induces mitochondrial protein cyclophilin D (Cyp-D)-dependent opening of the mitochondrial permeability transition pore (mPTP), which may contribute to cinobufotalin-induced non-apoptotic death of certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cinobufotalin","termGroup":"PT","termSource":"NCI"},{"termName":"14,15b-Epoxy-3b,5a,16b-trihydroxy-5b,20(22)-bufadienolide 16-Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"5-Beta-bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-, 16-Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"5b,20(22)-Bufadienolide-14,15b-epoxy-3b,5a,16b-triol 16-Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"CB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1108-68-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0QBZ37386"},{"name":"Maps_To","value":"Cinobufotalin"},{"name":"NCI_Drug_Dictionary_ID","value":"793122"},{"name":"NCI_META_CUI","value":"CL553268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793122"},{"name":"PDQ_Open_Trial_Search_ID","value":"793122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2599":{"preferredName":"Cintredekin Besudotox","code":"C2599","definitions":[{"definition":"A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R).The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is made by combining interleukin-13 with a toxin from Pseudomonas bacteria. It is a type of recombinant chimeric protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cintredekin Besudotox","termGroup":"PT","termSource":"NCI"},{"termName":"hIL13-PE38QQR","termGroup":"SY","termSource":"NCI"},{"termName":"IL 13-PE38QQR","termGroup":"AB","termSource":"NCI"},{"termName":"IL-13 Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"IL-13-PE38QQR Cytotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"IL-13PE","termGroup":"SY","termSource":"NCI"},{"termName":"IL13-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-13 PE38QQR Immunotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"372075-36-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL04JX89M7"},{"name":"Legacy Concept Name","value":"Interleukin-13_PE38QQR_Immunotoxin"},{"name":"Maps_To","value":"Cintredekin Besudotox"},{"name":"NCI_Drug_Dictionary_ID","value":"38095"},{"name":"NSC Number","value":"722759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38095"},{"name":"PDQ_Open_Trial_Search_ID","value":"38095"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1434448"}]}}{"C118284":{"preferredName":"Zilovertamab","code":"C118284","definitions":[{"definition":"A humanized monoclonal antibody against the extracellular domain of the human receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential antineoplastic activity. Upon administration, zilovertamab binds to ROR1 and blocks ROR1-mediated signaling. This prevents tumor cell proliferation in cancer cells overexpressing ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is normally expressed during embryogenesis.  It is overexpressed in certain leukemias and solid tumors, but minimally expressed in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zilovertamab","termGroup":"PT","termSource":"NCI"},{"termName":"Cirmtuzumab","termGroup":"SY","termSource":"NCI"},{"termName":"UC-961","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2485779-13-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FEH7RQ7B3J"},{"name":"Maps_To","value":"Cirmtuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"764235"},{"name":"NCI_META_CUI","value":"CL474136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764235"},{"name":"PDQ_Open_Trial_Search_ID","value":"764235"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99125":{"preferredName":"cis-Urocanic Acid","code":"C99125","definitions":[{"definition":"A derivative of the amino acid histidine, formed in the mammalian skin from trans-urocanic acid upon ultraviolet radiation, and protodynamic agent, with potential anti-inflammatory and antiproliferative activity. Upon intravesical instillation of cis-urocanic acid (cis-UCA), this agent is protonated at the imidazolyl moiety in the mildly acidic extracellular tumor environment and penetrates into the cancer cell. Once inside the cell and due to the slightly alkaline pH inside the tumor cell, cis-UCA is deprotonated, i.e. the imidazolyl proton is released into the cytosol which eventually raises the intracellular acidity. This acidification impairs many cellular processes, such as metabolic activity, and may lead to cell cycle arrest, an induction of cellular apoptosis and necrotic cell death. In addition, cis-UCA enhances ERK and JNK signaling pathways by inhibiting the activity of serine/threonine and tyrosine phosphatases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cis-Urocanic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"cis-UCA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7699-35-6"},{"name":"CHEBI_ID","value":"CHEBI:30818"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5LM7WD7VIC"},{"name":"Maps_To","value":"cis-Urocanic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"715688"},{"name":"NCI_META_CUI","value":"CL432945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715688"},{"name":"PDQ_Open_Trial_Search_ID","value":"715688"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C376":{"preferredName":"Cisplatin","code":"C376","definitions":[{"definition":"A drug used to treat many types of cancer. Cisplatin contains the metal platinum. It kills cancer cells by damaging their DNA and stopping them from dividing. Cisplatin is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(SP-4-2)-Diamminedichloroplatinum","termGroup":"SN","termSource":"NCI"},{"termName":"Abiplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Blastolem","termGroup":"FB","termSource":"NCI"},{"termName":"Briplatin","termGroup":"FB","termSource":"NCI"},{"termName":"CDDP","termGroup":"AB","termSource":"NCI"},{"termName":"Cis-diammine-dichloroplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-diamminedichloridoplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-diamminedichloro Platinum (II)","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-diamminedichloroplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-dichloroammine Platinum (II)","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinous Diamine Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinum II","termGroup":"SY","termSource":"NCI"},{"termName":"Cis-platinum II Diamine Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cismaplat","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatina","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatyl","termGroup":"FB","termSource":"NCI"},{"termName":"Citoplatino","termGroup":"FB","termSource":"NCI"},{"termName":"Citosin","termGroup":"FB","termSource":"NCI"},{"termName":"Cysplatyna","termGroup":"SY","termSource":"NCI"},{"termName":"DDP","termGroup":"AB","termSource":"NCI"},{"termName":"Lederplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Metaplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Neoplatin","termGroup":"FB","termSource":"NCI"},{"termName":"Peyrone's Chloride","termGroup":"SY","termSource":"NCI"},{"termName":"Peyrone's Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Placis","termGroup":"FB","termSource":"NCI"},{"termName":"Plastistil","termGroup":"FB","termSource":"NCI"},{"termName":"Platamine","termGroup":"FB","termSource":"NCI"},{"termName":"Platiblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Platiblastin-S","termGroup":"FB","termSource":"NCI"},{"termName":"Platinex","termGroup":"FB","termSource":"NCI"},{"termName":"Platinol","termGroup":"BR","termSource":"NCI"},{"termName":"Platinol- AQ","termGroup":"FB","termSource":"NCI"},{"termName":"Platinol-AQ","termGroup":"BR","termSource":"NCI"},{"termName":"Platinol-AQ VHA Plus","termGroup":"FB","termSource":"NCI"},{"termName":"Platinoxan","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum Diamminodichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum, Diaminedichloro-, cis- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Platiran","termGroup":"FB","termSource":"NCI"},{"termName":"Platistin","termGroup":"FB","termSource":"NCI"},{"termName":"Platosin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic testicular cancer; ovarian cancer; head and neck cancer; breast cancer; Hodgkin's and non-Hodgkin's lymphoma; myeloma and melanoma"},{"name":"CAS_Registry","value":"15663-27-1"},{"name":"CHEBI_ID","value":"CHEBI:27899"},{"name":"Chemical_Formula","value":"2Cl.Pt.2H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"Q20Q21Q62J"},{"name":"Legacy Concept Name","value":"Cisplatin"},{"name":"Maps_To","value":"Cisplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39515"},{"name":"NSC Number","value":"119875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39515"},{"name":"PDQ_Open_Trial_Search_ID","value":"39515"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008838"}]}}{"C2502":{"preferredName":"Cisplatin Liposomal","code":"C2502","definitions":[{"definition":"A synthetic formulation in which the antineoplastic agent cisplatin is encapsulated in lipids.  Cisplatin liposomal consists of small aggregates of cisplatin covered by a single lipid bilayer. Encasement in liposomes improves cisplatin's tumor bioavailability and toxicity profile. Liposomal encapsulation does not affect the pharmacological properties of cisplatin directly.  Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin Liposomal","termGroup":"PT","termSource":"NCI"},{"termName":"Cisplatin, Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"SPI-077","termGroup":"CN","termSource":"NCI"},{"termName":"SPI-77","termGroup":"CN","termSource":"NCI"},{"termName":"STEALTH Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"STEALTH Liposomal Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"STEALTH Liposomal Encapsulated Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"STEALTH Liposome Cisplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cisplatin_Liposomal"},{"name":"Maps_To","value":"Cisplatin Liposomal"},{"name":"NCI_Drug_Dictionary_ID","value":"43292"},{"name":"NSC Number","value":"719334"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43292"},{"name":"PDQ_Open_Trial_Search_ID","value":"43292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0964924"}]}}{"C17879":{"preferredName":"Cisplatin-E Therapeutic Implant","code":"C17879","definitions":[{"definition":"An injectable gel comprised of a collagen matrix containing the inorganic platinum (Pt) agent cisplatin and the sympathomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, cisplatin forms highly reactive, positively charged, platinum complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. This induces both intra- and inter-strand DNA cross-links. In addition, cisplatin forms DNA-Pt-protein cross-links. Cross-link formation results in both the induction of apoptosis and cell growth inhibition. Epinephrine, a potent vasoconstrictor, is added to the gel to both enhance the penetration of cisplatin into tumor tissue and reduce its dispersion into the surrounding tissues. Intratumoral injection of cisplatin-E therapeutic implant may increase local chemotherapeutic efficacy, as compared to the systemic administration of cisplatin, while reducing its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin-E Therapeutic Implant","termGroup":"PT","termSource":"NCI"},{"termName":"CDDP-e therapeutic implant","termGroup":"SY","termSource":"NCI"},{"termName":"CDDP/epi","termGroup":"SY","termSource":"NCI"},{"termName":"CDDP/epi gel","termGroup":"SY","termSource":"NCI"},{"termName":"CEG","termGroup":"AB","termSource":"NCI"},{"termName":"Cisplatin-Epinephrine","termGroup":"SY","termSource":"NCI"},{"termName":"Cisplatin/Epinephrine Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Intradose","termGroup":"SY","termSource":"NCI"},{"termName":"Intradose MPI-5010","termGroup":"SY","termSource":"NCI"},{"termName":"MP 5010 Therapeutic Implant","termGroup":"SY","termSource":"NCI"},{"termName":"MP 5010 TI","termGroup":"SY","termSource":"NCI"},{"termName":"MPI 5010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cisplatin-E_Therapeutic_Implant"},{"name":"Maps_To","value":"Cisplatin-E Therapeutic Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"42697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42697"},{"name":"PDQ_Open_Trial_Search_ID","value":"42697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677669"}]}}{"C136428":{"preferredName":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","code":"C136428","definitions":[{"definition":"A formulation composed of three agents in a fixed ratio: two chemotherapeutic agents, the platinum compound cisplatin and the vinca alkaloid vinblastine, and a proprietary amphiphilic excipient that acts as a penetration enhancer, with potential antineoplastic activity. Upon intra-tumoral (IT) injection of INT230-6, the dispersion/cell penetration enhancer excipient of INT230-6 facilitates dispersion of the two drugs throughout the tumor tissue and enables increased cellular uptake of these agents into tumor cells. Once inside the cell, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, which results in apoptosis and cell growth inhibition. Vinblastine kills the tumor cells through binding to tubulin and thereby inhibits microtubule formation, resulting in disruption of the mitotic spindle assembly and cell cycle arrest of tumor. In addition, the tumor cell killing leads to recruitment of dendritic cells (DCs) and induces a tumor-specific T-cell-mediated immune response that attacks both the injected tumor and distant tumor lesions. Local administration of both cisplatin and vinblastine, without the diffusion/penetration enhancer, results in to poor diffusion and a lack of cellular uptake of the agents; INT230-6 increases the intracellular concentration of cisplatin and vinblastine, thereby improving efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","termGroup":"PT","termSource":"NCI"},{"termName":"Cisplatin/Vinblastine Formulation with Cell Penetration Enhancer INT230-6","termGroup":"SY","termSource":"NCI"},{"termName":"INT 230-6","termGroup":"CN","termSource":"NCI"},{"termName":"INT230-6","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6"},{"name":"NCI_Drug_Dictionary_ID","value":"789458"},{"name":"NCI_META_CUI","value":"CL523731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789458"},{"name":"PDQ_Open_Trial_Search_ID","value":"789458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121641":{"preferredName":"Citarinostat","code":"C121641","definitions":[{"definition":"An orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, citarinostat inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Citarinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"5-Pyrimidinecarboxamide, 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"ACY-241","termGroup":"CN","termSource":"NCI"},{"termName":"CC-96241","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC-IN-2","termGroup":"SY","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor ACY-241","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1316215-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"441P620G3P"},{"name":"Maps_To","value":"Citarinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"770662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770662"},{"name":"PDQ_Open_Trial_Search_ID","value":"770662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053685"}]}}{"C71694":{"preferredName":"Citatuzumab Bogatox","code":"C71694","definitions":[{"definition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody Fab fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a modified bouganin cytotoxin with potential antineoplastic activity. Citatuzumab bogatox binds to EpCAM, delivering modified bouganin cytotoxin directly to EpCam-positive tumor cells, which may result in the inhibition of tumor cell protein synthesis and tumor cell death. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers. Bouganin is a plant-derived ribosome-inactivating protein (RIP), a toxic plant N-glycosidase that depurinates the universally conserved alpha-sarcin loop of ribosomal rRNA, inactivating the ribosome and preventing protein synthesis. Compared to unmodified bouganins, modified bouganins may have a reduced propensity to activate human T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Citatuzumab Bogatox","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EpCAM Antibody Fragment-Bouganin Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"VB6-845","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945228-49-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23J303Z5CA"},{"name":"Legacy Concept Name","value":"Anti-EpCAM-Bouganin_Fusion_Protein"},{"name":"Maps_To","value":"Citatuzumab Bogatox"},{"name":"NCI_Drug_Dictionary_ID","value":"555692"},{"name":"NCI_META_CUI","value":"CL376117"},{"name":"PDQ_Closed_Trial_Search_ID","value":"555692"},{"name":"PDQ_Open_Trial_Search_ID","value":"555692"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79828":{"preferredName":"Cixutumumab","code":"C79828","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It is a monoclonal antibody that is made in the laboratory and can bind to substances in the body. Cixutumumab blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cixutumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12","termGroup":"SY","termSource":"NCI"},{"termName":"IMC A12","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-A12","termGroup":"CN","termSource":"NCI"},{"termName":"IMCA12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"947687-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2285XW22DR"},{"name":"Legacy Concept Name","value":"Cixutumumab"},{"name":"Maps_To","value":"Cixutumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"561575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561575"},{"name":"PDQ_Open_Trial_Search_ID","value":"561575"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703174"}]}}{"C102849":{"preferredName":"CK2-targeting Synthetic Peptide CIGB-300","code":"C102849","definitions":[{"definition":"A synthetic peptide targeting the substrates of casein kinase 2 (CK2), with potential antineoplastic activity. Upon administration and nucleolar localization, CK2-targeting synthetic peptide CIGB-300 binds to phosphoacceptor sites on the CK2 substrates, in particular the oncoprotein nucleophosmin (B23 or NPM1). This blocks the activation of B23 and induces apoptosis, thereby inhibiting tumor cell growth in susceptible tumor cells. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. Overexpression of B23 has been correlated with increased cellular growth and proliferation as well as inhibition of differentiation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CK2-targeting Synthetic Peptide CIGB-300","termGroup":"PT","termSource":"NCI"},{"termName":"CIGB-300","termGroup":"CN","termSource":"NCI"},{"termName":"CIGB-325","termGroup":"CN","termSource":"NCI"},{"termName":"P15-tat","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1072877-99-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X6HMT2EDH9"},{"name":"Maps_To","value":"CK2-targeting Synthetic Peptide CIGB-300"},{"name":"NCI_Drug_Dictionary_ID","value":"737263"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737263"},{"name":"PDQ_Open_Trial_Search_ID","value":"737263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2605865"}]}}{"C1052":{"preferredName":"CL 246738","code":"C1052","definitions":[{"definition":"An immunomodulator, 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride, used in a phase I study for possible immunostimulatory effects in colorectal cancer. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CL 246738","termGroup":"PT","termSource":"NCI"},{"termName":"3,6-bis-(2-piperidinoethoxyl)acridine trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CL 246,738","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CL_246738"},{"name":"Maps_To","value":"CL 246738"},{"name":"NCI_Drug_Dictionary_ID","value":"40443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40443"},{"name":"PDQ_Open_Trial_Search_ID","value":"40443"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055843"}]}}{"C1336":{"preferredName":"Cladribine","code":"C1336","definitions":[{"definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cladribine","termGroup":"PT","termSource":"NCI"},{"termName":"2-CdA","termGroup":"AB","termSource":"NCI"},{"termName":"2-Chloro-2-Deoxyadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Chlorodeoxyadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"2CDA","termGroup":"AB","termSource":"NCI"},{"termName":"CdA","termGroup":"AB","termSource":"NCI"},{"termName":"Cladribina","termGroup":"SY","termSource":"NCI"},{"termName":"Leustat","termGroup":"FB","termSource":"NCI"},{"termName":"Leustatin","termGroup":"BR","termSource":"NCI"},{"termName":"Leustatine","termGroup":"FB","termSource":"NCI"},{"termName":"RWJ-26251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute myeloid leukemia; Chronic lymphocytic leukemia; Cutaneous T-cell lymphoma; Hairy cell leukemia; Langerhans cell histiocytosis; Non-Hodgkins lymphoma; Waldenstroms macroglobulinemia"},{"name":"CAS_Registry","value":"4291-63-8"},{"name":"CHEBI_ID","value":"CHEBI:567361"},{"name":"Chemical_Formula","value":"C10H12ClN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"http://www.cancercare.on.ca/pdfdrugs/Cladribi.pdf"},{"name":"FDA_UNII_Code","value":"47M74X9YT5"},{"name":"Legacy Concept Name","value":"Cladribine"},{"name":"Maps_To","value":"Cladribine"},{"name":"NCI_Drug_Dictionary_ID","value":"41184"},{"name":"NSC Number","value":"105014"},{"name":"NSC Number","value":"105014-F"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41184"},{"name":"PDQ_Open_Trial_Search_ID","value":"41184"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0092801"}]}}{"C78082":{"preferredName":"Clanfenur","code":"C78082","definitions":[{"definition":"A substituted benzoylphenylurea and an analogue of the pesticide diflubenzuron with potential antineoplastic activity. Upon administration, clanfenur binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clanfenur","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51213-99-1"},{"name":"Chemical_Formula","value":"C16H15ClFN3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KAM54NKT1Q"},{"name":"Legacy Concept Name","value":"Clanfenur"},{"name":"Maps_To","value":"Clanfenur"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253858"}]}}{"C1054":{"preferredName":"Clarithromycin","code":"C1054","definitions":[{"definition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An antibiotic drug used to treat infection. It belongs to the family of drugs called macrolides.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clarithromycin","termGroup":"PT","termSource":"NCI"},{"termName":"6-O-Methylerythromycin","termGroup":"SN","termSource":"NCI"},{"termName":"Abbott-56268","termGroup":"SY","termSource":"NCI"},{"termName":"Biaxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"H. pylori infection; Various bacterial infections"},{"name":"CAS_Registry","value":"81103-11-9"},{"name":"CHEBI_ID","value":"CHEBI:3732"},{"name":"Chemical_Formula","value":"C38H69NO13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"H1250JIK0A"},{"name":"Legacy Concept Name","value":"Clarithromycin"},{"name":"Maps_To","value":"Clarithromycin"},{"name":"NCI_Drug_Dictionary_ID","value":"42308"},{"name":"NSC Number","value":"643733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42308"},{"name":"PDQ_Open_Trial_Search_ID","value":"42308"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055856"}]}}{"C160606":{"preferredName":"Bocodepsin Besylate","code":"C160606","definitions":[{"definition":"The besylate form of bocodepsin, an orally bioavailable inhibitor of the histone deacetylase (HDAC) subtypes 1 and 4, with potential antineoplastic activity. Upon administration,bocodepsin targets, binds to and inhibits the activity of HDAC1/4. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This consequently results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC1/4. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins and plays a key role in transcriptional regulation and cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bocodepsin Besylate","termGroup":"PT","termSource":"NCI"},{"termName":"Class 1/4 Histone Deacetylase Inhibitor OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"Class-1/4 HDACi OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDAC Inhibitor OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDAC1/4i OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDACi 1/4 OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"HDACi OKI-179","termGroup":"SY","termSource":"NCI"},{"termName":"OKI 179","termGroup":"CN","termSource":"NCI"},{"termName":"OKI-179","termGroup":"CN","termSource":"NCI"},{"termName":"OKI179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1834513-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LVM50TS2UO"},{"name":"Maps_To","value":"Class 1/4 Histone Deacetylase Inhibitor OKI-179"},{"name":"NCI_Drug_Dictionary_ID","value":"801634"},{"name":"NCI_META_CUI","value":"CL969661"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801634"},{"name":"PDQ_Open_Trial_Search_ID","value":"801634"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71104":{"preferredName":"Clinical Trial","code":"C71104","definitions":[{"definition":"A research investigation involving human subjects that is designed to answer specific questions about the safety and efficacy of a biomedical intervention (drug, treatment, device) or new ways of using a known drug, treatment, or device). NOTE: NIH Office of Science Policy further specifies that a clinical trial is a type of research study that prospectively assigns subjects to interventions, and the EU clinical trial regulations set forth 3 specific conditions, any one of which qualifies a study as a clinical trial. These conditions include applying diagnostic or monitoring procedures not used in normal clinical practice to subjects. [After ICH E6 [R2], EU CTR 2014] (CDISC Glossary)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A research investigation involving human subjects that is designed to answer specific questions about the safety and efficacy of a biomedical intervention (drug, treatment, device) or new ways of using a known drug, treatment, or device). NOTE: NIH Office of Science Policy further specifies that a clinical trial is a type of research study that prospectively assigns subjects to interventions, and the EU clinical trial regulations set forth 3 specific conditions, any one of which qualifies a study as a clinical trial. These conditions include applying diagnostic or monitoring procedures not used in normal clinical practice to subjects. [After ICH E6 [R2], EU CTR 2014] See also clinical study, clinical investigation, randomized controlled trial (RCT).","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"A research investigation involving human subjects that is designed to answer specific questions about the safety and efficacy of a biomedical intervention (drug, treatment, device) or new ways of using a known drug, treatment, or device). NOTE: NIH Office of Science Policy further specifies that a clinical trial is a type of research study that prospectively assigns subjects to interventions. The EU clinical trial regulations include applying diagnostic or monitoring procedures not used in normal clinical practice to subjects in its criterion. [after ICH E6 [R2]; EU CTR 2014] See also clinical study, clinical investigation.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.","type":"DEFINITION","source":"NCI"},{"definition":"A research study that tests drugs, devices and treatments to see if they are safe and work in people. (https://mrctcenter.org/glossaryterm/clinical-trial/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Clinical Trial","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical Trials","termGroup":"SY","termSource":"NCI"},{"termName":"Clinical Trials, Unspecified","termGroup":"SY","termSource":"NCI"},{"termName":"Trial","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Clinical_Trial_Generic"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C0008976"}]}}{"C90373":{"preferredName":"Clinical Trial Agent","code":"C90373","definitions":[{"definition":"The pharmacological substance that is being administered in the study.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical Trial Agent","termGroup":"PT","termSource":"NCI"},{"termName":"Clinical Trial-Study Agent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clinical Trial"},{"name":"Maps_To","value":"Clinical Trial Agent"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C2983596"}]}}{"C65337":{"preferredName":"Clioquinol","code":"C65337","definitions":[{"definition":"An orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. Clioquinol forms a stable chelate with copper (copper (II) ions), which inhibits the chymotrypsin-like activity of the proteasome; consequently, ubiquitinated proteins may accumulate in tumor cells, followed by tumor cell apoptosis and the inhibition of tumor angiogenesis. In addition, the clioquinol-copper complex appears to decrease the expression of androgen receptors (AR) in human copper-enriched prostate cancer cells. Serum levels of copper are often elevated in patients with cancer; copper chelation may inhibit copper-dependent endothelial cell proliferation and tumor secretion of angiogenic factors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clioquinol","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-7-iodo-8-hydroxyquinoline","termGroup":"SN","termSource":"NCI"},{"termName":"5-Chloro-7-iodo-quinolin-8-ol","termGroup":"SN","termSource":"NCI"},{"termName":"AI3-16451","termGroup":"CN","termSource":"NCI"},{"termName":"Iodochlorohydroxyquinoline","termGroup":"SY","termSource":"NCI"},{"termName":"Mycoquin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130-26-7"},{"name":"Chemical_Formula","value":"C9H5ClINO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BHQ856EJ5"},{"name":"Legacy Concept Name","value":"Clioquinol"},{"name":"Maps_To","value":"Clioquinol"},{"name":"NCI_Drug_Dictionary_ID","value":"653982"},{"name":"NSC Number","value":"3531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653982"},{"name":"PDQ_Open_Trial_Search_ID","value":"653982"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021978"}]}}{"C88638":{"preferredName":"Clivatuzumab","code":"C88638","definitions":[{"definition":"A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1, with potential antineoplastic activity. Clivatuzumab binds to tumor cells expressing the MUC1 antigen and prevents MUC1-mediated signaling. MUC1, a mucin antigen, is overexpressed in pancreatic cancer but not in normal, healthy pancreatic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clivatuzumab","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622075-09-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RGU8A332UL"},{"name":"Maps_To","value":"Clivatuzumab"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2982120"}]}}{"C1418":{"preferredName":"Clodronate Disodium","code":"C1418","definitions":[{"definition":"A drug used as treatment for hypercalcemia (abnormally high levels of calcium in the blood) and for cancer that has spread to the bone (bone metastases). It may decrease pain, the risk of fractures, and the development of new bone metastases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clodronate Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Bonefos","termGroup":"FB","termSource":"NCI"},{"termName":"CL2MDP","termGroup":"CN","termSource":"NCI"},{"termName":"Clasteon","termGroup":"FB","termSource":"NCI"},{"termName":"Clodronate","termGroup":"SY","termSource":"NCI"},{"termName":"Clodronic Acid Disodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Dichloromethylene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Difosfonal","termGroup":"FB","termSource":"NCI"},{"termName":"Loron","termGroup":"FB","termSource":"NCI"},{"termName":"Mebonat","termGroup":"FB","termSource":"NCI"},{"termName":"Ossiten","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adjuvant usage in bone metastasis of Breast cancer"},{"name":"CAS_Registry","value":"88416-50-6"},{"name":"CHEBI_ID","value":"CHEBI:59587"},{"name":"Chemical_Formula","value":"CH2Cl2O6P2.2Na.4H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N030400H8J"},{"name":"Legacy Concept Name","value":"Clodronate_Disodium"},{"name":"Maps_To","value":"Clodronate Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"41862"},{"name":"NSC Number","value":"713466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41862"},{"name":"PDQ_Open_Trial_Search_ID","value":"41862"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0008994"}]}}{"C61685":{"preferredName":"Clodronic Acid","code":"C61685","definitions":[{"definition":"A first-generation bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Clodronic acid adsorbs onto the surface of the hydroxyapatite crystals in bone matrix. Although the exact mechanism through which clodronic acid exerts its cytotoxic effect on osteoclasts has yet to be fully elucidated, this agent is metabolized intracellularly to a toxic beta-gamma-methylene analog of adenosine triphosphate (ATP), AppCCl2p. The ATP analog AppCCl2p competitively inhibits ADP/ATP translocase, thereby interfering with mitochondrial membrane potential and cellular energy metabolism. This may cause osteoclast apoptosis and, eventually, inhibiting osteoclast-mediated bone resorption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clodronic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(Dichloromethylene)bisphosphonic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Clodronate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10596-23-3"},{"name":"CHEBI_ID","value":"CHEBI:110423"},{"name":"Chemical_Formula","value":"CH4Cl2O6P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0813BZ6866"},{"name":"Legacy Concept Name","value":"Clodronic_Acid"},{"name":"Maps_To","value":"Clodronic Acid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012081"}]}}{"C26638":{"preferredName":"Clofarabine","code":"C26638","definitions":[{"definition":"A drug used to treat certain types of acute lymphoblastic leukemia in children. It is also being studied in the treatment of other types of cancer. Clolar is a type of nucleoside analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clofarabine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine","termGroup":"SN","termSource":"NCI"},{"termName":"Clofarex","termGroup":"FB","termSource":"NCI"},{"termName":"Clolar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphoblastic leukemia, pediatric"},{"name":"CAS_Registry","value":"123318-82-1"},{"name":"CHEBI_ID","value":"CHEBI:47311"},{"name":"CHEBI_ID","value":"CHEBI:681569"},{"name":"Chemical_Formula","value":"C10H11ClFN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"762RDY0Y2H"},{"name":"Legacy Concept Name","value":"Clofarabine"},{"name":"Maps_To","value":"Clofarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"257309"},{"name":"NSC Number","value":"606869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257309"},{"name":"PDQ_Open_Trial_Search_ID","value":"257309"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0092777"}]}}{"C28888":{"preferredName":"Clomesone","code":"C28888","definitions":[{"definition":"The 2-chloroethyl ester of (methylsulfonyl) methanesulfonic acid with potential antineoplastic effects.  Acting as a chloroethylating agent, clomesone induces the formation of DNA interstrand crosslinks in some cell lines, and exhibits antitumor activity in some animal models.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clomesone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloroethyl (methylsulfonyl)methanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Chlorethyl SOSO","termGroup":"SY","termSource":"NCI"},{"termName":"SRI 6155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88343-72-0"},{"name":"Chemical_Formula","value":"C4H9ClO5S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2J031W0YZI"},{"name":"Legacy Concept Name","value":"Clomesone"},{"name":"Maps_To","value":"Clomesone"},{"name":"NSC Number","value":"338947"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0055920"}]}}{"C61607":{"preferredName":"Clomiphene","code":"C61607","definitions":[{"definition":"A triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer.  Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clomiphene","termGroup":"PT","termSource":"NCI"},{"termName":"2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911-45-5"},{"name":"CHEBI_ID","value":"CHEBI:3752"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1HRS458QU2"},{"name":"Legacy Concept Name","value":"Clomiphene_Base"},{"name":"Maps_To","value":"Clomiphene"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0009008"}]}}{"C379":{"preferredName":"Clomiphene Citrate","code":"C379","definitions":[{"definition":"The citrate salt form of clomiphene, a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clomiphene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine Citrate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Clomid","termGroup":"BR","termSource":"NCI"},{"termName":"Serophene","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-41-9"},{"name":"CHEBI_ID","value":"CHEBI:3753"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1B8447E7YI"},{"name":"Legacy Concept Name","value":"Clomiphene"},{"name":"Maps_To","value":"Clomiphene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"39542"},{"name":"NSC Number","value":"35770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39542"},{"name":"PDQ_Open_Trial_Search_ID","value":"39542"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546859"}]}}{"C62762":{"preferredName":"Clostridium Novyi-NT Spores","code":"C62762","definitions":[{"definition":"Spores of the bacterial strain Clostridium novyi-NT, the attenuated obligate anaerobic C. novyi, with potential immunostimulating, bacteriolytic, and antineoplastic activities. Upon intravenous administration, Clostridium novyi-NT spores germinate exclusively in hypoxic tissue, such as avascular regions of tumors. Germination results in lysis and destruction of surrounding viable tumor cells. Due to their anaerobic nature, C. novyi-NT spores do not proliferate in oxygenated tumor regions. However, this agent may stimulate the immune system to exert a cellular immune response, resulting in additional killing of tumor cells not lysed by the bacteria, including those in the well-oxygenated tumor area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clostridium Novyi-NT Spores","termGroup":"PT","termSource":"NCI"},{"termName":"C. novyi-NT Spores","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Clostridium_Novyi-NT_Spores"},{"name":"Maps_To","value":"Clostridium Novyi-NT Spores"},{"name":"NCI_Drug_Dictionary_ID","value":"502157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"502157"},{"name":"PDQ_Open_Trial_Search_ID","value":"502157"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831945"}]}}{"C68923":{"preferredName":"Cobimetinib","code":"C68923","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cobimetinib","termGroup":"PT","termSource":"NCI"},{"termName":"Cotellic","termGroup":"BR","termSource":"NCI"},{"termName":"GDC 0973","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0973","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0973","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor GDC-0973","termGroup":"SY","termSource":"NCI"},{"termName":"XL 518","termGroup":"CN","termSource":"NCI"},{"termName":"XL-518","termGroup":"CN","termSource":"NCI"},{"termName":"XL518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable or metastatic melanoma with BRAF V600E or V600K mutation"},{"name":"CAS_Registry","value":"934660-93-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ER29L26N1X"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_XL518"},{"name":"Maps_To","value":"Cobimetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"551654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551654"},{"name":"PDQ_Open_Trial_Search_ID","value":"551654"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346910"}]}}{"C124225":{"preferredName":"Cobomarsen","code":"C124225","definitions":[{"definition":"A locked nucleic acid (LNA)-based oligonucleotide inhibitor of microRNA (miRNA) 155 (miR-155), with potential antineoplastic activity. Upon administration, cobomarsen targets, binds to and inhibits miR-155. This silences miR-155 and prevents the translation of certain tumor promoting genes, which leads to the induction of cancer cell apoptosis and the inhibition of tumor cell growth. miR-155, an oncogenic single-stranded, non-coding RNA that is critical to the regulation of gene expression, is overexpressed in certain tumor cell types. Up-regulation of miR-155 plays a key role in increased tumor cell proliferation and survival. The LNA is an RNA analog in which the ribose ring is locked in a particular confirmation that increases stability. Compared to the unmodified oligonucleotide, the LNA-modified oligonucleotide shows increased affinity for its target miR-155.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cobomarsen","termGroup":"PT","termSource":"NCI"},{"termName":"MRG-106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1848257-52-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3JKW7CI9IU"},{"name":"Maps_To","value":"Cobomarsen"},{"name":"NCI_Drug_Dictionary_ID","value":"776775"},{"name":"NCI_META_CUI","value":"CL502605"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776775"},{"name":"PDQ_Open_Trial_Search_ID","value":"776775"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80043":{"preferredName":"Codrituzumab","code":"C80043","definitions":[{"definition":"A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Codrituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Glypican 3 Monoclonal Antibody GC33","termGroup":"SY","termSource":"NCI"},{"termName":"GC-33","termGroup":"CN","termSource":"NCI"},{"termName":"GC33","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7686","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5137382","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5137382","termGroup":"CN","termSource":"NCI"},{"termName":"RO5137382","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1365267-33-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U9I0PLD4HT"},{"name":"Legacy Concept Name","value":"Codrituzumab"},{"name":"Maps_To","value":"Codrituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"614683"},{"name":"NCI_META_CUI","value":"CL388379"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614683"},{"name":"PDQ_Open_Trial_Search_ID","value":"614683"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C916":{"preferredName":"Coenzyme Q10","code":"C916","definitions":[{"definition":"A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme Q10 functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme Q10 may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient that the body needs in small amounts to function and stay healthy. Coenzyme Q10 helps mitochondria (small structures in the cell) make energy. It is an antioxidant that helps prevent cell damage caused by free radicals (highly reactive chemicals). Coenzyme Q10 is fat-soluble (can dissolve in fats and oils) and is found in fatty fish, beef, soybeans, peanuts, and spinach. It is being studied in the prevention and treatment of some types of cancer and heart disease and in the relief of side effects caused by some cancer treatments.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Coenzyme Q10","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecanyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Co-Q10","termGroup":"AB","termSource":"NCI"},{"termName":"Ubidecarenone","termGroup":"SY","termSource":"NCI"},{"termName":"Ubiquinone 10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic heart failure; mitochondrial cytopathies"},{"name":"CAS_Registry","value":"303-98-0"},{"name":"CHEBI_ID","value":"CHEBI:46245"},{"name":"Chemical_Formula","value":"C59H90O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EJ27X76M46"},{"name":"Legacy Concept Name","value":"Coenzyme-Q"},{"name":"Maps_To","value":"Coenzyme Q10"},{"name":"NCI_Drug_Dictionary_ID","value":"39187"},{"name":"NSC Number","value":"140865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39187"},{"name":"PDQ_Open_Trial_Search_ID","value":"39187"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056077"}]}}{"C2679":{"preferredName":"Colchicine-Site Binding Agent ABT-751","code":"C2679","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called sulfonamides.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable antimitotic sulfonamide. ABT- 751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colchicine-Site Binding Agent ABT-751","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-751","termGroup":"CN","termSource":"NCI"},{"termName":"E 7010","termGroup":"CN","termSource":"NCI"},{"termName":"E-7010","termGroup":"CN","termSource":"NCI"},{"termName":"E7010","termGroup":"CN","termSource":"NCI"},{"termName":"N-[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"141430-65-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WDT5V5OB9F"},{"name":"Legacy Concept Name","value":"ABT-751"},{"name":"Maps_To","value":"Colchicine-Site Binding Agent ABT-751"},{"name":"NCI_Drug_Dictionary_ID","value":"38646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38646"},{"name":"PDQ_Open_Trial_Search_ID","value":"38646"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134654"}]}}{"C82344":{"preferredName":"Cold Contaminant-free Iobenguane I-131","code":"C82344","definitions":[{"definition":"An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine, manufactured with a proprietary process, with radioisotopic and potential antineoplastic activities. Cold contaminant-free iobenguane I 131 (MIBG) localizes to adrenergic tissue and may be used to image or eradicate tumor cells that accumulate and metabolize norepinephrine. This agent is manufactured using a technology that avoids the production of unwanted \"cold contaminants\" (i.e., carrier molecules), which may cause undesirable side effects and compete with MIBG for binding on target receptor sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cold Contaminant-free Iobenguane I-131","termGroup":"PT","termSource":"NCI"},{"termName":"Azedra","termGroup":"BR","termSource":"NCI"},{"termName":"Cold Contaminant-free I 131-MIBG","termGroup":"SY","termSource":"NCI"},{"termName":"Cold Contaminant-free Iobenguane I 131","termGroup":"SY","termSource":"NCI"},{"termName":"Ultratrace Iodine I 131 Metaiodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"Ultratrace MIBG","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL)"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cold_Contaminant-free_Iobenguane_I_131"},{"name":"Maps_To","value":"Cold Contaminant-free Iobenguane I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"629499"},{"name":"NCI_META_CUI","value":"CL388440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629499"},{"name":"PDQ_Open_Trial_Search_ID","value":"629499"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62538":{"preferredName":"Colloidal Gold-Bound Tumor Necrosis Factor","code":"C62538","definitions":[{"definition":"A nanoparticle delivery system for recombinant human tumor necrosis factor (TNF) consisting of recombinant TNF bound to pegylated colloidal gold nanoparticles with potential antineoplastic activity. Upon intravenous administration, colloidal gold-bound recombinant human TNF travels through the bloodstream, avoiding immune detection and uptake by the reticuloendothelial system because of nanoparticle pegylation. Due to their size, the colloidal gold nanoparticles exit the circulatory system only at hyperpermeable tumor neovasculature sites; TNF then binds to and activates tumor cell TNF receptors, which may result in an increase in tumor cell apoptosis and a reduction in tumor cell proliferation. Compared to the administration of unbound TNF, colloidal gold-bound TNF may improve the efficacy and safety of TNF administration by delivering TNF specifically to tumor tissue.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. Aurimmune is made in the laboratory by binding a cancer-killing protein called tumor necrosis factor (TNF) to the surface of very tiny particles of gold. These TNF-gold particles may kill cancer cells without harming healthy tissue.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Colloidal Gold-Bound Tumor Necrosis Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Aurimmune","termGroup":"BR","termSource":"NCI"},{"termName":"Colloidal Gold-Bound Recombinant Human Tumor Necrosis Factor","termGroup":"SY","termSource":"NCI"},{"termName":"colloidal gold-bound rhTNF","termGroup":"SY","termSource":"NCI"},{"termName":"colloidal gold-bound TNF","termGroup":"SY","termSource":"NCI"},{"termName":"CYT-6091","termGroup":"CN","termSource":"NCI"},{"termName":"TNF-bound colloidal gold","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colloidal_Gold-Bound_Tumor_Necrosis_Factor"},{"name":"Maps_To","value":"Colloidal Gold-Bound Tumor Necrosis Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"492715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492715"},{"name":"PDQ_Open_Trial_Search_ID","value":"492715"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831911"}]}}{"C154278":{"preferredName":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","code":"C154278","definitions":[{"definition":"A peptide cancer vaccine consisting of a combination of six synthetic polypeptides directed against cancer testis antigens (CTAs) frequently expressed in colorectal cancers, with potential antineoplastic and immunostimulatory activities. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colorectal Cancer Peptide Vaccine PolyPEPI1018","termGroup":"PT","termSource":"NCI"},{"termName":"PolyPEPI 1018","termGroup":"CN","termSource":"NCI"},{"termName":"PolyPEPI-1018","termGroup":"CN","termSource":"NCI"},{"termName":"PolyPEPI1018","termGroup":"CN","termSource":"NCI"},{"termName":"PolyPEPI1018 CRC Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"PolyPEPI1018 CRC Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colorectal Cancer Peptide Vaccine PolyPEPI1018"},{"name":"NCI_Drug_Dictionary_ID","value":"794166"},{"name":"NCI_META_CUI","value":"CL555275"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794166"},{"name":"PDQ_Open_Trial_Search_ID","value":"794166"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79806":{"preferredName":"Colorectal Tumor-Associated Peptides Vaccine IMA910","code":"C79806","definitions":[{"definition":"A synthetic tumor-associated peptide (TUMAP)-based cancer vaccine directed against colorectal cancer with potential immunostimulatory and antineoplastic activities. Synthetic colorectal tumor-associated peptides vaccine IMA910 contains 13 different synthetic TUMAPs, each of which represents a tumor associated antigen (TAA) specific for colorectal cancer. Upon administration, this agent may elicit a cytotoxic T-lymphocyte (CTL) response against colorectal tumors expressing these TAAs, which may result in a reduction in colorectal tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Colorectal Tumor-Associated Peptides Vaccine IMA910","termGroup":"PT","termSource":"NCI"},{"termName":"IMA910","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Colorectal_Tumor-Associated_Peptides_Vaccine_IMA910"},{"name":"Maps_To","value":"Colorectal Tumor-Associated Peptides Vaccine IMA910"},{"name":"NCI_Drug_Dictionary_ID","value":"626093"},{"name":"NCI_META_CUI","value":"CL388427"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626093"},{"name":"PDQ_Open_Trial_Search_ID","value":"626093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80014":{"preferredName":"Combretastatin","code":"C80014","definitions":[{"definition":"A stilbenoid phenol, originally isolated from the bark of the African bush willow tree Combretum caffrum, with vascular disrupting and antineoplastic activities. Combretastatin targets and binds to the colchicine-binding site of tubulin, thereby impairs the polymerization of tubulin dimers and prevents the formation of microtubules in the endothelial cells of tumor. As a result, this may eventually lead to a destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combretastatin","termGroup":"PT","termSource":"NCI"},{"termName":"3-Hydroxy-4-methoxy-alpha-(3,4,5-trimethoxyphenyl)benzeneethanol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"82855-09-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7O62J06F18"},{"name":"Legacy Concept Name","value":"Combretastatin"},{"name":"Maps_To","value":"Combretastatin"},{"name":"NSC Number","value":"348103"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056152"}]}}{"C162344":{"preferredName":"Combretastatin A-1","code":"C162344","definitions":[{"definition":"A stilbenoid originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 (CA1) promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis; destruction of the tumor vasculature; disruption of tumor blood flow; and tumor cell necrosis. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combretastatin A-1","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Benzenediol, 3-Methoxy-6-(2-(3,4,5-trimethoxyphenyl)ethenyl)-, (Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"CA1","termGroup":"AB","termSource":"NCI"},{"termName":"Combretastatin A1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"109971-63-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2222ATS339"},{"name":"Maps_To","value":"Combretastatin A-1"},{"name":"NCI_META_CUI","value":"CL970855"},{"name":"NSC Number","value":"600032"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84867":{"preferredName":"Combretastatin A1 Diphosphate","code":"C84867","definitions":[{"definition":"The diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 diphosphate (CA1P) is dephosphorylated to the active metabolite combretastatin A1 (CA1), which promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis, destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis may ensue. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production. CA1 binds to tubulin at the same site as colchicine but with higher affinity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Combretastatin A1 Diphosphate","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, 1,2-bis(dihydrogen Phosphate)","termGroup":"SN","termSource":"NCI"},{"termName":"CA1P","termGroup":"SY","termSource":"NCI"},{"termName":"Combretastatin A-1 bis(phosphate)","termGroup":"SY","termSource":"NCI"},{"termName":"OXI 4503","termGroup":"CN","termSource":"NCI"},{"termName":"OXi4503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"288847-35-8"},{"name":"Chemical_Formula","value":"C18H22O12P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JH6Z94GLUD"},{"name":"Maps_To","value":"Combretastatin A1 Diphosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"653978"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653978"},{"name":"PDQ_Open_Trial_Search_ID","value":"653978"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1143252"}]}}{"C120314":{"preferredName":"Compound Kushen Injection","code":"C120314","definitions":[{"definition":"A traditional Chinese medicine (TCM) formulation composed of compound Kushen injection (CKI) containing aqueous extracts from the roots of Kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma smilacis Glabrae), with potential antineoplastic and immunomodulating activities. CKI contains numerous chemicals including alkaloids, such as matrine and oxymatrine, flavonoids, alkylxanthones, quinones, triterpene glycosides, fatty acids, and essential oils. Although the exact mechanism(s) of action through which CKI exerts its effects has yet to be fully elucidated, CKI is able to interfere with the activation of various signal transduction pathways, such as the Wnt/beta-catenin signaling pathway, inhibit nuclear factor-kappa B (NF-KB) activation, and block the activity of multiple receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). CKI induces apoptosis in and inhibits proliferation, migration, invasion and adhesion of tumor cells. CKI also modulates the production of inflammatory mediators.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Compound Kushen Injection","termGroup":"PT","termSource":"NCI"},{"termName":"CKI","termGroup":"AB","termSource":"NCI"},{"termName":"Yanshu Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Compound Kushen Injection"},{"name":"NCI_Drug_Dictionary_ID","value":"768804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768804"},{"name":"PDQ_Open_Trial_Search_ID","value":"768804"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3890596"}]}}{"C71015":{"preferredName":"Conatumumab","code":"C71015","definitions":[{"definition":"A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 655","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-TRAIL Receptor 2 Monoclonal Antibody AMG 655","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Receptor Superfamily Member 10b (Death Receptor 5, Trail-R2, CD262 Antigen))","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))Gamma-1 Heavy Chain (225-215')-Disulphide With Kappa Light Chain (231-231'':234-234'')-Bisdisulphide Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"896731-82-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1P48L61KM0"},{"name":"Legacy Concept Name","value":"Anti-TRAIL_Receptor_2_Monoclonal_Antibody_AMG_655"},{"name":"Maps_To","value":"Conatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"573083"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573083"},{"name":"PDQ_Open_Trial_Search_ID","value":"573083"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346822"}]}}{"C162879":{"preferredName":"Conbercept","code":"C162879","definitions":[{"definition":"A recombinant, soluble, vascular endothelial growth factor receptor (VEGFR) protein composed of the second immunoglobulin (Ig) domain of VEGFR-1, the third and fourth Ig domains of VEGFR-2, and the constant region (Fc) of human immunoglobulin G1 (IgG1) with potential anti-angiogenic activities. Upon intravitreal injection, conbercept, functioning as a soluble decoy receptor, binds with high affinity to all VEGF-A isoforms, VEGF-B, as well as placenta growth factor (PlGF)-1 and PlGF-2. This prevents the binding of these growth factors to their endogenous receptors, potentially inhibiting angiogenesis and tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Conbercept","termGroup":"PT","termSource":"NCI"},{"termName":"FP 3","termGroup":"CN","termSource":"NCI"},{"termName":"FP-3","termGroup":"CN","termSource":"NCI"},{"termName":"FP3","termGroup":"CN","termSource":"NCI"},{"termName":"KH 902","termGroup":"CN","termSource":"NCI"},{"termName":"KH 903","termGroup":"CN","termSource":"NCI"},{"termName":"KH-902","termGroup":"CN","termSource":"NCI"},{"termName":"KH-903","termGroup":"CN","termSource":"NCI"},{"termName":"KH902","termGroup":"CN","termSource":"NCI"},{"termName":"KH903","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227158-72-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1P05PW62F3"},{"name":"Maps_To","value":"Conbercept"},{"name":"NCI_Drug_Dictionary_ID","value":"798956"},{"name":"NCI_META_CUI","value":"CL973317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798956"},{"name":"PDQ_Open_Trial_Search_ID","value":"798956"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165273":{"preferredName":"Concentrated Lingzhi Mushroom Extract","code":"C165273","definitions":[{"definition":"A nutritional supplement and traditional Chinese medicine (TCM) composed of a highly concentrated extract of the fruiting body of the red reishi mushroom Ganoderma lucidum  (G. lucidum; lingzhi), with potential immunomodulating activities. Upon administration, the concentrated lingzhi mushroom extract may support the body's immune function and may support the immune system to eliminate tumor cells. The lingzhi mushroom extract contains high amounts of G. lucidum polysaccharides and G. lucidum triterpenoids (GLTs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Concentrated Lingzhi Mushroom Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Concentrated Ganoderma lucidum Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Concentrated Red Reishi Mushroom Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Mikei Red Reishi Essence EX","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Concentrated Lingzhi Mushroom Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"799459"},{"name":"NCI_META_CUI","value":"CL978540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799459"},{"name":"PDQ_Open_Trial_Search_ID","value":"799459"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156141":{"preferredName":"Mecbotamab Vedotin","code":"C156141","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a conditionally active biologic (CAB) antibody against AXL receptor tyrosine kinase (AXL; UFO) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of mecbotamab vedotin, the anti-AXL antibody becomes activated through an as of yet not fully elucidated process only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells, and not in the microenvironment of normal, healthy tissues. Upon selective binding to AXL-expressing tumor cells and internalization, the cytotoxic agent kills the tumor cells through an as of yet undisclosed mechanism of action (MoA). AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases normally expressed on many normal, healthy cells and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis. The CAB antibody allows for efficient and reversible binding to AXL-expressing tumor cells under conditions that are present only in the TME, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy AXL-expressing cells under normal conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mecbotamab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BA3011","termGroup":"SY","termSource":"NCI"},{"termName":"BA 3011","termGroup":"CN","termSource":"NCI"},{"termName":"BA-3011","termGroup":"CN","termSource":"NCI"},{"termName":"BA3011","termGroup":"CN","termSource":"NCI"},{"termName":"CAB Anti-AXL ADC BA3011","termGroup":"SY","termSource":"NCI"},{"termName":"CAB-AXL-ADC BA3011","termGroup":"SY","termSource":"NCI"},{"termName":"Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460400-64-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VF40YVX65F"},{"name":"Maps_To","value":"Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011"},{"name":"NCI_Drug_Dictionary_ID","value":"795303"},{"name":"NCI_META_CUI","value":"CL562853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795303"},{"name":"PDQ_Open_Trial_Search_ID","value":"795303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96796":{"preferredName":"Copanlisib","code":"C96796","definitions":[{"definition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copanlisib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 80 6946","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 80-6946","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 806946","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-80-6946","termGroup":"CN","termSource":"NCI"},{"termName":"BAY806946","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor BAY 80-6946","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032568-63-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WI6V529FZ9"},{"name":"Maps_To","value":"Copanlisib"},{"name":"NCI_Drug_Dictionary_ID","value":"653981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653981"},{"name":"PDQ_Open_Trial_Search_ID","value":"653981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852004"}]}}{"C138994":{"preferredName":"Copanlisib Hydrochloride","code":"C138994","definitions":[{"definition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copanlisib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)","termGroup":"SY","termSource":"NCI"},{"termName":"Aliqopa","termGroup":"BR","termSource":"NCI"},{"termName":"BAY 80-6946 Dihydrochloride","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-80-6946 Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Copanlisib Dihydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402152-13-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"03ZI7RZ52O"},{"name":"Maps_To","value":"Copanlisib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"653981"},{"name":"NCI_META_CUI","value":"CL526449"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653981"},{"name":"PDQ_Open_Trial_Search_ID","value":"653981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79824":{"preferredName":"Copper Cu 64-ATSM","code":"C79824","definitions":[{"definition":"A radioconjugate consisting of a lipophilic copper(II)bis(thiosemicarbazone) labeled with the positron- and beta-emitting isotope (64)Cu with hypoxia-selective and antineoplastic activities. With a high membrane permeability and redox potential, copper Cu 64-ATSM is preferentially taken up by hypoxic cells compared to normoxic cells; the extent of retention in tissue is inversely related to the state of tissue oxygenation allowing the quantitation of tissue hypoxia by positron emission tomography (PET). In addition, the radioactive copper moiety of this agent may deliver a selective cytotoxic dose of beta radiation to hypoxic tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in PET imaging to detect certain types of tumors. Copper Cu 64 is a radioactive substance. It is linked to ATSM, which is taken up by tissues that have low levels of oxygen, such as some tumor tissues. A PET scanner is used to detect which cells in the body have taken up copper Cu 64-ATSM. It is a type of radioimaging agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Copper Cu 64-ATSM","termGroup":"PT","termSource":"NCI"},{"termName":"(64)Cu-ATSM","termGroup":"SY","termSource":"NCI"},{"termName":"Copper-64-diacetyl-bis(N4-methylthiosemicarbazone)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Copper_Cu_64-ATSM"},{"name":"Maps_To","value":"Copper Cu 64-ATSM"},{"name":"NCI_Drug_Dictionary_ID","value":"626166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626166"},{"name":"PDQ_Open_Trial_Search_ID","value":"626166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1828021"}]}}{"C80050":{"preferredName":"Copper Gluconate","code":"C80050","definitions":[{"definition":"The orally bioavailable copper salt of D-gluconic acid. In addition to its roles as an enzyme cofactor for cytochrome C oxidase and superoxide dismutase, copper forms complexes with the thiocarbamate disulfiram (DSF) forming DSF-copper complexes, which enhances the DSF-mediated inhibition of the 26S proteasome; proteasome inhibition may result in inhibition of cellular protein degradation, cessation of cell cycle progression, inhibition of cellular proliferation, and the induction of apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copper Gluconate","termGroup":"PT","termSource":"NCI"},{"termName":"Cupric Gluconate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"527-09-3"},{"name":"Chemical_Formula","value":"2C6H11O7.Cu"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RV823G6G67"},{"name":"Legacy Concept Name","value":"Copper_Gluconate"},{"name":"Maps_To","value":"Copper Gluconate"},{"name":"NCI_Drug_Dictionary_ID","value":"614606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614606"},{"name":"PDQ_Open_Trial_Search_ID","value":"614606"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0982097"}]}}{"C173877":{"preferredName":"Taniraleucel","code":"C173877","definitions":[{"definition":"A population of cryopreserved, off-the-shelf (OTS) allogeneic natural killer (NK) cells derived from human placental hematopoietic stem cells (HSCs) and expressing the CD56 surface antigen and exhibiting a lack of CD3, with potential immunomodulating, antineoplastic and antiviral activities. Upon infusion of taniraleucel, these cells are able to recognize tumor cells as well as virally-infected cells, secrete perforins, granzymes and cytokines, and induce apoptosis in tumor and virally-infected cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taniraleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic CD56+/CD3- Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"CD56+/CD3- NK Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"Cord Blood-derived Expanded Natural Killer Cells PNK-007","termGroup":"SY","termSource":"NCI"},{"termName":"Cord Blood-derived Expanded NK Cells PNK-007","termGroup":"SY","termSource":"NCI"},{"termName":"CYNK 001","termGroup":"CN","termSource":"NCI"},{"termName":"CYNK-001","termGroup":"CN","termSource":"NCI"},{"termName":"CYNK001","termGroup":"CN","termSource":"NCI"},{"termName":"Human CB-derived Natural Killer Cells PNK-007","termGroup":"SY","termSource":"NCI"},{"termName":"Human Placental HSC-derived CD56+/CD3- NKs CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"Natural Killer Cells CYNK-001","termGroup":"SY","termSource":"NCI"},{"termName":"PNK 007","termGroup":"CN","termSource":"NCI"},{"termName":"PNK-007","termGroup":"CN","termSource":"NCI"},{"termName":"PNK007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XO25H8E4QP"},{"name":"Maps_To","value":"Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001"},{"name":"Maps_To","value":"Cord Blood-derived Expanded Natural Killer Cells PNK-007"},{"name":"NCI_Drug_Dictionary_ID","value":"802398"},{"name":"NCI_META_CUI","value":"CL1407641"},{"name":"NCI_META_CUI","value":"CL509621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802398"},{"name":"PDQ_Open_Trial_Search_ID","value":"802398"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1057":{"preferredName":"Cordycepin","code":"C1057","definitions":[{"definition":"A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to a family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cordycepin","termGroup":"PT","termSource":"NCI"},{"termName":"3'-dA-CE Phosphoramidite","termGroup":"SN","termSource":"NCI"},{"termName":"3'-Deoxyadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"3-dAdenosine","termGroup":"SN","termSource":"NCI"},{"termName":"9-Cordyceposidoadenine","termGroup":"SN","termSource":"NCI"},{"termName":"COR","termGroup":"AB","termSource":"NCI"},{"termName":"Cordycepine","termGroup":"SY","termSource":"NCI"},{"termName":"Kordicepin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"TdT-positive acute lymphocytic leukemia."},{"name":"CAS_Registry","value":"73-03-0"},{"name":"CHEBI_ID","value":"CHEBI:29014"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GZ8VF4M2J8"},{"name":"Legacy Concept Name","value":"Cordycepin"},{"name":"Maps_To","value":"Cordycepin"},{"name":"NCI_Drug_Dictionary_ID","value":"42667"},{"name":"NSC Number","value":"401022"},{"name":"NSC Number","value":"627047"},{"name":"NSC Number","value":"63984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42667"},{"name":"PDQ_Open_Trial_Search_ID","value":"42667"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056331"}]}}{"C967":{"preferredName":"Cordycepin Triphosphate","code":"C967","definitions":[{"definition":"The triphosphate salt of cordycepin, a purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK), and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cordycepin Triphosphate","termGroup":"PT","termSource":"NCI"},{"termName":"3'-Deoxyadenosine-5'-(tetrahydrogen triphosphate)","termGroup":"SN","termSource":"NCI"},{"termName":"Cordycepin-5'-triphosphate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73-04-1"},{"name":"CHEBI_ID","value":"CHEBI:52316"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"59P84ZU54H"},{"name":"Legacy Concept Name","value":"Cordycepin_Triphosphate"},{"name":"Maps_To","value":"Cordycepin Triphosphate"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046803"}]}}{"C78184":{"preferredName":"Coriolus Versicolor Extract","code":"C78184","definitions":[{"definition":"A substance being studied in the treatment of breast cancer and other types of cancer. Coriolus versicolor is a type of mushroom. Its extract is used with other treatments in some cultures to treat cancer and other conditions. The extract may boost the immune system, slow the growth of some tumor cells, and lessen the side effects of chemotherapy and radiation therapy. It is a type of biological response modifier (BRM) and a type of dietary supplement.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An extract derived from the mushroom Coriolus versicolor, containing polysaccharide K (PSK) and polysaccharide-peptide (PSP), with potential immunomodulating and antineoplastic activities. Coriolus versicolor extract has been shown to stimulate the production of lymphocytes and cytokines, such as interferons and interleukins, and may exhibit antioxidant activities. However, the precise mechanism of action(s) of this agent is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coriolus Versicolor Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Yunzhi Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Coriolus_Versicolor_Extract"},{"name":"Maps_To","value":"Coriolus Versicolor Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"594403"},{"name":"NCI_META_CUI","value":"CL383577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594403"},{"name":"PDQ_Open_Trial_Search_ID","value":"594403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C76112":{"preferredName":"Corticorelin Acetate","code":"C76112","definitions":[{"definition":"A substance being studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt form of coticorelin, a synthetic peptide of neurohormone corticotropin-releasing factor (CRF), with potential antitumor and antiangiogenesis activities. Upon administration, corticorelin stimulates adrenocorticotropic hormone (ACTH) secretion from the anterior pituitary gland. In turn, ACTH stimulates cortisol production from the adrenal cortex and is regulated by a negative feedback mechanism. Corticorelin appears to inhibit swelling around brain tumors through reduction in vascular leakage and maintenance of endothelial cell integrity. This agent potentially suppresses vascularization and tumor cell growth through reduction of vascular endothelial growth factor (VEGF) that appears to be via activation of corticotrophin-releasing factor receptor 2 (CRFR2), a G protein-coupled receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Corticorelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"hCRF","termGroup":"AB","termSource":"NCI"},{"termName":"Human Corticotropin-Releasing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Xerecept","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86784-80-7"},{"name":"Chemical_Formula","value":"C208H344N60O63S2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2YF82QN5RY"},{"name":"Legacy Concept Name","value":"Corticorelin_Acetate"},{"name":"Maps_To","value":"Corticorelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"385686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385686"},{"name":"PDQ_Open_Trial_Search_ID","value":"385686"},{"name":"PubMedID_Primary_Reference","value":"19437022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515366"}]}}{"C1058":{"preferredName":"Cortisone Acetate","code":"C1058","definitions":[{"definition":"The acetate salt form of cortisone, a synthetic or semisynthetic analog of the naturally occurring cortisone hormone produced by the adrenal glands with anti-inflammatory and immunomodulating properties. Cortisone acetate diffuses through the cell membrane and binds to nuclear glucocorticoid receptors. The receptor-ligand complex binds to promotor regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cortisone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"21-(Acetyloxy)-17-hydroxypregn-4-ene-3,11,20-trione","termGroup":"SN","termSource":"NCI"},{"termName":"6alpha,9Difluoro-11beta,17,21-trihydroxypregna-1,4- diene-3,20-dione 21-acetate 17- Butyrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cortogen","termGroup":"BR","termSource":"NCI"},{"termName":"Cortone","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-04-4"},{"name":"Chemical_Formula","value":"C23H30O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"883WKN7W8X"},{"name":"Legacy Concept Name","value":"Cortisone_Acetate"},{"name":"Maps_To","value":"Cortisone Acetate"},{"name":"NSC Number","value":"49420"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056391"}]}}{"C1877":{"preferredName":"Cositecan","code":"C1877","definitions":[{"definition":"A drug being studied in the treatment of cancer.  It belongs to a family of drugs called topoisomerase inhibitors. It is related to the anticancer drug camptothecin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic silicon-containing agent related to camptothecin with antineoplastic properties.  Cositecan stabilizes the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks and consequently triggering apoptosis.  Because it is lipophilic, cositecan exhibits enhanced tissue penetration and bio-availability compared to water-soluble camptothecins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cositecan","termGroup":"PT","termSource":"NCI"},{"termName":"(4S)-4-Ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"BNP1350","termGroup":"CN","termSource":"NCI"},{"termName":"DB 172","termGroup":"CN","termSource":"NCI"},{"termName":"Karenitecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203923-89-1"},{"name":"Chemical_Formula","value":"C25H28N2O4Si"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"24R60NVC41"},{"name":"Legacy Concept Name","value":"Karenitecin"},{"name":"Maps_To","value":"Cositecan"},{"name":"NCI_Drug_Dictionary_ID","value":"38211"},{"name":"NSC Number","value":"710270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38211"},{"name":"PDQ_Open_Trial_Search_ID","value":"38211"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935985"}]}}{"C61493":{"preferredName":"Gebasaxturev","code":"C61493","definitions":[{"definition":"A preparation of naturally occurring, oncolytic enterovirus, with potential antineoplastic activity. Upon administration, gebasaxturev targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are overexpressed on certain malignant cells. After entering the cells, gebasaxturev replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gebasaxturev","termGroup":"PT","termSource":"NCI"},{"termName":"CAVATAK","termGroup":"BR","termSource":"NCI"},{"termName":"Coxsackievirus A21","termGroup":"SY","termSource":"NCI"},{"termName":"Coxsackievirus V937","termGroup":"SY","termSource":"NCI"},{"termName":"CVA21","termGroup":"AB","termSource":"NCI"},{"termName":"V 937","termGroup":"CN","termSource":"NCI"},{"termName":"V-937","termGroup":"CN","termSource":"NCI"},{"termName":"V937","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802360-06-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4B57CWT710"},{"name":"Legacy Concept Name","value":"Coxsackievirus_A21"},{"name":"Maps_To","value":"Coxsackievirus A21"},{"name":"Maps_To","value":"Coxsackievirus V937"},{"name":"NCI_Drug_Dictionary_ID","value":"486330"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486330"},{"name":"PDQ_Open_Trial_Search_ID","value":"486330"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1440507"}]}}{"C88342":{"preferredName":"CpG Oligodeoxynucleotide GNKG168","code":"C88342","definitions":[{"definition":"A synthetic, 21-mer, unmethylated CpG motif-based oligodeoxynucleotide (ODN), with immunostimulatory activity. CpG oligodeoxynucleotide GNKG168 binds to and activates Toll-like receptor 9 (TLR9) and is taken up into cells by endocytosis; once internalized, it may activate numerous signaling transduction pathways resulting in the release of multiple cytokines, such as immunoglobulins (Igs), interferons (IFNs), interleukins (ILs) and tumor necrosis factor (TNF). Through activation of TLR9, this ODN can directly stimulate B-lymphocytes, dendritic and natural killer (NK) cells, resulting in an increase in innate immunity and antibody-dependent cellular cytotoxicity (ADCC). In addition, through the release of IL-12 and IFN, this agent may induce a preferential shift to the T-helper 1(Th1) phenotype resulting in enhanced CD8+ T cell-mediated antitumor cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CpG Oligodeoxynucleotide GNKG168","termGroup":"PT","termSource":"NCI"},{"termName":"CpG ODN GNKG168","termGroup":"AB","termSource":"NCI"},{"termName":"GNKG-168","termGroup":"CN","termSource":"NCI"},{"termName":"GNKG168","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JK03C8HWHK"},{"name":"Maps_To","value":"CpG Oligodeoxynucleotide GNKG168"},{"name":"NCI_Drug_Dictionary_ID","value":"662816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662816"},{"name":"PDQ_Open_Trial_Search_ID","value":"662816"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981861"}]}}{"C64639":{"preferredName":"Crenolanib","code":"C64639","definitions":[{"definition":"An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crenolanib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine","termGroup":"SN","termSource":"NCI"},{"termName":"CP 868 596","termGroup":"CN","termSource":"NCI"},{"termName":"CP-868,596","termGroup":"CN","termSource":"NCI"},{"termName":"CP-868596","termGroup":"CN","termSource":"NCI"},{"termName":"CP868596","termGroup":"CN","termSource":"NCI"},{"termName":"PDGFR Inhibitor CP-868596","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"670220-88-9"},{"name":"Chemical_Formula","value":"C26H29N5O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LQF7I567TQ"},{"name":"Legacy Concept Name","value":"CP-868_596"},{"name":"Maps_To","value":"Crenolanib"},{"name":"NCI_Drug_Dictionary_ID","value":"518325"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518325"},{"name":"PDQ_Open_Trial_Search_ID","value":"518325"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831982"}]}}{"C106204":{"preferredName":"Crenolanib Besylate","code":"C106204","definitions":[{"definition":"The besylate salt form of crenolanib, an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crenolanib Besylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-, Benzenesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine Monobenzenesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"CP-868,596-26","termGroup":"CN","termSource":"NCI"},{"termName":"CP-86859626","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"670220-93-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MC4B01024K"},{"name":"Maps_To","value":"Crenolanib Besylate"},{"name":"NCI_Drug_Dictionary_ID","value":"779361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779361"},{"name":"PDQ_Open_Trial_Search_ID","value":"779361"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827141"}]}}{"C74061":{"preferredName":"Crizotinib","code":"C74061","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. It blocks enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crizotinib","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"MET Tyrosine Kinase Inhibitor PF-02341066","termGroup":"SY","termSource":"NCI"},{"termName":"PF 02341066","termGroup":"CN","termSource":"NCI"},{"termName":"PF-2341066","termGroup":"CN","termSource":"NCI"},{"termName":"PF02341066","termGroup":"CN","termSource":"NCI"},{"termName":"Xalkori","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Small Cell Lung Cancer; inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT)."},{"name":"CAS_Registry","value":"877399-52-5"},{"name":"CHEBI_ID","value":"CHEBI:64310"},{"name":"Chemical_Formula","value":"C21H22Cl2FN5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"53AH36668S"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_PF-02341066"},{"name":"Maps_To","value":"Crizotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"586080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586080"},{"name":"PDQ_Open_Trial_Search_ID","value":"586080"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2974289"}]}}{"C66938":{"preferredName":"Crolibulin","code":"C66938","definitions":[{"definition":"A small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Microtubulin inhibitor EPC2407 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of tubulin into microtubules, which may result in cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. As a vascular disruption agent (VDA), this agent also disrupts tumor neovascularization, which may result in a reduction in tumor blood flow and tumor hypoxia and ischemic necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crolibulin","termGroup":"PT","termSource":"NCI"},{"termName":"EPC2407","termGroup":"CN","termSource":"NCI"},{"termName":"Microtubule Inhibitor EPC2407","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000852-17-4"},{"name":"Chemical_Formula","value":"C18H17BrN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9ENT43KY91"},{"name":"Legacy Concept Name","value":"EPC2407"},{"name":"Maps_To","value":"Crolibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"536028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536028"},{"name":"PDQ_Open_Trial_Search_ID","value":"536028"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880474"}]}}{"C1546":{"preferredName":"Cryptophycin","code":"C1546","definitions":[{"definition":"The cryptophycins are a family of 16-membered macrolide antimitotic agents isolated from the cyanobacteria Nostoc sp. The mechanism of anticancer activity of the cryptophycins has been associated with their destabilization of microtubules and induction of bcl-2 phosphorylation leading to apoptosis. Cryptophycins demonstrated activity against the wide spectrum of solid tumors including those that overexpress the multidrug resistance efflux pump P-glycoprotein. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptophycin","termGroup":"PT","termSource":"NCI"},{"termName":"10-((3-Chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone","termGroup":"SN","termSource":"NCI"},{"termName":"Cryptophycin 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124689-65-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XO974V2M5T"},{"name":"Legacy Concept Name","value":"Cryptophycin"},{"name":"Maps_To","value":"Cryptophycin"},{"name":"NSC Number","value":"667642"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0257217"}]}}{"C1826":{"preferredName":"Cryptophycin 52","code":"C1826","definitions":[{"definition":"A member of the cryptophycin family of antitumor agents that binds to microtubules, inducing growth arrest and apoptosis in solid tumors. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cryptophycin 52","termGroup":"PT","termSource":"NCI"},{"termName":"C-52","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclo[2,2-dimethyl-beta-alanyl-(2S)-2-hydroxy-4-methylpentanoyl-(2E,5S,6S)-5-hydroxy-6-[(2R,3R)-3-phenyloxiranyl]-2-heptenoyl-3-chloro-O-methyl-D-tyrosyl]","termGroup":"SN","termSource":"NCI"},{"termName":"LY 355703","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186256-67-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I7FQ5A183L"},{"name":"Legacy Concept Name","value":"Cryptophycin_52"},{"name":"Maps_To","value":"Cryptophycin 52"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0756544"}]}}{"C95769":{"preferredName":"Genistein Sodium Dihydrate","code":"C95769","definitions":[{"definition":"The sodium salt dihydrate form of crystalline genistein, a soy-derived isoflavone and phytoestrogen, with potential antineoplastic, chemosensitizing, and antioxidant activities. Upon administration, genistein sodium dihydrate binds to and modulates the activities of the nuclear estrogen receptors ERalpha (ESR1) and ERbeta (ESR2), and activates the G-coupled estrogen receptor 1 (GPER1). In addition, this agent increases the expression of phosphatase and tensin homolog (PTEN), which deactivates protein kinase Akt and mitogen-activated protein kinases (MAPK1 and 3; ERK2 and 1), thereby disrupting PI3K/Akt signal transduction and inducing apoptosis. Genistein sodium dihydrate also induces antioxidant enzymes through AMP-activated protein kinase (AMPK) activation, inhibits nuclear factor kappa-B (NF-kB) activation and decreases inflammation response, thereby sensitizing tumors to chemotherapy. Compared to genistein itself, which has poor oral availability, this crystalline formulation shows improved solubility and bioavailability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genistein Sodium Dihydrate","termGroup":"PT","termSource":"NCI"},{"termName":"AXP107-11","termGroup":"CN","termSource":"NCI"},{"termName":"Crystalline Genistein Formulation AXP107-11","termGroup":"SY","termSource":"NCI"},{"termName":"Crystalline Genistein Sodium Dihydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229264-80-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z6D785B7J3"},{"name":"Maps_To","value":"Crystalline Genistein Formulation AXP107-11"},{"name":"NCI_Drug_Dictionary_ID","value":"683963"},{"name":"NCI_META_CUI","value":"CL428211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683963"},{"name":"PDQ_Open_Trial_Search_ID","value":"683963"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C129653":{"preferredName":"Sotuletinib","code":"C129653","definitions":[{"definition":"An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF-1R; CSF1R), with potential antineoplastic activity. CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. This inhibits the activity and proliferation of TAMs, and reprograms the immunosuppressive nature of existing TAMs. Altogether, this reduces TAM-mediated immune suppression in the tumor microenvironment, re-activates the immune system, and improves anti-tumor cell responses mediated by T-cells.  CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand, colony stimulating factor 1 (CSF1); this receptor is overexpressed by TAMs in the tumor microenvironment, and plays a major role in both immune suppression and the induction of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotuletinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-((2-(((1R,2R)-2-hydroxycyclohexyl)amino)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-[2((1R,2R)-2-Hydroxycyclohexylamino)-benzothiazol-6-yloxyl]-pyridine- 2-carboxylic Acid Methylamide","termGroup":"SN","termSource":"NCI"},{"termName":"BLZ 945","termGroup":"CN","termSource":"NCI"},{"termName":"BLZ-945","termGroup":"CN","termSource":"NCI"},{"termName":"BLZ945","termGroup":"CN","termSource":"NCI"},{"termName":"CSF-1R Inhibitor BLZ945","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"953769-46-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7W3V82OQ0P"},{"name":"Maps_To","value":"CSF-1R Inhibitor BLZ945"},{"name":"NCI_Drug_Dictionary_ID","value":"784318"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784318"},{"name":"PDQ_Open_Trial_Search_ID","value":"784318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3252423"}]}}{"C136424":{"preferredName":"CSF1R Inhibitor DCC-3014","code":"C136424","synonyms":[{"termName":"CSF1R Inhibitor DCC-3014","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Dec 08 11:10:29 EST 2021 - See 'Vimseltinib(C175876)'"},{"name":"OLD_PARENT","value":"C129825"},{"name":"OLD_PARENT","value":"C1967"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129688":{"preferredName":"CSF1R Inhibitor PLX73086","code":"C129688","definitions":[{"definition":"An inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antineoplastic activity. Upon administration, CSF1R inhibitor PLX73086 targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activity of tumor-associated macrophages (TAMs) in the tumor tissue and prevents TAM-related tumor cell growth. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CSF1R Inhibitor PLX73086","termGroup":"PT","termSource":"NCI"},{"termName":"AC-708","termGroup":"CN","termSource":"NCI"},{"termName":"AC708","termGroup":"CN","termSource":"NCI"},{"termName":"PLX7 3086","termGroup":"CN","termSource":"NCI"},{"termName":"PLX73086","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CSF1R Inhibitor PLX73086"},{"name":"NCI_META_CUI","value":"CL507868"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C202251":{"preferredName":"CT2584 Mesylate","code":"C202251","definitions":[{"definition":"The mesylate form of CT-2584, a lipid metabolism and phosphatidic acid modulator, with potential antineoplastic activity. Upon administration, CT-2584 inhibits phospholipid signaling which may inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CT2584 Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"1-(11-(dodecylamino)-10-hydroxyundecyl)-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione, Methanesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"1-(11-Dodecylamino-10-Hydroxyundecyl)-3,7-Dimethylxanthine, Methanesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CT 2584 HMS","termGroup":"SY","termSource":"NCI"},{"termName":"CT-2584 HMS","termGroup":"SY","termSource":"NCI"},{"termName":"CT-2584 Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"CT2584 HMS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"353525-62-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YX1G1VY8K"},{"name":"Maps_To","value":"CT2584 HMS"},{"name":"NCI_META_CUI","value":"CL1921215"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146765":{"preferredName":"Sovipostobart","code":"C146765","definitions":[{"definition":"A probody composed of ipilimumab, a recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of sovipostobart, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986249 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sovipostobart","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986249","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986249","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986249","termGroup":"CN","termSource":"NCI"},{"termName":"CTLA-4 Probody BMS-986249","termGroup":"SY","termSource":"NCI"},{"termName":"CTLA-4-directed Probody BMS-986249","termGroup":"SY","termSource":"NCI"},{"termName":"Protease-activated Anti-CTLA-4 Antibody Prodrug BMS-986249","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649371-19-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U1OMP6W1PM"},{"name":"Maps_To","value":"CTLA-4-directed Probody BMS-986249"},{"name":"NCI_Drug_Dictionary_ID","value":"792162"},{"name":"NCI_META_CUI","value":"CL544788"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792162"},{"name":"PDQ_Open_Trial_Search_ID","value":"792162"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C401":{"preferredName":"Curcumin","code":"C401","definitions":[{"definition":"A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties.  Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C.  These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A yellow pigment of the spice turmeric that is being studied in cancer prevention.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Curcumin","termGroup":"PT","termSource":"NCI"},{"termName":"(E,E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"C.I. 75300","termGroup":"CN","termSource":"NCI"},{"termName":"C.I. Natural Yellow 3","termGroup":"SY","termSource":"NCI"},{"termName":"Diferuloylmethane","termGroup":"SY","termSource":"NCI"},{"termName":"Turmeric Yellow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"458-37-7"},{"name":"CHEBI_ID","value":"CHEBI:3962"},{"name":"Chemical_Formula","value":"C21H20O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IT942ZTH98"},{"name":"Legacy Concept Name","value":"Curcumin"},{"name":"Maps_To","value":"Curcumin"},{"name":"NCI_Drug_Dictionary_ID","value":"43115"},{"name":"NSC Number","value":"32982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43115"},{"name":"PDQ_Open_Trial_Search_ID","value":"43115"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010467"}]}}{"C154569":{"preferredName":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110","code":"C154569","definitions":[{"definition":"A water-soluble, nano-sized formulation composed of nanoparticles encapsulating the poorly water-soluble curcumin, a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI), and the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of the curcumin/doxorubicin-encapsulating nanoparticle IMX-110, the curcumin moiety targets and inhibits the activation of STAT3 and NF-kB and prevents STAT3- and NF-kB-mediated signaling pathways, both of which are activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, tumor resistance to apoptosis, metastasis and immune evasion. The doxorubicin moiety intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and curcumin, by inhibiting NFkB and STAT3 activity, may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells. Chemotherapeutic agents, such as doxorubicin, upregulate the expression of NF-kB in tumor cells which generates chemotherapy-resistant tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110","termGroup":"PT","termSource":"NCI"},{"termName":"IMX 110","termGroup":"CN","termSource":"NCI"},{"termName":"IMX-110","termGroup":"CN","termSource":"NCI"},{"termName":"IMX110","termGroup":"CN","termSource":"NCI"},{"termName":"Stat3/NF-kB/poly-tyrosine Kinase Inhibitor/Doxorubicin-encapsulating Nanoparticle IMX-110","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110"},{"name":"NCI_Drug_Dictionary_ID","value":"794327"},{"name":"NCI_META_CUI","value":"CL555361"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794327"},{"name":"PDQ_Open_Trial_Search_ID","value":"794327"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106116":{"preferredName":"Cusatuzumab","code":"C106116","definitions":[{"definition":"A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cusatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 Monoclonal Antibody ARGX-110","termGroup":"SY","termSource":"NCI"},{"termName":"ARGX-110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1864871-20-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RR5U4UFJ8L"},{"name":"Maps_To","value":"Cusatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"748589"},{"name":"NCI_META_CUI","value":"CL447355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748589"},{"name":"PDQ_Open_Trial_Search_ID","value":"748589"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1055":{"preferredName":"Custirsen Sodium","code":"C1055","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks the production of a protein called clusterin, which helps cells live longer. This may kill cancer cells that need clusterin to grow. It may also make cells more sensitive to anticancer drugs. It is a type of antisense oligonucleotide, and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Custirsen Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"(3'-5')d(P-thio)([2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m5rC-A-G-C-A-G-A-G-T-C-T-T-C-A-[2'-O-(2- methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]m5rU), Eicosasodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Antisense Testosterone-Repressed Prostate Message 2","termGroup":"SY","termSource":"NCI"},{"termName":"Antisense TRPM-2","termGroup":"SY","termSource":"NCI"},{"termName":"Clusterin Antisense Oligonucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 112989","termGroup":"CN","termSource":"NCI"},{"termName":"OGX 011","termGroup":"CN","termSource":"NCI"},{"termName":"OGX-011","termGroup":"CN","termSource":"NCI"},{"termName":"OGX011","termGroup":"CN","termSource":"NCI"},{"termName":"TRPM-2 Antisense","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685922-56-9"},{"name":"Chemical_Formula","value":"C231H292N78O119P20S20.20Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ILE26V76EB"},{"name":"Legacy Concept Name","value":"OGX-011"},{"name":"Maps_To","value":"Custirsen Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"271195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"271195"},{"name":"PDQ_Open_Trial_Search_ID","value":"271195"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328699"}]}}{"C123383":{"preferredName":"CXC Chemokine Receptor 2 Antagonist AZD5069","code":"C123383","definitions":[{"definition":"An orally bioavailable, selective and reversible antagonist of CXC chemokine receptor 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells. In addition, AZD5069 reduces both neutrophil recruitment and migration from the systemic circulation into sites of inflammation, including the lung mucosa; it may also prevent neutrophil migration from the bone marrow. This results in the reduction of inflammation, mucus production, and neutrophil proteinase-mediated tissue destruction in the lung. CXCR2, a G protein-coupled receptor protein also known as IL-8 receptor B (IL-8RB), is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation and progression; it is known to be elevated in several inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXC Chemokine Receptor 2 Antagonist AZD5069","termGroup":"PT","termSource":"NCI"},{"termName":"AZD5069","termGroup":"CN","termSource":"NCI"},{"termName":"CXCR2 Antagonist AZD5069","termGroup":"SY","termSource":"NCI"},{"termName":"N-(2-(((2,3-difluorophenyl)methyl)thio)-6-(((1R,2S)-2,3-dihydroxy-1-methylpropyl)oxy)-4-pyrimidinyl)-1-azetidinesulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"878385-84-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4ADT8JXB9S"},{"name":"Maps_To","value":"CXC Chemokine Receptor 2 Antagonist AZD5069"},{"name":"NCI_Drug_Dictionary_ID","value":"774892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774892"},{"name":"PDQ_Open_Trial_Search_ID","value":"774892"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045791"}]}}{"C150389":{"preferredName":"CXCR1/2 Inhibitor SX-682","code":"C150389","definitions":[{"definition":"An orally bioavailable, selective and reversible antagonist of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration CXCR1/2 inhibitor SX-682 selectively and allosterically binds to CXCR 1 and 2 and inhibits their activation by tumor-secreted chemokines. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance and myeloid cell suppression. They play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR1/2 Inhibitor SX-682","termGroup":"PT","termSource":"NCI"},{"termName":"(2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"SX 682","termGroup":"CN","termSource":"NCI"},{"termName":"SX-682","termGroup":"CN","termSource":"NCI"},{"termName":"SX682","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1648843-04-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H5212R2DPM"},{"name":"Maps_To","value":"CXCR1/2 Inhibitor SX-682"},{"name":"NCI_Drug_Dictionary_ID","value":"792795"},{"name":"NCI_META_CUI","value":"CL552163"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792795"},{"name":"PDQ_Open_Trial_Search_ID","value":"792795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153151":{"preferredName":"CXCR2 Antagonist QBM076","code":"C153151","definitions":[{"definition":"An orally available small molecule antagonist of the G protein-coupled receptor, C-X-C motif chemokine receptor 2 (CXCR2), with potential immunomodulating and antineoplastic activities. Upon administration, QBM076 binds to and inhibits the activation of CXCR2, resulting in reduced neutrophil recruitment, myeloid-derived suppressor cell (MDSC) accumulation, and may potentially slow tumorigenesis and metastatic processes. CXCR2 is upregulated in a variety of cancer types, predominately in neutrophils/MDSCs rather than tumor cells, and is thought to contribute to tumor cell proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR2 Antagonist QBM076","termGroup":"PT","termSource":"NCI"},{"termName":"QBM 076","termGroup":"CN","termSource":"NCI"},{"termName":"QBM-076","termGroup":"CN","termSource":"NCI"},{"termName":"QBM076","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CXCR2 Antagonist QBM076"},{"name":"NCI_Drug_Dictionary_ID","value":"793940"},{"name":"NCI_META_CUI","value":"CL554404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793940"},{"name":"PDQ_Open_Trial_Search_ID","value":"793940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88309":{"preferredName":"Motixafortide","code":"C88309","definitions":[{"definition":"An orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. CXCR4 antagonist BL-8040 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor 1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood. The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; SDF-1/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motixafortide","termGroup":"PT","termSource":"NCI"},{"termName":"4F-Benzoyl-TN14003","termGroup":"SY","termSource":"NCI"},{"termName":"BKT 140","termGroup":"CN","termSource":"NCI"},{"termName":"BKT-140","termGroup":"CN","termSource":"NCI"},{"termName":"BKT140","termGroup":"CN","termSource":"NCI"},{"termName":"BL 8040","termGroup":"CN","termSource":"NCI"},{"termName":"BL-8040","termGroup":"CN","termSource":"NCI"},{"termName":"BL8040","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-fluoro-benzoyl)-l-arginyl-l-arginyl-(l-3-(naphthyl)alanyl)-l-cysteinyl-l-tyrosyl-l-citrullinyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-l-arginyl-l-citrullinyl-l-cysteinyl-l-arginine Amide,Cyclic (4-13)-disulfide","termGroup":"SY","termSource":"NCI"},{"termName":"TF 14016","termGroup":"SY","termSource":"NCI"},{"termName":"TF-14016","termGroup":"CN","termSource":"NCI"},{"termName":"TF14016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"664334-36-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DA9G065962"},{"name":"Maps_To","value":"CXCR4 Antagonist BL-8040"},{"name":"Maps_To","value":"Motixafortide"},{"name":"NCI_Drug_Dictionary_ID","value":"659935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659935"},{"name":"PDQ_Open_Trial_Search_ID","value":"659935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981825"}]}}{"C131534":{"preferredName":"CXCR4 Antagonist USL311","code":"C131534","definitions":[{"definition":"An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, USL311 binds to CXCR4, thereby preventing the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Antagonist USL311","termGroup":"PT","termSource":"NCI"},{"termName":"CXCR4 Inhibitor USL311","termGroup":"SY","termSource":"NCI"},{"termName":"USL 311","termGroup":"CN","termSource":"NCI"},{"termName":"USL311","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1373268-67-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BTG5MX2Q2"},{"name":"Maps_To","value":"CXCR4 Antagonist USL311"},{"name":"NCI_Drug_Dictionary_ID","value":"786185"},{"name":"NCI_META_CUI","value":"CL514455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786185"},{"name":"PDQ_Open_Trial_Search_ID","value":"786185"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74022":{"preferredName":"CXCR4 Inhibitor Q-122","code":"C74022","definitions":[{"definition":"An orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Inhibitor Q-122","termGroup":"PT","termSource":"NCI"},{"termName":"MSX-122","termGroup":"CN","termSource":"NCI"},{"termName":"Q 122","termGroup":"CN","termSource":"NCI"},{"termName":"Q-122","termGroup":"CN","termSource":"NCI"},{"termName":"Q122","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897657-95-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69D634Q702"},{"name":"Maps_To","value":"CXCR4 Inhibitor Q-122"},{"name":"NCI_Drug_Dictionary_ID","value":"586491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586491"},{"name":"PDQ_Open_Trial_Search_ID","value":"586491"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347544"}]}}{"C106253":{"preferredName":"CXCR4 Peptide Antagonist LY2510924","code":"C106253","definitions":[{"definition":"An inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4 Peptide Antagonist LY2510924","termGroup":"PT","termSource":"NCI"},{"termName":"LY2510924","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CXCR4 Peptide Antagonist LY2510924"},{"name":"NCI_Drug_Dictionary_ID","value":"703819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703819"},{"name":"PDQ_Open_Trial_Search_ID","value":"703819"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827103"}]}}{"C148166":{"preferredName":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115","code":"C148166","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor BCD 115 binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of certain tumor promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. CDK8 plays a key role in transcription regulation and is an important oncogenic driver in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115","termGroup":"PT","termSource":"NCI"},{"termName":"BCD 115","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-115","termGroup":"CN","termSource":"NCI"},{"termName":"BCD115","termGroup":"CN","termSource":"NCI"},{"termName":"CDK 8/19 Inhibitor BCD 115","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1449228-40-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E2X758P2BZ"},{"name":"Maps_To","value":"Cyclin-dependent Kinase 8/19 Inhibitor BCD 115"},{"name":"NCI_Drug_Dictionary_ID","value":"792544"},{"name":"NCI_META_CUI","value":"CL550778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792544"},{"name":"PDQ_Open_Trial_Search_ID","value":"792544"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151988":{"preferredName":"Ebvaciclib","code":"C151988","definitions":[{"definition":"An orally bioavailable, cyclin dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, ebvaciclib selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and proliferation and are frequently overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ebvaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CDK Inhibitor PF-06873600","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06873600","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06873600","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2185857-97-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3B512HJD65"},{"name":"Maps_To","value":"Cyclin-dependent Kinase Inhibitor PF-06873600"},{"name":"NCI_Drug_Dictionary_ID","value":"793673"},{"name":"NCI_META_CUI","value":"CL553210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793673"},{"name":"PDQ_Open_Trial_Search_ID","value":"793673"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62600":{"preferredName":"Davamotecan Pegadexamer","code":"C62600","definitions":[{"definition":"A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration of davamotecan pegadexamer, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Davamotecan Pegadexamer","termGroup":"PT","termSource":"NCI"},{"termName":"Camptothecin-Polymer Conjugate IT-101","termGroup":"SY","termSource":"NCI"},{"termName":"CRLX101","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclodextrin-Based Polymer-Camptothecin CRLX101","termGroup":"SY","termSource":"NCI"},{"termName":"EP0057","termGroup":"CN","termSource":"NCI"},{"termName":"IT-101","termGroup":"CN","termSource":"NCI"},{"termName":"Linear Cyclodextrin-cysteine-PEG Based Polymer Conjugate of Camptothecin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1883668-61-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NFH8D7ZGF5"},{"name":"Legacy Concept Name","value":"Cyclodextrin-Based_Polymer-Camptothecin"},{"name":"Maps_To","value":"Cyclodextrin-Based Polymer-Camptothecin CRLX101"},{"name":"NCI_Drug_Dictionary_ID","value":"489507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489507"},{"name":"PDQ_Open_Trial_Search_ID","value":"489507"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831896"}]}}{"C28899":{"preferredName":"Cyclodisone","code":"C28899","definitions":[{"definition":"A cyclic sulfonate ester with potential antineoplastic activity.  As an alkylating agent, clyclodisone induces the formation of DNA interstrand crosslinks, DNA strand breaks, and alkali-labile lesions in the DNA of some tumor cell lines.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclodisone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99591-73-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7YFV4WN79I"},{"name":"Legacy Concept Name","value":"Cyclodisone"},{"name":"Maps_To","value":"Cyclodisone"},{"name":"NSC Number","value":"348948"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056746"}]}}{"C404":{"preferredName":"Cycloleucine","code":"C404","definitions":[{"definition":"A non-metabolizable synthetic amino acid, formed through the cyclization of the amino acid leucine, with immunosuppressive, antineoplastic, and cytostatic activities. Cycloleucine competitively inhibits the enzyme methionine adenosyltransferase, resulting in the inhibition of S-adenosylmethionine (SAM) synthesis from methionine and ATP, and subsequent nucleic acid methylation and polyamine production; RNA, and perhaps to a lesser extent, DNA biosyntheses and cell cycle progression are finally disrupted. This agent is also a competitive inhibitor at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cycloleucine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Aminocyclopentane","termGroup":"SY","termSource":"NCI"},{"termName":"1-aminocyclopentanecarboxylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"ACP","termGroup":"AB","termSource":"NCI"},{"termName":"ACPC","termGroup":"AB","termSource":"NCI"},{"termName":"CB-1639","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52-52-8"},{"name":"Chemical_Formula","value":"C6H11NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0TQU7668EI"},{"name":"Legacy Concept Name","value":"Cycloleucine"},{"name":"Maps_To","value":"Cycloleucine"},{"name":"NCI_Drug_Dictionary_ID","value":"39200"},{"name":"NSC Number","value":"1026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39200"},{"name":"PDQ_Open_Trial_Search_ID","value":"39200"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010575"}]}}{"C1359":{"preferredName":"Cyclopentenyl Cytosine","code":"C1359","definitions":[{"definition":"A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5'-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclopentenyl Cytosine","termGroup":"PT","termSource":"NCI"},{"termName":"CPE-C","termGroup":"AB","termSource":"NCI"},{"termName":"Cyclopentenylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclopentenylcytosine Triphosphate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"90597-22-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69MO0NDN8K"},{"name":"Legacy Concept Name","value":"Cyclopentenyl_Cytosine"},{"name":"Maps_To","value":"Cyclopentenyl Cytosine"},{"name":"NCI_Drug_Dictionary_ID","value":"41433"},{"name":"NSC Number","value":"375575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41433"},{"name":"PDQ_Open_Trial_Search_ID","value":"41433"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0111606"}]}}{"C61694":{"preferredName":"Cyclophosphamide Anhydrous","code":"C61694","definitions":[{"definition":"The anhydrous form of cyclophosphamide, a synthetic nitrogen mustard alkylating agent, with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to active metabolites including phosphoramide mustard, which binds to and crosslinks DNA and RNA, thereby inhibiting DNA replication and protein synthesis. This agent, at low doses, is also a potent immunosuppressant primarily by depleting T-regulatory cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclophosphamide Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-Oxide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-18-0"},{"name":"CHEBI_ID","value":"CHEBI:4027"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O2P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6UXW23996M"},{"name":"Legacy Concept Name","value":"Cyclophosphamide_Anhydrous"},{"name":"Maps_To","value":"Cyclophosphamide Anhydrous"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880207"}]}}{"C406":{"preferredName":"Cyclosporine","code":"C406","definitions":[{"definition":"A drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyclosporine","termGroup":"PT","termSource":"NCI"},{"termName":"27-400","termGroup":"CN","termSource":"NCI"},{"termName":"Ciclosporin","termGroup":"SY","termSource":"NCI"},{"termName":"CsA","termGroup":"AB","termSource":"NCI"},{"termName":"CyA","termGroup":"AB","termSource":"NCI"},{"termName":"Cyclosporin","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclosporin A","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclosporine Modified","termGroup":"SY","termSource":"NCI"},{"termName":"Gengraf","termGroup":"BR","termSource":"NCI"},{"termName":"Neoral","termGroup":"BR","termSource":"NCI"},{"termName":"OL 27-400","termGroup":"CN","termSource":"NCI"},{"termName":"Sandimmune","termGroup":"BR","termSource":"NCI"},{"termName":"SangCya","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Allogenic transplants; prophylaxis of organ rejection in bone marrow; kidney; liver and heart transplants; psoriasis; rheumatoid arthritis; various diseases that involve autoimmune response"},{"name":"CAS_Registry","value":"59865-13-3"},{"name":"CHEBI_ID","value":"CHEBI:4031"},{"name":"Chemical_Formula","value":"C62H111N11O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"83HN0GTJ6D"},{"name":"Legacy Concept Name","value":"Cyclosporine"},{"name":"Maps_To","value":"Cyclosporine"},{"name":"NCI_Drug_Dictionary_ID","value":"39201"},{"name":"NSC Number","value":"290193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39201"},{"name":"PDQ_Open_Trial_Search_ID","value":"39201"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010592"}]}}{"C95716":{"preferredName":"CYL-02 Plasmid DNA","code":"C95716","definitions":[{"definition":"A gene transfer preparation of a plasmid DNA encoding mouse somatostatin receptor subtype 2 (sst2) and a fusion protein of human deoxycytidine kinase (DCK) and uridine monophosphate kinase (UMK), complexed to a synthetic polycationic carrier, polyethylenimine, with antineoplastic adjuvant application. Upon administration, CYL-02 plasmid DNA expresses DCK::UMK fusion protein that converts gemcitabine into its toxic phosphorylated metabolite. Expression of sst2 protein by this agent could induce both antioncogenic and local antitumor bystander effects. A loss of sst2 gene expression often is found in pancreatic and colorectal cancers, and is the receptor for somatostatin which negatively regulates a number of processes such as epithelial cell proliferation. Combination effects of these gene products allows for less chemotherapy to cause tumor cell lysis in not only the original tumor, but in distant tumors as well.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYL-02 Plasmid DNA","termGroup":"PT","termSource":"NCI"},{"termName":"CYL-02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CYL-02 Plasmid DNA"},{"name":"NCI_Drug_Dictionary_ID","value":"693517"},{"name":"NCI_META_CUI","value":"CL428180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693517"},{"name":"PDQ_Open_Trial_Search_ID","value":"693517"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156744":{"preferredName":"Opevesostat","code":"C156744","definitions":[{"definition":"An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-liming step in steroid hormone biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opevesostat","termGroup":"PT","termSource":"NCI"},{"termName":"CYP11A1 inhibitor ODM-208","termGroup":"SY","termSource":"NCI"},{"termName":"MK 5684","termGroup":"CN","termSource":"NCI"},{"termName":"MK-5684","termGroup":"CN","termSource":"NCI"},{"termName":"MK5684","termGroup":"CN","termSource":"NCI"},{"termName":"ODM 208","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-208","termGroup":"CN","termSource":"NCI"},{"termName":"ODM208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231294-96-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z7MAV4KQC"},{"name":"Maps_To","value":"CYP11A1 inhibitor ODM-208"},{"name":"NCI_Drug_Dictionary_ID","value":"795704"},{"name":"NCI_META_CUI","value":"CL935891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795704"},{"name":"PDQ_Open_Trial_Search_ID","value":"795704"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102855":{"preferredName":"CYP17/CYP11B2 Inhibitor LAE001","code":"C102855","definitions":[{"definition":"An orally bioavailable, non-steroidal, potent, reversible, dual inhibitor of cytochrome P450 17 (CYP17 or CYP17A1) and CYP11B2, with potential antiandrogen and antineoplastic activities. Upon oral administration, LAE001 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. LAE001 also inhibits the enzymatic activity of CYP11B2, thereby inhibiting aldosterone production. This may reduce the elevated aldosterone levels resulting from CYP17 inhibition and androgen deprivation, leading to a reduction in mineralocorticoid side effects including cardiovascular complications. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones. The cytochrome P450 enzyme CYP11B2, aldosterone synthase, is an enzyme that plays a key role in aldosterone biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP17/CYP11B2 Inhibitor LAE001","termGroup":"PT","termSource":"NCI"},{"termName":"CFG 920","termGroup":"CN","termSource":"NCI"},{"termName":"CFG-920","termGroup":"CN","termSource":"NCI"},{"termName":"CFG920","termGroup":"CN","termSource":"NCI"},{"termName":"LAE 001","termGroup":"CN","termSource":"NCI"},{"termName":"LAE-001","termGroup":"CN","termSource":"NCI"},{"termName":"LAE001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260006-20-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UP0K5026VB"},{"name":"Maps_To","value":"CYP17 Inhibitor CFG920"},{"name":"Maps_To","value":"CYP17/CYP11B2 Inhibitor LAE001"},{"name":"NCI_Drug_Dictionary_ID","value":"737730"},{"name":"NCI_META_CUI","value":"CL437136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737730"},{"name":"PDQ_Open_Trial_Search_ID","value":"737730"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120310":{"preferredName":"CYP17 Lyase Inhibitor ASN001","code":"C120310","definitions":[{"definition":"An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, CYP17 lyase inhibitor ASN001 selectively binds to and inhibits the lyase activity of CYP17A1 in both the testes and adrenal glands, resulting in a significant reduction in androgen production to castrate-range levels. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The selective inhibition of CYP17A1 lyase activity by ASN001 prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP17 Lyase Inhibitor ASN001","termGroup":"PT","termSource":"NCI"},{"termName":"ASN001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429329-63-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J03L4XRQ2R"},{"name":"Maps_To","value":"CYP17 Lyase Inhibitor ASN001"},{"name":"NCI_Drug_Dictionary_ID","value":"768724"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768724"},{"name":"PDQ_Open_Trial_Search_ID","value":"768724"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896913"}]}}{"C120304":{"preferredName":"CYP17/Androgen Receptor Inhibitor ODM 204","code":"C120304","definitions":[{"definition":"An orally available inhibitor of both the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17) and androgen receptor (AR), with potential anti-androgen and antineoplastic activities. Upon oral administration, CYP17/AR inhibitor ODM 204 selectively inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. In addition, ODM 204 binds to ARs in target tissues and inhibits androgen-induced receptor activation and AR nuclear translocation, which prevents the binding to and transcription of AR-responsive genes. This leads to an inhibition of growth in AR-expressing prostate cancer cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP17/Androgen Receptor Inhibitor ODM 204","termGroup":"PT","termSource":"NCI"},{"termName":"ODM 204","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-204","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CYP17/Androgen Receptor Inhibitor ODM 204"},{"name":"NCI_Drug_Dictionary_ID","value":"768588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768588"},{"name":"PDQ_Open_Trial_Search_ID","value":"768588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896798"}]}}{"C407":{"preferredName":"Cyproterone","code":"C407","definitions":[{"definition":"A synthetic steroidal anti-androgen with antineoplastic activity. Cyproterone, in its acetate form, binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation and inhibiting the growth of testosterone-sensitive tumor cells.  This agent also exerts progesterogenic activity, resulting in a reduction in testicular androgen secretion and total androgen blockade. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyproterone","termGroup":"PT","termSource":"NCI"},{"termName":"Med Cyproterone","termGroup":"BR","termSource":"NCI"},{"termName":"SH-881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098-66-0"},{"name":"CHEBI_ID","value":"CHEBI:50742"},{"name":"Chemical_Formula","value":"C22H27ClO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E61Q31EK2F"},{"name":"Legacy Concept Name","value":"Cyproterone"},{"name":"Maps_To","value":"Cyproterone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010621"}]}}{"C1059":{"preferredName":"Cyproterone Acetate","code":"C1059","definitions":[{"definition":"A synthetic hormone being studied for treatment of hot flashes in men with prostate cancer who have had both testicles removed by surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cyproterone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(Acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-","termGroup":"SN","termSource":"NCI"},{"termName":"6-Chloro-1b,2b-dihydro-17a-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Andro-Diane","termGroup":"FB","termSource":"NCI"},{"termName":"Androcur","termGroup":"FB","termSource":"NCI"},{"termName":"Chloro-6-hydroxy-17 Alpha Methylene-1 Alpha, 2 Alpha Pregnadiene-4,6 Dione-3, 20 Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"CyPat","termGroup":"AB","termSource":"NCI"},{"termName":"Cyprone","termGroup":"FB","termSource":"NCI"},{"termName":"Cyprostat","termGroup":"FB","termSource":"NCI"},{"termName":"Cyproteronazetat","termGroup":"SY","termSource":"NCI"},{"termName":"Cyproteroni Acetas","termGroup":"SY","termSource":"NCI"},{"termName":"Diane","termGroup":"FB","termSource":"NCI"},{"termName":"Dianette","termGroup":"FB","termSource":"NCI"},{"termName":"SH-714","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"427-51-0"},{"name":"CHEBI_ID","value":"CHEBI:50743"},{"name":"Chemical_Formula","value":"C24H29ClO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4KM2BN5JHF"},{"name":"Legacy Concept Name","value":"Cyproterone_Acetate"},{"name":"Maps_To","value":"Cyproterone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"39203"},{"name":"NSC Number","value":"81430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39203"},{"name":"PDQ_Open_Trial_Search_ID","value":"39203"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0056855"}]}}{"C408":{"preferredName":"Cytarabine","code":"C408","definitions":[{"definition":"A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","termGroup":"SY","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosylcytosine","termGroup":"SN","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","termGroup":"SY","termSource":"NCI"},{"termName":"4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone","termGroup":"SN","termSource":"NCI"},{"termName":"Alexan","termGroup":"FB","termSource":"NCI"},{"termName":"Ara-C","termGroup":"AB","termSource":"NCI"},{"termName":"ARA-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Arabine","termGroup":"FB","termSource":"NCI"},{"termName":"Arabinofuranosylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Arabinosylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Aracytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Aracytin","termGroup":"FB","termSource":"NCI"},{"termName":"Aracytine","termGroup":"FB","termSource":"NCI"},{"termName":"Beta-cytosine Arabinoside","termGroup":"SY","termSource":"NCI"},{"termName":"CHX-3311","termGroup":"CN","termSource":"NCI"},{"termName":"Cytarabinum","termGroup":"SY","termSource":"NCI"},{"termName":"Cytarbel","termGroup":"FB","termSource":"NCI"},{"termName":"Cytosar","termGroup":"FB","termSource":"NCI"},{"termName":"Cytosar-U","termGroup":"AQS","termSource":"NCI"},{"termName":"Cytosine-beta-arabinoside","termGroup":"SY","termSource":"NCI"},{"termName":"Erpalfa","termGroup":"FB","termSource":"NCI"},{"termName":"Starasid","termGroup":"FB","termSource":"NCI"},{"termName":"Tarabine PFS","termGroup":"SY","termSource":"NCI"},{"termName":"U 19920","termGroup":"CN","termSource":"NCI"},{"termName":"U-19920","termGroup":"CN","termSource":"NCI"},{"termName":"Udicil","termGroup":"FB","termSource":"NCI"},{"termName":"WR-28453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute Nonlymphocytic leukemia; Bone marrow transplantation; Carcinomatous meningitis; Chronic myelogenous leukemia; Hogkins disease;"},{"name":"Accepted_Therapeutic_Use_For","value":"Meningeal leukemia; Acute Myeloid Leukemia; Meningitis lymphomatous; Myelodysplasic syndrome; Non-Hodgkins lymphoma; Ovarian cancer, intraperitoneal treatment; Retinoblastoma"},{"name":"CAS_Registry","value":"147-94-4"},{"name":"CHEBI_ID","value":"CHEBI:28680"},{"name":"Chemical_Formula","value":"C9H13N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"04079A1RDZ"},{"name":"Legacy Concept Name","value":"Cytosine_Arabinoside"},{"name":"Maps_To","value":"Cytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"39015"},{"name":"NSC Number","value":"287459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39015"},{"name":"PDQ_Open_Trial_Search_ID","value":"39015"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010711"}]}}{"C128888":{"preferredName":"Cytarabine Monophosphate Prodrug MB07133","code":"C128888","definitions":[{"definition":"A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytarabine Monophosphate Prodrug MB07133","termGroup":"PT","termSource":"NCI"},{"termName":"(2R,4S)-4-amino-1-[5-O-[2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl]-beta-d-arabinofuranosyl]-2(1H)-pyrimidinone","termGroup":"SN","termSource":"NCI"},{"termName":"Cytarabine Prodrug MB07133","termGroup":"SY","termSource":"NCI"},{"termName":"MB07133","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytarabine Monophosphate Prodrug MB07133"},{"name":"NCI_Drug_Dictionary_ID","value":"352009"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352009"},{"name":"PDQ_Open_Trial_Search_ID","value":"352009"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328712"}]}}{"C153327":{"preferredName":"Aspacytarabine","code":"C153327","definitions":[{"definition":"A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aspacytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"Ara-C Asparagine Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Asparagine Ara-C Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Asparagine Cytarabine Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Astarabine","termGroup":"SY","termSource":"NCI"},{"termName":"BST 236","termGroup":"CN","termSource":"NCI"},{"termName":"BST-236","termGroup":"CN","termSource":"NCI"},{"termName":"BST236","termGroup":"CN","termSource":"NCI"},{"termName":"Cytarabine Asparagine Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098942-53-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JL7V54Z2BR"},{"name":"Maps_To","value":"Aspacytarabine"},{"name":"Maps_To","value":"Cytarabine-asparagine Prodrug BST-236"},{"name":"NCI_Drug_Dictionary_ID","value":"795601"},{"name":"NCI_META_CUI","value":"CL554435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795601"},{"name":"PDQ_Open_Trial_Search_ID","value":"795601"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113444":{"preferredName":"Roducitabine","code":"C113444","definitions":[{"definition":"An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, tRoducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roducitabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl)pyrimidin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"Cytidine Analog RX-3117","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorocyclopentenylcytosine","termGroup":"SY","termSource":"NCI"},{"termName":"RX-3117","termGroup":"CN","termSource":"NCI"},{"termName":"TV-1360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"865838-26-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0Z4A82I0JO"},{"name":"Maps_To","value":"Cytidine Analog RX-3117"},{"name":"Maps_To","value":"Roducitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"756625"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756625"},{"name":"PDQ_Open_Trial_Search_ID","value":"756625"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3834251"}]}}{"C28950":{"preferredName":"Cytochlor","code":"C28950","definitions":[{"definition":"A radio-sensitizing pyrimidine nucleoside with potential antineoplastic activity.  Cytochlor is metabolized first to a phosphate derivative, CldCMP, by the enzyme deoxycytidine kinase and then to the active uracyl derivative, CldUMP, by the enzyme dCMP deaminase; deoxycytidine kinase and dCMP deaminase have been found in abnormally high concentrations in most cancers. CldUMP, the active metabolite, incorporates into DNA and, upon exposure to radiation, induces the formation of uracil radicals and double-strand DNA breaks. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of radiosensitizer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Cytochlor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"32387-56-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J14D49ZN55"},{"name":"Legacy Concept Name","value":"Cytochlor"},{"name":"Maps_To","value":"Cytochlor"},{"name":"NCI_Drug_Dictionary_ID","value":"353478"},{"name":"NSC Number","value":"371331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"353478"},{"name":"PDQ_Open_Trial_Search_ID","value":"353478"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328172"}]}}{"C53396":{"preferredName":"Cytokine-based Biologic Agent IRX-2","code":"C53396","definitions":[{"definition":"A cell-free mixture comprised of a variety of naturally-derived cytokines obtained from normal, unrelated donor lymphocytes with potential immunostimulatory activity. The cytokines in IRX-2, including interleukin (IL)-1, -2, -6, -8, -10, -12, tumor necrosis factor alpha (TNF-a), interferon-gamma (IFN-g) and colony stimulating factors (CSFs), play vital roles in regulating cellular immunity and may synergistically stimulate a cellular immune response against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytokine-based Biologic Agent IRX-2","termGroup":"PT","termSource":"NCI"},{"termName":"IRX-2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"951209-71-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZDR4QSJ43F"},{"name":"Legacy Concept Name","value":"IRX-2"},{"name":"Maps_To","value":"Cytokine-based Biologic Agent IRX-2"},{"name":"NCI_Drug_Dictionary_ID","value":"462160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462160"},{"name":"PDQ_Open_Trial_Search_ID","value":"462160"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0758290"}]}}{"C69140":{"preferredName":"D-methionine Formulation MRX-1024","code":"C69140","definitions":[{"definition":"A proprietary oral formulation of D-methionine with antioxidant and antimucositis activities. D-methionine formulation MRX-1024 may selectively protect the oral mucosa from the toxic effects of chemotherapy and radiation therapy without compromising antitumor activity. D-methionine may be converted into the L- isomer in vivo, particularly in instances of L-methionine deprivation; both isomers have antioxidant activity which may be due, in part, to their sulfur moieties and chelating properties. L-methionine, an essential amino acid, also may help to maintain the ratio of reduced glutathione to oxidized glutathione in cells undergoing oxidative stress and may provide a source of L-cysteine for glutathione synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"D-methionine Formulation MRX-1024","termGroup":"PT","termSource":"NCI"},{"termName":"MRX-1024","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"348-67-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"868496F25R"},{"name":"Legacy Concept Name","value":"D-methionine_Formulation_MRX-1024"},{"name":"Maps_To","value":"D-methionine Formulation MRX-1024"},{"name":"NCI_Drug_Dictionary_ID","value":"540244"},{"name":"NCI_META_CUI","value":"CL371849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"540244"},{"name":"PDQ_Open_Trial_Search_ID","value":"540244"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2383":{"preferredName":"DAB389 Epidermal Growth Factor","code":"C2383","definitions":[{"definition":"A recombinant fusion protein composed of the diphtheria toxin with the receptor-binding domain replaced by human epidermal growth factor (EGF).  When administered, EGF binds to the endothelial cell growth factor receptor, EGFR, which is upregulated in many solid tumors.  After binding to the EGF receptor, the agent is internalized by the cell, where the diphtheria toxin moiety exerts its cytotoxic effect, inhibiting protein synthesis through ADP-ribosylation of elongation factor 2. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DAB389 Epidermal Growth Factor","termGroup":"PT","termSource":"NCI"},{"termName":"DAB389 EGF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DAB389_Epidermal_Growth_Factor"},{"name":"Maps_To","value":"DAB389 Epidermal Growth Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"42032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42032"},{"name":"PDQ_Open_Trial_Search_ID","value":"42032"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281573"}]}}{"C82386":{"preferredName":"Dabrafenib","code":"C82386","definitions":[{"definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dabrafenib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-","termGroup":"SN","termSource":"NCI"},{"termName":"BRAF Inhibitor GSK2118436","termGroup":"SY","termSource":"NCI"},{"termName":"GSK 2118436","termGroup":"CN","termSource":"NCI"},{"termName":"GSK 2118436A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-2118436","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-2118436A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2118436","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2118436A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation"},{"name":"CAS_Registry","value":"1195765-45-7"},{"name":"Chemical_Formula","value":"C23H20F3N5O2S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"QGP4HA4G1B"},{"name":"Legacy Concept Name","value":"BRAF_Inhibitor_GSK2118436"},{"name":"Maps_To","value":"Dabrafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"641977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641977"},{"name":"PDQ_Open_Trial_Search_ID","value":"641977"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467876"}]}}{"C128059":{"preferredName":"Dabrafenib Mesylate","code":"C128059","definitions":[{"definition":"The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dabrafenib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Dabrafenib Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2118436 Methane Sulfonate Salt","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2118436B","termGroup":"CN","termSource":"NCI"},{"termName":"Tafinlar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation"},{"name":"CAS_Registry","value":"1195768-06-9"},{"name":"Contributing_Source","value":"CTEP"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6DC89I63E"},{"name":"Maps_To","value":"Dabrafenib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"641977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641977"},{"name":"PDQ_Open_Trial_Search_ID","value":"641977"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3644554"}]}}{"C411":{"preferredName":"Dacarbazine","code":"C411","definitions":[{"definition":"A drug that is used to treat Hodgkin lymphoma and malignant melanoma and is being studied in the treatment of other types of cancer. It attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dacarbazine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"5-(3-3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"5-(dimethyltriazeno)imidazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Asercit","termGroup":"FB","termSource":"NCI"},{"termName":"Biocarbazine","termGroup":"SY","termSource":"NCI"},{"termName":"Dacarbazina","termGroup":"SY","termSource":"NCI"},{"termName":"Dacarbazina Almirall","termGroup":"SY","termSource":"NCI"},{"termName":"Dacarbazine - DTIC","termGroup":"SY","termSource":"NCI"},{"termName":"Dacatic","termGroup":"FB","termSource":"NCI"},{"termName":"Dakarbazin","termGroup":"SY","termSource":"NCI"},{"termName":"Deticene","termGroup":"FB","termSource":"NCI"},{"termName":"Detimedac","termGroup":"FB","termSource":"NCI"},{"termName":"DIC","termGroup":"AB","termSource":"NCI"},{"termName":"Dimethyl (triazeno) imidazolecarboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyl Triazeno Imidazol Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyl Triazeno Imidazole Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"dimethyl-triazeno-imidazole carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyl-triazeno-imidazole-carboximide","termGroup":"SY","termSource":"NCI"},{"termName":"DTIC","termGroup":"AB","termSource":"NCI"},{"termName":"DTIC-Dome","termGroup":"AQS","termSource":"NCI"},{"termName":"Fauldetic","termGroup":"FB","termSource":"NCI"},{"termName":"Imidazole Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Imidazole Carboxamide Dimethyltriazeno","termGroup":"SY","termSource":"NCI"},{"termName":"WR-139007","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Carcinoid cancer; Hodgkins disease; Islet cell carcinoma; Melanoma; Neuroblastoma; Soft tissue sarcoma"},{"name":"CAS_Registry","value":"4342-03-4"},{"name":"CHEBI_ID","value":"CHEBI:4305"},{"name":"Chemical_Formula","value":"C6H10N6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7GR28W0FJI"},{"name":"Legacy Concept Name","value":"Dacarbazine"},{"name":"Maps_To","value":"Dacarbazine"},{"name":"NCI_Drug_Dictionary_ID","value":"39768"},{"name":"NSC Number","value":"45388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39768"},{"name":"PDQ_Open_Trial_Search_ID","value":"39768"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010927"}]}}{"C62179":{"preferredName":"Dacetuzumab","code":"C62179","definitions":[{"definition":"A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that binds to cells that have the CD40 antigen on their surface, including cells from multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. SGN-40 is being studied in the treatment of cancer. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dacetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-huCD40 mAb","termGroup":"SY","termSource":"NCI"},{"termName":"huS2C6","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody SGN-40","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"880486-59-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UT59FF4T5X"},{"name":"Legacy Concept Name","value":"SGN-40"},{"name":"Maps_To","value":"Dacetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"365545"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365545"},{"name":"PDQ_Open_Trial_Search_ID","value":"365545"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742509"}]}}{"C64784":{"preferredName":"DACH Polymer Platinate AP5346","code":"C64784","definitions":[{"definition":"A low molecular weight polymer-conjugated platinum complex with potential antineoplastic activity. This polymer drug delivery system consists of cytotoxic diaminocyclohexane (DACH)-platinum (Pt) coupled to a water-soluble biocompatible hydroxypropylmethacrylamide (HPMA) copolymer via a pH sensitive linker. Due to decreased pH at the tumor site, the linker is cleaved and the chelated active moiety DACH-Pt is released in tumor cells. DACH-Pt alkylates macromolecules and causes both inter- and intra-strand platinum-DNA crosslinks, which impede DNA replication and transcription, thereby resulting in cell-cycle independent cytotoxicity. The HPMA-based drug delivery system enhances the concentration of DACH-Pt at the tumor site and prolongs the half life of the agent, thereby increasing exposure and efficacy at the target tumor sites while minimizing side effects in normal tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of head and neck cancer. It may kill cancer cells by carrying an anticancer drug into the tumor. It is a type of platinum compound.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DACH Polymer Platinate AP5346","termGroup":"PT","termSource":"NCI"},{"termName":"AP5346","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DACH_Polymer_Platinate_AP5346"},{"name":"Maps_To","value":"DACH Polymer Platinate AP5346"},{"name":"NCI_Drug_Dictionary_ID","value":"526175"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526175"},{"name":"PDQ_Open_Trial_Search_ID","value":"526175"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723251"}]}}{"C113175":{"preferredName":"DACH-Platin Micelle NC-4016","code":"C113175","definitions":[{"definition":"Polymeric micellar nanoparticles containing diaminocyclohexane platinum (DACH-platin or DACH-Pt) with potential antineoplastic activity. DACH-platin micelle NC-4016 is prepared through the formation of a polymer-metal complex between DACH-platin and the polyethylene glycol-poly (glutamic acid) block copolymer, PEG-P(Glu). DACH-platin, an active metabolite of the platinum-based antineoplastic agent oxaliplatin, is highly hydrophobic and toxic when administered systemically. The use of polymeric micelles incorporating DACH-platin may both increase cell permeability and enhance the retention of the agent. This allows an extended half-life in the blood circulation and a selective and high accumulation of DACH-platin at tumor sites. This results in increased anticancer efficacy while reducing side effects due to DACH-platin toxicity. Upon intravenous administration and internalization by tumor cells, DACH-platin binds to and causes both inter- and intra-strand cross-links in DNA, forming platinum adducts and triggering tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DACH-Platin Micelle NC-4016","termGroup":"PT","termSource":"NCI"},{"termName":"Dach-Platin Micelle NC-4016","termGroup":"SY","termSource":"NCI"},{"termName":"DACH-Pt/m NC-4016","termGroup":"SY","termSource":"NCI"},{"termName":"Diaminocyclohexane Platinum Micelle NC-4016","termGroup":"SY","termSource":"NCI"},{"termName":"NC-4016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DACH-Platin Micelle NC-4016"},{"name":"NCI_Drug_Dictionary_ID","value":"755556"},{"name":"NCI_META_CUI","value":"CL455246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755556"},{"name":"PDQ_Open_Trial_Search_ID","value":"755556"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1569":{"preferredName":"Daclizumab","code":"C1569","definitions":[{"definition":"A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daclizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Tac","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Tac Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Tac Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Dacliximab","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-Tac Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-Tac","termGroup":"SY","termSource":"NCI"},{"termName":"Zenapax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Kidney transplant rejection, prevention"},{"name":"CAS_Registry","value":"152923-56-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CUJ2MVI71Y"},{"name":"Legacy Concept Name","value":"Daclizumab"},{"name":"Maps_To","value":"Daclizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42006"},{"name":"NSC Number","value":"725173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42006"},{"name":"PDQ_Open_Trial_Search_ID","value":"42006"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0663182"}]}}{"C53398":{"preferredName":"Dacomitinib","code":"C53398","definitions":[{"definition":"A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dacomitinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide","termGroup":"SN","termSource":"NCI"},{"termName":"EGFR Inhibitor PF-00299804","termGroup":"SY","termSource":"NCI"},{"termName":"PF 00299804","termGroup":"CN","termSource":"NCI"},{"termName":"PF-00299804","termGroup":"CN","termSource":"NCI"},{"termName":"PF-00299804-03","termGroup":"CN","termSource":"NCI"},{"termName":"PF-299804","termGroup":"CN","termSource":"NCI"},{"termName":"PF00299804","termGroup":"CN","termSource":"NCI"},{"termName":"Vizimpro","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations"},{"name":"CAS_Registry","value":"1042385-75-0"},{"name":"Chemical_Formula","value":"C24H25ClFN5O2.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5092U85G58"},{"name":"Legacy Concept Name","value":"PF-00299804"},{"name":"Maps_To","value":"Dacomitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"462567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462567"},{"name":"PDQ_Open_Trial_Search_ID","value":"462567"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709400"}]}}{"C28955":{"preferredName":"Carboxyphthalato-1,2-diaminocyclohexaneplatinum","code":"C28955","definitions":[{"definition":"A second-generation platinum analog with potential antineoplastic activity.  Carboxyphthalato-1,2-diaminocyclohexaneplatinum alkylates DNA at the N-7 position of guanine, thereby producing DNA interstrand crosslinks and DNA strand breaks, and inhibiting DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carboxyphthalato-1,2-diaminocyclohexaneplatinum","termGroup":"PT","termSource":"NCI"},{"termName":"(4-carboxyphthalato)(1,2-diaminocyclohexane)-platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"(SP-4-3)-Hydrogen (1,2,4-benzenetricarboxylato(3-)-O(1),O(2))(1,2-cyclohexanediamine-N,N') platinate(1-)","termGroup":"SY","termSource":"NCI"},{"termName":"DAC Platinum","termGroup":"SY","termSource":"NCI"},{"termName":"DACCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65296-81-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"918CG3EO0F"},{"name":"Legacy Concept Name","value":"Dacplatinum"},{"name":"Maps_To","value":"Dacplatinum"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054768"}]}}{"C412":{"preferredName":"Dactinomycin","code":"C412","definitions":[{"definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dactinomycin","termGroup":"PT","termSource":"NCI"},{"termName":"2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3","termGroup":"SN","termSource":"NCI"},{"termName":"Actinomycin A IV","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin C1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin D","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin I1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin IV","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin X 1","termGroup":"SY","termSource":"NCI"},{"termName":"Actinomycin-[thr-val-pro-sar-meval]","termGroup":"SY","termSource":"NCI"},{"termName":"Cosmegen","termGroup":"BR","termSource":"NCI"},{"termName":"DACT","termGroup":"AB","termSource":"NCI"},{"termName":"Dactinomycine","termGroup":"SY","termSource":"NCI"},{"termName":"Lyovac Cosmegen","termGroup":"FB","termSource":"NCI"},{"termName":"Meractinomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Wilms' tumor; rhabdomyosarcoma; Ewing's sarcoma; testicular cancer; gestational trophoblastic neoplasia; choriocarcinoma; melanoma; neuroblastoma; retinoblastoma; uterine sarcomas; Kaposi's sarcoma; sarcoma botryoides; soft tissue sarcoma."},{"name":"CAS_Registry","value":"50-76-0"},{"name":"CHEBI_ID","value":"CHEBI:27666"},{"name":"Chemical_Formula","value":"C62H86N12O16"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"1CC1JFE158"},{"name":"Legacy Concept Name","value":"Dactinomycin"},{"name":"Maps_To","value":"Dactinomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39675"},{"name":"NSC Number","value":"3053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39675"},{"name":"PDQ_Open_Trial_Search_ID","value":"39675"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0010934"}]}}{"C74072":{"preferredName":"Dactolisib","code":"C74072","definitions":[{"definition":"An orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dactolisib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-","termGroup":"SN","termSource":"NCI"},{"termName":"BEZ235","termGroup":"CN","termSource":"NCI"},{"termName":"NVPBEZ235","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915019-65-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RUJ6Z9Y0DT"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_BEZ235"},{"name":"Maps_To","value":"Dactolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"589292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589292"},{"name":"PDQ_Open_Trial_Search_ID","value":"589292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2604817"}]}}{"C162346":{"preferredName":"Dactolisib Tosylate","code":"C162346","definitions":[{"definition":"The tosylate salt form of dactolisib, an orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Upon administration, dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dactolisib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile 4-Methylbenzenesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-, 4-Methylbenzenesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"NVP-BEZ235-ANA","termGroup":"SY","termSource":"NCI"},{"termName":"NVP-BEZ235-NX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1028385-32-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U54GT9151S"},{"name":"Maps_To","value":"Dactolisib Tosylate"},{"name":"NCI_META_CUI","value":"CL970853"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88296":{"preferredName":"Dalantercept","code":"C88296","definitions":[{"definition":"A soluble fusion protein containing the extracellular domain of activin receptor-like kinase-1 (ALK1) fused to a human Fc domain (ALK1-Fc fusion protein), with potential antiangiogenic and antineoplastic activities. Upon administration, dalantercept binds to various ALK1 ligands, preventing activation of tumor cell ALK1 receptors and so inhibiting the ALK1 signaling pathway; growth factor-induced angiogenesis is thus inhibited, which may result in the inhibition of tumor cell proliferation and tumor cell death. ALK1 is a type I cell surface receptor with serine/threonine kinase activity that mediates signaling by members of the transforming growth factor-beta (TGFbeta) superfamily and plays a key role in angiogenesis; ligands for this receptor include TGFbeta1 and TGFbeta2. The Fc moiety of this fusion protein mediates clearance of ligand-fusion protein complexes by the reticuloendothelial system (RES).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dalantercept","termGroup":"PT","termSource":"NCI"},{"termName":"ACE-041","termGroup":"CN","termSource":"NCI"},{"termName":"Activin Receptor-like Kinase 1 Inhibitor ACE-041","termGroup":"SY","termSource":"NCI"},{"termName":"ALK1-Fc Fusion Protein ACE-041","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1186210-24-1"},{"name":"Chemical_Formula","value":"C3206H4960N904O976S38"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EGC16R10V0"},{"name":"Maps_To","value":"Dalantercept"},{"name":"NCI_Drug_Dictionary_ID","value":"658276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658276"},{"name":"PDQ_Open_Trial_Search_ID","value":"658276"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537264"}]}}{"C74011":{"preferredName":"Dalotuzumab","code":"C74011","definitions":[{"definition":"A recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Dalotuzumab binds to membrane-bound IGF1R, preventing binding of the ligand IGF1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of many types of cancer. MK-0646 binds to a protein called insulin-like growth factor receptor (IGFR) on the surface of cells. This may prevent the cells from growing when IGF is present. It may also kill cancer cells. MK-0646 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dalotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody MK-0646","termGroup":"SY","termSource":"NCI"},{"termName":"MK-0646","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005389-60-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YI1L648RH"},{"name":"Legacy Concept Name","value":"Anti-IGF1R_Recombinant_Monoclonal_Antibody_MK-0646"},{"name":"Maps_To","value":"Dalotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"489297"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489297"},{"name":"PDQ_Open_Trial_Search_ID","value":"489297"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987605"}]}}{"C66984":{"preferredName":"Daniquidone","code":"C66984","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may kill cancer cells by causing damage to the DNA. Batracylin is a type of heterocyclic aryl amine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A water-insoluble heterocyclic amide with potential antineoplastic activity. Daniquidone inhibits topoisomerases I and II, thereby inhibiting DNA replication and repair, and RNA and protein synthesis. The acetylated form of daniquidone is highly toxic and is capable of inducing unscheduled DNA synthesis; rapid acetylators are more likely to experience toxicity with this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daniquidone","termGroup":"PT","termSource":"NCI"},{"termName":"8-Aminoisoindolo(1,2-b)quinazolin-12(10H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"Batracylin","termGroup":"SY","termSource":"NCI"},{"termName":"Bay H 2049","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67199-66-0"},{"name":"Chemical_Formula","value":"C15H11N3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E780TX33D2"},{"name":"Legacy Concept Name","value":"Daniquidone"},{"name":"Maps_To","value":"Daniquidone"},{"name":"NCI_Drug_Dictionary_ID","value":"539029"},{"name":"NSC Number","value":"320846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539029"},{"name":"PDQ_Open_Trial_Search_ID","value":"539029"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053006"}]}}{"C61587":{"preferredName":"Danusertib","code":"C61587","definitions":[{"definition":"A small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed. This agent may preferentially bind to and inhibit Aurora B kinase. Aurora kinases, a family of serine-threonine kinases, are important regulators of cellular proliferation and division.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of chronic myelogenous leukemia. PHA-739358 may stop tumor growth by blocking certain enzymes needed for cancer cells to divide and causing them to die. It is a type of kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Danusertib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)- methoxyphenylacetyl)pyrrolo(3,4-c)pyrazol-3-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"PHA-739358","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"827318-97-8"},{"name":"Chemical_Formula","value":"C26H30N6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M3X659D0FY"},{"name":"Legacy Concept Name","value":"PHA-739358"},{"name":"Maps_To","value":"Danusertib"},{"name":"NCI_Drug_Dictionary_ID","value":"489092"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489092"},{"name":"PDQ_Open_Trial_Search_ID","value":"489092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700603"}]}}{"C101368":{"preferredName":"Danvatirsen","code":"C101368","definitions":[{"definition":"An antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3) with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. STAT3, a protein overexpressed in a variety of human cancers, plays a critical role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Danvatirsen","termGroup":"PT","termSource":"NCI"},{"termName":"AZD9150","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS 481464","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-STAT3rx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402357-06-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31N550RD05"},{"name":"Maps_To","value":"Danvatirsen"},{"name":"NCI_Drug_Dictionary_ID","value":"729992"},{"name":"NCI_META_CUI","value":"CL435548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729992"},{"name":"PDQ_Open_Trial_Search_ID","value":"729992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67043":{"preferredName":"Daporinad","code":"C67043","definitions":[{"definition":"A small molecule with potential antineoplastic and antiangiogenic activities. Daporinad binds to and inhibits nicotinamide phosphoribosyltransferase (NMPRTase), inhibiting the biosynthesis of nicotinamide adenine dinucleotide (NAD+) from niacinamide (vitamin B3), which may deplete energy reserves in metabolically active tumor cells and induce tumor cell apoptosis. In addition, this agent may inhibit tumor cell production of vascular endothelial growth factor (VEGF), resulting in the inhibition of tumor angiogenesis. The coenzyme NAD+ plays an essential role in cellular redox reactions, including the redox reaction linking the citric acid cycle and oxidative phosphorylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daporinad","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-(1-Benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"APO866","termGroup":"AB","termSource":"NCI"},{"termName":"FK-866","termGroup":"CN","termSource":"NCI"},{"termName":"K 22.175","termGroup":"CN","termSource":"NCI"},{"termName":"NMPRTase Inhibitor APO866","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"658084-64-1"},{"name":"Chemical_Formula","value":"C24H29N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V71TF6V9M7"},{"name":"Legacy Concept Name","value":"APO866"},{"name":"Maps_To","value":"Daporinad"},{"name":"NCI_Drug_Dictionary_ID","value":"537396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537396"},{"name":"PDQ_Open_Trial_Search_ID","value":"537396"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879518"}]}}{"C74007":{"preferredName":"Daratumumab","code":"C74007","definitions":[{"definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daratumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Daratumumab Biosimilar HLX15","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab-fihj","termGroup":"SY","termSource":"NCI"},{"termName":"Darzalex","termGroup":"BR","termSource":"NCI"},{"termName":"HLX15","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-CD38","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 54767414","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-54767414","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ54767414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma"},{"name":"CAS_Registry","value":"945721-28-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4Z63YK6E0E"},{"name":"Legacy Concept Name","value":"Anti-CD38_Monoclonal_Antibody"},{"name":"Maps_To","value":"Daratumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"583564"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583564"},{"name":"PDQ_Open_Trial_Search_ID","value":"583564"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346802"}]}}{"C156401":{"preferredName":"Daratumumab and Recombinant Human Hyaluronidase","code":"C156401","definitions":[{"definition":"A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daratumumab and Recombinant Human Hyaluronidase","termGroup":"PT","termSource":"NCI"},{"termName":"DARA Co-formulated with rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"DARA/rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab + rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab and Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab and Hyaluronidase-fihj","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab and Vorhyaluronidase Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab with rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab-rHuPH20","termGroup":"CN","termSource":"NCI"},{"termName":"Daratumumab/Hyaluronidase-fihj","termGroup":"SY","termSource":"NCI"},{"termName":"Daratumumab/rHuPH20 Co-formulation","termGroup":"SY","termSource":"NCI"},{"termName":"Darzalex Faspro","termGroup":"BR","termSource":"NCI"},{"termName":"Darzalex/rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Darzquro","termGroup":"FB","termSource":"NCI"},{"termName":"HuMax-CD38-rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Hyaluronidase Mixed with Daratumumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with newly diagnosed or relapsed/refractory multiple myeloma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Daratumumab and Hyaluronidase-fihj"},{"name":"Maps_To","value":"Daratumumab/rHuPH20"},{"name":"NCI_Drug_Dictionary_ID","value":"795698"},{"name":"NCI_META_CUI","value":"CL563089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795698"},{"name":"PDQ_Open_Trial_Search_ID","value":"795698"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61490":{"preferredName":"Darinaparsin","code":"C61490","definitions":[{"definition":"A small-molecule organic arsenical with potential antineoplastic activity. Although the exact mechanism of action is unclear, darinaparsin, a highly toxic metabolic intermediate of inorganic arsenicals (iAs) that occurs in vivo, appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low. The arsenic compounds generated from darinaparsin disrupt mitochondrial bioenergetics, producing reactive oxygen species (ROS) and inducing ROS-mediated tumor cell apoptosis; in addition, this agent or its byproducts may initiate cell death by interrupting the G2/M phase of the cell cycle and may exhibit antiangiogenic effects. Compared to inorganic arsenic compounds such as arsenic trioxide (As2O3), darinaparsin appears to exhibit a wide therapeutic window.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darinaparsin","termGroup":"PT","termSource":"NCI"},{"termName":"Darvias","termGroup":"FB","termSource":"NCI"},{"termName":"DMAIII(SG)","termGroup":"AB","termSource":"NCI"},{"termName":"S-Dimethylarsino-Glutathione","termGroup":"SY","termSource":"NCI"},{"termName":"SP 02L","termGroup":"CN","termSource":"NCI"},{"termName":"SP-02L","termGroup":"CN","termSource":"NCI"},{"termName":"SP02L","termGroup":"CN","termSource":"NCI"},{"termName":"ZIO 101","termGroup":"CN","termSource":"NCI"},{"termName":"ZIO-101","termGroup":"CN","termSource":"NCI"},{"termName":"ZIO101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69819-86-9"},{"name":"Chemical_Formula","value":"C12H22AsN3O6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9XX54M675G"},{"name":"Legacy Concept Name","value":"S-Dimethylarsino-Glutathione"},{"name":"Maps_To","value":"Darinaparsin"},{"name":"NCI_Drug_Dictionary_ID","value":"486305"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486305"},{"name":"PDQ_Open_Trial_Search_ID","value":"486305"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872686"}]}}{"C90546":{"preferredName":"Darleukin","code":"C90546","definitions":[{"definition":"An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. The L19 moiety of L19-IL2 monoclonal antibody-cytokine fusion protein binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 moiety may locally activate natural killer (NK) cells and macrophages, and may induce T cell cytotoxic immune responses against ED-B fibronectin-expressing tumor cells. This may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darleukin","termGroup":"PT","termSource":"NCI"},{"termName":"L19-IL2","termGroup":"AB","termSource":"NCI"},{"termName":"L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2OQ3OPV2F8"},{"name":"Maps_To","value":"Darleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"665656"},{"name":"NCI_META_CUI","value":"CL416230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665656"},{"name":"PDQ_Open_Trial_Search_ID","value":"665656"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104748":{"preferredName":"Darolutamide","code":"C104748","definitions":[{"definition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darolutamide","termGroup":"PT","termSource":"NCI"},{"termName":"Antiandrogen ODM-201","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 1841788","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1841788","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1841788","termGroup":"CN","termSource":"NCI"},{"termName":"Nubeqa","termGroup":"BR","termSource":"NCI"},{"termName":"ODM 201","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-201","termGroup":"CN","termSource":"NCI"},{"termName":"ODM201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-metastatic castration-resistant prostate cancer"},{"name":"CAS_Registry","value":"1297538-32-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"X05U0N2RCO"},{"name":"Maps_To","value":"Darolutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"746231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746231"},{"name":"PDQ_Open_Trial_Search_ID","value":"746231"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641866"}]}}{"C154627":{"preferredName":"Daromun","code":"C154627","definitions":[{"definition":"A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), and fibromun (L19-TNFalpha), an immunocytokine consisting of human tumor necrosis factor alpha (TNFalpha) fused to a human scFv antibody fragment directed against the ED-B of L19, with potential antineoplastic and immunostimulating activities. Upon administration, the L-19 moieties of each immunocytokine bind to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 and TNF-alpha moieties of darleukin and fibromun, respectively, may locally induce an immune response against ED-B fibronectin-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daromun","termGroup":"PT","termSource":"NCI"},{"termName":"Darleukin and Fibromun","termGroup":"SY","termSource":"NCI"},{"termName":"Darleukin/Fibromun","termGroup":"SY","termSource":"NCI"},{"termName":"L19-IL2 and L19-TNF-alpha","termGroup":"SY","termSource":"NCI"},{"termName":"L19-IL2/L19-TNF-alpha","termGroup":"SY","termSource":"NCI"},{"termName":"L19IL2/L19TNF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Daromun"},{"name":"NCI_Drug_Dictionary_ID","value":"794649"},{"name":"NCI_META_CUI","value":"CL555512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794649"},{"name":"PDQ_Open_Trial_Search_ID","value":"794649"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38713":{"preferredName":"Dasatinib","code":"C38713","definitions":[{"definition":"A drug used to treat certain types of chronic myeloid leukemia and acute lymphoblastic leukemia. BMS-354825 is also being studied in the treatment of certain other blood diseases and types of cancer. BMS-354825 binds to and blocks BCR-ABL and other proteins that help cancer cells grow. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dasatinib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"BMS 354825","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-354825","termGroup":"CN","termSource":"NCI"},{"termName":"BMS354825","termGroup":"CN","termSource":"NCI"},{"termName":"Dasatinib Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Dasatinib Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Sprycel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"863127-77-9"},{"name":"Chemical_Formula","value":"C22H26ClN7O2S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RBZ1571X5H"},{"name":"Legacy Concept Name","value":"BMS-354825"},{"name":"Maps_To","value":"Dasatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"315885"},{"name":"NSC Number","value":"732517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"315885"},{"name":"PDQ_Open_Trial_Search_ID","value":"315885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1455147"}]}}{"C62091":{"preferredName":"Daunorubicin","code":"C62091","definitions":[{"definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat acute leukemias and some other types of cancer. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. It is a type of anthracycline antibiotic and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Daunorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-","termGroup":"SN","termSource":"NCI"},{"termName":"Daunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorrubicina","termGroup":"SY","termSource":"NCI"},{"termName":"DNR","termGroup":"AB","termSource":"NCI"},{"termName":"L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-","termGroup":"SN","termSource":"NCI"},{"termName":"Leukaemomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Rubidomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Rubomycin C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"20830-81-3"},{"name":"CHEBI_ID","value":"CHEBI:41977"},{"name":"Chemical_Formula","value":"C27H29NO10"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"ZS7284E0ZP"},{"name":"Legacy Concept Name","value":"Daunorubicin"},{"name":"Maps_To","value":"Daunorubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011015"}]}}{"C47471":{"preferredName":"Daunorubicin Citrate","code":"C47471","definitions":[{"definition":"A semi-synthetic anthracycline glycoside antibiotic obtained from Streptomyces with antineoplastic activity. Daunorubicin citrate intercalates DNA, which leads to inhibition of DNA and RNA synthesis, and consequently blocks cell division and results in apoptosis. This anti-tumor antibiotic is most active in the S phase of cell division. Daunorubicin is indicated in the treatment of a wide variety of cancers including acute non-lymphocytic leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor, and chronic myelocytic leukemia. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daunorubicin Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"371770-68-2"},{"name":"Chemical_Formula","value":"C27H29NO10.C6H8O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5L84T2Z6NP"},{"name":"Legacy Concept Name","value":"Daunorubicin_Citrate"},{"name":"Maps_To","value":"Daunorubicin Citrate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1289972"}]}}{"C1583":{"preferredName":"Daunorubicin Hydrochloride","code":"C1583","definitions":[{"definition":"A drug used to treat acute leukemias and some other types of cancer. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Cerubidine is a type of anthracycline antibiotic and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daunorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S-cis)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Cerubidin","termGroup":"FB","termSource":"NCI"},{"termName":"Cerubidine","termGroup":"BR","termSource":"NCI"},{"termName":"Cloridrato de Daunorubicina","termGroup":"SY","termSource":"NCI"},{"termName":"Daunoblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Daunoblastina","termGroup":"FB","termSource":"NCI"},{"termName":"Daunoblastine","termGroup":"SY","termSource":"NCI"},{"termName":"Daunomycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicini Hydrochloridum","termGroup":"SY","termSource":"NCI"},{"termName":"FI-6339","termGroup":"CN","termSource":"NCI"},{"termName":"L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-,hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Ondena","termGroup":"FB","termSource":"NCI"},{"termName":"RP-13057","termGroup":"CN","termSource":"NCI"},{"termName":"Rubidomycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Rubilem","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia"},{"name":"CAS_Registry","value":"23541-50-6"},{"name":"Chemical_Formula","value":"C27H29NO10.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UD984I04LZ"},{"name":"Legacy Concept Name","value":"Daunomycin"},{"name":"Maps_To","value":"Daunorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39779"},{"name":"NSC Number","value":"82151"},{"name":"NSC Number","value":"83142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39779"},{"name":"PDQ_Open_Trial_Search_ID","value":"39779"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282123"}]}}{"C170362":{"preferredName":"Rasdegafusp Alfa","code":"C170362","definitions":[{"definition":"A fusion protein consisting of a fully human monoclonal antibody directed against the endocytic dendritic cell (DC) receptor, DEC-205, linked to the tumor-associated antigen (TAA) NY-ESO-1 with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of rasdegafusp alfa1 binds to the endocytic DC receptor, which may result in DC endocytic internalization of this agent, specifically delivering the NY-ESO-1 moiety. DC processing of NY-ESO-1 may boost the immune system to mount a cytotoxic T-lymphocyte response (CTL) against cancer cells expressing NY-ESO-1. NY-ESO-1, a cell surface protein expressed in normal fetal and adult testes, is upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rasdegafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"CDX-1401","termGroup":"CN","termSource":"NCI"},{"termName":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1587257-96-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SU9AMV39DB"},{"name":"Maps_To","value":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401"},{"name":"NCI_Drug_Dictionary_ID","value":"651880"},{"name":"NCI_META_CUI","value":"CL1382603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651880"},{"name":"PDQ_Open_Trial_Search_ID","value":"651880"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C981":{"preferredName":"Decitabine","code":"C981","definitions":[{"definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that is used to treat myelodysplastic syndromes and is being studied in the treatment of other types of cancer. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Decitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-5-azacytidine","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-Aza-2'-deoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"5-Aza-2'-deoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Aza-2'deoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Aza-2-deoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Azadeoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"Dacogen","termGroup":"BR","termSource":"NCI"},{"termName":"Decitabine for Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxyazacytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Dezocitidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Myelodysplastic Syndrome"},{"name":"CAS_Registry","value":"2353-33-5"},{"name":"CHEBI_ID","value":"CHEBI:50131"},{"name":"Chemical_Formula","value":"C8H12N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"776B62CQ27"},{"name":"Legacy Concept Name","value":"Decitabine"},{"name":"Maps_To","value":"Decitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"39299"},{"name":"NSC Number","value":"127716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39299"},{"name":"PDQ_Open_Trial_Search_ID","value":"39299"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049065"}]}}{"C79809":{"preferredName":"Defactinib","code":"C79809","definitions":[{"definition":"An orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Defactinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"PF-04554878","termGroup":"CN","termSource":"NCI"},{"termName":"VS-6063","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1073154-85-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53O87HA2QU"},{"name":"Legacy Concept Name","value":"FAK_Inhibitor_PF-04554878"},{"name":"Maps_To","value":"Defactinib"},{"name":"NCI_Drug_Dictionary_ID","value":"746096"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746096"},{"name":"PDQ_Open_Trial_Search_ID","value":"746096"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703169"}]}}{"C128039":{"preferredName":"Defactinib Hydrochloride","code":"C128039","definitions":[{"definition":"The hydrochloride salt form of defactinib, an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Defactinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1073160-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L2S469LM49"},{"name":"Maps_To","value":"Defactinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"812840"},{"name":"NCI_META_CUI","value":"CL512846"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C416":{"preferredName":"Deferoxamine","code":"C416","definitions":[{"definition":"An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death. It is used in conjunction with other anticancer agents in pediatric neuroblastoma therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Deferoxamine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane","termGroup":"SN","termSource":"NCI"},{"termName":"Desferoxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"Desferrioxamine","termGroup":"SY","termSource":"NCI"},{"termName":"Desferrioxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"DFO-B","termGroup":"AB","termSource":"NCI"},{"termName":"N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxybutanediamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70-51-9"},{"name":"CHEBI_ID","value":"CHEBI:4356"},{"name":"Chemical_Formula","value":"C25H48N6O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"J06Y7MXW4D"},{"name":"Legacy Concept Name","value":"Deferoxamine"},{"name":"Maps_To","value":"Deferoxamine"},{"name":"NSC Number","value":"527604"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011145"}]}}{"C417":{"preferredName":"Deferoxamine Mesylate","code":"C417","definitions":[{"definition":"The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deferoxamine Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Deferoxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"Deferoxamine Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Deferrioxamine B","termGroup":"SY","termSource":"NCI"},{"termName":"Desferal","termGroup":"BR","termSource":"NCI"},{"termName":"Desferrioxamine Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"DFM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"138-14-7"},{"name":"CHEBI_ID","value":"CHEBI:31460"},{"name":"Chemical_Formula","value":"C25H48N6O8.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9TKO7EO6K"},{"name":"Legacy Concept Name","value":"Deferoxamine_Mesylate"},{"name":"Maps_To","value":"Deferoxamine Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"41696"},{"name":"NSC Number","value":"644468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41696"},{"name":"PDQ_Open_Trial_Search_ID","value":"41696"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011148"}]}}{"C48385":{"preferredName":"Degarelix","code":"C48385","definitions":[{"definition":"A drug that is used to treat advanced prostate cancer and is also being studied in the treatment of benign prostatic hyperplasia. Degarelix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This causes the body to stop making testosterone, which prostate cancer needs to grow. Degarelix is a type of GnRH antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Degarelix","termGroup":"PT","termSource":"NCI"},{"termName":"ASP 3550","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-3550","termGroup":"CN","termSource":"NCI"},{"termName":"ASP3550","termGroup":"CN","termSource":"NCI"},{"termName":"FE 200486","termGroup":"CN","termSource":"NCI"},{"termName":"FE-200486","termGroup":"CN","termSource":"NCI"},{"termName":"FE200486","termGroup":"CN","termSource":"NCI"},{"termName":"Firmagon","termGroup":"BR","termSource":"NCI"},{"termName":"Firmagon","termGroup":"FB","termSource":"NCI"},{"termName":"N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced prostate cancer"},{"name":"CAS_Registry","value":"214766-78-6"},{"name":"Chemical_Formula","value":"C82H103ClN18O16"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"SX0XJI3A11"},{"name":"Legacy Concept Name","value":"Degarelix"},{"name":"Maps_To","value":"Degarelix"},{"name":"NCI_Drug_Dictionary_ID","value":"441235"},{"name":"PDQ_Closed_Trial_Search_ID","value":"441235"},{"name":"PDQ_Open_Trial_Search_ID","value":"441235"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0971731"}]}}{"C80443":{"preferredName":"Degarelix Acetate","code":"C80443","definitions":[{"definition":"The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Degarelix Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3- pyridinyl)-D-alanyl-L- seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]- L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L- lysyl-L-prolyl, Acetate, Hydrate","termGroup":"SN","termSource":"NCI"},{"termName":"FE200486 Acetate Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Gonax","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced prostate cancer"},{"name":"CAS_Registry","value":"934246-14-7"},{"name":"Chemical_Formula","value":"C82H103ClN18O16.C2H4O2.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I18S89P20R"},{"name":"Legacy Concept Name","value":"Degarelix_Acetate"},{"name":"Maps_To","value":"Degarelix Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"813358"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2718533"}]}}{"C74075":{"preferredName":"Delanzomib","code":"C74075","definitions":[{"definition":"An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Delanzomib represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Delanzomib","termGroup":"PT","termSource":"NCI"},{"termName":"((1R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpyridine-2-carboxamido)butanamido)-3-methylbutyl)boronic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"CEP 18770","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-18770","termGroup":"CN","termSource":"NCI"},{"termName":"CT-47098","termGroup":"CN","termSource":"NCI"},{"termName":"NPH-007098","termGroup":"CN","termSource":"NCI"},{"termName":"NPH007098","termGroup":"CN","termSource":"NCI"},{"termName":"Proteasome Inhibitor CEP 18770","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"847499-27-8"},{"name":"Chemical_Formula","value":"C21H28BN3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6IF28942WO"},{"name":"Legacy Concept Name","value":"Proteasome_Inhibitor_CEP_18770"},{"name":"Maps_To","value":"Delanzomib"},{"name":"NCI_Drug_Dictionary_ID","value":"583540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583540"},{"name":"PDQ_Open_Trial_Search_ID","value":"583540"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467895"}]}}{"C80041":{"preferredName":"Demcizumab","code":"C80041","definitions":[{"definition":"A humanized monoclonal antibody directed against the N-terminal epitope of Notch ligand DLL4 (delta-like 4) with potential antineoplastic activity. Demcizumab binds to the membrane-binding portion of DLL4 and prevents its interaction with Notch-1 and Notch-4 receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated into the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Demcizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Delta-like 4 Monoclonal Antibody OMP-21M18","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-DLL4 Monoclonal Antibody OMP-21M18","termGroup":"SY","termSource":"NCI"},{"termName":"OMP-21M18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1243262-17-0"},{"name":"Chemical_Formula","value":"1243262-17-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SF168W7FW0"},{"name":"Legacy Concept Name","value":"Anti-DLL4_Monoclonal_Antibody_OMP-21M18"},{"name":"Maps_To","value":"Demcizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"614677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614677"},{"name":"PDQ_Open_Trial_Search_ID","value":"614677"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698134"}]}}{"C419":{"preferredName":"Demecolcine","code":"C419","definitions":[{"definition":"A colchicine analog with potential antimitotic and antineoplastic activities. Demecolcine acid binds to the colchicine-binding site of tubulin, inhibiting its polymerization into microtubules, causing cell cycle arrest at metaphase and preventing cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Demecolcine","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Colchamine","termGroup":"SY","termSource":"NCI"},{"termName":"Methylcolchicine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Methyl-N-desacetylcolchicine","termGroup":"SN","termSource":"NCI"},{"termName":"Santavy's Substance F","termGroup":"SY","termSource":"NCI"},{"termName":"X 153","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"477-30-5"},{"name":"CHEBI_ID","value":"CHEBI:4393"},{"name":"Chemical_Formula","value":"C21H25NO5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z01IVE25KI"},{"name":"Legacy Concept Name","value":"Demecolcine"},{"name":"Maps_To","value":"Demecolcine"},{"name":"NSC Number","value":"3096"},{"name":"NSC Number","value":"403147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011259"}]}}{"C85476":{"preferredName":"Demplatin Pegraglumer","code":"C85476","definitions":[{"definition":"A nanoparticle-based prodrug formulation consisting of polymeric micelles incorporating the inorganic platinum agent cisplatin with potential antineoplastic activity. In demplatin pegraglumer, cisplatin forms a polymer-metal complex with hydrophilic polyethylene glycol poly(glutamic acid) block copolymers by attaching to the micelle inner core consisting of the hydrophobic polyamino acids. Upon cell entry and release from the polymer-metal complex, cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-linking, DNA-protein cross-linking and, subsequently, tumor cell apoptosis and growth inhibition. Due to the hydrophilic nature of polyethylene glycol, this formulation increases the water-solubility of cisplatin and decreases the nephrotoxicity and neurotoxicity associated with the administration of cisplatin alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Demplatin Pegraglumer","termGroup":"PT","termSource":"NCI"},{"termName":"Nanoplatin","termGroup":"FB","termSource":"NCI"},{"termName":"NC-6004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1009838-50-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9DMG482P0R"},{"name":"Maps_To","value":"Demplatin Pegraglumer"},{"name":"NCI_Drug_Dictionary_ID","value":"647541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647541"},{"name":"PDQ_Open_Trial_Search_ID","value":"647541"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830141"}]}}{"C28310":{"preferredName":"Dendritic Cell Vaccine","code":"C28310","definitions":[{"definition":"A vaccine made of antigens and dendritic antigen-presenting cells (APCs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dendritic Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Dendritic Cell-based Cancer Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dendritic_Cell_Vaccine"},{"name":"Maps_To","value":"Dendritic Cell Vaccine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1511767"}]}}{"C26446":{"preferredName":"Dendritic Cell-Autologous Lung Tumor Vaccine","code":"C26446","definitions":[{"definition":"A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells.  The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient.  In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen.  Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendritic Cell-Autologous Lung Tumor Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"DCVax-L","termGroup":"SY","termSource":"NCI"},{"termName":"DCVax-Lung","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dendritic_Cell-Autologous_Lung_Tumor_Vaccine"},{"name":"Maps_To","value":"Dendritic Cell-Autologous Lung Tumor Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"256453"},{"name":"PDQ_Closed_Trial_Search_ID","value":"256453"},{"name":"PDQ_Open_Trial_Search_ID","value":"256453"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327750"}]}}{"C115976":{"preferredName":"Dendritic Cell-targeting Lentiviral Vector ID-LV305","code":"C115976","definitions":[{"definition":"An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendritic Cell-targeting Lentiviral Vector ID-LV305","termGroup":"PT","termSource":"NCI"},{"termName":"DCvex-NY-ESO-1","termGroup":"SY","termSource":"NCI"},{"termName":"ID-LV305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dendritic Cell-targeting Lentiviral Vector ID-LV305"},{"name":"NCI_Drug_Dictionary_ID","value":"760531"},{"name":"NCI_META_CUI","value":"CL473308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760531"},{"name":"PDQ_Open_Trial_Search_ID","value":"760531"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62492":{"preferredName":"Denenicokin","code":"C62492","definitions":[{"definition":"A recombinant peptide similar to or identical to endogenous human cytokine interleukin-21 (IL-21) with potential antineoplastic activity. Denenicokin binds to and activates IL-21 receptors, expressed on T-cells, B-cells, dendritic cells (DC), and natural killer (NK) cells, modulating the proliferation and/or differentiation of T and B cells, promoting T cell survival, and increasing the cytolytic activity of cytotoxic T lymphocytes (CTLs) and NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denenicokin","termGroup":"PT","termSource":"NCI"},{"termName":"IL-21","termGroup":"AB","termSource":"NCI"},{"termName":"L-methionyl(Human Interleukin-21)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Interleukin-21","termGroup":"SY","termSource":"NCI"},{"termName":"rhIL-21","termGroup":"AB","termSource":"NCI"},{"termName":"rIL-21","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"716840-32-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A4LY1V9F0H"},{"name":"Legacy Concept Name","value":"Recombinant_Human_Interleukin-21"},{"name":"Maps_To","value":"Denenicokin"},{"name":"NCI_Drug_Dictionary_ID","value":"409696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"409696"},{"name":"PDQ_Open_Trial_Search_ID","value":"409696"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831593"}]}}{"C77065":{"preferredName":"Denibulin","code":"C77065","definitions":[{"definition":"A small molecular vascular disrupting agent (VDA), with potential antimitotic and antineoplastic activities. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denibulin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"284019-34-7"},{"name":"Chemical_Formula","value":"C18H19N5O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K7037M241U"},{"name":"Legacy Concept Name","value":"Denibulin"},{"name":"Maps_To","value":"Denibulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699587"}]}}{"C72736":{"preferredName":"Denibulin Hydrochloride","code":"C72736","definitions":[{"definition":"The hydrochloride salt of denibulin, a small molecular vascular disrupting agent, with potential antimitotic and antineoplastic activities. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation., a small molecule vascular disrupting agent (VDA), with potential antimitotic and antineoplastic activity. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells (EC), ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denibulin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"MN-029","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"779356-64-8"},{"name":"Chemical_Formula","value":"C18H19N5O3S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0U575HR16Q"},{"name":"Legacy Concept Name","value":"Denibulin_Hydrochloride"},{"name":"Maps_To","value":"Denibulin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"746028"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746028"},{"name":"PDQ_Open_Trial_Search_ID","value":"746028"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1679364"}]}}{"C1476":{"preferredName":"Denileukin Diftitox","code":"C1476","definitions":[{"definition":"A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat cutaneous T-cell lymphoma that can bind the cytokine IL-2 and that has not responded to other treatment. It is also being studied in the treatment of other types of cancer. Ontak is made by combining a part of IL-2 with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and then the toxin kills the cells. Ontak is a type of immunotoxin and a type of fusion toxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Denileukin Diftitox","termGroup":"PT","termSource":"NCI"},{"termName":"DAB(389)-Interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"DAB(389)IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"DAB-IL2","termGroup":"CN","termSource":"NCI"},{"termName":"DAB389 Interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"DAB389 Interleukin-2 Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"DAB389IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"DAB389IL2","termGroup":"AB","termSource":"NCI"},{"termName":"DABIL2","termGroup":"SY","termSource":"NCI"},{"termName":"Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777","termGroup":"SY","termSource":"NCI"},{"termName":"E7777","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-2 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-2 Fusion Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"LY 335348","termGroup":"CN","termSource":"NCI"},{"termName":"LY-335348","termGroup":"CN","termSource":"NCI"},{"termName":"LY335348","termGroup":"CN","termSource":"NCI"},{"termName":"Ontak","termGroup":"BR","termSource":"NCI"},{"termName":"Remitoro","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cutaneous T-cell lymphoma"},{"name":"CAS_Registry","value":"173146-27-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"25E79B5CTM"},{"name":"Legacy Concept Name","value":"Denileukin_Diftitox"},{"name":"Maps_To","value":"Denileukin Diftitox"},{"name":"Maps_To","value":"Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777"},{"name":"NCI_Drug_Dictionary_ID","value":"42325"},{"name":"NSC Number","value":"714744"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42325"},{"name":"PDQ_Open_Trial_Search_ID","value":"42325"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0717670"}]}}{"C105150":{"preferredName":"Denintuzumab Mafodotin","code":"C105150","definitions":[{"definition":"An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases MMAF, which binds to tubulin and inhibits its polymerization. Inhibition of tubulin polymerization may result in G2/M phase arrest and tumor cell apoptosis. This causes inhibition of cell growth of CD19-expressing tumor cells. CD19, a B-cell antigen, is overexpressed by a variety of different cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denintuzumab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-19A","termGroup":"AB","termSource":"NCI"},{"termName":"Immunoglobulin G1-kappa Auristatin F Conjugate, Anti-(homosapiens CD19 (B Lymphocyte Surface Antigen B4, leu-12)), Humanized Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"SGN CD19A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-19A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD19A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD19A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1399672-02-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"H5324S1M7H"},{"name":"Maps_To","value":"Denintuzumab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"746594"},{"name":"NCI_META_CUI","value":"CL446112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746594"},{"name":"PDQ_Open_Trial_Search_ID","value":"746594"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61313":{"preferredName":"Denosumab","code":"C61313","definitions":[{"definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody being studied in the treatment of multiple myeloma (a cancer that forms in bones) and in the prevention and treatment of bone metastases (cancer that has spread to bone from another organ). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. AMG 162 binds to the protein RANKL and helps keep bone from breaking down.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Denosumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 162","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-162","termGroup":"CN","termSource":"NCI"},{"termName":"Denosumab Biosimilar MW032","termGroup":"SY","termSource":"NCI"},{"termName":"Denosumab Biosimilar QL1206","termGroup":"SY","termSource":"NCI"},{"termName":"Denosumab Biosimilar TK-006","termGroup":"SY","termSource":"NCI"},{"termName":"Prolia","termGroup":"BR","termSource":"NCI"},{"termName":"Ranmark","termGroup":"FB","termSource":"NCI"},{"termName":"TK-006","termGroup":"CN","termSource":"NCI"},{"termName":"Xgeva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Osteolytic Bone Metastases of Solid Tumors"},{"name":"CAS_Registry","value":"615258-40-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"4EQZ6YO2HI"},{"name":"Legacy Concept Name","value":"Densosumab"},{"name":"Maps_To","value":"Denosumab"},{"name":"NCI_Drug_Dictionary_ID","value":"481348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481348"},{"name":"PDQ_Open_Trial_Search_ID","value":"481348"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1690432"}]}}{"C82697":{"preferredName":"Radgocitabine","code":"C82697","definitions":[{"definition":"An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radgocitabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-L-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)- 2(1H)-pyrimidinone","termGroup":"SY","termSource":"NCI"},{"termName":"CNDAC","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxycytidine Analogue TAS-109","termGroup":"SY","termSource":"NCI"},{"termName":"TAS-109","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135598-68-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"00M634HD2V"},{"name":"Legacy Concept Name","value":"Deoxycytidine_Analogue_TAS-109"},{"name":"Maps_To","value":"Deoxycytidine Analogue TAS-109"},{"name":"Maps_To","value":"Radgocitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"633936"},{"name":"NCI_META_CUI","value":"CL388479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633936"},{"name":"PDQ_Open_Trial_Search_ID","value":"633936"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150430":{"preferredName":"Radgocitabine Hydrochloride","code":"C150430","definitions":[{"definition":"The hydrochloride salt form of radgocitabine, an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radgocitabine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CNDAC Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxycytidine Analogue TAS-109 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134665-72-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VSS4ZDZ2IE"},{"name":"Maps_To","value":"Deoxycytidine Analogue TAS-109 Hydrochloride"},{"name":"Maps_To","value":"Radgocitabine Hydrochloride"},{"name":"NCI_META_CUI","value":"CL552242"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95206":{"preferredName":"Depatuxizumab","code":"C95206","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) with antineoplastic activity. Depatuxizumab targets the EGFR deletion variant, de2-7 EGFR as well as wild-type EGFR expressed in cells overexpressing the receptor, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization result in an inhibition in signal transduction and anti-proliferative effects. This MoAb targets cells expressing aberrant EGFR, hence making it an ideal candidate for generation of radioisotope or toxin conjugates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Depatuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-806","termGroup":"CN","termSource":"NCI"},{"termName":"anti-EGFR mAb ABT-806","termGroup":"SY","termSource":"NCI"},{"termName":"anti-EGFR MoAb ABT-806","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor) (Human-mus musculus Monoclonal ABT-806 Heavy Chain), Disulfide with Human-mus musculus Monoclonal ABT-806 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"mAb-806","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1471999-69-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W984C353CG"},{"name":"Maps_To","value":"Depatuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"691187"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691187"},{"name":"PDQ_Open_Trial_Search_ID","value":"691187"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048804"}]}}{"C105612":{"preferredName":"Depatuxizumab Mafodotin","code":"C105612","definitions":[{"definition":"An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Depatuxizumab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1585973-65-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3R7A4P04N"},{"name":"Maps_To","value":"Depatuxizumab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"747249"},{"name":"NCI_META_CUI","value":"CL446449"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747249"},{"name":"PDQ_Open_Trial_Search_ID","value":"747249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104267":{"preferredName":"Derazantinib","code":"C104267","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Derazantinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 087","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ-087","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1234356-69-4"},{"name":"CHEBI_ID","value":"CHEBI:63453"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N9B0H171MJ"},{"name":"Maps_To","value":"Derazantinib"},{"name":"NCI_Drug_Dictionary_ID","value":"744652"},{"name":"NCI_META_CUI","value":"CL445613"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744652"},{"name":"PDQ_Open_Trial_Search_ID","value":"744652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38709":{"preferredName":"Deslorelin","code":"C38709","definitions":[{"definition":"A substance being studied in the treatment of cancer as a way to block sex hormones made by the ovaries or testicles. It is a type of gonadotropin-releasing hormone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deslorelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Tryptophan-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Swine)","termGroup":"SN","termSource":"NCI"},{"termName":"Ovuplant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Central precocious puberty"},{"name":"CAS_Registry","value":"57773-65-6"},{"name":"Chemical_Formula","value":"C64H83N17O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TKG3I66TVE"},{"name":"Legacy Concept Name","value":"Deslorelin"},{"name":"Maps_To","value":"Deslorelin"},{"name":"NCI_Drug_Dictionary_ID","value":"357620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357620"},{"name":"PDQ_Open_Trial_Search_ID","value":"357620"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0083220"}]}}{"C82600":{"preferredName":"Deslorelin Acetate","code":"C82600","definitions":[{"definition":"A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deslorelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"5-Oxo-L-Prolyl-L-Histidyl-L-Tryptophyl-L-Seryl-L-Tyrosyl-D-Tryptophyl-L-Leucyl-L-Arginyl-N-Ethyl-L-Prolinamide Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"6-D-Tryptophan-9-(N-Ethyl-L-Prolinamide)-1-9-Luteinizing Hormone-Releasing Factor (Swine) Acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"82318-06-7"},{"name":"Chemical_Formula","value":"C64H83N17O12.C2H4O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"679007NR5C"},{"name":"Legacy Concept Name","value":"Deslorelin_Acetate"},{"name":"Maps_To","value":"Deslorelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"357620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357620"},{"name":"PDQ_Open_Trial_Search_ID","value":"357620"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0378714"}]}}{"C132693":{"preferredName":"Detirelix","code":"C132693","synonyms":[{"termName":"Detirelix","termGroup":"PT","termSource":"NCI"},{"termName":"BRN 6564671","termGroup":"CN","termSource":"NCI"},{"termName":"D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N(sup 6)-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-L-arginyl-L-prolyl-","termGroup":"SN","termSource":"NCI"},{"termName":"N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,D-Ala(10)-GnRH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89662-30-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05ME7P8ZBJ"},{"name":"Maps_To","value":"Detirelix"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057576"}]}}{"C1066":{"preferredName":"Detorubicin","code":"C1066","definitions":[{"definition":"A semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Detorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"14-Diethoxyacetoxydaunorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"Diethoxy-,2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester,(2S-cis) Acetic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66211-92-5"},{"name":"Chemical_Formula","value":"C33H39NO14"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"822EC3XEJZ"},{"name":"Legacy Concept Name","value":"Detorubicin"},{"name":"Maps_To","value":"Detorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39213"},{"name":"NSC Number","value":"292652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39213"},{"name":"PDQ_Open_Trial_Search_ID","value":"39213"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057578"}]}}{"C132685":{"preferredName":"Deuteporfin","code":"C132685","definitions":[{"definition":"A photosensitizing agent composed of four sub-porphyrin derivatives, methoxyethy-hydroxyethyl-dipropionic, di-methoxyethyl-dipropionic, hydroxyethy-vinyl-dipropionic and methoxyethy-vinyl-dipropionic, with potential photosensitizing activity upon photodynamic therapy (PDT) and potential diagnostic imaging activity. Upon intravenous administration, deuteporfin preferentially targets and accumulates in cancer cells, especially those in the lymphatic system. Following photoactivation with an appropriate wavelength, deuteporfin generates highly cytotoxic singlet oxygen species, and induces oxidative stress that results in the damage and death of cancer cells. In addition, deuteporfin could be used as a tracer in near-infrared (NIR) fluorescence lymph node mapping.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deuteporfin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Deuteporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"787101"},{"name":"NCI_META_CUI","value":"CL519824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787101"},{"name":"PDQ_Open_Trial_Search_ID","value":"787101"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158096":{"preferredName":"Deutenzalutamide","code":"C158096","definitions":[{"definition":"A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Upon administration, deutenzalutamide competitively binds to and inhibits the activity of ARs expressed on prostate cancer cells, which impairs nuclear translocation and DNA binding, resulting in apoptosis of prostate cancer cells. This results in a reduction in prostate cancer cell growth. AR overexpression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. Deuterium incorporation, by replacing the hydrogen atoms of the N-CH3 moiety with deuterium atoms, decreases enzalutamide's metabolism and allows for an increased pharmacokinetic profile, thereby enhancing its anti-tumor efficacy compared to non-deuterated enzalutamide. As the deuterated form can't cross the blood-brain barrier (BBB), the deutenzalutamide form also reduces the unwanted brain-related side effects of enzalutamide and improves its safety profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deutenzalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"D3-ENT","termGroup":"SY","termSource":"NCI"},{"termName":"Deuterated Enzalutamide","termGroup":"SY","termSource":"NCI"},{"termName":"Enzalutamide Deuterated","termGroup":"SY","termSource":"NCI"},{"termName":"HC 1119","termGroup":"CN","termSource":"NCI"},{"termName":"HC-1119","termGroup":"CN","termSource":"NCI"},{"termName":"HC1119","termGroup":"CN","termSource":"NCI"},{"termName":"N-trideuteromethyl Enzalutamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443331-82-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3OKI556HC2"},{"name":"Maps_To","value":"Deuterated Enzalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"797006"},{"name":"NCI_META_CUI","value":"CL937681"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797006"},{"name":"PDQ_Open_Trial_Search_ID","value":"797006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80039":{"preferredName":"Devimistat","code":"C80039","definitions":[{"definition":"A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Devimistat","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha-Lipoic Acid Analogue CPI-613","termGroup":"SY","termSource":"NCI"},{"termName":"CPI 613","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-613","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95809-78-2"},{"name":"Chemical_Formula","value":"C22H28O2S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E76113IR49"},{"name":"Legacy Concept Name","value":"Alpha-Lipoic_Acid_Analogue_CPI-613"},{"name":"Maps_To","value":"Devimistat"},{"name":"NCI_Drug_Dictionary_ID","value":"614265"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614265"},{"name":"PDQ_Open_Trial_Search_ID","value":"614265"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703200"}]}}{"C422":{"preferredName":"Dexamethasone","code":"C422","definitions":[{"definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland). Dexamethasone is used to treat leukemia and lymphoma and may be used to treat some of the problems caused by other cancers and their treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dexamethasone","termGroup":"PT","termSource":"NCI"},{"termName":"(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"16Alpha-methyl-9alpha-fluoroprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"9alpha-Fluoro-16alpha- methylprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"9Alpha-fluoro-16alpha-methylprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"Aacidexam","termGroup":"FB","termSource":"NCI"},{"termName":"Adexone","termGroup":"FB","termSource":"NCI"},{"termName":"Aknichthol Dexa","termGroup":"FB","termSource":"NCI"},{"termName":"Alba-Dex","termGroup":"BR","termSource":"NCI"},{"termName":"Alin","termGroup":"FB","termSource":"NCI"},{"termName":"Alin Depot","termGroup":"FB","termSource":"NCI"},{"termName":"Alin Oftalmico","termGroup":"FB","termSource":"NCI"},{"termName":"Amplidermis","termGroup":"FB","termSource":"NCI"},{"termName":"Anemul mono","termGroup":"FB","termSource":"NCI"},{"termName":"Auricularum","termGroup":"FB","termSource":"NCI"},{"termName":"Auxiloson","termGroup":"FB","termSource":"NCI"},{"termName":"Baycadron","termGroup":"BR","termSource":"NCI"},{"termName":"Baycuten","termGroup":"FB","termSource":"NCI"},{"termName":"Baycuten N","termGroup":"FB","termSource":"NCI"},{"termName":"Cortidexason","termGroup":"FB","termSource":"NCI"},{"termName":"Cortisumman","termGroup":"FB","termSource":"NCI"},{"termName":"Decacort","termGroup":"FB","termSource":"NCI"},{"termName":"Decadrol","termGroup":"BR","termSource":"NCI"},{"termName":"Decadron","termGroup":"BR","termSource":"NCI"},{"termName":"Decadron DP","termGroup":"BR","termSource":"NCI"},{"termName":"Decalix","termGroup":"FB","termSource":"NCI"},{"termName":"Decameth","termGroup":"FB","termSource":"NCI"},{"termName":"Decasone R.p.","termGroup":"BR","termSource":"NCI"},{"termName":"Dectancyl","termGroup":"FB","termSource":"NCI"},{"termName":"Dekacort","termGroup":"FB","termSource":"NCI"},{"termName":"Deltafluorene","termGroup":"FB","termSource":"NCI"},{"termName":"Deronil","termGroup":"BR","termSource":"NCI"},{"termName":"Desamethasone","termGroup":"SY","termSource":"NCI"},{"termName":"Desameton","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-Mamallet","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-Rhinosan","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-Scheroson","termGroup":"FB","termSource":"NCI"},{"termName":"Dexa-sine","termGroup":"FB","termSource":"NCI"},{"termName":"Dexacortal","termGroup":"FB","termSource":"NCI"},{"termName":"Dexacortin","termGroup":"FB","termSource":"NCI"},{"termName":"Dexafarma","termGroup":"FB","termSource":"NCI"},{"termName":"Dexafluorene","termGroup":"FB","termSource":"NCI"},{"termName":"Dexalocal","termGroup":"FB","termSource":"NCI"},{"termName":"Dexamecortin","termGroup":"FB","termSource":"NCI"},{"termName":"Dexameth","termGroup":"BR","termSource":"NCI"},{"termName":"Dexamethasone Intensol","termGroup":"SY","termSource":"NCI"},{"termName":"Dexamethasone Intensol","termGroup":"BR","termSource":"NCI"},{"termName":"Dexamethasonum","termGroup":"SY","termSource":"NCI"},{"termName":"Dexamonozon","termGroup":"FB","termSource":"NCI"},{"termName":"Dexapos","termGroup":"FB","termSource":"NCI"},{"termName":"Dexinoral","termGroup":"FB","termSource":"NCI"},{"termName":"Dexone","termGroup":"FB","termSource":"NCI"},{"termName":"Dinormon","termGroup":"FB","termSource":"NCI"},{"termName":"Dxevo","termGroup":"BR","termSource":"NCI"},{"termName":"Fluoro-9alpha Methyl-16alpha Prednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"Fluorodelta","termGroup":"FB","termSource":"NCI"},{"termName":"Fortecortin","termGroup":"FB","termSource":"NCI"},{"termName":"Gammacorten","termGroup":"BR","termSource":"NCI"},{"termName":"Hemady","termGroup":"BR","termSource":"NCI"},{"termName":"Hexadecadrol","termGroup":"SY","termSource":"NCI"},{"termName":"Hexadrol","termGroup":"BR","termSource":"NCI"},{"termName":"LenaDex","termGroup":"FB","termSource":"NCI"},{"termName":"Lokalison-F","termGroup":"FB","termSource":"NCI"},{"termName":"Loverine","termGroup":"FB","termSource":"NCI"},{"termName":"Methylfluorprednisolone","termGroup":"SY","termSource":"NCI"},{"termName":"Millicorten","termGroup":"FB","termSource":"NCI"},{"termName":"Mymethasone","termGroup":"FB","termSource":"NCI"},{"termName":"Orgadrone","termGroup":"FB","termSource":"NCI"},{"termName":"Spersadex","termGroup":"FB","termSource":"NCI"},{"termName":"TaperDex","termGroup":"BR","termSource":"NCI"},{"termName":"Visumetazone","termGroup":"FB","termSource":"NCI"},{"termName":"ZoDex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Allergic disorders; antiemetic; corneal injury; inflammatory conditions"},{"name":"CAS_Registry","value":"50-02-2"},{"name":"CHEBI_ID","value":"CHEBI:41879"},{"name":"Chemical_Formula","value":"C22H29FO5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7S5I7G3JQL"},{"name":"Legacy Concept Name","value":"Dexamethasone"},{"name":"Maps_To","value":"Dexamethasone"},{"name":"NCI_Drug_Dictionary_ID","value":"39789"},{"name":"NSC Number","value":"34521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39789"},{"name":"PDQ_Open_Trial_Search_ID","value":"39789"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0011777"}]}}{"C77001":{"preferredName":"Dexamethasone Phosphate","code":"C77001","synonyms":[{"termName":"Dexamethasone Phosphate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"312-93-6"},{"name":"Chemical_Formula","value":"C22H30FO8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BP70L44PR"},{"name":"Legacy Concept Name","value":"Dexamethasone_Phosphate"},{"name":"Maps_To","value":"Dexamethasone Phosphate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770565"}]}}{"C1362":{"preferredName":"Dexamethasone Sodium Phosphate","code":"C1362","definitions":[{"definition":"A sodium phosphate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dexamethasone Sodium Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Cebedex","termGroup":"FB","termSource":"NCI"},{"termName":"Corson","termGroup":"FB","termSource":"NCI"},{"termName":"Dalalone","termGroup":"BR","termSource":"NCI"},{"termName":"Decaject","termGroup":"FB","termSource":"NCI"},{"termName":"Dekasol LA","termGroup":"FB","termSource":"NCI"},{"termName":"Dexacen","termGroup":"FB","termSource":"NCI"},{"termName":"Dexamethasone Sodium Phosphates","termGroup":"SY","termSource":"NCI"},{"termName":"Dexasone","termGroup":"BR","termSource":"NCI"},{"termName":"Dezone","termGroup":"FB","termSource":"NCI"},{"termName":"ReadySharp Dexamethasone","termGroup":"BR","termSource":"NCI"},{"termName":"Soludecadron","termGroup":"FB","termSource":"NCI"},{"termName":"Solurex","termGroup":"BR","termSource":"NCI"},{"termName":"Topidex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2392-39-4"},{"name":"CHEBI_ID","value":"CHEBI:4462"},{"name":"Chemical_Formula","value":"C22H28FO8P.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AI9376Y64P"},{"name":"Legacy Concept Name","value":"Dexamethasone_Sodium_Phosphate"},{"name":"Maps_To","value":"Dexamethasone Sodium Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"813361"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0113286"}]}}{"C99381":{"preferredName":"Dexanabinol","code":"C99381","definitions":[{"definition":"A synthetic, terpene-based cannabinoid derivative devoid of cannabinoid receptors 1 and 2 agonist activity and with potential neuroprotective, antiinflammatory and antineoplastic activities. Functioning as an N-Methyl-D-aspartate (NMDA) receptor antagonist, dexanabinol protects neuronal cells against NMDA and glutamate neurotoxicity. This agent also scavenges peroxy radicals and protects neurons from the damages of reactive oxygen species. Furthermore, dexanabinol inhibits the activity of nuclear factor kappa B (NF-kB), thereby preventing the expression of NF-kB target genes, such as tumor necrosis factor alpha, cytokines and inducible nitric oxide synthase. As a result, this agent may restore apoptotic processes in cancerous cells. NF-kB is activated in a variety of cancer cells and plays a key role in the regulation of apoptosis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dexanabinol","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol","termGroup":"SN","termSource":"NCI"},{"termName":"7-Hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl","termGroup":"SN","termSource":"NCI"},{"termName":"HU-211","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112924-45-5"},{"name":"Chemical_Formula","value":"C25H38O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6VT8U5372"},{"name":"Maps_To","value":"Dexanabinol"},{"name":"NCI_Drug_Dictionary_ID","value":"720043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"720043"},{"name":"PDQ_Open_Trial_Search_ID","value":"720043"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0526471"}]}}{"C1333":{"preferredName":"Dexrazoxane","code":"C1333","definitions":[{"definition":"A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat severe side effects caused by certain anticancer drugs. Under the brand name Totect it is used to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. Under the brand name Zinecard it is used to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dexrazoxane","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione)","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ADR 529","termGroup":"CN","termSource":"NCI"},{"termName":"ADR-529","termGroup":"CN","termSource":"NCI"},{"termName":"ADR529","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF 187","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF-187","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF187","termGroup":"CN","termSource":"NCI"},{"termName":"Razoxane (+)-form","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chemotherapy-induced cardiomyopathy"},{"name":"CAS_Registry","value":"24584-09-6"},{"name":"CHEBI_ID","value":"CHEBI:50223"},{"name":"Chemical_Formula","value":"C11H16N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"048L81261F"},{"name":"Legacy Concept Name","value":"Dexrazoxane"},{"name":"Maps_To","value":"Dexrazoxane"},{"name":"NSC Number","value":"169780"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086444"}]}}{"C66945":{"preferredName":"Dexrazoxane Hydrochloride","code":"C66945","definitions":[{"definition":"A drug used to treat severe side effects caused by certain anticancer drugs. It is used under the brand name Totect to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. It is also used under the brand name Zinecard to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane hydrochloride is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues.  This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dexrazoxane Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Cardioxane","termGroup":"BR","termSource":"NCI"},{"termName":"Totect","termGroup":"BR","termSource":"NCI"},{"termName":"Zinecard","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"severe side effects caused by certain types of chemotherapy including extravasation, cardiac side effects by doxorubicin."},{"name":"CAS_Registry","value":"149003-01-0"},{"name":"CHEBI_ID","value":"CHEBI:50224"},{"name":"Chemical_Formula","value":"C11H16N4O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5346058Q7S"},{"name":"Legacy Concept Name","value":"Dexrazoxane_Hydrochloride"},{"name":"Maps_To","value":"Dexrazoxane Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39485"},{"name":"PDQ_Open_Trial_Search_ID","value":"39485"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0982118"}]}}{"C968":{"preferredName":"Dezaguanine","code":"C968","definitions":[{"definition":"A purine nucleoside analogue with antineoplastic and antiviral activities.  By replacing guanine, dezaguanine incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dezaguanine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Deazaguanine","termGroup":"SY","termSource":"NCI"},{"termName":"CI-908","termGroup":"CN","termSource":"NCI"},{"termName":"Deazaguanine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41729-52-6"},{"name":"Chemical_Formula","value":"C6H6N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9DRB973HUI"},{"name":"Legacy Concept Name","value":"Dezaguanine"},{"name":"Maps_To","value":"Dezaguanine"},{"name":"NCI_Drug_Dictionary_ID","value":"40086"},{"name":"NSC Number","value":"261726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40086"},{"name":"PDQ_Open_Trial_Search_ID","value":"40086"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0047332"}]}}{"C80635":{"preferredName":"Dezaguanine Mesylate","code":"C80635","definitions":[{"definition":"The mesylate salt form of dezaguanine, a purine nucleoside analogue with antineoplastic and antiviral activities.  By competing with guanine, dezaguanine gets incorporated into DNA and inhibits DNA synthesis, thereby inducing cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dezaguanine Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"3-Deazaguanine Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87434-82-0"},{"name":"Chemical_Formula","value":"C6H6N4O.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H56TJ4554M"},{"name":"Legacy Concept Name","value":"Dezaguanine_Mesylate"},{"name":"Maps_To","value":"Dezaguanine Mesylate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825284"}]}}{"C107686":{"preferredName":"Dezapelisib","code":"C107686","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity. Dezapelisib specifically inhibits PI3Kdelta, which prevents both the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in PI3K-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is often overexpressed in tumor cells, especially those of hematologic origin, and plays a crucial role in tumor cell regulation and survival. The targeted inhibition of PI3Kdelta allows for PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dezapelisib","termGroup":"PT","termSource":"NCI"},{"termName":"5H-Thiazolo(3,2-a)pyrimidin-5-one, 6-(3-Fluorophenyl)-3-methyl-7-((1S)-1-(9H-purin-6-ylamino)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB040093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1262440-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2K59L7G59M"},{"name":"Maps_To","value":"Dezapelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"751623"},{"name":"NCI_META_CUI","value":"CL451874"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751623"},{"name":"PDQ_Open_Trial_Search_ID","value":"751623"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2649":{"preferredName":"DHA-Paclitaxel","code":"C2649","definitions":[{"definition":"A combination of DHA (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel.  Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).  DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DHA-Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"Docosahexaenoic Acid-Paclitaxel conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Taxoprexin","termGroup":"BR","termSource":"NCI"},{"termName":"TXP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73-67-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OJE5810C4F"},{"name":"Legacy Concept Name","value":"DHA-Paclitaxel"},{"name":"Maps_To","value":"DHA-Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"38414"},{"name":"NSC Number","value":"28247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38414"},{"name":"PDQ_Open_Trial_Search_ID","value":"38414"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134470"}]}}{"C2707":{"preferredName":"DHEA Mustard","code":"C2707","definitions":[{"definition":"A steroidal alkylating agent with potential antineoplastic activity.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DHEA Mustard","termGroup":"PT","termSource":"NCI"},{"termName":"dehydroepiandrosterone mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DHEA_Mustard"},{"name":"Maps_To","value":"DHEA Mustard"},{"name":"NCI_Drug_Dictionary_ID","value":"39214"},{"name":"NSC Number","value":"121210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39214"},{"name":"PDQ_Open_Trial_Search_ID","value":"39214"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0279151"}]}}{"C78451":{"preferredName":"DI-Leu16-IL2 Immunocytokine","code":"C78451","definitions":[{"definition":"A recombinant fusion protein consisting of de-immunized and humanized anti-CD20 monoclonal antibody Leu16 fused to human cytokine interleukin-2 (IL2) with potential antineoplastic activity. The antibody moiety of DI-Leu16-IL2 immunocytokine binds to tumor cells expressing the CD20 antigen, which may result in an antibody-dependent cell-mediated cytotoxicity (ADCC) towards CD20-expressing tumor cells; the localized IL2 moiety of this fusion protein may stimulate natural killer (NK) and T-lymphocyte mediated immune responses, enhancing the ADCC response. De-immunization involves the modification of potential helper T cell epitopes that bind to MHC class II molecules; humanization involves combining recombinant murine variable (V) regions with human immunoglobulin light and heavy chain constant regions. CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes, is overexpressed by various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DI-Leu16-IL2 Immunocytokine","termGroup":"PT","termSource":"NCI"},{"termName":"De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2","termGroup":"SY","termSource":"NCI"},{"termName":"DI-Leu16-IL-2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8PQK3QPW4P"},{"name":"Legacy Concept Name","value":"De-Immunized_DI-Leu16-IL2_Immunocytokine"},{"name":"Maps_To","value":"DI-Leu16-IL2 Immunocytokine"},{"name":"NCI_Drug_Dictionary_ID","value":"599668"},{"name":"NCI_META_CUI","value":"CL387463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599668"},{"name":"PDQ_Open_Trial_Search_ID","value":"599668"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1632":{"preferredName":"Diarylsulfonylurea Compound ILX-295501","code":"C1632","definitions":[{"definition":"A substance that is being studied as an anticancer drug.  It belongs to the family of drugs called diarylsulfonylureas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"ILX-295501 is a novel sulfonylurea compound that has demonstrated in-vivo antitumor activity against a broad spectrum of solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diarylsulfonylurea Compound ILX-295501","termGroup":"PT","termSource":"NCI"},{"termName":"ILX 295501","termGroup":"CN","termSource":"NCI"},{"termName":"ILX295501","termGroup":"CN","termSource":"NCI"},{"termName":"LY-295501","termGroup":"CN","termSource":"NCI"},{"termName":"LY295501","termGroup":"CN","termSource":"NCI"},{"termName":"N-(((3,4-Dichlorophenyl)amino)carbonyl)-2,3-dihydro-5-benzofuransulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-(5-(2,3-Dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"150869-74-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"240Y4YO0TN"},{"name":"Legacy Concept Name","value":"ILX-295501"},{"name":"Maps_To","value":"Diarylsulfonylurea Compound ILX-295501"},{"name":"NCI_Drug_Dictionary_ID","value":"37917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37917"},{"name":"PDQ_Open_Trial_Search_ID","value":"37917"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299218"}]}}{"C62508":{"preferredName":"Diazepinomicin","code":"C62508","definitions":[{"definition":"A potent inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity. Diazepinomicin binds to and inhibits Ras kinase, thereby preventing the phosphorylation and activation of proteins downstream of the Ras signal transduction pathway, including serine/threonine kinase RAF (BRAF) and extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK-2), that play a crucial role in regulating cell growth and survival. Diazepinomicin also selectively binds to the peripheral benzodiazepine receptor (BZRP), a receptor highly expressed in certain cancer cells, thus inducing cell cycle arrest and apoptosis in BZRP-expressing cells. In addition, diazepinomicin is able to cross the blood-brain barrier, thereby reaching therapeutic concentrations in the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diazepinomicin","termGroup":"PT","termSource":"NCI"},{"termName":"11h-dibenzo(B,E)(1,4)diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BU-4664L","termGroup":"CN","termSource":"NCI"},{"termName":"ECO-4601","termGroup":"CN","termSource":"NCI"},{"termName":"TLN-4601","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"733035-26-2"},{"name":"Chemical_Formula","value":"C28H34N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YPH994Y0RF"},{"name":"Legacy Concept Name","value":"ECO-4601"},{"name":"Maps_To","value":"Diazepinomicin"},{"name":"NCI_Drug_Dictionary_ID","value":"496938"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496938"},{"name":"PDQ_Open_Trial_Search_ID","value":"496938"},{"name":"PubMedID_Primary_Reference","value":"20655882"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048794"}]}}{"C1363":{"preferredName":"Diaziquone","code":"C1363","definitions":[{"definition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is able to cross the blood-brain barrier and kill cancer cells in the central nervous system.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diaziquone","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-cyclohexadiene-1,4-dicarbamic acid, 2, 5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-cyclohexadiene-1,4-dicarbamic acid,2,5-bis(1-aziridinyl)-3,6-dioxo,-diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-bis(1-aciridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-bis(1-aziridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-diaziridinyl-3,6-bis(ethoxycarbonyl-amino)-1,4-benzoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"[2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]biscarbamic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"Aziridinyl Benzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"Aziridinylbenzoquinone","termGroup":"SY","termSource":"NCI"},{"termName":"Aziridinylbenzoquinone carbamic acid","termGroup":"SY","termSource":"NCI"},{"termName":"AZQ","termGroup":"AB","termSource":"NCI"},{"termName":"carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1, 4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"CI-904","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57998-68-2"},{"name":"Chemical_Formula","value":"C16H20N4O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FQL5EUP13W"},{"name":"Legacy Concept Name","value":"Diaziquone"},{"name":"Maps_To","value":"Diaziquone"},{"name":"NCI_Drug_Dictionary_ID","value":"39161"},{"name":"NSC Number","value":"182986"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39161"},{"name":"PDQ_Open_Trial_Search_ID","value":"39161"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0113600"}]}}{"C427":{"preferredName":"Diazooxonorleucine","code":"C427","definitions":[{"definition":"An L-glutamine diazo analogue amino acid antibiotic isolated from a species of the bacterial genus Streptomyces with potential antineoplastic activity. Diazooxonorleucine inhibits several glutamine-dependent biosynthetic pathways involved in the syntheses of D-glucosamine phosphate, purines and pyrimidines. This agent inhibits phosphate-activated glutaminase, a key enzyme for the synthesis of releasable glutamine, depleting cells of this essential amino acid and reducing their capacity to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diazooxonorleucine","termGroup":"PT","termSource":"NCI"},{"termName":"6-diazo-5-oxo-L-norleucine","termGroup":"SN","termSource":"NCI"},{"termName":"6-diazo-5-oxo-norleucine","termGroup":"SN","termSource":"NCI"},{"termName":"DON","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157-03-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"03J0H273KZ"},{"name":"Legacy Concept Name","value":"Diazooxonorleucine"},{"name":"Maps_To","value":"Diazooxonorleucine"},{"name":"NCI_Drug_Dictionary_ID","value":"39224"},{"name":"NSC Number","value":"7365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39224"},{"name":"PDQ_Open_Trial_Search_ID","value":"39224"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0012020"}]}}{"C81362":{"preferredName":"Dibrospidium Chloride","code":"C81362","definitions":[{"definition":"A dispirotripiperazine derivative and alkylating agent with potential antineoplastic and anti-inflammatory activities. Dibrospidium chloride has been examined for the treatment of bone cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dibrospidium Chloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"86641-76-1"},{"name":"Chemical_Formula","value":"C18H32Br2N4O2.2Cl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GRX5L9Y3Z3"},{"name":"Legacy Concept Name","value":"Dibrospidium_Chloride"},{"name":"Maps_To","value":"Dibrospidium Chloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825594"}]}}{"C28959":{"preferredName":"Dichloroallyl Lawsone","code":"C28959","definitions":[{"definition":"A triazine derivative with antineoplastic activity.  Dichloroallyl lawsone inhibits mitochondrial dihydroorotate dehydrogenase (DHOD), an enzyme that catalyzes the only redox step in de novo pyrimidine biosynthesis, and nucleotide (RNA and DNA) biosynthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dichloroallyl Lawsone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"36417-16-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZE2BI297KA"},{"name":"Legacy Concept Name","value":"Dichloroallyl_Lawsone"},{"name":"Maps_To","value":"Dichloroallyl Lawsone"},{"name":"NSC Number","value":"126771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057845"}]}}{"C107676":{"preferredName":"Dicycloplatin","code":"C107676","definitions":[{"definition":"A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks. This mechanism results in the induction of apoptosis and cell growth inhibition. Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dicycloplatin","termGroup":"PT","termSource":"NCI"},{"termName":"DCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"287402-09-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0KC57I4UNB"},{"name":"Maps_To","value":"Dicycloplatin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3815135"}]}}{"C1338":{"preferredName":"Didox","code":"C1338","definitions":[{"definition":"A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides obligatory for synthesis of the proviral DNA intermediate of retrovirus replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Didox","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydroxybenzohydroxamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69839-83-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L106XFV0RQ"},{"name":"Legacy Concept Name","value":"Didox"},{"name":"Maps_To","value":"Didox"},{"name":"NCI_Drug_Dictionary_ID","value":"40191"},{"name":"NSC Number","value":"324360"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40191"},{"name":"PDQ_Open_Trial_Search_ID","value":"40191"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0094556"}]}}{"C87238":{"preferredName":"Dienogest","code":"C87238","definitions":[{"definition":"An orally-active, semisynthetic, fourth generation, nonethinylated progestogen with antiproliferative, antiandrogenic, anti-inflammatory and antiangiogenic activities that is used in hormone therapy and as a female contraceptive. Upon oral administration, dienogest binds intracellular progesterone receptors which then translocate to the nucleus where the drug-receptor complex interacts with progesterone response elements, thus altering the expression of target genes. Dienogest reduces the production of estradiol, prevents ovulation and alters the cervical mucus and endometrium. In addition, dienogest appears to suppress the expression of cell cycle regulator cyclin D1. Altogether, this may prevent the growth of endometrial epithelial cells and may reduce symptoms associated with leiomyoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dienogest","termGroup":"PT","termSource":"NCI"},{"termName":"17-Hydroxy-3-Oxo-19-Nor-17Alpha-Pregna-4,9-Diene-21-Nitrile","termGroup":"SN","termSource":"NCI"},{"termName":"19-Norpregna-4,9-Diene-21-Nitrile, 17-Hydroxy-3-Oxo-, (17Alpha)-","termGroup":"SN","termSource":"NCI"},{"termName":"M 18575","termGroup":"CN","termSource":"NCI"},{"termName":"MJR-35","termGroup":"CN","termSource":"NCI"},{"termName":"STS 557","termGroup":"CN","termSource":"NCI"},{"termName":"ZK 37659","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65928-58-7"},{"name":"Chemical_Formula","value":"C20H25NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46M3EV8HHE"},{"name":"Maps_To","value":"Dienogest"},{"name":"NCI_Drug_Dictionary_ID","value":"743773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743773"},{"name":"PDQ_Open_Trial_Search_ID","value":"743773"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057916"}]}}{"C1168":{"preferredName":"Diethylnorspermine","code":"C1168","definitions":[{"definition":"A synthetic bis-ethyl analogue of spermine with potential antineoplastic activity. N(1),N(11)-bis(ethyl)norspermine (DENSPM), a N-terminally alkylated tetraamine and polyamine mimetics, disrupts polyamine pool homeostasis by modulating the activities of the biosynthetic enzymes, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC). This agent also reduces polyamine concentrations through the induction of the catabolic enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT). Polyamines, an integral part of the DNA helix structure, play a critical role in cell division, differentiation and membrane function. Disruption of normal polyamine concentrations by DENSPM may lead to cell growth inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diethylnorspermine","termGroup":"PT","termSource":"NCI"},{"termName":"CI-1006","termGroup":"CN","termSource":"NCI"},{"termName":"DENSPM","termGroup":"AB","termSource":"NCI"},{"termName":"N(1),N(11)-diethylnorspermine","termGroup":"SN","termSource":"NCI"},{"termName":"N1,N11-bis(ethyl)norspermine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"121749-39-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HLI827Z1ST"},{"name":"Legacy Concept Name","value":"N_1_N_11_bis_ethyl_norspermine"},{"name":"Maps_To","value":"Diethylnorspermine"},{"name":"NCI_Drug_Dictionary_ID","value":"375649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"375649"},{"name":"PDQ_Open_Trial_Search_ID","value":"375649"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0067116"}]}}{"C2634":{"preferredName":"Digitoxin","code":"C2634","definitions":[{"definition":"A lipid soluble cardiac glycoside that inhibits the plasma membrane sodium potassium ATPase, leading to increased intracellular sodium and calcium levels and decreased intracellular potassium levels.  In studies increased intracellular calcium precedes cell death and decreased intracellular potassium increase caspase activation and DNA fragmentation, causing apoptosis and inhibition of cancer cell growth. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Digitoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Cardidigin","termGroup":"SY","termSource":"NCI"},{"termName":"CP4071","termGroup":"CN","termSource":"NCI"},{"termName":"Crystalline Digitalin","termGroup":"SY","termSource":"NCI"},{"termName":"Crystodigin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Atrial Fibrillation; Atrial Flutter; Congestive Heart Failure; Supraventricular Tachyarrhythmias."},{"name":"CAS_Registry","value":"71-63-6"},{"name":"CHEBI_ID","value":"CHEBI:28544"},{"name":"Chemical_Formula","value":"C41H64O13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E90NZP2L9U"},{"name":"Legacy Concept Name","value":"Digitoxin"},{"name":"Maps_To","value":"Digitoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"38332"},{"name":"NSC Number","value":"7529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38332"},{"name":"PDQ_Open_Trial_Search_ID","value":"38332"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012258"}]}}{"C28990":{"preferredName":"Digoxin","code":"C28990","definitions":[{"definition":"A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility.  This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity.  Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat irregular heartbeat and some types of heart failure. It is also being studied in the treatment of some types of cancer. Digoxin helps the heart work normally by controlling the amount of calcium that goes into the heart muscle. It also may kill cancer cells and make them more sensitive to anticancer drugs. It is a type of cardiac glycoside.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Digoxin","termGroup":"PT","termSource":"NCI"},{"termName":"12beta-Hydroxydigitoxin","termGroup":"SY","termSource":"NCI"},{"termName":"3beta,12beta,14-Trihydroxy-5beta,14beta-card-20(22)-enolid-3-tridigitoxosid","termGroup":"SN","termSource":"NCI"},{"termName":"Cardiogoxin","termGroup":"BR","termSource":"NCI"},{"termName":"Digoxigenin-tridigitoxosid","termGroup":"SY","termSource":"NCI"},{"termName":"Lanoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"20830-75-5"},{"name":"CHEBI_ID","value":"CHEBI:4551"},{"name":"Chemical_Formula","value":"C41H64O14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"73K4184T59"},{"name":"Legacy Concept Name","value":"Digoxin"},{"name":"Maps_To","value":"Digoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"485249"},{"name":"NSC Number","value":"95100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485249"},{"name":"PDQ_Open_Trial_Search_ID","value":"485249"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012265"}]}}{"C980":{"preferredName":"Dihydro-5-Azacytidine","code":"C980","definitions":[{"definition":"A synthetic nucleoside analogue of deoxycytidine. Dihydro-5-azacytidine inhibits DNA methyltransferase, thereby interfering with abnormal DNA methylation patterns that are associated with genetic instability in some tumor cells. Inhibition of this enzyme may restore expression of tumor-suppressor genes and result in antitumor activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dihydro-5-Azacytidine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5-triazin-2(1H)-one, 4-amino-3, 6-dihydro-1-beta-D-ribofuranosyl monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"5,6-dihydro-5-azacytidine HCl","termGroup":"SN","termSource":"NCI"},{"termName":"5,6-dihydro-5-azacytidine hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"DHAC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62488-57-7"},{"name":"Chemical_Formula","value":"C8H14N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0627D8VG1C"},{"name":"Legacy Concept Name","value":"Dihydro-5-Azacytidine"},{"name":"Maps_To","value":"Dihydro-5-Azacytidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39220"},{"name":"NSC Number","value":"264880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39220"},{"name":"PDQ_Open_Trial_Search_ID","value":"39220"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048906"}]}}{"C1463":{"preferredName":"Dihydrolenperone","code":"C1463","definitions":[{"definition":"A butyrophenone that has been investigated for antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dihydrolenperone","termGroup":"PT","termSource":"NCI"},{"termName":"1-Butanone, 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydro-lenperone","termGroup":"SY","termSource":"NCI"},{"termName":"RMI 11974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38077-12-2"},{"name":"Chemical_Formula","value":"C22H25F2NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RJ5N8VE7Z"},{"name":"Legacy Concept Name","value":"Dihydrolenperone"},{"name":"Maps_To","value":"Dihydrolenperone"},{"name":"NCI_Drug_Dictionary_ID","value":"40107"},{"name":"NSC Number","value":"343513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40107"},{"name":"PDQ_Open_Trial_Search_ID","value":"40107"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0208317"}]}}{"C158103":{"preferredName":"Dihydroorotate Dehydrogenase Inhibitor AG-636","code":"C158103","definitions":[{"definition":"An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, AG-636 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dihydroorotate Dehydrogenase Inhibitor AG-636","termGroup":"PT","termSource":"NCI"},{"termName":"AG 636","termGroup":"CN","termSource":"NCI"},{"termName":"AG-636","termGroup":"CN","termSource":"NCI"},{"termName":"AG636","termGroup":"CN","termSource":"NCI"},{"termName":"DHODH Inhibitor AG-636","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dihydroorotate Dehydrogenase Inhibitor AG-636"},{"name":"NCI_Drug_Dictionary_ID","value":"797356"},{"name":"NCI_META_CUI","value":"CL937737"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797356"},{"name":"PDQ_Open_Trial_Search_ID","value":"797356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153137":{"preferredName":"Orludodstat","code":"C153137","definitions":[{"definition":"An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, orludodstat specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) production, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orludodstat","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 2402234","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2402234","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2402234","termGroup":"CN","termSource":"NCI"},{"termName":"DHODH Inhibitor BAY2402234","termGroup":"SY","termSource":"NCI"},{"termName":"Dihydroorotate Dehydrogenase Inhibitor BAY2402234","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2225819-06-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X8GF945GMK"},{"name":"Maps_To","value":"Dihydroorotate Dehydrogenase Inhibitor BAY2402234"},{"name":"NCI_Drug_Dictionary_ID","value":"793941"},{"name":"NCI_META_CUI","value":"CL554394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793941"},{"name":"PDQ_Open_Trial_Search_ID","value":"793941"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C53434":{"preferredName":"Diindolylmethane","code":"C53434","definitions":[{"definition":"A phytonutrient and plant indole found in cruciferous vegetables including broccoli, Brussels sprouts, cabbage, cauliflower and kale, with potential anti-androgenic and antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) promotes beneficial estrogen metabolism in both sexes by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of 2-hydroxy estrogen metabolites, resulting in increased antioxidant activity. Although this agent induces apoptosis in tumor cells in vitro, the exact mechanism by which DIM exhibits its antineoplastic activity in vivo is unknown.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of prostate cancer and in the prevention of cervical cancer. Diindolylmethane is found in cruciferous vegetables like broccoli, brussels sprouts, cauliflower, cabbage, and kale. It is a type of plant indole.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Diindolylmethane","termGroup":"PT","termSource":"NCI"},{"termName":"3,3'-Diindolymethane","termGroup":"SN","termSource":"NCI"},{"termName":"3,3'-Methylenebis-1H-indole","termGroup":"SN","termSource":"NCI"},{"termName":"CCRIS 5806","termGroup":"CN","termSource":"NCI"},{"termName":"Di-Indoly Methane","termGroup":"SY","termSource":"NCI"},{"termName":"DIM-Plus","termGroup":"BR","termSource":"NCI"},{"termName":"DIMPRO","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1968-05-4"},{"name":"CHEBI_ID","value":"CHEBI:50182"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SSZ9HQT61Z"},{"name":"Legacy Concept Name","value":"Diindolylmethane"},{"name":"Maps_To","value":"Diindolylmethane"},{"name":"NCI_Drug_Dictionary_ID","value":"462587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462587"},{"name":"PDQ_Open_Trial_Search_ID","value":"462587"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1100708"}]}}{"C1073":{"preferredName":"Dimethylmyleran","code":"C1073","definitions":[{"definition":"An aliphatic analogue of busulfan with potential antineoplastic activity.  As an alkylating agent, dimethylbusulfan induces neutropenia and has been shown to exhibit antitumor effects in some animal models.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dimethylmyleran","termGroup":"PT","termSource":"NCI"},{"termName":"2,5-Dimethanesulfonoxyhexane","termGroup":"SN","termSource":"NCI"},{"termName":"Dimethyl-Myleran","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylbusulfan","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylmyleran","termGroup":"SY","termSource":"NCI"},{"termName":"DMB","termGroup":"AB","termSource":"NCI"},{"termName":"DMM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55-93-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dimethylbusulfan"},{"name":"Maps_To","value":"Dimethylmyleran"},{"name":"NCI_Drug_Dictionary_ID","value":"39221"},{"name":"NSC Number","value":"180541"},{"name":"NSC Number","value":"180542"},{"name":"NSC Number","value":"180543"},{"name":"NSC Number","value":"23890"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39221"},{"name":"PDQ_Open_Trial_Search_ID","value":"39221"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058272"}]}}{"C78854":{"preferredName":"Dinaciclib","code":"C78854","definitions":[{"definition":"A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of advanced melanoma (a type of skin cancer) and other types of cancer. It blocks cell division and may cause cancer cells to die. It is a type of cyclin-dependent kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dinaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- a]pyrimidin-5-yl]-, (2S)-","termGroup":"SN","termSource":"NCI"},{"termName":"CDK Inhibitor SCH 727965","termGroup":"SY","termSource":"NCI"},{"termName":"MK 7965","termGroup":"CN","termSource":"NCI"},{"termName":"MK-7965","termGroup":"CN","termSource":"NCI"},{"termName":"MK7965","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 727965","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-727965","termGroup":"CN","termSource":"NCI"},{"termName":"SCH727965","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"779353-01-4"},{"name":"Chemical_Formula","value":"C21H28N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4V8ECV0NBQ"},{"name":"Legacy Concept Name","value":"CDK_Inhibitor_SCH_727965"},{"name":"Maps_To","value":"Dinaciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"612855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612855"},{"name":"PDQ_Open_Trial_Search_ID","value":"612855"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698720"}]}}{"C1570":{"preferredName":"Dinutuximab","code":"C1570","definitions":[{"definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dinutuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Ch 14.18UTC","termGroup":"SY","termSource":"NCI"},{"termName":"Ch14.18","termGroup":"CN","termSource":"NCI"},{"termName":"Dinutuximab Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Qarziba","termGroup":"FB","termSource":"NCI"},{"termName":"Unituxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"childhood neuroblastoma"},{"name":"CAS_Registry","value":"1363687-32-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7SQY4ZUD30"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Ch14_18"},{"name":"Maps_To","value":"Dinutuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"42042"},{"name":"NSC Number","value":"623408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42042"},{"name":"PDQ_Open_Trial_Search_ID","value":"42042"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3871452"}]}}{"C115103":{"preferredName":"Dioscorea nipponica Makino Extract DNE3","code":"C115103","definitions":[{"definition":"An extract of the plant Dioscorea nipponica Makino and inhibitor of both the serine/threonine protein kinase Akt (protein kinase B) and members of the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases, with potential antineoplastic and anti-metastatic activities. Dioscorea nipponica Makino extracted with ethyl acetate (DNE3) binds to and inhibits PI3K and Akt. This inhibits PI3K/Akt-mediated signaling and prevents both growth and survival of PI3K/Akt-overexpressing tumor cells. In addition, DNE3 increases the expression of tissue inhibitor of metalloproteinase-2 (TIMP-2), inhibits the secretion of matrix metalloproteinases (MMPs), primarily MMP-2 and MMP-9, and inhibits the serine protease urokinase (urokinase-type plasminogen activator; u-PA). This inhibits tumor cell invasion, migration, motility, and adhesion. This agent also inhibits the activation of both cAMP response element-binding (CREB) and activating protein-1 (AP-1), and increases the expression of IkappaB (IkB), which inhibits the activation of nuclear factor-kappa B (NF-kB). These processes further contribute to this agent's anti-tumor potential in susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dioscorea nipponica Makino Extract DNE3","termGroup":"PT","termSource":"NCI"},{"termName":"Dioscorea nipponica Extract with Ethyl Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"DNE3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dioscorea nipponica Makino Extract DNE3"},{"name":"NCI_Drug_Dictionary_ID","value":"759832"},{"name":"NCI_META_CUI","value":"CL472634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759832"},{"name":"PDQ_Open_Trial_Search_ID","value":"759832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28994":{"preferredName":"Diphencyprone","code":"C28994","definitions":[{"definition":"A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diphencyprone","termGroup":"PT","termSource":"NCI"},{"termName":"Diphenylcyclopropenone","termGroup":"SY","termSource":"NCI"},{"termName":"DPCP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"886-38-4"},{"name":"CHEBI_ID","value":"CHEBI:53074"},{"name":"Chemical_Formula","value":"C15H10O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I7G14NW5EC"},{"name":"Legacy Concept Name","value":"Diphencyprone"},{"name":"Maps_To","value":"Diphencyprone"},{"name":"NCI_Drug_Dictionary_ID","value":"742143"},{"name":"NSC Number","value":"57541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742143"},{"name":"PDQ_Open_Trial_Search_ID","value":"742143"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058379"}]}}{"C432":{"preferredName":"Ditiocarb","code":"C432","definitions":[{"definition":"A sulfhydryl-containing carbamate that is the primary in vivo metabolite of disulfiram. Diethyldithiocarbamate chelates zinc, thereby inhibiting metalloproteinases, thereby preventing the degradation of the extracellular matrix and inhibiting an initial step in cancer metastasis and angiogenesis. A known inhibitor of superoxide dismutase, this agent can either potentiate or protect against cell oxidative damage caused by ionizing radiation, depending on the time of administration. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ditiocarb","termGroup":"PT","termSource":"NCI"},{"termName":"DDTC","termGroup":"AB","termSource":"NCI"},{"termName":"DIECA","termGroup":"AB","termSource":"NCI"},{"termName":"Diethylcarbamodithioic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldione","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithiocarbamate","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithiocarbamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithiocarbaminic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Diethyldithione","termGroup":"SY","termSource":"NCI"},{"termName":"DTC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"147-84-2"},{"name":"Chemical_Formula","value":"C5H11NS2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"99Z2744345"},{"name":"Legacy Concept Name","value":"Diethyldithiocarbamate"},{"name":"Maps_To","value":"Ditiocarb"},{"name":"NCI_Drug_Dictionary_ID","value":"40247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40247"},{"name":"PDQ_Open_Trial_Search_ID","value":"40247"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012194"}]}}{"C90539":{"preferredName":"Mipicoledine","code":"C90539","definitions":[{"definition":"A cholesterol carbonate derivative of 4-demethylpenclomedine (DM-PEN) with potential antineoplastic alkylating activity. Upon intravenous administration of mipicoledine, the carbonium moiety binds to and alkylates DNA at the N7 guanine position, thereby causing DNA crosslinks. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. In addition, due to its lipophilic cholesteryl moiety this agent is able to cross the blood brain barrier (BBB) and therefore can be given intravenously compared to other alkylating agents that need to be given intra-cranially.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mipicoledine","termGroup":"PT","termSource":"NCI"},{"termName":"4-Demethylcholesteryloxycarbonylpenclomedine","termGroup":"SN","termSource":"NCI"},{"termName":"DM-CHOC-PEN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"942149-56-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1S83F4T2WE"},{"name":"Maps_To","value":"DM-CHOC-PEN"},{"name":"NCI_Drug_Dictionary_ID","value":"664344"},{"name":"NCI_META_CUI","value":"CL416220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"664344"},{"name":"PDQ_Open_Trial_Search_ID","value":"664344"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77864":{"preferredName":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015","code":"C77864","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against the cell surface-associated protein Cripto and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of DM4-conjugated anti-Cripto monoclonal antibody BIIB015 binds to the tumor associated antigen (TAA) Cripto; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of Cripto-expressing tumor cells. Constitutively expressed during embryogenesis, Cripto belongs to the EGF-CFC family of growth factor-like molecules and plays a key role in signaling pathways of certain transforming growth factor-beta superfamily members; as a TAA, Cripto is overexpressed in carcinomas such as those of the breast, ovary, stomach, lung, and pancreas while its expression is absent in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"DM4-Conjugated_Anti-Cripto_Monoclonal_Antibody_BIIB015"},{"name":"Maps_To","value":"DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015"},{"name":"NCI_Drug_Dictionary_ID","value":"596550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596550"},{"name":"PDQ_Open_Trial_Search_ID","value":"596550"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2713087"}]}}{"C92588":{"preferredName":"DNA Interference Oligonucleotide PNT2258","code":"C92588","definitions":[{"definition":"A liposomal formulation of the 24-mer oligonucleotide PNT100, with potential antineoplastic activity. PNT2258 targets and complements to untranscribed DNA sequence upstream of BCL2 promoters, thereby interfering with DNA replication and transcription of the BCL2 gene. This may promote and restore the apoptotic pathway in BCL2-overexpressing tumor cells. BCL2, an anti-apoptotic protein, is overexpressed in a wide variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Interference Oligonucleotide PNT2258","termGroup":"PT","termSource":"NCI"},{"termName":"DNAi Drug PNT2258","termGroup":"BR","termSource":"NCI"},{"termName":"PNT2258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Interference Oligonucleotide PNT2258"},{"name":"NCI_Drug_Dictionary_ID","value":"685213"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685213"},{"name":"PDQ_Open_Trial_Search_ID","value":"685213"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985197"}]}}{"C29435":{"preferredName":"DNA Minor Groove Binding Agent SG2000","code":"C29435","definitions":[{"definition":"A sequence-selective pyrrolobenzodiazepine (PBD) dimer with potential antineoplastic activity. Following intravenous administration, DNA minor groove binding agent SG2000 preferentially and covalently binds to purine-GATC-pyrimidine sequences, with the imine/carbinolamine moieties of SG2000 binding to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links and inhibits both DNA replication and gene transcription, which lead to the inhibition of cell growth. With a preference for binding to purine-GATC-pyrimidine sequences, SG2000 adducts do not appear to be susceptible to p53-mediated DNA excision repair.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called DNA cross-linking agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DNA Minor Groove Binding Agent SG2000","termGroup":"PT","termSource":"NCI"},{"termName":"(11aS,11a'S)-8,8'-(propane-1,3-diylbis(oxy))bis(7-methoxy-2-methylene-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one)","termGroup":"SN","termSource":"NCI"},{"termName":"BN2629","termGroup":"CN","termSource":"NCI"},{"termName":"NSC 694501","termGroup":"CN","termSource":"NCI"},{"termName":"Pyrrolobenzodiazepine Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"SG2000","termGroup":"CN","termSource":"NCI"},{"termName":"SJG136","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"232931-57-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KT0ZQ64X1A"},{"name":"Legacy Concept Name","value":"SJG-136"},{"name":"Maps_To","value":"DNA Minor Groove Binding Agent SG2000"},{"name":"NCI_Drug_Dictionary_ID","value":"415963"},{"name":"NSC Number","value":"694501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415963"},{"name":"PDQ_Open_Trial_Search_ID","value":"415963"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519143"}]}}{"C116709":{"preferredName":"Rocakinogene Sifuplasmid","code":"C116709","definitions":[{"definition":"A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of rocakinogene sifuplasmid, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rocakinogene Sifuplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"DNA Plasmid Encoding Interleukin-12 INO-9012","termGroup":"SY","termSource":"NCI"},{"termName":"INO-9012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253753-17-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91JHE0ANN8"},{"name":"Maps_To","value":"DNA Plasmid Encoding Interleukin-12 INO-9012"},{"name":"Maps_To","value":"Rocakinogene Sifuplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"762182"},{"name":"NCI_META_CUI","value":"CL473906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762182"},{"name":"PDQ_Open_Trial_Search_ID","value":"762182"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163978":{"preferredName":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151","code":"C163978","definitions":[{"definition":"A DNA-based combined formulation composed of INO-5150, DNA plasmids encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), and INO-9012, a plasmid DNA vaccine encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery of INO-5151 and electroporation of the PSA/PSMA DNA plasmid INO-5150, PSA and PSMA are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing PSA and PSMA, resulting in tumor cell lysis. Upon electroporation of the DNA plasmid encoding IL-12 INO-9012, IL-12 is translated in cells and the expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of INO-5150 alone. PSA and PSMA are overexpressed on a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151","termGroup":"PT","termSource":"NCI"},{"termName":"Formulation INO-5150 with INO-9012","termGroup":"SY","termSource":"NCI"},{"termName":"INO 5151","termGroup":"CN","termSource":"NCI"},{"termName":"INO-5150 with INO-9012","termGroup":"SY","termSource":"NCI"},{"termName":"INO-5150/INO-9012 Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"INO-5151","termGroup":"CN","termSource":"NCI"},{"termName":"INO5151","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151"},{"name":"NCI_META_CUI","value":"CL977247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123919":{"preferredName":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457","code":"C123919","definitions":[{"definition":"A DNA-based combination immunotherapeutic, MEDI0457, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457","termGroup":"PT","termSource":"NCI"},{"termName":"INO 3112","termGroup":"CN","termSource":"NCI"},{"termName":"INO-3112","termGroup":"CN","termSource":"NCI"},{"termName":"INO-3112 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 0457","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-0457","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI0457","termGroup":"CN","termSource":"NCI"},{"termName":"VGX-3100 Plus INO-9012","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457"},{"name":"NCI_Drug_Dictionary_ID","value":"775854"},{"name":"NCI_META_CUI","value":"CL498283"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775854"},{"name":"PDQ_Open_Trial_Search_ID","value":"775854"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123923":{"preferredName":"DNA Vaccine VB10.16","code":"C123923","definitions":[{"definition":"A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA Vaccine VB10.16","termGroup":"PT","termSource":"NCI"},{"termName":"VB10.16","termGroup":"CN","termSource":"NCI"},{"termName":"VB10.16 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA Vaccine VB10.16"},{"name":"NCI_Drug_Dictionary_ID","value":"775928"},{"name":"NCI_META_CUI","value":"CL498287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775928"},{"name":"PDQ_Open_Trial_Search_ID","value":"775928"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129061":{"preferredName":"DNA-dependent Protein Kinase Inhibitor VX-984","code":"C129061","definitions":[{"definition":"An ATP-competitive inhibitor of the catalytic subunit of DNA-dependent protein kinase (DNA-PK), with potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, DNA-PK inhibitor VX-984 binds to and inhibits the catalytic subunit of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-dependent Protein Kinase Inhibitor VX-984","termGroup":"PT","termSource":"NCI"},{"termName":"DNA-PK Inhibitor VX-984","termGroup":"SY","termSource":"NCI"},{"termName":"VX-984","termGroup":"CN","termSource":"NCI"},{"termName":"VX984","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1476074-39-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0C33IBK195"},{"name":"Maps_To","value":"DNA-dependent Protein Kinase Inhibitor VX-984"},{"name":"NCI_Drug_Dictionary_ID","value":"783593"},{"name":"NCI_META_CUI","value":"CL512131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783593"},{"name":"PDQ_Open_Trial_Search_ID","value":"783593"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97040":{"preferredName":"DNA-PK/TOR Kinase Inhibitor CC-115","code":"C97040","definitions":[{"definition":"A dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. CC-115 binds to and inhibits the activity of DNA-PK and both raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2), which may lead to a reduction in cellular proliferation of cancer cells expressing DNA-PK and TOR. DNA-PK, a serine/threonine kinase and a member of the PI3K-related kinase subfamily of protein kinases, is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks via the DNA nonhomologous end joining (NHEJ) pathway; mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-PK/TOR Kinase Inhibitor CC-115","termGroup":"PT","termSource":"NCI"},{"termName":"CC-115","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228013-15-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FII75TFH5L"},{"name":"Maps_To","value":"DNA-PK/TOR Kinase Inhibitor CC-115"},{"name":"NCI_Drug_Dictionary_ID","value":"700650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700650"},{"name":"PDQ_Open_Trial_Search_ID","value":"700650"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273208"}]}}{"C2530":{"preferredName":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98","code":"C2530","definitions":[{"definition":"A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3' un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It blocks the production of a protein called DNA methyltransferase, which helps control gene expression. This may kill cancer cells that need DNA methyltransferase to grow. It is a type of antisense oligonucleotide.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98","termGroup":"PT","termSource":"NCI"},{"termName":"MG 98","termGroup":"CN","termSource":"NCI"},{"termName":"MG-98","termGroup":"CN","termSource":"NCI"},{"termName":"MG-98 oligonucleotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MG_98"},{"name":"Maps_To","value":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98"},{"name":"NCI_Drug_Dictionary_ID","value":"43475"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43475"},{"name":"PDQ_Open_Trial_Search_ID","value":"43475"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796640"}]}}{"C1526":{"preferredName":"Docetaxel","code":"C1526","definitions":[{"definition":"A drug used together with other drugs to treat certain types of breast cancer, stomach cancer, prostate cancer, and certain types of head and neck cancer. It is also being studied in the treatment of other types of cancer. Docetaxel is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"[2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Docecad","termGroup":"FB","termSource":"NCI"},{"termName":"N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol","termGroup":"SN","termSource":"NCI"},{"termName":"RP 56976","termGroup":"CN","termSource":"NCI"},{"termName":"RP-56976","termGroup":"CN","termSource":"NCI"},{"termName":"RP56976","termGroup":"CN","termSource":"NCI"},{"termName":"Taxotere","termGroup":"BR","termSource":"NCI"},{"termName":"Taxotere Injection Concentrate","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Esophageal cancer; Gastric cancer; Head/Neck cancers; Locally Advanced or Metastatic Non small-cell lung cancer; Ovarian cancer; Metastatic Prostate cancer"},{"name":"CAS_Registry","value":"148408-66-6"},{"name":"CHEBI_ID","value":"CHEBI:59809"},{"name":"Chemical_Formula","value":"C43H53NO14.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"15H5577CQD"},{"name":"Legacy Concept Name","value":"Docetaxel"},{"name":"Maps_To","value":"Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"41657"},{"name":"NSC Number","value":"628503"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41657"},{"name":"PDQ_Open_Trial_Search_ID","value":"41657"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0246415"}]}}{"C61734":{"preferredName":"Docetaxel Anhydrous","code":"C61734","definitions":[{"definition":"The anhydrous form of docetaxel, a semisynthetic side-chain analogue of paclitaxel with antineoplastic property. Docetaxel binds specifically to the beta-tubulin subunit of microtubules and thereby antagonizes the disassembly of the microtubule proteins. This results in the persistence of aberrant microtubule structures and results in cell-cycle arrest and subsequent cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"DOCEFREZ","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114977-28-5"},{"name":"CHEBI_ID","value":"CHEBI:4672"},{"name":"Chemical_Formula","value":"C43H53NO14"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"699121PHCA"},{"name":"Legacy Concept Name","value":"Docetaxel_Anhydrous"},{"name":"Maps_To","value":"Docetaxel Anhydrous"},{"name":"NSC Number","value":"628503"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771375"}]}}{"C78196":{"preferredName":"Docetaxel Emulsion ANX-514","code":"C78196","definitions":[{"definition":"An injectable emulsion formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Docetaxel emulsion ANX-514 is formulated without polysorbate 80 or other detergents in order to reduce the incidence and severity of hypersensitivity reactions. In addition, the exclusion of polysorbate 80 in this formulation precludes foaming during the preparation process, thus facilitating preparation and administration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Emulsion ANX-514","termGroup":"PT","termSource":"NCI"},{"termName":"ANX-514","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Docetaxel_Emulsion_ANX-514"},{"name":"Maps_To","value":"Docetaxel Emulsion ANX-514"},{"name":"NCI_Drug_Dictionary_ID","value":"595290"},{"name":"NCI_META_CUI","value":"CL383589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595290"},{"name":"PDQ_Open_Trial_Search_ID","value":"595290"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88322":{"preferredName":"Docetaxel Formulation CKD-810","code":"C88322","definitions":[{"definition":"An injectable formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Formulation CKD-810","termGroup":"PT","termSource":"NCI"},{"termName":"CKD-810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Formulation CKD-810"},{"name":"NCI_Drug_Dictionary_ID","value":"661020"},{"name":"NCI_META_CUI","value":"CL413582"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661020"},{"name":"PDQ_Open_Trial_Search_ID","value":"661020"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102568":{"preferredName":"Docetaxel Lipid Microspheres","code":"C102568","definitions":[{"definition":"A lipid microsphere (LM)-based formulation containing the poorly water soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which causes cell cycle arrest at the G2/M phase and leads to cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the LM formulation may enhance stability, improve efficacy and may reduce toxicity; this formulation does not contain toxic detergents needed to solubilize docetaxel which further improves its side effect profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Lipid Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"DLE","termGroup":"AB","termSource":"NCI"},{"termName":"Docetaxel Lipid Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"DT-LM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Lipid Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"735255"},{"name":"NCI_META_CUI","value":"CL436875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735255"},{"name":"PDQ_Open_Trial_Search_ID","value":"735255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121961":{"preferredName":"Docetaxel Nanoparticle CPC634","code":"C121961","definitions":[{"definition":"A polymeric nanoparticle (PNP) formulation containing the poorly water-soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel nanoparticle CPC634, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site, binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Nanoparticle CPC634","termGroup":"PT","termSource":"NCI"},{"termName":"CPC 634","termGroup":"CN","termSource":"NCI"},{"termName":"CPC-634","termGroup":"CN","termSource":"NCI"},{"termName":"CPC634","termGroup":"CN","termSource":"NCI"},{"termName":"CriPec (R) Docetaxel","termGroup":"FB","termSource":"NCI"},{"termName":"Docetaxel containing CriPec (R) Nanoparticles","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-containing CriPec (R) Nanoparticles CPC634","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle-encapsulated Docetaxel CPC634","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Nanoparticle CPC634"},{"name":"NCI_Drug_Dictionary_ID","value":"772251"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772251"},{"name":"PDQ_Open_Trial_Search_ID","value":"772251"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054421"}]}}{"C165263":{"preferredName":"Docetaxel Polymeric Micelles","code":"C165263","definitions":[{"definition":"A nanoparticle-based formulation consisting of polymeric micelles (PMs), made with poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) block polymers, encapsulating the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with potential antineoplastic activity. Upon intravenous administration of the docetaxel PMs, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site where it binds specifically to the beta-tubulin subunit of the microtubule, thereby stabilizing tubulin and inhibiting microtubule disassembly. This results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel Polymeric Micelles","termGroup":"PT","termSource":"NCI"},{"termName":"Docetaxel Lipid Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-loaded PM","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-loaded PMs","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-loaded Polymeric Micelles","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-PM","termGroup":"SY","termSource":"NCI"},{"termName":"NANOXEL-M","termGroup":"FB","termSource":"NCI"},{"termName":"NanoxelM","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel Polymeric Micelles"},{"name":"NCI_Drug_Dictionary_ID","value":"799405"},{"name":"NCI_META_CUI","value":"CL978531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799405"},{"name":"PDQ_Open_Trial_Search_ID","value":"799405"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121539":{"preferredName":"Docetaxel-loaded Nanopharmaceutical CRLX301","code":"C121539","definitions":[{"definition":"A nanoparticle-based formulation containing the poorly water-soluble, second-generation taxane analog docetaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel-loaded nanopharmaceutical CRLX301, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, CRLX301 is taken up by the tumor cell via macropinocytosis. Subsequently, docetaxel is slowly released into the cytoplasm where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This prevents mitosis and results in cell death. Compared to the administration of docetaxel alone, this formulation is able to increase docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel-loaded Nanopharmaceutical CRLX301","termGroup":"PT","termSource":"NCI"},{"termName":"CRLX301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel-loaded Nanopharmaceutical CRLX301"},{"name":"NCI_Drug_Dictionary_ID","value":"770081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770081"},{"name":"PDQ_Open_Trial_Search_ID","value":"770081"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053653"}]}}{"C91087":{"preferredName":"Docetaxel-PNP","code":"C91087","definitions":[{"definition":"A polymeric nanoparticle (PNP) formulation containing the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the PNP formulation may enhance stability and improve delivery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel-PNP","termGroup":"PT","termSource":"NCI"},{"termName":"PNP-DTX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel-PNP"},{"name":"NCI_Drug_Dictionary_ID","value":"671819"},{"name":"NCI_META_CUI","value":"CL421475"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671819"},{"name":"PDQ_Open_Trial_Search_ID","value":"671819"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162784":{"preferredName":"Docetaxel/Ritonavir","code":"C162784","definitions":[{"definition":"An orally bioavailable combination agent containing docetaxel, a second generation taxane, and ritonavir, a cytochrome P450 (CYP) 3A4 inhibitor, with potential enhanced antineoplastic activity. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death.  Docetaxel is metabolized by CYP3A4  enzymes which is inhibited by the presence of ritonavir. This increases the plasma concentration of docetaxel and may increase docetaxel's efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Docetaxel/Ritonavir","termGroup":"PT","termSource":"NCI"},{"termName":"ModraDoc006/r","termGroup":"FB","termSource":"NCI"},{"termName":"Oral Docetaxel/Ritonavir","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Docetaxel/Ritonavir"},{"name":"NCI_Drug_Dictionary_ID","value":"798993"},{"name":"NCI_META_CUI","value":"CL973164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798993"},{"name":"PDQ_Open_Trial_Search_ID","value":"798993"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1300":{"preferredName":"Dolastatin 10","code":"C1300","definitions":[{"definition":"A pentapeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Binding to tubulin, Dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis.  This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It binds to a protein that cells need to divide and it may kill cancer cells. Dolastatin 10 comes from a marine organism. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Dolastatin 10","termGroup":"PT","termSource":"NCI"},{"termName":"B720389K560","termGroup":"CN","termSource":"NCI"},{"termName":"Dolastatin-10","termGroup":"SY","termSource":"NCI"},{"termName":"L-Valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1- methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*[1S*,2S*,3(R*)]]]","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110417-88-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EI946JT51X"},{"name":"Legacy Concept Name","value":"Dolastatin_10"},{"name":"Maps_To","value":"Dolastatin 10"},{"name":"NCI_Drug_Dictionary_ID","value":"42316"},{"name":"NSC Number","value":"376128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42316"},{"name":"PDQ_Open_Trial_Search_ID","value":"42316"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0082338"}]}}{"C1439":{"preferredName":"Dolastatin 15","code":"C1439","definitions":[{"definition":"A depsipeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Less potent than the structurally-related compound dolastatin 10, dolastatin 15 binds weakly to tubulin and blocks microtubule assembly, thereby inhibiting mitosis.  Dolastatin 15 also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dolastatin 15","termGroup":"PT","termSource":"NCI"},{"termName":"L-Proline, 1-(1-(N-(N-(N,N-dimethyl-L-valyl)-L-valyl)-N-methyl-L-valyl)-L-prolyl)-, 1-((2,5-dihydro-3-methoxy-5-oxo-2-(phenylmethyl)-1H-pyrrol-1-yl)carbonyl)-2-methylpropyl ester, (S-(R*,R*))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123884-00-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J9ZKS885H5"},{"name":"Legacy Concept Name","value":"Dolastatin_15"},{"name":"Maps_To","value":"Dolastatin 15"},{"name":"NSC Number","value":"617668"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0170214"}]}}{"C96797":{"preferredName":"Domatinostat","code":"C96797","definitions":[{"definition":"An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity. Domatinostat selectively binds to and inhibits class I HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the selective transcription of tumor suppressor genes, and the tumor suppressor protein-mediated inhibition of tumor cell division and eventually the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Domatinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(2-aminophenyl)-3-(1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"4SC-202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"910462-43-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"264ARM7UXX"},{"name":"Maps_To","value":"Domatinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"700110"},{"name":"NCI_META_CUI","value":"CL429405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700110"},{"name":"PDQ_Open_Trial_Search_ID","value":"700110"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118294":{"preferredName":"Donafenib","code":"C118294","definitions":[{"definition":"An orally available multikinase inhibitor that targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, donafenib binds to and blocks the activity of Raf kinase, and inhibits Raf-mediated signal transduction pathways. This inhibits cell proliferation in Raf-expressing tumor cells. In addition, this agent may inhibit unidentified RTKs, and thus may further block tumor cell proliferation in susceptible tumor cells. Raf, a serine/threonine protein kinase, plays a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway. Deregulation of this pathway often results in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Donafenib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinecarboxamide, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-(4-((4-Chloro-3-(trifluoromethyl)phenyl)carbamoylamino)phenoxy)-N-(trideuteriomethyl)pyridine-2-carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"CM 4307","termGroup":"CN","termSource":"NCI"},{"termName":"CM-4307","termGroup":"CN","termSource":"NCI"},{"termName":"CM4307","termGroup":"CN","termSource":"NCI"},{"termName":"Zepsun","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1130115-44-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"41XGO0VS1U"},{"name":"Maps_To","value":"Donafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"764413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764413"},{"name":"PDQ_Open_Trial_Search_ID","value":"764413"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899341"}]}}{"C88345":{"preferredName":"Onzigolide","code":"C88345","definitions":[{"definition":"A chimeric dopamine (DA)-somatostatin (SST) compound, with potential antineoplastic activity. Upon administration, onzigolide binds with high affinity to dopamine D2 receptor (D2R) and somatostatin receptor subtype 2 (SSTR2), and to a lesser extent to somatostatin receptor subtype 5 (SSTR5). This agent appears to exert its effect mainly by binding to D2R to activate the ERK1/2 and p38 MAPK pathways, thus inducing apoptosis and inhibiting cellular proliferation in non-functioning pituitary adenoma (NFPA) and neuroendocrine tumors. By binding to SSTR2, this agent may inhibit the secretion of growth hormone (GH) by the pituitary gland.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onzigolide","termGroup":"PT","termSource":"NCI"},{"termName":"BIM-23A760","termGroup":"CN","termSource":"NCI"},{"termName":"Dopamine-Somatostatin Chimeric Molecule TBR-760","termGroup":"SY","termSource":"NCI"},{"termName":"TBR 760","termGroup":"CN","termSource":"NCI"},{"termName":"TBR-760","termGroup":"CN","termSource":"NCI"},{"termName":"TBR760","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"868562-36-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L32IM11DV4"},{"name":"Maps_To","value":"Dopamine-Somatostatin Chimeric Molecule BIM-23A760"},{"name":"NCI_Drug_Dictionary_ID","value":"661022"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661022"},{"name":"PDQ_Open_Trial_Search_ID","value":"661022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2604387"}]}}{"C148462":{"preferredName":"Delolimogene Mupadenorepvec","code":"C148462","definitions":[{"definition":"A double-armed oncolytic adenovirus composed of a recombinant genetically modified E1/E3-deleted, adenoviral serotype 5 (Ad5) vector, with the L5 segment of the Ad5 fiber replaced by the shaft and knob from the Ad35 serotype (Ad5/35), which expresses a trimerized (TMZ) form of the membrane-bound immunostimulator CD40 ligand (CD40L; TNFSF5) and the ligand for the signaling domain 4-1BB (4-1BBL; CD137L; TNFSF9), under the control of a CMV promoter, with potential immunostimulating and antineoplastic activities. Upon intratumoral administration of delolimogene mupadenorepvec, the virus infects and selectively replicates in tumor cells. This causes direct oncolysis and the release of a plethora of tumor-associated antigens (TAAs) from the tumor cells. The released TAAs stimulate the immune system and activate anti-tumor cytotoxic T-lymphocytes (CTLs), thereby further killing tumor cells. In addition, infected tumor cells and tumor stroma cells, including stellate cells and infiltrating immune cells, express the immunostimulants CD40L and 4-1BBL. The expressed CD40L and 4-1BBL proteins activate the CD40L- and 4-1BBL-mediated signaling pathways, respectively. This activates antigen-presenting cells (APCs), such as dendritic cells (DCs) and M1 macrophages. The DCs produce various cytokines, including interleukin-12 (IL12), IL21, tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFNg), which leads to the activation and expansion of both T-cells and natural killer (NK) cells. Altogether, this modulates immune suppression in the tumor microenvironment (TME), disrupts tumor stroma, and causes additional immune stimulation against tumor cells, thereby inducing further tumor cell lysis. In addition, CD40L reduces myeloid suppressor cells in the TME. Inclusion of the chimeric Ad5/35 fiber targets CD46 and increases viral uptake in cells. Transgene expression is driven by a separate promoter to allow for efficient expression in both tumor cells and tumor stroma. Replication is restricted to tumor cells by the presence of the delta24 mutation in the E1A gene, which deletes the retinoplastoma protein (pRb)-binding domain and forces viral replication to be conditional on hyperphosphorylated pRb and a dysfunctional Rb pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Delolimogene Mupadenorepvec","termGroup":"PT","termSource":"NCI"},{"termName":"LOAd 703","termGroup":"CN","termSource":"NCI"},{"termName":"LOAd-703","termGroup":"CN","termSource":"NCI"},{"termName":"LOAd703","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenovirus LOAd703","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2061938-98-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3ZQ57V6YWZ"},{"name":"Maps_To","value":"Delolimogene Mupadenorepvec"},{"name":"Maps_To","value":"Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703"},{"name":"NCI_Drug_Dictionary_ID","value":"802087"},{"name":"NCI_META_CUI","value":"CL551080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802087"},{"name":"PDQ_Open_Trial_Search_ID","value":"802087"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C76199":{"preferredName":"Dovitinib","code":"C76199","definitions":[{"definition":"A benzimidazole-quinolinone compound and receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. In addition, this agent also inhibits other members of the RTK superfamily, including fibroblast growth factor receptor 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1. This may further lead to a reduction of cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dovitinib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"405169-16-6"},{"name":"Chemical_Formula","value":"C21H21FN6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I35H55G906"},{"name":"Legacy Concept Name","value":"Dovitinib"},{"name":"Maps_To","value":"Dovitinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699806"}]}}{"C62435":{"preferredName":"Dovitinib Lactate","code":"C62435","definitions":[{"definition":"The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dovitinib Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one mono 2-hydroxypropanoate Hydrate","termGroup":"SN","termSource":"NCI"},{"termName":"CHIR 258","termGroup":"CN","termSource":"NCI"},{"termName":"CHIR-258","termGroup":"CN","termSource":"NCI"},{"termName":"CHIR258","termGroup":"CN","termSource":"NCI"},{"termName":"RTK Inhibitor TKI258","termGroup":"SY","termSource":"NCI"},{"termName":"TKI 258","termGroup":"CN","termSource":"NCI"},{"termName":"TKI-258","termGroup":"CN","termSource":"NCI"},{"termName":"TKI258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915769-50-5"},{"name":"Chemical_Formula","value":"C21H21FN6O.C3H6O3.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69VKY8P7EA"},{"name":"Legacy Concept Name","value":"CHIR-258"},{"name":"Maps_To","value":"Dovitinib Lactate"},{"name":"NCI_Drug_Dictionary_ID","value":"488976"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488976"},{"name":"PDQ_Open_Trial_Search_ID","value":"488976"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1568328"}]}}{"C61737":{"preferredName":"Doxazosin","code":"C61737","definitions":[{"definition":"A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxazosin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74191-85-8"},{"name":"CHEBI_ID","value":"CHEBI:4708"},{"name":"Chemical_Formula","value":"C23H25N5O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NW1291F1W8"},{"name":"Legacy Concept Name","value":"Doxazosin"},{"name":"Maps_To","value":"Doxazosin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0114873"}]}}{"C2645":{"preferredName":"Doxercalciferol","code":"C2645","definitions":[{"definition":"A substance being studied in the prevention of recurrent prostate cancer. It is a type of vitamin D analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analog of vitamin D with potential antineoplastic activity. In the liver, doxercalciferol is converted to its biologically active vitamin D metabolites, which control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. Through interaction with specific receptor proteins in target tissues, these vitamin D metabolites act directly on osteoblasts to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion. This agent has also been shown to inhibit the growth of retinoblastomas, and may exhibit some antiproliferative activity against prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxercalciferol","termGroup":"PT","termSource":"NCI"},{"termName":"(1alpha,3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol","termGroup":"SN","termSource":"NCI"},{"termName":"1-Alpha-Hydroxyvitamin D2","termGroup":"SN","termSource":"NCI"},{"termName":"Hectorol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Secondary hyperparathyroidism in end stage renal disease in patients on hemodialysis."},{"name":"CAS_Registry","value":"54573-75-0"},{"name":"Chemical_Formula","value":"C28H44O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3DIZ9LF5Y9"},{"name":"Legacy Concept Name","value":"Doxercalciferol"},{"name":"Maps_To","value":"Doxercalciferol"},{"name":"NCI_Drug_Dictionary_ID","value":"38406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38406"},{"name":"PDQ_Open_Trial_Search_ID","value":"38406"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043668"}]}}{"C978":{"preferredName":"Doxifluridine","code":"C978","definitions":[{"definition":"A fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxifluridine","termGroup":"PT","termSource":"NCI"},{"termName":"5'-Deoxy-5-fluorouridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-DFUR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3094-09-5"},{"name":"Chemical_Formula","value":"C9H11FN2O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"V1JK16Y2JP"},{"name":"Legacy Concept Name","value":"Doxifluridine"},{"name":"Maps_To","value":"Doxifluridine"},{"name":"NCI_Drug_Dictionary_ID","value":"481255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481255"},{"name":"PDQ_Open_Trial_Search_ID","value":"481255"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048808"}]}}{"C456":{"preferredName":"Doxorubicin","code":"C456","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. Doxorubicin comes from the bacterium Streptomyces peucetius. It damages DNA and may kill cancer cells. It is a type of anthracycline antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"14-Hydroxydaunomycin","termGroup":"SN","termSource":"NCI"},{"termName":"Adriablastin","termGroup":"SY","termSource":"NCI"},{"termName":"Hydroxydaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Hydroxyl Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Hydroxyldaunorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23214-92-8"},{"name":"CHEBI_ID","value":"CHEBI:28748"},{"name":"Chemical_Formula","value":"C27H29NO11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"80168379AG"},{"name":"Legacy Concept Name","value":"Doxorubicin"},{"name":"Maps_To","value":"Doxorubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0013089"}]}}{"C1326":{"preferredName":"Doxorubicin Hydrochloride","code":"C1326","definitions":[{"definition":"A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. Adriamycin PFS comes from the bacterium Streptomyces peucetius. It damages DNA and may kill cancer cells. It is a type of anthracycline antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"14-Hydroxydaunorubicin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"3-Hydroxyacetyldaunorubicin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ADM","termGroup":"AB","termSource":"NCI"},{"termName":"Adriacin","termGroup":"FB","termSource":"NCI"},{"termName":"Adriamycin","termGroup":"BR","termSource":"NCI"},{"termName":"Adriamycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Adriamycin PFS","termGroup":"AQS","termSource":"NCI"},{"termName":"Adriamycin RDF","termGroup":"AQS","termSource":"NCI"},{"termName":"Adriamycine","termGroup":"SY","termSource":"NCI"},{"termName":"Adriblastina","termGroup":"FB","termSource":"NCI"},{"termName":"Adriblastine","termGroup":"FB","termSource":"NCI"},{"termName":"Adrimedac","termGroup":"FB","termSource":"NCI"},{"termName":"Chloridrato de Doxorrubicina","termGroup":"SY","termSource":"NCI"},{"termName":"DOX","termGroup":"AB","termSource":"NCI"},{"termName":"DOXO-CELL","termGroup":"FB","termSource":"NCI"},{"termName":"Doxolem","termGroup":"FB","termSource":"NCI"},{"termName":"Doxorubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubin","termGroup":"FB","termSource":"NCI"},{"termName":"Farmiblastina","termGroup":"FB","termSource":"NCI"},{"termName":"FI 106","termGroup":"CN","termSource":"NCI"},{"termName":"FI-106","termGroup":"CN","termSource":"NCI"},{"termName":"FI106","termGroup":"CN","termSource":"NCI"},{"termName":"L-Lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Rubex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Wilms' tumor; neuroblastoma; soft tissue and bone sarcomas; small cell carcinoma of the lung; lymphomas; multiple myeloma; mesotheliomas; germ cell tumors of the ovary or testis."},{"name":"Accepted_Therapeutic_Use_For","value":"Carcinomas of breast, thyroid, gastric, ovarian, bronchogenic, head and neck, prostate, cervical, pancreatic, uterine, hepatic, and transitional cell bladder carcinomas."},{"name":"CAS_Registry","value":"25316-40-9"},{"name":"Chemical_Formula","value":"C27H29NO11.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"82F2G7BL4E"},{"name":"Legacy Concept Name","value":"Doxorubicin_Hydrochloride"},{"name":"Maps_To","value":"Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38860"},{"name":"NSC Number","value":"123127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38860"},{"name":"PDQ_Open_Trial_Search_ID","value":"38860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546861"}]}}{"C1853":{"preferredName":"Doxorubicin Prodrug L-377,202","code":"C1853","definitions":[{"definition":"A prodrug in which a peptide is covalently conjugated with the anthracycline antineoplastic antibiotic doxorubicin.  This complex is hydrolyzed by the enzyme prostate-specific antigen (PSA), resulting in the formation of doxorubicin and leucine-doxorubicin.  Selective targeting of these drugs to prostate tumor cells occurs because the hydrolyzing PSA enzyme is localized to the prostate gland.  Doxorubicin and leucine-doxorubicin intercalate into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  These agents also produce toxic free-radical intermediates and interact with cell membrane lipids causing lipid peroxidation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Doxorubicin Prodrug L-377,202","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 10-((3-(((4R)-1-(4-carboxy-1-oxobutyl)-4-hydroxy-L-prolyl-L-alanyl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl)amino)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-","termGroup":"SN","termSource":"NCI"},{"termName":"L-377202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"207395-85-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VDXVABRQTV"},{"name":"Legacy Concept Name","value":"L-377_202"},{"name":"Maps_To","value":"Doxorubicin Prodrug L-377,202"},{"name":"NCI_Drug_Dictionary_ID","value":"37792"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37792"},{"name":"PDQ_Open_Trial_Search_ID","value":"37792"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C0879383"}]}}{"C82419":{"preferredName":"Doxorubicin-Eluting Beads","code":"C82419","definitions":[{"definition":"A drug-device combination product consisting of small polymeric beads impregnated with the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with doxorubicin. During transarterial chemoembolization (TACE), doxorubicin-eluting beads embolize to the tumor vasculature and release cytotoxic doxorubicin, which may result in both ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature and doxorubicin-mediated inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-Eluting Beads","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Doxorubicin-Eluting_Beads"},{"name":"Maps_To","value":"Doxorubicin-Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"637761"},{"name":"NCI_META_CUI","value":"CL413528"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637761"},{"name":"PDQ_Open_Trial_Search_ID","value":"637761"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1366":{"preferredName":"Doxorubicin-HPMA Conjugate","code":"C1366","definitions":[{"definition":"A copolymer conjugate of the antineoplastic anthracycline doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipid. HPMA conjugation enhances the permeability and retention of this agent within the tumor vasculature. Poorly cleared by the lymphatic system, this formulation undergoes increased cleavage by tumor cell lysosomal proteinases, resulting in increased, sustained intracellular concentrations of free doxorubicin. Compared to other doxorubicin-containing formulations, this formulation may exhibit an improved toxicity profile due to the lower concentrations of free doxorubicin to which non-malignant tissues are exposed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-HPMA Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"Doxorubicin-HPMA","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin-HPMA Copolymer Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"HPMA-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"P(GFLG)-ADR","termGroup":"AB","termSource":"NCI"},{"termName":"PK1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Doxorubicin-HPMA_Conjugate"},{"name":"Maps_To","value":"Doxorubicin-HPMA Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"42904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42904"},{"name":"PDQ_Open_Trial_Search_ID","value":"42904"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0114882"}]}}{"C128897":{"preferredName":"Doxorubicin-loaded EGFR-targeting Nanocells","code":"C128897","definitions":[{"definition":"A nanocell formulation targeting the epidermal growth factor receptor (EGFR) using bispecific antibodies (bsAb) against EGFR and containing the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of doxorubicin-loaded EGFR-targeting nanocells, the nanocells are stable in the bloodstream and the anti-EGFR bsAb moiety targets and binds to EGFR-expressing tumor cells. Upon binding, the nanocell allows for specific delivery of doxorubicin to tumor cells overexpressing EGFR. Upon endocytosis by the tumor cells, the nanocell is broken down and releases doxorubicin, which intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted delivery of doxorubicin improves efficacy while lowering the toxicity profile. EGFR, a tyrosine kinase receptor, is overexpressed in many cancer cell types. The nanocell is a bacterially derived nanosphere; the bacterial components are unlikely to induce an immune response in the immunosuppressed tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-loaded EGFR-targeting Nanocells","termGroup":"PT","termSource":"NCI"},{"termName":"Doxorubicin-loaded EGFR-targeting Nanocell","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR (Vectibix Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR(V)-EDV-Dox","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR-targeted EnGeneIC Dream Vectors Containing Doxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Doxorubicin-loaded EGFR-targeting Nanocells"},{"name":"NCI_Drug_Dictionary_ID","value":"782631"},{"name":"NCI_META_CUI","value":"CL512145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782631"},{"name":"PDQ_Open_Trial_Search_ID","value":"782631"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2644":{"preferredName":"Doxorubicin-Magnetic Targeted Carrier Complex","code":"C2644","definitions":[{"definition":"A formulation of the anthracycline antibiotic doxorubicin in which doxorubicin is bound to microscopic beads of activated carbon and iron as a magnetic-targeted carrier (MTC). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipids. Guided by the placement of a magnet on the body surface overlying a tumor site, the doxorubicin-MTC complex delivers doxorubicin directly to the tumor site, thereby targeting and prolonging the duration of doxorubicin-mediated cytotoxicity to the tumor bed while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin-Magnetic Targeted Carrier Complex","termGroup":"PT","termSource":"NCI"},{"termName":"DOX-MTC","termGroup":"AB","termSource":"NCI"},{"termName":"MTC-DOX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Doxorubicin-Magnetic_Targeted_Carrier_Complex"},{"name":"Maps_To","value":"Doxorubicin-Magnetic Targeted Carrier Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"38388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38388"},{"name":"PDQ_Open_Trial_Search_ID","value":"38388"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134452"}]}}{"C120213":{"preferredName":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine","code":"C120213","definitions":[{"definition":"A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"G250 Peptide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DPT/BCG/Measles/Serratia/Pneumococcus Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"768355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768355"},{"name":"PDQ_Open_Trial_Search_ID","value":"768355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3890943"}]}}{"C120214":{"preferredName":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine","code":"C120214","definitions":[{"definition":"A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), typhoid, Staphylococcus aureus, paratyphoid A and paratyphoid B, with potential immunostimulating activity. Subcutaneous administration of the DPT/typhoid/Staphylococcus aureus/paratyphoid A/paratyphoid B vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"768356"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768356"},{"name":"PDQ_Open_Trial_Search_ID","value":"768356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899464"}]}}{"C131494":{"preferredName":"DPX-E7 HPV Vaccine","code":"C131494","definitions":[{"definition":"A therapeutic vaccine composed of a synthetic peptide consisting of amino acids 11 through 19 of the viral oncoprotein human papillomavirus (HPV) subtype 16 E7 (HPV16-E7 11-19), with potential antineoplastic and immunostimulating activities. Immunization with the DPX-E7 HPV vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the HPV16-E7 protein. HPV type 16 plays a key role in the carcinogenesis of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DPX-E7 HPV Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"DPX E7","termGroup":"CN","termSource":"NCI"},{"termName":"DPX-E7","termGroup":"CN","termSource":"NCI"},{"termName":"DPX-E7 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16-E7 11-19 Nanomer Vaccine DPX-E7","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16-E7 11-19 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DPX-E7 HPV Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"785825"},{"name":"NCI_META_CUI","value":"CL514623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785825"},{"name":"PDQ_Open_Trial_Search_ID","value":"785825"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153259":{"preferredName":"Tilogotamab","code":"C153259","definitions":[{"definition":"An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic activity. Upon administration, tilogotamab specifically binds to and activates DR5. This results in the activation of caspase cascades and the induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029 (DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced formation of antibody hexamers and receptor clusters at the cell surface due to E430G mutations in the Fc domains of both antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tilogotamab","termGroup":"PT","termSource":"NCI"},{"termName":"DR5 HexaBody Agonist GEN1029","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1029","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1029","termGroup":"CN","termSource":"NCI"},{"termName":"HexaBody-DR5-01/DR5-05","termGroup":"SY","termSource":"NCI"},{"termName":"HexaBody-DR5/DR5","termGroup":"SY","termSource":"NCI"},{"termName":"Hx-DR5-01/05","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2109731-10-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1BU5EGF80S"},{"name":"Maps_To","value":"DR5 HexaBody Agonist GEN1029"},{"name":"Maps_To","value":"Tilogotamab"},{"name":"NCI_Drug_Dictionary_ID","value":"794053"},{"name":"NCI_META_CUI","value":"CL554487"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794053"},{"name":"PDQ_Open_Trial_Search_ID","value":"794053"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116886":{"preferredName":"DR5-targeting Tetrameric Nanobody Agonist TAS266","code":"C116886","definitions":[{"definition":"An agonistic tetravalent nanobody, in which the four single, high affinity heavy chain variable domain (VHH) antibodies are separated by a peptide linker, targeting death receptor type 5 (DR5), with potential antineoplastic activity. Upon administration, DR5-targeting tetrameric nanobody agonist TAS266, with its four DR5-specific single-chain antibodies, specifically binds to and activates DR5 receptors. This results in the activation of caspase cascades and induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor (TNF)-receptor superfamily, triggers apoptosis. Compared to certain anti-DR5 antibody agonists, TAS266 shows increased receptor activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DR5-targeting Tetrameric Nanobody Agonist TAS266","termGroup":"PT","termSource":"NCI"},{"termName":"TAS266","termGroup":"CN","termSource":"NCI"},{"termName":"Tetrameric Nanobody Agonist-targeting death receptor 5 TAS266","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ND8DG76YE"},{"name":"Maps_To","value":"DR5-targeting Tetrameric Nanobody Agonist TAS266"},{"name":"NCI_Drug_Dictionary_ID","value":"725486"},{"name":"NCI_META_CUI","value":"CL433974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"725486"},{"name":"PDQ_Open_Trial_Search_ID","value":"725486"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1077":{"preferredName":"Dromostanolone Propionate","code":"C1077","definitions":[{"definition":"The propionate salt form of dromostanolone, a synthetic anabolic steroid related to dihydrotestosterone that has antiestrogenic effects.  Dromostanolone inhibits the growth of estrogen receptor-presenting breast cancers; its virilizing effects limit its clinical usefulness. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dromostanolone Propionate","termGroup":"PT","termSource":"NCI"},{"termName":"2 Alpha-Methyldihydrotestosterone Propionate","termGroup":"SN","termSource":"NCI"},{"termName":"2-Alpha-Methyldihydrotestosterone Propionate","termGroup":"SN","termSource":"NCI"},{"termName":"Compound 32379","termGroup":"SY","termSource":"NCI"},{"termName":"Drolban","termGroup":"BR","termSource":"NCI"},{"termName":"Drostanolone Propionate","termGroup":"SY","termSource":"NCI"},{"termName":"Emdisterone","termGroup":"SY","termSource":"NCI"},{"termName":"Masterid","termGroup":"FB","termSource":"NCI"},{"termName":"Masteril","termGroup":"FB","termSource":"NCI"},{"termName":"Masteron","termGroup":"FB","termSource":"NCI"},{"termName":"Masterone","termGroup":"FB","termSource":"NCI"},{"termName":"Permastril","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"521-12-0"},{"name":"CHEBI_ID","value":"CHEBI:31523"},{"name":"Chemical_Formula","value":"C23H36O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X20UZ57G4O"},{"name":"Legacy Concept Name","value":"Dromostanolone_Propionate"},{"name":"Maps_To","value":"Dromostanolone Propionate"},{"name":"NCI_Drug_Dictionary_ID","value":"39226"},{"name":"NSC Number","value":"12198"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39226"},{"name":"PDQ_Open_Trial_Search_ID","value":"39226"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058758"}]}}{"C95784":{"preferredName":"Drozitumab","code":"C95784","synonyms":[{"termName":"Drozitumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-DR5 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10B (death receptor 5, TRAIL-R2, CD262 antigen)); [113-lysine,116-threonine,360-glutamic acid,362-methionine]human monoclonal gamma-1 heavy chain (224-212')-disulfide with human monoclonal lambda-3 light chain (230-230'':233-233'')-bisdisulfide dimer","termGroup":"SY","termSource":"NCI"},{"termName":"PRO95780","termGroup":"CN","termSource":"NCI"},{"termName":"rhuMAb DR5","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"912628-39-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SQ67484MA7"},{"name":"Maps_To","value":"Drozitumab"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987421"}]}}{"C74043":{"preferredName":"Dual IGF-1R/InsR Inhibitor BMS-754807","code":"C74043","definitions":[{"definition":"An oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases with potential antineoplastic activity. Dual IGF-IR/InsR inhibitor BMS-754807 binds reversibly to and inhibits the activities of IGF-1R and InsR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R and InsR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in mitogenesis, angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dual IGF-1R/InsR Inhibitor BMS-754807","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-754807","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1001350-96-4"},{"name":"Chemical_Formula","value":"C23H26FN9O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W9E3353E8J"},{"name":"Legacy Concept Name","value":"IGF1R_Antagonist_BMS-754807"},{"name":"Maps_To","value":"Dual IGF-1R/InsR Inhibitor BMS-754807"},{"name":"NCI_Drug_Dictionary_ID","value":"583260"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583260"},{"name":"PDQ_Open_Trial_Search_ID","value":"583260"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346450"}]}}{"C116750":{"preferredName":"Dilpacimab","code":"C116750","definitions":[{"definition":"A bispecific, tetravalent immunoglobulin (Ig) G-like molecule containing the target-binding variable domains of two monoclonal antibodies, one targeting the Notch ligand delta-like 4 (DLL4) and the other one targeting the human tyrosine kinase vascular endothelial growth factor (VEGF), combined via linkers, with potential anti-angiogenic and antineoplastic activities. Upon administration, dilpacimab targets and binds to both DLL4 and VEGF. This prevents the activation of DLL-4/Notch- and VEGF/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dilpacimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-165","termGroup":"CN","termSource":"NCI"},{"termName":"DVD-Ig ABT-165","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin, Anti-(Notch Ligand DLL4/Vascular Endothelial Growth Factor) (Synthetic Human PR-1283233 Heavy Chain), Disulfide with Synthetic Human PR-1283233 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"PR-1283233","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10863","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1791420-09-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F27LAH6D5O"},{"name":"Maps_To","value":"Dilpacimab"},{"name":"Maps_To","value":"Dual Variable Domain Immunoglobulin ABT-165"},{"name":"NCI_Drug_Dictionary_ID","value":"753544"},{"name":"NCI_META_CUI","value":"CL471747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753544"},{"name":"PDQ_Open_Trial_Search_ID","value":"753544"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C136983":{"preferredName":"Obrindatamab","code":"C136983","definitions":[{"definition":"An Fc-bearing humanized bispecific dual-affinity re-targeting (DART) protein composed of Fv regions derived from monoclonal antibodies against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration of obrindatamab, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3. This cross-links the T-cells to B7-H3-expressing tumor cells, activates and redirects endogenous T-cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obrindatamab","termGroup":"PT","termSource":"NCI"},{"termName":"B7-H3 x CD3 DART Protein","termGroup":"SY","termSource":"NCI"},{"termName":"B7-H3 x CD3 Dual-affinity Re-targeting Protein MGD009","termGroup":"SY","termSource":"NCI"},{"termName":"DART Protein MGD009","termGroup":"SY","termSource":"NCI"},{"termName":"Dual-affinity B7-H3/CD3-targeted Protein MGD009","termGroup":"SY","termSource":"NCI"},{"termName":"MGD 009","termGroup":"CN","termSource":"NCI"},{"termName":"MGD-009","termGroup":"CN","termSource":"NCI"},{"termName":"MGD009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2069959-72-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YE8XXF1SDZ"},{"name":"Maps_To","value":"Dual-affinity B7-H3/CD3-targeted Protein MGD009"},{"name":"NCI_Drug_Dictionary_ID","value":"789782"},{"name":"NCI_META_CUI","value":"CL524772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789782"},{"name":"PDQ_Open_Trial_Search_ID","value":"789782"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127116":{"preferredName":"Dubermatinib","code":"C127116","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, dubermatinib targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dubermatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-((5-Chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"TP 0903","termGroup":"CN","termSource":"NCI"},{"termName":"TP-0903","termGroup":"CN","termSource":"NCI"},{"termName":"TP0903","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1341200-45-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14D65TV20J"},{"name":"Maps_To","value":"Dubermatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"780923"},{"name":"NCI_META_CUI","value":"CL507906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780923"},{"name":"PDQ_Open_Trial_Search_ID","value":"780923"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1062":{"preferredName":"Duborimycin","code":"C1062","definitions":[{"definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Duborimycin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duborimycin","termGroup":"PT","termSource":"NCI"},{"termName":"13-Hydroxydaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-, (8S-cis)-, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Daunomycinol","termGroup":"SY","termSource":"NCI"},{"termName":"Daunomycinol HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicineal","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicinol","termGroup":"SY","termSource":"NCI"},{"termName":"Duborimycin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Duborimycine","termGroup":"SY","termSource":"NCI"},{"termName":"Duborimycine, Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"28008-55-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YDU8YIP30L"},{"name":"Legacy Concept Name","value":"Duborimycin"},{"name":"Maps_To","value":"Duborimycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39228"},{"name":"NSC Number","value":"180510"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39228"},{"name":"PDQ_Open_Trial_Search_ID","value":"39228"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057159"}]}}{"C1685":{"preferredName":"Dulanermin","code":"C1685","definitions":[{"definition":"A recombinant human soluble protein corresponding to amino acids 114-281 of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (RhApo2L/TRAIL) with potential antineoplastic activity. Dulanermin binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, also known as DR4 (death receptor 4) and DR5 (death receptor 5), are members of the TNF receptor family and are overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dulanermin","termGroup":"PT","termSource":"NCI"},{"termName":"114-281-protein TRAIL","termGroup":"SY","termSource":"NCI"},{"termName":"AMG 951","termGroup":"CN","termSource":"NCI"},{"termName":"APO2L/TRAIL","termGroup":"SY","termSource":"NCI"},{"termName":"RG3639","termGroup":"CN","termSource":"NCI"},{"termName":"rTRAIL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer"},{"name":"CAS_Registry","value":"867153-61-5"},{"name":"Chemical_Formula","value":"C871H1329N243O260S4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L65E7T81M5"},{"name":"Legacy Concept Name","value":"Therapeutic_TNF-Related_Apoptosis-Inducing_Ligand"},{"name":"Maps_To","value":"Dulanermin"},{"name":"NCI_Drug_Dictionary_ID","value":"564398"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564398"},{"name":"PDQ_Open_Trial_Search_ID","value":"564398"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385242"}]}}{"C116628":{"preferredName":"Duligotuzumab","code":"C116628","definitions":[{"definition":"An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Duligotuzumab binds to both EGFR and HER3 and inhibits their activation. This may prevent EGFR/HER3-mediated signaling and inhibit EGFR/HER3-dependent tumor cell proliferation. In addition, MEHD7945A induces antibody-dependent cell-mediated cytotoxicity (ADCC) against EGR/HER3-expressing tumor cells. EGFR and HER3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in tumors; their expression is associated with both poor prognosis and drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duligotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Duligotumab","termGroup":"SY","termSource":"NCI"},{"termName":"MEHD 7945A","termGroup":"CN","termSource":"NCI"},{"termName":"MEHD-7945A","termGroup":"CN","termSource":"NCI"},{"termName":"MEHD7945A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7597","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312797-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8PMF8YQX2T"},{"name":"Maps_To","value":"Duligotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"686389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686389"},{"name":"PDQ_Open_Trial_Search_ID","value":"686389"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490133"}]}}{"C162455":{"preferredName":"Dupilumab","code":"C162455","definitions":[{"definition":"A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dupilumab","termGroup":"PT","termSource":"NCI"},{"termName":"Dupixent","termGroup":"BR","termSource":"NCI"},{"termName":"REGN 668","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-668","termGroup":"CN","termSource":"NCI"},{"termName":"REGN668","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 231893","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-231893","termGroup":"CN","termSource":"NCI"},{"termName":"SAR231893","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1190264-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"420K487FSG"},{"name":"Maps_To","value":"Dupilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"798743"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798743"},{"name":"PDQ_Open_Trial_Search_ID","value":"798743"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660996"}]}}{"C103194":{"preferredName":"Durvalumab","code":"C103194","definitions":[{"definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Durvalumab","termGroup":"PT","termSource":"NCI"},{"termName":"Imfinzi","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 4736","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-4736","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI4736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma; unresectable stage III non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1428935-60-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"28X28X9OKV"},{"name":"Maps_To","value":"Durvalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"740856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740856"},{"name":"PDQ_Open_Trial_Search_ID","value":"740856"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641122"}]}}{"C82683":{"preferredName":"Dusigitumab","code":"C82683","definitions":[{"definition":"A humanized monoclonal antibody directed against insulin-like growth factors 1 and 2 (IGF-1/2) with potential antineoplastic activity. Dusigitumab inhibits IGF1- and IGF2-stimulated activation of membrane-bound IGF receptors and the subsequent triggering of proliferation and survival signaling pathways. This may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF1/2 ligands stimulate cell proliferation, enable oncogenic transformation, and suppress apoptosis; IGF1/2 signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dusigitumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Insulin-Like Growth Factor 1/2 Monoclonal Antibody MEDI-573","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G2, Anti-(Human Insulin-like Growth Factor I/Insulin-like Growth Factor II); Human Monoclonal MEDI-573 gamma Heavy Chain (134-216')-Disulfide with Human Monoclonal MEDI-573 lambda Light Chain Dimer (222-222'':223-223'':226-226'':229-229'')-Tetrakisdisulfide","termGroup":"SN","termSource":"NCI"},{"termName":"MEDI-573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204390-13-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0Z70DT5PRX"},{"name":"Legacy Concept Name","value":"Anti-IGF_1_2_Monoclonal_Antibody_MEDI-573"},{"name":"Maps_To","value":"Dusigitumab"},{"name":"NCI_Drug_Dictionary_ID","value":"633311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633311"},{"name":"PDQ_Open_Trial_Search_ID","value":"633311"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830209"}]}}{"C116885":{"preferredName":"dUTPase/DPD Inhibitor TAS-114","code":"C116885","definitions":[{"definition":"An orally bioavailable inhibitor of both deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD), with potential antineoplastic adjuvant activity. Upon oral administration in combination with a prodrug of the pyrimidine antagonist 5-fluorouracil (5-FU), TAS-114 inhibits (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. This prevents first-pass metabolism of 5-FU, allowing oral administration of the 5-FU prodrug and increasing the efficacy of 5-FU. In addition, as a dUTPase inhibitor, TAS-114 enhances the antitumor activity of 5-FU by preventing the hydrolysis and breakdown of 5-fluoro-deoxyuridine triphosphate (FdUTP) and deoxyuridine triphosphate (dUTP), which are active metabolites of 5-FU. This promotes DNA polymerase-dependent incorporation of these antimetabolites into DNA and leads to DNA damage and tumor cell death. Co-administration with TAS-114 allows lower dosing of 5-FU prodrugs, which decreases 5-FU-related toxicity, while maintaining therapeutic levels of 5-FU at the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"dUTPase/DPD Inhibitor TAS-114","termGroup":"PT","termSource":"NCI"},{"termName":"TAS-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"dUTPase/DPD Inhibitor TAS-114"},{"name":"NCI_Drug_Dictionary_ID","value":"735151"},{"name":"NCI_META_CUI","value":"CL446618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735151"},{"name":"PDQ_Open_Trial_Search_ID","value":"735151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99225":{"preferredName":"Duvelisib","code":"C99225","definitions":[{"definition":"An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, duvelisib prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duvelisib","termGroup":"PT","termSource":"NCI"},{"termName":"1(2H)-Isoquinolinone, 8-Chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one","termGroup":"SY","termSource":"NCI"},{"termName":"Copiktra","termGroup":"BR","termSource":"NCI"},{"termName":"INK-1197","termGroup":"CN","termSource":"NCI"},{"termName":"IPI 145","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-145","termGroup":"CN","termSource":"NCI"},{"termName":"IPI145","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL)"},{"name":"CAS_Registry","value":"1201438-56-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"610V23S0JI"},{"name":"Maps_To","value":"Duvelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"718963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"718963"},{"name":"PDQ_Open_Trial_Search_ID","value":"718963"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274621"}]}}{"C122406":{"preferredName":"Duvortuxizumab","code":"C122406","definitions":[{"definition":"An anti-CD19/anti-CD3 bispecific, humanized antibody-like protein, with potential immunostimulatory and antineoplastic activities. Duvortuxizumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon administration, duvortuxizumab binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during normal B-cell development and on B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Duvortuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"CD19 x CD3 DART Protein JNJ-64052781","termGroup":"SY","termSource":"NCI"},{"termName":"hBU12(2.4)-hXR32-MP3 M1.2","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ-64052781","termGroup":"CN","termSource":"NCI"},{"termName":"MGD011","termGroup":"CN","termSource":"NCI"},{"termName":"RES192M1.2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1831098-91-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J545GSE96Y"},{"name":"Maps_To","value":"Duvortuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"772810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772810"},{"name":"PDQ_Open_Trial_Search_ID","value":"772810"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053583"}]}}{"C1928":{"preferredName":"Dynemicin","code":"C1928","definitions":[{"definition":"An antitumor antibiotic of the enediyne class. It has demonstrated high DNA cleavage activity in the presence of NADPH, antimicrobial and tumor growth-inhibiting properties. Dynemicin recognizes and cleaves conformationally flexible regions of DNA. It attacks bases at 3'-side of purine residues such as 5'-AG, 5'-AT, and 5'-GC sequences. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dynemicin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dynemicin"},{"name":"Maps_To","value":"Dynemicin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"UMLS_CUI","value":"C1512097"}]}}{"C1079":{"preferredName":"Dynemicin A","code":"C1079","definitions":[{"definition":"An enediyne antineoplastic antibiotic hybrid containing an anthraquinone moiety isolated from the bacterium Micromonospora chersina.  The anthraquinone moiety intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in double-strand breaks in DNA, inhibition of DNA replication and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dynemicin A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124412-57-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D3G8N2863A"},{"name":"Legacy Concept Name","value":"Dynemicin_A"},{"name":"Maps_To","value":"Dynemicin A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0058837"}]}}{"C64767":{"preferredName":"E2F1 Pathway Activator ARQ 171","code":"C64767","definitions":[{"definition":"A second-generation E2F1 pathway activator with potential antineoplastic activity. ARQ 171 induces the expression of E2F transcription factor 1, thereby activating the E2F1-mediated checkpoint process. E2F1, down-regulated in cancer cells, regulates expression of genes involved in the cell cycle progression from G1 into S phase. The G1/S checkpoint process selectively induces cell cycle arrest in cancer cells with irreparable DNA damages and triggers subsequent apoptosis, while allowing cell division to proceed in cells without or with minor reparable DNA damage. As a result, this agent exerts anti-tumor activity through checkpoint activation independent of p53 mediated tumor suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"E2F1 Pathway Activator ARQ 171","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 171","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ARQ_171"},{"name":"Maps_To","value":"E2F1 Pathway Activator ARQ 171"},{"name":"NCI_Drug_Dictionary_ID","value":"529342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529342"},{"name":"PDQ_Open_Trial_Search_ID","value":"529342"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832018"}]}}{"C159410":{"preferredName":"EBNA-1 inhibitor VK-2019","code":"C159410","definitions":[{"definition":"An orally available, small molecule inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1) with potential antineoplastic activity. Upon administration, EBNA-1 inhibitor VK-2019 binds to EBNA-1 and inhibits EBNA-1 DNA binding activity. This disrupts the replication, maintenance and segregation of the Epstein-Barr virus (EBV) genome, which may lead to tumor cell death in EBV-associated malignancies. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EBNA-1 inhibitor VK-2019","termGroup":"PT","termSource":"NCI"},{"termName":"Epstein-Barr Nuclear Antigen 1 Inhibitor VK-2019","termGroup":"SY","termSource":"NCI"},{"termName":"VK 2019","termGroup":"CN","termSource":"NCI"},{"termName":"VK-2019","termGroup":"CN","termSource":"NCI"},{"termName":"VK2019","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EBNA-1 inhibitor VK-2019"},{"name":"NCI_Drug_Dictionary_ID","value":"797645"},{"name":"NCI_META_CUI","value":"CL951268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797645"},{"name":"PDQ_Open_Trial_Search_ID","value":"797645"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C462":{"preferredName":"Echinomycin","code":"C462","definitions":[{"definition":"A polypeptide quinoxaline antineoplastic antibiotic isolated from the bacterium Streptomyces echinatus.  Echinomycin intercalates into DNA at two locations simultaneously in a sequence-specific fashion, thereby inhibiting DNA replication and RNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Echinomycin","termGroup":"PT","termSource":"NCI"},{"termName":"Bis-Quinoline Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"BRN 0078671","termGroup":"CN","termSource":"NCI"},{"termName":"Echinomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"Levomycin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N'-(2,4,12,15,17,25-hexamethyl-11,24-bis(1-methylethyl)-27-(methylthio)-3,6,10,13,16,19,23,26-octaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo(12.12.3)nonacosane-7,20-diyl)bis(2-quinoxalinecarboxamide)","termGroup":"SN","termSource":"NCI"},{"termName":"Quinomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"SK 302B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"512-64-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TG824J6RQT"},{"name":"Legacy Concept Name","value":"Echinomycin"},{"name":"Maps_To","value":"Echinomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39587"},{"name":"NSC Number","value":"526417"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39587"},{"name":"PDQ_Open_Trial_Search_ID","value":"39587"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0013508"}]}}{"C61095":{"preferredName":"Ecromeximab","code":"C61095","definitions":[{"definition":"A low-fucose, human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity targeting at the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. Monoclonal antibody KW-2871 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. This agent is prepared by fusing murine immunoglobulin (Ig) light and heavy variable regions derived from the murine IgG3 antibody KM-641 to a human constant (Fc) region. The low fucose content of the oligosaccharide side chains of this antibody may enhance binding of the antibody Fc region to lymphocyte Fc receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ecromeximab","termGroup":"PT","termSource":"NCI"},{"termName":"Chimeric Monoclonal Antibody KW-2871","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Gd3 Ganglioside) (Human-Mouse Monoclonal Km871 Gamma-1-Chain), Disulfide with Human-Mouse Monoclonal KM871 Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"KM871","termGroup":"CN","termSource":"NCI"},{"termName":"KW-2871","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody KW-2871","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"292819-64-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M76FX2JZRM"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_KW-2871"},{"name":"Maps_To","value":"Ecromeximab"},{"name":"NCI_Drug_Dictionary_ID","value":"467926"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467926"},{"name":"PDQ_Open_Trial_Search_ID","value":"467926"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1669509"}]}}{"C958":{"preferredName":"Edatrexate","code":"C958","definitions":[{"definition":"A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to a family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Edatrexate","termGroup":"PT","termSource":"NCI"},{"termName":"10-EDAM","termGroup":"AB","termSource":"NCI"},{"termName":"10-Ethyl-10-deaza-aminopterin","termGroup":"SN","termSource":"NCI"},{"termName":"CGP-30694","termGroup":"CN","termSource":"NCI"},{"termName":"EDAM","termGroup":"AB","termSource":"NCI"},{"termName":"N-[4-[1-[(2,4-Diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80576-83-6"},{"name":"Chemical_Formula","value":"C22H25N7O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JT4X6Z1HRR"},{"name":"Legacy Concept Name","value":"Edatrexate"},{"name":"Maps_To","value":"Edatrexate"},{"name":"NCI_Drug_Dictionary_ID","value":"40887"},{"name":"NSC Number","value":"626715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40887"},{"name":"PDQ_Open_Trial_Search_ID","value":"40887"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044667"}]}}{"C956":{"preferredName":"Edelfosine","code":"C956","definitions":[{"definition":"A synthetic analog of lysophosphatidylcholine, an ether lipid, possessing anti-leishmanial and antineoplastic activity.  The mechanism of action for edelfosine has not been fully elucidated.  Targeting cellular membranes, edelfosine modulates membrane permeability, membrane lipid composition, and phospholipid metabolism.  Edelfosine also inhibits the phosphatidylinositol 3 kinase (PI3K)-AKT/PKB survival pathway, possibly activating the pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  In addition, this agent inhibits protein kinase C, intracellular activation of the Fas/CD95 receptor, and intracellular acidification.  Anti-leishmanial activity may be due to inhibition of a glycosomal alkyl-specific-acylCoA acyltransferase. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edelfosine","termGroup":"PT","termSource":"NCI"},{"termName":"1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocholine","termGroup":"SN","termSource":"NCI"},{"termName":"Edelfosinum","termGroup":"SY","termSource":"NCI"},{"termName":"ET-18-OCH3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70641-51-9"},{"name":"Chemical_Formula","value":"C27H58NO6P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Y6SNA8L5S"},{"name":"Legacy Concept Name","value":"Edelfosine"},{"name":"Maps_To","value":"Edelfosine"},{"name":"NCI_Drug_Dictionary_ID","value":"41814"},{"name":"NSC Number","value":"324368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41814"},{"name":"PDQ_Open_Trial_Search_ID","value":"41814"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044549"}]}}{"C2665":{"preferredName":"Edotecarin","code":"C2665","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of topoisomerase I inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic indolocarbazole with antineoplastic activity. Edotecarin inhibits the enzyme topoisomerase I through stabilization of the DNA-enzyme complex and enhanced single-strand DNA cleavage, resulting in inhibition of DNA replication and decreased tumor cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edotecarin","termGroup":"PT","termSource":"NCI"},{"termName":"6-N-(1-hydroxymethyla-2-hydroxy)ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolol[3,4-c]-carbazole-5,7(6H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"J-107088","termGroup":"CN","termSource":"NCI"},{"termName":"J107088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"174402-32-5"},{"name":"Chemical_Formula","value":"C29H28N4O11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1V8X590XDP"},{"name":"Legacy Concept Name","value":"Edotecarin"},{"name":"Maps_To","value":"Edotecarin"},{"name":"NCI_Drug_Dictionary_ID","value":"38537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38537"},{"name":"PDQ_Open_Trial_Search_ID","value":"38537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328673"}]}}{"C1554":{"preferredName":"Edrecolomab","code":"C1554","definitions":[{"definition":"A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Edrecolomab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G2A (Mouse Monoclonal 17-1A Gamma-Chain Anti-Human Colon Cancer Tumor-Associated Antigen), Disulfide With Mouse Monoclonal 17-1A Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB 17-1A","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody 17-1A","termGroup":"SY","termSource":"NCI"},{"termName":"Panorex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156586-89-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0KYI9U9FSJ"},{"name":"Legacy Concept Name","value":"Edrecolomab"},{"name":"Maps_To","value":"Edrecolomab"},{"name":"NCI_Drug_Dictionary_ID","value":"39352"},{"name":"NSC Number","value":"377963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39352"},{"name":"PDQ_Open_Trial_Search_ID","value":"39352"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0279218"}]}}{"C133819":{"preferredName":"EED Inhibitor MAK683","code":"C133819","definitions":[{"definition":"An inhibitor of embryonic ectoderm development protein (EED) and allosteric inhibitor of polycomb repressive complex 2 (PRC2), with potential antineoplastic activity. Upon administration, MAK683 selectively binds to the domain of EED that interacts with trimethylated lysine 27 on histone 3 (H3K27me3), which leads to a conformational change in the EED H3K27me3-binding pocket and prevents the interaction of EED with the histone methyltransferase enhancer zeste homolog 2 (EZH2). Disruption of the EED-EZH2 protein-protein interaction (PPI) results in a loss of H3K27me3-stimulated PRC2 activity and prevents H3K27 trimethylation. This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2-mutated and PRC2-dependent cancer cells. PRC2, a histone H3 lysine 27 methyltransferase and multi-protein complex comprised of EZH2, EED and suppressor of zeste 12 (SUZ12), plays a key role in gene regulation, especially during embryonic development. EZH2, the catalytic subunit of PRC2, is overexpressed or mutated in a variety of cancer cells. EED is essential for the histone methyltransferase activity of PRC2 because EED directly binds to H3K27me3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EED Inhibitor MAK683","termGroup":"PT","termSource":"NCI"},{"termName":"Ectodermal Embryonic Development Inhibitor MAK683","termGroup":"SY","termSource":"NCI"},{"termName":"EED PPI Inhibitor MAK683","termGroup":"SY","termSource":"NCI"},{"termName":"EED Protein-protein Interaction Inhibitor MAK683","termGroup":"SY","termSource":"NCI"},{"termName":"MAK 683","termGroup":"CN","termSource":"NCI"},{"termName":"MAK683","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1951408-58-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4K446Z8N51"},{"name":"Maps_To","value":"EED Inhibitor MAK683"},{"name":"NCI_Drug_Dictionary_ID","value":"788547"},{"name":"NCI_META_CUI","value":"CL521741"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788547"},{"name":"PDQ_Open_Trial_Search_ID","value":"788547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83819":{"preferredName":"Efatutazone","code":"C83819","definitions":[{"definition":"An orally bioavailable thiazolidinedione and an agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity. Efatutazone binds to and activates PPAR-gamma thus inducing cell differentiation and apoptosis, leading to a reduction in cellular proliferation. PPAR-gamma is a nuclear hormone receptor and a ligand-activated transcription factor that controls the expression of genes involved in macromolecule metabolism and cell differentiation, specifically adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efatutazone","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Thiazolidinedione, 5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Inolitazone","termGroup":"SY","termSource":"NCI"},{"termName":"Rac-5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-1,3-Thiazolidine-2,4-Dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"223132-37-4"},{"name":"Chemical_Formula","value":"C27H26N4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M17ILL71MC"},{"name":"Maps_To","value":"Efatutazone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827204"}]}}{"C64764":{"preferredName":"Efatutazone Dihydrochloride","code":"C64764","definitions":[{"definition":"The dihydrochloride salt of efatutazone, an orally bioavailable agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity. Efatutazone binds to and activates PPAR-gamma, a nuclear hormone receptor and a ligand-activated transcription factor controling gene expression involved in macromolecule metabolism and cell differentiation, specifically adipocyte differentiation. Mediated through activation of PPAR-gamma, this agent is capable of inducing cell differentiation and apoptosis, thereby leading to a reduction in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efatutazone Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-thiazolidinedione, 5-((4-((6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)-, Hydrochloride (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"CS-7017","termGroup":"CN","termSource":"NCI"},{"termName":"Inolitazone Dihydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"223132-38-5"},{"name":"Chemical_Formula","value":"C27H26N4O4S.2ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"76B44WEA8O"},{"name":"Legacy Concept Name","value":"CS-7017"},{"name":"Maps_To","value":"Efatutazone Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"529846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529846"},{"name":"PDQ_Open_Trial_Search_ID","value":"529846"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721778"}]}}{"C118282":{"preferredName":"Efizonerimod","code":"C118282","definitions":[{"definition":"An agonistic monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, efizonerimod selectively binds to and activates the OX40 receptor, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efizonerimod","termGroup":"PT","termSource":"NCI"},{"termName":"Efizonerimod Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4 (10-proline) (Human Heavy Chain Fc Fragment) Fusion Protein with Tumor Necrosis Factor Receptor-associated Factor TRAF2 (Human C-C Domain Fragment) Fusion Protein with CD252 Antigen (Human Extracellular Domain Fragment), Hexamer","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI6383","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1635395-27-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1MH7C2X8KE"},{"name":"Maps_To","value":"Efizonerimod"},{"name":"NCI_Drug_Dictionary_ID","value":"764233"},{"name":"NCI_META_CUI","value":"CL474134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764233"},{"name":"PDQ_Open_Trial_Search_ID","value":"764233"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C226":{"preferredName":"Eflornithine","code":"C226","definitions":[{"definition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cancer. It belongs to the family of drugs called antiprotozoals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Eflornithine","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Difluoromethyl)-DL-ornithine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Difluoromethylornithine","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-Difluoromethylornithine","termGroup":"SY","termSource":"NCI"},{"termName":"D,L-alpha-Difluoromethylornithine","termGroup":"SN","termSource":"NCI"},{"termName":"DFMO","termGroup":"AB","termSource":"NCI"},{"termName":"Difluoromethylornithine","termGroup":"SY","termSource":"NCI"},{"termName":"Difluromethylornithine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hirsutism, facial; Trypanosoma brucei gambiense (sleeping sickness) infection"},{"name":"CAS_Registry","value":"67037-37-0"},{"name":"CAS_Registry","value":"70052-12-9"},{"name":"CHEBI_ID","value":"CHEBI:41948"},{"name":"Chemical_Formula","value":"C6H12F2N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ZQN1G5V6SR"},{"name":"Legacy Concept Name","value":"Eflornithine"},{"name":"Maps_To","value":"Eflornithine"},{"name":"NCI_Drug_Dictionary_ID","value":"39754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39754"},{"name":"PDQ_Open_Trial_Search_ID","value":"39754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002260"}]}}{"C1579":{"preferredName":"Eflornithine Hydrochloride","code":"C1579","definitions":[{"definition":"The hydrochloride form of eflornithine, a difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eflornithine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Difluoromethyl)-dl-ornithine Hydrochloride, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"2-Difluoromethyl-dl-ornithine, Monohydrochloride, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-Difluoromethylornithine hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Iwilfin","termGroup":"BR","termSource":"NCI"},{"termName":"MDL 71782","termGroup":"CN","termSource":"NCI"},{"termName":"MDL-71782","termGroup":"CN","termSource":"NCI"},{"termName":"MDL71782","termGroup":"CN","termSource":"NCI"},{"termName":"Ornidyl","termGroup":"BR","termSource":"NCI"},{"termName":"RMI 71782","termGroup":"CN","termSource":"NCI"},{"termName":"RMI-71782","termGroup":"CN","termSource":"NCI"},{"termName":"RMI71782","termGroup":"CN","termSource":"NCI"},{"termName":"Vaniqa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB)."},{"name":"CAS_Registry","value":"96020-91-6"},{"name":"Chemical_Formula","value":"C6H12F2N2O2.HCl.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4NH22NDW9H"},{"name":"Legacy Concept Name","value":"Eflornithine_Hydrochloride"},{"name":"Maps_To","value":"Eflornithine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39754"},{"name":"NSC Number","value":"270295"},{"name":"NSC Number","value":"337250"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39754"},{"name":"PDQ_Open_Trial_Search_ID","value":"39754"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282042"}]}}{"C62509":{"preferredName":"Eftilagimod Alpha","code":"C62509","definitions":[{"definition":"A T-cell immunostimulatory factor, derived from the soluble form of the lymphocyte-activation gene 3 (LAG-3) protein, with potential antineoplastic activity. Upon administration, alone or in combination with tumor antigens, eftilagimod alpha binds with high affinity to MHC class II molecules expressed by dendritic cells (DC), potentially resulting in DC maturation, DC migration to lymph nodes, enhanced DC cross-presentation of antigens to T cells, and antitumor cytotoxic T cell responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eftilagimod Alpha","termGroup":"PT","termSource":"NCI"},{"termName":"Immufact","termGroup":"FB","termSource":"NCI"},{"termName":"IMP321","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1800476-36-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SJ82PK3HWA"},{"name":"Legacy Concept Name","value":"IMP321"},{"name":"Maps_To","value":"Eftilagimod Alpha"},{"name":"NCI_Drug_Dictionary_ID","value":"496939"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496939"},{"name":"PDQ_Open_Trial_Search_ID","value":"496939"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1739076"}]}}{"C90557":{"preferredName":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205","code":"C90557","definitions":[{"definition":"A small-molecule inhibitor of the human kinesin-related motor protein Eg5 with potential antineoplastic activity. Eg5 kinesin-related motor protein inhibitor 4SC-205 selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and cell death. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein essential for the regulation of spindle dynamics, including assembly and maintenance, during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205","termGroup":"PT","termSource":"NCI"},{"termName":"4SC 205","termGroup":"CN","termSource":"NCI"},{"termName":"4SC-205","termGroup":"CN","termSource":"NCI"},{"termName":"4SC205","termGroup":"CN","termSource":"NCI"},{"termName":"Eg5 Kinesin Inhibitor 4SC-205","termGroup":"SY","termSource":"NCI"},{"termName":"SC-205","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205"},{"name":"NCI_Drug_Dictionary_ID","value":"666188"},{"name":"NCI_META_CUI","value":"CL416241"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666188"},{"name":"PDQ_Open_Trial_Search_ID","value":"666188"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82694":{"preferredName":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621","code":"C82694","definitions":[{"definition":"A small-molecule inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Eg5 kinesin-related motor protein inhibitor ARQ 621 selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and cell death. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein involved in the regulation of spindle dynamics, including assembly and maintenance, during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621","termGroup":"PT","termSource":"NCI"},{"termName":"ARQ 621","termGroup":"CN","termSource":"NCI"},{"termName":"Eg5 inhibitor ARQ 621","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UU55190C8S"},{"name":"Legacy Concept Name","value":"Eg5_Kinesin-Related_Motor_Protein_Inhibitor_ARQ_621"},{"name":"Maps_To","value":"Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621"},{"name":"NCI_Drug_Dictionary_ID","value":"634612"},{"name":"NCI_META_CUI","value":"CL388484"},{"name":"PDQ_Closed_Trial_Search_ID","value":"634612"},{"name":"PDQ_Open_Trial_Search_ID","value":"634612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26646":{"preferredName":"EGb761","code":"C26646","definitions":[{"definition":"A standardized ginkgo biloba extract with antioxidant and neuroprotective activities.  EGb761 has been shown to inhibit the proliferation of certain tumor cells in vitro. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cognitive dysfunction (slowed ability to think, reason, concentrate, or remember) in patients receiving chemotherapy. It comes from ginkgo biloba leaves.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"EGb761","termGroup":"PT","termSource":"NCI"},{"termName":"EGb761","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EGb761"},{"name":"Maps_To","value":"EGb761"},{"name":"NCI_Drug_Dictionary_ID","value":"257914"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257914"},{"name":"PDQ_Open_Trial_Search_ID","value":"257914"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1095795"}]}}{"C123722":{"preferredName":"EGFR Antagonist Hemay022","code":"C123722","definitions":[{"definition":"An orally available, irreversible inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, Hemay022 covalently binds to and inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Antagonist Hemay022","termGroup":"PT","termSource":"NCI"},{"termName":"EGFR Inhibitor Hemay022","termGroup":"SY","termSource":"NCI"},{"termName":"Hemay022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Antagonist Hemay022"},{"name":"NCI_Drug_Dictionary_ID","value":"775380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775380"},{"name":"PDQ_Open_Trial_Search_ID","value":"775380"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053636"}]}}{"C156732":{"preferredName":"EGFR Antisense DNA BB-401","code":"C156732","definitions":[{"definition":"A recombinant, plasmid DNA expression vector encoding a 39 nucleotide (nt) short hairpin RNA (shRNA) specific for the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon intratumoral administration, the EGFR antisense DNA BB-401 is taken up by tumor cells and shRNA is transcribed. The shRNA is converted into small interfering RNA (siRNA) via the RNA interference (RNAi) pathway. The siRNA targets and binds to EGFR RNA expressed by tumor cells. This blocks EGFR mRNA translation and prevents EGFR protein expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Antisense DNA BB-401","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR ddRNAi BB-401","termGroup":"SY","termSource":"NCI"},{"termName":"BB 401","termGroup":"CN","termSource":"NCI"},{"termName":"BB-401","termGroup":"CN","termSource":"NCI"},{"termName":"BB401","termGroup":"CN","termSource":"NCI"},{"termName":"ddRNAi BB-401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Antisense DNA BB-401"},{"name":"NCI_Drug_Dictionary_ID","value":"795589"},{"name":"NCI_META_CUI","value":"CL935856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795589"},{"name":"PDQ_Open_Trial_Search_ID","value":"795589"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118289":{"preferredName":"Zorifertinib","code":"C118289","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration,  zorifertinib binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zorifertinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD3759","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1626387-80-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67SX9H68W2"},{"name":"Maps_To","value":"EGFR Inhibitor AZD3759"},{"name":"Maps_To","value":"Zorifertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"764365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764365"},{"name":"PDQ_Open_Trial_Search_ID","value":"764365"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896908"}]}}{"C80868":{"preferredName":"Falnidamol","code":"C80868","definitions":[{"definition":"A drug that may inhibit tumor cells from multiplying. It is being studied for its ability to treat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Falnidamol","termGroup":"PT","termSource":"NCI"},{"termName":"BIBX-1382","termGroup":"CN","termSource":"NCI"},{"termName":"BIBX1382","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR Inhibitor BIBX 1382","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"196612-93-8"},{"name":"Chemical_Formula","value":"C18H19ClFN7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0MU316797D"},{"name":"Legacy Concept Name","value":"BIBX_1382"},{"name":"Legacy Concept Name","value":"Falnidamol"},{"name":"Maps_To","value":"EGFR Inhibitor BIBX 1382"},{"name":"NCI_Drug_Dictionary_ID","value":"43568"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825367"}]}}{"C153427":{"preferredName":"EGFR/HER2 Inhibitor ABT-101","code":"C153427","definitions":[{"definition":"An orally bioavailable dual kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), including EGFR L858R, EGFR T790M and HER2 exon 20 insertion (Ex20ins) mutations, with potential antineoplastic activity. Upon oral administration, EGFR/HER2 inhibitor ABT-101 targets, binds to and inhibits the activity of EGFR or HER2 insertions or mutations. This prevents EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 alterations constitutively upregulate kinase activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER2 Inhibitor ABT-101","termGroup":"PT","termSource":"NCI"},{"termName":"ABT 101","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-101","termGroup":"CN","termSource":"NCI"},{"termName":"ABT101","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR 112","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR-112","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Inhibitor DBPR112"},{"name":"NCI_Drug_Dictionary_ID","value":"794067"},{"name":"NCI_META_CUI","value":"CL554867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794067"},{"name":"PDQ_Open_Trial_Search_ID","value":"794067"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2727":{"preferredName":"EGFR Inhibitor PD-168393","code":"C2727","definitions":[{"definition":"A quinazolone compound with anti-tumor activity. PD-168393 is a cell-permeable, irreversible, and selective inhibitor of ligand-dependent epidermal growth factor (EGF) receptor (EGFR). This agent binds to the catalytic domain of EGFR with a 1:1 stoichiometry and inactivates the EGFR tyrosine kinase activity through alkylation of a cystine residue (Cys-773) within the ATP-binding pocket, thereby inhibiting proliferation of EGFR-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Inhibitor PD-168393","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(3-Bromophenyl)amino]-6-Acrylamidoquinazoline","termGroup":"SN","termSource":"NCI"},{"termName":"PD 168 393","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194423-15-9"},{"name":"Chemical_Formula","value":"C17H13BrN4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3R996Y9T0I"},{"name":"Legacy Concept Name","value":"PD-168393"},{"name":"Maps_To","value":"EGFR Inhibitor PD-168393"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518781"}]}}{"C154286":{"preferredName":"Rezivertinib","code":"C154286","definitions":[{"definition":"An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutations T790M and L858R, as well as exon 19 deletion, with potential antineoplastic activity. Upon administration, rezivertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, BPI-7711 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rezivertinib","termGroup":"PT","termSource":"NCI"},{"termName":"BPI 7711","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-7711","termGroup":"CN","termSource":"NCI"},{"termName":"BPI7711","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR Mutant-specific Inhibitor BPI-7711","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1835667-12-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U65F5M6BD5"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor BPI-7711"},{"name":"Maps_To","value":"Rezivertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"794290"},{"name":"NCI_META_CUI","value":"CL555283"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794290"},{"name":"PDQ_Open_Trial_Search_ID","value":"794290"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132023":{"preferredName":"EGFR Mutant-specific Inhibitor CK-101","code":"C132023","definitions":[{"definition":"An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and del 19 mutations, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor CK-101 specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CK-101 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Mutant-specific Inhibitor CK-101","termGroup":"PT","termSource":"NCI"},{"termName":"CK 101","termGroup":"CN","termSource":"NCI"},{"termName":"CK-101","termGroup":"CN","termSource":"NCI"},{"termName":"CK101","termGroup":"CN","termSource":"NCI"},{"termName":"RX-518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1660963-42-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"708TLB8J3Y"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor CK-101"},{"name":"NCI_Drug_Dictionary_ID","value":"786517"},{"name":"NCI_META_CUI","value":"CL521020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786517"},{"name":"PDQ_Open_Trial_Search_ID","value":"786517"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175747":{"preferredName":"Befotertinib","code":"C175747","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, befotertinib specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. Compared to some other EGFR inhibitors, befotertinib may have therapeutic benefits in tumors with T790M-mediated drug resistance. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Befotertinib","termGroup":"PT","termSource":"NCI"},{"termName":"D 0316","termGroup":"CN","termSource":"NCI"},{"termName":"D-0316","termGroup":"CN","termSource":"NCI"},{"termName":"D0316","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1835667-63-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0XT2CPR891"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor D-0316"},{"name":"NCI_Drug_Dictionary_ID","value":"795785"},{"name":"NCI_META_CUI","value":"CL935820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153173":{"preferredName":"EGFR Mutant-specific Inhibitor ZN-e4","code":"C153173","definitions":[{"definition":"An orally available selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor ZN-e4 specifically binds to and inhibits selective EGFR mutations, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors, ZN-e4 may offer therapeutic benefits in tumors with T790M-mediated drug resistance and may limit toxicities associated with non-selective EGFR inhibitors. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Mutant-specific Inhibitor ZN-e4","termGroup":"PT","termSource":"NCI"},{"termName":"KP-673","termGroup":"CN","termSource":"NCI"},{"termName":"ZN e4","termGroup":"CN","termSource":"NCI"},{"termName":"ZN-e4","termGroup":"CN","termSource":"NCI"},{"termName":"ZNe4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Mutant-specific Inhibitor ZN-e4"},{"name":"NCI_Drug_Dictionary_ID","value":"793946"},{"name":"NCI_META_CUI","value":"CL554308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793946"},{"name":"PDQ_Open_Trial_Search_ID","value":"793946"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131909":{"preferredName":"EGFR T790M Antagonist BPI-15086","code":"C131909","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M antagonist BPI-15086 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR T790M Antagonist BPI-15086","termGroup":"PT","termSource":"NCI"},{"termName":"BPI 15086","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-15086","termGroup":"CN","termSource":"NCI"},{"termName":"BPI15086","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR T790M Inhibitor BPI-15086","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR T790M Antagonist BPI-15086"},{"name":"NCI_Drug_Dictionary_ID","value":"786371"},{"name":"NCI_META_CUI","value":"CL520366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786371"},{"name":"PDQ_Open_Trial_Search_ID","value":"786371"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133691":{"preferredName":"Aumolertinib","code":"C133691","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, aumolertinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aumolertinib","termGroup":"PT","termSource":"NCI"},{"termName":"Almonertinib","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR Tyrosine Kinase Inhibitor HS-10296","termGroup":"SY","termSource":"NCI"},{"termName":"EQ143","termGroup":"CN","termSource":"NCI"},{"termName":"HS 10296","termGroup":"CN","termSource":"NCI"},{"termName":"HS-10296","termGroup":"CN","termSource":"NCI"},{"termName":"HS10296","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1899921-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T4RS462G19"},{"name":"Maps_To","value":"EGFR T790M Inhibitor HS-10296"},{"name":"NCI_Drug_Dictionary_ID","value":"788548"},{"name":"NCI_META_CUI","value":"CL521177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788548"},{"name":"PDQ_Open_Trial_Search_ID","value":"788548"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131492":{"preferredName":"Ruserontinib","code":"C131492","definitions":[{"definition":"An orally available inhibitor of epidermal growth factor receptor (EGFR), FMS-related tyrosine kinase 3 (FLT3, STK1, CD135 or FLK2), and the non-receptor tyrosine kinase ABL (Abl), with potential antineoplastic activity. Upon administration, ruserontinib specifically binds to and inhibits EGFR, FLT3 and Abl, which interferes with the activation of EGFR-, FLT3- and Abl-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress EGFR, FLT3 and/or Abl. EGFR, EGFR and Abl are all overexpressed in a variety of cancers and play key roles in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruserontinib","termGroup":"PT","termSource":"NCI"},{"termName":"9-Isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"9H-Purine-2,8-diamine, 9-(1-Methylethyl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-3-pyridinyl-","termGroup":"SN","termSource":"NCI"},{"termName":"EGFR/FLT3/Abl Inhibitor SKLB1028","termGroup":"SY","termSource":"NCI"},{"termName":"Multikinase Inhibitor SKLB1028","termGroup":"SY","termSource":"NCI"},{"termName":"SKLB 1028","termGroup":"CN","termSource":"NCI"},{"termName":"SKLB-1028","termGroup":"CN","termSource":"NCI"},{"termName":"SKLB1028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1350544-93-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AQ3TTU8UM7"},{"name":"Maps_To","value":"EGFR/FLT3/Abl Inhibitor SKLB1028"},{"name":"NCI_Drug_Dictionary_ID","value":"785726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785726"},{"name":"PDQ_Open_Trial_Search_ID","value":"785726"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3501119"}]}}{"C1871":{"preferredName":"EGFR/HER1/HER2 Inhibitor PKI166","code":"C1871","definitions":[{"definition":"A pyrrolo-pyrimidine epidermal growth factor receptor (EGFR) protein kinase inhibitor with anti-tumor activity. PKI-166 reversibly inhibits HER1 and HER2 tyrosine kinases, belong to the epidermal growth factor receptor family, thereby inhibiting tumor growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER1/HER2 Inhibitor PKI166","termGroup":"PT","termSource":"NCI"},{"termName":"CGP 75166","termGroup":"CN","termSource":"NCI"},{"termName":"CGP 75166/PKI166","termGroup":"SY","termSource":"NCI"},{"termName":"CGP75166]","termGroup":"CN","termSource":"NCI"},{"termName":"PKI-166","termGroup":"CN","termSource":"NCI"},{"termName":"PKI166","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"187724-61-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RIE5HW38P"},{"name":"Legacy Concept Name","value":"PKI166"},{"name":"Maps_To","value":"EGFR/HER1/HER2 Inhibitor PKI166"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0915195"}]}}{"C126752":{"preferredName":"Mobocertinib","code":"C126752","definitions":[{"definition":"An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mobocertinib","termGroup":"PT","termSource":"NCI"},{"termName":"AP 32788","termGroup":"CN","termSource":"NCI"},{"termName":"AP-32788","termGroup":"CN","termSource":"NCI"},{"termName":"AP32788","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/HER2 Inhibitor TAK-788","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 788","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-788","termGroup":"CN","termSource":"NCI"},{"termName":"TAK788","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1847461-43-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"39HBQ4A67L"},{"name":"Maps_To","value":"EGFR/HER2 Inhibitor AP32788"},{"name":"Maps_To","value":"Mobocertinib"},{"name":"NCI_META_CUI","value":"CL507888"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64627":{"preferredName":"EGFR/HER2 Inhibitor AV-412","code":"C64627","definitions":[{"definition":"A second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to first-generation kinase inhibitors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER2 Inhibitor AV-412","termGroup":"PT","termSource":"NCI"},{"termName":"AV 412","termGroup":"CN","termSource":"NCI"},{"termName":"AV-412","termGroup":"CN","termSource":"NCI"},{"termName":"AV412","termGroup":"CN","termSource":"NCI"},{"termName":"MP 412","termGroup":"CN","termSource":"NCI"},{"termName":"MP-412","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"451493-31-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z541VW0W40"},{"name":"Legacy Concept Name","value":"AV-412"},{"name":"Maps_To","value":"EGFR/HER2 Inhibitor AV-412"},{"name":"NCI_Drug_Dictionary_ID","value":"513167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513167"},{"name":"PDQ_Open_Trial_Search_ID","value":"513167"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831968"}]}}{"C90589":{"preferredName":"EGFR/HER2 Kinase Inhibitor TAK-285","code":"C90589","definitions":[{"definition":"An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with potential antineoplastic activity. EGFR/HER2 kinase inhibitor TAK-285 binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to trastuzumab. EGFR and HER2, receptor tyrosine kinases overexpressed in a variety of tumor cell types, play major roles in tumor cell proliferation and tumor vascularization. In addition, TAK-285 appears to pass the blood brain barrier (BBB) and does not appear to be a substrate for efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/HER2 Kinase Inhibitor TAK-285","termGroup":"PT","termSource":"NCI"},{"termName":"TAK-285","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871026-44-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"70CCB438L6"},{"name":"Maps_To","value":"EGFR/HER2 Kinase Inhibitor TAK-285"},{"name":"NCI_Drug_Dictionary_ID","value":"573406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573406"},{"name":"PDQ_Open_Trial_Search_ID","value":"573406"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983788"}]}}{"C67080":{"preferredName":"Eicosapentaenoic Acid","code":"C67080","definitions":[{"definition":"A class of polyunsaturated fatty acids with 20 carbons and 5 double bonds.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"An essential, polyunsaturated, 20-carbon omega-3 fatty acid with anti-inflammatory and potential antineoplastic and chemopreventive activities. Eicosapentaenoic acid (EPA) may activate caspase 3, resulting in apoptosis in susceptible tumor cell populations. In addition, this agent may inhibit cyclooxygenase-2 (COX-2), resulting in inhibition of prostaglandin synthesis and prostaglandin-mediated inflammatory processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eicosapentaenoic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"All cis-5,8,11,14,17-Eicosapentaenoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"EPA","termGroup":"AB","termSource":"NCI"},{"termName":"Icosapentaenoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"IPA","termGroup":"AB","termSource":"NCI"},{"termName":"Timnodonic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"25378-27-2"},{"name":"CHEBI_ID","value":"CHEBI:36006"},{"name":"Chemical_Formula","value":"C20H30O2"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Essential_Fatty_Acid","value":"Y"},{"name":"INFOODS","value":"F20D5"},{"name":"Legacy Concept Name","value":"Eicosapentaenoic_Acid"},{"name":"Macronutrient","value":"Y"},{"name":"Maps_To","value":"Eicosapentaenoic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"537376"},{"name":"Nutrient","value":"Y"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537376"},{"name":"PDQ_Open_Trial_Search_ID","value":"537376"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0000545"},{"name":"Unit","value":"g"}]}}{"C95740":{"preferredName":"eIF4E Antisense Oligonucleotide ISIS 183750","code":"C95740","definitions":[{"definition":"A second-generation antisense oligonucleotide targeting the eukaryotic translation initiation factor 4E (eIF4E) with potential antitumor activity. Antisense oligonucleotide ISIS EIF4ERx suppresses the expression of eIF4E in fast dividing tumor cells. Blocking the expression of eIF4E results in inhibition of the synthesis of tumor angiogenic factors, thereby leading to the inhibition of cellular proliferation and apoptosis in tumor cells. eIF4E is overexpressed in a variety of cancers, is involved in the mRNA-ribosome binding step of eukaryotic protein synthesis and is the rate-limiting component of the eukaryotic translation apparatus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"eIF4E Antisense Oligonucleotide ISIS 183750","termGroup":"PT","termSource":"NCI"},{"termName":"eIF4E Inhibitor ISIS 183750","termGroup":"SY","termSource":"NCI"},{"termName":"eIF4E Modulator ISIS 183750","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 183750","termGroup":"CN","termSource":"NCI"},{"termName":"LY2275796","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"eIF4E Antisense Oligonucleotide ISIS 183750"},{"name":"NCI_Drug_Dictionary_ID","value":"680421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"680421"},{"name":"PDQ_Open_Trial_Search_ID","value":"680421"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987390"}]}}{"C120211":{"preferredName":"Elacestrant","code":"C120211","definitions":[{"definition":"An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. This prevents ER-mediated signaling and inhibits proliferation of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elacestrant","termGroup":"PT","termSource":"NCI"},{"termName":"(6R)-6-(2-(Ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol","termGroup":"SY","termSource":"NCI"},{"termName":"ER-306323","termGroup":"CN","termSource":"NCI"},{"termName":"RAD 1901","termGroup":"CN","termSource":"NCI"},{"termName":"RAD-1901","termGroup":"CN","termSource":"NCI"},{"termName":"RAD1901","termGroup":"CN","termSource":"NCI"},{"termName":"SERD/SERM RAD1901","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"722533-56-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"FM6A2627A8"},{"name":"Maps_To","value":"Elacestrant"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896781"}]}}{"C53401":{"preferredName":"Elacytarabine","code":"C53401","definitions":[{"definition":"The lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As a prodrug, elacytarabine is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, elacytarabine shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elacytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-amino-1-[5-O-[(9E)-octadec-9-enoyl]-beta-D-arabinofuranosyl]pyrimidin-2(1H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"CP-4055","termGroup":"CN","termSource":"NCI"},{"termName":"Elacyt","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"188181-42-2"},{"name":"CAS_Registry","value":"675837-43-1"},{"name":"Chemical_Formula","value":"C27H45N3O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TA7WJG93AR"},{"name":"Legacy Concept Name","value":"CP-4055"},{"name":"Maps_To","value":"Elacytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"463939"},{"name":"PDQ_Closed_Trial_Search_ID","value":"463939"},{"name":"PDQ_Open_Trial_Search_ID","value":"463939"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707141"}]}}{"C153373":{"preferredName":"Elagolix","code":"C153373","definitions":[{"definition":"An orally bioavailable, second-generation, non-peptide based, small molecule compound and selective gonadotropin-releasing hormone (GnRH; LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, elagolix competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland. This inhibits the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. In women, inhibition of FSH and LH prevents the production of estrogen by the ovaries. Inhibition of GnRH signaling may treat or prevent symptoms of sex hormone-dependent disease states.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elagolix","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-620","termGroup":"CN","termSource":"NCI"},{"termName":"Butanoic Acid, 4-(((1R)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl)-1-phenylethyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"NBI 56418","termGroup":"CN","termSource":"NCI"},{"termName":"NBI-56418","termGroup":"CN","termSource":"NCI"},{"termName":"Orilissa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"pain associated with endometriosis in women"},{"name":"CAS_Registry","value":"834153-87-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5B2546MB5Z"},{"name":"Legacy Concept Name","value":"Degarelix_Acetate"},{"name":"Maps_To","value":"Elagolix"},{"name":"NCI_Drug_Dictionary_ID","value":"793786"},{"name":"NCI_META_CUI","value":"CL554529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793786"},{"name":"PDQ_Open_Trial_Search_ID","value":"793786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159973":{"preferredName":"Elbasvir/Grazoprevir","code":"C159973","definitions":[{"definition":"A fixed dose combination of elbasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A), and grazoprevir, a second-generation inhibitor of the HCV NS3/4A serine protease, with activity against certain HCV genotypes. Upon oral administration of elbasvir/grazoprevir, elbasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. Grazoprevir inhibits the NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elbasvir/Grazoprevir","termGroup":"PT","termSource":"NCI"},{"termName":"Elbasvir-Grazoprevir","termGroup":"SY","termSource":"NCI"},{"termName":"Grazoprevir-Elbasvir","termGroup":"SY","termSource":"NCI"},{"termName":"Grazoprevir/Elbasvir","termGroup":"SY","termSource":"NCI"},{"termName":"MK-8742/ MK-5172","termGroup":"CN","termSource":"NCI"},{"termName":"Zepatier","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Elbasvir/Grazoprevir"},{"name":"NCI_Drug_Dictionary_ID","value":"797922"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797922"},{"name":"PDQ_Open_Trial_Search_ID","value":"797922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4080453"}]}}{"C75291":{"preferredName":"Elesclomol","code":"C75291","definitions":[{"definition":"A small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol induces oxidative stress, creating high levels of reactive oxygen species (ROS), such as hydrogen peroxide, in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared to normal cells, the increase in oxidative stress beyond baseline levels elevates ROS beyond sustainable levels, exhausting tumor cell antioxidant capacity, which may result in the induction of the mitochondrial apoptosis pathway. Normal cells are spared because the increase in the level of oxidative stress induced by this agent is below the threshold at which apoptosis is induced.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elesclomol","termGroup":"PT","termSource":"NCI"},{"termName":"1-N'-benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl- oxopropanehydrazidide","termGroup":"SN","termSource":"NCI"},{"termName":"Propanedioic Acid, Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"488832-69-5"},{"name":"Chemical_Formula","value":"C19H20N4O2S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6UK191M53P"},{"name":"Legacy Concept Name","value":"Elesclomol"},{"name":"Maps_To","value":"Elesclomol"},{"name":"NCI_Drug_Dictionary_ID","value":"377539"},{"name":"PDQ_Closed_Trial_Search_ID","value":"377539"},{"name":"PDQ_Open_Trial_Search_ID","value":"377539"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2608060"}]}}{"C79840":{"preferredName":"Elesclomol Sodium","code":"C79840","definitions":[{"definition":"A drug used in the treatment of skin cancer that has spread. It is also being studied in the treatment of other types of cancer. It increases the amount of harmful oxygen molecules in cells and may kill cancer cells. It may also help other drugs kill cancer cells. It is a type of oxidative stress inducer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The water soluble sodium salt of a small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol induces oxidative stress, creating high levels of reactive oxygen species (ROS), such as hydrogen peroxide, in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared to normal cells, the increase in oxidative stress beyond baseline levels elevates ROS beyond sustainable levels, exhausting tumor cell antioxidant capacity, which may result in the induction of the mitochondrial apoptosis pathway. Normal cells are spared because the increase in the level of oxidative stress induced by this agent is below the threshold at which apoptosis is induced.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elesclomol Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"1-N'-benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl- oxopropanehydrazidide Sodium","termGroup":"SN","termSource":"NCI"},{"termName":"Propanedioic Acid, Bis[2-methyl-2-(phenylthioxomethyl)hydrazide], Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"STA-4783","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"874477-51-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L219C7807V"},{"name":"Legacy Concept Name","value":"Elesclomol_Sodium"},{"name":"Maps_To","value":"Elesclomol Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"631615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"631615"},{"name":"PDQ_Open_Trial_Search_ID","value":"631615"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541326"}]}}{"C101895":{"preferredName":"Elgemtumab","code":"C101895","definitions":[{"definition":"A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Elgemtumab binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elgemtumab","termGroup":"PT","termSource":"NCI"},{"termName":"LJM-716","termGroup":"CN","termSource":"NCI"},{"termName":"LJM716","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1512559-37-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5F1CN52GFM"},{"name":"Maps_To","value":"Elgemtumab"},{"name":"NCI_Drug_Dictionary_ID","value":"734177"},{"name":"NCI_META_CUI","value":"CL436278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734177"},{"name":"PDQ_Open_Trial_Search_ID","value":"734177"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1615":{"preferredName":"Elinafide","code":"C1615","definitions":[{"definition":"A symmetrical dimeric bis-naphthalimide compound and a topoisomerase II inhibitor with antineoplastic activity. Elinafide contains two neutral chromophores joined by a cationic linker and is capable of bis-intercalation at the TpG and CpA steps of the DNA hexanucleotide. Intercalation inhibits topoisomerase II activity and causing DNA stand breakage, thereby leads to inhibition of DNA, RNA, and protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that kills cancer cells by affecting DNA synthesis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Elinafide","termGroup":"PT","termSource":"NCI"},{"termName":"LU 79553","termGroup":"CN","termSource":"NCI"},{"termName":"LU-79553","termGroup":"CN","termSource":"NCI"},{"termName":"N,N'-(Trimethylenebis(iminoethylene))dinaphthalimide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"162706-37-8"},{"name":"Chemical_Formula","value":"C31H28N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HL580335SI"},{"name":"Legacy Concept Name","value":"LU_79553"},{"name":"Maps_To","value":"Elinafide"},{"name":"NCI_Drug_Dictionary_ID","value":"42578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42578"},{"name":"PDQ_Open_Trial_Search_ID","value":"42578"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1433453"}]}}{"C66949":{"preferredName":"Elisidepsin","code":"C66949","definitions":[{"definition":"A synthetic cyclic depsipeptide of the kahalalides family with potential antineoplastic activity. PM02734 is a derivative of a natural marine compound extracted from the sacoglossan sea slug, Elysia rufescens. Although the exact mechanism of action has yet to be elucidated, elisidepsin exhibits anti-proliferative activity in a wide variety of cancer types, such as breast, colon, pancreas, lung, and prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elisidepsin","termGroup":"PT","termSource":"NCI"},{"termName":"Depsipeptide PM02734","termGroup":"SY","termSource":"NCI"},{"termName":"L-Valine, N-((4S)-4-methyl-1-oxohexyl)-D-valyl-L-threonyl-L-valyl-D-valyl-D-prolyl-L-ornithyl-D-alloisoleucyl-D-allothreonyl-D-alloisoleucyl-D-valyl-L-phenylalanyl-(2Z)-2-amino-2-butenoyl-, (13-8)-lactone, 2,2,2-trifluoroacetate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"PM02734","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"681272-30-0"},{"name":"CAS_Registry","value":"915713-02-9"},{"name":"Chemical_Formula","value":"C57H87N7O15"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0FWR494EC9"},{"name":"Legacy Concept Name","value":"Depsipeptide_PM02734"},{"name":"Maps_To","value":"Elisidepsin"},{"name":"NCI_Drug_Dictionary_ID","value":"530791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530791"},{"name":"PDQ_Open_Trial_Search_ID","value":"530791"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467776"}]}}{"C90495":{"preferredName":"Elliptinium","code":"C90495","definitions":[{"definition":"A derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elliptinium","termGroup":"PT","termSource":"NCI"},{"termName":"9-Hydroxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazolium","termGroup":"SN","termSource":"NCI"},{"termName":"9-Hydroxy-2-methylellipticinium","termGroup":"SN","termSource":"NCI"},{"termName":"N-2-Methyl-9-hydroxyellipticinium","termGroup":"SN","termSource":"NCI"},{"termName":"NMHE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58337-34-1"},{"name":"Chemical_Formula","value":"C18H17N2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1F1959S062"},{"name":"Legacy Concept Name","value":"Elliptinium"},{"name":"Maps_To","value":"Elliptinium"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0115685"}]}}{"C1367":{"preferredName":"Elliptinium Acetate","code":"C1367","definitions":[{"definition":"Acetate salt of elliptinium, a derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elliptinium Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"9-Hydroxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazolium Acetate (Salt)","termGroup":"SN","termSource":"NCI"},{"termName":"9-Hydroxy-2-methylellipticinium Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Celiptium","termGroup":"BR","termSource":"NCI"},{"termName":"N-2-Methyl-9-hydroxyellipticinium Acetate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58337-35-2"},{"name":"Chemical_Formula","value":"C18H17N2O.C2H3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H9B41234P4"},{"name":"Legacy Concept Name","value":"Elliptinium"},{"name":"Maps_To","value":"Elliptinium Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"39231"},{"name":"NSC Number","value":"264137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39231"},{"name":"PDQ_Open_Trial_Search_ID","value":"39231"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0100593"}]}}{"C73262":{"preferredName":"Elmustine","code":"C73262","definitions":[{"definition":"A (2-chloroethy1)nitrosourea derivative related to carmustine, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elmustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"1-Nitroso-1-chloroethyl-3-hydroxyethylurea","termGroup":"SN","termSource":"NCI"},{"termName":"HeCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Hydroxyethyl CNU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60784-46-5"},{"name":"Chemical_Formula","value":"C5H10ClN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NAT2FD82D7"},{"name":"Legacy Concept Name","value":"Elmustine"},{"name":"Maps_To","value":"Elmustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059035"}]}}{"C66982":{"preferredName":"Elotuzumab","code":"C66982","definitions":[{"definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of advanced multiple myeloma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuLuc63 binds to CS1, a protein that is found mainly on the surface of multiple myeloma cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Elotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 901608","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-901608","termGroup":"CN","termSource":"NCI"},{"termName":"BMS901608","termGroup":"CN","termSource":"NCI"},{"termName":"Empliciti","termGroup":"BR","termSource":"NCI"},{"termName":"HuLuc-63","termGroup":"CN","termSource":"NCI"},{"termName":"HuLuc63","termGroup":"AB","termSource":"NCI"},{"termName":"PDL 063","termGroup":"CN","termSource":"NCI"},{"termName":"PDL-063","termGroup":"CN","termSource":"NCI"},{"termName":"PDL063","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma (MM)"},{"name":"CAS_Registry","value":"915296-00-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1351PE5UGS"},{"name":"Legacy Concept Name","value":"Anti-CS1_Monoclonal_Antibody_HuLuc63"},{"name":"Maps_To","value":"Elotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"532249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"532249"},{"name":"PDQ_Open_Trial_Search_ID","value":"532249"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832049"}]}}{"C74090":{"preferredName":"Elpamotide","code":"C74090","definitions":[{"definition":"A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elpamotide","termGroup":"PT","termSource":"NCI"},{"termName":"L-Arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-alpha-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine Human Soluble (Vascular Endothelial Growth Factor Receptor) VEGFR2-(169-177)-peptide","termGroup":"SY","termSource":"NCI"},{"termName":"VEGFR2-169","termGroup":"SY","termSource":"NCI"},{"termName":"VEGFR2-169 Peptide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"673478-49-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S68632MB2G"},{"name":"Legacy Concept Name","value":"VEGFR2-169_Peptide_Vaccine"},{"name":"Maps_To","value":"Elpamotide"},{"name":"NCI_Drug_Dictionary_ID","value":"589327"},{"name":"NCI_META_CUI","value":"CL383528"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589327"},{"name":"PDQ_Open_Trial_Search_ID","value":"589327"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1080":{"preferredName":"Elsamitrucin","code":"C1080","definitions":[{"definition":"An heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21.  Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elsamitrucin","termGroup":"PT","termSource":"NCI"},{"termName":"10-O-Elsaminosylelsarosylchartarin","termGroup":"SN","termSource":"NCI"},{"termName":"BBM 2478A","termGroup":"CN","termSource":"NCI"},{"termName":"Benzo(h)(1)benzopyrano(5,4,3-cde)(1)ebnzopyran-5,12-dione,10((2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl)oxy)-6-hydroxy-1-methyl","termGroup":"SN","termSource":"NCI"},{"termName":"BMY-28090","termGroup":"CN","termSource":"NCI"},{"termName":"BRN 5214813","termGroup":"CN","termSource":"NCI"},{"termName":"Elsamicin A","termGroup":"SY","termSource":"NCI"},{"termName":"Elsamitrucina","termGroup":"SY","termSource":"NCI"},{"termName":"Elsamitrucine","termGroup":"SY","termSource":"NCI"},{"termName":"Elsamitrucinum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97068-30-9"},{"name":"Chemical_Formula","value":"C33H35NO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZTV0FOB6NU"},{"name":"Legacy Concept Name","value":"Elsamitrucin"},{"name":"Maps_To","value":"Elsamitrucin"},{"name":"NCI_Drug_Dictionary_ID","value":"41409"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41409"},{"name":"PDQ_Open_Trial_Search_ID","value":"41409"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059041"}]}}{"C125193":{"preferredName":"Eltanexor","code":"C125193","definitions":[{"definition":"An orally bioavailable inhibitor of exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic activity. Upon administration, eltanexor binds to the XPO1 cargo binding site, which prevents the XPO1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p73, BRCA1/2, pRB, FOXO, and other growth regulatory proteins and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), KPT-8602 restores the nuclear localization and function of tumor suppressing proteins which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The export of tumor suppressor proteins into the cytoplasm prevents them from initiating apoptosis and leads to uncontrolled tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eltanexor","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide","termGroup":"SY","termSource":"NCI"},{"termName":"ATG 016","termGroup":"CN","termSource":"NCI"},{"termName":"ATG-016","termGroup":"CN","termSource":"NCI"},{"termName":"ATG016","termGroup":"CN","termSource":"NCI"},{"termName":"Exportin 1 Inhibitor KPT-8602","termGroup":"SY","termSource":"NCI"},{"termName":"KPT-8602","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Inhibitor of Nuclear Export KPT-8602","termGroup":"SY","termSource":"NCI"},{"termName":"XPO1-inhibiting SINE Compound KPT-8602","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1642300-52-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q59IQJ9NTK"},{"name":"Maps_To","value":"Eltanexor"},{"name":"NCI_Drug_Dictionary_ID","value":"778691"},{"name":"NCI_META_CUI","value":"CL504007"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778691"},{"name":"PDQ_Open_Trial_Search_ID","value":"778691"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125548":{"preferredName":"Emactuzumab","code":"C125548","definitions":[{"definition":"A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities. Upon administration, emactuzumab binds to CSF1R expressed on macrophages and inhibits the binding of colony-stimulating factor-1 (CSF-1) to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells, which blocks the production of inflammatory mediators by macrophages and reduces inflammation. By blocking both the activity of CSF1R-dependent tumor-associated macrophages (TAMs) and the recruitment of TAMs to the tumor microenvironment, emactuzumab enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emactuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"RG-7155","termGroup":"CN","termSource":"NCI"},{"termName":"RG7155","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5509554","termGroup":"CN","termSource":"NCI"},{"termName":"RO5509554","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448221-67-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6FY6EI1X8R"},{"name":"Maps_To","value":"Emactuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"721542"},{"name":"NCI_META_CUI","value":"CL433956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721542"},{"name":"PDQ_Open_Trial_Search_ID","value":"721542"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127123":{"preferredName":"Emapalumab","code":"C127123","definitions":[{"definition":"A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emapalumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IFN gamma Monoclonal Antibody NI-0501","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IFNg mAb NI-0501","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-interferon gamma Monoclonal Antibody NI-0501","termGroup":"SY","termSource":"NCI"},{"termName":"Emapalumab-lzsg","termGroup":"SY","termSource":"NCI"},{"termName":"Gamifant","termGroup":"BR","termSource":"NCI"},{"termName":"NI 0501","termGroup":"CN","termSource":"NCI"},{"termName":"NI-0501","termGroup":"CN","termSource":"NCI"},{"termName":"NI0501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"primary hemophagocytic lymphohistiocytosis (HLH)"},{"name":"CAS_Registry","value":"1709815-23-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3S252O2Z4X"},{"name":"Maps_To","value":"Emapalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"780986"},{"name":"NCI_META_CUI","value":"CL507913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780986"},{"name":"PDQ_Open_Trial_Search_ID","value":"780986"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2195":{"preferredName":"Emepepimut-S","code":"C2195","definitions":[{"definition":"A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emepepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"BLP 25","termGroup":"CN","termSource":"NCI"},{"termName":"BLP-25","termGroup":"CN","termSource":"NCI"},{"termName":"BLP-25 Liposomal Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"BLP25","termGroup":"CN","termSource":"NCI"},{"termName":"BLP25 Liposome Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"BP1-7-KLH","termGroup":"AB","termSource":"NCI"},{"termName":"EMD 531444","termGroup":"CN","termSource":"NCI"},{"termName":"Glycine, L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-L-alanyl-L-histidylglycyl-L-valyl-L-threonyl-L-seryl-L-alanyl-L-prolyl-L-alpha-aspartyl-L-threonyl-L-arginyl-L-prolyl-L-alanyl-L-prolylglycyl-L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-N6-(1-oxohexadecyl)-L-lysyl-","termGroup":"SN","termSource":"NCI"},{"termName":"L-BLP25","termGroup":"AB","termSource":"NCI"},{"termName":"Stimuvax","termGroup":"BR","termSource":"NCI"},{"termName":"Tecemotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"221214-84-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q7Y026G2CX"},{"name":"Legacy Concept Name","value":"BLP25"},{"name":"Maps_To","value":"Emepepimut-S"},{"name":"NCI_Drug_Dictionary_ID","value":"529341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529341"},{"name":"PDQ_Open_Trial_Search_ID","value":"529341"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832016"}]}}{"C1022":{"preferredName":"Emitefur","code":"C1022","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD) inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar ratio, with antineoplastic activity.  Upon administration, the prodrug emitefur is converted into 5-FU, while CNDP prevents the degradation of 5-FU by inhibiting DPYD and thereby prolonging the half-life of 5-FU. This increases 5-FU's concentration and thus its antitumor activity through inhibition of DNA and RNA synthesis, as well as inhibition of thymidylate synthase activity. In addition, by inhibiting the formation of 5-FU metabolites, some toxic effects associated with these metabolites may be reduced. DPYD is the rate-limiting enzyme in the catabolism of 5-FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emitefur","termGroup":"PT","termSource":"NCI"},{"termName":"(2) m-[[3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 2-Ester with 2,6-Dihydroxynicotinonitrile Benzoate (Ester)","termGroup":"SN","termSource":"NCI"},{"termName":"3-((3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"3-[3-(6-Benzoyloxy-3-cyrano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"[[Ethoxymethyl-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 6-(Benzoyloxy)-3-cyano-2-pyridinyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"BOF-A2","termGroup":"CN","termSource":"NCI"},{"termName":"Last-F","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110690-43-2"},{"name":"Chemical_Formula","value":"C28H19FN4O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9I50NF4AQ2"},{"name":"Legacy Concept Name","value":"Emitefur"},{"name":"Maps_To","value":"Emitefur"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053902"}]}}{"C29019":{"preferredName":"Emofolin Sodium","code":"C29019","definitions":[{"definition":"The sodium salt of a synthetic antimetabolite analogue of folate with antineoplastic activity.  Emfolin sodium competes for the folate binding site of the enzyme dihydrofolate reductase, resulting in inhibition of tetrahydrofolate synthesis, depletion of nucleotide pools, and inhibition of DNA, RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emofolin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"MeTHHF Disodium","termGroup":"AB","termSource":"NCI"},{"termName":"Methyltetrahydrohomofolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52386-42-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Emfolin_Sodium"},{"name":"Maps_To","value":"Emofolin Sodium"},{"name":"NSC Number","value":"139490"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0098575"}]}}{"C116074":{"preferredName":"Empesertib","code":"C116074","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase, with potential antineoplastic activity. Upon administration, empesertib binds to and inhibits the activity of Mps1. This causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy. This leads to the induction of cell death in cancer cells overexpressing Mps1. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for SAC functioning and controls chromosome alignment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Empesertib","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-2-(4-Fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide","termGroup":"SY","termSource":"NCI"},{"termName":"BAY116-1909","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1161909","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443763-60-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"02Y3Z2756M"},{"name":"Maps_To","value":"Empesertib"},{"name":"NCI_Drug_Dictionary_ID","value":"761238"},{"name":"NCI_META_CUI","value":"CL473492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761238"},{"name":"PDQ_Open_Trial_Search_ID","value":"761238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113786":{"preferredName":"Enadenotucirev","code":"C113786","definitions":[{"definition":"A complex, replication-selective, chimeric adenovirus type 11p (Ad11p)/Ad3 oncolytic virus vaccine, with potential antineoplastic and immunomodulating activities. Enadenotucirev has the Ad11p backbone with a large deletion in the E3-region and a small E4-domain (E4orf4) deleted, in addition to a partial E2B substitution by the Ad3 E2B genes. Upon intravenous administration of enadenotucirev, the adenovirus selectively reaches the tumor cells due to the leaky tumor vasculature and replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune response. This further kills tumor cells. This may also stimulate long-term anti-tumor immunity. Although the cancer-selectivity of enadenotucirev is not entirely understood, the virus does not efficiently infect normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enadenotucirev","termGroup":"PT","termSource":"NCI"},{"termName":"Chimeric Oncolytic Adenovirus Ad3/Ad11p Containing Two Deletions in the Viral Genome in the E3 Region (2444 bp) and in the E4 Region (24 bp) and 197 Non-homologous Nucleotides in the E2B Region","termGroup":"SY","termSource":"NCI"},{"termName":"ColoAd-1","termGroup":"CN","termSource":"NCI"},{"termName":"ColoAd1","termGroup":"CN","termSource":"NCI"},{"termName":"ColoAd1 Oncolytic Virus","termGroup":"SY","termSource":"NCI"},{"termName":"EnAd","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402042-02-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KX7ZYR6OQW"},{"name":"Maps_To","value":"Enadenotucirev"},{"name":"NCI_Drug_Dictionary_ID","value":"757141"},{"name":"NCI_META_CUI","value":"CL471767"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757141"},{"name":"PDQ_Open_Trial_Search_ID","value":"757141"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159599":{"preferredName":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A","code":"C159599","definitions":[{"definition":"An oncolytic adenoviral vector, enadenotucirev (EnAd), that expresses a full-length agonistic anti-CD40 monoclonal antibody, with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of NG-350A, enadenotucirev specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses the agonistic anti-CD40 antibody. The locally expressed anti-CD40 antibody targets and binds to CD40 on a variety of immune cells, including B-cells, T-cells and dendritic cells (DCs) in the tumor microenvironment (TME). This induces CD40-dependent signaling pathways, which activates these immune cells and induces a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response and leads to tumor cell death. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A","termGroup":"PT","termSource":"NCI"},{"termName":"NG 350A","termGroup":"CN","termSource":"NCI"},{"termName":"NG-350A","termGroup":"CN","termSource":"NCI"},{"termName":"NG350A","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector Expressing Anti-CD40 Antibody NG-350A","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector-expressing Anti-CD40 Agonistic Antibody NG-350A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A"},{"name":"NCI_Drug_Dictionary_ID","value":"797804"},{"name":"NCI_META_CUI","value":"CL951598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797804"},{"name":"PDQ_Open_Trial_Search_ID","value":"797804"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111573":{"preferredName":"Enasidenib","code":"C111573","definitions":[{"definition":"An orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enasidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AG 221","termGroup":"CN","termSource":"NCI"},{"termName":"AG-221","termGroup":"CN","termSource":"NCI"},{"termName":"AG221","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90007 Free Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446502-11-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3T1SS4E7AG"},{"name":"Maps_To","value":"Enasidenib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827168"}]}}{"C137825":{"preferredName":"Enasidenib Mesylate","code":"C137825","definitions":[{"definition":"The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enasidenib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"AG-221 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"CC 90007","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90007","termGroup":"CN","termSource":"NCI"},{"termName":"CC90007","termGroup":"CN","termSource":"NCI"},{"termName":"Enasidenib Methanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Idhifa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation"},{"name":"CAS_Registry","value":"1650550-25-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UF6PC17XAV"},{"name":"Maps_To","value":"Enasidenib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"752247"},{"name":"NCI_META_CUI","value":"CL524900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752247"},{"name":"PDQ_Open_Trial_Search_ID","value":"752247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80045":{"preferredName":"Enavatuzumab","code":"C80045","definitions":[{"definition":"A humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. Enavatuzumab binds to TWEAKR and inhibits TWEAK ligand binding and activation of NF-kappaB-mediated cytokine release, which may result in tumor cell apoptosis. TWEAKR is a cell-surface receptor with homology to tumor necrosis factor receptors. Upon binding with its ligand, TWEAKR has been shown to stimulate cytokine release and cell proliferation, migration, and survival; it may also promote apoptosis under some conditions. This receptor may be overexpressed in a variety of tumors including those of the pancreas, colon, lung, kidney, and breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enavatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-tumor Necrosis Factor-like Weak Inducer of Apoptosis Monoclonal Antibody PDL192","termGroup":"SY","termSource":"NCI"},{"termName":"PDL 192","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1062149-33-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"914910XFBB"},{"name":"Legacy Concept Name","value":"Anti-TWEAKR_Monoclonal_Antibody_PDL192"},{"name":"Maps_To","value":"Enavatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"613893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613893"},{"name":"PDQ_Open_Trial_Search_ID","value":"613893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698154"}]}}{"C28211":{"preferredName":"Enclomiphene","code":"C28211","definitions":[{"definition":"The trans-isomer of clomiphene citrate (CC).  Enclomiphene has a higher rate of clearance and is less active than the cis-isomer, cis-clomiphene.  Clomiphene citrate has been evaluated for antineoplastic activity against breast cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enclomiphene","termGroup":"PT","termSource":"NCI"},{"termName":"Enclomifene","termGroup":"SY","termSource":"NCI"},{"termName":"ICI 46476","termGroup":"CN","termSource":"NCI"},{"termName":"RMI 16,289","termGroup":"CN","termSource":"NCI"},{"termName":"trans Clomiphene","termGroup":"SY","termSource":"NCI"},{"termName":"trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15690-57-0"},{"name":"Chemical_Formula","value":"C26H28ClNO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6D2UI4FLS"},{"name":"Legacy Concept Name","value":"Enclomiphene"},{"name":"Maps_To","value":"Enclomiphene"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086213"}]}}{"C61745":{"preferredName":"Enclomiphene Citrate","code":"C61745","definitions":[{"definition":"The orally bioavailable citrate salt of enclomiphene, the trans-isomer of the nonsteroidal triphenylethylene compound clomiphene, with tissue-selective estrogenic and antiestrogenic activities. As a selective estrogen receptor modulator (SERM), enclomiphene binds to hypothalamic estrogen receptors, blocking the negative feedback of endogenous estrogens and stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus; released GnRH subsequently stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary, resulting in ovulation. In addition, this agent may bind to estrogen receptors on breast cancer cells, resulting in the inhibition of estrogen-stimulated proliferation in susceptible cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enclomiphene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Androxal","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7599-79-3"},{"name":"Chemical_Formula","value":"C26H28ClNO.C6H8O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J303A6U9Y6"},{"name":"Legacy Concept Name","value":"Enclomiphene_Citrate"},{"name":"Maps_To","value":"Enclomiphene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"39307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39307"},{"name":"PDQ_Open_Trial_Search_ID","value":"39307"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086214"}]}}{"C98283":{"preferredName":"Encorafenib","code":"C98283","definitions":[{"definition":"An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"Braftovi","termGroup":"BR","termSource":"NCI"},{"termName":"LGX 818","termGroup":"CN","termSource":"NCI"},{"termName":"LGX-818","termGroup":"CN","termSource":"NCI"},{"termName":"LGX818","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation"},{"name":"CAS_Registry","value":"1269440-17-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8L7891MRB6"},{"name":"Maps_To","value":"Encorafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"712549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712549"},{"name":"PDQ_Open_Trial_Search_ID","value":"712549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4079208"}]}}{"C26678":{"preferredName":"Endothelin Receptor Type A Antagonist YM598","code":"C26678","definitions":[{"definition":"A substance that is being studied as a treatment for advanced prostate cancer and for pain caused by prostate cancer that has spread to the bone. It belongs to the family of drugs called endothelin ETA receptor antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endothelin Receptor Type A Antagonist YM598","termGroup":"PT","termSource":"NCI"},{"termName":"Potassium (E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylenthene Sulfonamidate","termGroup":"SN","termSource":"NCI"},{"termName":"YM598","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"342005-82-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OK6K3MDZ98"},{"name":"Legacy Concept Name","value":"YM598"},{"name":"Maps_To","value":"Endothelin Receptor Type A Antagonist YM598"},{"name":"NCI_Drug_Dictionary_ID","value":"270682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"270682"},{"name":"PDQ_Open_Trial_Search_ID","value":"270682"},{"name":"PubMedID_Primary_Reference","value":"16843458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1175067"}]}}{"C162248":{"preferredName":"Engineered Human Umbilical Vein Endothelial Cells AB-205","code":"C162248","definitions":[{"definition":"A population of ex vivo expanded, genetically engineered CD31 (platelet endothelial cell adhesion molecule; PECAM-1)-positive human umbilical vein endothelial cells (HUVECs) derived from human umbilical vein tissue, that can be used to enhance the hematopoietic stem and progenitor cells (HSPCs) transplantation potential and improve blood cell recovery. Following autologous stem cell transplantation (ASCT) and upon the administration of the engineered HUVEC AB-205, the endothelial cells secrete angiocrine growth factors and interact with the HSPCs, thereby forming endothelial cell network structures and improving engraftment potential. AB-205 also interacts with injured or damaged vascular niche cells, thereby promoting blood cell recovery and improving tissue regeneration. This enhances recovery from toxicities related to chemo/radiation regimens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Human Umbilical Vein Endothelial Cells AB-205","termGroup":"PT","termSource":"NCI"},{"termName":"AB 205","termGroup":"CN","termSource":"NCI"},{"termName":"AB-205","termGroup":"CN","termSource":"NCI"},{"termName":"AB-205 Cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"AB205","termGroup":"CN","termSource":"NCI"},{"termName":"Engineered HUVEC AB-205","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Human Umbilical Vein Endothelial Cells AB-205"},{"name":"NCI_Drug_Dictionary_ID","value":"798637"},{"name":"NCI_META_CUI","value":"CL970717"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798637"},{"name":"PDQ_Open_Trial_Search_ID","value":"798637"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162649":{"preferredName":"Engineered Toxin Body Targeting HER2 MT-5111","code":"C162649","definitions":[{"definition":"An engineered toxin body (ETB) composed of a single chain variable fragment (scFv) from an antibody targeting the human epidermal growth factor receptor 2 (HER2; HER-2), fused to the enzymatically active de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration, the scFv moiety of MT-5111 specifically targets and binds to a distinct epitope on HER2-expressing cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and leads to apoptosis in HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Toxin Body Targeting HER2 MT-5111","termGroup":"PT","termSource":"NCI"},{"termName":"ETB Targeting HER2 MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"HER2-targeted ETB MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"MT 5111","termGroup":"CN","termSource":"NCI"},{"termName":"MT-5111","termGroup":"CN","termSource":"NCI"},{"termName":"MT5111","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Fusion Protein MT-5111","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted Engineered Toxin Body MT-5111","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Toxin Body Targeting HER2 MT-5111"},{"name":"NCI_Drug_Dictionary_ID","value":"798930"},{"name":"NCI_META_CUI","value":"CL971043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798930"},{"name":"PDQ_Open_Trial_Search_ID","value":"798930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C11252":{"preferredName":"Eniluracil/5-FU Combination Tablet","code":"C11252","definitions":[{"definition":"A combination tablet of ethynyluracil and fluorouracil. Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Ethynyluracil is an orally-active fluoropyrimidine analog that inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil in the liver. This may lead to an increase in the bioavailability and, effectiveness of fluorouracil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eniluracil/5-FU Combination Tablet","termGroup":"PT","termSource":"NCI"},{"termName":"776C85/5-FU","termGroup":"SY","termSource":"NCI"},{"termName":"Ethynyluracil/Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"GW776/5-Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"GW776/5-FU","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ethynyluracil_Fluorouracil"},{"name":"Maps_To","value":"Eniluracil/5-FU Combination Tablet"},{"name":"NCI_Drug_Dictionary_ID","value":"42618"},{"name":"NSC Number","value":"710026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42618"},{"name":"PDQ_Open_Trial_Search_ID","value":"42618"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393027"}]}}{"C95323":{"preferredName":"Enloplatin","code":"C95323","definitions":[{"definition":"A platinum-based alkylating agent with antineoplastic activity. Although its pharmacokinetic properties are similar to that of carboplatin, enloplatin appears to be non-cross resistant with other platinum-based agents, such as cisplatin and carboplatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enloplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-(1,1-Cyclobutanedicarboxylato)(Tetrahydro-4H-Pyran-4,4-Bis(Methylamine))Platinum","termGroup":"SN","termSource":"NCI"},{"termName":"CL 287,110","termGroup":"CN","termSource":"NCI"},{"termName":"CL-287110","termGroup":"CN","termSource":"NCI"},{"termName":"Platinum, (1,1-Cyclobutanedicarboxylato(2-))(Tetrahydro-4h-Pyran-4,4-Dimethanamine-N,N')-, (Sp-4-2)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111523-41-2"},{"name":"Chemical_Formula","value":"C7H16N2O.C6H6O4.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C7HT2IO79H"},{"name":"Maps_To","value":"Enloplatin"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165431"}]}}{"C97510":{"preferredName":"Enoblituzumab","code":"C97510","definitions":[{"definition":"An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enoblituzumab","termGroup":"PT","termSource":"NCI"},{"termName":"MGA271","termGroup":"CN","termSource":"NCI"},{"termName":"TJ 271","termGroup":"CN","termSource":"NCI"},{"termName":"TJ-271","termGroup":"CN","termSource":"NCI"},{"termName":"TJ271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353485-38-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M6030H73N9"},{"name":"Maps_To","value":"Enoblituzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"703720"},{"name":"NCI_META_CUI","value":"CL430254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703720"},{"name":"PDQ_Open_Trial_Search_ID","value":"703720"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C69161":{"preferredName":"Enobosarm","code":"C69161","definitions":[{"definition":"A non-steroidal agent with anabolic activity. Selective androgen receptor modulator (SARM) GTx-024 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone's action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enobosarm","termGroup":"PT","termSource":"NCI"},{"termName":"Gtx-024","termGroup":"CN","termSource":"NCI"},{"termName":"Ostarine","termGroup":"BR","termSource":"NCI"},{"termName":"Propanamide, 3-(4-cyanophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-, (2S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"841205-47-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3571H3R8N"},{"name":"Legacy Concept Name","value":"Selective_Androgen_Receptor_Modulator_Gtx-024"},{"name":"Maps_To","value":"Enobosarm"},{"name":"NCI_Drug_Dictionary_ID","value":"551564"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551564"},{"name":"PDQ_Open_Trial_Search_ID","value":"551564"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742262"}]}}{"C82367":{"preferredName":"Enoticumab","code":"C82367","definitions":[{"definition":"A human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity. Enoticumab specifically binds to human DLL4, preventing its binding to Notch receptors and inhibiting Notch signaling, which may result in defective tumor vascularization and, so, the inhibition of tumor cell growth. DLL4 is the only Notch ligand selectively expressed on endothelial cells; DLL4/Notch signaling is required for the development of functional tumor blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enoticumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Delta-Like 4 Monoclonal Antibody REGN421","termGroup":"SY","termSource":"NCI"},{"termName":"REGN421","termGroup":"CN","termSource":"NCI"},{"termName":"SAR153192","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1192578-27-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B59DCD0F7D"},{"name":"Legacy Concept Name","value":"Anti-Dll4_Monoclonal_Antibody_REGN421"},{"name":"Maps_To","value":"Enoticumab"},{"name":"NCI_Drug_Dictionary_ID","value":"640973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640973"},{"name":"PDQ_Open_Trial_Search_ID","value":"640973"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830058"}]}}{"C83689":{"preferredName":"Enpromate","code":"C83689","definitions":[{"definition":"A synthetic acetylenic carbamate, an alkylating agent, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enpromate","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Diphenyl-2-propynyl-N-cyclohexylcarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Acetylenic Carbamate","termGroup":"SY","termSource":"NCI"},{"termName":"Lilly 59156","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10087-89-5"},{"name":"Chemical_Formula","value":"C22H23NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HBS2850E4H"},{"name":"Maps_To","value":"Enpromate"},{"name":"NSC Number","value":"112682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050514"}]}}{"C102754":{"preferredName":"Ensartinib","code":"C102754","definitions":[{"definition":"An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ensartinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- N-{4-[(3R,5S)-3,5-dimethylpiperazine- 1-carbonyl]phenyl}pyridazine-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Ensacove","termGroup":"FB","termSource":"NCI"},{"termName":"X 396","termGroup":"CN","termSource":"NCI"},{"termName":"X-396","termGroup":"CN","termSource":"NCI"},{"termName":"X396","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1370651-20-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"SMA5ZS5B22"},{"name":"Maps_To","value":"Ensartinib"},{"name":"NCI_Drug_Dictionary_ID","value":"735953"},{"name":"NCI_META_CUI","value":"CL437011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735953"},{"name":"PDQ_Open_Trial_Search_ID","value":"735953"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90532":{"preferredName":"Ensituximab","code":"C90532","definitions":[{"definition":"A chimeric monoclonal antibody against human colorectal and pancreatic carcinoma-associated antigens (CPAAs) with potential immunomodulating and anti-tumor activities. Anti-CPAA monoclonal antibody NPC-1C binds to CPAAs, which may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cellular cytotoxicity (ADCC) response against CPAA-expressing tumor cells. CPAAs, cell surface proteins, are upregulated on colon and pancreatic tumor cells. NPC-1C contains the variable region of the heavy and light chain of murine NPC-1 and linked in-frame to constant regions of a human IgG1 isotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ensituximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Colorectal and Pancreatic Carcinoma-Associated Antigen Monoclonal Antibody NPC-1C","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CPAA Monoclonal Antibody NPC-1C","termGroup":"SY","termSource":"NCI"},{"termName":"NPC-1C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092658-06-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F988K568V2"},{"name":"Maps_To","value":"Ensituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"663436"},{"name":"NCI_META_CUI","value":"CL413613"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663436"},{"name":"PDQ_Open_Trial_Search_ID","value":"663436"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82660":{"preferredName":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride","code":"C82660","definitions":[{"definition":"An enteric-coated orally bioavailable formulation of the hydrochloride salt of a small-molecule agonist for transient receptor potential melastatin member 8 (TRPM8 or Trp-p8) with potential antineoplastic activity. The active ingredient in enteric-coated TRPM8 agonist D-3263 hydrochloride binds to and activates TRPM8, which may result in an increase in calcium and sodium entry; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. This agent may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and BPH. TRPM8 is a transmembrane calcium channel protein that is normally expressed in prostate cells and appears to be overexpressed in benign prostatic hyperplasia (BPH) and in prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"EC D-3263 HCl","termGroup":"SY","termSource":"NCI"},{"termName":"EC D-3263 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1008763-54-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R82GTC01OB"},{"name":"Legacy Concept Name","value":"Enteric-Coated_TRPM8_Agonist_D-3263_Hydrochloride"},{"name":"Maps_To","value":"Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"636649"},{"name":"NCI_META_CUI","value":"CL411370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636649"},{"name":"PDQ_Open_Trial_Search_ID","value":"636649"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160293":{"preferredName":"Enterococcus gallinarum Strain MRx0518","code":"C160293","definitions":[{"definition":"A live strain of the flagellin-producing Gram-positive bacterium Enterococcus (E.) gallinarum that is isolated from a healthy human gut, with potential immunomodulating and antineoplastic activities. Upon oral administration, MRx0518 modulates the intestinal microbiota and targets both intestinal epithelial cells (IECs), and various immune cells, such as macrophages and dendritic cells (DCs)  and is able to induce the production of both pro- and anti-inflammatory mediators, such as interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-a), IL-1beta, IL-6, IL-23, in these cells and activates the innate immune system. The flagellin produced by MRx0518 interacts with and activates toll-like receptor 5 (TLR5), thereby activating the adaptive immune system and modulating the tumor microenvironment (TME). This activates the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enterococcus gallinarum Strain MRx0518","termGroup":"PT","termSource":"NCI"},{"termName":"E. gallinarum MRx0518","termGroup":"SY","termSource":"NCI"},{"termName":"Gut Microbiota-derived Strain MRx0518","termGroup":"SY","termSource":"NCI"},{"termName":"MRx 0518","termGroup":"CN","termSource":"NCI"},{"termName":"MRx-0518","termGroup":"CN","termSource":"NCI"},{"termName":"MRx0518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Enterococcus gallinarum Strain MRx0518"},{"name":"NCI_Drug_Dictionary_ID","value":"798317"},{"name":"NCI_META_CUI","value":"CL969238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798317"},{"name":"PDQ_Open_Trial_Search_ID","value":"798317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1863":{"preferredName":"Entinostat","code":"C1863","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Carbamic Acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3- pyridinylmethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"MS 27-275","termGroup":"CN","termSource":"NCI"},{"termName":"MS 275","termGroup":"CN","termSource":"NCI"},{"termName":"MS-275","termGroup":"CN","termSource":"NCI"},{"termName":"MS275","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]b enzamide","termGroup":"SN","termSource":"NCI"},{"termName":"SNDX 275","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX-275","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX275","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"209783-80-2"},{"name":"Chemical_Formula","value":"C21H20N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1ZNY4FKK9H"},{"name":"Legacy Concept Name","value":"MS-27-275"},{"name":"Maps_To","value":"Entinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"38294"},{"name":"NSC Number","value":"706995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38294"},{"name":"PDQ_Open_Trial_Search_ID","value":"38294"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048552"}]}}{"C99166":{"preferredName":"Entolimod","code":"C99166","definitions":[{"definition":"A polypeptide derived from the Salmonella filament protein flagellin with potential radioprotective and anticancer activities. As a toll-like receptor 5 (TLR5) agonist, entolimod binds to and activates TLR5 thereby stimulating tumor necrosis factor production and activating nuclear factor kappa B (NF-kB). This induces NF-kB-mediated signaling pathways and inhibits the induction of apoptosis. This may prevent apoptosis in normal, healthy cells during radiotherapy of cancerous cells and may allow for increased doses of ionizing radiation. In addition, entolimod may inhibit radiation-independent proliferation in TLR5-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entolimod","termGroup":"PT","termSource":"NCI"},{"termName":"CBLB502","termGroup":"CN","termSource":"NCI"},{"termName":"TLR5 Agonist CBLB502","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"951628-22-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1UQ6D1ECM"},{"name":"Maps_To","value":"Entolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"717513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717513"},{"name":"PDQ_Open_Trial_Search_ID","value":"717513"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2353146"}]}}{"C105402":{"preferredName":"Entospletinib","code":"C105402","definitions":[{"definition":"An orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entospletinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine","termGroup":"SN","termSource":"NCI"},{"termName":"ENTO","termGroup":"AB","termSource":"NCI"},{"termName":"GS 9973","termGroup":"CN","termSource":"NCI"},{"termName":"GS-9973","termGroup":"CN","termSource":"NCI"},{"termName":"GS9973","termGroup":"CN","termSource":"NCI"},{"termName":"Imidazo(1,2-a)pyrazin-8-amine, 6-(1H-indazol-6-yl)-N-(4-(4-morpholinyl)phenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229208-44-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6I3O3W6O3B"},{"name":"Maps_To","value":"Entospletinib"},{"name":"NCI_Drug_Dictionary_ID","value":"746910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746910"},{"name":"PDQ_Open_Trial_Search_ID","value":"746910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642151"}]}}{"C114984":{"preferredName":"Entrectinib","code":"C114984","definitions":[{"definition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Entrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Rozlytrek","termGroup":"BR","termSource":"NCI"},{"termName":"RXDX 101","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-101","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion"},{"name":"CAS_Registry","value":"1108743-60-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"L5ORF0AN1I"},{"name":"Maps_To","value":"Entrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"759586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759586"},{"name":"PDQ_Open_Trial_Search_ID","value":"759586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896774"}]}}{"C129714":{"preferredName":"Envafolimab","code":"C129714","definitions":[{"definition":"An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Envafolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 MoAb KN035","termGroup":"SY","termSource":"NCI"},{"termName":"Enweida","termGroup":"FB","termSource":"NCI"},{"termName":"KN 035","termGroup":"CN","termSource":"NCI"},{"termName":"KN-035","termGroup":"CN","termSource":"NCI"},{"termName":"KN035","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2102192-68-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ES1M06M6QH"},{"name":"Maps_To","value":"Envafolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"784496"},{"name":"NCI_META_CUI","value":"CL512904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784496"},{"name":"PDQ_Open_Trial_Search_ID","value":"784496"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71744":{"preferredName":"Enzalutamide","code":"C71744","definitions":[{"definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enzalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"ASP9785","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MDV 3100","termGroup":"CN","termSource":"NCI"},{"termName":"MDV-3100","termGroup":"CN","termSource":"NCI"},{"termName":"MDV3100","termGroup":"CN","termSource":"NCI"},{"termName":"Xtandi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"castration-resistant prostate cancer (CRPC)"},{"name":"CAS_Registry","value":"915087-33-1"},{"name":"Chemical_Formula","value":"C21H16F4N4O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"93T0T9GKNU"},{"name":"Legacy Concept Name","value":"Selective_Androgen_Receptor_Modulator_MDV3100"},{"name":"Maps_To","value":"Enzalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"560774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560774"},{"name":"PDQ_Open_Trial_Search_ID","value":"560774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348174"}]}}{"C77392":{"preferredName":"Enzastaurin","code":"C77392","definitions":[{"definition":"A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Enzastaurin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"170364-57-5"},{"name":"Chemical_Formula","value":"C32H29N5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UC96G28EQF"},{"name":"Legacy Concept Name","value":"Enzastaurin"},{"name":"Maps_To","value":"Enzastaurin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327830"}]}}{"C26658":{"preferredName":"Enzastaurin Hydrochloride","code":"C26658","definitions":[{"definition":"A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin hydrochloride blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity.  Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enzastaurin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrole-2,5-dione, 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-, Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"3-(1-Methyl-1H-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Enzastaurin Monohydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"LY317615","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"359017-79-1"},{"name":"Chemical_Formula","value":"C32H29N5O2.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KX7K68Z2UH"},{"name":"Legacy Concept Name","value":"LY317615"},{"name":"Maps_To","value":"Enzastaurin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"269069"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269069"},{"name":"PDQ_Open_Trial_Search_ID","value":"269069"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1615613"}]}}{"C150376":{"preferredName":"EP4 Antagonist ONO-4578","code":"C150376","definitions":[{"definition":"An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist ONO-4578 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP4 Antagonist ONO-4578","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986310","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986310","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986310","termGroup":"CN","termSource":"NCI"},{"termName":"ONO 4578","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-4578","termGroup":"CN","termSource":"NCI"},{"termName":"ONO4578","termGroup":"CN","termSource":"NCI"},{"termName":"PGE2 Receptor Antagonist ONO-4578","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 Receptor Antagonist ONO-4578","termGroup":"SY","termSource":"NCI"},{"termName":"Selective PGE2 Receptor 4 Antagonist ONO-4578","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1965316-82-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VJ3OXN6K2H"},{"name":"Maps_To","value":"EP4 Antagonist ONO-4578"},{"name":"NCI_Drug_Dictionary_ID","value":"792745"},{"name":"NCI_META_CUI","value":"CL552175"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792745"},{"name":"PDQ_Open_Trial_Search_ID","value":"792745"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C92582":{"preferredName":"Epacadostat","code":"C92582","definitions":[{"definition":"An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. Epacadostat targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, INCB024360 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), NK cells, and T-lymphocytes, as well as interferon (IFN) production, and a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and DCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epacadostat","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,5-Oxadiazole-3-carboximidamide, 4-((2-((Aminosulfonyl)amino)ethyl)amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-, (C(Z))-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 024360","termGroup":"CN","termSource":"NCI"},{"termName":"INCB024360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204669-58-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71596A9R13"},{"name":"Maps_To","value":"Epacadostat"},{"name":"NCI_Drug_Dictionary_ID","value":"685310"},{"name":"NCI_META_CUI","value":"CL423831"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685310"},{"name":"PDQ_Open_Trial_Search_ID","value":"685310"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1866":{"preferredName":"Epipodophyllotoxin Analog GL331","code":"C1866","definitions":[{"definition":"An epipodophyllotoxin analogue possessing antineoplastic properties.  GL331 binds to and inhibits topoisomerase II, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epipodophyllotoxin Analog GL331","termGroup":"PT","termSource":"NCI"},{"termName":"GL331","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GL331"},{"name":"Maps_To","value":"Epipodophyllotoxin Analog GL331"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0908996"}]}}{"C78083":{"preferredName":"Epipropidine","code":"C78083","definitions":[{"definition":"An epoxide and alkylating agent with antineoplastic activity. Epipropidone is not used clinically due to its unstable nature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epipropidine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5696-17-3"},{"name":"Chemical_Formula","value":"C16H28N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T3RCY5OD7A"},{"name":"Legacy Concept Name","value":"Epipropidine"},{"name":"Maps_To","value":"Epipropidine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700003"}]}}{"C62028":{"preferredName":"Epirubicin","code":"C62028","definitions":[{"definition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used together with other drugs to treat early breast cancer that has spread to lymph nodes. It is also being studied in the treatment of other types of cancer. Epirubicin is a type of anthracycline antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Epirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"4'-epi DX","termGroup":"AB","termSource":"NCI"},{"termName":"4'-Epiadriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"4'-Epidoxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Epi DX","termGroup":"AB","termSource":"NCI"},{"termName":"Epidoxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Pidorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56420-45-2"},{"name":"CHEBI_ID","value":"CHEBI:47898"},{"name":"Chemical_Formula","value":"C27H29NO11"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3Z8479ZZ5X"},{"name":"Legacy Concept Name","value":"Epirubicin_Base"},{"name":"Maps_To","value":"Epirubicin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014582"}]}}{"C474":{"preferredName":"Epirubicin Hydrochloride","code":"C474","definitions":[{"definition":"A drug used together with other drugs to treat early breast cancer that has spread to lymph nodes. It is also being studied in the treatment of other types of cancer. Ellence is a type of anthracycline antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epirubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Ellence","termGroup":"BR","termSource":"NCI"},{"termName":"IMI-28","termGroup":"CN","termSource":"NCI"},{"termName":"Pharmorubicin PFS","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer"},{"name":"CAS_Registry","value":"56390-09-1"},{"name":"Chemical_Formula","value":"C27H29NO11.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22966TX7J5"},{"name":"Legacy Concept Name","value":"Epirubicin"},{"name":"Maps_To","value":"Epirubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39232"},{"name":"NSC Number","value":"256942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39232"},{"name":"PDQ_Open_Trial_Search_ID","value":"39232"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700582"}]}}{"C153095":{"preferredName":"Epitinib Succinate","code":"C153095","definitions":[{"definition":"The succinate salt form of epitinib, an orally available epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon administration, epitinib inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may lead to induction of cell death and inhibition of tumor growth in EGFR-overexpressing tumor cells. EGFR is a receptor tyrosine kinase (RTK) that is overexpressed in certain tumor types and plays a key role in tumor cell proliferation and vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epitinib Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL 813","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-813","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL813","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2252334-12-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2138WW3F3R"},{"name":"Maps_To","value":"Epitinib Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"793471"},{"name":"NCI_META_CUI","value":"CL554354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793471"},{"name":"PDQ_Open_Trial_Search_ID","value":"793471"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1089":{"preferredName":"Epitiostanol","code":"C1089","definitions":[{"definition":"An androgenic anabolic steroid having potent anti-estrogenic effect, which inhibits the progression of estrogen-stimulated cancers such as breast cancer. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epitiostanol","termGroup":"PT","termSource":"NCI"},{"termName":"10275-S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2363-58-8"},{"name":"Chemical_Formula","value":"C19H30OS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YE7586973L"},{"name":"Legacy Concept Name","value":"Epitiostanol"},{"name":"Maps_To","value":"Epitiostanol"},{"name":"NCI_Drug_Dictionary_ID","value":"39595"},{"name":"NSC Number","value":"194684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39595"},{"name":"PDQ_Open_Trial_Search_ID","value":"39595"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059457"}]}}{"C118450":{"preferredName":"Utidelone","code":"C118450","definitions":[{"definition":"A genetically engineered epothilone analog with potential antineoplastic activity. Upon administration, utidelone binds to tubulin, induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and enhanced activity against certain multidrug-resistant (MDR) tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Utidelone","termGroup":"PT","termSource":"NCI"},{"termName":"Epothilone Analog UTD1","termGroup":"SY","termSource":"NCI"},{"termName":"UTD1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Epothilone Analog UTD1"},{"name":"NCI_Drug_Dictionary_ID","value":"765129"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765129"},{"name":"PDQ_Open_Trial_Search_ID","value":"765129"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896752"}]}}{"C77892":{"preferredName":"Epothilone KOS-1584","code":"C77892","definitions":[{"definition":"A second-generation epothilone with potential antineoplastic activity. Epothilone KOS-1584 binds to tubulin and induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and efficacy with an enhanced pharmaceutical profile, including enhanced water solubility and tumor penetration, and reduced CNS exposure. In addition, epothilone KOS-1584 is a poor substrate for the P-glycoprotein (P-gp) drug efflux pump.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epothilone KOS-1584","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Didehydroepothilone D","termGroup":"SN","termSource":"NCI"},{"termName":"KOS-1584","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"350493-61-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82481G197K"},{"name":"Legacy Concept Name","value":"Epothilone_KOS-1584"},{"name":"Maps_To","value":"Epothilone KOS-1584"},{"name":"NCI_Drug_Dictionary_ID","value":"594152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594152"},{"name":"PDQ_Open_Trial_Search_ID","value":"594152"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099968"}]}}{"C1887":{"preferredName":"Epratuzumab","code":"C1887","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epratuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 412","termGroup":"CN","termSource":"NCI"},{"termName":"hLL2","termGroup":"AB","termSource":"NCI"},{"termName":"IMMU-HLL2","termGroup":"SY","termSource":"NCI"},{"termName":"LymphoCide","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Systemic lupus erythematosus"},{"name":"CAS_Registry","value":"205923-57-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3062P60MH9"},{"name":"Legacy Concept Name","value":"Epratuzumab"},{"name":"Maps_To","value":"Epratuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42234"},{"name":"NSC Number","value":"716711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42234"},{"name":"PDQ_Open_Trial_Search_ID","value":"42234"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1120776"}]}}{"C155794":{"preferredName":"Epratuzumab-cys-tesirine","code":"C155794","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a cysteine-engineered version of epratuzumab (hLL2), a humanized anti-CD22 monoclonal antibody derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2), site-specifically conjugated to the cross-linking cytotoxic agent tesirine (SG3249), a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine dimer (PBD), with potential antineoplastic activity. Upon administration of epratuzumab-cys-tesirine, the epratuzumab moiety targets and binds to the B cell-specific CD22 receptor and is rapidly internalized. Upon cleavage, the imine groups of tesirine target and bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD22-overexpressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Epratuzumab-cys-tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-602","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT-602","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT602","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD22/PBD ADC ADCT-602","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate ADCT-602","termGroup":"SY","termSource":"NCI"},{"termName":"Epratuzumab-cys-SG3249","termGroup":"SY","termSource":"NCI"},{"termName":"hLL2-cys-PBD","termGroup":"SY","termSource":"NCI"},{"termName":"hLL2-cys-SG3249","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7X6143A60Y"},{"name":"Maps_To","value":"Epratuzumab-cys-tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"794990"},{"name":"NCI_META_CUI","value":"CL556329"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794990"},{"name":"PDQ_Open_Trial_Search_ID","value":"794990"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C165420":{"preferredName":"Vepdegestrant","code":"C165420","definitions":[{"definition":"An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vepdegestrant","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Piperidinedione, 3-(1,3-dihydro-1-oxo-5-(4-((1-(4-((1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenyl)-4-piperidinyl)methyl)-1-piperazinyl)-2H-isoindol-2-yl)-, (3S)-","termGroup":"SN","termSource":"NCI"},{"termName":"ARV 471","termGroup":"CN","termSource":"NCI"},{"termName":"ARV-471","termGroup":"CN","termSource":"NCI"},{"termName":"ARV471","termGroup":"CN","termSource":"NCI"},{"termName":"ER alpha PROTAC Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"},{"termName":"ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"},{"termName":"Estrogen Receptor alpha PROTAC Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"},{"termName":"PF 07850327","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07850327","termGroup":"CN","termSource":"NCI"},{"termName":"PF07850327","termGroup":"CN","termSource":"NCI"},{"termName":"PROTAC Protein Degrader ARV-471","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2229711-68-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WC1U3R1YMI"},{"name":"Maps_To","value":"ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471"},{"name":"NCI_Drug_Dictionary_ID","value":"799764"},{"name":"NCI_META_CUI","value":"CL978634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799764"},{"name":"PDQ_Open_Trial_Search_ID","value":"799764"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95720":{"preferredName":"ERa36 Modulator Icaritin","code":"C95720","definitions":[{"definition":"A metabolite of icariin, a principal flavonoid glycoside in Herba Epimedii (a traditional Chinese medicine herb used in treating osteoporosis) with potential antineoplastic activity. ERa36 modulator icaritin selectively binds to a novel variant of estrogen receptor alpha, a36, and mediates a membrane-initiated \"nongenomic\" signaling pathway, which is linked to activate signaling pathways like the MAPK/ERK and the PI3K/Akt pathways. This agent induces cell cycle arrest at G1, or G2/M arrest depending upon the dose. Consistently with G1 arrest, icaritin increases protein expressions of pRb, p27(Kip1) and p16(Ink4a), while decreasing phosphorylated pRb, Cyclin D1 and CDK4. 40% of ER-negative breast cancer tumors express high levels of ERa36, and this subset of patients is less likely to benefit from tamoxifen treatment compared with those with ERa66-positive/ERa36-negative tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERa36 Modulator Icaritin","termGroup":"PT","termSource":"NCI"},{"termName":"4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118525-40-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERa36 Modulator Icaritin"},{"name":"NCI_Drug_Dictionary_ID","value":"694226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694226"},{"name":"PDQ_Open_Trial_Search_ID","value":"694226"},{"name":"PubMedID_Primary_Reference","value":"17382317"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567768"}]}}{"C70625":{"preferredName":"Erastin Analogue PRLX 93936","code":"C70625","definitions":[{"definition":"A structural analogue of erastin with potential antineoplastic activity. Erastin analogue PRLX 93936 appears to inhibit mitochondrial outer membrane protein VDACs (voltage-dependent anion channels) 2 and 3, resulting in an oxidative, non-apoptotic cell death. Erastin analogue PRLX 93936 exhibits greater lethality in cell lines harboring mutations in the GTPase protein oncogenes HRAS and KRAS or the serine-threonine protein kinase oncogene BRAF than in non-tumorigenic cell lines. VDACs 2 and 3 are up-regulated in a wide variety of tumor cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erastin Analogue PRLX 93936","termGroup":"PT","termSource":"NCI"},{"termName":"PRLX 93936","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Erastin_Analogue_PRLX93936"},{"name":"Maps_To","value":"Erastin Analogue PRLX 93936"},{"name":"NCI_Drug_Dictionary_ID","value":"570728"},{"name":"NCI_META_CUI","value":"CL375988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570728"},{"name":"PDQ_Open_Trial_Search_ID","value":"570728"},{"name":"PubMedID_Primary_Reference","value":"17568748"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73258":{"preferredName":"Erbulozole","code":"C73258","definitions":[{"definition":"A water soluble congener of tubulozole and a tubulin binding agent with potential antimitotic and antineoplastic activities. Erbulozole targets and binds to tubulin, thereby preventing the polymerization of tubulin. This may lead to an inhibition of cell division and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erbulozole","termGroup":"PT","termSource":"NCI"},{"termName":"Carbamic acid, (4-(((2-(1H-imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl)methyl)thio)phenyl)-,ethyl ester, cis-(+-)-","termGroup":"SN","termSource":"NCI"},{"termName":"R55104","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124784-31-2"},{"name":"Chemical_Formula","value":"C24H27N3O5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78XGN2K5RX"},{"name":"Legacy Concept Name","value":"Erbulozole"},{"name":"Maps_To","value":"Erbulozole"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059504"}]}}{"C103273":{"preferredName":"Erdafitinib","code":"C103273","definitions":[{"definition":"An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erdafitinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Balversa","termGroup":"BR","termSource":"NCI"},{"termName":"JNJ 42756493","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-42756493","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ42756493","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma"},{"name":"CAS_Registry","value":"1346242-81-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"890E37NHMV"},{"name":"Maps_To","value":"Erdafitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"741845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741845"},{"name":"PDQ_Open_Trial_Search_ID","value":"741845"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641169"}]}}{"C96748":{"preferredName":"Eribulin","code":"C96748","definitions":[{"definition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eribulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"E 7389","termGroup":"CN","termSource":"NCI"},{"termName":"E-7389","termGroup":"CN","termSource":"NCI"},{"termName":"ER 086526","termGroup":"CN","termSource":"NCI"},{"termName":"ER-086526","termGroup":"CN","termSource":"NCI"},{"termName":"ER086526","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast Cancer"},{"name":"CAS_Registry","value":"253128-41-5"},{"name":"CHEBI_ID","value":"CHEBI:63587"},{"name":"Chemical_Formula","value":"C40H59NO11"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LR24G6354G"},{"name":"Maps_To","value":"Eribulin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350866"}]}}{"C26644":{"preferredName":"Eribulin Mesylate","code":"C26644","definitions":[{"definition":"A drug used to treat metastatic breast cancer in patients who have already been treated with other chemotherapy. It is also being studied in the treatment of other types of cancer. Halaven may block cancer cell growth by stopping cell division. It belongs to the family of drugs called antitubulin agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eribulin Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"B1939 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"E7389","termGroup":"CN","termSource":"NCI"},{"termName":"ER-086526 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Halaven","termGroup":"BR","termSource":"NCI"},{"termName":"Halichondrin B Analog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable or metastatic liposarcoma; breast cancer"},{"name":"CAS_Registry","value":"253128-41-5"},{"name":"Chemical_Formula","value":"C40H59NO11.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AV9U0660CW"},{"name":"Legacy Concept Name","value":"E7389"},{"name":"Maps_To","value":"Eribulin Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"257773"},{"name":"NSC Number","value":"707389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257773"},{"name":"PDQ_Open_Trial_Search_ID","value":"257773"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2608038"}]}}{"C155785":{"preferredName":"Beroterkib Anhydrous","code":"C155785","definitions":[{"definition":"The anhydrous form of beroterkib, an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, beroterkib specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Beroterkib Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 029","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX-029","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX029","termGroup":"CN","termSource":"NCI"},{"termName":"AT-35029","termGroup":"CN","termSource":"NCI"},{"termName":"AT35029","termGroup":"CN","termSource":"NCI"},{"termName":"ERK 1/2 Inhibitor ASTX029","termGroup":"SY","termSource":"NCI"},{"termName":"ERK Inhibitor ASTX029","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor ASTX029","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase Inhibitor ASTX029","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095719-92-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14FDK6ISC9"},{"name":"Maps_To","value":"ERK 1/2 Inhibitor ASTX029"},{"name":"NCI_Drug_Dictionary_ID","value":"794989"},{"name":"NCI_META_CUI","value":"CL556263"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794989"},{"name":"PDQ_Open_Trial_Search_ID","value":"794989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119747":{"preferredName":"ERK Inhibitor CC-90003","code":"C119747","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, CC-90003 inhibits ERK activity, and prevents the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK Inhibitor CC-90003","termGroup":"PT","termSource":"NCI"},{"termName":"CC-90003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK Inhibitor CC-90003"},{"name":"NCI_Drug_Dictionary_ID","value":"767257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767257"},{"name":"PDQ_Open_Trial_Search_ID","value":"767257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896889"}]}}{"C170364":{"preferredName":"Ravoxertinib","code":"C170364","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, ravoxertinib inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ravoxertinib","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor GDC-0994","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0994","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453848-26-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6AXV96CRH"},{"name":"Maps_To","value":"ERK Inhibitor GDC-0994"},{"name":"NCI_Drug_Dictionary_ID","value":"750790"},{"name":"NCI_META_CUI","value":"CL1382601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750790"},{"name":"PDQ_Open_Trial_Search_ID","value":"750790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126687":{"preferredName":"Rineterkib","code":"C126687","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, rineterkib binds to and inhibits ERK, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in numerous tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rineterkib","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor LTT462","termGroup":"SY","termSource":"NCI"},{"termName":"LTT 462","termGroup":"CN","termSource":"NCI"},{"termName":"LTT462","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1715025-32-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15KFN616FK"},{"name":"Maps_To","value":"ERK Inhibitor LTT462"},{"name":"NCI_Drug_Dictionary_ID","value":"780511"},{"name":"NCI_META_CUI","value":"CL507900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780511"},{"name":"PDQ_Open_Trial_Search_ID","value":"780511"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104045":{"preferredName":"ERK Inhibitor MK-8353","code":"C104045","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, MK-8353 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways; thereby, preventing ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK Inhibitor MK-8353","termGroup":"PT","termSource":"NCI"},{"termName":"MK-8353","termGroup":"CN","termSource":"NCI"},{"termName":"MK-8353-001","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900353","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK Inhibitor MK-8353"},{"name":"NCI_Drug_Dictionary_ID","value":"701114"},{"name":"NCI_META_CUI","value":"CL433840"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701114"},{"name":"PDQ_Open_Trial_Search_ID","value":"701114"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150248":{"preferredName":"ERK1/2 Inhibitor ERAS-007","code":"C150248","definitions":[{"definition":"An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERAS-007 specifically binds to and inhibits the serine/threonine-protein kinase activities of both ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor ERAS-007","termGroup":"PT","termSource":"NCI"},{"termName":"ASN 007","termGroup":"CN","termSource":"NCI"},{"termName":"ASN-007","termGroup":"CN","termSource":"NCI"},{"termName":"ASN007","termGroup":"CN","termSource":"NCI"},{"termName":"ERAS 007","termGroup":"CN","termSource":"NCI"},{"termName":"ERAS-007","termGroup":"CN","termSource":"NCI"},{"termName":"ERAS007","termGroup":"CN","termSource":"NCI"},{"termName":"ERK Inhibitor ASN007","termGroup":"SY","termSource":"NCI"},{"termName":"ERK Inhibitor ERAS-007","termGroup":"SY","termSource":"NCI"},{"termName":"ERK1/2 Inhibitor ASN007","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor ASN007"},{"name":"NCI_Drug_Dictionary_ID","value":"805553"},{"name":"NCI_META_CUI","value":"CL552048"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141074":{"preferredName":"ERK1/2 Inhibitor KO-947","code":"C141074","definitions":[{"definition":"An inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon intravenous administration, KO-947 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor KO-947","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor KO-947","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor KO-947","termGroup":"SY","termSource":"NCI"},{"termName":"KO 947","termGroup":"CN","termSource":"NCI"},{"termName":"KO-947","termGroup":"CN","termSource":"NCI"},{"termName":"KO947","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor KO-947"},{"name":"NCI_Drug_Dictionary_ID","value":"791296"},{"name":"NCI_META_CUI","value":"CL539120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791296"},{"name":"PDQ_Open_Trial_Search_ID","value":"791296"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131335":{"preferredName":"Temuterkib","code":"C131335","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, temuterkib inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temuterkib","termGroup":"PT","termSource":"NCI"},{"termName":"ERK1/2 Inhibitor LY3214996","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3214996","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3214996","termGroup":"CN","termSource":"NCI"},{"termName":"LY3214996","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1951483-29-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V0Q46LFE6F"},{"name":"Maps_To","value":"ERK1/2 Inhibitor LY3214996"},{"name":"NCI_Drug_Dictionary_ID","value":"785705"},{"name":"NCI_META_CUI","value":"CL514490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785705"},{"name":"PDQ_Open_Trial_Search_ID","value":"785705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C65530":{"preferredName":"Erlotinib","code":"C65530","definitions":[{"definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erlotinib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183321-74-6"},{"name":"CHEBI_ID","value":"CHEBI:114785"},{"name":"Chemical_Formula","value":"C22H23N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"J4T82NDH7E"},{"name":"Legacy Concept Name","value":"Erlotinib_Base"},{"name":"Maps_To","value":"Erlotinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1135135"}]}}{"C2693":{"preferredName":"Erlotinib Hydrochloride","code":"C2693","definitions":[{"definition":"A drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib hydrochloride is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Erlotinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"CP 358","termGroup":"CN","termSource":"NCI"},{"termName":"CP-358","termGroup":"CN","termSource":"NCI"},{"termName":"Cp-358,774","termGroup":"CN","termSource":"NCI"},{"termName":"CP358","termGroup":"CN","termSource":"NCI"},{"termName":"Erlotinib Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"OSI 774","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-774","termGroup":"CN","termSource":"NCI"},{"termName":"OSI774","termGroup":"CN","termSource":"NCI"},{"termName":"Tarceva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant glioma; Locally advanced or metastic non-small cell lung carcinoma; Locally advanced, unresectable or metastatic pancreatic carcinoma"},{"name":"CAS_Registry","value":"183319-69-9"},{"name":"CHEBI_ID","value":"CHEBI:53509"},{"name":"Chemical_Formula","value":"C22H23N3O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DA87705X9K"},{"name":"Legacy Concept Name","value":"Erlotinib"},{"name":"Maps_To","value":"Erlotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"38428"},{"name":"NSC Number","value":"718781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38428"},{"name":"PDQ_Open_Trial_Search_ID","value":"38428"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1533491"}]}}{"C2658":{"preferredName":"Ertumaxomab","code":"C2658","definitions":[{"definition":"A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor-associated antigen that promotes tumor growth.  Ertumaxomab attaches to CD3-expressing T cells and HER-2-neu-expressing tumor cells, selectively cross-linking tumor and immunologic cells which results in the recruitment of cytotoxic T cells to the T cell/tumor cell aggregate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ertumaxomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3 x anti-HER-2-neu Bispecific Monoclonal Antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"509077-99-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L5L45YGP1O"},{"name":"Legacy Concept Name","value":"Anti-CD3_x_anti-HER-2-neu_Bispecific_Monoclonal_Antibody"},{"name":"Maps_To","value":"Ertumaxomab"},{"name":"NCI_Drug_Dictionary_ID","value":"38498"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38498"},{"name":"PDQ_Open_Trial_Search_ID","value":"38498"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723386"}]}}{"C99767":{"preferredName":"Eryaspase","code":"C99767","definitions":[{"definition":"A suspension of erythrocytes encapsulating L-asparaginase with potential antineoplastic activity. Upon administration of eryaspase, L-asparagine is hydrolyzed to L-aspartic acid and ammonia in plasma, thereby depleting tumor cells of asparagine. Due to low asparagine synthetase activity in tumor cells, de novo synthesis of asparagine is suppressed within tumor cells. Shortage of asparagine prevents synthesis of important proteins necessary for tumor cell growth. Encapsulation of asparaginase in erythrocytes decreases the immunogenicity of exogenous protein, enhances its circulation time and may limit toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eryaspase","termGroup":"PT","termSource":"NCI"},{"termName":"ERY001","termGroup":"CN","termSource":"NCI"},{"termName":"Erythrocyte-encapsulated L-asparaginase Suspension","termGroup":"SY","termSource":"NCI"},{"termName":"GRASPA","termGroup":"FB","termSource":"NCI"},{"termName":"L-asparaginase Encapsulated in RBCs","termGroup":"SY","termSource":"NCI"},{"termName":"L-asparaginase Encapsulated in Red Blood Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Erythrocyte-encapsulated L-asparaginase Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"724517"},{"name":"NCI_META_CUI","value":"CL433492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724517"},{"name":"PDQ_Open_Trial_Search_ID","value":"724517"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C972":{"preferredName":"Esorubicin","code":"C972","definitions":[{"definition":"A synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxyadriamycin","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Deoxydoxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"Deoxyadriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxydoxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Esorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"IMI-58","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63521-85-7"},{"name":"Chemical_Formula","value":"C27H29NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RMC41L2WQ3"},{"name":"Legacy Concept Name","value":"Deoxydoxorubicin"},{"name":"Maps_To","value":"Esorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39211"},{"name":"NSC Number","value":"267469"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39211"},{"name":"PDQ_Open_Trial_Search_ID","value":"39211"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0047760"}]}}{"C74943":{"preferredName":"Esorubicin Hydrochloride","code":"C74943","definitions":[{"definition":"A hydrochloride salt of esorubicin, a derivative of the anthracycline antineoplastic antibiotic doxorubicin, with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(2S-(2alpha(8R*,10R*),4beta,6beta))-10-((4-Aminotetrahydro-6-methyl-2H-pyran-2-yl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Deoxyadriamycin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"4'-Deoxydoxorubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxydoxorubicin HCI","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63950-06-1"},{"name":"Chemical_Formula","value":"C27H29NO10.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2UB1JJT82D"},{"name":"Legacy Concept Name","value":"Esorubicin_Hydrochloride"},{"name":"Maps_To","value":"Esorubicin Hydrochloride"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700018"}]}}{"C1301":{"preferredName":"Esperamicin A1","code":"C1301","definitions":[{"definition":"An enediyne antineoplastic antibiotic hybrid containing an anthranilate moiety.  Esperamicin A1 is isolated from the bacterium Actinomadura verrucosospora.  The anthranilate component of esperamicin A1 intercalates DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-stranded breaks in DNA and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esperamicin A1","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99674-26-7"},{"name":"CHEBI_ID","value":"CHEBI:53273"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PLX8T21X8G"},{"name":"Legacy Concept Name","value":"Esperamicin_A1"},{"name":"Maps_To","value":"Esperamicin A1"},{"name":"NSC Number","value":"372668"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0082481"}]}}{"C26649":{"preferredName":"Essiac","code":"C26649","definitions":[{"definition":"An herbal formula containing burdock root (Arctium lappa), Turkey rhubarb root (Rheum palmatum), sheep sorrel (Rumex acetosella), and slippery elm bark (Ulmus fulva) with potential immunostimulating, anti-inflammatory and anti-tumor activities. The extract's chemical profile, their respective concentrations and the mechanism of action of Essiac are largely unknown due to the proprietary nature of the formula and product inconsistency. Several chemical classes in Essiac are consistently represented and may attribute to its therapeutic effect, including anthraquinone derivatives such as rhein and emodin, high molecular polysaccharides, and lignans such as arctigenin. However, all these chemicals are unlikely to occur in high concentrations in Essiac, and its potential therapeutic effect may be attributed to a potential synergistic effect of these various compounds.","type":"DEFINITION","source":"NCI"},{"definition":"An herbal tea mixture that contains burdock root, Indian rhubarb root, sheep sorrel, and slippery elm bark. It has been claimed to remove toxins from the body, make the immune system stronger, relieve pain, control diabetes, treat AIDS, reduce tumor size, increase cancer survival, and improve quality of life. No clinical trial using Essiac in humans has been reported in a peer-reviewed, scientific journal, and the FDA has not approved the use of Essiac for the treatment of any medical conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Essiac","termGroup":"PT","termSource":"NCI"},{"termName":"Esiak","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Essiac"},{"name":"Maps_To","value":"Essiac"},{"name":"NCI_Drug_Dictionary_ID","value":"304440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304440"},{"name":"PDQ_Open_Trial_Search_ID","value":"304440"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0673827"}]}}{"C154677":{"preferredName":"Esterified Estrogens","code":"C154677","definitions":[{"definition":"A mixture of the sodium salts of the sulfate esters of estrogen including sodium estrone sulfate, sodium equilin sulfate and the concomitant component, 17 alpha-estradiol, that is used for estrogen replacement. Estrogens bind to nuclear receptors in estrogen-responsive tissues and modulate the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), stimulate skeletal growth, and have a widespread effect on metabolic processes including protein transport and electrolyte balance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Esterified Estrogens","termGroup":"PT","termSource":"NCI"},{"termName":"Estrogens, Esterified","termGroup":"SY","termSource":"NCI"},{"termName":"Menest (BR)","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3ASP8Q3768"},{"name":"Maps_To","value":"Esterified Estrogens"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0717752"}]}}{"C1090":{"preferredName":"Estradiol Valerate","code":"C1090","definitions":[{"definition":"The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estradiol Valerate","termGroup":"PT","termSource":"NCI"},{"termName":"Delestrogen","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"979-32-8"},{"name":"Chemical_Formula","value":"C23H32O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OKG364O896"},{"name":"Legacy Concept Name","value":"Estradiol_Valerate"},{"name":"Maps_To","value":"Estradiol Valerate"},{"name":"NCI_Drug_Dictionary_ID","value":"39270"},{"name":"NSC Number","value":"17590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39270"},{"name":"PDQ_Open_Trial_Search_ID","value":"39270"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059623"}]}}{"C479":{"preferredName":"Estramustine","code":"C479","definitions":[{"definition":"A combination of the hormone estradiol (an estrogen) and nitrogen mustard (an anticancer drug). Used in the palliative therapy of prostate cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estramustine","termGroup":"PT","termSource":"NCI"},{"termName":"17beta-(estra-1,3,5(10)-triene-3,17-diol 3-(bis(2-chloroethyl)carbamate))","termGroup":"SN","termSource":"NCI"},{"termName":"estra-1,3,5(10)triene-317beta-diol 3-[N,N-bis-(2-chloroethyl)carbamate]","termGroup":"SN","termSource":"NCI"},{"termName":"estradiol 3-bis(2-chloroethyl)carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"Leo 275","termGroup":"CN","termSource":"NCI"},{"termName":"RO 21-8837","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prostate Neoplasm"},{"name":"CAS_Registry","value":"2998-57-4"},{"name":"CHEBI_ID","value":"CHEBI:4868"},{"name":"Chemical_Formula","value":"C23H31Cl2NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"35LT29625A"},{"name":"Legacy Concept Name","value":"Estramustine"},{"name":"Maps_To","value":"Estramustine"},{"name":"NSC Number","value":"89201"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014921"}]}}{"C480":{"preferredName":"Estramustine Phosphate Sodium","code":"C480","definitions":[{"definition":"The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estramustine Phosphate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Emcyt","termGroup":"BR","termSource":"NCI"},{"termName":"Estracyt","termGroup":"FB","termSource":"NCI"},{"termName":"Estramustine 17-(Dihydrogenphosphate) Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Estramustine Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Estramustine Sodium Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Leo-299","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-21-8837/001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52205-73-9"},{"name":"CHEBI_ID","value":"CHEBI:31562"},{"name":"Chemical_Formula","value":"C23H30Cl2NO6P.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"75F375MT2N"},{"name":"Legacy Concept Name","value":"Estramustine_Phosphate_Sodium"},{"name":"Maps_To","value":"Estramustine Phosphate Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39235"},{"name":"NSC Number","value":"89199"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39235"},{"name":"PDQ_Open_Trial_Search_ID","value":"39235"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014922"}]}}{"C96432":{"preferredName":"Estrogen Receptor Agonist GTx-758","code":"C96432","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor (ER) alpha agonist with potential antineoplastic activity. Upon administration of GTx-758, this agent suppresses the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the pituitary gland through feedback inhibition. In males, the inhibition of LH secretion prevents the synthesis of androgens, including testosterone, by the testes. This may result in suppressed total serum testosterone to the levels observed in castration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogen Receptor Agonist GTx-758","termGroup":"PT","termSource":"NCI"},{"termName":"Capesaris","termGroup":"BR","termSource":"NCI"},{"termName":"GTx-758","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"938067-78-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"406GR1485Z"},{"name":"Maps_To","value":"Estrogen Receptor Agonist GTx-758"},{"name":"NCI_Drug_Dictionary_ID","value":"698431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698431"},{"name":"PDQ_Open_Trial_Search_ID","value":"698431"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272775"}]}}{"C482":{"preferredName":"Estrogens, Conjugated","code":"C482","definitions":[{"definition":"Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Estrogens, Conjugated","termGroup":"PT","termSource":"NCI"},{"termName":"ATC:G03CA57","termGroup":"CN","termSource":"NCI"},{"termName":"Conestron","termGroup":"FB","termSource":"NCI"},{"termName":"Conjugated Estrogens","termGroup":"SY","termSource":"NCI"},{"termName":"Femest","termGroup":"BR","termSource":"NCI"},{"termName":"Premarin","termGroup":"BR","termSource":"NCI"},{"termName":"Sodestrin","termGroup":"FB","termSource":"NCI"},{"termName":"Tag-39","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced androgen-dependent prostate cancer, palliative; Breast cancer, palliative; Estrogen replacement; Menopausal symptoms; Postmenopausal osteoporosis"},{"name":"CAS_Registry","value":"12126-59-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IU5QR144QX"},{"name":"Legacy Concept Name","value":"Conjugated_Estrogens"},{"name":"Maps_To","value":"Estrogens, Conjugated"},{"name":"NCI_Drug_Dictionary_ID","value":"39237"},{"name":"NSC Number","value":"18313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39237"},{"name":"PDQ_Open_Trial_Search_ID","value":"39237"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0014938"}]}}{"C1626":{"preferredName":"Etalocib","code":"C1626","definitions":[{"definition":"A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called leukotriene B4 receptor antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Etalocib","termGroup":"PT","termSource":"NCI"},{"termName":"2-[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"2-[3-[3-[(5-Ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LY293111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"161172-51-6"},{"name":"Chemical_Formula","value":"C33H33FO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"THY6RIW44R"},{"name":"Legacy Concept Name","value":"LY293111"},{"name":"Maps_To","value":"Etalocib"},{"name":"NCI_Drug_Dictionary_ID","value":"38111"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38111"},{"name":"PDQ_Open_Trial_Search_ID","value":"38111"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0298619"}]}}{"C2381":{"preferredName":"Etanercept","code":"C2381","definitions":[{"definition":"A drug that is commonly used to treat arthritis. It is also being studied in the treatment of cancer, and as a treatment for loss of appetite and weight loss in cancer patients. It belongs to the family of drugs called tumor necrosis factor (TNF) antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etanercept","termGroup":"PT","termSource":"NCI"},{"termName":"Enbrel","termGroup":"BR","termSource":"NCI"},{"termName":"TNFR:Fc","termGroup":"AB","termSource":"NCI"},{"termName":"Tumor Necrosis Factor Receptor IgG Chimera","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"juvenile arthritis; psoriatic arthritis; rheumatoid arthritis."},{"name":"CAS_Registry","value":"185243-69-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OP401G7OJC"},{"name":"Legacy Concept Name","value":"Etanercept"},{"name":"Maps_To","value":"Etanercept"},{"name":"NCI_Drug_Dictionary_ID","value":"257809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257809"},{"name":"PDQ_Open_Trial_Search_ID","value":"257809"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0717758"}]}}{"C1092":{"preferredName":"Etanidazole","code":"C1092","definitions":[{"definition":"A 2-nitroimidazole with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the cytotoxicity of ionizing radiation. This agent may also be useful as an imaging agent for identifying hypoxic, drug-resistant regions of primary tumors or metastases.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that increases the effectiveness of radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Etanidazole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Imidazole-1-acetamide, N-(2-hydroxyethyl)-2-nitro-","termGroup":"SN","termSource":"NCI"},{"termName":"2-Nitroimidazole-1-acetamide, N-(2-hydroxyethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"SR-2508","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"22668-01-5"},{"name":"Chemical_Formula","value":"C7H10N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"30DKA3Q1HL"},{"name":"Legacy Concept Name","value":"Etanidazole"},{"name":"Maps_To","value":"Etanidazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39446"},{"name":"NSC Number","value":"301467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39446"},{"name":"PDQ_Open_Trial_Search_ID","value":"39446"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059682"}]}}{"C1800":{"preferredName":"Etaracizumab","code":"C1800","definitions":[{"definition":"A humanized monoclonal IgG1 antibody directed against the vitronectin receptor alpha v beta 3 integrin. Etaracizumab blocks the binding of ligands, such as vitronectin, to alpha v beta 3 integrin, resulting in inhibition of angiogenesis and metastasis. Alpha v beta 3 integrin is a cell adhesion and signaling receptor that is expressed on the surface of tumor vessel endothelial cells, some tumor cells, and a number of other cell types.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer and other conditions. Abegrin binds to a protein on the surface of blood vessels and may prevent the growth of new blood vessels that tumors need to grow. It may also prevent the spread of cancer. It is a type of antiangiogenesis agent, a type of metastasis inhibitor, and a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Etaracizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Abegrin","termGroup":"BR","termSource":"NCI"},{"termName":"Humanized Monoclonal Antibody LM609","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-522","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-alpha V Beta 3 Integrin MEDI-522","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-Avb3 Integrin Medi-522","termGroup":"SY","termSource":"NCI"},{"termName":"Vitaxin","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"892553-42-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"41W9MFI160"},{"name":"Legacy Concept Name","value":"Vitaxin"},{"name":"Maps_To","value":"Etaracizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38491"},{"name":"NSC Number","value":"719850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38491"},{"name":"PDQ_Open_Trial_Search_ID","value":"38491"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350723"}]}}{"C96705":{"preferredName":"Etarotene","code":"C96705","definitions":[{"definition":"An ethylsulfonyl derivative of arotinoic acid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, etarotene binds to and activates retinoic acid receptors (RARs), thereby inducing changes in the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etarotene","termGroup":"PT","termSource":"NCI"},{"termName":"6-((E)-p-(Ethylsulfonyl)-alpha-methylstyryl)-1,2,3,4-tetrahydronaphthalene","termGroup":"SN","termSource":"NCI"},{"termName":"Arotinoid Ethyl Sulfone","termGroup":"SY","termSource":"NCI"},{"termName":"Arotinoid Ethyl Sulphone","termGroup":"SY","termSource":"NCI"},{"termName":"Naphthalene, 6-(2-(4-(ethylsulfonyl)phenyl)-1-methylethenyl)-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ro 15-1570/000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87719-32-2"},{"name":"Chemical_Formula","value":"C25H32O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PD3817FE9N"},{"name":"Maps_To","value":"Etarotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272976"}]}}{"C116713":{"preferredName":"Ethaselen","code":"C116713","definitions":[{"definition":"An orally bioavailable organoselenium inhibitor of thioredoxin reductase 1 (TrxR1), with potential antineoplastic activity. Upon oral administration, ethaselen specifically binds to the selenocysteine-cysteine redox pair in the C-terminal active site of TrxR1 and inhibits its activity, which may result in growth inhibition and the induction of apoptosis in TrxR1 overexpressing tumor cells. TrxR1, upregulated in many cancer cell types, plays a key role in various redox-dependent cellular pathways, regulates transcription factor activity, inhibits apoptosis, and promotes cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethaselen","termGroup":"PT","termSource":"NCI"},{"termName":"1, 2-[Bis (1, 2-Benzisoselenazolone-3 (2H) -Ketone)] Ethane","termGroup":"SN","termSource":"NCI"},{"termName":"BBSKE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"217798-39-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4Q2EZS1IWG"},{"name":"Maps_To","value":"Ethaselen"},{"name":"NCI_Drug_Dictionary_ID","value":"762438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762438"},{"name":"PDQ_Open_Trial_Search_ID","value":"762438"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1312515"}]}}{"C486":{"preferredName":"Ethinyl Estradiol","code":"C486","definitions":[{"definition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethinyl Estradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol","termGroup":"SN","termSource":"NCI"},{"termName":"Diogyn E","termGroup":"FB","termSource":"NCI"},{"termName":"Estinyl","termGroup":"BR","termSource":"NCI"},{"termName":"Ethinoral","termGroup":"BR","termSource":"NCI"},{"termName":"Ethinylestradiol","termGroup":"SY","termSource":"NCI"},{"termName":"Eticylol","termGroup":"FB","termSource":"NCI"},{"termName":"Feminone","termGroup":"BR","termSource":"NCI"},{"termName":"Inestra","termGroup":"FB","termSource":"NCI"},{"termName":"Lynoral","termGroup":"FB","termSource":"NCI"},{"termName":"Orestralyn","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced androgen-dependent prostate cancer, palliative; Breast cancer, palliative; Estrogen replacement; Menopausal symptoms; Postmenopausal osteoporosis"},{"name":"CAS_Registry","value":"57-63-6"},{"name":"CHEBI_ID","value":"CHEBI:4903"},{"name":"Chemical_Formula","value":"C20H24O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"423D2T571U"},{"name":"Legacy Concept Name","value":"Ethinyl_Estradiol"},{"name":"Maps_To","value":"Ethinyl Estradiol"},{"name":"NCI_Drug_Dictionary_ID","value":"39238"},{"name":"NSC Number","value":"10973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39238"},{"name":"PDQ_Open_Trial_Search_ID","value":"39238"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015011"}]}}{"C1009":{"preferredName":"Ethyleneimine","code":"C1009","definitions":[{"definition":"A monofunctional alkylating agent with potential antineoplastic activity.  Reacting with DNA mainly at guanine and adenine residues, ethylenimine alkylates DNA, thereby producing DNA interstrand crosslinks and DNA breaks, and interfering with DNA replication and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethyleneimine","termGroup":"PT","termSource":"NCI"},{"termName":"Aminoethylene","termGroup":"SY","termSource":"NCI"},{"termName":"Azacyclopropane","termGroup":"SY","termSource":"NCI"},{"termName":"Azirane","termGroup":"SY","termSource":"NCI"},{"termName":"Aziridine","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethyleneimine","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylenimine","termGroup":"SY","termSource":"NCI"},{"termName":"Ethylenimine","termGroup":"SY","termSource":"NCI"},{"termName":"Ethylimine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151-56-4"},{"name":"CHEBI_ID","value":"CHEBI:30969"},{"name":"Chemical_Formula","value":"C2H5N"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54P5FEX9FH"},{"name":"Legacy Concept Name","value":"Ethylenimine"},{"name":"Maps_To","value":"Ethyleneimine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0052794"}]}}{"C26563":{"preferredName":"Ethylnitrosourea","code":"C26563","definitions":[{"definition":"A nitrosourea with potential antineoplastic activity.  Used experimentally as a mutagen and carcinogen, ethylnitrosourea alkylates DNA and proteins, thereby damaging DNA and inducing point mutations. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethylnitrosourea","termGroup":"PT","termSource":"NCI"},{"termName":"1-Ethyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"ENU","termGroup":"AB","termSource":"NCI"},{"termName":"N-Ethyl-N-nitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"N-Nitroso-N-Ethylurea","termGroup":"SY","termSource":"NCI"},{"termName":"Nitrosoethylurea","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"759-73-9"},{"name":"CHEBI_ID","value":"CHEBI:23995"},{"name":"Chemical_Formula","value":"C3H7N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P8M1T4190R"},{"name":"Legacy Concept Name","value":"Ethylnitrosourea"},{"name":"Maps_To","value":"Ethylnitrosourea"},{"name":"NSC Number","value":"45403"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0015111"}]}}{"C125901":{"preferredName":"Etidronate-Cytarabine Conjugate MBC-11","code":"C125901","definitions":[{"definition":"A synthetic conjugate composed of the bisphosphonate etidronate linked to the cytostatic agent and antimetabolite cytarabine, with potential antineoplastic and antiresorptive activities. Upon intravenous administration of the etidronate-cytarabine conjugate MBC-11, the etidronate moiety targets bone and the two moieties are released upon hydrolysis. Etidronate binds to hydroxyapatite crystals in bone tissues and prevents its resorption. This prevents bone destruction and induces bone cell mineralization. In addition, the bone-targeting nature of this agent allows for the accumulation of cytarabine in bone tissue, where it is able to exert its antitumor effect locally by competing with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis, while reducing systemic exposure. This leads to a destruction of bone-associated tumor cells, an inhibition of tumor cell proliferation and bone metastasis, and prevents tumor-mediated bone destruction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etidronate-Cytarabine Conjugate MBC-11","termGroup":"PT","termSource":"NCI"},{"termName":"Etidronate-ara-C Conjugate MBC-11","termGroup":"SY","termSource":"NCI"},{"termName":"MBC-11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"332863-86-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4M53T688S5"},{"name":"Maps_To","value":"Etidronate-Cytarabine Conjugate MBC-11"},{"name":"NCI_Drug_Dictionary_ID","value":"778808"},{"name":"NCI_META_CUI","value":"CL504550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778808"},{"name":"PDQ_Open_Trial_Search_ID","value":"778808"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74069":{"preferredName":"Etirinotecan Pegol","code":"C74069","definitions":[{"definition":"An extended-release (ER) formulation composed of irinotecan, which is a semisynthetic derivative of camptothecin and a topoisomerase I-inhibitor prodrug, that is conjugated, via a proprietary biodegradable ester-based linker, to polyethylene glycol (PEG), with antineoplastic activity. Upon administration of etirinotecan pegol (EP), the agent penetrates into the leaky tumor vasculature and accumulates in the tumor. The linker slowly hydrolyzes and releases irinotecan, which leads to sustained exposure of the tumor to irinotecan. In turn, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN38) by a carboxylesterase. SN38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA; this results in DNA breaks that inhibit DNA replication and trigger apoptosis. Pegylation provides improved systemic exposure, increases drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etirinotecan Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"NKTR 102","termGroup":"CN","termSource":"NCI"},{"termName":"NKTR-102","termGroup":"CN","termSource":"NCI"},{"termName":"Onzeald","termGroup":"BR","termSource":"NCI"},{"termName":"PEG-Irinotecan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848779-32-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LJ16641SFT"},{"name":"Legacy Concept Name","value":"Pegylated_Irinotecan_NKTR_102"},{"name":"Maps_To","value":"Etirinotecan Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"586949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586949"},{"name":"PDQ_Open_Trial_Search_ID","value":"586949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659087"}]}}{"C489":{"preferredName":"Etoglucid","code":"C489","definitions":[{"definition":"An epoxide compound with potential antineoplastic alkylating activity. Etoglucid is able to crosslink DNA via its epoxide group, resulting in disruption of DNA function and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoglucid","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-bis[2-(2,3-epoxypropoxy)ethoxy]ethane","termGroup":"SN","termSource":"NCI"},{"termName":"1,2:15,16-diepoxy-4,7,10,13-tetraoxahexadecane","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bisoxirane","termGroup":"SN","termSource":"NCI"},{"termName":"Epodyl","termGroup":"BR","termSource":"NCI"},{"termName":"Ethoglucid","termGroup":"SY","termSource":"NCI"},{"termName":"ICI-32865","termGroup":"CN","termSource":"NCI"},{"termName":"Triethylene Glycol Diglycidyl Ether","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1954-28-5"},{"name":"Chemical_Formula","value":"C12H22O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4F9KUA0T4D"},{"name":"Legacy Concept Name","value":"Etoglucid"},{"name":"Maps_To","value":"Etoglucid"},{"name":"NCI_Drug_Dictionary_ID","value":"39233"},{"name":"NSC Number","value":"80439"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39233"},{"name":"PDQ_Open_Trial_Search_ID","value":"39233"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015039"}]}}{"C491":{"preferredName":"Etoposide","code":"C491","definitions":[{"definition":"A drug used to treat testicular and small cell lung cancers. It is also being studied in the treatment of several other types of cancer. Vepesid blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of podophyllotoxin derivative and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoposide","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]","termGroup":"SN","termSource":"NCI"},{"termName":"9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one","termGroup":"SN","termSource":"NCI"},{"termName":"Demethyl Epipodophyllotoxin Ethylidine Glucoside","termGroup":"SY","termSource":"NCI"},{"termName":"EPEG","termGroup":"AB","termSource":"NCI"},{"termName":"Lastet","termGroup":"BR","termSource":"NCI"},{"termName":"Vepesid","termGroup":"AQS","termSource":"NCI"},{"termName":"VP 16","termGroup":"CN","termSource":"NCI"},{"termName":"VP 16213","termGroup":"CN","termSource":"NCI"},{"termName":"VP-16","termGroup":"CN","termSource":"NCI"},{"termName":"VP-16-213","termGroup":"CN","termSource":"NCI"},{"termName":"VP-16213","termGroup":"CN","termSource":"NCI"},{"termName":"VP16","termGroup":"CN","termSource":"NCI"},{"termName":"VP16213","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute leukemia; Adrenal cortical cancer; Brain cancer; Chronic Lymphocytic leukemia; Choriocarcinoma; Esophageal cancer; Ewing's sarcoma; Gastric cancer; Germ Cell cancer; Gestational trophoblastic neoplasms; Hepatocellular cancer; Hodgkin's disease"},{"name":"Accepted_Therapeutic_Use_For","value":"Hypereosinophilic syndrome; Kaposi's sarcoma; Langerhans cell histiocytosis; Mobilization of peripheral-blood progenitor cells; Multiple myeloma; Neuroblastoma; Non-small lung cancer; Osteogenic sarcoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Ovarian cancer; Retinoblastoma; Small cell lung cancer; Soft tissue sarcomas; Testicular cancer; Thymoma; Thyroid cancer; Uterine cancer; Wilms' tumor"},{"name":"CAS_Registry","value":"33419-42-0"},{"name":"CHEBI_ID","value":"CHEBI:4911"},{"name":"Chemical_Formula","value":"C29H32O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"6PLQ3CP4P3"},{"name":"Legacy Concept Name","value":"Etoposide"},{"name":"Maps_To","value":"Etoposide"},{"name":"NCI_Drug_Dictionary_ID","value":"39207"},{"name":"NSC Number","value":"141540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39207"},{"name":"PDQ_Open_Trial_Search_ID","value":"39207"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015133"}]}}{"C1093":{"preferredName":"Etoposide Phosphate","code":"C1093","definitions":[{"definition":"A drug used to treat testicular and small cell lung cancers. It is also being studied in the treatment of several other types of cancer. Etopophos blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of podophyllotoxin derivative and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoposide Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Etopophos","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute leukemia; Adrenal cortical cancer; Brain cancer; Chronic lymphocytic leukemia; Choriocarcinoma; Esophageal cancer; Ewings sarcoma; Gastric cancer; Germ cell cancer; Gestational trophoblastic neoplasms"},{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular cancer; Hodgkins disease; Hypereosinophilic syndrome; Kaposis sarcoma; Testicular cancer; Thymoma; Thyroid cancer; Uterine cancer; Wilms tumor"},{"name":"Accepted_Therapeutic_Use_For","value":"Langerhans cell histiocytosis; Mobilization of peripheral-blood progenitor cells; Multiple myeloma; Neuroblastoma; Non-small lung cancer; Osteogenic sarcoma; Ovarian cancer; Retinoblastoma; Small cell lung cancer; Soft tissue sarcomas"},{"name":"CAS_Registry","value":"117091-64-2"},{"name":"Chemical_Formula","value":"C29H33O16P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"528XYJ8L1N"},{"name":"Legacy Concept Name","value":"Etoposide_Phosphate"},{"name":"Maps_To","value":"Etoposide Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"42801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42801"},{"name":"PDQ_Open_Trial_Search_ID","value":"42801"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059874"}]}}{"C114977":{"preferredName":"Etoposide Toniribate","code":"C114977","definitions":[{"definition":"A prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of etoposide toniribate, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoposide Toniribate","termGroup":"PT","termSource":"NCI"},{"termName":"CAP7.1","termGroup":"CN","termSource":"NCI"},{"termName":"EDO-S7.1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"433304-61-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A59HL2Q48U"},{"name":"Maps_To","value":"Etoposide Toniribate"},{"name":"NCI_Drug_Dictionary_ID","value":"759515"},{"name":"NCI_META_CUI","value":"CL472574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759515"},{"name":"PDQ_Open_Trial_Search_ID","value":"759515"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C73236":{"preferredName":"Etoprine","code":"C73236","definitions":[{"definition":"A lipophilic, diaminopyrimidine folate antagonist with potential antineoplastic activity. Etoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism. This may eventually result in a reduction of cellular growth and the induction of apoptosis. In addition, this agent inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble etoprine is capable of crossing the blood-brain barrier.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoprine","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-5-(3,4-dichlorophenyl)-6-ethylpyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"AI3-25008","termGroup":"CN","termSource":"NCI"},{"termName":"DDEP","termGroup":"AB","termSource":"NCI"},{"termName":"Ethodichlorophen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18588-57-3"},{"name":"Chemical_Formula","value":"C12H12Cl2N4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"406PGU9KGI"},{"name":"Legacy Concept Name","value":"Etoprine"},{"name":"Maps_To","value":"Etoprine"},{"name":"NSC Number","value":"3062"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059875"}]}}{"C52188":{"preferredName":"Etoricoxib","code":"C52188","definitions":[{"definition":"A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Etoricoxib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine","termGroup":"SN","termSource":"NCI"},{"termName":"Arcoxia","termGroup":"BR","termSource":"NCI"},{"termName":"L-791456","termGroup":"CN","termSource":"NCI"},{"termName":"MK-0663","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"202409-33-4"},{"name":"CHEBI_ID","value":"CHEBI:6339"},{"name":"Chemical_Formula","value":"C18H15ClN2O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WRX4NFY03R"},{"name":"Legacy Concept Name","value":"Etoricoxib"},{"name":"Maps_To","value":"Etoricoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"462092"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462092"},{"name":"PDQ_Open_Trial_Search_ID","value":"462092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0972314"}]}}{"C125657":{"preferredName":"Ets-family Transcription Factor Inhibitor TK216","code":"C125657","definitions":[{"definition":"A proprietary biologic that inhibits the transcriptional-promoting activity of E26 transformation-specific (Ets, E-twenty-six) family transcription factors, with potential antineoplastic activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration, Ets-family transcription factor inhibitor TK216 inhibits transcriptional activation mediated by Ets family proteins, including the oncogenic Ewing sarcoma breakpoint region 1/Friend leukemia virus integration 1 (EWSR1/FLI1; EWS/FLI1) fusion protein. This agent may both inhibit the malignant downstream effects mediated by genomic rearrangements that result in the overexpression of Ets family transcription factors and decrease tumor cell growth and proliferation. A chromosomal translocation t(11;22)(q24;q12) fuses the EWSR1 gene and the FLI1 gene and encodes the EWSR1/FLI1 fusion protein, which is an oncoprotein expressed by peripheral primitive neuroectodermal (pPNET) tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ets-family Transcription Factor Inhibitor TK216","termGroup":"PT","termSource":"NCI"},{"termName":"TK-216","termGroup":"CN","termSource":"NCI"},{"termName":"TK216","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ets-family Transcription Factor Inhibitor TK216"},{"name":"NCI_Drug_Dictionary_ID","value":"778521"},{"name":"NCI_META_CUI","value":"CL504343"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778521"},{"name":"PDQ_Open_Trial_Search_ID","value":"778521"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48387":{"preferredName":"Everolimus","code":"C48387","definitions":[{"definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat advanced kidney cancer that did not respond to treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Afinitor stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. It also decreases the body's immune responses. It is a type of immunosuppressant and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Everolimus","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone","termGroup":"SN","termSource":"NCI"},{"termName":"42-O-(2-Hydroxy)ethyl Rapamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Afinitor","termGroup":"BR","termSource":"NCI"},{"termName":"Certican","termGroup":"BR","termSource":"NCI"},{"termName":"RAD 001","termGroup":"CN","termSource":"NCI"},{"termName":"RAD-001","termGroup":"CN","termSource":"NCI"},{"termName":"RAD001","termGroup":"CN","termSource":"NCI"},{"termName":"Votubia","termGroup":"BR","termSource":"NCI"},{"termName":"Zortress","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"neuroendocrine tumors (NET) of gastrointestinal (GI), lung or pancreatic origin"},{"name":"CAS_Registry","value":"159351-69-6"},{"name":"Chemical_Formula","value":"C53H83NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9HW64Q8G6G"},{"name":"Legacy Concept Name","value":"Everolimus"},{"name":"Maps_To","value":"Everolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"372905"},{"name":"NSC Number","value":"733504"},{"name":"PDQ_Closed_Trial_Search_ID","value":"372905"},{"name":"PDQ_Open_Trial_Search_ID","value":"372905"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0541315"}]}}{"C102880":{"preferredName":"Everolimus Tablets for Oral Suspension","code":"C102880","definitions":[{"definition":"Tablets for oral suspension containing everolimus, a derivative of the natural macrocyclic lactone sirolimus, with immunosuppressive and antineoplastic activities. After suspension of the everolimus tablets in water and oral administration, this agent inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR) by binding to mTOR's cytosolic receptor immunophilin FK Binding Protein-12 (FKBP-12). Inhibition of the mTOR complex may result in the inhibition of the phosphatidylinositol 3 kinase/Akt/mTOR pathway and an inhibition in the expression of vascular endothelial cell growth factor (VEGF) and hypoxia-inducible factor. Ultimately, this may result in decreased tumor cell proliferation and tumor angiogenesis. This pediatric formulation can dissolve easily in a small volume of water making it easier to swallow and is available in smaller dose increments thereby allowing for greater dosing flexibility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Everolimus Tablets for Oral Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"Afinitor Disperz","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"tuberous sclerosis complex (TSC)-associated partial-onset seizures; TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Everolimus Tablets for Oral Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"739586"},{"name":"NCI_META_CUI","value":"CL437183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739586"},{"name":"PDQ_Open_Trial_Search_ID","value":"739586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71722":{"preferredName":"Evofosfamide","code":"C71722","definitions":[{"definition":"A hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division, and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evofosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"HAP TH-302","termGroup":"AB","termSource":"NCI"},{"termName":"Hypoxia-Activated Prodrug TH-302","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphorodiamidic Acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"TH-302","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"918633-87-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8A9RZ3HN8W"},{"name":"Legacy Concept Name","value":"HAP_TH-302"},{"name":"Maps_To","value":"Evofosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"560194"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560194"},{"name":"PDQ_Open_Trial_Search_ID","value":"560194"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348906"}]}}{"C131305":{"preferredName":"Ex Vivo-expanded Autologous T Cells IMA101","code":"C131305","definitions":[{"definition":"A preparation of autologous cytotoxic T-lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T-cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T-cells IMA101 target and kill tumor cells. The T-cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ex Vivo-expanded Autologous T Cells IMA101","termGroup":"PT","termSource":"NCI"},{"termName":"ACTolog IMA101","termGroup":"SY","termSource":"NCI"},{"termName":"IMA101","termGroup":"CN","termSource":"NCI"},{"termName":"IMA101 T-cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"IMA101 T-Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ex Vivo-expanded Autologous T Cells IMA101"},{"name":"NCI_Drug_Dictionary_ID","value":"785549"},{"name":"NCI_META_CUI","value":"CL514353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785549"},{"name":"PDQ_Open_Trial_Search_ID","value":"785549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1679":{"preferredName":"Exatecan Mesylate","code":"C1679","definitions":[{"definition":"A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogues. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Exatecan Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"10H,13H-Benzo(de)pyrano(3'm4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S-trans)-, Methanesulfonate (1:1) (Salt), Dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"DX-8951f","termGroup":"CN","termSource":"NCI"},{"termName":"Exatecan Mesylate Dihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Exatecan Mesylate Hydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197720-53-9"},{"name":"Chemical_Formula","value":"C24H22FN3O4.CH4O3S.2H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D2VJ1CC26Q"},{"name":"Legacy Concept Name","value":"Exatecan_Mesylate"},{"name":"Maps_To","value":"Exatecan Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"43386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43386"},{"name":"PDQ_Open_Trial_Search_ID","value":"43386"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935945"}]}}{"C162348":{"preferredName":"Exatecan Mesylate Anhydrous","code":"C162348","definitions":[{"definition":"The anhydrous, mesylate salt form of exatecan, a semisynthetic, water-soluble derivative of camptothecin, with antineoplastic activity. Upon administration, exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting re-ligation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exatecan Mesylate Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"10H,13H-Benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-Amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, Methanesulfonate (1:1)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"169869-90-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y76278R9RJ"},{"name":"Maps_To","value":"Exatecan Mesylate Anhydrous"},{"name":"NCI_META_CUI","value":"CL970851"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1097":{"preferredName":"Exemestane","code":"C1097","definitions":[{"definition":"A drug used to treat advanced breast cancer and to prevent recurrent breast cancer in postmenopausal women who have already been treated with tamoxifen. It is also being studied in the treatment of other types of cancer. Aromasin causes a decrease in the amount of estrogen made by the body. It is a type of aromatase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exemestane","termGroup":"PT","termSource":"NCI"},{"termName":"6-Methyleneandrosta-1,4-diene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Aromasin","termGroup":"BR","termSource":"NCI"},{"termName":"FCE-24304","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Estrogen Receptor-Positive Early Breast Cancer; early and advanced-stage breast cancer"},{"name":"CAS_Registry","value":"107868-30-4"},{"name":"CHEBI_ID","value":"CHEBI:4953"},{"name":"Chemical_Formula","value":"C20H24O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NY22HMQ4BX"},{"name":"Legacy Concept Name","value":"Exemestane"},{"name":"Maps_To","value":"Exemestane"},{"name":"NCI_Drug_Dictionary_ID","value":"42297"},{"name":"NSC Number","value":"713563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42297"},{"name":"PDQ_Open_Trial_Search_ID","value":"42297"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0851344"}]}}{"C1239":{"preferredName":"Exisulind","code":"C1239","definitions":[{"definition":"A drug being studied in the treatment and prevention of cancer. It has been shown to cause apoptosis (cell death) in cells that are malignant (cancer) and in cells that may become cancer. It acts through a group of cellular enzymes called cGMP phosphodiesterases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac.  After oral administration, sulindac undergoes extensive biotransformation including irreversible oxidation to sulindac sulfone.  Approximately, one half of an administered dose of sulindac is eliminated through the urine, mostly as the conjugated sulfone metabolite. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exisulind","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Indene-3-acetic Acid, 5-Fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene), (Z)","termGroup":"SN","termSource":"NCI"},{"termName":"Aptosyn","termGroup":"BR","termSource":"NCI"},{"termName":"FGN-1","termGroup":"CN","termSource":"NCI"},{"termName":"Sulindac Sulfone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colonic adenomatous polyps in the inherited disease adenomatous polyposis coli, control and suppression"},{"name":"CAS_Registry","value":"59973-80-7"},{"name":"CHEBI_ID","value":"CHEBI:64212"},{"name":"Chemical_Formula","value":"C20H17FO4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K619IIG2R9"},{"name":"Legacy Concept Name","value":"Sulindac_Sulfone"},{"name":"Maps_To","value":"Exisulind"},{"name":"NCI_Drug_Dictionary_ID","value":"43057"},{"name":"NSC Number","value":"719619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43057"},{"name":"PDQ_Open_Trial_Search_ID","value":"43057"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075616"}]}}{"C112498":{"preferredName":"Extended Release Flucytosine","code":"C112498","definitions":[{"definition":"An extended release (ER) oral tablet that contains flucytosine (5-FC), a fluorinated cytosine analog, with antifungal activity and potential anti-cancer activity. Following oral administration of ER 5-FC, the 5-FC is deaminated to its active metabolite 5-fluorouracil (5-FU). 5-FU replaces uracil during RNA synthesis, which consequently inhibits downstream protein synthesis. In addition, 5-FU is metabolized further to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase. Inhibition of this enzyme interrupts nucleotide synthesis, DNA replication and cell proliferation. Negative regulation of protein synthesis, DNA replication and cell proliferation can lead to cell death. Following ingestion of ER 5-FC, intravenous injection of a retroviral vector encoding cytosine deaminase (TC 511) at a tumor site may result in higher local concentrations of 5-FU and its metabolites, and increased tumor cell death than other 5-FU treatment regimens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extended Release Flucytosine","termGroup":"PT","termSource":"NCI"},{"termName":"Extended Release 5-FC","termGroup":"SY","termSource":"NCI"},{"termName":"Extended Release 5-Fluorocytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-Release 5-FC","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-Release 5-Fluorocytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-Release Flucytosine","termGroup":"SY","termSource":"NCI"},{"termName":"Toca FC","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extended Release Flucytosine"},{"name":"NCI_Drug_Dictionary_ID","value":"755027"},{"name":"NCI_META_CUI","value":"CL454672"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755027"},{"name":"PDQ_Open_Trial_Search_ID","value":"755027"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113797":{"preferredName":"Extended-release Onapristone","code":"C113797","definitions":[{"definition":"An extended-release (ER) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extended-release Onapristone","termGroup":"PT","termSource":"NCI"},{"termName":"ER Onapristone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extended-release Onapristone"},{"name":"NCI_Drug_Dictionary_ID","value":"757592"},{"name":"NCI_META_CUI","value":"CL471779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757592"},{"name":"PDQ_Open_Trial_Search_ID","value":"757592"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127114":{"preferredName":"Valemetostat","code":"C127114","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valemetostat","termGroup":"PT","termSource":"NCI"},{"termName":"DS 3201","termGroup":"CN","termSource":"NCI"},{"termName":"DS-3201","termGroup":"CN","termSource":"NCI"},{"termName":"DS3201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1809336-39-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"60RD0234VE"},{"name":"Maps_To","value":"EZH1/2 Inhibitor DS-3201"},{"name":"Maps_To","value":"Valemetostat"},{"name":"NCI_Drug_Dictionary_ID","value":"780797"},{"name":"NCI_META_CUI","value":"CL507903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780797"},{"name":"PDQ_Open_Trial_Search_ID","value":"780797"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121639":{"preferredName":"Lirametostat","code":"C121639","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, lirametostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, a histone lysine methyltransferase (HMT) class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirametostat","termGroup":"PT","termSource":"NCI"},{"termName":"CPI-1205","termGroup":"CN","termSource":"NCI"},{"termName":"EZH2 Inhibitor CPI-1205","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1621862-70-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"455J2479FY"},{"name":"Maps_To","value":"EZH2 Inhibitor CPI-1205"},{"name":"NCI_Drug_Dictionary_ID","value":"770459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770459"},{"name":"PDQ_Open_Trial_Search_ID","value":"770459"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053654"}]}}{"C156743":{"preferredName":"EZH2 Inhibitor PF-06821497","code":"C156743","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH2 inhibitor PF-06821497 selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH2 Inhibitor PF-06821497","termGroup":"PT","termSource":"NCI"},{"termName":"1(2H)-Isoquinolinone, 5,8-Dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"PF 06821497","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06821497","termGroup":"CN","termSource":"NCI"},{"termName":"PF06821497","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1844849-10-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S4L4MM20B6"},{"name":"Maps_To","value":"EZH2 Inhibitor PF-06821497"},{"name":"NCI_Drug_Dictionary_ID","value":"795703"},{"name":"NCI_META_CUI","value":"CL935894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795703"},{"name":"PDQ_Open_Trial_Search_ID","value":"795703"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158742":{"preferredName":"EZH2 Inhibitor SHR2554","code":"C158742","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH2 inhibitor SHR2554 selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH2 Inhibitor SHR2554","termGroup":"PT","termSource":"NCI"},{"termName":"Enhancer of Zeste Homolog 2 Inhibitor SHR2554","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 2554","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-2554","termGroup":"CN","termSource":"NCI"},{"termName":"SHR2554","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EZH2 Inhibitor SHR2554"},{"name":"NCI_Drug_Dictionary_ID","value":"797374"},{"name":"NCI_META_CUI","value":"CL950708"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797374"},{"name":"PDQ_Open_Trial_Search_ID","value":"797374"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91395":{"preferredName":"F16-IL2 Fusion Protein","code":"C91395","definitions":[{"definition":"An immunocytokine of the human monoclonal antibody fragment F16 (scFv) against the extra-domain A1 of tenascin-C fused, via a short 5-amino acid linker, to a recombinant form of the human cytokine interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. The monoclonal antibody portion of the F16-IL2 fusion protein binds to tumor cells expressing the tumor associated antigen (TAA) tenascin-C. In turn, the IL-2 moiety of the fusion protein stimulates natural killer (NK) cells, macrophages and neutrophils and induces T-cell antitumor cellular immune responses thereby selectively killing tenascin-C-expressing tumor cells. In addition, F16-IL2 may potentiate the cytotoxicity of other chemotherapeutic agents. Tenascin-C, a glycoprotein of the extracellular matrix, is expressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"F16-IL2 Fusion Protein","termGroup":"PT","termSource":"NCI"},{"termName":"Teleukin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"F16-IL2 Fusion Protein"},{"name":"NCI_Drug_Dictionary_ID","value":"674718"},{"name":"NCI_META_CUI","value":"CL421592"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674718"},{"name":"PDQ_Open_Trial_Search_ID","value":"674718"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107239":{"preferredName":"FACT Complex-targeting Curaxin CBL0137","code":"C107239","definitions":[{"definition":"An orally available curaxin-based agent targeting the Facilitates Chromatin Transcription (FACT) complex, with potential antineoplastic activity. Upon administration, CBL0137 binds to FACT and sequesters the FACT complex on chromatin, which inhibits its activity. This prevents transcription of certain genes involved in cancer-associated signaling pathways; it specifically inhibits the transcription of both NF-kappa B and heat shock transcription factor 1 (HSF1) and simultaneously activates p53. This causes an increase in tumor cell apoptosis and a decrease in tumor cell proliferation, in FACT-positive cancers. In addition, this agent is able to sensitize FACT-positive tumor cells to the cytotoxic effects of other chemotherapeutic agents. FACT, a transcription and replication factor composed of the Structure Specific Recognition Protein (SSRP1) and suppressor of Ty 16 (Spt16) proteins, is expressed in a variety of tumor cells while almost absent in normal cells; its expression is associated with increased tumor aggressiveness and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FACT Complex-targeting Curaxin CBL0137","termGroup":"PT","termSource":"NCI"},{"termName":"CBL0137","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FACT Complex-targeting Curaxin CBL0137"},{"name":"NCI_Drug_Dictionary_ID","value":"750614"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750614"},{"name":"PDQ_Open_Trial_Search_ID","value":"750614"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827145"}]}}{"C129313":{"preferredName":"Factor VII-targeting Immunoconjugate Protein ICON-1","code":"C129313","definitions":[{"definition":"A human immunoconjugate (ICON) fusion protein composed of a modified version of human factor VII (FVII) which targets tissue factor (TF) that is fused to the Fc domain of the human immunoglobulin G1, with potential anti-thrombotic and antineoplastic activities. Acting in a similar manner as plasma FVII, the natural ligand of TF, ICON-1 targets and binds to TF expressed on neovascular endothelia, thereby preventing TF-mediated signaling pathways, and leading to the initiation of an immune response and the destruction of neovascular tissue. This prevents angiogenesis, inflammation and blood coagulation. Upon intravitreal administration, ICON-1 may block TF-induced angiogenesis and treat wet age-related macular degeneration (AMD) and ocular melanoma. TF, a naturally occurring glycoprotein in humans, regulates blood clotting, angiogenesis, and inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Factor VII-targeting Immunoconjugate Protein ICON-1","termGroup":"PT","termSource":"NCI"},{"termName":"FVII Modified Conjugate ICON-1","termGroup":"SY","termSource":"NCI"},{"termName":"FVII-targeting Immunoconjugate Protein ICON-1","termGroup":"SY","termSource":"NCI"},{"termName":"Human Immuno-conjugate 1","termGroup":"SY","termSource":"NCI"},{"termName":"ICON-1","termGroup":"CN","termSource":"NCI"},{"termName":"VII-Fc Fusion Protein ICON-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Factor VII-targeting Immunoconjugate Protein ICON-1"},{"name":"NCI_Drug_Dictionary_ID","value":"783145"},{"name":"NCI_META_CUI","value":"CL512298"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783145"},{"name":"PDQ_Open_Trial_Search_ID","value":"783145"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88324":{"preferredName":"Factor VIIa Inhibitor PCI-27483","code":"C88324","definitions":[{"definition":"A reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential antineoplastic and antithrombotic activities.  FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, factor VIIa inhibitor PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells. In addition, this agent inhibits both the extrinsic and intrinsic coagulation cascades, preventing blood clot formation. TF, a blood protein overexpressed on the cell surface of a variety of tumor cell types, may correlate with poor prognosis; PAR-2 (also known as thrombin receptor-like 1) is a G protein-coupled receptor (GPCR) and a protease-activated receptor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Factor VIIa Inhibitor PCI-27483","termGroup":"PT","termSource":"NCI"},{"termName":"PCI-27483","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871266-63-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6073LCU8U9"},{"name":"Maps_To","value":"Factor VIIa Inhibitor PCI-27483"},{"name":"NCI_Drug_Dictionary_ID","value":"661024"},{"name":"NCI_META_CUI","value":"CL413585"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661024"},{"name":"PDQ_Open_Trial_Search_ID","value":"661024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1044":{"preferredName":"Fadrozole Hydrochloride","code":"C1044","definitions":[{"definition":"The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers. Aromatase, a member of the cytochrome P-450 superfamily, is found in many tissues; overexpression has been linked to the development of preneoplastic and neoplastic changes in breast tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fadrozole Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Afema","termGroup":"FB","termSource":"NCI"},{"termName":"Arensin","termGroup":"FB","termSource":"NCI"},{"termName":"CGS 16949A","termGroup":"CN","termSource":"NCI"},{"termName":"CGS-16949A","termGroup":"CN","termSource":"NCI"},{"termName":"CGS16949A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"102676-31-3"},{"name":"CAS_Registry","value":"102676-96-0"},{"name":"Chemical_Formula","value":"C14H13N3.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H0Q44H4ECQ"},{"name":"Legacy Concept Name","value":"Fadrozole_Hydrochloride"},{"name":"Maps_To","value":"Fadrozole Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41025"},{"name":"PDQ_Open_Trial_Search_ID","value":"41025"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0917743"}]}}{"C88346":{"preferredName":"FAK Inhibitor GSK2256098","code":"C88346","definitions":[{"definition":"A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt, thereby inhibiting tumor cell migration, proliferation and survival, and tumor angiogenesis. The tyrosine kinase FAK is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK Inhibitor GSK2256098","termGroup":"PT","termSource":"NCI"},{"termName":"Focal Adhesion Kinase Inhibitor GSK2256098","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2256098","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1224887-10-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R7O0O4110G"},{"name":"Maps_To","value":"FAK Inhibitor GSK2256098"},{"name":"NCI_Drug_Dictionary_ID","value":"658411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658411"},{"name":"PDQ_Open_Trial_Search_ID","value":"658411"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981865"}]}}{"C78199":{"preferredName":"FAK Inhibitor PF-00562271","code":"C78199","definitions":[{"definition":"An orally bioavailable small molecule and ATP-competitive focal adhesion kinase (FAK) inhibitor with potential antineoplastic and antiangiogenic activities. FAK inhibitor PF-00562271 inhibits the tyrosine kinase FAK, and to a lesser extent, proline-rich tyrosine kinase (PYK2), which may inhibit tumor cell migration, proliferation, and survival. As FAK is a signal transducer for integrins, inhibition of FAK by this agent may prevent integrin-mediated activation of several downstream signals including ERK, JNK/MAPK and PI3K/Akt. FAK and PYK2, upregulated in many tumor cell types, are involved in tumor cell invasion, migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK Inhibitor PF-00562271","termGroup":"PT","termSource":"NCI"},{"termName":"Focal Adhesion Kinase Inhibitor PF-00562271","termGroup":"SY","termSource":"NCI"},{"termName":"PF-00562271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"939791-38-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FK2M84H8UI"},{"name":"Legacy Concept Name","value":"FAK_Inhibitor_PF-00562271"},{"name":"Maps_To","value":"FAK Inhibitor PF-00562271"},{"name":"NCI_Drug_Dictionary_ID","value":"595536"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595536"},{"name":"PDQ_Open_Trial_Search_ID","value":"595536"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703113"}]}}{"C107238":{"preferredName":"FAK Inhibitor VS-4718","code":"C107238","definitions":[{"definition":"An orally bioavailable focal adhesion kinase (FAK) inhibitor with potential antineoplastic activity. Upon administration, VS-4718 inhibits FAK, blocks fibronectin-stimulated FAK autophosphorylation of Tyr397, and may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt. This results in the reduction of the number of cancer stem cells (CSCs) and inhibits tumor cell migration, proliferation and survival. The cytoplasmic tyrosine kinase FAK is a signal transducer for integrins and is constitutively activated in various tumor cell types; it is involved in tumor cell invasion, migration and proliferation and plays a key role in the development, function and survival of CSCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK Inhibitor VS-4718","termGroup":"PT","termSource":"NCI"},{"termName":"VS-4718","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1061353-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L2BD0MW4OL"},{"name":"Maps_To","value":"FAK Inhibitor VS-4718"},{"name":"NCI_Drug_Dictionary_ID","value":"750562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750562"},{"name":"PDQ_Open_Trial_Search_ID","value":"750562"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3177516"}]}}{"C29316":{"preferredName":"Falimarev","code":"C29316","definitions":[{"definition":"A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A cancer vaccine made with a form of a chicken virus that does not cause disease in humans. It is being studied in the treatment of some types of cancer. The virus is changed in the laboratory to make human proteins that may help immune cells in the body kill tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Falimarev","termGroup":"PT","termSource":"NCI"},{"termName":"fCEA-MUC-1-TRI","termGroup":"AB","termSource":"NCI"},{"termName":"Fowlpox-CEA(D609)-MUC1(L93)-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Fowlpox-CEA-MUC-1-TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"PANVAC-F","termGroup":"BR","termSource":"NCI"},{"termName":"rFowlpox-CEA(D609)/MUC1(L93)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685563-14-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"rFowlpox-CEA_D609_MUC1_L93_TRICOM"},{"name":"Maps_To","value":"Falimarev"},{"name":"NCI_Drug_Dictionary_ID","value":"385667"},{"name":"NSC Number","value":"727027"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385667"},{"name":"PDQ_Open_Trial_Search_ID","value":"385667"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1541350"}]}}{"C97512":{"preferredName":"Famitinib","code":"C97512","definitions":[{"definition":"An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs, dysregulated in a variety of tumors, including stem cell factor receptor (c-Kit; SCFR), vascular endothelial growth factor receptor (VEGFR) 2 and 3, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinases Flt1 and Flt3. Inhibition of these RTKs may result in an inhibition of tumor growth and angiogenesis, and eventually tumor regression in tumor cells overexpressing these RTKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Famitinib","termGroup":"PT","termSource":"NCI"},{"termName":"4H-pyrrolo(3,2-c)pyridin-4-one, 5-(2-(diethylamino)ethyl)-2-((5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-1,5,6,7-tetrahydro-3-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"SHR-1020","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1020","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1044040-56-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"768FW21J3L"},{"name":"Maps_To","value":"Famitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"703815"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703815"},{"name":"PDQ_Open_Trial_Search_ID","value":"703815"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273460"}]}}{"C61503":{"preferredName":"Farletuzumab","code":"C61503","definitions":[{"definition":"A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Farletuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"MORAb-003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"896723-44-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2O09BG0OWA"},{"name":"Legacy Concept Name","value":"Anti-GP-3_Monoclonal_Antibody"},{"name":"Maps_To","value":"Farletuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"486728"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486728"},{"name":"PDQ_Open_Trial_Search_ID","value":"486728"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700602"}]}}{"C1840":{"preferredName":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123","code":"C1840","definitions":[{"definition":"A benzonitrile derivative capable of inhibiting some prenyltransferases. L-778,123 is a dual inhibitor of farnesyl:protein and geranylgeranyl:protein transferases; both enzymes catalyze prenylation of oncoprotein KRAS, a prerequisite step in activation of KRAS in signal transduction pathway of apoptosis. Although this agent was developed in part as an anti-KRAS agent, L-778,123 failed in a Phase I trial to inhibit KRAS, which is associated with many types of solid tumors.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called enzyme inhibitors. It may inhibit the transformation of normal cells into cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123","termGroup":"PT","termSource":"NCI"},{"termName":"4-[[5-[[4-(3-Chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]benzonitrile Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"L 778123","termGroup":"CN","termSource":"NCI"},{"termName":"L-778123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"253863-00-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2A2059P49U"},{"name":"Legacy Concept Name","value":"L-778_123"},{"name":"Maps_To","value":"Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123"},{"name":"NCI_Drug_Dictionary_ID","value":"43144"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43144"},{"name":"PDQ_Open_Trial_Search_ID","value":"43144"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796327"}]}}{"C67041":{"preferredName":"Fas Receptor Agonist APO010","code":"C67041","definitions":[{"definition":"A recombinant, soluble, hexameric fusion protein consisting of three human Fas ligand (FasL) extracellular domains fused to the dimer-forming collagen domain of human adiponectin with potential pro-apoptotic and antineoplastic activities. Assembled into a soluble hexameric structure mimicking the ligand clustering of endogenous active FasL, Fas receptor agonist APO010 activates the Fas receptor, resulting in caspase-dependent apoptosis in susceptible tumor cell populations. FasL is a transmembrane protein of the tumor necrosis factor (TNF) superfamily and a pro-apoptotic ligand for the death receptor Fas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fas Receptor Agonist APO010","termGroup":"PT","termSource":"NCI"},{"termName":"APO010","termGroup":"AB","termSource":"NCI"},{"termName":"Mega-FasLigand","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"APO010"},{"name":"Maps_To","value":"Fas Receptor Agonist APO010"},{"name":"NCI_Drug_Dictionary_ID","value":"539307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539307"},{"name":"PDQ_Open_Trial_Search_ID","value":"539307"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879517"}]}}{"C142086":{"preferredName":"Fascin Inhibitor NP-G2-044","code":"C142086","definitions":[{"definition":"An orally available inhibitor of the protein fascin, with potential antineoplastic activity. Upon oral administration, NP-G2-044 targets and binds to fascin, thereby preventing the interaction of fascin with actin filaments, thereby preventing actin bundling and filopodia formation. By preventing actin cytoskeletal reorganization, the dynamic changes in cell shape that are necessary for tumor cell migration and invasion to occur are impaired, and tumor cell migration and metastasis are inhibited. Fascin, the main actin cross-linker protein in filopodia, is upregulated in many types of metastatic tumor cells while its expression is low or absent in normal adult epithelial cells; its expression is correlated with aggressive phenotypes, poor prognosis, and shorter survival. Filopodia, finger-like plasma membrane protrusions that are formed upon remodeling of the actin cytoskeleton, are found at a high frequency in metastatic tumor cells and their presence is correlated with tumor cell invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fascin Inhibitor NP-G2-044","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"NP G2 044","termGroup":"CN","termSource":"NCI"},{"termName":"NP-G2-044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1807454-59-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1ER2O3UZ4W"},{"name":"Maps_To","value":"Fascin Inhibitor NP-G2-044"},{"name":"NCI_Drug_Dictionary_ID","value":"793138"},{"name":"NCI_META_CUI","value":"CL540124"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793138"},{"name":"PDQ_Open_Trial_Search_ID","value":"793138"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118285":{"preferredName":"Denifanstat","code":"C118285","definitions":[{"definition":"An orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, denifanstat binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denifanstat","termGroup":"PT","termSource":"NCI"},{"termName":"ASC 40","termGroup":"CN","termSource":"NCI"},{"termName":"ASC-40","termGroup":"CN","termSource":"NCI"},{"termName":"ASC40","termGroup":"CN","termSource":"NCI"},{"termName":"FASN Inhibitor TVB-2640","termGroup":"SY","termSource":"NCI"},{"termName":"TVB 2640","termGroup":"CN","termSource":"NCI"},{"termName":"TVB-2640","termGroup":"CN","termSource":"NCI"},{"termName":"TVB2640","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1399177-37-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4GF95B2LZA"},{"name":"Maps_To","value":"FASN Inhibitor TVB-2640"},{"name":"NCI_Drug_Dictionary_ID","value":"764237"},{"name":"NCI_META_CUI","value":"CL474138"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764237"},{"name":"PDQ_Open_Trial_Search_ID","value":"764237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1096":{"preferredName":"Fazarabine","code":"C1096","definitions":[{"definition":"An anticancer drug that is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fazarabine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3, 5-Triazin-2(1H)-one, 4-Amino-1-beta-D- arabinofuranosyl- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"1-Beta-D-arabinofuranosyl-5-azacytosine","termGroup":"SN","termSource":"NCI"},{"termName":"Ara AC","termGroup":"AB","termSource":"NCI"},{"termName":"ara-AC","termGroup":"AB","termSource":"NCI"},{"termName":"Kymarabine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65886-71-7"},{"name":"Chemical_Formula","value":"C8H12N4O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5V71D8JOKK"},{"name":"Legacy Concept Name","value":"Fazarabine"},{"name":"Maps_To","value":"Fazarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"40564"},{"name":"NSC Number","value":"281272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40564"},{"name":"PDQ_Open_Trial_Search_ID","value":"40564"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060103"}]}}{"C65629":{"preferredName":"Febuxostat","code":"C65629","definitions":[{"definition":"An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Febuxostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Adenuric","termGroup":"FB","termSource":"NCI"},{"termName":"TMX 67","termGroup":"CN","termSource":"NCI"},{"termName":"Uloric","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144060-53-7"},{"name":"CHEBI_ID","value":"CHEBI:31596"},{"name":"Chemical_Formula","value":"C16H16N2O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"101V0R1N2E"},{"name":"Legacy Concept Name","value":"Febuxostat"},{"name":"Maps_To","value":"Febuxostat"},{"name":"NCI_Drug_Dictionary_ID","value":"743107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743107"},{"name":"PDQ_Open_Trial_Search_ID","value":"743107"},{"name":"PubMedID_Primary_Reference","value":"16339094"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0249529"}]}}{"C88293":{"preferredName":"Fedratinib","code":"C88293","definitions":[{"definition":"An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fedratinib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 302503","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-302503","termGroup":"CN","termSource":"NCI"},{"termName":"SAR302503","termGroup":"CN","termSource":"NCI"},{"termName":"TG 101348","termGroup":"CN","termSource":"NCI"},{"termName":"TG-101348","termGroup":"CN","termSource":"NCI"},{"termName":"TG101348","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936091-26-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6L1XP550I6"},{"name":"Maps_To","value":"Fedratinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2353170"}]}}{"C162995":{"preferredName":"Fedratinib Hydrochloride","code":"C162995","definitions":[{"definition":"The monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fedratinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, N-(1,1-Dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Fedratinib Dihydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Inrebic","termGroup":"BR","termSource":"NCI"},{"termName":"N-tert-butyl-3-((5-methyl-2-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)pyrimidin-4-yl)amino) Benzenesulfonamide Dihydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"SAR302503a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)."},{"name":"CAS_Registry","value":"1374744-69-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UH9J2HBQWJ"},{"name":"Maps_To","value":"Fedratinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"657793"},{"name":"NCI_META_CUI","value":"CL973405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"657793"},{"name":"PDQ_Open_Trial_Search_ID","value":"657793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116844":{"preferredName":"Fenebrutinib","code":"C116844","definitions":[{"definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenebrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton Tyrosine Kinase Inhibitor GDC-0853","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0853","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1434048-34-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E9L2885WUL"},{"name":"Maps_To","value":"Fenebrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"755178"},{"name":"NCI_META_CUI","value":"CL774945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755178"},{"name":"PDQ_Open_Trial_Search_ID","value":"755178"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1098":{"preferredName":"Fenretinide","code":"C1098","definitions":[{"definition":"A substance being studied in the treatment and prevention of some types of cancer. Fenretinide may cause ceramide (a wax-like substance) to build up in tumor cells and kill them. It is a type of retinoid, which are substances related to vitamin A.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenretinide","termGroup":"PT","termSource":"NCI"},{"termName":"4-(all-trans-retino-yl)aminophenol","termGroup":"SN","termSource":"NCI"},{"termName":"4-HPR","termGroup":"AB","termSource":"NCI"},{"termName":"4-Hydroxyphenylretinamide","termGroup":"SN","termSource":"NCI"},{"termName":"All-trans-4'-Hydroxyretinanilide","termGroup":"SN","termSource":"NCI"},{"termName":"all-trans-N-(4-Hydroxyphenyl)retinamide","termGroup":"SN","termSource":"NCI"},{"termName":"all-trans-N-4'-hydroxyretinanilide","termGroup":"SN","termSource":"NCI"},{"termName":"Fenretinimide","termGroup":"SY","termSource":"NCI"},{"termName":"HPR-4","termGroup":"AB","termSource":"NCI"},{"termName":"McN-R-1967","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-hydroxyphenyl)retinamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65646-68-6"},{"name":"CHEBI_ID","value":"CHEBI:42588"},{"name":"Chemical_Formula","value":"C26H33NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"187EJ7QEXL"},{"name":"Legacy Concept Name","value":"Fenretinide"},{"name":"Maps_To","value":"Fenretinide"},{"name":"NCI_Drug_Dictionary_ID","value":"39582"},{"name":"NSC Number","value":"374551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39582"},{"name":"PDQ_Open_Trial_Search_ID","value":"39582"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060197"}]}}{"C63482":{"preferredName":"Fenretinide Lipid Matrix","code":"C63482","definitions":[{"definition":"A powdered form of fenretinide that is being studied in the treatment of neuroblastoma. It may be used by the body more easily than the pill form. Fenretinide may cause ceramide (a wax-like substance) to build up in tumor cells and kill them. It is a type of retinoid, which are substances related to vitamin A.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable powder formulation of a synthetic phenylretinamide analogue of retinol with potential chemopreventive and antineoplastic activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types, including those of the colon, breast, prostate, and neuroblastoma. Independent of RAR activation, this agent also modulates gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS). Compared to the capsule form, the powder contains a mixture of wheat flour, fats, and sugar that may contribute to the enhanced bioavailability of fenretinide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenretinide Lipid Matrix","termGroup":"PT","termSource":"NCI"},{"termName":"Fenretinide LXS","termGroup":"BR","termSource":"NCI"},{"termName":"Fenretinide Lym-X-Sorb","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fenretinide_Lipid_Matrix"},{"name":"Maps_To","value":"Fenretinide Lipid Matrix"},{"name":"NCI_Drug_Dictionary_ID","value":"468556"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468556"},{"name":"PDQ_Open_Trial_Search_ID","value":"468556"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831747"}]}}{"C77970":{"preferredName":"FGF Receptor Antagonist HGS1036","code":"C77970","definitions":[{"definition":"A soluble fusion protein consisting of the extracellular domain of human fibroblast growth factor receptor 1 (FGFR1) fused to the Fc portion of human immunoglobulin G1 (IgG1) with potential antineoplastic and anti-angiogenic activities. FGFR1 receptor antagonist FP-1039 prevents FGFR ligands, such as FGF1, FGF2, FGF4, from binding to their cognate receptors, thereby inhibiting the activation of the related FGFR tyrosine kinases. Inhibition of FGFR1 by this agent may retard tumor cell proliferation and induce tumor cell death. FP-1039 may also inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis. FGFR1 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cellular proliferation, differentiation, angiogenesis, and survival; most ligands that bind to FGFR1 also bind to the related receptors FGFR3 and FGFR4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGF Receptor Antagonist HGS1036","termGroup":"PT","termSource":"NCI"},{"termName":"FP-1039","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3052230","termGroup":"CN","termSource":"NCI"},{"termName":"HGS1036","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1631072-93-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CTG26PRE5S"},{"name":"Legacy Concept Name","value":"FGF_Receptor_Antagonist_FP-1039"},{"name":"Maps_To","value":"FGF Receptor Antagonist HGS1036"},{"name":"NCI_Drug_Dictionary_ID","value":"599037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599037"},{"name":"PDQ_Open_Trial_Search_ID","value":"599037"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703098"}]}}{"C118672":{"preferredName":"Tasurgratinib","code":"C118672","definitions":[{"definition":"An inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, tasurgratinib selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasurgratinib","termGroup":"PT","termSource":"NCI"},{"termName":"E-7090","termGroup":"CN","termSource":"NCI"},{"termName":"E7090","termGroup":"CN","termSource":"NCI"},{"termName":"FGF/FGFR Pathway Inhibitor E7090","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622204-21-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TN7CUD1NGA"},{"name":"Maps_To","value":"FGF/FGFR Pathway Inhibitor E7090"},{"name":"NCI_Drug_Dictionary_ID","value":"766006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766006"},{"name":"PDQ_Open_Trial_Search_ID","value":"766006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896866"}]}}{"C122719":{"preferredName":"FGFR Inhibitor ASP5878","code":"C122719","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor ASP5878 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR Inhibitor ASP5878","termGroup":"PT","termSource":"NCI"},{"termName":"ASP5878","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453208-66-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C0Z095LL72"},{"name":"Maps_To","value":"FGFR Inhibitor ASP5878"},{"name":"NCI_Drug_Dictionary_ID","value":"756907"},{"name":"NCI_META_CUI","value":"CL471763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756907"},{"name":"PDQ_Open_Trial_Search_ID","value":"756907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88272":{"preferredName":"Fexagratinib","code":"C88272","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fexagratinib","termGroup":"PT","termSource":"NCI"},{"termName":"ABSK-091","termGroup":"CN","termSource":"NCI"},{"termName":"ABSK091","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4547","termGroup":"CN","termSource":"NCI"},{"termName":"FGFR Inhibitor AZD4547","termGroup":"SY","termSource":"NCI"},{"termName":"KB-74810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1035270-39-3"},{"name":"CHEBI_ID","value":"CHEBI:63453"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2167OG1EKJ"},{"name":"Maps_To","value":"FGFR Inhibitor AZD4547"},{"name":"NCI_Drug_Dictionary_ID","value":"655951"},{"name":"NCI_META_CUI","value":"CL412460"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655951"},{"name":"PDQ_Open_Trial_Search_ID","value":"655951"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174762":{"preferredName":"Zoligratinib","code":"C174762","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. Zoligratinib binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, is essential for tumor cellular proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zoligratinib","termGroup":"PT","termSource":"NCI"},{"termName":"CH5183284","termGroup":"CN","termSource":"NCI"},{"termName":"debio 1347","termGroup":"CN","termSource":"NCI"},{"termName":"debio 1347-101","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-1347","termGroup":"CN","termSource":"NCI"},{"termName":"Debio1347","termGroup":"CN","termSource":"NCI"},{"termName":"Debiopharm 1347","termGroup":"SY","termSource":"NCI"},{"termName":"FF284","termGroup":"CN","termSource":"NCI"},{"termName":"FGFR Inhibitor Debio 1347","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1265229-25-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NR9ZYH80Z8"},{"name":"Maps_To","value":"FGFR Inhibitor Debio 1347"},{"name":"NCI_Drug_Dictionary_ID","value":"808368"},{"name":"NCI_META_CUI","value":"CL1412276"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114283":{"preferredName":"Futibatinib","code":"C114283","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Futibatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propen-1-one, 1-((3S)-3-(4-Amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Lytgobi","termGroup":"BR","termSource":"NCI"},{"termName":"TAS 120","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-120","termGroup":"CN","termSource":"NCI"},{"termName":"TAS120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements."},{"name":"CAS_Registry","value":"1448169-71-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4B93MGE4AL"},{"name":"Maps_To","value":"FGFR Inhibitor TAS-120"},{"name":"Maps_To","value":"Futibatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"757896"},{"name":"NCI_META_CUI","value":"CL471791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757896"},{"name":"PDQ_Open_Trial_Search_ID","value":"757896"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116894":{"preferredName":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","code":"C116894","definitions":[{"definition":"A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FMS-related tyrosine kinase 3 (FLT3), and SRC, with potential antineoplastic activity. Upon administration, XL999 binds to and inhibits the activity of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR, PDGFR, FLT-3, and SRC are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","termGroup":"PT","termSource":"NCI"},{"termName":"Spectrum Selective Kinase Inhibitor XL999","termGroup":"SY","termSource":"NCI"},{"termName":"SSKI XL999","termGroup":"SY","termSource":"NCI"},{"termName":"XL-999","termGroup":"CN","termSource":"NCI"},{"termName":"XL999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"705946-27-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6I7PLF6N8L"},{"name":"Maps_To","value":"FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999"},{"name":"NCI_Drug_Dictionary_ID","value":"425377"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425377"},{"name":"PDQ_Open_Trial_Search_ID","value":"425377"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541529"}]}}{"C150383":{"preferredName":"FGFR1/2/3 Inhibitor HMPL-453","code":"C150383","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Upon administration, FGFR inhibitor HMPL-453 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR1/2/3 Inhibitor HMPL-453","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR Inhibitor HMPL-453","termGroup":"SY","termSource":"NCI"},{"termName":"HMPL 453","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-453","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR1/2/3 Inhibitor HMPL-453"},{"name":"NCI_Drug_Dictionary_ID","value":"792789"},{"name":"NCI_META_CUI","value":"CL552165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792789"},{"name":"PDQ_Open_Trial_Search_ID","value":"792789"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143067":{"preferredName":"FGFR4 Antagonist INCB062079","code":"C143067","definitions":[{"definition":"An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist INCB062079 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Antagonist INCB062079","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR4 Inhibitor INCB062079","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Antagonist INCB062079","termGroup":"SY","termSource":"NCI"},{"termName":"INCB 062079","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-062079","termGroup":"CN","termSource":"NCI"},{"termName":"INCB062079","termGroup":"CN","termSource":"NCI"},{"termName":"INCB62079","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR4 Antagonist INCB062079"},{"name":"NCI_Drug_Dictionary_ID","value":"791889"},{"name":"NCI_META_CUI","value":"CL541447"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791889"},{"name":"PDQ_Open_Trial_Search_ID","value":"791889"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162342":{"preferredName":"FGFR4 Inhibitor BLU 9931","code":"C162342","definitions":[{"definition":"An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist BLU 9931 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand, fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Inhibitor BLU 9931","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(2-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)-3-methylphenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"BLU 9931","termGroup":"CN","termSource":"NCI"},{"termName":"BLU-9931","termGroup":"CN","termSource":"NCI"},{"termName":"BLU9931","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)-3-methylphenyl)-2-propenamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1538604-68-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FQK825B5DX"},{"name":"Maps_To","value":"FGFR4 Inhibitor BLU 9931"},{"name":"NCI_META_CUI","value":"CL970841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120102":{"preferredName":"Roblitinib","code":"C120102","definitions":[{"definition":"An inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, roblitinib binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roblitinib","termGroup":"PT","termSource":"NCI"},{"termName":"FGF401","termGroup":"CN","termSource":"NCI"},{"termName":"FGFR4 Inhibitor FGF401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1708971-55-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M64JF6WMSA"},{"name":"Maps_To","value":"FGFR4 Inhibitor FGF401"},{"name":"Maps_To","value":"Roblitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"767955"},{"name":"NCI_META_CUI","value":"CL507817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767955"},{"name":"PDQ_Open_Trial_Search_ID","value":"767955"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128862":{"preferredName":"FGFR4 Inhibitor H3B-6527","code":"C128862","definitions":[{"definition":"An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival; FGFR4 expression is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Inhibitor H3B-6527","termGroup":"PT","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Inhibitor H3B-6527","termGroup":"SY","termSource":"NCI"},{"termName":"H3B 6527","termGroup":"CN","termSource":"NCI"},{"termName":"H3B-6527","termGroup":"CN","termSource":"NCI"},{"termName":"H3B6527","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1702259-66-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4HTE364XIK"},{"name":"Maps_To","value":"FGFR4 Inhibitor H3B-6527"},{"name":"NCI_Drug_Dictionary_ID","value":"783108"},{"name":"NCI_META_CUI","value":"CL512384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783108"},{"name":"PDQ_Open_Trial_Search_ID","value":"783108"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162852":{"preferredName":"FGFR4 Inhibitor ICP-105","code":"C162852","definitions":[{"definition":"An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, ICP-105 specifically targets, binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase overexpressed on a variety of cancer cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR4 Inhibitor ICP-105","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR4 Antagonist ICP-105","termGroup":"SY","termSource":"NCI"},{"termName":"ICP 105","termGroup":"CN","termSource":"NCI"},{"termName":"ICP-105","termGroup":"CN","termSource":"NCI"},{"termName":"ICP105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR4 Inhibitor ICP-105"},{"name":"NCI_Drug_Dictionary_ID","value":"798826"},{"name":"NCI_META_CUI","value":"CL973353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798826"},{"name":"PDQ_Open_Trial_Search_ID","value":"798826"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166939":{"preferredName":"Onfekafusp Alfa","code":"C166939","definitions":[{"definition":"An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onfekafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Fibromun","termGroup":"SY","termSource":"NCI"},{"termName":"L19-TNF-alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Fusion Protein L19TNFalpha","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1957239-88-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6HXC0O6JMV"},{"name":"Maps_To","value":"Fibromun"},{"name":"NCI_Drug_Dictionary_ID","value":"686947"},{"name":"NCI_META_CUI","value":"CL972185"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78844":{"preferredName":"Ficlatuzumab","code":"C78844","definitions":[{"definition":"A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Ficlatuzumab binds to the soluble ligand HGF, preventing the binding of HGF to its receptor c-Met and activation of the HGF/c-Met signaling pathway, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ficlatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HGF Monoclonal Antibody SCH900105","termGroup":"SY","termSource":"NCI"},{"termName":"AV-299","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1174900-84-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"77E89833TG"},{"name":"Legacy Concept Name","value":"Anti-HGF_Monoclonal_Antibody_SCH900105"},{"name":"Maps_To","value":"Ficlatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"610133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610133"},{"name":"PDQ_Open_Trial_Search_ID","value":"610133"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703138"}]}}{"C52187":{"preferredName":"Figitumumab","code":"C52187","definitions":[{"definition":"A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Figitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"CP 751,871","termGroup":"CN","termSource":"NCI"},{"termName":"CP-751,871","termGroup":"CN","termSource":"NCI"},{"termName":"CP-751871","termGroup":"CN","termSource":"NCI"},{"termName":"CP751,871","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943453-46-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"VE267FC2UB"},{"name":"Legacy Concept Name","value":"CP-751871"},{"name":"Maps_To","value":"Figitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"456793"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456793"},{"name":"PDQ_Open_Trial_Search_ID","value":"456793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713009"}]}}{"C68937":{"preferredName":"Filanesib","code":"C68937","definitions":[{"definition":"A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. Filanesib specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, this agent does not cause the peripheral neuropathy that is often associated with tubulin-targeting agents. KSP is an ATP-dependent microtubule motor protein that is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Filanesib","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,4-Thiadiazole-3(2H)-carboxamide, 2-(3-Aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-, (2S)-","termGroup":"SN","termSource":"NCI"},{"termName":"ARRY 520","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-520","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY520","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"885060-09-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8A49OSO368"},{"name":"Legacy Concept Name","value":"KSP_Inhibitor_ARRY-520"},{"name":"Maps_To","value":"Filanesib"},{"name":"NCI_Drug_Dictionary_ID","value":"546990"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546990"},{"name":"PDQ_Open_Trial_Search_ID","value":"546990"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346611"}]}}{"C155799":{"preferredName":"Filgotinib","code":"C155799","definitions":[{"definition":"An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Filgotinib","termGroup":"PT","termSource":"NCI"},{"termName":"GLPG 0634","termGroup":"CN","termSource":"NCI"},{"termName":"GLPG0634","termGroup":"CN","termSource":"NCI"},{"termName":"GS-6034","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1206161-97-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3XVL385Q0M"},{"name":"Maps_To","value":"Filgotinib"},{"name":"NCI_META_CUI","value":"CL556330"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1474":{"preferredName":"Filgrastim","code":"C1474","definitions":[{"definition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that is a type of hematopoietic (blood-forming) agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Filgrastim","termGroup":"PT","termSource":"NCI"},{"termName":"Filgrastim Biosimilar Filgrastim-sndz","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim Biosimilar Tbo-filgrastim","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim XM02","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim-aafi","termGroup":"SY","termSource":"NCI"},{"termName":"Filgrastim-ayow","termGroup":"SY","termSource":"NCI"},{"termName":"G-CSF","termGroup":"AB","termSource":"NCI"},{"termName":"Granix","termGroup":"BR","termSource":"NCI"},{"termName":"Neupogen","termGroup":"BR","termSource":"NCI"},{"termName":"Neutroval","termGroup":"BR","termSource":"NCI"},{"termName":"Nivestim","termGroup":"FB","termSource":"NCI"},{"termName":"Nivestym","termGroup":"BR","termSource":"NCI"},{"termName":"r-metHuG-CSF","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Releuko","termGroup":"BR","termSource":"NCI"},{"termName":"rG-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Tevagrastim","termGroup":"BR","termSource":"NCI"},{"termName":"XM02","termGroup":"CN","termSource":"NCI"},{"termName":"Zarxio","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Aplastic neutropenia; Bone marrow transplantation; Cancer patients receiving myelosuppressive chemotherapy; Congenital neutropenia; Idiopathic or cyclic neutropenia; Peripheral blood progenitor cell mobilization"},{"name":"CAS_Registry","value":"121181-53-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"PVI5M0M1GW"},{"name":"Legacy Concept Name","value":"Filgrastim"},{"name":"Maps_To","value":"Filgrastim"},{"name":"NCI_Drug_Dictionary_ID","value":"41057"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41057"},{"name":"PDQ_Open_Trial_Search_ID","value":"41057"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0210630"}]}}{"C104008":{"preferredName":"Fimepinostat","code":"C104008","definitions":[{"definition":"An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, fimepinostat inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fimepinostat","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC-907","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1339928-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S9RX35S5X"},{"name":"Maps_To","value":"Fimepinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"743908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743908"},{"name":"PDQ_Open_Trial_Search_ID","value":"743908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3530053"}]}}{"C70651":{"preferredName":"Firtecan Pegol","code":"C70651","definitions":[{"definition":"A polyethylene glycol (PEG) conjugate of 7-ethyl-10-hydroxycamptothecin with potential antineoplastic activity. After hydrolysis in vivo, 7-ethyl-10-hydroxycamptothecin (SN38), an active metabolite of irinotecan, is released from firtecan pegol; 7-ethyl-10-hydroxycamptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to unPEGylated 7-ethyl-10-hydroxycamptothecin, PEGylation improves solubility and allows for parental delivery, and may result in a longer half-life and higher exposure for tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Firtecan Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"EZN-2208","termGroup":"CN","termSource":"NCI"},{"termName":"PEG-SN38","termGroup":"AB","termSource":"NCI"},{"termName":"Poly(oxy-1,2-ethanediyl), alpha,alpha',alpha'',alpha'''-(oxydi-3,1,2-propanetriyl)tetrakis(omega-(2-((2-(((4S)- 4,11-diethyl-9-hydroxy-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano(3',4':6,7) indolizino(1,2-b)quinolin-4-yl)oxy)-2-oxoethyl)amino)-2-oxoethoxy)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946062-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WC4978T687"},{"name":"Legacy Concept Name","value":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin"},{"name":"Maps_To","value":"Firtecan Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"570645"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570645"},{"name":"PDQ_Open_Trial_Search_ID","value":"570645"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347621"}]}}{"C123826":{"preferredName":"Fisogatinib","code":"C123826","definitions":[{"definition":"An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fisogatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-","termGroup":"SY","termSource":"NCI"},{"termName":"BLU 554","termGroup":"CN","termSource":"NCI"},{"termName":"BLU-554","termGroup":"CN","termSource":"NCI"},{"termName":"BLU554","termGroup":"CN","termSource":"NCI"},{"termName":"CS 3008","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3008","termGroup":"CN","termSource":"NCI"},{"termName":"CS3008","termGroup":"CN","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 4 Inhibitor BLU-554","termGroup":"SY","termSource":"NCI"},{"termName":"N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1707289-21-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Q7R99CKV2"},{"name":"Maps_To","value":"Fisogatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"775629"},{"name":"NCI_META_CUI","value":"CL498220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775629"},{"name":"PDQ_Open_Trial_Search_ID","value":"775629"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91384":{"preferredName":"Flanvotumab","code":"C91384","definitions":[{"definition":"A monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. Anti-gp75 monoclonal antibody IMC-20D7S targets and binds to gp75. This may lead to the induction of cytotoxic T cell immune and antibody-mediated immune responses against melanoma cells expressing gp75. gp75, a pigmentation-associated antigen, is expressed in melanosomes of human melanocytes and melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flanvotumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-gp75 Monoclonal Antibody IMC-20D7S","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-20D7S","termGroup":"CN","termSource":"NCI"},{"termName":"IMC20D7S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188277-05-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZNV4738BS6"},{"name":"Maps_To","value":"Flanvotumab"},{"name":"NCI_Drug_Dictionary_ID","value":"675217"},{"name":"NCI_META_CUI","value":"CL421598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675217"},{"name":"PDQ_Open_Trial_Search_ID","value":"675217"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117238":{"preferredName":"Flotetuzumab","code":"C117238","definitions":[{"definition":"An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flotetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"CD123 x CD3 DART Bi-Specific Antibody MGD006","termGroup":"SY","termSource":"NCI"},{"termName":"CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006","termGroup":"SY","termSource":"NCI"},{"termName":"MGD006","termGroup":"CN","termSource":"NCI"},{"termName":"RES234","termGroup":"CN","termSource":"NCI"},{"termName":"S80880","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1664355-28-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0AHT0IC02G"},{"name":"Maps_To","value":"Flotetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"763236"},{"name":"NCI_META_CUI","value":"CL474112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763236"},{"name":"PDQ_Open_Trial_Search_ID","value":"763236"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C504":{"preferredName":"Floxuridine","code":"C504","definitions":[{"definition":"A drug used in the treatment of cancer. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Floxuridine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"2'-Deoxy-5-fluorouridine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Deoxy-5-fluorouridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-2'-deoxy-beta-uridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-2'-deoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorodeoxyuridine","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorouracil Deoxyriboside","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorouridine Deoxyribose","termGroup":"SN","termSource":"NCI"},{"termName":"5-FUdR","termGroup":"AB","termSource":"NCI"},{"termName":"FDUR","termGroup":"AB","termSource":"NCI"},{"termName":"Floxuridin","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorodeoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouridine Deoxyribose","termGroup":"SY","termSource":"NCI"},{"termName":"Fluoruridine Deoxyribose","termGroup":"SY","termSource":"NCI"},{"termName":"FUdR","termGroup":"AB","termSource":"NCI"},{"termName":"WR 138720","termGroup":"CN","termSource":"NCI"},{"termName":"WR-138720","termGroup":"CN","termSource":"NCI"},{"termName":"WR138720","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastrointestinal adenocarcinoma metastatic to the liver"},{"name":"CAS_Registry","value":"50-91-9"},{"name":"CHEBI_ID","value":"CHEBI:60761"},{"name":"Chemical_Formula","value":"C9H11FN2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"039LU44I5M"},{"name":"Legacy Concept Name","value":"Floxuridine"},{"name":"Maps_To","value":"Floxuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39242"},{"name":"NSC Number","value":"27640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39242"},{"name":"PDQ_Open_Trial_Search_ID","value":"39242"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016343"}]}}{"C137988":{"preferredName":"FLT3 Inhibitor FF-10101 Succinate","code":"C137988","definitions":[{"definition":"The succinate salt form of FF-10101, a FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) inhibitor, with potential antineoplastic activity. Upon administration of FLT3 inhibitor FF-10101 succinate (FF-10101-01), FF-10101 irreversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3 Inhibitor FF-10101 Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"FF-10101 Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"FF-10101-01","termGroup":"CN","termSource":"NCI"},{"termName":"FF10101 Succinate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3 Inhibitor FF-10101 Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"790705"},{"name":"NCI_META_CUI","value":"CL524957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790705"},{"name":"PDQ_Open_Trial_Search_ID","value":"790705"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165254":{"preferredName":"Tuspetinib","code":"C165254","definitions":[{"definition":"A selective, reversible type I inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) with potential antineoplastic activity. Upon administration, tuspetinib reversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuspetinib","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3 Inhibitor HM43239","termGroup":"SY","termSource":"NCI"},{"termName":"FMS-like Tyrosine Kinase 3 Inhibitor HM43239","termGroup":"SY","termSource":"NCI"},{"termName":"HM 43239","termGroup":"CN","termSource":"NCI"},{"termName":"HM-43239","termGroup":"CN","termSource":"NCI"},{"termName":"HM43239","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2294874-49-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C0WUS7XXE9"},{"name":"Maps_To","value":"FLT3 Inhibitor HM43239"},{"name":"NCI_Drug_Dictionary_ID","value":"799742"},{"name":"NCI_META_CUI","value":"CL978555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799742"},{"name":"PDQ_Open_Trial_Search_ID","value":"799742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155773":{"preferredName":"Denfivontinib Hydrochloride","code":"C155773","definitions":[{"definition":"The hydrochloride salt form of denfivontinib, an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, denfivontinib binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, denfivontinib also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Denfivontinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3 Inhibitor SKI-G-801","termGroup":"SY","termSource":"NCI"},{"termName":"FLT3 Kinase Inhibitor SKI-G-801","termGroup":"SY","termSource":"NCI"},{"termName":"FLT3 Tyrosine Kinase Inhibitor SKI-G-801","termGroup":"SY","termSource":"NCI"},{"termName":"G-749 HCl Salt","termGroup":"SY","termSource":"NCI"},{"termName":"G-749 Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"G-801","termGroup":"CN","termSource":"NCI"},{"termName":"SKI-G-801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1457983-33-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01ZQ25VJAL"},{"name":"Maps_To","value":"FLT3 Inhibitor SKI-G-801"},{"name":"NCI_Drug_Dictionary_ID","value":"794986"},{"name":"NCI_META_CUI","value":"CL556252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794986"},{"name":"PDQ_Open_Trial_Search_ID","value":"794986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123362":{"preferredName":"FLT3 Tyrosine Kinase Inhibitor TTT-3002","code":"C123362","definitions":[{"definition":"An orally bioavailable indolocarbazole derivative and inhibitor of constitutively active mutant forms of FMS-like tyrosine kinase 3 (FLT3) with potential antineoplastic activity. Following administration, FLT3 tyrosine kinase inhibitor TTT-3002 binds to and inhibits ligand-dependent dimerization and autophosphorylation of mutant forms of FLT3 with constitutively activating mutations, including FLT3 internal tandem duplication (FLT3/ITD) and the activating point mutation D835Y. Prevention of autophosphorylation inhibits uncontrolled FLT3 signaling and may result in the inhibition of proliferation in tumor cells expressing constitutively active mutant forms of FLT3. The ability of TTT-3002 to inhibit FLT3 proteins with activating point mutations may result in increased efficacy because the activity of these mutants are resistant to other FLT3 kinase inhibitors. FLT3, a tyrosine kinase receptor, plays a role in the regulation of hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. Constitutively activating mutations of FLT3 are the most frequent genetic alterations in acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3 Tyrosine Kinase Inhibitor TTT-3002","termGroup":"PT","termSource":"NCI"},{"termName":"TTT-3002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3 Tyrosine Kinase Inhibitor TTT-3002"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3850293"}]}}{"C116858":{"preferredName":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449","code":"C116858","definitions":[{"definition":"An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential antineoplastic activity. Upon administration, FLT3/ABL/Aurora kinase inhibitor KW-2449 specifically binds to and inhibits both wild-type and mutated forms of FLT3, ABL and aurora kinases, which both interferes with the activation of signal transduction pathways mediated by these kinases and reduces the proliferation of susceptible cancer cells. FLT3 and ABL kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis. Aurora kinases, serine-threonine kinases overexpressed by a wide variety of cancer cell types, play essential roles in mitotic checkpoint control.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449","termGroup":"PT","termSource":"NCI"},{"termName":"KW-2449","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"841258-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2D9N67F58G"},{"name":"Maps_To","value":"FLT3/ABL/Aurora Kinase Inhibitor KW-2449"},{"name":"NCI_Drug_Dictionary_ID","value":"496931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496931"},{"name":"PDQ_Open_Trial_Search_ID","value":"496931"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831922"}]}}{"C120209":{"preferredName":"FLT3/CDK4/6 Inhibitor FLX925","code":"C120209","definitions":[{"definition":"An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2) and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, FLT3/CDK4/6 inhibitor FLX925 specifically binds to and inhibits FLT3, which interferes with the activation of FLT3-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress FLT3. In addition FLX925 inhibits CDK4 and 6 and prevents the phosphorylation of retinoblastoma (Rb) protein in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, which causes G1 phase cell cycle arrest, suppresses DNA synthesis and inhibits cancer cell growth. FLT3, a class III tyrosine kinase receptor, is overexpressed in a variety of cancers. Overexpression of CDK4/6, which is seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/CDK4/6 Inhibitor FLX925","termGroup":"PT","termSource":"NCI"},{"termName":"FLX925","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3/CDK4/6 Inhibitor FLX925"},{"name":"NCI_Drug_Dictionary_ID","value":"768269"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768269"},{"name":"PDQ_Open_Trial_Search_ID","value":"768269"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896859"}]}}{"C101520":{"preferredName":"FLT3/KIT Kinase Inhibitor AKN-028","code":"C101520","definitions":[{"definition":"An orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/KIT Kinase Inhibitor AKN-028","termGroup":"PT","termSource":"NCI"},{"termName":"AKN-028","termGroup":"CN","termSource":"NCI"},{"termName":"BVT-II","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1175017-90-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y66IS3CS0R"},{"name":"Maps_To","value":"FLT3/KIT Kinase Inhibitor AKN-028"},{"name":"NCI_Drug_Dictionary_ID","value":"731885"},{"name":"PDQ_Closed_Trial_Search_ID","value":"731885"},{"name":"PDQ_Open_Trial_Search_ID","value":"731885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852612"}]}}{"C151407":{"preferredName":"Flt3/MerTK Inhibitor MRX-2843","code":"C151407","definitions":[{"definition":"An orally bioavailable inhibitor of two receptor tyrosine kinases (RTKs), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2) and tyrosine-protein kinase Mer (MerTK; proto-oncogene c-Mer; Mer), with potential antineoplastic activity. Upon administration, MRX-2843 targets and binds to both Flt3 and MerTK. This prevents ligand-dependent phosphorylation and activation of Flt3 and MerTK, which inhibits the activation of their downstream signaling pathways. This induces apoptosis and inhibits proliferation of Flt3- and/or MerTK-overexpressing tumor cells. Flt3 and MerTK, are overexpressed in certain tumor cell types and play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flt3/MerTK Inhibitor MRX-2843","termGroup":"PT","termSource":"NCI"},{"termName":"MRX 2843","termGroup":"SY","termSource":"NCI"},{"termName":"MRX-2843","termGroup":"CN","termSource":"NCI"},{"termName":"MRX2843","termGroup":"CN","termSource":"NCI"},{"termName":"UNC-2371A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429882-07-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2MT30EHI63"},{"name":"Maps_To","value":"Flt3/MerTK Inhibitor MRX-2843"},{"name":"NCI_Drug_Dictionary_ID","value":"793562"},{"name":"NCI_META_CUI","value":"CL553239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793562"},{"name":"PDQ_Open_Trial_Search_ID","value":"793562"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1094":{"preferredName":"Fludarabine","code":"C1094","definitions":[{"definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat B-cell chronic lymphocytic leukemia (CLL) that has not responded to treatment with other anticancer drugs or that has gotten worse. Fludarabine blocks cells from making DNA and may kill cancer cells. It is a type of purine antagonist and a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fludarabine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Fluoro-9-beta-arabinofuranosyladenine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Fluorovidarabine","termGroup":"SN","termSource":"NCI"},{"termName":"9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"9-Beta-D-arabinofuranosyl-2-fluoroadenine","termGroup":"SN","termSource":"NCI"},{"termName":"Fluradosa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute nonlymphocytic leukemia; Chronic lymphocytic leukemia; Indolent Non - Hodkins Lymphoma"},{"name":"CAS_Registry","value":"21679-14-1"},{"name":"Chemical_Formula","value":"C10H12FN5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"P2K93U8740"},{"name":"Legacy Concept Name","value":"Fludarabine"},{"name":"Maps_To","value":"Fludarabine"},{"name":"NSC Number","value":"118218"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0059985"}]}}{"C1102":{"preferredName":"Fludarabine Phosphate","code":"C1102","definitions":[{"definition":"A drug used to treat B-cell chronic lymphocytic leukemia (CLL) that has not responded to treatment with other anticancer drugs or that has gotten worse. It is also being studied in the treatment of other types of cancer. Fludara blocks cells from making DNA and may kill cancer cells. It is a type of purine antagonist and a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fludarabine Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"2-F-ara-AMP","termGroup":"AB","termSource":"NCI"},{"termName":"9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Beneflur","termGroup":"FB","termSource":"NCI"},{"termName":"Fludara","termGroup":"AQS","termSource":"NCI"},{"termName":"Fludarabine-5'-Monophosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Oforta","termGroup":"AQS","termSource":"NCI"},{"termName":"SH T 586","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Lymphocytic Leukemia"},{"name":"CAS_Registry","value":"75607-67-9"},{"name":"CHEBI_ID","value":"CHEBI:63599"},{"name":"Chemical_Formula","value":"C10H13FN5O7P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1X9VK9O1SC"},{"name":"Legacy Concept Name","value":"Fludarabine_Phosphate"},{"name":"Maps_To","value":"Fludarabine Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"486428"},{"name":"NSC Number","value":"312887"},{"name":"NSC Number","value":"328002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486428"},{"name":"PDQ_Open_Trial_Search_ID","value":"486428"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060483"}]}}{"C138991":{"preferredName":"Flumbatinib","code":"C138991","definitions":[{"definition":"An orally bioavailable tyrosine kinase inhibitor, with potential antineoplastic activity. Upon administration, flumbatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flumbatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Flumatinib","termGroup":"SY","termSource":"NCI"},{"termName":"HH GV 678","termGroup":"CN","termSource":"NCI"},{"termName":"HH-GV-678","termGroup":"CN","termSource":"NCI"},{"termName":"HH-GV678","termGroup":"CN","termSource":"NCI"},{"termName":"HHGV678","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"895519-90-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R4009Y24AI"},{"name":"Maps_To","value":"Flumatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"763682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763682"},{"name":"PDQ_Open_Trial_Search_ID","value":"763682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3888332"}]}}{"C117723":{"preferredName":"Flumatinib Mesylate","code":"C117723","definitions":[{"definition":"The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flumatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide Mesylate","termGroup":"SN","termSource":"NCI"},{"termName":"HH-GV-678 Mesylate","termGroup":"CN","termSource":"NCI"},{"termName":"HH-GV678 Mesylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"895519-91-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"95Y8L63NBC"},{"name":"Maps_To","value":"Flumatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"763682"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763682"},{"name":"PDQ_Open_Trial_Search_ID","value":"763682"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2973571"}]}}{"C29042":{"preferredName":"Fluorodopan","code":"C29042","definitions":[{"definition":"An alkylating agent with potential antineoplastic activity.  Fluorodopan alkylates DNA at the N7 position of guanine.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorodopan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"834-91-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O1EXJ975PT"},{"name":"Legacy Concept Name","value":"Fluorodopan"},{"name":"Maps_To","value":"Fluorodopan"},{"name":"NSC Number","value":"73754"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060560"}]}}{"C505":{"preferredName":"Fluorouracil","code":"C505","definitions":[{"definition":"A drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorouracil","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Dioxo-5-fluoropyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"5 Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"5 Fluorouracilum","termGroup":"SY","termSource":"NCI"},{"termName":"5 FU","termGroup":"AB","termSource":"NCI"},{"termName":"5-Fluoro-2,4(1H,3H)-pyrimidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"5-Fluracil","termGroup":"SY","termSource":"NCI"},{"termName":"5-FU","termGroup":"AB","termSource":"NCI"},{"termName":"5FU","termGroup":"AB","termSource":"NCI"},{"termName":"AccuSite","termGroup":"FB","termSource":"NCI"},{"termName":"Adrucil","termGroup":"AQS","termSource":"NCI"},{"termName":"Carac","termGroup":"BR","termSource":"NCI"},{"termName":"Fluoro Uracil","termGroup":"SY","termSource":"NCI"},{"termName":"Fluouracil","termGroup":"SY","termSource":"NCI"},{"termName":"Flurablastin","termGroup":"FB","termSource":"NCI"},{"termName":"Fluracedyl","termGroup":"FB","termSource":"NCI"},{"termName":"Fluracil","termGroup":"FB","termSource":"NCI"},{"termName":"Fluril","termGroup":"FB","termSource":"NCI"},{"termName":"Fluroblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Ribofluor","termGroup":"FB","termSource":"NCI"},{"termName":"Ro-2-9757","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Palliative treatment: Colorectal cancer, Breast cancer, Stomach cancer, Pancreatic cancer. Topical treatment for the following: Superficial basal cell carcinoma that cannot be treated with surgery, and Actinic keratosis."},{"name":"CAS_Registry","value":"51-21-8"},{"name":"CHEBI_ID","value":"CHEBI:46345"},{"name":"Chemical_Formula","value":"C4H3FN2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U3P01618RT"},{"name":"Legacy Concept Name","value":"Fluorouracil"},{"name":"Maps_To","value":"Fluorouracil"},{"name":"NCI_Drug_Dictionary_ID","value":"43130"},{"name":"NSC Number","value":"19893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43130"},{"name":"PDQ_Open_Trial_Search_ID","value":"43130"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016360"}]}}{"C90544":{"preferredName":"Fluorouracil Implant","code":"C90544","definitions":[{"definition":"An implant containing a sustained release particle of fluorouracil, an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine, with antineoplastic activity. Upon implantation and subsequent release, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with the pyrimidine uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and thus DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorouracil Implant","termGroup":"PT","termSource":"NCI"},{"termName":"Sinofuan","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fluorouracil Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"665364"},{"name":"NCI_META_CUI","value":"CL416225"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665364"},{"name":"PDQ_Open_Trial_Search_ID","value":"665364"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C17877":{"preferredName":"Fluorouracil-E Therapeutic Implant","code":"C17877","definitions":[{"definition":"An injectable collagen matrix gel containing the antimetabolite fluorouracil and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and, so, DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into tumor tissue and reduce dispersion to surrounding tissues, thus enhancing the local concentration of fluorouracil. Compared to systemic administration, the intratumoral injection of fluorouracil combined with epinephrine may increase fluorouracil's chemotherapeutic efficacy while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorouracil-E Therapeutic Implant","termGroup":"PT","termSource":"NCI"},{"termName":"5-Fluorouracil/epi","termGroup":"SY","termSource":"NCI"},{"termName":"5-FU-e TI","termGroup":"SY","termSource":"NCI"},{"termName":"5-FU/epi gel","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouracil-E Therapeutic Implant","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouracil-epinephrine therapeutic implant","termGroup":"SY","termSource":"NCI"},{"termName":"Fluorouracil/epi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fluorouracil-E_Therapeutic_Implant"},{"name":"Maps_To","value":"Fluorouracil-E Therapeutic Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"41859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41859"},{"name":"PDQ_Open_Trial_Search_ID","value":"41859"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281426"}]}}{"C507":{"preferredName":"Fluoxymesterone","code":"C507","definitions":[{"definition":"A halogenated derivative of 17-alpha-methyltestosterone.  Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus.  This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluoxymesterone","termGroup":"PT","termSource":"NCI"},{"termName":"(11Beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"11Beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"9Alpha-fluoro-11beta-hydroxy-17alpha-methyltestosterone","termGroup":"SN","termSource":"NCI"},{"termName":"Androfluorene","termGroup":"SY","termSource":"NCI"},{"termName":"Android-F","termGroup":"BR","termSource":"NCI"},{"termName":"Androsterolo","termGroup":"SY","termSource":"NCI"},{"termName":"Androxy","termGroup":"BR","termSource":"NCI"},{"termName":"FXM","termGroup":"AB","termSource":"NCI"},{"termName":"Halodrin","termGroup":"BR","termSource":"NCI"},{"termName":"Halotestin","termGroup":"BR","termSource":"NCI"},{"termName":"Ora-Testryl","termGroup":"BR","termSource":"NCI"},{"termName":"Oratestin","termGroup":"FB","termSource":"NCI"},{"termName":"Stenox","termGroup":"FB","termSource":"NCI"},{"termName":"Testoral","termGroup":"FB","termSource":"NCI"},{"termName":"Ultandren","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"76-43-7"},{"name":"CHEBI_ID","value":"CHEBI:5120"},{"name":"Chemical_Formula","value":"C20H29FO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9JU12S4YFY"},{"name":"Legacy Concept Name","value":"Fluoxymesterone"},{"name":"Maps_To","value":"Fluoxymesterone"},{"name":"NCI_Drug_Dictionary_ID","value":"494707"},{"name":"NSC Number","value":"12165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"494707"},{"name":"PDQ_Open_Trial_Search_ID","value":"494707"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016366"}]}}{"C509":{"preferredName":"Flutamide","code":"C509","definitions":[{"definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of antiandrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Flutamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Nitro-3'-trifluoromethylisobutyranilide","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha,alpha,alpha-trifluoro-2-methy-4'-nitro-m-propionotoluidide","termGroup":"SN","termSource":"NCI"},{"termName":"Apimid","termGroup":"FB","termSource":"NCI"},{"termName":"Cebatrol","termGroup":"FB","termSource":"NCI"},{"termName":"Chimax","termGroup":"FB","termSource":"NCI"},{"termName":"Cytomid","termGroup":"FB","termSource":"NCI"},{"termName":"Drogenil","termGroup":"FB","termSource":"NCI"},{"termName":"Euflex","termGroup":"FB","termSource":"NCI"},{"termName":"Eulexin","termGroup":"AQS","termSource":"NCI"},{"termName":"Eulexine","termGroup":"FB","termSource":"NCI"},{"termName":"Flucinom","termGroup":"SY","termSource":"NCI"},{"termName":"Flucinome","termGroup":"FB","termSource":"NCI"},{"termName":"Flugerel","termGroup":"SY","termSource":"NCI"},{"termName":"Fluken","termGroup":"FB","termSource":"NCI"},{"termName":"Flulem","termGroup":"FB","termSource":"NCI"},{"termName":"FLUT","termGroup":"AB","termSource":"NCI"},{"termName":"Fluta-Gry","termGroup":"FB","termSource":"NCI"},{"termName":"Flutabene","termGroup":"FB","termSource":"NCI"},{"termName":"Flutacan","termGroup":"FB","termSource":"NCI"},{"termName":"Flutamex","termGroup":"FB","termSource":"NCI"},{"termName":"Flutamin","termGroup":"FB","termSource":"NCI"},{"termName":"Flutan","termGroup":"FB","termSource":"NCI"},{"termName":"Flutaplex","termGroup":"FB","termSource":"NCI"},{"termName":"Fugerel","termGroup":"FB","termSource":"NCI"},{"termName":"Grisetin","termGroup":"FB","termSource":"NCI"},{"termName":"Niftolide","termGroup":"SY","termSource":"NCI"},{"termName":"Oncosal","termGroup":"FB","termSource":"NCI"},{"termName":"Profamid","termGroup":"FB","termSource":"NCI"},{"termName":"Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"Prostacur","termGroup":"FB","termSource":"NCI"},{"termName":"Prostadirex","termGroup":"FB","termSource":"NCI"},{"termName":"Prostica","termGroup":"FB","termSource":"NCI"},{"termName":"Prostogenat","termGroup":"FB","termSource":"NCI"},{"termName":"SCH 13521","termGroup":"CN","termSource":"NCI"},{"termName":"Tafenil","termGroup":"FB","termSource":"NCI"},{"termName":"Tecnoflut","termGroup":"FB","termSource":"NCI"},{"termName":"Testotard","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hirsutism; Prostate carcinoma"},{"name":"CAS_Registry","value":"13311-84-7"},{"name":"CHEBI_ID","value":"CHEBI:5132"},{"name":"Chemical_Formula","value":"C11H11F3N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"76W6J0943E"},{"name":"Legacy Concept Name","value":"Flutamide"},{"name":"Maps_To","value":"Flutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39811"},{"name":"NSC Number","value":"147834"},{"name":"NSC Number","value":"215876"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39811"},{"name":"PDQ_Open_Trial_Search_ID","value":"39811"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016384"}]}}{"C61768":{"preferredName":"Fluvastatin","code":"C61768","definitions":[{"definition":"A synthetic lipid-lowering agent with antilipidemic and potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated antigen-presenting cells such as human vascular endothelial cells. Due to its anti-inflammatory effects mediated by alterations of lipid metabolism, fluvastatin may possess chemopreventive and therapeutic antineoplastic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluvastatin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93957-54-1"},{"name":"CHEBI_ID","value":"CHEBI:38561"},{"name":"CHEBI_ID","value":"CHEBI:5136"},{"name":"Chemical_Formula","value":"C24H26FNO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4L066368AS"},{"name":"Legacy Concept Name","value":"Fluvastatin"},{"name":"Maps_To","value":"Fluvastatin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0082608"}]}}{"C29062":{"preferredName":"Fluvastatin Sodium","code":"C29062","definitions":[{"definition":"The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic activity. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Through the inhibition of mevalonate synthesis, statins, like fluvastatin, have been shown to inhibit the production of dolichol, geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP) and the isoprenylation of the intracellular G-proteins Ras and Rho, which may result in antiangiogenic, apoptotic, and antimetastatic effects in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluvastatin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,5S,6E)-(+/-)-7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Lescol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93957-55-2"},{"name":"Chemical_Formula","value":"C24H25FNO4.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PYF7O1FV7F"},{"name":"Legacy Concept Name","value":"Fluvastatin_Sodium"},{"name":"Maps_To","value":"Fluvastatin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"487588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487588"},{"name":"PDQ_Open_Trial_Search_ID","value":"487588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0246203"}]}}{"C126274":{"preferredName":"Fuzuloparib","code":"C126274","definitions":[{"definition":"An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration, fuzuloparib inhibits PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks, promotes genomic instability, and leads to an induction of apoptosis. The PARP family of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fuzuloparib","termGroup":"PT","termSource":"NCI"},{"termName":"4-((3-((5,6-Dihydro-2-(trifluoromethyl)(1,2,4)triazolo(1,5-a)pyrazin-7(8H)-yl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinone","termGroup":"SY","termSource":"NCI"},{"termName":"AiRuiYi","termGroup":"BR","termSource":"NCI"},{"termName":"Fluzoparib","termGroup":"SY","termSource":"NCI"},{"termName":"SHR-3162","termGroup":"CN","termSource":"NCI"},{"termName":"SHR3162","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1358715-18-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TWF0ML1CK8"},{"name":"Maps_To","value":"Fluzoparib"},{"name":"NCI_Drug_Dictionary_ID","value":"779303"},{"name":"NCI_META_CUI","value":"CL504851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779303"},{"name":"PDQ_Open_Trial_Search_ID","value":"779303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101519":{"preferredName":"Edicotinib","code":"C101519","definitions":[{"definition":"A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. Edicotinib blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS can not activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells. FMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation, recruitment, and activation as well as the regulation of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Edicotinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Imidazole-2-carboxamide, 5-Cyano-N-(2-(4,4-dimethyl-1-cyclohexen-1-yl)-6-(tetrahydro-2,2,6,6-tetramethyl-2H-pyran-4-yl)-3-pyridinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyl-tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"JNJ-40346527","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1142363-52-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3NU609VYNF"},{"name":"Maps_To","value":"Edicotinib"},{"name":"Maps_To","value":"FMS Inhibitor JNJ-40346527"},{"name":"NCI_Drug_Dictionary_ID","value":"730665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730665"},{"name":"PDQ_Open_Trial_Search_ID","value":"730665"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640124"}]}}{"C105804":{"preferredName":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate","code":"C105804","definitions":[{"definition":"The tosylate salt form of PLX7486, a selective inhibitor of the receptor tyrosine kinases colony-stimulating factor-1 receptor (CSF1R; fms) and neurotrophic tyrosine kinase receptor types 1, 2 and 3 (TrkA, TrkB, and TrkC, respectively) with potential antineoplastic activity. Upon administration, PLX7486 binds to and inhibits the activity of these tyrosine kinases. This inhibits Fms and Trk-mediated signaling transduction pathways that are upregulated in certain cancer cell types. This may eventually halt tumor cell proliferation in Fms and TrkA, TrkB, and/or TrkC-overexpressing tumor cells. Fms and TrkA, TrkB, and TrkC are receptor tyrosine kinases that are upregulated or mutated in a variety of tumors and promote tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"PLX7486-TsOH","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"747694"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747694"},{"name":"PDQ_Open_Trial_Search_ID","value":"747694"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3830093"}]}}{"C71524":{"preferredName":"Folate Receptor Targeted Epothilone BMS753493","code":"C71524","definitions":[{"definition":"A folate receptor-targeting antimitotic agent with potential antineoplastic activity. Folate receptor-targeted epothilone BMS753493 contains an epothilone moiety linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the antimitotic epothilone component into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the epothilone moiety induces microtubule polymerization and stabilizes microtubules against depolymerization, resulting in the inhibition of mitosis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor Targeted Epothilone BMS753493","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Folate_Receptor-Targeted_Epothilone_BMS753493"},{"name":"Maps_To","value":"Folate Receptor Targeted Epothilone BMS753493"},{"name":"NCI_Drug_Dictionary_ID","value":"575735"},{"name":"NCI_META_CUI","value":"CL376231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575735"},{"name":"PDQ_Open_Trial_Search_ID","value":"575735"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113176":{"preferredName":"Folate Receptor-Targeted Tubulysin Conjugate EC1456","code":"C113176","definitions":[{"definition":"An injectable targeted small molecule drug conjugate (SMDC) consisting of folate (vitamin B9) covalently linked to the potent mitotic poison and cytotoxic agent, tubulysin B hydrazide (Tub-B-H) with potential antineoplastic activity. Upon administration, the folate moiety of folate receptor-targeted tubulysin conjugate EC1456 preferentially binds to tumor cells expressing folate receptors (FR). After binding to FR, the agent is internalized by tumor cells and the Tub-B-H moiety inhibits the polymerization of tubulin into microtubules. This may lead to both cell cycle arrest and tumor cell apoptosis. FR, the membrane-bound, high-affinity receptor for folate, is overexpressed on a wide range of primary and metastatic human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor-Targeted Tubulysin Conjugate EC1456","termGroup":"PT","termSource":"NCI"},{"termName":"EC1456","termGroup":"CN","termSource":"NCI"},{"termName":"Folate Receptor-Targeting Folate-Tubulysin Conjugate EC1456","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Folate Receptor-Targeted Tubulysin Conjugate EC1456"},{"name":"NCI_Drug_Dictionary_ID","value":"755557"},{"name":"NCI_META_CUI","value":"CL455247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755557"},{"name":"PDQ_Open_Trial_Search_ID","value":"755557"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C81935":{"preferredName":"Folate Receptor-Targeted Vinca Alkaloid EC0489","code":"C81935","definitions":[{"definition":"A folate receptor-targeting cytotoxic drug conjugate consisting of a folate vitamin analogue linked to a vinca alkaloid microtubule destabilizing agent with potential antineoplastic activity. Mediated through its folate moiety, folate receptor-targeted vinca alkaloid EC0489 delivers the cytotoxic vinca alkaloid moiety directly to cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. The relative tumor cell specificity of this agent reduces the toxicity profile of its vinca alkaloid moiety.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor-Targeted Vinca Alkaloid EC0489","termGroup":"PT","termSource":"NCI"},{"termName":"EC0489","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Folate_Receptor_Targeted-Microtubule_Destabilizing_Agent_EC0489"},{"name":"Maps_To","value":"Folate Receptor-Targeted Vinca Alkaloid EC0489"},{"name":"NCI_Drug_Dictionary_ID","value":"638649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638649"},{"name":"PDQ_Open_Trial_Search_ID","value":"638649"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830054"}]}}{"C66987":{"preferredName":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225","code":"C66987","definitions":[{"definition":"A folate receptor-targeting cytotoxic agent with potential antineoplastic activity. Folate receptor-targeted vinca alkaloid/mitomycin C EC0225 contains two potent cytotoxic agents, a vinca alkaloid and mitomycin C, linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the cytotoxic agents directly into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. Mitomycin C alkylates DNA, producing DNA cross-links and inhibiting DNA replication. The relative tumor cell specificity of EC0225 reduces the toxicity profiles of its cytotoxic agent moieties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225","termGroup":"PT","termSource":"NCI"},{"termName":"EC0225","termGroup":"CN","termSource":"NCI"},{"termName":"Folate Linked Vinca Alkaloid/Mitomycin C EC0225","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EC0225"},{"name":"Maps_To","value":"Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225"},{"name":"NCI_Drug_Dictionary_ID","value":"539691"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539691"},{"name":"PDQ_Open_Trial_Search_ID","value":"539691"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880433"}]}}{"C62479":{"preferredName":"Folate-FITC","code":"C62479","definitions":[{"definition":"A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folate-FITC","termGroup":"PT","termSource":"NCI"},{"termName":"EC-17","termGroup":"CN","termSource":"NCI"},{"termName":"EC17","termGroup":"AB","termSource":"NCI"},{"termName":"Folate Fluorescein Isothiocyanate Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"L-glutamine, N2-(4-(((2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-n-(2-((((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3h),9'-(9h)xanthen)-5-yl)amino)thioxomethyl)amino)ethyl)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"583037-91-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7YQ6134AE"},{"name":"Legacy Concept Name","value":"EC17"},{"name":"Maps_To","value":"Folate-FITC"},{"name":"NCI_Drug_Dictionary_ID","value":"489286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489286"},{"name":"PDQ_Open_Trial_Search_ID","value":"489286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831885"}]}}{"C510":{"preferredName":"Folic Acid","code":"C510","definitions":[{"definition":"A collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. As a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Folate helps to make red blood cells. It is found in whole-grain breads and cereals, liver, green vegetables, orange juice, lentils, beans, and yeast. Folate is water-soluble (can dissolve in water) and must be taken in every day. Not enough folate can cause anemia (a condition in which the number of red blood cells is below normal), diseases of the heart and blood vessels, and defects in the brain and spinal cord in a fetus. Folate is being studied with vitamin B12 in the prevention and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Synthetic folate in fortified foods and supplements containing a single glutamate molecule.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Folic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid","termGroup":"SY","termSource":"NCI"},{"termName":"FA","termGroup":"AB","termSource":"NCI"},{"termName":"Ffolate","termGroup":"SY","termSource":"NCI"},{"termName":"Folacin","termGroup":"SY","termSource":"NCI"},{"termName":"N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid","termGroup":"SN","termSource":"NCI"},{"termName":"N-[4-[[(2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Vitamin B9","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin Bc","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59-30-3"},{"name":"CHEBI_ID","value":"CHEBI:27470"},{"name":"Chemical_Formula","value":"C19H19N7O6"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"935E97BOY8"},{"name":"INFOODS","value":"FOLAC"},{"name":"Legacy Concept Name","value":"Folic_Acid"},{"name":"Maps_To","value":"Folic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"39641"},{"name":"NSC Number","value":"3073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39641"},{"name":"PDQ_Open_Trial_Search_ID","value":"39641"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"Tolerable_Level","value":"Y"},{"name":"UMLS_CUI","value":"C0016410"},{"name":"Unit","value":"mcg"},{"name":"US_Recommended_Intake","value":"Y* (*for women of childbearing age)"},{"name":"USDA_ID","value":"431"}]}}{"C61304":{"preferredName":"Folitixorin","code":"C61304","definitions":[{"definition":"A folate-based biomodulator with potential antineoplastic activity. 5,10-methylenetetrahydrofolate (MTHF) stabilizes the covalent binding of the fluorouracil metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP) to its target enzyme, thymidylate synthase, which results in inhibition of thymidylate synthase, depletion of thymidine triphosphate (TTP), a necessary constituent of DNA, and tumor cell death. Unlike leucovorin, MTHF, as the active form of folate, does not require metabolic activation and may increase the chemotherapeutic effects of fluorouracil with lower toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Folitixorin","termGroup":"PT","termSource":"NCI"},{"termName":"5,10-methylene-5,6,7,8-tetrahydrofolic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5,10-Methylenetetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"CoFactor","termGroup":"BR","termSource":"NCI"},{"termName":"N-(4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Tetrahydromethylenefolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3432-99-3"},{"name":"CHEBI_ID","value":"CHEBI:1989"},{"name":"Chemical_Formula","value":"C20H23N7O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0SXY5ET48B"},{"name":"Legacy Concept Name","value":"_5_10-Methylenetetrahydrofolate"},{"name":"Maps_To","value":"Folitixorin"},{"name":"NCI_Drug_Dictionary_ID","value":"405875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"405875"},{"name":"PDQ_Open_Trial_Search_ID","value":"405875"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048858"}]}}{"C80058":{"preferredName":"Foretinib","code":"C80058","definitions":[{"definition":"A substance being studied in the treatment of cancer. Foretinib blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foretinib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1363089","termGroup":"CN","termSource":"NCI"},{"termName":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","termGroup":"SY","termSource":"NCI"},{"termName":"N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"XL880","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849217-64-7"},{"name":"Chemical_Formula","value":"C34H34F2N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81FH7VK1C4"},{"name":"Legacy Concept Name","value":"Multitargeted_Tyrosine_Kinase_Inhibitor_GSK1363089"},{"name":"Maps_To","value":"Foretinib"},{"name":"NCI_Drug_Dictionary_ID","value":"428188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"428188"},{"name":"PDQ_Open_Trial_Search_ID","value":"428188"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698272"}]}}{"C974":{"preferredName":"Formestane","code":"C974","definitions":[{"definition":"A synthetic steroidal substance with antineoplastic activity.  Formestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formestane","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hydroxyandrost-4-ene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hydroxyandrostenedione","termGroup":"SY","termSource":"NCI"},{"termName":"4-OHA","termGroup":"AB","termSource":"NCI"},{"termName":"4-OHAD","termGroup":"AB","termSource":"NCI"},{"termName":"CGP-32349","termGroup":"CN","termSource":"NCI"},{"termName":"Lentaron","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"566-48-3"},{"name":"Chemical_Formula","value":"C19H26O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PUB9T8T355"},{"name":"Legacy Concept Name","value":"Formestane"},{"name":"Maps_To","value":"Formestane"},{"name":"NCI_Drug_Dictionary_ID","value":"41766"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41766"},{"name":"PDQ_Open_Trial_Search_ID","value":"41766"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048306"}]}}{"C26655":{"preferredName":"Forodesine Hydrochloride","code":"C26655","definitions":[{"definition":"A substance being studied in the treatment of some types of leukemia and lymphoma. It is a type of purine nucleoside phosphorylase (PNP) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the synthetic high-affinity transition-state analogue forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes. A transition state analogue is a substrate designed to mimic the properties or the geometry of the transition state of reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Forodesine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BCX 1777","termGroup":"CN","termSource":"NCI"},{"termName":"BCX-1777","termGroup":"CN","termSource":"NCI"},{"termName":"BCX1777","termGroup":"CN","termSource":"NCI"},{"termName":"Fodosine","termGroup":"FB","termSource":"NCI"},{"termName":"Immucillin-H","termGroup":"SY","termSource":"NCI"},{"termName":"Mundesine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"284490-13-7"},{"name":"Chemical_Formula","value":"C11H14N4O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SN82Y9U73"},{"name":"Legacy Concept Name","value":"Immucillin-H"},{"name":"Maps_To","value":"Forodesine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"301648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301648"},{"name":"PDQ_Open_Trial_Search_ID","value":"301648"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1175653"}]}}{"C72787":{"preferredName":"Fosaprepitant","code":"C72787","definitions":[{"definition":"A water-soluble, N-phosphorylated prodrug of the substance P (SP; neurokinin 1 (NK1)) antagonist aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent selectively binds to and blocks the human substance P receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosaprepitant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"172673-20-0"},{"name":"CHEBI_ID","value":"CHEBI:64321"},{"name":"Chemical_Formula","value":"C23H22F7N4O6P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6L8OF9XRDC"},{"name":"Legacy Concept Name","value":"Fosaprepitant"},{"name":"Maps_To","value":"Fosaprepitant"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2349941"}]}}{"C82378":{"preferredName":"Fosbretabulin","code":"C82378","definitions":[{"definition":"A water-soluble prodrug derived from the African bush willow (Combretum caffrum) with antineoplastic activity. Fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which binds to tubulin and inhibits microtubule polymerization, resulting in mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosbretabulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Combretastatin A-4 Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, Dihydrogen Phosphate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222030-63-9"},{"name":"Chemical_Formula","value":"C18H21O8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I5590ES2QZ"},{"name":"Legacy Concept Name","value":"Fosbretabulin"},{"name":"Maps_To","value":"Fosbretabulin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796467"}]}}{"C2503":{"preferredName":"Fosbretabulin Disodium","code":"C2503","definitions":[{"definition":"The disodium salt of a water-soluble phosphate derivative of a natural stilbenoid phenol derived from the African bush willow (Combretum caffrum) with potential vascular disrupting and antineoplastic activities. Upon administration, the prodrug fosbretabulin is dephosphorylated to its active metabolite, the microtubule-depolymerizing agent combretastatin A4, which binds to tubulin dimers and prevents microtubule polymerization, resulting in mitotic arrest and apoptosis in endothelial cells. In addition, this agent disrupts the engagement of the endothelial cell-specific junctional molecule vascular endothelial-cadherin (VE-cadherin) and so the activity of the VE-cadherin/beta-catenin/Akt signaling pathway, which may result in the inhibition of endothelial cell migration and capillary tube formation. As a result of fosbretabulin's dual mechanism of action, the tumor vasculature collapses, resulting in reduced tumor blood flow and ischemic necrosis of tumor tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosbretabulin Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl Disodium Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"CA4DP","termGroup":"CN","termSource":"NCI"},{"termName":"Combretastatin A4 Disodium Phosphate","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, Dihydrogen Phosphate, Disodium Salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"222030-63-9"},{"name":"Chemical_Formula","value":"C18H19O8P.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"702RHR475O"},{"name":"Legacy Concept Name","value":"Combretastatin_A4_Phosphate"},{"name":"Maps_To","value":"Fosbretabulin Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43316"},{"name":"PDQ_Open_Trial_Search_ID","value":"43316"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0962508"}]}}{"C83721":{"preferredName":"Fosbretabulin Tromethamine","code":"C83721","definitions":[{"definition":"The tromethamine salt form of prodrug fosbretabulin, a water-soluble phosphate derivative of a stilbenoid phenol derived from the African bush willow (Combretum caffrum) with antineoplastic activities. Upon administration, fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which targets and binds to tubulin dimers and prevents microtubule polymerization, thereby resulting in mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosbretabulin Tromethamine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Dihydroxy-2-(Hydroxymethyl)Propan-2-Aminium 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Hydrogen Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"1,3-Propanediol, 2-Amino-2-(Hydroxymethyl)-, Compd. With 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Dihydrogen Phosphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CA4P","termGroup":"AB","termSource":"NCI"},{"termName":"Zybrestat","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"404886-32-4"},{"name":"Chemical_Formula","value":"C18H21O8P.C4H11NO3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GBW044919E"},{"name":"Maps_To","value":"Fosbretabulin Tromethamine"},{"name":"NCI_Drug_Dictionary_ID","value":"696306"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696306"},{"name":"PDQ_Open_Trial_Search_ID","value":"696306"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827157"}]}}{"C123824":{"preferredName":"Foslinanib","code":"C123824","definitions":[{"definition":"An orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foslinanib","termGroup":"PT","termSource":"NCI"},{"termName":"4(1H)-Quinolinone, 2-(3-Fluorophenyl)-6-methoxy-5-(phosphonooxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"CVM 1118","termGroup":"CN","termSource":"NCI"},{"termName":"CVM-1118","termGroup":"CN","termSource":"NCI"},{"termName":"CVM1118","termGroup":"CN","termSource":"NCI"},{"termName":"TRX 818","termGroup":"CN","termSource":"NCI"},{"termName":"TRX-818","termGroup":"CN","termSource":"NCI"},{"termName":"TRX818","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10721","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256037-60-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2X2DNM7NGX"},{"name":"Maps_To","value":"Foslinanib"},{"name":"NCI_Drug_Dictionary_ID","value":"775625"},{"name":"NCI_META_CUI","value":"CL498218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775625"},{"name":"PDQ_Open_Trial_Search_ID","value":"775625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163994":{"preferredName":"Foslinanib Disodium","code":"C163994","definitions":[{"definition":"The disodium salt form of foslinanib, an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foslinanib Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"4(1H)-Quinolinone, 2-(3-Fluorophenyl)-6-methoxy-5-(phosphonooxy)-, Sodium Salt (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"CVM-1118 Disodium","termGroup":"SY","termSource":"NCI"},{"termName":"TRX-818","termGroup":"CN","termSource":"NCI"},{"termName":"TRX818 Disodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256037-62-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8X5F5LAF7B"},{"name":"Maps_To","value":"Foslinanib Disodium"},{"name":"NCI_META_CUI","value":"CL977259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1371":{"preferredName":"Fosquidone","code":"C1371","definitions":[{"definition":"A water-soluble pentacyclic pyrolloquinone analogue of mitoquidone with potential antineoplastic activity. Currently, the mechanism of action of fosquidone is unknown. In vitro studies indicate that this agent does not bind to DNA or inhibit topoisomerases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosquidone","termGroup":"PT","termSource":"NCI"},{"termName":"GR 63178A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114517-02-1"},{"name":"Chemical_Formula","value":"C28H22NO6P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"NSC D611615 from CCR."},{"name":"FDA_UNII_Code","value":"FD6QP9BP8U"},{"name":"Legacy Concept Name","value":"Fosquidone"},{"name":"Maps_To","value":"Fosquidone"},{"name":"NCI_Drug_Dictionary_ID","value":"41153"},{"name":"NSC Number","value":"611615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41153"},{"name":"PDQ_Open_Trial_Search_ID","value":"41153"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0118171"}]}}{"C1372":{"preferredName":"Fostriecin","code":"C1372","definitions":[{"definition":"An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fostriecin","termGroup":"PT","termSource":"NCI"},{"termName":"2H-pyran-2-one,5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11,-tridecatetraenyl)-,trans","termGroup":"SN","termSource":"NCI"},{"termName":"FST","termGroup":"AB","termSource":"NCI"},{"termName":"Phosphotrienin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87810-56-8"},{"name":"Chemical_Formula","value":"C19H27O9P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZO1648L551"},{"name":"Legacy Concept Name","value":"Fostriecin"},{"name":"Maps_To","value":"Fostriecin"},{"name":"NCI_Drug_Dictionary_ID","value":"41703"},{"name":"NSC Number","value":"339638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41703"},{"name":"PDQ_Open_Trial_Search_ID","value":"41703"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0118175"}]}}{"C1106":{"preferredName":"Fotemustine","code":"C1106","definitions":[{"definition":"A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of brain tumors and metastatic melanoma of the eye. It is a type of nitrosourea.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Fotemustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-[N-(2-chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"[1-[[[(2-chloroethyl)nitrosamino]-carbonyl]amino]ethyl]phosphonic acid diethyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"diethyl[1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate","termGroup":"SN","termSource":"NCI"},{"termName":"Muphoran","termGroup":"FB","termSource":"NCI"},{"termName":"S 10036","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92118-27-9"},{"name":"Chemical_Formula","value":"C9H19ClN3O5P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"GQ7JL9P5I2"},{"name":"Legacy Concept Name","value":"Fotemustine"},{"name":"Maps_To","value":"Fotemustine"},{"name":"NCI_Drug_Dictionary_ID","value":"38865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38865"},{"name":"PDQ_Open_Trial_Search_ID","value":"38865"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060696"}]}}{"C65767":{"preferredName":"Fotretamine","code":"C65767","definitions":[{"definition":"A pentaethyleneimine derivative with antineoplastic alkylating activity. Fotretamine causes chromosomal breaks in lymphocytes which contributes to its immunosuppressive activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fotretamine","termGroup":"PT","termSource":"NCI"},{"termName":"2,2,4,4,6-Pentaethylenimino-6-morpholino-cyclotriphosphazatrien","termGroup":"SN","termSource":"NCI"},{"termName":"Fotrin","termGroup":"SY","termSource":"NCI"},{"termName":"Photrin","termGroup":"SY","termSource":"NCI"},{"termName":"Photrine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37132-72-2"},{"name":"Chemical_Formula","value":"C14H28N9OP3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7Z7670589C"},{"name":"Legacy Concept Name","value":"Fotretamine"},{"name":"Maps_To","value":"Fotretamine"},{"name":"NSC Number","value":"216135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060698"}]}}{"C141298":{"preferredName":"FPV Vaccine CV301","code":"C141298","definitions":[{"definition":"A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration following the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine MVA-BN-CV301, the FPV vaccine CV301, which is used as a booster vaccine, activates a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when FPV-CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. The TAAs CEA and MUC-1 are overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FPV Vaccine CV301","termGroup":"PT","termSource":"NCI"},{"termName":"Boost Vaccine FPV-CV301","termGroup":"SY","termSource":"NCI"},{"termName":"Fowlpox-based FPV-CV301","termGroup":"SY","termSource":"NCI"},{"termName":"FPV-CV-301","termGroup":"SY","termSource":"NCI"},{"termName":"FPV-CV301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FPV Vaccine CV301"},{"name":"NCI_Drug_Dictionary_ID","value":"797362"},{"name":"NCI_META_CUI","value":"CL539397"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797362"},{"name":"PDQ_Open_Trial_Search_ID","value":"797362"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148402":{"preferredName":"FPV-Brachyury-TRICOM Vaccine","code":"C148402","definitions":[{"definition":"A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FPV-Brachyury-TRICOM Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"FPV-Brachyury","termGroup":"SY","termSource":"NCI"},{"termName":"FPV-Brachyury Boost Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FPV-Brachyury-TRICOM Vaccine"},{"name":"NCI_META_CUI","value":"CL551011"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C63546":{"preferredName":"Fresolimumab","code":"C63546","definitions":[{"definition":"A monoclonal antibody being studied in the treatment of kidney cancer, melanoma, and pulmonary fibrosis. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-TGF-beta monoclonal antibody GC1008 binds to the protein transforming growth factor-beta (TGF?) and may block the growth of cancer cells that make it.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fresolimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TGF-Beta Monoclonal Antibody GC1008","termGroup":"SY","termSource":"NCI"},{"termName":"GC1008","termGroup":"CN","termSource":"NCI"},{"termName":"Human Anti-TGF-Beta Monoclonal Antibody GC1008","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G4, anti-(transforming growth factor beta) (human monoclonal GC-1008 heavy chain), disulfide with human monoclonal GC-1008 light chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, and cancer"},{"name":"CAS_Registry","value":"948564-73-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"375142VBIA"},{"name":"Legacy Concept Name","value":"Anti-TGF-Beta_Monoclonal_Antibody_GC1008"},{"name":"Maps_To","value":"Fresolimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"530302"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530302"},{"name":"PDQ_Open_Trial_Search_ID","value":"530302"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987643"}]}}{"C102852":{"preferredName":"Fruquintinib","code":"C102852","definitions":[{"definition":"An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fruquintinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(6,7-Dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Elunate","termGroup":"FB","termSource":"NCI"},{"termName":"Fruzaqla","termGroup":"BR","termSource":"NCI"},{"termName":"HMPL 013","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-013","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL013","termGroup":"CN","termSource":"NCI"},{"termName":"VEGFR-1/2/3 Inhibitor HMPL-013","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with metastatic colorectal cancer (mCRC)."},{"name":"CAS_Registry","value":"1194506-26-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"49DXG3M5ZW"},{"name":"Maps_To","value":"Fruquintinib"},{"name":"NCI_Drug_Dictionary_ID","value":"737616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737616"},{"name":"PDQ_Open_Trial_Search_ID","value":"737616"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640967"}]}}{"C1379":{"preferredName":"Fulvestrant","code":"C1379","definitions":[{"definition":"A drug used to treat certain types of breast cancer in postmenopausal women. It is also being studied in the treatment of other types of cancer. Faslodex blocks estrogen activity in the body and is a type of antiestrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fulvestrant","termGroup":"PT","termSource":"NCI"},{"termName":"7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol","termGroup":"SN","termSource":"NCI"},{"termName":"Faslodex","termGroup":"BR","termSource":"NCI"},{"termName":"ICI 182,780","termGroup":"CN","termSource":"NCI"},{"termName":"ICI-182780","termGroup":"CN","termSource":"NCI"},{"termName":"ICI182780","termGroup":"CN","termSource":"NCI"},{"termName":"ZD 9238","termGroup":"CN","termSource":"NCI"},{"termName":"ZD-9238","termGroup":"CN","termSource":"NCI"},{"termName":"ZD9238","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hormone receptor-positive metastatic breast cancer"},{"name":"CAS_Registry","value":"129453-61-8"},{"name":"CHEBI_ID","value":"CHEBI:31638"},{"name":"Chemical_Formula","value":"C32H47F5O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"22X328QOC4"},{"name":"Legacy Concept Name","value":"Fulvestrant"},{"name":"Maps_To","value":"Fulvestrant"},{"name":"NCI_Drug_Dictionary_ID","value":"43053"},{"name":"NSC Number","value":"719276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43053"},{"name":"PDQ_Open_Trial_Search_ID","value":"43053"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935916"}]}}{"C88321":{"preferredName":"Fumagillin-Derived Polymer Conjugate XMT-1107","code":"C88321","definitions":[{"definition":"A polymeric prodrug consisting of the fumagillol-derived small molecule XMT-1191 tethered to the hydrophilic, biodegradable70 kDa polymer poly[1-hydroxymethylethylene hydroxymethylformal] (PHF) with potential antiangiogenic and antineoplastic activities. Upon administration, fumagillin-derived polymer conjugate XMT-1107 releases XMT-1191, which may inhibit angiogenesis through the irreversible inhibition of the methionine aminopeptidase 2 (METAP2); although the exact mechanism of action has yet to be fully elucidated, this agent appears to induce cell cycle arrest in endothelial cells, inhibiting their proliferation and migration. Compared to an unconjugated fumagillin analog, XMT-1107 exhibits improved solubility and an extended half life due to its PHF backbone. METAP2, a member of the methionyl aminopeptidase family, binds two cobalt or manganese ions and protects the alpha subunit of eukaryotic initiation factor 2 (EIF2) from inhibitory phosphorylation by removing the amino-terminal methionine residue from nascent protein; this aminopeptidase may be overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fumagillin-Derived Polymer Conjugate XMT-1107","termGroup":"PT","termSource":"NCI"},{"termName":"XMT-1107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fumagillin-Derived Polymer Conjugate XMT-1107"},{"name":"NCI_Drug_Dictionary_ID","value":"660895"},{"name":"NCI_META_CUI","value":"CL413581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660895"},{"name":"PDQ_Open_Trial_Search_ID","value":"660895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121852":{"preferredName":"Fursultiamine","code":"C121852","definitions":[{"definition":"A nutritional supplement and vitamin B1 derivative, with potential antineoplastic activity. Upon oral administration, fursultiamine inhibits the expressions of octamer-binding transcription factor 4 (OCT-4), SRY (sex determining region Y)-box 2 (SOX-2), and Nanog homeobox (NANOG) in cancer stem cells (CSCs). This may inhibit the proliferation of CSCs thereby preventing tumor cell growth. In addition, fursultiamine inhibits the expression of ATP-binding cassette (ABC) transporters subfamily B member 1 (ABCB1) and subfamily G member 2 (ABCG2) in cancer CSCs, which may abrogate resistance to chemo- and radiotherapy in CSCs. CSCs promote tumor initiation, progression and metastasis; they play a key role in cancer recurrence and resistance to chemotherapy and radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fursultiamine","termGroup":"PT","termSource":"NCI"},{"termName":"Formamide, N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-1-methyl-2-(((tetrahydro-2-furanyl)methyl)dithio)-1-butenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Thiamine Tetrahydrofurfuryl Disulfide","termGroup":"SY","termSource":"NCI"},{"termName":"TTFD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"804-30-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05J61265PX"},{"name":"Maps_To","value":"Fursultiamine"},{"name":"NCI_Drug_Dictionary_ID","value":"771695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771695"},{"name":"PDQ_Open_Trial_Search_ID","value":"771695"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016865"}]}}{"C152971":{"preferredName":"Futuximab","code":"C152971","definitions":[{"definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR; ErbB1; HER1), with potential antineoplastic activity. Upon administration, futuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Futuximab","termGroup":"PT","termSource":"NCI"},{"termName":"992 DS","termGroup":"CN","termSource":"NCI"},{"termName":"992-DS","termGroup":"CN","termSource":"NCI"},{"termName":"992DS","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Extracellular Domain III) (Human-Mus Musculus Monoclonal 992 DS Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal 992 DS Light Chain, Dimer","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1310460-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B37J680LX0"},{"name":"Maps_To","value":"Futuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"793850"},{"name":"NCI_META_CUI","value":"CL554174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793850"},{"name":"PDQ_Open_Trial_Search_ID","value":"793850"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91381":{"preferredName":"Futuximab/Modotuximab Mixture","code":"C91381","definitions":[{"definition":"A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain III, with potential antineoplastic activity. Anti-EGFR monoclonal antibody mixture Sym004 binds to the extracellular domain of EGFR, thereby preventing ligand binding. This may prevent activation and subsequent dimerization of the receptor; the decrease in receptor activation may result in an inhibition of downstream ERK and JNK signaling pathways and thus inhibition of EGFR-dependent tumor cell proliferation and metastasis. In addition, binding of Sym004 to EGFRs causes EGFR internalization and degradation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Futuximab/Modotuximab Mixture","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR Monoclonal Antibody Mixture Sym004","termGroup":"SY","termSource":"NCI"},{"termName":"Futuximab/Modotuximab","termGroup":"SY","termSource":"NCI"},{"termName":"Futuximab/Zatuximab","termGroup":"SY","termSource":"NCI"},{"termName":"Sym004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Futuximab/Modotuximab Mixture"},{"name":"NCI_Drug_Dictionary_ID","value":"673604"},{"name":"NCI_META_CUI","value":"CL421582"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673604"},{"name":"PDQ_Open_Trial_Search_ID","value":"673604"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95893":{"preferredName":"G-Quadruplex Stabilizer BMVC","code":"C95893","definitions":[{"definition":"A carbazole derivative (3,6-bis[2-(1-methylpyridinium)vinyl]carbazole diiodide) that selectively targets to the G-quadruplex DNA structure, used as a fluorescent probe for cancer cytological diagnosis and with potential antitumor activity. G-quadruplex stabilizer BMVC, preferentially uptaken by cancer cells, binds to and stabilize the telomeric G-quadruplex structure at the end of DNA; when visualized with fluorescent imaging device, BMVC emits bright fluorescent light and can be used to differentiate tumor cells from normal cells. The BMVC/G-quadruplex complexes also interfere with the activity of telomerase, which is highly active in tumor cells and plays a key role in tumorigenesis while expressed at very low levels in most somatic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"G-Quadruplex Stabilizer BMVC","termGroup":"PT","termSource":"NCI"},{"termName":"3,6-bis (1-methyl-4-vinylpyridinium) Carbazole Diiodide","termGroup":"SN","termSource":"NCI"},{"termName":"3,6-bis[2-(1-methylpyridinium)vinyl]carbazole Diiodide","termGroup":"SN","termSource":"NCI"},{"termName":"BMVC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"G-Quadruplex Stabilizer BMVC"},{"name":"NCI_Drug_Dictionary_ID","value":"696431"},{"name":"NCI_META_CUI","value":"CL428290"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696431"},{"name":"PDQ_Open_Trial_Search_ID","value":"696431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C76791":{"preferredName":"Galamustine","code":"C76791","definitions":[{"definition":"A galactose mustard compound, an alkylating agent, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galamustine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"105618-02-8"},{"name":"Chemical_Formula","value":"C10H19Cl2NO5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P771FDQ1WJ"},{"name":"Legacy Concept Name","value":"Galamustine"},{"name":"Maps_To","value":"Galamustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700228"}]}}{"C81422":{"preferredName":"Galarubicin","code":"C81422","definitions":[{"definition":"An anthracycline derivative with antineoplastic activity developed to circumvent doxorubicin resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,10S)-10-((2.6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 8(sup 2)-ester with Beta-alanine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"140637-86-1"},{"name":"Chemical_Formula","value":"C30H32FNO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6F39648E92"},{"name":"Legacy Concept Name","value":"Galarubicin"},{"name":"Maps_To","value":"Galarubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825624"}]}}{"C115111":{"preferredName":"Belapectin","code":"C115111","definitions":[{"definition":"A carbohydrate-based galectin inhibitor, with potential antineoplastic activity. Belapectin binds to the carbohydrate-binding domain of galectins, especially galectin-3, and may result in an induction of apoptosis mediated through activation of both mitochondria and caspases. This may reduce tumor growth in galectin-overexpressing tumor cells. Galectins, often overexpressed on tumor cells, play a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belapectin","termGroup":"PT","termSource":"NCI"},{"termName":"Galactoarabino-rhamnogalacturonate","termGroup":"SY","termSource":"NCI"},{"termName":"GR-MD-02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1980787-47-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K7ODU55HT6"},{"name":"Maps_To","value":"Belapectin"},{"name":"Maps_To","value":"Galectin Inhibitor GR-MD-02"},{"name":"NCI_Drug_Dictionary_ID","value":"760131"},{"name":"NCI_META_CUI","value":"CL472642"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760131"},{"name":"PDQ_Open_Trial_Search_ID","value":"760131"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103828":{"preferredName":"Galectin-1 Inhibitor OTX008","code":"C103828","definitions":[{"definition":"A calixarene-based compound and galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. Upon subcutaneous administration, galectin-1 inhibitor OTX008 binds Gal-1 which leads to Gal-1 oxidation and proteasomal degradation, through an as of yet not fully elucidated mechanism, and eventually downregulation of Gal-1. This decreases tumor cell growth and inhibits angiogenesis. Gal-1, a multifunctional carbohydrate-binding protein, is often overexpressed on tumor cells and plays a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galectin-1 Inhibitor OTX008","termGroup":"PT","termSource":"NCI"},{"termName":"Gal-1 Inhibitor OTX008","termGroup":"SY","termSource":"NCI"},{"termName":"KM-0118","termGroup":"CN","termSource":"NCI"},{"termName":"OTX008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"286936-40-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8JI63CFH5V"},{"name":"Maps_To","value":"Galectin-1 Inhibitor OTX008"},{"name":"NCI_Drug_Dictionary_ID","value":"742751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742751"},{"name":"PDQ_Open_Trial_Search_ID","value":"742751"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641630"}]}}{"C84866":{"preferredName":"Galeterone","code":"C84866","definitions":[{"definition":"An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galeterone","termGroup":"PT","termSource":"NCI"},{"termName":"Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-","termGroup":"SN","termSource":"NCI"},{"termName":"Specific Androgen Receptor Modulator/CYP17 Lyase Inhibitor TOK-001","termGroup":"SY","termSource":"NCI"},{"termName":"TOK 001","termGroup":"CN","termSource":"NCI"},{"termName":"TOK-001","termGroup":"CN","termSource":"NCI"},{"termName":"TOK001","termGroup":"CN","termSource":"NCI"},{"termName":"VN/124","termGroup":"CN","termSource":"NCI"},{"termName":"VN/124-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"851983-85-2"},{"name":"Chemical_Formula","value":"C26H32N2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WA33E149SW"},{"name":"Maps_To","value":"Galeterone"},{"name":"NCI_Drug_Dictionary_ID","value":"653977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653977"},{"name":"PDQ_Open_Trial_Search_ID","value":"653977"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490719"}]}}{"C26447":{"preferredName":"Galiximab","code":"C26447","definitions":[{"definition":"A chimeric IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of follicular non-Hodgkin lymphoma. It binds to the protein CD80, which is found on certain normal white blood cells and on white blood cells that are cancer. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Galiximab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-B7-1","termGroup":"SY","termSource":"NCI"},{"termName":"anti-CD80 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"IDEC-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"357613-77-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9OX9692ZB"},{"name":"Legacy Concept Name","value":"IDEC-114_Monoclonal_Antibody"},{"name":"Maps_To","value":"Galiximab"},{"name":"NCI_Drug_Dictionary_ID","value":"285686"},{"name":"NSC Number","value":"734532"},{"name":"PDQ_Closed_Trial_Search_ID","value":"285686"},{"name":"PDQ_Open_Trial_Search_ID","value":"285686"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1098262"}]}}{"C73254":{"preferredName":"Galocitabine","code":"C73254","definitions":[{"definition":"An orally available 5-fluorouracil (5-FU) prodrug with potential antineoplastic activity. Upon administration, galocitabine is converted into 5'-deoxy-5-fluorocytidine, 5'-deoxy-fluorouridine, and 5-FU. 5-FU is further metabolized into other cytotoxic metabolites that interfere with RNA and DNA synthesis via inhibition of thymidylate synthase. As a result, this agent eventually inhibits tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galocitabine","termGroup":"PT","termSource":"NCI"},{"termName":"Ro 09-1390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124012-42-6"},{"name":"Chemical_Formula","value":"C19H22FN3O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X9788XI79O"},{"name":"Legacy Concept Name","value":"Galocitabine"},{"name":"Maps_To","value":"Galocitabine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084382"}]}}{"C116891":{"preferredName":"Galunisertib","code":"C116891","definitions":[{"definition":"An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), with potential antineoplastic activity. Upon administration, galunisertib specifically targets and binds to the kinase domain of TGFBR1, thereby preventing the activation of TGF-b-mediated signaling pathways. This may inhibit the proliferation of TGF-b-overexpressing tumor cells. Dysregulation of the TGF-b signaling pathway is seen in a number of cancers and is associated with increased cancer cell proliferation, migration, invasion and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Galunisertib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"LY-2157299","termGroup":"CN","termSource":"NCI"},{"termName":"LY2157299","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"700874-72-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3OKH1W5LZE"},{"name":"Maps_To","value":"Galunisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"687583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687583"},{"name":"PDQ_Open_Trial_Search_ID","value":"687583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3180910"}]}}{"C118444":{"preferredName":"Gamboge Resin Extract TSB-9-W1","code":"C118444","definitions":[{"definition":"An orally bioavailable extract from the yellow to brown gum-resin of the gamboge tree (genus Garcinia) belonging to the Clusiaceae (or Guttiferae) family, with potential anti-inflammatory and antineoplastic activities. Gamboge resin extract TSB-9-W1 contains various active ingredients, including gambogic acid, formoxanthone A, betulin, betulinic acid, morellic acid, isomorellic acid, isogambogic acid, isomorellinol and desoxymorellin. Upon oral administration, the various active components of the gamboge resin extract TSB-9-W1 may bind to and inhibit the activity of a variety of cancer-related proteins, may induce apoptosis, and may exert cytotoxic activity on tumor cells, thereby inhibiting tumor cell proliferation. TSB-9 is derived from TSB-14, which is the acetone-extract of gamboge resin, and pulverized into powder form; TSB-9 is 90% extract and 10% brown sugar. TSB-9-W1 is a milled form of TSB-9 with a particle size of 5 micrometers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamboge Resin Extract TSB-9-W1","termGroup":"PT","termSource":"NCI"},{"termName":"Garcinia Hanburyi Rhizome Resin","termGroup":"SY","termSource":"NCI"},{"termName":"Garcinia Hanburyi Root Resin","termGroup":"SY","termSource":"NCI"},{"termName":"TSB-9-W1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KQR4YN4C28"},{"name":"Maps_To","value":"Gamboge Resin Extract TSB-9-W1"},{"name":"NCI_Drug_Dictionary_ID","value":"764996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764996"},{"name":"PDQ_Open_Trial_Search_ID","value":"764996"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896755"}]}}{"C101517":{"preferredName":"Gamma-delta Tocotrienol","code":"C101517","definitions":[{"definition":"An orally available nutritional supplement containing the gamma and delta forms of the vitamin E family member tocotrienol, with hypocholesterolemic, antithrombotic, antioxidant, and potential antineoplastic activity. Upon oral administration, gamma-delta tocotrienol accumulates in cancer cells and may exert their anti-cancer activity in part through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase downregulation and/or degradation, cell cycle arrest, and induction of caspase-mediated apoptosis. In addition, this agent may inhibit angiogenesis partially through the blockage of vascular endothelial growth factor receptor (VEGFR) and the inhibition of tumor cell-induced vessel formation. Altogether, this may result in the inhibition of tumor cell growth. Further, this agent prevents free radical formation and inhibits lipid peroxidation. Tocotrienols contain 3 double bonds, absent in tocopherols, on its farnesyl isoprenoid side chain that likely contribute to its anti-cancer activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma-delta Tocotrienol","termGroup":"PT","termSource":"NCI"},{"termName":"GDT","termGroup":"AB","termSource":"NCI"},{"termName":"gdT3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gamma-delta Tocotrienol"},{"name":"NCI_Drug_Dictionary_ID","value":"730661"},{"name":"NCI_META_CUI","value":"CL435774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730661"},{"name":"PDQ_Open_Trial_Search_ID","value":"730661"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121535":{"preferredName":"Gamma-Secretase Inhibitor LY3039478","code":"C121535","synonyms":[{"termName":"Gamma-Secretase Inhibitor LY3039478","termGroup":"PT","termSource":"NCI"},{"termName":"4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide","termGroup":"SN","termSource":"NCI"},{"termName":"JSMD194","termGroup":"CN","termSource":"NCI"},{"termName":"LY 3039478","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3039478","termGroup":"CN","termSource":"NCI"},{"termName":"LY3039478","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1421438-81-4"},{"name":"Concept_Status","value":"Retired_Concept"},{"name":"DesignNote","value":"Wed Jul 07 17:27:51 EDT 2021 - See 'Crenigacestat(C171871)'"},{"name":"OLD_PARENT","value":"C471"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88333":{"preferredName":"Gamma-Secretase Inhibitor RO4929097","code":"C88333","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain enzymes that are needed for cell growth. This may slow the growth of cancer cells. It may also decrease the growth of new blood vessels that tumors need to grow. It is a type of gamma-secretase inhibitor and a type of Notch signaling inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, small-molecule gamma secretase (GS) inhibitor with potential antitumor activity. Gamma secretase inhibitor RO4929097 binds to GS and blocks activation of Notch receptors, which may inhibit tumor cell proliferation. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gamma-Secretase Inhibitor RO4929097","termGroup":"PT","termSource":"NCI"},{"termName":"R04929097","termGroup":"SY","termSource":"NCI"},{"termName":"RO4929097","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"847925-91-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KK8645V7LE"},{"name":"Maps_To","value":"Gamma-Secretase Inhibitor RO4929097"},{"name":"NCI_Drug_Dictionary_ID","value":"662240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662240"},{"name":"PDQ_Open_Trial_Search_ID","value":"662240"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742210"}]}}{"C116857":{"preferredName":"Gandotinib","code":"C116857","definitions":[{"definition":"An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. JAK2V617F has a substitution of phenylalanine for valine at amino acid position 617 and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gandotinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(Morpholinomethyl)imidazo(1,2-b)pyridazin-6-amine","termGroup":"SN","termSource":"NCI"},{"termName":"LY 2784544","termGroup":"CN","termSource":"NCI"},{"termName":"LY2784544","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229236-86-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ANC71R916O"},{"name":"Maps_To","value":"Gandotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"682801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682801"},{"name":"PDQ_Open_Trial_Search_ID","value":"682801"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659426"}]}}{"C77872":{"preferredName":"Ganetespib","code":"C77872","definitions":[{"definition":"A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganetespib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole 3h-1,2,4-triazol-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Hsp90 Inhibitor STA-9090","termGroup":"SY","termSource":"NCI"},{"termName":"STA 9090","termGroup":"CN","termSource":"NCI"},{"termName":"STA-9090","termGroup":"CN","termSource":"NCI"},{"termName":"STA9090","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1143571-94-1"},{"name":"Chemical_Formula","value":"C20H20N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2E8412Y946"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_STA-9090"},{"name":"Maps_To","value":"Ganetespib"},{"name":"NCI_Drug_Dictionary_ID","value":"598379"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598379"},{"name":"PDQ_Open_Trial_Search_ID","value":"598379"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2607234"}]}}{"C1110":{"preferredName":"Ganglioside GD2","code":"C1110","definitions":[{"definition":"A cell surface antigen expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastomas, sarcoma, astrocytomas, and small cell lung cancer. GD2, an O-acetylated disialoganglioside, belongs to the group of glycosphingolipids that are widely expressed in many tissues and organs in vertebrates and have been suggested to be involved in the regulation of development and differentiation as recognition molecules or signal modulators. Due to its high level of expression in neuroblastoma, GD2 has the potential to be used as a component of anti-neuroblastoma vaccines, in addition to being used in polyvalent anti-melanoma vaccines.","type":"DEFINITION","source":"NCI"},{"definition":"A sialic acid-containing glycosphingolipid antigen and a component of the cell plasma membrane that modulates cell signal transduction, with a designation of GD2. It can be considered as an autoantigen and is commonly associated with autoimmune neuropathies such as Guillain-Barre syndrome and multiple sclerosis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ganglioside GD2","termGroup":"PT","termSource":"NCI"},{"termName":"Disialoganglioside GD-2","termGroup":"SY","termSource":"NCI"},{"termName":"GalNAc(beta 1->4)-[NeuAc(alpha 2->8)NeuAc(alpha 2->3)]Gal(beta 1->4)GlcCer","termGroup":"SN","termSource":"NCI"},{"termName":"Ganglioside, GD2","termGroup":"SY","termSource":"NCI"},{"termName":"GD2","termGroup":"SY","termSource":"NCI"},{"termName":"GD2 Ganglioside","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65988-71-8"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FUI2V09E1C"},{"name":"Legacy Concept Name","value":"Ganglioside_GD2"},{"name":"Maps_To","value":"Ganglioside GD2"},{"name":"NCI_Drug_Dictionary_ID","value":"42295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42295"},{"name":"PDQ_Open_Trial_Search_ID","value":"42295"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061104"}]}}{"C516":{"preferredName":"Ganglioside GM2","code":"C516","definitions":[{"definition":"A glycosphingolipid antigen expressed by a variety of human cancer cells. GM2 containing vaccines have been shown to elicit antibodies production in melanoma patients without deleterious effects associated with an immune response to GM2. Mutations in at least 1 of 3 recessive genes: HEXA, HEXB, and GM2A cause defects in GM2 catabolism, leading to lysosomal lipid storage disorders that manifest primarily as neurodegenerative diseases, including Tay-Sachs and Sandhoff Disease.","type":"DEFINITION","source":"NCI"},{"definition":"A sialic acid-containing glycosphingolipid antigen and a component of the cell plasma membrane that modulates cell signal transduction, with a designation of GM2. It can be considered as an autoantigen and is commonly associated with autoimmune neuropathies such as Guillain-Barre syndrome and multiple sclerosis.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Ganglioside GM2","termGroup":"PT","termSource":"NCI"},{"termName":"GM2 ganglioside","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"19600-01-2"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ganglioside_GM2"},{"name":"Maps_To","value":"Ganglioside GM2"},{"name":"NCI_Drug_Dictionary_ID","value":"40785"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40785"},{"name":"PDQ_Open_Trial_Search_ID","value":"40785"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0016896"}]}}{"C71531":{"preferredName":"Ganitumab","code":"C71531","definitions":[{"definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganitumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 479","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-479","termGroup":"CN","termSource":"NCI"},{"termName":"AMG479","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-IGF-1R Human Monoclonal Antibody AMG-479","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"905703-97-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CK1441RCZ8"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Human_Monoclonal_Antibody_AMG-479"},{"name":"Maps_To","value":"Ganitumab"},{"name":"NCI_Drug_Dictionary_ID","value":"578040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"578040"},{"name":"PDQ_Open_Trial_Search_ID","value":"578040"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2744646"}]}}{"C118365":{"preferredName":"Ganoderma lucidum Spores Powder Capsule","code":"C118365","definitions":[{"definition":"An orally available powder-based nutritional supplement containing the spores of the mushroom Ganoderma lucidum (Ganoderma l.), a traditional Chinese medicine, with potential protective, sedative, anti-oxidant, immunomodulating, and antineoplastic activities. The spores contain various bioactive components including polysaccharides, triterpenoids, peptidoglycans, amino acids, fatty acids, vitamins, and minerals. Upon oral administration of the Ganoderma lucidum spores powder capsule, the active ingredients may modulate the immune system, may activate dendritic cells, natural killer cells, and macrophages and may modulate the production of certain cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin (IL) 1-beta (IL-1b), IL-2, IL-6 and IL-8. This supplement may improve cancer-related fatigue and may be used as a sleep aid; it may also have a beneficial effect on the heart, lung, liver, pancreas, kidney, and the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ganoderma lucidum Spores Powder Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Ganoderma l. Spores Powder Capsule","termGroup":"SY","termSource":"NCI"},{"termName":"Lingzhi Spores Powder Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ganoderma lucidum Spores Powder Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"764697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764697"},{"name":"PDQ_Open_Trial_Search_ID","value":"764697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3899040"}]}}{"C38706":{"preferredName":"Garlic","code":"C38706","definitions":[{"definition":"A European plant that has a bulb used to flavor food. It has also been used in some cultures to treat certain medical conditions including high cholesterol, high blood pressure, infections, and cancer. The scientific name is Allium sativum.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A bulbous herb isolated from the plant Allium sativum with potential antineoplastic activity. Garlic contains a number of different organosulfur compounds, some of which have displayed antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Garlic","termGroup":"PT","termSource":"NCI"},{"termName":"Ajo","termGroup":"SY","termSource":"NCI"},{"termName":"Allium Sativum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V1V998DC17"},{"name":"Legacy Concept Name","value":"Garlic"},{"name":"Maps_To","value":"Garlic"},{"name":"NCI_Drug_Dictionary_ID","value":"357490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357490"},{"name":"PDQ_Open_Trial_Search_ID","value":"357490"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0993630"}]}}{"C1692":{"preferredName":"Gastrin Immunotoxin","code":"C1692","definitions":[{"definition":"An immunotoxin containing an epitope of human gastrin conjugated to diphtheria toxin, with antineoplastic activity. The gastrin epitope in this vaccine is chemically identical or similar to the endogenous gastrin-17 (G-17), a 17-amino acid peptide hormone that stimulates secretion of gastric acid by the stomach. Diphtheria toxin inhibits protein synthesis via modifying translation elongation factor 2 (EF-2). Vaccination with this immunotoxin may elicit production of antibodies against gastrinoma cells overexpressing gastrin, in addition to the toxic effects on protein synthesis exerted by the diphtheria toxin moiety.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrin Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-gastrin 17","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Gastrin Therapeutic Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"G17DT","termGroup":"AB","termSource":"NCI"},{"termName":"G17DT Immunogen","termGroup":"SY","termSource":"NCI"},{"termName":"Gastrimmune","termGroup":"BR","termSource":"NCI"},{"termName":"Neutralize Hormone G17","termGroup":"SY","termSource":"NCI"},{"termName":"Neutralizing G17 Hormone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J9W34L3K8B"},{"name":"Legacy Concept Name","value":"Gastrin_Immunotoxin"},{"name":"Maps_To","value":"Gastrin Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"38352"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38352"},{"name":"PDQ_Open_Trial_Search_ID","value":"38352"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935889"}]}}{"C61329":{"preferredName":"Nastorazepide Calcium","code":"C61329","definitions":[{"definition":"A selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nastorazepide Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360","termGroup":"SY","termSource":"NCI"},{"termName":"Z-360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"343326-69-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GZ3I1DMI8Q"},{"name":"Legacy Concept Name","value":"Z-360"},{"name":"Maps_To","value":"Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360"},{"name":"NCI_Drug_Dictionary_ID","value":"485295"},{"name":"NCI_META_CUI","value":"CL937292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485295"},{"name":"PDQ_Open_Trial_Search_ID","value":"485295"},{"name":"PubMedID_Primary_Reference","value":"17961733"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66935":{"preferredName":"Gataparsen Sodium","code":"C66935","definitions":[{"definition":"A second-generation antisense oligonucleotide against survivin mRNA with potential antitumor activity. Gataparsen hybridizes to survivin mRNA, thereby blocking translation of survivin protein, a member of the inhibitor of apoptosis (IAP) family. Survivin, expressed during embryonal development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy. Silencing expression of survivin potentially leads to restoration of the apoptotic process in cancer cells, thereby facilitating chemotherapeutic treatments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gataparsen Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Antisurvivin Antisense Oligonucleotide LY2181308","termGroup":"SY","termSource":"NCI"},{"termName":"LY 2181308","termGroup":"CN","termSource":"NCI"},{"termName":"LY-2181308","termGroup":"CN","termSource":"NCI"},{"termName":"LY2181308","termGroup":"CN","termSource":"NCI"},{"termName":"LY2181308 Heptadecasodium Salt","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"928768-71-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3KY0EUQ36S"},{"name":"Legacy Concept Name","value":"LY2181308"},{"name":"Maps_To","value":"Gataparsen Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"532253"},{"name":"PDQ_Closed_Trial_Search_ID","value":"532253"},{"name":"PDQ_Open_Trial_Search_ID","value":"532253"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832051"}]}}{"C94220":{"preferredName":"Gatipotuzumab","code":"C94220","definitions":[{"definition":"A humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), with potential antineoplastic activity. Gatipotuzumab targets and binds to the TA-MUC1 epitopes expressed on the cell surface of tumor cells, thereby potentially activating the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against the TA-MUC1-expressing tumor cells. TA-MUC1 is designated to MUC1 epitopes with O-glycosylated carbohydrate-induced conformational structures that are tumor-specific, thereby enabling gatipotuzumab to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gatipotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"PankoMab","termGroup":"CN","termSource":"NCI"},{"termName":"PankoMab-GEX","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1264737-26-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"85V55ZLV2Z"},{"name":"Maps_To","value":"Gatipotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"687630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687630"},{"name":"PDQ_Open_Trial_Search_ID","value":"687630"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986405"}]}}{"C91732":{"preferredName":"Gedatolisib","code":"C91732","definitions":[{"definition":"An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, gedatolisib inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gedatolisib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(4-[[4-(dimethylamino)piperidin-1-yl]carbonyl]phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea","termGroup":"SN","termSource":"NCI"},{"termName":"PF 05212384","termGroup":"CN","termSource":"NCI"},{"termName":"PF-05212384","termGroup":"CN","termSource":"NCI"},{"termName":"PKI 587","termGroup":"CN","termSource":"NCI"},{"termName":"PKI-587","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1197160-78-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96265TNH2R"},{"name":"Maps_To","value":"Gedatolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"651189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651189"},{"name":"PDQ_Open_Trial_Search_ID","value":"651189"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933603"}]}}{"C1855":{"preferredName":"Gefitinib","code":"C1855","definitions":[{"definition":"A drug that is used to treat certain types of non-small cell lung cancer and is being studied in the treatment of other types of cancer. It is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gefitinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","termGroup":"SN","termSource":"NCI"},{"termName":"Iressa","termGroup":"BR","termSource":"NCI"},{"termName":"N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine","termGroup":"SN","termSource":"NCI"},{"termName":"ZD 1839","termGroup":"CN","termSource":"NCI"},{"termName":"ZD-1839","termGroup":"CN","termSource":"NCI"},{"termName":"ZD1839","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Small Cell Lung Carcinoma"},{"name":"CAS_Registry","value":"184475-35-2"},{"name":"CHEBI_ID","value":"CHEBI:49668"},{"name":"Chemical_Formula","value":"C22H24ClFN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"S65743JHBS"},{"name":"Legacy Concept Name","value":"Gefitinib"},{"name":"Maps_To","value":"Gefitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"43649"},{"name":"NSC Number","value":"715055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43649"},{"name":"PDQ_Open_Trial_Search_ID","value":"43649"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122962"}]}}{"C1112":{"preferredName":"Geldanamycin","code":"C1112","definitions":[{"definition":"A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Geldanamycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Geldanamycin","termGroup":"PT","termSource":"NCI"},{"termName":"Antibiotic U 29135","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"30562-34-6"},{"name":"CHEBI_ID","value":"CHEBI:5292"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z3K3VJ16KU"},{"name":"Legacy Concept Name","value":"Geldanamycin"},{"name":"Maps_To","value":"Geldanamycin"},{"name":"NSC Number","value":"122750"},{"name":"NSC Number","value":"212518"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061179"}]}}{"C133021":{"preferredName":"Gelonin","code":"C133021","definitions":[{"definition":"A class I ribosome-inactivating protein (RIP) and toxin derived from the seeds of the plant Gelonium multiflorum. Gelonin (rGel) exerts N-glycosidase activity on the 28S ribosomal RNA (rRNA) unit of eukaryotic ribosomes by cleaving out adenine at the 4324 site, which depurinates rRNA, inactivates ribosomes, inhibits protein synthesis, and results in cell death. Used as the toxin moiety of certain immunotoxins and linked to antibodies specific for a tumor-associated antigen (TAA), gelonin can be targeted to and induce specific cytotoxicity in tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gelonin","termGroup":"PT","termSource":"NCI"},{"termName":"GEL Protein, Gelonium multiflorum","termGroup":"SY","termSource":"NCI"},{"termName":"rGel","termGroup":"SY","termSource":"NCI"},{"termName":"Ribosome-inactivating Protein Gelonin, Gelonium multiflorum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75037-46-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gelonin"},{"name":"NCI_Drug_Dictionary_ID","value":"357568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357568"},{"name":"PDQ_Open_Trial_Search_ID","value":"357568"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061184"}]}}{"C66876":{"preferredName":"Gemcitabine","code":"C66876","definitions":[{"definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Gemcitabine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose","termGroup":"SN","termSource":"NCI"},{"termName":"2'Deoxy-2',2'-Difluorocytidine","termGroup":"SN","termSource":"NCI"},{"termName":"dFdC","termGroup":"AB","termSource":"NCI"},{"termName":"dFdCyd","termGroup":"AB","termSource":"NCI"},{"termName":"Difluorodeoxycytidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95058-81-4"},{"name":"CHEBI_ID","value":"CHEBI:175901"},{"name":"Chemical_Formula","value":"C9H11F2N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"B76N6SBZ8R"},{"name":"Legacy Concept Name","value":"Gemcitabine_Base"},{"name":"Maps_To","value":"Gemcitabine"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045093"}]}}{"C79803":{"preferredName":"Gemcitabine Elaidate","code":"C79803","definitions":[{"definition":"A lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Elaidate","termGroup":"PT","termSource":"NCI"},{"termName":"CP-4126","termGroup":"CN","termSource":"NCI"},{"termName":"Gemcitabine 5'-Elaidic Acid Ester","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"210829-30-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"231C73W7LG"},{"name":"Legacy Concept Name","value":"Gemcitabine_5-Elaidic_Acid_Ester"},{"name":"Maps_To","value":"Gemcitabine Elaidate"},{"name":"NCI_Drug_Dictionary_ID","value":"624375"},{"name":"PDQ_Closed_Trial_Search_ID","value":"624375"},{"name":"PDQ_Open_Trial_Search_ID","value":"624375"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703166"}]}}{"C961":{"preferredName":"Gemcitabine Hydrochloride","code":"C961","definitions":[{"definition":"A drug used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine hydrochloride blocks the cell from making DNA and may kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose, hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"2'Deoxy-2',2'-Difluorocytidine, Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"dFdCyd","termGroup":"SY","termSource":"NCI"},{"termName":"Difluorodeoxycytidine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Gemcitabine HCI","termGroup":"SY","termSource":"NCI"},{"termName":"Gemzar","termGroup":"BR","termSource":"NCI"},{"termName":"LY 188011","termGroup":"CN","termSource":"NCI"},{"termName":"LY-188011","termGroup":"CN","termSource":"NCI"},{"termName":"LY188011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Breast cancer; Carcinoma of unknown primary origin; Lung cancer; including non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma"},{"name":"CAS_Registry","value":"122111-03-9"},{"name":"CHEBI_ID","value":"CHEBI:31647"},{"name":"Chemical_Formula","value":"C9H11F2N3O4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U347PV74IL"},{"name":"Legacy Concept Name","value":"Gemcitabine"},{"name":"Maps_To","value":"Gemcitabine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41213"},{"name":"NSC Number","value":"613327"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41213"},{"name":"PDQ_Open_Trial_Search_ID","value":"41213"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771488"}]}}{"C105613":{"preferredName":"Gemcitabine Hydrochloride Emulsion","code":"C105613","definitions":[{"definition":"An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Hydrochloride Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"D07001-F4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gemcitabine Hydrochloride Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"747250"},{"name":"NCI_META_CUI","value":"CL446450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747250"},{"name":"PDQ_Open_Trial_Search_ID","value":"747250"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102856":{"preferredName":"Gemcitabine Prodrug LY2334737","code":"C102856","definitions":[{"definition":"An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine prodrug LY2334737 is hydrolyzed by carboxylesterase 2 (CES2) and releases gemcitabine systemically over a period of time consistent with formation rate-limited kinetics. In turn, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis. Compared to gemcitabine, this prodrug is able to avoid hydrolysis in enterocytes and the portal circulation thus avoiding first pass metabolism and increasing systemic gemcitabine availability. In addition, the slow release of gemcitabine may enhance efficacy while lowering toxicity. CES2, a serine ester hydrolase, is expressed in certain tumors which may allow for increased conversion of gemcitabine at the tumor site thus increases cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine Prodrug LY2334737","termGroup":"PT","termSource":"NCI"},{"termName":"LY-2334737","termGroup":"CN","termSource":"NCI"},{"termName":"LY2334737","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"892128-60-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YLR364XYSA"},{"name":"Maps_To","value":"Gemcitabine Prodrug LY2334737"},{"name":"NCI_Drug_Dictionary_ID","value":"737787"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737787"},{"name":"PDQ_Open_Trial_Search_ID","value":"737787"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3252354"}]}}{"C102752":{"preferredName":"Fosgemcitabine Palabenamide","code":"C102752","definitions":[{"definition":"A pyrimidine analogue and a proprietary prodrug based on an aryloxy phosphoramidate derivative of gemcitabine with potential antineoplastic activity. Upon intravenous administration and cellular uptake, fosgemcitabine palabenamide is converted into the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually induction of apoptosis. With the phosphoramidate moiety on the gemcitabine monophosphate group, NUC-1031 has improved properties over its parent molecule: 1) is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, 2) as the agent is delivered in the monophosphate form, the first phosphorylation step by deoxycytidine kinase is not required, 3) this agent is not susceptible to deactivation by cytidine deaminase cleavage of the monophosphorylated form. Altogether, this may help overcome resistance to gemcitabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosgemcitabine Palabenamide","termGroup":"PT","termSource":"NCI"},{"termName":"Acelarin","termGroup":"BR","termSource":"NCI"},{"termName":"Gemictabine ProTide","termGroup":"SY","termSource":"NCI"},{"termName":"NUC 1031","termGroup":"CN","termSource":"NCI"},{"termName":"NUC-1031","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1562406-27-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I17GWP65CE"},{"name":"Maps_To","value":"Fosgemcitabine Palabenamide"},{"name":"Maps_To","value":"Gemcitabine-Phosphoramidate Hydrochloride NUC-1031"},{"name":"NCI_Drug_Dictionary_ID","value":"735822"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735822"},{"name":"PDQ_Open_Trial_Search_ID","value":"735822"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640933"}]}}{"C150807":{"preferredName":"Gemcitabine-Releasing Intravesical System","code":"C150807","definitions":[{"definition":"A controlled-release intravesical system consisting of a small flexible tube-like device with a solid core composed of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. Upon placement of the gemcitabine-releasing intravesical system (GemRIS) into the bladder, gemcitabine is gradually and continuously released from the system over an extended period of time before being removed from the bladder. Upon release, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis of bladder tumor cells. In addition, dFdCDP inhibits ribonucleotide reductase (RNR) and reduces the deoxynucleotide pool available for DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemcitabine-Releasing Intravesical System","termGroup":"PT","termSource":"NCI"},{"termName":"GemRIS","termGroup":"BR","termSource":"NCI"},{"termName":"TAR 200","termGroup":"CN","termSource":"NCI"},{"termName":"TAR-200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gemcitabine-Releasing Intravesical System"},{"name":"NCI_Drug_Dictionary_ID","value":"793540"},{"name":"NCI_META_CUI","value":"CL552666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793540"},{"name":"PDQ_Open_Trial_Search_ID","value":"793540"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1806":{"preferredName":"Gemtuzumab Ozogamicin","code":"C1806","definitions":[{"definition":"A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gemtuzumab Ozogamicin","termGroup":"PT","termSource":"NCI"},{"termName":"Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"CDP-771","termGroup":"CN","termSource":"NCI"},{"termName":"CMA-676","termGroup":"CN","termSource":"NCI"},{"termName":"hP67.6-Calicheamicin","termGroup":"SY","termSource":"NCI"},{"termName":"Mylotarg","termGroup":"BR","termSource":"NCI"},{"termName":"WAY-CMA-676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Myeloid Leukemia."},{"name":"CAS_Registry","value":"220578-59-6"},{"name":"Chemical_Formula","value":"C73H96IN6O25S3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"8GZG754X6M"},{"name":"Legacy Concept Name","value":"Gemtuzumab_Ozogamicin"},{"name":"Maps_To","value":"Gemtuzumab Ozogamicin"},{"name":"NCI_Drug_Dictionary_ID","value":"42868"},{"name":"NSC Number","value":"720568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42868"},{"name":"PDQ_Open_Trial_Search_ID","value":"42868"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1533699"}]}}{"C1113":{"preferredName":"Genistein","code":"C1113","definitions":[{"definition":"A soy-derived isoflavone and phytoestrogen with antineoplastic activity. Genistein binds to and inhibits protein-tyrosine kinase, thereby disrupting signal transduction and inducing cell differentiation.  This agent also inhibits topoisomerase-II, leading to DNA fragmentation and apoptosis, and induces G2/M cell cycle arrest.  Genistein exhibits antioxidant, antiangiogenic, and immunosuppressive activities. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An isoflavone found in soy products. Soy isoflavones are being studied to see if they help prevent cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An isoflavone with a hydroxyl group on the B-ring and a second hydroxyl group on the A-ring.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Genistein","termGroup":"PT","termSource":"NCI"},{"termName":"4',5,7-Trihydroxyisoflavone","termGroup":"SN","termSource":"NCI"},{"termName":"5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"Genestein","termGroup":"SY","termSource":"NCI"},{"termName":"Genisteol","termGroup":"SY","termSource":"NCI"},{"termName":"Prunetol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"446-72-0"},{"name":"CHEBI_ID","value":"CHEBI:28088"},{"name":"Chemical_Formula","value":"C15H10O5"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DH2M523P0H"},{"name":"INFOODS","value":"GNSTEIN"},{"name":"Legacy Concept Name","value":"Genistein"},{"name":"Maps_To","value":"Genistein"},{"name":"NCI_Drug_Dictionary_ID","value":"43214"},{"name":"NSC Number","value":"36586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43214"},{"name":"PDQ_Open_Trial_Search_ID","value":"43214"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061202"},{"name":"Unit","value":"mcg"}]}}{"C154552":{"preferredName":"Gentuximab","code":"C154552","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gentuximab","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"794351"},{"name":"NCI_META_CUI","value":"CL555348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794351"},{"name":"PDQ_Open_Trial_Search_ID","value":"794351"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104414":{"preferredName":"Geranylgeranyltransferase I Inhibitor","code":"C104414","definitions":[{"definition":"A substance that inhibits protein geranylgeranyltransferase type 1 (GGTase-I), with potential antineoplastic activity. GGTase-I is involved in the posttranslational modification of a number of oncogenic GTPases, including K-Ras, N-Ras, RhoA, RhoC, Cdc42, RalA, RalB and Rac1. Inhibition of the prenylation of these oncogenic proteins inhibits both their oncogenic activity and membrane localization. This may result in cell cycle arrest and apoptosis. Protein geranylgeranylation, catayzed by GGTase-I, plays a critical role in malignant transformation and cancer cell proliferation, migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Geranylgeranyltransferase I Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"GGTase-I Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"GGTI-I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Geranylgeranyltransferase I Inhibitor"},{"name":"NCI_Drug_Dictionary_ID","value":"745403"},{"name":"NCI_META_CUI","value":"CL445681"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745403"},{"name":"PDQ_Open_Trial_Search_ID","value":"745403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61489":{"preferredName":"GI-4000 Vaccine","code":"C61489","definitions":[{"definition":"A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity. Upon administration, GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras. This may lead to a destruction of cancer cells expressing a Ras mutation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GI-4000 Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GI-4000_Vaccine"},{"name":"Maps_To","value":"GI-4000 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"486259"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486259"},{"name":"PDQ_Open_Trial_Search_ID","value":"486259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831831"}]}}{"C116722":{"preferredName":"Gilteritinib","code":"C116722","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gilteritinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ASP 2215","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-2215","termGroup":"CN","termSource":"NCI"},{"termName":"ASP2215","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory acute myeloid leukemia (AML)"},{"name":"CAS_Registry","value":"1254053-43-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"66D92MGC8M"},{"name":"Maps_To","value":"Gilteritinib"},{"name":"NCI_Drug_Dictionary_ID","value":"752319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752319"},{"name":"PDQ_Open_Trial_Search_ID","value":"752319"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896738"}]}}{"C119665":{"preferredName":"Gilteritinib Fumarate","code":"C119665","definitions":[{"definition":"The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gilteritinib Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-, (2E)-2-Butenedioate (2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"ASP-2215 Hemifumarate","termGroup":"CN","termSource":"NCI"},{"termName":"ASP2215 Hemifumarate","termGroup":"CN","termSource":"NCI"},{"termName":"Gilteritinib Hemifumarate","termGroup":"SY","termSource":"NCI"},{"termName":"Xospata","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment(s)."},{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation"},{"name":"CAS_Registry","value":"1254053-84-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5RZZ0Z1GJT"},{"name":"Maps_To","value":"Gilteritinib Fumarate"},{"name":"NCI_Drug_Dictionary_ID","value":"792549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792549"},{"name":"PDQ_Open_Trial_Search_ID","value":"792549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896946"}]}}{"C65804":{"preferredName":"Gimatecan","code":"C65804","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, semi-synthetic lipophilic analogue of camptothecin, a quinoline alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic and antiangiogenic activities. Gimatecan binds to and inhibits the activity of topoisomerase I, stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Although the mechanism of its antiangiogenic activity has yet to be full elucidated, this agent may inhibit endothelial cell migration, tumor neovascularization, and the expression of proangiogenic basic fibroblast growth factor (bFGF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gimatecan","termGroup":"PT","termSource":"NCI"},{"termName":"7-t-Butoxyiminomethylcamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"LBQ707","termGroup":"CN","termSource":"NCI"},{"termName":"STI481","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"292618-32-7"},{"name":"Chemical_Formula","value":"C25H25N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7KKS9R192F"},{"name":"Legacy Concept Name","value":"Gimatecan"},{"name":"Maps_To","value":"Gimatecan"},{"name":"NCI_Drug_Dictionary_ID","value":"537638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"537638"},{"name":"PDQ_Open_Trial_Search_ID","value":"537638"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0969276"}]}}{"C2416":{"preferredName":"Gimeracil","code":"C2416","definitions":[{"definition":"A pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly inhibiting the enzyme dihydropyrimidine dehydrogenase causing decreased degradation of the fluoropyrimidines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gimeracil","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-2,4-pyridinediol","termGroup":"SN","termSource":"NCI"},{"termName":"CDHP","termGroup":"AB","termSource":"NCI"},{"termName":"Chlorodihydroxypyridine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103766-25-2"},{"name":"Chemical_Formula","value":"C5H4ClNO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UA8SE1325T"},{"name":"Legacy Concept Name","value":"Chlorodihydroxypyridine"},{"name":"Maps_To","value":"Gimeracil"},{"name":"NCI_Drug_Dictionary_ID","value":"42587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42587"},{"name":"PDQ_Open_Trial_Search_ID","value":"42587"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0535459"}]}}{"C103300":{"preferredName":"Ginsenoside Rg3 Capsule","code":"C103300","definitions":[{"definition":"A capsule containing the steroidal saponin ginsenoside Rg3 isolated from the root of Panax ginseng, with potential cancer preventive and anti-angiogenic activities. Upon oral administration, ginsenoside Rg3 appears to inhibit endothelial cell proliferation, migration and tubular formation, and promotes cancer cell apoptosis. This agent also modulates the activities of certain growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinases (MMPs), on tumor angiogenesis. In addition, ginsenoside Rg3 may be able to sensitize cancer cells to some chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ginsenoside Rg3 Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"Shen Yi Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ginsenoside Rg3 Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"742493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742493"},{"name":"PDQ_Open_Trial_Search_ID","value":"742493"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385181"}]}}{"C1960":{"preferredName":"Girentuximab","code":"C1960","definitions":[{"definition":"A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, monoclonal antibody G250 (mAb G250) may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Girentuximab","termGroup":"PT","termSource":"NCI"},{"termName":"cG250","termGroup":"AB","termSource":"NCI"},{"termName":"Chimeric Monoclonal Antibody cG250","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb G250","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody G250","termGroup":"SY","termSource":"NCI"},{"termName":"Rencarex","termGroup":"BR","termSource":"NCI"},{"termName":"WX-G250","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"916138-87-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"539B57DFJF"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_G-250"},{"name":"Maps_To","value":"Girentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"373829"},{"name":"PDQ_Closed_Trial_Search_ID","value":"373829"},{"name":"PDQ_Open_Trial_Search_ID","value":"373829"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0540128"}]}}{"C1373":{"preferredName":"Girodazole","code":"C1373","definitions":[{"definition":"A compound isolated from the marine sponge Pseudaxinyssa cantharella exhibiting anti-tumor activity.  Studies indicate girodazole acts during the elongation/termination steps of protein synthesis, resulting in protein synthesis inhibition. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Girodazole","termGroup":"PT","termSource":"NCI"},{"termName":"3-Amino-1-[4-(2 amino-1H-imidazolyl)]-propanol, 2HCl","termGroup":"SN","termSource":"NCI"},{"termName":"Giroline","termGroup":"SY","termSource":"NCI"},{"termName":"RP 49532A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135824-74-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Girodazole"},{"name":"Maps_To","value":"Girodazole"},{"name":"NSC Number","value":"627434"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0119196"}]}}{"C169931":{"preferredName":"Efgivanermin Alfa","code":"C169931","definitions":[{"definition":"A homogenous hexameric agonist fusion protein composed of the extracellular domain (ECD) of the T-cell costimulatory receptor human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR) ligand (GITRL) and an immunoglobulin (Ig) G1 Fc domain, with potential immunomodulating and antineoplastic activities. Upon administration, efgivanermin alfa binds to and activates GITR found on multiple types of T-cells, thereby inducing both the activation and proliferation of tumor antigen-specific T effector cells. This abrogates the suppression of T effector cells which is induced by inappropriately activated T regulatory cells (Tregs), suppresses Tregs and decreases Treg tumor infiltration, and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including Tregs, effector T-cells, B-cells, dendritic cells (DCs) and natural killer (NK) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efgivanermin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"GITR Agonist MEDI1873","termGroup":"SY","termSource":"NCI"},{"termName":"GITR Stimulant MEDI1873","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 1873","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI1873","termGroup":"CN","termSource":"NCI"},{"termName":"TNFRSF18 Agonist MEDI1873","termGroup":"SY","termSource":"NCI"},{"termName":"TNFRSF18 Protein Stimulant MEDI1873","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1807864-13-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2R45V0JU8"},{"name":"Maps_To","value":"GITR Agonist MEDI1873"},{"name":"NCI_Drug_Dictionary_ID","value":"776837"},{"name":"NCI_META_CUI","value":"CL1382432"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71716":{"preferredName":"Givinostat","code":"C71716","definitions":[{"definition":"An orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. Givinostat inhibits class I and class II HDACs, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. At low, nonapoptotic concentrations, this agent inhibits the production of pro-inflammatory cytokines such as tumor necrosis factor- (TNF-), interleukin-1 (IL-1), IL-6 and interferon-gamma. Givinostat has also been shown to activate the intrinsic apoptotic pathway, inducing apoptosis in hepatoma cells and leukemic cells. This agent may also exhibit anti-angiogenic activity, inhibiting the production of angiogenic factors such as IL-6 and vascular endothelial cell growth factor (VEGF) by bone marrow stromal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Givinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Gavinostat","termGroup":"SY","termSource":"NCI"},{"termName":"ITF2357","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"497833-27-9"},{"name":"Chemical_Formula","value":"C24H27N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5P60F84FBH"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_ITF2357"},{"name":"Maps_To","value":"Givinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"560751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560751"},{"name":"PDQ_Open_Trial_Search_ID","value":"560751"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987670"}]}}{"C84862":{"preferredName":"Glasdegib","code":"C84862","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glasdegib","termGroup":"PT","termSource":"NCI"},{"termName":"PF 04449913","termGroup":"CN","termSource":"NCI"},{"termName":"PF-04449913","termGroup":"CN","termSource":"NCI"},{"termName":"PF04449913","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1095173-27-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K673DMO5H9"},{"name":"Maps_To","value":"Glasdegib"},{"name":"NCI_META_CUI","value":"CL412426"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156894":{"preferredName":"Glasdegib Maleate","code":"C156894","definitions":[{"definition":"The maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets, binds to and inhibits the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glasdegib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"1-((2R,4R)-2-(1H-Benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate","termGroup":"SN","termSource":"NCI"},{"termName":"Daurismo","termGroup":"BR","termSource":"NCI"},{"termName":"PF 04449913 Maleate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute myeloid leukemia (AML)"},{"name":"CAS_Registry","value":"2030410-25-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TH2EV99S4Z"},{"name":"Maps_To","value":"Glasdegib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"652940"},{"name":"NCI_META_CUI","value":"CL935991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"652940"},{"name":"PDQ_Open_Trial_Search_ID","value":"652940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1114":{"preferredName":"Glaucarubolone","code":"C1114","definitions":[{"definition":"A polycyclic lactone quassinoid phytochemical isolated from the seeds of Hannoa undulata and other plant species with potential antineoplastic activity.  This agent also has antiviral and antitumor properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glaucarubolone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1990-01-8"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Glaucarubolone"},{"name":"Maps_To","value":"Glaucarubolone"},{"name":"NSC Number","value":"126764"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061299"}]}}{"C160484":{"preferredName":"Glecaprevir/Pibrentasvir","code":"C160484","definitions":[{"definition":"A fixed dose combination of glecaprevir, an inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease, and pibrentasvir, an inhibitor of the HCV non-structural protein 5A (NS5A), with activity against HCV genotypes 1-6. Upon oral administration of glecaprevir/pibrentasvir, glecaprevir inhibits the HCV NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. Pibrentasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glecaprevir/Pibrentasvir","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-493/ABT-530","termGroup":"CN","termSource":"NCI"},{"termName":"GLE/PIB","termGroup":"BR","termSource":"NCI"},{"termName":"Glecaprevir and Pibrentasvir","termGroup":"SY","termSource":"NCI"},{"termName":"Glecaprevir-Pibrentasvir","termGroup":"SY","termSource":"NCI"},{"termName":"Mavyret","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glecaprevir/Pibrentasvir"},{"name":"NCI_Drug_Dictionary_ID","value":"798328"},{"name":"NCI_META_CUI","value":"CL777819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798328"},{"name":"PDQ_Open_Trial_Search_ID","value":"798328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78449":{"preferredName":"Glembatumumab Vedotin","code":"C78449","definitions":[{"definition":"An antibody-drug conjugate, consisting of the fully human monoclonal antibody CR011 directed against glycoprotein NMB (GPNMB) and conjugated via a cathepsin B-sensitive valine-citrulline (vc) linkage to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody CR011 moiety binds to glycoprotein nmb (GPNMB), expressed on the surfaces of a variety of cancer cell types; upon endocytosis, the synthetic dolastin analogue MMAE is released via enzymatic cleavage into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and apoptosis. The vc linkage system is highly stable in serum, rendering the cytotoxicity of glembatumumab vedotin specific for GPNMB-positive cells. GPNMB is a transmembrane protein overexpressed on the surfaces of various cancer cell types, including melanoma, breast, and prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glembatumumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate CR011-vcMMAE","termGroup":"SY","termSource":"NCI"},{"termName":"CDX-011","termGroup":"CN","termSource":"NCI"},{"termName":"CR011-vcMMAE","termGroup":"CN","termSource":"NCI"},{"termName":"CR011-vcMMAE Immunotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1182215-65-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1568H6A58U"},{"name":"Legacy Concept Name","value":"Antibody-Drug_Conjugate_CR011-vcMMAE"},{"name":"Maps_To","value":"Glembatumumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"599456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599456"},{"name":"PDQ_Open_Trial_Search_ID","value":"599456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698156"}]}}{"C77876":{"preferredName":"Glesatinib","code":"C77876","definitions":[{"definition":"An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Glesatinib binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glesatinib","termGroup":"PT","termSource":"NCI"},{"termName":"MG90265","termGroup":"CN","termSource":"NCI"},{"termName":"MG90265X","termGroup":"CN","termSource":"NCI"},{"termName":"MGCD265","termGroup":"CN","termSource":"NCI"},{"termName":"TKI MGCD265","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936694-12-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7Q29OXD98N"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor_MGCD265"},{"name":"Maps_To","value":"Glesatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"597305"},{"name":"NCI_META_CUI","value":"CL383618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"597305"},{"name":"PDQ_Open_Trial_Search_ID","value":"597305"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107502":{"preferredName":"Glioblastoma Cancer Vaccine ERC1671","code":"C107502","definitions":[{"definition":"A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma Cancer Vaccine ERC1671","termGroup":"PT","termSource":"NCI"},{"termName":"ERC-1671","termGroup":"CN","termSource":"NCI"},{"termName":"ERC1671","termGroup":"CN","termSource":"NCI"},{"termName":"Gliovac","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioblastoma Cancer Vaccine ERC1671"},{"name":"NCI_Drug_Dictionary_ID","value":"751319"},{"name":"NCI_META_CUI","value":"CL451748"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751319"},{"name":"PDQ_Open_Trial_Search_ID","value":"751319"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94211":{"preferredName":"Glioblastoma Multiforme Multipeptide Vaccine IMA950","code":"C94211","definitions":[{"definition":"A cancer vaccine comprised of 11 peptides associated with glioblastoma multiforme (GBM), with potential immunomodulating and antineoplastic activities. Vaccination with glioblastoma multiforme multi-antigen vaccine IMA950 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response as well as a T-helper (Th) immune response against tumor cells expressing these peptides, potentially resulting in decreased tumor growth of GBM. Peptides in IMA950 consist of the following: brevican (BCAN); chondroitin sulfate proteoglycan 4 (CSPG4); fatty acid binding protein 7, brain (FABP7); insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3); neuroligin 4, X-linked (NLGN4X); neuronal cell adhesion molecule (NRCAM); protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1); tenascin C (TNC); Met proto-oncogene (MET); baculoviral IAP repeat-containing 5 (BIRC5); and hepatitis B virus core antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioblastoma Multiforme Multipeptide Vaccine IMA950","termGroup":"PT","termSource":"NCI"},{"termName":"IMA950","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioblastoma Multiforme Multipeptide Vaccine IMA950"},{"name":"NCI_Drug_Dictionary_ID","value":"687015"},{"name":"NCI_META_CUI","value":"CL426024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687015"},{"name":"PDQ_Open_Trial_Search_ID","value":"687015"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139000":{"preferredName":"Glioma Lysate Vaccine GBM6-AD","code":"C139000","definitions":[{"definition":"An allogeneic cell lysate-based vaccine derived from the glioma stem cell line GBM6-AD, which was isolated from the brain tumor of a patient diagnosed with glioblastoma multiforme (GBM), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, the glioma lysate vaccine GBM6-AD exposes the immune system to an undefined amount of glioma-associated antigens (GAAs), and stimulates the immune system to mount a specific anti-tumoral, cytotoxic T-lymphocyte (CTL)-mediated response against the GAA-expressing cells, resulting in glioma cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioma Lysate Vaccine GBM6-AD","termGroup":"PT","termSource":"NCI"},{"termName":"GBM6-AD","termGroup":"CN","termSource":"NCI"},{"termName":"GBM6-AD Lysate Protein Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Glioma Cell Lysate Vaccine GBM6-AD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioma Lysate Vaccine GBM6-AD"},{"name":"NCI_Drug_Dictionary_ID","value":"790956"},{"name":"NCI_META_CUI","value":"CL526538"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790956"},{"name":"PDQ_Open_Trial_Search_ID","value":"790956"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114496":{"preferredName":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701","code":"C114496","definitions":[{"definition":"A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701","termGroup":"PT","termSource":"NCI"},{"termName":"SL-701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701"},{"name":"NCI_Drug_Dictionary_ID","value":"759093"},{"name":"NCI_META_CUI","value":"CL472322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759093"},{"name":"PDQ_Open_Trial_Search_ID","value":"759093"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119745":{"preferredName":"Globo H-DT Vaccine OBI-833","code":"C119745","definitions":[{"definition":"A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Globo H-DT Vaccine OBI-833","termGroup":"PT","termSource":"NCI"},{"termName":"Globo H-CRM197 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"OBI-833","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2142641-90-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NC1XBS5AET"},{"name":"Maps_To","value":"Globo H-DT Vaccine OBI-833"},{"name":"NCI_Drug_Dictionary_ID","value":"767196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767196"},{"name":"PDQ_Open_Trial_Search_ID","value":"767196"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896801"}]}}{"C346":{"preferredName":"Glucarpidase","code":"C346","definitions":[{"definition":"A bacterial enzyme that breaks down proteins and other substances, including methotrexate. It is being studied in the treatment of toxic effects caused by methotrexate. It may also help activate certain drugs to kill cancer cells. It is a type of chemoprotective agent and a type of prodrug activator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A zinc-dependent enzyme isolated from a strain of the bacterium Pseudomonas. Because glucarpidase rapidly hydrolyzes methotrexate into inactive metabolites, it may be useful as a rescue agent for methotrexate-induced nephrotoxicity. In antibody-directed enzyme prodrug therapy (ADEPT), this agent is conjugated with an antibody that binds to a specific tumor cell type, allowing for glucarpidase-catalyzed activation of a co-administered prodrug at the site of the tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glucarpidase","termGroup":"PT","termSource":"NCI"},{"termName":"Acetylaspartylglutamate Dipeptidase","termGroup":"SY","termSource":"NCI"},{"termName":"Carboxypeptidase G2","termGroup":"SY","termSource":"NCI"},{"termName":"CPDG2","termGroup":"AB","termSource":"NCI"},{"termName":"CPG2","termGroup":"AB","termSource":"NCI"},{"termName":"Megludase","termGroup":"FB","termSource":"NCI"},{"termName":"Poly(gamma-glutamic Acid) Endohydrolase","termGroup":"SY","termSource":"NCI"},{"termName":"Pteroylpolygammaglutamyl Hydrolase","termGroup":"SY","termSource":"NCI"},{"termName":"Voraxaze","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9074-87-7"},{"name":"Chemical_Formula","value":"C20H20O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2GFP9BJD79"},{"name":"Legacy Concept Name","value":"Carboxypeptidase-G2"},{"name":"Maps_To","value":"Glucarpidase"},{"name":"NCI_Drug_Dictionary_ID","value":"41665"},{"name":"NSC Number","value":"641273"},{"name":"NSC Number","value":"732443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41665"},{"name":"PDQ_Open_Trial_Search_ID","value":"41665"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0007072"}]}}{"C162509":{"preferredName":"Glucocorticoid Receptor Antagonist ORIC-101","code":"C162509","definitions":[{"definition":"A mifepristone-based steroidal glucocorticoid receptor (GR) antagonist with potential antineoplastic activity. Upon oral administration, ORIC-101 selectively binds to GRs, thereby inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers. Due to its reduced androgen receptor (AR) agonistic activity and improved cytochrome P450 2C8 (CYP2C8) and 2C9 (CYP2C9) inhibition profile, ORIC-101 may be useful in the treatment of AR-positive tumors with reduced potential for drug-drug interactions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glucocorticoid Receptor Antagonist ORIC-101","termGroup":"PT","termSource":"NCI"},{"termName":"19,21-Dinorchol-4-en-20(22)-yn-3-one, 17-Hydroxy-23,23-dimethyl-11-(4-(methyl(1-methylethyl)amino)phenyl)-, (11.Beta.,17.Alpha.)-","termGroup":"SN","termSource":"NCI"},{"termName":"GR Antagonist ORIC-101","termGroup":"SY","termSource":"NCI"},{"termName":"ORIC 101","termGroup":"CN","termSource":"NCI"},{"termName":"ORIC-101","termGroup":"CN","termSource":"NCI"},{"termName":"ORIC101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222344-98-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VI6E2D3CYP"},{"name":"Maps_To","value":"Glucocorticoid Receptor Antagonist ORIC-101"},{"name":"NCI_Drug_Dictionary_ID","value":"798818"},{"name":"NCI_META_CUI","value":"CL970945"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798818"},{"name":"PDQ_Open_Trial_Search_ID","value":"798818"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1612":{"preferredName":"Glufosfamide","code":"C1612","definitions":[{"definition":"A compound consisting of the mustard agent ifosforamide conjugated to glucose, with potential alkylating activity. Glufosfamide is cleaved by glucosidases in tumor cells and forms ifosforamide. In turn, ifosforamide alkylates and forms DNA crosslinks, thereby inhibiting DNA replication and subsequent cell growth. The glucose moiety may enhance this agent's uptake by tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Glufosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"Beta-D-Glucosyl-Ifosfamide Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"D-19575","termGroup":"CN","termSource":"NCI"},{"termName":"glc-IPM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"132682-98-5"},{"name":"Chemical_Formula","value":"C10H21Cl2N2O7P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1W5N8SZD9A"},{"name":"Legacy Concept Name","value":"Glufosfamide"},{"name":"Maps_To","value":"Glufosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"42676"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42676"},{"name":"PDQ_Open_Trial_Search_ID","value":"42676"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0380377"}]}}{"C156700":{"preferredName":"Gumarontinib","code":"C156700","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, gumarontinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gumarontinib","termGroup":"PT","termSource":"NCI"},{"termName":"Glumetinib","termGroup":"SY","termSource":"NCI"},{"termName":"SCC 244","termGroup":"CN","termSource":"NCI"},{"termName":"SCC-244","termGroup":"CN","termSource":"NCI"},{"termName":"SCC244","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1642581-63-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7JTT036WGX"},{"name":"Maps_To","value":"Glumetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"795718"},{"name":"NCI_META_CUI","value":"CL935869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795718"},{"name":"PDQ_Open_Trial_Search_ID","value":"795718"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114381":{"preferredName":"Telaglenastat","code":"C114381","definitions":[{"definition":"An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telaglenastat","termGroup":"PT","termSource":"NCI"},{"termName":"CB-839","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10815","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1439399-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U6CL98GLP4"},{"name":"Maps_To","value":"Glutaminase Inhibitor CB-839"},{"name":"Maps_To","value":"Telaglenastat"},{"name":"NCI_Drug_Dictionary_ID","value":"758477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758477"},{"name":"PDQ_Open_Trial_Search_ID","value":"758477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827146"}]}}{"C150413":{"preferredName":"Telaglenastat Hydrochloride","code":"C150413","definitions":[{"definition":"The hydrochloride salt form of CB-839, an orally bioavailable inhibitor of glutaminase, with potential antineoplastic and immunostimulating activities. Upon oral administration, CB-839 selectively and reversibly binds to and inhibits human glutaminase, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, CB-839 causes accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon cell death. As glutamine is essential for T-cell generation, CB-839 may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telaglenastat Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CB-839 HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Glutaminase Inhibitor CB-839 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1874231-60-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B33561JJ61"},{"name":"Maps_To","value":"Glutaminase Inhibitor CB-839 Hydrochloride"},{"name":"Maps_To","value":"Telaglenastat Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"801359"},{"name":"NCI_META_CUI","value":"CL552142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801359"},{"name":"PDQ_Open_Trial_Search_ID","value":"801359"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106121":{"preferredName":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101","code":"C106121","definitions":[{"definition":"A glutathione (GSH) pegylated, liposome-encapsulated preparation of the hydrochloride salt form of the anthracycline antineoplastic antibiotic doxorubicin, with potential anetineoplastic activity. Upon administration, the glutathione pegylated liposomal formulation 2B3-101 specifically delivers doxorubicin into the brain. Doxorubicin intercalates between DNA base pairs and interferes with topoisomerase II activity, which inhibits both DNA replication and RNA synthesis, resulting in cancer cell death and tumor regression. Doxorubicin also generates reactive oxygen species, which causes cell membrane lipid peroxidation leading to cytotoxicity. The pegylated liposomal delivery of doxorubicin improves drug penetration into tumors and prolongs circulation time, thereby increasing doxorubicin's efficacy and decreasing its toxicity. Conjugation of GSH to the PEG molecules directs the liposomes to the GSH transporters on the blood brain barrier (BBB) and improves the delivery of doxorubicin into the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101","termGroup":"PT","termSource":"NCI"},{"termName":"2B3-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101"},{"name":"NCI_Drug_Dictionary_ID","value":"748730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748730"},{"name":"PDQ_Open_Trial_Search_ID","value":"748730"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827174"}]}}{"C151952":{"preferredName":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01","code":"C151952","definitions":[{"definition":"A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01","termGroup":"PT","termSource":"NCI"},{"termName":"CHO H01","termGroup":"CN","termSource":"NCI"},{"termName":"CHO-H01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OJ72N0B4UC"},{"name":"Maps_To","value":"Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01"},{"name":"NCI_Drug_Dictionary_ID","value":"793171"},{"name":"NCI_META_CUI","value":"CL553180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793171"},{"name":"PDQ_Open_Trial_Search_ID","value":"793171"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97917":{"preferredName":"Glycooptimized Trastuzumab-GEX","code":"C97917","definitions":[{"definition":"A glycoengineered form of a monoclonal antibody directed against the human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. Glycooptimized trastuzumab-GEX specifically binds to the extracellular domain of HER2, thereby inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. This eventually results in apoptosis and growth inhibition of tumor cells. HER2, a member of the receptor tyrosine kinase EGFR superfamily, is overexpressed on the cell surfaces of various solid tumors. This agent has a specific glycosylation profile that may enhance its ADCC response against HER2-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glycooptimized Trastuzumab-GEX","termGroup":"PT","termSource":"NCI"},{"termName":"Ant-HER2 Monoclonal Antibody GT-Mab 7.3-GEX","termGroup":"SY","termSource":"NCI"},{"termName":"GT-Mab 7.3-GEX","termGroup":"SY","termSource":"NCI"},{"termName":"TrasGEX","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Glycooptimized Trastuzumab-GEX"},{"name":"NCI_Drug_Dictionary_ID","value":"708211"},{"name":"NCI_META_CUI","value":"CL430400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"708211"},{"name":"PDQ_Open_Trial_Search_ID","value":"708211"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98287":{"preferredName":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102","code":"C98287","definitions":[{"definition":"A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102","termGroup":"PT","termSource":"NCI"},{"termName":"CGTG-102","termGroup":"CN","termSource":"NCI"},{"termName":"ONCOS-102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GM-CSF-encoding Oncolytic Adenovirus CGTG-102"},{"name":"NCI_Drug_Dictionary_ID","value":"712555"},{"name":"NCI_META_CUI","value":"CL432405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712555"},{"name":"PDQ_Open_Trial_Search_ID","value":"712555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74037":{"preferredName":"Gold Sodium Thiomalate","code":"C74037","definitions":[{"definition":"The sodium salt of gold thiomalic acid, an organogold compound with antirheumatic and potential antineoplastic activities. Gold sodium thiomalate (GST) appears to inhibit the activity of atypical protein kinase C iota (PKCiota) by forming a cysteinyl-aurothiomalate adduct with the cysteine residue Cys-69 within the PB1 binding domain of PKCiota. This prevents the binding of Par6 (Partitioning defective protein 6) to PKCiota, thereby inhibiting PKCiota-mediated oncogenic signaling, which may result in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. Atypical PKCiota, a serine/threonine kinase overexpressed in numerous cancer cell types, plays an important role in cancer proliferation, invasion, and survival; Par6 is a scaffold protein that facilitates atypical PKC-mediated phosphorylation of cytoplasmic proteins involved in epithelial and neuronal cell polarization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gold Sodium Thiomalate","termGroup":"PT","termSource":"NCI"},{"termName":"Aurolate","termGroup":"BR","termSource":"NCI"},{"termName":"Aurothiomalate Disodium","termGroup":"SY","termSource":"NCI"},{"termName":"Myochrysine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12244-57-4"},{"name":"CHEBI_ID","value":"CHEBI:5516"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E4768ZY6GM"},{"name":"Legacy Concept Name","value":"Gold_Sodium_Thiomalate"},{"name":"Maps_To","value":"Gold Sodium Thiomalate"},{"name":"NCI_Drug_Dictionary_ID","value":"581226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581226"},{"name":"PDQ_Open_Trial_Search_ID","value":"581226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0018034"}]}}{"C26444":{"preferredName":"Golnerminogene Pradenovec","code":"C26444","definitions":[{"definition":"A gene therapy product that is being studied in combination with radiation therapy in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golnerminogene Pradenovec","termGroup":"PT","termSource":"NCI"},{"termName":"Ad 5-TNF Alpha","termGroup":"AB","termSource":"NCI"},{"termName":"Adenovirus 5-Tumor Necrosis Factor Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"ADgv EGR.TNF.11D","termGroup":"CN","termSource":"NCI"},{"termName":"TNFerade","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of solid tumors including pancreatic cancer"},{"name":"CAS_Registry","value":"957472-14-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Adenovirus_5-Tumor_Necrosis_Factor_Alpha"},{"name":"Maps_To","value":"Golnerminogene Pradenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"258431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"258431"},{"name":"PDQ_Open_Trial_Search_ID","value":"258431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327819"}]}}{"C76497":{"preferredName":"Golotimod","code":"C76497","definitions":[{"definition":"An orally bioavailable synthetic peptide containing the amino acids D-glutamine and L-tryptophan connected by a gamma-glutamyl linkage with potential immunostimulating, antimicrobial and antineoplastic activities. Although the exact mechanism of action is unknown, golotimod appears to inhibit the expression of STAT-3, reversing immunosuppression and stimulating an anti-tumor immune response. This agent may stimulate the production of T-lymphocytes, in particular the helper T (Th1) cells, activate macrophages, and increase levels of interleukin 2 and interferon gamma. STAT-3, a transcription factor upregulated in many cancer cell types, is involved in tumor cell growth and survival and immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golotimod","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"gamma-D-Glu-L-trp","termGroup":"AB","termSource":"NCI"},{"termName":"Gamma-D-Glutamyl-L-Tryptophan","termGroup":"SY","termSource":"NCI"},{"termName":"SCV 07","termGroup":"CN","termSource":"NCI"},{"termName":"SCV-07","termGroup":"CN","termSource":"NCI"},{"termName":"SCV07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"229305-39-9"},{"name":"Chemical_Formula","value":"C16H19N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"637C487Y09"},{"name":"Legacy Concept Name","value":"Golotimod"},{"name":"Maps_To","value":"Golotimod"},{"name":"NCI_Drug_Dictionary_ID","value":"617379"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617379"},{"name":"PDQ_Open_Trial_Search_ID","value":"617379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1173247"}]}}{"C82363":{"preferredName":"Golvatinib","code":"C82363","definitions":[{"definition":"An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golvatinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-cyclopropanedicarboxamide, N-(2-fluoro-4-((2-(((4-(4-methyl-1-piperazinyl)-1-piperidinyl)carbonyl)amino)-4-pyridinyl)oxy)phenyl)-N'-(4-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"c-Met/VEGFR-2 Kinase Inhibitor E7050","termGroup":"SY","termSource":"NCI"},{"termName":"E7050","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"928037-13-2"},{"name":"Chemical_Formula","value":"C33H37F2N7O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"516Z3YP58E"},{"name":"Legacy Concept Name","value":"c-Met_VEGFR_Kinase_Inhibitor_E7050"},{"name":"Maps_To","value":"Golvatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"640626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640626"},{"name":"PDQ_Open_Trial_Search_ID","value":"640626"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642430"}]}}{"C1910":{"preferredName":"Gonadotropin-releasing Hormone Analog","code":"C1910","definitions":[{"definition":"A substance that keeps the testicles and ovaries from making sex hormones by blocking other hormones that are needed to make them. In men, gonadotropin-releasing hormone agonists cause the testicles to stop making testosterone. In women, they cause the ovaries to stop making estrogen and progesterone. Some gonadotropin-releasing hormone agonists are used to treat prostate cancer. Also called GnRH agonist, LH-RH agonist, and luteinizing hormone-releasing hormone agonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gonadotropin-releasing Hormone Analog","termGroup":"PT","termSource":"NCI"},{"termName":"GnRH Agonist","termGroup":"SY","termSource":"NCI"},{"termName":"GnRH Analog","termGroup":"SY","termSource":"NCI"},{"termName":"Gonadotropin-Releasing Hormone Agonist","termGroup":"SY","termSource":"NCI"},{"termName":"Gonadotropin-Releasing Hormone Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"LH-RH Analogs","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinizing Hormone-Releasing Hormone Analog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Luteinizing_Hormone-releasing_Hormone_Agonist"},{"name":"Maps_To","value":"Gonadotropin-releasing Hormone Analog"},{"name":"NCI_Drug_Dictionary_ID","value":"42628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42628"},{"name":"PDQ_Open_Trial_Search_ID","value":"42628"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1268900"}]}}{"C1374":{"preferredName":"Goserelin","code":"C1374","definitions":[{"definition":"A drug that belongs to the family of drugs called gonadotropin-releasing hormone analogues. Goserelin is used to block hormone production in the ovaries or testicles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goserelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"ICI-118630","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Endometrial-thinning; Endometriosis; In vitro fertilization; Prostate cancer"},{"name":"CAS_Registry","value":"65807-02-5"},{"name":"Chemical_Formula","value":"C59H84N18O14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"0F65R8P09N"},{"name":"Legacy Concept Name","value":"Goserelin"},{"name":"Maps_To","value":"Goserelin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0120107"}]}}{"C1417":{"preferredName":"Goserelin Acetate","code":"C1417","definitions":[{"definition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goserelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"D-Ser(bu(t))(6)azgly(10)-LHRH Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"ZDX","termGroup":"AB","termSource":"NCI"},{"termName":"Zoladex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast Carcinoma; Prostate Carcinoma; Endometriosis"},{"name":"CAS_Registry","value":"65807-02-5"},{"name":"Chemical_Formula","value":"C59H84N18O14.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YUU2PV0U8"},{"name":"Legacy Concept Name","value":"Goserelin_Acetate"},{"name":"Maps_To","value":"Goserelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"40224"},{"name":"NSC Number","value":"606864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40224"},{"name":"PDQ_Open_Trial_Search_ID","value":"40224"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700476"}]}}{"C156710":{"preferredName":"Goserelin Acetate Extended-release Microspheres LY01005","code":"C156710","definitions":[{"definition":"A long-acting, extended-release microsphere formulation of the acetate form of goserelin, a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH), with potential antineoplastic activity. Upon administration, goserelin binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in an extended-release formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Goserelin Acetate Extended-release Microspheres LY01005","termGroup":"PT","termSource":"NCI"},{"termName":"Goserelin Acetate Extended-release Microspheres","termGroup":"SY","termSource":"NCI"},{"termName":"LY 01005","termGroup":"CN","termSource":"NCI"},{"termName":"LY-01005","termGroup":"SY","termSource":"NCI"},{"termName":"LY01005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Goserelin Acetate Extended-release Microspheres LY01005"},{"name":"NCI_Drug_Dictionary_ID","value":"795737"},{"name":"NCI_META_CUI","value":"CL935864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795737"},{"name":"PDQ_Open_Trial_Search_ID","value":"795737"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C529":{"preferredName":"Gossypol","code":"C529","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It comes from the seed of the cotton plant (Gossypium). It blocks the growth of cells and may kill cancer cells. Cottonseed meal toxin may also act as a male contraceptive (a type of birth control).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active polyphenolic aldehyde with potential antineoplastic activity. Derived primarily from unrefined cottonseed oil, gossypol induces cell cycle arrest at the G0/G1 phase, thereby inhibiting DNA replication and inducing apoptosis. This agent also inhibits cell-signaling enzymes, resulting in inhibition of cell growth, and may act as a male contraceptive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gossypol","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-Gossypol","termGroup":"SY","termSource":"NCI"},{"termName":"1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde","termGroup":"SN","termSource":"NCI"},{"termName":"1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3-3'-dimethyl[2,2'-binaphthalene]-8,8'-dicarboxaldehyde","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-bis(1,6,7-trihydroxy-4-methyl-5-isopropyl-8-aldehydonaphthalene)","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-bis[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]","termGroup":"SN","termSource":"NCI"},{"termName":"BL-193","termGroup":"CN","termSource":"NCI"},{"termName":"Cottonseed Meal Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"No Fertil","termGroup":"BR","termSource":"NCI"},{"termName":"Pogosin","termGroup":"SY","termSource":"NCI"},{"termName":"Tash 1","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"303-45-7"},{"name":"CHEBI_ID","value":"CHEBI:28584"},{"name":"Chemical_Formula","value":"C30H30O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KAV15B369O"},{"name":"Legacy Concept Name","value":"Gossypol"},{"name":"Maps_To","value":"Gossypol"},{"name":"NCI_Drug_Dictionary_ID","value":"505287"},{"name":"NSC Number","value":"56817"},{"name":"NSC Number","value":"624336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"505287"},{"name":"PDQ_Open_Trial_Search_ID","value":"505287"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0018096"}]}}{"C1118":{"preferredName":"Gossypol Acetic Acid","code":"C1118","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It is a form of a chemical taken from the seed of the cotton plant (Gossypium). It blocks the growth of cells and may kill cancer cells. Gossypol acetic acid may also act as a male contraceptive (form of birth control).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The naturally occurring acetic acid form of gossypol, and an orally available polyphenolic aldehyde derived mostly from cottonseed with potential antineoplastic activity.  The biologic activities of gossypol acetic acid are similar to those of gossypol and include suppression of DNA replication, inhibition of tumor cell proliferation, and male contraceptive effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gossypol Acetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Gossypol Acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12542-36-8"},{"name":"Chemical_Formula","value":"C30H30O8.C2H4O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S7RL72610R"},{"name":"Legacy Concept Name","value":"Gossypol_Acetic_Acid"},{"name":"Maps_To","value":"Gossypol Acetic Acid"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0061824"}]}}{"C124131":{"preferredName":"Grapiprant","code":"C124131","definitions":[{"definition":"An orally bioavailable antagonist of the prostaglandin E receptor subtype 4 (EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration of grapiprant, this agent selectively binds to and inhibits the binding of prostaglandin E2 (PGE2) and prevents the activation of the EP4 receptor. This inhibits PGE2-EP4 receptor-mediated signaling and prevents proliferation in tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 receptor inhibition modulates the immune system by preventing both interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. As EP4 is expressed by peripheral sensory neurons, blockade of EP4-mediated signaling may induce an analgesic effect. EP4, a prostanoid receptor subtype, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Grapiprant","termGroup":"PT","termSource":"NCI"},{"termName":"AAT-007","termGroup":"CN","termSource":"NCI"},{"termName":"AT-001","termGroup":"CN","termSource":"NCI"},{"termName":"CJ 023,423","termGroup":"CN","termSource":"NCI"},{"termName":"CJ-023,423","termGroup":"CN","termSource":"NCI"},{"termName":"CJ023,423","termGroup":"CN","termSource":"NCI"},{"termName":"N-[[2,4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenylethylamino]carbonyl]-4-methyl-benzenesulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"RQ-00000007","termGroup":"CN","termSource":"NCI"},{"termName":"RQ-07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"415903-37-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J9F5ZPH7NB"},{"name":"Maps_To","value":"Grapiprant"},{"name":"NCI_Drug_Dictionary_ID","value":"776626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776626"},{"name":"PDQ_Open_Trial_Search_ID","value":"776626"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4279768"}]}}{"C97514":{"preferredName":"Green Tea Extract-based Antioxidant Supplement","code":"C97514","definitions":[{"definition":"A dietary supplement containing a green tea extract including the catechin epigallocatechin gallate and other vitamins and antioxidants, with potential antineoplastic and chemopreventive activities. The polyphenols in green tea act as antioxidants and scavenge free radicals which may inhibit cellular oxidation and prevent free radical damage to cells. In addition, polyphenols may affect enzymes involved in cellular reproduction and tumor angiogenesis by modulating angiogenic factors. Other ingredients in green tea extract-based antioxidant supplement include dry cinnamon extract, germanium, zinc sulfate, manganese sulfate, arginine, cysteine, malic acid, ascorbic acid (vitamin c), glycyrrhizinic acid, glycine, glucosamine, pyridoxal (vitamin B6), calcium pantothenate (vitamin B5), folic acid, cyanocobalamin (vitamin B12).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Green Tea Extract-based Antioxidant Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Oncoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Green Tea Extract-based Antioxidant Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"703891"},{"name":"NCI_META_CUI","value":"CL430258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703891"},{"name":"PDQ_Open_Trial_Search_ID","value":"703891"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116872":{"preferredName":"Osugacestat","code":"C116872","definitions":[{"definition":"A small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon intravenous administration, osugacestat binds to GS and blocks activation of Notch receptors, which may inhibit the proliferation of tumor cells with an overly-active Notch pathway. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains that lead to their activation. Overactivation of the Notch signaling pathway, often triggered by activating mutations, has been correlated with increased cellular proliferation and poor prognosis in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osugacestat","termGroup":"PT","termSource":"NCI"},{"termName":"AL 101","termGroup":"CN","termSource":"NCI"},{"termName":"AL-101","termGroup":"CN","termSource":"NCI"},{"termName":"AL101","termGroup":"CN","termSource":"NCI"},{"termName":"BM-0018","termGroup":"CN","termSource":"NCI"},{"termName":"BM0018","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-906024","termGroup":"CN","termSource":"NCI"},{"termName":"GS/pan-Notch Inhibitor AL101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401066-79-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DRL23N424R"},{"name":"Maps_To","value":"GS/pan-Notch Inhibitor AL101"},{"name":"NCI_Drug_Dictionary_ID","value":"695660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695660"},{"name":"PDQ_Open_Trial_Search_ID","value":"695660"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896900"}]}}{"C118573":{"preferredName":"GS/pan-Notch Inhibitor AL102","code":"C118573","definitions":[{"definition":"An orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, GS/pan-Notch inhibitor AL102 binds to GS and blocks the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth of tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains and leads to their activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GS/pan-Notch Inhibitor AL102","termGroup":"PT","termSource":"NCI"},{"termName":"AL 102","termGroup":"CN","termSource":"NCI"},{"termName":"AL-102","termGroup":"CN","termSource":"NCI"},{"termName":"AL102","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986115","termGroup":"CN","termSource":"NCI"},{"termName":"WHG 626","termGroup":"CN","termSource":"NCI"},{"termName":"WHG-626","termGroup":"CN","termSource":"NCI"},{"termName":"WHG626","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1584647-27-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LSK1L593UU"},{"name":"Maps_To","value":"GS/pan-Notch Inhibitor BMS-986115"},{"name":"NCI_Drug_Dictionary_ID","value":"754986"},{"name":"NCI_META_CUI","value":"CL471756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754986"},{"name":"PDQ_Open_Trial_Search_ID","value":"754986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156792":{"preferredName":"Elraglusib","code":"C156792","definitions":[{"definition":"A maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3; serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Upon intravenous administration, elraglusib binds to and competitively inhibits GSK-3, which may lead to downregulation of nuclear factor kappa B (NF-kappaB) and decreased expression of NF-kappaB target genes including cyclin D1, B-cell lymphoma 2 (Bcl-2), anti-apoptotic protein XIAP, and B-cell lymphoma extra-large (Bcl-XL). This may inhibit NF-kappaB-mediated survival and chemoresistance in certain tumor types. GSK-3, a constitutively active serine/threonine kinase that plays a role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and metabolism, is aberrantly overexpressed in certain tumor types and may promote tumor cell survival and resistance to chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elraglusib","termGroup":"PT","termSource":"NCI"},{"termName":"9 ING 41","termGroup":"CN","termSource":"NCI"},{"termName":"9-ING-41","termGroup":"CN","termSource":"NCI"},{"termName":"Glycogen Synthase Kinase-3 Inhibitor 9-ING-41","termGroup":"SY","termSource":"NCI"},{"termName":"GSK-3 Inhibitor 9-ING-41","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1034895-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ND1SOF0DLU"},{"name":"Maps_To","value":"GSK-3 Inhibitor 9-ING-41"},{"name":"NCI_Drug_Dictionary_ID","value":"796464"},{"name":"NCI_META_CUI","value":"CL935798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796464"},{"name":"PDQ_Open_Trial_Search_ID","value":"796464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116849":{"preferredName":"GSK-3 Inhibitor LY2090314","code":"C116849","definitions":[{"definition":"An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK-3 in an ATP-competitive manner. This prevents GSK-3-mediated phosphorylation of beta-catenin, which inhibits the subsequent ubiquitination and proteasomal degradation of beta-catenin. This leads to the activation of the Wnt/beta-catenin pathway and the induction of apoptosis in susceptible tumor cells. GSK-3, a serine/threonine kinase, plays a key role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and apoptosis. The Wnt/beta-catenin signaling pathway plays key roles in both cellular proliferation and differentiation. The increased expression of beta-catenin, a transcriptional activator, correlates with decreased cellular proliferation and improved prognosis in select cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GSK-3 Inhibitor LY2090314","termGroup":"PT","termSource":"NCI"},{"termName":"3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"LY 2090314","termGroup":"CN","termSource":"NCI"},{"termName":"LY-2090314","termGroup":"CN","termSource":"NCI"},{"termName":"LY2090314","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"603288-22-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"822M3GYM67"},{"name":"Maps_To","value":"GSK-3 Inhibitor LY2090314"},{"name":"NCI_Drug_Dictionary_ID","value":"686910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686910"},{"name":"PDQ_Open_Trial_Search_ID","value":"686910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3713994"}]}}{"C95209":{"preferredName":"Guadecitabine","code":"C95209","definitions":[{"definition":"A dinucleotide antimetabolite composed of a decitabine linked via phosphodiester bond to a deoxyguanosine, with potential antineoplastic activity. Following metabolic activation via cleavage of the phosphodiester bond and incorporation of the decitabine moiety into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing non-specific, genome-wide hypomethylation, and induction of cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, which may result in gradual release of decitabine both extra- and intra-cellularly, leading to prolonged exposure to decitabine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guadecitabine","termGroup":"PT","termSource":"NCI"},{"termName":"DNMT inhibitor SGI-110","termGroup":"AB","termSource":"NCI"},{"termName":"S110","termGroup":"CN","termSource":"NCI"},{"termName":"SGI 110","termGroup":"CN","termSource":"NCI"},{"termName":"SGI-110","termGroup":"CN","termSource":"NCI"},{"termName":"SGI110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"929901-49-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2KT4YN1DP7"},{"name":"Maps_To","value":"Guadecitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"691684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691684"},{"name":"PDQ_Open_Trial_Search_ID","value":"691684"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986994"}]}}{"C65826":{"preferredName":"Guanabenz Acetate","code":"C65826","definitions":[{"definition":"The orally bioavailable, acetate salt form of guanabenz, a centrally-acting alpha-2 adrenergic receptor agonist, with anti-hypertensive and potential antineoplastic, cytoprotective and bone resorption inhibitory activities. Upon oral administration, guanabenz suppresses endoplasmic reticulum (ER) stress by inhibiting the stress-induced dephosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2a), thereby enhancing the phosphorylation level of eIF2a. This causes elF2a-mediated downregulation of the Rac1 pathway, upregulates the expression of activating transcription factor 4 (ATF4), which plays a key role in osteoblastogenesis, and downregulates the expression of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), which is a transcription factor that plays a key role in osteoclastogenesis. This enhances osteoblastogenesis and suppresses osteoclastogenesis. Altogether, this promotes new bone formation and prevents bone degradation. In addition, guanabenz blocks the proliferation, survival, motility and invasiveness of tumor cells through the eIF2a-mediated downregulation of Rac1 signaling. Rac1, a Ras-related small GTPase belonging to the Rho family, plays a key role in tumor cell proliferation, survival and motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guanabenz Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"3-((2,6-Dichlorophenyl)methylene)carbazamidine Monoacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Wytensin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23256-50-0"},{"name":"Chemical_Formula","value":"C8H8Cl2N4.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"443O19GK1A"},{"name":"Legacy Concept Name","value":"Guanabenz_Acetate"},{"name":"Maps_To","value":"Guanabenz Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"772252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772252"},{"name":"PDQ_Open_Trial_Search_ID","value":"772252"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0018313"}]}}{"C150390":{"preferredName":"Guselkumab","code":"C150390","definitions":[{"definition":"An orally available, human, immunoglobulin G1 (IgG1) kappa, monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon administration, guselkumab binds to the p19 subunit of IL-23, thereby blocking the binding of IL-23 to the IL-23 receptor. This inhibits IL-23-mediated signaling and the differentiation of CD4-positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated immune responses and inhibits the production of pro-inflammatory cytokines. This may prevent or reduce symptoms and severity of immune-mediated inflammatory disorders. IL-23 plays a key role in the regulation of inflammation and the immune system, and modulates the release of various pro-inflammatory cytokines and chemokines. It is upregulated in various immune-mediated inflammatory disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guselkumab","termGroup":"PT","termSource":"NCI"},{"termName":"CNTO 1959","termGroup":"CN","termSource":"NCI"},{"termName":"Tremfya","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1350289-85-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"089658A12D"},{"name":"Maps_To","value":"Guselkumab"},{"name":"NCI_Drug_Dictionary_ID","value":"792847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792847"},{"name":"PDQ_Open_Trial_Search_ID","value":"792847"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852217"}]}}{"C1598":{"preferredName":"Gusperimus Trihydrochloride","code":"C1598","definitions":[{"definition":"A derivative of the antitumor antibiotic spergualin with immunosuppressant activity.  Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gusperimus Trihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1-Amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione","termGroup":"SN","termSource":"NCI"},{"termName":"15-Deoxyspergualin","termGroup":"SN","termSource":"NCI"},{"termName":"15-Deoxyspergualin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"7-[(Aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amnio]-1-hydroxy-2-oxoethyl]heptanamide","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-181173","termGroup":"CN","termSource":"NCI"},{"termName":"BMY-42215-1","termGroup":"CN","termSource":"NCI"},{"termName":"Deoxyspergualin","termGroup":"SY","termSource":"NCI"},{"termName":"Deoxyspergualin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"DSG","termGroup":"AB","termSource":"NCI"},{"termName":"N-[[[4-[(3-Aminopropyl)amino]-butyl]carbamoyl]hydroxymethyl]-7-guanidinoheptanamide","termGroup":"SN","termSource":"NCI"},{"termName":"NKT-01","termGroup":"CN","termSource":"NCI"},{"termName":"Spanidin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84937-45-1"},{"name":"Chemical_Formula","value":"C17H37N7O3.3HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QZS4144IO0"},{"name":"Legacy Concept Name","value":"Gusperimus"},{"name":"Maps_To","value":"Gusperimus Trihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"40369"},{"name":"NSC Number","value":"356894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40369"},{"name":"PDQ_Open_Trial_Search_ID","value":"40369"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0284559"}]}}{"C1532":{"preferredName":"Gutolactone","code":"C1532","definitions":[{"definition":"A quassinoid phytochemical isolated from the plant Simaba guianensis with potential antineoplastic and antimalarial activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gutolactone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152369-48-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gutolactone"},{"name":"Maps_To","value":"Gutolactone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0250977"}]}}{"C2024":{"preferredName":"H-ras Antisense Oligodeoxynucleotide ISIS 2503","code":"C2024","definitions":[{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic oligodeoxynucleotide.  Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the oncogene H-Ras.  ISIS 2503 selectively inhibits the expression of H-Ras, and may inhibit the growth of some Ras-dependent tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H-ras Antisense Oligodeoxynucleotide ISIS 2503","termGroup":"PT","termSource":"NCI"},{"termName":"H-RAS Antisense","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 2503","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS-2503","termGroup":"CN","termSource":"NCI"},{"termName":"ISIS2503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149957-14-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I444I66XWH"},{"name":"Legacy Concept Name","value":"ISIS_2503"},{"name":"Maps_To","value":"H-ras Antisense Oligodeoxynucleotide ISIS 2503"},{"name":"NCI_Drug_Dictionary_ID","value":"37795"},{"name":"NSC Number","value":"718878"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37795"},{"name":"PDQ_Open_Trial_Search_ID","value":"37795"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879385"}]}}{"C114284":{"preferredName":"H1299 Tumor Cell Lysate Vaccine","code":"C114284","definitions":[{"definition":"A cell lysate derived from a lung cancer cell line, H1299, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, the H1299 tumor cell lysate exposes the immune system to an undefined amount of tumor associated antigens (TAA), particularly cancer testis antigens (CTAs), which may result in the induction of both anti-tumoral cytotoxic T-lymphocytes (CTL) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. CTAs, such as MAGE, are selectively expressed in a variety of cancers but are not expressed in normal, healthy cells outside the testis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"H1299 Tumor Cell Lysate Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"H1299 Lysate Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"H1299 Tumor Cell Lysate Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"757927"},{"name":"NCI_META_CUI","value":"CL471792"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757927"},{"name":"PDQ_Open_Trial_Search_ID","value":"757927"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148522":{"preferredName":"HAAH Lambda phage Vaccine SNS-301","code":"C148522","definitions":[{"definition":"A nanoparticle-based cancer vaccine composed of a neutralized bacteriophage Lambda construct that is genetically engineered to contain peptide fragments of human aspartyl/asparaginyl beta-hydroxylase (HAAH; ASPH) on its surface and are fused to the C-terminus of the head protein of phage lambda gpD, with potential immunostimulating and antineoplastic activities. HAAH lambda phage vaccine SNS-301 also contains DNA fragments representing the phage CpG motif that activate the MHC class II pathway. Upon intradermal administration of the HAAH lambda phage vaccine SNS-301, the bacteriophage exposes the immune system to HAAH, producing a HAAH-specific antibody response, and may activate the immune system to induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against HAAH-expressing tumor cells. HAAH is a transmembrane protein and highly conserved enzyme that catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of substrate proteins. HAAH is normally expressed in fetal development and is upregulated in a variety of cancer cell types, while its expression is nearly absent in healthy, normal cells. HAAH plays a key role in cancer cell growth, cell motility and invasiveness. Its expression is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HAAH Lambda phage Vaccine SNS-301","termGroup":"PT","termSource":"NCI"},{"termName":"Bacteriophage Cancer Vaccine SNS-301","termGroup":"SY","termSource":"NCI"},{"termName":"HAAH-1/2/3 Lambda Phage Vaccine SNS-301","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle HAAH Vaccine SNS-301","termGroup":"SY","termSource":"NCI"},{"termName":"PAN 301-1","termGroup":"CN","termSource":"NCI"},{"termName":"PAN-301-1","termGroup":"CN","termSource":"NCI"},{"termName":"SNS 301","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-301","termGroup":"CN","termSource":"NCI"},{"termName":"SNS301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HAAH Lambda phage Vaccine SNS-301"},{"name":"NCI_Drug_Dictionary_ID","value":"792681"},{"name":"NCI_META_CUI","value":"CL551142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792681"},{"name":"PDQ_Open_Trial_Search_ID","value":"792681"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98280":{"preferredName":"Hafnium Oxide-containing Nanoparticles NBTXR3","code":"C98280","definitions":[{"definition":"A suspension of nanoparticles containing inert inorganic hafnium oxide (HfO2) crystals with potential antineoplastic activity. Upon injection of NBTXR3 in the tumor, the hafnium oxide-containing nanoparticles accumulate into the tumor cells. Subsequent application of radiation beams to the tumor tissue causes HfO2 particles to emit huge amounts of electrons. This results in the formation of free radicals within the tumor cells, which in turn causes targeted destruction of the cancer cells. Compared to standard radiotherapy, because of the inert nature of NBTXR3, this agent emits electrons only during its exposure to radiation which improves radiotherapy efficiency.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hafnium Oxide-containing Nanoparticles NBTXR3","termGroup":"PT","termSource":"NCI"},{"termName":"NBTXR3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12055-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3C4Z4KG52T"},{"name":"Maps_To","value":"Hafnium Oxide-containing Nanoparticles NBTXR3"},{"name":"NCI_Drug_Dictionary_ID","value":"712103"},{"name":"NCI_META_CUI","value":"CL432399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712103"},{"name":"PDQ_Open_Trial_Search_ID","value":"712103"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156697":{"preferredName":"Halichondrin Analogue E7130","code":"C156697","definitions":[{"definition":"A halichondrin analogue derived from a marine sponge with potential antineoplastic activity. Upon intravenous infusion, halichondrin analogue E7130 may bind to the vinca domain of tubulin and inhibit the polymerization of tubulin and the assembly of microtubules, thereby inhibiting mitotic spindle assembly and inducing cell cycle arrest at the G2/M phase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halichondrin Analogue E7130","termGroup":"PT","termSource":"NCI"},{"termName":"E 7130","termGroup":"CN","termSource":"NCI"},{"termName":"E-7130","termGroup":"CN","termSource":"NCI"},{"termName":"E7130","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6WE4X56YH"},{"name":"Maps_To","value":"Halichondrin Analogue E7130"},{"name":"NCI_Drug_Dictionary_ID","value":"795713"},{"name":"NCI_META_CUI","value":"CL935716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795713"},{"name":"PDQ_Open_Trial_Search_ID","value":"795713"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1376":{"preferredName":"Halichondrin B","code":"C1376","definitions":[{"definition":"A complex macrolide polyether from marine sponge genera, such as Halichondria, Axinella, Phakellia, and Lissodendoryx that binds to tubulin, thereby inhibiting mitosis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halichondrin B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103614-76-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"269R6PFM59"},{"name":"Legacy Concept Name","value":"Halichondrin_B"},{"name":"Maps_To","value":"Halichondrin B"},{"name":"NSC Number","value":"609395"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0120715"}]}}{"C1120":{"preferredName":"Halofuginone","code":"C1120","definitions":[{"definition":"An orally-active quinazolinone alkaloid with potential antineoplastic activity. Halofuginone interferes with the signaling pathway of transforming growth factor beta (TGF beta) and inhibits expression of matrix metalloproteinase 2, thereby inhibiting collagen type I synthesis and inducing extracellular matrix degradation, resulting in inhibition of angiogenesis, tumor growth, or metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halofuginone","termGroup":"PT","termSource":"NCI"},{"termName":"trans-(+/-)-7-Bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55837-20-2"},{"name":"Chemical_Formula","value":"C16H17BrClN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L31MM1385E"},{"name":"Legacy Concept Name","value":"Halofuginone"},{"name":"Maps_To","value":"Halofuginone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062095"}]}}{"C2656":{"preferredName":"Halofuginone Hydrobromide","code":"C2656","definitions":[{"definition":"A substance that is being studied for its ability to slow the growth of connective tissue and to prevent the growth of new blood vessels that tumors need to grow. It is a type of quinazolinone alkaloid and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Halofuginone Hydrobromide","termGroup":"PT","termSource":"NCI"},{"termName":"Halofuginone IV (intravenous)","termGroup":"SY","termSource":"NCI"},{"termName":"RU 19110","termGroup":"CN","termSource":"NCI"},{"termName":"Tempostatin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Scleroderma and Antiprotozoal; Coccidiosis (Vet)."},{"name":"CAS_Registry","value":"17395-31-2"},{"name":"CAS_Registry","value":"64924-67-0"},{"name":"Chemical_Formula","value":"C16H17BrClN3O3.BrH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PTC2969MV1"},{"name":"Legacy Concept Name","value":"Halofuginone_Hydrobromide"},{"name":"Maps_To","value":"Halofuginone Hydrobromide"},{"name":"NCI_Drug_Dictionary_ID","value":"38485"},{"name":"NSC Number","value":"713205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38485"},{"name":"PDQ_Open_Trial_Search_ID","value":"38485"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0521922"}]}}{"C121570":{"preferredName":"HCV DNA Vaccine INO-8000","code":"C121570","definitions":[{"definition":"A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HCV DNA Vaccine INO-8000","termGroup":"PT","termSource":"NCI"},{"termName":"INO-8000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HCV DNA Vaccine INO-8000"},{"name":"NCI_Drug_Dictionary_ID","value":"771488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771488"},{"name":"PDQ_Open_Trial_Search_ID","value":"771488"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053630"}]}}{"C160706":{"preferredName":"HDAC Class I/IIb Inhibitor HG146","code":"C160706","definitions":[{"definition":"An orally available inhibitor of histone deacetylase (HDAC) classes I and IIb with potential antineoplastic activities. Upon oral administration, HDAC I/IIb inhibitor HG146 selectively inhibits the catalytic activity of class I and IIb HDACs, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Class I HDACs are located in the nucleus and include HDACs 1, 2, 3, and 8; class IIb HDACs include HDAC 6 and 10 and are located in both the nucleus and the cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Class I/IIb Inhibitor HG146","termGroup":"PT","termSource":"NCI"},{"termName":"Class I/IIb HDACi HG146","termGroup":"SY","termSource":"NCI"},{"termName":"HDAC I/IIb Selective Inhibitor HG146","termGroup":"SY","termSource":"NCI"},{"termName":"HG 146","termGroup":"CN","termSource":"NCI"},{"termName":"HG-146","termGroup":"SY","termSource":"NCI"},{"termName":"HG0146","termGroup":"CN","termSource":"NCI"},{"termName":"HG146","termGroup":"CN","termSource":"NCI"},{"termName":"HG280146","termGroup":"CN","termSource":"NCI"},{"termName":"HG280146-P1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC Class I/IIb Inhibitor HG146"},{"name":"NCI_Drug_Dictionary_ID","value":"797880"},{"name":"NCI_META_CUI","value":"CL969804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797880"},{"name":"PDQ_Open_Trial_Search_ID","value":"797880"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116850":{"preferredName":"HDAC Inhibitor REC-2282","code":"C116850","definitions":[{"definition":"An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, REC-2282 inhibits the catalytic activity of HDAC, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor REC-2282","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"AR-42","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC-42","termGroup":"CN","termSource":"NCI"},{"termName":"OSU-HDAC42","termGroup":"CN","termSource":"NCI"},{"termName":"REC-2282","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"935881-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E0GG29V0AQ"},{"name":"Maps_To","value":"HDAC Inhibitor AR-42"},{"name":"NCI_Drug_Dictionary_ID","value":"673209"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673209"},{"name":"PDQ_Open_Trial_Search_ID","value":"673209"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2001522"}]}}{"C94225":{"preferredName":"Ivaltinostat","code":"C94225","definitions":[{"definition":"A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Ivaltinosta tinhibits the catalytic activity of HDAC, resulting in an accumulation of highly acetylated chromatin histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. In particular, this agent enhances the histone acetylation of the tumor suppressor gene p53. This results in an accumulation of p53, p53-dependent transactivation and apoptosis in tumor cells. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivaltinostat","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-N(1)-(3-(dimethylamino)propyl)-N(8)-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide","termGroup":"SN","termSource":"NCI"},{"termName":"CG200745","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC inhibitor CG200745","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936221-33-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4I8MLM7L2H"},{"name":"Maps_To","value":"HDAC inhibitor CG200745"},{"name":"Maps_To","value":"Ivaltinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"688308"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688308"},{"name":"PDQ_Open_Trial_Search_ID","value":"688308"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3492625"}]}}{"C152539":{"preferredName":"Tefinostat","code":"C152539","definitions":[{"definition":"A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Tefinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tefinostat","termGroup":"PT","termSource":"NCI"},{"termName":"CHR 2845","termGroup":"CN","termSource":"NCI"},{"termName":"CHR-2845","termGroup":"CN","termSource":"NCI"},{"termName":"CHR2845","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"914382-60-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAU91150SB"},{"name":"Maps_To","value":"HDAC Inhibitor CHR-2845"},{"name":"Maps_To","value":"Tefinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"633696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633696"},{"name":"PDQ_Open_Trial_Search_ID","value":"633696"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830214"}]}}{"C148157":{"preferredName":"HDAC Inhibitor CKD-581","code":"C148157","definitions":[{"definition":"A highly water-soluble, pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, HDAC inhibitor CKD-581 targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor CKD-581","termGroup":"PT","termSource":"NCI"},{"termName":"CKD 581","termGroup":"CN","termSource":"NCI"},{"termName":"CKD-581","termGroup":"CN","termSource":"NCI"},{"termName":"CKD581","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC Inhibitor CKD-581"},{"name":"NCI_Drug_Dictionary_ID","value":"792522"},{"name":"NCI_META_CUI","value":"CL550791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792522"},{"name":"PDQ_Open_Trial_Search_ID","value":"792522"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C112177":{"preferredName":"Zabadinostat","code":"C112177","definitions":[{"definition":"A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zabadinostat","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 9468","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9468","termGroup":"CN","termSource":"NCI"},{"termName":"CXD101","termGroup":"CN","termSource":"NCI"},{"termName":"HDAC Inhibitor CXD101","termGroup":"SY","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor CXD101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934828-12-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5TNV87ICD2"},{"name":"Maps_To","value":"HDAC Inhibitor CXD101"},{"name":"NCI_Drug_Dictionary_ID","value":"754547"},{"name":"NCI_META_CUI","value":"CL454389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754547"},{"name":"PDQ_Open_Trial_Search_ID","value":"754547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120312":{"preferredName":"HDAC Inhibitor MPT0E028","code":"C120312","definitions":[{"definition":"An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon administration, HDAC inhibitor MPT0E028 selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in both an induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. This prevents cell division and induces both cell cycle arrest and apoptosis, which may inhibit the proliferation of susceptible tumor cells. In addition, MPT0E028 inhibits the phosphorylation and activation of Akt, which prevents the activation of downstream signaling pathways, independent of its HDAC inhibitory activity. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins. Akt, overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor MPT0E028","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide","termGroup":"SN","termSource":"NCI"},{"termName":"3-(1-Benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxy-acrylamide","termGroup":"SN","termSource":"NCI"},{"termName":"MPT 0E028","termGroup":"CN","termSource":"NCI"},{"termName":"MPT-0E028","termGroup":"CN","termSource":"NCI"},{"termName":"MPT0E028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1338320-94-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC Inhibitor MPT0E028"},{"name":"NCI_Drug_Dictionary_ID","value":"768773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768773"},{"name":"PDQ_Open_Trial_Search_ID","value":"768773"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661262"}]}}{"C121665":{"preferredName":"HDAC Inhibitor OBP-801","code":"C121665","definitions":[{"definition":"An inhibitor of histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon administration, OBP-801 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. This may inhibit proliferation of susceptible tumor cells. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC Inhibitor OBP-801","termGroup":"PT","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor OBP-801","termGroup":"SY","termSource":"NCI"},{"termName":"OBP-801","termGroup":"CN","termSource":"NCI"},{"termName":"YM753","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"328548-11-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"30Q3VS5HZ4"},{"name":"Maps_To","value":"HDAC Inhibitor OBP-801"},{"name":"NCI_Drug_Dictionary_ID","value":"771191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"771191"},{"name":"PDQ_Open_Trial_Search_ID","value":"771191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661318"}]}}{"C78850":{"preferredName":"HDAC/EGFR/HER2 Inhibitor CUDC-101","code":"C78850","definitions":[{"definition":"A multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential antineoplastic activity. HDAC/EGFR/HER2 inhibitor CUDC-101 inhibits the activity of these three enzymes but the exact mechanism of action is presently unknown. This agent may help overcome resistance to inhibition of EGFR and Her2 through a simultaneous, synergistic inhibition of EGFR, Her2, and HDAC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC/EGFR/HER2 Inhibitor CUDC-101","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1012054-59-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1A7Y9MP123"},{"name":"Legacy Concept Name","value":"HDAC_EGFR_HER2_Inhibitor_CUDC-101"},{"name":"Maps_To","value":"HDAC/EGFR/HER2 Inhibitor CUDC-101"},{"name":"NCI_Drug_Dictionary_ID","value":"612729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612729"},{"name":"PDQ_Open_Trial_Search_ID","value":"612729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703140"}]}}{"C135629":{"preferredName":"HDAC6 Inhibitor KA2507","code":"C135629","definitions":[{"definition":"An orally bioavailable inhibitor of histone deacetylase (HDAC) type 6 (HDAC6; HDAC-6), with potential antineoplastic activity. Upon administration, KA2507 targets, binds to and inhibits the activity of HDAC6. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. Specifically, inhibition of HDAC6 prevents STAT3 activity, which leads to a reduction in programmed death-1 (PD-1) expression. Eventually, this results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC6. HDAC6, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC6 Inhibitor KA2507","termGroup":"PT","termSource":"NCI"},{"termName":"HDAC6i KA2507","termGroup":"SY","termSource":"NCI"},{"termName":"KA2507","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VQ7NU11KRM"},{"name":"Maps_To","value":"HDAC6 Inhibitor KA2507"},{"name":"NCI_Drug_Dictionary_ID","value":"788956"},{"name":"NCI_META_CUI","value":"CL522984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788956"},{"name":"PDQ_Open_Trial_Search_ID","value":"788956"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159496":{"preferredName":"HDAC8 Inhibitor NBM-BMX","code":"C159496","definitions":[{"definition":"An orally bioavailable inhibitor of histone deacetylase (HDAC) type 8 (HDAC8; HDAC-8), with potential antineoplastic activity. Upon administration, NBM-BMX targets and inhibits the activity of HDAC8. This results in an accumulation of highly acetylated chromatin histones, chromatin remodeling, and selective transcription of tumor suppressor genes, ultimately promoting cell-cycle arrest and induction of tumor cell apoptosis. HDAC8, a class 1 histone deacetylase, plays a key role in transcriptional regulation and cell cycle progression. Aberrant expression of HDAC8 or deregulated interactions with transcription factors may contribute to tumorigenesis. Isotype-selective HDAC inhibitors may be associated with fewer adverse effects compared to pan-HDAC inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDAC8 Inhibitor NBM-BMX","termGroup":"PT","termSource":"NCI"},{"termName":"HDAC8i NBM-BMX","termGroup":"SY","termSource":"NCI"},{"termName":"NBM BMX","termGroup":"CN","termSource":"NCI"},{"termName":"NBM-BMX","termGroup":"CN","termSource":"NCI"},{"termName":"NBMBMX","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDAC8 Inhibitor NBM-BMX"},{"name":"NCI_Drug_Dictionary_ID","value":"797563"},{"name":"NCI_META_CUI","value":"CL951454"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797563"},{"name":"PDQ_Open_Trial_Search_ID","value":"797563"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116325":{"preferredName":"Siremadlin","code":"C116325","definitions":[{"definition":"An orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity. Siremadlin inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of both p53 signaling and p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Siremadlin","termGroup":"PT","termSource":"NCI"},{"termName":"HDM201","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-HDM 201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448867-41-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0282IF4JC8"},{"name":"Maps_To","value":"HDM2 Inhibitor HDM201"},{"name":"Maps_To","value":"Siremadlin"},{"name":"NCI_Drug_Dictionary_ID","value":"761551"},{"name":"NCI_META_CUI","value":"CL473659"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761551"},{"name":"PDQ_Open_Trial_Search_ID","value":"761551"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116867":{"preferredName":"HDM2 Inhibitor MK-8242","code":"C116867","definitions":[{"definition":"An orally bioavailable inhibitor of human homolog of double minute 2 (HDM2), with potential antineoplastic activity. Upon oral administration, HDM2 inhibitor MK-8242 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the degradation of p53 is inhibited, which may result in the restoration of p53 signaling. This induces p53-mediated tumor cell apoptosis. HDM2 is a member of the RING finger-type family of E3 ubiquitin protein ligases and targets p53 for degradation; it is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HDM2 Inhibitor MK-8242","termGroup":"PT","termSource":"NCI"},{"termName":"MK-8242","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900242","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDM2 Inhibitor MK-8242"},{"name":"NCI_Drug_Dictionary_ID","value":"714504"},{"name":"NCI_META_CUI","value":"CL433891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714504"},{"name":"PDQ_Open_Trial_Search_ID","value":"714504"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60772":{"preferredName":"Smoothened Antagonist IPI-609","code":"C60772","definitions":[{"definition":"A semi-synthetic cyclopamine analogue and an inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon administration, smoothened antagonist IPI-609 targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist IPI-609","termGroup":"PT","termSource":"NCI"},{"termName":"IPI 269609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI 609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-269609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI269609","termGroup":"CN","termSource":"NCI"},{"termName":"IPI609","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"878204-96-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0E0K1H745W"},{"name":"Legacy Concept Name","value":"IPI-609"},{"name":"Maps_To","value":"Hedgehog Inhibitor IPI-609"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881124"}]}}{"C1071":{"preferredName":"Porfimer Sodium","code":"C1071","definitions":[{"definition":"A drug used to treat some types of cancer. When absorbed by cancer cells and exposed to light, porfimer sodium becomes active and kills the cancer cells. It is a type of photodynamic therapy agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm wavelength laser light, resulting in tumor cell cytotoxicity. In addition, tumor cell death may occur due to ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by the release of thromboxane A2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porfimer Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"CL-184116","termGroup":"CN","termSource":"NCI"},{"termName":"DHE","termGroup":"AB","termSource":"NCI"},{"termName":"Dihematoporphyrin Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Dihematoporphyrin Ether","termGroup":"SY","termSource":"NCI"},{"termName":"Hematoporphyrin Derivative","termGroup":"SY","termSource":"NCI"},{"termName":"HPD","termGroup":"AB","termSource":"NCI"},{"termName":"Photobarr","termGroup":"FB","termSource":"NCI"},{"termName":"Photofrin II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Photosensitizer, bladder, esophagel, gastric, lung and rectal cancer"},{"name":"CAS_Registry","value":"87806-31-3"},{"name":"CHEBI_ID","value":"CHEBI:60773"},{"name":"Chemical_Formula","value":"(C34H35N4NaO5)n.(C34H33N4NaO4)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y3834SIK5F"},{"name":"Legacy Concept Name","value":"Porfimer_Sodium"},{"name":"Maps_To","value":"Hematoporphyrin Derivative"},{"name":"Maps_To","value":"Porfimer Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"40294"},{"name":"NCI_META_CUI","value":"CL524033"},{"name":"NSC Number","value":"603062"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49083":{"preferredName":"Hemiasterlin Analog E7974","code":"C49083","definitions":[{"definition":"An analog of the sponge-derived anti-microtubule tripeptide hemiasterlin with antimitotic and potential antineoplastic activities. Hemiasterlin analog E7974 binds to the Vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly; depolymerization of existing microtubules; inhibition of mitosis; and inhibition of cellular proliferation. This agent may have more affinity for the beta-3 tubulin isotype.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hemiasterlin Analog E7974","termGroup":"PT","termSource":"NCI"},{"termName":"E7974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"610787-07-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1BO0C11BSH"},{"name":"Legacy Concept Name","value":"Hemiasterlin_Analog_7974"},{"name":"Maps_To","value":"Hemiasterlin Analog E7974"},{"name":"NCI_Drug_Dictionary_ID","value":"447049"},{"name":"PDQ_Closed_Trial_Search_ID","value":"447049"},{"name":"PDQ_Open_Trial_Search_ID","value":"447049"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708344"}]}}{"C97949":{"preferredName":"Henatinib Maleate","code":"C97949","definitions":[{"definition":"The maleate salt form of henatinib, an orally bioavalable, multitargeted tyrosine kinase inhibitor with potential antitumor and antiangiogenic activities. Henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Henatinib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"(R,Z)-2-[(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c] azepin-4-ketone Maleate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Henatinib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"709376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709376"},{"name":"PDQ_Open_Trial_Search_ID","value":"709376"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2935073"}]}}{"C170206":{"preferredName":"Necuparanib","code":"C170206","definitions":[{"definition":"A low molecular weight heparin derivative and heparan sulfate proteoglycan (HSPG) mimetic with no or minimal anticoagulant activity and potential antineoplastic activities. Upon administration, necuparanib mimics HSPGs by binding to and inhibiting various heparin-binding growth factors, chemokines, and cytokines such as VEGF, HGF, FGF2, SDF-1a, heparanase and P-selectin all of which are essential for tumor angiogenesis and metastasis to occur. This inhibits heparin binding growth factor-mediated signaling and disrupts tumor-stromal interactions eventually leading to an inhibition of angiogenesis and tumor cell progression. In addition, M402 may enhance the cytotoxic effect of other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necuparanib","termGroup":"PT","termSource":"NCI"},{"termName":"Heparan Sulfate Glycosaminoglycan Mimetic M402","termGroup":"SY","termSource":"NCI"},{"termName":"HSGAG Mimetic M402","termGroup":"SY","termSource":"NCI"},{"termName":"M402","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415139-34-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ULS0NT2D68"},{"name":"Maps_To","value":"Heparan Sulfate Glycosaminoglycan Mimetic M402"},{"name":"NCI_Drug_Dictionary_ID","value":"735811"},{"name":"NCI_META_CUI","value":"CL1382683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104412":{"preferredName":"Roneparstat","code":"C104412","definitions":[{"definition":"An N-acetylated, glycol-split form of heparin that is devoid of anticoagulant activity and is an inhibitor of heparanase with antineoplastic and antiangiogenic activities. Upon subcutaneous administration, roneparstat inhibits the activity of heparanase. This prevents the heparanase-mediated cleavage of heparan sulfate (HS) proteoglycans on cell surfaces and within the extracellular matrix. In addition, this agent prevents the heparanase-induced production of a number of angiogenic growth factors, including matrix metalloproteinase-9, hepatocyte growth factor and vascular endothelial growth factor. Altogether, this leads to an inhibition of both tumor cell growth and angiogenesis. Heparanase, an enzyme that is responsible for the proteolytic cleavage of proteoglycans, is upregulated in a variety of tumor cell types and promotes tumor cell growth; it plays a key role in tumor cell invasion, metastasis and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roneparstat","termGroup":"PT","termSource":"NCI"},{"termName":"100NA,RO-H","termGroup":"SY","termSource":"NCI"},{"termName":"SST0001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1407492-04-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1J0593208B"},{"name":"Maps_To","value":"Heparin Derivative SST0001"},{"name":"Maps_To","value":"Roneparstat"},{"name":"NCI_Drug_Dictionary_ID","value":"745171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745171"},{"name":"PDQ_Open_Trial_Search_ID","value":"745171"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3177718"}]}}{"C128283":{"preferredName":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131","code":"C128283","definitions":[{"definition":"A cancer vaccine consisting of a fusion peptide, composed of three peptides derived from the extracellular domain (ECD) of the HER2 peptide antigen found on B-cells (P4, P6 and P7; P467), conjugated to the carrier protein DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), and combined with the immunoadjuvant montanide ISA 51, with potential immunostimulatory and antineoplastic activities. Upon administration, IMU-131 vaccine induces the production of polyclonal antibodies against the HER2 protein. In turn, the antibodies bind to three separate binding sites on HER2 expressed on tumor cells and inhibit HER2 dimerization and activity, which leads to the inhibition of HER2-mediated signal transduction pathways. This induces apoptosis in and reduces cellular proliferation of HER2-overexpressing tumor cells. In addition, IMU-131 induces a cytotoxic T-lymphocyte (CTL) response against the HER2-expressing tumor cells. The tumor-associated antigen (TAA) HER2, also called Neu or ErbB2, is a tyrosine kinase receptor for epidermal growth factor (EGF) and is often overexpressed by a variety of tumor cell types. Montanide ISA 51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. DT-CRM197 is used to increase the immunogenicity of the HER2/neu peptide antigen. In P467, the three B-cell epitopes were combined in a specific order into a single 49 amino acid peptide antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131","termGroup":"PT","termSource":"NCI"},{"termName":"HER-Vaxx","termGroup":"SY","termSource":"NCI"},{"termName":"HER-Vaxx Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"IMU-131","termGroup":"CN","termSource":"NCI"},{"termName":"IMU-131 HER2/Neu Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"IMU-131 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"P467-CRM197/Montanide Vaccine IMU-131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131"},{"name":"NCI_Drug_Dictionary_ID","value":"782063"},{"name":"NCI_META_CUI","value":"CL507937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782063"},{"name":"PDQ_Open_Trial_Search_ID","value":"782063"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99903":{"preferredName":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901","code":"C99903","definitions":[{"definition":"A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901","termGroup":"PT","termSource":"NCI"},{"termName":"Alphavirus-like Replicon Particles-containing Self Amplifying Replicon RNA for HER2 AVX901","termGroup":"SY","termSource":"NCI"},{"termName":"AVX 901","termGroup":"CN","termSource":"NCI"},{"termName":"AVX-901","termGroup":"CN","termSource":"NCI"},{"termName":"AVX901","termGroup":"CN","termSource":"NCI"},{"termName":"HER2 ECDTM VRP","termGroup":"SY","termSource":"NCI"},{"termName":"VRP-HER2 AVX901","termGroup":"SY","termSource":"NCI"},{"termName":"VRP-HER2 ECDTM","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901"},{"name":"NCI_Drug_Dictionary_ID","value":"725234"},{"name":"NCI_META_CUI","value":"CL433604"},{"name":"PDQ_Closed_Trial_Search_ID","value":"725234"},{"name":"PDQ_Open_Trial_Search_ID","value":"725234"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26648":{"preferredName":"HER2 Inhibitor CP-724,714","code":"C26648","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called ErbB receptor tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable quinazoline with potential antineoplastic activity.  CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth.  HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Inhibitor CP-724,714","termGroup":"PT","termSource":"NCI"},{"termName":"CP 724714","termGroup":"CN","termSource":"NCI"},{"termName":"CP-724,714","termGroup":"CN","termSource":"NCI"},{"termName":"CP-724-714","termGroup":"CN","termSource":"NCI"},{"termName":"CP724714","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"383432-38-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I05QZ0S4V3"},{"name":"Legacy Concept Name","value":"CP-724_714"},{"name":"Maps_To","value":"HER2 Inhibitor CP-724,714"},{"name":"NCI_Drug_Dictionary_ID","value":"285619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"285619"},{"name":"PDQ_Open_Trial_Search_ID","value":"285619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327906"}]}}{"C146810":{"preferredName":"HER2 Inhibitor TAS0728","code":"C146810","definitions":[{"definition":"An orally available covalent inhibitor of human epidermal growth factor receptor 2 (HER2; ERBB2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor TAS0728 specifically and irreversibly binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2- and HER3 (ErbB3)-expressing tumor cells. HER2, a receptor tyrosine kinase mutated or overexpressed in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization. HER3 has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Inhibitor TAS0728","termGroup":"PT","termSource":"NCI"},{"termName":"TAS 0728","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-0728","termGroup":"CN","termSource":"NCI"},{"termName":"TAS0728","termGroup":"CN","termSource":"NCI"},{"termName":"TPC-107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2 Inhibitor TAS0728"},{"name":"NCI_Drug_Dictionary_ID","value":"792168"},{"name":"NCI_META_CUI","value":"CL544751"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792168"},{"name":"PDQ_Open_Trial_Search_ID","value":"792168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148491":{"preferredName":"HER2-targeted DARPin MP0274","code":"C148491","definitions":[{"definition":"A proprietary, designed ankyrin repeat proteins (DARPin)-based agent targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential antineoplastic activity. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the HER2-targeted DARPin MP0274 binds to two distinct non-overlapping epitopes on HER2, thereby inhibiting the activity of HER2 and promoting HER2 internalization. This prevents HER2-mediated signaling, induces apoptosis and inhibits the growth of HER2-overexpressing tumor cells. DARPin also binds to human serum albumin, which extends the half-life of MP0274. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2-targeted DARPin MP0274","termGroup":"PT","termSource":"NCI"},{"termName":"DARPin MP0274","termGroup":"SY","termSource":"NCI"},{"termName":"HER-2-targeting DARPin MP0274","termGroup":"SY","termSource":"NCI"},{"termName":"HER2-targeting DARPin Drug MP0274","termGroup":"SY","termSource":"NCI"},{"termName":"MP 0274","termGroup":"CN","termSource":"NCI"},{"termName":"MP0274","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2-targeted DARPin MP0274"},{"name":"NCI_Drug_Dictionary_ID","value":"792625"},{"name":"NCI_META_CUI","value":"CL551054"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792625"},{"name":"PDQ_Open_Trial_Search_ID","value":"792625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96038":{"preferredName":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302","code":"C96038","definitions":[{"definition":"An antibody-targeted lipidic nano-carrier containing the antineoplastic anthracycline antibiotic doxorubicin encapsulated within liposomes, and conjugated to a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), with potential antitumor activity. Upon administration of HER2-targeted liposomal doxorubicin hydrochloride MM-302, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the HER2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted liposomal delivery of doxorubicin improves efficacy while lowering the toxicity profile. HER2, a tyrosine kinase receptor, is overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302","termGroup":"PT","termSource":"NCI"},{"termName":"MM-302","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302"},{"name":"NCI_Drug_Dictionary_ID","value":"696572"},{"name":"NCI_META_CUI","value":"CL428372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696572"},{"name":"PDQ_Open_Trial_Search_ID","value":"696572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118953":{"preferredName":"HER2-targeting Antibody Fc Fragment FS102","code":"C118953","definitions":[{"definition":"A proprietary, antibody fragment composed of a constant (Fc) region that is engineered to bind to the tumor-associated antigen human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. HER2-targeted antibody Fc fragment FS102 specifically binds to its HER2 epitope, and causes downregulation of HER2-mediated signaling. This leads to tumor cell apoptosis. HER2, a member of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) superfamily, is overexpressed on the cell surface of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2-targeting Antibody Fc Fragment FS102","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HER2 FCAB FS102","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986186","termGroup":"CN","termSource":"NCI"},{"termName":"Fcab FS102","termGroup":"SY","termSource":"NCI"},{"termName":"FS102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z27ZI1MZY9"},{"name":"Maps_To","value":"HER2-targeting Antibody Fc Fragment FS102"},{"name":"NCI_Drug_Dictionary_ID","value":"766415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766415"},{"name":"PDQ_Open_Trial_Search_ID","value":"766415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896857"}]}}{"C2661":{"preferredName":"Herba Scutellaria Barbata","code":"C2661","definitions":[{"definition":"A Chinese herb isolated from the plant Scutellaria barbata D. Don (Lamiaceae) with potential antineoplastic activity. Containing the antioxidant flavone scutellarin, herba Scutellaria barbata has been shown to induce apoptosis of ovarian and breast tumor cells in vitro.","type":"DEFINITION","source":"NCI"},{"definition":"An herb that belongs to a group of herbs named the Scutellaria species or scullcap. Both the root and the above-ground part have been used to make herbal medicines. The root has been used in traditional Chinese medicine to treat lung cancer and other medical problems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Herba Scutellaria Barbata","termGroup":"PT","termSource":"NCI"},{"termName":"Ban Zhi Lian","termGroup":"SY","termSource":"NCI"},{"termName":"Barbed Skullcap Herb","termGroup":"SY","termSource":"NCI"},{"termName":"Herba Scutellariae Barbatae","termGroup":"SY","termSource":"NCI"},{"termName":"HSB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DPR4R122E7"},{"name":"Legacy Concept Name","value":"Herba_Scutellariae_Barbatae"},{"name":"Maps_To","value":"Herba Scutellaria Barbata"},{"name":"NCI_Drug_Dictionary_ID","value":"467184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467184"},{"name":"PDQ_Open_Trial_Search_ID","value":"467184"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134548"}]}}{"C1124":{"preferredName":"Herbimycin","code":"C1124","definitions":[{"definition":"A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Herbimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Herbimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-Demethoxy-15-methoxy-11-O-methylgeldanamycin, (15R)-","termGroup":"SN","termSource":"NCI"},{"termName":"Herbimycin A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70563-58-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"815WDV2HST"},{"name":"Legacy Concept Name","value":"Herbimycin"},{"name":"Maps_To","value":"Herbimycin"},{"name":"NSC Number","value":"305978"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062565"}]}}{"C122401":{"preferredName":"Heterodimeric Interleukin-15","code":"C122401","definitions":[{"definition":"A fusion protein complex composed of heterodimeric IL-15 (hetIL-15), which consists of a synthetic form of the endogenous cytokine interleukin-15 chain (IL-15) complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL-15Ra) (IL15:sIL-15Ra), with potential immunomodulatory, anti-infective and antineoplastic activities. Upon administration, hetIL-15 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbeta-gamma) receptor on natural killer (NK) and T-lymphocytes, which activates and increases the levels of NK cells and CD8+ and CD4+ T-cells. The T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. Altogether, this enhances tumor cell killing and decreases tumor cell proliferation. By coupling IL-15 to IL15Ra, this agent has an improved pharmacokinetic profile, shows an increased ability to bind IL-2Rbeta-gamma, and shows increased immunostimulatory activity as compared to IL-15 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Heterodimeric Interleukin-15","termGroup":"PT","termSource":"NCI"},{"termName":"hetIL-15","termGroup":"AB","termSource":"NCI"},{"termName":"IL-15/sIL-15Ra","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heterodimeric Interleukin-15"},{"name":"NCI_Drug_Dictionary_ID","value":"772563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772563"},{"name":"PDQ_Open_Trial_Search_ID","value":"772563"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053488"}]}}{"C1125":{"preferredName":"Hexamethylene Bisacetamide","code":"C1125","definitions":[{"definition":"A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines.  Its precise mechanism of action is unknown. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hexamethylene Bisacetamide","termGroup":"PT","termSource":"NCI"},{"termName":"Acetamide, N,N'-1, 6-hexanediylbis-","termGroup":"SN","termSource":"NCI"},{"termName":"Acetamide, N,N'-hexamethylenebis-","termGroup":"SN","termSource":"NCI"},{"termName":"Hexamethylenebisacetamide","termGroup":"SY","termSource":"NCI"},{"termName":"Hexamethylenediacetamide","termGroup":"SY","termSource":"NCI"},{"termName":"HMBA","termGroup":"AB","termSource":"NCI"},{"termName":"N, N'-Diacetylhexamethylenediamine","termGroup":"SN","termSource":"NCI"},{"termName":"N,N'-1,6-Hexanediylbisacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N'-Hexamethylenebisacetamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3073-59-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LA133J59VU"},{"name":"Legacy Concept Name","value":"Hexamethylene_Bisacetamide"},{"name":"Maps_To","value":"Hexamethylene Bisacetamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39990"},{"name":"NSC Number","value":"95580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39990"},{"name":"PDQ_Open_Trial_Search_ID","value":"39990"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062641"}]}}{"C26654":{"preferredName":"Hexaminolevulinate","code":"C26654","definitions":[{"definition":"A substance that is used to find and kill tumor cells. It enters tumor cells and becomes activated when exposed to a special type of light. A chemical reaction causes the cells to produce fluorescent light and die.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hexyl ester of 5-aminolevulinic acid (ALA) with photodynamic properties. As a precursor of photoactive porphorins, hexyl 5-aminolevulinate induces the endogenous production of the photosensitizer protoporphyrin IX (PPIX) which accumulates selectively in tumor tissue. When exposed to specific wavelengths of light, PPIX is activated and, depending on the wavelength and/or intensity of light, either fluoresces, thereby allowing tumor imaging, or induces tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hexaminolevulinate","termGroup":"PT","termSource":"NCI"},{"termName":"HAL","termGroup":"AB","termSource":"NCI"},{"termName":"HexvixR","termGroup":"BR","termSource":"NCI"},{"termName":"Hexyl 5-Aminolevulinate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"140898-97-1"},{"name":"Chemical_Formula","value":"C11H21NO3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G7H20TKI67"},{"name":"Legacy Concept Name","value":"Hexyl_5-Aminolevulinate"},{"name":"Maps_To","value":"Hexaminolevulinate"},{"name":"NCI_Drug_Dictionary_ID","value":"269130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269130"},{"name":"PDQ_Open_Trial_Search_ID","value":"269130"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327841"}]}}{"C29092":{"preferredName":"Hexylresorcinol","code":"C29092","definitions":[{"definition":"A substituted phenol with bactericidal, antihelminthic and potential antineoplastic activities. Hexylresorcinol is used as an antiseptic in mouthwashes and skin wound cleansers. Hexylresorcinol may also inhibit oxidative DNA damage by enhancing the activity of antioxidant enzymes, including glutathione peroxidase and glutathione reductase, which facilitate scavenging reactive oxygen molecules by glutathione (GSH).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hexylresorcinol","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hexylresorcinol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"136-77-6"},{"name":"Chemical_Formula","value":"C12H18O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R9QTB5E82N"},{"name":"Legacy Concept Name","value":"Hexylresorcinol"},{"name":"Maps_To","value":"Hexylresorcinol"},{"name":"NSC Number","value":"1570"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0019497"}]}}{"C70953":{"preferredName":"HIF-1alpha Inhibitor PX-478","code":"C70953","definitions":[{"definition":"An orally active small molecule with potential antineoplastic activity. Although its mechanism of action has yet to be fully elucidated, HIF1-alpha inhibitor PX-478 appears to inhibit hypoxia-inducible factor 1-alpha (HIF1A) expression, which may result in decreased expression of HIF1A downstream target genes important to tumor growth and survival, a reduction in tumor cell proliferation, and the induction of tumor cell apoptosis. The inhibitory effect of this agent is independent of the tumor suppressor genes VHL and p53 and may be related to derangements in glucose uptake and metabolism due to inhibition of glucose transporter-1 (Glut-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIF-1alpha Inhibitor PX-478","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-4-(2-Amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline Oxide Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Hypoxia Inducible Factor 1-Alpha PX-478","termGroup":"SY","termSource":"NCI"},{"termName":"L-Phenylalanine, 4-[Bis(2-chloroethyl)oxidoamino]-, Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"L-Phenylalanine, 4-[Bis(2-chloroethyl)oxidoamino]-, Hydrochloride (1:2)","termGroup":"SY","termSource":"NCI"},{"termName":"PX-478","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685898-44-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T23U22X160"},{"name":"Legacy Concept Name","value":"Hypoxia_Inducible_Factor_1-Alpha_PX-478"},{"name":"Maps_To","value":"HIF-1alpha Inhibitor PX-478"},{"name":"NCI_Drug_Dictionary_ID","value":"570895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570895"},{"name":"PDQ_Open_Trial_Search_ID","value":"570895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1528551"}]}}{"C119618":{"preferredName":"HIF-2alpha Inhibitor PT2385","code":"C119618","definitions":[{"definition":"An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor PT2385 allosterically binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed in many cancers, promotes tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HIF-2alpha Inhibitor PT2385","termGroup":"PT","termSource":"NCI"},{"termName":"PT2385","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HIF-2alpha Inhibitor PT2385"},{"name":"NCI_Drug_Dictionary_ID","value":"766768"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766768"},{"name":"PDQ_Open_Trial_Search_ID","value":"766768"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896783"}]}}{"C135627":{"preferredName":"Belzutifan","code":"C135627","definitions":[{"definition":"An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belzutifan","termGroup":"PT","termSource":"NCI"},{"termName":"HIF-2alpha Inhibitor PT2977","termGroup":"SY","termSource":"NCI"},{"termName":"MK 6482","termGroup":"CN","termSource":"NCI"},{"termName":"MK-6482","termGroup":"CN","termSource":"NCI"},{"termName":"MK6482","termGroup":"CN","termSource":"NCI"},{"termName":"PT 2977","termGroup":"CN","termSource":"NCI"},{"termName":"PT-2977","termGroup":"CN","termSource":"NCI"},{"termName":"PT2977","termGroup":"CN","termSource":"NCI"},{"termName":"Welireg","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET)"},{"name":"CAS_Registry","value":"1672668-24-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7K28NB895L"},{"name":"Maps_To","value":"Belzutifan"},{"name":"Maps_To","value":"HIF-2alpha Inhibitor PT2977"},{"name":"NCI_Drug_Dictionary_ID","value":"788947"},{"name":"NCI_META_CUI","value":"CL522982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788947"},{"name":"PDQ_Open_Trial_Search_ID","value":"788947"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113334":{"preferredName":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126","code":"C113334","definitions":[{"definition":"A small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone-lysine N-methyltransferase EZH2, with potential antineoplastic activity. Upon administration, histone-lysine N-methyltransferase EZH2 inhibitor GSK2816126 inhibits the activity of EZH2 and specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in cancer cells that overexpress this enzyme. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancers and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126","termGroup":"PT","termSource":"NCI"},{"termName":"EZH2 Inhibitor GSK2816126","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2816126","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126"},{"name":"NCI_Drug_Dictionary_ID","value":"756211"},{"name":"NCI_META_CUI","value":"CL458162"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756211"},{"name":"PDQ_Open_Trial_Search_ID","value":"756211"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77424":{"preferredName":"Histrelin Acetate","code":"C77424","definitions":[{"definition":"The acetate salt form of histrelin, a long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Histrelin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Supprelin","termGroup":"BR","termSource":"NCI"},{"termName":"Vantas","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"76712-82-8"},{"name":"Chemical_Formula","value":"C66H86N18O12.C2H4O2.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QMG7HLD1ZE"},{"name":"Legacy Concept Name","value":"Histrelin_Acetate"},{"name":"Maps_To","value":"Histrelin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"732255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732255"},{"name":"PDQ_Open_Trial_Search_ID","value":"732255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0724597"}]}}{"C111689":{"preferredName":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001","code":"C111689","definitions":[{"definition":"A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT), TERT 572Y (YLFFYRKSV; TYR-Vx001) and TERT 572 (RLFFYRKSV; ARG-Vx001), with potential immunostimulating and antineoplastic activities. Subcutaneous injection of TERT(572Y) peptide followed by subcutaneous administration of the TERT(572) peptide may elicit a specific and possibly optimal cytotoxic T cell (CTL) response against hTERT-expressing tumor cells. hTERT, the catalytic subunit of human telomerase, is an human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase. TERT is expressed in the majority of human cancer cells, is not expressed or is expressed at very low levels in normal cells and plays a key role in tumorigenesis. TERT572Y is the optimized variant of the native cryptic peptide TERT572 in which tyrosine has been substituted for an arginine at position 1; TERT572Y shows increased HLA-A*0201 binding affinity compared to TERT572.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-A*0201 Restricted Telomerase-specific Vaccine Vx-001","termGroup":"SY","termSource":"NCI"},{"termName":"Vx-001","termGroup":"CN","termSource":"NCI"},{"termName":"Vx001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001"},{"name":"NCI_Drug_Dictionary_ID","value":"752897"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752897"},{"name":"PDQ_Open_Trial_Search_ID","value":"752897"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1958472"}]}}{"C101893":{"preferredName":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410","code":"C101893","definitions":[{"definition":"A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410","termGroup":"PT","termSource":"NCI"},{"termName":"S-488410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HLA-A*2402-Restricted Multipeptide Vaccine S-488410"},{"name":"NCI_Drug_Dictionary_ID","value":"733798"},{"name":"NCI_META_CUI","value":"CL436276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733798"},{"name":"PDQ_Open_Trial_Search_ID","value":"733798"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128489":{"preferredName":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201","code":"C128489","definitions":[{"definition":"A cancer peptide vaccine composed of four human leukocyte antigen (HLA)-A2 (HLA-A*02)-restricted peptides derived from four specific and separate tumor-associated antigens (TAAs) expressed by melanoma cells, with potential antineoplastic activity. Upon administration of the HLA-A2-restricted melanoma-specific peptides vaccine, the melanoma specific antigens in the vaccine activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the HLA-A2-positive melanoma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine GRN-1201","termGroup":"SY","termSource":"NCI"},{"termName":"GRN-1201","termGroup":"CN","termSource":"NCI"},{"termName":"Peptide Cancer Vaccine GRN-1201","termGroup":"SY","termSource":"NCI"},{"termName":"Peptide Vaccine GRN-1201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201"},{"name":"NCI_Drug_Dictionary_ID","value":"782566"},{"name":"NCI_META_CUI","value":"CL509065"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782566"},{"name":"PDQ_Open_Trial_Search_ID","value":"782566"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153102":{"preferredName":"HM2/MMAE Antibody-Drug Conjugate ALT-P7","code":"C153102","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of the trastuzumab biobetter HM2 conjugated, in a site-specific manner, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of ALT-P7, the antibody moiety targets and binds to human epidermal growth factor receptor 2 (HER2) on tumor cells. Upon antibody/antigen binding and internalization, the MMAE moiety is released, binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. HER2 is a receptor tyrosine kinase (RTK) that is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HM2/MMAE Antibody-Drug Conjugate ALT-P7","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ALT-P7","termGroup":"SY","termSource":"NCI"},{"termName":"ALT-P7","termGroup":"SY","termSource":"NCI"},{"termName":"HER2ALT-P7","termGroup":"CN","termSource":"NCI"},{"termName":"HM2-MMAE","termGroup":"SY","termSource":"NCI"},{"termName":"HM2/MMAE ADC ALT-P7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HM2/MMAE Antibody-Drug Conjugate ALT-P7"},{"name":"NCI_Drug_Dictionary_ID","value":"793586"},{"name":"NCI_META_CUI","value":"CL554360"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793586"},{"name":"PDQ_Open_Trial_Search_ID","value":"793586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61592":{"preferredName":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine","code":"C61592","definitions":[{"definition":"An allogeneic vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. In addition, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"KGEL Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hodgkin_s_Antigens-GM-CSF-Expressing_Cell_Vaccine"},{"name":"Maps_To","value":"Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"445421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"445421"},{"name":"PDQ_Open_Trial_Search_ID","value":"445421"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831712"}]}}{"C88336":{"preferredName":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres","code":"C88336","definitions":[{"definition":"Holmium Ho166 containing poly l-lactic acid (PLA) microspheres with potential antineoplastic actvity. Upon intra-arterial hepatic administration of holmium 166 microspheres, this agent is able to emit both beta particles direct killing cells and gamma photons for nuclear imaging. In addition, since holmium 166 is paramagnetic, this agent can be used for magnetic resonance imaging (MRI).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"Holmium-166 PLA Microspheres","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Holmium Ho 166 Poly(L-Lactic Acid) Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"735181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735181"},{"name":"PDQ_Open_Trial_Search_ID","value":"735181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981854"}]}}{"C2636":{"preferredName":"HPPH","code":"C2636","definitions":[{"definition":"A drug that is used in photodynamic therapy that is absorbed by tumor cells; when exposed to light, it becomes active and kills the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lipophilic, second-generation, chlorin-based photosensitizer. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When laser light is applied, a photodynamic reaction between HPPH and oxygen occurs, resulting in the production of cytotoxic free radicals and singlet oxygen and free radical-mediated cell death. Compared to the first-generation photosensitizer porfimer sodium, HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity which declines rapidly within a few days after administration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPPH","termGroup":"PT","termSource":"NCI"},{"termName":"2-(1-Hexyloxyethyl)-2-Devinyl Pyropheophorbide-a","termGroup":"SN","termSource":"NCI"},{"termName":"2-[1-Hexyloxyethyl]-2-devinyl Pyropheophorbide-alpha","termGroup":"SN","termSource":"NCI"},{"termName":"Photochlor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149402-51-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DOB7Y3RSX0"},{"name":"Legacy Concept Name","value":"HPPH"},{"name":"Maps_To","value":"HPPH"},{"name":"NCI_Drug_Dictionary_ID","value":"38335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38335"},{"name":"PDQ_Open_Trial_Search_ID","value":"38335"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0248392"}]}}{"C117240":{"preferredName":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c","code":"C117240","definitions":[{"definition":"An orally available Lactobacillis casei (L. casei)-based vaccine expressing the human papillomavirus (HPV) type 16 isoform E7 protein linked to the poly-gamma-glutamate synthetase complex gene pgsA, with potential immunostimulating activity. Upon oral administration, the expressed HPV 16 E7 may stimulate the immune system to mount a mucosal cytotoxic T-lymphocyte (CTL) response against HPV 16 E7-expressing tumor cells. The poly-glutamic acid synthetase PgsA from Bacillus subtilis acts as an anchoring motif that facilitates the expression of the HPV antigen protein on the surface of the bacteria. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in various viral-related cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c","termGroup":"PT","termSource":"NCI"},{"termName":"BLS-ILB-E710c","termGroup":"CN","termSource":"NCI"},{"termName":"BLS-ILS-E710c","termGroup":"CN","termSource":"NCI"},{"termName":"L. casei-E7 BLS_ILB_E710c","termGroup":"SY","termSource":"NCI"},{"termName":"L.casei-PgsA-E7","termGroup":"SY","termSource":"NCI"},{"termName":"LacE7 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c"},{"name":"NCI_Drug_Dictionary_ID","value":"763356"},{"name":"NCI_META_CUI","value":"CL474114"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763356"},{"name":"PDQ_Open_Trial_Search_ID","value":"763356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77909":{"preferredName":"Bizalimogene Ralaplasmid","code":"C77909","definitions":[{"definition":"A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, bizalimogene ralaplasmid expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bizalimogene Ralaplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"HPV DNA Plasmids Therapeutic Vaccine VGX-3100","termGroup":"SY","termSource":"NCI"},{"termName":"pGX3002","termGroup":"CN","termSource":"NCI"},{"termName":"VGX-3100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1977488-08-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D8W2DVO5ZJ"},{"name":"Legacy Concept Name","value":"HPV_DNA_Plasmids_Therapeutic_Vaccine_VGX-3100"},{"name":"Maps_To","value":"Bizalimogene Ralaplasmid"},{"name":"Maps_To","value":"HPV DNA Plasmids Therapeutic Vaccine VGX-3100"},{"name":"NCI_Drug_Dictionary_ID","value":"599041"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599041"},{"name":"PDQ_Open_Trial_Search_ID","value":"599041"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703096"}]}}{"C102787":{"preferredName":"HPV E6/E7 DNA Vaccine GX-188E","code":"C102787","definitions":[{"definition":"A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV E6/E7 DNA Vaccine GX-188E","termGroup":"PT","termSource":"NCI"},{"termName":"GX-188E","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV E6/E7 DNA Vaccine GX-188E"},{"name":"NCI_Drug_Dictionary_ID","value":"736688"},{"name":"NCI_META_CUI","value":"CL437024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736688"},{"name":"PDQ_Open_Trial_Search_ID","value":"736688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131495":{"preferredName":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C","code":"C131495","definitions":[{"definition":"An immunotherapeutic vaccine composed of the immunoadjuvant alpha-galactosylceramide (a-GC) and autologous antigen presenting cells (APCs), specifically B-lymphocytes and monocytes transfected with an adenoviral vector that expresses the tumor-associated antigens (TAAs) E6 and E7 derived from human papillomavirus (HPV) types 16 and 18 (HPV-16/18 E6/E7), with potential immunostimulating and antineoplastic activities. Upon administration of BVAC-C, the APCs stimulate the immune system to mount a TAA-specific cytotoxic T-lymphocyte (CTL) response, as well as natural killer (NK) cell, NK T-cell (NKT), helper T-cell and antibody-mediated immune responses, against the tumor cells. This directly or indirectly kills the TAA-expressing tumor cells. HPV-16/18 E6/E7 are overexpressed on certain tumor cell types and play key roles in tumor cell proliferation. a-GC, an NKT cell ligand, is used to specifically stimulate NKT cells and to further stimulate an anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Lymphocyte/Tumor Antigen Gene Vaccine BVAC-C","termGroup":"SY","termSource":"NCI"},{"termName":"BVAC-C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C"},{"name":"NCI_Drug_Dictionary_ID","value":"785876"},{"name":"NCI_META_CUI","value":"CL514359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785876"},{"name":"PDQ_Open_Trial_Search_ID","value":"785876"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102874":{"preferredName":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract","code":"C102874","definitions":[{"definition":"A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with an extract of Candida albicans, with potential immunomodulating and antineoplastic activities. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the Candida albicans may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions, and HPV may be a cause of some head and neck squamous cell carcinomas (HNSCCs). Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-16 E6 Peptides Vaccine/Candin","termGroup":"SY","termSource":"NCI"},{"termName":"PepCan","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV-16 E6 Peptides Vaccine/Candida albicans Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"738026"},{"name":"NCI_META_CUI","value":"CL437177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738026"},{"name":"PDQ_Open_Trial_Search_ID","value":"738026"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123378":{"preferredName":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106","code":"C123378","definitions":[{"definition":"A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-6 E6/E7 DNA Vaccine INO-3106","termGroup":"SY","termSource":"NCI"},{"termName":"HPV-6-targeting Immunotherapeutic INO-3106","termGroup":"SY","termSource":"NCI"},{"termName":"INO-3106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV-6-targeting Immunotherapeutic Vaccine INO-3106"},{"name":"NCI_Drug_Dictionary_ID","value":"764841"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764841"},{"name":"PDQ_Open_Trial_Search_ID","value":"764841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053632"}]}}{"C162459":{"preferredName":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101","code":"C162459","definitions":[{"definition":"A fusion protein composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, with a peptide epitope derived from the human papillomavirus type 16 (HPV16) E7 protein (amino acid residues 11-20), a reduced affinity human interleukin-2 (IL-2) variant, and an effector attenuated human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic and immunostimulatory activities. Upon administration, CUE-101 targets and selectively binds to E7-specific CD8-positive T-cells present in patients with HPV16-driven malignancies. This may induce the secretion of inflammatory cytokines such as interferon gamma (IFN gamma) and promote the activation and expansion of tumor-specific CD8-positive cells, which may lead to T-cell-mediated elimination of tumor cells expressing the HPV16 E7 antigen. The HPV16 E7 oncoprotein is a cell surface glycoprotein and tumor-associated antigen (TAA) that is overexpressed in various HPV-associated cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-HPV16 E7 Fusion Protein CUE-101","termGroup":"SY","termSource":"NCI"},{"termName":"CUE 101","termGroup":"CN","termSource":"NCI"},{"termName":"CUE-101","termGroup":"CN","termSource":"NCI"},{"termName":"CUE101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101"},{"name":"NCI_Drug_Dictionary_ID","value":"798742"},{"name":"NCI_META_CUI","value":"CL970959"},{"name":"PDQ_Open_Trial_Search_ID","value":"798742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121648":{"preferredName":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN","code":"C121648","definitions":[{"definition":"A recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\\E6\\E7), with potential immunoprotective and antineoplastic properties. Upon administration, HPV16 L2\\E6\\E7 fusion protein vaccine TA-CIN may stimulate the immune system to generate HPV16 E6\\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN","termGroup":"PT","termSource":"NCI"},{"termName":"TA-CIN","termGroup":"CN","termSource":"NCI"},{"termName":"Tissue Antigen-Cervical Intraepithelial Neoplasia Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN"},{"name":"NCI_Drug_Dictionary_ID","value":"770825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770825"},{"name":"PDQ_Open_Trial_Search_ID","value":"770825"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053587"}]}}{"C69139":{"preferredName":"Hsp90 Antagonist KW-2478","code":"C69139","definitions":[{"definition":"An agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 antagonist KW-2478 appears to inhibit Hsp90, resulting in impaired signal transduction, inhibition of cell proliferation, and the induction of apoptosis in tumor cells. HSP90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Antagonist KW-2478","termGroup":"PT","termSource":"NCI"},{"termName":"KW-2478","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"819812-18-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E628ZH6U2C"},{"name":"Legacy Concept Name","value":"Hsp90_Antagonist_KW-2478"},{"name":"Maps_To","value":"Hsp90 Antagonist KW-2478"},{"name":"NCI_Drug_Dictionary_ID","value":"548017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"548017"},{"name":"PDQ_Open_Trial_Search_ID","value":"548017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348995"}]}}{"C82691":{"preferredName":"Hsp90 Inhibitor AB-010","code":"C82691","definitions":[{"definition":"An orally bioavailable nanoparticle albumin-bound inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AB-010 selectively binds to Hsp90, inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This agent may inhibit the growth of a wide variety of cancer cell types; the incorporation of albumin into its formulation may facilitate its endothelial transcytosis through the gp60-regulated albumin transport pathway. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor AB-010","termGroup":"PT","termSource":"NCI"},{"termName":"AB-010","termGroup":"CN","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor AB-010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_AB-010"},{"name":"Maps_To","value":"Hsp90 Inhibitor AB-010"},{"name":"NCI_Drug_Dictionary_ID","value":"633820"},{"name":"NCI_META_CUI","value":"CL388478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633820"},{"name":"PDQ_Open_Trial_Search_ID","value":"633820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62517":{"preferredName":"Hsp90 Inhibitor BIIB021","code":"C62517","definitions":[{"definition":"An orally active inhibitor of heat shock protein 90 (HSP90) with potential antineoplastic activity. HSP90, a chaperon protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins. HSP90 inhibitor BIIB021 specifically blocks active HSP90, thereby inhibiting its chaperon function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. As a result, CNF2024 has the potential to inhibit the growth of a wide range of cancer cells in both solid tumors and blood-based cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor BIIB021","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB-021","termGroup":"CN","termSource":"NCI"},{"termName":"BIIB021","termGroup":"CN","termSource":"NCI"},{"termName":"CNF2024","termGroup":"CN","termSource":"NCI"},{"termName":"Hsp90 Antagonist CNF2024","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848695-25-0"},{"name":"Chemical_Formula","value":"C14H15ClN6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"851B9FQ7Q0"},{"name":"Legacy Concept Name","value":"CNF2024"},{"name":"Maps_To","value":"Hsp90 Inhibitor BIIB021"},{"name":"NCI_Drug_Dictionary_ID","value":"497050"},{"name":"PDQ_Closed_Trial_Search_ID","value":"497050"},{"name":"PDQ_Open_Trial_Search_ID","value":"497050"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831929"}]}}{"C78846":{"preferredName":"Hsp90 Inhibitor BIIB028","code":"C78846","definitions":[{"definition":"A small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2/Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to other molecules involved in cell cycle regulation and immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor BIIB028","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB028","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911398-13-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KD4GWWK597"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_BIIB02"},{"name":"Maps_To","value":"Hsp90 Inhibitor BIIB028"},{"name":"NCI_Drug_Dictionary_ID","value":"612037"},{"name":"NCI_META_CUI","value":"CL387614"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612037"},{"name":"PDQ_Open_Trial_Search_ID","value":"612037"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92572":{"preferredName":"Hsp90 Inhibitor Debio 0932","code":"C92572","definitions":[{"definition":"An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Debio 0932 specifically blocks Hsp90, thereby inhibiting its chaperone function and promoting the degradation of its client proteins, many of which are oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stabilization and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor Debio 0932","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC-305","termGroup":"CN","termSource":"NCI"},{"termName":"Debio 0932","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-0932","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1061318-81-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0V278OKN9G"},{"name":"Maps_To","value":"Hsp90 Inhibitor Debio 0932"},{"name":"NCI_Drug_Dictionary_ID","value":"682685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682685"},{"name":"PDQ_Open_Trial_Search_ID","value":"682685"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742735"}]}}{"C116851":{"preferredName":"Hsp90 Inhibitor DS-2248","code":"C116851","definitions":[{"definition":"An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor DS-2248","termGroup":"PT","termSource":"NCI"},{"termName":"DS-2248","termGroup":"CN","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor DS-2248","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1015051-35-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3HJ2545H66"},{"name":"Maps_To","value":"Hsp90 Inhibitor DS-2248"},{"name":"NCI_Drug_Dictionary_ID","value":"694996"},{"name":"NCI_META_CUI","value":"CL433776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694996"},{"name":"PDQ_Open_Trial_Search_ID","value":"694996"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82387":{"preferredName":"Hsp90 Inhibitor HSP990","code":"C82387","definitions":[{"definition":"An orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Hsp990 binds to and inhibits the activity of Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90, upregulated in a variety of tumor cells, is a molecular chaperone that plays a key role in the conformational maturation, stability and function of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation and/or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor HSP990","termGroup":"PT","termSource":"NCI"},{"termName":"HSP990","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Hsp90_Inhibitor_HSP990"},{"name":"Maps_To","value":"Hsp90 Inhibitor HSP990"},{"name":"NCI_Drug_Dictionary_ID","value":"641983"},{"name":"NCI_META_CUI","value":"CL408658"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641983"},{"name":"PDQ_Open_Trial_Search_ID","value":"641983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84836":{"preferredName":"Hsp90 Inhibitor LAM-003A","code":"C84836","definitions":[{"definition":"An orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor LAM-003A selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; this agent may inhibit the growth and survival of a wide variety of cancer cell types. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability, and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor LAM-003A","termGroup":"PT","termSource":"NCI"},{"termName":"LAM 003A","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-003A","termGroup":"CN","termSource":"NCI"},{"termName":"LAM003A","termGroup":"CN","termSource":"NCI"},{"termName":"MPC-3100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"958025-66-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9UMA2EEO9Q"},{"name":"Maps_To","value":"Hsp90 Inhibitor MPC-3100"},{"name":"NCI_Drug_Dictionary_ID","value":"649142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649142"},{"name":"PDQ_Open_Trial_Search_ID","value":"649142"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830123"}]}}{"C101227":{"preferredName":"Zelavespib","code":"C101227","definitions":[{"definition":"A purine-based heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Zelavespib specifically inhibits active Hsp90, thereby inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may result in the inhibition of cellular proliferation in susceptible tumor cell populations. Hsp90, a molecular chaperone protein, is upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zelavespib","termGroup":"PT","termSource":"NCI"},{"termName":"9H-Purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Hsp90 Inhibitor PU-H71","termGroup":"SY","termSource":"NCI"},{"termName":"PU-H-71","termGroup":"CN","termSource":"NCI"},{"termName":"PU-H71","termGroup":"CN","termSource":"NCI"},{"termName":"PUH71","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"873436-91-0"},{"name":"Chemical_Formula","value":"C18H21IN6O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"06IVK87M04"},{"name":"Maps_To","value":"Hsp90 Inhibitor PU-H71"},{"name":"Maps_To","value":"Zelavespib"},{"name":"NCI_Drug_Dictionary_ID","value":"732547"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732547"},{"name":"PDQ_Open_Trial_Search_ID","value":"732547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3502086"}]}}{"C91068":{"preferredName":"Hsp90 Inhibitor SNX-5422 Mesylate","code":"C91068","definitions":[{"definition":"A substance being studied in the treatment of cancer. SNX-5422 mesylate blocks a protein needed for cells to grow and may kill cancer cells. It is a type of heat shock protein 90 inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor SNX-5422 Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"SNX-5422 Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1173111-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K3BO8V06RM"},{"name":"Maps_To","value":"Hsp90 Inhibitor SNX-5422 Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"590712"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590712"},{"name":"PDQ_Open_Trial_Search_ID","value":"590712"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3253587"}]}}{"C74040":{"preferredName":"Hsp90 Inhibitor SNX-5542 Mesylate","code":"C74040","definitions":[{"definition":"The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5542 is rapidly converted to SNX-2112, which accumulates in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor SNX-5542 Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"SNX-5542 Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_SNX-5542_Mesylate"},{"name":"Maps_To","value":"Hsp90 Inhibitor SNX-5542 Mesylate"},{"name":"NCI_META_CUI","value":"CL383549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79835":{"preferredName":"Hsp90 Inhibitor XL888","code":"C79835","definitions":[{"definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor XL888 specifically binds to Hsp90, inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; inhibition of tumor cell proliferation may result. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins, including Her-2 and Met.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor XL888","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor XL888","termGroup":"SY","termSource":"NCI"},{"termName":"XL-888","termGroup":"CN","termSource":"NCI"},{"termName":"XL888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1149705-71-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7M346920EV"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_XL888"},{"name":"Maps_To","value":"Hsp90 Inhibitor XL888"},{"name":"NCI_Drug_Dictionary_ID","value":"629922"},{"name":"NCI_META_CUI","value":"CL388445"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629922"},{"name":"PDQ_Open_Trial_Search_ID","value":"629922"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151953":{"preferredName":"Locnartecan","code":"C151953","definitions":[{"definition":"A miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates  and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Locnartecan","termGroup":"PT","termSource":"NCI"},{"termName":"HDC SN-38","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90-targeted SN-38 Conjugate PEN-866","termGroup":"SY","termSource":"NCI"},{"termName":"PEN 866","termGroup":"CN","termSource":"NCI"},{"termName":"PEN-866","termGroup":"CN","termSource":"NCI"},{"termName":"PEN866","termGroup":"CN","termSource":"NCI"},{"termName":"STA-12-8666","termGroup":"CN","termSource":"NCI"},{"termName":"STA-8666","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1472614-83-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56DL1J49LR"},{"name":"Maps_To","value":"HSP90-targeted SN-38 Conjugate PEN-866"},{"name":"NCI_Drug_Dictionary_ID","value":"793183"},{"name":"NCI_META_CUI","value":"CL601355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793183"},{"name":"PDQ_Open_Trial_Search_ID","value":"793183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C134448":{"preferredName":"Pimitespib","code":"C134448","definitions":[{"definition":"A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, pimitespib specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. Hsp90, a family of molecular chaperone proteins that are upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability, and function of \"client\" proteins within the cell,; many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, cell-cycle regulators, transcription factors and hormone receptors. As TAS-116 selectively inhibits cytosolic HSP90alpha and beta only and does not inhibit HSP90 paralogs, such as endoplasmic reticulum GRP94 or mitochondrial TRAP1, this agent may have less off-target toxicity as compared to non-selective HSP90 inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimitespib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)benzamide","termGroup":"SY","termSource":"NCI"},{"termName":"Heat Shock Protein 90 alpha/beta Inhibitor TAS-116","termGroup":"SY","termSource":"NCI"},{"termName":"HSP90alpha/beta Inhibitor TAS-116","termGroup":"SY","termSource":"NCI"},{"termName":"TAS 116","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-116","termGroup":"CN","termSource":"NCI"},{"termName":"TAS116","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260533-36-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PLO044MUDZ"},{"name":"Maps_To","value":"HSP90alpha/beta Inhibitor TAS-116"},{"name":"Maps_To","value":"Pimitespib"},{"name":"NCI_Drug_Dictionary_ID","value":"788861"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788861"},{"name":"PDQ_Open_Trial_Search_ID","value":"788861"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4044757"}]}}{"C119616":{"preferredName":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301","code":"C119616","definitions":[{"definition":"A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301","termGroup":"PT","termSource":"NCI"},{"termName":"GX 301","termGroup":"CN","termSource":"NCI"},{"termName":"GX301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301"},{"name":"NCI_Drug_Dictionary_ID","value":"766744"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766744"},{"name":"PDQ_Open_Trial_Search_ID","value":"766744"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896843"}]}}{"C80055":{"preferredName":"hTERT Vaccine V934/V935","code":"C80055","definitions":[{"definition":"A cancer vaccine directed against human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. Upon administration, hTERT vaccine V934/V935 may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase is involved in the restoration and maintenance of telomere length and so the functional lifespan of cells. Abnormally reactivated in tumorigenesis, telomerase is expressed in the majority of human cancer cells but is not expressed or is expressed at very low levels in normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"hTERT Vaccine V934/V935","termGroup":"PT","termSource":"NCI"},{"termName":"V934/V935","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"hTERT_Vaccine_V934_V935"},{"name":"Maps_To","value":"hTERT Vaccine V934/V935"},{"name":"NCI_Drug_Dictionary_ID","value":"615723"},{"name":"NCI_META_CUI","value":"CL388391"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615723"},{"name":"PDQ_Open_Trial_Search_ID","value":"615723"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C119737":{"preferredName":"hTERT-encoding DNA Vaccine INVAC-1","code":"C119737","definitions":[{"definition":"A DNA vaccine consisting of a plasmid encoding a modified, inactive form of the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase which synthesizes telomeric DNA at the chromosome ends, fused to ubiquitin, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INVAC-1 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. hTERT conjugation to ubiquitin, a 76 amino-acid peptide involved in the regulation of normal protein intracellular turnover in the cytoplasm, enhances proteasome-dependent degradation of the hTERT protein, increases hTERT presentation by major histocompatibility complex (MHC) class I molecules and results in an increased immune response against hTERT.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"hTERT-encoding DNA Vaccine INVAC-1","termGroup":"PT","termSource":"NCI"},{"termName":"INVAC-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1708137-44-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S8GQZ8LF0D"},{"name":"Maps_To","value":"hTERT-encoding DNA Vaccine INVAC-1"},{"name":"NCI_Drug_Dictionary_ID","value":"766989"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766989"},{"name":"PDQ_Open_Trial_Search_ID","value":"766989"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896833"}]}}{"C162537":{"preferredName":"Lorukafusp alfa","code":"C162537","definitions":[{"definition":"A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1) chimeric monoclonal antibody directed against the surface disialoganglioside GD2, fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, the antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed on certain tumor cells. This may stimulate the activation of immune effector cells including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME), IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed on the surface of many tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lorukafusp alfa","termGroup":"PT","termSource":"NCI"},{"termName":"APN 301","termGroup":"CN","termSource":"NCI"},{"termName":"APN-301","termGroup":"CN","termSource":"NCI"},{"termName":"APN301","termGroup":"CN","termSource":"NCI"},{"termName":"EMD 273063","termGroup":"CN","termSource":"NCI"},{"termName":"EMD-273063","termGroup":"CN","termSource":"NCI"},{"termName":"Hu 14.18/IL - 2 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Hu14.18-IL2","termGroup":"SY","termSource":"NCI"},{"termName":"Hu14.18-IL2","termGroup":"AB","termSource":"NCI"},{"termName":"Hu14.18-IL2 Fusion Protein EMD 273063","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2131168-99-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PL21OR4LXE"},{"name":"Maps_To","value":"Hu14.18-IL2 Fusion Protein EMD 273063"},{"name":"NCI_Drug_Dictionary_ID","value":"43349"},{"name":"NCI_META_CUI","value":"CL971111"},{"name":"NSC Number","value":"721298"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82415":{"preferredName":"HuaChanSu","code":"C82415","definitions":[{"definition":"A traditional Chinese medicine (TCM) containing a water soluble Bufo toad skin extract that includes the cardiac glycosides bufalin, cinobufagin and resibufogenin with potential antineoplastic and antiangiogenic activities. Although the exact mechanism of action of this TCM has yet to be fully elucidated, huachansu, which may be administered in an injectable form, may induce cell cycle arrest and apoptosis by suppressing the expression of anti-apoptotic proteins, such as Bcl-2, while inducing the expression of pro-apoptotic proteins, such as BAX.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HuaChanSu","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HuaChanSu"},{"name":"Maps_To","value":"HuaChanSu"},{"name":"NCI_Drug_Dictionary_ID","value":"637352"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637352"},{"name":"PDQ_Open_Trial_Search_ID","value":"637352"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2745673"}]}}{"C125001":{"preferredName":"Huaier Extract Granule","code":"C125001","definitions":[{"definition":"An orally bioavailable traditional Chinese medicine (TCM) composed of a granule containing an aqueous extract of Trametes robiniophila murr (Huaier), a mushroom found on hardwood tree trunks, with potential antineoplastic and anti-angiogenic activities. Although the exact mechanism of action through which Huaier exerts its effects is largely unknown, upon administration, this agent induces cell cycle arrest and apoptosis, and inhibits proliferation and migration of susceptible cancer cells through the modulation of various signal transduction pathways involved in carcinogenesis and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Huaier Extract Granule","termGroup":"PT","termSource":"NCI"},{"termName":"Huaier Granule","termGroup":"SY","termSource":"NCI"},{"termName":"Trametes robiniophila murr Extract Granule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Huaier Extract Granule"},{"name":"NCI_Drug_Dictionary_ID","value":"777301"},{"name":"NCI_META_CUI","value":"CL503847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777301"},{"name":"PDQ_Open_Trial_Search_ID","value":"777301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2626":{"preferredName":"Huang Lian","code":"C2626","definitions":[{"definition":"A Chinese herb of a desiccated root from the plant Coptis chinensis. Although the mechanism of action remains to be fully elucidated, Huang Lian has antibacterial, antifungal, and antiprotozoal activities. In addition, this herb exhibits antioxidant property that influences positively on lipid metabolism, cause dilation of blood vessels, and may slow the growth of tumor cells. This herb contains rich amount of phytogens, such as berberine, palmatine, jatrorrhizine, columbamine, geniposide, and anti-HIV compound baicalin, which might explain the broad effects of this herb. Huang Lian is commonly used to treat diarrhea or dysentery in Chinese medicine.","type":"DEFINITION","source":"NCI"},{"definition":"A Chinese herb that has been used as a treatment for a variety of medical problems.  It is being studied as an anticancer drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Huang Lian","termGroup":"PT","termSource":"NCI"},{"termName":"Rhizoma Coptidis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Huang_Lian"},{"name":"Maps_To","value":"Huang Lian"},{"name":"NCI_Drug_Dictionary_ID","value":"38268"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38268"},{"name":"PDQ_Open_Trial_Search_ID","value":"38268"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0696725"}]}}{"C74041":{"preferredName":"huBC1-huIL12 Fusion Protein AS1409","code":"C74041","definitions":[{"definition":"An immunoconjugate consisting of the anti-tumor cytokine interleukin-12 (IL-12) fused to the tumor-targeting antibody BC1 with potential immunostimulatory and antineoplastic activities. The antibody moiety of huBC1-huIL12 fusion protein AS1409 binds to the human fibronectin splice variant ED-B, delivering IL-12 directly to the tumor vasculature; tumor vasculature-targeted IL-12 initiates localized immune cascade responses and exhibits cytotoxic and anti-angiogenic activity while minimizing the systemic side effects of IL-12. The human fibronectin splice variant ED-B is over-expressed in the extracellular matrix and blood vessels of tumor tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"huBC1-huIL12 Fusion Protein AS1409","termGroup":"PT","termSource":"NCI"},{"termName":"AS1409","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"huBC1-huIL12_Fusion_Protein_AS1409"},{"name":"Maps_To","value":"huBC1-huIL12 Fusion Protein AS1409"},{"name":"NCI_Drug_Dictionary_ID","value":"590612"},{"name":"NCI_META_CUI","value":"CL383540"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590612"},{"name":"PDQ_Open_Trial_Search_ID","value":"590612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116788":{"preferredName":"Ianalumab","code":"C116788","definitions":[{"definition":"A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ianalumab","termGroup":"PT","termSource":"NCI"},{"termName":"HuCAL-based Antibody VAY736","termGroup":"SY","termSource":"NCI"},{"termName":"Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736","termGroup":"SY","termSource":"NCI"},{"termName":"VAY 736","termGroup":"CN","termSource":"NCI"},{"termName":"VAY736","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1929549-92-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZN2GQ3II96"},{"name":"Maps_To","value":"Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736"},{"name":"Maps_To","value":"Ianalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"762784"},{"name":"NCI_META_CUI","value":"CL473936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762784"},{"name":"PDQ_Open_Trial_Search_ID","value":"762784"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66980":{"preferredName":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104","code":"C66980","definitions":[{"definition":"An allogeneic human cytotoxic T-lymphocyte cell line (TALL-104) with potential antineoplastic activity. TALL-104 is an IL-2-dependent human leukemic T cell line, expressing CD8 and T-cell receptor CD3, but not CD16. Because these cells are endowed with MHC-non-restricted killer activity, TALL-104 has destructive potential against a broad range of tumors, while sparing normal cells. Upon administration, TALL-104 targets and interacts with tumor cells and activates apoptotic and necrotic pathways, eventually leading to lysis of tumor cells. In addition, TALL-104 may induce secretion of various cytokines, such as interferon-gamma, thereby potentially enhancing the cytotoxic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104","termGroup":"PT","termSource":"NCI"},{"termName":"TALL-104","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_MHC_Non-Restricted_Cytotoxic_T-Cell_Line_TALL-104"},{"name":"Maps_To","value":"Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104"},{"name":"NCI_Drug_Dictionary_ID","value":"531055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531055"},{"name":"PDQ_Open_Trial_Search_ID","value":"531055"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832042"}]}}{"C29089":{"preferredName":"Human MOAB LICO 28a32","code":"C29089","definitions":[{"definition":"A human monoclonal immunoglobulin M (IgM) antibody with potential antineoplastic activity.  Human MOAB LICO 28a32 binds to the colon tumor-associated antigen 28A32 (CTAA 28A32) found on the cell surface and in the cytoplasm of colon carcinoma cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human MOAB LICO 28a32","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_MOAB_LICO_28a32"},{"name":"Maps_To","value":"Human MOAB LICO 28a32"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1512509"}]}}{"C62532":{"preferredName":"Human Monoclonal Antibody 216","code":"C62532","definitions":[{"definition":"A naturally-occurring human IgM monoclonal antibody with potential antineoplastic activity. Human monoclonal antibody 216, derived from the gene VH4-34, binds to the glycosylated epitope CDIM on the surface of both malignant and normal B cells. Upon binding to B cells, this antibody may crosslink two or more CDIM molecules, resulting in the formation of cell membrane pores, the disruption of cell membrane integrity, and B cell lysis; this mechanism of antibody-mediated cell death is direct and does not involve mechanisms of complement-mediated cytotoxicity or antibody-dependent cell-mediated cytotoxicity (ADCC). CDIM is the glyco-moiety of a 75kD B-cell cell surface glycoprotein.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Monoclonal Antibody 216","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb 216","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Monoclonal_Antibody_216"},{"name":"Maps_To","value":"Human Monoclonal Antibody 216"},{"name":"NCI_Drug_Dictionary_ID","value":"488467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488467"},{"name":"PDQ_Open_Trial_Search_ID","value":"488467"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C1831869"}]}}{"C77858":{"preferredName":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307","code":"C77858","definitions":[{"definition":"A human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. Upon internalization and processing, APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells. The tumor-associated antigen (TAA) hCG beta is selectively overexpressed by a number of tumors including breast, colorectal, pancreatic, bladder and ovarian tumors; its expression may correlate with the stage of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307","termGroup":"PT","termSource":"NCI"},{"termName":"CDX-1307","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Monoclonal_Antibody_B11-hCG_Beta_Fusion_Protein_CDX-1307"},{"name":"Maps_To","value":"Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307"},{"name":"NCI_Drug_Dictionary_ID","value":"593942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593942"},{"name":"PDQ_Open_Trial_Search_ID","value":"593942"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C2713084"}]}}{"C2569":{"preferredName":"Human Papillomavirus 16 E7 Peptide/Padre 965.10","code":"C2569","definitions":[{"definition":"A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms.  HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator.  This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas.  PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Human Papillomavirus 16 E7 Peptide/Padre 965.10","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E7/PADRE 965.10","termGroup":"SY","termSource":"NCI"},{"termName":"Lipidated HPV-16 E7/Padre-965.10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus_16_E7_Peptide-Padre_965_10"},{"name":"Maps_To","value":"Human Papillomavirus 16 E7 Peptide/Padre 965.10"},{"name":"NCI_Drug_Dictionary_ID","value":"42276"},{"name":"NSC Number","value":"679904"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42276"},{"name":"PDQ_Open_Trial_Search_ID","value":"42276"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338214"}]}}{"C550":{"preferredName":"Hycanthone","code":"C550","definitions":[{"definition":"A thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. Hycanthone interferes with parasite nerve function, resulting in parasite paralysis and death.  This agent also intercalates into DNA and inhibits RNA synthesis in vitro. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hycanthone","termGroup":"PT","termSource":"NCI"},{"termName":"Etrenol","termGroup":"BR","termSource":"NCI"},{"termName":"HYC","termGroup":"AB","termSource":"NCI"},{"termName":"Hycanthone Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3105-97-3"},{"name":"CHEBI_ID","value":"CHEBI:52768"},{"name":"Chemical_Formula","value":"C20H24N2O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BXX5EVN2A"},{"name":"Legacy Concept Name","value":"Hycanthone"},{"name":"Maps_To","value":"Hycanthone"},{"name":"NCI_Drug_Dictionary_ID","value":"39477"},{"name":"NSC Number","value":"134434"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39477"},{"name":"PDQ_Open_Trial_Search_ID","value":"39477"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020207"}]}}{"C551":{"preferredName":"Hydralazine Hydrochloride","code":"C551","definitions":[{"definition":"The hydrochloride salt of hydralazine, a phthalazine derivative with antihypertensive and potential antineoplastic activities. Hydralazine alters intracellular calcium release and interferes with smooth muscle cell calcium influx, resulting in arterial vasodilatation. This agent also inhibits the phosphorylation of myosin protein and chelation of trace metals required for smooth muscle contraction, resulting in an increase in heart rate, stroke volume and cardiac output. In addition to its cardiovascular effects, hydralazine inhibits DNA methyltransferase, which may result in inhibition of DNA methylation in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydralazine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Apresoline","termGroup":"BR","termSource":"NCI"},{"termName":"Apressin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"304-20-1"},{"name":"CHEBI_ID","value":"CHEBI:31672"},{"name":"Chemical_Formula","value":"C8H8N4.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FD171B778Y"},{"name":"Legacy Concept Name","value":"Hydralazine"},{"name":"Maps_To","value":"Hydralazine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41835"},{"name":"NSC Number","value":"89394"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41835"},{"name":"PDQ_Open_Trial_Search_ID","value":"41835"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699178"}]}}{"C1819":{"preferredName":"Hydrocortisone Sodium Succinate","code":"C1819","definitions":[{"definition":"The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydrocortisone Sodium Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"A-Hydrocort","termGroup":"BR","termSource":"NCI"},{"termName":"Buccalsone","termGroup":"FB","termSource":"NCI"},{"termName":"Corlan","termGroup":"FB","termSource":"NCI"},{"termName":"Cortisol Sodium Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"Cortop","termGroup":"FB","termSource":"NCI"},{"termName":"Efcortelan","termGroup":"FB","termSource":"NCI"},{"termName":"Emergent-EZ","termGroup":"BR","termSource":"NCI"},{"termName":"Flebocortid","termGroup":"FB","termSource":"NCI"},{"termName":"Hidroc Clora","termGroup":"FB","termSource":"NCI"},{"termName":"Hycorace","termGroup":"SY","termSource":"NCI"},{"termName":"Hydro-Adreson","termGroup":"FB","termSource":"NCI"},{"termName":"Hydrocort","termGroup":"FB","termSource":"NCI"},{"termName":"Hydrocortisone 21-Sodium Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"Hydrocortisone Na Succinate","termGroup":"SY","termSource":"NCI"},{"termName":"Kinogen","termGroup":"FB","termSource":"NCI"},{"termName":"Nordicort","termGroup":"FB","termSource":"NCI"},{"termName":"Nositrol","termGroup":"FB","termSource":"NCI"},{"termName":"Sinsurrene","termGroup":"FB","termSource":"NCI"},{"termName":"Solu-Cortef","termGroup":"BR","termSource":"NCI"},{"termName":"Solu-Glyc","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125-04-2"},{"name":"Chemical_Formula","value":"C25H33O8.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"50LQB69S1Z"},{"name":"Legacy Concept Name","value":"Hydrocortisone_Sodium_Succinate"},{"name":"Maps_To","value":"Hydrocortisone Sodium Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"39861"},{"name":"NSC Number","value":"9152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39861"},{"name":"PDQ_Open_Trial_Search_ID","value":"39861"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770560"}]}}{"C557":{"preferredName":"Hydroxychloroquine","code":"C557","definitions":[{"definition":"A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that decreases immune responses in the body.  It is used to treat some autoimmune diseases, and is being studied as a treatment for graft-versus-host disease. Hydroxychloroquine belongs to the family of drugs called antiprotozoals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hydroxychloroquine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malaria; Rheumatoid arthritis"},{"name":"CAS_Registry","value":"118-42-3"},{"name":"Chemical_Formula","value":"C18H26ClN3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4QWG6N8QKH"},{"name":"Legacy Concept Name","value":"Hydroxychloroquine"},{"name":"Maps_To","value":"Hydroxychloroquine"},{"name":"NCI_Drug_Dictionary_ID","value":"38571"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38571"},{"name":"PDQ_Open_Trial_Search_ID","value":"38571"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020336"}]}}{"C960":{"preferredName":"Hydroxyprogesterone Caproate","code":"C960","definitions":[{"definition":"A synthetic progestational agent similar to the endogenous progesterone used in hormone therapy or as a female contraceptive. Mimicking the action of progesterone, hydroxyprogesterone caporate binds to and activates nuclear progesterone receptors in the reproductive system and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. Due to the negative feedback mechanism seen with progesterone, this agent also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impeding the growth of estrogen-sensitive tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydroxyprogesterone Caproate","termGroup":"PT","termSource":"NCI"},{"termName":"17-[(1-Oxohexyl)oxy]pregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17alpha-Hydroxyprogesterone Caproate","termGroup":"SY","termSource":"NCI"},{"termName":"Delalutin","termGroup":"BR","termSource":"NCI"},{"termName":"Makena","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Endometrial cancer; amenorrhea"},{"name":"CAS_Registry","value":"630-56-8"},{"name":"Chemical_Formula","value":"C27H40O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"276F2O42F5"},{"name":"Legacy Concept Name","value":"Hydroxyprogesterone_Caproate"},{"name":"Maps_To","value":"Hydroxyprogesterone Caproate"},{"name":"NCI_Drug_Dictionary_ID","value":"39803"},{"name":"NSC Number","value":"17592"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39803"},{"name":"PDQ_Open_Trial_Search_ID","value":"39803"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044971"}]}}{"C63690":{"preferredName":"Hydroxytyrosol","code":"C63690","definitions":[{"definition":"A phenolic phytochemical naturally occurring in extra virgin olive oil, with potential antioxidant, anti-inflammatory and cancer preventive activities. Although the mechanisms of action through which hydroxytyrosol exerts its effects have yet to be fully determined, this agent affects the expression of various components of the inflammatory response, possibly through the modulation of the nuclear factor-kappa B (NF-kB) pathway. The effects include the modulation of pro-inflammatory cytokines, such as the inhibition of interleukin-1alpha (IL-1a), IL-1beta, IL-6, IL-12, and tumor necrosis factor-alpha (TNF-a); increased secretion of the anti-inflammatory cytokine IL-10; inhibition of the production of certain chemokines, such as C-X-C motif chemokine ligand 10 (CXCL10/IP-10), C-C motif chemokine ligand 2 (CCL2/MCP-1), and macrophage inflammatory protein-1beta (CCL4/MIP-1b); and inhibition of the expression of the enzymes inducible nitric oxide synthase (iNOS/NOS2) and prostaglandin E2 synthase (PGES), which prevent the production of nitric oxide (NO) and prostaglandin E (PGE2), respectively. In addition, hydroxytyrosol is able to regulate the expression of other genes involved in the regulation of tumor cell proliferation, such as extracellular signal-regulated and cyclin-dependent kinases. Also, hydroxytyrosol scavenges free radicals and prevents oxidative DNA damage. This induces apoptosis and inhibits proliferation in susceptible cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hydroxytyrosol","termGroup":"PT","termSource":"NCI"},{"termName":"2-(3,4-Dihydroxyphenyl)ethanol","termGroup":"SY","termSource":"NCI"},{"termName":"3,4-DHPEA","termGroup":"AB","termSource":"NCI"},{"termName":"3,4-Dihydroxyphenylethanol","termGroup":"SN","termSource":"NCI"},{"termName":"4-(2-Hydroxyethyl)-1,2-benzenediol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10597-60-1"},{"name":"Chemical_Formula","value":"C8H10O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QEU0NE4O90"},{"name":"Legacy Concept Name","value":"_3_4-Dihydroxyphenylethanol"},{"name":"Maps_To","value":"Hydroxytyrosol"},{"name":"NCI_Drug_Dictionary_ID","value":"758473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758473"},{"name":"PDQ_Open_Trial_Search_ID","value":"758473"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0046981"}]}}{"C560":{"preferredName":"Hydroxyurea","code":"C560","definitions":[{"definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hydroxyurea","termGroup":"PT","termSource":"NCI"},{"termName":"Droxia","termGroup":"BR","termSource":"NCI"},{"termName":"Hydrea","termGroup":"BR","termSource":"NCI"},{"termName":"Hydroxycarbamide","termGroup":"SY","termSource":"NCI"},{"termName":"Litalir","termGroup":"FB","termSource":"NCI"},{"termName":"Onco-Carbide","termGroup":"FB","termSource":"NCI"},{"termName":"Oncocarbide","termGroup":"FB","termSource":"NCI"},{"termName":"Oxeron","termGroup":"FB","termSource":"NCI"},{"termName":"SQ-1089","termGroup":"CN","termSource":"NCI"},{"termName":"Syrea","termGroup":"FB","termSource":"NCI"},{"termName":"WR 83799","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Myelogenous Leukemia; Head and Neck Cancer; Malignant Melanoma; Ovarian Carcinoma; Sickle Cell Anemia; Adjuvant in Retroviral Therapy."},{"name":"CAS_Registry","value":"127-07-1"},{"name":"CHEBI_ID","value":"CHEBI:44423"},{"name":"Chemical_Formula","value":"CH4N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"X6Q56QN5QC"},{"name":"Legacy Concept Name","value":"Hydroxyurea"},{"name":"Maps_To","value":"Hydroxyurea"},{"name":"NCI_Drug_Dictionary_ID","value":"40685"},{"name":"NSC Number","value":"32065"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40685"},{"name":"PDQ_Open_Trial_Search_ID","value":"40685"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020402"}]}}{"C37456":{"preferredName":"Hypericin","code":"C37456","definitions":[{"definition":"An anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John's wort) with antidepressant, potential antiviral, antineoplastic and immunostimulating activities. Hypericin appears to inhibit the neuronal uptake of serotonin, norepinephrine, dopamine, gamma-amino butyric acid (GABA) and L-glutamate, which may contribute to its antidepressant effect. Hypericin may also prevent the replication of encapsulated viruses probably due to inhibition of the assembly and shedding of virus particles in infected cells. This agent also exerts potent phototoxic effects by triggering apoptotic signaling that results in formation of reactive oxygen species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypericin","termGroup":"PT","termSource":"NCI"},{"termName":"4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethyl-mesonapthtodianthron","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"548-04-9"},{"name":"CHEBI_ID","value":"CHEBI:5835"},{"name":"Chemical_Formula","value":"C30H16O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7V2F1075HD"},{"name":"Legacy Concept Name","value":"Hypericin"},{"name":"Maps_To","value":"Hypericin"},{"name":"NSC Number","value":"407313"},{"name":"NSC Number","value":"622946"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063220"}]}}{"C101523":{"preferredName":"Hypoxia-activated Prodrug TH-4000","code":"C101523","definitions":[{"definition":"A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug TH-4000 is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hypoxia-activated Prodrug TH-4000","termGroup":"PT","termSource":"NCI"},{"termName":"Hypoxin","termGroup":"BR","termSource":"NCI"},{"termName":"PR610","termGroup":"CN","termSource":"NCI"},{"termName":"TH-4000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hypoxia-activated Prodrug TH-4000"},{"name":"NCI_Drug_Dictionary_ID","value":"732241"},{"name":"NCI_META_CUI","value":"CL435780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732241"},{"name":"PDQ_Open_Trial_Search_ID","value":"732241"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2357":{"preferredName":"I 131 Antiferritin Immunoglobulin","code":"C2357","definitions":[{"definition":"A radioimmunoconjugate of a rabbit antihuman ferritin IgG labeled with iodine 131 (I-131). Using anti-ferritin IgG as a carrier for I-131 may result in the targeted imaging and/or destruction of cells expressing ferritin. Observed in 35% to 100% of patients with hepatocellular carcinoma, high serum ferritin levels may be due to ferritin production by the tumor cells, or related to the associated iron overload and/or cirrhosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Antiferritin Immunoglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"I 131-AFI","termGroup":"AB","termSource":"NCI"},{"termName":"I 131-antiferritin IgG","termGroup":"SY","termSource":"NCI"},{"termName":"immunoglobulin, iodine I 131 antiferritin","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Antiferritin Immunoglobulin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Antiferritin_Immunoglobulin"},{"name":"Maps_To","value":"I 131 Antiferritin Immunoglobulin"},{"name":"NCI_Drug_Dictionary_ID","value":"40362"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40362"},{"name":"PDQ_Open_Trial_Search_ID","value":"40362"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280029"}]}}{"C2477":{"preferredName":"I 131 Monoclonal Antibody A33","code":"C2477","definitions":[{"definition":"A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 131 (I-131). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancers, with only restricted expression in normal colonic mucosa. Using MoAb A33 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressed A33 antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody A33","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody A33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_A33"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody A33"},{"name":"NCI_Drug_Dictionary_ID","value":"43095"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43095"},{"name":"PDQ_Open_Trial_Search_ID","value":"43095"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678093"}]}}{"C26442":{"preferredName":"I 131 Monoclonal Antibody CC49","code":"C26442","definitions":[{"definition":"A radioimmunoconjugate of the humanized monoclonal antibody CC49 labeled with iodine I 131. Iodine I 131 monoclonal antibody CC49 delivers beta and gamma radiation-emitting I 131 radionuclide specifically to tumor cells that express tumor-associated glycoprotein (TAG)-72, allowing localization of TAG-72-expressing tumor cells with radioimaging devices in diagnostic applications or resulting in specific TAG-72-expressing tumor cell radiocytotoxicity in therapeutic applications. Monoclonal antibody CC49 binds to TAG-72, a pancarcinoma antigen, with high affinity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody CC49","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody CC49"},{"name":"NCI_Drug_Dictionary_ID","value":"269166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269166"},{"name":"PDQ_Open_Trial_Search_ID","value":"269166"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327845"}]}}{"C2515":{"preferredName":"I 131 Monoclonal Antibody F19","code":"C2515","definitions":[{"definition":"A radioimmunoconjugate of a murine monoclonal antibody (MoAb) F19 labelled with Iodine 131 (I-131). MoAb F19 was raised against fibroblast activation protein (FAP), which is highly expressed by tumor stromal cells. Using MoAb F19 as a carrier for I-131 results in the targeted imaging and/or destruction of cells overexpressed FAP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody F19","termGroup":"PT","termSource":"NCI"},{"termName":"131I-mAbF19","termGroup":"AB","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody F19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_F19"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody F19"},{"name":"NCI_Drug_Dictionary_ID","value":"43385"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43385"},{"name":"PDQ_Open_Trial_Search_ID","value":"43385"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796525"}]}}{"C2103":{"preferredName":"I 131 Monoclonal Antibody Lym-1","code":"C2103","definitions":[{"definition":"A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with iodine 131 (I-131). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. I-131 MoAb Lym-1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express HLA-DR, thereby allowing imaging and/or treatment of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"I 131 Monoclonal Antibody Lym-1","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolym","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_Lym-1"},{"name":"Maps_To","value":"I 131 Monoclonal Antibody Lym-1"},{"name":"NCI_Drug_Dictionary_ID","value":"38533"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38533"},{"name":"PDQ_Open_Trial_Search_ID","value":"38533"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134561"}]}}{"C162535":{"preferredName":"Dasminapant","code":"C162535","definitions":[{"definition":"A small molecule, second mitochondria-derived activator of caspases (SMAC)-mimetic targeting inhibitor of apoptosis proteins (IAPs) with potential apoptosis-inducing and antineoplastic activities. Upon administration, dasminapant selectively binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, dasminapant may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dasminapant","termGroup":"PT","termSource":"NCI"},{"termName":"APG 1387","termGroup":"CN","termSource":"NCI"},{"termName":"APG-1387","termGroup":"CN","termSource":"NCI"},{"termName":"APG1387","termGroup":"CN","termSource":"NCI"},{"termName":"IAP Antagonist APG-1387","termGroup":"SY","termSource":"NCI"},{"termName":"IAP Inhibitor APG-1387","termGroup":"SY","termSource":"NCI"},{"termName":"Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, 3,3'-(1,3-phenylenebis(sulfonyl))bis(N-(diphenylmethyl)decahydro-5-(((2S)-2-(methylamino)-1-oxopropyl)amino)-6-oxo-, (5S,5'S,8S,8'S,10aR,10'ar)-","termGroup":"SN","termSource":"NCI"},{"termName":"SM-1387","termGroup":"CN","termSource":"NCI"},{"termName":"SMAC-mimetic APG-1387","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1570231-89-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E53VN70K2X"},{"name":"Maps_To","value":"IAP Inhibitor APG-1387"},{"name":"NCI_Drug_Dictionary_ID","value":"794301"},{"name":"NCI_META_CUI","value":"CL971113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794301"},{"name":"PDQ_Open_Trial_Search_ID","value":"794301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90574":{"preferredName":"Xevinapant","code":"C90574","definitions":[{"definition":"An orally available mimetic of the natural second mitochondrial-derived activator of caspases (Smac) and inhibitor of Inhibitor of Apoptosis Proteins (IAPs), with potential immunomodulating, apoptotic-inducing, chemo-radio-sensitizing and antineoplastic activities. Upon oral administration,xevinapant targets and binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP), and the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This inhibits the activities of these IAPs and promotes the induction of apoptosis. Additionally, as xevinapant inhibits the activity of IAPs, it may work synergistically with cytotoxic drugs and/or radiation to overcome tumor cell resistance to apoptosis. As IAPs regulate nuclear factor-kappa B (NFkB) signaling pathways, which drives the expression of genes involved in immune and inflammatory responses, xevinapant may enhance anti-tumor immune responses when administered with certain immunomodulating agents, such as immune checkpoint inhibitors. IAPs are overexpressed by many cancer cell types and suppress both intrinsic and extrinsic apoptosis by binding to and inhibiting active caspases via their baculoviral lAP repeat (BIR) domains. They contribute to chemo-radio-resistance of cancer cells to certain cytotoxic agents and radiation, promote tumor cell survival and are associated with poor prognosis in certain types of cancer. SMAC, a pro-apoptotic mitochondrial protein, is an endogenous inhibitor of the IAPs family of cellular proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xevinapant","termGroup":"PT","termSource":"NCI"},{"termName":"AT-406","termGroup":"CN","termSource":"NCI"},{"termName":"D1143","termGroup":"CN","termSource":"NCI"},{"termName":"Debio 1143","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-1143","termGroup":"CN","termSource":"NCI"},{"termName":"Debio1143","termGroup":"CN","termSource":"NCI"},{"termName":"IAPs Antagonist Debio 1143","termGroup":"SY","termSource":"NCI"},{"termName":"IAPs Inhibitor Debio 1143","termGroup":"SY","termSource":"NCI"},{"termName":"Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, n-((1,1'-biphenyl)-2-ylmethyl)decahydro-5-(((2s)-2-(methylamino)-1-oxopropyl)amino)-3-(3-methyl-1-oxobutyl)-6-oxo-, (5s,8s,10ar)","termGroup":"SY","termSource":"NCI"},{"termName":"Second Mitochondrial-derived Activator of Caspases Mimetic Debio 1143","termGroup":"SY","termSource":"NCI"},{"termName":"SM-406","termGroup":"CN","termSource":"NCI"},{"termName":"SMAC Mimetic Debio 1143","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1071992-81-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N65WC8PXDD"},{"name":"Maps_To","value":"IAP Inhibitor AT-406"},{"name":"Maps_To","value":"Xevinapant"},{"name":"NCI_Drug_Dictionary_ID","value":"667935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"667935"},{"name":"PDQ_Open_Trial_Search_ID","value":"667935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3177416"}]}}{"C78484":{"preferredName":"IAP Inhibitor HGS1029","code":"C78484","definitions":[{"definition":"The hydrochloride salt of a small-molecule inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins with potential antineoplastic activity. IAP inhibitor HGS1029 selectively inhibits the biological activity of IAP proteins, which may restore apoptotic signaling pathways; this agent may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IAP Inhibitor HGS1029","termGroup":"PT","termSource":"NCI"},{"termName":"AEG40826-2HCl","termGroup":"CN","termSource":"NCI"},{"termName":"HGS1029","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"IAP_Inhibitor_HGS1029"},{"name":"Maps_To","value":"IAP Inhibitor HGS1029"},{"name":"NCI_Drug_Dictionary_ID","value":"601033"},{"name":"NCI_META_CUI","value":"CL387473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601033"},{"name":"PDQ_Open_Trial_Search_ID","value":"601033"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1670":{"preferredName":"Ibandronate Sodium","code":"C1670","definitions":[{"definition":"A drug that is used to prevent and treat osteoporosis, and is being studied in the treatment of cancer that has spread to the bones. It belongs to the family of drugs called bisphosphonates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibandronate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Bondronate","termGroup":"FB","termSource":"NCI"},{"termName":"Boniva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Osteoporosis, treatment and prevention"},{"name":"CAS_Registry","value":"138926-19-9"},{"name":"Chemical_Formula","value":"C9H22NO7P2.Na.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J12U072QL0"},{"name":"Legacy Concept Name","value":"Ibandronate"},{"name":"Maps_To","value":"Ibandronate Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"365963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365963"},{"name":"PDQ_Open_Trial_Search_ID","value":"365963"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0772244"}]}}{"C129048":{"preferredName":"Iberdomide","code":"C129048","definitions":[{"definition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iberdomide","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"CC 220","termGroup":"CN","termSource":"NCI"},{"termName":"CC-220","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1323403-33-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8V66F27X44"},{"name":"Maps_To","value":"Iberdomide"},{"name":"NCI_Drug_Dictionary_ID","value":"783168"},{"name":"NCI_META_CUI","value":"CL512126"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783168"},{"name":"PDQ_Open_Trial_Search_ID","value":"783168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1680":{"preferredName":"Iboctadekin","code":"C1680","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, iboctadekin displays antitumor effects in vitro and in animal models. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iboctadekin","termGroup":"PT","termSource":"NCI"},{"termName":"Human Interleukin-18 (Recombinant, Expressed in Escherichia coli)","termGroup":"SN","termSource":"NCI"},{"termName":"Human Recombinant Interleukin-18","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-Gamma-Inducing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"IL-18","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon-Gamma-Inducing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-18","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Interleukin-18","termGroup":"SY","termSource":"NCI"},{"termName":"SB 485232","termGroup":"CN","termSource":"NCI"},{"termName":"SB-485232","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"479198-61-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X08H9UZ7TO"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-18"},{"name":"Maps_To","value":"Iboctadekin"},{"name":"Maps_To","value":"Recombinant Interleukin-18"},{"name":"NCI_Drug_Dictionary_ID","value":"386168"},{"name":"PDQ_Closed_Trial_Search_ID","value":"386168"},{"name":"PDQ_Open_Trial_Search_ID","value":"386168"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527127"}]}}{"C29981":{"preferredName":"Ibritumomab Tiuxetan","code":"C29981","definitions":[{"definition":"A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other types of B-cell tumors. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Ibritumomab binds to the protein called CD20, which is found on B cells. It is linked to the compound tiuxetan. This allows certain radioisotopes to be attached before it is given to a patient. It is a type of monoclonal antibody-chelator conjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibritumomab Tiuxetan","termGroup":"PT","termSource":"NCI"},{"termName":"IDEC-129","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-2B8","termGroup":"CN","termSource":"NCI"},{"termName":"Zevalin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"206181-63-7"},{"name":"Chemical_Formula","value":"C23H32N5O10S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4Q52C550XK"},{"name":"Legacy Concept Name","value":"Ibritumomab_Tiuxetan"},{"name":"Maps_To","value":"Ibritumomab Tiuxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"43080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43080"},{"name":"PDQ_Open_Trial_Search_ID","value":"43080"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0877880"}]}}{"C81934":{"preferredName":"Ibrutinib","code":"C81934","definitions":[{"definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BTK Inhibitor PCI-32765","termGroup":"SY","termSource":"NCI"},{"termName":"CRA 032765","termGroup":"CN","termSource":"NCI"},{"termName":"CRA-032765","termGroup":"CN","termSource":"NCI"},{"termName":"CRA032765","termGroup":"CN","termSource":"NCI"},{"termName":"Imbruvica","termGroup":"BR","termSource":"NCI"},{"termName":"PCI 32765","termGroup":"CN","termSource":"NCI"},{"termName":"PCI-32765","termGroup":"CN","termSource":"NCI"},{"termName":"PCI32765","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Waldenstrom's macroglobulinemia (WM); mantle cell lymphoma (MCL); chronic lymphocytic leukemia (CLL)"},{"name":"CAS_Registry","value":"936563-96-1"},{"name":"Chemical_Formula","value":"C25H24N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1X70OSD4VX"},{"name":"Legacy Concept Name","value":"BTK_Inhibitor_PCI-32765"},{"name":"Maps_To","value":"Ibrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"638648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638648"},{"name":"PDQ_Open_Trial_Search_ID","value":"638648"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830052"}]}}{"C99160":{"preferredName":"Icotinib Hydrochloride","code":"C99160","definitions":[{"definition":"The hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Icotinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"BPI 2009H","termGroup":"CN","termSource":"NCI"},{"termName":"BPI-2009H","termGroup":"CN","termSource":"NCI"},{"termName":"BPI2009H","termGroup":"CN","termSource":"NCI"},{"termName":"Conmana","termGroup":"FB","termSource":"NCI"},{"termName":"Icotinib HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204313-51-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JTD32I0J83"},{"name":"Maps_To","value":"Icotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"717145"},{"name":"NCI_META_CUI","value":"CL524350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717145"},{"name":"PDQ_Open_Trial_Search_ID","value":"717145"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79808":{"preferredName":"Icrucumab","code":"C79808","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Icrucumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody IMC-18F1","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VEGFR-1 Monoclonal Antibody IMC-18F1","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-18F1","termGroup":"CN","termSource":"NCI"},{"termName":"IMC18F1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1024603-92-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T7H0B1R64U"},{"name":"Legacy Concept Name","value":"Anti-VEGFR-1_Monoclonal_Antibody_IMC-18F1"},{"name":"Maps_To","value":"Icrucumab"},{"name":"NCI_Drug_Dictionary_ID","value":"625428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"625428"},{"name":"PDQ_Open_Trial_Search_ID","value":"625428"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703168"}]}}{"C124652":{"preferredName":"ICT-121 Dendritic Cell Vaccine","code":"C124652","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ICT-121 Dendritic Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"CD133 Peptides-pulsed Autologous DC Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CD133 Peptides-pulsed Autologous Dendritic Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"ICT-121","termGroup":"CN","termSource":"NCI"},{"termName":"ICT-121 DC Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ICT-121 Dendritic Cell Vaccine"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4086505"}]}}{"C562":{"preferredName":"Idarubicin","code":"C562","definitions":[{"definition":"A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Idarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Demethoxydaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"4-Demethoxydaunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"4-DMDR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute myeloid leukemia; acute nonlymphocytic leukemia"},{"name":"CAS_Registry","value":"58957-92-9"},{"name":"CHEBI_ID","value":"CHEBI:42068"},{"name":"Chemical_Formula","value":"C26H27NO9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"ZRP63D75JW"},{"name":"Legacy Concept Name","value":"Idarubicin"},{"name":"Maps_To","value":"Idarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39753"},{"name":"PDQ_Open_Trial_Search_ID","value":"39753"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020789"}]}}{"C1587":{"preferredName":"Idarubicin Hydrochloride","code":"C1587","definitions":[{"definition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idarubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Idamycin","termGroup":"BR","termSource":"NCI"},{"termName":"Idamycin PFS","termGroup":"BR","termSource":"NCI"},{"termName":"Idarubicin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"IMI-30","termGroup":"CN","termSource":"NCI"},{"termName":"SC-33428","termGroup":"CN","termSource":"NCI"},{"termName":"Zavedos","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"In combination therapies for acute myelogenous leukemia and pediatric acute lymphocytic leukemia."},{"name":"CAS_Registry","value":"57852-57-0"},{"name":"Chemical_Formula","value":"C26H27NO9.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5VV3MDU5IE"},{"name":"Legacy Concept Name","value":"Idarubicin_Hydrochloride"},{"name":"Maps_To","value":"Idarubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39753"},{"name":"NSC Number","value":"256439"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39753"},{"name":"PDQ_Open_Trial_Search_ID","value":"39753"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0939353"}]}}{"C90593":{"preferredName":"Idarubicin-Eluting Beads","code":"C90593","definitions":[{"definition":"A sustained-release drug delivery embolization system containing small polymeric beads impregnated with the anthracycline antibiotic idarubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with idarubicin. During transarterial chemoembolization (TACE) in the hepatic artery, idarubicin-eluting beads embolize to the tumor vasculature, occlude tumor blood vessels and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. Simultaneously, idarubicin-eluting beads release cytotoxic idarubicin locally and in a sustained manner. This may result in idarubicin-mediated inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idarubicin-Eluting Beads","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Idarubicin-Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"663437"},{"name":"NCI_META_CUI","value":"CL413614"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663437"},{"name":"PDQ_Open_Trial_Search_ID","value":"663437"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99131":{"preferredName":"Idasanutlin","code":"C99131","definitions":[{"definition":"An orally available, small molecule, antagonist of MDM2 (mouse double minute 2; Mdm2 p53 binding protein homolog), with potential antineoplastic activity. Idasanutlin binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idasanutlin","termGroup":"PT","termSource":"NCI"},{"termName":"RG-7388","termGroup":"CN","termSource":"NCI"},{"termName":"RG7388","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5503781","termGroup":"CN","termSource":"NCI"},{"termName":"RO5503781","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229705-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QSQ883V35U"},{"name":"Maps_To","value":"Idasanutlin"},{"name":"NCI_Drug_Dictionary_ID","value":"715916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715916"},{"name":"PDQ_Open_Trial_Search_ID","value":"715916"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3851180"}]}}{"C117729":{"preferredName":"Idecabtagene Vicleucel","code":"C117729","definitions":[{"definition":"A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idecabtagene Vicleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Abecma","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-BCMA CAR T Cells BB2121","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA-CAR-transduced T Cells BB2121","termGroup":"SY","termSource":"NCI"},{"termName":"BB2121","termGroup":"CN","termSource":"NCI"},{"termName":"BCMA-specific CAR-expressing T Lymphocytes BB2121","termGroup":"SY","termSource":"NCI"},{"termName":"Ide-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with multiple myeloma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8PX1X7UG4D"},{"name":"Maps_To","value":"Idecabtagene Vicleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"763837"},{"name":"NCI_META_CUI","value":"CL474124"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763837"},{"name":"PDQ_Open_Trial_Search_ID","value":"763837"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78825":{"preferredName":"Idelalisib","code":"C78825","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idelalisib","termGroup":"PT","termSource":"NCI"},{"termName":"5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"CAL 101","termGroup":"CN","termSource":"NCI"},{"termName":"CAL-101","termGroup":"CN","termSource":"NCI"},{"termName":"CAL101","termGroup":"CN","termSource":"NCI"},{"termName":"GS 1101","termGroup":"CN","termSource":"NCI"},{"termName":"GS-1101","termGroup":"CN","termSource":"NCI"},{"termName":"GS1101","termGroup":"CN","termSource":"NCI"},{"termName":"Phosphoinositide-3 Kinase Delta Inhibitor CAL-101","termGroup":"SY","termSource":"NCI"},{"termName":"Zydelig","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed chronic lymphocytic leukemia (CLL)"},{"name":"CAS_Registry","value":"870281-82-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YG57I8T5M0"},{"name":"Legacy Concept Name","value":"PI3K-delta_Inhibitor_CAL-101"},{"name":"Maps_To","value":"Idelalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"601486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601486"},{"name":"PDQ_Open_Trial_Search_ID","value":"601486"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698692"}]}}{"C121457":{"preferredName":"IDH1(R132) Inhibitor IDH305","code":"C121457","definitions":[{"definition":"An inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, IDH305 specifically inhibits IDH1(R132) mutant forms in the cytoplasm, which inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1(R132)-expressing tumor cells. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH1(R132) Inhibitor IDH305","termGroup":"PT","termSource":"NCI"},{"termName":"IDH305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDH1(R132) Inhibitor IDH305"},{"name":"NCI_Drug_Dictionary_ID","value":"770082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770082"},{"name":"PDQ_Open_Trial_Search_ID","value":"770082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053635"}]}}{"C117235":{"preferredName":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M","code":"C117235","definitions":[{"definition":"A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M","termGroup":"PT","termSource":"NCI"},{"termName":"PEPIDH1M","termGroup":"CN","termSource":"NCI"},{"termName":"PEPIDH1M Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDH1R132H-Specific Peptide Vaccine PEPIDH1M"},{"name":"NCI_Drug_Dictionary_ID","value":"763159"},{"name":"NCI_META_CUI","value":"CL474105"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763159"},{"name":"PDQ_Open_Trial_Search_ID","value":"763159"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74042":{"preferredName":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020","code":"C74042","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020","termGroup":"PT","termSource":"NCI"},{"termName":"APC8020","termGroup":"CN","termSource":"NCI"},{"termName":"Mylovenge","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Idiotype-Pulsed_Autologous_Dendritic_Cell_Vaccine_APC8020"},{"name":"Maps_To","value":"Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020"},{"name":"NCI_Drug_Dictionary_ID","value":"584999"},{"name":"NCI_META_CUI","value":"CL383479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"584999"},{"name":"PDQ_Open_Trial_Search_ID","value":"584999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159498":{"preferredName":"Imsapepimut","code":"C159498","definitions":[{"definition":"A second-generation peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. Vaccination with imsapepimut may activate the immune system to induce an immune response against IDO-expressing tumor cells. This may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imsapepimut","termGroup":"PT","termSource":"NCI"},{"termName":"IDO Peptide Vaccine IO102","termGroup":"SY","termSource":"NCI"},{"termName":"IDO-derived Vaccine IO102","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine 2,3-dioxygenase-derived Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"IO 102","termGroup":"CN","termSource":"NCI"},{"termName":"IO-102","termGroup":"SY","termSource":"NCI"},{"termName":"IO102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2130836-27-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V74I849BP9"},{"name":"Maps_To","value":"IDO Peptide Vaccine IO102"},{"name":"NCI_Drug_Dictionary_ID","value":"797514"},{"name":"NCI_META_CUI","value":"CL951456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797514"},{"name":"PDQ_Open_Trial_Search_ID","value":"797514"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C143068":{"preferredName":"IDO-1 Inhibitor LY3381916","code":"C143068","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor LY3381916 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, LY3381916 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO-1 Inhibitor LY3381916","termGroup":"PT","termSource":"NCI"},{"termName":"IDO1 Inhibitor LY3381916","termGroup":"SY","termSource":"NCI"},{"termName":"LY-3381916","termGroup":"CN","termSource":"NCI"},{"termName":"LY3381916","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2166616-75-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"10T9596ILQ"},{"name":"Maps_To","value":"IDO-1 Inhibitor LY3381916"},{"name":"NCI_Drug_Dictionary_ID","value":"794987"},{"name":"NCI_META_CUI","value":"CL541448"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794987"},{"name":"PDQ_Open_Trial_Search_ID","value":"794987"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151945":{"preferredName":"IDO/TDO Inhibitor HTI-1090","code":"C151945","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor HTI-1090 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, HTI-1090 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO/TDO Inhibitor HTI-1090","termGroup":"PT","termSource":"NCI"},{"termName":"HTI 1090","termGroup":"CN","termSource":"NCI"},{"termName":"HTI-1090","termGroup":"CN","termSource":"NCI"},{"termName":"SHR9146","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO/TDO Inhibitor HTI-1090"},{"name":"NCI_Drug_Dictionary_ID","value":"793153"},{"name":"NCI_META_CUI","value":"CL553173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793153"},{"name":"PDQ_Open_Trial_Search_ID","value":"793153"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129790":{"preferredName":"IDO1 Inhibitor KHK2455","code":"C129790","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor KHK2455 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, KHK2455 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes. KHK2455 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1 Inhibitor KHK2455","termGroup":"PT","termSource":"NCI"},{"termName":"IDO-1 Inhibitor KHK2455","termGroup":"SY","termSource":"NCI"},{"termName":"KHK 2455","termGroup":"CN","termSource":"NCI"},{"termName":"KHK2455","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1 Inhibitor KHK2455"},{"name":"NCI_Drug_Dictionary_ID","value":"784565"},{"name":"NCI_META_CUI","value":"CL512931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784565"},{"name":"PDQ_Open_Trial_Search_ID","value":"784565"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148235":{"preferredName":"IDO1 Inhibitor MK-7162","code":"C148235","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor MK-7162 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, MK-7162 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This agent may also induce increased interferon (IFN) production, which may lead to a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against and inhibit the growth of the IDO1-expressing tumor cells. IDO1, an enzyme overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1 Inhibitor MK-7162","termGroup":"PT","termSource":"NCI"},{"termName":"Indoleamine-2,3-dioxygenase-1 Inhibitor MK-7162","termGroup":"SY","termSource":"NCI"},{"termName":"MK 7162","termGroup":"CN","termSource":"NCI"},{"termName":"MK-7162","termGroup":"CN","termSource":"NCI"},{"termName":"MK7162","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1 Inhibitor MK-7162"},{"name":"NCI_META_CUI","value":"CL550836"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129375":{"preferredName":"IDO1 Inhibitor PF-06840003","code":"C129375","definitions":[{"definition":"An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor PF-06840003 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, PF-06840003 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes; PF-06840003 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1 Inhibitor PF-06840003","termGroup":"PT","termSource":"NCI"},{"termName":"IDO-1 Inhibitor PF-06840003","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase Inhibitor PF-06840003","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06840003","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06840003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198474-05-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5K1FUI0T2C"},{"name":"Maps_To","value":"IDO1 Inhibitor PF-06840003"},{"name":"NCI_Drug_Dictionary_ID","value":"783440"},{"name":"NCI_META_CUI","value":"CL512154"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783440"},{"name":"PDQ_Open_Trial_Search_ID","value":"783440"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162858":{"preferredName":"IDO1/TDO2 Inhibitor DN1406131","code":"C162858","definitions":[{"definition":"An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor DN1406131 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (KYN). This inhibits the IDO1/TDO2-KYN-AhR pathway. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types, plays a key role in immunosuppression and its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1/TDO2 Inhibitor DN1406131","termGroup":"PT","termSource":"NCI"},{"termName":"DN 1406131","termGroup":"CN","termSource":"NCI"},{"termName":"DN-1406131","termGroup":"CN","termSource":"NCI"},{"termName":"DN131","termGroup":"CN","termSource":"NCI"},{"termName":"DN1406131","termGroup":"CN","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase 2 Inhibitor DN1406131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1/TDO2 Inhibitor DN1406131"},{"name":"NCI_Drug_Dictionary_ID","value":"798903"},{"name":"NCI_META_CUI","value":"CL973340"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798903"},{"name":"PDQ_Open_Trial_Search_ID","value":"798903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2642":{"preferredName":"Idronoxil","code":"C2642","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idronoxil","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol","termGroup":"SN","termSource":"NCI"},{"termName":"NOX66","termGroup":"CN","termSource":"NCI"},{"termName":"NV-06","termGroup":"CN","termSource":"NCI"},{"termName":"Phenoxodiol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81267-65-4"},{"name":"Chemical_Formula","value":"C15H12O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"995FT1W541"},{"name":"Legacy Concept Name","value":"Phenoxodiol"},{"name":"Maps_To","value":"Idronoxil"},{"name":"NCI_Drug_Dictionary_ID","value":"38371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38371"},{"name":"PDQ_Open_Trial_Search_ID","value":"38371"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134444"}]}}{"C132257":{"preferredName":"Idronoxil Suppository NOX66","code":"C132257","definitions":[{"definition":"A proprietary, suppository-based formulation composed of idronoxil, a synthetic flavonoid derivative, surrounded by a proprietary lipid that protects idronoxil from phase 2 degradation, with potential chemo- and radio-sensitizing activities. Upon administration, idronoxil blocks the activity of ecto-NOX disulfide-thiol exchanger 2 (ENOX2; tNOX), a tumor-specific external NADH oxidase that maintains the transmembrane electron potential across the plasma membrane and is overexpressed in certain cancer cell types while absent in normal, healthy cells. Loss of this potential directly inhibits certain pro-survival signal transduction pathways, such as the PARP1/PI3 kinase/Akt signaling pathway. The inhibition of these pathways prevents resistance to standard chemo- and radio-therapy and makes tumor cells more susceptible to the anti-tumor activity of conventional chemotherapeutic agents and radiotherapy. The formulation prevents detoxification of idronoxil to an inactive form by bypassing phase 2 metabolism; this increases idronoxil's bioavailability as compared to idronoxil alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Idronoxil Suppository NOX66","termGroup":"PT","termSource":"NCI"},{"termName":"NOX66","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Idronoxil Suppository NOX66"},{"name":"NCI_Drug_Dictionary_ID","value":"787307"},{"name":"NCI_META_CUI","value":"CL520045"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787307"},{"name":"PDQ_Open_Trial_Search_ID","value":"787307"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116629":{"preferredName":"Ifabotuzumab","code":"C116629","definitions":[{"definition":"A non-fucosylated monoclonal antibody directed against the ephrin receptor A3 (EphA3), with potential antineoplastic activity. Upon administration, ifabotuzumab selectively binds to tumor cells expressing EphA3. This blocks both EphA3 activation and EphA3-mediated signaling, and induces apoptosis in EphA3-expressing tumor cells. In addition, ifabotuzumab can stimulate antibody dependent cell-mediated cytotoxicity (ADCC) against EphA3-expressing tumor cells. This agent also prevents tumor cell proliferation by inhibiting both EphA3 signaling and proliferation of endothelial cells in the tumor vasculature. The cell-surface receptor EphA3, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of tumor types but is not expressed in normal healthy adult tissues. It plays an important role in tumor cell proliferation. Non-fucosylation of the antibody enhances its ADCC activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifabotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Fibatuzumab","termGroup":"SY","termSource":"NCI"},{"termName":"KB 004","termGroup":"CN","termSource":"NCI"},{"termName":"KB-004","termGroup":"CN","termSource":"NCI"},{"termName":"KB004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1234137-51-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BN89552WP"},{"name":"Maps_To","value":"Ifabotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"686621"},{"name":"NCI_META_CUI","value":"CL433718"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686621"},{"name":"PDQ_Open_Trial_Search_ID","value":"686621"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C81570":{"preferredName":"Ifetroban","code":"C81570","definitions":[{"definition":"An orally bioavailable thromboxane (TxA2) and prostaglandin H2 (PGH2) (TP) receptor antagonist, with anti-thrombotic, anti-hypertensive, anti-asthmatic and potential anti-metastatic activities. Upon administration, ifetroban targets and binds to TxA2 and PGH2 receptors, thereby preventing the activity of both TxA2 and PGH2 and disrupting their downstream signaling pathways. This prevents platelet activation, aggregation and thrombosis. It also prevents vascular constriction and causes vasodilation. In addition, as cancer cells use platelets to metastasize to different parts of the body, ifetroban can reduce the stickiness of the platelets and prevent metastasis. TxA2 causes vascular contraction and platelet activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifetroban","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"143443-90-7"},{"name":"Chemical_Formula","value":"C25H32N2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E833KT807K"},{"name":"Legacy Concept Name","value":"Ifetroban"},{"name":"Maps_To","value":"Ifetroban"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0287939"}]}}{"C564":{"preferredName":"Ifosfamide","code":"C564","definitions":[{"definition":"A drug that is used with other drugs to treat germ cell testicular cancer that did not respond to previous treatment with other drugs. It is also being studied in the treatment of other types of cancer. Ifex attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent and a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-oxo-N,3-bis-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin- 2-amine","termGroup":"SN","termSource":"NCI"},{"termName":"3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"Asta Z-4942","termGroup":"CN","termSource":"NCI"},{"termName":"Cyfos","termGroup":"SY","termSource":"NCI"},{"termName":"Holoxan","termGroup":"FB","termSource":"NCI"},{"termName":"Holoxane","termGroup":"FB","termSource":"NCI"},{"termName":"Ifex","termGroup":"BR","termSource":"NCI"},{"termName":"IFO","termGroup":"AB","termSource":"NCI"},{"termName":"IFO-Cell","termGroup":"FB","termSource":"NCI"},{"termName":"Ifolem","termGroup":"FB","termSource":"NCI"},{"termName":"Ifomida","termGroup":"FB","termSource":"NCI"},{"termName":"Ifomide","termGroup":"SY","termSource":"NCI"},{"termName":"Ifosfamidum","termGroup":"SY","termSource":"NCI"},{"termName":"Ifoxan","termGroup":"FB","termSource":"NCI"},{"termName":"IFX","termGroup":"AB","termSource":"NCI"},{"termName":"Iphosphamid","termGroup":"SY","termSource":"NCI"},{"termName":"Iphosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Iso-Endoxan","termGroup":"SY","termSource":"NCI"},{"termName":"Isoendoxan","termGroup":"SY","termSource":"NCI"},{"termName":"Isophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Mitoxana","termGroup":"FB","termSource":"NCI"},{"termName":"MJF-9325","termGroup":"CN","termSource":"NCI"},{"termName":"N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"Naxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Seromida","termGroup":"FB","termSource":"NCI"},{"termName":"Tronoxal","termGroup":"FB","termSource":"NCI"},{"termName":"Z-4942","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; gastric carcinoma; lung cancer; lymphocytic leukemias; lymphoma; Hodgkins and Non-Hodgkins; ovarian cancer; pancreatic carcinoma; sarcomas; testicular cancer"},{"name":"CAS_Registry","value":"3778-73-2"},{"name":"CHEBI_ID","value":"CHEBI:5864"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O2P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"UM20QQM95Y"},{"name":"Legacy Concept Name","value":"Ifosfamide"},{"name":"Maps_To","value":"Ifosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"40024"},{"name":"NSC Number","value":"109724"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40024"},{"name":"PDQ_Open_Trial_Search_ID","value":"40024"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020823"}]}}{"C184764":{"preferredName":"IGF-1R Inhibition","code":"C184764","definitions":[{"definition":"Inhibition of insulin-like growth factor 1 receptor activity to prevent proliferation of cancer cells and tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-1R Inhibition","termGroup":"PT","termSource":"NCI"},{"termName":"CD221 Inhibition","termGroup":"SY","termSource":"NCI"},{"termName":"IGF1R Inhibition","termGroup":"SY","termSource":"NCI"},{"termName":"Insulin-Like Growth Factor 1 Receptor Inhibition","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IGF-1R Inhibitor"},{"name":"NCI_META_CUI","value":"CL1773085"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C104746":{"preferredName":"IGF-1R Inhibitor PL225B","code":"C104746","definitions":[{"definition":"An orally bioavailable inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor PL225B selectively binds to and inhibits the activities of IGF-1R, which may result in both the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis in IGF-1R-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a significant role in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-1R Inhibitor PL225B","termGroup":"PT","termSource":"NCI"},{"termName":"PL225B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IGF-1R Inhibitor PL225B"},{"name":"NCI_Drug_Dictionary_ID","value":"746194"},{"name":"NCI_META_CUI","value":"CL445817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746194"},{"name":"PDQ_Open_Trial_Search_ID","value":"746194"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84871":{"preferredName":"IGF-1R/IR Inhibitor KW-2450","code":"C84871","definitions":[{"definition":"An orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential antineoplastic activity. IGF-1R/IR inhibitor KW-2450 selectively binds to and inhibits the activities of IGF-1R and IR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-R1 and IR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-1R/IR Inhibitor KW-2450","termGroup":"PT","termSource":"NCI"},{"termName":"KW-2450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1360433-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2TRH1EX32K"},{"name":"Maps_To","value":"IGF-1R/IR Inhibitor KW-2450"},{"name":"NCI_Drug_Dictionary_ID","value":"648543"},{"name":"NCI_META_CUI","value":"CL412997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648543"},{"name":"PDQ_Open_Trial_Search_ID","value":"648543"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113789":{"preferredName":"IGF-methotrexate Conjugate","code":"C113789","definitions":[{"definition":"A conjugate containing the antimetabolite and antifolate agent methotrexate conjugated to insulin-like growth factor (IGF), with potential antineoplastic activity. After intravenous administration, the IGF moiety of the IGF-methotrexate conjugate binds to and is internalized by IGF receptors (IGFR) on the surface of tumor cells. Following cell entry, the methotrexate then binds to and inhibits the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. This results in both the inhibition of DNA and RNA synthesis and the induction of death in rapidly dividing cells. Binding to IGFR can localize the cytotoxic effect of methotrexate in tumor cells. This may increase its efficacy while decreasing its toxicity to normal, healthy cells. IGFR is overexpressed on many types of cancer cells and has been implicated in metastasis and resistance to apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IGF-methotrexate Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"765IGF-MTX","termGroup":"AB","termSource":"NCI"},{"termName":"IGF/MTX","termGroup":"CN","termSource":"NCI"},{"termName":"IGF/MTX Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IGF-methotrexate Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"757276"},{"name":"NCI_META_CUI","value":"CL471770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757276"},{"name":"PDQ_Open_Trial_Search_ID","value":"757276"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126840":{"preferredName":"IL-10 Immunomodulator MK-1966","code":"C126840","definitions":[{"definition":"An agent that downregulates the activity of the anti-inflammatory cytokine human interleukin-10 (IL-10), with potential immunomodulating and antineoplastic activities. Upon administration, IL-10 immunomodulator MK-1966 blocks the activity of IL-10 and may abrogate the IL-10-induced immunosuppressive tumor microenvironment. This activates cell-mediated immunity against cancer cells, increases cytokine production, including interferon-gamma (IFN-g), decreases T regulatory cell (Treg) activity, and induces a tumor-specific cytotoxic CD8+ T-cell-mediated immune response, which enhances tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-10 Immunomodulator MK-1966","termGroup":"PT","termSource":"NCI"},{"termName":"MK 1966","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1966","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-10 Immunomodulator MK-1966"},{"name":"NCI_Drug_Dictionary_ID","value":"780778"},{"name":"NCI_META_CUI","value":"CL507902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780778"},{"name":"PDQ_Open_Trial_Search_ID","value":"780778"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114294":{"preferredName":"IL-12-expressing HSV-1 NSC 733972","code":"C114294","definitions":[{"definition":"A genetically engineered, replication selective, infected cell protein (ICP) 34.5 gene-deleted, oncolytic human simplex virus type 1 (HSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12), with potential antineoplastic activity. Upon intratumoral administration of HSV-1 expressing IL-12 NSC 733972, the IL-12-expressing HSV-1 preferentially infects and replicates in tumor cells of neuronal origin causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. In addition, the IL-12-expressing HSV-1 promotes the secretion of IL-12 by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-12-expressing HSV-1 NSC 733972","termGroup":"PT","termSource":"NCI"},{"termName":"M032","termGroup":"CN","termSource":"NCI"},{"termName":"NSC 733972","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-12-expressing HSV-1 NSC 733972"},{"name":"NCI_Drug_Dictionary_ID","value":"758218"},{"name":"NCI_META_CUI","value":"CL471805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758218"},{"name":"PDQ_Open_Trial_Search_ID","value":"758218"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C114385":{"preferredName":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051","code":"C114385","definitions":[{"definition":"Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051","termGroup":"PT","termSource":"NCI"},{"termName":"GX-051","termGroup":"CN","termSource":"NCI"},{"termName":"MSCs/IL-12M","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051"},{"name":"NCI_Drug_Dictionary_ID","value":"758797"},{"name":"NCI_META_CUI","value":"CL471821"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758797"},{"name":"PDQ_Open_Trial_Search_ID","value":"758797"},{"name":"Semantic_Type","value":"Cell"}]}}{"C71743":{"preferredName":"IL-2 Recombinant Fusion Protein ALT-801","code":"C71743","definitions":[{"definition":"A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor suppressor p53-derived antigen with potential immunopotentiating and antineoplastic activities. The TCR moiety of IL-2 recombinant fusion protein ALT-801 binds to tumor cells displaying p53 epitope/MHC complexes; subsequently, the tumor cell-localized IL-2 moiety may stimulate natural killer (NK) cell and T cell cytotoxic immune responses against p53-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-2 Recombinant Fusion Protein ALT-801","termGroup":"PT","termSource":"NCI"},{"termName":"ALT-801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188450-53-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QWZ40O5W6K"},{"name":"Legacy Concept Name","value":"IL-2_Recombinant_Fusion_Protein_ALT-801"},{"name":"Maps_To","value":"IL-2 Recombinant Fusion Protein ALT-801"},{"name":"NCI_Drug_Dictionary_ID","value":"560749"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560749"},{"name":"PDQ_Open_Trial_Search_ID","value":"560749"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346454"}]}}{"C146636":{"preferredName":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1","code":"C146636","definitions":[{"definition":"A pegylated peptide antagonist that binds to the common gamma chain (gc; IL2RG; CD132) of the signaling receptor for the pro-inflammatory cytokines interleukin (IL)-2, IL-9, and IL-15, with potential immunomodulating and antineoplastic activities. Upon administration, IL-2/9/15 gc receptor inhibitor BNZ-1 specifically targets and binds to the IL binding site on the gc receptor and blocks IL-2, IL-9 and IL-15 binding, thereby inhibiting IL-2-, IL-9-, and IL-15-mediated signaling and downstream pathways. This may inhibit proliferation of tumor cells that are dependent on IL-2/9/15 signaling for their growth. IL-2/9/15 are upregulated in certain tumor cell types and play a key role in tumor progression and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1","termGroup":"PT","termSource":"NCI"},{"termName":"BNZ-1","termGroup":"CN","termSource":"NCI"},{"termName":"BNZ132-1-40","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1"},{"name":"NCI_Drug_Dictionary_ID","value":"792153"},{"name":"NCI_META_CUI","value":"CL544668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792153"},{"name":"PDQ_Open_Trial_Search_ID","value":"792153"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79843":{"preferredName":"Bizaxofusp","code":"C79843","definitions":[{"definition":"A fusion protein consisting of the cytokine interleukin-4 (IL-4) linked to a truncated form of Pseudomonas exotoxin with potential antineoplastic activity. Upon specific, high-affinity binding to IL-4 receptors located on the tumor cell surface., bizaxofusp is internalized; the exotoxin moiety then binds to translation elongation factor 2 (EF-2), which may result in ADP ribosylation, deactivation of EF-2, inhibition of protein synthesis, and tumor cell apoptosis. The Pseudomonas exotoxin moiety of this agent has been engineered to reduce non-specific binding to cells expressing its receptor, the multiligand cell surface receptor alpha 2-macroglobulin receptor/low-density lipoprotein receptor-related protein (alpha 2MR/LRP). IL-4R is a type I transmembrane protein that binds IL-4 and IL-13 and may be overexpressed by cancers such as renal cell carcinoma and glioma.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is made by combining interleukin-4 with a bacterial toxin. Interleukin-4 PE38KDEL immunotoxin is a type of recombinant chimeric protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Bizaxofusp","termGroup":"PT","termSource":"NCI"},{"termName":"IL-4 Fusion Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"IL-4 PE38KDEL Immunotoxin","termGroup":"SN","termSource":"NCI"},{"termName":"IL4-PE","termGroup":"AB","termSource":"NCI"},{"termName":"IL4-Pseudomonas Exotoxin Fusion Protein MDNA55","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4 Fusion Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4 PE38kdel Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-4 Pseudomonas Exotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"INxin","termGroup":"BR","termSource":"NCI"},{"termName":"MDNA55","termGroup":"CN","termSource":"NCI"},{"termName":"NBI-3001","termGroup":"CN","termSource":"NCI"},{"termName":"PRX-321","termGroup":"CN","termSource":"NCI"},{"termName":"PRX321","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1236019-35-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FRY3MOL2QU"},{"name":"Maps_To","value":"IL4-Pseudomonas Exotoxin Fusion Protein MDNA55"},{"name":"NCI_Drug_Dictionary_ID","value":"630680"},{"name":"NCI_META_CUI","value":"CL388450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"630680"},{"name":"PDQ_Open_Trial_Search_ID","value":"630680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99902":{"preferredName":"Ilixadencel","code":"C99902","definitions":[{"definition":"An off-the-shelf immune primer consisting of allogeneic monocyte-derived dendritic cells (MoDCs) that have been stimulated with a combination of activating factors to produce pro-inflammatory factors including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-12, p70 (IL-12 p70), C-C motif chemokine 4 (CCL4; macrophage inflammatory protein 1-beta; MIP-1-beta), C-C motif chemokine 5 (CCL5; RANTES), and C-X-C motif chemokine 10 (CXCL10), with potential immunostimulating and antineoplastic activities. Upon intratumoral injection of ilixadencel, the dendritic cells (DCs) release type 1 T-helper cell (Th1)-associated chemokines, including CCL4, CCL5 and CXCL10, that may recruit natural killer (NK)-cells and pre-DCs into the tumor microenvironment (TME). The interaction between NK cells and ilixadencel DCs may induce NK-cell-mediated killing of tumor cells, resulting in release of tumor-associated-antigens (TAAs). The production of interferon-gamma (IFN-gamma) by activated NK-cells and TNF-alpha/beta released by ilixadencel DCs will induce maturation and promote cross-presentation of TAAs by recruited endogenous \"bystander\" DCs. Migration of these antigen-loaded and matured \"bystander\" DCs to the tumor-draining lymph node will lead to a Th1-polarized activation of tumor-specific T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ilixadencel","termGroup":"PT","termSource":"NCI"},{"termName":"COMBIG-DC","termGroup":"SY","termSource":"NCI"},{"termName":"Intuvax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PY29292DVJ"},{"name":"Maps_To","value":"Ilixadencel"},{"name":"NCI_Drug_Dictionary_ID","value":"797415"},{"name":"NCI_META_CUI","value":"CL433603"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797415"},{"name":"PDQ_Open_Trial_Search_ID","value":"797415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48397":{"preferredName":"Iloprost","code":"C48397","definitions":[{"definition":"A prostacyclin analogue with potential chemopreventive activity. Iloprost binds to the prostacyclin receptor in various target cells, thereby causing vasodilation, inhibition of platelet aggregation, and decreased tumor cell adhesion to endothelium among other effects. Prostacyclin is a naturally occurring eicosanoid with anti-inflammatory, antineoplastic, and anti-metastatic properties. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of lung cancer. It belongs to the family of drugs called prostaglandin analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iloprost","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Ciloprost","termGroup":"SY","termSource":"NCI"},{"termName":"Iloprost Clathrate","termGroup":"SY","termSource":"NCI"},{"termName":"Pentanoic Acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ventavis","termGroup":"SY","termSource":"NCI"},{"termName":"ZK 36374","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"78919-13-8"},{"name":"CHEBI_ID","value":"CHEBI:63916"},{"name":"Chemical_Formula","value":"C22H32O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JED5K35YGL"},{"name":"Legacy Concept Name","value":"Iloprost"},{"name":"Maps_To","value":"Iloprost"},{"name":"NCI_Drug_Dictionary_ID","value":"365679"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365679"},{"name":"PDQ_Open_Trial_Search_ID","value":"365679"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079594"}]}}{"C116729":{"preferredName":"Ilorasertib","code":"C116729","definitions":[{"definition":"An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ilorasertib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(4-(4-Amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"A-968660.0","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-348","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227939-82-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6L5D03D975"},{"name":"Maps_To","value":"Ilorasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"672556"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672556"},{"name":"PDQ_Open_Trial_Search_ID","value":"672556"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660880"}]}}{"C104260":{"preferredName":"Imalumab","code":"C104260","definitions":[{"definition":"A human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, imalumab binds to MIF, blocking its activity and preventing the MIF-mediated secretion of certain cytokines, including interleukin-1 beta and tumor necrosis factor-alpha. This may lead to an inhibition of cancer cell proliferation in MIF-overexpressing tumor cells. MIF, a pro-inflammatory cytokine overexpressed in some cancers, plays a key role in inflammation, immune responses and cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imalumab","termGroup":"PT","termSource":"NCI"},{"termName":"BAX-69","termGroup":"CN","termSource":"NCI"},{"termName":"BAX069","termGroup":"CN","termSource":"NCI"},{"termName":"BAX69","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1-kappa, Anti-(Homo sapiens MIF (Macrophage Migration Inhibitory Factor, Glycosylation-inhibiting Factor, GlIF, GIF)), Homo sapiens Monoclonal Antibody","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1430205-07-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22F97PC79G"},{"name":"Maps_To","value":"Imalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"740468"},{"name":"NCI_META_CUI","value":"CL446652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740468"},{"name":"PDQ_Open_Trial_Search_ID","value":"740468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62035":{"preferredName":"Imatinib","code":"C62035","definitions":[{"definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152459-95-5"},{"name":"CHEBI_ID","value":"CHEBI:45783"},{"name":"Chemical_Formula","value":"C29H31N7O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"BKJ8M8G5HI"},{"name":"Legacy Concept Name","value":"Imatinib_Base"},{"name":"Maps_To","value":"Imatinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935989"}]}}{"C1687":{"preferredName":"Imatinib Mesylate","code":"C1687","definitions":[{"definition":"A drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Imatinib mesylate blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"CGP 57148","termGroup":"CN","termSource":"NCI"},{"termName":"CGP 57148B","termGroup":"CN","termSource":"NCI"},{"termName":"CGP-57148","termGroup":"CN","termSource":"NCI"},{"termName":"CGP-57148B","termGroup":"CN","termSource":"NCI"},{"termName":"CGP57148","termGroup":"CN","termSource":"NCI"},{"termName":"CGP57148B","termGroup":"CN","termSource":"NCI"},{"termName":"Gleevec","termGroup":"BR","termSource":"NCI"},{"termName":"Glivec","termGroup":"FB","termSource":"NCI"},{"termName":"STI-571","termGroup":"CN","termSource":"NCI"},{"termName":"STI571","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia, gastrointestinal stromal tumor, hypereosinophillic syndrome, dermatofibrosarcoma protuberans, mutated-PDGFR myelodysplastic/myeloproliferative diseases."},{"name":"CAS_Registry","value":"220127-57-1"},{"name":"CHEBI_ID","value":"CHEBI:31690"},{"name":"Chemical_Formula","value":"C29H31N7O.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8A1O1M485B"},{"name":"Legacy Concept Name","value":"Imatinib"},{"name":"Maps_To","value":"Imatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"37862"},{"name":"NSC Number","value":"716051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37862"},{"name":"PDQ_Open_Trial_Search_ID","value":"37862"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0939537"}]}}{"C49084":{"preferredName":"Imetelstat","code":"C49084","definitions":[{"definition":"A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imetelstat","termGroup":"PT","termSource":"NCI"},{"termName":"DNA, d(3'-amino-3'-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3- [(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate]","termGroup":"SN","termSource":"NCI"},{"termName":"GRN 163L","termGroup":"CN","termSource":"NCI"},{"termName":"GRN 163L","termGroup":"SY","termSource":"NCI"},{"termName":"GRN-163L","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"868169-64-6"},{"name":"Chemical_Formula","value":"C148H211N68O53P13S13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F60NE4XB53"},{"name":"Legacy Concept Name","value":"GRN163L"},{"name":"Maps_To","value":"Imetelstat"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2746063"}]}}{"C84511":{"preferredName":"Imetelstat Sodium","code":"C84511","definitions":[{"definition":"The sodium salt of imetelstat, a synthetic lipid-conjugated, 13-mer oligonucleotide N3' P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase RNA (hTR), imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a \"telomerase template antagonist\"), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imetelstat Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"DNA, d(3'-amino-3'-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3- [(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate], Sodium Salt (1:13)","termGroup":"SN","termSource":"NCI"},{"termName":"GRN163L, Sodium Salt","termGroup":"CN","termSource":"NCI"},{"termName":"Rytelo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia"},{"name":"CAS_Registry","value":"1007380-31-5"},{"name":"Chemical_Formula","value":"C148H198N68O53P13S13.13Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2AW48LAZ4I"},{"name":"Maps_To","value":"Imetelstat Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"447136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"447136"},{"name":"PDQ_Open_Trial_Search_ID","value":"447136"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708156"}]}}{"C29115":{"preferredName":"Imexon","code":"C29115","definitions":[{"definition":"A 2-cyanoaziridine derivative with antitumor activity in multiple myeloma.  Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8.  Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It belongs to the family of drugs called cyanoaziridine derivatives.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Imexon","termGroup":"PT","termSource":"NCI"},{"termName":"4-imino-1,3-diazabicyclo[3,1,0]-hexan-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"Amplimexon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59643-91-3"},{"name":"Chemical_Formula","value":"C4H5N3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8F63U28T2V"},{"name":"Legacy Concept Name","value":"Imexon"},{"name":"Maps_To","value":"Imexon"},{"name":"NCI_Drug_Dictionary_ID","value":"468469"},{"name":"NSC Number","value":"714597"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468469"},{"name":"PDQ_Open_Trial_Search_ID","value":"468469"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0097147"}]}}{"C2216":{"preferredName":"Imidazole Mustard","code":"C2216","definitions":[{"definition":"A synthetic derivative of imidazole with potent antineoplastic properties.  Imidazole mustard alkylates DNA, preferentially at guanine residues, resulting in DNA interstrand crosslinks and inhibition of DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imidazole Mustard","termGroup":"PT","termSource":"NCI"},{"termName":"5-[3,3-Bis(2-Chloroethyl)-1-Triazeno]Imidazole-4-Carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BIC","termGroup":"AB","termSource":"NCI"},{"termName":"TIC Mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5034-77-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OY338X4M2P"},{"name":"Legacy Concept Name","value":"Imidazole_Mustard"},{"name":"Maps_To","value":"Imidazole Mustard"},{"name":"NCI_Drug_Dictionary_ID","value":"39483"},{"name":"NSC Number","value":"82196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39483"},{"name":"PDQ_Open_Trial_Search_ID","value":"39483"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063382"}]}}{"C29344":{"preferredName":"Imidazole-Pyrazole","code":"C29344","definitions":[{"definition":"A synthetic agent, also known as IMPY, with antineoplastic properties.  IMPY inhibits ribonucleotide reductase, an enzyme that converts ribonucleotides to deoxyribonucleotides during DNA synthesis; this agent specifically binds the smaller, nonheme-iron subunit of the enzyme. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imidazole-Pyrazole","termGroup":"PT","termSource":"NCI"},{"termName":"2,3-Dihydro-1H-imidazo(1,2-b)pyrazole","termGroup":"SN","termSource":"NCI"},{"termName":"BRN 0742753","termGroup":"CN","termSource":"NCI"},{"termName":"Imidazolepyrazole","termGroup":"SY","termSource":"NCI"},{"termName":"IMPY","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6714-29-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Inhibits the nonheme-iron subunit of ribonucleotide reductase"},{"name":"FDA_UNII_Code","value":"MX6Z942BKY"},{"name":"Legacy Concept Name","value":"Pyrazole_Imidazole"},{"name":"Maps_To","value":"Imidazole-Pyrazole"},{"name":"NSC Number","value":"51143"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045368"}]}}{"C126638":{"preferredName":"Imipramine Blue","code":"C126638","definitions":[{"definition":"A triphenylmethane-based dye and an inhibitor of nicotinamide adenine dinucleotide phosphate (NADP+) oxidase 4 (NOX4), with potential anti-invasive and anti-oxidative activities. Upon administration, imipramine blue (IB) inhibits the activity of NOX4 and prevents NOX4-mediated cell signaling. This prevents the formation of NOX4-mediated reactive oxygen species (ROS), abrogates the ROS-induced inhibition of protein tyrosine phosphatase (PTP) activation, and induces both G2/M cell cycle arrest and apoptosis. NOX4, an enzyme belonging to the NOX family of proteins, promotes the production of ROS and plays a key role in the suppression of PTP activation; it is upregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imipramine Blue","termGroup":"PT","termSource":"NCI"},{"termName":"IB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Imipramine Blue"},{"name":"NCI_META_CUI","value":"CL505071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1431":{"preferredName":"Imiquimod","code":"C1431","definitions":[{"definition":"A drug used to treat early basal cell skin cancer and certain other skin conditions. It is being studied in the treatment of other types of cancer. Imiquimod is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imiquimod","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline","termGroup":"SN","termSource":"NCI"},{"termName":"Aldara","termGroup":"BR","termSource":"NCI"},{"termName":"R 837","termGroup":"CN","termSource":"NCI"},{"termName":"S 26308","termGroup":"CN","termSource":"NCI"},{"termName":"Zyclara","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Condyloma; Superficial Basal Cell Carcinoma; Actinic Keratosis"},{"name":"CAS_Registry","value":"99011-02-6"},{"name":"CHEBI_ID","value":"CHEBI:36704"},{"name":"Chemical_Formula","value":"C14H16N4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P1QW714R7M"},{"name":"Legacy Concept Name","value":"Imiquimod"},{"name":"Maps_To","value":"Imiquimod"},{"name":"NCI_Drug_Dictionary_ID","value":"38558"},{"name":"NSC Number","value":"369100"},{"name":"NSC Number","value":"741062"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38558"},{"name":"PDQ_Open_Trial_Search_ID","value":"38558"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0718327"}]}}{"C113795":{"preferredName":"Immediate-release Onapristone","code":"C113795","definitions":[{"definition":"An immediate-release (IR) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immediate-release Onapristone","termGroup":"PT","termSource":"NCI"},{"termName":"IR Onapristone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immediate-release Onapristone"},{"name":"NCI_Drug_Dictionary_ID","value":"757590"},{"name":"NCI_META_CUI","value":"CL471777"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757590"},{"name":"PDQ_Open_Trial_Search_ID","value":"757590"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113658":{"preferredName":"Immediate-release Tablet Afuresertib","code":"C113658","definitions":[{"definition":"An immediate-release (IR) tablet formulation containing afuresertib, an inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Upon oral administration of the IR formulation, afuresertib binds to and inhibits the activity of Akt, which may result in the inhibition of PI3K/Akt signaling pathway, decreased tumor cell proliferation and the induction of tumor cell apoptosis in Akt-expressing tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immediate-release Tablet Afuresertib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2110183 IR Tablet","termGroup":"SY","termSource":"NCI"},{"termName":"IR Afuresertib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immediate-release Tablet Afuresertib"},{"name":"NCI_Drug_Dictionary_ID","value":"757069"},{"name":"NCI_META_CUI","value":"CL458371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757069"},{"name":"PDQ_Open_Trial_Search_ID","value":"757069"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141421":{"preferredName":"Anti-TIGIT Monoclonal Antibody ASP8374","code":"C141421","definitions":[{"definition":"A fully human, immunoglobulin G4 (IgG4) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody ASP8374 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIGIT Monoclonal Antibody ASP8374","termGroup":"PT","termSource":"NCI"},{"termName":"ASP 8374","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-8374","termGroup":"CN","termSource":"NCI"},{"termName":"ASP8374","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TB50XV90MW"},{"name":"Maps_To","value":"Immune Checkpoint Inhibitor ASP8374"},{"name":"NCI_Drug_Dictionary_ID","value":"791403"},{"name":"NCI_META_CUI","value":"CL539507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791403"},{"name":"PDQ_Open_Trial_Search_ID","value":"791403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104058":{"preferredName":"Lumretuzumab","code":"C104058","definitions":[{"definition":"An immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3), with potential antineoplastic activity. Upon administration,  lumretuzumab binds to the extracellular domain of HER3 and inhibits HER3 dimerization; thereby, preventing EGFR-dependent signaling. In addition, RO5479599 stimulates the immune system to exert antibody-dependent cellular cytotoxicity (ADCC). This may decrease proliferation of HER3-overexpressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lumretuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"RO5479599","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448327-63-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y6M3205516"},{"name":"Maps_To","value":"Immunoconjugate RO5479599"},{"name":"Maps_To","value":"Lumretuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"744816"},{"name":"NCI_META_CUI","value":"CL433954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744816"},{"name":"PDQ_Open_Trial_Search_ID","value":"744816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97961":{"preferredName":"Immunocytokine NHS-IL12","code":"C97961","definitions":[{"definition":"A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunocytokine NHS-IL12","termGroup":"PT","termSource":"NCI"},{"termName":"M-9241","termGroup":"CN","termSource":"NCI"},{"termName":"M9241","termGroup":"CN","termSource":"NCI"},{"termName":"NHS-IL-12","termGroup":"CN","termSource":"NCI"},{"termName":"NHS-IL12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1807503-77-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KF6D9Z1MER"},{"name":"Maps_To","value":"Immunocytokine NHS-IL12"},{"name":"NCI_Drug_Dictionary_ID","value":"710539"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710539"},{"name":"PDQ_Open_Trial_Search_ID","value":"710539"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273725"}]}}{"C82411":{"preferredName":"Immunocytokine NHS-IL2-LT","code":"C82411","definitions":[{"definition":"A fusion protein consisting of a mouse-human chimeric antibody directed against DNA released by necrotic tumor cells fused to two molecules of a genetically modified human interleukin-2 (IL-2) with potential antineoplastic activity. Upon administration, the antibody moiety of immunocytokine NHS-IL2-LT binds to DNA released by necrotic tumor cells located primarily at the core of necrotic solid tumors, delivering the IL-2 moiety. In turn, the IL-2 moiety of this agent activates the immune system to mount a cytotoxic T lymphocyte response against nearby tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunocytokine NHS-IL2-LT","termGroup":"PT","termSource":"NCI"},{"termName":"Ch.14.18-IL2","termGroup":"AB","termSource":"NCI"},{"termName":"EMD 521873","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-2 Fusion Protein MSB0010445","termGroup":"SY","termSource":"NCI"},{"termName":"MSB0010445","termGroup":"CN","termSource":"NCI"},{"termName":"NHS-IL2","termGroup":"CN","termSource":"NCI"},{"termName":"Selectikine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1223034-72-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EI74F49ZLJ"},{"name":"Legacy Concept Name","value":"Selectikine"},{"name":"Maps_To","value":"Immunocytokine NHS-IL2-LT"},{"name":"NCI_Drug_Dictionary_ID","value":"641919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641919"},{"name":"PDQ_Open_Trial_Search_ID","value":"641919"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830085"}]}}{"C152979":{"preferredName":"Hsp90 Inhibitor LAM-003","code":"C152979","definitions":[{"definition":"An L-alanine ester prodrug of LAM-003A, an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, LAM-003 is converted to LAM-003A. LAM-003A selectively targets and binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may inhibit the growth and survival of a wide variety of cancer cell types. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability, and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor LAM-003","termGroup":"PT","termSource":"NCI"},{"termName":"LAM 003","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-003","termGroup":"CN","termSource":"NCI"},{"termName":"LAM-003A Prodrug LAM-003","termGroup":"SY","termSource":"NCI"},{"termName":"LAM003","termGroup":"CN","termSource":"NCI"},{"termName":"Prodrug LAM-003","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunomodulator LAM-003"},{"name":"NCI_Drug_Dictionary_ID","value":"793859"},{"name":"NCI_META_CUI","value":"CL554182"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793859"},{"name":"PDQ_Open_Trial_Search_ID","value":"793859"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49092":{"preferredName":"Immunomodulator OHR/AVR118","code":"C49092","definitions":[{"definition":"A broad-spectrum peptide nucleic acid formulation comprised of breakdown products of casein, peptone, RNA and serum albumin, with potential anti-inflammatory, immunomodulatory, anti-anorectic and anti-cachexia activities. AVR118 mainly contains two peptides, peptide A and peptide B, in approximately a 1:1 ratio: peptide A (31 a. a.) is derived from bovine casein; peptide B (21 a. a.) is covalently linked via phosphodiester bond to a diadenosine unit. In addition, AVR118 contains nucleosides, nucleoside diphosphates and nucleoside monophosphates. Upon subcutaneous injection of AVR118, this agent affects the synthesis of many pro-inflammatory chemokines and cytokines, especially monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-8, IL-1 beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha). In particular, AVR118 stimulates macrophages to produce these mediators while in highly activated macrophages this agent inhibits their synthesis. This way, AVR118 may prevent the excessive release of cytokines seen during chemotherapy. Controlling the release of pro-inflammatory mediators may ultimately improve appetite and mood, increase strength and weight gain, and decrease fatigue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunomodulator OHR/AVR118","termGroup":"PT","termSource":"NCI"},{"termName":"AVR118","termGroup":"CN","termSource":"NCI"},{"termName":"Product R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AVR118"},{"name":"Maps_To","value":"Immunomodulator OHR/AVR118"},{"name":"NCI_Drug_Dictionary_ID","value":"453546"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453546"},{"name":"PDQ_Open_Trial_Search_ID","value":"453546"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1172837"}]}}{"C101370":{"preferredName":"Immunomodulatory Agent CC-11006","code":"C101370","definitions":[{"definition":"A proprietary, orally available, small molecule and thalidomide analog, with potential immunomodulating and antineoplastic activity. CC-11006 appears to have a similar mechanism to thalidomide and may modulate the expression of proinflammatory and regulatory cytokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunomodulatory Agent CC-11006","termGroup":"PT","termSource":"NCI"},{"termName":"CC-11006","termGroup":"CN","termSource":"NCI"},{"termName":"CC-11006-MDS-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444287-44-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6DC9826KIM"},{"name":"Maps_To","value":"Immunomodulatory Agent CC-11006"},{"name":"NCI_Drug_Dictionary_ID","value":"730575"},{"name":"NCI_META_CUI","value":"CL435550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730575"},{"name":"PDQ_Open_Trial_Search_ID","value":"730575"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49182":{"preferredName":"Immunomodulatory Oligonucleotide HYB2055","code":"C49182","definitions":[{"definition":"A second generation synthetic oligonucleotide with immunomodulatory and potential antineoplastic activities. HYB2055 consists of unmethylated CpG dinucleotide motifs that are present abundantly in bacterial and parasitic DNA, and a novel DNA structure, called an immunomer that contributes to metabolic stability of the agent. Upon infections, CpG-containing DNA released from pathogenic organisms triggers host immune responses, which are mediated by the action of intracellular toll-like receptor 9 (TLR9), a pattern recognition receptor. This agent mimics bacterial DNA and selectively activates TLR9, thereby initiating immune signaling pathways, and leading to activation of B-cells and dendritic cells and induction of Th1-type cytokine production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunomodulatory Oligonucleotide HYB2055","termGroup":"PT","termSource":"NCI"},{"termName":"Amplivax","termGroup":"BR","termSource":"NCI"},{"termName":"IMO-2055","termGroup":"SY","termSource":"NCI"},{"termName":"Imoxine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HYB2055"},{"name":"Maps_To","value":"Immunomodulatory Oligonucleotide HYB2055"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708303"}]}}{"C122922":{"preferredName":"Immunotherapeutic Combination Product CMB305","code":"C122922","definitions":[{"definition":"An immunotherapeutic combination product composed of LV305, an engineered lentiviral vector that both targets dendritic cells (DCs) and contains nucleic acids encoding the human tumor-associated cancer-testis antigen NY-ESO-1 (CTAG1), and G305, a cancer vaccine comprised of an NY-ESO-1 recombinant protein and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential synergistic immunostimulatory and antineoplastic activities. Upon intradermal administration of LV305, the DC-targeting lentiviral vector targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, which stimulates DC maturation, and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells; this may result in tumor cell lysis. Upon the sequential intramuscular injection of G305, the adjuvant portion of G305 binds to toll-like receptor 4 (TLR-4) expressed on various immune cells, including DCs, monocytes, macrophages and B-cells. The activated DCs present the NY-ESO-1 antigen to CD4-positive Th1 T-lymphocytes. The induction of antigen-specific CD4-positive T-lymphocytes further induces a CTL response against NY-ESO-1-expressing tumor cells. In addition, G305 induces an NY-ESO-1-specific antibody response. NY-ESO-1, expressed in normal testes and on the surfaces of various tumor cells, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunotherapeutic Combination Product CMB305","termGroup":"PT","termSource":"NCI"},{"termName":"CMB 305","termGroup":"CN","termSource":"NCI"},{"termName":"CMB305","termGroup":"CN","termSource":"NCI"},{"termName":"ID-CMB305","termGroup":"CN","termSource":"NCI"},{"termName":"ID-LV305 Plus ID G305","termGroup":"SY","termSource":"NCI"},{"termName":"LV 305 Plus G 305","termGroup":"SY","termSource":"NCI"},{"termName":"LV305 Plus G305","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Immunotherapeutic Combination Product CMB305"},{"name":"NCI_Drug_Dictionary_ID","value":"777295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777295"},{"name":"PDQ_Open_Trial_Search_ID","value":"777295"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053576"}]}}{"C77971":{"preferredName":"Immunotherapy Regimen MKC-1106-MT","code":"C77971","definitions":[{"definition":"A regimen containing three components: a plasmid encoding portions of the two melanoma-associated antigens Melan A (also called MART-1) and tyrosinase and two synthetic analogs of Melan-A and tyrosinase antigen epitopes with potential immunostimulating and antitumor activities. First, the plasmid is injected directly into lymph nodes in order to sensitize or prime antigen-presenting cells (APCs) and central memory T cells in lymph nodes to plasmid-expressed Melan A and tyrosinase.  After several priming injections with plasmids, the Melan A and tyrosinase synthetic epitope analogs are injected directly into lymph nodes; upon binding to major histocompatibility complex (MHC) molecules on APC cell surfaces, these synthetic epitope analogs may stimulate a \"primed\" cytotoxic T lymphocyte (CTL) response against melanoma tumor cells, resulting in tumor cell lysis. Melan-A and tyrosinase are overexpressed by melanoma tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunotherapy Regimen MKC-1106-MT","termGroup":"PT","termSource":"NCI"},{"termName":"MKC-1106-MT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MKC-1106-MT"},{"name":"Maps_To","value":"Immunotherapy Regimen MKC-1106-MT"},{"name":"NCI_Drug_Dictionary_ID","value":"598417"},{"name":"NCI_META_CUI","value":"CL386958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598417"},{"name":"PDQ_Open_Trial_Search_ID","value":"598417"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62480":{"preferredName":"Immunotoxin CMD-193","code":"C62480","definitions":[{"definition":"A humanized immunotoxin directed against the Lewis Y antigen conjugated with calicheamicin, a hydrophobic enediyne antibiotic, with potential antineoplastic activity. CMD193 binds to the Lewis Y antigen, a tetrasaccharide expressed on the cell surfaces of many tumor cell types. Upon binding, CMD-193 is internalized, thereby delivering the attached calicheamicin to Lewis Y antigen-expressing tumor cells. Calicheamicin binds non-covalently to the minor groove of DNA and prompts conformational changes and DNA oxidation, thereby inhibiting DNA synthesis and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunotoxin CMD-193","termGroup":"PT","termSource":"NCI"},{"termName":"CMD 193","termGroup":"CN","termSource":"NCI"},{"termName":"CMD-193","termGroup":"CN","termSource":"NCI"},{"termName":"CMD193","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1080645-97-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CMD-193"},{"name":"Maps_To","value":"Immunotoxin CMD-193"},{"name":"NCI_Drug_Dictionary_ID","value":"489295"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489295"},{"name":"PDQ_Open_Trial_Search_ID","value":"489295"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879965"}]}}{"C77863":{"preferredName":"IMT-1012 Immunotherapeutic Vaccine","code":"C77863","definitions":[{"definition":"A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IMT-1012 Immunotherapeutic Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"IMT-1012","termGroup":"CN","termSource":"NCI"},{"termName":"OCPM Immunotherapeutic Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"IMT-1012_Immunotherapeutic_Vaccine"},{"name":"Maps_To","value":"IMT-1012 Immunotherapeutic Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"596541"},{"name":"NCI_META_CUI","value":"CL383604"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596541"},{"name":"PDQ_Open_Trial_Search_ID","value":"596541"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C29317":{"preferredName":"Inalimarev","code":"C29317","definitions":[{"definition":"A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A cancer vaccine made with a form of vaccinia virus that does not cause disease in humans. It is being studied in the treatment of some types of cancer. The virus is changed in the laboratory to make human proteins, including the tumor markers called CEA and MUC-1, that may help immune cells in the body kill tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Inalimarev","termGroup":"PT","termSource":"NCI"},{"termName":"PANVAC-V","termGroup":"BR","termSource":"NCI"},{"termName":"rVaccinia-CEA(D609)/MUC1(L93)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Vaccinia-CEA-MUC1-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"685563-13-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"rVaccinia-CEA_D609_MUC1_L93_TRICOM"},{"name":"Maps_To","value":"Inalimarev"},{"name":"NCI_Drug_Dictionary_ID","value":"385666"},{"name":"NSC Number","value":"727026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"385666"},{"name":"PDQ_Open_Trial_Search_ID","value":"385666"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1541349"}]}}{"C2454":{"preferredName":"Incyclinide","code":"C2454","definitions":[{"definition":"A chemically-modified tetracycline with potential antineoplastic activity. Incyclinide inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent also causes mitochondrial depolarization in tumor cells and induces both cellular apoptosis and tissue necrosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. COL-3 may block the growth of new blood vessels that tumors need to grow. It is a type of matrix metalloproteinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Incyclinide","termGroup":"PT","termSource":"NCI"},{"termName":"4-dedimethylamino sancycline","termGroup":"SN","termSource":"NCI"},{"termName":"4-Dimethlyamino Sancycline","termGroup":"SN","termSource":"NCI"},{"termName":"4-Dimethlyaminosancycline","termGroup":"SN","termSource":"NCI"},{"termName":"6-deoxy, 6-demethyl, 4-de-dimethylamino tetracycline","termGroup":"SN","termSource":"NCI"},{"termName":"6-deoxy-6-demethyl-4-dedimethylaminotetracycline","termGroup":"SN","termSource":"NCI"},{"termName":"CMT-3","termGroup":"CN","termSource":"NCI"},{"termName":"COL 3","termGroup":"CN","termSource":"NCI"},{"termName":"COL-3","termGroup":"CN","termSource":"NCI"},{"termName":"Metastat","termGroup":"BR","termSource":"NCI"},{"termName":"Tetracycline CMT-3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15866-90-7"},{"name":"Chemical_Formula","value":"C19H17NO7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"21G64WZQ4I"},{"name":"Legacy Concept Name","value":"COL-3"},{"name":"Maps_To","value":"Incyclinide"},{"name":"NCI_Drug_Dictionary_ID","value":"42884"},{"name":"NSC Number","value":"683551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42884"},{"name":"PDQ_Open_Trial_Search_ID","value":"42884"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0763138"}]}}{"C2049":{"preferredName":"Indibulin","code":"C2049","definitions":[{"definition":"A synthetic small molecule with antimitotic and potential antineoplastic activities. Indibulin binds to a site on tubulin that is different from taxane- or Vinca alkaloid-binding sites, destabilizing tubulin polymerization and inducing tumor cell cycle arrest and apoptosis. This agent has been shown to be active against multidrug-resistant (MDR) and taxane- resistant tumor cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indibulin","termGroup":"PT","termSource":"NCI"},{"termName":"D 24851","termGroup":"CN","termSource":"NCI"},{"termName":"D-24851","termGroup":"CN","termSource":"NCI"},{"termName":"N-(Pyridin-4-yl)-(1-(4-chlorobenzyl)indol-3-yl)glycoxylamide","termGroup":"SN","termSource":"NCI"},{"termName":"ZIO-301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"204205-90-3"},{"name":"Chemical_Formula","value":"C22H16ClN3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"80K4H2RB8P"},{"name":"Legacy Concept Name","value":"D_24851"},{"name":"Maps_To","value":"Indibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"587341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587341"},{"name":"PDQ_Open_Trial_Search_ID","value":"587341"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1956330"}]}}{"C1134":{"preferredName":"Indicine-N-Oxide","code":"C1134","definitions":[{"definition":"A natural pyrrolizidine alkaloid with antineoplastic properties.  Indicine-N-oxide alkylates and crosslinks DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indicine-N-Oxide","termGroup":"PT","termSource":"NCI"},{"termName":"2,3-Dihydroxy-2-(1-methylethyl)butanoic Acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl Ester N-Oxide","termGroup":"SN","termSource":"NCI"},{"termName":"Butanoic Acid, 2,3-Dihydroxy-2-(1-methylethyl)- (2,3,5, 7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) Methyl Ester, N-Oxide,(1R-(1alpha,7(2R*,3S*),7a-beta))-(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Indicine N-Oxide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41708-76-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"69L6IW0Y7P"},{"name":"Legacy Concept Name","value":"Indicine-N-Oxide"},{"name":"Maps_To","value":"Indicine-N-Oxide"},{"name":"NCI_Drug_Dictionary_ID","value":"39482"},{"name":"NSC Number","value":"132319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39482"},{"name":"PDQ_Open_Trial_Search_ID","value":"39482"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063465"}]}}{"C25797":{"preferredName":"Indisulam","code":"C25797","definitions":[{"definition":"A drug that belongs to the family of drugs called sulfonamides.  It is being studied for its ability to treat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A novel sulfonamide compound with potential antineoplastic activity. Indisulam inhibits cyclin-dependent kinases (CDK), which regulate cell cycle progression and are usually over-expressed in cancerous cells. Inhibition of CDK results in G1/S phase arrest of the cell cycle, and may lead to induction of apoptosis and inhibition of tumor cell proliferation. In addition, indisulam also inhibits carbonic anhydrases (CA), especially isoforms IX and XII that are involved in aqueous humor production and are highly overexpressed in some types of cancers. Inhibition of CA IX and XII results in interference with ion exchange and pH in hypoxic tumor tissue and preventing chemoresistance to weakly basic antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indisulam","termGroup":"PT","termSource":"NCI"},{"termName":"E7070","termGroup":"CN","termSource":"NCI"},{"termName":"N-(3-Chloro-7-indoyl)-1,4-Benzenedisulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"165668-41-7"},{"name":"Chemical_Formula","value":"C14H12ClN3O4S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WJ98J3NM90"},{"name":"Legacy Concept Name","value":"E7070"},{"name":"Maps_To","value":"Indisulam"},{"name":"NCI_Drug_Dictionary_ID","value":"43559"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43559"},{"name":"PDQ_Open_Trial_Search_ID","value":"43559"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099211"}]}}{"C158750":{"preferredName":"Pegsitacianine","code":"C158750","definitions":[{"definition":"A micellar polymer tracer labeled with the near-infrared (NIR) fluorescent imaging dye indocyanine green (ICG), with potential fluorescent imaging activity. Upon administration, pegsitacianine accumulates in tumor tissue. The micelles dissociate and subsequently fluoresce upon exposure to the acidic conditions of the tumor microenvironment (TME), allowing the visualization of tumors using infrared-based cameras.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegsitacianine","termGroup":"PT","termSource":"NCI"},{"termName":"Indocyanine Green-labeled Polymeric Micelles ONM-100","termGroup":"SY","termSource":"NCI"},{"termName":"ONM 100","termGroup":"CN","termSource":"NCI"},{"termName":"ONM-100","termGroup":"CN","termSource":"NCI"},{"termName":"ONM100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2396651-85-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49X2Q41T99"},{"name":"Maps_To","value":"Indocyanine Green-labeled Polymeric Micelles ONM-100"},{"name":"NCI_Drug_Dictionary_ID","value":"797414"},{"name":"NCI_META_CUI","value":"CL950716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797414"},{"name":"PDQ_Open_Trial_Search_ID","value":"797414"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"}]}}{"C1135":{"preferredName":"Indole-3-Carbinol","code":"C1135","definitions":[{"definition":"A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a cancer prevention drug.  It is found in cruciferous vegetables.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indole with a carbinol group (-C2OH) attached at the 3 position of the pyrrole ring. The chemical structure is C1=CC=C2C(=C1)C(=CN2)CO.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Indole-3-Carbinol","termGroup":"PT","termSource":"NCI"},{"termName":"1H-indole-3-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"I3C","termGroup":"AB","termSource":"NCI"},{"termName":"Indole-3-carbinol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"700-06-1"},{"name":"CHEBI_ID","value":"CHEBI:24814"},{"name":"Chemical_Formula","value":"C9H9NO"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C11E72455F"},{"name":"Legacy Concept Name","value":"Indole-3-Carbinol"},{"name":"Maps_To","value":"Indole-3-Carbinol"},{"name":"NCI_Drug_Dictionary_ID","value":"38058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38058"},{"name":"PDQ_Open_Trial_Search_ID","value":"38058"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063491"}]}}{"C576":{"preferredName":"Indomethacin","code":"C576","definitions":[{"definition":"A drug that reduces pain, fever, swelling, and redness. It is also being used to reduce tumor-induced suppression of the immune system and to increase the effectiveness of anticancer drugs. It is a type of nonsteroidal anti-inflammatory drug (NSAID).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indomethacin","termGroup":"PT","termSource":"NCI"},{"termName":"1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1-H-indole-3-acetic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Indocin","termGroup":"BR","termSource":"NCI"},{"termName":"Indometacin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dysmennorhea; Inflammatory disorders; Pain"},{"name":"CAS_Registry","value":"53-86-1"},{"name":"CHEBI_ID","value":"CHEBI:49662"},{"name":"Chemical_Formula","value":"C19H16ClNO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"XXE1CET956"},{"name":"Legacy Concept Name","value":"Indomethacin"},{"name":"Maps_To","value":"Indomethacin"},{"name":"NCI_Drug_Dictionary_ID","value":"39489"},{"name":"NSC Number","value":"77541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39489"},{"name":"PDQ_Open_Trial_Search_ID","value":"39489"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021246"}]}}{"C71535":{"preferredName":"Indoximod","code":"C71535","definitions":[{"definition":"A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of melanoma and many other types of cancer. 1-methyl-d-tryptophan blocks the breakdown of the amino acid tryptophan, which is needed for T cells (a type of immune system cell) to kill tumor cells. Giving 1-methyl-d-tryptophan to patients who have received chemotherapy for cancer may help kill more tumor cells. It is a type of enzyme inhibitor and immunosuppressant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Indoximod","termGroup":"PT","termSource":"NCI"},{"termName":"1-Methyl-D-tryptophan","termGroup":"SY","termSource":"NCI"},{"termName":"1-MT","termGroup":"AB","termSource":"NCI"},{"termName":"D-(+)-1-Methyltryptophan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110117-83-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TX5CYN1KMZ"},{"name":"Legacy Concept Name","value":"_1-Methyl-d-Tryptophan"},{"name":"Maps_To","value":"Indoximod"},{"name":"NCI_Drug_Dictionary_ID","value":"579646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579646"},{"name":"PDQ_Open_Trial_Search_ID","value":"579646"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045546"}]}}{"C150393":{"preferredName":"Indoximod Prodrug NLG802","code":"C150393","definitions":[{"definition":"An orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against IDO1-expressing tumor cells, thereby inhibiting their growth. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system. NLG802 elicits increased plasma concentrations of indoximod and improves its efficacy, compared to the direct administration of indoximod.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Indoximod Prodrug NLG802","termGroup":"PT","termSource":"NCI"},{"termName":"IDO1 Inhibitor NLG802","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase (IDO) Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"NLG 802","termGroup":"CN","termSource":"NCI"},{"termName":"NLG-1564","termGroup":"CN","termSource":"NCI"},{"termName":"NLG-802","termGroup":"CN","termSource":"NCI"},{"termName":"NLG802","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2071683-98-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NVJ85QZ036"},{"name":"Maps_To","value":"Indoximod Prodrug NLG802"},{"name":"NCI_Drug_Dictionary_ID","value":"792849"},{"name":"NCI_META_CUI","value":"CL552162"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792849"},{"name":"PDQ_Open_Trial_Search_ID","value":"792849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83818":{"preferredName":"Inecalcitol","code":"C83818","definitions":[{"definition":"An analog of calcitriol and a vitamin D3 receptor (VDR) agonist, with potential antineoplastic activity. Upon administration, inecalcitol targets and binds to VDR. This activates VDR and VDR-mediated signal transduction pathways. This modulates the VDR-mediated expression of certain genes, including the expression of anti-cancer genes, enhances cellular differentiation, induces tumor cell apoptosis and inhibits tumor cell growth. VDR plays a central role in calcium homeostasis and in the growth of certain cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inecalcitol","termGroup":"PT","termSource":"NCI"},{"termName":"(7E)-19-Nor-9,10-seco-14beta-cholesta-5,7-dien-23-yne-1alpha,3beta,25-triol","termGroup":"SN","termSource":"NCI"},{"termName":"ICC","termGroup":"AB","termSource":"NCI"},{"termName":"TX 522","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"163217-09-2"},{"name":"Chemical_Formula","value":"C26H40O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05FZV98342"},{"name":"Maps_To","value":"Inecalcitol"},{"name":"NCI_Drug_Dictionary_ID","value":"782341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782341"},{"name":"PDQ_Open_Trial_Search_ID","value":"782341"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827203"}]}}{"C88302":{"preferredName":"Infigratinib","code":"C88302","definitions":[{"definition":"An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infigratinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea","termGroup":"SY","termSource":"NCI"},{"termName":"BGJ 398","termGroup":"CN","termSource":"NCI"},{"termName":"BGJ-398","termGroup":"CN","termSource":"NCI"},{"termName":"BGJ398","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"872511-34-7"},{"name":"CHEBI_ID","value":"CHEBI:63451"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A4055ME1VK"},{"name":"Maps_To","value":"Infigratinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981819"}]}}{"C162568":{"preferredName":"Infigratinib Mesylate","code":"C162568","definitions":[{"definition":"The mesylate salt of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infigratinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"BGJ 398 Mesylate","termGroup":"CN","termSource":"NCI"},{"termName":"BGJ-398 Mesylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1310746-12-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E223Z0KWCC"},{"name":"Maps_To","value":"Infigratinib Mesylate"},{"name":"NCI_META_CUI","value":"CL971083"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1789":{"preferredName":"Infliximab","code":"C1789","definitions":[{"definition":"A monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Infliximab","termGroup":"PT","termSource":"NCI"},{"termName":"Avakine","termGroup":"SY","termSource":"NCI"},{"termName":"cA2","termGroup":"CN","termSource":"NCI"},{"termName":"Remicade","termGroup":"BR","termSource":"NCI"},{"termName":"Remsima","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Ankylosis spondylitis; Crohns disease; Plaque psoriasis; Rheumatoid arthritis; Sarcoidosis"},{"name":"CAS_Registry","value":"170277-31-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B72HH48FLU"},{"name":"Legacy Concept Name","value":"Infliximab"},{"name":"Maps_To","value":"Infliximab"},{"name":"NCI_Drug_Dictionary_ID","value":"38698"},{"name":"NSC Number","value":"728729"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38698"},{"name":"PDQ_Open_Trial_Search_ID","value":"38698"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0666743"}]}}{"C48398":{"preferredName":"Ingenol Mebutate","code":"C48398","definitions":[{"definition":"A selective small-molecule activator of protein kinase C (PKC) isolated from the plant Euphorbia peplus with potential antineoplastic activity. Ingenol mebutate activates various protein kinase C (PKC) isoforms, thereby inducing apoptosis in some tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes including proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ingenol Mebutate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Butenoic acid, 2-methyl-, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-1a,2,5,5a,6,9,10,10a- octahydro-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1H-2,8a- methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl ester, (2Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"I3A","termGroup":"AB","termSource":"NCI"},{"termName":"Ingenol-3-angelate","termGroup":"SY","termSource":"NCI"},{"termName":"PEP-005","termGroup":"CN","termSource":"NCI"},{"termName":"PEP005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75567-37-2"},{"name":"Chemical_Formula","value":"C25H34O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7686S50JAH"},{"name":"Legacy Concept Name","value":"Ingenol_3-Angelate"},{"name":"Maps_To","value":"Ingenol Mebutate"},{"name":"NCI_Drug_Dictionary_ID","value":"432941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"432941"},{"name":"PDQ_Open_Trial_Search_ID","value":"432941"},{"name":"PubMedID_Primary_Reference","value":"19178487"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1452152"}]}}{"C118776":{"preferredName":"Ingenol Mebutate Gel","code":"C118776","definitions":[{"definition":"A topical, aqueous gel formulation containing the mebutate salt form of ingenol, a selective small-molecule activator of protein kinase C (PKC) that is isolated from the sap of Euphorbia species, with potential antineoplastic activity. Upon topical application of the ingenol mebutate gel, ingenol activates various PKC isoforms, which induces apoptosis in certain tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes, including proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ingenol Mebutate Gel","termGroup":"PT","termSource":"NCI"},{"termName":"Ingenol-3-angelate Gel","termGroup":"SY","termSource":"NCI"},{"termName":"PEP-005 Topical Gel","termGroup":"CN","termSource":"NCI"},{"termName":"PEP005 Gel","termGroup":"CN","termSource":"NCI"},{"termName":"Picato","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ingenol Mebutate Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"766480"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766480"},{"name":"PDQ_Open_Trial_Search_ID","value":"766480"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3257744"}]}}{"C62526":{"preferredName":"Iniparib","code":"C62526","definitions":[{"definition":"A small molecule iodobenzamide with potential cytotoxic and antineoplastic activities. Although the mechanism of action is unknown, iniparib appears to be cytotoxic in cells with DNA alterations or DNA damage, like that found in tumor cells with mutations in the ataxia telangiectasia mutated (ATM) gene. ATM encodes a serine/threonine protein kinase and mutations of the gene are associated with ataxia telangiectasia and contribute to certain cancers such as T-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia and B-cell non-Hodgkin lymphomas.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. BSI-201 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iniparib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Iodo-3-Nitrobenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"BSI-201","termGroup":"CN","termSource":"NCI"},{"termName":"PARP-1 Inhibitor BSI-201","termGroup":"SY","termSource":"NCI"},{"termName":"SAR240550","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160003-66-7"},{"name":"CAS_Registry","value":"937799-96-7"},{"name":"Chemical_Formula","value":"C7H5IN2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2ZWI7KHK8F"},{"name":"Legacy Concept Name","value":"BSI-201"},{"name":"Maps_To","value":"Iniparib"},{"name":"NCI_Drug_Dictionary_ID","value":"488465"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488465"},{"name":"PDQ_Open_Trial_Search_ID","value":"488465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0291482"}]}}{"C82362":{"preferredName":"Innate Immunostimulator rBBX-01","code":"C82362","definitions":[{"definition":"A recombinant 19 kDa protein derived from the Apicomplexa protozoan Eimeria with potential immunostimulating and antitumor activities. Upon administration, innate immunostimulator rBBX-01 activates dendritic cells (DCs), stimulates the Toll-like receptor 11 (TLR-11)-mediated release of interleukin-12 (Il-12) from DCs, and induces a T-helper 1 (Th1) type immune response, which may induce an immune response against tumor cells. Infection with Eimeria, a coccidian commonly infecting the intestine, may be negatively correlated with tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Innate Immunostimulator rBBX-01","termGroup":"PT","termSource":"NCI"},{"termName":"rBBX-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Innate_Immunostimulator_rBBX-01"},{"name":"Maps_To","value":"Innate Immunostimulator rBBX-01"},{"name":"NCI_Drug_Dictionary_ID","value":"640624"},{"name":"NCI_META_CUI","value":"CL408641"},{"name":"PDQ_Closed_Trial_Search_ID","value":"640624"},{"name":"PDQ_Open_Trial_Search_ID","value":"640624"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61315":{"preferredName":"INO-1001","code":"C61315","definitions":[{"definition":"A isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"INO-1001","termGroup":"PT","termSource":"NCI"},{"termName":"INO 1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"624747-02-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"55E08EN074"},{"name":"Legacy Concept Name","value":"INO-1001"},{"name":"Maps_To","value":"INO-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"485165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485165"},{"name":"PDQ_Open_Trial_Search_ID","value":"485165"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1504945"}]}}{"C157333":{"preferredName":"Inodiftagene Vixteplasmid","code":"C157333","definitions":[{"definition":"A recombinant DNA plasmid carrying the gene for diphtheria toxin-A (dT-A) chain under the regulation of the H19 promoter, with potential antineoplastic activity. Upon intravesical administration, dT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The dT-A chain binds to nicotinamide adenine dinucleotide (NAD) and inactivates the ADP-ribosylation of elongation factor 2 (EF2), resulting in the inhibition of protein synthesis and cell death leading to tumor cell destruction. Inodiftagene Vixteplasmid does not carry the gene for the diphtheria toxin-B (dT-B) chain, thereby preventing the transfer of the toxic dT-A chain between cells. H19, a paternally imprinted, oncofetal gene, is highly expressed in embryonic and certain malignant tissues, but minimally expressed in normal, adult tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inodiftagene Vixteplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"BC 819","termGroup":"CN","termSource":"NCI"},{"termName":"BC-819","termGroup":"CN","termSource":"NCI"},{"termName":"BC819","termGroup":"CN","termSource":"NCI"},{"termName":"Diphtheria-toxin-A-H19","termGroup":"SY","termSource":"NCI"},{"termName":"dT-A-H19","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2166100-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98YK326XZ6"},{"name":"Maps_To","value":"Inodiftagene Vixteplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"796809"},{"name":"NCI_META_CUI","value":"CL937035"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796809"},{"name":"PDQ_Open_Trial_Search_ID","value":"796809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116728":{"preferredName":"iNOS Dimerization Inhibitor FK-330","code":"C116728","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of inducible nitric oxide synthase (iNOS) with potential antineoplastic activity. Upon administration, iNOS Dimerization Inhibitor FK-330 inhibits iNOS dimerization, which results in decreased nitric oxide (NO) production. iNOS expression is upregulated in certain cancers and may invoke a chronic inflammatory state in tumor cells that promotes metastatic growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iNOS Dimerization Inhibitor FK-330","termGroup":"PT","termSource":"NCI"},{"termName":"FK-330","termGroup":"CN","termSource":"NCI"},{"termName":"FR-260330","termGroup":"CN","termSource":"NCI"},{"termName":"iNOS Dimerization Inhibitor ASP9853","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"442198-67-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K47C68D94B"},{"name":"Maps_To","value":"iNOS Dimerization Inhibitor ASP9853"},{"name":"NCI_Drug_Dictionary_ID","value":"741936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741936"},{"name":"PDQ_Open_Trial_Search_ID","value":"741936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3900153"}]}}{"C122835":{"preferredName":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01","code":"C122835","definitions":[{"definition":"An orally bioavailable inhibitor of inosine 5'- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration, IMPDH inhibitor FF-10501-01 competitively inhibits the enzyme IMPDH, thereby preventing the conversion of inosine monophosphate to xanthosine monophosphate. This inhibits the synthesis of guanine nucleotides, deprives cancer cells of guanosine triphosphate (GTP), disrupts DNA and RNA synthesis, and decreases tumor cell proliferation. Tumor cells are highly susceptible to IMPDH inhibition because they are rapidly dividing cells that are dependent on rapid DNA synthesis, which requires a high concentration of nucleotides. IMPDH, an enzyme that catalyzes the rate-limiting step in the synthesis of guanosine triphosphate (GTP), is overexpressed in numerous tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01","termGroup":"PT","termSource":"NCI"},{"termName":"FF-10501","termGroup":"CN","termSource":"NCI"},{"termName":"FF-10501-01","termGroup":"CN","termSource":"NCI"},{"termName":"IMPDH Inhibitor FF-10501","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01"},{"name":"NCI_Drug_Dictionary_ID","value":"763219"},{"name":"NCI_META_CUI","value":"CL474107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763219"},{"name":"PDQ_Open_Trial_Search_ID","value":"763219"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49181":{"preferredName":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944","code":"C49181","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks cells from making DNA and RNA and may kill cancer cells. It is a type of inosine monophosphate dehydrogenase (IMPDH) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine triphosphate (GTP), a purine molecule required for DNA and RNA synthesis.  Inhibition of IMPDH deprives cancer cells of GTP, resulting in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 appears to have a selective effect on cancer cells in that deprivation of GTP in normal cells results in a temporary slowing of cell growth only. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944","termGroup":"PT","termSource":"NCI"},{"termName":"AVN944","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"297730-17-7"},{"name":"Chemical_Formula","value":"C25H27N5O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I3NPL1V48Q"},{"name":"Legacy Concept Name","value":"AVN944"},{"name":"Maps_To","value":"Inosine Monophosphate Dehydrogenase Inhibitor AVN944"},{"name":"NCI_Drug_Dictionary_ID","value":"486333"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486333"},{"name":"PDQ_Open_Trial_Search_ID","value":"486333"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706677"}]}}{"C28163":{"preferredName":"Inositol","code":"C28163","definitions":[{"definition":"A natural sugar found in cell membrane phospholipids, plasma lipoproteins, and (as the phosphate form) in the nucleus with potential chemopreventive properties. As one of a number of intracellular phosphate compounds, inositol is involved in cell signaling and may stimulate tumor cell differentiation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Myoinositol helps cells make membranes and respond to messages from their environment. It has the same chemical formula as glucose (the chief source of energy for living organisms) but has a different arrangement of atoms. It is found in beans, peas, brown rice, wheat bran and nuts. It is water-soluble (can dissolve in water) and must be taken in every day. Myoinositol is being studied in the prevention of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Inositol","termGroup":"PT","termSource":"NCI"},{"termName":"cis-1,2,3,5-trans-4,6-Cyclohexanehexol","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclohexanehexol","termGroup":"SN","termSource":"NCI"},{"termName":"myo-Inositol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87-89-8"},{"name":"CHEBI_ID","value":"CHEBI:17268"},{"name":"Chemical_Formula","value":"C6H12O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4L6452S749"},{"name":"Legacy Concept Name","value":"Inositol"},{"name":"Maps_To","value":"Inositol"},{"name":"NCI_Drug_Dictionary_ID","value":"305828"},{"name":"NSC Number","value":"55552"},{"name":"NSC Number","value":"8101"},{"name":"PDQ_Closed_Trial_Search_ID","value":"305828"},{"name":"PDQ_Open_Trial_Search_ID","value":"305828"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021547"}]}}{"C71542":{"preferredName":"Inotuzumab Ozogamicin","code":"C71542","definitions":[{"definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inotuzumab Ozogamicin","termGroup":"PT","termSource":"NCI"},{"termName":"Besponsa","termGroup":"BR","termSource":"NCI"},{"termName":"CMC 544","termGroup":"CN","termSource":"NCI"},{"termName":"CMC-544","termGroup":"CN","termSource":"NCI"},{"termName":"CMC544","termGroup":"CN","termSource":"NCI"},{"termName":"Way 207294","termGroup":"CN","termSource":"NCI"},{"termName":"WAY-207294","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)."},{"name":"CAS_Registry","value":"635715-01-4"},{"name":"Chemical_Formula","value":"C73H96IN6O25S3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"P93RUU11P7"},{"name":"Legacy Concept Name","value":"Anti-CD22-CalichDMH_Conjugate"},{"name":"Maps_To","value":"Inotuzumab Ozogamicin"},{"name":"NCI_Drug_Dictionary_ID","value":"352004"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352004"},{"name":"PDQ_Open_Trial_Search_ID","value":"352004"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567130"}]}}{"C65919":{"preferredName":"Inproquone","code":"C65919","definitions":[{"definition":"A benzoquinone-based antineoplastic agent. Inproquone was never marketed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inproquone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"436-40-8"},{"name":"Chemical_Formula","value":"C16H22N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C6Y700V0M4"},{"name":"Legacy Concept Name","value":"Inproquone"},{"name":"Maps_To","value":"Inproquone"},{"name":"NSC Number","value":"17261"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063600"}]}}{"C61501":{"preferredName":"Integrin alpha-2 Inhibitor E7820","code":"C61501","definitions":[{"definition":"A small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Integrin alpha-2 Inhibitor E7820","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"289483-69-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TVH5K7949N"},{"name":"Legacy Concept Name","value":"E7820"},{"name":"Maps_To","value":"Integrin alpha-2 Inhibitor E7820"},{"name":"NCI_Drug_Dictionary_ID","value":"363619"},{"name":"PDQ_Closed_Trial_Search_ID","value":"363619"},{"name":"PDQ_Open_Trial_Search_ID","value":"363619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1172515"}]}}{"C96223":{"preferredName":"Integrin Receptor Antagonist GLPG0187","code":"C96223","definitions":[{"definition":"A small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity. Upon administration, GLPG0187 binds to and blocks the activity of 5 RGD-integrin receptor subtypes, including alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6 and alpha5beta1. This may result in the inhibition of endothelial cell-cell interactions and endothelial cell-matrix interactions, and the prevention of angiogenesis and metastasis in tumor cells expressing these integrin receptors. Integrin receptors are transmembrane glycoproteins expressed on the surface of tumor vessel endothelial cells and some types of cancer cells, and play a crucial role in endothelial cell adhesion and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Integrin Receptor Antagonist GLPG0187","termGroup":"PT","termSource":"NCI"},{"termName":"GLPG0187","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1320346-97-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43A5P87Z4T"},{"name":"Maps_To","value":"Integrin Receptor Antagonist GLPG0187"},{"name":"NCI_Drug_Dictionary_ID","value":"697397"},{"name":"NCI_META_CUI","value":"CL429007"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697397"},{"name":"PDQ_Open_Trial_Search_ID","value":"697397"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C20493":{"preferredName":"Interferon","code":"C20493","definitions":[{"definition":"A biological response modifier (a substance that can improve the body's natural response to infection and disease). Interferons interfere with the division of cancer cells and can slow tumor growth. There are several types of interferons, including interferon-alpha, -beta, and -gamma. These substances are normally produced by the body. They are also made in the laboratory for use in treating cancer and other diseases.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon","termGroup":"PT","termSource":"NCI"},{"termName":"Human Fibroblast Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Human Leukocyte Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Human Lymphoblastoid Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Interferon"},{"name":"Maps_To","value":"Interferon"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0021747"}]}}{"C2220":{"preferredName":"Interferon Alfa-N1","code":"C2220","definitions":[{"definition":"A highly purified alpha interferon produced by a human lymphoid cell line.  Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.  In contrast, recombinant alpha interferons are individual non-glycosylated proteins produced from individual alpha interferon genes.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose proteins have antiviral, antiproliferative, anticancer, and immune-modulating effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Alfa-N1","termGroup":"PT","termSource":"NCI"},{"termName":"Humoferon","termGroup":"FB","termSource":"NCI"},{"termName":"Interferon Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"Wellferon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Hepatitis C"},{"name":"CAS_Registry","value":"308067-63-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"41697D4Z5C"},{"name":"Legacy Concept Name","value":"Interferon_Alfa-N1"},{"name":"Maps_To","value":"Interferon Alfa-N1"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699817"}]}}{"C30136":{"preferredName":"Interferon Alfa-N3","code":"C30136","definitions":[{"definition":"A formulated therapeutic analog of the endogenous alpha interferon containing multiple interferon species with antiviral and antitumor properties.  Interferons bind to specific cell-surface receptors, leading to the transcription and translation of genes with an interferon-specific response element, thereby inducing: antiviral effects (the most important being inhibition of viral protein synthesis); antiproliferative effects (including inhibition of cellular growth and alteration of cellular differentiation); anticancer effects (including interference with oncogene expression); and immune-modulating effects (including activation of natural killer cells, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Alfa-N3","termGroup":"PT","termSource":"NCI"},{"termName":"Alfa-N3 Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Alferon N","termGroup":"BR","termSource":"NCI"},{"termName":"Altemol","termGroup":"FB","termSource":"NCI"},{"termName":"Interferon Alfa-3N, Human Leukocyte Derived","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9008-11-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"47BPR3V3MP"},{"name":"Legacy Concept Name","value":"Interferon_Alfa-N3"},{"name":"Maps_To","value":"Interferon Alfa-N3"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1621234"}]}}{"C1766":{"preferredName":"Interferon Alfacon-1","code":"C1766","definitions":[{"definition":"An analogue of consensus interferon which contains an additional methionyl amino acid residue.  Consensus interferon (also known as interferon alfacon-1, rCon-IFN, and CIFN) is a genetically engineered synthetic interferon created from the most common amino acid sequences from the naturally occurring alpha interferons.  Alpha interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Alfacon-1","termGroup":"PT","termSource":"NCI"},{"termName":"Advaferon","termGroup":"FB","termSource":"NCI"},{"termName":"CIFN","termGroup":"AB","termSource":"NCI"},{"termName":"Consensus Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN Alfacon-1","termGroup":"SY","termSource":"NCI"},{"termName":"Infergen","termGroup":"BR","termSource":"NCI"},{"termName":"Interferon Consensus, Methionyl","termGroup":"SY","termSource":"NCI"},{"termName":"Methionyl Interferon Consensus","termGroup":"SY","termSource":"NCI"},{"termName":"Methionyl-Interferon-Consensus","termGroup":"SY","termSource":"NCI"},{"termName":"r-metHuIFN-Con1","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Consensus Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant methionyl human consensus interferon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118390-30-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56588OP40D"},{"name":"Legacy Concept Name","value":"Interferon_Alfacon-1"},{"name":"Maps_To","value":"Interferon Alfacon-1"},{"name":"NCI_Drug_Dictionary_ID","value":"42870"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42870"},{"name":"PDQ_Open_Trial_Search_ID","value":"42870"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0164613"}]}}{"C1823":{"preferredName":"Interferon Beta-1A","code":"C1823","definitions":[{"definition":"A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities. Upon administration, interferon beta-1a targets and binds to specific type I IFN receptors, which eventually results in the transcription and translation of genes containing an interferon-specific response element and leads to the production of various anti-viral proteins and modulates the production of various immune-modulating proteins. This reduces the production of certain pro-inflammatory cytokines while upregulating the anti-inflammatory cytokine interleukin 10 (IL-10), upregulates the expression of major histocompatibility (MHC) I proteins which allows for increased presentation of peptides derived from viral antigens, and activates CD8+ T cells as well as other immune cells. Endogenous IFN-beta-1a is produced following viral infection and it plays a key role in innate immune response against viral pathogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Beta-1A","termGroup":"PT","termSource":"NCI"},{"termName":"Avonex","termGroup":"BR","termSource":"NCI"},{"termName":"BG9418","termGroup":"CN","termSource":"NCI"},{"termName":"Rebif","termGroup":"BR","termSource":"NCI"},{"termName":"Recombinant interferon beta-1a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Multiple sclerosis"},{"name":"CAS_Registry","value":"145258-61-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XRO4566Q4R"},{"name":"Legacy Concept Name","value":"Interferon_Beta-1A"},{"name":"Maps_To","value":"Interferon Beta-1A"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0982234"}]}}{"C100089":{"preferredName":"Interferon Gamma-1b","code":"C100089","definitions":[{"definition":"A recombinant form of the endogenous cytokine human interferon (IFN) gamma-1b, with immunomodulating activity. Upon administration, IFN gamma-1b targets, binds to, and activates the cell-surface IFN-gamma receptor, stimulating antibody dependent cellular cytotoxicity (ADCC), activating natural killer (NK) cells, and enhancing the oxidative metabolism of macrophages. IFN-gamma plays important roles in the innate and adaptive immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon Gamma-1b","termGroup":"PT","termSource":"NCI"},{"termName":"Actimmune","termGroup":"BR","termSource":"NCI"},{"termName":"gamma Interferon 1B","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-g-1b","termGroup":"AB","termSource":"NCI"},{"termName":"IFN-gamma 1b","termGroup":"SY","termSource":"NCI"},{"termName":"IFNg-1b","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon gamma-1b, Recombinant","termGroup":"SY","termSource":"NCI"},{"termName":"N(Sup 2)-L-Methionyl-1-139-Interferon G","termGroup":"SY","termSource":"NCI"},{"termName":"N(sup 2)-L-Methionyl-1-139-interferon gamma (Human Lymphocyte Protein Moiety Reduced)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Interferon Gamma-1b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98059-61-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"21K6M2I7AG"},{"name":"Maps_To","value":"Interferon Gamma-1b"},{"name":"NCI_Drug_Dictionary_ID","value":"784898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784898"},{"name":"PDQ_Open_Trial_Search_ID","value":"784898"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1579322"}]}}{"C66972":{"preferredName":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002","code":"C66972","definitions":[{"definition":"A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002","termGroup":"PT","termSource":"NCI"},{"termName":"Ad-IFNg","termGroup":"AB","termSource":"NCI"},{"termName":"ASN-002","termGroup":"CN","termSource":"NCI"},{"termName":"INFg-expressing Ad Vaccine ASN-002","termGroup":"SY","termSource":"NCI"},{"termName":"TG1042","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interferon-gamma-expressing Adenovirus Vaccine ASN-002"},{"name":"NCI_Drug_Dictionary_ID","value":"530060"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530060"},{"name":"PDQ_Open_Trial_Search_ID","value":"530060"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832028"}]}}{"C15543":{"preferredName":"Interleukin Therapy","code":"C15543","definitions":[{"definition":"The use of interleukin in the treatment of any disease or disorder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Interleukin_Therapy"},{"name":"Maps_To","value":"Interleukin Therapy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0281177"}]}}{"C2373":{"preferredName":"Interleukin-2 Liposome","code":"C2373","definitions":[{"definition":"A formulation in which liposomes are loaded with the cytokine interleukin-2 (IL-2). By activating cytotoxic T-lymphocytes, such as lymphokine-activated killer cells, and increasing levels of the cytotoxic cytokines interferon-gamma (IFN-gamma) and transforming growth factor-beta (TGF-beta), IL-2 may exhibit antitumoral activity.  Liposomal formulations of IL-2 may promote entry of the cytokine into target tumor cells and may be used as an immunoadjuvant in cancer vaccine therapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-2 Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"Liposome encapsulated interleukin-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Interleukin-2_Liposome"},{"name":"Maps_To","value":"Interleukin-2 Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"41486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41486"},{"name":"PDQ_Open_Trial_Search_ID","value":"41486"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0281031"}]}}{"C128107":{"preferredName":"Nemvaleukin Alfa","code":"C128107","definitions":[{"definition":"A selective effector cell activator protein and agonist of the intermediate-affinity interleukin-2 (IL-2) receptor with potential immunostimulating and antineoplastic activity. Upon administration, nemvaleukin alfa binds to and signals through the intermediate-affinity IL-2 receptor complex; this may selectively stimulate and activate natural killer (NK) cells and memory CD8 T-cells, leading to tumor cell elimination, while circumventing the activation of immunosuppressive cells that may prevent the anti-tumor response. IL-2 is a cytokine signaling molecule that plays a critical role in the immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemvaleukin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"ALKS 4230","termGroup":"CN","termSource":"NCI"},{"termName":"Intermediate-affinity IL-2R Agonist ALKS 4230","termGroup":"SY","termSource":"NCI"},{"termName":"Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230","termGroup":"SY","termSource":"NCI"},{"termName":"RDB 1450","termGroup":"CN","termSource":"NCI"},{"termName":"RDB-1450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2315268-27-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7ZX1Q9SJ1F"},{"name":"Maps_To","value":"Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230"},{"name":"NCI_Drug_Dictionary_ID","value":"782089"},{"name":"NCI_META_CUI","value":"CL507938"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782089"},{"name":"PDQ_Open_Trial_Search_ID","value":"782089"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61070":{"preferredName":"Intetumumab","code":"C61070","definitions":[{"definition":"A pan alpha-v human monoclonal antibody that recognizes alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, and alpha-v beta-6 integrins with antiangiogenic and antitumor activities. Intetumumab competitively binds to and blocks both alpha-v beta-3 and alpha-v beta-5 integrins, resulting in inhibition of integrin-mediated tumor angiogenesis and tumor growth. Integrins facilitate the adhesion of stimulated endothelial cells to the extracellular matrix (ECM); trigger the secretion of ECM-rearranging proteases; and propagate signaling events that promote the survival and differentiation of cells in newly formed vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intetumumab","termGroup":"PT","termSource":"NCI"},{"termName":"CNTO 095","termGroup":"CN","termSource":"NCI"},{"termName":"CNTO-95","termGroup":"CN","termSource":"NCI"},{"termName":"Human Anti-Alpha-5 Integrin Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Human Monoclonal CNTO 95 gamma1 heavy chain (222-215')-disulfide with Human Monoclonal CNTO 95 kappa light chain dimer (228-228'':231-231'')-bisdisulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human integrin alpha-V (vitronectin receptor subunit alpha or CD51))","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"725735-28-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GQE1BJE2NI"},{"name":"Legacy Concept Name","value":"Human_Anti-Alpha-5_Integrin_Monoclonal_Antibody"},{"name":"Maps_To","value":"Intetumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"473196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473196"},{"name":"PDQ_Open_Trial_Search_ID","value":"473196"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881068"}]}}{"C83820":{"preferredName":"Intiquinatine","code":"C83820","definitions":[{"definition":"An antineoplastic agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intiquinatine","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-2-(4-((7-Bromoquinolin-2-yl)Oxy)Phenoxy)Propanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Tiliquinatine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"445041-75-8"},{"name":"Chemical_Formula","value":"C18H14BrNO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G5067X5156"},{"name":"Maps_To","value":"Intiquinatine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827205"}]}}{"C1495":{"preferredName":"Intoplicine","code":"C1495","definitions":[{"definition":"A benzopyridoindole derivative with antineoplastic property. Intoplicine inhibits activities of both topoisomerase I and II via intercalating DNA helix, thereby hindering the movements of enzymes along DNA molecules during DNA transcription and replication, respectively. Furthermore, this agent stabilizes DNA-enzyme complexes during unwinding processes by both topoisomerases, leading to double- and single-stranded DNA breaks. Consequently, these effects bring about cell growth inhibition and apoptosis of tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that has been studied in the treatment of some types of cancer. Intoplicine blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Intoplicine","termGroup":"PT","termSource":"NCI"},{"termName":"7H-benzo(e)pyrido(4,3-b)indol-3-ol, 11-((3-(dimethylamino)propyl)amino)-8-methyl","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125974-72-3"},{"name":"Chemical_Formula","value":"C21H24N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FB2CIN6HMI"},{"name":"Legacy Concept Name","value":"Intoplicine"},{"name":"Maps_To","value":"Intoplicine"},{"name":"NCI_Drug_Dictionary_ID","value":"43318"},{"name":"NSC Number","value":"645008"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43318"},{"name":"PDQ_Open_Trial_Search_ID","value":"43318"},{"name":"PubMedID_Primary_Reference","value":"12570767"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0217476"}]}}{"C61506":{"preferredName":"Inulin","code":"C61506","definitions":[{"definition":"A naturally occurring, indigestible and non-absorbable oligosaccharide produced by certain plants with prebiotic and potential anticancer activity. Inulin stimulates the growth of beneficial bacteria in the colon, including Bifidobacteria and Lactobacilli, thereby modulating the composition of microflora. This creates an environment that protects against pathogens, toxins and carcinogens, which can cause inflammation and cancer. In addition, fermentation of inulin leads to an increase in short-chain fatty acids and lactic acid production, thereby reducing colonic pH, which may further control pathogenic bacteria growth and may contribute to inulin's cancer protective properties.","type":"DEFINITION","source":"NCI"},{"definition":"Class of oligosaccharides produced by plants that are polymers mainly comprised of fructose (generally 2 to 140) units usually with a glucose end. These units are joined by beta-(2-1) glycosidic links.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Inulin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9005-80-5"},{"name":"CHEBI_ID","value":"CHEBI:15443"},{"name":"Chemical_Formula","value":"C18H32O16(C6H10O5)n"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JOS53KRJ01"},{"name":"INFOODS","value":"INULN"},{"name":"Legacy Concept Name","value":"Inulin"},{"name":"Maps_To","value":"Inulin"},{"name":"NCI_Drug_Dictionary_ID","value":"486745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486745"},{"name":"PDQ_Open_Trial_Search_ID","value":"486745"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021936"}]}}{"C970":{"preferredName":"Iobenguane I-131","code":"C970","definitions":[{"definition":"A radioactive substance that is used in imaging tests, and is being studied in the treatment of cancer. It is a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Iobenguane localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iobenguane I-131","termGroup":"PT","termSource":"NCI"},{"termName":"(131)I-MIBG","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 Meta-iodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 Metaiodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"Iobenguane (131I)","termGroup":"SY","termSource":"NCI"},{"termName":"Iobenguane I 131","termGroup":"SY","termSource":"NCI"},{"termName":"Iobenguane I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Metaiodobenzylguanidine","termGroup":"SY","termSource":"NCI"},{"termName":"MIBG I-131","termGroup":"AB","termSource":"NCI"},{"termName":"Raiatt MIBG-I 131","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diagnostic imaging; Neuroendocrine tumors."},{"name":"CAS_Registry","value":"77679-27-7"},{"name":"Chemical_Formula","value":"C8H10IN3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q461L7AK4R"},{"name":"Legacy Concept Name","value":"Meta-Iodobenzylguanidine"},{"name":"Maps_To","value":"Iobenguane I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"38020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38020"},{"name":"PDQ_Open_Trial_Search_ID","value":"38020"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879568"}]}}{"C2440":{"preferredName":"Iodine I 124 Monoclonal Antibody A33","code":"C2440","definitions":[{"definition":"A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 124 (I-124). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancer metastases, with only restricted expression in normal colonic mucosa. I-124 MoAb A33 delivers beta particle emitting I-124 nuclide directly to metastatic colorectal tissues, thereby this agent could be used in kinetics studies or radioimmunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 124 Monoclonal Antibody A33","termGroup":"PT","termSource":"NCI"},{"termName":"I 124 Monoclonal Antibody A33","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 124 MOAB A33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_124_Monoclonal_Antibody_A33"},{"name":"Maps_To","value":"Iodine I 124 Monoclonal Antibody A33"},{"name":"NCI_Drug_Dictionary_ID","value":"42707"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42707"},{"name":"PDQ_Open_Trial_Search_ID","value":"42707"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C0677678"}]}}{"C158629":{"preferredName":"Iodine I 124 Monoclonal Antibody M5A","code":"C158629","definitions":[{"definition":"A radioimmunoconjugate comprised of M5A, a humanized monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), labeled with iodine I 124 (I-124) with potential radiolocalization applications. Upon administration, the antibody moiety of iodine I 124 monoclonal antibody M5A specifically binds to cells expressing CEA. Upon binding, the radioisotope moiety can be detected using positron-emission tomography (PET), thereby allowing the imaging and quantification of CEA-expressing tumor cells. CEA, a tumor associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 124 Monoclonal Antibody M5A","termGroup":"PT","termSource":"NCI"},{"termName":"124I-hT84.66-M5A","termGroup":"SY","termSource":"NCI"},{"termName":"124I-M5A","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 124 Anti-CEA Monoclonal Antibody hT84.66-M5A","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 124 Anti-CEA Monoclonal Antibody M5A","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 124 Monoclonal Antibody hT84.66-M5A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 124 Monoclonal Antibody M5A"},{"name":"NCI_Drug_Dictionary_ID","value":"797482"},{"name":"NCI_META_CUI","value":"CL950662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797482"},{"name":"PDQ_Open_Trial_Search_ID","value":"797482"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74051":{"preferredName":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody","code":"C74051","definitions":[{"definition":"A radioimmunoconjugate consisting of a murine IgG2a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR) labeled with iodine I 125 with potential antineoplastic activity. Iodine I 125 anti-EGFR-425 monoclonal antibody binds specifically to the epidermal growth factor receptor (EGFR). Upon binding to EGFR-expressing tumor cells, this agent is internalized, selectively delivering a potentially cytotoxic dose of gamma radiation. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iodine_I_125-Anti-EGFR-425_Monoclonal_Antibody"},{"name":"Maps_To","value":"Iodine I 125-Anti-EGFR-425 Monoclonal Antibody"},{"name":"NCI_Drug_Dictionary_ID","value":"586304"},{"name":"NCI_META_CUI","value":"CL383810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586304"},{"name":"PDQ_Open_Trial_Search_ID","value":"586304"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91389":{"preferredName":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP","code":"C91389","definitions":[{"definition":"An iodine 131 radioimmunoconjugate of a small immunoprotein (SIP), derived from the variable region fragment of human monoclonal antibody L19, that is directed against the extra-domain B (ED-B) of fibronectin, with potential radioimmunotherapeutic activity. The SIP moiety of iodine I 131 anti-fibronectin antibody fragment L19-SIP binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. Upon internalization, the I 131 radionuclide may selectively detect or deliver cytotoxic radiation to fibronectin-expressing tumor cells. ED-B of fibronectin, a naturally occurring marker of tissue remodeling and angiogenesis, is expressed in the majority of aggressive solid human tumors, whereas it is not detectable in normal vessels and tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP","termGroup":"PT","termSource":"NCI"},{"termName":"L19-SIP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP"},{"name":"NCI_Drug_Dictionary_ID","value":"674133"},{"name":"NCI_META_CUI","value":"CL421588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674133"},{"name":"PDQ_Open_Trial_Search_ID","value":"674133"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2223":{"preferredName":"Iodine I 131 Derlotuximab Biotin","code":"C2223","definitions":[{"definition":"An iodine 131 labeled radioimmunoconjugate of monoclonal antibody (MOAB) TNT-1/B with radioimaging and antineoplastic properties. MOAB TNT-1/B was developed for radioimmunotherapy of solid tumors, designated as Tumor Necrosis Treatment (TNT). TNT exploits the presence of degenerating and necrotic cells within tumors by utilizing MOAbs directed against universal, intracellular nucleosomal determinants consisting of histone H1 and DNA. This MOAB was conjugated with biotin (B) molecules, which increase pharmacokinetic performance of the monoclonal antibody. Upon administration, iodine I 131 derlotuximab biotin delivers I 131 to tumor cells and results in the targeted imaging and/or destruction of cells with exposed necrotic antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Derlotuximab Biotin","termGroup":"PT","termSource":"NCI"},{"termName":"Cotara","termGroup":"BR","termSource":"NCI"},{"termName":"I 131 MOAB TNT-1/B","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody TNT-1/B","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB TNT-1/B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"340013-96-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1724UJB90B"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_TNT-1_B"},{"name":"Maps_To","value":"Iodine I 131 Derlotuximab Biotin"},{"name":"NCI_Drug_Dictionary_ID","value":"43561"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43561"},{"name":"PDQ_Open_Trial_Search_ID","value":"43561"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879273"}]}}{"C2696":{"preferredName":"Iodine I 131 Ethiodized Oil","code":"C2696","definitions":[{"definition":"A cytotoxic radioconjugate consisting of lipiodol, an iodinated ethyl ester derived from poppy seed oil, labeled with iodine 131 (I-131).  I-131 Lipiodol accumulates in hepatocellular carcinoma and hepatoblastoma tumor cells, resulting in targeted cytotoxicity to tumor cells while sparing surrounding normal cells and tissues. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A radioactive substance being studied in the treatment of liver cancer. It is a form of poppy seed oil that contains iodine, some of which is the radioactive substance iodine I 131. It builds up in the blood and lymph vessels in the liver and may kill cancer cells. It is a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iodine I 131 Ethiodized Oil","termGroup":"PT","termSource":"NCI"},{"termName":"131 I-Ethiodized Oil","termGroup":"SY","termSource":"NCI"},{"termName":"I 131 Lipiodol","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Lipiodol","termGroup":"SY","termSource":"NCI"},{"termName":"Lipiocis","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Lipiodol"},{"name":"Maps_To","value":"Iodine I 131 Ethiodized Oil"},{"name":"NCI_Drug_Dictionary_ID","value":"38497"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38497"},{"name":"PDQ_Open_Trial_Search_ID","value":"38497"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527224"}]}}{"C131821":{"preferredName":"Iodine I 131 MIP-1095","code":"C131821","definitions":[{"definition":"A radioconjugate composed of MIP-1095, a urea-based ligand for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) radiolabeled with iodine I 131 (I131), with potential antineoplastic activity. Upon administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells. PSMA is a transmembrane glycoprotein that is highly expressed by malignant prostate epithelial cells and certain other tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 MIP-1095","termGroup":"PT","termSource":"NCI"},{"termName":"((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(131)I]iodophenyl)ureido)pentyl)ureido)pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"(131) I-MIP-1095","termGroup":"SY","termSource":"NCI"},{"termName":"131I-MIP-1095","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 MIP-1095","termGroup":"SY","termSource":"NCI"},{"termName":"MIP-1095 I-131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1258980-67-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7DM27RQ9V0"},{"name":"Maps_To","value":"Iodine I 131 MIP-1095"},{"name":"NCI_Drug_Dictionary_ID","value":"786538"},{"name":"NCI_META_CUI","value":"CL514422"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786538"},{"name":"PDQ_Open_Trial_Search_ID","value":"786538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2488":{"preferredName":"Iodine I 131 Monoclonal Antibody 81C6","code":"C2488","definitions":[{"definition":"A radioimmunoconjugate consisting of 81C6, a murine IgG2 anti-tenascin monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic activities. Using monoclonal antibody 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"81C6-I-131","termGroup":"SY","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Neuradiab","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000874-23-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D4E1UP3RMV"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_81C6"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody 81C6"},{"name":"NCI_Drug_Dictionary_ID","value":"43146"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43146"},{"name":"PDQ_Open_Trial_Search_ID","value":"43146"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796329"}]}}{"C2527":{"preferredName":"Iodine I 131 Apamistamab","code":"C2527","definitions":[{"definition":"A monoclonal antibody that contains the radioactive substance iodine I131. It is being studied in the treatment of acute myeloid leukemia. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Iodine I 131 monoclonal antibody BC8 binds to the protein CD45, which is found on most white blood cells and myeloid and lymphoid leukemia cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45. CD45 is tyrosine phosphatase expressed on virtually all leukocytes, including myeloid and lymphoid precursors in bone marrow and mature lymphocytes in lymph nodes; it is also expressed on most myeloid and lymphoid leukemic cells, but not on mature erythrocytes or platelets. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Apamistamab","termGroup":"PT","termSource":"NCI"},{"termName":"I 131 MOAB BC8","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody BC8","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine (131I) Apamistamab","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB BC8","termGroup":"SY","termSource":"NCI"},{"termName":"Iomab-B","termGroup":"BR","termSource":"NCI"},{"termName":"MOAB BC8, iodine I 131","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody BC8, iodine I 131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097132-02-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71RR81V666"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_BC8"},{"name":"Maps_To","value":"Iodine I 131 Apamistamab"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody BC8"},{"name":"NCI_Drug_Dictionary_ID","value":"43463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43463"},{"name":"PDQ_Open_Trial_Search_ID","value":"43463"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796627"}]}}{"C2697":{"preferredName":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2","code":"C2697","definitions":[{"definition":"A radioimmunoconjugate consisting of the humanized CH2 domain-deleted monoclonal antibody CC49 and iodine I 131 with antineoplastic activity. Monoclonal antibody CC49-deltaCH2 targets the tumor-associated glycoprotein 72 (TAG-72) that is expressed by a wide range of human neoplasms including colorectal, gastric, pancreatic, ovarian, endometrial, breast, non-small cell lung, and prostate cancers. Iodine I 131 monoclonal antibody CC49-deltaCH2 binds to tumor cells expressing TAG-72, selectively delivering a cytotoxic dose of beta and gamma radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2","termGroup":"PT","termSource":"NCI"},{"termName":"131I-HuCC49-deltaCH2","termGroup":"AB","termSource":"NCI"},{"termName":"131I-MOAB CC49-deltaCH2","termGroup":"AB","termSource":"NCI"},{"termName":"I131 MOAB CC49-deltaCH2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iodine_I_131_Monoclonal_Antibody_CC49-deltaCH2"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody CC49-deltaCH2"},{"name":"NCI_Drug_Dictionary_ID","value":"453590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453590"},{"name":"PDQ_Open_Trial_Search_ID","value":"453590"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134477"}]}}{"C95025":{"preferredName":"Iodine I 131 Monoclonal Antibody F16SIP","code":"C95025","definitions":[{"definition":"A fully human monoclonal antibody (MoAb) against human A1 domain of tenascin-C, in small immunoprotein (SIP) format conjugated with iodine 131 with potential antineoplastic activity. Iodine I 131 MoAb F16SIP binds to tenascin-C on the vascular tissues and delivers cytotoxic radiation to the tumors, thereby minimizing systemic radiotoxicity. Tenascin-C is a glycoprotein of the extracellular matrix, and the large isoform of this matrix protein is expressed and restricted around vascular structures in the tumor stroma of a variety of different tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody F16SIP","termGroup":"PT","termSource":"NCI"},{"termName":"(131I) Monoclonal Antibody F16SIP","termGroup":"SY","termSource":"NCI"},{"termName":"131I-F16SIP","termGroup":"AB","termSource":"NCI"},{"termName":"F16-131I","termGroup":"AB","termSource":"NCI"},{"termName":"Tenarad","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody F16SIP"},{"name":"NCI_Drug_Dictionary_ID","value":"689747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689747"},{"name":"PDQ_Open_Trial_Search_ID","value":"689747"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986856"}]}}{"C2449":{"preferredName":"Iodine I 131 Monoclonal Antibody G-250","code":"C2449","definitions":[{"definition":"A radioimmunoconjugate comprised of the chimeric monoclonal antibody G-250 conjugated with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 chimeric monoclonal antibody G-250 binds to G-250, a renal-cell carcinoma-associated antigen, delivering cytotoxic iodine I 131 specifically to renal carcinoma cells that express G-250.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody G-250","termGroup":"PT","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody G-250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB G 250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB G-250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 MOAB G250","termGroup":"SY","termSource":"NCI"},{"termName":"iodine I 131 monoclonal antibody G250","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_G-250"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody G-250"},{"name":"NCI_Drug_Dictionary_ID","value":"42854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42854"},{"name":"PDQ_Open_Trial_Search_ID","value":"42854"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677789"}]}}{"C2604":{"preferredName":"Iodine I 131 Monoclonal Antibody muJ591","code":"C2604","definitions":[{"definition":"A radioimmunoconjugate of a mouse monoclonal antibody (MoAb) J591 labeled with Iodine 131 (I-131). MoAb muJ591 recognizes the extracellular domain of the prostate-specific membrane antigen (PSMA) and reacts with tumor vascular endothelium. Using MoAb muJ591 as a carrier for I-131 results in the targeted imaging and/or destruction of cells overexpressed PSM.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Monoclonal Antibody muJ591","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Iodine_I_131_Monoclonal_Antibody_muJ591"},{"name":"Maps_To","value":"Iodine I 131 Monoclonal Antibody muJ591"},{"name":"NCI_Drug_Dictionary_ID","value":"38113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38113"},{"name":"PDQ_Open_Trial_Search_ID","value":"38113"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935700"}]}}{"C48400":{"preferredName":"Iodine I 131 Omburtamab","code":"C48400","definitions":[{"definition":"A radioimmunoconjugate consisting of the iodine 131-radiolabeled murine IgG1 monoclonal antibody 8H9 directed against the surface immunomodulatory glycoprotein 4Ig-B7-H3 with potential radioimaging and radioimmunotherapeutic uses. Iodine I 131 monoclonal antibody 8H9 binds to 4Ig-B7-H3 (human B7-H3 with 4 Ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4Ig-B7-H3 inhibits T-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mdDCs). In vitro, it has been shown that monoclonal antibody-mediated masking of 4Ig-B7-H3 on neuroblastoma cells resulted in the enhancement of natural killer (NK)-mediated lysis of target cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Omburtamab","termGroup":"PT","termSource":"NCI"},{"termName":"Iodine I 131 MOAB 8H9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B6PMV8U3C4"},{"name":"Legacy Concept Name","value":"Iodine_I_131_Monoclonal_Antibody_8H9"},{"name":"Maps_To","value":"Iodine I 131 Omburtamab"},{"name":"NCI_Drug_Dictionary_ID","value":"380753"},{"name":"PDQ_Closed_Trial_Search_ID","value":"380753"},{"name":"PDQ_Open_Trial_Search_ID","value":"380753"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541591"}]}}{"C102981":{"preferredName":"Iodine I 131 Rituximab","code":"C102981","definitions":[{"definition":"A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Rituximab","termGroup":"PT","termSource":"NCI"},{"termName":"(131)I-Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"131I-Rituxan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K2I4B6I9L1"},{"name":"Maps_To","value":"Iodine I 131 Rituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"739942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739942"},{"name":"PDQ_Open_Trial_Search_ID","value":"739942"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1676077"}]}}{"C124996":{"preferredName":"Iodine I 131 Tenatumomab","code":"C124996","definitions":[{"definition":"A radioimmunoconjugate of tenatumomab, a murine monoclonal antibody targeting the tumor-associated antigen (TAA) tenascin-C (TNC), labeled with iodine I 131, with potential antineoplastic activity. The antibody moiety of iodine I 131 tenatumomab binds to TNC, thereby delivering a cytotoxic dose of iodine I 131 specifically to tumors expressing TNC. TNC, an extracellular matrix protein, is upregulated in a variety of tumor cell types; it plays a key role in invasion, tumor cell proliferation and immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Tenatumomab","termGroup":"PT","termSource":"NCI"},{"termName":"131I-Tenatumomab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 Tenatumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"777273"},{"name":"NCI_META_CUI","value":"CL503842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777273"},{"name":"PDQ_Open_Trial_Search_ID","value":"777273"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48263":{"preferredName":"Iodine I 131 TM-601","code":"C48263","definitions":[{"definition":"An iodine 131 (I 131) radioconjugate of the synthetic chlorotoxin (CTX) TM-601 with potential antiangiogenic and antineoplastic activities. CTX is a 36 amino acid neurotoxin found in the venom of the giant yellow scorpion Leiurus quinquestriatus that preferentially binds malignant cells of neuroectodermal origin. The recombinant version of this peptide, TM-601, is expressed in and purified from E. coli and then covalently linked to I 131 to produce 131I-TM-601. 131I-TM-601 binds to tumor cells of neuroectodermal origin and is internalized; administered once, it may be used as a radioimaging agent; repeated administration may result in a tumor-specific, cumulative radiocytotoxic dose of I 131. In addition, TM-601 alone, similar to native CTX, may inhibit angiogenesis due to its ability to bind to and inhibit matrix metalloproteinase 2 (MMP-2), an endopeptidase involved in tissue remodeling processes such as angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 TM-601","termGroup":"PT","termSource":"NCI"},{"termName":"131I-Chlorotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"131I-TM-601","termGroup":"SY","termSource":"NCI"},{"termName":"131I-TM601","termGroup":"AB","termSource":"NCI"},{"termName":"I 131 TM-601","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"I_131_TM-601"},{"name":"Maps_To","value":"Iodine I 131 TM-601"},{"name":"NCI_Drug_Dictionary_ID","value":"440314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"440314"},{"name":"PDQ_Open_Trial_Search_ID","value":"440314"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2316450"}]}}{"C2444":{"preferredName":"Iodine I 131 Tositumomab","code":"C2444","definitions":[{"definition":"A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types of non-Hodgkin lymphoma. It belongs to the family of drugs called radioconjugated monoclonal antibodies. When iodine I 131 tositumomab and tositumomab are given together, the combination is called the Bexxar regimen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Tositumomab","termGroup":"PT","termSource":"NCI"},{"termName":"131-I-Anti-B1 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Bexxar","termGroup":"BR","termSource":"NCI"},{"termName":"I 131 Monoclonal Antibody Anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"I 131 Tositumomab","termGroup":"SY","termSource":"NCI"},{"termName":"I131-MOAB-B1","termGroup":"AB","termSource":"NCI"},{"termName":"Iodine I 131 MOAB Anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Monoclonal Antibody Anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 Anti-B1 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 Anti-CD20 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 Tositumomab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"CD-20-antigen-expressing, relapsed or refractory, low-grade, follicular, or transformed Non-Hodgkins lymphoma"},{"name":"CAS_Registry","value":"192391-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K1KT5M40JC"},{"name":"Legacy Concept Name","value":"I_131_Monoclonal_Antibody_Anti-B1"},{"name":"Maps_To","value":"Iodine I 131 Tositumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"42806"},{"name":"NSC Number","value":"715813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42806"},{"name":"PDQ_Open_Trial_Search_ID","value":"42806"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0768182"}]}}{"C1639":{"preferredName":"Iodine I-131","code":"C1639","definitions":[{"definition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I-131","termGroup":"PT","termSource":"NCI"},{"termName":"131-Iodine","termGroup":"SY","termSource":"NCI"},{"termName":"Bound Iodide I-131","termGroup":"SY","termSource":"NCI"},{"termName":"I 131","termGroup":"AB","termSource":"NCI"},{"termName":"I-131","termGroup":"AB","termSource":"NCI"},{"termName":"Iodide I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodide, I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine 131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131","termGroup":"SY","termSource":"NCI"},{"termName":"Iodotope","termGroup":"BR","termSource":"NCI"},{"termName":"Iodotrope","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hyperthyroidism"},{"name":"CAS_Registry","value":"10043-66-0"},{"name":"Chemical_Formula","value":"I"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I5X6L61HUT"},{"name":"Legacy Concept Name","value":"Iodine_131"},{"name":"Maps_To","value":"Iodine I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"43630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43630"},{"name":"PDQ_Open_Trial_Search_ID","value":"43630"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0303029"}]}}{"C80056":{"preferredName":"Ioflubenzamide I-131","code":"C80056","definitions":[{"definition":"An iodine 131-radiolabeled small-molecule benzamide compound with potential antineoplastic activity. The benzamide moiety of 131-I-MIP-1145 binds to melanin, selectively delivering a cyotoxic dose of gamma and beta radiation to melanin-expressing tumor cells. Melanin pigments, polymer derivatives of the amino acid tyrosine, are over-expressed in approximately 40% of melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ioflubenzamide I-131","termGroup":"PT","termSource":"NCI"},{"termName":"Ioflubenzamide (131I)","termGroup":"SY","termSource":"NCI"},{"termName":"MIP-1145","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-(diethylamino)ethyl)-4-((4-fluorobenzoyl)amino)-5-((sup 131)I)iodo-2-methoxybenzamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1214283-52-9"},{"name":"Chemical_Formula","value":"C21H25FIN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65O1D58Z6V"},{"name":"Legacy Concept Name","value":"Iodine_I_131_MIP-1145"},{"name":"Maps_To","value":"Ioflubenzamide I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"615097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615097"},{"name":"PDQ_Open_Trial_Search_ID","value":"615097"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934646"}]}}{"C596":{"preferredName":"Ionomycin","code":"C596","definitions":[{"definition":"A polyether antibiotic isolated from Streptomyces conglobatus sp. nov. Trejo with antineoplastic activity.  Ionomycin is a calcium ionophore that increases intracellular Ca++ levels, possibly relating to endonuclease activation of lymphocytes and decreased ratio of Bcl-2 to Bax and ultimately apoptosis.  In addition, this agent is used to investigate the role of intracellular calcium in cellular processes. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ionomycin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56092-81-0"},{"name":"CHEBI_ID","value":"CHEBI:63954"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54V905V6AT"},{"name":"Legacy Concept Name","value":"Ionomycin"},{"name":"Maps_To","value":"Ionomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"43046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43046"},{"name":"PDQ_Open_Trial_Search_ID","value":"43046"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0022020"}]}}{"C102565":{"preferredName":"Ipafricept","code":"C102565","definitions":[{"definition":"A proprietary fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with potential antineoplastic activity. Upon intravenous administration, ipafricept competes with the membrane-bound Fzd8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling. This may result in the inhibition of Wnt-driven tumor growth. Fzd8, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipafricept","termGroup":"PT","termSource":"NCI"},{"termName":"Fusion Protein For Immune Applications (fpia) Comprising Homo Sapiens FZD8 (Frizzled Family Receptor 8, Frizzled-8) Extracellular Domain, Fused With Homo Sapiens Immunoglobulin G1 Fc Fragment","termGroup":"SY","termSource":"NCI"},{"termName":"Fzd8-Fc","termGroup":"CN","termSource":"NCI"},{"termName":"OMP 54F28","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-54F28","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1391727-24-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2N71QUE3NL"},{"name":"Maps_To","value":"Ipafricept"},{"name":"NCI_Drug_Dictionary_ID","value":"734935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734935"},{"name":"PDQ_Open_Trial_Search_ID","value":"734935"},{"name":"PubMedID_Primary_Reference","value":"17545618"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4049114"}]}}{"C91072":{"preferredName":"Ipatasertib","code":"C91072","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipatasertib","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one","termGroup":"SN","termSource":"NCI"},{"termName":"GDC 0068","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0068","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0068","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7440","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7440","termGroup":"CN","termSource":"NCI"},{"termName":"RG7440","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1001264-89-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"524Y3IB4HQ"},{"name":"Maps_To","value":"Ipatasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"669600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"669600"},{"name":"PDQ_Open_Trial_Search_ID","value":"669600"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984014"}]}}{"C2654":{"preferredName":"Ipilimumab","code":"C2654","definitions":[{"definition":"A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipilimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 734016","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-734016","termGroup":"CN","termSource":"NCI"},{"termName":"BMS734016","termGroup":"CN","termSource":"NCI"},{"termName":"Ipilimumab Biosimilar CS1002","termGroup":"SY","termSource":"NCI"},{"termName":"MDX 010","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-010","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-CTLA4","termGroup":"AB","termSource":"NCI"},{"termName":"MDX010","termGroup":"CN","termSource":"NCI"},{"termName":"Yervoy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Unresectable or Metastatic Melanoma"},{"name":"CAS_Registry","value":"477202-00-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6T8C155666"},{"name":"Legacy Concept Name","value":"Anti-Cytotoxic_T-Lymphocyte-Associated_Antigen-4_Monoclonal_Antibody"},{"name":"Maps_To","value":"Ipilimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38447"},{"name":"NSC Number","value":"720801"},{"name":"NSC Number","value":"732442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38447"},{"name":"PDQ_Open_Trial_Search_ID","value":"38447"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1367202"}]}}{"C976":{"preferredName":"Ipomeanol","code":"C976","definitions":[{"definition":"A natural toxic furan isolated from a fungus-infected sweet potato (Ipomoea batatas) with potential antineoplastic activity.  Ipomeanol is activated by mixed function oxidases in vivo to its epoxide form, an alkylating agent that covalently binds cell macromolecules. This agent causes cell death by a p53-independent mechanism. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ipomeanol","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3-furanyl)-4-hydroxy-1-pentanone","termGroup":"SN","termSource":"NCI"},{"termName":"4-ipomeanol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"32954-58-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"URT1FLO407"},{"name":"Legacy Concept Name","value":"Ipomeanol"},{"name":"Maps_To","value":"Ipomeanol"},{"name":"NCI_Drug_Dictionary_ID","value":"38852"},{"name":"NSC Number","value":"349438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38852"},{"name":"PDQ_Open_Trial_Search_ID","value":"38852"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048420"}]}}{"C1070":{"preferredName":"Iproplatin","code":"C1070","definitions":[{"definition":"A synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death.  Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iproplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(OC-6-33)-dichlorodihydroxybis(2-propanamine)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"CHIP","termGroup":"AB","termSource":"NCI"},{"termName":"Diisopropylammine-trans-dihydroxymalonatoplatinum(IV)","termGroup":"SN","termSource":"NCI"},{"termName":"JM-9","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62928-11-4"},{"name":"CAS_Registry","value":"83291-20-7"},{"name":"Chemical_Formula","value":"2C3H9N.2Cl.Pt.2HO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5R9F9NE9Z2"},{"name":"Legacy Concept Name","value":"Iproplatin"},{"name":"Maps_To","value":"Iproplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39183"},{"name":"NSC Number","value":"256927"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39183"},{"name":"PDQ_Open_Trial_Search_ID","value":"39183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0057856"}]}}{"C164140":{"preferredName":"iPSC-derived CD16-expressing Natural Killer Cells FT516","code":"C164140","definitions":[{"definition":"An allogeneic, off-the-shelf, natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived CD16-expressing NK cells FT516 bind to the Fc portion of tumor cell-bound monoclonal antibodies and activate NK cell activation, cytokine secretion and antibody-dependent cellular cytotoxicity (ADCC). CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response. FT516 NK cells' hnCD16 Fc receptor prevents downregulation and optimizes binding to tumor-targeting antibodies for enhanced ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iPSC-derived CD16-expressing Natural Killer Cells FT516","termGroup":"PT","termSource":"NCI"},{"termName":"FT 516","termGroup":"CN","termSource":"NCI"},{"termName":"FT-516","termGroup":"CN","termSource":"NCI"},{"termName":"FT516","termGroup":"CN","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived CD16-expressing Natural Killer Cells FT516","termGroup":"SY","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived CD16-expressing NK Cells FT516","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3NBZ936ONT"},{"name":"Maps_To","value":"iPSC-derived CD16-expressing Natural Killer Cells FT516"},{"name":"NCI_Drug_Dictionary_ID","value":"799446"},{"name":"NCI_META_CUI","value":"CL977336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799446"},{"name":"PDQ_Open_Trial_Search_ID","value":"799446"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158438":{"preferredName":"iPSC-derived Natural Killer Cells FT500","code":"C158438","definitions":[{"definition":"A preparation of off-the-shelf, natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived natural killer cells FT500 bind to stress-induced ligands on tumor cells, leading to tumor cell lysis and release of tumor neoantigens. Additionally, iPSC-NK cells secrete inflammatory cytokines and chemokines including interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokines 3, 4, and 22 (CCL3, CCL4, and CCL22), and C-X-C motif chemokine 10 (CXCL10), thereby enhancing T-cell activity and recruitment to the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iPSC-derived Natural Killer Cells FT500","termGroup":"PT","termSource":"NCI"},{"termName":"FT 500","termGroup":"CN","termSource":"NCI"},{"termName":"FT-500","termGroup":"CN","termSource":"NCI"},{"termName":"FT500","termGroup":"CN","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived Natural Killer Cells FT500","termGroup":"SY","termSource":"NCI"},{"termName":"iPSC-derived NK Cells FT500","termGroup":"SY","termSource":"NCI"},{"termName":"iPSC-NK Cells FT500","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"iPSC-derived Natural Killer Cells FT500"},{"name":"NCI_Drug_Dictionary_ID","value":"801298"},{"name":"NCI_META_CUI","value":"CL937880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801298"},{"name":"PDQ_Open_Trial_Search_ID","value":"801298"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148455":{"preferredName":"Emavusertib","code":"C148455","definitions":[{"definition":"An orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential antineoplastic, immunomodulating and anti-inflammatory activities. Upon oral administration, emavusertib targets, binds to, and blocks the kinase activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. In addition, CA-4948 may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emavusertib","termGroup":"PT","termSource":"NCI"},{"termName":"AU 4948","termGroup":"CN","termSource":"NCI"},{"termName":"AU-4948","termGroup":"CN","termSource":"NCI"},{"termName":"CA 4948","termGroup":"CN","termSource":"NCI"},{"termName":"CA-4948","termGroup":"CN","termSource":"NCI"},{"termName":"CA4948","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948","termGroup":"SY","termSource":"NCI"},{"termName":"IRAK4 Inhibitor CA-4948","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801343-74-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MH5DMF9JKY"},{"name":"Maps_To","value":"IRAK4 Inhibitor CA-4948"},{"name":"NCI_Drug_Dictionary_ID","value":"794871"},{"name":"NCI_META_CUI","value":"CL551081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794871"},{"name":"PDQ_Open_Trial_Search_ID","value":"794871"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26441":{"preferredName":"Iratumumab","code":"C26441","definitions":[{"definition":"A fully human monoclonal antibody with potential antineoplastic activity.  MDX-060 is a fully humanized antibody that targets CD30, a member of the tumor necrosis factor receptor superfamily found on activated lymphocytes.  CD30 is over-expressed in various lymphoproliferative disorders, Hodgkin disease and other lymphomas, and other cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some lymphomas. Monoclonal antibodies are produced in the laboratory and can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Iratumumab","termGroup":"PT","termSource":"NCI"},{"termName":"MDX-060","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody MDX-060","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"640735-09-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AYH22O1B1U"},{"name":"Legacy Concept Name","value":"MDX-060_Monoclonal_Antibody"},{"name":"Maps_To","value":"Iratumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"301900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301900"},{"name":"PDQ_Open_Trial_Search_ID","value":"301900"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327954"}]}}{"C104270":{"preferredName":"Iridium Ir 192","code":"C104270","definitions":[{"definition":"A radioactive isotope of iridium. Iridium-192 emits gamma rays and has a half-life of 74 days. A high dose rate of this radioisotope can be used in brachytherapy to treat tumors by selectively delivering a cytotoxic dose of radiation to the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iridium Ir 192","termGroup":"PT","termSource":"NCI"},{"termName":"Ir-192","termGroup":"AB","termSource":"NCI"},{"termName":"Iridium-192","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"14694-69-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"064LI0IBFL"},{"name":"Maps_To","value":"Iridium Ir 192"},{"name":"NCI_Drug_Dictionary_ID","value":"744818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744818"},{"name":"PDQ_Open_Trial_Search_ID","value":"744818"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C0303472"}]}}{"C62040":{"preferredName":"Irinotecan","code":"C62040","definitions":[{"definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Irinotecan","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"[1,4'-bipiperidine]-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97682-44-5"},{"name":"Chemical_Formula","value":"C33H38N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7673326042"},{"name":"Legacy Concept Name","value":"Irinotecan_Base"},{"name":"Maps_To","value":"Irinotecan"},{"name":"NSC Number","value":"616348"},{"name":"NSC Number","value":"728073"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0123931"}]}}{"C1381":{"preferredName":"Irinotecan Hydrochloride","code":"C1381","definitions":[{"definition":"A drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Camptosar blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Campto","termGroup":"FB","termSource":"NCI"},{"termName":"Camptosar","termGroup":"BR","termSource":"NCI"},{"termName":"Camptothecin-11","termGroup":"SY","termSource":"NCI"},{"termName":"CPT-11","termGroup":"CN","termSource":"NCI"},{"termName":"CPT11","termGroup":"CN","termSource":"NCI"},{"termName":"Irinomedac","termGroup":"FB","termSource":"NCI"},{"termName":"Irinotecan Hydrochloride Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Monohydrochloride Trihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"U 101440E","termGroup":"CN","termSource":"NCI"},{"termName":"U-101440E","termGroup":"CN","termSource":"NCI"},{"termName":"U101440E","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"State IVB Cervical cancer; Colorectal cancer; Esophageal cancer; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer"},{"name":"CAS_Registry","value":"136572-09-3"},{"name":"Chemical_Formula","value":"C33H38N4O6.HCl.3H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"042LAQ1IIS"},{"name":"Legacy Concept Name","value":"Irinotecan"},{"name":"Maps_To","value":"Irinotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41714"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41714"},{"name":"PDQ_Open_Trial_Search_ID","value":"41714"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0594375"}]}}{"C82682":{"preferredName":"Irinotecan-Eluting Beads","code":"C82682","definitions":[{"definition":"Microporous hydrospheres of polyvinylalcohol (PVA) impregnated with irinotecan with potential antineoplastic activity. In transarterial chemoembolization (TACE), irinotecan-eluting beads are administered into blood vessels that feed the tumor, occluding tumor blood vessels and inducing ischemic tumor necrosis while simultaneously delivering high-dose chemotherapy locally. Irinotecan, a semisynthetic derivative of camptothecin, inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan-Eluting Beads","termGroup":"PT","termSource":"NCI"},{"termName":"CM-BC2","termGroup":"CN","termSource":"NCI"},{"termName":"Irinotecan Hydrochloride Drug-eluting Beads","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Irinotecan-Eluting_Beads"},{"name":"Maps_To","value":"Irinotecan-Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"632992"},{"name":"NCI_META_CUI","value":"CL388467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632992"},{"name":"PDQ_Open_Trial_Search_ID","value":"632992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88280":{"preferredName":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet","code":"C88280","definitions":[{"definition":"An orally bioavailable combination tablet containing the semisynthetic camptothecin derivative irinotecan and the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181AK, with potential antineoplastic activity. HM30181A binds to P-gp and prevents the P-gp-mediated efflux of irinotecan from tumor cells, which may result in greater intracellular concentrations of irinotecan and enhanced cytotoxicity. Retained intracellularly, the prodrug irinotecan is converted, by a carboxylesterase-converting enzyme, to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38). SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters and is overexpressed by some MDR tumors, preventing the intracellular accumulation of various cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet","termGroup":"PT","termSource":"NCI"},{"termName":"Oratecan","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet"},{"name":"NCI_Drug_Dictionary_ID","value":"656527"},{"name":"NCI_META_CUI","value":"CL412470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656527"},{"name":"PDQ_Open_Trial_Search_ID","value":"656527"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1717":{"preferredName":"Irofulven","code":"C1717","definitions":[{"definition":"A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. Irofulven attaches to the cell's DNA and may block cancer cell growth. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Irofulven","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"6-Hydroxymethylacylfulvene","termGroup":"SY","termSource":"NCI"},{"termName":"HMAF","termGroup":"AB","termSource":"NCI"},{"termName":"Hydroxymethylacylfulvene","termGroup":"SY","termSource":"NCI"},{"termName":"MGI 114","termGroup":"CN","termSource":"NCI"},{"termName":"MGI-114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"158440-71-2"},{"name":"Chemical_Formula","value":"C15H18O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6B799IH05A"},{"name":"Legacy Concept Name","value":"Irofulven"},{"name":"Maps_To","value":"Irofulven"},{"name":"NCI_Drug_Dictionary_ID","value":"43097"},{"name":"NSC Number","value":"683863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43097"},{"name":"PDQ_Open_Trial_Search_ID","value":"43097"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0532362"}]}}{"C79827":{"preferredName":"Irosustat","code":"C79827","definitions":[{"definition":"Steroid sulfatase inhibitor BN 83495 selectively binds to and inhibits steroid sulfatase (STS), which may inhibit the production of locally active estrogens and so inhibit estrogen-dependent cell growth in tumor cells, such as those of the breast, ovary, and endometrium. STS is a cytoplasmic enzyme responsible for the conversion of circulating inactive estrone sulfate and estradiol sulfate to biologically active unconjugated estrone and estradiol, respectively.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irosustat","termGroup":"PT","termSource":"NCI"},{"termName":"667 Coumate","termGroup":"SY","termSource":"NCI"},{"termName":"BN83495","termGroup":"CN","termSource":"NCI"},{"termName":"Steroid Sulfatase Inhibitor BN 83495","termGroup":"SY","termSource":"NCI"},{"termName":"STX 64","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"288628-05-7"},{"name":"Chemical_Formula","value":"C14H15NO5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"366037O6O7"},{"name":"Legacy Concept Name","value":"Steroid_Sulfatase_Inhibitor_BN_83495"},{"name":"Maps_To","value":"Irosustat"},{"name":"NCI_Drug_Dictionary_ID","value":"626715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626715"},{"name":"PDQ_Open_Trial_Search_ID","value":"626715"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853843"}]}}{"C90578":{"preferredName":"Isatuximab","code":"C90578","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isatuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Hu 38SB19","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human CD38 Antigen) (Human-mus musculus Monoclonal HU38SB19 Heavy Chain), Disulfide with Human-mus musculus Monoclonal HU38SB19 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Isatuximab-irfc","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 650984","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-650984","termGroup":"CN","termSource":"NCI"},{"termName":"SAR650984","termGroup":"CN","termSource":"NCI"},{"termName":"Sarclisa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1461640-62-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R30772KCU0"},{"name":"Maps_To","value":"Isatuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"668181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"668181"},{"name":"PDQ_Open_Trial_Search_ID","value":"668181"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983777"}]}}{"C97332":{"preferredName":"Iso-fludelone","code":"C97332","definitions":[{"definition":"A third-generation epothilone B analogue with potential anti-mitotic and antineoplastic activites. Iso-fludelone binds to tubulin and induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to other generations of epothilones, iso-fludelone exhibits increased stability, water solubility, potency, duration of action, tumor penetration as well as reduced toxicity. In addition, this agent is a not a substrate of the P-glycoprotein (P-gp), a multidrug resistance pump often overexpressed in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iso-fludelone","termGroup":"PT","termSource":"NCI"},{"termName":"17-Iso-oxazole-26-F3-9,10-dehydro-12,13-desoxy-epothilone B","termGroup":"SN","termSource":"NCI"},{"termName":"17-Iso-oxazole-fludelone","termGroup":"SY","termSource":"NCI"},{"termName":"KOS-1803","termGroup":"CN","termSource":"NCI"},{"termName":"KOSN-1724","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"693272-98-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6MUO20693U"},{"name":"Maps_To","value":"Iso-fludelone"},{"name":"NCI_Drug_Dictionary_ID","value":"703135"},{"name":"NCI_META_CUI","value":"CL429824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703135"},{"name":"PDQ_Open_Trial_Search_ID","value":"703135"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1774":{"preferredName":"Isobrucein B","code":"C1774","definitions":[{"definition":"A quassinoid phytochemical isolated from the tropical plant Cedronia granatensis with potential antineoplastic and chemopreventive activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isobrucein B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53663-03-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Isobrucein_B"},{"name":"Maps_To","value":"Isobrucein B"},{"name":"NSC Number","value":"238181"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0653458"}]}}{"C1888":{"preferredName":"Isocoumarin NM-3","code":"C1888","definitions":[{"definition":"An orally bioavailable antiangiogenic isocoumarin with potential antineoplastic activity.  NM-3 inhibits vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor, thereby inhibiting endothelial cell proliferation.  This agent also induces apoptosis by a mechanism involving reactive oxygen species. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isocoumarin NM-3","termGroup":"PT","termSource":"NCI"},{"termName":"NM-3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"181427-78-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5797K23F95"},{"name":"Legacy Concept Name","value":"NM-3"},{"name":"Maps_To","value":"Isocoumarin NM-3"},{"name":"NCI_Drug_Dictionary_ID","value":"355804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355804"},{"name":"PDQ_Open_Trial_Search_ID","value":"355804"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122058"}]}}{"C603":{"preferredName":"Isotretinoin","code":"C603","definitions":[{"definition":"A drug that is used in the treatment of acne and psoriasis and is being studied in cancer prevention. It is a type of retinoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Isotretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"13-cis-Retinoate","termGroup":"SY","termSource":"NCI"},{"termName":"13-cis-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"13-cis-Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"13-cRA","termGroup":"AB","termSource":"NCI"},{"termName":"3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Absorica","termGroup":"BR","termSource":"NCI"},{"termName":"Accure","termGroup":"FB","termSource":"NCI"},{"termName":"Accutane","termGroup":"BR","termSource":"NCI"},{"termName":"Amnesteem","termGroup":"BR","termSource":"NCI"},{"termName":"cis-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Cistane","termGroup":"BR","termSource":"NCI"},{"termName":"Claravis","termGroup":"BR","termSource":"NCI"},{"termName":"Isotretinoinum","termGroup":"SY","termSource":"NCI"},{"termName":"Isotrex","termGroup":"FB","termSource":"NCI"},{"termName":"Isotrexin","termGroup":"FB","termSource":"NCI"},{"termName":"Myorisan","termGroup":"BR","termSource":"NCI"},{"termName":"Neovitamin A","termGroup":"SY","termSource":"NCI"},{"termName":"Neovitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Oratane","termGroup":"FB","termSource":"NCI"},{"termName":"Retinoicacid-13-cis","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 4-3780","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-4-3780","termGroup":"CN","termSource":"NCI"},{"termName":"Roaccutan","termGroup":"FB","termSource":"NCI"},{"termName":"Roaccutane","termGroup":"FB","termSource":"NCI"},{"termName":"Roacutan","termGroup":"FB","termSource":"NCI"},{"termName":"Sotret","termGroup":"BR","termSource":"NCI"},{"termName":"ZENATANE","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Severe recalcitrant nodular acne; psoriasis; cornification disorders; cutaneous T-cell lymphoma; juvenile metastatic neuroblastoma and leukemia"},{"name":"CAS_Registry","value":"4759-48-2"},{"name":"CHEBI_ID","value":"CHEBI:6067"},{"name":"Chemical_Formula","value":"C20H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"EH28UP18IF"},{"name":"Legacy Concept Name","value":"Isotretinoin"},{"name":"Maps_To","value":"Isotretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"42657"},{"name":"NSC Number","value":"329481"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42657"},{"name":"PDQ_Open_Trial_Search_ID","value":"42657"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0022265"}]}}{"C38131":{"preferredName":"Ispinesib","code":"C38131","definitions":[{"definition":"A substance being studied in the treatment of cancer. Ispinesib blocks a protein that tumor cells need to divide. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ispinesib","termGroup":"PT","termSource":"NCI"},{"termName":"CK0238273","termGroup":"CN","termSource":"NCI"},{"termName":"SB-715992","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"336113-53-2"},{"name":"Chemical_Formula","value":"C30H33ClN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BKT5F9C2NI"},{"name":"Legacy Concept Name","value":"SB-715992"},{"name":"Maps_To","value":"Ispinesib"},{"name":"NCI_Drug_Dictionary_ID","value":"391236"},{"name":"NSC Number","value":"727990"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391236"},{"name":"PDQ_Open_Trial_Search_ID","value":"391236"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527260"}]}}{"C77518":{"preferredName":"Ispinesib Mesylate","code":"C77518","definitions":[{"definition":"The mesylate salt form of ispinesib, a synthetic small molecule, derived from quinazolinone, and kinesin spindle protein (KSP) inhibitor, with antineoplastic activity. Ispinesib selectively inhibits KSP and prevents its binding to microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the M-phase, and cell death in tumor cells that are actively dividing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ispinesib Mesylate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"514820-03-2"},{"name":"Chemical_Formula","value":"C30H33ClN4O2.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R6ZMD4UH3D"},{"name":"Legacy Concept Name","value":"Ispinesib_Mesylate"},{"name":"Maps_To","value":"Ispinesib Mesylate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697824"}]}}{"C61080":{"preferredName":"ISS 1018 CpG Oligodeoxynucleotide","code":"C61080","definitions":[{"definition":"A short, synthetic, unmethylated CpG motif-based oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. As an immunostimulatory sequence (ISS) that signals through Toll-like receptor 9 (TLR9), ISS 1018 CpG ODN induces the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin (IL) -12, and tumor necrosis factor (TNF) -alpha by plasmacytoid dendritic cells (pDC). pDC, through cell-cell contact, and IFN-alpha and -beta, in turn, induce natural killer (NK) cell proliferation, NK cell production of IFN-gamma, and NK cell-mediated cytotoxicity; secreted IFNs also stimulate bystander T cell activation and differentiation of naive CD4+ T cells into T-helper 1 cells on specific antigen challenge. In addition, ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ISS 1018 CpG Oligodeoxynucleotide","termGroup":"PT","termSource":"NCI"},{"termName":"1018 ISS","termGroup":"SY","termSource":"NCI"},{"termName":"CPG 1018","termGroup":"CN","termSource":"NCI"},{"termName":"DNA, D(P-THIO)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"937402-51-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25DT549L0G"},{"name":"Legacy Concept Name","value":"ISS1018_Oligodeoxynucleotide"},{"name":"Maps_To","value":"ISS 1018 CpG Oligodeoxynucleotide"},{"name":"NCI_Drug_Dictionary_ID","value":"474964"},{"name":"PDQ_Closed_Trial_Search_ID","value":"474964"},{"name":"PDQ_Open_Trial_Search_ID","value":"474964"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506199"}]}}{"C116855":{"preferredName":"Itacitinib","code":"C116855","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itacitinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Azetidineacetonitrile, 1-(1-((3-Fluoro-2-(trifluoromethyl)-4-pyridinyl)carbonyl)-4-piperidinyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 039110","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-039110","termGroup":"CN","termSource":"NCI"},{"termName":"INCB039110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1334298-90-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19J3781LPM"},{"name":"Maps_To","value":"Itacitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"740328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740328"},{"name":"PDQ_Open_Trial_Search_ID","value":"740328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896836"}]}}{"C158906":{"preferredName":"Itacitinib Adipate","code":"C158906","definitions":[{"definition":"The adipate salt form of itacitinib, an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itacitinib Adipate","termGroup":"PT","termSource":"NCI"},{"termName":"INCB-039110 Adipate","termGroup":"SY","termSource":"NCI"},{"termName":"INCB039110 Adipate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1334302-63-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XZG407XE0Y"},{"name":"Maps_To","value":"Itacitinib Adipate"},{"name":"NCI_Drug_Dictionary_ID","value":"740328"},{"name":"NCI_META_CUI","value":"CL950797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740328"},{"name":"PDQ_Open_Trial_Search_ID","value":"740328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162010":{"preferredName":"Soquelitinib","code":"C162010","definitions":[{"definition":"An orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) with potential immunomodulatory and antineoplastic activities. Upon oral administration, soquelitinib selectively and covalently binds to the cysteine residue at position 442 (CYS-442) of ITK, thereby disrupting ITK-mediated signal transduction, while sparing tyrosine-protein kinase TXK (resting lymphocyte kinase, RLK) activity. This may abrogate T-cell receptor (TCR) signaling through ITK and inhibit TCR-induced proliferation of malignant T-cells. Additionally, inhibiting ITK activation may prevent the upregulation of GATA-3, a transcription factor that drives T-helper 2 (Th2) cell differentiation and is overexpressed in certain T-cell lymphomas. Thus, selective inhibition of ITK may inhibit Th2 responses without affecting T-helper 1 (Th1)-dependent immunity. ITK, a member of the Tec family of non-receptor protein tyrosine kinases plays a significant role in the T-cell development, differentiation and production of pro-inflammatory cytokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soquelitinib","termGroup":"PT","termSource":"NCI"},{"termName":"CPI 818","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-818","termGroup":"CN","termSource":"NCI"},{"termName":"CPI818","termGroup":"CN","termSource":"NCI"},{"termName":"Interleukin-2 Inducible T-cell Kinase Inhibitor CPI-818","termGroup":"SY","termSource":"NCI"},{"termName":"ITK Inhibitor CPI-818","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226636-04-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6I5H17AN3I"},{"name":"Maps_To","value":"ITK Inhibitor CPI-818"},{"name":"NCI_Drug_Dictionary_ID","value":"798593"},{"name":"NCI_META_CUI","value":"CL970662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798593"},{"name":"PDQ_Open_Trial_Search_ID","value":"798593"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1138":{"preferredName":"Itraconazole","code":"C1138","definitions":[{"definition":"A drug used to prevent or treat fungal infections.  It belongs to the family of drugs called antifungal agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itraconazole","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one","termGroup":"SN","termSource":"NCI"},{"termName":"Lozanoc","termGroup":"FB","termSource":"NCI"},{"termName":"Oriconazole","termGroup":"SY","termSource":"NCI"},{"termName":"R 51,211","termGroup":"CN","termSource":"NCI"},{"termName":"Sporanox","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Fungal Infections"},{"name":"CAS_Registry","value":"84625-61-6"},{"name":"CHEBI_ID","value":"CHEBI:6076"},{"name":"Chemical_Formula","value":"C35H38Cl2N8O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"304NUG5GF4"},{"name":"Legacy Concept Name","value":"Itraconazole"},{"name":"Maps_To","value":"Itraconazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39106"},{"name":"PDQ_Open_Trial_Search_ID","value":"39106"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064113"}]}}{"C104048":{"preferredName":"Itraconazole Dispersion In Polymer Matrix","code":"C104048","definitions":[{"definition":"A proprietary oral formulation composed of the poorly soluble, synthetic triazole agent, itraconazole, dispersed in a polymer matrix, with antifungal and potential anti-angiogenic activities. Upon oral administration, itraconazole inhibits the enzyme cytochrome P450 lanosterol 14 alpha-demethylase, resulting in a decrease in fungal ergosterol synthesis. Although the exact mechanism through which itraconazole inhibits angiogenesis has yet to be fully elucidated, this agent appears to inhibit the Hedgehog (Hh) signaling pathway, cholesterol synthesis and mammalian target of rapamycin (mTOR) signaling in endothelial cells. This agent may also prevent the activation of and signaling by various angiogenic growth factors. By decreasing the tumor vasculature and nutrient supply, itraconazole ultimately inhibits tumor cell growth. The solid dispersion of itraconazole in the polymer matrix enhances dissolution of itraconazole in the gastrointestinal tract and increases its bioavailability; this allows for the administration of a much lower dose compared to itraconazole alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Itraconazole Dispersion In Polymer Matrix","termGroup":"PT","termSource":"NCI"},{"termName":"SUBA-Itraconazole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Itraconazole Dispersion In Polymer Matrix"},{"name":"NCI_Drug_Dictionary_ID","value":"744267"},{"name":"NCI_META_CUI","value":"CL439067"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744267"},{"name":"PDQ_Open_Trial_Search_ID","value":"744267"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114383":{"preferredName":"Ivosidenib","code":"C114383","definitions":[{"definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivosidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AG 120","termGroup":"CN","termSource":"NCI"},{"termName":"AG-120","termGroup":"CN","termSource":"NCI"},{"termName":"AG120","termGroup":"CN","termSource":"NCI"},{"termName":"Tibsovo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation"},{"name":"CAS_Registry","value":"1448347-49-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q2PCN8MAM6"},{"name":"Maps_To","value":"Ivosidenib"},{"name":"NCI_Drug_Dictionary_ID","value":"758551"},{"name":"NCI_META_CUI","value":"CL471818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758551"},{"name":"PDQ_Open_Trial_Search_ID","value":"758551"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C37452":{"preferredName":"Ixabepilone","code":"C37452","definitions":[{"definition":"A drug used to treat metastatic or locally advanced breast cancer that has not improved after treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Ixempra stops the growth of tumor cells by blocking cell division. It is a type of epothilone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ixabepilone","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Azaepothilone B","termGroup":"SY","termSource":"NCI"},{"termName":"BMS 247550","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-247550","termGroup":"CN","termSource":"NCI"},{"termName":"BMS247550","termGroup":"CN","termSource":"NCI"},{"termName":"Epothilone","termGroup":"SY","termSource":"NCI"},{"termName":"Epothilone-B BMS 247550","termGroup":"SY","termSource":"NCI"},{"termName":"Ixempra","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic or locally advanced breast cancer."},{"name":"CAS_Registry","value":"219989-84-1"},{"name":"CHEBI_ID","value":"CHEBI:63605"},{"name":"Chemical_Formula","value":"C27H42N2O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K27005NP0A"},{"name":"Legacy Concept Name","value":"Ixabepilone"},{"name":"Maps_To","value":"Ixabepilone"},{"name":"NCI_Drug_Dictionary_ID","value":"37860"},{"name":"NSC Number","value":"710428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37860"},{"name":"PDQ_Open_Trial_Search_ID","value":"37860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1135132"}]}}{"C97940":{"preferredName":"Ixazomib","code":"C97940","definitions":[{"definition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ixazomib","termGroup":"PT","termSource":"NCI"},{"termName":"MLN 2238","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-2238","termGroup":"CN","termSource":"NCI"},{"termName":"MLN2238","termGroup":"CN","termSource":"NCI"},{"termName":"{(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1072833-77-2"},{"name":"Chemical_Formula","value":"C14H19BCl2N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"71050168A2"},{"name":"Maps_To","value":"Ixazomib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467949"}]}}{"C82653":{"preferredName":"Ixazomib Citrate","code":"C82653","definitions":[{"definition":"The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ixazomib Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,2-dioxaborinane-4-acetic acid, 4-carboxy-2-((1r)-1-((2-((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl)-6-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"MLN 9708","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-9708","termGroup":"CN","termSource":"NCI"},{"termName":"MLN9708","termGroup":"CN","termSource":"NCI"},{"termName":"Ninlaro","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma (MM)"},{"name":"CAS_Registry","value":"1239908-20-3"},{"name":"Chemical_Formula","value":"C20H23BCl2N2O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46CWK97Z3K"},{"name":"Legacy Concept Name","value":"Proteasome_Inhibitor_MLN9708"},{"name":"Maps_To","value":"Ixazomib Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"635527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"635527"},{"name":"PDQ_Open_Trial_Search_ID","value":"635527"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830202"}]}}{"C111761":{"preferredName":"JAK Inhibitor INCB047986","code":"C111761","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinases (JAK), with potential antineoplastic activity. Upon oral administration, INCB047986 specifically binds to and inhibits the phosphorylation of JAK, which affects JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK Inhibitor INCB047986","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 047986","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-047986","termGroup":"CN","termSource":"NCI"},{"termName":"INCB047986","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JAK Inhibitor INCB047986"},{"name":"NCI_Drug_Dictionary_ID","value":"753081"},{"name":"NCI_META_CUI","value":"CL454148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753081"},{"name":"PDQ_Open_Trial_Search_ID","value":"753081"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156774":{"preferredName":"Golidocitinib","code":"C156774","definitions":[{"definition":"An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golidocitinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 4205","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-4205","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4205","termGroup":"CN","termSource":"NCI"},{"termName":"JAK1 Inhibitor AZD4205","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2091134-68-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3BY9Z3M34G"},{"name":"Maps_To","value":"JAK1 Inhibitor AZD4205"},{"name":"NCI_Drug_Dictionary_ID","value":"795786"},{"name":"NCI_META_CUI","value":"CL935810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795786"},{"name":"PDQ_Open_Trial_Search_ID","value":"795786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118629":{"preferredName":"JAK1 Inhibitor INCB052793","code":"C118629","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, INCB052793 specifically binds to and inhibits the phosphorylation of JAK1, which interferes with JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK1 Inhibitor INCB052793","termGroup":"PT","termSource":"NCI"},{"termName":"INCB052793","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JAK1 Inhibitor INCB052793"},{"name":"NCI_Drug_Dictionary_ID","value":"765639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765639"},{"name":"PDQ_Open_Trial_Search_ID","value":"765639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896740"}]}}{"C91394":{"preferredName":"JAK2 Inhibitor AZD1480","code":"C91394","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Inhibitor AZD1480","termGroup":"PT","termSource":"NCI"},{"termName":"AZD1480","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"935666-88-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KL2Z2TLF01"},{"name":"Maps_To","value":"JAK2 Inhibitor AZD1480"},{"name":"NCI_Drug_Dictionary_ID","value":"672901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672901"},{"name":"PDQ_Open_Trial_Search_ID","value":"672901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2745423"}]}}{"C95702":{"preferredName":"JAK2 Inhibitor BMS-911543","code":"C95702","definitions":[{"definition":"An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS-911543 selectively inhibits JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Inhibitor BMS-911543","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 911543","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-911543","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1271022-90-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7N03P021J8"},{"name":"Maps_To","value":"JAK2 Inhibitor BMS-911543"},{"name":"NCI_Drug_Dictionary_ID","value":"689517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689517"},{"name":"PDQ_Open_Trial_Search_ID","value":"689517"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987343"}]}}{"C90573":{"preferredName":"JAK2 Inhibitor XL019","code":"C90573","definitions":[{"definition":"An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. XL019 inhibits the activation of JAK2 as well as the mutated form JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and may induce apoptosis. The JAK2 mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK2 Inhibitor XL019","termGroup":"PT","termSource":"NCI"},{"termName":"XL019","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945755-56-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4L1AM42NVA"},{"name":"Maps_To","value":"JAK2 Inhibitor XL019"},{"name":"NCI_Drug_Dictionary_ID","value":"667451"},{"name":"NCI_META_CUI","value":"CL416257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"667451"},{"name":"PDQ_Open_Trial_Search_ID","value":"667451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98109":{"preferredName":"Ilginatinib","code":"C98109","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. Ilginatinib competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, ilginatinib inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs); JAK2V617F is a constitutively activated kinase that activates the JAK/STAT signaling pathway and dysregulates cell growth and function, and its expression transforms hematopoietic cells to cytokine-independent growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ilginatinib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-","termGroup":"SN","termSource":"NCI"},{"termName":"NS-018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1239358-86-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56R994WX4L"},{"name":"Maps_To","value":"Ilginatinib"},{"name":"Maps_To","value":"JAK2/Src Inhibitor NS-018"},{"name":"NCI_Drug_Dictionary_ID","value":"710644"},{"name":"NCI_META_CUI","value":"CL430628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710644"},{"name":"PDQ_Open_Trial_Search_ID","value":"710644"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61316":{"preferredName":"Jin Fu Kang","code":"C61316","definitions":[{"definition":"A traditional Chinese herbal medicine derived from the plant Astragalus membranaceus with potential immunopotentiation activity. Jin Fu Kang may stimulate anti-tumor macrophage and natural killer cell activity and may enhance immune recognition of tumor cells by inhibiting the production of T-helper cell type 2 (Th2) cytokines such as interleukin-4 (IL-4) and interleukin-10 (IL-10).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Jin Fu Kang","termGroup":"PT","termSource":"NCI"},{"termName":"Jinfukang","termGroup":"SY","termSource":"NCI"},{"termName":"Jinfukang Koufuye","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Jin_Fu_Kang"},{"name":"Maps_To","value":"Jin Fu Kang"},{"name":"NCI_Drug_Dictionary_ID","value":"484642"},{"name":"PDQ_Closed_Trial_Search_ID","value":"484642"},{"name":"PDQ_Open_Trial_Search_ID","value":"484642"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831812"}]}}{"C49095":{"preferredName":"JNK Inhibitor CC-401","code":"C49095","definitions":[{"definition":"A second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. Based on the chemistry of SP600125, another anthrapyrazolone inhibitor of JNK, CC-401 competitively binds the ATP binding site of JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of transcription factor c-Jun; decreased transcription activity of c-Jun; and a variety of cellular effects including decreased cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JNK Inhibitor CC-401","termGroup":"PT","termSource":"NCI"},{"termName":"CC-401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"395104-30-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NOE38VQA1W"},{"name":"Legacy Concept Name","value":"CC-401"},{"name":"Maps_To","value":"JNK Inhibitor CC-401"},{"name":"NCI_Drug_Dictionary_ID","value":"453550"},{"name":"NCI_META_CUI","value":"CL937289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453550"},{"name":"PDQ_Open_Trial_Search_ID","value":"453550"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91705":{"preferredName":"Kanglaite","code":"C91705","definitions":[{"definition":"An injectable microemulsion of a purified oil extracted from the seeds of the traditional Chinese medicinal herb Coix lacryma-jobi (Job's tears), with potential antineoplastic activity. Although the exact mechanism of action is unknown, kanglaite exhibits an antineoplastic effect, potentially via interfering with the cell cycle and halting tumor cells in the G2/M phase, which may eventually inhibit mitosis and proliferation of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kanglaite","termGroup":"PT","termSource":"NCI"},{"termName":"Coicis Semen Oil","termGroup":"SY","termSource":"NCI"},{"termName":"KLT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YCB6D9ELEQ"},{"name":"Maps_To","value":"Kanglaite"},{"name":"NCI_Drug_Dictionary_ID","value":"361791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"361791"},{"name":"PDQ_Open_Trial_Search_ID","value":"361791"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1568044"}]}}{"C605":{"preferredName":"Ketoconazole","code":"C605","definitions":[{"definition":"A drug that treats infection caused by a fungus. It is also used as a treatment for prostate cancer because it can block the production of male sex hormones.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ketoconazole","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine","termGroup":"SN","termSource":"NCI"},{"termName":"Fungarest","termGroup":"FB","termSource":"NCI"},{"termName":"Fungoral","termGroup":"FB","termSource":"NCI"},{"termName":"Ketoderm","termGroup":"FB","termSource":"NCI"},{"termName":"Ketoisdin","termGroup":"FB","termSource":"NCI"},{"termName":"Nizoral","termGroup":"BR","termSource":"NCI"},{"termName":"Orifungal M","termGroup":"FB","termSource":"NCI"},{"termName":"Panfungol","termGroup":"FB","termSource":"NCI"},{"termName":"R-41400","termGroup":"CN","termSource":"NCI"},{"termName":"Xolegel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Seborrheic Dermatitis; Prostate cancer"},{"name":"CAS_Registry","value":"65277-42-1"},{"name":"CHEBI_ID","value":"CHEBI:47519"},{"name":"Chemical_Formula","value":"C26H28Cl2N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"R9400W927I"},{"name":"Legacy Concept Name","value":"Ketoconazole"},{"name":"Maps_To","value":"Ketoconazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39488"},{"name":"NSC Number","value":"317629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39488"},{"name":"PDQ_Open_Trial_Search_ID","value":"39488"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0022625"}]}}{"C77403":{"preferredName":"Ketotrexate","code":"C77403","definitions":[{"definition":"A folic acid antagonist and mammalian dihydrofolate reductase inhibitor with antineoplastic activity. Ketotrexate inhibits dihydrofolate reductase, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid which is essential for the synthesis of purine nucleotides and thymidylate. By depleting tetrahydrofolic acid availability, DNA synthesis is halted.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ketotrexate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"877017-93-1"},{"name":"Chemical_Formula","value":"C21H27N7O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"504RN634MM"},{"name":"Legacy Concept Name","value":"Ketotrexate"},{"name":"Maps_To","value":"Ketotrexate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697842"}]}}{"C157493":{"preferredName":"Adagrasib","code":"C157493","definitions":[{"definition":"An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adagrasib","termGroup":"PT","termSource":"NCI"},{"termName":"KRAS G12C Inhibitor MRTX849","termGroup":"SY","termSource":"NCI"},{"termName":"Krazati","termGroup":"BR","termSource":"NCI"},{"termName":"MRTX 849","termGroup":"CN","termSource":"NCI"},{"termName":"MRTX-849","termGroup":"CN","termSource":"NCI"},{"termName":"MRTX849","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)."},{"name":"CAS_Registry","value":"2326521-71-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8EOO6HQF8Y"},{"name":"Maps_To","value":"KRAS G12C Inhibitor MRTX849"},{"name":"NCI_Drug_Dictionary_ID","value":"796791"},{"name":"NCI_META_CUI","value":"CL937069"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796791"},{"name":"PDQ_Open_Trial_Search_ID","value":"796791"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154287":{"preferredName":"Sotorasib","code":"C154287","definitions":[{"definition":"An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotorasib","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 510","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-510","termGroup":"CN","termSource":"NCI"},{"termName":"AMG510","termGroup":"CN","termSource":"NCI"},{"termName":"Lumakras","termGroup":"BR","termSource":"NCI"},{"termName":"Lumykras","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"2296729-00-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2B2VM6UC8G"},{"name":"Maps_To","value":"KRAS Mutant-targeting AMG 510"},{"name":"Maps_To","value":"Sotorasib"},{"name":"NCI_Drug_Dictionary_ID","value":"794411"},{"name":"NCI_META_CUI","value":"CL555284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794411"},{"name":"PDQ_Open_Trial_Search_ID","value":"794411"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164218":{"preferredName":"SHP2 Inhibitor JAB-3312","code":"C164218","definitions":[{"definition":"An orally bioavailable allosteric inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3312 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements, which are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP2 Inhibitor JAB-3312","termGroup":"PT","termSource":"NCI"},{"termName":"JAB 3312","termGroup":"CN","termSource":"NCI"},{"termName":"JAB-3312","termGroup":"CN","termSource":"NCI"},{"termName":"JAB3312","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"KRAS-MAPK Signaling Pathway Inhibitor JAB-3312"},{"name":"NCI_Drug_Dictionary_ID","value":"799443"},{"name":"NCI_META_CUI","value":"CL977520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799443"},{"name":"PDQ_Open_Trial_Search_ID","value":"799443"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1614":{"preferredName":"KRN5500","code":"C1614","definitions":[{"definition":"A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces alanosinicus.  KRN 5500 inhibits protein synthesis by interfering with endoplasmic reticulum and Golgi apparatus functions.  This agent also induces cell differentiation and caspase-dependent apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to a family of drugs called antitumor antibiotics. It is an anthracycline.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"KRN5500","termGroup":"PT","termSource":"NCI"},{"termName":"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-beta-L-mannohepto-pyranosyl]amino-9H-purine","termGroup":"SN","termSource":"NCI"},{"termName":"KRN5500","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151276-95-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8VH13L5K20"},{"name":"Legacy Concept Name","value":"KRN5500"},{"name":"Maps_To","value":"KRN5500"},{"name":"NCI_Drug_Dictionary_ID","value":"42581"},{"name":"NSC Number","value":"650426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42581"},{"name":"PDQ_Open_Trial_Search_ID","value":"42581"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0294829"}]}}{"C64522":{"preferredName":"KSP Inhibitor AZD4877","code":"C64522","definitions":[{"definition":"A synthetic kinesin spindle protein (KSP) inhibitor with potential antineoplastic activity. AZD4877 selectively inhibits microtubule motor protein KSP (also called kinesin-5 or Eg5), which is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis. Inhibition of KSP results in an inhibition of mitotic spindle assembly, activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, thereby causing cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, AZD4877 may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KSP Inhibitor AZD4877","termGroup":"PT","termSource":"NCI"},{"termName":"AZD4877","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1176760-49-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19ORU63E06"},{"name":"Legacy Concept Name","value":"AZD4877"},{"name":"Maps_To","value":"KSP Inhibitor AZD4877"},{"name":"NCI_Drug_Dictionary_ID","value":"522717"},{"name":"PDQ_Closed_Trial_Search_ID","value":"522717"},{"name":"PDQ_Open_Trial_Search_ID","value":"522717"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879525"}]}}{"C52199":{"preferredName":"KSP Inhibitor SB-743921","code":"C52199","definitions":[{"definition":"A synthetic small molecule with potential antineoplastic properties. SB-743921 selectively inhibits kinesin spindle protein (KSP), an important protein involved in the early stages of mitosis that is expressed in proliferating cells. Inhibition of KSP results in inhibition of mitotic spindle assembly and interrupts cell division, thereby causing cell cycle arrest and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KSP Inhibitor SB-743921","termGroup":"PT","termSource":"NCI"},{"termName":"SB 743921","termGroup":"CN","termSource":"NCI"},{"termName":"SB-743921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"618430-39-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"24DSZ1VN92"},{"name":"Legacy Concept Name","value":"SB-743921"},{"name":"Maps_To","value":"KSP Inhibitor SB-743921"},{"name":"NCI_Drug_Dictionary_ID","value":"456262"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456262"},{"name":"PDQ_Open_Trial_Search_ID","value":"456262"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709979"}]}}{"C67049":{"preferredName":"Kunecatechins Ointment","code":"C67049","definitions":[{"definition":"A topical ointment containing a green tea polyphenol mixture (kunecatechins) with potential antiviral, antibacterial, antioxidant, and chemopreventive activities. Kunecatechins is a partially purified fraction of the aqueous extract of green tea leaves from Camellia sinensis and contains catechins and other green tea components. Catechins, polyphenolic antioxidant plant metabolites or flavonoids, comprise most of the drug substance in kunecatechins with epigallocatechin gallate (EGCG) present as the primary catechin. Catechins may inhibit basic functions of human papillomavirus (HPV), counteract specific changes in tumor cells, affect cell signaling, and stimulate the immune system. Topical application of kunecatechins ointment has been reported to reduce HPV-induced genital and anal warts through a not yet fully understood mechanism, which may involve anti-oxidative activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kunecatechins Ointment","termGroup":"PT","termSource":"NCI"},{"termName":"Defined Green Tea Catechin Extract OIntment","termGroup":"SY","termSource":"NCI"},{"termName":"Polyphenon E Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Polyphenon E Topical Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Veregen","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Genital and Perianal Warts"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Kunecatechin_Ointment"},{"name":"Maps_To","value":"Kunecatechins Ointment"},{"name":"NCI_Drug_Dictionary_ID","value":"533915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"533915"},{"name":"PDQ_Open_Trial_Search_ID","value":"533915"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1816306"}]}}{"C62178":{"preferredName":"L-Gossypol","code":"C62178","definitions":[{"definition":"The levo-enantiomer of an orally bioavailable polyphenolic aldehyde, derived primarily from unrefined cottonseed oil, with potential antineoplastic activity. Mimicking the inhibitory BH3 (Bcl-2 homology 3) domain of endogenous antagonists of Bcl-2, L-gossypol binds to and inhibits various anti-apoptotic Bcl-2 proteins, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. This agent has greater affinity for Bcl-2 proteins than racemic gossypol.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"L-Gossypol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"90141-22-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"L-Gossypol"},{"name":"Maps_To","value":"L-Gossypol"},{"name":"NCI_Drug_Dictionary_ID","value":"570759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570759"},{"name":"PDQ_Open_Trial_Search_ID","value":"570759"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831823"}]}}{"C107240":{"preferredName":"L-methylfolate","code":"C107240","definitions":[{"definition":"A nutritional supplement containing the biologically active form of the B9 vitamin folate, 5-methyltetrahydrofolate (L-methylfolate), with potential antineoplastic activity. Upon administration, L-methylfolate is able to provide methyl groups allowing an increase in the level of DNA methylation in the promoter regions of certain tumor-promoting genes, thereby reversing the DNA hypomethylation of these genes and inactivating them. This may result in a decrease of both tumor cell proliferation and tumor progression. In addition, administration of L-methylfolate may sensitize tumor cells to the cytotoxic effects of other chemotherapeutic agents. Unlike folic acid, L-methylfolate is able to cross the blood brain barrier and could be beneficial in the treatment of brain tumors. DNA hypomethylation of certain genes leads to chromosome instability and contributes to tumor development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"L-methylfolate","termGroup":"PT","termSource":"NCI"},{"termName":"5-Methyl terahydrofolic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"5-Methyltetrahydrofolate","termGroup":"SY","termSource":"NCI"},{"termName":"5-MTHF","termGroup":"AB","termSource":"NCI"},{"termName":"Deplin","termGroup":"BR","termSource":"NCI"},{"termName":"L-Glutamic Acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5- methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"L-methyltetrahydrofolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"L-methylfolate"},{"name":"NCI_Drug_Dictionary_ID","value":"750726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750726"},{"name":"PDQ_Open_Trial_Search_ID","value":"750726"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0049315"}]}}{"C95710":{"preferredName":"Labetuzumab Govitecan","code":"C95710","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent topoisomerase I inhibitor SN-38, with antineoplastic activity.  The monoclonal antibody moiety of labetuzumab govitecan selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5), which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication and transcription and leading to tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Labetuzumab Govitecan","termGroup":"PT","termSource":"NCI"},{"termName":"ADC IMMU-130","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate IMMU-130","termGroup":"SY","termSource":"NCI"},{"termName":"hMN14-SN38","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1469876-18-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8E3HI6QQ9J"},{"name":"Maps_To","value":"Labetuzumab Govitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"692828"},{"name":"NCI_META_CUI","value":"CL428175"},{"name":"PDQ_Closed_Trial_Search_ID","value":"692828"},{"name":"PDQ_Open_Trial_Search_ID","value":"692828"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90547":{"preferredName":"Ruxotemitide","code":"C90547","definitions":[{"definition":"A peptide derived from human lactoferrin, with potential lytic and immunostimulating activities. Upon transdermal injection directly into the tumor, ruxotemitide may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis. In turn, presentation of the tumor antigens to the immune system may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells. This may trigger an immune response against tumor associated antigens on tumors distant from the primary tumor. Human lactoferrin, a 692 amino acid glycoprotein, belongs to the transferrin family of metal-binding proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruxotemitide","termGroup":"PT","termSource":"NCI"},{"termName":"LTX-315","termGroup":"CN","termSource":"NCI"},{"termName":"Oncopore","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1345407-05-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"75FBL12IZ7"},{"name":"Maps_To","value":"Lactoferrin-derived Lytic Peptide LTX-315"},{"name":"Maps_To","value":"Ruxotemitide"},{"name":"NCI_Drug_Dictionary_ID","value":"665662"},{"name":"NCI_META_CUI","value":"CL416231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665662"},{"name":"PDQ_Open_Trial_Search_ID","value":"665662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124999":{"preferredName":"Lacutamab","code":"C124999","definitions":[{"definition":"A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. Upon administration, lacutamab binds to KIR3DL2 expressed on certain tumor cells. This recruits natural killer (NK) cells and leads to lysis of KIR3DL2-expressing tumor cells. In addition, IPH4102 induces antibody-dependent cellular cytotoxicity (ADCC), thereby further eliminating tumor cells. KIR3DL2, a tumor-associated antigen (TAA) and inhibitory receptor of the KIR family, is specifically expressed in most subtypes of cutaneous T-cell lymphomas (CTCL) and expressed only on a fraction of normal NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lacutamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-KIR3DL2 mAb IPH4102","termGroup":"SY","termSource":"NCI"},{"termName":"IPH-4102","termGroup":"CN","termSource":"NCI"},{"termName":"IPH4102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2187368-16-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N8O7MY0VNS"},{"name":"Maps_To","value":"Lacutamab"},{"name":"NCI_Drug_Dictionary_ID","value":"777272"},{"name":"NCI_META_CUI","value":"CL503845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777272"},{"name":"PDQ_Open_Trial_Search_ID","value":"777272"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83861":{"preferredName":"Ladirubicin","code":"C83861","definitions":[{"definition":"A 4-demethoxydaunorubicin (idarubicin) analog with an aziridinyl group in position C-3' and a methylsulphonyl on position C-4', with potential antineoplastic activity. Upon intravenous administration, ladirubicin alkylates guanine residues at the N7 position in the DNA major groove, resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ladirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"FCE 28729","termGroup":"CN","termSource":"NCI"},{"termName":"Idarubicin Analog PNU-159548","termGroup":"SY","termSource":"NCI"},{"termName":"PNU 159548","termGroup":"CN","termSource":"NCI"},{"termName":"PNU-159548","termGroup":"CN","termSource":"NCI"},{"termName":"PNU159548","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"171047-47-5"},{"name":"Chemical_Formula","value":"C29H31NO11S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U395ERO49H"},{"name":"Maps_To","value":"Ladirubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827222"}]}}{"C29149":{"preferredName":"Laetrile","code":"C29149","definitions":[{"definition":"A substance found in the pits of many fruits such as apricots and papayas, and in other foods. It has been tried in some countries as a treatment for cancer, but it has not been shown to work in clinical studies. Laetrile is not approved for use in the United States.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laetrile","termGroup":"PT","termSource":"NCI"},{"termName":"Beta-D-Glucopyranosiduronic acid, alpha-cyanobenzyl","termGroup":"SN","termSource":"NCI"},{"termName":"Cyanophenylmethyl-beta-D-glucopyranosiduronic acid","termGroup":"SN","termSource":"NCI"},{"termName":"L-Mandelonitrile-beta-glucuronoside","termGroup":"SN","termSource":"NCI"},{"termName":"Laetrille","termGroup":"SY","termSource":"NCI"},{"termName":"Mandelonitrile-beta-glucuronide","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin B17","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Chemical_Formula","value":"C14-H15-N-O7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Laetrille"},{"name":"Maps_To","value":"Laetrile"},{"name":"NCI_Drug_Dictionary_ID","value":"257611"},{"name":"NSC Number","value":"103055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257611"},{"name":"PDQ_Open_Trial_Search_ID","value":"257611"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0878244"}]}}{"C28698":{"preferredName":"Laniquidar","code":"C28698","definitions":[{"definition":"A stereoisomer of verapamil and third-generation P-glycoprotein inhibitor. Laniquidar inhibits the drug efflux pump P-glycoprotein, resulting in higher concentrations of antineoplastic agents in tumor cells that are multi-drug resistant due to the overexpression of P-glycoprotein. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied for its ability to make cancer cells respond to drugs to which they have become resistant. It belongs to the family of drugs called multidrug resistance inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Laniquidar","termGroup":"PT","termSource":"NCI"},{"termName":"R101933","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197509-46-9"},{"name":"Chemical_Formula","value":"C37H36N4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K3FRN4DDOY"},{"name":"Legacy Concept Name","value":"Laniquidar"},{"name":"Maps_To","value":"Laniquidar"},{"name":"NCI_Drug_Dictionary_ID","value":"38526"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38526"},{"name":"PDQ_Open_Trial_Search_ID","value":"38526"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0916124"}]}}{"C74584":{"preferredName":"Lanreotide Acetate","code":"C74584","definitions":[{"definition":"The acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lanreotide Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"AT-1001","termGroup":"CN","termSource":"NCI"},{"termName":"L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide, acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Somatuline Depot","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"127984-74-1"},{"name":"Chemical_Formula","value":"C54H69N11O10S2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"IEU56G3J9C"},{"name":"Legacy Concept Name","value":"Lanreotide_Acetate"},{"name":"Maps_To","value":"Lanreotide Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"750171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750171"},{"name":"PDQ_Open_Trial_Search_ID","value":"750171"},{"name":"PubMedID_Primary_Reference","value":"9641549"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771414"}]}}{"C28694":{"preferredName":"Lapachone","code":"C28694","definitions":[{"definition":"A poorly soluble, ortho-naphthoquinone with potential antineoplastic and radiosensitizing activity. Beta-lapachone (b-lap) is bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), creating a futile oxidoreduction that generates high levels of superoxide. In turn, the highly reactive oxygen species (ROS) interact with DNA, thereby causing single-strand DNA breaks and calcium release from endoplasmic reticulum (ER) stores. Eventually, the extensive DNA damage causes hyperactivation of poly(ADP-ribose) polymerase-1 (PARP-1), an enzyme facilitating DNA repair, accompanied by rapid depletion of NAD+/ATP nucleotide levels. As a result, a caspase-independent and ER-stress induced mu-calpain-mediated cell death occurs in NQO1-overexpressing tumor cells. NQO1, a flavoprotein and two-electron oxidoreductase, is overexpressed in a variety of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapachone","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"ARQ 501","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ501","termGroup":"CN","termSource":"NCI"},{"termName":"Beta-Lap-WJ","termGroup":"BR","termSource":"NCI"},{"termName":"Beta-Lapachone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4707-32-8"},{"name":"Chemical_Formula","value":"C15H14O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6N4FA2QQ6A"},{"name":"Legacy Concept Name","value":"beta-Lapachone"},{"name":"Maps_To","value":"Lapachone"},{"name":"NCI_Drug_Dictionary_ID","value":"357565"},{"name":"NSC Number","value":"26326"},{"name":"NSC Number","value":"629749"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357565"},{"name":"PDQ_Open_Trial_Search_ID","value":"357565"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053471"}]}}{"C26653":{"preferredName":"Lapatinib","code":"C26653","definitions":[{"definition":"A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapatinib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK572016","termGroup":"CN","termSource":"NCI"},{"termName":"GW 572016","termGroup":"CN","termSource":"NCI"},{"termName":"GW-572016","termGroup":"CN","termSource":"NCI"},{"termName":"GW2016","termGroup":"CN","termSource":"NCI"},{"termName":"GW572016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"231277-92-2"},{"name":"CHEBI_ID","value":"CHEBI:49603"},{"name":"Chemical_Formula","value":"C29H26ClFN4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0VUA21238F"},{"name":"Legacy Concept Name","value":"GW572016"},{"name":"Maps_To","value":"Lapatinib"},{"name":"NSC Number","value":"727989"},{"name":"PubMedID_Primary_Reference","value":"12214266"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506770"}]}}{"C66878":{"preferredName":"Lapatinib Ditosylate","code":"C66878","definitions":[{"definition":"A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib ditosylate is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapatinib Ditosylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl), bis(4-methylbenzenesulfonate), Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Tykerb","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2 positive metastatic breast cancer"},{"name":"CAS_Registry","value":"388082-78-8"},{"name":"Chemical_Formula","value":"C29H26ClFN4O4S.2C7H8O3S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G873GX646R"},{"name":"Legacy Concept Name","value":"Lapatinib_Ditosylate"},{"name":"Maps_To","value":"Lapatinib Ditosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"269659"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269659"},{"name":"PDQ_Open_Trial_Search_ID","value":"269659"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1504917"}]}}{"C2057":{"preferredName":"Lapuleucel-T","code":"C2057","definitions":[{"definition":"A cell-based vaccine targets tumors expressing the HER2/neu marker.  HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers.  APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient.  These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lapuleucel-T","termGroup":"PT","termSource":"NCI"},{"termName":"APC 8024","termGroup":"CN","termSource":"NCI"},{"termName":"APC8024","termGroup":"CN","termSource":"NCI"},{"termName":"DN24 02","termGroup":"CN","termSource":"NCI"},{"termName":"DN24-02","termGroup":"CN","termSource":"NCI"},{"termName":"DN2402","termGroup":"CN","termSource":"NCI"},{"termName":"Neuvenge","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845680-07-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"J5Z87L8ROA"},{"name":"Legacy Concept Name","value":"APC_8024"},{"name":"Maps_To","value":"Lapuleucel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"735849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735849"},{"name":"PDQ_Open_Trial_Search_ID","value":"735849"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515856"}]}}{"C2653":{"preferredName":"Laromustine","code":"C2653","definitions":[{"definition":"A drug used to treat acute myelogenous leukemia (AML). It is also being studied in the treatment of several other types of cancer. It blocks cell growth by damaging the cell's DNA and may kill cancer cells. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfonyl hydrazine prodrug with antineoplastic activity. Laromustine releases the DNA chloroethylating agent 90CE after entering the blood stream; 90CE chloroethylates alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. Intracellular metabolism of this agent also releases methyl isocyanate which inhibits O6-alkyl-guanine transferase, an enzyme involved with DNA repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Laromustine","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"101M","termGroup":"CN","termSource":"NCI"},{"termName":"Cloretazine","termGroup":"SY","termSource":"NCI"},{"termName":"Onrigin","termGroup":"BR","termSource":"NCI"},{"termName":"VNP40101M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"173424-77-6"},{"name":"Chemical_Formula","value":"C6H14ClN3O5S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14J2G0U3NQ"},{"name":"Legacy Concept Name","value":"VNP40101M"},{"name":"Maps_To","value":"Laromustine"},{"name":"NCI_Drug_Dictionary_ID","value":"38440"},{"name":"NSC Number","value":"734246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38440"},{"name":"PDQ_Open_Trial_Search_ID","value":"38440"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713559"}]}}{"C48427":{"preferredName":"Larotaxel","code":"C48427","definitions":[{"definition":"A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of breast cancer. It belongs to the family of drugs called taxane derivatives.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Larotaxel","termGroup":"PT","termSource":"NCI"},{"termName":"RPR 109881A","termGroup":"CN","termSource":"NCI"},{"termName":"RPR-109881","termGroup":"CN","termSource":"NCI"},{"termName":"Taxoid-109881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156294-36-9"},{"name":"Chemical_Formula","value":"C45H53NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TWQ8K8A81Y"},{"name":"Legacy Concept Name","value":"XRP9881"},{"name":"Maps_To","value":"Larotaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"42554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42554"},{"name":"PDQ_Open_Trial_Search_ID","value":"42554"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0392979"}]}}{"C115977":{"preferredName":"Larotrectinib","code":"C115977","definitions":[{"definition":"An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larotrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-","termGroup":"SN","termSource":"NCI"},{"termName":"3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ARRY 470","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO 101","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO-101","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1223403-58-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PF9462I9HX"},{"name":"Maps_To","value":"Larotrectinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4278057"}]}}{"C156895":{"preferredName":"Larotrectinib Sulfate","code":"C156895","definitions":[{"definition":"The sulfate salt form of larotrectinib, an orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larotrectinib Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide;sulfuric acid","termGroup":"SN","termSource":"NCI"},{"termName":"1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, Sulfate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"ARRY 470 Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"LOXO 101 Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"LOXO-101 Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"Vitrakvi","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation"},{"name":"CAS_Registry","value":"1223405-08-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RDF76R62ID"},{"name":"Maps_To","value":"Larotrectinib Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"760532"},{"name":"NCI_META_CUI","value":"CL935988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760532"},{"name":"PDQ_Open_Trial_Search_ID","value":"760532"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1142":{"preferredName":"Lavendustin A","code":"C1142","definitions":[{"definition":"A compound isolated from strains of Streptomyces griseolavendus that may exert antitumor activity by inhibition of protein tyrosine kinase and tubulin polymerization. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lavendustin A","termGroup":"PT","termSource":"NCI"},{"termName":"5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy Benzoic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125697-92-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3Y0G32G2RV"},{"name":"Legacy Concept Name","value":"Lavendustin_A"},{"name":"Maps_To","value":"Lavendustin A"},{"name":"NSC Number","value":"678027"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064695"}]}}{"C148147":{"preferredName":"Lazertinib","code":"C148147","definitions":[{"definition":"An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lazertinib","termGroup":"PT","termSource":"NCI"},{"termName":"GNS 1480","termGroup":"CN","termSource":"NCI"},{"termName":"GNS-1480","termGroup":"CN","termSource":"NCI"},{"termName":"GNS1480","termGroup":"CN","termSource":"NCI"},{"termName":"Leclaza","termGroup":"BR","termSource":"NCI"},{"termName":"N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"YH 25448","termGroup":"CN","termSource":"NCI"},{"termName":"YH-25448","termGroup":"CN","termSource":"NCI"},{"termName":"YH25448","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1903008-80-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4A2Y23XK11"},{"name":"Maps_To","value":"Lazertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"792503"},{"name":"NCI_META_CUI","value":"CL550797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792503"},{"name":"PDQ_Open_Trial_Search_ID","value":"792503"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97500":{"preferredName":"Lead Pb 212 TCMC-trastuzumab","code":"C97500","definitions":[{"definition":"A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional chelating agent TCMC ((1,4,7,10-Tetra-(2-Carbamoyl Methyl)-Cyclododecane), and radiolabeled with the alpha-emitting isotope lead Pb 212, with potential anti-tumor activity. Upon administration, the antibody moiety of lead Pb 212 TCMC-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2); after internalization, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed on the cell surface of a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lead Pb 212 TCMC-trastuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"[212]Pb TCMC-Herceptin","termGroup":"SY","termSource":"NCI"},{"termName":"[212]Pb TCMC-trastuzumab","termGroup":"SY","termSource":"NCI"},{"termName":"Lead Pb 212 TCMC-Herceptin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lead Pb 212 TCMC-trastuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"703322"},{"name":"NCI_META_CUI","value":"CL430248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703322"},{"name":"PDQ_Open_Trial_Search_ID","value":"703322"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94207":{"preferredName":"Lefitolimod","code":"C94207","definitions":[{"definition":"A synthetic oligonucleotide based on a proprietary double stem-loop immunomodulator design with potential immunostimulating activity. Lefitolimod binds to and activates intracellular Toll-like receptor 9 (TLR9) in monocytes/macrophages, plasmacytoidal and myeloid dendritic cells (DCs), and natural killer (NK) cells, initiating immune signaling pathways and inducing T-helper 1 cell (Th1) production leading to the production of memory T cells and a Th1-mediated immune response. By activating the immune system, MGN1703 may attack tumor associated antigen (TAAs). TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lefitolimod","termGroup":"PT","termSource":"NCI"},{"termName":"dSLIM-30L1","termGroup":"SY","termSource":"NCI"},{"termName":"MGN-1703","termGroup":"CN","termSource":"NCI"},{"termName":"MGN1703","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1548439-51-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SO72A12FN"},{"name":"Maps_To","value":"Lefitolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"686500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686500"},{"name":"PDQ_Open_Trial_Search_ID","value":"686500"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986392"}]}}{"C1128":{"preferredName":"Leflunomide","code":"C1128","definitions":[{"definition":"A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties.  As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes.  This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that works by inhibiting a cancer cell growth factor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leflunomide","termGroup":"PT","termSource":"NCI"},{"termName":"4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Arava","termGroup":"BR","termSource":"NCI"},{"termName":"SU101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75706-12-6"},{"name":"CHEBI_ID","value":"CHEBI:6402"},{"name":"Chemical_Formula","value":"C12H9F3N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G162GK9U4W"},{"name":"Legacy Concept Name","value":"Leflunomide"},{"name":"Maps_To","value":"Leflunomide"},{"name":"NCI_Drug_Dictionary_ID","value":"42253"},{"name":"NSC Number","value":"677411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42253"},{"name":"PDQ_Open_Trial_Search_ID","value":"42253"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0063041"}]}}{"C2668":{"preferredName":"Lenalidomide","code":"C2668","definitions":[{"definition":"A drug that is similar to thalidomide, and is used to treat multiple myeloma and certain types of anemia. It is also being studied in the treatment of other types of cancer. Lenalidomide belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenalidomide","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"CC 5013","termGroup":"CN","termSource":"NCI"},{"termName":"CC-5013","termGroup":"CN","termSource":"NCI"},{"termName":"CC5013","termGroup":"CN","termSource":"NCI"},{"termName":"CDC 501","termGroup":"CN","termSource":"NCI"},{"termName":"Revlimid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndrome; multiple myeloma, lymphoma"},{"name":"CAS_Registry","value":"191732-72-6"},{"name":"CHEBI_ID","value":"CHEBI:63791"},{"name":"Chemical_Formula","value":"C13H13N3O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F0P408N6V4"},{"name":"Legacy Concept Name","value":"CC-5013"},{"name":"Maps_To","value":"Lenalidomide"},{"name":"NCI_Drug_Dictionary_ID","value":"38564"},{"name":"NSC Number","value":"703813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38564"},{"name":"PDQ_Open_Trial_Search_ID","value":"38564"},{"name":"PubMedID_Primary_Reference","value":"16085014"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1144149"}]}}{"C162878":{"preferredName":"Lenalidomide Analog KPG-121","code":"C162878","definitions":[{"definition":"A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenalidomide Analog KPG-121","termGroup":"PT","termSource":"NCI"},{"termName":"KPG 121","termGroup":"CN","termSource":"NCI"},{"termName":"KPG-121","termGroup":"CN","termSource":"NCI"},{"termName":"KPG121","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lenalidomide Analog KPG-121"},{"name":"NCI_Drug_Dictionary_ID","value":"798954"},{"name":"NCI_META_CUI","value":"CL973359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798954"},{"name":"PDQ_Open_Trial_Search_ID","value":"798954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28168":{"preferredName":"Lentinan","code":"C28168","definitions":[{"definition":"A beta-glucan (a type of polysaccharide) from the mushroom Lentinus edodes (shiitake mushroom).  It has been studied in Japan as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lentinan","termGroup":"PT","termSource":"NCI"},{"termName":"LC-33","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37339-90-5"},{"name":"Chemical_Formula","value":"(C12H20O10)n.HO(C6H10O5)n"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6751655D1D"},{"name":"Legacy Concept Name","value":"Lentinan"},{"name":"Maps_To","value":"Lentinan"},{"name":"NSC Number","value":"130122"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0023324"}]}}{"C95124":{"preferredName":"Lenvatinib","code":"C95124","definitions":[{"definition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenvatinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"E 7080","termGroup":"CN","termSource":"NCI"},{"termName":"E-7080","termGroup":"CN","termSource":"NCI"},{"termName":"E7080","termGroup":"CN","termSource":"NCI"},{"termName":"ER-203492-00","termGroup":"CN","termSource":"NCI"},{"termName":"Multi-Kinase Inhibitor E7080","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable hepatocellular carcinoma (HCC)"},{"name":"CAS_Registry","value":"417716-92-8"},{"name":"Chemical_Formula","value":"C21H19ClN4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"EE083865G2"},{"name":"Maps_To","value":"Lenvatinib"},{"name":"PubMedID_Primary_Reference","value":"18765537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986924"}]}}{"C48636":{"preferredName":"Lenvatinib Mesylate","code":"C48636","definitions":[{"definition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenvatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, methanesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"E7080 Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Lenvima","termGroup":"BR","termSource":"NCI"},{"termName":"Multi-Kinase Inhibitor E7080 Mesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer; advanced renal cell carcinoma (RCC); first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)."},{"name":"CAS_Registry","value":"857890-39-2"},{"name":"Chemical_Formula","value":"C21H19ClN4O4.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3J78384F61"},{"name":"Legacy Concept Name","value":"E7080"},{"name":"Maps_To","value":"Lenvatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"445461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"445461"},{"name":"PDQ_Open_Trial_Search_ID","value":"445461"},{"name":"PubMedID_Primary_Reference","value":"18765537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4018332"}]}}{"C125081":{"preferredName":"Lenzilumab","code":"C125081","definitions":[{"definition":"A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenzilumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1-kappa, Anti-(Homo sapiens CSF2 (Colony Stimulating Factor 2 (Granulocyte-Macrophage), Granulocyte Macrophage Colony Stimulating Factor, GM-CSF)), Homo sapiens Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"KB 003","termGroup":"CN","termSource":"NCI"},{"termName":"KB003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1229575-09-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IE4X6497XK"},{"name":"Maps_To","value":"Lenzilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"778430"},{"name":"NCI_META_CUI","value":"CL503921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778430"},{"name":"PDQ_Open_Trial_Search_ID","value":"778430"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48402":{"preferredName":"Lestaurtinib","code":"C48402","definitions":[{"definition":"A drug being studied in the treatment of acute leukemias and some other types of cancer. It binds to a protein that is present on the surface of some types of cancer cells and stops them from dividing. CEP-701 is a type of receptor tyrosine kinase inhibitor and a type of indolocarbazole alkaloid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lestaurtinib","termGroup":"PT","termSource":"NCI"},{"termName":"9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-","termGroup":"SN","termSource":"NCI"},{"termName":"CEP 701","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-701","termGroup":"CN","termSource":"NCI"},{"termName":"CEP701","termGroup":"CN","termSource":"NCI"},{"termName":"KT-5555","termGroup":"CN","termSource":"NCI"},{"termName":"SPM-924","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111358-88-4"},{"name":"Chemical_Formula","value":"C26H21N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DO989GC5D1"},{"name":"Legacy Concept Name","value":"Lestaurtinib"},{"name":"Maps_To","value":"Lestaurtinib"},{"name":"NCI_Drug_Dictionary_ID","value":"367053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"367053"},{"name":"PDQ_Open_Trial_Search_ID","value":"367053"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541677"}]}}{"C1527":{"preferredName":"Letrozole","code":"C1527","definitions":[{"definition":"A drug used to treat advanced breast cancer in postmenopausal women. Letrozole causes a decrease in the amount of estrogen made by the body. It is a type of aromatase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Letrozole","termGroup":"PT","termSource":"NCI"},{"termName":"4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"CGS 20267","termGroup":"CN","termSource":"NCI"},{"termName":"CGS-20267","termGroup":"CN","termSource":"NCI"},{"termName":"CGS20267","termGroup":"CN","termSource":"NCI"},{"termName":"Femara","termGroup":"BR","termSource":"NCI"},{"termName":"Fempro","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hormone receptor-positive early breast cancer; Delayed puberty; Endometrial cancer; Ovulatory induction"},{"name":"CAS_Registry","value":"112809-51-5"},{"name":"CHEBI_ID","value":"CHEBI:6413"},{"name":"Chemical_Formula","value":"C17H11N5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7LKK855W8I"},{"name":"Legacy Concept Name","value":"Letrozole"},{"name":"Maps_To","value":"Letrozole"},{"name":"NCI_Drug_Dictionary_ID","value":"42086"},{"name":"NSC Number","value":"719345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42086"},{"name":"PDQ_Open_Trial_Search_ID","value":"42086"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0246421"}]}}{"C71631":{"preferredName":"Leucovorin","code":"C71631","definitions":[{"definition":"A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil's converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to lessen the toxic effects of substances that block the action of folic acid, especially the anticancer drug methotrexate. Folinic acid is used to treat some types of anemia and is also used with fluorouracil to treat colorectal cancer. It is also being studied in the treatment of other types of cancer and other conditions. Folinic acid is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leucovorin","termGroup":"PT","termSource":"NCI"},{"termName":"5-Formyltetrahydrofolate","termGroup":"SN","termSource":"NCI"},{"termName":"Folinic acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58-05-9"},{"name":"CHEBI_ID","value":"CHEBI:15640"},{"name":"Chemical_Formula","value":"C20H23N7O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q573I9DVLP"},{"name":"Legacy Concept Name","value":"Leucovorin"},{"name":"Maps_To","value":"Leucovorin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0023413"}]}}{"C607":{"preferredName":"Leucovorin Calcium","code":"C607","definitions":[{"definition":"A drug used to lessen the toxic effects of substances that block the action of folic acid, especially the anticancer drug methotrexate. Leucovorin calcium is used to treat some types of anemia and is also used with fluorouracil to treat colorectal cancer. It is also being studied in the treatment of other types of cancer and other conditions. Leucovorin calcium is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leucovorin Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"5-Formyl Tetrahydrofolate","termGroup":"SN","termSource":"NCI"},{"termName":"5-Formyl-5,6,7,8-tetrahydrofolic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Adinepar","termGroup":"FB","termSource":"NCI"},{"termName":"Calcifolin","termGroup":"FB","termSource":"NCI"},{"termName":"Calcium (6S)-Folinate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Folinate","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium Leucovorin","termGroup":"SY","termSource":"NCI"},{"termName":"Calcium N-(p-((((6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Calfolex","termGroup":"FB","termSource":"NCI"},{"termName":"Calinat","termGroup":"FB","termSource":"NCI"},{"termName":"Cehafolin","termGroup":"FB","termSource":"NCI"},{"termName":"Citofolin","termGroup":"FB","termSource":"NCI"},{"termName":"Citrec","termGroup":"FB","termSource":"NCI"},{"termName":"Citrovorum Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Cromatonbic Folinico","termGroup":"FB","termSource":"NCI"},{"termName":"Dalisol","termGroup":"FB","termSource":"NCI"},{"termName":"Disintox","termGroup":"FB","termSource":"NCI"},{"termName":"Divical","termGroup":"FB","termSource":"NCI"},{"termName":"Ecofol","termGroup":"FB","termSource":"NCI"},{"termName":"Emovis","termGroup":"FB","termSource":"NCI"},{"termName":"Factor, Citrovorum","termGroup":"SY","termSource":"NCI"},{"termName":"Flynoken A","termGroup":"FB","termSource":"NCI"},{"termName":"Folaren","termGroup":"FB","termSource":"NCI"},{"termName":"Folaxin","termGroup":"FB","termSource":"NCI"},{"termName":"FOLI-cell","termGroup":"FB","termSource":"NCI"},{"termName":"Foliben","termGroup":"FB","termSource":"NCI"},{"termName":"Folidan","termGroup":"FB","termSource":"NCI"},{"termName":"Folidar","termGroup":"FB","termSource":"NCI"},{"termName":"Folinac","termGroup":"FB","termSource":"NCI"},{"termName":"Folinate Calcium","termGroup":"SY","termSource":"NCI"},{"termName":"Folinic Acid Calcium Salt Pentahydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Folinoral","termGroup":"FB","termSource":"NCI"},{"termName":"Folinvit","termGroup":"FB","termSource":"NCI"},{"termName":"Foliplus","termGroup":"FB","termSource":"NCI"},{"termName":"Folix","termGroup":"FB","termSource":"NCI"},{"termName":"Imo","termGroup":"FB","termSource":"NCI"},{"termName":"Lederfolat","termGroup":"FB","termSource":"NCI"},{"termName":"Lederfolin","termGroup":"FB","termSource":"NCI"},{"termName":"Leucosar","termGroup":"FB","termSource":"NCI"},{"termName":"N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid, Calcium Salt (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Rescufolin","termGroup":"FB","termSource":"NCI"},{"termName":"Rescuvolin","termGroup":"FB","termSource":"NCI"},{"termName":"Tonofolin","termGroup":"FB","termSource":"NCI"},{"termName":"Wellcovorin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Megaloblastic anemia due to folate deficiency; Enhanced fluorouracil inhibition of thymidylate synthase; Reverse dihydrofolate reductase inhibition by methotrexate; Folic acid antagonist overdose; Nitrous Oxide toxicity"},{"name":"CAS_Registry","value":"1492-18-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RPR1R4C0P4"},{"name":"Legacy Concept Name","value":"Leucovorin_Calcium"},{"name":"Maps_To","value":"Leucovorin Calcium"},{"name":"NCI_Drug_Dictionary_ID","value":"42584"},{"name":"NSC Number","value":"3590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42584"},{"name":"PDQ_Open_Trial_Search_ID","value":"42584"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0731033"}]}}{"C62042":{"preferredName":"Leuprolide","code":"C62042","definitions":[{"definition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat symptoms of advanced prostate cancer. It is also used to treat early puberty in children and certain gynecologic conditions. It is being studied in the treatment of other conditions and types of cancer. Leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of gonadotropin-releasing hormone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Leuprolide","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig)","termGroup":"SN","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig)","termGroup":"SN","termSource":"NCI"},{"termName":"Leuprorelin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53714-56-0"},{"name":"CHEBI_ID","value":"CHEBI:6427"},{"name":"Chemical_Formula","value":"C59H84N16O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"EFY6W0M8TG"},{"name":"Legacy Concept Name","value":"Leuprolide_Base"},{"name":"Maps_To","value":"Leuprolide"},{"name":"NSC Number","value":"377526"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0085272"}]}}{"C1319":{"preferredName":"Leuprolide Acetate","code":"C1319","definitions":[{"definition":"A drug used to treat symptoms of advanced prostate cancer. It is also being studied in the treatment of other conditions and types of cancer. The active ingredient leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. Some brands of leuprolide are also used to treat early puberty in children and certain gynecologic conditions. Leuprolide acetate is a type of gonadotropin-releasing hormone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leuprolide Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate","termGroup":"SN","termSource":"NCI"},{"termName":"6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate","termGroup":"SN","termSource":"NCI"},{"termName":"A 43818","termGroup":"CN","termSource":"NCI"},{"termName":"A-43818","termGroup":"CN","termSource":"NCI"},{"termName":"A43818","termGroup":"CN","termSource":"NCI"},{"termName":"Abbott 43818","termGroup":"CN","termSource":"NCI"},{"termName":"Abbott-43818","termGroup":"CN","termSource":"NCI"},{"termName":"Carcinil","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Eligard","termGroup":"FB","termSource":"NCI"},{"termName":"Enanton","termGroup":"FB","termSource":"NCI"},{"termName":"Enantone","termGroup":"FB","termSource":"NCI"},{"termName":"Enantone-Gyn","termGroup":"FB","termSource":"NCI"},{"termName":"Fensolvi","termGroup":"BR","termSource":"NCI"},{"termName":"Ginecrin","termGroup":"FB","termSource":"NCI"},{"termName":"LEUP","termGroup":"AB","termSource":"NCI"},{"termName":"Leuplin","termGroup":"FB","termSource":"NCI"},{"termName":"Leuprorelin Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"Lucrin","termGroup":"FB","termSource":"NCI"},{"termName":"Lucrin Depot","termGroup":"FB","termSource":"NCI"},{"termName":"Luprodex Depot","termGroup":"FB","termSource":"NCI"},{"termName":"Lupron","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot-3 Month","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot-4 Month","termGroup":"BR","termSource":"NCI"},{"termName":"Lupron Depot-Ped","termGroup":"BR","termSource":"NCI"},{"termName":"Lutrate","termGroup":"FB","termSource":"NCI"},{"termName":"Procren","termGroup":"FB","termSource":"NCI"},{"termName":"Procrin","termGroup":"FB","termSource":"NCI"},{"termName":"Prostap","termGroup":"FB","termSource":"NCI"},{"termName":"TAP 144","termGroup":"CN","termSource":"NCI"},{"termName":"TAP-144","termGroup":"CN","termSource":"NCI"},{"termName":"TAP144","termGroup":"CN","termSource":"NCI"},{"termName":"Trenantone","termGroup":"FB","termSource":"NCI"},{"termName":"Uno-Enantone","termGroup":"FB","termSource":"NCI"},{"termName":"Viadur","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Endometriosis; In-vitro fertilization; Precocious puberty; Premenstrual syndrome; Prostate cancer; Uterine fibroid tumors"},{"name":"CAS_Registry","value":"74381-53-6"},{"name":"CHEBI_ID","value":"CHEBI:63597"},{"name":"Chemical_Formula","value":"C59H84N16O12.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37JNS02E7V"},{"name":"Legacy Concept Name","value":"Leuprolide"},{"name":"Maps_To","value":"Leuprolide Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"40058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40058"},{"name":"PDQ_Open_Trial_Search_ID","value":"40058"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700596"}]}}{"C118363":{"preferredName":"Leuprolide Mesylate Injectable Suspension","code":"C118363","definitions":[{"definition":"A depot suspension for injection composed of the mesylate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous injection of the depot suspension, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leuprolide Mesylate Injectable Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"LMIS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Leuprolide Mesylate Injectable Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"764623"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764623"},{"name":"PDQ_Open_Trial_Search_ID","value":"764623"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896651"}]}}{"C81421":{"preferredName":"Leurubicin","code":"C81421","definitions":[{"definition":"An N-L-leucyl prodrug of the anthracycline doxorubicin, with antineoplastic activity. Leurubicin is converted to its active form doxorubicin in or on tumor cells by hydrolytic enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Leurubicin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70774-25-3"},{"name":"Chemical_Formula","value":"C33H40N2O12"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1Z20MGK851"},{"name":"Legacy Concept Name","value":"Leurubicin"},{"name":"Maps_To","value":"Leurubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825623"}]}}{"C47581":{"preferredName":"Levetiracetam","code":"C47581","definitions":[{"definition":"A drug used to treat seizures (involuntary muscle movements) caused by epilepsy (a group of brain disorders). Keppra is being studied in the treatment of seizures in patients with cancer that has spread to the brain. It is a type of anticonvulsant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levetiracetam","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-,(S)-","termGroup":"SN","termSource":"NCI"},{"termName":"Keppra","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treating partial-onset seizures in patients with epilepsy."},{"name":"CAS_Registry","value":"102767-28-2"},{"name":"CHEBI_ID","value":"CHEBI:6437"},{"name":"Chemical_Formula","value":"C8H14N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44YRR34555"},{"name":"Legacy Concept Name","value":"Levetiracetam"},{"name":"Maps_To","value":"Levetiracetam"},{"name":"NCI_Drug_Dictionary_ID","value":"526173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526173"},{"name":"PDQ_Open_Trial_Search_ID","value":"526173"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0377265"}]}}{"C62080":{"preferredName":"Levothyroxine","code":"C62080","definitions":[{"definition":"A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levothyroxine","termGroup":"PT","termSource":"NCI"},{"termName":"L-Thyroxine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51-48-9"},{"name":"CHEBI_ID","value":"CHEBI:18332"},{"name":"Chemical_Formula","value":"C15H11I4NO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q51BO43MG4"},{"name":"Legacy Concept Name","value":"Levothyroxine"},{"name":"Maps_To","value":"Levothyroxine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881373"}]}}{"C888":{"preferredName":"Levothyroxine Sodium","code":"C888","definitions":[{"definition":"The sodium salt of levothyroxine, a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levothyroxine Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Levothroid","termGroup":"BR","termSource":"NCI"},{"termName":"Synthroid","termGroup":"BR","termSource":"NCI"},{"termName":"Therapeutic Levothyroxine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"25416-65-3"},{"name":"Chemical_Formula","value":"C15H10I4NO4.Na.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"9J765S329G"},{"name":"Legacy Concept Name","value":"Therapeutic_Levothyroxine"},{"name":"Maps_To","value":"Levothyroxine Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39298"},{"name":"NSC Number","value":"36397"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39298"},{"name":"PDQ_Open_Trial_Search_ID","value":"39298"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079691"}]}}{"C64621":{"preferredName":"Lexatumumab","code":"C64621","definitions":[{"definition":"A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. HGS-ETR2 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lexatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2","termGroup":"SY","termSource":"NCI"},{"termName":"HGS-ETR2","termGroup":"SY","termSource":"NCI"},{"termName":"HGS-ETR2","termGroup":"CN","termSource":"NCI"},{"termName":"HGS1018","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody HGS-ETR2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845816-02-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"967Q0SJD77"},{"name":"Legacy Concept Name","value":"Lexatumumab"},{"name":"Maps_To","value":"Lexatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"528015"},{"name":"PDQ_Closed_Trial_Search_ID","value":"528015"},{"name":"PDQ_Open_Trial_Search_ID","value":"528015"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721684"}]}}{"C77882":{"preferredName":"Lexibulin","code":"C77882","definitions":[{"definition":"An orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. Lexibulin inhibits tubulin polymerization in tumor blood vessel endothelial cells and tumor cells, blocking the formation of the mitotic spindle and leading to cell cycle arrest at the G2/M phase; this may result in disruption of the tumor vasculature and tumor blood flow, and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lexibulin","termGroup":"PT","termSource":"NCI"},{"termName":"1-ethyl-3-(2-methoxy-4-(5-methyl-4-(((1s)-1-(pyridin-3-yl)butyl)amino)pyrimidin-2-yl)phenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"CYT997","termGroup":"CN","termSource":"NCI"},{"termName":"Tubulin Inhibitor CYT997","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917111-44-5"},{"name":"Chemical_Formula","value":"C24H30N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2GTU230HA1"},{"name":"Legacy Concept Name","value":"Tubulin_Inhibitor_CYT997"},{"name":"Maps_To","value":"Lexibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"598799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598799"},{"name":"PDQ_Open_Trial_Search_ID","value":"598799"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703082"}]}}{"C1433":{"preferredName":"Liarozole","code":"C1433","definitions":[{"definition":"An anticancer drug that promotes differentiation by increasing the levels of retinoic acid within the tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liarozole","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Liazal","termGroup":"BR","termSource":"NCI"},{"termName":"R 75251","termGroup":"CN","termSource":"NCI"},{"termName":"R-61405","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"115575-11-6"},{"name":"Chemical_Formula","value":"C17H13ClN4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K0Q29TGV9Y"},{"name":"Legacy Concept Name","value":"Liarozole"},{"name":"Maps_To","value":"Liarozole"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165479"}]}}{"C1524":{"preferredName":"Liarozole Fumarate","code":"C1524","definitions":[{"definition":"The orally active fumarate salt of the benzimidazole derivative liarozole with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liarozole Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-5-(m-Chloro-alpha-imidazol-1-ylbenzyl)benzimidazole Fumarate (2:3)","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-, (+-)-, (E)-2-butenedioate (2:3)","termGroup":"SN","termSource":"NCI"},{"termName":"R85246","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145858-52-2"},{"name":"Chemical_Formula","value":"2C17H13ClN4.3C4H4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91W7VLK7J3"},{"name":"Legacy Concept Name","value":"Liarozole_Fumarate"},{"name":"Maps_To","value":"Liarozole Fumarate"},{"name":"NCI_Drug_Dictionary_ID","value":"41252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41252"},{"name":"PDQ_Open_Trial_Search_ID","value":"41252"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245820"}]}}{"C80333":{"preferredName":"Liarozole Hydrochloride","code":"C80333","definitions":[{"definition":"The fumarate salt of an orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liarozole Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-5-(m-Chloro-alpha-imidazol-1-ylbenzyl)benzimidazole Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-, Monohydrochloride, (+-)-","termGroup":"SN","termSource":"NCI"},{"termName":"Liarozole HCl","termGroup":"SY","termSource":"NCI"},{"termName":"R 75251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145858-50-0"},{"name":"Chemical_Formula","value":"C17H13ClN4.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29T7S2IB97"},{"name":"Legacy Concept Name","value":"Liarozole_Hydrochloride"},{"name":"Maps_To","value":"Liarozole Hydrochloride"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697919"}]}}{"C104275":{"preferredName":"Licartin","code":"C104275","definitions":[{"definition":"An immunoradioconjugate containing metuximab, an antibody fragment targeting the hepatocellular cancer (HCC)-associated antigen HAb18G/CD147, that is conjugated to the radioisotope iodine I 131, with potential antineoplastic activity. Upon administration, the metuximab moiety of licartin targets and binds to HAb18G/CD147 on HCC cells; upon internalization, the radioisotope I 131 delivers a cytotoxic dose of gamma radiation, thereby causing selective destruction of HAb18G/CD147-expressing cells. HAb18G/CD147, a member of CD147 family, is overexpressed in HCC and fibroblasts and its expression is associated with cancer cell progression and increased adhesion, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Licartin","termGroup":"PT","termSource":"NCI"},{"termName":"(131)I-labeled HAb18 F(ab')(2)","termGroup":"SY","termSource":"NCI"},{"termName":"[131I] mAb HAb18G/CD147","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine I 131 Metuximab","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine[131I] Metuximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Licartin"},{"name":"NCI_Drug_Dictionary_ID","value":"744892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744892"},{"name":"PDQ_Open_Trial_Search_ID","value":"744892"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1722701"}]}}{"C61436":{"preferredName":"Licorice","code":"C61436","definitions":[{"definition":"A substance prepared from dried roots of the plant Glycyrrhiza glabra. It is used as a flavoring in medicines, drinks, and sweets, and it is being studied in the treatment of cancer. Licorice root extract contains several compounds that reduce inflammation, kill certain bacteria and viruses, act like estrogen and other hormones, and may cause cancer cells to die. It is a type of antioxidant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An herbal extract derived from the root of the plant Glycyrrhiza glabra with potential anti-inflammatory, antioxidant, and antineoplastic activities. Licorice root extract contains glycoside glycyrrhizinic acid and numerous flavonoids. Glycyrrhizinic acid in licorice root extract is hydrolyzed to glycyrrhetic acid (GA); GA inhibits 11 beta-hydroxysteroid dehydrogenase, resulting in inhibition of the conversion of cortisol to the inactive steroid cortisone and elevated cortisol levels. In addition, GA inhibits 17,20-lyase and 17 beta-hydroxysteroid dehydrogenase, resulting in decreased conversions of 17-hydroxyprogesterone to androstenedione and androstenedione to testosterone. The primary antioxidant found in licorice root, the flavonoid glabridin, may inactivate or inhibit the activities of some cytochrome P450 enzymes. In tumor cells, beta-hydroxy-DHP, another flavonoid, may induce Bcl-2 phosphorylation, apoptosis, and G2/M cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Licorice","termGroup":"PT","termSource":"NCI"},{"termName":"Glycyrrhiza","termGroup":"SY","termSource":"NCI"},{"termName":"Glycyrrhizae Radix","termGroup":"SY","termSource":"NCI"},{"termName":"Licorice Root Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"61ZBX54883"},{"name":"Legacy Concept Name","value":"Licorice_Root_Extract"},{"name":"Maps_To","value":"Licorice"},{"name":"NCI_Drug_Dictionary_ID","value":"471833"},{"name":"PDQ_Closed_Trial_Search_ID","value":"471833"},{"name":"PDQ_Open_Trial_Search_ID","value":"471833"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0086555"}]}}{"C116747":{"preferredName":"Lifastuzumab Vedotin","code":"C116747","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the sodium-dependent phosphate transport protein 2B (NaPi2b), and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DNIB0600A binds to NaPi2b-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. NaPi2b, a tumor-associated antigen (TAA), overexpressed in a variety of cancer cell types, plays a key role in transport of inorganic phosphate and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lifastuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DNIB0600A","termGroup":"SY","termSource":"NCI"},{"termName":"DNIB0600A","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7599","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401812-88-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7IUT83FK6S"},{"name":"Maps_To","value":"Lifastuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"701789"},{"name":"NCI_META_CUI","value":"CL433844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701789"},{"name":"PDQ_Open_Trial_Search_ID","value":"701789"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137951":{"preferredName":"Belzupacap Sarotalocan","code":"C137951","definitions":[{"definition":"A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belzupacap Sarotalocan","termGroup":"PT","termSource":"NCI"},{"termName":"AU-011","termGroup":"CN","termSource":"NCI"},{"termName":"HPV-NP AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Virus-like Particles Conjugated with IR700 Dye AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"Light-activated AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"Viral Nanoparticle Conjugates AU-011","termGroup":"SY","termSource":"NCI"},{"termName":"VNC AU-011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2390462-37-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DK0ZGA5Y2R"},{"name":"Maps_To","value":"Light-activated AU-011"},{"name":"NCI_Drug_Dictionary_ID","value":"790618"},{"name":"NCI_META_CUI","value":"CL524973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790618"},{"name":"PDQ_Open_Trial_Search_ID","value":"790618"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79833":{"preferredName":"Olvimulogene Nanivacirepvec","code":"C79833","definitions":[{"definition":"An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olvimulogene Nanivacirepvec","termGroup":"PT","termSource":"NCI"},{"termName":"GL-ONC1","termGroup":"CN","termSource":"NCI"},{"termName":"GLV-1h68","termGroup":"CN","termSource":"NCI"},{"termName":"Olvi-Vec","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1473430-36-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CF19SF72O5"},{"name":"Legacy Concept Name","value":"Light-Emitting_Oncolytic_Vaccinia_Virus_GL-ONC1"},{"name":"Maps_To","value":"Light-Emitting Oncolytic Vaccinia Virus GL-ONC1"},{"name":"Maps_To","value":"Olvimulogene Nanivacirepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"629379"},{"name":"NCI_META_CUI","value":"CL388438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629379"},{"name":"PDQ_Open_Trial_Search_ID","value":"629379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61714":{"preferredName":"Limonene, (+)-","code":"C61714","definitions":[{"definition":"A terpene with two isoprene units forming a ring. The chemical structure is CC1=CCC(CC1)C(=C)C.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"An oral dietary supplement containing a natural cyclic monoterpene, and a major component of the oil extracted from citrus peels, with potential chemopreventive and antineoplastic activities. Upon oral administration, D-limonene activates aldehyde dehydrogenase 3A1 (ALDH3A1), thereby decreasing aldehyde level. This may protect salivary stem/progenitor cells (SSPCs) from toxic aldehydes and prevent or improve radiation-induced xerostomia. Limonene and its metabolites perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol may also inhibit tumor growth through inhibition of p21-dependent signaling and may induce apoptosis via the induction of the transforming growth factor beta-signaling pathway. In addition, they inhibit post-translational modification of signal transduction proteins, resulting in G1 cell cycle arrest as well as differential expression of cell cycle- and apoptosis-related genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Limonene, (+)-","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-(R)-4-isopropenyl-1-methylcyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"(+)-alpha-Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"(+)-limonene","termGroup":"SY","termSource":"NCI"},{"termName":"(4R)-1-methyl-4-(1-methylethenyl)cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"(R)-(+)-limonene","termGroup":"SY","termSource":"NCI"},{"termName":"(R)-4-isopropenyl-1-methylcyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"1-methyl-4-isopropenyl-1-cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"Alda 341","termGroup":"CN","termSource":"NCI"},{"termName":"Alda-341","termGroup":"CN","termSource":"NCI"},{"termName":"Alda341","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclohexene, 1-methyl-4-(1-methylethenyl)-, (4R)-","termGroup":"SN","termSource":"NCI"},{"termName":"D-Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"Limonene, D-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5989-27-5"},{"name":"CAS_Registry","value":"7705-13-7"},{"name":"CHEBI_ID","value":"CHEBI:15382"},{"name":"Chemical_Formula","value":"C10H16"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GFD7C86Q1W"},{"name":"Legacy Concept Name","value":"D-Limonene"},{"name":"Maps_To","value":"Limonene, (+)-"},{"name":"NCI_Drug_Dictionary_ID","value":"664042"},{"name":"PDQ_Closed_Trial_Search_ID","value":"664042"},{"name":"PDQ_Open_Trial_Search_ID","value":"664042"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0950252"}]}}{"C61709":{"preferredName":"Limonene, (+/-)-","code":"C61709","definitions":[{"definition":"A racemic mixture of limonene, a natural cyclic monoterpene and major component of the oil extracted from citrus rind with chemo-preventive and antitumor activities. The metabolites of DL-limonene, perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol are suggested to inhibit tumor growth through inhibition of p21-dependent signaling, induce apoptosis via the induction of the transforming growth factor beta-signaling pathway, inhibit post-translational modification of signal transduction proteins, result in G1 cell cycle arrest as well as cause differential expression of cell cycle- and apoptosis-related genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Limonene, (+/-)-","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-1-methyl-4-(1-methylethenyl)cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"1-methyl-4-(1-methylethenyl)cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"1-methyl-4-prop-1-en-2-yl-cyclohexene","termGroup":"SN","termSource":"NCI"},{"termName":"Cajeputene","termGroup":"SY","termSource":"NCI"},{"termName":"Cinene","termGroup":"SY","termSource":"NCI"},{"termName":"Dipentene","termGroup":"SY","termSource":"NCI"},{"termName":"DL-Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"Eulimen","termGroup":"SY","termSource":"NCI"},{"termName":"Limonene","termGroup":"SY","termSource":"NCI"},{"termName":"Nesol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"138-86-3"},{"name":"CHEBI_ID","value":"CHEBI:15384"},{"name":"Chemical_Formula","value":"C10H16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9MC3I34447"},{"name":"Legacy Concept Name","value":"DL-Limonene"},{"name":"Maps_To","value":"Limonene, (+/-)-"},{"name":"NSC Number","value":"21446"},{"name":"NSC Number","value":"844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1880232"}]}}{"C71759":{"preferredName":"Linifanib","code":"C71759","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. ABT-869 blocks the action of several growth factors. It may also block the growth of new blood vessels that tumors need to grow and may cause cancer cells to die. It is a type of receptor tyrosine kinase inhibitor and a type of angiogensis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linifanib","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-869","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"796967-16-3"},{"name":"Chemical_Formula","value":"C21H18FN5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CO93X137CW"},{"name":"Legacy Concept Name","value":"Receptor_Tyrosine_Kinase_Inhibitor_ABT-869"},{"name":"Maps_To","value":"Linifanib"},{"name":"NCI_Drug_Dictionary_ID","value":"558913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558913"},{"name":"PDQ_Open_Trial_Search_ID","value":"558913"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4048786"}]}}{"C101792":{"preferredName":"Linoleyl Carbonate-Paclitaxel","code":"C101792","definitions":[{"definition":"A formulation of the 6-omega fatty acid derivative 2'-linoleyl carbonate (LOC) conjugated to paclitaxel, a taxane compound extracted from the Pacific yew tree Taxus brevifolia, with potential antineoplastic activity. Paclitaxel binds to and stabilizes tubulin, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. LOC enhances the uptake of paclitaxel by tumor cells, thereby concentrating this agent in tumor cells compared to normal cells, and may decrease its toxicity profile; fatty acids serve as energy sources and biochemical precursors for the fast growing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linoleyl Carbonate-Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"2-Linoleyl Carbonate-paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"LOC-paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Linoleyl Carbonate-Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"733643"},{"name":"NCI_META_CUI","value":"CL435910"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733643"},{"name":"PDQ_Open_Trial_Search_ID","value":"733643"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C141135":{"preferredName":"Linrodostat","code":"C141135","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, linrodostat specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, BMS-986205 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linrodostat","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide","termGroup":"SN","termSource":"NCI"},{"termName":"BMS 986205","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986205","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986205","termGroup":"CN","termSource":"NCI"},{"termName":"IDO-1 Inhibitor BMS-986205","termGroup":"SY","termSource":"NCI"},{"termName":"Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205","termGroup":"SY","termSource":"NCI"},{"termName":"ONO-7701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1923833-60-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0A7729F42K"},{"name":"Maps_To","value":"Linrodostat"},{"name":"NCI_Drug_Dictionary_ID","value":"791293"},{"name":"NCI_META_CUI","value":"CL539187"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791293"},{"name":"PDQ_Open_Trial_Search_ID","value":"791293"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70982":{"preferredName":"Linsitinib","code":"C70982","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks a protein called IGF-1R, which is found at high levels in some types of tumors. IGF-1R is needed for cell growth and blocking it may cause tumor cells to die. IGF-1R inhibitor OSI-906 is a type of IGF-1R inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linsitinib","termGroup":"PT","termSource":"NCI"},{"termName":"cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, cis-","termGroup":"SN","termSource":"NCI"},{"termName":"OSI-906","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-906AA","termGroup":"CN","termSource":"NCI"},{"termName":"OSI906","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"867160-71-2"},{"name":"Chemical_Formula","value":"C26H23N5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"15A52GPT8T"},{"name":"Legacy Concept Name","value":"IGF-1R_Inhibitor_OSI-906"},{"name":"Maps_To","value":"Linsitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"566191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"566191"},{"name":"PDQ_Open_Trial_Search_ID","value":"566191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346449"}]}}{"C1716":{"preferredName":"Lintuzumab","code":"C1716","definitions":[{"definition":"A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of myelodysplastic syndromes and some types of leukemia. It binds to CD33, a protein on the surface of certain normal blood stem cells and some abnormal blood cells. It causes the immune system to kill these cells. Lintuzumab is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lintuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Hu-M195 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"HuG1-M195 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized M195","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb HuG1-M195","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb HuM195","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody HuG1-M195","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody HuM195","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody HuM195 HuG1-M195","termGroup":"SY","termSource":"NCI"},{"termName":"SGN-33","termGroup":"CN","termSource":"NCI"},{"termName":"SMART M195","termGroup":"SY","termSource":"NCI"},{"termName":"Zamyl","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"166089-32-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V00Y10W60W"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuG1-M195"},{"name":"Maps_To","value":"Lintuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"42049"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42049"},{"name":"PDQ_Open_Trial_Search_ID","value":"42049"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0530093"}]}}{"C2396":{"preferredName":"Liothyronine I-131","code":"C2396","definitions":[{"definition":"A radioconjugate of synthetic active thyroid hormone, liothyronine (T3), labeled with Iodine 131. Liothyronine involves many important metabolic functions and is essential to the proper development and differentiation of all cells. I131 liothyronine may be used in radiotherapy in thyroid cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liothyronine I-131","termGroup":"PT","termSource":"NCI"},{"termName":"I 131 Liothyronine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"20196-64-9"},{"name":"Chemical_Formula","value":"C15H12I3NO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"86AZ0G22V2"},{"name":"Legacy Concept Name","value":"I_131_Liothyronine"},{"name":"Maps_To","value":"Liothyronine I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"39721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39721"},{"name":"PDQ_Open_Trial_Search_ID","value":"39721"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338103"}]}}{"C2581":{"preferredName":"Liothyronine Sodium","code":"C2581","definitions":[{"definition":"A drug that is used to treat certain thyroid (a gland located near the voice box) conditions. It is also being studied in the treatment of thyroid cancer. Cytomel is made in the laboratory and is a form of the thyroid hormone triiodthyronine (T3).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liothyronine Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Cytomel","termGroup":"BR","termSource":"NCI"},{"termName":"Triostat","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"55-06-1"},{"name":"CHEBI_ID","value":"CHEBI:6484"},{"name":"Chemical_Formula","value":"C15H11I3NO4.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GCA9VV7D2N"},{"name":"Legacy Concept Name","value":"Liothyronine_Sodium"},{"name":"Maps_To","value":"Liothyronine Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43629"},{"name":"PDQ_Open_Trial_Search_ID","value":"43629"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0546882"}]}}{"C116889":{"preferredName":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1","code":"C116889","definitions":[{"definition":"short interfering RNAs (siRNAs) directed against polo-like kinase 1 (PLK1, STPK13), with potential antineoplastic activity. Upon administration of lipid-encapsulated anti-PLK1 siRNA TKM-PLK1, siRNA binds to PLK1 mRNA, which results in the inhibition of both the translation and expression of the PLK1 protein. Blockage of PLK1 expression prevents proper tumor cell mitosis, causes cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis; its expression is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation. The pegylated lipid bilayer of SNALP provides stability and protects siRNA degradation; it facilitates uptake into the cell and release from endosomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1","termGroup":"PT","termSource":"NCI"},{"termName":"PLK1 SNALP","termGroup":"SY","termSource":"NCI"},{"termName":"PLK1424","termGroup":"CN","termSource":"NCI"},{"termName":"TKM-080301","termGroup":"CN","termSource":"NCI"},{"termName":"TKM-PLK1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1"},{"name":"NCI_Drug_Dictionary_ID","value":"691765"},{"name":"NCI_META_CUI","value":"CL433763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691765"},{"name":"PDQ_Open_Trial_Search_ID","value":"691765"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160867":{"preferredName":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191","code":"C160867","definitions":[{"definition":"A formulation consisting of lipid nanoparticle encapsulated messenger RNA (mRNA) encoding human interleukin-12 subunit beta (IL-12B; IL-12 subunit p40) and interleukin-12 subunit alpha (IL-12A; IL-12 subunit p35) with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon intratumoral injection, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the IL-12A and IL-12B mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce a single-chain fusion protein of IL-12B and IL-12A subunits, which is secreted into the local tumor microenvironment (TME). Secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191","termGroup":"PT","termSource":"NCI"},{"termName":"LNP Encapsulated Human IL-12A/IL-12B mRNAs MEDI-1191","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-1191","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI1191","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191"},{"name":"NCI_Drug_Dictionary_ID","value":"798427"},{"name":"NCI_META_CUI","value":"CL969889"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798427"},{"name":"PDQ_Open_Trial_Search_ID","value":"798427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142137":{"preferredName":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416","code":"C142137","definitions":[{"definition":"A proprietary formulation consisting of a lipid nanoparticle encapsulating a synthetic messenger RNA (mRNA) encoding the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), with potential immunomodulatory and antitumor activities. Although the mechanism of action has not been completely characterized, following intratumoral injection of lipid nanoparticle encapsulated OX40L mRNA-2416, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the OX40L mRNA into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes. Altogether, this may enhance an immune response that promotes the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L","termGroup":"SY","termSource":"NCI"},{"termName":"mRNA 2416","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-2416","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulated OX40L mRNA-2416"},{"name":"NCI_Drug_Dictionary_ID","value":"791451"},{"name":"NCI_META_CUI","value":"CL540181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791451"},{"name":"PDQ_Open_Trial_Search_ID","value":"791451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157247":{"preferredName":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","code":"C157247","definitions":[{"definition":"A lipid nanoparticle encapsulating mRNAs encoding for the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), the pro-inflammatory cytokines interleukin-23 (IL-23) and interleukin-36gamma (IL-36gamma), with potential immunomodulatory and anti-tumor activities. Upon intratumoral (IT) injection of the lipid nanoparticle encapsulated mRNAs encoding human OX40L/IL-23/IL-36gamma mRNA-2752, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNAs into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes against the nearby tumor cells. The co-administration of IL-23 and IL-36gamma further stimulates anti-tumor immune responses. Altogether, this may enhance T-cell mediated anti-tumor immune responses thereby killing of the tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. IL-36gamma activates innate immune cells and promotes T-helper 1 (Th1) responses, whereas IL-23 has been implicated in Th1/Th17 immunity as well as in the modulation of antigen-presenting cells (APCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulated mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752","termGroup":"SY","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulated OX40L/IL-23/IL-36gamma mRNAs mRNA-2752","termGroup":"SY","termSource":"NCI"},{"termName":"mRNA 2752","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-2752","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA2752","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752"},{"name":"NCI_Drug_Dictionary_ID","value":"796816"},{"name":"NCI_META_CUI","value":"CL936882"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796816"},{"name":"PDQ_Open_Trial_Search_ID","value":"796816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95718":{"preferredName":"Liposomal c-raf Antisense Oligonucleotide","code":"C95718","definitions":[{"definition":"The liposomal formulation of a c-raf-1 antisense oligonucleotide, with potential antineoplastic activity. Liposomal c-raf antisense oligonucleotide targets the translation initiation site of human c-raf-1 mRNA, thereby blocking the expression and production of Raf-1 protein and thus inhibit tumor cell growth and development. Raf-1 plays a key role in the RAF/MEK/ERK signaling pathway, which regulates mammalian cell proliferation and growth. The liposomal formulation increases the solubility of the c-raf antisense oligonucleotide, thus improving its pharmacodynamic profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal c-raf Antisense Oligonucleotide","termGroup":"PT","termSource":"NCI"},{"termName":"c-raf Antisense Oligodeoxynucleotide Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"LErafAON","termGroup":"AB","termSource":"NCI"},{"termName":"liposome-encapsulated c-raf Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal c-raf Antisense Oligonucleotide"},{"name":"NCI_Drug_Dictionary_ID","value":"419645"},{"name":"PDQ_Closed_Trial_Search_ID","value":"419645"},{"name":"PDQ_Open_Trial_Search_ID","value":"419645"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1436330"}]}}{"C116322":{"preferredName":"Liposomal Curcumin","code":"C116322","definitions":[{"definition":"A liposomal formulation containing curcumin, a poorly water-soluble polylphenol pigment isolated from the plant Curcuma longa, with potential antineoplastic, chemopreventive, antioxidant, anti-angiogenic and anti-inflammatory activities. Upon intravenous administration of liposomal curcumin, this agent blocks the formation of reactive-oxygen species, neutralizes free radicals, and exhibits anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation. In addition, curcumin disrupts various cell signal transduction pathways involved in carcinogenesis, inhibits the activity of nuclear factor-kappa B (NF-kB), SRC, and annexin A2 (ANXA2), and reduces the expression of both matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor receptor 2 (VEGFR2). This prevents and/or inhibits tumor cell formation and proliferation. Liposome encapsulation of curcumin improves its efficacy, when compared to the administration of unencapsulated curcumin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Curcumin","termGroup":"PT","termSource":"NCI"},{"termName":"Curcumin Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Curcumin"},{"name":"NCI_Drug_Dictionary_ID","value":"761276"},{"name":"NCI_META_CUI","value":"CL473656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761276"},{"name":"PDQ_Open_Trial_Search_ID","value":"761276"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2388":{"preferredName":"Liposomal Cytarabine","code":"C2388","definitions":[{"definition":"A form of the anticancer drug cytarabine that is contained inside very tiny, fat-like particles. It may have fewer side effects and work better than cytarabine. It is used to treat lymphoma that has spread to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. It is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Cytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"Cytarabine Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Cytarabine Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"DepoCyt","termGroup":"BR","termSource":"NCI"},{"termName":"DepoCyte","termGroup":"FB","termSource":"NCI"},{"termName":"DepoFoam Encapsulated Cytarabine","termGroup":"SY","termSource":"NCI"},{"termName":"DTC 101","termGroup":"CN","termSource":"NCI"},{"termName":"Encapsulated Cytarabine","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Ara-C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Lymphomatous meningitis"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Liposomal_Cytarabine"},{"name":"Maps_To","value":"Liposomal Cytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"42260"},{"name":"NSC Number","value":"715320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42260"},{"name":"PDQ_Open_Trial_Search_ID","value":"42260"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0795597"}]}}{"C2213":{"preferredName":"Liposomal Daunorubicin Citrate","code":"C2213","definitions":[{"definition":"A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Daunorubicin Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Daunorubicin Citrate Liposome Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicin Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"DaunoXome","termGroup":"BR","termSource":"NCI"},{"termName":"Liposomal Daunorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Nonlymphocytic Leukemia; Acute Lymphocytic Leukemia; Advanced HIV-associated Karposi Sarcoma."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Liposomal_Daunorubicin_Citrate"},{"name":"Maps_To","value":"Liposomal Daunorubicin Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"37796"},{"name":"NSC Number","value":"697732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37796"},{"name":"PDQ_Open_Trial_Search_ID","value":"37796"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0717668"}]}}{"C92581":{"preferredName":"Liposomal Docetaxel","code":"C92581","definitions":[{"definition":"A formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel encapsulated within liposomes, with antineoplastic activity.  Upon intravenous administration, docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death.  This liposomal formulation solubilizes docetaxel without the use of toxic solvents such as Tween 80, permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity, including hypersensitivity reactions. In addition, liposomal delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"LE-DT","termGroup":"AB","termSource":"NCI"},{"termName":"Liposome Entrapped Docetaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"684963"},{"name":"NCI_META_CUI","value":"CL423830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684963"},{"name":"PDQ_Open_Trial_Search_ID","value":"684963"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111899":{"preferredName":"Liposomal Eribulin Mesylate","code":"C111899","definitions":[{"definition":"A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance derived from the marine sponge genus Halichondria, with potential antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits both the polymerization of tubulin and the assembly of microtubules. This results in the inhibition of mitotic spindle assembly, the induction of cell cycle arrest at G2/M phase, as well as tumor cell apoptosis. Compared to the administration of eribulin alone, liposomal delivery of eribulin allows for a longer half-life, which allows increased drug concentration in target tissues while decreasing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Eribulin Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"E7389 Liposomal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"E7389-LF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Eribulin Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"753504"},{"name":"NCI_META_CUI","value":"CL454231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753504"},{"name":"PDQ_Open_Trial_Search_ID","value":"753504"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111688":{"preferredName":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","code":"C111688","definitions":[{"definition":"A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","termGroup":"PT","termSource":"NCI"},{"termName":"mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"PDS0101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101"},{"name":"NCI_Drug_Dictionary_ID","value":"752827"},{"name":"NCI_META_CUI","value":"CL454078"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752827"},{"name":"PDQ_Open_Trial_Search_ID","value":"752827"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82676":{"preferredName":"Irinotecan Sucrosofate","code":"C82676","definitions":[{"definition":"A liposomal dispersion formulated with the semisynthetic camptothecin analogue irinotecan, provided as the hydrochloride trihydrate form, which is encapsulated and entrapped within liposomes in a gelated or precipitated state as the irinotecan sucrose octasulfate (sucrosulfate) salt form, with potential antineoplastic activity. Upon administration of the liposomes containing irinotecan sucrosulfate, irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. During the S-phase, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell, extends the circulation of irinotecan, and prolongs the duration of active therapy at the site of tumor to inhibit tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irinotecan Sucrosofate","termGroup":"PT","termSource":"NCI"},{"termName":"inotecan Hydrochloride as Sucrosulfate Salt Form Liposomal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Sucrosofate Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Irinotecan Sucrosofate-containing Pegylated Liposomal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"MM 398","termGroup":"CN","termSource":"NCI"},{"termName":"MM-398","termGroup":"CN","termSource":"NCI"},{"termName":"MM398","termGroup":"CN","termSource":"NCI"},{"termName":"nal-IRI","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoliposomal Irinotecan","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoliposomal Irinotecan as Sucrosofate","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Liposome Formulation of Irinotecan","termGroup":"SY","termSource":"NCI"},{"termName":"Onivyde","termGroup":"BR","termSource":"NCI"},{"termName":"PEP 02","termGroup":"CN","termSource":"NCI"},{"termName":"PEP-02","termGroup":"CN","termSource":"NCI"},{"termName":"PEP02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic adenocarcinoma of the pancreas"},{"name":"CAS_Registry","value":"1361317-83-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OL741S3N8B"},{"name":"Legacy Concept Name","value":"Liposome-Encapsulated_Irinotecan_Hydrochloride_PEP02"},{"name":"Maps_To","value":"Irinotecan Sucrosofate"},{"name":"Maps_To","value":"Liposomal Irinotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"632436"},{"name":"PDQ_Closed_Trial_Search_ID","value":"632436"},{"name":"PDQ_Open_Trial_Search_ID","value":"632436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4057931"}]}}{"C116064":{"preferredName":"Liposomal Mitoxantrone Hydrochloride","code":"C116064","definitions":[{"definition":"A formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in the rapidly dividing cancer cells. The liposomal delivery of mitoxantrone improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering the toxic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Mitoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Mitoxantrone Hydrochloride Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Mitoxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"760808"},{"name":"NCI_META_CUI","value":"CL473483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760808"},{"name":"PDQ_Open_Trial_Search_ID","value":"760808"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101262":{"preferredName":"Liposomal MUC1/PET-lipid A Vaccine ONT-10","code":"C101262","definitions":[{"definition":"A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine ONT-10 results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal MUC1/PET-lipid A Vaccine ONT-10","termGroup":"PT","termSource":"NCI"},{"termName":"ONT-10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal MUC1/PET-lipid A Vaccine ONT-10"},{"name":"NCI_Drug_Dictionary_ID","value":"729635"},{"name":"NCI_META_CUI","value":"CL435510"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729635"},{"name":"PDQ_Open_Trial_Search_ID","value":"729635"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1383":{"preferredName":"Liposomal NDDP","code":"C1383","definitions":[{"definition":"A synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement of the 2 long-chain aliphatic leaving groups (neodecanoic acid), platinum diaminocyclohexane (DACH) complexes become highly reactive and alkylate macromolecules, forming both inter- and intra-stranded DNA cross-linkings and inhibiting DNA synthesis, which results in tumor cell cytotoxicity. Because DNA mismatch-repair (MMR) complexes do not recognize DACH-platinum adducts, DNA repair mechanisms are inhibited, overcoming limitations observed with other platinum-based agents. In addition, the liposomal encapsulation improves the bioavailability of NDDP and reduces its toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal NDDP","termGroup":"PT","termSource":"NCI"},{"termName":"Aroplatin","termGroup":"BR","termSource":"NCI"},{"termName":"L-NDDP","termGroup":"AB","termSource":"NCI"},{"termName":"Liposomal Neodecanoic Acid Platinum Complex","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal-Cisplatin Analogue","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal-Entrapped Cis-Bis-Neodecanoate-trans-R,R-1,2-Diaminocyclohexane Platinum (II)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"114488-24-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J7M4Z2D183"},{"name":"Legacy Concept Name","value":"Liposomal-Cisplatin_Analogue"},{"name":"Maps_To","value":"Liposomal NDDP"},{"name":"NCI_Drug_Dictionary_ID","value":"43010"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43010"},{"name":"PDQ_Open_Trial_Search_ID","value":"43010"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0125061"}]}}{"C188608":{"preferredName":"Rhenium Re 186 Obisbemeda","code":"C188608","definitions":[{"definition":"A therapeutic preparation consisting of the beta-emitting radioisotope rhenium Re 186 encapsulated in a nanoliposome, with potential antineoplastic activity. Upon intratumoral infusion of liposomal rhenium Re 186, the radioisotope releases radiation, which directly kills the tumor cells. The nanoliposomes facilitate the retention of the radioisotope by the tumor cells and localize the radiocytotoxicity to the tumor while sparing surrounding normal, healthy cells. Re-186 has a short half-life and a short path length, which contributes further to limiting the radiotoxicity to the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re 186 Obisbemeda","termGroup":"PT","termSource":"NCI"},{"termName":"(186)Re-Liposomes","termGroup":"SY","termSource":"NCI"},{"termName":"186RNL","termGroup":"AB","termSource":"NCI"},{"termName":"Liposomal Rhenium Re 186","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Rhenium-186","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium (186re) Obisbemeda","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-186 Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"644961-22-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O5L8T4LD4L"},{"name":"Maps_To","value":"Liposomal Rhenium Re 186"},{"name":"NCI_Drug_Dictionary_ID","value":"751420"},{"name":"NCI_META_CUI","value":"CL1793795"},{"name":"NCI_META_CUI","value":"CL451869"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95717":{"preferredName":"Liposomal SN-38","code":"C95717","definitions":[{"definition":"The liposomal formulation of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. SN-38 has been reported to exhibit up to 1,000-fold more cytotoxic activity against various cancer cells in vitro than irinotecan. The liposomal formulation of SN-38 increases the solubility of SN-38, which is a relatively insoluble compound, and improves the pharmacodynamic profile as compared to SN-38 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal SN-38","termGroup":"PT","termSource":"NCI"},{"termName":"7-Ethyl-10-hydroxycamptothecin Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"LE-SN38","termGroup":"AB","termSource":"NCI"},{"termName":"SN-38 Liposome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal SN-38"},{"name":"NCI_Drug_Dictionary_ID","value":"355805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355805"},{"name":"PDQ_Open_Trial_Search_ID","value":"355805"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328201"}]}}{"C165505":{"preferredName":"Liposomal Topotecan FF-10850","code":"C165505","definitions":[{"definition":"A liposome encapsulated formulation of the semisynthetic camptothecin analogue topotecan with potential antineoplastic activity. Upon administration, liposomal topotecan FF-10850 preferentially releases topotecan, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminate, into the tumor environment. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The novel liposome used in this agent prolongs its serum half-life while promoting efficient drug delivery into the cytosol from the endosome compartment of the tumor cell, which may minimize the adverse effect of bone marrow suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Topotecan FF-10850","termGroup":"PT","termSource":"NCI"},{"termName":"FF 10850","termGroup":"CN","termSource":"NCI"},{"termName":"FF-10850","termGroup":"CN","termSource":"NCI"},{"termName":"FF10850","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Topotecan FF-10850"},{"name":"NCI_Drug_Dictionary_ID","value":"799933"},{"name":"NCI_META_CUI","value":"CL978696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799933"},{"name":"PDQ_Open_Trial_Search_ID","value":"799933"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62790":{"preferredName":"Liposomal Vinorelbine","code":"C62790","definitions":[{"definition":"A formulation of the semisynthetic vinca alkaloid, vinorelbine, encapsulated within liposomes, with antineoplastic activity. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in cell cycle arrest in metaphase. Like other vinca alkaloids, vinorelbine may also interfere with the metabolism of nucleic acids, lipids, amino acids, cAMP, and glutathione, as well as other biological processes including calmodulin-dependent Ca2+-transport, ATPase activity, or cellular respiration. Liposomal delivery of vinorelbine improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Vinorelbine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liposomal_Vinorelbine"},{"name":"Maps_To","value":"Liposomal Vinorelbine"},{"name":"NCI_Drug_Dictionary_ID","value":"507579"},{"name":"PDQ_Closed_Trial_Search_ID","value":"507579"},{"name":"PDQ_Open_Trial_Search_ID","value":"507579"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831959"}]}}{"C135619":{"preferredName":"Liposomal Vinorelbine Tartrate","code":"C135619","definitions":[{"definition":"A formulation of the tartrate salt form of vinorelbine, a semisynthetic vinca alkaloid, encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, vinorelbine binds to tubulin within tumor cells and prevents the formation of the mitotic spindle, resulting in cell cycle arrest, induction of apoptosis and an inhibition of tumor cell growth. Compared to the administration of vinorelbine alone, the liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing vinorelbine's efficacy while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Vinorelbine Tartrate","termGroup":"PT","termSource":"NCI"},{"termName":"TLC-178","termGroup":"CN","termSource":"NCI"},{"termName":"TLC178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Vinorelbine Tartrate"},{"name":"NCI_Drug_Dictionary_ID","value":"789502"},{"name":"NCI_META_CUI","value":"CL522975"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789502"},{"name":"PDQ_Open_Trial_Search_ID","value":"789502"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C18208":{"preferredName":"Liposome","code":"C18208","definitions":[{"definition":"A very tiny, fat-like particle that is made in the laboratory. In medicine, liposomes containing drugs or other substances are used in the treatment of cancer and other diseases. Drugs given in liposomes may have fewer side effects and work better than the same drugs given alone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Substances composed of layers of lipid that form hollow microscopic spheres within which drugs or agents could be contained for enhanced safety and efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liposome"},{"name":"Maps_To","value":"Liposome"},{"name":"Semantic_Type","value":"Drug Delivery Device"},{"name":"UMLS_CUI","value":"C0023828"}]}}{"C67504":{"preferredName":"Liposome-encapsulated Daunorubicin-Cytarabine","code":"C67504","definitions":[{"definition":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated Daunorubicin-Cytarabine","termGroup":"PT","termSource":"NCI"},{"termName":"CPX 351","termGroup":"CN","termSource":"NCI"},{"termName":"CPX-351","termGroup":"CN","termSource":"NCI"},{"termName":"CPX351","termGroup":"CN","termSource":"NCI"},{"termName":"Cytarabine and Daunorubicin Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Cytarabine-Daunorubicin Liposome for Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal AraC-Daunorubicin CPX-351","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Cytarabine-Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Liposome-encapsulated Combination of Daunorubicin and Cytarabine","termGroup":"SY","termSource":"NCI"},{"termName":"Vyxeos","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Liposomal_Cytarabine-Daunorubicin_CPX-351"},{"name":"Maps_To","value":"Liposome-encapsulated Daunorubicin-Cytarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"554979"},{"name":"NCI_META_CUI","value":"CL372099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"554979"},{"name":"PDQ_Open_Trial_Search_ID","value":"554979"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61317":{"preferredName":"Liposome-Encapsulated Doxorubicin Citrate","code":"C61317","definitions":[{"definition":"A form of the anticancer drug doxorubicin citrate that is contained inside very tiny, fat-like particles. It is being studied in the treatment of breast cancer that has spread and in the treatment of other types of cancer. Doxorubicin citrate damages DNA and may kill cancer cells. Liposomal-encapsulated doxorubicin citrate may have fewer side effects and may work better than doxorubicin citrate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-Encapsulated Doxorubicin Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Myocet","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111266-55-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"AJQ2ZNG2WL"},{"name":"Legacy Concept Name","value":"Liposome-Encapsulated_Doxorubicin_Citrate"},{"name":"Maps_To","value":"Liposome-Encapsulated Doxorubicin Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"481301"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481301"},{"name":"PDQ_Open_Trial_Search_ID","value":"481301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1512062"}]}}{"C105802":{"preferredName":"Liposome-encapsulated miR-34 Mimic MRX34","code":"C105802","definitions":[{"definition":"A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated miR-34 Mimic MRX34","termGroup":"PT","termSource":"NCI"},{"termName":"MRX34","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposome-encapsulated miR-34 Mimic MRX34"},{"name":"NCI_Drug_Dictionary_ID","value":"747643"},{"name":"NCI_META_CUI","value":"CL447293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747643"},{"name":"PDQ_Open_Trial_Search_ID","value":"747643"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38694":{"preferredName":"Liposome-encapsulated OSI-7904","code":"C38694","definitions":[{"definition":"A liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called thymidylate synthase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Liposome-encapsulated OSI-7904","termGroup":"PT","termSource":"NCI"},{"termName":"GS7904L","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-7904L","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"139987-54-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ON177ZCE7M"},{"name":"Legacy Concept Name","value":"OSI-7904L"},{"name":"Maps_To","value":"Liposome-encapsulated OSI-7904"},{"name":"NCI_Drug_Dictionary_ID","value":"352016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352016"},{"name":"PDQ_Open_Trial_Search_ID","value":"352016"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328144"}]}}{"C106271":{"preferredName":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94","code":"C106271","definitions":[{"definition":"A systemic gene therapy anti-cancer agent composed of cationic liposomes, which encapsulates plasmid DNA encoding for the tumor suppressor gene RB94 and is complexed with anti-transferrin receptor single chain antibody fragment (TfRscFv), with potential antineoplastic activity. Upon systemic administration of liposome-encapsulated RB94 plasmid DNA gene therapy agent SGT-94, the TfRscFv portion of this agent selectively targets the tumor cells expressing transferrin receptors. TfRscFv binding to the transferrin receptor allows receptor-mediated endocytosis and transfection, followed by the expression of RB94 gene. This induces tumor cell apoptosis through an as of yet unknown pathway. RB94 is a modified, N-terminal truncated form of the full-length protein retinoblastoma gene RB110, and exerts enhanced antitumor activity. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin, and is overexpressed in a variety of tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94","termGroup":"PT","termSource":"NCI"},{"termName":"SGT-94","termGroup":"CN","termSource":"NCI"},{"termName":"TfRscFv/Lip/RB94","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94"},{"name":"NCI_Drug_Dictionary_ID","value":"724243"},{"name":"NCI_META_CUI","value":"CL433963"},{"name":"PDQ_Closed_Trial_Search_ID","value":"724243"},{"name":"PDQ_Open_Trial_Search_ID","value":"724243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103820":{"preferredName":"Lirilumab","code":"C103820","definitions":[{"definition":"A fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon administration, lirilumab binds to KIR, thereby preventing the binding of KIR ligands to KIR on natural killer (NK) cells. By blocking these inhibitory receptors, NK cells become activated and attack cancer cells leading to tumor cell death. KIR, a member of the immunoglobulin superfamily, is expressed on the surface of NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirilumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-986015","termGroup":"CN","termSource":"NCI"},{"termName":"IPH2102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000676-41-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9XDI9W918"},{"name":"Maps_To","value":"Lirilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"742530"},{"name":"NCI_META_CUI","value":"CL438303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742530"},{"name":"PDQ_Open_Trial_Search_ID","value":"742530"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97664":{"preferredName":"Lisavanbulin","code":"C97664","definitions":[{"definition":"An orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL27862 with potential antitumor activity. Upon administration of lisavanbulin and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lisavanbulin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2,6-Diamino-N-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1H-benzimidazol-1-yl)acetyl)phenyl)hexanamide","termGroup":"SN","termSource":"NCI"},{"termName":"BAL-101553","termGroup":"CN","termSource":"NCI"},{"termName":"BAL101553","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1263384-43-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5PT0QP06X5"},{"name":"Maps_To","value":"Lisavanbulin"},{"name":"NCI_Drug_Dictionary_ID","value":"706747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706747"},{"name":"PDQ_Open_Trial_Search_ID","value":"706747"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273554"}]}}{"C125192":{"preferredName":"Lisocabtagene Maraleucel","code":"C125192","definitions":[{"definition":"A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lisocabtagene Maraleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017","termGroup":"SY","termSource":"NCI"},{"termName":"Breyanzi","termGroup":"BR","termSource":"NCI"},{"termName":"JCAR 017","termGroup":"CN","termSource":"NCI"},{"termName":"JCAR-017","termGroup":"CN","termSource":"NCI"},{"termName":"JCAR017","termGroup":"CN","termSource":"NCI"},{"termName":"Liso-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with certain types of large B-cell lymphoma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7K2YOJ14X0"},{"name":"Maps_To","value":"Lisocabtagene Maraleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"778386"},{"name":"NCI_META_CUI","value":"CL504006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778386"},{"name":"PDQ_Open_Trial_Search_ID","value":"778386"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120103":{"preferredName":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142","code":"C120103","definitions":[{"definition":"A cancer vaccine containing a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a fusion protein composed of the tumor-associated antigen (TAA) human prostate-specific antigen (PSA) fused to a fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-LLO-PSA vaccine ADXS31-142, the expressed LLO-PSA is processed by antigen presenting cells (APCs), presented to the immune system by both major histocompatibility complex (MHC) I and II molecules, and activates the immune system to exert both an innate and adaptive immune response involving the recruitment and activation of T-lymphocytes against PSA-expressing tumor cells as well as the inhibition of tumor-infiltrating T regulatory cells (T regs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS-PSA","termGroup":"SY","termSource":"NCI"},{"termName":"ADXS31-142","termGroup":"CN","termSource":"NCI"},{"termName":"Lm-LLO-PSA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142"},{"name":"NCI_Drug_Dictionary_ID","value":"767990"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767990"},{"name":"PDQ_Open_Trial_Search_ID","value":"767990"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896925"}]}}{"C88328":{"preferredName":"Litronesib","code":"C88328","definitions":[{"definition":"An inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein that plays an essential role during mitosis, particularly in the regulation of spindle dynamics, including assembly and maintenance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Litronesib","termGroup":"PT","termSource":"NCI"},{"termName":"KF89617","termGroup":"CN","termSource":"NCI"},{"termName":"LY2523355","termGroup":"CN","termSource":"NCI"},{"termName":"Propanamide, N-[4-(2,2-dimethyl-1-oxopropyl)-5-[[[[2-(ethylamino)ethyl]sulfonyl] amino]methyl]-4,5-dihydro-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethyl-, (-)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"910634-41-2"},{"name":"Chemical_Formula","value":"C23H37N5O4S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6611F8KYCV"},{"name":"Maps_To","value":"Litronesib"},{"name":"NCI_Drug_Dictionary_ID","value":"661443"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661443"},{"name":"PDQ_Open_Trial_Search_ID","value":"661443"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981845"}]}}{"C125631":{"preferredName":"Opolimogene Capmilisbac","code":"C125631","definitions":[{"definition":"A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, opolimogene capmilisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opolimogene Capmilisbac","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-741","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64041809","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-809","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2O95SM11L5"},{"name":"Maps_To","value":"Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809"},{"name":"Maps_To","value":"Opolimogene Capmilisbac"},{"name":"NCI_Drug_Dictionary_ID","value":"778079"},{"name":"NCI_META_CUI","value":"CL504330"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778079"},{"name":"PDQ_Open_Trial_Search_ID","value":"778079"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74055":{"preferredName":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","code":"C74055","definitions":[{"definition":"A recombinant Listeria-based cancer vaccine containing a live-attenuated strain of the facultative intracellular bacterium Listeria monocytogenes (Lm) expressing human mesothelin with potential immunostimulatory and antineoplastic activities. Upon administration of this vaccine, Listeria invade professional phagocytes within the immune system and express mesothelin, which may activate a cytotoxic T-lymphocyte (CTL) response against mesothelin-expressing tumor cells, resulting in tumor cell lysis. In addition, the Listeria vector itself may induce a potent innate and adaptive immunity unrelated to mesothelin expression. Mesothelin is a cell surface glycoprotein involved in cell adhesion and is overexpressed in many epithelial-derived cancers, including pancreatic, ovarian and lung cancers, and malignant mesotheliomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","termGroup":"PT","termSource":"NCI"},{"termName":"CRS-207","termGroup":"CN","termSource":"NCI"},{"termName":"LADD Listeria monocytogenes CRS-207","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JJX4JHS4PO"},{"name":"Legacy Concept Name","value":"Live-Attenuated_Listeria_Encoding_Human_Mesothelin_Vaccine_CRS-207"},{"name":"Maps_To","value":"Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207"},{"name":"NCI_Drug_Dictionary_ID","value":"586104"},{"name":"NCI_META_CUI","value":"CL383482"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586104"},{"name":"PDQ_Open_Trial_Search_ID","value":"586104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111998":{"preferredName":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623","code":"C111998","definitions":[{"definition":"A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-623","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623"},{"name":"NCI_Drug_Dictionary_ID","value":"754227"},{"name":"NCI_META_CUI","value":"CL454287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754227"},{"name":"PDQ_Open_Trial_Search_ID","value":"754227"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131910":{"preferredName":"Abequolixron","code":"C131910","definitions":[{"definition":"An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abequolixron","termGroup":"PT","termSource":"NCI"},{"termName":"Liver X Receptor beta Agonist RGX-104","termGroup":"SY","termSource":"NCI"},{"termName":"LXR-b Agonist RGX-104","termGroup":"SY","termSource":"NCI"},{"termName":"RGX 104","termGroup":"CN","termSource":"NCI"},{"termName":"RGX-104","termGroup":"CN","termSource":"NCI"},{"termName":"RGX104","termGroup":"CN","termSource":"NCI"},{"termName":"SB-742881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"610318-54-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q26B92650V"},{"name":"Maps_To","value":"Liver X Receptor beta Agonist RGX-104"},{"name":"NCI_Drug_Dictionary_ID","value":"786379"},{"name":"NCI_META_CUI","value":"CL520758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786379"},{"name":"PDQ_Open_Trial_Search_ID","value":"786379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148380":{"preferredName":"Lm-tLLO-neoantigens Vaccine ADXS-NEO","code":"C148380","definitions":[{"definition":"A proprietary, personalized plasmid DNA-based cancer vaccine composed of a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a proprietary plasmid vector encoding multiple, patient-specific, immunogenic neoepitopes fused to a truncated form of the immunostimulant listeriolysin O (tLLO), with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-tLLO-neoantigens vaccine ADXS-NEO, the ADXS-NEO is taken up by antigen presenting cells (APCs), such as dendritic cells (DCs), and the expressed tLLO-neoantigens fusion protein is processed and presented to the immune system by both major histocompatibility complex (MHC) I and II molecules. This activates the immune system to exert both innate and adaptive immune responses involving the recruitment and activation of T-lymphocytes against the tumor-associated antigens (TAAs) specifically expressed by the patient's tumor cells, and inhibits the immunosuppressive tumor-infiltrating T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME). This results in tumor cell lysis. The various unique mutation-derived TAAs that are used in ADXS-NEO are identified from a biopsy of the patient's tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lm-tLLO-neoantigens Vaccine ADXS-NEO","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS NEO","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS-NEO","termGroup":"CN","termSource":"NCI"},{"termName":"Neoepitope-based Immunotherapeutic ADXS-NEO","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lm-tLLO-neoantigens Vaccine ADXS-NEO"},{"name":"NCI_Drug_Dictionary_ID","value":"793901"},{"name":"NCI_META_CUI","value":"CL551029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793901"},{"name":"PDQ_Open_Trial_Search_ID","value":"793901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2499":{"preferredName":"LMB-1 Immunotoxin","code":"C2499","definitions":[{"definition":"A chimeric protein consisting of the Fv portion of a monoclonal antibody attached to a fragment of Pseudomonas exotoxin A without its cell-binding region.  LMB-1 immunotoxin targets B3, a Lewis Y-related carbohydrate epitope found on some solid tumors.  The antibody attaches to the tumor cell and the exotoxin stops protein synthesis by inactivating elongation factor 2. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-1 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"B3-NLysPE38","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-1","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-1_Immunotoxin"},{"name":"Maps_To","value":"LMB-1 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43265"},{"name":"NSC Number","value":"651311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43265"},{"name":"PDQ_Open_Trial_Search_ID","value":"43265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796420"}]}}{"C2513":{"preferredName":"LMB-2 Immunotoxin","code":"C2513","definitions":[{"definition":"A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-2 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Tac(Fv)-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized AntiTac Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-2","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-2","termGroup":"AB","termSource":"NCI"},{"termName":"LMB-2 (Anti-TAC(FV)-PE-38)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-2_Immunotoxin"},{"name":"Maps_To","value":"LMB-2 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43377"},{"name":"NSC Number","value":"676422"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43377"},{"name":"PDQ_Open_Trial_Search_ID","value":"43377"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0655013"}]}}{"C1619":{"preferredName":"LMB-7 Immunotoxin","code":"C1619","definitions":[{"definition":"A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells.  The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-7 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"B3(Fv)-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"B3(Fv)-PE38 Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"HB21(Fv)PE40","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-7","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-7 (Single-Chain Immunotoxin)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-7_Immunotoxin"},{"name":"Maps_To","value":"LMB-7 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"42683"},{"name":"NSC Number","value":"658931"},{"name":"NSC Number","value":"659639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42683"},{"name":"PDQ_Open_Trial_Search_ID","value":"42683"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0296314"}]}}{"C2472":{"preferredName":"LMB-9 Immunotoxin","code":"C2472","definitions":[{"definition":"A recombinant disulfide stabilized anti-Lewis Y IgG immunotoxin containing a 38 KD toxic element derived from the Pseudomonas aeruginosa exotoxin A and a monoclonal antibody fragment, designed to target adenocarcinomas expressing Lewis Y. LMB-9 immunotoxin attaches to tumor cells, facilitating he entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.","type":"DEFINITION","source":"NCI"},{"definition":"A toxic substance linked to an antibody that attaches to tumor cells and kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"LMB-9 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"B3 (dsFv)-PE38","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotoxin LMB-9","termGroup":"SY","termSource":"NCI"},{"termName":"LMB-9","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMB-9_Immunotoxin"},{"name":"Maps_To","value":"LMB-9 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"43018"},{"name":"NSC Number","value":"691236"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43018"},{"name":"PDQ_Open_Trial_Search_ID","value":"43018"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678023"}]}}{"C121541":{"preferredName":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164","code":"C121541","definitions":[{"definition":"A cancer vaccine containing a live, highly attenuated strain of the Gram-positive bacterium Listeria monocytogenes (LmddA) encoding a fusion protein composed of a chimeric peptide comprised of three highly immunogenic epitopes of the human tumor-associated antigen (TAA) HER2/neu (chHER2) fused to a non-hemolytic fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the LmddA-LLO-chHER2 vaccine OST31-164, the LmddA is taken up by phagocytic cells; then the listeriolysin portion of the expressed LLO-chHER2 can form pores in the phagolysosomes and the fusion protein can escape into the cytosol. In turn, the LLO-chHER2 is processed and presented to the immune system by major histocompatibility complex (MHC) I on the phagocytic cells. Antigen presentation activates the immune system to exert an immune response involving the recruitment and activation of T-lymphocytes against HER2-expressing tumor cells, and inhibits tumor-infiltrating T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis. HER2/neu, a tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, is overexpressed in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164","termGroup":"PT","termSource":"NCI"},{"termName":"ADXS 31164","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS-HER2","termGroup":"CN","termSource":"NCI"},{"termName":"ADXS31-164","termGroup":"CN","termSource":"NCI"},{"termName":"OST-HER2","termGroup":"CN","termSource":"NCI"},{"termName":"OST31 164","termGroup":"CN","termSource":"NCI"},{"termName":"OST31164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164"},{"name":"NCI_Drug_Dictionary_ID","value":"770190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770190"},{"name":"PDQ_Open_Trial_Search_ID","value":"770190"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053682"}]}}{"C62767":{"preferredName":"LMP-2:340-349 Peptide Vaccine","code":"C62767","definitions":[{"definition":"A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP-2:340-349 Peptide Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMP-2_340-349_Peptide_Vaccine"},{"name":"Maps_To","value":"LMP-2:340-349 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"504594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504594"},{"name":"PDQ_Open_Trial_Search_ID","value":"504594"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831952"}]}}{"C62768":{"preferredName":"LMP-2:419-427 Peptide Vaccine","code":"C62768","definitions":[{"definition":"A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP-2:419-427 Peptide Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LMP-2_419-427_Peptide_Vaccine"},{"name":"Maps_To","value":"LMP-2:419-427 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"504596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504596"},{"name":"PDQ_Open_Trial_Search_ID","value":"504596"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831953"}]}}{"C1434":{"preferredName":"Lobaplatin","code":"C1434","definitions":[{"definition":"A substance that contains the metal platinum and may kill cancer cells by damaging their DNA and stopping them from dividing. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A third-generation, water-soluble platinum compound with potential antineoplastic activity. Lobaplatin forms highly reactive, charged, platinum complexes that bind to nucleophilic groups such as GC- and AG-rich sites in DNA, inducing intrastrand DNA cross-links. These cross-links will ultimately result in induction of apoptosis and cell growth inhibition. Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lobaplatin","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-diammino-methy lcyclobutane-platinum (II) lactate","termGroup":"SN","termSource":"NCI"},{"termName":"D 19466","termGroup":"CN","termSource":"NCI"},{"termName":"D-19466","termGroup":"CN","termSource":"NCI"},{"termName":"D19466","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135558-11-1"},{"name":"Chemical_Formula","value":"C6H14N2.C3H4O3.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OX5XK1JD8C"},{"name":"Legacy Concept Name","value":"Lobaplatin"},{"name":"Maps_To","value":"Lobaplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"41669"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41669"},{"name":"PDQ_Open_Trial_Search_ID","value":"41669"},{"name":"PubMedID_Primary_Reference","value":"21034513"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165747"}]}}{"C979":{"preferredName":"Lometrexol","code":"C979","definitions":[{"definition":"A folate analog antimetabolite with antineoplastic activity. As the 6R diastereomer of 5,10-dideazatetrahydrofolate, lometrexol inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis, arresting cells in the S phase of the cell cycle, and inhibiting tumor cell proliferation.  The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called antifolates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lometrexol","termGroup":"PT","termSource":"NCI"},{"termName":"(6R)-DDATHF","termGroup":"AB","termSource":"NCI"},{"termName":"6R-5,10-Dideazatetrahydrofolate","termGroup":"SN","termSource":"NCI"},{"termName":"L-Glutamic acid, N-(4-(2-((6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"L-Glutamic acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (R)-","termGroup":"SN","termSource":"NCI"},{"termName":"Pyrido[2,3-d]pyrimidine, L-glutamic acid derivative (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"106400-81-1"},{"name":"Chemical_Formula","value":"C21H25N5O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6P3AVY8A7Q"},{"name":"Legacy Concept Name","value":"Lometrexol"},{"name":"Maps_To","value":"Lometrexol"},{"name":"NCI_Drug_Dictionary_ID","value":"41670"},{"name":"NSC Number","value":"660025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41670"},{"name":"PDQ_Open_Trial_Search_ID","value":"41670"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048852"}]}}{"C90623":{"preferredName":"Lometrexol Sodium","code":"C90623","definitions":[{"definition":"The sodium salt form of lometrexol, a folate analogue antimetabolite with antineoplastic activity. As the stereoisomer of 5,10-dideazatetrahydrofolate, lometrexol selectively inhibits glycinamide ribonucleotide formyltransferase (GARFT), the enzyme that catalyzes the first step in the de novo purine biosynthetic pathway, thereby inhibiting DNA synthesis and leading to an inhibition of tumor cell proliferation.  The agent has been shown to be active against tumors that are resistant to the folate antagonist methotrexate, but causes severe, dose-limiting toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lometrexol Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"LY264618 Disodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"120408-07-3"},{"name":"Chemical_Formula","value":"C21H23N5O6.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"US81N1145T"},{"name":"Maps_To","value":"Lometrexol Sodium"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983806"}]}}{"C617":{"preferredName":"Lomustine","code":"C617","definitions":[{"definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lomustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Belustin","termGroup":"FB","termSource":"NCI"},{"termName":"Belustine","termGroup":"FB","termSource":"NCI"},{"termName":"CCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Cecenu","termGroup":"FB","termSource":"NCI"},{"termName":"CeeNU","termGroup":"BR","termSource":"NCI"},{"termName":"Chloroethylcyclo- hexylnitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Chloroethylcyclohexylnitrosourea","termGroup":"SY","termSource":"NCI"},{"termName":"Citostal","termGroup":"FB","termSource":"NCI"},{"termName":"Gleostine","termGroup":"BR","termSource":"NCI"},{"termName":"Lomeblastin","termGroup":"FB","termSource":"NCI"},{"termName":"Lomustinum","termGroup":"SY","termSource":"NCI"},{"termName":"Lucostin","termGroup":"FB","termSource":"NCI"},{"termName":"Lucostine","termGroup":"FB","termSource":"NCI"},{"termName":"N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Prava","termGroup":"FB","termSource":"NCI"},{"termName":"RB-1509","termGroup":"CN","termSource":"NCI"},{"termName":"WR-139017","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Brain tumors; Hodgkins disease"},{"name":"CAS_Registry","value":"13010-47-4"},{"name":"Chemical_Formula","value":"C9H16ClN3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7BRF0Z81KG"},{"name":"Legacy Concept Name","value":"Lomustine"},{"name":"Maps_To","value":"Lomustine"},{"name":"NCI_Drug_Dictionary_ID","value":"43065"},{"name":"NSC Number","value":"79037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43065"},{"name":"PDQ_Open_Trial_Search_ID","value":"43065"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0023972"}]}}{"C1829":{"preferredName":"Lonafarnib","code":"C1829","definitions":[{"definition":"A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called enzyme inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lonafarnib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[2-[4-(3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Sarasar","termGroup":"BR","termSource":"NCI"},{"termName":"SCH 66336","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-66336","termGroup":"CN","termSource":"NCI"},{"termName":"SCH66336","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"193275-84-2"},{"name":"Chemical_Formula","value":"C27H31Br2ClN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IOW153004F"},{"name":"Legacy Concept Name","value":"Lonafarnib"},{"name":"Maps_To","value":"Lonafarnib"},{"name":"NCI_Drug_Dictionary_ID","value":"43503"},{"name":"NSC Number","value":"719467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43503"},{"name":"PDQ_Open_Trial_Search_ID","value":"43503"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1257385"}]}}{"C125549":{"preferredName":"Loncastuximab Tesirine","code":"C125549","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Loncastuximab Tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-402","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT 402","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT-402","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT402","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD19 PBD-conjugate ADCT-402","termGroup":"SY","termSource":"NCI"},{"termName":"Loncastuximab Tesirine-lpyl","termGroup":"SY","termSource":"NCI"},{"termName":"MT 2111","termGroup":"CN","termSource":"NCI"},{"termName":"MT-2111","termGroup":"CN","termSource":"NCI"},{"termName":"MT2111","termGroup":"CN","termSource":"NCI"},{"termName":"Zynlonta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with relapsed or refractory large B-cell lymphoma"},{"name":"CAS_Registry","value":"1879918-31-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7K5O7P6QIU"},{"name":"Maps_To","value":"Loncastuximab Tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"778954"},{"name":"NCI_META_CUI","value":"CL504277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778954"},{"name":"PDQ_Open_Trial_Search_ID","value":"778954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116067":{"preferredName":"Long Peptide Vaccine 7","code":"C116067","definitions":[{"definition":"A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Long Peptide Vaccine 7","termGroup":"PT","termSource":"NCI"},{"termName":"LPV7","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Long Peptide Vaccine 7"},{"name":"NCI_Drug_Dictionary_ID","value":"760895"},{"name":"NCI_META_CUI","value":"CL473486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760895"},{"name":"PDQ_Open_Trial_Search_ID","value":"760895"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113656":{"preferredName":"Long-acting Release Pasireotide","code":"C113656","definitions":[{"definition":"A long-acting release (LAR) formulation containing pasireotide, a synthetic long-acting cyclohexapeptide, with somatostatin-like activity. Upon intramuscular administration of the LAR formulation of pasireotide, this somatostatin analog strongly binds to and activates somatostatin receptor (SSTR) subtypes 1, 2, 3, and 5. This leads to an inhibition in the secretion of human growth hormone (hGH) and results in decreased production of insulin-like growth factor (IGF-1), which may inhibit IGF-1-mediated cell signaling pathways. This may lead to an inhibition in tumor cell growth and an increase in apoptosis in IGF-1-overexpressing tumor cells. In addition, this agent causes a reduction in adrenocorticotropic hormone (ACTH), which leads to an inhibition of cortisol secretion. ACTH-producing tumors cause hypersecretion of cortisol which results in many unwanted symptoms. This agent may also block other key survival pathways such as the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) signaling pathways. Pasireotide also inhibits vascular endothelial growth factor (VEGF) secretion, thereby decreasing angiogenesis and tumor cell growth in VEGF-overexpressing tumor cells. The long-acting form of pasireotide allows for less frequent administration as compared to the original form of this agent. SSTRs are overexpressed by some neuroendocrine and non-neuroendocrine tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Long-acting Release Pasireotide","termGroup":"PT","termSource":"NCI"},{"termName":"LAR Pasireotide","termGroup":"SY","termSource":"NCI"},{"termName":"SOM230 LAR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Long-acting Release Pasireotide"},{"name":"NCI_Drug_Dictionary_ID","value":"756940"},{"name":"NCI_META_CUI","value":"CL458369"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756940"},{"name":"PDQ_Open_Trial_Search_ID","value":"756940"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2830":{"preferredName":"Lontucirev","code":"C2830","definitions":[{"definition":"A modified cold virus that selectively grows in and destroys certain types of cancer cells and leaves normal cells undamaged.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of lontucirev-mediated tumor cell cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lontucirev","termGroup":"PT","termSource":"NCI"},{"termName":"CI 1042","termGroup":"CN","termSource":"NCI"},{"termName":"CI-1042","termGroup":"CN","termSource":"NCI"},{"termName":"E1B 55kDa mutant adenovirus dl1520","termGroup":"SY","termSource":"NCI"},{"termName":"E1B-Attenuated Adenovirus","termGroup":"SY","termSource":"NCI"},{"termName":"Lontucirev (Replicating Adenovirus)","termGroup":"SY","termSource":"NCI"},{"termName":"ONYX-015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"437981-77-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F1F4B2ILM1"},{"name":"Legacy Concept Name","value":"ONYX-015"},{"name":"Maps_To","value":"Lontucirev"},{"name":"NCI_Drug_Dictionary_ID","value":"43035"},{"name":"NSC Number","value":"688653"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43035"},{"name":"PDQ_Open_Trial_Search_ID","value":"43035"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678040"}]}}{"C113655":{"preferredName":"Lorlatinib","code":"C113655","definitions":[{"definition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lorlatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-","termGroup":"SY","termSource":"NCI"},{"termName":"7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"Lorbrena","termGroup":"BR","termSource":"NCI"},{"termName":"Lorviqua","termGroup":"FB","termSource":"NCI"},{"termName":"PF 06463922","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06463922","termGroup":"CN","termSource":"NCI"},{"termName":"PF06463922","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1454846-35-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OSP71S83EU"},{"name":"Maps_To","value":"Lorlatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"756930"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756930"},{"name":"PDQ_Open_Trial_Search_ID","value":"756930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3884739"}]}}{"C38714":{"preferredName":"Lorvotuzumab Mertansine","code":"C38714","definitions":[{"definition":"A substance that combines a monoclonal antibody (huN901) with an anticancer drug (DM1), and is being studied in the treatment of certain cancers, including non-small cell lung cancer. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lorvotuzumab Mertansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Human NCAM-1 Monoclonal Antibody N901","termGroup":"SY","termSource":"NCI"},{"termName":"BB-10901","termGroup":"CN","termSource":"NCI"},{"termName":"huN901-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"IMGN901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1008106-64-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0IVD6ASY0W"},{"name":"Legacy Concept Name","value":"BB-10901"},{"name":"Maps_To","value":"Lorvotuzumab Mertansine"},{"name":"NCI_Drug_Dictionary_ID","value":"346110"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346110"},{"name":"PDQ_Open_Trial_Search_ID","value":"346110"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987530"}]}}{"C120556":{"preferredName":"Losatuxizumab Vedotin","code":"C120556","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of losatuxizumab vedotin selectively targets and binds to EGFR. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Losatuxizumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-221","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1685249-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"17C83BVV62"},{"name":"Maps_To","value":"Losatuxizumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"769542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769542"},{"name":"PDQ_Open_Trial_Search_ID","value":"769542"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4055621"}]}}{"C1521":{"preferredName":"Losoxantrone","code":"C1521","definitions":[{"definition":"An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antipyrazoles.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Losoxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"Biantrazole","termGroup":"SY","termSource":"NCI"},{"termName":"CI-941","termGroup":"CN","termSource":"NCI"},{"termName":"DuP 941","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88303-60-0"},{"name":"Chemical_Formula","value":"C22H27N5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"47KPH00809"},{"name":"Legacy Concept Name","value":"Losoxantrone"},{"name":"Maps_To","value":"Losoxantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"41809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41809"},{"name":"PDQ_Open_Trial_Search_ID","value":"41809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245032"}]}}{"C72077":{"preferredName":"Losoxantrone Hydrochloride","code":"C72077","definitions":[{"definition":"The hydrochloride salt form of losoxantrone, an anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Losoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Losoxantrone HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Losoxantrone Hydrochloride Hydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"132937-89-4"},{"name":"Chemical_Formula","value":"2C22H27N5O4.4ClH.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6E275IURX"},{"name":"Legacy Concept Name","value":"Losoxantrone_Hydrochloride"},{"name":"Maps_To","value":"Losoxantrone Hydrochloride"},{"name":"NSC Number","value":"357885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346902"}]}}{"C620":{"preferredName":"Lovastatin","code":"C620","definitions":[{"definition":"A drug used to lower the amount of cholesterol in the blood. It is also being studied in the prevention and treatment of some types of cancer. Lovastatin is a type of HMG-CoA reductase inhibitor (statin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering and potential antineoplastic activities. Lovastatin is hydrolyzed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in cholesterol biosynthesis. In addition, this agent may induce tumor cell apoptosis and inhibit tumor cell invasiveness, possibly by inhibiting protein farnesylation and protein geranylgeranylation, and may arrest cells in the G1 phase of the cell cycle. The latter effect sensitizes tumor cells to the cytotoxic effects of ionizing radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lovastatin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-Methylbutanoic Acid, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Lovastatin Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Mevacor","termGroup":"BR","termSource":"NCI"},{"termName":"Mevinolin","termGroup":"SY","termSource":"NCI"},{"termName":"Monacolin K","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Atherosclerosis; Coronary heart disease, prevention; Hypercholesterolemia"},{"name":"CAS_Registry","value":"75330-75-5"},{"name":"CHEBI_ID","value":"CHEBI:40303"},{"name":"Chemical_Formula","value":"C24H36O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9LHU78OQFD"},{"name":"Legacy Concept Name","value":"Lovastatin"},{"name":"Maps_To","value":"Lovastatin"},{"name":"NCI_Drug_Dictionary_ID","value":"41658"},{"name":"NSC Number","value":"633781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41658"},{"name":"PDQ_Open_Trial_Search_ID","value":"41658"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0024027"}]}}{"C160691":{"preferredName":"Lenumlostat","code":"C160691","definitions":[{"definition":"An orally available, small-molecule, irreversible inhibitor of lysyl oxidase homolog 2 (lysyl oxidase-like protein 2; LOXL2) with potential antifibrotic activity. Upon oral administration, the aminomethyl pyridine moiety of lenumlostat interacts with the active site of LOXL2 to form a pseudo-irreversible inhibitory complex, thereby inhibiting the catalytic activity of LOXL2. LOXL2, a secreted glycoprotein, catalyzes the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, leading to the formation of deaminated lysine (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages that impact remodeling of the extracellular matrix (ECM), potentially leading to fibrosis. Inhibition of LOXL2, which is often upregulated in fibrotic tissue, may reduce fibrosis in certain chronic fibrotic diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lenumlostat","termGroup":"PT","termSource":"NCI"},{"termName":"GB 2064","termGroup":"CN","termSource":"NCI"},{"termName":"GB-2064","termGroup":"CN","termSource":"NCI"},{"termName":"GB2064","termGroup":"CN","termSource":"NCI"},{"termName":"LOXL2 Inhibitor GB2064","termGroup":"SY","termSource":"NCI"},{"termName":"Lysyl Oxidase-like Protein 2 Inhibitor PAT-1251","termGroup":"SY","termSource":"NCI"},{"termName":"PAT 1251","termGroup":"CN","termSource":"NCI"},{"termName":"PAT-1251","termGroup":"CN","termSource":"NCI"},{"termName":"PAT1251","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098884-52-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y3HMF6G24B"},{"name":"Maps_To","value":"LOXL2 Inhibitor PAT-1251"},{"name":"NCI_Drug_Dictionary_ID","value":"800789"},{"name":"NCI_META_CUI","value":"CL969613"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800789"},{"name":"PDQ_Open_Trial_Search_ID","value":"800789"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165553":{"preferredName":"LRP5/6 Antagonist BI 905677","code":"C165553","definitions":[{"definition":"A humanized biparatopic nanobody composed of two blocking domains for the Wnt ligand co-receptors lipoprotein receptor-related proteins (LRP) 5 and 6, with potential antineoplastic and immunomodulating activities. Upon administration, BI 905677 targets and binds to LRP5 and LRP6, thereby blocking the binding of Wnt ligands to LRP5/6. This prevents the activation of the Frizzled (FZD)-Wnt-LRP5/6 trimeric complex and prevents the inactivation of the beta-catenin degradation complex, which leads to beta-catenin degradation. This inhibits the Wnt/beta-catenin signaling pathway, prevents the beta-catenin-mediated activation of Wnt target genes, and inhibits the proliferation and survival of Wnt-driven tumor cells. In addition, inhibition of Wnt signaling by BI 905677 prevents Wnt-mediated immune escape, thereby re-activating the immune system, specifically inducing the activation of dendritic cells (DCs) and activation as well as infiltration of cytotoxic T-cells into the tumor tissue. The FZD-Wnt-LRP5/6 trimeric complex induces phosphorylation of LRP5 or LRP6 intracellular domains leading to inactivation of the beta-catenin degradation complex, allowing beta-catenin accumulation; stabilized beta-catenin enters the nucleus and acts as a transcriptional activator of Wnt target genes. Wnt/beta-catenin signaling plays a key role in tumorigenesis and resistance to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRP5/6 Antagonist BI 905677","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LRP5/6 Nanobody BI 905677","termGroup":"SY","termSource":"NCI"},{"termName":"BI 905677","termGroup":"CN","termSource":"NCI"},{"termName":"BI-905677","termGroup":"CN","termSource":"NCI"},{"termName":"BI905677","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LRP5/6 Antagonist BI 905677"},{"name":"NCI_Drug_Dictionary_ID","value":"799658"},{"name":"NCI_META_CUI","value":"CL978683"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799658"},{"name":"PDQ_Open_Trial_Search_ID","value":"799658"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131303":{"preferredName":"Pulrodemstat","code":"C131303","definitions":[{"definition":"An orally available inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, pulrodemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor (remove hyphen) suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family that is overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pulrodemstat","termGroup":"PT","termSource":"NCI"},{"termName":"CC 90011","termGroup":"CN","termSource":"NCI"},{"termName":"CC-90011","termGroup":"CN","termSource":"NCI"},{"termName":"CC90011","termGroup":"CN","termSource":"NCI"},{"termName":"LSD1 Inhibitor CC-90011","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine-specific Demethylase 1 Inhibitor CC-90011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1821307-10-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W6F4FRQ5QC"},{"name":"Maps_To","value":"LSD1 Inhibitor CC-90011"},{"name":"NCI_Drug_Dictionary_ID","value":"785511"},{"name":"NCI_META_CUI","value":"CL514523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785511"},{"name":"PDQ_Open_Trial_Search_ID","value":"785511"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113646":{"preferredName":"LSD1 Inhibitor GSK2879552","code":"C113646","definitions":[{"definition":"An orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LSD1 Inhibitor GSK2879552","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2879552","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LSD1 Inhibitor GSK2879552"},{"name":"NCI_Drug_Dictionary_ID","value":"756742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756742"},{"name":"PDQ_Open_Trial_Search_ID","value":"756742"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827120"}]}}{"C131827":{"preferredName":"Bomedemstat","code":"C131827","definitions":[{"definition":"An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; thus, inhibition of LSD1 also promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression, tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bomedemstat","termGroup":"PT","termSource":"NCI"},{"termName":"IMG 7289","termGroup":"CN","termSource":"NCI"},{"termName":"IMG-7289","termGroup":"CN","termSource":"NCI"},{"termName":"LSD-1 Inhibitor IMG-7289","termGroup":"SY","termSource":"NCI"},{"termName":"Lysine-specific Demethylase 1 Inhibitor IMG-7289","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1990504-34-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y2T4ALDEAT"},{"name":"Maps_To","value":"Bomedemstat"},{"name":"Maps_To","value":"LSD1 Inhibitor IMG-7289"},{"name":"NCI_Drug_Dictionary_ID","value":"786176"},{"name":"NCI_META_CUI","value":"CL514400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786176"},{"name":"PDQ_Open_Trial_Search_ID","value":"786176"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131908":{"preferredName":"Iadademstat","code":"C131908","definitions":[{"definition":"An orally available inhibitor of lysine specific histone demethylase 1 (KDM1A; LSD1), with potential antineoplastic activity. Upon administration, iadademstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9, which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in in the regulation of gene expression, tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iadademstat","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-Cyclohexanediamine, N1-((1R,2S)-2-Phenylcyclopropyl)-, trans-","termGroup":"SN","termSource":"NCI"},{"termName":"ORY 1001","termGroup":"CN","termSource":"NCI"},{"termName":"ORY-1001","termGroup":"CN","termSource":"NCI"},{"termName":"RG 6016","termGroup":"CN","termSource":"NCI"},{"termName":"RG6016","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7051790","termGroup":"CN","termSource":"NCI"},{"termName":"RO7051790","termGroup":"CN","termSource":"NCI"},{"termName":"trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1431304-21-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54T74394F8"},{"name":"Maps_To","value":"Iadademstat"},{"name":"Maps_To","value":"LSD1 Inhibitor RO7051790"},{"name":"NCI_Drug_Dictionary_ID","value":"786364"},{"name":"NCI_META_CUI","value":"CL521133"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786364"},{"name":"PDQ_Open_Trial_Search_ID","value":"786364"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83925":{"preferredName":"Lucanthone","code":"C83925","definitions":[{"definition":"An orally available thioxanthone-based DNA intercalator and inhibitor of the DNA repair enzyme apurinic-apyrimidinic endonuclease 1 (APEX1 or APE1), with anti-schistosomal and potential antineoplastic activity. Lucanthone intercalates DNA and interferes with the activity of topoisomerases I and II during replication and transcription, thereby inhibiting the synthesis of macromolecules. In addition, this agent specifically inhibits the endonuclease activity of APE1, without affecting its redox activity, resulting in un-repaired DNA strand breaks which may induce apoptosis. Therefore, lucanthone may sensitize tumor cells to radiation and chemotherapy. Furthermore, lucanthone inhibits autophagy through the disruption of lysosomal function. The multifunctional nuclease APE1 is a key component for DNA repair; its expression is often correlated with tumor cell resistance to radio- and chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucanthone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"479-50-5"},{"name":"CHEBI_ID","value":"CHEBI:51052"},{"name":"Chemical_Formula","value":"C20H24N2OS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FC6D57000M"},{"name":"Maps_To","value":"Lucanthone"},{"name":"NCI_Drug_Dictionary_ID","value":"733534"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733534"},{"name":"PDQ_Open_Trial_Search_ID","value":"733534"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0024071"}]}}{"C48405":{"preferredName":"Lucatumumab","code":"C48405","definitions":[{"definition":"A fully human monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. Lucatumumab binds to and inhibits CD40, thereby inhibiting CD40 ligand-induced cell proliferation and triggering cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells overexpressing CD40. CD40, an integral membrane protein found on the surface of B lymphocytes, is a member of the tumor necrosis factor receptor superfamily and is highly expressed in a number of B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD40 Monoclonal Antibody CHIR-12.12","termGroup":"SY","termSource":"NCI"},{"termName":"CHIR-12.12","termGroup":"CN","termSource":"NCI"},{"termName":"HCD-122","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody CHIR-12.12","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"903512-50-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P0EP9VFC4R"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CHIR-12_12"},{"name":"Maps_To","value":"Lucatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"432936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"432936"},{"name":"PDQ_Open_Trial_Search_ID","value":"432936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2980061"}]}}{"C95726":{"preferredName":"Lucitanib","code":"C95726","definitions":[{"definition":"A novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. Lucitanib inhibits VEGFR-1, -2, -3 and FGFR-1, -2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and FGFRs belong to the family of receptor tyrosine kinases that may be upregulated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucitanib","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"AL3810","termGroup":"CN","termSource":"NCI"},{"termName":"E-3810","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1058137-23-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PP449XA4BH"},{"name":"Maps_To","value":"Lucitanib"},{"name":"NCI_Drug_Dictionary_ID","value":"694590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694590"},{"name":"PDQ_Open_Trial_Search_ID","value":"694590"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3887575"}]}}{"C71467":{"preferredName":"Luminespib","code":"C71467","definitions":[{"definition":"A derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Luminespib has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luminespib","termGroup":"PT","termSource":"NCI"},{"termName":"AUY922","termGroup":"CN","termSource":"NCI"},{"termName":"NVP AUY 922","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-AUY 922","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"747412-64-2"},{"name":"Chemical_Formula","value":"C27H33N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C6V1DAR5EB"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_AUY922"},{"name":"Maps_To","value":"Luminespib"},{"name":"NCI_Drug_Dictionary_ID","value":"570982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570982"},{"name":"PDQ_Open_Trial_Search_ID","value":"570982"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348996"}]}}{"C162567":{"preferredName":"Luminespib Mesylate","code":"C162567","definitions":[{"definition":"The mesylate salt of luminespib, a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Upon administration, luminespib binds with high affinity to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luminespib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Luminespib Mesilate","termGroup":"SY","termSource":"NCI"},{"termName":"Luminespib Mesylate Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"NVP-AUY922-AGB","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1051919-26-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6R0MAC137G"},{"name":"Maps_To","value":"Luminespib Mesylate"},{"name":"NCI_META_CUI","value":"CL971084"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118623":{"preferredName":"Lung-targeted Immunomodulator QBKPN","code":"C118623","definitions":[{"definition":"A proprietary, lung-targeted, site specific immunomodulator (SSI), with potential immunostimulating and antineoplastic activities. Although the exact type and composition of the lung-targeted immunomodulator QBKPN has yet to be fully disclosed, upon subcutaneous administration, this agent is able to activate a local innate immune response in the lung tissue. This results in an increased number of M1 macrophages, which induces a shift from M2 to M1 macrophage dominance in the tumor microenvironment, and stimulates the recruitment of other immune cells. The M1 macrophages exert antitumor activity and eradicate lung cancer cells through phagocytosis. QBKPN does not induce a systemic immune response or affect other organs or tissues. Altogether, this SSI may decrease tumor cell growth in the lungs. SSIs contain specific, inactivated components of pathogens, such as bacteria and/or viruses, which normally cause an acute infection in the specific organ or tissue of interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung-targeted Immunomodulator QBKPN","termGroup":"PT","termSource":"NCI"},{"termName":"QBKPN","termGroup":"CN","termSource":"NCI"},{"termName":"Site Specific Immunomodulator QBKPN","termGroup":"SY","termSource":"NCI"},{"termName":"SSI QBKPN","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lung-targeted Immunomodulator QBKPN"},{"name":"NCI_Drug_Dictionary_ID","value":"765293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765293"},{"name":"PDQ_Open_Trial_Search_ID","value":"765293"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896726"}]}}{"C82382":{"preferredName":"Lurbinectedin","code":"C82382","definitions":[{"definition":"A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lurbinectedin","termGroup":"PT","termSource":"NCI"},{"termName":"PM 01183","termGroup":"CN","termSource":"NCI"},{"termName":"PM-01183","termGroup":"CN","termSource":"NCI"},{"termName":"PM01183","termGroup":"CN","termSource":"NCI"},{"termName":"Zepzelca","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy"},{"name":"CAS_Registry","value":"497871-47-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2CN60TN6ZS"},{"name":"Legacy Concept Name","value":"DNA_Minor_Groove_Binding_Agent_PM01183"},{"name":"Maps_To","value":"Lurbinectedin"},{"name":"NCI_Drug_Dictionary_ID","value":"641468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641468"},{"name":"PDQ_Open_Trial_Search_ID","value":"641468"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830066"}]}}{"C1610":{"preferredName":"Lurtotecan","code":"C1610","definitions":[{"definition":"A semisynthetic analogue of camptothecin with antineoplastic activity. Lurtotecan selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. Independent from DNA replication inhibition, lurtotecan also inhibits RNA synthesis, multi-ubiquitination and degradation of topoisomerase I and chromatin reorganization.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Lurtotecan","termGroup":"PT","termSource":"NCI"},{"termName":"7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"GG 211","termGroup":"CN","termSource":"NCI"},{"termName":"GI147211","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149882-10-0"},{"name":"Chemical_Formula","value":"C28H30N4O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4J1L80T08I"},{"name":"Legacy Concept Name","value":"Lurtotecan"},{"name":"Maps_To","value":"Lurtotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"42331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42331"},{"name":"PDQ_Open_Trial_Search_ID","value":"42331"},{"name":"PubMedID_Primary_Reference","value":"15571957"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0293658"}]}}{"C1876":{"preferredName":"Lurtotecan Liposome","code":"C1876","definitions":[{"definition":"A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lurtotecan Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"liposomal lurtotecan","termGroup":"SY","termSource":"NCI"},{"termName":"liposome, lurtotecan","termGroup":"SY","termSource":"NCI"},{"termName":"NX211","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-211","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lurtotecan_Liposome"},{"name":"Maps_To","value":"Lurtotecan Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"43473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43473"},{"name":"PDQ_Open_Trial_Search_ID","value":"43473"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935959"}]}}{"C142176":{"preferredName":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","code":"C142176","definitions":[{"definition":"A radioimmunoconjugate comprised of a human monoclonal antibody (huMAb-5B1) against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9) that is conjugated to the chelator 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A''-DTPA) and labeled with the beta-emitting radioisotope lutetium Lu 177 (Lu 177), with radioisotopic activity and potential use as an antineoplastic radiotherapeutic and an imaging agent in both planar imaging and single-photon emission computed tomography (SPECT). The antibody moiety of Lu 177 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9-expressing tumor cells. This may promote killing of CA19-9-expressing tumor cells through the local induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Additionally, upon binding and internalization, the Lu 177 moiety can deliver a cytotoxic dose of beta radiation to the CA19-9-expressing tumor cells. Furthermore, the radioisotope moiety may be imaged using planar imaging and SPECT, thus allowing evaluation of the pharmacokinetic profile of the agent, and the imaging and quantification of CA19-9-expressing tumor cells, respectively. CA19-9, a Lewis-type carbohydrate antigen overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu Human Monoclonal Antibody 5B1","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-CHX-A''-DTPA-HuMab-5B1","termGroup":"SY","termSource":"NCI"},{"termName":"Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","termGroup":"SY","termSource":"NCI"},{"termName":"MVT-1075","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"473BOU89F3"},{"name":"Maps_To","value":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1"},{"name":"NCI_Drug_Dictionary_ID","value":"791457"},{"name":"NCI_META_CUI","value":"CL540167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791457"},{"name":"PDQ_Open_Trial_Search_ID","value":"791457"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113801":{"preferredName":"Lutetium Lu 177 DOTA-biotin","code":"C113801","definitions":[{"definition":"A radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 DOTA-biotin","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-ST2210","termGroup":"SY","termSource":"NCI"},{"termName":"[177Lu]DOTA-biotin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5U8L0A8I80"},{"name":"Maps_To","value":"Lutetium Lu 177 DOTA-biotin"},{"name":"NCI_Drug_Dictionary_ID","value":"757658"},{"name":"NCI_META_CUI","value":"CL471782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757658"},{"name":"PDQ_Open_Trial_Search_ID","value":"757658"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158044":{"preferredName":"Lutetium Lu 177 DOTA-N3-CTT1403","code":"C158044","definitions":[{"definition":"A radioconjucate consisting of CTT1403, a phosphoramidate-based irreversible inhibitor of human prostate-specific membrane antigen with an albumin binding moiety, connected via click chemistry to lutetium Lu 177-dodecanetetraacetic acid-azide (177Lu-DOTA-N3), with potential antineoplastic activity. Upon administration, lutetium Lu 177-DOTA-N3-CTT1403 targets and binds to PSMA expressed on tumor cells via its CTT1403 moiety, and upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on most prostate tumor cells. The albumin binding motif extends circulation half-life thereby improving tumor cell uptake of the radioconjugate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 DOTA-N3-CTT1403","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-azide-CTT1403","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA-N3-CTT1403","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA-azide-CTT1403","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177 DOTA-N3-CTT1403"},{"name":"NCI_Drug_Dictionary_ID","value":"797172"},{"name":"NCI_META_CUI","value":"CL937593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797172"},{"name":"PDQ_Open_Trial_Search_ID","value":"797172"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105403":{"preferredName":"Lutetium Lu 177 DOTA-Tetulomab","code":"C105403","definitions":[{"definition":"A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 DOTA-Tetulomab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-HH1","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Dota-Tetulomab","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-HH1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CPW7BR9UY7"},{"name":"Maps_To","value":"Lutetium Lu 177 DOTA-Tetulomab"},{"name":"NCI_Drug_Dictionary_ID","value":"746917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746917"},{"name":"PDQ_Open_Trial_Search_ID","value":"746917"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659253"}]}}{"C95020":{"preferredName":"Lutetium Lu 177 Dotatate","code":"C95020","definitions":[{"definition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Dotatate","termGroup":"PT","termSource":"NCI"},{"termName":"177 Lu-DOTA-TATE","termGroup":"AB","termSource":"NCI"},{"termName":"177 Lu-DOTA-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA0-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutathera","termGroup":"BR","termSource":"NCI"},{"termName":"Lutetium (177Lu) Oxodotreotide","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 Dotatate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"lutetium Lu 177-DOTATATE","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Oxodotreotide Lu-177","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"omatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"},{"name":"CAS_Registry","value":"437608-50-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"AE221IM3BB"},{"name":"Maps_To","value":"Lutetium Lu 177 Dotatate"},{"name":"NCI_Drug_Dictionary_ID","value":"715523"},{"name":"NCI_META_CUI","value":"CL433757"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715523"},{"name":"PDQ_Open_Trial_Search_ID","value":"715523"},{"name":"PubMedID_Primary_Reference","value":"18649310"},{"name":"PubMedID_Primary_Reference","value":"20168290"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162565":{"preferredName":"Lutetium Lu 177 Lilotomab-satetraxetan","code":"C162565","definitions":[{"definition":"A radioconjugate consisting of lilotomab, a murine immunoglobulin G1 (IgG1) antibody directed against the CD37 antigen, conjugated via the chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA) with potential antineoplastic activities. Upon administration of lutetium Lu 177 lilotomab-satetraxetan, the lilotomab moiety binds to CD37 expressed on certain tumor cells. Upon binding, lutetium Lu 177 lilotomab-satetraxetan delivers a cytotoxic dose of beta radiation to CD37-expressing cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Lilotomab-satetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu Lilotomab Satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Lilotomab-satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Betalutin","termGroup":"BR","termSource":"NCI"},{"termName":"Lutetium Lu-177 Lilotomab Satetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu-177 Lilotomab-satetraxetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453362-90-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"054ZP16K2Q"},{"name":"Maps_To","value":"Lutetium Lu 177 Lilotomab-satetraxetan"},{"name":"NCI_META_CUI","value":"CL446324"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2598":{"preferredName":"Lutetium Lu 177 Monoclonal Antibody CC49","code":"C2598","definitions":[{"definition":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Monoclonal Antibody CC49","termGroup":"PT","termSource":"NCI"},{"termName":"177 Lu-CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177_Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"Lutetium Lu 177 Monoclonal Antibody CC49"},{"name":"NCI_Drug_Dictionary_ID","value":"38083"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38083"},{"name":"PDQ_Open_Trial_Search_ID","value":"38083"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935675"}]}}{"C38701":{"preferredName":"Lutetium Lu 177 Rosopatamab Tetraxetan","code":"C38701","definitions":[{"definition":"A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Rosopatamab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-TLX591","termGroup":"SY","termSource":"NCI"},{"termName":"DOTA-HUJ-591 LU-177","termGroup":"SY","termSource":"NCI"},{"termName":"Lu 177 MOAB J591","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium Lu 177 Monoclonal Antibody J591","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 Rosopatamab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-Rosopatamab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-TLX591","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JB9647672Z"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177_Monoclonal_Antibody_J591"},{"name":"Maps_To","value":"Lutetium Lu 177 Monoclonal Antibody J591"},{"name":"NCI_Drug_Dictionary_ID","value":"361550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"361550"},{"name":"PDQ_Open_Trial_Search_ID","value":"361550"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518042"}]}}{"C114499":{"preferredName":"Lutetium Lu 177 PP-F11N","code":"C114499","definitions":[{"definition":"A radioconjugate composed of PP-F11N, a gastrin analog, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and potential use as an imaging agent for scintigraphy. Following intravenous administration, the PP-F11N moiety binds to the cholecystokinin-2 (CCK-2) receptor. Subsequently, the CCK-2 receptor-expressing tumor cells can be visualized scintigraphically. In addition, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CCK-2 receptor-expressing tumor cells. CCK-2 receptors are expressed on a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 PP-F11N","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-PP-F11N","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1771736-69-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"639NVQ0SXF"},{"name":"Maps_To","value":"Lutetium Lu 177 PP-F11N"},{"name":"NCI_Drug_Dictionary_ID","value":"759373"},{"name":"NCI_META_CUI","value":"CL472324"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759373"},{"name":"PDQ_Open_Trial_Search_ID","value":"759373"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124929":{"preferredName":"Lutetium Lu 177 Satoreotide Tetraxetan","code":"C124929","definitions":[{"definition":"A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-JR11 binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Satoreotide Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA-JR11","termGroup":"SY","termSource":"NCI"},{"termName":"Lu-177 OPS-201","termGroup":"SY","termSource":"NCI"},{"termName":"Satoreotide Tetraxetan Lutetium-177","termGroup":"SY","termSource":"NCI"},{"termName":"SOMther","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1934243-21-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CAX3X53UL6"},{"name":"Maps_To","value":"Lutetium Lu 177 Satoreotide Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"777267"},{"name":"NCI_META_CUI","value":"CL503798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777267"},{"name":"PDQ_Open_Trial_Search_ID","value":"777267"},{"name":"PubMedID_Primary_Reference","value":"24963127"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154549":{"preferredName":"Lutetium Lu 177-DOTA-EB-TATE","code":"C154549","definitions":[{"definition":"A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intravenous administration, lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), specifically with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-DOTA-EB-TATE","termGroup":"PT","termSource":"NCI"},{"termName":"(177)Lu-DOTA-EB-TATE","termGroup":"SY","termSource":"NCI"},{"termName":"177 Lu-DOTA-EB-TATE","termGroup":"AB","termSource":"NCI"},{"termName":"177Lu-DOTA-EB-TATE","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-DOTA0-EB-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA(0)-EB-Tyr(3)-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-DOTA-EB-Tyr3-Octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans blue-octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177-DOTA-EB-TATE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177-DOTA-EB-TATE"},{"name":"NCI_Drug_Dictionary_ID","value":"794348"},{"name":"NCI_META_CUI","value":"CL555349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794348"},{"name":"PDQ_Open_Trial_Search_ID","value":"794348"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88277":{"preferredName":"Lutetium Lu 177-Edotreotide","code":"C88277","definitions":[{"definition":"A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-Edotreotide","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTATOC","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Edo","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-Edotreotide","termGroup":"SY","termSource":"NCI"},{"termName":"[177LuDOTA]-TOC","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium 177Lu-Edotreotide","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA-Tyr3-octreotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"321835-55-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RGO812Q0C8"},{"name":"Maps_To","value":"Lutetium Lu 177-Edotreotide"},{"name":"NCI_Drug_Dictionary_ID","value":"656307"},{"name":"NCI_META_CUI","value":"CL412466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656307"},{"name":"PDQ_Open_Trial_Search_ID","value":"656307"},{"name":"PubMedID_Primary_Reference","value":"18448552"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158734":{"preferredName":"Lutetium Lu 177-NeoB","code":"C158734","definitions":[{"definition":"A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-NeoB","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-NeoB","termGroup":"SY","termSource":"NCI"},{"termName":"[177Lu]-NeoB","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium 177-NeoB","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177 DOTA-NeoBOMB1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177-NeoB"},{"name":"NCI_Drug_Dictionary_ID","value":"797487"},{"name":"NCI_META_CUI","value":"CL950703"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797487"},{"name":"PDQ_Open_Trial_Search_ID","value":"797487"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148145":{"preferredName":"Lutetium Lu 177 Vipivotide Tetraxetan","code":"C148145","definitions":[{"definition":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177 Vipivotide Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-labeled PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"177Lu-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"AAA 617","termGroup":"CN","termSource":"NCI"},{"termName":"AAA-617","termGroup":"CN","termSource":"NCI"},{"termName":"AAA617","termGroup":"CN","termSource":"NCI"},{"termName":"Lu177-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu 177-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177-PSMA-617","termGroup":"SY","termSource":"NCI"},{"termName":"Pluvicto","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."},{"name":"CAS_Registry","value":"1703749-62-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G6UF363ECX"},{"name":"Maps_To","value":"Lutetium Lu 177-PSMA-617"},{"name":"NCI_Drug_Dictionary_ID","value":"792497"},{"name":"NCI_META_CUI","value":"CL550803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792497"},{"name":"PDQ_Open_Trial_Search_ID","value":"792497"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67039":{"preferredName":"Lutetium Lu-177 Capromab","code":"C67039","definitions":[{"definition":"A radioimmunoconjugate consisting of capromab linked to lutetium Lu 177 via the bifunctional macrocyclic chelator methoxy-tetraazacyclododecane-tetraacetic acid (MeO-DOTA) with potential antineoplastic activity. Lutetium Lu 177-capromab binds to human prostate specific membrane antigen (PSMA) expressed on tumor cell surfaces via its capromab moiety and, upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA is a cell surface glycoprotein abundantly expressed by prostate epithelium and is typically overexpressed by prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 Capromab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-meO-DOTA-7E11","termGroup":"AB","termSource":"NCI"},{"termName":"CYT-500","termGroup":"CN","termSource":"NCI"},{"termName":"Lutetium Lu 177-Labeled Capromab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177_Monoclonal_Antibody_7E11"},{"name":"Maps_To","value":"Lutetium Lu-177 Capromab"},{"name":"NCI_Drug_Dictionary_ID","value":"539702"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539702"},{"name":"PDQ_Open_Trial_Search_ID","value":"539702"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881486"}]}}{"C66978":{"preferredName":"Lutetium Lu-177 Girentuximab","code":"C66978","definitions":[{"definition":"A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 Girentuximab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DOTA-cG250","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium Lu-177-DOTA-Chimeric Monoclonal Antibody cG250","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177 Labeled cG250","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lutetium_Lu_177-DOTA-Chimeric_Monoclonal_Antibody_cG250"},{"name":"Maps_To","value":"Lutetium Lu-177 Girentuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"531051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531051"},{"name":"PDQ_Open_Trial_Search_ID","value":"531051"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881485"}]}}{"C150467":{"preferredName":"Lutetium Lu-177 PSMA-R2","code":"C150467","definitions":[{"definition":"A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 177Lu-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 PSMA-R2","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-PSMA-R2","termGroup":"SY","termSource":"NCI"},{"termName":"177LuPSMA-R2","termGroup":"SY","termSource":"NCI"},{"termName":"Lu177-PSMA-R2","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177 PSMA-R2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu-177 PSMA-R2"},{"name":"NCI_Drug_Dictionary_ID","value":"793409"},{"name":"NCI_META_CUI","value":"CL552202"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793409"},{"name":"PDQ_Open_Trial_Search_ID","value":"793409"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162563":{"preferredName":"Lutetium Lu-177 Rituximab","code":"C162563","definitions":[{"definition":"A radioconjugate composed of rituximab, a recombinant chimeric murine/human immunoglobulin G1 (IgG1) antibody directed against the CD20 antigen, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, the rituximab moiety targets and binds to CD20 expressed on tumor cells and delivers a cytotoxic dose of beta radiation to CD20-expressing cells. CD20 is expressed on the surface of pre-B and mature B-lymphocytes and is overexpressed in a variety of B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu-177 Rituximab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Lu-177 Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium-177 Labeled Rituximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu-177 Rituximab"},{"name":"NCI_META_CUI","value":"CL971073"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78832":{"preferredName":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1","code":"C78832","definitions":[{"definition":"A whole-cell cancer vaccine, containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein encoded by a self-inactivating lentiviral vector (LV), with potential antineoplastic and immunomodulating activities. Upon administration, LV.IL-2/B7.1-transduced AML blast vaccine RFUSIN2-AML1 may stimulate a host cytotoxic T lymphocyte (CTL) response against AML cells.  The single fusion protein encoded by the LV is postsynthetically cleaved to produce biologically active membrane-anchored B7.1 and secreted IL-2 in AML blasts; combined expression of IL-2 and the co-stimulatory molecule B7.1 by AML blasts may increase stimulation of both allogeneic and autologous cytotoxic T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1","termGroup":"PT","termSource":"NCI"},{"termName":"Lentivirus-transduced AML Blasts Expressing B7.1 and IL-2","termGroup":"SY","termSource":"NCI"},{"termName":"RFUSIN2-AML1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LV_IL-2_B7_1-Transduced_AML_Blast_Vaccine"},{"name":"Maps_To","value":"LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1"},{"name":"NCI_Drug_Dictionary_ID","value":"609860"},{"name":"NCI_META_CUI","value":"CL387720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"609860"},{"name":"PDQ_Open_Trial_Search_ID","value":"609860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99163":{"preferredName":"Lyophilized Black Raspberry Lozenge","code":"C99163","definitions":[{"definition":"A lozenge containing lyophilized black raspberry with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, proanthocyanidins, and flavonoids. The anthocyanins appear to contribute significantly to this agent's effects. Anthocyanins inhibit both the activation of several signal transduction pathways, including the mitogen-activated protein kinase-mediated pathways, and certain transcription factors, such as nuclear factor kappa B (NF-kB), activator protein-1 (AP-1) complex, and nuclear factor in activated T-cells (NFAT). This inhibitory activity modulates the expression of downstream target genes that are upregulated in a variety of cancer cell types, including inducible nitric oxide synthase, cyclooxygenase-2, vascular endothelial growth factor and the anti-apoptotic protein survivin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lyophilized Black Raspberry Lozenge","termGroup":"PT","termSource":"NCI"},{"termName":"Black Raspberry Confection","termGroup":"SY","termSource":"NCI"},{"termName":"BRB Confection","termGroup":"SY","termSource":"NCI"},{"termName":"LBR Lozenge","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lyophilized Black Raspberry Lozenge"},{"name":"NCI_Drug_Dictionary_ID","value":"717458"},{"name":"NCI_META_CUI","value":"CL433013"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717458"},{"name":"PDQ_Open_Trial_Search_ID","value":"717458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99164":{"preferredName":"Lyophilized Black Raspberry Saliva Substitute","code":"C99164","definitions":[{"definition":"A saliva substitute (or artificial saliva) containing lyophilized black raspberry with potential antioxidant, pro-apoptotic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in flavonols of which the anthocyanins appear to contribute significantly to this agent's chemopreventive effects. Anthocyanins inhibit the activation of several signal transduction pathways, including the mitogen-activated protein kinase-mediated pathways, and certain transcription factors, such as nuclear factor kappa B (NF-kB), activator protein-1 (AP-1) complex, and nuclear factor in activated T-cells (NFAT). This in turn modulates the expression of downstream target genes that are upregulated in a variety of cancer cell types, including inducible nitric oxide synthase, cyclooxygenase-2, vascular endothelial growth factor and the anti-apoptotic protein survivin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lyophilized Black Raspberry Saliva Substitute","termGroup":"PT","termSource":"NCI"},{"termName":"LBR Saliva Substitute","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lyophilized Black Raspberry Saliva Substitute"},{"name":"NCI_Drug_Dictionary_ID","value":"717459"},{"name":"NCI_META_CUI","value":"CL433014"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717459"},{"name":"PDQ_Open_Trial_Search_ID","value":"717459"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126421":{"preferredName":"Lysine-specific Demethylase 1 Inhibitor INCB059872","code":"C126421","definitions":[{"definition":"An orally available inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, INCB059872 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively, through amine oxidation. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression and in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lysine-specific Demethylase 1 Inhibitor INCB059872","termGroup":"PT","termSource":"NCI"},{"termName":"INCB059872","termGroup":"CN","termSource":"NCI"},{"termName":"LSD1 Inhibitor INCB059872","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802909-49-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"12XU6D9FLM"},{"name":"Maps_To","value":"Lysine-specific Demethylase 1 Inhibitor INCB059872"},{"name":"NCI_Drug_Dictionary_ID","value":"780284"},{"name":"NCI_META_CUI","value":"CL504960"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780284"},{"name":"PDQ_Open_Trial_Search_ID","value":"780284"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61571":{"preferredName":"Lyso-Thermosensitive Liposome Doxorubicin","code":"C61571","definitions":[{"definition":"A temperature-sensitive liposomal formulation of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Upon intravenous administration, circulating thermosensitive liposomes are activated locally by increasing the tumor temperature to 40-41 degrees Celsius using an external heat source. The elevated temperature causes compositional changes in the liposomes, creating openings that allow for the release of encapsulated doxorubicin. Compared to non-thermosensitive liposomes, lyso-thermosensitive liposomes deliver higher concentrations of a cytotoxic agent to a heat-treated tumor site while sparing normal tissues unexposed to heat treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lyso-Thermosensitive Liposome Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"Heat-Activated Liposomal Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Temperature Sensitive Liposome Encapsulated Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"ThermoDox","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Lyso-Thermosensitive_Liposome_Doxorubicin"},{"name":"Maps_To","value":"Lyso-Thermosensitive Liposome Doxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"491935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"491935"},{"name":"PDQ_Open_Trial_Search_ID","value":"491935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831903"}]}}{"C95123":{"preferredName":"Macimorelin","code":"C95123","definitions":[{"definition":"An orally available synthetic mimetic of the growth hormone (GH) secretagogue ghrelin with potential anti-cachexia activity. Upon oral administration, macimorelin mimics endogenous ghrelin by stimulating appetite and binds to the growth hormone secretagogue receptor GHSR in the central nervous system, thereby mimicking the GH-releasing effects of ghrelin from the pituitary gland. Stimulation of GH secretion increases insulin-like growth factor-I (IGF-I) levels which may further stimulate protein synthesis. In addition, ghrelin reduces the production of pro-inflammatory cytokines, which may play a direct role in cancer-related loss of appetite.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macimorelin","termGroup":"PT","termSource":"NCI"},{"termName":"AEZS-130","termGroup":"CN","termSource":"NCI"},{"termName":"D-Tryptophanamide,2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"EP 1572","termGroup":"CN","termSource":"NCI"},{"termName":"JMV 1843","termGroup":"CN","termSource":"NCI"},{"termName":"Solorel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"381231-18-1"},{"name":"Chemical_Formula","value":"C26H30N6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8680B21W73"},{"name":"Maps_To","value":"Macimorelin"},{"name":"NCI_Drug_Dictionary_ID","value":"735530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735530"},{"name":"PDQ_Open_Trial_Search_ID","value":"735530"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986922"}]}}{"C87728":{"preferredName":"Macitentan","code":"C87728","definitions":[{"definition":"An orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macitentan","termGroup":"PT","termSource":"NCI"},{"termName":"ACT-064992","termGroup":"CN","termSource":"NCI"},{"termName":"Actelion-1","termGroup":"SY","termSource":"NCI"},{"termName":"N-(5-(4-Bromophenyl)-6-(2-((5-Bromopyrimidin-2-Yl)Oxi)Ethoxy)Pyrimidin-4-Yl)-N'-Propylsulfuric Diamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Pulmonary arterial hypertension, idiopathic pulmonary fibrosis, oncology"},{"name":"CAS_Registry","value":"441798-33-0"},{"name":"Chemical_Formula","value":"C19H20Br2N6O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z9K9Y9WMVL"},{"name":"Maps_To","value":"Macitentan"},{"name":"NCI_Drug_Dictionary_ID","value":"721764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721764"},{"name":"PDQ_Open_Trial_Search_ID","value":"721764"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2606556"}]}}{"C154567":{"preferredName":"Maekmoondong-tang","code":"C154567","definitions":[{"definition":"A traditional East Asian herbal medicine composed of six herbs, including Ophiopogonis tuber, Pinelliae tuber, Glycyrrhizae radix, Zizyphi fructus, Ginseng radix, and Oryzae semen, with potential anti-tussive activity. Maekmoondong-tang is traditionally prescribed for respiratory symptoms to direct the qi downwards and compensate for lung-yin deficiency or dry lung by tonifying yin and moistening the lung. Although the exact mechanisms through which Maekmoondong-tang exerts its effects have yet to be fully elucidated, this agent may, upon administration, improve the severity of chronic cough, reduce airway hyper-responsiveness possibly by reducing the cough reflex and bronchodilation, and airway inflammation possibly through anti-inflammatory and immunomodulatory effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maekmoondong-tang","termGroup":"PT","termSource":"NCI"},{"termName":"Bakumondo-to","termGroup":"SY","termSource":"NCI"},{"termName":"Maekgeuron Granules","termGroup":"SY","termSource":"NCI"},{"termName":"Mai-men-dong-tang","termGroup":"SY","termSource":"NCI"},{"termName":"MMDT","termGroup":"AB","termSource":"NCI"},{"termName":"Ophiopogonis tuber/Pinelliae tuber/Glycyrrhizae radix/Zizyphi fructus/Ginseng radix/Oryzae semen Herbal Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"TJ-29","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maekmoondong-tang"},{"name":"NCI_Drug_Dictionary_ID","value":"794323"},{"name":"NCI_META_CUI","value":"CL555363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794323"},{"name":"PDQ_Open_Trial_Search_ID","value":"794323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1150":{"preferredName":"Mafosfamide","code":"C1150","definitions":[{"definition":"A form of cyclophosphamide that can be administered as an intrathecal infusion.  Mafosfamide is being studied as an anticancer drug.  It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic oxazaphosphorine derivative with antineoplastic properties.  Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis.  Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mafosfamide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"88859-04-5"},{"name":"Chemical_Formula","value":"C9H19Cl2N2O5PS2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5970HH9923"},{"name":"Legacy Concept Name","value":"Mafosfamide"},{"name":"Maps_To","value":"Mafosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"41254"},{"name":"NSC Number","value":"345842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41254"},{"name":"PDQ_Open_Trial_Search_ID","value":"41254"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065506"}]}}{"C2681":{"preferredName":"MAGE-10.A2","code":"C2681","definitions":[{"definition":"A synthetic nonapeptide derived from a melanoma-associated antigen. Vaccination with MAGE-10.A2 may stimulate a host cytotoxic T-cell response against tumor cells that express the melanoma-associated antigen, resulting in tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-10.A2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MAGE-10_A2"},{"name":"Maps_To","value":"MAGE-10.A2"},{"name":"NCI_Drug_Dictionary_ID","value":"38649"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38649"},{"name":"PDQ_Open_Trial_Search_ID","value":"38649"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134715"}]}}{"C166968":{"preferredName":"Biropepimut-S","code":"C166968","definitions":[{"definition":"A proprietary, peptide cancer vaccine comprised of multiple peptides derived from human melanoma antigen A3 (MAGE-A3; MAGEA3), with potential immunostimulating and antineoplastic activities. Upon administration, biropepimut-S may stimulate the immune system to mount specific responses from B-cells, and CD4-positive and CD8-positive cells against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biropepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"GL-0817","termGroup":"CN","termSource":"NCI"},{"termName":"GL-0817 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GL0817","termGroup":"CN","termSource":"NCI"},{"termName":"MAGE-A3 Multipeptide Vaccine GL-0817","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A3 Peptide Vaccine GL-0817","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911338-45-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6XJF4EZC5Z"},{"name":"Maps_To","value":"MAGE-A3 Multipeptide Vaccine GL-0817"},{"name":"NCI_Drug_Dictionary_ID","value":"391278"},{"name":"NCI_META_CUI","value":"CL512878"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91710":{"preferredName":"MAGE-A3 Peptide Vaccine","code":"C91710","definitions":[{"definition":"A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A3 Peptide Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A3 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"391278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391278"},{"name":"PDQ_Open_Trial_Search_ID","value":"391278"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541478"}]}}{"C123649":{"preferredName":"MAGE-A3-specific Immunotherapeutic GSK 2132231A","code":"C123649","definitions":[{"definition":"An immunotherapeutic agent composed of a fusion protein containing the human melanoma-associated antigen MAGE-A3 fused to a lipidated protein D derived from Haemophilus influenzae and combined with the immunoadjuvant AS15, with potential immunostimulating and antineoplastic activities. Upon intramuscular (IM) administration, GSK 2132231A may stimulate a specific cytotoxic T-lymphocyte (CTL) response against MAGE-A3-expressing tumor cells, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen, is upregulated in a variety of cancer cell types. This fusion protein may boost antitumoral immune responses. AS15, a liposomal formulation containing the immunostimulating compounds CpG 7909, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and QS-21, increases the immune response against MAGE-A3-expressing tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A3-specific Immunotherapeutic GSK 2132231A","termGroup":"PT","termSource":"NCI"},{"termName":"Antigen Specific Cancer Immunotherapeutic GSK 2132231A","termGroup":"SY","termSource":"NCI"},{"termName":"ASCI GSK 2132231A","termGroup":"SY","termSource":"NCI"},{"termName":"GSK 2132231A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK2132231A","termGroup":"CN","termSource":"NCI"},{"termName":"MAGE-A3 ASCI GSK 2132231A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A3-specific Immunotherapeutic GSK 2132231A"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053638"}]}}{"C114978":{"preferredName":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201","code":"C114978","definitions":[{"definition":"Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T-lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201","termGroup":"PT","termSource":"NCI"},{"termName":"TBI-1201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201"},{"name":"NCI_Drug_Dictionary_ID","value":"759543"},{"name":"NCI_META_CUI","value":"CL472575"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759543"},{"name":"PDQ_Open_Trial_Search_ID","value":"759543"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71156":{"preferredName":"Magnesium Valproate","code":"C71156","definitions":[{"definition":"The magnesium salt of valproic acid (2-propylpentanoic acid) with antiepileptic and potential antineoplastic activities. Magnesium valproate dissociates in the gastrointestinal tract and is absorbed into the circulation as magnesium ions and valproic acid ions; valproic acid may inhibit histone deacetylases, inducing tumor cell differentiation, apoptosis, and growth arrest. In addition, valproic acid exerts an antiepileptic effect, likely by inhibiting enzymes that catabolize the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) catabolism and so increasing concentrations of GABA in the central nervous system (CNS). The presence of the magnesium in this agent may contribute to its anticonvulsant activity and sedative properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Magnesium Valproate","termGroup":"PT","termSource":"NCI"},{"termName":"Magnesium Dipropylacetate","termGroup":"SY","termSource":"NCI"},{"termName":"Pentanoic acid, 2-propyl-, Magnesium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Valproate Magnesium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62959-43-7"},{"name":"Chemical_Formula","value":"2C8H15O2.Mg"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q400352CM2"},{"name":"Legacy Concept Name","value":"Magnesium_Valproate"},{"name":"Maps_To","value":"Magnesium Valproate"},{"name":"NCI_Drug_Dictionary_ID","value":"573418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573418"},{"name":"PDQ_Open_Trial_Search_ID","value":"573418"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0524735"}]}}{"C160147":{"preferredName":"Safimaltib","code":"C160147","definitions":[{"definition":"An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, safimaltib targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor-kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Safimaltib","termGroup":"PT","termSource":"NCI"},{"termName":"1-(1-Oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"JNJ 67856633","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-67856633","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ67856633","termGroup":"CN","termSource":"NCI"},{"termName":"MALT1 Inhibitor JNJ-67856633","termGroup":"SY","termSource":"NCI"},{"termName":"Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor JNJ-67856633","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230273-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L9790S42AI"},{"name":"Maps_To","value":"MALT1 Inhibitor JNJ-67856633"},{"name":"NCI_Drug_Dictionary_ID","value":"798315"},{"name":"NCI_META_CUI","value":"CL969161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798315"},{"name":"PDQ_Open_Trial_Search_ID","value":"798315"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83904":{"preferredName":"Mannosulfan","code":"C83904","definitions":[{"definition":"An alkyl sulfonate with potential antineoplastic activity. Mannosulfan alkylates DNA, thereby producing DNA intra- or interstrand crosslinks, and ultimately results in inhibiting DNA replication and cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mannosulfan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7518-35-6"},{"name":"Chemical_Formula","value":"C10H22O14S4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"135FQ40L36"},{"name":"Maps_To","value":"Mannosulfan"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065696"}]}}{"C1990":{"preferredName":"Mannosylerythritol Lipid","code":"C1990","definitions":[{"definition":"A yeast glycolipid biosurfactant with potential antineoplastic activity.  Mannosylerythritol lipid activates protein kinase signal cascades, resulting in cell differentiation, condensation of chromatin, DNA fragmentation, G1 phase cell-cycle arrest, and apoptosis of tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mannosylerythritol Lipid","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mannosylerythritol_Lipid"},{"name":"Maps_To","value":"Mannosylerythritol Lipid"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099170"}]}}{"C61502":{"preferredName":"Mapatumumab","code":"C61502","definitions":[{"definition":"A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL R1 on the surface of some tumor cells. This may kill the tumor cells. Anti-TRAIL R1-mAb is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mapatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TRAIL R1-mAb","termGroup":"SY","termSource":"NCI"},{"termName":"HGS-ETR1","termGroup":"CN","termSource":"NCI"},{"termName":"TRM-1 mAb","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"658052-09-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WZ1025JPGR"},{"name":"Legacy Concept Name","value":"Mapatumumab"},{"name":"Maps_To","value":"Mapatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"486626"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486626"},{"name":"PDQ_Open_Trial_Search_ID","value":"486626"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1665688"}]}}{"C157776":{"preferredName":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7","code":"C157776","definitions":[{"definition":"A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7","termGroup":"PT","termSource":"NCI"},{"termName":"MG1-E6/E7","termGroup":"SY","termSource":"NCI"},{"termName":"MG1-E6E7","termGroup":"SY","termSource":"NCI"},{"termName":"MG1-expressing Mutant HPV E6/E7","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic MG1 Virus-encoding E6E7","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Virus MG1-E6E7","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maraba Oncolytic Virus Expressing Mutant HPV E6/E7"},{"name":"NCI_Drug_Dictionary_ID","value":"797163"},{"name":"NCI_META_CUI","value":"CL937424"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797163"},{"name":"PDQ_Open_Trial_Search_ID","value":"797163"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1152":{"preferredName":"Marcellomycin","code":"C1152","definitions":[{"definition":"An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum.  Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marcellomycin","termGroup":"PT","termSource":"NCI"},{"termName":"1-Naphthacenecarboxylic acid, 4-[[O-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-O-2, 6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-2,3, 6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-2-e thyl-1,2,3,4,6,11-hexahydro-2,5,7,10-tetrahydroxy-6,11-dioxo-, methyl ester, (1R-(1alpha,2beta,4beta))- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Rhodirubin E","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63710-10-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3296X8L13E"},{"name":"Legacy Concept Name","value":"Marcellomycin"},{"name":"Maps_To","value":"Marcellomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39758"},{"name":"NSC Number","value":"265211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39758"},{"name":"PDQ_Open_Trial_Search_ID","value":"39758"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065718"}]}}{"C156733":{"preferredName":"MARCKS Protein Inhibitor BIO-11006","code":"C156733","definitions":[{"definition":"An aerosolized 10-amino acid peptide that inhibits the myristoylated alanine rich protein kinase C substrate (MARCKS) protein, with potential immunomodulating and antineoplastic activities. Upon inhalation, the MARCKS protein inhibitor BIO-11006 targets, binds to and inhibits the phosphorylation of MARCKS (P-MARCKS). This prevents MARCKS-mediated signaling, thereby preventing the release of phosphatidylinositol 4,5-bisphosphate (PIP2) from the cell membrane upon MARCKS binding. This prevents the PIP2-mediated activation of focal adhesion kinase (FAK) and the FAK-mediated activation of the PI3K/AKT pathway and the activation of integrins, talin, vinculin and paxillin. This leads to an inhibition of tumor cell proliferation, migration, metastasis and survival. In addition, inhibition of MARCKS prevents mucin granule release and reduces the overproduction of mucus in the lungs. This may abrogate airway obstruction, impaired lung function, airway inflammation and bacterial infections associated with overproduction of mucus in the lungs. The MARCKS protein, a filamentous actin crosslinking protein and substrate for protein kinase C (PKC) is localized on the plasma membrane. Upon phosphorylation by PKC or binding to the calcium-calmodulin complex, the association of MARCKS with actin and with the plasma membrane is blocked, leading to its presence in the cytoplasm. The MARCKS protein plays a key role in the exocytosis of a number of vesicles and granules, cell movement, mitogenesis and membrane trafficking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MARCKS Protein Inhibitor BIO-11006","termGroup":"PT","termSource":"NCI"},{"termName":"Aerosolized BIO-11006","termGroup":"SY","termSource":"NCI"},{"termName":"BIO 11006","termGroup":"CN","termSource":"NCI"},{"termName":"BIO-11006","termGroup":"CN","termSource":"NCI"},{"termName":"BIO-11006 Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"BIO11006","termGroup":"CN","termSource":"NCI"},{"termName":"Myristoylated Alanine Rich C Kinase Substrate Inhibitor BIO-11006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"901117-03-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"609AWV0US2"},{"name":"Maps_To","value":"MARCKS Protein Inhibitor BIO-11006"},{"name":"NCI_Drug_Dictionary_ID","value":"795591"},{"name":"NCI_META_CUI","value":"CL935857"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795591"},{"name":"PDQ_Open_Trial_Search_ID","value":"795591"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91733":{"preferredName":"Margetuximab","code":"C91733","definitions":[{"definition":"A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Margetuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human Neu (Receptor)) (Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Heavy Chain), Disulfide with Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Margenza","termGroup":"BR","termSource":"NCI"},{"termName":"Margetuximab-cmkb","termGroup":"SY","termSource":"NCI"},{"termName":"MGA H22","termGroup":"CN","termSource":"NCI"},{"termName":"MGA-H22","termGroup":"CN","termSource":"NCI"},{"termName":"MGAH-22","termGroup":"CN","termSource":"NCI"},{"termName":"MGAH22","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic HER2-positive breast cancer"},{"name":"CAS_Registry","value":"1350624-75-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K911R84KEW"},{"name":"Maps_To","value":"Margetuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"681010"},{"name":"NCI_META_CUI","value":"CL421637"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681010"},{"name":"PDQ_Open_Trial_Search_ID","value":"681010"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1652":{"preferredName":"Marimastat","code":"C1652","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Marimastat is a matrix metalloproteinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marimastat","termGroup":"PT","termSource":"NCI"},{"termName":"(2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"(2S,3R)-3-{(S)-[2,2-Dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BB-2516","termGroup":"CN","termSource":"NCI"},{"termName":"Marimistat","termGroup":"AQS","termSource":"NCI"},{"termName":"TA-2516","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154039-60-8"},{"name":"CHEBI_ID","value":"CHEBI:50662"},{"name":"Chemical_Formula","value":"C15H29N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D5EQV23TDS"},{"name":"Legacy Concept Name","value":"Marimastat"},{"name":"Maps_To","value":"Marimastat"},{"name":"NCI_Drug_Dictionary_ID","value":"42443"},{"name":"NSC Number","value":"689451"},{"name":"NSC Number","value":"719333"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42443"},{"name":"PDQ_Open_Trial_Search_ID","value":"42443"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338344"}]}}{"C64634":{"preferredName":"Marizomib","code":"C64634","definitions":[{"definition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Marizomib","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,4R,5S)-4-(2-chloroethyl)-1-{(S)-[(1S)-cyclohex-2-en-1-yl]hydroxymethyl}-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Marizomib","termGroup":"SY","termSource":"NCI"},{"termName":"ML 858","termGroup":"CN","termSource":"NCI"},{"termName":"NPI-0052","termGroup":"CN","termSource":"NCI"},{"termName":"Salinosporamide A","termGroup":"SY","termSource":"NCI"},{"termName":"Salinosporin A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"437742-34-2"},{"name":"CHEBI_ID","value":"CHEBI:48045"},{"name":"Chemical_Formula","value":"C15H20ClNO4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"703P9YDP7F"},{"name":"Legacy Concept Name","value":"NPI-0052"},{"name":"Maps_To","value":"Marizomib"},{"name":"NCI_Drug_Dictionary_ID","value":"518316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518316"},{"name":"PDQ_Open_Trial_Search_ID","value":"518316"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1259854"}]}}{"C79831":{"preferredName":"Masitinib Mesylate","code":"C79831","definitions":[{"definition":"The orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masitinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide Mesylate","termGroup":"SN","termSource":"NCI"},{"termName":"AB 1010","termGroup":"CN","termSource":"NCI"},{"termName":"AB-1010","termGroup":"CN","termSource":"NCI"},{"termName":"AB1010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1048007-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZK89EG3A18"},{"name":"Legacy Concept Name","value":"Masitinib_Mesylate"},{"name":"Maps_To","value":"Masitinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"629109"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629109"},{"name":"PDQ_Open_Trial_Search_ID","value":"629109"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351399"}]}}{"C701":{"preferredName":"Masoprocol","code":"C701","definitions":[{"definition":"A drug put on the skin to treat growths caused by sun exposure. A form of Masoprocol that is taken by mouth is being studied in the treatment of prostate cancer. Masoprocol is an antioxidant, and it may block certain enzymes needed for tumor growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally occurring antioxidant dicatechol originally derived from the creosote bush Larrea divaricatta with antipromoter, anti-inflammatory, and antineoplastic activities. Masoprocol directly inhibits activation of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu receptor, resulting in decreased proliferation of susceptible tumor cell populations. This agent may induce apoptosis in susceptible tumor cell populations as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases (SAPKs). In addition, masoprocol inhibits arachidonic acid 5-lipoxygenase (5LOX), resulting in diminished synthesis of inflammatory mediators such as prostaglandins and leukotrienes. It may prevent leukocyte infiltration into tissues and the release of reactive oxygen species.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masoprocol","termGroup":"PT","termSource":"NCI"},{"termName":"4,4'-(2,3-Dimethyl-1,4-butanediyl)bis[1,2-benzenediol]","termGroup":"SN","termSource":"NCI"},{"termName":"Actinex","termGroup":"BR","termSource":"NCI"},{"termName":"NDGA","termGroup":"AB","termSource":"NCI"},{"termName":"NDHGA","termGroup":"AB","termSource":"NCI"},{"termName":"Nordihydroguaiaretic Acid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"27686-84-6"},{"name":"Chemical_Formula","value":"C18H22O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7BO8G1BYQU"},{"name":"Legacy Concept Name","value":"Nordihydroguaiaretic_Acid"},{"name":"Maps_To","value":"Masoprocol"},{"name":"NCI_Drug_Dictionary_ID","value":"479648"},{"name":"NSC Number","value":"4291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"479648"},{"name":"PDQ_Open_Trial_Search_ID","value":"479648"},{"name":"PubMedID_Primary_Reference","value":"8450672"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0733397"}]}}{"C153180":{"preferredName":"MAT2A Inhibitor AG-270","code":"C153180","definitions":[{"definition":"An orally available small molecule inhibitor of methionine adenosyltransferase II alpha (MAT2A) with potential antineoplastic activity. Upon administration, AG-270 inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-Adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in methylthioadenosine phosphorylase (MTAP), a critical enzyme in the methionine salvage pathway, that is deleted in some human cancers. Inhibition of MAT2A may potentially inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAT2A Inhibitor AG-270","termGroup":"PT","termSource":"NCI"},{"termName":"AG 270","termGroup":"CN","termSource":"NCI"},{"termName":"AG-270","termGroup":"CN","termSource":"NCI"},{"termName":"AG270","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2201056-66-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E1P2TDU69L"},{"name":"Maps_To","value":"MAT2A Inhibitor AG-270"},{"name":"NCI_Drug_Dictionary_ID","value":"793947"},{"name":"NCI_META_CUI","value":"CL554312"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793947"},{"name":"PDQ_Open_Trial_Search_ID","value":"793947"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2045":{"preferredName":"Matrix Metalloproteinase Inhibitor MMI270","code":"C2045","definitions":[{"definition":"An orally-active synthetic hydroxamic acid derivative with potential antineoplastic activity.  MMI270 inhibits a broad spectrum of matrix metalloproteinases (MMPs) (specifically MMP-1, 2, 3, 9, and 13), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also downregulate lymphangiogenesis, resulting in decreased lymphatic system-related metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Matrix Metalloproteinase Inhibitor MMI270","termGroup":"PT","termSource":"NCI"},{"termName":"(2R)-N-Hydroxy-2-[[(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methylbutanamide Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CGS27023","termGroup":"CN","termSource":"NCI"},{"termName":"CGS27023A","termGroup":"CN","termSource":"NCI"},{"termName":"MMI 270B CGS27023A","termGroup":"SY","termSource":"NCI"},{"termName":"N-hydroxy-2(R)-[(4-methoxysulfony) (3-picolyl)-amino]-3-metylbutaneamide hydrochloride monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"N-hydroxy-2(R)-[[4- methoxysulfonyl](3-picolyl)amino]-3-methylbutaneamide hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MMI270"},{"name":"Maps_To","value":"Matrix Metalloproteinase Inhibitor MMI270"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385829"}]}}{"C2012":{"preferredName":"Matuzumab","code":"C2012","definitions":[{"definition":"A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and inhibiting receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. EMD 72000 binds to the epithelial growth factor receptor (EGFR) on tumor cells and blocks growth signals.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Matuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 72000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"339186-68-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MG4M3QB242"},{"name":"Legacy Concept Name","value":"EMD_72000"},{"name":"Maps_To","value":"Matuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"350433"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350433"},{"name":"PDQ_Open_Trial_Search_ID","value":"350433"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328134"}]}}{"C120307":{"preferredName":"Mavelertinib","code":"C120307","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mavelertinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)-3-pyrrolidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"PF-06747775","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1776112-90-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YXX2180047"},{"name":"Maps_To","value":"Mavelertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"768709"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768709"},{"name":"PDQ_Open_Trial_Search_ID","value":"768709"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896785"}]}}{"C126660":{"preferredName":"Mavorixafor","code":"C126660","definitions":[{"definition":"An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T-cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mavorixafor","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"AMD-070","termGroup":"CN","termSource":"NCI"},{"termName":"AMD-11070","termGroup":"CN","termSource":"NCI"},{"termName":"AMD11070","termGroup":"CN","termSource":"NCI"},{"termName":"X4P 001","termGroup":"CN","termSource":"NCI"},{"termName":"X4P-001","termGroup":"CN","termSource":"NCI"},{"termName":"X4P001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"558447-26-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0G9LGB5O2W"},{"name":"Maps_To","value":"Mavorixafor"},{"name":"NCI_Drug_Dictionary_ID","value":"780512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780512"},{"name":"PDQ_Open_Trial_Search_ID","value":"780512"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2930725"}]}}{"C626":{"preferredName":"Maytansine","code":"C626","definitions":[{"definition":"An ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata. Maytansine binds to tubulin at the rhizoxin binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.  Maytansine exhibits cytotoxicity against many tumor cell lines and may inhibit tumor growth in vivo. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maytansine","termGroup":"PT","termSource":"NCI"},{"termName":"alanine, N-acetyl-N-methyl-, 6-ester with 11-chloro-6, 21-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1(10,24).0(3,5)]hexacosa-10,12,14[26], 16,18-pentaene-8,23-dione","termGroup":"SN","termSource":"NCI"},{"termName":"L-alanine, N-acetyl-N-methyl-, 11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03, 5]hexacosa-10,12,14(26),16,18-pentaen-6-yl ester, [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]","termGroup":"SN","termSource":"NCI"},{"termName":"Maitansine","termGroup":"SY","termSource":"NCI"},{"termName":"Maysanine","termGroup":"SY","termSource":"NCI"},{"termName":"Maytansin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"35846-53-8"},{"name":"Chemical_Formula","value":"C34H46ClN3O10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14083FR882"},{"name":"Legacy Concept Name","value":"Maytansine"},{"name":"Maps_To","value":"Maytansine"},{"name":"NCI_Drug_Dictionary_ID","value":"39492"},{"name":"NSC Number","value":"153858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39492"},{"name":"PDQ_Open_Trial_Search_ID","value":"39492"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0024975"}]}}{"C127817":{"preferredName":"Tapotoclax","code":"C127817","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tapotoclax","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 176","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1883727-34-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"97W7N9T08G"},{"name":"Maps_To","value":"MCL-1 Inhibitor AMG 176"},{"name":"Maps_To","value":"Tapotoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"781850"},{"name":"NCI_META_CUI","value":"CL507931"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781850"},{"name":"PDQ_Open_Trial_Search_ID","value":"781850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156740":{"preferredName":"Murizatoclax","code":"C156740","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor AMG 397 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Murizatoclax","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 397","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-397","termGroup":"CN","termSource":"NCI"},{"termName":"AMG397","termGroup":"CN","termSource":"NCI"},{"termName":"MCL-1 inhibitor AMG 397","termGroup":"SY","termSource":"NCI"},{"termName":"Myeloid Cell Leukemia 1 Inhibitor AMG 397","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2245848-05-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BO0V7196L2"},{"name":"Maps_To","value":"MCL-1 inhibitor AMG 397"},{"name":"Maps_To","value":"Murizatoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"795697"},{"name":"NCI_META_CUI","value":"CL935903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795697"},{"name":"PDQ_Open_Trial_Search_ID","value":"795697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137989":{"preferredName":"Mcl-1 Inhibitor AZD5991","code":"C137989","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, AZD5991 binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins, and promoting apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mcl-1 Inhibitor AZD5991","termGroup":"PT","termSource":"NCI"},{"termName":"AZD-5991","termGroup":"CN","termSource":"NCI"},{"termName":"AZD5991","termGroup":"CN","termSource":"NCI"},{"termName":"MCL1 Inhibitor AZD5991","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2143010-83-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E3T5XXY9HX"},{"name":"Maps_To","value":"Mcl-1 Inhibitor AZD5991"},{"name":"NCI_Drug_Dictionary_ID","value":"790242"},{"name":"NCI_META_CUI","value":"CL524956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790242"},{"name":"PDQ_Open_Trial_Search_ID","value":"790242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133174":{"preferredName":"Mcl-1 Inhibitor MIK665","code":"C133174","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mcl-1 Inhibitor MIK665","termGroup":"PT","termSource":"NCI"},{"termName":"MIK 665","termGroup":"CN","termSource":"NCI"},{"termName":"MIK-665","termGroup":"CN","termSource":"NCI"},{"termName":"MIK665","termGroup":"CN","termSource":"NCI"},{"termName":"S 64315","termGroup":"CN","termSource":"NCI"},{"termName":"S-64315","termGroup":"CN","termSource":"NCI"},{"termName":"S64315","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1799638-19-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"801XYWHNOS"},{"name":"Maps_To","value":"Mcl-1 Inhibitor MIK665"},{"name":"NCI_Drug_Dictionary_ID","value":"788002"},{"name":"NCI_META_CUI","value":"CL520448"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788002"},{"name":"PDQ_Open_Trial_Search_ID","value":"788002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162749":{"preferredName":"MDM2 Antagonist ASTX295","code":"C162749","definitions":[{"definition":"An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Antagonist ASTX295","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 295","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX-295","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX295","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2 Inhibitor ASTX295","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MDM2 Antagonist ASTX295"},{"name":"NCI_Drug_Dictionary_ID","value":"798989"},{"name":"NCI_META_CUI","value":"CL973194"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798989"},{"name":"PDQ_Open_Trial_Search_ID","value":"798989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91724":{"preferredName":"MDM2 Antagonist RO5045337","code":"C91724","definitions":[{"definition":"An MDM2 (human homolog of double minutes-2; HDM2) antagonist with potential antineoplastic activity. RO5045337 binds to MDM2, thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Antagonist RO5045337","termGroup":"PT","termSource":"NCI"},{"termName":"R7112","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5045337","termGroup":"CN","termSource":"NCI"},{"termName":"RO5045337","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"939981-39-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q8MI0X869M"},{"name":"Maps_To","value":"MDM2 Antagonist RO5045337"},{"name":"NCI_Drug_Dictionary_ID","value":"581121"},{"name":"NCI_META_CUI","value":"CL421615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581121"},{"name":"PDQ_Open_Trial_Search_ID","value":"581121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114980":{"preferredName":"MDM2 Antagonist RO6839921","code":"C114980","definitions":[{"definition":"An MDM2 (human homolog of murine double minute-2; HDM2) antagonist with potential antineoplastic activity. Upon intravenous administration, RO6839921 binds to MDM2 and prevents the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling, followed by p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway and is often overexpressed in cancer cells; p53 inhibition has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Antagonist RO6839921","termGroup":"PT","termSource":"NCI"},{"termName":"RO6839921","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MDM2 Antagonist RO6839921"},{"name":"NCI_Drug_Dictionary_ID","value":"759578"},{"name":"NCI_META_CUI","value":"CL472577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759578"},{"name":"PDQ_Open_Trial_Search_ID","value":"759578"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116624":{"preferredName":"Navtemadlin","code":"C116624","definitions":[{"definition":"An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration,navtemadlin binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navtemadlin","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"AMG 232","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-232","termGroup":"CN","termSource":"NCI"},{"termName":"KRT 232","termGroup":"CN","termSource":"NCI"},{"termName":"KRT-232","termGroup":"CN","termSource":"NCI"},{"termName":"KRT232","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2 Inhibitor KRT-232","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1352066-68-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7R7G6EH5UL"},{"name":"Maps_To","value":"MDM2 Inhibitor AMG-232"},{"name":"Maps_To","value":"MDM2 Inhibitor KRT-232"},{"name":"NCI_Drug_Dictionary_ID","value":"742695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742695"},{"name":"PDQ_Open_Trial_Search_ID","value":"742695"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852521"}]}}{"C156709":{"preferredName":"Brigimadlin","code":"C156709","definitions":[{"definition":"An orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, brigimadlin binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. Compared to currently available MDM2 inhibitors, the pharmacokinetic properties of BI 907828 allow for more optimal dosing and dose schedules that may reduce myelosuppression, an on-target, dose-limiting toxicity for this class of inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brigimadlin","termGroup":"PT","termSource":"NCI"},{"termName":"BI 907828","termGroup":"CN","termSource":"NCI"},{"termName":"BI-907828","termGroup":"CN","termSource":"NCI"},{"termName":"BI907828","termGroup":"SY","termSource":"NCI"},{"termName":"MDM2 Inhibitor BI 907828","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095116-40-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9A934ZAN94"},{"name":"Maps_To","value":"MDM2 Inhibitor BI 907828"},{"name":"NCI_Drug_Dictionary_ID","value":"795735"},{"name":"NCI_META_CUI","value":"CL935863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795735"},{"name":"PDQ_Open_Trial_Search_ID","value":"795735"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118669":{"preferredName":"Sulanemadlin","code":"C118669","definitions":[{"definition":"An orally available peptide inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, sulanemadlin binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulanemadlin","termGroup":"PT","termSource":"NCI"},{"termName":"ALRN-6924","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2/MDMX Inhibitor ALRN-6924","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1451199-98-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6BGF28R54M"},{"name":"Maps_To","value":"MDM2/MDMX Inhibitor ALRN-6924"},{"name":"NCI_Drug_Dictionary_ID","value":"765720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765720"},{"name":"PDQ_Open_Trial_Search_ID","value":"765720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896920"}]}}{"C67042":{"preferredName":"MDR Modulator CBT-1","code":"C67042","definitions":[{"definition":"A naturally-occurring, orally bioavailable bisbenzylisoquinoline plant alkaloid with potential chemosensitization activity. MDR modulator CBT-1 binds to and inhibits the MDR efflux pump P-glycoprotein (P-gp), which may inhibit the efflux of various chemotherapeutic agents from tumor cells and reverse P-gp-mediated tumor cell MDR. P-gp is a transmembrane ATP-binding cassette (ABC) transporter and is overexpressed by some multidrug resistant tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance taken from plants that is being studied in the treatment of cancer. It may help drugs kill tumor cells that have become resistant to drugs. It is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"MDR Modulator CBT-1","termGroup":"PT","termSource":"NCI"},{"termName":"CBT-1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CBT-1"},{"name":"Maps_To","value":"MDR Modulator CBT-1"},{"name":"NCI_Drug_Dictionary_ID","value":"538747"},{"name":"PDQ_Closed_Trial_Search_ID","value":"538747"},{"name":"PDQ_Open_Trial_Search_ID","value":"538747"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0916470"}]}}{"C62056":{"preferredName":"Mechlorethamine","code":"C62056","definitions":[{"definition":"A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The nitrogen mustard vesicant HN-2.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Mechlorethamine","termGroup":"PT","termSource":"NCI"},{"termName":"Bis(2-chloroethyl)methylamine","termGroup":"SN","termSource":"NCI"},{"termName":"chlorethazine","termGroup":"SY","termSource":"NCI"},{"termName":"Chlormethine","termGroup":"SY","termSource":"NCI"},{"termName":"chloromethine","termGroup":"SY","termSource":"NCI"},{"termName":"ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl","termGroup":"SN","termSource":"NCI"},{"termName":"HN 2","termGroup":"AB","termSource":"NCI"},{"termName":"Methylbis(beta-chloroethyl)amine","termGroup":"SN","termSource":"NCI"},{"termName":"methylchlorethamine","termGroup":"SY","termSource":"NCI"},{"termName":"Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"Mustine","termGroup":"SY","termSource":"NCI"},{"termName":"Nitrogen Mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51-75-2"},{"name":"CHEBI_ID","value":"CHEBI:28925"},{"name":"Chemical_Formula","value":"C5H11Cl2N"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"50D9XSG0VR"},{"name":"Legacy Concept Name","value":"Mechlorethamine"},{"name":"Maps_To","value":"Mechlorethamine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025033"}]}}{"C627":{"preferredName":"Mechlorethamine Hydrochloride","code":"C627","definitions":[{"definition":"A drug used to treat some types of cancer and some skin conditions that may become cancer. It attaches to the cell's DNA and may kill cancer cells. Mechlorethamine hydrochloride is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of mechlorethamine, a nitrogen mustard and an analogue of sulfur mustard, with antineoplastic and immunosuppressive activities. Mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that alkylates DNA, particularly the 7 nitrogen of guanine residues, resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. This agent also exhibits lympholytic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mechlorethamine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Bis(2-chloroethyl)methylamine Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Caryolysine","termGroup":"FB","termSource":"NCI"},{"termName":"Chlorethamine HCl","termGroup":"SY","termSource":"NCI"},{"termName":"chlorethamine hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorethazine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Chlormethine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Chloromethine HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Chloromethine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Cloramin","termGroup":"FB","termSource":"NCI"},{"termName":"Erasol","termGroup":"FB","termSource":"NCI"},{"termName":"ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"HN 2 Hydrochloride","termGroup":"AB","termSource":"NCI"},{"termName":"mechlorethamine HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Methylbis(beta-chloroethyl)amine Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Methylchlorethamine Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mustargen","termGroup":"BR","termSource":"NCI"},{"termName":"Mustargen HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Mustargen Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mustine Hydrochloride","termGroup":"FB","termSource":"NCI"},{"termName":"N-Lost","termGroup":"SY","termSource":"NCI"},{"termName":"Onco-Cloramin","termGroup":"FB","termSource":"NCI"},{"termName":"WR-147650","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bronchogenic carcinoma; chronic lymphocytic and myelcytic leukemia; Hodgkins dieseas, palliative; lymphosarcoma; mycosis fungoides; polycythemia vera"},{"name":"CAS_Registry","value":"55-86-7"},{"name":"CHEBI_ID","value":"CHEBI:55368"},{"name":"Chemical_Formula","value":"C5H11Cl2N.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L0MR697HHI"},{"name":"Legacy Concept Name","value":"Nitrogen_Mustard"},{"name":"Maps_To","value":"Mechlorethamine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"43434"},{"name":"NSC Number","value":"762"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43434"},{"name":"PDQ_Open_Trial_Search_ID","value":"43434"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0600266"}]}}{"C119736":{"preferredName":"Mechlorethamine Hydrochloride Gel","code":"C119736","definitions":[{"definition":"A gel formulation composed of the hydrochloride salt form of mechlorethamine, which is a nitrogen mustard alkylating agent and an analog of sulfur mustard, with antineoplastic and immunosuppressive activities. Upon topical application, mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that binds to and alkylates DNA, with a high affinity to the N7 nitrogen of guanine residues. This results in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mechlorethamine Hydrochloride Gel","termGroup":"PT","termSource":"NCI"},{"termName":"Mechlorethamine HCl Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Valchlor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mechlorethamine Hydrochloride Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"766986"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766986"},{"name":"PDQ_Open_Trial_Search_ID","value":"766986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3666714"}]}}{"C87599":{"preferredName":"Medorubicin","code":"C87599","definitions":[{"definition":"A demethoxy derivative of doxorubicin with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S)-3-Glycoloyl-1,2,3,4,6,11-Hexahydro-3,5,12-Trihydroxy-6,11-Dioxo-1-Naphthacenyl 3-Amino-2,3,6-Trideoxy-Alpha-L-Lyxo-Hexopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"4-Demethoxydoxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64314-52-9"},{"name":"Chemical_Formula","value":"C26H27NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NU158DGH9E"},{"name":"Maps_To","value":"Medorubicin"},{"name":"NSC Number","value":"256438"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0048224"}]}}{"C629":{"preferredName":"Medroxyprogesterone","code":"C629","definitions":[{"definition":"A hormonal anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called progestins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medroxyprogesterone","termGroup":"PT","termSource":"NCI"},{"termName":"(6Alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17Alpha-hydroxy-6alpha-methylprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6Alpha-methyl-17alpha-hydroxyprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6Alpha-methyl-4-pregnen-17alpha-ol-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Curretab","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast carcinoma; Contraception; Endometrial carcinoma; Renal cell carcinoma"},{"name":"CAS_Registry","value":"520-85-4"},{"name":"CHEBI_ID","value":"CHEBI:6715"},{"name":"Chemical_Formula","value":"C22H32O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HSU1C9YRES"},{"name":"Legacy Concept Name","value":"Medroxyprogesterone"},{"name":"Maps_To","value":"Medroxyprogesterone"},{"name":"NCI_Drug_Dictionary_ID","value":"39813"},{"name":"NSC Number","value":"27408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39813"},{"name":"PDQ_Open_Trial_Search_ID","value":"39813"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025147"}]}}{"C1155":{"preferredName":"Medroxyprogesterone Acetate","code":"C1155","definitions":[{"definition":"A drug used to prevent endometrial cancer. It is also used to treat menstrual disorders and as a form of birth control. It is a form of the female hormone progesterone and belongs to the family of drugs called progestins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Medroxyprogesterone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"(6alpha)-17-(Acetyloxy)-6-methylpregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17-(Acetyloxy)-6alpha-methylpregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"17Alpha-acetoxy-6alpha-methylprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6-Alpha-methyl-17alpha-acetoxyprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"Amen","termGroup":"BR","termSource":"NCI"},{"termName":"Aragest","termGroup":"FB","termSource":"NCI"},{"termName":"Ciclotal","termGroup":"FB","termSource":"NCI"},{"termName":"Clinofem","termGroup":"FB","termSource":"NCI"},{"termName":"Clinovir","termGroup":"FB","termSource":"NCI"},{"termName":"Cycrin","termGroup":"BR","termSource":"NCI"},{"termName":"Depo-Clinovir","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Provera","termGroup":"BR","termSource":"NCI"},{"termName":"Depot-Medroxyprogestereone Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"Farlutal","termGroup":"FB","termSource":"NCI"},{"termName":"G-Farlutal","termGroup":"FB","termSource":"NCI"},{"termName":"Gestapuran","termGroup":"FB","termSource":"NCI"},{"termName":"Hysron","termGroup":"FB","termSource":"NCI"},{"termName":"Lutoral","termGroup":"FB","termSource":"NCI"},{"termName":"Medroxyprogesterone 17-Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"Medroxyprogesteroni Acetas","termGroup":"SY","termSource":"NCI"},{"termName":"Methylacetoxyprogesterone","termGroup":"SY","termSource":"NCI"},{"termName":"Metipregnone","termGroup":"SY","termSource":"NCI"},{"termName":"MPA","termGroup":"AB","termSource":"NCI"},{"termName":"Nadigest (vet)","termGroup":"FB","termSource":"NCI"},{"termName":"Nidaxin (vet)","termGroup":"FB","termSource":"NCI"},{"termName":"Oragest","termGroup":"BR","termSource":"NCI"},{"termName":"Perlutex","termGroup":"FB","termSource":"NCI"},{"termName":"Prodasone","termGroup":"FB","termSource":"NCI"},{"termName":"Provera","termGroup":"BR","termSource":"NCI"},{"termName":"Sodelut G","termGroup":"FB","termSource":"NCI"},{"termName":"Veramix","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71-58-9"},{"name":"CHEBI_ID","value":"CHEBI:6716"},{"name":"Chemical_Formula","value":"C24H34O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C2QI4IOI2G"},{"name":"Legacy Concept Name","value":"Medroxyprogesterone_17-Acetate"},{"name":"Maps_To","value":"Medroxyprogesterone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"39813"},{"name":"NSC Number","value":"21171"},{"name":"NSC Number","value":"26386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39813"},{"name":"PDQ_Open_Trial_Search_ID","value":"39813"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065864"}]}}{"C1156":{"preferredName":"Megestrol Acetate","code":"C1156","definitions":[{"definition":"A drug used to block estrogen and suppress the effects of estrogen and androgens. It is used to treat breast and endometrial cancer, and is being studied in the treatment of other types of cancer. It is also used to improve appetite in patients with cancer. Megace belongs to the group of hormones called progestins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Megestrol Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"(9beta,10alpha)-17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17 Alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"6-Dehydro-6-methyl-17 alpha-acetoxyprogesterone","termGroup":"SN","termSource":"NCI"},{"termName":"6-Methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"BDH-1298","termGroup":"CN","termSource":"NCI"},{"termName":"Maygace","termGroup":"FB","termSource":"NCI"},{"termName":"Megace","termGroup":"BR","termSource":"NCI"},{"termName":"Megestat","termGroup":"FB","termSource":"NCI"},{"termName":"Megestil","termGroup":"FB","termSource":"NCI"},{"termName":"Niagestin","termGroup":"FB","termSource":"NCI"},{"termName":"Ovaban","termGroup":"SY","termSource":"NCI"},{"termName":"Pallace","termGroup":"SY","termSource":"NCI"},{"termName":"SC 10363","termGroup":"CN","termSource":"NCI"},{"termName":"SC-10363","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Appetite enhancement, AIDS patients; Breast cancer, palliative treatment; Endometrial carcinoma, palliative treatment"},{"name":"CAS_Registry","value":"595-33-5"},{"name":"CHEBI_ID","value":"CHEBI:6723"},{"name":"Chemical_Formula","value":"C24H32O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TJ2M0FR8ES"},{"name":"Legacy Concept Name","value":"Megestrol_Acetate"},{"name":"Maps_To","value":"Megestrol Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"43435"},{"name":"NSC Number","value":"71423"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43435"},{"name":"PDQ_Open_Trial_Search_ID","value":"43435"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065879"}]}}{"C98832":{"preferredName":"MEK 1/2 Inhibitor AS703988/MSC2015103B","code":"C98832","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2 with potential antineoplastic activity. MEK1/2 inhibitor AS703988/MSC2015103B selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK 1/2 Inhibitor AS703988/MSC2015103B","termGroup":"PT","termSource":"NCI"},{"termName":"AS703988","termGroup":"CN","termSource":"NCI"},{"termName":"AS703988/MSC2015103B","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2015103B","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK 1/2 Inhibitor AS703988/MSC2015103B"},{"name":"NCI_Drug_Dictionary_ID","value":"714900"},{"name":"NCI_META_CUI","value":"CL432851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714900"},{"name":"PDQ_Open_Trial_Search_ID","value":"714900"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C69143":{"preferredName":"MEK Inhibitor AZD8330","code":"C69143","definitions":[{"definition":"An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor AZD8330","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-424704","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-704","termGroup":"CN","termSource":"NCI"},{"termName":"AZD8330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"869357-68-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G4990BOZ66"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_AZD8330"},{"name":"Maps_To","value":"MEK Inhibitor AZD8330"},{"name":"NCI_Drug_Dictionary_ID","value":"543526"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543526"},{"name":"PDQ_Open_Trial_Search_ID","value":"543526"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346908"}]}}{"C2670":{"preferredName":"MEK Inhibitor CI-1040","code":"C2670","definitions":[{"definition":"An agent that inhibits both mitogen-activated protein kinase kinases 1 and 2 (MEK1 and MEK2), substrates of Raf and phosphorylates extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2), preventing phosphorylation and activation of the Mitogen-Activated Protein Kinase (MAPK) pathways, involved with signal transduction pathways and tumor proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor CI-1040","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"CI-1040","termGroup":"CN","termSource":"NCI"},{"termName":"PD 184352/CI-1040","termGroup":"SY","termSource":"NCI"},{"termName":"PD-184352","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"212631-79-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R3K9Y00J04"},{"name":"Legacy Concept Name","value":"CI-1040"},{"name":"Maps_To","value":"MEK Inhibitor CI-1040"},{"name":"NCI_Drug_Dictionary_ID","value":"38593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38593"},{"name":"PDQ_Open_Trial_Search_ID","value":"38593"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0769765"}]}}{"C155971":{"preferredName":"MEK inhibitor CS3006","code":"C155971","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, MEK inhibitor CS3006 specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins including extracellular signal-regulated kinase (ERK) and inhibits the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the  RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in a variety of tumor cell types. The RAS/RAF/MEK/ERK pathway regulates key cellular activities including cell growth, proliferation, survival, differentiation and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK inhibitor CS3006","termGroup":"PT","termSource":"NCI"},{"termName":"CS 3006","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3006","termGroup":"CN","termSource":"NCI"},{"termName":"CS3006","termGroup":"CN","termSource":"NCI"},{"termName":"MAPK Kinase Inhibitor CS3006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK inhibitor CS3006"},{"name":"NCI_Drug_Dictionary_ID","value":"795024"},{"name":"NCI_META_CUI","value":"CL562716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795024"},{"name":"PDQ_Open_Trial_Search_ID","value":"795024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95738":{"preferredName":"MEK Inhibitor GDC-0623","code":"C95738","definitions":[{"definition":"An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor GDC-0623","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0623","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1168091-68-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HW67545I4Q"},{"name":"Maps_To","value":"MEK Inhibitor GDC-0623"},{"name":"NCI_Drug_Dictionary_ID","value":"673612"},{"name":"NCI_META_CUI","value":"CL421583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673612"},{"name":"PDQ_Open_Trial_Search_ID","value":"673612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52195":{"preferredName":"Mirdametinib","code":"C52195","definitions":[{"definition":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirdametinib","termGroup":"PT","termSource":"NCI"},{"termName":"MEK Inhibitor PD0325901","termGroup":"SY","termSource":"NCI"},{"termName":"PD 901","termGroup":"CN","termSource":"NCI"},{"termName":"PD-0325901","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"391210-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"86K0J5AK6M"},{"name":"Legacy Concept Name","value":"PD-0325901"},{"name":"Maps_To","value":"MEK Inhibitor PD0325901"},{"name":"Maps_To","value":"Mirdametinib"},{"name":"NCI_Drug_Dictionary_ID","value":"456780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456780"},{"name":"PDQ_Open_Trial_Search_ID","value":"456780"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1675748"}]}}{"C82696":{"preferredName":"MEK Inhibitor RO4987655","code":"C82696","definitions":[{"definition":"An orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor RO4987655 binds to and inhibits MEK, which may result in the inhibition of MEK-dependent cell signaling and the inhibition of tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor RO4987655","termGroup":"PT","termSource":"NCI"},{"termName":"RO4987655","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"874101-00-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I3733P75ML"},{"name":"Legacy Concept Name","value":"MEK_Serine_Threonine_Kinase_Inhibitor_RO4987655"},{"name":"Maps_To","value":"MEK Inhibitor RO4987655"},{"name":"NCI_Drug_Dictionary_ID","value":"633506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633506"},{"name":"PDQ_Open_Trial_Search_ID","value":"633506"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830219"}]}}{"C150680":{"preferredName":"MEK Inhibitor SHR 7390","code":"C150680","definitions":[{"definition":"An orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor SHR 7390 selectively binds to and inhibits the activity of MEK. This prevents the activation of MEK-dependent effector proteins, which results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase family that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor SHR 7390","termGroup":"PT","termSource":"NCI"},{"termName":"MAP2K Inhibitor SHR 7390","termGroup":"SY","termSource":"NCI"},{"termName":"MAPK Kinase Inhibitor SHR 7390","termGroup":"SY","termSource":"NCI"},{"termName":"MEKi SHR 7390","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 7390","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-7390","termGroup":"CN","termSource":"NCI"},{"termName":"SHR7390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK Inhibitor SHR 7390"},{"name":"NCI_Drug_Dictionary_ID","value":"793097"},{"name":"NCI_META_CUI","value":"CL552486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793097"},{"name":"PDQ_Open_Trial_Search_ID","value":"793097"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84858":{"preferredName":"MEK Inhibitor REC-4881","code":"C84858","definitions":[{"definition":"An orally bioavailable, non-ATP-competitive, allosteric, small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and MEK2, with potential antineoplastic activity. Upon oral administration, MEK inhibitor REC-4881 selectively binds to and inhibits the activity of MEK1/2. This prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor REC-4881","termGroup":"PT","termSource":"NCI"},{"termName":"REC 4881","termGroup":"CN","termSource":"NCI"},{"termName":"REC-4881","termGroup":"CN","termSource":"NCI"},{"termName":"REC4881","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-733","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1035555-63-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5J61HSP0QJ"},{"name":"Maps_To","value":"MEK Inhibitor TAK-733"},{"name":"NCI_Drug_Dictionary_ID","value":"651550"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651550"},{"name":"PDQ_Open_Trial_Search_ID","value":"651550"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827535"}]}}{"C101532":{"preferredName":"MEK Inhibitor WX-554","code":"C101532","definitions":[{"definition":"An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic activity. MEK inhibitor WX-554 selectively binds to and inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins including some transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK Inhibitor WX-554","termGroup":"PT","termSource":"NCI"},{"termName":"WX-554","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK Inhibitor WX-554"},{"name":"NCI_Drug_Dictionary_ID","value":"732484"},{"name":"NCI_META_CUI","value":"CL435784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732484"},{"name":"PDQ_Open_Trial_Search_ID","value":"732484"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79848":{"preferredName":"MEK-1/MEKK-1 Inhibitor E6201","code":"C79848","definitions":[{"definition":"A synthetic, fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK-1/MEKK-1 Inhibitor E6201","termGroup":"PT","termSource":"NCI"},{"termName":"E6201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"603987-35-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CZP9GB25HO"},{"name":"Legacy Concept Name","value":"MEK-1_MEKK-1_Tyrosine_Kinase_Inhibitor_E6201"},{"name":"Maps_To","value":"MEK-1/MEKK-1 Inhibitor E6201"},{"name":"NCI_Drug_Dictionary_ID","value":"629676"},{"name":"NCI_META_CUI","value":"CL388442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"629676"},{"name":"PDQ_Open_Trial_Search_ID","value":"629676"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106126":{"preferredName":"MEK/Aurora Kinase Inhibitor BI 847325","code":"C106126","definitions":[{"definition":"An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells.  Altogether, this leads to the inhibition of cell proliferation and tumor growth as well as the induction of tumor regression. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK/Aurora Kinase Inhibitor BI 847325","termGroup":"PT","termSource":"NCI"},{"termName":"BI 847325","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK/Aurora Kinase Inhibitor BI 847325"},{"name":"NCI_Drug_Dictionary_ID","value":"698315"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698315"},{"name":"PDQ_Open_Trial_Search_ID","value":"698315"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827151"}]}}{"C29178":{"preferredName":"Melanoma Monoclonal Antibody hIgG2A","code":"C29178","definitions":[{"definition":"One of a number human monoclonal antibodies of the immunoglobulin subclass IgG2a directed against melanoma antigens with potential antineoplastic activity.  A melanoma monoclonal antibody, subclass IgG2A, may have potential use as a diagnostic agent and, therapeutically, may induce macrophage-mediated cytotoxicity against antibody-bound melanoma cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma Monoclonal Antibody hIgG2A","termGroup":"PT","termSource":"NCI"},{"termName":"M A IG2A Human Melanoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Melanoma_Monoclonal_Antibody_hIgG2A"},{"name":"Maps_To","value":"Melanoma Monoclonal Antibody hIgG2A"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513096"}]}}{"C91380":{"preferredName":"Melanoma TRP2 CTL Epitope Vaccine SCIB1","code":"C91380","definitions":[{"definition":"A proprietary DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. Upon intramuscular injection and electroporation, melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melanoma TRP2 CTL Epitope Vaccine SCIB1","termGroup":"PT","termSource":"NCI"},{"termName":"SCIB1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Melanoma TRP2 CTL Epitope Vaccine SCIB1"},{"name":"NCI_Drug_Dictionary_ID","value":"675320"},{"name":"NCI_META_CUI","value":"CL421601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675320"},{"name":"PDQ_Open_Trial_Search_ID","value":"675320"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120183":{"preferredName":"Eltrapuldencel-T","code":"C120183","definitions":[{"definition":"A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, eltrapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eltrapuldencel-T","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous DCs Loaded with Irradiated Autologous Tumor Cells in GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Dendritic Cells Loaded with Irradiated Autologous Tumor Cells in Granulocyte-macrophage Colony-stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"DC-TC","termGroup":"AB","termSource":"NCI"},{"termName":"Melapuldencel-T","termGroup":"SY","termSource":"NCI"},{"termName":"NBS-20","termGroup":"CN","termSource":"NCI"},{"termName":"NBS20","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M2LBQ7RN2X"},{"name":"Maps_To","value":"Melapuldencel-T"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896681"}]}}{"C111569":{"preferredName":"MELK Inhibitor OTS167","code":"C111569","definitions":[{"definition":"An orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity. Upon administration, OTS167 binds to MELK, which prevents both MELK phosphorylation and activation; thus inhibiting the phosphorylation of downstream MELK substrates. This may lead to an inhibition of both cell proliferation and survival in MELK-expressing tumor cells. MELK, a serine/threonine kinase, is involved in cancer cell survival, invasiveness and cancer-stem cell formation and maintenance; it is highly upregulated in various types of cancer cells and absent in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MELK Inhibitor OTS167","termGroup":"PT","termSource":"NCI"},{"termName":"OTS-167","termGroup":"CN","termSource":"NCI"},{"termName":"OTS167","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1431697-89-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VY778IXU5T"},{"name":"Maps_To","value":"MELK Inhibitor OTS167"},{"name":"NCI_Drug_Dictionary_ID","value":"751983"},{"name":"NCI_META_CUI","value":"CL453977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751983"},{"name":"PDQ_Open_Trial_Search_ID","value":"751983"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C633":{"preferredName":"Melphalan","code":"C633","definitions":[{"definition":"A drug that is used to treat multiple myeloma and ovarian epithelial cancer and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melphalan","termGroup":"PT","termSource":"NCI"},{"termName":"4-[bis(2-chloroethyl)amino]-L-phenylalanine","termGroup":"SN","termSource":"NCI"},{"termName":"CB-3025","termGroup":"CN","termSource":"NCI"},{"termName":"L-PAM","termGroup":"AB","termSource":"NCI"},{"termName":"L-Phenylalanine Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"L-sarcolysin","termGroup":"SY","termSource":"NCI"},{"termName":"L-Sarcolysin Phenylalanine mustard","termGroup":"SY","termSource":"NCI"},{"termName":"L-Sarcolysine","termGroup":"SY","termSource":"NCI"},{"termName":"Melphalanum","termGroup":"FB","termSource":"NCI"},{"termName":"p-di(chloroethyl)amino-L-phenylalanine","termGroup":"SN","termSource":"NCI"},{"termName":"Phenylalanine Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"Phenylalanine Nitrogen Mustard","termGroup":"SY","termSource":"NCI"},{"termName":"Sarcoclorin","termGroup":"SY","termSource":"NCI"},{"termName":"Sarkolysin","termGroup":"FB","termSource":"NCI"},{"termName":"WR-19813","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; neuroblastoma; palliative treatment of multiple myeloma and nonresectable epithelial ovarian carcinoma; rhabdomyosarcoma"},{"name":"CAS_Registry","value":"148-82-3"},{"name":"CHEBI_ID","value":"CHEBI:28876"},{"name":"Chemical_Formula","value":"C13H18Cl2N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"Q41OR9510P"},{"name":"Legacy Concept Name","value":"Melphalan"},{"name":"Maps_To","value":"Melphalan"},{"name":"NCI_Drug_Dictionary_ID","value":"779085"},{"name":"NSC Number","value":"241286"},{"name":"NSC Number","value":"8806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779085"},{"name":"PDQ_Open_Trial_Search_ID","value":"779085"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025241"}]}}{"C107680":{"preferredName":"Melphalan Flufenamide","code":"C107680","definitions":[{"definition":"A peptide-drug conjugate composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to the alkylating agent melphalan, with potential antineoplastic and anti-angiogenic activities. Upon administration, the highly lipophilic melphalan flufenamide penetrates cell membranes and enters cells. In aminopeptidase-positive tumor cells, melphalan flufenamide is hydrolyzed by peptidases to release the hydrophilic alkylating agent melphalan. This results in the specific release and accumulation of melphalan in aminopeptidase-positive tumor cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells. The administration of melphalan flufenamide allows for enhanced efficacy and reduced toxicity compared to melphalan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melphalan Flufenamide","termGroup":"PT","termSource":"NCI"},{"termName":"Ethyl (2S)-2-((2S)-2-Amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate","termGroup":"SY","termSource":"NCI"},{"termName":"J-1","termGroup":"CN","termSource":"NCI"},{"termName":"J1","termGroup":"CN","termSource":"NCI"},{"termName":"L-melphalanyl-p-L-fluorophenylalanine Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Melflufen","termGroup":"SY","termSource":"NCI"},{"termName":"Prodrug J1","termGroup":"SY","termSource":"NCI"},{"termName":"Ygalo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"380449-51-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F70C5K4786"},{"name":"Maps_To","value":"Melphalan Flufenamide"},{"name":"NCI_Drug_Dictionary_ID","value":"751473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751473"},{"name":"PDQ_Open_Trial_Search_ID","value":"751473"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1435750"}]}}{"C48002":{"preferredName":"Melphalan Hydrochloride","code":"C48002","definitions":[{"definition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","type":"DEFINITION","source":"NCI"},{"definition":"A drug that is used to treat multiple myeloma and ovarian epithelial cancer and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Melphalan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"3-(p-(bis(2-chloroethyl)amino)phenyl)-L-Alanine, Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Alkeran","termGroup":"BR","termSource":"NCI"},{"termName":"Alkerana","termGroup":"FB","termSource":"NCI"},{"termName":"Evomela","termGroup":"BR","termSource":"NCI"},{"termName":"Hepzato","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3223-07-2"},{"name":"Chemical_Formula","value":"C13H18Cl2N2O2.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1VXP4V453T"},{"name":"Legacy Concept Name","value":"Melphalan_Hydrochloride"},{"name":"Maps_To","value":"Melphalan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42973"},{"name":"NSC Number","value":"241286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42973"},{"name":"PDQ_Open_Trial_Search_ID","value":"42973"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771055"}]}}{"C84878":{"preferredName":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex","code":"C84878","definitions":[{"definition":"A propylene glycol-free intravenous formulation containing the hydrochloride salt of the nitrogen mustard phenylalanine derivative melphalan complexed with polyanionic sulfobutyl ether beta-cyclodextrin (SBE-CD) with potential antineoplastic activity. Upon administration, melphalan is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA; RNA and proteins may also be alkylated. Subsequently, RNA transcription and protein synthesis are inhibited, resulting in cell growth arrest. The addition of sulfobutyl ether beta-cyclodextrin to the formulation improves the solubility, stability and ease of use of melphalan; cyclodextrins are cyclic dextrins derived from starch.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex","termGroup":"PT","termSource":"NCI"},{"termName":"Captisol-enabled Melphalan IV","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"649061"},{"name":"NCI_META_CUI","value":"CL412380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649061"},{"name":"PDQ_Open_Trial_Search_ID","value":"649061"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84860":{"preferredName":"Onvitrelin Ucalontide","code":"C84860","definitions":[{"definition":"A water-soluble, positively charged fusion protein consisting of a luteinizing hormone releasing hormone (LHRH) receptor-targeting ligand conjugated to the membrane-disrupting peptide CLIP 71 with membrane-disrupting and potential antineoplastic activities. The LHRH ligand moiety of onvitrelin ucalontide specifically binds to LHRH receptors, which are upregulated on a variety of human cancer cell types. Subsequently, the positively charged CLIP 71 moiety of this agent interacts with the negatively charged membrane on the cancer cell surface, which may result in cell membrane disruption and cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onvitrelin Ucalontide","termGroup":"PT","termSource":"NCI"},{"termName":"EP-100","termGroup":"CN","termSource":"NCI"},{"termName":"Membrane-Disrupting Peptide EP-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620643-19-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UF1EL37E41"},{"name":"Maps_To","value":"Membrane-Disrupting Peptide EP-100"},{"name":"NCI_Drug_Dictionary_ID","value":"652192"},{"name":"NCI_META_CUI","value":"CL412421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"652192"},{"name":"PDQ_Open_Trial_Search_ID","value":"652192"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C52194":{"preferredName":"Menatetrenone","code":"C52194","definitions":[{"definition":"A menaquinone compound and form of vitamin K2 with potential antineoplastic activity. Menatetrenone may act by modulating the signalling of certain tyrosine kinases, thereby affecting several transcription factors including c-myc and c-fos. This agent inhibits tumor cell growth by inducing apoptosis and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Menatetrenone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-3-trans-tetraprenyl-1,4-naphthoquinone","termGroup":"SN","termSource":"NCI"},{"termName":"E0167","termGroup":"CN","termSource":"NCI"},{"termName":"Menaquinone K4","termGroup":"SY","termSource":"NCI"},{"termName":"Menaquinone-4","termGroup":"SN","termSource":"NCI"},{"termName":"Vitamin MK 4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"863-61-6"},{"name":"Chemical_Formula","value":"C31H40O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27Y876D139"},{"name":"Legacy Concept Name","value":"Menatetrenone"},{"name":"Maps_To","value":"Menatetrenone"},{"name":"NCI_Drug_Dictionary_ID","value":"459755"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459755"},{"name":"PDQ_Open_Trial_Search_ID","value":"459755"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065936"}]}}{"C1389":{"preferredName":"Menogaril","code":"C1389","definitions":[{"definition":"A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Menogaril","termGroup":"PT","termSource":"NCI"},{"termName":"7-(R)-O-methylnogarol","termGroup":"SN","termSource":"NCI"},{"termName":"7-con-O-methylnogarol","termGroup":"SN","termSource":"NCI"},{"termName":"7-con-O-methylnorgarol","termGroup":"SN","termSource":"NCI"},{"termName":"7-OMEN","termGroup":"AB","termSource":"NCI"},{"termName":"[2R-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha)]-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione","termGroup":"SN","termSource":"NCI"},{"termName":"MEN","termGroup":"AB","termSource":"NCI"},{"termName":"Menogarol","termGroup":"BR","termSource":"NCI"},{"termName":"TUT-7","termGroup":"AB","termSource":"NCI"},{"termName":"U-52047","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"71628-96-1"},{"name":"Chemical_Formula","value":"C28H31NO10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8JSV4O30HQ"},{"name":"Legacy Concept Name","value":"Menogaril"},{"name":"Maps_To","value":"Menogaril"},{"name":"NCI_Drug_Dictionary_ID","value":"40153"},{"name":"NSC Number","value":"269148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40153"},{"name":"PDQ_Open_Trial_Search_ID","value":"40153"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127527"}]}}{"C1390":{"preferredName":"Merbarone","code":"C1390","definitions":[{"definition":"A nonsedating derivative of thiobarbituric acid and a novel catalytic topoisomerase II inhibitor with antineoplastic activity. Merbarone interferes with DNA replication via binding directly to topoisomerase II at a domain that maybe shared by other topoisomerase II cleavage-enhancing agents, ex., etoposide. Its mechanism of action appears to be a novel one, since merbarone does not intercalate DNA nor stabilize DNA-topoisomerase II cleavable complexes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Merbarone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97534-21-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YWB9IF596V"},{"name":"Legacy Concept Name","value":"Merbarone"},{"name":"Maps_To","value":"Merbarone"},{"name":"NCI_Drug_Dictionary_ID","value":"40220"},{"name":"NSC Number","value":"336628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40220"},{"name":"PDQ_Open_Trial_Search_ID","value":"40220"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127565"}]}}{"C195":{"preferredName":"Mercaptopurine","code":"C195","definitions":[{"definition":"A drug used to treat acute lymphatic leukemia. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mercaptopurine","termGroup":"PT","termSource":"NCI"},{"termName":"1,7-Dihydro-6H-purine-6-thione","termGroup":"SN","termSource":"NCI"},{"termName":"1,7-Dihydro-6H-purine-6-thione Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"3H-Purine-6-thiol","termGroup":"SN","termSource":"NCI"},{"termName":"6 Thiohypoxanthine","termGroup":"SY","termSource":"NCI"},{"termName":"6 Thiopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6-Mercaptopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6-Mercaptopurine Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"6-MP","termGroup":"AB","termSource":"NCI"},{"termName":"6-Purinethiol","termGroup":"SY","termSource":"NCI"},{"termName":"6-Thiopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6-Thioxopurine","termGroup":"SY","termSource":"NCI"},{"termName":"6H-Purine-6-thione, 1,7-dihydro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"7-Mercapto-1,3,4,6-tetrazaindene","termGroup":"SN","termSource":"NCI"},{"termName":"Alti-Mercaptopurine","termGroup":"FB","termSource":"NCI"},{"termName":"Azathiopurine","termGroup":"SY","termSource":"NCI"},{"termName":"BW 57-323H","termGroup":"CN","termSource":"NCI"},{"termName":"Flocofil","termGroup":"FB","termSource":"NCI"},{"termName":"Ismipur","termGroup":"FB","termSource":"NCI"},{"termName":"Leukerin","termGroup":"FB","termSource":"NCI"},{"termName":"Leupurin","termGroup":"SY","termSource":"NCI"},{"termName":"Mercaleukim","termGroup":"FB","termSource":"NCI"},{"termName":"Mercaleukin","termGroup":"SY","termSource":"NCI"},{"termName":"Mercaptina","termGroup":"FB","termSource":"NCI"},{"termName":"Mercapto-6-purine","termGroup":"SN","termSource":"NCI"},{"termName":"Mercaptopurinum","termGroup":"BR","termSource":"NCI"},{"termName":"Mercapurin","termGroup":"SY","termSource":"NCI"},{"termName":"Mern","termGroup":"SY","termSource":"NCI"},{"termName":"Puri-Nethol","termGroup":"FB","termSource":"NCI"},{"termName":"Purimethol","termGroup":"SY","termSource":"NCI"},{"termName":"Purine-6-thiol (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Purine-6-thiol Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Purine-6-thiol, Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"Purinethiol","termGroup":"FB","termSource":"NCI"},{"termName":"Purinethol","termGroup":"BR","termSource":"NCI"},{"termName":"U-4748","termGroup":"CN","termSource":"NCI"},{"termName":"WR-2785","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphocytic leukemia; Acute myelogenous leukemia; Crohns disease; Hodgkins lymphoma in children; Lymphoblastic lymphoma; Ulcerative colitis"},{"name":"CAS_Registry","value":"6112-76-1"},{"name":"CHEBI_ID","value":"CHEBI:31822"},{"name":"Chemical_Formula","value":"C5H4N4S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"E7WED276I5"},{"name":"Legacy Concept Name","value":"Mercaptopurine"},{"name":"Maps_To","value":"Mercaptopurine"},{"name":"NCI_Drug_Dictionary_ID","value":"43436"},{"name":"NSC Number","value":"755"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43436"},{"name":"PDQ_Open_Trial_Search_ID","value":"43436"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0000618"}]}}{"C61832":{"preferredName":"Mercaptopurine Anhydrous","code":"C61832","definitions":[{"definition":"The anhydrous form of mercaptopurine, a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mercaptopurine Anhydrous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-44-2"},{"name":"CHEBI_ID","value":"CHEBI:2208"},{"name":"CHEBI_ID","value":"CHEBI:50667"},{"name":"Chemical_Formula","value":"C5H4N4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PKK6MUZ20G"},{"name":"Legacy Concept Name","value":"Mercaptopurine_Anhydrous"},{"name":"Maps_To","value":"Mercaptopurine Anhydrous"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881785"}]}}{"C111757":{"preferredName":"Mercaptopurine Oral Suspension","code":"C111757","definitions":[{"definition":"An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mercaptopurine Oral Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"6-MP Oral Suspension","termGroup":"SY","termSource":"NCI"},{"termName":"Purixan","termGroup":"BR","termSource":"NCI"},{"termName":"Xaluprine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute lymphoblastic leukemia (ALL)"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mercaptopurine Oral Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"752956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752956"},{"name":"PDQ_Open_Trial_Search_ID","value":"752956"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3820263"}]}}{"C95729":{"preferredName":"Merestinib","code":"C95729","definitions":[{"definition":"An orally available, small molecule inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Merestinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinecarboxamide, N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"LY-2801653","termGroup":"CN","termSource":"NCI"},{"termName":"LY2801653","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1206799-15-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5OGS5K699E"},{"name":"Maps_To","value":"Merestinib"},{"name":"NCI_Drug_Dictionary_ID","value":"694732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694732"},{"name":"PDQ_Open_Trial_Search_ID","value":"694732"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987379"}]}}{"C192":{"preferredName":"Mesna","code":"C192","definitions":[{"definition":"A drug that helps protect the kidneys and bladder from the toxic effects of anticancer drugs such as ifosfamide and cyclophosphamide.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesna","termGroup":"PT","termSource":"NCI"},{"termName":"2-Mercaptoethanesulfonic Acid Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Ausobronc","termGroup":"FB","termSource":"NCI"},{"termName":"D-7093","termGroup":"CN","termSource":"NCI"},{"termName":"Filesna","termGroup":"FB","termSource":"NCI"},{"termName":"Mercaptoethane Sulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Mercaptoethanesulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"Mesnex","termGroup":"BR","termSource":"NCI"},{"termName":"Mesnil","termGroup":"FB","termSource":"NCI"},{"termName":"Mesnum","termGroup":"SY","termSource":"NCI"},{"termName":"Mexan","termGroup":"FB","termSource":"NCI"},{"termName":"Mistabron","termGroup":"FB","termSource":"NCI"},{"termName":"Mistabronco","termGroup":"FB","termSource":"NCI"},{"termName":"Mitexan","termGroup":"FB","termSource":"NCI"},{"termName":"Mucofluid","termGroup":"FB","termSource":"NCI"},{"termName":"Mucolene","termGroup":"FB","termSource":"NCI"},{"termName":"Sodium 2-Mercaptoethane Sulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Sodium 2-Mercaptoethanesulphonate","termGroup":"SN","termSource":"NCI"},{"termName":"UCB 3983","termGroup":"CN","termSource":"NCI"},{"termName":"Uromitexan","termGroup":"FB","termSource":"NCI"},{"termName":"Ziken","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Ifosfamide-induced hemorrhagic cystitis, prophylaxis"},{"name":"CAS_Registry","value":"19767-45-4"},{"name":"Chemical_Formula","value":"C2H5O3S2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NR7O1405Q9"},{"name":"Legacy Concept Name","value":"Mesna"},{"name":"Maps_To","value":"Mesna"},{"name":"NCI_Drug_Dictionary_ID","value":"39759"},{"name":"NSC Number","value":"113891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39759"},{"name":"PDQ_Open_Trial_Search_ID","value":"39759"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0000294"}]}}{"C162935":{"preferredName":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536","code":"C162935","definitions":[{"definition":"recombinant antibody derivative composed of a tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) mesothelin (MSLN) and the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes which are both linked to either side of an anti-albumin single domain antibody, with potential immunostimulating and antineoplastic activities. Upon administration of the MSLN/CD3e TriTAC HPN536, the anti-MSLN single antibody domain targets and binds MSLN on tumor cells and the anti-CD3e single-chain variable fragment (scFv) targets and binds to CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing MSLN-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of MSLN-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN536. MSLN is overexpressed on the surface of certain tumor cell types. Overexpression of MSLN is often associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536","termGroup":"PT","termSource":"NCI"},{"termName":"HPN 536","termGroup":"CN","termSource":"NCI"},{"termName":"HPN-536","termGroup":"CN","termSource":"NCI"},{"termName":"HPN536","termGroup":"CN","termSource":"NCI"},{"termName":"Mesothelin-targeting T-cell Engager HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"Mesothelin/CD3e-specific TriTAC HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"MSLN-specific TriTAC HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"MSLN/CD3e TriTAC HPN536","termGroup":"SY","termSource":"NCI"},{"termName":"TriTAC HPN536","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536"},{"name":"NCI_Drug_Dictionary_ID","value":"799094"},{"name":"NCI_META_CUI","value":"CL973294"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799094"},{"name":"PDQ_Open_Trial_Search_ID","value":"799094"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148537":{"preferredName":"MET Kinase Inhibitor OMO-1","code":"C148537","definitions":[{"definition":"An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Kinase Inhibitor OMO-1","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-38877618","termGroup":"CN","termSource":"NCI"},{"termName":"OMO-1","termGroup":"CN","termSource":"NCI"},{"termName":"OMO1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_BMS-777607"},{"name":"Maps_To","value":"MET Kinase Inhibitor OMO-1"},{"name":"NCI_Drug_Dictionary_ID","value":"792712"},{"name":"NCI_META_CUI","value":"CL551128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792712"},{"name":"PDQ_Open_Trial_Search_ID","value":"792712"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74060":{"preferredName":"MET Tyrosine Kinase Inhibitor BMS-777607","code":"C74060","definitions":[{"definition":"An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor BMS-777607","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-777607","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1025720-94-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A3MMS6HDO1"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_BMS-777607"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor BMS-777607"},{"name":"NCI_Drug_Dictionary_ID","value":"587999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587999"},{"name":"PDQ_Open_Trial_Search_ID","value":"587999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346911"}]}}{"C91097":{"preferredName":"MET Tyrosine Kinase Inhibitor EMD 1204831","code":"C91097","definitions":[{"definition":"An inhibitor of the receptor tyrosine kinase Met (hepatocyte growth factor receptor) with potential antineoplastic activity. MET inhibitor EMD 1204831 selectively binds to Met tyrosine kinase, thereby disrupting MET mediated signal transduction pathways. This may induce cell death in tumor cells overexpressing this kinase. MET is overexpressed or mutated in many tumor cell types, and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor EMD 1204831","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 1204831","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor EMD 1204831"},{"name":"NCI_Drug_Dictionary_ID","value":"672542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672542"},{"name":"PDQ_Open_Trial_Search_ID","value":"672542"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984036"}]}}{"C78483":{"preferredName":"MET Tyrosine Kinase Inhibitor PF-04217903","code":"C78483","definitions":[{"definition":"An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. The receptor tyrosine kinase c-Met, also known as hepatocyte growth factor (HGF) receptor, is overexpressed or mutated in many tumor cell types, playing an important role in tumor cell proliferation, survival, invasion, and metastasis and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor PF-04217903","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol","termGroup":"SN","termSource":"NCI"},{"termName":"PF-04217903","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"956905-27-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CYJ9ATV1IJ"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_PF-04217903"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor PF-04217903"},{"name":"NCI_Drug_Dictionary_ID","value":"601032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"601032"},{"name":"PDQ_Open_Trial_Search_ID","value":"601032"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703125"}]}}{"C97511":{"preferredName":"MET Tyrosine Kinase Inhibitor SAR125844","code":"C97511","definitions":[{"definition":"An inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Upon intravenous administration, c-Met inhibitor SAR125844 binds to c-Met, thereby disrupting c-Met-mediated signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of cancers, plays an important role in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor SAR125844","termGroup":"PT","termSource":"NCI"},{"termName":"SAR125844","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1116743-46-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XH93U6NIJE"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor SAR125844"},{"name":"NCI_Drug_Dictionary_ID","value":"703771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703771"},{"name":"PDQ_Open_Trial_Search_ID","value":"703771"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273459"}]}}{"C74062":{"preferredName":"MET Tyrosine Kinase Inhibitor SGX523","code":"C74062","definitions":[{"definition":"An orally bioavailable small molecule, c-Met inhibitor with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MET Tyrosine Kinase Inhibitor SGX523","termGroup":"PT","termSource":"NCI"},{"termName":"SGX523","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1022150-57-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WH8SQN09KJ"},{"name":"Legacy Concept Name","value":"MET_Tyrosine_Kinase_Inhibitor_SGX523"},{"name":"Maps_To","value":"MET Tyrosine Kinase Inhibitor SGX523"},{"name":"NCI_Drug_Dictionary_ID","value":"588972"},{"name":"PDQ_Closed_Trial_Search_ID","value":"588972"},{"name":"PDQ_Open_Trial_Search_ID","value":"588972"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346913"}]}}{"C83946":{"preferredName":"Metamelfalan","code":"C83946","definitions":[{"definition":"The meta form of the levo isomer melphalan, an alkylating nitrogen mustard with potential antineoplastic activity. Metamelfalan causes crosslinking of DNA, thereby preventing DNA replication and eventually cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metamelfalan","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1088-80-8"},{"name":"Chemical_Formula","value":"C13H18Cl2N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3B30XBE7S2"},{"name":"Maps_To","value":"Metamelfalan"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127767"}]}}{"C162480":{"preferredName":"MetAP2 Inhibitor APL-1202","code":"C162480","definitions":[{"definition":"An orally available inhibitor of methionine aminopeptidase II type (MetAP2) with potential antiangiogenic and antineoplastic activities. Upon administration, APL-1202 binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MetAP2 Inhibitor APL-1202","termGroup":"PT","termSource":"NCI"},{"termName":"APL 1202","termGroup":"CN","termSource":"NCI"},{"termName":"APL-1202","termGroup":"CN","termSource":"NCI"},{"termName":"APL1202","termGroup":"CN","termSource":"NCI"},{"termName":"Methionine Aminopeptidase Type II Inhibitor APL-1202","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MetAP2 Inhibitor APL-1202"},{"name":"NCI_Drug_Dictionary_ID","value":"798664"},{"name":"NCI_META_CUI","value":"CL970968"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798664"},{"name":"PDQ_Open_Trial_Search_ID","value":"798664"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128030":{"preferredName":"Evexomostat","code":"C128030","definitions":[{"definition":"A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent's efficacy as compared to non-polymer conjugates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evexomostat","termGroup":"PT","termSource":"NCI"},{"termName":"MetAP2 Inhibitor SDX-7320","termGroup":"SY","termSource":"NCI"},{"termName":"Methionine aminopeptidase type II Inhibitor SDX-7320","termGroup":"SY","termSource":"NCI"},{"termName":"SDX-7320","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416263-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z7116W3IFA"},{"name":"Maps_To","value":"MetAP2 Inhibitor SDX-7320"},{"name":"NCI_Drug_Dictionary_ID","value":"781275"},{"name":"NCI_META_CUI","value":"CL507924"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781275"},{"name":"PDQ_Open_Trial_Search_ID","value":"781275"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113294":{"preferredName":"Metatinib Tromethamine","code":"C113294","definitions":[{"definition":"An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL tyrosine kinase inhibitor BL001 may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metatinib Tromethamine","termGroup":"PT","termSource":"NCI"},{"termName":"BCR-ABL Tyrosine Kinase Inhibitor BL001","termGroup":"SY","termSource":"NCI"},{"termName":"BL001","termGroup":"CN","termSource":"NCI"},{"termName":"Metatinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metatinib Tromethamine"},{"name":"NCI_Drug_Dictionary_ID","value":"755994"},{"name":"NCI_META_CUI","value":"CL458141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755994"},{"name":"PDQ_Open_Trial_Search_ID","value":"755994"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61612":{"preferredName":"Metformin","code":"C61612","definitions":[{"definition":"A specific agent belonging to the biguanide class of antihyperglycemic agents","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Metformin is a type of antidiabetic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Metformin","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dimethylbiguanide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N-dimethylbiguanide","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-Dimethylimidodicarbonimidic Diamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"657-24-9"},{"name":"CHEBI_ID","value":"CHEBI:6801"},{"name":"Chemical_Formula","value":"C4H11N5"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9100L32L2N"},{"name":"Legacy Concept Name","value":"Metformin"},{"name":"Maps_To","value":"Metformin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025598"}]}}{"C29251":{"preferredName":"Metformin Hydrochloride","code":"C29251","definitions":[{"definition":"A drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Glucophage is a type of antidiabetic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metformin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dimethylbiguanide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"APO-Metformin","termGroup":"SY","termSource":"NCI"},{"termName":"Cidophage","termGroup":"SY","termSource":"NCI"},{"termName":"Dimefor","termGroup":"FB","termSource":"NCI"},{"termName":"Glifage","termGroup":"FB","termSource":"NCI"},{"termName":"Glucoformin","termGroup":"FB","termSource":"NCI"},{"termName":"Glucophage","termGroup":"BR","termSource":"NCI"},{"termName":"Glucophage ER","termGroup":"BR","termSource":"NCI"},{"termName":"Metformin HCl","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-Dimethylimidodicarbonimidic Diamide Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Riomet","termGroup":"BR","termSource":"NCI"},{"termName":"Siofor","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1115-70-4"},{"name":"Chemical_Formula","value":"C4H11N5.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"786Z46389E"},{"name":"Legacy Concept Name","value":"Metformin_Hydrochloride"},{"name":"Maps_To","value":"Metformin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"593641"},{"name":"NSC Number","value":"91485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593641"},{"name":"PDQ_Open_Trial_Search_ID","value":"593641"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770893"}]}}{"C1159":{"preferredName":"Methanol Extraction Residue of BCG","code":"C1159","definitions":[{"definition":"A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methanol Extraction Residue of BCG","termGroup":"PT","termSource":"NCI"},{"termName":"MER-BCG","termGroup":"AB","termSource":"NCI"},{"termName":"Methanol Extraction Residue of Bacillus Calmette-Guerin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methanol_Extraction_Residue_of_BCG"},{"name":"Maps_To","value":"Methanol Extraction Residue of BCG"},{"name":"NCI_Drug_Dictionary_ID","value":"39495"},{"name":"NSC Number","value":"143769"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39495"},{"name":"PDQ_Open_Trial_Search_ID","value":"39495"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0065973"}]}}{"C61318":{"preferredName":"Methazolamide","code":"C61318","definitions":[{"definition":"A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance resistance to cytotoxic therapy in some hypoxic tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methazolamide","termGroup":"PT","termSource":"NCI"},{"termName":"Glauctabs","termGroup":"BR","termSource":"NCI"},{"termName":"MZM","termGroup":"BR","termSource":"NCI"},{"termName":"N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"Neptazane","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"554-57-4"},{"name":"Chemical_Formula","value":"C5H8N4O3S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W733B0S9SD"},{"name":"Legacy Concept Name","value":"Methazolamide"},{"name":"Maps_To","value":"Methazolamide"},{"name":"NCI_Drug_Dictionary_ID","value":"484587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"484587"},{"name":"PDQ_Open_Trial_Search_ID","value":"484587"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025631"}]}}{"C142831":{"preferredName":"Methionine Aminopeptidase 2 Inhibitor M8891","code":"C142831","definitions":[{"definition":"A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methionine Aminopeptidase 2 Inhibitor M8891","termGroup":"PT","termSource":"NCI"},{"termName":"M8891","termGroup":"CN","termSource":"NCI"},{"termName":"MetAP2 Inhibitor M8891","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methionine Aminopeptidase 2 Inhibitor M8891"},{"name":"NCI_Drug_Dictionary_ID","value":"791701"},{"name":"NCI_META_CUI","value":"CL540704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791701"},{"name":"PDQ_Open_Trial_Search_ID","value":"791701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38129":{"preferredName":"Methionine Aminopeptidase 2 Inhibitor PPI-2458","code":"C38129","definitions":[{"definition":"A synthetic derivative of fumagillin with antineoplastic and cytotoxic properties.  PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methionine Aminopeptidase 2 Inhibitor PPI-2458","termGroup":"PT","termSource":"NCI"},{"termName":"MetAP-2 Inhibitor PPI-2458","termGroup":"SY","termSource":"NCI"},{"termName":"PPI-2458","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"431077-35-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NA0Y2SRR29"},{"name":"Legacy Concept Name","value":"PPI-2458"},{"name":"Maps_To","value":"Methionine Aminopeptidase 2 Inhibitor PPI-2458"},{"name":"NCI_Drug_Dictionary_ID","value":"415572"},{"name":"NSC Number","value":"720735"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415572"},{"name":"PDQ_Open_Trial_Search_ID","value":"415572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1505437"}]}}{"C1735":{"preferredName":"Methotrexate Sodium","code":"C1735","definitions":[{"definition":"The sodium salt of methotrexate, an antimetabolite with antineoplastic and immunomodulating properties.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Sodium Methotrexate","termGroup":"SY","termSource":"NCI"},{"termName":"Trexall","termGroup":"BR","termSource":"NCI"},{"termName":"Xatmep","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7413-34-5"},{"name":"CHEBI_ID","value":"CHEBI:50679"},{"name":"Chemical_Formula","value":"C20H20N8O5.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3IG1E710ZN"},{"name":"Legacy Concept Name","value":"Sodium_Methotrexate"},{"name":"Maps_To","value":"Methotrexate Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"41719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41719"},{"name":"PDQ_Open_Trial_Search_ID","value":"41719"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0949359"}]}}{"C17876":{"preferredName":"Methotrexate-E Therapeutic Implant","code":"C17876","definitions":[{"definition":"An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate-E Therapeutic Implant","termGroup":"PT","termSource":"NCI"},{"termName":"Methotrexate-E Therapeutic Implant","termGroup":"SY","termSource":"NCI"},{"termName":"Methotrexate-epinephrine therapeutic implant","termGroup":"SY","termSource":"NCI"},{"termName":"Methotrexate/epi","termGroup":"SY","termSource":"NCI"},{"termName":"MTX-e TI","termGroup":"SY","termSource":"NCI"},{"termName":"MTX/epi gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methotrexate-E_Therapeutic_Implant"},{"name":"Maps_To","value":"Methotrexate-E Therapeutic Implant"},{"name":"NCI_Drug_Dictionary_ID","value":"41858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41858"},{"name":"PDQ_Open_Trial_Search_ID","value":"41858"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281425"}]}}{"C125656":{"preferredName":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","code":"C125656","definitions":[{"definition":"A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","termGroup":"PT","termSource":"NCI"},{"termName":"MTX-ATMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"778520"},{"name":"NCI_META_CUI","value":"CL504342"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778520"},{"name":"PDQ_Open_Trial_Search_ID","value":"778520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C643":{"preferredName":"Methoxsalen","code":"C643","definitions":[{"definition":"A drug used together with UV light to treat psoriasis, vitiligo, and skin nodules of cutaneous T-cell lymphoma. It is also being studied in the treatment of graft-versus-host disease. It belongs to the family of drugs called psoralens and furocoumarins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxsalen","termGroup":"PT","termSource":"NCI"},{"termName":"8-Methoxypsoralen","termGroup":"SY","termSource":"NCI"},{"termName":"8-MOP","termGroup":"AB","termSource":"NCI"},{"termName":"9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one","termGroup":"SN","termSource":"NCI"},{"termName":"Ammoidin","termGroup":"BR","termSource":"NCI"},{"termName":"Deltasoralen","termGroup":"FB","termSource":"NCI"},{"termName":"Dermox","termGroup":"FB","termSource":"NCI"},{"termName":"Geralen","termGroup":"FB","termSource":"NCI"},{"termName":"Geroxalen","termGroup":"FB","termSource":"NCI"},{"termName":"Meladinina","termGroup":"FB","termSource":"NCI"},{"termName":"Meladinine","termGroup":"FB","termSource":"NCI"},{"termName":"Methoxypsoralen","termGroup":"SY","termSource":"NCI"},{"termName":"Metoxaleno","termGroup":"FB","termSource":"NCI"},{"termName":"Mopsoralen","termGroup":"FB","termSource":"NCI"},{"termName":"Oxsoralen","termGroup":"BR","termSource":"NCI"},{"termName":"Oxsoralen-Ultra","termGroup":"BR","termSource":"NCI"},{"termName":"Puvasoralen","termGroup":"FB","termSource":"NCI"},{"termName":"Ultramop","termGroup":"FB","termSource":"NCI"},{"termName":"Uvadex","termGroup":"BR","termSource":"NCI"},{"termName":"Xanthotoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cutaneous T-cell lymphoma; psoriasis; vitiligo"},{"name":"CAS_Registry","value":"298-81-7"},{"name":"CHEBI_ID","value":"CHEBI:18358"},{"name":"Chemical_Formula","value":"C12H8O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U4VJ29L7BQ"},{"name":"Legacy Concept Name","value":"Methoxsalen"},{"name":"Maps_To","value":"Methoxsalen"},{"name":"NCI_Drug_Dictionary_ID","value":"39499"},{"name":"NSC Number","value":"45923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39499"},{"name":"PDQ_Open_Trial_Search_ID","value":"39499"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025684"}]}}{"C78084":{"preferredName":"Methoxyamine","code":"C78084","definitions":[{"definition":"An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxyamine","termGroup":"PT","termSource":"NCI"},{"termName":"TRC102 Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67-62-9"},{"name":"Chemical_Formula","value":"CH5NO"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9TZH4WY30J"},{"name":"Legacy Concept Name","value":"Methoxyamine"},{"name":"Maps_To","value":"Methoxyamine"},{"name":"NCI_Drug_Dictionary_ID","value":"599836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599836"},{"name":"PDQ_Open_Trial_Search_ID","value":"599836"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066156"}]}}{"C78085":{"preferredName":"Methoxyamine Hydrochloride","code":"C78085","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks the ability of a cell to repair damage to its DNA and may kill cancer cells. It may also help some anticancer drugs work better. It is a type of antineoplastic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of methoxyamine, an alkoxyamine with potential chemotherapeutic adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic DNA damage sites and thereby inhibits base excision repair (BER) process, which may prevent repair of DNA strand breaks and result in an induction of apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methoxyamine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"TRC 102","termGroup":"CN","termSource":"NCI"},{"termName":"TRC-102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"593-56-6"},{"name":"Chemical_Formula","value":"CH5NO.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"203546OLMF"},{"name":"Legacy Concept Name","value":"Methoxyamine_Hydrochloride"},{"name":"Maps_To","value":"Methoxyamine Hydrochloride"},{"name":"NSC Number","value":"3801"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0951345"}]}}{"C2647":{"preferredName":"Methyl-5-Aminolevulinate Hydrochloride Cream","code":"C2647","definitions":[{"definition":"A drug used in photodynamic therapy; it is absorbed by tumor cells and, when exposed to light, becomes active and kills the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A topical cream formulation containing the hydrochloride salt of methyl-5-aminolevulinate, a lipophilic methyl ester of 5-aminolevulinic acid, with photosensitizer prodrug activity. Upon topical administration, methyl-5-aminolevulinate in the cream is selectively absorbed by tumor cells where it is converted to the photosensitizer protoporphyrin IX (PpIX). Upon photoirradiation, PpIX is activated and transfers energy to oxygen, generating singlet oxygen and superoxide and hydroxyl radicals, which may result in free-radical-mediated DNA damage and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methyl-5-Aminolevulinate Hydrochloride Cream","termGroup":"PT","termSource":"NCI"},{"termName":"Methyl Aminolevulinate Hydrochloride Cream","termGroup":"SY","termSource":"NCI"},{"termName":"Metvix","termGroup":"FB","termSource":"NCI"},{"termName":"Metvixia","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Methyl-5-Aminolevulinate"},{"name":"Maps_To","value":"Methyl-5-Aminolevulinate Hydrochloride Cream"},{"name":"NCI_Drug_Dictionary_ID","value":"38410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38410"},{"name":"PDQ_Open_Trial_Search_ID","value":"38410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713112"}]}}{"C2352":{"preferredName":"Methylmercaptopurine Riboside","code":"C2352","definitions":[{"definition":"A purine derivative with antineoplastic and anti-angiogenic properties.  6-methylmercaptopurine riboside (6-MMPR) inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylmercaptopurine Riboside","termGroup":"PT","termSource":"NCI"},{"termName":"6-(methylmercapto)purine ribonucleoside","termGroup":"SN","termSource":"NCI"},{"termName":"6-(methylthio) inosine","termGroup":"SN","termSource":"NCI"},{"termName":"6-(methylthio)purine ribonucleoside","termGroup":"SN","termSource":"NCI"},{"termName":"6-(methylthio)purine riboside","termGroup":"SN","termSource":"NCI"},{"termName":"6-methyl MP riboside","termGroup":"SN","termSource":"NCI"},{"termName":"6-methylmercaptopurine riboside","termGroup":"SN","termSource":"NCI"},{"termName":"6-methylthioinosine","termGroup":"SN","termSource":"NCI"},{"termName":"6-MMPR","termGroup":"AB","termSource":"NCI"},{"termName":"9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl- (8CI 9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl-, dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"9H-purine, 6-(methylthio)-9beta-D-ribofuranosyl","termGroup":"SN","termSource":"NCI"},{"termName":"beta-D-ribosyl-6-methylthiopurine","termGroup":"SN","termSource":"NCI"},{"termName":"methylthioinosine","termGroup":"SY","termSource":"NCI"},{"termName":"MMPR","termGroup":"AB","termSource":"NCI"},{"termName":"NCI-C04784","termGroup":"CN","termSource":"NCI"},{"termName":"purine-6-thiol,6-methyl-9-ribofuranosyl","termGroup":"SN","termSource":"NCI"},{"termName":"SQ 21977","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"342-69-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y5G39SHR0V"},{"name":"Legacy Concept Name","value":"Methylmercaptopurine_Riboside"},{"name":"Maps_To","value":"Methylmercaptopurine Riboside"},{"name":"NCI_Drug_Dictionary_ID","value":"39497"},{"name":"NSC Number","value":"40774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39497"},{"name":"PDQ_Open_Trial_Search_ID","value":"39497"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025828"}]}}{"C647":{"preferredName":"Methylprednisolone","code":"C647","definitions":[{"definition":"A corticosteroid hormone replacement.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylprednisolone","termGroup":"PT","termSource":"NCI"},{"termName":"(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"6Alpha-Methylprednisolone","termGroup":"SN","termSource":"NCI"},{"termName":"Adlone","termGroup":"FB","termSource":"NCI"},{"termName":"Caberdelta M","termGroup":"FB","termSource":"NCI"},{"termName":"DepMedalone","termGroup":"FB","termSource":"NCI"},{"termName":"Depo Moderin","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Nisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Duralone","termGroup":"FB","termSource":"NCI"},{"termName":"Emmetipi","termGroup":"FB","termSource":"NCI"},{"termName":"Esametone","termGroup":"FB","termSource":"NCI"},{"termName":"Firmacort","termGroup":"FB","termSource":"NCI"},{"termName":"Medlone 21","termGroup":"BR","termSource":"NCI"},{"termName":"Medrol","termGroup":"BR","termSource":"NCI"},{"termName":"Medrol Veriderm","termGroup":"FB","termSource":"NCI"},{"termName":"Medrone","termGroup":"FB","termSource":"NCI"},{"termName":"Mega-Star","termGroup":"FB","termSource":"NCI"},{"termName":"Meprolone","termGroup":"BR","termSource":"NCI"},{"termName":"Methylprednisolonum","termGroup":"SY","termSource":"NCI"},{"termName":"Metilbetasone Solubile","termGroup":"FB","termSource":"NCI"},{"termName":"Metrocort","termGroup":"BR","termSource":"NCI"},{"termName":"Metypresol","termGroup":"FB","termSource":"NCI"},{"termName":"Metysolon","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-M-Tablinen","termGroup":"FB","termSource":"NCI"},{"termName":"Prednilen","termGroup":"FB","termSource":"NCI"},{"termName":"Radilem","termGroup":"FB","termSource":"NCI"},{"termName":"Sieropresol","termGroup":"FB","termSource":"NCI"},{"termName":"Solpredone","termGroup":"FB","termSource":"NCI"},{"termName":"Summicort","termGroup":"BR","termSource":"NCI"},{"termName":"Urbason","termGroup":"FB","termSource":"NCI"},{"termName":"Veriderm Medrol","termGroup":"FB","termSource":"NCI"},{"termName":"Wyacort","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adrenocortical insufficiency; Conditions requiring immunosuppression; Inflammatory conditions; Multiple Sclerosis; Nephrotic syndrome"},{"name":"CAS_Registry","value":"83-43-2"},{"name":"CHEBI_ID","value":"CHEBI:6888"},{"name":"Chemical_Formula","value":"C22H30O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"X4W7ZR7023"},{"name":"Legacy Concept Name","value":"Methylprednisolone"},{"name":"Maps_To","value":"Methylprednisolone"},{"name":"NCI_Drug_Dictionary_ID","value":"41528"},{"name":"NSC Number","value":"19987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41528"},{"name":"PDQ_Open_Trial_Search_ID","value":"41528"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025815"}]}}{"C48003":{"preferredName":"Methylprednisolone Acetate","code":"C48003","definitions":[{"definition":"The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylprednisolone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"D-Med","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Medrate","termGroup":"FB","termSource":"NCI"},{"termName":"Depo-Medrol","termGroup":"BR","termSource":"NCI"},{"termName":"Depo-Medrone","termGroup":"FB","termSource":"NCI"},{"termName":"ReadySharp MethylPrednisolone 80","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53-36-1"},{"name":"CHEBI_ID","value":"CHEBI:6889"},{"name":"Chemical_Formula","value":"C24H32O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43502P7F0P"},{"name":"Legacy Concept Name","value":"Methylprednisolone_Acetate"},{"name":"Maps_To","value":"Methylprednisolone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"41528"},{"name":"NSC Number","value":"48985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41528"},{"name":"PDQ_Open_Trial_Search_ID","value":"41528"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0600901"}]}}{"C48004":{"preferredName":"Methylprednisolone Sodium Succinate","code":"C48004","definitions":[{"definition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylprednisolone Sodium Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"A-MethaPred","termGroup":"FB","termSource":"NCI"},{"termName":"Asmacortone","termGroup":"FB","termSource":"NCI"},{"termName":"Cryosolona","termGroup":"FB","termSource":"NCI"},{"termName":"Medrate","termGroup":"FB","termSource":"NCI"},{"termName":"Metypred","termGroup":"BR","termSource":"NCI"},{"termName":"Prednilem","termGroup":"FB","termSource":"NCI"},{"termName":"Solu Moderin","termGroup":"FB","termSource":"NCI"},{"termName":"Solu-Medrol","termGroup":"BR","termSource":"NCI"},{"termName":"Solu-Medrone","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2375-03-3"},{"name":"Chemical_Formula","value":"C26H33O8.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LEC9GKY20K"},{"name":"Legacy Concept Name","value":"Methylprednisolone_Sodium_Succinate"},{"name":"Maps_To","value":"Methylprednisolone Sodium Succinate"},{"name":"NSC Number","value":"48989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700546"}]}}{"C63678":{"preferredName":"Methylselenocysteine","code":"C63678","definitions":[{"definition":"A naturally occurring organoselenium compound found in many plants, including garlic, onions, and broccoli, with potential antioxidant and chemopreventive activities. Se-Methyl-seleno-L-cysteine (MSC) is an amino acid analogue of cysteine in which a methylselenium moiety replaces the sulphur atom of cysteine. This agent acts as an antioxidant when incorporated into glutathione peroxidase and has been shown to exhibit potent chemopreventive activity in animal models.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that contains the element selenium (a nutrient that protects cells against damage) and is found in certain plants such as garlic and broccoli. Se-methyl-seleno-L-cysteine can act as an antioxidant and may help prevent or slow the growth of cancer cells. It is a type of amino acid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Methylselenocysteine","termGroup":"PT","termSource":"NCI"},{"termName":"3-(Methylseleno)-l-alanine","termGroup":"SN","termSource":"NCI"},{"termName":"L-Se-Methylselenocysteine","termGroup":"SY","termSource":"NCI"},{"termName":"Methylselenocycteine","termGroup":"SY","termSource":"NCI"},{"termName":"MSC","termGroup":"AB","termSource":"NCI"},{"termName":"Se-Methyl-seleno-L-cysteine","termGroup":"SY","termSource":"NCI"},{"termName":"Se-Methylselenocysteine","termGroup":"SN","termSource":"NCI"},{"termName":"Selenium-methylselenocystine","termGroup":"SY","termSource":"NCI"},{"termName":"SeMSC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26046-90-2"},{"name":"CHEBI_ID","value":"CHEBI:27812"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TWK220499Z"},{"name":"Legacy Concept Name","value":"Methylselenocysteine"},{"name":"Maps_To","value":"Methylselenocysteine"},{"name":"NCI_Drug_Dictionary_ID","value":"554706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"554706"},{"name":"PDQ_Open_Trial_Search_ID","value":"554706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074299"}]}}{"C648":{"preferredName":"Methyltestosterone","code":"C648","definitions":[{"definition":"A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methyltestosterone","termGroup":"PT","termSource":"NCI"},{"termName":"(17Beta)-17-hydroxy-17-methylandrost-4-en-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"17 Alpha-methyl-delta4-androsten-17beta-ol-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"17-Methyltestosterone","termGroup":"SY","termSource":"NCI"},{"termName":"Android","termGroup":"BR","termSource":"NCI"},{"termName":"Eldec","termGroup":"FB","termSource":"NCI"},{"termName":"Ero Test","termGroup":"FB","termSource":"NCI"},{"termName":"Estratest","termGroup":"BR","termSource":"NCI"},{"termName":"Glosso-Sterandryl","termGroup":"BR","termSource":"NCI"},{"termName":"Malogen","termGroup":"SY","termSource":"NCI"},{"termName":"Metandren","termGroup":"BR","termSource":"NCI"},{"termName":"Methitest","termGroup":"BR","termSource":"NCI"},{"termName":"Methyltestosteronum","termGroup":"SY","termSource":"NCI"},{"termName":"Neohombreol M","termGroup":"BR","termSource":"NCI"},{"termName":"Orchisterone-M","termGroup":"BR","termSource":"NCI"},{"termName":"Oreton Methyl","termGroup":"BR","termSource":"NCI"},{"termName":"Testomet","termGroup":"FB","termSource":"NCI"},{"termName":"Testotonic B","termGroup":"FB","termSource":"NCI"},{"termName":"Testovis","termGroup":"FB","termSource":"NCI"},{"termName":"Testred","termGroup":"BR","termSource":"NCI"},{"termName":"Virilon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58-18-4"},{"name":"CHEBI_ID","value":"CHEBI:27436"},{"name":"Chemical_Formula","value":"C20H30O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9EFU16ZIF"},{"name":"Legacy Concept Name","value":"Methyltestosterone"},{"name":"Maps_To","value":"Methyltestosterone"},{"name":"NSC Number","value":"9701"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0025826"}]}}{"C1161":{"preferredName":"Metoprine","code":"C1161","definitions":[{"definition":"A diaminopyrimidine folate antagonist with potential antineoplastic activity.  Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metoprine","termGroup":"PT","termSource":"NCI"},{"termName":"BW 197U","termGroup":"CN","termSource":"NCI"},{"termName":"DDMP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7761-45-7"},{"name":"Chemical_Formula","value":"C11H10Cl2N4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2L9RKX796Q"},{"name":"Legacy Concept Name","value":"Metoprine"},{"name":"Maps_To","value":"Metoprine"},{"name":"NCI_Drug_Dictionary_ID","value":"39206"},{"name":"NSC Number","value":"19494"},{"name":"NSC Number","value":"7364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39206"},{"name":"PDQ_Open_Trial_Search_ID","value":"39206"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066142"}]}}{"C87686":{"preferredName":"Mibefradil","code":"C87686","synonyms":[{"termName":"Mibefradil","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,2S)-(2-((3-(2-Benzimidazolyl)Propyl)Methylamino)Ethyl)-6-Fluoro-1,2,3,4-Tetrahydro-1-Isopropyl-2-Naphthyl Methoxyacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1S-cis)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"116644-53-2"},{"name":"Chemical_Formula","value":"C29H38FN3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27B90X776A"},{"name":"Maps_To","value":"Mibefradil"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286185"}]}}{"C87687":{"preferredName":"Mibefradil Dihydrochloride","code":"C87687","synonyms":[{"termName":"Mibefradil Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,2S)-(2-((3-(2-Benzimidazolyl)Propyl)Methylamino)Ethyl)-6-Fluoro-1,2,3,4-Tetrahydro-1-Isopropyl-2-Naphthyl Methoxyacetate, Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Acetic Acid, Methoxy-, 2-(2-((3-(1H-Benzimidazol-2-yl)Propyl)Methylamino)Ethyl)-6-Fluoro-1,2,3,4-Tetrahydro-1-(1-Methylethyl)-2-Naphthalenyl Ester, Dihydrochloride, (1S-cis)-","termGroup":"SN","termSource":"NCI"},{"termName":"RO 40-5967/001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"116666-63-8"},{"name":"Chemical_Formula","value":"C29H38FN3O3.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"842TUP3PQ8"},{"name":"Maps_To","value":"Mibefradil Dihydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286186"}]}}{"C139003":{"preferredName":"Micellar Nanoparticle-encapsulated Epirubicin","code":"C139003","definitions":[{"definition":"A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micellar Nanoparticle-encapsulated Epirubicin","termGroup":"PT","termSource":"NCI"},{"termName":"Epirubicin-incorporating Micelle","termGroup":"SY","termSource":"NCI"},{"termName":"K-912","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoparticle Epirubicin","termGroup":"SY","termSource":"NCI"},{"termName":"NC-6300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RQU6X0IM9R"},{"name":"Maps_To","value":"Micellar Nanoparticle-encapsulated Epirubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"790960"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790960"},{"name":"PDQ_Open_Trial_Search_ID","value":"790960"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2974723"}]}}{"C156665":{"preferredName":"Micro Needle Array-Doxorubicin","code":"C156665","definitions":[{"definition":"A formulation composed of dissolvable small, adhesive-like patches composed of a biocompatible material which is coated with the anthracycline antibiotic doxorubicin, with potential antineoplastic and immunomodulating activities. Upon cutaneous administration of the microneedle-array-doxorubicin, the microneedles degrade once inserted into the skin and doxorubicin is released from the dissolvable microneedle array delivery device directly into the tumor microenvironment (TME). Doxorubicin is taken up by tumor cells and intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. In addition, doxorubicin induces innate, adaptive, and tumor-specific effector and memory immune responses, thereby further killing the tumor cells. Delivery of doxorubicin using the microneedle array delivery system allows direct and specific administration of doxorubicin to the TME which may improve drug concentration into tumor cells and may reduce systemic toxicity, compared to the administration of systemic doxorubicin alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micro Needle Array-Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"D-MNA","termGroup":"AB","termSource":"NCI"},{"termName":"Dissolvable Microneedles-containing Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin-coated Patches","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin-loaded Patches","termGroup":"SY","termSource":"NCI"},{"termName":"Micro-needle Array Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Microneedle Applicator-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Microneedle Array Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"MNA-D","termGroup":"AB","termSource":"NCI"},{"termName":"MNA-D Patches","termGroup":"SY","termSource":"NCI"},{"termName":"MNA-Doxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Micro Needle Array-Doxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"795832"},{"name":"NCI_META_CUI","value":"CL935685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795832"},{"name":"PDQ_Open_Trial_Search_ID","value":"795832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64631":{"preferredName":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300","code":"C64631","definitions":[{"definition":"A formulation of a plasmid DNA encoding an inactivated form of the carcinogen activator cytochrome P450 1B1 (CYP1B1) encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles with potential antineoplastic activity. CYP1B1, an extrahepatic monooxygenase of the cytochrome P450 family, is overexpressed in many cancers with only restricted expression in normal tissues. Vaccination with ZYC300 may stimulate the immune system to elicit a cytotoxic T lymphocyte (CTL) response against the tumor associated antigen CYP1B1, thereby causing lysis of tumor cells expressing CYP1B1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300","termGroup":"PT","termSource":"NCI"},{"termName":"ZYC300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"ZYC300"},{"name":"Maps_To","value":"Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300"},{"name":"NCI_Drug_Dictionary_ID","value":"513166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513166"},{"name":"PDQ_Open_Trial_Search_ID","value":"513166"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831967"}]}}{"C143158":{"preferredName":"Microtubule Inhibitor SCB01A","code":"C143158","definitions":[{"definition":"An aroylindole derivative and tubulin polymerization inhibitor, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activities. Upon administration, tubulin polymerization inhibitor SCB01A binds at the colchicine binding site of tubulin and prevents its polymerization in tumor blood vessel endothelial cells and in tumor cells. This blocks the formation of the mitotic spindle and leads to both cell cycle arrest at the G2/M phase and tumor cell apoptosis. Also, this agent's effect on the tumor blood vessel endothelial cells leads to a disruption of the tumor vasculature and tumor blood flow, which deprives tumor cells of nutrients and induces tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microtubule Inhibitor SCB01A","termGroup":"PT","termSource":"NCI"},{"termName":"6-Methoxy-3-(3',4',5'-trimethoxybenzoyl) Indole","termGroup":"SN","termSource":"NCI"},{"termName":"BPR 0L075","termGroup":"CN","termSource":"NCI"},{"termName":"DBPR104","termGroup":"CN","termSource":"NCI"},{"termName":"SB 01","termGroup":"CN","termSource":"NCI"},{"termName":"SCB 01A","termGroup":"CN","termSource":"NCI"},{"termName":"SCB-01A","termGroup":"CN","termSource":"NCI"},{"termName":"SCB01A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microtubule Inhibitor SCB01A"},{"name":"NCI_Drug_Dictionary_ID","value":"791849"},{"name":"NCI_META_CUI","value":"CL541607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791849"},{"name":"PDQ_Open_Trial_Search_ID","value":"791849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1872":{"preferredName":"Midostaurin","code":"C1872","definitions":[{"definition":"A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called protein kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Midostaurin","termGroup":"PT","termSource":"NCI"},{"termName":"CGP41251","termGroup":"CN","termSource":"NCI"},{"termName":"N-Benzoyl-Staurosporine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Benzoylstaurosporine","termGroup":"SY","termSource":"NCI"},{"termName":"PKC 412","termGroup":"CN","termSource":"NCI"},{"termName":"PKC-412","termGroup":"CN","termSource":"NCI"},{"termName":"PKC412","termGroup":"CN","termSource":"NCI"},{"termName":"Rydapt","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+)"},{"name":"CAS_Registry","value":"120685-11-2"},{"name":"CHEBI_ID","value":"CHEBI:63452"},{"name":"Chemical_Formula","value":"C35H30N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"ID912S5VON"},{"name":"Legacy Concept Name","value":"Midostaurin"},{"name":"Maps_To","value":"Midostaurin"},{"name":"NCI_Drug_Dictionary_ID","value":"462346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462346"},{"name":"PDQ_Open_Trial_Search_ID","value":"462346"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0526371"}]}}{"C1394":{"preferredName":"Mifamurtide","code":"C1394","definitions":[{"definition":"A drug being studied in the treatment of young adults with bone cancer that has gotten worse or come back. L-MTP-PE activates certain types of white blood cells and helps the immune system kill cancer cells. It is a type of immunostimulant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its half-life and enhances tissue targeting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mifamurtide","termGroup":"PT","termSource":"NCI"},{"termName":"CGP 19835A Lipid","termGroup":"CN","termSource":"NCI"},{"termName":"Junovan","termGroup":"BR","termSource":"NCI"},{"termName":"L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-((7R)-4-hydroxy-4-oxido-10-oxo-7-((1-oxohexadecyl)oxy)-3,5,9-trioxa-4-phosphapentacos-1-yl)-, Monosodium Salt, Hydrate","termGroup":"SN","termSource":"NCI"},{"termName":"L-MTP-PE","termGroup":"AB","termSource":"NCI"},{"termName":"Mepact","termGroup":"FB","termSource":"NCI"},{"termName":"MTP-PE Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Muramyl Tripeptide Phosphatidylethanolamine Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"MuramylNAc-Ala-isoGln-Lys-tripeptide-PE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"838853-48-8"},{"name":"Chemical_Formula","value":"C59H108N6O19P.Na.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"1LM890Q4FY"},{"name":"Legacy Concept Name","value":"Muramyl_Tripeptide_Phosphatidylethanolamine"},{"name":"Maps_To","value":"Mifamurtide"},{"name":"NCI_Drug_Dictionary_ID","value":"41541"},{"name":"NSC Number","value":"628280"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41541"},{"name":"PDQ_Open_Trial_Search_ID","value":"41541"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0129341"}]}}{"C655":{"preferredName":"Mifepristone","code":"C655","definitions":[{"definition":"A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to end early pregnancies. It is also being studied in the treatment of some types of cancer and other conditions. Mifepristone blocks the action of progesterone, a hormone that helps some cancers grow. It is a type of antiprogesterone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mifepristone","termGroup":"PT","termSource":"NCI"},{"termName":"(aa Beta, 17 beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"11 Beta-[4-(N,N-dimethylamino)phenyl]-17alpha-(propyl-1-ynyl)-delta-4,9-estradiene-17 beta-ol-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"11-((4-dimethylamino) phenyl)-17-Hydroxy-17-(1-propynyl) Estra-4,9- dien-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"Korlym","termGroup":"BR","termSource":"NCI"},{"termName":"Mifegyne","termGroup":"FB","termSource":"NCI"},{"termName":"Mifeprex","termGroup":"BR","termSource":"NCI"},{"termName":"RU 486","termGroup":"CN","termSource":"NCI"},{"termName":"RU-38486","termGroup":"CN","termSource":"NCI"},{"termName":"RU-486","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84371-65-3"},{"name":"CHEBI_ID","value":"CHEBI:50692"},{"name":"Chemical_Formula","value":"C29H35NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"320T6RNW1F"},{"name":"Legacy Concept Name","value":"Mifepristone"},{"name":"Maps_To","value":"Mifepristone"},{"name":"NCI_Drug_Dictionary_ID","value":"40888"},{"name":"NSC Number","value":"652104"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40888"},{"name":"PDQ_Open_Trial_Search_ID","value":"40888"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026088"}]}}{"C107384":{"preferredName":"Milademetan Tosylate","code":"C107384","definitions":[{"definition":"The tosylate form of milademetan, an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milademetan Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"DS-3032 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"DS-3032b","termGroup":"CN","termSource":"NCI"},{"termName":"DS-3032b Tosylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1398569-75-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6M27443B0N"},{"name":"Maps_To","value":"Milademetan Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"750863"},{"name":"NCI_META_CUI","value":"CL449595"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750863"},{"name":"PDQ_Open_Trial_Search_ID","value":"750863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66983":{"preferredName":"Milatuzumab","code":"C66983","definitions":[{"definition":"A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Milatuzumab specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. hLL1 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Milatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"hLL1","termGroup":"AB","termSource":"NCI"},{"termName":"Humanized Anti-CD74 Monoclonal Antibody hLL1","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-115","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody hLL1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"899796-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2OP4E0GC6V"},{"name":"Legacy Concept Name","value":"Milatuzumab"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_hLL1"},{"name":"Maps_To","value":"Milatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"534127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"534127"},{"name":"PDQ_Open_Trial_Search_ID","value":"534127"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2716103"}]}}{"C91086":{"preferredName":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110","code":"C91086","definitions":[{"definition":"A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. IMMU-110 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An immunoconjugate consisting of milatuzumab, a humanized monoclonal antibody against CD74, conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The milatuzumab moiety of this ADC selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage. As a result, this agent may inhibit the proliferation of cancer cells that overexpress CD74. CD74, an integral membrane protein and tumor associated antigen (TAA), is overexpressed in certain cancer cells and promotes survival in rapidly proliferating tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110","termGroup":"PT","termSource":"NCI"},{"termName":"hLL1-DOX","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110"},{"name":"NCI_Drug_Dictionary_ID","value":"671813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671813"},{"name":"PDQ_Open_Trial_Search_ID","value":"671813"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1615035"}]}}{"C88312":{"preferredName":"Milciclib Maleate","code":"C88312","definitions":[{"definition":"The maleate salt form of milciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milciclib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrazolo(4,3-H)quinazoline-3-carboxamide, 4,5-dihydro-N,1,4,4-tetramethyl-8-((4-(4-methyl-1-piperazinyl)phenyl)amino)-, (2Z)-2-Butenedioate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"N,1,4,4-Tetramethyl-8-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"PHA-848125 AC","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1253645-38-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82W826FL6S"},{"name":"Maps_To","value":"Milciclib Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"660138"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660138"},{"name":"PDQ_Open_Trial_Search_ID","value":"660138"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934615"}]}}{"C29261":{"preferredName":"Milk Thistle","code":"C29261","definitions":[{"definition":"A plant that has been used in some cultures to treat certain medical problems, including stomach, liver, and gallbladder disorders. The active extract of milk thistle seeds is called silymarin. It is being studied in the prevention of liver damage caused by some cancer treatments.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milk Thistle","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65666-07-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U946SH95EE"},{"name":"Legacy Concept Name","value":"Milk_Thistle"},{"name":"Maps_To","value":"Milk Thistle"},{"name":"NCI_Drug_Dictionary_ID","value":"459958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459958"},{"name":"PDQ_Open_Trial_Search_ID","value":"459958"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0937640"}]}}{"C1170":{"preferredName":"Miltefosine","code":"C1170","definitions":[{"definition":"An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity.  Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Miltefosine","termGroup":"PT","termSource":"NCI"},{"termName":"2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt","termGroup":"SY","termSource":"NCI"},{"termName":"D-18506","termGroup":"CN","termSource":"NCI"},{"termName":"Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Hexadecylphosphocholine","termGroup":"SY","termSource":"NCI"},{"termName":"Miltefosin","termGroup":"SY","termSource":"NCI"},{"termName":"Miltefosina","termGroup":"SY","termSource":"NCI"},{"termName":"Miltefosinum","termGroup":"SY","termSource":"NCI"},{"termName":"Miltex","termGroup":"FB","termSource":"NCI"},{"termName":"n-Hexadecylphosphorylcholine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Skin metastasis of breast cancer"},{"name":"CAS_Registry","value":"58066-85-6"},{"name":"Chemical_Formula","value":"C21H46NO4P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53EY29W7EC"},{"name":"Legacy Concept Name","value":"Miltefosine"},{"name":"Maps_To","value":"Miltefosine"},{"name":"NCI_Drug_Dictionary_ID","value":"41212"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41212"},{"name":"PDQ_Open_Trial_Search_ID","value":"41212"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068006"}]}}{"C2567":{"preferredName":"Minretumomab","code":"C2567","definitions":[{"definition":"A second-generation murine monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Minretumomab","termGroup":"PT","termSource":"NCI"},{"termName":"Antibody CC49, Monoclonal","termGroup":"SY","termSource":"NCI"},{"termName":"CC-49 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MAb CC49","termGroup":"AB","termSource":"NCI"},{"termName":"MOAB CC-49/TAG72 (DW)","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb CC49","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody CC-49","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"195189-17-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"235435CH6L"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"Minretumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"41760"},{"name":"NSC Number","value":"620537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41760"},{"name":"PDQ_Open_Trial_Search_ID","value":"41760"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281345"}]}}{"C90554":{"preferredName":"Mipsagargin","code":"C90554","definitions":[{"definition":"A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, mipsagargin targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. Mipsagargin is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, G-202 may be able to inhibit tumor growth. Compared to thapsigargin alone, thapsigargin prodrug G-202 is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mipsagargin","termGroup":"PT","termSource":"NCI"},{"termName":"G-202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1245732-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q032I35QMX"},{"name":"Maps_To","value":"Mipsagargin"},{"name":"NCI_Drug_Dictionary_ID","value":"666090"},{"name":"NCI_META_CUI","value":"CL416238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666090"},{"name":"PDQ_Open_Trial_Search_ID","value":"666090"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90633":{"preferredName":"Mirabegron","code":"C90633","definitions":[{"definition":"An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirabegron","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-Aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] Acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Thiazoleacetamide, 2-Amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Betanis","termGroup":"FB","termSource":"NCI"},{"termName":"Myrbetriq","termGroup":"BR","termSource":"NCI"},{"termName":"YM-178","termGroup":"CN","termSource":"NCI"},{"termName":"YM178","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Overactive bladder with symptoms of urge incontinence"},{"name":"CAS_Registry","value":"223673-61-8"},{"name":"Chemical_Formula","value":"C21H24N4O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MVR3JL3B2V"},{"name":"Maps_To","value":"Mirabegron"},{"name":"NCI_Drug_Dictionary_ID","value":"767328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767328"},{"name":"PDQ_Open_Trial_Search_ID","value":"767328"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983812"}]}}{"C102566":{"preferredName":"Mirvetuximab Soravtansine","code":"C102566","definitions":[{"definition":"An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mirvetuximab Soravtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Elahere","termGroup":"BR","termSource":"NCI"},{"termName":"IMGN 853","termGroup":"CN","termSource":"NCI"},{"termName":"IMGN-853","termGroup":"CN","termSource":"NCI"},{"termName":"IMGN853","termGroup":"CN","termSource":"NCI"},{"termName":"M9346A-sulfo-SPDB-DM4","termGroup":"SY","termSource":"NCI"},{"termName":"Mirvetuximab Soravtansine-gynx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer."},{"name":"CAS_Registry","value":"1453084-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"98DE7VN88D"},{"name":"Maps_To","value":"Mirvetuximab Soravtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"734941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734941"},{"name":"PDQ_Open_Trial_Search_ID","value":"734941"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640818"}]}}{"C657":{"preferredName":"Misonidazole","code":"C657","definitions":[{"definition":"A nitroimidazole with radiosensitizing and antineoplastic properties. Exhibiting high electron affinity, misonidazole induces the formation of free radicals and depletes radioprotective thiols, thereby sensitizing hypoxic cells to the cytotoxic effects of ionizing radiation. This single-strand breaks in DNA induced by this agent result in the inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Misonidazole","termGroup":"PT","termSource":"NCI"},{"termName":"1-(alpha-methoxymethyl ethanol)-2-Nitroimidazole","termGroup":"SN","termSource":"NCI"},{"termName":"Ro-07-0582","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-7-0582","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13551-87-6"},{"name":"Chemical_Formula","value":"C7H11N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8FE7LTN8XE"},{"name":"Legacy Concept Name","value":"Misonidazole"},{"name":"Maps_To","value":"Misonidazole"},{"name":"NCI_Drug_Dictionary_ID","value":"39504"},{"name":"NSC Number","value":"261037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39504"},{"name":"PDQ_Open_Trial_Search_ID","value":"39504"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026218"}]}}{"C29195":{"preferredName":"Mitindomide","code":"C29195","definitions":[{"definition":"A bisdioxopiperazines analog with antineoplastic activity.  Mitinomide inhibits topoisomerase II and slowly promotes DNA-interstrand cross-linking, thereby inhibiting DNA repair, RNA and protein synthesis.  This agent acts without increasing topoisomerase II-DNA covalent cleavable complex formation, as do most topoisomerase inhibitors. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitindomide","termGroup":"PT","termSource":"NCI"},{"termName":"4, 8-Ethenopyrrolo[3',4':3,4]cyclobut[1,2-f]isoindole-1,3,5,7(2H, 6H)tetrone, octahydro-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10403-51-7"},{"name":"Chemical_Formula","value":"C14H12N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DK61ZER6T7"},{"name":"Legacy Concept Name","value":"MITINDOMIDE"},{"name":"Maps_To","value":"Mitindomide"},{"name":"NSC Number","value":"284356"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066593"}]}}{"C659":{"preferredName":"Mitobronitol","code":"C659","definitions":[{"definition":"A brominated analog of mannitol with potential antineoplastic activity. Mitobronitol most likely acts through alkylation via derived epoxide groups.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitobronitol","termGroup":"PT","termSource":"NCI"},{"termName":"1,6-Dibromo-1,6-dideoxy-D-mannitol","termGroup":"SN","termSource":"NCI"},{"termName":"DBM","termGroup":"AB","termSource":"NCI"},{"termName":"Dibromomannitol","termGroup":"SY","termSource":"NCI"},{"termName":"Myelobromol","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"488-41-5"},{"name":"Chemical_Formula","value":"C6H12Br2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5UP30YED7N"},{"name":"Legacy Concept Name","value":"Mitobronitol"},{"name":"Maps_To","value":"Mitobronitol"},{"name":"NSC Number","value":"94100"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026236"}]}}{"C111758":{"preferredName":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101","code":"C111758","definitions":[{"definition":"An orally bioavailable inhibitor of mitochondrial oxidative phosphorylation with potential antineoplastic activity. Upon administration, ATR-101 inhibits the activity of F1F0-ATP synthase, elevates the mitochondrial membrane potential and depletes ATP in adrenocortical cells. The mitochondrial dysfunction caused by the release of reactive oxygen and triggered cytochrome c release leads to caspase-mediated cell death. ATR-101 may be useful in treating certain types of adrenocortical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101"},{"name":"NCI_Drug_Dictionary_ID","value":"753012"},{"name":"NCI_META_CUI","value":"CL454145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753012"},{"name":"PDQ_Open_Trial_Search_ID","value":"753012"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66164":{"preferredName":"Mitoclomine","code":"C66164","definitions":[{"definition":"An aromatic nitrogen mustard derivative with potential antineoplastic activity. Mitoclomine alkylates DNA and appears to concentrate primarily in the spleen and thymus where it causes lymphocyte depletion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoclomine","termGroup":"PT","termSource":"NCI"},{"termName":"N,N-bis(2-chloroethyl)4-amino-2-methyl-1-methoxy-naphthalene","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17692-54-5"},{"name":"Chemical_Formula","value":"C16H19Cl2NO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"02DQX562CR"},{"name":"Legacy Concept Name","value":"Mitoclomine"},{"name":"Maps_To","value":"Mitoclomine"},{"name":"NSC Number","value":"114575"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066605"}]}}{"C1101":{"preferredName":"Mitoflaxone","code":"C1101","definitions":[{"definition":"A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation.  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoflaxone","termGroup":"PT","termSource":"NCI"},{"termName":"2-Phenyl-8-(carboxymethyl)-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"4H-1-benzopyran-8-acetic Acid, 4-Oxo-2-phenyl","termGroup":"SN","termSource":"NCI"},{"termName":"FAA","termGroup":"AB","termSource":"NCI"},{"termName":"Flavone Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Flavone-8-Acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"LM 975","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"87626-55-9"},{"name":"Chemical_Formula","value":"C17H12O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X230G6E63B"},{"name":"Legacy Concept Name","value":"Flavone_Acetic_Acid"},{"name":"Maps_To","value":"Mitoflaxone"},{"name":"NCI_Drug_Dictionary_ID","value":"40152"},{"name":"NSC Number","value":"347512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40152"},{"name":"PDQ_Open_Trial_Search_ID","value":"40152"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060441"}]}}{"C661":{"preferredName":"Mitoguazone","code":"C661","definitions":[{"definition":"A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoguazone","termGroup":"PT","termSource":"NCI"},{"termName":"1,1'-((methylethanediylidene)dinitrilo)diguanidine","termGroup":"SN","termSource":"NCI"},{"termName":"2,2\"-(methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]","termGroup":"SN","termSource":"NCI"},{"termName":"DRG-0223","termGroup":"CN","termSource":"NCI"},{"termName":"Me-GAG","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl GAG","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl-G","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl-GAG","termGroup":"FB","termSource":"NCI"},{"termName":"Methylglyoxal bis(amidinohydrazone)","termGroup":"SN","termSource":"NCI"},{"termName":"methylglyoxal bis(guanylhydrazone)","termGroup":"SY","termSource":"NCI"},{"termName":"Methylglyoxal Bisguanylhydrazone","termGroup":"SY","termSource":"NCI"},{"termName":"MGBG","termGroup":"AB","termSource":"NCI"},{"termName":"pyruvaldehyde bis(amidinohydrazone)","termGroup":"SY","termSource":"NCI"},{"termName":"Zyrkamine","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"459-86-9"},{"name":"Chemical_Formula","value":"C5H12N8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OD5Q0L447W"},{"name":"Legacy Concept Name","value":"Mitoguazone"},{"name":"Maps_To","value":"Mitoguazone"},{"name":"NCI_Drug_Dictionary_ID","value":"39500"},{"name":"NSC Number","value":"32946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39500"},{"name":"PDQ_Open_Trial_Search_ID","value":"39500"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026251"}]}}{"C91409":{"preferredName":"Mitoguazone Dihydrochloride","code":"C91409","definitions":[{"definition":"A substance being studied in the treatment of some leukemias and lymphomas. It blocks the growth of cells and may cause cancer cells to die. It is a type of polyamine synthesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoguazone Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1,1'-((Methylethanediylidene)Dinitrilo)Diguanidine Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"2,2'-(1-Methyl-1,2-Ethanediylidene)Bis(Hydrazinecarboximidamide) Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Methylglyoxal Bis(amidinohydrazone) Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"MGBG 2HCl","termGroup":"AB","termSource":"NCI"},{"termName":"Pyruvaldehyde Bis(amidinohydrazone) Hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7059-23-6"},{"name":"Chemical_Formula","value":"C5H12N8.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NNI098FX5Q"},{"name":"Maps_To","value":"Mitoguazone Dihydrochloride"},{"name":"NSC Number","value":"32946"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771772"}]}}{"C662":{"preferredName":"Mitolactol","code":"C662","definitions":[{"definition":"A synthetic derivative of hexitol with antineoplastic and radiosensitizing properties.  Mitolactol alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA and RNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mitolactol","termGroup":"PT","termSource":"NCI"},{"termName":"6-Dibromodideoxydulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"6-Dibromodulcitol","termGroup":"SN","termSource":"NCI"},{"termName":"DBD","termGroup":"AB","termSource":"NCI"},{"termName":"Dibromdicil","termGroup":"SY","termSource":"NCI"},{"termName":"Dibromodulcitol","termGroup":"SY","termSource":"NCI"},{"termName":"Elobromol","termGroup":"FB","termSource":"NCI"},{"termName":"Mitolac","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10318-26-0"},{"name":"Chemical_Formula","value":"C6H12Br2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LJ2P1SIK8Y"},{"name":"Legacy Concept Name","value":"Mitolactol"},{"name":"Maps_To","value":"Mitolactol"},{"name":"NCI_Drug_Dictionary_ID","value":"39216"},{"name":"NSC Number","value":"104800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39216"},{"name":"PDQ_Open_Trial_Search_ID","value":"39216"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026252"}]}}{"C1820":{"preferredName":"Mitomycin","code":"C1820","definitions":[{"definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin","termGroup":"PT","termSource":"NCI"},{"termName":"(1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"[1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Ametycine","termGroup":"FB","termSource":"NCI"},{"termName":"Jelmyto","termGroup":"BR","termSource":"NCI"},{"termName":"MITO","termGroup":"AB","termSource":"NCI"},{"termName":"MITO-C","termGroup":"AB","termSource":"NCI"},{"termName":"Mito-Medac","termGroup":"FB","termSource":"NCI"},{"termName":"Mitocin","termGroup":"FB","termSource":"NCI"},{"termName":"Mitocin-C","termGroup":"FB","termSource":"NCI"},{"termName":"Mitolem","termGroup":"FB","termSource":"NCI"},{"termName":"Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycin-C","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycin-X","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycine C","termGroup":"SY","termSource":"NCI"},{"termName":"Mitosol","termGroup":"BR","termSource":"NCI"},{"termName":"Mitozytrex","termGroup":"BR","termSource":"NCI"},{"termName":"Mutamycin","termGroup":"BR","termSource":"NCI"},{"termName":"Mutamycine","termGroup":"FB","termSource":"NCI"},{"termName":"NCI-C04706","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastric Carcinoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Pancreatic Adenocarcinoma"},{"name":"CAS_Registry","value":"50-07-7"},{"name":"CHEBI_ID","value":"CHEBI:27504"},{"name":"Chemical_Formula","value":"C15H18N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"50SG953SK6"},{"name":"Legacy Concept Name","value":"Mitomycin_C"},{"name":"Maps_To","value":"Mitomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"42674"},{"name":"NSC Number","value":"26980"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42674"},{"name":"PDQ_Open_Trial_Search_ID","value":"42674"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002475"}]}}{"C1164":{"preferredName":"Mitomycin A","code":"C1164","definitions":[{"definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin A generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Mitomycin A is more toxic than mitomycin C due to increased and nonselective DNA cross-linking in both aerobic and hypoxic cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin A","termGroup":"PT","termSource":"NCI"},{"termName":"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4055-39-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"87TMG6FJHV"},{"name":"Legacy Concept Name","value":"Mitomycin_A"},{"name":"Maps_To","value":"Mitomycin A"},{"name":"NSC Number","value":"75986"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066608"}]}}{"C1392":{"preferredName":"Mitomycin B","code":"C1392","definitions":[{"definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin B generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin B","termGroup":"PT","termSource":"NCI"},{"termName":"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8a-hydroxy-8-(hydroxymethyl)-6-methoxy-1,5-dimethyl-, 8-carbamate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4055-40-7"},{"name":"Chemical_Formula","value":"C16H19N3O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VT1IGL3D7V"},{"name":"Legacy Concept Name","value":"Mitomycin_B"},{"name":"Maps_To","value":"Mitomycin B"},{"name":"NSC Number","value":"75987"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0128596"}]}}{"C1140":{"preferredName":"Mitomycin C Analog KW-2149","code":"C1140","definitions":[{"definition":"A semisynthetic water-soluble disulfide derivative of the antineoplastic antibiotic mitomycin C.  Activated by serum and glutathione, KW-2149 causes interstrand DNA cross-links and DNA-protein cross-links, resulting in single-strand DNA breaks and inhibition of DNA synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitomycin C Analog KW-2149","termGroup":"PT","termSource":"NCI"},{"termName":"7-N-(2-((2-(gamma-L-Glutamylamino)ethyl)dithio)ethyl)mitomycin C","termGroup":"SN","termSource":"NCI"},{"termName":"KT6149","termGroup":"CN","termSource":"NCI"},{"termName":"KW 2149","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118359-59-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AK8DKI0KMN"},{"name":"Legacy Concept Name","value":"KW-2149"},{"name":"Maps_To","value":"Mitomycin C Analog KW-2149"},{"name":"NCI_Drug_Dictionary_ID","value":"42572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42572"},{"name":"PDQ_Open_Trial_Search_ID","value":"42572"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064443"}]}}{"C151933":{"preferredName":"Hec1/Nek2 Inhibitor T-1101 Tosylate","code":"C151933","definitions":[{"definition":"The tosylate salt form of T-1101, an orally bioavailable inhibitor of highly expressed in cancer 1 (Hec1) and NIMA-related kinase 2 (Nek2), with potential antineoplastic activity. Upon oral administration, T-1101 specifically targets, binds to and inhibits the interaction of Hec1 with Nek2. This prevents Hec1/Nek2-mediated signal transduction pathways, inhibits mitosis, induces apoptosis and tumor cell proliferation. Hec1, overexpressed in some cancers, is located at the centromere during cell mitosis and plays an essential role in the pathway of spindle checkpoint. It is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hec1/Nek2 Inhibitor T-1101 Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"T 1101 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"T1101 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"TAI-95","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mitosis Inhibitor T 1101 Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"793127"},{"name":"NCI_META_CUI","value":"CL553272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793127"},{"name":"PDQ_Open_Trial_Search_ID","value":"793127"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C664":{"preferredName":"Mitotane","code":"C664","definitions":[{"definition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug used in treating adrenocortical cancer and ACTH-producing pituitary tumors (Cushing's disease).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mitotane","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane","termGroup":"SN","termSource":"NCI"},{"termName":"1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene","termGroup":"SN","termSource":"NCI"},{"termName":"2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane","termGroup":"SN","termSource":"NCI"},{"termName":"2,4'-Dichlorodiphenyldichloroethane","termGroup":"SN","termSource":"NCI"},{"termName":"2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane","termGroup":"SN","termSource":"NCI"},{"termName":"CB-313","termGroup":"CN","termSource":"NCI"},{"termName":"Chloditan","termGroup":"SY","termSource":"NCI"},{"termName":"Chlodithane","termGroup":"SY","termSource":"NCI"},{"termName":"DDD","termGroup":"AB","termSource":"NCI"},{"termName":"Khloditan","termGroup":"SY","termSource":"NCI"},{"termName":"Lisodren","termGroup":"FB","termSource":"NCI"},{"termName":"Lysodren","termGroup":"BR","termSource":"NCI"},{"termName":"Mytotan","termGroup":"SY","termSource":"NCI"},{"termName":"o,p' - DDD","termGroup":"AB","termSource":"NCI"},{"termName":"o,p'-DDD","termGroup":"SY","termSource":"NCI"},{"termName":"o,p'-DDD","termGroup":"AB","termSource":"NCI"},{"termName":"Ortho,para-DDD","termGroup":"SY","termSource":"NCI"},{"termName":"WR-13045","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adrenocortical carcinoma"},{"name":"CAS_Registry","value":"53-19-0"},{"name":"Chemical_Formula","value":"C14H10Cl4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"78E4J5IB5J"},{"name":"Legacy Concept Name","value":"Mitotane"},{"name":"Maps_To","value":"Mitotane"},{"name":"NCI_Drug_Dictionary_ID","value":"39506"},{"name":"NSC Number","value":"38721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39506"},{"name":"PDQ_Open_Trial_Search_ID","value":"39506"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026256"}]}}{"C66167":{"preferredName":"Mitotenamine","code":"C66167","definitions":[{"definition":"A nucleotoxic with potential antineoplastic activity. The mechanism of action through which mitotenamine exerts its effect has yet to be fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitotenamine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7696-00-6"},{"name":"Chemical_Formula","value":"C13H15BrClNS"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2879S26V4P"},{"name":"Legacy Concept Name","value":"Mitotenamine"},{"name":"Maps_To","value":"Mitotenamine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881869"}]}}{"C62050":{"preferredName":"Mitoxantrone","code":"C62050","definitions":[{"definition":"A drug used to treat advanced prostate cancer that does not respond to hormones, adult acute nonlymphocytic leukemia, and advanced or chronic multiple sclerosis. It is also being studied in the treatment of other cancers. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydroxyanthracenedione","termGroup":"SY","termSource":"NCI"},{"termName":"Mitozantrone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"65271-80-9"},{"name":"CHEBI_ID","value":"CHEBI:50729"},{"name":"Chemical_Formula","value":"C22H28N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"BZ114NVM5P"},{"name":"Legacy Concept Name","value":"Mitoxantrone_Base"},{"name":"Maps_To","value":"Mitoxantrone"},{"name":"NSC Number","value":"279836"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026259"}]}}{"C665":{"preferredName":"Mitoxantrone Hydrochloride","code":"C665","definitions":[{"definition":"A drug used to treat advanced prostate cancer that does not respond to hormones, adult acute nonlymphocytic leukemia, and advanced or chronic multiple sclerosis. It is also being studied in the treatment of other cancers. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CL 232315","termGroup":"CN","termSource":"NCI"},{"termName":"DHAD","termGroup":"AB","termSource":"NCI"},{"termName":"DHAQ","termGroup":"AB","termSource":"NCI"},{"termName":"Dihydroxyanthracenedione Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mitoxantrone Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mitoxantroni Hydrochloridum","termGroup":"SY","termSource":"NCI"},{"termName":"Mitozantrone Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mitroxone","termGroup":"FB","termSource":"NCI"},{"termName":"Neotalem","termGroup":"FB","termSource":"NCI"},{"termName":"Novantrone","termGroup":"AQS","termSource":"NCI"},{"termName":"Onkotrone","termGroup":"FB","termSource":"NCI"},{"termName":"Pralifan","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Leukemia; Breast cancer; Non Hodgkins Lymphoma; Multiple sclerosis; Prostate cancer"},{"name":"CAS_Registry","value":"70476-82-3"},{"name":"CHEBI_ID","value":"CHEBI:50727"},{"name":"Chemical_Formula","value":"C22H28N4O6.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U6USW86RD0"},{"name":"Legacy Concept Name","value":"Mitoxantrone"},{"name":"Maps_To","value":"Mitoxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39219"},{"name":"NSC Number","value":"301739"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39219"},{"name":"PDQ_Open_Trial_Search_ID","value":"39219"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700458"}]}}{"C1166":{"preferredName":"Mitozolomide","code":"C1166","definitions":[{"definition":"A prodrug of imidazotetrazine alkylating agent with antineoplastic property. Mitozolomide undergoes ring opening upon the nucleophilic attack at C-4 by an activated molecule of water within the major groove of DNA. The resulting bioactive mono-alkyltriazene species are capable of alkylating nucleophilic residues in the immediate vicinity such as N-7 and/or O-6 sites of guanine, thereby causes intra- or inter-stranded DNA cross-links and trigger apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mitozolomide","termGroup":"PT","termSource":"NCI"},{"termName":"Azolastone","termGroup":"BR","termSource":"NCI"},{"termName":"imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3-(2-chloroethyl)-3,4-dihydro-4-oxo","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85622-95-3"},{"name":"Chemical_Formula","value":"C7H7ClN6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E3U7286V3W"},{"name":"Legacy Concept Name","value":"Mitozolomide"},{"name":"Maps_To","value":"Mitozolomide"},{"name":"NCI_Drug_Dictionary_ID","value":"40221"},{"name":"NSC Number","value":"353451"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40221"},{"name":"PDQ_Open_Trial_Search_ID","value":"40221"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066618"}]}}{"C113162":{"preferredName":"Mivavotinib","code":"C113162","definitions":[{"definition":"An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivavotinib","termGroup":"PT","termSource":"NCI"},{"termName":"3H-Pyrrolo(3,4-C)pyridin-3-one, 6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Spleen Tyrosine Kinase Inhibitor TAK659","termGroup":"SY","termSource":"NCI"},{"termName":"syk Inhibitor TAK-659","termGroup":"SY","termSource":"NCI"},{"termName":"syk Inhibitor TAK659","termGroup":"SY","termSource":"NCI"},{"termName":"syk-Inhibitor TAK-659","termGroup":"SY","termSource":"NCI"},{"termName":"syk-Inhibitor TAK659","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-659 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"TAK659 Free Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312691-33-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8QR88H79VX"},{"name":"Maps_To","value":"Mivavotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"755930"},{"name":"NCI_META_CUI","value":"CL455236"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755930"},{"name":"PDQ_Open_Trial_Search_ID","value":"755930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121829":{"preferredName":"Mivebresib","code":"C121829","definitions":[{"definition":"An inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, mivebresib binds to the acetyl-lysine binding site of  BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivebresib","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV-075","termGroup":"CN","termSource":"NCI"},{"termName":"Ethanesulfonamide, N-(4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo(2,3-C)pyridin-4-yl)phenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1445993-26-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VR86R11J7J"},{"name":"Maps_To","value":"Mivebresib"},{"name":"NCI_Drug_Dictionary_ID","value":"773809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"773809"},{"name":"PDQ_Open_Trial_Search_ID","value":"773809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053689"}]}}{"C87698":{"preferredName":"Mivobulin","code":"C87698","definitions":[{"definition":"A synthetic, colchicine analogue with potential antineoplastic activity. Mivobulin targets and binds to colchicine-binding site on tubulin, thereby inhibiting microtubule polymerization, the assembly of the mitotic spindle and mitosis. This eventually results in cell cycle arrest, apoptosis and a reduction in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivobulin","termGroup":"PT","termSource":"NCI"},{"termName":"Carbamic Acid, (5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido(3,4-B)Pyrazin-7-Yl) Ethyl Ester, (S)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ethyl (S)-5-Amino-1,2-Dihydro-2-Methyl-3-Phenylpyrido(3,4-B)Pyrazine-7-Carbamate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"122332-18-7"},{"name":"Chemical_Formula","value":"C17H19N5O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96U5LG549X"},{"name":"Maps_To","value":"Mivobulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981335"}]}}{"C1357":{"preferredName":"Mivobulin Isethionate","code":"C1357","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The isethionate salt of mivobulin, a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mivobulin Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"CI 980","termGroup":"CN","termSource":"NCI"},{"termName":"CI-980","termGroup":"CN","termSource":"NCI"},{"termName":"CI980","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"126268-81-3"},{"name":"Chemical_Formula","value":"C17H19N5O2.C2H6O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8J08028R66"},{"name":"Legacy Concept Name","value":"Mivobulin_Isethionate"},{"name":"Maps_To","value":"Mivobulin Isethionate"},{"name":"NCI_Drug_Dictionary_ID","value":"41656"},{"name":"NSC Number","value":"635370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41656"},{"name":"PDQ_Open_Trial_Search_ID","value":"41656"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0109740"}]}}{"C74063":{"preferredName":"Mixed Bacteria Vaccine","code":"C74063","definitions":[{"definition":"A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mixed Bacteria Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Coley's Toxin","termGroup":"SY","termSource":"NCI"},{"termName":"MBV","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mixed_Bacteria_Vaccine"},{"name":"Maps_To","value":"Mixed Bacteria Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"590146"},{"name":"NCI_META_CUI","value":"CL383537"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590146"},{"name":"PDQ_Open_Trial_Search_ID","value":"590146"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49174":{"preferredName":"MK0731","code":"C49174","definitions":[{"definition":"A synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MK0731","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845256-65-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8HIJ5G3O02"},{"name":"Legacy Concept Name","value":"MK0731"},{"name":"Maps_To","value":"MK0731"},{"name":"NCI_Drug_Dictionary_ID","value":"446551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"446551"},{"name":"PDQ_Open_Trial_Search_ID","value":"446551"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708823"}]}}{"C2507":{"preferredName":"MKC-1","code":"C2507","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It may prevent cancer cells from dividing. It belongs to the family of drugs called cell cycle inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. In addition, this agent has been shown to inhibit the activities of the oncogenic kinase Akt, the mTOR pathway, and importin-beta, a protein essential to the transport of other proteins from the cytosol into the nucleus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MKC-1","termGroup":"PT","termSource":"NCI"},{"termName":"MKC-1","termGroup":"SY","termSource":"NCI"},{"termName":"R440","termGroup":"CN","termSource":"NCI"},{"termName":"Ro 31-7453","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125313-92-0"},{"name":"Chemical_Formula","value":"C22H16N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DNZ11VPY7Q"},{"name":"Legacy Concept Name","value":"Ro_31-7453"},{"name":"Maps_To","value":"MKC-1"},{"name":"NCI_Drug_Dictionary_ID","value":"486351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486351"},{"name":"PDQ_Open_Trial_Search_ID","value":"486351"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796487"}]}}{"C121956":{"preferredName":"MKNK1 Inhibitor BAY 1143269","code":"C121956","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1), with potential antineoplastic activity. Upon oral administration, MKNK1 inhibitor BAY 1143269 binds to MKNK1, thereby preventing its activation and the downstream MKNK1-mediated phosphorylation and activation of eukaryotic translation initiation factor 4E (eIF4E). As eIF4E enhances the synthesis of oncogenic proteins, preventing eIF4E activity inhibits the synthesis of tumor angiogenic factors and leads to both the inhibition of cellular proliferation and apoptosis in susceptible tumor cells. eIF4E, overexpressed in a variety of cancer cells, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MKNK1 Inhibitor BAY 1143269","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1143269","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MKNK1 Inhibitor BAY 1143269"},{"name":"NCI_Drug_Dictionary_ID","value":"772160"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772160"},{"name":"PDQ_Open_Trial_Search_ID","value":"772160"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053671"}]}}{"C2671":{"preferredName":"MMP Inhibitor S-3304","code":"C2671","definitions":[{"definition":"An orally-agent agent with potential antineoplastic activity.  S-3304 inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MMP Inhibitor S-3304","termGroup":"PT","termSource":"NCI"},{"termName":"S-3304","termGroup":"CN","termSource":"NCI"},{"termName":"S3304","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"203640-27-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK459F050X"},{"name":"Legacy Concept Name","value":"S-3304"},{"name":"Maps_To","value":"MMP Inhibitor S-3304"},{"name":"NCI_Drug_Dictionary_ID","value":"38596"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38596"},{"name":"PDQ_Open_Trial_Search_ID","value":"38596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134613"}]}}{"C153262":{"preferredName":"Tinodasertib","code":"C153262","definitions":[{"definition":"A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, tinodasertib may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinodasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AUM-001","termGroup":"CN","termSource":"NCI"},{"termName":"AUM001","termGroup":"CN","termSource":"NCI"},{"termName":"ETC 1907206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC 206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC-1907206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC-206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC1907206","termGroup":"CN","termSource":"NCI"},{"termName":"ETC206","termGroup":"CN","termSource":"NCI"},{"termName":"MNK1/2 Inhibitor ETC-1907206","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1464151-33-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MND3WX2R7I"},{"name":"Maps_To","value":"MNK1/2 Inhibitor ETC-1907206"},{"name":"NCI_Drug_Dictionary_ID","value":"794054"},{"name":"NCI_META_CUI","value":"CL554490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794054"},{"name":"PDQ_Open_Trial_Search_ID","value":"794054"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62521":{"preferredName":"Mocetinostat","code":"C62521","definitions":[{"definition":"A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Mocetinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-","termGroup":"SN","termSource":"NCI"},{"termName":"MG-0103","termGroup":"CN","termSource":"NCI"},{"termName":"MGCD 0103","termGroup":"CN","termSource":"NCI"},{"termName":"MGCD-0103","termGroup":"CN","termSource":"NCI"},{"termName":"MGCD0103","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"726169-73-9"},{"name":"Chemical_Formula","value":"C23H20N6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A6GWB8T96J"},{"name":"Legacy Concept Name","value":"MGCD0103"},{"name":"Maps_To","value":"Mocetinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"486941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486941"},{"name":"PDQ_Open_Trial_Search_ID","value":"486941"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002471"}]}}{"C131824":{"preferredName":"Modified Vitamin D Binding Protein Macrophage Activator EF-022","code":"C131824","definitions":[{"definition":"A modified version of vitamin D binding protein (VDBP; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Vitamin D Binding Protein Macrophage Activator EF-022","termGroup":"PT","termSource":"NCI"},{"termName":"EF-022","termGroup":"CN","termSource":"NCI"},{"termName":"Modified VDBP-Macrophage Activator EF-022","termGroup":"SY","termSource":"NCI"},{"termName":"MVDP-Macrophage Activator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Modified Vitamin D Binding Protein Macrophage Activator EF-022"},{"name":"NCI_Drug_Dictionary_ID","value":"786093"},{"name":"NCI_META_CUI","value":"CL514564"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786093"},{"name":"PDQ_Open_Trial_Search_ID","value":"786093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C152075":{"preferredName":"Modotuximab","code":"C152075","definitions":[{"definition":"A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is often overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modotuximab","termGroup":"PT","termSource":"NCI"},{"termName":"1024 DS","termGroup":"CN","termSource":"NCI"},{"termName":"1024-DS","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human epidermal growth factor receptor extracellular domain III) (human-mus musculus monoclonal 1024 DS heavy chain), Disulfide with human-mus musculus monoclonal 1024 DS light chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Zatuximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1310460-86-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1W7BD1M08N"},{"name":"Maps_To","value":"Modotuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"793840"},{"name":"NCI_META_CUI","value":"CL553284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793840"},{"name":"PDQ_Open_Trial_Search_ID","value":"793840"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148280":{"preferredName":"MOF Compound RiMO-301","code":"C148280","definitions":[{"definition":"A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MOF Compound RiMO-301","termGroup":"PT","termSource":"NCI"},{"termName":"RiMO-301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MOF Compound RiMO-301"},{"name":"NCI_Drug_Dictionary_ID","value":"795715"},{"name":"NCI_META_CUI","value":"CL550908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795715"},{"name":"PDQ_Open_Trial_Search_ID","value":"795715"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63667":{"preferredName":"Mofarotene","code":"C63667","definitions":[{"definition":"An arotinoic acid derivative with a morpholine structure in the polar end group with differentiation inducing and antineoplastic activity. Like other retinoic acid agents, mofarotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells. In addition, this agent is able to inhibit melanoma cell motility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mofarotene","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-4-[2-[4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]phenoxy]ethyl]morpholine","termGroup":"SN","termSource":"NCI"},{"termName":"Mofarontene","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 40-8757","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125533-88-2"},{"name":"Chemical_Formula","value":"C29H39NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8K3CVY8F8V"},{"name":"Legacy Concept Name","value":"Mofarotene"},{"name":"Maps_To","value":"Mofarotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0247161"}]}}{"C62510":{"preferredName":"Mogamulizumab","code":"C62510","definitions":[{"definition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mogamulizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"KM8761","termGroup":"CN","termSource":"NCI"},{"termName":"KW 0761","termGroup":"CN","termSource":"NCI"},{"termName":"KW-0761","termGroup":"CN","termSource":"NCI"},{"termName":"KW0761","termGroup":"CN","termSource":"NCI"},{"termName":"Mogamulizumab-kpkc","termGroup":"SY","termSource":"NCI"},{"termName":"Poteligeo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS)"},{"name":"CAS_Registry","value":"1159266-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YI437801BE"},{"name":"Legacy Concept Name","value":"KW-0761"},{"name":"Maps_To","value":"Mogamulizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"500479"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500479"},{"name":"PDQ_Open_Trial_Search_ID","value":"500479"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987603"}]}}{"C101538":{"preferredName":"Molibresib","code":"C101538","definitions":[{"definition":"A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Molibresib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK-525762A","termGroup":"CN","termSource":"NCI"},{"termName":"GSK525762","termGroup":"CN","termSource":"NCI"},{"termName":"I-BET 762","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260907-17-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5QIO6SRZ2R"},{"name":"Maps_To","value":"Molibresib"},{"name":"NCI_Drug_Dictionary_ID","value":"733799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733799"},{"name":"PDQ_Open_Trial_Search_ID","value":"733799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2975231"}]}}{"C159943":{"preferredName":"Molibresib Besylate","code":"C159943","definitions":[{"definition":"The besylate salt of molibresib, a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Molibresib Besylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-((4S)-6-(4-Chlorophenyl)-8-methoxy-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepin-4-yl)-N-ethylacetamide monobenzenesulfonate salt","termGroup":"SN","termSource":"NCI"},{"termName":"GSK525762C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1895049-20-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K04D7I4BCH"},{"name":"Maps_To","value":"Molibresib Besylate"},{"name":"NCI_Drug_Dictionary_ID","value":"801626"},{"name":"NCI_META_CUI","value":"CL969105"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801626"},{"name":"PDQ_Open_Trial_Search_ID","value":"801626"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88311":{"preferredName":"Momelotinib","code":"C88311","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity. Upon oral administration, momelotinib competes with JAK1/2 for ATP binding, which results in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and leads to the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. In addition, the inhibition of ALK2 prevents liver hepcidin formation, increases iron availability and increases red blood cell (RBC) production. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Momelotinib","termGroup":"PT","termSource":"NCI"},{"termName":"CYT 387","termGroup":"CN","termSource":"NCI"},{"termName":"CYT-387","termGroup":"CN","termSource":"NCI"},{"termName":"CYT387","termGroup":"CN","termSource":"NCI"},{"termName":"GS 0387","termGroup":"CN","termSource":"NCI"},{"termName":"GS-0387","termGroup":"CN","termSource":"NCI"},{"termName":"GS0387","termGroup":"CN","termSource":"NCI"},{"termName":"N-(Cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1056634-68-4"},{"name":"Chemical_Formula","value":"C23H22N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6O01GMS00P"},{"name":"Maps_To","value":"Momelotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"660135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2744845"}]}}{"C120208":{"preferredName":"Monalizumab","code":"C120208","definitions":[{"definition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"IPH-2201","termGroup":"CN","termSource":"NCI"},{"termName":"IPH2201","termGroup":"CN","termSource":"NCI"},{"termName":"NN-8765","termGroup":"CN","termSource":"NCI"},{"termName":"NN8765","termGroup":"CN","termSource":"NCI"},{"termName":"NN8765-3658","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228763-95-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3ZXZ2V0588"},{"name":"Maps_To","value":"Monalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"768226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768226"},{"name":"PDQ_Open_Trial_Search_ID","value":"768226"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896730"}]}}{"C105399":{"preferredName":"Monocarboxylate Transporter 1 Inhibitor AZD3965","code":"C105399","definitions":[{"definition":"An orally available inhibitor of monocarboxylate transporter 1 (MCT1), with potential antineoplastic activity. Upon oral administration, MCT1 inhibitor AZD3965 binds to MCT1 and prevents the transport of lactate into and out of the cell. This leads to an accumulation of lactate, intracellular acidification, and eventually cancer cell death. MCT1, a protein overexpressed on tumor cells, is responsible for the transport of monocarboxylates across the cell membrane and plays a key role in cell metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monocarboxylate Transporter 1 Inhibitor AZD3965","termGroup":"PT","termSource":"NCI"},{"termName":"AZD3965","termGroup":"CN","termSource":"NCI"},{"termName":"MCT1 Inhibitor AZD3965","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448671-31-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39OM5Y4K2F"},{"name":"Maps_To","value":"Monocarboxylate Transporter 1 Inhibitor AZD3965"},{"name":"NCI_Drug_Dictionary_ID","value":"746809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746809"},{"name":"PDQ_Open_Trial_Search_ID","value":"746809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642150"}]}}{"C2648":{"preferredName":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine","code":"C2648","definitions":[{"definition":"A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_105AD7_Anti-idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 105AD7 Anti-idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38413"},{"name":"PDQ_Open_Trial_Search_ID","value":"38413"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134469"}]}}{"C2446":{"preferredName":"Monoclonal Antibody 11D10","code":"C2446","definitions":[{"definition":"A murine monoclonal anti-idiotype antibody (anti-Id). Anti-Id 11D10 mimics a specific epitope of the high molecular weight human milk fat globule (HMFG) glycoprotein primarily expressed by human breast and some other tumor cells at high density. This specific HMFG epitope is identified by mAb BrE1, which was used as the immunizing antibody, or Ab1 to generate the anti-Id (Ab2) 11D10. Anti-ID 11D10 reacts specifically with breast tumor cells and with minimal reactivity with normal tissues. Vaccination with anti-Id 11D10 induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 11D10","termGroup":"PT","termSource":"NCI"},{"termName":"11D10","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 11D10","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_11D10"},{"name":"Maps_To","value":"Monoclonal Antibody 11D10"},{"name":"NCI_Drug_Dictionary_ID","value":"42822"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42822"},{"name":"PDQ_Open_Trial_Search_ID","value":"42822"},{"name":"PubMedID_Primary_Reference","value":"7533665"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677765"}]}}{"C2606":{"preferredName":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine","code":"C2606","definitions":[{"definition":"A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope.  Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"11D10 Anti-Idiotype Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TriAb","termGroup":"BR","termSource":"NCI"},{"termName":"TriAb anti-idiotype antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_11D10_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 11D10 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38135"},{"name":"PDQ_Open_Trial_Search_ID","value":"38135"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935720"}]}}{"C2368":{"preferredName":"Monoclonal Antibody 14G2A","code":"C2368","definitions":[{"definition":"A murine monoclonal antibody directed against the ganglioside GD2 with potential antineoplastic activity. Monoclonal antibody 14G2A binds to the ganglioside GD2 and induces antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 14G2A","termGroup":"PT","termSource":"NCI"},{"termName":"14G2A","termGroup":"SY","termSource":"NCI"},{"termName":"14G2A, monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody 14G2A, Monoclonal","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 14G2A","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TC4U60XS42"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_14G2A"},{"name":"Maps_To","value":"Monoclonal Antibody 14G2A"},{"name":"NCI_Drug_Dictionary_ID","value":"41244"},{"name":"NSC Number","value":"624345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41244"},{"name":"PDQ_Open_Trial_Search_ID","value":"41244"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280838"}]}}{"C29198":{"preferredName":"Monoclonal Antibody 1F5","code":"C29198","definitions":[{"definition":"A murine monoclonal antibody directed against CD20, a cross-membrane ion channel phosphoprotein expressed by B cells, with potential antineoplastic activity.  MOAB 1F5 binds to CD20, thereby directly inhibiting B-cell proliferation and differentiation. When cross-linked by secondary anti-mouse antibodies or Fc receptor-bearing cells, MOAB 1F5 may induce activation of B-cell protein tyrosine kinases, increases in B-cell intracellular calcium ion concentrations, and B-cell caspase activation, resulting in apoptosis of B cells expressing CD20. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 1F5","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody 1F5","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB 1F5","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_1F5"},{"name":"Maps_To","value":"Monoclonal Antibody 1F5"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513414"}]}}{"C2470":{"preferredName":"Monoclonal Antibody 3622W94","code":"C2470","definitions":[{"definition":"A humanized murine monoclonal antibody (MoAb) against the 17-1A antigen, with potential adjuvant therapeutic properties in colorectal cancer. 17-1A antigen (EpCAM), a human epithelial cell adhesion molecule, expresses in a variety of carcinoma tissues, such as those of colon and breast carcinomas. Immunization with MoAb 3622W94 may elicit immune responses, which could result in eradicating tumor cells expressing 17-1A antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 3622W94","termGroup":"PT","termSource":"NCI"},{"termName":"3622W94","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 3622W94","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_3622W94"},{"name":"Maps_To","value":"Monoclonal Antibody 3622W94"},{"name":"NCI_Drug_Dictionary_ID","value":"42985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42985"},{"name":"PDQ_Open_Trial_Search_ID","value":"42985"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677996"}]}}{"C2370":{"preferredName":"Monoclonal Antibody 3F8","code":"C2370","definitions":[{"definition":"A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody 3F8","termGroup":"PT","termSource":"NCI"},{"termName":"3F8","termGroup":"SY","termSource":"NCI"},{"termName":"3F8 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"anti-Ganglioside (GD2) Monoclonal Antibody 3F8","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 3F8","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3GFS72WN4M"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_3F8"},{"name":"Maps_To","value":"Monoclonal Antibody 3F8"},{"name":"NCI_Drug_Dictionary_ID","value":"41259"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41259"},{"name":"PDQ_Open_Trial_Search_ID","value":"41259"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280849"}]}}{"C2424":{"preferredName":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine","code":"C2424","definitions":[{"definition":"A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA).  This agent is used as a cancer vaccine against tumors that express CEA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"CEA-Vac","termGroup":"SY","termSource":"NCI"},{"termName":"CeaVac","termGroup":"BR","termSource":"NCI"},{"termName":"MoAb 3H1 anti-idiotype vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_3H1_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 3H1 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42652"},{"name":"NSC Number","value":"720063"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42652"},{"name":"PDQ_Open_Trial_Search_ID","value":"42652"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393051"}]}}{"C2227":{"preferredName":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine","code":"C2227","definitions":[{"definition":"A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities.  Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"4B5 monoclonal antibody anti-idiotype vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 4B5 anti-idiotype vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_4B5_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody 4B5 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"37797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37797"},{"name":"PDQ_Open_Trial_Search_ID","value":"37797"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879386"}]}}{"C2739":{"preferredName":"Monoclonal Antibody 7C11","code":"C2739","definitions":[{"definition":"A murine IgM monoclonal antibody against Fas antigen with antineoplastic property. Fas antigen is a member of tumor necrosis factor family that mediates antibody-triggered apoptosis. Upon binds to Fas, monoclonal antibody 7C11 (MoAb 7C11) induces apoptosis in Fas-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 7C11","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb 7C11","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb IMC-7C11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_7C11"},{"name":"Maps_To","value":"Monoclonal Antibody 7C11"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513423"}]}}{"C1958":{"preferredName":"Monoclonal Antibody 81C6","code":"C1958","definitions":[{"definition":"A murine IgG2 monoclonal antibody (MoAb) 81C6 raised against the extracellular matrix antigen tenascin (hexabrachion), up-regulated in gliomas and other cancers. Conjugated MoAb 81C6 may be used in diagnosis or treatment of cancers that over-express tenascin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody 81C6","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-tenascin Monoclonal Antibody 81C6","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-tenascin murine 81C6 mAb","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-tenascin murine 81C6 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"mu81C6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D18JQ86QNM"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_81C6"},{"name":"Maps_To","value":"Monoclonal Antibody 81C6"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1513424"}]}}{"C2436":{"preferredName":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine","code":"C2436","definitions":[{"definition":"An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"A1G4 anti-idiotype monoclonal antibody vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_A1G4_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody A1G4 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42698"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42698"},{"name":"PDQ_Open_Trial_Search_ID","value":"42698"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677670"}]}}{"C2447":{"preferredName":"Monoclonal Antibody A27.15","code":"C2447","definitions":[{"definition":"A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27.15 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody A27.15","termGroup":"PT","termSource":"NCI"},{"termName":"A27.15","termGroup":"SY","termSource":"NCI"},{"termName":"ANTI-TRANSFERRIN MOAB 27.15","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb A27.15","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_A27_15"},{"name":"Maps_To","value":"Monoclonal Antibody A27.15"},{"name":"NCI_Drug_Dictionary_ID","value":"42834"},{"name":"NSC Number","value":"644261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42834"},{"name":"PDQ_Open_Trial_Search_ID","value":"42834"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677772"}]}}{"C2410":{"preferredName":"Monoclonal Antibody A33","code":"C2410","definitions":[{"definition":"A humanized monoclonal antibody directed against the human A33 antigen. Monoclonal antibody A33 recognizes the human A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, which is highly and homogenously expressed in 95% of colorectal cancer metastases with only restricted expression in normal colonic mucosa.","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody A33","termGroup":"PT","termSource":"NCI"},{"termName":"A33","termGroup":"SY","termSource":"NCI"},{"termName":"A33 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb A33","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_A33"},{"name":"Maps_To","value":"Monoclonal Antibody A33"},{"name":"NCI_Drug_Dictionary_ID","value":"42527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42527"},{"name":"PDQ_Open_Trial_Search_ID","value":"42527"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0392959"}]}}{"C99162":{"preferredName":"Monoclonal Antibody AbGn-7","code":"C99162","definitions":[{"definition":"A chimeric monoclonal antibody against a Lewis-A-like glycotope (AbGn-7 antigen) with potential immunomodulating and antineoplastic activities. Monoclonal antibody AbGn-7 targets and binds to the carbohydrate AbGn-7 antigen on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), thereby killing AbGn-7-epitope positive tumor cells. AbGn-7 antigen is expressed on a variety of tumor cell types, including human colorectal, pancreatic and gastric tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody AbGn-7","termGroup":"PT","termSource":"NCI"},{"termName":"AbGn-7","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Monoclonal Antibody AbGn-7"},{"name":"NCI_Drug_Dictionary_ID","value":"717457"},{"name":"NCI_META_CUI","value":"CL433012"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717457"},{"name":"PDQ_Open_Trial_Search_ID","value":"717457"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129591":{"preferredName":"Lirentelimab","code":"C129591","definitions":[{"definition":"A humanized, nonfucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory receptor sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) expressed on human mast cells and eosinophils, with potential anti-inflammatory activity. Upon administration, lirentelimab targets and binds to Siglec-8 expressed on the surface of mast cells and eosinophils. This may inhibit mast cell activation and deplete eosinophils through antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. This may reduce abnormal proliferation of mast cells and eosinophils, which plays a key role in allergic and inflammatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirentelimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 002","termGroup":"CN","termSource":"NCI"},{"termName":"AK002","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody AK 002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2283348-97-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SWS48LJU3T"},{"name":"Maps_To","value":"Monoclonal Antibody AK002"},{"name":"NCI_Drug_Dictionary_ID","value":"783857"},{"name":"NCI_META_CUI","value":"CL512560"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783857"},{"name":"PDQ_Open_Trial_Search_ID","value":"783857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156402":{"preferredName":"Anti-NRP1 Antibody ASP1948","code":"C156402","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody directed against neuropilin-1 (NRP1; CD304; BDCA-4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-NRP1 antibody ASP1948 specifically targets and binds to NRP1. This prevents the binding of NRP1 to its ligand and may block the immune inhibitory actions of regulatory T-cells (Tregs) mediated by the interaction of NRP1 with its ligand. This may enhance the immune response against tumor cells. NRP1 is a transmembrane co-receptor protein expressed in Tregs; it plays an important role in maintaining the stability and function of Tregs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NRP1 Antibody ASP1948","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-neuropilin-1 Antibody ASP1948","termGroup":"SY","termSource":"NCI"},{"termName":"ASP 1948","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-1948","termGroup":"CN","termSource":"NCI"},{"termName":"ASP1948","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ 329","termGroup":"CN","termSource":"NCI"},{"termName":"PTZ-329","termGroup":"SY","termSource":"NCI"},{"termName":"PTZ329","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"857Y17E6U4"},{"name":"Maps_To","value":"Anti-NRP1 Antibody ASP1948"},{"name":"Maps_To","value":"Monoclonal Antibody ASP1948"},{"name":"NCI_Drug_Dictionary_ID","value":"795699"},{"name":"NCI_META_CUI","value":"CL563090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795699"},{"name":"PDQ_Open_Trial_Search_ID","value":"795699"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C2659":{"preferredName":"Monoclonal Antibody CAL","code":"C2659","definitions":[{"definition":"A humanized monoclonal antibody directed against parathyroid hormone-related protein (PTH-rP). As a poly-hormone with diverse biological roles, PTH-rP is expressed by normal tissues, acting in local tissue environments in a variety of ways; it is commonly overexpressed by breast, prostate, and other cancers, acting systemically by promoting bone resorption, inhibiting calcium excretion from the kidney, inducing hypercalcemia, and possibly playing a role in the formation of bony metastases. By blocking the effects of PTH-rP on calcium metabolism, monoclonal antibody CAL may inhibit cancer-related hypercalcemia. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody CAL","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CAL"},{"name":"Maps_To","value":"Monoclonal Antibody CAL"},{"name":"NCI_Drug_Dictionary_ID","value":"38505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38505"},{"name":"PDQ_Open_Trial_Search_ID","value":"38505"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1135160"}]}}{"C2698":{"preferredName":"Monoclonal Antibody CC49-delta CH2","code":"C2698","definitions":[{"definition":"A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody CC49-delta CH2","termGroup":"PT","termSource":"NCI"},{"termName":"CC-49 Delta CH2","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB CC49-deltaCH2","termGroup":"AB","termSource":"NCI"},{"termName":"MOAB HCC49DCH2","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb HuCC49DeltaCH2","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody HCC49DCH2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CC49-delta_CH2"},{"name":"Maps_To","value":"Monoclonal Antibody CC49-delta CH2"},{"name":"NCI_Drug_Dictionary_ID","value":"38456"},{"name":"NSC Number","value":"696081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38456"},{"name":"PDQ_Open_Trial_Search_ID","value":"38456"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134500"}]}}{"C98296":{"preferredName":"Monoclonal Antibody CEP-37250/KHK2804","code":"C98296","definitions":[{"definition":"A humanized monoclonal antibody targeting glycolipids, with potential immunomodulating and antineoplastic activity. Upon administration, monoclonal antibody CEP-37250/KHK2804 targets and binds to a specific tumor antigen, thereby stimulating the immune system to exert an antibody-dependent cellular cytotoxicity (ADCC) against the tumor associated antigen (TAA)-expressing cancer cells. This agent has shown to be active in both wild-type and mutant K-RAS-expressing colorectal cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody CEP-37250/KHK2804","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-37250/KHK2804","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Monoclonal Antibody CEP-37250/KHK2804"},{"name":"NCI_Drug_Dictionary_ID","value":"714212"},{"name":"NCI_META_CUI","value":"CL432414"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714212"},{"name":"PDQ_Open_Trial_Search_ID","value":"714212"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2683":{"preferredName":"Monoclonal Antibody D6.12","code":"C2683","definitions":[{"definition":"A murine IgG2a monoclonal antibody directed against a 48 kDa antigen expressed on the cell surface of normal and malignant gastrointestinal epithelium. MoAb D6.12 has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This MoAb, either alone or in combination with other immunotherapeutic agents, may have possible diagnostic or therapeutic applications in gastrointestinal cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody D6.12","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb D6.12","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb D612","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_D6_12"},{"name":"Maps_To","value":"Monoclonal Antibody D6.12"},{"name":"NCI_Drug_Dictionary_ID","value":"38656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38656"},{"name":"PDQ_Open_Trial_Search_ID","value":"38656"},{"name":"PubMedID_Primary_Reference","value":"8402627"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134661"}]}}{"C2448":{"preferredName":"Monoclonal Antibody E2.3","code":"C2448","definitions":[{"definition":"A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody E2.3 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody E2.3","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Transferrin MOAB E2.3","termGroup":"SY","termSource":"NCI"},{"termName":"E2.3","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb E2.3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_E2_3"},{"name":"Maps_To","value":"Monoclonal Antibody E2.3"},{"name":"NCI_Drug_Dictionary_ID","value":"42835"},{"name":"NSC Number","value":"644262"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42835"},{"name":"PDQ_Open_Trial_Search_ID","value":"42835"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0677773"}]}}{"C2514":{"preferredName":"Monoclonal Antibody F19","code":"C2514","definitions":[{"definition":"A murine monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby MoAb F19 has possible diagnostic and therapeutic applications in epithelial cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody F19","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-F19 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FAP (Fibroblast Activation Protein), F19 Epitope, Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"F19 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb F19","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_F19"},{"name":"Maps_To","value":"Monoclonal Antibody F19"},{"name":"NCI_Drug_Dictionary_ID","value":"43384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43384"},{"name":"PDQ_Open_Trial_Search_ID","value":"43384"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0796524"}]}}{"C26450":{"preferredName":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine","code":"C26450","definitions":[{"definition":"A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity.  Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).  GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_GD2_Anti-Idiotype_Vaccine"},{"name":"Maps_To","value":"Monoclonal Antibody GD2 Anti-Idiotype Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"257174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257174"},{"name":"PDQ_Open_Trial_Search_ID","value":"257174"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328690"}]}}{"C2505":{"preferredName":"Monoclonal Antibody HeFi-1","code":"C2505","definitions":[{"definition":"A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody HeFi-1","termGroup":"PT","termSource":"NCI"},{"termName":"HeFi-1","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb HeFi-1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HeFi-1"},{"name":"Maps_To","value":"Monoclonal Antibody HeFi-1"},{"name":"NCI_Drug_Dictionary_ID","value":"43332"},{"name":"NSC Number","value":"603573"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43332"},{"name":"PDQ_Open_Trial_Search_ID","value":"43332"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0796480"}]}}{"C2547":{"preferredName":"Monoclonal Antibody Hu3S193","code":"C2547","definitions":[{"definition":"A humanized monoclonal antibody directed against the Lewis Y antigen, a tumor-associated epithelial antigen, with potential antineoplastic activity. Following binding, monoclonal antibody Hu3S193 triggers an antibody-dependent cell-mediated cytotoxicity in cells expressing Lewis Y antigen. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Hu3S193 binds to the protein Lewis(y), which is found on colon, breast, lung, ovary, and prostate cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody Hu3S193","termGroup":"PT","termSource":"NCI"},{"termName":"Hu3S193","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb Hu3S193","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946415-49-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Hu3S193"},{"name":"Maps_To","value":"Monoclonal Antibody Hu3S193"},{"name":"NCI_Drug_Dictionary_ID","value":"38031"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38031"},{"name":"PDQ_Open_Trial_Search_ID","value":"38031"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0879578"}]}}{"C48407":{"preferredName":"Monoclonal Antibody HuAFP31","code":"C48407","definitions":[{"definition":"A humanized monoclonal antibody directed against alpha fetoprotein with potential antineoplastic activity. Upon administration, monoclonal antibody HuAFP31 (mAb HuAFP31) binds to and stimulates a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of several types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuAFP31 attaches to tumor cells that make alpha fetoprotein (AFP). This makes it easier for T cells to find and kill the tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody HuAFP31","termGroup":"PT","termSource":"NCI"},{"termName":"hAFP-31","termGroup":"CN","termSource":"NCI"},{"termName":"MOAB HuAFP31","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuAPF31"},{"name":"Maps_To","value":"Monoclonal Antibody HuAFP31"},{"name":"NCI_Drug_Dictionary_ID","value":"425344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425344"},{"name":"PDQ_Open_Trial_Search_ID","value":"425344"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541524"}]}}{"C38697":{"preferredName":"Sontuzumab","code":"C38697","definitions":[{"definition":"A humanized monoclonal antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, sontuzumab targets and binds to MUC1 expressed on the surface of tumor cells, which may activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that binds to the protein MUC1, which is found on breast, ovarian, pancreatic, gastric, and colon cancer cells. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuHMFG1 is being studied in the treatment of some types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sontuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AS1402","termGroup":"CN","termSource":"NCI"},{"termName":"Epitumomab","termGroup":"SY","termSource":"NCI"},{"termName":"HuHMFG1","termGroup":"AB","termSource":"NCI"},{"termName":"R1550","termGroup":"CN","termSource":"NCI"},{"termName":"Therex","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"372075-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3VD89OE565"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuHMFG1"},{"name":"Maps_To","value":"Monoclonal Antibody HuHMFG1"},{"name":"NCI_Drug_Dictionary_ID","value":"322247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"322247"},{"name":"PDQ_Open_Trial_Search_ID","value":"322247"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328704"}]}}{"C2652":{"preferredName":"Rosopatamab","code":"C2652","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in the malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, over-expression indicates an aggressive phenotype of the prostate cancer. Rosopatamab was generated by replacing murine Ig sequences with human ones, thereby MoAb huJ591can be administered to patients on multiple occasions over long time periods without inducing an immune response. Radiolabelled MoAb huJ591 may be used in immunotherapy of prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosopatamab","termGroup":"PT","termSource":"NCI"},{"termName":"huJ591","termGroup":"CN","termSource":"NCI"},{"termName":"MLN591","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody huJ591","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2260767-49-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2TTE6SSR0J"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_huJ591"},{"name":"Maps_To","value":"Monoclonal Antibody huJ591"},{"name":"Maps_To","value":"Rosopatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"38425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38425"},{"name":"PDQ_Open_Trial_Search_ID","value":"38425"},{"name":"PubMedID_Primary_Reference","value":"14716739"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134478"}]}}{"C48408":{"preferredName":"Monoclonal Antibody HuPAM4","code":"C48408","definitions":[{"definition":"A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1 with potential antineoplastic activity. Monoclonal antibody HuPAM4 (mAb HuPAM4) binds to cells expressing MUC1 antigen; mAb HuPAM4 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody HuPAM4","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB HuPAM4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_HuPAM4"},{"name":"Maps_To","value":"Monoclonal Antibody HuPAM4"},{"name":"NCI_Drug_Dictionary_ID","value":"425351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425351"},{"name":"PDQ_Open_Trial_Search_ID","value":"425351"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541527"}]}}{"C29224":{"preferredName":"Monoclonal Antibody IMMU-14","code":"C29224","definitions":[{"definition":"An anti-carcinoembryonic antigen (anti-CEA) murine monoclonal immunoglobulin G (IgG) with potential antineoplastic activity.  CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers.  MOAB IMMU-14 can be conjugated with a radioactive element for use in radioimmunotherapy (RIT), a regimen that uses a tumor-specific monoclonal antibody to deliver targeted radiation to cancer cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody IMMU-14","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB IMMU-14","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_IMMU-14"},{"name":"Maps_To","value":"Monoclonal Antibody IMMU-14"},{"name":"NSC Number","value":"624339"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1513453"}]}}{"C2372":{"preferredName":"Monoclonal Antibody L6","code":"C2372","definitions":[{"definition":"A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells.  This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody L6","termGroup":"PT","termSource":"NCI"},{"termName":"L6","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb L6","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_L6"},{"name":"Maps_To","value":"Monoclonal Antibody L6"},{"name":"NCI_Drug_Dictionary_ID","value":"41472"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41472"},{"name":"PDQ_Open_Trial_Search_ID","value":"41472"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0281019"}]}}{"C1561":{"preferredName":"Monoclonal Antibody Lym-1","code":"C1561","definitions":[{"definition":"A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells.  When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues.  This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody Lym-1","termGroup":"PT","termSource":"NCI"},{"termName":"IgG2a murine monoclonal antibody Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Lym-1","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody Lym-1, IgG2a Murine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Lym-1"},{"name":"Maps_To","value":"Monoclonal Antibody Lym-1"},{"name":"NCI_Drug_Dictionary_ID","value":"41126"},{"name":"NSC Number","value":"620858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41126"},{"name":"PDQ_Open_Trial_Search_ID","value":"41126"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0280726"}]}}{"C1959":{"preferredName":"Monoclonal Antibody m170","code":"C1959","definitions":[{"definition":"A panadenocarcinoma murine monoclonal antibody (MoAb) with potential antineoplastic activity. MoAb m170 recognizes MUC-1 antigen present on the surface of many adenocarcinomas. It may be conjugated with a radioactive element and used in radioimmunotherapy (RIT), a procedure that uses a tumor-specific monoclonal antibody to target radiation to cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody m170","termGroup":"PT","termSource":"NCI"},{"termName":"Monoclonal Antibody 170","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody M170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_170"},{"name":"Maps_To","value":"Monoclonal Antibody m170"},{"name":"NCI_Drug_Dictionary_ID","value":"38169"},{"name":"NCI_META_CUI","value":"CL448315"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38169"},{"name":"PDQ_Open_Trial_Search_ID","value":"38169"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"}]}}{"C2409":{"preferredName":"Monoclonal Antibody Me1-14 F(ab')2","code":"C2409","definitions":[{"definition":"The F(ab)2 fragment of Me1-14, a murine IgG2a monoclonal antibody directed against proteoglycan chondroitin sulfate-associated protein expressed by gliomas and melanomas.  By binding to proteoglycan chondroitin sulfate-associated protein, monoclonal antibody Me1-14 F(ab')2 conjugated to a radioisotope may localize gliomas and melanomas when used as a tracer in radioimaging applications; in radioimmunotherapeutic applications, this agent conjugated to a radioisotope may be used to deliver targeted radiotoxicity to these tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody Me1-14 F(ab')2","termGroup":"PT","termSource":"NCI"},{"termName":"Me1-14 F(ab')2","termGroup":"SY","termSource":"NCI"},{"termName":"Me1-14 F(ab')2 monoclonal antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Me1-14 F(ab')2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_Me1-14_F_ab_2"},{"name":"Maps_To","value":"Monoclonal Antibody Me1-14 F(ab')2"},{"name":"NCI_Drug_Dictionary_ID","value":"42523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42523"},{"name":"PDQ_Open_Trial_Search_ID","value":"42523"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0392955"}]}}{"C2476":{"preferredName":"Monoclonal Antibody muJ591","code":"C2476","definitions":[{"definition":"A murine IgG monoclonal antibody against the external domain of the prostate-specific membrane antigen (PSMA), overexpressed in the malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, over-expression indicates an aggressive phenotype of the prostate cancer. Radiolabelled MoAb muJ591 may be used in prostate cancer diagnosis and therapy.","type":"DEFINITION","source":"NCI"},{"definition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody muJ591","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb muJ591","termGroup":"AB","termSource":"NCI"},{"termName":"muJ591","termGroup":"SY","termSource":"NCI"},{"termName":"muJ591 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_muJ591"},{"name":"Maps_To","value":"Monoclonal Antibody muJ591"},{"name":"NCI_Drug_Dictionary_ID","value":"43087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43087"},{"name":"PDQ_Open_Trial_Search_ID","value":"43087"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0678086"}]}}{"C2417":{"preferredName":"Monoclonal Antibody MX35 F(ab')2","code":"C2417","definitions":[{"definition":"The F(ab)2 fragment of monoclonal antibody (MoAb) MX35 that recognizes a 95 kD glycoprotein with homogeneous distribution on 80% of ovarian tumor specimens. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against tumor cells that express this glycoprotein. Containing only the antigen-binding fragment of the Ig molecule, MoAb MX35 F(ab')2 offers the advantages of smaller size and lower cross-reactivity compared to complete antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody MX35 F(ab')2","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb MX35 F(ab')2","termGroup":"AB","termSource":"NCI"},{"termName":"MX35 F(ab')2","termGroup":"SY","termSource":"NCI"},{"termName":"MX35 F(ab')2 monoclonal antibody","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_MX35_F_ab_2"},{"name":"Maps_To","value":"Monoclonal Antibody MX35 F(ab')2"},{"name":"NCI_Drug_Dictionary_ID","value":"42598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42598"},{"name":"PDQ_Open_Trial_Search_ID","value":"42598"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0393012"}]}}{"C156398":{"preferredName":"Monoclonal Antibody NEO-201","code":"C156398","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody derived from an immunogenic preparation of tumor-associated antigens (TAAs) from pooled allogeneic colon cancer tissue extracts, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, monoclonal antibody NEO-201 targets and binds to malignant tissues with tumor-specific mutations in the membrane-anchored proteins, carcinoembryonic antigen-related cell adhesion molecules 5 and 6 (CEACAM5 and CEACAM6). This prevents the interaction between tumor cell CEACAM 5 and natural killer (NK) cell CEACAM1, and reverses CEACAM1-dependent inhibition of NK cytotoxicity. This may result in the activation of NKs and results in NK-mediated tumor cell killing. Additionally, monoclonal antibody NEO-201 may activate innate immune responses against tumor cells such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CEACAM 5, and 6 are members of the CEA family of proteins. These membrane proteins are over expressed in a variety of cancer cell types and play a key role in cell migration, invasion, and adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody NEO-201","termGroup":"PT","termSource":"NCI"},{"termName":"h16C3","termGroup":"SY","termSource":"NCI"},{"termName":"h16C3 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"NEO 201","termGroup":"CN","termSource":"NCI"},{"termName":"NEO-201","termGroup":"CN","termSource":"NCI"},{"termName":"NEO201","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen-targeting Antibody NEO-201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"41E6FO0DX2"},{"name":"Maps_To","value":"Monoclonal Antibody NEO-201"},{"name":"NCI_Drug_Dictionary_ID","value":"795513"},{"name":"NCI_META_CUI","value":"CL563093"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795513"},{"name":"PDQ_Open_Trial_Search_ID","value":"795513"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2349":{"preferredName":"Monoclonal Antibody R24","code":"C2349","definitions":[{"definition":"An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells.  Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody R24","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb R24","termGroup":"AB","termSource":"NCI"},{"termName":"R24","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_R24"},{"name":"Maps_To","value":"Monoclonal Antibody R24"},{"name":"NCI_Drug_Dictionary_ID","value":"39362"},{"name":"NSC Number","value":"608918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39362"},{"name":"PDQ_Open_Trial_Search_ID","value":"39362"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0279226"}]}}{"C48409":{"preferredName":"Monoclonal Antibody RAV12","code":"C48409","definitions":[{"definition":"A chimeric monoclonal antibody directed against a primate-restricted N-linked carbohydrate epitope (glycotope) expressed on various human carcinomas with potential antineoplastic activity. Following binding, monoclonal antibody RAV12 disrupts sodium channels of tumor cells expressing this glycotope, resulting in cell and organelle swelling, loss of membrane integrity, and cell death. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. It binds to a carbohydrate (sugar) molecule that is found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Monoclonal Antibody RAV12","termGroup":"PT","termSource":"NCI"},{"termName":"anti-RAAG12 MOAB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_RAV12"},{"name":"Maps_To","value":"Monoclonal Antibody RAV12"},{"name":"NCI_Drug_Dictionary_ID","value":"415732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415732"},{"name":"PDQ_Open_Trial_Search_ID","value":"415732"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541489"}]}}{"C2005":{"preferredName":"Monoclonal Antibody SGN-14","code":"C2005","definitions":[{"definition":"A humanized monoclonal antibody targeting the CD40 antigen with potential antineoplastic activity. CD-40, an integral membrane protein found on the surface of B lymphocytes and member of the tumor necrosis factor receptor super-family, is highly overexpressed on the cell surface of a number of B-cell malignancies. Monoclonal antibody SGN-14 specifically binds to and inhibits CD-40, thereby inhibiting cell proliferation and inducing cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody SGN-14","termGroup":"PT","termSource":"NCI"},{"termName":"SGN-14","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SGN-14"},{"name":"Maps_To","value":"Monoclonal Antibody SGN-14"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1519138"}]}}{"C142826":{"preferredName":"Monoclonal Antibody TRK-950","code":"C142826","definitions":[{"definition":"A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Antibody TRK-950","termGroup":"PT","termSource":"NCI"},{"termName":"TRK 950","termGroup":"CN","termSource":"NCI"},{"termName":"TRK-950","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L1R0M8P1GD"},{"name":"Maps_To","value":"Monoclonal Antibody TRK-950"},{"name":"NCI_Drug_Dictionary_ID","value":"791700"},{"name":"NCI_META_CUI","value":"CL540696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791700"},{"name":"PDQ_Open_Trial_Search_ID","value":"791700"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155907":{"preferredName":"Monoclonal Microbial EDP1503","code":"C155907","definitions":[{"definition":"An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monoclonal Microbial EDP1503","termGroup":"PT","termSource":"NCI"},{"termName":"EDP 1503","termGroup":"CN","termSource":"NCI"},{"termName":"EDP-1503","termGroup":"CN","termSource":"NCI"},{"termName":"EDP1503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A69GHF9QFF"},{"name":"Maps_To","value":"Monoclonal Microbial EDP1503"},{"name":"NCI_Drug_Dictionary_ID","value":"795263"},{"name":"NCI_META_CUI","value":"CL562766"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795263"},{"name":"PDQ_Open_Trial_Search_ID","value":"795263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94208":{"preferredName":"Tebentafusp","code":"C94208","definitions":[{"definition":"A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tebentafusp","termGroup":"PT","termSource":"NCI"},{"termName":"IMC-gp100","termGroup":"CN","termSource":"NCI"},{"termName":"IMCgp100","termGroup":"CN","termSource":"NCI"},{"termName":"ImmTAC-gp100","termGroup":"SY","termSource":"NCI"},{"termName":"KIMMTRAK","termGroup":"BR","termSource":"NCI"},{"termName":"Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100","termGroup":"SY","termSource":"NCI"},{"termName":"Tebentafusp-tebn","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma."},{"name":"CAS_Registry","value":"1874157-95-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"N658GY6L3E"},{"name":"Maps_To","value":"Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100"},{"name":"Maps_To","value":"Tebentafusp"},{"name":"NCI_Drug_Dictionary_ID","value":"686537"},{"name":"NCI_META_CUI","value":"CL426021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686537"},{"name":"PDQ_Open_Trial_Search_ID","value":"686537"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122637":{"preferredName":"Monomethyl Auristatin E","code":"C122637","definitions":[{"definition":"A dolastatin-10 peptide derivative with potent antimitotic activity and potential antineoplastic activity as part of an antibody-drug conjugate (ADC). Monomethyl auristatin E (MMAE) binds to tubulin, blocks tubulin polymerization, and inhibits microtubule formation, which results in both disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. To minimize toxicity and maximize efficacy, MMAE is conjugated, via a cleavable peptide linker, to a monoclonal antibody that specifically targets a patient's tumor. The linker is stable in the extracellular milieu but is readily cleaved to release MMAE following binding and internalization of the ADC by the target cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Monomethyl Auristatin E","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide","termGroup":"SN","termSource":"NCI"},{"termName":"L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1- methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MMAE","termGroup":"AB","termSource":"NCI"},{"termName":"Monomethylauristatin E","termGroup":"SY","termSource":"NCI"},{"termName":"N(sup 2)-(N-methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2- phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N(sup 1)-methyl-L-valinamide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"474645-27-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V7I58RC5EJ"},{"name":"Maps_To","value":"Monomethyl Auristatin E"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1565020"}]}}{"C26662":{"preferredName":"Morinda Citrifolia Fruit Extract","code":"C26662","definitions":[{"definition":"An extract prepared from the fruit of Morinda citrifolia, a plant that yields various herbal preparations. Morinda citrifolia fruit juice has antioxidant properties and may prevent tumorigenesis via inhibition of DNA-carcinogen adduct formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Morinda Citrifolia Fruit Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Indian Mulberry Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Morinda citrifolia Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Noni","termGroup":"SY","termSource":"NCI"},{"termName":"Noni Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Noni Juice","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Morinda_citrifolia"},{"name":"Maps_To","value":"Morinda Citrifolia Fruit Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"304320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304320"},{"name":"PDQ_Open_Trial_Search_ID","value":"304320"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C1328724"}]}}{"C1442":{"preferredName":"Morpholinodoxorubicin","code":"C1442","definitions":[{"definition":"A semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin.  As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin.  Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II.  Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Morpholinodoxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2, 3, 6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl] oxy]-, hydrochloride, (8S-cis)-","termGroup":"SN","termSource":"NCI"},{"termName":"morpholino-ADR","termGroup":"SY","termSource":"NCI"},{"termName":"morpholino-adriamycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89196-04-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X0N4EFN4AI"},{"name":"Legacy Concept Name","value":"Morpholinodoxorubicin"},{"name":"Maps_To","value":"Morpholinodoxorubicin"},{"name":"NSC Number","value":"354646"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0173377"}]}}{"C123775":{"preferredName":"Mosedipimod","code":"C123775","definitions":[{"definition":"A synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Although the exact mechanism of action through which EC-18 exerts its pharmacological effect has yet to be fully identified, upon administration, mosedipimod stimulates calcium influx into T-lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T- and B-lymphocytes, dendritic cells (DCs) and macrophages. Therefore, EC18 may stimulate the immune system to target cancer cells. In addition, EC-18 enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mosedipimod","termGroup":"PT","termSource":"NCI"},{"termName":"1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol","termGroup":"SY","termSource":"NCI"},{"termName":"9,12-Octadecadienoic acid (9Z,12Z)-, 1-((Acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"EC-18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"221139-79-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"88928BS57E"},{"name":"Maps_To","value":"Mosedipimod"},{"name":"NCI_Drug_Dictionary_ID","value":"775590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775590"},{"name":"PDQ_Open_Trial_Search_ID","value":"775590"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1455477"}]}}{"C129691":{"preferredName":"Mosunetuzumab","code":"C129691","definitions":[{"definition":"A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mosunetuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A","termGroup":"SY","termSource":"NCI"},{"termName":"BTCT 4465A","termGroup":"CN","termSource":"NCI"},{"termName":"BTCT-4465A","termGroup":"CN","termSource":"NCI"},{"termName":"BTCT4465A","termGroup":"CN","termSource":"NCI"},{"termName":"CD20/CD3 BiMAb BTCT4465A","termGroup":"SY","termSource":"NCI"},{"termName":"Lunsumio","termGroup":"BR","termSource":"NCI"},{"termName":"Mosunetuzumab-axgb","termGroup":"SY","termSource":"NCI"},{"termName":"RG 7828","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7828","termGroup":"CN","termSource":"NCI"},{"termName":"RG7828","termGroup":"CN","termSource":"NCI"},{"termName":"RO7030816","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1905409-39-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LDJ89SS0YG"},{"name":"Maps_To","value":"Mosunetuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"774847"},{"name":"NCI_META_CUI","value":"CL507850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774847"},{"name":"PDQ_Open_Trial_Search_ID","value":"774847"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71896":{"preferredName":"Motesanib","code":"C71896","definitions":[{"definition":"An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motesanib","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"453562-69-1"},{"name":"CHEBI_ID","value":"CHEBI:51098"},{"name":"Chemical_Formula","value":"C22H23N5O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U1JK633AYI"},{"name":"Legacy Concept Name","value":"Motesanib"},{"name":"Maps_To","value":"Motesanib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347295"}]}}{"C48374":{"preferredName":"Motesanib Diphosphate","code":"C48374","definitions":[{"definition":"A substance that is being studied in the treatment of some types of cancer. It belongs to the families of drugs called angiogenesis inhibitors and protein kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motesanib Diphosphate","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"AMG 706","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-706","termGroup":"CN","termSource":"NCI"},{"termName":"AMG706","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857876-30-3"},{"name":"Chemical_Formula","value":"C22H23N5O.2H3O4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T6Q3060U91"},{"name":"Legacy Concept Name","value":"AMG706"},{"name":"Maps_To","value":"Motesanib Diphosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"391228"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391228"},{"name":"PDQ_Open_Trial_Search_ID","value":"391228"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541476"}]}}{"C1881":{"preferredName":"Motexafin Gadolinium","code":"C1881","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It is a type of metalloporphyrin complex.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motexafin Gadolinium","termGroup":"PT","termSource":"NCI"},{"termName":"API-GP3","termGroup":"CN","termSource":"NCI"},{"termName":"Gadolinium Texaphyrin","termGroup":"SY","termSource":"NCI"},{"termName":"Gd (III) Texaphryin","termGroup":"SY","termSource":"NCI"},{"termName":"Gd-Tex","termGroup":"AB","termSource":"NCI"},{"termName":"PCI-0120","termGroup":"CN","termSource":"NCI"},{"termName":"Xcytrin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156436-89-4"},{"name":"CHEBI_ID","value":"CHEBI:50161"},{"name":"CHEBI_ID","value":"CHEBI:50162"},{"name":"Chemical_Formula","value":"C48H66N5O10.2C2H3O2.Gd"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6433A42F4F"},{"name":"Legacy Concept Name","value":"Motexafin_Gadolinium"},{"name":"Maps_To","value":"Motexafin Gadolinium"},{"name":"NCI_Drug_Dictionary_ID","value":"42391"},{"name":"NSC Number","value":"695238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42391"},{"name":"PDQ_Open_Trial_Search_ID","value":"42391"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0964264"}]}}{"C1651":{"preferredName":"Motexafin Lutetium","code":"C1651","definitions":[{"definition":"A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer using photodynamic therapy. It belongs to the family of drugs called metallotexaphyrins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Motexafin Lutetium","termGroup":"PT","termSource":"NCI"},{"termName":"Antrin","termGroup":"BR","termSource":"NCI"},{"termName":"Lu-Tex","termGroup":"AB","termSource":"NCI"},{"termName":"Lutetium Texaphrin","termGroup":"SY","termSource":"NCI"},{"termName":"Lutetium Texaphyrin","termGroup":"SY","termSource":"NCI"},{"termName":"Lutex","termGroup":"BR","termSource":"NCI"},{"termName":"Lutrin","termGroup":"BR","termSource":"NCI"},{"termName":"Optrin","termGroup":"BR","termSource":"NCI"},{"termName":"PCI-0123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156436-90-7"},{"name":"CAS_Registry","value":"246252-04-0"},{"name":"Chemical_Formula","value":"C48H66N5O10.2C2H3O2.Lu.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0A85BJ22L6"},{"name":"Legacy Concept Name","value":"Motexafin_Lutetium"},{"name":"Maps_To","value":"Motexafin Lutetium"},{"name":"NCI_Drug_Dictionary_ID","value":"42402"},{"name":"NSC Number","value":"695239"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42402"},{"name":"PDQ_Open_Trial_Search_ID","value":"42402"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338310"}]}}{"C80521":{"preferredName":"Motolimod","code":"C80521","definitions":[{"definition":"A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. Motolimod binds to TLR8, present in cutaneous dendritic cells, monocytes/macrophages, and mast cells, which may result in the activation of the central transcription factor nuclear factor-B, the secretion of proinflammatory cytokines and other mediators, and a Th1-weighted antitumoral cellular immune response. Primarily localized to endosomal membranes intracellularly, TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motolimod","termGroup":"PT","termSource":"NCI"},{"termName":"Toll-like Receptor 8 Agonist VTX-2337","termGroup":"SY","termSource":"NCI"},{"termName":"VTX-2337","termGroup":"CN","termSource":"NCI"},{"termName":"VTX-378","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"926927-61-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WP6PY72ZH3"},{"name":"Legacy Concept Name","value":"TLR8_Agonist_VTX-2337"},{"name":"Maps_To","value":"Motolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"599455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599455"},{"name":"PDQ_Open_Trial_Search_ID","value":"599455"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825237"}]}}{"C2638":{"preferredName":"MOv-gamma Chimeric Receptor Gene","code":"C2638","definitions":[{"definition":"A recombinant engineered chimeric gene derived from the murine gene encoding the variable region of monoclonal antibody MOv18 against folate-binding protein, which is often overexpressed in human ovarian cancer cells, and the gene encoding the Fc receptor for the gamma subunit of human IgG and IgE. Peripheral blood lymphocytes expressing the MOv-gamma gene may be used in the immunotherapeutic treatment of ovarian cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MOv-gamma Chimeric Receptor Gene","termGroup":"PT","termSource":"NCI"},{"termName":"MOv-g","termGroup":"SY","termSource":"NCI"},{"termName":"MOv-gamma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"MOv-gamma_Chimeric_Receptor_Gene"},{"name":"Maps_To","value":"MOv-gamma Chimeric Receptor Gene"},{"name":"NCI_Drug_Dictionary_ID","value":"38341"},{"name":"NSC Number","value":"673412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38341"},{"name":"PDQ_Open_Trial_Search_ID","value":"38341"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935881"}]}}{"C68819":{"preferredName":"Moxetumomab Pasudotox","code":"C68819","definitions":[{"definition":"A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD22 immunotoxin CAT-8015 is made in the laboratory. It binds to CD22, a protein on the surface of normal B cells and B-cell tumors, and kills the cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moxetumomab Pasudotox","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD22 Immunotoxin CAT-8015","termGroup":"SY","termSource":"NCI"},{"termName":"CAT 8015","termGroup":"CN","termSource":"NCI"},{"termName":"CAT-8015","termGroup":"CN","termSource":"NCI"},{"termName":"CAT8015","termGroup":"CN","termSource":"NCI"},{"termName":"GCR-8015","termGroup":"CN","termSource":"NCI"},{"termName":"HA22","termGroup":"CN","termSource":"NCI"},{"termName":"Immunotoxin CAT-8015","termGroup":"SY","termSource":"NCI"},{"termName":"Lumoxiti","termGroup":"BR","termSource":"NCI"},{"termName":"Moxetumomab Pasudotox-TDFK","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory hairy cell leukemia (HCL)"},{"name":"CAS_Registry","value":"1020748-57-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2NDX4B6N8F"},{"name":"Legacy Concept Name","value":"Anti-CD22_Immunotoxin_CAT-8015"},{"name":"Maps_To","value":"Moxetumomab Pasudotox"},{"name":"NCI_Drug_Dictionary_ID","value":"540032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"540032"},{"name":"PDQ_Open_Trial_Search_ID","value":"540032"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2717021"}]}}{"C122707":{"preferredName":"Mps1 Inhibitor BAY 1217389","code":"C122707","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BAY 1217389 selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC), accelerates mitosis, causes chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for proper SAC functioning and chromosome alignment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mps1 Inhibitor BAY 1217389","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1217389","termGroup":"CN","termSource":"NCI"},{"termName":"TTK Inhibitor BAY 1217389","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mps1 Inhibitor BAY 1217389"},{"name":"NCI_Drug_Dictionary_ID","value":"769545"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769545"},{"name":"PDQ_Open_Trial_Search_ID","value":"769545"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053670"}]}}{"C155895":{"preferredName":"Mps1 Inhibitor BOS172722","code":"C155895","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BOS172722 binds to and inhibits the activity of Mps1, a core component of the spindle assembly checkpoint (SAC). Inhibition of Mps1 activity compromises spindle assembly checkpoint, increases chromosome missegregation errors and decreases cancer cell viability. Mps1, a dual-specificity protein kinase expressed in proliferating normal tissues and aberrantly overexpressed in certain tumor types, is activated during mitosis and is essential in proper SAC function and chromosomal alignment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mps1 Inhibitor BOS172722","termGroup":"PT","termSource":"NCI"},{"termName":"BOS 172722","termGroup":"CN","termSource":"NCI"},{"termName":"BOS172722","termGroup":"CN","termSource":"NCI"},{"termName":"Monopolar Spindle 1 Inhibitor BOS172722","termGroup":"SY","termSource":"NCI"},{"termName":"TTK Inhibitor BOS172722","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mps1 Inhibitor BOS172722"},{"name":"NCI_Drug_Dictionary_ID","value":"794872"},{"name":"NCI_META_CUI","value":"CL562779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794872"},{"name":"PDQ_Open_Trial_Search_ID","value":"794872"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146813":{"preferredName":"mRNA-based Personalized Cancer Vaccine mRNA-4157","code":"C146813","definitions":[{"definition":"An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, the mRNA-based PCV mRNA-4157 is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based Personalized Cancer Vaccine mRNA-4157","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA 4157","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-4157","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-based PCV mRNA-4157","termGroup":"SY","termSource":"NCI"},{"termName":"PCV mRNA-4157","termGroup":"SY","termSource":"NCI"},{"termName":"V 940","termGroup":"CN","termSource":"NCI"},{"termName":"V-940","termGroup":"CN","termSource":"NCI"},{"termName":"V940","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based Personalized Cancer Vaccine mRNA-4157"},{"name":"NCI_Drug_Dictionary_ID","value":"792256"},{"name":"NCI_META_CUI","value":"CL544754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792256"},{"name":"PDQ_Open_Trial_Search_ID","value":"792256"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148239":{"preferredName":"mRNA-based Personalized Cancer Vaccine NCI-4650","code":"C148239","definitions":[{"definition":"An mRNA-based therapeutic personalized cancer vaccine (PCV) targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed and subjected to RNA sequencing to identify mutant and immunogenic epitopes. The neoantigen epitopes are screened to select those that induce a strong immune response in tumor- infiltrating lymphocytes (TILs) isolated from the patient. The selected mRNA sequences encoding up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. Upon administration, the mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based Personalized Cancer Vaccine NCI-4650","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA-based PCV NCI-4650","termGroup":"SY","termSource":"NCI"},{"termName":"NCI 4650","termGroup":"CN","termSource":"NCI"},{"termName":"NCI-4650","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based Personalized Cancer Vaccine NCI-4650"},{"name":"NCI_Drug_Dictionary_ID","value":"795447"},{"name":"NCI_META_CUI","value":"CL550832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795447"},{"name":"PDQ_Open_Trial_Search_ID","value":"795447"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C154274":{"preferredName":"mRNA-based TriMix Melanoma Vaccine ECI-006","code":"C154274","definitions":[{"definition":"A melanoma vaccine consisting of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and a TriMix platform comprised of three mRNAs encoding for constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70, with potential immunomodulatory and antineoplastic activities. Upon intranodal injection, mRNA based TriMix vaccine ECI-006 may stimulate the immune system to mount both humoral and cellular responses against tumor cells expressing the five TAAs specific to the vaccine, potentially decreasing cellular proliferation of cells expressing these antigens. The TriMix adjuvants CD40L and caTLR4 promote the generation of mature and active dendritic cells (DCs), and CD70 provides a costimulatory signal to CD27+ naive T-cells, thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based TriMix Melanoma Vaccine ECI-006","termGroup":"PT","termSource":"NCI"},{"termName":"ECI 006","termGroup":"CN","termSource":"NCI"},{"termName":"ECI-006","termGroup":"CN","termSource":"NCI"},{"termName":"ECI006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based TriMix Melanoma Vaccine ECI-006"},{"name":"NCI_Drug_Dictionary_ID","value":"794159"},{"name":"NCI_META_CUI","value":"CL555271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794159"},{"name":"PDQ_Open_Trial_Search_ID","value":"794159"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156926":{"preferredName":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902","code":"C156926","definitions":[{"definition":"An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the mRNA-based tumor-specific neoantigen boosting vaccine GRT-R902, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901.  The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902","termGroup":"PT","termSource":"NCI"},{"termName":"Boosting Cancer Vaccine GRT-R902","termGroup":"SY","termSource":"NCI"},{"termName":"GRT R902","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-R902","termGroup":"CN","termSource":"NCI"},{"termName":"GRTR902","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-based TSNA Boosting Vaccine GRT-R902","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902"},{"name":"NCI_Drug_Dictionary_ID","value":"796480"},{"name":"NCI_META_CUI","value":"CL935911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796480"},{"name":"PDQ_Open_Trial_Search_ID","value":"796480"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162186":{"preferredName":"mRNA-derived KRAS-targeted Vaccine V941","code":"C162186","definitions":[{"definition":"A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-derived KRAS-targeted Vaccine V941","termGroup":"PT","termSource":"NCI"},{"termName":"mRNA 5671","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-5671","termGroup":"CN","termSource":"NCI"},{"termName":"mRNA-5671 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V 941","termGroup":"CN","termSource":"NCI"},{"termName":"V941","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-derived KRAS-targeted Vaccine V941"},{"name":"NCI_Drug_Dictionary_ID","value":"798633"},{"name":"NCI_META_CUI","value":"CL970771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798633"},{"name":"PDQ_Open_Trial_Search_ID","value":"798633"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111574":{"preferredName":"mRNA-derived Lung Cancer Vaccine BI 1361849","code":"C111574","definitions":[{"definition":"A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-derived Lung Cancer Vaccine BI 1361849","termGroup":"PT","termSource":"NCI"},{"termName":"BI 1361849","termGroup":"CN","termSource":"NCI"},{"termName":"BI1361849","termGroup":"CN","termSource":"NCI"},{"termName":"CV9202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-derived Lung Cancer Vaccine BI 1361849"},{"name":"NCI_Drug_Dictionary_ID","value":"752248"},{"name":"NCI_META_CUI","value":"CL453982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752248"},{"name":"PDQ_Open_Trial_Search_ID","value":"752248"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82654":{"preferredName":"mRNA-Derived Prostate Cancer Vaccine CV9103","code":"C82654","definitions":[{"definition":"A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-Derived Prostate Cancer Vaccine CV9103","termGroup":"PT","termSource":"NCI"},{"termName":"CV9103","termGroup":"CN","termSource":"NCI"},{"termName":"Messenger RNA-Derived Prostate Cancer Vaccine CV9103","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"mRNA-Derived_Prostate_Cancer_Vaccine_CV9103"},{"name":"Maps_To","value":"mRNA-Derived Prostate Cancer Vaccine CV9103"},{"name":"NCI_Drug_Dictionary_ID","value":"636121"},{"name":"NCI_META_CUI","value":"CL388486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636121"},{"name":"PDQ_Open_Trial_Search_ID","value":"636121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106231":{"preferredName":"mRNA-derived Prostate Cancer Vaccine CV9104","code":"C106231","definitions":[{"definition":"A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), and mucin 1 (MUC1), with potential antineoplastic and immunomodulating activities. Upon intradermal administration of mRNA-derived prostate cancer vaccine CV9104, this agent enters cells, the mRNAs are translated into the respective prostate specific antigens and may cause the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PAP- and MUC1-expressing prostate tumor cells. The mRNAs used in this vaccine are modified to have enhanced translational potency and adjuvant activities. PSA, PSMA, PAP and MUC1 are frequently upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mRNA-derived Prostate Cancer Vaccine CV9104","termGroup":"PT","termSource":"NCI"},{"termName":"CV9104","termGroup":"CN","termSource":"NCI"},{"termName":"RNActive-derived Prostate Cancer Vaccine CV9104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mRNA-derived Prostate Cancer Vaccine CV9104"},{"name":"NCI_Drug_Dictionary_ID","value":"748869"},{"name":"NCI_META_CUI","value":"CL447407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748869"},{"name":"PDQ_Open_Trial_Search_ID","value":"748869"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95724":{"preferredName":"MTF-1 Inhibitor APTO-253 HCl","code":"C95724","definitions":[{"definition":"The hydrochloride salt of a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1) with potential antitumor activity. MTF-1 inhibitor APTO-253 inhibits MTF-1 activity and thereby induces the expression of MTF-1 dependent tumor suppressor factor Kruppel like factor 4 (KLF4). This subsequently leads to the downregulation of cyclin D1, blocking cell cycle progression and proliferation. This agent also causes decreased expression of genes involved in tumor hypoxia and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MTF-1 Inhibitor APTO-253 HCl","termGroup":"PT","termSource":"NCI"},{"termName":"2-(6-Fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"APTO-253 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"LOR-253 HCl","termGroup":"CN","termSource":"NCI"},{"termName":"LT-253 HCl","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422731-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"266N56YWTZ"},{"name":"Maps_To","value":"MTF-1 Inhibitor APTO-253 HCl"},{"name":"NCI_Drug_Dictionary_ID","value":"694483"},{"name":"NCI_META_CUI","value":"CL428185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694483"},{"name":"PDQ_Open_Trial_Search_ID","value":"694483"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133227":{"preferredName":"mTOR Inhibitor GDC-0349","code":"C133227","definitions":[{"definition":"An orally bioavailable, ATP-competitive, tetrahydroquinazoline (THQ)-based inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Upon administration, GDC-0349 selectively binds to and inhibits the activity of mTOR, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR Inhibitor GDC-0349","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"GDC 0349","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0349","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0349","termGroup":"CN","termSource":"NCI"},{"termName":"RG7603","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1207360-89-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"579255I6O9"},{"name":"Maps_To","value":"mTOR Inhibitor GDC-0349"},{"name":"NCI_Drug_Dictionary_ID","value":"700941"},{"name":"NCI_META_CUI","value":"CL433839"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700941"},{"name":"PDQ_Open_Trial_Search_ID","value":"700941"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78856":{"preferredName":"mTOR Kinase Inhibitor AZD8055","code":"C78856","definitions":[{"definition":"An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR Kinase Inhibitor AZD8055","termGroup":"PT","termSource":"NCI"},{"termName":"AZD8055","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1009298-09-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"970JJ37FPW"},{"name":"Legacy Concept Name","value":"mTOR_Kinase_Inhibitor_AZD8055"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor AZD8055"},{"name":"NCI_Drug_Dictionary_ID","value":"612860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612860"},{"name":"PDQ_Open_Trial_Search_ID","value":"612860"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703143"}]}}{"C92575":{"preferredName":"Onatasertib","code":"C92575","definitions":[{"definition":"An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onatasertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATG-008","termGroup":"CN","termSource":"NCI"},{"termName":"CC-223","termGroup":"CN","termSource":"NCI"},{"termName":"TORKi","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 11237","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1228013-30-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I8RA3543SY"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor CC-223"},{"name":"Maps_To","value":"Onatasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"683644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683644"},{"name":"PDQ_Open_Trial_Search_ID","value":"683644"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985184"}]}}{"C78476":{"preferredName":"mTOR Kinase Inhibitor CERC-006","code":"C78476","definitions":[{"definition":"An orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor, with potential antineoplastic activity. Upon oral administration, mTOR kinase inhibitor CERC-006 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR Kinase Inhibitor CERC-006","termGroup":"PT","termSource":"NCI"},{"termName":"AEVI 006","termGroup":"CN","termSource":"NCI"},{"termName":"AEVI-006","termGroup":"CN","termSource":"NCI"},{"termName":"AEVI006","termGroup":"CN","termSource":"NCI"},{"termName":"ASP 7486","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-7486","termGroup":"CN","termSource":"NCI"},{"termName":"ASP7486","termGroup":"CN","termSource":"NCI"},{"termName":"CERC 006","termGroup":"CN","termSource":"NCI"},{"termName":"CERC-006","termGroup":"CN","termSource":"NCI"},{"termName":"CERC006","termGroup":"CN","termSource":"NCI"},{"termName":"Mammalian Target of Rapamycin Kinase Inhibitor OSI-027","termGroup":"SY","termSource":"NCI"},{"termName":"mTOR Kinase Inhibitor OSI-027","termGroup":"SY","termSource":"NCI"},{"termName":"OSI-027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936890-98-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25MKH1SZ0M"},{"name":"Legacy Concept Name","value":"mTOR_Kinase_Inhibitor_OSI-027"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor OSI-027"},{"name":"NCI_Drug_Dictionary_ID","value":"600513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600513"},{"name":"PDQ_Open_Trial_Search_ID","value":"600513"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703121"}]}}{"C128632":{"preferredName":"mTOR Kinase Inhibitor PP242","code":"C128632","synonyms":[{"termName":"mTOR Kinase Inhibitor PP242","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol","termGroup":"SN","termSource":"NCI"},{"termName":"PP-242","termGroup":"CN","termSource":"NCI"},{"termName":"PP242","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092351-67-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H5669VNZ7V"},{"name":"Maps_To","value":"mTOR Kinase Inhibitor PP242"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3492864"}]}}{"C101132":{"preferredName":"mTOR1/2 Kinase Inhibitor ME-344","code":"C101132","definitions":[{"definition":"An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTOR1/2 Kinase Inhibitor ME-344","termGroup":"PT","termSource":"NCI"},{"termName":"ME-344","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1374524-68-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"843G0TDV51"},{"name":"Maps_To","value":"mTOR1/2 Kinase Inhibitor ME-344"},{"name":"NCI_Drug_Dictionary_ID","value":"728650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"728650"},{"name":"PDQ_Open_Trial_Search_ID","value":"728650"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3639999"}]}}{"C148528":{"preferredName":"mTORC 1/2 Inhibitor LXI-15029","code":"C148528","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTORC 1/2 Inhibitor LXI-15029","termGroup":"PT","termSource":"NCI"},{"termName":"LXI-15029","termGroup":"CN","termSource":"NCI"},{"termName":"LXI15029","termGroup":"CN","termSource":"NCI"},{"termName":"MTI-31","termGroup":"CN","termSource":"NCI"},{"termName":"SCC-31","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1567915-38-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RM15YYQ1CI"},{"name":"Maps_To","value":"mTORC 1/2 Inhibitor LXI-15029"},{"name":"NCI_Drug_Dictionary_ID","value":"792688"},{"name":"NCI_META_CUI","value":"CL551141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792688"},{"name":"PDQ_Open_Trial_Search_ID","value":"792688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122836":{"preferredName":"mTORC1/2 Kinase Inhibitor BI 860585","code":"C122836","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 kinase inhibitor BI 860585 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"mTORC1/2 Kinase Inhibitor BI 860585","termGroup":"PT","termSource":"NCI"},{"termName":"BI 860585","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mTORC1/2 Kinase Inhibitor BI 860585"},{"name":"NCI_Drug_Dictionary_ID","value":"753378"},{"name":"NCI_META_CUI","value":"CL471745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753378"},{"name":"PDQ_Open_Trial_Search_ID","value":"753378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117290":{"preferredName":"Ibrilatazar","code":"C117290","definitions":[{"definition":"An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, ibrilatazar binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ibrilatazar inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This induces autophagy-induced cell death and further inhibition of cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ibrilatazar","termGroup":"PT","termSource":"NCI"},{"termName":"2-Hydroxylinoleic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"9,12-Octadecadienoic Acid, 2-Hydroxy-, (9Z,12Z)-","termGroup":"SY","termSource":"NCI"},{"termName":"ABTL0812","termGroup":"CN","termSource":"NCI"},{"termName":"LP-10218","termGroup":"CN","termSource":"NCI"},{"termName":"LP10218","termGroup":"CN","termSource":"NCI"},{"termName":"mTORC1/mTORC2/DHFR Inhibitor ABTL0812","termGroup":"SY","termSource":"NCI"},{"termName":"SCLN-0812","termGroup":"CN","termSource":"NCI"},{"termName":"SCLN0812","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57818-44-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0DE74TJ7EZ"},{"name":"Maps_To","value":"mTORC1/mTORC2/DHFR Inhibitor ABTL0812"},{"name":"NCI_Drug_Dictionary_ID","value":"763422"},{"name":"NCI_META_CUI","value":"CL474116"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763422"},{"name":"PDQ_Open_Trial_Search_ID","value":"763422"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95722":{"preferredName":"MUC1-targeted Peptide GO-203-2C","code":"C95722","definitions":[{"definition":"An optimized small peptide drug candidate targeting epithelial mucin (MUC1) with antineoplastic activity. MUC1-targeted peptide GO-203-2C interacts with oncoprotein MUC1 C-terminal subunit on the cell surface, thereby impeding cell-cell interactions, signaling, and metastasis. MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is over-expressed in many diverse human carcinomas including those of the breast, prostate, lung, colon, pancreas, and ovary, and has been associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC1-targeted Peptide GO-203-2C","termGroup":"PT","termSource":"NCI"},{"termName":"GO-203-2C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1469735-88-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5YSY733NA3"},{"name":"Maps_To","value":"MUC1-targeted Peptide GO-203-2C"},{"name":"NCI_Drug_Dictionary_ID","value":"694292"},{"name":"NCI_META_CUI","value":"CL428184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694292"},{"name":"PDQ_Open_Trial_Search_ID","value":"694292"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107188":{"preferredName":"Mucoadhesive Paclitaxel Formulation","code":"C107188","definitions":[{"definition":"An orally available, mucoadhesive lipid preparation consisting of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, in a formulation that is comprised of a mixture of monoolein, tricarprylin, and Tween 80, with potential antineoplastic activity. Upon oral administration, DHP107 forms droplets and micelles in the intestine; these adhere to mucoepithelial cells in the gastrointestinal tract and are absorbed through lipid-based uptake mechanisms. Upon absorption, paclitaxel binds to and stabilizes tubulin molecules, which results in the inhibition of both microtubule depolymerization and cell division. This agent also induces apoptosis by both binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2).The mucoadhesive paclitaxel formulation does not contain P-glycoprotein inhibitors, the solvent cremophor or any other toxic solvent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mucoadhesive Paclitaxel Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"DHP107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mucoadhesive Paclitaxel Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"750455"},{"name":"NCI_META_CUI","value":"CL449448"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750455"},{"name":"PDQ_Open_Trial_Search_ID","value":"750455"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101786":{"preferredName":"Multi-AGC Kinase Inhibitor AT13148","code":"C101786","definitions":[{"definition":"An orally available, small molecule inhibitor of AGC group kinases, with potential antineoplastic activity. AT13148 inhibits, in an ATP-competitive manner, the enzymatic activity of two AGC kinases, protein kinase B (PKB or AKT) and p70S6K which play key roles in the PI3K/PKB/mTOR signaling pathway. Blockade of this pathway leads to an inhibition of cell growth and the induction of apoptosis in susceptible tumor cells. PI3K/PKB/mTOR pathway is dysregulated in greater than 50% of tumors, and is often correlated with resistance and increased tumor survival. AGC group kinases are serine/threonine kinases that are regulated by secondary messengers such as cyclic AMP and lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-AGC Kinase Inhibitor AT13148","termGroup":"PT","termSource":"NCI"},{"termName":"AT13148","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1056901-62-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A49037RP1E"},{"name":"Maps_To","value":"Multi-AGC Kinase Inhibitor AT13148"},{"name":"NCI_Drug_Dictionary_ID","value":"732857"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732857"},{"name":"PDQ_Open_Trial_Search_ID","value":"732857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640215"}]}}{"C128898":{"preferredName":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200","code":"C128898","definitions":[{"definition":"A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor 1 (FOLR1; FR-alpha), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope anti-folate receptor peptide vaccine TPIV 200 may induce a cytotoxic T-lymphocyte (CTL) response against FR-alpha-overexpressing tumor cells. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200","termGroup":"PT","termSource":"NCI"},{"termName":"TPIV 200","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV 200 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TPIV-200","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV200","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV200/huFR-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200"},{"name":"NCI_Drug_Dictionary_ID","value":"782632"},{"name":"NCI_META_CUI","value":"CL512164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782632"},{"name":"PDQ_Open_Trial_Search_ID","value":"782632"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165292":{"preferredName":"Multi-epitope HER2 Peptide Vaccine H2NVAC","code":"C165292","definitions":[{"definition":"A peptide vaccine containing four immunogenic epitopes derived from the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; HER-2; ErbB2; Neu), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope HER2 peptide vaccine H2NVAC may induce a helper T-cell mediated immune response against HER2-overexpressing tumor cells. This may result in long-term immunopotentiation against HER2-expressing tumor cells by increasing the helper T-cell response. HER2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed in various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-epitope HER2 Peptide Vaccine H2NVAC","termGroup":"PT","termSource":"NCI"},{"termName":"H2NVAC","termGroup":"CN","termSource":"NCI"},{"termName":"HER2 Peptide Vaccine H2NVAC","termGroup":"SY","termSource":"NCI"},{"termName":"HER2 Specific Helper T-cell Epitope Vaccine H2NVAC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-epitope HER2 Peptide Vaccine H2NVAC"},{"name":"NCI_Drug_Dictionary_ID","value":"799763"},{"name":"NCI_META_CUI","value":"CL978527"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799763"},{"name":"PDQ_Open_Trial_Search_ID","value":"799763"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124054":{"preferredName":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","code":"C124054","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","termGroup":"PT","termSource":"NCI"},{"termName":"ICT-107","termGroup":"CN","termSource":"NCI"},{"termName":"Multi-glioblastoma-peptide-pulsed Autologous DC Vaccine ICT-107","termGroup":"SY","termSource":"NCI"},{"termName":"Multi-glioblastoma-peptide-targeting Autologous DC Vaccine ICT-107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107"},{"name":"NCI_Drug_Dictionary_ID","value":"776267"},{"name":"NCI_META_CUI","value":"CL498408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776267"},{"name":"PDQ_Open_Trial_Search_ID","value":"776267"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162676":{"preferredName":"Elzovantinib","code":"C162676","definitions":[{"definition":"An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Elzovantinib","termGroup":"PT","termSource":"NCI"},{"termName":"MET/Src/CSF1R Tyrosine Kinase Inhibitor TPX-0022","termGroup":"SY","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor TPX-0022","termGroup":"SY","termSource":"NCI"},{"termName":"Multikinase Inhibitor TPX-0022","termGroup":"SY","termSource":"NCI"},{"termName":"TPX 0022","termGroup":"CN","termSource":"NCI"},{"termName":"TPX-0022","termGroup":"CN","termSource":"NCI"},{"termName":"TPX0022","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2271119-26-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TTY12Q00LY"},{"name":"Maps_To","value":"Multi-kinase Inhibitor TPX-0022"},{"name":"NCI_Drug_Dictionary_ID","value":"798966"},{"name":"NCI_META_CUI","value":"CL973112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798966"},{"name":"PDQ_Open_Trial_Search_ID","value":"798966"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C161598":{"preferredName":"Zanzalintinib","code":"C161598","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, with potential anti-angiogenesis and antineoplastic activities. Upon oral administration, zanzalintinib targets and binds to c-Met, VEGFR2, AXL and MER, and prevents their RTK activity. This blocks c-Met/VEGFR2/AXL/MER-mediated signal transduction pathways, and inhibits the proliferation and migration of c-Met-, VEGFR2-, AXL- and MER-overexpressing tumor cells. c-Met, overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. VEGFR2, overexpressed in certain tumor types, plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells. AXL and MER, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanzalintinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-(4-((7-methoxy-6-((methylamino)carbonyl)-4-quinolinyl)oxy)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor XL092","termGroup":"SY","termSource":"NCI"},{"termName":"N-(4-Fluorophenyl)-N'-(4-((7-methoxy-6- (methylcarbamoyl)quinolin-4- yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"XL 092","termGroup":"CN","termSource":"NCI"},{"termName":"XL-092","termGroup":"CN","termSource":"NCI"},{"termName":"XL092","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2367004-54-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KC2JC2ZA04"},{"name":"Maps_To","value":"Multi-kinase Inhibitor XL092"},{"name":"NCI_Drug_Dictionary_ID","value":"798432"},{"name":"NCI_META_CUI","value":"CL970131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798432"},{"name":"PDQ_Open_Trial_Search_ID","value":"798432"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C164211":{"preferredName":"Multi-mode Kinase Inhibitor EOC317","code":"C164211","definitions":[{"definition":"An orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-mode Kinase Inhibitor EOC317","termGroup":"PT","termSource":"NCI"},{"termName":"ACTB-1003","termGroup":"CN","termSource":"NCI"},{"termName":"EDP317","termGroup":"CN","termSource":"NCI"},{"termName":"EOC 317","termGroup":"CN","termSource":"NCI"},{"termName":"EOC-317","termGroup":"CN","termSource":"NCI"},{"termName":"EOC317","termGroup":"CN","termSource":"NCI"},{"termName":"ONC201MMKI EOC317","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"939805-30-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44750KD9OE"},{"name":"Maps_To","value":"Multi-mode Kinase Inhibitor EOC317"},{"name":"NCI_Drug_Dictionary_ID","value":"799401"},{"name":"NCI_META_CUI","value":"CL977499"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799401"},{"name":"PDQ_Open_Trial_Search_ID","value":"799401"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26645":{"preferredName":"Multi-neo-epitope Vaccine OSE 2101","code":"C26645","definitions":[{"definition":"A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. EP-2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes.  This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called cancer vaccines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multi-neo-epitope Vaccine OSE 2101","termGroup":"PT","termSource":"NCI"},{"termName":"EP-2101","termGroup":"CN","termSource":"NCI"},{"termName":"EP2101","termGroup":"CN","termSource":"NCI"},{"termName":"IDM2101","termGroup":"CN","termSource":"NCI"},{"termName":"OSE-2101","termGroup":"CN","termSource":"NCI"},{"termName":"Tedopi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EP-2101"},{"name":"Maps_To","value":"Multi-neo-epitope Vaccine OSE 2101"},{"name":"NCI_Drug_Dictionary_ID","value":"301640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"301640"},{"name":"PDQ_Open_Trial_Search_ID","value":"301640"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2606659"}]}}{"C101260":{"preferredName":"Multifunctional/Multitargeted Anticancer Agent OMN54","code":"C101260","definitions":[{"definition":"An orally available, multivalent herbal formulation containing a novel mixture of whole extracts from three commonly used Chinese medicinal herbs Ganoderma lucidum (lingzhi mushroom), Salvia miltiorrhiza (Chinese sage, or danshen) and Scutellaria barbata (ban zhi lian), with potential immunomodulating, antiangiogenic, anti-inflammatory, antiproliferative and antiviral activities. Although the exact mechanism of action remains to be fully elucidated due to the complexity of the multiple phytochemicals, multifunctional/multitargeted anticancer agent OMN54 appears to work in an additive and synergistic manner by acting on a variety of signaling pathways and on multiple targets, such as vascular endothelial growth factor, nuclear factor kappa B, interleukin-1beta, fibroblast growth factor, and epidermal growth factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multifunctional/Multitargeted Anticancer Agent OMN54","termGroup":"PT","termSource":"NCI"},{"termName":"Aneustat","termGroup":"BR","termSource":"NCI"},{"termName":"MFMT OMN54","termGroup":"SY","termSource":"NCI"},{"termName":"OMN54","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multifunctional/Multitargeted Anticancer Agent OMN54"},{"name":"NCI_Drug_Dictionary_ID","value":"729454"},{"name":"NCI_META_CUI","value":"CL435508"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729454"},{"name":"PDQ_Open_Trial_Search_ID","value":"729454"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90553":{"preferredName":"Multikinase Inhibitor 4SC-203","code":"C90553","definitions":[{"definition":"A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multikinase Inhibitor 4SC-203","termGroup":"PT","termSource":"NCI"},{"termName":"4SC-203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"895533-09-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RFG3GJ6251"},{"name":"Maps_To","value":"Multikinase Inhibitor 4SC-203"},{"name":"NCI_Drug_Dictionary_ID","value":"666086"},{"name":"NCI_META_CUI","value":"CL416237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666086"},{"name":"PDQ_Open_Trial_Search_ID","value":"666086"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66947":{"preferredName":"Multikinase Inhibitor AT9283","code":"C66947","definitions":[{"definition":"A small synthetic molecule and aurora kinase (AK) inhibitor with potential antineoplastic activity. AT9283 selectively binds to and inhibits AKs A and B, which are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of these kinases results in an inhibition of cellular division and proliferation in tumor cells that overexpress AKs.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It blocks enzymes (Aurora kinases) involved in cell division and may kill cancer cells. AT9283 is a type of serine/threonine protein kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Multikinase Inhibitor AT9283","termGroup":"PT","termSource":"NCI"},{"termName":"AT9283","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"896466-04-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XAV9KYN9WL"},{"name":"Legacy Concept Name","value":"AT9283"},{"name":"Maps_To","value":"Multikinase Inhibitor AT9283"},{"name":"NCI_Drug_Dictionary_ID","value":"534287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"534287"},{"name":"PDQ_Open_Trial_Search_ID","value":"534287"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879521"}]}}{"C88278":{"preferredName":"Multikinase Inhibitor SAR103168","code":"C88278","definitions":[{"definition":"A multikinase inhibitor with potential antineoplastic activity. Upon intravenous infusion, multikinase inhibitor SAR103168 may, through the inhibition of multiple kinases, inhibit the phosphorylation and activation of signal transducer and activator of transcription 5 (STAT5). STAT5, a protein often upregulated in cancer cells, plays a key role in signal transduction pathways and the suppression of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multikinase Inhibitor SAR103168","termGroup":"PT","termSource":"NCI"},{"termName":"SAR103168","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multikinase Inhibitor SAR103168"},{"name":"NCI_Drug_Dictionary_ID","value":"656309"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656309"},{"name":"PDQ_Open_Trial_Search_ID","value":"656309"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981800"}]}}{"C125692":{"preferredName":"Multipeptide Vaccine S-588210","code":"C125692","definitions":[{"definition":"A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multipeptide Vaccine S-588210","termGroup":"PT","termSource":"NCI"},{"termName":"S-488210/S-488211","termGroup":"SY","termSource":"NCI"},{"termName":"S-588210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multipeptide Vaccine S-588210"},{"name":"NCI_Drug_Dictionary_ID","value":"778596"},{"name":"NCI_META_CUI","value":"CL504368"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778596"},{"name":"PDQ_Open_Trial_Search_ID","value":"778596"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77866":{"preferredName":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327","code":"C77866","definitions":[{"definition":"An orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). By inhibiting several different signaling molecules that play crucial roles at various stages in tumorigenesis, this agent may inhibit tumor growth, invasion, migration and metastasis. In addition, JNJ-26483327 crosses the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-26483327","termGroup":"CN","termSource":"NCI"},{"termName":"TKI JNJ-26483327","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"807640-87-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16720VER1H"},{"name":"Legacy Concept Name","value":"Multitargeted_Kinase_Inhibitor_JNJ-26483327"},{"name":"Maps_To","value":"Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327"},{"name":"NCI_Drug_Dictionary_ID","value":"596693"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596693"},{"name":"PDQ_Open_Trial_Search_ID","value":"596693"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713088"}]}}{"C38690":{"preferredName":"Muparfostat","code":"C38690","definitions":[{"definition":"A mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity. Muparfostat inhibits the endo-beta-D-glucuronidase heparanase, which may interfere with the heparanase-mediated degradation of heparan-sulfate proteoglycans in extracellular matrices, an important step in the metastatic process. This agent may also bind with high affinity to the heparan sulfate-binding domains of vascular endothelial growth factor (VEGF) and fibroblast growth factors 1 and 2, thereby reducing their functional activities and inhibiting VEGF and FGF stimulation of tumor angiogenesis. Increased heparanase activity has been implicated in tumor angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antiangiogenesis agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Muparfostat","termGroup":"PT","termSource":"NCI"},{"termName":"6-O-(dihydrogen Phosphate)-2,3,4-tris-O-(hydrogen Sulfate)-alpha-d-mannopyranosyl-(1->poly(3)-2,4,6-tris-O-(hydrogen Sulfate)-alpha-d-mannopyranosyl-(1->)2)-1,3,4,6-tetrakis-O-(hydrogen Sulfate)-d-mannopyranose","termGroup":"SY","termSource":"NCI"},{"termName":"alpha-D-Mannan, (1->3)-, 6-(Dihydrogen Phosphate) Tris(Hydrogen Sulfate)","termGroup":"SN","termSource":"NCI"},{"termName":"Phosphomannopentose Sulfate PI-88","termGroup":"SY","termSource":"NCI"},{"termName":"PI 88","termGroup":"CN","termSource":"NCI"},{"termName":"PI-88","termGroup":"CN","termSource":"NCI"},{"termName":"Sulfated Phosphomanno-oligosaccharide PI-88","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant melanoma"},{"name":"CAS_Registry","value":"1020105-89-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P2BKS6T40H"},{"name":"Legacy Concept Name","value":"PI-88"},{"name":"Maps_To","value":"Muparfostat"},{"name":"NCI_Drug_Dictionary_ID","value":"339562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"339562"},{"name":"PDQ_Open_Trial_Search_ID","value":"339562"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0769628"}]}}{"C2234":{"preferredName":"Mureletecan","code":"C2234","definitions":[{"definition":"A water-soluble prodrug, consisting of camptothecin covalently linked to polymeric backbone methacryloylglycynamide, with potential antineoplastic activity. After entering tumor cells, the active moiety camptothecin is slowly released from mureletecan via hydrolysis of the ester linkage. Camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces potentially lethal double-stranded DNA breaks when encountered by the DNA replication machinery, resulting in the inhibition of DNA replication and apoptosis. Compared to camtpothecin, this prodrug formulation increases camptothecin drug delivery to the tumor site while reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mureletecan","termGroup":"PT","termSource":"NCI"},{"termName":"MAG-Camptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"MAG-CPT","termGroup":"SY","termSource":"NCI"},{"termName":"PNU 166148","termGroup":"CN","termSource":"NCI"},{"termName":"PNU166148","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"246527-99-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TTJ03QI76T"},{"name":"Legacy Concept Name","value":"PNU_166148"},{"name":"Maps_To","value":"Mureletecan"},{"name":"NCI_Drug_Dictionary_ID","value":"43584"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43584"},{"name":"PDQ_Open_Trial_Search_ID","value":"43584"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527216"}]}}{"C148134":{"preferredName":"Safusidenib","code":"C148134","definitions":[{"definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), with potential antineoplastic activity. Upon oral administration, safusidenib specifically binds to and inhibits certain mutant forms of IDH1, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutations. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. Safusidenib minimally targets and affects wild-type IDH1, which is expressed in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Safusidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AB 218","termGroup":"CN","termSource":"NCI"},{"termName":"AB-218","termGroup":"CN","termSource":"NCI"},{"termName":"AB218","termGroup":"CN","termSource":"NCI"},{"termName":"DS 1001","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1001","termGroup":"CN","termSource":"NCI"},{"termName":"DS-1001b","termGroup":"CN","termSource":"NCI"},{"termName":"Mutant Isocitrate Dehydrogenase Type 1 Inhibitor DS-1001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1898206-17-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RCK8KK7SB9"},{"name":"Maps_To","value":"Mutant IDH1 Inhibitor DS-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"792460"},{"name":"NCI_META_CUI","value":"CL550810"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792460"},{"name":"PDQ_Open_Trial_Search_ID","value":"792460"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121951":{"preferredName":"Mutant p53 Activator COTI-2","code":"C121951","definitions":[{"definition":"An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon oral administration, mutant p53 activator COTI-2 targets and binds to the misfolded mutant forms of the p53 protein, which induces a conformational change that normalizes p53 and restores its activity. This induces apoptosis in tumor cells in which the p53 protein is mutated. In addition, COTI-2 inhibits the activation of Akt2 and prevents the activation of the PI3K/AKT/mTOR pathway, thereby inducing apoptosis in cancer cells in which this pathway is overexpressed. p53, a tumor suppressor protein, plays a key role in controlling cellular proliferation and survival. High levels of mutant p53 are seen in many cancers and are associated with uncontrolled cellular growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutant p53 Activator COTI-2","termGroup":"PT","termSource":"NCI"},{"termName":"Coti-2","termGroup":"CN","termSource":"NCI"},{"termName":"COTI2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1039455-84-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2BTA1O65BR"},{"name":"Maps_To","value":"Mutant p53 Activator COTI-2"},{"name":"NCI_Drug_Dictionary_ID","value":"772024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772024"},{"name":"PDQ_Open_Trial_Search_ID","value":"772024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053651"}]}}{"C119624":{"preferredName":"Mutant-selective EGFR Inhibitor PF-06459988","code":"C119624","definitions":[{"definition":"An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mutant-selective EGFR Inhibitor PF-06459988","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06459988","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1428774-45-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5IE92SK9EB"},{"name":"Maps_To","value":"Mutant-selective EGFR Inhibitor PF-06459988"},{"name":"NCI_Drug_Dictionary_ID","value":"766942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766942"},{"name":"PDQ_Open_Trial_Search_ID","value":"766942"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896788"}]}}{"C162806":{"preferredName":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","code":"C162806","definitions":[{"definition":"An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","termGroup":"SY","termSource":"NCI"},{"termName":"Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-209-FSP","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP"},{"name":"NCI_Drug_Dictionary_ID","value":"800851"},{"name":"NCI_META_CUI","value":"CL973172"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800851"},{"name":"PDQ_Open_Trial_Search_ID","value":"800851"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88279":{"preferredName":"MVA-FCU1 TG4023","code":"C88279","definitions":[{"definition":"A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVA-FCU1 TG4023","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Ankara Virus-Mediated Suicide Gene Delivery Vector TG4023","termGroup":"SY","termSource":"NCI"},{"termName":"TG4023","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MVA-FCU1 TG4023"},{"name":"NCI_Drug_Dictionary_ID","value":"656523"},{"name":"NCI_META_CUI","value":"CL412469"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656523"},{"name":"PDQ_Open_Trial_Search_ID","value":"656523"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123382":{"preferredName":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1","code":"C123382","definitions":[{"definition":"A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient, and a capsule implanted with a genetically modified allogeneic cell line that continuously releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic cell capsules and the autologous irradiated cells isolated from the patient's tumor are co-localized in the patient's tissue. This permits the production of GM-CSF and exposes the immune system to the tumor-associated antigens (TAA) expressed by the autologous tumor cells at the injection site. Local expression of GM-CSF recruits and activates antigen-presenting cells (APC), which induces both antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site of the injection and systemically. This may lead to tumor regression. By using the patient's own irradiated cancer cells as vaccine antigens, the patient's immune system is exposed to the entire repertoire of this individual's TAAs. The encapsulated cell technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine, is a strong immune booster and plays an important role in the activation of immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1","termGroup":"PT","termSource":"NCI"},{"termName":"MVX-ONCO-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1"},{"name":"NCI_Drug_Dictionary_ID","value":"763210"},{"name":"NCI_META_CUI","value":"CL474106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763210"},{"name":"PDQ_Open_Trial_Search_ID","value":"763210"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C115108":{"preferredName":"MYC-targeting siRNA DCR-MYC","code":"C115108","definitions":[{"definition":"A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MYC-targeting siRNA DCR-MYC","termGroup":"PT","termSource":"NCI"},{"termName":"DCR-M1711","termGroup":"CN","termSource":"NCI"},{"termName":"DCR-MYC","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MYC-targeting siRNA DCR-MYC"},{"name":"NCI_Drug_Dictionary_ID","value":"759983"},{"name":"NCI_META_CUI","value":"CL472639"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759983"},{"name":"PDQ_Open_Trial_Search_ID","value":"759983"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118445":{"preferredName":"Mycobacterium tuberculosis Arabinomannan Z-100","code":"C118445","definitions":[{"definition":"An extract from Mycobacterium tuberculosis (M. tuberculosis) containing the polysaccharide arabinomannan, with potential immunostimulating activity. Upon administration of M. tuberculosis arabinomannan Z-100, this agent may activate the immune system by increasing the expression of various cytokines, such as interferon-gamma (IFNg) and interleukin-12. This inhibits the activity of suppressor T-cells, increases T helper 1 cell (Th1) activity and may restore the balance between Th1/Th2 cells. Additionally, Z-100 may inhibit metastasis and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium tuberculosis Arabinomannan Z-100","termGroup":"PT","termSource":"NCI"},{"termName":"Z-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GE82Y78JTT"},{"name":"Maps_To","value":"Mycobacterium tuberculosis Arabinomannan Z-100"},{"name":"NCI_Drug_Dictionary_ID","value":"764997"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764997"},{"name":"PDQ_Open_Trial_Search_ID","value":"764997"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0149256"}]}}{"C70969":{"preferredName":"Mycobacterium w","code":"C70969","definitions":[{"definition":"An attenuated strain of Mycobacterium w, a non-pathogenic, rapidly growing, atypical mycobacterium, with non-specific immunopotentiating properties. In addition to sharing a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis, Mycobacterium w (Mw) also shares an immunogenic determinant with prostate specific antigen (PSA). In vitro and in vivo studies have shown that heat-killed Mw can induce significant T-cell responses. This agent may induce host T-cell responses against tumor cells expressing PSA. PSA is a glycoprotein secreted by prostatic epithelial and ductal cells and may be overexpressed in prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycobacterium w","termGroup":"PT","termSource":"NCI"},{"termName":"Immuvac","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8R0TB70HKB"},{"name":"Legacy Concept Name","value":"Mycobacterium_w"},{"name":"Maps_To","value":"Mycobacterium w"},{"name":"NCI_Drug_Dictionary_ID","value":"571076"},{"name":"NCI_META_CUI","value":"CL375836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"571076"},{"name":"PDQ_Open_Trial_Search_ID","value":"571076"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C673":{"preferredName":"Mycophenolic Acid","code":"C673","definitions":[{"definition":"An antineoplastic antibiotic derived from various Penicillium fungal species.  Mycophenolic acid is an active metabolite of the prodrug mycophenolate mofetil.  Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate and synthesis of lymphocyte DNA that results in inhibition of lymphocyte proliferation, antibody production, cellular adhesion, and migration of T and B lymphocytes.  Mycophenolic acid also has antibacterial, antifungal, and antiviral activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mycophenolic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"Acide mycophenolique","termGroup":"SY","termSource":"NCI"},{"termName":"Acido micofenolico","termGroup":"SY","termSource":"NCI"},{"termName":"Acidum mycophenolicum","termGroup":"SY","termSource":"NCI"},{"termName":"Lilly-68618","termGroup":"CN","termSource":"NCI"},{"termName":"Ly 68618","termGroup":"CN","termSource":"NCI"},{"termName":"MPA","termGroup":"AB","termSource":"NCI"},{"termName":"Myfortic","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prophylaxis of organ rejection after allogenic renal; cardiac; or hepatic transplants; psoriasis"},{"name":"CAS_Registry","value":"24280-93-1"},{"name":"CAS_Registry","value":"483-60-3"},{"name":"CHEBI_ID","value":"CHEBI:168396"},{"name":"Chemical_Formula","value":"C17H20O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HU9DX48N0T"},{"name":"Legacy Concept Name","value":"Mycophenolic_Acid"},{"name":"Maps_To","value":"Mycophenolic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"732227"},{"name":"NSC Number","value":"129185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732227"},{"name":"PDQ_Open_Trial_Search_ID","value":"732227"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026933"}]}}{"C44168":{"preferredName":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea","code":"C44168","definitions":[{"definition":"An orally available isoxazole urea with potential anti-tumor activity.  In preclinical trials, N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl)urea inhibited raf kinase, an enzyme capable of reversing the phenotype of ras-transformed cells and blocking tumor growth. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea","termGroup":"PT","termSource":"NCI"},{"termName":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl)urea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N-_5-tert-butyl-3-isoxazolyl_-N-_4-_4-pyridinyl_oxyphenyl_-Urea"},{"name":"Maps_To","value":"N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517613"}]}}{"C1163":{"preferredName":"N-Methylformamide","code":"C1163","definitions":[{"definition":"A water-soluble organic solvent.  As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N-Methylformamide","termGroup":"PT","termSource":"NCI"},{"termName":"EK 7011","termGroup":"CN","termSource":"NCI"},{"termName":"Formamide, N-methyl","termGroup":"SY","termSource":"NCI"},{"termName":"formylmethylamine","termGroup":"SY","termSource":"NCI"},{"termName":"monomethylformamide","termGroup":"SY","termSource":"NCI"},{"termName":"NMF","termGroup":"AB","termSource":"NCI"},{"termName":"X 188","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123-39-7"},{"name":"CHEBI_ID","value":"CHEBI:7438"},{"name":"Chemical_Formula","value":"C2H5NO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XPE4G7Y986"},{"name":"Legacy Concept Name","value":"N-Methylformamide"},{"name":"Maps_To","value":"N-Methylformamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39511"},{"name":"NSC Number","value":"3051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39511"},{"name":"PDQ_Open_Trial_Search_ID","value":"39511"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0066373"}]}}{"C2084":{"preferredName":"N,N-Dibenzyl Daunomycin","code":"C2084","definitions":[{"definition":"The N-alkylated analogue of the anthracycline antineoplastic antibiotic daunomycin.  N,N-Dibenzyl Daunomycin interacts with topoisomerase II, thereby inhibiting DNA replication and repair and promoting DNA fragmentation.  This agent is less cardiotoxic than daunomycin. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N,N-Dibenzyl Daunomycin","termGroup":"PT","termSource":"NCI"},{"termName":"N,N-dibenzyl daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-dibenzyldaunomycin","termGroup":"SY","termSource":"NCI"},{"termName":"N,N-dibenzyldaunorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"N_N-Dibenzyl_Daunomycin"},{"name":"Maps_To","value":"N,N-Dibenzyl Daunomycin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0067345"}]}}{"C37450":{"preferredName":"NA17-A Antigen","code":"C37450","definitions":[{"definition":"A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyltransferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NA17-A Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"NA17-A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NA17-A_Antigen"},{"name":"Maps_To","value":"NA17-A Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"38647"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38647"},{"name":"PDQ_Open_Trial_Search_ID","value":"38647"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1134655"}]}}{"C2680":{"preferredName":"NA17.A2 Peptide Vaccine","code":"C2680","definitions":[{"definition":"A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NA17.A2 Peptide Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NA17.A2","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NA17_A2_Antigen"},{"name":"Maps_To","value":"NA17.A2 Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"685201"},{"name":"NCI_META_CUI","value":"CL423775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685201"},{"name":"PDQ_Open_Trial_Search_ID","value":"685201"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C2688":{"preferredName":"Nab-paclitaxel","code":"C2688","definitions":[{"definition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat breast cancer that has spread or that has come back within 6 months after chemotherapy. It is also being studied in the treatment of newly diagnosed breast cancer and other types of cancer. ABI-007 is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nab-paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"ABI 007","termGroup":"CN","termSource":"NCI"},{"termName":"ABI-007","termGroup":"CN","termSource":"NCI"},{"termName":"ABI007","termGroup":"CN","termSource":"NCI"},{"termName":"Abraxane","termGroup":"BR","termSource":"NCI"},{"termName":"Albumin-bound Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Albumin-Stabilized Nanoparticle Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Albumin-bound Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Naveruclif","termGroup":"FB","termSource":"NCI"},{"termName":"Paclitaxel Albumin","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel Nanoparticle Albumin-bound","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel Protein-Bound","termGroup":"SY","termSource":"NCI"},{"termName":"Protein-bound Paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic breast cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"ABI-007"},{"name":"Maps_To","value":"Nab-paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"38690"},{"name":"NSC Number","value":"736631"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38690"},{"name":"PDQ_Open_Trial_Search_ID","value":"38690"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134696"}]}}{"C131213":{"preferredName":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","code":"C131213","definitions":[{"definition":"A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","termGroup":"PT","termSource":"NCI"},{"termName":"Abraxane coated with Rituximab","termGroup":"SY","termSource":"NCI"},{"termName":"Abraxane Coated with Rituximab 160nm Nanoparticle","termGroup":"SY","termSource":"NCI"},{"termName":"Abraxane/Rituxan 160 Complex","termGroup":"SY","termSource":"NCI"},{"termName":"AR160","termGroup":"CN","termSource":"NCI"},{"termName":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160"},{"name":"NCI_Drug_Dictionary_ID","value":"786023"},{"name":"NCI_META_CUI","value":"CL514179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786023"},{"name":"PDQ_Open_Trial_Search_ID","value":"786023"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71011":{"preferredName":"Nadofaragene Firadenovec","code":"C71011","definitions":[{"definition":"A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nadofaragene Firadenovec","termGroup":"PT","termSource":"NCI"},{"termName":"Adstiladrin","termGroup":"BR","termSource":"NCI"},{"termName":"Instiladrin","termGroup":"BR","termSource":"NCI"},{"termName":"Nadofaragene Firadenovec-vncg","termGroup":"SY","termSource":"NCI"},{"termName":"Nadofaragene Firadenovec/Syn3","termGroup":"SY","termSource":"NCI"},{"termName":"rAd-IFN","termGroup":"AB","termSource":"NCI"},{"termName":"rAd-IFN-2b","termGroup":"AB","termSource":"NCI"},{"termName":"rAd-IFN/Syn3","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Adenovirus-Interferon SCH 721015","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Adenovirus-Interferon With Syn3","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Adenovirus-Interferon/Syn3","termGroup":"SY","termSource":"NCI"},{"termName":"SCH 721015","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-721015","termGroup":"CN","termSource":"NCI"},{"termName":"SCH721015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors."},{"name":"CAS_Registry","value":"1823059-12-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0OOS09O1FH"},{"name":"Legacy Concept Name","value":"Recombinant_Adenovirus-Interferon_SCH_721015"},{"name":"Maps_To","value":"Nadofaragene Firadenovec"},{"name":"NCI_Drug_Dictionary_ID","value":"573538"},{"name":"NCI_META_CUI","value":"CL376219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573538"},{"name":"PDQ_Open_Trial_Search_ID","value":"573538"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83981":{"preferredName":"Namirotene","code":"C83981","definitions":[{"definition":"A synthetic analogue of retinoic acid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, namirotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Namirotene","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"101506-83-6"},{"name":"Chemical_Formula","value":"C17H18O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1FG8FGL0YI"},{"name":"Maps_To","value":"Namirotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827271"}]}}{"C79826":{"preferredName":"Namodenoson","code":"C79826","definitions":[{"definition":"An orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity. Namodenoson selectively binds to and activates the cell surface-expressed A3AR, deregulating Wnt and NF-kB signal transduction pathways downstream, which may result in apoptosis of A3AR-expressing tumor cells. A3AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of various solid tumor cell types, including hepatocellular carcinoma (HCC) cells, and plays an important role in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Namodenoson","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide","termGroup":"SN","termSource":"NCI"},{"termName":"2-Cl-IB-MECA","termGroup":"AB","termSource":"NCI"},{"termName":"A3AdR Agonist CF102","termGroup":"SY","termSource":"NCI"},{"termName":"Adenosine Receptor A3 Agonist CF102","termGroup":"SY","termSource":"NCI"},{"termName":"beta-D-Ribofuranuronamide, 1-(2-Chloro-6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-1-deoxy-N-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"C-Ibza-MU","termGroup":"AB","termSource":"NCI"},{"termName":"CF102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"163042-96-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z07JR07J6C"},{"name":"Legacy Concept Name","value":"Adenosine_A3_Receptor_Agonist_CF102"},{"name":"Maps_To","value":"Namodenoson"},{"name":"NCI_Drug_Dictionary_ID","value":"626663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626663"},{"name":"PDQ_Open_Trial_Search_ID","value":"626663"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0289969"}]}}{"C162742":{"preferredName":"NAMPT Inhibitor OT-82","code":"C162742","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon oral administration, NAMPT inhibitor OT-82 binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in cell death in NAMPT-overexpressing cancer cells. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is overexpressed in a variety of cancers and metabolic disorders; tumor cells rely on NAMPT activity for their NAD supply.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NAMPT Inhibitor OT-82","termGroup":"PT","termSource":"NCI"},{"termName":"NAMPTi OT-82","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotinamide Phosphoribosyltransferase Inhibitor OT-82","termGroup":"SY","termSource":"NCI"},{"termName":"OT 82","termGroup":"CN","termSource":"NCI"},{"termName":"OT-82","termGroup":"CN","termSource":"NCI"},{"termName":"OT82","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NAMPT Inhibitor OT-82"},{"name":"NCI_Drug_Dictionary_ID","value":"798968"},{"name":"NCI_META_CUI","value":"CL973230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798968"},{"name":"PDQ_Open_Trial_Search_ID","value":"798968"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C72594":{"preferredName":"Nanafrocin","code":"C72594","definitions":[{"definition":"A quinone antibiotic isolated from Streptomyces rosa var. notoensis with activity against gram-positive bacteria, mycoplasmas and fungi. Within an organism, nanaomycin A is first reduced by flavin or NADH dehydrogenase then rapidly autooxidized leading to the production of singlet molecular oxygen (O2-). The increase in intracellular O2- results in inhibition of DNA, RNA and cell-wall peptidoglycan synthesis. Further, nanaomycin A may have antineoplastic properties resulting from a reduction in DNA methylation by inhibiting DNA methyltransferase 3B (DNMT3B) and reactivating the tumor suppressor gene RASSF1A.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanafrocin","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3R)-3,4,5,10-Tetrahydro-9-hydroxy-1-methyl-5,10-dioxo-1H-naphtho[2,3-c]pyran-3-acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Nanaomycin A","termGroup":"SY","termSource":"NCI"},{"termName":"OS 3966-A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52934-83-5"},{"name":"CHEBI_ID","value":"CHEBI:48202"},{"name":"Chemical_Formula","value":"C16H14O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8XBV72641V"},{"name":"Legacy Concept Name","value":"Nanafrocin"},{"name":"Maps_To","value":"Nanafrocin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068391"}]}}{"C78475":{"preferredName":"Nanatinostat","code":"C78475","definitions":[{"definition":"An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC), with potential antineoplastic activity. Nanatinostat targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanatinostat","termGroup":"PT","termSource":"NCI"},{"termName":"5-Pyrimidinecarboxamide, 2-((1Alpha,5alpha,6alpha)-6-(((6-fluoro-2-quinolinyl)methyl)amino)-3-azabicyclo(3.1.0)hex-3-yl)-N-hydroxy-","termGroup":"SY","termSource":"NCI"},{"termName":"CHR 3996","termGroup":"CN","termSource":"NCI"},{"termName":"CHR-3996","termGroup":"CN","termSource":"NCI"},{"termName":"Histone Deacetylase Inhibitor VRx-3996","termGroup":"SY","termSource":"NCI"},{"termName":"VRx 3996","termGroup":"CN","termSource":"NCI"},{"termName":"VRx-3996","termGroup":"CN","termSource":"NCI"},{"termName":"VRx3996","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10911","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1235859-13-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YTL7A418KQ"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_CHR-3996"},{"name":"Maps_To","value":"Nanatinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"600512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600512"},{"name":"PDQ_Open_Trial_Search_ID","value":"600512"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703120"}]}}{"C121214":{"preferredName":"Nanocell-encapsulated miR-16-based microRNA Mimic","code":"C121214","definitions":[{"definition":"A nanoparticle-based formulation composed of a microRNA 16 (miR-16) mimic, a double-stranded, 23 base pair, synthetic RNA molecule, encapsulated in nonliving bacterial minicells and coated with anti-epidermal growth factor receptor (EGFR) antibodies, with potential antineoplastic activity. Upon intravenous administration and subsequent transfection, nanocell-encapsulated miR-16-based microRNA mimic targets EGFR-expressing tumor cells and facilitates the restoration of expression of the miR-16 family. This leads to the downregulation of the expression of tumor promoting genes and the inhibition of tumor cell growth. In addition, restoration of miR-16 expression sensitizes the tumor cell to certain chemotherapeutic agents. miR-16, a family of microRNAs, is critical to the regulation of gene expression and appears to have a tumor suppressor function; its expression is downregulated in various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanocell-encapsulated miR-16-based microRNA Mimic","termGroup":"PT","termSource":"NCI"},{"termName":"TargomiRs","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanocell-encapsulated miR-16-based microRNA Mimic"},{"name":"NCI_Drug_Dictionary_ID","value":"769608"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769608"},{"name":"PDQ_Open_Trial_Search_ID","value":"769608"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054425"}]}}{"C71696":{"preferredName":"Nanoparticle Albumin-Bound Docetaxel","code":"C71696","definitions":[{"definition":"A nanoparticle albumin-bound formulation of the taxane docetaxel with antineoplastic activity. Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. This nanoparticle albumin-bound formulation solubilizes docetaxel without the use of the nonionic solubilizer Cremophor ELP, permitting the administration of larger doses of docetaxel while avoiding Cremophor ELP-associated toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle Albumin-Bound Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"ABI-008","termGroup":"CN","termSource":"NCI"},{"termName":"CPO 100","termGroup":"CN","termSource":"NCI"},{"termName":"CPO-100","termGroup":"CN","termSource":"NCI"},{"termName":"CPO100","termGroup":"CN","termSource":"NCI"},{"termName":"Docetaxel Albumin-bound","termGroup":"SY","termSource":"NCI"},{"termName":"DTX-HSA","termGroup":"AB","termSource":"NCI"},{"termName":"Nab-Docetaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nanoparticle_Albumin-Bound_Docetaxel"},{"name":"Maps_To","value":"Nanoparticle Albumin-Bound Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"557567"},{"name":"NCI_META_CUI","value":"CL376119"},{"name":"PDQ_Closed_Trial_Search_ID","value":"557567"},{"name":"PDQ_Open_Trial_Search_ID","value":"557567"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74065":{"preferredName":"Sirolimus Albumin-bound Nanoparticles","code":"C74065","definitions":[{"definition":"The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirolimus Albumin-bound Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"ABI 009","termGroup":"CN","termSource":"NCI"},{"termName":"ABI-009","termGroup":"CN","termSource":"NCI"},{"termName":"ABI009","termGroup":"CN","termSource":"NCI"},{"termName":"Albumin-bound Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Fyarro","termGroup":"BR","termSource":"NCI"},{"termName":"Nab-Rapamycin","termGroup":"AB","termSource":"NCI"},{"termName":"Nab-sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Albumin-Bound Rapamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle Albumin-bound Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"Sirolimus Albumin-bound Particles","termGroup":"SY","termSource":"NCI"},{"termName":"Sirolimus Protein-bound Particles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"dult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Nanoparticle_Albumin-Bound_Rapamycin"},{"name":"Maps_To","value":"Nanoparticle Albumin-Bound Rapamycin"},{"name":"NCI_Drug_Dictionary_ID","value":"583541"},{"name":"NCI_META_CUI","value":"CL383470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583541"},{"name":"PDQ_Open_Trial_Search_ID","value":"583541"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116890":{"preferredName":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404","code":"C116890","definitions":[{"definition":"A nanoparticle albumin-bound formulation of a thiocolchicine dimer, an inhibitor of both microtubule and topoisomerase I (TOP1), with antineoplastic and vascular disrupting activities. Upon administration of nanoparticle albumin-bound thiocolchicine dimer nab-5404, this agent binds to tubulin and inhibits its polymerization, which blocks mitotic spindle formation and leads to cell cycle arrest and tumor endothelial cell apoptosis. This disrupts the tumor vasculature and leads to tumor necrosis. In addition, nab-5404 binds to topoisomerase I (TOPI) and inhibits its activity. This results in the inhibition of the repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. The nanoparticle albumin-based formulation permits the albumin-mediated endocytosis of the thiocolchicine dimer by tumor cells and endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404","termGroup":"PT","termSource":"NCI"},{"termName":"ABI-011","termGroup":"CN","termSource":"NCI"},{"termName":"IDN 5404","termGroup":"CN","termSource":"NCI"},{"termName":"nab-5404","termGroup":"CN","termSource":"NCI"},{"termName":"nab-Thiocolchicine Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"NTB-011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"361169-05-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5C3JG9RQU3"},{"name":"Maps_To","value":"Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404"},{"name":"NCI_Drug_Dictionary_ID","value":"682217"},{"name":"NCI_META_CUI","value":"CL421664"},{"name":"PDQ_Closed_Trial_Search_ID","value":"682217"},{"name":"PDQ_Open_Trial_Search_ID","value":"682217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C146821":{"preferredName":"Nanoparticle Paclitaxel Ointment SOR007","code":"C146821","definitions":[{"definition":"A topical ointment composed of the water-insoluble taxane paclitaxel that has been processed to form uncoated nanoparticles, with potential antineoplastic activity. Upon topical administration of nanoparticle paclitaxel ointment SOR007 to the affected area, and following epithelial and dermal penetration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The nanoparticles in the nanoparticle paclitaxel ointment are produced through a specific proprietary submicron particle production.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle Paclitaxel Ointment SOR007","termGroup":"PT","termSource":"NCI"},{"termName":"NanoPac Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Nanopartcle Paclitaxel SOR007","termGroup":"SY","termSource":"NCI"},{"termName":"SOR007","termGroup":"CN","termSource":"NCI"},{"termName":"SOR007 Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Topical Nanoparticle Paclitaxel Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"Uncoated Nanoparticle Paclitaxel Ointment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoparticle Paclitaxel Ointment SOR007"},{"name":"NCI_Drug_Dictionary_ID","value":"792258"},{"name":"NCI_META_CUI","value":"CL544868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792258"},{"name":"PDQ_Open_Trial_Search_ID","value":"792258"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118648":{"preferredName":"Nanoparticle-based Paclitaxel Suspension","code":"C118648","definitions":[{"definition":"A nanoparticle-based suspension containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intraperitoneal administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division. The nanoparticle-based formulation is devoid of toxic solvents, such as cremophor; therefore, this agent has fewer side effects than the standard, solvent-based paclitaxel formulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle-based Paclitaxel Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"Nanotax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoparticle-based Paclitaxel Suspension"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3898158"}]}}{"C102875":{"preferredName":"Nanoparticle-encapsulated Doxorubicin Hydrochloride","code":"C102875","definitions":[{"definition":"A formulation of nanoparticles encapsulating the hydrochloride salt form of the anthracycline antibiotic doxorubicin, with potential antitumor activity. Upon intravenous administration, doxorubicin intercalates DNA, interferes with the activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoparticle-encapsulated Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"BA-003","termGroup":"CN","termSource":"NCI"},{"termName":"Doxorubicin Transdrug","termGroup":"FB","termSource":"NCI"},{"termName":"Livatag","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoparticle-encapsulated Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"738259"},{"name":"NCI_META_CUI","value":"CL437178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738259"},{"name":"PDQ_Open_Trial_Search_ID","value":"738259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157499":{"preferredName":"Nanoscale Coordination Polymer Nanoparticles CPI-100","code":"C157499","definitions":[{"definition":"A preparation of self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles containing an as of yet undisclosed payload with potential immunostimulating and antineoplastic activities. Upon intravenous administration, NCP nanoparticle formulation CPI-100 delivers its payload to tumor cells, which may lead to enhanced immune-mediated killing and regression of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanoscale Coordination Polymer Nanoparticles CPI-100","termGroup":"PT","termSource":"NCI"},{"termName":"CPI 100","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-100","termGroup":"CN","termSource":"NCI"},{"termName":"CPI100","termGroup":"CN","termSource":"NCI"},{"termName":"NCP Nanoparticles CPI-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanoscale Coordination Polymer Nanoparticles CPI-100"},{"name":"NCI_Drug_Dictionary_ID","value":"796802"},{"name":"NCI_META_CUI","value":"CL937066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796802"},{"name":"PDQ_Open_Trial_Search_ID","value":"796802"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111570":{"preferredName":"Nanosomal Docetaxel Lipid Suspension","code":"C111570","definitions":[{"definition":"A lipid-based nanosomal formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel, with potential antineoplastic activity. Upon intravenous injection, docetaxel binds to and stabilizes tubulin, which inhibits microtubule disassembly and results in both cell cycle arrest at the G2/M phase and cell death. This liposomal formulation solubilizes docetaxel without the use of toxic solvents, such as polysorbate 80. This permits the administration of larger doses of docetaxel and improves the drug's safety profile by avoiding solvent-associated toxicities, such as hypersensitivity reactions and neurotoxicity. In addition, the nanosomal lipid-based delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, all of which prolong the duration of docetaxel's therapeutic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanosomal Docetaxel Lipid Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"DTX-LNS","termGroup":"AB","termSource":"NCI"},{"termName":"NDLS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nanosomal Docetaxel Lipid Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"752055"},{"name":"NCI_META_CUI","value":"CL453978"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752055"},{"name":"PDQ_Open_Trial_Search_ID","value":"752055"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96429":{"preferredName":"Napabucasin","code":"C96429","definitions":[{"definition":"An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Napabucasin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Acetylnaphtho(2,3-b)furan-4,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"BB608","termGroup":"CN","termSource":"NCI"},{"termName":"BBI-608","termGroup":"CN","termSource":"NCI"},{"termName":"BBI608","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83280-65-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z1HHM49K7O"},{"name":"Maps_To","value":"Napabucasin"},{"name":"NCI_Drug_Dictionary_ID","value":"698351"},{"name":"NCI_META_CUI","value":"CL429115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698351"},{"name":"PDQ_Open_Trial_Search_ID","value":"698351"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102850":{"preferredName":"Naphthalimide Analogue UNBS5162","code":"C102850","definitions":[{"definition":"An amonafide (naphthalimide) derivative and pan-antagonist of chemokine ligand (CXCL) expression, with potential anti-angiogenic activity. Although UNBS5162 is a derivative of amonafide, this agent appears to have a different profile to that of amonafide and its exact mechanism of action remains to be fully elucidated. This agent seems to decrease the expression of various proangiogenic CXCL chemokines in vitro and may have synergistic effects with radiotherapy or chemotherapy. CXCLs are small cytokines in the CXC chemokine family that are overexpressed in certain cancers; CXCL-mediated signaling plays a key role in angiogenesis and tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naphthalimide Analogue UNBS5162","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-(2-(Dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"UNBS5162","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"956590-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JY9JF7D78N"},{"name":"Maps_To","value":"Naphthalimide Analogue UNBS5162"},{"name":"NCI_Drug_Dictionary_ID","value":"737303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737303"},{"name":"PDQ_Open_Trial_Search_ID","value":"737303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2603824"}]}}{"C95789":{"preferredName":"Naptumomab Estafenatox","code":"C95789","definitions":[{"definition":"A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120), with immunomodulating and antineoplastic activities. The Fab moiety of naptumomab estafenatox binds to 5T4, an antigen expressed by various tumor cells. In turn, the superantigen binds to both major histocompatibility complex class II molecules and to the T-cell receptor beta chain, which results in a massive activation of T lymphocytes and induces a potent T-cell-mediated killing of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naptumomab Estafenatox","termGroup":"PT","termSource":"NCI"},{"termName":"ABR-217620","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"676258-98-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"93T929W6LC"},{"name":"Maps_To","value":"Naptumomab Estafenatox"},{"name":"NCI_Drug_Dictionary_ID","value":"355730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355730"},{"name":"PDQ_Open_Trial_Search_ID","value":"355730"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742795"}]}}{"C115110":{"preferredName":"Naquotinib","code":"C115110","definitions":[{"definition":"An orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naquotinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinecarboxamide, 6-Ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"ASP8273","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448232-80-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"47DD4548PB"},{"name":"Maps_To","value":"Naquotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"760029"},{"name":"NCI_META_CUI","value":"CL472641"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760029"},{"name":"PDQ_Open_Trial_Search_ID","value":"760029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91382":{"preferredName":"Narnatumab","code":"C91382","definitions":[{"definition":"A fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor), with potential antineoplastic activity. Anti-RON monoclonal antibody IMC-RON8 binds to RON, thereby preventing binding of its ligand hepatocyte growth factor-like protein (HGFL or macrophage-stimulating protein (MSP)). This may prevent RON receptor-mediated signaling and may prevent cellular proliferation in tumor cells overexpressing RON. RON, a receptor tyrosine kinase, is overexpressed in a variety of epithelial cancer cell types and plays an important role in cellular proliferation, migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Narnatumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-RON Monoclonal Antibody IMC-RON8","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-RON8","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188275-92-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R42YK40U9M"},{"name":"Maps_To","value":"Narnatumab"},{"name":"NCI_Drug_Dictionary_ID","value":"673714"},{"name":"NCI_META_CUI","value":"CL421584"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673714"},{"name":"PDQ_Open_Trial_Search_ID","value":"673714"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77862":{"preferredName":"Natalizumab","code":"C77862","definitions":[{"definition":"A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities.  Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue.  Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Natalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"AN100226","termGroup":"CN","termSource":"NCI"},{"termName":"Antegren","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-alph4 Integrin Monoclonal Antibody AN100226","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-VLA4","termGroup":"AB","termSource":"NCI"},{"termName":"Tysabri","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple sclerosis, Crohn's disease"},{"name":"CAS_Registry","value":"189261-10-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3JB47N2Q2P"},{"name":"Legacy Concept Name","value":"Natalizumab"},{"name":"Maps_To","value":"Natalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"596513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596513"},{"name":"PDQ_Open_Trial_Search_ID","value":"596513"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1172734"}]}}{"C71159":{"preferredName":"Natural IFN-alpha OPC-18","code":"C71159","definitions":[{"definition":"A proprietary preparation of natural human interferon alpha (IFN alpha) with potential immunomodulatory and antineoplastic activities. Natural human interferon alpha OPC-18 binds to cell-surface IFN alpha receptors (IFNARs), resulting in the transcription and translation of genes whose products mediate antiviral, antiproliferative, and immune-modulating effects. IFN alpha is a type I interferon produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products and is the primary interferon produced by virus-induced leukocyte cultures. In addition to its pronounced antiviral activity, it activates NK cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Natural IFN-alpha OPC-18","termGroup":"PT","termSource":"NCI"},{"termName":"nIFN-alpha OPC-18","termGroup":"AB","termSource":"NCI"},{"termName":"OPC-18","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Natural_IFN-alpha_OPC-18"},{"name":"Maps_To","value":"Natural IFN-alpha OPC-18"},{"name":"NCI_Drug_Dictionary_ID","value":"571792"},{"name":"NCI_META_CUI","value":"CL376209"},{"name":"PDQ_Closed_Trial_Search_ID","value":"571792"},{"name":"PDQ_Open_Trial_Search_ID","value":"571792"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85466":{"preferredName":"Natural Killer Cells ZRx101","code":"C85466","definitions":[{"definition":"A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Natural Killer Cells ZRx101","termGroup":"PT","termSource":"NCI"},{"termName":"NK Cells ZRx101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Natural Killer Cells ZRx101"},{"name":"NCI_Drug_Dictionary_ID","value":"643814"},{"name":"NCI_META_CUI","value":"CL412341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643814"},{"name":"PDQ_Open_Trial_Search_ID","value":"643814"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156730":{"preferredName":"Navarixin","code":"C156730","definitions":[{"definition":"An orally available small molecule antagonist of the C-X-C motif chemokine receptor 1 (CXCR1; interleukin-8 receptor alpha; IL8RA) and 2 (CXCR2; interleukin-8 receptor beta; IL8RB), with potential immunomodulating and antineoplastic activities. Upon administration, navarixin binds to and inhibits the activation of CXCR 1 and 2. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR 1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance, myeloid cell suppression, and inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navarixin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Hydroxy-N,N-dimethyl-3-((2-((1R)-1-(5-methylfuran-2-yl)propyl)amine)-3,4- dioxocyclobut-1-enyl)amino)benzamide Monohydrate","termGroup":"SN","termSource":"NCI"},{"termName":"MK-7123","termGroup":"CN","termSource":"NCI"},{"termName":"PS291822","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 527123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"862464-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7V3BY6G538"},{"name":"Maps_To","value":"Navarixin"},{"name":"NCI_Drug_Dictionary_ID","value":"795588"},{"name":"NCI_META_CUI","value":"CL935858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795588"},{"name":"PDQ_Open_Trial_Search_ID","value":"795588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64776":{"preferredName":"Navitoclax","code":"C64776","definitions":[{"definition":"A substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying. It is a type of Bcl-2 family inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active, synthetic small molecule and an antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. Navitoclax selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w, which are frequently overexpressed in a wide variety of cancers, including those of the lymph, breast, lung, prostate, and colon, and are linked to tumor drug resistance. Inhibition of these apoptosis suppressors prevents their binding to the apoptotic effectors Bax and Bak proteins, thereby triggering apoptotic processes in cells overexpressing Bcl-2, Bcl-XL, and Bcl-w. This eventually reduces tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navitoclax","termGroup":"PT","termSource":"NCI"},{"termName":"A-855071.0","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-263","termGroup":"CN","termSource":"NCI"},{"termName":"BcI-2 Family Protein Inhibitor ABT-263","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923564-51-6"},{"name":"Chemical_Formula","value":"C47H55ClF3N5O6S3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XKJ5VVK2WD"},{"name":"Legacy Concept Name","value":"ABT-263"},{"name":"Maps_To","value":"Navitoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"523413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"523413"},{"name":"PDQ_Open_Trial_Search_ID","value":"523413"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2975395"}]}}{"C113793":{"preferredName":"Navoximod","code":"C113793","definitions":[{"definition":"An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, navoximod targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and plays an important role in immunosuppression. Tryptophan depletion is associated with immunosuppression caused by T-cell suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navoximod","termGroup":"PT","termSource":"NCI"},{"termName":"5H-Imidazo(5,1-a)isoindole-5-ethanol, 6-Fluoro-alpha-(trans-4-hydroxycyclohexyl)-, (AlphaR,5S)-","termGroup":"SN","termSource":"NCI"},{"termName":"GDC-0919","termGroup":"CN","termSource":"NCI"},{"termName":"NLG-919","termGroup":"CN","termSource":"NCI"},{"termName":"NLG919","termGroup":"CN","termSource":"NCI"},{"termName":"RG6078","termGroup":"CN","termSource":"NCI"},{"termName":"RO7077339-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1402837-78-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"926SHL95NC"},{"name":"Maps_To","value":"Navoximod"},{"name":"NCI_Drug_Dictionary_ID","value":"757383"},{"name":"NCI_META_CUI","value":"CL471774"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757383"},{"name":"PDQ_Open_Trial_Search_ID","value":"757383"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111687":{"preferredName":"Navy Bean Powder","code":"C111687","definitions":[{"definition":"The powder form of the cooked navy bean with potential antioxidant and chemopreventive activities. Navy beans are rich in fiber, minerals, vitamins, and phytochemicals such as flavonoids and phytosterols. They appear to prevent carcinogenesis by inducing tumor cell apoptosis. Intake of navy bean powder may have a beneficial effect on intestinal microflora.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Navy Bean Powder","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Navy Bean Powder"},{"name":"NCI_Drug_Dictionary_ID","value":"752815"},{"name":"NCI_META_CUI","value":"CL454077"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752815"},{"name":"PDQ_Open_Trial_Search_ID","value":"752815"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123428":{"preferredName":"Naxitamab","code":"C123428","definitions":[{"definition":"A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naxitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized","termGroup":"SY","termSource":"NCI"},{"termName":"Danyelza","termGroup":"BR","termSource":"NCI"},{"termName":"Hu3F8","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Anti-GD2 Antibody 3F8","termGroup":"SY","termSource":"NCI"},{"termName":"Humanized Monoclonal Antibody Hu3f8-IGG1","termGroup":"SY","termSource":"NCI"},{"termName":"Naxitamab-gqgk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"high-risk neuroblastoma in bone or bone marrow"},{"name":"CAS_Registry","value":"1879925-92-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9K8GNJ2874"},{"name":"Maps_To","value":"Naxitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"778692"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778692"},{"name":"PDQ_Open_Trial_Search_ID","value":"778692"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054758"}]}}{"C115109":{"preferredName":"Nazartinib","code":"C115109","definitions":[{"definition":"An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nazartinib","termGroup":"PT","termSource":"NCI"},{"termName":"EGF 816","termGroup":"CN","termSource":"NCI"},{"termName":"EGF816","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1508250-71-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KE7K32EME8"},{"name":"Maps_To","value":"Nazartinib"},{"name":"NCI_Drug_Dictionary_ID","value":"760001"},{"name":"NCI_META_CUI","value":"CL472640"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760001"},{"name":"PDQ_Open_Trial_Search_ID","value":"760001"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123825":{"preferredName":"Mulnitorsen","code":"C123825","definitions":[{"definition":"A proprietary antisense oligonucleotide targeting a novel non-coding mitochondrial RNA (ncmtRNA), with potential antineoplastic activity. Upon administration, mulnitorsen binds to ncmtRNA, which is overexpressed in rapidly proliferating cells, such as cancer cells, and not expressed in resting cells. This may decrease the expression of the ncmtRNA, which may inhibit cell proliferation and eventually induce apoptosis in susceptible cancer cells. The proprietary mitochondrial RNA (mtRNA) belongs to the family of non-coding RNAs (ncRNA); it contains an inverted repeat (IR) of 815 nucleotides (nt), which can form a covalent link to the 5' end of the mitochondrial 16S ribosomal RNA (16S mtrRNA).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mulnitorsen","termGroup":"PT","termSource":"NCI"},{"termName":"Andes-1537","termGroup":"CN","termSource":"NCI"},{"termName":"ncmtRNA Oligonucleotide Andes-1537","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2576358-63-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0DYR6BJ4AG"},{"name":"Maps_To","value":"ncmtRNA Oligonucleotide Andes-1537"},{"name":"NCI_Drug_Dictionary_ID","value":"775628"},{"name":"NCI_META_CUI","value":"CL498219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775628"},{"name":"PDQ_Open_Trial_Search_ID","value":"775628"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88281":{"preferredName":"Necitumumab","code":"C88281","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8","termGroup":"SY","termSource":"NCI"},{"termName":"IMC 11F8","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-11F8","termGroup":"CN","termSource":"NCI"},{"termName":"IMC11F8","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor (Receptor Tyrosine-Protein Kinase ErbB-1, EC 2.7.10.1)); Human Monoclonal IMC-11F8 Gamma1 Heavy Chain (224-214')-Disulfide with Human Monoclonal IMC-11F8 Kappa Light Chain, Dimer (230- 230'':233-233'')-Bisdisulfide","termGroup":"SY","termSource":"NCI"},{"termName":"Portrazza","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic squamous non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"906805-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2BT4C47RUI"},{"name":"Maps_To","value":"Necitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"656651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"656651"},{"name":"PDQ_Open_Trial_Search_ID","value":"656651"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2352806"}]}}{"C61099":{"preferredName":"Nedaplatin","code":"C61099","definitions":[{"definition":"A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nedaplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(Glycolato-O,O')diammineplatinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"254-S","termGroup":"CN","termSource":"NCI"},{"termName":"CDGP","termGroup":"AB","termSource":"NCI"},{"termName":"cis-Diammine(glucolato)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"NDP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95734-82-0"},{"name":"CHEBI_ID","value":"CHEBI:31898"},{"name":"Chemical_Formula","value":"C2H2O3.Pt.2H3N"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8UQ3W6JXAN"},{"name":"Legacy Concept Name","value":"Nedaplatin"},{"name":"Maps_To","value":"Nedaplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"468844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468844"},{"name":"PDQ_Open_Trial_Search_ID","value":"468844"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0093999"}]}}{"C136418":{"preferredName":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464","code":"C136418","definitions":[{"definition":"An inhibitor of NEDD8 (neural precursor cell expressed, developmentally down-regulated 8) activating enzyme E1 (NAE), with potential antineoplastic activity. Upon administration, TAS4464 selectively binds to and inhibits NAE, which prevents NAE/NEDD8-mediated signaling and prevents the NEDD8 conjugation of cullin-RING ligase complexes (CRLs). This inactivates the CRLs leading to an accumulation of CRL substrate proteins, such as CDT1, p27, p21 and phosphorylated IkappaB, and inactivates nuclear factor-kappaB (NF-kB) as well as downregulates anti-apoptotic proteins. This causes cell cycle dysregulation, induces apoptosis, and inhibits tumor cell proliferation and survival. NAE catalyzes the first step in the NEDD8 conjugation (neddylation) pathway which controls cancer cell growth and survival through activation of CRLs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464","termGroup":"PT","termSource":"NCI"},{"termName":"NAE Inhibitor TAS4464","termGroup":"SY","termSource":"NCI"},{"termName":"TAS4464","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NEDD8 Activating Enzyme E1 Inhibitor TAS4464"},{"name":"NCI_Drug_Dictionary_ID","value":"789222"},{"name":"NCI_META_CUI","value":"CL523721"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789222"},{"name":"PDQ_Open_Trial_Search_ID","value":"789222"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120036":{"preferredName":"Peposertib","code":"C120036","definitions":[{"definition":"An orally bioavailable inhibitor of DNA-dependent protein kinase (DNA-PK) with potential antineoplastic activity, and potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, peposertib binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peposertib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-","termGroup":"SY","termSource":"NCI"},{"termName":"M 3814","termGroup":"CN","termSource":"NCI"},{"termName":"M-3814","termGroup":"CN","termSource":"NCI"},{"termName":"M3814","termGroup":"CN","termSource":"NCI"},{"termName":"MSC 2490484A","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-2490484A","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2490484A","termGroup":"CN","termSource":"NCI"},{"termName":"Nedisertib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637542-33-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GN429E725A"},{"name":"Maps_To","value":"Nedisertib"},{"name":"Maps_To","value":"Peposertib"},{"name":"NCI_Drug_Dictionary_ID","value":"767372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767372"},{"name":"PDQ_Open_Trial_Search_ID","value":"767372"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896805"}]}}{"C1704":{"preferredName":"Nelarabine","code":"C1704","definitions":[{"definition":"A drug used to treat certain types of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nelarabine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino, 6-Methoxypurine Arabinoside","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine","termGroup":"SN","termSource":"NCI"},{"termName":"506U78","termGroup":"CN","termSource":"NCI"},{"termName":"Arranon","termGroup":"BR","termSource":"NCI"},{"termName":"Compound 506U78","termGroup":"SY","termSource":"NCI"},{"termName":"GW506U78","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma"},{"name":"CAS_Registry","value":"121032-29-9"},{"name":"CHEBI_ID","value":"CHEBI:63612"},{"name":"Chemical_Formula","value":"C11H15N5O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"60158CV180"},{"name":"Legacy Concept Name","value":"Nelarabine"},{"name":"Maps_To","value":"Nelarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"43260"},{"name":"NSC Number","value":"686673"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43260"},{"name":"PDQ_Open_Trial_Search_ID","value":"43260"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0907349"}]}}{"C117985":{"preferredName":"Nelipepimut-S","code":"C117985","definitions":[{"definition":"A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nelipepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"E75 Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-","termGroup":"SY","termSource":"NCI"},{"termName":"Nelipepimut S","termGroup":"SY","termSource":"NCI"},{"termName":"NeuVax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160212-35-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7M0A29CD8B"},{"name":"Maps_To","value":"Nelipepimut-S"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3898150"}]}}{"C99228":{"preferredName":"Nelipepimut-S Plus GM-CSF Vaccine","code":"C99228","definitions":[{"definition":"A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nelipepimut-S Plus GM-CSF Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"E75 Plus GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"E75 Vaccine Plus GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Nelipepimut-S Plus Sargramostim","termGroup":"SY","termSource":"NCI"},{"termName":"NeuVax Plus GM-CSF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nelipepimut-S Plus GM-CSF Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"719080"},{"name":"NCI_META_CUI","value":"CL433057"},{"name":"PDQ_Closed_Trial_Search_ID","value":"719080"},{"name":"PDQ_Open_Trial_Search_ID","value":"719080"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C83999":{"preferredName":"Nemorubicin","code":"C83999","definitions":[{"definition":"A morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450 CYP3A enzyme to a highly cytotoxic derivative. Unlike most anthracyclines, nemorubicin is a topoisomerase I inhibitor and appears to exert its effect through the nucleotide excision repair (NER) system. In addition, this agent does not show cross-resistance with other anthracyclines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemorubicin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"108852-90-0"},{"name":"CHEBI_ID","value":"CHEBI:42053"},{"name":"Chemical_Formula","value":"C32H37NO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7618O47BQM"},{"name":"Maps_To","value":"Nemorubicin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827283"}]}}{"C84000":{"preferredName":"Nemorubicin Hydrochloride","code":"C84000","definitions":[{"definition":"The hydrochloride salt form of nemorubicin, a morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450 CYP3A enzyme to a highly cytotoxic derivative. Unlike most anthracyclines, nemorubicin is a topoisomerase I inhibitor and appears to exert its effect through the nucleotide excision repair (NER) system. In addition, this agent does not show cross-resistance with other anthracyclines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nemorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5,12-Naphthacenedione, 7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-10-((2,3,6-Trideoxy-3-((2S)-2-Methoxy-4-Morpholinyl)-Alpha-L-Lyxo-Hexopyranosyl)Oxy)-, Hydrochloride, (8S,10S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"108943-08-4"},{"name":"Chemical_Formula","value":"C32H37NO13.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2Q6F8JYX76"},{"name":"Maps_To","value":"Nemorubicin Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827284"}]}}{"C162874":{"preferredName":"Neoantigen Vaccine GEN-009","code":"C162874","definitions":[{"definition":"A peptide-based, personalized cancer vaccine consisting of patient-specific mutated synthetic long peptides (SLPs), which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon subcutaneous vaccination with the personalized neoantigen peptide vaccine GEN-009, and administration along with the immunoadjuvant poly-ICLC, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The Antigen Lead Acquisition System (ATLAS) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T-cells and will be incorporated into GEN-009 in the form of SLPs. Each personalized vaccine contains between four and twenty SLPs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen Vaccine GEN-009","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-009 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"GEN009","termGroup":"CN","termSource":"NCI"},{"termName":"Personalized Cancer Vaccine GEN-009","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen Vaccine GEN-009"},{"name":"NCI_Drug_Dictionary_ID","value":"798938"},{"name":"NCI_META_CUI","value":"CL973355"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798938"},{"name":"PDQ_Open_Trial_Search_ID","value":"798938"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118960":{"preferredName":"Neoantigen-based Glioblastoma Vaccine","code":"C118960","definitions":[{"definition":"A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes (neoantigens), with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based glioblastoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens are tumor-specific antigens derived from mutated proteins that are present only in a specific tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Glioblastoma Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NeoVax (TM) Glioblastoma Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen Glioblastoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Glioblastoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"766449"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766449"},{"name":"PDQ_Open_Trial_Search_ID","value":"766449"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3898149"}]}}{"C112003":{"preferredName":"Neoantigen-based Melanoma-Poly-ICLC Vaccine","code":"C112003","definitions":[{"definition":"A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Melanoma-Poly-ICLC Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NeoVax Melanoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Melanoma-Poly-ICLC Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"754239"},{"name":"NCI_META_CUI","value":"CL454292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754239"},{"name":"PDQ_Open_Trial_Search_ID","value":"754239"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158694":{"preferredName":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine","code":"C158694","definitions":[{"definition":"A peptide-based renal cell carcinoma (RCC) vaccine consisting of neoantigens and peptides derived from immunogenic epitopes identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based RCC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"NeoVax RCC Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"NeoVax Renal Cell Carcinoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"797484"},{"name":"NCI_META_CUI","value":"CL950784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797484"},{"name":"PDQ_Open_Trial_Search_ID","value":"797484"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165514":{"preferredName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903","code":"C165514","definitions":[{"definition":"A cancer priming vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of neoantigen-based therapeutic cancer vaccine GRT-C903, followed by the boosting vaccine GRT-R904, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903","termGroup":"PT","termSource":"NCI"},{"termName":"GRT C903","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-C903","termGroup":"CN","termSource":"NCI"},{"termName":"GRTC903","termGroup":"CN","termSource":"NCI"},{"termName":"Priming Cancer Vaccine GRT-C903","termGroup":"SY","termSource":"NCI"},{"termName":"Priming Vaccine GRT-C903","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Neoantigen Cancer Vaccine Prime GRT-C903","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Neoantigen Priming Cancer Vaccine GRT-C903","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Therapeutic Cancer Vaccine GRT-C903"},{"name":"NCI_Drug_Dictionary_ID","value":"799972"},{"name":"NCI_META_CUI","value":"CL978704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799972"},{"name":"PDQ_Open_Trial_Search_ID","value":"799972"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165515":{"preferredName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904","code":"C165515","definitions":[{"definition":"A cancer boosting vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-based therapeutic cancer vaccine GRT-R904, which is administered after the initial administration of the priming vaccine GRT-C903, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904","termGroup":"PT","termSource":"NCI"},{"termName":"Boosting Cancer Vaccine GRT-R904","termGroup":"SY","termSource":"NCI"},{"termName":"Boosting Vaccine GRT-R904","termGroup":"SY","termSource":"NCI"},{"termName":"GRT R904","termGroup":"CN","termSource":"NCI"},{"termName":"GRT-R904","termGroup":"CN","termSource":"NCI"},{"termName":"GRTR904","termGroup":"CN","termSource":"NCI"},{"termName":"Shared Neoantigen Boosting Cancer Vaccine GRT-R904","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Neoantigen Cancer Vaccine Boost GRT-R904","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-based Therapeutic Cancer Vaccine GRT-R904"},{"name":"NCI_Drug_Dictionary_ID","value":"799974"},{"name":"NCI_META_CUI","value":"CL978705"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799974"},{"name":"PDQ_Open_Trial_Search_ID","value":"799974"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C135018":{"preferredName":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017","code":"C135018","definitions":[{"definition":"A proprietary, personalized autologous synthetic cancer vaccine composed of patient-specific synthetic cancer neo-epitopes complexed with heat shock protein 70 (HSP 70; HSP70), with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-HSP70 peptide cancer vaccine AGEN2017, the HSPs present the neoantigens to antigen presenting cells (APCs) and help elicit a potent neoantigen-specific T-cell-based anti-tumor immune response, thereby killing the neoantigen-expressing cancer cells. HSP70 is able to the transport the neo-epitopes, activate APCs and enhance the T-cell-mediated immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 2017","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-2017","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN2017","termGroup":"CN","termSource":"NCI"},{"termName":"ASV","termGroup":"BR","termSource":"NCI"},{"termName":"ASV AGEN2017","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Cancer Vaccine AGEN2017","termGroup":"SY","termSource":"NCI"},{"termName":"AutoSynVax","termGroup":"BR","termSource":"NCI"},{"termName":"AutoSynVax AGEN2017","termGroup":"SY","termSource":"NCI"},{"termName":"AutoSynVax Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Neoantigen Vaccine AGEN2017","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017"},{"name":"NCI_Drug_Dictionary_ID","value":"788954"},{"name":"NCI_META_CUI","value":"CL523816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788954"},{"name":"PDQ_Open_Trial_Search_ID","value":"788954"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49094":{"preferredName":"Neratinib","code":"C49094","definitions":[{"definition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neratinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide","termGroup":"SY","termSource":"NCI"},{"termName":"2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"HKI 272","termGroup":"CN","termSource":"NCI"},{"termName":"HKI-272","termGroup":"CN","termSource":"NCI"},{"termName":"HKI272","termGroup":"CN","termSource":"NCI"},{"termName":"PB 272","termGroup":"CN","termSource":"NCI"},{"termName":"PB-272","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"early stage HER2-overexpressed/amplified breast cancer"},{"name":"CAS_Registry","value":"698387-09-6"},{"name":"CHEBI_ID","value":"CHEBI:61397"},{"name":"Chemical_Formula","value":"C30H29ClN6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JJH94R3PWB"},{"name":"Legacy Concept Name","value":"KI-272"},{"name":"Maps_To","value":"Neratinib"},{"name":"NCI_Drug_Dictionary_ID","value":"453548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453548"},{"name":"PDQ_Open_Trial_Search_ID","value":"453548"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1704439"}]}}{"C136891":{"preferredName":"Neratinib Maleate","code":"C136891","definitions":[{"definition":"The maleate salt form of neratinib, an orally available, quinazoline-based, irreversible inhibitor of both the receptor tyrosine kinases (RTKs) human epidermal growth factor receptor 2 (HER2; ERBB2) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, neratinib targets and covalently binds to the cysteine residue in the ATP-binding pockets of both HER2 and EGFR. This inhibits their activity and results in the inhibition of downstream signal transduction events, induces cell cycle arrest, apoptosis and ultimately decreases cellular proliferation in HER2- and EGFR-expressing tumor cells. EGFR and HER2, RTKs that are mutated or overactivated in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neratinib Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"HKI-272 Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"Nerlynx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"early stage HER2-overexpressed/amplified breast cancer"},{"name":"CAS_Registry","value":"915942-22-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RM7XY23ZS"},{"name":"Maps_To","value":"Neratinib Maleate"},{"name":"NCI_META_CUI","value":"CL524716"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95712":{"preferredName":"Nesvacumab","code":"C95712","definitions":[{"definition":"A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nesvacumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ANG2 MOAB REGN910","termGroup":"SY","termSource":"NCI"},{"termName":"REGN910","termGroup":"CN","termSource":"NCI"},{"termName":"SAR307746","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1296818-77-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WX8293WGLC"},{"name":"Maps_To","value":"Nesvacumab"},{"name":"NCI_Drug_Dictionary_ID","value":"693224"},{"name":"NCI_META_CUI","value":"CL428177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693224"},{"name":"PDQ_Open_Trial_Search_ID","value":"693224"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96232":{"preferredName":"NG-nitro-L-arginine","code":"C96232","definitions":[{"definition":"An amino acid derivative and nitric oxide synthase (NOS) inhibitor with potential antineoplastic and antiangiogenic activities. Upon administration, NG-nitro-L-arginine inhibits the enzyme nitric oxide synthase, thereby preventing the formation of nitric oxide (NO). By preventing NO generation, the vasodilatory effects of NO are abrogated leading to vasoconstriction, reduction in vascular permeability and an inhibition of angiogenesis. As blood flow to tumors is restricted, this may result in an inhibition of tumor cell proliferation. NO plays an important role in tumor blood flow and stimulation of angiogenesis, tumor progression, survival, migration and invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NG-nitro-L-arginine","termGroup":"PT","termSource":"NCI"},{"termName":"L-NNA","termGroup":"AB","termSource":"NCI"},{"termName":"NOLA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2149-70-4"},{"name":"CHEBI_ID","value":"CHEBI:27960"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7O8V7H6P2J"},{"name":"Maps_To","value":"NG-nitro-L-arginine"},{"name":"NCI_Drug_Dictionary_ID","value":"697835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697835"},{"name":"PDQ_Open_Trial_Search_ID","value":"697835"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068821"}]}}{"C2327":{"preferredName":"Niacinamide","code":"C2327","definitions":[{"definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacinamide helps some enzymes make energy in the cell. It is found in many plant and animal products. It is water-soluble (can dissolve in water) and must be taken in daily. It is being studied to increase the effect of radiation therapy on tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The active form of vitamin B3 and a component of the coenzyme nicotinamide adenine dinucleotide (NAD). Niacinamide acts as a chemo- and radio-sensitizing agent by enhancing tumor blood flow, thereby reducing tumor hypoxia.  This agent also inhibits poly(ADP-ribose) polymerases, enzymes involved in the rejoining of DNA strand breaks induced by radiation or chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niacinamide","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinecarboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Nicamid","termGroup":"FB","termSource":"NCI"},{"termName":"Nicosedine","termGroup":"FB","termSource":"NCI"},{"termName":"Nicotinamide","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotinamidum","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotinic Acid Amide","termGroup":"SY","termSource":"NCI"},{"termName":"Nicotylamide","termGroup":"SY","termSource":"NCI"},{"termName":"Pellagra-Preventing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Vitamin PP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Pellegra, treatment and prophylaxis; Various dermatologic conditions"},{"name":"CAS_Registry","value":"98-92-0"},{"name":"CHEBI_ID","value":"CHEBI:17154"},{"name":"Chemical_Formula","value":"C6H6N2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"25X51I8RD4"},{"name":"Legacy Concept Name","value":"Niacinamide"},{"name":"Maps_To","value":"Niacinamide"},{"name":"NCI_Drug_Dictionary_ID","value":"42044"},{"name":"NSC Number","value":"13128"},{"name":"NSC Number","value":"27452"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42044"},{"name":"PDQ_Open_Trial_Search_ID","value":"42044"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"UMLS_CUI","value":"C0028027"}]}}{"C66240":{"preferredName":"Niclosamide","code":"C66240","definitions":[{"definition":"An orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Upon oral administration, niclosamide specifically induces degradation of the androgen receptor (AR) variant V7 (AR-V7) through the proteasome-mediated pathway. This downregulates the expression of the AR variant, inhibits AR-V7-mediated transcriptional activity, and reduces AR-V7 recruitment to the prostate-specific antigen (PSA) gene promoter. Niclosamide also prevents AR-V7-mediated STAT3 phosphorylation and activation. This inhibits AR/STAT3-mediated signaling and prevents expression of STAT3 target genes. Altogether, this may inhibit growth of AR-V7-overexpressing cancer cells. The AR-V7 variant, which is encoded by contiguous splicing of AR exons 1/2/3/CE3, is upregulated in a variety of cancer cell types, and is associated with both cancer progression and resistance to AR-targeted therapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niclosamide","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Salicylanilide, 2',5-Dichloro-4'-nitro-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-65-7"},{"name":"Chemical_Formula","value":"C13H8Cl2N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8KK8CQ2K8G"},{"name":"Legacy Concept Name","value":"Niclosamide"},{"name":"Maps_To","value":"Niclosamide"},{"name":"NCI_Drug_Dictionary_ID","value":"775866"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775866"},{"name":"PDQ_Open_Trial_Search_ID","value":"775866"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699963"}]}}{"C158078":{"preferredName":"Nicotinamide Riboside","code":"C158078","definitions":[{"definition":"An orally available form of vitamin B3 and precursor of nicotinamide adenine dinucleotide (NAD+) with potential use in the treatment of chemotherapy induced peripheral neuropathy (CIPN). Upon oral administration, nicotinamide riboside (NR) is converted to nicotinamide mononucleotide by the NR kinases, nicotinamide riboside kinase 1 (NRK 1) and nicotinamide riboside kinase 2 (NRK 2), to which a second adenine is transferred by nicotinamide mononucleotide adenylyl transferase to generate NAD+. NAD+, an essential redox coenzyme, may offer protective effects against axonal injury from both mechanical and neurotoxic injury, and maintenance of NAD+ may be protective in mitochondrial disease. NR may help elevate and maintain NAD+ levels, which may ameliorate potential mechanisms implicated in the development of CIPN including mitochondrial dysfunction and peripheral nerve degeneration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nicotinamide Riboside","termGroup":"PT","termSource":"NCI"},{"termName":"Niagen","termGroup":"BR","termSource":"NCI"},{"termName":"NR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1341-23-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0I8H2M0L7N"},{"name":"Maps_To","value":"Nicotinamide Riboside"},{"name":"NCI_Drug_Dictionary_ID","value":"797351"},{"name":"NCI_META_CUI","value":"CL937699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797351"},{"name":"PDQ_Open_Trial_Search_ID","value":"797351"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Vitamin"}]}}{"C153375":{"preferredName":"Nidanilimab","code":"C153375","definitions":[{"definition":"A low fucose, fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) against the interleukin 1 receptor accessory protein (interleukin-1 receptor associated protein; IL1RAP), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, nidanilimab targets and binds to IL1RAP, thereby preventing IL1RAP-mediated signaling, and disrupting IL-1 and IL-33 mediated nuclear factor kappa beta (NFkB) activation. This prevents the secretion of tumor stimulating cytokines, decreases tumor inflammation and inhibits tumor cell proliferation. In addition, nidanilimab induces antibody-dependent cellular cytotoxicity (ADCC), and stimulates natural killer (NK) cells to attack tumor cells, thereby killing the IL1RAP-poisitive tumor cells. IL1RAP, a co-receptor of the IL-1 receptor (IL1R1) and the IL-33 receptor (ST2), is upregulated in certain tumor cells, and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nidanilimab","termGroup":"PT","termSource":"NCI"},{"termName":"CAN 04","termGroup":"CN","termSource":"NCI"},{"termName":"CAN-04","termGroup":"CN","termSource":"NCI"},{"termName":"CAN04","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2171061-85-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ND296JF21I"},{"name":"Maps_To","value":"Nidanilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"793891"},{"name":"NCI_META_CUI","value":"CL554531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793891"},{"name":"PDQ_Open_Trial_Search_ID","value":"793891"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71734":{"preferredName":"Nifurtimox","code":"C71734","definitions":[{"definition":"A nitrofuran derivative with antiprotozoal and potential antineoplastic activities. Nifurtimox is reduced by cytosol enzymes or flavin-containing microsomal enzymes to a highly reactive nitro anion free radical; autooxidation of the nitro anion free radical generates cytotoxic superoxide anion (02-). In addition, nifurtimox-derived nitro anion free radicals may alkylate macromolecules such as nucleic acids and proteins, resulting in the disruption of their structure and function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nifurtimox","termGroup":"PT","termSource":"NCI"},{"termName":"4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 2502","termGroup":"CN","termSource":"NCI"},{"termName":"BAYER 2502","termGroup":"CN","termSource":"NCI"},{"termName":"Lampit","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23256-30-6"},{"name":"Chemical_Formula","value":"C10H13N3O5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M84I3K7C2O"},{"name":"Legacy Concept Name","value":"Nifurtimox"},{"name":"Maps_To","value":"Nifurtimox"},{"name":"NCI_Drug_Dictionary_ID","value":"558911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558911"},{"name":"PDQ_Open_Trial_Search_ID","value":"558911"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028073"}]}}{"C48375":{"preferredName":"Nilotinib","code":"C48375","definitions":[{"definition":"A drug used to treat certain types of chronic myelogenous leukemia (CML). It is used in patients who have not gotten better after treatment with other anticancer drugs or who are not able to take imatinib mesylate. It is also being studied in the treatment of other types of cancer. Nilotinib blocks a protein called BCR/ABL which is made in CML cells that contain the Philadelphia chromosome (an abnormal chromosome 22 that has part of chromosome 9 attached). It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilotinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"AMN 107 Base Form","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"641571-10-0"},{"name":"CHEBI_ID","value":"CHEBI:52172"},{"name":"Chemical_Formula","value":"C28H22F3N7O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F41401512X"},{"name":"Legacy Concept Name","value":"AMN107"},{"name":"Maps_To","value":"Nilotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"435988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"435988"},{"name":"PDQ_Open_Trial_Search_ID","value":"435988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721377"}]}}{"C95223":{"preferredName":"Nilotinib Hydrochloride Anhydrous","code":"C95223","definitions":[{"definition":"The hydrochloride salt of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilotinib Hydrochloride Anhydrous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923288-95-3"},{"name":"Chemical_Formula","value":"C28H22F3N7O.HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K37N7BYX3X"},{"name":"Maps_To","value":"Nilotinib Hydrochloride Anhydrous"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987005"}]}}{"C95229":{"preferredName":"Nilotinib Hydrochloride Monohydrate","code":"C95229","definitions":[{"definition":"The monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilotinib Hydrochloride Monohydrate","termGroup":"PT","termSource":"NCI"},{"termName":"4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"AMN 107","termGroup":"CN","termSource":"NCI"},{"termName":"AMN-107","termGroup":"CN","termSource":"NCI"},{"termName":"AMN107","termGroup":"CN","termSource":"NCI"},{"termName":"Nilotinib Monohydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Tasigna","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"923288-90-8"},{"name":"Chemical_Formula","value":"C28H22F3N7O.HCl.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5JHU0N1R6K"},{"name":"Maps_To","value":"Nilotinib Hydrochloride Monohydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"435988"},{"name":"PDQ_Closed_Trial_Search_ID","value":"435988"},{"name":"PDQ_Open_Trial_Search_ID","value":"435988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1966375"}]}}{"C1173":{"preferredName":"Nilutamide","code":"C1173","definitions":[{"definition":"A drug that blocks the effects of male hormones in the body. It is a type of antiandrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nilutamide","termGroup":"PT","termSource":"NCI"},{"termName":"1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-3,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"5,5-Dimethyl-3-[4-nitro-3-(trifluoro-methyl)phenyl]-2,4-imidazolidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"Anandron","termGroup":"FB","termSource":"NCI"},{"termName":"Nilandron","termGroup":"BR","termSource":"NCI"},{"termName":"RU-23908","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Prostate cancer"},{"name":"CAS_Registry","value":"63612-50-0"},{"name":"CHEBI_ID","value":"CHEBI:7573"},{"name":"Chemical_Formula","value":"C12H10F3N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"51G6I8B902"},{"name":"Legacy Concept Name","value":"Nilutamide"},{"name":"Maps_To","value":"Nilutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"40450"},{"name":"NSC Number","value":"684588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40450"},{"name":"PDQ_Open_Trial_Search_ID","value":"40450"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0722107"}]}}{"C157231":{"preferredName":"Nimesulide-Hyaluronic Acid Conjugate CA102N","code":"C157231","definitions":[{"definition":"A covalently bound conjugate composed of the biological polymer sodium hyaluronate (NaHA) and the hydrophobic, cyclooxygenase 2 (COX-2) inhibitor and cytotoxic agent nimesulide (Nim), with potential antineoplastic activity. Upon intravenous administration of Nim-HA conjugate CA102N, the HA moiety targets and binds to CD44. Following endocytosis of CA102N and enzymatic degradation within the lysosomal compartment, Nim is released inside CD44-expressing tumor cells, causing Nim-mediated induction of cell cycle arrest tumor cell apoptosis and decreases tumor cell growth. In addition, Nim inhibits various tumor cell signaling pathways thereby further inhibiting tumor cell proliferation. CD44, a transmembrane glycoprotein and HA receptor expressed in healthy tissue, plays a key role in cellular growth, survival, differentiation and motility. Overexpressed in a variety of cancer cell types, CD44 plays a key role in tumor cell proliferation, migration and survival. Conjugation of HA to Nim allows for increased solubility of Nim and for targeted delivery of Nim to CD44-expressing tumor cells, thereby increasing efficacy and safety of Nim.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nimesulide-Hyaluronic Acid Conjugate CA102N","termGroup":"PT","termSource":"NCI"},{"termName":"CA 102N","termGroup":"CN","termSource":"NCI"},{"termName":"CA-102N","termGroup":"CN","termSource":"NCI"},{"termName":"CA102N","termGroup":"CN","termSource":"NCI"},{"termName":"HA-Nim Conjugate CA102N","termGroup":"SY","termSource":"NCI"},{"termName":"HA-Nimesulide","termGroup":"SY","termSource":"NCI"},{"termName":"Hyaluronic Acid Nimesulide-NH2 Bioconjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Nim-HA Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nimesulide-Hyaluronic Acid Conjugate CA102N"},{"name":"NCI_Drug_Dictionary_ID","value":"799428"},{"name":"NCI_META_CUI","value":"CL936840"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799428"},{"name":"PDQ_Open_Trial_Search_ID","value":"799428"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C692":{"preferredName":"Nimodipine","code":"C692","definitions":[{"definition":"A dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity. Nimodipine inhibits the transmembrane influx of calcium ions in response to depolarization in smooth muscle cells, thereby inhibiting vascular smooth muscle contraction and inducing vasodilatation. Nimodipine has a greater effect on cerebral arteries than on peripheral smooth muscle cells and myocardial cells, probably because this agent can cross the blood brain barrier due to its lipophilic nature. Furthermore, this agent also inhibits the drug efflux pump P-glycoprotein, which is overexpressed in some multi-drug resistant tumors, and may improve the efficacy of some antineoplastic agents.","type":"DEFINITION","source":"NCI"},{"definition":"Belongs to a family of drugs called calcium channel blockers. It is being investigated for use with anticancer drugs to prevent or overcome drug resistance and improve response to chemotherapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nimodipine","termGroup":"PT","termSource":"NCI"},{"termName":"NIMO","termGroup":"AB","termSource":"NCI"},{"termName":"Nimotop","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66085-59-4"},{"name":"CHEBI_ID","value":"CHEBI:7575"},{"name":"Chemical_Formula","value":"C21H26N2O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"57WA9QZ5WH"},{"name":"Legacy Concept Name","value":"Nimodipine"},{"name":"Maps_To","value":"Nimodipine"},{"name":"NCI_Drug_Dictionary_ID","value":"41210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41210"},{"name":"PDQ_Open_Trial_Search_ID","value":"41210"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678207"}]}}{"C2733":{"preferredName":"Nimotuzumab","code":"C2733","definitions":[{"definition":"A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Nimotuzumab binds the epidermal growth factor receptor (EGFR) and blocks cancer cells that depend on epidermal growth factor for growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nimotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"H-R3","termGroup":"CN","termSource":"NCI"},{"termName":"hR3","termGroup":"CN","termSource":"NCI"},{"termName":"Thera-CIM-hr3","termGroup":"SY","termSource":"NCI"},{"termName":"TheraCim hR3","termGroup":"SY","termSource":"NCI"},{"termName":"Theraloc","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Glioma"},{"name":"CAS_Registry","value":"828933-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6NS400BXKH"},{"name":"Legacy Concept Name","value":"TheraCim_hR3"},{"name":"Maps_To","value":"Nimotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"507582"},{"name":"PDQ_Closed_Trial_Search_ID","value":"507582"},{"name":"PDQ_Open_Trial_Search_ID","value":"507582"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1570482"}]}}{"C693":{"preferredName":"Nimustine","code":"C693","definitions":[{"definition":"A nitrosourea with antineoplastic activity. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of brain cancer. It belongs to the family of drugs called nitrosoureas.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nimustine","termGroup":"PT","termSource":"NCI"},{"termName":"3-((4-Amino-2-Methyl-5-Pyrimidinyl)Methyl)-1-(2-Chloroethyl)-1-Nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"ACNU","termGroup":"AB","termSource":"NCI"},{"termName":"N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Nidran","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42471-28-3"},{"name":"Chemical_Formula","value":"C9H13ClN6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0S726V972K"},{"name":"Legacy Concept Name","value":"Nimustine"},{"name":"Maps_To","value":"Nimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"38853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38853"},{"name":"PDQ_Open_Trial_Search_ID","value":"38853"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028096"}]}}{"C95325":{"preferredName":"Nimustine Hydrochloride","code":"C95325","definitions":[{"definition":"The hydrochloride salt of nimustine, a nitrosourea with antineoplastic activity. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nimustine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"3-((4-Amino-2-Methyl-5-Pyrimidinyl)Methyl)-1-(2-Chloroethyl)-1-Nitrosourea Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ACNU HCl","termGroup":"AB","termSource":"NCI"},{"termName":"CS 439 HCl","termGroup":"SY","termSource":"NCI"},{"termName":"N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Nidran HCl","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42471-28-3"},{"name":"CHEBI_ID","value":"CHEBI:7576"},{"name":"Chemical_Formula","value":"C9H13ClN6O2.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DFR965WKBU"},{"name":"Maps_To","value":"Nimustine Hydrochloride"},{"name":"NSC Number","value":"245382"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0771987"}]}}{"C148529":{"preferredName":"Ningetinib Tosylate","code":"C148529","definitions":[{"definition":"The tosylate salt form of ningetinib, an orally available inhibitor of the receptor tyrosine kinases c-MET/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR2 KDR), Axl (UFO), Mer, and Fms-like tyrosine kinase 3 (Flt3; CD135; STK1; FLK2), with antineoplastic activity. Upon administration, ningetinib binds to a variety of kinases, including c-Met, VEGFR2, Axl, Mer and Flt3, thereby inhibiting their signaling pathways. This inhibits growth, angiogenesis and metastasis of tumor cells that overexpress these kinases. c-Met, VEGFR2, Axl, Mer and Flt3 are overexpressed by many tumor cell types and play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ningetinib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"CT-053 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"CT-053-PTSA","termGroup":"CN","termSource":"NCI"},{"termName":"CT-053PTSA","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1394820-77-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R7I5725FES"},{"name":"Maps_To","value":"Ningetinib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"792698"},{"name":"NCI_META_CUI","value":"CL551136"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792698"},{"name":"PDQ_Open_Trial_Search_ID","value":"792698"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62765":{"preferredName":"Nintedanib","code":"C62765","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. BIBF 1120 blocks enzymes needed for cells to grow, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nintedanib","termGroup":"PT","termSource":"NCI"},{"termName":"BIBF 1120","termGroup":"CN","termSource":"NCI"},{"termName":"BIBF-1120","termGroup":"CN","termSource":"NCI"},{"termName":"BIBF1120","termGroup":"CN","termSource":"NCI"},{"termName":"Intedanib","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"Multitargeted Tyrosine Kinase Inhibitor BIBF 1120","termGroup":"SY","termSource":"NCI"},{"termName":"Vargatef","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"656247-17-5"},{"name":"Chemical_Formula","value":"C31H33N5O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G6HRD2P839"},{"name":"Legacy Concept Name","value":"BIBF_1120"},{"name":"Maps_To","value":"Nintedanib"},{"name":"NCI_Drug_Dictionary_ID","value":"504524"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504524"},{"name":"PDQ_Open_Trial_Search_ID","value":"504524"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2930789"}]}}{"C80059":{"preferredName":"Niraparib","code":"C80059","definitions":[{"definition":"An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niraparib","termGroup":"PT","termSource":"NCI"},{"termName":"MK 4827","termGroup":"CN","termSource":"NCI"},{"termName":"MK-4827","termGroup":"CN","termSource":"NCI"},{"termName":"MK4827","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1038915-60-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HMC2H89N35"},{"name":"Legacy Concept Name","value":"PARP_Inhibitor_MK4827"},{"name":"Maps_To","value":"Niraparib"},{"name":"NCI_Drug_Dictionary_ID","value":"615263"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615263"},{"name":"PDQ_Open_Trial_Search_ID","value":"615263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2744440"}]}}{"C133238":{"preferredName":"Niraparib Tosylate Monohydrate","code":"C133238","definitions":[{"definition":"An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Niraparib Tosylate Monohydrate","termGroup":"PT","termSource":"NCI"},{"termName":"2H-Indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)-, 4-Methylbenzenesulfonate, Hydrate (1:1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Zejula","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer"},{"name":"CAS_Registry","value":"1613220-15-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"195Q483UZD"},{"name":"Maps_To","value":"Niraparib Tosylate Monohydrate"},{"name":"NCI_Drug_Dictionary_ID","value":"615263"},{"name":"NCI_META_CUI","value":"CL520459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615263"},{"name":"PDQ_Open_Trial_Search_ID","value":"615263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82383":{"preferredName":"Nirogacestat","code":"C82383","definitions":[{"definition":"A selective gamma secretase (GS) inhibitor with antitumor activity. Upon administration, nirogacestat targets and binds to GS, thereby blocking the proteolytic activation of Notch receptors. This inhibits the Notch signaling pathway and results in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nirogacestat","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide","termGroup":"SY","termSource":"NCI"},{"termName":"PF 03084014","termGroup":"CN","termSource":"NCI"},{"termName":"PF-03084014","termGroup":"CN","termSource":"NCI"},{"termName":"PF03084014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1290543-63-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"QZ62892OFJ"},{"name":"Legacy Concept Name","value":"Gamma_Secretase_Inhibitor_PF-03084014"},{"name":"Maps_To","value":"Nirogacestat"},{"name":"NCI_Drug_Dictionary_ID","value":"641472"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641472"},{"name":"PDQ_Open_Trial_Search_ID","value":"641472"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830067"}]}}{"C61499":{"preferredName":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative","code":"C61499","definitions":[{"definition":"A nitric oxide (NO) donating derivative of acetylsalicylic acid with anti-inflammatory, analgesic, antipyretic, antithrombotic, gastroprotective and potential antitumor activities. The acetylsalicylic acid derivative moiety of this agent inhibits the activities of cyclooxygenase (COX) I and II, preventing the formation of prostaglandins and thromboxanes. A reduction in prostaglandin synthesis accounts for this agent's anti-inflammatory, anti-pyretic and analgesic activities; a reduction in thromboxane A2 synthesis results in an irreversible inhibition of platelet aggregation. NO donation by this agent, after cleavage from the acetylsalicylic acid derivative in vivo, may protect the gastric mucosa against the damaging effects of the aspirin derivative by modulating prostaglandins. In tumor cells, the NO donating moiety may block the cell cycle in the G1 and G2 phases and may induce apoptosis through caspase-mediated mechanisms.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the prevention of colorectal cancer. It is a form of aspirin that gives off nitric oxide gas and is less irritating to the lining of the stomach than plain aspirin. It is a type of nonsteroidal anti-inflammatory drug (NSAID).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic Acid, 2-(Acetyl-oxy)-3-[(nitrooxy)methyl]phenyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"NCX 4016","termGroup":"AB","termSource":"NCI"},{"termName":"Nitric Oxide-Releasing Aspirin Derivative","termGroup":"SY","termSource":"NCI"},{"termName":"Nitroaspirin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"175033-36-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EH04H13L6B"},{"name":"Legacy Concept Name","value":"Nitric_Oxide-Releasing_Acetylsalicylic_Acid_Derivative"},{"name":"Maps_To","value":"Nitric Oxide-Releasing Acetylsalicylic Acid Derivative"},{"name":"NCI_Drug_Dictionary_ID","value":"486415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486415"},{"name":"PDQ_Open_Trial_Search_ID","value":"486415"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0531264"}]}}{"C61590":{"preferredName":"Nitrogen Mustard Prodrug PR-104","code":"C61590","definitions":[{"definition":"A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous administration, PR-104 is converted by systemic phosphatases to the alcohol intermediate PR-104A, which is reduced to form the active DNA-crosslinking mustard species hydroxylamine PR-104H intracellularly under hypoxic conditions. PR-104H specifically crosslinks hypoxic tumor cell DNA, resulting in the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis in susceptible hypoxic tumor cell populations while sparing normoxic tissues.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. PR-104 becomes active when cancer cells don't receive enough oxygen. It may kill cancer cells by damaging their DNA.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Nitrogen Mustard Prodrug PR-104","termGroup":"PT","termSource":"NCI"},{"termName":"((2-Bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)-carbonyl)anilino)ethyl Methanesulphonate","termGroup":"SN","termSource":"NCI"},{"termName":"PR-104","termGroup":"CN","termSource":"NCI"},{"termName":"PR104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"851627-62-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V16D2ZT7DT"},{"name":"Legacy Concept Name","value":"PR-104"},{"name":"Maps_To","value":"Nitrogen Mustard Prodrug PR-104"},{"name":"NCI_Drug_Dictionary_ID","value":"492222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492222"},{"name":"PDQ_Open_Trial_Search_ID","value":"492222"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831907"}]}}{"C103272":{"preferredName":"Nitroglycerin Transdermal Patch","code":"C103272","definitions":[{"definition":"A sustained release transdermal patch containing the organic nitrate nitroglycerin, with vasodilator and potential immunomodulating activities. Upon application to the skin, nitroglycerin is continuously released from the patch and absorbed. In turn, nitroglycerin is converted into nitric oxide (NO), which activates guanylyl cyclase, increasing cyclic guanosine monophosphate concentration thus resulting in smooth muscle relaxation. In addition, activation of NO-mediated signaling pathways may inhibit hypoxia-induced tumor cell invasiveness, chemoresistance, evasion of immune cell recognition and cancer cell progression. Particularly, reactivation of NO-mediated signaling appears to inhibit the increased tumor cell shedding of the major histocompatibility complex class I chain-related (MIC) molecules MICA and MICB as is seen in hypoxic tumor environments; MIC molecules play key roles in tumor cell immune surveillance through their interaction with the C-type lectin-like NKG2D receptor on natural killer, lymphokine-activated killer and effector T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nitroglycerin Transdermal Patch","termGroup":"PT","termSource":"NCI"},{"termName":"Glyceryl Trinitrate Transdermal Patch","termGroup":"SY","termSource":"NCI"},{"termName":"GTN Transdermal Patch","termGroup":"SY","termSource":"NCI"},{"termName":"Minitran","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nitroglycerin Transdermal Patch"},{"name":"NCI_Drug_Dictionary_ID","value":"741836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741836"},{"name":"PDQ_Open_Trial_Search_ID","value":"741836"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699222"}]}}{"C68814":{"preferredName":"Nivolumab","code":"C68814","definitions":[{"definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nivolumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 206","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-263","termGroup":"CN","termSource":"NCI"},{"termName":"BMS 936558","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-936558","termGroup":"CN","termSource":"NCI"},{"termName":"BMS936558","termGroup":"CN","termSource":"NCI"},{"termName":"CMAB819","termGroup":"CN","termSource":"NCI"},{"termName":"MDX 1106","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-1106","termGroup":"CN","termSource":"NCI"},{"termName":"MDX1106","termGroup":"CN","termSource":"NCI"},{"termName":"NIVO","termGroup":"AB","termSource":"NCI"},{"termName":"Nivolumab Biosimilar ABP 206","termGroup":"SY","termSource":"NCI"},{"termName":"Nivolumab Biosimilar BCD-263","termGroup":"SY","termSource":"NCI"},{"termName":"Nivolumab Biosimilar CMAB819","termGroup":"SY","termSource":"NCI"},{"termName":"ONO 4538","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-4538","termGroup":"CN","termSource":"NCI"},{"termName":"ONO4538","termGroup":"CN","termSource":"NCI"},{"termName":"Opdivo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced or metastatic urothelial carcinoma; recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN); renal cell carcinoma (RCC) ; metastatic melanoma; non-small cell lung cancer (NSCLC); classical Hodgkin lymphoma (cHL); BRAF V600 wild-type, unresectable or metastatic melanoma; metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy."},{"name":"CAS_Registry","value":"946414-94-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"31YO63LBSN"},{"name":"Legacy Concept Name","value":"Anti-PD-1_Human_Monoclonal_Antibody_MDX-1106"},{"name":"Maps_To","value":"Nivolumab"},{"name":"NCI_Drug_Dictionary_ID","value":"539733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539733"},{"name":"PDQ_Open_Trial_Search_ID","value":"539733"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3657270"}]}}{"C155945":{"preferredName":"NLRP3 Agonist BMS-986299","code":"C155945","definitions":[{"definition":"A nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD Containing Protein 3; NALP3) agonist with potential immunomodulatory and antineoplastic activities. Upon administration, NLRP3 agonist BMS-986299 binds to and activates NLRP3, potentially promoting NLRP3 inflammasome-mediated secretion of interleukin-8 (IL-8), which may induce tumoricidal activity of natural killer (NK) cells against tumor cells. NLRP3, a sensor component of the NLRP3 inflammasome plays a significant role in immunity and inflammation, and may protect against tumorigenesis in some cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NLRP3 Agonist BMS-986299","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986299","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986299","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986299","termGroup":"CN","termSource":"NCI"},{"termName":"NLR Family Pyrin Domain Containing 3 Agonist BMS-986299","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2242952-69-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VS58MO4P47"},{"name":"Maps_To","value":"NLRP3 Agonist BMS-986299"},{"name":"NCI_Drug_Dictionary_ID","value":"795266"},{"name":"NCI_META_CUI","value":"CL562818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795266"},{"name":"PDQ_Open_Trial_Search_ID","value":"795266"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75228":{"preferredName":"Nocodazole","code":"C75228","definitions":[{"definition":"A synthetic tubulin-binding agent with antineoplastic activity. Nocodazole binds to beta-tubulin and disrupts microtubule assembly/disassembly dynamics. This prevents mitosis and induces apoptosis in tumor cells. Although nocodazole binding site overlaps with that of colchicine, the two agents are structurally quite different.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nocodazole","termGroup":"PT","termSource":"NCI"},{"termName":"Methyl (5-(2-thienylcarbonyl))-1H-benzimidazol-2-yl","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31430-18-9"},{"name":"CHEBI_ID","value":"CHEBI:34892"},{"name":"Chemical_Formula","value":"C14H11N3O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SH1WY3R615"},{"name":"Legacy Concept Name","value":"Nocodazole"},{"name":"Maps_To","value":"Nocodazole"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028247"}]}}{"C700":{"preferredName":"Nogalamycin","code":"C700","definitions":[{"definition":"An anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces nogalater.  Nogalamycin intercalates into DNA and interacts with topoisomerase I, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nogalamycin","termGroup":"PT","termSource":"NCI"},{"termName":"[2R-(2alpha,3beta,4alpha,5beta,6alpha,11beta,13alpha,14alpha)]-11-[(6-deoxy-3-C-methyl-2,3,4-tri-O-methyl-alpha-L-mannopyranosyl)oxy]-4(dimethylamino)-3,4,5,6,9,11,12,13,14,16-decahydro-3,5,8,10,13-pentahydroxy-6,13-dimethyl-9,16-dioxo-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-14-carboxylic acid methyl ester","termGroup":"SN","termSource":"NCI"},{"termName":"Antibiotic 205T3","termGroup":"SY","termSource":"NCI"},{"termName":"U-15167","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1404-15-5"},{"name":"CHEBI_ID","value":"CHEBI:44504"},{"name":"Chemical_Formula","value":"C39H49NO16"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L059DCD6IP"},{"name":"Legacy Concept Name","value":"Nogalamycin"},{"name":"Maps_To","value":"Nogalamycin"},{"name":"NSC Number","value":"70845"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028261"}]}}{"C1577":{"preferredName":"Nolatrexed Dihydrochloride","code":"C1577","definitions":[{"definition":"A substance that is being studied in the treatment of liver cancer. It belongs to the family of drugs called thymidylate synthase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nolatrexed Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydro-2-amino-6-methyl-4-oxy-5-(4-pyridylthio)-quinazoline Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"AG-337","termGroup":"CN","termSource":"NCI"},{"termName":"Nolatrexed Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Thymitaq","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular carcinoma"},{"name":"CAS_Registry","value":"152946-68-4"},{"name":"Chemical_Formula","value":"C14H12N4OS.2ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1XA69O733O"},{"name":"Legacy Concept Name","value":"Nolatrexed"},{"name":"Maps_To","value":"Nolatrexed Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42223"},{"name":"PDQ_Open_Trial_Search_ID","value":"42223"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796399"}]}}{"C84872":{"preferredName":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201","code":"C84872","definitions":[{"definition":"A non-small cell lung cancer (NSCLC) vaccine containing modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities. Upon subcutaneous administration, non-small cell lung cancer mRNA-derived vaccine CV9201 may stimulate the immune system to mount a cytotoxic, antigen-specific T lymphocyte response (CTL) against NSCLC cells. The modified mRNAs in this vaccine are taken up by cells after injection and exhibit enhanced translational potency. The five tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201","termGroup":"PT","termSource":"NCI"},{"termName":"CV9201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201"},{"name":"NCI_Drug_Dictionary_ID","value":"648549"},{"name":"NCI_META_CUI","value":"CL412376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648549"},{"name":"PDQ_Open_Trial_Search_ID","value":"648549"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C703":{"preferredName":"Norgestrel","code":"C703","definitions":[{"definition":"A synthetic progestin commonly used alone or in combination with an estrogen for contraception.  Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes.  This agent also exhibits antiproliferative activity in endometrial tissue and may exhibit chemopreventive and antineoplastic activities in endometrial carcinoma. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Norgestrel","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-13-Ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yne-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"Neogest","termGroup":"BR","termSource":"NCI"},{"termName":"Ovrette","termGroup":"BR","termSource":"NCI"},{"termName":"Wy-3707","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Oral contraception"},{"name":"CAS_Registry","value":"6533-00-2"},{"name":"CHEBI_ID","value":"CHEBI:50901"},{"name":"CHEBI_ID","value":"CHEBI:7630"},{"name":"Chemical_Formula","value":"C21H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3J8Q1747Z2"},{"name":"Legacy Concept Name","value":"Norgestrel"},{"name":"Maps_To","value":"Norgestrel"},{"name":"NCI_Drug_Dictionary_ID","value":"39310"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39310"},{"name":"PDQ_Open_Trial_Search_ID","value":"39310"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028368"}]}}{"C99122":{"preferredName":"North American Ginseng Extract AFX-2","code":"C99122","definitions":[{"definition":"An orally available proprietary aqueous extract from the North American ginseng (Panax quinquefolius) dried root, primarily containing poly-furanosyl-pyranosyl-saccharides, with potential immunostimulating activity. Upon administration, North American ginseng extract AFX-2 may stimulate the proliferation and activation of B-lymphocytes and stimulates IgG production by B cells. Also, this agent induces maturation of dendritic cells, induces T cell proliferation and activates peritoneal exudate macrophages leading to an increase in the production of the cytokines interleukin -1 and -6, tumor necrosis factor-alpha, interferon-gamma and nitric oxide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"North American Ginseng Extract AFX-2","termGroup":"PT","termSource":"NCI"},{"termName":"AFX-2","termGroup":"CN","termSource":"NCI"},{"termName":"COLD-fX","termGroup":"BR","termSource":"NCI"},{"termName":"CVT-E002","termGroup":"CN","termSource":"NCI"},{"termName":"Panax quinquefolius Extract AFX-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"North American Ginseng Extract AFX-2"},{"name":"NCI_Drug_Dictionary_ID","value":"715600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715600"},{"name":"PDQ_Open_Trial_Search_ID","value":"715600"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Plant"},{"name":"UMLS_CUI","value":"C1722695"}]}}{"C81423":{"preferredName":"Nortopixantrone","code":"C81423","definitions":[{"definition":"A 9-aza-anthrapyrazole-based antineoplastic antibiotic. Nortopixantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Nortopixantrone is less cardiotoxicity than anthracyclines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nortopixantrone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156090-17-4"},{"name":"Chemical_Formula","value":"C20H24N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PH2639TAB4"},{"name":"Legacy Concept Name","value":"Nortopixantrone"},{"name":"Maps_To","value":"Nortopixantrone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825625"}]}}{"C80589":{"preferredName":"Noscapine","code":"C80589","definitions":[{"definition":"A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Noscapine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"128-62-1"},{"name":"Chemical_Formula","value":"C22H23NO7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8V32U4AOQU"},{"name":"Legacy Concept Name","value":"Noscapine"},{"name":"Maps_To","value":"Noscapine"},{"name":"NSC Number","value":"5366"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028426"}]}}{"C61103":{"preferredName":"Noscapine Hydrochloride","code":"C61103","definitions":[{"definition":"The orally available hydrochloride salt of the opioid agonist noscapine, a phthalideisoquinoline alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine binds to tubulin and alters its conformation, resulting in a disruption of the dynamics of microtubule assembly (by increasing the time that microtubules spend idle in a paused state) and subsequently, the inhibition of mitosis and tumor cell death. Unlike other tubulin inhibitors such as the taxanes and vinca alkaloids, noscapine does not affect microtubule polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Noscapine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1(3H)Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3,-dioxolo(4,5-g)isoquinolin-5-yl)-hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Narcotine hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Noscapine HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cough"},{"name":"CAS_Registry","value":"912-60-7"},{"name":"Chemical_Formula","value":"C22H23NO7.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TTN62ITH9I"},{"name":"Legacy Concept Name","value":"Noscapine_Hydrochloride"},{"name":"Maps_To","value":"Noscapine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"469778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"469778"},{"name":"PDQ_Open_Trial_Search_ID","value":"469778"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1450474"}]}}{"C118569":{"preferredName":"Notch Signaling Inhibitor PF-06650808","code":"C118569","synonyms":[{"termName":"Notch Signaling Inhibitor PF-06650808","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06650808","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Notch Signaling Inhibitor PF-06650808"},{"name":"NCI_META_CUI","value":"CL474089"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49175":{"preferredName":"Notch Signaling Pathway Inhibitor MK0752","code":"C49175","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks signals between growing cells and may kill cancer cells. It is a type of signal transduction inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic small molecule with potential antineoplastic activity. MK0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated. The Notch signaling pathway plays an important role in cell-fate determination, cell survival, and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Notch Signaling Pathway Inhibitor MK0752","termGroup":"PT","termSource":"NCI"},{"termName":"MK-0752","termGroup":"CN","termSource":"NCI"},{"termName":"MK0752","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"471905-41-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9JD9B4S53T"},{"name":"Legacy Concept Name","value":"MK0752"},{"name":"Maps_To","value":"Notch Signaling Pathway Inhibitor MK0752"},{"name":"NCI_Drug_Dictionary_ID","value":"446541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"446541"},{"name":"PDQ_Open_Trial_Search_ID","value":"446541"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708824"}]}}{"C118948":{"preferredName":"Taletrectinib","code":"C118948","definitions":[{"definition":"An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, with potential antineoplastic activity. Upon oral administration, taletrectinib binds to and inhibits ROS1 and the NTRK family members. This inhibition leads to a disruption of ROS1- and NTRK-mediated signaling and eventually inhibits the growth of tumor cells that are overexpressing ROS1 and/or NTRKs. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells. NTRK mutations or rearrangements play a key role in cancer progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taletrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"AB 106","termGroup":"CN","termSource":"NCI"},{"termName":"AB-106","termGroup":"CN","termSource":"NCI"},{"termName":"AB106","termGroup":"CN","termSource":"NCI"},{"termName":"DS-6051A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1505514-27-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W4141180YD"},{"name":"Maps_To","value":"NTRK/ROS1 Inhibitor DS-6051b"},{"name":"Maps_To","value":"Taletrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"766123"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766123"},{"name":"PDQ_Open_Trial_Search_ID","value":"766123"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896871"}]}}{"C103297":{"preferredName":"Nucleolin Antagonist IPP-204106N","code":"C103297","definitions":[{"definition":"A synthetic, multivalent, lysine-rich, pseudopeptide and nucleolin antagonist with potential anti-angiogenic, antineoplastic and pro-apoptotic activities. Upon administration, IPP-204106N antagonizes nucleolin leading to a downregulation of cell-surface nucleolin; preventing the binding of certain growth promoting ligands to nucleolin may suppress tumor cell proliferation and angiogenesis. In addition, IPP-204106N is able to translocate to the nucleolus and bind to nucleolar nucleolin. This prevents nucleolin from binding to and stabilizing mRNA of the anti-apoptotic Bcl2; destabilizing Bcl2 mRNA leads to a reduction in Bcl2 protein synthesis and induces apoptosis. Further, this agent can antagonize nucleophosmin. Nucleolin, a nucleolar phosphoprotein, is overexpressed on the cell surface of certain cancer cells and binds ligands involved in cell proliferation, adhesion and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleolin Antagonist IPP-204106N","termGroup":"PT","termSource":"NCI"},{"termName":"IPP-204106","termGroup":"CN","termSource":"NCI"},{"termName":"N6L","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nucleolin Antagonist IPP-204106N"},{"name":"NCI_Drug_Dictionary_ID","value":"742115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742115"},{"name":"PDQ_Open_Trial_Search_ID","value":"742115"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641183"}]}}{"C116744":{"preferredName":"Nucleoside Analog DFP-10917","code":"C116744","definitions":[{"definition":"A deoxycytosine analog with potential antineoplastic activity. Upon administration, DFP-10917 is phosphorylated to generate its nucleotide form that functions as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, which results in G2/M phase-arrest and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleoside Analog DFP-10917","termGroup":"PT","termSource":"NCI"},{"termName":"2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine","termGroup":"SN","termSource":"NCI"},{"termName":"DFP-10917","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nucleoside Analog DFP-10917"},{"name":"NCI_Drug_Dictionary_ID","value":"741505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741505"},{"name":"PDQ_Open_Trial_Search_ID","value":"741505"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0091023"}]}}{"C156680":{"preferredName":"Fosifloxuridine Nafalbenamide","code":"C156680","definitions":[{"definition":"A phosphoramidate-based prodrug of the monophosphate (MP) form of 5-fluoro-2'-deoxyuridine (FUdR; FUDR), the active metabolite of fluorouracil (5-FU), an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity. Upon administration of the nucleotide analog prodrug fosifloxuridine nafalbenamide, fosifloxuridine nafalbenamide is readily taken up by tumor cells. In the tumor cell, the phosphoramidate moiety is removed and fosifloxuridine nafalbenamide is converted to its active form FUDR-MP. In turn, FUDR-MP binds to and inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate (TTP) and thus DNA synthesis. With the phosphoramidate moiety attached to FUDR-MP, fosifloxuridine nafalbenamide, compared to 5-FU, is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, thereby generating higher intracellular concentrations. In addition, compared to 5-FU, once inside the cell FUDR-MP does not need to be phosphorylated and is already in its active form. Unlike 5-FU, fosifloxuridine nafalbenamide does not get deactivated or converted into toxic metabolites by dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP), which leads to both a longer half-life and less toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosifloxuridine Nafalbenamide","termGroup":"PT","termSource":"NCI"},{"termName":"5-FU Analog Prodrug NUC-3373","termGroup":"SY","termSource":"NCI"},{"termName":"L-Alanine, N-(-2'-Deoxy-2',2'-difluoro-p-1-naphthalenyl-5'-cytidylyl)-, Phenylmethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"NUC 3373","termGroup":"CN","termSource":"NCI"},{"termName":"NUC-3373","termGroup":"CN","termSource":"NCI"},{"termName":"NUC3373","termGroup":"CN","termSource":"NCI"},{"termName":"Nucleotide Analog NUC-3373","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphoramidate-FUDR-MP Prodrug NUC-3373","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1332837-31-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4YO6QT3SZ9"},{"name":"Maps_To","value":"Fosifloxuridine Nafalbenamide"},{"name":"Maps_To","value":"Nucleotide Analog Prodrug NUC-3373"},{"name":"NCI_Drug_Dictionary_ID","value":"795584"},{"name":"NCI_META_CUI","value":"CL935731"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795584"},{"name":"PDQ_Open_Trial_Search_ID","value":"795584"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71742":{"preferredName":"Nucleotide Analogue GS 9219","code":"C71742","definitions":[{"definition":"A prodrug of the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG) with potential antineoplastic activity. Formulated to selectively accumulate in lymphocytes, nucleotide analogue GS 9219 is converted to its active metabolite, PMEG diphosphate (PMEGpp), via enzymatic hydrolysis, deamination, and phosphorylation; subsequently, PMEGpp is incorporated into nascent DNA chains by DNA polymerases, which may result in the termination of DNA synthesis, S-phase cell cycle arrest, and the induction of apoptosis in susceptible lymphoma cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nucleotide Analogue GS 9219","termGroup":"PT","termSource":"NCI"},{"termName":"9-(2-phosphonylmethoxyethyl)guanine nucleotide analogue prodrug GS 9219","termGroup":"SY","termSource":"NCI"},{"termName":"GS9219","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Nucleotide_Analogue_GS_9219"},{"name":"Maps_To","value":"Nucleotide Analogue GS 9219"},{"name":"NCI_Drug_Dictionary_ID","value":"560932"},{"name":"NCI_META_CUI","value":"CL376149"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560932"},{"name":"PDQ_Open_Trial_Search_ID","value":"560932"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74594":{"preferredName":"Rebemadlin","code":"C74594","definitions":[{"definition":"A small molecule and MDM2 (murine double minute 2) inhibitor, with potential antineoplastic activity. In cancer cells, rebemadlin antagonizes the binding of MDM2 to p53, thereby preventing MDM2-mediated p53 degradation. This results in stabilizing and activating p53-dependent cell cycle arrest and apoptosis. The protein MDM2, a negative regulator of p53 activity, is overexpressed in many cancer cell types; the tumor suppressor p53 is mutated or deleted in about 50% of all cancers but active in the other 50%.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebemadlin","termGroup":"PT","termSource":"NCI"},{"termName":"Nutlin-3a","termGroup":"SY","termSource":"NCI"},{"termName":"SML-0580","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"675576-98-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L7C92IOE65"},{"name":"Legacy Concept Name","value":"Nutlin-3a"},{"name":"Maps_To","value":"Nutlin-3a"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1956368"}]}}{"C96036":{"preferredName":"Nutraceutical TBL-12","code":"C96036","definitions":[{"definition":"An orally available nutritional supplement and proprietary formulation containing extracts from the sea cucumber, sea sponge, shark fin, sea urchin and the marine grass Sargassum, with potential antioxidant, antitumor, anti-angiogenic and immunomodulating activities. TBL-12 contains various amino acids, minerals, vitamins and omega-3 fatty acids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nutraceutical TBL-12","termGroup":"PT","termSource":"NCI"},{"termName":"TBL-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nutraceutical TBL-12"},{"name":"NCI_Drug_Dictionary_ID","value":"696523"},{"name":"NCI_META_CUI","value":"CL428370"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696523"},{"name":"PDQ_Open_Trial_Search_ID","value":"696523"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62452":{"preferredName":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611","code":"C62452","definitions":[{"definition":"A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1 plasmid DNA cancer vaccine pPJV7611 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1 is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611","termGroup":"PT","termSource":"NCI"},{"termName":"pPJV7611","termGroup":"CN","termSource":"NCI"},{"termName":"pPJV7611 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NY-ESO-1_Plasmid_DNA_Vaccine"},{"name":"Maps_To","value":"NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611"},{"name":"NCI_Drug_Dictionary_ID","value":"489121"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489121"},{"name":"PDQ_Open_Trial_Search_ID","value":"489121"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831877"}]}}{"C120557":{"preferredName":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301","code":"C120557","definitions":[{"definition":"Human peripheral blood T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and introduction into the patient, the NY-ESO-1-specific TCR gene-transduced T lymphocytes TBI-1301 bind to NY-ESO-1 on tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301","termGroup":"PT","termSource":"NCI"},{"termName":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"TBI-1301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301"},{"name":"NCI_Drug_Dictionary_ID","value":"769543"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769543"},{"name":"PDQ_Open_Trial_Search_ID","value":"769543"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053586"}]}}{"C113432":{"preferredName":"NY-ESO-1/GLA-SE Vaccine ID-G305","code":"C113432","definitions":[{"definition":"A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-1/GLA-SE Vaccine ID-G305","termGroup":"PT","termSource":"NCI"},{"termName":"ID-G305","termGroup":"CN","termSource":"NCI"},{"termName":"IDC-G305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"NY-ESO-1/GLA-SE Vaccine ID-G305"},{"name":"NCI_Drug_Dictionary_ID","value":"756236"},{"name":"NCI_META_CUI","value":"CL458226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756236"},{"name":"PDQ_Open_Trial_Search_ID","value":"756236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26680":{"preferredName":"NY-ESO-B","code":"C26680","definitions":[{"definition":"A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"NY-ESO-B","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NY-ESO-B"},{"name":"Maps_To","value":"NY-ESO-B"},{"name":"NCI_Drug_Dictionary_ID","value":"257347"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257347"},{"name":"PDQ_Open_Trial_Search_ID","value":"257347"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1327762"}]}}{"C1298":{"preferredName":"O-Chloroacetylcarbamoylfumagillol","code":"C1298","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"O-Chloroacetylcarbamoylfumagillol","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,4S,5S,6R)-5-Methoxy-4- [(2R,3R)-2-methyl-3-(3-methyl-2-butenyl) -oxiranyl]-1-oxaspiro [2,5] oct-6-yl(chloroacetyl) Carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl) carbamate","termGroup":"SN","termSource":"NCI"},{"termName":"AGM-1470","termGroup":"CN","termSource":"NCI"},{"termName":"TNP-470","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129298-91-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X47GR46481"},{"name":"Legacy Concept Name","value":"TNP-470"},{"name":"Maps_To","value":"O-Chloroacetylcarbamoylfumagillol"},{"name":"NCI_Drug_Dictionary_ID","value":"41725"},{"name":"NSC Number","value":"642492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41725"},{"name":"PDQ_Open_Trial_Search_ID","value":"41725"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0081489"}]}}{"C1306":{"preferredName":"O6-Benzylguanine","code":"C1306","definitions":[{"definition":"A drug that may improve the response of cancer cells to chemotherapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"O6-Benzylguanine","termGroup":"PT","termSource":"NCI"},{"termName":"2-amino-6-(benzyloxy)purine","termGroup":"SN","termSource":"NCI"},{"termName":"2-amino-6-(phenylmethoxy)-9h-purine","termGroup":"SN","termSource":"NCI"},{"termName":"O(6)-Benzylguanine","termGroup":"SY","termSource":"NCI"},{"termName":"O-6-Benzylguanine","termGroup":"SN","termSource":"NCI"},{"termName":"O6-Benzylguanine","termGroup":"SN","termSource":"NCI"},{"termName":"O6-BG","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"19916-73-5"},{"name":"Chemical_Formula","value":"C12H11N5O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"01KC87F8FE"},{"name":"Legacy Concept Name","value":"O_6_Benzylguanine"},{"name":"Maps_To","value":"O6-Benzylguanine"},{"name":"NCI_Drug_Dictionary_ID","value":"42113"},{"name":"NSC Number","value":"637037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42113"},{"name":"PDQ_Open_Trial_Search_ID","value":"42113"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0083812"}]}}{"C62771":{"preferredName":"Obatoclax Mesylate","code":"C62771","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It is a form of obatoclax, which blocks the activity of certain proteins needed for cells to live and may cause tumor cells to die. It is a type of apoptosis inducer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of obatoclax, a synthetic small-molecule inhibitor of the bcl-2 family of proteins with potential pro-apoptotic and antineoplastic activities. Obatoclax binds to members of the Bcl-2 protein family, preventing the binding of these anti-apoptotic proteins to the pro-apoptotic proteins Bax and Bak and so promoting the activation of the apoptotic pathway in Bcl-2-overexpressing cells. The Bcl-2 family of proteins (bcl-2, bcl-xl, bcl-w, and Mcl-1) are overexpressed in a wide variety of cancers, including those of the lymphatic system, breast, lung, prostate, and colon.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obatoclax Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylidene]-3-methoxy-2H-pyrrol-5-yl)-1H-indole Monomethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"GX15-070MS","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"803712-79-0"},{"name":"Chemical_Formula","value":"C20H19N3O.CH4O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"39200FJ43J"},{"name":"Legacy Concept Name","value":"Obatoclax_Mesylate"},{"name":"Maps_To","value":"Obatoclax Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"504100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"504100"},{"name":"PDQ_Open_Trial_Search_ID","value":"504100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831948"}]}}{"C70741":{"preferredName":"Obinutuzumab","code":"C70741","definitions":[{"definition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obinutuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Afutuzumab","termGroup":"AQS","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody R7159","termGroup":"SY","termSource":"NCI"},{"termName":"GA 101","termGroup":"CN","termSource":"NCI"},{"termName":"GA-101","termGroup":"CN","termSource":"NCI"},{"termName":"GA101","termGroup":"CN","termSource":"NCI"},{"termName":"Gazyva","termGroup":"BR","termSource":"NCI"},{"termName":"huMAB(CD20)","termGroup":"SY","termSource":"NCI"},{"termName":"R 7159","termGroup":"CN","termSource":"NCI"},{"termName":"R-7159","termGroup":"CN","termSource":"NCI"},{"termName":"R7159","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5072759","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5072759","termGroup":"CN","termSource":"NCI"},{"termName":"RO5072759","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"follicular lymphoma (FL); chronic lymphocytic leukemia"},{"name":"CAS_Registry","value":"949142-50-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"O43472U9X8"},{"name":"Legacy Concept Name","value":"Anti-CD20_Monoclonal_Antibody_R7159"},{"name":"Maps_To","value":"Obinutuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"570643"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570643"},{"name":"PDQ_Open_Trial_Search_ID","value":"570643"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742503"}]}}{"C66722":{"preferredName":"Oblimersen Sodium","code":"C66722","definitions":[{"definition":"A substance being studied in the treatment of cancer. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs. It is a type of antisense oligodeoxyribonucleotide.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oblimersen Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Anticode G3139","termGroup":"SY","termSource":"NCI"},{"termName":"Augmerosen","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-2 Antisense Oligodeoxynucleotide G3139","termGroup":"SY","termSource":"NCI"},{"termName":"BCL-2 Antisense/G3139","termGroup":"SY","termSource":"NCI"},{"termName":"G 3139","termGroup":"CN","termSource":"NCI"},{"termName":"G-3139","termGroup":"CN","termSource":"NCI"},{"termName":"G3139","termGroup":"CN","termSource":"NCI"},{"termName":"G3139 Antisense Oligonucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"G3139 BCL-2 Antisense Oligo","termGroup":"SY","termSource":"NCI"},{"termName":"G3139 BCL-2 Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"G3139 BCL-2 Antisense Oligonucleotide","termGroup":"SY","termSource":"NCI"},{"termName":"Genasense","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"190977-41-4"},{"name":"Chemical_Formula","value":"C172H204N62O91P17S17.17Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SH55B0RQ9K"},{"name":"Legacy Concept Name","value":"Oblimersen_Sodium"},{"name":"Maps_To","value":"Oblimersen Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"42935"},{"name":"NSC Number","value":"683428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42935"},{"name":"PDQ_Open_Trial_Search_ID","value":"42935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935954"}]}}{"C2524":{"preferredName":"Ocaratuzumab","code":"C2524","definitions":[{"definition":"An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20. The Fc portion of this monoclonal antibody has been engineered to possess a higher binding affinity for variant Fc receptors on T helper cells, resulting in an augmentation of the anti-tumor immune response. Because of Fc engineering, this agent may be significantly more potent than rituximab in inducing B cell-directed ADCC. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ocaratuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AME-133v","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody AME-133v","termGroup":"SY","termSource":"NCI"},{"termName":"LY 2469298","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb CD20","termGroup":"AB","termSource":"NCI"},{"termName":"monoclonal antibody, CD20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1169956-08-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NTY9893GD0"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_CD20"},{"name":"Maps_To","value":"Ocaratuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"500055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"500055"},{"name":"PDQ_Open_Trial_Search_ID","value":"500055"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831936"}]}}{"C66250":{"preferredName":"Ocrelizumab","code":"C66250","definitions":[{"definition":"A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ocrelizumab","termGroup":"PT","termSource":"NCI"},{"termName":"PR070769","termGroup":"CN","termSource":"NCI"},{"termName":"PRO-70769","termGroup":"CN","termSource":"NCI"},{"termName":"PRO70769","termGroup":"CN","termSource":"NCI"},{"termName":"rhuMAb 2H7","termGroup":"SY","termSource":"NCI"},{"termName":"RO4964913","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"637334-45-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A10SJL62JY"},{"name":"Legacy Concept Name","value":"Ocrelizumab"},{"name":"Maps_To","value":"Ocrelizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"780147"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780147"},{"name":"PDQ_Open_Trial_Search_ID","value":"780147"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882138"}]}}{"C711":{"preferredName":"Octreotide","code":"C711","definitions":[{"definition":"A drug similar to the naturally occurring growth hormone inhibitor somatostatin. Octreotide is used to treat diarrhea and flushing associated with certain types of tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Octreotide","termGroup":"PT","termSource":"NCI"},{"termName":"D-Phenylalanyl-L-cysteinyl-L-phenyl-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2->7)-Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol Cyclic (2->7)-Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"SMS 201 995","termGroup":"CN","termSource":"NCI"},{"termName":"SMS 201995","termGroup":"CN","termSource":"NCI"},{"termName":"SMS-201-995","termGroup":"CN","termSource":"NCI"},{"termName":"SMS201995","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acromegaly; Diarrhea"},{"name":"CAS_Registry","value":"83150-76-9"},{"name":"CHEBI_ID","value":"CHEBI:7726"},{"name":"Chemical_Formula","value":"C49H66N10O10S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RWM8CCW8GP"},{"name":"Legacy Concept Name","value":"Octreotide"},{"name":"Maps_To","value":"Octreotide"},{"name":"PubMedID_Primary_Reference","value":"16917205"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028833"}]}}{"C53447":{"preferredName":"Octreotide Acetate","code":"C53447","definitions":[{"definition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Octreotide Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Longastatin","termGroup":"SY","termSource":"NCI"},{"termName":"Longastatina","termGroup":"FB","termSource":"NCI"},{"termName":"Mycapssa","termGroup":"BR","termSource":"NCI"},{"termName":"Samilstin","termGroup":"FB","termSource":"NCI"},{"termName":"Sandostatin","termGroup":"BR","termSource":"NCI"},{"termName":"Sandostatin LAR","termGroup":"SY","termSource":"NCI"},{"termName":"Sandostatin Lar Depot","termGroup":"BR","termSource":"NCI"},{"termName":"Sandostatina","termGroup":"FB","termSource":"NCI"},{"termName":"Sandostatine","termGroup":"FB","termSource":"NCI"},{"termName":"SMS 201-995","termGroup":"SY","termSource":"NCI"},{"termName":"SMS 201-995 AC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acromegaly; Diarrhea"},{"name":"CAS_Registry","value":"79517-01-4"},{"name":"Chemical_Formula","value":"C49H66N10O10S2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"75R0U2568I"},{"name":"Legacy Concept Name","value":"Octreotide_Acetate"},{"name":"Maps_To","value":"Octreotide Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"38866"},{"name":"NSC Number","value":"671663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38866"},{"name":"PDQ_Open_Trial_Search_ID","value":"38866"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0678117"}]}}{"C2402":{"preferredName":"Octreotide Pamoate","code":"C2402","definitions":[{"definition":"A synthetic long-acting octapeptide analogue of endogenous somatostatin.  Octreotide pamoate binds to somatostatin receptors expressed by some neuroendocrine and non-neuroendocrine tumor cells, thereby initiating somatostatin receptor-mediated apoptosis. Other possible antineoplastic activities of this agent include suppression of tumor angiogenesis and tumor growth-promoting insulin-like growth factor 1 (IGF-1).  (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Octreotide Pamoate","termGroup":"PT","termSource":"NCI"},{"termName":"Octreotide Embpnate","termGroup":"SY","termSource":"NCI"},{"termName":"OncoLar","termGroup":"BR","termSource":"NCI"},{"termName":"OP LAR","termGroup":"SY","termSource":"NCI"},{"termName":"SMS 201-995 PA","termGroup":"CN","termSource":"NCI"},{"termName":"SMS 201-995 pa LAR","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135467-16-2"},{"name":"Chemical_Formula","value":"C49H66N10O10S2.C23H16O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MWH8YQ1AIO"},{"name":"Legacy Concept Name","value":"Octreotide_Pamoate"},{"name":"Maps_To","value":"Octreotide Pamoate"},{"name":"NCI_Drug_Dictionary_ID","value":"42358"},{"name":"NSC Number","value":"685403"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42358"},{"name":"PDQ_Open_Trial_Search_ID","value":"42358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338271"}]}}{"C66952":{"preferredName":"Ofatumumab","code":"C66952","definitions":[{"definition":"A drug used to treat chronic lymphocytic leukemia (CLL) that has not gotten better with other chemotherapy. It is also being studied in the treatment of other types of cancer, including follicular non-Hodgkin lymphoma. Arzerra binds to CD20, a protein on the surface of normal B cells and most B-cell tumors. This may kill the cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ofatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Arzerra","termGroup":"BR","termSource":"NCI"},{"termName":"GSK1841157","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-CD20","termGroup":"FB","termSource":"NCI"},{"termName":"HuMax-CD20, 2F2","termGroup":"AB","termSource":"NCI"},{"termName":"Kesimpta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia (CLL)"},{"name":"CAS_Registry","value":"679818-59-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M95KG522R0"},{"name":"Legacy Concept Name","value":"Ofatumumab"},{"name":"Maps_To","value":"Ofatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"530015"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530015"},{"name":"PDQ_Open_Trial_Search_ID","value":"530015"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832027"}]}}{"C2558":{"preferredName":"Oglufanide Disodium","code":"C2558","definitions":[{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disodium salt of a synthetic form of a naturally-occurring dipeptide consisting of L-glutamic acid and L-tryptophan with potential antiangiogenic and potential immunomodulating activities. Oglufanide inhibits vascular endothelial growth factor (VEGF), which may inhibit angiogenesis. This agent has also been reported to stimulate the immune response to hepatitic C virus and intracellular bacterial infections.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oglufanide Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Glufanide Disodium","termGroup":"SY","termSource":"NCI"},{"termName":"IM 862","termGroup":"CN","termSource":"NCI"},{"termName":"IM862","termGroup":"CN","termSource":"NCI"},{"termName":"L-Tryptophan, L-alpha-glutamyl-, disodium salt","termGroup":"SN","termSource":"NCI"},{"termName":"Oglufanide Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Thymogen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"237068-57-4"},{"name":"Chemical_Formula","value":"C16H17N3O5.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q60AU1LLNU"},{"name":"Legacy Concept Name","value":"Glufanide_Disodium"},{"name":"Maps_To","value":"Oglufanide Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"43387"},{"name":"NCI_META_CUI","value":"CL032903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43387"},{"name":"PDQ_Open_Trial_Search_ID","value":"43387"},{"name":"PubMedID_Primary_Reference","value":"12180893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71721":{"preferredName":"Olaparib","code":"C71721","definitions":[{"definition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast, ovarian, and prostate cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. AZD2281 may cause cancer cells to die. It is a type of targeted therapy agent and a type of poly (ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Olaparib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 2281","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-2281","termGroup":"CN","termSource":"NCI"},{"termName":"AZD2281","termGroup":"CN","termSource":"NCI"},{"termName":"KU 0059436","termGroup":"CN","termSource":"NCI"},{"termName":"KU-0059436","termGroup":"CN","termSource":"NCI"},{"termName":"KU0059436","termGroup":"CN","termSource":"NCI"},{"termName":"Lynparza","termGroup":"BR","termSource":"NCI"},{"termName":"Olanib","termGroup":"FB","termSource":"NCI"},{"termName":"Olaparix","termGroup":"FB","termSource":"NCI"},{"termName":"PARP Inhibitor AZD2281","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."},{"name":"Accepted_Therapeutic_Use_For","value":"deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer; deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer"},{"name":"CAS_Registry","value":"763113-22-0"},{"name":"Chemical_Formula","value":"C24H23FN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WOH1JD9AR8"},{"name":"Legacy Concept Name","value":"PARP_Inhibitor_AZD2281"},{"name":"Maps_To","value":"Olaparib"},{"name":"NCI_Drug_Dictionary_ID","value":"560191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560191"},{"name":"PDQ_Open_Trial_Search_ID","value":"560191"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2316164"}]}}{"C99379":{"preferredName":"Olaptesed Pegol","code":"C99379","definitions":[{"definition":"A 45-mer L-stereoisomer RNA oligonucleotide linked to a 40 kDa polyethyleneglycol that targets the small chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) with potential antineoplastic and hematopoietic stem cell-mobilization activities. SDF-1 targeted agent NOX-A12 specifically binds to SDF-1 thereby preventing the binding of SDF-1 to its receptors CXCR4 and CXCR7 blocking the subsequent receptor activation. This may prevent angiogenesis, tumor cell proliferation, invasion and metastasis and could sensitize tumor cells to chemotherapy. In addition, inhibition of SDF-1/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into blood. The unique mirror-image configuration of this agent renders it resistant to hydrolysis and does not hybridize with native nucleic acids. Furthermore, this agent does not induce the innate immune response and has shown a favorable immunogenicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olaptesed Pegol","termGroup":"PT","termSource":"NCI"},{"termName":"NOX-A12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1390628-22-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MTM792B442"},{"name":"Maps_To","value":"Olaptesed Pegol"},{"name":"NCI_Drug_Dictionary_ID","value":"719932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"719932"},{"name":"PDQ_Open_Trial_Search_ID","value":"719932"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274704"}]}}{"C79825":{"preferredName":"Olaratumab","code":"C79825","definitions":[{"definition":"A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of glioblastoma (a type of brain tumor) that has come back. It binds to receptors for a protein called platelet-derived growth factor (PDGF). This keeps PDGF from binding to the cells. This may stop the growth of cancer cells and blood vessels that have the receptors for PDGF. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Olaratumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PDGFR alpha Monoclonal Antibody IMC-3G3","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Platelet-Derived Growth Factor Receptor alpha Monoclonal Antibody IMC-3G3","termGroup":"SY","termSource":"NCI"},{"termName":"IMC-3G3","termGroup":"CN","termSource":"NCI"},{"termName":"Lartruvo","termGroup":"BR","termSource":"NCI"},{"termName":"LY 3012207","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3012207","termGroup":"CN","termSource":"NCI"},{"termName":"LY3012207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"soft tissue sarcoma (STS)"},{"name":"CAS_Registry","value":"1024603-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"TT6HN20MVF"},{"name":"Legacy Concept Name","value":"Anti-PDGFR_alpha_Monoclonal_Antibody_IMC-3G3"},{"name":"Maps_To","value":"Olaratumab"},{"name":"NCI_Drug_Dictionary_ID","value":"626630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"626630"},{"name":"PDQ_Open_Trial_Search_ID","value":"626630"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703171"}]}}{"C90586":{"preferredName":"Oleandrin","code":"C90586","definitions":[{"definition":"A lipid soluble cardiac glycoside with potential antineoplastic activity. Upon administration, oleandrin specifically binds to and inhibits the alpha3 subunit of the Na/K-ATPase pump in human cancer cells. This may inhibit the phosphorylation of Akt, upregulate MAPK, inhibit NF-kb activation and inhibit FGF-2 export and may downregulate mTOR thereby inhibiting p70S6K and S6 protein expression. All of this may lead to an induction of apoptosis. As cancer cells with relatively higher expression of the alpha3 subunit and with limited expression of the alpha1 subunit are more sensitive to oleandrin, one may predict the tumor response to treatment with lipid-soluble cardiac glycosides such as oleandrin based on the tumors Na/K-ATPase pump protein subunit expression. Overexpression of the alpha3 subunit in tumor cells correlates with tumor proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oleandrin","termGroup":"PT","termSource":"NCI"},{"termName":"PBI-05204","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"465-16-7"},{"name":"CHEBI_ID","value":"CHEBI:59030"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"II95UDU7I4"},{"name":"Maps_To","value":"Oleandrin"},{"name":"NCI_Drug_Dictionary_ID","value":"579304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579304"},{"name":"PDQ_Open_Trial_Search_ID","value":"579304"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069397"}]}}{"C123914":{"preferredName":"Oleclumab","code":"C123914","definitions":[{"definition":"A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oleclumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD73 Monoclonal Antibody MEDI9447","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI9447","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1803176-05-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5CRY01URYQ"},{"name":"Maps_To","value":"Oleclumab"},{"name":"NCI_Drug_Dictionary_ID","value":"775839"},{"name":"NCI_META_CUI","value":"CL498278"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775839"},{"name":"PDQ_Open_Trial_Search_ID","value":"775839"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61325":{"preferredName":"Oligonucleotide SPC2996","code":"C61325","definitions":[{"definition":"A synthetic antisense oligonucleotide against Bcl-2 messenger RNA with potential antitumor activity. Oligonucleotide SPC2996 binds to and inactivates Bcl-2 mRNA, thereby inhibiting the expression of Bcl-2 protein, promoting tumor cell apoptosis, and potentially enhancing the efficacy of standard cytotoxic chemotherapy. Linked to tumor drug resistance, the antiapoptotic protein Bcl-2 is upregulated in several types of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligonucleotide SPC2996","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SPC2996_Oligonucleotide"},{"name":"Maps_To","value":"Oligonucleotide SPC2996"},{"name":"NCI_Drug_Dictionary_ID","value":"485272"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485272"},{"name":"PDQ_Open_Trial_Search_ID","value":"485272"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831825"}]}}{"C715":{"preferredName":"Olivomycin","code":"C715","definitions":[{"definition":"A preparation containing a mixture of glycosidic antibiotics isolated from Streptomyces olivoreticuli with fluorescent microscopy applications and potential antineoplastic activities. Olivomycin preferentially binds to DNA and can be utilized as a fluorescent marker during the characterization of heterochromatin. Additionally, binding to DNA inhibits both RNA transcription and RNA elongation by RNA polymerase; therefore protein synthesis is inhibited. In addition, olivomycin antibiotics are able to induce apoptosis in tumor cells through a mechanism that has not yet been fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olivomycin","termGroup":"PT","termSource":"NCI"},{"termName":"Oligomycin A, mixt. with oligomycin B","termGroup":"SY","termSource":"NCI"},{"termName":"Olivomycins","termGroup":"SY","termSource":"NCI"},{"termName":"Toyomycin R","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11006-70-5"},{"name":"CHEBI_ID","value":"CHEBI:52515"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44003517D1"},{"name":"Legacy Concept Name","value":"Olivomycin_Antibiotic"},{"name":"Maps_To","value":"Olivomycin"},{"name":"NSC Number","value":"76411"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0028967"}]}}{"C101791":{"preferredName":"Olmutinib","code":"C101791","definitions":[{"definition":"An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olmutinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"BI 1482694","termGroup":"CN","termSource":"NCI"},{"termName":"HM61713","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353550-13-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CHL9B67L95"},{"name":"Maps_To","value":"Olmutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"733621"},{"name":"NCI_META_CUI","value":"CL435909"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733621"},{"name":"PDQ_Open_Trial_Search_ID","value":"733621"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1177":{"preferredName":"Oltipraz","code":"C1177","definitions":[{"definition":"A drug used in cancer prevention.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. Although the exact mechanism through which the anti-angiogenesis effect remains to be fully elucidated, oltipraz maybe able to modulate the expression of a number of angiogenic factors, thereby blocking the sustained and focal neovascularization in multiple tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oltipraz","termGroup":"PT","termSource":"NCI"},{"termName":"3H-1,2-Dithiole-3-thione,4-methyl-5-pyrazinyl","termGroup":"SN","termSource":"NCI"},{"termName":"4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"5-[2-Pyrazinyl]-4-methyl-1,2-3-thione","termGroup":"SN","termSource":"NCI"},{"termName":"RP-35,972","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64224-21-1"},{"name":"Chemical_Formula","value":"C8H6N2S3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6N510JUL1Y"},{"name":"Legacy Concept Name","value":"Oltipraz"},{"name":"Maps_To","value":"Oltipraz"},{"name":"NCI_Drug_Dictionary_ID","value":"41866"},{"name":"NSC Number","value":"347901"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41866"},{"name":"PDQ_Open_Trial_Search_ID","value":"41866"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069456"}]}}{"C129687":{"preferredName":"Olutasidenib","code":"C129687","definitions":[{"definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), with potential antineoplastic activity. Upon administration, olutasidenib specifically inhibits IDH1(R132), thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH(R132). IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olutasidenib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"FT 2102","termGroup":"CN","termSource":"NCI"},{"termName":"FT-2102","termGroup":"CN","termSource":"NCI"},{"termName":"FT2102","termGroup":"CN","termSource":"NCI"},{"termName":"IDH1-R132 Inhibitor FT-2102","termGroup":"SY","termSource":"NCI"},{"termName":"Rezlidhia","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1887014-12-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0T4IMT8S5Z"},{"name":"Maps_To","value":"Olutasidenib"},{"name":"NCI_Drug_Dictionary_ID","value":"780143"},{"name":"NCI_META_CUI","value":"CL507891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780143"},{"name":"PDQ_Open_Trial_Search_ID","value":"780143"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1127":{"preferredName":"Omacetaxine Mepesuccinate","code":"C1127","definitions":[{"definition":"A semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the plant alkaloid family of drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Omacetaxine Mepesuccinate","termGroup":"PT","termSource":"NCI"},{"termName":"Ceflatonin","termGroup":"BR","termSource":"NCI"},{"termName":"Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)","termGroup":"SN","termSource":"NCI"},{"termName":"Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"CGX-635","termGroup":"CN","termSource":"NCI"},{"termName":"HHT","termGroup":"AB","termSource":"NCI"},{"termName":"Omapro","termGroup":"FB","termSource":"NCI"},{"termName":"Synribo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26833-87-4"},{"name":"Chemical_Formula","value":"C29H39NO9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6FG8041S5B"},{"name":"Legacy Concept Name","value":"Homoharringtonine"},{"name":"Maps_To","value":"Omacetaxine Mepesuccinate"},{"name":"NCI_Drug_Dictionary_ID","value":"39476"},{"name":"NSC Number","value":"141633"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39476"},{"name":"PDQ_Open_Trial_Search_ID","value":"39476"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062941"}]}}{"C78480":{"preferredName":"Ombrabulin","code":"C78480","definitions":[{"definition":"A synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ombrabulin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-amino-3-hydroxy-n-(2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)propanamide","termGroup":"SN","termSource":"NCI"},{"termName":"AC7700","termGroup":"CN","termSource":"NCI"},{"termName":"AVE8062","termGroup":"CN","termSource":"NCI"},{"termName":"Combretastatin A4 Analogue AVE8062","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"181816-48-8"},{"name":"Chemical_Formula","value":"C21H26N2O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82JB1524Q6"},{"name":"Legacy Concept Name","value":"Combretastatin_A4_Analogue_AVE8062"},{"name":"Maps_To","value":"Ombrabulin"},{"name":"NCI_Drug_Dictionary_ID","value":"600816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600816"},{"name":"PDQ_Open_Trial_Search_ID","value":"600816"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0910081"}]}}{"C88270":{"preferredName":"Omipalisib","code":"C88270","definitions":[{"definition":"A small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. Omipalisib binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Omipalisib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, 2,4-Difluoro-N-(2-methoxy-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"GSK2126458","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1086062-66-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1X8F5A3NA0"},{"name":"Maps_To","value":"Omipalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"655580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655580"},{"name":"PDQ_Open_Trial_Search_ID","value":"655580"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981793"}]}}{"C85454":{"preferredName":"Onalespib","code":"C85454","definitions":[{"definition":"A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onalespib","termGroup":"PT","termSource":"NCI"},{"termName":"(2,4-Dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone","termGroup":"SN","termSource":"NCI"},{"termName":"AT 13387","termGroup":"CN","termSource":"NCI"},{"termName":"AT-13387","termGroup":"CN","termSource":"NCI"},{"termName":"AT13387","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"912999-49-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q7Y33N57ZZ"},{"name":"Maps_To","value":"Onalespib"},{"name":"NCI_Drug_Dictionary_ID","value":"642817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642817"},{"name":"PDQ_Open_Trial_Search_ID","value":"642817"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2975147"}]}}{"C129425":{"preferredName":"Onalespib Lactate","code":"C129425","definitions":[{"definition":"The lactate form of onalespib, a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onalespib Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"AT-13387 Lactate","termGroup":"CN","termSource":"NCI"},{"termName":"ATI-13387A","termGroup":"CN","termSource":"NCI"},{"termName":"ATI-13387AU","termGroup":"CN","termSource":"NCI"},{"termName":"Propanoic Acid, 2-Hydroxy-, (2S)-, Compound with (1,3-Dihydro-5-((4-methyl-1-piperazinyl)methyl)-2H-isoindol-2-yl)(2,4-dihydroxy-5-(1-methylethyl)phenyl)methanone (1:1)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1019889-35-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"66226JUH2I"},{"name":"Maps_To","value":"Onalespib Lactate"},{"name":"NCI_META_CUI","value":"CL512600"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82348":{"preferredName":"Onartuzumab","code":"C82348","definitions":[{"definition":"A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity. Anti-MET monoclonal antibody MetMAb binds to the extracellular domain of c-Met, preventing the binding of its ligand, hepatocyte growth factor (HGF); the activation of the c-Met signaling pathway is thus inhibited, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase, is overexpressed on the cell surfaces of a variety of cancer cell types and may play a key role in their proliferation, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onartuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-MET Monoclonal Antibody MetMAb","termGroup":"SY","termSource":"NCI"},{"termName":"MetMAb","termGroup":"CN","termSource":"NCI"},{"termName":"OA-5D5","termGroup":"CN","termSource":"NCI"},{"termName":"PRO 143966","termGroup":"CN","termSource":"NCI"},{"termName":"RO5490258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1133766-06-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MS1J9720WC"},{"name":"Legacy Concept Name","value":"Anti-MET_Monoclonal_Antibody_MetMAb"},{"name":"Maps_To","value":"Onartuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"639516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639516"},{"name":"PDQ_Open_Trial_Search_ID","value":"639516"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2826110"}]}}{"C74067":{"preferredName":"Tasadenoturev","code":"C74067","definitions":[{"definition":"An adenovirus serotype 5 strain, selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, with potential oncolytic activity. Tasadenoturev contains an integrin binding RGD-4C motif, allowing Coxsackie adenovirus receptor-independent infection of tumor cells, which are often deficient for Coxsackie and adenovirus receptors (CARs). Selectively replication competent in cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16), active replication of oncolytic adenovirus Ad5-Delta 24RGD in tumor cells may induce oncolysis or cell lysis. As integral components of the late G1 restriction point, the Rb gene product and p16 are negative regulators of the cell cycle; ovarian cancer cells and non-small cell lung cancer cells may be defective in the Rb/p16 pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasadenoturev","termGroup":"PT","termSource":"NCI"},{"termName":"Ad5-Delta24RGD","termGroup":"AB","termSource":"NCI"},{"termName":"DNX 2401","termGroup":"CN","termSource":"NCI"},{"termName":"DNX-2401","termGroup":"CN","termSource":"NCI"},{"termName":"DNX2401","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Ad5-Delta 24RGD","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenovirus Ad5-Delta 24RGD","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenovirus Ad5-DNX-2401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448774-00-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"79ME7DT193"},{"name":"Legacy Concept Name","value":"Oncolytic_Ad5-Delta_24RGD"},{"name":"Maps_To","value":"Oncolytic Adenovirus Ad5-DNX-2401"},{"name":"Maps_To","value":"Tasadenoturev"},{"name":"NCI_Drug_Dictionary_ID","value":"590711"},{"name":"NCI_META_CUI","value":"CL383850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590711"},{"name":"PDQ_Open_Trial_Search_ID","value":"590711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162635":{"preferredName":"Oncolytic HSV-1 C134","code":"C162635","definitions":[{"definition":"A neurovirulent, oncolytic second-generation, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1) where the gene for ICP34.5 has been deleted and the gene encoding the human cytomegalovirus (HCMV), protein kinase R (PKR) evasion protein IRS1, with potential oncolytic and immunostimulating activities. Upon intratumoral administration, oncolytic HSV-1 C134 specifically infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells. IRS1 expression allows the virus to replicate within tumors but limits viral spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 C134","termGroup":"PT","termSource":"NCI"},{"termName":"C 134","termGroup":"CN","termSource":"NCI"},{"termName":"C-134","termGroup":"CN","termSource":"NCI"},{"termName":"C134","termGroup":"CN","termSource":"NCI"},{"termName":"C134-HSV-1","termGroup":"SY","termSource":"NCI"},{"termName":"IRS-1 HSV C134","termGroup":"SY","termSource":"NCI"},{"termName":"oHSV C134","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 C134"},{"name":"NCI_Drug_Dictionary_ID","value":"798723"},{"name":"NCI_META_CUI","value":"CL971027"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798723"},{"name":"PDQ_Open_Trial_Search_ID","value":"798723"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C2676":{"preferredName":"Oncolytic HSV-1 G207","code":"C2676","definitions":[{"definition":"A neuroattenuated, replication-competent, recombinant herpes simplex virus-1 (HSV-1) with potential oncolytic activity. Upon intracerebral administration, oncolytic HSV-1 G207 preferentially replicates within glioma cells, which may elicit tumor-specific systemic immune and cytotoxic T lymphocyte (CTL) responses in addition to direct cytopathic effects. Derived from wild-type HSV-1 strain F, this agent has been neuroattenuated by deletions in both copies of the gamma34.5 gene, the major determinant of HSV neurovirulence. In addition, the HSV-1 gene UL39, encoding the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6), has been inactivated through the insertion of the Escherichia coli lacZ gene. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in nondividing cells but not in dividing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 G207","termGroup":"PT","termSource":"NCI"},{"termName":"G207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"G207"},{"name":"Maps_To","value":"Oncolytic HSV-1 G207"},{"name":"NCI_Drug_Dictionary_ID","value":"38634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38634"},{"name":"PDQ_Open_Trial_Search_ID","value":"38634"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1134718"}]}}{"C2623":{"preferredName":"Oncolytic HSV-1 NV1020","code":"C2623","definitions":[{"definition":"A genetically engineered oncolytic virus with potential antineoplastic property. NV1020 is constructed from the herpes simplex virus 1 (HSV-1) by the deletion of a single copy of the gamma (1)34.5 gene and the substitution of the UL23 region of the thymidine kinase (tk) gene with a DNA fragment from HSV-2, thereby resulting in a replication-competent, attenuated virus. This modified virus preferentially transfects rapidly dividing cells, which causes cell lysis in tumor cells. NV1020 has shown reduced virulence against normal tissues and a decreased neurovirulence in comparison with some other modified HSV strains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 NV1020","termGroup":"PT","termSource":"NCI"},{"termName":"NV1020","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"NV1020"},{"name":"Maps_To","value":"Oncolytic HSV-1 NV1020"},{"name":"NCI_Drug_Dictionary_ID","value":"38237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38237"},{"name":"PDQ_Open_Trial_Search_ID","value":"38237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0935802"}]}}{"C139551":{"preferredName":"Oncolytic HSV-1 rQNestin34.5v.2","code":"C139551","definitions":[{"definition":"A neuroattenuated, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1), with potential oncolytic and immunostimulating activities. In rQNestin34.5v.2, the UL39 gene encoding for the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6) and both endogenous copies of the gamma34.5 gene that encodes for the RL1 neurovirulence protein infected cell protein 34.5 (ICP34.5), which is needed for robust viral growth in an infected cell, are deleted, and one copy of the gamma34.5 gene is reinserted under control of a nestin promoter, which is selectively activated in gliomas. Upon intratumoral administration, oncolytic HSV-1 rQNestin34.5v.2 preferentially infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. rQNestin34.5v.2 also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in non-dividing, healthy cells but not in dividing cells. Glioma-selective expression of ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 rQNestin34.5v.2","termGroup":"PT","termSource":"NCI"},{"termName":"Genetically Engineered HSV-1 Virus rQNestin34.5v.2","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic rQNestin34.5v.2","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic rQNestin34.5v.2 HSV Virus","termGroup":"SY","termSource":"NCI"},{"termName":"rQNestin34.5v.2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 rQNestin34.5v.2"},{"name":"NCI_Drug_Dictionary_ID","value":"791103"},{"name":"NCI_META_CUI","value":"CL526908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791103"},{"name":"PDQ_Open_Trial_Search_ID","value":"791103"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C90563":{"preferredName":"Oncolytic HSV-1 rRp450","code":"C90563","definitions":[{"definition":"A gene therapy agent containing an attenuated, replication-competent, genetically engineered mutant form of the Herpes simplex virus 1 (HSV-1) strain KOS with potential antineoplastic activity. Upon infusion into the hepatic artery, oncolytic HSV-1 rRp450 replicates in hepatocellular carcinoma (HCC) cells and exerts direct cytotoxic effects eventually disrupting cancer cell membranes and liberating progeny virions thereby infecting adjacent tumor cells. In addition, rRp450 expresses the cytochrome P450 transgene that activates oxazaphosphorines, such as cyclophosphamide (CPA). Therefore, CPA can become activated in the presence of rRp450 and exert its antineoplastic effect. rRp450 is deleted for the HSV-1 gene UL39, encoding the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6), thereby disrupting the activity of viral ribonucleotide reductase and resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in nondividing cells but not in dividing cells. UL39 is replaced by the rat CYP2B1 gene, encoding a cytochrome P450 enzyme that activates oxazaphosphorines. rRp450 also expresses viral thymidine kinase, which activates the cancer prodrug ganciclovir.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 rRp450","termGroup":"PT","termSource":"NCI"},{"termName":"rRp450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 rRp450"},{"name":"NCI_Drug_Dictionary_ID","value":"666906"},{"name":"NCI_META_CUI","value":"CL416247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"666906"},{"name":"PDQ_Open_Trial_Search_ID","value":"666906"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84840":{"preferredName":"Oncolytic HSV1716","code":"C84840","definitions":[{"definition":"A neuroattenuated, replication-restricted, ICP34.5 deleted (RL1 gene)-mutant herpes simplex virus (HSV) type I, constructed from wild-type strain 17, with potential oncolytic activity. Upon intratumoral injection, oncolytic HSV1716 transfects, replicates in, and lyses rapidly dividing cells such as tumor cells. Because the RL1 gene is deleted, HSV1716 is unable to replicate in non-dividing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV1716","termGroup":"PT","termSource":"NCI"},{"termName":"HSV1716","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"26WEP2905N"},{"name":"Maps_To","value":"Oncolytic HSV1716"},{"name":"NCI_Drug_Dictionary_ID","value":"650036"},{"name":"NCI_META_CUI","value":"CL412391"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650036"},{"name":"PDQ_Open_Trial_Search_ID","value":"650036"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165457":{"preferredName":"Oncolytic Newcastle Disease Virus MEDI5395","code":"C165457","definitions":[{"definition":"An oncolytic viral agent containing the oncolytic, live-attenuated, replication-competent strain of the avian paramyxovirus Newcastle disease virus (NDV) that has been engineered to include a transgene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunostimulating activities. Upon administration, MEDI5395 specifically infects and replicates in cancer cells. This may result in a direct cytotoxic effect involving the lysis of tumor cells via apoptotic mechanisms and may eventually lead to an inhibition of cancer cell proliferation through the increased production and secretion of pro-inflammatory cytokines and chemokines which are able to recruit mediators of both the innate and adaptive immune responses. Additionally, the inclusion of the GM-CSF transgene in the viral construct leads to expression of GM-CSF, which may potentiate and strengthen the anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Newcastle Disease Virus MEDI5395","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI 5395","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-5395","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI5395","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic NDV MEDI5395","termGroup":"SY","termSource":"NCI"},{"termName":"recNDV(GM-CSF)","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant NDV Expressing GM-CSF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Newcastle Disease Virus MEDI5395"},{"name":"NCI_Drug_Dictionary_ID","value":"799776"},{"name":"NCI_META_CUI","value":"CL978581"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799776"},{"name":"PDQ_Open_Trial_Search_ID","value":"799776"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C91700":{"preferredName":"Oncolytic Newcastle Disease Virus MTH-68H","code":"C91700","definitions":[{"definition":"An oncolytic viral agent containing the oncolytic, live-attenuated strain of the paramyxovirus Newcastle disease virus (NDV), with potential antineoplastic activity. Upon administration, NDV MTH-68H specifically infects and replicates in cancer cells. This may result in a direct cytotoxic effect involving the lysis of tumor cells via apoptotic mechanisms and may eventually lead to an inhibition of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Newcastle Disease Virus MTH-68H","termGroup":"PT","termSource":"NCI"},{"termName":"MTH-68H","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic NDV MTH-68H","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Newcastle Disease Virus MTH-68H"},{"name":"NCI_Drug_Dictionary_ID","value":"257613"},{"name":"NCI_META_CUI","value":"CL422080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257613"},{"name":"PDQ_Open_Trial_Search_ID","value":"257613"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C2799":{"preferredName":"Oncolytic Newcastle Disease Virus Strain PV701","code":"C2799","definitions":[{"definition":"A virus that is being studied in the treatment of cancer. It belongs to the family of viruses that cause Newcastle disease in birds.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An attenuated, replication-competent, oncolytic strain of Newcastle disease virus. PV701 selectively lyses tumor cells. The selectivity of this agent is related to defects in the interferon-mediated antiviral response found in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Newcastle Disease Virus Strain PV701","termGroup":"PT","termSource":"NCI"},{"termName":"PV701","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PV701"},{"name":"Maps_To","value":"Oncolytic Newcastle Disease Virus Strain PV701"},{"name":"NCI_Drug_Dictionary_ID","value":"258388"},{"name":"NSC Number","value":"700553"},{"name":"PDQ_Closed_Trial_Search_ID","value":"258388"},{"name":"PDQ_Open_Trial_Search_ID","value":"258388"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1327815"}]}}{"C161021":{"preferredName":"Oncolytic Virus ASP9801","code":"C161021","definitions":[{"definition":"An engineered oncolytic virus with potential antineoplastic and immunomodulating activities. Upon intratumoral injection of ASP-9801, the oncolytic virus selectively targets and replicates in cancer cells without being able to infect and replicate in normal, healthy cells. This induces selective oncolytic virus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent tumor cells, which both induces further tumor cell oncolysis and may activate the immune system to exert an anti-tumor immune response against the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Virus ASP9801","termGroup":"PT","termSource":"NCI"},{"termName":"ASP 9801","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-9801","termGroup":"CN","termSource":"NCI"},{"termName":"ASP9801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Virus ASP9801"},{"name":"NCI_Drug_Dictionary_ID","value":"798437"},{"name":"NCI_META_CUI","value":"CL969987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798437"},{"name":"PDQ_Open_Trial_Search_ID","value":"798437"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C158074":{"preferredName":"Vusolimogene Oderparepvec","code":"C158074","definitions":[{"definition":"A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In RP1, ICP34.5 and 47 proteins of the HSV1 strain have been deleted; RP1 expresses a fusogenic protein for optimal tumor cell infection and killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vusolimogene Oderparepvec","termGroup":"PT","termSource":"NCI"},{"termName":"Genetically Modified HSV-1 Oncolytic Immunotherapeutic RP1","termGroup":"SY","termSource":"NCI"},{"termName":"HSV-1 Engineered RP1","termGroup":"SY","termSource":"NCI"},{"termName":"HSV-1 Oncolytic Viral Strain RP1","termGroup":"SY","termSource":"NCI"},{"termName":"HSV-1 RP1","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Virus RP1","termGroup":"SY","termSource":"NCI"},{"termName":"RP-1","termGroup":"CN","termSource":"NCI"},{"termName":"RP1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2305659-09-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"45KLN7N6UV"},{"name":"Maps_To","value":"Oncolytic Virus RP1"},{"name":"NCI_Drug_Dictionary_ID","value":"797350"},{"name":"NCI_META_CUI","value":"CL937703"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797350"},{"name":"PDQ_Open_Trial_Search_ID","value":"797350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48007":{"preferredName":"Ondansetron Hydrochloride","code":"C48007","definitions":[{"definition":"The active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. It is a type of serotonin receptor antagonist and a type of antiemetic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of the racemic form of ondansetron, a carbazole derivative and a selective, competitive serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist with antiemetic activity. Although its mechanism of action has not been fully characterized, ondansetron appears to competitively block the action of serotonin at 5HT3 receptors peripherally in the gastrointestinal tract as well as centrally in the area postrema of the CNS, where the chemoreceptor trigger zone (CTZ) for vomiting is located, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ondansetron Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Carbazol-4-one, 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, Monohydrochloride, (+-)-, Dihydrate","termGroup":"SN","termSource":"NCI"},{"termName":"GR 38032F","termGroup":"CN","termSource":"NCI"},{"termName":"GR-C507/75","termGroup":"CN","termSource":"NCI"},{"termName":"SN 307","termGroup":"CN","termSource":"NCI"},{"termName":"SN-307","termGroup":"CN","termSource":"NCI"},{"termName":"SN307","termGroup":"CN","termSource":"NCI"},{"termName":"Zofran","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Nausea and vomiting prophylaxis, chemotherapy-induced and postoperative"},{"name":"CAS_Registry","value":"103639-04-9"},{"name":"Chemical_Formula","value":"C18H19N3O.HCl.2H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NMH84OZK2B"},{"name":"Legacy Concept Name","value":"Ondansetron_Hydrochloride"},{"name":"Maps_To","value":"Ondansetron Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"489533"},{"name":"NSC Number","value":"665799"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489533"},{"name":"PDQ_Open_Trial_Search_ID","value":"489533"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700478"}]}}{"C82406":{"preferredName":"Ontuxizumab","code":"C82406","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Ontuxizumab binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ontuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Protein TEM1 (Tumor Endothelial Marker 1)) (Human-Mouse Monoclonal MORAb-004 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-004 kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb-004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946415-62-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0M2XT000YC"},{"name":"Legacy Concept Name","value":"Anti-Endosialin_Monoclonal_Antibody_MORAb-004"},{"name":"Maps_To","value":"Ontuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"638168"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638168"},{"name":"PDQ_Open_Trial_Search_ID","value":"638168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2826153"}]}}{"C143162":{"preferredName":"Onvansertib","code":"C143162","definitions":[{"definition":"An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onvansertib","termGroup":"PT","termSource":"NCI"},{"termName":"NMS-1286937","termGroup":"CN","termSource":"NCI"},{"termName":"PCM 075","termGroup":"CN","termSource":"NCI"},{"termName":"PCM-075","termGroup":"CN","termSource":"NCI"},{"termName":"PLK-1 Inhibitor PCM-075","termGroup":"SY","termSource":"NCI"},{"termName":"PLK1 Inhibitor PCM-075","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor NMS-1286937","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor PCM-075","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1034616-18-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67RM91WDHQ"},{"name":"Maps_To","value":"Onvansertib"},{"name":"Maps_To","value":"Polo-like Kinase 1 Inhibitor NMS-1286937"},{"name":"NCI_Drug_Dictionary_ID","value":"792149"},{"name":"NCI_META_CUI","value":"CL541611"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792149"},{"name":"PDQ_Open_Trial_Search_ID","value":"792149"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98278":{"preferredName":"Opaganib","code":"C98278","definitions":[{"definition":"An orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, opaganib competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2. SK2 and its isoenzyme SK1 are overexpressed in numerous cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opaganib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Pyridinylmethyl-3-(4-chlorophenyl) Adamantane Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"ABC 294640","termGroup":"CN","termSource":"NCI"},{"termName":"ABC294640","termGroup":"CN","termSource":"NCI"},{"termName":"SK2 inhibitor ABC294640","termGroup":"SY","termSource":"NCI"},{"termName":"Tricyclo(3.3.1.13,7)decane-1-carboxamide, 3-(4-Chlorophenyl)-N-(4-pyridinylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Yeliva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915385-81-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DRG21OQ517"},{"name":"Maps_To","value":"Opaganib"},{"name":"NCI_Drug_Dictionary_ID","value":"712053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712053"},{"name":"PDQ_Open_Trial_Search_ID","value":"712053"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933331"}]}}{"C90545":{"preferredName":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","code":"C90545","definitions":[{"definition":"A capsule containing a fermented soymilk extract and oligomeric proanthocyanidins (OPCs), green tea, spirullina, curcumin and antrodia camphorate powder, with potential antioxidant, immunomodulating, anti-infective and anti-cancer activities. OPCs/green tea/spirullina/curcumin/antrodia camphorate/fermented soymilk extract capsule may boost the immune system and may alleviate fatigue and poor appetite in cancer chemotherapy patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","termGroup":"PT","termSource":"NCI"},{"termName":"MB-6","termGroup":"CN","termSource":"NCI"},{"termName":"Oligomeric Proanthocyanidins/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule"},{"name":"NCI_Drug_Dictionary_ID","value":"665369"},{"name":"NCI_META_CUI","value":"CL416226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665369"},{"name":"PDQ_Open_Trial_Search_ID","value":"665369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48413":{"preferredName":"Opioid Growth Factor","code":"C48413","definitions":[{"definition":"A substance that relieves pain and is being studied in the treatment of some types of cancer. Opioid growth factors bind to cells in the body, including tumor cells, which have opioid growth factor receptors on the surface. This may help stop the growth of the tumor cells. It may also prevent the growth of blood vessels that tumors need to grow. An opioid growth factor is a type of biological response modifier and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An endogenous pentapeptide with potential antineoplastic and antiangiogenic activities. Opioid growth factor (OGF) binds to and activates the OGF receptor, present on some tumor cells and vascular cells, thereby inhibiting tumor cell proliferation and angiogenesis. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Opioid Growth Factor","termGroup":"PT","termSource":"NCI"},{"termName":"OGF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Opioid_Growth_Factor"},{"name":"Maps_To","value":"Opioid Growth Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"428488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"428488"},{"name":"PDQ_Open_Trial_Search_ID","value":"428488"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541553"}]}}{"C61307":{"preferredName":"Oportuzumab Monatox","code":"C61307","definitions":[{"definition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of certain types of head and neck cancer. Anti-EpCAM-Pseudomonas-exotoxin fusion protein is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. It binds to EpCAM (a protein on the surface of epithelial cells and some types of cancer cells).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Oportuzumab Monatox","termGroup":"PT","termSource":"NCI"},{"termName":"Proxinium","termGroup":"BR","termSource":"NCI"},{"termName":"VB4 845","termGroup":"CN","termSource":"NCI"},{"termName":"VB4-845","termGroup":"CN","termSource":"NCI"},{"termName":"Vicinium","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"advanced, recurrent head and neck cancer"},{"name":"CAS_Registry","value":"945228-48-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"945CY7ZMI2"},{"name":"Legacy Concept Name","value":"Anti-EpCAM-Pseudomonas-exotoxin_Fusion_Protein"},{"name":"Maps_To","value":"Oportuzumab Monatox"},{"name":"NCI_Drug_Dictionary_ID","value":"485164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485164"},{"name":"PDQ_Open_Trial_Search_ID","value":"485164"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831819"}]}}{"C91388":{"preferredName":"Oprozomib","code":"C91388","definitions":[{"definition":"An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oprozomib","termGroup":"PT","termSource":"NCI"},{"termName":"O-methyl-N-((2-methylthiazol-5-yl)carbonyl)-l-seryl-O-methyl-N-((1S)-1-benzyl-2-((2R)-2-methyloxiran-2-yl)-2-oxoethyl)-l-serinamide","termGroup":"SY","termSource":"NCI"},{"termName":"ONX 0912","termGroup":"CN","termSource":"NCI"},{"termName":"ONX-0912","termGroup":"CN","termSource":"NCI"},{"termName":"ONX0912","termGroup":"CN","termSource":"NCI"},{"termName":"PR-047","termGroup":"CN","termSource":"NCI"},{"termName":"Proteasome Inhibitor ONX 0912","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"935888-69-0"},{"name":"Chemical_Formula","value":"C25H32N4O7S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MZ37792Y8J"},{"name":"Maps_To","value":"Oprozomib"},{"name":"NCI_Drug_Dictionary_ID","value":"674605"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674605"},{"name":"PDQ_Open_Trial_Search_ID","value":"674605"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2976183"}]}}{"C99763":{"preferredName":"Oral Aminolevulinic Acid Hydrochloride","code":"C99763","definitions":[{"definition":"A powder for an oral solution comprised of the hydrochloride salt of 5-aminolevulinic acid (ALA) with a potential application for photodynamic therapy. After oral administration, ALA is converted intracellularly into the photosensitizer protoporphyrin IX (PpIX). Upon exposure to light of appropriate wavelength (violet to blue range), excited PpIX emits a characteristic red fluorescence which could facilitate guided resection, and generates excited singlet oxygen molecules that could kill cells when appropriate laser dosage is applied. ALA is preferentially taken up by and accumulates in many types of cancer cells compared to normal, healthy cells. Consequently, cancer cells can be visualized and can be distinguished from normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Aminolevulinic Acid Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5-Aminolevulinic Acid Hydrochloride, Oral","termGroup":"SY","termSource":"NCI"},{"termName":"Gleolan","termGroup":"BR","termSource":"NCI"},{"termName":"Gliolan","termGroup":"FB","termSource":"NCI"},{"termName":"Oral 5-ALA","termGroup":"AB","termSource":"NCI"},{"termName":"Oral ALA HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adjunct for the visualization of malignant tissue (glioma) during surgery"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Aminolevulinic Acid Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"723865"},{"name":"NCI_META_CUI","value":"CL433488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"723865"},{"name":"PDQ_Open_Trial_Search_ID","value":"723865"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118288":{"preferredName":"Oral Azacitidine","code":"C118288","definitions":[{"definition":"An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Azacitidine","termGroup":"PT","termSource":"NCI"},{"termName":"Azacitidine Oral","termGroup":"SY","termSource":"NCI"},{"termName":"CC 486","termGroup":"CN","termSource":"NCI"},{"termName":"CC-486","termGroup":"CN","termSource":"NCI"},{"termName":"CC486","termGroup":"CN","termSource":"NCI"},{"termName":"Onureg","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Oral Azacitidine"},{"name":"NCI_Drug_Dictionary_ID","value":"764239"},{"name":"NCI_META_CUI","value":"CL474140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764239"},{"name":"PDQ_Open_Trial_Search_ID","value":"764239"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159540":{"preferredName":"Oral Cancer Vaccine V3-OVA","code":"C159540","definitions":[{"definition":"An orally available cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. Upon oral administration of the oral cancer vaccine V3-OVA, the ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Cancer Vaccine V3-OVA","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine V3-OVA","termGroup":"SY","termSource":"NCI"},{"termName":"Tableted Vaccine V3-OVA","termGroup":"SY","termSource":"NCI"},{"termName":"V3 OVA","termGroup":"CN","termSource":"NCI"},{"termName":"V3-OVA","termGroup":"CN","termSource":"NCI"},{"termName":"V3OVA","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Cancer Vaccine V3-OVA"},{"name":"NCI_Drug_Dictionary_ID","value":"797490"},{"name":"NCI_META_CUI","value":"CL951378"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797490"},{"name":"PDQ_Open_Trial_Search_ID","value":"797490"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131903":{"preferredName":"Oral Docetaxel","code":"C131903","definitions":[{"definition":"An oral proprietary P-glycoprotein (P-gp) pump inhibitor-based formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, and a P-gp pump inhibitor, with potential antineoplastic activity. Upon administration of oral docetaxel, the P-gp pump inhibitor moiety, which is not absorbed, binds to the P-gp pump in the gastrointestinal (GI) tract and prevents the P-gp pump-mediated efflux of docetaxel from cells the docetaxel has been internalized by back into the GI tract. This decreases P-gp-mediated excretion and enhances absorption of docetaxel. Upon absorption, docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizes tubulin and inhibits microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. The P-gp pump inhibitor enhances the bioavailability of certain poorly bioavailable agents and thereby allows oral administration of those agents. P-gp, an efflux membrane transporter, plays a key role in active drug export, and prevents cellular uptake and accumulation of certain substances.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Docetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"Docetaxel-P-glycoprotein Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"Docetaxel-P-gp Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"Oradoxel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Docetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"786271"},{"name":"NCI_META_CUI","value":"CL521226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786271"},{"name":"PDQ_Open_Trial_Search_ID","value":"786271"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64338":{"preferredName":"Oral Fludarabine Phosphate","code":"C64338","definitions":[{"definition":"An oral formulation of the phosphate salt of fludarabine, a synthetic purine nucleoside analogue antimetabolite with antineoplastic activity. Fudarabine is preferentially transported into malignant cells and metabolized by deoxycytidine kinase to its active form, 2-fluoro-ara-ATP; 2-fluoro-ara-ATP competes directly with deoxyadenosine triphosphate (dATP) and inhibits alpha DNA polymerase, RNA reductase, and DNA primase, which may result in inhibition of DNA synthesis and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Fludarabine Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Fludara Oral","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Fludarabine_Phosphate"},{"name":"Maps_To","value":"Oral Fludarabine Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"486428"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486428"},{"name":"PDQ_Open_Trial_Search_ID","value":"486428"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831839"}]}}{"C78843":{"preferredName":"Oral Hsp90 Inhibitor IPI-493","code":"C78843","definitions":[{"definition":"An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or \"client\" proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Hsp90 Inhibitor IPI-493","termGroup":"PT","termSource":"NCI"},{"termName":"17-Aminodemethoxygeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"17-Aminogeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor IPI-493","termGroup":"SY","termSource":"NCI"},{"termName":"IPI-493","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64202-81-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SLQ1AJG3VB"},{"name":"Legacy Concept Name","value":"Hsp90_Inhibitor_IPI-493"},{"name":"Maps_To","value":"Oral Hsp90 Inhibitor IPI-493"},{"name":"NCI_Drug_Dictionary_ID","value":"610131"},{"name":"NSC Number","value":"255109"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610131"},{"name":"PDQ_Open_Trial_Search_ID","value":"610131"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703137"}]}}{"C63478":{"preferredName":"Oral Ixabepilone","code":"C63478","definitions":[{"definition":"An enteric-coated formulation of ixabepilone, a semisynthetic analogue of epothilone B and a non-taxane tubulin inhibitor, with antineoplastic activity. Ixabepilone binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in cell cycle arrest at the G2-M phase and leads to apoptosis within fast growing tumor cells. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. Compared to intravenously administered ixabepilone, the oral formulation provides a more manageable way to administer this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Ixabepilone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Ixabepilone"},{"name":"Maps_To","value":"Oral Ixabepilone"},{"name":"NCI_Drug_Dictionary_ID","value":"486610"},{"name":"NCI_META_CUI","value":"CL415081"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486610"},{"name":"PDQ_Open_Trial_Search_ID","value":"486610"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71132":{"preferredName":"Oral Microencapsulated Diindolylmethane","code":"C71132","definitions":[{"definition":"An orally bioavailable microencapsulated formulation of diindolylmethane, an indole phytonutrient found in cruciferous vegetables, with estrogen-modulating, antiandrogenic, and potential antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) modulates estrogen balance by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of beneficial 2-hydroxy estrogen metabolites. DIM also antagonizes androgen receptor activity, which may result in diminished cell proliferation and apoptosis in susceptible tumor cell populations. Pure DIM, which is relatively hydrophobic, is poorly absorbed after oral administration. This oral formulation, which consists of DIM, d-alpha-tocopheryl acid succinate, phosphatidylcholine, and silica microencapsulated in starch, significantly improves the gastrointestinal absorption of DIM.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Microencapsulated Diindolylmethane","termGroup":"PT","termSource":"NCI"},{"termName":"BioResponse DIM","termGroup":"BR","termSource":"NCI"},{"termName":"BR-DIM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Microencapsulated_Diindolylmethane"},{"name":"Maps_To","value":"Oral Microencapsulated Diindolylmethane"},{"name":"NCI_Drug_Dictionary_ID","value":"577331"},{"name":"NCI_META_CUI","value":"CL377701"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577331"},{"name":"PDQ_Open_Trial_Search_ID","value":"577331"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77880":{"preferredName":"Milataxel","code":"C77880","definitions":[{"definition":"An orally bioavailable taxane with potential antineoplastic activity. Upon oral administration, milataxel and its major active metabolite M-10 bind to and stabilize tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, milataxel appears to be a poor substrate for the multidrug resistance (MDR) membrane-associated P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milataxel","termGroup":"PT","termSource":"NCI"},{"termName":"MAC-321","termGroup":"CN","termSource":"NCI"},{"termName":"TL-00139","termGroup":"CN","termSource":"NCI"},{"termName":"TL139","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"352425-37-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J41Q4S20GS"},{"name":"Legacy Concept Name","value":"Oral_Milataxel"},{"name":"Maps_To","value":"Milataxel"},{"name":"Maps_To","value":"Oral Milataxel"},{"name":"NCI_Drug_Dictionary_ID","value":"597742"},{"name":"NCI_META_CUI","value":"CL387339"},{"name":"PDQ_Closed_Trial_Search_ID","value":"597742"},{"name":"PDQ_Open_Trial_Search_ID","value":"597742"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158745":{"preferredName":"Oral Myoma Vaccine V3-myoma","code":"C158745","definitions":[{"definition":"An orally available therapeutic myoma vaccine containing pooled antigens derived from hydrolyzed, inactivated blood and tumor tissue samples from patients with uterine myoma, with potential antineoplastic and immunomodulatory activities. Upon oral administration, V3-myoma may stimulate the immune system to mount a cytotoxic T-lymphocyte-mediated response against cells expressing myoma-associated antigens. This may reduce the myoma growth and improve myoma-related symptoms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Myoma Vaccine V3-myoma","termGroup":"PT","termSource":"NCI"},{"termName":"V3 Myoma","termGroup":"SY","termSource":"NCI"},{"termName":"V3 Myoma Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V3-myoma","termGroup":"SY","termSource":"NCI"},{"termName":"V3-myoma Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Myoma Vaccine V3-myoma"},{"name":"NCI_Drug_Dictionary_ID","value":"797410"},{"name":"NCI_META_CUI","value":"CL950711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797410"},{"name":"PDQ_Open_Trial_Search_ID","value":"797410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150400":{"preferredName":"Oral Pancreatic Cancer Vaccine V3-P","code":"C150400","definitions":[{"definition":"An orally bioavailable, therapeutic cancer vaccine composed of the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19.9; CA19-9) that is derived from pooled blood of pancreatic cancer patients, with potential immunomodulating activity. Upon oral administration of the oral pancreatic cancer vaccine V3-P, the CA19.9 antigens may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against pancreatic cancer cells expressing the CA19.9 antigen. CA19.9 is overexpressed on a number of different tumor cell types and plays a key role in tumor cell survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Pancreatic Cancer Vaccine V3-P","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine V3-P","termGroup":"SY","termSource":"NCI"},{"termName":"Oral Tableted Therapeutic Vaccine V3-P","termGroup":"SY","termSource":"NCI"},{"termName":"V3 P","termGroup":"CN","termSource":"NCI"},{"termName":"V3-P","termGroup":"CN","termSource":"NCI"},{"termName":"V3-P Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V3P","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oral Pancreatic Cancer Vaccine V3-P"},{"name":"NCI_Drug_Dictionary_ID","value":"792852"},{"name":"NCI_META_CUI","value":"CL552151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792852"},{"name":"PDQ_Open_Trial_Search_ID","value":"792852"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68924":{"preferredName":"Oral Picoplatin","code":"C68924","definitions":[{"definition":"An oral preparation of picoplatin, a third generation platinum compound with antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and RNA transcription and the induction of apoptosis. Because of the increase in steric bulk around the platinum center, there is a relative reduction in the inactivation of picoplatin by thiol-containing species such as glutathione and metallothionein in comparison to cisplatin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Picoplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Picoplatin (Oral)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Picoplatin"},{"name":"Maps_To","value":"Oral Picoplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"551562"},{"name":"NCI_META_CUI","value":"CL374343"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551562"},{"name":"PDQ_Open_Trial_Search_ID","value":"551562"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C67083":{"preferredName":"Oral Sodium Phenylbutyrate","code":"C67083","definitions":[{"definition":"An orally active derivative of the short-chain fatty acid butyrate with potential antineoplastic activity. 4-Phenylbutyrate inhibits histone deacetylase, resulting in cell cycle gene expression modulation, reduced cell proliferation, increased cell differentiation, and apoptosis. This agent also initiates fragmentation of genomic DNA, resulting in decreased DNA synthesis and the inhibition of tumor cell migration and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Sodium Phenylbutyrate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Sodium_Phenylbutyrate"},{"name":"Maps_To","value":"Oral Sodium Phenylbutyrate"},{"name":"NCI_Drug_Dictionary_ID","value":"41827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41827"},{"name":"PDQ_Open_Trial_Search_ID","value":"41827"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882164"}]}}{"C63477":{"preferredName":"Oral Topotecan Hydrochloride","code":"C63477","definitions":[{"definition":"An oral formulation of the hydrochloride salt of topotecan, a semisynthetic derivative of the quinoline alkaloid camptothecin, with potential antineoplastic activity. Topotecan selectively inhibits topoisomerase I activity by stabilizing topoisomerase I-DNA covalent complexes during the S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Topotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4'; 6,7] indolizino[1,2-b] quinoline-3,14-(4H,12H)-dione monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Oral Hycamtin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Oral_Topotecan_Hydrochloride"},{"name":"Maps_To","value":"Oral Topotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"489122"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489122"},{"name":"PDQ_Open_Trial_Search_ID","value":"489122"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831879"}]}}{"C1884":{"preferredName":"Orantinib","code":"C1884","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable receptor tyrosine kinase inhibitor.  SU6668 binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation.  SU6668 also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orantinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2,4-Dimethyl-5-((2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-1H-pyrrol-3-yl)propionic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Orantinibum","termGroup":"SY","termSource":"NCI"},{"termName":"SU6668","termGroup":"CN","termSource":"NCI"},{"termName":"Sugen SU6668","termGroup":"CN","termSource":"NCI"},{"termName":"TSU 68","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"252916-29-3"},{"name":"Chemical_Formula","value":"C18H18N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RL37ZZ665"},{"name":"Legacy Concept Name","value":"SU6668"},{"name":"Maps_To","value":"Orantinib"},{"name":"NCI_Drug_Dictionary_ID","value":"38421"},{"name":"NSC Number","value":"702827"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38421"},{"name":"PDQ_Open_Trial_Search_ID","value":"38421"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2001702"}]}}{"C112000":{"preferredName":"Oraxol","code":"C112000","definitions":[{"definition":"A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oraxol","termGroup":"PT","termSource":"NCI"},{"termName":"Paclitaxel-HM30181 Methanesulfonate Monohydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel/HM30181A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oraxol"},{"name":"NCI_Drug_Dictionary_ID","value":"754236"},{"name":"NCI_META_CUI","value":"CL454289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754236"},{"name":"PDQ_Open_Trial_Search_ID","value":"754236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1784":{"preferredName":"Oregovomab","code":"C1784","definitions":[{"definition":"A monoclonal antibody that is being studied in the treatment of ovarian cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Oregovomab binds to the CA-125 antigen, which is found on most ovarian cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oregovomab","termGroup":"PT","termSource":"NCI"},{"termName":"B43.13","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb B43.13","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody B43.13","termGroup":"SY","termSource":"NCI"},{"termName":"OvaRex","termGroup":"BR","termSource":"NCI"},{"termName":"OvaRex Monoclonal Antibody B43.13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Epithelial ovarian cancer"},{"name":"CAS_Registry","value":"213327-37-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HX101E7L6S"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_B43_13"},{"name":"Maps_To","value":"Oregovomab"},{"name":"NCI_Drug_Dictionary_ID","value":"43251"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43251"},{"name":"PDQ_Open_Trial_Search_ID","value":"43251"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664207"}]}}{"C1250":{"preferredName":"Ormaplatin","code":"C1250","definitions":[{"definition":"A platinum(IV) analogue with antineoplastic activity. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ormaplatin","termGroup":"PT","termSource":"NCI"},{"termName":"tetrachloro(1,2-cyclohexanediamine-N,N')-, (OC-6-22-(trans))Platinum","termGroup":"SN","termSource":"NCI"},{"termName":"Tetraplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62816-98-2"},{"name":"Chemical_Formula","value":"C6H14N2.4Cl.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SFK1SGY8V1"},{"name":"Legacy Concept Name","value":"Ormaplatin"},{"name":"Maps_To","value":"Ormaplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"41211"},{"name":"NSC Number","value":"363812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41211"},{"name":"PDQ_Open_Trial_Search_ID","value":"41211"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076329"}]}}{"C1867":{"preferredName":"Ortataxel","code":"C1867","definitions":[{"definition":"A semisynthetic, second-generation taxane derivative with potential antineoplastic activity. Ortataxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in the inhibition of cell division and cellular proliferation. As it represents a poor substrate for P-glycoprotein (P-gp), multi-drug resistance protein (MRP-1) and breast cancer resistance protein (BCRP) mediated efflux, ortataxel modulates multi-drug resistance mechanisms and may be useful for treating multi-drug resistant tumors that express Pgp, MRP-1 and BCRP.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called taxanes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ortataxel","termGroup":"PT","termSource":"NCI"},{"termName":"(3aS,4R,5E,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-Bis(acetyloxy)-13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano-13aH-oxeto(2',3':5',6')benzo(1',2':4,5)cyclodeca(1,2-d)-1,3-dioxol-4-yl(2R,3S)-3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methylhexanoate","termGroup":"SY","termSource":"NCI"},{"termName":"Bay 59-8862","termGroup":"CN","termSource":"NCI"},{"termName":"BAY59-8862","termGroup":"CN","termSource":"NCI"},{"termName":"IDN5109","termGroup":"CN","termSource":"NCI"},{"termName":"SB-T-101131","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186348-23-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8H61Y4E29N"},{"name":"Legacy Concept Name","value":"Orataxel"},{"name":"Maps_To","value":"Ortataxel"},{"name":"NCI_Drug_Dictionary_ID","value":"38635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38635"},{"name":"PDQ_Open_Trial_Search_ID","value":"38635"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527103"}]}}{"C90582":{"preferredName":"Orteronel","code":"C90582","definitions":[{"definition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orteronel","termGroup":"PT","termSource":"NCI"},{"termName":"6-((7S)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Androgen Synthesis Inhibitor TAK-700","termGroup":"SY","termSource":"NCI"},{"termName":"CYP17A1 Lyase Inhibitor TAK-700","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 700","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-700","termGroup":"CN","termSource":"NCI"},{"termName":"TAK700","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"566939-85-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"UE5K2FNS92"},{"name":"Maps_To","value":"Orteronel"},{"name":"NCI_Drug_Dictionary_ID","value":"583018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583018"},{"name":"PDQ_Open_Trial_Search_ID","value":"583018"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983781"}]}}{"C131535":{"preferredName":"Osilodrostat","code":"C131535","definitions":[{"definition":"An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), with potential anti-adrenal activity and ability to treat Cushing disease (CD). Upon administration, osilodrostat binds to and inhibits the activity of CYP11B1, the enzyme that catalyzes the final step of cortisol synthesis from the precursor 11-deoxycortisol, and CYP11B2, the enzyme that catalyzes aldosterone synthesis from corticosterone and 11-deoxycorticosterone in the adrenal gland. The inhibition of CYP11B1 prevents the production of excess cortisol, thereby decreasing and normalizing the levels of cortisol. CD is most often caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osilodrostat","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"LCI 699","termGroup":"CN","termSource":"NCI"},{"termName":"LCI-699","termGroup":"CN","termSource":"NCI"},{"termName":"LCI699","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"928134-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5YL4IQ1078"},{"name":"Maps_To","value":"Osilodrostat"},{"name":"NCI_Drug_Dictionary_ID","value":"786177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786177"},{"name":"PDQ_Open_Trial_Search_ID","value":"786177"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2976005"}]}}{"C116377":{"preferredName":"Osimertinib","code":"C116377","definitions":[{"definition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osimertinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 9291","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-9291","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9291","termGroup":"CN","termSource":"NCI"},{"termName":"Mereletinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"1421373-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"3C06JJ0Z2O"},{"name":"Maps_To","value":"Osimertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"747632"},{"name":"PDQ_Closed_Trial_Search_ID","value":"747632"},{"name":"PDQ_Open_Trial_Search_ID","value":"747632"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896906"}]}}{"C74006":{"preferredName":"Otlertuzumab","code":"C74006","definitions":[{"definition":"A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential immunostimulatory and antineoplastic activities. Otlertuzumab binds to CD37 on B-cells, which may result in antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. CD37 is a transmembrane glycoprotein expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. This agent may have a longer half-life in vivo than conventional monoclonal antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Otlertuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin, Anti-(Human CD Antigen CD37) (Synthetic Human-Mus Musculus Fragment TRU-016), Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"TRU 016","termGroup":"CN","termSource":"NCI"},{"termName":"TRU-016","termGroup":"CN","termSource":"NCI"},{"termName":"TRU016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1372645-37-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2MZ3L2664T"},{"name":"Legacy Concept Name","value":"Anti-CD37_Single-Chain_Polypeptide_TRU-016"},{"name":"Maps_To","value":"Otlertuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"589521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589521"},{"name":"PDQ_Open_Trial_Search_ID","value":"589521"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346800"}]}}{"C113651":{"preferredName":"Ovapuldencel-T","code":"C113651","definitions":[{"definition":"A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovapuldencel-T","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FK2WI4Y35P"},{"name":"Maps_To","value":"Ovapuldencel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"756846"},{"name":"NCI_META_CUI","value":"CL458364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756846"},{"name":"PDQ_Open_Trial_Search_ID","value":"756846"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96739":{"preferredName":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006","code":"C96739","definitions":[{"definition":"A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006","termGroup":"PT","termSource":"NCI"},{"termName":"DC-006","termGroup":"CN","termSource":"NCI"},{"termName":"DC-006 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006"},{"name":"NCI_Drug_Dictionary_ID","value":"699229"},{"name":"NCI_META_CUI","value":"CL429364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699229"},{"name":"PDQ_Open_Trial_Search_ID","value":"699229"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2350":{"preferredName":"Ovine Submaxillary Mucin","code":"C2350","definitions":[{"definition":"A naturally occurring mucin glycoprotein. Ovine submaxillary mucin (OSM), extracted from an ovine submaxillary gland, provides a rich source of the sialylated Tn antigen (sTn), which is a carbohydrate antigen found on mucins of many epithelial tumors. Vaccination with OSM may result in the production of antibodies as well as elicitation of a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing sTn, thereby results in decreased tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ovine Submaxillary Mucin","termGroup":"PT","termSource":"NCI"},{"termName":"Ovine Sialomucin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ovine_Submaxillary_Mucin"},{"name":"Maps_To","value":"Ovine Submaxillary Mucin"},{"name":"NCI_Drug_Dictionary_ID","value":"39375"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39375"},{"name":"PDQ_Open_Trial_Search_ID","value":"39375"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0279238"}]}}{"C160192":{"preferredName":"Tezemlimogene Daxadenorepvec","code":"C160192","definitions":[{"definition":"A selectively replication competent oncolytic adenovirus that is engineered to express OX40 ligand (OX40L) with potential oncolytic and immunostimulatory activities. Upon administration, tezemlimogene daxadenorepvec, which contains an integrin binding RGD-4C motif, infects tumor cells in a Coxsackievirus-adenovirus receptor-independent manner and selectively replicates in tumor cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16). Tumor cell selectivity is achieved through a 24-base pair deletion in the E1A gene, which renders the oncolytic adenovirus unable to replicate in normal cells that maintain a functional Rb pathway, but fully replication competent in Rb/p16 defective tumor cells.  Active replication of the OX40L-expressing oncolytic adenovirus within tumor cells may induce oncolysis and release of OX40L. OX40L may then bind to and activate signaling pathways downstream of its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes and promote the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. The Rb gene product and p16 are negative regulators of the cell cycle and are defective in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tezemlimogene Daxadenorepvec","termGroup":"PT","termSource":"NCI"},{"termName":"DNX 2440","termGroup":"CN","termSource":"NCI"},{"termName":"DNX-2440","termGroup":"CN","termSource":"NCI"},{"termName":"DNX2440","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenovirus Armed With OX40L DNX-2440","termGroup":"SY","termSource":"NCI"},{"termName":"OX40L-expressing Oncolytic Adenovirus DNX-2440","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2642046-11-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B7N7BR6M4A"},{"name":"Maps_To","value":"OX40L-expressing Oncolytic Adenovirus DNX-2440"},{"name":"NCI_Drug_Dictionary_ID","value":"797863"},{"name":"NCI_META_CUI","value":"CL969332"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797863"},{"name":"PDQ_Open_Trial_Search_ID","value":"797863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1181":{"preferredName":"Oxaliplatin","code":"C1181","definitions":[{"definition":"A drug used with other drugs to treat colorectal cancer that is advanced or has come back. It is also being studied in the treatment of other types of cancer. Eloxatin attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxaliplatin","termGroup":"PT","termSource":"NCI"},{"termName":"1-OHP","termGroup":"AB","termSource":"NCI"},{"termName":"[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum","termGroup":"SN","termSource":"NCI"},{"termName":"[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum","termGroup":"SN","termSource":"NCI"},{"termName":"Ai Heng","termGroup":"FB","termSource":"NCI"},{"termName":"Aiheng","termGroup":"FB","termSource":"NCI"},{"termName":"Dacotin","termGroup":"FB","termSource":"NCI"},{"termName":"Dacplat","termGroup":"FB","termSource":"NCI"},{"termName":"Diaminocyclohexane Oxalatoplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"Eloxatin","termGroup":"BR","termSource":"NCI"},{"termName":"Eloxatine","termGroup":"FB","termSource":"NCI"},{"termName":"Elplat","termGroup":"FB","termSource":"NCI"},{"termName":"JM 83","termGroup":"CN","termSource":"NCI"},{"termName":"JM-83","termGroup":"CN","termSource":"NCI"},{"termName":"JM83","termGroup":"CN","termSource":"NCI"},{"termName":"oxalato (1R,2R-cyclohexanediamine)platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)","termGroup":"SN","termSource":"NCI"},{"termName":"Oxalatoplatin","termGroup":"SY","termSource":"NCI"},{"termName":"Oxalatoplatinum","termGroup":"SY","termSource":"NCI"},{"termName":"RP-54780","termGroup":"CN","termSource":"NCI"},{"termName":"RP54780","termGroup":"CN","termSource":"NCI"},{"termName":"SR 96669","termGroup":"CN","termSource":"NCI"},{"termName":"SR-96669","termGroup":"CN","termSource":"NCI"},{"termName":"SR96669","termGroup":"CN","termSource":"NCI"},{"termName":"trans-l DACH oxalatoplatinum","termGroup":"SN","termSource":"NCI"},{"termName":"trans-l diaminocyclohexane oxalatoplatinum","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Metastatic colorectal cancer; ovarian cancer"},{"name":"CAS_Registry","value":"61825-94-3"},{"name":"CHEBI_ID","value":"CHEBI:31941"},{"name":"Chemical_Formula","value":"C8H14N2O4Pt"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"04ZR38536J"},{"name":"Legacy Concept Name","value":"Oxaliplatin"},{"name":"Maps_To","value":"Oxaliplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"42374"},{"name":"NSC Number","value":"266046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42374"},{"name":"PDQ_Open_Trial_Search_ID","value":"42374"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069717"}]}}{"C91074":{"preferredName":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome","code":"C91074","definitions":[{"definition":"A nanoparticle formulation containing N-glutaryl phosphatidylethanolamine (NGPE)-liposomes encapsulating oxaliplatin and conjugated to the human transferrin (Tf) ligand, with potential antineoplastic activity. Upon infusion of oxaliplatin-encapsulated transferrin-conjugated NGPE liposomes, the transferrin moiety targets and binds to the Tf receptor, which is overexpressed on a variety of human cancer cells. Upon binding and internalization, oxaliplatin is released and its active derivatives alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which results in an inhibition of DNA replication and transcription. By extending the circulation time and specifically targeting transferrin receptors, this formulation may improve the efficacy and safety of oxaliplatin therapy, compared to administration of oxaliplatin alone. NGPE, a reactive phospholipid, is used as a linker to attach the Tf ligand, to the liposome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"MBP-426","termGroup":"CN","termSource":"NCI"},{"termName":"Oxaliplatin-Encapsulated Tf-Conjugated NGPE-Liposome","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"669661"},{"name":"NCI_META_CUI","value":"CL416281"},{"name":"PDQ_Closed_Trial_Search_ID","value":"669661"},{"name":"PDQ_Open_Trial_Search_ID","value":"669661"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C47643":{"preferredName":"Oxcarbazepine","code":"C47643","definitions":[{"definition":"A dibenzazepine carboxamide derivative with an anticonvulsant property. As a prodrug, oxcarbazepine is converted to its active metabolite, 10-monohydroxy. Although the mechanism of action has not been fully elucidated, electrophysiological studies indicate this agent blocks voltage-gated sodium channels, thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing the propagation of synaptic impulses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxcarbazepine","termGroup":"PT","termSource":"NCI"},{"termName":"10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Trileptal","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"28721-07-5"},{"name":"CHEBI_ID","value":"CHEBI:7824"},{"name":"Chemical_Formula","value":"C15H12N2O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VZI5B1W380"},{"name":"Legacy Concept Name","value":"Oxcarbazepine"},{"name":"Maps_To","value":"Oxcarbazepine"},{"name":"NCI_Drug_Dictionary_ID","value":"758784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758784"},{"name":"PDQ_Open_Trial_Search_ID","value":"758784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069751"}]}}{"C132271":{"preferredName":"Oxeclosporin","code":"C132271","synonyms":[{"termName":"Oxeclosporin","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclo(((2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-O-(2-hydroxyethyl)-D-seryl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclosporin A, 2-(O-(2-hydroxyethyl)-D-serine)-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135548-15-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R7988D03JM"},{"name":"Maps_To","value":"Oxeclosporin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0170835"}]}}{"C130012":{"preferredName":"Oxidative Phosphorylation Inhibitor IACS-010759","code":"C130012","definitions":[{"definition":"An orally bioavailable oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration of the OxPhos inhibitor IACS-010759, this agent binds to and inhibits complex I of the electron transport chain (NADH ubiquinone oxidoreductase), thereby selectively depriving tumor cells of nutrients, and energy, and inhibiting nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation. Mitochondrial complex I, which is hyperactivated in cancer cells to meet their increased demands for energy, plays a key role in the promotion of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxidative Phosphorylation Inhibitor IACS-010759","termGroup":"PT","termSource":"NCI"},{"termName":"IACS-010759","termGroup":"CN","termSource":"NCI"},{"termName":"OXPHOS Inhibitor IACS-010759","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1570496-34-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42W52V11DJ"},{"name":"Maps_To","value":"Oxidative Phosphorylation Inhibitor IACS-010759"},{"name":"NCI_Drug_Dictionary_ID","value":"784867"},{"name":"NCI_META_CUI","value":"CL513977"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784867"},{"name":"PDQ_Open_Trial_Search_ID","value":"784867"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153372":{"preferredName":"Lixumistat Acetate","code":"C153372","definitions":[{"definition":"The acetate salt form of lixumistat, an orally bioavailable biguanide compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration, lixumistat inhibits oxidative phosphorylation, decreases mitochondrial function, prevents tumor cell metabolism and deprives tumor cells of energy, thereby preventing tumor cell proliferation. Mitochondrial OxPhos is overactivated in cancer cells and plays a key role in tumor cell proliferation. Drug resistant tumor cells are very susceptible to decreased mitochondrial OxPhos as they cannot easily compensate for the decrease in mitochondrial function by increasing glycolysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lixumistat Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"HL271 Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"IM 156","termGroup":"CN","termSource":"NCI"},{"termName":"IM-156","termGroup":"CN","termSource":"NCI"},{"termName":"IM156","termGroup":"CN","termSource":"NCI"},{"termName":"Mitochondrial Oxidative Phosphorylation Inhibitor IM156","termGroup":"SY","termSource":"NCI"},{"termName":"Oxidative Phosphorylation Inhibitor IM156","termGroup":"SY","termSource":"NCI"},{"termName":"OxPhos Inhibitor IM156","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1422365-94-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8MS59W493C"},{"name":"Maps_To","value":"Oxidative Phosphorylation Inhibitor IM156"},{"name":"NCI_Drug_Dictionary_ID","value":"793779"},{"name":"NCI_META_CUI","value":"CL554528"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793779"},{"name":"PDQ_Open_Trial_Search_ID","value":"793779"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1316":{"preferredName":"Oxidopamine","code":"C1316","definitions":[{"definition":"An antagonist of the neurotransmitter dopamine with potential antineoplastic activity. 6-Hydroxydopamine (6-HOD) can be taken up by selective adrenergic terminals, thereby causing acute degeneration of adrenergic terminals that leads to depletion of norepinephrine, and of dopamine in the dopamine-sensitive sites. This agent is auto-oxidated at physiological pH that leads to the formation of reactive free radicals, thereby leading to cytotoxicity in neural cells.  6-Hydroxydopamine is often used to induce CNS and sympathetic neural lesions that model aging and various nervous disorders in animal systems.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxidopamine","termGroup":"PT","termSource":"NCI"},{"termName":"2,4,5-Trihydroxyphenethylamine","termGroup":"SN","termSource":"NCI"},{"termName":"5-(2-Aminoethyl)-1,2,4-benzenetriol","termGroup":"SN","termSource":"NCI"},{"termName":"6-Hydroxydopamine","termGroup":"SY","termSource":"NCI"},{"termName":"6-OHDA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1199-18-4"},{"name":"Chemical_Formula","value":"C8H11NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8HW4YBZ748"},{"name":"Legacy Concept Name","value":"_6-Hydroxydopamine"},{"name":"Maps_To","value":"Oxidopamine"},{"name":"NCI_Drug_Dictionary_ID","value":"41295"},{"name":"NSC Number","value":"233898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41295"},{"name":"PDQ_Open_Trial_Search_ID","value":"41295"},{"name":"PubMedID_Primary_Reference","value":"2511086"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0085196"}]}}{"C118283":{"preferredName":"OxPhos Inhibitor VLX600","code":"C118283","definitions":[{"definition":"A lipophilic cation-based triazinoindolyl-hydrazone compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon infusion, in normal cells and proliferating tumor cells where glucose is readily available, inhibition of OxPhos by VLX600 induces a hypoxia-inducible factor 1-alpha (HIF-1alpha)-dependent shift to, and an increase in glycolysis. Glycolysis alone does not produce enough energy to support the growth of tumor cells in this environment, and the induction of autophagy occurs. In the metabolically compromised tumor microenvironment, the availability of oxygen and glucose is limited due to poor vascularization and perfusion of tumor micro-areas. Tumor cells growing in this environment are thus unable to compensate for decreased mitochondrial function by increasing glycolysis. This leads to nutrient depletion, decreased energy production, induction of autophagy, tumor cell death and an inhibition of cell proliferation in quiescent tumor cells. Mitochondrial OxPhos, which is hyperactivated in cancer cells, plays a key role in the promotion of cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"OxPhos Inhibitor VLX600","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Pyridinyl)ethanone(6-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)hydrazone","termGroup":"SN","termSource":"NCI"},{"termName":"VLX-600","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"327031-55-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YZO6DG19MG"},{"name":"Maps_To","value":"OxPhos Inhibitor VLX600"},{"name":"NCI_Drug_Dictionary_ID","value":"764234"},{"name":"NCI_META_CUI","value":"CL474135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764234"},{"name":"PDQ_Open_Trial_Search_ID","value":"764234"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95214":{"preferredName":"Ozarelix","code":"C95214","definitions":[{"definition":"A highly modified, fourth generation linear decapeptide with gonadotropin-releasing hormone (GnRH or LHRH) antagonizing properties. Ozarelix competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ozarelix","termGroup":"PT","termSource":"NCI"},{"termName":"D 63153","termGroup":"CN","termSource":"NCI"},{"termName":"D-63 153","termGroup":"CN","termSource":"NCI"},{"termName":"D63 153","termGroup":"CN","termSource":"NCI"},{"termName":"D63153","termGroup":"CN","termSource":"NCI"},{"termName":"LHRH antagonist SPI-153","termGroup":"SY","termSource":"NCI"},{"termName":"SPI-153","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"295350-45-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1IF8M2YL3"},{"name":"Maps_To","value":"Ozarelix"},{"name":"NCI_Drug_Dictionary_ID","value":"690937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690937"},{"name":"PDQ_Open_Trial_Search_ID","value":"690937"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987000"}]}}{"C91723":{"preferredName":"P-cadherin Antagonist PF-03732010","code":"C91723","definitions":[{"definition":"An agent that inhibits P-cadherin (cdh3), with potential antineoplastic activity. PF-03732010 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of solid tumors, and plays a role in cell adhesion, motility, invasion and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-cadherin Antagonist PF-03732010","termGroup":"PT","termSource":"NCI"},{"termName":"PF-03732010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2070913-84-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LPW79O1J5Z"},{"name":"Maps_To","value":"P-cadherin Antagonist PF-03732010"},{"name":"NCI_Drug_Dictionary_ID","value":"580366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"580366"},{"name":"PDQ_Open_Trial_Search_ID","value":"580366"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3179737"}]}}{"C121216":{"preferredName":"P-cadherin Inhibitor PCA062","code":"C121216","definitions":[{"definition":"An agent that inhibits p-cadherin, with potential antineoplastic activity. Upon intravenous infusion, PCA062 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-cadherin Inhibitor PCA062","termGroup":"PT","termSource":"NCI"},{"termName":"P-CAD Inhibitor PCA062","termGroup":"SY","termSource":"NCI"},{"termName":"P-cadherin Antagonist PCA062","termGroup":"SY","termSource":"NCI"},{"termName":"PCA062","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"P-cadherin Inhibitor PCA062"},{"name":"NCI_Drug_Dictionary_ID","value":"769816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769816"},{"name":"PDQ_Open_Trial_Search_ID","value":"769816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053579"}]}}{"C125607":{"preferredName":"P-cadherin-targeting Agent PF-06671008","code":"C125607","definitions":[{"definition":"An agent that targets p-cadherin (CDH3), with potential antineoplastic activity. Upon administration, PF-06671008 binds to and inhibits the activity of p-cadherin; this may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-cadherin-targeting Agent PF-06671008","termGroup":"PT","termSource":"NCI"},{"termName":"PF-06671008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2GWZ8HN70W"},{"name":"Maps_To","value":"P-cadherin-targeting Agent PF-06671008"},{"name":"NCI_Drug_Dictionary_ID","value":"778591"},{"name":"NCI_META_CUI","value":"CL504311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778591"},{"name":"PDQ_Open_Trial_Search_ID","value":"778591"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113293":{"preferredName":"P-p68 Inhibitor RX-5902","code":"C113293","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, P-p68 inhibitor RX-5902 may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. p21 is a potent cyclin-dependent kinase inhibitor which regulates cell cycle progression and mediates both growth arrest and cellular senescence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"P-p68 Inhibitor RX-5902","termGroup":"PT","termSource":"NCI"},{"termName":"RX-5902","termGroup":"CN","termSource":"NCI"},{"termName":"Supinoxin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"888478-45-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZU8OM8V5WF"},{"name":"Maps_To","value":"P-p68 Inhibitor RX-5902"},{"name":"NCI_Drug_Dictionary_ID","value":"755944"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755944"},{"name":"PDQ_Open_Trial_Search_ID","value":"755944"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827081"}]}}{"C121456":{"preferredName":"Atuveciclib","code":"C121456","definitions":[{"definition":"An inhibitor of positive transcription elongation factor b (P-TEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin-T (CycT), with potential antineoplastic activity. Upon administration, atuveciclib binds to and inhibits the activity of P-TEFb, thereby preventing the phosphorylation of its downstream target, the carboxyl terminal domain (CTD) of RNA polymerase II (RNA Pol II), and inhibiting the activation of transcriptional elongation by RNA Pol II. This prevents the transcription of tumor promoting genes, induces tumor cell apoptosis, and inhibits tumor cell proliferation. P-TEFb plays an important role in the regulation of gene transcription; over-activation in cancer cells leads to both the transcription of key tumor-promoting genes and cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atuveciclib","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5-Triazin-2-amine, 4-(4-Fluoro-2-methoxyphenyl)-N-(3-((S-methylsulfonimidoyl)methyl)phenyl)-, (+)-","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 1143572","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1143572","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1414943-94-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"63Q7F59W0V"},{"name":"Maps_To","value":"Atuveciclib"},{"name":"Maps_To","value":"P-TEFb Inhibitor BAY1143572"},{"name":"NCI_Drug_Dictionary_ID","value":"753347"},{"name":"NCI_META_CUI","value":"CL471744"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753347"},{"name":"PDQ_Open_Trial_Search_ID","value":"753347"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160195":{"preferredName":"Inobrodib","code":"C160195","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, inobrodib selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inobrodib","termGroup":"PT","termSource":"NCI"},{"termName":"CCS 1477","termGroup":"CN","termSource":"NCI"},{"termName":"CCS-1477","termGroup":"CN","termSource":"NCI"},{"termName":"CCS1477","termGroup":"CN","termSource":"NCI"},{"termName":"p300 HAT/CREB Binding Protein Inhibitor CCS1477","termGroup":"SY","termSource":"NCI"},{"termName":"p300/CBP Bromodomain Inhibitor CCS1477","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222941-37-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BW5QA5GEW7"},{"name":"Maps_To","value":"p300/CBP Bromodomain Inhibitor CCS1477"},{"name":"NCI_Drug_Dictionary_ID","value":"797847"},{"name":"NCI_META_CUI","value":"CL969329"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797847"},{"name":"PDQ_Open_Trial_Search_ID","value":"797847"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99134":{"preferredName":"p38 MAPK Inhibitor LY3007113","code":"C99134","definitions":[{"definition":"An orally active p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activity. Upon administration, LY3007113 inhibits the activity of p38, thereby preventing p38 MAPK-mediated signaling. This may result in the inhibition of the production of proinflammatory cytokines and the induction of tumor cell apoptosis. p38 MAPK, a serine/threonine protein kinase often upregulated in cancer cells, plays a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p38 MAPK Inhibitor LY3007113","termGroup":"PT","termSource":"NCI"},{"termName":"LY3007113","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p38 MAPK Inhibitor LY3007113"},{"name":"NCI_Drug_Dictionary_ID","value":"716106"},{"name":"NCI_META_CUI","value":"CL432952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"716106"},{"name":"PDQ_Open_Trial_Search_ID","value":"716106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1986":{"preferredName":"p53 Peptide Vaccine MPS-128","code":"C1986","definitions":[{"definition":"A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p53 Peptide Vaccine MPS-128","termGroup":"PT","termSource":"NCI"},{"termName":"MPS-128","termGroup":"SY","termSource":"NCI"},{"termName":"MPS-128","termGroup":"CN","termSource":"NCI"},{"termName":"p53:264-272 Peptide","termGroup":"SY","termSource":"NCI"},{"termName":"PR-147","termGroup":"SY","termSource":"NCI"},{"termName":"PR-147","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"p53_Peptide_Vaccine"},{"name":"Maps_To","value":"p53 Peptide Vaccine MPS-128"},{"name":"NCI_Drug_Dictionary_ID","value":"43633"},{"name":"NSC Number","value":"717111"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43633"},{"name":"PDQ_Open_Trial_Search_ID","value":"43633"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879339"}]}}{"C106120":{"preferredName":"p53-HDM2 Interaction Inhibitor MI-773","code":"C106120","definitions":[{"definition":"An orally available spiro-oxindole HDM2 (human double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, the p53-HDM2 protein-protein interaction inhibitor MI-773 binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p53-HDM2 Interaction Inhibitor MI-773","termGroup":"PT","termSource":"NCI"},{"termName":"MI-773","termGroup":"CN","termSource":"NCI"},{"termName":"p53-MDM2 Interaction Inhibitor MI-773","termGroup":"SY","termSource":"NCI"},{"termName":"SAR405838","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1303607-60-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8570LZ3RCA"},{"name":"Maps_To","value":"p53-HDM2 Interaction Inhibitor MI-773"},{"name":"NCI_Drug_Dictionary_ID","value":"737146"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737146"},{"name":"PDQ_Open_Trial_Search_ID","value":"737146"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853940"}]}}{"C132991":{"preferredName":"Alrizomadlin","code":"C132991","definitions":[{"definition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alrizomadlin","termGroup":"PT","termSource":"NCI"},{"termName":"AA-115","termGroup":"CN","termSource":"NCI"},{"termName":"APG 115","termGroup":"CN","termSource":"NCI"},{"termName":"APG-115","termGroup":"CN","termSource":"NCI"},{"termName":"MDM2-p53 Inhibitor APG-115","termGroup":"SY","termSource":"NCI"},{"termName":"p53-HDM2 Protein-protein Interaction Inhibitor APG-115","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1818393-16-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15QAU0SI9J"},{"name":"Maps_To","value":"p53-HDM2 Protein-protein Interaction Inhibitor APG-115"},{"name":"NCI_Drug_Dictionary_ID","value":"787602"},{"name":"NCI_META_CUI","value":"CL520348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787602"},{"name":"PDQ_Open_Trial_Search_ID","value":"787602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104280":{"preferredName":"p53/HDM2 Interaction Inhibitor CGM097","code":"C104280","definitions":[{"definition":"An orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p53/HDM2 Interaction Inhibitor CGM097","termGroup":"PT","termSource":"NCI"},{"termName":"CGM097","termGroup":"CN","termSource":"NCI"},{"termName":"HDM2/p53 Inhibitor CGM097","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313363-54-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4UF6MSL0ZH"},{"name":"Maps_To","value":"p53/HDM2 Interaction Inhibitor CGM097"},{"name":"NCI_Drug_Dictionary_ID","value":"744999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"744999"},{"name":"PDQ_Open_Trial_Search_ID","value":"744999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641742"}]}}{"C91393":{"preferredName":"p70S6K Inhibitor LY2584702","code":"C91393","definitions":[{"definition":"An orally available inhibitor of p70S6K signaling, with potential antineoplastic activity. p70S6K inhibitor LY2584702 inhibits ribosomal protein S6 Kinase (p70S6K), and prevents phosphorylation of the S6 subunit of ribosomes, thereby inhibiting normal ribosomal function within tumor cells leading to a decrease in protein synthesis and in cellular proliferation. P70S6K, a serine/threonine kinase, acts downstream of PIP3 and phosphoinositide-dependent kinase-1 in the PI3 kinase pathway, is often upregulated in a variety of cancer cells, and is involved in the regulation of cell growth, proliferation, motility, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p70S6K Inhibitor LY2584702","termGroup":"PT","termSource":"NCI"},{"termName":"LY2584702","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1082949-67-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I4965C6W4O"},{"name":"Maps_To","value":"p70S6K Inhibitor LY2584702"},{"name":"NCI_Drug_Dictionary_ID","value":"673507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673507"},{"name":"PDQ_Open_Trial_Search_ID","value":"673507"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984214"}]}}{"C112004":{"preferredName":"Rupitasertib","code":"C112004","definitions":[{"definition":"An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, rupitasertib binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rupitasertib","termGroup":"PT","termSource":"NCI"},{"termName":"M-2698","termGroup":"CN","termSource":"NCI"},{"termName":"MSC-2363318A","termGroup":"CN","termSource":"NCI"},{"termName":"MSC2363318A","termGroup":"CN","termSource":"NCI"},{"termName":"p70S6K/Akt Inhibitor M-2698","termGroup":"SY","termSource":"NCI"},{"termName":"p70S6K/Akt Inhibitor MSC2363318A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1379545-95-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0DXG50I4WD"},{"name":"Maps_To","value":"p70S6K/Akt Inhibitor MSC2363318A"},{"name":"NCI_Drug_Dictionary_ID","value":"754258"},{"name":"NCI_META_CUI","value":"CL454293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754258"},{"name":"PDQ_Open_Trial_Search_ID","value":"754258"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118287":{"preferredName":"p97 Inhibitor CB-5083","code":"C118287","definitions":[{"definition":"An orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity. Upon oral administration, CB-5083 specifically binds to and inhibits the activity of p97. This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins. The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and inhibition of cell proliferation in susceptible tumor cells. p97, a type II AAA ATPase, plays a key role in cellular protein homeostasis. Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p97 Inhibitor CB-5083","termGroup":"PT","termSource":"NCI"},{"termName":"CB-5083","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1542705-92-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"591IV6UL6J"},{"name":"Maps_To","value":"p97 Inhibitor CB-5083"},{"name":"NCI_Drug_Dictionary_ID","value":"764238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764238"},{"name":"PDQ_Open_Trial_Search_ID","value":"764238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896891"}]}}{"C1411":{"preferredName":"Paclitaxel","code":"C1411","definitions":[{"definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine","termGroup":"SN","termSource":"NCI"},{"termName":"[2aR-[2a Alpha,4beta,4a beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Anzatax","termGroup":"FB","termSource":"NCI"},{"termName":"Asotax","termGroup":"FB","termSource":"NCI"},{"termName":"Bristaxol","termGroup":"FB","termSource":"NCI"},{"termName":"Praxel","termGroup":"FB","termSource":"NCI"},{"termName":"Taxol","termGroup":"AQS","termSource":"NCI"},{"termName":"Taxol Konzentrat","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"AIDS-related Kaposi's sarcoma; Bladder cancer; Breast cancer; Cervical cancer; Endometrial adenocarcinoma; Esophageal cancer; Head and Neck cancer; Lung cancer; non-small cell; Lymphoma; Ovarian cancer; Prostate cancer; Testicular cancer"},{"name":"CAS_Registry","value":"33069-62-4"},{"name":"CHEBI_ID","value":"CHEBI:45863"},{"name":"Chemical_Formula","value":"C47H51NO14"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"P88XT4IS4D"},{"name":"Legacy Concept Name","value":"Paclitaxel"},{"name":"Maps_To","value":"Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"39762"},{"name":"NSC Number","value":"125973"},{"name":"NSC Number","value":"673089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39762"},{"name":"PDQ_Open_Trial_Search_ID","value":"39762"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0144576"}]}}{"C96934":{"preferredName":"Paclitaxel Ceribate","code":"C96934","definitions":[{"definition":"The ceribate ester form of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to and stabilizes tubulin thereby inhibiting the disassembly of microtubules, resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (BCL2).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Ceribate","termGroup":"PT","termSource":"NCI"},{"termName":"7beta-((2RS)-2,3-dihydroxypropoxycarbonyloxy)-1-hydroxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoate)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186040-50-6"},{"name":"Chemical_Formula","value":"C51H57NO18"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B3C86E80A0"},{"name":"Maps_To","value":"Paclitaxel Ceribate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273125"}]}}{"C96037":{"preferredName":"Paclitaxel Injection Concentrate for Nanodispersion","code":"C96037","definitions":[{"definition":"A nanoparticle-based injectable concentrate containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity.  Upon reconstitution and administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and allows for administration of higher doses resulting in higher concentrations of paclitaxel at the tumor site, and an increased safety profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Injection Concentrate for Nanodispersion","termGroup":"PT","termSource":"NCI"},{"termName":"PICN","termGroup":"AB","termSource":"NCI"},{"termName":"SPARC1023","termGroup":"CN","termSource":"NCI"},{"termName":"SPARC1028","termGroup":"CN","termSource":"NCI"},{"termName":"SPARC1210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paclitaxel Injection Concentrate for Nanodispersion"},{"name":"NCI_Drug_Dictionary_ID","value":"696555"},{"name":"NCI_META_CUI","value":"CL428371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696555"},{"name":"PDQ_Open_Trial_Search_ID","value":"696555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2631":{"preferredName":"Paclitaxel Liposome","code":"C2631","definitions":[{"definition":"A form of the anticancer drug paclitaxel that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of several types of cancer. Paclitaxel liposome blocks the ability of cells to divide and may kill cancer cells. It is a type of mitotic inhibitor and a type of antimicrotubule agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposome-encapsulated formulation of paclitaxel, a taxoid compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic property. Paclitaxel binds to tubulin and interferes with the assembly/disassembly dynamics of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"Liposome-Encapsulated Paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paclitaxel_Liposome"},{"name":"Maps_To","value":"Paclitaxel Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"38323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38323"},{"name":"PDQ_Open_Trial_Search_ID","value":"38323"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935868"}]}}{"C1795":{"preferredName":"Paclitaxel Poliglumex","code":"C1795","definitions":[{"definition":"A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone. Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Poliglumex","termGroup":"PT","termSource":"NCI"},{"termName":"CT-2103","termGroup":"CN","termSource":"NCI"},{"termName":"CT2103","termGroup":"CN","termSource":"NCI"},{"termName":"Paclitaxel Polyglutamate","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel-Polyglutamate Polymer","termGroup":"SY","termSource":"NCI"},{"termName":"PG-TXL","termGroup":"AB","termSource":"NCI"},{"termName":"Poly-L-Glutamic acid-Paclitaxel Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Polyglutamic Acid Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Xyotax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"263351-82-2"},{"name":"Chemical_Formula","value":"C10H16N2O7(C52H56N2O16)n(C5H7NO3)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TQ64FZ98ZN"},{"name":"Legacy Concept Name","value":"Paclitaxel_Polyglutamate"},{"name":"Maps_To","value":"Paclitaxel Poliglumex"},{"name":"NCI_Drug_Dictionary_ID","value":"38325"},{"name":"NSC Number","value":"724773"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38325"},{"name":"PDQ_Open_Trial_Search_ID","value":"38325"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1702776"}]}}{"C148531":{"preferredName":"Paclitaxel Polymeric Micelle Formulation NANT-008","code":"C148531","definitions":[{"definition":"A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Polymeric Micelle Formulation NANT-008","termGroup":"PT","termSource":"NCI"},{"termName":"Cynviloq","termGroup":"BR","termSource":"NCI"},{"termName":"Genexol-PM","termGroup":"FB","termSource":"NCI"},{"termName":"IG-001","termGroup":"CN","termSource":"NCI"},{"termName":"Micellar Nanoparticle-encapsulated NANT-008","termGroup":"SY","termSource":"NCI"},{"termName":"NANT 008","termGroup":"CN","termSource":"NCI"},{"termName":"NANT-008","termGroup":"CN","termSource":"NCI"},{"termName":"Nant-paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"NANT008","termGroup":"CN","termSource":"NCI"},{"termName":"Paclitaxel-loaded Micellar Diblock Copolymer NANT-008","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel-loaded Polymeric Micelle NANT-008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Paclitaxel Polymeric Micelle Formulation NANT-008"},{"name":"NCI_Drug_Dictionary_ID","value":"434427"},{"name":"NCI_META_CUI","value":"CL551138"},{"name":"PDQ_Closed_Trial_Search_ID","value":"434427"},{"name":"PDQ_Open_Trial_Search_ID","value":"434427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2785":{"preferredName":"Paclitaxel PPE Microspheres","code":"C2785","definitions":[{"definition":"A paclitaxel formulation containing paclitaxel incorporated in biodegradable polyphosphoester (PPE) polymer form with potential antineoplastic activity. Upon intraperitoneal delivery, paclitaxel PPE microspheres slowly and continuously dissolve and deliver paclitaxel to the tumor site, where it binds to tubulin and inhibits the dynamics of disassembly-assembly of microtubules. As a result, this formulation induces cell cycle arrest and leads to cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel PPE Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"Paclimer Microspheres","termGroup":"BR","termSource":"NCI"},{"termName":"Paclimer Microspheres (Polilactofate/Paclitaxel)","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel Biopolymer Formulation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paclitaxel_PPE_Microspheres"},{"name":"Maps_To","value":"Paclitaxel PPE Microspheres"},{"name":"NSC Number","value":"715074"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518843"}]}}{"C99461":{"preferredName":"Paclitaxel Trevatide","code":"C99461","definitions":[{"definition":"A peptide-drug conjugate containing the taxane paclitaxel covalently linked to the proprietary 19 amino acid peptide angiopep-2, in a 3:1 ratio, with potential antineoplastic activity. Upon administration, paclitaxel trevatide, via angiopep-2 moiety, binds to LRP-1 (low density lipoprotein receptor-related protein 1), which is highly expressed in blood brain barrier (BBB) and glioma cells. This binding allows the transcytosis of the agent across the BBB and the delivery of the cytotoxic agent paclitaxel. Compared to paclitaxel alone, GRN1005 is able to increase the concentration of paclitaxel in the brain and is also able to specifically deliver paclitaxel to LRP-1-overexpressing tumor cells, both in the brain and in the periphery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Trevatide","termGroup":"PT","termSource":"NCI"},{"termName":"ANG-1005","termGroup":"CN","termSource":"NCI"},{"termName":"ANG1005","termGroup":"CN","termSource":"NCI"},{"termName":"GRN1005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1075214-55-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8P77G99D3P"},{"name":"Maps_To","value":"Paclitaxel Trevatide"},{"name":"NCI_Drug_Dictionary_ID","value":"721733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721733"},{"name":"PDQ_Open_Trial_Search_ID","value":"721733"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2604058"}]}}{"C61079":{"preferredName":"Paclitaxel Vitamin E-Based Emulsion","code":"C61079","definitions":[{"definition":"A cremophor-free, P-glycoprotein-inhibiting, vitamin E-based emulsion particle formulation of paclitaxel with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2). The vitamin-E based emulsion allows bolus infusion without steroid premedication and may diminish hypersensitivity reactions. The tumor tissue may be passively targeted due to preferential deposition of emulsion particles while an emulsion formulation component inhibits the P-glycoprotein drug efflux pump.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paclitaxel Vitamin E-Based Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"Paclitaxel Injectable Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"PIE","termGroup":"AB","termSource":"NCI"},{"termName":"S-8184","termGroup":"CN","termSource":"NCI"},{"termName":"Tocosol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tocosol_Paclitaxel"},{"name":"Maps_To","value":"Paclitaxel Vitamin E-Based Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"474798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"474798"},{"name":"PDQ_Open_Trial_Search_ID","value":"474798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541793"}]}}{"C48415":{"preferredName":"Paclitaxel-Loaded Polymeric Micelle","code":"C48415","definitions":[{"definition":"A biodegradable poly(ethylene glycol)-poly(D,L-lactide) copolymer micelle nanoparticle-entrapped formulation of paclitaxel with antineoplastic activity. Paclitaxel promotes microtubule assembly and prevents depolymerization, thus interfering with normal mitosis. The copolymer residue increases the water-solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone.","type":"DEFINITION","source":"NCI"},{"definition":"A form of the anticancer drug paclitaxel used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used with another drug to treat non-small cell lung cancer. Paclitaxel is mixed with very tiny particles of a substance that makes it easier to dissolve in water. This allows higher doses of paclitaxel to be given. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Paclitaxel-Loaded Polymeric Micelle","termGroup":"PT","termSource":"NCI"},{"termName":"Cynviloq TM","termGroup":"SY","termSource":"NCI"},{"termName":"Genexol PM","termGroup":"FB","termSource":"NCI"},{"termName":"IG-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paclitaxel-Loaded_Polymeric_Micelle"},{"name":"Maps_To","value":"Paclitaxel-Loaded Polymeric Micelle"},{"name":"NCI_Drug_Dictionary_ID","value":"434427"},{"name":"PDQ_Closed_Trial_Search_ID","value":"434427"},{"name":"PDQ_Open_Trial_Search_ID","value":"434427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709446"}]}}{"C78837":{"preferredName":"Pacritinib","code":"C78837","definitions":[{"definition":"An orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, pacritinib competes with JAK2 and the JAK2 mutant JAK2V617F for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-signal transducer and activator of transcription (STAT) signaling pathway, and the induction of apoptosis. In addition, pacritinib targets, binds to and inhibits the activity of FLT3. This inhibits FLT3-mediated signaling and the proliferation of FLT3-expressing cancer cells. JAK2, often upregulated or mutated in a variety of cancer cells, plays a key role in tumor cell proliferation and survival. The JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. In addition, JAK2 and FLT3 play a key role in the regulation of the inflammatory response and dendritic cell (DC) proliferation, differentiation and function. Inhibition of JAK2- and FLT3-mediated signaling may suppress the generation and differentiation of DCs, and may regulate inflammatory and immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacritinib","termGroup":"PT","termSource":"NCI"},{"termName":"Oral JAK2 Inhibitor SB1518","termGroup":"SY","termSource":"NCI"},{"termName":"SB 1518","termGroup":"CN","termSource":"NCI"},{"termName":"SB-1518","termGroup":"CN","termSource":"NCI"},{"termName":"SB1518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"937272-79-2"},{"name":"Chemical_Formula","value":"C28H32N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G22N65IL3O"},{"name":"Legacy Concept Name","value":"JAK2_Inhibitor_SB1518"},{"name":"Maps_To","value":"Pacritinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703133"}]}}{"C78481":{"preferredName":"Padeliporfin","code":"C78481","definitions":[{"definition":"A vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative with potential antineoplastic activity. Upon administration, paldeliporfin is activated locally when the tumor bed is exposed to low-power laser light; reactive oxygen species (ROS) are formed upon activation and ROS-mediated necrosis may occur at the site of interaction between the photosensitizer, light and oxygen. Vascular-targeted photodynamic therapy (VTP) with padeliporfin may allow tumor-site specific cytotoxicity while sparing adjacent normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Padeliporfin","termGroup":"PT","termSource":"NCI"},{"termName":"Palladium-Bacteriochlorophyll Derivative WST11","termGroup":"SY","termSource":"NCI"},{"termName":"WST11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"759457-82-4"},{"name":"Chemical_Formula","value":"C37H43N5O9S.Pd"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"EEO29FZT86"},{"name":"Legacy Concept Name","value":"Palladium-Bacteriochlorophyll_Derivative_WST11"},{"name":"Maps_To","value":"Padeliporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"600817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600817"},{"name":"PDQ_Open_Trial_Search_ID","value":"600817"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1610374"}]}}{"C61321":{"preferredName":"Padoporfin","code":"C61321","definitions":[{"definition":"A novel palladium-substituted bacteriochlorophyll derivative and photosensitizer with potential antitumor activity. Upon administration, inactive padoporfin is activated locally when the tumor bed is exposed to photoirradiation; the activated form induces local cytotoxic processes, resulting in local tissue damage, disruption of tumor vasculature, and tumor hypoxia and necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Padoporfin","termGroup":"PT","termSource":"NCI"},{"termName":"(Hydrogen 3-((2(sup 2)R,7R,8R,17S,18S)-12-acetyl-7-ethyl-2(sup 2)-(methoxycarbonyl)-3,8,13,17-tetramethyl-2(sup 1)-oxo-2(sup 1),2(sup 2),7,8,17,18-hexahydrocyclopenta(at)porphyrin-18-yl)propanoato-kappa4N(sup 21),N(sup 22),N(sup 23),N(sup 24))palladium","termGroup":"SY","termSource":"NCI"},{"termName":"Tookad","termGroup":"FB","termSource":"NCI"},{"termName":"WST09","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"274679-00-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OIH1H7CJCJ"},{"name":"Legacy Concept Name","value":"Palladium-Bacteriopheophorbide"},{"name":"Maps_To","value":"Padoporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"483132"},{"name":"PDQ_Closed_Trial_Search_ID","value":"483132"},{"name":"PDQ_Open_Trial_Search_ID","value":"483132"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1136634"}]}}{"C84841":{"preferredName":"PAK4 Inhibitor PF-03758309","code":"C84841","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PAK4 inhibitor PF-03758309 binds to PAK4, inhibiting PAK4 activity and cancer cell growth. PAK4, a serine/threonine kinase belonging to the p21-activated kinase (PAK) family, is often upregulated in a variety of cancer cell types and plays an important role in cancer cell motility, proliferation, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PAK4 Inhibitor PF-03758309","termGroup":"PT","termSource":"NCI"},{"termName":"PF-03758309","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"898044-15-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PK459EA5I2"},{"name":"Maps_To","value":"PAK4 Inhibitor PF-03758309"},{"name":"NCI_Drug_Dictionary_ID","value":"650124"},{"name":"NCI_META_CUI","value":"CL412392"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650124"},{"name":"PDQ_Open_Trial_Search_ID","value":"650124"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126646":{"preferredName":"Padnarsertib","code":"C126646","definitions":[{"definition":"An orally bioavailable inhibitor of both the serine/threonine kinase P21-activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon administration, padnarsertib allosterically binds to, destabilizes and causes degradation of PAK4. This inhibits PAK4-mediated signaling, induces cell death in, and inhibits the proliferation of PAK4-overexpressing tumor cells. In addition, padnarsertib binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in tumor cell death in NAMPT-overexpressing cancer cells. PAK4, a serine/threonine kinase and member of the PAK family of proteins upregulated in various cancer cell types, regulates cell motility, proliferation and survival. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is often overexpressed in a variety of cancers and metabolic disorders and tumor cells rely on NAMPT activity for their NAD supply.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Padnarsertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATG 019","termGroup":"CN","termSource":"NCI"},{"termName":"ATG-019","termGroup":"CN","termSource":"NCI"},{"termName":"ATG019","termGroup":"CN","termSource":"NCI"},{"termName":"KCP-9274","termGroup":"CN","termSource":"NCI"},{"termName":"KPT-9274","termGroup":"CN","termSource":"NCI"},{"termName":"PAK4/NAMPT Inhibitor ATG-019","termGroup":"SY","termSource":"NCI"},{"termName":"PAK4/NAMPT Inhibitor KPT-9274","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1643913-93-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9T56TV18X7"},{"name":"Maps_To","value":"PAK4/NAMPT Inhibitor KPT-9274"},{"name":"NCI_Drug_Dictionary_ID","value":"779707"},{"name":"NCI_META_CUI","value":"CL503763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779707"},{"name":"PDQ_Open_Trial_Search_ID","value":"779707"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49176":{"preferredName":"Palbociclib","code":"C49176","definitions":[{"definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palbociclib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one","termGroup":"SY","termSource":"NCI"},{"termName":"Ibrance","termGroup":"BR","termSource":"NCI"},{"termName":"PD 0332991","termGroup":"CN","termSource":"NCI"},{"termName":"PD 332991","termGroup":"CN","termSource":"NCI"},{"termName":"PD 991","termGroup":"CN","termSource":"NCI"},{"termName":"PD-0332991","termGroup":"CN","termSource":"NCI"},{"termName":"PD0332991","termGroup":"CN","termSource":"NCI"},{"termName":"Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer"},{"name":"CAS_Registry","value":"571190-30-2"},{"name":"Chemical_Formula","value":"C24H29N7O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G9ZF61LE7G"},{"name":"Legacy Concept Name","value":"PD-0332991"},{"name":"Maps_To","value":"Palbociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"454586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454586"},{"name":"PDQ_Open_Trial_Search_ID","value":"454586"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3853822"}]}}{"C120259":{"preferredName":"Palbociclib Isethionate","code":"C120259","definitions":[{"definition":"The isethionate salt form of palbociclib, an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palbociclib Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino(pyrido(2,3-d)pyrimidin-7(8h)-one mono(2-hydroxyethanesulfonate)","termGroup":"SN","termSource":"NCI"},{"termName":"PD 0332991-0054","termGroup":"CN","termSource":"NCI"},{"termName":"PF-00080665-73","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"827022-33-3"},{"name":"Chemical_Formula","value":"C24H29N7O2.C2-H6-O4-S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W1NYL2IRDR"},{"name":"Maps_To","value":"Palbociclib Isethionate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896941"}]}}{"C66990":{"preferredName":"Palifosfamide","code":"C66990","definitions":[{"definition":"A synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lysine for stability, palifosfamide irreversibly alkylates and cross-links DNA through GC base pairs, resulting in irreparable 7-atom inter-strand cross-links; inhibition of DNA replication and cell death follow. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palifosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"IPM-Lysine","termGroup":"AB","termSource":"NCI"},{"termName":"Isophosphoramide Mustard-Lysine","termGroup":"SY","termSource":"NCI"},{"termName":"N,N'-Di-(2-chloroethyl)phosphorodiamidic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ZIO-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"31645-39-3"},{"name":"Chemical_Formula","value":"C4H11Cl2N2O2P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6A4U6NN813"},{"name":"Legacy Concept Name","value":"Isophosphoramide_Mustard-Lysine"},{"name":"Maps_To","value":"Palifosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"538996"},{"name":"NSC Number","value":"297900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"538996"},{"name":"PDQ_Open_Trial_Search_ID","value":"538996"},{"name":"PubMedID_Primary_Reference","value":"6821629"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0064039"}]}}{"C95703":{"preferredName":"Palifosfamide Tromethamine","code":"C95703","definitions":[{"definition":"A synthetic mustard compound of the tromethamine (tris) salt of palifosfamide (Isophosphamide mustard), with potential antineoplastic activity. As the stabilized active metabolite of ifosfamide, palifosfamide irreversibly alkylates and crosslinks DNA through GC base pairs, resulting in irreparable 7-atom interstrand crosslinks. This leads to an inhibition of DNA replication and ultimately cell death. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide. Stabilization with tris instead of lysine further increases stability and may further decrease nephrotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palifosfamide Tromethamine","termGroup":"PT","termSource":"NCI"},{"termName":"Palifosfamide Tris","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphorodiamidic Acid, N,N'-bis(2-chloroethyl)-, Compd. with 2-Amino-2-(hydroxymethyl)-1,3-propanediol (1:1)","termGroup":"SY","termSource":"NCI"},{"termName":"ZIO-201-T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1070409-31-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0X5A3C04ID"},{"name":"Maps_To","value":"Palifosfamide Tromethamine"},{"name":"NCI_Drug_Dictionary_ID","value":"689807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689807"},{"name":"PDQ_Open_Trial_Search_ID","value":"689807"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987344"}]}}{"C2550":{"preferredName":"Palladium Pd-103","code":"C2550","definitions":[{"definition":"A radioactive form of palladium (a metallic element that resembles platinum). When used to treat prostate cancer, radioactive seeds (small pellets that contain radioactive palladium) are placed in the prostate. Cancer cells are killed by the energy given off as the radioactive material breaks down and becomes more stable.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioisotope of the metal palladium used in brachytherapy implants or 'seed'. With a half-life of 17 days, palladium 103 administered with brachytherapy allows continuous, tumor-site specific low-energy irradiation to the tumor cell population while sparing normal adjacent tissues from radiotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palladium Pd-103","termGroup":"PT","termSource":"NCI"},{"termName":"Palladium Pd 103","termGroup":"SY","termSource":"NCI"},{"termName":"Palladium-103","termGroup":"SY","termSource":"NCI"},{"termName":"Pd 103","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Early Stage Prostate Cancer; Localized Tumours of the Head, Neck, Lung, Pancreas, Breast, Intraocular and Uterus."},{"name":"CAS_Registry","value":"14967-68-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68QTV136DF"},{"name":"Legacy Concept Name","value":"Palladium_103"},{"name":"Maps_To","value":"Palladium Pd-103"},{"name":"NCI_Drug_Dictionary_ID","value":"38046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38046"},{"name":"PDQ_Open_Trial_Search_ID","value":"38046"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"UMLS_CUI","value":"C0303566"}]}}{"C47650":{"preferredName":"Palonosetron Hydrochloride","code":"C47650","definitions":[{"definition":"A drug used to treat nausea and vomiting caused by cancer treatment. It is a type of serotonin receptor antagonist and a type of antiemetic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of palonosetron, a carbazole derivative and a selective serotonin receptor antagonist with antiemetic activity. Palonosetron competitively blocks the action of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting. The CTZ is located in the area postrema on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle and outside the blood-brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palonosetron Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benz(de)isoquinolin-1-one, 2-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, Monohydrochloride,(3aS)-","termGroup":"SN","termSource":"NCI"},{"termName":"Aloxi","termGroup":"BR","termSource":"NCI"},{"termName":"palonosetron HCl","termGroup":"SY","termSource":"NCI"},{"termName":"RS 25259-197","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"prevention of chemotherapy-induced nausea and vomiting"},{"name":"CAS_Registry","value":"135729-62-3"},{"name":"Chemical_Formula","value":"C19H24N2O.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23310D4I19"},{"name":"Legacy Concept Name","value":"Palonosetron_Hydrochloride"},{"name":"Maps_To","value":"Palonosetron Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"486366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486366"},{"name":"PDQ_Open_Trial_Search_ID","value":"486366"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1310734"}]}}{"C1345":{"preferredName":"Pamidronate Disodium","code":"C1345","definitions":[{"definition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamidronate Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Aminomux","termGroup":"FB","termSource":"NCI"},{"termName":"Aredia","termGroup":"BR","termSource":"NCI"},{"termName":"GCP-23339A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypercalcemia of malignancy; Osteolytic bone lesions of multiple myeloma; Osteolytic bone metastases of breast cancer; Pagets disease"},{"name":"CAS_Registry","value":"109552-15-0"},{"name":"Chemical_Formula","value":"C3H9NO7P2.2Na.5H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8742T8ZQZA"},{"name":"Legacy Concept Name","value":"Pamidronate_Disodium"},{"name":"Maps_To","value":"Pamidronate Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39149"},{"name":"NSC Number","value":"720699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39149"},{"name":"PDQ_Open_Trial_Search_ID","value":"39149"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0356588"}]}}{"C61875":{"preferredName":"Pamidronic Acid","code":"C61875","definitions":[{"definition":"A drug that is used to treat hypercalcemia (too much calcium in the blood) and cancer that has spread to the bones. It belongs to the family of drugs called bisphosphonates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An amino- bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Pamidronic acid binds to and adsorbs onto hydroxyapatite crystals in the bone matrix, thereby preventing osteoclast resorption. This agent also binds to and inhibits farnesyl pyrophosphate synthase, an enzyme that plays an important role in the mevalonate pathway. This inhibits the formation of isoprenoid metabolites that are substrates for protein prenylation. This prevents farnesylation and geranylgeranylation of proteins essential for osteoclast function, leading to the induction of apoptosis of osteoclasts. By preventing osteoclast-mediated bone resorption, pamidronic acid decreases bone turnover rate, stabilizes the bone matrix and reduces hypercalcemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamidronic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Pamidronate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"40391-99-9"},{"name":"Chemical_Formula","value":"C3H11NO7P2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"OYY3447OMC"},{"name":"Legacy Concept Name","value":"Pamidronic_Acid"},{"name":"Maps_To","value":"Pamidronic Acid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043603"}]}}{"C120553":{"preferredName":"Pamiparib","code":"C120553","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pamiparib","termGroup":"PT","termSource":"NCI"},{"termName":"5,6,7a,11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-Fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)-","termGroup":"SN","termSource":"NCI"},{"termName":"BGB-290","termGroup":"CN","termSource":"NCI"},{"termName":"PARP Inhibitor BGB-290","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446261-44-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8375F9S90C"},{"name":"Maps_To","value":"Pamiparib"},{"name":"NCI_Drug_Dictionary_ID","value":"769217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769217"},{"name":"PDQ_Open_Trial_Search_ID","value":"769217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053665"}]}}{"C124931":{"preferredName":"pan FGFR Inhibitor PRN1371","code":"C124931","definitions":[{"definition":"A highly specific covalent inhibitor of human fibroblast growth factor receptor types 1, 2, 3 and 4 (FGFR1-4) with potential antiangiogenic and antineoplastic activities. FGFR1-4 tyrosine kinase inhibitor PRN1371 specifically binds to a conserved cysteine residue in the glycine-rich loop in FGFRs and inhibits their tyrosine kinase activity, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation, proliferation and survival, and in tumor angiogenesis. This agent potently inhibits FGFR1-4 but does not inhibit other tyrosine kinases, even those that share the conserved cysteine, which may improve therapeutic responses and decrease toxicity when compared with less selective inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan FGFR Inhibitor PRN1371","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR 1-4 Inhibitor PRN1371","termGroup":"SY","termSource":"NCI"},{"termName":"pan FGFR Inhibitor PRN1371","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FGFR Tyrosine Kinase Inhibitor PRN1371","termGroup":"SY","termSource":"NCI"},{"termName":"PRN 1371","termGroup":"CN","termSource":"NCI"},{"termName":"PRN1371","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802929-43-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3OPE9IA3Q"},{"name":"Maps_To","value":"pan FGFR Inhibitor PRN1371"},{"name":"NCI_Drug_Dictionary_ID","value":"777939"},{"name":"NCI_META_CUI","value":"CL503800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777939"},{"name":"PDQ_Open_Trial_Search_ID","value":"777939"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C68832":{"preferredName":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514","code":"C68832","definitions":[{"definition":"A pyrrolotriazine-based compound and a pan inhibitor of receptor tyrosine kinases with potential antineoplastic activity. Pan HER/VEGFR2 receptor tyrosine kinase inhibitor BMS-690514 binds to human epidermal growth factor receptors (EGFR) 1, 2 and 4 (HER1, HER2 and HER4) and vascular endothelial growth factor receptor 1, 2 and 3 (VEGFR-1, -2 and -3), all of which are frequently overexpressed by a variety of tumor types. Binding of this agent to these receptors may result in the inhibition of tumor cell proliferation; the inhibition of endothelial cell migration and proliferation and angiogenesis; and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-690514","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"859853-30-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VKU5X213Q7"},{"name":"Legacy Concept Name","value":"Pan_HER_VEGFR2_Receptor_Tyrosine_Kinase_Inhibitor_BMS-690154"},{"name":"Maps_To","value":"Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514"},{"name":"NCI_Drug_Dictionary_ID","value":"489386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489386"},{"name":"PDQ_Open_Trial_Search_ID","value":"489386"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831893"}]}}{"C128250":{"preferredName":"Pan-AKT Inhibitor ARQ751","code":"C128250","definitions":[{"definition":"An orally bioavailable pan inhibitor of the serine/threonine protein kinase AKT (protein kinase B) enzyme family with potential antineoplastic activity. Upon oral administration, AKT inhibitor ARQ 751 selectively binds to and inhibits the activity of the AKT isoforms 1, 2 and 3, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. This may lead to a reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-AKT Inhibitor ARQ751","termGroup":"PT","termSource":"NCI"},{"termName":"AKT Inhibitor ARQ751","termGroup":"SY","termSource":"NCI"},{"termName":"ARQ 751","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ751","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-AKT Inhibitor ARQ751"},{"name":"NCI_Drug_Dictionary_ID","value":"781919"},{"name":"NCI_META_CUI","value":"CL507932"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781919"},{"name":"PDQ_Open_Trial_Search_ID","value":"781919"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71711":{"preferredName":"Pan-AKT Kinase Inhibitor GSK690693","code":"C71711","definitions":[{"definition":"An aminofurazan-derived inhibitor of Akt kinases with potential antineoplastic activity. Pan-AKT kinase inhibitor GSK-690693 binds to and inhibits Akt kinases 1, 2, and 3, which may result in the inhibition of protein phosphorylation events downstream from Akt kinases in the PI3K/Akt signaling pathway, and, subsequently, the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. In addition, this agent may inhibit other protein kinases including protein kinase C (PKC) and protein kinase A (PKA). As serine/threonine protein kinases which are involved in a number of biological processes, AKT kinases promote cell survival by inhibiting apoptosis and are required for glucose transport.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-AKT Kinase Inhibitor GSK690693","termGroup":"PT","termSource":"NCI"},{"termName":"GSK690693","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"937174-76-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GWH480321B"},{"name":"Legacy Concept Name","value":"Pan-AKT_Inhibitor_GSK-690693"},{"name":"Maps_To","value":"Pan-AKT Kinase Inhibitor GSK690693"},{"name":"NCI_Drug_Dictionary_ID","value":"560189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560189"},{"name":"PDQ_Open_Trial_Search_ID","value":"560189"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347443"}]}}{"C139004":{"preferredName":"Pan-FGFR Inhibitor LY2874455","code":"C139004","definitions":[{"definition":"An orally bioavailable pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, FGFR inhibitor LY2874455 binds to and inhibits FGFR subtypes 1 (FGFR1), 2 (FGFR2), 3 (FGFR3) and 4 (FGFR4), which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-FGFR Inhibitor LY2874455","termGroup":"PT","termSource":"NCI"},{"termName":"LY2874455","termGroup":"CN","termSource":"NCI"},{"termName":"Pan FGFR Inhibitor LY2874455","termGroup":"SY","termSource":"NCI"},{"termName":"Pan Fibroblast Growth Factor Receptor Inhibitor LY2874455","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1254473-64-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E9M363811V"},{"name":"Maps_To","value":"Pan-FGFR Inhibitor LY2874455"},{"name":"NCI_Drug_Dictionary_ID","value":"790959"},{"name":"NCI_META_CUI","value":"CL433720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790959"},{"name":"PDQ_Open_Trial_Search_ID","value":"790959"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162573":{"preferredName":"Luxeptinib","code":"C162573","definitions":[{"definition":"An orally bioavailable reversible, pan-inhibitor of both FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) and Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon oral administration, luxeptinib targets, non-covalently binds to and inhibits the activity of both FLT3, including both wild-type (WT) FLT3 and FLT3-ITD (internal tandem duplications), tyrosine kinase domain (FLT3-TKD), and gatekeeper (FLT3-F691L) mutant forms, and BTK, including both the WT and its C481S mutant (BTK-C481S) form. This inhibits both uncontrolled FLT3-mediated and B-cell antigen receptor (BCR)-mediated signaling, respectively. This results in the inhibition of proliferation in tumor cells overexpressing FLT3 and BTK. In addition, CG-806 also inhibits, to a lesser degree, other oncogenic kinases, such as MET, RET, discoidin domain-containing receptor 2 (DDR2), Aurora kinase A, and interleukin-2-inducible T-cell kinase (ITK). FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs), and plays a key role in tumor cell proliferation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases essential to BCR signaling, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luxeptinib","termGroup":"PT","termSource":"NCI"},{"termName":"32,72,74,76-Tetrafluoro-14-methyl-21,23-dihydro-11h-4,6-diaza-2(4,7)-isoindola- 1(2)-imidazola-3(1,4),7(1)-dibenzenaheptaphane-2,35-dione","termGroup":"SY","termSource":"NCI"},{"termName":"CG 806","termGroup":"CN","termSource":"NCI"},{"termName":"CG'806","termGroup":"CN","termSource":"NCI"},{"termName":"CG-026806","termGroup":"CN","termSource":"NCI"},{"termName":"CG-806","termGroup":"CN","termSource":"NCI"},{"termName":"CG806","termGroup":"CN","termSource":"NCI"},{"termName":"FLT3/BTK Inhibitor CG 806","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FLT3/BTK Multi-Kinase Inhibitor CG 806","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FLT3/Pan-BTK Inhibitor CG-806","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616428-23-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TQ6PBX1JU0"},{"name":"Maps_To","value":"Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806"},{"name":"NCI_Drug_Dictionary_ID","value":"798821"},{"name":"NCI_META_CUI","value":"CL971079"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798821"},{"name":"PDQ_Open_Trial_Search_ID","value":"798821"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48380":{"preferredName":"pan-HER Kinase Inhibitor AC480","code":"C48380","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-HER Kinase Inhibitor AC480","termGroup":"PT","termSource":"NCI"},{"termName":"AC480","termGroup":"SY","termSource":"NCI"},{"termName":"AC480","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-599626","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"714971-09-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2252724U5N"},{"name":"Legacy Concept Name","value":"BMS-599626"},{"name":"Maps_To","value":"pan-HER Kinase Inhibitor AC480"},{"name":"NCI_Drug_Dictionary_ID","value":"655952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655952"},{"name":"PDQ_Open_Trial_Search_ID","value":"655952"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541473"}]}}{"C152914":{"preferredName":"Vorasidenib","code":"C152914","definitions":[{"definition":"An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically inhibits mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH mutations. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB). IDH1 and 2, metabolic enzymes that catalyze the conversion of isocitrate into a-KG, play key roles in energy production and are mutated in a variety of cancer cell types. In addition, mutant forms of IDH1 and 2 catalyze the formation of 2HG and drive cancer growth by blocking cellular differentiation and inducing cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorasidenib","termGroup":"PT","termSource":"NCI"},{"termName":"AG 881","termGroup":"CN","termSource":"NCI"},{"termName":"AG-881","termGroup":"CN","termSource":"NCI"},{"termName":"AG881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1644545-52-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"789Q85GA8P"},{"name":"Maps_To","value":"Pan-IDH Mutant Inhibitor AG-881"},{"name":"Maps_To","value":"Vorasidenib"},{"name":"NCI_Drug_Dictionary_ID","value":"774431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774431"},{"name":"PDQ_Open_Trial_Search_ID","value":"774431"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053681"}]}}{"C131690":{"preferredName":"Pan-Mutant-IDH1 Inhibitor Bay-1436032","code":"C131690","definitions":[{"definition":"An orally available pan-inhibitor of mutant forms of the metabolic enzyme isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including forms with mutations of arginine 132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, pan-mutant-IDH-1 inhibitor BAY-1436032 specifically inhibits the activity of IDH1 mutant forms, which prevents the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutant forms. IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-Mutant-IDH1 Inhibitor Bay-1436032","termGroup":"PT","termSource":"NCI"},{"termName":"3-(2-((4-(Trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 1436032","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1436032","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1436032","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1803274-65-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-Mutant-IDH1 Inhibitor Bay-1436032"},{"name":"NCI_Drug_Dictionary_ID","value":"786302"},{"name":"NCI_META_CUI","value":"CL514346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786302"},{"name":"PDQ_Open_Trial_Search_ID","value":"786302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117230":{"preferredName":"pan-PI3K Inhibitor CLR457","code":"C117230","definitions":[{"definition":"An orally bioavailable pan inhibitor of phosphatidylinositol-3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, pan-PI3K inhibitor CLR457 inhibits all of the PI3K kinase isoforms, which may result in apoptosis and growth inhibition in tumor cells overexpressing PI3K. Activation of the PI3K pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PI3K Inhibitor CLR457","termGroup":"PT","termSource":"NCI"},{"termName":"CLR457","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pan-PI3K Inhibitor CLR457"},{"name":"NCI_Drug_Dictionary_ID","value":"763082"},{"name":"NCI_META_CUI","value":"CL474098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763082"},{"name":"PDQ_Open_Trial_Search_ID","value":"763082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85469":{"preferredName":"pan-PI3K/mTOR Inhibitor SF1126","code":"C85469","definitions":[{"definition":"A water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities. The targeting peptide SF1174 moiety of pan-PI3K/mTOR inhibitor SF1126 selectively binds to cell surface integrins and, upon cell entry, the agent is hydrolyzed to the active drug SF1101; SF1101 selectively inhibits all isoforms of phosphoinositide-3-kinase (PI3K) and other members of the PI3K superfamily, such as the mammalian target of rapamycin (mTOR) and DNA-PK. By inhibiting the PI3K signaling pathway, this agent may inhibit tumor cell and tumor endothelial cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PI3K/mTOR Inhibitor SF1126","termGroup":"PT","termSource":"NCI"},{"termName":"SF1126","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936487-67-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DL0Q912033"},{"name":"Maps_To","value":"pan-PI3K/mTOR Inhibitor SF1126"},{"name":"NCI_Drug_Dictionary_ID","value":"644818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"644818"},{"name":"PDQ_Open_Trial_Search_ID","value":"644818"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351370"}]}}{"C124226":{"preferredName":"Uzansertib","code":"C124226","definitions":[{"definition":"An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, uzansertib binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uzansertib","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 053914","termGroup":"CN","termSource":"NCI"},{"termName":"INCB053914","termGroup":"CN","termSource":"NCI"},{"termName":"INCB53914","termGroup":"CN","termSource":"NCI"},{"termName":"Pan-PIM Inhibitor INCB053914","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-PIM Kinase Inhibitor INCB053914","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620012-39-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0237X8153Q"},{"name":"Maps_To","value":"Pan-PIM Inhibitor INCB053914"},{"name":"Maps_To","value":"Uzansertib"},{"name":"NCI_Drug_Dictionary_ID","value":"776689"},{"name":"NCI_META_CUI","value":"CL502606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776689"},{"name":"PDQ_Open_Trial_Search_ID","value":"776689"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99380":{"preferredName":"pan-PIM Kinase Inhibitor AZD1208","code":"C99380","definitions":[{"definition":"An orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. Pan-PIM kinase inhibitor AZD1208 inhibits the activities of PIM1, PIM2 and PIM3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, thereby causing cell cycle arrest and inducing apoptosis in cells that overexpress PIMs. The growth inhibition of several leukemia cell lines by this agent is correlated with the expression levels of PIM1, which is the substrate of STAT transcription factors. PIM kinases are downstream effectors of many cytokine and growth factor signaling pathways and are upregulated in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PIM Kinase Inhibitor AZD1208","termGroup":"PT","termSource":"NCI"},{"termName":"AZD1208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pan-PIM Kinase Inhibitor AZD1208"},{"name":"NCI_Drug_Dictionary_ID","value":"720042"},{"name":"PDQ_Closed_Trial_Search_ID","value":"720042"},{"name":"PDQ_Open_Trial_Search_ID","value":"720042"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274705"}]}}{"C128615":{"preferredName":"pan-PIM Kinase Inhibitor NVP-LGB-321","code":"C128615","definitions":[{"definition":"An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, pan-PIM kinase inhibitor NVP-LGB-321 binds to and prevents the activation of the three PIM family kinases, PIM1, PIM2 and PIM3. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-PIM Kinase Inhibitor NVP-LGB-321","termGroup":"PT","termSource":"NCI"},{"termName":"LGB321","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-LGB-321","termGroup":"CN","termSource":"NCI"},{"termName":"PIM Inhibitor NVP-LGB-321","termGroup":"SY","termSource":"NCI"},{"termName":"PIM Kinase Inhibitor NVP-LGB-321","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pan-PIM Kinase Inhibitor NVP-LGB-321"},{"name":"NCI_META_CUI","value":"CL509289"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125003":{"preferredName":"Naporafenib","code":"C125003","definitions":[{"definition":"An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Naporafenib","termGroup":"PT","termSource":"NCI"},{"termName":"LXH 254","termGroup":"CN","termSource":"NCI"},{"termName":"LXH-254","termGroup":"CN","termSource":"NCI"},{"termName":"LXH254","termGroup":"CN","termSource":"NCI"},{"termName":"pan-RAF Inhibitor LXH254","termGroup":"SY","termSource":"NCI"},{"termName":"pan-RAF Kinase Inhibitor LXH254","termGroup":"SY","termSource":"NCI"},{"termName":"Raf Family Kinase Inhibitor LXH254","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1800398-38-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"15JL80DG6H"},{"name":"Maps_To","value":"pan-RAF Inhibitor LXH254"},{"name":"NCI_Drug_Dictionary_ID","value":"778192"},{"name":"NCI_META_CUI","value":"CL503849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778192"},{"name":"PDQ_Open_Trial_Search_ID","value":"778192"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116861":{"preferredName":"Pan-RAF Inhibitor LY3009120","code":"C116861","definitions":[{"definition":"An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-RAF Inhibitor LY3009120","termGroup":"PT","termSource":"NCI"},{"termName":"DP-4978","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3009120","termGroup":"CN","termSource":"NCI"},{"termName":"LY3009120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1454682-72-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1GDT36RARO"},{"name":"Maps_To","value":"Pan-RAF Inhibitor LY3009120"},{"name":"NCI_Drug_Dictionary_ID","value":"756062"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756062"},{"name":"PDQ_Open_Trial_Search_ID","value":"756062"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896821"}]}}{"C121952":{"preferredName":"pan-RAF Kinase Inhibitor CCT3833","code":"C121952","definitions":[{"definition":"An orally available inhibitor of the serine/threonine protein kinase family Raf, including A-Raf, B-Raf and C-Raf, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor CCT3833 inhibits Raf-mediated signal transduction pathways, which may inhibit the proliferation of Raf-overexpressing tumor cells. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pan-RAF Kinase Inhibitor CCT3833","termGroup":"PT","termSource":"NCI"},{"termName":"BAL 3833","termGroup":"CN","termSource":"NCI"},{"termName":"BAL-3833","termGroup":"CN","termSource":"NCI"},{"termName":"BAL3833","termGroup":"CN","termSource":"NCI"},{"termName":"CCT 3833","termGroup":"CN","termSource":"NCI"},{"termName":"CCT-3833","termGroup":"CN","termSource":"NCI"},{"termName":"CCT3833","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1777832-90-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RG8FC8W2LX"},{"name":"Maps_To","value":"pan-RAF Kinase Inhibitor CCT3833"},{"name":"NCI_Drug_Dictionary_ID","value":"772112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772112"},{"name":"PDQ_Open_Trial_Search_ID","value":"772112"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053656"}]}}{"C106254":{"preferredName":"Tovorafenib","code":"C106254","definitions":[{"definition":"An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tovorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BIIB-024","termGroup":"CN","termSource":"NCI"},{"termName":"DAY 101","termGroup":"CN","termSource":"NCI"},{"termName":"DAY-101","termGroup":"CN","termSource":"NCI"},{"termName":"DAY101","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-2480","termGroup":"CN","termSource":"NCI"},{"termName":"MLN2480","termGroup":"CN","termSource":"NCI"},{"termName":"Ojemda","termGroup":"BR","termSource":"NCI"},{"termName":"pan-RAF Kinase Inhibitor DAY101","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-580","termGroup":"CN","termSource":"NCI"},{"termName":"TAK580","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation."},{"name":"CAS_Registry","value":"1096708-71-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZN90E4027M"},{"name":"Maps_To","value":"pan-RAF Kinase Inhibitor TAK-580"},{"name":"NCI_Drug_Dictionary_ID","value":"710688"},{"name":"NCI_META_CUI","value":"CL433881"},{"name":"PDQ_Closed_Trial_Search_ID","value":"710688"},{"name":"PDQ_Open_Trial_Search_ID","value":"710688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2062":{"preferredName":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550","code":"C2062","definitions":[{"definition":"An orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.  LGD 1550 selectively binds to all three retinoic acid receptors (RAR-alpha, RAR-beta, and RAR-gamma), resulting in alterations in the expression of genes responsible for cell differentiation and proliferation.  This agent also acts as an inhibitor of activator protein 1 (AP-1), a protein that mediates trophic responses and malignant transformation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550","termGroup":"PT","termSource":"NCI"},{"termName":"LGD 1550","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"178600-20-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"LGD_1550"},{"name":"Maps_To","value":"Pan-RAR Agonist/AP-1 Inhibitor LGD 1550"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517688"}]}}{"C140379":{"preferredName":"Pan-TRK Inhibitor ONO-7579","code":"C140379","definitions":[{"definition":"An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, ONO-7579 specifically targets and binds to TRK and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC).  This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes.The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-TRK Inhibitor ONO-7579","termGroup":"PT","termSource":"NCI"},{"termName":"ONO 7579","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-7579","termGroup":"CN","termSource":"NCI"},{"termName":"ONO7579","termGroup":"CN","termSource":"NCI"},{"termName":"TRK Inhibitor ONO-7579","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-TRK Inhibitor ONO-7579"},{"name":"NCI_Drug_Dictionary_ID","value":"793096"},{"name":"NCI_META_CUI","value":"CL538536"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793096"},{"name":"PDQ_Open_Trial_Search_ID","value":"793096"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82379":{"preferredName":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981","code":"C82379","definitions":[{"definition":"An orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR) and Tie2 receptor tyrosine kinases with potential antiangiogenic and antineoplastic activities. Pan-VEGFR/Tie2 tyrosine kinase inhibitor CEP-11981 selectively binds to VEGFR and Tie2 receptor tyrosine kinases, which may result in the inhibition of endothelial cell migration, proliferation and survival and the inhibition of tumor cell proliferation and tumor cell death. VEGFR and Tie2 are frequently overexpressed by a variety of tumor cell types and play crucial roles in the regulation of angiogenesis and the maintenance of tumor blood vessels. Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains) is activated by angiopoietin-1 (Ang-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Indazolo(5,4-a)pyrrolo(3,4-C)carbazol-4-one, 2,5,6,11,12,13-Hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-","termGroup":"SN","termSource":"NCI"},{"termName":"BOL-303213X","termGroup":"CN","termSource":"NCI"},{"termName":"CEP 11981","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-11981","termGroup":"CN","termSource":"NCI"},{"termName":"ESK 981","termGroup":"CN","termSource":"NCI"},{"termName":"ESK-981","termGroup":"SY","termSource":"NCI"},{"termName":"ESK981","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"856691-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J8AY0Z4CBP"},{"name":"Legacy Concept Name","value":"Oral_Pan-VEGFR_TIE2_Tyrosine_Kinase_Inhibitor_CEP-11981"},{"name":"Maps_To","value":"Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981"},{"name":"NCI_Drug_Dictionary_ID","value":"641461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641461"},{"name":"PDQ_Open_Trial_Search_ID","value":"641461"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830064"}]}}{"C1184":{"preferredName":"Pancratistatin","code":"C1184","definitions":[{"definition":"A isoquinoline alkaloid from amaryllis with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pancratistatin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96281-31-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pancratistatin"},{"name":"Maps_To","value":"Pancratistatin"},{"name":"NSC Number","value":"349156"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070005"}]}}{"C1857":{"preferredName":"Panitumumab","code":"C1857","definitions":[{"definition":"A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. ABX-EGF binds to the epidermal growth factor receptor (EGFR) and may block tumor cell growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Panitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"ABX-EGF","termGroup":"AB","termSource":"NCI"},{"termName":"ABX-EGF Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"ABX-EGF, Clone E7.6.3","termGroup":"SY","termSource":"NCI"},{"termName":"E7.6.3","termGroup":"CN","termSource":"NCI"},{"termName":"Human IgG2K Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb ABX-EGF","termGroup":"AB","termSource":"NCI"},{"termName":"MoAb E7.6.3","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody ABX-EGF","termGroup":"SY","termSource":"NCI"},{"termName":"Monoclonal Antibody E7.6.3","termGroup":"SY","termSource":"NCI"},{"termName":"Vectibix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced Stage Colorectal Cancer"},{"name":"CAS_Registry","value":"339177-26-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6A901E312A"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_ABX-EGF"},{"name":"Maps_To","value":"Panitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"37857"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37857"},{"name":"PDQ_Open_Trial_Search_ID","value":"37857"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1513448"}]}}{"C66948":{"preferredName":"Panobinostat","code":"C66948","definitions":[{"definition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","type":"DEFINITION","source":"NCI"},{"definition":"A drug being studied in the treatment of cancer. It blocks enzymes needed for cells to grow and divide and may kill cancer cells. Panobinostat may also prevent the growth of new blood vessels that tumors need to grow. It is a type of histone deacetylase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Panobinostat","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"Faridak","termGroup":"FB","termSource":"NCI"},{"termName":"LBH 589","termGroup":"CN","termSource":"NCI"},{"termName":"LBH-589","termGroup":"CN","termSource":"NCI"},{"termName":"LBH589","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma (MM)"},{"name":"CAS_Registry","value":"404950-80-7"},{"name":"Chemical_Formula","value":"C21H23N3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9647FM7Y3Z"},{"name":"Legacy Concept Name","value":"LBH589"},{"name":"Maps_To","value":"Panobinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"530790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"530790"},{"name":"PDQ_Open_Trial_Search_ID","value":"530790"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1998098"}]}}{"C150717":{"preferredName":"Panobinostat Nanoparticle Formulation MTX110","code":"C150717","definitions":[{"definition":"A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Panobinostat Nanoparticle Formulation MTX110","termGroup":"PT","termSource":"NCI"},{"termName":"MTX 110","termGroup":"CN","termSource":"NCI"},{"termName":"MTX-110","termGroup":"CN","termSource":"NCI"},{"termName":"MTX110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Panobinostat Nanoparticle Formulation MTX110"},{"name":"NCI_Drug_Dictionary_ID","value":"793526"},{"name":"NCI_META_CUI","value":"CL552518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793526"},{"name":"PDQ_Open_Trial_Search_ID","value":"793526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38693":{"preferredName":"Paricalcitol","code":"C38693","definitions":[{"definition":"A substance that is being used to treat overactive parathyroid glands in patients with kidney failure. It is also being studied in the treatment of cancer. Paricalcitol belongs to the family of drugs called vitamin D analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic noncalcemic, nonphosphatemic vitamin D analogue.  Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paricalcitol","termGroup":"PT","termSource":"NCI"},{"termName":"(7e,22e)-19-Nor-9,10-Secoergosta-5,7,22-Triene-1Alpha,3Beta,25-Triol","termGroup":"SN","termSource":"NCI"},{"termName":"Compound 49510","termGroup":"SY","termSource":"NCI"},{"termName":"Zemplar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Secondary hyperparathyroidism, prevention and treatment"},{"name":"CAS_Registry","value":"131918-61-1"},{"name":"CHEBI_ID","value":"CHEBI:7931"},{"name":"Chemical_Formula","value":"C27H44O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6702D36OG5"},{"name":"Legacy Concept Name","value":"Paricalcitol"},{"name":"Maps_To","value":"Paricalcitol"},{"name":"NCI_Drug_Dictionary_ID","value":"315740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"315740"},{"name":"PDQ_Open_Trial_Search_ID","value":"315740"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0724464"}]}}{"C154560":{"preferredName":"PARP 1/2 Inhibitor NOV1401","code":"C154560","definitions":[{"definition":"An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, NOV1401 selectively binds to PARP-1 and -2, thereby preventing PARP-1 and -2-mediated DNA repair. This promotes genetic instability and enhances the accumulation of single and double strand DNA breaks, ultimately leading to apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP 1/2 Inhibitor NOV1401","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP 1/2 Inhibitor NOV1401"},{"name":"NCI_Drug_Dictionary_ID","value":"794354"},{"name":"NCI_META_CUI","value":"CL555354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794354"},{"name":"PDQ_Open_Trial_Search_ID","value":"794354"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95201":{"preferredName":"PARP Inhibitor AZD2461","code":"C95201","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor AZD2461 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor AZD2461","termGroup":"PT","termSource":"NCI"},{"termName":"AZD2461","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP Inhibitor AZD2461"},{"name":"NCI_Drug_Dictionary_ID","value":"690473"},{"name":"PDQ_Closed_Trial_Search_ID","value":"690473"},{"name":"PDQ_Open_Trial_Search_ID","value":"690473"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986988"}]}}{"C84880":{"preferredName":"PARP Inhibitor CEP-9722","code":"C84880","definitions":[{"definition":"A small-molecule prodrug of CEP-8983, a novel 4-methoxy-carbazole inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration and conversion from CEP-9722, CEP-8983 selectively binds to PARP 1 and 2, preventing repair of damaged DNA via base excision repair (BER). This agent enhances the accumulation of DNA strand breaks and promotes genomic instability and apoptosis. CEP-8983 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and can be activated by single strand breaks in DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor CEP-9722","termGroup":"PT","termSource":"NCI"},{"termName":"CEP-9722","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"916574-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B68083E4YG"},{"name":"Maps_To","value":"PARP Inhibitor CEP-9722"},{"name":"NCI_Drug_Dictionary_ID","value":"649505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649505"},{"name":"PDQ_Open_Trial_Search_ID","value":"649505"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827554"}]}}{"C91387":{"preferredName":"PARP Inhibitor E7016","code":"C91387","definitions":[{"definition":"An inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemo- and/or radiosensitizing activity. PARP inhibitor E7016 selectively binds to PARP and prevents PARP mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. In addition, this agent may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor E7016","termGroup":"PT","termSource":"NCI"},{"termName":"E7016","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"902128-92-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M8926C7ILX"},{"name":"Maps_To","value":"PARP Inhibitor E7016"},{"name":"NCI_Drug_Dictionary_ID","value":"674406"},{"name":"NCI_META_CUI","value":"CL421589"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674406"},{"name":"PDQ_Open_Trial_Search_ID","value":"674406"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96795":{"preferredName":"PARP-1/2 Inhibitor ABT-767","code":"C96795","definitions":[{"definition":"An orally available inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, ABT-767 selectively binds to PARP 1 and 2, thereby preventing repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of DNA strand breaks and promotes genomic instability eventually leading to apoptosis. ABT-767 may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and can be activated by single strand DNA (ssDNA) breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP-1/2 Inhibitor ABT-767","termGroup":"PT","termSource":"NCI"},{"termName":"ABT-767","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP-1/2 Inhibitor ABT-767"},{"name":"NCI_Drug_Dictionary_ID","value":"699738"},{"name":"NCI_META_CUI","value":"CL429404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699738"},{"name":"PDQ_Open_Trial_Search_ID","value":"699738"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102746":{"preferredName":"PARP/Tankyrase Inhibitor 2X-121 ","code":"C102746","definitions":[{"definition":"An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, E7449 selectively binds to PARP 1 and 2, thereby preventing the repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of single and double strand DNA breaks and promotes genomic instability eventually leading to apoptosis. PARP 1/2 inhibitor E7449 may enhance the cytotoxicity of DNA-damaging agents and of radiotherapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP/Tankyrase Inhibitor 2X-121 ","termGroup":"PT","termSource":"NCI"},{"termName":"2X-121","termGroup":"CN","termSource":"NCI"},{"termName":"E-7449","termGroup":"CN","termSource":"NCI"},{"termName":"E7449","termGroup":"CN","termSource":"NCI"},{"termName":"PARP/TNKS Inhibitor 2X-121","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1140964-99-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9X5A2QIA7C"},{"name":"Maps_To","value":"PARP/Tankyrase Inhibitor 2X-121"},{"name":"NCI_Drug_Dictionary_ID","value":"735791"},{"name":"NCI_META_CUI","value":"CL601883"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735791"},{"name":"PDQ_Open_Trial_Search_ID","value":"735791"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90567":{"preferredName":"Parsatuzumab","code":"C90567","definitions":[{"definition":"A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parsatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Epidermal Growth Factor-like Domain 7 Monoclonal Antibody MEGF0444A","termGroup":"SY","termSource":"NCI"},{"termName":"MEGF 0444A","termGroup":"CN","termSource":"NCI"},{"termName":"MEGF0444A","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7414","termGroup":"CN","termSource":"NCI"},{"termName":"RG7414","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312797-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"435M4HCP2M"},{"name":"Maps_To","value":"Parsatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"646991"},{"name":"NCI_META_CUI","value":"CL416251"},{"name":"PDQ_Closed_Trial_Search_ID","value":"646991"},{"name":"PDQ_Open_Trial_Search_ID","value":"646991"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96229":{"preferredName":"Parvovirus H-1","code":"C96229","definitions":[{"definition":"A replication-competent oncolytic parvovirus with potential antineoplastic activity. Upon infection of host cells, parvovirus H-1 preferentially replicates in tumor cells compared to healthy normal cells, thereby potentially resulting in tumor cell lysis and leading to an inhibition of tumor cell proliferation. In addition, H1-infected tumor cells strongly induce the release of the inducible heat shock protein 72 (Hsp72i), which chaperone tumor associated antigens in the H1-mediated tumor lysates and may activate antigen presenting cells (APCs), thereby leading to antitumor immune responses. Parvovirus H-1 does not cause any pathogenic effect in normal, healthy cells and is able to cross the blood brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parvovirus H-1","termGroup":"PT","termSource":"NCI"},{"termName":"H-1PV","termGroup":"AB","termSource":"NCI"},{"termName":"ParvOryx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Parvovirus H-1"},{"name":"NCI_Drug_Dictionary_ID","value":"697624"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697624"},{"name":"PDQ_Open_Trial_Search_ID","value":"697624"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C0319116"}]}}{"C69131":{"preferredName":"Pasireotide","code":"C69131","definitions":[{"definition":"A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pasireotide","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-)","termGroup":"SN","termSource":"NCI"},{"termName":"SOM230","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"396091-73-9"},{"name":"Chemical_Formula","value":"C58H66N10O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98H1T17066"},{"name":"Legacy Concept Name","value":"Pasireotide"},{"name":"Maps_To","value":"Pasireotide"},{"name":"NCI_Drug_Dictionary_ID","value":"540440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"540440"},{"name":"PDQ_Open_Trial_Search_ID","value":"540440"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872203"}]}}{"C103827":{"preferredName":"Pasotuxizumab","code":"C103827","definitions":[{"definition":"A recombinant T-cell engaging bispecific monoclonal antibody (BiTE) directed against human prostate specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex, with potential immunostimulating and antineoplastic activities.  Pasotuxizumab possesses two antigen-recognition sites, one for PSMA, and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings PSMA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) together, which may result in the CTL-mediated cell death of PSMA-expressing cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pasotuxizumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG-212","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2010112","termGroup":"CN","termSource":"NCI"},{"termName":"MT112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1442657-12-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9J6SW7G28J"},{"name":"Maps_To","value":"Pasotuxizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"742717"},{"name":"NCI_META_CUI","value":"CL438307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742717"},{"name":"PDQ_Open_Trial_Search_ID","value":"742717"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80063":{"preferredName":"Patidegib","code":"C80063","definitions":[{"definition":"An orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, patidegib binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signaling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patidegib","termGroup":"PT","termSource":"NCI"},{"termName":"FIN-5","termGroup":"CN","termSource":"NCI"},{"termName":"IP9 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"IPI-926","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-926 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"Saridegib","termGroup":"AQS","termSource":"NCI"},{"termName":"Saridegib","termGroup":"SY","termSource":"NCI"},{"termName":"Smoothened Antagonist IPI-926","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1037210-93-7"},{"name":"Chemical_Formula","value":"C29H48N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JT96FPU35X"},{"name":"Legacy Concept Name","value":"Smoothened_Antagonist_IPI-926"},{"name":"Maps_To","value":"Patidegib"},{"name":"NCI_Drug_Dictionary_ID","value":"616875"},{"name":"PDQ_Closed_Trial_Search_ID","value":"616875"},{"name":"PDQ_Open_Trial_Search_ID","value":"616875"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703211"}]}}{"C158420":{"preferredName":"Patidegib Topical Gel","code":"C158420","definitions":[{"definition":"A topical gel containing patidegib, a cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon topical application of the patidegib gel, patidegib binds to and inhibits the activity of the G-protein coupled receptor smoothened (SMO), thereby inhibiting Hh pathway signaling. This decreases proliferation and survival in tumor cells in which the Hh pathway is overactivated. Upregulated Hh signaling is associated with uncontrolled tumor cell proliferation. Topical application of patidegib allows for local anti-tumor activity while avoiding systemic exposure and unwanted systemic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patidegib Topical Gel","termGroup":"PT","termSource":"NCI"},{"termName":"IPI-926 Topical Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Patidegib Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Patidegib Topical Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"802168"},{"name":"NCI_META_CUI","value":"CL937835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802168"},{"name":"PDQ_Open_Trial_Search_ID","value":"802168"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78853":{"preferredName":"Patritumab","code":"C78853","definitions":[{"definition":"A fully human monoclonal antibody directed against the membrane-bound receptor HER3 (ERBB3) with potential antineoplastic activity. Patritumab binds to and inhibits HER3 activation, which may result in inhibition of HER3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Patritumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 888","termGroup":"CN","termSource":"NCI"},{"termName":"U3-1287","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1262787-83-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"86780VJI1Q"},{"name":"Legacy Concept Name","value":"Anti-HER3_Monoclonal_Antibody_U3-1287"},{"name":"Maps_To","value":"Patritumab"},{"name":"NCI_Drug_Dictionary_ID","value":"612849"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612849"},{"name":"PDQ_Open_Trial_Search_ID","value":"612849"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2698144"}]}}{"C1623":{"preferredName":"Patupilone","code":"C1623","definitions":[{"definition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Patupilone may cause complete cell-cycle arrest.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of epothilone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Patupilone","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Epothilone B","termGroup":"SY","termSource":"NCI"},{"termName":"(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"EPO-906A","termGroup":"CN","termSource":"NCI"},{"termName":"Epothilone B","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"152044-54-7"},{"name":"Chemical_Formula","value":"C27H41NO6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UEC0H0URSE"},{"name":"Legacy Concept Name","value":"Epothilone_B"},{"name":"Maps_To","value":"Patupilone"},{"name":"NCI_Drug_Dictionary_ID","value":"38702"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38702"},{"name":"PDQ_Open_Trial_Search_ID","value":"38702"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0297960"}]}}{"C74547":{"preferredName":"Pazopanib","code":"C74547","definitions":[{"definition":"A drug that is used to treat kidney cancer and is being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. It is a type of protein tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pazopanib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"GW786034","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444731-52-6"},{"name":"CAS_Registry","value":"790713-33-6"},{"name":"Chemical_Formula","value":"C21H23N7O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7RN5DR86CK"},{"name":"Legacy Concept Name","value":"Pazopanib_Base"},{"name":"Maps_To","value":"Pazopanib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831796"}]}}{"C60779":{"preferredName":"Pazopanib Hydrochloride","code":"C60779","definitions":[{"definition":"A drug that is used to treat kidney cancer and is being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. It is a type of protein tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pazopanib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"5-((4-((2,3-Dimethyl-2h-Indazol-6-Yl)Methylamino)Pyrimidin-2-yl)Amino)-2-Methylbenzenesulfonamide Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"GW 786034B","termGroup":"CN","termSource":"NCI"},{"termName":"GW-786034B","termGroup":"CN","termSource":"NCI"},{"termName":"GW786034B","termGroup":"CN","termSource":"NCI"},{"termName":"Pazopater","termGroup":"FB","termSource":"NCI"},{"termName":"Votrient","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"635702-64-6"},{"name":"Chemical_Formula","value":"C21H23N7O2S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33Y9ANM545"},{"name":"Legacy Concept Name","value":"Pazopanib"},{"name":"Maps_To","value":"Pazopanib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"476479"},{"name":"NSC Number","value":"737754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"476479"},{"name":"PDQ_Open_Trial_Search_ID","value":"476479"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872226"}]}}{"C99639":{"preferredName":"pbi-shRNA STMN1 Lipoplex","code":"C99639","definitions":[{"definition":"A proprietary RNA interference construct consisting of bifunctional short hairpin RNAs (shRNA) against human stathmin 1 (STMN1) encapsulated in the cationic bilamellar invaginated vesicle lipoplex (LP) with potential antineoplastic activity. pbi-shRNA STMN1 LP contains 2 stem-loop structures encoded by a plasmid vector. Upon intratumoral administration, one shRNA unit with a perfectly matched sequence renders the suppression of STMN1 mRNA translation (mRNA sequestration and cleavage-independent degradation) while the other unit with an imperfectly matched sequence renders STMN1 mRNA degradation via RNase H-like cleavage (cleavage-dependent mRNA silencing). The suppression of STMN1 expression in tumor cells result in a reduction of tumor cell proliferation. STMN1, a ubiquitous cytosolic phosphoprotein and tubulin modulator that plays a key role in mitosis, is overexpressed in a variety of tumors and correlates with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pbi-shRNA STMN1 Lipoplex","termGroup":"PT","termSource":"NCI"},{"termName":"pbi-shRNA STMN1 LP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0TG7ZQ45R5"},{"name":"Maps_To","value":"pbi-shRNA STMN1 Lipoplex"},{"name":"NCI_Drug_Dictionary_ID","value":"722324"},{"name":"NCI_META_CUI","value":"CL433303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"722324"},{"name":"PDQ_Open_Trial_Search_ID","value":"722324"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77600":{"preferredName":"Disufenton Sodium","code":"C77600","definitions":[{"definition":"A disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Disufenton Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Benzenedisulfonic Acid, 4-(((1,1-Dimethylethyl)oxidoimino)methyl), Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"2,4-Disulfonyl PBN","termGroup":"SY","termSource":"NCI"},{"termName":"2,4-Disulfophenyl-tert-butylnitrone Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"HPN-07","termGroup":"CN","termSource":"NCI"},{"termName":"NXY-059","termGroup":"CN","termSource":"NCI"},{"termName":"OKN-007","termGroup":"CN","termSource":"NCI"},{"termName":"OKN007","termGroup":"CN","termSource":"NCI"},{"termName":"PBN Derivative OKN-007","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"168021-79-2"},{"name":"Chemical_Formula","value":"C11H13NO7S2.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7M1J3HN9VO"},{"name":"Legacy Concept Name","value":"Disufenton_Sodium"},{"name":"Maps_To","value":"PBN Derivative OKN-007"},{"name":"NCI_Drug_Dictionary_ID","value":"739669"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1701245"}]}}{"C1186":{"preferredName":"PCNU","code":"C1186","definitions":[{"definition":"A chloroethylnitrosourea compound and an alkylating agent with antineoplastic property. PCNU inhibits DNA synthesis by alkylating DNA and causing DNA cross links, thereby inducing apoptosis. In addition, this agent may be associated with pulmonary, hepatic, and hematologic toxicities. Unlike other nitrosoureas, PCNU has strong alkylating while weak carbamoylating activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PCNU","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(2,6-Dioxo-3-Piperidyl)-1-Nitrourea","termGroup":"SN","termSource":"NCI"},{"termName":"Urea, N-(2-chloroethyl)-N'-(2,6-dioxo-3-piperidinyl)-N-nitroso-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13909-02-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AZW59V4Q3B"},{"name":"Legacy Concept Name","value":"PCNU"},{"name":"Maps_To","value":"PCNU"},{"name":"NCI_Drug_Dictionary_ID","value":"39549"},{"name":"NSC Number","value":"95466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39549"},{"name":"PDQ_Open_Trial_Search_ID","value":"39549"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070165"}]}}{"C160716":{"preferredName":"PD-1 Directed Probody CX-188","code":"C160716","definitions":[{"definition":"A probody composed of a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), linked to a proprietary masking peptide that covers the active antigen binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of PD-1-directed probody CX-188, the masking peptide is cleaved by tumor-associated proteases within the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to PD-1, thereby disrupting PD-1 signaling. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-1 Directed Probody CX-188","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Probody CX-188","termGroup":"SY","termSource":"NCI"},{"termName":"CX 188","termGroup":"CA2","termSource":"NCI"},{"termName":"CX-188","termGroup":"CN","termSource":"NCI"},{"termName":"CX188","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-1 Directed Probody CX-188"},{"name":"NCI_Drug_Dictionary_ID","value":"797958"},{"name":"NCI_META_CUI","value":"CL969825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797958"},{"name":"PDQ_Open_Trial_Search_ID","value":"797958"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124946":{"preferredName":"PD1 Inhibitor","code":"C124946","definitions":[{"definition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD1 Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Agent","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1 Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1-targeting Agent","termGroup":"SY","termSource":"NCI"},{"termName":"Programmed Cell Death Protein 1 Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"Protein PD-1 Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-1 Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C4086713"}]}}{"C158532":{"preferredName":"PD-L1 Inhibitor INCB086550","code":"C158532","definitions":[{"definition":"An orally available, small molecule inhibitor of the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, PD-L1 inhibitor INCB086550 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1 Inhibitor INCB086550","termGroup":"PT","termSource":"NCI"},{"termName":"INCB 086550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 86550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-086550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-86550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB086550","termGroup":"CN","termSource":"NCI"},{"termName":"INCB86550","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 Ligand 1 Inhibitor INCB086550","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230911-59-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T8B91S15VF"},{"name":"Maps_To","value":"PD-L1 Inhibitor INCB086550"},{"name":"NCI_Drug_Dictionary_ID","value":"797120"},{"name":"NCI_META_CUI","value":"CL937968"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797120"},{"name":"PDQ_Open_Trial_Search_ID","value":"797120"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129594":{"preferredName":"PD-L1/PD-L2/VISTA Antagonist CA-170","code":"C129594","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1/PD-L2/VISTA Antagonist CA-170","termGroup":"PT","termSource":"NCI"},{"termName":"AUPM 170","termGroup":"CN","termSource":"NCI"},{"termName":"Aurigene 1","termGroup":"SY","termSource":"NCI"},{"termName":"CA-170","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1/PD-L2/VISTA Checkpoint Antagonist CA-170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1673534-76-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"646MN6KQ16"},{"name":"Maps_To","value":"PD-L1/PD-L2/VISTA Antagonist CA-170"},{"name":"NCI_Drug_Dictionary_ID","value":"783861"},{"name":"NCI_META_CUI","value":"CL512601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783861"},{"name":"PDQ_Open_Trial_Search_ID","value":"783861"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88271":{"preferredName":"PDK1 Inhibitor AR-12","code":"C88271","definitions":[{"definition":"An orally bioavailable, small-molecule, celecoxib-derived inhibitor of phosphoinositide-dependent kinase-1 (PDK1) with potential antineoplastic activity. Devoid of any COX inhibiting activity, PDK1 inhibitor AR-12 binds to and inhibits the phosphorylation of 3-phosphoinositide-dependent kinase-1 (PDK-1).; subsequently, the phosphorylation and activation of the serine/threonine protein kinase Akt (protein kinase B or PKB) is inhibited, which may result in inhibition of the PI3K/Akt signaling pathway, inhibition of tumor cell proliferation, and the induction of tumor cell apoptosis.  In addition, this agent appears to induce the activity of protein kinase R-like endoplasmic reticulum kinase (PERK), which plays a key role in the endoplasmic reticulum stress pathway. Activation and dysregulation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PDK1 Inhibitor AR-12","termGroup":"PT","termSource":"NCI"},{"termName":"AR-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"742112-33-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EX3O2Q61UV"},{"name":"Maps_To","value":"PDK1 Inhibitor AR-12"},{"name":"NCI_Drug_Dictionary_ID","value":"655950"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655950"},{"name":"PDQ_Open_Trial_Search_ID","value":"655950"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1569671"}]}}{"C157262":{"preferredName":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0","code":"C157262","definitions":[{"definition":"A whole cell cancer vaccine composed of irradiated autologous whole tumor cells that are transfected, ex vivo, with a plasmid DNA encoding the highly immunogenic Streptococcus pyogenes (S. pyogenes) bacterial antigen Emm55, with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IFx-Hu2.0, the tumor cells expressing the Emm55 bacterial antigen on their cell surface are taken up and processed by antigen-presenting cells (APCs), thereby presenting both the Emm55 and the patient-specific tumor-associated antigens (TAAs) to the immune system. This activates the immune system to elicit a tumor antigen-specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Cancer Cell-transfected with Plasmid DNA Encoding for Emm55 Streptococcal Antigen IFx-Hu2.0","termGroup":"SY","termSource":"NCI"},{"termName":"IFx-Hu2.0","termGroup":"CN","termSource":"NCI"},{"termName":"ImmuneFx","termGroup":"BR","termSource":"NCI"},{"termName":"pDNA Autologous Cancer Cell Vaccine IFx-Hu2.0","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmid DNA Autologous Cancer Vaccine IFx-Hu2.0","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmid DNA Vaccine Encoding S. pyogenes Emm55 Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0"},{"name":"NCI_Drug_Dictionary_ID","value":"796807"},{"name":"NCI_META_CUI","value":"CL936865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796807"},{"name":"PDQ_Open_Trial_Search_ID","value":"796807"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126276":{"preferredName":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1","code":"C126276","definitions":[{"definition":"A fusion protein consisting of a peptide sequence of human papillomavirus (HPV) type 16 E7 nuclear protein and fused to the Pseudomonas aeruginosa exotoxin A (PE) and a endoplasmic reticulum (ER) retention signal (KDEL), with potential antineoplastic activity. Upon administration of PE/HPV16 E7/KDEL fusion protein TVGV-1, the PE moiety binds to CD91 (LRP1) expressed on a variety of cells, including antigen-presenting cells such as dendritic cells (DCs), which facilitates the internalization, through endocytosis, of TVGV-1. Following endocytosis, this agent is proteolytically cleaved by the proteasome and the epitopes from the HPV E7 protein become bound to MHC-I molecules and are presented on the DC-cell surface. This facilitates a cytotoxic T-cell- mediated immune response against HPV16 E7 expressing-tumor cells. KDEL targets the fusion protein to the ER, which increases this agent's potential to be bound by MHC-I molecules; this increases the immune response against HPV16 E7-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1","termGroup":"PT","termSource":"NCI"},{"termName":"PE-E7-KDEL/GPI-0100 TVGV-1","termGroup":"SY","termSource":"NCI"},{"termName":"PEK Fusion Protein/GPI-0100 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TVGV-1","termGroup":"CN","termSource":"NCI"},{"termName":"TVGV-1 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1"},{"name":"NCI_Drug_Dictionary_ID","value":"779306"},{"name":"NCI_META_CUI","value":"CL504853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779306"},{"name":"PDQ_Open_Trial_Search_ID","value":"779306"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1304":{"preferredName":"PEG-interleukin-2","code":"C1304","definitions":[{"definition":"A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEG-interleukin-2","termGroup":"PT","termSource":"NCI"},{"termName":"PEG-IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"Polyethylene Glycol-Modified Recombinant Interleukin-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PEG-interleukin-2"},{"name":"Maps_To","value":"PEG-interleukin-2"},{"name":"NCI_Drug_Dictionary_ID","value":"39577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39577"},{"name":"PDQ_Open_Trial_Search_ID","value":"39577"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0083036"}]}}{"C49178":{"preferredName":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001","code":"C49178","definitions":[{"definition":"A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) encapsulated in a biodegradable, biocompatible lipoplex composed of polyethylene glycol (PEG), polyethylenimine (PEI), and cholesterol, with potential immunoactivating and antineoplastic activities. Upon intraperitoneal (IP) delivery of the PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector IMNN-001, the lipoplex is endocytosed by nearby cells, and the plasmid DNA is transported into the nucleus, which leads to local expresssion of IL-12. In turn, the increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-cell responses against tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 1","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1","termGroup":"CN","termSource":"NCI"},{"termName":"IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer","termGroup":"SY","termSource":"NCI"},{"termName":"IMNN 001","termGroup":"CN","termSource":"NCI"},{"termName":"IMNN-001","termGroup":"CN","termSource":"NCI"},{"termName":"IMNN001","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoparticle-encased IL-12 DNA Plasmid Vector","termGroup":"SY","termSource":"NCI"},{"termName":"phIL-12-005","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"EGEN-001"},{"name":"Maps_To","value":"PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1"},{"name":"NCI_Drug_Dictionary_ID","value":"454593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"454593"},{"name":"PDQ_Open_Trial_Search_ID","value":"454593"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707844"}]}}{"C111892":{"preferredName":"Ropeginterferon Alfa-2B","code":"C111892","definitions":[{"definition":"A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ropeginterferon Alfa-2B","termGroup":"PT","termSource":"NCI"},{"termName":"AOP 2014","termGroup":"CN","termSource":"NCI"},{"termName":"AOP-2014","termGroup":"CN","termSource":"NCI"},{"termName":"AOP2014","termGroup":"CN","termSource":"NCI"},{"termName":"Besremi","termGroup":"BR","termSource":"NCI"},{"termName":"P-1101","termGroup":"CN","termSource":"NCI"},{"termName":"P1101","termGroup":"CN","termSource":"NCI"},{"termName":"PEG-P-IFN-Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-P-IFN-Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-Proline-Interferon Alfa-2b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1335098-50-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"981TME683S"},{"name":"Maps_To","value":"PEG-Proline-Interferon Alfa-2b"},{"name":"Maps_To","value":"Ropeginterferon Alfa-2B"},{"name":"NCI_Drug_Dictionary_ID","value":"753252"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753252"},{"name":"PDQ_Open_Trial_Search_ID","value":"753252"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827091"}]}}{"C91702":{"preferredName":"Pegargiminase","code":"C91702","definitions":[{"definition":"A substance being studied in the treatment of melanoma, liver cancer, and other types of cancer. It breaks down the amino acid arginine and may block the growth of cancer cells that need arginine to grow. It is a type of iminohydrolase.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An agent consisting of the arginine-degrading enzyme arginine deiminase combined with polyethylene glycol (20,000 MW) (ADI-PEG 20) with potential antineoplastic activity. Upon administration, pegargiminase breaks down the amino acid arginine into citrulline. Although arginine is a nonessential amino acid for normal human cells, certain cancer cells are autotrophic for arginine and need arginine in order to survive. Depletion of arginine may lead to an inhibition of cellular proliferation in those cancer cells. ADI is coupled to PEG in order to enhance this agent's half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegargiminase","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1394129-74-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0B7PYQ9YRT"},{"name":"Maps_To","value":"Pegargiminase"},{"name":"NCI_Drug_Dictionary_ID","value":"355725"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355725"},{"name":"PDQ_Open_Trial_Search_ID","value":"355725"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328192"}]}}{"C1200":{"preferredName":"Pegaspargase","code":"C1200","definitions":[{"definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the drug asparaginase that is linked to a substance called PEG, which makes the drug stay in the body longer. Asparaginase is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pegaspargase","termGroup":"PT","termSource":"NCI"},{"termName":"(Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase","termGroup":"SN","termSource":"NCI"},{"termName":"L-Asparaginase with Polyethylene Glycol","termGroup":"SY","termSource":"NCI"},{"termName":"Oncaspar","termGroup":"BR","termSource":"NCI"},{"termName":"Oncaspar-IV","termGroup":"BR","termSource":"NCI"},{"termName":"PEG-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-L-Asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"PEGLA","termGroup":"AB","termSource":"NCI"},{"termName":"Polyethylene Glycol-L-Asparaginase","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute lymphoblastic leukemia"},{"name":"CAS_Registry","value":"130167-69-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7D96IR0PPM"},{"name":"Legacy Concept Name","value":"Pegaspargase"},{"name":"Maps_To","value":"Pegaspargase"},{"name":"NCI_Drug_Dictionary_ID","value":"40312"},{"name":"NSC Number","value":"624239"},{"name":"NSC Number","value":"644954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40312"},{"name":"PDQ_Open_Trial_Search_ID","value":"40312"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071568"}]}}{"C62791":{"preferredName":"Pegdinetanib","code":"C62791","definitions":[{"definition":"A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. CT-322 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pegdinetanib","termGroup":"PT","termSource":"NCI"},{"termName":"Angiocept","termGroup":"BR","termSource":"NCI"},{"termName":"BMS-844203","termGroup":"CN","termSource":"NCI"},{"termName":"CT-322","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"906450-24-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SSB56T0M0L"},{"name":"Legacy Concept Name","value":"CT-322"},{"name":"Maps_To","value":"Pegdinetanib"},{"name":"NCI_Drug_Dictionary_ID","value":"575516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"575516"},{"name":"PDQ_Open_Trial_Search_ID","value":"575516"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831965"}]}}{"C1854":{"preferredName":"Pegfilgrastim","code":"C1854","definitions":[{"definition":"A drug used to increase numbers of white blood cells in patients who are receiving chemotherapy. It is a type of colony-stimulating factor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegfilgrastim","termGroup":"PT","termSource":"NCI"},{"termName":"Dulastin","termGroup":"BR","termSource":"NCI"},{"termName":"Filgrastim SD-01","termGroup":"SY","termSource":"NCI"},{"termName":"Fulphila","termGroup":"BR","termSource":"NCI"},{"termName":"Fylnetra","termGroup":"BR","termSource":"NCI"},{"termName":"G-Lasta","termGroup":"FB","termSource":"NCI"},{"termName":"HSP-130","termGroup":"CN","termSource":"NCI"},{"termName":"Jinyouli","termGroup":"FB","termSource":"NCI"},{"termName":"Neulasta","termGroup":"BR","termSource":"NCI"},{"termName":"Neulastim","termGroup":"FB","termSource":"NCI"},{"termName":"Neupopeg","termGroup":"FB","termSource":"NCI"},{"termName":"Nyvepria","termGroup":"BR","termSource":"NCI"},{"termName":"Pegcyte","termGroup":"FB","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar HSP-130","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Nyvepria","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Pegcyte","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar PF-06881894","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Udenyca","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim Biosimilar Ziextenzo","termGroup":"SY","termSource":"NCI"},{"termName":"pegfilgrastim-apgf","termGroup":"SY","termSource":"NCI"},{"termName":"pegfilgrastim-bmez","termGroup":"SY","termSource":"NCI"},{"termName":"pegfilgrastim-cbqv","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim-fpgk","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim-jmdb","termGroup":"SY","termSource":"NCI"},{"termName":"Pegfilgrastim-pbbk","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated G-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated GCSF","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Granulocyte Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"PF-06881894","termGroup":"CN","termSource":"NCI"},{"termName":"SD-01","termGroup":"SY","termSource":"NCI"},{"termName":"SD-01 sustained duration G-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"Stimufend","termGroup":"BR","termSource":"NCI"},{"termName":"Tripegfilgrastim","termGroup":"SY","termSource":"NCI"},{"termName":"Udenyca","termGroup":"BR","termSource":"NCI"},{"termName":"Ziextenzo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chemotherapy-induced neutropenia"},{"name":"CAS_Registry","value":"208265-92-3"},{"name":"Chemical_Formula","value":"C3H8NO(C2H4O)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"3A58010674"},{"name":"Legacy Concept Name","value":"Pegfilgrastim"},{"name":"Maps_To","value":"Pegfilgrastim"},{"name":"NCI_Drug_Dictionary_ID","value":"37807"},{"name":"NSC Number","value":"725961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37807"},{"name":"PDQ_Open_Trial_Search_ID","value":"37807"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1136535"}]}}{"C113295":{"preferredName":"Pegilodecakin","code":"C113295","definitions":[{"definition":"A covalent conjugate of recombinant human interleukin-10 (IL-10) and polyethylene glycol (PEG), with potential anti-fibrotic, anti-inflammatory, immunomodulating and antineoplastic activities. Upon subcutaneous administration, pegilodecakin may activate cell-mediated immunity against cancer cells by stimulating the differentiation and expansion of tumor specific cytotoxic CD8+ T cells. This agent may also lower serum cholesterol levels and reduce atherosclerotic plaques by inhibiting the synthesis of pro-inflammatory cytokines, such as Interferon-gamma, IL-2, IL-3, TNF-alpha, and GM-CSF. The PEG moiety inhibits proteolytic breakdown and clearance of AM0010, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegilodecakin","termGroup":"PT","termSource":"NCI"},{"termName":"AM-0010","termGroup":"CN","termSource":"NCI"},{"termName":"AM0010","termGroup":"CN","termSource":"NCI"},{"termName":"PEG-rHuIL-10 AM0010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1966111-35-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5Z9850I25F"},{"name":"Maps_To","value":"Pegilodecakin"},{"name":"NCI_Drug_Dictionary_ID","value":"756011"},{"name":"NCI_META_CUI","value":"CL458142"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756011"},{"name":"PDQ_Open_Trial_Search_ID","value":"756011"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C33987":{"preferredName":"Peginterferon Alfa-2a","code":"C33987","definitions":[{"definition":"A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peginterferon Alfa-2a","termGroup":"PT","termSource":"NCI"},{"termName":"PEG-Interferon Alfa-2a","termGroup":"SY","termSource":"NCI"},{"termName":"Pegasys","termGroup":"BR","termSource":"NCI"},{"termName":"Pegylated Interferon Alfa-2a","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic hepatitis C; renal cell carcinoma; advanced melanoma; chronic myelogenous leukaemia"},{"name":"CAS_Registry","value":"198153-51-4"},{"name":"Chemical_Formula","value":"C10H18N3O5(C2H4O)n(C2H4O)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q46947FE7K"},{"name":"Legacy Concept Name","value":"PEG-Interferon_Alfa-2a"},{"name":"Maps_To","value":"Peginterferon Alfa-2a"},{"name":"NCI_Drug_Dictionary_ID","value":"335280"},{"name":"NSC Number","value":"729130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"335280"},{"name":"PDQ_Open_Trial_Search_ID","value":"335280"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0391001"}]}}{"C1845":{"preferredName":"Peginterferon Alfa-2b","code":"C1845","definitions":[{"definition":"A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peginterferon Alfa-2b","termGroup":"PT","termSource":"NCI"},{"termName":"PEG Interferon Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG Intron","termGroup":"BR","termSource":"NCI"},{"termName":"PEG-IFN Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-IFN-a 2b","termGroup":"AB","termSource":"NCI"},{"termName":"PEG-Interferon Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"PEG-Intron","termGroup":"FB","termSource":"NCI"},{"termName":"PegIntron","termGroup":"BR","termSource":"NCI"},{"termName":"Pegylated Interferon alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Interferon Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"Polyethylene Glycol IFN-A2b","termGroup":"SY","termSource":"NCI"},{"termName":"Polyethylene Glycol Interferon Alfa-2b","termGroup":"SY","termSource":"NCI"},{"termName":"SCH-54031","termGroup":"CN","termSource":"NCI"},{"termName":"SCH54031","termGroup":"CN","termSource":"NCI"},{"termName":"Sylatron","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic hepatitis C; renal cell carcinoma"},{"name":"CAS_Registry","value":"215647-85-1"},{"name":"CHEBI_ID","value":"CHEBI:63615"},{"name":"Chemical_Formula","value":"C2H4NO2(C2H4O)n"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G8RGG88B68"},{"name":"Legacy Concept Name","value":"PEG-Interferon_Alfa-2B"},{"name":"Maps_To","value":"Peginterferon Alfa-2b"},{"name":"NCI_Drug_Dictionary_ID","value":"43407"},{"name":"NSC Number","value":"720033"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43407"},{"name":"PDQ_Open_Trial_Search_ID","value":"43407"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796545"}]}}{"C61881":{"preferredName":"Pegvisomant","code":"C61881","definitions":[{"definition":"A pegylated, recombinant, human growth hormone (GH) structural analog with GH receptor antagonist activity. As a GH analog, the structure of pegvisomant is similar to that of native GH with the exception of 9 amino acid substitutions. Pegvisomant selectively binds to GH receptors on cell surfaces, interfering with endogenous GH receptor binding and so GH signal transduction. Inhibition of GH signal transduction results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and other GH-responsive serum proteins, including IGF binding protein-3 (IGFBP-3) and the acid-labile subunit (ALS), and may inhibit the growth of cancers in which IGF-1 is upregulated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegvisomant","termGroup":"PT","termSource":"NCI"},{"termName":"Somatotropin (18-Aspartic Acid, 21-Asparagine, 120-Lysine, 167-Asparagine, 168-Alanine, 171-Serine, 172-Arginine, 174-Serine, 179-Threonine) (Human), Pegylated","termGroup":"SY","termSource":"NCI"},{"termName":"Somavert","termGroup":"BR","termSource":"NCI"},{"termName":"Trovert","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"218620-50-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N824AOU5XV"},{"name":"Legacy Concept Name","value":"Pegvisomant"},{"name":"Maps_To","value":"Pegvisomant"},{"name":"NCI_Drug_Dictionary_ID","value":"655949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655949"},{"name":"PDQ_Open_Trial_Search_ID","value":"655949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0913469"}]}}{"C162508":{"preferredName":"Pegylated Deoxycytidine Analogue DFP-14927","code":"C162508","definitions":[{"definition":"A pegylated formulation containing DFP-10917, an analogue of the nucleoside deoxycytidine, with potential antineoplastic activity. Upon administration, the pegylated deoxycytidine analogue DFP-14927 is incorporated into the DNA of rapidly proliferating cells, such as tumor cells, and directly inhibits the activity of DNA polymerase, which results in the inhibition of DNA replication and cell cycle arrest, DNA fragmentation, and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Deoxycytidine Analogue DFP-14927","termGroup":"PT","termSource":"NCI"},{"termName":"DFP 14927","termGroup":"CN","termSource":"NCI"},{"termName":"DFP-14927","termGroup":"CN","termSource":"NCI"},{"termName":"DFP14927","termGroup":"CN","termSource":"NCI"},{"termName":"PEGylated DFP-10917","termGroup":"SY","termSource":"NCI"},{"termName":"Polymeric Nucleoside Analogue DFP-14927","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated Deoxycytidine Analogue DFP-14927"},{"name":"NCI_Drug_Dictionary_ID","value":"798748"},{"name":"NCI_META_CUI","value":"CL970946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798748"},{"name":"PDQ_Open_Trial_Search_ID","value":"798748"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2491":{"preferredName":"Pegylated Interferon Alfa","code":"C2491","definitions":[{"definition":"A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety.  Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Interferon Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"PEG-IFN-a","termGroup":"AB","termSource":"NCI"},{"termName":"PEG-interferon alfa","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatitis C."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pegylated_Interferon_Alfa"},{"name":"Maps_To","value":"Pegylated Interferon Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"43151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43151"},{"name":"PDQ_Open_Trial_Search_ID","value":"43151"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0907160"}]}}{"C61437":{"preferredName":"Pegylated Liposomal Belotecan","code":"C61437","definitions":[{"definition":"A sterically stabilized, pegylated liposomal formulation containing belotecan, a semi-synthetic analogue of campthotecin with potential antitumor activity. Belotecan inhibits the action of topoisomerase I, an enzyme that produces reversible single-strand breaks in DNA during DNA replication. This agent stabilizes the topoisomerase I and DNA complex, resulting in the inhibition of religation of DNA breaks, inhibition of DNA replication, and apoptotic cell death. The polyethylene glycol coating allows for greater plasma circulation time, thus enhancing the concentration of belotecan at the tumor site. Encapsulation of belotecan preserves the active lactone form, resulting in an increased cytotoxic effect of belotecan.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Belotecan","termGroup":"PT","termSource":"NCI"},{"termName":"S-CKD602","termGroup":"CN","termSource":"NCI"},{"termName":"STEALTH Liposomal Belotecan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"S-CKD602"},{"name":"Maps_To","value":"Pegylated Liposomal Belotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"471934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"471934"},{"name":"PDQ_Open_Trial_Search_ID","value":"471934"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831764"}]}}{"C1555":{"preferredName":"Pegylated Liposomal Doxorubicin Hydrochloride","code":"C1555","definitions":[{"definition":"A form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin. Doxil is used to treat ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma in patients whose disease has not gotten better after treatment with other anticancer drugs. It may be used together with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Doxil is a type of anthracycline antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ATI-0918","termGroup":"CN","termSource":"NCI"},{"termName":"Caelyx","termGroup":"FB","termSource":"NCI"},{"termName":"DOX-SL","termGroup":"BR","termSource":"NCI"},{"termName":"Doxil","termGroup":"BR","termSource":"NCI"},{"termName":"Doxilen","termGroup":"FB","termSource":"NCI"},{"termName":"Doxorubicin HCl Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin HCl Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Doxorubicin Hydrochloride Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Duomeisu","termGroup":"FB","termSource":"NCI"},{"termName":"Evacet","termGroup":"BR","termSource":"NCI"},{"termName":"LipoDox","termGroup":"BR","termSource":"NCI"},{"termName":"Lipodox 50","termGroup":"BR","termSource":"NCI"},{"termName":"Liposomal Adriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal-Encapsulated Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Doxorubicin HCl Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Liposomal Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"S-Liposomal Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Stealth Liposomal Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"TLC D-99","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Refractory metastatic carcinoma of the ovary; AIDS-related Kaposi's sarcoma; breast cancer; relapsed/refractory multiple myeloma (with bortezomib)."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Doxorubicin_Hydrochloride_Liposome"},{"name":"Maps_To","value":"Pegylated Liposomal Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39424"},{"name":"NSC Number","value":"712227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39424"},{"name":"PDQ_Open_Trial_Search_ID","value":"39424"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522690"}]}}{"C62789":{"preferredName":"Pegylated Liposomal Irinotecan","code":"C62789","definitions":[{"definition":"A formulation of polyethylene glycol (PEG)-modified liposomes encapsulating the semisynthetic derivative of camptothecin irinotecan, with antineoplastic activity. As a prodrug, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. In turn, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA, resulting in DNA breaks. This results in an inhibition of DNA replication and an induction of apoptosis. Pegylated liposomal delivery of irinotecan improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of exposure while lowering systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Irinotecan","termGroup":"PT","termSource":"NCI"},{"termName":"IHL-305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Liposomal_Irinotecan"},{"name":"Maps_To","value":"Pegylated Liposomal Irinotecan"},{"name":"NCI_Drug_Dictionary_ID","value":"506099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"506099"},{"name":"PDQ_Open_Trial_Search_ID","value":"506099"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831956"}]}}{"C103276":{"preferredName":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug","code":"C103276","definitions":[{"definition":"A pegylated liposomal formulation comprised of a lipophilic prodrug of the antineoplastic antibiotic mitomycin C containing a cleavable disulfide bond (PL-MLP), with potential antineoplastic activity. Upon administration of the pegylated liposomal mitomycin C lipid-based prodrug, the MLP moiety becomes activated upon thiolysis at the tumor site, thereby releasing mitomycin C. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  The thiolytic environment and upregulated expression of thioredoxins at the tumor site allow for the activation and release of mitomycin C. This prodrug formulation allows for greater circulation time, less systemic toxicity and increased accumulation of mitomycin C at the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ-27548547","termGroup":"CN","termSource":"NCI"},{"termName":"PL-MLP","termGroup":"AB","termSource":"NCI"},{"termName":"Promitil","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"303983-00-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3I8JKL1CHB"},{"name":"Maps_To","value":"Pegylated Liposomal Mitomycin C Lipid-based Prodrug"},{"name":"NCI_Drug_Dictionary_ID","value":"741900"},{"name":"NCI_META_CUI","value":"CL438127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741900"},{"name":"PDQ_Open_Trial_Search_ID","value":"741900"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C131307":{"preferredName":"Pegylated Liposomal Mitoxantrone Hydrochloride","code":"C131307","definitions":[{"definition":"A pegylated liposomal mitoxantrone formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within pegylated small unilamellar vesicles (SUVs), with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in rapidly dividing cancer cells. The pegylated liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering toxic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Mitoxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"PLM60","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated Liposomal Mitoxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"785702"},{"name":"NCI_META_CUI","value":"CL514320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785702"},{"name":"PDQ_Open_Trial_Search_ID","value":"785702"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116869":{"preferredName":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010","code":"C116869","definitions":[{"definition":"A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor's vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel's efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010","termGroup":"PT","termSource":"NCI"},{"termName":"MNK-010","termGroup":"CN","termSource":"NCI"},{"termName":"MP-3549-1","termGroup":"CN","termSource":"NCI"},{"termName":"Pegylated Liposomal Docetaxel Prodrug MNK-010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010"},{"name":"NCI_Drug_Dictionary_ID","value":"757071"},{"name":"NCI_META_CUI","value":"CL471764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757071"},{"name":"PDQ_Open_Trial_Search_ID","value":"757071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63476":{"preferredName":"Pegylated Paclitaxel","code":"C63476","definitions":[{"definition":"A formulation of polyethylene glycol (PEG) conjugated paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic activity. Paclitaxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2). Compared to paclitaxel alone, pegylated paclitaxel has an enhanced water solubility leading to an increase in bioavailability, and decreases its toxicity profile. Therefore, the pegylated formulation potentially supports delivery of higher doses of paclitaxel to the specific site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"PEG Paclitaxel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Pegylated_Paclitaxel"},{"name":"Maps_To","value":"Pegylated Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"363602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"363602"},{"name":"PDQ_Open_Trial_Search_ID","value":"363602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541201"}]}}{"C88286":{"preferredName":"Pegylated Recombinant Human Arginase I BCT-100","code":"C88286","definitions":[{"definition":"A recombinant human arginase I (liver arginase) covalently attached, via a succinamide propionic acid (SPA) linker, to a polyethylene glycol (PEG) of molecular weight 5,000 [rhArg-peg(5,000mw)] with potential antineoplastic activity. Upon intravenous administration of pegylated recombinant human arginase I BCT-100, arginase metabolizes the amino acid arginine to ornithine and urea, depleting intracellular arginine, which may inhibit proliferation of cells that are auxotrophic for arginine such as hepatocellular carcinoma (HCC) cells.  This agent may also work synergistically with various cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated Recombinant Human Arginase I BCT-100","termGroup":"PT","termSource":"NCI"},{"termName":"BCT-100","termGroup":"CN","termSource":"NCI"},{"termName":"RH-ARG1-PEG-5,000 MW","termGroup":"SY","termSource":"NCI"},{"termName":"rhArgIpeg5000","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1433787-75-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3HC6XX81X"},{"name":"Maps_To","value":"Pegylated Recombinant Human Arginase I BCT-100"},{"name":"NCI_Drug_Dictionary_ID","value":"657226"},{"name":"NCI_META_CUI","value":"CL413535"},{"name":"PDQ_Closed_Trial_Search_ID","value":"657226"},{"name":"PDQ_Open_Trial_Search_ID","value":"657226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82659":{"preferredName":"Pegvorhyaluronidase Alfa","code":"C82659","definitions":[{"definition":"A pegylated formulation of a recombinant form of human hyaluronidase with potential antitumor activity. Upon intravenous administration, pegvorhyaluronidase alfa degrades hyaluronic acid (HA) coating tumor cells, which may result in the inhibition of tumor cell growth. In addition, the degradation of HA may result in a lowering of the interstitial fluid pressure (IFP), allowing better penetration of chemotherapeutic agents into the tumor bed. HA is a glycosaminoglycan found in the extracellular matrix (ECM) that is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increased tumor cell growth, metastatic potential, tumor progression, increased resistance to chemotherapeutic agents, and an elevation in tumor IFP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegvorhyaluronidase Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"PEGPH20","termGroup":"AB","termSource":"NCI"},{"termName":"Pegylated Recombinant Human Hyaluronidase PH20","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant Human PH20","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"PH20","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620390-06-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P01I4980ZS"},{"name":"Legacy Concept Name","value":"Pegylated_Recombinant_Human_Hyaluronidase_PH20"},{"name":"Maps_To","value":"Pegvorhyaluronidase Alfa"},{"name":"Maps_To","value":"Pegylated Recombinant Human Hyaluronidase PH20"},{"name":"NCI_Drug_Dictionary_ID","value":"636196"},{"name":"NCI_META_CUI","value":"CL388491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"636196"},{"name":"PDQ_Open_Trial_Search_ID","value":"636196"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162645":{"preferredName":"Pegenzileukin","code":"C162645","definitions":[{"definition":"A pegylated recombinant, engineered variant of cytokine interleukin-2 (IL-2; IL2) where novel amino acid is encoded in the IL-2 gene that is leveraged for use in site-specific pegylation, with potential immunostimulating activity. Upon administration of pegenzileukin, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells, such as cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, thereby activating these cells and inducing their expansion. It also induces the expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. The addition of the novel amino acid and the concurrent pegylation prevents the binding of the IL-2 moiety to the IL-2 receptor alpha chain (IL2Ra), thereby blocking the IL2Ra-mediated activation of CD4-positive regulatory and immunosuppressive T-cells (Tregs). Since it cannot bind to IL2Ra expressed on innate lymphoid cells in the vascular endothelium, pegenzileukin prevents IL-2-mediated recruitment and activation of eosinophils, and inhibits the induction of eosinophil-mediated vascular leak syndrome (VLS). Pegylation also extends the half-life of pegenzileukin. Compared to recombinant IL-2, pegenzileukin allows for increased IL-2Rbg binding and proliferation of CTLs without stimulating the toxicity caused by binding to IL-2Ra.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegenzileukin","termGroup":"PT","termSource":"NCI"},{"termName":"IL-2 Variant THOR-707","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant IL-2 Variant THOR-707","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant Interleukin-2 THOR-707","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 444245","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-444245","termGroup":"CN","termSource":"NCI"},{"termName":"SAR444245","termGroup":"CN","termSource":"NCI"},{"termName":"THOR 707","termGroup":"CN","termSource":"NCI"},{"termName":"THOR-707","termGroup":"CN","termSource":"NCI"},{"termName":"THOR707","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2573074-47-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"10WR240QN7"},{"name":"Maps_To","value":"Pegylated Recombinant Interleukin-2 THOR-707"},{"name":"NCI_Drug_Dictionary_ID","value":"798926"},{"name":"NCI_META_CUI","value":"CL971032"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798926"},{"name":"PDQ_Open_Trial_Search_ID","value":"798926"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C170297":{"preferredName":"Pegcrisantaspase","code":"C170297","definitions":[{"definition":"A recombinant, pegylated form of Erwinia asparaginase (crisantaspase), derived from the bacterium Erwinia chrysanthemi and genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Recombinant Erwinia asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Recombinant Erwinia asparaginase can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegcrisantaspase","termGroup":"PT","termSource":"NCI"},{"termName":"Asparec","termGroup":"FB","termSource":"NCI"},{"termName":"JZP 416","termGroup":"CN","termSource":"NCI"},{"termName":"JZP-416","termGroup":"CN","termSource":"NCI"},{"termName":"JZP416","termGroup":"CN","termSource":"NCI"},{"termName":"mPEG-R-crisantaspase","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Erwinia asparaginase","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant L-asparaginase Erwinia chrysanthemi","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448590-54-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y8KTZ6Y35U"},{"name":"Maps_To","value":"Pegylated Recombinant L-asparaginase Erwinia chrysanthemi"},{"name":"NCI_Drug_Dictionary_ID","value":"729150"},{"name":"NCI_Drug_Dictionary_ID","value":"804180"},{"name":"NCI_META_CUI","value":"CL1382536"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125143":{"preferredName":"Pegzilarginase","code":"C125143","definitions":[{"definition":"A recombinant modified form of the human enzyme arginase 1 (ARG1), in which cobalt is substituted for manganese as a cofactor, covalently attached to polyethylene glycol (PEG), with potential arginine degrading and antineoplastic activities. Upon intravenous administration of pegzilarginase, ARG1 metabolizes the amino acid arginine to ornithine and urea, thereby lowering blood arginine levels. This normalizes blood arginine levels in patients with ARG1 deficiency and prevents hyperargininemia. This also inhibits the proliferation of cancer cells that are dependent on extracellular arginine uptake for their proliferation. In normal, healthy cells, arginine is synthesized intracellularly by the enzymes ornithine transcarbamylase (OTC), argininosuccinate synthase (ASS), and argininosuccinate lyase (ASL); thus they are not dependent on extracellular arginine for survival. In cancer cells these enzymes are disabled; therefore, this agent may inhibit proliferation and survival of these cells by depleting extracellular arginine. Pegylation improves blood circulation times and cobalt substitution increases the catalytic activity of ARG1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegzilarginase","termGroup":"PT","termSource":"NCI"},{"termName":"AEB-1102","termGroup":"CN","termSource":"NCI"},{"termName":"AEB1102","termGroup":"CN","termSource":"NCI"},{"termName":"Co-ArgI-PEG","termGroup":"SY","termSource":"NCI"},{"termName":"Pegylated Recombinant Arginase AEB1102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1659310-95-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4YV4KW88GD"},{"name":"Maps_To","value":"Pegzilarginase"},{"name":"NCI_Drug_Dictionary_ID","value":"778251"},{"name":"NCI_META_CUI","value":"CL503972"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778251"},{"name":"PDQ_Open_Trial_Search_ID","value":"778251"},{"name":"Semantic_Type","value":"Enzyme"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60774":{"preferredName":"Pelareorep","code":"C60774","definitions":[{"definition":"An isolate of the oncolytic, human wild-type serotype 3 Dearing (T3D) strain of the double-stranded RNA virus reovirus (Respiratory Enteric Orphan virus), with potential oncolytic activity. Upon administration, pelareorep is able to replicate specifically in cancer cells bearing an activated Ras pathway. This induces apoptosis in Ras-activated tumor cells and subsequently frees progeny viral particles to infect, replicate in and induce cell death of surrounding cancer cells. In addition, viral replication causes the activation of innate and adaptive immune responses, causing a natural killer (NK)-cell-mediated and a cytotoxic T-cell (CTL)-mediated killing of tumor cells, respectively. Ras-activated tumor cells are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelareorep","termGroup":"PT","termSource":"NCI"},{"termName":"PO BB0209","termGroup":"CN","termSource":"NCI"},{"termName":"PO-BB0209","termGroup":"CN","termSource":"NCI"},{"termName":"Reolysin","termGroup":"BR","termSource":"NCI"},{"termName":"Reovirus Serotype 3","termGroup":"SY","termSource":"NCI"},{"termName":"Wild-type Reovirus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1383626-61-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9J80L3D1U"},{"name":"Legacy Concept Name","value":"Reolysin"},{"name":"Maps_To","value":"Pelareorep"},{"name":"NCI_Drug_Dictionary_ID","value":"563224"},{"name":"NSC Number","value":"729968"},{"name":"PDQ_Closed_Trial_Search_ID","value":"563224"},{"name":"PDQ_Open_Trial_Search_ID","value":"563224"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882931"}]}}{"C1650":{"preferredName":"Peldesine","code":"C1650","definitions":[{"definition":"A pyrimidine analogue and purine nucleoside phosphorylase inhibitor with immunosuppressive and antineoplastic properties. Peldesine inhibits purine nucleoside phosphorylase (PNP) that plays a pivotal role in T-cell proliferation and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2'-deoxyribonucleosides. Inhibition of PNP results in accumulation of dGTP and the subsequent failure of DNA synthesis. This agent maybe used in T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohn s disease and T-cell cancers","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied for the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Peldesine","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Pyrrolo(3,2-d)pyrimidin-4-one,1,5-dihydro-2-amino-7-(3-pyridinylmethyl)","termGroup":"SN","termSource":"NCI"},{"termName":"9-(3-Pyridinylmethyl)-7H-9-deazaguanine","termGroup":"SN","termSource":"NCI"},{"termName":"BCX-34","termGroup":"CN","termSource":"NCI"},{"termName":"Peldesina","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"133432-71-0"},{"name":"Chemical_Formula","value":"C12H11N5O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7B646RJ70F"},{"name":"Legacy Concept Name","value":"Peldesine"},{"name":"Maps_To","value":"Peldesine"},{"name":"NCI_Drug_Dictionary_ID","value":"42367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42367"},{"name":"PDQ_Open_Trial_Search_ID","value":"42367"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338278"}]}}{"C2713":{"preferredName":"Pelitinib","code":"C2713","definitions":[{"definition":"A 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.  Pelitinib irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called epidermal growth factor receptor inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pelitinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"EKB 569","termGroup":"CN","termSource":"NCI"},{"termName":"WAY-EKB 569","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"257933-82-7"},{"name":"CHEBI_ID","value":"CHEBI:38927"},{"name":"Chemical_Formula","value":"C24H23ClFN5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X5DWL380Z6"},{"name":"Legacy Concept Name","value":"EKB-569"},{"name":"Maps_To","value":"Pelitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"352165"},{"name":"NSC Number","value":"729742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352165"},{"name":"PDQ_Open_Trial_Search_ID","value":"352165"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0961045"}]}}{"C2633":{"preferredName":"Pelitrexol","code":"C2633","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called glycinamide ribonucleotide formyl transferase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelitrexol","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-(((5-(2-((6S)-2-Amino-4-oxo-1,4,5,6,7,8-hexahydropyrido(2,3-d)pyrimidin-6-yl)ethyl)-4-methylthiophen-2-yl)carbonyl)amino)pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"(2S)-2-[[[5-[2-[(6S)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophen-2-yl]carbonyl]amino]pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AG2037","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"446022-33-9"},{"name":"Chemical_Formula","value":"C20H25N5O6S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DHT6E8M4KP"},{"name":"Legacy Concept Name","value":"AG2037"},{"name":"Maps_To","value":"Pelitrexol"},{"name":"NCI_Drug_Dictionary_ID","value":"38329"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38329"},{"name":"PDQ_Open_Trial_Search_ID","value":"38329"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1871457"}]}}{"C106432":{"preferredName":"Pembrolizumab","code":"C106432","definitions":[{"definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pembrolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"BCD-201","termGroup":"CN","termSource":"NCI"},{"termName":"GME 751","termGroup":"CN","termSource":"NCI"},{"termName":"GME751","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Keytruda","termGroup":"BR","termSource":"NCI"},{"termName":"Lambrolizumab","termGroup":"SY","termSource":"NCI"},{"termName":"MK 3475","termGroup":"CN","termSource":"NCI"},{"termName":"MK-3475","termGroup":"CN","termSource":"NCI"},{"termName":"MK3475","termGroup":"CN","termSource":"NCI"},{"termName":"Pembrolizumab Biosimilar BCD-201","termGroup":"SY","termSource":"NCI"},{"termName":"Pembrolizumab Biosimilar GME751","termGroup":"SY","termSource":"NCI"},{"termName":"Pembrolizumab Biosimilar QL2107","termGroup":"SY","termSource":"NCI"},{"termName":"QL2107","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 900475","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-900475","termGroup":"CN","termSource":"NCI"},{"termName":"SCH900475","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer; recurrent or metastatic head and neck squamous cell carcinoma (HNSCC); metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1; unresectable or metastatic melanoma or melanoma with involvement of lymph node(s) following complete resection; metastatic small cell lung cancer (SCLC); advanced renal cell carcinoma (RCC); recurrent or metastatic cervical cancer; refractory primary mediastinal large B-cell lymphoma (PMBCL); urothelial cancer; hepatocellular carcinoma (HCC); recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)"},{"name":"Accepted_Therapeutic_Use_For","value":"soft tissue sarcoma (STS)"},{"name":"CAS_Registry","value":"1374853-91-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"DPT0O3T46P"},{"name":"Maps_To","value":"Pembrolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"695789"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695789"},{"name":"PDQ_Open_Trial_Search_ID","value":"695789"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658706"}]}}{"C61614":{"preferredName":"Pemetrexed","code":"C61614","definitions":[{"definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemetrexed","termGroup":"PT","termSource":"NCI"},{"termName":"L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)","termGroup":"SN","termSource":"NCI"},{"termName":"MTA","termGroup":"AB","termSource":"NCI"},{"termName":"Multitargeted Antifolate","termGroup":"SY","termSource":"NCI"},{"termName":"Pemfexy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"137281-23-3"},{"name":"CHEBI_ID","value":"CHEBI:63616"},{"name":"Chemical_Formula","value":"C20H21N5O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"04Q9AIZ7NO"},{"name":"Legacy Concept Name","value":"Pemetrexed_Base"},{"name":"Maps_To","value":"Pemetrexed"},{"name":"NSC Number","value":"698037"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0210657"}]}}{"C1533":{"preferredName":"Pemetrexed Disodium","code":"C1533","definitions":[{"definition":"A drug used alone or with another drug to treat certain types of non-small cell lung cancer and malignant pleural mesothelioma. It is being studied in the treatment of other types of cancer. Pemetrexed disodium blocks DNA synthesis and may kill cancer cells. It is a type of folate antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemetrexed Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"Alimta","termGroup":"BR","termSource":"NCI"},{"termName":"Almita","termGroup":"FB","termSource":"NCI"},{"termName":"LY231514","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant pleural mesothelioma; Non-small cell lung cancer"},{"name":"CAS_Registry","value":"150399-23-8"},{"name":"CHEBI_ID","value":"CHEBI:63722"},{"name":"Chemical_Formula","value":"C20H19N5O6.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2PKU919BA9"},{"name":"Legacy Concept Name","value":"Pemetrexed"},{"name":"Maps_To","value":"Pemetrexed Disodium"},{"name":"NCI_Drug_Dictionary_ID","value":"42328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42328"},{"name":"PDQ_Open_Trial_Search_ID","value":"42328"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0936142"}]}}{"C121553":{"preferredName":"Pemigatinib","code":"C121553","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemigatinib","termGroup":"PT","termSource":"NCI"},{"termName":"2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 054828","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-054828","termGroup":"CN","termSource":"NCI"},{"termName":"INCB054828","termGroup":"CN","termSource":"NCI"},{"termName":"Pemazyre","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement"},{"name":"CAS_Registry","value":"1513857-77-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Y6BX7BL23K"},{"name":"Maps_To","value":"Pemigatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"770381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770381"},{"name":"PDQ_Open_Trial_Search_ID","value":"770381"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053633"}]}}{"C124843":{"preferredName":"Pemlimogene Merolisbac","code":"C124843","definitions":[{"definition":"A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding the tumor-associated antigens (TAAs) epidermal growth factor receptor mutant form EGFRvIII and human mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the live-attenuated Listeria monocytogenes encoding EGFRvIII-mesothelin vaccine Pemlimogene merolisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). EGFRvIII and mesothelin are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against EGFRvIII- and mesothelin-expressing tumor cells, eventually resulting in tumor cell lysis. EGFRvIII and mesothelin are overexpressed in many types of cancer. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemlimogene Merolisbac","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-214","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64041757","termGroup":"SY","termSource":"NCI"},{"termName":"LADD Listeria monocytogenes JNJ-64041757","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S2EGO8116S"},{"name":"Maps_To","value":"Pemlimogene Merolisbac"},{"name":"NCI_Drug_Dictionary_ID","value":"778079"},{"name":"NCI_META_CUI","value":"CL503062"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778079"},{"name":"PDQ_Open_Trial_Search_ID","value":"778079"},{"name":"Semantic_Type","value":"Bacterium"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1187":{"preferredName":"Penberol","code":"C1187","definitions":[{"definition":"A derivative of bromoacrylic acid with cytostatic activity. Although the mechanism of action is unclear, penberol might inhibit tumor growth mediated through inhibition of the cell energetic metabolism.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penberol","termGroup":"PT","termSource":"NCI"},{"termName":"cis-beta-4-pentoxy-benzoyl-beta-bromoacrylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"24740-92-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5KAI8N485T"},{"name":"Legacy Concept Name","value":"Penberol"},{"name":"Maps_To","value":"Penberol"},{"name":"NCI_Drug_Dictionary_ID","value":"39551"},{"name":"NSC Number","value":"172760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39551"},{"name":"PDQ_Open_Trial_Search_ID","value":"39551"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070218"}]}}{"C1188":{"preferredName":"Penclomedine","code":"C1188","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of pyrimidine with antineoplastic activity. Penclomedine alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis. This agent is more active against tumor cells that are defective in p53 function. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Penclomedine","termGroup":"PT","termSource":"NCI"},{"termName":"3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine","termGroup":"SN","termSource":"NCI"},{"termName":"CRC 88-04","termGroup":"CN","termSource":"NCI"},{"termName":"PEN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"108030-77-9"},{"name":"Chemical_Formula","value":"C8H6Cl5NO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"66Q80IL7CW"},{"name":"Legacy Concept Name","value":"Penclomedine"},{"name":"Maps_To","value":"Penclomedine"},{"name":"NCI_Drug_Dictionary_ID","value":"41973"},{"name":"NSC Number","value":"338720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41973"},{"name":"PDQ_Open_Trial_Search_ID","value":"41973"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070220"}]}}{"C729":{"preferredName":"Penicillamine","code":"C729","definitions":[{"definition":"A beta dimethyl analog of the amino acid cysteine.  As a degradation product of penicillin antibiotics, penicillamine chelates with heavy metals and increases their urinary excretion.  Possessing antineoplastic properties, penicillamine induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that removes copper from the body and is used to treat diseases in which there is an excess of this metal. It is also being studied as a possible angiogenesis inhibitor in brain tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Penicillamine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Mercapto-D-valine","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-amino-beta-methyl-beta-mercaptobutyric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Atamir","termGroup":"FB","termSource":"NCI"},{"termName":"Beta,Beta-dimethylcysteine","termGroup":"SN","termSource":"NCI"},{"termName":"Beta-thiovaline","termGroup":"SN","termSource":"NCI"},{"termName":"Cuprenil","termGroup":"BR","termSource":"NCI"},{"termName":"Cuprimine","termGroup":"BR","termSource":"NCI"},{"termName":"Cupripen","termGroup":"FB","termSource":"NCI"},{"termName":"D-Mercaptovaline","termGroup":"SY","termSource":"NCI"},{"termName":"D-Penicillamine","termGroup":"SY","termSource":"NCI"},{"termName":"Depamine","termGroup":"SY","termSource":"NCI"},{"termName":"Depen","termGroup":"BR","termSource":"NCI"},{"termName":"Distamine","termGroup":"FB","termSource":"NCI"},{"termName":"Kelatin","termGroup":"FB","termSource":"NCI"},{"termName":"Mercaptyl","termGroup":"FB","termSource":"NCI"},{"termName":"Metalcaptase","termGroup":"FB","termSource":"NCI"},{"termName":"Pendramine","termGroup":"FB","termSource":"NCI"},{"termName":"Perdolat","termGroup":"BR","termSource":"NCI"},{"termName":"Sufortan","termGroup":"BR","termSource":"NCI"},{"termName":"Trolovol","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Wilsons disease; heavy metal intoxication; cystinuria; rheumatoid arthritis; primary biliary cirrhosis; Feltys syndrome; rheumatoid vasculitis"},{"name":"CAS_Registry","value":"52-67-5"},{"name":"CHEBI_ID","value":"CHEBI:7959"},{"name":"Chemical_Formula","value":"C5H11NO2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GNN1DV99GX"},{"name":"Legacy Concept Name","value":"Penicillamine"},{"name":"Maps_To","value":"Penicillamine"},{"name":"NCI_Drug_Dictionary_ID","value":"42546"},{"name":"NSC Number","value":"81549"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42546"},{"name":"PDQ_Open_Trial_Search_ID","value":"42546"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030817"}]}}{"C1189":{"preferredName":"Pentamethylmelamine","code":"C1189","definitions":[{"definition":"A principal metabolite of hexamethylmelamine with antineoplastic activity.  Pentamethylmelamine alkylates DNA and other macromolecules and forms DNA intrastrand and DNA-protein crosslinks, thereby preventing DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pentamethylmelamine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3,5-Triazine-2,4,6-triamine, N,N,N',N', N''-pentamethyl-, monohydrochloride (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Melamine","termGroup":"SY","termSource":"NCI"},{"termName":"melamine, N2,N2,N4,N4,N6-pentamethyl-, monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N,N,N',N',N\"-pentamethyl-1,3,5-triazine","termGroup":"SN","termSource":"NCI"},{"termName":"Pentamethylmelamine MonoHCl","termGroup":"SY","termSource":"NCI"},{"termName":"Pentamethylmelamine Monohydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"PMM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"16268-62-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UEF6R96K8R"},{"name":"Legacy Concept Name","value":"Pentamethylmelamine"},{"name":"Maps_To","value":"Pentamethylmelamine"},{"name":"NCI_Drug_Dictionary_ID","value":"39553"},{"name":"NSC Number","value":"118742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39553"},{"name":"PDQ_Open_Trial_Search_ID","value":"39553"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070302"}]}}{"C66341":{"preferredName":"Pentamustine","code":"C66341","definitions":[{"definition":"A (2-chloroethy1)nitrosourea compound with antineoplastic activity. Petamustine was never marketed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pentamustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-neopentyl-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"NCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Neptamustine","termGroup":"SY","termSource":"NCI"},{"termName":"Salisburystin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73105-03-0"},{"name":"Chemical_Formula","value":"C8H16ClN3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VB67O9FBGM"},{"name":"Legacy Concept Name","value":"Pentamustine"},{"name":"Maps_To","value":"Pentamustine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1882315"}]}}{"C732":{"preferredName":"Pentostatin","code":"C732","definitions":[{"definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pentostatin","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol","termGroup":"SN","termSource":"NCI"},{"termName":"2'-Deoxycoformycin","termGroup":"SY","termSource":"NCI"},{"termName":"CI-825","termGroup":"CN","termSource":"NCI"},{"termName":"Co-Vidarabine","termGroup":"SY","termSource":"NCI"},{"termName":"Covidarabine","termGroup":"SY","termSource":"NCI"},{"termName":"DCF","termGroup":"AB","termSource":"NCI"},{"termName":"Deoxycoformycin","termGroup":"SY","termSource":"NCI"},{"termName":"Nipent","termGroup":"BR","termSource":"NCI"},{"termName":"PD-81565","termGroup":"CN","termSource":"NCI"},{"termName":"Pentostatine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic lymphocytic leukemia; Cutaneous t-cell lymphoma; Hairy cell leukemia"},{"name":"CAS_Registry","value":"53910-25-1"},{"name":"CAS_Registry","value":"63677-95-2"},{"name":"Chemical_Formula","value":"C11H16N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"395575MZO7"},{"name":"Legacy Concept Name","value":"Pentostatin"},{"name":"Maps_To","value":"Pentostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39210"},{"name":"NSC Number","value":"218321"},{"name":"NSC Number","value":"247520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39210"},{"name":"PDQ_Open_Trial_Search_ID","value":"39210"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030896"}]}}{"C733":{"preferredName":"Pentoxifylline","code":"C733","definitions":[{"definition":"A drug used to prevent blood clotting and as a treatment that may help decrease weight loss in people with cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pentoxifylline","termGroup":"PT","termSource":"NCI"},{"termName":"3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Oxpentifylline","termGroup":"SY","termSource":"NCI"},{"termName":"Pentoxyphylline","termGroup":"SY","termSource":"NCI"},{"termName":"PTX","termGroup":"AB","termSource":"NCI"},{"termName":"Trental","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6493-05-6"},{"name":"Chemical_Formula","value":"C13H18N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SD6QCT3TSU"},{"name":"Legacy Concept Name","value":"Pentoxifylline"},{"name":"Maps_To","value":"Pentoxifylline"},{"name":"NCI_Drug_Dictionary_ID","value":"41432"},{"name":"NSC Number","value":"637086"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41432"},{"name":"PDQ_Open_Trial_Search_ID","value":"41432"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030899"}]}}{"C148635":{"preferredName":"PEOX-based Polymer Encapsulated Paclitaxel FID-007","code":"C148635","definitions":[{"definition":"A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel's solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEOX-based Polymer Encapsulated Paclitaxel FID-007","termGroup":"PT","termSource":"NCI"},{"termName":"FID 007","termGroup":"CN","termSource":"NCI"},{"termName":"FID-007","termGroup":"CN","termSource":"NCI"},{"termName":"FID007","termGroup":"CN","termSource":"NCI"},{"termName":"Nanoencapsulated Paclitaxel FID-007","termGroup":"SY","termSource":"NCI"},{"termName":"Paclitaxel in Polyethyloxazoline Polymer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cationic_Liposome-Encapsulated_Paclitaxel"},{"name":"Maps_To","value":"PEOX-based Polymer Encapsulated Paclitaxel FID-007"},{"name":"NCI_Drug_Dictionary_ID","value":"796978"},{"name":"NCI_META_CUI","value":"CL551158"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796978"},{"name":"PDQ_Open_Trial_Search_ID","value":"796978"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74070":{"preferredName":"PEP-3-KLH Conjugate Vaccine","code":"C74070","definitions":[{"definition":"A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PEP-3-KLH Conjugate Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"PEP-3-KLH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PEP-3-KLH_Conjugate_Vaccine"},{"name":"Maps_To","value":"PEP-3-KLH Conjugate Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"391254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"391254"},{"name":"PDQ_Open_Trial_Search_ID","value":"391254"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541477"}]}}{"C96222":{"preferredName":"Pepinemab","code":"C96222","definitions":[{"definition":"A humanized IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100) with potential immunomodulating and antineoplastic activities. Upon administration, pepinemab binds to and neutralizes SEMA4D, thereby preventing binding of SEMA4D to its receptor plexin-B1 (PLXNB1). By blocking the interaction of SEMA4D and PLXNB1, pepinemab may cause an inhibition of endothelial cell activation and migration, eventually leading to an inhibition of angiogenesis and tumor cell proliferation. Semaphorin 4D, a large cell surface antigen found on the resting T-cell and overexpressed in a variety of tumor cell types, plays an important role in vascular growth, tumor progression, invasion and immune cell regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pepinemab","termGroup":"PT","termSource":"NCI"},{"termName":"moAb VX15/2503","termGroup":"AB","termSource":"NCI"},{"termName":"VX15/2503","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097151-87-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BPZ4A29SYE"},{"name":"Maps_To","value":"Pepinemab"},{"name":"NCI_Drug_Dictionary_ID","value":"697328"},{"name":"NCI_META_CUI","value":"CL429006"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697328"},{"name":"PDQ_Open_Trial_Search_ID","value":"697328"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1399":{"preferredName":"Peplomycin","code":"C1399","definitions":[{"definition":"A semisynthetic analog of Bleomycin, a mixture of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peplomycin","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-n1-[3-[(1-phenylethyl)amino]propyl]bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"n1-[3[[(S)-alpha-methylbenzyl]amino]propyl]bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"PEP","termGroup":"AB","termSource":"NCI"},{"termName":"Pepleomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68247-85-8"},{"name":"Chemical_Formula","value":"C61H88N18O21S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"56H9L80NIZ"},{"name":"Legacy Concept Name","value":"Peplomycin"},{"name":"Maps_To","value":"Peplomycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39552"},{"name":"NSC Number","value":"276382"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39552"},{"name":"PDQ_Open_Trial_Search_ID","value":"39552"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0135981"}]}}{"C1400":{"preferredName":"Peplomycin Sulfate","code":"C1400","definitions":[{"definition":"The sulfate salt of the bleomycin analogue peplomycin.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peplomycin Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"N1-(3-(((S)-(alpha-methylbenzyl))amino)propyl)bleomycinamide Sulfate (1:1) (Salt)","termGroup":"SN","termSource":"NCI"},{"termName":"NK-631","termGroup":"CN","termSource":"NCI"},{"termName":"Pepleo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"73228-94-1"},{"name":"Chemical_Formula","value":"C61H88N18O21S2.H2O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6A668951HW"},{"name":"Legacy Concept Name","value":"Peplomycin_Sulfate"},{"name":"Maps_To","value":"Peplomycin Sulfate"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0917878"}]}}{"C734":{"preferredName":"Peptichemio","code":"C734","definitions":[{"definition":"A mixture of six synthetic oligopeptides in which the peptides are conjugated to metamelphalan, with alkylating and potential antineoplastic activity. Peptichemio causes crosslinking of DNA, thereby preventing DNA replication and eventually cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptichemio","termGroup":"PT","termSource":"NCI"},{"termName":"Multialchilpeptide","termGroup":"SY","termSource":"NCI"},{"termName":"peptide bound m-L-sarcolysin","termGroup":"SY","termSource":"NCI"},{"termName":"PTC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9076-25-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peptichemio"},{"name":"Maps_To","value":"Peptichemio"},{"name":"NCI_Drug_Dictionary_ID","value":"39541"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39541"},{"name":"PDQ_Open_Trial_Search_ID","value":"39541"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030927"}]}}{"C2466":{"preferredName":"Peptide 946 Melanoma Vaccine","code":"C2466","definitions":[{"definition":"A melanoma peptide vaccine with potential antineoplastic activity. Peptide 946 melanoma vaccine contains one of the peptide sequences for a melanoma-specific epitope that is recognized by melanoma-specific cytotoxic T lymphocytes (CTL). This vaccine contains a peptide sequence homologous to the native epitope and is often formulated with an adjuvant such as QS-21 or Montanide ISA-51 to boost its immune stimulation. Vaccination with peptide 946 vaccine may produce antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against cells expressing this antigen, resulting in decreased tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptide 946 Melanoma Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peptide_946_Melanoma_Vaccine"},{"name":"Maps_To","value":"Peptide 946 Melanoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42974"},{"name":"PDQ_Open_Trial_Search_ID","value":"42974"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677986"}]}}{"C2467":{"preferredName":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine","code":"C2467","definitions":[{"definition":"A melanoma peptide vaccine complexed with tetanus toxoid with potential antineoplastic activity. Peptide 946 contains a melanoma-specific epitope recognized by melanoma-specific cytotoxic T lymphocytes (CTL). In addition to the peptide 946 sequence, this vaccine contains tetanus toxin, a protein known to stimulate the induction of CD4+ T lymphocytes; it thereby enhances antigen processing and presentation. Vaccination with the peptide 946-tetanus conjugate melanoma vaccine may produce antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response in tumor cells expressing the 946 epitope, thereby decreasing tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peptide_946-Tetanus_Peptide_Conjugate_Melanoma_Vaccine"},{"name":"Maps_To","value":"Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"42975"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42975"},{"name":"PDQ_Open_Trial_Search_ID","value":"42975"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677987"}]}}{"C87202":{"preferredName":"Peretinoin","code":"C87202","definitions":[{"definition":"An orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and activates nuclear retinoic acid receptors (RAR), which in turn recruit coactivator proteins and promote, with other transcriptional complexes, the transcription of target genes. As a result, this agent may modulate the expression of genes involved in the regulation of cell proliferation, cell differentiation, and apoptosis of both normal and tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"(2E,4E,6E,10E)-3,7,11,15-Tetramethylhexadeca-2,4,6,10,14-Pentaenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"NIK-333","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81485-25-8"},{"name":"Chemical_Formula","value":"C20H30O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"11ALM7A4RV"},{"name":"Maps_To","value":"Peretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"737371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737371"},{"name":"PDQ_Open_Trial_Search_ID","value":"737371"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1453741"}]}}{"C116804":{"preferredName":"Perflenapent Emulsion","code":"C116804","definitions":[{"definition":"An oil-in-water nano-emulsion composed of the perfluorocarbon perflenapent, that has oxygen-carrying capacity, can be used as a contrast agent and has potential antihypoxic and radiosensitizing activities. Upon intravenous administration of the perflenapent emulsion, this agent increases the oxygen-carrying capacity of blood, enhances the transport of oxygen to hypoxic and ischemic tissues and increases the oxygen concentration in these tissues. Hypoxic tumors are correlated with increased resistance to radiation treatment; therefore, since perflenapent may increase tumor oxygenation, it may improve the tumor's sensitivity to radiation therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perflenapent Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"DDFP LIquid Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"Dodecafluoropentane Emulsion","termGroup":"SY","termSource":"NCI"},{"termName":"NVX-108","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Perflenapent Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"763081"},{"name":"NCI_META_CUI","value":"CL473943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763081"},{"name":"PDQ_Open_Trial_Search_ID","value":"763081"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1423":{"preferredName":"Perfosfamide","code":"C1423","definitions":[{"definition":"The active metabolite of the nitrogen mustard cyclophosphamide with potent antineoplastic and immunosuppressive properties. Perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perfosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-[bis(2-chloroethyl)amino]-4-hydroperoxytetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Hydroperoxycyclophosphamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-HC","termGroup":"SN","termSource":"NCI"},{"termName":"4-Hydroperoxycyclophosphamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Pergamid","termGroup":"SN","termSource":"NCI"},{"termName":"cis-2-[bis(2-chloroethyl)amino]tetrahydro-3H-1,3,2-oxazaphosphorin-4-yl hydroperoxide P-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"cis-4-hydroperoxycyclophosphamide","termGroup":"SN","termSource":"NCI"},{"termName":"Hydroperoxycyclophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Pergamid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia"},{"name":"CAS_Registry","value":"39800-16-3"},{"name":"CHEBI_ID","value":"CHEBI:196991"},{"name":"Chemical_Formula","value":"C7H15Cl2N2O4P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U880A4FUDA"},{"name":"Legacy Concept Name","value":"Perfosfamide"},{"name":"Maps_To","value":"Perfosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"40474"},{"name":"NSC Number","value":"181815"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40474"},{"name":"PDQ_Open_Trial_Search_ID","value":"40474"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0163054"}]}}{"C1727":{"preferredName":"Perifosine","code":"C1727","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called alkylphospholipids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perifosine","termGroup":"PT","termSource":"NCI"},{"termName":"4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt","termGroup":"SN","termSource":"NCI"},{"termName":"D21266","termGroup":"CN","termSource":"NCI"},{"termName":"KRX 0401","termGroup":"CN","termSource":"NCI"},{"termName":"KRX-0401","termGroup":"CN","termSource":"NCI"},{"termName":"KRX0401","termGroup":"CN","termSource":"NCI"},{"termName":"Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Octadecylphosphopiperidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157716-52-4"},{"name":"Chemical_Formula","value":"C25H52NO4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2GWV496552"},{"name":"Legacy Concept Name","value":"Perifosine"},{"name":"Maps_To","value":"Perifosine"},{"name":"NCI_Drug_Dictionary_ID","value":"43408"},{"name":"NSC Number","value":"639966"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43408"},{"name":"PDQ_Open_Trial_Search_ID","value":"43408"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0754570"}]}}{"C1461":{"preferredName":"Perillyl Alcohol","code":"C1461","definitions":[{"definition":"A naturally occurring monoterpene related to limonene with antineoplastic activity. Perillyl alcohol inhibits farnesyl transferase and geranylgeranyl transferase, thereby preventing post-translational protein farnesylation and isoprenylation and activation of oncoproteins such as p21-ras, and arresting tumor cells in the G1 phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cancer. It belongs to the family of plant drugs called monoterpenes.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A terpene with two isoprene units forming a ring and with a hydroxyl group attached to the head methyl group. The chemical structure is CC(=C)C1CCC(=CC1)CO.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Perillyl Alcohol","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-(-)-Perillyl Alcohol","termGroup":"SN","termSource":"NCI"},{"termName":"1-Cyclohexene-1-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"4-(1-Methylethenyl)","termGroup":"SN","termSource":"NCI"},{"termName":"4-(1-Methylethenyl)-1-cyclohexene-1-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"4-Isopropenylcyclohex-1-ene-1-methanol","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydrocuminyl Alcohol","termGroup":"SY","termSource":"NCI"},{"termName":"NEO100","termGroup":"CN","termSource":"NCI"},{"termName":"p-Mentha-1,8-dien-7-ol","termGroup":"SN","termSource":"NCI"},{"termName":"Perilla Alcohol","termGroup":"SY","termSource":"NCI"},{"termName":"Perillic Alcohol","termGroup":"SY","termSource":"NCI"},{"termName":"Perillol","termGroup":"SY","termSource":"NCI"},{"termName":"POH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18457-55-1"},{"name":"CAS_Registry","value":"536-59-4"},{"name":"CHEBI_ID","value":"CHEBI:10782"},{"name":"CHEBI_ID","value":"CHEBI:15420"},{"name":"Chemical_Formula","value":"C10H16O"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"319R5C7293"},{"name":"Legacy Concept Name","value":"Perillyl_Alcohol"},{"name":"Maps_To","value":"Perillyl Alcohol"},{"name":"NCI_Drug_Dictionary_ID","value":"42334"},{"name":"NSC Number","value":"641066"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42334"},{"name":"PDQ_Open_Trial_Search_ID","value":"42334"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0207661"}]}}{"C159601":{"preferredName":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine","code":"C159601","definitions":[{"definition":"An individualized peptide-based cancer vaccine comprised of three to five human leukocyte antigen (HLA) binding tumor-specific peptides obtained from the autologous mutated proteins from the tumor cells of patients with acute lymphoblastic leukemia (ALL), with potential immunomodulating and antineoplastic activity. Upon intradermal administration of the personalized multi-HLA-binding peptide vaccine, the peptides may induce a tumor-specific cytotoxic T-lymphocyte (CTL) response against the peptides that are expressed by the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Individualized Multi-HLA-binding Peptide Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Multi-HLA-binding Peptide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized ALL-specific Multi-HLA-binding Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"797494"},{"name":"NCI_META_CUI","value":"CL951600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797494"},{"name":"PDQ_Open_Trial_Search_ID","value":"797494"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175745":{"preferredName":"Autogene Cevumeran","code":"C175745","definitions":[{"definition":"An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autogene Cevumeran","termGroup":"PT","termSource":"NCI"},{"termName":"BNT 122","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-122","termGroup":"CN","termSource":"NCI"},{"termName":"BNT122","termGroup":"CN","termSource":"NCI"},{"termName":"PCV RO7198457","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Cancer Vaccine RO7198457","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6180","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7198457","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7198457","termGroup":"CN","termSource":"NCI"},{"termName":"RO7198457","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2365453-34-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L8HDH9IB06"},{"name":"Maps_To","value":"Personalized Cancer Vaccine RO7198457"},{"name":"NCI_Drug_Dictionary_ID","value":"804149"},{"name":"NCI_META_CUI","value":"CL538249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162633":{"preferredName":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01","code":"C162633","definitions":[{"definition":"A peptide-based, personalized cancer vaccine consisting of patient-specific mutated long peptides, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized neoantigen peptide vaccine iNeo-Vac-P01, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01","termGroup":"PT","termSource":"NCI"},{"termName":"iNeo-Vac-P01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01"},{"name":"NCI_Drug_Dictionary_ID","value":"798703"},{"name":"NCI_META_CUI","value":"CL971029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798703"},{"name":"PDQ_Open_Trial_Search_ID","value":"798703"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158749":{"preferredName":"Personalized Neoepitope Yeast Vaccine YE-NEO-001","code":"C158749","definitions":[{"definition":"A cancer vaccine composed of a heat-killed yeast that has been genetically modified to express patient-specific neoantigen epitopes. Upon vaccination, neoepitope yeast vaccine YE-NEO-001 may elicit a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response against tumor cells expressing these specific epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoepitope Yeast Vaccine YE-NEO-001","termGroup":"PT","termSource":"NCI"},{"termName":"YE-NEO-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoepitope Yeast Vaccine YE-NEO-001"},{"name":"NCI_Drug_Dictionary_ID","value":"797413"},{"name":"NCI_META_CUI","value":"CL950715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797413"},{"name":"PDQ_Open_Trial_Search_ID","value":"797413"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129935":{"preferredName":"Personalized Peptide Cancer Vaccine NEO-PV-01","code":"C129935","definitions":[{"definition":"A synthetic peptide-based, personalized cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Peptide Cancer Vaccine NEO-PV-01","termGroup":"PT","termSource":"NCI"},{"termName":"NEO PV 01","termGroup":"CN","termSource":"NCI"},{"termName":"NEO-PV 01","termGroup":"CN","termSource":"NCI"},{"termName":"NEO-PV-01","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen-based Anticancer Vaccine NEO-PV-01","termGroup":"SY","termSource":"NCI"},{"termName":"Neoantigen-based Peptide Vaccine NEO-PV-01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Peptide Cancer Vaccine NEO-PV-01"},{"name":"NCI_META_CUI","value":"CL512888"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38692":{"preferredName":"Pertuzumab","code":"C38692","definitions":[{"definition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of cancer. Monoclonal antibodies are produced in the laboratory and can locate and bind to cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pertuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"2C4","termGroup":"SY","termSource":"NCI"},{"termName":"2C4 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"BCD-178","termGroup":"CN","termSource":"NCI"},{"termName":"EG1206A","termGroup":"CN","termSource":"NCI"},{"termName":"HLX11","termGroup":"CN","termSource":"NCI"},{"termName":"HS627","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"MoAb 2C4","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody 2C4","termGroup":"SY","termSource":"NCI"},{"termName":"Omnitarg","termGroup":"SY","termSource":"NCI"},{"termName":"Perjeta","termGroup":"BR","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar BCD-178","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar EG1206A","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar HLX11","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar HS627","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab Biosimilar TQB2440","termGroup":"SY","termSource":"NCI"},{"termName":"Rhumab 2C4","termGroup":"SY","termSource":"NCI"},{"termName":"rhuMAb2C4","termGroup":"SY","termSource":"NCI"},{"termName":"RO4368451","termGroup":"CN","termSource":"NCI"},{"termName":"TQB 2440","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-2440","termGroup":"CN","termSource":"NCI"},{"termName":"TQB2440","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"380610-27-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K16AIQ8CTM"},{"name":"Legacy Concept Name","value":"Pertuzumab"},{"name":"Maps_To","value":"Pertuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"322808"},{"name":"NSC Number","value":"740102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"322808"},{"name":"PDQ_Open_Trial_Search_ID","value":"322808"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328025"}]}}{"C77906":{"preferredName":"Pevonedistat","code":"C77906","definitions":[{"definition":"A small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity. Pevonedistat binds to and inhibits NAE, which may result in the inhibition of tumor cell proliferation and survival. NAE activates Nedd8 (Neural precursor cell expressed, developmentally down-regulated 8), an ubiquitin-like (UBL) protein that modifies cellular targets in a pathway that is parallel to but distinct from the ubiquitin-proteasome pathway (UPP). Functioning in diverse regulatory activities, proteins conjugated to UBLs like Nedd8 typically are not targeted for proteasomal degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pevonedistat","termGroup":"PT","termSource":"NCI"},{"termName":"((1S,2S,4R)-4-(4-((1S)-2,3-Dihydro-1H-inden-1-ylamino)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulphamate","termGroup":"SN","termSource":"NCI"},{"termName":"MLN4924","termGroup":"CN","termSource":"NCI"},{"termName":"Nedd8-Activating Enzyme Inhibitor MLN4924","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"905579-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S3AZD8D215"},{"name":"Legacy Concept Name","value":"NAE_Inhibitor_MLN4924"},{"name":"Maps_To","value":"Pevonedistat"},{"name":"NCI_Drug_Dictionary_ID","value":"596795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596795"},{"name":"PDQ_Open_Trial_Search_ID","value":"596795"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703093"}]}}{"C71533":{"preferredName":"Pexastimogene Devacirepvec","code":"C71533","definitions":[{"definition":"An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pexastimogene Devacirepvec","termGroup":"PT","termSource":"NCI"},{"termName":"JX 594","termGroup":"CN","termSource":"NCI"},{"termName":"JX-594","termGroup":"CN","termSource":"NCI"},{"termName":"JX594","termGroup":"CN","termSource":"NCI"},{"termName":"Pexa-vec","termGroup":"FB","termSource":"NCI"},{"termName":"TG-6006","termGroup":"CN","termSource":"NCI"},{"termName":"Thymidine Kinase (-) Vaccinia-GM-CSF JX-594 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Thymidine Kinase-deleted Vaccinia-hGM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"VAC GM-CSF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1058624-46-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K82DG47I0G"},{"name":"Legacy Concept Name","value":"Thymidine_Kinase-Deleted_Vaccinia-GM-CSF_JX-594_Vaccine"},{"name":"Maps_To","value":"Pexastimogene Devacirepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"579292"},{"name":"NCI_META_CUI","value":"CL378156"},{"name":"PDQ_Closed_Trial_Search_ID","value":"579292"},{"name":"PDQ_Open_Trial_Search_ID","value":"579292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88303":{"preferredName":"Pexidartinib","code":"C88303","definitions":[{"definition":"A small-molecule receptor tyrosine kinase (RTK) inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), with antineoplastic activity. Upon oral administration, pexidartinib targets, binds to and inhibits phosphorylation of KIT, CSF1R and FLT3 harboring an internal tandem duplication (ITD) mutation. This results in the inhibition of tumor cell proliferation. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pexidartinib","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CML-261","termGroup":"CN","termSource":"NCI"},{"termName":"PLX 3397","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-3397","termGroup":"CN","termSource":"NCI"},{"termName":"PLX3397","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1029044-16-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6783M2LV5X"},{"name":"Maps_To","value":"Pexidartinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981820"}]}}{"C85481":{"preferredName":"Pexmetinib","code":"C85481","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of p38 and Tie2 kinases with potential antineoplastic, anti-inflammatory and antiangiogenic activities. Pexmetinib binds to and inhibits the activities of p38 and Tie2 kinases, which may inhibit the production of proinflammatory cytokines and may decrease tumor angiogenesis and tumor cell growth and survival. p38 is a MAP kinase that is often upregulated in cancer cells, playing a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6. Tie2 is an endothelial cell specific receptor that is activated by angiopoietins, growth factors required for angiogenesis. This agent has also been reported to inhibit other kinases including vascular endothelial growth factor receptor (VEGFR2) and Src tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pexmetinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-614","termGroup":"CN","termSource":"NCI"},{"termName":"N-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)-N'-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945614-12-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3750D0U8B5"},{"name":"Maps_To","value":"Pexmetinib"},{"name":"NCI_Drug_Dictionary_ID","value":"647828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647828"},{"name":"PDQ_Open_Trial_Search_ID","value":"647828"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830143"}]}}{"C78463":{"preferredName":"Odetiglucan","code":"C78463","definitions":[{"definition":"An injectable formulation of the polysaccharide beta-1,3/1,6 glucan derived from the cell wall of a strain from the yeast Saccharomyces cerevisiae and pathogen-associated molecular pattern (PAMP) molecule, with potential immunomodulating and antineoplastic activities. Upon administration, odetiglucan binds to innate immune effector cells through complement receptor 3 (CR3) and Fc gamma receptor IIA (FcgammaIIA; CD32A), thereby activating innate immune cells and enabling direct killing of tumor cells. In addition, odetiglucan repolarizes the immunosuppressive tumor microenvironment (TME), shifts the suppressive M2-state macrophages to a more M1 pro-inflammatory state, activates the maturation of antigen presenting cells (APCs), enables CD4 and CD8 T-cell expansion, and increases production of certain anti-tumor cytokines, such as interferon gamma (IFNg). Altogether, this induces and enhances anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Odetiglucan","termGroup":"PT","termSource":"NCI"},{"termName":"BTH 1677","termGroup":"CN","termSource":"NCI"},{"termName":"BTH-1677","termGroup":"CN","termSource":"NCI"},{"termName":"BTH1677","termGroup":"CN","termSource":"NCI"},{"termName":"Imprime PGG","termGroup":"BR","termSource":"NCI"},{"termName":"PGG Beta-Glucan","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose Beta-glucan","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53238-80-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q6X9CNN54X"},{"name":"Legacy Concept Name","value":"PGG_Beta-Glucan"},{"name":"Maps_To","value":"PGG Beta-Glucan"},{"name":"NCI_Drug_Dictionary_ID","value":"599816"},{"name":"NCI_META_CUI","value":"CL387566"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599816"},{"name":"PDQ_Open_Trial_Search_ID","value":"599816"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71692":{"preferredName":"PGLA/PEG Copolymer-Based Paclitaxel","code":"C71692","definitions":[{"definition":"A controlled-release, intratumoral paclitaxel formulation in which paclitaxel is incorporated into a thermosensitive, biodegradable triblock copolymer consisting of poly(lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG). Upon intratumoral injection, paclitaxel is released slowly and continuously into tumor tissues from the gelled thermosensitive triblock copolymer over a period of 4 to 6 weeks; in tumor cells, paclitaxel binds to tubulin and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. The thermosensitive triblock copolymer component of this formulation transforms from a water-soluble polymer at room temperature to a water-insoluble, biodegradable gel depot at body temperature; intratumoral controlled-release of paclitaxel from the gel minimizes systemic exposure to paclitaxel and the paclitaxel toxicity profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PGLA/PEG Copolymer-Based Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"OncoGel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PGLA_PEG_Copolymer-Based_Paclitaxel"},{"name":"Maps_To","value":"PGLA/PEG Copolymer-Based Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"555445"},{"name":"NCI_META_CUI","value":"CL376115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"555445"},{"name":"PDQ_Open_Trial_Search_ID","value":"555445"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113790":{"preferredName":"PH20 Hyaluronidase-expressing Adenovirus VCN-01","code":"C113790","definitions":[{"definition":"An oncolytic, replication-competent adenovirus encoding the human glycosylphosphatidylinositol-anchored enzyme PH20 hyaluronidase with potential antitumor activity. After intratumoral administration, PH20 hyaluronidase-expressing adenovirus VCN-01 selectively replicates in tumor cells, which may both cause oncolytic virus-induced cell death and induce the infection of adjacent tumor cells. In addition, the virus expresses hyaluronidase, which hydrolyzes and degrades the hyaluronic acid (HA) that coats tumor cells. The degradation of HA may result in a decrease for both the viscosity of the interstitial space and the tumor's interstitial fluid pressure (IFP). This increases viral spread and may result in the inhibition of tumor cell growth. In addition, HA degradation facilitates the penetration of chemotherapeutic agents into the tumor. HA is a glycosaminoglycan found in the extracellular matrix (ECM) and is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increases in tumor cell growth, metastatic potential, tumor progression and resistance to chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PH20 Hyaluronidase-expressing Adenovirus VCN-01","termGroup":"PT","termSource":"NCI"},{"termName":"Genetically Modified Adenovirus-encoding Human PH20 Hyaluronidase VCN-01","termGroup":"SY","termSource":"NCI"},{"termName":"VCN-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PH20 Hyaluronidase-expressing Adenovirus VCN-01"},{"name":"NCI_Drug_Dictionary_ID","value":"757334"},{"name":"NCI_META_CUI","value":"CL471771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757334"},{"name":"PDQ_Open_Trial_Search_ID","value":"757334"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91739":{"preferredName":"Phaleria macrocarpa Extract DLBS-1425","code":"C91739","definitions":[{"definition":"An extract of the flesh from the fruit of Phaleria macrocarpa, an Indonesian herbal medicine, with potential antineoplastic activity. Although the active ingredients and exact components are unclear, gallic acid and its derivatives in DLBS-1425 appear to inhibit the phosphoinositide-3 kinase (PI3K)/protein kinase B (AKT) signaling pathway by reducing PI3K transcription followed by a reduction in AKT phosphorylation. This extract also appears to induce apoptosis through induction of pro-apoptotic genes such as BAX, BAD and PUMA and inhibition of the apoptosis suppressor Bcl-2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phaleria macrocarpa Extract DLBS-1425","termGroup":"PT","termSource":"NCI"},{"termName":"DLBS-1425","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phaleria macrocarpa Extract DLBS-1425"},{"name":"NCI_Drug_Dictionary_ID","value":"659153"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659153"},{"name":"PDQ_Open_Trial_Search_ID","value":"659153"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984527"}]}}{"C156461":{"preferredName":"Pharmacological Ascorbate","code":"C156461","definitions":[{"definition":"A high dose (HD) of ascorbic acid, a pro-oxidant agent, with potential antineoplastic and radio-chemo-sensitizing activities. Upon intravenous (IV) administration, pharmacological ascorbate is able to generate reactive oxygen species (ROS) by donating an electron to oxygen (O2) and forming hydrogen peroxide (H2O2), thereby causing oxidative stress and overwhelming the cell's anti-oxidant defense mechanisms. This induces DNA double-stranded breaks (DSBs) and cell death. Tumor cells are highly susceptible to ascorbate-mediated oxidative stress and cytotoxicity while normal, healthy cells are mostly unaffected. This induces the cell death of susceptible tumor cells and decreases tumor cell growth. Higher plasma ascorbate concentrations are achieved upon higher intravenous doses of ascorbate; oral administration of ascorbate is limited and uptake does not increase after a certain amount is administered. Only IV ascorbate produces plasma concentrations high enough to induce ascorbate-mediated cytotoxicity to susceptible tumor cells. In addition, HD parenteral ascorbate enhances radio- and chemo-sensitivity of susceptible cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pharmacological Ascorbate","termGroup":"PT","termSource":"NCI"},{"termName":"Ascorbate Injection","termGroup":"SY","termSource":"NCI"},{"termName":"Ascorbic Acid Injection","termGroup":"SY","termSource":"NCI"},{"termName":"HD Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"HD P-AscH-","termGroup":"SY","termSource":"NCI"},{"termName":"HD Vitamin C","termGroup":"SY","termSource":"NCI"},{"termName":"High Dose Ascorbic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"High-dose Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"High-dose Ascorbic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"High-Dose Parenteral Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"High-Dose Vitamin C","termGroup":"SY","termSource":"NCI"},{"termName":"Intravenous Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"Intravenous High Dose Ascorbate","termGroup":"SY","termSource":"NCI"},{"termName":"IV Ascorbate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pharmacological Ascorbate"},{"name":"NCI_Drug_Dictionary_ID","value":"795829"},{"name":"NCI_META_CUI","value":"CL563189"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795829"},{"name":"PDQ_Open_Trial_Search_ID","value":"795829"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C103230":{"preferredName":"Phellodendron amurense Bark Extract","code":"C103230","definitions":[{"definition":"A proprietary formulation consisting of a Phellodendron amurense (Amur cork tree) bark extract, often used in traditional Chinese medicine, with anti-inflammatory, anti-oxidant and potential chemopreventive and antineoplastic activities. Phellodendron amurense bark extract contains certain isoquinoline alkaloids, flavone glycosides and phenolic compounds. Upon administration of Phellodendron amurense bark extract, the various phytochemicals in this formulation modulate multiple signal transduction pathways. This agent appears to block the activation of the transcription factor cAMP response binding protein (CREB) and inhibits Akt signaling, thereby inhibiting tumor cell growth and inducing apoptosis in Akt- and CREB-overexpressing cancer cells. In addition, this agent inhibits cyclooxygenase type 2 (COX-2), nuclear factor kappa b (NF-kB) and tumor necrosis factor alpha (TNF-a)-mediated signaling; COX-2, NF-kB and TNF-a are upregulated in certain types of cancer and during inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phellodendron amurense Bark Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Nexrutine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PBG27B754G"},{"name":"Maps_To","value":"Phellodendron amurense Bark Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"741824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"741824"},{"name":"PDQ_Open_Trial_Search_ID","value":"741824"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3256251"}]}}{"C1190":{"preferredName":"Phenesterin","code":"C1190","definitions":[{"definition":"A steroidal nitrogen mustard with antineoplastic and mutagenic activities. After attachment to cell-surface steroid receptors and uptake, phenesterin enters the nucleus where it alkylates macromolecules, resulting in decreased cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenesterin","termGroup":"PT","termSource":"NCI"},{"termName":"(3-beta)-cholest-5-en-3-ol 4-(bis(2-chloroethyl)amino)benzeneacetate","termGroup":"SN","termSource":"NCI"},{"termName":"(4-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester","termGroup":"SN","termSource":"NCI"},{"termName":"(p-(bis(2-chloroethyl)amino)phenyl) acetate cholesterol","termGroup":"SN","termSource":"NCI"},{"termName":"(p-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester","termGroup":"SN","termSource":"NCI"},{"termName":"5-Cholesten-3-beta-ol 3-(p-(bis(2-chloroethyl)amino)phenyl)acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Cholest-5-en-3beta-ol 4-(bis(2-chloroethyl)amino)benzeneacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Cholesteryl p-bis(2-chloroethyl)aminophenylacetate","termGroup":"SN","termSource":"NCI"},{"termName":"Fenesterin","termGroup":"SY","termSource":"NCI"},{"termName":"Fenestrin","termGroup":"SY","termSource":"NCI"},{"termName":"NCI-C01558","termGroup":"CN","termSource":"NCI"},{"termName":"p-bis(2-chloroethyl)amino phenylacetate cholesterol","termGroup":"SN","termSource":"NCI"},{"termName":"Phenesterine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3546-10-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"34021JC2Z6"},{"name":"Legacy Concept Name","value":"Phenesterin"},{"name":"Maps_To","value":"Phenesterin"},{"name":"NSC Number","value":"104469"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070556"}]}}{"C2233":{"preferredName":"Phenethyl Isothiocyanate","code":"C2233","definitions":[{"definition":"A substance being studied in the prevention of cancer. It is a naturally occurring compound found in some cruciferous vegetables.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An isothiocyanate found in cruciferous vegetables with chemopreventive and potential antitumor activities. Although the mechanism of action is unclear, phenethyl Isothiocyanate (PEITC) was shown to induce apoptosis in tumor cells, possibly mediated through its metabolic intermediates, reactive oxygen species (ROS). PEITC also is able to activate ERK and JNK signal transduction, which in turn induces expression of stress-responsive genes. Specifically, this agent has been shown to reactivate gene expression of a detoxification enzyme, glutathione S-transferase that is silenced in prostate carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenethyl Isothiocyanate","termGroup":"PT","termSource":"NCI"},{"termName":"(2-Isothiocyanatoethyl)benzene","termGroup":"SN","termSource":"NCI"},{"termName":"2-Phenylethyl Isothiocyanate","termGroup":"SN","termSource":"NCI"},{"termName":"PEITC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2257-09-2"},{"name":"CHEBI_ID","value":"CHEBI:351346"},{"name":"Chemical_Formula","value":"C9H9NS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6U7TFK75KV"},{"name":"Legacy Concept Name","value":"Phenethyl_Isothiocyanate"},{"name":"Maps_To","value":"Phenethyl Isothiocyanate"},{"name":"NCI_Drug_Dictionary_ID","value":"37977"},{"name":"NSC Number","value":"87868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37977"},{"name":"PDQ_Open_Trial_Search_ID","value":"37977"},{"name":"PubMedID_Primary_Reference","value":"16921492"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0070558"}]}}{"C105392":{"preferredName":"Phenethyl Isothiocyanate-containing Watercress Juice","code":"C105392","definitions":[{"definition":"A juice extracted from watercress containing high amounts of phenethyl isothiocyanate (PEITC), with potential chemopreventive and antitumor activities. Although the mechanism(s) of action through which PEITC exerts its effect(s) has yet to be fully elucidated, PEITC is able to induce apoptosis in tumor cells through the induction of reactive oxygen species (ROS). Additionally, PEITC is able to modulate extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK) signal transduction pathways, activating the expression of stress-responsive genes and eventually inducing apoptosis. PEITC also inhibits the expression of genes involved in tumor progression such as HIF, STAT-3, HER2, BCL-XL, and XIAP and induces the expression of genes involved in tumor suppression such as p53, ATF-2, and p57. Furthermore, this agent has been shown to reactivate the gene expression of certain detoxification enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenethyl Isothiocyanate-containing Watercress Juice","termGroup":"PT","termSource":"NCI"},{"termName":"PEITC-containing Watercress Juice","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phenethyl Isothiocyanate-containing Watercress Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"746772"},{"name":"NCI_META_CUI","value":"CL446318"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746772"},{"name":"PDQ_Open_Trial_Search_ID","value":"746772"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1501":{"preferredName":"Phenyl Acetate","code":"C1501","definitions":[{"definition":"A drug being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenyl Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Acetic Acid Phenyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Acetylphenol","termGroup":"SY","termSource":"NCI"},{"termName":"Phenyl Acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adjunctive therapy for the prevention and treatment of hyperammonemia in the chronic management of patients with urea cycle enzymopathy"},{"name":"CAS_Registry","value":"122-79-2"},{"name":"CHEBI_ID","value":"CHEBI:8082"},{"name":"Chemical_Formula","value":"C8H8O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"355G9R500Y"},{"name":"Legacy Concept Name","value":"Phenyl_Acetate"},{"name":"Maps_To","value":"Phenyl Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"41664"},{"name":"NSC Number","value":"27795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41664"},{"name":"PDQ_Open_Trial_Search_ID","value":"41664"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0220893"}]}}{"C48011":{"preferredName":"Phenytoin Sodium","code":"C48011","definitions":[{"definition":"A drug used to treat or prevent seizures or convulsions that may be caused by epilepsy, brain surgery, or treatment for brain cancer. It is a type of anticonvulsant agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of phenytoin, a hydantoin derivate and non-sedative antiepileptic agent with anticonvulsant activity. Phenytoin sodium promotes sodium efflux from neurons located in the motor cortex, thereby stabilizing the neuron and inhibiting synaptic transmission. This leads to a reduction in posttetanic potentiation at synapses, an inhibition of repetitive firing of action potentials and ultimately inhibits the spread of seizure activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phenytoin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"5,5-Diphenyl-2,4-imidazolidinedione, Monosodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Dilantin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"630-93-3"},{"name":"Chemical_Formula","value":"C15H11N2O2.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4182431BJH"},{"name":"Legacy Concept Name","value":"Phenytoin_Sodium"},{"name":"Maps_To","value":"Phenytoin Sodium"},{"name":"NSC Number","value":"8722"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0237417"}]}}{"C121375":{"preferredName":"Imifoplatin","code":"C121375","definitions":[{"definition":"A platinum (Pt)-based agent belonging to the phosphaplatin family comprised of Pt complexed to a pyrophosphate ligand, with potential antineoplastic activity. Although the exact mechanisms through which imifoplatin exerts its effect have yet to be fully elucidated, this agent, upon intravenous administration, binds to certain transmembrane proteins and activates several genes involved in tumor suppression and apoptosis. This leads to the activation of various signal transduction pathways, induces S/G2 phase cell cycle, and causes tumor cell apoptosis. In addition, imifoplatin may inhibit angiogenesis. Unlike conventional Pt-based chemotherapeutics, imifoplatin does not bind to DNA and is able to overcome drug resistance, which occurs with conventional Pt-based chemotherapeutics; it also has a more favorable side effect profile and is more stable in plasma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imifoplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclohexanediamine Pyrophosphatoplatinum(II), (1R,2R)-","termGroup":"SY","termSource":"NCI"},{"termName":"Phosphaplatin PT-112","termGroup":"SY","termSource":"NCI"},{"termName":"PT 112","termGroup":"CN","termSource":"NCI"},{"termName":"PT-112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1339960-28-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F5I3T42BXC"},{"name":"Maps_To","value":"Imifoplatin"},{"name":"Maps_To","value":"Phosphaplatin PT-112"},{"name":"NCI_Drug_Dictionary_ID","value":"795706"},{"name":"NCI_META_CUI","value":"CL474103"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795706"},{"name":"PDQ_Open_Trial_Search_ID","value":"795706"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71883":{"preferredName":"Phosphatidylcholine-Bound Silybin","code":"C71883","definitions":[{"definition":"An oral preparation of the flavonoid silybin with potential antioxidant and chemopreventive activities. Silybin, also known as silibinin, is a mixture of two stereoisomers, denoted silybin A and silybin B, and is the major active constituent of silymarin, a mixture of flavonolignans extracted from blessed milk thistle (Silybum marianum). Silybin modulates P-glycoprotein (P-gp)-mediated cellular efflux; has oxygen radical-scavenging effects; inhibits the arachidonic acid pathway; and inhibits various cytochrome P450 enzymes. This agent may also exhibit anti-angiogenic activity, possibly by inducing endothelial cell apoptosis via modulation of the transcription factor NF-kB, the Bcl-2 family of proteins, and caspases. Complexing silybin with phosphatidylcholine increases its bioavailability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphatidylcholine-Bound Silybin","termGroup":"PT","termSource":"NCI"},{"termName":"Silybin-Phytosome","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Phosphatidylcholine-Bound_Silybin"},{"name":"Maps_To","value":"Phosphatidylcholine-Bound Silybin"},{"name":"NCI_Drug_Dictionary_ID","value":"558906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558906"},{"name":"PDQ_Open_Trial_Search_ID","value":"558906"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1873062"}]}}{"C84879":{"preferredName":"Iodine I 131 Iopofosine","code":"C84879","definitions":[{"definition":"A radioconjugate composed of iopofosine, a phospholipid ether analog, labeled with the radioactive isotope iodine I 131, with potential antineoplastic activity. Upon administration, iodine I 131 iopofosine selectively accumulates in and retains within tumor cells for a prolonged period of time due to the decreased activity of a phospholipase D (PLD) in tumor cells compared to normal cells, thereby delivering cytotoxic radiation specifically to tumor cells.  PLD is an enzyme found in the cell membrane of normal cells that degrades phospholipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 Iopofosine","termGroup":"PT","termSource":"NCI"},{"termName":"131I-CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"131I-NM-404","termGroup":"SY","termSource":"NCI"},{"termName":"131I-NM404","termGroup":"SY","termSource":"NCI"},{"termName":"[(131)I]NM404","termGroup":"SY","termSource":"NCI"},{"termName":"[131I]-CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"CLR 131","termGroup":"CN","termSource":"NCI"},{"termName":"CLR 1404 I-131","termGroup":"SY","termSource":"NCI"},{"termName":"CLR-131","termGroup":"SY","termSource":"NCI"},{"termName":"CLR-1404 I-131","termGroup":"SY","termSource":"NCI"},{"termName":"CLR131","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 PLE Analogue CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"I-131-CLR1404","termGroup":"SY","termSource":"NCI"},{"termName":"I-131-CLR1404","termGroup":"AB","termSource":"NCI"},{"termName":"Iopofosine I 131","termGroup":"SY","termSource":"NCI"},{"termName":"NM-404 I-131","termGroup":"SY","termSource":"NCI"},{"termName":"PDC CLR 131","termGroup":"SY","termSource":"NCI"},{"termName":"Phospholipid Ether-drug Conjugate CLR 131","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"873438-88-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R048696O9L"},{"name":"Maps_To","value":"Phospholipid Ether-drug Conjugate CLR 131"},{"name":"NCI_Drug_Dictionary_ID","value":"649140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649140"},{"name":"PDQ_Open_Trial_Search_ID","value":"649140"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045705"}]}}{"C29322":{"preferredName":"Phosphoramide Mustard","code":"C29322","definitions":[{"definition":"One of a number of chemically-related alkylating agents with antineoplastic properties.  The prototype of this group of agents is cyclophosphamide.  Most phosphoramide mustards are administered as prodrugs that undergo reductive activation in hypoxic environments to yield cytotoxic metabolites. These agents alkylate and crosslink DNA, resulting in inhibition of DNA replication. Phosphoramide mustards are also immunosuppressants, mutagens and teratogens. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphoramide Mustard","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:8163"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Phosphoramide_Mustard"},{"name":"Maps_To","value":"Phosphoramide Mustard"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0070913"}]}}{"C62518":{"preferredName":"Phosphorodiamidate Morpholino Oligomer AVI-4126","code":"C62518","definitions":[{"definition":"A c-Myc antisense phosphorodiamidate morpholino oligomer (PMO) with potential antineoplastic activity. Phosphorodiamidate morpholino oligomer AVI-4126 binds to c-Myc mRNA and blocks its translation, which may result in the death of tumor cells overexpressing c-Myc. Differing from traditional antisense oligodeoxynucleotides (ODNs), neutrally charged PMOs are composed of subunits of nucleic acid bases linked to a synthetic backbone and, so, are less prone to enzymatic degradation. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphorodiamidate Morpholino Oligomer AVI-4126","termGroup":"PT","termSource":"NCI"},{"termName":"AVI-4126","termGroup":"AB","termSource":"NCI"},{"termName":"Oncomyc-NG","termGroup":"SY","termSource":"NCI"},{"termName":"PMO AVI-4126","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AVI-4126"},{"name":"Maps_To","value":"Phosphorodiamidate Morpholino Oligomer AVI-4126"},{"name":"NCI_Drug_Dictionary_ID","value":"496940"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496940"},{"name":"PDQ_Open_Trial_Search_ID","value":"496940"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1450425"}]}}{"C1698":{"preferredName":"Phosphorus P-32","code":"C1698","definitions":[{"definition":"A radioactive form of phosphorus used in the treatment of cancer. It is also used to help locate areas of DNA damage.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phosphorus P-32","termGroup":"PT","termSource":"NCI"},{"termName":"P32","termGroup":"AB","termSource":"NCI"},{"termName":"Phosphorus P 32","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:37972"},{"name":"Chemical_Formula","value":"P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"690284A407"},{"name":"Legacy Concept Name","value":"Phosphorus-32"},{"name":"Maps_To","value":"Phosphorus P-32"},{"name":"NCI_Drug_Dictionary_ID","value":"39554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39554"},{"name":"PDQ_Open_Trial_Search_ID","value":"39554"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C0851287"}]}}{"C114382":{"preferredName":"Redaporfin","code":"C114382","definitions":[{"definition":"A bacteriochlorin-based photosensitizer, with antineoplastic activity upon photodynamic therapy (PDT). Following intravenous administration, redaporfin preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of laser light at the tumor site results in the absorption of light by this agent and a photodynamic reaction between LUZ 11 and oxygen. This results in the production of reactive oxygen species (ROS), which includes singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated DNA damage and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Redaporfin","termGroup":"PT","termSource":"NCI"},{"termName":"LUZ 11","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1224104-08-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZP3QP1H44W"},{"name":"Maps_To","value":"Photosensitizer LUZ 11"},{"name":"Maps_To","value":"Redaporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"758537"},{"name":"NCI_META_CUI","value":"CL471817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758537"},{"name":"PDQ_Open_Trial_Search_ID","value":"758537"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126802":{"preferredName":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex","code":"C126802","definitions":[{"definition":"A photosensitizer composed of the sodium salt form of chlorin e6 and its derivatives complexed with a low-molecular weight polyvinylpyrrolidone (PVP) polymer component, with diagnostic and antineoplastic activities upon photodynamic therapy (PDT). Upon intravenous administration, the photosensitizer phytochlorin-PVP sodium complex preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of light with a certain wavelength to the tumor site results in the absorption of light by this agent leading to its photoactivation. This results in a photodynamic reaction between phytochlorin and oxygen, which causes the production of reactive oxygen species (ROS), including singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated oxidative DNA damage followed by apoptosis of tumor cells. Chlorin e6-PVP is able to penetrate deeply into tissues and is therefore able to treat hard-to-reach tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex","termGroup":"PT","termSource":"NCI"},{"termName":"BLC-1013","termGroup":"CN","termSource":"NCI"},{"termName":"Chlorin E6-polyvinylpyrrolidone","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorin E6-PVP","termGroup":"SY","termSource":"NCI"},{"termName":"Chlorin E6/PVP","termGroup":"SY","termSource":"NCI"},{"termName":"Fotolon","termGroup":"FB","termSource":"NCI"},{"termName":"Photolon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phytochlorin Sodium-Polyvinylpyrrolidone Complex"},{"name":"NCI_Drug_Dictionary_ID","value":"780299"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780299"},{"name":"PDQ_Open_Trial_Search_ID","value":"780299"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351765"}]}}{"C103861":{"preferredName":"PI3K Alpha/Beta Inhibitor BAY1082439","code":"C103861","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity. PI3K alpha/beta inhibitor BAY1082439 selectively inhibits both PI3K alpha, including mutated forms of PIK3CA, and PI3K beta in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K-expressing and/or PTEN-driven tumor cells. By specifically targeting class I PI3K alpha and beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in increased tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Alpha/Beta Inhibitor BAY1082439","termGroup":"PT","termSource":"NCI"},{"termName":"BAY1082439","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1375469-38-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"59784ZX4GD"},{"name":"Maps_To","value":"PI3K Alpha/Beta Inhibitor BAY1082439"},{"name":"NCI_Drug_Dictionary_ID","value":"743262"},{"name":"NCI_META_CUI","value":"CL438339"},{"name":"PDQ_Closed_Trial_Search_ID","value":"743262"},{"name":"PDQ_Open_Trial_Search_ID","value":"743262"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97915":{"preferredName":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate","code":"C97915","definitions":[{"definition":"The mesylate salt form of PWT33597, an orally bioavailable dual inhibitor of phosphatidylinositide 3-kinase (PI3K) alpha and mammalian target of rapamycin (mTOR) kinase with potential antineoplastic activity. PI3K alpha/mTOR dual inhibitor PWT33597 selectively inhibits both PI3K alpha kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"PWT33597 Mesylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"708121"},{"name":"NCI_META_CUI","value":"CL430398"},{"name":"PDQ_Closed_Trial_Search_ID","value":"708121"},{"name":"PDQ_Open_Trial_Search_ID","value":"708121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95891":{"preferredName":"PI3K-delta Inhibitor AMG 319","code":"C95891","definitions":[{"definition":"A highly selective, potent, and orally bioavailable small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities.  PI3K-delta inhibitor AMG 319 prevents the activation of the PI3K signaling pathway through inhibition of the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), thus decreasing proliferation and inducing cell death.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-delta Inhibitor AMG 319","termGroup":"PT","termSource":"NCI"},{"termName":"ACP-319","termGroup":"CN","termSource":"NCI"},{"termName":"AMG 319","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor ACP-319","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1608125-21-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19DG7G1U5Q"},{"name":"Maps_To","value":"PI3K Inhibitor ACP-319"},{"name":"Maps_To","value":"PI3K-delta Inhibitor AMG 319"},{"name":"NCI_Drug_Dictionary_ID","value":"696292"},{"name":"NCI_META_CUI","value":"CL428288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696292"},{"name":"PDQ_Open_Trial_Search_ID","value":"696292"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74073":{"preferredName":"PI3K Inhibitor BGT226","code":"C74073","definitions":[{"definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BGT226 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability; apoptotic cell death may ensue. Bax is a member of the proapoptotic Bcl2 family of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor BGT226","termGroup":"PT","termSource":"NCI"},{"termName":"BGT226","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-BGT-226","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-BGT226","termGroup":"CN","termSource":"NCI"},{"termName":"NVP-BGT226 Free Base","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_BGT226"},{"name":"Maps_To","value":"PI3K Inhibitor BGT226"},{"name":"NCI_Drug_Dictionary_ID","value":"587478"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587478"},{"name":"PDQ_Open_Trial_Search_ID","value":"587478"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347426"}]}}{"C116877":{"preferredName":"Paxalisib","code":"C116877","definitions":[{"definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. paxalisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paxalisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0084","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0084","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor GDC-0084","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1382979-44-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P5DKZ70636"},{"name":"Maps_To","value":"Paxalisib"},{"name":"Maps_To","value":"PI3K Inhibitor GDC-0084"},{"name":"NCI_Drug_Dictionary_ID","value":"728900"},{"name":"NCI_META_CUI","value":"CL446606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"728900"},{"name":"PDQ_Open_Trial_Search_ID","value":"728900"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132166":{"preferredName":"Inavolisib","code":"C132166","definitions":[{"definition":"An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inavolisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 0077","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0077","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0077","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K Inhibitor GDC0077","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6114","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6114","termGroup":"CN","termSource":"NCI"},{"termName":"RG6114","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7113755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2060571-02-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L4C1UY2NYH"},{"name":"Maps_To","value":"PI3K Inhibitor GDC0077"},{"name":"NCI_Drug_Dictionary_ID","value":"787122"},{"name":"NCI_META_CUI","value":"CL521134"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787122"},{"name":"PDQ_Open_Trial_Search_ID","value":"787122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78470":{"preferredName":"PI3K Inhibitor GSK1059615","code":"C78470","definitions":[{"definition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GSK1059615 inhibits PI3K in the PI3K/AKT kinase signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane and an increase in mitochondrial membrane permeability, followed by apoptosis. Bax is a member of the proapoptotic Bcl-2 family of proteins. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor GSK1059615","termGroup":"PT","termSource":"NCI"},{"termName":"GSK1059615","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"958852-01-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"07YMO87363"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_GSK1059615"},{"name":"Maps_To","value":"PI3K Inhibitor GSK1059615"},{"name":"NCI_Drug_Dictionary_ID","value":"600076"},{"name":"NCI_META_CUI","value":"CL387567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600076"},{"name":"PDQ_Open_Trial_Search_ID","value":"600076"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107386":{"preferredName":"PI3K Inhibitor WX-037","code":"C107386","definitions":[{"definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor WX-037 specifically inhibits PI3K, which prevents the activation of the PI3K/protein kinase B-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor WX-037","termGroup":"PT","termSource":"NCI"},{"termName":"WX-037","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1000795-26-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YGE99UD9C2"},{"name":"Maps_To","value":"PI3K Inhibitor WX-037"},{"name":"NCI_Drug_Dictionary_ID","value":"750893"},{"name":"NCI_META_CUI","value":"CL449597"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750893"},{"name":"PDQ_Open_Trial_Search_ID","value":"750893"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95723":{"preferredName":"PI3K Inhibitor ZSTK474","code":"C95723","definitions":[{"definition":"An orally available, s-triazine derivative, ATP-competitive phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor ZSTK474 inhibits all four PI3K isoforms. Inhibiting the activation of the PI3K/AKT kinase (or protein kinase B) signaling pathway results in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. This agent does not induce apoptosis but rather induces strong G(0)/G(1) arrest, which might contribute to its favorable efficacy in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K Inhibitor ZSTK474","termGroup":"PT","termSource":"NCI"},{"termName":"Phosphatidylinositol 3-kinase Inhibitor ZSTK474","termGroup":"SY","termSource":"NCI"},{"termName":"ZSTK474","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"475110-96-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K0068GK39A"},{"name":"Maps_To","value":"PI3K Inhibitor ZSTK474"},{"name":"NCI_Drug_Dictionary_ID","value":"694436"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694436"},{"name":"PDQ_Open_Trial_Search_ID","value":"694436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721602"}]}}{"C126271":{"preferredName":"PI3K p110beta/delta Inhibitor CVL237","code":"C126271","definitions":[{"definition":"A dual selective inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K-beta/delta), with potential antineoplastic activity. PI3K-beta/delta inhibitor CVL237 selectively inhibits the PI3K-beta and -delta isoforms and prevents their activation, which inhibits PI3K-beta/delta-mediated signal transduction pathways. This decreases proliferation and induces cell death in susceptible tumor cells. Unlike other isoforms of PI3K, PI3K-beta and -delta are overexpressed primarily in solid and hematological tumor cells and play crucial roles in tumor cell survival, and immunoregulation. The targeted inhibition of these PI3Ks allows this agent to potentially be more efficacious and less toxic than pan PI3K inhibitors, which also affect normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K p110beta/delta Inhibitor CVL237","termGroup":"PT","termSource":"NCI"},{"termName":"CVL 237","termGroup":"CN","termSource":"NCI"},{"termName":"CVL-237","termGroup":"CN","termSource":"NCI"},{"termName":"CVL237","termGroup":"CN","termSource":"NCI"},{"termName":"KA 2237","termGroup":"CN","termSource":"NCI"},{"termName":"KA2237","termGroup":"CN","termSource":"NCI"},{"termName":"PI3 Kinase b/d Inhibitor KA2237","termGroup":"SY","termSource":"NCI"},{"termName":"PI3K p110beta/delta Inhibitor KA2237","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K p110beta/delta Inhibitor KA2237"},{"name":"NCI_Drug_Dictionary_ID","value":"779211"},{"name":"NCI_META_CUI","value":"CL504848"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158603":{"preferredName":"Izorlisib","code":"C158603","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. Upon administration, izorlisib selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, izorlisib may be more efficacious and less toxic than pan-PI3K inhibitors. In addition, izorlisib also targets mutated forms of PI3K gamma (PI3Kg). It may also stimulate the immune system to restore CD8+ T-cell activation and cytotoxicity. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. In most solid tumors, the activation of the PI3K pathway is induced by mutations of PIK3CA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Izorlisib","termGroup":"PT","termSource":"NCI"},{"termName":"5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-selective PI3K Inhibitor MEN1611","termGroup":"SY","termSource":"NCI"},{"termName":"CH 5132799","termGroup":"CN","termSource":"NCI"},{"termName":"CH-5132799","termGroup":"CN","termSource":"NCI"},{"termName":"CH5132799","termGroup":"CN","termSource":"NCI"},{"termName":"MEN 1611","termGroup":"CN","termSource":"NCI"},{"termName":"MEN-1611","termGroup":"CN","termSource":"NCI"},{"termName":"MEN1611","termGroup":"CN","termSource":"NCI"},{"termName":"PA 799","termGroup":"CN","termSource":"NCI"},{"termName":"PA-799","termGroup":"CN","termSource":"NCI"},{"termName":"PA799","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K-alpha Inhibitor MEN1611","termGroup":"SY","termSource":"NCI"},{"termName":"PI3Kalpha Inhibitor MEN1611","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1007207-67-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JCL936W835"},{"name":"Maps_To","value":"PI3K-alpha Inhibitor MEN1611"},{"name":"NCI_Drug_Dictionary_ID","value":"797093"},{"name":"NCI_META_CUI","value":"CL938076"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797093"},{"name":"PDQ_Open_Trial_Search_ID","value":"797093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106261":{"preferredName":"PI3K-beta Inhibitor GSK2636771","code":"C106261","definitions":[{"definition":"An orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-beta Inhibitor GSK2636771","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2636771","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1372540-25-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DW94IAT0LS"},{"name":"Maps_To","value":"PI3K-beta Inhibitor GSK2636771"},{"name":"NCI_Drug_Dictionary_ID","value":"715683"},{"name":"NCI_META_CUI","value":"CL433894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715683"},{"name":"PDQ_Open_Trial_Search_ID","value":"715683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116882":{"preferredName":"PI3K-beta Inhibitor SAR260301","code":"C116882","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor SAR260301 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in apoptosis and growth inhibition in PI3K beta-expressing and/or phosphatase and tensin homolog (PTEN)-deficient tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and contributes to increased tumor cell growth, tumor cell survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan-PI3K inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-beta Inhibitor SAR260301","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"SAR 260301","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-260301","termGroup":"CN","termSource":"NCI"},{"termName":"SAR260301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1260612-13-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33639WNC7Q"},{"name":"Maps_To","value":"PI3K-beta Inhibitor SAR260301"},{"name":"NCI_Drug_Dictionary_ID","value":"739784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739784"},{"name":"PDQ_Open_Trial_Search_ID","value":"739784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3852556"}]}}{"C148532":{"preferredName":"Amdizalisib","code":"C148532","definitions":[{"definition":"An orally bioavailable selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (phosphoinositide 3'-kinase delta; PI3Kd; PI3K-d), with potential antineoplastic activity. Upon oral administration, amdizalisib selectively binds to and inhibits PI3Kd, and prevents the activation of the PI3Kd/AKT signaling pathway, and B-cell activation. This both decreases proliferation and induces cell death in PI3Kd-overexpressing tumor cells. PI3Kd plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of hematologic cancer cells. The targeted inhibition of PI3Kd is designed to preserve PI3K signaling in normal, non-neoplastic cells and thereby to minimize serious side effects. PI3Kd, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amdizalisib","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL 689","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-689","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL689","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K-d Inhibitor HMPL 689","termGroup":"SY","termSource":"NCI"},{"termName":"PI3K-delta Inhibitor HMPL 689","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1894229-05-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3YMY7783P"},{"name":"Maps_To","value":"PI3K-delta Inhibitor HMPL 689"},{"name":"NCI_Drug_Dictionary_ID","value":"792706"},{"name":"NCI_META_CUI","value":"CL551137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792706"},{"name":"PDQ_Open_Trial_Search_ID","value":"792706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113434":{"preferredName":"Parsaclisib","code":"C113434","definitions":[{"definition":"An inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parsaclisib","termGroup":"PT","termSource":"NCI"},{"termName":"(4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one","termGroup":"SY","termSource":"NCI"},{"termName":"IBI376","termGroup":"CN","termSource":"NCI"},{"termName":"INCB 50465","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-50465","termGroup":"CN","termSource":"NCI"},{"termName":"INCB050465","termGroup":"CN","termSource":"NCI"},{"termName":"INCB50465","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10589","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1426698-88-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OS7097575K"},{"name":"Maps_To","value":"Parsaclisib"},{"name":"Maps_To","value":"PI3K-delta Inhibitor INCB050465"},{"name":"NCI_Drug_Dictionary_ID","value":"756266"},{"name":"NCI_META_CUI","value":"CL458228"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756266"},{"name":"PDQ_Open_Trial_Search_ID","value":"756266"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123925":{"preferredName":"Zandelisib","code":"C123925","definitions":[{"definition":"An orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zandelisib","termGroup":"PT","termSource":"NCI"},{"termName":"ME 401","termGroup":"CN","termSource":"NCI"},{"termName":"ME-401","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K-delta Inhibitor PWT143","termGroup":"SY","termSource":"NCI"},{"termName":"PWT-143","termGroup":"CN","termSource":"NCI"},{"termName":"PWT143","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401436-95-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8Z28M5SX0X"},{"name":"Maps_To","value":"PI3K-delta Inhibitor PWT143"},{"name":"Maps_To","value":"Zandelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"775930"},{"name":"NCI_META_CUI","value":"CL498289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775930"},{"name":"PDQ_Open_Trial_Search_ID","value":"775930"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165266":{"preferredName":"PI3K-delta Inhibitor SHC014748M","code":"C165266","definitions":[{"definition":"An orally available selective inhibitor of the delta isoform of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, PI3K delta inhibitor SHC014748M selectively binds to and inhibits PI3K delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K delta over-expressing tumor cells. PI3K delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K-delta Inhibitor SHC014748M","termGroup":"PT","termSource":"NCI"},{"termName":"PI3Kd Inhibitor SHC014748M","termGroup":"SY","termSource":"NCI"},{"termName":"SHC 014748M","termGroup":"CN","termSource":"NCI"},{"termName":"SHC-014748M","termGroup":"CN","termSource":"NCI"},{"termName":"SHC014748M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K-delta Inhibitor SHC014748M"},{"name":"NCI_Drug_Dictionary_ID","value":"799414"},{"name":"NCI_META_CUI","value":"CL978533"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799414"},{"name":"PDQ_Open_Trial_Search_ID","value":"799414"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158508":{"preferredName":"Linperlisib","code":"C158508","definitions":[{"definition":"An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linperlisib","termGroup":"PT","termSource":"NCI"},{"termName":"PI3K-delta Inhibitor YY-20394","termGroup":"SY","termSource":"NCI"},{"termName":"YY 20394","termGroup":"CN","termSource":"NCI"},{"termName":"YY-20394","termGroup":"CN","termSource":"NCI"},{"termName":"YY20394","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1702816-75-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05HYK3CV9N"},{"name":"Maps_To","value":"Linperlisib"},{"name":"Maps_To","value":"PI3K-delta Inhibitor YY-20394"},{"name":"NCI_Drug_Dictionary_ID","value":"797151"},{"name":"NCI_META_CUI","value":"CL938053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797151"},{"name":"PDQ_Open_Trial_Search_ID","value":"797151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125471":{"preferredName":"Eganelisib","code":"C125471","definitions":[{"definition":"An orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eganelisib","termGroup":"PT","termSource":"NCI"},{"termName":"IPI 549","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-549","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1693758-51-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FOF5155FMZ"},{"name":"Maps_To","value":"PI3K-gamma Inhibitor IPI-549"},{"name":"NCI_Drug_Dictionary_ID","value":"778361"},{"name":"NCI_META_CUI","value":"CL504218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778361"},{"name":"PDQ_Open_Trial_Search_ID","value":"778361"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148229":{"preferredName":"PI3K/BET Inhibitor LY294002","code":"C148229","definitions":[{"definition":"A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/BET Inhibitor LY294002","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one","termGroup":"SY","termSource":"NCI"},{"termName":"2-Morpholin-4-yl-8-phenylchromen-4-one","termGroup":"SY","termSource":"NCI"},{"termName":"4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-","termGroup":"SN","termSource":"NCI"},{"termName":"LY 294002","termGroup":"CN","termSource":"NCI"},{"termName":"LY-294002","termGroup":"CN","termSource":"NCI"},{"termName":"LY294002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154447-36-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31M2U1DVID"},{"name":"Maps_To","value":"PI3K/BET Inhibitor LY294002"},{"name":"NCI_META_CUI","value":"CL550844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97254":{"preferredName":"PI3K/mTOR Kinase Inhibitor DS-7423","code":"C97254","definitions":[{"definition":"An orally bioavailable inhibitor of phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor DS-7423 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor DS-7423","termGroup":"PT","termSource":"NCI"},{"termName":"DS-7423","termGroup":"CN","termSource":"NCI"},{"termName":"Dual PI3 Kinase/mTOR Inhibitor DS-7423","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor DS-7423"},{"name":"NCI_Drug_Dictionary_ID","value":"701858"},{"name":"NCI_META_CUI","value":"CL429785"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701858"},{"name":"PDQ_Open_Trial_Search_ID","value":"701858"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84837":{"preferredName":"PI3K/mTOR Kinase Inhibitor PF-04691502","code":"C84837","definitions":[{"definition":"An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor PF-04691502 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor PF-04691502","termGroup":"PT","termSource":"NCI"},{"termName":"PF-04691502","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1013101-36-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4W39NS61KI"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor PF-04691502"},{"name":"NCI_Drug_Dictionary_ID","value":"649523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649523"},{"name":"PDQ_Open_Trial_Search_ID","value":"649523"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827515"}]}}{"C112497":{"preferredName":"PI3K/mTOR Kinase Inhibitor VS-5584","code":"C112497","definitions":[{"definition":"A potent and selective inhibitor of both phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor VS-5584 inhibits mTOR kinase and all class I PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR is a serine/threonine kinase downstream of PI3K, which also has PI3K-independent activity. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor VS-5584","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrimidinamine, 5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2-","termGroup":"SN","termSource":"NCI"},{"termName":"5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2-Pyrimidinamine","termGroup":"SN","termSource":"NCI"},{"termName":"PI3K/mTOR Inhibitor VS-5584","termGroup":"SY","termSource":"NCI"},{"termName":"SB 2343","termGroup":"SY","termSource":"NCI"},{"termName":"SB-2343","termGroup":"SY","termSource":"NCI"},{"termName":"SB2343","termGroup":"SY","termSource":"NCI"},{"termName":"VS 5584","termGroup":"SY","termSource":"NCI"},{"termName":"VS-5584","termGroup":"CN","termSource":"NCI"},{"termName":"VS5584","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1246560-33-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W71J4X250V"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor VS-5584"},{"name":"NCI_Drug_Dictionary_ID","value":"755179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755179"},{"name":"PDQ_Open_Trial_Search_ID","value":"755179"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3711165"}]}}{"C159499":{"preferredName":"PI3K/mTOR Kinase Inhibitor WXFL10030390","code":"C159499","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of certain phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon oral administration, PI3K/mTOR inhibitor WXFL10030390 (WX390) inhibits mTOR kinase and certain PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTOR Kinase Inhibitor WXFL10030390","termGroup":"PT","termSource":"NCI"},{"termName":"PI3K/mTOR Kinase Inhibitor WX390","termGroup":"SY","termSource":"NCI"},{"termName":"WX 390","termGroup":"CN","termSource":"NCI"},{"termName":"WX-390","termGroup":"SY","termSource":"NCI"},{"termName":"WX390","termGroup":"CN","termSource":"NCI"},{"termName":"WXFL 10030390","termGroup":"CN","termSource":"NCI"},{"termName":"WXFL-10030390","termGroup":"SY","termSource":"NCI"},{"termName":"WXFL10030390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K/mTOR Kinase Inhibitor WXFL10030390"},{"name":"NCI_Drug_Dictionary_ID","value":"797519"},{"name":"NCI_META_CUI","value":"CL951457"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797519"},{"name":"PDQ_Open_Trial_Search_ID","value":"797519"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C104292":{"preferredName":"Panulisib","code":"C104292","definitions":[{"definition":"An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, panulisib inhibits the activity of all four kinases. This prevents PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor types and increases endothelial cell proliferation and migration. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Panulisib","termGroup":"PT","termSource":"NCI"},{"termName":"AK15176","termGroup":"CN","termSource":"NCI"},{"termName":"P7170","termGroup":"CN","termSource":"NCI"},{"termName":"PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1356033-60-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S9WA04F921"},{"name":"Maps_To","value":"Panulisib"},{"name":"Maps_To","value":"PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170"},{"name":"NCI_Drug_Dictionary_ID","value":"745036"},{"name":"NCI_META_CUI","value":"CL445627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745036"},{"name":"PDQ_Open_Trial_Search_ID","value":"745036"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116351":{"preferredName":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901","code":"C116351","definitions":[{"definition":"An inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity. Upon intravenous infusion, PI3K/mTORC1/mTORC2 inhibitor DCBCI0901 binds to and inhibits PI3K as well as both mTORC1 and mTORC2, which may result in both apoptosis and a decrease in cell proliferation in tumor cells overexpressing PI3K, mTORC1, and mTORC2. Activation of the PI3K/mTOR signaling pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901","termGroup":"PT","termSource":"NCI"},{"termName":"DCBCI0901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901"},{"name":"NCI_Drug_Dictionary_ID","value":"761750"},{"name":"NCI_META_CUI","value":"CL473670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761750"},{"name":"PDQ_Open_Trial_Search_ID","value":"761750"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90291":{"preferredName":"PI3Ka/mTOR Inhibitor PKI-179","code":"C90291","definitions":[{"definition":"A second generation, small-molecule mimetic of ATP that targets the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. PKI-179 selectively inhibits mTOR and phosphoinositide-3-kinase (PI3K) alpha. By inhibiting the PI3K/mTOR signaling pathway, this agent may inhibit tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Ka/mTOR Inhibitor PKI-179","termGroup":"PT","termSource":"NCI"},{"termName":"PKI-179","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1197160-28-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CNN7Y60164"},{"name":"Maps_To","value":"PI3Ka/mTOR Inhibitor PKI-179"},{"name":"NCI_Drug_Dictionary_ID","value":"658412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658412"},{"name":"PDQ_Open_Trial_Search_ID","value":"658412"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933673"}]}}{"C118624":{"preferredName":"PI3Kalpha Inhibitor AZD8835","code":"C118624","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor AZD8835 selectively binds to and inhibits PIK3CA and its mutated forms, in the PI3K/Akt (protein kinase B) /mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, this agent may be more efficacious and less toxic than pan-PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Kalpha Inhibitor AZD8835","termGroup":"PT","termSource":"NCI"},{"termName":"AZD8835","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1620576-64-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B97A88D35"},{"name":"Maps_To","value":"PI3Kalpha Inhibitor AZD8835"},{"name":"NCI_Drug_Dictionary_ID","value":"765451"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765451"},{"name":"PDQ_Open_Trial_Search_ID","value":"765451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896907"}]}}{"C107684":{"preferredName":"PI3Kbeta Inhibitor AZD8186","code":"C107684","definitions":[{"definition":"An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation and induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Kbeta Inhibitor AZD8186","termGroup":"PT","termSource":"NCI"},{"termName":"AZD-8186","termGroup":"CN","termSource":"NCI"},{"termName":"AZD8186","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1296270-45-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AIQ4OWD0RA"},{"name":"Maps_To","value":"PI3Kbeta Inhibitor AZD8186"},{"name":"NCI_Drug_Dictionary_ID","value":"751594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751594"},{"name":"PDQ_Open_Trial_Search_ID","value":"751594"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827157"}]}}{"C121374":{"preferredName":"PI3Kdelta Inhibitor GS-9901","code":"C121374","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3Kdelta) with potential immunomodulating and antineoplastic activities. Upon oral administration, PI3Kdelta inhibitor GS-9901 selectively binds to the delta isoform of PI3K and inhibits its activity. This inhibits the activation of the PI3Kdelta-mediated signaling pathway and prevents proliferation of PI3Kdelta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is expressed primarily in certain tumor cell types and plays a key role in tumor cell proliferation, motility and survival. The targeted inhibition of PI3Kdelta is designed to preserve PI3K signaling in normal, non-neoplastic cells and thus reduces toxicity to normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PI3Kdelta Inhibitor GS-9901","termGroup":"PT","termSource":"NCI"},{"termName":"GS-9901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1640247-87-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U09Q76B8VK"},{"name":"Maps_To","value":"PI3Kdelta Inhibitor GS-9901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053639"}]}}{"C546":{"preferredName":"Pibenzimol","code":"C546","definitions":[{"definition":"A fluorescent dye of benzimidazole derivative.  Pibenzimol binds to AT-specific sites in the minor groove of duplex DNA and inhibits topoisomerase I, and DNA polymerase, thereby preventing DNA replication. This agent prolongs the G2 phase of the cell cycle and initiates apoptosis in tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pibenzimol","termGroup":"PT","termSource":"NCI"},{"termName":"Bisbenzimidazole","termGroup":"SY","termSource":"NCI"},{"termName":"HOE 33258","termGroup":"CN","termSource":"NCI"},{"termName":"Hoechst 33258","termGroup":"CN","termSource":"NCI"},{"termName":"Hoechst Dye 33258","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 4-(5-(4-methyl-1-piperazinyl)(2,5'-bi-1H-benzimidazol)-2'-yl)-, Trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Phenol, p-[5-[5-(4-methyl-1-piperazinyl)-2-benzimidazolyl]-2- benzimidazolyl]-, Trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Pibenzimol Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"23491-45-4"},{"name":"CHEBI_ID","value":"CHEBI:52082"},{"name":"Chemical_Formula","value":"C25H24N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LHQ7J5KV9B"},{"name":"Legacy Concept Name","value":"Pibenzimol"},{"name":"Maps_To","value":"Pibenzimol"},{"name":"NCI_Drug_Dictionary_ID","value":"39193"},{"name":"NSC Number","value":"322921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39193"},{"name":"PDQ_Open_Trial_Search_ID","value":"39193"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0019832"}]}}{"C1542":{"preferredName":"Pibrozelesin","code":"C1542","definitions":[{"definition":"A semisynthetic anticancer drug that is a type of antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2.  Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pibrozelesin","termGroup":"PT","termSource":"NCI"},{"termName":"Benzo(1,2-b:4,3-b')dipyrrole-1-carboxylic Acid, 8-(bromomethyl)-3,6,7,8-tetrahydro-2-methy-4-(((4-methyl-1-piperazinyl)carbonyl)oxy)-6-((5,6,7,-trimethoxy-1H-indol-2-yl)carbonyl)-, Methyl Ester (S)","termGroup":"SN","termSource":"NCI"},{"termName":"Duocamycin B2 Analog","termGroup":"SY","termSource":"NCI"},{"termName":"KW 2189","termGroup":"CN","termSource":"NCI"},{"termName":"KW-2189","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154889-68-6"},{"name":"Chemical_Formula","value":"C32H36BrN5O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IHK933KCIC"},{"name":"Legacy Concept Name","value":"KW_2189"},{"name":"Maps_To","value":"Pibrozelesin"},{"name":"NCI_Drug_Dictionary_ID","value":"42429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42429"},{"name":"PDQ_Open_Trial_Search_ID","value":"42429"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0254093"}]}}{"C73816":{"preferredName":"Pibrozelesin Hydrobromide","code":"C73816","definitions":[{"definition":"The hydrobromide salt form of pibrozelesin, a semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2, with antineoplastic activity. Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pibrozelesin Hydrobromide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"148778-32-9"},{"name":"Chemical_Formula","value":"C32H36BrN5O8.BrH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0481JCC90T"},{"name":"Legacy Concept Name","value":"Pibrozelesin_Hydrobromide"},{"name":"Maps_To","value":"Pibrozelesin Hydrobromide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347514"}]}}{"C745":{"preferredName":"Picibanil","code":"C745","definitions":[{"definition":"A lyophilized formulation containing cultures of a low-virulent strain of Streptococcus pyogenes, treated and killed with penicillin G, with potential sclerosing, immunostimulating and antineoplastic activity. Besides from picibanil's direct damaging effect as a sclerosing agent, it seems to have multiple effects on the immune system as a non-specific immunostimulant.  Picibanil activates the host immune system by stimulating the activity of natural killer cells, macrophages and lymphocytes, and by enhancing the production of several key immune mediators, including interleukins and tumor necrosis factor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Picibanil","termGroup":"PT","termSource":"NCI"},{"termName":"OK-432","termGroup":"CN","termSource":"NCI"},{"termName":"Picibanil","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"39325-01-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2F42BH7X2L"},{"name":"Legacy Concept Name","value":"OK-432"},{"name":"Maps_To","value":"Picibanil"},{"name":"NCI_Drug_Dictionary_ID","value":"489137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489137"},{"name":"PDQ_Open_Trial_Search_ID","value":"489137"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0031875"}]}}{"C48416":{"preferredName":"Picoplatin","code":"C48416","definitions":[{"definition":"A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer.  It belongs to the family of drugs called platinum analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Picoplatin","termGroup":"PT","termSource":"NCI"},{"termName":"AMD473","termGroup":"CN","termSource":"NCI"},{"termName":"Cis-Amminedichloro (2-Methylpyridine) Platinum (II)","termGroup":"SN","termSource":"NCI"},{"termName":"JM473","termGroup":"CN","termSource":"NCI"},{"termName":"NX-473","termGroup":"CN","termSource":"NCI"},{"termName":"Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)-","termGroup":"SN","termSource":"NCI"},{"termName":"ZD0473","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"181630-15-9"},{"name":"Chemical_Formula","value":"C6H7N.2Cl.Pt.H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B5TAN0L720"},{"name":"Legacy Concept Name","value":"Picoplatin"},{"name":"Maps_To","value":"Picoplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"441243"},{"name":"PDQ_Closed_Trial_Search_ID","value":"441243"},{"name":"PDQ_Open_Trial_Search_ID","value":"441243"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0671135"}]}}{"C1771":{"preferredName":"Picrasinoside H","code":"C1771","definitions":[{"definition":"A quassinoid glycoside phytochemical isolated from the plant Picrasma ailanthoides with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Picrasinoside H","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-2-en-1-one, 13-(acetyloxy)-16-(beta-D-glucopyranosyloxy)-2-methoxy-11,12-(methylenebis(oxy))-, (11alpha,12beta,16alpha)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135638-54-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Picrasinoside_H"},{"name":"Maps_To","value":"Picrasinoside H"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0648685"}]}}{"C87736":{"preferredName":"Picropodophyllin","code":"C87736","definitions":[{"definition":"A cyclolignan alkaloid found in the mayapple plant family (Podophyllum peltatum), and a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Picropodophyllin specifically inhibits the activity and downregulates the cellular expression of IGF1R without interfering with activities of other growth factor receptors, such as receptors for insulin, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and mast/stem cell growth factor (KIT). This agent shows potent activity in the suppression o f tumor cell proliferation and the induction of tumor cell apoptosis. IGF1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a critical role in the growth and survival of many types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Picropodophyllin","termGroup":"PT","termSource":"NCI"},{"termName":"AXL1717","termGroup":"CN","termSource":"NCI"},{"termName":"Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one,5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-,(5R-(5-alpha,5a-alpha,8a-alpha,9-alpha))-","termGroup":"SN","termSource":"NCI"},{"termName":"Picropodophyllotoxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"477-47-4"},{"name":"Chemical_Formula","value":"C22H22O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0F35AOI227"},{"name":"Maps_To","value":"Picropodophyllin"},{"name":"NCI_Drug_Dictionary_ID","value":"729917"},{"name":"NSC Number","value":"36407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729917"},{"name":"PDQ_Open_Trial_Search_ID","value":"729917"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0961664"}]}}{"C165479":{"preferredName":"Pictilisib","code":"C165479","definitions":[{"definition":"A small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pictilisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-(1H-indazol-4-yl)-6-((4-(methanesulfonyl)piperazin-1-yl)methyl)-4-(morpholin-4-yl)thieno(3,2-d)pyrimidine","termGroup":"SY","termSource":"NCI"},{"termName":"4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno(3,2-d)pyrimidin-4-yl)morpholine","termGroup":"SY","termSource":"NCI"},{"termName":"GDC 0941","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0941","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0941","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"957054-30-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ICY00EMP8P"},{"name":"Maps_To","value":"Pictilisib"},{"name":"NCI_META_CUI","value":"CL978574"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82380":{"preferredName":"Pictilisib Bismesylate","code":"C82380","definitions":[{"definition":"The orally bioavailable bismesylate salt of pictilisib, a small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pictilisib Bismesylate","termGroup":"PT","termSource":"NCI"},{"termName":"2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine, bimesylate salt","termGroup":"SN","termSource":"NCI"},{"termName":"GDC-0941 Bismesylate","termGroup":"SY","termSource":"NCI"},{"termName":"GDC-0941 Dimesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Pictilisib Dimesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Thieno(3,2-d)pyrimidine, 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)-, Methanesulfonate (1:2)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"957054-33-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G3D7HF2GS9"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_GDC-0941_Bismesylate"},{"name":"Maps_To","value":"Pictilisib Bismesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"641462"},{"name":"NCI_META_CUI","value":"CL408651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641462"},{"name":"PDQ_Open_Trial_Search_ID","value":"641462"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71014":{"preferredName":"Pidilizumab","code":"C71014","definitions":[{"definition":"A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pidilizumab","termGroup":"PT","termSource":"NCI"},{"termName":"CT 011","termGroup":"CN","termSource":"NCI"},{"termName":"CT-011","termGroup":"CN","termSource":"NCI"},{"termName":"CT011","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal CT-011 Gamma1 Heavy Chain (220-213')-disulfide with Humanized Mouse Monoclonal CT-011 Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide, Glycosylated (CT-011 is Expressed in NSO Cells)","termGroup":"SN","termSource":"NCI"},{"termName":"MDV9300","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1036730-42-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"B932PAQ1BQ"},{"name":"Legacy Concept Name","value":"Anti-PD-1_Monoclonal_Antibody_CT-011"},{"name":"Maps_To","value":"Pidilizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"573227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573227"},{"name":"PDQ_Open_Trial_Search_ID","value":"573227"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346821"}]}}{"C71705":{"preferredName":"Pilaralisib","code":"C71705","definitions":[{"definition":"An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Pilaralisib reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pilaralisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino-N-(3-(N-(3-((2-chloro-5-methoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide","termGroup":"SY","termSource":"NCI"},{"termName":"SAR245408","termGroup":"CN","termSource":"NCI"},{"termName":"XL 147","termGroup":"CN","termSource":"NCI"},{"termName":"XL-147","termGroup":"CN","termSource":"NCI"},{"termName":"XL147","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934526-89-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"60ES45KTMK"},{"name":"Legacy Concept Name","value":"PI3K_Family_Kinase_Inhibitor_XL147"},{"name":"Maps_To","value":"Pilaralisib"},{"name":"NCI_Drug_Dictionary_ID","value":"558909"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558909"},{"name":"PDQ_Open_Trial_Search_ID","value":"558909"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347424"}]}}{"C106259":{"preferredName":"PIM Kinase Inhibitor LGH447","code":"C106259","definitions":[{"definition":"An orally available pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor LGH447 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of the pro-apoptotic Bcl2 protein and tumor cell apoptosis in cells that overexpress PIMs. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM Kinase Inhibitor LGH447","termGroup":"PT","termSource":"NCI"},{"termName":"LGH-447","termGroup":"CN","termSource":"NCI"},{"termName":"LGH447","termGroup":"CN","termSource":"NCI"},{"termName":"PIM 447","termGroup":"CN","termSource":"NCI"},{"termName":"PIM-447","termGroup":"CN","termSource":"NCI"},{"termName":"PIM447","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1210608-43-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9TG5O4V25H"},{"name":"Maps_To","value":"PIM Kinase Inhibitor LGH447"},{"name":"NCI_Drug_Dictionary_ID","value":"715643"},{"name":"NCI_META_CUI","value":"CL433893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715643"},{"name":"PDQ_Open_Trial_Search_ID","value":"715643"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82404":{"preferredName":"PIM Kinase Inhibitor SGI-1776","code":"C82404","definitions":[{"definition":"A small-molecule pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor SGI-1776 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of pro-apoptotic Bcl2 proteins and tumor cell apoptosis. PIM kinases play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM Kinase Inhibitor SGI-1776","termGroup":"PT","termSource":"NCI"},{"termName":"SGI-1776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1025065-69-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"72AUA0603W"},{"name":"Legacy Concept Name","value":"Pim_Kinase_Inhibitor_SGI-1776"},{"name":"Maps_To","value":"PIM Kinase Inhibitor SGI-1776"},{"name":"NCI_Drug_Dictionary_ID","value":"638088"},{"name":"PDQ_Closed_Trial_Search_ID","value":"638088"},{"name":"PDQ_Open_Trial_Search_ID","value":"638088"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742218"}]}}{"C160203":{"preferredName":"PIM Kinase Inhibitor TP-3654","code":"C160203","definitions":[{"definition":"An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, PIM kinase inhibitor TP-3654 selectively binds to and prevents the activation of the PIM kinases. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIM. PIMs, constitutively active proto-oncogenic serine/threonine kinases, are upregulated in various types of cancers and play key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PIM Kinase Inhibitor TP-3654","termGroup":"PT","termSource":"NCI"},{"termName":"2-((1R,4R)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol","termGroup":"SN","termSource":"NCI"},{"termName":"PIM Inhibitor TP-3654","termGroup":"SY","termSource":"NCI"},{"termName":"SGI 9481","termGroup":"CN","termSource":"NCI"},{"termName":"SGI-9481","termGroup":"CN","termSource":"NCI"},{"termName":"SGI9481","termGroup":"CN","termSource":"NCI"},{"termName":"TP 3654","termGroup":"CN","termSource":"NCI"},{"termName":"TP-3654","termGroup":"CN","termSource":"NCI"},{"termName":"TP3654","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1361951-15-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EOB0N7BOY4"},{"name":"Legacy Concept Name","value":"Pim_Kinase_Inhibitor_SGI-1776"},{"name":"Maps_To","value":"PIM Kinase Inhibitor TP-3654"},{"name":"NCI_Drug_Dictionary_ID","value":"797841"},{"name":"NCI_META_CUI","value":"CL969336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797841"},{"name":"PDQ_Open_Trial_Search_ID","value":"797841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133540":{"preferredName":"Dapolsertib","code":"C133540","definitions":[{"definition":"An orally available inhibitor of PIM family serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3; STK1) with potential antineoplastic activity. Upon oral administration, dapolsertib binds to and inhibits the kinase activities of PIM-1, -2 and -3, and mutant forms of FLT3, which may result in the interruption of the G1/S phase cell cycle transition, an inhibition of cell proliferation, and an induction of apoptosis in tumor cells that overexpress PIMs or express mutant forms of FLT3. FLT3, a tyrosine kinase receptor that is overexpressed or mutated in various cancers, plays a role in signaling pathways that regulate hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, including the FLT3 signaling pathway, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dapolsertib","termGroup":"PT","termSource":"NCI"},{"termName":"Dual PIM/FLT3 Kinase Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"PIM/FLT3 Kinase Inhibitor SEL24","termGroup":"SY","termSource":"NCI"},{"termName":"SEL 24","termGroup":"CN","termSource":"NCI"},{"termName":"SEL24","termGroup":"CN","termSource":"NCI"},{"termName":"SEL24-B489","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616359-00-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9M7X64VTLI"},{"name":"Maps_To","value":"PIM/FLT3 Kinase Inhibitor SEL24"},{"name":"NCI_Drug_Dictionary_ID","value":"788368"},{"name":"NCI_META_CUI","value":"CL520500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788368"},{"name":"PDQ_Open_Trial_Search_ID","value":"788368"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84864":{"preferredName":"Pimasertib","code":"C84864","definitions":[{"definition":"An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimasertib","termGroup":"PT","termSource":"NCI"},{"termName":"AS703026","termGroup":"CN","termSource":"NCI"},{"termName":"EMD 1036239","termGroup":"CN","termSource":"NCI"},{"termName":"MSC1936369","termGroup":"CN","termSource":"NCI"},{"termName":"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4- iodophenyl)amino]isonicotinamide Hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1236699-92-5"},{"name":"Chemical_Formula","value":"C15H15FIN3O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6ON9RK82AL"},{"name":"Maps_To","value":"Pimasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"653634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653634"},{"name":"PDQ_Open_Trial_Search_ID","value":"653634"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830124"}]}}{"C1279":{"preferredName":"Pingyangmycin","code":"C1279","definitions":[{"definition":"The naturally-occurring bleomycin antineoplastic antibiotic isolated from the bacterium Streptomyces pingyangensisn.  Pingyangmycin induces tumor cell apoptosis, possibly via a mechanism mediated by the mitogen-activated protein kinase (MAPK) pathway. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pingyangmycin","termGroup":"PT","termSource":"NCI"},{"termName":"Bleomycetin","termGroup":"SY","termSource":"NCI"},{"termName":"Bleomycin A5","termGroup":"SY","termSource":"NCI"},{"termName":"N1-(3-((4-Aminobutyl)amino)propyl)bleomycinamide","termGroup":"SN","termSource":"NCI"},{"termName":"Zhengguangmycin A5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"77108-50-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5DY91Y7601"},{"name":"Legacy Concept Name","value":"Pingyangmycin"},{"name":"Maps_To","value":"Pingyangmycin"},{"name":"NSC Number","value":"350895"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053847"}]}}{"C103179":{"preferredName":"Pinometostat","code":"C103179","definitions":[{"definition":"A small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Upon intravenous administration, pinometostat specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes. This eventually leads to an induction of apoptosis in the leukemic cells bearing the MLL gene translocations. DOT1L, a non-SET domain-containing histone methyltransferase, specifically methylates H3K79 and plays a key role in normal cell differentiation and in the development of leukemia with MLL gene rearrangement on chromosome 11 and promotes the expression of leukemia-causing genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pinometostat","termGroup":"PT","termSource":"NCI"},{"termName":"DOT1L Inhibitor EPZ-5676","termGroup":"SY","termSource":"NCI"},{"termName":"EPZ-5676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1380288-87-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8V9YR09EF3"},{"name":"Maps_To","value":"Pinometostat"},{"name":"NCI_Drug_Dictionary_ID","value":"740411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"740411"},{"name":"PDQ_Open_Trial_Search_ID","value":"740411"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641112"}]}}{"C71633":{"preferredName":"Pioglitazone","code":"C71633","definitions":[{"definition":"A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth) from developing into cancer. It is a type of thiazolidinedione.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pioglitazone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111025-46-8"},{"name":"CHEBI_ID","value":"CHEBI:8228"},{"name":"Chemical_Formula","value":"C19H20N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X4OV71U42S"},{"name":"Legacy Concept Name","value":"Pioglitazone_Base"},{"name":"Maps_To","value":"Pioglitazone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071097"}]}}{"C29367":{"preferredName":"Pioglitazone Hydrochloride","code":"C29367","definitions":[{"definition":"A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth) from developing into cancer. It is a type of thiazolidinedione.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pioglitazone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Actos","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112529-15-4"},{"name":"Chemical_Formula","value":"C19H20N2O3S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JQT35NPK6C"},{"name":"Legacy Concept Name","value":"Pioglitazone"},{"name":"Maps_To","value":"Pioglitazone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"398145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"398145"},{"name":"PDQ_Open_Trial_Search_ID","value":"398145"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0872972"}]}}{"C1874":{"preferredName":"Pipendoxifene","code":"C1874","definitions":[{"definition":"A nonsteroidal 2-phenyl indole and a selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Pipendoxifene antagonizes binding of estradiol to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated gene expression, interfering with estrogen activity and inhibiting estrogen-stimulated growth in estrogen-dependent breast cancer. In addition, this agent also exerts intrinsic estrogenic activity depending on the tissue types.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to a family of drugs called antiestrogens.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pipendoxifene","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Hydroxyphenyl)-3-methyl-1-[4-(2-piperidin-1-ylethoxy)benzyl]-1H-indol-5-ol Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"ERA 923","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198480-55-6"},{"name":"Chemical_Formula","value":"C29H32N2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TPC5Q8496G"},{"name":"Legacy Concept Name","value":"ERA_923"},{"name":"Maps_To","value":"Pipendoxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"38112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38112"},{"name":"PDQ_Open_Trial_Search_ID","value":"38112"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935699"}]}}{"C1401":{"preferredName":"Piperazinedione","code":"C1401","definitions":[{"definition":"A crystalline antibiotic fermentation product isolated from the bacterium Streptomyces griseoluteus with antineoplastic activity. Piperazinedione alkylates DNA at the N-7 position of guanine, inhibiting DNA replication and inducing cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piperazinedione","termGroup":"PT","termSource":"NCI"},{"termName":"2, 5-piperazinedione, 3,6-bis-(5-chloro-2-piperidyl)-, dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"2,5-piperazinedione, 3, 6-bis(5-chloro-2-piperidinyl)-, dihydrochloride, [3S-[3alpha(2S*,5R*),6alpha(2S*,5R*)]]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"593A","termGroup":"CN","termSource":"NCI"},{"termName":"Compound 593A","termGroup":"SY","termSource":"NCI"},{"termName":"Merck Compound 593A","termGroup":"SY","termSource":"NCI"},{"termName":"PZD","termGroup":"AB","termSource":"NCI"},{"termName":"PZD dihydrochloride, 3,6-bis(5-chloro-2-piperidinyl)-, dihydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41109-80-2"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Piperazinedione"},{"name":"Maps_To","value":"Piperazinedione"},{"name":"NCI_Drug_Dictionary_ID","value":"39556"},{"name":"NSC Number","value":"135758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39556"},{"name":"PDQ_Open_Trial_Search_ID","value":"39556"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0888240"}]}}{"C48417":{"preferredName":"Piperine Extract (Standardized)","code":"C48417","definitions":[{"definition":"A standardized extract containing the active alkaloid piperine, derived from the fruit of the plant Piper nigrum (black pepper) and/or the plant Piper longum L. (long pepper), with thermogenic properties. Co-ingestion of piperidine enhances the bioavailability of various nutrients, including beta-carotene, curcumin, selenium, pyridoxine and coenzyme Q10. In addition, this agent may exert anti-inflammatory and anti-tumor activities and may enhance the production of serotonin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piperine Extract (Standardized)","termGroup":"PT","termSource":"NCI"},{"termName":"Bioperine","termGroup":"BR","termSource":"NCI"},{"termName":"Standardized Piperine Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Piperine_Extract_Standardized"},{"name":"Maps_To","value":"Piperine Extract (Standardized)"},{"name":"NCI_Drug_Dictionary_ID","value":"440023"},{"name":"PDQ_Closed_Trial_Search_ID","value":"440023"},{"name":"PDQ_Open_Trial_Search_ID","value":"440023"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709545"}]}}{"C750":{"preferredName":"Pipobroman","code":"C750","definitions":[{"definition":"A piperazine derivative with potential antineoplastic alkyating activity. Although the exact mechanism of action of pipobroman has yet to be fully elucidated, this agent appears to act by alkylating DNA, leading to disruption of DNA replication and eventually cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pipobroman","termGroup":"PT","termSource":"NCI"},{"termName":"Amedel","termGroup":"BR","termSource":"NCI"},{"termName":"Vercyte","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54-91-1"},{"name":"Chemical_Formula","value":"C10H16Br2N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6Q99RDT97R"},{"name":"Legacy Concept Name","value":"Pipobroman"},{"name":"Maps_To","value":"Pipobroman"},{"name":"NSC Number","value":"25154"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0031965"}]}}{"C1783":{"preferredName":"Piposulfan","code":"C1783","definitions":[{"definition":"An alkyl sulfonate with potential antineoplastic activity.  Piposulfan alkylates DNA, thereby producing DNA interstrand crosslinks and DNA strand breaks and inhibiting DNA replication.  This agent has been shown to exhibit antitumor activity in an animal model of prostate cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piposulfan","termGroup":"PT","termSource":"NCI"},{"termName":"A-20968","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2608-24-4"},{"name":"Chemical_Formula","value":"C12H22N2O8S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VY5DPN1TDU"},{"name":"Legacy Concept Name","value":"Piposulfan"},{"name":"Maps_To","value":"Piposulfan"},{"name":"NSC Number","value":"47774"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0663942"}]}}{"C1197":{"preferredName":"Pirarubicin","code":"C1197","definitions":[{"definition":"An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(2\"R)-4'-O-Tetrahydropyranyladriamycin","termGroup":"SN","termSource":"NCI"},{"termName":"(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-3-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"1609-RB","termGroup":"CN","termSource":"NCI"},{"termName":"1609RB","termGroup":"CN","termSource":"NCI"},{"termName":"4'-O-Tetrahydropyranyl Doxorubicin","termGroup":"SN","termSource":"NCI"},{"termName":"[8S-[8Alpha,10alpha(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione","termGroup":"SN","termSource":"NCI"},{"termName":"Pinorubicin","termGroup":"FB","termSource":"NCI"},{"termName":"Tepirubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Tetrahydropyranyl-Doxorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Theprubicin","termGroup":"FB","termSource":"NCI"},{"termName":"Theprubicine","termGroup":"FB","termSource":"NCI"},{"termName":"Therarubicin","termGroup":"FB","termSource":"NCI"},{"termName":"THP-ADM","termGroup":"AB","termSource":"NCI"},{"termName":"THP-Adriamycin","termGroup":"SY","termSource":"NCI"},{"termName":"THP-DOX","termGroup":"AB","termSource":"NCI"},{"termName":"THP-Doxorubicin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72496-41-4"},{"name":"Chemical_Formula","value":"C32H37NO12"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D58G680W0G"},{"name":"Legacy Concept Name","value":"Pirarubicin"},{"name":"Maps_To","value":"Pirarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"38775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38775"},{"name":"PDQ_Open_Trial_Search_ID","value":"38775"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071126"}]}}{"C95319":{"preferredName":"Pirarubicin Hydrochloride","code":"C95319","definitions":[{"definition":"The hydrochloride salt form of pirarubicin, an analogue of the anthracycline antineoplastic antibiotic doxorubicin with antineoplastic activity. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirarubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(2\"R)-4'-O-Tetrahydropyranyladriamycin Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"4'-O-Tetrahydropyranyl Doxorubicin HCl","termGroup":"SN","termSource":"NCI"},{"termName":"THP-adriamycin Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72496-41-4"},{"name":"Chemical_Formula","value":"C32H37NO12.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E7V83174BE"},{"name":"Maps_To","value":"Pirarubicin Hydrochloride"},{"name":"NSC Number","value":"333054"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0898957"}]}}{"C2635":{"preferredName":"Pirfenidone","code":"C2635","definitions":[{"definition":"A substance that is being studied in the prevention and treatment of scar tissue caused by radiation therapy. It belongs to the family of drugs called anti-inflammatory agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirfenidone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53179-13-8"},{"name":"Chemical_Formula","value":"C12H11NO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D7NLD2JX7U"},{"name":"Legacy Concept Name","value":"Pirfenidone"},{"name":"Maps_To","value":"Pirfenidone"},{"name":"NCI_Drug_Dictionary_ID","value":"38334"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38334"},{"name":"PDQ_Open_Trial_Search_ID","value":"38334"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0298067"}]}}{"C1031":{"preferredName":"Piritrexim","code":"C1031","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called folate antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piritrexim","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"6-[(2,5-Dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"BW-301U","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72732-56-0"},{"name":"Chemical_Formula","value":"C17H19N5O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MK2A783ZUT"},{"name":"Legacy Concept Name","value":"Piritrexim"},{"name":"Maps_To","value":"Piritrexim"},{"name":"NCI_Drug_Dictionary_ID","value":"40070"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40070"},{"name":"PDQ_Open_Trial_Search_ID","value":"40070"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0054332"}]}}{"C91407":{"preferredName":"Piritrexim Isethionate","code":"C91407","definitions":[{"definition":"The isethionate salt of piritrexim, a synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piritrexim Isethionate","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine mono(2-hydroxyethanesulfonate)","termGroup":"SN","termSource":"NCI"},{"termName":"BW-301U Isethionate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"79483-69-5"},{"name":"Chemical_Formula","value":"C17H19N5O2.C2H6O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V77I71FH72"},{"name":"Maps_To","value":"Piritrexim Isethionate"},{"name":"NSC Number","value":"351521"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522061"}]}}{"C121960":{"preferredName":"Pirotinib","code":"C121960","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with potential antineoplastic activity. Upon administration, pirotinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4). This may result in the inhibition of cell growth and angiogenesis in tumors overexpressing these RTKs. EGFRs play major roles in both tumor cell proliferation and tumor vascularization, and are overexpressed in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pirotinib","termGroup":"PT","termSource":"NCI"},{"termName":"KBP-5209","termGroup":"CN","termSource":"NCI"},{"termName":"KBP5209","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pirotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"772247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772247"},{"name":"PDQ_Open_Trial_Search_ID","value":"772247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054177"}]}}{"C1182":{"preferredName":"Piroxantrone","code":"C1182","definitions":[{"definition":"An anthrapyrazole antineoplastic antibiotic.  Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piroxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra(1,9-cd)pyrazol-6(2H)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)","termGroup":"SN","termSource":"NCI"},{"termName":"CI-942","termGroup":"CN","termSource":"NCI"},{"termName":"Oxanthrazole","termGroup":"SY","termSource":"NCI"},{"termName":"Oxantrazole","termGroup":"SY","termSource":"NCI"},{"termName":"PD-111815","termGroup":"CN","termSource":"NCI"},{"termName":"Piroxantrone HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91441-23-5"},{"name":"Chemical_Formula","value":"C21H25N5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YL4TY9WH22"},{"name":"Legacy Concept Name","value":"Piroxantrone"},{"name":"Maps_To","value":"Piroxantrone"},{"name":"NCI_Drug_Dictionary_ID","value":"40791"},{"name":"NSC Number","value":"349174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40791"},{"name":"PDQ_Open_Trial_Search_ID","value":"40791"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069736"}]}}{"C72829":{"preferredName":"Piroxantrone Hydrochloride","code":"C72829","definitions":[{"definition":"The hydrochloride salt form of piroxantrone, an anthrapyrazole antineoplastic antibiotic. Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Piroxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"105118-12-5"},{"name":"Chemical_Formula","value":"C21H25N5O4.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PS51OZG63Z"},{"name":"Legacy Concept Name","value":"Piroxantrone_Hydrochloride"},{"name":"Maps_To","value":"Piroxantrone Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347520"}]}}{"C26663":{"preferredName":"Pixantrone","code":"C26663","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pixantrone","termGroup":"PT","termSource":"NCI"},{"termName":"6,9-Bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144510-96-3"},{"name":"Chemical_Formula","value":"C17H19N5O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F5SXN2KNMR"},{"name":"Legacy Concept Name","value":"Pixantrone"},{"name":"Maps_To","value":"Pixantrone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253355"}]}}{"C82398":{"preferredName":"Pixantrone Dimaleate","code":"C82398","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pixantrone Dimaleate","termGroup":"PT","termSource":"NCI"},{"termName":"6,9-Bis((2-Aminoethyl)Amino)Benzo(g)Isoquinoline-5,10-Dione (2z)-But-2-Enedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"BBR 2778","termGroup":"CN","termSource":"NCI"},{"termName":"BBR-2778","termGroup":"CN","termSource":"NCI"},{"termName":"BBR2778","termGroup":"CN","termSource":"NCI"},{"termName":"Benz(g)Isoquinoline-5,10-Dione, 6,9-Bis((2-Aminoethyl)Amino)-, (2z)-2-Butenedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"Pixantrone Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"Pixuvri","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-Hodgkin's lyphoma"},{"name":"CAS_Registry","value":"144675-97-8"},{"name":"Chemical_Formula","value":"C17H19N5O2.2C4H4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P0R64C4CR9"},{"name":"Legacy Concept Name","value":"Pixantrone_Dimaleate"},{"name":"Maps_To","value":"Pixantrone Dimaleate"},{"name":"NCI_Drug_Dictionary_ID","value":"269678"},{"name":"NCI_META_CUI","value":"CL408667"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269678"},{"name":"PDQ_Open_Trial_Search_ID","value":"269678"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1810":{"preferredName":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231","code":"C1810","definitions":[{"definition":"A drug that may inhibit the growth of malignant tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A mixed backbone oligonucleotide exhibiting antitumor activity.  GEM-231 is complementary to the RI alpha subunit of Protein Kinase A (PKA), resulting in downregulation of PKA expression and ultimately tumor growth. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231","termGroup":"PT","termSource":"NCI"},{"termName":"GEM 231","termGroup":"CN","termSource":"NCI"},{"termName":"GEM-231","termGroup":"CN","termSource":"NCI"},{"termName":"GEM231","termGroup":"CN","termSource":"NCI"},{"termName":"Gene Expression Modulator 231","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GEM_231"},{"name":"Maps_To","value":"PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231"},{"name":"NCI_Drug_Dictionary_ID","value":"42971"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42971"},{"name":"PDQ_Open_Trial_Search_ID","value":"42971"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677981"}]}}{"C1788":{"preferredName":"Aprinocarsen","code":"C1788","definitions":[{"definition":"A substance that is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, aprinocarsen hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aprinocarsen","termGroup":"PT","termSource":"NCI"},{"termName":"Affinitac","termGroup":"BR","termSource":"NCI"},{"termName":"Affinitak","termGroup":"BR","termSource":"NCI"},{"termName":"CGP 64128A","termGroup":"CN","termSource":"NCI"},{"termName":"DNA, d(P-thio)(GTTCTCGCTGGTGAGTTTCA)","termGroup":"SY","termSource":"NCI"},{"termName":"ISIS 3521","termGroup":"CN","termSource":"NCI"},{"termName":"LY900003","termGroup":"CN","termSource":"NCI"},{"termName":"Protein Kinase C-Alpha Antisense","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151879-73-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FMT95051CQ"},{"name":"Legacy Concept Name","value":"ISIS_3521"},{"name":"Maps_To","value":"Aprinocarsen"},{"name":"Maps_To","value":"PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521"},{"name":"NCI_Drug_Dictionary_ID","value":"42953"},{"name":"NSC Number","value":"719337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42953"},{"name":"PDQ_Open_Trial_Search_ID","value":"42953"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0666551"}]}}{"C148422":{"preferredName":"PKC-beta Inhibitor MS-553","code":"C148422","definitions":[{"definition":"An orally available inhibitor of the beta-isoform of protein kinase C (PKC), with potential immunosuppressive and antineoplastic activities. Upon oral administration, PKC-beta inhibitor MS-553 selectively binds to and inhibits PKC-beta, which prevents the activation of PKC-beta-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC-beta, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PKC-beta Inhibitor MS-553","termGroup":"PT","termSource":"NCI"},{"termName":"MS 553","termGroup":"CN","termSource":"NCI"},{"termName":"MS-553","termGroup":"CN","termSource":"NCI"},{"termName":"MS553","termGroup":"CN","termSource":"NCI"},{"termName":"PKC-b Inhibitor MS-553","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PKC-beta Inhibitor MS-553"},{"name":"NCI_Drug_Dictionary_ID","value":"795373"},{"name":"NCI_META_CUI","value":"CL550994"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795373"},{"name":"PDQ_Open_Trial_Search_ID","value":"795373"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C753":{"preferredName":"Placebo","code":"C753","definitions":[{"definition":"A pharmaceutical preparation that does not contain the investigational agent and is generally prepared to be physically indistinguishable from the preparation containing the investigational product.","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","type":"DEFINITION","source":"NCI"},{"definition":"Something that looks like the treatment being studied, but doesn't contain any medicine. (https://mrctcenter.org/glossaryterm/placebo/)","type":"ALT_DEFINITION","source":"MRCT-Ctr"}],"synonyms":[{"termName":"Placebo","termGroup":"PT","termSource":"NCI"},{"termName":"PLCB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MRCT-Ctr"},{"name":"Legacy Concept Name","value":"Placebo"},{"name":"Maps_To","value":"Placebo"},{"name":"NCI_Drug_Dictionary_ID","value":"43469"},{"name":"NCI_META_CUI","value":"CL473981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43469"},{"name":"PDQ_Open_Trial_Search_ID","value":"43469"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C69005":{"preferredName":"Pladienolide Derivative E7107","code":"C69005","definitions":[{"definition":"A synthetic urethane derivative of pladienolide D with potential antineoplastic activity. Pladienolide derivative E7107 is generated from the 12-membered macrolide pladienolide D, one of several macrolides derived from the bacterium Streptomyces platensis Mer-11107. This agent appears to bind to the 130-kDa subunit 3 (spliceosome-associated protein 130; SAP130) of the splicing factor 3b (SF3b), resulting in inhibition of pre-messenger RNA splicing and the arrest of cell-cycle progression. The splicing factor SF3b is a multiprotein complex integral to the accurate excision of introns from pre-messenger RNA; the subunit SAP130 associates with U2 snRNP and is recruited to prespliceosomal complexes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pladienolide Derivative E7107","termGroup":"PT","termSource":"NCI"},{"termName":"E7107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"630100-90-2"},{"name":"Chemical_Formula","value":"C40H66N2O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R60DZX1E2N"},{"name":"Legacy Concept Name","value":"Pladienolide_Derivative_E7107"},{"name":"Maps_To","value":"Pladienolide Derivative E7107"},{"name":"NCI_Drug_Dictionary_ID","value":"546981"},{"name":"NCI_META_CUI","value":"CL375254"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546981"},{"name":"PDQ_Open_Trial_Search_ID","value":"546981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C756":{"preferredName":"Platinum","code":"C756","definitions":[{"definition":"A metal that is an important component of some anticancer drugs, such as cisplatin and carboplatin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An element with atomic symbol Pt, atomic number 78, and atomic weight 195.09.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum","termGroup":"PT","termSource":"NCI"},{"termName":"C.I. 77795","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum Metallicum","termGroup":"SY","termSource":"NCI"},{"termName":"Pt","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7440-06-4"},{"name":"CHEBI_ID","value":"CHEBI:33364"},{"name":"CHEBI_ID","value":"CHEBI:33400"},{"name":"Chemical_Formula","value":"Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"49DFR088MY"},{"name":"Legacy Concept Name","value":"Platinum"},{"name":"Maps_To","value":"Platinum"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"UMLS_CUI","value":"C0032207"}]}}{"C153425":{"preferredName":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles","code":"C153425","definitions":[{"definition":"A preparation of platinum acetylacetonate supported by sol-gel technology functionalized titania, with potential antineoplastic activity. Upon intravenous administration, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the nanoparticle formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"NPt","termGroup":"CN","termSource":"NCI"},{"termName":"NPt Nanomaterial","termGroup":"SY","termSource":"NCI"},{"termName":"NPt Nanoparticles","termGroup":"SY","termSource":"NCI"},{"termName":"NPt-Ca","termGroup":"CN","termSource":"NCI"},{"termName":"Sol-gel NPt Nanomaterial","termGroup":"SY","termSource":"NCI"},{"termName":"Sol-gel NPt Nanoparticles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Platinum Acetylacetonate-Titanium Dioxide Nanoparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"793980"},{"name":"NCI_META_CUI","value":"CL554861"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793980"},{"name":"PDQ_Open_Trial_Search_ID","value":"793980"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1450":{"preferredName":"Platinum Compound","code":"C1450","definitions":[{"definition":"A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum Compound","termGroup":"PT","termSource":"NCI"},{"termName":"Platinum Agents","termGroup":"SY","termSource":"NCI"},{"termName":"Platinum-Based Chemotherapeutic Agent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:33749"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Platinum_Compound"},{"name":"Maps_To","value":"Platinum Compound"},{"name":"Semantic_Type","value":"Chemical Viewed Structurally"},{"name":"UMLS_CUI","value":"C0206135"}]}}{"C1629":{"preferredName":"Plevitrexed","code":"C1629","definitions":[{"definition":"An orally bioavailable, small molecule, non-polyglutamatable, antifolate quinazoline derivative thymidine synthetase inhibitor with potential antineoplastic activity. Plevitrexed is transported into the cell via the physiological reduced folate carrier (RFC) system. Intracellularly, this agent selectively binds to the folate binding site of thymidylate synthase and inhibits thymidine synthesis, which may result in DNA synthesis inhibition and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plevitrexed","termGroup":"PT","termSource":"NCI"},{"termName":"(alphaS)-alpha-[[4-[[(1,4-Dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-1H-tetrazole-5-butanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BGC 9331","termGroup":"CN","termSource":"NCI"},{"termName":"Vamidex","termGroup":"SY","termSource":"NCI"},{"termName":"Vamydex","termGroup":"SY","termSource":"NCI"},{"termName":"ZD9331","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"153537-73-6"},{"name":"Chemical_Formula","value":"C26H25FN8O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L9P2881C3H"},{"name":"Legacy Concept Name","value":"ZD9331"},{"name":"Maps_To","value":"Plevitrexed"},{"name":"NCI_Drug_Dictionary_ID","value":"38264"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38264"},{"name":"PDQ_Open_Trial_Search_ID","value":"38264"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299046"}]}}{"C658":{"preferredName":"Plicamycin","code":"C658","definitions":[{"definition":"A drug used to treat some types of testicular cancer. It is also used to treat a higher-than-normal amounts of calcium in the blood or urine. Plicamycin binds to DNA and prevents cells from making RNA and proteins. It is a type of antineoplastic antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plicamycin","termGroup":"PT","termSource":"NCI"},{"termName":"A-2371","termGroup":"CN","termSource":"NCI"},{"termName":"Aureolic acid","termGroup":"SY","termSource":"NCI"},{"termName":"Mithracin","termGroup":"BR","termSource":"NCI"},{"termName":"Mithracine","termGroup":"FB","termSource":"NCI"},{"termName":"Mithramycin","termGroup":"SY","termSource":"NCI"},{"termName":"MTH","termGroup":"AB","termSource":"NCI"},{"termName":"PA-144","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18378-89-7"},{"name":"CHEBI_ID","value":"CHEBI:31856"},{"name":"Chemical_Formula","value":"C52H76O24"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"NIJ123W41V"},{"name":"Legacy Concept Name","value":"Plicamycin"},{"name":"Maps_To","value":"Plicamycin"},{"name":"NCI_Drug_Dictionary_ID","value":"41738"},{"name":"NSC Number","value":"24559"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41738"},{"name":"PDQ_Open_Trial_Search_ID","value":"41738"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0026234"}]}}{"C62444":{"preferredName":"Plinabulin","code":"C62444","definitions":[{"definition":"An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively targets and binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics. This disrupts mitotic spindle assembly leading to cell cycle arrest at M phase and blockage of cell division. In addition, plinabulin may also inhibit growth of proliferating vascular endothelial cells, thereby disrupting the function of tumor vasculature that further contributes to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plinabulin","termGroup":"PT","termSource":"NCI"},{"termName":"(3Z,6Z)-6-benzylidene-3-{[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylidene}piperazine-2,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"NPI 2358","termGroup":"CN","termSource":"NCI"},{"termName":"NPI-2358","termGroup":"CN","termSource":"NCI"},{"termName":"NPI2358","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"714272-27-2"},{"name":"Chemical_Formula","value":"C19H20N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"986FY7F8XR"},{"name":"Legacy Concept Name","value":"NPI-2358"},{"name":"Maps_To","value":"Plinabulin"},{"name":"NCI_Drug_Dictionary_ID","value":"488984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488984"},{"name":"PDQ_Open_Trial_Search_ID","value":"488984"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1741609"}]}}{"C1689":{"preferredName":"Plitidepsin","code":"C1689","definitions":[{"definition":"A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It is obtained from a marine organism.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plitidepsin","termGroup":"PT","termSource":"NCI"},{"termName":"APLD","termGroup":"AB","termSource":"NCI"},{"termName":"Aplidin","termGroup":"BR","termSource":"NCI"},{"termName":"Aplidine","termGroup":"SY","termSource":"NCI"},{"termName":"DDB","termGroup":"AB","termSource":"NCI"},{"termName":"Dehydrodemnin B","termGroup":"SY","termSource":"NCI"},{"termName":"Dehydrodidemnin B","termGroup":"SY","termSource":"NCI"},{"termName":"N-[1-(1,2-Dioxopropyl)-L-prolyl]didemnin A","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"137219-37-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y76ID234HW"},{"name":"Legacy Concept Name","value":"Aplidine"},{"name":"Maps_To","value":"Plitidepsin"},{"name":"NCI_Drug_Dictionary_ID","value":"460052"},{"name":"NSC Number","value":"638719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"460052"},{"name":"PDQ_Open_Trial_Search_ID","value":"460052"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0388638"}]}}{"C49091":{"preferredName":"Plk1 Inhibitor BI 2536","code":"C49091","definitions":[{"definition":"A small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It prevents cells from dividing and may block the growth of some tumors. It is a type of mitotic inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plk1 Inhibitor BI 2536","termGroup":"PT","termSource":"NCI"},{"termName":"BI 2536","termGroup":"CN","termSource":"NCI"},{"termName":"BI-2536","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"755038-02-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4LJG22T9C6"},{"name":"Legacy Concept Name","value":"BI_2536"},{"name":"Maps_To","value":"Plk1 Inhibitor BI 2536"},{"name":"NCI_Drug_Dictionary_ID","value":"452943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"452943"},{"name":"PDQ_Open_Trial_Search_ID","value":"452943"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706888"}]}}{"C162375":{"preferredName":"Plogosertib","code":"C162375","definitions":[{"definition":"A competitive inhibitor for adenosine triphosphate (ATP) binding to polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, plogosertib selectively targets, binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation, transformation and invasion. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plogosertib","termGroup":"PT","termSource":"NCI"},{"termName":"CYC 140","termGroup":"CN","termSource":"NCI"},{"termName":"CYC-140","termGroup":"CN","termSource":"NCI"},{"termName":"CYC140","termGroup":"CN","termSource":"NCI"},{"termName":"PLK-1 Inhibitor CYC140","termGroup":"SY","termSource":"NCI"},{"termName":"PLK1 Inhibitor CYC140","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor CYC140","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1137212-79-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IW5U2LC9XI"},{"name":"Maps_To","value":"PLK1 Inhibitor CYC140"},{"name":"NCI_Drug_Dictionary_ID","value":"798706"},{"name":"NCI_META_CUI","value":"CL970820"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798706"},{"name":"PDQ_Open_Trial_Search_ID","value":"798706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92587":{"preferredName":"PLK1 Inhibitor TAK-960","code":"C92587","definitions":[{"definition":"An orally available, Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressed tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PLK1 Inhibitor TAK-960","termGroup":"PT","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor TAK-960","termGroup":"SY","termSource":"NCI"},{"termName":"TAK-960","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1137868-52-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3831VFM1ZB"},{"name":"Maps_To","value":"PLK1 Inhibitor TAK-960"},{"name":"NCI_Drug_Dictionary_ID","value":"683854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683854"},{"name":"PDQ_Open_Trial_Search_ID","value":"683854"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2985196"}]}}{"C95888":{"preferredName":"Plocabulin","code":"C95888","definitions":[{"definition":"A marine-derived, synthetically produced compound with potential antineoplastic activity. Plocabulin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plocabulin","termGroup":"PT","termSource":"NCI"},{"termName":"PM-060184","termGroup":"CN","termSource":"NCI"},{"termName":"PM060184","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"960210-99-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"52Y8L60CR7"},{"name":"Maps_To","value":"Plocabulin"},{"name":"NCI_Drug_Dictionary_ID","value":"696184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696184"},{"name":"PDQ_Open_Trial_Search_ID","value":"696184"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272412"}]}}{"C88308":{"preferredName":"Plozalizumab","code":"C88308","definitions":[{"definition":"A humanized monoclonal antibody directed against the human chemokine receptor 2 (CCR2), with potential antiangiogenic, immunomodulating, antimetastatic, and antineoplastic activities. Plozalizumab binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and so inhibition of angiogenesis, tumor cell migration, and tumor cell proliferation. In addition, this agent may reduce levels of C-reactive protein (CRP). The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied as a treatment for atherosclerosis (a build-up of fat in the arteries). It is also being studied in the treatment of cancers that spread to the bone. Anti-CCR2 monoclonal antibody MLN1202 binds to a protein called CCR2, which is found on the surface of certain bone cells, white blood cells, and cancer cells. Anti-CCR2 monoclonal antibody MLN1202 blocks the action of a substance that is involved in keeping healthy bone mass. It may help keep the cancer cells from spreading to and growing in the bone. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Plozalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human CC Chemokine Receptor CCR2) (Human-mus musculus Monoclonal 1d9 Heavy Chain), Disulfide with Human-mus musculus Monoclonal 1d9 kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"MLN1202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610761-46-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4XG66BMN0D"},{"name":"Maps_To","value":"Plozalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"659685"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659685"},{"name":"PDQ_Open_Trial_Search_ID","value":"659685"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981824"}]}}{"C126798":{"preferredName":"Pidnarulex","code":"C126798","definitions":[{"definition":"An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, pidnarulex selectively binds to and inhibits Pol I, prevents Pol I-mediated ribosomal RNA (rRNA) synthesis, induces apoptosis, and inhibits tumor cell growth. Pol I, the multiprotein complex that synthesizes rRNA, is upregulated in cancer cells and plays a key role in cell proliferation and survival. Hyperactivated rRNA transcription is associated with uncontrolled cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pidnarulex","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"2-(4-Methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"CX-5461","termGroup":"CN","termSource":"NCI"},{"termName":"CX5461","termGroup":"CN","termSource":"NCI"},{"termName":"Pol I Inhibitor CX5461","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Pol I Inhibitor CX5461","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1138549-36-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3R4C5YLB9I"},{"name":"Maps_To","value":"Pol I Inhibitor CX5461"},{"name":"NCI_Drug_Dictionary_ID","value":"780145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780145"},{"name":"PDQ_Open_Trial_Search_ID","value":"780145"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3180849"}]}}{"C104153":{"preferredName":"Polatuzumab Vedotin","code":"C104153","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polatuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DCDS4501A","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-Drug Conjugate DCDS4501A","termGroup":"SY","termSource":"NCI"},{"termName":"DCDS4501A","termGroup":"CN","termSource":"NCI"},{"termName":"FCU 2711","termGroup":"CN","termSource":"NCI"},{"termName":"FCU-2711","termGroup":"CN","termSource":"NCI"},{"termName":"FCU2711","termGroup":"CN","termSource":"NCI"},{"termName":"polatuzumab vedotin-piiq","termGroup":"SY","termSource":"NCI"},{"termName":"Polivy","termGroup":"BR","termSource":"NCI"},{"termName":"RG 7596","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7596","termGroup":"CN","termSource":"NCI"},{"termName":"RG7596","termGroup":"CN","termSource":"NCI"},{"termName":"Ro 5541077-000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"},{"name":"CAS_Registry","value":"1313206-42-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"KG6VO684Z6"},{"name":"Maps_To","value":"Polatuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"695317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695317"},{"name":"PDQ_Open_Trial_Search_ID","value":"695317"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4078806"}]}}{"C158511":{"preferredName":"Polidocanol","code":"C158511","definitions":[{"definition":"An alkyl polyglycol ether of lauryl alcohol with sclerosing and potential antineoplastic activities. Upon intralesional administration, polidocanol induces endothelial cell injury by disrupting calcium signaling and nitric oxide pathways. Following endothelial damage, platelets aggregate at the site of injury and attach to the venous wall, resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Inducing endothelial cell damage within melanoma metastases may incite an antitumor response in untreated bystander lesions and inhibit the growth of in transit metastases and other cutaneous lesions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polidocanol","termGroup":"PT","termSource":"NCI"},{"termName":"Aethoxysklerol","termGroup":"FB","termSource":"NCI"},{"termName":"Asclera","termGroup":"BR","termSource":"NCI"},{"termName":"Dodecylnonaoxyethylene Glycol Monoether","termGroup":"SY","termSource":"NCI"},{"termName":"Laureth 9","termGroup":"SY","termSource":"NCI"},{"termName":"Laureth-9","termGroup":"SY","termSource":"NCI"},{"termName":"Lauromacrogol 400","termGroup":"SY","termSource":"NCI"},{"termName":"Nonaethylene Glycol Monododecyl Ether","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3055-99-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0AWH8BFG9A"},{"name":"Maps_To","value":"Polidocanol"},{"name":"NCI_Drug_Dictionary_ID","value":"797212"},{"name":"NCI_META_CUI","value":"CL563467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797212"},{"name":"PDQ_Open_Trial_Search_ID","value":"797212"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157372":{"preferredName":"Poliglusam","code":"C157372","definitions":[{"definition":"A naturally occurring polysaccharide composed of beta-1,4-linked glucosamine residues with potential antineoplastic activity. Upon administration, poliglusam may, through a not yet fully elucidated mechanism, reduce advanced glycation end product (AGE) levels. This may reduce the interaction between AGEs and the receptor for advanced glycation end products (RAGE, AGER), which is overexpressed in some tumor types and is associated with poor patient outcomes. AGE-RAGE interaction may induce the phosphorylation and subsequent degradation of retinoblastoma protein (Rb), a key cell cycle inhibitor and tumor suppressor, through the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) signaling pathway. Hyperphosphorylation of Rb leads to the dissociation of the Rb-E2F complex, which triggers the activation of genes required for G1/S transition and tumorigenesis. Reducing AGE levels may limit AGE-RAGE interaction and normalize the G1 to S-phase transition, potentially reducing the development and progression of certain cancers. AGEs are non-enzymatic protein modifications produced during the normal aging process that have been shown to play a role in the development and progression of some cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poliglusam","termGroup":"PT","termSource":"NCI"},{"termName":"Chitosan","termGroup":"SY","termSource":"NCI"},{"termName":"Deacetylchitin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9012-76-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"82LKS4QV2Y"},{"name":"Maps_To","value":"Poliglusam"},{"name":"NCI_Drug_Dictionary_ID","value":"796923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796923"},{"name":"PDQ_Open_Trial_Search_ID","value":"796923"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0162969"}]}}{"C70948":{"preferredName":"Polo-like Kinase 1 Inhibitor GSK461364","code":"C70948","definitions":[{"definition":"A small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polo-like Kinase 1 Inhibitor GSK461364","termGroup":"PT","termSource":"NCI"},{"termName":"GSK461364","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"929095-18-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8QO27TK6Q4"},{"name":"Legacy Concept Name","value":"Polo-like_Kinase_1_Inhibitor_GSK461364"},{"name":"Maps_To","value":"Polo-like Kinase 1 Inhibitor GSK461364"},{"name":"NCI_Drug_Dictionary_ID","value":"573587"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573587"},{"name":"PDQ_Open_Trial_Search_ID","value":"573587"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347618"}]}}{"C82389":{"preferredName":"Polo-like Kinase 1 Inhibitor MK1496","code":"C82389","definitions":[{"definition":"An orally bioavailable Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor MK1496 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polo-like Kinase 1 Inhibitor MK1496","termGroup":"PT","termSource":"NCI"},{"termName":"MK1496","termGroup":"CN","termSource":"NCI"},{"termName":"PLK1 Inhibitor MK1496","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polo-like_Kinase_1_Inhibitor_MK1496"},{"name":"Maps_To","value":"Polo-like Kinase 1 Inhibitor MK1496"},{"name":"NCI_Drug_Dictionary_ID","value":"642286"},{"name":"NCI_META_CUI","value":"CL408660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642286"},{"name":"PDQ_Open_Trial_Search_ID","value":"642286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111990":{"preferredName":"Ocifisertib Fumarate","code":"C111990","definitions":[{"definition":"An orally available fumarate salt form of CFI-400945, a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon oral administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ocifisertib Fumarate","termGroup":"PT","termSource":"NCI"},{"termName":"CFI 400945 Fumarate","termGroup":"SY","termSource":"NCI"},{"termName":"CFI-400945","termGroup":"CN","termSource":"NCI"},{"termName":"CFI-400945 Fumarate","termGroup":"SY","termSource":"NCI"},{"termName":"PLK4 Inhibitor CFI-400945 Fumarate","termGroup":"SY","termSource":"NCI"},{"termName":"Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616420-30-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"09OB3E5QTD"},{"name":"Maps_To","value":"Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate"},{"name":"NCI_Drug_Dictionary_ID","value":"754001"},{"name":"NCI_META_CUI","value":"CL454279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754001"},{"name":"PDQ_Open_Trial_Search_ID","value":"754001"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101894":{"preferredName":"Poly-alendronate Dextran-Guanidine Conjugate","code":"C101894","definitions":[{"definition":"A polybisphosphonate dextran-guanidine conjugate with potential anti-resorptive and antineoplastic activities. Alendronic acid and aminoguanidine were conjugated sequentially to oxidized dextran resulting in an average of 8 alendronate and 50 guanidine groups coupled to the dextran backbone. Upon administration, the poly-alendronate dextran-guanidine conjugate inhibits the mevalonate pathway by inhibiting farnesyl diphosphate synthase (FDPS) which leads to a reduction in protein prenylation and to the loss of downstream metabolites essential for osteoclast function. This eventually leads to the induction of apoptosis in osteoclasts. Also, by preventing osteoclast-mediated bone resorption, this agent decreases bone turnover and stabilizes the bone matrix. The guanidine moiety increases the nitrogen content and possibly the activity of the bisphosphonate and its ability to inhibit FDPS. In addition, the guanidine moiety facilitates cell internalization and may contribute to this agent's cytotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly-alendronate Dextran-Guanidine Conjugate","termGroup":"PT","termSource":"NCI"},{"termName":"Dextran/Alendronate/Guanidine-containing Polybisphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"ODX","termGroup":"AB","termSource":"NCI"},{"termName":"Osteodex","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Poly-alendronate Dextran-Guanidine Conjugate"},{"name":"NCI_Drug_Dictionary_ID","value":"733915"},{"name":"NCI_META_CUI","value":"CL436277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733915"},{"name":"PDQ_Open_Trial_Search_ID","value":"733915"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106124":{"preferredName":"Poly-gamma Glutamic Acid","code":"C106124","definitions":[{"definition":"A water-soluble and biodegradable polymer naturally synthesized by various strains of Bacillus and composed of D- and L-glutamic acid polymerized via gamma-amide linkages, with potential antineoplastic activity. Upon administration, poly-gamma glutamic acid may augment the immune response by increasing the production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) and inducing the activation of macrophage and natural killer (NK) cells. IFN-gamma is a major mediator of innate and adaptive immunity against viral and intracellular bacterial infections as well as for tumor control. TNF-alpha is a cytokine involved in systemic inflammation, which is capable of inducing apoptotic cell death and exhibits anti-tumoral effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly-gamma Glutamic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"gamma-PGA","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-polyglutamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Poly-gamma-glutamate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Poly-gamma Glutamic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"748858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748858"},{"name":"PDQ_Open_Trial_Search_ID","value":"748858"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1723263"}]}}{"C38130":{"preferredName":"Polyamine Analog SL11093","code":"C38130","definitions":[{"definition":"A synthetic compound of the polyamine class of chemicals with potential antineoplastic activity. Natural endogenous polyamines bind to DNA and are involved in a number of cellular processes such as cell division, differentiation, and membrane function. SL11093 displaces these polyamines from their DNA binding sites, resulting in cessation of cell growth and cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyamine Analog SL11093","termGroup":"PT","termSource":"NCI"},{"termName":"3,8,13,18-Tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane Tetrahydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CGC 11093","termGroup":"CN","termSource":"NCI"},{"termName":"CGC-11093","termGroup":"CN","termSource":"NCI"},{"termName":"CGC11093","termGroup":"CN","termSource":"NCI"},{"termName":"SL 11093","termGroup":"CN","termSource":"NCI"},{"termName":"SL-11093","termGroup":"CN","termSource":"NCI"},{"termName":"SL11093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SL11093"},{"name":"Maps_To","value":"Polyamine Analog SL11093"},{"name":"NSC Number","value":"724908"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1259818"}]}}{"C60816":{"preferredName":"Polyamine Analogue PG11047","code":"C60816","definitions":[{"definition":"A second generation polyamine analogue, synthesized through the restriction of molecular conformations of parent polyamine compounds, with potential antineoplastic activity. Polyamine analogue PG11047 may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of lymphoma. It belongs to the family of drugs called polyamine analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Polyamine Analogue PG11047","termGroup":"PT","termSource":"NCI"},{"termName":"BESpm","termGroup":"AB","termSource":"NCI"},{"termName":"CGC-11047","termGroup":"CN","termSource":"NCI"},{"termName":"N(1),-N(12)-bis(ethyl)-cis-6,7-dehydrospermine","termGroup":"SN","termSource":"NCI"},{"termName":"N(1),-N(12)-bis(ethyl)-cis-6,7-dehydrospermine tetrahydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N(1),N(12)-bisethylspermine","termGroup":"SN","termSource":"NCI"},{"termName":"PG11047","termGroup":"CN","termSource":"NCI"},{"termName":"SL11047","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"206991-64-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HU43305R7O"},{"name":"Legacy Concept Name","value":"SL11047"},{"name":"Maps_To","value":"Polyamine Analogue PG11047"},{"name":"NCI_Drug_Dictionary_ID","value":"467739"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467739"},{"name":"PDQ_Open_Trial_Search_ID","value":"467739"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1963112"}]}}{"C142788":{"preferredName":"Ivospemin Hydrochloride","code":"C142788","definitions":[{"definition":"The hydrochloride salt form of ivospemin, an analogue of naturally occurring polyamine (PA), with potential antineoplastic activity. Upon subcutaneous administration,  ivospemin displaces endogenous PAs from PA-binding sites on the cell surface, which prevents internalization of PA. This inhibits PA-dependent cell cycle processes and results in cell cycle arrest, the induction of apoptosis, and inhibition of tumor cell proliferation. PA uptake is upregulated in various tumor types and increased levels of PA leads to enhanced tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivospemin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Diethyl Dihydroxyhomospermine","termGroup":"SY","termSource":"NCI"},{"termName":"HO2-DEHSPM","termGroup":"SY","termSource":"NCI"},{"termName":"Polyamine Analogue SBP-101","termGroup":"SY","termSource":"NCI"},{"termName":"SBP 101 Tetrahydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"SBP-101 Tetrahydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"259657-09-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2RKV12BBA7"},{"name":"Maps_To","value":"Polyamine Analogue SBP-101"},{"name":"NCI_Drug_Dictionary_ID","value":"791597"},{"name":"NCI_META_CUI","value":"CL540733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791597"},{"name":"PDQ_Open_Trial_Search_ID","value":"791597"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148487":{"preferredName":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate","code":"C148487","definitions":[{"definition":"The dicaprate salt form of AMXT-1501, an orally bioavailable polyamine transport inhibitor, with immunostimulating and antineoplastic activities.  Upon administration, AMXT-1501 targets, binds to and blocks polyamine transport from the bloodstream into the tumor microenvironment (TME), thereby preventing cancer cell uptake. This decreases polyamine concentrations inside the TME and tumor cell, inhibits tumor cell proliferation and induces apoptosis. In addition, AMXT-1501 may abrogate polyamine-mediated immune suppression in the TME. Polyamines, naturally found in normal, heathy cells, are required for normal cell growth and division. In cancer cells, polyamines play key roles in tumor cell proliferation and tumor-induced suppression of the patient's immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate","termGroup":"PT","termSource":"NCI"},{"termName":"AMX 513 Dicaprate","termGroup":"SY","termSource":"NCI"},{"termName":"AMX513 Dicaprate","termGroup":"SY","termSource":"NCI"},{"termName":"AMXT 1501 Dicaprate","termGroup":"SY","termSource":"NCI"},{"termName":"AMXT-1501 Dicaprate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polyamine Transport Inhibitor AMXT-1501 Dicaprate"},{"name":"NCI_Drug_Dictionary_ID","value":"792572"},{"name":"NCI_META_CUI","value":"CL551058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792572"},{"name":"PDQ_Open_Trial_Search_ID","value":"792572"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1628":{"preferredName":"Polyandrol","code":"C1628","definitions":[{"definition":"A quassinoid phytochemical isolated from Castela polyandra and other plant species with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyandrol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polyandrol"},{"name":"Maps_To","value":"Polyandrol"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0298893"}]}}{"C92583":{"preferredName":"Polyethylene Glycol Recombinant Endostatin","code":"C92583","definitions":[{"definition":"A formulation containing recombinant endostatin attached to polyethylene glycol (PEG), with potential anti-angiogenic and antineoplastic activities. Endostatin, a 20 kDa C-terminal proteolytic fragment of collagen XVIII, induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction of tumor cell growth. Modification with PEG extends the circulation half-life of endostatin, improves stability and increases solubility in organic solvents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyethylene Glycol Recombinant Endostatin","termGroup":"PT","termSource":"NCI"},{"termName":"M2ES","termGroup":"CN","termSource":"NCI"},{"termName":"M2ES","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SLQ3VZ4GSC"},{"name":"Maps_To","value":"Polyethylene Glycol Recombinant Endostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"670652"},{"name":"NCI_META_CUI","value":"CL419349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670652"},{"name":"PDQ_Open_Trial_Search_ID","value":"670652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125243":{"preferredName":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318","code":"C125243","definitions":[{"definition":"A long-acting formulation composed of 7-ethyl-10-hydroxycamptothecin (SN38), a camptothecin derivative and active metabolite of irinotecan conjugated to polyethylene glycol (PEG), via a proprietary, cleavable linker, with potential antineoplastic activity. Upon administration, the proprietary linkage system allows for very slow release of SN38 from the formulation. Upon release, SN38 selectively stabilizes covalent topoisomerase I-DNA complexes, and results in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to other PEG-SN38-based formulations, the linker system in DFP-13318 increases its half-life and the exposure time for tumor cells, while decreasing both blood plasma concentrations and exposure to off-target organs; this results in increased efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318","termGroup":"PT","termSource":"NCI"},{"termName":"DFP-13318","termGroup":"CN","termSource":"NCI"},{"termName":"PEG SN38 DFP-13318","termGroup":"SY","termSource":"NCI"},{"termName":"PL 0264","termGroup":"CN","termSource":"NCI"},{"termName":"PL-0264","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-0264","termGroup":"CN","termSource":"NCI"},{"termName":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"Ultra-long Acting PEG-SN38","termGroup":"SY","termSource":"NCI"},{"termName":"Ultra-Long-Acting-PEG-SN-38","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NA676B3565"},{"name":"Maps_To","value":"Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318"},{"name":"NCI_Drug_Dictionary_ID","value":"778327"},{"name":"NCI_META_CUI","value":"CL504040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778327"},{"name":"PDQ_Open_Trial_Search_ID","value":"778327"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150508":{"preferredName":"Polymer-encapsulated Luteolin Nanoparticle","code":"C150508","definitions":[{"definition":"A nanoparticle formulation containing the poorly water-soluble naturally-occurring flavonoid luteolin encapsulated within a water-soluble polymer, with potential anti-oxidant, anti-inflammatory, apoptosis-inducing and chemopreventive activities. Upon administration of the polymer-encapsulated luteolin nanoparticle, luteolin scavenges free radicals, protects cells from reactive oxygen species (ROS)-induced damage and induces direct tumor cell cycle arrest and apoptosis in tumor cells. This inhibits tumor cell proliferation and suppresses metastasis. Compared to luteolin alone, encapsulation increases the delivery of luteolin to the tumor cells by protecting the drug against clearance and degradation, increases blood circulation time and enhances delivery into the tumor through the leaky vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymer-encapsulated Luteolin Nanoparticle","termGroup":"PT","termSource":"NCI"},{"termName":"3',4',5,7-Tetrahydroxyflavone-encapsulated Polymer Nanoparticles","termGroup":"SY","termSource":"NCI"},{"termName":"Nano-luteolin","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoluteolin","termGroup":"SY","termSource":"NCI"},{"termName":"Nanoparticle-based Luteolin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polymer-encapsulated Luteolin Nanoparticle"},{"name":"NCI_Drug_Dictionary_ID","value":"793030"},{"name":"NCI_META_CUI","value":"CL552290"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793030"},{"name":"PDQ_Open_Trial_Search_ID","value":"793030"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C69079":{"preferredName":"Polymeric Camptothecin Prodrug XMT-1001","code":"C69079","definitions":[{"definition":"A polymeric prodrug of camptothecin (CPT) with potential antineoplastic activity. Polymeric camptothecin prodrug XMT-1001 consists of CPT conjugated to the 60-70 kDa, inert, bio-degradable, hydrophilic copolymer poly[1-hydroxymethylene hydroxymethyl formal] (PHF). Through a dual-phase, non-enzymatic release mechanism, CPT is first released in plasma from XMT-1001 as the lipophilic prodrugs CPT-SI (a succinimidoglycinate derivative) and CPT-SA (a succinamidoyl glycinate derivative), which are then hydrolyzed within tissues to release the lactone form of CPT. CPT inhibits the catalytic activity of DNA topoisomerase I, thereby inhibiting DNA replication and inducing apoptosis. This agent may exhibit a more favorable pharmacokinetic profile than other agents in the same class.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymeric Camptothecin Prodrug XMT-1001","termGroup":"PT","termSource":"NCI"},{"termName":"MER-1001","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polymeric_Camptothecin_Prodrug_XMT-1001"},{"name":"Maps_To","value":"Polymeric Camptothecin Prodrug XMT-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"544567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"544567"},{"name":"PDQ_Open_Trial_Search_ID","value":"544567"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347623"}]}}{"C129595":{"preferredName":"Polypodium leucotomos Extract","code":"C129595","definitions":[{"definition":"A nutritional supplement composed of an aqueous extract derived from the leaves of the tropical fern belonging to the Polypodiaceae family, Polypodium leucotomos (PL; Phlebodium aureum), with potential photoprotective, skin protective, anti-inflammatory, immunomodulating and antioxidant activities. This extract contains many phenolic compounds, such as ferulic, caffeic, coumaric and vanillic acid, which are mainly responsible for this extract's effects. Upon administration, Polypodium leucotomos extract (PLE) exerts antioxidant activity by scavenging free radicals and inhibiting the generation and release of reactive oxygen species (ROS), thereby preventing ultraviolet (UV)-induced as well as ROS-induced DNA damage. In addition, the chemicals in this extract protect antioxidant enzymes and modulate expression of cancer and inflammation-related genes, including the induction of the expression of tumor suppressor genes and the inhibition of the expression of pro-inflammatory cytokines and inflammatory enzymes, thereby inhibiting the activation of signal transduction pathways involved in carcinogenesis and inflammation, respectively. PLE also stimulates tissue inhibitors of metalloproteinases (TIMPs) and inhibits matrix metalloproteinases (MMPs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polypodium leucotomos Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Fernblock","termGroup":"FB","termSource":"NCI"},{"termName":"PL Extract","termGroup":"SY","termSource":"NCI"},{"termName":"PLE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polypodium leucotomos Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"783987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783987"},{"name":"PDQ_Open_Trial_Search_ID","value":"783987"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1614561"}]}}{"C1204":{"preferredName":"Polysaccharide-K","code":"C1204","definitions":[{"definition":"A protein-bound polysaccharide derived from the mushroom Trametes versicolor (Turkey Tail) with immunoadjuvant and potential antitumor activities. Although its mechanism of action has yet to be fully elucidated, in vitro and in vivo studies indicate that polysaccharide-K induces peripheral blood monocyte secretion of IL-8 and TNF-alpha, induces T cell proliferation, and prevents cyclophosphamide-induced immunosuppression. This agent has also been reported to stimulate macrophages to produce reactive nitrogen intermediates and superoxide anions and to promote apoptosis in the promyelocytic leukemia cell line HL-60.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polysaccharide-K","termGroup":"PT","termSource":"NCI"},{"termName":"Krestin","termGroup":"FB","termSource":"NCI"},{"termName":"Krestin","termGroup":"BR","termSource":"NCI"},{"termName":"KS-2","termGroup":"AB","termSource":"NCI"},{"termName":"PSK","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66455-27-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polysaccharide-K"},{"name":"Maps_To","value":"Polysaccharide-K"},{"name":"NCI_Drug_Dictionary_ID","value":"39574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39574"},{"name":"PDQ_Open_Trial_Search_ID","value":"39574"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0072522"}]}}{"C1201":{"preferredName":"Polysialic Acid","code":"C1201","definitions":[{"definition":"A highly negative-charged carbohydrate composed of a linear polymer of alpha 2,8-linked sialic acid residue with potential immunotherapeutic activity. Polysialic acid (PSA) is mainly attached to the neural cell adhesion molecule (NCAM), a membrane-bound glycoprotein overexpressed in certain types of cancers. In embryonic tissue PSA-NCAM is abundantly expressed and PSA plays an important role in formation and remodeling of the neural system through modulation of the adhesive properties of NCAM, thereby reducing cell-cell interactions and promoting cellular mobility. In adult tissue however, the expression of PSA-NCAM is associated with a variety of malignant tumors, signifying its potential role in tumor metastasis. When administered in a vaccine formulation, PSA may stimulate a cytotoxic T cell response against tumors expressing PSA, thereby resulting in a reduction in tumor size.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polysialic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"PolySA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:26206"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polysialic_Acid"},{"name":"Maps_To","value":"Polysialic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"37839"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37839"},{"name":"PDQ_Open_Trial_Search_ID","value":"37839"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0071677"}]}}{"C67038":{"preferredName":"Polyunsaturated Fatty Acid","code":"C67038","definitions":[{"definition":"A class of dietary fatty acids containing two or more double bonds.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"A fatty acid containing more than one double bond (C=C). The essential fatty acids omega-3 and omega-6 are polyunsaturated fatty acids (PUFAs) that contain 2 or more cis double bonds. Dietary intake of some PUFAs may have beneficial effects on blood pressure, serum lipds, and inflammation. Some PUFAs, such as omega-3 PUFAs, may have antineoplastic or chemopreventive activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyunsaturated Fatty Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Fatty Acid, Total Polyunsaturated","termGroup":"SY","termSource":"NCI"},{"termName":"Polyunsaturated Fatty Acids","termGroup":"SY","termSource":"NCI"},{"termName":"PUFA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:26208"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"INFOODS","value":"FAPU"},{"name":"Legacy Concept Name","value":"Polyunsaturated_Fatty_Acid"},{"name":"Maps_To","value":"Polyunsaturated Fatty Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"539359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539359"},{"name":"PDQ_Open_Trial_Search_ID","value":"539359"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0032615"},{"name":"Unit","value":"g"},{"name":"USDA_ID","value":"646"}]}}{"C1633":{"preferredName":"Polyvalent Melanoma Vaccine","code":"C1633","definitions":[{"definition":"A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens.  Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polyvalent Melanoma Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"PMCV","termGroup":"AB","termSource":"NCI"},{"termName":"Polyvalent Melanoma Cell Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Polyvalent_Melanoma_Vaccine"},{"name":"Maps_To","value":"Polyvalent Melanoma Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43301"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43301"},{"name":"PDQ_Open_Trial_Search_ID","value":"43301"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0299555"}]}}{"C72560":{"preferredName":"Pomalidomide","code":"C72560","definitions":[{"definition":"A substance being studied in the treatment of prostate cancer, multiple myeloma, and other types of cancer. Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pomalidomide","termGroup":"PT","termSource":"NCI"},{"termName":"3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione","termGroup":"SN","termSource":"NCI"},{"termName":"4-Aminothalidomide","termGroup":"SY","termSource":"NCI"},{"termName":"Actimid","termGroup":"BR","termSource":"NCI"},{"termName":"CC 4047","termGroup":"CN","termSource":"NCI"},{"termName":"CC-4047","termGroup":"CN","termSource":"NCI"},{"termName":"CC4047","termGroup":"CN","termSource":"NCI"},{"termName":"Imnovid","termGroup":"FB","termSource":"NCI"},{"termName":"Pomalyst","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative"},{"name":"CAS_Registry","value":"19171-19-8"},{"name":"Chemical_Formula","value":"C13H11N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D2UX06XLB5"},{"name":"Legacy Concept Name","value":"Pomalidomide"},{"name":"Maps_To","value":"Pomalidomide"},{"name":"NCI_Drug_Dictionary_ID","value":"653314"},{"name":"PDQ_Closed_Trial_Search_ID","value":"653314"},{"name":"PDQ_Open_Trial_Search_ID","value":"653314"},{"name":"PubMedID_Primary_Reference","value":"16085014"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2347624"}]}}{"C26665":{"preferredName":"Pomegranate Juice","code":"C26665","definitions":[{"definition":"A natural juice isolated from the fruit of the plant Punica granatum with antioxidant, potential antineoplastic, and chemopreventive activities.  Pomegranate juice contains flavonoids which promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thereby inhibiting angiogenesis. The flavonoids in pomegranate juice also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pomegranate Juice","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"99S671U9KB"},{"name":"Legacy Concept Name","value":"Pomegranate_Juice"},{"name":"Maps_To","value":"Pomegranate Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"304321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304321"},{"name":"PDQ_Open_Trial_Search_ID","value":"304321"},{"name":"Semantic_Type","value":"Food"},{"name":"UMLS_CUI","value":"C1327962"}]}}{"C78866":{"preferredName":"Pomegranate Liquid Extract","code":"C78866","definitions":[{"definition":"A liquid extract preparation derived from pomegranate (Punica granatum) seeds with antioxidant, and potential antineoplastic and chemopreventive activities. Pomegranate liquid extract contains flavonoids which may promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thus inhibiting angiogenesis. Pomegranate liquid extract flavanoids also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pomegranate Liquid Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Dadima Fruit Water","termGroup":"SY","termSource":"NCI"},{"termName":"Punica granatum Fruit Volatile Oil","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P52EO36K90"},{"name":"Legacy Concept Name","value":"Pomegranate_Liquid_Extract"},{"name":"Maps_To","value":"Pomegranate Liquid Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"613221"},{"name":"NCI_META_CUI","value":"CL387635"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613221"},{"name":"PDQ_Open_Trial_Search_ID","value":"613221"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95777":{"preferredName":"Ponatinib","code":"C95777","definitions":[{"definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ponatinib","termGroup":"PT","termSource":"NCI"},{"termName":"AP 24534","termGroup":"CN","termSource":"NCI"},{"termName":"AP-24534","termGroup":"CN","termSource":"NCI"},{"termName":"AP24534","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943319-70-8"},{"name":"Chemical_Formula","value":"C29H27F3N6O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4340891KFS"},{"name":"Maps_To","value":"Ponatinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987417"}]}}{"C78194":{"preferredName":"Ponatinib Hydrochloride","code":"C78194","definitions":[{"definition":"The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ponatinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"AP24534 HCl","termGroup":"AB","termSource":"NCI"},{"termName":"Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)-, Hydrochloride (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Iclusig","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1114544-31-8"},{"name":"Chemical_Formula","value":"C29H27F3N6O.ClH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96R6PU3D8J"},{"name":"Legacy Concept Name","value":"Multitargeted_Receptor_Tyrosine_Kinase_Inhibitor_AP24534"},{"name":"Maps_To","value":"Ponatinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"595060"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595060"},{"name":"PDQ_Open_Trial_Search_ID","value":"595060"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981174"}]}}{"C146853":{"preferredName":"Porcupine Inhibitor CGX1321","code":"C146853","definitions":[{"definition":"An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic, protective and regenerative activities. Upon oral administration, PORCN inhibitor CGX1321 specifically targets and binds to PORCN in the endoplasmic reticulum (ER), thereby inhibiting the post-translational palmitoylation and secretion of Wnt ligands, thus preventing the activation of Wnt-mediated signaling, and inhibiting cell growth in Wnt-driven tumors. In addition, by inhibiting the secretion of Wnt ligands and preventing Wnt-mediated signaling, CGX1321 may also limit fibrosis and promote regeneration of certain tissues upon cell injury. PORCN catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers and plays a key role in tumor cell proliferation. It also plays a key role in tissue regeneration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor CGX1321","termGroup":"PT","termSource":"NCI"},{"termName":"CGX 1321","termGroup":"CN","termSource":"NCI"},{"termName":"CGX-1321","termGroup":"CN","termSource":"NCI"},{"termName":"CGX1321","termGroup":"CN","termSource":"NCI"},{"termName":"PORCN Inhibitor CGX1321","termGroup":"SY","termSource":"NCI"},{"termName":"WNT Signaling Inhibitor CGX1321","termGroup":"SY","termSource":"NCI"},{"termName":"WTN Inhibitor CGX1321","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Porcupine Inhibitor CGX1321"},{"name":"NCI_Drug_Dictionary_ID","value":"792268"},{"name":"NCI_META_CUI","value":"CL544835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792268"},{"name":"PDQ_Open_Trial_Search_ID","value":"792268"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123830":{"preferredName":"Porcupine Inhibitor ETC-1922159","code":"C123830","definitions":[{"definition":"An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, ETC-1922159 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational palmitoylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor ETC-1922159","termGroup":"PT","termSource":"NCI"},{"termName":"ETC-159","termGroup":"CN","termSource":"NCI"},{"termName":"ETC-1922159","termGroup":"CN","termSource":"NCI"},{"termName":"PORCN Inhibitor ETC-1922159","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638250-96-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5L854240DQ"},{"name":"Maps_To","value":"Porcupine Inhibitor ETC-1922159"},{"name":"NCI_Drug_Dictionary_ID","value":"775936"},{"name":"NCI_META_CUI","value":"CL498223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775936"},{"name":"PDQ_Open_Trial_Search_ID","value":"775936"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156701":{"preferredName":"Zamaporvint","code":"C156701","definitions":[{"definition":"An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, zamaporvint binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zamaporvint","termGroup":"PT","termSource":"NCI"},{"termName":"Porcupine Inhibitor RXC004","termGroup":"SY","termSource":"NCI"},{"termName":"RXC 004","termGroup":"SY","termSource":"NCI"},{"termName":"RXC-004","termGroup":"SY","termSource":"NCI"},{"termName":"RXC004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1900754-56-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M56M7CHN8E"},{"name":"Maps_To","value":"Porcupine Inhibitor RXC004"},{"name":"NCI_Drug_Dictionary_ID","value":"795722"},{"name":"NCI_META_CUI","value":"CL935870"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795722"},{"name":"PDQ_Open_Trial_Search_ID","value":"795722"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116860":{"preferredName":"Porcupine Inhibitor WNT974","code":"C116860","definitions":[{"definition":"An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, WNT974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor WNT974","termGroup":"PT","termSource":"NCI"},{"termName":"2-(2,3-Dimethyl-[2,4-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"LGK 974","termGroup":"CN","termSource":"NCI"},{"termName":"LGK-974","termGroup":"CN","termSource":"NCI"},{"termName":"LGK974","termGroup":"CN","termSource":"NCI"},{"termName":"PORCN inhibitor LGK974","termGroup":"SY","termSource":"NCI"},{"termName":"WNT 974","termGroup":"CN","termSource":"NCI"},{"termName":"WNT974","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1243244-14-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U27F40013Q"},{"name":"Maps_To","value":"Porcupine Inhibitor WNT974"},{"name":"NCI_Drug_Dictionary_ID","value":"700477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700477"},{"name":"PDQ_Open_Trial_Search_ID","value":"700477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3851400"}]}}{"C763":{"preferredName":"Porfiromycin","code":"C763","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An N-methyl derivative of the antineoplastic antibiotic mitomycin C isolated from the bacterium Streptomyces ardus and other Streptomyces bacterial species.  Bioreduced porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks, thereby inhibiting DNA synthesis.  Porfiromycin is preferentially toxic to hypoxic cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porfiromycin","termGroup":"PT","termSource":"NCI"},{"termName":"[1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Azirino[2',3':3,4]pyrrolo[1, 2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a, 8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-1,5-dimethyl-, carbamate (ester)(8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-,[1aR-(1a-alpha,8beta, 8a-alpha,8b-alpha)]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ENT-50825","termGroup":"CN","termSource":"NCI"},{"termName":"Methyl Mitomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Methylmitomycin","termGroup":"SY","termSource":"NCI"},{"termName":"N-methylmitomycin C","termGroup":"SN","termSource":"NCI"},{"termName":"Porfiromycine","termGroup":"SY","termSource":"NCI"},{"termName":"Porphyromycin","termGroup":"SY","termSource":"NCI"},{"termName":"Promycin","termGroup":"BR","termSource":"NCI"},{"termName":"U-14,743","termGroup":"CN","termSource":"NCI"},{"termName":"U-14743","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"801-52-5"},{"name":"Chemical_Formula","value":"C16H20N4O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H1WK901OA6"},{"name":"Legacy Concept Name","value":"Porfiromycin"},{"name":"Maps_To","value":"Porfiromycin"},{"name":"NCI_Drug_Dictionary_ID","value":"39610"},{"name":"NSC Number","value":"56410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39610"},{"name":"PDQ_Open_Trial_Search_ID","value":"39610"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032697"}]}}{"C98838":{"preferredName":"Poziotinib","code":"C98838","definitions":[{"definition":"An orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poziotinib","termGroup":"PT","termSource":"NCI"},{"termName":"HM781-36","termGroup":"CN","termSource":"NCI"},{"termName":"NOV120101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092364-38-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OEI6OOU6IK"},{"name":"Maps_To","value":"Poziotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"715507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715507"},{"name":"PDQ_Open_Trial_Search_ID","value":"715507"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3180480"}]}}{"C2235":{"preferredName":"PR1 Leukemia Peptide Vaccine","code":"C2235","definitions":[{"definition":"A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PR1 Leukemia Peptide Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Leukemia Peptide Vaccine, PR1","termGroup":"SY","termSource":"NCI"},{"termName":"Proteinase 3:PR1 Peptide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"182253-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"54XUF2TZ7G"},{"name":"Legacy Concept Name","value":"PR1_Leukemia_Peptide_Vaccine"},{"name":"Maps_To","value":"PR1 Leukemia Peptide Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"37873"},{"name":"NSC Number","value":"698102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37873"},{"name":"PDQ_Open_Trial_Search_ID","value":"37873"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879440"}]}}{"C71708":{"preferredName":"Pracinostat","code":"C71708","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. SB939 blocks the action of an enzyme called histone deacetylase (HDAC) and may stop tumor cells from dividing. It is a type of HDAC inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pracinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1h-benzimidazol-5-yl)-N-hydroxy-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"HDAC Inhibitor SB939","termGroup":"SY","termSource":"NCI"},{"termName":"kaempferol 3-o-beta-d-(6-E-P-coumaroylglucoside)","termGroup":"SN","termSource":"NCI"},{"termName":"SB 939","termGroup":"CN","termSource":"NCI"},{"termName":"SB-939","termGroup":"CN","termSource":"NCI"},{"termName":"SB939","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"929016-96-6"},{"name":"Chemical_Formula","value":"C20H30N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"GPO2JN4UON"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_SB939"},{"name":"Maps_To","value":"Pracinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"559644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"559644"},{"name":"PDQ_Open_Trial_Search_ID","value":"559644"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467801"}]}}{"C2250":{"preferredName":"Pralatrexate","code":"C2250","definitions":[{"definition":"A drug used in the treatment of peripheral T-cell lymphoma (a fast-growing form of non-Hodgkin lymphoma). It is also being studied in the treatment of other types of cancer. Pralatrexate may block the growth of cancer cells and cause them to die. It is a type of dihydrofolate reductase (DHFR) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pralatrexate","termGroup":"PT","termSource":"NCI"},{"termName":"(2S)-2-[[4-[(1RS)-1-[(2, 4-Diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"10-Propargyl-10-Deazaaminopterin","termGroup":"SN","termSource":"NCI"},{"termName":"Difolta","termGroup":"FB","termSource":"NCI"},{"termName":"Folotyn","termGroup":"BR","termSource":"NCI"},{"termName":"N-(4-{1-[(2,4-Diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"PDX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"146464-95-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A8Q8I19Q20"},{"name":"Legacy Concept Name","value":"_10-Propargyl-10-Deazaaminopterin"},{"name":"Maps_To","value":"Pralatrexate"},{"name":"NCI_Drug_Dictionary_ID","value":"37828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37828"},{"name":"PDQ_Open_Trial_Search_ID","value":"37828"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879404"}]}}{"C128029":{"preferredName":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701","code":"C128029","definitions":[{"definition":"Human allogeneic T-lymphocytes transduced with a retroviral vector encoding a high-affinity T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-01-restricted, preferentially-expressed antigen in melanoma (PRAME) and containing the chemical induction of dimerization (CID) suicide/safety switch, composed of a drug binding domain coupled to the signaling domain of the suicide enzyme caspase-9, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-PRAME-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, PRAME-targeting T-cell receptor-based therapy BPX-701 binds to tumor cells expressing PRAME, which may induce cell death in and halt the growth of PRAME-expressing cancer cells. The tumor-associated antigen PRAME is overexpressed by a variety of cancer cell types. If potential T-cell toxicity due to graft-versus-host disease (GvHD) occurs, the chemical dimerizer rimiducid (AP1903) can be adminstered. Rimiducid binds to the drug binding domain expressed by the BPX-701 T-cells, and triggers activation of the caspase-9 domain, which leads to caspase 9-mediated signaling, the induction of apoptosis and to selective and complete elimination of BPX-701 cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701","termGroup":"PT","termSource":"NCI"},{"termName":"BPX-701","termGroup":"CN","termSource":"NCI"},{"termName":"CaspaCID-based PRAME-TCR Allogeneic T-lymphocytes BPX-701","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701"},{"name":"NCI_Drug_Dictionary_ID","value":"781247"},{"name":"NCI_META_CUI","value":"CL507923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781247"},{"name":"PDQ_Open_Trial_Search_ID","value":"781247"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29375":{"preferredName":"Pravastatin Sodium","code":"C29375","definitions":[{"definition":"A drug used to lower the amount of cholesterol in the blood and to prevent stroke and heart attack. It is also being studied in the treatment of cancer and other conditions. Pravastatin sodium blocks an enzyme that helps make cholesterol in the body. It may also make tumor cells more sensitive to anticancer drugs. It is a type of HMG-CoA reductase inhibitor, a type of statin, and a type of chemosensitizer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pravastatin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Pravachol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81131-70-6"},{"name":"CHEBI_ID","value":"CHEBI:8361"},{"name":"Chemical_Formula","value":"C23H35O7.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3M8608UQ61"},{"name":"Legacy Concept Name","value":"Pravastatin"},{"name":"Maps_To","value":"Pravastatin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"424450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"424450"},{"name":"PDQ_Open_Trial_Search_ID","value":"424450"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700474"}]}}{"C768":{"preferredName":"Prednimustine","code":"C768","definitions":[{"definition":"The prednisolone ester of chlorambucil and nitrogen mustard alkylating agent with antineoplastic activity. Prednimustine itself is not cytotoxic, however, it becomes cytotoxic upon hydrolysis by serum esterases to chlorambucil. Therefore, the increased potency of prednimustine is linked to the prolonged availability of free chlorambucil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednimustine","termGroup":"PT","termSource":"NCI"},{"termName":"11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-[4-[p-[bis(3-chloroethyl)amino]phenyl]butyrate]","termGroup":"SN","termSource":"NCI"},{"termName":"11beta-21-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxypregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Chlorambucil Prednisolone Ester","termGroup":"SY","termSource":"NCI"},{"termName":"LEO-1031","termGroup":"CN","termSource":"NCI"},{"termName":"Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-,21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate)","termGroup":"SN","termSource":"NCI"},{"termName":"Sterecyt","termGroup":"FB","termSource":"NCI"},{"termName":"Stereocyt","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"29069-24-7"},{"name":"Chemical_Formula","value":"C35H45Cl2NO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9403SIO2S8"},{"name":"Legacy Concept Name","value":"Prednimustine"},{"name":"Maps_To","value":"Prednimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"39560"},{"name":"NSC Number","value":"134087"},{"name":"NSC Number","value":"171345"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39560"},{"name":"PDQ_Open_Trial_Search_ID","value":"39560"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032949"}]}}{"C769":{"preferredName":"Prednisolone","code":"C769","definitions":[{"definition":"A drug that lessens inflammation and suppresses the body's immune response. It may also kill cancer cells. Prednisolone is used to treat disorders in many organ systems and to treat the symptoms of several types of leukemia and lymphoma. It is also being studied in the treatment of other types of cancer. Prednisolone is a type of therapeutic glucocorticoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisolone","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1,2-Dehydrohydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"Adnisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Aprednislon","termGroup":"FB","termSource":"NCI"},{"termName":"Capsoid","termGroup":"FB","termSource":"NCI"},{"termName":"Cortalone","termGroup":"BR","termSource":"NCI"},{"termName":"Cortisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Dacortin H","termGroup":"FB","termSource":"NCI"},{"termName":"Decaprednil","termGroup":"FB","termSource":"NCI"},{"termName":"Decortin H","termGroup":"FB","termSource":"NCI"},{"termName":"Delta(1)Hydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Delta- Cortef","termGroup":"FB","termSource":"NCI"},{"termName":"Delta-Cortef","termGroup":"BR","termSource":"NCI"},{"termName":"Delta-Diona","termGroup":"FB","termSource":"NCI"},{"termName":"Delta-F","termGroup":"SY","termSource":"NCI"},{"termName":"Delta-Phoricol","termGroup":"FB","termSource":"NCI"},{"termName":"Delta1-dehydro-hydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltacortril","termGroup":"FB","termSource":"NCI"},{"termName":"Deltahydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltasolone","termGroup":"FB","termSource":"NCI"},{"termName":"Deltidrosol","termGroup":"FB","termSource":"NCI"},{"termName":"Dhasolone","termGroup":"FB","termSource":"NCI"},{"termName":"Di-Adreson-F","termGroup":"FB","termSource":"NCI"},{"termName":"Dontisolon D","termGroup":"FB","termSource":"NCI"},{"termName":"Estilsona","termGroup":"FB","termSource":"NCI"},{"termName":"Fisopred","termGroup":"FB","termSource":"NCI"},{"termName":"Frisolona","termGroup":"FB","termSource":"NCI"},{"termName":"Gupisone","termGroup":"FB","termSource":"NCI"},{"termName":"Hostacortin H","termGroup":"FB","termSource":"NCI"},{"termName":"Hydeltra","termGroup":"BR","termSource":"NCI"},{"termName":"Hydeltrasol","termGroup":"BR","termSource":"NCI"},{"termName":"Klismacort","termGroup":"FB","termSource":"NCI"},{"termName":"Kuhlprednon","termGroup":"FB","termSource":"NCI"},{"termName":"Lenisolone","termGroup":"FB","termSource":"NCI"},{"termName":"Lepi-Cortinolo","termGroup":"FB","termSource":"NCI"},{"termName":"Linola-H N","termGroup":"FB","termSource":"NCI"},{"termName":"Linola-H-Fett N","termGroup":"FB","termSource":"NCI"},{"termName":"Longiprednil","termGroup":"FB","termSource":"NCI"},{"termName":"Metacortandralone","termGroup":"SY","termSource":"NCI"},{"termName":"Meti Derm","termGroup":"SY","termSource":"NCI"},{"termName":"Meticortelone","termGroup":"FB","termSource":"NCI"},{"termName":"Opredsone","termGroup":"FB","termSource":"NCI"},{"termName":"Panafcortelone","termGroup":"FB","termSource":"NCI"},{"termName":"Precortisyl","termGroup":"FB","termSource":"NCI"},{"termName":"Pred-Clysma","termGroup":"FB","termSource":"NCI"},{"termName":"Predeltilone","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-Coelin","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-Helvacort","termGroup":"FB","termSource":"NCI"},{"termName":"Prednicortelone","termGroup":"FB","termSource":"NCI"},{"termName":"Prednisolonum","termGroup":"SY","termSource":"NCI"},{"termName":"Prelone","termGroup":"BR","termSource":"NCI"},{"termName":"Prenilone","termGroup":"FB","termSource":"NCI"},{"termName":"Sterane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Inflammatory conditions; Allergic conditions; Hematologic conditions; Neoplastic conditions; Autoimmune conditions; Replacement therapy in adrenal insufficiency"},{"name":"CAS_Registry","value":"50-24-8"},{"name":"CHEBI_ID","value":"CHEBI:8378"},{"name":"Chemical_Formula","value":"C21H28O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9PHQ9Y1OLM"},{"name":"Legacy Concept Name","value":"Prednisolone"},{"name":"Maps_To","value":"Prednisolone"},{"name":"NCI_Drug_Dictionary_ID","value":"43296"},{"name":"NSC Number","value":"9120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43296"},{"name":"PDQ_Open_Trial_Search_ID","value":"43296"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032950"}]}}{"C1202":{"preferredName":"Prednisolone Acetate","code":"C1202","definitions":[{"definition":"The acetate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone acetate binds to specific intracellular glucocorticoid receptors, and causes the ligand-receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisolone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Ak-Tate","termGroup":"FB","termSource":"NCI"},{"termName":"Articulose-50","termGroup":"BR","termSource":"NCI"},{"termName":"Balpred","termGroup":"FB","termSource":"NCI"},{"termName":"Deltacortilen","termGroup":"FB","termSource":"NCI"},{"termName":"Deltastab","termGroup":"FB","termSource":"NCI"},{"termName":"Di-Adreson-F","termGroup":"FB","termSource":"NCI"},{"termName":"Diopred","termGroup":"FB","termSource":"NCI"},{"termName":"Econopred","termGroup":"BR","termSource":"NCI"},{"termName":"Flo-Pred","termGroup":"BR","termSource":"NCI"},{"termName":"Hexacortone","termGroup":"FB","termSource":"NCI"},{"termName":"Hydrocortancyl","termGroup":"FB","termSource":"NCI"},{"termName":"Inf-Oph","termGroup":"FB","termSource":"NCI"},{"termName":"Inflanefran","termGroup":"FB","termSource":"NCI"},{"termName":"Key-Pred","termGroup":"BR","termSource":"NCI"},{"termName":"Locaseptil-Neo","termGroup":"FB","termSource":"NCI"},{"termName":"Ophtho-Tate","termGroup":"FB","termSource":"NCI"},{"termName":"Pred Fort","termGroup":"FB","termSource":"NCI"},{"termName":"Pred Forte","termGroup":"BR","termSource":"NCI"},{"termName":"Pred Mild","termGroup":"BR","termSource":"NCI"},{"termName":"Predaject","termGroup":"BR","termSource":"NCI"},{"termName":"Predalone","termGroup":"FB","termSource":"NCI"},{"termName":"Predate","termGroup":"FB","termSource":"NCI"},{"termName":"Predcor","termGroup":"FB","termSource":"NCI"},{"termName":"Prednefrin SF","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-H","termGroup":"FB","termSource":"NCI"},{"termName":"Predni-POS","termGroup":"FB","termSource":"NCI"},{"termName":"Prednihexal","termGroup":"FB","termSource":"NCI"},{"termName":"Predniocil","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52-21-1"},{"name":"Chemical_Formula","value":"C23H30O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B2807733D"},{"name":"Legacy Concept Name","value":"Prednisolone_Acetate"},{"name":"Maps_To","value":"Prednisolone Acetate"},{"name":"NSC Number","value":"10966"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0071839"}]}}{"C1402":{"preferredName":"Prednisolone Sodium Phosphate","code":"C1402","definitions":[{"definition":"The sodium phosphate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone sodium phosphate binds to specific intracellular glucocorticoid receptors, and causes the ligand- receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisolone Sodium Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"Ak-Pred","termGroup":"BR","termSource":"NCI"},{"termName":"Inflamase","termGroup":"BR","termSource":"NCI"},{"termName":"Key-Pred SP","termGroup":"BR","termSource":"NCI"},{"termName":"Millipred","termGroup":"BR","termSource":"NCI"},{"termName":"Orapred","termGroup":"BR","termSource":"NCI"},{"termName":"Orapred ODT","termGroup":"BR","termSource":"NCI"},{"termName":"Pediapred","termGroup":"BR","termSource":"NCI"},{"termName":"Polypred","termGroup":"FB","termSource":"NCI"},{"termName":"Predmix","termGroup":"FB","termSource":"NCI"},{"termName":"Prednabene","termGroup":"FB","termSource":"NCI"},{"termName":"Prednesol","termGroup":"FB","termSource":"NCI"},{"termName":"Prednisol","termGroup":"BR","termSource":"NCI"},{"termName":"Prednisolone Sodium Phosphate ODT","termGroup":"SY","termSource":"NCI"},{"termName":"Predsol","termGroup":"FB","termSource":"NCI"},{"termName":"Veripred 20","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"125-02-0"},{"name":"CHEBI_ID","value":"CHEBI:8379"},{"name":"Chemical_Formula","value":"C21H27O8P.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IV021NXA9J"},{"name":"Legacy Concept Name","value":"Prednisolone_Sodium_Phosphate"},{"name":"Maps_To","value":"Prednisolone Sodium Phosphate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0138273"}]}}{"C770":{"preferredName":"Prednisone","code":"C770","definitions":[{"definition":"A drug used to lessen inflammation and lower the body's immune response. It is used with other drugs to treat leukemia and lymphoma and other types of cancer. It is also used alone or with other drugs to prevent or treat many other conditions. These include conditions related to cancer, such as anemia (a low level of red blood cells), allergic reactions, and loss of appetite. Prednisone is a type of therapeutic glucocorticoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prednisone","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Dehydrocortisone","termGroup":"SN","termSource":"NCI"},{"termName":"17,21-Dihydroxypregna-1,4-diene-3,11,20-trione","termGroup":"SN","termSource":"NCI"},{"termName":"Adasone","termGroup":"FB","termSource":"NCI"},{"termName":"Cortancyl","termGroup":"FB","termSource":"NCI"},{"termName":"Dacortin","termGroup":"FB","termSource":"NCI"},{"termName":"DeCortin","termGroup":"FB","termSource":"NCI"},{"termName":"Decortisyl","termGroup":"FB","termSource":"NCI"},{"termName":"Decorton","termGroup":"FB","termSource":"NCI"},{"termName":"Delta 1-Cortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Delta-Dome","termGroup":"AQS","termSource":"NCI"},{"termName":"Deltacortene","termGroup":"FB","termSource":"NCI"},{"termName":"Deltacortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltadehydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Deltison","termGroup":"FB","termSource":"NCI"},{"termName":"Deltra","termGroup":"FB","termSource":"NCI"},{"termName":"Econosone","termGroup":"FB","termSource":"NCI"},{"termName":"Liquid Pred","termGroup":"AQS","termSource":"NCI"},{"termName":"Lisacort","termGroup":"AQS","termSource":"NCI"},{"termName":"Meprosona-F","termGroup":"FB","termSource":"NCI"},{"termName":"Metacortandracin","termGroup":"SY","termSource":"NCI"},{"termName":"Meticorten","termGroup":"AQS","termSource":"NCI"},{"termName":"Ofisolona","termGroup":"FB","termSource":"NCI"},{"termName":"Orasone","termGroup":"AQS","termSource":"NCI"},{"termName":"Panafcort","termGroup":"FB","termSource":"NCI"},{"termName":"Panasol-S","termGroup":"FB","termSource":"NCI"},{"termName":"Paracort","termGroup":"FB","termSource":"NCI"},{"termName":"Perrigo Prednisone","termGroup":"BR","termSource":"NCI"},{"termName":"PRED","termGroup":"AB","termSource":"NCI"},{"termName":"Predeltin","termGroup":"AQS","termSource":"NCI"},{"termName":"Predicor","termGroup":"FB","termSource":"NCI"},{"termName":"Predicorten","termGroup":"FB","termSource":"NCI"},{"termName":"Prednicen-M","termGroup":"AQS","termSource":"NCI"},{"termName":"Prednicort","termGroup":"FB","termSource":"NCI"},{"termName":"Prednidib","termGroup":"FB","termSource":"NCI"},{"termName":"Prednilonga","termGroup":"FB","termSource":"NCI"},{"termName":"Predniment","termGroup":"FB","termSource":"NCI"},{"termName":"Prednisone Intensol","termGroup":"SY","termSource":"NCI"},{"termName":"Prednisone Intensol","termGroup":"BR","termSource":"NCI"},{"termName":"Prednisonum","termGroup":"SY","termSource":"NCI"},{"termName":"Prednitone","termGroup":"FB","termSource":"NCI"},{"termName":"Promifen","termGroup":"FB","termSource":"NCI"},{"termName":"Rayos","termGroup":"BR","termSource":"NCI"},{"termName":"Servisone","termGroup":"FB","termSource":"NCI"},{"termName":"Sk-Prednisone","termGroup":"AQS","termSource":"NCI"},{"termName":"Sterapred","termGroup":"AQS","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Inflammatory conditions; Allergic conditions; Hematologic conditions; Neoplastic conditions; Autoimmune conditions; Replacement therapy in adrenal insufficiency"},{"name":"CAS_Registry","value":"53-03-2"},{"name":"CHEBI_ID","value":"CHEBI:8382"},{"name":"Chemical_Formula","value":"C21H26O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"VB0R961HZT"},{"name":"Legacy Concept Name","value":"Prednisone"},{"name":"Maps_To","value":"Prednisone"},{"name":"NCI_Drug_Dictionary_ID","value":"42487"},{"name":"NSC Number","value":"10023"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42487"},{"name":"PDQ_Open_Trial_Search_ID","value":"42487"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0032952"}]}}{"C91392":{"preferredName":"Prexasertib","code":"C91392","definitions":[{"definition":"An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prexasertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyrazinecarbonitrile, 5-((5-(2-(3-Aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"ACR 368","termGroup":"CN","termSource":"NCI"},{"termName":"ACR-368","termGroup":"CN","termSource":"NCI"},{"termName":"ACR368","termGroup":"CN","termSource":"NCI"},{"termName":"LY2606368","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1234015-52-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"820NH671E6"},{"name":"Maps_To","value":"Prexasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"673506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673506"},{"name":"PDQ_Open_Trial_Search_ID","value":"673506"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984213"}]}}{"C91736":{"preferredName":"Prexigebersen","code":"C91736","definitions":[{"definition":"A liposomal formulation containing the antisense oligodeoxynucleotide (ODN) growth factor receptor-bound protein 2 (Grb2), with potential antineoplastic activity. Upon administration, liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of cancer cells overexpressing Grb2. Grb2, an adaptor protein involved in growth signaling pathways, is upregulated in certain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prexigebersen","termGroup":"PT","termSource":"NCI"},{"termName":"BP-100-1.01","termGroup":"CN","termSource":"NCI"},{"termName":"BP-1001","termGroup":"CN","termSource":"NCI"},{"termName":"BP1001","termGroup":"CN","termSource":"NCI"},{"termName":"Liposomal Grb2 AS ODN","termGroup":"SY","termSource":"NCI"},{"termName":"Liposome-Incorporated Grb2 Antisense Oligodeoxynucleotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"202484-91-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8W1O4Y961B"},{"name":"Maps_To","value":"Prexigebersen"},{"name":"NCI_Drug_Dictionary_ID","value":"681815"},{"name":"NCI_META_CUI","value":"CL421657"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681815"},{"name":"PDQ_Open_Trial_Search_ID","value":"681815"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85465":{"preferredName":"Eprenetapopt","code":"C85465","definitions":[{"definition":"A methylated derivative and structural analog of PRIMA-1 (p53 re-activation and induction of massive apoptosis), with potential antineoplastic activity. Upon administration, eprenetapopt covalently modifies the core domain of mutated forms of cellular tumor antigen p53 (p53) through the alkylation of thiol groups. These modifications restore both the wild-type conformation and function to mutant p53, which reconstitutes endogenous p53 activity, leading to cell cycle arrest and apoptosis in tumor cells. This agent may work synergistically with other antineoplastic agents. p53, a tumor suppressor and transcription factor normally activated upon DNA damage, is frequently mutated and overexpressed in cancer cells; it plays a key role in both DNA repair and the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eprenetapopt","termGroup":"PT","termSource":"NCI"},{"termName":"APR-246","termGroup":"CN","termSource":"NCI"},{"termName":"PRIMA-1MET","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5291-32-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z41TGB4080"},{"name":"Maps_To","value":"PRIMA-1 Analog APR-246"},{"name":"NCI_Drug_Dictionary_ID","value":"643796"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643796"},{"name":"PDQ_Open_Trial_Search_ID","value":"643796"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830138"}]}}{"C143059":{"preferredName":"Prime Cancer Vaccine MVA-BN-CV301","code":"C143059","definitions":[{"definition":"A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301, a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prime Cancer Vaccine MVA-BN-CV301","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara-Bavarian Nordic Vaccine CV301","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-BN Vaccine CV301","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-BN-CV301","termGroup":"SY","termSource":"NCI"},{"termName":"Prime Vaccine CV301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prime Cancer Vaccine MVA-BN-CV301"},{"name":"NCI_Drug_Dictionary_ID","value":"791888"},{"name":"NCI_META_CUI","value":"CL541455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791888"},{"name":"PDQ_Open_Trial_Search_ID","value":"791888"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C1811":{"preferredName":"Prinomastat","code":"C1811","definitions":[{"definition":"A synthetic hydroxamic acid derivative with potential antineoplastic activity.  Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  As a lipophilic agent, prinomastat crosses the blood-brain barrier. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. Prinomastat is a matrix metalloproteinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Prinomastat","termGroup":"PT","termSource":"NCI"},{"termName":"(3S)-N-Hydroxy-2,2-dimethyl-4-{{4-(4-piridinyloxy)phenyl}sulfonyl}-3-thiomorpholinecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"AG3340","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192329-42-3"},{"name":"Chemical_Formula","value":"C18H21N3O5S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"10T6626FRK"},{"name":"Legacy Concept Name","value":"Prinomastat"},{"name":"Maps_To","value":"Prinomastat"},{"name":"NCI_Drug_Dictionary_ID","value":"43058"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43058"},{"name":"PDQ_Open_Trial_Search_ID","value":"43058"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919273"}]}}{"C156759":{"preferredName":"PRMT1 Inhibitor GSK3368715","code":"C156759","definitions":[{"definition":"An orally available inhibitor of protein arginine N-methyltransferase 1 (PRMT1; Histone-arginine N-methyltransferase PRMT1; Interferon receptor 1-bound protein 4) with potential antineoplastic activity. Upon administration, GSK3368715 inhibits monomethylation and asymmetric dimethylation of arginine-bearing substrates, including histones, estrogen receptors, RNA-binding proteins, and numerous non-histone substrates catalyzed by PRMT1. This may inhibit tumor cell proliferation, migration, and invasion that is potentially driven by PRMT1 overexpression or dysregulation. PRMT1-mediated methylation plays a key role in the modulation of protein function, gene expression and cellular signaling. Dysregulation and overexpression of PRMT1 has been associated with a number of solid and hematopoietic cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRMT1 Inhibitor GSK3368715","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 3368715","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3368715","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3368715","termGroup":"CN","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 1 Inhibitor GSK3368715","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PRMT1 Inhibitor GSK3368715"},{"name":"NCI_Drug_Dictionary_ID","value":"795836"},{"name":"NCI_META_CUI","value":"CL935878"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795836"},{"name":"PDQ_Open_Trial_Search_ID","value":"795836"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C163980":{"preferredName":"Onametostat","code":"C163980","definitions":[{"definition":"An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration,onametostat selectively targets and irreversibly binds to the S-adenosylmethionine (SAM)- and substrate-binding pockets of the PRMT5/methylosome protein 50 (MEP50) complex, and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onametostat","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 64619178","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-64619178","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ64619178","termGroup":"CN","termSource":"NCI"},{"termName":"PRMT5 Inhibitor JNJ-64619178","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 5 Inhibitor JNJ-64619178","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2086772-26-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N8VKI8FPW0"},{"name":"Maps_To","value":"PRMT5 Inhibitor JNJ-64619178"},{"name":"NCI_Drug_Dictionary_ID","value":"799112"},{"name":"NCI_META_CUI","value":"CL977245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799112"},{"name":"PDQ_Open_Trial_Search_ID","value":"799112"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133019":{"preferredName":"Proapoptotic Sulindac Analog CP-461","code":"C133019","definitions":[{"definition":"An orally bioavailable second-generation selective apoptotic antineoplastic drug (SAAND) and analog of the nonsteroidal anti-inflammatory drug (NSAID) sulindac, with potential pro-apoptotic and antineoplastic activities. Upon administration, CP-461 specifically binds to and blocks the activity of cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway. Inhibition of cGMP-PDE permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. cGMP-PDE is overexpressed in a variety of cancer cell types; therefore, CP-461 selectively induces apoptosis in cancer cells, with minimal or no effect in healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proapoptotic Sulindac Analog CP-461","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Indene-3-acetamide, 5-Fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, Monohydrochloride, (1Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"CEL 031","termGroup":"CN","termSource":"NCI"},{"termName":"CP 461","termGroup":"CN","termSource":"NCI"},{"termName":"CP-461","termGroup":"CN","termSource":"NCI"},{"termName":"CP461","termGroup":"CN","termSource":"NCI"},{"termName":"OSI 461","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"227619-96-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"68OJX9I7DT"},{"name":"Maps_To","value":"Proapoptotic Sulindac Analog CP-461"},{"name":"NCI_Drug_Dictionary_ID","value":"354217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354217"},{"name":"PDQ_Open_Trial_Search_ID","value":"354217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1101538"}]}}{"C62072":{"preferredName":"Procarbazine","code":"C62072","definitions":[{"definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug that is used to treat advanced Hodgkin lymphoma and is being studied in the treatment of other types of cancer. Procarbazine blocks cells from making proteins and damages DNA. It may kill cancer cells. It is a type of antineoplastic agent and a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Procarbazine","termGroup":"PT","termSource":"NCI"},{"termName":"Benzethyzin","termGroup":"SY","termSource":"NCI"},{"termName":"Ibenzmethyzin","termGroup":"SY","termSource":"NCI"},{"termName":"N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-Methylhydrazine","termGroup":"SN","termSource":"NCI"},{"termName":"p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Procarbazin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"671-16-9"},{"name":"Chemical_Formula","value":"C12H19N3O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"35S93Y190K"},{"name":"Legacy Concept Name","value":"Procarbazine_Base"},{"name":"Maps_To","value":"Procarbazine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0033223"}]}}{"C773":{"preferredName":"Procarbazine Hydrochloride","code":"C773","definitions":[{"definition":"A drug that is used to treat advanced Hodgkin lymphoma and is being studied in the treatment of other types of cancer. Matulane blocks cells from making proteins and damages DNA. It may kill cancer cells. It is a type of antineoplastic agent and a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Procarbazine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Matulane","termGroup":"BR","termSource":"NCI"},{"termName":"MIH hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Natulan","termGroup":"FB","termSource":"NCI"},{"termName":"Natulanar","termGroup":"FB","termSource":"NCI"},{"termName":"Natunalar","termGroup":"FB","termSource":"NCI"},{"termName":"NCI C01810","termGroup":"CN","termSource":"NCI"},{"termName":"NCI-C01810","termGroup":"CN","termSource":"NCI"},{"termName":"NCIC01810","termGroup":"CN","termSource":"NCI"},{"termName":"p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"p-toluamide, N-isopropyl-alpha-(2-methylhydrazino)-, monohydrochloride (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"PCB","termGroup":"AB","termSource":"NCI"},{"termName":"PCB Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"PCZ","termGroup":"AB","termSource":"NCI"},{"termName":"Ro 4-6467/1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Brain tumors; Hodgkins diseases; Non-Hodgkins lymphoma"},{"name":"CAS_Registry","value":"366-70-1"},{"name":"Chemical_Formula","value":"C12H19N3O.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XH0NPH5ZX8"},{"name":"Legacy Concept Name","value":"Procarbazine"},{"name":"Maps_To","value":"Procarbazine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41607"},{"name":"NSC Number","value":"77213"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41607"},{"name":"PDQ_Open_Trial_Search_ID","value":"41607"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0205909"}]}}{"C120318":{"preferredName":"Procaspase Activating Compound-1 VO-100","code":"C120318","definitions":[{"definition":"An orally bioavailable procaspase activating compound-1 (PAC-1), with potential proapoptotic and antineoplastic activities. Upon administration, VO-100 binds to and forms a chelating complex with zinc (Zn) ions inside cells, which prevents the binding of Zn ions to procaspase-3 (PC3) and abrogates the Zn-mediated inhibition of PC3. This allows for the proteolytic autoactivation of PC3 into the active form caspase-3. This results in the selective caspase-3-mediated induction of apoptosis and cell death in cancer cells. In addition, VO-100 is able to cross the blood-brain-barrier (BBB). PC3, a Zn-inhibited proenzyme, is upregulated in a variety of cancer cell types, while its expression is minimal in normal healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Procaspase Activating Compound-1 VO-100","termGroup":"PT","termSource":"NCI"},{"termName":"PAC-1","termGroup":"AB","termSource":"NCI"},{"termName":"PAC-1 VO-100","termGroup":"SY","termSource":"NCI"},{"termName":"VO-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"315183-21-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9LIS8N0B2C"},{"name":"Maps_To","value":"Procaspase Activating Compound-1 VO-100"},{"name":"NCI_Drug_Dictionary_ID","value":"768985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768985"},{"name":"PDQ_Open_Trial_Search_ID","value":"768985"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3889731"}]}}{"C184790":{"preferredName":"Progestational Intrauterine Device","code":"C184790","definitions":[{"definition":"An intrauterine device impregnated with progestin (synthetic progesterone) that can be inserted into the uterus to prevent conception.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progestational Intrauterine Device","termGroup":"PT","termSource":"NCI"},{"termName":"Progestational IUD","termGroup":"SY","termSource":"NCI"},{"termName":"Progestin IUD","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Progestational IUD"},{"name":"NCI_META_CUI","value":"CL763749"},{"name":"Semantic_Type","value":"Medical Device"}]}}{"C95709":{"preferredName":"Prohibitin-Targeting Peptide 1","code":"C95709","definitions":[{"definition":"A chimeric, 25-mer peptide that targets prohibitin, with potential antineoplastic activity. Prohibitin-targeting peptide 1 (prohibitin-TP01) consists of a fat-targeting motif (CKGGRAKDC), two repeats of a proapoptotic peptide motif (KLAKLAK) and a GG linker. This peptide binds specifically to prohibitin in the white adipose vasculature; upon receptor-mediated cell internalization, the ligand/receptor complex triggers apoptosis and results in ablation of white fat. Destruction of white fat may potentially have positive consequences for men with prostate cancer since a high level of white fat has been implicated as a critical contributing factor in poor prostate cancer outcome. Prohibitin, a multifunctional membrane-associated protein that is thought to regulate cell survival and growth, has been shown by immunohistochemical analysis to be expressed in the membrane of endothelial cells in white adipose tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prohibitin-Targeting Peptide 1","termGroup":"PT","termSource":"NCI"},{"termName":"Prohibitin-TP01","termGroup":"SY","termSource":"NCI"},{"termName":"TP01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prohibitin-Targeting Peptide 1"},{"name":"NCI_Drug_Dictionary_ID","value":"691802"},{"name":"NCI_META_CUI","value":"CL428174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691802"},{"name":"PDQ_Open_Trial_Search_ID","value":"691802"},{"name":"PubMedID_Primary_Reference","value":"15133506"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129689":{"preferredName":"Palupiprant","code":"C129689","definitions":[{"definition":"An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Palupiprant","termGroup":"PT","termSource":"NCI"},{"termName":"AN 0025","termGroup":"CN","termSource":"NCI"},{"termName":"AN-0025","termGroup":"CN","termSource":"NCI"},{"termName":"AN0025","termGroup":"CN","termSource":"NCI"},{"termName":"E 7046","termGroup":"CN","termSource":"NCI"},{"termName":"E-7046","termGroup":"CN","termSource":"NCI"},{"termName":"E7046","termGroup":"CN","termSource":"NCI"},{"termName":"EP4 Antagonist E7046","termGroup":"SY","termSource":"NCI"},{"termName":"EP4 Inhibitor E7046","termGroup":"SY","termSource":"NCI"},{"termName":"ER-886046","termGroup":"CN","termSource":"NCI"},{"termName":"Prostaglandin E EP4 Receptor Antagonist E7046","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 EP4 Receptor Inhibitor AN0025","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1369489-71-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YWY620GU8I"},{"name":"Maps_To","value":"Prostaglandin E2 EP4 Receptor Inhibitor AN0025"},{"name":"Maps_To","value":"Prostaglandin E2 EP4 Receptor Inhibitor E7046"},{"name":"NCI_Drug_Dictionary_ID","value":"792739"},{"name":"NCI_META_CUI","value":"CL507851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792739"},{"name":"PDQ_Open_Trial_Search_ID","value":"792739"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71723":{"preferredName":"Prostate Cancer Vaccine ONY-P1","code":"C71723","definitions":[{"definition":"A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Cancer Vaccine ONY-P1","termGroup":"PT","termSource":"NCI"},{"termName":"ONY-P1","termGroup":"CN","termSource":"NCI"},{"termName":"Onyvax-P","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prostate_Cancer_Vaccine_ONY-P1"},{"name":"Maps_To","value":"Prostate Cancer Vaccine ONY-P1"},{"name":"NCI_Drug_Dictionary_ID","value":"561135"},{"name":"PDQ_Closed_Trial_Search_ID","value":"561135"},{"name":"PDQ_Open_Trial_Search_ID","value":"561135"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1667068"}]}}{"C77860":{"preferredName":"Prostate Health Cocktail Dietary Supplement","code":"C77860","definitions":[{"definition":"A dietary supplement consisting of a blend of 8 natural ingredients with potential antineoplastic and chemopreventive activities. This dietary supplement contains vitamin D3 (as cholecalciferol), vitamin E (as d-alpha tocopherol), selenium (as L-selenomethionine), epigallocatechin (green tea extract), saw palmetto (berry extract), lycopene, and the isoflavonoids daidzein and genistein. This combination preparation may decrease prostate cell growth and inhibit prostate carcinogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostate Health Cocktail Dietary Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Cholecalciferol/d-Alpha Tocopherol/L-Selenomethionine/Green Tea Extract/Saw Palmetto Berry Extract/Daidzein/Genistein/Lycopene Prostate Health Supplement","termGroup":"SY","termSource":"NCI"},{"termName":"PHC","termGroup":"BR","termSource":"NCI"},{"termName":"Prostate Health Cocktail","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Prostate_Health_Cocktail_Dietary_Supplement"},{"name":"Maps_To","value":"Prostate Health Cocktail Dietary Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"596155"},{"name":"NCI_META_CUI","value":"CL383736"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596155"},{"name":"PDQ_Open_Trial_Search_ID","value":"596155"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2548":{"preferredName":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024","code":"C2548","definitions":[{"definition":"A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024","termGroup":"PT","termSource":"NCI"},{"termName":"PA2024","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N5E5Q8249O"},{"name":"Legacy Concept Name","value":"Prostatic_Acid_Phosphatase-Sargramostim_Fusion_Protein"},{"name":"Maps_To","value":"Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024"},{"name":"NCI_Drug_Dictionary_ID","value":"38040"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38040"},{"name":"PDQ_Open_Trial_Search_ID","value":"38040"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879585"}]}}{"C132192":{"preferredName":"Pacmilimab","code":"C132192","definitions":[{"definition":"A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pacmilimab","termGroup":"PT","termSource":"NCI"},{"termName":"CX 072","termGroup":"CN","termSource":"NCI"},{"termName":"CX-072","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1 Probody Therapeutic CX-072","termGroup":"SY","termSource":"NCI"},{"termName":"Probody CX-072","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2101273-62-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZXP96ZI2RA"},{"name":"Maps_To","value":"Pacmilimab"},{"name":"Maps_To","value":"Protease-activated Anti-PD-L1 Antibody Prodrug CX-072"},{"name":"NCI_Drug_Dictionary_ID","value":"787226"},{"name":"NCI_META_CUI","value":"CL520194"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787226"},{"name":"PDQ_Open_Trial_Search_ID","value":"787226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142177":{"preferredName":"Pemrametostat","code":"C142177","definitions":[{"definition":"An orally available, selective small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not been completely determined, pemrametostat binds to the substrate recognition site of PRMT5 following oral administration and inhibits its methyltransferase activity, which decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cell proliferation. Therefore, this agent may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation and may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pemrametostat","termGroup":"PT","termSource":"NCI"},{"termName":"EPZ015938","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3326595","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3326595","termGroup":"CN","termSource":"NCI"},{"termName":"PRMT5 Inhibitor GSK3326595","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 5 Inhibitor GSK3326595","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616392-22-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VXT8SZ6875"},{"name":"Maps_To","value":"Protein Arginine Methyltransferase 5 Inhibitor GSK3326595"},{"name":"NCI_Drug_Dictionary_ID","value":"791458"},{"name":"NCI_META_CUI","value":"CL540166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791458"},{"name":"PDQ_Open_Trial_Search_ID","value":"791458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158100":{"preferredName":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999","code":"C158100","definitions":[{"definition":"An orally available inhibitor of protein arginine N-methyltransferase 5 (histone-arginine N-methyltransferase PRMT5; PRMT5) with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not yet been fully elucidated, orally administered PRMT5 inhibitor PF-06939999 inhibits the methyltransferase activity of PRMT5, thereby decreasing the levels of monomethylated and dimethylated arginine residues in histones H2A, H3, and H4, and modulating the expression of genes involved in several cellular processes including cell proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, and may decrease the growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999","termGroup":"PT","termSource":"NCI"},{"termName":"PF 06939999","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06939999","termGroup":"CN","termSource":"NCI"},{"termName":"PF06939999","termGroup":"CN","termSource":"NCI"},{"termName":"PRMT5 Inhibitor PF-06939999","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2159123-14-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JY9FEZ3ZDX"},{"name":"Maps_To","value":"Protein Arginine Methyltransferase 5 Inhibitor PF-06939999"},{"name":"NCI_Drug_Dictionary_ID","value":"797355"},{"name":"NCI_META_CUI","value":"CL937738"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797355"},{"name":"PDQ_Open_Trial_Search_ID","value":"797355"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162454":{"preferredName":"Protein Arginine Methyltransferase 5 Inhibitor PRT543","code":"C162454","definitions":[{"definition":"An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the exact mechanism of action has not been completely determined, upon oral administration, PRMT5 inhibitor PRT543 selectively binds to the substrate recognition site of PRMT5 and inhibits its methyltransferase activity. This decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cellular proliferation. As a result, PRT543 may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Arginine Methyltransferase 5 Inhibitor PRT543","termGroup":"PT","termSource":"NCI"},{"termName":"PRMT5 inhibitor PRT543","termGroup":"SY","termSource":"NCI"},{"termName":"PRT 543","termGroup":"CN","termSource":"NCI"},{"termName":"PRT-543","termGroup":"CN","termSource":"NCI"},{"termName":"PRT543","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Protein Arginine Methyltransferase 5 Inhibitor PRT543"},{"name":"NCI_Drug_Dictionary_ID","value":"798738"},{"name":"NCI_META_CUI","value":"CL970998"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798738"},{"name":"PDQ_Open_Trial_Search_ID","value":"798738"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124796":{"preferredName":"Darovasertib","code":"C124796","definitions":[{"definition":"An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, darovasertib inds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Darovasertib","termGroup":"PT","termSource":"NCI"},{"termName":"IDE 196","termGroup":"CN","termSource":"NCI"},{"termName":"IDE-196","termGroup":"CN","termSource":"NCI"},{"termName":"IDE196","termGroup":"CN","termSource":"NCI"},{"termName":"LXS196","termGroup":"CN","termSource":"NCI"},{"termName":"PKC Inhibitor IDE196","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase C Inhibitor IDE196","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Kinase C Inhibitor LXS196","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1874276-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E0YF0M8O09"},{"name":"Maps_To","value":"Protein Kinase C Inhibitor IDE196"},{"name":"NCI_Drug_Dictionary_ID","value":"777033"},{"name":"NCI_META_CUI","value":"CL503026"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777033"},{"name":"PDQ_Open_Trial_Search_ID","value":"777033"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106430":{"preferredName":"Protein Phosphatase 2A Inhibitor LB-100","code":"C106430","definitions":[{"definition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Phosphatase 2A Inhibitor LB-100","termGroup":"PT","termSource":"NCI"},{"termName":"LB-100","termGroup":"CN","termSource":"NCI"},{"termName":"PP2A Inhibitor LB-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1632032-53-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0C1JUU9S0L"},{"name":"Maps_To","value":"Protein Phosphatase 2A Inhibitor LB-100"},{"name":"NCI_Drug_Dictionary_ID","value":"749984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749984"},{"name":"PDQ_Open_Trial_Search_ID","value":"749984"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827105"}]}}{"C90534":{"preferredName":"Protein Stabilized Liposomal Docetaxel Nanoparticles","code":"C90534","definitions":[{"definition":"A formulation containing protein-stabilized liposome nanoparticles encapsulating the poorly water-soluble, second-generation taxane analog docetaxel with antineoplastic activity. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Compared to the use of toxic carriers to increase solubilization of docetaxel, protein-stabilized liposomal docetaxel improves drug solubility while avoiding carrier-associated toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Stabilized Liposomal Docetaxel Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"ATI-1123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Protein Stabilized Liposomal Docetaxel Nanoparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"663670"},{"name":"NCI_META_CUI","value":"CL413616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663670"},{"name":"PDQ_Open_Trial_Search_ID","value":"663670"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C130036":{"preferredName":"Proxalutamide","code":"C130036","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon oral administration, proxalutamide binds to AR in target tissues, inhibits androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. In addition, proxalutamide induces AR downregulation, thereby further preventing AR-mediated signaling. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells. AR is overexpressed in prostate cancer and plays a key role in prostate cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proxalutamide","termGroup":"PT","termSource":"NCI"},{"termName":"GT-0918","termGroup":"CN","termSource":"NCI"},{"termName":"GT0918","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1398046-21-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QX6O64GP40"},{"name":"Maps_To","value":"Proxalutamide"},{"name":"NCI_Drug_Dictionary_ID","value":"784935"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784935"},{"name":"PDQ_Open_Trial_Search_ID","value":"784935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4043276"}]}}{"C114289":{"preferredName":"PSA/IL-2/GM-CSF Vaccine","code":"C114289","definitions":[{"definition":"A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSA/IL-2/GM-CSF Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"ProscaVax","termGroup":"SY","termSource":"NCI"},{"termName":"Prostatac","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSA/IL-2/GM-CSF Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"758104"},{"name":"NCI_META_CUI","value":"CL471798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758104"},{"name":"PDQ_Open_Trial_Search_ID","value":"758104"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123283":{"preferredName":"PSA/PSMA DNA Plasmid INO-5150","code":"C123283","definitions":[{"definition":"A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSA/PSMA DNA Plasmid INO-5150","termGroup":"PT","termSource":"NCI"},{"termName":"INO 5150","termGroup":"CN","termSource":"NCI"},{"termName":"INO-5150","termGroup":"CN","termSource":"NCI"},{"termName":"PSA/PSMA Synthetic DNA Vaccine INO-5150","termGroup":"SY","termSource":"NCI"},{"termName":"PSA/PSMA-encoding DNA Plasmid INO-5150","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSA/PSMA DNA Plasmid INO-5150"},{"name":"NCI_Drug_Dictionary_ID","value":"775020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775020"},{"name":"PDQ_Open_Trial_Search_ID","value":"775020"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C4053631"}]}}{"C87389":{"preferredName":"Pseudoisocytidine","code":"C87389","definitions":[{"definition":"A synthetic, pyrimidine C-5 nucleoside with antineoplastic activity. Pseudoisocytidine, after conversion into pseudoisocytidine triphosphate, is incorporated into DNA and RNA eventually halting tumor cell proliferation. Compared to 5-azacytidine and cytarabine, this agent shows enhanced stability and resistance to enzymatic deamination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pseudoisocytidine","termGroup":"PT","termSource":"NCI"},{"termName":"4(1H)-Pyrimidinone, 2-Amino-5-Beta-D-Ribofuranosyl-","termGroup":"SN","termSource":"NCI"},{"termName":"5-(Beta-D-Ribofuranosyl)Isocytosine","termGroup":"SN","termSource":"NCI"},{"termName":"psi Icyd","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"57100-18-2"},{"name":"Chemical_Formula","value":"C9H13N3O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TDH73L8XQD"},{"name":"Maps_To","value":"Pseudoisocytidine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0072540"}]}}{"C95892":{"preferredName":"PSMA-targeted Docetaxel Nanoparticles BIND-014","code":"C95892","definitions":[{"definition":"A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane antigen (PSMA), with antineoplastic activity. PSMA-targeted docetaxel nanoparticles BIND-014 carry docetaxel within a matrix of polylactic acid covered with a coating of polyethylene glycol; embedded on the surface of the polyethylene glycol coating are ligands targeted to PSMA. BIND-014 allows gradual release of docetaxel upon degradation of the polylactic acid, and the PEG encapsulation escapes the host immune response while PSMA ligands on the surface restrict the cytotoxic effect to PSMA-expressing cells. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. PSMA is a cell-surface antigen that is abundantly present on the surface of cancer cells and on the neovasculature that feeds a wide variety of tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA-targeted Docetaxel Nanoparticles BIND-014","termGroup":"PT","termSource":"NCI"},{"termName":"BIND-014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSMA-targeted Docetaxel Nanoparticles BIND-014"},{"name":"NCI_Drug_Dictionary_ID","value":"696293"},{"name":"NCI_META_CUI","value":"CL428289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696293"},{"name":"PDQ_Open_Trial_Search_ID","value":"696293"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117291":{"preferredName":"PSMA-targeted Tubulysin B-containing Conjugate EC1169","code":"C117291","definitions":[{"definition":"An injectable, water soluble, small molecule drug conjugate (SMDC) containing a ligand specific for prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to the cytotoxic agent tubulysin B hydrazide (TubBH), with potential antineoplastic activity. Upon administration of PSMA-targeted tubulysin B-containing conjugate EC1169, the PSMA ligand specifically targets and binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells as well as on the neovasculature of many solid tumors. This allows for the specific delivery of TubBH to PSMA-expressing cancer cells. Upon internalization and cleavage, tubulysin B binds to tubulin and inhibits microtubule polymerization, which blocks cell division and results in G2/M phase arrest, tumor cell apoptosis and a decrease in PSMA-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA-targeted Tubulysin B-containing Conjugate EC1169","termGroup":"PT","termSource":"NCI"},{"termName":"EC1169","termGroup":"CN","termSource":"NCI"},{"termName":"EC1719","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PSMA-targeted Tubulysin B-containing Conjugate EC1169"},{"name":"NCI_Drug_Dictionary_ID","value":"763440"},{"name":"NCI_META_CUI","value":"CL474117"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763440"},{"name":"PDQ_Open_Trial_Search_ID","value":"763440"},{"name":"Semantic_Type","value":"Chemical"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"}]}}{"C156681":{"preferredName":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424","code":"C156681","definitions":[{"definition":"A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA; FOLH1) and the CD3 antigen found on T-lymphocytes and an albumin-binding domain, with potential immunostimulating and antineoplastic activities.  Upon administration, PSMA/CD3 tri-specific T-cell antibody construct HPN424 targets and binds PSMA on tumor cells and CD3 on cytotoxic T-lymphocytes (CTLs), thereby bringing PSMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN424. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PSMA/CD3 TriTAC HPN424","termGroup":"SY","termSource":"NCI"},{"termName":"HPN 424","termGroup":"CN","termSource":"NCI"},{"termName":"HPN-424","termGroup":"CN","termSource":"NCI"},{"termName":"HPN424","termGroup":"CN","termSource":"NCI"},{"termName":"PSMA/CD3 TriTAC HPN424","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA/CD3-specific TriTAC HPN424","termGroup":"SY","termSource":"NCI"},{"termName":"TriTAC HPN424","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZAA5KE2UAS"},{"name":"Maps_To","value":"PSMA/CD3 Tri-specific T-cell Activating Construct HPN424"},{"name":"NCI_Drug_Dictionary_ID","value":"795833"},{"name":"NCI_META_CUI","value":"CL935732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795833"},{"name":"PDQ_Open_Trial_Search_ID","value":"795833"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128266":{"preferredName":"Enitociclib","code":"C128266","definitions":[{"definition":"An inhibitor of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF- b; PTEFb), with potential antineoplastic activity. Upon administration, enitociclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. The protein complex PTEF-b, a heterodimer consisting of CDK9 and a regulatory cyclin subunit of the T family, is over-activated in various tumor cell types; it plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enitociclib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 1251152","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1251152","termGroup":"CN","termSource":"NCI"},{"termName":"PTEF-b/CDK9 Inhibitor BAY1251152","termGroup":"SY","termSource":"NCI"},{"termName":"PTEF-b/CDK9 Inhibitor VIP152","termGroup":"SY","termSource":"NCI"},{"termName":"VIP 152","termGroup":"CN","termSource":"NCI"},{"termName":"VIP-152","termGroup":"CN","termSource":"NCI"},{"termName":"VIP152","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610408-97-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1255AT22ZJ"},{"name":"Maps_To","value":"PTEF-b/CDK9 Inhibitor BAY1251152"},{"name":"NCI_Drug_Dictionary_ID","value":"806116"},{"name":"NCI_META_CUI","value":"CL507865"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153353":{"preferredName":"Pterostilbene","code":"C153353","definitions":[{"definition":"A naturally-derived stilbenoid structurally related to resveratrol, with potential antioxidant, anti-inflammatory, pro-apoptotic, antineoplastic and cytoprotective activities. Upon administration, pterostilbene exerts its anti-oxidant activity by scavenging reactive oxygen species (ROS), thereby preventing oxidative stress and ROS-induced cell damage. It may also activate the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated pathway and increase the expression of various antioxidant enzymes, such as superoxide dismutase (SOD).  In addition, pterostilbene is able to inhibit inflammation by reducing the expression of various inflammatory mediators, such as interleukin (IL) 1beta, tumor necrosis factor alpha (TNF-a), inducible nitric oxide synthase (iNOS), cyclooxygenases (COX), and nuclear factor kappa B (NF-kB). It also inhibits or prevents the activation of many signaling pathways involved in carcinogenesis, and increases expression of various tumor suppressor genes while decreasing expression of certain tumor promoting genes. It also directly induces apoptosis in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pterostilbene","termGroup":"PT","termSource":"NCI"},{"termName":"3',5'-Dimethoxy-4-stilbenol","termGroup":"SY","termSource":"NCI"},{"termName":"3,5-Dimethoxy-4'-hydroxystilbene","termGroup":"SY","termSource":"NCI"},{"termName":"Phenol, 4-(2-(3,5-Dimethoxyphenyl)ethenyl)-, (E)-","termGroup":"SN","termSource":"NCI"},{"termName":"Trans-3,5-dimethoxy-4-hydroxystilbene","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"537-42-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"26R60S6A5I"},{"name":"Maps_To","value":"Pterostilbene"},{"name":"NCI_Drug_Dictionary_ID","value":"794141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794141"},{"name":"PDQ_Open_Trial_Search_ID","value":"794141"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664965"}]}}{"C73239":{"preferredName":"Pumitepa","code":"C73239","definitions":[{"definition":"A thiotepa derivative with potential antineoplastic alkylating activity. Although the exact mechanism of action of pumitepa has yet to be fully elucidated, this agent appears to work through alkylation, thereby causing DNA damage and cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pumitepa","termGroup":"PT","termSource":"NCI"},{"termName":"Fopurin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"42061-52-9"},{"name":"Chemical_Formula","value":"C12H19N8OP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7AYY495RE0"},{"name":"Legacy Concept Name","value":"Pumitepa"},{"name":"Maps_To","value":"Pumitepa"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0060632"}]}}{"C162555":{"preferredName":"Puquitinib","code":"C162555","definitions":[{"definition":"An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puquitinib","termGroup":"PT","termSource":"NCI"},{"termName":"XC-302 Free Base","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"916890-10-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WFG29AB872"},{"name":"Maps_To","value":"Puquitinib"},{"name":"NCI_META_CUI","value":"CL971126"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162556":{"preferredName":"Puquitinib Mesylate","code":"C162556","definitions":[{"definition":"The mesylate salt of puquitinib, an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puquitinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"XC-302 Anhydrous","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1018818-41-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z4NA6BNF2L"},{"name":"Maps_To","value":"Puquitinib Mesylate"},{"name":"NCI_META_CUI","value":"CL971077"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C787":{"preferredName":"Puromycin","code":"C787","definitions":[{"definition":"An aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger.  Acting as an analog of the 3' terminal end of aminoacyl-tRNA, puromycin incorporates itself into a growing polypeptide chain and causes its premature termination, thereby inhibiting protein synthesis.  This agent has antimicrobial, antitrypanosomal, and antineoplastic properties; it is used as an antibiotic in cell culture. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puromycin","termGroup":"PT","termSource":"NCI"},{"termName":"Adenosine, 3'-((2-amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyl-, (S)-","termGroup":"SN","termSource":"NCI"},{"termName":"Adenosine, 3'-(alpha-amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyl-, L-","termGroup":"SN","termSource":"NCI"},{"termName":"CL 16536","termGroup":"CN","termSource":"NCI"},{"termName":"L-3'-(alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine","termGroup":"SN","termSource":"NCI"},{"termName":"P-638","termGroup":"CN","termSource":"NCI"},{"termName":"Puromicina","termGroup":"SY","termSource":"NCI"},{"termName":"Puromycine","termGroup":"SY","termSource":"NCI"},{"termName":"Puromycinum","termGroup":"SY","termSource":"NCI"},{"termName":"Stillomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Stylomycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53-79-2"},{"name":"CHEBI_ID","value":"CHEBI:17939"},{"name":"Chemical_Formula","value":"C22H29N7O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4A6ZS6Q2CL"},{"name":"Legacy Concept Name","value":"Puromycin"},{"name":"Maps_To","value":"Puromycin"},{"name":"NSC Number","value":"3055"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034145"}]}}{"C75148":{"preferredName":"Puromycin Hydrochloride","code":"C75148","definitions":[{"definition":"The hydrochloride salt form of puromycin, an aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger. Acting as an analog of the 3' terminal end of aminoacyl-tRNA, puromycin incorporates itself into a growing polypeptide chain and causes its premature termination, thereby inhibiting protein synthesis. This agent has antimicrobial, antitrypanosomal, and antineoplastic properties; it is used as an antibiotic in cell culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Puromycin Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58-58-2"},{"name":"Chemical_Formula","value":"C22H29N7O5.2HCl"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PGN54228S5"},{"name":"Legacy Concept Name","value":"Puromycin_Hydrochloride"},{"name":"Maps_To","value":"Puromycin Hydrochloride"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0282329"}]}}{"C53412":{"preferredName":"Rose Bengal Solution PV-10","code":"C53412","definitions":[{"definition":"An injectable ten percent solution of rose bengal disodium, an iodinated fluorescein derivative, with potential antineoplastic and radiosensitizing activities. When injected into tumor tissue, PV-10 specifically targets and concentrates in tumor cells, producing cytotoxic singlet oxygen when exposed to ionizing radiation. In addition, PV-10 may stimulate an anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rose Bengal Solution PV-10","termGroup":"PT","termSource":"NCI"},{"termName":"4,5,6,7-Tetrachloro-2',4',5',7'-tetraiodofluorescein Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Injectable Rose Bengal 10%","termGroup":"SY","termSource":"NCI"},{"termName":"Provecta","termGroup":"BR","termSource":"NCI"},{"termName":"PV-10","termGroup":"CN","termSource":"NCI"},{"termName":"Rose Bengal Disodium 10%","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PV-10"},{"name":"Maps_To","value":"PV-10"},{"name":"Maps_To","value":"Rose Bengal Solution PV-10"},{"name":"NCI_Drug_Dictionary_ID","value":"463937"},{"name":"PDQ_Closed_Trial_Search_ID","value":"463937"},{"name":"PDQ_Open_Trial_Search_ID","value":"463937"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709443"}]}}{"C71149":{"preferredName":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride","code":"C71149","definitions":[{"definition":"An embolic material composed of microspheres of polyvinyl alcohol (PVA) polymers loaded with doxorubicin hydrochloride with antineoplastic activity. Doxorubicin hydrochloride-loaded microspheres may be used as a drug delivery vehicle during embolization of tumor vasculature. Doxorubicin intercalates DNA, interferes with catalytic activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. When used in tumor vasculature embolization, this preparation may provide more tumor-specific treatment with doxorubicin compared to the systemic administration of doxorubicin, thereby reducing the systemic toxicity of doxorubicin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"HepaSphere Microspheres/Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"QuadraSphere Microspheres/Doxorubicin Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PVA_Microporous_Hydrospheres_Doxorubicin_Hydrochloride"},{"name":"Maps_To","value":"PVA Microporous Hydrospheres/Doxorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"574045"},{"name":"NCI_META_CUI","value":"CL376223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574045"},{"name":"PDQ_Open_Trial_Search_ID","value":"574045"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29395":{"preferredName":"Pyrazinamide","code":"C29395","definitions":[{"definition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyrazinamide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98-96-4"},{"name":"CHEBI_ID","value":"CHEBI:45285"},{"name":"Chemical_Formula","value":"C5H5N3O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2KNI5N06TI"},{"name":"Legacy Concept Name","value":"Pyrazinamide"},{"name":"Maps_To","value":"Pyrazinamide"},{"name":"NCI_Drug_Dictionary_ID","value":"701809"},{"name":"NSC Number","value":"14911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701809"},{"name":"PDQ_Open_Trial_Search_ID","value":"701809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034239"}]}}{"C1564":{"preferredName":"Pyrazoloacridine","code":"C1564","definitions":[{"definition":"A 9-methoxy acridine compound containing a reducible 5-nitro substituent.  Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called acridines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Pyrazoloacridine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"99009-20-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L24XJN68OW"},{"name":"Legacy Concept Name","value":"Pyrazoloacridine"},{"name":"Maps_To","value":"Pyrazoloacridine"},{"name":"NCI_Drug_Dictionary_ID","value":"41418"},{"name":"NSC Number","value":"366140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41418"},{"name":"PDQ_Open_Trial_Search_ID","value":"41418"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280970"}]}}{"C1852":{"preferredName":"Pyridyl Cyanoguanidine CHS 828","code":"C1852","definitions":[{"definition":"A drug that is being studied as a treatment for solid tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A pyridyl cyanoguanidine that exhibits antitumor activity by an unknown mechanism. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyridyl Cyanoguanidine CHS 828","termGroup":"PT","termSource":"NCI"},{"termName":"CHS 828","termGroup":"CN","termSource":"NCI"},{"termName":"CHS-828","termGroup":"CN","termSource":"NCI"},{"termName":"N-(6-(4-Chlorophenoxy)hexyl)-N'-Cyano-N''-4-Pyridylcyanoguanidine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"200484-11-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8LAP87DNSZ"},{"name":"Legacy Concept Name","value":"CHS_828"},{"name":"Maps_To","value":"Pyridyl Cyanoguanidine CHS 828"},{"name":"NCI_Drug_Dictionary_ID","value":"43567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43567"},{"name":"PDQ_Open_Trial_Search_ID","value":"43567"},{"name":"PubMedID_Primary_Reference","value":"18201551"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879285"}]}}{"C111895":{"preferredName":"Pyrotinib","code":"C111895","definitions":[{"definition":"An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyrotinib","termGroup":"PT","termSource":"NCI"},{"termName":"SHR 1258","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1258","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1269662-73-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CJN36EQM0H"},{"name":"Maps_To","value":"Pyrotinib"},{"name":"NCI_Drug_Dictionary_ID","value":"753336"},{"name":"NCI_META_CUI","value":"CL454228"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753336"},{"name":"PDQ_Open_Trial_Search_ID","value":"753336"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162554":{"preferredName":"Pyrotinib Dimaleate","code":"C162554","definitions":[{"definition":"The dimaleate ester of pyrotinib, an orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR, ErbB1 or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyrotinib Dimaleate","termGroup":"PT","termSource":"NCI"},{"termName":"Pyrotinib Maleate","termGroup":"SY","termSource":"NCI"},{"termName":"SHR-1258 Maleate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1397922-61-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"85KUE857XM"},{"name":"Maps_To","value":"Pyrotinib Dimaleate"},{"name":"NCI_Drug_Dictionary_ID","value":"801532"},{"name":"NCI_META_CUI","value":"CL971127"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801532"},{"name":"PDQ_Open_Trial_Search_ID","value":"801532"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2801":{"preferredName":"Pyroxamide","code":"C2801","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called histone deacetylase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of hydroxamic acid with antineoplastic properties, Pyroxamide inhibits histone deacetylases involved in transcription; induces hyperacetylation of core histones, modulating chromatin structure and affecting transcription of some genes that inhibit tumor growth; and induces growth arrest and apoptosis. Pyroxamide is used in clinical studies for cancer chemotherapy. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyroxamide","termGroup":"PT","termSource":"NCI"},{"termName":"Suberoyl-3-aminopyridineamide Hydroxamic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"382180-17-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"12N86DSS23"},{"name":"Legacy Concept Name","value":"Pyroxamide"},{"name":"Maps_To","value":"Pyroxamide"},{"name":"NCI_Drug_Dictionary_ID","value":"256405"},{"name":"NSC Number","value":"696085"},{"name":"PDQ_Closed_Trial_Search_ID","value":"256405"},{"name":"PDQ_Open_Trial_Search_ID","value":"256405"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0966748"}]}}{"C67087":{"preferredName":"Pyruvate Kinase Inhibitor TLN-232","code":"C67087","definitions":[{"definition":"A synthetic cyclic heptapeptide with potential antineoplastic activity. Pyruvate kinase (PK) inhibitor TLN-232 targets pyruvate kinase M2 (M2PK), which may disrupt tumor cell anaerobic glycolysis. M2PK is a dimeric isoform of PK and the predominant PK isoform found in tumor cells","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyruvate Kinase Inhibitor TLN-232","termGroup":"PT","termSource":"NCI"},{"termName":"CAP-232","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CAP-232"},{"name":"Maps_To","value":"Pyruvate Kinase Inhibitor TLN-232"},{"name":"NCI_Drug_Dictionary_ID","value":"536241"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536241"},{"name":"PDQ_Open_Trial_Search_ID","value":"536241"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0531400"}]}}{"C155882":{"preferredName":"Qilisheng Immunoregulatory Oral Solution","code":"C155882","definitions":[{"definition":"An oral solution containing Spondias axillaris, Panax ginseng, schisandra berry, hawthorn, soybean and an as of yet not elucidated bacterium, with potential immunomodulating activity. Upon oral administration of the qilisheng immunoregulatory oral solution, the ingredients in qilisheng may modulate the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Qilisheng Immunoregulatory Oral Solution","termGroup":"PT","termSource":"NCI"},{"termName":"Qilisheng","termGroup":"SY","termSource":"NCI"},{"termName":"Qilisheng Solution","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Qilisheng Immunoregulatory Oral Solution"},{"name":"NCI_Drug_Dictionary_ID","value":"794790"},{"name":"NCI_META_CUI","value":"CL562700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794790"},{"name":"PDQ_Open_Trial_Search_ID","value":"794790"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61087":{"preferredName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","code":"C61087","definitions":[{"definition":"A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.","type":"DEFINITION","source":"NCI"},{"definition":"A vaccine used to prevent cervical, vulvar, and vaginal cancer caused by human papillomavirus (HPV) types 16 and 18 and genital warts caused by HPV types 6 and 11. It is also used to prevent lesions that are caused by these viruses and that can lead to cervical, vulvar, or vaginal cancer. Quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine is used in females aged 9-26 years. It is also used to prevent genital warts in males aged 9-26 years. Quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine is being studied in the treatment of other medical conditions.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Gardasil","termGroup":"BR","termSource":"NCI"},{"termName":"Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"V501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Quadrivalent_Human_Papillomavirus_Recombinant_Vaccine"},{"name":"Maps_To","value":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"476576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"476576"},{"name":"PDQ_Open_Trial_Search_ID","value":"476576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831799"}]}}{"C71726":{"preferredName":"Quarfloxin","code":"C71726","definitions":[{"definition":"A fluoroquinolone derivative with antineoplastic activity. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis that is overexpressed in cancer cells; disruption of this G-quadruplex DNA:protein interaction in aberrant rRNA biogenesis may result in the inhibition of ribosome synthesis and tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quarfloxin","termGroup":"PT","termSource":"NCI"},{"termName":"3H-Benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide, 5-fluoro-N-(2-((2S)- 1-methyl-2-pyrrolidinyl)ethyl)-3-oxo-6-(3-pyrazinyl-1-pyrrolidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-N-(2-((2S)-1-methylpyrrolidin-2-yl)ethyl)-3-oxo-6-(3-(pyrazin-2- yl)pyrrolidin-1-yl)-3H-benzo(b)pyrido(3,2,1-kl)phenoxazine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CX-3543","termGroup":"CN","termSource":"NCI"},{"termName":"Quarfloxacin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"865311-47-3"},{"name":"Chemical_Formula","value":"C35H33FN6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8M31J5031Q"},{"name":"Legacy Concept Name","value":"Quarfloxacin"},{"name":"Maps_To","value":"Quarfloxin"},{"name":"NCI_Drug_Dictionary_ID","value":"558903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558903"},{"name":"PDQ_Open_Trial_Search_ID","value":"558903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713025"}]}}{"C67059":{"preferredName":"Quinacrine Hydrochloride","code":"C67059","definitions":[{"definition":"The dihydrochloride salt of the 9-aminoacridine derivative quinacrine with potential antineoplastic and antiparasitic activities. Quinacrine may inhibit the transcription and activity of both basal and inducible nuclear factor-kappaB (NF-kappaB), which may result in the induction of tumor suppressor p53 transcription, the restoration of p53-dependent apoptotic pathways, and tumor cell apoptosis. Continuous NF-kappaB signaling, present in many tumors and in chronic inflammatory processes, promotes the expression of antiapoptotic proteins and cytokines while downregulating the expression of proapoptotic proteins, such as p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quinacrine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"6-Chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Atabrine Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Mepacrine Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Quinacrine Dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"SN 390","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6151-30-0"},{"name":"Chemical_Formula","value":"C23H30ClN3O.2ClH.2H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G6242H2NAA"},{"name":"Legacy Concept Name","value":"Quinacrine_Dihydrochloride"},{"name":"Maps_To","value":"Quinacrine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"531122"},{"name":"NCI_META_CUI","value":"CL550623"},{"name":"NSC Number","value":"14229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"531122"},{"name":"PDQ_Open_Trial_Search_ID","value":"531122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C794":{"preferredName":"Quinine","code":"C794","definitions":[{"definition":"A quinidine alkaloid isolated from the bark of the cinchona tree. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quinine","termGroup":"PT","termSource":"NCI"},{"termName":"QUIN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130-95-0"},{"name":"CHEBI_ID","value":"CHEBI:15854"},{"name":"Chemical_Formula","value":"C20H24N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"A7V27PHC7A"},{"name":"Legacy Concept Name","value":"Quinine"},{"name":"Maps_To","value":"Quinine"},{"name":"NCI_Drug_Dictionary_ID","value":"41253"},{"name":"NSC Number","value":"192949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41253"},{"name":"PDQ_Open_Trial_Search_ID","value":"41253"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034417"}]}}{"C77912":{"preferredName":"Quisinostat","code":"C77912","definitions":[{"definition":"An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quisinostat","termGroup":"PT","termSource":"NCI"},{"termName":"HDAC Inhibitor JNJ-26481585","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 26481585","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-26481585","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ26481585","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"875320-29-9"},{"name":"Chemical_Formula","value":"C21H26N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9BJ85K1J8S"},{"name":"Legacy Concept Name","value":"HDAC_Inhibitor_JNJ-26481585"},{"name":"Maps_To","value":"Quisinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"596704"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596704"},{"name":"PDQ_Open_Trial_Search_ID","value":"596704"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703097"}]}}{"C68936":{"preferredName":"Quizartinib","code":"C68936","definitions":[{"definition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quizartinib","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide","termGroup":"SN","termSource":"NCI"},{"termName":"AC 220","termGroup":"CN","termSource":"NCI"},{"termName":"AC-220","termGroup":"CN","termSource":"NCI"},{"termName":"AC010220","termGroup":"CN","termSource":"NCI"},{"termName":"AC220","termGroup":"CN","termSource":"NCI"},{"termName":"ASP 2689","termGroup":"CN","termSource":"NCI"},{"termName":"ASP-2689","termGroup":"CN","termSource":"NCI"},{"termName":"ASP2689","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea","termGroup":"SN","termSource":"NCI"},{"termName":"Vanflyta","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"950769-58-1"},{"name":"Chemical_Formula","value":"C29H32N6O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"7LA4O6Q0D3"},{"name":"Legacy Concept Name","value":"FLT-3_Kinase_Inhibitor_AC220"},{"name":"Maps_To","value":"Quizartinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2980091"}]}}{"C78348":{"preferredName":"R-(-)-Gossypol Acetic Acid","code":"C78348","definitions":[{"definition":"The orally bioavailable solvate of the R-(-) enantiomer of gossypol and acetic acid with potential antineoplastic activity. As a BH3 mimetic, R-(-)-gossypol binds to the hydrophobic surface binding groove BH3 of the anti-apoptotic proteins Bcl-2 and Bcl-xL, blocking their heterodimerization with pro-apoptotic members of the Bcl-2 family of proteins such as Bad, Bid, and Bim; this may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Racemic gossypol is a polyphenolic compound isolated from cottonseed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"R-(-)-Gossypol Acetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Gossypol Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"(2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-(R)-5,5'-bis(1-methylethyl)-, (2R)-, compd. with acetic acid (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"AT 101","termGroup":"CN","termSource":"NCI"},{"termName":"AT-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"866541-93-7"},{"name":"Chemical_Formula","value":"C30H30O8.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U9GNI6VT5N"},{"name":"Legacy Concept Name","value":"R-Gossypol_Acetic_Acid"},{"name":"Maps_To","value":"R-(-)-Gossypol Acetic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"594869"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594869"},{"name":"PDQ_Open_Trial_Search_ID","value":"594869"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831824"}]}}{"C81937":{"preferredName":"Rabusertib","code":"C81937","definitions":[{"definition":"An inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rabusertib","termGroup":"PT","termSource":"NCI"},{"termName":"1-[5-bromo-4-methyl-2-S-(morpholin-2-yl-methoxy)-phenyl]-3-(5-methyl-pyrazin-2-yl)-urea","termGroup":"SN","termSource":"NCI"},{"termName":"Checkpoint Kinase 2 Inhibitor LY2603618","termGroup":"SY","termSource":"NCI"},{"termName":"LY2603618","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"911222-45-2"},{"name":"Chemical_Formula","value":"C18H22BrN5O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S9L1NU6U7"},{"name":"Legacy Concept Name","value":"CHK2_Inhibitor_LY2603618"},{"name":"Maps_To","value":"Rabusertib"},{"name":"NCI_Drug_Dictionary_ID","value":"637612"},{"name":"PDQ_Closed_Trial_Search_ID","value":"637612"},{"name":"PDQ_Open_Trial_Search_ID","value":"637612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2825835"}]}}{"C95024":{"preferredName":"Racotumomab","code":"C95024","definitions":[{"definition":"An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Racotumomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-P3 Antibody Idiotype Monoclonal Antibody 1E10","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb 1E10","termGroup":"CN","termSource":"NCI"},{"termName":"Vaxira","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946832-34-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"52G405U1E5"},{"name":"Maps_To","value":"Racotumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"689646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689646"},{"name":"PDQ_Open_Trial_Search_ID","value":"689646"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2986854"}]}}{"C165436":{"preferredName":"Emzadirib","code":"C165436","definitions":[{"definition":"An orally bioavailable inhibitor of the DNA damage repair protein RAD51, with potential antineoplastic and sensitizing activities. Upon oral administration, emzadirib targets, binds to and inhibits the activity of RAD51. This prevents RAD51-mediated DNA damage repair in susceptible tumor cells and induces tumor cell apoptosis. RAD51, the central protein involved in homologous repair (HR) of DNA double-strand breaks (DSBs), is overexpressed in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emzadirib","termGroup":"PT","termSource":"NCI"},{"termName":"CYT 0851","termGroup":"CN","termSource":"NCI"},{"termName":"CYT-0851","termGroup":"CN","termSource":"NCI"},{"termName":"CYT0851","termGroup":"CN","termSource":"NCI"},{"termName":"RAD51 Inhibitor CYT-0851","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2301085-04-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B7AM3X83ZO"},{"name":"Maps_To","value":"RAD51 Inhibitor CYT-0851"},{"name":"NCI_Drug_Dictionary_ID","value":"799774"},{"name":"NCI_META_CUI","value":"CL978621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799774"},{"name":"PDQ_Open_Trial_Search_ID","value":"799774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2462":{"preferredName":"Radioactive Iodine","code":"C2462","definitions":[{"definition":"A radioactive form of iodine, often used for imaging tests or to treat an overactive thyroid, thyroid cancer, and certain other cancers. For imaging tests, the patient takes a small dose of radioactive iodine that collects in thyroid cells and certain kinds of tumors and can be detected by a scanner. To treat thyroid cancer, the patient takes a large dose of radioactive iodine, which kills thyroid cells. Radioactive iodine is also used in internal radiation therapy for prostate cancer, intraocular (eye) melanoma, and carcinoid tumors. Radioactive iodine is given by mouth as a liquid or in capsules, by infusion, or sealed in seeds, which are placed in or near the tumor to kill cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Radioactive Iodine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radioactive_Iodine"},{"name":"Maps_To","value":"Radioactive Iodine"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"UMLS_CUI","value":"C1441129"}]}}{"C2729":{"preferredName":"Radiolabeled CC49","code":"C2729","definitions":[{"definition":"A radioimmunoconjugate comprised of a humanized monoclonal antibody with antitumor activity. The monoclonal antibody CC49 is developed from the murine monoclonal antibody B72.3 and is humanized by grafting the hypervariable regions onto the variable light (VL) and variable heavy (VH) frameworks of the monoclonal antibodies LEN and 21/28' CL. The resultant antibody binds the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Furthermore, the antibody is commonly radiolabeled resulting in an effective agent for use in radioimmunotherapy for treatment of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiolabeled CC49","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radiolabeled_CC49"},{"name":"Maps_To","value":"Radiolabeled CC49"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514701"}]}}{"C62535":{"preferredName":"Radium Ra 223 Dichloride","code":"C62535","definitions":[{"definition":"A radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium Ra 223, with antineoplastic activity. Like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. Radium Ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. The radioisotope Ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing DNA double-strand breaks and tumor regression in the skeleton. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy bone tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radium Ra 223 Dichloride","termGroup":"PT","termSource":"NCI"},{"termName":"Alpharadin","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 88-8223","termGroup":"CN","termSource":"NCI"},{"termName":"BAY88-8223","termGroup":"CN","termSource":"NCI"},{"termName":"Radium 223 Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Radium-223 Chloride","termGroup":"SY","termSource":"NCI"},{"termName":"Radium-223 Dichloride","termGroup":"SY","termSource":"NCI"},{"termName":"Xofigo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444811-40-9"},{"name":"Chemical_Formula","value":"2Cl.Ra"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RJ00KV3VTG"},{"name":"Legacy Concept Name","value":"Radium-223"},{"name":"Maps_To","value":"Radium Ra 223 Dichloride"},{"name":"NCI_Drug_Dictionary_ID","value":"749662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749662"},{"name":"PDQ_Open_Trial_Search_ID","value":"749662"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3541342"}]}}{"C159537":{"preferredName":"Radium Ra 224-labeled Calcium Carbonate Microparticles","code":"C159537","definitions":[{"definition":"A radiopharmaceutical composed of biodegradable calcium carbonate microspheres labeled with the alpha-emitting radioisotope radium Ra 224, with antineoplastic activity. Upon intraperitoneal (IP) administration of the radium Ra 224-labeled calcium carbonate microparticles, Ra 224 kills tumor cells through local emission of high energy alpha particles, causing DNA double-strand breaks. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radium Ra 224-labeled Calcium Carbonate Microparticles","termGroup":"PT","termSource":"NCI"},{"termName":"224Ra-labeled Calcium Carbonate Micro-particles","termGroup":"SY","termSource":"NCI"},{"termName":"Alpha-emitting 224Ra Calcium Carbonate Microspheres","termGroup":"SY","termSource":"NCI"},{"termName":"Ra-224 Alpha-emitting Calcium Carbonate Microparticles","termGroup":"SY","termSource":"NCI"},{"termName":"Radspherin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radium Ra 224-labeled Calcium Carbonate Microparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"797476"},{"name":"NCI_META_CUI","value":"CL951431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797476"},{"name":"PDQ_Open_Trial_Search_ID","value":"797476"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113297":{"preferredName":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement","code":"C113297","definitions":[{"definition":"A traditional Chinese medicine comprising of Radix Angelicae Sinensis (RAS) and Radix Astragali (RA), with potential anti-inflammatory, immunostimulatory, neuroprotective, anti-hepatotoxic and antineoplastic activities. The main chemical constituents of RAS include ferulic acid, Z-ligustilide, butylidenephthalide and various polysaccharides. RA is the dried root of Astragalus membranaceus with primary constituents such polysaccharides, triterpenoids as well as isoflavones. Though their mechanisms of action remain largely elusive, Radix Angelicae Sinensis/Radix Astragali herbal supplements are commonly used for the treatment of various health conditions affecting women including premenstrual syndrome, dysmenorrhea, pelvic pain, recovery from childbirth and menopausal symptoms. These agents are also used for alleviating constipation, preventing and treating anemia and allergic attacks, and for the management of hypertension, joint pain and ulcers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Danggui Buxue Decoction No.1","termGroup":"CN","termSource":"NCI"},{"termName":"DB1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radix Angelicae Sinensis/Radix Astragali Herbal Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"756038"},{"name":"NCI_META_CUI","value":"CL471832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756038"},{"name":"PDQ_Open_Trial_Search_ID","value":"756038"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99644":{"preferredName":"Radotinib Hydrochloride","code":"C99644","definitions":[{"definition":"An orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent efficacy in CML cells that are resistant to the first-generation standard tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radotinib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"IY5511HCl","termGroup":"CN","termSource":"NCI"},{"termName":"Supect","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"926037-85-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EF516G9REZ"},{"name":"Maps_To","value":"Radotinib Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"723999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"723999"},{"name":"PDQ_Open_Trial_Search_ID","value":"723999"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467958"}]}}{"C121646":{"preferredName":"Belvarafenib","code":"C121646","definitions":[{"definition":"An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Belvarafenib","termGroup":"PT","termSource":"NCI"},{"termName":"HM95573","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446113-23-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31M3WLJ3KG"},{"name":"Maps_To","value":"Belvarafenib"},{"name":"Maps_To","value":"Raf Kinase Inhibitor HM95573"},{"name":"NCI_Drug_Dictionary_ID","value":"770820"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770820"},{"name":"PDQ_Open_Trial_Search_ID","value":"770820"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053637"}]}}{"C2722":{"preferredName":"RAF Kinase Inhibitor L-779450","code":"C2722","definitions":[{"definition":"A synthetic triarylimidazole with potential antineoplastic activity.  As a Raf kinase inhibitor, L-779450 competes with ATP for binding to the Raf-1 and A-Raf catalytic sites, thus inhibiting their enzymatic activities and blocking various signal transduction pathways that depend on Raf-1 kinase (particularly the Ras-Raf-MEK-ERK cascade which is often up-regulated in neoplasms). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAF Kinase Inhibitor L-779450","termGroup":"PT","termSource":"NCI"},{"termName":"L-779,450","termGroup":"CN","termSource":"NCI"},{"termName":"L-779450","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"L-779450"},{"name":"Maps_To","value":"RAF Kinase Inhibitor L-779450"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517681"}]}}{"C69135":{"preferredName":"RAF Kinase Inhibitor XL281","code":"C69135","definitions":[{"definition":"An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. RAS mutations may result in constitutive activation of the RAS/RAF/MEK/ERK kinase signaling pathway, and have been found to occur frequently in human tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RAF Kinase Inhibitor XL281","termGroup":"PT","termSource":"NCI"},{"termName":"XL-281","termGroup":"CN","termSource":"NCI"},{"termName":"XL281","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"RAF_Kinase_Inhibitor_XL281"},{"name":"Maps_To","value":"RAF Kinase Inhibitor XL281"},{"name":"NCI_Drug_Dictionary_ID","value":"543515"},{"name":"NCI_META_CUI","value":"CL371855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543515"},{"name":"PDQ_Open_Trial_Search_ID","value":"543515"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124654":{"preferredName":"Ralaniten Acetate","code":"C124654","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the acetate form of ralaniten, a N-terminal domain (NTD) of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration of ralaniten acetate, ralaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ralaniten Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Propanediol, 3-(4-(1-(4-((2S)-2-(acetyloxy)-3-chloropropoxy)phenyl)-1-methylethyl)phenoxy)-, 1,2-Diacetate, (2S)-","termGroup":"SN","termSource":"NCI"},{"termName":"AR Inhibitor EPI-506","termGroup":"SY","termSource":"NCI"},{"termName":"EPI-506","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1637573-04-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L10K286T2H"},{"name":"Maps_To","value":"Ralaniten Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"777367"},{"name":"NCI_META_CUI","value":"CL502886"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777367"},{"name":"PDQ_Open_Trial_Search_ID","value":"777367"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C105853":{"preferredName":"Ralimetinib Mesylate","code":"C105853","definitions":[{"definition":"The dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities. Upon administration, ralimetinib inhibits the activity of p38, particularly the alpha and beta isoforms, thereby inhibiting MAPKAPK2 phosphorylation and preventing p38 MAPK-mediated signaling. This may inhibit the production of a variety of cytokines involved in inflammation, cellular proliferation and angiogenesis such as tumor necrosis factor alpha (TNFa), interleukin (IL)-1, -6 and -8, vascular endothelial growth factor, and macrophage inflammatory protein-1 alpha. Ultimately this induces apoptosis and reduces tumor cell proliferation. In addition, inhibition of the p38 MAPK pathway by LY2228820 increases the antineoplastic activity of certain chemotherapeutic agents. p38 MAPK, a serine/threonine protein kinase that is often upregulated in cancer cells, plays a crucial role in tumor cell proliferation, angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ralimetinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, Methanesulfonate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"LY-2228820","termGroup":"CN","termSource":"NCI"},{"termName":"LY2228820","termGroup":"CN","termSource":"NCI"},{"termName":"LY2228820 Dimesylate","termGroup":"SY","termSource":"NCI"},{"termName":"Ralimetinib Dimesylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"862507-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QUW7B71FO9"},{"name":"Maps_To","value":"Ralimetinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"687387"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687387"},{"name":"PDQ_Open_Trial_Search_ID","value":"687387"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659483"}]}}{"C1518":{"preferredName":"Raloxifene","code":"C1518","definitions":[{"definition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who have osteoporosis. It is also used to prevent and treat osteoporosis in postmenopausal women. It is also being studied in the prevention of breast cancer in certain premenopausal women and in the prevention and treatment of other conditions. Raloxifene blocks the effects of the hormone estrogen in the breast and increases the amount of calcium in bone. It is a type of selective estrogen receptor modulator (SERM).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Raloxifene","termGroup":"PT","termSource":"NCI"},{"termName":"[6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone","termGroup":"SN","termSource":"NCI"},{"termName":"Keoxifene","termGroup":"SY","termSource":"NCI"},{"termName":"LY 139481","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Cardiovascular Disease prophylaxis; Osteoporosis"},{"name":"CAS_Registry","value":"84449-90-1"},{"name":"CHEBI_ID","value":"CHEBI:8772"},{"name":"Chemical_Formula","value":"C28H27NO4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YX9162EO3I"},{"name":"Legacy Concept Name","value":"Raloxifene"},{"name":"Maps_To","value":"Raloxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"43109"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43109"},{"name":"PDQ_Open_Trial_Search_ID","value":"43109"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0752233"}]}}{"C1762":{"preferredName":"Raloxifene Hydrochloride","code":"C1762","definitions":[{"definition":"A drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who have osteoporosis. It is also used to prevent and treat osteoporosis in postmenopausal women. It is also being studied in the prevention of breast cancer in certain premenopausal women and in the prevention and treatment of other conditions. Evista blocks the effects of the hormone estrogen in the breast and increases the amount of calcium in bone. It is a type of selective estrogen receptor modulator (SERM).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raloxifene Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Evista","termGroup":"BR","termSource":"NCI"},{"termName":"Keoxifene Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"LY-156758","termGroup":"CN","termSource":"NCI"},{"termName":"Optruma","termGroup":"FB","termSource":"NCI"},{"termName":"Raloxifene HCl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer prevention"},{"name":"CAS_Registry","value":"82640-04-8"},{"name":"CHEBI_ID","value":"CHEBI:50740"},{"name":"Chemical_Formula","value":"C28H27NO4S.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4F86W47BR6"},{"name":"Legacy Concept Name","value":"Raloxifene_Hydrochloride"},{"name":"Maps_To","value":"Raloxifene Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"43109"},{"name":"NSC Number","value":"706725"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43109"},{"name":"PDQ_Open_Trial_Search_ID","value":"43109"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0618111"}]}}{"C1804":{"preferredName":"Raltitrexed","code":"C1804","definitions":[{"definition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that stops tumor cells from growing by blocking the ability of cells to make DNA. It belongs to the family of drugs called thymidylate synthase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Raltitrexed","termGroup":"PT","termSource":"NCI"},{"termName":"D1694","termGroup":"CN","termSource":"NCI"},{"termName":"ICI D1694","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-[N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ZD 1694","termGroup":"CN","termSource":"NCI"},{"termName":"ZD-1694","termGroup":"CN","termSource":"NCI"},{"termName":"ZD1694","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112887-68-0"},{"name":"Chemical_Formula","value":"C21H22N4O6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"FCB9EGG971"},{"name":"Legacy Concept Name","value":"Raltitrexed"},{"name":"Maps_To","value":"Raltitrexed"},{"name":"NCI_Drug_Dictionary_ID","value":"42625"},{"name":"NSC Number","value":"639186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42625"},{"name":"PDQ_Open_Trial_Search_ID","value":"42625"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677667"}]}}{"C70792":{"preferredName":"Ramucirumab","code":"C70792","definitions":[{"definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ramucirumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B","termGroup":"SY","termSource":"NCI"},{"termName":"Cyramza","termGroup":"BR","termSource":"NCI"},{"termName":"IMC 1121B","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-1121B","termGroup":"CN","termSource":"NCI"},{"termName":"IMC1121B","termGroup":"CN","termSource":"NCI"},{"termName":"LY 3009806","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3009806","termGroup":"CN","termSource":"NCI"},{"termName":"LY3009806","termGroup":"CN","termSource":"NCI"},{"termName":"Monoclonal Antibody HGS-ETR2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic colorectal cancer (mCRC); advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma; hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of >= 400 ng/mL"},{"name":"Accepted_Therapeutic_Use_For","value":"multicentric Castleman's disease (MCD)"},{"name":"CAS_Registry","value":"947687-13-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"D99YVK4L0X"},{"name":"Legacy Concept Name","value":"Anti-VEGFR-2_Fully_Human_Monoclonal_Antibody_IMC-1121B"},{"name":"Maps_To","value":"Ramucirumab"},{"name":"NCI_Drug_Dictionary_ID","value":"570535"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570535"},{"name":"PDQ_Open_Trial_Search_ID","value":"570535"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742502"}]}}{"C67562":{"preferredName":"Ranibizumab","code":"C67562","definitions":[{"definition":"A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ranibizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain","termGroup":"SY","termSource":"NCI"},{"termName":"Lucentis","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"347396-82-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZL1R02VT79"},{"name":"Legacy Concept Name","value":"Ranibizumab"},{"name":"Maps_To","value":"Ranibizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"544572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"544572"},{"name":"PDQ_Open_Trial_Search_ID","value":"544572"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566537"}]}}{"C1515":{"preferredName":"Ranimustine","code":"C1515","definitions":[{"definition":"A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ranimustine","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-D-glucopyranoside, methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Cymer","termGroup":"FB","termSource":"NCI"},{"termName":"Cymerin","termGroup":"FB","termSource":"NCI"},{"termName":"MCNU","termGroup":"AB","termSource":"NCI"},{"termName":"methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl) amino)-6-deoxy-alpha-D-glucopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"methyl 6-(3-(2-chloroethyl)-3-nitrosoiureido)-6-deoxy-alpha-D-glucopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"methyl 6-(3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy-alpha-D-glucopyranoside","termGroup":"SN","termSource":"NCI"},{"termName":"Ranomustine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58994-96-0"},{"name":"Chemical_Formula","value":"C10H18ClN3O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RYH2T97J77"},{"name":"Legacy Concept Name","value":"Ranimustine"},{"name":"Maps_To","value":"Ranimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"470235"},{"name":"NSC Number","value":"270516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"470235"},{"name":"PDQ_Open_Trial_Search_ID","value":"470235"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0243666"}]}}{"C66507":{"preferredName":"Ranolazine","code":"C66507","definitions":[{"definition":"An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti-ischemic effects has yet to be fully elucidated but may involve the alteration of the trans-cellular late sodium current in the ischemic myocyte. By preventing the rise of intracellular sodium levels, ranolazine may affect the transport activity of sodium-dependent calcium channels and prevent the calcium overload during myocardial ischemia, thereby preventing cellular injury. Ranolazine's potential antineoplastic effect may depend on its inhibitory effect on fatty acid oxidation, which may sensitize tumor cells to apoptosis and decrease tumor cell proliferation; fatty acid oxidation provides energy and promotes tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ranolazine","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Ranexa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"95635-55-5"},{"name":"Chemical_Formula","value":"C24H33N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A6IEZ5M406"},{"name":"Legacy Concept Name","value":"Ranolazine"},{"name":"Maps_To","value":"Ranolazine"},{"name":"NCI_Drug_Dictionary_ID","value":"753754"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753754"},{"name":"PDQ_Open_Trial_Search_ID","value":"753754"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073633"}]}}{"C1183":{"preferredName":"Ranpirnase","code":"C1183","definitions":[{"definition":"A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens.  Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of ribonuclease enzyme.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ranpirnase","termGroup":"PT","termSource":"NCI"},{"termName":"Onconase","termGroup":"BR","termSource":"NCI"},{"termName":"P-30","termGroup":"SY","termSource":"NCI"},{"termName":"P-30 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"P30","termGroup":"SY","termSource":"NCI"},{"termName":"P30 Protein","termGroup":"SY","termSource":"NCI"},{"termName":"RANPIRNASE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Mesothelioma"},{"name":"CAS_Registry","value":"196488-72-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZE15FIT23E"},{"name":"Legacy Concept Name","value":"Ranpirnase"},{"name":"Maps_To","value":"Ranpirnase"},{"name":"NCI_Drug_Dictionary_ID","value":"41305"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41305"},{"name":"PDQ_Open_Trial_Search_ID","value":"41305"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069919"}]}}{"C77899":{"preferredName":"RARalpha Agonist IRX5183","code":"C77899","definitions":[{"definition":"An orally bioavailable retinoid acid receptor alpha (RARalpha) agonist and vitamin A derivative, with potential antineoplastic activity. Upon administration, RARalpha agonist IRX5183 binds to and activates RARalpha, which promotes RARalpha-mediated signaling. This results in the transcription of RARalpha-responsive genes, which are responsible for cellular differentiation and proliferation. This results in the induction of cellular differentiation and apoptosis, and leads to the inhibition of cellular proliferation and tumorigenesis. RARalpha is a nuclear receptor and a member of the steroid receptor superfamily; reduced RARalpha signaling is correlated with cancer development in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RARalpha Agonist IRX5183","termGroup":"PT","termSource":"NCI"},{"termName":"AGN 195183","termGroup":"CN","termSource":"NCI"},{"termName":"AGN-195183","termGroup":"CN","termSource":"NCI"},{"termName":"IRX 5183","termGroup":"CN","termSource":"NCI"},{"termName":"IRX5183","termGroup":"CN","termSource":"NCI"},{"termName":"NRX 195183","termGroup":"CN","termSource":"NCI"},{"termName":"NRX195183","termGroup":"CN","termSource":"NCI"},{"termName":"RARa Agonist IRX5183","termGroup":"SY","termSource":"NCI"},{"termName":"VTP 195183","termGroup":"CN","termSource":"NCI"},{"termName":"VTP-195183","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"367273-07-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RC87L028HU"},{"name":"Legacy Concept Name","value":"Retinoid_Analogue_NRX_195183"},{"name":"Maps_To","value":"RARalpha Agonist IRX5183"},{"name":"NCI_Drug_Dictionary_ID","value":"596530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596530"},{"name":"PDQ_Open_Trial_Search_ID","value":"596530"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527761"}]}}{"C1902":{"preferredName":"Ras Inhibitor","code":"C1902","definitions":[{"definition":"An agent designed to inhibit the signal transduction process by interfering with the action of the ras family of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Inhibitor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Examples include carboxyaminoimidazole (CAI), Iovastatin, limonene, and perillyl alcohol."},{"name":"Legacy Concept Name","value":"Ras_Inhibitor"},{"name":"Maps_To","value":"Ras Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C1514727"}]}}{"C2802":{"preferredName":"Ras Peptide ASP","code":"C2802","definitions":[{"definition":"A synthetic form of the ras peptide containing a point mutation at position 12 (glycine to aspartic acid) with potential antineoplastic activity.  Vaccination with ras peptide Asp may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this ras mutation, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Peptide ASP","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ras_Peptide_ASP"},{"name":"Maps_To","value":"Ras Peptide ASP"},{"name":"NSC Number","value":"667938"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514728"}]}}{"C2803":{"preferredName":"Ras Peptide CYS","code":"C2803","definitions":[{"definition":"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to cysteine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Peptide CYS","termGroup":"PT","termSource":"NCI"},{"termName":"Ras (sub 5-17) Peptide (C12)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ras_Peptide_CYS"},{"name":"Maps_To","value":"Ras Peptide CYS"},{"name":"NSC Number","value":"667937"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514729"}]}}{"C2804":{"preferredName":"Ras Peptide VAL","code":"C2804","definitions":[{"definition":"A synthetic form of the Ras peptide containing a point mutation at position 12 (glycine to valine) with potential antineoplastic activity.  Vaccination with this peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for this Ras mutation, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ras Peptide VAL","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ras_Peptide_VAL"},{"name":"Maps_To","value":"Ras Peptide VAL"},{"name":"NSC Number","value":"665824"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514730"}]}}{"C801":{"preferredName":"Razoxane","code":"C801","definitions":[{"definition":"An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Razoxane","termGroup":"PT","termSource":"NCI"},{"termName":"ICI 59118","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF 159","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF-159","termGroup":"CN","termSource":"NCI"},{"termName":"ICRF159","termGroup":"CN","termSource":"NCI"},{"termName":"Razoxin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"21416-67-1"},{"name":"CAS_Registry","value":"21416-87-5"},{"name":"CHEBI_ID","value":"CHEBI:50225"},{"name":"Chemical_Formula","value":"C11H16N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5AR83PR647"},{"name":"Legacy Concept Name","value":"Razoxane"},{"name":"Maps_To","value":"Razoxane"},{"name":"NCI_Drug_Dictionary_ID","value":"39480"},{"name":"NSC Number","value":"129943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39480"},{"name":"PDQ_Open_Trial_Search_ID","value":"39480"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0034738"}]}}{"C117289":{"preferredName":"Realgar-Indigo naturalis Formulation","code":"C117289","definitions":[{"definition":"An orally bioavailable, traditional Chinese medicine (TCM)-based formulation composed of Realgar-Indigo naturalis formula (RIF) with potential antineoplastic activity. The main constituents in RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (As4S4), indirubin and tanshinone IIA as the main active ingredients, respectively, which appear to exert synergistic effects on cancer cells. Tetraarsenic tetrasulfide specifically induces the ubiquitination and degradation of promyelocytic leukemia retinoic acid receptor alpha (PML-RARalpha) oncoprotein. In addition, the active ingredients in the Realgar-Indigo naturalis formulation enhance the expression of myeloid differentiation genes, and induce G(1)/G(0) cell cycle arrest. PML-RARalpha, an acute promyelocytic leukemia (APL)-specific fusion gene, inhibits differentiation and promotes survival of myeloid precursor cells","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Realgar-Indigo naturalis Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"Compound Huangdai","termGroup":"SY","termSource":"NCI"},{"termName":"RIF","termGroup":"AB","termSource":"NCI"},{"termName":"RIF Formula","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Realgar-Indigo naturalis Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"763399"},{"name":"NCI_META_CUI","value":"CL474115"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763399"},{"name":"PDQ_Open_Trial_Search_ID","value":"763399"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82693":{"preferredName":"Rebastinib Tosylate","code":"C82693","definitions":[{"definition":"The tosylate salt of rebastinib, an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Rebastinib binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebastinib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"DCC-2036","termGroup":"CN","termSource":"NCI"},{"termName":"DP-1919.TO","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1033893-29-6"},{"name":"CHEBI_ID","value":"CHEBI:62166"},{"name":"Chemical_Formula","value":"C30H28FN7O3.C7H8O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"042A5NJE6B"},{"name":"Legacy Concept Name","value":"Multitargeted_Tyrosine_Kinase_Inhibitor_DCC-2036"},{"name":"Maps_To","value":"Rebastinib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"634547"},{"name":"PDQ_Closed_Trial_Search_ID","value":"634547"},{"name":"PDQ_Open_Trial_Search_ID","value":"634547"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830217"}]}}{"C1213":{"preferredName":"Rebeccamycin","code":"C1213","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antineoplastic antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolocarbazole glycoside antineoplastic antibiotic isolated from the bacterium Saccharothrix aerocolonigenes.  Rebeccamycin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebeccamycin","termGroup":"PT","termSource":"NCI"},{"termName":"5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione,1,11-dichloro-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"BRN 4732638","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93908-02-2"},{"name":"CHEBI_ID","value":"CHEBI:135511"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y96MQM21V9"},{"name":"Legacy Concept Name","value":"Rebeccamycin"},{"name":"Maps_To","value":"Rebeccamycin"},{"name":"NSC Number","value":"359079"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073012"}]}}{"C1875":{"preferredName":"Rebimastat","code":"C1875","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rebimastat","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-275291","termGroup":"CN","termSource":"NCI"},{"termName":"D2163","termGroup":"CN","termSource":"NCI"},{"termName":"N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"259188-38-0"},{"name":"Chemical_Formula","value":"C23H41N5O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1B47R6ZX4K"},{"name":"Legacy Concept Name","value":"BMS-275291"},{"name":"Maps_To","value":"Rebimastat"},{"name":"NCI_Drug_Dictionary_ID","value":"38088"},{"name":"NSC Number","value":"713763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38088"},{"name":"PDQ_Open_Trial_Search_ID","value":"38088"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935902"}]}}{"C71710":{"preferredName":"Receptor Tyrosine Kinase Inhibitor R1530","code":"C71710","definitions":[{"definition":"A pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. Mitosis-angiogenesis inhibitor (MAI) R1530 inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta, FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Receptor Tyrosine Kinase Inhibitor R1530","termGroup":"PT","termSource":"NCI"},{"termName":"MAI R1530","termGroup":"AB","termSource":"NCI"},{"termName":"R1530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Mitosis_and_Apoptosis_Inhibitor_R1530"},{"name":"Maps_To","value":"Receptor Tyrosine Kinase Inhibitor R1530"},{"name":"NCI_Drug_Dictionary_ID","value":"560180"},{"name":"NCI_META_CUI","value":"CL376137"},{"name":"PDQ_Closed_Trial_Search_ID","value":"560180"},{"name":"PDQ_Open_Trial_Search_ID","value":"560180"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2423":{"preferredName":"Recombinant Adenovirus-p53 SCH-58500","code":"C2423","definitions":[{"definition":"A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that has been studied in the treatment of some types of cancer. rAd/p53 is a weakened adenovirus that carries the p53 gene into tumor cells, causing them to die. It is a type of gene therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Adenovirus-p53 SCH-58500","termGroup":"PT","termSource":"NCI"},{"termName":"rAd/p53","termGroup":"AB","termSource":"NCI"},{"termName":"SCH 58500","termGroup":"CN","termSource":"NCI"},{"termName":"SCH-58500","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Primary ovarian cancer"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Adenovirus-p53"},{"name":"Maps_To","value":"Recombinant Adenovirus-p53 SCH-58500"},{"name":"NCI_Drug_Dictionary_ID","value":"42631"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42631"},{"name":"PDQ_Open_Trial_Search_ID","value":"42631"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1514767"}]}}{"C116880":{"preferredName":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A","code":"C116880","definitions":[{"definition":"An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A","termGroup":"PT","termSource":"NCI"},{"termName":"ASCI GSK2302024A","termGroup":"SY","termSource":"NCI"},{"termName":"GSK2302024A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Anti-WT1 Immunotherapeutic GSK2302024A"},{"name":"NCI_Drug_Dictionary_ID","value":"687580"},{"name":"NCI_META_CUI","value":"CL433728"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687580"},{"name":"PDQ_Open_Trial_Search_ID","value":"687580"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60882":{"preferredName":"Recombinant Bispecific Single-Chain Antibody rM28","code":"C60882","definitions":[{"definition":"A recombinant, bispecific, single-chain antibody directed against both the T-cell surface-associated costimulatory molecule CD28 and a melanoma-associated proteoglycan (MAPG) with potential antitumor activity. By targeting both CD28 and MAPG, recombinant bispecific single-chain antibody rM28 enhances cytotoxic T-cell recognition of melanoma cells, which may result in immune effector cell-mediated tumor cell death and a decrease in distant metastases. This agent appears to have a long serum half-life secondary to the formation of dimers. When activated, CD28 facilitates interactions between T-cells and other immune effector cells resulting in cytotoxic T-lymphocyte responses; MAPG is a surface antigen expressed on the majority of melanomas, including primary cutaneous, ocular, and metastatic melanomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Bispecific Single-Chain Antibody rM28","termGroup":"PT","termSource":"NCI"},{"termName":"rM28","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Bispecific_Single-Chain_Antibody_rM28"},{"name":"Maps_To","value":"Recombinant Bispecific Single-Chain Antibody rM28"},{"name":"NCI_Drug_Dictionary_ID","value":"467183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467183"},{"name":"PDQ_Open_Trial_Search_ID","value":"467183"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1831730"}]}}{"C1437":{"preferredName":"Recombinant CD40-Ligand","code":"C1437","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to CD40-ligand. CD40-ligand, also known as CD40L/TRAP and CD154, is a type II membrane protein which binds to CD40, a cell surface receptor that belongs to the tumor necrosis factor receptor family; CD40 is expressed on B lymphocytes, monocytes, dendritic cells (DC), hematopoietic progenitors, endothelial cells and epithelial cells. Recombinant CD40-ligand may be used to activate DC ex vivo via CD40 binding; CD40-ligand-activated DC may provide or augment a protective antitumor immunity when administered in dendritic cell cancer vaccines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant CD40-Ligand","termGroup":"PT","termSource":"NCI"},{"termName":"CD154 antigen","termGroup":"SY","termSource":"NCI"},{"termName":"CD40L","termGroup":"AB","termSource":"NCI"},{"termName":"gp39","termGroup":"SY","termSource":"NCI"},{"termName":"rhu CD40L","termGroup":"AB","termSource":"NCI"},{"termName":"T-BAM","termGroup":"SY","termSource":"NCI"},{"termName":"T-Cell Antigen gp39","termGroup":"SY","termSource":"NCI"},{"termName":"TNF-Related Activation Protein","termGroup":"SY","termSource":"NCI"},{"termName":"TRAP Ligand","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"147205-72-9"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_CD40-Ligand"},{"name":"Maps_To","value":"Recombinant CD40-Ligand"},{"name":"NCI_Drug_Dictionary_ID","value":"43639"},{"name":"NSC Number","value":"696600"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43639"},{"name":"PDQ_Open_Trial_Search_ID","value":"43639"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527003"}]}}{"C477":{"preferredName":"Recombinant Erythropoietin","code":"C477","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Erythropoietin","termGroup":"PT","termSource":"NCI"},{"termName":"Erythrocyte Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Erythropoietin","termGroup":"SY","termSource":"NCI"},{"termName":"Hematopoietin","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant EPO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11096-26-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"64FS3BFH5W"},{"name":"Legacy Concept Name","value":"Recombinant_Erythropoietin"},{"name":"Maps_To","value":"Recombinant Erythropoietin"},{"name":"NSC Number","value":"628281"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0376541"}]}}{"C1538":{"preferredName":"Recombinant Fas Ligand","code":"C1538","definitions":[{"definition":"A recombinant agent, which is chemically identical to or similar to the endogenous protein Fas ligand, a protein related to tumor necrosis factor (TNF) with potential antineoplastic activity.  Fas ligand binds to the Fas receptor, thereby activating caspases and inducing apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Fas Ligand","termGroup":"PT","termSource":"NCI"},{"termName":"Fas Ligand","termGroup":"SY","termSource":"NCI"},{"termName":"Fas-L","termGroup":"AB","termSource":"NCI"},{"termName":"FAS-Ligand","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Fas_Ligand"},{"name":"Maps_To","value":"Recombinant Fas Ligand"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515370"}]}}{"C2257":{"preferredName":"Recombinant Fractalkine","code":"C2257","definitions":[{"definition":"A pro-inflammatory delta chemokine with potential antineoplastic activity.  Fractalkine induces the adhesion and migration of T lymphocytes, monocytes and natural killer (NK) cells.  In lymphomas, this agent may promote cell-mediated lympholysis by recruiting activated NK cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Fractalkine","termGroup":"PT","termSource":"NCI"},{"termName":"CX3CL1","termGroup":"SY","termSource":"NCI"},{"termName":"Fractalkine","termGroup":"SY","termSource":"NCI"},{"termName":"Neurotactin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Fractalkine"},{"name":"Maps_To","value":"Recombinant Fractalkine"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522507"}]}}{"C1288":{"preferredName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","code":"C1288","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Colony-Stimulating Factor, Granulocyte-Macrophage","termGroup":"SY","termSource":"NCI"},{"termName":"CSF 39300","termGroup":"CN","termSource":"NCI"},{"termName":"CSF 39300/GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"CSF-GM (Hoechst)","termGroup":"SY","termSource":"NCI"},{"termName":"GM CSF","termGroup":"AB","termSource":"NCI"},{"termName":"GM-CSF","termGroup":"SY","termSource":"NCI"},{"termName":"GM-CSF (Schering)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinanr Colony-Stimulating Factor 2","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Colony-Stimulating Factor 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"83869-56-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Granulocyte-Macrophage_Colony-Stimulating_Factor"},{"name":"Maps_To","value":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor"},{"name":"NSC Number","value":"613795"},{"name":"NSC Number","value":"617589"},{"name":"NSC Number","value":"622183"},{"name":"NSC Number","value":"643496"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0376563"}]}}{"C1792":{"preferredName":"Recombinant Human 6Ckine","code":"C1792","definitions":[{"definition":"A therapeutic recombinant analogue of a member of the endogenous CC chemokines with potential antineoplastic activity. Expressed by various lymphoid tissues, endogenous 6Ckine is chemotactic for B and T lymphocytes and dendritic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human 6Ckine","termGroup":"PT","termSource":"NCI"},{"termName":"6ckine","termGroup":"SY","termSource":"NCI"},{"termName":"CCL21","termGroup":"SY","termSource":"NCI"},{"termName":"ck beta 9","termGroup":"SY","termSource":"NCI"},{"termName":"Exodus-2","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Secondary Lymphoid-Tissue Chemokine","termGroup":"SY","termSource":"NCI"},{"termName":"Secondary Lymphoid-Tissue Chemokine","termGroup":"SY","termSource":"NCI"},{"termName":"TCA4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Secondary_Lymphoid-Tissue_Chemokine"},{"name":"Maps_To","value":"Recombinant Human 6Ckine"},{"name":"NCI_Drug_Dictionary_ID","value":"459900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459900"},{"name":"PDQ_Open_Trial_Search_ID","value":"459900"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1523979"}]}}{"C107504":{"preferredName":"Recombinant Human Adenovirus Type 5 H101","code":"C107504","definitions":[{"definition":"A replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. Upon intratumoral injection of recombinant human adenovirus type 5, the adenovirus selectively replicates in cancer cells while preventing viral replication in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. In addition, viral spread to adjacent cells, following lysis of infected cells, may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation, which promotes viral replication; deletion of E1B allows for p53 activation in normal cells, which prevents viral replication in normal, healthy cells. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of E3, encoding the adenovirus death protein, enhances the safety profile of the administered adenovirus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Adenovirus Type 5 H101","termGroup":"PT","termSource":"NCI"},{"termName":"H101","termGroup":"CN","termSource":"NCI"},{"termName":"Oncorine","termGroup":"FB","termSource":"NCI"},{"termName":"rAd5 H101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802358-15-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QH36X20ODG"},{"name":"Maps_To","value":"Recombinant Human Adenovirus Type 5 H101"},{"name":"NCI_Drug_Dictionary_ID","value":"751381"},{"name":"NCI_META_CUI","value":"CL451750"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751381"},{"name":"PDQ_Open_Trial_Search_ID","value":"751381"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C85447":{"preferredName":"Alunacedase Alfa","code":"C85447","definitions":[{"definition":"A recombinant, soluble glycosylated form of human angiotensin converting enzyme 2 (rhACE2) with antihypertensive and potential antineoplastic activities. Alunacedase Alfa may normalize ACE2 levels, cleaving angiotensin II to create angiotensin-(1-7) and restoring the function of the renin-angiotensin system (RAS). ACE2, a homolog of ACE1, appears to function as a negative regulator of the RAS system by converting angiotensin II to angiotensin-(1-7), a peptide with actions that counteract the cardiovascular actions of angiotensin II. In addition, angiotensin-(1-7) may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) G protein-coupled receptor Mas, resulting in diminished tumor cell proliferation. ACE2 levels may be reduced in malignancy and diabetes and in liver, cardiovascular and lung diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alunacedase Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"APN01","termGroup":"CN","termSource":"NCI"},{"termName":"rhACE2 APN01","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416824-55-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FA2I4Z873U"},{"name":"Maps_To","value":"Recombinant Human Angiotensin Converting Enzyme 2 APN01"},{"name":"NCI_Drug_Dictionary_ID","value":"642531"},{"name":"NCI_META_CUI","value":"CL412316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642531"},{"name":"PDQ_Open_Trial_Search_ID","value":"642531"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116864":{"preferredName":"Recombinant Human Apolipoprotein(a) Kringle V MG1102","code":"C116864","definitions":[{"definition":"An 86 amino-acid long polypeptide fragment of a recombinant form of human apolipoprotein (a) (apo(a)) kringle V, with potential anti-angiogenic and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration, recombinant human apo(a) kringle V MG1102 inhibits the fibronectin-mediated migration of endothelial cells, binds to and blocks the activity of alpha 3 beta 1 integrin (a3b1 integrin), inhibits the activation of focal adhesion kinase (FAK) and FAK-mediated signaling, and leads to the inhibition of the p130 Crk-associated substrate (p130CAS)-c-Jun NH2-terminal kinase (JNK) pathway. This inhibits tumor angiogenesis, induces mitochondrial-mediated apoptosis of tumor cells and tumor-associated endothelial cells, and suppresses tumor growth and metastasis. Apo(a), a glycoprotein component of human lipoprotein(a), contains repeated kringle domains; certain kringle domains of apo(a), including the plasminogen kringle V homolog (KV), have anti-angiogenic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Apolipoprotein(a) Kringle V MG1102","termGroup":"PT","termSource":"NCI"},{"termName":"MG1102","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Human Apo (a) Kringle V MG1102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Apolipoprotein(a) Kringle V MG1102"},{"name":"NCI_Drug_Dictionary_ID","value":"688419"},{"name":"NCI_META_CUI","value":"CL433737"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688419"},{"name":"PDQ_Open_Trial_Search_ID","value":"688419"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70674":{"preferredName":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine","code":"C70674","definitions":[{"definition":"A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Center of Molecular Immunology Epidermal Growth Factor Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Cimavax","termGroup":"SY","termSource":"NCI"},{"termName":"CIMAvax EGF","termGroup":"AB","termSource":"NCI"},{"termName":"CIMAvax Epidermal Growth Factor Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CimaVax Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"CIMAvax-EGF","termGroup":"AB","termSource":"NCI"},{"termName":"Recombinant Human EGF-P64K/Montanide Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Human_EGF-rP64K_Montanide_ISA_51_Vaccine"},{"name":"Maps_To","value":"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"570107"},{"name":"NCI_META_CUI","value":"CL376048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570107"},{"name":"PDQ_Open_Trial_Search_ID","value":"570107"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C45515":{"preferredName":"Recombinant Human Endostatin","code":"C45515","definitions":[{"definition":"A recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. Endostatin induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction in tumor burden. This agent also may decrease hepatic metastasis by inhibiting proinflammatory cytokines and vascular cell adhesion molecule (VCAM)-dependent cell attachment to the hepatic microvasculature.  (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Endostatin is made from a type of collagen (a protein found in cartilage and other connective tissue). It may prevent the growth of new blood vessels that tumors need to grow. Endostatin is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Human Endostatin","termGroup":"PT","termSource":"NCI"},{"termName":"Endostar","termGroup":"FB","termSource":"NCI"},{"termName":"Endostatin","termGroup":"SY","termSource":"NCI"},{"termName":"N-Terminal-MGGSHHHHH-Endostatin (Human Recombinant)","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Endostatin","termGroup":"SY","termSource":"NCI"},{"termName":"rhEndostatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67RHC0R671"},{"name":"Legacy Concept Name","value":"Recombinant_Endostatin"},{"name":"Maps_To","value":"Recombinant Human Endostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"459758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"459758"},{"name":"PDQ_Open_Trial_Search_ID","value":"459758"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1705207"}]}}{"C103830":{"preferredName":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine","code":"C103830","definitions":[{"definition":"A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"742760"},{"name":"NCI_META_CUI","value":"CL438310"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742760"},{"name":"PDQ_Open_Trial_Search_ID","value":"742760"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48395":{"preferredName":"Recombinant Human Papillomavirus Bivalent Vaccine","code":"C48395","definitions":[{"definition":"A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.","type":"DEFINITION","source":"NCI"},{"definition":"A vaccine used to prevent cervical cancer caused by human papillomaviruses (HPV) types 16 and 18. It is also used to prevent lesions that are caused by these viruses and that can lead to cervical, vulvar, or vaginal cancer. Cervarix is used in females aged 10-25 years. It is also being studied in the treatment of other medical conditions. It is a type of bivalent vaccine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Human Papillomavirus Bivalent Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Cervarix","termGroup":"BR","termSource":"NCI"},{"termName":"HPV-16/18 VLP/AS04 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Vaccine L1 16,18","termGroup":"SY","termSource":"NCI"},{"termName":"Human Papillomavirus Vaccine, L1 Type 16, 18","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant HPV Bivalent Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Human_Papillomavirus_16_18_L1_Virus-Like_Particle_AS04_Vaccine"},{"name":"Maps_To","value":"Recombinant Human Papillomavirus Bivalent Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"442270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"442270"},{"name":"PDQ_Open_Trial_Search_ID","value":"442270"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721789"}]}}{"C119664":{"preferredName":"Recombinant Human Papillomavirus Nonavalent Vaccine","code":"C119664","definitions":[{"definition":"A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Papillomavirus Nonavalent Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Gardasil 9","termGroup":"BR","termSource":"NCI"},{"termName":"Nonavalent HPV VLP Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant HPV Nonavalent Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Human Papillomavirus 9-valent Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Papillomavirus Nonavalent Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"767261"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767261"},{"name":"PDQ_Open_Trial_Search_ID","value":"767261"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3864947"}]}}{"C162524":{"preferredName":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828","code":"C162524","definitions":[{"definition":"A recombinant human plasminogen kringle 5 domain with potential antiangiogenic and antineoplastic activities. Upon administration, recombinant human plasminogen kringle 5 domain ABT 828 may promote caspase activity and apoptosis in proliferating endothelial cells, thereby inhibiting migration. Kringle 5 (K5), an internal proteolytic fragment of plasminogen specifically inhibits endothelial cell growth via its interaction with endothelial cell surface ATP synthase, which sequentially triggers the activation of caspases -8, -9, and -3.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828","termGroup":"PT","termSource":"NCI"},{"termName":"ABT 828","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-828","termGroup":"CN","termSource":"NCI"},{"termName":"ABT828","termGroup":"CN","termSource":"NCI"},{"termName":"rhK5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Plasminogen Kringle 5 Domain ABT 828"},{"name":"NCI_META_CUI","value":"CL971108"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C584":{"preferredName":"Recombinant Interferon","code":"C584","definitions":[{"definition":"One of a group of recombinant therapeutic glycoprotein cytokines with antiviral, anti-proliferative, and immunomodulating activities. Interferons bind to specific cell-surface receptors, leading to the transcription and translation of genes with interferon-specific response elements (ISREs). The resultant proteins mediate many complex effects, ultimately leading to inhibition of viral protein synthesis and cellular growth, alteration of cellular differentiation, interference with oncogene expression, activation of natural killer cells, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity. The production of endogenous interferons is induced in response to foreign agents such as bacteria, viruses and parasites and to tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon","termGroup":"PT","termSource":"NCI"},{"termName":"Human Leukocyte Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Human Lymphoblastoid Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN","termGroup":"AB","termSource":"NCI"},{"termName":"Interferons","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9008-1-11"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon"},{"name":"Maps_To","value":"Recombinant Interferon"},{"name":"NCI_Drug_Dictionary_ID","value":"40863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40863"},{"name":"PDQ_Open_Trial_Search_ID","value":"40863"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522537"}]}}{"C225":{"preferredName":"Recombinant Interferon Alfa","code":"C225","definitions":[{"definition":"A class of naturally-isolated or recombinant therapeutic peptides used as antiviral and anti-tumor agents.  Alpha interferons are cytokines produced by nucleated cells (predominantly natural killer (NK) leukocytes) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products.  These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element.  The proteins so produced mediate many complex effects, including antiviral effects (viral protein synthesis); antiproliferative effects (cellular growth inhibition and alteration of cellular differentiation); anticancer effects (interference with oncogene expression); and immune-modulating effects (natural killer cell activation, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Alferon","termGroup":"BR","termSource":"NCI"},{"termName":"Alpha Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"alpha-Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoblast Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphoblastoid Interferon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"See specific agents."},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon_Alfa"},{"name":"Maps_To","value":"Recombinant Interferon Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"40467"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40467"},{"name":"PDQ_Open_Trial_Search_ID","value":"40467"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0002199"}]}}{"C53411":{"preferredName":"Recombinant Interferon Alfa-1b","code":"C53411","definitions":[{"definition":"The non-glycosylated recombinant interferon alpha, subtype 1b, with immunostimulatory and antineoplastic activities. Alpha interferon-1b binds to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa-1b","termGroup":"PT","termSource":"NCI"},{"termName":"IFN-alfa-1b","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon Alfa-1b","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Interferon Alpha-1b","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G7407IV2FS"},{"name":"Legacy Concept Name","value":"Interferon_Alfa-1b"},{"name":"Maps_To","value":"Recombinant Interferon Alfa-1b"},{"name":"NCI_Drug_Dictionary_ID","value":"466520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"466520"},{"name":"PDQ_Open_Trial_Search_ID","value":"466520"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831728"}]}}{"C1952":{"preferredName":"Recombinant Interferon Alfa-2a","code":"C1952","definitions":[{"definition":"A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa-2a","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha 2 Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN alpha-2A","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-Alpha 2","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon alfa 2a","termGroup":"SY","termSource":"NCI"},{"termName":"Laroferon","termGroup":"FB","termSource":"NCI"},{"termName":"Recombinant Interferon Alpha-2a","termGroup":"SY","termSource":"NCI"},{"termName":"rHuIFN-a 2a","termGroup":"AB","termSource":"NCI"},{"termName":"Roceron-A","termGroup":"FB","termSource":"NCI"},{"termName":"Roferon A","termGroup":"BR","termSource":"NCI"},{"termName":"Roferon-A","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia; hairy cell leukemia; chronic hepatitis C; AIDs-related Kaposis sarcoma; bladder; ovarian; cervical cancer; non-Hodgkins lymphoma; renal cell carcinoma; melanoma."},{"name":"CAS_Registry","value":"76543-88-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"47RRR83SK7"},{"name":"Legacy Concept Name","value":"Interferon_Alpha-2a"},{"name":"Maps_To","value":"Recombinant Interferon Alfa-2a"},{"name":"NCI_Drug_Dictionary_ID","value":"467189"},{"name":"NSC Number","value":"367982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467189"},{"name":"PDQ_Open_Trial_Search_ID","value":"467189"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021734"}]}}{"C1953":{"preferredName":"Recombinant Interferon Alfa-2b","code":"C1953","definitions":[{"definition":"A drug used to treat some infections caused by viruses and several types of cancer. These include hairy cell leukemia, melanoma, and follicular lymphoma. It is a form of interferon alfa (a substance normally made by cells of the immune system) that is made in the laboratory. It is a type of biological response modifier.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alfa-2b","termGroup":"PT","termSource":"NCI"},{"termName":"Alfatronol","termGroup":"FB","termSource":"NCI"},{"termName":"Glucoferon","termGroup":"FB","termSource":"NCI"},{"termName":"Heberon Alfa","termGroup":"FB","termSource":"NCI"},{"termName":"IFN alpha-2B","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon alfa 2b","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Alfa-2B","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Alpha-2b","termGroup":"SY","termSource":"NCI"},{"termName":"Intron A","termGroup":"BR","termSource":"NCI"},{"termName":"Sch 30500","termGroup":"CN","termSource":"NCI"},{"termName":"Urifron","termGroup":"FB","termSource":"NCI"},{"termName":"Viraferon","termGroup":"FB","termSource":"NCI"},{"termName":"Viraferon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98530-12-2"},{"name":"CAS_Registry","value":"99210-65-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"43K1W2T1M6"},{"name":"Legacy Concept Name","value":"Recombinant_Interferon_Alfa-2b"},{"name":"Maps_To","value":"Recombinant Interferon Alfa-2b"},{"name":"NCI_Drug_Dictionary_ID","value":"462279"},{"name":"NSC Number","value":"377523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"462279"},{"name":"PDQ_Open_Trial_Search_ID","value":"462279"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0021735"}]}}{"C97503":{"preferredName":"Recombinant Interferon Alpha 2b-like Protein","code":"C97503","definitions":[{"definition":"A proprietary recombinant protein highly resembling human interferon alpha 2b (IFN-a2b), with potential anti-tumor, anti-inflammatory, immunomodulating and antiviral activities. Upon injection, recombinant IFN alpha 2b-like protein binds to specific IFN alpha cell surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs). This may activate the immune system, including the activation of natural killer cells (NKs) and may result in an inhibition of tumor cell proliferation, tumor angiogenesis, metastasis and an induction of apoptosis. Compared to human IFN-a2b (HuINF-a2b), this agent exhibits enhanced antiviral and antiproliferative activities. In addition, this agent exhibits antiviral activity against a variety of viruses, including hepatitis B and C viruses, human immunodeficiency virus (HIV) and Avian Influenza.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Alpha 2b-like Protein","termGroup":"PT","termSource":"NCI"},{"termName":"Novaferon","termGroup":"BR","termSource":"NCI"},{"termName":"Recombinant IFN Alfa-2b-like Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H9CK7SS0T6"},{"name":"Maps_To","value":"Recombinant Interferon Alpha 2b-like Protein"},{"name":"NCI_Drug_Dictionary_ID","value":"703323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703323"},{"name":"PDQ_Open_Trial_Search_ID","value":"703323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273451"}]}}{"C495":{"preferredName":"Recombinant Interferon Beta","code":"C495","definitions":[{"definition":"A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Beta","termGroup":"PT","termSource":"NCI"},{"termName":"Beta Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Betantrone","termGroup":"FB","termSource":"NCI"},{"termName":"Feron","termGroup":"FB","termSource":"NCI"},{"termName":"Human Interferon Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon, Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon-B","termGroup":"SY","termSource":"NCI"},{"termName":"Naferon","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple sclerosis"},{"name":"CAS_Registry","value":"77238-31-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9GU1EM8SF"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon_Beta"},{"name":"Maps_To","value":"Recombinant Interferon Beta"},{"name":"NCI_Drug_Dictionary_ID","value":"40468"},{"name":"NSC Number","value":"373361"},{"name":"NSC Number","value":"658933"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40468"},{"name":"PDQ_Open_Trial_Search_ID","value":"40468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0015980"}]}}{"C583":{"preferredName":"Recombinant Interferon Gamma","code":"C583","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous lymphokine interferon gamma (IFN-gamma) with antineoplastic, immunoregulatory, and antiviral activities. Therapeutic IFN-gamma binds to and activates the cell-surface IFN-gamma receptor, stimulating antibody-dependent cytotoxicity and enhances natural killer cell attachment to tumor cells. This agent also activates caspases, thereby inducing apoptosis in malignant cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interferon Gamma","termGroup":"PT","termSource":"NCI"},{"termName":"Gamma Interferon (GEN)","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma Interferon-SCH","termGroup":"SY","termSource":"NCI"},{"termName":"Gamma-Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"Ginterferon","termGroup":"SY","termSource":"NCI"},{"termName":"IFN-g","termGroup":"AB","termSource":"NCI"},{"termName":"Interferon Gamma (BIO)","termGroup":"SY","termSource":"NCI"},{"termName":"Interferon, Gamma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic granulomatous disease; Osteopetrosis"},{"name":"CAS_Registry","value":"82115-62-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P050J5FWC5"},{"name":"Legacy Concept Name","value":"Therapeutic_Interferon_Gamma"},{"name":"Maps_To","value":"Recombinant Interferon Gamma"},{"name":"NCI_Drug_Dictionary_ID","value":"40469"},{"name":"NSC Number","value":"600662"},{"name":"NSC Number","value":"635256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40469"},{"name":"PDQ_Open_Trial_Search_ID","value":"40469"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3539881"}]}}{"C1380":{"preferredName":"Edodekin alfa","code":"C1380","definitions":[{"definition":"A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity.  Edodekin alfa binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-12 is made mainly by B lymphocytes and macrophages. It causes other immune cells to make cytokines and increases the growth of T lymphocytes. It may also block the growth of new blood vessels. Interleukin-12 made in the laboratory is used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-12 is a type of cytokine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Edodekin alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Cytotoxic Lymphocyte Maturation Factor","termGroup":"SY","termSource":"NCI"},{"termName":"IL-12","termGroup":"AB","termSource":"NCI"},{"termName":"Natural Killer Cell Stimulatory Factor","termGroup":"SY","termSource":"NCI"},{"termName":"NM-IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant human interleukin-12 (IL-12) cytokine","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 24-7472","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"187348-17-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"31Z82G8ME1"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-12"},{"name":"Maps_To","value":"Edodekin alfa"},{"name":"Maps_To","value":"Recombinant Interleukin-12"},{"name":"NCI_Drug_Dictionary_ID","value":"42153"},{"name":"NSC Number","value":"672423"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42153"},{"name":"PDQ_Open_Trial_Search_ID","value":"42153"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1524115"}]}}{"C1489":{"preferredName":"Recombinant Interleukin-13","code":"C1489","definitions":[{"definition":"The recombinant analogue of an endogenous cytokine interleukin 13 with potential antineoplastic activity. Produced by lymphocytes and exhibiting a variety of functions, interleukin-13 (therapeutic) inhibits DNA synthesis and regulates inflammatory and immune responses. In animal models, this agent has been shown to kill tumor cells both directly and indirectly by activating the host immune system at the tumor site. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Interleukin-13","termGroup":"PT","termSource":"NCI"},{"termName":"IL-13","termGroup":"AB","termSource":"NCI"},{"termName":"Interleukin 13","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"148157-34-0"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-13"},{"name":"Maps_To","value":"Recombinant Interleukin-13"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522557"}]}}{"C587":{"preferredName":"Recombinant Interleukin-2","code":"C587","definitions":[{"definition":"Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-2 is made by a type of T lymphocyte. It increases the growth and activity of other T lymphocytes and B lymphocytes, and affects the development of the immune system. Aldesleukin (interleukin-2 made in the laboratory) is being used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-2 is a type of cytokine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Interleukin-2","termGroup":"PT","termSource":"NCI"},{"termName":"IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"Interleukin II","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"Lymphocyte Mitogenic Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Mitogenic Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Ro-236019","termGroup":"CN","termSource":"NCI"},{"termName":"T-Cell Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"TCGF","termGroup":"AB","termSource":"NCI"},{"termName":"Thymocyte Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"TSF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colorectal cancer; metastatic melanoma; metastatic renal cell carcinoma; Non-Hodgkins lymphoma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FNO32LO217"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-2"},{"name":"Maps_To","value":"Recombinant Interleukin-2"},{"name":"NCI_Drug_Dictionary_ID","value":"812847"},{"name":"NSC Number","value":"373364"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919268"}]}}{"C591":{"preferredName":"Recombinant Interleukin-6","code":"C591","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-6 (IL-6) with antiapoptotic, proinflammatory, antiinflammatory, proproliferative and proangiogenic activities. IL-6 binds to its receptor (IL-6R), activating a receptor-CD130 receptor complex; the CD130 portion of the complex is a signal transduction protein that activates JAK kinases and Ras-mediated signaling pathways, which in turn activate downstream signaling pathways, resulting in the activation of various transcription factors (STAT, ELK-1, NF-IL-6, etc.) and gene transcription. The physiological effects of IL-6 are complex and varied and include hematopoietic, pyrogenic and thermogenic, proinflammatory, antiinflammatory, proproliferative (anti-apoptotic), and angiogenic effects.","type":"DEFINITION","source":"NCI"},{"definition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-6 is made mainly by some T lymphocytes. It causes B lymphocytes to make more antibodies and also causes fever by affecting areas of the brain that control body temperature. Interleukin-6 made in the laboratory is used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-6 is a type of cytokine.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Recombinant Interleukin-6","termGroup":"PT","termSource":"NCI"},{"termName":"B Cell Differentiation Factor 2","termGroup":"SY","termSource":"NCI"},{"termName":"B-Cell Stimulatory Factor-2","termGroup":"SY","termSource":"NCI"},{"termName":"Hepatocyte Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"HPGF","termGroup":"AB","termSource":"NCI"},{"termName":"HSF","termGroup":"AB","termSource":"NCI"},{"termName":"Hybridoma Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"IFN Beta 2","termGroup":"SY","termSource":"NCI"},{"termName":"IL-6","termGroup":"AB","termSource":"NCI"},{"termName":"Myeloid Differentiation Inducing Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmacytoma Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Sigosix","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O4QWG0B3C"},{"name":"Legacy Concept Name","value":"Therapeutic_Interleukin-6"},{"name":"Maps_To","value":"Recombinant Interleukin-6"},{"name":"NCI_Drug_Dictionary_ID","value":"41474"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41474"},{"name":"PDQ_Open_Trial_Search_ID","value":"41474"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527132"}]}}{"C28721":{"preferredName":"Recombinant KSA Glycoprotein CO17-1A","code":"C28721","definitions":[{"definition":"A recombinant counterpart of tumor-associated KSA antigen (Ep-CAM), a type-I transmembrane glycoprotein cellular adhesion molecule with a molecular mass of 40 kDa, overexpressed on the majority of tumor cells of most human epithelia in a of variety of tumor tissues such as stomach, colon, pancreas, gall bladder, bile duct, mammary gland, breast, and lung carcinoma. It has been suggested to be involved in the differentiation, growth, and organization of epithelial cells within tissues under normal physiological conditions. The antigen has been used as a target for diagnosis and for passive and active immunotherapy of colorectal cancer. Immunization with KSA Glycoprotein elicits both humoral and Th1-associated cellular immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant KSA Glycoprotein CO17-1A","termGroup":"PT","termSource":"NCI"},{"termName":"CO17-1A","termGroup":"SY","termSource":"NCI"},{"termName":"EGP","termGroup":"SY","termSource":"NCI"},{"termName":"Ep-CAM","termGroup":"SY","termSource":"NCI"},{"termName":"GA733","termGroup":"SY","termSource":"NCI"},{"termName":"KSA Glycoprotein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_KSA_Glycoprotein"},{"name":"Maps_To","value":"Recombinant KSA Glycoprotein CO17-1A"},{"name":"NCI_Drug_Dictionary_ID","value":"43440"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43440"},{"name":"PDQ_Open_Trial_Search_ID","value":"43440"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1527244"}]}}{"C2413":{"preferredName":"Recombinant Leukocyte Interleukin","code":"C2413","definitions":[{"definition":"A cocktail preparation of synthetic interleukin (IL) -1, IL-2, IL-6, tumor necrosis factor (TNF)-alpha, interferon gamma and other cytokines that are chemically identical to or similar to signaling molecules secreted by leukocyte cells. Leukocyte interleukins are essential in many immune responses, such as antibodies production, modulating secretion of other cytokines, and activation of bone marrow stem cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Leukocyte Interleukin","termGroup":"PT","termSource":"NCI"},{"termName":"BC-IL","termGroup":"AB","termSource":"NCI"},{"termName":"Buffy Coat Interleukin","termGroup":"SY","termSource":"NCI"},{"termName":"Leukocyte Interleukin, Inj.","termGroup":"SY","termSource":"NCI"},{"termName":"Multikine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"neoadjuvant therapy for patients with squamous cell carcinoma of the head and neck"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Leukocyte_Interleukin"},{"name":"Maps_To","value":"Recombinant Leukocyte Interleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"42580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42580"},{"name":"PDQ_Open_Trial_Search_ID","value":"42580"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0392999"}]}}{"C1143":{"preferredName":"Recombinant Leukoregulin","code":"C1143","definitions":[{"definition":"A formulated therapeutic analog of the endogenous lymphokine leukoregulin with potential antineoplastic activity.  Leukoregulin displays direct and indirect cytotoxicity through tumor cell lysis and enhancing tumor cell susceptibility to natural killer cell-mediated cytotoxicity.  This agent enhances membrane permeability and decreases p-glycoprotein expression, thereby promoting cytotoxic drug uptake into tumor cells.  Leukoregulin also induces the synthesis of collagenase and hyaluronan, expression and secretion of interleukin-8, and upregulates stromelysin-1 gene expression in human fibroblasts, thereby regulating extracellular matrix degradation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Leukoregulin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Leukoregulin"},{"name":"Maps_To","value":"Recombinant Leukoregulin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515385"}]}}{"C612":{"preferredName":"Recombinant Luteinizing Hormone","code":"C612","definitions":[{"definition":"A hormone made in the pituitary gland. In females, it acts on the ovaries to make follicles release their eggs and to make hormones that get the uterus ready for a fertilized egg to be implanted. In males, it acts on the testes to cause cells to grow and make testosterone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any recombinant form of the endogenously produced heterodimer glycoprotein luteinizing hormone (LH) normally made by the anterior pituitary gland, that can be used for the treatment of LH deficiency. Upon administration, recombinant LH mimics the biological activity of endogenous LH. In females, this triggers ovulation and the development of the corpus luteum. In males, LH stimulates Leydig cells to produce testosterone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Luteinizing Hormone","termGroup":"PT","termSource":"NCI"},{"termName":"Interstitial Cell-Stimulating Hormone","termGroup":"SY","termSource":"NCI"},{"termName":"Leuteinizing Hormone","termGroup":"SY","termSource":"NCI"},{"termName":"Luteinizing Hormone","termGroup":"SY","termSource":"NCI"},{"termName":"Lutropin","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant LH","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic LH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9002-67-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8XA4VN1LH4"},{"name":"Legacy Concept Name","value":"Therapeutic_Luteinizing_Hormone"},{"name":"Maps_To","value":"Recombinant Luteinizing Hormone"},{"name":"NCI_Drug_Dictionary_ID","value":"811468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1704298"}]}}{"C1290":{"preferredName":"Recombinant Macrophage Colony-Stimulating Factor","code":"C1290","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous protein cytokine macrophage colony-stimulating factor (M-CSF). Synthesized endogenously by mesenchymal cells, M-CSF stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series and can reverse treatment-related neutropenias. Recombinant M-CSF may also enhance antigen presentation and activate antitumoral cytotoxic T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Macrophage Colony-Stimulating Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Macrophage Colony Stimulating Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Colony Stimulating Factor 1","termGroup":"SY","termSource":"NCI"},{"termName":"rM-CSF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"81627-83-0"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Macrophage_Colony-Stimulating_Factor"},{"name":"Maps_To","value":"Recombinant Macrophage Colony-Stimulating Factor"},{"name":"NCI_Drug_Dictionary_ID","value":"40240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40240"},{"name":"PDQ_Open_Trial_Search_ID","value":"40240"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0079784"}]}}{"C38724":{"preferredName":"Recombinant MAGE-3.1 Antigen","code":"C38724","definitions":[{"definition":"A recombinant tumor-specific melanoma antigen. Vaccination with recombinant MAGE-3.1 antigen may induce a host immune response against MAGE-expressing cells, resulting in antitumoral T cell-mediated cytotoxicity. MAGE-expressing cells are found in melanoma, non-small-cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma, transitional cell carcinoma of the bladder, and esophageal carcinoma. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant MAGE-3.1 Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"MAGE-3","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-3.1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QU3R73GB8N"},{"name":"Legacy Concept Name","value":"Recombinant_MAGE-3-1_Antigen"},{"name":"Maps_To","value":"Recombinant MAGE-3.1 Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"42271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42271"},{"name":"PDQ_Open_Trial_Search_ID","value":"42271"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1510427"}]}}{"C98294":{"preferredName":"Nagrestipen","code":"C98294","definitions":[{"definition":"A recombinant form of a human macrophage inflammatory protein-1 alpha (MIP1-alpha) with a substitution of aspartate to alanine at position 26, with potential immunomodulating and radiotherapy potentiating activity. Intravenous administration of nagrestipen after local tumor irradiation enhances the anti-tumor effect of ionizing radiation at the irradiated site as well as the antitumor effect at non-irradiated tumor sites (known as the abscopal effect). The abscopal effect appears to be attributed to this agent's ability to recruit and activate leukocytes, such as monocytes, dendritic cells, natural killer cells and T lymphocytes, thereby initiating an anti-tumor immune response against cancer cells. MIP1-alpha, also known as chemokine (C-C motif) ligand 3, is a ligand for the chemokine receptors CCR1, CCR4 and CCR5 that are involved in immune and inflammatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nagrestipen","termGroup":"PT","termSource":"NCI"},{"termName":"26-L-Alaninelymphokine MIP 1alpha (Human clone pAT464 MacrophageIinflammatory)","termGroup":"SY","termSource":"NCI"},{"termName":"BB-10010","termGroup":"CN","termSource":"NCI"},{"termName":"ECI301","termGroup":"CN","termSource":"NCI"},{"termName":"eMIP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"166089-33-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9350121Z8S"},{"name":"Maps_To","value":"Nagrestipen"},{"name":"Maps_To","value":"Recombinant MIP1-alpha Variant ECI301"},{"name":"NCI_Drug_Dictionary_ID","value":"713863"},{"name":"NCI_META_CUI","value":"CL432412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713863"},{"name":"PDQ_Open_Trial_Search_ID","value":"713863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49087":{"preferredName":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine","code":"C49087","definitions":[{"definition":"A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant MVA-5T4 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Pox Virus Encoding 5T4 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"TroVax","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P258UUW1OD"},{"name":"Legacy Concept Name","value":"Recombinant_Modified_Vaccinia_Ankara-5T4_Vaccine"},{"name":"Maps_To","value":"Recombinant Modified Vaccinia Ankara-5T4 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"449683"},{"name":"PDQ_Closed_Trial_Search_ID","value":"449683"},{"name":"PDQ_Open_Trial_Search_ID","value":"449683"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541801"}]}}{"C184921":{"preferredName":"Lerapolturev","code":"C184921","definitions":[{"definition":"A recombinant, live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. Upon administration of lerapolturev, the poliovirus is selectively taken up by and replicates in tumor cells expressing CD155 (poliovirus receptor, PVR or NECL5) eventually causing tumor cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune response. This further kills tumor cells. This may also stimulate long-term anti-tumor immunity. Additionally, lerapolturev can induce a systemic anti-tumor immune response through engagement with antigen-presenting cells (APCs) upon CD155 binding thereby further killing tumor cells. CD155, an oncofetal cell adhesion molecule and tumor antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme (GMB), and plays an important role in tumor cell migration, invasion, and metastasis. Due to the heterologous HRV2 IRES in this recombinant virus, lerapolturev only propagates in susceptible CD155-expressing, nonneuronal neoplastic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lerapolturev","termGroup":"PT","termSource":"NCI"},{"termName":"PVS-RIPO","termGroup":"CN","termSource":"NCI"},{"termName":"PVSRIPO","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2430048-02-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MQ5GV2WUK4"},{"name":"Maps_To","value":"Recombinant Oncolytic Poliovirus PVS-RIPO"},{"name":"NCI_Drug_Dictionary_ID","value":"721361"},{"name":"NCI_META_CUI","value":"CL1772885"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C2251":{"preferredName":"Iroplact","code":"C2251","definitions":[{"definition":"A recombinant form of the endogenous chemokine platelet factor 4 with potential antiangiogenesis and antineoplastic activities. As a heparin-binding tetramer, iroplact inhibits growth factor-stimulated endothelial cell proliferation, migration, and angiogenesis; it has been shown that this agent inhibits fibroblast growth factor 2 (FGF2) angiogenic activity downstream from the FGF2 receptor. Its activity is antagonized by heparin. Recombinant platelet factor 4 may also directly inhibit the proliferation of some tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iroplact","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant CXCL4","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Platelet Factor 4","termGroup":"SY","termSource":"NCI"},{"termName":"rhPF4","termGroup":"AB","termSource":"NCI"},{"termName":"rPF4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37270-94-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T381WW8L8Y"},{"name":"Legacy Concept Name","value":"Therapeutic_Platelet_Factor_4"},{"name":"Maps_To","value":"Iroplact"},{"name":"Maps_To","value":"Recombinant Platelet Factor 4"},{"name":"NCI_Drug_Dictionary_ID","value":"42317"},{"name":"NSC Number","value":"671662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42317"},{"name":"PDQ_Open_Trial_Search_ID","value":"42317"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3887655"}]}}{"C92586":{"preferredName":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A","code":"C92586","definitions":[{"definition":"A recombinant form of the human PRAME (Preferentially Expressed Antigen of Melanoma) protein combined with the AS15 adjuvant, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, GSK2302025A may stimulate the host immune response to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress the PRAME protein, resulting in tumor cell lysis. The tumor-associated antigen PRAME is often overexpressed by a variety of tumor cell types. AS15 is an potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid, and QS-21.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A"},{"name":"NCI_Drug_Dictionary_ID","value":"681046"},{"name":"NCI_META_CUI","value":"CL421638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681046"},{"name":"PDQ_Open_Trial_Search_ID","value":"681046"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82371":{"preferredName":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207","code":"C82371","definitions":[{"definition":"A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207","termGroup":"PT","termSource":"NCI"},{"termName":"GI-6207","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FIJ3OLQ3N8"},{"name":"Legacy Concept Name","value":"Recombinant_Saccharomyces_Cerevisia-CEA_610D_Expressing_Vaccine_GI-6207"},{"name":"Maps_To","value":"Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207"},{"name":"NCI_Drug_Dictionary_ID","value":"641167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641167"},{"name":"PDQ_Open_Trial_Search_ID","value":"641167"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830061"}]}}{"C121542":{"preferredName":"Recombinant Super-compound Interferon","code":"C121542","definitions":[{"definition":"A recombinant form of the naturally-occurring cytokine interferon-alpha (IFN-a) that has a modified spatial configuration, with immunomodulating, antiviral and antineoplastic activities. Upon administration of recombinant super-compound interferon (rSIFN-co), this agent binds to IFN-specific cell surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects. The 3-dimensional conformational change improves efficacy and causes less side effects compared to IFN-a.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Super-compound Interferon","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant Super Compound Interferon","termGroup":"SY","termSource":"NCI"},{"termName":"rSIFN-co","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Super-compound Interferon"},{"name":"NCI_Drug_Dictionary_ID","value":"770206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770206"},{"name":"PDQ_Open_Trial_Search_ID","value":"770206"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053486"}]}}{"C884":{"preferredName":"Recombinant Thyroglobulin","code":"C884","definitions":[{"definition":"A recombinant form of thyroglobulin identical to or similar to the endogenous iodine-containing glycoprotein. Thyroglobulin is synthesized in the thyroid follicular cell, and is the precursor of thyroid hormones T3 and T4. Thyroglobulin levels can serve as a tumor marker for monitoring the status of differentiated thyroid carcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Thyroglobulin","termGroup":"PT","termSource":"NCI"},{"termName":"Proloid","termGroup":"BR","termSource":"NCI"},{"termName":"Therapeutic TG","termGroup":"AB","termSource":"NCI"},{"termName":"Thyroglobulin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypothyroidism"},{"name":"CAS_Registry","value":"9010-34-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NN2P9VPL7M"},{"name":"Legacy Concept Name","value":"Therapeutic_Thyroglobulin"},{"name":"Maps_To","value":"Recombinant Thyroglobulin"},{"name":"NCI_Drug_Dictionary_ID","value":"39300"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39300"},{"name":"PDQ_Open_Trial_Search_ID","value":"39300"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527123"}]}}{"C61322":{"preferredName":"Recombinant Thyrotropin Alfa","code":"C61322","definitions":[{"definition":"A form of thyroid-stimulating hormone (TSH) that is made in the laboratory. It is used to test for remaining or recurring cancer cells in patients who have been treated for thyroid cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant form of the human anterior pituitary glycoprotein thyroid stimulating hormone (TSH) with use in the diagnostic setting. With an amino acid sequence identical to that of human TSH, thyrotropin alfa binds to TSH receptors on normal thyroid epithelial cells or well-differentiated thyroid cancer cells, stimulating iodine uptake and organification, synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Thyrotropin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant Thyrotropin Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant TSH Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Thyrogen","termGroup":"BR","termSource":"NCI"},{"termName":"Thyroid Stimulating Hormone Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"Thyrotropin Alfa","termGroup":"SY","termSource":"NCI"},{"termName":"TSH-alpha","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194100-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AVX3D5A4LM"},{"name":"Legacy Concept Name","value":"Recombinant_Thyrotropin_Alfa"},{"name":"Maps_To","value":"Recombinant Thyrotropin Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"481277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"481277"},{"name":"PDQ_Open_Trial_Search_ID","value":"481277"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2587204"}]}}{"C898":{"preferredName":"Recombinant Transforming Growth Factor-Beta","code":"C898","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine transforming growth factor-beta (TGF-beta) with proapoptotic and antineoplastic properties. TGF-beta may suppress tumor cell growth by decreasing the expression of cyclin D1, a cell cycle regulatory protein, and downregulating the expression of the oncogene c-myc. This agent is also involved in T cell-mediated immunosuppression by CD4+CD25+ T cells, which permits cancer cells to evade immune surveillance. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Transforming Growth Factor-Beta","termGroup":"PT","termSource":"NCI"},{"termName":"Bone-Derived Transforming Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"rTGF-Beta","termGroup":"SY","termSource":"NCI"},{"termName":"TGF-Beta","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic Milk Growth Factor","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutic TGF B","termGroup":"AB","termSource":"NCI"},{"termName":"Therapeutic TGF-Beta","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Transforming_Growth_Factor-Beta"},{"name":"Maps_To","value":"Recombinant Transforming Growth Factor-Beta"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527196"}]}}{"C1286":{"preferredName":"Recombinant Transforming Growth Factor-Beta-2","code":"C1286","definitions":[{"definition":"A recombinant polypeptide chemically identical to or similar to the endogenous cytokine transforming growth factor-beta-2 (TGF-beta-2). TGF-beta-2 modulates cell growth and immune function and may promote or inhibit tumor growth, depending on the tumor cell type. TGF-beta-2 may also suppress host immune system recognition of and/or response to tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Transforming Growth Factor-Beta-2","termGroup":"PT","termSource":"NCI"},{"termName":"Cartilage-Inducing Factor-B","termGroup":"SY","termSource":"NCI"},{"termName":"Glioblastoma-Derived T-Cell Suppressor Factor","termGroup":"SY","termSource":"NCI"},{"termName":"TGF-Beta 2","termGroup":"SY","termSource":"NCI"},{"termName":"Transforming Growth Factor-Beta 2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157238-32-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"693Y43MXY4"},{"name":"Legacy Concept Name","value":"Therapeutic_Transforming_Growth_Factor-Beta_2"},{"name":"Maps_To","value":"Recombinant Transforming Growth Factor-Beta-2"},{"name":"NCI_Drug_Dictionary_ID","value":"42024"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42024"},{"name":"PDQ_Open_Trial_Search_ID","value":"42024"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522073"}]}}{"C913":{"preferredName":"Recombinant Tumor Necrosis Factor-Alpha","code":"C913","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine tumor necrosis factor-alpha with antineoplastic properties.  Tumor necrosis factor-alpha binds to and activates \"death receptors\" on the cell surface, resulting in apoptosis and cell death by the p53-independent extrinsic pathway. This agent also disrupts tumor vascularization. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Tumor Necrosis Factor-Alpha","termGroup":"PT","termSource":"NCI"},{"termName":"Cachectin","termGroup":"SY","termSource":"NCI"},{"termName":"TNF-Alpha","termGroup":"SY","termSource":"NCI"},{"termName":"TNFA","termGroup":"AB","termSource":"NCI"},{"termName":"Tumor Necrosis Factor (TNF-alpha)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"308079-78-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X2C8Z061MB"},{"name":"Legacy Concept Name","value":"Therapeutic_Tumor_Necrosis_Factor-Alpha"},{"name":"Maps_To","value":"Recombinant Tumor Necrosis Factor-Alpha"},{"name":"NCI_Drug_Dictionary_ID","value":"43225"},{"name":"NSC Number","value":"697068"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43225"},{"name":"PDQ_Open_Trial_Search_ID","value":"43225"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522669"}]}}{"C38682":{"preferredName":"Recombinant Tyrosinase-Related Protein-2","code":"C38682","definitions":[{"definition":"A recombinant therapeutic agent which is chemically identical to or similar to an endogenous non-mutated melanocyte differentiation antigen expressed by both normal and malignant melanocytes. Vaccinations with recombinant tyrosinase-related protein-2 may elicit an antitumoral cytotoxic T-cell response against tumor cells and some normal cells that express tyrosinase-related protein-2. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Tyrosinase-Related Protein-2","termGroup":"PT","termSource":"NCI"},{"termName":"TRP-2","termGroup":"AB","termSource":"NCI"},{"termName":"Tyrosinase-Related Protein-2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Recombinant_Tyrosinase-Related_Protein-2"},{"name":"Maps_To","value":"Recombinant Tyrosinase-Related Protein-2"},{"name":"NCI_Drug_Dictionary_ID","value":"38407"},{"name":"NCI_META_CUI","value":"CL035331"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38407"},{"name":"PDQ_Open_Trial_Search_ID","value":"38407"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C131580":{"preferredName":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","code":"C131580","definitions":[{"definition":"A recombinant, replication competent form of the oncolytic RNA virus vesicular stomatitis virus (VSV), based on the Indiana strain of VSV, that is genetically engineered to express the genes for the human cytokine interferon beta (IFNbeta) and the human thyroidal sodium-iodide symporter (NIS), with potential oncolytic and imaging activities. Upon intravenous administration, VSV-hIFNbeta-NIS is preferentially taken up by tumor cells, resulting in tumor cell infection, viral replication and a direct virus-mediated cytolytic effect against the infected tumor cells. IFN-mediated signaling is defective in tumor cells and tumor cells are unable to exert an anti-viral response against VSV. As normal, healthy cells secrete and respond normally to IFNbeta and are able to activate IFN-mediated anti-viral pathways, the expressed IFNbeta from the VSV-infected tumor cells helps protect normal cells from VSV infection. Upon subsequent administration of certain isotope-containing imaging agents, NIS expression by the infected tumor cells allows visualization and tracking of VSV biodistribution, and analysis and quantification of VSV-infected tumor cells by positron emission tomography (PET). Also, upon subsequent administration of the radioisotope iodine I 131 (I131), I131 can be taken up by NIS and allows for a cytotoxic dose of radiation to accumulate in the NIS-expressing VSV-infected tumor cells, which also leads to tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","termGroup":"PT","termSource":"NCI"},{"termName":"Oncolytic VSV-hIFNbeta-NIS","termGroup":"SY","termSource":"NCI"},{"termName":"Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter","termGroup":"SY","termSource":"NCI"},{"termName":"Voyager-V1","termGroup":"BR","termSource":"NCI"},{"termName":"VSV-expressing hIFNb and NIS","termGroup":"SY","termSource":"NCI"},{"termName":"VSV-hIFNb-NIS","termGroup":"SY","termSource":"NCI"},{"termName":"VSV-hIFNbeta-NIS","termGroup":"SY","termSource":"NCI"},{"termName":"VV1","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter"},{"name":"NCI_Drug_Dictionary_ID","value":"788964"},{"name":"NCI_META_CUI","value":"CL514461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788964"},{"name":"PDQ_Open_Trial_Search_ID","value":"788964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C74059":{"preferredName":"Refametinib","code":"C74059","definitions":[{"definition":"An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refametinib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY 869766","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-869766","termGroup":"CN","termSource":"NCI"},{"termName":"BAY86-9766","termGroup":"CN","termSource":"NCI"},{"termName":"BAY869766","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor RDEA119","termGroup":"SY","termSource":"NCI"},{"termName":"RDEA119","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923032-37-5"},{"name":"Chemical_Formula","value":"C19H20F3IN2O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"JPX07AFM0N"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_RDEA119"},{"name":"Maps_To","value":"Refametinib"},{"name":"NCI_Drug_Dictionary_ID","value":"589128"},{"name":"PDQ_Closed_Trial_Search_ID","value":"589128"},{"name":"PDQ_Open_Trial_Search_ID","value":"589128"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346909"}]}}{"C78204":{"preferredName":"Regorafenib Anhydrous","code":"C78204","definitions":[{"definition":"The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Regorafenib Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 73 4506","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 73-4506","termGroup":"AB","termSource":"NCI"},{"termName":"BAY 734506","termGroup":"CN","termSource":"NCI"},{"termName":"Regorafenib Anhydrous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"hepatocellular carcinoma (HCC)"},{"name":"CAS_Registry","value":"755037-03-7"},{"name":"Chemical_Formula","value":"C21H15ClF4N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"24T2A1DOYB"},{"name":"Legacy Concept Name","value":"Multitargeted_Receptor_Tyrosine_Kinase_Inhibitor_BAY_73-4506"},{"name":"Maps_To","value":"Regorafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"595192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595192"},{"name":"PDQ_Open_Trial_Search_ID","value":"595192"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2980094"}]}}{"C127838":{"preferredName":"Relacorilant","code":"C127838","definitions":[{"definition":"An orally available antagonist of the glucocorticoid receptor (GR), with potential antineoplastic activity. Upon administration,  relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. This decreases the negative effects that result from excess levels of endogenous glucocorticoids, like those seen when tumors overproduce glucocorticoids. In addition, by binding to GRs and preventing their activity, inhibition with CORT125134 also inhibits the proliferation of GR-overexpressing cancer cells. GRs are overexpressed in certain tumor cell types and promote tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relacorilant","termGroup":"PT","termSource":"NCI"},{"termName":"((4aR)-1-(4-Fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone","termGroup":"SY","termSource":"NCI"},{"termName":"CORT-125134","termGroup":"CN","termSource":"NCI"},{"termName":"CORT125134","termGroup":"CN","termSource":"NCI"},{"termName":"Methanone, ((4aR)-1-(4-Fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1496510-51-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2158753C7E"},{"name":"Maps_To","value":"Relacorilant"},{"name":"NCI_Drug_Dictionary_ID","value":"781149"},{"name":"NCI_META_CUI","value":"CL507918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781149"},{"name":"PDQ_Open_Trial_Search_ID","value":"781149"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111999":{"preferredName":"Relatlimab","code":"C111999","definitions":[{"definition":"A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T-lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relatlimab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986016","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986016","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986016","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1673516-98-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AF75XOF6W3"},{"name":"Maps_To","value":"Relatlimab"},{"name":"NCI_Drug_Dictionary_ID","value":"754229"},{"name":"NCI_META_CUI","value":"CL454288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754229"},{"name":"PDQ_Open_Trial_Search_ID","value":"754229"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114498":{"preferredName":"Relugolix","code":"C114498","definitions":[{"definition":"An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Relugolix","termGroup":"PT","termSource":"NCI"},{"termName":"N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea","termGroup":"SY","termSource":"NCI"},{"termName":"Orgovyx","termGroup":"BR","termSource":"NCI"},{"termName":"Relugolix","termGroup":"SY","termSource":"NCI"},{"termName":"Relumina","termGroup":"FB","termSource":"NCI"},{"termName":"TAK 385","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-385","termGroup":"CN","termSource":"NCI"},{"termName":"TAK385","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with advanced prostate cancer."},{"name":"CAS_Registry","value":"737789-87-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"P76B05O5V6"},{"name":"Maps_To","value":"Relugolix"},{"name":"NCI_Drug_Dictionary_ID","value":"759257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759257"},{"name":"PDQ_Open_Trial_Search_ID","value":"759257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3252109"}]}}{"C97513":{"preferredName":"Remetinostat","code":"C97513","definitions":[{"definition":"A topical formulation containing the histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Upon cutaneous administration, SHP-141 selectively binds to and inhibits HDAC, resulting in an accumulation of highly acetylated histones in the skin (dermis and epidermis), the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. These events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. Topical administration of SHP-141 allows for high concentrations of this agent locally while minimizing systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Remetinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Methyl 4-((8-(Hydroxyamino)-8-Oxooctanoyl)oxy)benzoate","termGroup":"SN","termSource":"NCI"},{"termName":"Methylparaben Suberohydroxamic Acid Phenyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"SHAPE","termGroup":"AB","termSource":"NCI"},{"termName":"SHP-141","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"946150-57-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37NT056AT4"},{"name":"Maps_To","value":"Remetinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"703816"},{"name":"NCI_META_CUI","value":"CL430257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"703816"},{"name":"PDQ_Open_Trial_Search_ID","value":"703816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70968":{"preferredName":"Renal Cell Carcinoma Peptides Vaccine IMA901","code":"C70968","definitions":[{"definition":"A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Cell Carcinoma Peptides Vaccine IMA901","termGroup":"PT","termSource":"NCI"},{"termName":"IMA901","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Renal_Cell_Carcinoma_Peptides_Vaccine_IMA901"},{"name":"Maps_To","value":"Renal Cell Carcinoma Peptides Vaccine IMA901"},{"name":"NCI_Drug_Dictionary_ID","value":"570963"},{"name":"NCI_META_CUI","value":"CL375872"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570963"},{"name":"PDQ_Open_Trial_Search_ID","value":"570963"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66515":{"preferredName":"Reparixin","code":"C66515","definitions":[{"definition":"An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration, reparixin allosterically binds to CXCR1 and prevents CXCR1 activation by its ligand interleukin 8 (IL-8 or CXCL8). This may cause cancer stem cell (CSC) apoptosis and may inhibit tumor cell progression and metastasis. CXCR1, overexpressed on CSCs, plays a key role in CSC survival and the ability of CSC to self-renew; it is also linked to tumor resistance to chemotherapy. Inhibition of the IL-8/CXCR1 interaction also potentiates the cytotoxic effect of chemotherapeutic agents. In addition, reparixin inhibits CXCR2 activation and may reduce both neutrophil recruitment and vascular permeability during inflammation or injury.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reparixin","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-Isobutylphenyl)propionylmethanesulfonamide","termGroup":"SY","termSource":"NCI"},{"termName":"Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-N- (methylsulfonyl)- (alphaR)-","termGroup":"SN","termSource":"NCI"},{"termName":"DF 1681Y","termGroup":"CN","termSource":"NCI"},{"termName":"Repertaxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"266359-83-5"},{"name":"Chemical_Formula","value":"C14H21NO3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U604E1NB3K"},{"name":"Legacy Concept Name","value":"Reparixin"},{"name":"Maps_To","value":"Reparixin"},{"name":"NCI_Drug_Dictionary_ID","value":"750172"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750172"},{"name":"PDQ_Open_Trial_Search_ID","value":"750172"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1506747"}]}}{"C133821":{"preferredName":"Repotrectinib","code":"C133821","definitions":[{"definition":"An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Repotrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005","termGroup":"SY","termSource":"NCI"},{"termName":"Augtyro","termGroup":"BR","termSource":"NCI"},{"termName":"Multi-kinase Inhibitor TPX-0005","termGroup":"SY","termSource":"NCI"},{"termName":"Multikinase Inhibitor TPX-0005","termGroup":"SY","termSource":"NCI"},{"termName":"TPX 0005","termGroup":"CN","termSource":"NCI"},{"termName":"TPX-0005","termGroup":"CN","termSource":"NCI"},{"termName":"TPX0005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"ocally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)."},{"name":"CAS_Registry","value":"1802220-02-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"08O3FQ4UNP"},{"name":"Maps_To","value":"Repotrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"788549"},{"name":"NCI_META_CUI","value":"CL521742"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788549"},{"name":"PDQ_Open_Trial_Search_ID","value":"788549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63958":{"preferredName":"Resiquimod","code":"C63958","definitions":[{"definition":"A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An imidazoquinolinamine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic cells, macrophages, and B-lymphocytes. This induces the nuclear translocation of the transcription activator NF-kB as well as activation of other transcription factors. This may lead to an increase in mRNA levels and subsequent production of cytokines, especially interferon-alpha (INF-a) and other cytokines, thereby enhancing T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate Langerhans' cells, leading to an enhanced activation of T-lymphocytes. Due to its immunostimulatory activity, this agent may potentially be useful as a vaccine adjuvant.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resiquimod","termGroup":"PT","termSource":"NCI"},{"termName":"4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol","termGroup":"SN","termSource":"NCI"},{"termName":"R848","termGroup":"CN","termSource":"NCI"},{"termName":"S 28463","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"144875-48-9"},{"name":"CHEBI_ID","value":"CHEBI:36706"},{"name":"Chemical_Formula","value":"C17H22N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V3DMU7PVXF"},{"name":"Legacy Concept Name","value":"Resiquimod"},{"name":"Maps_To","value":"Resiquimod"},{"name":"NCI_Drug_Dictionary_ID","value":"544217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"544217"},{"name":"PDQ_Open_Trial_Search_ID","value":"544217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0389573"}]}}{"C88259":{"preferredName":"Resiquimod Topical Gel","code":"C88259","definitions":[{"definition":"A topical gel containing the Toll-like receptor (TLR) agonist resiquimod, an imidazoquinolinamine and with potential immunomodulating activity. Resiquimod binds toTLR7 and 8, mainly on dendritic cells, macrophages, and B-lymphocytes, and activates the TLR signaling pathway, resulting in the induction of the nuclear translocation of transcription activator NF-kB and activation of other transcription factors; subsequently, gene expression increases and the production of cytokines increases, especially interferon-alpha (INF-a), resulting in the enhancement of T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate epidermal Langerhans cells, leading to an enhanced activation of T-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resiquimod Topical Gel","termGroup":"PT","termSource":"NCI"},{"termName":"R848 Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resiquimod Topical Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"654328"},{"name":"NCI_META_CUI","value":"CL412435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654328"},{"name":"PDQ_Open_Trial_Search_ID","value":"654328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C94233":{"preferredName":"Resistant Starch","code":"C94233","definitions":[{"definition":"A form of dietary fiber that resists degradation by gastrointestinal (GI) enzymes in the small intestine with potential chemopreventive and prebiotic activity. Upon consumption of resistant starch, the fiber is not metabolized or absorbed in the small intestine and enters the colon unaltered. Once in the colon, the starch is fermented by anaerobic colonic bacteria and produces short-chain fatty acids (SCFA), including butyrate, which has anti-inflammatory and immunoregulatory activities. In addition, butyrate appears to exert antitumor effects by inhibiting tumor cell proliferation, inducing tumor cell differentiation and promoting apoptosis in colorectal cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resistant Starch","termGroup":"PT","termSource":"NCI"},{"termName":"RS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resistant Starch"},{"name":"NCI_Drug_Dictionary_ID","value":"687429"},{"name":"NCI_META_CUI","value":"CL426045"},{"name":"PDQ_Closed_Trial_Search_ID","value":"687429"},{"name":"PDQ_Open_Trial_Search_ID","value":"687429"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C84856":{"preferredName":"Resminostat","code":"C84856","definitions":[{"definition":"An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, inhibition of the transcription of tumor suppressor genes, inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resminostat","termGroup":"PT","termSource":"NCI"},{"termName":"4SC-201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"864814-88-0"},{"name":"Chemical_Formula","value":"C16H19N3O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1578EUB98L"},{"name":"Maps_To","value":"Resminostat"},{"name":"NCI_Drug_Dictionary_ID","value":"651465"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651465"},{"name":"PDQ_Open_Trial_Search_ID","value":"651465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2935131"}]}}{"C1215":{"preferredName":"Resveratrol","code":"C1215","definitions":[{"definition":"A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A substance found in the skins of grapes and in certain other plants, fruits, and seeds. It is made by various plants to help defend against invading fungi, stress, injury, infection, and too much sunlight. It is being studied in the prevention of cancer and heart disease. It is a type of antioxidant and a type of polyphenol.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Resveratrol","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol","termGroup":"SN","termSource":"NCI"},{"termName":"3,4',5-Stilbenetriol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501-36-0"},{"name":"CHEBI_ID","value":"CHEBI:27881"},{"name":"CHEBI_ID","value":"CHEBI:45713"},{"name":"Chemical_Formula","value":"C14H12O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q369O8926L"},{"name":"Legacy Concept Name","value":"Resveratrol"},{"name":"Maps_To","value":"Resveratrol"},{"name":"NCI_Drug_Dictionary_ID","value":"405819"},{"name":"NSC Number","value":"327430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"405819"},{"name":"PDQ_Open_Trial_Search_ID","value":"405819"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073096"}]}}{"C85484":{"preferredName":"Resveratrol Formulation SRT501","code":"C85484","definitions":[{"definition":"A proprietary formulation of resveratrol, a polyphenolic phytoalexin derived from grapes and other food products with potential antioxidant, anti-obesity, antidiabetic and chemopreventive activities. Resveratrol may activate sirtuin subtype 1 (SIRT-1). SIRT1 activation has been reported to inhibit tumorigenesis and tumor cell proliferation. SIRT-1 is a member of the silent information regulator 2 (SIR2) (or sirtuin) family of enzymes that plays an important role in mitochondrial activity and acts as a protein deacetylase. SIRT1 appears to be involved in the regulation of numerous transcription factors such as NF-kB and p53.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resveratrol Formulation SRT501","termGroup":"PT","termSource":"NCI"},{"termName":"SRT501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resveratrol Formulation SRT501"},{"name":"NCI_Drug_Dictionary_ID","value":"648245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648245"},{"name":"PDQ_Open_Trial_Search_ID","value":"648245"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002402"}]}}{"C158093":{"preferredName":"Zeteletinib","code":"C158093","definitions":[{"definition":"An orally bioavailable selective inhibitor of wild-type, fusion products and mutated forms, including gatekeeper mutations, of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, zeteletinib selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zeteletinib","termGroup":"PT","termSource":"NCI"},{"termName":"BOS 172738","termGroup":"CN","termSource":"NCI"},{"termName":"BOS-172738","termGroup":"CN","termSource":"NCI"},{"termName":"BOS172738","termGroup":"CN","termSource":"NCI"},{"termName":"CAXM-1190B","termGroup":"CN","termSource":"NCI"},{"termName":"DS 5010B","termGroup":"CN","termSource":"NCI"},{"termName":"DS-5010B","termGroup":"CN","termSource":"NCI"},{"termName":"DS5010B","termGroup":"CN","termSource":"NCI"},{"termName":"RET Inhibitor DS-5010","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2216753-97-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EP0P7SHM0U"},{"name":"Maps_To","value":"RET Inhibitor DS-5010"},{"name":"NCI_Drug_Dictionary_ID","value":"796992"},{"name":"NCI_META_CUI","value":"CL937686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796992"},{"name":"PDQ_Open_Trial_Search_ID","value":"796992"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132295":{"preferredName":"Pralsetinib","code":"C132295","definitions":[{"definition":"An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pralsetinib","termGroup":"PT","termSource":"NCI"},{"termName":"(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BLU 667","termGroup":"CN","termSource":"NCI"},{"termName":"BLU-667","termGroup":"CN","termSource":"NCI"},{"termName":"BLU667","termGroup":"CN","termSource":"NCI"},{"termName":"Gavreto","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)"},{"name":"CAS_Registry","value":"2097132-94-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1WPE73O1WV"},{"name":"Maps_To","value":"Pralsetinib"},{"name":"Maps_To","value":"RET Mutation/Fusion Inhibitor BLU-667"},{"name":"NCI_Drug_Dictionary_ID","value":"787354"},{"name":"NCI_META_CUI","value":"CL520212"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787354"},{"name":"PDQ_Open_Trial_Search_ID","value":"787354"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80378":{"preferredName":"Retaspimycin","code":"C80378","definitions":[{"definition":"A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retaspimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-Allylamino-17-demethoxygeldanamycin Hydroquinone","termGroup":"SN","termSource":"NCI"},{"termName":"Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857402-23-4"},{"name":"Chemical_Formula","value":"C31H45N3O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"BZF2ZM0I5Z"},{"name":"Legacy Concept Name","value":"Retaspimycin"},{"name":"Maps_To","value":"Retaspimycin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1743502"}]}}{"C48401":{"preferredName":"Retaspimycin Hydrochloride","code":"C48401","definitions":[{"definition":"The hydrochloride salt of a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retaspimycin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"17-Allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"IPI 504","termGroup":"CN","termSource":"NCI"},{"termName":"IPI-504","termGroup":"CN","termSource":"NCI"},{"termName":"IPI504","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857402-63-2"},{"name":"Chemical_Formula","value":"C31H45N3O8.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"928Q33Q049"},{"name":"Legacy Concept Name","value":"IPI-504"},{"name":"Maps_To","value":"Retaspimycin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"437784"},{"name":"PDQ_Closed_Trial_Search_ID","value":"437784"},{"name":"PDQ_Open_Trial_Search_ID","value":"437784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1708447"}]}}{"C73241":{"preferredName":"Retelliptine","code":"C73241","definitions":[{"definition":"An ellipticine derivative and topoisomerase II inhibitor with antineoplastic activity. Retelliptine intercalates with DNA and inhibits topoisomerase II during DNA replication. In addition, this agent appears to induce cell cycle arrest at G2/M phase and apoptosis mediated through the Fas/Fas ligand death receptor and the mitochondrial pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retelliptine","termGroup":"PT","termSource":"NCI"},{"termName":"1-((3-(Diethylamino)propyl)amino)-5,11-dimethyl-9-methoxy-6H-pyrido(4,3-b)carbazole","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"72238-02-9"},{"name":"Chemical_Formula","value":"C25H32N4O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SZ0F94M68J"},{"name":"Legacy Concept Name","value":"Retelliptine"},{"name":"Maps_To","value":"Retelliptine"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084319"}]}}{"C64174":{"preferredName":"Retinoic Acid Agent Ro 16-9100","code":"C64174","definitions":[{"definition":"A synthetic retinoid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, Ro 16-9100 binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinoic Acid Agent Ro 16-9100","termGroup":"PT","termSource":"NCI"},{"termName":"Retinoid Ro 16-9100","termGroup":"SY","termSource":"NCI"},{"termName":"Ro 16-9100","termGroup":"CN","termSource":"NCI"},{"termName":"Ro-16-9100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"160372-07-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ro_16-9100"},{"name":"Maps_To","value":"Retinoic Acid Agent Ro 16-9100"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0913966"}]}}{"C80061":{"preferredName":"Retinoid 9cUAB30","code":"C80061","definitions":[{"definition":"A substance being studied in the treatment and prevention of cancer. It blocks an enzyme that keeps cells alive by adding material to the ends of chromosomes.  Blocking this enzyme may cause the cancer cells to die. 9cUAB30 is a type of retinoic acid and a type of telomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic analogue of 9-cis retinoic acid with potential antineoplastic and chemopreventive activities. Retinoid 9cUAB30 binds to and activates retinoid X receptor (RXR) homodimers and/or and retinoic acid receptor (RAR)/RXR heterodimers, which may result in the dissociation of corepressor protein and the recruitment of coactivator protein, followed by transcription of downstream target genes into mRNAs and protein translation. Gene transcription regulated by these transcription factors may result in inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinoid 9cUAB30","termGroup":"PT","termSource":"NCI"},{"termName":"(9Z)-UAB-30","termGroup":"SY","termSource":"NCI"},{"termName":"UAB-30","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"205252-57-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PFP09575EX"},{"name":"Legacy Concept Name","value":"Retinoid_9cUAB30"},{"name":"Maps_To","value":"Retinoid 9cUAB30"},{"name":"NCI_Drug_Dictionary_ID","value":"614594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"614594"},{"name":"PDQ_Open_Trial_Search_ID","value":"614594"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311390"}]}}{"C68302":{"preferredName":"Retinol","code":"C68302","definitions":[{"definition":"Retinoid with a hydroxyl group. Active form of vitamin A which can be converted to the other usable forms; retinal (an aldehyde) and retinoic acid (a carboxylic acid).","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"The fat soluble vitamin retinol. Vitamin A binds to and activates retinoid receptors (RARs), thereby inducing cell differentiation and apoptosis of some cancer cell types and inhibiting carcinogenesis. Vitamin A plays an essential role in many physiologic processes, including proper functioning of the retina, growth and differentiation of target tissues, proper functioning of the reproductive organs, and modulation of immune function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinol","termGroup":"PT","termSource":"NCI"},{"termName":"3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol","termGroup":"SN","termSource":"NCI"},{"termName":"All Trans Retinol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"11103-57-4"},{"name":"CAS_Registry","value":"68-26-8"},{"name":"CHEBI_ID","value":"CHEBI:17336"},{"name":"Chemical_Formula","value":"C20H30O"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G2SH0XKK91"},{"name":"INFOODS","value":"RETOL"},{"name":"Legacy Concept Name","value":"Retinol"},{"name":"Maps_To","value":"Retinol"},{"name":"NCI_Drug_Dictionary_ID","value":"39735"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39735"},{"name":"PDQ_Open_Trial_Search_ID","value":"39735"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"UMLS_CUI","value":"C0087161"},{"name":"Unit","value":"mcg"},{"name":"USDA_ID","value":"322"}]}}{"C1216":{"preferredName":"Retinyl Acetate","code":"C1216","definitions":[{"definition":"A naturally-occurring fatty acid ester form of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Retinyl acetate binds to and activates retinoid receptors, inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation in some cancer cell types and exhibits immunomodulatory properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinyl Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"Retinol Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"vitamin A acetate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dietary supplement; vitamin A deficiency"},{"name":"CAS_Registry","value":"127-47-9"},{"name":"CHEBI_ID","value":"CHEBI:32095"},{"name":"Chemical_Formula","value":"C22H32O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3LE3D9D6OY"},{"name":"Legacy Concept Name","value":"Retinyl_Acetate"},{"name":"Maps_To","value":"Retinyl Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"40313"},{"name":"NSC Number","value":"122045"},{"name":"NSC Number","value":"122760"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40313"},{"name":"PDQ_Open_Trial_Search_ID","value":"40313"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073109"}]}}{"C1217":{"preferredName":"Retinyl Palmitate","code":"C1217","definitions":[{"definition":"A drug being studied in cancer prevention.  It belongs to the family of drugs called retinoids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A naturally-occurring phenyl analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  As the most common form of vitamin A taken for dietary supplementation, retinyl palmitate binds to and activates retinoid receptors, thereby inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation, induces apoptosis in some cancer cell types, and exhibits immunomodulatory properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retinyl Palmitate","termGroup":"PT","termSource":"NCI"},{"termName":"Palmitate-1-14C","termGroup":"SN","termSource":"NCI"},{"termName":"Retinol Hexadecanoate","termGroup":"SY","termSource":"NCI"},{"termName":"Retinol Palmitate","termGroup":"SY","termSource":"NCI"},{"termName":"Retinol-15-3H","termGroup":"SN","termSource":"NCI"},{"termName":"Retinyl-10,11-14C2","termGroup":"SN","termSource":"NCI"},{"termName":"Vitamin A Palmitate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Dietary supplement; vitamin A deficiency; reduction in falciparum malaria episodes in children older than 12 months old; acne; diminishing malignant cell growth; enhancing the immune system; reduction in mortality of HIV-infected children"},{"name":"CAS_Registry","value":"79-81-2"},{"name":"CHEBI_ID","value":"CHEBI:17616"},{"name":"Chemical_Formula","value":"C36H60O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1D1K0N0VVC"},{"name":"Legacy Concept Name","value":"Retinyl_Palmitate"},{"name":"Maps_To","value":"Retinyl Palmitate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073115"}]}}{"C49082":{"preferredName":"Retrovector Encoding Mutant Anti-Cyclin G1","code":"C49082","definitions":[{"definition":"A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retrovector Encoding Mutant Anti-Cyclin G1","termGroup":"PT","termSource":"NCI"},{"termName":"DeltaRex-G","termGroup":"BR","termSource":"NCI"},{"termName":"Mx-dnG1","termGroup":"SY","termSource":"NCI"},{"termName":"REXIN-G","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Retrovector_Encoding_Anti-Cyclin_G"},{"name":"Maps_To","value":"Retrovector Encoding Mutant Anti-Cyclin G1"},{"name":"NCI_Drug_Dictionary_ID","value":"446577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"446577"},{"name":"PDQ_Open_Trial_Search_ID","value":"446577"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1709935"}]}}{"C74076":{"preferredName":"Rexinoid NRX 194204","code":"C74076","definitions":[{"definition":"An orally bioavailable synthetic retinoid X receptor (RXR) agonist with potential antineoplastic and anti-inflammatory activities. Rexinoid NRX 194204 selectively binds to and activates RXRs. Because RXRs can form heterodimers with several nuclear receptors (NRs), RXR activation by this agent may result in a broad range of gene expression depending on the effector DNA response elements activated. Rexinoid NRX 194204 may inhibit the tumor-necrosis factor (TNF)-mediated release of nitric oxide (NO) and interleukin 6 (IL6) and may inhibit tumor cell proliferation. This agent appears to be less toxic than RAR-selective ligands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rexinoid NRX 194204","termGroup":"PT","termSource":"NCI"},{"termName":"AGN194204","termGroup":"CN","termSource":"NCI"},{"termName":"NRX194204","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"260262-39-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"877M97Z38Y"},{"name":"Legacy Concept Name","value":"Rexinoid_NRX_194204"},{"name":"Maps_To","value":"Rexinoid NRX 194204"},{"name":"NCI_Drug_Dictionary_ID","value":"592353"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592353"},{"name":"PDQ_Open_Trial_Search_ID","value":"592353"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0967787"}]}}{"C61498":{"preferredName":"RFT5-dgA Immunotoxin IMTOX25","code":"C61498","definitions":[{"definition":"A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of melanoma that has spread to distant parts of the body. IgG-RFT5-dgA is made in the laboratory. It can find and kill certain white blood cells that prevent the immune system from killing cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant immunotoxin consisting of the anti-CD25 monoclonal antibody RFT5 fused to the deglycosylated ricin A-chain (dgA) with potential antitumor activity.  The monoclonal antibody moiety of RFT5-dgA immunotoxin attaches to CD25 (the alpha chain of the IL-2 receptor complex) on the cell membrane; after internalization, the dgA moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death.  CD25 is expressed on activated normal T and B cells and macrophages and is frequently upregulated in many hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RFT5-dgA Immunotoxin IMTOX25","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD25 Immunotoxin IMTOX25","termGroup":"SY","termSource":"NCI"},{"termName":"IgG-RFT5-dgA","termGroup":"AB","termSource":"NCI"},{"termName":"IMTOX25","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"RFT5-dgA_Immunotoxin"},{"name":"Maps_To","value":"RFT5-dgA Immunotoxin IMTOX25"},{"name":"NCI_Drug_Dictionary_ID","value":"486413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486413"},{"name":"PDQ_Open_Trial_Search_ID","value":"486413"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831838"}]}}{"C118670":{"preferredName":"Rhenium Re 188 BMEDA-labeled Liposomes","code":"C118670","definitions":[{"definition":"A liposome-based preparation consisting of the beta- and gamma-emitting radionuclide rhenium Re 188 (Re 188) linked to the chelator N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA) and encapsulated in liposomes, with potential tumor imaging and antineoplastic activities. Upon intravenous infusion of rhenium Re 188 BMEDA-labeled liposomes, the liposomes selectively target tumor cells, facilitate the retention of the radioisotope by those cells, and cause localized antitumor radiocytotoxicity while sparing surrounding normal, healthy cells. In addition, Re 188 BMEDA-labeled liposomes can be used for imaging purposes. Re 188 has a short half-life and a short path length, which further contribute to limiting the radiotoxicity to the tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re 188 BMEDA-labeled Liposomes","termGroup":"PT","termSource":"NCI"},{"termName":"(188) Re-BMEDA-liposomes","termGroup":"SY","termSource":"NCI"},{"termName":"188Re-BMEDA-liposomes","termGroup":"SY","termSource":"NCI"},{"termName":"188Re-N,N-bis (2-Mercaptoethyl)-N',N'-diethylethylenediamine-labeled Liposomes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rhenium Re 188 BMEDA-labeled Liposomes"},{"name":"NCI_Drug_Dictionary_ID","value":"765863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765863"},{"name":"PDQ_Open_Trial_Search_ID","value":"765863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897117"}]}}{"C1562":{"preferredName":"Rhenium Re 186 Etidronate","code":"C1562","definitions":[{"definition":"An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re 186 Etidronate","termGroup":"PT","termSource":"NCI"},{"termName":"186Re-Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Re 186 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Re-186 HEDP","termGroup":"AB","termSource":"NCI"},{"termName":"Re-186 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium Re-186 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-186 HEDP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"140709-07-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DV7W6W681S"},{"name":"Legacy Concept Name","value":"Re_186_Hydroxyethylidene_Diphosphonate"},{"name":"Maps_To","value":"Rhenium Re-186 Hydroxyethylidene Diphosphonate"},{"name":"NCI_Drug_Dictionary_ID","value":"41205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41205"},{"name":"PDQ_Open_Trial_Search_ID","value":"41205"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0280809"}]}}{"C91390":{"preferredName":"Rhenium Re-188 Ethiodized Oil","code":"C91390","definitions":[{"definition":"A rhenium (Re) 188 conjugate of ethiodized oil (lipiodol), an iodinated ethyl ester derived from poppy seed oil, with potential antineoplastic activity. Upon hepatic intra-arterial injection rhenium Re 188 ethiodized oil accumulates in hepatocellular carcinoma (HCC) tumor cells, thereby delivering a cytotoxic dose of radiation through Re 188 directly to the tumor cells. This may kill tumor cells while sparing surrounding normal cells and tissues. Compared to iodine I 131, Re 188 has a shorter half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re-188 Ethiodized Oil","termGroup":"PT","termSource":"NCI"},{"termName":"Rhenium Re 188 Lipiodol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rhenium Re-188 Ethiodized Oil"},{"name":"NCI_Drug_Dictionary_ID","value":"674326"},{"name":"PDQ_Closed_Trial_Search_ID","value":"674326"},{"name":"PDQ_Open_Trial_Search_ID","value":"674326"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1530677"}]}}{"C156698":{"preferredName":"Rhenium Re-188 Etidronate","code":"C156698","definitions":[{"definition":"A synthetic compound containing the bisphosphonate etidronate (hydroxyethylidene diphosphonate, HEDP) labeled with rhenium Re188, a beta-emitting radioisotope with potential antineoplastic activity. Upon administration, Re-188 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. The beta-radiation may provide localized anti-tumor radiotoxicity while sparing extramedullary bone marrow tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rhenium Re-188 Etidronate","termGroup":"PT","termSource":"NCI"},{"termName":"188Re-HEDP","termGroup":"SY","termSource":"NCI"},{"termName":"88Re-Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Re 188 Etidronic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Re 188 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Re-188 Etidronate","termGroup":"AB","termSource":"NCI"},{"termName":"Re-188 HEDP","termGroup":"SY","termSource":"NCI"},{"termName":"Re-188 Hydroxyethylidene Diphosphonate","termGroup":"SY","termSource":"NCI"},{"termName":"Re-188Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium Re-188 Hydroxyethylidene Diphosphonate (SY)","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-188 Etidronate","termGroup":"SY","termSource":"NCI"},{"termName":"Rhenium-188 HEDP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XWW2JNQ850"},{"name":"Maps_To","value":"Rhenium Re-188 Etidronate"},{"name":"NCI_Drug_Dictionary_ID","value":"795714"},{"name":"NCI_META_CUI","value":"CL935713"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795714"},{"name":"PDQ_Open_Trial_Search_ID","value":"795714"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1218":{"preferredName":"Rhizoxin","code":"C1218","definitions":[{"definition":"A macrocyclic lactone. Rhizoxin binds to tubulin and inhibits microtubule assembly, thereby inducing cytotoxicity. This agent also may inhibit endothelial cell-induced angiogenic activity, which may result in decreased tumor cell proliferation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It comes from a fungus and is similar to vinca alkaloid drugs. It belongs to the family of drugs called antimitotic agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rhizoxin","termGroup":"PT","termSource":"NCI"},{"termName":"WF-1360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"90996-54-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C1V1Y784E4"},{"name":"Legacy Concept Name","value":"Rhizoxin"},{"name":"Maps_To","value":"Rhizoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"41718"},{"name":"NSC Number","value":"332598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41718"},{"name":"PDQ_Open_Trial_Search_ID","value":"41718"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073184"}]}}{"C151937":{"preferredName":"Onilcamotide","code":"C151937","definitions":[{"definition":"A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Onilcamotide","termGroup":"PT","termSource":"NCI"},{"termName":"RhoC Peptide Vaccine RV001V","termGroup":"SY","termSource":"NCI"},{"termName":"RV 001","termGroup":"CN","termSource":"NCI"},{"termName":"RV 001V","termGroup":"CN","termSource":"NCI"},{"termName":"RV001 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"RV001V","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1164096-85-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UQE6KP7T0D"},{"name":"Maps_To","value":"RhoC Peptide Vaccine RV001V"},{"name":"NCI_Drug_Dictionary_ID","value":"793139"},{"name":"NCI_META_CUI","value":"CL553276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793139"},{"name":"PDQ_Open_Trial_Search_ID","value":"793139"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95701":{"preferredName":"Ribociclib","code":"C95701","definitions":[{"definition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribociclib","termGroup":"PT","termSource":"NCI"},{"termName":"7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"Kisqali","termGroup":"BR","termSource":"NCI"},{"termName":"LEE 011","termGroup":"CN","termSource":"NCI"},{"termName":"LEE-011","termGroup":"CN","termSource":"NCI"},{"termName":"LEE011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"breast cancer"},{"name":"CAS_Registry","value":"1211441-98-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"TK8ERE8P56"},{"name":"Maps_To","value":"Ribociclib"},{"name":"NCI_Drug_Dictionary_ID","value":"689330"},{"name":"PDQ_Closed_Trial_Search_ID","value":"689330"},{"name":"PDQ_Open_Trial_Search_ID","value":"689330"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045494"}]}}{"C154675":{"preferredName":"Ribociclib/Letrozole","code":"C154675","definitions":[{"definition":"An orally available co-packaged agent combination of ribociclib, a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Ribociclib specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribociclib/Letrozole","termGroup":"PT","termSource":"NCI"},{"termName":"Kisqali and Femara Co-pack","termGroup":"BR","termSource":"NCI"},{"termName":"Kisqali Femara Co-pack","termGroup":"SY","termSource":"NCI"},{"termName":"Kisqali/Femara","termGroup":"BR","termSource":"NCI"},{"termName":"Ribociclib + Letrozole","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib and Letrozole Co-pack","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib Plus Letrozole","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib-Letrozole","termGroup":"SY","termSource":"NCI"},{"termName":"Ribociclib-Letrozole Regimen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ribociclib/Letrozole"},{"name":"NCI_META_CUI","value":"CL759918"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82689":{"preferredName":"Ribonuclease QBI-139","code":"C82689","definitions":[{"definition":"A nuclease of mammalian origin that cleaves the phosphodiester bond between nucleotides of ribonucleic acids with potential antineoplastic activity. Ribonuclease QBI-139 catalyzes the hydrolysis and degradation of RNA leading to the inhibition of protein synthesis and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ribonuclease QBI-139","termGroup":"PT","termSource":"NCI"},{"termName":"QBI-139","termGroup":"CN","termSource":"NCI"},{"termName":"RNase QBI-139","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ribonuclease_QBI-139"},{"name":"Maps_To","value":"Ribonuclease QBI-139"},{"name":"NCI_Drug_Dictionary_ID","value":"633695"},{"name":"NCI_META_CUI","value":"CL388476"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633695"},{"name":"PDQ_Open_Trial_Search_ID","value":"633695"},{"name":"Semantic_Type","value":"Enzyme"}]}}{"C78188":{"preferredName":"Aviscumine","code":"C78188","definitions":[{"definition":"A recombinant protein that inactivates the ribosome with potential antineoplastic and immunomodulating activities. Aviscumine binds to the cell surface sialyltransferase CD75 and is internalized; intracellularly, aviscumine cleaves an adenine-specific N-glycosidic bond on the 28S ribosomal subunit, which may result in tumor cell apoptosis. This agent has also been shown to activate natural killer (NK) cells, induce cytokine receptor expression, and stimulate the release of cytokines. CD75 is expressed on mature B-cells and subsets of T-cells and erythrocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aviscumine","termGroup":"PT","termSource":"NCI"},{"termName":"CY 503","termGroup":"CN","termSource":"NCI"},{"termName":"CY-503","termGroup":"CN","termSource":"NCI"},{"termName":"CY503","termGroup":"CN","termSource":"NCI"},{"termName":"Toxin ML-I (Mistletoe Lectin I) (Viscum album)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"223577-45-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4B18YVW82N"},{"name":"Legacy Concept Name","value":"Ribosome-Inactivating_Protein_CY503"},{"name":"Maps_To","value":"Aviscumine"},{"name":"Maps_To","value":"Ribosome-Inactivating Protein CY503"},{"name":"NCI_Drug_Dictionary_ID","value":"594770"},{"name":"NCI_META_CUI","value":"CL383580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594770"},{"name":"PDQ_Open_Trial_Search_ID","value":"594770"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1865":{"preferredName":"Ribozyme RPI.4610","code":"C1865","definitions":[{"definition":"A nuclease-stabilized synthetic ribozyme (ribonucleic acid enzyme) with potential anti-angiogenesis activity. Ribozyme RPI.4610 specifically recognizes the mRNA for FLT1 (vascular endothelial growth factor receptor 1; VEGFR1), and hydrolyzes the mRNA, thereby preventing VEGFR1 proteins from being made. This may prevent VEGF-stimulated angiogenesis in cancerous tissue and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. RPI.4610 is a special type of RNA made in the laboratory. It stops a protein called vascular endothelial growth factor receptor (VEGFR) from being made. This may prevent the growth of new blood vessels that tumors need to grow. It is a type of angiogenesis inhibitor and a type of ribozyme.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ribozyme RPI.4610","termGroup":"PT","termSource":"NCI"},{"termName":"Angiozyme","termGroup":"BR","termSource":"NCI"},{"termName":"Anti-Flt-1 Ribozyme","termGroup":"SY","termSource":"NCI"},{"termName":"RPI.4610","termGroup":"CN","termSource":"NCI"},{"termName":"RPI4610","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Angiozyme"},{"name":"Maps_To","value":"Ribozyme RPI.4610"},{"name":"NCI_Drug_Dictionary_ID","value":"38358"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38358"},{"name":"PDQ_Open_Trial_Search_ID","value":"38358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0908892"}]}}{"C111686":{"preferredName":"Rice Bran","code":"C111686","definitions":[{"definition":"The nutrient-rich hard outer layer of the rice cereal grain, with potential chemopreventive, antioxidant, iron chelating, anticholesterol and anti-inflammatory activities. Rice bran is rich in fiber, such as beta-glucan, pectin and gum; it also comprises vitamins and minerals, such as iron, magnesium and phosphorus, and essential fatty acids. In addition, Rice bran contains various bioactive components, including ferulic acid, tricin, beta-sitosterol, gamma-oryzanol, phytic acid, and inositol hexaphosphate (IP6). The potential anticancer activity of rice bran may be due to the synergistic effects of these phytochemicals on their ability to induce apoptosis, inhibit cell proliferation, and alter cell cycle progression in cancer cells. Rice bran's bioactive components also protect against tissue damage by scavenging free radicals and blocking chronic inflammatory responses. In addition, they are able to modulate the gut microflora and carcinogen-metabolizing enzymes, thereby further exerting a chemopreventive effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rice Bran","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R60QEP13IC"},{"name":"Maps_To","value":"Rice Bran"},{"name":"NCI_Drug_Dictionary_ID","value":"752814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752814"},{"name":"PDQ_Open_Trial_Search_ID","value":"752814"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3810876"}]}}{"C96431":{"preferredName":"Ricolinostat","code":"C96431","definitions":[{"definition":"An orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Ricolinostat selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ricolinostat","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ACY 1215","termGroup":"CN","termSource":"NCI"},{"termName":"ACY-1215","termGroup":"CN","termSource":"NCI"},{"termName":"ACY1215","termGroup":"CN","termSource":"NCI"},{"termName":"Histone Deacetylase 6 Inhibitor ACY-1215","termGroup":"SY","termSource":"NCI"},{"termName":"Rocilinostat","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1316214-52-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"WKT909C62B"},{"name":"Maps_To","value":"Ricolinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"698408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698408"},{"name":"PDQ_Open_Trial_Search_ID","value":"698408"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3492270"}]}}{"C49061":{"preferredName":"Ridaforolimus","code":"C49061","definitions":[{"definition":"A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of soft tissue and bone cancers. It is also being studied in the treatment of other solid tumors and hematologic cancer. Ridaforolimus stops cells from dividing and may cause cancer cells to die. It is a type of mTOR inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ridaforolimus","termGroup":"PT","termSource":"NCI"},{"termName":"AP23573","termGroup":"CN","termSource":"NCI"},{"termName":"Deforolimus","termGroup":"SY","termSource":"NCI"},{"termName":"MK-8669","termGroup":"CN","termSource":"NCI"},{"termName":"Rapamycin, 42-(dimethylphosphinate)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"572924-54-0"},{"name":"Chemical_Formula","value":"C53H84NO14P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48Z35KB15K"},{"name":"Legacy Concept Name","value":"AP23573"},{"name":"Maps_To","value":"Ridaforolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"354223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354223"},{"name":"PDQ_Open_Trial_Search_ID","value":"354223"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2713007"}]}}{"C152216":{"preferredName":"Rigosertib","code":"C152216","definitions":[{"definition":"A synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rigosertib","termGroup":"PT","termSource":"NCI"},{"termName":"Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) methyl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-(2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) phenyl)glycine","termGroup":"SY","termSource":"NCI"},{"termName":"ON 01910","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"592542-59-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67DOW7F9GL"},{"name":"Maps_To","value":"Rigosertib"},{"name":"NCI_META_CUI","value":"CL553420"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71355":{"preferredName":"Rigosertib Sodium","code":"C71355","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain proteins that are needed for cell growth and may kill cancer cells. ON 01910.Na is a type of protein kinase inhibitor and a type of benzyl styryl sulfone analog.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt form of rigosertib, a synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rigosertib Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"ON 01910.Na","termGroup":"CN","termSource":"NCI"},{"termName":"Polo-like kinase 1 Inhibitor ON 01910.Na","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"592542-60-4"},{"name":"Chemical_Formula","value":"C21H24NO8S.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"406FL5G00V"},{"name":"Legacy Concept Name","value":"Polo-like_kinase_1_Inhibitor_ON_01910_Na"},{"name":"Maps_To","value":"Rigosertib Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"573371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573371"},{"name":"PDQ_Open_Trial_Search_ID","value":"573371"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467794"}]}}{"C38681":{"preferredName":"Rilimogene Galvacirepvec","code":"C38681","definitions":[{"definition":"A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilimogene Galvacirepvec","termGroup":"PT","termSource":"NCI"},{"termName":"PROSTVAC","termGroup":"BR","termSource":"NCI"},{"termName":"Prostvac-V","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Vaccinia-PSA(L155)-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Vaccinia-PSA(L155)/TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Vaccinia-PSA(L155)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"rVaccinia-Prostate-Specific Antigen/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"rVaccinia-PSA(L155)-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1225283-43-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"59WJ3TGA5K"},{"name":"Legacy Concept Name","value":"Vaccinia-PSA-TRICOM_Vaccine"},{"name":"Maps_To","value":"Rilimogene Galvacirepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"305934"},{"name":"NSC Number","value":"717170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"305934"},{"name":"PDQ_Open_Trial_Search_ID","value":"305934"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"},{"name":"UMLS_CUI","value":"C1519903"}]}}{"C132990":{"preferredName":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","code":"C132990","definitions":[{"definition":"A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilimogene Galvacirepvec/Rilimogene Glafolivec","termGroup":"PT","termSource":"NCI"},{"termName":"PROSTVAC","termGroup":"BR","termSource":"NCI"},{"termName":"PROSTVAC-V-PROSTVAC-F","termGroup":"SY","termSource":"NCI"},{"termName":"PROSTVAC-V/F","termGroup":"SY","termSource":"NCI"},{"termName":"PROSTVAC-VF-TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"PROSTVAC-VF/TRICOM","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Vaccinia-Fowlpox-Prostate-specific Antigen-TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Rilimogene Galvacirepvec-Rilimogene Glafolivec","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rilimogene Galvacirepvec/Rilimogene Glafolivec"},{"name":"NCI_Drug_Dictionary_ID","value":"787601"},{"name":"NCI_META_CUI","value":"CL520248"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787601"},{"name":"PDQ_Open_Trial_Search_ID","value":"787601"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C29560":{"preferredName":"Rilimogene Glafolivec","code":"C29560","definitions":[{"definition":"A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM).  Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilimogene Glafolivec","termGroup":"PT","termSource":"NCI"},{"termName":"PROSTVAC-F","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"rFowlpox-PSA(L155)/TRICOM Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1225283-42-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7PLH7RM47T"},{"name":"Legacy Concept Name","value":"rFowlpox-PSA_L155_TRICOM"},{"name":"Maps_To","value":"Rilimogene Glafolivec"},{"name":"NCI_Drug_Dictionary_ID","value":"305933"},{"name":"NSC Number","value":"717171"},{"name":"PDQ_Closed_Trial_Search_ID","value":"305933"},{"name":"PDQ_Open_Trial_Search_ID","value":"305933"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515688"}]}}{"C67079":{"preferredName":"Rilotumumab","code":"C67079","definitions":[{"definition":"A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It binds to a protein called hepatocyte growth factor (HGF), which may cause cancer cells to grow. Blocking this may cause cancer cells to die. AMG 102 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rilotumumab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 102","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-102","termGroup":"CN","termSource":"NCI"},{"termName":"AMG102","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-HGF Monoclonal Antibody AMG 102","termGroup":"SY","termSource":"NCI"},{"termName":"Fully Human Anti-HGF Monoclonal Antibody AMG 102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"872514-65-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"51WEW898IJ"},{"name":"Legacy Concept Name","value":"Anti-HGF_Monoclonal_Antibody_AMG_102"},{"name":"Maps_To","value":"Rilotumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"536240"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536240"},{"name":"PDQ_Open_Trial_Search_ID","value":"536240"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2743963"}]}}{"C69076":{"preferredName":"Rindopepimut","code":"C69076","definitions":[{"definition":"A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rindopepimut","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFRvIII Vaccine CDX-110","termGroup":"SY","termSource":"NCI"},{"termName":"CDX-110","termGroup":"CN","termSource":"NCI"},{"termName":"L-Cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-(1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)-, complex with hemocyanin (Megathura crenulata)","termGroup":"SN","termSource":"NCI"},{"termName":"PF-04948568","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Immunotherapy for glioblastoma multiforme"},{"name":"CAS_Registry","value":"946156-74-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K3L4X0501F"},{"name":"Legacy Concept Name","value":"Anti-EGFRvIII_Vaccine_CDX-110"},{"name":"Maps_To","value":"Rindopepimut"},{"name":"NCI_Drug_Dictionary_ID","value":"546970"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546970"},{"name":"PDQ_Open_Trial_Search_ID","value":"546970"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3181262"}]}}{"C156737":{"preferredName":"RIPK1 Inhibitor GSK3145095","code":"C156737","definitions":[{"definition":"An orally available, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential antineoplastic and immunomodulatory activities.  Upon administration, GSK3145095 disrupts RIPK1-mediated signaling, which may reduce C-X-C motif chemokine ligand 1 (CXCL1)-driven recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME). This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. RIPK1, a serine-threonine kinase that normally plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition, is overexpressed in certain cancer types and may be associated with oncogenesis and promotion of the immunosuppressive nature of the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RIPK1 Inhibitor GSK3145095","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 3145095","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3145095","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3145095","termGroup":"CN","termSource":"NCI"},{"termName":"Receptor-interacting Serine/Threonine-protein Kinase 1 Inhibitor GSK3145095","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622849-43-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B4D3WPS7JY"},{"name":"Maps_To","value":"RIPK1 Inhibitor GSK3145095"},{"name":"NCI_Drug_Dictionary_ID","value":"795835"},{"name":"NCI_META_CUI","value":"CL935900"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795835"},{"name":"PDQ_Open_Trial_Search_ID","value":"795835"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C124067":{"preferredName":"Ripretinib","code":"C124067","definitions":[{"definition":"An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ripretinib","termGroup":"PT","termSource":"NCI"},{"termName":"1-N'-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxyphenyl]-1-N'-phenylcyclopropane-1,1-dicarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"DCC 2618","termGroup":"CN","termSource":"NCI"},{"termName":"DCC-2618","termGroup":"CN","termSource":"NCI"},{"termName":"DCC2618","termGroup":"CN","termSource":"NCI"},{"termName":"Qinlock","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib."},{"name":"CAS_Registry","value":"1225278-16-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9XW757O13D"},{"name":"Maps_To","value":"Ripertamab"},{"name":"Maps_To","value":"Ripretinib"},{"name":"NCI_Drug_Dictionary_ID","value":"776638"},{"name":"NCI_META_CUI","value":"CL502501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776638"},{"name":"PDQ_Open_Trial_Search_ID","value":"776638"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131306":{"preferredName":"Risperidone Formulation in Rumenic Acid","code":"C131306","definitions":[{"definition":"An orally bioavailable capsule formulation containing the antipsychotic agent risperidone suspended in the lipid rumenic acid, with potential antineoplastic activity. Upon administration of VAL401, risperidone may, through an as of yet not elucidated mechanism of action, reduce cellular activity and tumor cell proliferation in multiple cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Risperidone Formulation in Rumenic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Risperidone Lipid Formulation VAL401","termGroup":"SY","termSource":"NCI"},{"termName":"VAL-401","termGroup":"CN","termSource":"NCI"},{"termName":"VAL401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Risperidone Formulation in Rumenic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"785676"},{"name":"NCI_META_CUI","value":"CL514450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785676"},{"name":"PDQ_Open_Trial_Search_ID","value":"785676"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75294":{"preferredName":"Ritrosulfan","code":"C75294","definitions":[{"definition":"A sulfonate-based alkylation agent with potential antineoplastic activity. Ritrosulfan appears to alkylate DNA, thereby producing DNA crosslinks, resulting in cell cycle arrest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ritrosulfan","termGroup":"PT","termSource":"NCI"},{"termName":"Lycurim","termGroup":"BR","termSource":"NCI"},{"termName":"R-74","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4148-16-7"},{"name":"Chemical_Formula","value":"C10H24N2O8S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YIY0662KX9"},{"name":"Legacy Concept Name","value":"Ritrosulfan"},{"name":"Maps_To","value":"Ritrosulfan"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073401"}]}}{"C1702":{"preferredName":"Rituximab","code":"C1702","definitions":[{"definition":"A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rituximab","termGroup":"PT","termSource":"NCI"},{"termName":"ABP 798","termGroup":"CN","termSource":"NCI"},{"termName":"BI 695500","termGroup":"CN","termSource":"NCI"},{"termName":"BI-695500","termGroup":"CN","termSource":"NCI"},{"termName":"BI695500","termGroup":"CN","termSource":"NCI"},{"termName":"Blitzima","termGroup":"FB","termSource":"NCI"},{"termName":"C2B8 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"Chimeric Anti-CD20 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"CT-P10","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC 102","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-102","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-C2B8","termGroup":"CN","termSource":"NCI"},{"termName":"IDEC-C2B8 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"IDEC102","termGroup":"CN","termSource":"NCI"},{"termName":"Ikgdar","termGroup":"FB","termSource":"NCI"},{"termName":"Mabtas","termGroup":"FB","termSource":"NCI"},{"termName":"MabThera","termGroup":"FB","termSource":"NCI"},{"termName":"Monoclonal Antibody IDEC-C2B8","termGroup":"SY","termSource":"NCI"},{"termName":"PF 05280586","termGroup":"CN","termSource":"NCI"},{"termName":"PF-05280586","termGroup":"CN","termSource":"NCI"},{"termName":"PF05280586","termGroup":"CN","termSource":"NCI"},{"termName":"Riabni","termGroup":"BR","termSource":"NCI"},{"termName":"Ritemvia","termGroup":"FB","termSource":"NCI"},{"termName":"Rituxan","termGroup":"BR","termSource":"NCI"},{"termName":"Rituximab ABBS","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab ARRX","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar ABP 798","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar BI 695500","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar CT-P10","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar GB241","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar IBI301","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar JHL1101","termGroup":"CN","termSource":"NCI"},{"termName":"Rituximab Biosimilar PF-05280586","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar RTXM83","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar SAIT101","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab Biosimilar SIBP-02","termGroup":"SY","termSource":"NCI"},{"termName":"rituximab biosimilar TQB2303","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab PVVR","termGroup":"SY","termSource":"NCI"},{"termName":"rituximab-abbs","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab-arrx","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab-pvvr","termGroup":"SY","termSource":"NCI"},{"termName":"Rixathon","termGroup":"FB","termSource":"NCI"},{"termName":"Riximyo","termGroup":"FB","termSource":"NCI"},{"termName":"RTXM 83","termGroup":"CN","termSource":"NCI"},{"termName":"RTXM-83","termGroup":"CN","termSource":"NCI"},{"termName":"RTXM83","termGroup":"CN","termSource":"NCI"},{"termName":"Ruxience","termGroup":"BR","termSource":"NCI"},{"termName":"Truxima","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diffuse Large B-cell, CD20-positive, Non-Hodgkins Lymphoma (NHL)"},{"name":"CAS_Registry","value":"174722-31-7"},{"name":"CHEBI_ID","value":"CHEBI:64357"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4F4X42SYQ6"},{"name":"Legacy Concept Name","value":"Rituximab"},{"name":"Maps_To","value":"Rituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"42613"},{"name":"NSC Number","value":"687451"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42613"},{"name":"PDQ_Open_Trial_Search_ID","value":"42613"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393022"}]}}{"C136821":{"preferredName":"Rituximab and Hyaluronidase Human","code":"C136821","definitions":[{"definition":"A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).  When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.  CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rituximab and Hyaluronidase Human","termGroup":"PT","termSource":"NCI"},{"termName":"Rituxan Hycela","termGroup":"BR","termSource":"NCI"},{"termName":"Rituximab Plus Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab/Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Rituximab/Hyaluronidase Human","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Rituximab and Hyaluronidase Human"},{"name":"NCI_Drug_Dictionary_ID","value":"789585"},{"name":"NCI_META_CUI","value":"CL524655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789585"},{"name":"PDQ_Open_Trial_Search_ID","value":"789585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148162":{"preferredName":"Rituximab Conjugate CON-4619","code":"C148162","definitions":[{"definition":"A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rituximab Conjugate CON-4619","termGroup":"PT","termSource":"NCI"},{"termName":"Aurixim","termGroup":"BR","termSource":"NCI"},{"termName":"Aurixim Antibody Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"CON-4619","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rituximab Conjugate CON-4619"},{"name":"NCI_Drug_Dictionary_ID","value":"792533"},{"name":"NCI_META_CUI","value":"CL550782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792533"},{"name":"PDQ_Open_Trial_Search_ID","value":"792533"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64762":{"preferredName":"Riviciclib","code":"C64762","definitions":[{"definition":"A flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Riviciclib","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin Dependent Kinase Inhibitor P276","termGroup":"SY","termSource":"NCI"},{"termName":"P-276-00 Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"P276","termGroup":"CN","termSource":"NCI"},{"termName":"P276-00","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"920113-02-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9EK26WE8QN"},{"name":"Legacy Concept Name","value":"P276"},{"name":"Maps_To","value":"Riviciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"529362"},{"name":"PDQ_Closed_Trial_Search_ID","value":"529362"},{"name":"PDQ_Open_Trial_Search_ID","value":"529362"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832023"}]}}{"C152237":{"preferredName":"Rivoceranib","code":"C152237","definitions":[{"definition":"An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rivoceranib","termGroup":"PT","termSource":"NCI"},{"termName":"-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"Apatinib","termGroup":"SY","termSource":"NCI"},{"termName":"Apatinib Free Base","termGroup":"SY","termSource":"NCI"},{"termName":"YN968D1 Free Base","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"811803-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5S371K6132"},{"name":"Maps_To","value":"Rivoceranib"},{"name":"NCI_META_CUI","value":"CL553441"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74012":{"preferredName":"Rivoceranib Mesylate","code":"C74012","definitions":[{"definition":"The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rivoceranib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Aitan","termGroup":"FB","termSource":"NCI"},{"termName":"Apatinib Mesylate","termGroup":"SY","termSource":"NCI"},{"termName":"YN 968D1","termGroup":"CN","termSource":"NCI"},{"termName":"YN-968D1","termGroup":"CN","termSource":"NCI"},{"termName":"YN968D1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1218779-75-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TK02X14ASJ"},{"name":"Legacy Concept Name","value":"Rivoceranib Mesylate"},{"name":"Maps_To","value":"Rivoceranib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"592508"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592508"},{"name":"PDQ_Open_Trial_Search_ID","value":"592508"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346836"}]}}{"C114976":{"preferredName":"RNR Inhibitor COH29","code":"C114976","definitions":[{"definition":"An orally available, aromatically substituted thiazole and inhibitor of the human ribonucleotide reductase (RNR), with potential antineoplastic activity. Upon oral administration, the RNR inhibitor COH29 binds to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail. This blocks the interaction between the hRRM1 and hRRM2 subunits and interferes with the assembly of the active hRRM1/hRRM2 complex of RNR. Inhibition of RNR activity decreases the pool of deoxyribonucleotide triphosphates available for DNA synthesis. The resulting decrease in DNA synthesis causes cell cycle arrest and growth inhibition. In addition, this agent may inhibit the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 1, which prevents the repair of damaged DNA, and causes both the accumulation of single and double strand DNA breaks and the induction of apoptosis. RNR, an enzyme that catalyzes the conversion of ribonucleoside diphosphate to deoxyribonucleoside diphosphate, is essential for de novo DNA synthesis and plays an important role in cell growth; it is overexpressed in many cancer cell types and is associated with increased drug resistance, cancer cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RNR Inhibitor COH29","termGroup":"PT","termSource":"NCI"},{"termName":"COH-29","termGroup":"CN","termSource":"NCI"},{"termName":"COH29","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Ribonucleotide Reductase Holoenzyme Inhibitor COH29","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1190932-38-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"07802BU06S"},{"name":"Maps_To","value":"RNR Inhibitor COH29"},{"name":"NCI_Drug_Dictionary_ID","value":"759501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759501"},{"name":"PDQ_Open_Trial_Search_ID","value":"759501"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896938"}]}}{"C71527":{"preferredName":"Robatumumab","code":"C71527","definitions":[{"definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Robatumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal SCH 717454 Heavy Chain), Disulfide with Human Monoclonal SCH 717454 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Sch717454","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934235-44-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V983921H3B"},{"name":"Legacy Concept Name","value":"Anti-IGF-1R_Recombinant_Monoclonal_Antibody_SCH_717454"},{"name":"Maps_To","value":"Robatumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"577364"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577364"},{"name":"PDQ_Open_Trial_Search_ID","value":"577364"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3467798"}]}}{"C77907":{"preferredName":"Rocapuldencel-T","code":"C77907","definitions":[{"definition":"A cancer vaccine in which autologous dendritic cells are transfected with patient-specific renal cell carcinoma (RCC) RNA and a synthetic, truncated human CD40 ligand (CD40L) RNA with potential immunostimulatory and antineoplastic activities. Individual RCC-specific RNA, encoding a unique repertoire of tumor-associated antigens (TAAs) (including telomerase reverse transcriptase, G250, and oncofetal antigen) is electroporated into autologous dendritic cells (DCs), transfected with synthetic RNA that encodes a truncated version of the T-cell protein CD40L; the transfected autologous DCs express and process both patient-specific RCC TAAs and the truncated CD40L protein. When reintroduced back to the patient, rocapuldencel-T may elicit a highly specific cytotoxic T-cell (CTL) response against RCC cells expressing the patient-specific RCC TAA repertoire. The signal cascade initiated by stimulation of the truncated, ectopically expressed co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12 downstream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rocapuldencel-T","termGroup":"PT","termSource":"NCI"},{"termName":"AGS-003","termGroup":"CN","termSource":"NCI"},{"termName":"CMN-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8I9S6401XZ"},{"name":"Legacy Concept Name","value":"Renal_Tumor_RNA_CD40L-Transfected_Dendritic_Cell_Vaccine"},{"name":"Maps_To","value":"Rocapuldencel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"599024"},{"name":"NCI_META_CUI","value":"CL387046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599024"},{"name":"PDQ_Open_Trial_Search_ID","value":"599024"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99905":{"preferredName":"Rociletinib","code":"C99905","definitions":[{"definition":"An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rociletinib","termGroup":"PT","termSource":"NCI"},{"termName":"CO 1686","termGroup":"CN","termSource":"NCI"},{"termName":"CO-1686","termGroup":"CN","termSource":"NCI"},{"termName":"CO1686","termGroup":"CN","termSource":"NCI"},{"termName":"N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide","termGroup":"SN","termSource":"NCI"},{"termName":"Rociletinib","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1374640-70-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"72AH61702G"},{"name":"Maps_To","value":"Rociletinib"},{"name":"NCI_Drug_Dictionary_ID","value":"725346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"725346"},{"name":"PDQ_Open_Trial_Search_ID","value":"725346"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4045493"}]}}{"C97275":{"preferredName":"Rodorubicin","code":"C97275","definitions":[{"definition":"A synthetic tetraglycosidic anthracycline antibiotic with antineoplastic activity. Rodorubicin appears to intercalate DNA and causes cell death. Due to its severe cardiotoxic effects, this agent was never marketed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rodorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"Cytorhodin S","termGroup":"SY","termSource":"NCI"},{"termName":"HLB 817","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"96497-67-5"},{"name":"Chemical_Formula","value":"C48H64N2O17"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XCZ4D2241Y"},{"name":"Maps_To","value":"Rodorubicin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073554"}]}}{"C1832":{"preferredName":"Rofecoxib","code":"C1832","definitions":[{"definition":"A drug that was being used for pain relief and was being studied for its ability to prevent cancer and to prevent the growth of new blood vessels that tumors need to grow. It is a type of nonsteroidal anti-inflammatory drug and a type of antiangiogenesis agent. Rofecoxib was taken off the market in the U.S. because of safety concerns.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties.  Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins.  COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rofecoxib","termGroup":"PT","termSource":"NCI"},{"termName":"4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone","termGroup":"SN","termSource":"NCI"},{"termName":"MK 966","termGroup":"CN","termSource":"NCI"},{"termName":"Vioxx","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Pain; dysmenorrhea; osteoarthritis; rheumatoid arthritis"},{"name":"CAS_Registry","value":"162011-90-7"},{"name":"CHEBI_ID","value":"CHEBI:8887"},{"name":"Chemical_Formula","value":"C17H14O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0QTW8Z7MCR"},{"name":"Legacy Concept Name","value":"Rofecoxib"},{"name":"Maps_To","value":"Rofecoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"38568"},{"name":"NSC Number","value":"720256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38568"},{"name":"PDQ_Open_Trial_Search_ID","value":"38568"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0762662"}]}}{"C76890":{"preferredName":"Roflumilast","code":"C76890","definitions":[{"definition":"An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR signaling pathway, which may result in the induction of apoptosis. PDE4, a member of the PDE superfamily that hydrolyses cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates, is upregulated in a variety of cancers and may contribute to chemoresistance; it also plays a key role in inflammation, especially in inflammatory airway diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roflumilast","termGroup":"PT","termSource":"NCI"},{"termName":"3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"B9302-107","termGroup":"CN","termSource":"NCI"},{"termName":"BY217","termGroup":"CN","termSource":"NCI"},{"termName":"BYK20869","termGroup":"CN","termSource":"NCI"},{"termName":"Daliresp","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Obstructive Pulmonary Disease (COPD)"},{"name":"CAS_Registry","value":"162401-32-3"},{"name":"Chemical_Formula","value":"C17H14Cl2F2N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0P6C6ZOP5U"},{"name":"Legacy Concept Name","value":"Roflumilast"},{"name":"Maps_To","value":"Roflumilast"},{"name":"NCI_Drug_Dictionary_ID","value":"750521"},{"name":"PDQ_Closed_Trial_Search_ID","value":"750521"},{"name":"PDQ_Open_Trial_Search_ID","value":"750521"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0965618"}]}}{"C112205":{"preferredName":"Rogaratinib","code":"C112205","definitions":[{"definition":"A pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Rogaratinib inhibits the activities of FGFRs, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rogaratinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-((4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)methyl)piperazin-2-one","termGroup":"SN","termSource":"NCI"},{"termName":"BAY-1163877","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1163877","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443530-05-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98BSN6N516"},{"name":"Maps_To","value":"Rogaratinib"},{"name":"NCI_Drug_Dictionary_ID","value":"754526"},{"name":"NCI_META_CUI","value":"CL454405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"754526"},{"name":"PDQ_Open_Trial_Search_ID","value":"754526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1427":{"preferredName":"Rogletimide","code":"C1427","definitions":[{"definition":"An orally active aminoglutethimide derivative with potential antineoplastic activity. Rogletimide reversibly inhibits the activity of aromatase, a cytochrome P450 family enzyme found in many tissues and the key enzyme in the oxidative aromatization process of androgens to estrogens. In estrogen-dependent cancers, the inhibition of aromatase by this agent leads to a reduction in the synthesis of estrogen, thereby inhibiting estrogen-mediated signal transduction and consequently reducing tumor cell growth. In addition, rogletimide also inhibits enzymes that catalyzing conversion of cholesterol to corticosteroids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rogletimide","termGroup":"PT","termSource":"NCI"},{"termName":"Pyridoglutethimide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92788-10-8"},{"name":"Chemical_Formula","value":"C12H14N2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"14P4QR28QF"},{"name":"Legacy Concept Name","value":"Rogletimide"},{"name":"Maps_To","value":"Rogletimide"},{"name":"NCI_Drug_Dictionary_ID","value":"41461"},{"name":"NSC Number","value":"619778"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41461"},{"name":"PDQ_Open_Trial_Search_ID","value":"41461"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0164550"}]}}{"C1544":{"preferredName":"Romidepsin","code":"C1544","definitions":[{"definition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. Romidepsin is a type of depsipeptide and histone deacetylase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Romidepsin","termGroup":"PT","termSource":"NCI"},{"termName":"Antibiotic FR 901228","termGroup":"SY","termSource":"NCI"},{"termName":"Depsipeptide","termGroup":"SY","termSource":"NCI"},{"termName":"FK 228","termGroup":"CN","termSource":"NCI"},{"termName":"FK-228","termGroup":"CN","termSource":"NCI"},{"termName":"FK228","termGroup":"CN","termSource":"NCI"},{"termName":"FR 901228","termGroup":"CN","termSource":"NCI"},{"termName":"FR-901228","termGroup":"CN","termSource":"NCI"},{"termName":"FR901228","termGroup":"CN","termSource":"NCI"},{"termName":"Istodax","termGroup":"BR","termSource":"NCI"},{"termName":"L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))-","termGroup":"SN","termSource":"NCI"},{"termName":"N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"128517-07-7"},{"name":"CHEBI_ID","value":"CHEBI:61080"},{"name":"Chemical_Formula","value":"C24H36N4O6S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CX3T89XQBK"},{"name":"Legacy Concept Name","value":"Depsipeptide"},{"name":"Maps_To","value":"Romidepsin"},{"name":"NCI_Drug_Dictionary_ID","value":"42600"},{"name":"NSC Number","value":"630176"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42600"},{"name":"PDQ_Open_Trial_Search_ID","value":"42600"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527027"}]}}{"C92579":{"preferredName":"Roniciclib","code":"C92579","definitions":[{"definition":"An orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Roniciclib selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roniciclib","termGroup":"PT","termSource":"NCI"},{"termName":"BAY1000394","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1223498-69-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0W9Q8U337A"},{"name":"Maps_To","value":"Roniciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"684718"},{"name":"NCI_META_CUI","value":"CL423828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684718"},{"name":"PDQ_Open_Trial_Search_ID","value":"684718"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48813":{"preferredName":"Ropidoxuridine","code":"C48813","definitions":[{"definition":"An orally available 5-substituted 2-pyrimidinone-2'-deoxyribonucleoside analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Upon oral administration, ropidoxuridine (IPdR) is efficiently converted to idoxuridine (IUdR) by a hepatic aldehyde oxidase. In turn, IUdR is incorporated into DNA during replication, thereby sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ropidoxuridine","termGroup":"PT","termSource":"NCI"},{"termName":"2(1H)-Pyrimidinone, 1-(2-deoxy-beta-D-erythro-pentofuranosyl)-5-iodo-","termGroup":"SN","termSource":"NCI"},{"termName":"5-Iodo-2-pyrimidinone 2' deoxyribonucleoside","termGroup":"SY","termSource":"NCI"},{"termName":"5-Iodo-2-pyrimidinone-2'-deoxyribose","termGroup":"SY","termSource":"NCI"},{"termName":"IPdR","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"93265-81-7"},{"name":"Chemical_Formula","value":"C9H11IN2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3HX21A3SQF"},{"name":"Legacy Concept Name","value":"_5-Iodo-2-Pyrimidinone-2-Deoxyribose"},{"name":"Maps_To","value":"Ropidoxuridine"},{"name":"NCI_Drug_Dictionary_ID","value":"770080"},{"name":"NSC Number","value":"726188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770080"},{"name":"PDQ_Open_Trial_Search_ID","value":"770080"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0088688"}]}}{"C1519":{"preferredName":"Roquinimex","code":"C1519","definitions":[{"definition":"A quinoline-3-carboxamide with potential antineoplastic activity.  Roquinimex inhibits endothelial cell proliferation, migration, and basement membrane invasion; reduces the secretion of the angiogenic factor tumor necrosis factor alpha by tumor-associated macrophages (TAMs); and inhibits angiogenesis.  This agent is also an immune modulator that appears to alter cytokine profiles and enhance the activity of T cells, natural killer cells, and macrophages. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Roquinimex","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-3-quinolinecarboxanilide","termGroup":"SN","termSource":"NCI"},{"termName":"1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"FCF 89","termGroup":"CN","termSource":"NCI"},{"termName":"Linomide","termGroup":"BR","termSource":"NCI"},{"termName":"LS 2616","termGroup":"CN","termSource":"NCI"},{"termName":"N-Phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84088-42-6"},{"name":"Chemical_Formula","value":"C18H16N2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"372T2944C0"},{"name":"Legacy Concept Name","value":"Roquinimex"},{"name":"Maps_To","value":"Roquinimex"},{"name":"NCI_Drug_Dictionary_ID","value":"41410"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41410"},{"name":"PDQ_Open_Trial_Search_ID","value":"41410"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244748"}]}}{"C131294":{"preferredName":"Cintirorgon","code":"C131294","definitions":[{"definition":"An orally bioavailable agonist of retinoic acid-related orphan receptor gamma (RORg), with potential immunomodulatory and antineoplastic activities. Upon oral administration of cintirorgon, this agent selectively binds to the nuclear receptor transcription factor RORg, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T-cells, including Th17 (helper T-cells) and Tc17 (cytotoxic T-cells). This may increase the expression of co-stimulatory molecules and decrease the expression of co-inhibitory molecules on T-cells leading to increased production of cytokines and chemokines by T-cells, decreased proliferation of regulatory T-cells (Tregs), and abrogation of tumor-induced immunosuppression. This ultimately induces a T-cell-mediated immune response against cancer cells and leads to a reduction in tumor cell growth. RORg, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cintirorgon","termGroup":"PT","termSource":"NCI"},{"termName":"LYC-55716","termGroup":"CN","termSource":"NCI"},{"termName":"LYC55716","termGroup":"CN","termSource":"NCI"},{"termName":"RORg Agonist LYC-55716","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2055536-64-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LPN433P0EA"},{"name":"Maps_To","value":"Cintirorgon"},{"name":"Maps_To","value":"RORgamma Agonist LYC-55716"},{"name":"NCI_Drug_Dictionary_ID","value":"786008"},{"name":"NCI_META_CUI","value":"CL514576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786008"},{"name":"PDQ_Open_Trial_Search_ID","value":"786008"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77066":{"preferredName":"Rosabulin","code":"C77066","definitions":[{"definition":"A small molecule vascular disrupting agent, with potential antimitotic and antineoplastic activities. Rosabulin binds to tubulin in a similar manner as colchicine and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest and blockage of cell division. By destroying proliferating vascular cells, blood flow to the tumor is reduced and eventually leads to a decrease in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosabulin","termGroup":"PT","termSource":"NCI"},{"termName":"3-[(4-Cyanophenyl)methyl]-N-(3-methyl-5-isothiazolyl)-alpha-oxo-1-indolizineacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"STA-5312","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501948-05-6"},{"name":"Chemical_Formula","value":"C22H16N4O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Z674O12T6"},{"name":"Legacy Concept Name","value":"Rosabulin"},{"name":"Maps_To","value":"Rosabulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541461"}]}}{"C2583":{"preferredName":"Rosiglitazone Maleate","code":"C2583","definitions":[{"definition":"A drug that helps control the amount of glucose (sugar) in the blood and is being studied in the prevention and treatment of some types of cancer. Avandia stops cells from growing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of thiazolidinedione and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.  Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosiglitazone Maleate","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, ( Z )-2-Butenedioate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Avandia","termGroup":"BR","termSource":"NCI"},{"termName":"BRL49653","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Insulin-Dependent Diabetes Mellitus and Type II Diabetes Mellitus"},{"name":"Accepted_Therapeutic_Use_For","value":"Type 2 diabetes"},{"name":"CAS_Registry","value":"155141-29-0"},{"name":"CHEBI_ID","value":"CHEBI:8892"},{"name":"Chemical_Formula","value":"C18H19N3O3S.C4H4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KX2339DP44"},{"name":"Legacy Concept Name","value":"Rosiglitazone"},{"name":"Maps_To","value":"Rosiglitazone Maleate"},{"name":"NCI_Drug_Dictionary_ID","value":"37793"},{"name":"NSC Number","value":"717764"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37793"},{"name":"PDQ_Open_Trial_Search_ID","value":"37793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0795660"}]}}{"C122921":{"preferredName":"Rosmantuzumab","code":"C122921","definitions":[{"definition":"An immunoglobulin (Ig) G1 humanized monoclonal antibody targeting human R-spondin 3 (RSPO3), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, rosmantuzumab targets and binds to RSPO3 expressed on tumor cells. This prevents the activation of RSPO3, and inhibits both the binding of RSPO3 to leucine-rich repeat-containing G-coupled receptors (LGRs) and the activation of the RSPO-LGR pathway. This may result in an inhibition of both cancer stem cell (CSC) survival and the proliferation of cancer cells in which this pathway is overactivated. The RSPO-LGR pathway is a CSC pathway activated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosmantuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"OMP-131R10","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1684393-04-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VD026R6TCI"},{"name":"Maps_To","value":"Rosmantuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"774650"},{"name":"PDQ_Closed_Trial_Search_ID","value":"774650"},{"name":"PDQ_Open_Trial_Search_ID","value":"774650"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053609"}]}}{"C66523":{"preferredName":"Rosuvastatin","code":"C66523","definitions":[{"definition":"A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rosuvastatin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"287714-41-4"},{"name":"CHEBI_ID","value":"CHEBI:38545"},{"name":"Chemical_Formula","value":"C22H28FN3O6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"413KH5ZJ73"},{"name":"Legacy Concept Name","value":"Rosuvastatin"},{"name":"Maps_To","value":"Rosuvastatin"},{"name":"NCI_Drug_Dictionary_ID","value":"654583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"654583"},{"name":"PDQ_Open_Trial_Search_ID","value":"654583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0965129"}]}}{"C107678":{"preferredName":"Rovalpituzumab Tesirine","code":"C107678","definitions":[{"definition":"An antibody-drug conjugate (ADC) containing a humanized IgG1 monoclonal antibody (MAb) directed against the delta-like protein 3 (DLL3), conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a maleimide-containing linker with an eight-carbon polyethylene glycol spacer and a cathepsin B-cleavable valine-alanine dipeptide, with potential antineoplastic activity. The MAb moiety of rovalpituzumab tesirine selectively binds to DLL3 on tumor cell surfaces. Upon internalization of the ADC, the dipeptide linker is cleaved and D6.5 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rovalpituzumab Tesirine","termGroup":"PT","termSource":"NCI"},{"termName":"Rova-T","termGroup":"AB","termSource":"NCI"},{"termName":"SC16LD6.5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1613313-09-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P256HB60FF"},{"name":"Maps_To","value":"Rovalpituzumab Tesirine"},{"name":"NCI_Drug_Dictionary_ID","value":"751419"},{"name":"NCI_META_CUI","value":"CL451868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751419"},{"name":"PDQ_Open_Trial_Search_ID","value":"751419"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1485":{"preferredName":"Rubitecan","code":"C1485","definitions":[{"definition":"A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.  Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An alkaloid drug belonging to a class of anticancer agents called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Rubitecan","termGroup":"PT","termSource":"NCI"},{"termName":"9-NC","termGroup":"AB","termSource":"NCI"},{"termName":"9-Nitro-20(S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"9-nitrocamptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"Camptogen","termGroup":"BR","termSource":"NCI"},{"termName":"Nitrocamptothecin","termGroup":"SY","termSource":"NCI"},{"termName":"Orathecin","termGroup":"BR","termSource":"NCI"},{"termName":"RFS 2000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"AIDs, pediatric; HIV infection, pediatric"},{"name":"CAS_Registry","value":"91421-42-0"},{"name":"Chemical_Formula","value":"C20H15N3O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H19C446XXB"},{"name":"Legacy Concept Name","value":"Rubitecan"},{"name":"Maps_To","value":"Rubitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"42528"},{"name":"NSC Number","value":"603070"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42528"},{"name":"PDQ_Open_Trial_Search_ID","value":"42528"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0213800"}]}}{"C137800":{"preferredName":"Rucaparib","code":"C137800","definitions":[{"definition":"An orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucaparib","termGroup":"PT","termSource":"NCI"},{"termName":"6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one","termGroup":"SY","termSource":"NCI"},{"termName":"AG 14447","termGroup":"CN","termSource":"NCI"},{"termName":"AG-14447","termGroup":"CN","termSource":"NCI"},{"termName":"AG14447","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"ecurrent ovarian, fallopian tube, or primary peritoneal cancer"},{"name":"CAS_Registry","value":"283173-50-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8237F3U7EH"},{"name":"Maps_To","value":"Rucaparib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3661315"}]}}{"C131178":{"preferredName":"Rucaparib Camsylate","code":"C131178","definitions":[{"definition":"The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucaparib Camsylate","termGroup":"PT","termSource":"NCI"},{"termName":"8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Bicyclo(2.2.1)heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, Compound with 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"CO 338","termGroup":"CN","termSource":"NCI"},{"termName":"CO-338","termGroup":"CN","termSource":"NCI"},{"termName":"CO338","termGroup":"CN","termSource":"NCI"},{"termName":"Rubraca","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer"},{"name":"Accepted_Therapeutic_Use_For","value":"patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy."},{"name":"CAS_Registry","value":"1859053-21-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"41AX9SJ8KO"},{"name":"Maps_To","value":"Rucaparib Camsylate"},{"name":"NCI_Drug_Dictionary_ID","value":"785902"},{"name":"NCI_META_CUI","value":"CL513492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785902"},{"name":"PDQ_Open_Trial_Search_ID","value":"785902"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78186":{"preferredName":"Rucaparib Phosphate","code":"C78186","definitions":[{"definition":"A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. AG014699 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The phosphate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucaparib Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"AG 014699","termGroup":"CN","termSource":"NCI"},{"termName":"AG-014699","termGroup":"CN","termSource":"NCI"},{"termName":"AG014699","termGroup":"CN","termSource":"NCI"},{"termName":"PARP1 Inhibitor PF-01367338","termGroup":"SY","termSource":"NCI"},{"termName":"PF-01367338","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"459868-92-9"},{"name":"Chemical_Formula","value":"C19H18FN3O.H3O4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H3M9955244"},{"name":"Legacy Concept Name","value":"PARP-1_Inhibitor_AG014699"},{"name":"Maps_To","value":"Rucaparib Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"594405"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594405"},{"name":"PDQ_Open_Trial_Search_ID","value":"594405"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2603422"}]}}{"C38686":{"preferredName":"Ruthenium Ru-106","code":"C38686","definitions":[{"definition":"A radioactive isotope of the rare element ruthenium, a member of the light platinum group. A radioactive plaque containing ruthenium 106 may be inserted into the eye to irradiate ophthalmic tumors. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruthenium Ru-106","termGroup":"PT","termSource":"NCI"},{"termName":"Ru-106","termGroup":"AB","termSource":"NCI"},{"termName":"Ruthenium Ru 106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Ruthenium_106"},{"name":"Maps_To","value":"Ruthenium Ru-106"},{"name":"NCI_Drug_Dictionary_ID","value":"357497"},{"name":"PDQ_Closed_Trial_Search_ID","value":"357497"},{"name":"PDQ_Open_Trial_Search_ID","value":"357497"},{"name":"Semantic_Type","value":"Element, Ion, or Isotope"},{"name":"UMLS_CUI","value":"C0303733"}]}}{"C97948":{"preferredName":"Ruthenium-based Transferrin Targeting Agent NKP-1339","code":"C97948","definitions":[{"definition":"A ruthenium-containing cancer agent targeting transferrin with potential antineoplastic activity. Upon intravenous administration, NKP-1339 (Ru3+) binds to transferrin (Tf) and is taken up via Tf receptors (TfR), which are overexpressed on cancer cells. Once inside the cell, NKP-1339 is released from Tf and is reduced, within the acidic environment of the endosomes, to its active form NKP-119 (Ru2+). In turn, the active form induces a redox reaction, thereby leading to the formation of reactive oxygen species (ROS) which inhibits GRP78 and SOD, endoplasmic reticulum-stress modulating molecules as well as BAG4 and ERK, program cell death regulating molecules. This eventually induces caspase-dependent apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruthenium-based Transferrin Targeting Agent NKP-1339","termGroup":"PT","termSource":"NCI"},{"termName":"NKP-1339","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"197723-00-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7OSJ9KS483"},{"name":"Maps_To","value":"Ruthenium-based Transferrin Targeting Agent NKP-1339"},{"name":"NCI_Drug_Dictionary_ID","value":"709242"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709242"},{"name":"PDQ_Open_Trial_Search_ID","value":"709242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3273716"}]}}{"C77888":{"preferredName":"Ruxolitinib","code":"C77888","definitions":[{"definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruxolitinib","termGroup":"PT","termSource":"NCI"},{"termName":"(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile","termGroup":"SN","termSource":"NCI"},{"termName":"INCB 018424","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-018424","termGroup":"CN","termSource":"NCI"},{"termName":"INCB-18424","termGroup":"CN","termSource":"NCI"},{"termName":"INCB18424","termGroup":"CN","termSource":"NCI"},{"termName":"Oral JAK Inhibitor INCB18424","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"steroid-refractory acute graft-versus-host disease (GVHD)"},{"name":"CAS_Registry","value":"941678-49-5"},{"name":"Chemical_Formula","value":"C17H18N6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"82S8X8XX8H"},{"name":"Legacy Concept Name","value":"Oral_JAK_Inhibitor_INCB18424"},{"name":"Maps_To","value":"Ruxolitinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2715577"}]}}{"C97937":{"preferredName":"Ruxolitinib Phosphate","code":"C97937","definitions":[{"definition":"The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruxolitinib Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile Phosphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-, phosphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"INCB-18424 Phosphate","termGroup":"CN","termSource":"NCI"},{"termName":"Jakafi","termGroup":"BR","termSource":"NCI"},{"termName":"Jakavi","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1092939-17-7"},{"name":"Chemical_Formula","value":"C17H18N6H3O4P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"436LRU32H5"},{"name":"Maps_To","value":"Ruxolitinib Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"593437"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593437"},{"name":"PDQ_Open_Trial_Search_ID","value":"593437"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3247913"}]}}{"C63661":{"preferredName":"S-Adenosylmethionine","code":"C63661","definitions":[{"definition":"A nutritional supplement that is synthesized from adenosine triphosphate (ATP) and the amino acid methionine by the endogenous essential enzyme methionine adenosyltransferase (MAT), with potential antineoplastic activity.  Upon administration, S-adenosylmethionine acts as a methyl donor for various transmethylation reactions. In cancer cells, this agent induces the methylation of tumor promoting genes, reverses DNA hypomethylation, and leads to the suppression of oncogene transcription. This induces apoptosis in and inhibits proliferation of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"S-Adenosylmethionine","termGroup":"PT","termSource":"NCI"},{"termName":"5'-[(3-Amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine Hydroxide, Inner Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Active Methionine","termGroup":"SY","termSource":"NCI"},{"termName":"S-Adenosyl-l-methionine","termGroup":"SY","termSource":"NCI"},{"termName":"S-Adenosyl-l-methionine 1,4-Butanedisulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"S-Adenosyl-methionine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"29908-03-0"},{"name":"CHEBI_ID","value":"CHEBI:15414"},{"name":"Chemical_Formula","value":"C15H22N6O5S"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"S-Adenosylmethionine"},{"name":"Maps_To","value":"S-Adenosylmethionine"},{"name":"NCI_Drug_Dictionary_ID","value":"776686"},{"name":"PDQ_Closed_Trial_Search_ID","value":"776686"},{"name":"PDQ_Open_Trial_Search_ID","value":"776686"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0036002"}]}}{"C120313":{"preferredName":"S-equol","code":"C120313","definitions":[{"definition":"An orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"S-equol","termGroup":"PT","termSource":"NCI"},{"termName":"(-)-Equol","termGroup":"SY","termSource":"NCI"},{"termName":"(3S)-3,4-dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol","termGroup":"SY","termSource":"NCI"},{"termName":"2H-1-benzopyran-7-ol, 3,4-Dihydro-3-(4-hydroxyphenyl)-, (3S)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"531-95-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2T6D2HPX7Q"},{"name":"Maps_To","value":"S-equol"},{"name":"NCI_Drug_Dictionary_ID","value":"768802"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768802"},{"name":"PDQ_Open_Trial_Search_ID","value":"768802"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896945"}]}}{"C106368":{"preferredName":"Mocravimod Hydrochloride","code":"C106368","definitions":[{"definition":"The hydrochloride salt form of mocravimod, a sphingosine 1-phosphate (S1P) receptor agonist, with potential immunosuppressive activity. Upon administration of mocravimod, this agent binds to S1P receptors on lymphocytes, which prevents binding of serum S1P to S1P receptors and leads to S1P receptor internalization. This reduces the number of circulating blood leukocytes and accelerates lymphocyte homing into peripheral lymph nodes, thereby preventing their infiltration into peripheral inflammatory sites. This agent also decreases the production of inflammatory cytokines by lymphocytes, such as interferon gamma (IFN-g), interleukin-12 (IL-12), and tumor necrosis factor (TNF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mocravimod Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino-2-propanediol Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"KRP-203","termGroup":"CN","termSource":"NCI"},{"termName":"KRP203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"509088-69-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3YH0N35CE3"},{"name":"Maps_To","value":"S1P Receptor Agonist KRP203"},{"name":"NCI_Drug_Dictionary_ID","value":"749378"},{"name":"PDQ_Closed_Trial_Search_ID","value":"749378"},{"name":"PDQ_Open_Trial_Search_ID","value":"749378"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1570777"}]}}{"C1706":{"preferredName":"Sabarubicin","code":"C1706","definitions":[{"definition":"A disaccharide analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Sabarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces apoptosis through a p53-independent mechanism.  Sabarubicin is less cardiotoxic than doxorubicin.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antitumor antibiotics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sabarubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(7S,9S)-7-{(4-O-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)oxy}-6,9,11-trihydroxy-9-(hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione","termGroup":"SN","termSource":"NCI"},{"termName":"BMS-195615","termGroup":"CN","termSource":"NCI"},{"termName":"MEN-10755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"211100-13-9"},{"name":"Chemical_Formula","value":"C32H37NO13"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XS499WOZ93"},{"name":"Legacy Concept Name","value":"MEN-10755"},{"name":"Maps_To","value":"Sabarubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"42684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42684"},{"name":"PDQ_Open_Trial_Search_ID","value":"42684"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0664590"}]}}{"C102783":{"preferredName":"Sacituzumab Govitecan","code":"C102783","definitions":[{"definition":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sacituzumab Govitecan","termGroup":"PT","termSource":"NCI"},{"termName":"hRS7-SN38 Antibody Drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU 132","termGroup":"CN","termSource":"NCI"},{"termName":"IMMU-132","termGroup":"CN","termSource":"NCI"},{"termName":"IMMU132","termGroup":"CN","termSource":"NCI"},{"termName":"RS7 SN38","termGroup":"CN","termSource":"NCI"},{"termName":"RS7-SN38","termGroup":"AB","termSource":"NCI"},{"termName":"RS7SN38","termGroup":"CN","termSource":"NCI"},{"termName":"Sacituzumab Govitecan-hziy","termGroup":"SY","termSource":"NCI"},{"termName":"Trodelvy","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC); advanced urothelial cancer."},{"name":"CAS_Registry","value":"1491917-83-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"M9BYU8XDQ6"},{"name":"Maps_To","value":"Sacituzumab Govitecan"},{"name":"NCI_Drug_Dictionary_ID","value":"736415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736415"},{"name":"PDQ_Open_Trial_Search_ID","value":"736415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640943"}]}}{"C162629":{"preferredName":"Sacubitril/Valsartan","code":"C162629","definitions":[{"definition":"A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sacubitril/Valsartan","termGroup":"PT","termSource":"NCI"},{"termName":"3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate","termGroup":"SY","termSource":"NCI"},{"termName":"Entresto","termGroup":"BR","termSource":"NCI"},{"termName":"L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. with alpha-ethyl(alphaR,gammaS)-gamma-((3-carboxy-1-oxopropyl)amino)-alpha-methyl(1,1'-biphenyl)-4-pentanoate, sodium salt, hydrate (2:2:6:5)","termGroup":"SY","termSource":"NCI"},{"termName":"LCZ 696","termGroup":"CN","termSource":"NCI"},{"termName":"LCZ-696","termGroup":"SY","termSource":"NCI"},{"termName":"LCZ696","termGroup":"CN","termSource":"NCI"},{"termName":"Sacubitril Mixture With Valsartan","termGroup":"SY","termSource":"NCI"},{"termName":"Sacubitril-Valsartan","termGroup":"SY","termSource":"NCI"},{"termName":"Sacubitril/Valsartan Sodium Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) hemipentahydrate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"936623-90-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WB8FT61183"},{"name":"Maps_To","value":"Sacubitril/Valsartan"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2933614"}]}}{"C1568":{"preferredName":"Safingol","code":"C1568","definitions":[{"definition":"A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), safingol competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Safingol","termGroup":"PT","termSource":"NCI"},{"termName":"(2S,3S)-2-Amino-1,3-Octadecanediol","termGroup":"SN","termSource":"NCI"},{"termName":"Kynacyte","termGroup":"BR","termSource":"NCI"},{"termName":"L-(-)-threo-Sphingnine","termGroup":"SY","termSource":"NCI"},{"termName":"L-threo-2-Amino-1,3-octadecanediol","termGroup":"SY","termSource":"NCI"},{"termName":"L-Threo-Dihydrosphingosine","termGroup":"SY","termSource":"NCI"},{"termName":"L-Threo-Dihydrosphingosine","termGroup":"SN","termSource":"NCI"},{"termName":"SPC-100270","termGroup":"CN","termSource":"NCI"},{"termName":"Sphinganine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15639-50-6"},{"name":"Chemical_Formula","value":"C18H39NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OWA98U788S"},{"name":"Legacy Concept Name","value":"Dihydrosphingosine"},{"name":"Maps_To","value":"Safingol"},{"name":"NCI_Drug_Dictionary_ID","value":"41910"},{"name":"NSC Number","value":"714503"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41910"},{"name":"PDQ_Open_Trial_Search_ID","value":"41910"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281466"}]}}{"C61072":{"preferredName":"Sagopilone","code":"C61072","definitions":[{"definition":"A form of the substance epothilone that is made in the laboratory. It is being studied in the treatment of some types of cancer. Epothilone ZK2219477 stops the growth of tumor cells by blocking cell division. It is a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A fully synthetic low-molecular-weight epothilone with potential antineoplastic activity. Sagopilone binds to tubulin and induces microtubule polymerization while stabilizing microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. The agent is not a substrate for the P-glycoprotein (P-gp) efflux pump and so may exhibit activity in multidrug-resistant (MDR) tumors. The epothilone class of metabolites was originally isolated from the myxobacterium Solangium cellulosum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sagopilone","termGroup":"PT","termSource":"NCI"},{"termName":"(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione","termGroup":"SN","termSource":"NCI"},{"termName":"DE-03757","termGroup":"CN","termSource":"NCI"},{"termName":"Epothilone ZK219477","termGroup":"SY","termSource":"NCI"},{"termName":"SH-Y03757A","termGroup":"CN","termSource":"NCI"},{"termName":"ZK-219477","termGroup":"CN","termSource":"NCI"},{"termName":"ZK-EPO","termGroup":"AB","termSource":"NCI"},{"termName":"ZK-Epothilone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"305841-29-6"},{"name":"Chemical_Formula","value":"C30H41NO6S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KY72JU32FO"},{"name":"Legacy Concept Name","value":"ZK219477"},{"name":"Maps_To","value":"Sagopilone"},{"name":"NCI_Drug_Dictionary_ID","value":"615854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"615854"},{"name":"PDQ_Open_Trial_Search_ID","value":"615854"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2355512"}]}}{"C71146":{"preferredName":"Salirasib","code":"C71146","definitions":[{"definition":"A salicylic acid derivative with potential antineoplastic activity. Salirasib dislodges all Ras isoforms from their membrane-anchoring sites, thereby preventing activation of RAS signaling cascades that mediated cell proliferation, differentiation, and senescence. RAS signaling is believed to be abnormally activated in one-third of human cancers, including cancers of the pancreas, colon, lung and breast.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salirasib","termGroup":"PT","termSource":"NCI"},{"termName":"2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"S-Farnesylthiosalicylic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"162520-00-5"},{"name":"Chemical_Formula","value":"C22H30O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MZH0OM550M"},{"name":"Legacy Concept Name","value":"Salirasib"},{"name":"Maps_To","value":"Salirasib"},{"name":"NCI_Drug_Dictionary_ID","value":"573226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"573226"},{"name":"PDQ_Open_Trial_Search_ID","value":"573226"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0297001"}]}}{"C2556":{"preferredName":"Salmonella VNP20009","code":"C2556","definitions":[{"definition":"A genetically modified Salmonella bacterium that is injected into the tumor.  It is being studied for its ability to shrink solid tumors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A genetically stable Salmonella typhimurium strain, attenuated by chromosomal deletion of the purI and msbB genes, with tumor-targeting activity. In rodent models, salmonella VNP20009 has been shown to selectively accumulate and grow in a variety of tumor types, inhibiting the growth of primary and metastatic tumors. This agent may be genetically engineered to contain transgenes that express therapeutic agents or cell surface tumor-associated antigen-specific antibodies, such as CEA-specific antibodies, which may improve its tumor targeting and therapeutic potential.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salmonella VNP20009","termGroup":"PT","termSource":"NCI"},{"termName":"Auxotrophic Lipid A S. Typhimurium mutant","termGroup":"SY","termSource":"NCI"},{"termName":"Live, Attenuated Salmonella Typhimurium","termGroup":"SY","termSource":"NCI"},{"termName":"VNP 20009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"VNP20009"},{"name":"Maps_To","value":"Salmonella VNP20009"},{"name":"NCI_Drug_Dictionary_ID","value":"37800"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37800"},{"name":"PDQ_Open_Trial_Search_ID","value":"37800"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879622"}]}}{"C97663":{"preferredName":"Sam68 Modulator CWP232291","code":"C97663","definitions":[{"definition":"A small molecule and prodrug of CWP232204 targeting Src associated in mitosis, of 68 kDa (Sam68 or KHDRBS1), with potential antineoplastic activity. CWP232291 is converted in serum into its active form CWP232204 which binds to Sam68, thereby resulting in the induction of apoptosis in selective cancer cells. Due to the multimodular structure of Sam68, the apoptosis mediated by CWP232204-Sam68 interaction can attribute from 1) activation of transcription factor NF-kB induced by tumor necrosis factor alpha signaling, 2) alternative splicing of BCL-2 apoptosis gene, driving the balance towards pro-apoptotic as opposed to anti-apoptotic isoforms, 3) down-regulation of the anti-apoptotic protein survivin via Wnt signaling. Sam68, a KH domain RNA-binding protein belonging to the signal transduction and activation of RNA (STAR) family, plays a key role in various cellular processes including cell cycle progression and apoptosis; it is upregulated in many types of cancer cells and its expression is associated with increased cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sam68 Modulator CWP232291","termGroup":"PT","termSource":"NCI"},{"termName":"CWP232291","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sam68 Modulator CWP232291"},{"name":"NCI_Drug_Dictionary_ID","value":"706549"},{"name":"NCI_META_CUI","value":"CL430318"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706549"},{"name":"PDQ_Open_Trial_Search_ID","value":"706549"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77891":{"preferredName":"Samalizumab","code":"C77891","definitions":[{"definition":"A humanized monoclonal antibody directed against the human immunosuppressive molecule CD200 (OX-2) with potential immunomodulating and antineoplastic activities. Samalizumab binds to CD200, blocking the binding of CD200 to its receptor, CD200R, present on cells of the macrophage lineage; inhibition of CD200 may augment the cytotoxic T-lymphocyte (CTL) mediated immune response against CD200-expressing tumor cells.  CD200 is a type 1a transmembrane protein, related to the B7 family of co-stimulatory receptors, and is upregulated on the surface of multiple hematologic malignant cells; this transmembrane protein appears to be involved in the downregulation of a Th1 (helper T cell) immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"ALXN6000","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-(CD200 (Antigen)) (Human-mouse Monoclonal ALXN6000 Heavy Chain), Disulfide with Human-mouse Monoclonal ALXN6000 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1073059-33-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"64EUX713G6"},{"name":"Legacy Concept Name","value":"Anti-CD200_Monoclonal_Antibody_ALXN6000"},{"name":"Maps_To","value":"Samalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"593933"},{"name":"NCI_META_CUI","value":"CL383569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593933"},{"name":"PDQ_Open_Trial_Search_ID","value":"593933"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165558":{"preferredName":"Samarium Sm 153-DOTMP","code":"C165558","definitions":[{"definition":"A radioconjugate composed of the phosphonic acid chelator DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid) conjugated to the beta- and gamma-emitting radioisotope samarium Sm 153, with potential antineoplastic activity. Upon administration of samarium Sm 153-DOTMP, the DOTMP moiety targets and binds to growing bone, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to bone tumor and metastases, which may help destroy bone metastases and mitigate pain from bone metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samarium Sm 153-DOTMP","termGroup":"PT","termSource":"NCI"},{"termName":"153 Sm-DOTMP","termGroup":"SY","termSource":"NCI"},{"termName":"153Sm-DOTMP","termGroup":"SY","termSource":"NCI"},{"termName":"CycloSam","termGroup":"BR","termSource":"NCI"},{"termName":"Sm-153-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra(methylene)phosphonic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Sm-153-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene)tetrakisphosphonic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Sm-153-DOTMP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"633308-21-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S5NN2E9ZKF"},{"name":"Maps_To","value":"Samarium Sm 153-DOTMP"},{"name":"NCI_Drug_Dictionary_ID","value":"799673"},{"name":"NCI_META_CUI","value":"CL978665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799673"},{"name":"PDQ_Open_Trial_Search_ID","value":"799673"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121817":{"preferredName":"Samotolisib","code":"C121817","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of certain class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Samotolisib inhibits both certain PI3K isoforms and mTOR in an ATP-competitive manner which may inhibit both the PI3K/mTOR signaling pathway in and proliferation of tumor cells overexpressing PI3K and/or mTOR. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone. In addition, LY3023414 may inhibit DNA-dependent protein kinase (DNA-PK), thereby inhibiting the ability of tumor cells to repair damaged DNA. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Samotolisib","termGroup":"PT","termSource":"NCI"},{"termName":"2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3023414","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3023414","termGroup":"CN","termSource":"NCI"},{"termName":"LY3023414","termGroup":"CN","termSource":"NCI"},{"termName":"WHO 10889","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1386874-06-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C88817F47Y"},{"name":"Maps_To","value":"Samotolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"738090"},{"name":"NCI_META_CUI","value":"CL446628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738090"},{"name":"PDQ_Open_Trial_Search_ID","value":"738090"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64541":{"preferredName":"Sapacitabine","code":"C64541","definitions":[{"definition":"An orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine is hydrolyzed by amidases to the deoxycytosine analogue CNDAC (2'-Cyano-2'-deoxyarabinofuranosylcytosine), which is then phosphorylated into the active triphosphate form. As an analogue of deoxycytidine triphosphate, CNDAC triphosphate incorporates into DNA strands during replication, resulting in single-stranded DNA breaks during polymerization due to beta-elimination during the fidelity checkpoint process; cell cycle arrest in the G2 phase and apoptosis ensue. The unmetabolized prodrug may exhibit antineoplastic activity as well.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sapacitabine","termGroup":"PT","termSource":"NCI"},{"termName":"CS 682","termGroup":"CN","termSource":"NCI"},{"termName":"CS-682","termGroup":"CN","termSource":"NCI"},{"termName":"CS682","termGroup":"CN","termSource":"NCI"},{"termName":"CYC682","termGroup":"CN","termSource":"NCI"},{"termName":"N-(1-(2-Cyano-2-deoxy-beta-D-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4-yl)-hexadecanamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"151823-14-2"},{"name":"Chemical_Formula","value":"C26H42N4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"W335P73C3L"},{"name":"Legacy Concept Name","value":"Sapacitabine"},{"name":"Maps_To","value":"Sapacitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"513165"},{"name":"PDQ_Closed_Trial_Search_ID","value":"513165"},{"name":"PDQ_Open_Trial_Search_ID","value":"513165"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0764827"}]}}{"C90548":{"preferredName":"Sapanisertib","code":"C90548","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity. Sapanisertib binds to and inhibits both TORC1 and TORC2 complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sapanisertib","termGroup":"PT","termSource":"NCI"},{"termName":"INK-128","termGroup":"CN","termSource":"NCI"},{"termName":"INK128","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-0128","termGroup":"CN","termSource":"NCI"},{"termName":"MLN0128","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1224844-38-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JGH0DF1U03"},{"name":"Maps_To","value":"Sapanisertib"},{"name":"NCI_Drug_Dictionary_ID","value":"665687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"665687"},{"name":"PDQ_Open_Trial_Search_ID","value":"665687"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983747"}]}}{"C77887":{"preferredName":"Sapitinib","code":"C77887","definitions":[{"definition":"An erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. erbB kinase inhibitor AZD8931 binds to and inhibits erbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing erbB. The erbB protein family, also called the epidermal growth factor receptor (EGFR) family, plays major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sapitinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-(4-((4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"AZD8931","termGroup":"CN","termSource":"NCI"},{"termName":"ErbB Kinase Inhibitor AZD8931","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848942-61-0"},{"name":"Chemical_Formula","value":"C23H25ClFN5O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3499328002"},{"name":"Legacy Concept Name","value":"ErbB_Kinase_Inhibitor_AZD8931"},{"name":"Maps_To","value":"Sapitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"593099"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593099"},{"name":"PDQ_Open_Trial_Search_ID","value":"593099"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703086"}]}}{"C48378":{"preferredName":"Saracatinib","code":"C48378","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. AZD0530 blocks enzymes needed for cancer growth. It is a type of tyrosine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saracatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-","termGroup":"SN","termSource":"NCI"},{"termName":"AZD0530","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-Chloro-1,3-Benzodioxol-4-Yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Oxan-4-yl)Oxy)Quinazolin-4-Amine","termGroup":"SN","termSource":"NCI"},{"termName":"SRC Kinase Inhibitor AZD0530","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"379231-04-6"},{"name":"Chemical_Formula","value":"C27H32ClN5O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9KD24QGH76"},{"name":"Legacy Concept Name","value":"AZD0530"},{"name":"Maps_To","value":"Saracatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"453588"},{"name":"NSC Number","value":"735464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"453588"},{"name":"PDQ_Open_Trial_Search_ID","value":"453588"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2828242"}]}}{"C95224":{"preferredName":"Saracatinib Difumarate","code":"C95224","definitions":[{"definition":"The difumarate salt of saracatinib, an orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Saracatinib Difumarate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(5-Chloro-1,3-Benzodioxol-4-yl)-7-(2-(4-Methyl-1-Piperazinyl)Ethoxy)-5-((Tetrahydro-2H-Pyran-4-yl)Oxy)-, (2e)-2-Butenedioate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-0530 Difumarate","termGroup":"CN","termSource":"NCI"},{"termName":"AZD0530 Difumarate","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5-Chloro-1,3-Benzodioxol-4-yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-(Tetrahydro-2H-Pyran-4-yloxy)Quinazolin-4-Amine Di((2e)-but-2-Enedioate)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"893428-72-3"},{"name":"Chemical_Formula","value":"C27H32ClN5O5.2C4H4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8R1DYT4EAW"},{"name":"Maps_To","value":"Saracatinib Difumarate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987006"}]}}{"C963":{"preferredName":"SarCNU","code":"C963","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An alkylating chloroethylnitrosourea with antineoplastic activity.  Selectively accumulating in some tumor cells, SarCNU forms covalent linkages with nucleophilic centers in DNA, causing depurination, base pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SarCNU","termGroup":"PT","termSource":"NCI"},{"termName":"2-Chloroethyl-3-Sarcosinamide-1-Nitrosourea","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92891-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BHB013S3MO"},{"name":"Legacy Concept Name","value":"SarCNU"},{"name":"Maps_To","value":"SarCNU"},{"name":"NCI_Drug_Dictionary_ID","value":"43325"},{"name":"NSC Number","value":"364432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43325"},{"name":"PDQ_Open_Trial_Search_ID","value":"43325"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045644"}]}}{"C1673":{"preferredName":"Sardomozide","code":"C1673","definitions":[{"definition":"A methylglyoxal-bis(guanylhydrazone) (MGBG) derivative with potential antineoplastic and antiviral properties. Sardomozide selectively binds to and inhibits S-adenosylmethionine decarboxylase (SAMDC), an enzyme essential for the biosynthesis of polyamines, such as spermine and spermidine that bind to DNA and play critical roles in cell division, cell differentiation and membrane function. By inhibiting SAMDC, sardomozide reduces the intracellular polyamine concentration, thereby interfering with cell growth and differentiation. In addition, this agent also exhibits anti-HIV effect via suppressing expression of eukaryotic translation initiation factor 5A (eIF-5A), which is essential for retroviral replication.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called S-adenosylmethionine decarboxylase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sardomozide","termGroup":"PT","termSource":"NCI"},{"termName":"2-[4-(Aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene]hydrazinecarboximidamide","termGroup":"SN","termSource":"NCI"},{"termName":"Amidinoindan-1-one.2'-amidinohydrazone","termGroup":"SN","termSource":"NCI"},{"termName":"CGP-48664","termGroup":"CN","termSource":"NCI"},{"termName":"SAM 486A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149400-88-4"},{"name":"Chemical_Formula","value":"C11H14N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CEB05S0B9I"},{"name":"Legacy Concept Name","value":"Sardomozide"},{"name":"Maps_To","value":"Sardomozide"},{"name":"NCI_Drug_Dictionary_ID","value":"42601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42601"},{"name":"PDQ_Open_Trial_Search_ID","value":"42601"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0960654"}]}}{"C1492":{"preferredName":"Sargramostim","code":"C1492","definitions":[{"definition":"A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23.  Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets. It is a cytokine that is a type of hematopoietic (blood-forming) agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sargramostim","termGroup":"PT","termSource":"NCI"},{"termName":"23-L-Leucinecolony-Stimulating Factor 2","termGroup":"SY","termSource":"NCI"},{"termName":"DRG-0012","termGroup":"CN","termSource":"NCI"},{"termName":"Leukine","termGroup":"BR","termSource":"NCI"},{"termName":"Prokine","termGroup":"BR","termSource":"NCI"},{"termName":"rhu GM-CFS","termGroup":"AB","termSource":"NCI"},{"termName":"Sagramostim","termGroup":"SY","termSource":"NCI"},{"termName":"Sargramostatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Melanoma; Neutropenia-chemotherapy induced"},{"name":"CAS_Registry","value":"123774-72-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5TAA004E22"},{"name":"Legacy Concept Name","value":"Sargramostim"},{"name":"Maps_To","value":"Sargramostim"},{"name":"NCI_Drug_Dictionary_ID","value":"40566"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40566"},{"name":"PDQ_Open_Trial_Search_ID","value":"40566"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0216231"}]}}{"C1493":{"preferredName":"Satraplatin","code":"C1493","definitions":[{"definition":"A substance being studied in the treatment of prostate and other types of cancer. It contains the metal platinum and may kill cancer cells by damaging their DNA and stopping them from dividing. It is a type of alkylating agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Satraplatin","termGroup":"PT","termSource":"NCI"},{"termName":"(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum","termGroup":"SN","termSource":"NCI"},{"termName":"BMY-45594","termGroup":"CN","termSource":"NCI"},{"termName":"JM-216","termGroup":"CN","termSource":"NCI"},{"termName":"Orplatna","termGroup":"BR","termSource":"NCI"},{"termName":"platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129580-63-8"},{"name":"Chemical_Formula","value":"C6H13N.2C2H3O2.2Cl.Pt.H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8D7B37T28G"},{"name":"Legacy Concept Name","value":"Satraplatin"},{"name":"Maps_To","value":"Satraplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"42141"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42141"},{"name":"PDQ_Open_Trial_Search_ID","value":"42141"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1142934"}]}}{"C104732":{"preferredName":"Savolitinib","code":"C104732","definitions":[{"definition":"An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Savolitinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 6094","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6094","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-504","termGroup":"CN","termSource":"NCI"},{"termName":"Volitinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1313725-88-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2A2DA6857R"},{"name":"Maps_To","value":"Savolitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"745761"},{"name":"PDQ_Closed_Trial_Search_ID","value":"745761"},{"name":"PDQ_Open_Trial_Search_ID","value":"745761"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642466"}]}}{"C29418":{"preferredName":"SBIL-2","code":"C29418","definitions":[{"definition":"An retroviral vector encoding human IL-2 with potential antineoplastic property. SBIL-2 (Surgery Branch IL-2) can be used to transfect tumor infiltrating lymphocytes, which can then be re-introduced back to cancer patients, thereby stimulate T cell activation and immunopotentiation responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SBIL-2","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SBIL-2"},{"name":"Maps_To","value":"SBIL-2"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519128"}]}}{"C126100":{"preferredName":"Scopoletin","code":"C126100","definitions":[{"definition":"A coumarin compound found in several plants including those in the genus Scopolia and the genus Brunfelsia, as well as chicory (Cichorium), redstem wormwood (Artemisia scoparia), stinging nettle (Urtica dioica), passion flower (Passiflora), noni (Morinda citrifolia fruit) and European black nightshade (Solanum nigrum) that is comprised of umbelliferone with a methoxy group substituent at position 6. Scopoletin is used to standardize and establish pharmacokinetic properties for products derived from the plants that produce it, such as noni extract. Although the mechanism(s) of action have not yet been established, this agent has potential antineoplastic, antidopaminergic, antioxidant, anti-inflammatory and anticholinesterase effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scopoletin","termGroup":"PT","termSource":"NCI"},{"termName":"2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"6-Methoxyumbelliferone","termGroup":"SY","termSource":"NCI"},{"termName":"6-Methylesculetin","termGroup":"SY","termSource":"NCI"},{"termName":"6-O-Methylesculetin","termGroup":"SY","termSource":"NCI"},{"termName":"7-Hydroxy-5-Methoxycoumarin","termGroup":"SY","termSource":"NCI"},{"termName":"7-Hydroxy-6-Methoxychromen-2-One","termGroup":"SN","termSource":"NCI"},{"termName":"7-Hydroxy-6-Methoxycoumarin","termGroup":"SN","termSource":"NCI"},{"termName":"Chrysatropic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Coumarin, 7-Hydroxy-6-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Escopoletin","termGroup":"SY","termSource":"NCI"},{"termName":"Esculetin-6-Methyl Ether","termGroup":"SY","termSource":"NCI"},{"termName":"Gelseminic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Methylesculetin","termGroup":"SY","termSource":"NCI"},{"termName":"Murrayetin","termGroup":"SY","termSource":"NCI"},{"termName":"Scopoletine","termGroup":"SY","termSource":"NCI"},{"termName":"Scopoletol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"92-61-5"},{"name":"CHEBI_ID","value":"CHEBI:17488"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KLF1HS0SXJ"},{"name":"Maps_To","value":"Scopoletin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0036447"}]}}{"C154328":{"preferredName":"Seclidemstat","code":"C154328","definitions":[{"definition":"An orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seclidemstat","termGroup":"PT","termSource":"NCI"},{"termName":"LSD1 Inhibitor SP-2577","termGroup":"SY","termSource":"NCI"},{"termName":"SP 2577","termGroup":"CN","termSource":"NCI"},{"termName":"SP-2577","termGroup":"CN","termSource":"NCI"},{"termName":"SP2577","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1423715-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TYH386V3WJ"},{"name":"Maps_To","value":"Seclidemstat"},{"name":"NCI_Drug_Dictionary_ID","value":"794410"},{"name":"NCI_META_CUI","value":"CL555222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794410"},{"name":"PDQ_Open_Trial_Search_ID","value":"794410"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1576":{"preferredName":"Sedoxantrone Trihydrochloride","code":"C1576","definitions":[{"definition":"A substance being studied in the treatment of some types of cancer. Sedoxantrone trihydrochloride binds to DNA and stops cells, including cancer cells, from repairing damage to DNA and from making more DNA, RNA, and protein. It is a type of DNA intercalator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The trihydrochloride salt of the anthrapyrazole antineoplastic antibiotic sedoxantrone with potential antineoplastic activity. Sedoxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sedoxantrone Trihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"2H-(1)Benzothiopyrano(4,3,2-cd)indazol-8-ol, 5-((2-aminoethyl)amino)-2-(2-(diethylamino)ethyl)-, Trihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CI 958","termGroup":"CN","termSource":"NCI"},{"termName":"CI-958","termGroup":"CN","termSource":"NCI"},{"termName":"Ledoxantrone Trihydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"119221-49-7"},{"name":"Chemical_Formula","value":"C21H27N5OS.3ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X9GSL37ED0"},{"name":"Legacy Concept Name","value":"Sedoxantrone_Trihydrochloride"},{"name":"Maps_To","value":"Sedoxantrone Trihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"42217"},{"name":"NSC Number","value":"635371"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42217"},{"name":"PDQ_Open_Trial_Search_ID","value":"42217"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281727"}]}}{"C111764":{"preferredName":"Selatinib Ditosilate","code":"C111764","definitions":[{"definition":"An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selatinib Ditosilate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1452886-38-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6Q2E32HVE7"},{"name":"Maps_To","value":"Selatinib Ditosilate"},{"name":"NCI_Drug_Dictionary_ID","value":"753197"},{"name":"NCI_META_CUI","value":"CL454151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753197"},{"name":"PDQ_Open_Trial_Search_ID","value":"753197"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C137950":{"preferredName":"Vosilasarm","code":"C137950","definitions":[{"definition":"An orally bioavailable, non-steroidal selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activities. Upon oral administration, vosilasarm acts as an agonist in select tissues, such as skeletal muscle and bone, where it binds to and activates androgen receptors (ARs). In the prostate and breasts, vosilasarm acts as an antagonist and blocks AR activation and AR-mediated cellular proliferation. Therefore, this agent may improve bone formation and muscle mass and strength, and may inhibit both the growth of the prostate in males and AR-dependent breast cancer cell proliferation. Compared to anabolic agents, SARMs have reduced androgenic properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vosilasarm","termGroup":"PT","termSource":"NCI"},{"termName":"EP 0062","termGroup":"CN","termSource":"NCI"},{"termName":"EP-0062","termGroup":"CN","termSource":"NCI"},{"termName":"EP0062","termGroup":"CN","termSource":"NCI"},{"termName":"RAD 140","termGroup":"CN","termSource":"NCI"},{"termName":"RAD-140","termGroup":"CN","termSource":"NCI"},{"termName":"RAD140","termGroup":"CN","termSource":"NCI"},{"termName":"SARM RAD140","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Androgen Receptor Modulator RAD140","termGroup":"SY","termSource":"NCI"},{"termName":"Testolone","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1182367-47-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O87Q44KNC"},{"name":"Maps_To","value":"Selective Androgen Receptor Modulator RAD140"},{"name":"Maps_To","value":"Vosilasarm"},{"name":"NCI_Drug_Dictionary_ID","value":"790616"},{"name":"NCI_META_CUI","value":"CL524969"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790616"},{"name":"PDQ_Open_Trial_Search_ID","value":"790616"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2210":{"preferredName":"Selective Cytokine Inhibitory Drug CC-1088","code":"C2210","definitions":[{"definition":"A drug that is being studied in the treatment of cancer. It is similar but not identical to thalidomide. CC-1088 belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analog of thalidomide with potential antineoplastic activity that belongs to the functional class of agents called selective cytokine inhibitory drugs (SelCIDs).  SelCIDs inhibit phosphodiesterase-4 (PDE 4), an enzyme involved in tumor necrosis factor alpha (TNF alpha) production.  CC-1088 inhibits production of the cytokines vascular endothelial growth factor (VEGF) (a pro-angiogenic factor) and interleukin-6 (IL-6). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Cytokine Inhibitory Drug CC-1088","termGroup":"PT","termSource":"NCI"},{"termName":"CC-1088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192819-27-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"95HB56U8P8"},{"name":"Legacy Concept Name","value":"CC-1088"},{"name":"Maps_To","value":"Selective Cytokine Inhibitory Drug CC-1088"},{"name":"NCI_Drug_Dictionary_ID","value":"38051"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38051"},{"name":"PDQ_Open_Trial_Search_ID","value":"38051"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879595"}]}}{"C122834":{"preferredName":"Selective Estrogen Receptor Degrader AZD9496","code":"C122834","definitions":[{"definition":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader AZD9496","termGroup":"PT","termSource":"NCI"},{"termName":"(E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 9496","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-9496","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9496","termGroup":"CN","termSource":"NCI"},{"termName":"SERD AZD9496","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1639042-08-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DA9P7LN909"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader AZD9496"},{"name":"NCI_Drug_Dictionary_ID","value":"764993"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764993"},{"name":"PDQ_Open_Trial_Search_ID","value":"764993"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053676"}]}}{"C160603":{"preferredName":"Camizestrant","code":"C160603","definitions":[{"definition":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camizestrant","termGroup":"PT","termSource":"NCI"},{"termName":"AZ-14066724","termGroup":"CN","termSource":"NCI"},{"termName":"AZD 9833","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-9833","termGroup":"CN","termSource":"NCI"},{"termName":"AZD9833","termGroup":"CN","termSource":"NCI"},{"termName":"N-(1-(3-Fluoropropyl)-3-azetidinyl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader AZD9833","termGroup":"SY","termSource":"NCI"},{"termName":"SERD AZD9833","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222844-89-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JUP57A8EPZ"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader AZD9833"},{"name":"NCI_Drug_Dictionary_ID","value":"799429"},{"name":"NCI_META_CUI","value":"CL969664"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799429"},{"name":"PDQ_Open_Trial_Search_ID","value":"799429"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128280":{"preferredName":"Selective Estrogen Receptor Degrader LSZ102","code":"C128280","definitions":[{"definition":"An selective estrogen receptor (ER) degrader (SERD), with potential antineoplastic activity. Upon administration of LSZ102, this agent binds to the ER and induces the degradation of the receptor. This prevents ER activation and ER-mediated signaling, and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader LSZ102","termGroup":"PT","termSource":"NCI"},{"termName":"LSZ 102","termGroup":"CN","termSource":"NCI"},{"termName":"LSZ102","termGroup":"CN","termSource":"NCI"},{"termName":"SERD LSZ 102","termGroup":"SY","termSource":"NCI"},{"termName":"SERD LSZ102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2135600-76-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0Y175XGX4P"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader LSZ102"},{"name":"NCI_Drug_Dictionary_ID","value":"782046"},{"name":"NCI_META_CUI","value":"CL507934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782046"},{"name":"PDQ_Open_Trial_Search_ID","value":"782046"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120037":{"preferredName":"Selective Estrogen Receptor Degrader SRN-927","code":"C120037","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD SRN-927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader SRN-927","termGroup":"PT","termSource":"NCI"},{"termName":"SERD SRN-927","termGroup":"SY","termSource":"NCI"},{"termName":"SRN-927","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader SRN-927"},{"name":"NCI_Drug_Dictionary_ID","value":"767384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767384"},{"name":"PDQ_Open_Trial_Search_ID","value":"767384"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896765"}]}}{"C38711":{"preferredName":"Selective Estrogen Receptor Modulator CC-8490","code":"C38711","definitions":[{"definition":"A benzopyran with potential antineoplastic activity.  CC-8490 acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells.  This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of brain cancer. It belongs to the family of drugs called benzopyrans.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Selective Estrogen Receptor Modulator CC-8490","termGroup":"PT","termSource":"NCI"},{"termName":"CC-8490","termGroup":"CN","termSource":"NCI"},{"termName":"SPC8490","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CC-8490"},{"name":"Maps_To","value":"Selective Estrogen Receptor Modulator CC-8490"},{"name":"NCI_Drug_Dictionary_ID","value":"346082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346082"},{"name":"PDQ_Open_Trial_Search_ID","value":"346082"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328106"}]}}{"C61494":{"preferredName":"Selective Estrogen Receptor Modulator TAS-108","code":"C61494","definitions":[{"definition":"A synthetic, antiestrogenic steroidal compound with potential antitumor activity. TAS-108 binds to and inhibits estrogenic receptor alpha (ERa), mainly expressed in the mammary gland and uterus and upregulated in estrogen-dependent tumors. Blockage of ERa by TAS-108 prevents the binding and effects of estrogen and may lead to an inhibition of estrogen-dependent cancer cell proliferation. TAS-108 also is a partial agonist of the estrogenic receptor beta (ERb), expressed in many tissues including the central nervous system, urogenital tract, bone and cardiovascular system, thereby exerting a positive effect on these tissues. In addition, TAS-108 activates the co-repressor Silencing Mediator for Retinoid and Thyroid hormone receptor (SMRT), a protein that inhibits the activities of the estrogen receptors, which may contribute to the antitumor activity of TAS-108.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Modulator TAS-108","termGroup":"PT","termSource":"NCI"},{"termName":"(7)-21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"SR16234","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"354808-47-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9B29N23K7E"},{"name":"Legacy Concept Name","value":"TAS-108"},{"name":"Maps_To","value":"Selective Estrogen Receptor Modulator TAS-108"},{"name":"NCI_Drug_Dictionary_ID","value":"486347"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486347"},{"name":"PDQ_Open_Trial_Search_ID","value":"486347"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1435232"}]}}{"C153309":{"preferredName":"Exicorilant","code":"C153309","definitions":[{"definition":"An orally available, selective glucocorticoid receptor (GR) antagonist, with potential antineoplastic activity. Upon oral administration, exicorilant competitively and selectively binds to GRs, inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exicorilant","termGroup":"PT","termSource":"NCI"},{"termName":"CORT 125281","termGroup":"CN","termSource":"NCI"},{"termName":"CORT-1252","termGroup":"CN","termSource":"NCI"},{"termName":"CORT125281","termGroup":"CN","termSource":"NCI"},{"termName":"Glucocorticoid Receptor Antagonist CORT125281","termGroup":"SY","termSource":"NCI"},{"termName":"Methanone, ((4aR,8aS)-1-(4-Fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"WHO 10854","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1781244-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GTB859B7K8"},{"name":"Maps_To","value":"Exicorilant"},{"name":"Maps_To","value":"Selective Glucocorticoid Receptor Antagonist CORT125281"},{"name":"NCI_Drug_Dictionary_ID","value":"794071"},{"name":"NCI_META_CUI","value":"CL554423"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794071"},{"name":"PDQ_Open_Trial_Search_ID","value":"794071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150363":{"preferredName":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","code":"C150363","definitions":[{"definition":"A benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","termGroup":"PT","termSource":"NCI"},{"termName":"3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol","termGroup":"SN","termSource":"NCI"},{"termName":"ERa Partial Agonist TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Mimic TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Modulator TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"SEM TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"ShERPA TTC-352","termGroup":"SY","termSource":"NCI"},{"termName":"TTC 352","termGroup":"CN","termSource":"NCI"},{"termName":"TTC-352","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1607819-68-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65ILH3Y0MI"},{"name":"Maps_To","value":"Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352"},{"name":"NCI_Drug_Dictionary_ID","value":"793141"},{"name":"NCI_META_CUI","value":"CL552181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793141"},{"name":"PDQ_Open_Trial_Search_ID","value":"793141"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62783":{"preferredName":"Seliciclib","code":"C62783","definitions":[{"definition":"An orally available small molecule and cyclin-dependent kinase (CDK) inhibitor with potential apoptotic and antineoplastic activity. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Seliciclib primarily inhibits CDK 2, 7, and 9 by competing for the ATP binding sites on these kinases, leading to a disruption of cell cycle progression. In addition, this agent seems to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, thereby inhibiting RNA polymerase II-dependent transcription. This may lead to the down-regulation of anti-apoptotic factors, such as myeloid cell leukemia sequence 1 (Mcl-1), a protein crucial for the survival of a range of tumor cell types. The down-regulation of anti-apoptotic factors may lead to an induction of apoptosis, thereby further contributing to seliciclib's antiproliferative effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seliciclib","termGroup":"PT","termSource":"NCI"},{"termName":"CYC202","termGroup":"CN","termSource":"NCI"},{"termName":"R-roscovitine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186692-46-6"},{"name":"Chemical_Formula","value":"C19H26N6O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0ES1C2KQ94"},{"name":"Legacy Concept Name","value":"Seliciclib"},{"name":"Maps_To","value":"Seliciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"511023"},{"name":"PDQ_Closed_Trial_Search_ID","value":"511023"},{"name":"PDQ_Open_Trial_Search_ID","value":"511023"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1436187"}]}}{"C102546":{"preferredName":"Selinexor","code":"C102546","definitions":[{"definition":"An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selinexor","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenoic Acid, 3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-Pyrazinyl)hydrazide, (2Z)-","termGroup":"SN","termSource":"NCI"},{"termName":"ATG-010","termGroup":"CN","termSource":"NCI"},{"termName":"CRM1 Nuclear Export Inhibitor KPT-330","termGroup":"SY","termSource":"NCI"},{"termName":"KPT 330","termGroup":"CN","termSource":"NCI"},{"termName":"KPT-330","termGroup":"CN","termSource":"NCI"},{"termName":"KPT330","termGroup":"CN","termSource":"NCI"},{"termName":"Nexpovio","termGroup":"FB","termSource":"NCI"},{"termName":"Selective Inhibitor of Nuclear Export KPT-330","termGroup":"SY","termSource":"NCI"},{"termName":"SINE KPT-330","termGroup":"SY","termSource":"NCI"},{"termName":"Xpovio","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multiple myeloma"},{"name":"CAS_Registry","value":"1393477-72-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"31TZ62FO8F"},{"name":"Maps_To","value":"Selinexor"},{"name":"NCI_Drug_Dictionary_ID","value":"734824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734824"},{"name":"PDQ_Open_Trial_Search_ID","value":"734824"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640806"}]}}{"C138160":{"preferredName":"Selitrectinib","code":"C138160","definitions":[{"definition":"An orally bioavailable, selective tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, LOXO-195 specifically targets and binds to TRK, including the fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1), 2 (NTRK2), and 3 (NTRK3).  This prevents neurotrophin-TRK interaction and TRK activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. LOXO-195 targets specific point mutations that occur after treatment with and result in acquired resistance to another TRK inhibitor; therefore, LOXO-195 is able to overcome acquired resistance to other TRK inhibitors. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of or fusion proteins involving NTRK family members results in uncontrolled TRK signaling and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selitrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 2731954","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO 195","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO-195","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO195","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2097002-61-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0J45910S3X"},{"name":"Maps_To","value":"Selitrectinib"},{"name":"NCI_Drug_Dictionary_ID","value":"790661"},{"name":"NCI_META_CUI","value":"CL525677"},{"name":"PDQ_Closed_Trial_Search_ID","value":"790661"},{"name":"PDQ_Open_Trial_Search_ID","value":"790661"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121943":{"preferredName":"Selonsertib","code":"C121943","definitions":[{"definition":"An orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. Upon oral administration, selonsertib targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. This prevents the phosphorylation of downstream kinases, such as c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK). By preventing the activation of ASK1-dependent signal transduction pathways, GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. ASK1, also called mitogen-activated protein kinase kinase kinase 5 (MAP3K5), is activated in response to oxidative and endoplasmic reticulum (ER) stress, calcium influx and infection. It plays a key role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, as well as certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selonsertib","termGroup":"PT","termSource":"NCI"},{"termName":"GS-4997","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448428-04-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NS3988A2TC"},{"name":"Maps_To","value":"Selonsertib"},{"name":"NCI_Drug_Dictionary_ID","value":"773700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"773700"},{"name":"PDQ_Open_Trial_Search_ID","value":"773700"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053640"}]}}{"C134987":{"preferredName":"Selpercatinib","code":"C134987","definitions":[{"definition":"An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selpercatinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"LOXO 292","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO-292","termGroup":"CN","termSource":"NCI"},{"termName":"LOXO292","termGroup":"CN","termSource":"NCI"},{"termName":"RET Kinase Inhibitor LOXO-292","termGroup":"SY","termSource":"NCI"},{"termName":"Retevmo","termGroup":"BR","termSource":"NCI"},{"termName":"Retsevmo","termGroup":"FB","termSource":"NCI"},{"termName":"WHO 10967","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); • Adult and pediatric patients >=12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; • Adult and pediatric patients >=12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)."},{"name":"CAS_Registry","value":"2152628-33-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CEGM9YBNGD"},{"name":"Maps_To","value":"Selpercatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"789226"},{"name":"NCI_META_CUI","value":"CL522497"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789226"},{"name":"PDQ_Open_Trial_Search_ID","value":"789226"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66939":{"preferredName":"Selumetinib","code":"C66939","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. AZD6244 blocks proteins needed for cell growth and may kill cancer cells. It is a type of protein kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selumetinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-142886","termGroup":"CN","termSource":"NCI"},{"termName":"AZD 6244","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-6244","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6244","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor AZD6244","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"606143-52-6"},{"name":"Chemical_Formula","value":"C17H15BrClFN4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6UH91I579U"},{"name":"Legacy Concept Name","value":"AZD6244"},{"name":"Maps_To","value":"Selumetinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832054"}]}}{"C95225":{"preferredName":"Selumetinib Sulfate","code":"C95225","definitions":[{"definition":"The sulfate salt of selumetinib, an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selumetinib Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benzimidazole-6-Carboxamide, 5-((4-Bromo-2-Chlorophenyl)Amino)-4-Fluoro-N-(2- Hydroxyethoxy)-1-Methyl-, Sulfate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"1h-Benzimidazole-6-Carboxamide,5-((4-Bromo-2-Chlorophenyl)Amino)-4-Fluoro-N-(2- Hydroxyethoxy)-1-Methyl-, Sulphate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"5-((4-Bromo-2-Chlorophenyl)amino)-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H- Benzimidazole-6-Carboxamide Sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"5-((4-Bromo-2-Chlorophenyl)amino)-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H- Benzimidazole-6-Carboxamide Sulphate","termGroup":"SN","termSource":"NCI"},{"termName":"AZD-6244 Hydrogen Sulfate","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6244 Hydrogen Sulfate","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6244 Hydrogen Sulphate","termGroup":"CN","termSource":"NCI"},{"termName":"Koselugo","termGroup":"BR","termSource":"NCI"},{"termName":"Selumetinib Sulphate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)."},{"name":"CAS_Registry","value":"943332-08-9"},{"name":"Chemical_Formula","value":"C17H15BrClFN4O3.H2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"807ME4B7IJ"},{"name":"Maps_To","value":"Selumetinib Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"532294"},{"name":"PDQ_Closed_Trial_Search_ID","value":"532294"},{"name":"PDQ_Open_Trial_Search_ID","value":"532294"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987007"}]}}{"C1831":{"preferredName":"Semaxanib","code":"C1831","definitions":[{"definition":"A quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that has been studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and tyrosine kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Semaxanib","termGroup":"PT","termSource":"NCI"},{"termName":"H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-","termGroup":"SN","termSource":"NCI"},{"termName":"Semoxind","termGroup":"SY","termSource":"NCI"},{"termName":"SU5416","termGroup":"CN","termSource":"NCI"},{"termName":"Sugen 5416","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194413-58-6"},{"name":"Chemical_Formula","value":"C15H14N2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71IA9S35AJ"},{"name":"Legacy Concept Name","value":"Semaxanib"},{"name":"Maps_To","value":"Semaxanib"},{"name":"NCI_Drug_Dictionary_ID","value":"43310"},{"name":"NSC Number","value":"696819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43310"},{"name":"PDQ_Open_Trial_Search_ID","value":"43310"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1135174"}]}}{"C78447":{"preferredName":"Semuloparin","code":"C78447","definitions":[{"definition":"An ultralow-molecular-weight heparin (ULMWH) (Mw: 2000-3000 daltons)consisting of a polydisperse mixture of oligomeric heparin fragments with potential anticoagulant activity. Ultralow-molecular-weight heparin AVE5026 binds to and activates antithrombin III (ATIII), which may result in the inhibition of activated factor Xa and, to a much lesser extent, factor IIa (thrombin) and so the inhibition of fibrin formation. Compared to low-molecular-weight heparins (LMWHs), AVE5026 exhibits an even higher ratio of anti-Factor Xa to anti-Factor IIa activity (>30:1). Compared to unfractionated heparins, the use of LMWHs is associated with lower incidences of major bleeding, osteoporosis and heparin-induced thrombocytopenia. Like LMWHs, this agent may inhibit tumor growth by regulating angiogenesis and apoptosis. AVE5026 is prepared by partial depolymerization of unfractionated porcine mucosal heparin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Semuloparin","termGroup":"PT","termSource":"NCI"},{"termName":"AVE 5026","termGroup":"CN","termSource":"NCI"},{"termName":"AVE-5026","termGroup":"CN","termSource":"NCI"},{"termName":"AVE5026","termGroup":"CN","termSource":"NCI"},{"termName":"ULMW heparin AVE5026","termGroup":"AB","termSource":"NCI"},{"termName":"Ultra-low-molecular-weight Heparin (2000-3000 MW; Phosphazene Depolymerization)","termGroup":"SY","termSource":"NCI"},{"termName":"Ultralow-Molecular-Weight Heparin AVE5026","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9005-49-6"},{"name":"CHEBI_ID","value":"CHEBI:28304"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4QW4AN84NQ"},{"name":"Legacy Concept Name","value":"Ultralow-Molecular-Weight_Heparin_AVE5026"},{"name":"Maps_To","value":"Semuloparin"},{"name":"NCI_Drug_Dictionary_ID","value":"599247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599247"},{"name":"PDQ_Open_Trial_Search_ID","value":"599247"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700104"}]}}{"C827":{"preferredName":"Semustine","code":"C827","definitions":[{"definition":"A methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Semustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(Trans-4-Methylcyclohexane)-1-Nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"Lomustine, Methyl","termGroup":"SY","termSource":"NCI"},{"termName":"MCCNU","termGroup":"AB","termSource":"NCI"},{"termName":"MeCCNU","termGroup":"AB","termSource":"NCI"},{"termName":"Methyl CCNU","termGroup":"SY","termSource":"NCI"},{"termName":"Methyl Lomustine","termGroup":"SY","termSource":"NCI"},{"termName":"trans-Methyl-CCNU","termGroup":"SY","termSource":"NCI"},{"termName":"urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-, trans- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"urea, N-(2-chloroethyl)-N'-(4-methylcyclohexyl)-N-nitroso-, trans- (9CI)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13909-09-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6YY7T1T567"},{"name":"Legacy Concept Name","value":"Semustine"},{"name":"Maps_To","value":"Semustine"},{"name":"NCI_Drug_Dictionary_ID","value":"43727"},{"name":"NSC Number","value":"95441"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43727"},{"name":"PDQ_Open_Trial_Search_ID","value":"43727"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0036637"}]}}{"C62524":{"preferredName":"Seneca Valley Virus-001","code":"C62524","definitions":[{"definition":"A replication-competent oncolytic picornavirus with potential antineoplastic activity. Administered systemically, Seneca Valley virus-001 specifically targets and infects tumor cells with neuroendocrine characteristics. Upon infection, this agent replicates intracellularly, resulting in tumor cell lysis and reduced tumor cell proliferation. The selective tropism of virus replication may involve receptor-mediated internalization.","type":"DEFINITION","source":"NCI"},{"definition":"A virus being studied in the treatment of neuroendocrine tumors and other types of cancer. Neuroendocrine tumors form from cells that release hormones in response to a signal from the nervous system. The virus infects and breaks down these tumor cells but not normal cells. It is a type of oncolytic virus.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Seneca Valley Virus-001","termGroup":"PT","termSource":"NCI"},{"termName":"NTX-010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Seneca_Valley_Virus"},{"name":"Maps_To","value":"Seneca Valley Virus-001"},{"name":"NCI_Drug_Dictionary_ID","value":"488482"},{"name":"NCI_META_CUI","value":"CL365090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488482"},{"name":"PDQ_Open_Trial_Search_ID","value":"488482"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C26669":{"preferredName":"Seocalcitol","code":"C26669","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called vitamin D analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A vitamin D3 analogue with potential antineoplastic activity. Seocalcitol binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, seocalcitol may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seocalcitol","termGroup":"PT","termSource":"NCI"},{"termName":"(1R-(1alpha(1R*,2E,4E),3abeta,4E(1R*,3S*,5Z),7aalpha))-5-((1-(6-Ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-1,3-cyclohexanediol","termGroup":"SN","termSource":"NCI"},{"termName":"1(S),3(R)-Dihydroxy-20(R)-(5'-ethyl-5'-hydroxyhepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene","termGroup":"SN","termSource":"NCI"},{"termName":"EB1089","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"134404-52-7"},{"name":"Chemical_Formula","value":"C30H46O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q0OZ0D9223"},{"name":"Legacy Concept Name","value":"Seocalcitol"},{"name":"Maps_To","value":"Seocalcitol"},{"name":"NCI_Drug_Dictionary_ID","value":"298863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"298863"},{"name":"PDQ_Open_Trial_Search_ID","value":"298863"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0905598"}]}}{"C61091":{"preferredName":"Sepantronium Bromide","code":"C61091","definitions":[{"definition":"A small-molecule proapoptotic agent with potential antineoplastic activity. Sepantronium bromide selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sepantronium Bromide","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Naphth(2,3-d)imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazinylmethyl)-, Bromide","termGroup":"SN","termSource":"NCI"},{"termName":"Survivin Inhibitor YM155","termGroup":"SY","termSource":"NCI"},{"termName":"YM-155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"781661-94-7"},{"name":"Chemical_Formula","value":"C20H19N4O3.Br"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7H5Q4J1CM5"},{"name":"Legacy Concept Name","value":"YM155"},{"name":"Maps_To","value":"Sepantronium Bromide"},{"name":"NCI_Drug_Dictionary_ID","value":"476771"},{"name":"PDQ_Closed_Trial_Search_ID","value":"476771"},{"name":"PDQ_Open_Trial_Search_ID","value":"476771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002939"}]}}{"C98844":{"preferredName":"Serabelisib","code":"C98844","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha isoform with potential antineoplastic activity. Serabelisib selectively inhibits PI3K alpha kinase, including mutations of PIK3CA, in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K alpha-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy; PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serabelisib","termGroup":"PT","termSource":"NCI"},{"termName":"(6-(2-Amino-5-benzoxazolyl)imidazo(1,2-a)pyridin-3-yl)-4-morpholinylmethanone","termGroup":"SY","termSource":"NCI"},{"termName":"INK1117","termGroup":"CN","termSource":"NCI"},{"termName":"MLN-1117","termGroup":"CN","termSource":"NCI"},{"termName":"MLN1117","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 117","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-117","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268454-23-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"43J9Q56T3W"},{"name":"Maps_To","value":"Serabelisib"},{"name":"NCI_Drug_Dictionary_ID","value":"714372"},{"name":"NCI_META_CUI","value":"CL432860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"714372"},{"name":"PDQ_Open_Trial_Search_ID","value":"714372"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156735":{"preferredName":"Taragarestrant","code":"C156735","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, taragarestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taragarestrant","termGroup":"PT","termSource":"NCI"},{"termName":"(2E)-3-(3,5-Dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1hpyrido(3,4-b)indol-1-yl)phenyl)prop-2-enoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"2-Propenoic acid, 3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1H-pyrido(3,4-b)indol-1-yl)phenyl)-, (2E)-","termGroup":"SN","termSource":"NCI"},{"termName":"D 0502","termGroup":"CN","termSource":"NCI"},{"termName":"D-0502","termGroup":"CN","termSource":"NCI"},{"termName":"D0502","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator D-0502","termGroup":"SY","termSource":"NCI"},{"termName":"SERD D-0502","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2118899-51-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KD4HIM135V"},{"name":"Maps_To","value":"SERD D-0502"},{"name":"NCI_Drug_Dictionary_ID","value":"795596"},{"name":"NCI_META_CUI","value":"CL935902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795596"},{"name":"PDQ_Open_Trial_Search_ID","value":"795596"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175853":{"preferredName":"Rintodestrant","code":"C175853","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, rintodestrant specifically targets and binds to the estrogen receptor alpha (ERalpha; ERa; ESR1) and induces a conformational change that promotes ERalpha degradation and downregulation. This prevents ERalpha-mediated signaling and inhibits both the growth and survival of ERalpha-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rintodestrant","termGroup":"PT","termSource":"NCI"},{"termName":"G1T48","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader G1T48","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator G1T48","termGroup":"SY","termSource":"NCI"},{"termName":"SERD G1T48","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2088518-51-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W3Y784Y0ES"},{"name":"Maps_To","value":"SERD G1T48"},{"name":"NCI_Drug_Dictionary_ID","value":"793441"},{"name":"NCI_META_CUI","value":"CL552249"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C147030":{"preferredName":"Giredestrant","code":"C147030","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Giredestrant","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 9545","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-49545","termGroup":"CN","termSource":"NCI"},{"termName":"RG6171","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader GDC-9545","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator GDC-9545","termGroup":"SY","termSource":"NCI"},{"termName":"SERD GDC-9545","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1953133-47-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"28P3DU6DB3"},{"name":"Maps_To","value":"Giredestrant"},{"name":"Maps_To","value":"SERD GDC-9545"},{"name":"NCI_Drug_Dictionary_ID","value":"792379"},{"name":"NCI_META_CUI","value":"CL545029"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792379"},{"name":"PDQ_Open_Trial_Search_ID","value":"792379"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174915":{"preferredName":"Amcenestrant","code":"C174915","definitions":[{"definition":"An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, amcenestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amcenestrant","termGroup":"PT","termSource":"NCI"},{"termName":"SAR 439859","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-439859","termGroup":"CN","termSource":"NCI"},{"termName":"SAR439859","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader SAR439859","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator SAR439859","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2114339-57-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TBF1NHY02O"},{"name":"Maps_To","value":"SERD SAR439859"},{"name":"NCI_Drug_Dictionary_ID","value":"793484"},{"name":"NCI_META_CUI","value":"CL538418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793484"},{"name":"PDQ_Open_Trial_Search_ID","value":"793484"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165550":{"preferredName":"SERD SHR9549","code":"C165550","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD SHR9549 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SERD SHR9549","termGroup":"PT","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader SHR9549","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator SHR9549","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 9549","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-9549","termGroup":"CN","termSource":"NCI"},{"termName":"SHR9549","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SERD SHR9549"},{"name":"NCI_Drug_Dictionary_ID","value":"799640"},{"name":"NCI_META_CUI","value":"CL978680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799640"},{"name":"PDQ_Open_Trial_Search_ID","value":"799640"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77904":{"preferredName":"Serdemetan","code":"C77904","definitions":[{"definition":"An orally bioavailable HDM2 antagonist with potential antineoplastic activity. Serdemetan inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serdemetan","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 26854165","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-26854165","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-(1H-Indol-3-yl)ethyl)-n'-(pyridin-4-yl)benzene-1,4-diamine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"881202-45-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ID6YB4W3V8"},{"name":"Legacy Concept Name","value":"HDM2_Inhibitor_JNJ-26854165"},{"name":"Maps_To","value":"Serdemetan"},{"name":"NCI_Drug_Dictionary_ID","value":"596734"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596734"},{"name":"PDQ_Open_Trial_Search_ID","value":"596734"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703092"}]}}{"C1763":{"preferredName":"Sergiolide","code":"C1763","definitions":[{"definition":"A quassinoid phytochemical isolated from Cedronia granatensis and other plant species with potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sergiolide","termGroup":"PT","termSource":"NCI"},{"termName":"Sergeolide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sergiolide"},{"name":"Maps_To","value":"Sergiolide"},{"name":"NSC Number","value":"344025"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0624649"}]}}{"C78859":{"preferredName":"Seribantumab","code":"C78859","definitions":[{"definition":"A fully human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Seribantumab binds to and inhibits ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seribantumab","termGroup":"PT","termSource":"NCI"},{"termName":"MM-121","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 256212","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1334296-12-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1N3L70MDFX"},{"name":"Legacy Concept Name","value":"Anti-ErbB3_Receptor_Monoclonal_Antibody_MM-121"},{"name":"Maps_To","value":"Seribantumab"},{"name":"NCI_Drug_Dictionary_ID","value":"613844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613844"},{"name":"PDQ_Open_Trial_Search_ID","value":"613844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4042753"}]}}{"C71529":{"preferredName":"Serine/Threonine Kinase Inhibitor CBP501","code":"C71529","definitions":[{"definition":"A peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C); disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2/cyclin B, preventing entry into the mitotic phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serine/Threonine Kinase Inhibitor CBP501","termGroup":"PT","termSource":"NCI"},{"termName":"CBP 501","termGroup":"CN","termSource":"NCI"},{"termName":"CBP-501","termGroup":"CN","termSource":"NCI"},{"termName":"CBP501","termGroup":"CN","termSource":"NCI"},{"termName":"Cdc25C Phosphatase (211-221)","termGroup":"SY","termSource":"NCI"},{"termName":"D-Arginine, 4-Benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D- arginyl-D-arginyl-D-glutaminyl-D-arginyl-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"565434-85-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XH2662798I"},{"name":"Legacy Concept Name","value":"Serine_Threonine_Kinase_Inhibitor_CBP501"},{"name":"Maps_To","value":"Serine/Threonine Kinase Inhibitor CBP501"},{"name":"NCI_Drug_Dictionary_ID","value":"577812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"577812"},{"name":"PDQ_Open_Trial_Search_ID","value":"577812"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348193"}]}}{"C68963":{"preferredName":"Serine/Threonine Kinase Inhibitor XL418","code":"C68963","definitions":[{"definition":"A selective, orally active small molecule, targeting protein kinase B (PKB or AKT) and ribosomal protein S6 Kinase (p70S6K), with potential antineoplastic activity. XL418 inhibits the activities of PKB and p70S6K, both acting downstream of phosphoinosotide-3 kinase (PI3K). These kinases are often upregulated in a variety of cancers. Inhibition of PKB by this agent will induce apoptosis, while inhibition of p70S6K will result in the inhibition of translation within tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Serine/Threonine Kinase Inhibitor XL418","termGroup":"PT","termSource":"NCI"},{"termName":"XL418","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"871343-09-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OLJ18SRI8A"},{"name":"Legacy Concept Name","value":"Serine_Threonine_Kinase_Inhibitor_XL418"},{"name":"Maps_To","value":"Serine/Threonine Kinase Inhibitor XL418"},{"name":"NCI_Drug_Dictionary_ID","value":"546978"},{"name":"NCI_META_CUI","value":"CL374493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"546978"},{"name":"PDQ_Open_Trial_Search_ID","value":"546978"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122403":{"preferredName":"Suvemcitug","code":"C122403","definitions":[{"definition":"A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, suvemcitug specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suvemcitug","termGroup":"PT","termSource":"NCI"},{"termName":"APX 003","termGroup":"CN","termSource":"NCI"},{"termName":"BD 0801","termGroup":"CN","termSource":"NCI"},{"termName":"BD-0801","termGroup":"CN","termSource":"NCI"},{"termName":"BD0801","termGroup":"CN","termSource":"NCI"},{"termName":"Sevacizumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610010-57-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T7Y5VC4ERJ"},{"name":"Maps_To","value":"Sevacizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"772607"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772607"},{"name":"PDQ_Open_Trial_Search_ID","value":"772607"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4054033"}]}}{"C113652":{"preferredName":"Seviteronel","code":"C113652","definitions":[{"definition":"An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, seviteronel selectively inhibits the enzymatic activity of the cytochrome P450 C17,20 lyase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The lyase-selective activity of seviteronel prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seviteronel","termGroup":"PT","termSource":"NCI"},{"termName":"1H-1,2,3-Triazole-5-methanol, Alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (AlphaS)-","termGroup":"SN","termSource":"NCI"},{"termName":"VT-464","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610537-15-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8S5OIN36X4"},{"name":"Maps_To","value":"Seviteronel"},{"name":"NCI_Drug_Dictionary_ID","value":"756850"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756850"},{"name":"PDQ_Open_Trial_Search_ID","value":"756850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827068"}]}}{"C29424":{"preferredName":"Shared Anti-Idiotype-AB-S006","code":"C29424","definitions":[{"definition":"A murine monoclonal anti-idiotype antibody that targets human B-cell lymphomas with potential antineoplastic activity.  Shared Anti-Id-Ab-S006 binds to antigens on neoplastic B cells, resulting in tumor cell destruction by the reticuloendothelial system or cytotoxic T lymphocytes (CTL). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shared Anti-Idiotype-AB-S006","termGroup":"PT","termSource":"NCI"},{"termName":"Murine Monoclonal Antibody To Human B Cell Lymphomas (Anti- Idiotypes) (S006)","termGroup":"SY","termSource":"NCI"},{"termName":"Shared Anti-Idiotype AB-S006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Shared_Anti-Idiotype-AB-S006"},{"name":"Maps_To","value":"Shared Anti-Idiotype-AB-S006"},{"name":"NSC Number","value":"655532"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519287"}]}}{"C29432":{"preferredName":"Shared Anti-Idiotype-AB-S024A","code":"C29432","definitions":[{"definition":"A murine monoclonal anti-idiotype antibody with potential antineoplastic activity. Shared anti-id-Ab-S024A binds to tumor-associated antigens (TAAs) on the surface of neoplastic cells resulting in tumor cell destruction by the reticuloendothelial system or cytotoxic T lymphocytes (CTL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shared Anti-Idiotype-AB-S024A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Shared_Anti-Idiotype-AB-S024A"},{"name":"Maps_To","value":"Shared Anti-Idiotype-AB-S024A"},{"name":"NSC Number","value":"655540"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519294"}]}}{"C2318":{"preferredName":"Shark Cartilage","code":"C2318","definitions":[{"definition":"A nutritional supplement gleaned from the exoskeleton of the shark. Shark cartilage inhibits metalloproteinases (MMPs) and possesses antiangiogenic and antimetastatic properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shark Cartilage","termGroup":"PT","termSource":"NCI"},{"termName":"BeneFin (Lane Shark Cartilage Powder)","termGroup":"BR","termSource":"NCI"},{"termName":"Cartilade","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"305838-77-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D2YCN1I522"},{"name":"Legacy Concept Name","value":"Shark_Cartilage"},{"name":"Maps_To","value":"Shark Cartilage"},{"name":"NCI_Drug_Dictionary_ID","value":"304435"},{"name":"NSC Number","value":"706457"},{"name":"PDQ_Closed_Trial_Search_ID","value":"304435"},{"name":"PDQ_Open_Trial_Search_ID","value":"304435"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281563"}]}}{"C1798":{"preferredName":"Shark Cartilage Extract AE-941","code":"C1798","definitions":[{"definition":"A multifunctional antiangiogenic agent derived from shark cartilage with potential antineoplastic activity. Shark cartilage extract AE-941 competitively inhibits the binding of pro-angiogenic vascular endothelial growth factor (VEGF) to its cellular receptor, thereby inhibiting endothelial cell proliferation. This agent also inhibits matrix metalloproteinases (MMPs), stimulates tissue plasminogen activator (tPA), and activates caspase-mediated apoptotic pathways in endothelial cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance made from shark cartilage that is being studied for its ability to prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Shark Cartilage Extract AE-941","termGroup":"PT","termSource":"NCI"},{"termName":"[AElig]-941","termGroup":"CN","termSource":"NCI"},{"termName":"AE-941","termGroup":"CN","termSource":"NCI"},{"termName":"Neovastat","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"305838-77-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Neovastat"},{"name":"Maps_To","value":"Shark Cartilage Extract AE-941"},{"name":"NCI_Drug_Dictionary_ID","value":"42021"},{"name":"NSC Number","value":"706456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42021"},{"name":"PDQ_Open_Trial_Search_ID","value":"42021"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1963096"}]}}{"C2690":{"preferredName":"Sho-Saiko-To","code":"C2690","definitions":[{"definition":"A Japanese formulation of seven Chinese herbs that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A botanical formulation with potential chemopreventive activities. Sho-Saiko-to, an herbal mixture, contains seven herbal extracts whose mechanism of action if not fully understood. There is evidence of antiproliferative effects against hepatocellular carcinoma in vitro. Other effects of this agent described in animal models include the prevention of liver injury and hepatocyte-regenerating activity. Antitumor effects associated with this herbal product may include induction of apoptosis, cell cycle arrest at the G0/G1 phase, and activation of an immune response, characterized by the release of cytokines as well as activation of effector cells, such as macrophages and natural killer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sho-Saiko-To","termGroup":"PT","termSource":"NCI"},{"termName":"Keisho-To","termGroup":"SY","termSource":"NCI"},{"termName":"Minor Bupleurum Formula","termGroup":"SY","termSource":"NCI"},{"termName":"TJ-9","termGroup":"CN","termSource":"NCI"},{"termName":"Xiao Chai Hu Tang","termGroup":"SY","termSource":"NCI"},{"termName":"Xiao-Chai-Hu-Tang","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sho-Saiko-To"},{"name":"Maps_To","value":"Sho-Saiko-To"},{"name":"NCI_Drug_Dictionary_ID","value":"38708"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38708"},{"name":"PDQ_Open_Trial_Search_ID","value":"38708"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1138004"}]}}{"C156695":{"preferredName":"SHP-1 Agonist SC-43","code":"C156695","definitions":[{"definition":"An orally available, small molecule agonist of Src homology region 2 domain-containing phosphatase-1 (SHP-1; tyrosine-protein phosphatase non-receptor type 6; PTPN6) with potential antineoplastic activity. Upon administration, SHP-1 agonist SC-43 enhances SHP-1 activity by impairing the association between the N-terminal Src homology 2 (N-SH2) domain and the protein tyrosine phosphatase (PTP) domain of SHP-1, triggering a conformational change of SHP-1 and relieving its autoinhibition. Activation of SHP-1 represses signal transducer and activator of transcription 3 (STAT3) signaling by inhibiting constitutive and interleukin-6 (IL-6)-induced STAT3 phosphorylation. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence, stemness, and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP-1 Agonist SC-43","termGroup":"PT","termSource":"NCI"},{"termName":"1-[4-Chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] Urea","termGroup":"SN","termSource":"NCI"},{"termName":"SC 43","termGroup":"CN","termSource":"NCI"},{"termName":"SC-43","termGroup":"CN","termSource":"NCI"},{"termName":"SC-43 Oral Solution","termGroup":"SY","termSource":"NCI"},{"termName":"SC43","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1400989-25-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OT4AQX5MLU"},{"name":"Maps_To","value":"SHP-1 Agonist SC-43"},{"name":"NCI_Drug_Dictionary_ID","value":"795711"},{"name":"NCI_META_CUI","value":"CL935710"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795711"},{"name":"PDQ_Open_Trial_Search_ID","value":"795711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160207":{"preferredName":"SHP2 Inhibitor JAB-3068","code":"C160207","definitions":[{"definition":"An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3068 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP2 Inhibitor JAB-3068","termGroup":"PT","termSource":"NCI"},{"termName":"JAB 3068","termGroup":"CN","termSource":"NCI"},{"termName":"JAB-3068","termGroup":"CN","termSource":"NCI"},{"termName":"JAB3068","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V6Q7413SA8"},{"name":"Maps_To","value":"SHP2 Inhibitor JAB-3068"},{"name":"NCI_Drug_Dictionary_ID","value":"797845"},{"name":"NCI_META_CUI","value":"CL969346"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797845"},{"name":"PDQ_Open_Trial_Search_ID","value":"797845"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155850":{"preferredName":"Vociprotafib","code":"C155850","definitions":[{"definition":"An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, vociprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-MEK-ERK signaling pathway. The RAS-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vociprotafib","termGroup":"PT","termSource":"NCI"},{"termName":"(6-((2-Amino-3-chloropyridin-4-yl)sulfanyl)-3-((3S,4S)-4-amino- 3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)- 5-methylpyrazin-2-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyrazinemethanol, 6-((2-amino-3-chloro-4-pyridinyl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-5-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"PTPN11 Inhibitor RMC-4630","termGroup":"SY","termSource":"NCI"},{"termName":"RMC 4630","termGroup":"CN","termSource":"NCI"},{"termName":"RMC-4630","termGroup":"CN","termSource":"NCI"},{"termName":"RMC4630","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 442720","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442720","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442720","termGroup":"CN","termSource":"NCI"},{"termName":"SHP2 Inhibitor RMC-4630","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2172652-48-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C4YBF9170L"},{"name":"Maps_To","value":"SHP2 Inhibitor RMC-4630"},{"name":"NCI_Drug_Dictionary_ID","value":"798916"},{"name":"NCI_META_CUI","value":"CL562678"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798916"},{"name":"PDQ_Open_Trial_Search_ID","value":"798916"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139559":{"preferredName":"Batoprotafib","code":"C139559","definitions":[{"definition":"An inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration,batoprotafib binds to and inhibits SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-ERK signaling pathway. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Batoprotafib","termGroup":"PT","termSource":"NCI"},{"termName":"PTPN11 Inhibitor TNO155","termGroup":"SY","termSource":"NCI"},{"termName":"SHP2 Inhibitor TNO155","termGroup":"SY","termSource":"NCI"},{"termName":"TNO155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801765-04-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FPJWORQEGI"},{"name":"Maps_To","value":"SHP2 Inhibitor TNO155"},{"name":"NCI_Drug_Dictionary_ID","value":"791106"},{"name":"NCI_META_CUI","value":"CL526915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791106"},{"name":"PDQ_Open_Trial_Search_ID","value":"791106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120207":{"preferredName":"Shu Yu Wan Formula","code":"C120207","definitions":[{"definition":"A traditional Chinese medicine comprising different herbs that may be used for a variety of medical purposes. Shu Yu Wan contains the following herbs: Da Zao (Fructus Jujubae), Shu Yu (Radix Dioscoreae Quinquelobae), Gan Cao (Radix Glycyrrhizae Uralensis), Shu Di Huang (Radix Rehmanniae Glutinosae Praeparata), Dang Gui (Radix Angelicae Sinensis), Shen Qu (Massa Medica Fermentata), Gui Zhi (Ramulus Cinnamomi Cassiae), Da Dou Juan (Semen Glycines Germinatum), E Jiao (Gelatinum Corii Asini), Ren Shen (Radix Ginseng), Bai Zhu (Rhizoma Atractylodis Macrocephalae), Fu Ling (Sclerotium Poriae Cocos), Chuan Xiong (Radix Ligustici Wallichii), Bai Shao Yao (Radix Paeoniae Lactiflorae), Mai Men Dong (Tuber Ophiopogonis Japonici), Chai Hu (Radix Bupleuri), Fang Feng (Radix Ledebouriellae Divaricatae), Jie Geng (Radix Platycodi Grandiflori), Xing Ren (Semen Pruni Armeniacae), Bai Lian (Radix Ampelopsis Japonicae) and Sheng Jiang (Rhizoma Zingiberis Officinalis Recens). This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shu Yu Wan Formula","termGroup":"PT","termSource":"NCI"},{"termName":"Pill of Chinese Yam","termGroup":"SY","termSource":"NCI"},{"termName":"Shu Yu Wan","termGroup":"SY","termSource":"NCI"},{"termName":"Shuyu Wan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Shu Yu Wan Formula"},{"name":"NCI_Drug_Dictionary_ID","value":"768217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768217"},{"name":"PDQ_Open_Trial_Search_ID","value":"768217"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897616"}]}}{"C1226":{"preferredName":"Sialyl Tn Antigen","code":"C1226","definitions":[{"definition":"A tumor-associated core-region carbohydrate antigen of epithelial mucin, expressed in most colon carcinoma, mucinous carcinoma, pancreatic cancer, gastric, lung, breast, and ovarian carcinoma. Sialosyl-Tn (STn) antigen has been shown to be highly sensitive and a specific marker of colorectal cancer, associated with more aggressive diseases and poor prognosis. STn antigen and its immediate precursor, Tn antigen, are mucin type glycoprotein structures associated with the earliest steps of mucin O-linked glycosylation. When combined with a carrier molecule, keyhole limpet hemocyanin (KLH), this antigen may be co-administered with oral cyclophosphamide as an immune modulator.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialyl Tn Antigen","termGroup":"PT","termSource":"NCI"},{"termName":"CD175s","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl-Tn","termGroup":"SY","termSource":"NCI"},{"termName":"Sialyl-Tn Antigen","termGroup":"SY","termSource":"NCI"},{"termName":"STn","termGroup":"AB","termSource":"NCI"},{"termName":"STn Antigen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sialyl_Tn_Antigen"},{"name":"Maps_To","value":"Sialyl Tn Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"41616"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41616"},{"name":"PDQ_Open_Trial_Search_ID","value":"41616"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0074480"}]}}{"C1690":{"preferredName":"Sialyl Tn-KLH Vaccine","code":"C1690","definitions":[{"definition":"A vaccine composed of a substance that enhances immunity plus an antigen found on some tumors of the colon, breast, lung, ovary, pancreas, and stomach.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sialyl Tn-KLH Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Sialyl Tn-KLH","termGroup":"SY","termSource":"NCI"},{"termName":"STn-KLH Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Theratope","termGroup":"BR","termSource":"NCI"},{"termName":"Theratope siayl-Tn-KLH vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Theratope STn-KLH Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Theratope Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sialyl_Tn-KLH_Vaccine"},{"name":"Maps_To","value":"Sialyl Tn-KLH Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"43279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43279"},{"name":"PDQ_Open_Trial_Search_ID","value":"43279"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0388828"}]}}{"C156438":{"preferredName":"Sibrotuzumab","code":"C156438","definitions":[{"definition":"A humanized monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby sibrotuzumab has possible diagnostic and therapeutic applications in epithelial cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sibrotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Humanized F19 Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"HuMoAb F19","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"216669-97-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"552U6E1NIW"},{"name":"Maps_To","value":"Sibrotuzumab"},{"name":"NCI_META_CUI","value":"CL563157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95772":{"preferredName":"siG12D LODER","code":"C95772","definitions":[{"definition":"A proprietary, miniature biodegradable polymeric matrix containing small-interfering RNAs for the mutated KRAS oncogene, KRASG12D, (siG12D), with potential antitumor activity. Upon intratumoral injection, this siG12D is released locally, thereby preventing translation of KRAS proteins and potentially inhibiting growth of tumor cells overexpressing KRAS. KRAS, a member of the small GTPase superfamily, is mutated in over 90% of human pancreatic ductal adenocarcinomas (PDAC) and is associated with tumor cell proliferation and reduced survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"siG12D LODER","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NNQ0PKZ9EV"},{"name":"Maps_To","value":"siG12D LODER"},{"name":"NCI_Drug_Dictionary_ID","value":"685237"},{"name":"NCI_META_CUI","value":"CL428214"},{"name":"PDQ_Closed_Trial_Search_ID","value":"685237"},{"name":"PDQ_Open_Trial_Search_ID","value":"685237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64618":{"preferredName":"Silatecan AR-67","code":"C64618","definitions":[{"definition":"A synthetic, highly lipophilic derivative of camptothecin, with potential antineoplastic and radiosensitizing activities. 7-tert-butyldimethylsilyl-10-hydroxycamptothecin binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces lethal double-stranded DNA breaks when encountered by the DNA replication machinery, thereby inhibiting DNA replication and inducing apoptosis. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active lactone structure to an inactive carboxylate form. Modifications on the E ring of camptothecin prevent binding of human serum albumin, which prefers the inactive carboxylate form, thereby enhancing the stability of the active lactone structure and resulting in prolonged agent activity. In addition, this agent sensitizes tumor cells toward radiation treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silatecan AR-67","termGroup":"PT","termSource":"NCI"},{"termName":"7-t-butyldimethylsilyl-10-hydroxycamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"7-Tert-butyldimethylsilyl-10-hydroxycamptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"AR-67","termGroup":"CN","termSource":"NCI"},{"termName":"DB-67","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220913-32-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3YEA04NV6H"},{"name":"Legacy Concept Name","value":"_7-Tert-butyldimethylsilyl-10-hydroxycamptothecin"},{"name":"Maps_To","value":"Silatecan AR-67"},{"name":"NCI_Drug_Dictionary_ID","value":"522726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"522726"},{"name":"PDQ_Open_Trial_Search_ID","value":"522726"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1955483"}]}}{"C152359":{"preferredName":"Silibinin","code":"C152359","synonyms":[{"termName":"Silibinin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1265089-69-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4RKY41TBTF"},{"name":"Maps_To","value":"Silibinin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0600334"}]}}{"C2651":{"preferredName":"Silicon Phthalocyanine 4","code":"C2651","definitions":[{"definition":"A substance being studied in the treatment of cancer. When absorbed by cancer cells and exposed to light, it becomes active and kills the cancer cells. It is a type of photodynamic therapy agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic photosensitizer agent containing a large macrocyclic ring chelated with silicon. Silicon phthalocyanine 4 localizes primarily in mitochondrial cytosolic membranes and, after photoexcitation, forms reactive oxygen species that induce apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silicon Phthalocyanine 4","termGroup":"PT","termSource":"NCI"},{"termName":"Pc-4 (Silicone phthalocyanine)","termGroup":"SY","termSource":"NCI"},{"termName":"Pc4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"135719-28-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VM2R9Z8DTW"},{"name":"Legacy Concept Name","value":"Silicon_Phthalocyanine_4"},{"name":"Maps_To","value":"Silicon Phthalocyanine 4"},{"name":"NCI_Drug_Dictionary_ID","value":"38423"},{"name":"NSC Number","value":"676418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38423"},{"name":"PDQ_Open_Trial_Search_ID","value":"38423"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328695"}]}}{"C85460":{"preferredName":"Silmitasertib Sodium","code":"C85460","definitions":[{"definition":"The sodium salt form of silmitasertib, an orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and immunomodulatory activities. Upon oral administration, silmitasertib selectively binds to and inhibits the activity of CK2. This may inhibit proliferation of CK2-expressing tumor cells, and may also inhibit the replication of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). In addition, this may restore normal host cell cytokine regulation, prevent cytokine storm and suppress the hyperactivation of the innate immune system. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. CK2 regulates a diverse array of pro-survival cellular processes including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT/mTOR signaling, hedgehog (Hh) signaling, Hsp90 machinery, hypoxia, and interleukin (IL)-6 expression. CK2 also regulates the activity of XRCC1 and MDC1, two mediator/adaptor proteins that are essential for DNA repair. CK2 is upregulated by SARS-COV-2 and is associated with SARS-COV-2 viral replication and the development of cytokine storm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Silmitasertib Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"5-((3-chlorophenyl)amino)-benzo(c)-2,6-naphthyridine-8-carboxylic Acid Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"CK2 Inhibitor CX-4945","termGroup":"SY","termSource":"NCI"},{"termName":"CX 4945 Sodium","termGroup":"CN","termSource":"NCI"},{"termName":"CX-4945 Sodium","termGroup":"CN","termSource":"NCI"},{"termName":"CX4945 Sodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1309357-15-0"},{"name":"Chemical_Formula","value":"C19H11ClN3O2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N1E607PU86"},{"name":"Maps_To","value":"Silmitasertib Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"643477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"643477"},{"name":"PDQ_Open_Trial_Search_ID","value":"643477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830136"}]}}{"C61084":{"preferredName":"Siltuximab","code":"C61084","definitions":[{"definition":"A chimeric (made from human and mouse proteins) monoclonal antibody being studied in the treatment of advanced kidney cancer and other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-IL-6 chimeric monoclonal antibody works by blocking inflammation and tumor growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Siltuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-6 Chimeric Monoclonal Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"cCLB8","termGroup":"SY","termSource":"NCI"},{"termName":"CNTO-328","termGroup":"CN","termSource":"NCI"},{"termName":"CNTO328","termGroup":"CN","termSource":"NCI"},{"termName":"Sylvant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"multicentric Castleman's disease (MCD)"},{"name":"CAS_Registry","value":"541502-14-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T4H8FMA7IM"},{"name":"Legacy Concept Name","value":"Anti-IL-6_Chimeric_Monoclonal_Antibody"},{"name":"Maps_To","value":"Siltuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"475765"},{"name":"NCI_META_CUI","value":"CL776663"},{"name":"PDQ_Closed_Trial_Search_ID","value":"475765"},{"name":"PDQ_Open_Trial_Search_ID","value":"475765"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1227":{"preferredName":"Simalikalactone D","code":"C1227","definitions":[{"definition":"A quassinoid phytochemical isolated from Simaba multiflora, Quassia africana and other plant species with potential antineoplastic activity.  This agent also has antimalarial and antiviral properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simalikalactone D","termGroup":"PT","termSource":"NCI"},{"termName":"Picras-3-ene-2,16-dione, 13,20-epoxy-1,11,12-trihydroxy-15-(2-methyl-1-oxobutoxy)-, (11beta)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"35321-80-3"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Simalikalactone_D"},{"name":"Maps_To","value":"Simalikalactone D"},{"name":"NSC Number","value":"266494"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074548"}]}}{"C129015":{"preferredName":"Simeprevir","code":"C129015","definitions":[{"definition":"An orally bioavailable inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with activity against HCV genotype 1. Upon administration, simeprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simeprevir","termGroup":"PT","termSource":"NCI"},{"termName":"HSDB 8227","termGroup":"CN","termSource":"NCI"},{"termName":"N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"Olysio","termGroup":"BR","termSource":"NCI"},{"termName":"TMC 435","termGroup":"CN","termSource":"NCI"},{"termName":"TMC-435","termGroup":"CN","termSource":"NCI"},{"termName":"TMC435","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"923604-59-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9WS5RD66HZ"},{"name":"Maps_To","value":"Simeprevir"},{"name":"NCI_Drug_Dictionary_ID","value":"783151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783151"},{"name":"PDQ_Open_Trial_Search_ID","value":"783151"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2605855"}]}}{"C116871":{"preferredName":"Simotaxel","code":"C116871","definitions":[{"definition":"A semi-synthetic, orally bioavailable, third-generation taxane derivative and microtubule-stabilizing agent, with potential antineoplastic activity. Upon administration, simotaxel binds to tubulin, promotes microtubule assembly and stabilization, and prevents microtubule depolymerization. This results in G2/M arrest, apoptosis and the inhibition of cell proliferation in susceptible tumor cells. This agent is a poor substrate for P-glycoprotein-related drug resistance mechanisms; therefore, it may be useful for treating multi-drug resistant tumors. MST-997 is more potent than paclitaxel and docetaxel and overcomes paclitaxel and docetaxel resistance in certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simotaxel","termGroup":"PT","termSource":"NCI"},{"termName":"5Beta,20-epoxy-1,2alpa,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one-4-acetate 2-benzoate Ester with (2R,3S)-N-Isopropoxycarbonyl-3-(2-thienyl) Isoserine","termGroup":"SN","termSource":"NCI"},{"termName":"MST-997","termGroup":"CN","termSource":"NCI"},{"termName":"Taxane-997","termGroup":"SY","termSource":"NCI"},{"termName":"TL-909","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"791635-59-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E1M30YOE59"},{"name":"Maps_To","value":"Simotaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"387809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"387809"},{"name":"PDQ_Open_Trial_Search_ID","value":"387809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541465"}]}}{"C91735":{"preferredName":"Simtuzumab","code":"C91735","definitions":[{"definition":"A humanized monoclonal antibody against lysyl oxidase-like 2 (LOXL2), with potential antineoplastic activity. Anti-LOXL2 monoclonal antibody GS 6624 targets and specifically binds to the scavenger receptor cysteine rich domain 4 (SRCR-4) on LOXL2, thereby preventing the crosslinking of collagen and inhibiting the recruitment and activation of fibroblasts. Inhibiting fibroblast activation and the subsequent production of growth factors and chemokines may lead to an inhibition of tumor cell proliferation. LOXL2, a member of the lysyl oxidase (LO) gene family, is an extracellular, copper-dependent enzyme overexpressed in a variety of tumor cell types, and contributes to tumor cell invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simtuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"AB-0024","termGroup":"CN","termSource":"NCI"},{"termName":"AB0024","termGroup":"CN","termSource":"NCI"},{"termName":"GS 6624","termGroup":"CN","termSource":"NCI"},{"termName":"GS-6624","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1318075-13-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"11Z5AIU653"},{"name":"Maps_To","value":"Simtuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"681814"},{"name":"NCI_META_CUI","value":"CL421656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681814"},{"name":"PDQ_Open_Trial_Search_ID","value":"681814"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C132992":{"preferredName":"Sintilimab","code":"C132992","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sintilimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody IBI308","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PDCD1 Monoclonal Antibody IBI308","termGroup":"SY","termSource":"NCI"},{"termName":"Daboshu","termGroup":"FB","termSource":"NCI"},{"termName":"IBI 308","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-308","termGroup":"CN","termSource":"NCI"},{"termName":"IBI308","termGroup":"CN","termSource":"NCI"},{"termName":"Tyvyt","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2072873-06-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8FU7FQ8UPK"},{"name":"Maps_To","value":"Sintilimab"},{"name":"NCI_Drug_Dictionary_ID","value":"787603"},{"name":"NCI_META_CUI","value":"CL520576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787603"},{"name":"PDQ_Open_Trial_Search_ID","value":"787603"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38685":{"preferredName":"Siplizumab","code":"C38685","definitions":[{"definition":"A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of certain lymphoproliferative disorders and psoriasis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Siplizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(human CD2 (Antigen))(Human-rat Monoclonal MEDI-507 G1-chain), Disulfide with Human-rat Monoclonal MEDI-507 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-507","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"T-cell lymphoma"},{"name":"CAS_Registry","value":"288392-69-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KUW1QG1ZM3"},{"name":"Legacy Concept Name","value":"Siplizumab"},{"name":"Maps_To","value":"Siplizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"346499"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346499"},{"name":"PDQ_Open_Trial_Search_ID","value":"346499"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328709"}]}}{"C1985":{"preferredName":"Sipuleucel-T","code":"C1985","definitions":[{"definition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A drug used to treat prostate cancer that has spread. It is made from immune system cells collected from a patient with prostate cancer. The cells are treated with a protein that is made by combining a protein found on prostate cancer cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate cancer cells. Provenge is a type of vaccine and a type of cellular adoptive immunotherapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sipuleucel-T","termGroup":"PT","termSource":"NCI"},{"termName":"APC 8015","termGroup":"CN","termSource":"NCI"},{"termName":"APC-8015","termGroup":"CN","termSource":"NCI"},{"termName":"APC8015","termGroup":"CN","termSource":"NCI"},{"termName":"APC8015 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Provenge","termGroup":"BR","termSource":"NCI"},{"termName":"SipT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917381-47-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"8Q622VDR18"},{"name":"Legacy Concept Name","value":"APC8015_Vaccine"},{"name":"Maps_To","value":"Sipuleucel-T"},{"name":"NCI_Drug_Dictionary_ID","value":"38038"},{"name":"NSC Number","value":"720270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38038"},{"name":"PDQ_Open_Trial_Search_ID","value":"38038"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1706668"}]}}{"C116353":{"preferredName":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401","code":"C116353","definitions":[{"definition":"Autologous peripheral blood mononuclear cells (PBMCs) transfected ex vivo with small-interfering ribonucleic acid (siRNA) directed against the E3 ubiquitin ligase casitas B-lineage lymphoma-b gene (Cbl-b), with potential immunoactivating and antineoplastic activities. The Cbl-b gene is silenced ex vivo through the binding of Cbl-b siRNA to Cbl-b mRNA, which prevents the translation of the Cbl-b protein in T-lymphocytes. Upon infusion, the activated, Cbl-b-silenced T-lymphocytes are able to increase the production of cytokines, proliferate and activate the immune system, which leads to cancer cell eradication. Cbl-b, a negative regulator of the immune system, is mutated in a variety of cancer cell types. Its expression is inversely correlated with activation of T-lymphocytes and tumor cell eradication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401","termGroup":"PT","termSource":"NCI"},{"termName":"APN401","termGroup":"CN","termSource":"NCI"},{"termName":"siRNA-transfected PBMC APN401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"siRNA-transfected Peripheral Blood Mononuclear Cells APN401"},{"name":"NCI_Drug_Dictionary_ID","value":"761870"},{"name":"NCI_META_CUI","value":"CL473671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761870"},{"name":"PDQ_Open_Trial_Search_ID","value":"761870"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1212":{"preferredName":"Sirolimus","code":"C1212","definitions":[{"definition":"A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamune blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamune was previously called rapamycin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirolimus","termGroup":"PT","termSource":"NCI"},{"termName":"9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2","termGroup":"SN","termSource":"NCI"},{"termName":"AY 22989","termGroup":"CN","termSource":"NCI"},{"termName":"AY-22989","termGroup":"CN","termSource":"NCI"},{"termName":"AY22989","termGroup":"CN","termSource":"NCI"},{"termName":"RAPA","termGroup":"AB","termSource":"NCI"},{"termName":"Rapamune","termGroup":"BR","termSource":"NCI"},{"termName":"Rapamycin","termGroup":"SY","termSource":"NCI"},{"termName":"SILA 9268A","termGroup":"CN","termSource":"NCI"},{"termName":"SILA-9268A","termGroup":"CN","termSource":"NCI"},{"termName":"SILA9268A","termGroup":"CN","termSource":"NCI"},{"termName":"WY 090217","termGroup":"CN","termSource":"NCI"},{"termName":"WY-090217","termGroup":"CN","termSource":"NCI"},{"termName":"WY090217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Kidney transplant rejection, prevention"},{"name":"CAS_Registry","value":"53123-88-9"},{"name":"CHEBI_ID","value":"CHEBI:9168"},{"name":"Chemical_Formula","value":"C51H79NO13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"W36ZG6FT64"},{"name":"Legacy Concept Name","value":"Sirolimus"},{"name":"Maps_To","value":"Sirolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"42555"},{"name":"NSC Number","value":"226080"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42555"},{"name":"PDQ_Open_Trial_Search_ID","value":"42555"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0072980"}]}}{"C125718":{"preferredName":"Ontorpacept","code":"C125718","definitions":[{"definition":"A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ontorpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ontorpacept","termGroup":"PT","termSource":"NCI"},{"termName":"SIRPa-Fc Fusion Protein TTI-621","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPaFc","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 621","termGroup":"CN","termSource":"NCI"},{"termName":"TTI-621","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2131089-46-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q8A4U1Z9N2"},{"name":"Maps_To","value":"Ontorpacept"},{"name":"Maps_To","value":"SIRPa-Fc Fusion Protein TTI-621"},{"name":"NCI_META_CUI","value":"CL504374"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150756":{"preferredName":"Maplirpacept","code":"C150756","definitions":[{"definition":"A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, maplirpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maplirpacept","termGroup":"PT","termSource":"NCI"},{"termName":"PF 07901801","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07901801","termGroup":"CN","termSource":"NCI"},{"termName":"PF07901801","termGroup":"CN","termSource":"NCI"},{"termName":"SIRPa-IgG4 Fc","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-IgG4 Fc TTI-622","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-IgG4-Fc Fusion Protein TTI-622","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 622","termGroup":"CN","termSource":"NCI"},{"termName":"TTI-622","termGroup":"CN","termSource":"NCI"},{"termName":"TTI622","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44D51T6SZH"},{"name":"Maps_To","value":"SIRPa-IgG4-Fc Fusion Protein TTI-622"},{"name":"NCI_Drug_Dictionary_ID","value":"793524"},{"name":"NCI_META_CUI","value":"CL552621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793524"},{"name":"PDQ_Open_Trial_Search_ID","value":"793524"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162553":{"preferredName":"Sitimagene Ceradenovec","code":"C162553","definitions":[{"definition":"A replication-deficient adenovirus type 5 (Ad5) with E1 and partial E3 deletions containing cDNA for the herpes simplex virus thymidine kinase (HSV-Tk), which, when administered in combination with ganciclovir (GCV), possesses potential antineoplastic activity. Following administration, transgene-expressing cells produce thymidine kinase, which phosphorylates GCV to ganciclovir triphosphate, a cytotoxic nucleotide analog that is incorporated into DNA resulting in chain termination and induction of apoptosis in rapidly dividing cells. This process spares normal neurons as they do not proliferate and are therefore not susceptible to the toxic effects of GCV metabolites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sitimagene Ceradenovec","termGroup":"PT","termSource":"NCI"},{"termName":"EG 009","termGroup":"CN","termSource":"NCI"},{"termName":"EG-009","termGroup":"CN","termSource":"NCI"},{"termName":"EG009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"898830-54-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sitimagene Ceradenovec"},{"name":"NCI_META_CUI","value":"CL971128"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C117734":{"preferredName":"Sitravatinib","code":"C117734","definitions":[{"definition":"An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, sitravatinib binds to and inhibits the activity of several RTKs including hepatocyte growth factor receptor (HGFR; c-Met; MET), tyrosine-protein kinase receptor UFO (AXL receptor tyrosine kinase; AXL), mast/stem cell growth factor receptor (SCFR; c-kit; KIT), the receptor tyrosine kinase MER, discoidin domain receptor 2 (DDR2), vascular endothelial growth factor receptor (VEGFR) types 1 (VEGFR-1; FLT1), 2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3), members of the platelet-derived growth factor receptor (PDGFR) family, RET (rearranged during transfection), tropomyosin-related kinases (TRK) and members of the ephrin (Eph) family of receptor tyrosine kinases. This may result in both the inhibition of signal transduction pathways mediated by these RTKs and the reduction of tumor cell proliferation in cancer cell types that overexpress these RTKs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sitravatinib","termGroup":"PT","termSource":"NCI"},{"termName":"1,1-Cyclopropanedicarboxamide, N-(3-Fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-N'-(4-fluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"MGCD516","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1123837-84-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CWG62Q1VTB"},{"name":"Maps_To","value":"Sitravatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"764051"},{"name":"NCI_META_CUI","value":"CL474129"},{"name":"PDQ_Closed_Trial_Search_ID","value":"764051"},{"name":"PDQ_Open_Trial_Search_ID","value":"764051"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61305":{"preferredName":"Sivifene","code":"C61305","definitions":[{"definition":"The phenylhydrazone 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone formulated as a topical agent with immunomodulating and potential antineoplastic activities. Applied topically as a gel, sivifene may stimulate a local immune response against human papillomavirus (HPV)-induced cervical intraepithelial neoplasia (CIN).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sivifene","termGroup":"PT","termSource":"NCI"},{"termName":"4,4'-Dihydroxybenzophenone 2,4-dinitrophenylhydrazone","termGroup":"SY","termSource":"NCI"},{"termName":"A-007","termGroup":"AB","termSource":"NCI"},{"termName":"Aryl Hydrazone A-007 Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2675-35-6"},{"name":"Chemical_Formula","value":"C19H14N4O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XAV05295I5"},{"name":"Legacy Concept Name","value":"A-007"},{"name":"Maps_To","value":"Sivifene"},{"name":"NCI_Drug_Dictionary_ID","value":"485274"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485274"},{"name":"PDQ_Open_Trial_Search_ID","value":"485274"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0385861"}]}}{"C824":{"preferredName":"Sizofiran","code":"C824","definitions":[{"definition":"A soluble beta-D-glucan produced by the Basidiomycetes fungus, Schizophyllum commune Fries, with potential immunomodulating and antitumor activities. Although sizofiran's exact mechanism of action has yet to be fully elucidated, this agent appears to stimulate the immune system by increasing cytokine production, activating macrophages and enhancing the activity of polymorphonuclear leukocytes (PML) and natural killer (NK) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sizofiran","termGroup":"PT","termSource":"NCI"},{"termName":"MC-Glucan","termGroup":"BR","termSource":"NCI"},{"termName":"Poly(3-(O-beta-D-glucopyranosyl-(1-3)-O-(beta-D-glucopyranosyl-(1-6))-O-beta-D-glucopyranosyl-(1-3)-O-beta-D-glucopyranosyl)-1)","termGroup":"SN","termSource":"NCI"},{"termName":"Schizophyllan","termGroup":"BR","termSource":"NCI"},{"termName":"Schizophyllan","termGroup":"SY","termSource":"NCI"},{"termName":"Schizophyllane","termGroup":"SY","termSource":"NCI"},{"termName":"Sixofilan","termGroup":"BR","termSource":"NCI"},{"termName":"Sonifilan","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9050-67-3"},{"name":"CHEBI_ID","value":"CHEBI:50653"},{"name":"Chemical_Formula","value":"(C24H38O19)n"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7F763NNC9X"},{"name":"Legacy Concept Name","value":"Sizofiran"},{"name":"Maps_To","value":"Sizofiran"},{"name":"NCI_Drug_Dictionary_ID","value":"752996"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752996"},{"name":"PDQ_Open_Trial_Search_ID","value":"752996"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0036359"}]}}{"C153354":{"preferredName":"Ompenaclid","code":"C153354","definitions":[{"definition":"An orally available, small molecule inhibitor of the creatine transporter, solute carrier family 6, member 8 (SLC6a8), with potential antineoplastic activity. Upon oral administration, ompenaclid inhibits phosphocreatine uptake by SLC6a8, thereby reducing intracellular levels of phosphocreatine available for ATP synthesis in tumor cells. SLC6a8 is overexpressed in some cancer types and inhibition of its activity may potentially limit tumor cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ompenaclid","termGroup":"PT","termSource":"NCI"},{"termName":"RGX 202","termGroup":"CN","termSource":"NCI"},{"termName":"RGX-202","termGroup":"CN","termSource":"NCI"},{"termName":"RGX-202-01","termGroup":"CN","termSource":"NCI"},{"termName":"RGX202","termGroup":"CN","termSource":"NCI"},{"termName":"SLC6A8 Inhibitor RGX-202","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"353-09-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UL1984YRKA"},{"name":"Maps_To","value":"SLC6A8 Inhibitor RGX-202"},{"name":"NCI_Drug_Dictionary_ID","value":"794147"},{"name":"NCI_META_CUI","value":"CL554455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794147"},{"name":"PDQ_Open_Trial_Search_ID","value":"794147"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C184909":{"preferredName":"Ezurpimtrostat","code":"C184909","definitions":[{"definition":"An orally bioavailable, quinolone-derived, small molecule inhibitor of palmitoyl-protein thioesterase 1 (PPT1), with potential antineoplastic activity. Upon oral administration, ezurpimtrostat targets and inhibits the activity of PPT1 and induces lysosomal disruption, which results in the inhibition of autophagy and the induction of apoptosis via caspase activation. This may inhibit tumor cell proliferation and tumor growth. PPT1, a lysosomal thioesterase that plays an important role in lysosomal function and autophagy, is overexpressed in certain cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ezurpimtrostat","termGroup":"PT","termSource":"NCI"},{"termName":"GNS 561","termGroup":"CN","termSource":"NCI"},{"termName":"GNS-561","termGroup":"CN","termSource":"NCI"},{"termName":"GNS561","termGroup":"CN","termSource":"NCI"},{"termName":"SLCT Inhibitor GNS561","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1914148-72-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MS6LGW5JFK"},{"name":"Maps_To","value":"SLCT Inhibitor GNS561"},{"name":"NCI_Drug_Dictionary_ID","value":"794352"},{"name":"NCI_META_CUI","value":"CL555353"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150507":{"preferredName":"SMAC Mimetic BI 891065","code":"C150507","definitions":[{"definition":"A mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins), with potential antineoplastic activity. Upon administration, Smac mimetic BI 891065 targets and binds to the Smac binding groove on IAPs, including the caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting certain caspases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMAC Mimetic BI 891065","termGroup":"PT","termSource":"NCI"},{"termName":"BI 891065","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SMAC Mimetic BI 891065"},{"name":"NCI_Drug_Dictionary_ID","value":"793013"},{"name":"NCI_META_CUI","value":"CL552291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793013"},{"name":"PDQ_Open_Trial_Search_ID","value":"793013"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88274":{"preferredName":"Smac Mimetic GDC-0152","code":"C88274","definitions":[{"definition":"A second mitochondrial activator of caspases (Smac) mimetic inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0152 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2, which may inhibit their activities and promote the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains. Smac, the endogenous IAP antagonist, relies on its N-terminal four amino-acid motif for binding to IAPs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smac Mimetic GDC-0152","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0152","termGroup":"CN","termSource":"NCI"},{"termName":"IAP Antagonist GDC-0152","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"873652-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4KW1M48SHS"},{"name":"Maps_To","value":"Smac Mimetic GDC-0152"},{"name":"NCI_Drug_Dictionary_ID","value":"655953"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655953"},{"name":"PDQ_Open_Trial_Search_ID","value":"655953"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981796"}]}}{"C103825":{"preferredName":"Smac Mimetic GDC-0917","code":"C103825","definitions":[{"definition":"An orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0917 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smac Mimetic GDC-0917","termGroup":"PT","termSource":"NCI"},{"termName":"CUDC 427","termGroup":"CN","termSource":"NCI"},{"termName":"CUDC-427","termGroup":"CN","termSource":"NCI"},{"termName":"CUDC427","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0917","termGroup":"CN","termSource":"NCI"},{"termName":"IAP Antagonist GDC-0917","termGroup":"SY","termSource":"NCI"},{"termName":"L-Prolinamide, N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-(2-(2-oxazolyl)-4-phenyl-5-thiazolyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"RG 7459","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7459","termGroup":"CN","termSource":"NCI"},{"termName":"RG7459","termGroup":"CN","termSource":"NCI"},{"termName":"SMAC/DIABLO Mimetic GDC-0917","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1446182-94-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KWH46ZDG32"},{"name":"Maps_To","value":"Smac Mimetic GDC-0917"},{"name":"NCI_Drug_Dictionary_ID","value":"688091"},{"name":"NCI_META_CUI","value":"CL433733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688091"},{"name":"PDQ_Open_Trial_Search_ID","value":"688091"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91079":{"preferredName":"Smac Mimetic LCL161","code":"C91079","definitions":[{"definition":"An orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity. SMAC mimetic LCL161 binds to IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding and inhibiting active caspases-3, -7 and -9, which play essential roles in apoptosis (programmed cell death), necrosis and inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smac Mimetic LCL161","termGroup":"PT","termSource":"NCI"},{"termName":"LCL161","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005342-46-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6TNS415Y3P"},{"name":"Maps_To","value":"Smac Mimetic LCL161"},{"name":"NCI_Drug_Dictionary_ID","value":"670651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670651"},{"name":"PDQ_Open_Trial_Search_ID","value":"670651"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984020"}]}}{"C159535":{"preferredName":"SMO Protein Inhibitor ZSP1602","code":"C159535","definitions":[{"definition":"An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SMO Protein Inhibitor ZSP1602","termGroup":"PT","termSource":"NCI"},{"termName":"Smoothened Inhibitor ZSP1602","termGroup":"SY","termSource":"NCI"},{"termName":"ZSP 1602","termGroup":"CN","termSource":"NCI"},{"termName":"ZSP-1602","termGroup":"CN","termSource":"NCI"},{"termName":"ZSP1602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Smoothened_Antagonist_BMS-833923"},{"name":"Maps_To","value":"SMO Protein Inhibitor ZSP1602"},{"name":"NCI_Drug_Dictionary_ID","value":"797467"},{"name":"NCI_META_CUI","value":"CL951429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797467"},{"name":"PDQ_Open_Trial_Search_ID","value":"797467"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77861":{"preferredName":"Smoothened Antagonist BMS-833923","code":"C77861","definitions":[{"definition":"An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist BMS-833923","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-833923","termGroup":"CN","termSource":"NCI"},{"termName":"Smoothened Antagonist BMS-833923","termGroup":"SY","termSource":"NCI"},{"termName":"XL139","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"483ONS63WN"},{"name":"Legacy Concept Name","value":"Smoothened_Antagonist_BMS-833923"},{"name":"Maps_To","value":"Smoothened Antagonist BMS-833923"},{"name":"NCI_Drug_Dictionary_ID","value":"596304"},{"name":"PDQ_Closed_Trial_Search_ID","value":"596304"},{"name":"PDQ_Open_Trial_Search_ID","value":"596304"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699316"}]}}{"C88337":{"preferredName":"Smoothened Antagonist LDE225 Topical","code":"C88337","definitions":[{"definition":"A topical formulation of the small-molecule Smoothened (Smo) antagonist LDE225 with potential antineoplastic activity. Upon topical application, smoothened antagonist LDE225 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist LDE225 Topical","termGroup":"PT","termSource":"NCI"},{"termName":"LDE225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoothened Antagonist LDE225 Topical"},{"name":"NCI_Drug_Dictionary_ID","value":"662542"},{"name":"NCI_META_CUI","value":"CL413601"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662542"},{"name":"PDQ_Open_Trial_Search_ID","value":"662542"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91089":{"preferredName":"Smoothened Antagonist LEQ506","code":"C91089","definitions":[{"definition":"An orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Smoothened antagonist LEQ506 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway, thereby inhibiting tumor cell growth. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Dysregulated activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist LEQ506","termGroup":"PT","termSource":"NCI"},{"termName":"LEQ506","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1204975-42-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6SJX1T5HJD"},{"name":"Maps_To","value":"Smoothened Antagonist LEQ506"},{"name":"NCI_Drug_Dictionary_ID","value":"671850"},{"name":"NCI_META_CUI","value":"CL421477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"671850"},{"name":"PDQ_Open_Trial_Search_ID","value":"671850"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116874":{"preferredName":"Smoothened Antagonist TAK-441","code":"C116874","definitions":[{"definition":"An orally bioavailable pyrrolopyridine derivative and Smoothened (Smo) antagonist with potential antineoplastic activity. Smo antagonist TAK-441 selectively binds to and inhibits the activity Smo, which is a cell surface co-receptor for ligands in the Hedgehog (Hh) family. This may result in a suppression of Hh-mediated signaling pathways, thereby inhibiting the growth of tumor cells in which this pathway is aberrantly activated.  Smo is a G-protein coupled receptor that lies just downstream of the Hh cell surface receptor Patched-1 in the Hh pathway; in the absence of ligand, Patched-1 (Ptch1) inhibits Smo, and ligand binding to Ptch1 results in increased levels of Smo. The Hh-mediated signaling pathways play an important role in cellular growth and differentiation, and tissue repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoothened Antagonist TAK-441","termGroup":"PT","termSource":"NCI"},{"termName":"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"TAK-441","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1186231-83-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CY3QT94KWP"},{"name":"Maps_To","value":"Smoothened Antagonist TAK-441"},{"name":"NCI_Drug_Dictionary_ID","value":"686270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"686270"},{"name":"PDQ_Open_Trial_Search_ID","value":"686270"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660685"}]}}{"C71521":{"preferredName":"SN-38-Loaded Polymeric Micelles NK012","code":"C71521","definitions":[{"definition":"A formulation consisting of polymeric micelles loaded with the irinotecan metabolite SN-38 with potential antineoplastic activity. SN-38-loaded polymeric micelles NK012 is an SN-38-releasing nanodevice constructed by covalently attaching SN-38 to the block copolymer PEG-PGlu, followed by self-assembly of amphiphilic block copolymers in an aqueous milieu. SN-38 (7-ethyl-10-hydroxy-camptothecin), a biological active metabolite of the prodrug irinotecan (CPT-11), binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. SN-38 has been reported to exhibit up to 1,000-fold more cytotoxic activity against various cancer cells in vitro than irinotecan. This formulation increases the water-solubility of SN-38 and allows the delivery of higher doses of SN-38 than those achievable with SN-38 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SN-38-Loaded Polymeric Micelles NK012","termGroup":"PT","termSource":"NCI"},{"termName":"NK012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SN-38-Loaded_Polymeric_Micelle"},{"name":"Maps_To","value":"SN-38-Loaded Polymeric Micelles NK012"},{"name":"NCI_Drug_Dictionary_ID","value":"574615"},{"name":"NCI_META_CUI","value":"CL376227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574615"},{"name":"PDQ_Open_Trial_Search_ID","value":"574615"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C98288":{"preferredName":"SNS01-T Nanoparticles","code":"C98288","definitions":[{"definition":"A colloidal mixture of nanoparticles consisting of small interfering RNA (siRNA) targeting the native eukaryotic translation initiation factor 5A (eIF5A), plasmids expressing a pro-apoptotic mutant of elF5A under the control of a B-cell specific promoter (B29), and a synthetic cationic polymer polyethylenimine (PEI) as a delivery vehicle, with potential antineoplastic activity. Upon administration, the siRNA component of SNS01-T suppresses elF5A expression, thereby interfering with translation of eIF5A and reducing levels of hypusinated elF5A in cancer cells. In turn, this inhibits activation of the transcription factor NF-kB and induces apoptosis. In addition, the B-cell specific plasmid component expresses an arginine substituted form of eIF5A, eIF5AK50R, which can not be hypusinated, thus leads to a selective induction of apoptosis in B-cells. The native unhypusinated form of eIF5A is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (DHS) and subsequently deoxyhypusine hydroxylase (DHH), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. The delivery vehicle protects the siRNA and plasmid from degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SNS01-T Nanoparticles","termGroup":"PT","termSource":"NCI"},{"termName":"SNS01-T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SNS01-T Nanoparticles"},{"name":"NCI_Drug_Dictionary_ID","value":"712786"},{"name":"NCI_META_CUI","value":"CL432406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"712786"},{"name":"PDQ_Open_Trial_Search_ID","value":"712786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66540":{"preferredName":"Sobuzoxane","code":"C66540","definitions":[{"definition":"The orally available active prodrug of ICRF-154, a bisdioxopiperazine derivative, with cardioprotective and antineoplastic activities. Like other ICRF compounds, sobuzoxane and its active metabolite ICRF-154 interfere with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition. Furthermore, sobuzoxane chelates metal cations thereby limiting the formation of free radical-generating anthracycline-metal complexes and may prevent anthracycline-induced oxidative damage to cardiac and soft tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sobuzoxane","termGroup":"PT","termSource":"NCI"},{"termName":"1,2-Bis(4-isobutoxycarbonyloxymethyl-3,5-dioxo-piperazin-1-yl)ethane","termGroup":"SN","termSource":"NCI"},{"termName":"MST-16","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"98631-95-9"},{"name":"Chemical_Formula","value":"C22H34N4O10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1308VH37P"},{"name":"Legacy Concept Name","value":"Sobuzoxane"},{"name":"Maps_To","value":"Sobuzoxane"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0378253"}]}}{"C2208":{"preferredName":"Sodium Borocaptate","code":"C2208","definitions":[{"definition":"A boron-carrying compound. After parenteral administration, sodium borocaptate accumulates preferentially in tumor cells. When exposed to neutron irradiation, borocaptate absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance used in a type of radiation therapy called boron neutron capture therapy. Sodium borocaptate is injected into a vein and becomes concentrated in tumor cells. The patient then receives radiation treatment with atomic particles called neutrons. The neutrons react with the boron in sodium borocaptate and make radioactive particles that kill the tumor cells without harming normal cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sodium Borocaptate","termGroup":"PT","termSource":"NCI"},{"termName":"Borocaptate Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Borocarpin","termGroup":"FB","termSource":"NCI"},{"termName":"BSH","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80-17-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Borocaptate_Sodium"},{"name":"Maps_To","value":"Sodium Borocaptate"},{"name":"NCI_Drug_Dictionary_ID","value":"306451"},{"name":"NSC Number","value":"643"},{"name":"PDQ_Closed_Trial_Search_ID","value":"306451"},{"name":"PDQ_Open_Trial_Search_ID","value":"306451"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0127575"}]}}{"C2337":{"preferredName":"Sodium Butyrate","code":"C2337","definitions":[{"definition":"The sodium salt of butyrate with potential antineoplastic activity. Butyrate, a short chain fatty acid, competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). This binding affects hyperacetylation of histones, resulting in a modified DNA conformation, which subsequently leads to the uncoiling or relaxing of chromatin. Enhanced accessibility of chromatin to transcription-regulatory complexes leads to increased transcriptional activation of various epigenetically suppressed genes. Butyrate, a HDAC inhibitor, induces cell cycle arrest in G1 or G2/M and also increases the expression of other genes and proteins involved in cellular differentiation and apoptotic signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Butyrate","termGroup":"PT","termSource":"NCI"},{"termName":"Butyrate","termGroup":"SY","termSource":"NCI"},{"termName":"butyric acid, sodium salt","termGroup":"SY","termSource":"NCI"},{"termName":"sodium butanoate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156-54-7"},{"name":"CHEBI_ID","value":"CHEBI:64103"},{"name":"Chemical_Formula","value":"C4H7O2.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8RAS91C36W"},{"name":"Legacy Concept Name","value":"Sodium_Butyrate"},{"name":"Maps_To","value":"Sodium Butyrate"},{"name":"NCI_Drug_Dictionary_ID","value":"39601"},{"name":"NSC Number","value":"174280"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39601"},{"name":"PDQ_Open_Trial_Search_ID","value":"39601"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0142812"}]}}{"C73591":{"preferredName":"Sodium Dichloroacetate","code":"C73591","definitions":[{"definition":"The sodium salt of dichloroacetic acid with potential antineoplastic activity. Dichloroacetate ion inhibits pyruvate dehydrogenase kinase, resulting in the inhibition of glycolysis and a decrease in lactate production. This agent may stimulate apoptosis in cancer cells by restoring normal mitochondrial-induced apoptotic signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Dichloroacetate","termGroup":"PT","termSource":"NCI"},{"termName":"CPC 211","termGroup":"CN","termSource":"NCI"},{"termName":"Dichloroacetic Acid, Sodium Salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2156-56-1"},{"name":"Chemical_Formula","value":"C2HCl2O2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42932X67B5"},{"name":"Legacy Concept Name","value":"Sodium_Dichloroacetate"},{"name":"Maps_To","value":"Sodium Dichloroacetate"},{"name":"NCI_Drug_Dictionary_ID","value":"582893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"582893"},{"name":"PDQ_Open_Trial_Search_ID","value":"582893"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0037501"}]}}{"C47725":{"preferredName":"Sodium Iodide I-131","code":"C47725","definitions":[{"definition":"A radiopharmaceutical containing the beta- and gamma-emitting radioisotope I-131. After absorption, the iodide is distributed through the extracellular fluid of the body and accumulates in the thyroid gland, thereby allowing the imaging of the thyroid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Iodide I-131","termGroup":"PT","termSource":"NCI"},{"termName":"(131-I)Sodium Iodide","termGroup":"SY","termSource":"NCI"},{"termName":"HICON","termGroup":"BR","termSource":"NCI"},{"termName":"I 131 Mini","termGroup":"SY","termSource":"NCI"},{"termName":"Iodotope I-131","termGroup":"SY","termSource":"NCI"},{"termName":"Natrium Radio-iodatum(131 I)","termGroup":"SY","termSource":"NCI"},{"termName":"Oriodide","termGroup":"SY","termSource":"NCI"},{"termName":"Radiocaps-131","termGroup":"SY","termSource":"NCI"},{"termName":"Sodium Iodide (131I)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7790-26-3"},{"name":"Chemical_Formula","value":"I.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29VCO8ACHH"},{"name":"Legacy Concept Name","value":"Sodium_Iodide_I-131"},{"name":"Maps_To","value":"Sodium Iodide I-131"},{"name":"NCI_Drug_Dictionary_ID","value":"721984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721984"},{"name":"PDQ_Open_Trial_Search_ID","value":"721984"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0304982"}]}}{"C91098":{"preferredName":"Sodium Metaarsenite","code":"C91098","definitions":[{"definition":"A highly soluble, orally available trivalent arsenic-containing telomerase inhibitor with potential antitumor activity. Although the exact mechanism through which sodium metaarsenite exerts its effect has yet to be fully elucidated, this agent appears to target and bind to telomeric sequences, specifically TTAGGG repeats, leading to a shortening of telomeres, and subsequent induction of apoptosis and inhibition of tumor cell growth. In addition, sodium metaarsenite also leads to the translocation of the catalytic subunit of telomerase into the cytoplasm and inhibition of the activity of telomerase. Telomerase is active in most tumors cells and is responsible for the maintenance of telomere length and plays a key role in cellular proliferation, but is quiescent in normal, healthy cells. The susceptibility to sodium metaarsenite seems to be inversely correlated with initial length of telomeres.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Metaarsenite","termGroup":"PT","termSource":"NCI"},{"termName":"KML-001","termGroup":"CN","termSource":"NCI"},{"termName":"Sodium Arsenite","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7784-46-5"},{"name":"CHEBI_ID","value":"CHEBI:29678"},{"name":"Chemical_Formula","value":"AsO2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"48OVY2OC72"},{"name":"Maps_To","value":"Sodium Metaarsenite"},{"name":"NCI_Drug_Dictionary_ID","value":"672554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"672554"},{"name":"PDQ_Open_Trial_Search_ID","value":"672554"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0074719"}]}}{"C1440":{"preferredName":"Sodium Phenylbutyrate","code":"C1440","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called differentiating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Phenylbutyrate","termGroup":"PT","termSource":"NCI"},{"termName":"4-Phenylbutyric Acid, Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Buphenyl","termGroup":"BR","termSource":"NCI"},{"termName":"Phenylbutyrate Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Sodium 4-Phenylbutyrate","termGroup":"SN","termSource":"NCI"},{"termName":"SPB11","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Adjunctive therapy for urea cycle disorders involving deficiencies of carbamoylphosphate synthetase; ornithine transcarbamylase; or argininosuccinic acid synthetase; S-S and S-C sickle cell disease; S-thalassemia hemoglobinopathy"},{"name":"CAS_Registry","value":"1716-12-7"},{"name":"Chemical_Formula","value":"C10H11O2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NT6K61736T"},{"name":"Legacy Concept Name","value":"_4-Phenylbutyrate"},{"name":"Maps_To","value":"Sodium Phenylbutyrate"},{"name":"NCI_Drug_Dictionary_ID","value":"536018"},{"name":"NSC Number","value":"657802"},{"name":"PDQ_Closed_Trial_Search_ID","value":"536018"},{"name":"PDQ_Open_Trial_Search_ID","value":"536018"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0718066"}]}}{"C834":{"preferredName":"Sodium Salicylate","code":"C834","definitions":[{"definition":"A drug that is a type of nonsteroidal anti-inflammatory drug. Sodium salicylate may be tolerated by people who are sensitive to aspirin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of salicylic acid. As a nonsteroidal anti-inflammatory drug (NSAID), sodium salicylate irreversibly acetylates cyclooxygenases I and II, thereby inhibiting prostaglandin synthesis and associated inflammation and pain.  This agent may also activate mitogen-activated protein kinase (p38MAPK), thereby inducing apoptosis in cancer cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Salicylate","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic acid, 2-hydroxy-, monosodium salt","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Fever; Inflammatory conditions; Pain"},{"name":"CAS_Registry","value":"54-21-7"},{"name":"Chemical_Formula","value":"C7H5O3.Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WIQ1H85SYP"},{"name":"Legacy Concept Name","value":"Sodium_Salicylate"},{"name":"Maps_To","value":"Sodium Salicylate"},{"name":"NCI_Drug_Dictionary_ID","value":"43094"},{"name":"NSC Number","value":"202167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43094"},{"name":"PDQ_Open_Trial_Search_ID","value":"43094"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0037549"}]}}{"C87346":{"preferredName":"Sodium Selenite","code":"C87346","definitions":[{"definition":"An inorganic form of the trace element selenium with potential antineoplastic activity. Selenium, administered in the form of sodium selenite, is reduced to hydrogen selenide (H2Se) in the presence of glutathione (GSH) and subsequently generates superoxide radicals upon reaction with oxygen. This may inhibit the expression and activity of the transcription factor Sp1; in turn Sp1 down-regulates androgen receptor (AR) expression and blocks AR signaling. Eventually, selenium may induce apoptosis in prostate cancer cells and inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Selenite","termGroup":"PT","termSource":"NCI"},{"termName":"Disodium Selenium Trioxide","termGroup":"SY","termSource":"NCI"},{"termName":"Selenious Acid Disodium Salt","termGroup":"SY","termSource":"NCI"},{"termName":"Selenious Acid, Sodium Salt (1:2)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10102-18-8"},{"name":"CHEBI_ID","value":"CHEBI:48843"},{"name":"Chemical_Formula","value":"2Na.O3Se"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HIW548RQ3W"},{"name":"Maps_To","value":"Sodium Selenite"},{"name":"NCI_Drug_Dictionary_ID","value":"681583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681583"},{"name":"PDQ_Open_Trial_Search_ID","value":"681583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0142923"}]}}{"C61083":{"preferredName":"Sodium Stibogluconate","code":"C61083","definitions":[{"definition":"A substance being studied in the treatment of certain solid tumors, lymphoma, and myeloma. Sodium stibogluconate may block enzymes needed for cancer growth. It is a type of pentavalent antimonial.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phosphorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Stibogluconate","termGroup":"PT","termSource":"NCI"},{"termName":"Antimony Sodium Gluconate","termGroup":"SY","termSource":"NCI"},{"termName":"Lenocta","termGroup":"BR","termSource":"NCI"},{"termName":"Myostibin","termGroup":"FB","termSource":"NCI"},{"termName":"Pentostam","termGroup":"FB","termSource":"NCI"},{"termName":"Solustibosan","termGroup":"FB","termSource":"NCI"},{"termName":"Solustin","termGroup":"FB","termSource":"NCI"},{"termName":"SSG","termGroup":"AB","termSource":"NCI"},{"termName":"VQD001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12001-86-4"},{"name":"CAS_Registry","value":"16037-91-5"},{"name":"CHEBI_ID","value":"CHEBI:28148"},{"name":"Chemical_Formula","value":"C12H18O17Sb2.2Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V083S0159D"},{"name":"Legacy Concept Name","value":"Sodium_Stibogluconate"},{"name":"Maps_To","value":"Sodium Stibogluconate"},{"name":"NCI_Drug_Dictionary_ID","value":"475763"},{"name":"PDQ_Closed_Trial_Search_ID","value":"475763"},{"name":"PDQ_Open_Trial_Search_ID","value":"475763"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0030895"}]}}{"C156728":{"preferredName":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108","code":"C156728","definitions":[{"definition":"A small-molecule, inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with potential antineoplastic activity. Upon administration, RX108 inhibits the activity of the Na+/K+-ATPase, which prevents the activation of various signal transduction pathways that play a key role in tumor proliferation. This may lead to cell-cycle arrest, apoptosis, and autophagic cell death. Na+/K+-ATPase is overexpressed in certain tumor types and may serve as a scaffold for the assembly of multiple-protein signaling complexes that regulate cell proliferation and motility. In normal, healthy cells, the Na+/K+-ATPase controls transportation of Na+ and K+ across the cell membrane and is essential for electrochemical gradient maintenance, osmotic balance, and cellular pH.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108","termGroup":"PT","termSource":"NCI"},{"termName":"Na+/K+-ATPase Inhibitor RX108","termGroup":"SY","termSource":"NCI"},{"termName":"RX 108","termGroup":"CN","termSource":"NCI"},{"termName":"RX-108","termGroup":"CN","termSource":"NCI"},{"termName":"RX108","termGroup":"CN","termSource":"NCI"},{"termName":"Sodium-Potassium Pump Inhibitor RX10","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108"},{"name":"NCI_Drug_Dictionary_ID","value":"795834"},{"name":"NCI_META_CUI","value":"CL935853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795834"},{"name":"PDQ_Open_Trial_Search_ID","value":"795834"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106119":{"preferredName":"Sofituzumab Vedotin","code":"C106119","definitions":[{"definition":"An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of sofituzumab vedotin selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sofituzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"DMUC5754A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1418200-58-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2X3CKG601L"},{"name":"Maps_To","value":"Sofituzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"699480"},{"name":"NCI_META_CUI","value":"CL433830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699480"},{"name":"PDQ_Open_Trial_Search_ID","value":"699480"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77854":{"preferredName":"Solitomab","code":"C77854","definitions":[{"definition":"A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating and antineoplastic activities. Solitomab attaches to both CD3-expressing T lymphocytes and EpCAM-expressing tumor cells, thereby selectively cross-linking tumor and T lymphocytes; this may result in the recruitment of cytotoxic T lymphocytes (CTL) to T lymphocyte/tumor cell aggregates and the CTL-mediated death of EpCAM-expressing tumor cells. CD3 is an antigen expressed on mature T cells; EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solitomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EpCAM BiTE","termGroup":"AB","termSource":"NCI"},{"termName":"MT110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005198-65-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZQQ51B5708"},{"name":"Legacy Concept Name","value":"Anti-EpCAM_Anti-CD3_Recombinant_Bispecific_Monoclonal_Antibody_MT110"},{"name":"Maps_To","value":"Solitomab"},{"name":"NCI_Drug_Dictionary_ID","value":"592863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592863"},{"name":"PDQ_Open_Trial_Search_ID","value":"592863"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642415"}]}}{"C78195":{"preferredName":"Sonepcizumab","code":"C78195","definitions":[{"definition":"A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonepcizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Asonep","termGroup":"BR","termSource":"NCI"},{"termName":"LT1009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1031360-18-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O4T5UXS4P2"},{"name":"Legacy Concept Name","value":"Sonepcizumab"},{"name":"Maps_To","value":"Sonepcizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"595163"},{"name":"NCI_META_CUI","value":"CL383585"},{"name":"PDQ_Closed_Trial_Search_ID","value":"595163"},{"name":"PDQ_Open_Trial_Search_ID","value":"595163"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82385":{"preferredName":"Sonidegib","code":"C82385","definitions":[{"definition":"An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonidegib","termGroup":"PT","termSource":"NCI"},{"termName":"(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-","termGroup":"SN","termSource":"NCI"},{"termName":"Erismodegib","termGroup":"SY","termSource":"NCI"},{"termName":"LDE 225","termGroup":"CN","termSource":"NCI"},{"termName":"LDE-225","termGroup":"CN","termSource":"NCI"},{"termName":"LDE225","termGroup":"CN","termSource":"NCI"},{"termName":"Odomzo","termGroup":"BR","termSource":"NCI"},{"termName":"Smoothened Antagonist LDE225","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"locally advanced basal cell carcinoma (BCC)"},{"name":"CAS_Registry","value":"956697-53-3"},{"name":"Chemical_Formula","value":"C26H26F3N3O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0RLU3VTK5M"},{"name":"Legacy Concept Name","value":"Oral_Smoothened_Antagonist_LDE225"},{"name":"Maps_To","value":"Sonidegib"},{"name":"NCI_Drug_Dictionary_ID","value":"641974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641974"},{"name":"PDQ_Open_Trial_Search_ID","value":"641974"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830069"}]}}{"C78848":{"preferredName":"Sonolisib","code":"C78848","definitions":[{"definition":"A small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonolisib","termGroup":"PT","termSource":"NCI"},{"termName":"(4E)-4-(((Bis(prop-2-en-1-yl)amino)methylidene)-6-hydroxy-1alpha-(methoxymethyl)-3,7,17-trioxo-2-oxaandrosta-5,8-dien-11alpha-yl Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"acetic acid (1S,4E,10R,11R,13S,14R)-4-diallylaminomethylene-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,3,4,7,10,11,12,13,14,15,16,17-dodecahydro-2-oxa-cyclopenta[a]phenanthren-11-yl ester","termGroup":"SN","termSource":"NCI"},{"termName":"acetic acid 4-diallylaminomethylene-6-hydroxy-1-alpha 12-methoxymethyl-10beta,13beta-dimethyl-3,7,17-trioxo-1,3,4,7,10,11beta,12,13,14alpha,15,16,17-dodecahydro-2-oxa-cyclopenta[a]phenanthren-11-yl ester","termGroup":"SN","termSource":"NCI"},{"termName":"PX 866","termGroup":"CN","termSource":"NCI"},{"termName":"PX-866","termGroup":"CN","termSource":"NCI"},{"termName":"PX866","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"502632-66-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"987796874T"},{"name":"Legacy Concept Name","value":"PI3K_Inhibitor_PX-866"},{"name":"Maps_To","value":"Sonolisib"},{"name":"NCI_Drug_Dictionary_ID","value":"612038"},{"name":"PDQ_Closed_Trial_Search_ID","value":"612038"},{"name":"PDQ_Open_Trial_Search_ID","value":"612038"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566038"}]}}{"C61948":{"preferredName":"Sorafenib","code":"C61948","definitions":[{"definition":"A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Sorafenib stops cells from dividing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorafenib","termGroup":"PT","termSource":"NCI"},{"termName":"BA4 43 9006","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 43 9006","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 43-9006","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 439006","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-43-9006","termGroup":"CN","termSource":"NCI"},{"termName":"Bay-439006","termGroup":"CN","termSource":"NCI"},{"termName":"BAY439006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"284461-73-0"},{"name":"CHEBI_ID","value":"CHEBI:50924"},{"name":"Chemical_Formula","value":"C21H16ClF3N4O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"9ZOQ3TZI87"},{"name":"Legacy Concept Name","value":"Sorafenib"},{"name":"Maps_To","value":"Sorafenib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1516119"}]}}{"C2194":{"preferredName":"Sorafenib Tosylate","code":"C2194","definitions":[{"definition":"A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Nexavar stops cells from dividing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorafenib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic Acid Methyamide-4-methylbenzenesulfonate Tosylate","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 43-9006 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 54 9085","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 54-9085","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 549085","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-54-9085","termGroup":"CN","termSource":"NCI"},{"termName":"BAY549085","termGroup":"CN","termSource":"NCI"},{"termName":"Nexavar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced renal cell carcinoma; Metastatic Colorectal Cancer"},{"name":"Accepted_Therapeutic_Use_For","value":"Major Depressive Disorder"},{"name":"CAS_Registry","value":"475207-59-1"},{"name":"CHEBI_ID","value":"CHEBI:50928"},{"name":"Chemical_Formula","value":"C21H16ClF3N4O3.C7H8O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5T62Q3B36J"},{"name":"Legacy Concept Name","value":"BAY_43-9006"},{"name":"Maps_To","value":"Sorafenib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"299013"},{"name":"NSC Number","value":"724772"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299013"},{"name":"PDQ_Open_Trial_Search_ID","value":"299013"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1676709"}]}}{"C111681":{"preferredName":"Sorghum bicolor Supplement","code":"C111681","definitions":[{"definition":"An herbal-based nutritional supplement containing the leaf sheaths of the plant Sorghum bicolor, with potential antioxidant, anti-inflammatory, chemopreventive and immunomodulating activities. Sorghum bicolor supplement contains various phytochemicals, including phenolic acids and polyphenols such as proanthocyanidins. Sorghum bicolor supplement is particularly rich in 3-deoxyanthocyanins, such as luteolinidin and apigeninidin, and appears to induce apoptosis and inhibit cell proliferation in cancer cells through the stimulation of various apoptosis promoter genes and the downregulation of certain apoptosis inhibitor genes. In addition, due to the strong antioxidant nature of the phytochemicals, these compounds are able to scavenge free radicals and prevent tissue damage. Also, intake of this supplement modulates the immune system by both increasing the activity of natural killer (NK) cells and initiating the activation of macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sorghum bicolor Supplement","termGroup":"PT","termSource":"NCI"},{"termName":"Jobelyn","termGroup":"FB","termSource":"NCI"},{"termName":"Sorghum bicolor Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sorghum bicolor Supplement"},{"name":"NCI_Drug_Dictionary_ID","value":"752436"},{"name":"NCI_META_CUI","value":"CL454073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752436"},{"name":"PDQ_Open_Trial_Search_ID","value":"752436"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C80630":{"preferredName":"Sotrastaurin","code":"C80630","definitions":[{"definition":"An orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively. Both PKCs are important in the activation of nuclear factor-kappaB (NF-kB). Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotrastaurin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"425637-18-9"},{"name":"Chemical_Formula","value":"C25H22N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7I279E1NZ8"},{"name":"Legacy Concept Name","value":"Sotrastaurin"},{"name":"Maps_To","value":"Sotrastaurin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742796"}]}}{"C80631":{"preferredName":"Sotrastaurin Acetate","code":"C80631","definitions":[{"definition":"The acetate salt form of sotrastaurin, an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively. Both PKCs are important in the activation of nuclear factor-kappaB (NF-kB). Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sotrastaurin Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4- yl)-1H-pyrrole-2,5-dione Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"AEB 071","termGroup":"CN","termSource":"NCI"},{"termName":"AEB071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"908351-31-5"},{"name":"Chemical_Formula","value":"C25H22N6O2.C2H4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R1SIA15KZ1"},{"name":"Legacy Concept Name","value":"Sotrastaurin_Acetate"},{"name":"Maps_To","value":"Sotrastaurin Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"708113"},{"name":"PDQ_Closed_Trial_Search_ID","value":"708113"},{"name":"PDQ_Open_Trial_Search_ID","value":"708113"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830197"}]}}{"C65152":{"preferredName":"Soy Isoflavones","code":"C65152","definitions":[{"definition":"A dietary supplement isolated from soybeans containing phytoestrogen isoflavones. Although the mechanism of action is unclear, soy isoflavones mimic estrogen action mediated through estrogen receptors. In addition, this agent also modulates estrogen metabolism. As a result, soy isoflavones have been shown to reduce tumor cell proliferation and induce tumor cell apoptosis, as well as to be able to regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soy Isoflavones","termGroup":"PT","termSource":"NCI"},{"termName":"NovaSoy","termGroup":"BR","termSource":"NCI"},{"termName":"Solgen 40","termGroup":"BR","termSource":"NCI"},{"termName":"Soybean Isoflavone Mixture","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71B37NR06D"},{"name":"Legacy Concept Name","value":"Soy_Isoflavones"},{"name":"Maps_To","value":"Soy Isoflavones"},{"name":"NCI_Drug_Dictionary_ID","value":"466602"},{"name":"PDQ_Closed_Trial_Search_ID","value":"466602"},{"name":"PDQ_Open_Trial_Search_ID","value":"466602"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4076257"}]}}{"C1803":{"preferredName":"Soy Protein Isolate","code":"C1803","definitions":[{"definition":"A dietary protein isolated from soybeans that contains isoflavone phytoestrogens.  Soy protein isolate has been shown to reduce tumor incidence and growth in some animal studies, possibly by modulating estrogen metabolism, reducing tumor cell proliferation, and inducing tumor cell apoptosis.  Soy protein isolate may also inhibit endothelial cell proliferation.  Isoflavone phytoestrogens display mild estrogen-like activities which may regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Soy Protein Isolate","termGroup":"PT","termSource":"NCI"},{"termName":"Soybean Protein Isolate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Heart disease prevention; hyperlipidemia; menopausal symptoms"},{"name":"CAS_Registry","value":"9010-10-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R44IWB3RN5"},{"name":"Legacy Concept Name","value":"Soy_Protein_Isolate"},{"name":"Maps_To","value":"Soy Protein Isolate"},{"name":"NCI_Drug_Dictionary_ID","value":"42493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42493"},{"name":"PDQ_Open_Trial_Search_ID","value":"42493"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677666"}]}}{"C2353":{"preferredName":"Sparfosate Sodium","code":"C2353","definitions":[{"definition":"The disodium salt form of N-phosphonacetyl-L-aspartate (PALA), a pyrimidine antimetabolite with antineoplastic activity.  PALA inhibits pyrimidine biosynthesis and increases the extent to which fluorouracil is incorporated into RNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sparfosate Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"CI-882","termGroup":"CN","termSource":"NCI"},{"termName":"L-Aspartic Acid, N-(phosphonoacetyl)-, Disodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"N-Phosphonacetyl-L-aspartate Disodium","termGroup":"SN","termSource":"NCI"},{"termName":"PALA Disodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"66569-27-5"},{"name":"Chemical_Formula","value":"C6H8NO8P.2Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5R33Q73DYD"},{"name":"Legacy Concept Name","value":"PALA_Disodium"},{"name":"Maps_To","value":"Sparfosate Sodium"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1518775"}]}}{"C1398":{"preferredName":"Sparfosic Acid","code":"C1398","definitions":[{"definition":"A stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is being studied to increase the effectiveness of the chemotherapy drug fluorouracil.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Sparfosic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"L-Aspartic acid, N-(phosphonoacetyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-Phosphonacetyl-L-aspartate","termGroup":"SN","termSource":"NCI"},{"termName":"PALA","termGroup":"AB","termSource":"NCI"},{"termName":"Phosphonacetyl-L-aspartic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Sparfosate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51321-79-0"},{"name":"Chemical_Formula","value":"C6H10NO8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78QVZ7RG8L"},{"name":"Legacy Concept Name","value":"N-Phosphonacetyl-L-aspartate"},{"name":"Maps_To","value":"Sparfosic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"39547"},{"name":"NSC Number","value":"224131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39547"},{"name":"PDQ_Open_Trial_Search_ID","value":"39547"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0135096"}]}}{"C121625":{"preferredName":"Spartalizumab","code":"C121625","definitions":[{"definition":"A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spartalizumab","termGroup":"PT","termSource":"NCI"},{"termName":"PDR-001","termGroup":"CN","termSource":"NCI"},{"termName":"PDR001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1935694-88-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QOG25L6Z8Z"},{"name":"Maps_To","value":"Spartalizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"770801"},{"name":"NCI_META_CUI","value":"CL507832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770801"},{"name":"PDQ_Open_Trial_Search_ID","value":"770801"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97037":{"preferredName":"Spebrutinib","code":"C97037","definitions":[{"definition":"An orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, spebrutinib targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spebrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"AVL 292","termGroup":"CN","termSource":"NCI"},{"termName":"AVL-292","termGroup":"CN","termSource":"NCI"},{"termName":"AVL292","termGroup":"CN","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor CC-292","termGroup":"SY","termSource":"NCI"},{"termName":"CC 292","termGroup":"CN","termSource":"NCI"},{"termName":"CC-292","termGroup":"CN","termSource":"NCI"},{"termName":"CC292","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1202757-89-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"DRU6NG543J"},{"name":"Maps_To","value":"Spebrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"700570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700570"},{"name":"PDQ_Open_Trial_Search_ID","value":"700570"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3642455"}]}}{"C131368":{"preferredName":"Spherical Nucleic Acid Nanoparticle NU-0129","code":"C131368","definitions":[{"definition":"A spherical nucleic acid (SNA) gold nanoparticle formulation composed of small interfering RNAs (siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence and conjugated to gold nanoparticles, with potential antineoplastic activity. Upon administration of SNA NU-0129, the siRNA prevents the translation of the BCL2L12 gene. Inhibiting the expression of BCL2L12 by NU-0129 induces tumor cell apoptosis. Bcl2L12, a protein belonging to the Bcl-2 protein family, is overexpressed in glioblastoma multiforme (GBM) and plays a role in tumor cell progression and tumor cell resistance to apoptosis. NU-0129 is able to cross the blood brain barrier (BBB).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spherical Nucleic Acid Nanoparticle NU-0129","termGroup":"PT","termSource":"NCI"},{"termName":"NU-0129","termGroup":"CN","termSource":"NCI"},{"termName":"SNA Gold Nanoparticle NU-0129","termGroup":"SY","termSource":"NCI"},{"termName":"SNA NU-0129","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spherical Nucleic Acid Nanoparticle NU-0129"},{"name":"NCI_Drug_Dictionary_ID","value":"786841"},{"name":"NCI_META_CUI","value":"CL514431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786841"},{"name":"PDQ_Open_Trial_Search_ID","value":"786841"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1232":{"preferredName":"Spirogermanium","code":"C1232","definitions":[{"definition":"A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spirogermanium","termGroup":"PT","termSource":"NCI"},{"termName":"2-[3-(Dimethyl-amino)propyl]-8,8-diethyl-2-aza-8-germaspiro[4,5]decane","termGroup":"SN","termSource":"NCI"},{"termName":"8,8-Diethyl-N,N-dimethyl-3-aza-8-germaspiro[4,5]decane-2-propanamine","termGroup":"SN","termSource":"NCI"},{"termName":"S 99 A","termGroup":"CN","termSource":"NCI"},{"termName":"SPG","termGroup":"AB","termSource":"NCI"},{"termName":"Spiro-32","termGroup":"AB","termSource":"NCI"},{"termName":"Spirogermanium Compound","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41992-23-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1F01P3Y61E"},{"name":"Legacy Concept Name","value":"Spirogermanium"},{"name":"Maps_To","value":"Spirogermanium"},{"name":"NCI_Drug_Dictionary_ID","value":"39605"},{"name":"NSC Number","value":"192965"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39605"},{"name":"PDQ_Open_Trial_Search_ID","value":"39605"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075018"}]}}{"C1233":{"preferredName":"Spiromustine","code":"C1233","definitions":[{"definition":"A bifunctional nitrogen alkylating agent with antineoplastic activity and lipophilic properties. Containing a lipophilic hydantoin group that serves as a carrier to cross the blood brain barrier, spiromustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spiromustine","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-diazaspiro(4,5)decane-2,4-dione,3-(2-(bis-chloroethyl)amino)ethyl","termGroup":"SN","termSource":"NCI"},{"termName":"SHM","termGroup":"AB","termSource":"NCI"},{"termName":"Spirohydantoin Mustard","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56605-16-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J3HB83X76Z"},{"name":"Legacy Concept Name","value":"Spiromustine"},{"name":"Maps_To","value":"Spiromustine"},{"name":"NCI_Drug_Dictionary_ID","value":"39441"},{"name":"NSC Number","value":"172112"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39441"},{"name":"PDQ_Open_Trial_Search_ID","value":"39441"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075019"}]}}{"C1234":{"preferredName":"Spiroplatin","code":"C1234","definitions":[{"definition":"A synthetic derivative of cyclohexane sulfatoplatinum with antineoplastic properties.  Spiroplatin induces DNA cross-links, thereby inhibiting DNA replication and RNA and protein synthesis. Similar to other platinum compounds, this agent has been shown to be mutagenic and carcinogenic. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spiroplatin","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-1,1-diamino-methylcyclohexane sulfato-platinum","termGroup":"SN","termSource":"NCI"},{"termName":"Platinum, (1,1-cyclohexanedimethanamine-n,n')(sulfato(2-)-O,O')-, (sp-4-2)-","termGroup":"SN","termSource":"NCI"},{"termName":"TNO-6","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74790-08-2"},{"name":"Chemical_Formula","value":"C8H18N2.O4S.Pt"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H2V318W7LE"},{"name":"Legacy Concept Name","value":"Spiroplatin"},{"name":"Maps_To","value":"Spiroplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39763"},{"name":"NSC Number","value":"311056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39763"},{"name":"PDQ_Open_Trial_Search_ID","value":"39763"},{"name":"Semantic_Type","value":"Inorganic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075022"}]}}{"C129546":{"preferredName":"Splicing Inhibitor H3B-8800","code":"C129546","definitions":[{"definition":"An orally bioavailable inhibitor of the splicing factor 3B subunit 1 (SF3B1), with potential antineoplastic activity. Upon administration, H3B-8800 binds to and blocks the activity of SF3B1, a core spliceosome protein that is mutated in various cancer cells. This modulates RNA splicing by preventing aberrant mRNA splicing by the spliceosome, blocks RNA mis-splicing, enhances proper RNA splicing and prevents the expression of certain tumor-associated genes. This leads to an induction of apoptosis and prevents tumor cell proliferation. In many cancer cells, core spliceosome proteins, including SF3B1, U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2) and U2 small nuclear ribonucleoprotein auxiliary factor subunit-related protein 2 (ZRSR2), are mutated and aberrantly activated leading to a dysregulation of mRNA splicing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splicing Inhibitor H3B-8800","termGroup":"PT","termSource":"NCI"},{"termName":"H3B 8800","termGroup":"CN","termSource":"NCI"},{"termName":"H3B-8800","termGroup":"CN","termSource":"NCI"},{"termName":"Splicing Factor Inhibitor H3B-8800","termGroup":"SY","termSource":"NCI"},{"termName":"Splicing Modulator H3B-8800","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1825302-42-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"90YLS47BRX"},{"name":"Maps_To","value":"Splicing Inhibitor H3B-8800"},{"name":"NCI_Drug_Dictionary_ID","value":"784315"},{"name":"NCI_META_CUI","value":"CL512654"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784315"},{"name":"PDQ_Open_Trial_Search_ID","value":"784315"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2051":{"preferredName":"Spongistatin","code":"C2051","definitions":[{"definition":"A highly cytotoxic macrocyclic lactone polyether with antitumor activity. Spongistatin, originally isolated from marine Spongia species, binds to the vinca domain of tubulin, thereby interferes with microtubule assembly and results in inhibition of mitosis. This agent does not affect the binding of colchicine to tubulin, but it was a potent inhibitor of the binding of vinblastine and GTP to tubulin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spongistatin","termGroup":"PT","termSource":"NCI"},{"termName":"Altohyrtin A","termGroup":"SY","termSource":"NCI"},{"termName":"Spongistatin 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"148179-94-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Spongistatin"},{"name":"Maps_To","value":"Spongistatin"},{"name":"PubMedID_Primary_Reference","value":"8232226"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0248118"}]}}{"C1482":{"preferredName":"Squalamine Lactate","code":"C1482","definitions":[{"definition":"A drug that belongs to the family of drugs called angiogenesis inhibitors. It prevents the growth of new blood vessels into a solid tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The lactate salt form of squalamine, an aminosterol isolated from tissues of the dogfish shark Squalus acanthias.  Possessing anti-angiogenic properties, squalamine inhibits the sodium-hydrogen exchanger NHE3, resulting in suppression of endothelial cell proliferation and migration.  This agent also has broad-spectrum antimicrobial properties. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Squalamine Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"MSI-1256F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"320725-47-1"},{"name":"Chemical_Formula","value":"C34H65N3O5S.C3H6O3.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4WE915J1KX"},{"name":"Legacy Concept Name","value":"Squalamine"},{"name":"Maps_To","value":"Squalamine Lactate"},{"name":"NCI_Drug_Dictionary_ID","value":"43041"},{"name":"NSC Number","value":"715056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43041"},{"name":"PDQ_Open_Trial_Search_ID","value":"43041"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0213314"}]}}{"C61435":{"preferredName":"SR-BP1/HSI Inhibitor SR31747A","code":"C61435","definitions":[{"definition":"A synthetic peripheral sigma receptor ligand with immunomodulatory and potential antitumor activities. Although the exact mechanism by which SR31747A exerts its antitumor effects has not been fully established, SR31747A binds to and inhibits the sigma1 receptor (SR31747A-binding protein-1 or SR-BP1), human sterol isomerase (HSI), also known as emopamil-binding protein (EBP), and the sigma2 receptor, which may result in a reduction in tumor cell proliferation and tumor cell apoptosis. In addition, this agent inhibits the production of pro-inflammatory cytokines while increasing anti-inflammatory cytokines. Upregulated in various cancers, the sigma1 and sigma2 receptors and human sterol isomerase are proteins that are involved in the regulation of cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SR-BP1/HSI Inhibitor SR31747A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SR31747A"},{"name":"Maps_To","value":"SR-BP1/HSI Inhibitor SR31747A"},{"name":"NCI_Drug_Dictionary_ID","value":"471256"},{"name":"NCI_META_CUI","value":"CL937293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"471256"},{"name":"PDQ_Open_Trial_Search_ID","value":"471256"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99460":{"preferredName":"SR-T100 Gel","code":"C99460","definitions":[{"definition":"A cutaneous gel preparation containing an extract from Solanum incanum with potential antineoplastic activity. SR-T100 gel contains high amounts of the steroidal alkaloid glycoside solamargine. Solamargine is able to upregulate expression of tumor necrosis factor receptors 1 (TNFR1) and 6 (TNFRSF6 or Fas), and their signaling adaptors TNFR1-associated death domain, and Fas-associated death domain. In addition, this agent is able to upregulate expression of apoptosis promoter Bax, and suppress the expression of the anti-apoptotic proteins Bcl-xL and Bcl-2. Altogether, this induces apoptosis in tumor cells and may lead to an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SR-T100 Gel","termGroup":"PT","termSource":"NCI"},{"termName":"SR-T100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SR-T100 Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"721725"},{"name":"NCI_META_CUI","value":"CL433216"},{"name":"PDQ_Closed_Trial_Search_ID","value":"721725"},{"name":"PDQ_Open_Trial_Search_ID","value":"721725"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162533":{"preferredName":"Src Kinase Inhibitor AP 23846","code":"C162533","definitions":[{"definition":"A novel small molecule Src family kinase inhibitor with potential antiangiogenic activity. Upon administration, Src kinase inhibitor AP23846 selectively binds to and stabilizes an inactive ATP-binding site conformation leading to reduced Src kinase activity. This may reduce the production of pro-angiogenic factors, vascular endothelial growth factor (VEGF) and interleukin (IL)-8. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src Kinase Inhibitor AP 23846","termGroup":"PT","termSource":"NCI"},{"termName":"AP 23846","termGroup":"CN","termSource":"NCI"},{"termName":"AP-23846","termGroup":"CN","termSource":"NCI"},{"termName":"AP23846","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"878654-51-4"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Src Kinase Inhibitor AP 23846"},{"name":"NCI_META_CUI","value":"CL971115"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74077":{"preferredName":"Tirbanibulin","code":"C74077","definitions":[{"definition":"A substance being studied in the treatment of cancer. KX2-391 blocks an enzyme needed for growth of cells and may kill cancer cells. It is a type of Src kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tirbanibulin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Pyridineacetamide, 5-(4-(2-(4-Morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"KX01","termGroup":"CN","termSource":"NCI"},{"termName":"KX2-391","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897016-82-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4V9848RS5G"},{"name":"Legacy Concept Name","value":"Src_Kinase_Inhibitor_KX2-391"},{"name":"Maps_To","value":"Src Kinase Inhibitor KX2-391"},{"name":"Maps_To","value":"Tirbanibulin"},{"name":"NCI_Drug_Dictionary_ID","value":"590687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590687"},{"name":"PDQ_Open_Trial_Search_ID","value":"590687"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348411"}]}}{"C120210":{"preferredName":"Topical Tirbanibulin","code":"C120210","definitions":[{"definition":"An ointment containing an inhibitor for both Src tyrosine kinase and tubulin polymerization, with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin binds to the peptide substrate binding site of Src kinase, upon topical application. This inhibits both downstream signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. Tirbanibulin also binds to tubulin heterodimers and inhibits microtubule polymerization, which disrupts microtubule formation and mitosis, leading to further inhibition of cell proliferation. In addition, Tirbanibulin inhibits T-cell migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Tirbanibulin","termGroup":"PT","termSource":"NCI"},{"termName":"KX2 391 Ointment","termGroup":"SY","termSource":"NCI"},{"termName":"KX2-391 Ointment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Src Kinase Inhibitor KX2-391 Ointment"},{"name":"NCI_Drug_Dictionary_ID","value":"768270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768270"},{"name":"PDQ_Open_Trial_Search_ID","value":"768270"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897543"}]}}{"C162339":{"preferredName":"Src Kinase Inhibitor M475271","code":"C162339","definitions":[{"definition":"An inhibitor of Src tyrosine kinase, with potential antineoplastic activity. Upon administration, Src kinase inhibitor M-475271 targets and binds to Src kinase. This inhibits Src-mediated signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src Kinase Inhibitor M475271","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-","termGroup":"SY","termSource":"NCI"},{"termName":"AZM 475271","termGroup":"CN","termSource":"NCI"},{"termName":"AZM-475271","termGroup":"CN","termSource":"NCI"},{"termName":"AZM475271","termGroup":"CN","termSource":"NCI"},{"termName":"M 475271","termGroup":"CN","termSource":"NCI"},{"termName":"M-475271","termGroup":"CN","termSource":"NCI"},{"termName":"M475271","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2-Chloro-5-methoxyphenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"476159-98-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0361Z8214O"},{"name":"Maps_To","value":"Src Kinase Inhibitor M475271"},{"name":"NCI_META_CUI","value":"CL970844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102976":{"preferredName":"Src/Abl Kinase Inhibitor AZD0424","code":"C102976","definitions":[{"definition":"An orally bioavailable small molecule tyrosine kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Upon oral administration, AZD0424 selectively inhibits both Src and Abl kinase activity which may result in the inhibition of tumor growth in susceptible tumor cells. Src and Abl kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src/Abl Kinase Inhibitor AZD0424","termGroup":"PT","termSource":"NCI"},{"termName":"AZD0424","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"692054-06-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"642PS51324"},{"name":"Maps_To","value":"Src/Abl Kinase Inhibitor AZD0424"},{"name":"NCI_Drug_Dictionary_ID","value":"739328"},{"name":"NCI_META_CUI","value":"CL437215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739328"},{"name":"PDQ_Open_Trial_Search_ID","value":"739328"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120101":{"preferredName":"Src/tubulin Inhibitor KX2-361","code":"C120101","definitions":[{"definition":"A lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral administration,Src/tubulin Inhibitor KX2-361 binds to and inhibits the activity of Src kinase. This inhibits both downstream signaling and the proliferation of Src kinase-expressing tumor cells. KX02 also binds to tubulin heterodimers and inhibits microtubule polymerization, thereby disrupting microtubule formation, mitosis, and further proliferation. Src, a non-receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, angiogenesis, migration, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Src/tubulin Inhibitor KX2-361","termGroup":"PT","termSource":"NCI"},{"termName":"KX02","termGroup":"CN","termSource":"NCI"},{"termName":"KX2-361","termGroup":"CN","termSource":"NCI"},{"termName":"Src/tubulin Inhibitor KX02","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"897016-26-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RVW387BA9U"},{"name":"Maps_To","value":"Src/tubulin Inhibitor KX02"},{"name":"NCI_Drug_Dictionary_ID","value":"767819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767819"},{"name":"PDQ_Open_Trial_Search_ID","value":"767819"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896828"}]}}{"C150401":{"preferredName":"ssRNA-based Immunomodulator CV8102","code":"C150401","definitions":[{"definition":"A 547 nucleotide (nt), noncoding, uncapped single-stranded RNA (ssRNA) containing several polyU-repeats complexed with a polymeric carrier formed by disulfide-crosslinked cationic peptides, with potential immunostimulating activity. Upon intratumoral injection, the ssRNA in CV8102 activates toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG I; RIG-I; DDX58). This stimulates a T-helper type 1 cell (Th1) response, the production of a variety of pro-inflammatory cytokines and chemokines, and activates a systemic cytotoxic-T-lymphocyte (CTL)-mediated immune response against the tumor cells when simultaneously exposed to tumor-associated antigens (TAAs). The cationic carrier peptides protect the ssRNA from RNase degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ssRNA-based Immunomodulator CV8102","termGroup":"PT","termSource":"NCI"},{"termName":"CV 8102","termGroup":"CN","termSource":"NCI"},{"termName":"CV-8102","termGroup":"CN","termSource":"NCI"},{"termName":"CV8102","termGroup":"CN","termSource":"NCI"},{"termName":"RNA-based Adjuvant CV8102","termGroup":"SY","termSource":"NCI"},{"termName":"RNAdjuvant","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ULM5THL8W5"},{"name":"Maps_To","value":"ssRNA-based Immunomodulator CV8102"},{"name":"NCI_Drug_Dictionary_ID","value":"792862"},{"name":"NCI_META_CUI","value":"CL552154"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792862"},{"name":"PDQ_Open_Trial_Search_ID","value":"792862"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C131562":{"preferredName":"Nendratareotide Uzatansine","code":"C131562","definitions":[{"definition":"A miniaturized drug conjugate composed of a peptide analog of somatostatin that targets the somatostatin receptor 2 (SSTR2) and is conjugated, through a cleavable linker, to the microtubule-binding cytotoxic maytansinoid DM1 (mertansine), with potential anti-tumor activity. Upon administration, the peptide ligand moiety of nendratareotide uzatansine targets and binds to SSTR2, which is overexpressed on certain tumor cell types. Binding stimulates SSTR2-mediated endocytosis of the agent; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of SSTR2-expressing cancer cells. Compared to antibody-drug conjugates (ADCs), miniaturized drug conjugates are much smaller and can more easily penetrate and distribute in dense tumor tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nendratareotide Uzatansine","termGroup":"PT","termSource":"NCI"},{"termName":"PEN 221","termGroup":"CN","termSource":"NCI"},{"termName":"PEN-221","termGroup":"CN","termSource":"NCI"},{"termName":"PEN221","termGroup":"CN","termSource":"NCI"},{"termName":"SSTR2-targeting Protein/DM1 Conjugate PEN-221","termGroup":"SY","termSource":"NCI"},{"termName":"SSTR2PEN-221","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1853254-97-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L8993M383E"},{"name":"Maps_To","value":"SSTR2-targeting Protein/DM1 Conjugate PEN-221"},{"name":"NCI_Drug_Dictionary_ID","value":"786270"},{"name":"NCI_META_CUI","value":"CL514580"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786270"},{"name":"PDQ_Open_Trial_Search_ID","value":"786270"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2589":{"preferredName":"St. John's Wort","code":"C2589","definitions":[{"definition":"An herbal extract prepared from the plant Hypericum perforatum (St. John's wort) with photodynamic, antineoplastic, and antidepressant activities. Hypericin, one of the active compounds found in Hypericum perforatum, is a photosensitizer that, when exposed to a particular wavelength and intensity of light, may induce tumor cell apoptosis. Another compound, hyperforin, induces caspase-dependent apoptosis in certain tumor cell lines. Hypericum perforatum preparations may also stimulate the activity of cytochrome P450 enzymes and P-glycoprotein drug transporters, resulting in increased metabolism and decreased efficacy of various chemotherapeutic agents and other drugs.","type":"DEFINITION","source":"NCI"},{"definition":"An herbal product sold as an over-the-counter treatment for depression. It is being studied for its ability to lessen certain side effects of cancer treatment.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"St. John's Wort","termGroup":"PT","termSource":"NCI"},{"termName":"Hypericum Perforatum Extract","termGroup":"SY","termSource":"NCI"},{"termName":"St John's Wort","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84082-80-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UFH8805FKA"},{"name":"Legacy Concept Name","value":"Hypericum_Perforatum"},{"name":"Maps_To","value":"St. John's Wort"},{"name":"NCI_Drug_Dictionary_ID","value":"37989"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37989"},{"name":"PDQ_Open_Trial_Search_ID","value":"37989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0813171"}]}}{"C1517":{"preferredName":"Stallimycin","code":"C1517","definitions":[{"definition":"An oligopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces distallicus.  Distamycin preferentially binds to adenine-thymine (A-T) rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and RNA transcription.  In addition to antitumor effects, distamycin also possesses antiviral and antiprotozoal activities and is used as a chromosome dye. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Stallimycin","termGroup":"PT","termSource":"NCI"},{"termName":"Distamycin 3","termGroup":"SY","termSource":"NCI"},{"termName":"Distamycin A","termGroup":"SY","termSource":"NCI"},{"termName":"Herperetin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"636-47-5"},{"name":"Chemical_Formula","value":"C22H27N9O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"80O63P88IS"},{"name":"Legacy Concept Name","value":"Distamycin"},{"name":"Maps_To","value":"Stallimycin"},{"name":"NSC Number","value":"82150"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244119"}]}}{"C1083":{"preferredName":"Staphylococcal Enterotoxin A","code":"C1083","definitions":[{"definition":"A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin A (SEA), a gram positive bacterial superantigen (SAg), is a potent stimulator of T-cell activation. SEA superantigen binds directly to class II major histocompatibility complex (MHC) molecules and to the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEA, both CD4+ and CD8+ cells proliferate, secrete cytokines, and demonstrate enhanced cytotoxic activity against a broad range of antigens. Vaccination with the SEA protein, administered by direct transfection into tumor cells, may elicit a non-specific cytotoxic T-cell (CTL) response and result in decreased tumor cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"The biotoxin Staphylococcal enterotoxin A.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staphylococcal Enterotoxin A","termGroup":"PT","termSource":"NCI"},{"termName":"SEA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"37337-57-8"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Staphylococcal_Enterotoxin_A"},{"name":"Maps_To","value":"Staphylococcal Enterotoxin A"},{"name":"NCI_Drug_Dictionary_ID","value":"42927"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42927"},{"name":"PDQ_Open_Trial_Search_ID","value":"42927"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0059385"}]}}{"C1084":{"preferredName":"Staphylococcal Enterotoxin B","code":"C1084","definitions":[{"definition":"A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin B (SEB), a gram positive superantigen produced by Staphylococcus aureus, is a potent stimulator of T-cell activation. SEB binds directly to class II major histocompatibility complex (MHC) molecules and the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEB, both CD4+ and CD8+ cells proliferate, secrete cytokines and demonstrate enhanced cytotoxic activity against a broad range of antigens. Co-administration of SEB with interleukin-2 (IL-2) by direct injection into tumor cells, may induce clonal T-cell expansion and potentiate apoptosis of tumor cells, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"},{"definition":"The biotoxin Staphylococcal enterotoxin B.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staphylococcal Enterotoxin B","termGroup":"PT","termSource":"NCI"},{"termName":"SEB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"39424-53-8"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Staphylococcal_Enterotoxin_B"},{"name":"Maps_To","value":"Staphylococcal Enterotoxin B"},{"name":"NCI_Drug_Dictionary_ID","value":"37929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37929"},{"name":"PDQ_Open_Trial_Search_ID","value":"37929"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0059386"}]}}{"C116873":{"preferredName":"STAT Inhibitor OPB-111077","code":"C116873","definitions":[{"definition":"An orally bioavailable inhibitor of one or more signal transducer and activator of transcription (STAT) protein(s), with potential antineoplastic activity. Upon oral administration, OPB-111077 binds to and inhibits the phosphorylation of STATs. This prevents binding of STATs to DNA sequences on a variety of STAT-responsive gene promoters, which may result in the inhibition of both STAT-mediated transcription and tumor cell proliferation. STATs are constitutively activated in a variety of cancers and play a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT Inhibitor OPB-111077","termGroup":"PT","termSource":"NCI"},{"termName":"OPB-111077","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT Inhibitor OPB-111077"},{"name":"NCI_Drug_Dictionary_ID","value":"742040"},{"name":"NCI_META_CUI","value":"CL446660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742040"},{"name":"PDQ_Open_Trial_Search_ID","value":"742040"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151994":{"preferredName":"STAT3 Inhibitor DSP-0337","code":"C151994","definitions":[{"definition":"An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor DSP-0337","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Stemness Inhibitor DSP-0337","termGroup":"SY","termSource":"NCI"},{"termName":"DSP 0337","termGroup":"CN","termSource":"NCI"},{"termName":"DSP-0337","termGroup":"CN","termSource":"NCI"},{"termName":"Napabucasin Prodrug DSP-0337","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT3 Inhibitor DSP-0337"},{"name":"NCI_Drug_Dictionary_ID","value":"793774"},{"name":"NCI_META_CUI","value":"CL553215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793774"},{"name":"PDQ_Open_Trial_Search_ID","value":"793774"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90588":{"preferredName":"STAT3 Inhibitor OPB-31121","code":"C90588","definitions":[{"definition":"An orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. OPB-31121 inhibits the phosphorylation of STAT3, which prevents binding of STAT3 to DNA sequences on a variety of STAT3-responsive promoters and may result in the inhibition of STAT3-mediated transcription and, potentially, the inhibition of tumor cell proliferation. STAT3 is constitutively activated in a variety of cancers, contributing to the loss of cell growth control and neoplastic transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor OPB-31121","termGroup":"PT","termSource":"NCI"},{"termName":"OPB-31121","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT3 Inhibitor OPB-31121"},{"name":"NCI_Drug_Dictionary_ID","value":"570187"},{"name":"NCI_META_CUI","value":"CL376190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570187"},{"name":"PDQ_Open_Trial_Search_ID","value":"570187"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95889":{"preferredName":"STAT3 Inhibitor OPB-51602","code":"C95889","definitions":[{"definition":"An orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. STAT3 inhibitor OPB-51602 inhibits the phosphorylation and thus the activation of STAT3 protein, impeding STAT3 protein from translocating from the cytoplasm to the nucleus and thereby blocking STAT3's regulation of gene expression through direct binding to the promoters of responsive genes. STAT3 regulates the cellular functions that lead to the cancer phenotype, and constitutive activation of STAT3 is observed in a wide range of human cancers, inducing uncontrolled proliferation and neoplastic transformation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor OPB-51602","termGroup":"PT","termSource":"NCI"},{"termName":"OPB-51602","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STAT3 Inhibitor OPB-51602"},{"name":"NCI_Drug_Dictionary_ID","value":"684303"},{"name":"NCI_META_CUI","value":"CL428286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684303"},{"name":"PDQ_Open_Trial_Search_ID","value":"684303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151932":{"preferredName":"STAT3 Inhibitor C-188-9","code":"C151932","definitions":[{"definition":"An orally bioavailable, binaphthol-sulfonamide-based inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, the STAT3 inhibitor C-188-9 specifically targets and binds to the phosphotyrosyl peptide binding site within the Src homology 2 (SH2) domain of STAT3. This inhibits the Janus kinase (JAK)-mediated tyrosine phosphorylation and activation of STAT3. This impedes nuclear translocation of STAT3, prevents STAT3 binding to responsive gene promoters and blocks STAT3-mediated regulation of gene expression. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor C-188-9","termGroup":"PT","termSource":"NCI"},{"termName":"C188-9","termGroup":"CN","termSource":"NCI"},{"termName":"STAT3 Inhibitor TTI-101","termGroup":"SY","termSource":"NCI"},{"termName":"STAT3 Inhibitor XIII","termGroup":"SY","termSource":"NCI"},{"termName":"TTI 101","termGroup":"CN","termSource":"NCI"},{"termName":"TTI-101","termGroup":"CN","termSource":"NCI"},{"termName":"TTI101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"432001-19-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KZ3DLD11RQ"},{"name":"Maps_To","value":"STAT3 Inhibitor TTI-101"},{"name":"NCI_Drug_Dictionary_ID","value":"793126"},{"name":"NCI_META_CUI","value":"CL553271"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793126"},{"name":"PDQ_Open_Trial_Search_ID","value":"793126"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111042":{"preferredName":"STAT3 Inhibitor WP1066","code":"C111042","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of signaling transducer and activator 3 (STAT3), with potential antineoplastic and immunomodulatory activities. Upon administration, STAT3 inhibitor WP1066 blocks the intranuclear translocation of p-STAT, thereby suppressing STAT3 signaling and decreasing the levels of downstream products including c-Myc. Additionally, WP1066 may upregulate costimulatory molecules including CD80 and CD86 on human microglia, and reverse glioma cancer stem cell (gCSC)-mediated innate and adaptive immune suppression allowing for the restoration of antitumor effector immune responses. The STAT3 pathway is overly active in many cancer types and is implicated in CSC-mediated growth, recurrence and resistance to conventional chemotherapies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STAT3 Inhibitor WP1066","termGroup":"PT","termSource":"NCI"},{"termName":"(S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide","termGroup":"SN","termSource":"NCI"},{"termName":"WP 1066","termGroup":"CN","termSource":"NCI"},{"termName":"WP-1066","termGroup":"CN","termSource":"NCI"},{"termName":"WP1066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"857064-38-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"63V8AIE65T"},{"name":"Maps_To","value":"STAT3 Inhibitor WP1066"},{"name":"NCI_Drug_Dictionary_ID","value":"751888"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751888"},{"name":"PDQ_Open_Trial_Search_ID","value":"751888"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1957161"}]}}{"C1237":{"preferredName":"Staurosporine","code":"C1237","definitions":[{"definition":"A cell permeable alkaloid isolated from Streptomyces staurosporeus exhibiting anti-cancer activity.  Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C.  This agent induces apoptosis by an undetermined mechanism. (NCI)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that belongs to the family of drugs called alkaloids. It is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Staurosporine","termGroup":"PT","termSource":"NCI"},{"termName":"(9alpha,10beta,11beta,13alpha)-(+)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H-9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one","termGroup":"SN","termSource":"NCI"},{"termName":"8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-","termGroup":"SN","termSource":"NCI"},{"termName":"AM-2282","termGroup":"CN","termSource":"NCI"},{"termName":"Antibiotic 230","termGroup":"SY","termSource":"NCI"},{"termName":"Antibiotic AM 2282","termGroup":"SY","termSource":"NCI"},{"termName":"CGP-39360","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"62996-74-1"},{"name":"CHEBI_ID","value":"CHEBI:15738"},{"name":"Chemical_Formula","value":"C28H26N4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H88EPA0A3N"},{"name":"Legacy Concept Name","value":"Staurosporine"},{"name":"Maps_To","value":"Staurosporine"},{"name":"NSC Number","value":"618487"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0075193"}]}}{"C132258":{"preferredName":"Ulevostinag","code":"C132258","definitions":[{"definition":"A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulevostinag","termGroup":"PT","termSource":"NCI"},{"termName":"MK 1454","termGroup":"CN","termSource":"NCI"},{"termName":"MK-1454","termGroup":"CN","termSource":"NCI"},{"termName":"STING Agonist MK-1454","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2082743-96-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CKP8AS5W73"},{"name":"Maps_To","value":"STING Agonist MK-1454"},{"name":"NCI_Drug_Dictionary_ID","value":"787239"},{"name":"NCI_META_CUI","value":"CL520450"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787239"},{"name":"PDQ_Open_Trial_Search_ID","value":"787239"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125902":{"preferredName":"STING-activating Cyclic Dinucleotide Agonist MIW815","code":"C125902","definitions":[{"definition":"A synthetic, cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the STING agonist MIW815 binds to STING and stimulates STING-mediated pathways. This activates the immune response through the activation of certain immune cells, including dendritic cells (DCs), which induces the expression of cytokines and chemokines, and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING-activating Cyclic Dinucleotide Agonist MIW815","termGroup":"PT","termSource":"NCI"},{"termName":"ADU-S100","termGroup":"CN","termSource":"NCI"},{"termName":"CDN Agonist ADU-S100","termGroup":"SY","termSource":"NCI"},{"termName":"MIW815","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638750-95-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FMW9ZVF53N"},{"name":"Maps_To","value":"STING-activating Cyclic Dinucleotide Agonist MIW815"},{"name":"NCI_Drug_Dictionary_ID","value":"778826"},{"name":"NCI_META_CUI","value":"CL504551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"778826"},{"name":"PDQ_Open_Trial_Search_ID","value":"778826"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C844":{"preferredName":"Streptonigrin","code":"C844","definitions":[{"definition":"An aminoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces flocculus.  Streptonigrin complexes with DNA and topoisomerase II, resulting in DNA cleavage and inhibition of DNA replication and RNA synthesis.  This agent also acts as a reverse transcriptase inhibitor and causes free radical-mediated cellular damage. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Streptonigrin","termGroup":"PT","termSource":"NCI"},{"termName":"5-Amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl-2-pyridinecarboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5-Amino-6-(70-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpicolinic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"BA-163","termGroup":"CN","termSource":"NCI"},{"termName":"Bruneomycin","termGroup":"SY","termSource":"NCI"},{"termName":"PC-501","termGroup":"CN","termSource":"NCI"},{"termName":"Rufocromomycin","termGroup":"SY","termSource":"NCI"},{"termName":"STN","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3930-19-6"},{"name":"CHEBI_ID","value":"CHEBI:9287"},{"name":"Chemical_Formula","value":"C25H22N4O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"261Q3JB310"},{"name":"Legacy Concept Name","value":"Streptonigrin"},{"name":"Maps_To","value":"Streptonigrin"},{"name":"NCI_Drug_Dictionary_ID","value":"39703"},{"name":"NSC Number","value":"45383"},{"name":"NSC Number","value":"83950"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39703"},{"name":"PDQ_Open_Trial_Search_ID","value":"39703"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038427"}]}}{"C845":{"preferredName":"Streptozocin","code":"C845","definitions":[{"definition":"A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Streptozocin","termGroup":"PT","termSource":"NCI"},{"termName":"2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"2-deoxy-2-[[(methylnitrosamino)-carbonyl]amino]-D-glucopyranose","termGroup":"SN","termSource":"NCI"},{"termName":"Streptozotocin","termGroup":"SY","termSource":"NCI"},{"termName":"STZ","termGroup":"AB","termSource":"NCI"},{"termName":"U-9889","termGroup":"CN","termSource":"NCI"},{"termName":"Zanosar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Carcinoid tumor and syndrome; Colorectal cancer, palliative; Hodgkin's disease; Metastatic islet cell carcinoma of the pancreas"},{"name":"CAS_Registry","value":"18883-66-4"},{"name":"CHEBI_ID","value":"CHEBI:9288"},{"name":"Chemical_Formula","value":"C8H15N3O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5W494URQ81"},{"name":"Legacy Concept Name","value":"Streptozocin"},{"name":"Maps_To","value":"Streptozocin"},{"name":"NCI_Drug_Dictionary_ID","value":"42831"},{"name":"NSC Number","value":"85998"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42831"},{"name":"PDQ_Open_Trial_Search_ID","value":"42831"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038432"}]}}{"C1238":{"preferredName":"Strontium Chloride Sr-89","code":"C1238","definitions":[{"definition":"A salt form of the radioactive metal strontium-89 that is absorbed by a part of growing bone. It is being studied in the treatment of bone pain caused by cancer that has spread to the bone.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Strontium Chloride Sr-89","termGroup":"PT","termSource":"NCI"},{"termName":"Metastron","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Palliation of pain in bone metastases"},{"name":"CAS_Registry","value":"38270-90-5"},{"name":"Chemical_Formula","value":"2Cl.Sr"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5R78837D4A"},{"name":"Legacy Concept Name","value":"Strontium_Chloride_Sr_89"},{"name":"Maps_To","value":"Strontium Chloride Sr-89"},{"name":"NCI_Drug_Dictionary_ID","value":"41810"},{"name":"NSC Number","value":"721349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41810"},{"name":"PDQ_Open_Trial_Search_ID","value":"41810"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0919292"}]}}{"C162773":{"preferredName":"Submicron Particle Paclitaxel Sterile Suspension","code":"C162773","definitions":[{"definition":"A suspension composed of uncoated, stable, submicron particles of the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intra-tumoral administration of the submicron particle paclitaxel sterile suspension, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The submicron particle paclitaxel is produced through a specific proprietary method of submicron particle production without the need for coating agents or carriers and allows for prolonged retention and sustained release at the tumor site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Submicron Particle Paclitaxel Sterile Suspension","termGroup":"PT","termSource":"NCI"},{"termName":"NanoPac","termGroup":"BR","termSource":"NCI"},{"termName":"Sterile Nanoparticle-based Paclitaxel Suspension","termGroup":"SY","termSource":"NCI"},{"termName":"Sterile Nanoparticulate Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Submicron Particle Paclitaxel","termGroup":"SY","termSource":"NCI"},{"termName":"Submicron Particle Paclitaxel Formulation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Submicron Particle Paclitaxel Sterile Suspension"},{"name":"NCI_Drug_Dictionary_ID","value":"799071"},{"name":"NCI_META_CUI","value":"CL973205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799071"},{"name":"PDQ_Open_Trial_Search_ID","value":"799071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116066":{"preferredName":"Sulfatinib","code":"C116066","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulfatinib","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL-012","termGroup":"CN","termSource":"NCI"},{"termName":"Surufatinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1308672-74-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B2K5L1L8S9"},{"name":"Maps_To","value":"Sulfatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"760894"},{"name":"NCI_META_CUI","value":"CL473485"},{"name":"PDQ_Closed_Trial_Search_ID","value":"760894"},{"name":"PDQ_Open_Trial_Search_ID","value":"760894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1424":{"preferredName":"Sulforaphane","code":"C1424","definitions":[{"definition":"A naturally-occurring phytochemical belonging to the class of isothiocyanates.  As the aglycone metabolite of glucosinolate glucoraphanin (sulforaphane glucosinolate), sulforaphane acts as an antioxidant and potent stimulator of endogenous detoxifying enzymes.  This agent displays anticarcinogenic properties due to its ability to induce phase II detoxification enzymes, such as glutathione S-transferase and quinone reductase, thereby providing protection against certain carcinogens and toxic, reactive oxygen species.  Broccoli sprouts contain large amounts of sulforaphane, which is also found in other cruciferous vegetables including cabbage and kale. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An isothiocyanate with a methylsulphinyl butane chain. The chemical structure is CS(=O)CCCCN=C=S.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Sulforaphane","termGroup":"PT","termSource":"NCI"},{"termName":"(+/-)-Sulforaphane","termGroup":"SY","termSource":"NCI"},{"termName":"1-Isothiocyanato-4-(methylsulfinyl)butane","termGroup":"SN","termSource":"NCI"},{"termName":"Sulfaforaphane","termGroup":"SY","termSource":"NCI"},{"termName":"Sulforafan","termGroup":"SY","termSource":"NCI"},{"termName":"Sulphoraphane","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"4478-93-7"},{"name":"CHEBI_ID","value":"CHEBI:47807"},{"name":"Chemical_Formula","value":"C6H11NOS2"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GA49J4310U"},{"name":"Legacy Concept Name","value":"Sulforaphane"},{"name":"Maps_To","value":"Sulforaphane"},{"name":"NCI_Drug_Dictionary_ID","value":"691987"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691987"},{"name":"PDQ_Open_Trial_Search_ID","value":"691987"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0163159"}]}}{"C850":{"preferredName":"Sulindac","code":"C850","definitions":[{"definition":"A nonsteroidal anti-inflammatory drug (NSAID) that is being studied as a treatment for cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulindac","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Aflodac","termGroup":"BR","termSource":"NCI"},{"termName":"Algocetil","termGroup":"FB","termSource":"NCI"},{"termName":"Apo-Sulin","termGroup":"FB","termSource":"NCI"},{"termName":"Arthrocine","termGroup":"FB","termSource":"NCI"},{"termName":"Artribid","termGroup":"FB","termSource":"NCI"},{"termName":"cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Citireuma","termGroup":"FB","termSource":"NCI"},{"termName":"Clinoril","termGroup":"BR","termSource":"NCI"},{"termName":"Clisundac","termGroup":"FB","termSource":"NCI"},{"termName":"Imbaral","termGroup":"FB","termSource":"NCI"},{"termName":"MK-231","termGroup":"CN","termSource":"NCI"},{"termName":"Novo-Sundac","termGroup":"FB","termSource":"NCI"},{"termName":"Reumofil","termGroup":"FB","termSource":"NCI"},{"termName":"Reumyl","termGroup":"FB","termSource":"NCI"},{"termName":"Sudac","termGroup":"FB","termSource":"NCI"},{"termName":"Sulindac Sulfoxide","termGroup":"SY","termSource":"NCI"},{"termName":"Sulinol","termGroup":"FB","termSource":"NCI"},{"termName":"Sulreuma","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Arthritis; inflammatory conditions"},{"name":"CAS_Registry","value":"38194-50-2"},{"name":"CHEBI_ID","value":"CHEBI:9352"},{"name":"Chemical_Formula","value":"C20H17FO3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"184SNS8VUH"},{"name":"Legacy Concept Name","value":"Sulindac"},{"name":"Maps_To","value":"Sulindac"},{"name":"NCI_Drug_Dictionary_ID","value":"41538"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41538"},{"name":"PDQ_Open_Trial_Search_ID","value":"41538"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038792"}]}}{"C1432":{"preferredName":"Sulofenur","code":"C1432","definitions":[{"definition":"A diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sulofenur","termGroup":"PT","termSource":"NCI"},{"termName":"LY186641","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"110311-27-8"},{"name":"Chemical_Formula","value":"C16H15ClN2O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z45N070N3S"},{"name":"Legacy Concept Name","value":"Sulofenur"},{"name":"Maps_To","value":"Sulofenur"},{"name":"NCI_Drug_Dictionary_ID","value":"41122"},{"name":"NSC Number","value":"656667"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41122"},{"name":"PDQ_Open_Trial_Search_ID","value":"41122"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0165187"}]}}{"C156270":{"preferredName":"Subasumstat","code":"C156270","definitions":[{"definition":"A small molecule inhibitor of sumoylation, with potential immune-activating and antineoplastic activities. Upon intravenous administration, subasumstat targets and covalently binds to the small ubiquitin-like modifier (SUMO; small ubiquitin-related modifier) protein, forming an adduct with SUMO protein (subasumstat-SUMO adduct). This prevents the transfer of SUMO from the SUMO-activating enzyme (SAE) to SUMO-conjugating enzyme UBC9. This prevents SUMO conjugation to lysine residues on target proteins and abrogates many sumoylated protein-mediated cellular processes that play key roles in tumor cells, including proliferation, DNA repair, metastasis and survival. In addition, by preventing sumoylation, subasumstat is able to increase the production of type 1 interferon (IFN), thereby increasing type 1 IFN-mediated signaling, activating innate effector cells and enhancing the antitumor innate immune responses. This may further increase tumor cell killing. Sumoylation, a post-translational modification that attaches the SUMO protein to target proteins, plays a key role in regulating their activity, function, subcellular localization and stability.  Sumoylation also plays a key role in inhibiting innate immune responses, specifically by inhibiting the pattern recognition receptor (PRR) pathway and preventing type 1 IFN expression. Abnormal sumoylation of target proteins is associated with many cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Subasumstat","termGroup":"PT","termSource":"NCI"},{"termName":"TAK 981","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-981","termGroup":"CN","termSource":"NCI"},{"termName":"TAK981","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858276-04-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XQ43H3V6M1"},{"name":"Maps_To","value":"Sumoylation Inhibitor TAK-981"},{"name":"NCI_Drug_Dictionary_ID","value":"795544"},{"name":"NCI_META_CUI","value":"CL562995"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795544"},{"name":"PDQ_Open_Trial_Search_ID","value":"795544"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71622":{"preferredName":"Sunitinib","code":"C71622","definitions":[{"definition":"A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). Sunitinib is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sunitinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"557795-19-4"},{"name":"CHEBI_ID","value":"CHEBI:38940"},{"name":"Chemical_Formula","value":"C22H27FN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"V99T50803M"},{"name":"Legacy Concept Name","value":"Sunitinib"},{"name":"Maps_To","value":"Sunitinib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1176020"}]}}{"C26673":{"preferredName":"Sunitinib Malate","code":"C26673","definitions":[{"definition":"A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). SU011248 is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sunitinib Malate","termGroup":"PT","termSource":"NCI"},{"termName":"Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"SU 011248","termGroup":"CN","termSource":"NCI"},{"termName":"SU 11248","termGroup":"CN","termSource":"NCI"},{"termName":"SU-011248","termGroup":"CN","termSource":"NCI"},{"termName":"SU-11248","termGroup":"CN","termSource":"NCI"},{"termName":"SU011248","termGroup":"CN","termSource":"NCI"},{"termName":"SU11248","termGroup":"CN","termSource":"NCI"},{"termName":"Sutent","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Gastrointestinal Stromal Tumor; Advanced Metastatic Renal Cell Carcinoma"},{"name":"CAS_Registry","value":"341031-54-7"},{"name":"Chemical_Formula","value":"C22H27FN4O2.C4H6O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LVX8N1UT73"},{"name":"Legacy Concept Name","value":"SU11248"},{"name":"Maps_To","value":"Sunitinib Malate"},{"name":"NCI_Drug_Dictionary_ID","value":"299061"},{"name":"NSC Number","value":"736511"},{"name":"PDQ_Closed_Trial_Search_ID","value":"299061"},{"name":"PDQ_Open_Trial_Search_ID","value":"299061"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1700685"}]}}{"C158082":{"preferredName":"Super Enhancer Inhibitor GZ17-6.02","code":"C158082","definitions":[{"definition":"A synthetic formulation of the Arum palaestinum plant that has been fortified with the already naturally occurring constituents of isovanillin, linolenic acid, and beta-sitosterol, with potential antineoplastic activity. Upon oral administration, GZ17-6.02 may induce apoptosis through caspase-3 activation and poly(ADP-ribose) polymerase (PARP) cleavage, inhibit tumor cell progression by attenuating macrophage infiltration, and inhibit the phosphorylation of several mediators of tumor cell proliferation including Src kinase, extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), epidermal growth factor receptor (EGFR), serine/threonine protein kinase AKT (protein kinase B), signal transducer and activator of transcription 2 (STAT-2), and serine/threonine-protein kinase Chk2 (Chk-2). GZ17-6.02 may also inhibit certain super enhancers (SEs) that play an important role in the regulation of the sonic hedgehog (SHH) pathway and cancer stem cell activity. Super enhancers (SEs) are unique areas of the genome that are densely bound by numerous transcription factors and play a pivotal role in the cell, including tissue specification, identity and maintenance. SEs are known to regulate the expression of associated genes and often drive high-level transcription.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Super Enhancer Inhibitor GZ17-6.02","termGroup":"PT","termSource":"NCI"},{"termName":"GZ17 6.02","termGroup":"CN","termSource":"NCI"},{"termName":"GZ17-6.02","termGroup":"CN","termSource":"NCI"},{"termName":"GZ176.02","termGroup":"CN","termSource":"NCI"},{"termName":"Synthetic Arum palaestinum derivative GZ17-6.02","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Super Enhancer Inhibitor GZ17-6.02"},{"name":"NCI_Drug_Dictionary_ID","value":"797048"},{"name":"NCI_META_CUI","value":"CL937695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797048"},{"name":"PDQ_Open_Trial_Search_ID","value":"797048"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C107503":{"preferredName":"Nogapendekin Alfa","code":"C107503","definitions":[{"definition":"A mutated form of the cytokine interleukin (IL)-15 (IL-15N72D), with potential immunomodulating and antineoplastic activities. Upon administration, nogapendekin alfa binds to the IL-15 receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory T-cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nogapendekin Alfa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1622189-43-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EW92EB4VEN"},{"name":"Maps_To","value":"Nogapendekin Alfa"},{"name":"Maps_To","value":"Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658787"}]}}{"C853":{"preferredName":"Suramin","code":"C853","definitions":[{"definition":"A drug that is used to treat infections caused by parasites. It is also being studied in the treatment of cancer. It belongs to the families of drugs called antiprotozoals and anthelmintics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suramin","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Trypanosomiasis; hormone-refractory prostate cancer"},{"name":"CAS_Registry","value":"145-63-1"},{"name":"CHEBI_ID","value":"CHEBI:45906"},{"name":"Chemical_Formula","value":"C51H40N6O23S6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6032D45BEM"},{"name":"Legacy Concept Name","value":"Suramin"},{"name":"Maps_To","value":"Suramin"},{"name":"NCI_Drug_Dictionary_ID","value":"40052"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40052"},{"name":"PDQ_Open_Trial_Search_ID","value":"40052"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0038880"}]}}{"C1848":{"preferredName":"Suramin Sodium","code":"C1848","definitions":[{"definition":"A sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suramin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"309 F","termGroup":"FB","termSource":"NCI"},{"termName":"8,8'-(Carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid Hexasodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"Antrypol","termGroup":"FB","termSource":"NCI"},{"termName":"Bayer 205","termGroup":"CN","termSource":"NCI"},{"termName":"Belganyl","termGroup":"FB","termSource":"NCI"},{"termName":"CI-1003","termGroup":"CN","termSource":"NCI"},{"termName":"Fourneau 309","termGroup":"FB","termSource":"NCI"},{"termName":"Germanin","termGroup":"FB","termSource":"NCI"},{"termName":"Metaret","termGroup":"BR","termSource":"NCI"},{"termName":"Moranyl","termGroup":"FB","termSource":"NCI"},{"termName":"Naganin","termGroup":"FB","termSource":"NCI"},{"termName":"Naganinum","termGroup":"FB","termSource":"NCI"},{"termName":"Naganol","termGroup":"FB","termSource":"NCI"},{"termName":"Naphuride","termGroup":"FB","termSource":"NCI"},{"termName":"Sodium Suramin","termGroup":"SY","termSource":"NCI"},{"termName":"Suramin Hexasodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"African trypanosomiasis; onchocerciasis"},{"name":"CAS_Registry","value":"129-46-4"},{"name":"Chemical_Formula","value":"C51H34N6O23S6.6Na"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"89521262IH"},{"name":"Legacy Concept Name","value":"Suramin_Sodium"},{"name":"Maps_To","value":"Suramin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"40052"},{"name":"NSC Number","value":"34936"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40052"},{"name":"PDQ_Open_Trial_Search_ID","value":"40052"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0813205"}]}}{"C37449":{"preferredName":"Survivin Antigen","code":"C37449","definitions":[{"definition":"A tumor-associated antigen. Vaccination with survivin antigen may result in a cytotoxic T-cell response against survivin antigen-expressing tumor cells, resulting in decreased tumor cell proliferation and tumor cell death. Overexpressed in many tumors, endogenous survivin inhibits tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Survivin Antigen","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Survivin_Antigen"},{"name":"Maps_To","value":"Survivin Antigen"},{"name":"NCI_Drug_Dictionary_ID","value":"346072"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346072"},{"name":"PDQ_Open_Trial_Search_ID","value":"346072"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1515097"}]}}{"C97951":{"preferredName":"Maveropepimut-S","code":"C97951","definitions":[{"definition":"A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of Maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maveropepimut-S","termGroup":"PT","termSource":"NCI"},{"termName":"DPX-Survivac","termGroup":"SY","termSource":"NCI"},{"termName":"MVP-S","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Survivin Antigen Vaccine DPX-Survivac"},{"name":"NCI_Drug_Dictionary_ID","value":"709395"},{"name":"NCI_META_CUI","value":"CL430558"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709395"},{"name":"PDQ_Open_Trial_Search_ID","value":"709395"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92578":{"preferredName":"Survivin mRNA Antagonist EZN-3042","code":"C92578","definitions":[{"definition":"A locked nucleic acid (LNA) antisense oligonucleotide targeting survivin mRNA, with potential antineoplastic activity. EZN-3042 hybridizes to survivin mRNA, thereby blocking translation of survivin protein and inhibiting survivin-induced anti-apoptotic activity and promoting tumor cell apoptosis in survivin-overexpressing tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. LNAs contain a methylene bridge linking 2'-oxygen and 4'-carbon of ribose sugar rings, thereby increasing their stability and decreasing degradation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Survivin mRNA Antagonist EZN-3042","termGroup":"PT","termSource":"NCI"},{"termName":"EZN-3042","termGroup":"CN","termSource":"NCI"},{"termName":"LNA-RNA Antagonist EZN-3042","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Survivin mRNA Antagonist EZN-3042"},{"name":"NCI_Drug_Dictionary_ID","value":"684391"},{"name":"PDQ_Closed_Trial_Search_ID","value":"684391"},{"name":"PDQ_Open_Trial_Search_ID","value":"684391"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2973480"}]}}{"C158607":{"preferredName":"Survivin-expressing CVD908ssb-TXSVN Vaccine","code":"C158607","definitions":[{"definition":"An orally bioavailable Salmonella-based survivin vaccine composed of a weakened form of a live strain of  Salmonella bacteria (CVD908ssb strain) that has been genetically modified to produce the tumor-associated antigen (TAA) survivin, with potential immunopotentiating and antineoplastic activities. Upon administration of the CVD908ssb-TXSVN vaccine, the expressed survivin stimulates the immune response to elicit a cytotoxic T-lymphocyte (CTL)-mediated immune response against survivin-expressing cancer cells, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Survivin-expressing CVD908ssb-TXSVN Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"CVD908ssb-TXSVN","termGroup":"CN","termSource":"NCI"},{"termName":"Salmonella-based Survivin Vaccine CVD908ssb-TXSVN","termGroup":"SY","termSource":"NCI"},{"termName":"TXSVN","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Survivin-expressing CVD908ssb-TXSVN Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"797123"},{"name":"NCI_META_CUI","value":"CL938073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797123"},{"name":"PDQ_Open_Trial_Search_ID","value":"797123"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116884":{"preferredName":"Sustained-release Lipid Inhaled Cisplatin","code":"C116884","definitions":[{"definition":"A sustained-release formulation for inhalation in which the inorganic platinum (Pt) agent cisplatin is encapsulated in lipids, with potential antineoplastic activity. Upon inhalation of the sustained-release lipid inhalation targeting (SLIT) cisplatin into the lungs, this agent forms highly reactive, positively charged, Pt complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. Pt complex binding introduces intrastrand and interstrand DNA cross-links, and DNA-Pt-protein cross-links. These cross-links result in apoptosis and cell growth inhibition of lung cancer cells. Encasement in liposomes prolongs cisplatin's efficacy when compared to intravenously administered cisplatin; inhalation of cisplatin improves its concentration at tumor sites in the lungs while minimizing its systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sustained-release Lipid Inhaled Cisplatin","termGroup":"PT","termSource":"NCI"},{"termName":"SLIT Cisplatin","termGroup":"BR","termSource":"NCI"},{"termName":"SR Inhaled Lipid Cisplatin","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained-release Lipid Inhalation Targeting Cisplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sustained-release Lipid Inhaled Cisplatin"},{"name":"NCI_Drug_Dictionary_ID","value":"420851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"420851"},{"name":"PDQ_Open_Trial_Search_ID","value":"420851"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541510"}]}}{"C126642":{"preferredName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101","code":"C126642","definitions":[{"definition":"A sustained-release (SR) hydrogel polymer-based formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon local administration of the SR MMC hydrogel formulation to the upper urinary tract via a ureteral catheter, the gel solidifies and deposits MMC locally to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures and solidifies at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for upper tract urothelial carcinoma (UTUC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101","termGroup":"PT","termSource":"NCI"},{"termName":"Mitogel","termGroup":"BR","termSource":"NCI"},{"termName":"MP77-08","termGroup":"CN","termSource":"NCI"},{"termName":"RTGel with Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"RTGel with MMC","termGroup":"SY","termSource":"NCI"},{"termName":"SR Mitomycin C","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained-release Mitomycin C Gel Formulation","termGroup":"SY","termSource":"NCI"},{"termName":"UGN-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sustained-release Mitomycin C Hydrogel Formulation UGN-101"},{"name":"NCI_Drug_Dictionary_ID","value":"779705"},{"name":"NCI_META_CUI","value":"CL503759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779705"},{"name":"PDQ_Open_Trial_Search_ID","value":"779705"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C158422":{"preferredName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102","code":"C158422","definitions":[{"definition":"A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-102, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in UGN-102 the strength of MMC is lower.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102","termGroup":"PT","termSource":"NCI"},{"termName":"Intravesical Mitomycin Gel UGN-102","termGroup":"SY","termSource":"NCI"},{"termName":"Mitomycin Urothelial Gel UGN-102","termGroup":"SY","termSource":"NCI"},{"termName":"MMC + UG-1 Gel","termGroup":"SY","termSource":"NCI"},{"termName":"RTGel with Mitomycin C UGN-102","termGroup":"SY","termSource":"NCI"},{"termName":"UGN 102","termGroup":"CN","termSource":"NCI"},{"termName":"UGN-102","termGroup":"CN","termSource":"NCI"},{"termName":"UGN102","termGroup":"CN","termSource":"NCI"},{"termName":"Vesigel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sustained-release Mitomycin C Hydrogel Formulation UGN-102"},{"name":"NCI_Drug_Dictionary_ID","value":"797493"},{"name":"NCI_META_CUI","value":"CL937895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797493"},{"name":"PDQ_Open_Trial_Search_ID","value":"797493"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"}]}}{"C123912":{"preferredName":"Sovleplenib","code":"C123912","definitions":[{"definition":"An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration of sovleplenib, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sovleplenib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-7-(4-(1-(Methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido(4,3-b)pyrazin-5-amine","termGroup":"SN","termSource":"NCI"},{"termName":"HMPL 523","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-523","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL523","termGroup":"CN","termSource":"NCI"},{"termName":"Spleen Tyrosine Kinase Inhibitor HMPL-523","termGroup":"SY","termSource":"NCI"},{"termName":"Syk Inhibitor HMPL-523","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1415792-84-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9CL6353KHO"},{"name":"Maps_To","value":"Syk Inhibitor HMPL-523"},{"name":"NCI_Drug_Dictionary_ID","value":"775837"},{"name":"NCI_META_CUI","value":"CL498276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775837"},{"name":"PDQ_Open_Trial_Search_ID","value":"775837"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2650":{"preferredName":"Synchrotope TA2M Plasmid DNA Vaccine","code":"C2650","definitions":[{"definition":"A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synchrotope TA2M Plasmid DNA Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synchrotope_TA2M_Plasmid_DNA_Vaccine"},{"name":"Maps_To","value":"Synchrotope TA2M Plasmid DNA Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38415"},{"name":"PDQ_Open_Trial_Search_ID","value":"38415"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134471"}]}}{"C28549":{"preferredName":"Synchrovax SEM Plasmid DNA Vaccine","code":"C28549","definitions":[{"definition":"A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synchrovax SEM Plasmid DNA Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Synchrotope MA2M Plasmid DNA Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synchrovax_SEM_Plasmid_DNA_Vaccine"},{"name":"Maps_To","value":"Synchrovax SEM Plasmid DNA Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38555"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38555"},{"name":"PDQ_Open_Trial_Search_ID","value":"38555"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134580"}]}}{"C62763":{"preferredName":"Synthetic Alkaloid PM00104","code":"C62763","definitions":[{"definition":"A synthetic alkaloid compound, related to natural alkaloid compounds, found in molluscs (jorumycin) and sponges (renieramycins), with potential antineoplastic activity. PM00104 reversibly binds to DNA, thereby inducing cytotoxicity due to its interference with DNA replication, transcription, and translation processes. DNA binding by this agent does not trigger DNA damage checkpoint responses, hence PM00104 demonstrates a manageable and reversible cytotoxicity as part of its antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Alkaloid PM00104","termGroup":"PT","termSource":"NCI"},{"termName":"Zalypsis","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"308359-57-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C21EZR41AY"},{"name":"Legacy Concept Name","value":"PM00104"},{"name":"Maps_To","value":"Synthetic Alkaloid PM00104"},{"name":"NCI_Drug_Dictionary_ID","value":"502184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"502184"},{"name":"PDQ_Open_Trial_Search_ID","value":"502184"},{"name":"PubMedID_Primary_Reference","value":"19584237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1568937"}]}}{"C116332":{"preferredName":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2","code":"C116332","definitions":[{"definition":"A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient's own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2","termGroup":"PT","termSource":"NCI"},{"termName":"APVAC2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2"},{"name":"NCI_Drug_Dictionary_ID","value":"761688"},{"name":"NCI_META_CUI","value":"CL473666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761688"},{"name":"PDQ_Open_Trial_Search_ID","value":"761688"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116331":{"preferredName":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1","code":"C116331","definitions":[{"definition":"A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1","termGroup":"PT","termSource":"NCI"},{"termName":"APVAC1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1"},{"name":"NCI_Drug_Dictionary_ID","value":"761678"},{"name":"NCI_META_CUI","value":"CL473665"},{"name":"PDQ_Closed_Trial_Search_ID","value":"761678"},{"name":"PDQ_Open_Trial_Search_ID","value":"761678"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120118":{"preferredName":"Synthetic hTERT DNA Vaccine INO-1400","code":"C120118","definitions":[{"definition":"A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic hTERT DNA Vaccine INO-1400","termGroup":"PT","termSource":"NCI"},{"termName":"INO-1400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic hTERT DNA Vaccine INO-1400"},{"name":"NCI_Drug_Dictionary_ID","value":"768008"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768008"},{"name":"PDQ_Open_Trial_Search_ID","value":"768008"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896835"}]}}{"C142139":{"preferredName":"Synthetic hTERT DNA Vaccine INO-1401","code":"C142139","definitions":[{"definition":"A DNA vaccine consisting of a plasmid encoding a synthetic, full-length sequence of the tumor-associated antigen (TAA) telomerase reverse transcriptase (TERT), which was derived from the consensus sequence from humans and primates and contains two immunogenic mutations (SynCon TERT), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of INO-1401 in combination with electroporation, TERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. TERT is the catalytic subunit of telomerase and synthesizes telomeric DNA at the chromosome ends. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, TERT is expressed by many types of human cancer cells, but its expression is low or non-existent in normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic hTERT DNA Vaccine INO-1401","termGroup":"PT","termSource":"NCI"},{"termName":"INO-1401","termGroup":"CN","termSource":"NCI"},{"termName":"SynCon TERT","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic hTERT DNA Vaccine INO-1401"},{"name":"NCI_Drug_Dictionary_ID","value":"791450"},{"name":"NCI_META_CUI","value":"CL540179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791450"},{"name":"PDQ_Open_Trial_Search_ID","value":"791450"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122400":{"preferredName":"Synthetic Hypericin","code":"C122400","definitions":[{"definition":"A topical ointment formulation containing a synthetic form of hypericin, an anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John's wort), with potential antineoplastic and photosensitizing activities. Upon topical administration of the ointment to the tumor site, hypericin becomes activated through the application of visible fluorescent light. During photoactivation, hypericin generates singlet oxygen, which induces DNA damage, necrosis and apoptosis, thereby inhibiting tumor cell growth. The use of visible light for activation avoids the risk of developing secondary malignancies, which are frequently associated with other photodynamic therapies that are dependent on ultraviolet A exposure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Hypericin","termGroup":"PT","termSource":"NCI"},{"termName":"Topical SGX301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Hypericin"},{"name":"NCI_Drug_Dictionary_ID","value":"772561"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772561"},{"name":"PDQ_Open_Trial_Search_ID","value":"772561"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053962"}]}}{"C129652":{"preferredName":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201","code":"C129652","definitions":[{"definition":"A therapeutic peptide vaccine consisting of two highly immunogenic synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoprotein E6, and conjugated to a proprietary toll-like receptor 2 (TLR2) ligand (TLR2-L) immunoadjuvant, with potential immunostimulating and antitumor activities. Upon administration, the TLR2-L moiety of the synthetic long E6 peptides TLR ligand conjugate vaccine targets and binds to TLRs expressed on antigen-presenting cells (APCs), particularly dendritic cells (DCs). This increases the direct targeting of, binding to, uptake by, and processing of the SLPs into small pieces by the DCs. The processed viral epitopes are presented by DCs, which activate and stimulate the host immune system to mount specific cytotoxic T-lymphocyte (CTL) and helper T (Th) cell responses against HPV E6-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased growth of HPV E6-expressing tumor cells. The E6 oncoprotein is implicated in tumorigenesis in a variety of cancers. The TLR2-L improves antigen processing and presentation by, and activation of APCs, thereby improving the immunostimulatory effect of the vaccine. The two peptides cover the most immunodominant regions of the HPV16 E6 oncogenic protein and contain both Th and CTL epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201","termGroup":"PT","termSource":"NCI"},{"termName":"Hespecta","termGroup":"FB","termSource":"NCI"},{"termName":"HPV E Six Peptide Conjugated to Amplivant","termGroup":"SY","termSource":"NCI"},{"termName":"HPV16 peptides AMPLIVANT Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"ISA201","termGroup":"CN","termSource":"NCI"},{"termName":"PV E6 Peptides-Amplivant","termGroup":"SY","termSource":"NCI"},{"termName":"PV16 E6 Peptide Conjugated to Amplivant","termGroup":"SY","termSource":"NCI"},{"termName":"SLP HPV16 E6/Amplivant Vaccine ISA201","termGroup":"SY","termSource":"NCI"},{"termName":"SLP-Amplivant ISA201","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201"},{"name":"NCI_Drug_Dictionary_ID","value":"784216"},{"name":"NCI_META_CUI","value":"CL512627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784216"},{"name":"PDQ_Open_Trial_Search_ID","value":"784216"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111037":{"preferredName":"Synthetic Long E6/E7 Peptides Vaccine HPV-01","code":"C111037","definitions":[{"definition":"A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Long E6/E7 Peptides Vaccine HPV-01","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-01","termGroup":"CN","termSource":"NCI"},{"termName":"ISA101","termGroup":"CN","termSource":"NCI"},{"termName":"SLP-HPV-01","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Long E6/E7 Peptides Vaccine HPV-01"},{"name":"NCI_Drug_Dictionary_ID","value":"751803"},{"name":"NCI_META_CUI","value":"CL453544"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751803"},{"name":"PDQ_Open_Trial_Search_ID","value":"751803"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C150809":{"preferredName":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b","code":"C150809","definitions":[{"definition":"A therapeutic peptide vaccine consisting of nine overlapping synthetic long peptides (SLPs), 25 to 32 amino acids in size, derived from the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E6 and three SLPs, each 35 amino acids in size, derived from HPV16 E7, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the synthetic long HPV16 E6/E7 peptides vaccine ISA101b is taken up and the long peptides are proteolytically degraded to form shorter peptide epitopes by dendritic cells (DCs). The processed viral epitopes are presented by DCs, which stimulate the host immune system to mount helper T-cell and cytotoxic T-lymphocyte (CTL) responses against HPV16 E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The HPV16 E6 and E7 oncoproteins are implicated in the tumorigenesis of a variety of cancers. The SLPs allow optimal presentation by antigen-presenting cells (APCs). Compared to ISA101, the E6 SLPs in ISA101b are identical, overlap by ten to eighteen residues and cover the complete sequence of HPV16 E6. However, ISA101 has four overlapping SLPs E7 peptides while ISA101b has three E7 SLPs, which leaves seven amino acids of the E7 SLPs uncovered in ISA101b but this modification is not likely to alter the immunogenicity of ISA101b.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E6/E7-SLP ISA101b","termGroup":"SY","termSource":"NCI"},{"termName":"ISA 101b","termGroup":"CN","termSource":"NCI"},{"termName":"ISA-101b","termGroup":"CN","termSource":"NCI"},{"termName":"ISA101b","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b"},{"name":"NCI_Drug_Dictionary_ID","value":"793552"},{"name":"NCI_META_CUI","value":"CL552668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793552"},{"name":"PDQ_Open_Trial_Search_ID","value":"793552"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26674":{"preferredName":"T900607","code":"C26674","definitions":[{"definition":"A pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called tubulin-binding agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"T900607","termGroup":"PT","termSource":"NCI"},{"termName":"T900607","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"261944-52-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IC9O2HT1X1"},{"name":"Legacy Concept Name","value":"T900607"},{"name":"Maps_To","value":"T900607"},{"name":"NCI_Drug_Dictionary_ID","value":"271169"},{"name":"PDQ_Closed_Trial_Search_ID","value":"271169"},{"name":"PDQ_Open_Trial_Search_ID","value":"271169"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327873"}]}}{"C91727":{"preferredName":"Tabalumab","code":"C91727","definitions":[{"definition":"A human IgG4 monoclonal antibody against B-cell activating factor (BAFF), with potential immunomodulating and antineoplastic activities. Tabalumab binds to and inhibits the activity of both soluble and cell surface-bound BAFF. This may reduce the activity, proliferation and survival of B-cells. A dysregulated expression of BAFF, a member of the tumor necrosis factor (TNF) family of proteins, is often seen in certain autoimmune diseases and certain cancers, and may promote B lymphocyte activation, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tabalumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BAFF Monoclonal Antibody LY2127399","termGroup":"SY","termSource":"NCI"},{"termName":"LY2127399","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1143503-67-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PQP8VH3MJW"},{"name":"Maps_To","value":"Tabalumab"},{"name":"NCI_Drug_Dictionary_ID","value":"600180"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600180"},{"name":"PDQ_Open_Trial_Search_ID","value":"600180"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984518"}]}}{"C143140":{"preferredName":"Tabelecleucel","code":"C143140","definitions":[{"definition":"Allogeneic cytotoxic T-lymphocytes (CTLs) selective for the tumor-associated antigens (TAAs) expressed by the Epstein-Barr virus (EBV), with potential immunostimulating and antineoplastic activities. Upon administration, and after hematopoietic cell transplants (HCT) or solid organ transplants (SOT), or during certain other immunocompromised states, tabelecleucel targets and binds to EBV-associated antigens expressed on EBV-infected cells. This results in lysis of EBV-infected cells and prevents growth of EBV-associated cancer cells. EBV is associated with a variety of cancers and post-transplant lymphoproliferative disorders (EBV+ PTLD).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tabelecleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic EBV-specific CTLs ATA129","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic EBV-specific Cytotoxic T-lymphocytes","termGroup":"SY","termSource":"NCI"},{"termName":"ATA 129","termGroup":"CN","termSource":"NCI"},{"termName":"ATA-129","termGroup":"CN","termSource":"NCI"},{"termName":"ATA129","termGroup":"CN","termSource":"NCI"},{"termName":"CTLs ATA129","termGroup":"SY","termSource":"NCI"},{"termName":"EBV-CTLs","termGroup":"SY","termSource":"NCI"},{"termName":"Ebvallo","termGroup":"FB","termSource":"NCI"},{"termName":"Tab-cel","termGroup":"FB","termSource":"NCI"},{"termName":"Teb-cel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"G3NJ7M8N4H"},{"name":"Maps_To","value":"Tabelecleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"792147"},{"name":"NCI_META_CUI","value":"CL541621"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792147"},{"name":"PDQ_Open_Trial_Search_ID","value":"792147"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2202":{"preferredName":"Tacedinaline","code":"C2202","definitions":[{"definition":"A substance being studied in the treatment of non-small cell lung cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by the induction of differentiation, the inhibition of cell proliferation, and apoptosis in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tacedinaline","termGroup":"PT","termSource":"NCI"},{"termName":"4-(Acetylamino)-N-(2-aminophenyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Acetyldinaline","termGroup":"SY","termSource":"NCI"},{"termName":"CI-994","termGroup":"CN","termSource":"NCI"},{"termName":"GOE5549","termGroup":"CN","termSource":"NCI"},{"termName":"N-acetyl Dinaline","termGroup":"SN","termSource":"NCI"},{"termName":"N-acetyldinaline","termGroup":"SN","termSource":"NCI"},{"termName":"PD 123654","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"112522-64-2"},{"name":"Chemical_Formula","value":"C15H15N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UMF554N5FG"},{"name":"Legacy Concept Name","value":"Acetyldinaline"},{"name":"Maps_To","value":"Tacedinaline"},{"name":"NCI_Drug_Dictionary_ID","value":"37825"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37825"},{"name":"PDQ_Open_Trial_Search_ID","value":"37825"},{"name":"PubMedID_Primary_Reference","value":"18497959"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0217598"}]}}{"C64769":{"preferredName":"Tagraxofusp-erzs","code":"C64769","definitions":[{"definition":"A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with potential antineoplastic activity. Upon intravenous administration of tagraxofusp-erzs, the IL3 moiety binds to IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin both catalyzes the ADP-ribosylation of, and inactivates, translation elongation factor 2 (EF-2), which results in the inhibition of translation during protein synthesis. IL3 may be overexpressed by a variety of cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia (AML).","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of myeloid leukemia (a disease in which too many immature non-lymphocyte white blood cells are found in the blood and bone marrow). DT388IL3 fusion protein is made by combining IL-3 with a toxic substance. The IL-3 attaches to the cancer cells and the toxic substance kills them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tagraxofusp-erzs","termGroup":"PT","termSource":"NCI"},{"termName":"Diphtheria Toxin(388)-Interleukin-3 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"DT(388)-IL3 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"Elzonris","termGroup":"BR","termSource":"NCI"},{"termName":"IL3R-targeting Fusion Protein SL-401","termGroup":"SY","termSource":"NCI"},{"termName":"S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol","termGroup":"SN","termSource":"NCI"},{"termName":"SL 401","termGroup":"CN","termSource":"NCI"},{"termName":"SL-401","termGroup":"CN","termSource":"NCI"},{"termName":"SL401","termGroup":"CN","termSource":"NCI"},{"termName":"Tagraxofusp","termGroup":"SY","termSource":"NCI"},{"termName":"Tagraxofusp ERZS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"blastic plasmacytoid dendritic cell neoplasm (BPDCN)"},{"name":"CAS_Registry","value":"2055491-00-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8ZHS5657EH"},{"name":"Legacy Concept Name","value":"Diphtheria_Toxin_388_Interleukin-3_Fusion_Protein"},{"name":"Maps_To","value":"Tagraxofusp-erzs"},{"name":"NCI_Drug_Dictionary_ID","value":"516002"},{"name":"PDQ_Closed_Trial_Search_ID","value":"516002"},{"name":"PDQ_Open_Trial_Search_ID","value":"516002"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3886200"}]}}{"C48264":{"preferredName":"Talabostat","code":"C48264","definitions":[{"definition":"A small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer, including certain types of lung, pancreas, and brain cancer. Talabostat may help the immune system block the growth of cancer cells. It may also increase the growth of new blood cells. It is a type of enzyme inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Talabostat","termGroup":"PT","termSource":"NCI"},{"termName":"[(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BXCL 701","termGroup":"CN","termSource":"NCI"},{"termName":"BXCL-701","termGroup":"CN","termSource":"NCI"},{"termName":"BXCL701","termGroup":"CN","termSource":"NCI"},{"termName":"PT-100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"149682-77-9"},{"name":"Chemical_Formula","value":"C9H19BN2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KZ1O2SH88Z"},{"name":"Legacy Concept Name","value":"Talabostat"},{"name":"Maps_To","value":"Talabostat"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002307"}]}}{"C80682":{"preferredName":"Talabostat Mesylate","code":"C80682","definitions":[{"definition":"A substance being studied in the treatment of cancer, including certain types of lung, pancreas, and brain cancer. Talabostat mesylate may help the immune system block the growth of cancer cells. It may also increase the growth of new blood cells. It is a type of enzyme inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The mesylate salt of an orally active small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talabostat Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"((2R)-1-((2S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)boronic Acid Methanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Val-boro-Pro","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"150080-09-4"},{"name":"Chemical_Formula","value":"C9H19BN2O3.CH4O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V8ZG4Y1B51"},{"name":"Legacy Concept Name","value":"Talabostat_Mesylate"},{"name":"Maps_To","value":"Talabostat Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"372906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"372906"},{"name":"PDQ_Open_Trial_Search_ID","value":"372906"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311786"}]}}{"C102784":{"preferredName":"Talacotuzumab","code":"C102784","definitions":[{"definition":"A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talacotuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IL-3 Receptor Alpha Monoclonal Antibody CSL362","termGroup":"SY","termSource":"NCI"},{"termName":"CSL 362","termGroup":"CN","termSource":"NCI"},{"termName":"CSL362","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-56022473","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ56022473","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1826831-79-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X8JR0I7JE1"},{"name":"Maps_To","value":"Talacotuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"736467"},{"name":"NCI_META_CUI","value":"CL437022"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736467"},{"name":"PDQ_Open_Trial_Search_ID","value":"736467"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78460":{"preferredName":"Talactoferrin Alfa","code":"C78460","definitions":[{"definition":"A drug being studied in the treatment of kidney cancer that has spread. It is also being studied in the treatment of other types of cancer and other conditions. Talactoferrin increases the activity of dendritic cells (a type of immune cell) to help kill cancer cells. It is a form of human lactoferrin (a protein found in milk, tears, mucus, bile, and some white blood cells) that is made in the laboratory. Talactoferrin is a type of recombinant protein and a type of immunomodulatory protein.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable recombinant human lactoferrin produced in the fungus Aspergillus niger with potential antineoplastic and immunomodulating activities. Upon oral administration, talactoferrin is transported into small intestinal Peyer's patches of the gut-associated lymphoreticular tissues (GALT), where it recruits circulating immature dendritic cells (DCs) bearing tumor antigens and induces their maturation. In the GALT, DC maturation in the presence of tumor antigens and lymphoid effector cells may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells; activation of tumor-draining lymph nodes, cellular infiltration of distant tumors, and tumor-cell death may follow. Raising the initial immune response in the GALT, distant from the primary tumor, may counter local tumor-mediated immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talactoferrin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Oral Recombinant Human Lactoferrin","termGroup":"SY","termSource":"NCI"},{"termName":"Oral rhLF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"renal cell carcinoma"},{"name":"CAS_Registry","value":"308240-58-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7A055A9QRR"},{"name":"Legacy Concept Name","value":"Talactoferrin"},{"name":"Maps_To","value":"Talactoferrin Alfa"},{"name":"NCI_Drug_Dictionary_ID","value":"394101"},{"name":"PDQ_Closed_Trial_Search_ID","value":"394101"},{"name":"PDQ_Open_Trial_Search_ID","value":"394101"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872514"}]}}{"C103826":{"preferredName":"Taladegib","code":"C103826","definitions":[{"definition":"An orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity. Taladegib inhibits signaling that is mediated by the Hh pathway protein Smo, which may result in a suppression of the Hh signaling pathway and may lead to the inhibition of the proliferation of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taladegib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Benzamide, 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"LY-2940680","termGroup":"CN","termSource":"NCI"},{"termName":"LY2940680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1258861-20-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QY8BWX1LJ5"},{"name":"Maps_To","value":"Taladegib"},{"name":"NCI_Drug_Dictionary_ID","value":"688313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688313"},{"name":"PDQ_Open_Trial_Search_ID","value":"688313"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641628"}]}}{"C38139":{"preferredName":"Talampanel","code":"C38139","definitions":[{"definition":"A substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity.  Talampanel antagonizes the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talampanel","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-(-)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine","termGroup":"SN","termSource":"NCI"},{"termName":"GYKI-53773","termGroup":"CN","termSource":"NCI"},{"termName":"LY-300164","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"161832-65-1"},{"name":"Chemical_Formula","value":"C19H19N3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CVS43XG1L5"},{"name":"Legacy Concept Name","value":"Talampanel"},{"name":"Maps_To","value":"Talampanel"},{"name":"NCI_Drug_Dictionary_ID","value":"315898"},{"name":"PDQ_Closed_Trial_Search_ID","value":"315898"},{"name":"PDQ_Open_Trial_Search_ID","value":"315898"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0250723"}]}}{"C26675":{"preferredName":"Talaporfin Sodium","code":"C26675","definitions":[{"definition":"A drug used in photodynamic therapy. When absorbed by cancer cells and exposed to light, the drug becomes active and kills the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.  After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talaporfin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Laserphyrin","termGroup":"FB","termSource":"NCI"},{"termName":"LS11","termGroup":"CN","termSource":"NCI"},{"termName":"ME2906","termGroup":"CN","termSource":"NCI"},{"termName":"Mono-L-aspartyl Chlorin e6","termGroup":"SN","termSource":"NCI"},{"termName":"NPe6","termGroup":"AB","termSource":"NCI"},{"termName":"Taporfin Sodium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220201-34-3"},{"name":"Chemical_Formula","value":"C38H37N5O9.4Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L63605PZ70"},{"name":"Legacy Concept Name","value":"Taporfin_Sodium"},{"name":"Maps_To","value":"Talaporfin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"258313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"258313"},{"name":"PDQ_Open_Trial_Search_ID","value":"258313"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2350202"}]}}{"C95733":{"preferredName":"Talazoparib","code":"C95733","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talazoparib","termGroup":"PT","termSource":"NCI"},{"termName":"BMN 673","termGroup":"CN","termSource":"NCI"},{"termName":"BMN-673","termGroup":"CN","termSource":"NCI"},{"termName":"BMN673","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1207456-01-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9QHX048FRV"},{"name":"Maps_To","value":"Talazoparib"},{"name":"NCI_Drug_Dictionary_ID","value":"694964"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694964"},{"name":"PDQ_Open_Trial_Search_ID","value":"694964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4042960"}]}}{"C61314":{"preferredName":"Talimogene Laherparepvec","code":"C61314","definitions":[{"definition":"An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talimogene Laherparepvec","termGroup":"PT","termSource":"NCI"},{"termName":"ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene","termGroup":"SY","termSource":"NCI"},{"termName":"Imlygic","termGroup":"BR","termSource":"NCI"},{"termName":"JS1 34.5-hGMCSF 47- pA-","termGroup":"CN","termSource":"NCI"},{"termName":"OncoVEX GM-CSF","termGroup":"AQS","termSource":"NCI"},{"termName":"T-VEC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery"},{"name":"CAS_Registry","value":"1187560-31-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"07730V90L6"},{"name":"Legacy Concept Name","value":"GM-CSF-Encoding_Oncolytic_Herpes_Simplex_Virus_Vaccine"},{"name":"Maps_To","value":"Talimogene Laherparepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"485296"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485296"},{"name":"PDQ_Open_Trial_Search_ID","value":"485296"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831828"}]}}{"C1603":{"preferredName":"Tallimustine","code":"C1603","definitions":[{"definition":"A benzoyl mustard derivative of the antiviral agent distamycin A with potential antineoplastic activity. Tallimustine selectively binds to A-T rich regions in the minor groove of DNA and alkylates at the N3 position of adenine in a highly sequence-specific manner. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. Moreover, unlike other clinical nitrogen mustards, tallimustine does not carry out guanine-N7 alkylation in the major groove of DNA, which may lead to a high selectivity of action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tallimustine","termGroup":"PT","termSource":"NCI"},{"termName":"FCE 24517","termGroup":"CN","termSource":"NCI"},{"termName":"PNU-152241","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"115308-98-0"},{"name":"Chemical_Formula","value":"C32H38Cl2N10O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"71193OXG6S"},{"name":"Legacy Concept Name","value":"Tallimustine"},{"name":"Maps_To","value":"Tallimustine"},{"name":"NCI_Drug_Dictionary_ID","value":"42145"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42145"},{"name":"PDQ_Open_Trial_Search_ID","value":"42145"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0286890"}]}}{"C79841":{"preferredName":"Talmapimod","code":"C79841","definitions":[{"definition":"An orally bioavailable, small-molecule, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activities. Talmapimod specifically binds to and inhibits the phosphorylation of p38 MAPK, which may result in the induction of tumor cell apoptosis, the inhibition of tumor cell proliferation, and the inhibition of tumor angiogenesis. This agent may also enhance proteasome inhibitor-induced apoptosis. p38 MAPK is a serine/threonine protein kinase involved in a MAPK signaling cascade that controls cellular responses to various environmental stresses, cytokines, and endotoxins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talmapimod","termGroup":"PT","termSource":"NCI"},{"termName":"1H-indole-3-acetamide, 6-Chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1- piperazinyl]carbonyl]-N,N,1-trimethyl-alpha-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"2-[6-Chloro-5-[[(2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazin-1-yl]carbonyl]-1- methyl-1H-indol-3-yl]-N,N-dimethyl-2-oxoacetamide","termGroup":"SN","termSource":"NCI"},{"termName":"SCIO 469","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"309913-83-5"},{"name":"Chemical_Formula","value":"C27H30ClFN4O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B1E00KQ6NT"},{"name":"Legacy Concept Name","value":"Talmapimod"},{"name":"Maps_To","value":"Talmapimod"},{"name":"NCI_Drug_Dictionary_ID","value":"387795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"387795"},{"name":"PDQ_Open_Trial_Search_ID","value":"387795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541463"}]}}{"C29341":{"preferredName":"Talotrexin","code":"C29341","definitions":[{"definition":"A substance that is being studied in the treatment of leukemia and some other types of cancer. It belongs to the family of drugs called antifolates.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talotrexin","termGroup":"PT","termSource":"NCI"},{"termName":"N(alpha)-(4-Amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine","termGroup":"SN","termSource":"NCI"},{"termName":"PT523","termGroup":"CN","termSource":"NCI"},{"termName":"Talopterin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"113857-87-7"},{"name":"Chemical_Formula","value":"C27H27N9O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A8E516A20K"},{"name":"Legacy Concept Name","value":"PT523"},{"name":"Maps_To","value":"Talotrexin"},{"name":"NSC Number","value":"623017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0251361"}]}}{"C80159":{"preferredName":"Talotrexin Ammonium","code":"C80159","definitions":[{"definition":"An ammonium salt of tallotrexin, an analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Talotrexin Ammonium","termGroup":"PT","termSource":"NCI"},{"termName":"2-(((4S)-4-Carboxy-4-((4-(((2,4-diaminopteridin-6-yl)methyl)amino)benzoyl)amino)butyl)carbamoyl)benzoic Acid Monoammonium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"PT-523","termGroup":"CN","termSource":"NCI"},{"termName":"PT523","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"648420-92-2"},{"name":"Chemical_Formula","value":"C27H27N9O6.H3N"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"686WJT9102"},{"name":"Legacy Concept Name","value":"Talotrexin_Ammonium"},{"name":"Maps_To","value":"Talotrexin Ammonium"},{"name":"NCI_Drug_Dictionary_ID","value":"387796"},{"name":"NSC Number","value":"712783"},{"name":"PDQ_Closed_Trial_Search_ID","value":"387796"},{"name":"PDQ_Open_Trial_Search_ID","value":"387796"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0288639"}]}}{"C75998":{"preferredName":"Taltobulin","code":"C75998","definitions":[{"definition":"An analogue of the naturally occurring tripeptide hemiasterlin, with potential antimitotic and antineoplastic activities. Taltobulin binds tubulin in a similar manner as colchicine and inhibits tubulin polymerization. This results in the disruption of the cytoskeleton, ultimately leading to cell cycle arrest in G2/M phase, blockage of cell division and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taltobulin","termGroup":"PT","termSource":"NCI"},{"termName":"HTI-286","termGroup":"CN","termSource":"NCI"},{"termName":"SPA-110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"228266-40-8"},{"name":"Chemical_Formula","value":"C27H43N3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J6D6912BXS"},{"name":"Legacy Concept Name","value":"Taltobulin"},{"name":"Maps_To","value":"Taltobulin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1258191"}]}}{"C150585":{"preferredName":"TAM/c-Met Inhibitor RXDX-106","code":"C150585","definitions":[{"definition":"An orally available and selective inhibitor of the receptor tyrosine kinase (RTK) activity of both hepatocyte growth factor receptor (c-Met; HGFR) and receptors in the TYRO3, AXL, and MER (TAM) family, with potential immunomodulating and antineoplastic activities. Upon oral administration of TAM/c-Met inhibitor RXDX-106, this agent selectively targets and binds to TYRO3, AXL, MER and c-Met, and prevents their RTK activity. This blocks TYRO3/AXL/MER/c-Met-mediated signal transduction pathways, and inhibits the proliferation and migration of TYRO3-, AXL-, MER- and c-Met-overexpressing tumor cells. Inhibition of the TAM family in the tumor microenvironment (TME) activates the immune system in the TME, reverses TAM mediated immunosuppression and enhances the anti-tumor immune response, which lead to immune-mediated tumor cell killing. TYRO3, AXL and MER, members of the TAM family of RTKs, are overexpressed in many tumor cell types. TAMs play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis. c-Met, also overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. In the TME, TAM expression on immune cells contributes to tumor cell evasion of immune surveillance and to the negative regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAM/c-Met Inhibitor RXDX-106","termGroup":"PT","termSource":"NCI"},{"termName":"CEP 40783","termGroup":"CN","termSource":"NCI"},{"termName":"CEP-40783","termGroup":"CN","termSource":"NCI"},{"termName":"CEP40783","termGroup":"CN","termSource":"NCI"},{"termName":"N-[4-(6,7-Dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"RXDX 106","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX-106","termGroup":"CN","termSource":"NCI"},{"termName":"RXDX106","termGroup":"CN","termSource":"NCI"},{"termName":"TYRO3/AXL/MER/c-Met Inhibitor RXDX-106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1437321-24-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1969ZJE05Q"},{"name":"Maps_To","value":"TAM/c-Met Inhibitor RXDX-106"},{"name":"NCI_Drug_Dictionary_ID","value":"793447"},{"name":"NCI_META_CUI","value":"CL552337"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793447"},{"name":"PDQ_Open_Trial_Search_ID","value":"793447"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71025":{"preferredName":"Tamibarotene","code":"C71025","definitions":[{"definition":"An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamibarotene","termGroup":"PT","termSource":"NCI"},{"termName":"4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)","termGroup":"SY","termSource":"NCI"},{"termName":"Am-80","termGroup":"CN","termSource":"NCI"},{"termName":"Am80","termGroup":"CN","termSource":"NCI"},{"termName":"Benzoic Acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-Tetramethyl-2-naphthalenyl)amino)carbonyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"INNO-507","termGroup":"CN","termSource":"NCI"},{"termName":"N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Retinobenzoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"SY-1425","termGroup":"CN","termSource":"NCI"},{"termName":"TM-411","termGroup":"CN","termSource":"NCI"},{"termName":"TOS-80T","termGroup":"CN","termSource":"NCI"},{"termName":"Z-208","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"94497-51-5"},{"name":"CHEBI_ID","value":"CHEBI:32181"},{"name":"Chemical_Formula","value":"C22H25NO3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"08V52GZ3H9"},{"name":"Legacy Concept Name","value":"Tamibarotene"},{"name":"Maps_To","value":"Tamibarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"571791"},{"name":"NSC Number","value":"608000"},{"name":"PDQ_Closed_Trial_Search_ID","value":"571791"},{"name":"PDQ_Open_Trial_Search_ID","value":"571791"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567753"}]}}{"C121664":{"preferredName":"Taminadenant","code":"C121664","definitions":[{"definition":"An orally bioavailable adenosine A2A receptor (A2AR) antagonist, with potential antineoplastic activity. Upon administration, A2AR antagonist PBF-509 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This abrogates the adenosine/A2AR-mediated inhibition of T-lymphocytes and activates a T-cell-mediated immune response against tumor cells, thereby reducing proliferation of susceptible tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often produced in excess by cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taminadenant","termGroup":"PT","termSource":"NCI"},{"termName":"4-Pyrimidinamine, 5-Bromo-2,6-di-1H-pyrazol-1-yl-","termGroup":"SY","termSource":"NCI"},{"termName":"A2AR Antagonist PBF-509","termGroup":"SY","termSource":"NCI"},{"termName":"PBF-509","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1337962-47-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"84I5UEP321"},{"name":"Maps_To","value":"Taminadenant"},{"name":"NCI_Drug_Dictionary_ID","value":"770798"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770798"},{"name":"PDQ_Open_Trial_Search_ID","value":"770798"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053608"}]}}{"C62078":{"preferredName":"Tamoxifen","code":"C62078","definitions":[{"definition":"A drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamoxifen","termGroup":"PT","termSource":"NCI"},{"termName":"1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene","termGroup":"SN","termSource":"NCI"},{"termName":"TMX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"10540-29-1"},{"name":"CHEBI_ID","value":"CHEBI:41774"},{"name":"Chemical_Formula","value":"C26H29NO"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"094ZI81Y45"},{"name":"Legacy Concept Name","value":"Tamoxifen_Base"},{"name":"Maps_To","value":"Tamoxifen"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039286"}]}}{"C855":{"preferredName":"Tamoxifen Citrate","code":"C855","definitions":[{"definition":"A drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen citrate is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen citrate is a type of antiestrogen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tamoxifen Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate","termGroup":"SN","termSource":"NCI"},{"termName":"(Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate","termGroup":"SN","termSource":"NCI"},{"termName":"1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene Citrate","termGroup":"SN","termSource":"NCI"},{"termName":"Apo-Tamox","termGroup":"FB","termSource":"NCI"},{"termName":"Clonoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Dignotamoxi","termGroup":"FB","termSource":"NCI"},{"termName":"Ebefen","termGroup":"FB","termSource":"NCI"},{"termName":"Emblon","termGroup":"FB","termSource":"NCI"},{"termName":"Estroxyn","termGroup":"FB","termSource":"NCI"},{"termName":"Fentamox","termGroup":"FB","termSource":"NCI"},{"termName":"Gen-Tamoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Genox","termGroup":"FB","termSource":"NCI"},{"termName":"ICI 46,474","termGroup":"CN","termSource":"NCI"},{"termName":"ICI 46474","termGroup":"CN","termSource":"NCI"},{"termName":"ICI-46474","termGroup":"CN","termSource":"NCI"},{"termName":"ICI46474","termGroup":"CN","termSource":"NCI"},{"termName":"Jenoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Kessar","termGroup":"FB","termSource":"NCI"},{"termName":"Ledertam","termGroup":"FB","termSource":"NCI"},{"termName":"Lesporene","termGroup":"FB","termSource":"NCI"},{"termName":"Nolgen","termGroup":"FB","termSource":"NCI"},{"termName":"Noltam","termGroup":"FB","termSource":"NCI"},{"termName":"Nolvadex","termGroup":"BR","termSource":"NCI"},{"termName":"Nolvadex-D","termGroup":"FB","termSource":"NCI"},{"termName":"Nourytam","termGroup":"FB","termSource":"NCI"},{"termName":"Novo-Tamoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Novofen","termGroup":"FB","termSource":"NCI"},{"termName":"Noxitem","termGroup":"FB","termSource":"NCI"},{"termName":"Oestrifen","termGroup":"FB","termSource":"NCI"},{"termName":"Oncotam","termGroup":"FB","termSource":"NCI"},{"termName":"PMS-Tamoxifen","termGroup":"FB","termSource":"NCI"},{"termName":"Soltamox","termGroup":"BR","termSource":"NCI"},{"termName":"TAM","termGroup":"AB","termSource":"NCI"},{"termName":"Tamax","termGroup":"FB","termSource":"NCI"},{"termName":"Tamaxin","termGroup":"FB","termSource":"NCI"},{"termName":"Tamifen","termGroup":"FB","termSource":"NCI"},{"termName":"Tamizam","termGroup":"FB","termSource":"NCI"},{"termName":"Tamofen","termGroup":"FB","termSource":"NCI"},{"termName":"Tamoxasta","termGroup":"FB","termSource":"NCI"},{"termName":"Tamoxifeni Citras","termGroup":"FB","termSource":"NCI"},{"termName":"Zemide","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Endometrial cancer; Gynecomastia; Melanoma; Ovarian cancer"},{"name":"CAS_Registry","value":"54965-24-1"},{"name":"CHEBI_ID","value":"CHEBI:9397"},{"name":"Chemical_Formula","value":"C26H29NO.C6H8O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7FRV7310N6"},{"name":"Legacy Concept Name","value":"Tamoxifen"},{"name":"Maps_To","value":"Tamoxifen Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"42901"},{"name":"NSC Number","value":"180973"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42901"},{"name":"PDQ_Open_Trial_Search_ID","value":"42901"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0700621"}]}}{"C48404":{"preferredName":"Tandutinib","code":"C48404","definitions":[{"definition":"A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It may stop cancer cell growth by blocking certain enzymes. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tandutinib","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"CT53518","termGroup":"CN","termSource":"NCI"},{"termName":"MLN 518","termGroup":"CN","termSource":"NCI"},{"termName":"MLN518","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"387867-13-2"},{"name":"Chemical_Formula","value":"C31H42N6O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E1IO3ICJ9A"},{"name":"Legacy Concept Name","value":"MLN518"},{"name":"Maps_To","value":"Tandutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"353146"},{"name":"NSC Number","value":"726292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"353146"},{"name":"PDQ_Open_Trial_Search_ID","value":"353146"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1143028"}]}}{"C37899":{"preferredName":"Tanespimycin","code":"C37899","definitions":[{"definition":"A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin.  Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is made from an antibiotic called geldanamycin. Tanespimycin helps cause the breakdown of certain proteins in the cell, and may kill cancer cells. It is a type of antineoplastic antibiotic and a type of HSP90 inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tanespimycin","termGroup":"PT","termSource":"NCI"},{"termName":"17-(Allylamino)-17-demethoxygeldanamycin","termGroup":"SY","termSource":"NCI"},{"termName":"17-AAG","termGroup":"AB","termSource":"NCI"},{"termName":"17-Allylamino-17-demethoxygeldanamycin","termGroup":"SN","termSource":"NCI"},{"termName":"17-Demethoxy-17-(2-propenylamino)geldanamycin","termGroup":"SN","termSource":"NCI"},{"termName":"17-N-allylamino-17-demethoxygeldanamycin","termGroup":"SN","termSource":"NCI"},{"termName":"KOS-953","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Chronic Myelogenous Leukemia"},{"name":"CAS_Registry","value":"75747-14-7"},{"name":"CHEBI_ID","value":"CHEBI:64153"},{"name":"Chemical_Formula","value":"C31H43N3O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4GY0AVT3L4"},{"name":"Legacy Concept Name","value":"_17-Allylamino_17-demethoxygeldanamycin"},{"name":"Maps_To","value":"Tanespimycin"},{"name":"NCI_Drug_Dictionary_ID","value":"43635"},{"name":"NSC Number","value":"330507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43635"},{"name":"PDQ_Open_Trial_Search_ID","value":"43635"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0675974"}]}}{"C102877":{"preferredName":"Olinvacimab","code":"C102877","definitions":[{"definition":"A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Olinvacimab","termGroup":"PT","termSource":"NCI"},{"termName":"TTAC-0001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2095504-49-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VFH55IZ5VI"},{"name":"Maps_To","value":"Olinvacimab"},{"name":"Maps_To","value":"Tanibirumab"},{"name":"NCI_Drug_Dictionary_ID","value":"738495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738495"},{"name":"PDQ_Open_Trial_Search_ID","value":"738495"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3490677"}]}}{"C1705":{"preferredName":"Tanomastat","code":"C1705","definitions":[{"definition":"A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tanomastat","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-3-[(4'-Chloro-4-biphenylyl)carbonyl]-2-[(phenylthio)methyl]propionic acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-[4-(chlorophenyl)phenyl]-4-oxo-2S-(phenylthiomethyl) butanoic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 12-9566","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-12-9566","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"179545-77-8"},{"name":"Chemical_Formula","value":"C23H19ClO3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AM1ZX94EXH"},{"name":"Legacy Concept Name","value":"Tanomastat"},{"name":"Maps_To","value":"Tanomastat"},{"name":"NCI_Drug_Dictionary_ID","value":"42675"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42675"},{"name":"PDQ_Open_Trial_Search_ID","value":"42675"},{"name":"PubMedID_Primary_Reference","value":"16442153"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0393069"}]}}{"C26666":{"preferredName":"Tarenflurbil","code":"C26666","definitions":[{"definition":"A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally active synthetic enantiomer of flurbiprofen.  Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tarenflurbil","termGroup":"PT","termSource":"NCI"},{"termName":"(R)-2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"E-7869","termGroup":"CN","termSource":"NCI"},{"termName":"Flurizan","termGroup":"BR","termSource":"NCI"},{"termName":"MPC-7869","termGroup":"CN","termSource":"NCI"},{"termName":"R-flurbiprofen","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51543-40-9"},{"name":"CHEBI_ID","value":"CHEBI:38666"},{"name":"Chemical_Formula","value":"C15H13FO2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"501W00OOWA"},{"name":"Legacy Concept Name","value":"R-flurbiprofen"},{"name":"Maps_To","value":"Tarenflurbil"},{"name":"NCI_Drug_Dictionary_ID","value":"257154"},{"name":"NSC Number","value":"685699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257154"},{"name":"PDQ_Open_Trial_Search_ID","value":"257154"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1527219"}]}}{"C95719":{"preferredName":"Tarextumab","code":"C95719","definitions":[{"definition":"A monoclonal antibody directed against the Notch receptor with potential antineoplastic activity. Tarextumab binds to Notch on the cell surface, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Notch receptors are important for cell-cell communication, which involves gene regulation mechanisms that control multiple cell differentiation processes during embryonic and adult life. Dysregulated Notch signaling is implicated in many diseases including T-ALL (T-cell acute lymphoblastic leukemia), CADASIL (Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy), MS (Multiple Sclerosis), and many other disease states.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tarextumab","termGroup":"PT","termSource":"NCI"},{"termName":"MoAb OMP-59R5","termGroup":"AB","termSource":"NCI"},{"termName":"OMP 59R5","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-59R5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1359940-55-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"333YMY788E"},{"name":"Maps_To","value":"Tarextumab"},{"name":"NCI_Drug_Dictionary_ID","value":"693946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693946"},{"name":"PDQ_Open_Trial_Search_ID","value":"693946"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053948"}]}}{"C2246":{"preferredName":"Tariquidar","code":"C2246","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It may help tumor cells respond again to drugs they have become resistant (unable to respond) to. Tariquidar is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tariquidar","termGroup":"PT","termSource":"NCI"},{"termName":"XR9576","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"206873-63-4"},{"name":"Chemical_Formula","value":"C38H38N4O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J58862DTVD"},{"name":"Legacy Concept Name","value":"Tariquidar"},{"name":"Maps_To","value":"Tariquidar"},{"name":"NCI_Drug_Dictionary_ID","value":"37877"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37877"},{"name":"PDQ_Open_Trial_Search_ID","value":"37877"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879444"}]}}{"C116876":{"preferredName":"Taselisib","code":"C116876","definitions":[{"definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taselisib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC-0032","termGroup":"CN","termSource":"NCI"},{"termName":"RO5537381","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1282512-48-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L08J2O299M"},{"name":"Maps_To","value":"Taselisib"},{"name":"NCI_Drug_Dictionary_ID","value":"695816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695816"},{"name":"PDQ_Open_Trial_Search_ID","value":"695816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3660928"}]}}{"C77067":{"preferredName":"Tasidotin","code":"C77067","definitions":[{"definition":"A third generation, synthetic, water-soluble, pentapeptide analog of the marine depsipeptide dolastatin 15, with potential antimitotic and antineoplastic activities. Tasidotin and its metabolite, tasidotin C-carboxylate, suppress the dynamic instability behavior of the microtubules through a reduction of the shortening rate (disassembly); reduction of the switching frequency from growth to shortening; and by reducing microtubules growth time. This may eventually result in a reduction of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasidotin","termGroup":"PT","termSource":"NCI"},{"termName":"ILX651","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192658-64-3"},{"name":"Chemical_Formula","value":"C32H58N6O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"05G07285DK"},{"name":"Legacy Concept Name","value":"Tasidotin"},{"name":"Maps_To","value":"Tasidotin"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1610484"}]}}{"C62794":{"preferredName":"Tasisulam","code":"C62794","definitions":[{"definition":"An acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasisulam","termGroup":"PT","termSource":"NCI"},{"termName":"LY-573636","termGroup":"CN","termSource":"NCI"},{"termName":"LY573636","termGroup":"CN","termSource":"NCI"},{"termName":"N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"519055-62-0"},{"name":"Chemical_Formula","value":"C11H6BrCl2NO3S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1YC4W9MSLJ"},{"name":"Legacy Concept Name","value":"LY573636"},{"name":"Maps_To","value":"Tasisulam"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831958"}]}}{"C88304":{"preferredName":"Tasisulam Sodium","code":"C88304","definitions":[{"definition":"The sodium salt of an acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasisulam Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-[(5-Bromo-2-thienyl)sulfonyl]-2,4-dichloro-, Sodium Salt","termGroup":"SN","termSource":"NCI"},{"termName":"LY-573636.Na","termGroup":"CN","termSource":"NCI"},{"termName":"LY573636-Sodium","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"519055-63-1"},{"name":"Chemical_Formula","value":"C11H5BrCl2NO3S2.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3955SHR9J"},{"name":"Maps_To","value":"Tasisulam Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"506118"},{"name":"PDQ_Closed_Trial_Search_ID","value":"506118"},{"name":"PDQ_Open_Trial_Search_ID","value":"506118"},{"name":"PubMedID_Primary_Reference","value":"18949427"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3537265"}]}}{"C74080":{"preferredName":"Tasquinimod","code":"C74080","definitions":[{"definition":"A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tasquinimod","termGroup":"PT","termSource":"NCI"},{"termName":"ABR-215050","termGroup":"CN","termSource":"NCI"},{"termName":"TASQ","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"254964-60-8"},{"name":"Chemical_Formula","value":"C20H17F3N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"756U07KN1R"},{"name":"Legacy Concept Name","value":"Tasquinimod"},{"name":"Maps_To","value":"Tasquinimod"},{"name":"NCI_Drug_Dictionary_ID","value":"581229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"581229"},{"name":"PDQ_Open_Trial_Search_ID","value":"581229"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1956491"}]}}{"C2639":{"preferredName":"Taurolidine","code":"C2639","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called anti-infectives.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic broad-spectrum antimicrobial with antibacterial, antifungal, anticoagulant, and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taurolidine","termGroup":"PT","termSource":"NCI"},{"termName":"Bis(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)-methane","termGroup":"SN","termSource":"NCI"},{"termName":"Taurolin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bronchiectasis; Catheter-Related Sepsis; Otitis Media; Peritonitis; Thoracic Empyema"},{"name":"CAS_Registry","value":"19388-87-5"},{"name":"Chemical_Formula","value":"C7H16N4O4S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8OBZ1M4V3V"},{"name":"Legacy Concept Name","value":"Taurolidine"},{"name":"Maps_To","value":"Taurolidine"},{"name":"NCI_Drug_Dictionary_ID","value":"38354"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38354"},{"name":"PDQ_Open_Trial_Search_ID","value":"38354"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0144567"}]}}{"C954":{"preferredName":"Tauromustine","code":"C954","definitions":[{"definition":"A water-soluble taurine-based nitrosourea with potential antineoplastic activity. Tauromustine alkylates DNA and causes DNA cross links independent of cell cycle, thereby resulting in disruption of DNA function and induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tauromustine","termGroup":"PT","termSource":"NCI"},{"termName":"1-(2-Chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea","termGroup":"SN","termSource":"NCI"},{"termName":"LS-2667","termGroup":"CN","termSource":"NCI"},{"termName":"TCNU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"85977-49-7"},{"name":"Chemical_Formula","value":"C7H15ClN4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"511F69K76Y"},{"name":"Legacy Concept Name","value":"Tauromustine"},{"name":"Maps_To","value":"Tauromustine"},{"name":"NCI_Drug_Dictionary_ID","value":"40279"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40279"},{"name":"PDQ_Open_Trial_Search_ID","value":"40279"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0044133"}]}}{"C75290":{"preferredName":"Taurultam","code":"C75290","definitions":[{"definition":"A reversible metabolite of taurolidine and an amino acid taurine derivative, with antibacterial and antineoplastic activity. Taurultam, like its congener taurolidine, inhibits proliferation of microvascular endothelial cells, although to a lesser extent, by selectively inhibiting the adhesion of endothelial cells to laminin but not to collagen I and fibronectin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taurultam","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38668-01-8"},{"name":"Chemical_Formula","value":"C3H8N2O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LIX7OM008P"},{"name":"Legacy Concept Name","value":"Taurultam"},{"name":"Maps_To","value":"Taurultam"},{"name":"PubMedID_Primary_Reference","value":"17395893"},{"name":"PubMedID_Primary_Reference","value":"9552463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0673101"}]}}{"C159500":{"preferredName":"Misetionamide","code":"C159500","definitions":[{"definition":"An oxathiazine-based structural analogue of taurultam (TRLT), which is the main derivative of the anti-infective agent taurolidine (TRD), with potential antineoplastic activity. Upon administration,misetionamide selectively induces reactive oxygen species (ROS)-mediated apoptosis in and inhibits proliferation of susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Misetionamide","termGroup":"PT","termSource":"NCI"},{"termName":"GP 2250","termGroup":"CN","termSource":"NCI"},{"termName":"GP-2250","termGroup":"CN","termSource":"NCI"},{"termName":"GP2250","termGroup":"CN","termSource":"NCI"},{"termName":"Taurultam Analogue GP-2250","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"856785-75-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"489TQ24FC1"},{"name":"Maps_To","value":"Taurultam Analogue GP-2250"},{"name":"NCI_Drug_Dictionary_ID","value":"797809"},{"name":"NCI_META_CUI","value":"CL951458"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797809"},{"name":"PDQ_Open_Trial_Search_ID","value":"797809"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156363":{"preferredName":"Tavokinogene Telseplasmid","code":"C156363","definitions":[{"definition":"A DNA plasmid that encodes genes for both the p35 and p40 subunits of the heterodimeric human interleukin 12 (hIL-12) protein that are separated by an internal ribosome entry site (IRES) and under the control of a single cytomegalovirus (CMV) promoter, with potential immunomodulatory and antineoplastic activities. Upon administration via intratumoral injection and electroporation, the plasmid is introduced into human cells resulting in expression and highly-localized secretion of a functional IL-12 p70 protein into the tumor microenvironment (TME). IL-12 is a pro-inflammatory cytokine that plays a significant role in priming and maintaining T-helper (Th) cells, activating natural killer (NK) cells, and regulating the reactivation and survival of memory T-cells (Tm). Increased levels of IL-12 in the TME may augment host immune response against tumor cells by inhibiting regulatory T-cells (Tregs), T-helper 2 (Th2) responses, and myeloid-derived suppressor cells (MDSCs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tavokinogene Telseplasmid","termGroup":"PT","termSource":"NCI"},{"termName":"IT-Tavo-EP","termGroup":"SY","termSource":"NCI"},{"termName":"Plasmid IL-12 pUMVC3-hIL-12-NGVL3","termGroup":"SY","termSource":"NCI"},{"termName":"Tavo","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1971880-37-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MF4P7VQ2K8"},{"name":"Maps_To","value":"Tavokinogene Telseplasmid"},{"name":"NCI_Drug_Dictionary_ID","value":"795694"},{"name":"NCI_META_CUI","value":"CL563071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795694"},{"name":"PDQ_Open_Trial_Search_ID","value":"795694"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120041":{"preferredName":"Tavolimab","code":"C120041","definitions":[{"definition":"An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, tavolimab selectively binds to and activates the OX40 receptor. OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this agent may promote an immune response against TAAs-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tavolimab","termGroup":"PT","termSource":"NCI"},{"termName":"MEDI-0562","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI0562","termGroup":"CN","termSource":"NCI"},{"termName":"Tavolixizumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1635395-25-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4LU9B48U4D"},{"name":"Maps_To","value":"Tavolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"767471"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767471"},{"name":"PDQ_Open_Trial_Search_ID","value":"767471"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896818"}]}}{"C48424":{"preferredName":"Taxane Analogue TPI 287","code":"C48424","definitions":[{"definition":"A synthetic, third generation taxane with potential antineoplastic activity. TPI 287 binds to tubulin and stabilizes microtubules, resulting in inhibition of microtubule assembly/disassembly dynamics, cell cycle arrest at the G2/M phase, and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taxane Analogue TPI 287","termGroup":"PT","termSource":"NCI"},{"termName":"TPI 287","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"849213-15-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TPI_287"},{"name":"Maps_To","value":"Taxane Analogue TPI 287"},{"name":"NCI_Drug_Dictionary_ID","value":"438803"},{"name":"PDQ_Closed_Trial_Search_ID","value":"438803"},{"name":"PDQ_Open_Trial_Search_ID","value":"438803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1710314"}]}}{"C1490":{"preferredName":"Taxane Compound","code":"C1490","definitions":[{"definition":"A type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Taxane Compound","termGroup":"PT","termSource":"NCI"},{"termName":"Taxanes","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1605-68-1"},{"name":"CHEBI_ID","value":"CHEBI:36064"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Taxane_Compound"},{"name":"Maps_To","value":"Taxane Compound"},{"name":"Semantic_Type","value":"Chemical Viewed Structurally"},{"name":"UMLS_CUI","value":"C0796419"}]}}{"C84839":{"preferredName":"Taxol Analogue SID 530","code":"C84839","definitions":[{"definition":"An intravenous formulation containing docetaxel, a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata, with potential antineoplastic activity. Taxol analogue SID 530 binds to and stabilizes tubulin, inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Taxol Analogue SID 530","termGroup":"PT","termSource":"NCI"},{"termName":"SID 530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Taxol Analogue SID 530"},{"name":"NCI_Drug_Dictionary_ID","value":"650025"},{"name":"NCI_META_CUI","value":"CL412390"},{"name":"PDQ_Closed_Trial_Search_ID","value":"650025"},{"name":"PDQ_Open_Trial_Search_ID","value":"650025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29487":{"preferredName":"Tazarotene","code":"C29487","definitions":[{"definition":"A drug used on the skin to treat several skin conditions. It is also being studied in the treatment of basal cell skin cancer and basal cell nevus syndrome. Tazarotene is related to vitamin A and is made in the laboratory. It turns on a gene that may help stop the growth of skin cancer cells. Tazarotene is a type of synthetic retinoid.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic, topical retinoid.  Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.  In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tazarotene","termGroup":"PT","termSource":"NCI"},{"termName":"6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-Pyridinecarboxylic Acid, Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"AGN-190168","termGroup":"CN","termSource":"NCI"},{"termName":"Avage","termGroup":"BR","termSource":"NCI"},{"termName":"Ethyl 6-(2-(4,4-Dimethylthiochroman-6-yl)ethynyl)nicotinate","termGroup":"SN","termSource":"NCI"},{"termName":"Tazorac","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Topical treatment of facial acne vulgaris; stable plaque psoriasis; mitigation (palliation) of facial fine wrinkling; facial mottled hyper- and hypopigmentation; benign facial lentigines"},{"name":"CAS_Registry","value":"118292-40-3"},{"name":"CHEBI_ID","value":"CHEBI:32184"},{"name":"Chemical_Formula","value":"C21H21NO2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"81BDR9Y8PS"},{"name":"Legacy Concept Name","value":"Tazarotene"},{"name":"Maps_To","value":"Tazarotene"},{"name":"NCI_Drug_Dictionary_ID","value":"553530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"553530"},{"name":"PDQ_Open_Trial_Search_ID","value":"553530"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0288792"}]}}{"C107506":{"preferredName":"Tazemetostat","code":"C107506","definitions":[{"definition":"An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tazemetostat","termGroup":"PT","termSource":"NCI"},{"termName":"E 7438","termGroup":"CN","termSource":"NCI"},{"termName":"E-7438","termGroup":"CN","termSource":"NCI"},{"termName":"E7438","termGroup":"CN","termSource":"NCI"},{"termName":"EPZ 6438","termGroup":"CN","termSource":"NCI"},{"termName":"EPZ-6438","termGroup":"CN","termSource":"NCI"},{"termName":"EPZ6438","termGroup":"CN","termSource":"NCI"},{"termName":"N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1403254-99-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q40W93WPE1"},{"name":"Maps_To","value":"Tazemetostat"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827128"}]}}{"C1605":{"preferredName":"Tecogalan Sodium","code":"C1605","definitions":[{"definition":"A sulfated polysaccharide isolated from various Arthrobacter bacterial species.  Possessing potential antiangiogenic and antineoplastic properties, tecogalan binds to basic fibroblast growth factor (bFGF), thereby preventing bFGF from binding to its receptors.  Disruption of this receptor binding results in the inhibition of bFGF-stimulated endothelial cell growth, proliferation, and migration. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tecogalan Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"DS-4152","termGroup":"CN","termSource":"NCI"},{"termName":"SP-PG","termGroup":"AB","termSource":"NCI"},{"termName":"Sulfated Polysaccharide Tecogalan DS-4152","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tecogalan_Sodium"},{"name":"Maps_To","value":"Tecogalan Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"42149"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42149"},{"name":"PDQ_Open_Trial_Search_ID","value":"42149"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0212199"}]}}{"C513":{"preferredName":"Tegafur","code":"C513","definitions":[{"definition":"A congener of the antimetabolite fluorouracil with antineoplastic activity. Tegafur is a prodrug that is gradually converted to fluorouracil in the liver by the cytochrome P-450 enzyme. Subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by inhibiting thymidylate synthase and reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tegafur","termGroup":"PT","termSource":"NCI"},{"termName":"5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-(1H,3H)-pyrimidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-Fluoro-1-(tetrahydro-2-furyl)-uracil","termGroup":"SN","termSource":"NCI"},{"termName":"Citofur","termGroup":"FB","termSource":"NCI"},{"termName":"Coparogin","termGroup":"FB","termSource":"NCI"},{"termName":"Exonal","termGroup":"FB","termSource":"NCI"},{"termName":"Fental","termGroup":"FB","termSource":"NCI"},{"termName":"Florafur","termGroup":"BR","termSource":"NCI"},{"termName":"Fluorofur","termGroup":"BR","termSource":"NCI"},{"termName":"FT","termGroup":"AB","termSource":"NCI"},{"termName":"FT-207","termGroup":"CN","termSource":"NCI"},{"termName":"Ftorafur","termGroup":"FB","termSource":"NCI"},{"termName":"Ftoral","termGroup":"FB","termSource":"NCI"},{"termName":"Ftoralon","termGroup":"FB","termSource":"NCI"},{"termName":"Fulaid","termGroup":"FB","termSource":"NCI"},{"termName":"Fulfeel","termGroup":"FB","termSource":"NCI"},{"termName":"Furafluor","termGroup":"FB","termSource":"NCI"},{"termName":"Furofutran","termGroup":"FB","termSource":"NCI"},{"termName":"Futraful","termGroup":"FB","termSource":"NCI"},{"termName":"Lamar","termGroup":"FB","termSource":"NCI"},{"termName":"Lifril","termGroup":"FB","termSource":"NCI"},{"termName":"MJF-12264","termGroup":"CN","termSource":"NCI"},{"termName":"N1-(2'-Furanidyl)-5-fluorouracil","termGroup":"SN","termSource":"NCI"},{"termName":"Neberk","termGroup":"FB","termSource":"NCI"},{"termName":"Nitobanil","termGroup":"FB","termSource":"NCI"},{"termName":"Riol","termGroup":"FB","termSource":"NCI"},{"termName":"Sinoflurol","termGroup":"FB","termSource":"NCI"},{"termName":"Sunfural","termGroup":"FB","termSource":"NCI"},{"termName":"Tefsiel","termGroup":"FB","termSource":"NCI"},{"termName":"Utefos","termGroup":"FB","termSource":"NCI"},{"termName":"WR-220066","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17902-23-7"},{"name":"Chemical_Formula","value":"C8H9FN2O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1548R74NSZ"},{"name":"Legacy Concept Name","value":"Tegafur"},{"name":"Maps_To","value":"Tegafur"},{"name":"NCI_Drug_Dictionary_ID","value":"39248"},{"name":"NSC Number","value":"148958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39248"},{"name":"PDQ_Open_Trial_Search_ID","value":"39248"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0016778"}]}}{"C1833":{"preferredName":"Tegafur-gimeracil-oteracil Potassium","code":"C1833","definitions":[{"definition":"A drug that is being studied for its ability to enhance the effectiveness of fluorouracil and prevent gastrointestinal side effects caused by fluorouracil. It belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tegafur-gimeracil-oteracil Potassium","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 247616","termGroup":"CN","termSource":"NCI"},{"termName":"S-1","termGroup":"CN","termSource":"NCI"},{"termName":"Tegafur, mixture with Gimeracil and Potassium Oxonate","termGroup":"SY","termSource":"NCI"},{"termName":"Tegafur/Gimeracil/Oteracil","termGroup":"SY","termSource":"NCI"},{"termName":"Teysuno","termGroup":"FB","termSource":"NCI"},{"termName":"TS-1","termGroup":"CN","termSource":"NCI"},{"termName":"TS-One","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154239-56-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"S-1"},{"name":"Maps_To","value":"Tegafur-gimeracil-oteracil Potassium"},{"name":"NCI_Drug_Dictionary_ID","value":"43548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43548"},{"name":"PDQ_Open_Trial_Search_ID","value":"43548"},{"name":"PubMedID_Primary_Reference","value":"15224197"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879262"}]}}{"C120099":{"preferredName":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation","code":"C120099","definitions":[{"definition":"An orally bioavailable granular formulation composed of the fluoropyrimidine antagonist tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and oteracil potassium, and the folic acid derivative leucovorin calcium, with potential antineoplastic activity. Tegafur is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that is further metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits thymidylate synthase, DNA synthesis and cell division; FUTP competes with uridine triphosphate (UTP), thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Oteracil potassium preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), which converts tegafur to 5-FU. This decreases the amount of 5-FU in the gut and prevents activated 5-FU-related gastrointestinal (GI) toxicity. Leucovorin calcium, an active metabolite of folic acid, counteracts the toxic effects of 5-FU, thereby 'rescuing' the patient while permitting the antitumor activity of 5-FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation","termGroup":"PT","termSource":"NCI"},{"termName":"TAS-118","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation"},{"name":"NCI_Drug_Dictionary_ID","value":"767716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767716"},{"name":"PDQ_Open_Trial_Search_ID","value":"767716"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897369"}]}}{"C9506":{"preferredName":"Tegafur-Uracil","code":"C9506","definitions":[{"definition":"A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. It is a combination of tegafur and uracil. The tegafur is taken up by the cancer cells and breaks down into 5-FU, a substance that kills tumor cells. The uracil causes higher amounts of 5-FU to stay inside the cells and kill them. Tegafur-uracil is a type of antimetabolite.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tegafur-Uracil","termGroup":"PT","termSource":"NCI"},{"termName":"Oral Fluorouracil-Uracil","termGroup":"SY","termSource":"NCI"},{"termName":"Tefudex","termGroup":"FB","termSource":"NCI"},{"termName":"Tegafur and Uracil","termGroup":"SY","termSource":"NCI"},{"termName":"UFT","termGroup":"AB","termSource":"NCI"},{"termName":"Uftoral","termGroup":"FB","termSource":"NCI"},{"termName":"Uftoral","termGroup":"BR","termSource":"NCI"},{"termName":"Ufur","termGroup":"FB","termSource":"NCI"},{"termName":"Uracil and Ftorafur","termGroup":"SY","termSource":"NCI"},{"termName":"Uracil and Tegafur","termGroup":"SY","termSource":"NCI"},{"termName":"Uracil and Tetrahydrofuranyl-5-Fluorouracil","termGroup":"SY","termSource":"NCI"},{"termName":"Uracil/Tegafur (UFT)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"74578-38-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"HMI5GR78FR"},{"name":"Legacy Concept Name","value":"Tegafur_Uracil"},{"name":"Maps_To","value":"Tegafur-Uracil"},{"name":"NCI_Drug_Dictionary_ID","value":"461135"},{"name":"NSC Number","value":"719164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"461135"},{"name":"PDQ_Open_Trial_Search_ID","value":"461135"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1446539"}]}}{"C155885":{"preferredName":"Tegavivint","code":"C155885","definitions":[{"definition":"A small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tegavivint","termGroup":"PT","termSource":"NCI"},{"termName":"9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-","termGroup":"SN","termSource":"NCI"},{"termName":"BC 2059","termGroup":"CN","termSource":"NCI"},{"termName":"BC-2059","termGroup":"CN","termSource":"NCI"},{"termName":"BC2059","termGroup":"CN","termSource":"NCI"},{"termName":"Tegatrabetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227637-23-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"18AP231HUP"},{"name":"Maps_To","value":"Tegavivint"},{"name":"NCI_Drug_Dictionary_ID","value":"795712"},{"name":"NCI_META_CUI","value":"CL562695"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795712"},{"name":"PDQ_Open_Trial_Search_ID","value":"795712"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90746":{"preferredName":"Teglarinad","code":"C90746","definitions":[{"definition":"A water-soluble prodrug of a pyridyl cyanoguanidine compound and an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with potential antineoplastic activity. Teglarinad is rapidly converted in the bloodstream into an active compound through hydrolytic cleavage of the carbonate ester bond. The activated form inhibits NAMPT, thereby inhibiting nicotinamide adenine dinucleotide (NAD+) biosynthesis and induces a rapid decline in intracellular NAD+ followed by ATP reduction. As NAD+ is essential for tumor cell growth, inhibition of NAMPT induces tumor cell death. NAMPT is an essential enzyme in the synthesis of NAD+ and is upregulated in some cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teglarinad","termGroup":"PT","termSource":"NCI"},{"termName":"Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]amino](cyanoamino)methylene]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"766501-75-1"},{"name":"Chemical_Formula","value":"C30H43ClN5O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NUG9P5GWZB"},{"name":"Maps_To","value":"Teglarinad"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2983861"}]}}{"C68931":{"preferredName":"Teglarinad Chloride","code":"C68931","definitions":[{"definition":"A water-soluble prodrug of a cyanoguanidine compound with potential antineoplastic activity. In vivo, teglarinad chloride is rapidly converted into active drug through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, the active drug appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teglarinad Chloride","termGroup":"PT","termSource":"NCI"},{"termName":"CHS828 Prodrug","termGroup":"SY","termSource":"NCI"},{"termName":"EB1627","termGroup":"SY","termSource":"NCI"},{"termName":"GMX1777","termGroup":"CN","termSource":"NCI"},{"termName":"Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]amino](cyanoamino) methylene]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)-, chloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"432037-57-5"},{"name":"Chemical_Formula","value":"C30H43ClN5O8.Cl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D6V5QYX9MZ"},{"name":"Legacy Concept Name","value":"Apoptosis_Inducer_GMX1777"},{"name":"Maps_To","value":"Teglarinad Chloride"},{"name":"NCI_Drug_Dictionary_ID","value":"547816"},{"name":"PDQ_Closed_Trial_Search_ID","value":"547816"},{"name":"PDQ_Open_Trial_Search_ID","value":"547816"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2346839"}]}}{"C104057":{"preferredName":"Telapristone","code":"C104057","definitions":[{"definition":"An orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, telapristone competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telapristone","termGroup":"PT","termSource":"NCI"},{"termName":"11Beta-(4-(dimethylamino)phenyl)-17-hydroxy-21-methoxy-19- norpregna-4,9-diene-3,20-dione","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198414-30-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"65703MV349"},{"name":"Maps_To","value":"Telapristone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3641719"}]}}{"C104055":{"preferredName":"Telapristone Acetate","code":"C104055","definitions":[{"definition":"The acetate form of the 21-substituted-19-nor-progestin telapristone, an orally available selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, CDB-4124 competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telapristone Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,11R,13S,14S,17R)-11-(4-(Dimethylamino)phenyl)-17-(2-methoxyacetyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl Acetate","termGroup":"SN","termSource":"NCI"},{"termName":"CDB-4124","termGroup":"CN","termSource":"NCI"},{"termName":"Proellex","termGroup":"SY","termSource":"NCI"},{"termName":"Progenta","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"198414-31-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1K9EYK92PQ"},{"name":"Maps_To","value":"Telapristone Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"598776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598776"},{"name":"PDQ_Open_Trial_Search_ID","value":"598776"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3501648"}]}}{"C87837":{"preferredName":"Telatinib Mesylate","code":"C87837","definitions":[{"definition":"The orally bioavailable mesylate salt of the 17-allylaminogeldanamycin (17-AAG) small-molecule inhibitor of several receptor protein tyrosine kinases with potential antiangiogenic and antineoplastic activities. Telatinib binds to and inhibits the vascular endothelial growth factor receptors (VEGFRs) type 2 and 3, platelet-derived growth factor receptor beta (PDGFRb) and c-Kit, which may result in the inhibition of angiogenesis and cellular proliferation in tumors in which these receptors are upregulated. These telatinib-inhibited receptor protein tyrosine kinases are overexpressed or mutated in many tumor cell types and may play key roles in tumor angiogenesis and tumor cell proliferation. 17-AAG is a synthetic analogue of the benzoquinone ansamycin antibiotic geldanamycin and has also been found to inhibit the molecular chaperone Hsp90.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telatinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"17-Demethoxy-17-Allylaminogeldanamycin Mesylate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"332013-26-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"571LVA9UMS"},{"name":"Maps_To","value":"Telatinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"652798"},{"name":"NCI_META_CUI","value":"CL415590"},{"name":"PDQ_Closed_Trial_Search_ID","value":"652798"},{"name":"PDQ_Open_Trial_Search_ID","value":"652798"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118571":{"preferredName":"Telisotuzumab Vedotin","code":"C118571","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telisotuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 399","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-399","termGroup":"CN","termSource":"NCI"},{"termName":"ABT 399","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-399","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-700-VCMMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1714088-51-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"976X9VXC3Z"},{"name":"Maps_To","value":"Telisotuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"759579"},{"name":"NCI_META_CUI","value":"CL474084"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759579"},{"name":"PDQ_Open_Trial_Search_ID","value":"759579"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2715":{"preferredName":"Telomerase Inhibitor FJ5002","code":"C2715","definitions":[{"definition":"A derivative of rhodacyanine with potential antineoplastic activity.  FJ5002 inhibits telomerase by interfering with holoenzyme assembly and telomere interaction, thus leading to replication-dependent shortening of telomeres with a concurrent increase in aneuploid metaphases and apoptotic cells.  Telomerase is active in most tumors cells, but is quiescent in adjacent normal cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telomerase Inhibitor FJ5002","termGroup":"PT","termSource":"NCI"},{"termName":"FJ5002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"FJ5002"},{"name":"Maps_To","value":"Telomerase Inhibitor FJ5002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0908717"}]}}{"C119617":{"preferredName":"Suratadenoturev","code":"C119617","definitions":[{"definition":"A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. Suratadenoturev contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Suratadenoturev","termGroup":"PT","termSource":"NCI"},{"termName":"OBP-301","termGroup":"CN","termSource":"NCI"},{"termName":"Telomelycin","termGroup":"SY","termSource":"NCI"},{"termName":"Telomelysin","termGroup":"BR","termSource":"NCI"},{"termName":"Telomerase-specific Type 5 Adenovirus OBP-301","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268642-13-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FV0JG1SX76"},{"name":"Maps_To","value":"Telomerase-specific Type 5 Adenovirus OBP-301"},{"name":"NCI_Drug_Dictionary_ID","value":"766745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766745"},{"name":"PDQ_Open_Trial_Search_ID","value":"766745"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896800"}]}}{"C1520":{"preferredName":"Teloxantrone","code":"C1520","definitions":[{"definition":"An anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teloxantrone","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra(1,9-cd)pyrazol-6(2H)-one,7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)-","termGroup":"SN","termSource":"NCI"},{"termName":"CI-937","termGroup":"CN","termSource":"NCI"},{"termName":"Moxantrazole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"91441-48-4"},{"name":"Chemical_Formula","value":"C21H25N5O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"96521WL61B"},{"name":"Legacy Concept Name","value":"Teloxantrone"},{"name":"Maps_To","value":"Teloxantrone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0244823"}]}}{"C74544":{"preferredName":"Teloxantrone Hydrochloride","code":"C74544","definitions":[{"definition":"The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teloxantrone Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Anthra(1,9-cd)pyrazol-6(2H)-one,7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino) Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CI-937 Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"DUP 937","termGroup":"CN","termSource":"NCI"},{"termName":"Moxantrazole Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"132937-88-3"},{"name":"Chemical_Formula","value":"C21H25N5O4.2HCl.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7ZQK8VIO6V"},{"name":"Legacy Concept Name","value":"Teloxantrone_Hydrochloride"},{"name":"Maps_To","value":"Teloxantrone Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39411"},{"name":"NSC Number","value":"355644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39411"},{"name":"PDQ_Open_Trial_Search_ID","value":"39411"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0970561"}]}}{"C124653":{"preferredName":"Telratolimod","code":"C124653","definitions":[{"definition":"A toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, telratolimod binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Telratolimod","termGroup":"PT","termSource":"NCI"},{"termName":"3M 052","termGroup":"CN","termSource":"NCI"},{"termName":"3M-052","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI 9197","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-9197","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI9197","termGroup":"CN","termSource":"NCI"},{"termName":"TLR7/TLR8 Dual Agonist MEDI9197","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor 7/8 Agonist MEDI9197","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1359993-59-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16598XQ2BT"},{"name":"Maps_To","value":"Telratolimod"},{"name":"NCI_Drug_Dictionary_ID","value":"777376"},{"name":"NCI_META_CUI","value":"CL502885"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777376"},{"name":"PDQ_Open_Trial_Search_ID","value":"777376"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C63953":{"preferredName":"Temarotene","code":"C63953","definitions":[{"definition":"A synthetic bioactive retinoid with differentiation inducing and potential antineoplastic activities. Like other retinoic acid agents, temarotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temarotene","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3,4-Tetrahydro-1,1,4,4-tetramethyl-6-[(1E)-1-methyl-2-phenylethenyl]naphthalene","termGroup":"SN","termSource":"NCI"},{"termName":"Ro 15-0778","termGroup":"CN","termSource":"NCI"},{"termName":"Temaroten","termGroup":"SY","termSource":"NCI"},{"termName":"TTNPB, Decarboxylated Analog","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"75078-91-0"},{"name":"Chemical_Formula","value":"C23H28"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A28G39IJ7K"},{"name":"Legacy Concept Name","value":"Temarotene"},{"name":"Maps_To","value":"Temarotene"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076076"}]}}{"C1669":{"preferredName":"Temoporfin","code":"C1669","definitions":[{"definition":"A synthetic light-activated chlorin with photodynamic activity. Upon systemic administration, temoporfin distributes throughout the body and is taken up by tumor cells. Upon stimulation of temoporfin by non-thermal laser light (at 652 nm), and in the presence of oxygen, this agent produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to tumor cells. This may kill tumor cells and may reduce the tumor size.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called photosensitizing agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Temoporfin","termGroup":"PT","termSource":"NCI"},{"termName":"5,10,15,20-Tetra-(m-hydroxyphenyl)chlorin","termGroup":"SN","termSource":"NCI"},{"termName":"Foscan","termGroup":"FB","termSource":"NCI"},{"termName":"m-Tetrahydroxyphenyl-chlorin","termGroup":"SY","termSource":"NCI"},{"termName":"meta-Tetrahydroxyphenyl Chlorin","termGroup":"SN","termSource":"NCI"},{"termName":"meta-Tetrahydroxyphenylchlorin","termGroup":"SN","termSource":"NCI"},{"termName":"mTHPC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"122341-38-2"},{"name":"CHEBI_ID","value":"CHEBI:9437"},{"name":"Chemical_Formula","value":"C44H32N4O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"FU21S769PF"},{"name":"Legacy Concept Name","value":"Temoporfin"},{"name":"Maps_To","value":"Temoporfin"},{"name":"NCI_Drug_Dictionary_ID","value":"42851"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42851"},{"name":"PDQ_Open_Trial_Search_ID","value":"42851"},{"name":"PubMedID_Primary_Reference","value":"17516041"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0379149"}]}}{"C1244":{"preferredName":"Temozolomide","code":"C1244","definitions":[{"definition":"A drug that is used to treat certain types of brain tumors in adults and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temozolomide","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"CCRG-81045","termGroup":"CN","termSource":"NCI"},{"termName":"Gliotem","termGroup":"FB","termSource":"NCI"},{"termName":"imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-","termGroup":"SN","termSource":"NCI"},{"termName":"M & B 39831","termGroup":"CN","termSource":"NCI"},{"termName":"M and B 39831","termGroup":"CN","termSource":"NCI"},{"termName":"Methazolastone","termGroup":"BR","termSource":"NCI"},{"termName":"RP-46161","termGroup":"CN","termSource":"NCI"},{"termName":"SCH 52365","termGroup":"CN","termSource":"NCI"},{"termName":"Temcad","termGroup":"FB","termSource":"NCI"},{"termName":"Temizole","termGroup":"FB","termSource":"NCI"},{"termName":"Temodal","termGroup":"FB","termSource":"NCI"},{"termName":"Temodar","termGroup":"BR","termSource":"NCI"},{"termName":"Temomedac","termGroup":"SY","termSource":"NCI"},{"termName":"TMZ","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Malignant glioma (Anaplastic astrocytoma; Anaplastic oligodendrogliomas; Anaplastic oligoastrocytomas; Glioblastoma multiforme); Metastatic melanoma"},{"name":"CAS_Registry","value":"85622-93-1"},{"name":"Chemical_Formula","value":"C6H6N6O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YF1K15M17Y"},{"name":"Legacy Concept Name","value":"Temozolomide"},{"name":"Maps_To","value":"Temozolomide"},{"name":"NCI_Drug_Dictionary_ID","value":"41671"},{"name":"NSC Number","value":"362856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41671"},{"name":"PDQ_Open_Trial_Search_ID","value":"41671"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076080"}]}}{"C1844":{"preferredName":"Temsirolimus","code":"C1844","definitions":[{"definition":"A drug used to treat advanced renal cell carcinoma (a type of kidney cancer). It is also being studied in the treatment of other types of cancer. Temsirolimus blocks a protein involved in cell division, and may kill cancer cells. It is a type of rapamycin analog and a type of serine/threonine kinase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Temsirolimus","termGroup":"PT","termSource":"NCI"},{"termName":"42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin","termGroup":"SN","termSource":"NCI"},{"termName":"CCI 779","termGroup":"CN","termSource":"NCI"},{"termName":"CCI-779","termGroup":"CN","termSource":"NCI"},{"termName":"CCI-779 Rapamycin Analog","termGroup":"SY","termSource":"NCI"},{"termName":"CCI779","termGroup":"CN","termSource":"NCI"},{"termName":"Cell Cycle Inhibitor 779","termGroup":"SY","termSource":"NCI"},{"termName":"Rapamycin Analog","termGroup":"SY","termSource":"NCI"},{"termName":"Rapamycin Analog CCI-779","termGroup":"SY","termSource":"NCI"},{"termName":"Torisel","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced renal cell carcinoma"},{"name":"Accepted_Therapeutic_Use_For","value":"Renal Cell Carcinoma"},{"name":"CAS_Registry","value":"162635-04-3"},{"name":"Chemical_Formula","value":"C56H87NO16"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"624KN6GM2T"},{"name":"Legacy Concept Name","value":"CCI-779"},{"name":"Maps_To","value":"Temsirolimus"},{"name":"NCI_Drug_Dictionary_ID","value":"43369"},{"name":"NSC Number","value":"683864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43369"},{"name":"PDQ_Open_Trial_Search_ID","value":"43369"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1707080"}]}}{"C113433":{"preferredName":"Tenalisib","code":"C113433","definitions":[{"definition":"An orally active, highly selective, small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, tenalisib inhibits the PI3K delta and gamma isoforms and prevents the activation of the PI3K/AKT-mediated signaling pathway. This may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. In addition, this agent modulates inflammatory responses through various mechanisms, including the inhibition of both the release of reactive oxygen species (ROS) from neutrophils and tumor necrosis factor (TNF)-alpha activity. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and in inflammatory and autoimmune diseases. By selectively targeting these isoforms, PI3K signaling in normal, non-neoplastic cells is minimally impacted or not affected at all, which minimizes the side effect profile for this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tenalisib","termGroup":"PT","termSource":"NCI"},{"termName":"3-(3-Fluorophenyl)-2-((1S)-1-((7H-purin-6-yl)amino)propyl)-4H-1-benzopyran-4-one","termGroup":"SN","termSource":"NCI"},{"termName":"4H-1-Benzopyran-4-one, 3-(3-fluorophenyl)-2-((1S)-1-(9H-purin-6-ylamino)propyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"RP 6530","termGroup":"CN","termSource":"NCI"},{"termName":"RP-6530","termGroup":"CN","termSource":"NCI"},{"termName":"RP6530","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1639417-53-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2261HH611H"},{"name":"Maps_To","value":"Tenalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"756264"},{"name":"NCI_META_CUI","value":"CL458227"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756264"},{"name":"PDQ_Open_Trial_Search_ID","value":"756264"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64772":{"preferredName":"Tenifatecan","code":"C64772","definitions":[{"definition":"A highly lipophilic preparation of 7-Ethyl-10-hydroxycamptothecin (SN-38) with potential antineoplastic activity. SN2310 is an oil-in-water emulsion of tocopherol covalently linked, via a succinate linker, to SN-38, a synthetic derivative of the cytotoxic alkaloid camptothecin. After succinate linker is hydrolyzed in vivo, the active moiety SN-38 is released and selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks and inducing lethal double-stranded DNA breaks. This inhibits DNA replication and triggers programmed cell death. SN2310 emulsion provides longer circulation time and potentiates drug exposure as compared to the unconjugated SN-38.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tenifatecan","termGroup":"PT","termSource":"NCI"},{"termName":"(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin- 9-yl (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl Butanedioate","termGroup":"SN","termSource":"NCI"},{"termName":"SN-2310","termGroup":"CN","termSource":"NCI"},{"termName":"SN2310","termGroup":"CN","termSource":"NCI"},{"termName":"Tocopherol Succinate 7-Ethyl-10-Hydroxycamptothecin","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"850728-18-6"},{"name":"Chemical_Formula","value":"C55H72N2O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7G0Y719Q80"},{"name":"Legacy Concept Name","value":"Tocopherol_Succinate_7-Ethyl-10-Hydroxycamptothecin"},{"name":"Maps_To","value":"Tenifatecan"},{"name":"NCI_Drug_Dictionary_ID","value":"518315"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518315"},{"name":"PDQ_Open_Trial_Search_ID","value":"518315"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1883354"}]}}{"C857":{"preferredName":"Teniposide","code":"C857","definitions":[{"definition":"A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Teniposide","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside)","termGroup":"SN","termSource":"NCI"},{"termName":"4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside","termGroup":"SN","termSource":"NCI"},{"termName":"[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one","termGroup":"SN","termSource":"NCI"},{"termName":"EPT","termGroup":"AB","termSource":"NCI"},{"termName":"PTG","termGroup":"AB","termSource":"NCI"},{"termName":"Thenylidene Lignan","termGroup":"SY","termSource":"NCI"},{"termName":"Vehem","termGroup":"FB","termSource":"NCI"},{"termName":"VM-26","termGroup":"CN","termSource":"NCI"},{"termName":"VM26","termGroup":"CN","termSource":"NCI"},{"termName":"Vumon","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"29767-20-2"},{"name":"Chemical_Formula","value":"C32H32O13S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"957E6438QA"},{"name":"Legacy Concept Name","value":"Teniposide"},{"name":"Maps_To","value":"Teniposide"},{"name":"NCI_Drug_Dictionary_ID","value":"43671"},{"name":"NSC Number","value":"122819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43671"},{"name":"PDQ_Open_Trial_Search_ID","value":"43671"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039512"}]}}{"C95797":{"preferredName":"Teprotumumab","code":"C95797","definitions":[{"definition":"A human monoclonal antibody being studied in the treatment of several types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. R1507 blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teprotumumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IGF-1R Monoclonal Antibody R1507","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I Receptor)(Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Light Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"R1507","termGroup":"CN","termSource":"NCI"},{"termName":"RG1507","termGroup":"CN","termSource":"NCI"},{"termName":"RO4858696-000","termGroup":"CN","termSource":"NCI"},{"termName":"RV001 Monoclonal","termGroup":"SY","termSource":"NCI"},{"termName":"Teprotumumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of solid and hematologic tumors"},{"name":"CAS_Registry","value":"89957-37-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y64GQ0KC0A"},{"name":"Maps_To","value":"Teprotumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"557569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"557569"},{"name":"PDQ_Open_Trial_Search_ID","value":"557569"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3181764"}]}}{"C61441":{"preferredName":"Terameprocol","code":"C61441","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks proteins needed for cancer growth. It is a type of transcriptional inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In virally-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2), survivin, and vascular endothelial growth factor (VEGF), which are overexpressed in a variety of cancers. By suppressing Sp1-regulated transcription of these genes, terameprocol may reduce tumor angiogenesis and tumor cell proliferation and induce tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Terameprocol","termGroup":"PT","termSource":"NCI"},{"termName":"1,1'-(2,3-Dimethyl-1,4-butanediyl)bis(3,4-dimethoxybenzene)","termGroup":"SN","termSource":"NCI"},{"termName":"EM-1421","termGroup":"CN","termSource":"NCI"},{"termName":"M4N","termGroup":"AB","termSource":"NCI"},{"termName":"Tetra-O-methyl Nordihydroguaiaretic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Tetra-O-methyl-NDGA","termGroup":"SN","termSource":"NCI"},{"termName":"Tetramethoxynordihydroguaiaretic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"TMNDGA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"24150-24-1"},{"name":"Chemical_Formula","value":"C22H30O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"53YET703F2"},{"name":"Legacy Concept Name","value":"EM-1421"},{"name":"Maps_To","value":"Terameprocol"},{"name":"NCI_Drug_Dictionary_ID","value":"472205"},{"name":"NSC Number","value":"136955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"472205"},{"name":"PDQ_Open_Trial_Search_ID","value":"472205"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0654036"}]}}{"C75292":{"preferredName":"Terfluranol","code":"C75292","definitions":[{"definition":"A trifluoroethyl derivative with antineoplastic agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Terfluranol","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64396-09-4"},{"name":"Chemical_Formula","value":"C17H17F3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WUF1DL156G"},{"name":"Legacy Concept Name","value":"Terfluranol"},{"name":"Maps_To","value":"Terfluranol"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699917"}]}}{"C66985":{"preferredName":"Tergenpumatucel-L","code":"C66985","definitions":[{"definition":"An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a 'xenograft'. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tergenpumatucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Hyperacute Lung Cancer Vaccine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Alpha-1_3-Galactosyltransferase-Expressing_Allogeneic_Lung_Tumor_Cell_Vaccine"},{"name":"Maps_To","value":"Tergenpumatucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"539100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"539100"},{"name":"PDQ_Open_Trial_Search_ID","value":"539100"},{"name":"PubMedID_Primary_Reference","value":"15161001"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1879682"}]}}{"C2320":{"preferredName":"Teroxirone","code":"C2320","definitions":[{"definition":"A triazene triepoxide with antineoplastic activity. Teroxine alkylates and cross-links DNA, thereby inhibiting DNA replication. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Teroxirone","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-1,3,5-triglycidyl-s-triazinetrione","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-TGI","termGroup":"SN","termSource":"NCI"},{"termName":"alpha-Triglycidyl Isocyanurate","termGroup":"SN","termSource":"NCI"},{"termName":"Henkel's Compound","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"59653-73-5"},{"name":"Chemical_Formula","value":"C12H15N3O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"456V4159SL"},{"name":"Legacy Concept Name","value":"Teroxirone"},{"name":"Maps_To","value":"Teroxirone"},{"name":"NCI_Drug_Dictionary_ID","value":"39722"},{"name":"NSC Number","value":"296934"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39722"},{"name":"PDQ_Open_Trial_Search_ID","value":"39722"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0043891"}]}}{"C62756":{"preferredName":"Tertomotide","code":"C62756","definitions":[{"definition":"A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tertomotide","termGroup":"PT","termSource":"NCI"},{"termName":"GV 1001","termGroup":"CN","termSource":"NCI"},{"termName":"GV-1001","termGroup":"CN","termSource":"NCI"},{"termName":"GV1001","termGroup":"CN","termSource":"NCI"},{"termName":"Human Telomerase Reverse Transcriptase (EC 2.7.7.49)-(611-626)-Peptide (Telomerase Catalytic Subunit Fragment)","termGroup":"SN","termSource":"NCI"},{"termName":"PrimoVax","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"915019-08-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"55R7RG342O"},{"name":"Legacy Concept Name","value":"GV1001"},{"name":"Maps_To","value":"Tertomotide"},{"name":"NCI_Drug_Dictionary_ID","value":"502114"},{"name":"PDQ_Closed_Trial_Search_ID","value":"502114"},{"name":"PDQ_Open_Trial_Search_ID","value":"502114"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831942"}]}}{"C37451":{"preferredName":"Tesetaxel","code":"C37451","definitions":[{"definition":"A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic and antiangiogenic properties. Tesetaxel binds to and stabilizes tubulin, promoting microtubule assembly and thereby preventing microtubule depolymerization. This may lead to cell cycle arrest and an inhibition of cell proliferation. This agent may also inhibit pro-angiogenic factors such as vascular endothelial growth factor (VEGF). As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. It is a type of taxane derivative.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tesetaxel","termGroup":"PT","termSource":"NCI"},{"termName":"DJ 927","termGroup":"CN","termSource":"NCI"},{"termName":"DJ-927","termGroup":"CN","termSource":"NCI"},{"termName":"DJ927","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"333754-36-2"},{"name":"Chemical_Formula","value":"C46H60FN3O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"UG97LO5M8Y"},{"name":"Legacy Concept Name","value":"DJ-927"},{"name":"Maps_To","value":"Tesetaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"346914"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346914"},{"name":"PDQ_Open_Trial_Search_ID","value":"346914"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1872681"}]}}{"C62496":{"preferredName":"Tesevatinib","code":"C62496","definitions":[{"definition":"An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tesevatinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta(c)pyrrol-5-yl)methoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"EXEL 7647","termGroup":"CN","termSource":"NCI"},{"termName":"KD 019","termGroup":"CN","termSource":"NCI"},{"termName":"KD019","termGroup":"CN","termSource":"NCI"},{"termName":"XL647","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"781613-23-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6XM2TN5A1"},{"name":"Legacy Concept Name","value":"XL647"},{"name":"Maps_To","value":"Tesevatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"386183"},{"name":"PDQ_Closed_Trial_Search_ID","value":"386183"},{"name":"PDQ_Open_Trial_Search_ID","value":"386183"},{"name":"PubMedID_Primary_Reference","value":"22011666"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541356"}]}}{"C129315":{"preferredName":"Tesidolumab","code":"C129315","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the complement pathway protein C5, with complement pathway inhibitory activity and potential immunomodulating activity. Upon administration, tesidolumab targets and binds to C5, thereby preventing both C5 convertase-mediated cleavage of C5 and the formation of C5a and C5b. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction. C5 plays a key role in the activation of the complement cascade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tesidolumab","termGroup":"PT","termSource":"NCI"},{"termName":"LFG-316","termGroup":"CN","termSource":"NCI"},{"termName":"LFG316","termGroup":"CN","termSource":"NCI"},{"termName":"NOV-4","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1531594-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3FO6689MSD"},{"name":"Maps_To","value":"Tesidolumab"},{"name":"NCI_Drug_Dictionary_ID","value":"783588"},{"name":"NCI_META_CUI","value":"CL512306"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783588"},{"name":"PDQ_Open_Trial_Search_ID","value":"783588"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2301":{"preferredName":"Testolactone","code":"C2301","definitions":[{"definition":"A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testolactone","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic Acid Delta-Lactone","termGroup":"SN","termSource":"NCI"},{"termName":"1-Dehydrotestololactone","termGroup":"SN","termSource":"NCI"},{"termName":"13-Hydroxy-3-0x0-13,17-secoandrosta-1,4-dien-17-oic Acid Delta-Lactone","termGroup":"SN","termSource":"NCI"},{"termName":"17Alpha-oxo-D-homo-1,4-androstadiene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Delta-1-Testololactone","termGroup":"SN","termSource":"NCI"},{"termName":"Fludestrin","termGroup":"SY","termSource":"NCI"},{"termName":"SQ-9538","termGroup":"CN","termSource":"NCI"},{"termName":"Teslac","termGroup":"BR","termSource":"NCI"},{"termName":"Therapeutic Testolactone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"968-93-4"},{"name":"CHEBI_ID","value":"CHEBI:9460"},{"name":"Chemical_Formula","value":"C19H24O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6J9BLA949Q"},{"name":"Legacy Concept Name","value":"Testolactone"},{"name":"Maps_To","value":"Testolactone"},{"name":"NCI_Drug_Dictionary_ID","value":"42916"},{"name":"NSC Number","value":"23759"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42916"},{"name":"PDQ_Open_Trial_Search_ID","value":"42916"},{"name":"Semantic_Type","value":"Hormone"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039600"}]}}{"C1247":{"preferredName":"Testosterone Enanthate","code":"C1247","definitions":[{"definition":"A long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males, delayed puberty, and metastatic mammary cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Testosterone Enanthate","termGroup":"PT","termSource":"NCI"},{"termName":"Andro LA","termGroup":"BR","termSource":"NCI"},{"termName":"Androtardyl","termGroup":"FB","termSource":"NCI"},{"termName":"Delatestryl","termGroup":"BR","termSource":"NCI"},{"termName":"Everone","termGroup":"BR","termSource":"NCI"},{"termName":"Primosteston","termGroup":"BR","termSource":"NCI"},{"termName":"Testate","termGroup":"SY","termSource":"NCI"},{"termName":"Testinon","termGroup":"FB","termSource":"NCI"},{"termName":"Testo-Enant","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Male Hypogonadotrophic Hypogonadism; Delayed Puberty-Male and Primary Hypogonadism."},{"name":"CAS_Registry","value":"315-37-7"},{"name":"CHEBI_ID","value":"CHEBI:9464"},{"name":"Chemical_Formula","value":"C26H40O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7Z6522T8N9"},{"name":"Legacy Concept Name","value":"Testosterone_Enanthate"},{"name":"Maps_To","value":"Testosterone Enanthate"},{"name":"NCI_Drug_Dictionary_ID","value":"795022"},{"name":"NSC Number","value":"17591"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795022"},{"name":"PDQ_Open_Trial_Search_ID","value":"795022"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076189"}]}}{"C2660":{"preferredName":"Tetanus Toxoid Vaccine","code":"C2660","definitions":[{"definition":"A preparation of formaldehyde-deactivated toxin isolated from the bacterium Clostridium tetani. Tetanus toxoid is used for booster injection and can stimulate the production of antitoxin antibodies. This agent may be used as an adjuvant in cancer vaccines.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is derived from the toxin released by the bacterium that causes the disease tetanus.  It is used as a vaccine to prevent tetanus or to help boost the immune response to other vaccines.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tetanus Toxoid Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Tetanus Toxoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Tetanus Prophylaxis"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Tetanus_Toxoid"},{"name":"Maps_To","value":"Tetanus Toxoid Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"38508"},{"name":"NSC Number","value":"722666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38508"},{"name":"PDQ_Open_Trial_Search_ID","value":"38508"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C0305062"}]}}{"C866":{"preferredName":"Tetradecanoylphorbol Acetate","code":"C866","definitions":[{"definition":"A phorbol ester with potential antineoplastic effects.  Tetradecanoylphorbol acetate (TPA) induces maturation and differentiation of hematopoietic cell lines, including leukemic cells. This agent may induce gene expression and protein kinase C (PKC) activity.  In addition to potential antineoplastic effects, TPA may exhibit tumor promoting activity. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of leukemias and lymphomas. It is also being studied in the treatment of other types of cancer. Tetradecanoylphorbol acetate affects many cell actions and may cause tumor cells to die. It is a type of phorbol ester.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tetradecanoylphorbol Acetate","termGroup":"PT","termSource":"NCI"},{"termName":"12-O-tetradecanoylphorbol-13-acetate","termGroup":"SN","termSource":"NCI"},{"termName":"Lonomycin","termGroup":"SY","termSource":"NCI"},{"termName":"Phorbol Myristate Acetate","termGroup":"SY","termSource":"NCI"},{"termName":"PMA","termGroup":"AB","termSource":"NCI"},{"termName":"TPA (Phorbol Ester)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"16561-29-8"},{"name":"CHEBI_ID","value":"CHEBI:37537"},{"name":"Chemical_Formula","value":"C36H56O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NI40JAQ945"},{"name":"Legacy Concept Name","value":"Tetradecanoylphorbol_Acetate"},{"name":"Maps_To","value":"Tetradecanoylphorbol Acetate"},{"name":"NCI_Drug_Dictionary_ID","value":"43661"},{"name":"NSC Number","value":"262244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43661"},{"name":"PDQ_Open_Trial_Search_ID","value":"43661"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039654"}]}}{"C868":{"preferredName":"Tetrahydrouridine","code":"C868","definitions":[{"definition":"A substance that makes tumor cells more sensitive to radiation therapy and is being studied in the treatment of cancer. It belongs to the families of drugs called cytidine deaminase inhibitors, multidrug resistance modulators, and radiosensitizers.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2'-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2'-deoxycytidine monophosphate (CldCMP) to 5-chloro-2'-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2'-deoxyuridine). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetrahydrouridine","termGroup":"PT","termSource":"NCI"},{"termName":"2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-","termGroup":"SN","termSource":"NCI"},{"termName":"THU","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"18771-50-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0NIZ8H6OL8"},{"name":"Legacy Concept Name","value":"Tetrahydrouridine"},{"name":"Maps_To","value":"Tetrahydrouridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39710"},{"name":"NSC Number","value":"112907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39710"},{"name":"PDQ_Open_Trial_Search_ID","value":"39710"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039677"}]}}{"C88344":{"preferredName":"Fimaporfin A","code":"C88344","definitions":[{"definition":"The A isomer of fimaporfin, a synthetic light-activated compound, with potential photosensitizing activity. Upon administration, fimaporfin A incorporates into the cell's endosome and lysosome membranes. Subsequently, cytotoxic agents are administered and accumulate in endosomal and lysosomal compartments; upon local activation by light, fimaporfin A produces reactive oxygen species (ROS), such as singlet oxygen, damaging endo/lysosomal membranes and accumulated cytotoxic agents are released into the tumor cell cytosol. This photochemical internalization (PCI) method can enhance the efficacy and selectivity of cytotoxic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fimaporfin A","termGroup":"PT","termSource":"NCI"},{"termName":"Amphinex","termGroup":"FB","termSource":"NCI"},{"termName":"Disulfonated Tetraphenylchlorin","termGroup":"SY","termSource":"NCI"},{"termName":"Tetraphenyl Chlorin Disulfonate","termGroup":"SY","termSource":"NCI"},{"termName":"TPCS2a","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501083-97-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P4BBY8S91N"},{"name":"Maps_To","value":"Fimaporfin A"},{"name":"Maps_To","value":"Tetraphenyl Chlorin Disulfonate"},{"name":"NCI_Drug_Dictionary_ID","value":"658036"},{"name":"NCI_META_CUI","value":"CL413542"},{"name":"PDQ_Closed_Trial_Search_ID","value":"658036"},{"name":"PDQ_Open_Trial_Search_ID","value":"658036"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160684":{"preferredName":"Tetrathiomolybdate","code":"C160684","definitions":[{"definition":"An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetrathiomolybdate","termGroup":"PT","termSource":"NCI"},{"termName":"CCRIS 9412","termGroup":"CN","termSource":"NCI"},{"termName":"Molybdate(2-), Tetrathioxo-, (T-4)- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Tetrathioxomolybdate(2-)","termGroup":"SY","termSource":"NCI"},{"termName":"TM","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"16330-92-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"91U3TGV99T"},{"name":"Maps_To","value":"Tetrathiomolybdate"},{"name":"NCI_META_CUI","value":"CL969619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1539":{"preferredName":"Tezacitabine","code":"C1539","definitions":[{"definition":"A drug that belongs to a family of drugs called ribonucleotide reductase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication. This agent is relatively resistant to metabolic deactivation by cytidine deaminase. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates necessary for DNA synthesis and is overexpressed in many tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tezacitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-2'-(fluoromethylene)cytidine","termGroup":"SN","termSource":"NCI"},{"termName":"FMdC","termGroup":"AB","termSource":"NCI"},{"termName":"MDL 101,731","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"171176-43-5"},{"name":"Chemical_Formula","value":"C10H12FN3O4.H2O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UCC4EQS7WL"},{"name":"Legacy Concept Name","value":"Tezacitabine"},{"name":"Maps_To","value":"Tezacitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"354256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"354256"},{"name":"PDQ_Open_Trial_Search_ID","value":"354256"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0253087"}]}}{"C95916":{"preferredName":"Tezacitabine Anhydrous","code":"C95916","definitions":[{"definition":"The anhydrous form of tezacitabine, a synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and eventually tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, thereby further inhibiting DNA replication. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates, a necessary step for DNA synthesis, and is overexpressed in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tezacitabine Anhydrous","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-2'-(fluoromethylene)cytidine Anhydrous","termGroup":"SN","termSource":"NCI"},{"termName":"FMdC Anhydrous","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"130306-02-4"},{"name":"Chemical_Formula","value":"C10H12FN3O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7607Y95N9S"},{"name":"Maps_To","value":"Tezacitabine Anhydrous"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3272436"}]}}{"C160258":{"preferredName":"TGF-beta Receptor 1 Inhibitor PF-06952229","code":"C160258","definitions":[{"definition":"An orally bioavailable inhibitor of transforming growth factor-beta receptor 1 (TGFbR1), with potential antineoplastic activity. Upon administration, TGF-betaR1 inhibitor PF-06952229 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGF-beta Receptor 1 Inhibitor PF-06952229","termGroup":"PT","termSource":"NCI"},{"termName":"PF 06952229","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06952229","termGroup":"CN","termSource":"NCI"},{"termName":"PF06952229","termGroup":"CN","termSource":"NCI"},{"termName":"TGFbR1 Inhibitor PF-06952229","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801333-55-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1KKS7U3X86"},{"name":"Maps_To","value":"TGF-beta Receptor 1 Inhibitor PF-06952229"},{"name":"NCI_Drug_Dictionary_ID","value":"798316"},{"name":"NCI_META_CUI","value":"CL969270"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798316"},{"name":"PDQ_Open_Trial_Search_ID","value":"798316"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C29483":{"preferredName":"TGFa-PE38 Immunotoxin","code":"C29483","definitions":[{"definition":"A recombinant, chimeric toxin composed of human transforming growth factor alpha (TGF-alpha) fused to a fragment of Pseudomonas exotoxin (PE38) without its cell-binding domain.  The TGF-alpha moiety of the agent attaches to tumor cells expressing the epithelial growth factor receptor (EGFR); the exotoxin induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of brain tumors. It combines a protein that binds to certain tumor cells with a bacterial toxin that kills tumor cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"TGFa-PE38 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Cervene","termGroup":"BR","termSource":"NCI"},{"termName":"TP-38","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TP-38"},{"name":"Maps_To","value":"TGFa-PE38 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"346468"},{"name":"NSC Number","value":"726586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"346468"},{"name":"PDQ_Open_Trial_Search_ID","value":"346468"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328109"}]}}{"C132013":{"preferredName":"TGFbeta Inhibitor LY3200882","code":"C132013","definitions":[{"definition":"An orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGFbeta Inhibitor LY3200882","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3200882","termGroup":"CN","termSource":"NCI"},{"termName":"LY3200882","termGroup":"CN","termSource":"NCI"},{"termName":"TGFb Inhibitor LY 3200882","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1898283-02-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"19HY34R6UN"},{"name":"Maps_To","value":"TGFbeta Inhibitor LY3200882"},{"name":"NCI_Drug_Dictionary_ID","value":"787604"},{"name":"NCI_META_CUI","value":"CL520999"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787604"},{"name":"PDQ_Open_Trial_Search_ID","value":"787604"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C159817":{"preferredName":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein BMS-986416","code":"C159817","definitions":[{"definition":"A fusion protein composed of the ectodomain of the transforming growth factor (TGF) beta (TGF-beta; TGFb) receptor fused to the human immunoglobulin G (IgG) Fc domain, with potential antineoplastic, immunomodulating and anti-fibrotic activities. Upon administration of the TGFb receptor ectodomain-IgG Fc fusion protein BMS-986416, the fusion protein specifically and selectively targets, binds to and neutralizes the TGF ligands TGF-beta isoform 1 (TGFb1) and 3 (TGFb3). This prevents TGF ligands from binding to TGF receptors and prevents TGFb-mediated signaling. This abrogates TGFb1/3-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. By preventing TGFb1/3-mediated signaling, BMS-986416 also prevents bone marrow fibrosis and promotes the proliferation of normal hematopoietic progenitors. TGFb, overproduced in myelodysplastic syndrome (MDS) and in many other types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression. The TGFb1 and TGFb3 isoforms are negative regulators of hematopoiesis that play key roles in the pathogenesis and progression of fibrotic diseases. By selectively targeting only specific isoforms of TGFb with minimal activity against TGFb2, BMS-986416 minimizes the potential for cardiotoxicity and promotion of metastasis. The TGFb2 isoform promotes hematopoiesis and plays a key role in normal cardiac function while the inhibition of the TGFb2 isoform promotes metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein BMS-986416","termGroup":"PT","termSource":"NCI"},{"termName":"AVID 200","termGroup":"CN","termSource":"NCI"},{"termName":"AVID-200","termGroup":"CN","termSource":"NCI"},{"termName":"AVID200","termGroup":"CN","termSource":"NCI"},{"termName":"BMS 986416","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986416","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986416","termGroup":"CN","termSource":"NCI"},{"termName":"TGF-beta 1/3 Inhibitor AVID200","termGroup":"SY","termSource":"NCI"},{"termName":"TGFb Inhibitor AVID200","termGroup":"SY","termSource":"NCI"},{"termName":"TGFbeta Ligand Trap AVID200","termGroup":"SY","termSource":"NCI"},{"termName":"TGFbeta-neutralizing Agent AVID200","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2269485-28-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6EX05GL2VK"},{"name":"Maps_To","value":"TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200"},{"name":"NCI_Drug_Dictionary_ID","value":"797961"},{"name":"NCI_META_CUI","value":"CL951620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797961"},{"name":"PDQ_Open_Trial_Search_ID","value":"797961"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C869":{"preferredName":"Thalicarpine","code":"C869","definitions":[{"definition":"A natural aporphine benzylisoquinoline vinca alkaloid with antineoplastic activity. Thalicarpine binds to and inhibits p-glycoprotein, the multidrug resistance efflux pump. Thalicarpine also induces single-strand breaks in DNA and arrests cancer cells at the G2/M and G1 phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thalicarpine","termGroup":"PT","termSource":"NCI"},{"termName":"4H-Dibenzo[de,g]quinoline, 5,6,6a, 7-tetrahydro-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-1,2,10-trimethoxy-6-methyl-","termGroup":"SN","termSource":"NCI"},{"termName":"4H-dibenzo[de,g]quinoline, 9-[4, 5-dimethoxy-2-[(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, [S-(R*,R*)]- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"6a-Alpha-aporphine, 9-[[4, 5-dimethoxy-alpha-(1beta,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1,2, 10-trimethoxy- (8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"6a-Alpha-aporphine, 9-[[4,5-dimethoxy-alpha-((S)-1,2,3, 4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1, 2,10-trimethoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"[S-(R*,R*)]-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)-methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-4H-dibenzo[de,g]quinoline","termGroup":"SN","termSource":"NCI"},{"termName":"Taliblastine","termGroup":"SY","termSource":"NCI"},{"termName":"Thaliblastine","termGroup":"SY","termSource":"NCI"},{"termName":"Thalicarpin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5373-42-2"},{"name":"CHEBI_ID","value":"CHEBI:9509"},{"name":"Chemical_Formula","value":"C41H48N2O8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8X1D791RF6"},{"name":"Legacy Concept Name","value":"Thalicarpine"},{"name":"Maps_To","value":"Thalicarpine"},{"name":"NCI_Drug_Dictionary_ID","value":"39712"},{"name":"NSC Number","value":"68075"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39712"},{"name":"PDQ_Open_Trial_Search_ID","value":"39712"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039735"}]}}{"C870":{"preferredName":"Thalidomide","code":"C870","definitions":[{"definition":"A drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalomid belongs to the family of drugs called angiogenesis inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thalidomide","termGroup":"PT","termSource":"NCI"},{"termName":"2,6-Dioxo-3-phthalimidopiperidine","termGroup":"SN","termSource":"NCI"},{"termName":"2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"3-Phthalimidoglutarimide","termGroup":"SN","termSource":"NCI"},{"termName":"Alpha-Phthalimidoglutarimide","termGroup":"SY","termSource":"NCI"},{"termName":"Contergan","termGroup":"FB","termSource":"NCI"},{"termName":"Distaval","termGroup":"FB","termSource":"NCI"},{"termName":"Kevadon","termGroup":"FB","termSource":"NCI"},{"termName":"N-(2,6-Dioxo-3-piperidyl)phthalimide","termGroup":"SN","termSource":"NCI"},{"termName":"N-Phthaloylglutamimide","termGroup":"SY","termSource":"NCI"},{"termName":"N-Phthalylglutamic Acid Imide","termGroup":"SY","termSource":"NCI"},{"termName":"Neurosedyn","termGroup":"FB","termSource":"NCI"},{"termName":"Pantosediv","termGroup":"FB","termSource":"NCI"},{"termName":"Sedalis","termGroup":"FB","termSource":"NCI"},{"termName":"Sedoval K-17","termGroup":"FB","termSource":"NCI"},{"termName":"Sedoval K17","termGroup":"FB","termSource":"NCI"},{"termName":"Softenon","termGroup":"FB","termSource":"NCI"},{"termName":"Synovir","termGroup":"BR","termSource":"NCI"},{"termName":"Talimol","termGroup":"FB","termSource":"NCI"},{"termName":"Thalomid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Aphthous stomatitis; Crohns disease; cutaneous manifestations of erythema nodosum leprosum; GVHD; HIV-associated wasting syndrome; Karposi sarcoma; lepromatous leprosy; multiple myeloma; mycobacterium tuberculosis and nontuberculosis; primary brain tumors"},{"name":"CAS_Registry","value":"50-35-1"},{"name":"CHEBI_ID","value":"CHEBI:9513"},{"name":"Chemical_Formula","value":"C13H10N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"4Z8R6ORS6L"},{"name":"Legacy Concept Name","value":"Thalidomide"},{"name":"Maps_To","value":"Thalidomide"},{"name":"NCI_Drug_Dictionary_ID","value":"42332"},{"name":"NSC Number","value":"66847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42332"},{"name":"PDQ_Open_Trial_Search_ID","value":"42332"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039736"}]}}{"C162552":{"preferredName":"Xiliertinib","code":"C162552","definitions":[{"definition":"An orally available, ATP-competitive inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, xiliertinib binds to and inhibits the activity of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xiliertinib","termGroup":"PT","termSource":"NCI"},{"termName":"HMPL 309","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL-309","termGroup":"CN","termSource":"NCI"},{"termName":"HMPL309","termGroup":"CN","termSource":"NCI"},{"termName":"Theliatinib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1353644-70-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6ZZ3B7NZ0B"},{"name":"Maps_To","value":"Theliatinib"},{"name":"Maps_To","value":"Xiliertinib"},{"name":"NCI_META_CUI","value":"CL971129"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2385":{"preferredName":"Theramide","code":"C2385","definitions":[{"definition":"A lipophilic disaccharide derivative of muramyl dipeptide (MDP) with strong immunostimulating activity and used as a vaccine adjuvant. MDP, a component of bacterial cell wall, is the minimum chemical structure required for macrophage activation. Due to MDP's toxicity and short duration of action, theramide was developed with improved stability, and can be administered without a liposome carrier. Theramide stimulates macrophage activity, which in turn potentiates other immune responses, including the release of proinflammatory interleukins and tumor necrosis factor alpha (TNF alpha). The release of these cytokines further augments the activation of cellular and humoral immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Theramide","termGroup":"PT","termSource":"NCI"},{"termName":"DTP-DPP","termGroup":"AB","termSource":"NCI"},{"termName":"N-acetylglucsamnmyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Theramide"},{"name":"Maps_To","value":"Theramide"},{"name":"NCI_Drug_Dictionary_ID","value":"42146"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42146"},{"name":"PDQ_Open_Trial_Search_ID","value":"42146"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281665"}]}}{"C68962":{"preferredName":"Therapeutic Angiotensin-(1-7)","code":"C68962","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. Therapeutic angiotensin-(1-7) is a hormone that is made in the laboratory, and helps control blood pressure. It may stop the growth of some types of cancer cells and may stop the growth of blood vessels needed by tumors to grow. It is a type of antiproliferative agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic heptapeptide identical to endogenous angiotensin-(1-7) with vasodilator and antiproliferative activities. Therapeutic angiotensin 1-7 may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) receptor Mas, resulting in diminished tumor cell proliferation. Activation of the angiotensin-(1-7) receptor Mas, a G-protein coupled, seven transmembrane protein, may down-regulate the phosphorylation and activation of Erk1 and Erk2 in the Erk1/Erk2 MAPK signaling pathway. In the renin-angiotensin system, the vasodilating activity of angiotensin- (1-7), hydrolysed from angiotensin II by the type I transmembrane metallopeptidase and carboxypeptidase angiotensin converting enzyme 2 (ACE2) in vivo, counteracts the vasoconstricting activity of angiotensin II.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Angiotensin-(1-7)","termGroup":"PT","termSource":"NCI"},{"termName":"Ang 1-7","termGroup":"SY","termSource":"NCI"},{"termName":"Angiotensin 1-7","termGroup":"SY","termSource":"NCI"},{"termName":"TXA 127","termGroup":"CN","termSource":"NCI"},{"termName":"TXA-127","termGroup":"CN","termSource":"NCI"},{"termName":"TXA127","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51833-78-4"},{"name":"CHEBI_ID","value":"CHEBI:55438"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IJ3FUK8MOF"},{"name":"Legacy Concept Name","value":"Therapeutic_Angiotensin_1-7"},{"name":"Maps_To","value":"Therapeutic Angiotensin-(1-7)"},{"name":"NCI_Drug_Dictionary_ID","value":"543940"},{"name":"PDQ_Closed_Trial_Search_ID","value":"543940"},{"name":"PDQ_Open_Trial_Search_ID","value":"543940"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0103306"}]}}{"C91077":{"preferredName":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907","code":"C91077","definitions":[{"definition":"A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): Topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907","termGroup":"PT","termSource":"NCI"},{"termName":"DPX-0907","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907"},{"name":"NCI_Drug_Dictionary_ID","value":"670456"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670456"},{"name":"PDQ_Open_Trial_Search_ID","value":"670456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984018"}]}}{"C478":{"preferredName":"Therapeutic Estradiol","code":"C478","definitions":[{"definition":"A synthetic form of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females, that may be used as hormone replacement therapy. Typically esterified, estradiol derivatives are formulated for oral, intravaginal, transdermal, or parenteral administration. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. It may play a role in immune and inflammatory processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Estradiol","termGroup":"PT","termSource":"NCI"},{"termName":"(17beta)-Estra-1,3,5(10)-triene-3,17-diol","termGroup":"SN","termSource":"NCI"},{"termName":"17 Beta-Estradiol","termGroup":"SY","termSource":"NCI"},{"termName":"Aquadiol","termGroup":"BR","termSource":"NCI"},{"termName":"Climara","termGroup":"BR","termSource":"NCI"},{"termName":"Dimenformon","termGroup":"FB","termSource":"NCI"},{"termName":"Diogyn","termGroup":"FB","termSource":"NCI"},{"termName":"Diogynets","termGroup":"FB","termSource":"NCI"},{"termName":"Estrace","termGroup":"BR","termSource":"NCI"},{"termName":"Estraldine","termGroup":"SY","termSource":"NCI"},{"termName":"Ovocylin","termGroup":"FB","termSource":"NCI"},{"termName":"Progynon","termGroup":"FB","termSource":"NCI"},{"termName":"Vagifem","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-28-2"},{"name":"CHEBI_ID","value":"CHEBI:16469"},{"name":"Chemical_Formula","value":"C18H24O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4TI98Z838E"},{"name":"Legacy Concept Name","value":"Therapeutic_Estradiol"},{"name":"Maps_To","value":"Therapeutic Estradiol"},{"name":"NCI_Drug_Dictionary_ID","value":"39236"},{"name":"NSC Number","value":"20293"},{"name":"NSC Number","value":"9895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39236"},{"name":"PDQ_Open_Trial_Search_ID","value":"39236"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0699359"}]}}{"C555":{"preferredName":"Therapeutic Hydrocortisone","code":"C555","definitions":[{"definition":"A drug used to relieve the symptoms of certain hormone shortages and to suppress an immune response.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Hydrocortisone","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Aeroseb-HC","termGroup":"BR","termSource":"NCI"},{"termName":"Barseb-HC","termGroup":"SY","termSource":"NCI"},{"termName":"Cetacort","termGroup":"BR","termSource":"NCI"},{"termName":"Cort-Dome","termGroup":"BR","termSource":"NCI"},{"termName":"Cortef","termGroup":"BR","termSource":"NCI"},{"termName":"Cortenema","termGroup":"BR","termSource":"NCI"},{"termName":"Cortifan","termGroup":"SY","termSource":"NCI"},{"termName":"Cortisol","termGroup":"SY","termSource":"NCI"},{"termName":"Cortispray","termGroup":"BR","termSource":"NCI"},{"termName":"Cortril","termGroup":"BR","termSource":"NCI"},{"termName":"Dermacort","termGroup":"BR","termSource":"NCI"},{"termName":"Domolene","termGroup":"SY","termSource":"NCI"},{"termName":"Eldecort","termGroup":"BR","termSource":"NCI"},{"termName":"Hautosone","termGroup":"SY","termSource":"NCI"},{"termName":"Heb-Cort","termGroup":"SY","termSource":"NCI"},{"termName":"Hydrocortisone","termGroup":"SY","termSource":"NCI"},{"termName":"Hydrocortone","termGroup":"BR","termSource":"NCI"},{"termName":"Hytone","termGroup":"BR","termSource":"NCI"},{"termName":"Komed-HC","termGroup":"SY","termSource":"NCI"},{"termName":"Nutracort","termGroup":"BR","termSource":"NCI"},{"termName":"Proctocort","termGroup":"BR","termSource":"NCI"},{"termName":"Rectoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50-23-7"},{"name":"CHEBI_ID","value":"CHEBI:17650"},{"name":"Chemical_Formula","value":"C21H30O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"WI4X0X7BPJ"},{"name":"Legacy Concept Name","value":"Therapeutic_Hydrocortisone"},{"name":"Maps_To","value":"Therapeutic Hydrocortisone"},{"name":"NCI_Drug_Dictionary_ID","value":"39274"},{"name":"NSC Number","value":"10482"},{"name":"NSC Number","value":"10483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39274"},{"name":"PDQ_Open_Trial_Search_ID","value":"39274"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0020268"}]}}{"C151942":{"preferredName":"Therapeutic Liver Cancer Peptide Vaccine IMA970A","code":"C151942","definitions":[{"definition":"An off-the-shelf hepatocellular cancer (HCC) multi-peptide-based therapeutic vaccine composed of sixteen peptides derived from tumor-associated antigens (TAAs) expressed by hepatic tumor cells, of which seven are restricted to human leukocyte antigen (HLA)-A2 (HLA-A*02), five to HLA-A*24 and four to HLA class II, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the therapeutic liver cancer peptide vaccine IMA970A, the liver-specific peptides in the vaccine activate the immune system to exert both CD4+ T-helper and CD8+ cytotoxic T-lymphocyte (CTL)-mediated immune responses against liver cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Liver Cancer Peptide Vaccine IMA970A","termGroup":"PT","termSource":"NCI"},{"termName":"HCC Vaccine IMA970A","termGroup":"SY","termSource":"NCI"},{"termName":"IMA970A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Therapeutic Liver Cancer Peptide Vaccine IMA970A"},{"name":"NCI_Drug_Dictionary_ID","value":"793143"},{"name":"NCI_META_CUI","value":"CL553170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793143"},{"name":"PDQ_Open_Trial_Search_ID","value":"793143"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C92589":{"preferredName":"Thiarabine","code":"C92589","definitions":[{"definition":"A analog of antimetabolite cytarabine (ara-C), with potential antineoplastic activity. Upon administration, thiarabine (T-araC) is phosphorylated to the triphosphate form T-araCTP and competes with cytidine for incorporation into DNA. This results in an inhibition of DNA replication and RNA synthesis, chain termination and may eventually decrease tumor cell proliferation. Compared to ara-C, T-araC appears to have a longer half-life and has a higher efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thiarabine","termGroup":"PT","termSource":"NCI"},{"termName":"4-thio-araC","termGroup":"AB","termSource":"NCI"},{"termName":"GS7836","termGroup":"CN","termSource":"NCI"},{"termName":"OSI-7836","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"26599-17-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YCO2764D5Z"},{"name":"Maps_To","value":"Thiarabine"},{"name":"NCI_Drug_Dictionary_ID","value":"675426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"675426"},{"name":"PDQ_Open_Trial_Search_ID","value":"675426"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0915967"}]}}{"C75295":{"preferredName":"Thiodiglycol","code":"C75295","definitions":[{"definition":"A hydrolysis product of mustard gas, an alkylating agent, with antineoplastic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thiodiglycol","termGroup":"PT","termSource":"NCI"},{"termName":"beta-Hydroxyethyl Sulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Bis(2-hydroxyethyl)sulfide","termGroup":"SN","termSource":"NCI"},{"termName":"Thiodiethylene Glycol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"111-48-8"},{"name":"Chemical_Formula","value":"C4H10O2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9BW5T43J04"},{"name":"Legacy Concept Name","value":"Thiodiglycol"},{"name":"Maps_To","value":"Thiodiglycol"},{"name":"NSC Number","value":"6289"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0045267"}]}}{"C876":{"preferredName":"Thioguanine","code":"C876","definitions":[{"definition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thioguanine","termGroup":"PT","termSource":"NCI"},{"termName":"2-Amino 6MP","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-1,7-dihydro-6H-purine-6-thione","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-6-mercaptopurine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-6-purinethiol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurin-6-thiol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurine-6(1H)-thione","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurine-6-thiol","termGroup":"SN","termSource":"NCI"},{"termName":"2-Aminopurine-6-thiol Hemihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"6 Mercaptoguanine","termGroup":"SN","termSource":"NCI"},{"termName":"6 Thioguanine","termGroup":"SN","termSource":"NCI"},{"termName":"6-Mercapto-2-aminopurine","termGroup":"SN","termSource":"NCI"},{"termName":"6-TG","termGroup":"AB","termSource":"NCI"},{"termName":"6-Thioguanine","termGroup":"SN","termSource":"NCI"},{"termName":"6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"BW 5071","termGroup":"CN","termSource":"NCI"},{"termName":"Lanvis","termGroup":"FB","termSource":"NCI"},{"termName":"Tabloid","termGroup":"BR","termSource":"NCI"},{"termName":"Thioguanine Hemihydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Thioguanine Hydrate","termGroup":"SY","termSource":"NCI"},{"termName":"Tioguanin","termGroup":"SY","termSource":"NCI"},{"termName":"Tioguanine","termGroup":"SY","termSource":"NCI"},{"termName":"Wellcome U3B","termGroup":"CN","termSource":"NCI"},{"termName":"WR-1141","termGroup":"CN","termSource":"NCI"},{"termName":"X 27","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute nonlymphocytic leukemia"},{"name":"CAS_Registry","value":"5580-03-0"},{"name":"Chemical_Formula","value":"C5H5N5S.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"FTK8U1GZNX"},{"name":"Legacy Concept Name","value":"Thioguanine"},{"name":"Maps_To","value":"Thioguanine"},{"name":"NCI_Drug_Dictionary_ID","value":"43669"},{"name":"NSC Number","value":"752"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43669"},{"name":"PDQ_Open_Trial_Search_ID","value":"43669"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039902"}]}}{"C61970":{"preferredName":"Thioguanine Anhydrous","code":"C61970","definitions":[{"definition":"The anhydrous salt form of thioguanine, a synthetic guanosine analogue antimetabolite, with antineoplastic activity. Thioguanine is phosphorylated by hypoxanthine-guanine phosphoribosyltransferase to 6-thioguanylic acid (TGMP) and upon conversion to thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP), this agent is incorporated into DNA and RNA, resulting in inhibition of DNA and RNA synthesis and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine ribonulceotide synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioguanine Anhydrous","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"154-42-7"},{"name":"Chemical_Formula","value":"C5H5N5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WIX31ZPX66"},{"name":"Legacy Concept Name","value":"Thioguanine_Anhydrous"},{"name":"Maps_To","value":"Thioguanine Anhydrous"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1883309"}]}}{"C877":{"preferredName":"Thioinosine","code":"C877","definitions":[{"definition":"A sulfhydryl analog of inosine and an antimetabolite with potential antineoplastic and immunosuppressive properties. Thioinosine interferes with de novo purine synthesis and perturbs the pool of nucleotides necessary for DNA replication. As a result, this agent inhibits DNA synthesis, blocks cellular proliferation and induces apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioinosine","termGroup":"PT","termSource":"NCI"},{"termName":"6-mercaptopurine ribonucleoside","termGroup":"SN","termSource":"NCI"},{"termName":"6-mercaptopurine riboside","termGroup":"SN","termSource":"NCI"},{"termName":"inosine, 6-thio","termGroup":"SN","termSource":"NCI"},{"termName":"Mercaptopurine Riboside","termGroup":"SY","termSource":"NCI"},{"termName":"ribosyl-6-mercaptopurine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"574-25-4"},{"name":"Chemical_Formula","value":"C10H12N4O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"46S541971T"},{"name":"Legacy Concept Name","value":"Thioinosine"},{"name":"Maps_To","value":"Thioinosine"},{"name":"NCI_Drug_Dictionary_ID","value":"39496"},{"name":"NSC Number","value":"4911"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39496"},{"name":"PDQ_Open_Trial_Search_ID","value":"39496"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039904"}]}}{"C74082":{"preferredName":"Thioredoxin-1 Inhibitor PX-12","code":"C74082","definitions":[{"definition":"An orally bioavailable small molecule with potential antineoplastic activity. Thioredoxin-1 inhibitor PX-12 irreversibly binds to thioredoxin-1 (Trx-1) and inhibits its activity, which may result in growth inhibition and the induction of apoptosis. Overexpressed in many cancer cell types, the low molecular weight redox protein Trx-1 regulates transcription factor activity and inhibits apoptosis, promoting cell growth and survival; it also interacts with growth factors extracellularly to stimulate cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioredoxin-1 Inhibitor PX-12","termGroup":"PT","termSource":"NCI"},{"termName":"1-Methylpropyl 2-Imidazolyl Disulfide","termGroup":"SN","termSource":"NCI"},{"termName":"PX-12","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"141400-58-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8PQ9CZ8BTJ"},{"name":"Legacy Concept Name","value":"Thioredoxin-1_Inhibitor_PX-12"},{"name":"Maps_To","value":"Thioredoxin-1 Inhibitor PX-12"},{"name":"NCI_Drug_Dictionary_ID","value":"590656"},{"name":"PDQ_Closed_Trial_Search_ID","value":"590656"},{"name":"PDQ_Open_Trial_Search_ID","value":"590656"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0960559"}]}}{"C875":{"preferredName":"Thiotepa","code":"C875","definitions":[{"definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Thiotepa","termGroup":"PT","termSource":"NCI"},{"termName":"1,1',1\"-phosphinothioylidynetrisaziridine","termGroup":"SN","termSource":"NCI"},{"termName":"1,1',1''-Phosphinothioyldynetrisaziridine","termGroup":"SN","termSource":"NCI"},{"termName":"N,N',N''-triethylenethiophosphoramide","termGroup":"SN","termSource":"NCI"},{"termName":"Tepadina","termGroup":"FB","termSource":"NCI"},{"termName":"Tepadina","termGroup":"BR","termSource":"NCI"},{"termName":"TESPA","termGroup":"AB","termSource":"NCI"},{"termName":"Thiofosfamide","termGroup":"SY","termSource":"NCI"},{"termName":"Thiophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Thiophosphoamide","termGroup":"SY","termSource":"NCI"},{"termName":"Thiophosphoramide","termGroup":"SY","termSource":"NCI"},{"termName":"Thioplex","termGroup":"AQS","termSource":"NCI"},{"termName":"Triethylene Thiophosphoramide","termGroup":"SY","termSource":"NCI"},{"termName":"triethylenethiophosphoramide","termGroup":"SY","termSource":"NCI"},{"termName":"tris(1-aziridinyl)phosphine sulfide","termGroup":"SN","termSource":"NCI"},{"termName":"TSPA","termGroup":"AB","termSource":"NCI"},{"termName":"WR 45312","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Breast cancer; Ovarian cancer; Hodgkins lymphoma; Non-hodgkins lymphoma"},{"name":"CAS_Registry","value":"52-24-4"},{"name":"Chemical_Formula","value":"C6H12N3PS"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"905Z5W3GKH"},{"name":"Legacy Concept Name","value":"Thiotepa"},{"name":"Maps_To","value":"Thiotepa"},{"name":"NCI_Drug_Dictionary_ID","value":"42933"},{"name":"NSC Number","value":"6396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42933"},{"name":"PDQ_Open_Trial_Search_ID","value":"42933"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0039871"}]}}{"C102881":{"preferredName":"Thioureidobutyronitrile","code":"C102881","definitions":[{"definition":"A water-soluble, small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. Upon intravenous administration, thioureidobutyronitrile activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis. Thioureidobutyronitrile may be effective in drug-resistant cancers with mutated p53. p53 tumor suppressor, a transcription factor regulating the expression of many stress response genes and mediating various anti-proliferative processes, is often mutated in cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thioureidobutyronitrile","termGroup":"PT","termSource":"NCI"},{"termName":"4-Isothioureidobutyronitrile","termGroup":"SY","termSource":"NCI"},{"termName":"Carbamimidothioic Acid, 3-Cyanopropyl Ester","termGroup":"SY","termSource":"NCI"},{"termName":"Kevetrin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"500863-50-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C3059TG1KN"},{"name":"Maps_To","value":"Thioureidobutyronitrile"},{"name":"NCI_Drug_Dictionary_ID","value":"739050"},{"name":"NCI_META_CUI","value":"CL437184"},{"name":"PDQ_Closed_Trial_Search_ID","value":"739050"},{"name":"PDQ_Open_Trial_Search_ID","value":"739050"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88275":{"preferredName":"THL-P","code":"C88275","definitions":[{"definition":"A proprietary, oral Chinese medicinal herb preparation with potential antioxidant, immunomodulating, and antineoplastic activities. THL-P (Tien-Hsien Liquid-P) contains fourteen Chinese medicinal herbs including: Cordyceps sinensis, Oldenlandia diffusa, Indigo pulverata levis, Polyporus umbellatus, Radix astragali, Panax ginseng, Solanum nigrum L., Pogostemon cablin, Atractylodis macrocephalae rhizoma, Trichosanthes radix, Clematis radix, Margarite, Ligustrum lucidum Ait and Glycyrrhiza radix. Administered as an oral liquid, THL-P may modulate the activity of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs), macrophages and polymorphonuclear leukocytes, and enhance the secretion of interleukins (ILs) and interferon-gamma (IFN-gamma). This agent may also induce G2/M cell cycle arrest and downregulate several important oncogenic signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"THL-P","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"THL-P"},{"name":"NCI_Drug_Dictionary_ID","value":"655959"},{"name":"NCI_META_CUI","value":"CL412464"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655959"},{"name":"PDQ_Open_Trial_Search_ID","value":"655959"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155977":{"preferredName":"Thorium Th 227 Anetumab Corixetan","code":"C155977","definitions":[{"definition":"A radioimmunoconjugate consisting of anetumab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein mesothelin, conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 anetumab corixetan, the anetumab moiety binds to the tumor-associated antigen (TAA) mesothelin, delivering a cytotoxic dose of alpha radiation to cells expressing mesothelin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thorium Th 227 Anetumab Corixetan","termGroup":"PT","termSource":"NCI"},{"termName":"227Th Anetumab Corixetan","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2287411","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2287411","termGroup":"CN","termSource":"NCI"},{"termName":"Thorium Th 227 Monoclonal Antibody BAY2287411","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Anetumab","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Antibody-chelator Conjugate BAY2287411","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2222980-98-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"22OG9ZC9MN"},{"name":"Maps_To","value":"Thorium Th 227 Anetumab"},{"name":"Maps_To","value":"Thorium Th 227 Anetumab Corixetan"},{"name":"NCI_Drug_Dictionary_ID","value":"795118"},{"name":"NCI_META_CUI","value":"CL562713"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795118"},{"name":"PDQ_Open_Trial_Search_ID","value":"795118"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128288":{"preferredName":"Luvixasertib","code":"C128288","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the dual specificity protein kinase TTK (monopolar spindle 1 kinase, Mps1), with potential antineoplastic activity. Upon administration, luvixasertib selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC) and accelerates mitosis, which results in chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a tyrosine and serine/threonine kinase expressed in proliferating normal tissues, is essential for proper SAC functioning and chromosome alignment. Overexpressed in various human tumors, Mps1 plays a key role in uncontrolled tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Luvixasertib","termGroup":"PT","termSource":"NCI"},{"termName":"CFI-402257","termGroup":"CN","termSource":"NCI"},{"termName":"MSP1 Inhibitor CFI-402257","termGroup":"SY","termSource":"NCI"},{"termName":"N-cyclopropyl-4-(7-((((1s,3s)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-2-yloxy)pyrazolo[1,5-a]pyridin-3-yl)-2-methylbenzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Threonine Tyrosine Kinase Inhibitor CFI-402257","termGroup":"SY","termSource":"NCI"},{"termName":"TTK Inhibitor CFI-402257","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1610759-22-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HE97PTK3Q6"},{"name":"Maps_To","value":"Threonine Tyrosine Kinase Inhibitor CFI-402257"},{"name":"NCI_Drug_Dictionary_ID","value":"782180"},{"name":"NCI_META_CUI","value":"CL507939"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782180"},{"name":"PDQ_Open_Trial_Search_ID","value":"782180"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116720":{"preferredName":"Thymidylate Synthase Inhibitor DFP-11207","code":"C116720","definitions":[{"definition":"An orally available thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon oral administration, DFP-11207 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymidylate Synthase Inhibitor DFP-11207","termGroup":"PT","termSource":"NCI"},{"termName":"DFP-11207","termGroup":"CN","termSource":"NCI"},{"termName":"TS Inhibitor DFP-11207","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1296177-16-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33RN5G108E"},{"name":"Maps_To","value":"Thymidylate Synthase Inhibitor DFP-11207"},{"name":"NCI_Drug_Dictionary_ID","value":"762603"},{"name":"NCI_META_CUI","value":"CL473914"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762603"},{"name":"PDQ_Open_Trial_Search_ID","value":"762603"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1294":{"preferredName":"Thymopentin","code":"C1294","definitions":[{"definition":"A synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin enhances the production of thymic T cells and may help restore immunocompetence in immunosuppressed subjects. This agent also augments the effects of ionizing radiation by arresting cancer cells in the G2/M phase of the cell cycle. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymopentin","termGroup":"PT","termSource":"NCI"},{"termName":"Immunox","termGroup":"BR","termSource":"NCI"},{"termName":"Mepentil","termGroup":"FB","termSource":"NCI"},{"termName":"N-(N-(N-(N(2)-L-Arginyl-L-Lysyl)-L-alpha-Aspartyl)-L-Valyl)-L-Tyrosine","termGroup":"SN","termSource":"NCI"},{"termName":"ORF-15244","termGroup":"CN","termSource":"NCI"},{"termName":"Sintomodulina","termGroup":"FB","termSource":"NCI"},{"termName":"Timunox","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69558-55-0"},{"name":"Chemical_Formula","value":"C30H49N9O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O3Y80ZF13F"},{"name":"Legacy Concept Name","value":"Thymopentin"},{"name":"Maps_To","value":"Thymopentin"},{"name":"NCI_Drug_Dictionary_ID","value":"41655"},{"name":"NSC Number","value":"645363"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41655"},{"name":"PDQ_Open_Trial_Search_ID","value":"41655"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0080225"}]}}{"C2565":{"preferredName":"Thyroid Extract","code":"C2565","definitions":[{"definition":"An animal source of thyroid used in hormonal replacement therapy. Thyroid extract or desiccated thyroid contains both levothyroxine (thyroxine or T4) and liothyronine (triiodothyronine or T3). Levothyroxine is deiodinated in the peripheral tissues to produce increased levels of its active form, liothyronine (T3). Thyroid hormones play an important role in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation as well as regulating the metabolism of proteins, carbohydrates, and lipids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Armour Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Levothyroxine/Liothyronine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Extract"},{"name":"Maps_To","value":"Thyroid Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"39301"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39301"},{"name":"PDQ_Open_Trial_Search_ID","value":"39301"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0718658"}]}}{"C1254":{"preferredName":"Tiazofurin","code":"C1254","definitions":[{"definition":"A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug being studied to stop cell growth.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tiazofurin","termGroup":"PT","termSource":"NCI"},{"termName":"2-Beta-D-ribofuranosyl-4-thiazolecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"2-Beta-D-ribofuranosylthiazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"4-Thiazolecarboxamide, 2-Beta-D-ribofuranosyl- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Riboxamide","termGroup":"BR","termSource":"NCI"},{"termName":"TCAR","termGroup":"AB","termSource":"NCI"},{"termName":"Tiazofurine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60084-10-8"},{"name":"Chemical_Formula","value":"C9H12N2O5S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ULJ82834RE"},{"name":"Legacy Concept Name","value":"Tiazofurin"},{"name":"Maps_To","value":"Tiazofurin"},{"name":"NCI_Drug_Dictionary_ID","value":"39717"},{"name":"NSC Number","value":"286193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39717"},{"name":"PDQ_Open_Trial_Search_ID","value":"39717"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076656"}]}}{"C146820":{"preferredName":"Tidutamab","code":"C146820","definitions":[{"definition":"A humanized, Fc domain-containing, bispecific monoclonal antibody targeting human CD3, a T-cell surface antigen, and somatostatin receptor 2 (SSTR2), a tumor-associated antigen (TAA) expressed on certain cancer cells, with potential antineoplastic activity. Upon administration, tidutamab binds to both T-cells and SSTR2-expressing cancer cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the SSTR2-expressing cancer cells. The inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tidutamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-SSTR2 x Anti-CD3 Monoclonal Antibody XmAb18087","termGroup":"SY","termSource":"NCI"},{"termName":"XmAb 18087","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb-18087","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb18087","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2148354-90-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"88635FW2QX"},{"name":"Maps_To","value":"Tidutamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792257"},{"name":"NCI_META_CUI","value":"CL544867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792257"},{"name":"PDQ_Open_Trial_Search_ID","value":"792257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78474":{"preferredName":"Tigapotide","code":"C78474","definitions":[{"definition":"A synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tigapotide","termGroup":"PT","termSource":"NCI"},{"termName":"PCK3145","termGroup":"CN","termSource":"NCI"},{"termName":"Prostate-Secretory Protein-94-Derived Peptide PCK3145","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"848084-83-3"},{"name":"Chemical_Formula","value":"C82H119N21O34S3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1WZ6S45S94"},{"name":"Legacy Concept Name","value":"PSP-94-Derived_Synthetic_Peptide_PCK3145"},{"name":"Maps_To","value":"Tigapotide"},{"name":"NCI_Drug_Dictionary_ID","value":"600185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600185"},{"name":"PDQ_Open_Trial_Search_ID","value":"600185"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1670100"}]}}{"C62482":{"preferredName":"Tigatuzumab","code":"C62482","definitions":[{"definition":"A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tigatuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-[Homo sapiens TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily Member 10B, DR5, TRAIL-R2, CD262)] Humanized Monoclonal TRA-8","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-DR5 MoAb","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TRAIL-R2 MoAb","termGroup":"SY","termSource":"NCI"},{"termName":"CS 1008","termGroup":"CN","termSource":"NCI"},{"termName":"CS-1008","termGroup":"CN","termSource":"NCI"},{"termName":"CS1008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"918127-53-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"237GB6IDKO"},{"name":"Legacy Concept Name","value":"CS-1008"},{"name":"Maps_To","value":"Tigatuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"489323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489323"},{"name":"PDQ_Open_Trial_Search_ID","value":"489323"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2973415"}]}}{"C140041":{"preferredName":"Vibostolimab","code":"C140041","definitions":[{"definition":"An antagonistic agent targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin and ITIM domain), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vibostolimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells, and activates CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, is overexpressed on tumor antigen-specific CD8+ T-cells and CD8+ TILs and plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vibostolimab","termGroup":"PT","termSource":"NCI"},{"termName":"MK 7684","termGroup":"CN","termSource":"NCI"},{"termName":"MK-7684","termGroup":"CN","termSource":"NCI"},{"termName":"MK7684","termGroup":"CN","termSource":"NCI"},{"termName":"T-cell Immunoglobulin and Immunoreceptor Tyrosine-based Inhibitory Motif Inhibitor MK-7684","termGroup":"SY","termSource":"NCI"},{"termName":"TIGIT Inhibitor MK-7684","termGroup":"SY","termSource":"NCI"},{"termName":"TIGIT-targeting Agent MK-7684","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2231305-30-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5XO3JF0FEK"},{"name":"Maps_To","value":"TIGIT-targeting Agent MK-7684"},{"name":"Maps_To","value":"Vibostolimab"},{"name":"NCI_Drug_Dictionary_ID","value":"791161"},{"name":"NCI_META_CUI","value":"CL538225"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791161"},{"name":"PDQ_Open_Trial_Search_ID","value":"791161"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1178":{"preferredName":"Tilarginine","code":"C1178","definitions":[{"definition":"A pan-nitric oxide synthase (NOS) inhibitor, with potential immunomodulating and antineoplastic activities. Upon administration, tilarginine binds to and inhibits NOS, a free radical signaling molecule that promotes angiogenesis, metastasis, and immunosuppression in the tumor microenvironment (TME). Reduction in NOS activity may abrogate the immunosuppressive TME, enhance tumor antigen-specific immune response and inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"An amino acid derivative used to counteract high blood pressure caused by interleukin-2.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tilarginine","termGroup":"PT","termSource":"NCI"},{"termName":"L-NMMA","termGroup":"AB","termSource":"NCI"},{"termName":"MMA","termGroup":"SY","termSource":"NCI"},{"termName":"Monomethylarginine","termGroup":"SN","termSource":"NCI"},{"termName":"N-Methylarginine","termGroup":"SY","termSource":"NCI"},{"termName":"N5-(Methylamidino)-L-ornithine","termGroup":"SN","termSource":"NCI"},{"termName":"NG-Monomethyl-L-Arginine","termGroup":"SN","termSource":"NCI"},{"termName":"NMA","termGroup":"AB","termSource":"NCI"},{"termName":"omega-N-Monomethylarginine","termGroup":"SN","termSource":"NCI"},{"termName":"Targinine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"17035-90-4"},{"name":"CHEBI_ID","value":"CHEBI:28229"},{"name":"Chemical_Formula","value":"C7H16N4O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27JT06E6GR"},{"name":"Legacy Concept Name","value":"NG-Monomethyl-L-Arginine"},{"name":"Maps_To","value":"Tilarginine"},{"name":"NCI_Drug_Dictionary_ID","value":"42258"},{"name":"NSC Number","value":"683245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42258"},{"name":"PDQ_Open_Trial_Search_ID","value":"42258"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0069477"}]}}{"C125080":{"preferredName":"Tilsotolimod Sodium","code":"C125080","definitions":[{"definition":"The sodium salt form of tilsotolimod, a proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tilsotolimod Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"IMO 2125","termGroup":"CN","termSource":"NCI"},{"termName":"IMO-2125","termGroup":"CN","termSource":"NCI"},{"termName":"TLR9 Agonist IMO-2125","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2089768-67-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I6CNU8SY0F"},{"name":"Maps_To","value":"Tilsotolimod Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"777995"},{"name":"NCI_META_CUI","value":"CL503920"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777995"},{"name":"PDQ_Open_Trial_Search_ID","value":"777995"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2354":{"preferredName":"Timonacic","code":"C2354","definitions":[{"definition":"A cyclic sulfur amino acid derivative with potential antineoplastic and antioxidant activities. Acting on cellular membranes of malignant cells through an unknown mechanism, timonacic may induce malignant cells to revert back to an untransformed state. This agent may also restore contact inhibition, a phenomenon characterized by the paracrine inhibition of mitosis following the formation of a critical cell mass, presumably the result of cell-to-cell signal transfer. Timonacic may also produce antioxidant effects secondary to its release of cysteine and restoration of glutathione concentrations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Timonacic","termGroup":"PT","termSource":"NCI"},{"termName":"4-Thiazolidine Carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"4-Thiazolidinecarboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"ATC","termGroup":"AB","termSource":"NCI"},{"termName":"Detoxepa","termGroup":"FB","termSource":"NCI"},{"termName":"Hepalidine","termGroup":"FB","termSource":"NCI"},{"termName":"Heparegen","termGroup":"FB","termSource":"NCI"},{"termName":"Thiaproline","termGroup":"SY","termSource":"NCI"},{"termName":"Thiazolidine Carboxylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Thiazolidine-4-carboxylic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Thiazolidinecarboxylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Thioproline","termGroup":"SY","termSource":"NCI"},{"termName":"Tiazolidin","termGroup":"SY","termSource":"NCI"},{"termName":"Timonacic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"444-27-9"},{"name":"CHEBI_ID","value":"CHEBI:64564"},{"name":"Chemical_Formula","value":"C4H7NO2S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E5913T3IBL"},{"name":"Legacy Concept Name","value":"Thiazolidine_Carboxylic_Acid"},{"name":"Maps_To","value":"Timonacic"},{"name":"NCI_Drug_Dictionary_ID","value":"39714"},{"name":"NSC Number","value":"25855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39714"},{"name":"PDQ_Open_Trial_Search_ID","value":"39714"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076425"}]}}{"C1255":{"preferredName":"Tin Ethyl Etiopurpurin","code":"C1255","definitions":[{"definition":"A synthetic purpurin with photosensitizing activity.  Tin ethyl etiopurpurin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called photosensitizing agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tin Ethyl Etiopurpurin","termGroup":"PT","termSource":"NCI"},{"termName":"DRG-0268","termGroup":"CN","termSource":"NCI"},{"termName":"SnET2","termGroup":"AB","termSource":"NCI"},{"termName":"Tin, (ethyl tetramethyl-20-phorbinecarboxylato(2-)-N23,N24,N25,N26)-, (SP-4-2)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"113471-15-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tin_Ethyl_Etiopurpurin"},{"name":"Maps_To","value":"Tin Ethyl Etiopurpurin"},{"name":"NCI_Drug_Dictionary_ID","value":"42606"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42606"},{"name":"PDQ_Open_Trial_Search_ID","value":"42606"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076691"}]}}{"C126105":{"preferredName":"Tinostamustine","code":"C126105","definitions":[{"definition":"An alkylating histone-deacetylase inhibitor (HDACi) fusion molecule composed of the alkylating agent bendamustine fused to the pan-HDACi vorinostat, with potential bi-functional antineoplastic activity. Upon administration of tinostamustine the vorinostat moiety targets and binds to HDACs. This leads to an accumulation of highly acetylated histones, which results in an induction of chromatin remodeling, a modulation of gene expression, an inhibition of tumor cell division and the induction of tumor cell apoptosis. The bendamustine moiety binds to, alkylates and crosslinks macromolecules, inhibiting DNA, RNA and protein synthesis, which also results in tumor cell apoptosis. Thus, tinostamustine shows superior efficacy compared to the activity of either agent alone. In addition, the inhibition of HDAC6 activity by tinostamustine induces the activation of inositol-requiring enzyme 1 (IRE-1), the key regulatory protein for the unfolded protein response (UPR). Induction of the UPR increases the sensitivity of certain cancer cell types to certain chemotherapeutic agents, such as proteasome inhibitors. Therefore, tinostamustine may work synergistically with proteasome inhibitors. HDACs, enzymes that deacetylate chromatin histone proteins, are overexpressed in various cancers and play a key role in proliferation and resistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinostamustine","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Benzimidazole-2-heptanamide, 5-(Bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-","termGroup":"SY","termSource":"NCI"},{"termName":"7-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide","termGroup":"SN","termSource":"NCI"},{"termName":"EDO-S 101","termGroup":"CN","termSource":"NCI"},{"termName":"EDO-S-101","termGroup":"CN","termSource":"NCI"},{"termName":"EDO-S101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1236199-60-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29DKI2H2NY"},{"name":"Maps_To","value":"Tinostamustine"},{"name":"NCI_Drug_Dictionary_ID","value":"779305"},{"name":"NCI_META_CUI","value":"CL504700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779305"},{"name":"PDQ_Open_Trial_Search_ID","value":"779305"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60810":{"preferredName":"Tinzaparin Sodium","code":"C60810","definitions":[{"definition":"A drug that is used with another drug, warfarin, to treat blood clots that form deep in the veins and to prevent new blood clots from forming. It is a type of anticoagulant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties.  Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tinzaparin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Enzyme Depolymerized Heparin (MW 6500)","termGroup":"SY","termSource":"NCI"},{"termName":"Inno-hep","termGroup":"BR","termSource":"NCI"},{"termName":"Innohep","termGroup":"BR","termSource":"NCI"},{"termName":"LNH-1","termGroup":"CN","termSource":"NCI"},{"termName":"Logiparin","termGroup":"FB","termSource":"NCI"},{"termName":"Tinzaparin","termGroup":"SY","termSource":"NCI"},{"termName":"Tinzaparin Sodium","termGroup":"SY","termSource":"NCI"},{"termName":"Tinzaparin Sodium Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of acute symptomatic deep venous thrombosis (DVT) with or without a pulmonary embolism (PE), in conjunction with warfarin."},{"name":"CAS_Registry","value":"9041-08-1"},{"name":"Chemical_Formula","value":"(C14H18NO11)n.2(C12H15NO13S)n.3Na.3O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3S182ET3UA"},{"name":"Legacy Concept Name","value":"Tinzaparin"},{"name":"Maps_To","value":"Tinzaparin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"467737"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467737"},{"name":"PDQ_Open_Trial_Search_ID","value":"467737"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0354599"}]}}{"C74001":{"preferredName":"Tiomolibdate Diammonium","code":"C74001","definitions":[{"definition":"A substance being studied in the treatment of many types of cancer. Ammonium tetrathiomolybdate removes extra copper from the body. Removing the copper may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. Ammonium tetrathiomolybdate is a type of chelating agent and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tiomolibdate Diammonium","termGroup":"PT","termSource":"NCI"},{"termName":"Ammonium Molybdenum Sulfide","termGroup":"SY","termSource":"NCI"},{"termName":"Ammonium Tetrathiomolybdate","termGroup":"SY","termSource":"NCI"},{"termName":"ATTM","termGroup":"AB","termSource":"NCI"},{"termName":"Coprexa","termGroup":"BR","termSource":"NCI"},{"termName":"Diammonium Tetrathiomolybdate","termGroup":"SY","termSource":"NCI"},{"termName":"Molybdate(2-), Tetrathioxo-, Ammonium (1:2), (T-4)-","termGroup":"SN","termSource":"NCI"},{"termName":"Molybdate(2-), Tetrathioxo-, Diammonium, (T-4)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"15060-55-6"},{"name":"Chemical_Formula","value":"MoS4.2H4N"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4V6I63LW1E"},{"name":"Legacy Concept Name","value":"Ammonium_Tetrathiomolybdate"},{"name":"Maps_To","value":"Tiomolibdate Diammonium"},{"name":"NCI_Drug_Dictionary_ID","value":"467218"},{"name":"NSC Number","value":"286644"},{"name":"NSC Number","value":"714598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"467218"},{"name":"PDQ_Open_Trial_Search_ID","value":"467218"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076339"}]}}{"C88326":{"preferredName":"Tipapkinogene Sovacivec","code":"C88326","definitions":[{"definition":"A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with tipapkinogene sovacivec stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tipapkinogene Sovacivec","termGroup":"PT","termSource":"NCI"},{"termName":"HPV16 E6/E7-encoding MVA Vaccine TG4001","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-HPV-IL2","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-HPV16E6/E7-IL2","termGroup":"SY","termSource":"NCI"},{"termName":"R3484","termGroup":"CN","termSource":"NCI"},{"termName":"RG3484","termGroup":"CN","termSource":"NCI"},{"termName":"RO5217790","termGroup":"CN","termSource":"NCI"},{"termName":"TG 4001","termGroup":"CN","termSource":"NCI"},{"termName":"TG-4001","termGroup":"CN","termSource":"NCI"},{"termName":"TG4001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1052105-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P34L5Y2SR5"},{"name":"Maps_To","value":"Tipapkinogene Sovacivec"},{"name":"NCI_Drug_Dictionary_ID","value":"661166"},{"name":"NCI_META_CUI","value":"CL413588"},{"name":"PDQ_Closed_Trial_Search_ID","value":"661166"},{"name":"PDQ_Open_Trial_Search_ID","value":"661166"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1703":{"preferredName":"Tipifarnib","code":"C1703","definitions":[{"definition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tipifarnib","termGroup":"PT","termSource":"NCI"},{"termName":"(+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone","termGroup":"SN","termSource":"NCI"},{"termName":"R115777","termGroup":"CN","termSource":"NCI"},{"termName":"Zarnestra","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"192185-72-1"},{"name":"Chemical_Formula","value":"C27H22Cl2N4O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"MAT637500A"},{"name":"Legacy Concept Name","value":"Tipifarnib"},{"name":"Maps_To","value":"Tipifarnib"},{"name":"NCI_Drug_Dictionary_ID","value":"42626"},{"name":"NSC Number","value":"702818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42626"},{"name":"PDQ_Open_Trial_Search_ID","value":"42626"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1176289"}]}}{"C152646":{"preferredName":"Tipiracil","code":"C152646","synonyms":[{"termName":"Tipiracil","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183204-74-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NGO10K751P"},{"name":"Maps_To","value":"Tipiracil"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4056441"}]}}{"C152647":{"preferredName":"Tipiracil Hydrochloride","code":"C152647","synonyms":[{"termName":"Tipiracil Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"183204-72-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4H59KLQ0A4"},{"name":"Maps_To","value":"Tipiracil Hydrochloride"},{"name":"NCI_META_CUI","value":"CL553979"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102876":{"preferredName":"Tirabrutinib","code":"C102876","definitions":[{"definition":"An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B cell receptor signaling and impeding B cell development. As a result, this agent may inhibit the proliferation of B cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tirabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one","termGroup":"SY","termSource":"NCI"},{"termName":"8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)","termGroup":"SY","termSource":"NCI"},{"termName":"GS 4059","termGroup":"CN","termSource":"NCI"},{"termName":"GS-4059","termGroup":"CN","termSource":"NCI"},{"termName":"GS4059","termGroup":"CN","termSource":"NCI"},{"termName":"ONO-4059","termGroup":"CN","termSource":"NCI"},{"termName":"ONO4059","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1351636-18-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"LXG44NDL2T"},{"name":"Maps_To","value":"Tirabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"738477"},{"name":"PDQ_Closed_Trial_Search_ID","value":"738477"},{"name":"PDQ_Open_Trial_Search_ID","value":"738477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3640989"}]}}{"C131291":{"preferredName":"Tiragolumab","code":"C131291","definitions":[{"definition":"A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tiragolumab","termGroup":"PT","termSource":"NCI"},{"termName":"MTIG7192A","termGroup":"CN","termSource":"NCI"},{"termName":"RG6058","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1918185-84-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6XG22YQM2Z"},{"name":"Maps_To","value":"Tiragolumab"},{"name":"NCI_Drug_Dictionary_ID","value":"782262"},{"name":"NCI_META_CUI","value":"CL507941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782262"},{"name":"PDQ_Open_Trial_Search_ID","value":"782262"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1464":{"preferredName":"Tirapazamine","code":"C1464","definitions":[{"definition":"A benzotriazine di-N-oxide with potential antineoplastic activity.  Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.  This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A drug that makes tumor cells more sensitive to radiation therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tirapazamine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Amino-1,2,4-benzotriazine-1,4-dioxide","termGroup":"SN","termSource":"NCI"},{"termName":"SR 4233","termGroup":"CN","termSource":"NCI"},{"termName":"SR-4233","termGroup":"CN","termSource":"NCI"},{"termName":"SR4233","termGroup":"CN","termSource":"NCI"},{"termName":"Tirazone","termGroup":"BR","termSource":"NCI"},{"termName":"WIN 59075","termGroup":"CN","termSource":"NCI"},{"termName":"WIN-59075","termGroup":"CN","termSource":"NCI"},{"termName":"WIN59075","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"27314-97-2"},{"name":"Chemical_Formula","value":"C7H6N4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"1UD32YR59G"},{"name":"Legacy Concept Name","value":"Tirapazamine"},{"name":"Maps_To","value":"Tirapazamine"},{"name":"NCI_Drug_Dictionary_ID","value":"42158"},{"name":"NSC Number","value":"130181"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42158"},{"name":"PDQ_Open_Trial_Search_ID","value":"42158"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0208407"}]}}{"C102758":{"preferredName":"Tisagenlecleucel","code":"C102758","definitions":[{"definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tisagenlecleucel","termGroup":"PT","termSource":"NCI"},{"termName":"CART-19","termGroup":"AB","termSource":"NCI"},{"termName":"CART19","termGroup":"AB","termSource":"NCI"},{"termName":"CTL 019","termGroup":"CN","termSource":"NCI"},{"termName":"CTL-019","termGroup":"CN","termSource":"NCI"},{"termName":"CTL019","termGroup":"CN","termSource":"NCI"},{"termName":"CTL019 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Kymriah","termGroup":"BR","termSource":"NCI"},{"termName":"Tisa-cel","termGroup":"SY","termSource":"NCI"},{"termName":"Tisagenlecleucel-T","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma and DLBCL arising from follicular lymphoma"},{"name":"CAS_Registry","value":"1823078-37-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"Q6C9WHR03O"},{"name":"Maps_To","value":"Tisagenlecleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"736184"},{"name":"NCI_META_CUI","value":"CL437013"},{"name":"PDQ_Closed_Trial_Search_ID","value":"736184"},{"name":"PDQ_Open_Trial_Search_ID","value":"736184"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121775":{"preferredName":"Tislelizumab","code":"C121775","definitions":[{"definition":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tislelizumab","termGroup":"PT","termSource":"NCI"},{"termName":"BGB A317","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A317","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA317","termGroup":"CN","termSource":"NCI"},{"termName":"Tevimbra","termGroup":"BR","termSource":"NCI"},{"termName":"Tirelizumab","termGroup":"SY","termSource":"NCI"},{"termName":"Tislelizumab-jsgr","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858168-59-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0KVO411B3N"},{"name":"Maps_To","value":"Tislelizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"770893"},{"name":"PDQ_Closed_Trial_Search_ID","value":"770893"},{"name":"PDQ_Open_Trial_Search_ID","value":"770893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053664"}]}}{"C113164":{"preferredName":"Tisotumab Vedotin","code":"C113164","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic activities. Upon administration of tisotumab vedotin, the tisotumab moiety binds to cell surface TF and is internalized. Tisotumab binds to factor VIIa (FVIIa), which interferes with the activation of factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. After internalization of the agent, the MMAE moiety is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor-resident endothelial cells. Expression of TF is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tisotumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"HuMax-TF-ADC","termGroup":"SY","termSource":"NCI"},{"termName":"Tisotumab Vedotin-tftv","termGroup":"SY","termSource":"NCI"},{"termName":"Tivdak","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"adult patients with recurrent or metastatic cervical cancer."},{"name":"CAS_Registry","value":"1418731-10-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T41737F88A"},{"name":"Maps_To","value":"Tisotumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"755933"},{"name":"NCI_META_CUI","value":"CL455237"},{"name":"PDQ_Closed_Trial_Search_ID","value":"755933"},{"name":"PDQ_Open_Trial_Search_ID","value":"755933"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62437":{"preferredName":"Tivantinib","code":"C62437","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tivantinib","termGroup":"PT","termSource":"NCI"},{"termName":"(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione","termGroup":"SN","termSource":"NCI"},{"termName":"ARQ 197","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ-197","termGroup":"CN","termSource":"NCI"},{"termName":"ARQ197","termGroup":"CN","termSource":"NCI"},{"termName":"c-Met Inhibitor ARQ 197","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"905854-02-6"},{"name":"Chemical_Formula","value":"C23H19N3O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"PJ4H73IL17"},{"name":"Legacy Concept Name","value":"ARQ_197"},{"name":"Maps_To","value":"Tivantinib"},{"name":"NCI_Drug_Dictionary_ID","value":"488957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488957"},{"name":"PDQ_Open_Trial_Search_ID","value":"488957"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831873"}]}}{"C85444":{"preferredName":"Tivozanib","code":"C85444","definitions":[{"definition":"An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.  Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tivozanib","termGroup":"PT","termSource":"NCI"},{"termName":"AV 951","termGroup":"CN","termSource":"NCI"},{"termName":"AV-951","termGroup":"CN","termSource":"NCI"},{"termName":"AV951","termGroup":"CN","termSource":"NCI"},{"termName":"Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"475108-18-0"},{"name":"Chemical_Formula","value":"C22H19ClN4O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"172030934T"},{"name":"Maps_To","value":"Tivozanib"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827667"}]}}{"C2102":{"preferredName":"TLC ELL-12","code":"C2102","definitions":[{"definition":"A liposomal formulation of the ether lipid 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with potential antineoplastic activity.  TLC ELL-12 induces tumor cell apoptosis via mitochondria- and caspase-mediated mechanisms.  Liposomal encapsulation reduces the free agent's hemolytic toxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLC ELL-12","termGroup":"PT","termSource":"NCI"},{"termName":"1-0-Octadecyl-2-O-methyl-Sn-3-glycero-phosphocholine Liposome","termGroup":"SN","termSource":"NCI"},{"termName":"ELL-12","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TLC_ELL-12"},{"name":"Maps_To","value":"TLC ELL-12"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1313443"}]}}{"C156395":{"preferredName":"TLR Agonist BDB001","code":"C156395","definitions":[{"definition":"A toll-like receptor (TLR) agonist with potential immunostimulating and antineoplastic activities. Upon administration, TLR agonist BDB001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha (IFNa); production of proinflammatory cytokines; upregulation of co-stimulatory molecules; enhanced T- and B-cell stimulatory responses; T-cell proliferation; and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR Agonist BDB001","termGroup":"PT","termSource":"NCI"},{"termName":"BDB 001","termGroup":"CN","termSource":"NCI"},{"termName":"BDB-001","termGroup":"CN","termSource":"NCI"},{"termName":"BDB001","termGroup":"CN","termSource":"NCI"},{"termName":"Toll-like Receptor Agonist BDB001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR Agonist BDB001"},{"name":"NCI_Drug_Dictionary_ID","value":"795388"},{"name":"NCI_META_CUI","value":"CL563098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795388"},{"name":"PDQ_Open_Trial_Search_ID","value":"795388"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C158747":{"preferredName":"TLR Agonist BSG-001","code":"C158747","definitions":[{"definition":"A toll-like receptor (TLR) agonist with potential immunomodulating and antineoplastic activities. Upon inhalation, TLR agonist BSG-001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation, secretion of interferon alpha (IFNa), production of proinflammatory cytokines, upregulation of co-stimulatory molecules, enhanced T- and B-cell stimulatory responses, T-cell proliferation and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others. Immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR Agonist BSG-001","termGroup":"PT","termSource":"NCI"},{"termName":"BSG 001","termGroup":"CN","termSource":"NCI"},{"termName":"BSG-001","termGroup":"CN","termSource":"NCI"},{"termName":"BSG001","termGroup":"CN","termSource":"NCI"},{"termName":"Syngenon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR Agonist BSG-001"},{"name":"NCI_Drug_Dictionary_ID","value":"797412"},{"name":"NCI_META_CUI","value":"CL950713"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797412"},{"name":"PDQ_Open_Trial_Search_ID","value":"797412"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77884":{"preferredName":"TLR Agonist CADI-05","code":"C77884","definitions":[{"definition":"A poly-Toll-like receptor (TLR) agonist polyantigenic vaccine containing heat killed Mycobacterium indicus pranii (Mycobacterium w or Mw) with potential immunostimulating and antineoplastic activities. Upon administration, poly-TLR agonist polyantigenic vaccine activates a number of TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha; production of pro-inflammatory cytokines; upregulation of co-stimulatory molecules, enhanced T and B-cell stimulatory responses; T cell proliferation, and a Th1 immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in antineoplastic effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR Agonist CADI-05","termGroup":"PT","termSource":"NCI"},{"termName":"CADI-05","termGroup":"CN","termSource":"NCI"},{"termName":"Mycobacterium Indicus Pranii (Heat Killed)","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor Agonist CADI-05","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M4PN1DW08K"},{"name":"Legacy Concept Name","value":"TLR_Agonist_CADI-05"},{"name":"Maps_To","value":"TLR Agonist CADI-05"},{"name":"NCI_Drug_Dictionary_ID","value":"598873"},{"name":"NCI_META_CUI","value":"CL387125"},{"name":"PDQ_Closed_Trial_Search_ID","value":"598873"},{"name":"PDQ_Open_Trial_Search_ID","value":"598873"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82353":{"preferredName":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100","code":"C82353","definitions":[{"definition":"A cationic lipid DNA complex (CLDC) consisting of DOTIM/cholesterol liposomes and plasmid DNA, containing immunostimulatory CpG and non-CpG motifs, with potential immunostimulating and antineoplastic activities. Upon systemic administration, TLR-directed cationic lipid-DNA complex JVRS-100 enters dendritic cells (DCs) and macrophages; immunostimulatory DNA binds to and activates Toll-like receptors (TLRs), which may result in the generation of anti-tumor natural killer (NK) cell and T-cell responses by the innate immune system. In addition, as a vaccine adjuvant, this agent may induce a strong cytotoxic T-lymphocyte (CTL) response to co-administered antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100","termGroup":"PT","termSource":"NCI"},{"termName":"JVRS-100","termGroup":"CN","termSource":"NCI"},{"termName":"Toll-Like Receptor-Directed Cationic Lipid-DNA Complex JVRS-100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cationic_Lipid-DNA_Complex_JVRS-100"},{"name":"Maps_To","value":"TLR-Directed Cationic Lipid-DNA Complex JVRS-100"},{"name":"NCI_Drug_Dictionary_ID","value":"639691"},{"name":"NCI_META_CUI","value":"CL408634"},{"name":"PDQ_Closed_Trial_Search_ID","value":"639691"},{"name":"PDQ_Open_Trial_Search_ID","value":"639691"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61104":{"preferredName":"TLR7 Agonist 852A","code":"C61104","definitions":[{"definition":"A substance being studied in the treatment of certain adult and childhood blood cancers and other types of cancer. 852A may help the patient's immune system block tumor growth. It is a type of immune system modulator.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic imidazoquinoline Toll-like receptor 7 (TLR7) agonist with immunostimulating and potential antitumor activities. TLR7 agonist 852A binds to and activates TLR7, thereby stimulating plasmacytoid dendritic cells (pDC) through the TLR7-MyD88-dependent signaling pathway. Activation of pDC results in secretion of interferon alpha, the production of proimflammatory cytokines, the upregulation of co-stimulatory molecules, and enhanced T and B-cell stimulatory responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR7 Agonist 852A","termGroup":"PT","termSource":"NCI"},{"termName":"852A","termGroup":"CN","termSource":"NCI"},{"termName":"PF-4878691","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"532959-63-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6PJC3KPK6S"},{"name":"Legacy Concept Name","value":"_852A"},{"name":"Maps_To","value":"TLR7 Agonist 852A"},{"name":"NCI_Drug_Dictionary_ID","value":"396824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"396824"},{"name":"PDQ_Open_Trial_Search_ID","value":"396824"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541384"}]}}{"C114975":{"preferredName":"Bazlitoran","code":"C114975","definitions":[{"definition":"An oligonucleotide targeted to the mRNA of MYD88 L265P, a mutant form of the linker protein MYD88, with potential antitumor activity. Bazlitoran binds to and inhibits the translation of mutated MYD88 L265P mRNA. This prevents overactivation of signaling pathways mediated by toll-like receptors (TLRs) 7, 8, and 9, nuclear factor-kappa B (NF-kB) activity, Janus-associated kinases-signal transducer and activator of transcription (JAK-STAT) signaling and the production of various cytokines. Together, this leads to an induction of apoptosis and an inhibition of tumor cell proliferation in MYD88 L265P-expressing tumor cells. MYD88, a key adaptor protein in the TLR signaling pathway, is mutated in a variety of B-cell lymphomas, including Waldenstrom's macroglobulinemia (WM) and activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bazlitoran","termGroup":"PT","termSource":"NCI"},{"termName":"IMO-8400","termGroup":"CN","termSource":"NCI"},{"termName":"Oligonucleotide IMO-8400","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1378549-07-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2U46M95B5M"},{"name":"Maps_To","value":"Bazlitoran"},{"name":"Maps_To","value":"TLR7/8/9 Antagonist IMO-8400"},{"name":"NCI_Drug_Dictionary_ID","value":"759500"},{"name":"NCI_META_CUI","value":"CL472572"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759500"},{"name":"PDQ_Open_Trial_Search_ID","value":"759500"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C160500":{"preferredName":"TLR8 Agonist DN1508052","code":"C160500","definitions":[{"definition":"A small molecule Toll-like receptor 8 (TLR8; CD288) agonist with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, TLR8 agonist DN1508052 binds to TLR8, which is expressed in myeloid dendritic cells (mDCs), monocytes, and natural killer (NK) cells. This may lead to the activation of nuclear factor NF-kappa-B, the release of proinflammatory cytokines and a Th1-weighted anti-tumor immune response. Additionally, activation of TLR8 signaling in tumor cells may block the induction and reverse the suppression of senescent naive and tumor-specific T-cells, resulting in enhanced anti-tumor immunity. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR8 Agonist DN1508052","termGroup":"PT","termSource":"NCI"},{"termName":"DN A1","termGroup":"CN","termSource":"NCI"},{"termName":"DN-1508052","termGroup":"CN","termSource":"NCI"},{"termName":"DN-A1","termGroup":"CN","termSource":"NCI"},{"termName":"DN1508052","termGroup":"CN","termSource":"NCI"},{"termName":"DN1508052-01","termGroup":"CN","termSource":"NCI"},{"termName":"DNA1","termGroup":"CN","termSource":"NCI"},{"termName":"TLR8 Agonist DN-A1","termGroup":"SY","termSource":"NCI"},{"termName":"TLR8 Agonist DN1508052-01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR8 Agonist DN1508052"},{"name":"NCI_Drug_Dictionary_ID","value":"798329"},{"name":"NCI_META_CUI","value":"CL969563"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798329"},{"name":"PDQ_Open_Trial_Search_ID","value":"798329"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C157771":{"preferredName":"Cavrotolimod","code":"C157771","definitions":[{"definition":"A spherical nucleic acid (SN)-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, cavrotolimod targets and is able to enter various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and B cells, through endocytosis. Within the endosome, it binds to and activates TLR9. TLR9 activation induces immune signaling pathways and activates various immune cells, including B-cells, pDCs, NKs, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response as well as a cytotoxic T-lymphocyte (CTL)-based immune response against tumor cells. This results in an inhibition of tumor cell proliferation. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate and adaptive immune responses. The SNA is a dense, radial arrangement of nucleic acids (DNA) on the surface of liposomal nanoparticles, providing a 3D-construct, that has a high cellular uptake and an increased presentation of the DNA for TLR9 agonism. It also protects against breakdown by nucleases and increases the half-life of the construct compared to linear oligonucleotides that are not in SNA format.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cavrotolimod","termGroup":"PT","termSource":"NCI"},{"termName":"AST 008","termGroup":"CN","termSource":"NCI"},{"termName":"AST-008","termGroup":"CN","termSource":"NCI"},{"termName":"AST008","termGroup":"CN","termSource":"NCI"},{"termName":"SNA AST-008","termGroup":"SY","termSource":"NCI"},{"termName":"TLR9 Agonist AST-008","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor 9 Activator AST-008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2378664-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2Z5JOV1PPN"},{"name":"Maps_To","value":"TLR9 Agonist AST-008"},{"name":"NCI_Drug_Dictionary_ID","value":"797159"},{"name":"NCI_META_CUI","value":"CL937384"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797159"},{"name":"PDQ_Open_Trial_Search_ID","value":"797159"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C84217":{"preferredName":"Tocilizumab","code":"C84217","definitions":[{"definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tocilizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Actemra","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"},{"termName":"MRA","termGroup":"AB","termSource":"NCI"},{"termName":"R-1569","termGroup":"CN","termSource":"NCI"},{"termName":"RoActemra","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of COVID-19-emergency use authorization (EUA)."},{"name":"CAS_Registry","value":"375823-41-9"},{"name":"CHEBI_ID","value":"CHEBI:64360"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"I031V2H011"},{"name":"Maps_To","value":"Tocilizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"713832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713832"},{"name":"PDQ_Open_Trial_Search_ID","value":"713832"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1609165"}]}}{"C2571":{"preferredName":"Tocladesine","code":"C2571","definitions":[{"definition":"A substance that is being studied as an anticancer drug.  It is an analogue of a substance that occurs naturally in the body (cyclic adenosine monophosphate).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An antimetabolite and a chlorine derivative of the intracellular secondary messenger, cyclic adenosine 3,5-monophosphate (cAMP), with potential antineoplastic activity. Tocladesine appears to be converted to 8-chloro-adenosine by phosphodiesterases and subsequently phosphorylated to 8-chloro-ATP, which functions as a purine analogue and competes with ATP in transcription. In addition, generation of 8-chloro-ATP depletes endogenous ATP pool that is essential for many biological reactions in intracellular energy transfer. As a result, this agent causes RNA synthesis inhibition, blocks cellular proliferation, and induces apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tocladesine","termGroup":"PT","termSource":"NCI"},{"termName":"8-Chloro Cyclic AMP","termGroup":"SY","termSource":"NCI"},{"termName":"8-Chloroadenosine Cyclic 3':5'-Monophosphate","termGroup":"SN","termSource":"NCI"},{"termName":"8-Cl-cAMP","termGroup":"AB","termSource":"NCI"},{"termName":"Adenazole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41941-56-4"},{"name":"Chemical_Formula","value":"C10H11ClN5O6P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BQ94Z7E5OR"},{"name":"Legacy Concept Name","value":"Tocladesine"},{"name":"Maps_To","value":"Tocladesine"},{"name":"NCI_Drug_Dictionary_ID","value":"42670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42670"},{"name":"PDQ_Open_Trial_Search_ID","value":"42670"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0050063"}]}}{"C68318":{"preferredName":"Tocotrienol","code":"C68318","definitions":[{"definition":"Any of the four forms, alpha, beta, gamma and delta, of a member of the vitamin E family, with potential hypocholesterolemic, antithrombotic, antioxidant, immunomodulating and antineoplastic activities. Tocotrienol inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thereby lowering cholesterol levels. In addition, tocotrienol acts through multiple signal transduction pathways to induce cell cycle arrest and caspase-mediated apoptosis, and to decrease tumor cell proliferation. In addition, this agent may inhibit angiogenesis through the blockage of vascular endothelial growth factor receptor (VEGFR) and the subsequent inhibition of tumor cell-induced vessel formation. Also, this agent prevents free radical formation and inhibits lipid peroxidation, thereby preventing DNA cell damage. Tocotrienol farnesyl isoprenoid side chains contain 3 double bonds, which are absent in tocopherols, likely contribute to its anti-cancer activities.","type":"DEFINITION","source":"NCI"},{"definition":"Class of compounds having one to three methyl groups on a chromanol ring with a long unsaturated 12-carbon side chain with three methyl groups along the chain and two methyl groups at the end; may contribute to vitamin E activity.","type":"ALT_DEFINITION","source":"CRCH"}],"synonyms":[{"termName":"Tocotrienol","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-Tocotrienol","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6829-55-6"},{"name":"CHEBI_ID","value":"CHEBI:33235"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0867I0N41V"},{"name":"Legacy Concept Name","value":"Tocotrienol"},{"name":"Maps_To","value":"Tocotrienol"},{"name":"NCI_Drug_Dictionary_ID","value":"779794"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779794"},{"name":"PDQ_Open_Trial_Search_ID","value":"779794"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"UMLS_CUI","value":"C0949647"},{"name":"Unit","value":"mg"}]}}{"C101518":{"preferredName":"Tocotrienol-rich Fraction","code":"C101518","definitions":[{"definition":"An orally available nutritional supplement containing high amounts of the vitamin E family member tocotrienol with antioxidant, hypolipidemic and potential immunomodulating and antiproliferative activity. Upon oral administration, tocotrienol-rich fraction (TRF) accumulates in tumor cells and induces cell cycle arrest, programmed cell death, and inhibits tumor cell proliferation. In addition, this agent suppresses 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity and inhibits angiogenesis. Rice bran oil, palm oil and annatto seed oil are common sources of TRF.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tocotrienol-rich Fraction","termGroup":"PT","termSource":"NCI"},{"termName":"TRF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tocotrienol-rich Fraction"},{"name":"NCI_Drug_Dictionary_ID","value":"730662"},{"name":"NCI_META_CUI","value":"CL435775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"730662"},{"name":"PDQ_Open_Trial_Search_ID","value":"730662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153314":{"preferredName":"Guretolimod","code":"C153314","definitions":[{"definition":"A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of  cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Guretolimod","termGroup":"PT","termSource":"NCI"},{"termName":"(((4-((2-Amino-4-(((3s)-1-hydroxyhexan-3-yl)amino)-6-methylpyrimidin-5-yl)methyl)-3- methoxyphenyl)methyl)(2,2,2-trifluoroethyl)amino)acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"DSP 0509","termGroup":"CN","termSource":"NCI"},{"termName":"DSP-0509","termGroup":"CN","termSource":"NCI"},{"termName":"DSP0509","termGroup":"CN","termSource":"NCI"},{"termName":"TLR7 Agonist DSP-0509","termGroup":"SY","termSource":"NCI"},{"termName":"Toll-like Receptor 7 Agonist DSP-0509","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1488364-57-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2UG29YVL56"},{"name":"Maps_To","value":"Toll-like Receptor 7 Agonist DSP-0509"},{"name":"NCI_Drug_Dictionary_ID","value":"794076"},{"name":"NCI_META_CUI","value":"CL554427"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794076"},{"name":"PDQ_Open_Trial_Search_ID","value":"794076"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75293":{"preferredName":"Tolnidamine","code":"C75293","definitions":[{"definition":"An indazole carboxylic acid derivative with antispermatogenic and potential antineoplastic activity. As a male contraceptive, tolnidamine may irreversibly inhibit sperm production. This agent is less nephrotoxic than ionidamide, but it is just as effective in antispermatogenic action to ionidamide.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tolnidamine","termGroup":"PT","termSource":"NCI"},{"termName":"1b Indozadole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"50454-68-7"},{"name":"Chemical_Formula","value":"C16H13ClN2O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z5M7SC6D5P"},{"name":"Legacy Concept Name","value":"Tolnidamine"},{"name":"Maps_To","value":"Tolnidamine"},{"name":"NSC Number","value":"283448"},{"name":"PubMedID_Primary_Reference","value":"17040103"},{"name":"PubMedID_Primary_Reference","value":"8415857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076802"}]}}{"C120554":{"preferredName":"Tomaralimab","code":"C120554","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2), with potential anti-inflammatory and antineoplastic activities. Upon intravenous administration, tomaralimab binds to the ligand-binding site on the TLR2 receptor and blocks the activation of TLR2-mediated innate immunity signaling. This prevents the TLR2-mediated production of pro-inflammatory mediators and prevents inflammation. TLR2, a member of the TLR family primarily found on leukocytes, plays a key role in the activation of innate immunity; it is overexpressed in various inflammatory diseases and in certain types of cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tomaralimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TLR2 Monoclonal Antibody OPN-305","termGroup":"SY","termSource":"NCI"},{"termName":"OPN-305","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1449294-76-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P45C2W27DU"},{"name":"Maps_To","value":"Tomaralimab"},{"name":"NCI_Drug_Dictionary_ID","value":"769468"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769468"},{"name":"PDQ_Open_Trial_Search_ID","value":"769468"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3712029"}]}}{"C88300":{"preferredName":"Tomato-Soy Juice","code":"C88300","definitions":[{"definition":"A juice containing tomato extract and soy protein with potential chemopreventive and antiproliferative activities. Tomato-soy juice contains phytochemicals, including flavonoids, such as the soy isoflavone genistein, and carotenoids, including lycopene. These phytochemicals may exhibit antioxidative activity, antitumor activity by modulating certain tumor-associated signal transduction pathways, and apoptosis-inducing activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tomato-Soy Juice","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tomato-Soy Juice"},{"name":"NCI_Drug_Dictionary_ID","value":"659065"},{"name":"NCI_META_CUI","value":"CL413551"},{"name":"PDQ_Closed_Trial_Search_ID","value":"659065"},{"name":"PDQ_Open_Trial_Search_ID","value":"659065"},{"name":"Semantic_Type","value":"Food"}]}}{"C125062":{"preferredName":"Tomivosertib","code":"C125062","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase (MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic activity. Upon oral administration, tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling. This inhibits tumor cell proliferation in MNK1/2-overexpressing tumor cells. MNK1/2 are overexpressed in a variety of tumor cell types and promote phosphorylation of eIF4E; eIF4E is overexpressed in many tumor cell types and contributes to tumor development, maintenance and resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tomivosertib","termGroup":"PT","termSource":"NCI"},{"termName":"EFT-508","termGroup":"CN","termSource":"NCI"},{"termName":"eFT508","termGroup":"CN","termSource":"NCI"},{"termName":"Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl-","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1849590-01-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U2H19X4WBV"},{"name":"Maps_To","value":"Tomivosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"777456"},{"name":"NCI_META_CUI","value":"CL503903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777456"},{"name":"PDQ_Open_Trial_Search_ID","value":"777456"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78477":{"preferredName":"Topical Betulinic Acid","code":"C78477","definitions":[{"definition":"A topical formulation of a pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial factors involved in apoptosis, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Betulinic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Topical ALS-357","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Topical_Betulinic_Acid"},{"name":"Maps_To","value":"Topical Betulinic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"600544"},{"name":"NCI_META_CUI","value":"CL387585"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600544"},{"name":"PDQ_Open_Trial_Search_ID","value":"600544"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148519":{"preferredName":"Topical Celecoxib","code":"C148519","definitions":[{"definition":"A topical cream formulation containing celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), with anti-inflammatory and potential keratolytic, chemopreventive and antineoplastic activities. Upon topical application to the affected area, celecoxib selectively binds to and inhibits cyclooxygenase-2 activity (COX-2), which may result in localized keratinocyte apoptosis. The breakdown of keratinocytes prevents their proliferation locally and may reduce tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Celecoxib","termGroup":"PT","termSource":"NCI"},{"termName":"Celecoxib Cream","termGroup":"SY","termSource":"NCI"},{"termName":"Celecoxib Topical","termGroup":"SY","termSource":"NCI"},{"termName":"DFD-07","termGroup":"CN","termSource":"NCI"},{"termName":"DFD07","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Celecoxib"},{"name":"NCI_Drug_Dictionary_ID","value":"792678"},{"name":"NCI_META_CUI","value":"CL551149"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792678"},{"name":"PDQ_Open_Trial_Search_ID","value":"792678"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125194":{"preferredName":"Topical Fluorouracil","code":"C125194","definitions":[{"definition":"A topical formulation containing the antimetabolite 5-fluorouracil (5-FU), with antineoplastic activity. Upon topical administration, 5-FU is converted into the active metabolite 5-fluoroxyuridine monophosphate (F-UMP), which competes with uracil during RNA synthesis and inhibits RNA processing. Conversion of 5-FU into another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase; this results in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in DNA synthesis, and thus inhibits DNA synthesis. Altogether, this prevents the proliferation of tumor cells locally.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Fluorouracil","termGroup":"PT","termSource":"NCI"},{"termName":"Actino-Hermal","termGroup":"FB","termSource":"NCI"},{"termName":"Arumel","termGroup":"FB","termSource":"NCI"},{"termName":"Carac","termGroup":"BR","termSource":"NCI"},{"termName":"Cytosafe","termGroup":"FB","termSource":"NCI"},{"termName":"Efudex","termGroup":"BR","termSource":"NCI"},{"termName":"Efurix","termGroup":"FB","termSource":"NCI"},{"termName":"Fiverocil","termGroup":"FB","termSource":"NCI"},{"termName":"Fluoroplex","termGroup":"BR","termSource":"NCI"},{"termName":"Flurox","termGroup":"FB","termSource":"NCI"},{"termName":"Timazin","termGroup":"FB","termSource":"NCI"},{"termName":"Tolak","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Fluorouracil"},{"name":"NCI_Drug_Dictionary_ID","value":"777929"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777929"},{"name":"PDQ_Open_Trial_Search_ID","value":"777929"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0720488"}]}}{"C74085":{"preferredName":"Topical Gemcitabine Hydrochloride","code":"C74085","definitions":[{"definition":"A topical preparation of gemcitabine hydrochloride with antineoplastic activity. Gemcitabine, an analogue of the antimetabolite nucleoside deoxycytidine, is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Gemcitabine Hydrochloride","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Topical_Gemcitabine_Hydrochloride"},{"name":"Maps_To","value":"Topical Gemcitabine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"587041"},{"name":"NCI_META_CUI","value":"CL383495"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587041"},{"name":"PDQ_Open_Trial_Search_ID","value":"587041"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C151946":{"preferredName":"Topical Potassium Dobesilate","code":"C151946","definitions":[{"definition":"A topical formulation composed of an inhibitor of fibroblast growth factor (FGF), with potential antineoplastic activity. Upon topical administration potassium dobesilate selectively binds to and blocks the activity of FGF, interferes with the binding of FGF to FGFR and prevents FGFR-mediated signaling. This inhibits angiogenesis and tumor cell proliferation, and induces cell death in FGFR-overexpressing tumor cells. FGF plays a key role in angiogenesis, tumor cell proliferation, survival and invasiveness, and is upregulated in many tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Potassium Dobesilate","termGroup":"PT","termSource":"NCI"},{"termName":"AM-001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Potassium Dobesilate"},{"name":"NCI_Drug_Dictionary_ID","value":"793156"},{"name":"NCI_META_CUI","value":"CL553174"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793156"},{"name":"PDQ_Open_Trial_Search_ID","value":"793156"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C125002":{"preferredName":"Topical Trichloroacetic Acid","code":"C125002","definitions":[{"definition":"A topical solution containing the caustic agent trichloroacetic acid (TCA), with potential keratolytic, anti-viral and antineoplastic activities. Upon topical application to the affected area, TCA causes tissue necrosis through coagulation of proteins, leads to the destruction of human papilloma virus (HPV)-associated warts and inhibits HPV-driven proliferation of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topical Trichloroacetic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Topical TCA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topical Trichloroacetic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"777303"},{"name":"NCI_META_CUI","value":"CL503848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"777303"},{"name":"PDQ_Open_Trial_Search_ID","value":"777303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C75124":{"preferredName":"Topixantrone","code":"C75124","definitions":[{"definition":"A 9-aza-anthrapyrazole antineoplastic antibiotic. Topixantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Compared to other DNA intercalators, this agent shows minimal cardiotoxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topixantrone","termGroup":"PT","termSource":"NCI"},{"termName":"BBR 3576","termGroup":"CN","termSource":"NCI"},{"termName":"Indazolo(4,3-gh)isoquinolin-6(2H)-one, 5-((2-(dimethylamino)ethyl)amino)-2-(2-((2-hydroxyethyl)amino)ethyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"156090-18-5"},{"name":"Chemical_Formula","value":"C21H26N6O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R40RXC296C"},{"name":"Legacy Concept Name","value":"Topixantrone"},{"name":"Maps_To","value":"Topixantrone"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1528075"}]}}{"C84851":{"preferredName":"Topoisomerase I Inhibitor Genz-644282","code":"C84851","definitions":[{"definition":"A non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I Inhibitor Genz-644282","termGroup":"PT","termSource":"NCI"},{"termName":"Genz-644282","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"529488-28-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"717I541I2R"},{"name":"Maps_To","value":"Topoisomerase I Inhibitor Genz-644282"},{"name":"NCI_Drug_Dictionary_ID","value":"651243"},{"name":"PDQ_Closed_Trial_Search_ID","value":"651243"},{"name":"PDQ_Open_Trial_Search_ID","value":"651243"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2827528"}]}}{"C90594":{"preferredName":"Topoisomerase I Inhibitor LMP400","code":"C90594","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain enzymes that break and rejoin DNA strands. These enzymes are needed for cells to divide and grow. Blocking them may cause cancer cells to die. LMP400 also helps anticancer drugs kill cancers that are resistant to some other drugs. LMP400 is a type of indenoisoquinoline and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP400 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I Inhibitor LMP400","termGroup":"PT","termSource":"NCI"},{"termName":"LMP400","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topoisomerase I Inhibitor LMP400"},{"name":"NCI_Drug_Dictionary_ID","value":"663024"},{"name":"NCI_META_CUI","value":"CL413610"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663024"},{"name":"PDQ_Open_Trial_Search_ID","value":"663024"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C90595":{"preferredName":"Topoisomerase I Inhibitor LMP776","code":"C90595","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks certain enzymes that break and rejoin DNA strands. These enzymes are needed for cells to divide and grow. Blocking them may cause cancer cells to die. LMP776 also helps anticancer drugs kill cancers that are resistant to some other drugs. LMP776 is a type of indenoisoquinoline and a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP776 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I Inhibitor LMP776","termGroup":"PT","termSource":"NCI"},{"termName":"LMP776","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topoisomerase I Inhibitor LMP776"},{"name":"NCI_Drug_Dictionary_ID","value":"663025"},{"name":"NCI_META_CUI","value":"CL413611"},{"name":"PDQ_Closed_Trial_Search_ID","value":"663025"},{"name":"PDQ_Open_Trial_Search_ID","value":"663025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C128557":{"preferredName":"Topoisomerase I/II Inhibitor NEV-801","code":"C128557","definitions":[{"definition":"A multi-targeted agent with potential antineoplastic activity. Upon administration, NEV-801 appears to selectively inhibit topoisomerase (Topo) I and II, and activates hypoxia-inducible factor 1 (HIF-1) transcription and the expression of vascular endothelial growth factor (VEGF) mRNA. NEV-801 is also able to overcome multidrug resistance (MDR) 1-mediated resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase I/II Inhibitor NEV-801","termGroup":"PT","termSource":"NCI"},{"termName":"NEV-801","termGroup":"CN","termSource":"NCI"},{"termName":"NEV801","termGroup":"CN","termSource":"NCI"},{"termName":"TopI/II NEV-801","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topoisomerase I/II Inhibitor NEV-801"},{"name":"NCI_Drug_Dictionary_ID","value":"782337"},{"name":"NCI_META_CUI","value":"CL507943"},{"name":"PDQ_Closed_Trial_Search_ID","value":"782337"},{"name":"PDQ_Open_Trial_Search_ID","value":"782337"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C127900":{"preferredName":"Topoisomerase-1 Inhibitor LMP744","code":"C127900","definitions":[{"definition":"An indenoisoquinoline derivative and topoisomerase 1 (Top1) inhibitor, with potential antineoplastic activity. Upon administration, LMP744 binds to and stabilizes cleaved DNA-Top1 complexes, which prevents DNA re-ligation, induces stable, irreversible DNA strand breaks, prevents DNA repair, and leads to cell cycle arrest and apoptosis. As tumor cells proliferate at a much higher rate than normal cells, LMP744 specifically targets cancer cells. Top1, a DNA modifying enzyme essential for transcription, replication, and repair of double-strand DNA breaks, is overexpressed in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase-1 Inhibitor LMP744","termGroup":"PT","termSource":"NCI"},{"termName":"5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-Hydroxyethyl)amino)propyl)-2,3-dimethoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"Indenoisoquinoline LMP744","termGroup":"SY","termSource":"NCI"},{"termName":"LMP-744","termGroup":"CN","termSource":"NCI"},{"termName":"LMP744","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"308246-52-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29BY7HQV0T"},{"name":"Maps_To","value":"Topoisomerase-1 Inhibitor LMP744"},{"name":"NCI_Drug_Dictionary_ID","value":"787756"},{"name":"NCI_META_CUI","value":"CL509262"},{"name":"PDQ_Closed_Trial_Search_ID","value":"787756"},{"name":"PDQ_Open_Trial_Search_ID","value":"787756"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2825":{"preferredName":"Topoisomerase-II Inhibitor Racemic XK469","code":"C2825","definitions":[{"definition":"The racemic form of a synthetic quinoxaline phenoxypropionic acid derivative with antineoplastic properties. XK469R selectively inhibits topoisomerase II by stabilizing the enzyme-DNA intermediates in which topoisomerase subunits are covalently linked to DNA through 5-phosphotyrosyl linkages, thereby interfering with DNA repair and replication, RNA and protein synthesis. This agent possesses unusual solid tumor selectivity and activity against multidrug-resistant cancer cells. XK469R is more water soluble and active than the pure isomers, R(+)XK469 and S(-)XK469. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase-II Inhibitor Racemic XK469","termGroup":"PT","termSource":"NCI"},{"termName":"Propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]-phenoxy]-, (+ /-)-","termGroup":"SN","termSource":"NCI"},{"termName":"XK469 Racemic","termGroup":"SY","termSource":"NCI"},{"termName":"XK469R","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"157542-91-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XK469R"},{"name":"Maps_To","value":"Topoisomerase-II Inhibitor Racemic XK469"},{"name":"NCI_Drug_Dictionary_ID","value":"440966"},{"name":"NSC Number","value":"698215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"440966"},{"name":"PDQ_Open_Trial_Search_ID","value":"440966"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1611867"}]}}{"C2662":{"preferredName":"Topoisomerase-II-beta Inhibitor Racemic XK469","code":"C2662","definitions":[{"definition":"A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called topoisomerase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The R-isomer of a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topoisomerase-II-beta Inhibitor Racemic XK469","termGroup":"PT","termSource":"NCI"},{"termName":"2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid","termGroup":"SN","termSource":"NCI"},{"termName":"Propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy]-, (+ )-(R)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XK469"},{"name":"Maps_To","value":"Topoisomerase-II-beta Inhibitor Racemic XK469"},{"name":"NCI_Drug_Dictionary_ID","value":"38517"},{"name":"NSC Number","value":"698215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38517"},{"name":"PDQ_Open_Trial_Search_ID","value":"38517"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0765292"}]}}{"C1413":{"preferredName":"Topotecan","code":"C1413","definitions":[{"definition":"A drug used to treat certain types of ovarian cancer, lung cancer, and cervical cancer. Topotecan is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan","termGroup":"PT","termSource":"NCI"},{"termName":"(s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione","termGroup":"SN","termSource":"NCI"},{"termName":"9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin","termGroup":"SN","termSource":"NCI"},{"termName":"Hycamptamine","termGroup":"SY","termSource":"NCI"},{"termName":"Topotecan Lactone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123948-87-8"},{"name":"CHEBI_ID","value":"CHEBI:63632"},{"name":"Chemical_Formula","value":"C23H23N3O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7M7YKX2N15"},{"name":"Legacy Concept Name","value":"Topotecan"},{"name":"Maps_To","value":"Topotecan"},{"name":"NSC Number","value":"641007"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0146224"}]}}{"C2828":{"preferredName":"Topotecan Hydrochloride","code":"C2828","definitions":[{"definition":"A drug used to treat certain types of ovarian cancer, lung cancer, and cervical cancer. Hycamtin is a type of topoisomerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Camptothecin is a cytotoxic quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino[1,2-b] quinoline-3,14-(4H,12H)-dione Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Evotopin","termGroup":"FB","termSource":"NCI"},{"termName":"Hycamptamine","termGroup":"SY","termSource":"NCI"},{"termName":"Hycamtin","termGroup":"BR","termSource":"NCI"},{"termName":"Nogitecan Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Potactasol","termGroup":"FB","termSource":"NCI"},{"termName":"SKF S 104864 A","termGroup":"CN","termSource":"NCI"},{"termName":"SKF S-104864-A","termGroup":"CN","termSource":"NCI"},{"termName":"SKF S104864A","termGroup":"CN","termSource":"NCI"},{"termName":"Topotec","termGroup":"FB","termSource":"NCI"},{"termName":"Topotecan HCl","termGroup":"SY","termSource":"NCI"},{"termName":"topotecan hydrochloride (oral)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Small Cell Lung Carcinoma; Cervical Cancer"},{"name":"CAS_Registry","value":"119413-54-6"},{"name":"Chemical_Formula","value":"C23H23N3O5.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"956S425ZCY"},{"name":"Legacy Concept Name","value":"Topotecan_Hydrochloride"},{"name":"Maps_To","value":"Topotecan Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"41185"},{"name":"NSC Number","value":"609699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41185"},{"name":"PDQ_Open_Trial_Search_ID","value":"41185"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0886549"}]}}{"C80065":{"preferredName":"Topotecan Hydrochloride Liposomes","code":"C80065","definitions":[{"definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin mixed with sphingomyelin/cholesterol and sonicated to form small unilamellar vesicles containing topotecan, with potential antineoplastic activity. Topotecan hydrochloride liposomes mediates efficient drug delivery of topotecan into the cytosol from the endosome compartment. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan Hydrochloride Liposomes","termGroup":"PT","termSource":"NCI"},{"termName":"Brakiva","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Topotecan_Hydrochloride_Liposomes"},{"name":"Maps_To","value":"Topotecan Hydrochloride Liposomes"},{"name":"NCI_Drug_Dictionary_ID","value":"617377"},{"name":"NCI_META_CUI","value":"CL388400"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617377"},{"name":"PDQ_Open_Trial_Search_ID","value":"617377"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64779":{"preferredName":"Topsalysin","code":"C64779","definitions":[{"definition":"A targeted prodrug consisting of a recombinant modified form of the Aeromonas protoxin, proaerolysin (PA), bearing a prostate-specific protease cleavage site, with potential antineoplastic activity. When injected directly into the prostate, topsalysin is hydrolyzed to the active toxin aerolysin by the serine protease prostate specific antigen (PSA), a protein overexpressed by prostate cancers and prostate cells in hyperplastic prostatic tissue. Aerolysin molecules then oligomerize to form ring-like heptamers that are incorporated into the lipid bilayers of cell membranes, forming large membrane channels and resulting in the leakage of cellular contents and lysis of PSA-expressing prostate cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topsalysin","termGroup":"PT","termSource":"NCI"},{"termName":"Pore-forming Protein (Synthetic Proaerolysin) Fusion Protein with Prostate-specific Antigen (Human)","termGroup":"SY","termSource":"NCI"},{"termName":"PORxin 302","termGroup":"SY","termSource":"NCI"},{"termName":"PRX 302","termGroup":"CN","termSource":"NCI"},{"termName":"PSA-PAH1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917121-25-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LSA9D0A43Q"},{"name":"Legacy Concept Name","value":"PRX302"},{"name":"Maps_To","value":"Topsalysin"},{"name":"NCI_Drug_Dictionary_ID","value":"517173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"517173"},{"name":"PDQ_Open_Trial_Search_ID","value":"517173"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831975"}]}}{"C101795":{"preferredName":"TORC1/2 Kinase Inhibitor DS-3078a","code":"C101795","definitions":[{"definition":"An orally bioavailable inhibitor of raptor-mTOR protein complex (TORC1) and rictor-mTOR protein complex (TORC2) with potential antineoplastic activity. TORC1/2 inhibitor DS-3078a binds to and inhibits both TORC1 and TORC2, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TORC1/2 Kinase Inhibitor DS-3078a","termGroup":"PT","termSource":"NCI"},{"termName":"DS-3078a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TORC1/2 Kinase Inhibitor DS-3078a"},{"name":"NCI_Drug_Dictionary_ID","value":"733685"},{"name":"NCI_META_CUI","value":"CL435913"},{"name":"PDQ_Closed_Trial_Search_ID","value":"733685"},{"name":"PDQ_Open_Trial_Search_ID","value":"733685"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1256":{"preferredName":"Toremifene","code":"C1256","definitions":[{"definition":"A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of drugs called antiestrogens. Toremifene blocks the effect of the hormone estrogen in the body. It may help control some cancers from growing, and it may delay or reduce the risk of cancer recurrence.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Toremifene","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine","termGroup":"SN","termSource":"NCI"},{"termName":"(Z)-4-Chloro-1,2-diphenyl-1[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene","termGroup":"SN","termSource":"NCI"},{"termName":"Farestone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Desmoid tumors"},{"name":"CAS_Registry","value":"89778-26-7"},{"name":"CHEBI_ID","value":"CHEBI:9635"},{"name":"Chemical_Formula","value":"C26H28ClNO"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"7NFE54O27T"},{"name":"Legacy Concept Name","value":"Toremifene"},{"name":"Maps_To","value":"Toremifene"},{"name":"NCI_Drug_Dictionary_ID","value":"41103"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41103"},{"name":"PDQ_Open_Trial_Search_ID","value":"41103"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076836"}]}}{"C1756":{"preferredName":"Toremifene Citrate","code":"C1756","definitions":[{"definition":"The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toremifene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"(Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)- N,N-dimethylethylamine citrate (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"Acapodene","termGroup":"BR","termSource":"NCI"},{"termName":"Fareston","termGroup":"BR","termSource":"NCI"},{"termName":"FC-1157a","termGroup":"CN","termSource":"NCI"},{"termName":"GTx-006","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"89778-27-8"},{"name":"Chemical_Formula","value":"C26H28ClNO.C6H8O7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2498Y783QT"},{"name":"Legacy Concept Name","value":"Toremifene_Citrate"},{"name":"Maps_To","value":"Toremifene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"41103"},{"name":"NSC Number","value":"613680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41103"},{"name":"PDQ_Open_Trial_Search_ID","value":"41103"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0117339"}]}}{"C131334":{"preferredName":"Toripalimab","code":"C131334","definitions":[{"definition":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toripalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody JS001","termGroup":"SY","termSource":"NCI"},{"termName":"JS 001","termGroup":"CN","termSource":"NCI"},{"termName":"JS-001","termGroup":"CN","termSource":"NCI"},{"termName":"JS001","termGroup":"CN","termSource":"NCI"},{"termName":"Loqtorzi","termGroup":"BR","termSource":"NCI"},{"termName":"TAB 001","termGroup":"CN","termSource":"NCI"},{"termName":"TAB-001","termGroup":"CN","termSource":"NCI"},{"termName":"Toripalimab-tpzi","termGroup":"SY","termSource":"NCI"},{"termName":"Tuoyi","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"recurrent unresectable or metastatic NPC"},{"name":"CAS_Registry","value":"1924598-82-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"8JXN261VVA"},{"name":"Maps_To","value":"Toripalimab"},{"name":"NCI_Drug_Dictionary_ID","value":"785704"},{"name":"NCI_META_CUI","value":"CL514245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"785704"},{"name":"PDQ_Open_Trial_Search_ID","value":"785704"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70650":{"preferredName":"Tosedostat","code":"C70650","definitions":[{"definition":"A proprietary orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Aminopeptidase inhibitor CHR-2797 is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid deprivation, inhibition of protein synthesis due to a decrease in the intracellular free amino acid pool, an increase in the level of the proapoptotic protein Noxa, and cell death. Noxa is a member of the BH3 (Bcl-2 homology 3)-only subgroup of the proapoptotic Bcl-2 (B-cell CLL/lymphoma 2) protein family.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tosedostat","termGroup":"PT","termSource":"NCI"},{"termName":"Aminopeptidase inhibitor CHR-2797","termGroup":"SY","termSource":"NCI"},{"termName":"CHR 2797","termGroup":"CN","termSource":"NCI"},{"termName":"CHR-2797","termGroup":"CN","termSource":"NCI"},{"termName":"CHR2797","termGroup":"CN","termSource":"NCI"},{"termName":"Cyclopentyl (2S)-2-{(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4- methylpentanamido}-2-phenylacetate","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"238750-77-1"},{"name":"Chemical_Formula","value":"C21H30N2O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"KZK563J2UW"},{"name":"Legacy Concept Name","value":"Aminopeptidase_Inhibitor_CHR-2797"},{"name":"Maps_To","value":"Tosedostat"},{"name":"NCI_Drug_Dictionary_ID","value":"570670"},{"name":"PDQ_Closed_Trial_Search_ID","value":"570670"},{"name":"PDQ_Open_Trial_Search_ID","value":"570670"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2606804"}]}}{"C2543":{"preferredName":"Tositumomab","code":"C2543","definitions":[{"definition":"A monoclonal antibody that is used in the treatment of certain types of non-Hodgkin lymphoma. When tositumomab and iodine I 131 tositumomab (a form of tositumomab that has been chemically changed by adding radioactive iodine) are given together, the combination is called the Bexxar regimen.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tositumomab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-B1","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD20 Antibody","termGroup":"SY","termSource":"NCI"},{"termName":"MoAb Anti-B1","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody Anti-B1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"CD20 Positive Follicular Non-Hodgkins Lymphoma Refractory to Rituximab"},{"name":"CAS_Registry","value":"192391-48-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0343IGH41U"},{"name":"Legacy Concept Name","value":"Tositumomab"},{"name":"Maps_To","value":"Tositumomab"},{"name":"NCI_Drug_Dictionary_ID","value":"37818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37818"},{"name":"PDQ_Open_Trial_Search_ID","value":"37818"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879399"}]}}{"C94614":{"preferredName":"Total Androgen Blockade","code":"C94614","definitions":[{"definition":"Therapy used to eliminate male sex hormones (androgens) in the body. This may be done with surgery, hormonal therapy, or a combination.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Total Androgen Blockade","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Total Androgen Blockade"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C2986598"}]}}{"C82684":{"preferredName":"Tovetumab","code":"C82684","definitions":[{"definition":"A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Tovetumab inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tovetumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Platelet-Derived Growth Factor Receptor Alpha Monoclonal Antibody MEDI-575","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI-575","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1243266-04-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2XY62K75UV"},{"name":"Legacy Concept Name","value":"Anti-PDGFR_Alpha_Monoclonal_Antibody_MEDI-575"},{"name":"Maps_To","value":"Tovetumab"},{"name":"NCI_Drug_Dictionary_ID","value":"633312"},{"name":"PDQ_Closed_Trial_Search_ID","value":"633312"},{"name":"PDQ_Open_Trial_Search_ID","value":"633312"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830210"}]}}{"C61319":{"preferredName":"Tozasertib Lactate","code":"C61319","definitions":[{"definition":"The lactate salt of tozasertib, a synthetic, small-molecule Aurora kinase inhibitor with potential antitumor activity. Tozasertib binds to and inhibits Aurora kinases (AKs), thereby inducing apoptosis in tumor cells in which AKs are overexpressed. AKs, a family of serine-threonine kinases, are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tozasertib Lactate","termGroup":"PT","termSource":"NCI"},{"termName":"Aurora Kinase Inhibitor MK-0457","termGroup":"SY","termSource":"NCI"},{"termName":"L-001281814","termGroup":"CN","termSource":"NCI"},{"termName":"MK-0457","termGroup":"CN","termSource":"NCI"},{"termName":"Propanoic acid, 2-hydroxy-, (2S)-, compd. with N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)cyclopropanecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"VX-680","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"899827-04-4"},{"name":"Chemical_Formula","value":"C23H28N8OS.C3H6O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CN8EF9N084"},{"name":"Legacy Concept Name","value":"MK-0457"},{"name":"Maps_To","value":"Tozasertib Lactate"},{"name":"NCI_Drug_Dictionary_ID","value":"485305"},{"name":"PDQ_Closed_Trial_Search_ID","value":"485305"},{"name":"PDQ_Open_Trial_Search_ID","value":"485305"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451033"}]}}{"C2374":{"preferredName":"TP40 Immunotoxin","code":"C2374","definitions":[{"definition":"A chimeric fusion protein containing human transforming growth factor alpha (TGF-a) covalently linked to a truncated form of the bacterial toxin Pseudomonas exotoxin A, PE40, with potential antitumor activity. PE40 lacks the cell-binding domain, but retains domains II and III that are involved in membrane translocation and inhibition of protein synthesis in eukaryotic cells. TGF-a moiety of the TP40 immunotoxin binds to and activates epidermal growth factor receptor (EGFR), a tyrosine kinase receptor overexpressed on certain cancer cells. After internalization, the endotoxin moiety of the immunotoxin-receptor complex causes protein synthesis inhibition via modifying translation elongation factor 2 (EF-2), thereby impedes tumor cell growth and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TP40 Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"TP40","termGroup":"SY","termSource":"NCI"},{"termName":"Transforming Growth Factor-Alpha-Pseudomonas Exotoxin-40","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TP40_Immunotoxin"},{"name":"Maps_To","value":"TP40 Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"41531"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41531"},{"name":"PDQ_Open_Trial_Search_ID","value":"41531"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0247342"}]}}{"C1691":{"preferredName":"Trabectedin","code":"C1691","definitions":[{"definition":"A substance that comes from a type of sea squirt and is being studied in the treatment of cancer. It binds to DNA and causes breaks in the DNA. It also blocks the ability of the cell to repair the DNA damage, and may cause cancer cells to die. Trabectedin is also made in the laboratory. It is a type of DNA excision repair inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabectedin","termGroup":"PT","termSource":"NCI"},{"termName":"Ecteinascidin","termGroup":"SY","termSource":"NCI"},{"termName":"Ecteinascidin 743","termGroup":"SY","termSource":"NCI"},{"termName":"ET 743","termGroup":"CN","termSource":"NCI"},{"termName":"ET-743","termGroup":"AB","termSource":"NCI"},{"termName":"ET743","termGroup":"CN","termSource":"NCI"},{"termName":"Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-Octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-","termGroup":"SN","termSource":"NCI"},{"termName":"Yondelis","termGroup":"FB","termSource":"NCI"},{"termName":"Yondelis","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"unresectable or metastatic liposarcoma or leiomyosarcoma"},{"name":"CAS_Registry","value":"114899-77-3"},{"name":"Chemical_Formula","value":"C39H43N3O11S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"ID0YZQ2TCP"},{"name":"Legacy Concept Name","value":"Ecteinascidin_743"},{"name":"Maps_To","value":"Trabectedin"},{"name":"NCI_Drug_Dictionary_ID","value":"42577"},{"name":"NSC Number","value":"648766"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42577"},{"name":"PDQ_Open_Trial_Search_ID","value":"42577"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1311070"}]}}{"C80066":{"preferredName":"Trabedersen","code":"C80066","definitions":[{"definition":"A transforming growth factor (TGF)-beta2 specific phosphorothioate antisense oligodeoxynucleotide with the sequence 5'-CGGCATGTCTATTTTGTA-3', with potential antineoplastic activity. Trebedersen binds to TGF-beta2 mRNA causing inhibition of protein translation, thereby decreasing TGF-beta2 protein levels; decreasing intratumoral TGF-beta2 levels may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trabedersen","termGroup":"PT","termSource":"NCI"},{"termName":"AP 12009","termGroup":"CN","termSource":"NCI"},{"termName":"OT 101","termGroup":"CN","termSource":"NCI"},{"termName":"OT-101","termGroup":"CN","termSource":"NCI"},{"termName":"OT101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"925681-61-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"98OYR854NY"},{"name":"Legacy Concept Name","value":"Trabedersen"},{"name":"Maps_To","value":"Trabedersen"},{"name":"NCI_Drug_Dictionary_ID","value":"617455"},{"name":"PDQ_Closed_Trial_Search_ID","value":"617455"},{"name":"PDQ_Open_Trial_Search_ID","value":"617455"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2699985"}]}}{"C146854":{"preferredName":"Eftozanermin Alfa","code":"C146854","definitions":[{"definition":"A fusion protein composed of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist consisting of six receptor binding domains (RBDs) of TRAIL fused to the Fc-domain of a human immunoglobulin G1 (IgG1) antibody, with potential pro-apoptotic and antineoplastic activities. Upon administration of eftozanermin alfa, this fusion protein binds to TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby inducing tumor cell apoptosis.  ABBV-621 is designed to maximize receptor clustering for optimal efficacy. TRAIL, a member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eftozanermin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 621","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-621","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV621","termGroup":"CN","termSource":"NCI"},{"termName":"APG880","termGroup":"CN","termSource":"NCI"},{"termName":"HERA Ligand ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"Hexavalent TRAIL Receptor Agonist ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL Receptor Agonist ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL-Fc Protein ABBV-621","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL-receptor Agonist Fusion Protein ABBV-621","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1820660-69-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1K9TTP1WS"},{"name":"Maps_To","value":"Eftozanermin Alfa"},{"name":"Maps_To","value":"TRAIL Receptor Agonist ABBV-621"},{"name":"NCI_Drug_Dictionary_ID","value":"792269"},{"name":"NCI_META_CUI","value":"CL544836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792269"},{"name":"PDQ_Open_Trial_Search_ID","value":"792269"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77908":{"preferredName":"Trametinib","code":"C77908","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trametinib","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 1120212","termGroup":"CN","termSource":"NCI"},{"termName":"GSK 212","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-1120212","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-212","termGroup":"CN","termSource":"NCI"},{"termName":"GSK1120212","termGroup":"CN","termSource":"NCI"},{"termName":"GSK212","termGroup":"CN","termSource":"NCI"},{"termName":"JTP 74057","termGroup":"CN","termSource":"NCI"},{"termName":"JTP-74057","termGroup":"CN","termSource":"NCI"},{"termName":"JTP74057","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor GSK1120212","termGroup":"SY","termSource":"NCI"},{"termName":"N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation; unresectable or metastatic melanoma with BRAF V600E or V600K mutations"},{"name":"CAS_Registry","value":"871700-17-3"},{"name":"Chemical_Formula","value":"C26H23FIN5O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"33E86K87QN"},{"name":"Legacy Concept Name","value":"MEK_Inhibitor_GSK1120212"},{"name":"Maps_To","value":"Trametinib"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2697961"}]}}{"C152711":{"preferredName":"Trametinib Dimethyl Sulfoxide","code":"C152711","definitions":[{"definition":"A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trametinib Dimethyl Sulfoxide","termGroup":"PT","termSource":"NCI"},{"termName":"Mekinist","termGroup":"BR","termSource":"NCI"},{"termName":"Meqsel","termGroup":"FB","termSource":"NCI"},{"termName":"Spexotras","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1187431-43-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BSB9VJ5TUT"},{"name":"Maps_To","value":"Trametinib Dimethyl Sulfoxide"},{"name":"NCI_Drug_Dictionary_ID","value":"599034"},{"name":"NCI_META_CUI","value":"CL553915"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599034"},{"name":"PDQ_Open_Trial_Search_ID","value":"599034"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C82695":{"preferredName":"Trans Sodium Crocetinate","code":"C82695","definitions":[{"definition":"The sodium salt of the trans-isomer of the carotenoid crocetin with potential antihypoxic and radiosensitizing activities. Trans sodium crocetinate (TSC) increases the diffusion rate of oxygen in aqueous solutions such as from plasma to body tissue. The agent has been shown to increase available oxygen during hypoxic and ischemic conditions that may occur in hemorrhage, vascular and neurological disorders, and in the tumor microenvionment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trans Sodium Crocetinate","termGroup":"PT","termSource":"NCI"},{"termName":"2,4,6,8,10,12,14-Hexadecaheptaenedioic Acid, 2,6,11,15-Tetramethyl-, Sodium Salt (1:2), (2E,4E,6E,8E,10E,12E,14E)-","termGroup":"SN","termSource":"NCI"},{"termName":"TSC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"591230-99-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YP57637WMX"},{"name":"Legacy Concept Name","value":"Trans_Sodium_Crocetinate"},{"name":"Maps_To","value":"Trans Sodium Crocetinate"},{"name":"NCI_Drug_Dictionary_ID","value":"634790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"634790"},{"name":"PDQ_Open_Trial_Search_ID","value":"634790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1453926"}]}}{"C120308":{"preferredName":"Transdermal 17beta-Estradiol Gel BHR-200","code":"C120308","definitions":[{"definition":"A proprietary, transdermal, hydroalcoholic gel formulation containing 17beta-estradiol, with potential antineoplastic activity. Upon topical administration, 17beta-estradiol exerts its antineoplastic effect(s) through as of yet not fully elucidated mechanism(s) of action(s). This formulation may induce feedback inhibition via the hypothalamic-pituitary-gonadal axis feedback loop, block the secretion of luteinizing hormone (LH) and prevent the release of testosterone from Leydig cells in the testes, thus suppressing testosterone secretion. In addition, 17beta-estradiol inhibits enzymes involved in steroidogenesis, thereby further inhibiting androgen production. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In addition, 17beta-estradiol prevents bone loss, and suppresses andropause symptoms, such as hot flashes, which appear during androgen-deprivation therapy (ADT) where the standard of care is the use of gonadotrophin releasing hormone (GnRH) analogs. Compared to oral estrogens, the topical gel formulation lowers the risk of cardiovascular side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transdermal 17beta-Estradiol Gel BHR-200","termGroup":"PT","termSource":"NCI"},{"termName":"BHR-200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transdermal 17beta-Estradiol Gel BHR-200"},{"name":"NCI_Drug_Dictionary_ID","value":"768720"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768720"},{"name":"PDQ_Open_Trial_Search_ID","value":"768720"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896903"}]}}{"C114103":{"preferredName":"Transdermal 4-Hydroxytestosterone","code":"C114103","definitions":[{"definition":"A transdermal formulation containing 4-hydroxytestosterone (4-OHT), a steroidal aromatase inhibitor (AI) and androgen receptor (AR) antagonist, with potential antineoplastic activity. 4-OHT is largely converted into 4-hydroxyandrostenedione (4-OHA) and irreversibly binds to and inhibits aromatase, thereby blocking the conversion of androstenedione to estrone, and testosterone to estradiol. This may inhibit tumor cell proliferation in estrogen-dependent tumor cells. In addition, 4-OHT binds to the AR and may inhibit AR-mediated tumor cell growth. Aromatase, a cytochrome P-450 enzyme, is overexpressed in a variety of cancer cells; it plays a key role in estrogen biosynthesis. Compared to oral 4-OHT, the transdermal formulation allows for continuous release of 4-OHT into the bloodstream and prevents first pass metabolism by the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transdermal 4-Hydroxytestosterone","termGroup":"PT","termSource":"NCI"},{"termName":"Transdermal 4-OHT","termGroup":"SY","termSource":"NCI"},{"termName":"Transdermal CR1447","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transdermal 4-Hydroxytestosterone"},{"name":"NCI_Drug_Dictionary_ID","value":"758421"},{"name":"NCI_META_CUI","value":"CL471813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"758421"},{"name":"PDQ_Open_Trial_Search_ID","value":"758421"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C78450":{"preferredName":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01","code":"C78450","definitions":[{"definition":"A proprietary transferrin receptor-targeted nanoparticle preparation of a non-chemically modified small-interfering RNA (siRNA) directed against the M2 subunit of ribonucleotide reductase (RRM2) with potential antineoplastic activity. Upon administration, transferrin receptor-targeted anti-RRM2 siRNA CALAA-01 binds to transferrin receptors (TfRs), releasing anti-RRM2 siRNA after endocytosis; anti-RRM2 siRNA silences the expression of RRM2 via the RNAi pathway, impeding the assembly of the holoenzyme ribonucleotide reductase (RR) which catalyzes the production of deoxyribonucleotides. As a result, inhibition of cellular proliferation may occur in cells expressing TfR, a cell surface protein overexpressed on various cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01","termGroup":"PT","termSource":"NCI"},{"termName":"CALAA-01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transferrin_Receptor-Targeted_Nanocomplexed_Anti-R2_siRNA_CALAA-01"},{"name":"Maps_To","value":"Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01"},{"name":"NCI_Drug_Dictionary_ID","value":"599463"},{"name":"PDQ_Closed_Trial_Search_ID","value":"599463"},{"name":"PDQ_Open_Trial_Search_ID","value":"599463"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703116"}]}}{"C29474":{"preferredName":"Transferrin Receptor-Targeted Liposomal p53 cDNA","code":"C29474","definitions":[{"definition":"A cationic liposomal, tumor-targeting p53 (TP53) gene delivery system with potential anti-tumor activity. Transferrin receptor-targeted liposomal p53 cDNA contains plasmid DNA encoding the tumor suppressor protein p53 packaged in membrane-like liposome capsules that are complexed with anti-transferrin receptor single-chain antibody (TfRscFv). Upon systemic administration, the anti-TfRscFv selectively binds to tumor cells expressing transferrin receptors. The p53 plasmid is delivered into the nucleus and as a result, p53 protein is produced in tumor cells that have altered p53 function. This results in the restoration of normal cell growth control mechanisms as well as normal response mechanisms to DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transferrin Receptor-Targeted Liposomal p53 cDNA","termGroup":"PT","termSource":"NCI"},{"termName":"SGT-53","termGroup":"AB","termSource":"NCI"},{"termName":"Synerlip p53","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Synerlip_p53"},{"name":"Maps_To","value":"Transferrin Receptor-Targeted Liposomal p53 cDNA"},{"name":"NCI_Drug_Dictionary_ID","value":"551892"},{"name":"NCI_META_CUI","value":"CL319865"},{"name":"NSC Number","value":"709399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"551892"},{"name":"PDQ_Open_Trial_Search_ID","value":"551892"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C26676":{"preferredName":"Transferrin-CRM107","code":"C26676","definitions":[{"definition":"A substance being studied in the treatment of brain tumors. Transferrin-CRM107 is made by linking a diphtheria toxin to transferrin, a protein that binds to fast growing cells, such as tumor cells. The diphtheria toxin then kills the tumor cells. Transferrin-CRM107 is a type of immunotoxin.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic targeted protein toxin which consists of human transferrin (Tf) conjugated to a diphtheria toxin that contains a point mutation (CRM107). After binding to the transferrin receptor expressed on the tumor cell surface, transferrin-CRM107 is internalized, where the diphtheria toxin moiety exerts its cytotoxic effect intracellularly by inhibiting protein synthesis through ADP-ribosylation of elongation factor. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transferrin-CRM107","termGroup":"PT","termSource":"NCI"},{"termName":"HN-66000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transferrin-CRM107"},{"name":"Maps_To","value":"Transferrin-CRM107"},{"name":"NCI_Drug_Dictionary_ID","value":"269064"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269064"},{"name":"PDQ_Open_Trial_Search_ID","value":"269064"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0912205"}]}}{"C61980":{"preferredName":"Tranylcypromine Sulfate","code":"C61980","definitions":[{"definition":"The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tranylcypromine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"(+-)-Trans-2-Phenylcyclopropylamine Sulfate (2:1)","termGroup":"SN","termSource":"NCI"},{"termName":"1-Amino-2-phenylcyclopropane Sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"Parnate","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"13492-01-8"},{"name":"CHEBI_ID","value":"CHEBI:9653"},{"name":"Chemical_Formula","value":"2C9H11N.H2SO4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7ZAT6ES870"},{"name":"Legacy Concept Name","value":"Tranylcypromine_Sulfate"},{"name":"Maps_To","value":"Tranylcypromine Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"765903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765903"},{"name":"PDQ_Open_Trial_Search_ID","value":"765903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0304369"}]}}{"C1665":{"preferredName":"Trapoxin","code":"C1665","definitions":[{"definition":"An epoxide-containing cyclotetrapeptide with antitumor activity.  It is an irreversible inhibitor of histone deacetylase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trapoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclo((S)-gamma-oxo-L-alpha-aminooxiraneoctanoyl-L-phenylalanyl-L-phenylalanyl-D-2-piperidinecarbonyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclo((S)-phenylalanyl-(S)-phenylalanyl-(R)-pipecolinyl-(2S,9S)-2-amino-8-oxo-9,10-epoxydecanoyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Cyclo(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8-oxo -9,10-epoxy - decanoyl)","termGroup":"SN","termSource":"NCI"},{"termName":"Trapoxin A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"133155-89-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GSS8DX555X"},{"name":"Legacy Concept Name","value":"Trapoxin"},{"name":"Maps_To","value":"Trapoxin"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084839"}]}}{"C148165":{"preferredName":"Trastuzumab Conjugate BI-CON-02","code":"C148165","definitions":[{"definition":"A conjugated form of trastuzumab, a humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ERBB2), with potential immunomodulating and antineoplastic activities. Upon administration, the trastuzumab conjugate BI-CON-02 targets and binds to HER2 on the tumor cell surface, thereby inducing both cytotoxic T-lymphocyte (CTL) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Conjugate BI-CON-02","termGroup":"PT","termSource":"NCI"},{"termName":"BI-CON-02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trastuzumab Conjugate BI-CON-02"},{"name":"NCI_Drug_Dictionary_ID","value":"792543"},{"name":"NCI_META_CUI","value":"CL550783"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792543"},{"name":"PDQ_Open_Trial_Search_ID","value":"792543"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118674":{"preferredName":"Trastuzumab Duocarmazine","code":"C118674","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA), with potential antineoplastic activity. Upon administration of trastuzumab duocarmazine, the trastuzumab moiety binds to HER2 on the tumor cell surface, which triggers the endocytosis of this agent. The linker is then cleaved inside the tumor cell by proteases at the dipeptide valine-citrulline (vc), and releases the active moiety, duocarmycin. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. In addition, trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed by many carcinomas and is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Duocarmazine","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SYD985","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate SYD985","termGroup":"SY","termSource":"NCI"},{"termName":"SYD985","termGroup":"CN","termSource":"NCI"},{"termName":"Trastuzumab VC-seco-DUBA","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-drug Conjugate SYD985","termGroup":"SY","termSource":"NCI"},{"termName":"vic-Trastuzumab Duocarmazine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1642152-40-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XCR2BZ80N7"},{"name":"Maps_To","value":"Trastuzumab Duocarmazine"},{"name":"NCI_Drug_Dictionary_ID","value":"766012"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766012"},{"name":"PDQ_Open_Trial_Search_ID","value":"766012"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896762"}]}}{"C82492":{"preferredName":"Trastuzumab Emtansine","code":"C82492","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Emtansine","termGroup":"PT","termSource":"NCI"},{"termName":"Ado Trastuzumab Emtansine","termGroup":"SY","termSource":"NCI"},{"termName":"ADO-Trastuzumab Emtansine","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine","termGroup":"SN","termSource":"NCI"},{"termName":"Kadcyla","termGroup":"BR","termSource":"NCI"},{"termName":"PRO 132365","termGroup":"CN","termSource":"NCI"},{"termName":"PRO-132365","termGroup":"CN","termSource":"NCI"},{"termName":"PRO132365","termGroup":"CN","termSource":"NCI"},{"termName":"RO5304020","termGroup":"CN","termSource":"NCI"},{"termName":"T-DM1","termGroup":"AB","termSource":"NCI"},{"termName":"TDM1","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-MCC-DM1","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-MCC-DM1 Antibody-Drug Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-MCC-DM1 Immunoconjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2-positive, metastatic breast cancer"},{"name":"CAS_Registry","value":"1018448-65-1"},{"name":"Chemical_Formula","value":"C47H63ClN5O13S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"SE2KH7T06F"},{"name":"Legacy Concept Name","value":"Trastuzumab-MCC-DM1_Conjugate"},{"name":"Maps_To","value":"Trastuzumab Emtansine"},{"name":"NCI_Drug_Dictionary_ID","value":"564399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564399"},{"name":"PDQ_Open_Trial_Search_ID","value":"564399"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2935436"}]}}{"C158060":{"preferredName":"Trastuzumab/Hyaluronidase-oysk","code":"C158060","definitions":[{"definition":"A ready-to-use combination of trastuzumab, a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 (rHuPH20), that may be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-oysk temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of trastuzumab into the bloodstream. Trastuzumab binds to the extracellular ligand-binding domain of HER2 and mediates the activation of an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab/Hyaluronidase-oysk","termGroup":"PT","termSource":"NCI"},{"termName":"Herceptin Hylecta","termGroup":"BR","termSource":"NCI"},{"termName":"Trastuzumab and Hyaluronidase","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab and Hyaluronidase-oysk","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab and Recombinant Human Hyaluronidase PH20","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab and rHuPH20","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-Hyaluronidase-oysk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2 overexpressing breast cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Trastuzumab/Hyaluronidase-oysk"},{"name":"NCI_Drug_Dictionary_ID","value":"797111"},{"name":"NCI_META_CUI","value":"CL937577"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797111"},{"name":"PDQ_Open_Trial_Search_ID","value":"797111"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C139800":{"preferredName":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502","code":"C139800","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of an engineered version of the humanized monoclonal anti-human epidermal growth factor receptor 2 (HER2) immunoglobulin G1 (IgG1) trastuzumab that is site-specifically conjugated, via a cleavable linker, to the cytotoxic, DNA cross-linking pyrrolobenzodiazepine (PBD) dimer-based drug tesirine, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the trastuzumab moiety of trastuzumab/tesirine ADC ADCT-502 targets the cell surface antigen HER2, which is expressed on various cancer cells. Upon antibody/antigen binding, internalization of the ADC and cleavage of the linker, the cytotoxic PBD moiety is released. The imine groups of tesirine bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death and inhibits the proliferation of HER2-overexpressing tumor cells. The tumor-associated antigen (TAA) HER2 is expressed by various solid tumors and is associated with a poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502","termGroup":"PT","termSource":"NCI"},{"termName":"ADC ADCT-502","termGroup":"SY","termSource":"NCI"},{"termName":"ADCT 502","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT-502","termGroup":"CN","termSource":"NCI"},{"termName":"ADCT502","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-HER2/PBD ADC ADCT 502","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502"},{"name":"NCI_Drug_Dictionary_ID","value":"791110"},{"name":"NCI_META_CUI","value":"CL537974"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791110"},{"name":"PDQ_Open_Trial_Search_ID","value":"791110"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91711":{"preferredName":"Trebananib","code":"C91711","definitions":[{"definition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trebananib","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 386","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-386","termGroup":"CN","termSource":"NCI"},{"termName":"AMG386","termGroup":"CN","termSource":"NCI"},{"termName":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"894356-79-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"X8Y5U6NC7E"},{"name":"Maps_To","value":"Trebananib"},{"name":"NCI_Drug_Dictionary_ID","value":"423474"},{"name":"PDQ_Closed_Trial_Search_ID","value":"423474"},{"name":"PDQ_Open_Trial_Search_ID","value":"423474"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541521"}]}}{"C49085":{"preferredName":"Tremelimumab","code":"C49085","definitions":[{"definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody being studied in the treatment of melanoma and some other types of cancer. Ticilimumab is made in the laboratory and binds to a protein called CTLA-4 on T cells (a type of white blood cell). CTLA-4 is involved in preventing the activation of T-cells. Ticilimumab may block CTLA-4 and help the immune system kill cancer cells. It is a type of immunomodulatory agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tremelimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA4 Human Monoclonal Antibody CP-675,206","termGroup":"SY","termSource":"NCI"},{"termName":"CP 675","termGroup":"CN","termSource":"NCI"},{"termName":"CP 675206","termGroup":"CN","termSource":"NCI"},{"termName":"CP-675","termGroup":"CN","termSource":"NCI"},{"termName":"CP-675,206","termGroup":"CN","termSource":"NCI"},{"termName":"CP-675206","termGroup":"CN","termSource":"NCI"},{"termName":"CP675","termGroup":"CN","termSource":"NCI"},{"termName":"CP675206","termGroup":"CN","termSource":"NCI"},{"termName":"Imjudo","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"Ticilimumab","termGroup":"SY","termSource":"NCI"},{"termName":"Tremelimumab-actl","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"for adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab."},{"name":"CAS_Registry","value":"745013-59-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"QEN1X95CIX"},{"name":"Legacy Concept Name","value":"Anti-CTLA4_Human_Monoclonal_Antibody_CP-675_206"},{"name":"Maps_To","value":"Tremelimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"448620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"448620"},{"name":"PDQ_Open_Trial_Search_ID","value":"448620"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2351038"}]}}{"C1257":{"preferredName":"Treosulfan","code":"C1257","definitions":[{"definition":"A substance that is being studied as a treatment for cancer.  It belongs to the family of drugs called alkylating agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treosulfan","termGroup":"PT","termSource":"NCI"},{"termName":"(S-(R*,R*))-1,2,3,4-butanetetrol,1,4-dimethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydroxybusulfan","termGroup":"SY","termSource":"NCI"},{"termName":"L-Threitol 1,4-dimethanesulfonate","termGroup":"SN","termSource":"NCI"},{"termName":"Ovastat","termGroup":"FB","termSource":"NCI"},{"termName":"Trecondi","termGroup":"FB","termSource":"NCI"},{"termName":"Treosulphan","termGroup":"SY","termSource":"NCI"},{"termName":"Tresulfon","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"299-75-2"},{"name":"Chemical_Formula","value":"C6H14O8S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"CO61ER3EPI"},{"name":"Legacy Concept Name","value":"Treosulfan"},{"name":"Maps_To","value":"Treosulfan"},{"name":"NCI_Drug_Dictionary_ID","value":"39720"},{"name":"NSC Number","value":"39069"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39720"},{"name":"PDQ_Open_Trial_Search_ID","value":"39720"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0076959"}]}}{"C81554":{"preferredName":"Tretazicar","code":"C81554","definitions":[{"definition":"A prodrug of a bifunctional alkylating, dinitrobenzamide derivative with antineoplastic activity. Tretazicar can be activated by the human enzyme quinone oxidoreductase 2 (NQO2) in the presence of the cosubstrate caricotamide, an analogue of the natural cosubstrate dihydronicotinamide riboside (NRH), which acts as an electron donor. The resulting active, but short-lived metabolite, dinitrobenzamide, leads to DNA replication inhibition and the induction of apoptosis in NQO2 expressing cancer cells. Due to the lack of the natural cosubstrate NRH, NQO2 expression is normally latent but is upregulated in certain types of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tretazicar","termGroup":"PT","termSource":"NCI"},{"termName":"CB1954","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"21919-05-1"},{"name":"Chemical_Formula","value":"C9H8N4O5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7865D5D01M"},{"name":"Legacy Concept Name","value":"Tretazicar"},{"name":"Maps_To","value":"Tretazicar"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0097964"}]}}{"C900":{"preferredName":"Tretinoin","code":"C900","definitions":[{"definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient that that body needs in small amounts to function and stay healthy. All-trans retinoic acid is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. A form of all-trans retinoic acid made in the laboratory is put on the skin to treat conditions such as acne and is taken by mouth to treat acute promyelocytic leukemia (a fast-growing cancer in which there are too many immature blood-forming cells in the blood and bone marrow). All-trans retinoic acid is being studied in the prevention and treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Tretinoin","termGroup":"PT","termSource":"NCI"},{"termName":"(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Aberel","termGroup":"BR","termSource":"NCI"},{"termName":"Airol","termGroup":"FB","termSource":"NCI"},{"termName":"Aknoten","termGroup":"BR","termSource":"NCI"},{"termName":"All-trans Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"All-trans Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"ATRA","termGroup":"AB","termSource":"NCI"},{"termName":"Avita","termGroup":"BR","termSource":"NCI"},{"termName":"beta-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Cordes Vas","termGroup":"FB","termSource":"NCI"},{"termName":"Dermairol","termGroup":"FB","termSource":"NCI"},{"termName":"Epi-Aberel","termGroup":"FB","termSource":"NCI"},{"termName":"Eudyna","termGroup":"FB","termSource":"NCI"},{"termName":"Renova","termGroup":"BR","termSource":"NCI"},{"termName":"Retin-A","termGroup":"BR","termSource":"NCI"},{"termName":"Retin-A MICRO","termGroup":"BR","termSource":"NCI"},{"termName":"Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Retisol-A","termGroup":"FB","termSource":"NCI"},{"termName":"Ro 5488","termGroup":"CN","termSource":"NCI"},{"termName":"Stieva-A","termGroup":"FB","termSource":"NCI"},{"termName":"Stieva-A Forte","termGroup":"FB","termSource":"NCI"},{"termName":"Trans Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Trans Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"trans-Retinoic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Tretinoinum","termGroup":"SY","termSource":"NCI"},{"termName":"Vesanoid","termGroup":"BR","termSource":"NCI"},{"termName":"Vitamin A Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Vitinoin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"(Oral) Acute promyelocytic leukemia (APL), characterized by the t(15;17) translocation or the PML/RARa gene refractory to or have relapsed from anthracycline chemotherapy, or for where anthracycline-based chemotherapy is contraindicated"},{"name":"Accepted_Therapeutic_Use_For","value":"(Topical) acne vulgaris; other dermatologic conditions; some skin cancers"},{"name":"CAS_Registry","value":"302-79-4"},{"name":"CHEBI_ID","value":"CHEBI:15367"},{"name":"Chemical_Formula","value":"C20H28O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"5688UTC01R"},{"name":"Legacy Concept Name","value":"Vitamin_A_Acid"},{"name":"Maps_To","value":"Tretinoin"},{"name":"NCI_Drug_Dictionary_ID","value":"41258"},{"name":"NSC Number","value":"122758"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41258"},{"name":"PDQ_Open_Trial_Search_ID","value":"41258"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040845"}]}}{"C2398":{"preferredName":"Tretinoin Liposome","code":"C2398","definitions":[{"definition":"An intravenous formulation of tretinoin (vitamin A acid or all-trans retinoic acid) encased in liposomes. Tretinoin is a naturally occurring retinoic acid agent that binds to and activates retinoic acid receptors (RAR), effecting changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of carcinogenesis.  This agent also inhibits telomerase, leading to telomere shortening and eventual apoptosis of certain tumor cell types. Liposome encapsulation extends the half-life of intravenously administered tretinoin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tretinoin Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"All-trans-retinoic acid liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"AR-623","termGroup":"CN","termSource":"NCI"},{"termName":"Atragen","termGroup":"BR","termSource":"NCI"},{"termName":"Liposomal all-trans-retinoic acid","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal tretinoin","termGroup":"SY","termSource":"NCI"},{"termName":"Tretinoin Liposomal","termGroup":"SY","termSource":"NCI"},{"termName":"TretinoinLF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tretinoin_Liposome"},{"name":"Maps_To","value":"Tretinoin Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"42285"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42285"},{"name":"PDQ_Open_Trial_Search_ID","value":"42285"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338222"}]}}{"C48027":{"preferredName":"Triamcinolone Acetonide","code":"C48027","definitions":[{"definition":"The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triamcinolone Acetonide","termGroup":"PT","termSource":"NCI"},{"termName":"9-alpha-Fluoro-11-beta,21-dihydroxy-16-alpha-isopropylidenedioxy-1,4-pregnadiene,3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"AllerNaze","termGroup":"BR","termSource":"NCI"},{"termName":"Aristocort A","termGroup":"BR","termSource":"NCI"},{"termName":"Kenalog","termGroup":"BR","termSource":"NCI"},{"termName":"Nasacort","termGroup":"BR","termSource":"NCI"},{"termName":"ReadySharp Triamcinolone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Allergic Rhinitis"},{"name":"CAS_Registry","value":"76-25-5"},{"name":"Chemical_Formula","value":"C24H31FO6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F446C597KA"},{"name":"Legacy Concept Name","value":"Triamcinolone_Acetonide"},{"name":"Maps_To","value":"Triamcinolone Acetonide"},{"name":"NCI_Drug_Dictionary_ID","value":"649799"},{"name":"NSC Number","value":"21916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"649799"},{"name":"PDQ_Open_Trial_Search_ID","value":"649799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040866"}]}}{"C48026":{"preferredName":"Triamcinolone Hexacetonide","code":"C48026","definitions":[{"definition":"The hexacetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone hexacetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triamcinolone Hexacetonide","termGroup":"PT","termSource":"NCI"},{"termName":"(11beta,16alpha)-21-(3,3-Dimethyl-1-oxobutoxy)-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))pregna-1,4-diene-3,20-dione","termGroup":"SN","termSource":"NCI"},{"termName":"Aristospan","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"5611-51-8"},{"name":"Chemical_Formula","value":"C30H41FO7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I7GT1U99Y9"},{"name":"Legacy Concept Name","value":"Triamcinolone_Hexacetonide"},{"name":"Maps_To","value":"Triamcinolone Hexacetonide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077004"}]}}{"C2242":{"preferredName":"Triapine","code":"C2242","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. This agent has been shown to inhibit tumor growth in vitro. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triapine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone","termGroup":"SN","termSource":"NCI"},{"termName":"3-AP","termGroup":"AB","termSource":"NCI"},{"termName":"3-Apct","termGroup":"AB","termSource":"NCI"},{"termName":"OCX-191","termGroup":"CN","termSource":"NCI"},{"termName":"OCX191","termGroup":"CN","termSource":"NCI"},{"termName":"PAN-811","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"236392-56-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U4XIL4091C"},{"name":"Legacy Concept Name","value":"Triapine"},{"name":"Maps_To","value":"Triapine"},{"name":"NCI_Drug_Dictionary_ID","value":"37830"},{"name":"NSC Number","value":"663249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37830"},{"name":"PDQ_Open_Trial_Search_ID","value":"37830"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0210403"}]}}{"C2367":{"preferredName":"Triazene Derivative CB10-277","code":"C2367","definitions":[{"definition":"A synthetic derivative of dimethylphenyl-triazene related to dacarbazine, with antineoplastic properties.  Related to the agent dacarbazine, CB10-277 is converted in vivo to a monomethyl triazene form that alkylates DNA, resulting in inhibition of DNA replication and repair; in addition, this agent may act as a purine analogue, resulting in inhibition of DNA synthesis, and may interact with protein sulfhydryl groups. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triazene Derivative CB10-277","termGroup":"PT","termSource":"NCI"},{"termName":"1-p-carboxy-3,3-dimethylphenyltriazine","termGroup":"SN","termSource":"NCI"},{"termName":"CB10-277","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"CB10-277"},{"name":"Maps_To","value":"Triazene Derivative CB10-277"},{"name":"NCI_Drug_Dictionary_ID","value":"41154"},{"name":"NSC Number","value":"208107"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41154"},{"name":"PDQ_Open_Trial_Search_ID","value":"41154"},{"name":"PubMedID_Primary_Reference","value":"phase II trial shown to be inactive; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394365/"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0088835"}]}}{"C95208":{"preferredName":"Triazene Derivative TriN2755","code":"C95208","definitions":[{"definition":"A synthetic triazene derivative with antineoplastic activity. Upon metabolic activation via N-demethylation, TriN2755 is converted into highly reactive carbocations that can alkylate DNA and other macromolecules, thereby resulting in DNA cross links, inhibiting DNA replication and repair, and subsequently inducing apoptosis. This agent has high hydrophilicity and photostability and shows a favorable toxicity profile over the other triazenes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triazene Derivative TriN2755","termGroup":"PT","termSource":"NCI"},{"termName":"TriN2755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Triazene Derivative TriN2755"},{"name":"NCI_Drug_Dictionary_ID","value":"691486"},{"name":"NCI_META_CUI","value":"CL426697"},{"name":"PDQ_Closed_Trial_Search_ID","value":"691486"},{"name":"PDQ_Open_Trial_Search_ID","value":"691486"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1258":{"preferredName":"Triazinate","code":"C1258","definitions":[{"definition":"A synthetic dihydrotriazine derivative with antineoplastic properties.  As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis.  Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triazinate","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-(2-chloro-4-(4,6-diamino-2,2-dimethyl-s-trizin-1(2H)-yl)phenoxy)-N,N-dimethyl-m-toluamide ethanesulfonic acid","termGroup":"SN","termSource":"NCI"},{"termName":"BAF","termGroup":"AB","termSource":"NCI"},{"termName":"Baker's Antifol","termGroup":"SY","termSource":"NCI"},{"termName":"Baker's Antifolate","termGroup":"SY","termSource":"NCI"},{"termName":"Bakers Antifol","termGroup":"SY","termSource":"NCI"},{"termName":"Bakers Antifolate","termGroup":"SY","termSource":"NCI"},{"termName":"benzenesulfonyl fluoride, 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenyl]butyl]-, monoethanesulfonate (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Ethanesulfonic Acid Compound","termGroup":"SY","termSource":"NCI"},{"termName":"ethanesulfonic acid compound with 3-((2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenoxy)methyl)-N,N-dimethylben zamide (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(8CI)","termGroup":"SN","termSource":"NCI"},{"termName":"ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride","termGroup":"SN","termSource":"NCI"},{"termName":"ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3, 5-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"Soluble Baker's Antifol","termGroup":"SY","termSource":"NCI"},{"termName":"TZT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"41191-04-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DD99Y262WC"},{"name":"Legacy Concept Name","value":"Triazinate"},{"name":"Maps_To","value":"Triazinate"},{"name":"NCI_Drug_Dictionary_ID","value":"39162"},{"name":"NSC Number","value":"139105"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39162"},{"name":"PDQ_Open_Trial_Search_ID","value":"39162"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077008"}]}}{"C903":{"preferredName":"Triaziquone","code":"C903","definitions":[{"definition":"An aziridinylbenzoquinone-based alkylating agent with potential antineoplastic activity. The alkylating group in triaziquone becomes activated upon reduction of quinone to the hydroquinone form. This eventually results in the alkylation and crosslinking of DNA, thereby inhibiting DNA replication followed by an induction of apoptosis. In addition, reactive oxygen species may form during redox cycling which may contribute to this agent's cytotoxic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triaziquone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68-76-8"},{"name":"CHEBI_ID","value":"CHEBI:27090"},{"name":"Chemical_Formula","value":"C12H13N3O2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F3D5D9P25I"},{"name":"Legacy Concept Name","value":"Triaziquone"},{"name":"Maps_To","value":"Triaziquone"},{"name":"NSC Number","value":"29215"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040878"}]}}{"C1260":{"preferredName":"Tributyrin","code":"C1260","definitions":[{"definition":"A triglyceride drug that may inhibit cell growth and induce cell differentiation. Differentiating agents may be effective in changing cancer cells back into normal cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A triglyceride prodrug of butyric acid with potential antineoplastic activity. Butyrate, the active metabolite of tributyrin, inhibits histone deacetylase, resulting in increased differentiation, decreased proliferation, cell cycle arrest, and apoptosis in some tumor cell lines. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tributyrin","termGroup":"PT","termSource":"NCI"},{"termName":"1,2,3-Propanetriyl Butanoate","termGroup":"SN","termSource":"NCI"},{"termName":"1,2,3-Tributyrylglycerol","termGroup":"SN","termSource":"NCI"},{"termName":"Butanoic Acid 1,2,3-Propanetriyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"Butyryl Triglyceride","termGroup":"SY","termSource":"NCI"},{"termName":"Glyceryl Tributyrate","termGroup":"SY","termSource":"NCI"},{"termName":"TB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"60-01-5"},{"name":"Chemical_Formula","value":"C15H26O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S05LZ624MF"},{"name":"Legacy Concept Name","value":"Tributyrin"},{"name":"Maps_To","value":"Tributyrin"},{"name":"NCI_Drug_Dictionary_ID","value":"42290"},{"name":"NSC Number","value":"661583"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42290"},{"name":"PDQ_Open_Trial_Search_ID","value":"42290"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077025"}]}}{"C1262":{"preferredName":"Triciribine Phosphate","code":"C1262","definitions":[{"definition":"The phosphate salt of the synthetic, cell-permeable tricyclic nucleoside triciribine with potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Akts are anti-apoptotic serine/threonine-specific protein kinases that phosphorylate and inactivate components of the apoptotic machinery, including Bcl-xL/Bcl-2-associated death promoter (BAD) and caspase 9.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triciribine Phosphate","termGroup":"PT","termSource":"NCI"},{"termName":"1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine","termGroup":"SN","termSource":"NCI"},{"termName":"1,4, 5,6,8-pentaazaacenaphthylen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)- (9CI)","termGroup":"SN","termSource":"NCI"},{"termName":"1,4,5,6, 8-pentaazaacenaphthalen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)","termGroup":"SN","termSource":"NCI"},{"termName":"3-amino-1, 5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene 5'-(dihydrogen phosphate)","termGroup":"SN","termSource":"NCI"},{"termName":"TCN","termGroup":"AB","termSource":"NCI"},{"termName":"Triciribine","termGroup":"SY","termSource":"NCI"},{"termName":"Tricyclic Nucleoside 5'-Phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"Tricycloside Phosphate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"61966-08-3"},{"name":"Chemical_Formula","value":"C13H17N6O7P"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5L5GE3DV88"},{"name":"Legacy Concept Name","value":"Triciribine_Phosphate"},{"name":"Maps_To","value":"Triciribine Phosphate"},{"name":"NCI_Drug_Dictionary_ID","value":"39723"},{"name":"NSC Number","value":"280594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39723"},{"name":"PDQ_Open_Trial_Search_ID","value":"39723"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077070"}]}}{"C61987":{"preferredName":"Trientine Hydrochloride","code":"C61987","definitions":[{"definition":"The hydrochloride salt form of a metal chelating agent with potential anti-angiogenic activity. Trientine chelates excess copper (Cu) ions in the body; the excess copper is subsequently removed from the body through the kidneys. As Cu is an essential cofactor for cuproenzymes, such as superoxide dismutase 1 (SOD1), depletion of copper may inhibit the activation of signal transduction pathways required for cellular proliferation and angiogenesis. In addition, trientine may inhibit copper-induced secretion of interleukin-8 (IL-8).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trientine Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"N,N-bis (2-aminoethyl)-1,2-ethanediamine Dihydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Syprine","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"38260-01-4"},{"name":"Chemical_Formula","value":"C6H18N4.2HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HC3NX54582"},{"name":"Legacy Concept Name","value":"Trientine_Hydrochloride"},{"name":"Maps_To","value":"Trientine Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"683662"},{"name":"PDQ_Closed_Trial_Search_ID","value":"683662"},{"name":"PDQ_Open_Trial_Search_ID","value":"683662"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0770325"}]}}{"C29858":{"preferredName":"Triethylenemelamine","code":"C29858","definitions":[{"definition":"A trisaziridine alkylating agent with antineoplastic and carcinogenic properties.  Used to induce cancer in experimental animal models, triethylenemelamine ethylates DNA, resulting in inhibition of DNA replication, unscheduled DNA synthesis, chromosomal aberrations, and sister chromatid exchanges.  This agent also exhibits reproductive toxicities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triethylenemelamine","termGroup":"PT","termSource":"NCI"},{"termName":"TEM","termGroup":"AB","termSource":"NCI"},{"termName":"Tretamine","termGroup":"SY","termSource":"NCI"},{"termName":"Triethylene Melamine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"51-18-3"},{"name":"CHEBI_ID","value":"CHEBI:27919"},{"name":"Chemical_Formula","value":"C9H12N6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"F7IY6HZG9D"},{"name":"Legacy Concept Name","value":"Triethylenemelamine"},{"name":"Maps_To","value":"Triethylenemelamine"},{"name":"NSC Number","value":"9706"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040975"}]}}{"C905":{"preferredName":"Trifluridine","code":"C905","definitions":[{"definition":"A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trifluridine","termGroup":"PT","termSource":"NCI"},{"termName":"2'-Deoxy-5-trifluoromethyluridine","termGroup":"SN","termSource":"NCI"},{"termName":"F3TdR","termGroup":"AB","termSource":"NCI"},{"termName":"Triflorothymidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"70-00-8"},{"name":"Chemical_Formula","value":"C10H11F3N2O5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RMW9V5RW38"},{"name":"Legacy Concept Name","value":"Trifluridine"},{"name":"Maps_To","value":"Trifluridine"},{"name":"NCI_Drug_Dictionary_ID","value":"39240"},{"name":"NSC Number","value":"75520"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39240"},{"name":"PDQ_Open_Trial_Search_ID","value":"39240"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0040987"}]}}{"C102554":{"preferredName":"Trifluridine and Tipiracil Hydrochloride","code":"C102554","definitions":[{"definition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trifluridine and Tipiracil Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"FTD-TPI","termGroup":"AB","termSource":"NCI"},{"termName":"Lonsurf","termGroup":"BR","termSource":"NCI"},{"termName":"TAS 102","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-102","termGroup":"CN","termSource":"NCI"},{"termName":"TAS102","termGroup":"CN","termSource":"NCI"},{"termName":"Thymidine, Alpha,alpha,alpha-trifluoro-, Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Tipiracil Hydrochloride Mixture with Trifluridine","termGroup":"SY","termSource":"NCI"},{"termName":"Trifluridine and Tipiracil","termGroup":"SY","termSource":"NCI"},{"termName":"Trifluridine/Tipiracil","termGroup":"SY","termSource":"NCI"},{"termName":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"metastatic colorectal cancer; metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma"},{"name":"CAS_Registry","value":"733030-01-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Trifluridine and Tipiracil Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"734891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"734891"},{"name":"PDQ_Open_Trial_Search_ID","value":"734891"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451803"}]}}{"C142847":{"preferredName":"Troriluzole","code":"C142847","definitions":[{"definition":"A formulation comprised of a prodrug form of the benzothiazole derivative riluzole, with potential anti-depressant, anxiolytic and antineoplastic activities. Following oral administration, troriluzole is converted into the active form riluzole. While the mechanism of action of riluzole is unknown, its pharmacological activities, some of which may be related to its effect, include the following: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. These activities may result in myorelaxation and sedation due to the blockade of glutamatergic neurotransmission. Additionally, these activities may result in the inhibition of enzymes that are necessary for cell growth, which may decrease tumor cell growth and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Troriluzole","termGroup":"PT","termSource":"NCI"},{"termName":"BHV 4157","termGroup":"CN","termSource":"NCI"},{"termName":"BHV-4157","termGroup":"CN","termSource":"NCI"},{"termName":"Glycinamide, Glycylglycyl-N2-methyl-N-(6-(trifluoromethoxy)-2-benzothiazolyl)-","termGroup":"SY","termSource":"NCI"},{"termName":"Trigriluzole","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1926203-09-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S7H48S6K7H"},{"name":"Maps_To","value":"Trigriluzole"},{"name":"Maps_To","value":"Troriluzole"},{"name":"NCI_Drug_Dictionary_ID","value":"791792"},{"name":"NCI_META_CUI","value":"CL540756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791792"},{"name":"PDQ_Open_Trial_Search_ID","value":"791792"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123281":{"preferredName":"Trilaciclib","code":"C123281","definitions":[{"definition":"A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), with potential antineoplastic and chemoprotective activities. Upon intravenous administration, trilaciclib binds to and inhibits the activity of CDK4/6, thereby blocking the phosphorylation of the retinoblastoma protein (Rb) in early G1. This prevents G1/S phase transition, causes cell cycle arrest in the G1 phase, induces apoptosis, and inhibits the proliferation of CDK4/6-overexpressing tumor cells. In patients with CDK4/6-independent tumor cells, G1T28 may protect against multi-lineage chemotherapy-induced myelosuppression (CIM) by transiently and reversibly inducing G1 cell cycle arrest in hematopoietic stem and progenitor cells (HSPCs) and preventing transition to the S phase. This protects all hematopoietic lineages, including red blood cells, platelets, neutrophils and lymphocytes, from the DNA-damaging effects of certain chemotherapeutics and preserves the function of the bone marrow and the immune system. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. HSPCs are dependent upon CDK4/6 for proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trilaciclib","termGroup":"PT","termSource":"NCI"},{"termName":"2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one","termGroup":"SY","termSource":"NCI"},{"termName":"G1T28","termGroup":"CN","termSource":"NCI"},{"termName":"Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1374743-00-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"U6072DO9XG"},{"name":"Maps_To","value":"Trilaciclib"},{"name":"NCI_Drug_Dictionary_ID","value":"775021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775021"},{"name":"PDQ_Open_Trial_Search_ID","value":"775021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053642"}]}}{"C29485":{"preferredName":"Trimelamol","code":"C29485","definitions":[{"definition":"A synthetic derivative of trimethylmelamine with antineoplastic properties.  An analogue of siderophores (microbial iron chelators), trimelamol induces the formation of a reactive iminium species which may crosslink DNA. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimelamol","termGroup":"PT","termSource":"NCI"},{"termName":"BRN 4261541","termGroup":"CN","termSource":"NCI"},{"termName":"Methanol, ((s-triazine-2,4,6-triyl)trimethyltrinitrilo)tri-","termGroup":"SN","termSource":"NCI"},{"termName":"Trimethyloltrimethylmelamine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"64124-21-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UST4Z70290"},{"name":"Legacy Concept Name","value":"Trimelamole"},{"name":"Maps_To","value":"Trimelamol"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077149"}]}}{"C169928":{"preferredName":"Efaprinermin Alfa","code":"C169928","definitions":[{"definition":"A Fc-engineered human fusion protein composed of two trimers of tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18; GlTRL) linked to an immunoglobulin Fc domain (GITRL-Fc), with potential immunostimulatory and antineoplastic activities. Upon administration, efaprinermin alfa targets, binds to and activates its co-stimulatory surface receptor (glucocorticoid-induced tumor necrosis factor receptor (GITR; TNFRSF18) expressed on T-lymphocytes and certain tumor cell types. This activates T-lymphocytes, causes T-lymphocyte proliferation and suppresses the activity of regulatory T-cells (Treg). This promotes cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells. GITRL, a member of the tumor necrosis factor (TNF) family of ligands, functions to activate the co-stimulatory receptor GITR to enhance T-cell modulated immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Efaprinermin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"GITRL-Fc","termGroup":"SY","termSource":"NCI"},{"termName":"GITRL-Fc Trimer","termGroup":"SY","termSource":"NCI"},{"termName":"OMP 336B11","termGroup":"CN","termSource":"NCI"},{"termName":"OMP-336B11","termGroup":"CN","termSource":"NCI"},{"termName":"Trimeric GITRL-Fc OMP-336B11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2102200-64-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y7Z934Q02C"},{"name":"Maps_To","value":"Trimeric GITRL-Fc OMP-336B11"},{"name":"NCI_Drug_Dictionary_ID","value":"791681"},{"name":"NCI_META_CUI","value":"CL1382425"},{"name":"NCI_META_CUI","value":"CL541604"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1264":{"preferredName":"Trimethylcolchicinic Acid","code":"C1264","definitions":[{"definition":"A colchicine analog with potential antineoplastic activity.  Trimethylcolchicinic acid binds to tubulin, inhibiting its polymerization into microtubules and preventing cell division. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimethylcolchicinic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"Colchicinic Acid, Trimethyl-","termGroup":"SY","termSource":"NCI"},{"termName":"Desacetyl Colchicine D-tartrate","termGroup":"SY","termSource":"NCI"},{"termName":"Desacetylcholchiceine","termGroup":"SY","termSource":"NCI"},{"termName":"N-Deacetylcolchiceine","termGroup":"SN","termSource":"NCI"},{"termName":"SKF 284","termGroup":"CN","termSource":"NCI"},{"termName":"TMCA","termGroup":"AB","termSource":"NCI"},{"termName":"Trimethylcolchicinic Acid Methyl Ether d-tartrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3482-37-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"333BVY614O"},{"name":"Legacy Concept Name","value":"Trimethylcolchicinic_Acid"},{"name":"Maps_To","value":"Trimethylcolchicinic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"39719"},{"name":"NSC Number","value":"36796"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39719"},{"name":"PDQ_Open_Trial_Search_ID","value":"39719"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077183"}]}}{"C1314":{"preferredName":"Trimetrexate","code":"C1314","definitions":[{"definition":"A methotrexate derivative with potential antineoplastic activity.  Trimetrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate also exhibits antiviral activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimetrexate","termGroup":"PT","termSource":"NCI"},{"termName":"5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine","termGroup":"SN","termSource":"NCI"},{"termName":"CI-898","termGroup":"CN","termSource":"NCI"},{"termName":"TMQ","termGroup":"AB","termSource":"NCI"},{"termName":"Trimexate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52128-35-5"},{"name":"Chemical_Formula","value":"C19H23N5O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"UPN4ITI8T4"},{"name":"Legacy Concept Name","value":"Trimetrexate"},{"name":"Maps_To","value":"Trimetrexate"},{"name":"NSC Number","value":"249008"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0085176"}]}}{"C1265":{"preferredName":"Trimetrexate Glucuronate","code":"C1265","definitions":[{"definition":"A drug that belongs to the family of drugs called antimetabolites. It is used in the treatment of pneumocystis carinii pneumonia and is being studied in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trimetrexate Glucuronate","termGroup":"PT","termSource":"NCI"},{"termName":"2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline mono-D-glucuronate","termGroup":"SN","termSource":"NCI"},{"termName":"Neutrexin","termGroup":"BR","termSource":"NCI"},{"termName":"TMTX","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Head and neck cancer; Metastatic colorectal adenocarcinoma; Non-small cell lung cancer; Osteogenic sarcoma; Pancreatic adenocarcinoma; Pneumocystitis carinii pneumonia"},{"name":"CAS_Registry","value":"82952-64-5"},{"name":"Chemical_Formula","value":"C19H23N5O3.C6H10O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L137U4A79K"},{"name":"Legacy Concept Name","value":"Trimetrexate_Glucuronate"},{"name":"Maps_To","value":"Trimetrexate Glucuronate"},{"name":"NCI_Drug_Dictionary_ID","value":"39764"},{"name":"NSC Number","value":"352122"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39764"},{"name":"PDQ_Open_Trial_Search_ID","value":"39764"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077209"}]}}{"C1266":{"preferredName":"Trioxifene","code":"C1266","definitions":[{"definition":"A nonsteroidal selective estrogen receptor modulator (SERM) with potential antineoplastic activity.  Trioxifene competes with estradiol in binding to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated signal transduction and gene expression. In addition, trioxifene exerts intrinsic estrogenic activity depending on the tissue. Clinical development of trioxifene has not been preceded due to its side effect profile and lack of increased efficacy over tamoxifen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trioxifene","termGroup":"PT","termSource":"NCI"},{"termName":"(3,4-Dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl) Methanone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"63619-84-1"},{"name":"Chemical_Formula","value":"C30H31NO3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R0130F043H"},{"name":"Legacy Concept Name","value":"Trioxifene"},{"name":"Maps_To","value":"Trioxifene"},{"name":"NCI_Drug_Dictionary_ID","value":"39726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39726"},{"name":"PDQ_Open_Trial_Search_ID","value":"39726"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077238"}]}}{"C1827":{"preferredName":"Triplatin Tetranitrate","code":"C1827","definitions":[{"definition":"A cationic tri-nuclear platinum complex related to cisplatin.  BBR 3464 binds to and forms DNA crosslinks and platinum-DNA adducts, preventing DNA replication and tumor cell division.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied as an anticancer drug.  It belongs to the family of platinum-based drugs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Triplatin Tetranitrate","termGroup":"PT","termSource":"NCI"},{"termName":"BBR 3464","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"172903-00-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HAJ1000ARC"},{"name":"Legacy Concept Name","value":"BBR_3464"},{"name":"Maps_To","value":"Triplatin Tetranitrate"},{"name":"NCI_Drug_Dictionary_ID","value":"38246"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38246"},{"name":"PDQ_Open_Trial_Search_ID","value":"38246"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0756613"}]}}{"C111762":{"preferredName":"Triptolide Analog","code":"C111762","definitions":[{"definition":"A water soluble analog of the diterpenoid triepoxide triptolide isolated from the Chinese herb Tripterygium wilfordii Hook.f., with potential antineoplastic activity. Upon intravenous administration, the triptolide analog inhibits heat shock protein 70 (HSP70) and prevents HSP70-mediated inhibition of apoptosis. This leads to both the induction of apoptosis and a reduction of cancer cell growth. HSP70, a molecular chaperone upregulated in various cancer cells, plays a key role in the inhibition of caspase-dependent and -independent apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triptolide Analog","termGroup":"PT","termSource":"NCI"},{"termName":"Minnelide","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1254702-87-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1CIV2UMO40"},{"name":"Maps_To","value":"Triptolide Analog"},{"name":"NCI_Drug_Dictionary_ID","value":"753195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753195"},{"name":"PDQ_Open_Trial_Search_ID","value":"753195"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3657815"}]}}{"C1267":{"preferredName":"Triptorelin","code":"C1267","definitions":[{"definition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triptorelin","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Tryptophan-LH-RH","termGroup":"SY","termSource":"NCI"},{"termName":"6-D-Tryptophanluteinizing Hormone-releasing Factor","termGroup":"SY","termSource":"NCI"},{"termName":"AY 25650","termGroup":"CN","termSource":"NCI"},{"termName":"AY-25650","termGroup":"CN","termSource":"NCI"},{"termName":"AY25650","termGroup":"CN","termSource":"NCI"},{"termName":"CL 118532","termGroup":"CN","termSource":"NCI"},{"termName":"CL-118,532","termGroup":"CN","termSource":"NCI"},{"termName":"CL-118532","termGroup":"CN","termSource":"NCI"},{"termName":"CL118532","termGroup":"CN","termSource":"NCI"},{"termName":"Detryptoreline","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Palliative treatment prostate carcinoma"},{"name":"CAS_Registry","value":"57773-63-4"},{"name":"CHEBI_ID","value":"CHEBI:63633"},{"name":"Chemical_Formula","value":"C64H82N18O13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_UNII_Code","value":"9081Y98W2V"},{"name":"Legacy Concept Name","value":"Triptorelin"},{"name":"Maps_To","value":"Triptorelin"},{"name":"NCI_Drug_Dictionary_ID","value":"42944"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42944"},{"name":"PDQ_Open_Trial_Search_ID","value":"42944"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077275"}]}}{"C29523":{"preferredName":"Triptorelin Pamoate","code":"C29523","definitions":[{"definition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Triptorelin Pamoate","termGroup":"PT","termSource":"NCI"},{"termName":"6-D-Tryptophan-, 4,4'Mmethylenebis(3-hydroxy-2-naphthalenecarboxylate) (Salt)","termGroup":"SN","termSource":"NCI"},{"termName":"Decapeptyl","termGroup":"FB","termSource":"NCI"},{"termName":"Diphereline","termGroup":"FB","termSource":"NCI"},{"termName":"Pamorelin","termGroup":"SY","termSource":"NCI"},{"termName":"Trelstar","termGroup":"BR","termSource":"NCI"},{"termName":"Triptorelin Embonate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"124508-66-3"},{"name":"Chemical_Formula","value":"C64H82N18O13.C23H16O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"08AN7WA2G0"},{"name":"Legacy Concept Name","value":"Triptorelin_Pamoate"},{"name":"Maps_To","value":"Triptorelin Pamoate"},{"name":"NCI_Drug_Dictionary_ID","value":"468834"},{"name":"NSC Number","value":"724666"},{"name":"PDQ_Closed_Trial_Search_ID","value":"468834"},{"name":"PDQ_Open_Trial_Search_ID","value":"468834"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1137102"}]}}{"C1758":{"preferredName":"Tritylcysteine","code":"C1758","definitions":[{"definition":"A derivative of cysteine with antimitotic activity and potential antineoplastic activity. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tritylcysteine","termGroup":"PT","termSource":"NCI"},{"termName":"3-Tritylthio-L-Alanine","termGroup":"SY","termSource":"NCI"},{"termName":"S-Trityl-L-Cysteine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2799-07-7"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tritylcysteine"},{"name":"Maps_To","value":"Tritylcysteine"},{"name":"NSC Number","value":"124663"},{"name":"NSC Number","value":"83265"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"UMLS_CUI","value":"C0601886"}]}}{"C80491":{"preferredName":"TRK Inhibitor AZD6918","code":"C80491","definitions":[{"definition":"An orally available liquid suspension containing the tropomyosin receptor kinase (Trk) inhibitor AZD6918 with potential antineoplastic activity. AZD6918 binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, and may eventually result in cell cycle arrest and apoptosis of tumor cells that express Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRK Inhibitor AZD6918","termGroup":"PT","termSource":"NCI"},{"termName":"AZD6918","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"AZD6918"},{"name":"Maps_To","value":"TRK Inhibitor AZD6918"},{"name":"NCI_Drug_Dictionary_ID","value":"613519"},{"name":"NCI_META_CUI","value":"CL388367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"613519"},{"name":"PDQ_Open_Trial_Search_ID","value":"613519"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C153116":{"preferredName":"TrkA Inhibitor VMD-928","code":"C153116","definitions":[{"definition":"An orally bioavailable, selective inhibitor of tropomyosin receptor kinase A (TrkA; neurotrophic tyrosine receptor kinase (NTRK) type 1; NTRK1; TRK1-transforming tyrosine kinase protein), with potential antineoplastic activity. Upon oral administration, VMD-928 specifically targets and binds to TrkA, inhibits neurotrophin-TrkA interaction and prevents TrkA activation. This prevents the activation of downstream signaling pathways and inhibits cell growth in tumors that overexpress TrkA. Uncontrolled TrkA signaling plays an important role in tumor cell growth, survival, invasion and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TrkA Inhibitor VMD-928","termGroup":"PT","termSource":"NCI"},{"termName":"NTRK1 Inhibitor VMD-928","termGroup":"SY","termSource":"NCI"},{"termName":"VMD 928","termGroup":"CN","termSource":"NCI"},{"termName":"VMD-928","termGroup":"CN","termSource":"NCI"},{"termName":"VMD928","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1802770-18-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"1JT6DVS51P"},{"name":"Maps_To","value":"TrkA Inhibitor VMD-928"},{"name":"NCI_Drug_Dictionary_ID","value":"793945"},{"name":"NCI_META_CUI","value":"CL554374"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793945"},{"name":"PDQ_Open_Trial_Search_ID","value":"793945"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C123882":{"preferredName":"Trodusquemine","code":"C123882","definitions":[{"definition":"A naturally-occurring cholestane and non-competitive, allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B), with potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation. In addition, as trodusquemine can cross the blood-brain barrier (BBB), it centrally suppresses appetite and causes weight loss. PTP1B, a tyrosine phosphatase, is elevated in certain cancer cells; it is specifically upregulated in human epidermal growth factor receptor 2 (HER2)-driven cancers where it promotes cell growth, and is correlated with a poor prognosis and increased metastatic potential. In diabetes, PTP1B upregulation plays a major role in insulin resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trodusquemine","termGroup":"PT","termSource":"NCI"},{"termName":"(24R)-3beta-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-7alpha-hydroxy-5alpha-cholestan-24-yl Hydrogen Sulfate","termGroup":"SN","termSource":"NCI"},{"termName":"Cholestane-7,24-diol, 3-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-, 24-(Hydrogen Sulfate), (3beta,5alpha,7alpha,24R)-","termGroup":"SN","termSource":"NCI"},{"termName":"MSI-1436","termGroup":"CN","termSource":"NCI"},{"termName":"MSI-1436C","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186139-09-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KKC12PIF16"},{"name":"Maps_To","value":"Trodusquemine"},{"name":"NCI_Drug_Dictionary_ID","value":"775873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775873"},{"name":"PDQ_Open_Trial_Search_ID","value":"775873"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1099662"}]}}{"C1268":{"preferredName":"Trofosfamide","code":"C1268","definitions":[{"definition":"An orally bioavailable oxazaphosphorine prodrug with antineoplastic activity. Trofosfamide (TFF) is metabolized predominantly to the cyclophosphamide analogue ifosfamide (IFO), which is then metabolized by liver cytochrome P450s to the active isophosphoramide mustard (IPM). IPM alkylates DNA to form DNA-DNA cross-links, which may result in inhibition of DNA, RNA and protein synthesis, and ultimately lead to tumor cell apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trofosfamide","termGroup":"PT","termSource":"NCI"},{"termName":"2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxaphosphorine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"A-4828","termGroup":"CN","termSource":"NCI"},{"termName":"Genoxal Trofosfamida","termGroup":"FB","termSource":"NCI"},{"termName":"Ixoten","termGroup":"BR","termSource":"NCI"},{"termName":"N,N,3-tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide","termGroup":"SN","termSource":"NCI"},{"termName":"N,N,N'-tris(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide","termGroup":"SN","termSource":"NCI"},{"termName":"Trilophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Trofosfamid","termGroup":"SY","termSource":"NCI"},{"termName":"Trophosphamide","termGroup":"SY","termSource":"NCI"},{"termName":"Z-4828","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"22089-22-1"},{"name":"Chemical_Formula","value":"C9H18Cl3N2O2P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"H64JRU6GJ0"},{"name":"Legacy Concept Name","value":"Trofosfamide"},{"name":"Maps_To","value":"Trofosfamide"},{"name":"NCI_Drug_Dictionary_ID","value":"39725"},{"name":"NSC Number","value":"109723"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39725"},{"name":"PDQ_Open_Trial_Search_ID","value":"39725"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077375"}]}}{"C1522":{"preferredName":"Troglitazone","code":"C1522","definitions":[{"definition":"An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity.  Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Troglitazone","termGroup":"PT","termSource":"NCI"},{"termName":"5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione","termGroup":"SN","termSource":"NCI"},{"termName":"CI-991","termGroup":"CN","termSource":"NCI"},{"termName":"CS-045","termGroup":"CN","termSource":"NCI"},{"termName":"Prelay","termGroup":"BR","termSource":"NCI"},{"termName":"Rezulin","termGroup":"BR","termSource":"NCI"},{"termName":"Romozin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"97322-87-7"},{"name":"CHEBI_ID","value":"CHEBI:9753"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I66ZZ0ZN0E"},{"name":"Legacy Concept Name","value":"Troglitazone"},{"name":"Maps_To","value":"Troglitazone"},{"name":"NCI_Drug_Dictionary_ID","value":"42706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42706"},{"name":"PDQ_Open_Trial_Search_ID","value":"42706"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0245514"}]}}{"C99161":{"preferredName":"Utatrectinib","code":"C99161","definitions":[{"definition":"A tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. Upon administration, utatrectinib binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Utatrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD7451","termGroup":"CN","termSource":"NCI"},{"termName":"TRK Inhibitor AZD7451","termGroup":"SY","termSource":"NCI"},{"termName":"Tropomyosin Receptor Kinase Inhibitor AZD7451","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1079274-94-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VNM956Y27V"},{"name":"Maps_To","value":"Tropomyosin Receptor Kinase Inhibitor AZD7451"},{"name":"NCI_Drug_Dictionary_ID","value":"717230"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717230"},{"name":"PDQ_Open_Trial_Search_ID","value":"717230"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3274575"}]}}{"C1438":{"preferredName":"Troxacitabine","code":"C1438","definitions":[{"definition":"A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A drug being studied for use as an anticancer agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Troxacitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2(1H)-Pyrimidinone, 4-amino-1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BCH-4556","termGroup":"CN","termSource":"NCI"},{"termName":"L-Oddc","termGroup":"CN","termSource":"NCI"},{"termName":"Troxatyl","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"145918-75-8"},{"name":"Chemical_Formula","value":"C8H11N3O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"60KQZ0388Y"},{"name":"Legacy Concept Name","value":"Troxacitabine"},{"name":"Maps_To","value":"Troxacitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"43646"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43646"},{"name":"PDQ_Open_Trial_Search_ID","value":"43646"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0877874"}]}}{"C157496":{"preferredName":"Fostroxacitabine Bralpamide","code":"C157496","definitions":[{"definition":"A liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, fostroxacitabine bralpamide is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fostroxacitabine Bralpamide","termGroup":"PT","termSource":"NCI"},{"termName":"MIV 818","termGroup":"CN","termSource":"NCI"},{"termName":"MIV-818","termGroup":"CN","termSource":"NCI"},{"termName":"MIV818","termGroup":"CN","termSource":"NCI"},{"termName":"Troxacitabine Nucleotide Prodrug MIV-818","termGroup":"SY","termSource":"NCI"},{"termName":"Troxacitabine Prodrug MIV-818","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2129993-56-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q1I6YZ0NGF"},{"name":"Maps_To","value":"Troxacitabine Nucleotide Prodrug MIV-818"},{"name":"NCI_Drug_Dictionary_ID","value":"796799"},{"name":"NCI_META_CUI","value":"CL937071"},{"name":"PDQ_Closed_Trial_Search_ID","value":"796799"},{"name":"PDQ_Open_Trial_Search_ID","value":"796799"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162345":{"preferredName":"TRPM8 Agonist D-3263","code":"C162345","definitions":[{"definition":"A small-molecule agonist for transient receptor potential melastatin member 8 (TRPM8 or Trp-p8), with potential antineoplastic activity. Upon administration, TRPM8 agonist D-3263 targets, binds to and activates TRPM8, which may result in an increase in intracellular calcium and sodium influx; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. This agent may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and benign prostatic hyperplasia (BPH). TRPM8 is a transmembrane calcium channel protein that is normally expressed in prostate cells and appears to be overexpressed in BPH and in prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRPM8 Agonist D-3263","termGroup":"PT","termSource":"NCI"},{"termName":"D 3263","termGroup":"CN","termSource":"NCI"},{"termName":"D-3263","termGroup":"CN","termSource":"NCI"},{"termName":"D3263","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"947257-66-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"70FBL3TX3E"},{"name":"Legacy Concept Name","value":"Enteric-Coated_TRPM8_Agonist_D-3263_Hydrochloride"},{"name":"Maps_To","value":"TRPM8 Agonist D-3263"},{"name":"NCI_META_CUI","value":"CL970854"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101525":{"preferredName":"TRPV6 Calcium Channel Inhibitor SOR-C13","code":"C101525","definitions":[{"definition":"An inhibitor of transient receptor potential cation channel vanilloid family member 6 (TRPV6, CaT1 or CATL) with potential antineoplastic activity. TRPV6 calcium channel inhibitor SOR-C13 binds to TRPV6 and prevents the influx of calcium ions into TRPV6-expressing tumor cells. This inhibits the activation of nuclear factor of activated T-cell (NFAT) transcription complex which may result in an inhibition of calcium-dependent cancer cell proliferation and an induction of apoptosis in tumor cells overexpressing TRPV6. The TRPV6 ion channel plays a key role in calcium homeostasis and is highly selective for calcium compared to other cations; it is overexpressed in a variety of tumors and initiates tumor cell growth, proliferation and metastases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRPV6 Calcium Channel Inhibitor SOR-C13","termGroup":"PT","termSource":"NCI"},{"termName":"SOR-C13","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1187852-48-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C79B5A73C4"},{"name":"Maps_To","value":"TRPV6 Calcium Channel Inhibitor SOR-C13"},{"name":"NCI_Drug_Dictionary_ID","value":"732361"},{"name":"NCI_META_CUI","value":"CL435782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"732361"},{"name":"PDQ_Open_Trial_Search_ID","value":"732361"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C37447":{"preferredName":"TSP-1 Mimetic ABT-510","code":"C37447","definitions":[{"definition":"A substance being studied in the treatment of cancer. It is a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1).  ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSP-1 Mimetic ABT-510","termGroup":"PT","termSource":"NCI"},{"termName":"ABT510","termGroup":"CN","termSource":"NCI"},{"termName":"L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl-","termGroup":"SN","termSource":"NCI"},{"termName":"NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt","termGroup":"SY","termSource":"NCI"},{"termName":"TSP-1-mimetic Peptide ABT-510","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"251579-55-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CRR8E37XOB"},{"name":"Legacy Concept Name","value":"ABT-510"},{"name":"Maps_To","value":"TSP-1 Mimetic ABT-510"},{"name":"NCI_Drug_Dictionary_ID","value":"350157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350157"},{"name":"PDQ_Open_Trial_Search_ID","value":"350157"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1704426"}]}}{"C82384":{"preferredName":"TSP-1 Mimetic Fusion Protein CVX-045","code":"C82384","definitions":[{"definition":"A fusion protein containing two thrombospondin (TSP-1)-derived nonamer peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic monoclonal aldolase monoclonal antibody with potential antiangiogenic and antineoplastic activities.  The TSP-1 mimetic peptide moieties of TSP-1 mimetic fusion protein CVX-045 bind to TSP-1 receptors, such as CD36, and inhibit tumor angiogenesis, which may result in the inhibition of tumor cell proliferation. The proprietary humanized catalytic monoclonal aldolase monoclonal antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the TSP-1 mimetic peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TSP-1 Mimetic Fusion Protein CVX-045","termGroup":"PT","termSource":"NCI"},{"termName":"CVX-045","termGroup":"CN","termSource":"NCI"},{"termName":"Thrombospondin-1 Mimetic Fusion Protein CVX-045","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TSP-1_Mimetic_Fusion_Protein_CVX-045"},{"name":"Maps_To","value":"TSP-1 Mimetic Fusion Protein CVX-045"},{"name":"NCI_Drug_Dictionary_ID","value":"641917"},{"name":"NCI_META_CUI","value":"CL408655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"641917"},{"name":"PDQ_Open_Trial_Search_ID","value":"641917"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C911":{"preferredName":"Tubercidin","code":"C911","definitions":[{"definition":"An antibiotic and adenosine analog isolated from the bacterium Streptomyces tubercidicus with potential antineoplastic activity.  Tubercidin is incorporated into DNA and inhibits polymerases, thereby inhibiting DNA replication and RNA and protein synthesis.  This agent also exhibits antifungal and antiviral activities. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubercidin","termGroup":"PT","termSource":"NCI"},{"termName":"4-amino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine","termGroup":"SN","termSource":"NCI"},{"termName":"7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine","termGroup":"SN","termSource":"NCI"},{"termName":"7-deazaadenosine","termGroup":"SN","termSource":"NCI"},{"termName":"U-10071","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"69-33-0"},{"name":"CHEBI_ID","value":"CHEBI:48267"},{"name":"Chemical_Formula","value":"C11H14N4O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M351LCX45Y"},{"name":"Legacy Concept Name","value":"Tubercidin"},{"name":"Maps_To","value":"Tubercidin"},{"name":"NCI_Drug_Dictionary_ID","value":"39728"},{"name":"NSC Number","value":"56408"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39728"},{"name":"PDQ_Open_Trial_Search_ID","value":"39728"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0041286"}]}}{"C78842":{"preferredName":"Tubulin Inhibitor ALB 109564 Dihydrochloride","code":"C78842","definitions":[{"definition":"A semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB 109564 dihydrochloride binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin Inhibitor ALB 109564 Dihydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"ALB-109564 dihydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Alb-109564(a)","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1300114-12-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G2Z7R4P95M"},{"name":"Maps_To","value":"Tubulin Inhibitor ALB 109564 Dihydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"610130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610130"},{"name":"PDQ_Open_Trial_Search_ID","value":"610130"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703136"}]}}{"C162527":{"preferredName":"Tubulin Inhibitor ALB-109564","code":"C162527","definitions":[{"definition":"A semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB-109564 binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle. Check for active clinical trials using this agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin Inhibitor ALB-109564","termGroup":"PT","termSource":"NCI"},{"termName":"ALB 109564","termGroup":"CN","termSource":"NCI"},{"termName":"ALB-109564","termGroup":"CN","termSource":"NCI"},{"termName":"ALB109564","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"854756-74-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EUY2631TAL"},{"name":"Maps_To","value":"Tubulin Inhibitor ALB-109564"},{"name":"NCI_META_CUI","value":"CL971105"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162525":{"preferredName":"Tubulin Polymerization Inhibitor AEZS 112","code":"C162525","definitions":[{"definition":"An orally bioavailable small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Upon oral administration, tubulin polymerization inhibitor AEZS 112 binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin Polymerization Inhibitor AEZS 112","termGroup":"PT","termSource":"NCI"},{"termName":"AEZS 112","termGroup":"CN","termSource":"NCI"},{"termName":"AEZS-112","termGroup":"CN","termSource":"NCI"},{"termName":"AEZS112","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN 012","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN-012","termGroup":"CN","termSource":"NCI"},{"termName":"ZEN012","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1214741-69-1"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tubulin Polymerization Inhibitor AEZS 112"},{"name":"NCI_META_CUI","value":"CL971107"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C101264":{"preferredName":"Valecobulin","code":"C101264","definitions":[{"definition":"A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activity. Upon administration, valecobulin is converted into its active metabolite S-516 that binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valecobulin","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-N-(4-(3-(1H-1,2,4-Triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"CKD-516","termGroup":"CN","termSource":"NCI"},{"termName":"Tubulin Polymerization Inhibitor CKD-516","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1188371-47-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P48P97V001"},{"name":"Maps_To","value":"Tubulin Polymerization Inhibitor CKD-516"},{"name":"Maps_To","value":"Valecobulin"},{"name":"NCI_Drug_Dictionary_ID","value":"729699"},{"name":"PDQ_Closed_Trial_Search_ID","value":"729699"},{"name":"PDQ_Open_Trial_Search_ID","value":"729699"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2974542"}]}}{"C158517":{"preferredName":"Sabizabulin","code":"C158517","definitions":[{"definition":"An orally bioavailable, small molecule tubulin inhibitor, with potential antineoplastic, antiviral and anti-inflammatory activities. Upon oral administration, sabizabulin binds to the colchicine-binding site of alpha- and beta-tubulin subunits of microtubules and crosslinks the microtubules, thereby inhibiting microtubule polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature, tumor blood flow, deprives tumor cells of nutrients, and induces apoptosis. In addition, as microtubules plays an important role in intracellular transport, the inhibition of its polymerization may disrupt the transport of the androgen receptor (AR) into the cell nucleus, as well as virus trafficking around the cell. This may decrease viral replication and assembly. Inhibition of tubulin polymerization may also inhibit the release of pro-inflammatory cytokines and disrupt inflammatory cell activities. Sabizabulin is not a substrate of P-glycoprotein (Pgp), an efflux pump that when overexpressed, may confer resistance to taxane agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sabizabulin","termGroup":"PT","termSource":"NCI"},{"termName":"VERU 111","termGroup":"CN","termSource":"NCI"},{"termName":"VERU-111","termGroup":"CN","termSource":"NCI"},{"termName":"VERU111","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1332881-26-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37L1JX37J5"},{"name":"Maps_To","value":"Tubulin Polymerization Inhibitor VERU-111"},{"name":"NCI_Drug_Dictionary_ID","value":"797224"},{"name":"NCI_META_CUI","value":"CL1659534"},{"name":"PDQ_Closed_Trial_Search_ID","value":"797224"},{"name":"PDQ_Open_Trial_Search_ID","value":"797224"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C71525":{"preferredName":"Tubulin-Binding Agent SSR97225","code":"C71525","definitions":[{"definition":"An antimitotic tubulin-binding agent with potential antineoplastic activity. Tubulin-binding agent SSR97225 binds to tubulin, arresting the cell cycle at the G2/M checkpoint and preventing mitosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tubulin-Binding Agent SSR97225","termGroup":"PT","termSource":"NCI"},{"termName":"SSR 97225","termGroup":"CN","termSource":"NCI"},{"termName":"SSR-97225","termGroup":"CN","termSource":"NCI"},{"termName":"SSR97225","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SSR97225"},{"name":"Maps_To","value":"Tubulin-Binding Agent SSR97225"},{"name":"NCI_Drug_Dictionary_ID","value":"576686"},{"name":"NCI_META_CUI","value":"CL378284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"576686"},{"name":"PDQ_Open_Trial_Search_ID","value":"576686"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C77896":{"preferredName":"Tucatinib","code":"C77896","definitions":[{"definition":"An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tucatinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY 380","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-380","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY380","termGroup":"CN","termSource":"NCI"},{"termName":"Irbinitinib","termGroup":"SY","termSource":"NCI"},{"termName":"N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"ONT 380","termGroup":"CN","termSource":"NCI"},{"termName":"ONT-380","termGroup":"CN","termSource":"NCI"},{"termName":"ONT380","termGroup":"CN","termSource":"NCI"},{"termName":"Tukysa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting."},{"name":"CAS_Registry","value":"937263-43-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"234248D0HH"},{"name":"Legacy Concept Name","value":"ErbB-2_Inhibitor_ARRY-380"},{"name":"Maps_To","value":"Tucatinib"},{"name":"NCI_Drug_Dictionary_ID","value":"594366"},{"name":"NCI_META_CUI","value":"CL383576"},{"name":"PDQ_Closed_Trial_Search_ID","value":"594366"},{"name":"PDQ_Open_Trial_Search_ID","value":"594366"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97263":{"preferredName":"Tucidinostat","code":"C97263","definitions":[{"definition":"An orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Upon administration, tucidinostat binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins. This agent also inhibits the expression of kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, a class of enzymes that deacetylate chromatin histone proteins, are upregulated in many tumor types and play key roles in gene expression. Compared to some other benzamide-type HDAC inhibitors, chidamide is more stable, more resistant to degradation and has a longer half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tucidinostat","termGroup":"PT","termSource":"NCI"},{"termName":"Chidamide","termGroup":"SY","termSource":"NCI"},{"termName":"CS 055","termGroup":"CN","termSource":"NCI"},{"termName":"CS-055","termGroup":"CN","termSource":"NCI"},{"termName":"CS055","termGroup":"CN","termSource":"NCI"},{"termName":"Epidaza","termGroup":"SY","termSource":"NCI"},{"termName":"HBI 8000","termGroup":"CN","termSource":"NCI"},{"termName":"HBI-8000","termGroup":"CN","termSource":"NCI"},{"termName":"HBI8000","termGroup":"CN","termSource":"NCI"},{"termName":"Hiyasta","termGroup":"FB","termSource":"NCI"},{"termName":"N-(2-amino-5-fluorine benzyl)-4-[N-(pyridine-3-acrylyl) ammonia methyl] Benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-(2-amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-benzamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1616493-44-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"87CIC980Y0"},{"name":"Maps_To","value":"Tucidinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"702501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"702501"},{"name":"PDQ_Open_Trial_Search_ID","value":"702501"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2932486"}]}}{"C2630":{"preferredName":"Tucotuzumab Celmoleukin","code":"C2630","definitions":[{"definition":"A recombinant fusion protein comprised of a human monoclonal antibody directed against the epithelial cell adhesion molecule (EpCAM or KS) linked to an active interleukin-2 (IL2) molecule with potential antineoplastic activity. Tucotuzumab Celmoleukin recognizes and binds to EpCAM, a cell surface epithelial protein that is expressed on a wide variety of cancer cells, thereby concentrating IL2 in EpCAM-expressing tumor tissue. Subsequently, the localized IL2 moiety of the fusion protein may stimulate a cytotoxic T-cell antitumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tucotuzumab Celmoleukin","termGroup":"PT","termSource":"NCI"},{"termName":"EMD 273066","termGroup":"CN","termSource":"NCI"},{"termName":"EMD-273066","termGroup":"CN","termSource":"NCI"},{"termName":"huKS-IL2 Fusion Protein","termGroup":"SY","termSource":"NCI"},{"termName":"KSA-IL-2","termGroup":"AB","termSource":"NCI"},{"termName":"KSA-interleukin-2","termGroup":"SY","termSource":"NCI"},{"termName":"KSA-Interleukin-2 Fusion Protein","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"339986-90-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4ON7FF680U"},{"name":"Legacy Concept Name","value":"KSA-Interleukin-2_Fusion_Protein"},{"name":"Maps_To","value":"Tucotuzumab Celmoleukin"},{"name":"NCI_Drug_Dictionary_ID","value":"456358"},{"name":"PDQ_Closed_Trial_Search_ID","value":"456358"},{"name":"PDQ_Open_Trial_Search_ID","value":"456358"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1721369"}]}}{"C77856":{"preferredName":"Tyroserleutide","code":"C77856","definitions":[{"definition":"A tripeptide consisting of tyrosine, serine, and leucine with potential antineoplastic activity. Although the mechanism of its antitumor activity has yet to be fully elucidated, tyroserleutide appears to inhibit the expression of ICAM-1 (CD54), a cell adhesion factor of the immunoglobulin (Ig) superfamily that plays an important role in the invasion, adhesion, and metastasis of tumor cells. In addition, this agent may influence the Ca2+/calmodulin pathway, inhibiting phosphatidylinositol 3 kinase (PI3K); PI3K is upregulated in tumor cells and is involved in cellular proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyroserleutide","termGroup":"PT","termSource":"NCI"},{"termName":"CMS 024","termGroup":"CN","termSource":"NCI"},{"termName":"YSL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"138168-48-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L9TIM50J8N"},{"name":"Legacy Concept Name","value":"Tyroserleutide"},{"name":"Maps_To","value":"Tyroserleutide"},{"name":"NCI_Drug_Dictionary_ID","value":"593430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"593430"},{"name":"PDQ_Open_Trial_Search_ID","value":"593430"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451018"}]}}{"C2401":{"preferredName":"Tyrosinase Peptide","code":"C2401","definitions":[{"definition":"A protein that is made from tumor cells and is used in a vaccine against melanoma. A tyrosinase peptide vaccine may stimulate the body's immune system to find and kill melanoma cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"One of a number of recombinant peptides consisting of amino acid residues of the enzyme tyrosinase, a protein frequently expressed by melanoma cells.  Vaccination with tyrosinase peptide may stimulate cytotoxic T lymphocyte response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinase Peptide","termGroup":"PT","termSource":"NCI"},{"termName":"Tyrosinase Peptides","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosinase_Peptide"},{"name":"Maps_To","value":"Tyrosinase Peptide"},{"name":"NCI_Drug_Dictionary_ID","value":"42338"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42338"},{"name":"PDQ_Open_Trial_Search_ID","value":"42338"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0338254"}]}}{"C2384":{"preferredName":"Tyrosinase-KLH","code":"C2384","definitions":[{"definition":"A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinase-KLH","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosinase-KLH"},{"name":"Maps_To","value":"Tyrosinase-KLH"},{"name":"NCI_Drug_Dictionary_ID","value":"42106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42106"},{"name":"PDQ_Open_Trial_Search_ID","value":"42106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0281633"}]}}{"C48630":{"preferredName":"Tyrosinase:146-156 Peptide","code":"C48630","definitions":[{"definition":"A synthetic peptide consisting of amino acid residues 146 through 156 of the enzyme tyrosinase, a protein frequently expressed by melanoma cells, with antitumor activity. Vaccination with tyrosinase:146-156 peptide may stimulate cytotoxic T lymphocyte response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth and cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosinase:146-156 Peptide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosinase_146-156_Peptide"},{"name":"Maps_To","value":"Tyrosinase:146-156 Peptide"},{"name":"NSC Number","value":"731579"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"UMLS_CUI","value":"C1710512"}]}}{"C1967":{"preferredName":"Tyrosine Kinase Inhibitor","code":"C1967","definitions":[{"definition":"A drug that interferes with cell communication and growth and may prevent tumor growth. Some tyrosine kinase inhibitors are used to treat cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Tyrosine Kinase Inhibitors","termGroup":"SY","termSource":"NCI"},{"termName":"PTK Inhibitors","termGroup":"SY","termSource":"NCI"},{"termName":"TK Inhibitors","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:38637"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C1268567"}]}}{"C70981":{"preferredName":"Tyrosine Kinase Inhibitor OSI-930","code":"C70981","definitions":[{"definition":"A selective thiophene-derived tyrosine kinase inhibitor with potential antineoplastic activity. Tyrosine kinase inhibitor OSI-930 inhibits stem cell factor receptor (c-Kit) and the vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of both tumor cell proliferation and tumor angiogenesis. Both c-Kit and VEGFR2 are overexpressed in a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor OSI-930","termGroup":"PT","termSource":"NCI"},{"termName":"OSI-930","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"728033-96-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"G1PEG5Q9Y2"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor_OSI-930"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor OSI-930"},{"name":"NCI_Drug_Dictionary_ID","value":"566188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"566188"},{"name":"PDQ_Open_Trial_Search_ID","value":"566188"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1615605"}]}}{"C1725":{"preferredName":"Tyrosine Kinase Inhibitor SU5402","code":"C1725","definitions":[{"definition":"An indolinone-based small molecule selective tyrosine kinase inhibitor with potential antineoplastic activity. SU5402 blocks the activities of vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor 1 (FGFR1) via competing with ATP for the specific binding site within the catalytic domain of these receptors. This agent was shown to inhibit cell growth, decrease cell viability in dose-dependent manner, and induce apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor SU5402","termGroup":"PT","termSource":"NCI"},{"termName":"3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone","termGroup":"SN","termSource":"NCI"},{"termName":"SU 5402","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:63449"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"SU5402"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor SU5402"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0538431"}]}}{"C68929":{"preferredName":"Tyrosine Kinase Inhibitor XL228","code":"C68929","definitions":[{"definition":"A synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis. In addition, this agent may be a potent inhibitor of the T315I mutant form of the Abl protein, which is associated with the resistance of chronic myelogenous leukemia (CML) to other tyrosine kinase inhibitors. IGF1R and Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. Bcr-Abl translocation leads to constitutive activation of ABL kinase and is commonly associated with Philadelphia-positive acute lymphocytic leukemia (ALL).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tyrosine Kinase Inhibitor XL228","termGroup":"PT","termSource":"NCI"},{"termName":"XL228","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"898280-07-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33M2XSK003"},{"name":"Legacy Concept Name","value":"Tyrosine_Kinase_Inhibitor_XL228"},{"name":"Maps_To","value":"Tyrosine Kinase Inhibitor XL228"},{"name":"NCI_Drug_Dictionary_ID","value":"549001"},{"name":"NCI_META_CUI","value":"CL374367"},{"name":"PDQ_Closed_Trial_Search_ID","value":"549001"},{"name":"PDQ_Open_Trial_Search_ID","value":"549001"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113788":{"preferredName":"UAE Inhibitor TAK-243","code":"C113788","definitions":[{"definition":"A small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity. UAE inhibitor TAK-243 binds to and inhibits UAE, which prevents both protein ubiquitination and subsequent protein degradation by the proteasome. This results in an excess of proteins in the cells and may lead to endoplasmic reticulum (ER) stress-mediated apoptosis. This inhibits tumor cell proliferation and survival. UAE, also called ubiquitin E1 enzyme (UBA1; E1), is more active in cancer cells than in normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"UAE Inhibitor TAK-243","termGroup":"PT","termSource":"NCI"},{"termName":"AOB87172","termGroup":"CN","termSource":"NCI"},{"termName":"MLN7243","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-243","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1450833-55-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V9GGV0YCDI"},{"name":"Maps_To","value":"UAE Inhibitor TAK-243"},{"name":"NCI_Drug_Dictionary_ID","value":"757275"},{"name":"NCI_META_CUI","value":"CL471769"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757275"},{"name":"PDQ_Open_Trial_Search_ID","value":"757275"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1015":{"preferredName":"Ubenimex","code":"C1015","definitions":[{"definition":"A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ubenimex","termGroup":"PT","termSource":"NCI"},{"termName":"[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"[S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"Bestatin","termGroup":"SY","termSource":"NCI"},{"termName":"N-[(2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl]-L-leucine","termGroup":"SN","termSource":"NCI"},{"termName":"NK 421","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"58970-76-6"},{"name":"Chemical_Formula","value":"C16H24N2O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I0J33N5627"},{"name":"Legacy Concept Name","value":"Ubenimex"},{"name":"Maps_To","value":"Ubenimex"},{"name":"NCI_Drug_Dictionary_ID","value":"39164"},{"name":"NSC Number","value":"265489"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39164"},{"name":"PDQ_Open_Trial_Search_ID","value":"39164"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0053355"}]}}{"C118621":{"preferredName":"Ubidecarenone Nanodispersion BPM31510n","code":"C118621","definitions":[{"definition":"A nanodispersion containing the benzoquinone ubidecarenone (coenzyme Q10), with potential protective, antioxidant and antineoplastic activities. Upon administration, ubidecarenone nanodispersion BPM31510 modulates tumor cell metabolism and causes an anti-Warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. This inhibits tumor cell proliferation. BPM 31510 also induces the activation and maturation of T-lymphocytes, and changes the surface expression of certain immune checkpoint modulators. In addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of LDL-cholesterol. Ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (ATP).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ubidecarenone Nanodispersion BPM31510n","termGroup":"PT","termSource":"NCI"},{"termName":"BP31510","termGroup":"CN","termSource":"NCI"},{"termName":"Coenzyme Q10 Injectable Nanosuspension","termGroup":"SY","termSource":"NCI"},{"termName":"Ubiquinone Injectable Nanosuspension","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ubidecarenone Nanodispersion BPM31510n"},{"name":"NCI_Drug_Dictionary_ID","value":"791848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791848"},{"name":"PDQ_Open_Trial_Search_ID","value":"791848"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3897258"}]}}{"C91078":{"preferredName":"Ublituximab","code":"C91078","definitions":[{"definition":"A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ublituximab","termGroup":"PT","termSource":"NCI"},{"termName":"Briumvi","termGroup":"BR","termSource":"NCI"},{"termName":"LFB R603","termGroup":"CN","termSource":"NCI"},{"termName":"LFB-R603","termGroup":"CN","termSource":"NCI"},{"termName":"LFBR603","termGroup":"CN","termSource":"NCI"},{"termName":"TG 1101","termGroup":"CN","termSource":"NCI"},{"termName":"TG 20","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1101","termGroup":"CN","termSource":"NCI"},{"termName":"TG-20","termGroup":"CN","termSource":"NCI"},{"termName":"TG1101","termGroup":"CN","termSource":"NCI"},{"termName":"TG20","termGroup":"CN","termSource":"NCI"},{"termName":"TGTX 1101","termGroup":"CN","termSource":"NCI"},{"termName":"TGTX-1101","termGroup":"CN","termSource":"NCI"},{"termName":"TGTX1101","termGroup":"CN","termSource":"NCI"},{"termName":"Ublituximab-xiiy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1174014-05-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"U59UGK3IPC"},{"name":"Maps_To","value":"Ublituximab"},{"name":"NCI_Drug_Dictionary_ID","value":"670500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670500"},{"name":"PDQ_Open_Trial_Search_ID","value":"670500"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2934225"}]}}{"C102851":{"preferredName":"Ulinastatin","code":"C102851","definitions":[{"definition":"A multivalent Kunitz-type serine protease inhibitor derived from human urine, with potential protective, anti-fibrinolytic and anticoagulant activities. Upon administration, ulinastatin (or urinary trypsinogen inhibitor) inhibits the activities of a variety of enzymes, including trypsin, chymotrypsin, thrombin, kallikrein, plasmin, elastase, cathepsin, lipase, hyaluronidase, factors IXa, Xa, XIa, and XlIa, and polymorphonuclear leukocyte elastase. In addition, ulinastatin inhibits the excessive release of proinflammatory mediators, such as tumor necrosis factor-alpha, interleukin-6 and -8, and chemokines. Altogether, this agent may improve the microcirculation, perfusion and function of tissues and may protect organ injury.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulinastatin","termGroup":"PT","termSource":"NCI"},{"termName":"Bikunin","termGroup":"SY","termSource":"NCI"},{"termName":"Trypsin Inhibitor, Bikunin","termGroup":"SY","termSource":"NCI"},{"termName":"Urinary Trypsin Inhibitor","termGroup":"SY","termSource":"NCI"},{"termName":"UTI","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"80449-32-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OR3S9IF86U"},{"name":"Maps_To","value":"Ulinastatin"},{"name":"NCI_Drug_Dictionary_ID","value":"737612"},{"name":"PDQ_Closed_Trial_Search_ID","value":"737612"},{"name":"PDQ_Open_Trial_Search_ID","value":"737612"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0077906"}]}}{"C104744":{"preferredName":"Ulixertinib","code":"C104744","definitions":[{"definition":"An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, ulixertinib inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulixertinib","termGroup":"PT","termSource":"NCI"},{"termName":"1H-Pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BVD-523","termGroup":"CN","termSource":"NCI"},{"termName":"VRT752271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"869886-67-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"16ZDH50O1U"},{"name":"Maps_To","value":"Ulixertinib"},{"name":"NCI_Drug_Dictionary_ID","value":"746054"},{"name":"NCI_META_CUI","value":"CL445815"},{"name":"PDQ_Closed_Trial_Search_ID","value":"746054"},{"name":"PDQ_Open_Trial_Search_ID","value":"746054"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95755":{"preferredName":"Ulocuplumab","code":"C95755","definitions":[{"definition":"An orally bioavailable monoclonal antibody against CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. Ulocuplumab binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ulocuplumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 936564","termGroup":"CN","termSource":"NCI"},{"termName":"MDX-1338","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1375830-34-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7KNP87L4X4"},{"name":"Maps_To","value":"Ulocuplumab"},{"name":"NCI_Drug_Dictionary_ID","value":"673715"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673715"},{"name":"PDQ_Open_Trial_Search_ID","value":"673715"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3658941"}]}}{"C104413":{"preferredName":"Umbralisib","code":"C104413","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity.  PI3K-delta inhibitor TGR-1202 inhibits PI3K and prevents the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in susceptible tumor cells.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in tumor cells and cells of the hematopoietic lineage. The targeted inhibition of PI3K-delta allows for PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Umbralisib","termGroup":"PT","termSource":"NCI"},{"termName":"2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one","termGroup":"SY","termSource":"NCI"},{"termName":"RP-5264","termGroup":"CN","termSource":"NCI"},{"termName":"RP5264","termGroup":"CN","termSource":"NCI"},{"termName":"TGR 1202","termGroup":"CN","termSource":"NCI"},{"termName":"TGR-1202","termGroup":"CN","termSource":"NCI"},{"termName":"TGR1202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1532533-67-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"38073MQB2A"},{"name":"Maps_To","value":"Umbralisib"},{"name":"NCI_META_CUI","value":"CL445680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113799":{"preferredName":"Uncaria tomentosa Extract","code":"C113799","definitions":[{"definition":"An extract of Uncaria tomentosa (U. tomentosa), also called Cat's claw, a native Amazonian plant belonging to the Rubiaceae species, with potential anti-inflammatory, immunomodulating, antioxidant and antineoplastic activities. Although the exact mechanism(s) by which U. tomentosa extract exerts its effect(s) has yet to be fully elucidated, this extract may inhibit the proliferation of certain types of cancer cells. This extract may modulate inflammatory and immune responses through the stimulation of T- and B-lymphocytes and certain cytokines, including interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-a). Components in U. tomentosa may both induce repair of chemically-induced DNA damage and scavenge free radicals, which may protect against reactive oxygen species (ROS)-mediated cellular damage. In addition, this extract stimulates myelopoiesis, which may prevent chemotherapy-induced neutropenia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uncaria tomentosa Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Cat's Claw Herbal Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9060PRM18Q"},{"name":"Maps_To","value":"Uncaria tomentosa Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"757651"},{"name":"PDQ_Closed_Trial_Search_ID","value":"757651"},{"name":"PDQ_Open_Trial_Search_ID","value":"757651"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0939876"}]}}{"C73985":{"preferredName":"Upamostat","code":"C73985","definitions":[{"definition":"A substance being studied in the treatment of several types of cancer. It blocks the action of certain enzymes, and it may help keep cancer cells from growing and spreading. It is a type of serine protease inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, upamostat is converted to the active N alpha-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Upamostat","termGroup":"PT","termSource":"NCI"},{"termName":"1-Piperazinecarboxylic Acid, 4-((2S)-3-(3-((E)-Amino(hydroxyimino)methyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, Ethyl Ester","termGroup":"SN","termSource":"NCI"},{"termName":"WX-671","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1191101-18-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S5M7KW6U17"},{"name":"Legacy Concept Name","value":"Serine_Protease_Inhibitor_WX-671"},{"name":"Maps_To","value":"Upamostat"},{"name":"NCI_Drug_Dictionary_ID","value":"557106"},{"name":"PDQ_Closed_Trial_Search_ID","value":"557106"},{"name":"PDQ_Open_Trial_Search_ID","value":"557106"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348191"}]}}{"C119743":{"preferredName":"Uproleselan","code":"C119743","definitions":[{"definition":"A synthetic, glycomimetic molecule and E-selectin (CD62E) antagonist, with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Upon administration, uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. GMI-1271 also interferes with the binding of selectin E-expressing vascular endothelial cells to selectin-E ligand-expressing monocytes and neutrophils, thereby disrupting their activation. Consequently, this inhibits both the activation of the coagulation cascade and thrombus formation. This agent also prevents both leukocyte activation and inflammation. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis; it also plays a crucial role in inflammatory processes and cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uproleselan","termGroup":"PT","termSource":"NCI"},{"termName":"GMI-1271","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1983970-12-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PE952ANF83"},{"name":"Maps_To","value":"Uproleselan"},{"name":"NCI_Drug_Dictionary_ID","value":"767121"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767121"},{"name":"PDQ_Open_Trial_Search_ID","value":"767121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896849"}]}}{"C84870":{"preferredName":"Uprosertib","code":"C84870","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Uprosertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uprosertib","termGroup":"PT","termSource":"NCI"},{"termName":"2-Furancarboxamide, N-((1S)-2-Amino-1-((3,4-difluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-","termGroup":"SN","termSource":"NCI"},{"termName":"GSK2141795","termGroup":"CN","termSource":"NCI"},{"termName":"Oral Akt Inhibitor GSK2141795","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1047634-65-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZXM835LQ5E"},{"name":"Maps_To","value":"Uprosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"648336"},{"name":"PDQ_Closed_Trial_Search_ID","value":"648336"},{"name":"PDQ_Open_Trial_Search_ID","value":"648336"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2830127"}]}}{"C91083":{"preferredName":"Uracil Ointment","code":"C91083","definitions":[{"definition":"A 0.1% topical formulation of uracil used potentially to lower the incidence of hand-foot syndrome (HFS) (or palmar-plantar erythrodysesthesia) during 5-fluorouracil (5-FU) or 5-FU prodrug capecitabine chemotherapy. Upon local administration of uracil ointment to the skin, uracil competes with capecitabine or 5-FU as substrates for the activating enzyme thymidine phosphorylase and the metabolizing enzyme dihydropyrimidine dehydrogenase. This may prevent the production of 5-FU as well as the breakdown of 5-FU into the toxic metabolites locally. As the 5-FU metabolites are responsible for the presentation of HFS, inhibiting their formation may prevent this adverse effect. By applying a high concentration of uracil locally, the skin toxicities of 5-FU may be countered while preserving the systemic anti-cancer activity of the 5FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uracil Ointment","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uracil Ointment"},{"name":"NCI_Drug_Dictionary_ID","value":"670894"},{"name":"NCI_META_CUI","value":"CL416292"},{"name":"PDQ_Closed_Trial_Search_ID","value":"670894"},{"name":"PDQ_Open_Trial_Search_ID","value":"670894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62449":{"preferredName":"Urelumab","code":"C62449","definitions":[{"definition":"A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137 monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes; its ligand has been found to play an important role in the regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urelumab","termGroup":"PT","termSource":"NCI"},{"termName":"BMS-663513","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934823-49-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"230902QLLC"},{"name":"Legacy Concept Name","value":"Anti-CD137_Monoclonal_Antibody"},{"name":"Maps_To","value":"Urelumab"},{"name":"NCI_Drug_Dictionary_ID","value":"489120"},{"name":"PDQ_Closed_Trial_Search_ID","value":"489120"},{"name":"PDQ_Open_Trial_Search_ID","value":"489120"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831875"}]}}{"C162545":{"preferredName":"Uroacitides","code":"C162545","definitions":[{"definition":"A mixture of peptides, organic acids, pigments, and phenylacetylglutamine isolated from healthy human urine with potential antineoplastic activity. Upon administration, uroacitides, also known as cell differentiation agent II (CDA-II) may inhibit telomerase activity in tumor cells. This may lead to an accumulation of tumor cells in G1 phase and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Uroacitides","termGroup":"PT","termSource":"NCI"},{"termName":"CDA-II","termGroup":"AB","termSource":"NCI"},{"termName":"Cell Differentiation Agent II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Uroacitides"},{"name":"NCI_META_CUI","value":"CL971119"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"}]}}{"C91709":{"preferredName":"Urokinase-Derived Peptide A6","code":"C91709","definitions":[{"definition":"A substance being studied in the treatment of cancer. A6 is a small piece of a protein called urokinase (an enzyme that dissolves blood clots or prevents them from forming). It is a type of antiangiogenesis agent and a type of antimetastatic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Urokinase-Derived Peptide A6","termGroup":"PT","termSource":"NCI"},{"termName":"A6","termGroup":"CN","termSource":"NCI"},{"termName":"uPA-derived Peptide A6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"220334-14-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KM64V5W7RA"},{"name":"Maps_To","value":"Urokinase-Derived Peptide A6"},{"name":"NCI_Drug_Dictionary_ID","value":"377541"},{"name":"NCI_META_CUI","value":"CL433998"},{"name":"PDQ_Closed_Trial_Search_ID","value":"377541"},{"name":"PDQ_Open_Trial_Search_ID","value":"377541"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121215":{"preferredName":"USP14/UCHL5 Inhibitor VLX1570","code":"C121215","definitions":[{"definition":"An inhibitor of the 19S proteasome-specific deubiquitylating enzymes (DUBs) USP14 and UCHL5, with apoptosis-inducing and antineoplastic activities. Upon administration, VLX1570 specifically binds to both USP14 and UCHL5, thereby blocking their deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. USP14 and UCHL5, overexpressed in various tumor cell types, play a key role in the correct folding and deubiquitination of proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"USP14/UCHL5 Inhibitor VLX1570","termGroup":"PT","termSource":"NCI"},{"termName":"VLX1570","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1956378-23-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K6067N5M6N"},{"name":"Maps_To","value":"USP14/UCHL5 Inhibitor VLX1570"},{"name":"NCI_Drug_Dictionary_ID","value":"769736"},{"name":"PDQ_Closed_Trial_Search_ID","value":"769736"},{"name":"PDQ_Open_Trial_Search_ID","value":"769736"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053575"}]}}{"C116619":{"preferredName":"Utomilumab","code":"C116619","definitions":[{"definition":"A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Utomilumab","termGroup":"PT","termSource":"NCI"},{"termName":"PF 05082566","termGroup":"CN","termSource":"NCI"},{"termName":"PF 5082566","termGroup":"CN","termSource":"NCI"},{"termName":"PF-05082566","termGroup":"CN","termSource":"NCI"},{"termName":"PF-2566","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1417318-27-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6YY8O697VF"},{"name":"Maps_To","value":"Utomilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"696781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"696781"},{"name":"PDQ_Open_Trial_Search_ID","value":"696781"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3529795"}]}}{"C61069":{"preferredName":"V930 Vaccine","code":"C61069","definitions":[{"definition":"A novel cancer vaccine designed to treat HER-2- and/or CEA-expressing cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"V930 Vaccine","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"V930_Vaccine"},{"name":"Maps_To","value":"V930 Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"473030"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473030"},{"name":"PDQ_Open_Trial_Search_ID","value":"473030"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831771"}]}}{"C2542":{"preferredName":"Vaccine-Sensitized Draining Lymph Node Cells","code":"C2542","definitions":[{"definition":"Cells isolated from lymph nodes from patients, and activated in vitro to generate tumor-specific effector T cells.  Lymph nodes in the lymphatics draining tumors often contain T cells that are immunologically sensitized but functionally deficient. Vaccine-sensitized draining lymph node cells are prepared by isolating these lymphocytes in vitro and stimulating them with cytokines to differentiate into mature effector cells.  Vaccine-draining lymph node cells may also be produced by pharmacological activation of lymph node-derived lymphocytes with drugs such as ionomycin or with bacterial toxin; these activated lymphocytes may be expanded in culture with cytokines such as interleukin-2 prior to infusion into the patient. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vaccine-Sensitized Draining Lymph Node Cells","termGroup":"PT","termSource":"NCI"},{"termName":"VDLN Cells","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vaccine-Sensitized_Draining_Lymph_Node_Cells"},{"name":"Maps_To","value":"Vaccine-Sensitized Draining Lymph Node Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"43655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43655"},{"name":"PDQ_Open_Trial_Search_ID","value":"43655"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879357"}]}}{"C102748":{"preferredName":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules","code":"C102748","definitions":[{"definition":"A proprietary suspension formulation prepared from granules of standardized extracts from the fruits of Vaccinium myrtillus, the aerial parts of Macleaya cordata and the roots of Echinacea angustifolia, with potential anti-mucositis, anti-inflammatory, and analgesic activities. The main active ingredients of this formulation include anthocyanosides and procyanidins, benzophenanthridinic alkaloids, and alkylamides from V. myrtillus, M. cordata and E. angustifolia extracts, respectively. Upon administration in the mucosal cavity, the anthocyanosides scavenge free radicals, form a protective barrier on the mucosa, and protect the integrity of the capillary vessels; the benzophenanthridine alkaloids prevent the production of pro-inflammatory cytokines by inhibiting NF-kB and may halt the growth of microorganisms; the alkylamides inhibit cyclooxygenase and 5-lipoxygenase thereby blocking productions of prostaglandin and leukotriene. Furthermore, alkylamides modulate the expression of tumor necrosis factor alpha and other cytokines involved in inflammation processes through cannabinoid type 2 receptors and as cannabinomimetics they may also exert analgesic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules","termGroup":"PT","termSource":"NCI"},{"termName":"Samital Granules","termGroup":"FB","termSource":"NCI"},{"termName":"V. myrtillus/M. cordata/E. angustfolia Extract Granules","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules"},{"name":"NCI_Drug_Dictionary_ID","value":"735790"},{"name":"NCI_META_CUI","value":"CL437005"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735790"},{"name":"PDQ_Open_Trial_Search_ID","value":"735790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116357":{"preferredName":"Vactosertib","code":"C116357","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vactosertib","termGroup":"PT","termSource":"NCI"},{"termName":"TEW-7197","termGroup":"CN","termSource":"NCI"},{"termName":"TEW7197","termGroup":"CN","termSource":"NCI"},{"termName":"TGFBR1 Inhibitor TEW-7197","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1352608-82-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6T4O391P5Y"},{"name":"Maps_To","value":"Vactosertib"},{"name":"NCI_Drug_Dictionary_ID","value":"762093"},{"name":"NCI_META_CUI","value":"CL473674"},{"name":"PDQ_Closed_Trial_Search_ID","value":"762093"},{"name":"PDQ_Open_Trial_Search_ID","value":"762093"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C133718":{"preferredName":"Vadacabtagene Leraleucel","code":"C133718","definitions":[{"definition":"Genetically modified CD3-positive-enriched autologous T-lymphocytes transduced with a replication incompetent gamma retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, vadacabtagene leraleucel,is directed to CD19-expressing tumor cells, and, upon binding to the T-cells, induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vadacabtagene Leraleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/CD28/zeta Modified CAR CD3+ T Lymphocytes JCAR015","termGroup":"SY","termSource":"NCI"},{"termName":"JCAR 015","termGroup":"CN","termSource":"NCI"},{"termName":"JCAR 15","termGroup":"CN","termSource":"NCI"},{"termName":"JCAR015","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"Clinical trial NCT02973191 has been terminated due to incidence of neurotoxicity and related deaths. 04/18/2017"},{"name":"FDA_UNII_Code","value":"A4O2H9W17Y"},{"name":"Maps_To","value":"Vadacabtagene Leraleucel"},{"name":"NCI_Drug_Dictionary_ID","value":"788214"},{"name":"NCI_META_CUI","value":"CL520442"},{"name":"PDQ_Closed_Trial_Search_ID","value":"788214"},{"name":"PDQ_Open_Trial_Search_ID","value":"788214"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111039":{"preferredName":"Vadastuximab Talirine","code":"C111039","definitions":[{"definition":"An immunoconjugate consisting of a humanized monoclonal antibody that is engineered to contain cysteine residues that are conjugated to the synthetic, DNA cross-linking, pyrrolobenzodiazepine dimer SGD-1882, via the protease-cleavable linker maleimidocaproyl-valine-alanine dipeptide, with potential antineoplastic activity. The monoclonal antibody portion of vadastuximab talirine specifically binds to the cell surface antigen CD33. This causes the internalization of SGN-CD33A, and the release of the cytotoxic moiety SGD-1882. SGD-1882 binds to and crosslinks DNA, which results in both cell cycle arrest and the induction of apoptosis in CD33-expressing tumor cells. CD33, a transmembrane receptor, is expressed on myeloid leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vadastuximab Talirine","termGroup":"PT","termSource":"NCI"},{"termName":"SGN CD33A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD33A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD33A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1436390-64-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"T13V17U431"},{"name":"Maps_To","value":"Vadastuximab Talirine"},{"name":"NCI_Drug_Dictionary_ID","value":"751848"},{"name":"NCI_META_CUI","value":"CL453546"},{"name":"PDQ_Closed_Trial_Search_ID","value":"751848"},{"name":"PDQ_Open_Trial_Search_ID","value":"751848"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2504":{"preferredName":"Vadimezan","code":"C2504","definitions":[{"definition":"A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis.  This agent also stimulates the anti-tumor activity of tumor-associated macrophages.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that is a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vadimezan","termGroup":"PT","termSource":"NCI"},{"termName":"5,6-Dimethylxanthenone-4-Acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"5,6-MexXAA","termGroup":"AB","termSource":"NCI"},{"termName":"AS 1404","termGroup":"CN","termSource":"NCI"},{"termName":"AS A404","termGroup":"CN","termSource":"NCI"},{"termName":"AS-1404","termGroup":"CN","termSource":"NCI"},{"termName":"AS-A404","termGroup":"CN","termSource":"NCI"},{"termName":"AS1404","termGroup":"CN","termSource":"NCI"},{"termName":"ASA404","termGroup":"CN","termSource":"NCI"},{"termName":"Dimethyloxoxanthene Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"Dimethylxanthenone Acetic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"DMXAA","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"117570-53-3"},{"name":"Chemical_Formula","value":"C17H14O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0829J8133H"},{"name":"Legacy Concept Name","value":"Dimethylxanthenone_Acetic_Acid"},{"name":"Maps_To","value":"Vadimezan"},{"name":"NCI_Drug_Dictionary_ID","value":"43320"},{"name":"NSC Number","value":"640488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43320"},{"name":"PDQ_Open_Trial_Search_ID","value":"43320"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2930490"}]}}{"C29536":{"preferredName":"Valproic Acid","code":"C29536","definitions":[{"definition":"A drug used to treat epileptic seizures and bipolar disorder and to prevent migraine headaches. It is also being studied in the treatment of several types of cancer. It blocks an enzyme that cells need to grow and may cause cancer cells to die. It also blocks the growth of new blood vessels that tumors need to grow. It is a type of anticonvulsant, histone deacetylase (HDAC) inhibitor, antimaniacal, migraine headache prophylactic, and antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valproic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"2-Propylpentanoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"2-Propylvaleric Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Depakene","termGroup":"BR","termSource":"NCI"},{"termName":"Di-n-propylacetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Valproate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Epilepsy; Mania; Migraine"},{"name":"CAS_Registry","value":"99-66-1"},{"name":"CHEBI_ID","value":"CHEBI:39867"},{"name":"Chemical_Formula","value":"C8H16O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"614OI1Z5WI"},{"name":"Legacy Concept Name","value":"Valproic_Acid"},{"name":"Maps_To","value":"Valproic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"350047"},{"name":"NSC Number","value":"93819"},{"name":"PDQ_Closed_Trial_Search_ID","value":"350047"},{"name":"PDQ_Open_Trial_Search_ID","value":"350047"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042291"}]}}{"C1340":{"preferredName":"Valrubicin","code":"C1340","definitions":[{"definition":"A drug used to treat bladder cancer that does not respond to BCG (Bacillus Calmette Guerin). It is an anthracycline and is a type of antitumor antibiotic.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valrubicin","termGroup":"PT","termSource":"NCI"},{"termName":"AD 32","termGroup":"CN","termSource":"NCI"},{"termName":"AD-32","termGroup":"CN","termSource":"NCI"},{"termName":"AD32","termGroup":"CN","termSource":"NCI"},{"termName":"N-Trifluoroacetyladriamycin-14-valerate","termGroup":"SN","termSource":"NCI"},{"termName":"Valstar","termGroup":"BR","termSource":"NCI"},{"termName":"Valtaxin","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"56124-62-0"},{"name":"Chemical_Formula","value":"C34H36F3NO13"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"2C6NUM6878"},{"name":"Legacy Concept Name","value":"Valrubicin"},{"name":"Maps_To","value":"Valrubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"39135"},{"name":"NSC Number","value":"246131"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39135"},{"name":"PDQ_Open_Trial_Search_ID","value":"39135"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0068314"}]}}{"C1405":{"preferredName":"Valspodar","code":"C1405","definitions":[{"definition":"A substance that is being studied for its ability to prevent or overcome the resistance of tumor cells to some anticancer drugs. It belongs to the family of drugs called cyclosporine analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Valspodar","termGroup":"PT","termSource":"NCI"},{"termName":"6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic Acid]cyclosporin D","termGroup":"SN","termSource":"NCI"},{"termName":"Amdray","termGroup":"BR","termSource":"NCI"},{"termName":"Cyclo((2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl)-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-me","termGroup":"SN","termSource":"NCI"},{"termName":"PSC-833","termGroup":"CN","termSource":"NCI"},{"termName":"PSC833","termGroup":"CN","termSource":"NCI"},{"termName":"SZD PSC 833","termGroup":"CN","termSource":"NCI"},{"termName":"VP16","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"121584-18-7"},{"name":"Chemical_Formula","value":"C63H111N11O12"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q7ZP55KF3X"},{"name":"Legacy Concept Name","value":"Valspodar"},{"name":"Maps_To","value":"Valspodar"},{"name":"NCI_Drug_Dictionary_ID","value":"41750"},{"name":"NSC Number","value":"648265"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41750"},{"name":"PDQ_Open_Trial_Search_ID","value":"41750"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0753474"}]}}{"C2737":{"preferredName":"Vandetanib","code":"C2737","definitions":[{"definition":"A substance being studied in the treatment of lung cancer and other types of cancer. It may block the growth and spread of tumor cells and prevent the growth of new blood vessels that tumors need to grow. Vandetanib is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vandetanib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 6474","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-6474","termGroup":"CN","termSource":"NCI"},{"termName":"AZD6474","termGroup":"CN","termSource":"NCI"},{"termName":"Caprelsa","termGroup":"BR","termSource":"NCI"},{"termName":"Lucivand","termGroup":"FB","termSource":"NCI"},{"termName":"Zactima","termGroup":"BR","termSource":"NCI"},{"termName":"ZD-6474","termGroup":"CN","termSource":"NCI"},{"termName":"ZD6474","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Thyroid Cancer"},{"name":"CAS_Registry","value":"443913-73-3"},{"name":"CHEBI_ID","value":"CHEBI:49960"},{"name":"Chemical_Formula","value":"C22H24BrFN4O2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YO460OQ37K"},{"name":"Legacy Concept Name","value":"ZD-6474"},{"name":"Maps_To","value":"Vandetanib"},{"name":"NCI_Drug_Dictionary_ID","value":"269177"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269177"},{"name":"PDQ_Open_Trial_Search_ID","value":"269177"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1384659"}]}}{"C150384":{"preferredName":"Vandetanib-eluting Radiopaque Bead BTG-002814","code":"C150384","definitions":[{"definition":"Radiopaque drug-eluting beads (DEBs) that are loaded with vandetanib, a dual inhibitor of both vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with potential antineoplastic, anti-angiogenic and imaging activities. Upon intra-arterial hepatic artery administration of vandetanib (VTB)-eluting Radiopaque beads (VERBs) BTG-002814, the DEBs occlude the tumor blood vessels and deprive tumor cells of oxygen and nutrients, thereby causing hepatic arterial embolization and direct tumor cell death. The VERBs release vandetanib from the beads in a sustained manner. Vandetanib selectively inhibits the tyrosine kinase activity of both VEGFR and EGFR, thereby blocking both VEGF/VEGFR- and EGF/EGFR-stimulated signaling and inhibiting cell proliferation, migration and angiogenesis in VEGFR/EGFR-expressing hepatic tumor cells. The DEBs, controlled release microspherical devices, cause low systemic exposure and prevent systemic toxicity of vandetanib. DEBs also deliver high concentrations of vandetanib in the tumor for a controlled and extended period of time. Use of radiopaque DEBs allows for visualization of both the bead location and the degree of embolization upon imaging.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vandetanib-eluting Radiopaque Bead BTG-002814","termGroup":"PT","termSource":"NCI"},{"termName":"BTG-002814","termGroup":"CN","termSource":"NCI"},{"termName":"Vandetanib-eluting Radiopaque Embolic Beads","termGroup":"SY","termSource":"NCI"},{"termName":"VERB","termGroup":"AB","termSource":"NCI"},{"termName":"VERB BTG-002814","termGroup":"SY","termSource":"NCI"},{"termName":"VTB-loaded Beads","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vandetanib-eluting Radiopaque Bead BTG-002814"},{"name":"NCI_Drug_Dictionary_ID","value":"792793"},{"name":"NCI_META_CUI","value":"CL552167"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792793"},{"name":"PDQ_Open_Trial_Search_ID","value":"792793"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C116748":{"preferredName":"Vandortuzumab Vedotin","code":"C116748","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the six transmembrane epithelial antigen of the prostate 1 (STEAP1), and conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of vandortuzumab vedotin, the monoclonal antibody moiety of vandortuzumab vedotin binds to STEAP1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. STEAP1, a tumor-associated antigen (TAA), is overexpressed in a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vandortuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"DSTP3086S","termGroup":"CN","termSource":"NCI"},{"termName":"MSTP2109A","termGroup":"CN","termSource":"NCI"},{"termName":"RG7450","termGroup":"CN","termSource":"NCI"},{"termName":"Thio-anti-STEAP1-MC-vc-PAB-MMAE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1471985-92-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44OUQ00D1U"},{"name":"Maps_To","value":"Vandortuzumab Vedotin"},{"name":"NCI_Drug_Dictionary_ID","value":"694576"},{"name":"NCI_META_CUI","value":"CL433770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"694576"},{"name":"PDQ_Open_Trial_Search_ID","value":"694576"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C96799":{"preferredName":"Vantictumab","code":"C96799","definitions":[{"definition":"A monoclonal antibody directed against the Wnt signaling pathway with potential antineoplastic activity. Upon administration, vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This may result in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. The Wnt signaling pathway is dysregulated in many cancer cell types and appears to play a major role in CSC regulation and activity; CSC are tumor initiating cells that are able to self-renew and are responsible for tumor growth and resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vantictumab","termGroup":"PT","termSource":"NCI"},{"termName":"OMP-18R5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1345009-45-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"88WBI2D80S"},{"name":"Maps_To","value":"Vantictumab"},{"name":"NCI_Drug_Dictionary_ID","value":"700131"},{"name":"NCI_META_CUI","value":"CL429406"},{"name":"PDQ_Closed_Trial_Search_ID","value":"700131"},{"name":"PDQ_Open_Trial_Search_ID","value":"700131"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118578":{"preferredName":"Vanucizumab","code":"C118578","definitions":[{"definition":"A humanized bispecific immunoglobulin G (IgG1) monoclonal antibody targeting both the vascular endothelial growth factor receptor (VEGFR) ligand VEGF-A and the Tie2 receptor ligand angiopoietin-2 (Ang-2), with potential antineoplastic and anti-angiogenic activities. Upon administration of vanucizumab, the anti-VEGF-A arm, which is based on bevacizumab, targets and binds to VEGF-A and the anti-Ang2 arm, which is based on the anti-Ang-2 antibody LC06, targets and binds to Ang2, thereby simultaneously binding and neutralizing both VEGF-A and Ang2. This prevents the activation of both VEGF-A/VEGFR- and Ang2/Tie2-mediated signaling pathways. Altogether, this results in the inhibition of proliferation of VEGF-A- and/or Ang2-overexpressing tumor cells. VEGF-A and Ang2, both upregulated in a variety of tumor cell types, play key roles in tumor cell proliferation, angiogenesis and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vanucizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Ang2-VEGF-A CrossMab RO5520985","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin Recombined G1-kappa/lambda, Anti-(Homo sapiens Angpt2 (Angiopoietin 2, Ang2))/Anti-Homo sapiens VEGFa (Vascular Endothelial Growth Factor A, VEGF-a, VEGF)), Humanized Monoclonal Antibody","termGroup":"SN","termSource":"NCI"},{"termName":"RG-7221","termGroup":"CN","termSource":"NCI"},{"termName":"RG7221","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5520985","termGroup":"CN","termSource":"NCI"},{"termName":"RO5520985","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1448221-05-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B800Z06O8K"},{"name":"Maps_To","value":"Vanucizumab"},{"name":"NCI_META_CUI","value":"CL446653"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1429":{"preferredName":"Vapreotide","code":"C1429","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called somatostatin analogs.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic cyclic octapeptide analogue of somatostatin with direct and indirect antitumor effects. Vapreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and to SSTR-5 with a lesser affinity, in the similar behaviors as other octapeptide somatostatin analogues. Like octreotide, this agent has direct and indirect antitumor effects via inhibiting the release of growth hormone and other peptides that regulate release of insulin, gastrointestinal hormones. Furthermore, vapreotide may also be useful for inducing hemostasis in cases of acute hemorrhage of the upper gastrointestinal tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vapreotide","termGroup":"PT","termSource":"NCI"},{"termName":"BMY-41606","termGroup":"CN","termSource":"NCI"},{"termName":"Docrised","termGroup":"FB","termSource":"NCI"},{"termName":"RC-160","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103222-11-3"},{"name":"Chemical_Formula","value":"C57H70N12O9S2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2PK59M9GFF"},{"name":"Legacy Concept Name","value":"Vapreotide"},{"name":"Maps_To","value":"Vapreotide"},{"name":"NCI_Drug_Dictionary_ID","value":"38258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38258"},{"name":"PDQ_Open_Trial_Search_ID","value":"38258"},{"name":"PubMedID_Primary_Reference","value":"16917205"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0164678"}]}}{"C99127":{"preferredName":"Varlilumab","code":"C99127","definitions":[{"definition":"A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of varlilumab, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Varlilumab","termGroup":"PT","termSource":"NCI"},{"termName":"CDX 1127","termGroup":"CN","termSource":"NCI"},{"termName":"CDX-1127","termGroup":"CN","termSource":"NCI"},{"termName":"CDX1127","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1393344-72-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"0125DUV5XC"},{"name":"Maps_To","value":"Varlilumab"},{"name":"NCI_Drug_Dictionary_ID","value":"715751"},{"name":"NCI_META_CUI","value":"CL432946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"715751"},{"name":"PDQ_Open_Trial_Search_ID","value":"715751"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62530":{"preferredName":"Varlitinib","code":"C62530","definitions":[{"definition":"An orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Varlitinib","termGroup":"PT","termSource":"NCI"},{"termName":"ARRY-334543","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"845272-21-1"},{"name":"Chemical_Formula","value":"C22H19ClN6O2S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"846Y8197W1"},{"name":"Legacy Concept Name","value":"ARRY-334543"},{"name":"Maps_To","value":"Varlitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"487532"},{"name":"PDQ_Closed_Trial_Search_ID","value":"487532"},{"name":"PDQ_Open_Trial_Search_ID","value":"487532"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831861"}]}}{"C95226":{"preferredName":"Varlitinib Tosylate","code":"C95226","definitions":[{"definition":"The tosylate salt form of varlitinib, an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Varlitinib Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"4,6-Quinazolinediamine, N(Sup 4)-(3-Chloro-4-(2-Thiazolylmethoxy)Phenyl)-N(Sup 6)-((4r)-4,5-Dihydro-4-Methyl-2-Oxazolyl)-, 4-Methylbenzenesulphonate (1:2)","termGroup":"SN","termSource":"NCI"},{"termName":"4-N-(3-Chloro-4-(Thiazol-2-Ylmethoxy)Phenyl)-6-N-((4r)-4-Methyl-4,5-Dihydrooxazol-2- Yl)Quinazoline-4,6-Diamine Bis(4-Methylbenzenesulphonate)","termGroup":"SN","termSource":"NCI"},{"termName":"AR00334543 Ditosilate","termGroup":"CN","termSource":"NCI"},{"termName":"AR00334543 Ditosylate","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-334543 Ditosylate","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-543 Ditosilate","termGroup":"CN","termSource":"NCI"},{"termName":"ARRY-543 Ditosylate","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1146629-86-8"},{"name":"Chemical_Formula","value":"C22H19ClN6O2S.2C7H8O3S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V4M8FWS152"},{"name":"Maps_To","value":"Varlitinib Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"793457"},{"name":"PDQ_Closed_Trial_Search_ID","value":"793457"},{"name":"PDQ_Open_Trial_Search_ID","value":"793457"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2987008"}]}}{"C162343":{"preferredName":"Vascular Disrupting Agent BNC105","code":"C162343","definitions":[{"definition":"A vascular disrupting agent (VDA), with potential anti-vascular and antineoplastic activities. Upon administration, vascular disrupting agent BNC105 binds to tubulin and inhibits its polymerization, which results in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. This deprives tumor cells of nutrients and results in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Disrupting Agent BNC105","termGroup":"PT","termSource":"NCI"},{"termName":"2-Methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran","termGroup":"SY","termSource":"NCI"},{"termName":"BNC 105","termGroup":"CN","termSource":"NCI"},{"termName":"BNC-105","termGroup":"CN","termSource":"NCI"},{"termName":"BNC105","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945771-74-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z3S2Z6H7B0"},{"name":"Maps_To","value":"Vascular Disrupting Agent BNC105"},{"name":"NCI_META_CUI","value":"CL970840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88338":{"preferredName":"Vascular Disrupting Agent BNC105P","code":"C88338","definitions":[{"definition":"A benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Disrupting Agent BNC105P","termGroup":"PT","termSource":"NCI"},{"termName":"BNC105P","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"945771-96-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E3052198GM"},{"name":"Maps_To","value":"Vascular Disrupting Agent BNC105P"},{"name":"NCI_Drug_Dictionary_ID","value":"662727"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662727"},{"name":"PDQ_Open_Trial_Search_ID","value":"662727"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981856"}]}}{"C2736":{"preferredName":"Vascular Disrupting Agent ZD6126","code":"C2736","definitions":[{"definition":"A substance that has been studied in the treatment of several types of cancer. ZD6126 destroys blood vessels in tumors and may prevent the growth of new blood vessels that tumors need to grow. It is a type of vascular targeting agent and a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. ZD-6126 is converted in vivo into N-acetylcolchinol. N-acetylcolchinol binds to and destabilizes the tubulin cytoskeleton of endothelial cells in tumor blood vessels, which may result in tumor endothelial cell apoptosis, the selective occlusion of tumor blood vessels, cessation of tumor blood flow, and tumor necrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vascular Disrupting Agent ZD6126","termGroup":"PT","termSource":"NCI"},{"termName":"ANG453","termGroup":"CN","termSource":"NCI"},{"termName":"N-[(5S)-6,7-Dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"N-acetylcochinol-O-phosphate","termGroup":"SN","termSource":"NCI"},{"termName":"ZD-6126","termGroup":"CN","termSource":"NCI"},{"termName":"ZD6126","termGroup":"SY","termSource":"NCI"},{"termName":"ZM-445526","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"219923-05-4"},{"name":"Chemical_Formula","value":"C20H24NO8P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GBO3S6M9W7"},{"name":"Legacy Concept Name","value":"ZD-6126"},{"name":"Maps_To","value":"Vascular Disrupting Agent ZD6126"},{"name":"NCI_Drug_Dictionary_ID","value":"353153"},{"name":"PDQ_Closed_Trial_Search_ID","value":"353153"},{"name":"PDQ_Open_Trial_Search_ID","value":"353153"},{"name":"PubMedID_Primary_Reference","value":"18219445"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1122628"}]}}{"C1868":{"preferredName":"Vatalanib","code":"C1868","definitions":[{"definition":"A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and VEGF receptor kinase inhibitors.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vatalanib","termGroup":"PT","termSource":"NCI"},{"termName":"CGP 79787","termGroup":"CN","termSource":"NCI"},{"termName":"CGP-79787","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine","termGroup":"SN","termSource":"NCI"},{"termName":"PTK787","termGroup":"CN","termSource":"NCI"},{"termName":"ZK-232934","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"212141-54-3"},{"name":"Chemical_Formula","value":"C20H15ClN4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5DX9U76296"},{"name":"Legacy Concept Name","value":"PTK787"},{"name":"Maps_To","value":"Vatalanib"},{"name":"NCI_Drug_Dictionary_ID","value":"43530"},{"name":"NSC Number","value":"719335"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43530"},{"name":"PDQ_Open_Trial_Search_ID","value":"43530"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0912586"}]}}{"C74945":{"preferredName":"Vatalanib Succinate","code":"C74945","definitions":[{"definition":"The succinate salt of vatalanib, an anilinophthalazine derivative, with antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vatalanib Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"1-[4-Chloroanilino]-4-[4-pyridylmethyl]phthalazine Succinate","termGroup":"SN","termSource":"NCI"},{"termName":"CGP 79787D","termGroup":"CN","termSource":"NCI"},{"termName":"PTK 787","termGroup":"CN","termSource":"NCI"},{"termName":"PTK-787","termGroup":"CN","termSource":"NCI"},{"termName":"PTK787","termGroup":"CN","termSource":"NCI"},{"termName":"ZK 222584","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"212142-18-2"},{"name":"Chemical_Formula","value":"C20H15ClN4.C4H6O4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V5FUB77031"},{"name":"Legacy Concept Name","value":"Vatalanib_Succinate"},{"name":"Maps_To","value":"Vatalanib Succinate"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1524078"}]}}{"C136416":{"preferredName":"Vecabrutinib","code":"C136416","definitions":[{"definition":"An orally available second-generation, reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, vecabrutinib non-covalently binds to and inhibits the activity of both wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, SNS-062 does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. Other irreversible BTK inhibitors covalently bind to the C481 site to inhibit BTK's activity; the C481S mutation prevents that binding. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vecabrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"BIIB-062","termGroup":"CN","termSource":"NCI"},{"termName":"BIIB062","termGroup":"CN","termSource":"NCI"},{"termName":"BSK-4841","termGroup":"CN","termSource":"NCI"},{"termName":"FP-182","termGroup":"CN","termSource":"NCI"},{"termName":"SNS 062","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-062","termGroup":"CN","termSource":"NCI"},{"termName":"SNS062","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1510829-06-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PQ7O0OB5GU"},{"name":"Maps_To","value":"Vecabrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"789221"},{"name":"NCI_META_CUI","value":"CL523719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"789221"},{"name":"PDQ_Open_Trial_Search_ID","value":"789221"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C70971":{"preferredName":"Vector-peptide Conjugated Paclitaxel","code":"C70971","definitions":[{"definition":"A proprietary conjugate of paclitaxel with antineoplastic activity. Similar to the free drug, the paclitaxel moiety in vector-peptide conjugated paclitaxel binds to and stabilizes tubulin molecules, promoting assembly of microtubules and inhibiting tubulin disassembly which results in the inhibition of cell division. The Kunitz domain-derived vector-peptide carries the conjugated paclitaxel through the blood brain barrier (BBB), bypassing the transmembrane p-glycoprotein (P-gp) efflux pump, which may result in higher concentrations of paclitaxel in the brain parenchyma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vector-peptide Conjugated Paclitaxel","termGroup":"PT","termSource":"NCI"},{"termName":"Taxol-Angiopep Conjugate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vector-peptide_Conjugated_Paclitaxel"},{"name":"Maps_To","value":"Vector-peptide Conjugated Paclitaxel"},{"name":"NCI_Drug_Dictionary_ID","value":"574047"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574047"},{"name":"PDQ_Open_Trial_Search_ID","value":"574047"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2349111"}]}}{"C95798":{"preferredName":"Vedolizumab","code":"C95798","definitions":[{"definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vedolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Entyvio","termGroup":"BR","termSource":"NCI"},{"termName":"Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer","termGroup":"SY","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Integrin LPAM-1 (Lymphocyte Peyer's Patch Adhesion Molecule 1)) (Human-Mus musculus Heavy Chain), Disulfide with Human-Mus musculus kappa-chain, Dimer","termGroup":"SN","termSource":"NCI"},{"termName":"LDP 02","termGroup":"CN","termSource":"NCI"},{"termName":"LDP-02","termGroup":"CN","termSource":"NCI"},{"termName":"LDP02","termGroup":"CN","termSource":"NCI"},{"termName":"MLN0002","termGroup":"CN","termSource":"NCI"},{"termName":"MLN02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Treatment of ulcerative colitis and Crohn's disease"},{"name":"CAS_Registry","value":"943609-66-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9RV78Q2002"},{"name":"Maps_To","value":"Vedolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"781604"},{"name":"PDQ_Closed_Trial_Search_ID","value":"781604"},{"name":"PDQ_Open_Trial_Search_ID","value":"781604"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2742797"}]}}{"C91100":{"preferredName":"Emvododstat","code":"C91100","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor (VEGF) synthesis with potential antiangiogenesis and antineoplastic activities. Emvododstat targets post-transcriptionally by selectively binding the 5'- and 3'-untranslated regions (UTR) of VEGF messenger RNA (mRNA), thereby preventing translation of VEGF. This inhibits VEGF protein production and decreases its levels in the tumor and bloodstream. In turn, this may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and eventually the induction of tumor cell death. VEGFs are upregulated in a variety of tumor cell types and play key roles during angiogenesis. In addition, emvododstat may enhance the antitumor activity of other chemotherapeutic agents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emvododstat","termGroup":"PT","termSource":"NCI"},{"termName":"PTC299","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1256565-36-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"053QD2I96A"},{"name":"Maps_To","value":"VEGF Inhibitor PTC299"},{"name":"NCI_Drug_Dictionary_ID","value":"564407"},{"name":"PDQ_Closed_Trial_Search_ID","value":"564407"},{"name":"PDQ_Open_Trial_Search_ID","value":"564407"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2984037"}]}}{"C117236":{"preferredName":"VEGF/HGF-targeting DARPin MP0250","code":"C117236","definitions":[{"definition":"A designed ankyrin repeat proteins (DARPin)-based agent targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), with potential antiangiogenic and antineoplastic activities. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the VEGF/HGF-targeting DARPin MP0250 binds to and inhibits both HGF and VEGF. This prevents HGF- and VEGF-mediated signaling, and inhibits the growth of HGF/VEGF-overexpressing tumor cells. This agent also prevents osteolysis, due to the inhibitory effect on HGF signaling. HGF and VEGF are overexpressed in a variety of cancer cell types and are associated with increased cell proliferation, migration and adhesion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGF/HGF-targeting DARPin MP0250","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific VEGF/HGF-targeting Darpin","termGroup":"SY","termSource":"NCI"},{"termName":"MP0250","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1816305-70-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UGI01OSA4N"},{"name":"Maps_To","value":"VEGF/HGF-targeting DARPin MP0250"},{"name":"NCI_Drug_Dictionary_ID","value":"763220"},{"name":"NCI_META_CUI","value":"CL474108"},{"name":"PDQ_Closed_Trial_Search_ID","value":"763220"},{"name":"PDQ_Open_Trial_Search_ID","value":"763220"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88267":{"preferredName":"VEGFR Inhibitor KRN951","code":"C88267","definitions":[{"definition":"An orally bioavailable quinoline-urea derivative inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1 and 2 with potential antiangiogenesis and antineoplastic activities. VEGFR inhibitor KRN951 inhibits VEGF-induced phosphorylation of VEGFRs 1 and 2, which may result in inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR Inhibitor KRN951","termGroup":"PT","termSource":"NCI"},{"termName":"KRN951","termGroup":"CN","termSource":"NCI"},{"termName":"N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) Urea Hydrochloride Monohydrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"VEGFR Inhibitor KRN951"},{"name":"NCI_Drug_Dictionary_ID","value":"655018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"655018"},{"name":"PDQ_Open_Trial_Search_ID","value":"655018"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2976524"}]}}{"C99378":{"preferredName":"VEGFR-2 DNA Vaccine VXM01","code":"C99378","definitions":[{"definition":"An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR-2 DNA Vaccine VXM01","termGroup":"PT","termSource":"NCI"},{"termName":"VXM01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"VEGFR-2 DNA Vaccine VXM01"},{"name":"NCI_Drug_Dictionary_ID","value":"719728"},{"name":"NCI_META_CUI","value":"CL433162"},{"name":"PDQ_Closed_Trial_Search_ID","value":"719728"},{"name":"PDQ_Open_Trial_Search_ID","value":"719728"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C118628":{"preferredName":"VEGFR/FGFR Inhibitor ODM-203","code":"C118628","definitions":[{"definition":"An orally available inhibitor of the human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), with potential antiangiogenic and antineoplastic activities. VEGFR/FGFR inhibitor ODM-203 inhibits both VEGFRs and FGFRs, which may result in the inhibition of VEGFR- and FGFR-mediated signaling. This leads to an inhibition of angiogenesis and cell proliferation in tumor cells overexpressing VEGFR and/or FGFR. Both VEGFRs and FGFRs belong to the superfamily of receptor tyrosine kinases and are upregulated in various tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR/FGFR Inhibitor ODM-203","termGroup":"PT","termSource":"NCI"},{"termName":"ODM 203","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1430723-35-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y7HJ4D4CRT"},{"name":"Maps_To","value":"VEGFR/FGFR Inhibitor ODM-203"},{"name":"NCI_Drug_Dictionary_ID","value":"765615"},{"name":"PDQ_Closed_Trial_Search_ID","value":"765615"},{"name":"PDQ_Open_Trial_Search_ID","value":"765615"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896799"}]}}{"C79794":{"preferredName":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593","code":"C79794","definitions":[{"definition":"An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593","termGroup":"PT","termSource":"NCI"},{"termName":"TAK-593","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1005780-62-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H3I42X8XX7"},{"name":"Legacy Concept Name","value":"VEGFR_PDGFR_Tyrosine_Kinase_Inhibitor_TAK-593"},{"name":"Maps_To","value":"VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593"},{"name":"NCI_Drug_Dictionary_ID","value":"618858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"618858"},{"name":"PDQ_Open_Trial_Search_ID","value":"618858"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703162"}]}}{"C97950":{"preferredName":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210","code":"C97950","definitions":[{"definition":"An orally available ATP-competitive inhibitor of the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, the VEGFR2 tyrosine kinase inhibitor PF-00337210 selectively binds to VEGFR2 and prevents its phosphorylation which may result in an inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and may eventually cause tumor cell death. VEGFR2, a receptor tyrosine kinase, is frequently overexpressed by a variety of tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210","termGroup":"PT","termSource":"NCI"},{"termName":"PF-00337210","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"854514-88-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3K3KYC9LES"},{"name":"Maps_To","value":"VEGFR2 Tyrosine Kinase Inhibitor PF-00337210"},{"name":"NCI_Drug_Dictionary_ID","value":"709389"},{"name":"PDQ_Closed_Trial_Search_ID","value":"709389"},{"name":"PDQ_Open_Trial_Search_ID","value":"709389"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3253799"}]}}{"C61507":{"preferredName":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813","code":"C61507","definitions":[{"definition":"An orally-active, tyrosine kinase receptor inhibitor with potential antitumor activity. SU014813 binds to and inhibits the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-Kit and Fms-related tyrosine kinase 3 (Flt-3). This leads to an inhibition of cellular proliferation and angiogenesis and an induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"452105-23-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZZ6VH5MZ17"},{"name":"Legacy Concept Name","value":"SU014813"},{"name":"Maps_To","value":"VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813"},{"name":"NCI_Drug_Dictionary_ID","value":"486831"},{"name":"NCI_META_CUI","value":"CL937294"},{"name":"PDQ_Closed_Trial_Search_ID","value":"486831"},{"name":"PDQ_Open_Trial_Search_ID","value":"486831"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C60768":{"preferredName":"Veliparib","code":"C60768","definitions":[{"definition":"A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. ABT-888 may cause cancer cells to die. It is a type of poly(ADP-ribose) polymerase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Veliparib","termGroup":"PT","termSource":"NCI"},{"termName":"2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"ABT 888","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-888","termGroup":"CN","termSource":"NCI"},{"termName":"ABT888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"912444-00-9"},{"name":"CHEBI_ID","value":"CHEBI:62880"},{"name":"Chemical_Formula","value":"C13H16N4O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"01O4K0631N"},{"name":"Legacy Concept Name","value":"ABT-888"},{"name":"Maps_To","value":"Veliparib"},{"name":"NCI_Drug_Dictionary_ID","value":"496464"},{"name":"NSC Number","value":"737664"},{"name":"PDQ_Closed_Trial_Search_ID","value":"496464"},{"name":"PDQ_Open_Trial_Search_ID","value":"496464"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1958300"}]}}{"C48406":{"preferredName":"Veltuzumab","code":"C48406","definitions":[{"definition":"A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in cells that overexpress CD20. CD20 antigen is a hydrophobic transmembrane protein located on pre-B and mature B lymphocytes.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. IMMU-106 is a type of monoclonal antibody.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Veltuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 Monoclonal Antibody hA20","termGroup":"SY","termSource":"NCI"},{"termName":"IMMU-106","termGroup":"CN","termSource":"NCI"},{"termName":"MoAb hA20","termGroup":"AB","termSource":"NCI"},{"termName":"Monoclonal Antibody hA20","termGroup":"SY","termSource":"NCI"},{"termName":"Veltuzumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"non-Hodgkin's lymphoma"},{"name":"CAS_Registry","value":"728917-18-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"BPD4DGQ314"},{"name":"Legacy Concept Name","value":"Monoclonal_Antibody_hA20"},{"name":"Maps_To","value":"Veltuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"428486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"428486"},{"name":"PDQ_Open_Trial_Search_ID","value":"428486"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2746054"}]}}{"C64768":{"preferredName":"Vemurafenib","code":"C64768","definitions":[{"definition":"A substance being studied in the treatment of cancer. BRAF (V600E) kinase is a mutated (changed) form of a cell protein called BRAF. It is found in several types of cancer, including melanoma (a type of skin cancer). Inhibiting this kinase may cause cancer cells to die. BRAF (V600E) kinase is a type of serine/threonine kinase inhibitor and a type of targeted therapy agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vemurafenib","termGroup":"PT","termSource":"NCI"},{"termName":"1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"BRAF(V600E) Kinase Inhibitor RO5185426","termGroup":"SY","termSource":"NCI"},{"termName":"PLX 4032","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-4032","termGroup":"CN","termSource":"NCI"},{"termName":"RG 7204","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7204","termGroup":"CN","termSource":"NCI"},{"termName":"RG7204","termGroup":"CN","termSource":"NCI"},{"termName":"RO 5185426","termGroup":"CN","termSource":"NCI"},{"termName":"RO-5185426","termGroup":"CN","termSource":"NCI"},{"termName":"Zelboraf","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Advanced Melanoma"},{"name":"CAS_Registry","value":"918504-65-1"},{"name":"CHEBI_ID","value":"CHEBI:63637"},{"name":"Chemical_Formula","value":"C23H18ClF2N3O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"207SMY3FQT"},{"name":"Legacy Concept Name","value":"PLX4032"},{"name":"Maps_To","value":"Vemurafenib"},{"name":"NCI_Drug_Dictionary_ID","value":"528954"},{"name":"PDQ_Closed_Trial_Search_ID","value":"528954"},{"name":"PDQ_Open_Trial_Search_ID","value":"528954"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832009"}]}}{"C103147":{"preferredName":"Venetoclax","code":"C103147","definitions":[{"definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venetoclax","termGroup":"PT","termSource":"NCI"},{"termName":"4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"ABT 199","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-0199","termGroup":"CN","termSource":"NCI"},{"termName":"ABT-199","termGroup":"CN","termSource":"NCI"},{"termName":"ABT199","termGroup":"CN","termSource":"NCI"},{"termName":"GDC 0199","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0199","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0199","termGroup":"CN","termSource":"NCI"},{"termName":"RG7601","termGroup":"CN","termSource":"NCI"},{"termName":"Venclexta","termGroup":"BR","termSource":"NCI"},{"termName":"Venclyxto","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia (CLL) with 17p deletion and or small lymphocytic lymphoma (SLL)"},{"name":"CAS_Registry","value":"1257044-40-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"N54AIC43PW"},{"name":"Maps_To","value":"Venetoclax"},{"name":"NCI_Drug_Dictionary_ID","value":"698675"},{"name":"PDQ_Closed_Trial_Search_ID","value":"698675"},{"name":"PDQ_Open_Trial_Search_ID","value":"698675"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3659811"}]}}{"C928":{"preferredName":"Verapamil","code":"C928","definitions":[{"definition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verapamil","termGroup":"PT","termSource":"NCI"},{"termName":"alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"52-53-9"},{"name":"CHEBI_ID","value":"CHEBI:9948"},{"name":"Chemical_Formula","value":"C27H38N2O4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CJ0O37KU29"},{"name":"Legacy Concept Name","value":"Verapamil"},{"name":"Maps_To","value":"Verapamil"},{"name":"NCI_Drug_Dictionary_ID","value":"39730"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39730"},{"name":"PDQ_Open_Trial_Search_ID","value":"39730"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042523"}]}}{"C2811":{"preferredName":"Verpasep Caltespen","code":"C2811","definitions":[{"definition":"A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7.  Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers.  E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the prevention of cancer. It belongs to the family of drugs called fusion proteins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Verpasep Caltespen","termGroup":"PT","termSource":"NCI"},{"termName":"BCG65-E7","termGroup":"SY","termSource":"NCI"},{"termName":"Bovine HSP fusion with E7 of HPV16","termGroup":"SY","termSource":"NCI"},{"termName":"HPV 16 E7/HSP65 Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HPV E7 Peptide Epitope Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HspE7","termGroup":"AB","termSource":"NCI"},{"termName":"SGN-00101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"295371-00-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z7T0JI2E2I"},{"name":"Legacy Concept Name","value":"HspE7"},{"name":"Maps_To","value":"Verpasep Caltespen"},{"name":"NCI_Drug_Dictionary_ID","value":"269165"},{"name":"NSC Number","value":"713219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"269165"},{"name":"PDQ_Open_Trial_Search_ID","value":"269165"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1327844"}]}}{"C96747":{"preferredName":"Verubulin","code":"C96747","definitions":[{"definition":"A quinazoline derivative with potential antineoplastic activities. Verubulin binds to and inhibits tubulin polymerization and interrupts microtubule formation, resulting in disruption of mitotic spindle assembly, cell cycle arrest in the G2/M phase, and cell death. This agent is not a substrate for several subtypes of multidrug resistance ABC transporters, and may be useful for treating multidrug resistant tumors. In addition, as a vascular disrupting agent, verubulin disrupts tumor microvasculature specifically, which may result in acute ischemia and massive tumor cell death. In addition, verubulin is able to cross the blood-brain barrier and accumulate in the brain.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verubulin","termGroup":"PT","termSource":"NCI"},{"termName":"4-quinazolinamine, N-(4-methoxyphenyl)-N,2-dimethyl-","termGroup":"SN","termSource":"NCI"},{"termName":"MX-128495","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"827031-83-4"},{"name":"Chemical_Formula","value":"C17H17N3O"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X97O9FTB92"},{"name":"Maps_To","value":"Verubulin"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2002404"}]}}{"C64782":{"preferredName":"Verubulin Hydrochloride","code":"C64782","definitions":[{"definition":"The hydrochloride salt form of verubulin, a quinazoline derivative with potential dual antineoplastic activities. Verubulin binds to and inhibits tubulin polymerization and interrupts microtubule formation, resulting in disruption of mitotic spindle assembly, cell cycle arrest in the G2/M phase, and cell death. This agent is not a substrate for several subtypes of multidrug resistance ABC transporters, such as P-glycoprotein, multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1); therefore, it may be useful for treating multidrug resistant (MDR) tumors that express these transporters. In addition, as a vascular disrupting agent (VDA), verubulin appears to disrupt tumor microvasculature specifically, which may result in acute ischemia and massive tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Verubulin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"Azixa","termGroup":"BR","termSource":"NCI"},{"termName":"Microtubule Inhibitor MPC-6827","termGroup":"SY","termSource":"NCI"},{"termName":"MPC-6827","termGroup":"CN","termSource":"NCI"},{"termName":"N-(4-methoxyphenyl)-n,2-dimethylquinazolin-4-amine Hydrochloride","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"917369-31-4"},{"name":"Chemical_Formula","value":"C17H17N3O.HCl"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33380QZ0QW"},{"name":"Legacy Concept Name","value":"MPC-6827"},{"name":"Maps_To","value":"Verubulin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"526176"},{"name":"PDQ_Closed_Trial_Search_ID","value":"526176"},{"name":"PDQ_Open_Trial_Search_ID","value":"526176"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1832001"}]}}{"C113653":{"preferredName":"Vesigenurtucel-L","code":"C113653","definitions":[{"definition":"An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of vesigenurtucel-L, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vesigenurtucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"HS-410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9IE620X9FY"},{"name":"Maps_To","value":"Vesigenurtucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"756851"},{"name":"NCI_META_CUI","value":"CL458366"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756851"},{"name":"PDQ_Open_Trial_Search_ID","value":"756851"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2016":{"preferredName":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220","code":"C2016","definitions":[{"definition":"A mixed-backbone antisense oligonucleotide that is complementary to a pro-angiogenic vascular endothelial growth factor (VEGF) mRNA sequence.  Because of its antiangiogenic properties, GEM 220 has been studied as a potential antineoplastic agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220","termGroup":"PT","termSource":"NCI"},{"termName":"GEM 220","termGroup":"CN","termSource":"NCI"},{"termName":"Gene Expression Modulator 220","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"GEM_220"},{"name":"Maps_To","value":"VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1517360"}]}}{"C49090":{"preferredName":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820","code":"C49090","definitions":[{"definition":"An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the receptor tyrosine kinases for vascular endothelial growth factor (VEGF), c-kit, and platelet-derived growth factor (PDGF). In tumor models of breast carcinomas, gliomas, and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820","termGroup":"PT","termSource":"NCI"},{"termName":"XL 820","termGroup":"CN","termSource":"NCI"},{"termName":"XL-820","termGroup":"CN","termSource":"NCI"},{"termName":"XL820","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"XL820"},{"name":"Maps_To","value":"VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820"},{"name":"NCI_Drug_Dictionary_ID","value":"452042"},{"name":"NCI_META_CUI","value":"CL937288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"452042"},{"name":"PDQ_Open_Trial_Search_ID","value":"452042"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C61073":{"preferredName":"Viagenpumatucel-L","code":"C61073","definitions":[{"definition":"A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Viagenpumatucel-L","termGroup":"PT","termSource":"NCI"},{"termName":"Gp96-Ig Fusion Protein-Expressing Non-Small Cell Lung Cancer Cell Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HS-110","termGroup":"CN","termSource":"NCI"},{"termName":"HS110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"13H90KC831"},{"name":"Legacy Concept Name","value":"Gp96-Ig_Fusion_Protein-Expressing_Non-Small_Cell_Lung_Cancer_Cell_Vaccine"},{"name":"Maps_To","value":"Viagenpumatucel-L"},{"name":"NCI_Drug_Dictionary_ID","value":"473873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"473873"},{"name":"PDQ_Open_Trial_Search_ID","value":"473873"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831778"}]}}{"C148505":{"preferredName":"Vilaprisan","code":"C148505","definitions":[{"definition":"An orally available progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, vilaprisan competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system and may inhibit PR-mediated proliferative effects in cells overexpressing PRs. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue or uterine fibroid formation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vilaprisan","termGroup":"PT","termSource":"NCI"},{"termName":"(8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 1002670","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-1002670","termGroup":"CN","termSource":"NCI"},{"termName":"BAY1002670","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1262108-14-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IN59K53GI9"},{"name":"Maps_To","value":"Vilaprisan"},{"name":"NCI_Drug_Dictionary_ID","value":"792636"},{"name":"NCI_META_CUI","value":"CL551037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792636"},{"name":"PDQ_Open_Trial_Search_ID","value":"792636"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C930":{"preferredName":"Vinblastine","code":"C930","definitions":[{"definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used together with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Vinblastine comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vinblastine","termGroup":"PT","termSource":"NCI"},{"termName":"Vincaleucoblastine","termGroup":"SY","termSource":"NCI"},{"termName":"VLB","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Bladder cancer; Breast cancer; Choriocarcinoma; Germ cell tumors; Idiopathic thrombocytopenic purpura; Kaposi sarcoma; Letterer-Siwe disease; Various Lymphomas; Melanoma; Mycosis fungoides; Prostate cancer; Testicular cancer"},{"name":"CAS_Registry","value":"865-21-4"},{"name":"CHEBI_ID","value":"CHEBI:27375"},{"name":"Chemical_Formula","value":"C46H58N4O9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"5V9KLZ54CY"},{"name":"Legacy Concept Name","value":"Vinblastine"},{"name":"Maps_To","value":"Vinblastine"},{"name":"NCI_Drug_Dictionary_ID","value":"42951"},{"name":"NSC Number","value":"90636"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42951"},{"name":"PDQ_Open_Trial_Search_ID","value":"42951"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042670"}]}}{"C931":{"preferredName":"Vinblastine Sulfate","code":"C931","definitions":[{"definition":"A drug used with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Velban comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties.  Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinblastine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"29060-LE","termGroup":"CN","termSource":"NCI"},{"termName":"Exal","termGroup":"FB","termSource":"NCI"},{"termName":"Velban","termGroup":"BR","termSource":"NCI"},{"termName":"Velbe","termGroup":"FB","termSource":"NCI"},{"termName":"Velsar","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"143-67-9"},{"name":"CHEBI_ID","value":"CHEBI:9984"},{"name":"Chemical_Formula","value":"C46H58N4O9.H2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N00W22YO2B"},{"name":"Legacy Concept Name","value":"Vinblastine_Sulfate"},{"name":"Maps_To","value":"Vinblastine Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"688303"},{"name":"NSC Number","value":"49842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688303"},{"name":"PDQ_Open_Trial_Search_ID","value":"688303"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042671"}]}}{"C933":{"preferredName":"Vincristine","code":"C933","definitions":[{"definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"The active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vincristine","termGroup":"PT","termSource":"NCI"},{"termName":"22-Oxovincaleukoblastine","termGroup":"SN","termSource":"NCI"},{"termName":"LCR","termGroup":"AB","termSource":"NCI"},{"termName":"Leurocristine","termGroup":"SY","termSource":"NCI"},{"termName":"VCR","termGroup":"AB","termSource":"NCI"},{"termName":"Vincrystine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute leukemia; Brain tumors; Chronic lymphocytic leukemia; Gestational trophoblastic neoplasms; Head and Neck squamous cell carcinoma; Kaposis sarcoma; Liver cancer;"},{"name":"Accepted_Therapeutic_Use_For","value":"Lymphoma, Hodgkins, Non-Hodgkins; Malignant thymoma; Multiple myeloma; Osteogenic sarcoma; Ovarian cancer; Pheochromocytoma; Retinoblastoma; Rhabdomyosarcoma; Soft tissue sarcoma; Testicular cancer; Wilms tumor"},{"name":"CAS_Registry","value":"57-22-7"},{"name":"CHEBI_ID","value":"CHEBI:28445"},{"name":"Chemical_Formula","value":"C46H56N4O10"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"5J49Q6B70F"},{"name":"Legacy Concept Name","value":"Vincristine"},{"name":"Maps_To","value":"Vincristine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042679"}]}}{"C2104":{"preferredName":"Vincristine Liposomal","code":"C2104","definitions":[{"definition":"A liposomal formulation of Vincristine designed to reduce toxicity and improve efficacy.  Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vincristine Liposomal","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid-Encapsulated Vincristine","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Vincristine","termGroup":"SY","termSource":"NCI"},{"termName":"Onco TCS","termGroup":"BR","termSource":"NCI"},{"termName":"Vincacine","termGroup":"SY","termSource":"NCI"},{"termName":"VincaXome","termGroup":"BR","termSource":"NCI"},{"termName":"Vincristine Liposome","termGroup":"SY","termSource":"NCI"},{"termName":"Vincristine, Liposomal","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Legacy Concept Name","value":"Vincristine_Liposomal"},{"name":"Maps_To","value":"Vincristine Liposomal"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1519991"}]}}{"C1739":{"preferredName":"Vincristine Sulfate","code":"C1739","definitions":[{"definition":"A drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Oncovin is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vincristine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"Kyocristine","termGroup":"FB","termSource":"NCI"},{"termName":"Leurocristine Sulfate","termGroup":"SY","termSource":"NCI"},{"termName":"Oncovin","termGroup":"BR","termSource":"NCI"},{"termName":"Vincasar","termGroup":"FB","termSource":"NCI"},{"termName":"Vincasar PFS","termGroup":"AQS","termSource":"NCI"},{"termName":"Vincosid","termGroup":"BR","termSource":"NCI"},{"termName":"Vincrex","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Neuroblastoma"},{"name":"CAS_Registry","value":"2068-78-2"},{"name":"Chemical_Formula","value":"C46H56N4O10.H2O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T5IRO3534A"},{"name":"Legacy Concept Name","value":"Vincristine_Sulfate"},{"name":"Maps_To","value":"Vincristine Sulfate"},{"name":"NCI_Drug_Dictionary_ID","value":"42251"},{"name":"NSC Number","value":"67574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42251"},{"name":"PDQ_Open_Trial_Search_ID","value":"42251"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042680"}]}}{"C2702":{"preferredName":"Vincristine Sulfate Liposome","code":"C2702","definitions":[{"definition":"A sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid isolated from the plant Vinca rosea, irreversibly binds to and stabilizes tubulin, thereby interrupting microtubule assembly/disassembly dynamics, thereby preventing the formation of the mitotic spindle and leading to cell cycle arrest in metaphase. Liposomal encapsulation prolongs bioavailability of vincristine, increases its delivery to tumor tissues and reduces its toxicity profile. Compared to standard liposomal delivery, sphingosomal drug delivery further increases circulation time of serum drug and enhances drug accumulation at tumor sites, thereby leading to a further increase in efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vincristine Sulfate Liposome","termGroup":"PT","termSource":"NCI"},{"termName":"Marqibo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"acute lymphoblastic leukemia (ALL)"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vincristine_Sulfate_Liposomes"},{"name":"Maps_To","value":"Vincristine Sulfate Liposome"},{"name":"NCI_Drug_Dictionary_ID","value":"38100"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38100"},{"name":"PDQ_Open_Trial_Search_ID","value":"38100"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935690"}]}}{"C934":{"preferredName":"Vindesine","code":"C934","definitions":[{"definition":"A synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of plant drugs called vinca alkaloids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vindesine","termGroup":"PT","termSource":"NCI"},{"termName":"3-(Aminocarbonyl)-O4-deacetyl-3-de-(methoxycarbonyl)vincaleukoblastine","termGroup":"SN","termSource":"NCI"},{"termName":"Compound 112531","termGroup":"SY","termSource":"NCI"},{"termName":"DAVA","termGroup":"AB","termSource":"NCI"},{"termName":"Deacetyl Vinblastine Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Deacetylvinblastine Carboxamide","termGroup":"SY","termSource":"NCI"},{"termName":"Desacetylvinblastine Amide","termGroup":"SY","termSource":"NCI"},{"termName":"DVA","termGroup":"AB","termSource":"NCI"},{"termName":"Lilly CT-3231","termGroup":"CN","termSource":"NCI"},{"termName":"VDS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"53643-48-4"},{"name":"CHEBI_ID","value":"CHEBI:36373"},{"name":"Chemical_Formula","value":"C43H55N5O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"RSA8KO39WH"},{"name":"Legacy Concept Name","value":"Vindesine"},{"name":"Maps_To","value":"Vindesine"},{"name":"NCI_Drug_Dictionary_ID","value":"39732"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39732"},{"name":"PDQ_Open_Trial_Search_ID","value":"39732"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0042682"}]}}{"C1274":{"preferredName":"Vinepidine","code":"C1274","definitions":[{"definition":"A vinca alkaloid compound and semi-synthetic vincristine derivative with antineoplastic activity. Vinepidine binds to and stabilizes tubulin, thereby preventing tubulin polymerization and depolymerization, which result in microtubule assembly and disassembly, respectively. Treated cells are unable to complete mitosis process and are arrested in the metaphase, thereby leading to an inhibition of cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinepidine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxyepivincristine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"68170-69-4"},{"name":"Chemical_Formula","value":"C46H56N4O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W3375J6V0Y"},{"name":"Legacy Concept Name","value":"Vinepidine"},{"name":"Maps_To","value":"Vinepidine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0078255"}]}}{"C61564":{"preferredName":"Vinflunine","code":"C61564","definitions":[{"definition":"A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of bladder cancer, lung cancer, and other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vinflunine","termGroup":"PT","termSource":"NCI"},{"termName":"4'-Deoxy-20',20'-difluoro-C'-norvincaleukoblastine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"162652-95-1"},{"name":"Chemical_Formula","value":"C45H54F2N4O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"5BF646324K"},{"name":"Legacy Concept Name","value":"Vinflunine"},{"name":"Maps_To","value":"Vinflunine"},{"name":"NCI_Drug_Dictionary_ID","value":"419548"},{"name":"PDQ_Closed_Trial_Search_ID","value":"419548"},{"name":"PDQ_Open_Trial_Search_ID","value":"419548"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0672663"}]}}{"C76266":{"preferredName":"Vinflunine Ditartrate","code":"C76266","definitions":[{"definition":"A substance being studied in the treatment of bladder cancer, lung cancer, and other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The ditartrate salt of vinflunine, a bi-fluorinated derivative of the semisynthetic vinca alkaloid vinorelbine with potential antimitotic and antineoplastic activities. Vinflunine binds to tubulin and inhibits tubulin assembly and disrupts microtubule assembly dynamics. This results in cell cycle arrest in mitosis and an induction of apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinflunine Ditartrate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"194468-36-5"},{"name":"Chemical_Formula","value":"C45H54F2N4O8.2C4H6O6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"33MG53C7XW"},{"name":"Legacy Concept Name","value":"Vinflunine_Ditartrate"},{"name":"Maps_To","value":"Vinflunine Ditartrate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2700251"}]}}{"C2378":{"preferredName":"Vinfosiltine","code":"C2378","definitions":[{"definition":"An aminophosphonate derivative of a vinca alkaloid with potential antineoplastic activity. Vinfosiltine exerts its antineoplastic action just like its parent compound, vinblastine, by immobilizing tubulin molecules, thereby interrupting microtubule assembly/disassembly dynamics. As a result, vinfosiltine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinfosiltine","termGroup":"PT","termSource":"NCI"},{"termName":"S12363","termGroup":"CN","termSource":"NCI"},{"termName":"Vincaleukoblastine, O4-Deacetyl-3-de(methoxycarbonyl)-3-(((1-(diethoxyphosphinyl)-2-methylpropyl)amin)carbonyl)-,(3(S))-,Sulfate(Salt)","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123286-00-0"},{"name":"Chemical_Formula","value":"C51H72N5O10P"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AW1UYE6Q9I"},{"name":"Legacy Concept Name","value":"Vinfosiltine"},{"name":"Maps_To","value":"Vinfosiltine"},{"name":"NCI_Drug_Dictionary_ID","value":"41716"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41716"},{"name":"PDQ_Open_Trial_Search_ID","value":"41716"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084429"}]}}{"C1275":{"preferredName":"Vinorelbine","code":"C1275","definitions":[{"definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","type":"DEFINITION","source":"NCI"},{"definition":"An anticancer drug that belongs to the family of plant drugs called vinca alkaloids.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vinorelbine","termGroup":"PT","termSource":"NCI"},{"termName":"3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine","termGroup":"SN","termSource":"NCI"},{"termName":"5'-Nor-Anhydrovinblastine","termGroup":"SN","termSource":"NCI"},{"termName":"Dihydroxydeoxynorvinkaleukoblastine","termGroup":"SY","termSource":"NCI"},{"termName":"nor-5'-Anhydrovinblastine","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Breast cancer; Cervical cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer"},{"name":"CAS_Registry","value":"71486-22-1"},{"name":"CHEBI_ID","value":"CHEBI:480999"},{"name":"Chemical_Formula","value":"C45H54N4O8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"Q6C979R91Y"},{"name":"Legacy Concept Name","value":"Vinorelbine"},{"name":"Maps_To","value":"Vinorelbine"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0078257"}]}}{"C1395":{"preferredName":"Vinorelbine Tartrate","code":"C1395","definitions":[{"definition":"A drug used to treat advanced non-small cell lung cancer. It blocks cell growth by stopping cell division and may cause cancer cells to die. It is a type of vinca alkaloid and a type of antimitotic agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinorelbine Tartrate","termGroup":"PT","termSource":"NCI"},{"termName":"Biovelbin","termGroup":"FB","termSource":"NCI"},{"termName":"Eunades","termGroup":"FB","termSource":"NCI"},{"termName":"KW 2307","termGroup":"CN","termSource":"NCI"},{"termName":"KW-2307","termGroup":"CN","termSource":"NCI"},{"termName":"KW2307","termGroup":"CN","termSource":"NCI"},{"termName":"Navelbine","termGroup":"FB","termSource":"NCI"},{"termName":"Navelbine Ditartrate","termGroup":"SY","termSource":"NCI"},{"termName":"NVB","termGroup":"AB","termSource":"NCI"},{"termName":"Vinorelbine Ditartrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-small cell lung cancer; metastatic breast cancer; uterine and cervical cancer; desmoid tumors; advanced Kaposi's sarcoma"},{"name":"CAS_Registry","value":"125317-39-7"},{"name":"CHEBI_ID","value":"CHEBI:32296"},{"name":"Chemical_Formula","value":"C45H54N4O8.2C4H6O6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"253GQW851Q"},{"name":"Legacy Concept Name","value":"Vinorelbine_Ditartrate"},{"name":"Maps_To","value":"Vinorelbine Tartrate"},{"name":"NCI_Drug_Dictionary_ID","value":"40449"},{"name":"NSC Number","value":"608210"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40449"},{"name":"PDQ_Open_Trial_Search_ID","value":"40449"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0377401"}]}}{"C66943":{"preferredName":"Vinorelbine Tartrate Emulsion","code":"C66943","definitions":[{"definition":"An emulsion containing the tartrate salt of the semisynthetic vinca alkaloid vinorelbine with antineoplastic activity. Vinorelbine binds to tubulin, inhibiting tubulin polymerization into microtubules; cell division is prevented, the cell cycle is arrested metaphase and cell death ensues. In this formulation vinorelbine is emulsified in a homogeneous suspension of nanoparticles, which protects the venous endothelium from coming into direct contact with the active ingredient, potentially reducing vinorelbine-associated venous toxicity at the venous injection site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinorelbine Tartrate Emulsion","termGroup":"PT","termSource":"NCI"},{"termName":"ANX-530","termGroup":"CN","termSource":"NCI"},{"termName":"Vinorelbine Tartrate Injectable Emulsion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vinorelbine_Tartrate_Emulsion"},{"name":"Maps_To","value":"Vinorelbine Tartrate Emulsion"},{"name":"NCI_Drug_Dictionary_ID","value":"538399"},{"name":"PDQ_Closed_Trial_Search_ID","value":"538399"},{"name":"PDQ_Open_Trial_Search_ID","value":"538399"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1883539"}]}}{"C85457":{"preferredName":"Vinorelbine Tartrate Oral","code":"C85457","definitions":[{"definition":"An orally bioavailable tartrate salt of vinorelbine, a semisynthetic vinca alkaloid with potential antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinorelbine Tartrate Oral","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vinorelbine Tartrate Oral"},{"name":"NCI_Drug_Dictionary_ID","value":"642976"},{"name":"NCI_META_CUI","value":"CL412328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"642976"},{"name":"PDQ_Open_Trial_Search_ID","value":"642976"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C62525":{"preferredName":"Vintafolide","code":"C62525","definitions":[{"definition":"A water-soluble, folate-receptor-targeted conjugate of folate and the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) with potential antineoplastic activity. The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis. Folic acid receptors are frequently upregulated on the surfaces of many tumor cell types. DAVLBH is a derivative of the natural product vinblastine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vintafolide","termGroup":"PT","termSource":"NCI"},{"termName":"EC145","termGroup":"CN","termSource":"NCI"},{"termName":"Folate-Vinca Alkaloid Conjugate EC145","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"742092-03-1"},{"name":"Chemical_Formula","value":"C86H109N21O26S2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"36O410ZD4I"},{"name":"Legacy Concept Name","value":"EC145"},{"name":"Maps_To","value":"Vintafolide"},{"name":"NCI_Drug_Dictionary_ID","value":"488470"},{"name":"PDQ_Closed_Trial_Search_ID","value":"488470"},{"name":"PDQ_Open_Trial_Search_ID","value":"488470"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831870"}]}}{"C1276":{"preferredName":"Vinzolidine","code":"C1276","definitions":[{"definition":"An orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinzolidine","termGroup":"PT","termSource":"NCI"},{"termName":"2H-3,7-Methanoazacycloundecino(5,4-b)indole-9-carboxylic acid, 9-((2-beta,3-beta,4-beta,5-alpha,12-beta,19-alpha)-4-(acetyloxy)-3'-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2',4'-dioxospiro(aspidospermidine-3,5'-oxazolidin)-15-yl)-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3R-(3R*,5S*,7R*,9S*))-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67699-40-5"},{"name":"Chemical_Formula","value":"C48H58ClN5O9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"533U947V6Q"},{"name":"Legacy Concept Name","value":"Vinzolidine"},{"name":"Maps_To","value":"Vinzolidine"},{"name":"NCI_Drug_Dictionary_ID","value":"39733"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39733"},{"name":"PDQ_Open_Trial_Search_ID","value":"39733"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0078282"}]}}{"C87288":{"preferredName":"Vinzolidine Sulfate","code":"C87288","definitions":[{"definition":"The sulfate salt of vinzolidine, an orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vinzolidine Sulfate","termGroup":"PT","termSource":"NCI"},{"termName":"2h-3,7-Methanoazacycloundecino(5,4-Beta)Indole-9-Carboxylic Acid, 9-((2Beta,3Beta,4Beta,5Alpha,12Beta,19Alpha)-4-(Acetyloxy)-3'-(2-Chloroethyl)-6,7-Didehydro-16-Methoxy-1-Methyl-2',4'-Dioxospiro(Aspidospermidine-3,5'-Oxazolidin)-15-Yl)-5-Ethy","termGroup":"SN","termSource":"NCI"},{"termName":"LY104208","termGroup":"CN","termSource":"NCI"},{"termName":"Methyl (3R,5S,7R,9S)-9-[3'-(2-Chloroethyl)-6,7-Didehydro-4Beta-Hydroxy-16-Methoxy-1-Methyl-2',4'-Dioxo-2Beta,3Beta,5Alpha,12Beta,19Alpha-Spiro(Aspidospermidine-3,5'-Oxazolidin]-15-yl)-5-Ethyl-1,4,5,6,7,8,9,10-Octahydro-5-Hydroxy-2H-3,7-Methano","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"67699-41-6"},{"name":"Chemical_Formula","value":"C48H58ClN5O9.H2O4S"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"78NZ2PMP25"},{"name":"Maps_To","value":"Vinzolidine Sulfate"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2828244"}]}}{"C26677":{"preferredName":"Virulizin","code":"C26677","definitions":[{"definition":"A natural biological response modifier (BRM) isolated from bovine reticuloendothelial tissue. Viruzlin may enhance cell-mediated immune response to tumor cells by direct macrophage activation. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A substance that activates some types of immune system cells, and is being studied as a treatment for cancer. It belongs to the family of drugs called biological therapy agents.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Virulizin","termGroup":"PT","termSource":"NCI"},{"termName":"Bos Taurus Bile Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Bos Taurus Bile Immunomodulator","termGroup":"SY","termSource":"NCI"},{"termName":"Bovine Bile Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Bovine Bile Immunomodulator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"216586-46-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E5SF1Z7U1S"},{"name":"Legacy Concept Name","value":"Virulizin"},{"name":"Maps_To","value":"Virulizin"},{"name":"NCI_Drug_Dictionary_ID","value":"257159"},{"name":"PDQ_Closed_Trial_Search_ID","value":"257159"},{"name":"PDQ_Open_Trial_Search_ID","value":"257159"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0254455"}]}}{"C74038":{"preferredName":"Vismodegib","code":"C74038","definitions":[{"definition":"A substance being studied in the treatment of cancer. It blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells. It is a type of Hedgehog signaling pathway antagonist.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vismodegib","termGroup":"PT","termSource":"NCI"},{"termName":"2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide","termGroup":"SN","termSource":"NCI"},{"termName":"Erivedge","termGroup":"BR","termSource":"NCI"},{"termName":"GDC 0449","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-0449","termGroup":"CN","termSource":"NCI"},{"termName":"GDC0449","termGroup":"CN","termSource":"NCI"},{"termName":"Hedgehog Antagonist GDC-0449","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"basal cell carcinoma"},{"name":"CAS_Registry","value":"879085-55-9"},{"name":"Chemical_Formula","value":"C19H14Cl2N2O3S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"25X868M3DS"},{"name":"Legacy Concept Name","value":"Hedgehog_Antagonist_GDC-0449"},{"name":"Maps_To","value":"Vismodegib"},{"name":"NCI_Drug_Dictionary_ID","value":"586417"},{"name":"PDQ_Closed_Trial_Search_ID","value":"586417"},{"name":"PDQ_Open_Trial_Search_ID","value":"586417"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348949"}]}}{"C88329":{"preferredName":"Vistusertib","code":"C88329","definitions":[{"definition":"An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vistusertib","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 2014","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-2014","termGroup":"CN","termSource":"NCI"},{"termName":"AZD2014","termGroup":"CN","termSource":"NCI"},{"termName":"Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1009298-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0BSC3P4H5X"},{"name":"Maps_To","value":"Vistusertib"},{"name":"NCI_Drug_Dictionary_ID","value":"662098"},{"name":"PDQ_Closed_Trial_Search_ID","value":"662098"},{"name":"PDQ_Open_Trial_Search_ID","value":"662098"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2981846"}]}}{"C1883":{"preferredName":"Vitamin D3 Analogue ILX23-7553","code":"C1883","definitions":[{"definition":"A substance that is being studied as an anticancer drug.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A vitamin D3 analogue with potential antineoplastic activity.  ILX23-7553 binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, ILX23-7553 may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vitamin D3 Analogue ILX23-7553","termGroup":"PT","termSource":"NCI"},{"termName":"1,25-dihydroxy-16-ene-23-yne-cholecalciferol","termGroup":"SN","termSource":"NCI"},{"termName":"16-23-D3","termGroup":"SY","termSource":"NCI"},{"termName":"9,10-Secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol, (1alpha,3beta,5Z,7E)-","termGroup":"SN","termSource":"NCI"},{"termName":"BXL 353","termGroup":"CN","termSource":"NCI"},{"termName":"ILEX 23-7553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX 237553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX-237553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX23-7553","termGroup":"CN","termSource":"NCI"},{"termName":"ILX237553","termGroup":"CN","termSource":"NCI"},{"termName":"RO 237553","termGroup":"CN","termSource":"NCI"},{"termName":"RO-237553","termGroup":"CN","termSource":"NCI"},{"termName":"Ro23-7553","termGroup":"CN","termSource":"NCI"},{"termName":"RO237553","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"118694-43-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O13QTC8612"},{"name":"Legacy Concept Name","value":"ILX23-7553"},{"name":"Maps_To","value":"Vitamin D3 Analogue ILX23-7553"},{"name":"NCI_Drug_Dictionary_ID","value":"37861"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37861"},{"name":"PDQ_Open_Trial_Search_ID","value":"37861"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0966846"}]}}{"C942":{"preferredName":"Vitamin E Compound","code":"C942","definitions":[{"definition":"A fat-soluble vitamin which is primarily a chain-breaking antioxidant that prevents the propagation of lipid peroxidation.","type":"ALT_DEFINITION","source":"CRCH"},{"definition":"A natural fat-soluble antioxidant with potential chemopreventive activity. Also known as tocopherol, vitamin E ameliorates free-radical damage to biological membranes, protecting polyunsaturated fatty acids (PUFA) within membrane phospholipids and within circulating lipoproteins. Peroxyl radicals react 1000-fold faster with vitamin E than with PUFA.  In the case of oxygen free radical-mediated tumorigenesis, vitamin E may be chemopreventive. (NCI04)","type":"DEFINITION","source":"NCI"},{"definition":"A nutrient that the body needs in small amounts to function and stay healthy. Vitamin E helps prevent cell damage caused by free radicals (highly reactive chemicals). It is fat-soluble (can dissolve in fats and oils) and is found in seeds, nuts, leafy vegetables, and vegetable oils. Not enough vitamin E can result in infertility (the inability to produce children). It is being studied in the prevention and treatment of some types of cancer. Vitamin E is a type of antioxidant.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Vitamin E Compound","termGroup":"PT","termSource":"NCI"},{"termName":"3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol","termGroup":"SN","termSource":"NCI"},{"termName":"5,7,8-Trimethyltocol","termGroup":"SN","termSource":"NCI"},{"termName":"E Vitamin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Vitamin E deficiency"},{"name":"CAS_Registry","value":"1406-18-4"},{"name":"CHEBI_ID","value":"CHEBI:33234"},{"name":"Contributing_Source","value":"CRCH"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Vitamin_E"},{"name":"Maps_To","value":"Vitamin E Compound"},{"name":"Micronutrient","value":"Y"},{"name":"NCI_Drug_Dictionary_ID","value":"38321"},{"name":"Nutrient","value":"Y"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38321"},{"name":"PDQ_Open_Trial_Search_ID","value":"38321"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Vitamin"},{"name":"Tolerable_Level","value":"Y"},{"name":"UMLS_CUI","value":"C0042874"},{"name":"Unit","value":"mg"},{"name":"US_Recommended_Intake","value":"Y"}]}}{"C2432":{"preferredName":"Vitespen","code":"C2432","definitions":[{"definition":"A vaccine made from a patient's tumor cells that may help the body's immune system kill cancer cells. This vaccine is used to treat kidney cancer, a type of brain cancer called glioma, and metastatic melanoma (a type of skin cancer that has spread). It is also being studied in the treatment of other types of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An autologous cancer vaccine derived from tumor-specific gp96 heat shock proteins.  Heat shock proteins chaperone peptides through the endoplasmic reticulum, are key regulators of dendritic cell maturation, migration and antigen processing, and are involved in T-cell activation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vitespen","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous gp96 Heat Shock Protein Peptide Complex Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"gp96 Heat Shock Protein-Peptide Complex","termGroup":"SY","termSource":"NCI"},{"termName":"gp96 HSP-Peptide Complex","termGroup":"SY","termSource":"NCI"},{"termName":"Heat Shock Protein Peptide Complex-96","termGroup":"SY","termSource":"NCI"},{"termName":"HSP gp96-Peptide Complex","termGroup":"SY","termSource":"NCI"},{"termName":"HSPPC-96","termGroup":"CN","termSource":"NCI"},{"termName":"Oncophage","termGroup":"BR","termSource":"NCI"},{"termName":"Recombinant Human Tumor Rejection Antigen 1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"492448-75-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H3598Y1TLJ"},{"name":"Legacy Concept Name","value":"Autologous_gp96_Heat_Shock_Protein_Peptide_Complex_Vaccine"},{"name":"Maps_To","value":"Vitespen"},{"name":"NCI_Drug_Dictionary_ID","value":"42682"},{"name":"NSC Number","value":"725085"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42682"},{"name":"PDQ_Open_Trial_Search_ID","value":"42682"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935952"}]}}{"C175875":{"preferredName":"Vidutolimod","code":"C175875","definitions":[{"definition":"A virus-like particle (VLP) composed of the Qbeta bacteriophage capsid encapsulating the toll-like receptor 9 (TLR9) agonist G10, an unmethylated CpG-A oligodeoxynucleotide (ODN), with potential immunostimulating and antineoplastic activities. Upon administration of vidutolimod, the VLPs are specifically taken up by and release the oligonucleotide into antigen-presenting cells (APCs), including dendritic cells (DCs). In turn, the oligonucleotide binds to and activates intracellular TLR9. This stimulates immune signaling pathways, induces the innate immune system and may promote the immune system to attack tumor cells. VLPs stimulate the immune system. TLR9, a member of the TLR family, plays a key role in both pathogen recognition and the activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vidutolimod","termGroup":"PT","termSource":"NCI"},{"termName":"ARB-1598","termGroup":"CN","termSource":"NCI"},{"termName":"CMP-001","termGroup":"CN","termSource":"NCI"},{"termName":"CYT 003","termGroup":"CN","termSource":"NCI"},{"termName":"CYT-003","termGroup":"CN","termSource":"NCI"},{"termName":"QbG10","termGroup":"CN","termSource":"NCI"},{"termName":"VLP-encapsulated TLR9 Agonist CMP-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"147063-80-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D68OW5RS98"},{"name":"Maps_To","value":"VLP-encapsulated TLR9 Agonist CMP-001"},{"name":"NCI_Drug_Dictionary_ID","value":"779977"},{"name":"NCI_META_CUI","value":"CL1413087"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C91734":{"preferredName":"Vocimagene Amiretrorepvec","code":"C91734","definitions":[{"definition":"A replication competent retroviral vector, derived from the Moloney murine leukemia virus (MoMLV), encoding a modified form of the yeast suicide gene cytosine deaminase (CD) (Toca 511) used as an antineoplastic adjuvant. Upon transcranial injection, vocimagene amiretrorepvec preferentially enters and transfects tumor cells, and expresses cytosine deaminase, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vocimagene Amiretrorepvec","termGroup":"PT","termSource":"NCI"},{"termName":"DNA (Synthetic Toca 511-encoding Retroviral Vector AC3-yCD2(V))","termGroup":"SY","termSource":"NCI"},{"termName":"Toca 511","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1300724-82-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DC4WO3WA4Q"},{"name":"Maps_To","value":"Vocimagene Amiretrorepvec"},{"name":"NCI_Drug_Dictionary_ID","value":"681586"},{"name":"NCI_META_CUI","value":"CL421655"},{"name":"PDQ_Closed_Trial_Search_ID","value":"681586"},{"name":"PDQ_Open_Trial_Search_ID","value":"681586"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C116863":{"preferredName":"Vofatamab","code":"C116863","definitions":[{"definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3), with potential antineoplastic activity. Upon intravenous administration, vofatamab specifically binds to and inhibits both wild-type and mutated forms of FGFR3. This may result in the inhibition of FGFR3 phosphorylation, and thereby preventing its activation and FGFR3-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vofatamab","termGroup":"PT","termSource":"NCI"},{"termName":"B-701","termGroup":"CN","termSource":"NCI"},{"termName":"MFGR-1877S","termGroup":"CN","termSource":"NCI"},{"termName":"MFGR1877A","termGroup":"CN","termSource":"NCI"},{"termName":"MFGR1877S","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7444","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1312305-12-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JMH6YR91PG"},{"name":"Maps_To","value":"Vofatamab"},{"name":"NCI_Drug_Dictionary_ID","value":"673995"},{"name":"NCI_META_CUI","value":"CL421586"},{"name":"PDQ_Closed_Trial_Search_ID","value":"673995"},{"name":"PDQ_Open_Trial_Search_ID","value":"673995"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C79844":{"preferredName":"Volasertib","code":"C79844","definitions":[{"definition":"A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Volasertib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-(Trans-4-(4-(Cyclopropylmethyl)-1-Piperazinyl)Cyclohexyl)-4-(((7r)-7-Ethyl-5,6,7,8-Tetrahydro-5-Methyl-8-(1-Methylethyl)-6-Oxo-2-Pteridinyl)Amino)-3-Methoxy-","termGroup":"SN","termSource":"NCI"},{"termName":"BI 6727","termGroup":"CN","termSource":"NCI"},{"termName":"BI-6727","termGroup":"CN","termSource":"NCI"},{"termName":"BI6727","termGroup":"CN","termSource":"NCI"},{"termName":"Polo-like Kinase 1 Inhibitor BI 6727","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"755038-65-4"},{"name":"Chemical_Formula","value":"C34H50N8O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"6EM57086EA"},{"name":"Legacy Concept Name","value":"Polo-like_Kinase_1_Inhibitor_BI_6727"},{"name":"Maps_To","value":"Volasertib"},{"name":"NCI_Drug_Dictionary_ID","value":"630756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"630756"},{"name":"PDQ_Open_Trial_Search_ID","value":"630756"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2703181"}]}}{"C48426":{"preferredName":"Volociximab","code":"C48426","definitions":[{"definition":"A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI05)","type":"DEFINITION","source":"NCI"},{"definition":"A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Volociximab binds to a protein that is found on cells that line some tumor blood vessels. It is a type of angiogenesis inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Volociximab","termGroup":"PT","termSource":"NCI"},{"termName":"anti-a5-beta1 Integrin","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-alpha5-beta1 Integrin","termGroup":"SY","termSource":"NCI"},{"termName":"M200","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"558480-40-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"496K5Z02NW"},{"name":"Legacy Concept Name","value":"Volociximab"},{"name":"Maps_To","value":"Volociximab"},{"name":"NCI_Drug_Dictionary_ID","value":"415313"},{"name":"PDQ_Closed_Trial_Search_ID","value":"415313"},{"name":"PDQ_Open_Trial_Search_ID","value":"415313"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541160"}]}}{"C121376":{"preferredName":"Vonlerolizumab","code":"C121376","definitions":[{"definition":"An agonistic humanized monoclonal antibody against the receptor, OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, vonlerolizumab selectively binds to and activates OX40, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 activation induces proliferation of effector T-lymphocytes and inhibits the activity of regulatory T-cells. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vonlerolizumab","termGroup":"PT","termSource":"NCI"},{"termName":"MOXR0916","termGroup":"CN","termSource":"NCI"},{"termName":"Pogalizumab","termGroup":"SY","termSource":"NCI"},{"termName":"RG 7888","termGroup":"CN","termSource":"NCI"},{"termName":"RG-7888","termGroup":"CN","termSource":"NCI"},{"termName":"RG7888","termGroup":"CN","termSource":"NCI"},{"termName":"RO7021608","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1638935-72-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C78148TF1D"},{"name":"Maps_To","value":"Vonlerolizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"792458"},{"name":"NCI_META_CUI","value":"CL474130"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792458"},{"name":"PDQ_Open_Trial_Search_ID","value":"792458"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129876":{"preferredName":"Vopratelimab","code":"C129876","definitions":[{"definition":"An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, anti-ICOS agonist monoclonal antibody JTX-2011 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vopratelimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ICOS Agonist MAb JTX-2011","termGroup":"SY","termSource":"NCI"},{"termName":"ICOS Agonist Monoclonal Antibody JTX-2011","termGroup":"SY","termSource":"NCI"},{"termName":"JTX-2011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2039148-04-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QXN20J93AH"},{"name":"Maps_To","value":"Vopratelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"784959"},{"name":"NCI_META_CUI","value":"CL512902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"784959"},{"name":"PDQ_Open_Trial_Search_ID","value":"784959"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1796":{"preferredName":"Vorinostat","code":"C1796","definitions":[{"definition":"A drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Vorinostat is a type of histone deacetylase inhibitor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorinostat","termGroup":"PT","termSource":"NCI"},{"termName":"L-001079038","termGroup":"CN","termSource":"NCI"},{"termName":"MSK-390","termGroup":"CN","termSource":"NCI"},{"termName":"N-Hydroxy-N'-phenyloctanediamide","termGroup":"SN","termSource":"NCI"},{"termName":"SAHA","termGroup":"AB","termSource":"NCI"},{"termName":"Suberanilohydroxamic Acid","termGroup":"CN","termSource":"NCI"},{"termName":"Suberoylanilide Hydroxamic Acid","termGroup":"CN","termSource":"NCI"},{"termName":"Zolinza","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Cutaneous T-cell Lymphoma"},{"name":"CAS_Registry","value":"149647-78-9"},{"name":"Chemical_Formula","value":"C14H20N2O3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"58IFB293JI"},{"name":"Legacy Concept Name","value":"Suberoylanilide_Hydroxamic_Acid"},{"name":"Maps_To","value":"Vorinostat"},{"name":"NCI_Drug_Dictionary_ID","value":"37944"},{"name":"NSC Number","value":"701852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"37944"},{"name":"PDQ_Open_Trial_Search_ID","value":"37944"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0672708"}]}}{"C95896":{"preferredName":"Vorolanib","code":"C95896","definitions":[{"definition":"An orally available small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with antiangiogenic and antineoplastic activities. Vorolanib inhibits all isoforms of VEGFR and PDGFR, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and PDGFRs are receptor tyrosine kinases that may be upregulated in various tumor cell types. Vorolanib has been shown to reduce tissue toxicity by 95 percent compared with first-generation kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorolanib","termGroup":"PT","termSource":"NCI"},{"termName":"(S,Z)-N-(1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"CM 082","termGroup":"CN","termSource":"NCI"},{"termName":"CM-082","termGroup":"CN","termSource":"NCI"},{"termName":"CM082","termGroup":"CN","termSource":"NCI"},{"termName":"X 82","termGroup":"CN","termSource":"NCI"},{"termName":"X-82","termGroup":"CN","termSource":"NCI"},{"termName":"X82","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1013920-15-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"YP8G3I74EL"},{"name":"Maps_To","value":"Vorolanib"},{"name":"NCI_Drug_Dictionary_ID","value":"695817"},{"name":"NCI_META_CUI","value":"CL428293"},{"name":"PDQ_Closed_Trial_Search_ID","value":"695817"},{"name":"PDQ_Open_Trial_Search_ID","value":"695817"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C88315":{"preferredName":"Vorsetzumab Mafodotin","code":"C88315","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to the auristatin analogue monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. The anti-CD70 antibody moiety of vorsetuzumab mafodotin selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the MMAF moiety is released, binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest, tumor cell apoptosis and inhibition of cellular proliferation in tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vorsetzumab Mafodotin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD70 MoAb SGN70-MMAF Conjugate","termGroup":"SY","termSource":"NCI"},{"termName":"SGN 75","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-75","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1165741-01-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"699619YVTQ"},{"name":"Maps_To","value":"Vorsetzumab Mafodotin"},{"name":"NCI_Drug_Dictionary_ID","value":"660730"},{"name":"NCI_META_CUI","value":"CL413570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"660730"},{"name":"PDQ_Open_Trial_Search_ID","value":"660730"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95148":{"preferredName":"Vosaroxin","code":"C95148","definitions":[{"definition":"A small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result, inhibition of DNA replication, RNA and protein synthesis occurs, followed by cell cycle arrest at G2 phase and induced p53-independent apoptosis. This agent shows a favorable toxicity profile in several aspects: it does not generate reactive oxygen species, as do anthracyclines, hence reducing the risk of cardiotoxicity; it is not a P-glycoprotein (P-gp) substrate, and thereby evades the common mechanism for multidrug resistance; and it has limited distribution to normal tissues and a more chemically stable molecular structure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vosaroxin","termGroup":"PT","termSource":"NCI"},{"termName":"1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid","termGroup":"SN","termSource":"NCI"},{"termName":"AG-7352","termGroup":"CN","termSource":"NCI"},{"termName":"SNS 595","termGroup":"CN","termSource":"NCI"},{"termName":"SNS-595","termGroup":"CN","termSource":"NCI"},{"termName":"SNS595","termGroup":"CN","termSource":"NCI"},{"termName":"SPC 595","termGroup":"CN","termSource":"NCI"},{"termName":"Voreloxin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"175414-77-4"},{"name":"Chemical_Formula","value":"C18H19N5O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"K6A90IIZ19"},{"name":"Maps_To","value":"Vosaroxin"},{"name":"NCI_Drug_Dictionary_ID","value":"393833"},{"name":"PDQ_Closed_Trial_Search_ID","value":"393833"},{"name":"PDQ_Open_Trial_Search_ID","value":"393833"},{"name":"PubMedID_Primary_Reference","value":"20233886"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1451341"}]}}{"C71704":{"preferredName":"Voxtalisib","code":"C71704","definitions":[{"definition":"An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Voxtalisib","termGroup":"PT","termSource":"NCI"},{"termName":"SAR-245409","termGroup":"CN","termSource":"NCI"},{"termName":"SAR245409","termGroup":"CN","termSource":"NCI"},{"termName":"XL-765","termGroup":"CN","termSource":"NCI"},{"termName":"XL765","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"934493-76-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CVL1685GPH"},{"name":"Legacy Concept Name","value":"Dual_Kinase_Inhibitor_XL765"},{"name":"Maps_To","value":"Voxtalisib"},{"name":"NCI_Drug_Dictionary_ID","value":"558907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"558907"},{"name":"PDQ_Open_Trial_Search_ID","value":"558907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348352"}]}}{"C1658":{"preferredName":"Warfarin Sodium","code":"C1658","definitions":[{"definition":"The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins.  As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Warfarin Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"Coumadin","termGroup":"BR","termSource":"NCI"},{"termName":"Marevan","termGroup":"FB","termSource":"NCI"},{"termName":"Panwarfin","termGroup":"BR","termSource":"NCI"},{"termName":"Prothromadin","termGroup":"SY","termSource":"NCI"},{"termName":"Tintorane","termGroup":"SY","termSource":"NCI"},{"termName":"Waran","termGroup":"FB","termSource":"NCI"},{"termName":"Warfilone","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"129-06-6"},{"name":"CHEBI_ID","value":"CHEBI:10034"},{"name":"Chemical_Formula","value":"C19H15O4.Na"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6153CWM0CL"},{"name":"Legacy Concept Name","value":"Warfarin_Sodium"},{"name":"Maps_To","value":"Warfarin Sodium"},{"name":"NCI_Drug_Dictionary_ID","value":"39740"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39740"},{"name":"PDQ_Open_Trial_Search_ID","value":"39740"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0376218"}]}}{"C126649":{"preferredName":"White Carrot","code":"C126649","definitions":[{"definition":"A vegetable, also known as Arracacha, with potential chemoprevenitve, anti-oxidant and protective activities. White carrot contains a variety of nutrients, including minerals and vitamins. Polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate are mainly responsible for its potential anti-cancer activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"White Carrot","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"White Carrot"},{"name":"NCI_Drug_Dictionary_ID","value":"779793"},{"name":"NCI_META_CUI","value":"CL503765"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779793"},{"name":"PDQ_Open_Trial_Search_ID","value":"779793"},{"name":"Semantic_Type","value":"Food"}]}}{"C122693":{"preferredName":"Wnt Signaling Inhibitor SM04755","code":"C122693","definitions":[{"definition":"An orally bioavailable small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, Wnt signaling inhibitor SM04755 targets and binds to an as of yet undisclosed target in the Wnt signaling pathway, thereby preventing Wnt-mediated signaling. This may inhibit growth of tumor cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is upregulated in many cancers and plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wnt Signaling Inhibitor SM04755","termGroup":"PT","termSource":"NCI"},{"termName":"SM04755","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wnt Signaling Inhibitor SM04755"},{"name":"NCI_META_CUI","value":"CL474102"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C142777":{"preferredName":"Wnt Signaling Pathway Inhibitor SM08502","code":"C142777","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, SM08502 inhibits the expression of genes involved in the Wnt signaling pathway through an as of yet not fully elucidated mechanism. This decreased expression of Wnt pathway-related genes prevents Wnt signaling and may inhibit proliferation of cancer cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is dysregulated in many cancer cell types and plays a crucial role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wnt Signaling Pathway Inhibitor SM08502","termGroup":"PT","termSource":"NCI"},{"termName":"SM 08502","termGroup":"CN","termSource":"NCI"},{"termName":"SM-08502","termGroup":"CN","termSource":"NCI"},{"termName":"SM08502","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wnt Signaling Pathway Inhibitor SM08502"},{"name":"NCI_Drug_Dictionary_ID","value":"791574"},{"name":"NCI_META_CUI","value":"CL540726"},{"name":"PDQ_Closed_Trial_Search_ID","value":"791574"},{"name":"PDQ_Open_Trial_Search_ID","value":"791574"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C113435":{"preferredName":"Wnt-5a Mimic Hexapeptide Foxy-5","code":"C113435","definitions":[{"definition":"A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wnt-5a Mimic Hexapeptide Foxy-5","termGroup":"PT","termSource":"NCI"},{"termName":"Foxy-5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"881188-51-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CBZ9UL0ARB"},{"name":"Maps_To","value":"Wnt-5a Mimic Hexapeptide Foxy-5"},{"name":"NCI_Drug_Dictionary_ID","value":"756269"},{"name":"NCI_META_CUI","value":"CL458229"},{"name":"PDQ_Closed_Trial_Search_ID","value":"756269"},{"name":"PDQ_Open_Trial_Search_ID","value":"756269"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C28501":{"preferredName":"Wobe-Mugos E","code":"C28501","definitions":[{"definition":"A mixture made from an extract of the calf thymus gland and enzymes (proteins that speed up chemical reactions in the body) from the papaya plant, the pancreas of cows, and the pancreas of pigs. It has been used in Europe as a treatment for a variety of cancers and for herpes virus infections.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An enzymatic preparation containing proteolytic enzymes papain, trypsin and chymotrypsin with potential anti-inflammatory and anticarcinogenic activities. Papain can be extracted from the fruit of the papaya plant. Trypsin and chymotrypsin are serine proteases produced and secreted by the pancreas. Although its exact mechanisms has yet to be fully illustrated, Wobe-Mugos E appears to have the ability to modulate the immune system by degrading cytokines, and cytokine receptors and clearing circulating immune protein complexes, as well as disrupting adhesion molecules. This agent has been shown to reduce chemotherapy-induced toxicity, inhibit tumor cell proliferation and prolong survival rates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wobe-Mugos E","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Wobe-Mugos_E"},{"name":"Maps_To","value":"Wobe-Mugos E"},{"name":"NCI_Drug_Dictionary_ID","value":"38247"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38247"},{"name":"PDQ_Open_Trial_Search_ID","value":"38247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935809"}]}}{"C106257":{"preferredName":"WT1 Peptide Vaccine OCV-501","code":"C106257","definitions":[{"definition":"A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Peptide Vaccine OCV-501","termGroup":"PT","termSource":"NCI"},{"termName":"OCV-501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1 Peptide Vaccine OCV-501"},{"name":"NCI_Drug_Dictionary_ID","value":"713831"},{"name":"NCI_META_CUI","value":"CL433890"},{"name":"PDQ_Closed_Trial_Search_ID","value":"713831"},{"name":"PDQ_Open_Trial_Search_ID","value":"713831"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C102751":{"preferredName":"WT1 Peptide Vaccine WT2725","code":"C102751","definitions":[{"definition":"A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Peptide Vaccine WT2725","termGroup":"PT","termSource":"NCI"},{"termName":"WT2725","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1 Peptide Vaccine WT2725"},{"name":"NCI_Drug_Dictionary_ID","value":"735821"},{"name":"NCI_META_CUI","value":"CL437008"},{"name":"PDQ_Closed_Trial_Search_ID","value":"735821"},{"name":"PDQ_Open_Trial_Search_ID","value":"735821"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121957":{"preferredName":"WT1 Protein-derived Peptide Vaccine DSP-7888","code":"C121957","definitions":[{"definition":"A peptide cancer vaccine comprised of peptides derived from the Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT1 protein-derived peptide vaccine DSP-7888 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. In addition, DSP-7888 induces a helper T-lymphocyte-mediated immune response against WT1 expressing tumor cells. WT1 protein, a zinc finger DNA-binding protein and transcription factor, is overexpressed in leukemic cells and in many non-hematological solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1 Protein-derived Peptide Vaccine DSP-7888","termGroup":"PT","termSource":"NCI"},{"termName":"DSP-7888","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1 Protein-derived Peptide Vaccine DSP-7888"},{"name":"NCI_Drug_Dictionary_ID","value":"772161"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772161"},{"name":"PDQ_Open_Trial_Search_ID","value":"772161"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053649"}]}}{"C78865":{"preferredName":"WT1-A10/AS01B Immunotherapeutic GSK2130579A","code":"C78865","definitions":[{"definition":"An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities.  Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1-A10/AS01B Immunotherapeutic GSK2130579A","termGroup":"PT","termSource":"NCI"},{"termName":"GSK2130579A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"WT1_Vaccine_GSK2130579A"},{"name":"Maps_To","value":"WT1-A10/AS01B Immunotherapeutic GSK2130579A"},{"name":"NCI_Drug_Dictionary_ID","value":"610132"},{"name":"NCI_META_CUI","value":"CL387745"},{"name":"PDQ_Closed_Trial_Search_ID","value":"610132"},{"name":"PDQ_Open_Trial_Search_ID","value":"610132"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148480":{"preferredName":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401","code":"C148480","definitions":[{"definition":"A preparation composed of three separate DNA plasmids encoding the tumor-associated antigens (TAAs) Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), with potential immunostimulating and antineoplastic activites. Upon intramuscular delivery and electroporation of the WT1/PSMA/hTERT-encoding plasmid DNA INO-5401, the genes are translated into their respective proteins inside the cell. The expressed proteins activate the immune system and induce a cytotoxic T-lymphocyte (CTL)-mediated response against cells expressing the WT1, PSMA and hTERT antigens, causing tumor cell lysis. hTERT, WT1 and PSMA are upregulated in many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401","termGroup":"PT","termSource":"NCI"},{"termName":"INO 5401","termGroup":"CN","termSource":"NCI"},{"termName":"INO-5401","termGroup":"CN","termSource":"NCI"},{"termName":"INO5401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401"},{"name":"NCI_Drug_Dictionary_ID","value":"795318"},{"name":"NCI_META_CUI","value":"CL551059"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795318"},{"name":"PDQ_Open_Trial_Search_ID","value":"795318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C121950":{"preferredName":"Xanthohumol","code":"C121950","definitions":[{"definition":"A prenylated flavonoid derived from the female flowers of the hops plant (Humulus lupulus L), with potential chemopreventive and antineoplastic activities. Upon administration, xanthohumol scavenges reactive oxygen species (ROS), thereby preventing DNA damage due to oxidative stress. In addition, xanthohumol is able to increase the expression of phase II cytoprotective enzymes, thereby inactivating carcinogens. This agent exerts anti-inflammatory activity, through the inhibition of inflammation-inducing enzymes, inhibits DNA synthesis, and induces apoptosis of susceptible cancer cells. Xanthohumol also decreases the expression of C-X-C chemokine receptor 4 (CXCR4), thereby preventing cancer cell invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xanthohumol","termGroup":"PT","termSource":"NCI"},{"termName":"3'-[3,3-Dimethyl allyl]-2',4',4-trihydroxy-6'-methoxychalcone","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"6754-58-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T4467YT1NT"},{"name":"Maps_To","value":"Xanthohumol"},{"name":"NCI_Drug_Dictionary_ID","value":"772021"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772021"},{"name":"PDQ_Open_Trial_Search_ID","value":"772021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0536128"}]}}{"C103823":{"preferredName":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","code":"C103823","definitions":[{"definition":"A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.  The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","termGroup":"PT","termSource":"NCI"},{"termName":"PVX-410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410"},{"name":"NCI_Drug_Dictionary_ID","value":"742602"},{"name":"NCI_META_CUI","value":"CL438306"},{"name":"PDQ_Closed_Trial_Search_ID","value":"742602"},{"name":"PDQ_Open_Trial_Search_ID","value":"742602"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C106118":{"preferredName":"Xentuzumab","code":"C106118","definitions":[{"definition":"A humanized IgG1 insulin-like growth factor (IGF) monoclonal antibody targeting the IGF ligands 1 (IGF-1) and 2 (IGF-2), with potential antineoplastic activity. Upon administration, xentuzumab binds to both IGF-1 and IGF-2 and inhibits the binding of these ligands to their receptor, IGF-1R. This blocks the insulin growth factor (IGF) signaling pathway, which is upregulated in a number of cancer cell types and plays a key role in cancer cell proliferation and chemoresistance. In addition, BI 836845 prevents the binding of IGF-2 to insulin receptor variant A (IR-A), preventing its activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xentuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"BI 836845","termGroup":"CN","termSource":"NCI"},{"termName":"Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I) (Human Monoclonal PS05388 Heavy Chain), Disulfide with Human Monoclonal PS05388 Light Chain, Dimer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1417158-65-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X86Z1O656G"},{"name":"Maps_To","value":"Xentuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"697680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"697680"},{"name":"PDQ_Open_Trial_Search_ID","value":"697680"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827152"}]}}{"C165272":{"preferredName":"Xiaoai Jiedu Decoction","code":"C165272","definitions":[{"definition":"A traditional Chinese medicine (TCM) decoction composed of Oldenlandia, Kuh-seng, Codonopsis pilosula, bighead atractylodes rhizome, smoked plum, the rhizome of Chinese goldthread, rhizome zingiberis preparata and semen Coicis, with potential chemopreventive and antineoplastic activities. Upon administration of Xiaoai Jiedu decoction, the active ingredients in this decoction may inhibit a variety of signal transduction pathways involved in carcinogenesis. This may induce cell cycle arrest and tumor cell apoptosis and inhibit tumor cell formation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xiaoai Jiedu Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"Xiaoai Jiedu Recipe","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Xiaoai Jiedu Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"799435"},{"name":"NCI_META_CUI","value":"CL978539"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799435"},{"name":"PDQ_Open_Trial_Search_ID","value":"799435"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C49180":{"preferredName":"XIAP Antisense Oligonucleotide AEG35156","code":"C49180","definitions":[{"definition":"A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of cancer. AEG35156 may kill cancer cells by blocking the production of a protein called XIAP that helps cells live longer. It also makes cancer cells more sensitive to anticancer drugs. It is a type of antisense oligonucleotide, and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"XIAP Antisense Oligonucleotide AEG35156","termGroup":"PT","termSource":"NCI"},{"termName":"AEG 35156","termGroup":"CN","termSource":"NCI"},{"termName":"AEG-35156","termGroup":"CN","termSource":"NCI"},{"termName":"AEG35156","termGroup":"CN","termSource":"NCI"},{"termName":"GEM640","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T4V3YL9QHU"},{"name":"Legacy Concept Name","value":"AEG35156"},{"name":"Maps_To","value":"XIAP Antisense Oligonucleotide AEG35156"},{"name":"NCI_Drug_Dictionary_ID","value":"492218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"492218"},{"name":"PDQ_Open_Trial_Search_ID","value":"492218"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1567121"}]}}{"C123913":{"preferredName":"Tolinapant","code":"C123913","definitions":[{"definition":"An orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptotic activities. Upon administration, tolinapant selectively binds to and inhibits the activity of XIAP and cIAP1. This restores and promotes the induction of apoptotic signaling pathways in cancer cells, and inactivates the nuclear factor-kappa B (NF-kB)-mediated survival pathway. XIAP and cIAP1 are overexpressed by many cancer cell types and suppress apoptosis by inhibiting the activity of certain caspases; they promote both cancer cell survival and chemotherapy resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tolinapant","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 660","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX660","termGroup":"CN","termSource":"NCI"},{"termName":"XIAP/cIAP1 Antagonist ASTX660","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1799328-86-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2LHZ9ZC3YO"},{"name":"Maps_To","value":"XIAP/cIAP1 Antagonist ASTX660"},{"name":"NCI_Drug_Dictionary_ID","value":"775838"},{"name":"NCI_META_CUI","value":"CL498277"},{"name":"PDQ_Closed_Trial_Search_ID","value":"775838"},{"name":"PDQ_Open_Trial_Search_ID","value":"775838"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171660":{"preferredName":"Felezonexor","code":"C171660","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear export protein exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic and pro-apoptotic activities. Upon administration, felezonexor reversibly binds to the cargo binding site of XPO1, and prevents the XPO1-mediated nuclear export of cargo proteins, including tumor suppressor proteins (TSPs), such as p53, FOXO, p21, and p27, and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), SL-801 restores the nuclear localization and function of TSPs, which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins and RNA from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The dysregulated export of TSPs into the cytoplasm prevents TSP-initiated apoptosis. XPO1 overexpression leads to uncontrolled tumor cell proliferation and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Felezonexor","termGroup":"PT","termSource":"NCI"},{"termName":"CBS 9106","termGroup":"CN","termSource":"NCI"},{"termName":"SL 801","termGroup":"CN","termSource":"NCI"},{"termName":"SL-801","termGroup":"CN","termSource":"NCI"},{"termName":"XPO1 Inhibitor SL-801","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1076235-04-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PAW9EP9BXO"},{"name":"Maps_To","value":"XPO1 Inhibitor SL-801"},{"name":"NCI_Drug_Dictionary_ID","value":"782045"},{"name":"NCI_META_CUI","value":"CL1405652"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2597":{"preferredName":"Y 90 Monoclonal Antibody CC49","code":"C2597","definitions":[{"definition":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with Yttrium 90 (Y-90). MoAb CC49 recognizes the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Y-90 MoAb CC49 delivers beta particles emitting Y-90 radionuclide directly to tumor cells that express TAG-72, thereby this agent may be used in radioimmunotherapeutic treatment of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody CC49","termGroup":"PT","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody CC49","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_CC49"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody CC49"},{"name":"NCI_Drug_Dictionary_ID","value":"38082"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38082"},{"name":"PDQ_Open_Trial_Search_ID","value":"38082"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935674"}]}}{"C2541":{"preferredName":"Y 90 Monoclonal Antibody HMFG1","code":"C2541","definitions":[{"definition":"A radioimmunoconjugate consisting of HMFG1, a humanized monoclonal antibody directed against the tumor associated antigen mucin-1 (MUC-1), labeled with the beta-emitting radioisotope yttrium 90 (Y-90), with potential antineoplastic activities. Upon administration, the monoclonal antibody moiety targets and binds to MUC-1 on the surface of certain tumor cells. Upon binding and internalization, pemtumomab and delivers a cytotoxic dose of beta radiation to MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody HMFG1","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB HMFG1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody HMFG1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Theragyn","termGroup":"FB","termSource":"NCI"},{"termName":"Y 90 MoAb HMFG1","termGroup":"AB","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB HMFG1","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody HMFG1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_HMFG1"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody HMFG1"},{"name":"NCI_Drug_Dictionary_ID","value":"43644"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43644"},{"name":"PDQ_Open_Trial_Search_ID","value":"43644"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879349"}]}}{"C2247":{"preferredName":"Y 90 Monoclonal Antibody Lym-1","code":"C2247","definitions":[{"definition":"A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. Y-90 MoAb Lym-1 delivers Y-90 radionuclide directly to tumor cells that express HLA-DR antigen, thereby this agent may be used in radioimmunotherapy of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody Lym-1","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB Lym-1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody Lym-1, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb Lym-1","termGroup":"AB","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB Lym-1","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody Lym-1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_Lym-1"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody Lym-1"},{"name":"NCI_Drug_Dictionary_ID","value":"43509"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43509"},{"name":"PDQ_Open_Trial_Search_ID","value":"43509"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796675"}]}}{"C2532":{"preferredName":"Y 90 Monoclonal Antibody m170","code":"C2532","definitions":[{"definition":"A radioimmunoconjugate of m170 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb m170 is a murine MoAb that recognizes MUC-1 antigen present on the surface of many adenocarcinomas. This radioimmunoconjugate emits beta particles that cause cytotoxicity in tumor cells and has both imaging and therapeutic uses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody m170","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB m170, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody m170, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb m170","termGroup":"AB","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB m170","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody m170","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_m170"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody m170"},{"name":"NCI_Drug_Dictionary_ID","value":"43501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43501"},{"name":"PDQ_Open_Trial_Search_ID","value":"43501"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0796669"}]}}{"C2248":{"preferredName":"Y 90 Monoclonal Antibody M195","code":"C2248","definitions":[{"definition":"A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface antigen CD33, a glycoprotein found on myeloid leukemia blasts and early hematopoietic progenitor cells but not on normal stem cells. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Y 90 Monoclonal Antibody M195","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB M195, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody M195, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb M195","termGroup":"AB","termSource":"NCI"},{"termName":"Yttrium Y 90 Monoclonal Antibody M195","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_M195"},{"name":"Maps_To","value":"Y 90 Monoclonal Antibody M195"},{"name":"NCI_Drug_Dictionary_ID","value":"38025"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38025"},{"name":"PDQ_Open_Trial_Search_ID","value":"38025"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879572"}]}}{"C132024":{"preferredName":"Yang Yin Fu Zheng","code":"C132024","definitions":[{"definition":"A traditional Chinese medicine (TCM)-based formulation, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, Yang Yin Fu Zheng may activate the immune system and may help inhibit tumor cell proliferation. This TCM may also help remove toxic substances.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yang Yin Fu Zheng","termGroup":"PT","termSource":"NCI"},{"termName":"Fu Zheng Yang Yin","termGroup":"SY","termSource":"NCI"},{"termName":"Fu Zheng Yang Yin Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"TCM Yang Yin Fu Zheng","termGroup":"SY","termSource":"NCI"},{"termName":"Yang Yin Fu Zheng Jie Du","termGroup":"SY","termSource":"NCI"},{"termName":"Yangyin Fuzheng Jiedu","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yang Yin Fu Zheng"},{"name":"NCI_Drug_Dictionary_ID","value":"786518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786518"},{"name":"PDQ_Open_Trial_Search_ID","value":"786518"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2355396"}]}}{"C111897":{"preferredName":"Yangzheng Xiaoji Extract","code":"C111897","definitions":[{"definition":"A traditional Chinese medicine (TCM)-based formulation containing the Yangzheng Xiaoji (YZXJ) extract, consisting of various components, with potential antineoplastic and anti-angiogenic activities. Some of the main components in Yangzheng Xiaoji are Radix Astragali, Fructus Ligustri Lucidi, Radix Ginseng, Ganoderma, Rhizoma Curcumac, Fried Rhizoma Atractylodis, Macrocephalae and Herba Hedyotidis. Although the exact mechanism(s) through which Yangzheng Xiaoji exerts its effects have yet to be fully elucidated, this agent, upon administration, inhibits the activation of various signaling protein kinases, such as focal adhesion kinase (FAK) and paxillin. This prevents signal transduction pathways that are upregulated in cancer, prevents the adhesion and migration of tumor cells and inhibits tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yangzheng Xiaoji Extract","termGroup":"PT","termSource":"NCI"},{"termName":"DME25","termGroup":"CN","termSource":"NCI"},{"termName":"YZXJ Extract","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yangzheng Xiaoji Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"753388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"753388"},{"name":"PDQ_Open_Trial_Search_ID","value":"753388"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3827131"}]}}{"C132026":{"preferredName":"Yiqi-yangyin-jiedu Herbal Decoction","code":"C132026","definitions":[{"definition":"A traditional Chinese medicine (TCM) based formulation consisting of milkvetch root, glehnia root, asparagus root, lilyturf root, grossy privet fruit, spikemoss herb, Chinese sage herb, and manyleaf paris rhizome, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, yiqi-yangyin-jiedu decoction (YYJD) may activate the immune system by enhancing T-lymphocyte activity, and inhibiting tumor cell proliferation. YYJD may also ameliorate the qi-yin deficiency syndrome by strengthening qi and nourishing yin. YYJD may help remove toxic substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yiqi-yangyin-jiedu Herbal Decoction","termGroup":"PT","termSource":"NCI"},{"termName":"TCM Yiqi-yangyin-jiedu Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"Yiqi Yangyin Jiedu Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"YYJ Decoction","termGroup":"SY","termSource":"NCI"},{"termName":"YYJD","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yiqi-yangyin-jiedu Herbal Decoction"},{"name":"NCI_Drug_Dictionary_ID","value":"786577"},{"name":"NCI_META_CUI","value":"CL521287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"786577"},{"name":"PDQ_Open_Trial_Search_ID","value":"786577"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74092":{"preferredName":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12","code":"C74092","definitions":[{"definition":"A radioimmunoconjugate consisting of the murine IgG1 anti-CD19 monoclonal antibody (MoAb) BU12 labeled with the beta-emitting radioisotope yttrium Y 90 with radioisotopic and antibody activities. Yttrium Y 90 anti-CD19 monoclonal antibody BU12 binds to the CD19 molecule, specifically delivering cytotoxic beta radiation to CD19-expressing B cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Anti-CD19_Monoclonal_Antibody_BU12"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12"},{"name":"NCI_Drug_Dictionary_ID","value":"592567"},{"name":"NCI_META_CUI","value":"CL383553"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592567"},{"name":"PDQ_Open_Trial_Search_ID","value":"592567"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C74093":{"preferredName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12","code":"C74093","definitions":[{"definition":"A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal antibody AHN-12 binds to the tyrosine phosphatase CD45, expressed on the surface of normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12","termGroup":"PT","termSource":"NCI"},{"termName":"Y 90 AHN-12","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Anti-CD45_Monoclonal_Antibody_AHN-12"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12"},{"name":"NCI_Drug_Dictionary_ID","value":"587979"},{"name":"NCI_META_CUI","value":"CL383503"},{"name":"PDQ_Closed_Trial_Search_ID","value":"587979"},{"name":"PDQ_Open_Trial_Search_ID","value":"587979"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C95698":{"preferredName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","code":"C95698","definitions":[{"definition":"A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with yttrium 90 (Y90), with potential immunotherapeutic activity. Yttrium Y 90 anti-CD45 monoclonal antibody BC8 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Anti-CD45 MoAb BC8","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8"},{"name":"NCI_Drug_Dictionary_ID","value":"688830"},{"name":"NCI_META_CUI","value":"CL428164"},{"name":"PDQ_Closed_Trial_Search_ID","value":"688830"},{"name":"PDQ_Open_Trial_Search_ID","value":"688830"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C122405":{"preferredName":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","code":"C122405","definitions":[{"definition":"A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","termGroup":"PT","termSource":"NCI"},{"termName":"FF-21101(90Y)","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101"},{"name":"NCI_Drug_Dictionary_ID","value":"772801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"772801"},{"name":"PDQ_Open_Trial_Search_ID","value":"772801"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C4053526"}]}}{"C77885":{"preferredName":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66","code":"C77885","definitions":[{"definition":"A radioimmunoconjugate comprised of a chimeric monoclonal antibody against human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y90 DOTA anti-CEA monoclonal antibody cT84.66 binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66","termGroup":"PT","termSource":"NCI"},{"termName":"cT84.66","termGroup":"CN","termSource":"NCI"},{"termName":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody cT84.66","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Anti-CEA_Monoclonal_Antibody_cT84_66"},{"name":"Maps_To","value":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66"},{"name":"NCI_Drug_Dictionary_ID","value":"592860"},{"name":"NCI_META_CUI","value":"CL387153"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592860"},{"name":"PDQ_Open_Trial_Search_ID","value":"592860"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C99167":{"preferredName":"Yttrium Y 90 Basiliximab","code":"C99167","definitions":[{"definition":"A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium Y 90 basiliximab selectively binds to IL-2R alpha expressed on the surface of activated T-lymphocytes, thereby preventing IL-2 binding and blocking the IL-2-mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the IL-2 receptor. This may prevent T cell-mediated activation of the immune system against a certain transplant and may prevent transplant rejection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Basiliximab","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Basiliximab","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90-DOTA-Basiliximab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Basiliximab"},{"name":"NCI_Drug_Dictionary_ID","value":"717514"},{"name":"NCI_META_CUI","value":"CL433016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717514"},{"name":"PDQ_Open_Trial_Search_ID","value":"717514"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C114495":{"preferredName":"Yttrium Y 90 Colloid","code":"C114495","definitions":[{"definition":"An injectable, colloidal formulation of the radioisotope yttrium Y 90, with potential antineoplastic activity. When injected into the tumor, the yttrium Y 90 colloid selectively delivers a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Colloid","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Colloid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Colloid"},{"name":"NCI_Drug_Dictionary_ID","value":"759092"},{"name":"NCI_META_CUI","value":"CL472321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"759092"},{"name":"PDQ_Open_Trial_Search_ID","value":"759092"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2600":{"preferredName":"Yttrium Y 90 Daclizumab","code":"C2600","definitions":[{"definition":"A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity.  Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes.  As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Daclizumab","termGroup":"PT","termSource":"NCI"},{"termName":"Y90 Daclizumab","termGroup":"SY","termSource":"NCI"},{"termName":"Y90 MOAB Anti-Tac","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Daclizumab"},{"name":"Maps_To","value":"Yttrium Y 90 Daclizumab"},{"name":"NCI_Drug_Dictionary_ID","value":"38097"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38097"},{"name":"PDQ_Open_Trial_Search_ID","value":"38097"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935688"}]}}{"C77853":{"preferredName":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A","code":"C77853","definitions":[{"definition":"A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. M5A is a monoclonal antibody that binds to a protein called CEA on the surface of some tumor cells. It is linked to a radioisotope called yttrium Y 90, which may help kill the cancer cells. Yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A is a type of radioimmunoconjugate and a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A","termGroup":"PT","termSource":"NCI"},{"termName":"Y90-DOTA-M5A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"I9O4Z8CE5L"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Anti-CEA_Monoclonal_Antibody_M5A"},{"name":"Maps_To","value":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A"},{"name":"NCI_Drug_Dictionary_ID","value":"592693"},{"name":"NCI_META_CUI","value":"CL383554"},{"name":"PDQ_Closed_Trial_Search_ID","value":"592693"},{"name":"PDQ_Open_Trial_Search_ID","value":"592693"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C38679":{"preferredName":"Yttrium Y 90 Glass Microspheres","code":"C38679","definitions":[{"definition":"An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90.  When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Glass Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"TheraSphere","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular carcinoma, transarterial internal radiation"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Glass_Microspheres"},{"name":"Maps_To","value":"Y-90 Therasphere"},{"name":"Maps_To","value":"Yttrium Y 90 Glass Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"38672"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38672"},{"name":"PDQ_Open_Trial_Search_ID","value":"38672"},{"name":"Semantic_Type","value":"Drug Delivery Device"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134675"}]}}{"C2614":{"preferredName":"Yttrium Y 90 Monoclonal Antibody B3","code":"C2614","definitions":[{"definition":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody B3","termGroup":"PT","termSource":"NCI"},{"termName":"90 Y-B3","termGroup":"SY","termSource":"NCI"},{"termName":"MOAB B3, Yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 Monoclonal Antibody B3","termGroup":"SY","termSource":"NCI"},{"termName":"Y90-B3","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Monoclonal_Antibody_B3"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody B3"},{"name":"NCI_Drug_Dictionary_ID","value":"38188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38188"},{"name":"PDQ_Open_Trial_Search_ID","value":"38188"},{"name":"PubMedID_Primary_Reference","value":"10815890"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935761"}]}}{"C2607":{"preferredName":"Yttrium Y 90 Monoclonal Antibody BrE-3","code":"C2607","definitions":[{"definition":"A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody BrE-3","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB BrE-3, Yttrium Y 90","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Monoclonal_Antibody_BrE-3"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody BrE-3"},{"name":"NCI_Drug_Dictionary_ID","value":"38148"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38148"},{"name":"PDQ_Open_Trial_Search_ID","value":"38148"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0935731"}]}}{"C38678":{"preferredName":"Yttrium Y 90 Monoclonal Antibody Hu3S193","code":"C38678","definitions":[{"definition":"A radioimmunotherapeutic agent consisting of a humanized murine monoclonal antibody (hu3S193) directed against the tumor-associated Lewis Y epithelial antigen chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody Hu3S193 binds to Lewis Y epithelial antigen-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody Hu3S193","termGroup":"PT","termSource":"NCI"},{"termName":"Y90 MOAB Hu3S193","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Monoclonal_Antibody_Hu3S193"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody Hu3S193"},{"name":"NCI_Drug_Dictionary_ID","value":"340956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"340956"},{"name":"PDQ_Open_Trial_Search_ID","value":"340956"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328082"}]}}{"C2249":{"preferredName":"Yttrium Y 90 Monoclonal Antibody MN-14","code":"C2249","definitions":[{"definition":"A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Monoclonal Antibody MN-14","termGroup":"PT","termSource":"NCI"},{"termName":"MOAB MN-14, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"monoclonal antibody MN-14, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb MN-14","termGroup":"AB","termSource":"NCI"},{"termName":"Y 90 Monoclonal Antibody MN-14","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium 90 Monoclonal Antibody MN-14","termGroup":"SY","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB MN-14","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Y_90_Monoclonal_Antibody_MN-14"},{"name":"Maps_To","value":"Yttrium Y 90 Monoclonal Antibody MN-14"},{"name":"NCI_Drug_Dictionary_ID","value":"43511"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43511"},{"name":"PDQ_Open_Trial_Search_ID","value":"43511"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879253"}]}}{"C64539":{"preferredName":"Yttrium Y 90 Resin Microspheres","code":"C64539","definitions":[{"definition":"An injectable formulation of the radioisotope yttrium Y 90 encapsulated in resin microspheres with potential antineoplastic activity. When injected into arterial vasculature supplying the tumor, yttrium Y 90 resin microspheres occlude tumor blood vessels and selectively deliver a cytotoxic dose of beta emitting yttrium Y 90 to the tumor site, which may result in tumor cell death and tumor regression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Resin Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"SIR-Spheres","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hepatocellular carcinoma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Resin_Microspheres"},{"name":"Maps_To","value":"Y-90 Sirsphere"},{"name":"Maps_To","value":"Yttrium Y 90 Resin Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"523414"},{"name":"PDQ_Closed_Trial_Search_ID","value":"523414"},{"name":"PDQ_Open_Trial_Search_ID","value":"523414"},{"name":"Semantic_Type","value":"Drug Delivery Device"},{"name":"UMLS_CUI","value":"C1831993"}]}}{"C1808":{"preferredName":"Yttrium Y 90-DOTA-Biotin","code":"C1808","definitions":[{"definition":"A compound that contains the radioisotope yttrium Y 90 linked to the chemical biotin. Biotin is a molecule that binds strongly to the chemical streptavidin. Yttrium Y 90 DOTA-biotin will find tumor cells in the body that have been targeted by an antibody linked to streptavidin and kill them. It is being studied together with CC49-streptavidin in the treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A radioconjugate of biotin and yttrium Y 90 (Y-90) linked through the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) with radioimmunotherapy property. Biotin is a water-soluble B-complex vitamin, present in minute amounts in every living cell, while its level in cancerous tissue is higher than that of normal tissue. Y 90-DOTA-Biotin could be used in 3-step pre-targeting radioimmunotherapy that employs a tumor targeting antibody conjugated with streptavidin, the natural ligand of biotin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90-DOTA-Biotin","termGroup":"PT","termSource":"NCI"},{"termName":"90Y-DOTA-Biotin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"_90Y-DOTA-Biotin"},{"name":"Maps_To","value":"Yttrium Y 90-DOTA-Biotin"},{"name":"NCI_Drug_Dictionary_ID","value":"365680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"365680"},{"name":"PDQ_Open_Trial_Search_ID","value":"365680"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0677849"}]}}{"C119738":{"preferredName":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","code":"C119738","definitions":[{"definition":"A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the beta-emitting radionuclide yttrium 90 (Y-90), with radioimmunotherapeutic activity. After pre-treating and targeting tumor cells with a bi-specific monoclonal antibody (BiMoAB) directed against both a tumor-associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of the administered yttrium Y 90-DOTA-di-HSG peptide IMP-288 binds to the anti-HSG sequence on the BiMoAB. In turn, Y-90 delivers a cytotoxic dose of beta radiation to tumor cells expressing the specific TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","termGroup":"PT","termSource":"NCI"},{"termName":"90-Y-IMP-288","termGroup":"AB","termSource":"NCI"},{"termName":"90Y-IMP288","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288"},{"name":"NCI_Drug_Dictionary_ID","value":"766993"},{"name":"PDQ_Closed_Trial_Search_ID","value":"766993"},{"name":"PDQ_Open_Trial_Search_ID","value":"766993"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896702"}]}}{"C2601":{"preferredName":"Yttrium Y 90-Edotreotide","code":"C2601","definitions":[{"definition":"A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of some types of cancer. Yttrium Y 90 edotreotide contains yttrium Y 90 (a radioactive form of the metal yttrium) attached to a molecule that binds to certain types of neuroendocrine tumors (tumors that come from cells that release hormones). The radioactivity from yttrium Y 90 may kill the cancer cells.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y 90-Edotreotide","termGroup":"PT","termSource":"NCI"},{"termName":"90Y-DOTA-3-Tyr-Octreotide","termGroup":"SY","termSource":"NCI"},{"termName":"OctreoTher","termGroup":"BR","termSource":"NCI"},{"termName":"Onalta","termGroup":"BR","termSource":"NCI"},{"termName":"Yttrium Y 90 -DOTATOC","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 SMT 487","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90-DOTA-3-tyrosine-octreotide","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90-DOTA-Tyr3-Octreotide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"322407-70-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ABF7OG3FA3"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_SMT_487"},{"name":"Maps_To","value":"Yttrium Y 90-Edotreotide"},{"name":"NCI_Drug_Dictionary_ID","value":"38102"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38102"},{"name":"PDQ_Open_Trial_Search_ID","value":"38102"},{"name":"PubMedID_Primary_Reference","value":"20168290"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2003893"}]}}{"C99168":{"preferredName":"Yttrium Y 90 Tabituximab Barzuxetan","code":"C99168","definitions":[{"definition":"A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) OTSA101 against FZD10 and labeled with yttrium y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101 binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except for the placenta.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y 90 Tabituximab Barzuxetan","termGroup":"PT","termSource":"NCI"},{"termName":"90Y Tabituximab Barzuxetan","termGroup":"SY","termSource":"NCI"},{"termName":"OTSA101-DTPA-90Y","termGroup":"AB","termSource":"NCI"},{"termName":"Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Yttrium Y 90 Tabituximab Barzuxetan"},{"name":"Maps_To","value":"Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101"},{"name":"NCI_Drug_Dictionary_ID","value":"717536"},{"name":"NCI_META_CUI","value":"CL433017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"717536"},{"name":"PDQ_Open_Trial_Search_ID","value":"717536"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C48429":{"preferredName":"Yttrium Y-90 Clivatuzumab Tetraxetan","code":"C48429","definitions":[{"definition":"A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of advanced pancreatic cancer. HuPAM4 is a monoclonal antibody that can locate and bind to pancreatic cancer cells. It is linked to a radioactive substance called yttrium Y90, which may help kill cancer cells. Yttrium Y 90 DOTA monoclonal antibody HuPAM4 is a type of radioimmunoconjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y-90 Clivatuzumab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"90Y-hPAM4","termGroup":"AB","termSource":"NCI"},{"termName":"hPAM4-Cide","termGroup":"BR","termSource":"NCI"},{"termName":"hPAM4-DOTA","termGroup":"CN","termSource":"NCI"},{"termName":"IMMU-107","termGroup":"CN","termSource":"NCI"},{"termName":"Yttrium (90Y) Clivatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Clivatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 DOTA Monoclonal Antibody HuPAM4","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"943976-23-6"},{"name":"Chemical_Formula","value":"C16H25N5O7.Y"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2L271110ED"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Monoclonal_Antibody_HuPAM4"},{"name":"Maps_To","value":"Yttrium Y-90 Clivatuzumab Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"425350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425350"},{"name":"PDQ_Open_Trial_Search_ID","value":"425350"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541526"}]}}{"C2582":{"preferredName":"Yttrium Y-90 Epratuzumab Tetraxetan","code":"C2582","definitions":[{"definition":"A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium Y-90 Epratuzumab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"Monoclonal antibody LL2, yttrium Y 90","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 Humanized Monoclonal Antibody LL2","termGroup":"SY","termSource":"NCI"},{"termName":"Y 90 MoAb LL2","termGroup":"AB","termSource":"NCI"},{"termName":"Y 90 monoclonal antibody LL2","termGroup":"SY","termSource":"NCI"},{"termName":"Y90 Humanized Epratuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Humanized Epratuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Humanized Monoclonal Antibody LL2","termGroup":"SY","termSource":"NCI"},{"termName":"yttrium Y 90 MOAB LL2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"501423-25-2"},{"name":"Chemical_Formula","value":"C16H25N5O7.Y"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J36232195E"},{"name":"Legacy Concept Name","value":"Y_90_Humanized_Monoclonal_Antibody_LL2"},{"name":"Maps_To","value":"Yttrium Y-90 Epratuzumab Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"43648"},{"name":"PDQ_Closed_Trial_Search_ID","value":"43648"},{"name":"PDQ_Open_Trial_Search_ID","value":"43648"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879352"}]}}{"C1812":{"preferredName":"Yttrium Y-90 Ibritumomab Tiuxetan","code":"C1812","definitions":[{"definition":"A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. Y 90 ibritumomab tiuxetan is a type of radiopharmaceutical.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y-90 Ibritumomab Tiuxetan","termGroup":"PT","termSource":"NCI"},{"termName":"IDEC-Y2B8","termGroup":"AB","termSource":"NCI"},{"termName":"Y 90 Ibritumomab Tiuxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Ibritumomab Tiuxetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Non-Hodgkin's Lymphoma"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QA846JAV5B"},{"name":"Legacy Concept Name","value":"Y_90_Ibritumomab_Tiuxetan"},{"name":"Maps_To","value":"Yttrium Y-90 Ibritumomab Tiuxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"38483"},{"name":"NSC Number","value":"710085"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38483"},{"name":"PDQ_Open_Trial_Search_ID","value":"38483"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0879283"}]}}{"C48428":{"preferredName":"Yttrium Y-90 Tacatuzumab Tetraxetan","code":"C48428","definitions":[{"definition":"A radioimmunoconjugate comprised of the humanized monoclonal antibody tacatuzumab, directed against alpha fetoprotein, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, thereby selectively delivering a cytotoxic dose of beta radiation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of liver cancer. HuAFP31 is a monoclonal antibody that can bind to tumor cells that make a protein called alpha fetoprotein (AFP). It is linked to a radioactive substance called yttrium Y 90, which may help kill the cancer cells. Yttrium Y 90 DOTA monoclonal antibody HuAFP31 is a type of radioimmunoconjugate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Yttrium Y-90 Tacatuzumab Tetraxetan","termGroup":"PT","termSource":"NCI"},{"termName":"AFP-Cide","termGroup":"BR","termSource":"NCI"},{"termName":"Y-90 hAFP-31","termGroup":"AB","termSource":"NCI"},{"termName":"Yttrium (90Y) Tacatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y 90 Tacatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"},{"termName":"Yttrium Y-90 Tacatuzumab Tetraxetan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"476413-07-7"},{"name":"Chemical_Formula","value":"C16H25N5O7.Y"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GJ2416WK6Y"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_DOTA_Monoclonal_Antibody_HuAFP31"},{"name":"Maps_To","value":"Yttrium Y-90 Tacatuzumab Tetraxetan"},{"name":"NCI_Drug_Dictionary_ID","value":"425347"},{"name":"PDQ_Closed_Trial_Search_ID","value":"425347"},{"name":"PDQ_Open_Trial_Search_ID","value":"425347"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1541525"}]}}{"C80739":{"preferredName":"Yttrium-90 Polycarbonate Brachytherapy Plaque","code":"C80739","definitions":[{"definition":"A polycarbonate-based semicylindrical plaque impregnated with yttrium Y 90 with radioisotopic and antineoplastic activities. An yttrium-90 polycarbonate brachytherapy plaque may be applied to a tumor site with a special brachytherapy applicator for a predetermined interval of time, selectively delivering a cytotoxic dose of beta-emitting yttrium Y 90.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Yttrium-90 Polycarbonate Brachytherapy Plaque","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Yttrium_Y_90_Plaque_Applicator"},{"name":"Maps_To","value":"Yttrium-90 Polycarbonate Brachytherapy Plaque"},{"name":"NCI_Drug_Dictionary_ID","value":"600953"},{"name":"NCI_META_CUI","value":"CL388351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"600953"},{"name":"PDQ_Open_Trial_Search_ID","value":"600953"},{"name":"Semantic_Type","value":"Drug Delivery Device"}]}}{"C95713":{"preferredName":"Endoxifen Hydrochloride","code":"C95713","definitions":[{"definition":"The hydrochloride salt and the z (cis-) stereoisomer of endoxifen with potential antineoplastic activity. Endoxifen, the active metabolite of tamoxifen, competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA and thus reducing DNA synthesis. Unlike tamoxifen, however, which relies on CYP2D6 activity for its conversion to the active metabolite endoxifen, the direct administration of endoxifen bypasses the CYP2D6 route. As CYP2D6 activity can vary widely among individuals due to genetic CYP2D6 polymorphisms, endoxifen is therefore theoretically more potent and more uniform in its bioavailability across patient populations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endoxifen Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hydroxy-N-Desmethyltamoxifen Hydrochloride","termGroup":"SN","termSource":"NCI"},{"termName":"Z-Endoxifen HCl","termGroup":"SY","termSource":"NCI"},{"termName":"Z-Endoxifen Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1032008-74-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"308PA1L567"},{"name":"Maps_To","value":"Z-Endoxifen Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"693335"},{"name":"NCI_META_CUI","value":"CL428178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"693335"},{"name":"PDQ_Open_Trial_Search_ID","value":"693335"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C430":{"preferredName":"Zalcitabine","code":"C430","definitions":[{"definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zalcitabine","termGroup":"PT","termSource":"NCI"},{"termName":"2',3'-Dideoxycytidine","termGroup":"SN","termSource":"NCI"},{"termName":"ddC","termGroup":"AB","termSource":"NCI"},{"termName":"Dideoxycytidine","termGroup":"SY","termSource":"NCI"},{"termName":"Hivid","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7481-89-2"},{"name":"CHEBI_ID","value":"CHEBI:10101"},{"name":"Chemical_Formula","value":"C9H13N3O3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6L3XT8CB3I"},{"name":"Legacy Concept Name","value":"Zalcitabine"},{"name":"Maps_To","value":"Zalcitabine"},{"name":"NCI_Drug_Dictionary_ID","value":"40349"},{"name":"NSC Number","value":"606170"},{"name":"PDQ_Closed_Trial_Search_ID","value":"40349"},{"name":"PDQ_Open_Trial_Search_ID","value":"40349"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0012132"}]}}{"C126113":{"preferredName":"Zalifrelimab","code":"C126113","definitions":[{"definition":"A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zalifrelimab","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN-1884","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1884","termGroup":"CN","termSource":"NCI"},{"termName":"UGN 301","termGroup":"CN","termSource":"NCI"},{"termName":"UGN-301","termGroup":"CN","termSource":"NCI"},{"termName":"UGN301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2148321-69-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FE7L22H028"},{"name":"Maps_To","value":"Zalifrelimab"},{"name":"NCI_Drug_Dictionary_ID","value":"779578"},{"name":"NCI_META_CUI","value":"CL504706"},{"name":"PDQ_Closed_Trial_Search_ID","value":"779578"},{"name":"PDQ_Open_Trial_Search_ID","value":"779578"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C64620":{"preferredName":"Zalutumumab","code":"C64620","definitions":[{"definition":"A fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR is a cell surface receptor tyrosine kinase, overexpressed on many cancer cells. Zalutumumab selectively binds to and blocks binding of EGF and transforming growth factor-alpha (TGF-a) to the EGFR receptor, thereby interfering with cellular signaling, leading to cell growth inhibition and apoptosis in tumor cells. In addition, zalutumumab also triggers cell lysis mediated through antibody dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zalutumumab","termGroup":"PT","termSource":"NCI"},{"termName":"2FB","termGroup":"CN","termSource":"NCI"},{"termName":"HuMax-EGFr, 2F8","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"667901-13-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DA709Q5020"},{"name":"Legacy Concept Name","value":"Zalutumumab"},{"name":"Maps_To","value":"Zalutumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"518289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"518289"},{"name":"PDQ_Open_Trial_Search_ID","value":"518289"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1831978"}]}}{"C91701":{"preferredName":"Zanolimumab","code":"C91701","definitions":[{"definition":"A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities. Zanolimumab targets and binds to the CD4 receptor on certain T-cells thereby preventing the interaction between the CD4 receptor and the major histocompatibility complex class II molecule. This prevents activation of CD4 positive T cells. In addition, zanolimumab is able to induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD4-expressing tumor cells. CD4, a receptor located on a subset of T-lymphocytes, is upregulated in T-cell lymphomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanolimumab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD4 Monoclonal Antibody HuMax","termGroup":"SY","termSource":"NCI"},{"termName":"HuMax-CD4","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"652153-01-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HG3L8885M0"},{"name":"Maps_To","value":"Zanolimumab"},{"name":"NCI_Drug_Dictionary_ID","value":"352000"},{"name":"PDQ_Closed_Trial_Search_ID","value":"352000"},{"name":"PDQ_Open_Trial_Search_ID","value":"352000"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1957794"}]}}{"C141428":{"preferredName":"Zanubrutinib","code":"C141428","definitions":[{"definition":"An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zanubrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BGB 3111","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-3111","termGroup":"CN","termSource":"NCI"},{"termName":"BGB3111","termGroup":"CN","termSource":"NCI"},{"termName":"Brukinsa","termGroup":"BR","termSource":"NCI"},{"termName":"BTK-InhB","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"CAS_Registry","value":"1691249-45-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"AG9MHG098Z"},{"name":"Maps_To","value":"Zanubrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"768510"},{"name":"PDQ_Closed_Trial_Search_ID","value":"768510"},{"name":"PDQ_Open_Trial_Search_ID","value":"768510"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896894"}]}}{"C37455":{"preferredName":"Zebularine","code":"C37455","definitions":[{"definition":"A synthetic cytidine analogue and a cytidine deaminase inhibitor with anticancer activity. Following metabolic activation by phosphorylation and incorporation into DNA, zebularine inhibits DNA methyltransferase through covalent complex formation between the enzyme and zebularine-substituted DNA, hence resulting in non-specific, genome-wide induction of demethylation including the removal of aberrant methylation of promoter regions of genes critical for normal cellular functions.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zebularine","termGroup":"PT","termSource":"NCI"},{"termName":"1-beta-D-Ribofuranosyl-2(1H)-pyrimidinone","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyrimidone-1-beta-D-riboside","termGroup":"SN","termSource":"NCI"},{"termName":"4-Deoxyuridine","termGroup":"SY","termSource":"NCI"},{"termName":"Pyrimidin-2-one beta-Ribofuranoside","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"3690-10-6"},{"name":"CHEBI_ID","value":"CHEBI:46938"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7A9Y5SX0GY"},{"name":"Legacy Concept Name","value":"Zebularine"},{"name":"Maps_To","value":"Zebularine"},{"name":"NSC Number","value":"309132"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0084253"}]}}{"C48430":{"preferredName":"Zibotentan","code":"C48430","definitions":[{"definition":"A substance that is being studied in the treatment of prostate cancer. It belongs to the family of drugs called endothelin-receptor antagonists.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zibotentan","termGroup":"PT","termSource":"NCI"},{"termName":"3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pridine-3- sulfonamide","termGroup":"SN","termSource":"NCI"},{"termName":"ZD-4054","termGroup":"SY","termSource":"NCI"},{"termName":"ZD4054","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"186497-07-4"},{"name":"Chemical_Formula","value":"C19H16N6O4S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8054MM4902"},{"name":"Legacy Concept Name","value":"ZD4054"},{"name":"Maps_To","value":"Zibotentan"},{"name":"NCI_Drug_Dictionary_ID","value":"355727"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355727"},{"name":"PDQ_Open_Trial_Search_ID","value":"355727"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1328193"}]}}{"C129588":{"preferredName":"Zinc Finger Nuclease ZFN-603","code":"C129588","definitions":[{"definition":"A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-603 into HPV16-positive cells, ZFN-603 targets, binds to and cleaves the HPV16 E7 oncogene in HPV16-infected cells. By cleaving the HPV16 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and inhibition of tumor cell proliferation in HPV16-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinc Finger Nuclease ZFN-603","termGroup":"PT","termSource":"NCI"},{"termName":"ZFN ZFN-603","termGroup":"SY","termSource":"NCI"},{"termName":"ZFN-603","termGroup":"CN","termSource":"NCI"},{"termName":"ZFN603","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Zinc Finger Nuclease ZFN-603"},{"name":"NCI_Drug_Dictionary_ID","value":"783802"},{"name":"NCI_META_CUI","value":"CL512593"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783802"},{"name":"PDQ_Open_Trial_Search_ID","value":"783802"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C129589":{"preferredName":"Zinc Finger Nuclease ZFN-758","code":"C129589","definitions":[{"definition":"A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 18 (HPV18) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-758 into HPV18-positive cells, ZFN-758 targets, binds to and cleaves the HPV18 E7 oncogene in HPV18-infected cells. By cleaving the HPV18 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and an inhibition of tumor cell proliferation in HPV18-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinc Finger Nuclease ZFN-758","termGroup":"PT","termSource":"NCI"},{"termName":"ZFN ZFN-758","termGroup":"SY","termSource":"NCI"},{"termName":"ZFN-758","termGroup":"CN","termSource":"NCI"},{"termName":"ZFN758","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Zinc Finger Nuclease ZFN-758"},{"name":"NCI_Drug_Dictionary_ID","value":"783803"},{"name":"NCI_META_CUI","value":"CL512594"},{"name":"PDQ_Closed_Trial_Search_ID","value":"783803"},{"name":"PDQ_Open_Trial_Search_ID","value":"783803"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C682":{"preferredName":"Zinostatin","code":"C682","definitions":[{"definition":"An enediyne antineoplastic antibiotic hybrid containing an aminoglycoside chromophore.  Zinostatin is isolated from the bacterium Streptomyces carzinostaticus.  The aminoglycoside component of zinostatin intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-strand breaks in DNA and apoptosis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinostatin","termGroup":"PT","termSource":"NCI"},{"termName":"A 8544527G1","termGroup":"CN","termSource":"NCI"},{"termName":"Holoneocarzinostatin","termGroup":"SY","termSource":"NCI"},{"termName":"NCS","termGroup":"AB","termSource":"NCI"},{"termName":"Neocarzinostatin","termGroup":"SY","termSource":"NCI"},{"termName":"Vinostatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"9014-02-2"},{"name":"Chemical_Formula","value":"C35H35NO12"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PP082U6W1L"},{"name":"Legacy Concept Name","value":"Zinostatin"},{"name":"Maps_To","value":"Zinostatin"},{"name":"NCI_Drug_Dictionary_ID","value":"39510"},{"name":"NSC Number","value":"157365"},{"name":"NSC Number","value":"69856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39510"},{"name":"PDQ_Open_Trial_Search_ID","value":"39510"},{"name":"PubMedID_Primary_Reference","value":"20735485"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0027597"}]}}{"C162544":{"preferredName":"Zinostatin Stimalamer","code":"C162544","definitions":[{"definition":"A highly lipophilic conjugate protein comprised of the lipophilic antitumor protein, neocarzinostatin (NCS), conjugated with a water-soluble copolymer of styrene-maleic acid (SMA) with potential antineoplastic activity. Upon intra-hepatic arterial administration, zinostatin stimalamer is deposited within tumor tissues, where the NCS moiety induces sequence-specific single and double-stranded breaks via free-radical based mechanisms, resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zinostatin Stimalamer","termGroup":"PT","termSource":"NCI"},{"termName":"SMANCS","termGroup":"FB","termSource":"NCI"},{"termName":"YM 881","termGroup":"CN","termSource":"NCI"},{"termName":"YM-881","termGroup":"SY","termSource":"NCI"},{"termName":"YM881","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"123760-07-6"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Zinostatin Stimalamer"},{"name":"NCI_META_CUI","value":"CL971120"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C156043":{"preferredName":"Zirconium Zr 89 Panitumumab","code":"C156043","definitions":[{"definition":"A radioimmunoconjugate composed of panitumumab, a human immunoglobulin G2 (IgG2) monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 panitumumab, the antibody moiety targets and binds to the extracellular domain of EGFR on tumor cells. Upon PET imaging, EGFR-expressing tumor cells can be visualized and assessed. This allows quantification of EGFR-expressing tumor cells and may allow selection of patients that would respond to panitumumab therapy. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zirconium Zr 89 Panitumumab","termGroup":"PT","termSource":"NCI"},{"termName":"89Zr-labeled Panitumumab","termGroup":"SY","termSource":"NCI"},{"termName":"89Zr-panitumumab","termGroup":"SY","termSource":"NCI"},{"termName":"Zr 89-Panitumumab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9S814K02BB"},{"name":"Maps_To","value":"Zirconium Zr 89 Panitumumab"},{"name":"NCI_Drug_Dictionary_ID","value":"795428"},{"name":"NCI_META_CUI","value":"CL562883"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795428"},{"name":"PDQ_Open_Trial_Search_ID","value":"795428"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C2682":{"preferredName":"Ziv-Aflibercept","code":"C2682","definitions":[{"definition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","type":"DEFINITION","source":"NCI"},{"definition":"A substance being studied in the treatment of several types of cancer. Vascular endothelial growth factor trap blocks the action of vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Ziv-Aflibercept","termGroup":"PT","termSource":"NCI"},{"termName":"Aflibercept","termGroup":"SY","termSource":"NCI"},{"termName":"Aflibercept beta","termGroup":"SY","termSource":"NCI"},{"termName":"AVE0005","termGroup":"SY","termSource":"NCI"},{"termName":"Eylea","termGroup":"BR","termSource":"NCI"},{"termName":"Vascular Endothelial Growth Factor Trap","termGroup":"SY","termSource":"NCI"},{"termName":"VEGF Trap R1R2","termGroup":"SY","termSource":"NCI"},{"termName":"Zaltrap","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"862111-32-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"15C2VL427D"},{"name":"Legacy Concept Name","value":"VEGF_Trap"},{"name":"Maps_To","value":"Ziv-Aflibercept"},{"name":"NCI_Drug_Dictionary_ID","value":"38652"},{"name":"NSC Number","value":"724770"},{"name":"PDQ_Closed_Trial_Search_ID","value":"38652"},{"name":"PDQ_Open_Trial_Search_ID","value":"38652"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1134659"}]}}{"C85475":{"preferredName":"Zolbetuximab","code":"C85475","definitions":[{"definition":"A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, zolbetuximab specifically targets and binds to CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zolbetuximab","termGroup":"PT","termSource":"NCI"},{"termName":"Claudiximab","termGroup":"SY","termSource":"NCI"},{"termName":"GC 182","termGroup":"SY","termSource":"NCI"},{"termName":"IMAB 362","termGroup":"CN","termSource":"NCI"},{"termName":"IMAB-362","termGroup":"CN","termSource":"NCI"},{"termName":"IMAB362","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1496553-00-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"TF5MPQ8WGY"},{"name":"Maps_To","value":"Zolbetuximab"},{"name":"NCI_Drug_Dictionary_ID","value":"647103"},{"name":"NCI_META_CUI","value":"CL554291"},{"name":"PDQ_Closed_Trial_Search_ID","value":"647103"},{"name":"PDQ_Open_Trial_Search_ID","value":"647103"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C1699":{"preferredName":"Zoledronic Acid","code":"C1699","definitions":[{"definition":"A drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zoledronic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Aclasta","termGroup":"FB","termSource":"NCI"},{"termName":"CGP 42446","termGroup":"CN","termSource":"NCI"},{"termName":"CGP42446A","termGroup":"CN","termSource":"NCI"},{"termName":"NDC-Zoledronate","termGroup":"SY","termSource":"NCI"},{"termName":"Reclast","termGroup":"BR","termSource":"NCI"},{"termName":"ZOL 446","termGroup":"CN","termSource":"NCI"},{"termName":"Zoledronate","termGroup":"SY","termSource":"NCI"},{"termName":"Zometa","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Hypercalcemia of malignancy; Multiple myeloma and metastatic bone lesions from solid tumors; Paget's disease"},{"name":"CAS_Registry","value":"165800-06-6"},{"name":"Chemical_Formula","value":"C5H10N2O7P2.H2O"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_UNII_Code","value":"6XC1PAD3KF"},{"name":"Legacy Concept Name","value":"Zoledronate"},{"name":"Maps_To","value":"Zoledronic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"42507"},{"name":"NSC Number","value":"721517"},{"name":"PDQ_Closed_Trial_Search_ID","value":"42507"},{"name":"PDQ_Open_Trial_Search_ID","value":"42507"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0257685"}]}}{"C74025":{"preferredName":"Zoptarelin Doxorubicin","code":"C74025","definitions":[{"definition":"A peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Zoptarelin doxorubicin binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zoptarelin Doxorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"AEZS-108","termGroup":"CN","termSource":"NCI"},{"termName":"AEZS108","termGroup":"CN","termSource":"NCI"},{"termName":"AN 152","termGroup":"CN","termSource":"NCI"},{"termName":"AN-152","termGroup":"CN","termSource":"NCI"},{"termName":"Doxorubicin-GNRH Agonist Conjugate AEZS-108","termGroup":"SY","termSource":"NCI"},{"termName":"ZEN-008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"139570-93-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27844X2J29"},{"name":"Legacy Concept Name","value":"Doxorubicin-GNRH_Agonist_Conjugate_AEZS-108"},{"name":"Maps_To","value":"Zoptarelin Doxorubicin"},{"name":"NCI_Drug_Dictionary_ID","value":"583257"},{"name":"PDQ_Closed_Trial_Search_ID","value":"583257"},{"name":"PDQ_Open_Trial_Search_ID","value":"583257"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0658619"}]}}{"C91365":{"preferredName":"Zorubicin","code":"C91365","definitions":[{"definition":"A benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zorubicin","termGroup":"PT","termSource":"NCI"},{"termName":"(2S-cis)-Benzoic Acid[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"Benzoic Acid Hydrazide 3-Hydrazone with Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Benzoylhydrazone Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Daunomycin Benzoylhydrazone","termGroup":"SY","termSource":"NCI"},{"termName":"Rubidazon","termGroup":"SY","termSource":"NCI"},{"termName":"Rubidazone","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"54083-22-6"},{"name":"Chemical_Formula","value":"C34H35N3O10"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"V25F9362OP"},{"name":"Maps_To","value":"Zorubicin"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0073688"}]}}{"C1458":{"preferredName":"Zorubicin Hydrochloride","code":"C1458","definitions":[{"definition":"A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin.  Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zorubicin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(2S-cis)-Benzoic Acid[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3-naphthacenyl]ethylidene]hydrazide","termGroup":"SN","termSource":"NCI"},{"termName":"Benzoyl Hydrazone Daunorubicin","termGroup":"SY","termSource":"NCI"},{"termName":"Daunorubicin Benzoylhydrazone Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"RP 22,050 Hydrochloride","termGroup":"CN","termSource":"NCI"},{"termName":"Rubidazone","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"36508-71-1"},{"name":"Chemical_Formula","value":"C34H35N3O10.ClH"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WXM8D9M6DE"},{"name":"Legacy Concept Name","value":"Zorubicin"},{"name":"Maps_To","value":"Zorubicin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"39590"},{"name":"NSC Number","value":"164011"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39590"},{"name":"PDQ_Open_Trial_Search_ID","value":"39590"},{"name":"Semantic_Type","value":"Antibiotic"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0206788"}]}}{"C28322":{"preferredName":"Zuclomiphene Citrate","code":"C28322","definitions":[{"definition":"The cis isomer of clomiphene which exhibits weak estrogen agonist activity evaluated for antineoplastic activity against breast cancer. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zuclomiphene Citrate","termGroup":"PT","termSource":"NCI"},{"termName":"Cis-Clomiphene Citrate","termGroup":"SY","termSource":"NCI"},{"termName":"Cisclomiphene Citrate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"7619-53-6"},{"name":"Chemical_Formula","value":"C26H28ClNO.C6H8O7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UY5X264QZV"},{"name":"Legacy Concept Name","value":"Cisclomiphene"},{"name":"Maps_To","value":"Zuclomiphene Citrate"},{"name":"NCI_Drug_Dictionary_ID","value":"798814"},{"name":"NSC Number","value":"151466"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798814"},{"name":"PDQ_Open_Trial_Search_ID","value":"798814"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1522596"}]}}{"C171381":{"preferredName":"Fosdesdenosine Sipalabenamide","code":"C171381","definitions":[{"definition":"A phosphoramidate derivative of the monophosphate form of cordycepin (3'-deoxyadenosine; 3'-dA), an adenosine derivative first isolated from Cordyceps sinensis, with potential antineoplastic, antioxidant, and anti-inflammatory activities. Upon administration and cellular uptake of fosdesdenosine sipalabenamide by passive diffusion, cordycepin monophosphate (3'-dAMP) is converted into its active anti-cancer metabolite 3'-deoxyadenosine triphosphate (3'-dATP). 3'-dATP functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis. Also, 3'-dAMP activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling. This prevents the hyperphosphorylation of the translation repressor protein 4E-BP1. This results in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers. Compared to cordycepin alone, the addition of the phosphoramidate moiety may overcome cancer resistance and allow for greater cytotoxicity as fosdesdenosine sipalabenamide does not require a nucleoside transporter for cellular uptake, is independent of  enzymatic activation by adenosine kinase (AK) and is not susceptible to enzymatic degradation by adenosine deaminase (ADA). Altogether, this may help overcome cancer resistance to cordycepin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fosdesdenosine Sipalabenamide","termGroup":"PT","termSource":"NCI"},{"termName":"3'-dA Phosphoramidate NUC-7738","termGroup":"SY","termSource":"NCI"},{"termName":"NUC 7738","termGroup":"CN","termSource":"NCI"},{"termName":"NUC-7738","termGroup":"CN","termSource":"NCI"},{"termName":"NUC7738","termGroup":"CN","termSource":"NCI"},{"termName":"Nucleoside Analog NUC-7738","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2348493-39-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y7BFN2M72F"},{"name":"Maps_To","value":"3'-dA Phosphoramidate NUC-7738"},{"name":"NCI_Drug_Dictionary_ID","value":"800960"},{"name":"NCI_META_CUI","value":"CL1405486"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800960"},{"name":"PDQ_Open_Trial_Search_ID","value":"800960"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172109":{"preferredName":"Inupadenant","code":"C172109","definitions":[{"definition":"An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, inupadenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inupadenant","termGroup":"PT","termSource":"NCI"},{"termName":"A2A Receptor Antagonist EOS100850","termGroup":"SY","termSource":"NCI"},{"termName":"EOS 100850","termGroup":"CN","termSource":"NCI"},{"termName":"EOS-100850","termGroup":"CN","termSource":"NCI"},{"termName":"EOS100850","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2246607-08-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HQ700V0X06"},{"name":"Maps_To","value":"A2A Receptor Antagonist EOS100850"},{"name":"NCI_Drug_Dictionary_ID","value":"801361"},{"name":"NCI_META_CUI","value":"CL1413218"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801361"},{"name":"PDQ_Open_Trial_Search_ID","value":"801361"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175468":{"preferredName":"Adenosine A2A Receptor Antagonist CS3005","code":"C175468","definitions":[{"definition":"An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist CS3005 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenosine A2A Receptor Antagonist CS3005","termGroup":"PT","termSource":"NCI"},{"termName":"A2AR Antagonist CS3005","termGroup":"SY","termSource":"NCI"},{"termName":"CS 3005","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3005","termGroup":"CN","termSource":"NCI"},{"termName":"CS3005","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenosine A2A Receptor Antagonist CS3005"},{"name":"NCI_Drug_Dictionary_ID","value":"802908"},{"name":"NCI_META_CUI","value":"CL1412853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802908"},{"name":"PDQ_Open_Trial_Search_ID","value":"802908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173640":{"preferredName":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","code":"C173640","definitions":[{"definition":"A recombinant adenoviral serotype 5 (Ad5) in which the Ad5-based vector fiber is replaced by the fiber from the human B adenovirus serotype 35 (F35), encoding for the human guanylyl cyclase C (hGCC), and fused to the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the Ad5/F35-hGCC-PADRE, the Ad5/F35 targets CD46, which is expressed widely on most tumor cells, and the virus is taken up by cells. Once inside the cells, the virus expresses hGCC. The expressed hGCC induces both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated killing of tumor cells. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response. The inclusion of the chimeric Ad5/F35 fiber increases viral uptake in cells through CD46.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","termGroup":"PT","termSource":"NCI"},{"termName":"Ad5.F35-hGCC-PADRE","termGroup":"SY","termSource":"NCI"},{"termName":"Ad5/F35-hGCC-PADRE","termGroup":"SY","termSource":"NCI"},{"termName":"Adenovirus 5/F35-HGCC-PADRE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE"},{"name":"NCI_Drug_Dictionary_ID","value":"802251"},{"name":"NCI_META_CUI","value":"CL1407372"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802251"},{"name":"PDQ_Open_Trial_Search_ID","value":"802251"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167360":{"preferredName":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918","code":"C167360","definitions":[{"definition":"A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 16 (HPV16), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV16 vaccine JNJ-63682918, the adenovirus infects and expresses HPV16. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 antigens, thereby inducing tumor cell lysis. HPV16 infection plays a key role in the development of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918","termGroup":"PT","termSource":"NCI"},{"termName":"Ad26-expressing HPV16 Vaccine JNJ-63682918","termGroup":"SY","termSource":"NCI"},{"termName":"Ad26.HPV16 JNJ-63682918","termGroup":"SY","termSource":"NCI"},{"termName":"Adenovirus Serotype 26-Human Papillomavirus 16 JNJ-63682918","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63682918","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63682918","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63682918","termGroup":"CN","termSource":"NCI"},{"termName":"Monovalent HPV16 Ad26-vectored Vaccine JNJ-63682918","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918"},{"name":"NCI_Drug_Dictionary_ID","value":"810657"},{"name":"NCI_META_CUI","value":"CL972334"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167361":{"preferredName":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931","code":"C167361","definitions":[{"definition":"A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV18 vaccine JNJ-63682931, the adenovirus infects and expresses HPV18. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV18 antigens, thereby inducing tumor cell lysis. HPV18 infection plays a key role in the development of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931","termGroup":"PT","termSource":"NCI"},{"termName":"Ad26-expressing HPV18 Vaccine JNJ-63682931","termGroup":"SY","termSource":"NCI"},{"termName":"Ad26.HPV18 JNJ-63682931","termGroup":"SY","termSource":"NCI"},{"termName":"Adenovirus Serotype 26-Human Papillomavirus 18 JNJ-63682931","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 63682931","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-63682931","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ63682931","termGroup":"CN","termSource":"NCI"},{"termName":"Monovalent HPV18 Ad26-vectored Vaccine JNJ-63682931","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931"},{"name":"NCI_Drug_Dictionary_ID","value":"810658"},{"name":"NCI_META_CUI","value":"CL972333"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171615":{"preferredName":"ALK Inhibitor TAE684","code":"C171615","definitions":[{"definition":"A small molecule inhibitor of the receptor tyrosine kinases (RTKs) anaplastic lymphoma kinase (ALK) and nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), with potential antineoplastic activity. Upon administration, TAE684 binds to and inhibits ALK and NPM-ALK tyrosine kinases, which leads to a disruption of ALK- and NPM-ALK mediated signaling and eventually inhibits tumor cell growth in ALK- and NPM-ALK overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. NPM-ALK is an oncogenic fusion protein associated with ALK-positive anaplastic large cell lymphoma. ALK mutations are also associated with acquired resistance to small molecule tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ALK Inhibitor TAE684","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-n4-(2-(isopropylsulfonyl)phenyl)-n2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine","termGroup":"SN","termSource":"NCI"},{"termName":"NPM-ALK Inhibitor TAE684","termGroup":"SY","termSource":"NCI"},{"termName":"NVP-TAE684","termGroup":"CN","termSource":"NCI"},{"termName":"TAE 684","termGroup":"CN","termSource":"NCI"},{"termName":"TAE-684","termGroup":"CN","termSource":"NCI"},{"termName":"TAE684","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"761439-42-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"EH1713MN4K"},{"name":"Maps_To","value":"ALK Inhibitor TAE684"},{"name":"NCI_META_CUI","value":"CL1405839"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173430":{"preferredName":"Unecritinib","code":"C173430","definitions":[{"definition":"An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK), C-ros oncogene 1 (ROS1) and Met (hepatocyte growth factor receptor; HGFR; c-Met), with potential antineoplastic activity. Upon oral administration,unecritinib targets, binds to and inhibits the activity of ALK, ROS1 and c-Met, which leads to the disruption of ALK-, ROS1- and c-Met-mediated signaling and the inhibition of cell growth in ALK-, ROS1- and c-Met-expressing tumor cells. ALK, ROS1 and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unecritinib","termGroup":"PT","termSource":"NCI"},{"termName":"ALK/ROS1/Met Inhibitor TQ-B3101","termGroup":"SY","termSource":"NCI"},{"termName":"TQB 3101","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3101","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1418026-92-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4T3Z98RR86"},{"name":"Maps_To","value":"ALK/ROS1/Met Inhibitor TQ-B3101"},{"name":"NCI_Drug_Dictionary_ID","value":"801758"},{"name":"NCI_META_CUI","value":"CL1407437"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801758"},{"name":"PDQ_Open_Trial_Search_ID","value":"801758"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165779":{"preferredName":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715","code":"C165779","definitions":[{"definition":"A preparation of allogeneic, 'off-the-shelf' (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are deleted from the CAR T-cells. Upon administration, the allogeneic anti-BCMA CAR-transduced T-cells ALLO-715 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. Deletion of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The donor-derived, gene-edited CAR T cells have reduced production times and have increased availability when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. In addition, if the ALLO-715 cells cause unacceptable side effects, the incorporated CD20-based off-switch permits selective depletion of the ALLO-715 cells when the anti-CD20 monoclonal antibody rituximab is administered.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715","termGroup":"PT","termSource":"NCI"},{"termName":"ALLO 715","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-715","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-715 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ALLO715","termGroup":"CN","termSource":"NCI"},{"termName":"ALLOCar T ALLO-715","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA Allogeneic CAR T Cells ALLO-715","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q137JC2CLV"},{"name":"Maps_To","value":"Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715"},{"name":"NCI_Drug_Dictionary_ID","value":"800201"},{"name":"NCI_META_CUI","value":"CL979064"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800201"},{"name":"PDQ_Open_Trial_Search_ID","value":"800201"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171066":{"preferredName":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A","code":"C171066","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-BCMA-CAR T-cells PBCAR269A specifically recognize and kill BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-BCMA-CAR T-cells PBCAR269A"},{"name":"NCI_Drug_Dictionary_ID","value":"801229"},{"name":"NCI_META_CUI","value":"CL1405454"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801229"},{"name":"PDQ_Open_Trial_Search_ID","value":"801229"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173967":{"preferredName":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells","code":"C173967","definitions":[{"definition":"A preparation of allogeneic T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting both the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-BCMA/CS1 bispecific CAR-T cells target and bind to tumor cells expressing BCMA and/or CS1 and induce selective cytotoxicity in those cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells. Targeting the two different TAAs highly expressed on malignant plasma cells may improve coverage and protect against antigen escape and resistance as tumor cells would need to lose both antigens. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-BCMA/CS1 Bispecific CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-BCMA/SLAMF7 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic BCMA/CS1 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic BCMA/SLAMF7 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802179"},{"name":"NCI_META_CUI","value":"CL1407845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802179"},{"name":"PDQ_Open_Trial_Search_ID","value":"802179"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172708":{"preferredName":"Cemacabtagene Ansegedleucel","code":"C172708","definitions":[{"definition":"A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon administration, cemacabtagene ansegedleucel specifically targets and binds to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cemacabtagene Ansegedleucel","termGroup":"PT","termSource":"NCI"},{"termName":"ALLO 501A","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO-501A","termGroup":"CN","termSource":"NCI"},{"termName":"ALLO501A","termGroup":"CN","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 CAR T-cells ALLO-501A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 CAR T-lymphocytes ALLO-501A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 CAR-T Cells ALLO-501A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic CD19-specific CAR T-cells ALLO-501A","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W3X22HS7XD"},{"name":"Maps_To","value":"Allogeneic Anti-CD19 CAR T-cells ALLO-501A"},{"name":"NCI_Drug_Dictionary_ID","value":"802025"},{"name":"NCI_META_CUI","value":"CL1406567"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802025"},{"name":"PDQ_Open_Trial_Search_ID","value":"802025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173959":{"preferredName":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101","code":"C173959","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), universal, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 universal CAR-T cells CTA101 specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. CTA101 is genetically engineered to prevent graft-versus-host disease (GvHD) by the donor T-cells. OTS CAR-T cells require reduced production times when compared to autologous CAR-T cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-CD19 UCAR-T Cells CTA101","termGroup":"SY","termSource":"NCI"},{"termName":"CTA 101","termGroup":"CN","termSource":"NCI"},{"termName":"CTA-101","termGroup":"CN","termSource":"NCI"},{"termName":"CTA101","termGroup":"CN","termSource":"NCI"},{"termName":"Universal CD19-directed CAR-T Cells CTA101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-CD19 Universal CAR-T Cells CTA101"},{"name":"NCI_Drug_Dictionary_ID","value":"802167"},{"name":"NCI_META_CUI","value":"CL1407868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802167"},{"name":"PDQ_Open_Trial_Search_ID","value":"802167"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174397":{"preferredName":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S","code":"C174397","definitions":[{"definition":"A preparation of donor-derived T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T-cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S","termGroup":"PT","termSource":"NCI"},{"termName":"LUCAR 20S","termGroup":"CN","termSource":"NCI"},{"termName":"LUCAR-20S","termGroup":"CN","termSource":"NCI"},{"termName":"LUCAR-20S CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"LUCAR20S","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-CD20 CAR T-cells LUCAR-20S"},{"name":"NCI_Drug_Dictionary_ID","value":"802323"},{"name":"NCI_META_CUI","value":"CL1411949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802323"},{"name":"PDQ_Open_Trial_Search_ID","value":"802323"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168570":{"preferredName":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A","code":"C168570","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), T-lymphocytes, derived from healthy donors, that have been genetically modified using a proprietary synthetic endonuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20-CAR T-cells PBCAR20A specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Anti-CD20 CAR T-lymphocytes PBCAR20A","termGroup":"SY","termSource":"NCI"},{"termName":"PBCAR 20A","termGroup":"CN","termSource":"NCI"},{"termName":"PBCAR-20A","termGroup":"CN","termSource":"NCI"},{"termName":"PBCAR20A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Anti-CD20-CAR T-cells PBCAR20A"},{"name":"NCI_Drug_Dictionary_ID","value":"800688"},{"name":"NCI_META_CUI","value":"CL972895"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800688"},{"name":"PDQ_Open_Trial_Search_ID","value":"800688"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165696":{"preferredName":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22","code":"C165696","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, allogeneic CD22-specific universal CAR-expressing T-lymphocytes UCART22 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Gene-edited CAR T-Cells UCART22","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic TALEN Gene-edited CAR T-Cells UCART22","termGroup":"SY","termSource":"NCI"},{"termName":"Allogenic Engineered T-cells Expressing Anti- CD22 CAR UCART22","termGroup":"SY","termSource":"NCI"},{"termName":"UCART 22","termGroup":"CN","termSource":"NCI"},{"termName":"UCART-22","termGroup":"CN","termSource":"NCI"},{"termName":"UCART22","termGroup":"CN","termSource":"NCI"},{"termName":"UCART22 Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22"},{"name":"NCI_Drug_Dictionary_ID","value":"800127"},{"name":"NCI_META_CUI","value":"CL978908"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800127"},{"name":"PDQ_Open_Trial_Search_ID","value":"800127"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170887":{"preferredName":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001","code":"C170887","definitions":[{"definition":"A preparation of allogeneic CD8+ T cells targeting multiple undisclosed leukemia-associated antigens, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection from the original stem cell donor and ex vivo priming and expansion, the allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001 are re-introduced into the leukemia patient, where they target and kill tumor cells expressing these leukemia-associated antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001","termGroup":"PT","termSource":"NCI"},{"termName":"NEXI 001","termGroup":"CN","termSource":"NCI"},{"termName":"NEXI-001","termGroup":"CN","termSource":"NCI"},{"termName":"NEXI001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001"},{"name":"NCI_Drug_Dictionary_ID","value":"801194"},{"name":"NCI_META_CUI","value":"CL1383035"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801194"},{"name":"PDQ_Open_Trial_Search_ID","value":"801194"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172741":{"preferredName":"Motacabtagene Lurevgedleucel","code":"C172741","definitions":[{"definition":"A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, motacabtagene lurevgedleucel recognize and bind to BCMA-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of BCMA-positive tumor cells. BCMA, a receptor for proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. The disruption of endogenous TCR prevents graft-versus-host disease (GvHD). The disruption of MHC class I molecules increases the persistence of the CAR T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Motacabtagene Lurevgedleucel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120","termGroup":"SY","termSource":"NCI"},{"termName":"CRISPR/Cas9 Gene-edited Allogeneic Anti-BCMA CAR-T Cells CTX120","termGroup":"SY","termSource":"NCI"},{"termName":"CTX 120","termGroup":"CN","termSource":"NCI"},{"termName":"CTX-120","termGroup":"CN","termSource":"NCI"},{"termName":"CTX120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7CH7MR6SN5"},{"name":"Maps_To","value":"Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120"},{"name":"NCI_Drug_Dictionary_ID","value":"802026"},{"name":"NCI_META_CUI","value":"CL1406620"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802026"},{"name":"PDQ_Open_Trial_Search_ID","value":"802026"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173153":{"preferredName":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130","code":"C173153","definitions":[{"definition":"A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD70 CAR T-cells CTX130 recognize and bind to CD70-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. Disruption of endogenous TCR prevents graft-versus-host disease (GvHD); the disruption of MHC class I molecules increases the persistence of the CAR T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic CRISPR-Cas9-engineered T Cells CTX130","termGroup":"SY","termSource":"NCI"},{"termName":"CRISPR/Cas9 Gene-edited Allogeneic Anti-CD70 CAR-T Cells CTX130","termGroup":"SY","termSource":"NCI"},{"termName":"CTX 130","termGroup":"CN","termSource":"NCI"},{"termName":"CTX-130","termGroup":"CN","termSource":"NCI"},{"termName":"CTX130","termGroup":"CN","termSource":"NCI"},{"termName":"Donor-derived Gene-edited Allogeneic CAR-T Cells CTX130","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130"},{"name":"NCI_Drug_Dictionary_ID","value":"802058"},{"name":"NCI_META_CUI","value":"CL1407020"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802058"},{"name":"PDQ_Open_Trial_Search_ID","value":"802058"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165661":{"preferredName":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A","code":"C165661","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon transfusion of allogeneic CS1-specific universal CAR-expressing T-lymphocytes UCARTCS1A, these cells target and bind to cancer cells expressing CS1. This induces selective toxicity in and causes lysis of CS1-expressing tumor cells. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Gene-edited CAR T-Cells UCARTCS1A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic TALEN Gene-edited CAR T-Cells UCARTCS1A","termGroup":"SY","termSource":"NCI"},{"termName":"Allogenic Engineered T-cells Expressing Anti- CS1 CAR UCARTCS1A","termGroup":"SY","termSource":"NCI"},{"termName":"UCART CS1A","termGroup":"CN","termSource":"NCI"},{"termName":"UCART-CS1A","termGroup":"CN","termSource":"NCI"},{"termName":"UCARTCS1A","termGroup":"CN","termSource":"NCI"},{"termName":"UCARTCS1A Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A"},{"name":"NCI_Drug_Dictionary_ID","value":"800121"},{"name":"NCI_META_CUI","value":"CL978955"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800121"},{"name":"PDQ_Open_Trial_Search_ID","value":"800121"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173427":{"preferredName":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01","code":"C173427","definitions":[{"definition":"An off-the-shelf (OTS) preparation composed of irradiated allogeneic plasmacytoid dendritic cells (pDCs) loaded with seven immunogenic, human leukocyte antigen (HLA)-A*02:01 serotype-restricted peptides derived from the lung tumor antigens cancer/testis antigen 1 (NY-ESO-1), melanoma antigen A3 (MAGE-A3), MAGE-A4, multi-MAGE, a peptide shared by multiple MAGE-A proteins, survivin, mucin1 (MUC1) and melanoma antigen recognized by T-cells 1 (Mart-1; Melan-A), with potential immunostimulating and antineoplastic activities. Upon administration of the allogeneic pDCs expressing lung tumor antigens PDC*lung01, the pDCs may activate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against HLA-A*0201 positive lung cancer cells expressing the TAAs NY-ESO-1, MAGE-A3, MAGEA4, multi-MAGE, survivin, MUC1 and melan-A. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic pDCs- expressing Lung Tumor Antigens PDC*lung01","termGroup":"SY","termSource":"NCI"},{"termName":"PDC*lung01","termGroup":"CN","termSource":"NCI"},{"termName":"PDClung01","termGroup":"CN","termSource":"NCI"},{"termName":"Therapeutic Cancer Vaccine PDC*lung01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01"},{"name":"NCI_Drug_Dictionary_ID","value":"801755"},{"name":"NCI_META_CUI","value":"CL1407435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801755"},{"name":"PDQ_Open_Trial_Search_ID","value":"801755"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174401":{"preferredName":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19","code":"C174401","definitions":[{"definition":"A preparation of allogeneic, third-party, CD4+ T-lymphocytes that specifically recognizes the human leukocyte antigen (HLA)-DPB1*0401 and transduced with a suicide gene, with potential antineoplastic activity. Upon administration, allogeneic third-party suicide gene-transduced anti-HLA-DPB1*0401 CD4+ T-cells CTL 19 specifically target and kill HLA-DPB1*0401-positive leukemic cells. The suicide gene causes the destruction of the T-cell clone upon the administration and presence of ganciclovir, which enhances the safety of the agent. HLA-DP is expressed by many leukemic cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19","termGroup":"PT","termSource":"NCI"},{"termName":"CTL 19","termGroup":"CN","termSource":"NCI"},{"termName":"CTL-19","termGroup":"CN","termSource":"NCI"},{"termName":"CTL19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19"},{"name":"NCI_Drug_Dictionary_ID","value":"802327"},{"name":"NCI_META_CUI","value":"CL1411953"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802327"},{"name":"PDQ_Open_Trial_Search_ID","value":"802327"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171059":{"preferredName":"Tuxobertinib","code":"C171059","definitions":[{"definition":"An orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. Upon oral administration, tuxobertinib selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations. EGFR and HER2, ErbB receptor tyrosine kinases mutated or overexpressed in many tumor cell types, play a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuxobertinib","termGroup":"PT","termSource":"NCI"},{"termName":"Allosteric ErbB Inhibitor BDTX-189","termGroup":"SY","termSource":"NCI"},{"termName":"BDTX 189","termGroup":"CN","termSource":"NCI"},{"termName":"BDTX-189","termGroup":"CN","termSource":"NCI"},{"termName":"BDTX189","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/HER2 Inhibitor BDTX-189","termGroup":"SY","termSource":"NCI"},{"termName":"ErbB Mutant-specific Inhibitor BDTX-189","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2414572-47-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6CE2107J4T"},{"name":"Maps_To","value":"Allosteric ErbB Inhibitor BDTX-189"},{"name":"NCI_Drug_Dictionary_ID","value":"801228"},{"name":"NCI_META_CUI","value":"CL1405430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801228"},{"name":"PDQ_Open_Trial_Search_ID","value":"801228"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170744":{"preferredName":"Alofanib","code":"C170744","definitions":[{"definition":"An inhibitor of the fibroblast growth factor receptor (FGFR) type 2 (FGFR2), with potential antineoplastic and anti-angiogenic activities. Upon administration, alofanib targets, allosterically binds to the extracellular domain of FGFR2 and inhibits the activity of FGFR2, which may result in the inhibition of basic FGF (bFGF)/FGFR2-related signal transduction pathways. This inhibits FGF-induced endothelial cell proliferation and migration, and inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alofanib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzoic Acid, 3-(((4-Methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"ES000835","termGroup":"CN","termSource":"NCI"},{"termName":"RPT 835","termGroup":"CN","termSource":"NCI"},{"termName":"RPT-835","termGroup":"CN","termSource":"NCI"},{"termName":"RPT835","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1612888-66-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LQX7RFK8MZ"},{"name":"Maps_To","value":"Alofanib"},{"name":"NCI_Drug_Dictionary_ID","value":"800699"},{"name":"NCI_META_CUI","value":"CL1383158"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800699"},{"name":"PDQ_Open_Trial_Search_ID","value":"800699"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172097":{"preferredName":"Alpha V Beta 8 Antagonist PF-06940434","code":"C172097","definitions":[{"definition":"An antagonist of integrin alpha v beta 8, with potential antineoplastic activity. Upon administration, PF-06940434 selectively binds to and blocks the receptor for integrin alpha v beta 8, thereby preventing integrin alpha v beta 8 binding. This may result in the inhibition of cell adhesion in the tumor microenvironment (TME) and blocks the activation of the cytokine transforming growth factor-beta 1 (TGF-b1), preventing TGF-b1-mediated signal transduction. This abrogates TGF-b1-mediated immunosuppression, enhances anti-tumor immunity in the TME and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGF-b1-dependent proliferation of cancer cells. Alpha v beta 8 integrin plays a key role in tumor initiation, growth, and progression through TGF-b1 activation. It is expressed in a variety of tumor cell types and is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alpha V Beta 8 Antagonist PF-06940434","termGroup":"PT","termSource":"NCI"},{"termName":"Alpha V Beta 8 Inhibitor PF-06940434","termGroup":"SY","termSource":"NCI"},{"termName":"PF 06940434","termGroup":"CN","termSource":"NCI"},{"termName":"PF-06940434","termGroup":"CN","termSource":"NCI"},{"termName":"PF06940434","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Alpha V Beta 8 Antagonist PF-06940434"},{"name":"NCI_Drug_Dictionary_ID","value":"802007"},{"name":"NCI_META_CUI","value":"CL1406223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802007"},{"name":"PDQ_Open_Trial_Search_ID","value":"802007"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173364":{"preferredName":"Androgen Receptor Degrader CC-94676","code":"C173364","definitions":[{"definition":"An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, AR degrader CC-94676 causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor Degrader CC-94676","termGroup":"PT","termSource":"NCI"},{"termName":"AR Degrader CC-94676","termGroup":"SY","termSource":"NCI"},{"termName":"CC 94676","termGroup":"CN","termSource":"NCI"},{"termName":"CC-94676","termGroup":"CN","termSource":"NCI"},{"termName":"CC94676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"VA228VR2DI"},{"name":"Maps_To","value":"Androgen Receptor Degrader CC-94676"},{"name":"NCI_Drug_Dictionary_ID","value":"801809"},{"name":"NCI_META_CUI","value":"CL1407191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801809"},{"name":"PDQ_Open_Trial_Search_ID","value":"801809"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173374":{"preferredName":"Masofaniten","code":"C173374","definitions":[{"definition":"An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, masofaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. Masofaniten may be more active and metabolically stable than first-generation AR NTD inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masofaniten","termGroup":"PT","termSource":"NCI"},{"termName":"Androgen Receptor Inhibitor EPI-7386","termGroup":"SY","termSource":"NCI"},{"termName":"AR Inhibitor EPI-7386","termGroup":"SY","termSource":"NCI"},{"termName":"EPI 7386","termGroup":"CN","termSource":"NCI"},{"termName":"EPI-7386","termGroup":"CN","termSource":"NCI"},{"termName":"EPI7386","termGroup":"CN","termSource":"NCI"},{"termName":"Methanesulfonamide, N-(4-((4-(1-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)-1-methylethyl)phenoxy)methyl)-2-pyrimidinyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"N-(4-((4-(2-(3-Chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2416716-62-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OQ2SF7P8B2"},{"name":"Maps_To","value":"Androgen Receptor Inhibitor EPI-7386"},{"name":"NCI_Drug_Dictionary_ID","value":"801842"},{"name":"NCI_META_CUI","value":"CL1407198"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801842"},{"name":"PDQ_Open_Trial_Search_ID","value":"801842"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172104":{"preferredName":"Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10","code":"C172104","definitions":[{"definition":"An orally bioavailable steroidal cortexolone derivative and antagonist of the androgen receptor (AR) and glucocorticoid receptor (GR), with potential antineoplastic activity. Upon oral administration, AR/GR antagonist CB-03-10 specifically binds to AR and GR, inhibits AR and GR activation, and prevents AR- and GR-mediated signaling. This leads to an induction of both extrinsic and intrinsic apoptotic pathways and inhibits cell growth in AR- and GR-overexpressing tumor cells. AR and GR are overexpressed in certain types of cancer cells and are involved in proliferation, survival and chemoresistance of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10","termGroup":"PT","termSource":"NCI"},{"termName":"AR/GR Antagonist CB-03-10","termGroup":"SY","termSource":"NCI"},{"termName":"CB 03 10","termGroup":"CN","termSource":"NCI"},{"termName":"CB-03-10","termGroup":"CN","termSource":"NCI"},{"termName":"CB0310","termGroup":"CN","termSource":"NCI"},{"termName":"Cortexolone 17alpha-Valerate-21-propionate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10"},{"name":"NCI_Drug_Dictionary_ID","value":"801352"},{"name":"NCI_META_CUI","value":"CL1406219"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801352"},{"name":"PDQ_Open_Trial_Search_ID","value":"801352"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168687":{"preferredName":"Anhydrous Enol-oxaloacetate","code":"C168687","definitions":[{"definition":"The anhydrous form of enol-oxaloacetate, a small molecule blood glutamate scavenger, that can be used to lower glutamate plasma levels, and has potential neuroprotective activity. Upon administration, enol-oxaloacetate targets and binds to glutamate in the bloodstream. This lowers glutamate plasma levels and lowers the free glutamate available to be picked up by cells, such as tumor brain cells, thereby preventing glutamate metabolism and glutamate-mediated signaling. This prevents the proliferation of rapidly growing cells, such as brain tumor cells. And by lowering glutamate plasma levels, a molecular imbalance is formed and glutamate is excreted across the blood-brain barrier, resulting in lower free brain glutamate.  This may help protect the brain from excitotoxicity in conditions where there is a surge of glutamate production, such as traumatic brain injury, thereby protecting neuronal cells. Glutamate, a non-essential amino acid and the major excitatory neurotransmitter in the central nervous system (CNS), provides energy and generates building blocks for the production of macromolecules, which are needed for cellular growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anhydrous Enol-oxaloacetate","termGroup":"PT","termSource":"NCI"},{"termName":"AEO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"328-42-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2F399MM81J"},{"name":"Maps_To","value":"Anhydrous Enol-oxaloacetate"},{"name":"NCI_Drug_Dictionary_ID","value":"800694"},{"name":"NCI_META_CUI","value":"CL1378618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800694"},{"name":"PDQ_Open_Trial_Search_ID","value":"800694"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173556":{"preferredName":"Anti-5T4 Antibody-drug Conjugate ASN004","code":"C173556","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody directed against 5T4 and conjugated, via a non-cleavable linker, to a proprietary polymer carrying multiple auristatin analog molecules via a cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of ASN004 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell cytosol, free auristatin analog molecules binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-5T4 Antibody-drug Conjugate ASN004","termGroup":"PT","termSource":"NCI"},{"termName":"5T4-ADC ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"5T4-targeted Antibody-drug Conjugate ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"5T4-targeted Dolaflexin ADC ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-5T4 ADC ASN004","termGroup":"SY","termSource":"NCI"},{"termName":"ASN 004","termGroup":"CN","termSource":"NCI"},{"termName":"ASN-004","termGroup":"CN","termSource":"NCI"},{"termName":"ASN004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-5T4 Antibody-drug Conjugate ASN004"},{"name":"NCI_Drug_Dictionary_ID","value":"801910"},{"name":"NCI_META_CUI","value":"CL1407317"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801910"},{"name":"PDQ_Open_Trial_Search_ID","value":"801910"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175444":{"preferredName":"Anti-5T4 Antibody-drug Conjugate SYD1875","code":"C175444","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the oncofetal antigen 5T4 and site-specifically conjugated to a duocarmycin-based linker-drug valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA), with potential antineoplastic activity. Upon administration, the antibody moiety of SYD1875 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell by proteases, the free and activated duocarmycin payload binds to the minor groove of DNA and alkylates adenine at the N3 position, which eventually leads to tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-5T4 Antibody-drug Conjugate SYD1875","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SYD1875","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-5T4 ADC SYD1875","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate SYD1875","termGroup":"SY","termSource":"NCI"},{"termName":"SYD 1875","termGroup":"CN","termSource":"NCI"},{"termName":"SYD-1875","termGroup":"CN","termSource":"NCI"},{"termName":"SYD1875","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-5T4 Antibody-drug Conjugate SYD1875"},{"name":"NCI_Drug_Dictionary_ID","value":"802782"},{"name":"NCI_META_CUI","value":"CL1412814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802782"},{"name":"PDQ_Open_Trial_Search_ID","value":"802782"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171577":{"preferredName":"Ifinatamab Deruxtecan","code":"C171577","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-B7-H3/DXd ADC DS-7300a, the anti-B7-H3 antibody targets and binds to B7-H3-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifinatamab Deruxtecan","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B7-H3/DXd ADC DS-7300a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-B7H3/DXd Antibody-drug Conjugate DS-7300a","termGroup":"SY","termSource":"NCI"},{"termName":"DS 7300","termGroup":"CN","termSource":"NCI"},{"termName":"DS 7300a","termGroup":"CN","termSource":"NCI"},{"termName":"DS-7300","termGroup":"CN","termSource":"NCI"},{"termName":"DS-7300a","termGroup":"CN","termSource":"NCI"},{"termName":"DS7300","termGroup":"CN","termSource":"NCI"},{"termName":"DS7300a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2484870-92-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C6I0GC0GX5"},{"name":"Maps_To","value":"Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a"},{"name":"NCI_Drug_Dictionary_ID","value":"801901"},{"name":"NCI_META_CUI","value":"CL1405790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801901"},{"name":"PDQ_Open_Trial_Search_ID","value":"801901"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170915":{"preferredName":"Ispectamab Debotansine","code":"C170915","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of ispectamab, a humanized immunoglobulin G1 (IgG1)-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor (TNF) receptor superfamily, member 17; TNFRSF17) site-specifically conjugated, with a non-cleavable linker, to a maytansinoid payload, with potential antineoplastic activity. Upon administration of ispectamab debotansine, the ispectamab moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon binding and internalization, the maytansinoid payload binds to tubulin, thereby affecting microtubule assembly/disassembly dynamic, and prevents cell division and reduces cell growth of BCMA-expressing cancer cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; TNF ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is overexpressed on malignant plasma cells and plays a key role in plasma survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ispectamab Debotansine","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA ADC CC-99712","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA Antibody Drug Conjugate CC-99712","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA Antibody-drug Conjugate CC-99712","termGroup":"SY","termSource":"NCI"},{"termName":"BMS-986352","termGroup":"CN","termSource":"NCI"},{"termName":"CC 99712","termGroup":"CN","termSource":"NCI"},{"termName":"CC-99712","termGroup":"CN","termSource":"NCI"},{"termName":"CC99712","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2413386-21-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WY39ZX6NZU"},{"name":"Maps_To","value":"Anti-BCMA Antibody-drug Conjugate CC-99712"},{"name":"NCI_Drug_Dictionary_ID","value":"800869"},{"name":"NCI_META_CUI","value":"CL1383075"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800869"},{"name":"PDQ_Open_Trial_Search_ID","value":"800869"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167337":{"preferredName":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA","code":"C167337","definitions":[{"definition":"An immunotherapeutic combination agent composed of antigen receptor complex T cells (ARC-T cells) which contain a proprietary binding domain specific for a universal TAG instead of a single chain variable fragment (scFv) binding domain, and a tumor-targeting antigen protein, soluble protein antigen-receptor X-linker (sparX) protein, containing a TAG moiety fused to two B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) binding domains, with potential antineoplastic activities. Upon administration of the anti-BCMA sparX protein plus BCMA-directed ARC T-cells CART-ddBCMA, the sparX protein, with its two BCMA binding domains, specifically targets and binds to two BCMA expressed on tumor cells. In turn, the ARC-T cells, with their anti-TAG domain, target and bind to the TAG domain on the sparX protein. This directly links the ARC-T cells to the BCMA-expressing tumor cells, through the ARC-T cell- sparX -tumor cell complex formation, thereby causing direct tumor cell killing. BCMA, a tumor-associated antigen (TAA), is found on the surfaces of plasma cells and is overexpressed on a variety of tumor cell types. Compared to anti-BCMA CAR-T cells, CART-ddBCMA, containing ARC-T cells that are re-programmed in vivo by the TAG sparX protein, shows enhanced efficiency and an improved safety profile. As ARC-T activity is dependent on the sparX dose administered, the rate of tumor cell killing, and related toxicities are also dependent on the sparX dose administered.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein","termGroup":"SY","termSource":"NCI"},{"termName":"ARC-T Plus Anti-BCMA SparX","termGroup":"SY","termSource":"NCI"},{"termName":"Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA","termGroup":"SY","termSource":"NCI"},{"termName":"TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA"},{"name":"NCI_Drug_Dictionary_ID","value":"800471"},{"name":"NCI_META_CUI","value":"CL972316"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800471"},{"name":"PDQ_Open_Trial_Search_ID","value":"800471"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165656":{"preferredName":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459","code":"C165656","definitions":[{"definition":"A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody REGN5459 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BCMA/CD3 Bispecific Antibody REGN5459","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD3/Anti-BCMA Bispecific Antibody REGN5459","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5459","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5459","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5459","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459"},{"name":"NCI_Drug_Dictionary_ID","value":"800119"},{"name":"NCI_META_CUI","value":"CL978958"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800119"},{"name":"PDQ_Open_Trial_Search_ID","value":"800119"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168617":{"preferredName":"Tifcemalimab","code":"C168617","definitions":[{"definition":"A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and antineoplastic activities. Upon intravenous infusion administration, tifcemalimab targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells (DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tifcemalimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-B- and T-lymphocyte Attenuator Monoclonal Antibody TAB004","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-BTLA Monoclonal Antibody TAB004","termGroup":"SY","termSource":"NCI"},{"termName":"Icatolimab","termGroup":"SY","termSource":"NCI"},{"termName":"JS 004","termGroup":"CN","termSource":"NCI"},{"termName":"JS-004","termGroup":"CN","termSource":"NCI"},{"termName":"JS004","termGroup":"CN","termSource":"NCI"},{"termName":"TAB 004","termGroup":"CN","termSource":"NCI"},{"termName":"TAB-004","termGroup":"CN","termSource":"NCI"},{"termName":"TAB004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2236068-83-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D40H7X1YZ0"},{"name":"Maps_To","value":"Anti-BTLA Monoclonal Antibody TAB004"},{"name":"NCI_Drug_Dictionary_ID","value":"800693"},{"name":"NCI_META_CUI","value":"CL1378714"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800693"},{"name":"PDQ_Open_Trial_Search_ID","value":"800693"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175508":{"preferredName":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01","code":"C175508","definitions":[{"definition":"A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-BTN3A agonistic monoclonal antibody ICT01 targets and binds to BTN3A present on epithelial and tumor cells. BTN3A binding may sensitize tumor cells to gamma 9 delta 2 (Vg9Vd2) T cell killing. The Vg9Vd2 T cells secrete effector cytokines and exert a cytolytic effect on tumor cells. This may abrogate BTN3A-mediated tumor immunity and may enhance anti-tumor immune response. BTN3A, a member of the butyrophilin superfamily of immunomodulators, is upregulated in tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BTN3A Agonist Monoclonal Antibody ICT01","termGroup":"SY","termSource":"NCI"},{"termName":"ICT 01","termGroup":"CN","termSource":"NCI"},{"termName":"ICT-01","termGroup":"CN","termSource":"NCI"},{"termName":"ICT01","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-BTN3A Agonistic Monoclonal Antibody ICT01"},{"name":"NCI_Drug_Dictionary_ID","value":"802942"},{"name":"NCI_META_CUI","value":"CL1412871"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802942"},{"name":"PDQ_Open_Trial_Search_ID","value":"802942"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174391":{"preferredName":"Anti-c-Met Monoclonal Antibody HLX55","code":"C174391","definitions":[{"definition":"A humanized immunoglobulin (Ig) G2 monoclonal antibody directed against the human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-c-Met monoclonal antibody HLX55 specifically binds to the semaphorin (Sema)/Plexins-Semaphorins-Integrins (PSI) domain of c-Met, which prevents the binding of c-Met to its ligand HGF and the subsequent activation of the HGF/c-Met signaling pathway. In addition, HLX55 promotes c-Met degradation, which further inhibits c-Met-mediated signaling. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-c-Met Monoclonal Antibody HLX55","termGroup":"PT","termSource":"NCI"},{"termName":"HLX 55","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-55","termGroup":"CN","termSource":"NCI"},{"termName":"HLX55","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-c-Met Monoclonal Antibody HLX55"},{"name":"NCI_Drug_Dictionary_ID","value":"802302"},{"name":"NCI_META_CUI","value":"CL1411962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802302"},{"name":"PDQ_Open_Trial_Search_ID","value":"802302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175477":{"preferredName":"Anti-CCR7 Antibody-drug Conjugate JBH492","code":"C175477","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody targeting CC chemokine receptor 7 (CCR7) and conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-CCR7 ADC JBH492, the antibody moiety targets and binds to CCR7 on tumor cells. Upon antibody/antigen binding and internalization, the ADC releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics. This results in the inhibition of cell division and cell growth of CCR7-expressing tumor cells. CCR7, a G-protein coupled receptor, is normally expressed by subsets of immune cells and overexpressed by various types of cancer cells. Its overexpression has been associated with lymph node metastasis and poor survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CCR7 Antibody-drug Conjugate JBH492","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CCR7 ADC JBH492","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CCR7-DM4 Antibody-drug Conjugate JBH492","termGroup":"SY","termSource":"NCI"},{"termName":"JBH 492","termGroup":"CN","termSource":"NCI"},{"termName":"JBH-492","termGroup":"CN","termSource":"NCI"},{"termName":"JBH492","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CCR7 Antibody-drug Conjugate JBH492"},{"name":"NCI_Drug_Dictionary_ID","value":"802920"},{"name":"NCI_META_CUI","value":"CL1412845"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802920"},{"name":"PDQ_Open_Trial_Search_ID","value":"802920"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174050":{"preferredName":"Briquilimab","code":"C174050","definitions":[{"definition":"A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs). Upon administration, briquilimab targets and binds to CD117. This prevents the binding of stem cell factor (SCF) to its receptor CD117 on HSCs.  As CD117 binding to SCF is critical for survival and maintenance of blood forming stem cells, blocking this interaction causes the HSCs that are present in the bone marrow niches to be depleted. Briquilimab can potentially be used as a conditioning regimen to prepare patients for hematopoietic stem cell transplantation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Briquilimab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 191","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-191","termGroup":"CN","termSource":"NCI"},{"termName":"AMG191","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-c-Kit Monoclonal Antibody JSP191","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD117 Monoclonal Antibody JSP191","termGroup":"SY","termSource":"NCI"},{"termName":"JSP 191","termGroup":"CN","termSource":"NCI"},{"termName":"JSP-191","termGroup":"CN","termSource":"NCI"},{"termName":"JSP191","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2574591-89-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QWX84D0DRC"},{"name":"Maps_To","value":"Anti-CD117 Monoclonal Antibody JSP191"},{"name":"NCI_Drug_Dictionary_ID","value":"802461"},{"name":"NCI_META_CUI","value":"CL1407956"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802461"},{"name":"PDQ_Open_Trial_Search_ID","value":"802461"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168522":{"preferredName":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373","code":"C168522","definitions":[{"definition":"A conditionally-active, fully human immunoglobulin G1 (IgG1) agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody AGEN2373 targets and binds to a non-ligand blocking epitope on CD137, thereby activating CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. In addition, as AGEN2373 engages with CD137 only in the presence of CD137 ligand and/or Fc gamma receptor-expressing antigen-presenting cells (APCs), this agent may have a decreased toxicity profile and improved tolerability compared to other agents that activate CD137 signaling beyond the tumor site in humans.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 2373","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-2373","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN2373","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody AGEN2373","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonist Monoclonal Antibody AGEN2373","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Monoclonal Antibody AGEN2373","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody AGEN2373"},{"name":"NCI_Drug_Dictionary_ID","value":"800682"},{"name":"NCI_META_CUI","value":"CL972852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800682"},{"name":"PDQ_Open_Trial_Search_ID","value":"800682"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173548":{"preferredName":"Evunzekibart","code":"C173548","definitions":[{"definition":"A humanized agonistic immunoglobulin G4 (IgG4) monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, evunzekibart targets and binds to CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells, and CD137 is activated upon crosslinking to Fc-gamma receptors (FcgRs) on macrophages. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. 4-1BB and FcgRs are both highly expressed in the tumor environment (TME) while their co-expression in non-tumor tissues is low. This may prevent systemic adverse effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Evunzekibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-4-1BB Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonist Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Monoclonal Antibody ATOR-1017","termGroup":"SY","termSource":"NCI"},{"termName":"ATOR 1017","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR-1017","termGroup":"CN","termSource":"NCI"},{"termName":"ATOR1017","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2639688-77-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AKZ8CT8FMF"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017"},{"name":"NCI_Drug_Dictionary_ID","value":"801898"},{"name":"NCI_META_CUI","value":"CL1407499"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801898"},{"name":"PDQ_Open_Trial_Search_ID","value":"801898"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171541":{"preferredName":"Exlinkibart","code":"C171541","definitions":[{"definition":"A humanized agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, exlinkibart targets and binds to CD137, thereby activating CD137 expressed on avariety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exlinkibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-4-1BB Agonistic Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonist Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Agonistic Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD137 Monoclonal Antibody LVGN6051","termGroup":"SY","termSource":"NCI"},{"termName":"LVGN 6051","termGroup":"CN","termSource":"NCI"},{"termName":"LVGN-6051","termGroup":"CN","termSource":"NCI"},{"termName":"LVGN6051","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2642171-64-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"23C7TO9S06"},{"name":"Maps_To","value":"Anti-CD137 Agonistic Monoclonal Antibody LVGN6051"},{"name":"NCI_Drug_Dictionary_ID","value":"801858"},{"name":"NCI_META_CUI","value":"CL1405761"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801858"},{"name":"PDQ_Open_Trial_Search_ID","value":"801858"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C172202":{"preferredName":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003","code":"C172202","definitions":[{"definition":"A preparation of T-lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T-cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 AbTCR-expressing T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19-TCR T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"CD19-targeted T-cells ET019003","termGroup":"SY","termSource":"NCI"},{"termName":"ET 019003","termGroup":"CN","termSource":"NCI"},{"termName":"ET-019003","termGroup":"CN","termSource":"NCI"},{"termName":"ET019003","termGroup":"CN","termSource":"NCI"},{"termName":"ET019003-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003"},{"name":"NCI_Drug_Dictionary_ID","value":"801620"},{"name":"NCI_META_CUI","value":"CL1406089"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801620"},{"name":"PDQ_Open_Trial_Search_ID","value":"801620"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170903":{"preferredName":"Anti-CD19 iCAR NK Cells","code":"C170903","definitions":[{"definition":"A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19 iCAR NK Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19 iCAR Natural Killer Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 iCAR-NK Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19 Inhibitory Chimeric Antigen Receptor-Natural Killer Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19 iCAR NK Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"800852"},{"name":"NCI_META_CUI","value":"CL1383049"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800852"},{"name":"PDQ_Open_Trial_Search_ID","value":"800852"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170904":{"preferredName":"Anti-CD19/CD22 CAR NK Cells","code":"C170904","definitions":[{"definition":"A preparation of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD22 CAR-NK cells target and bind to CD19 and CD22 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD19/CD22 CAR NK Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD19/Anti-CD22 CAR Natural Killer Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/CD22 CAR-Natural Killer Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/CD22 CAR-NK Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD19/CD22 Chimeric Antigen Receptor-Natural Killer Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD19/CD22 CAR NK Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"800858"},{"name":"NCI_META_CUI","value":"CL1383046"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800858"},{"name":"PDQ_Open_Trial_Search_ID","value":"800858"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173955":{"preferredName":"Anti-CD20 Monoclonal Antibody BAT4306F","code":"C173955","definitions":[{"definition":"A recombinant, glycosylation-modified monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody BAT4306F, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The complete defucosylation of BAT4306F may result in enhanced ADCC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody BAT4306F","termGroup":"PT","termSource":"NCI"},{"termName":"BAT 4306F","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-4306F","termGroup":"CN","termSource":"NCI"},{"termName":"BAT4306F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody BAT4306F"},{"name":"NCI_Drug_Dictionary_ID","value":"802165"},{"name":"NCI_META_CUI","value":"CL1407872"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802165"},{"name":"PDQ_Open_Trial_Search_ID","value":"802165"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166140":{"preferredName":"Anti-CD20 Monoclonal Antibody MIL62","code":"C166140","definitions":[{"definition":"A glyco-engineered recombinant humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody MIL62, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, MIL62 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD20 Monoclonal Antibody MIL62","termGroup":"PT","termSource":"NCI"},{"termName":"MIL 62","termGroup":"CN","termSource":"NCI"},{"termName":"MIL-62","termGroup":"CN","termSource":"NCI"},{"termName":"MIL62","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD20 Monoclonal Antibody MIL62"},{"name":"NCI_Drug_Dictionary_ID","value":"799905"},{"name":"NCI_META_CUI","value":"CL979195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799905"},{"name":"PDQ_Open_Trial_Search_ID","value":"799905"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165598":{"preferredName":"Anti-CD205 Antibody-drug Conjugate OBT076","code":"C165598","definitions":[{"definition":"An antibody-drug conjugate (ADC) comprised of an anti-CD205 (lymphocyte antigen 75; Ly75) humanized immunoglobin G1 (IgG1) monoclonal antibody conjugated to DM4, a maytansinoid microtubule disruptor, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate (SPDB) linker, with potential antineoplastic activity. Upon intravenous administration, anti-CD205 ADC OBT076 specifically targets and binds to CD205, a receptor involved in antigen capture and endocytosis, expressed on tumor cells. Following rapid internalization of the ADC/CD205 complex, OBT076 releases its DM4 payload due to cleavage of the SPDB linker by intracellular proteases. Then the DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of both cell division and cell growth of CD205-expressing tumor cells. CD205, a type I transmembrane surface glycoprotein belonging to the C-type lectin receptor family, is normally expressed on various antigen-presenting cells (APCs) and some leukocyte sub-populations but it is overexpressed in multiple cancer types where it plays a key role in facilitating metastatic invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD205 Antibody-drug Conjugate OBT076","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD205 ADC OBT076","termGroup":"SY","termSource":"NCI"},{"termName":"MEN 1309","termGroup":"CN","termSource":"NCI"},{"termName":"MEN-1309","termGroup":"CN","termSource":"NCI"},{"termName":"MEN1309","termGroup":"CN","termSource":"NCI"},{"termName":"OBT 076","termGroup":"CN","termSource":"NCI"},{"termName":"OBT-076","termGroup":"CN","termSource":"NCI"},{"termName":"OBT076","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD205 Antibody-drug Conjugate OBT076"},{"name":"NCI_Drug_Dictionary_ID","value":"799986"},{"name":"NCI_META_CUI","value":"CL978811"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799986"},{"name":"PDQ_Open_Trial_Search_ID","value":"799986"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168772":{"preferredName":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A","code":"C168772","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized antibody targeting the cell surface antigen cluster of differentiation (CD228; melanotransferrin; MFI2; MELTF) that is conjugated, via a beta-glucuronidase-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-CD228/MMAE ADC SGN-CD228A targets and binds to CD228 on the surface of tumor cells. Following internalization of SGN-CD228A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD228 Antibody-drug Conjugate SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD228-MMAE ADC SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD228/MMAE ADC SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-melanotransferrin ADC SGN-CD228A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD228A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD228A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD228A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A"},{"name":"NCI_Drug_Dictionary_ID","value":"800848"},{"name":"NCI_META_CUI","value":"CL1378671"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800848"},{"name":"PDQ_Open_Trial_Search_ID","value":"800848"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173969":{"preferredName":"Vopikitug","code":"C173969","definitions":[{"definition":"A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, vopikitug targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vopikitug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD25 Monoclonal Antibody RG6292","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD25 Monoclonal Antibody RO7296682","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6292","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6292","termGroup":"CN","termSource":"NCI"},{"termName":"RG6292","termGroup":"CN","termSource":"NCI"},{"termName":"RO 7296682","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7296682","termGroup":"CN","termSource":"NCI"},{"termName":"RO7296682","termGroup":"CN","termSource":"NCI"},{"termName":"T-regulatory Cell-depleting Antibody RO7296682","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2733581-99-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HV8TQI2IKP"},{"name":"Maps_To","value":"Anti-CD25 Monoclonal Antibody RO7296682"},{"name":"NCI_Drug_Dictionary_ID","value":"802183"},{"name":"NCI_META_CUI","value":"CL1407855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802183"},{"name":"PDQ_Open_Trial_Search_ID","value":"802183"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172056":{"preferredName":"Boserolimab","code":"C172056","definitions":[{"definition":"A humanized agonistic monoclonal antibody targeting the cell surface antigen CD27, with potential immunostimulatory and antineoplastic activities. Upon administration, boserolimab targets and binds to CD27 on a variety of immune cell types, including most T-lymphocytes. This induces CD27-dependent signaling pathways and enhances T-cell-mediated responses, including the expansion of antigen-activated T-cells and the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes, memory B-cells and natural killer (NK) cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation. It is overexpressed in certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Boserolimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD27 Agonist Monoclonal Antibody MK-5890","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD27 Agonistic Monoclonal Antibody MK-5890","termGroup":"SY","termSource":"NCI"},{"termName":"MK 5890","termGroup":"CN","termSource":"NCI"},{"termName":"MK-5890","termGroup":"CN","termSource":"NCI"},{"termName":"MK5890","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2209116-30-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"576SCZ7V2P"},{"name":"Maps_To","value":"Anti-CD27 Agonistic Monoclonal Antibody MK-5890"},{"name":"NCI_Drug_Dictionary_ID","value":"802005"},{"name":"NCI_META_CUI","value":"CL1406192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802005"},{"name":"PDQ_Open_Trial_Search_ID","value":"802005"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173369":{"preferredName":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044","code":"C173369","definitions":[{"definition":"A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD3/anti-5T4 bispecific antibody GEN1044 simultaneously targets and binds to CD3 expressed on T-cells and 5T4 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/5T4 Bispecific Antibody GEN1044","termGroup":"SY","termSource":"NCI"},{"termName":"DuoBody-CD3x5T4","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1044","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1044","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044"},{"name":"NCI_Drug_Dictionary_ID","value":"801833"},{"name":"NCI_META_CUI","value":"CL1407193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801833"},{"name":"PDQ_Open_Trial_Search_ID","value":"801833"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166258":{"preferredName":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119","code":"C166258","definitions":[{"definition":"A bispecific antibody against human CD3, a T-cell surface antigen, and human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential antineoplastic activity. Upon administration, anti-CD3/anti-GUCY2C bispecific antibody PF-07062119 targets and binds to both CD3 on T-cells and GUCY2C expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3 x Anti-GUCY2C Bispecific Antibody PF-07062119","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GUCY2C/Anti-CD3 Bispecific Antibody PF-07062119","termGroup":"SY","termSource":"NCI"},{"termName":"PF 07062119","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07062119","termGroup":"CN","termSource":"NCI"},{"termName":"PF07062119","termGroup":"CN","termSource":"NCI"},{"termName":"T-cell Bispecific Antibody PF-07062119","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119"},{"name":"NCI_Drug_Dictionary_ID","value":"800221"},{"name":"NCI_META_CUI","value":"CL971303"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800221"},{"name":"PDQ_Open_Trial_Search_ID","value":"800221"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165583":{"preferredName":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin","code":"C165583","definitions":[{"definition":"An immunotoxin (IT) combination composed of two antibody-drug conjugates (ADCs), one containing a monoclonal antibody against CD3 and one against the CD7 antigen on activated T-cells and natural killer (NK) cells, and both conjugated to ricin toxin A (RTA), the A-chain form of the potent plant toxin ricin, that can potentially be used to destroy activated T- and NK cells. Upon administration of the anti-CD3/CD7-RTA immunotoxin, the anti-CD3 antibody moiety targets and binds to activated T-cells; the anti-CD7 antibody moiety targets and binds to CD7 on activated T-cells and NK cells. Upon internalization and cleavage, the RTA moiety irreversibly inhibits protein synthesis and induces apoptosis in the activated T-cells. This may eliminate activated T-cells and may improve conditions such as graft-versus-host-disease (GvHD). In addition, the binding and blocking of the anti-CD3 antibody to the T-cell receptor/CD3 complex (TCR/CD3) results in activation-induced cell death (AICD) and immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD3/CD7-RTA Immunotoxin","termGroup":"SY","termSource":"NCI"},{"termName":"CD3/CD7-Ricin A IT","termGroup":"SY","termSource":"NCI"},{"termName":"T-Guard","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD3/CD7-Ricin Toxin A Immunotoxin"},{"name":"NCI_Drug_Dictionary_ID","value":"799985"},{"name":"NCI_META_CUI","value":"CL978824"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799985"},{"name":"PDQ_Open_Trial_Search_ID","value":"799985"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172064":{"preferredName":"Anti-CD30/DM1 Antibody-drug Conjugate F0002","code":"C172064","definitions":[{"definition":"An antibody drug conjugate (ADC) consisting of a monoclonal antibody directed against the tumor necrosis factor (TNF) receptor CD30 conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of F0002 targets and binds to CD30-expressing tumor cells. Upon cellular uptake and internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits both cell division and the proliferation of tumor cells that express CD30. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8; TNFRSF8) may be constitutively expressed in some hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD30/DM1 Antibody-drug Conjugate F0002","termGroup":"PT","termSource":"NCI"},{"termName":"ADC F0002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD30/DM1 ADC F0002","termGroup":"SY","termSource":"NCI"},{"termName":"F 0002","termGroup":"CN","termSource":"NCI"},{"termName":"F-0002","termGroup":"CN","termSource":"NCI"},{"termName":"F0002","termGroup":"CN","termSource":"NCI"},{"termName":"F0002-ADC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD30/DM1 Antibody-drug Conjugate F0002"},{"name":"NCI_Drug_Dictionary_ID","value":"801498"},{"name":"NCI_META_CUI","value":"CL1406212"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801498"},{"name":"PDQ_Open_Trial_Search_ID","value":"801498"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172443":{"preferredName":"Ivicentamab","code":"C172443","definitions":[{"definition":"An Fc-engineered, humanized, bispecific hexamer formation-enhanced immunoglobulin (Ig) G1 monoclonal antibody that targets two separate epitopes on the tumor-associated antigen (TAA) CD37, with the E430G hexamerization-enhancing mutation, with potential immunomodulating and antineoplastic activities. Upon administration, ivicentamab specifically targets and binds to two non-overlapping CD37 epitopes, thereby inducing an assembly of antibody hexamers through intermolecular Fc-Fc interactions at the cell surface of CD37-overexpressing tumor cells. These hexamers recruit and activate C1, the first component of complement, thereby triggering the complement cascade which activates the immune system to induce complement-dependent cytotoxicity (CDC). In addition, the binding of ivicentamab to the CD37-overexpressing tumor cells also causes antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). CD37, a member of the tetraspanin superfamily of cell surface antigens, is expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. The E430G mutation in the Fc domains enhances Fc-mediated IgG hexamerization upon cellular target binding, and enhances CDC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivicentamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD37 Bispecific Monoclonal Antibody GEN3009","termGroup":"SY","termSource":"NCI"},{"termName":"DuoHexaBody-CD37","termGroup":"SY","termSource":"NCI"},{"termName":"DuoHexaBody-CD37 GEN3009","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 3009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-3009","termGroup":"CN","termSource":"NCI"},{"termName":"GEN3009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2364496-42-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O7JS64H45"},{"name":"Maps_To","value":"Anti-CD37 Bispecific Monoclonal Antibody GEN3009"},{"name":"NCI_Drug_Dictionary_ID","value":"802024"},{"name":"NCI_META_CUI","value":"CL1406362"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802024"},{"name":"PDQ_Open_Trial_Search_ID","value":"802024"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174057":{"preferredName":"Anti-CD38 Antibody-drug Conjugate STI-6129","code":"C174057","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of STI-5171, a fully human monoclonal antibody targeting human cell surface glycoprotein and tumor-associated antigen (TAA) CD38, site-specifically conjugated, via a non-polyethylene glycol linker, to a monomethyl auristatin F (MMAF)-derived cytotoxic payload, with potential antineoplastic activity. Upon administration of anti-CD38 ADC STI-6129, the antibody moiety targets and binds to CD38 on tumor cells. Upon antibody/antigen binding and internalization, the MMAF derivative binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38 Antibody-drug Conjugate STI-6129","termGroup":"PT","termSource":"NCI"},{"termName":"ADC STI-6129","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38 ADC STI-6129","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD38-Duostatin 5.2 ADC STI-6129","termGroup":"SY","termSource":"NCI"},{"termName":"CD38-077","termGroup":"CN","termSource":"NCI"},{"termName":"LNDS1001","termGroup":"CN","termSource":"NCI"},{"termName":"STI 6129","termGroup":"CN","termSource":"NCI"},{"termName":"STI-6129","termGroup":"CN","termSource":"NCI"},{"termName":"STI6129","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD38 Antibody-drug Conjugate STI-6129"},{"name":"NCI_Drug_Dictionary_ID","value":"802462"},{"name":"NCI_META_CUI","value":"CL1407961"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802462"},{"name":"PDQ_Open_Trial_Search_ID","value":"802462"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166376":{"preferredName":"Anti-CD38 Monoclonal Antibody SAR442085","code":"C166376","definitions":[{"definition":"A preparation of Fc-engineered monoclonal antibody that targets the cell surface glycoprotein CD-38 with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SAR442085 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38 Monoclonal Antibody SAR442085","termGroup":"PT","termSource":"NCI"},{"termName":"SAR 442085","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442085","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442085","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD38 Monoclonal Antibody SAR442085"},{"name":"NCI_Drug_Dictionary_ID","value":"800231"},{"name":"NCI_META_CUI","value":"CL971630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800231"},{"name":"PDQ_Open_Trial_Search_ID","value":"800231"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173645":{"preferredName":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257","code":"C173645","definitions":[{"definition":"A tri-specific T-cell engager and monoclonal antibody targeting CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), CD3, a T-cell surface antigen, and CD28, a T-cell specific surface glycoprotein and co-stimulatory molecule, with potential antineoplastic activity. Upon intravenous administration, anti-CD38/CD3/CD28 tri-specific monoclonal antibody SAR442257 targets and binds to CD3 and CD28 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. In addition, SAR442257 can also directly target CD28 expressed on tumor cells, such as multiple myeloma cells, thereby enhancing the anti-tumor activity of this agent and allowing it to bind to tumor cells when CD38 is occupied by other antibodies. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257","termGroup":"PT","termSource":"NCI"},{"termName":"SAR 442257","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442257","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442257","termGroup":"CN","termSource":"NCI"},{"termName":"Tri-specific T-cell Engager SAR442257","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257"},{"name":"NCI_Drug_Dictionary_ID","value":"802010"},{"name":"NCI_META_CUI","value":"CL1407369"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802010"},{"name":"PDQ_Open_Trial_Search_ID","value":"802010"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171450":{"preferredName":"Perenostobart","code":"C171450","definitions":[{"definition":"A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, perenostobart specifically binds to the CD39 antigen, thereby preventing the conversion and degradation of adenosine triphosphate (ATP) to adenosine monophosphate (AMP). This leads to an increase in the extracellular levels of immunogenic ATP and a decrease in the levels of immunosuppressive adenosine within the tumor microenvironment (TME). A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic and other myeloid-derived cells that are necessary for innate and adaptive immunity. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy. Blocking its action may improve anti-tumor immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Perenostobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD39 Monoclonal Antibody SRF617","termGroup":"SY","termSource":"NCI"},{"termName":"SRF 617","termGroup":"CN","termSource":"NCI"},{"termName":"SRF-617","termGroup":"CN","termSource":"NCI"},{"termName":"SRF617","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2643331-31-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O84ZK2F68E"},{"name":"Maps_To","value":"Anti-CD39 Monoclonal Antibody SRF617"},{"name":"NCI_Drug_Dictionary_ID","value":"801999"},{"name":"NCI_META_CUI","value":"CL1405530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801999"},{"name":"PDQ_Open_Trial_Search_ID","value":"801999"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168604":{"preferredName":"Tecaginlimab","code":"C168604","definitions":[{"definition":"A humanized immunoglobulin (Ig) G1, Fc-silenced, bispecific, agonistic monoclonal antibody targeting both CD40 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration,  tecaginlimab simultaneously binds to CD40 and 4-1BB, crosslinks CD40 and 4-1BB positive cells, induces conditional stimulation, and activates both CD40- and 4-1BB-medicated signaling. The activation of CD40-mediated signaling triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The activation of 4-1BB-mediated signaling induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system. 4-1BB, a surface glycoprotein of the TNFRSF, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tecaginlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40/Anti-CD137 Bispecific Agonist Monoclonal Antibody GEN1042","termGroup":"SY","termSource":"NCI"},{"termName":"BNT 312","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-312","termGroup":"CN","termSource":"NCI"},{"termName":"BNT312","termGroup":"CN","termSource":"NCI"},{"termName":"DuoBody-CD40x4-1BB GEN1042","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1042","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1042","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1042","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253891-70-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"27X2015N23"},{"name":"Maps_To","value":"Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042"},{"name":"NCI_Drug_Dictionary_ID","value":"800410"},{"name":"NCI_META_CUI","value":"CL972921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800410"},{"name":"PDQ_Open_Trial_Search_ID","value":"800410"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173421":{"preferredName":"Anti-CD47 ADC SGN-CD47M","code":"C173421","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against human cell surface antigen CD47 conjugated to an as of yet not fully elucidated toxin, with potential antineoplastic activity. Upon administration of SGN-CD47M, the anti-CD47 monoclonal antibody moiety targets and binds to CD47 on tumor cell surfaces; upon internalization, the toxin moiety kills tumor cells through a mechanism of action that has not been elucidated. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 ADC SGN-CD47M","termGroup":"PT","termSource":"NCI"},{"termName":"ADC SGN-CD47M","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD47 Antibody-drug Conjugate SGN-CD47M","termGroup":"SY","termSource":"NCI"},{"termName":"SGN CD47M","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-CD47M","termGroup":"CN","termSource":"NCI"},{"termName":"SGNCD47M","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 ADC SGN-CD47M"},{"name":"NCI_Drug_Dictionary_ID","value":"801749"},{"name":"NCI_META_CUI","value":"CL1407430"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801749"},{"name":"PDQ_Open_Trial_Search_ID","value":"801749"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174192":{"preferredName":"Anti-CD47 Monoclonal Antibody IMC-002","code":"C174192","definitions":[{"definition":"A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody IMC-002 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. IMC-002 does not bind to red blood cells (RBCs). This may prevent adverse effects such as anemia that can result from the blockade of CD47 expressed on RBCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CD47 Monoclonal Antibody IMC-002","termGroup":"PT","termSource":"NCI"},{"termName":"IMC 002","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-002","termGroup":"CN","termSource":"NCI"},{"termName":"IMC002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CD47 Monoclonal Antibody IMC-002"},{"name":"NCI_Drug_Dictionary_ID","value":"802480"},{"name":"NCI_META_CUI","value":"CL1407837"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802480"},{"name":"PDQ_Open_Trial_Search_ID","value":"802480"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166137":{"preferredName":"Zeripatamig","code":"C166137","definitions":[{"definition":"A bispecific monoclonal antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of zeripatamig, the anti-CD19 moiety selectively targets and binds to CD19 on CD19-positive B-cells, thereby improving binding of the anti-CD47 moiety to the CD19+ malignant B-cells. The CD47 binding by TG-1801 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD19/CD47-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD19/CD47-expressing tumor cells. In addition, zeripatamig induces an anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. CD19 is a membrane antigen that is widely expressed during B-cell development and in B-cell malignancies. By co-targeting CD47 and CD19, zeripatamig has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs) which causes unwanted macrophage-mediated phagocytosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zeripatamig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Monoclonal Antibody TG-1801","termGroup":"SY","termSource":"NCI"},{"termName":"TG 1801","termGroup":"CN","termSource":"NCI"},{"termName":"TG-1801","termGroup":"CN","termSource":"NCI"},{"termName":"TG1801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2607644-43-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK3WC9ZP7A"},{"name":"Maps_To","value":"Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801"},{"name":"NCI_Drug_Dictionary_ID","value":"799809"},{"name":"NCI_META_CUI","value":"CL979205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799809"},{"name":"PDQ_Open_Trial_Search_ID","value":"799809"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173724":{"preferredName":"Anti-claudin18.2 Monoclonal Antibody AB011","code":"C173724","definitions":[{"definition":"A recombinant humanized monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-claudin18.2 monoclonal antibody AB011 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-claudin18.2 Monoclonal Antibody AB011","termGroup":"PT","termSource":"NCI"},{"termName":"AB 011","termGroup":"CN","termSource":"NCI"},{"termName":"AB-011","termGroup":"CN","termSource":"NCI"},{"termName":"AB011","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CLDN18.2 Monoclonal Antibody AB011","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-claudin18.2 Monoclonal Antibody AB011"},{"name":"NCI_Drug_Dictionary_ID","value":"802013"},{"name":"NCI_META_CUI","value":"CL1407568"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802013"},{"name":"PDQ_Open_Trial_Search_ID","value":"802013"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173726":{"preferredName":"Osemitamab","code":"C173726","definitions":[{"definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, osemitamab specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation.  CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. Osemitamab is produced with reduced fucosylation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Osemitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Claudin18.2 Monoclonal Antibody TST001","termGroup":"SY","termSource":"NCI"},{"termName":"TST 001","termGroup":"CN","termSource":"NCI"},{"termName":"TST-001","termGroup":"CN","termSource":"NCI"},{"termName":"TST001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460539-61-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H14V1A2F4D"},{"name":"Maps_To","value":"Anti-Claudin18.2 Monoclonal Antibody TST001"},{"name":"NCI_Drug_Dictionary_ID","value":"802035"},{"name":"NCI_META_CUI","value":"CL1407570"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802035"},{"name":"PDQ_Open_Trial_Search_ID","value":"802035"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C166139":{"preferredName":"Firastotug","code":"C166139","definitions":[{"definition":"A human monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, firastotug targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Firastotug","termGroup":"PT","termSource":"NCI"},{"termName":"ADG 116","termGroup":"CN","termSource":"NCI"},{"termName":"ADG-116","termGroup":"CN","termSource":"NCI"},{"termName":"ADG116","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody ADG116","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2750031-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8B1J60R28A"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody ADG116"},{"name":"NCI_Drug_Dictionary_ID","value":"799904"},{"name":"NCI_META_CUI","value":"CL979207"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799904"},{"name":"PDQ_Open_Trial_Search_ID","value":"799904"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173540":{"preferredName":"Porustobart","code":"C173540","definitions":[{"definition":"A recombinant human heavy chain only antibody (HCAb) directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, porustobart targets and binds to CTLA-4 expressed on T-cells, and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. In addition, porustobart induces an antibody-dependent cell cytotoxicity (ADCC). CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. Porustobart, being a HCAb, is smaller than conventional antibodies which may allow for increased tissue penetration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porustobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody HBM4003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA4 Monoclonal Antibody HBM4003","termGroup":"SY","termSource":"NCI"},{"termName":"HBM 4003","termGroup":"CN","termSource":"NCI"},{"termName":"HBM-4003","termGroup":"CN","termSource":"NCI"},{"termName":"HBM4003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649372-91-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JJY4JHN685"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody HBM4003"},{"name":"NCI_Drug_Dictionary_ID","value":"801868"},{"name":"NCI_META_CUI","value":"CL1407491"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801868"},{"name":"PDQ_Open_Trial_Search_ID","value":"801868"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173547":{"preferredName":"Gotistobart","code":"C173547","definitions":[{"definition":"A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, gotistobart targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. As gotistobart is dissociated from CTLA-4 under low pH, it does not cause lysosomal degradation of CTLA-4, preserving CTLA-4 and allowing the recycling of CTLA-4. This may result in more efficient and selective CTLA-4-targeted regulatory T-cell (Treg) depletion within the tumor microenvironment (TME) while preserving CTLA-4 functions outside the TME, thereby reducing toxicities. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gotistobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4 Monoclonal Antibody ONC-392","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA4 Monoclonal Antibody ONC-392","termGroup":"SY","termSource":"NCI"},{"termName":"ONC 392","termGroup":"CN","termSource":"NCI"},{"termName":"ONC-392","termGroup":"CN","termSource":"NCI"},{"termName":"ONC392","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2226344-78-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4R46M31XXP"},{"name":"Maps_To","value":"Anti-CTLA-4 Monoclonal Antibody ONC-392"},{"name":"NCI_Drug_Dictionary_ID","value":"801887"},{"name":"NCI_META_CUI","value":"CL1407498"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801887"},{"name":"PDQ_Open_Trial_Search_ID","value":"801887"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173435":{"preferredName":"Anti-CTLA-4 Probody BMS-986288","code":"C173435","definitions":[{"definition":"A probody composed of a modified version of ipilimumab, a recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of anti-CTLA-4 probody BMS-986288, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986288 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4 Probody BMS-986288","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986288","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986288","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986288","termGroup":"CN","termSource":"NCI"},{"termName":"Probody BMS-986288","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4 Probody BMS-986288"},{"name":"NCI_Drug_Dictionary_ID","value":"801762"},{"name":"NCI_META_CUI","value":"CL1407418"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801762"},{"name":"PDQ_Open_Trial_Search_ID","value":"801762"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172196":{"preferredName":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","code":"C172196","definitions":[{"definition":"A fixed dose combination of two monoclonal antibodies of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217 targets and binds to both PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA-4/PD-1 Monoclonal Antibody Combination BCD-217","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CTLA4/Anti-PD1 Monoclonal Antibody Combination BCD-217","termGroup":"SY","termSource":"NCI"},{"termName":"BCD 217","termGroup":"CN","termSource":"NCI"},{"termName":"BCD-217","termGroup":"CN","termSource":"NCI"},{"termName":"BCD217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217"},{"name":"NCI_Drug_Dictionary_ID","value":"801536"},{"name":"NCI_META_CUI","value":"CL1406094"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801536"},{"name":"PDQ_Open_Trial_Search_ID","value":"801536"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173422":{"preferredName":"Anti-CTLA4 Antibody Fc Fusion Protein KN044","code":"C173422","definitions":[{"definition":"A recombinant, humanized fusion protein consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) single domain antibody linked to a Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 antibody Fc fusion protein KN044 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-CTLA4 Antibody Fc Fusion Protein KN044","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CTLA4 Antibody Fusion Protein KN044","termGroup":"SY","termSource":"NCI"},{"termName":"KN 044","termGroup":"CN","termSource":"NCI"},{"termName":"KN-044","termGroup":"CN","termSource":"NCI"},{"termName":"KN044","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-CTLA4 Antibody Fc Fusion Protein KN044"},{"name":"NCI_Drug_Dictionary_ID","value":"801856"},{"name":"NCI_META_CUI","value":"CL1407438"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801856"},{"name":"PDQ_Open_Trial_Search_ID","value":"801856"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171163":{"preferredName":"Anti-EGFR/CD16A Bispecific Antibody AFM24","code":"C171163","definitions":[{"definition":"A human, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor (EGFR) and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-EGFR/CD16A bispecific antibody AFM24 simultaneously targets and binds to the CD16A expressed on natural killer (NK) cells and macrophages, and to EGFR on EGFR-expressing tumor cells, thereby selectively cross-linking EGFR-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and eventually tumor cell lysis. EGFR, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. CD16A is specifically expressed on the surface of NK cells and macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-EGFR/CD16A Bispecific Antibody AFM24","termGroup":"PT","termSource":"NCI"},{"termName":"AFM 24","termGroup":"CN","termSource":"NCI"},{"termName":"AFM-24","termGroup":"CN","termSource":"NCI"},{"termName":"AFM24","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-EGFR/Anti-CD16A Bispecific Antibody AFM24","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/CD16A Tetravalent Bispecific Antibody AFM24","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific EGFR/CD16A Innate Cell Engager AFM24","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-EGFR/CD16A Bispecific Antibody AFM24"},{"name":"NCI_Drug_Dictionary_ID","value":"801966"},{"name":"NCI_META_CUI","value":"CL1405396"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801966"},{"name":"PDQ_Open_Trial_Search_ID","value":"801966"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173946":{"preferredName":"Farletuzumab Ecteribulin","code":"C173946","definitions":[{"definition":"An antibody drug conjugate (ADC) composed of farletuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the folate receptor alpha (FRA; FolRa; FOLR1), and conjugated, via a cathepsin B-cleavable linker, to the microtubule-targeting agent (MTA) eribulin, a derivative of the macrocyclic polyether natural product halichondrin B, with potential antineoplastic activity. Upon administration of farletuzumab ecteribulin, the farletuzumab moiety targets and binds to FRA expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and the induction of tumor cell death in FRA-expressing cells. FRA is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Farletuzumab Ecteribulin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FRA ADC MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FRA/Eribulin ADC MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202","termGroup":"SY","termSource":"NCI"},{"termName":"MORAb 202","termGroup":"CN","termSource":"NCI"},{"termName":"MORAb-202","termGroup":"CN","termSource":"NCI"},{"termName":"MORAb202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2407465-18-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UVG3B5TZN3"},{"name":"Maps_To","value":"Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802404"},{"name":"NCI_META_CUI","value":"CL1407865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802404"},{"name":"PDQ_Open_Trial_Search_ID","value":"802404"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165684":{"preferredName":"Livmoniplimab","code":"C165684","definitions":[{"definition":"A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T-cells (Tregs).  Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Livmoniplimab","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 151","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-151","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV151","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-GARP Monoclonal Antibody ABBV-151","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-glycoprotein A Repetitions Predominant Monoclonal Antibody ABBV-151","termGroup":"SY","termSource":"NCI"},{"termName":"ARGX 115","termGroup":"CN","termSource":"NCI"},{"termName":"ARGX-115","termGroup":"CN","termSource":"NCI"},{"termName":"ARGX115","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2412004-88-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"42SH7JCD82"},{"name":"Maps_To","value":"Anti-GARP Monoclonal Antibody ABBV-151"},{"name":"NCI_Drug_Dictionary_ID","value":"800125"},{"name":"NCI_META_CUI","value":"CL978918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800125"},{"name":"PDQ_Open_Trial_Search_ID","value":"800125"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165657":{"preferredName":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999","code":"C165657","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of OBI-888 (OBI 888), a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) globohexaosylceramide (globo H), covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-globo H/MMAE ADC OBI 999, the antibody moiety of OBI 999, OBI 888, targets and binds to globo H on tumor cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE targets and binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in globo H-expressing tumor cells. Globo H, a hexasaccharide glycosphingolipid, is (over)expressed on the surface of many types of tumor cells. Globo H is minimally or not expressed on healthy, normal cells; its expression on cancer cells is associated with increased proliferation and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999","termGroup":"PT","termSource":"NCI"},{"termName":"ADC OBI 999","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Globo H/MMAE ADC OBI 999","termGroup":"SY","termSource":"NCI"},{"termName":"OBI 999","termGroup":"CN","termSource":"NCI"},{"termName":"OBI-888/MMAE ADC OBI-999","termGroup":"SY","termSource":"NCI"},{"termName":"OBI-999","termGroup":"CN","termSource":"NCI"},{"termName":"OBI999","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999"},{"name":"NCI_Drug_Dictionary_ID","value":"800120"},{"name":"NCI_META_CUI","value":"CL978959"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800120"},{"name":"PDQ_Open_Trial_Search_ID","value":"800120"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172987":{"preferredName":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a","code":"C172987","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the G protein-coupled receptor 20 (GPR20) conjugated to the cytotoxic DNA topoisomerase I inhibitor and exatecan derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-GPR20/DXd ADC DS-6157a, the anti-GPR20 antibody targets and binds to GPR20-expressing tumor cells. Upon cellular uptake, the DXd moiety targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of GPR20-expressing tumor cells. GPR20 is overexpressed on certain tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DS-6157a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GPR20 ADC DS-6157a","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-GPR20/DXd ADC DS-6157a","termGroup":"SY","termSource":"NCI"},{"termName":"DS 6157a","termGroup":"CN","termSource":"NCI"},{"termName":"DS-6157a","termGroup":"CN","termSource":"NCI"},{"termName":"DS6157a","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a"},{"name":"NCI_Drug_Dictionary_ID","value":"802044"},{"name":"NCI_META_CUI","value":"CL1406780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802044"},{"name":"PDQ_Open_Trial_Search_ID","value":"802044"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173701":{"preferredName":"Ginisortamab","code":"C173701","definitions":[{"definition":"A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration, ginisortamab specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ginisortamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-GREM1 Monoclonal Antibody UCB6114","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-gremlin-1 Monoclonal Antibody UCB6114","termGroup":"SY","termSource":"NCI"},{"termName":"UCB 6114","termGroup":"CN","termSource":"NCI"},{"termName":"UCB-6114","termGroup":"CN","termSource":"NCI"},{"termName":"UCB6114","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2390147-17-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"6808SG2XRK"},{"name":"Maps_To","value":"Anti-gremlin-1 Monoclonal Antibody UCB6114"},{"name":"NCI_Drug_Dictionary_ID","value":"802055"},{"name":"NCI_META_CUI","value":"CL1407518"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802055"},{"name":"PDQ_Open_Trial_Search_ID","value":"802055"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173076":{"preferredName":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702","code":"C173076","definitions":[{"definition":"An off-the-shelf preparation of natural killer (NK) cells conjugated to a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential antineoplastic activity. Upon administration of anti-HER2 antibody conjugated natural killer cells ACE1702, the antibody moiety targets and binds to HER2 on tumor cells, which may lead to cell lysis of HER2-expressing tumor cells by the NK cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702","termGroup":"PT","termSource":"NCI"},{"termName":"ACE 1702","termGroup":"CN","termSource":"NCI"},{"termName":"ACE-1702","termGroup":"CN","termSource":"NCI"},{"termName":"ACE1702","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-HER2 Antibody Conjugated NK Cells ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Antibody Natural Killer Cell Conjugate ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Conjugated NK Cells ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 NK Cells ACE1702","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 oNK Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702"},{"name":"NCI_Drug_Dictionary_ID","value":"802031"},{"name":"NCI_META_CUI","value":"CL1406967"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802031"},{"name":"PDQ_Open_Trial_Search_ID","value":"802031"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173966":{"preferredName":"Anti-HER2 Antibody-drug Conjugate BAT8001","code":"C173966","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated via an uncleavable linker to an as of yet undisclosed maytansine derivative, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC BAT8001, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the cytotoxic maytansine derivative binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits tumor cell proliferation and induces apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Antibody-drug Conjugate BAT8001","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BAT8001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC BAT8001","termGroup":"SY","termSource":"NCI"},{"termName":"BAT 8001","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-8001","termGroup":"CN","termSource":"NCI"},{"termName":"BAT8001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate BAT8001"},{"name":"NCI_Drug_Dictionary_ID","value":"802162"},{"name":"NCI_META_CUI","value":"CL1407842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802162"},{"name":"PDQ_Open_Trial_Search_ID","value":"802162"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173962":{"preferredName":"Trastuzumab Envedotin","code":"C173962","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and site-specifically conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab envedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Trastuzumab envedotin has an average drug-to-antibody (DAR) ratio of 2.0; the two MMAE molecules are attached site-specifically through transamidation to residue Q295 in the antibody heavy chain's constant region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Envedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC DP303c","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 Antibody-drug Conjugate DP303c","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate DP303c","termGroup":"SY","termSource":"NCI"},{"termName":"DP 303c","termGroup":"CN","termSource":"NCI"},{"termName":"DP-303c","termGroup":"CN","termSource":"NCI"},{"termName":"DP303c","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2865132-89-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37DMF82G1F"},{"name":"Maps_To","value":"Anti-HER2 Antibody-drug Conjugate DP303c"},{"name":"NCI_Drug_Dictionary_ID","value":"802152"},{"name":"NCI_META_CUI","value":"CL1407846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802152"},{"name":"PDQ_Open_Trial_Search_ID","value":"802152"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174121":{"preferredName":"Anti-HER2 Monoclonal Antibody B002","code":"C174121","definitions":[{"definition":"A humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody B002 targets and binds to HER2 on HER2-expressing tumor cells. This prevents HER2-mediated signaling and may lead to antitumor activity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Monoclonal Antibody B002","termGroup":"PT","termSource":"NCI"},{"termName":"B 002","termGroup":"CN","termSource":"NCI"},{"termName":"B-002","termGroup":"CN","termSource":"NCI"},{"termName":"B002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody B002"},{"name":"NCI_Drug_Dictionary_ID","value":"802228"},{"name":"NCI_META_CUI","value":"CL1407790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802228"},{"name":"PDQ_Open_Trial_Search_ID","value":"802228"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172198":{"preferredName":"Anti-HER2 Monoclonal Antibody HLX22","code":"C172198","definitions":[{"definition":"A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody HLX22 targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-lymphocyte (CTL) response as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2 Monoclonal Antibody HLX22","termGroup":"PT","termSource":"NCI"},{"termName":"HLX 22","termGroup":"CN","termSource":"NCI"},{"termName":"HLX-22","termGroup":"CN","termSource":"NCI"},{"termName":"HLX22","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2 Monoclonal Antibody HLX22"},{"name":"NCI_Drug_Dictionary_ID","value":"801537"},{"name":"NCI_META_CUI","value":"CL1406092"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801537"},{"name":"PDQ_Open_Trial_Search_ID","value":"801537"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173420":{"preferredName":"Anti-HER2-DM1 ADC B003","code":"C173420","definitions":[{"definition":"An antibody-drug conjugate (ADC) consisting of a recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC), with potential antineoplastic activity. Upon administration of B003, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics, inhibiting cell division and the proliferation of cancer cells that overexpress HER2.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2-DM1 ADC B003","termGroup":"PT","termSource":"NCI"},{"termName":"ADC B003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2-DM1 Antibody-drug Conjugate B003","termGroup":"SY","termSource":"NCI"},{"termName":"B 003","termGroup":"CN","termSource":"NCI"},{"termName":"B-003","termGroup":"CN","termSource":"NCI"},{"termName":"B003","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Humanized Anti-HER2 Monoclonal Antibody-MCC-DM1 B003","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2-DM1 ADC B003"},{"name":"NCI_Drug_Dictionary_ID","value":"801748"},{"name":"NCI_META_CUI","value":"CL1407429"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801748"},{"name":"PDQ_Open_Trial_Search_ID","value":"801748"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173827":{"preferredName":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001","code":"C173827","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated, via a site-specific linker, to the cytotoxic maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration of anti-HER2-DM1 ADC GQ1001, the antibody moiety targets and binds to HER2 on tumor cell surfaces. Upon cellular uptake and internalization, DM1 binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits cell division and the proliferation of tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001","termGroup":"PT","termSource":"NCI"},{"termName":"ADC GQ1001","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2-DM1 ADC GQ1001","termGroup":"SY","termSource":"NCI"},{"termName":"GQ 1001","termGroup":"CN","termSource":"NCI"},{"termName":"GQ-1001","termGroup":"CN","termSource":"NCI"},{"termName":"GQ1001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HER2-DM1 Antibody-drug Conjugate GQ1001"},{"name":"NCI_Drug_Dictionary_ID","value":"802397"},{"name":"NCI_META_CUI","value":"CL1407629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802397"},{"name":"PDQ_Open_Trial_Search_ID","value":"802397"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174205":{"preferredName":"Trastuzumab Vedotin","code":"C174205","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab vedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Vedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MRG002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/MMAE ADC MRG002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2/MMAE Antibody-drug Conjugate MRG002","termGroup":"SY","termSource":"NCI"},{"termName":"MRG 002","termGroup":"CN","termSource":"NCI"},{"termName":"MRG-002","termGroup":"CN","termSource":"NCI"},{"termName":"MRG002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2740607-04-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W95G28K44S"},{"name":"Maps_To","value":"Anti-HER2/MMAE Antibody-drug Conjugate MRG002"},{"name":"NCI_Drug_Dictionary_ID","value":"804156"},{"name":"NCI_META_CUI","value":"CL1411781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"804156"},{"name":"PDQ_Open_Trial_Search_ID","value":"804156"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175374":{"preferredName":"Anti-HLA-G Antibody TTX-080","code":"C175374","definitions":[{"definition":"An antibody targeting HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G antibody TTX-080 targets and binds to HLA-G, thereby preventing the binding of HLA-G to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs). This may prevent the HLA-G-mediated immune suppression, thereby activating both innate and adaptive immune responses. This may activate anti-tumor immune responses. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-HLA-G Antibody TTX-080","termGroup":"PT","termSource":"NCI"},{"termName":"HLA-G Antagonist TTX-080","termGroup":"SY","termSource":"NCI"},{"termName":"TTX 080","termGroup":"CN","termSource":"NCI"},{"termName":"TTX-080","termGroup":"CN","termSource":"NCI"},{"termName":"TTX080","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-HLA-G Antibody TTX-080"},{"name":"NCI_Drug_Dictionary_ID","value":"803279"},{"name":"NCI_META_CUI","value":"CL1412700"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803279"},{"name":"PDQ_Open_Trial_Search_ID","value":"803279"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172391":{"preferredName":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A","code":"C172391","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized antibody targeting integrin beta-6 and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-integrin beta-6/MMAE ADC SGN-B6A targets and binds to integrin beta-6 on the surface of tumor cells. Following internalization of SGN-B6A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in integrin beta-6-expressing tumor cells. Integrin beta-6 is a subunit of integrin alpha-V beta-6 (aVb6). Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-integrin Beta-6 Antibody-drug Conjugate SGN-B6A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-integrin Beta-6-MMAE ADC SGN-B6A","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-integrin Beta-6/MMAE ADC SGN-B6A","termGroup":"SY","termSource":"NCI"},{"termName":"SGN B6A","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-B6A","termGroup":"CN","termSource":"NCI"},{"termName":"SGNB6A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A"},{"name":"NCI_Drug_Dictionary_ID","value":"802023"},{"name":"NCI_META_CUI","value":"CL1406348"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802023"},{"name":"PDQ_Open_Trial_Search_ID","value":"802023"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173725":{"preferredName":"Frenlosirsen","code":"C173725","definitions":[{"definition":"An antisense oligonucleotide (ASO) targeting the interferon regulatory factor 4 (IRF4) mRNA, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, frenlosirsen hybridizes with IRF4 mRNA, which blocks translation of the IRF4 protein. Reduction of IRF4 levels prevents the expression of IRF4-controlled tumor promoter genes, and may enhance tumor cell apoptosis and prevent T-cell exhaustion. IRF4, a transcription factor expressed in lymphocytes and essential for plasma cell differentiation, is involved in immune cell development and plays a key role in T-cell functions. It is overexpressed in certain tumor cell types and is a key regulator of multiple genes controlling tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Frenlosirsen","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-IRF4 Antisense Oligonucleotide ION251","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IRF4 ASO ION251","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-IRF4 ASO IONIS-IRF4-2.5Rx","termGroup":"SY","termSource":"NCI"},{"termName":"ION 251","termGroup":"CN","termSource":"NCI"},{"termName":"ION-251","termGroup":"CN","termSource":"NCI"},{"termName":"ION251","termGroup":"CN","termSource":"NCI"},{"termName":"IONIS-IRF4-2.5Rx","termGroup":"SY","termSource":"NCI"},{"termName":"ON-935918","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2304711-81-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J2Y9QT3BWL"},{"name":"Maps_To","value":"Anti-IRF4 Antisense Oligonucleotide ION251"},{"name":"NCI_Drug_Dictionary_ID","value":"802018"},{"name":"NCI_META_CUI","value":"CL1407569"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802018"},{"name":"PDQ_Open_Trial_Search_ID","value":"802018"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168603":{"preferredName":"Negalstobart","code":"C168603","definitions":[{"definition":"A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, negalstobart targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Negalstobart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody IBI-110","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LAG-3 Monoclonal Antibody IBI110","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 110","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-110","termGroup":"CN","termSource":"NCI"},{"termName":"IBI110","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2360418-68-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZH12W2AA34"},{"name":"Maps_To","value":"Anti-LAG-3 Monoclonal Antibody IBI-110"},{"name":"NCI_Drug_Dictionary_ID","value":"800401"},{"name":"NCI_META_CUI","value":"CL972918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800401"},{"name":"PDQ_Open_Trial_Search_ID","value":"800401"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173598":{"preferredName":"Linavonkibart","code":"C173598","definitions":[{"definition":"A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, linavonkibart specifically targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Linavonkibart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-latent TGF-b1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-latent TGFb1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TGF-beta 1 Monoclonal Antibody SRK-181","termGroup":"SY","termSource":"NCI"},{"termName":"SRK 181","termGroup":"CN","termSource":"NCI"},{"termName":"SRK-181","termGroup":"CN","termSource":"NCI"},{"termName":"SRK181","termGroup":"CN","termSource":"NCI"},{"termName":"SRT-BETA-1-AB3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2640981-30-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8SSL98OST3"},{"name":"Maps_To","value":"Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181"},{"name":"NCI_Drug_Dictionary_ID","value":"802238"},{"name":"NCI_META_CUI","value":"CL1407357"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802238"},{"name":"PDQ_Open_Trial_Search_ID","value":"802238"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175411":{"preferredName":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102","code":"C175411","definitions":[{"definition":"A humanized monoclonal antibody directed against human tumor-associated carbohydrate antigens (TACAs) Lewis B (LeB) and Lewis Y (LeY), with potential antineoplastic activity. Upon administration, anti-LeB/LeY monoclonal antibody GNX102 binds to branched LeB and LeY glycans, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against LeB- and LeY-expressing tumor cells. LeB and LeY antigens, tetrasaccharides with low to moderate expression in monomeric form in normal adult tissues, is overexpressed in branched form in multiple forms of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-branched Lewis B/Lewis Y Monoclonal Antibody GNX102","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-LeB/LeY Monoclonal Antibody GNX102","termGroup":"SY","termSource":"NCI"},{"termName":"GNX 102","termGroup":"CN","termSource":"NCI"},{"termName":"GNX-102","termGroup":"CN","termSource":"NCI"},{"termName":"GNX102","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102"},{"name":"NCI_Drug_Dictionary_ID","value":"803029"},{"name":"NCI_META_CUI","value":"CL1412719"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803029"},{"name":"PDQ_Open_Trial_Search_ID","value":"803029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174485":{"preferredName":"Anti-LILRB4 Monoclonal Antibody IO-202","code":"C174485","definitions":[{"definition":"A monoclonal antibody directed against the immune inhibitory receptor leukocyte immunoglobulin-like receptor B4 (LILRB4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody IO-202 targets, binds to and inhibits LILRB4 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells, and inhibit tumor infiltration. LILRB4, an immune inhibitory receptor normally expressed on monocytic cells and highly expressed on monocytic acute myeloid leukemia (AML) cells, functions as an immune checkpoint that negatively regulates T-cell activation as its extracellular domain inhibits T-cell activity. It plays an important role in tumor infiltration in leukemias through multiple signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-LILRB4 Monoclonal Antibody IO-202","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-leukocyte Immunoglobulin-like Receptor B4 Monoclonal Antibody IO-202","termGroup":"SY","termSource":"NCI"},{"termName":"IO 202","termGroup":"CN","termSource":"NCI"},{"termName":"IO-202","termGroup":"CN","termSource":"NCI"},{"termName":"IO202","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-LILRB4 Monoclonal Antibody IO-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802926"},{"name":"NCI_META_CUI","value":"CL1411991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802926"},{"name":"PDQ_Open_Trial_Search_ID","value":"802926"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174395":{"preferredName":"Misitatug Blivedotin","code":"C174395","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of an antibody directed against the human cell surface glycoprotein mesothelin and conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of misitatug blivedotin, the antibody moiety targets and binds to the tumor associated antigen (TAA) mesothelin on the surface of tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Misitatug Blivedotin","termGroup":"PT","termSource":"NCI"},{"termName":"ADC RC88","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-mesothelin Antibody-drug Conjugate RC88","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-mesothelin/MMAE ADC RC88","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-mesothelin/MMAE Antibody-drug Conjugate RC88","termGroup":"SY","termSource":"NCI"},{"termName":"RC 88","termGroup":"CN","termSource":"NCI"},{"termName":"RC-88","termGroup":"CN","termSource":"NCI"},{"termName":"RC88","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2767203-06-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NS5GTS5FLQ"},{"name":"Maps_To","value":"Anti-mesothelin/MMAE Antibody-drug Conjugate RC88"},{"name":"NCI_Drug_Dictionary_ID","value":"802312"},{"name":"NCI_META_CUI","value":"CL1411951"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802312"},{"name":"PDQ_Open_Trial_Search_ID","value":"802312"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165588":{"preferredName":"Vepsitamab","code":"C165588","definitions":[{"definition":"A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T-lymphocytes, with potential antineoplastic activity. Upon administration vepsitamab binds to both CD3 on T-cells and MUC17 expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vepsitamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 199","termGroup":"CN","termSource":"NCI"},{"termName":"AMG199","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-MUC17 x Anti-CD3 BiTE AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-MUC17/CD3 Bispecific Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-MUC17/CD3 BiTE Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"MUC17/CD3-directed Bispecific T-cell Engager Antibody AMG 199","termGroup":"SY","termSource":"NCI"},{"termName":"MUC17xCD3 Bispecific T-cell Engager AMG 199","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2413453-53-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZR1EEO1ZLS"},{"name":"Maps_To","value":"Anti-MUC17/CD3 BiTE Antibody AMG 199"},{"name":"NCI_Drug_Dictionary_ID","value":"799758"},{"name":"NCI_META_CUI","value":"CL978828"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799758"},{"name":"PDQ_Open_Trial_Search_ID","value":"799758"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173702":{"preferredName":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592","code":"C173702","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of XMT-1535, a humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), that is site-specifically bioconjugated to the cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upon administration of anti-NaPi2b ADC XMT-1592, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Following internalization of XMT-1592 and release of AF-HPA, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-NaPi2b ADC XMT-1592","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-NaPi2b/Auristatin F-HPA ADC XMT-1592","termGroup":"SY","termSource":"NCI"},{"termName":"NaPi2b-targeted Antibody-drug Conjugate XMT-1592","termGroup":"SY","termSource":"NCI"},{"termName":"XMT 1592","termGroup":"CN","termSource":"NCI"},{"termName":"XMT-1592","termGroup":"CN","termSource":"NCI"},{"termName":"XMT1592","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-NaPi2b Antibody-drug Conjugate XMT-1592"},{"name":"NCI_Drug_Dictionary_ID","value":"802039"},{"name":"NCI_META_CUI","value":"CL1407519"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802039"},{"name":"PDQ_Open_Trial_Search_ID","value":"802039"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175453":{"preferredName":"Gimistotug","code":"C175453","definitions":[{"definition":"An agonistic monoclonal antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, gimistotug selectively binds to OX40, thereby activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gimistotug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Agonist Monoclonal Antibody BGB-A445","termGroup":"SY","termSource":"NCI"},{"termName":"BGB A445","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A445","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA445","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2768487-95-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PT47RQF9HF"},{"name":"Maps_To","value":"Anti-OX40 Agonist Monoclonal Antibody BGB-A445"},{"name":"NCI_Drug_Dictionary_ID","value":"802825"},{"name":"NCI_META_CUI","value":"CL1412805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802825"},{"name":"PDQ_Open_Trial_Search_ID","value":"802825"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173983":{"preferredName":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106","code":"C173983","definitions":[{"definition":"An agonistic, recombinant, humanized, hexavalent immunoglobulin G (IgG) antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 hexavalent agonist antibody INBRX-106 selectively binds to six OX40 receptors per molecule, thereby clustering and activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells. Utilizing a hexavalent OX40 antibody may improve receptor clustering and downstream signaling over tetravalent or bivalent OX40 antibodies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-OX40 Agonistic Antibody INBRX-106","termGroup":"SY","termSource":"NCI"},{"termName":"ES 102","termGroup":"CN","termSource":"NCI"},{"termName":"ES-102","termGroup":"CN","termSource":"NCI"},{"termName":"ES102","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX 106","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX-106","termGroup":"CN","termSource":"NCI"},{"termName":"INBRX106","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-OX40 Hexavalent Agonist Antibody INBRX-106"},{"name":"NCI_Drug_Dictionary_ID","value":"802449"},{"name":"NCI_META_CUI","value":"CL1407892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802449"},{"name":"PDQ_Open_Trial_Search_ID","value":"802449"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174140":{"preferredName":"Latikafusp","code":"C174140","definitions":[{"definition":"An antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the cytokine interleukin-21 (IL-21), with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of latikafusp, the antibody moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The IL-21 mutein moiety binds to the IL-21 receptor and activates IL-21 cytokine signaling in PD-1-expressing cells. This may modulate the proliferation and/or differentiation, promote survival, and increase the cytolytic activity of PD-1-expressing T-cells, thereby enhancing T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-21 plays an important role in the regulation of cellular immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Latikafusp","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 256","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-256","termGroup":"CN","termSource":"NCI"},{"termName":"AMG256","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1 Antibody-IL-21 Mutein Fusion Protein AMG 256","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1-targeted IL-21 Receptor Agonist AMG 256","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2552814-07-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F188ZI78F7"},{"name":"Maps_To","value":"Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256"},{"name":"NCI_Drug_Dictionary_ID","value":"802477"},{"name":"NCI_META_CUI","value":"CL1407782"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802477"},{"name":"PDQ_Open_Trial_Search_ID","value":"802477"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172820":{"preferredName":"Anti-PD-1 Monoclonal Antibody 609A","code":"C172820","definitions":[{"definition":"A recombinant immunoglobulin G4 (IgG4) kappa monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody 609A targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1 Monoclonal Antibody 609A","termGroup":"PT","termSource":"NCI"},{"termName":"609 A","termGroup":"CN","termSource":"NCI"},{"termName":"609-A","termGroup":"CN","termSource":"NCI"},{"termName":"609A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody 609A"},{"name":"NCI_Drug_Dictionary_ID","value":"801688"},{"name":"NCI_META_CUI","value":"CL1406852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801688"},{"name":"PDQ_Open_Trial_Search_ID","value":"801688"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170758":{"preferredName":"Finotonlimab","code":"C170758","definitions":[{"definition":"A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, finotonlimab targets, binds to, and inhibits PD-1 and its downstream signaling pathways. This may restore immune functions through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Finotonlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 Monoclonal Antibody SCT-I10A","termGroup":"SY","termSource":"NCI"},{"termName":"SCT I10A","termGroup":"CN","termSource":"NCI"},{"termName":"SCT-I10A","termGroup":"CN","termSource":"NCI"},{"termName":"SCTI10A","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2350298-85-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"533Z4G2286"},{"name":"Maps_To","value":"Anti-PD-1 Monoclonal Antibody SCT-I10A"},{"name":"NCI_Drug_Dictionary_ID","value":"800786"},{"name":"NCI_META_CUI","value":"CL1383152"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800786"},{"name":"PDQ_Open_Trial_Search_ID","value":"800786"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174419":{"preferredName":"Fidasimtamab","code":"C174419","definitions":[{"definition":"A recombinant human immunoglobulin G1 (IgG1) bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fidasimtamab simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fidasimtamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315","termGroup":"SY","termSource":"NCI"},{"termName":"BH 2950","termGroup":"CN","termSource":"NCI"},{"termName":"BH-2950","termGroup":"CN","termSource":"NCI"},{"termName":"BH2950","termGroup":"CN","termSource":"NCI"},{"termName":"HER2/PD-1 Bi-specific Antibody BH 2950","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 315","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-315","termGroup":"CN","termSource":"NCI"},{"termName":"IBI315","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2377419-89-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JXN644CQ6P"},{"name":"Maps_To","value":"Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315"},{"name":"NCI_Drug_Dictionary_ID","value":"802264"},{"name":"NCI_META_CUI","value":"CL1411981"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802264"},{"name":"PDQ_Open_Trial_Search_ID","value":"802264"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173539":{"preferredName":"Tobemstomig","code":"C173539","definitions":[{"definition":"A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tobemstomig targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tobemstomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD1/Anti-LAG3 Bispecific Antibody RO7247669","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7247669","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7247669","termGroup":"CN","termSource":"NCI"},{"termName":"RO7247669","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2648839-43-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"93NRF4S9HR"},{"name":"Maps_To","value":"Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669"},{"name":"NCI_Drug_Dictionary_ID","value":"801886"},{"name":"NCI_META_CUI","value":"CL1407490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801886"},{"name":"PDQ_Open_Trial_Search_ID","value":"801886"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171938":{"preferredName":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","code":"C171938","definitions":[{"definition":"A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody IBI318 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1, which is expressed on tumor cells. This crosslinks PD-1-expressing T cells and PD-L1-expressing tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1/PD-L1 Bispecific Antibody IBI318","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific Antibody IBI318","termGroup":"SY","termSource":"NCI"},{"termName":"IBI 318","termGroup":"CN","termSource":"NCI"},{"termName":"IBI-318","termGroup":"CN","termSource":"NCI"},{"termName":"IBI318","termGroup":"CN","termSource":"NCI"},{"termName":"Recombinant Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318"},{"name":"NCI_Drug_Dictionary_ID","value":"801472"},{"name":"NCI_META_CUI","value":"CL1405902"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801472"},{"name":"PDQ_Open_Trial_Search_ID","value":"801472"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C168600":{"preferredName":"Anti-PD-1/CD47 Fusion Protein HX009","code":"C168600","definitions":[{"definition":"A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 fusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-1/CD47 Fusion Protein HX009","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1/CD47 Bi-specific Antibody Fusion Protein HX009","termGroup":"SY","termSource":"NCI"},{"termName":"HX 009","termGroup":"CN","termSource":"NCI"},{"termName":"HX-009","termGroup":"CN","termSource":"NCI"},{"termName":"HX009","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-1/CD47 Infusion Protein HX009"},{"name":"NCI_Drug_Dictionary_ID","value":"800318"},{"name":"NCI_META_CUI","value":"CL972917"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800318"},{"name":"PDQ_Open_Trial_Search_ID","value":"800318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171937":{"preferredName":"Volrustomig","code":"C171937","definitions":[{"definition":"An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. In addition, volrustomig is internalized and is able to degrade PD-1. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with volrustomig may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. It may also decrease toxicity by avoiding the binding to CTLA-4-expressing T-cells that are devoid of PD-1. The engineered Fc domain may reduce Fc effector function.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Volrustomig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-1 x CTLA-4 Bispecific Antibody MEDI5752","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-CTLA-4 Bispecific Antibody MEDI5752","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752","termGroup":"SY","termSource":"NCI"},{"termName":"MEDI 5752","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI-5752","termGroup":"CN","termSource":"NCI"},{"termName":"MEDI5752","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2407760-40-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K96EGJ218N"},{"name":"Maps_To","value":"Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752"},{"name":"NCI_Drug_Dictionary_ID","value":"802004"},{"name":"NCI_META_CUI","value":"CL1405903"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802004"},{"name":"PDQ_Open_Trial_Search_ID","value":"802004"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C184865":{"preferredName":"Ivonescimab","code":"C184865","definitions":[{"definition":"A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, ivonescimab simultaneously targets and binds to both PD-1 expressed on certain T-cells and VEGF expressed on tumor cells. The binding of ivonescimab to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of ivonescimab to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1 and/or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ivonescimab","termGroup":"PT","termSource":"NCI"},{"termName":"AK 112","termGroup":"CN","termSource":"NCI"},{"termName":"AK-112","termGroup":"CN","termSource":"NCI"},{"termName":"AK112","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-PD-1/Anti-VEGF Bispecific Antibody AK112","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-PD-1/VEGF Bispecific Antibody AK112","termGroup":"SY","termSource":"NCI"},{"termName":"PD-1/VEGF Bispecific Antibody AK112","termGroup":"SY","termSource":"NCI"},{"termName":"SMT 112","termGroup":"CN","termSource":"NCI"},{"termName":"SMT-112","termGroup":"CN","termSource":"NCI"},{"termName":"SMT112","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2428381-53-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y0O332CU66"},{"name":"Maps_To","value":"Anti-PD-1/VEGF Bispecific Antibody AK112"},{"name":"NCI_Drug_Dictionary_ID","value":"800843"},{"name":"NCI_META_CUI","value":"CL1772938"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172819":{"preferredName":"Danburstotug","code":"C172819","definitions":[{"definition":"A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, danburstotug specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, anti-PD-L1 monoclonal antibody IMC-001 also induces antibody-dependent cell-mediated cytotoxicity (ADCC). PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Danburstotug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1 Monoclonal Antibody IMC-001","termGroup":"SY","termSource":"NCI"},{"termName":"IMC 001","termGroup":"CN","termSource":"NCI"},{"termName":"IMC-001","termGroup":"CN","termSource":"NCI"},{"termName":"IMC001","termGroup":"CN","termSource":"NCI"},{"termName":"STI 3031","termGroup":"CN","termSource":"NCI"},{"termName":"STI3031","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2307144-65-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F44C4N45HG"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody IMC-001"},{"name":"NCI_Drug_Dictionary_ID","value":"801687"},{"name":"NCI_META_CUI","value":"CL1406853"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801687"},{"name":"PDQ_Open_Trial_Search_ID","value":"801687"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C174520":{"preferredName":"Anti-PD-L1 Monoclonal Antibody RC98","code":"C174520","definitions":[{"definition":"A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody RC98 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1 Monoclonal Antibody RC98","termGroup":"PT","termSource":"NCI"},{"termName":"RC 98","termGroup":"CN","termSource":"NCI"},{"termName":"RC-98","termGroup":"CN","termSource":"NCI"},{"termName":"RC98","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1 Monoclonal Antibody RC98"},{"name":"NCI_Drug_Dictionary_ID","value":"802372"},{"name":"NCI_META_CUI","value":"CL1411836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802372"},{"name":"PDQ_Open_Trial_Search_ID","value":"802372"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172194":{"preferredName":"Acasunlimab","code":"C172194","definitions":[{"definition":"A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, acasunlimab simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, acasunlimab acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, acasunlimab prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acasunlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046","termGroup":"SY","termSource":"NCI"},{"termName":"BNT 311","termGroup":"CN","termSource":"NCI"},{"termName":"DuoBody PD-L1 x 4-1BB GEN1046","termGroup":"SY","termSource":"NCI"},{"termName":"GEN 1046","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-1046","termGroup":"CN","termSource":"NCI"},{"termName":"GEN1046","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2253937-12-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H52ITZ9X9D"},{"name":"Maps_To","value":"Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046"},{"name":"NCI_Drug_Dictionary_ID","value":"801584"},{"name":"NCI_META_CUI","value":"CL1406283"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801584"},{"name":"PDQ_Open_Trial_Search_ID","value":"801584"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173592":{"preferredName":"Anti-PD-L1/IL-15 Fusion Protein KD033","code":"C173592","definitions":[{"definition":"A fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) fused to the immunostimulatory cytokine interleukin-15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration of the anti-PD-L1/IL-15 fusion protein KD033, the anti-PD-L1 antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor microenvironment (TME). In turn, IL-15 stimulates the proliferation of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the TME, which induces an anti-tumor immune response. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. PD-L1, a transmembrane protein, is expressed on the surface of antigen presenting cells (APCs) and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PD-L1/IL-15 Fusion Protein KD033","termGroup":"PT","termSource":"NCI"},{"termName":"KD 033","termGroup":"CN","termSource":"NCI"},{"termName":"KD-033","termGroup":"CN","termSource":"NCI"},{"termName":"KD033","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PD-L1/IL-15 Fusion Protein KD033"},{"name":"NCI_Drug_Dictionary_ID","value":"802237"},{"name":"NCI_META_CUI","value":"CL1407359"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802237"},{"name":"PDQ_Open_Trial_Search_ID","value":"802237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170976":{"preferredName":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C","code":"C170976","definitions":[{"definition":"A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon administration of IMC-F106C, the TCR moiety of this agent targets and binds to PRAME on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C","termGroup":"PT","termSource":"NCI"},{"termName":"ImmTAC IMC-F106C","termGroup":"SY","termSource":"NCI"},{"termName":"ImmTAC Molecule IMC-F106C","termGroup":"SY","termSource":"NCI"},{"termName":"Immune Mobilizing Monoclonal TCR Against Cancer IMC-F106C","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C"},{"name":"NCI_Drug_Dictionary_ID","value":"801222"},{"name":"NCI_META_CUI","value":"CL1383231"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801222"},{"name":"PDQ_Open_Trial_Search_ID","value":"801222"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169053":{"preferredName":"Anti-PSMA/CD3 Bispecific Antibody CCW702","code":"C169053","definitions":[{"definition":"A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-PSMA/CD3 bispecific antibody CCW702, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-PSMA/CD3 Bispecific Antibody CCW702","termGroup":"PT","termSource":"NCI"},{"termName":"CCW 702","termGroup":"CN","termSource":"NCI"},{"termName":"CCW-702","termGroup":"CN","termSource":"NCI"},{"termName":"CCW702","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-PSMA/CD3 Bispecific Antibody CCW702"},{"name":"NCI_Drug_Dictionary_ID","value":"800617"},{"name":"NCI_META_CUI","value":"CL1378858"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800617"},{"name":"PDQ_Open_Trial_Search_ID","value":"800617"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174406":{"preferredName":"Anti-RANKL Monoclonal Antibody GB-223","code":"C174406","definitions":[{"definition":"A monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with potential antiosteoclast and antineoplastic activities. Upon administration, anti-RANKL monoclonal antibody GB-223 specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This results in the inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. By blocking the activation of the RANK/RANKL-mediated signaling pathway, GB-223 may also reduce tumor-associated bone destruction and may result in tumor regression in bone tumors with high RANK and RANKL expressions. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-RANKL Monoclonal Antibody GB-223","termGroup":"PT","termSource":"NCI"},{"termName":"GB 223","termGroup":"CN","termSource":"NCI"},{"termName":"GB-223","termGroup":"CN","termSource":"NCI"},{"termName":"GB223","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-RANKL Monoclonal Antibody GB-223"},{"name":"NCI_Drug_Dictionary_ID","value":"802325"},{"name":"NCI_META_CUI","value":"CL1411946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802325"},{"name":"PDQ_Open_Trial_Search_ID","value":"802325"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C190458":{"preferredName":"Narlumosbart","code":"C190458","definitions":[{"definition":"A recombinant, human, immunoglobulin G4 (IgG4) monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL), with potential antiosteoclast and bone-sparing activities. Upon administration, narlumosbart specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This may inhibit osteoclast activity, decrease bone resorption, increase bone mineral density, and may protect bones from tumor metastasis. This may abrogate hypercalcemia of malignancy and may correct serum calcium levels. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Narlumosbart","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-RANKL Monoclonal Antibody JMT103","termGroup":"SY","termSource":"NCI"},{"termName":"JMT 103","termGroup":"CN","termSource":"NCI"},{"termName":"JMT-103","termGroup":"CN","termSource":"NCI"},{"termName":"JMT103","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J38KT46AH8"},{"name":"Maps_To","value":"Anti-RANKL Monoclonal Antibody JMT103"},{"name":"NCI_Drug_Dictionary_ID","value":"802778"},{"name":"NCI_META_CUI","value":"CL1798893"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172924":{"preferredName":"Alextatug","code":"C172924","definitions":[{"definition":"An engineered, human immunoglobulin (Ig) G1 monoclonal antibody directed against a ribonucleoprotein (RNP) complex, with potential immunostimulating and antineoplastic activities. Upon administration, alextatug targets and binds to its RNP complex antigen on tumor cells. This may activate the innate immune system, change the local tumor microenvironment (TME) and promote T cell-mediated killing of tumor cells. The tumor-restricted RNP complex is expressed in a variety of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Alextatug","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-Ribonucleoprotein Antibody ATRC-101","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-RNP Antibody ATRC-101","termGroup":"SY","termSource":"NCI"},{"termName":"ATRC 101","termGroup":"CN","termSource":"NCI"},{"termName":"ATRC-101","termGroup":"CN","termSource":"NCI"},{"termName":"ATRC101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2768264-93-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LF64CQ4EC6"},{"name":"Maps_To","value":"Anti-Ribonucleoprotein Antibody ATRC-101"},{"name":"NCI_Drug_Dictionary_ID","value":"802038"},{"name":"NCI_META_CUI","value":"CL1406946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802038"},{"name":"PDQ_Open_Trial_Search_ID","value":"802038"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174012":{"preferredName":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002","code":"C174012","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) site-specifically conjugated to a derivative of the highly potent anthracycline PNU-159682, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of NBE-002 targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the anthracycline-based toxin intercalates into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication and repair, and prevents RNA and protein synthesis. This kills the ROR1-expressing cancer cells. In addition, the PNU-159682 derivate may promote immunogenic cell death (ICD) and activate a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response, thereby further killing the ROR1-expressing tumor cells. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002","termGroup":"PT","termSource":"NCI"},{"termName":"ADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anthracycline-based Immune-stimulatory ADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-ROR1/PNU-159682 Derivative ADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"iADC NBE-002","termGroup":"SY","termSource":"NCI"},{"termName":"NBE 002","termGroup":"CN","termSource":"NCI"},{"termName":"NBE-002","termGroup":"CN","termSource":"NCI"},{"termName":"NBE002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002"},{"name":"NCI_Drug_Dictionary_ID","value":"802454"},{"name":"NCI_META_CUI","value":"CL1407925"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802454"},{"name":"PDQ_Open_Trial_Search_ID","value":"802454"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170906":{"preferredName":"Ociperlimab","code":"C170906","definitions":[{"definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, ociperlimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ociperlimab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-TIGIT Monoclonal Antibody BGB-A1217","termGroup":"SY","termSource":"NCI"},{"termName":"BGB A1217","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-A1217","termGroup":"CN","termSource":"NCI"},{"termName":"BGBA1217","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2342597-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7JNY4KV3NK"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody BGB-A1217"},{"name":"NCI_Drug_Dictionary_ID","value":"800838"},{"name":"NCI_META_CUI","value":"CL1383052"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800838"},{"name":"PDQ_Open_Trial_Search_ID","value":"800838"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174037":{"preferredName":"Anti-TIGIT Monoclonal Antibody COM902","code":"C174037","definitions":[{"definition":"A fully human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody COM902 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIGIT Monoclonal Antibody COM902","termGroup":"PT","termSource":"NCI"},{"termName":"COM 902","termGroup":"CN","termSource":"NCI"},{"termName":"COM-902","termGroup":"CN","termSource":"NCI"},{"termName":"COM902","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody COM902"},{"name":"NCI_Drug_Dictionary_ID","value":"802457"},{"name":"NCI_META_CUI","value":"CL1407907"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802457"},{"name":"PDQ_Open_Trial_Search_ID","value":"802457"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173630":{"preferredName":"Anti-TIGIT Monoclonal Antibody SGN-TGT","code":"C173630","definitions":[{"definition":"A nonfucosylated human immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, anti-TIGIT monoclonal antibody SGN-TGT targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs). This prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), and enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This enhances depletion of TIGIT-positive regulatory T-cells (Tregs) and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIGIT Monoclonal Antibody SGN-TGT","termGroup":"PT","termSource":"NCI"},{"termName":"SEA TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SEA-TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SEATGT","termGroup":"CN","termSource":"NCI"},{"termName":"SGN TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SGN-TGT","termGroup":"CN","termSource":"NCI"},{"termName":"SGNTGT","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TIGIT Monoclonal Antibody SGN-TGT"},{"name":"NCI_Drug_Dictionary_ID","value":"802244"},{"name":"NCI_META_CUI","value":"CL1407380"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802244"},{"name":"PDQ_Open_Trial_Search_ID","value":"802244"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172108":{"preferredName":"Anti-TIM3 Monoclonal Antibody SHR-1702","code":"C172108","definitions":[{"definition":"A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIM3 monoclonal antibody SHR-1702 targets and binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TIM3 Monoclonal Antibody SHR-1702","termGroup":"PT","termSource":"NCI"},{"termName":"SHR 1702","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1702","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1702","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TIM3 Monoclonal Antibody SHR-1702"},{"name":"NCI_Drug_Dictionary_ID","value":"801357"},{"name":"NCI_META_CUI","value":"CL1406215"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801357"},{"name":"PDQ_Open_Trial_Search_ID","value":"801357"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173541":{"preferredName":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711","code":"C173541","definitions":[{"definition":"A tetravalent bispecific antibody targeting both the pro-apoptotic death receptor tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2; death receptor 5; DR5) and cadherin-17 (CDH17), with potential pro-apoptotic and antineoplastic activities. Upon administration of anti-TRAILR2/CDH17 tetravalent bispecific antibody BI 905711, the antibody targets and binds to both TRAILR2 and CDH17, expressed on tumor cells. Receptor clustering and activation of TRAILR2 induces apoptosis in CDH17-positive cancer cells. Activation of TRAILR2 plays a key role in the induction of apoptosis. CDH17-dependent clustering of TRAILR2 allows BI 905711 to selectively induce apoptosis in CDH17-expressing tumor cells thereby increasing efficacy and decreasing liver toxicity. CDH17 is overexpressed in a variety of cancer cell types while its expression is restricted in normal liver tissue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711","termGroup":"PT","termSource":"NCI"},{"termName":"BI 905711","termGroup":"CN","termSource":"NCI"},{"termName":"BI-905711","termGroup":"CN","termSource":"NCI"},{"termName":"Bi-specific Agent BI 905711","termGroup":"SY","termSource":"NCI"},{"termName":"BI905711","termGroup":"CN","termSource":"NCI"},{"termName":"CDH17-targeting TRAILR2 Agonist BI 905711","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711"},{"name":"NCI_Drug_Dictionary_ID","value":"801873"},{"name":"NCI_META_CUI","value":"CL1407500"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801873"},{"name":"PDQ_Open_Trial_Search_ID","value":"801873"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172060":{"preferredName":"Anti-TROP2 Antibody-drug Conjugate BAT8003","code":"C172060","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated via an uncleavable linker to an as of yet undisclosed maytansine derivative toxin, with potential antineoplastic activity. Upon administration of the anti-TROP2 ADC BAT8003, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the cytotoxic maytansine derivative binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-TROP2 Antibody-drug Conjugate BAT8003","termGroup":"PT","termSource":"NCI"},{"termName":"ADC BAT8003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-Trop-2 Antibody-drug Conjugate BAT8003","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2 ADC BAT8003","termGroup":"SY","termSource":"NCI"},{"termName":"BAT 8003","termGroup":"CN","termSource":"NCI"},{"termName":"BAT-8003","termGroup":"CN","termSource":"NCI"},{"termName":"BAT8003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-TROP2 Antibody-drug Conjugate BAT8003"},{"name":"NCI_Drug_Dictionary_ID","value":"801492"},{"name":"NCI_META_CUI","value":"CL1406188"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801492"},{"name":"PDQ_Open_Trial_Search_ID","value":"801492"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166409":{"preferredName":"Sacituzumab Tirumotecan","code":"C166409","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration sacituzumab tirumotecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sacituzumab Tirumotecan","termGroup":"PT","termSource":"NCI"},{"termName":"ADC MK-2870","termGroup":"SY","termSource":"NCI"},{"termName":"ADC SKB264","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2 Antibody-drug Conjugate MK-2870","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-TROP2 Antibody-drug Conjugate SKB264","termGroup":"SY","termSource":"NCI"},{"termName":"MK 2870","termGroup":"CN","termSource":"NCI"},{"termName":"MK-2870","termGroup":"CN","termSource":"NCI"},{"termName":"MK2870","termGroup":"CN","termSource":"NCI"},{"termName":"SKB 264","termGroup":"CN","termSource":"NCI"},{"termName":"SKB-264","termGroup":"CN","termSource":"NCI"},{"termName":"SKB264","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2768350-77-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"3DV5TD1VL3"},{"name":"Maps_To","value":"Anti-TROP2 Antibody-drug Conjugate SKB264"},{"name":"NCI_Drug_Dictionary_ID","value":"800236"},{"name":"NCI_META_CUI","value":"CL971661"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800236"},{"name":"PDQ_Open_Trial_Search_ID","value":"800236"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174422":{"preferredName":"Anti-VEGFR2 Monoclonal Antibody MSB0254","code":"C174422","definitions":[{"definition":"A humanized monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, anti-VEGFR2 monoclonal antibody MSB0254 specifically binds to and inhibits VEGFR2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Anti-VEGFR2 Monoclonal Antibody MSB0254","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-VEGFR-2 Monoclonal Antibody MSB0254","termGroup":"SY","termSource":"NCI"},{"termName":"MSB 0254","termGroup":"CN","termSource":"NCI"},{"termName":"MSB-0254","termGroup":"CN","termSource":"NCI"},{"termName":"MSB0254","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Anti-VEGFR2 Monoclonal Antibody MSB0254"},{"name":"NCI_Drug_Dictionary_ID","value":"802274"},{"name":"NCI_META_CUI","value":"CL1411984"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802274"},{"name":"PDQ_Open_Trial_Search_ID","value":"802274"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C162452":{"preferredName":"Antisense Oligonucleotide QR-313","code":"C162452","definitions":[{"definition":"A twenty-one nucleotide-containing antisense oligonucleotide (AON) with potential use in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene. Upon topical administration, QR-313 hybridizes to a specific sequence in COL7A1 pre-mRNA, resulting in exclusion of exon 73 from mRNA and translation of a functional type VII collagen protein. This may restore functionality of integument anchoring fibrils, prevent blistering, and improve wound healing in patients with DEB. Type VII collagen is a major component of anchoring fibrils, attachment structures that mediate dermal-epidermal adherence in human skin. DEB is an inherited mechano-bullous disorder caused by mutations in the COL7A1 gene, which lead to perturbations in anchoring fibrils.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Antisense Oligonucleotide QR-313","termGroup":"PT","termSource":"NCI"},{"termName":"QR 313","termGroup":"CN","termSource":"NCI"},{"termName":"QR-313","termGroup":"CN","termSource":"NCI"},{"termName":"QR313","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Antisense Oligonucleotide QR-313"},{"name":"NCI_Drug_Dictionary_ID","value":"798741"},{"name":"NCI_META_CUI","value":"CL971000"},{"name":"PDQ_Closed_Trial_Search_ID","value":"798741"},{"name":"PDQ_Open_Trial_Search_ID","value":"798741"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171151":{"preferredName":"Aryl Hydrocarbon Receptor Inhibitor IK-175","code":"C171151","definitions":[{"definition":"An orally bioavailable selective inhibitor of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76), with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR inhibitor IK-175 specifically targets and binds to AhR, inhibits AhR activation, prevents AhR-mediated signaling, and AhR-dependent tumor cell proliferation. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs), regulatory T-cells (Tregs) and decreases suppressive cytokines in the tumor microenvironment (TME). It stimulates cytotoxic T-cell activation and expansion. This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, plays key roles in regulating immunity and cellular differentiation. It mediates the expression of multiple immune related and tumor cell signal transduction and proliferation genes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aryl Hydrocarbon Receptor Inhibitor IK-175","termGroup":"PT","termSource":"NCI"},{"termName":"AhR Antagonist IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"AhR Inhibitor IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"AhRi IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"AhRi KYN-175","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Antagonist IK-175","termGroup":"SY","termSource":"NCI"},{"termName":"Aryl Hydrocarbon Receptor Antagonist KYN-175","termGroup":"SY","termSource":"NCI"},{"termName":"IK 175","termGroup":"CN","termSource":"NCI"},{"termName":"IK-175","termGroup":"CN","termSource":"NCI"},{"termName":"IK175","termGroup":"CN","termSource":"NCI"},{"termName":"KYN 175","termGroup":"CN","termSource":"NCI"},{"termName":"KYN-175","termGroup":"CN","termSource":"NCI"},{"termName":"KYN175","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aryl Hydrocarbon Receptor Inhibitor IK-175"},{"name":"NCI_Drug_Dictionary_ID","value":"801964"},{"name":"NCI_META_CUI","value":"CL1405381"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801964"},{"name":"PDQ_Open_Trial_Search_ID","value":"801964"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174206":{"preferredName":"Camonsertib","code":"C174206","definitions":[{"definition":"An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, camonsertib selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Camonsertib","termGroup":"PT","termSource":"NCI"},{"termName":"1R,3R,5S)-3-(6-((R)-3-Methylmorpholino)-1-(1H-pyrazol-3-yl)-1H-pyrazolo(3,4-b)pyridin-4-yl)-8-oxabicyclo(3.2.1)octan-3-ol","termGroup":"SN","termSource":"NCI"},{"termName":"8-Oxabicyclo(3.2.1)octan-3-ol, 3-(6-((3R)-3-methyl-4-morpholinyl)-1-(1H-pyrazol-3-yl)-1H-pyrazolo(3,4-b)pyridin-4-yl)-, (3-endo)-","termGroup":"SN","termSource":"NCI"},{"termName":"ATR Inhibitor RP-3500","termGroup":"SY","termSource":"NCI"},{"termName":"RP 3500","termGroup":"CN","termSource":"NCI"},{"termName":"RP-3500","termGroup":"CN","termSource":"NCI"},{"termName":"RP3500","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417489-10-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S1Z7Y5G56T"},{"name":"Maps_To","value":"ATR Inhibitor RP-3500"},{"name":"NCI_Drug_Dictionary_ID","value":"803074"},{"name":"NCI_META_CUI","value":"CL1411776"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803074"},{"name":"PDQ_Open_Trial_Search_ID","value":"803074"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171067":{"preferredName":"Tuvusertib","code":"C171067","definitions":[{"definition":"An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, tuvusertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tuvusertib","termGroup":"PT","termSource":"NCI"},{"termName":"ATR Kinase Inhibitor M1774","termGroup":"SY","termSource":"NCI"},{"termName":"M 1774","termGroup":"CN","termSource":"NCI"},{"termName":"M-1774","termGroup":"CN","termSource":"NCI"},{"termName":"M1774","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"JE1BE6ZGZ7"},{"name":"Maps_To","value":"ATR Kinase Inhibitor M1774"},{"name":"NCI_Drug_Dictionary_ID","value":"801231"},{"name":"NCI_META_CUI","value":"CL1405453"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801231"},{"name":"PDQ_Open_Trial_Search_ID","value":"801231"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175440":{"preferredName":"Attenuated Measles Virus Encoding SCD Transgene TMV-018","code":"C175440","definitions":[{"definition":"A recombinant, attenuated oncolytic measles virus (MV) encoding the prodrug converting enzyme super cytosine deaminase (SCD), that can potentially be used as an antineoplastic adjuvant and with potential antineoplastic activity. Upon intra-tumoral injection, TMV-018 preferentially enters and transfects tumor cells, and expresses SCD, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-fluorocytosine; 5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU by SCD. In addition, the oncolytic MV may infect and lyse tumor cells. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. This may further eradicate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Attenuated Measles Virus Encoding SCD Transgene TMV-018","termGroup":"PT","termSource":"NCI"},{"termName":"TMV 018","termGroup":"CN","termSource":"NCI"},{"termName":"TMV-018","termGroup":"CN","termSource":"NCI"},{"termName":"TMV018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Attenuated Measles Virus Encoding SCD Transgene TMV-018"},{"name":"NCI_Drug_Dictionary_ID","value":"802771"},{"name":"NCI_META_CUI","value":"CL1412818"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802771"},{"name":"PDQ_Open_Trial_Search_ID","value":"802771"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173429":{"preferredName":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055","code":"C173429","definitions":[{"definition":"A preparation of human autologous T-lymphocytes transduced with a lentiviral vector encoding for a T-cell receptor (TCR) recognizing the human leukocyte antigen (HLA)-A*02:01 restricted human alpha-fetoprotein (AFP) 158-166 peptide (FMNKFIYEI), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the AFP specific TCR transduced T cells recognize and bind to AFP antigen-positive cells, which results in lysis and killing of AFP-positive cancer cells. AFP is overexpressed in a variety of cancers while its expression is restricted in normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous AFP-specific TCR-transduced T-cells C-TCR055","termGroup":"SY","termSource":"NCI"},{"termName":"C-TCR 055","termGroup":"SY","termSource":"NCI"},{"termName":"C-TCR-055","termGroup":"CN","termSource":"NCI"},{"termName":"C-TCR055","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055"},{"name":"NCI_Drug_Dictionary_ID","value":"801757"},{"name":"NCI_META_CUI","value":"CL1407436"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801757"},{"name":"PDQ_Open_Trial_Search_ID","value":"801757"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174124":{"preferredName":"Autologous Anti-BCMA CAR T-cells PHE885","code":"C174124","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential antineoplastic activity. Upon administration, the autologous anti-BCMA CAR T-cells PHE885 recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA CAR T-cells PHE885","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous BCMA-specific CAR T-cells PHE885","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-directed Autologous CAR-T Cells PHE885","termGroup":"SY","termSource":"NCI"},{"termName":"PHE 885","termGroup":"CN","termSource":"NCI"},{"termName":"PHE-885","termGroup":"CN","termSource":"NCI"},{"termName":"PHE885","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA CAR T-cells PHE885"},{"name":"NCI_Drug_Dictionary_ID","value":"802475"},{"name":"NCI_META_CUI","value":"CL1407791"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802475"},{"name":"PDQ_Open_Trial_Search_ID","value":"802475"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173434":{"preferredName":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11","code":"C173434","definitions":[{"definition":"A preparation of autologous CD8-positive T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA CD8+ CAR T-cells Descartes-11 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD8+ T-cells Expressing Anti-BCMA CAR Descartes-11","termGroup":"SY","termSource":"NCI"},{"termName":"Descartes 11","termGroup":"CN","termSource":"NCI"},{"termName":"Descartes-011","termGroup":"CN","termSource":"NCI"},{"termName":"Descartes-11","termGroup":"CN","termSource":"NCI"},{"termName":"Descartes11","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11"},{"name":"NCI_Drug_Dictionary_ID","value":"801760"},{"name":"NCI_META_CUI","value":"CL1407417"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801760"},{"name":"PDQ_Open_Trial_Search_ID","value":"801760"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170747":{"preferredName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088","code":"C170747","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the epitome cluster E3 in the extracellular domain (ECD) of the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous BCMA-directed CAR-T Cells C-CAR088","termGroup":"SY","termSource":"NCI"},{"termName":"C-CAR 088","termGroup":"CN","termSource":"NCI"},{"termName":"C-CAR-088","termGroup":"CN","termSource":"NCI"},{"termName":"C-CAR088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088"},{"name":"NCI_Drug_Dictionary_ID","value":"800733"},{"name":"NCI_META_CUI","value":"CL1383157"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800733"},{"name":"PDQ_Open_Trial_Search_ID","value":"800733"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171167":{"preferredName":"Autologous Anti-CD123 CAR-T Cells","code":"C171167","definitions":[{"definition":"A preparation of autologous T-cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD123 CAR-T cells target and bind to CD123 expressed on the surface of tumor cells. This induces selective toxicity in CD123-expressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. It is overexpressed on a variety of cancers, including myeloid leukemia, and the increased expression of CD123 on leukemic stem cells (LSCs) is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD123 CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD123 CAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD123 Chimeric Antigen Receptor T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123 CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD123 CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801968"},{"name":"NCI_META_CUI","value":"CL1405393"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801968"},{"name":"PDQ_Open_Trial_Search_ID","value":"801968"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173622":{"preferredName":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx","code":"C173622","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR T-cells 19(T2)28z1xx specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells. CD28 and CD3zeta provide co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T-cells. The 19(T2)28z1xx CAR T-cells include a 1928zeta mutant, 1xx, which contains one instead of all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation and exhaustion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx","termGroup":"PT","termSource":"NCI"},{"termName":"19(T2)28z1xx","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous 19(T2)28z1xx CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells 19(T2)28z1xx","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-Targeted CAR T-cells 19(T2)28z1xx","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx"},{"name":"NCI_Drug_Dictionary_ID","value":"802242"},{"name":"NCI_META_CUI","value":"CL1407373"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802242"},{"name":"PDQ_Open_Trial_Search_ID","value":"802242"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175465":{"preferredName":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19","code":"C175465","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR-T Cells CNCT19","termGroup":"SY","termSource":"NCI"},{"termName":"CNCT 19","termGroup":"CN","termSource":"NCI"},{"termName":"CNCT-19","termGroup":"CN","termSource":"NCI"},{"termName":"CNCT19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19"},{"name":"NCI_Drug_Dictionary_ID","value":"802902"},{"name":"NCI_META_CUI","value":"CL1412856"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802902"},{"name":"PDQ_Open_Trial_Search_ID","value":"802902"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172746":{"preferredName":"Obecabtagene Autoleucel","code":"C172746","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Obecabtagene Autoleucel","termGroup":"PT","termSource":"NCI"},{"termName":"AUTO 1","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO-1","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO1","termGroup":"CN","termSource":"NCI"},{"termName":"AUTO1 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19 Chimeric Antigen Receptor T-lymphocytes AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-targeted CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"CD19CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"CD19CAT-41BBZ CAR T-cells AUTO1","termGroup":"SY","termSource":"NCI"},{"termName":"Obe-cel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"760HJB0YRD"},{"name":"Maps_To","value":"Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1"},{"name":"NCI_Drug_Dictionary_ID","value":"801949"},{"name":"NCI_META_CUI","value":"CL1406598"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801949"},{"name":"PDQ_Open_Trial_Search_ID","value":"801949"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172055":{"preferredName":"Autologous Anti-CD19 TAC-T cells TAC01-CD19","code":"C172055","definitions":[{"definition":"A preparation of autologous T-lymphocytes genetically engineered with a T cell Antigen Coupler (TAC), comprising of a domain that targets the tumor-associated antigen (TAA) cluster of differentiation 19 (CD 19) and another domain that binds to the endogenous T cell receptor (TCR), anchored in the membrane via the CD4 co-receptor domain, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 TAC-T cells TAC01-CD19 targets and binds to CD19-expressing tumor cells and activates TCR-mediated signaling pathways, leading to T cell-mediated killing of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19 TAC-T cells TAC01-CD19","termGroup":"PT","termSource":"NCI"},{"termName":"CD19-targeted T Cell Antigen Coupler TAC01-CD19","termGroup":"SY","termSource":"NCI"},{"termName":"TAC01 CD19","termGroup":"CN","termSource":"NCI"},{"termName":"TAC01-CD19","termGroup":"CN","termSource":"NCI"},{"termName":"TAC01CD19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19 TAC-T cells TAC01-CD19"},{"name":"NCI_Drug_Dictionary_ID","value":"801474"},{"name":"NCI_META_CUI","value":"CL1406193"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801474"},{"name":"PDQ_Open_Trial_Search_ID","value":"801474"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172057":{"preferredName":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells","code":"C172057","definitions":[{"definition":"A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that is nanobody-based and specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19/CD20 bispecific nanobody-based CAR-T cells target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19/20 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-CD19/CD20 Bispecific Nanobody-derived CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19/CD20 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801489"},{"name":"NCI_META_CUI","value":"CL1406191"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801489"},{"name":"PDQ_Open_Trial_Search_ID","value":"801489"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C155897":{"preferredName":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells","code":"C155897","definitions":[{"definition":"A preparation of autologous human T-lymphocytes engineered to express dual chimeric antigen receptors (CARs) consisting of both anti-CD19 and anti-CD22 binding domains, fused to an as of yet undisclosed co-stimulatory domain, and linked to truncated forms of the human epidermal growth factor receptor 2 (HER2t) and the human epidermal growth factor receptor (EGFRt), respectively with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against tumor cells expressing CD19 and CD22. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt and HER2t facilitate both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through an antibody-dependent cellular cytotoxicity (ADCC) response. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells"},{"name":"NCI_Drug_Dictionary_ID","value":"794873"},{"name":"NCI_META_CUI","value":"CL562780"},{"name":"PDQ_Closed_Trial_Search_ID","value":"794873"},{"name":"PDQ_Open_Trial_Search_ID","value":"794873"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172063":{"preferredName":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1","code":"C172063","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), and CD4/CD8 enriched, with potential immunostimulating and antineoplastic activities. Upon administration, MB-CART20.1 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies and certain melanoma cell subpopulations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 CAR T Cells MB-CART20.1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD20-targeted CAR-transduced CD4/CD8 Enriched T Cells MB-CART20.1","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-targeting CAR T Cells MB-CART20.1","termGroup":"SY","termSource":"NCI"},{"termName":"MB-CART20.1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1"},{"name":"NCI_Drug_Dictionary_ID","value":"801497"},{"name":"NCI_META_CUI","value":"CL1406185"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801497"},{"name":"PDQ_Open_Trial_Search_ID","value":"801497"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173958":{"preferredName":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes","code":"C173958","definitions":[{"definition":"A preparation of autologous, C-X-C chemokine receptor type 5 (CXCR 5)-modified T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes target and bind to EGFR-expressing tumor cells, thereby inducing selective toxicity in EGFR-expressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. CXCR5, and its ligand C-X-C motif chemokine 13 (CXCL13), are associated with a variety of tumors. CXCR5-CXCL13 interactions may be involved in the regulation of lymphocyte infiltration within the tumor microenvironment (TME).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CXCR5-modified Anti-EGFR CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"802166"},{"name":"NCI_META_CUI","value":"CL1407866"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802166"},{"name":"PDQ_Open_Trial_Search_ID","value":"802166"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172197":{"preferredName":"Autologous Anti-FLT3 CAR T Cells AMG 553","code":"C172197","definitions":[{"definition":"A preparation of autologous T-lymphocytes genetically engineered with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-FLT3 CAR T cells AMG 553 target and bind to tumor cells expressing FLT3, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of FLT3-expressing tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-FLT3 CAR T Cells AMG 553","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 553","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-553","termGroup":"CN","termSource":"NCI"},{"termName":"AMG553","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous Anti-FLT3 CAR T-lymphocytes AMG 553","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous FLT3 CAR-T Cells AMG 553","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-FLT3 CAR T Cells AMG 553"},{"name":"NCI_Drug_Dictionary_ID","value":"801528"},{"name":"NCI_META_CUI","value":"CL1406093"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801528"},{"name":"PDQ_Open_Trial_Search_ID","value":"801528"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173378":{"preferredName":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100","code":"C173378","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) containing the Inserted (I) domain variant of lymphocyte function-associated antigen-1 (LFA-1) which targets intercellular adhesion molecule-1 (ICAM-1 or CD54), and the co-stimulatory signaling domains of CD28, 4-1BB (CD137) and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100 recognize and kill ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers. CAR T-cells AIC100 are also engineered to express somatostatin receptor subtype 2 (SSTR2), allowing the imaging of the CAR T-cells in patients.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100","termGroup":"PT","termSource":"NCI"},{"termName":"AIC 100","termGroup":"CN","termSource":"NCI"},{"termName":"AIC-100","termGroup":"CN","termSource":"NCI"},{"termName":"AIC100","termGroup":"CN","termSource":"NCI"},{"termName":"Autologous ICAM-1-targeted CAR T Cells AIC100","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ICAM-1-targeted CAR T-cells AIC100","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous ICAM-1-targeted CAR T-lymphocytes AIC100","termGroup":"SY","termSource":"NCI"},{"termName":"CAR T-cells AIC100","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100"},{"name":"NCI_Drug_Dictionary_ID","value":"801844"},{"name":"NCI_META_CUI","value":"CL1407200"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801844"},{"name":"PDQ_Open_Trial_Search_ID","value":"801844"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175446":{"preferredName":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes","code":"C175446","definitions":[{"definition":"A preparation of autologous T-lymphocytes (ATL) that have been genetically modified to express a chimeric antigen receptor (CAR) directed against the kappa light chain of immunoglobulin (Ig) and linked to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-kappa light chain CAR-CD28-expressing T-lymphocytes target and bind to the kappa light chain of Ig expressed on tumor cells, resulting in T-cell-mediated tumor cell lysis. In some B-cell malignancies, the expression of the Ig light chain kappa may be increased compared to the expression of Ig light chain lambda.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"ATLCAR.κ.28 Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CAR.k.28 Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"802840"},{"name":"NCI_META_CUI","value":"CL1412808"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802840"},{"name":"PDQ_Open_Trial_Search_ID","value":"802840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172191":{"preferredName":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes","code":"C172191","definitions":[{"definition":"A preparation of autologous tumor infiltrating lymphocytes (TILs) activated by an anti-programmed cell death protein 1 (PD1) antibody, with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and ex-vivo activated in the presence of anti-PD-1 antibody. Upon infusion of the autologous anti-PD1 antibody-activated TILs back into the patient, the cells specifically target and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-PD1 Antibody-activated Autologous TILs","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-PD-1 Antibody-activated TILs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"801527"},{"name":"NCI_META_CUI","value":"CL1406286"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801527"},{"name":"PDQ_Open_Trial_Search_ID","value":"801527"},{"name":"Semantic_Type","value":"Cell"}]}}{"C175511":{"preferredName":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101","code":"C175511","definitions":[{"definition":"A preparation of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac), encoding both a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA), and a human-derived safety switch that can be activated by rimiducid, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-PSMA CAR-T cells P-PSMA-101 specifically recognize and induce selective toxicity in PSMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than CAR T-cells based on antibody-derived single chain variable fragments (scFv), and may allow for increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can be activated by the administration of rimiducid, which results in the rapid attenuation or elimination of P-PSMA-101. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-PSMA CAR T Cells P-PSMA-101","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-PSMA CAR T-cells P-PSMA-101","termGroup":"SY","termSource":"NCI"},{"termName":"P-PSMA 101","termGroup":"CN","termSource":"NCI"},{"termName":"P-PSMA-101","termGroup":"CN","termSource":"NCI"},{"termName":"P-PSMA101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Anti-PSMA CAR-T Cells P-PSMA-101"},{"name":"NCI_Drug_Dictionary_ID","value":"803027"},{"name":"NCI_META_CUI","value":"CL1412868"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803027"},{"name":"PDQ_Open_Trial_Search_ID","value":"803027"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173699":{"preferredName":"Autologous BCMA-targeted CAR T Cells CC-98633","code":"C173699","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T cells CC-98633 specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous BCMA-targeted CAR T Cells CC-98633","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous BCMA-targeted CAR T-cells CC-98633","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous BCMA-targeted NEX-T CAR T Cells CC-98633","termGroup":"SY","termSource":"NCI"},{"termName":"CC 98633","termGroup":"CN","termSource":"NCI"},{"termName":"CC-98633","termGroup":"CN","termSource":"NCI"},{"termName":"CC98633","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous BCMA-targeted CAR T Cells CC-98633"},{"name":"NCI_Drug_Dictionary_ID","value":"802040"},{"name":"NCI_META_CUI","value":"CL1407516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802040"},{"name":"PDQ_Open_Trial_Search_ID","value":"802040"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175471":{"preferredName":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F","code":"C175471","definitions":[{"definition":"A preparation of autologous T-lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific BCMA/CD19-targeted CAR-T cells GC012F specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. The processing platform used, FasT CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-BCMA/CD19 Dual CAR T Cells GC012F","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous GC012F CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"GC 012F","termGroup":"CN","termSource":"NCI"},{"termName":"GC-012F","termGroup":"CN","termSource":"NCI"},{"termName":"GC012F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F"},{"name":"NCI_Drug_Dictionary_ID","value":"802916"},{"name":"NCI_META_CUI","value":"CL1412846"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802916"},{"name":"PDQ_Open_Trial_Search_ID","value":"802916"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171093":{"preferredName":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022","code":"C171093","definitions":[{"definition":"A preparation of autologous human T-lymphocytes engineered to express chimeric T-cell receptors (chimeric antigen receptors or CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific CD19/CD22-targeted CAR-T cells GC022 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific CAR T Cells GC022","termGroup":"SY","termSource":"NCI"},{"termName":"Dual CAR-T Cells GC022","termGroup":"SY","termSource":"NCI"},{"termName":"GC 022","termGroup":"CN","termSource":"NCI"},{"termName":"GC-022","termGroup":"CN","termSource":"NCI"},{"termName":"GC022","termGroup":"CN","termSource":"NCI"},{"termName":"GC022F","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022"},{"name":"NCI_Drug_Dictionary_ID","value":"800937"},{"name":"NCI_META_CUI","value":"CL1405322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800937"},{"name":"PDQ_Open_Trial_Search_ID","value":"800937"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172103":{"preferredName":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1","code":"C172103","definitions":[{"definition":"A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with the lentiviral vector pLTG1563 expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD19 CAR-transduced CD4/CD8 Enriched T-cells MB-CART19.1","termGroup":"SY","termSource":"NCI"},{"termName":"MB CART19.1","termGroup":"SY","termSource":"NCI"},{"termName":"MB-CART19.1","termGroup":"CN","termSource":"NCI"},{"termName":"MBCART19.1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1"},{"name":"NCI_Drug_Dictionary_ID","value":"801342"},{"name":"NCI_META_CUI","value":"CL1406220"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801342"},{"name":"PDQ_Open_Trial_Search_ID","value":"801342"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175049":{"preferredName":"Autologous CD19-targeted CAR T Cells CC-97540","code":"C175049","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD19-targeted CAR T cells CC-97540 specifically target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19-targeted CAR T Cells CC-97540","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CD19-targeted CAR T-cells CC-97540","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CD19-targeted NEX-T CAR T Cells CC-97540","termGroup":"SY","termSource":"NCI"},{"termName":"CC 97540","termGroup":"CN","termSource":"NCI"},{"termName":"CC-97540","termGroup":"CN","termSource":"NCI"},{"termName":"CC97540","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19-targeted CAR T Cells CC-97540"},{"name":"NCI_Drug_Dictionary_ID","value":"802907"},{"name":"NCI_META_CUI","value":"CL1412307"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802907"},{"name":"PDQ_Open_Trial_Search_ID","value":"802907"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171092":{"preferredName":"Autologous CD19-targeted CAR-T Cells GC007F","code":"C171092","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to as of yet not fully elucidated co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, autologous CD19-targeted CAR-T cells GC007F target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The processing platform used, FasT (F) CAR-T, shortens the manufacturing time to produce the CAR-T cells within 24 hours.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19-targeted CAR-T Cells GC007F","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19-CAR-T Cells GC007F","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous CAR-T Cells GC007F","termGroup":"SY","termSource":"NCI"},{"termName":"CD19 FasT CAR-T Cells GC007F","termGroup":"SY","termSource":"NCI"},{"termName":"FasT CAR-19","termGroup":"SY","termSource":"NCI"},{"termName":"FasTCAR-19","termGroup":"SY","termSource":"NCI"},{"termName":"GC 007F","termGroup":"CN","termSource":"NCI"},{"termName":"GC-007F","termGroup":"CN","termSource":"NCI"},{"termName":"GC007F","termGroup":"CN","termSource":"NCI"},{"termName":"GC007F CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19-targeted CAR-T Cells GC007F"},{"name":"NCI_Drug_Dictionary_ID","value":"800931"},{"name":"NCI_META_CUI","value":"CL1405323"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800931"},{"name":"PDQ_Open_Trial_Search_ID","value":"800931"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172387":{"preferredName":"Autologous CD19/PD-1 Bispecific CAR-T Cells","code":"C172387","definitions":[{"definition":"A preparation of autologous T-lymphocytes that are transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) and a programmed cell death protein 1 (PD1)/CD28 chimera, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD19/PD-1 bispecific CAR-T cells target and bind to CD19 and the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2), expressed on tumor cells. The binding to CD19 leads to a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and cell lysis of these cells. The binding of the PD1/CD28 chimera to PD-L1 prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This enhances T-lymphocyte proliferation and anti-tumor activity. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. PD-1 protein, found on activated T-cells, negatively regulates T-cell activity. It plays a key role in immune evasion and prevents tumor cell lysis. The construct of the PD1/CD28 chimera converts PD-L1 into a co-stimulation ligand of primary human CD8+ cytotoxic T-lymphocytes (CTLs). CD28 is a costimulatory molecule expressed by T-cells that enhances T-lymphocyte proliferation and activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CD19/PD-1 Bispecific CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-CD19/PD-1 Bispecific CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD19/PD-1 Bispecific CAR T-Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MC-19PD1 CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CD19/PD-1 Bispecific CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801669"},{"name":"NCI_META_CUI","value":"CL1406515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801669"},{"name":"PDQ_Open_Trial_Search_ID","value":"801669"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171097":{"preferredName":"Autologous Clonal Neoantigen T Cells ATL001","code":"C171097","definitions":[{"definition":"A preparation of personalized tumor-derived T-lymphocytes composed of tumor infiltrating lymphocytes (TILs) that are reactive to clonal cancer neoantigens, with potential immunostimulating and antineoplastic activities. The TILs are removed from the suppressive tumor microenvironment (TME) and re-activated. Upon reintroduction into the patient, the clonal neoantigen T (cNeT) cells recognize and bind to tumor cells expressing the targeted neoantigen, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Clonal Neoantigen T Cells ATL001","termGroup":"PT","termSource":"NCI"},{"termName":"ATL 001","termGroup":"CN","termSource":"NCI"},{"termName":"ATL-001","termGroup":"CN","termSource":"NCI"},{"termName":"ATL001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Clonal Neoantigen T Cells ATL001"},{"name":"NCI_Drug_Dictionary_ID","value":"800942"},{"name":"NCI_META_CUI","value":"CL1405344"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800942"},{"name":"PDQ_Open_Trial_Search_ID","value":"800942"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170914":{"preferredName":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19","code":"C170914","definitions":[{"definition":"A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, and electroporated with clustered regularly interspaced short palindromic repeats (CRISPR) guide RNA to disrupt expression of endogenous hematopoietic progenitor kinase 1 (HPK1), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the autologous CRISPR-edited anti-CD19 CAR T-cells XYF19 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Disrupting the expression of HPK1 may enhance immune response and autoimmunity. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. HPK1 is a Ste20-like serine/threonine kinase that suppresses immune responses and autoimmunity. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CRISPR-edited CD19-specific CAR-T Cells XYF19","termGroup":"SY","termSource":"NCI"},{"termName":"CAR-T Cells XYF19","termGroup":"SY","termSource":"NCI"},{"termName":"CRISPR (HPK1)-edited CD19-specific CAR-T Cells XYF19","termGroup":"SY","termSource":"NCI"},{"termName":"XYF 19","termGroup":"CN","termSource":"NCI"},{"termName":"XYF-19","termGroup":"CN","termSource":"NCI"},{"termName":"XYF19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19"},{"name":"NCI_Drug_Dictionary_ID","value":"800868"},{"name":"NCI_META_CUI","value":"CL1383074"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800868"},{"name":"PDQ_Open_Trial_Search_ID","value":"800868"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173442":{"preferredName":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC","code":"C173442","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous, monocyte-derived dendritic cells (mDCs) pulsed with tumor cell lysate containing tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration,the autologous tumor cell lysate-pulsed mDCs vaccine PV-001-DC may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the patient's tumor cell-specific TAAs, which may result in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Monocyte-derived Lysate Pulsed DCs PV-001-DC","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cells PV-001-DC","termGroup":"SY","termSource":"NCI"},{"termName":"PV-001-DC","termGroup":"CN","termSource":"NCI"},{"termName":"PV-001-Dendritic Cell","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC"},{"name":"NCI_Drug_Dictionary_ID","value":"801794"},{"name":"NCI_META_CUI","value":"CL1407425"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801794"},{"name":"PDQ_Open_Trial_Search_ID","value":"801794"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170908":{"preferredName":"Autologous Multi-lineage Potential Cells","code":"C170908","definitions":[{"definition":"A preparation of autologous multi-lineage potential cells (AMPC) which were induced to de-differentiate from somatic leukocytes from peripheral blood, with potential immunomodulating and antineoplastic activities. Upon introduction into the patient, the AMPC may help replace the abnormal cells in the body to create healthy bone marrow in the treatment of acute myeloid leukemia (AML).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Multi-lineage Potential Cells","termGroup":"PT","termSource":"NCI"},{"termName":"AMPC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Multi-lineage Potential Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"800860"},{"name":"NCI_META_CUI","value":"CL1383050"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800860"},{"name":"PDQ_Open_Trial_Search_ID","value":"800860"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172386":{"preferredName":"Autologous Nectin-4/FAP-targeted CAR-T Cells","code":"C172386","definitions":[{"definition":"A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) nectin-4 and cell surface protein fibroblast activation protein (FAP), and additionally an inducible expression cassette encoding transgenic interleukin (IL) 7 (IL-7) or 12 (IL-12), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the autologous nectin-4/FAP-targeted CAR-T cells target and bind to nectin-4-expressing tumor cells and FAP-expressing cancer associated fibroblasts (CAFs). This results in a cytotoxic T-lymphocyte (CTL) response against nectin-4-expressing tumor cells and FAP-expressing CAFs, leading to cell lysis of these cells. Upon the binding to nectin-4 and FAP and the activation of the CAR-T cells, cytokine IL-7 or IL-12 is also released. This further augments the immune responses against the tumor cells, which may include the attack of nectin-4-negative tumor cells by tumor necrosis factor alpha (TNFa). Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer. FAP, a cell surface glycoprotein, is overexpressed on CAFs but minimally expressed on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Nectin-4/FAP-targeted CAR-T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Anti-nectin-4/Anti-FAP CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Anti-nectin-4/FAP CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Nectin4/FAP-targeted CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Nectin-4/FAP-targeted CAR-T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801659"},{"name":"NCI_META_CUI","value":"CL1406512"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801659"},{"name":"PDQ_Open_Trial_Search_ID","value":"801659"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173710":{"preferredName":"Autologous NKG2D CAR T-cells CYAD-02","code":"C173710","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a retroviral vector to co-express a chimeric antigen receptor (CAR) encoding human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) with a short hairpin RNA (shRNA) targeting MHC class I chain-related protein A (MICA) and MICB, with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR T-cells CYAD-02 specifically recognize and bind to tumor cells expressing NKG2D ligands, resulting in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-02 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MICA, MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The shRNA downregulates the expression of MICA and MICB on the CAR-T cells, which increases in-vitro cell expansion. This may enhance their persistence and increase anti-tumor activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous NKG2D CAR T-cells CYAD-02","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous NKG2D CAR T-lymphocytes CYAD-02","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKG2D CAR-T Cells CYAD-02","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous NKG2D-based CAR T-cells CYAD-02","termGroup":"SY","termSource":"NCI"},{"termName":"CYAD 02","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD-02","termGroup":"CN","termSource":"NCI"},{"termName":"CYAD02","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous NKG2D CAR T-cells CYAD-02"},{"name":"NCI_Drug_Dictionary_ID","value":"802256"},{"name":"NCI_META_CUI","value":"CL1407525"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802256"},{"name":"PDQ_Open_Trial_Search_ID","value":"802256"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173968":{"preferredName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine","code":"C173968","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate and mRNA containing and encoding tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration by perinodal injection using ultrasound guidance, the autologous pancreatic adenocarcinoma lysate and mRNA-loaded DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the patient's tumor cell-specific TAAs, which may result in tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded DC Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded DCs","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"802181"},{"name":"NCI_META_CUI","value":"CL1407844"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802181"},{"name":"PDQ_Open_Trial_Search_ID","value":"802181"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167208":{"preferredName":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001","code":"C167208","definitions":[{"definition":"A preparation of autologous peripheral blood lymphocytes (PBLs) harvested from chronic lymphocytic leukemia (CLL) patients previously treated with the Brutons' tyrosine kinase (BTK) inhibitor ibrutinib with potential immunostimulating and antineoplastic activities. Upon intravenous administration, IOV-2001 generates an enhanced cytotoxic T-cell response against autologous leukemic B-cells in patients who have relapsed during treatment with ibrutinib. IOV-2001 is mostly comprised of T-cells of which the majority are of the effector memory phenotype which augments the specificity of the immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous PBLs from Ibrutinib-treated CLL Patients","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous PBLs IOV-2001","termGroup":"SY","termSource":"NCI"},{"termName":"IOV 2001","termGroup":"CN","termSource":"NCI"},{"termName":"IOV-2001","termGroup":"CN","termSource":"NCI"},{"termName":"IOV2001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"44FWZ2CW4W"},{"name":"Maps_To","value":"Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001"},{"name":"NCI_Drug_Dictionary_ID","value":"800421"},{"name":"NCI_META_CUI","value":"CL972433"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800421"},{"name":"PDQ_Open_Trial_Search_ID","value":"800421"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174405":{"preferredName":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201","code":"C174405","definitions":[{"definition":"A preparation of autologous rapamycin-resistant Th1/Tc1 cells, with potential immunomodulating activity. Upon administration, autologous rapamycin-resistant Th1/Tc1 cells RAPA-201 may recognize and kill tumor cells. Ex-vivo induction of rapamycin-resistance may increase the persistence of T-cells after adoptive transfer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201","termGroup":"PT","termSource":"NCI"},{"termName":"RAPA 201","termGroup":"CN","termSource":"NCI"},{"termName":"RAPA-201","termGroup":"CN","termSource":"NCI"},{"termName":"RAPA201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Z96NAN6CUA"},{"name":"Maps_To","value":"Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201"},{"name":"NCI_Drug_Dictionary_ID","value":"802318"},{"name":"NCI_META_CUI","value":"CL1411941"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802318"},{"name":"PDQ_Open_Trial_Search_ID","value":"802318"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175306":{"preferredName":"Autologous TCRm-expressing T-cells ET140203","code":"C175306","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) construct targeting as of yet undisclosed tumor associated antigen(s) (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration, the autologous TCRm-expressing T-cells ET140203 specifically recognize and selectively bind to the as of yet undisclosed TAA(s). This results in cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells expressing the TAA(s).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous TCRm-expressing T-cells ET140203","termGroup":"PT","termSource":"NCI"},{"termName":"ET 140203","termGroup":"CN","termSource":"NCI"},{"termName":"ET-140203","termGroup":"CN","termSource":"NCI"},{"termName":"ET140203","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous TCRm-expressing T-cells ET140203"},{"name":"NCI_Drug_Dictionary_ID","value":"803275"},{"name":"NCI_META_CUI","value":"CL1412643"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803275"},{"name":"PDQ_Open_Trial_Search_ID","value":"803275"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168775":{"preferredName":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG","code":"C168775","definitions":[{"definition":"A therapeutic cancer vaccine composed of autologous, dendritic cells (DCs) that have been loaded with a proprietary selection of four antigens that covers more than ninety percent of all non-small cell lung cancer (NSCLC) patients, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous tetravalent dendritic cell vaccine MIDRIX4-LUNG may induce and stimulate both T-helper and antigen-specific cytotoxic T-lymphocyte (CTL) responses, leading to tumor cell lysis in patients with NSCLC.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous DC Vaccine MIDRIX4-LUNG","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tetravalent DC Vaccine MIDRIX4-LUNG","termGroup":"SY","termSource":"NCI"},{"termName":"MIDRIX4-LUNG","termGroup":"CN","termSource":"NCI"},{"termName":"Tetravalent Autologous Dendritic Cell Vaccine MIDRIX4-LUNG","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG"},{"name":"NCI_Drug_Dictionary_ID","value":"800431"},{"name":"NCI_META_CUI","value":"CL1378684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800431"},{"name":"PDQ_Open_Trial_Search_ID","value":"800431"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173508":{"preferredName":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1","code":"C173508","definitions":[{"definition":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating and antineoplastic activities. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145-S1 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous TILs LN-145-S1","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous Tumor-infiltrating Lymphocytes LN-145-S1","termGroup":"SY","termSource":"NCI"},{"termName":"LN 145-S1","termGroup":"CN","termSource":"NCI"},{"termName":"LN-145-S1","termGroup":"CN","termSource":"NCI"},{"termName":"LN145-S1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1"},{"name":"NCI_Drug_Dictionary_ID","value":"802231"},{"name":"NCI_META_CUI","value":"CL1407476"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802231"},{"name":"PDQ_Open_Trial_Search_ID","value":"802231"},{"name":"Semantic_Type","value":"Cell"}]}}{"C175463":{"preferredName":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T","code":"C175463","definitions":[{"definition":"A preparation of autologous T-lymphocytes that has been genetically engineered to express a fully humanized, universal, second generation chimeric antigen receptor (CAR) with a CD28/CD3zeta co-stimulatory domain, and a binding domain that can recognize a peptide motive of an antigen-specific targeting module (TM), with potential immunomodulating and antineoplastic activities. Upon administration, autologous universal CAR-expressing T-lymphocytes UniCAR02-T remain inactivated. Upon administration of an antigen-specific TM, the binding domain of UniCAR02-T binds to the nuclear antigen motif of the TM, and UniCAR02-T is activated when the antigen-binding moiety of the TM binds to the specific antigen expressed on tumor cells. This induces selective toxicity in and causes lysis of tumor cells expressing the specific antigen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous Universal CAR-T Cells UniCAR02-T","termGroup":"SY","termSource":"NCI"},{"termName":"UniCAR-T","termGroup":"SY","termSource":"NCI"},{"termName":"UniCAR02 T","termGroup":"CN","termSource":"NCI"},{"termName":"UniCAR02-T","termGroup":"CN","termSource":"NCI"},{"termName":"UniCAR02-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"UniCAR02T","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T"},{"name":"NCI_Drug_Dictionary_ID","value":"802895"},{"name":"NCI_META_CUI","value":"CL1412854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802895"},{"name":"PDQ_Open_Trial_Search_ID","value":"802895"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173362":{"preferredName":"AXL Inhibitor SLC-391","code":"C173362","definitions":[{"definition":"An orally bioavailable and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential immunostimulating and antineoplastic activities. Upon oral administration, SLC-391 targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways, and inhibits both AXL-mediated tumor cell growth, proliferation and migration and AXL-mediated immunosuppression. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types and also expressed in a variety of immune cells including macrophages, natural killer (NK) cells, and regulatory T-cells (Tregs). It plays a key role in tumor cell proliferation, survival, invasion and metastasis, and is a mediator of immunosuppression. Its expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL Inhibitor SLC-391","termGroup":"PT","termSource":"NCI"},{"termName":"SLC 391","termGroup":"CN","termSource":"NCI"},{"termName":"SLC-391","termGroup":"CN","termSource":"NCI"},{"termName":"SLC391","termGroup":"CN","termSource":"NCI"},{"termName":"XZB 0004","termGroup":"CN","termSource":"NCI"},{"termName":"XZB-0004","termGroup":"CN","termSource":"NCI"},{"termName":"XZB0004","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL Inhibitor SLC-391"},{"name":"NCI_Drug_Dictionary_ID","value":"801796"},{"name":"NCI_META_CUI","value":"CL1407197"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801796"},{"name":"PDQ_Open_Trial_Search_ID","value":"801796"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173961":{"preferredName":"AXL/FLT3/VEGFR2 Inhibitor KC1036","code":"C173961","definitions":[{"definition":"An orally bioavailable inhibitor of three receptor tyrosine kinases: AXL (UFO), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2), and the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon oral administration, KC1036 targets, binds to and prevents the activation of AXL, FLT3 and VEGFR2. This blocks AXL, FLT3 and VEGFR2-mediated signal transduction pathways, and inhibits both AXL-, FLT3- and VEGFR2-mediated proliferation of tumor cells and the VEGFR2-mediated proliferation, survival and migration of endothelial cells. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types and also expressed in a variety of immune cells including macrophages, natural killer (NK) cells, and regulatory T-cells (Tregs). It plays a key role in tumor cell proliferation, survival, invasion and metastasis, and is a mediator of immunosuppression. Its expression is associated with drug resistance and poor prognosis. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias. VEGFR2 is frequently overexpressed by a variety of tumor types and tumor-associated endothelial cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AXL/FLT3/VEGFR2 Inhibitor KC1036","termGroup":"PT","termSource":"NCI"},{"termName":"KC 1036","termGroup":"CN","termSource":"NCI"},{"termName":"KC-1036","termGroup":"CN","termSource":"NCI"},{"termName":"KC1036","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"AXL/FLT3/VEGFR2 Inhibitor KC1036"},{"name":"NCI_Drug_Dictionary_ID","value":"802085"},{"name":"NCI_META_CUI","value":"CL1407847"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802085"},{"name":"PDQ_Open_Trial_Search_ID","value":"802085"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175543":{"preferredName":"Axl/Mer Inhibitor PF-07265807","code":"C175543","definitions":[{"definition":"An inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, Axl/Mer inhibitor PF-07265807 specifically targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Axl/Mer Inhibitor PF-07265807","termGroup":"PT","termSource":"NCI"},{"termName":"PF 07265807","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07265807","termGroup":"CN","termSource":"NCI"},{"termName":"PF07265807","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Axl/Mer Inhibitor INCB081776"},{"name":"Maps_To","value":"Axl/Mer Inhibitor PF-07265807"},{"name":"NCI_Drug_Dictionary_ID","value":"803296"},{"name":"NCI_META_CUI","value":"CL1412891"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803296"},{"name":"PDQ_Open_Trial_Search_ID","value":"803296"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175489":{"preferredName":"Sonrotoclax","code":"C175489","definitions":[{"definition":"An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, sonrotoclax specifically binds to and inhibits the activity of the pro-survival protein Bcl-2. This restores apoptotic processes and inhibits cell proliferation in Bcl-2-overexpressing tumor cells. Bcl-2, a protein that belongs to the Bcl-2 family, is overexpressed in various tumor cell types and plays an important role in the negative regulation of apoptosis. Its tumor expression is associated with increased drug resistance and cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonrotoclax","termGroup":"PT","termSource":"NCI"},{"termName":"B-cell Lymphoma-2 Inhibitor BGB-11417","termGroup":"SY","termSource":"NCI"},{"termName":"Bcl-2 Inhibitor BGB-11417","termGroup":"SY","termSource":"NCI"},{"termName":"BGB 11417","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-11417","termGroup":"CN","termSource":"NCI"},{"termName":"BGB11417","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2383086-06-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"30R67U9KYS"},{"name":"Maps_To","value":"Bcl-2 Inhibitor BGB-11417"},{"name":"NCI_Drug_Dictionary_ID","value":"803186"},{"name":"NCI_META_CUI","value":"CL1412833"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803186"},{"name":"PDQ_Open_Trial_Search_ID","value":"803186"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C203075":{"preferredName":"Lacutoclax","code":"C203075","definitions":[{"definition":"An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lacutoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lacutoclax","termGroup":"PT","termSource":"NCI"},{"termName":"Bcl-2 Inhibitor LP-108","termGroup":"SY","termSource":"NCI"},{"termName":"LP 108","termGroup":"CN","termSource":"NCI"},{"termName":"LP-108","termGroup":"CN","termSource":"NCI"},{"termName":"LP108","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2291166-56-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"PMG5245L91"},{"name":"Maps_To","value":"Bcl-2 Inhibitor LP-108"},{"name":"NCI_Drug_Dictionary_ID","value":"801885"},{"name":"NCI_META_CUI","value":"CL1922240"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174412":{"preferredName":"BCMA-CD19 Compound CAR T Cells","code":"C174412","definitions":[{"definition":"A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the BCMA-CD19 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BCMA-CD19 Compound CAR T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"BCMA-CD19 cCAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA-CD19 cCAR T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BCMA/CD3e Tri-specific T-cell Activating Construct HPN217"},{"name":"NCI_META_CUI","value":"CL1411933"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171631":{"preferredName":"Podentamig","code":"C171631","definitions":[{"definition":"A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; TNFRSF17), the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes, and albumin, with potential immunostimulating and antineoplastic activities. Upon administration, podentamig targets and binds to BCMA on tumor cells and CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing BCMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of podentamig. BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF), is overexpressed on malignant plasma cells and plays a key role in plasma cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Podentamig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-BCMA/CD3e TriTAC HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3 Tri-specific T-cell Activating Construct HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3e Tri-specific T-cell Activating Construct HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3e TriTAC HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"BCMA/CD3e-specific TriTAC HPN217","termGroup":"SY","termSource":"NCI"},{"termName":"HPN 217","termGroup":"CN","termSource":"NCI"},{"termName":"HPN-217","termGroup":"CN","termSource":"NCI"},{"termName":"HPN217","termGroup":"CN","termSource":"NCI"},{"termName":"TriTAC HPN217","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2851863-52-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ZT35532VPU"},{"name":"Maps_To","value":"BCMA-CD19 Compound CAR T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802002"},{"name":"NCI_META_CUI","value":"CL1405854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802002"},{"name":"PDQ_Open_Trial_Search_ID","value":"802002"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172188":{"preferredName":"Betaglucin Gel","code":"C172188","definitions":[{"definition":"A soluble gel containing the beta-glucan betaglucin, with potential immunostimulating activity. Upon topical administration of the betaglucin gel, betaglucin is able to increase the number of macrophages and natural killer (NK) cells. NK cells and macrophages may kill a variety of tumor cells, and virally infected cells. This may treat human papillomavirus (HPV)-related anogenital warts.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Betaglucin Gel","termGroup":"PT","termSource":"NCI"},{"termName":"Betaglucin Soluble Gel","termGroup":"SY","termSource":"NCI"},{"termName":"Epiglucan Gel","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Essential_Amino_Acid","value":"NCT03901690"},{"name":"Maps_To","value":"Betaglucin Gel"},{"name":"NCI_Drug_Dictionary_ID","value":"801525"},{"name":"NCI_META_CUI","value":"CL1406289"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801525"},{"name":"PDQ_Open_Trial_Search_ID","value":"801525"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171161":{"preferredName":"Bispecific Antibody AGEN1223","code":"C171161","definitions":[{"definition":"A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens co-expressed specifically on tumor-infiltrating regulatory T-cells (Tregs), with potential immunomodulating and antineoplastic activities. Upon administration, AGEN1223 targets and binds to the two antigens co-expressed specifically on tumor-infiltrating Tregs. This leads to the selective depletion of immunosuppressive Tregs in the tumor microenvironment (TME), while sparing peripheral Tregs and effector T-cells, enhancing the overall antitumor response. AGEN1223 may also co-stimulate antigen-specific effector T-cells, resulting in tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bispecific Antibody AGEN1223","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 1223","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-1223","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1223","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bispecific Antibody AGEN1223"},{"name":"NCI_Drug_Dictionary_ID","value":"801965"},{"name":"NCI_META_CUI","value":"CL1405398"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801965"},{"name":"PDQ_Open_Trial_Search_ID","value":"801965"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168580":{"preferredName":"Xaluritamig","code":"C168580","definitions":[{"definition":"A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, xaluritamig targets and binds to the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Xaluritamig","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 509","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-509","termGroup":"CN","termSource":"NCI"},{"termName":"AMG509","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Antibody AMG 509","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"ODG03B9M4U"},{"name":"Maps_To","value":"Bispecific Antibody AMG 509"},{"name":"NCI_Drug_Dictionary_ID","value":"800690"},{"name":"NCI_META_CUI","value":"CL972905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800690"},{"name":"PDQ_Open_Trial_Search_ID","value":"800690"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167206":{"preferredName":"Dalutrafusp Alfa","code":"C167206","definitions":[{"definition":"A bispecific antibody that simultaneously binds two different as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, dalutrafusp alfa targets and binds the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dalutrafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"AGEN 1423","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN-1423","termGroup":"CN","termSource":"NCI"},{"termName":"AGEN1423","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Antibody GS-1423","termGroup":"SY","termSource":"NCI"},{"termName":"GS 1423","termGroup":"CN","termSource":"NCI"},{"termName":"GS-1423","termGroup":"CN","termSource":"NCI"},{"termName":"GS1423","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2419918-89-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KNL22F1WCK"},{"name":"Maps_To","value":"Bispecific Antibody GS-1423"},{"name":"NCI_Drug_Dictionary_ID","value":"800422"},{"name":"NCI_META_CUI","value":"CL972431"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800422"},{"name":"PDQ_Open_Trial_Search_ID","value":"800422"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C184829":{"preferredName":"Gresonitamab","code":"C184829","definitions":[{"definition":"A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, gresonitamab simultaneously binds to both CD3-expressing T-cells and CLDN18.2-expressing cancer cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gresonitamab","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 910","termGroup":"CN","termSource":"NCI"},{"termName":"AMG-910","termGroup":"CN","termSource":"NCI"},{"termName":"AMG910","termGroup":"CN","termSource":"NCI"},{"termName":"Bispecific Antibody AMG 910","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager AMG 910","termGroup":"SY","termSource":"NCI"},{"termName":"Bispecific T-cell Engager Antibody AMG 910","termGroup":"SY","termSource":"NCI"},{"termName":"BiTE Antibody AMG 910","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2413817-97-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"0SIB91V6TP"},{"name":"Maps_To","value":"BiTE Antibody AMG 910"},{"name":"NCI_Drug_Dictionary_ID","value":"801178"},{"name":"NCI_META_CUI","value":"CL1382994"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173633":{"preferredName":"Brimarafenib","code":"C173633","definitions":[{"definition":"An orally available inhibitor of both monomer and dimer forms of activating mutations of the serine/threonine-protein kinase BRAF (B-raf) protein, including V600 BRAF mutations, non-V600 BRAF mutations, and RAF fusions, with potential antineoplastic activity. Upon administration, brimarafenib targets and binds to both monomeric and dimeric forms of activating BRAF mutations and fusions. This may result in the inhibition of BRAF-mediated signaling and inhibit proliferation in tumor cells expressing BRAF mutations and fusions. BRAF belongs to the RAF family of serine/threonine protein kinases and plays a role in regulating the mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. BRAF mutations and fusions have been identified in a number of solid tumors and are drivers of cancer growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Brimarafenib","termGroup":"PT","termSource":"NCI"},{"termName":"BGB 3245","termGroup":"CN","termSource":"NCI"},{"termName":"BGB-3245","termGroup":"CN","termSource":"NCI"},{"termName":"BGB3245","termGroup":"CN","termSource":"NCI"},{"termName":"BRAF Inhibitor BGB-3245","termGroup":"SY","termSource":"NCI"},{"termName":"BRAF Monomer/Dimer Inhibitor BGB-3245","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF Inhibitor BGB-3245"},{"name":"NCI_Drug_Dictionary_ID","value":"802245"},{"name":"NCI_META_CUI","value":"CL1407365"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802245"},{"name":"PDQ_Open_Trial_Search_ID","value":"802245"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170951":{"preferredName":"BRAF(V600E) Kinase Inhibitor ABM-1310","code":"C170951","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of mutant (V600E) v-raf murine sarcoma viral oncogene homolog B1 (BRAF) with potential antineoplastic activity. Upon oral administration, BRAF(V600E) kinase inhibitor ABM-1310 selectively binds to and inhibits the activity of BRAF(V600E) kinase, which may result in the inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. BRAF belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway. The valine to glutamic acid substitution at residue 600 accounts for about 90% of BRAF gene mutations. The oncogenic product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) mutation has been found to occur in about 8% of all tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BRAF(V600E) Kinase Inhibitor ABM-1310","termGroup":"PT","termSource":"NCI"},{"termName":"ABM 1310","termGroup":"CN","termSource":"NCI"},{"termName":"ABM-1310","termGroup":"CN","termSource":"NCI"},{"termName":"ABM1310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BRAF(V600E) Kinase Inhibitor ABM-1310"},{"name":"NCI_Drug_Dictionary_ID","value":"801208"},{"name":"NCI_META_CUI","value":"CL1383226"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801208"},{"name":"PDQ_Open_Trial_Search_ID","value":"801208"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174394":{"preferredName":"BTK Inhibitor HZ-A-018","code":"C174394","definitions":[{"definition":"An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, BTK inhibitor HZ-A-018 targets, binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BTK Inhibitor HZ-A-018","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor HZ-A-018","termGroup":"SY","termSource":"NCI"},{"termName":"HZ-A 018","termGroup":"CN","termSource":"NCI"},{"termName":"HZ-A-018","termGroup":"CN","termSource":"NCI"},{"termName":"HZ-A018","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BTK Inhibitor HZ-A-018"},{"name":"NCI_Drug_Dictionary_ID","value":"802311"},{"name":"NCI_META_CUI","value":"CL1411950"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802311"},{"name":"PDQ_Open_Trial_Search_ID","value":"802311"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170765":{"preferredName":"c-Met Inhibitor ABN401","code":"C170765","definitions":[{"definition":"An orally bioavailable, highly selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, ABN401 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor ABN401","termGroup":"PT","termSource":"NCI"},{"termName":"ABN 401","termGroup":"CN","termSource":"NCI"},{"termName":"ABN-401","termGroup":"CN","termSource":"NCI"},{"termName":"ABN401","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor ABN401"},{"name":"NCI_Drug_Dictionary_ID","value":"800797"},{"name":"NCI_META_CUI","value":"CL1383179"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800797"},{"name":"PDQ_Open_Trial_Search_ID","value":"800797"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175449":{"preferredName":"c-Met Inhibitor GST-HG161","code":"C175449","definitions":[{"definition":"An orally bioavailable, selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, c-Met inhibitor GST-HG161 targets and binds to c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"c-Met Inhibitor GST-HG161","termGroup":"PT","termSource":"NCI"},{"termName":"GST HG161","termGroup":"CN","termSource":"NCI"},{"termName":"GST-HG161","termGroup":"CN","termSource":"NCI"},{"termName":"GSTHG161","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"c-Met Inhibitor GST-HG161"},{"name":"NCI_Drug_Dictionary_ID","value":"802843"},{"name":"NCI_META_CUI","value":"CL1412809"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802843"},{"name":"PDQ_Open_Trial_Search_ID","value":"802843"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174169":{"preferredName":"Lucicebtide","code":"C174169","definitions":[{"definition":"A peptide antagonist of the transcription factor CCAAT/enhancer-binding protein beta (C/EBP beta), with potential antineoplastic activity. Upon administration, lucicebtide targets and inhibits the activity of C/EBP beta. This prevents the expression of C/EBP beta target genes and proteins, including the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), cyclins and inhibitor of differentiation (ID) family of proteins, which are involved in cell proliferation, differentiation, and cell cycle regulation. This may lead to apoptosis in tumor cells. C/EBP beta is overexpressed in many cancers and plays an important role in the regulation of cell differentiation; its expression is associated with tumor cell survival and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lucicebtide","termGroup":"PT","termSource":"NCI"},{"termName":"C/EBP Beta Antagonist ST101","termGroup":"SY","termSource":"NCI"},{"termName":"CCAAT/Enhancer-binding Protein Beta Inhibitor ST101","termGroup":"SY","termSource":"NCI"},{"termName":"ST 101","termGroup":"CN","termSource":"NCI"},{"termName":"ST-101","termGroup":"CN","termSource":"NCI"},{"termName":"ST101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2407100-74-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CT77XS2YLT"},{"name":"Maps_To","value":"C/EBP Beta Antagonist ST101"},{"name":"NCI_Drug_Dictionary_ID","value":"802478"},{"name":"NCI_META_CUI","value":"CL1407795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802478"},{"name":"PDQ_Open_Trial_Search_ID","value":"802478"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166417":{"preferredName":"Zegocractin","code":"C166417","definitions":[{"definition":"A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential anti-inflammatory and protective activities. Upon administration, zegocractin targets, binds to and inhibits the calcium release-activated calcium channel protein 1 (Orai1), which forms the pore of CRAC, and is expressed on both parenchymal cells and immune cells. This prevents the transport of extracellular Ca2+ into the cell and inhibits the subsequent activation of Ca2+-mediated signaling and transcription of target genes. This may prevent Ca2+ entry-mediated cell death. It may also inhibit the proliferation of immune cells and prevents the release of various inflammatory cytokines in immune cells, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a). This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), mediate store operated Ca2+ entry (SOCE) and play a key role in calcium homeostasis. CRACs are overactivated in a variety of cell types, especially certain immune cells during inflammation, including T-lymphocytes, neutrophils and macrophages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zegocractin","termGroup":"PT","termSource":"NCI"},{"termName":"Calcium Release-activated Channel Inhibitor CM4620","termGroup":"SY","termSource":"NCI"},{"termName":"CM 4620","termGroup":"CN","termSource":"NCI"},{"termName":"CM-4620","termGroup":"CN","termSource":"NCI"},{"termName":"CM4620","termGroup":"CN","termSource":"NCI"},{"termName":"CRAC Inhibitor CM4620","termGroup":"SY","termSource":"NCI"},{"termName":"Orai Ca2+ Channel Inhibitor CM4620","termGroup":"SY","termSource":"NCI"},{"termName":"Orai1 Inhibitor CM4620","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1713240-67-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"564AW1RR37"},{"name":"Maps_To","value":"Calcium Release-activated Channel Inhibitor CM4620"},{"name":"NCI_Drug_Dictionary_ID","value":"800239"},{"name":"NCI_META_CUI","value":"CL971668"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800239"},{"name":"PDQ_Open_Trial_Search_ID","value":"800239"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173441":{"preferredName":"Carbon C 14-pamiparib","code":"C173441","definitions":[{"definition":"An orally bioavailable radioconjugate composed of pamiparib, a nuclear enzyme poly(ADP-ribose) polymerase (PARP) inhibitor, radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of pamiparib. Pamiparib targets, binds to and inhibits PARP, which results in the inhibition of tumor cell proliferation and survival. Labeling of pamiparib with the radioactive tracer carbon C 14 allows for the evaluation of pamiparib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Carbon C 14-pamiparib","termGroup":"PT","termSource":"NCI"},{"termName":"14C-pamiparib","termGroup":"SY","termSource":"NCI"},{"termName":"[14C]-pamiparib","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Carbon C 14-pamiparib"},{"name":"NCI_Drug_Dictionary_ID","value":"801792"},{"name":"NCI_META_CUI","value":"CL1407424"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801792"},{"name":"PDQ_Open_Trial_Search_ID","value":"801792"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171374":{"preferredName":"Cationic Peptide Cream Cypep-1","code":"C171374","definitions":[{"definition":"A topical cream containing Cypep-1, a cationic lytic peptide of 27 amino acids, with potential antineoplastic activity. Upon topical administration, Cypep-1 selectively targets tumor cells with negatively charged cell membranes and ruptures the cell membranes. This leads to tumor cell lysis and the release of neoantigens into the tumor microenvironment (TME) and circulation. This elicits a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens. Warts are benign skin tumors caused by human papilloma virus (HPV).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cationic Peptide Cream Cypep-1","termGroup":"PT","termSource":"NCI"},{"termName":"Cypep-1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cationic Peptide Cream Cypep-1"},{"name":"NCI_Drug_Dictionary_ID","value":"801302"},{"name":"NCI_META_CUI","value":"CL1405490"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801302"},{"name":"PDQ_Open_Trial_Search_ID","value":"801302"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165605":{"preferredName":"CD11b Agonist GB1275","code":"C165605","definitions":[{"definition":"An orally bioavailable small molecule agonist of CD11b (integrin alpha-M; ITGAM; integrin alpha M chain), with potential immunomodulating activity. Upon administration, CD11b agonist GB1275 targets and binds to CD11b, thereby activating CD11b. This leads to CD11b-mediated signaling and promotes pro-inflammatory macrophage polarization while suppressing immunosuppressive macrophage polarization. This reduces influx of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), promotes anti-tumor immune responses, induces cytotoxic T-lymphocytes (CTLs) and suppresses tumor growth. CD11b, a member of the integrin family of cell adhesion receptors highly expressed on immune system cells, is a negative regulator of immune suppression and activates anti-tumor innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD11b Agonist GB1275","termGroup":"PT","termSource":"NCI"},{"termName":"GB 1275","termGroup":"CN","termSource":"NCI"},{"termName":"GB-1275","termGroup":"CN","termSource":"NCI"},{"termName":"GB1275","termGroup":"CN","termSource":"NCI"},{"termName":"Integrin Alpha-M Agonist GB1275","termGroup":"SY","termSource":"NCI"},{"termName":"Integrin CD11b Agonist GB1275","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD11b Agonist GB1275"},{"name":"NCI_Drug_Dictionary_ID","value":"799988"},{"name":"NCI_META_CUI","value":"CL978817"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799988"},{"name":"PDQ_Open_Trial_Search_ID","value":"799988"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173970":{"preferredName":"CD123-CD33 Compound CAR T Cells","code":"C173970","definitions":[{"definition":"A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the CD123 (interleukin-3 receptor alpha chain or IL3RA) antigen and one specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, the CD123-CD33 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing CD123 and/or CD33. This induces selective toxicity in tumor cells that express the CD123 antigen and/or the CD33 antigen. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens. Additionally, the CD123-CD33 cCAR T cells express CD52 on the cell surface. This allows the depletion of the CD123-CD33 cCAR T cells with the administration of the anti-CD52 monoclonal antibody alemtuzumab, in case of unacceptable side effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD123-CD33 Compound CAR T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"123b-33bcCAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-CD33 cCAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-CD33 cCAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD123/CD33-expressing Compound CAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD123-CD33 Compound CAR T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802178"},{"name":"NCI_META_CUI","value":"CL1407854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802178"},{"name":"PDQ_Open_Trial_Search_ID","value":"802178"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175461":{"preferredName":"CD123-specific Targeting Module TM123","code":"C175461","definitions":[{"definition":"A preparation of soluble adapter molecules consisting of an antigen-binding moiety targeting CD123 linked to a peptide motif recognizable by UniCAR02-T, that may be used to activate UniCAR02-T.  Upon administration of CD123-specific targeting module (TM) TM123, and upon co-administration of UniCAR02-T, the antigen-binding moiety of TM123 targets and binds to cancer cells expressing CD123, and the binding domain of UniCAR02-T binds to the nuclear antigen motif of TM123. This activates UniCAR02-T, and induces selective toxicity in and causes lysis of CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD123-specific Targeting Module TM123","termGroup":"PT","termSource":"NCI"},{"termName":"CD123 Target Module TM123","termGroup":"SY","termSource":"NCI"},{"termName":"CD123-specific TM TM123","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant Antibody Derivative TM123","termGroup":"SY","termSource":"NCI"},{"termName":"TM 123","termGroup":"CN","termSource":"NCI"},{"termName":"TM-123","termGroup":"CN","termSource":"NCI"},{"termName":"TM123","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD123-specific Targeting Module TM123"},{"name":"NCI_Drug_Dictionary_ID","value":"802894"},{"name":"NCI_META_CUI","value":"CL1412859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802894"},{"name":"PDQ_Open_Trial_Search_ID","value":"802894"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173960":{"preferredName":"CD20-CD19 Compound CAR T Cells","code":"C173960","definitions":[{"definition":"A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the CD20-CD19 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing CD20 and/or CD19. This induces selective toxicity in tumor cells that express CD20 and/or CD19. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD20-CD19 Compound CAR T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"CD19/CD20-expressing Compound CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-CD19 cCAR T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD20-CD19 cCAR-T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD20-CD19 Compound CAR T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802177"},{"name":"NCI_META_CUI","value":"CL1407867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802177"},{"name":"PDQ_Open_Trial_Search_ID","value":"802177"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C179069":{"preferredName":"Acazicolcept","code":"C179069","definitions":[{"definition":"An Fc fusion protein comprised of a human inducible T-cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD) that binds to both inducible T-cell costimulator (ICOS; CD278) and cluster of differentiation 28 (CD28), with potential immunomodulating activity. Upon administration, acazicolcept targets and binds to both CD28 and ICOS expressed on certain T-cells. This prevents the activation of CD28 and ICOS by its ligands, thereby blocking the two T-cell costimulatory pathways and the resulting T-cell activation. CD28 is involved in initiation of the pathogenic process in graft versus host disease (GVHD). Following initial activation, CD28 is often downregulated while ICOS is upregulated, possibly sustaining GVHD. Dual blockade of CD28 and ICOS may be superior to individual blockade of CD28 or ICOS alone.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acazicolcept","termGroup":"PT","termSource":"NCI"},{"termName":"ALPN 101","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN-101","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN101","termGroup":"CN","termSource":"NCI"},{"termName":"CD28/ICOS Antagonist ALPN-101","termGroup":"SY","termSource":"NCI"},{"termName":"ICOSL vIgD-Fc","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2270247-50-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"W507556HV0"},{"name":"Maps_To","value":"CD28/ICOS Antagonist ALPN-101"},{"name":"NCI_Drug_Dictionary_ID","value":"800691"},{"name":"NCI_META_CUI","value":"CL972908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173368":{"preferredName":"CD44v6-specific CAR T-cells","code":"C173368","definitions":[{"definition":"A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector encoding a fourth-generation specific chimeric antigen receptor (4SCAR) specific for CD44 variant domain 6 (CD44v6), with potential immunomodulating and antineoplastic activities. Upon administration, CD44v6-specific CAR T-cells specifically recognize and kill CD44v6-expressing tumor cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types. CD44v6, the isoform containing the variant domain 6 of CD44 gene, plays a key role in tumor cell invasion, proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD44v6-specific CAR T-cells","termGroup":"PT","termSource":"NCI"},{"termName":"4SCAR-CD44v6 T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"4SCAR-CD44v6 T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD44v6 CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD44v6 CAR-T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"CD44v6-specific CAR Gene-engineered T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CD44v6-specific CAR T-cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801822"},{"name":"NCI_META_CUI","value":"CL1407192"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801822"},{"name":"PDQ_Open_Trial_Search_ID","value":"801822"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167156":{"preferredName":"Quemliclustat","code":"C167156","definitions":[{"definition":"A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon administration, quemliclustat targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Quemliclustat","termGroup":"PT","termSource":"NCI"},{"termName":"AB 680","termGroup":"CN","termSource":"NCI"},{"termName":"AB-680","termGroup":"CN","termSource":"NCI"},{"termName":"AB680","termGroup":"CN","termSource":"NCI"},{"termName":"CD73 Inhibitor AB680","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2105904-82-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J6K8WSV73A"},{"name":"Maps_To","value":"CD73 Inhibitor AB680"},{"name":"NCI_Drug_Dictionary_ID","value":"800218"},{"name":"NCI_META_CUI","value":"CL972383"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800218"},{"name":"PDQ_Open_Trial_Search_ID","value":"800218"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170952":{"preferredName":"CD73 Inhibitor LY3475070","code":"C170952","definitions":[{"definition":"An orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon oral administration, CD73 inhibitor LY3475070 targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against tumor cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine. It is upregulated in a number of cancer cell types and plays a key role in adenosine-mediated immunosuppression within the TME.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD73 Inhibitor LY3475070","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3475070","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3475070","termGroup":"CN","termSource":"NCI"},{"termName":"LY3475070","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AKA9175T4N"},{"name":"Maps_To","value":"CD73 Inhibitor LY3475070"},{"name":"NCI_Drug_Dictionary_ID","value":"801213"},{"name":"NCI_META_CUI","value":"CL1383223"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801213"},{"name":"PDQ_Open_Trial_Search_ID","value":"801213"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174515":{"preferredName":"Davoceticept","code":"C174515","definitions":[{"definition":"A fusion protein composed of the N-terminal Ig variable-like (IgV) domain of CD80 fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration, davoceticept targets and binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) expressed on tumor cells, which blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279), and leads to PD-L1-dependent CD28 binding and co-stimulation in the local tumor microenvironment (TME). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling, leads to the co-stimulation of T-cell responses including the activation of naïve and memory T-cells in the TME and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, davoceticept targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4) expressed on T-cells. This prevents the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation. This further promotes T-cell activity. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells (APCs) that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Davoceticept","termGroup":"PT","termSource":"NCI"},{"termName":"ALPN 202","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN-202","termGroup":"CN","termSource":"NCI"},{"termName":"ALPN202","termGroup":"CN","termSource":"NCI"},{"termName":"CD80 vIgD-Fc Fusion Protein ALPN-202","termGroup":"SY","termSource":"NCI"},{"termName":"CD80-Fc Fusion Protein ALPN-202","termGroup":"SY","termSource":"NCI"},{"termName":"CD80-vlgD-Fc ALPN-202","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2307144-64-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DE9GN7CD21"},{"name":"Maps_To","value":"CD80-Fc Fusion Protein ALPN-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802337"},{"name":"NCI_META_CUI","value":"CL1412018"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802337"},{"name":"PDQ_Open_Trial_Search_ID","value":"802337"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169063":{"preferredName":"CD80-Fc Fusion Protein FPT155","code":"C169063","definitions":[{"definition":"A recombinant fusion protein composed of the extracellular domain (ECD) of human CD80 (B7.1) fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration of CD80-Fc fusion protein FPT155, the CD80 moiety targets and binds to CD28, which in the presence of antigenic T-cell receptor (TCR) signaling, leads to the co-stimulation of T-cell responses including the activation of naïve and memory T-cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. FPT155 also targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4), preventing the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation in the tumor microenvironment. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD80-Fc Fusion Protein FPT155","termGroup":"PT","termSource":"NCI"},{"termName":"FPT 155","termGroup":"CN","termSource":"NCI"},{"termName":"FPT-155","termGroup":"CN","termSource":"NCI"},{"termName":"FPT155","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2337381-31-2"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"WK58XJB6UK"},{"name":"Maps_To","value":"CD80-Fc Fusion Protein FPT155"},{"name":"NCI_Drug_Dictionary_ID","value":"800619"},{"name":"NCI_META_CUI","value":"CL1378876"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800619"},{"name":"PDQ_Open_Trial_Search_ID","value":"800619"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175251":{"preferredName":"Tagtociclib","code":"C175251","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, tagtociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tagtociclib","termGroup":"PT","termSource":"NCI"},{"termName":"(1R,3S)-3-(3-(3-(Methoxymethyl)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-5-yl)cyclopentyl isopropylcarbamate","termGroup":"SN","termSource":"NCI"},{"termName":"CDK2 Inhibitor PF-07104091","termGroup":"SY","termSource":"NCI"},{"termName":"Cyclin-dependent Kinase 2 Inhibitor PF-07104091","termGroup":"SY","termSource":"NCI"},{"termName":"PF 07104091","termGroup":"CN","termSource":"NCI"},{"termName":"PF-07104091","termGroup":"CN","termSource":"NCI"},{"termName":"PF07104091","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2460249-19-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"XBD0JF5EHJ"},{"name":"Maps_To","value":"CDK2 Inhibitor PF-07104091"},{"name":"NCI_Drug_Dictionary_ID","value":"803259"},{"name":"NCI_META_CUI","value":"CL1412749"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803259"},{"name":"PDQ_Open_Trial_Search_ID","value":"803259"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174417":{"preferredName":"CDK4/6 Inhibitor CS3002","code":"C174417","definitions":[{"definition":"An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor CS3002 selectively targets and inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor CS3002","termGroup":"PT","termSource":"NCI"},{"termName":"CS 3002","termGroup":"CN","termSource":"NCI"},{"termName":"CS-3002","termGroup":"CN","termSource":"NCI"},{"termName":"CS3002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor CS3002"},{"name":"NCI_Drug_Dictionary_ID","value":"802263"},{"name":"NCI_META_CUI","value":"CL1411938"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802263"},{"name":"PDQ_Open_Trial_Search_ID","value":"802263"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170749":{"preferredName":"CDK4/6 Inhibitor HS-10342","code":"C170749","definitions":[{"definition":"An orally bioavailable, small molecular, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor HS-10342 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor HS-10342","termGroup":"PT","termSource":"NCI"},{"termName":"HS 10342","termGroup":"CN","termSource":"NCI"},{"termName":"HS-10342","termGroup":"CN","termSource":"NCI"},{"termName":"HS10342","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor HS-10342"},{"name":"NCI_Drug_Dictionary_ID","value":"800781"},{"name":"NCI_META_CUI","value":"CL1383163"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800781"},{"name":"PDQ_Open_Trial_Search_ID","value":"800781"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171344":{"preferredName":"CDK4/6 Inhibitor TQB3616","code":"C171344","definitions":[{"definition":"An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor TQB3616 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK4/6 Inhibitor TQB3616","termGroup":"PT","termSource":"NCI"},{"termName":"TQB 3616","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3616","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3616","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CDK4/6 Inhibitor TQB3616"},{"name":"NCI_Drug_Dictionary_ID","value":"801305"},{"name":"NCI_META_CUI","value":"CL1405461"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801305"},{"name":"PDQ_Open_Trial_Search_ID","value":"801305"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172390":{"preferredName":"CDK7 Inhibitor SY-5609","code":"C172390","definitions":[{"definition":"An orally bioavailable, selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon oral administration, SY-5609 selectively targets, binds to and inhibits the activity of CDK7, thereby inhibiting CDK7-mediated signaling. Specifically, inhibition of CDK7 prevents phosphorylation of the carboxy-terminal domain (CTD) of RNA Polymerase II, thereby preventing transcription of important cancer-promoting genes. In addition, it prevents phosphorylation of the cell cycle kinases CDK1, 2, 4, and 6, thereby disrupting uncontrolled cell cycle progression. Altogether, this may induce apoptosis, cause cell cycle arrest, inhibit DNA damage repair and inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc and beta-catenin, through the phosphorylation of RNA polymerase II.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK7 Inhibitor SY-5609","termGroup":"PT","termSource":"NCI"},{"termName":"Cyclin-dependent Kinase 7 Inhibitor SY-5609","termGroup":"SY","termSource":"NCI"},{"termName":"SY 5609","termGroup":"CN","termSource":"NCI"},{"termName":"SY-5609","termGroup":"CN","termSource":"NCI"},{"termName":"SY5609","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417302-07-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TW6044C3O6"},{"name":"Maps_To","value":"CDK7 Inhibitor SY-5609"},{"name":"NCI_Drug_Dictionary_ID","value":"802022"},{"name":"NCI_META_CUI","value":"CL1406516"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802022"},{"name":"PDQ_Open_Trial_Search_ID","value":"802022"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165747":{"preferredName":"CDK8/19 Inhibitor RVU120","code":"C165747","definitions":[{"definition":"An orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor RVU120 targets, binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDK8/19, serine/threonine kinases involved in the regulation of the cell cycle, are overexpressed in certain cancer cell types and play key roles in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CDK8/19 Inhibitor RVU120","termGroup":"PT","termSource":"NCI"},{"termName":"CDK8/19 Inhibitor SEL 120","termGroup":"SY","termSource":"NCI"},{"termName":"RVU 120","termGroup":"CN","termSource":"NCI"},{"termName":"RVU-120","termGroup":"CN","termSource":"NCI"},{"termName":"RVU120","termGroup":"CN","termSource":"NCI"},{"termName":"SEL 120","termGroup":"CN","termSource":"NCI"},{"termName":"SEL 120-34","termGroup":"CN","termSource":"NCI"},{"termName":"SEL 120-34A","termGroup":"CN","termSource":"NCI"},{"termName":"SEL-120","termGroup":"CN","termSource":"NCI"},{"termName":"SEL120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1429515-59-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SDM3M518PJ"},{"name":"Maps_To","value":"CDK8/19 Inhibitor SEL 120"},{"name":"NCI_Drug_Dictionary_ID","value":"800129"},{"name":"NCI_META_CUI","value":"CL978865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800129"},{"name":"PDQ_Open_Trial_Search_ID","value":"800129"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171649":{"preferredName":"Cedazuridine/Azacitidine Combination Agent ASTX030","code":"C171649","definitions":[{"definition":"An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite azacitidine, with potential antineoplastic activity. Upon oral administration of the cedazuridine/azacitidine combination agent ASTX030, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of azacitidine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of azacitidine. Azacitidine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase (DNMT), thereby blocking DNA methylation and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cedazuridine/Azacitidine Combination Agent ASTX030","termGroup":"PT","termSource":"NCI"},{"termName":"ASTX 030","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX-030","termGroup":"CN","termSource":"NCI"},{"termName":"ASTX030","termGroup":"CN","termSource":"NCI"},{"termName":"AZA/CDZ Combination","termGroup":"SY","termSource":"NCI"},{"termName":"Cedazuridine + Azacitidine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cedazuridine/Azacitidine Combination Agent ASTX030"},{"name":"NCI_Drug_Dictionary_ID","value":"802003"},{"name":"NCI_META_CUI","value":"CL1405630"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802003"},{"name":"PDQ_Open_Trial_Search_ID","value":"802003"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172396":{"preferredName":"Golcadomide","code":"C172396","definitions":[{"definition":"A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, golcadomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Golcadomide","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986369","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986369","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986369","termGroup":"CN","termSource":"NCI"},{"termName":"CC -99282","termGroup":"CN","termSource":"NCI"},{"termName":"CC 99282","termGroup":"CN","termSource":"NCI"},{"termName":"CC99282","termGroup":"CN","termSource":"NCI"},{"termName":"CelMod CC-99282","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon E3 Ubiquitin Ligase Modulating Drug CC-99282","termGroup":"SY","termSource":"NCI"},{"termName":"Cereblon Modulator CC-99282","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"953769-46-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"29HLR8Z5BR"},{"name":"Maps_To","value":"Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282"},{"name":"NCI_Drug_Dictionary_ID","value":"801633"},{"name":"NCI_META_CUI","value":"CL1406350"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801633"},{"name":"PDQ_Open_Trial_Search_ID","value":"801633"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167056":{"preferredName":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes","code":"C167056","definitions":[{"definition":"A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of a CD28 co-stimulatory signaling domain fused to the zeta chain of the TCR/CD3 complex (CD3zeta), a truncated form of CD19 (CD19t), an immunoglobulin (Ig) G4-Fc (EQ) spacer, and a peptide derived from chlorotoxin (CLTX), with potential imaging and antineoplastic activities. Upon administration, chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes are re-directed to specific tumor cells in the brain inducing selective toxicity in these tumor cells. CLTX, a 36-amino acid peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus) and a chloride channel blocker, preferentially binds to glioma (and other neuroectodermal origin) cells via membrane bound forms of the endopeptidase matrix metalloproteinase-2 (MMP-2). This may direct the T-lymphocytes to and induce selective toxicity in MMP-2-expressing tumor cells. Additionally, binding to MMP-2 on glioma cells may both interfere with transmembrane chloride exchange and inhibit proteolytic extracellular matrix remodeling by MMP-2, which may further limit the spread of these tumor cells. MMP-2 is specifically upregulated in gliomas and related cancers, but is not normally expressed in brain. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling; its inclusion may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3 zeta chain alone. IgG4-Fc (EQ) contains two point mutations in its spacer region which prevents recognition of the CAR by Fc receptors (FcRs) without altering the ability of the CAR to mediate antigen-specific lysis. CD19t, which lacks the cytoplasmic signaling tail, provides a non-immunogenic surface marker that allows for accurate measurement, efficient cell tracking and/or imaging of the therapeutic T-cells in vivo following adoptive transfer. Additionally, co-expression of CD19t functions as a \"suicide\" switch via clinically available antibodies or immunotoxins which can be used to selectively eliminate the genetically modified cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"802824"},{"name":"NCI_META_CUI","value":"CL972048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802824"},{"name":"PDQ_Open_Trial_Search_ID","value":"802824"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169027":{"preferredName":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51","code":"C169027","definitions":[{"definition":"The ditosylated salt of A51, an orally bioavailable inhibitor of casein kinase 1alpha (CK1alpha) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), with potential antineoplastic activity. Upon administration, BTX-A51 binds to and inhibits the activity of CK1alpha, CDK7, and CDK9. Blocking the phosphorylation and kinase activity of CK1alpha prevents the enhanced binding of murine double minute X (MDMX) to p53, the formation of CK1alpha and MDM2 complex, and the resulting inhibition of p53. This induces p53-mediated cell cycle arrest, slowing tumor cell proliferation. Blocking the phosphorylation and kinase activity of CDK7 and CDK9 prevents the positive transcription elongation factor b (PTEFb)-mediated activation of RNA polymerase II (RNA Pol II) and leads to the inhibition of gene transcription of various anti-apoptotic proteins. This also induces cell cycle arrest and apoptosis, slowing tumor cell proliferation. CK1alpha, a serine/threonine kinase and a leukemic stem cell target, acts as a tumor suppressor in several cancers through the negative regulation of Wnt/beta-catenin signaling and p53. It negatively regulates p53 by phosphorylating MDMX, thus enhancing binding of MDMX to p53, as well as by forming a complex with MDM2. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA Pol II. CDK9, also a serine/threonine kinase, regulates elongation of transcription through phosphorylation of RNA Pol II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of RNA Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51","termGroup":"PT","termSource":"NCI"},{"termName":"BTX A51","termGroup":"CN","termSource":"NCI"},{"termName":"BTX-A51","termGroup":"CN","termSource":"NCI"},{"termName":"BTXA51","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CK1alpha/CDK7/CDK9 Inhibitor BTX-A51"},{"name":"NCI_Drug_Dictionary_ID","value":"801169"},{"name":"NCI_META_CUI","value":"CL1378832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801169"},{"name":"PDQ_Open_Trial_Search_ID","value":"801169"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167393":{"preferredName":"Commensal Bacterial Strain Formulation VE800","code":"C167393","definitions":[{"definition":"An orally bioavailable formulation composed of eleven alive, distinct nonpathogenic, nontoxigenic, human commensal bacterial strains, isolated from healthy human donor feces, with potential immunostimulating and antineoplastic activities. Upon administration of the commensal bacterial strain formulation VE800, the bacterial strains induce an interferon-gamma (IFN-g)-producing CD8-positive T-cell-mediated immune response in the intestines. This may activate an IFN-g-expressing CD8+ T-cell -mediated anti-cancer immune response and may eradicate tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Commensal Bacterial Strain Formulation VE800","termGroup":"PT","termSource":"NCI"},{"termName":"Bacterial Consortium-based Formulation VE800","termGroup":"SY","termSource":"NCI"},{"termName":"LBP VE800","termGroup":"SY","termSource":"NCI"},{"termName":"Live Biotherapeutic Product VE800","termGroup":"SY","termSource":"NCI"},{"termName":"VE 800","termGroup":"CN","termSource":"NCI"},{"termName":"VE-800","termGroup":"CN","termSource":"NCI"},{"termName":"VE800","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Commensal Bacterial Strain Formulation VE800"},{"name":"NCI_Drug_Dictionary_ID","value":"802787"},{"name":"NCI_META_CUI","value":"CL972578"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802787"},{"name":"PDQ_Open_Trial_Search_ID","value":"802787"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171370":{"preferredName":"Copper Cu 67 Ucasareotide Dasaroxetan","code":"C171370","definitions":[{"definition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional chelator 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar) and radiolabeled with the beta-emitting radioisotope copper Cu 67, with potential antineoplastic activity. Upon administration, copper Cu 67 ucasareotide dasaroxetan binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. TATE is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copper Cu 67 Ucasareotide Dasaroxetan","termGroup":"PT","termSource":"NCI"},{"termName":"67Cu-labeled MeCOSar-Tyr3-octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"67Cu-SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Copper 67 SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Copper Cu 67 TATE","termGroup":"SY","termSource":"NCI"},{"termName":"Copper Cu 67 Tyr3-octreotate","termGroup":"SY","termSource":"NCI"},{"termName":"Copper Cu 67-SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Cu-67 SARTATE","termGroup":"SY","termSource":"NCI"},{"termName":"Ucasareotide Dasaroxetan Cu-67","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Y6WKJ2X9X8"},{"name":"Maps_To","value":"Copper Cu 67 Tyr3-octreotate"},{"name":"NCI_Drug_Dictionary_ID","value":"801332"},{"name":"NCI_META_CUI","value":"CL1405493"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801332"},{"name":"PDQ_Open_Trial_Search_ID","value":"801332"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172058":{"preferredName":"Cord Blood Derived CAR T-Cells","code":"C172058","definitions":[{"definition":"A preparation of umbilical cord blood (CB)-derived T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of the cord blood derived CAR T-cells, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cord Blood Derived CAR T-Cells","termGroup":"PT","termSource":"NCI"},{"termName":"CB Derived CAR T-Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Cord Blood CAR T-Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cord Blood Derived CAR T-Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801490"},{"name":"NCI_META_CUI","value":"CL1406190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801490"},{"name":"PDQ_Open_Trial_Search_ID","value":"801490"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173651":{"preferredName":"Pimicotinib","code":"C173651","definitions":[{"definition":"An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon oral administration, pimicotinib targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pimicotinib","termGroup":"PT","termSource":"NCI"},{"termName":"ABSK 021","termGroup":"CN","termSource":"NCI"},{"termName":"ABSK-021","termGroup":"CN","termSource":"NCI"},{"termName":"ABSK021","termGroup":"CN","termSource":"NCI"},{"termName":"CSF-1R Inhibitor ABSK021","termGroup":"SY","termSource":"NCI"},{"termName":"CSF1R Inhibitor ABSK021","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"HV1XI8HST2"},{"name":"Maps_To","value":"CSF1R Inhibitor ABSK021"},{"name":"NCI_Drug_Dictionary_ID","value":"802252"},{"name":"NCI_META_CUI","value":"CL1407395"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802252"},{"name":"PDQ_Open_Trial_Search_ID","value":"802252"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167271":{"preferredName":"CXCR4/E-selectin Antagonist GMI-1359","code":"C167271","definitions":[{"definition":"An antagonist of both the C-X-C chemokine receptor type 4 (CXCR4) and E-selectin (CD62E), with potential antineoplastic activity. Upon administration, CXCR4/E-selectin antagonist GMI-1359 binds to both CXCR4 and E-selectin expressed on endothelial cells. The binding to CXCR4 prevents the binding of stromal-cell derived factor-1 (SDF-1; CXCL12) to CXCR4 and inhibits CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. The binding to E-selectin expressed on endothelial cells prevents their interaction with E-selectin ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis. Its overexpression has been associated with tumor angiogenesis and metastasis in several cancers. ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CXCR4/E-selectin Antagonist GMI-1359","termGroup":"PT","termSource":"NCI"},{"termName":"GMI 1359","termGroup":"CN","termSource":"NCI"},{"termName":"GMI-1359","termGroup":"CN","termSource":"NCI"},{"termName":"GMI1359","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CXCR4/E-selectin Antagonist GMI-1359"},{"name":"NCI_Drug_Dictionary_ID","value":"802777"},{"name":"NCI_META_CUI","value":"CL972258"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802777"},{"name":"PDQ_Open_Trial_Search_ID","value":"802777"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172052":{"preferredName":"CYP11A1 Inhibitor ODM-209","code":"C172052","definitions":[{"definition":"An orally bioavailable inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc)(CYP11A1), with potential antineoplastic activity. Upon oral administration, CYP11A1 inhibitor ODM-209 targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit the proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-limiting step in steroid hormone biosynthesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CYP11A1 Inhibitor ODM-209","termGroup":"PT","termSource":"NCI"},{"termName":"ODM 209","termGroup":"CN","termSource":"NCI"},{"termName":"ODM-209","termGroup":"CN","termSource":"NCI"},{"termName":"ODM209","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CYP11A1 Inhibitor ODM-209"},{"name":"NCI_Drug_Dictionary_ID","value":"801473"},{"name":"NCI_META_CUI","value":"CL1406195"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801473"},{"name":"PDQ_Open_Trial_Search_ID","value":"801473"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173660":{"preferredName":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466","code":"C173660","definitions":[{"definition":"A drug-dendrimer conjugate composed of a B-cell lymphoma 2 (Bcl-2)/Bcl-XL inhibitor AZD4320 that is chemically conjugated to a proprietary 5-generation pegylated poly-lysine dendrimer via a hydrolytically labile linker, with potential pro-apoptotic and antineoplastic activities. Upon administration of AZD0466, AZD4320 is released through hydrolytic cleavage of the linker. AZD4320 is a Bcl2-homology domain 3 (BH3) mimetic that specifically binds to and inhibits the activity of the anti-apoptotic proteins Bcl-2 and Bcl-XL. This restores apoptotic processes and inhibits cell proliferation in Bcl-2/Bcl-XL-dependent tumor cells. Bcl-2 and Bcl-XL, proteins belonging to the Bcl-2 family that are overexpressed in many cancers, play an important role in the negative regulation of apoptosis. Their expression in tumors is associated with increased drug resistance and cancer cell survival. The conjugation of AZD 4320 to the dendrimer construct may allow extended release of the agent, which may improve efficacy and lower toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466","termGroup":"PT","termSource":"NCI"},{"termName":"AZD 0466","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-0466","termGroup":"CN","termSource":"NCI"},{"termName":"AZD0466","termGroup":"CN","termSource":"NCI"},{"termName":"AZD4320-dendrimer Conjugate AZD0466","termGroup":"SY","termSource":"NCI"},{"termName":"Bcl-2/Bcl-XL Inhibitor-dendrimer Conjugate AZD0466","termGroup":"SY","termSource":"NCI"},{"termName":"Bcl-2/Bcl-XL Inhibitor-DEP Dendrimer Conjugate AZD0466","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466"},{"name":"NCI_Drug_Dictionary_ID","value":"802253"},{"name":"NCI_META_CUI","value":"CL1407404"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802253"},{"name":"PDQ_Open_Trial_Search_ID","value":"802253"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173443":{"preferredName":"Dengue Virus Adjuvant PV-001-DV","code":"C173443","definitions":[{"definition":"An attenuated strain of dengue virus that was originally developed as a potential preventative vaccine for dengue fever by the US Army as Dengue Virus-1 #45AZ5, with potential immunostimulating activity. Upon administration of dengue virus adjuvant PV-001-DV, the virus may activate both the innate and adaptive immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dengue Virus Adjuvant PV-001-DV","termGroup":"PT","termSource":"NCI"},{"termName":"Dengue Virus-1 PV-001-DV","termGroup":"SY","termSource":"NCI"},{"termName":"PV 001-DV","termGroup":"CN","termSource":"NCI"},{"termName":"PV-001-Dengue Virus","termGroup":"SY","termSource":"NCI"},{"termName":"PV-001-DV","termGroup":"CN","termSource":"NCI"},{"termName":"PV001-DV","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Dengue Virus Adjuvant PV-001-DV"},{"name":"NCI_Drug_Dictionary_ID","value":"801795"},{"name":"NCI_META_CUI","value":"CL1407426"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801795"},{"name":"PDQ_Open_Trial_Search_ID","value":"801795"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168692":{"preferredName":"DNA-PK inhibitor AZD7648","code":"C168692","definitions":[{"definition":"An orally bioavailable ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK), with potential chemo/radiosensitizing and antineoplastic activites. Upon oral administration, DNA-PK inhibitor AZD7648 selectively targets, binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity leading to enhanced tumor cell death. AZD7648 may also increase the effect of poly(ADP-ribose) polymerase (PARP) inhibitors and may work as a monotherapy in tumors with high endogenous levels of DNA damage resulting from defects in other DNA repair pathways. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. DNA-PK plays a key role in the NHEJ pathway and DSB repair.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-PK inhibitor AZD7648","termGroup":"PT","termSource":"NCI"},{"termName":"7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one","termGroup":"SN","termSource":"NCI"},{"termName":"AZD 7648","termGroup":"CN","termSource":"NCI"},{"termName":"AZD-7648","termGroup":"CN","termSource":"NCI"},{"termName":"AZD7648","termGroup":"CN","termSource":"NCI"},{"termName":"DNA-dependent Protein Kinase Inhibitor AZD7648","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230820-11-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"97A09L5JCK"},{"name":"Maps_To","value":"DNA-PK inhibitor AZD7648"},{"name":"NCI_Drug_Dictionary_ID","value":"800695"},{"name":"NCI_META_CUI","value":"CL1378628"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800695"},{"name":"PDQ_Open_Trial_Search_ID","value":"800695"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172111":{"preferredName":"DNA-PK/PI3K-delta Inhibitor BR101801","code":"C172111","definitions":[{"definition":"An orally bioavailable inhibitor of phosphoinositide 3-kinase delta (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta) and DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and immunomodulating activities. Upon oral administration, the DNA-PK/PI3K-delta inhibitor BR101801 inhibits the activity of both PI3K-delta and DNA-PK. This prevents PI3K-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K-overexpressing tumor cells. Specifically, since PI3K regulates c-myc expression, inhibition of PI3K signaling may lead to a decrease in proliferation of c-myc-expressing tumor cells. Also, by inhibiting the activity of DNA-PK, this agent interferes with the non-homologous end joining (NHEJ) process and prevents the repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity by inhibiting the ability of tumor cells to repair damaged DNA. The PI3K pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. In addition, BR101801 is able to decrease Tregs and increase CD8 lymphocytes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNA-PK/PI3K-delta Inhibitor BR101801","termGroup":"PT","termSource":"NCI"},{"termName":"BR 101801","termGroup":"CN","termSource":"NCI"},{"termName":"BR-101801","termGroup":"CN","termSource":"NCI"},{"termName":"BR101801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNA-PK/PI3K-delta Inhibitor BR101801"},{"name":"NCI_Drug_Dictionary_ID","value":"801432"},{"name":"NCI_META_CUI","value":"CL1406238"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801432"},{"name":"PDQ_Open_Trial_Search_ID","value":"801432"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174424":{"preferredName":"DNMT1 Inhibitor NTX-301","code":"C174424","definitions":[{"definition":"An orally bioavailable inhibitor of human DNA methyltransferase 1 (DNMT1), with potential antineoplastic activity. Upon oral administration, DNMT1 inhibitor NTX-301 targets ad binds to DNMT1, thereby inhibiting the activity of DNMT1. This may prevent DNA methylation, induce DNA hypomethylation, and activate tumor suppressor genes silenced by hypermethylation. This may inhibit tumor cell proliferation. DNMT1, a member of the DNA methyltransferase (DNMT) family, plays an important role in maintaining the DNA methylation pattern. Dysregulation of DNMT1 has been associated with a number of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DNMT1 Inhibitor NTX-301","termGroup":"PT","termSource":"NCI"},{"termName":"NTX 301","termGroup":"CN","termSource":"NCI"},{"termName":"NTX-301","termGroup":"CN","termSource":"NCI"},{"termName":"NTX301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DNMT1 Inhibitor NTX-301"},{"name":"NCI_Drug_Dictionary_ID","value":"802300"},{"name":"NCI_META_CUI","value":"CL1411982"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802300"},{"name":"PDQ_Open_Trial_Search_ID","value":"802300"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167221":{"preferredName":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370","code":"C167221","definitions":[{"definition":"A formulation consisting of SQL70, a prodrug-activating biomaterial, and SQP33, a prodrug of the anthracycline antineoplastic antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of SQ3370, which consists of the injection of SQL70 at the tumor site followed by the intravenous administration of SQ3370, the prodrug SQP33 binds to, through an as of yet not identifiable mechanism, to SQL70 at the tumor site. After binding, doxorubicin is released over a period of days, intercalates into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication and repair, and prevents RNA and protein synthesis. Compared to the systemic administration of doxorubicin alone, SQ3370 may allow for higher and sustained delivery of active doxorubicin directly to the tumor, which may increase its efficacy and limit its off-site, systemic toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370","termGroup":"PT","termSource":"NCI"},{"termName":"Doxorubicin Prodrug SQP33/Prodrug-activating Biomaterial SQL7","termGroup":"SY","termSource":"NCI"},{"termName":"SQ 3370","termGroup":"CN","termSource":"NCI"},{"termName":"SQ-3370","termGroup":"CN","termSource":"NCI"},{"termName":"SQ3370","termGroup":"CN","termSource":"NCI"},{"termName":"SQL70-SQP33","termGroup":"SY","termSource":"NCI"},{"termName":"SQL70/SQP33","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370"},{"name":"NCI_Drug_Dictionary_ID","value":"800071"},{"name":"NCI_META_CUI","value":"CL972446"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800071"},{"name":"PDQ_Open_Trial_Search_ID","value":"800071"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173999":{"preferredName":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555","code":"C173999","definitions":[{"definition":"An orally bioavailable combination of DTRMWXHS-12, a Bruton's tyrosine kinase (BTK) inhibitor, everolimus, a mammalian Target of Rapamycin (mTOR) inhibitor, and pomalidomide, an immunomodulatory drug (IMiD), that may be used for the treatment of B-cell malignancies. Upon oral administration of DTRM-555, the DTRMWXHS-12 component inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, and leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes. The everolimus component binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of mTOR, a key regulatory kinase. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway. The pomalidomide component may inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoiesis. The combination of a BTK inhibitor, an mTOR inhibitor and an IMiD may work synergistically to kill malignant B-cells and prevent drug resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555","termGroup":"PT","termSource":"NCI"},{"termName":"DTRM 555","termGroup":"CN","termSource":"NCI"},{"termName":"DTRM-555","termGroup":"CN","termSource":"NCI"},{"termName":"DTRM555","termGroup":"CN","termSource":"NCI"},{"termName":"DTRMWXHS-12-Everolimus-Pomalidomide","termGroup":"SY","termSource":"NCI"},{"termName":"DTRMWXHS-12/Everolimus/Pomalidomide","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555"},{"name":"NCI_Drug_Dictionary_ID","value":"802451"},{"name":"NCI_META_CUI","value":"CL1407876"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802451"},{"name":"PDQ_Open_Trial_Search_ID","value":"802451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175445":{"preferredName":"EGFR Inhibitor TY-9591","code":"C175445","definitions":[{"definition":"An orally available inhibitor of epidermal growth factor receptor (EGFR), including activating mutations, with potential antineoplastic activity. Upon administration, the EGFR inhibitor TY-9591 binds to and inhibits EGFR activating mutations, including the resistance mutation T790M, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Inhibitor TY-9591","termGroup":"PT","termSource":"NCI"},{"termName":"EGFR Tyrosine Kinase Inhibitor TY-9591","termGroup":"SY","termSource":"NCI"},{"termName":"TY 9591","termGroup":"CN","termSource":"NCI"},{"termName":"TY-9591","termGroup":"CN","termSource":"NCI"},{"termName":"TY9591","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Inhibitor TY-9591"},{"name":"NCI_Drug_Dictionary_ID","value":"802783"},{"name":"NCI_META_CUI","value":"CL1412813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802783"},{"name":"PDQ_Open_Trial_Search_ID","value":"802783"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173415":{"preferredName":"EGFR Mutant-selective Inhibitor TQB3804","code":"C173415","definitions":[{"definition":"A fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor TQB3804 binds to and inhibits the activity of mutant forms of EGFR, including the C797S EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. TQB3804 inhibits mutated forms of EGFR including C797S, which prevents covalent bond formation with third-generation EGFR inhibitor osimertinib leading to drug resistance. TQB3804 may have enhanced anti-tumor effects in tumors with C797S-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR Mutant-selective Inhibitor TQB3804","termGroup":"PT","termSource":"NCI"},{"termName":"Epidermal Growth Factor Receptor Inhibitor TQB3804","termGroup":"SY","termSource":"NCI"},{"termName":"TQB 3804","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3804","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3804","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR Mutant-selective  Inhibitor TQB3804"},{"name":"NCI_Drug_Dictionary_ID","value":"801857"},{"name":"NCI_META_CUI","value":"CL1407432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801857"},{"name":"PDQ_Open_Trial_Search_ID","value":"801857"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165778":{"preferredName":"EGFR/EGFRvIII Inhibitor WSD0922-FU","code":"C165778","definitions":[{"definition":"A blood-brain-barrier (BBB) penetrable selective inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including but not limited to the EGFR variant III (EGFRvIII) mutant form, with potential antineoplastic activity. Upon administration of EGFR/EGFRvIII inhibitor WSD0922-FU, this agent is able to penetrate the BBB and specifically targets, binds to and inhibits EGFR and specific EGFR mutations, which prevents EGFR/EGFR mutant-mediated signaling and leads to cell death in EGFR/EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors that are not able to penetrate the BBB, WSD0922-FU may have therapeutic benefits in brain tumors, such as glioblastoma (GBM) and metastatic CNS tumors. EGFR, a receptor tyrosine kinase (RTK) that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/EGFRvIII Inhibitor WSD0922-FU","termGroup":"PT","termSource":"NCI"},{"termName":"BBB Penetrable EGFR/EGFRvIII Inhibitor WSD0922-FU","termGroup":"SY","termSource":"NCI"},{"termName":"EGFR Mutant Inhibitor WSD0922-FU","termGroup":"SY","termSource":"NCI"},{"termName":"WSD 0922-FU","termGroup":"CN","termSource":"NCI"},{"termName":"WSD-0922-FU","termGroup":"CN","termSource":"NCI"},{"termName":"WSD0922-FU","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR/EGFRvIII Inhibitor WSD0922-FU"},{"name":"NCI_Drug_Dictionary_ID","value":"800200"},{"name":"NCI_META_CUI","value":"CL979063"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800200"},{"name":"PDQ_Open_Trial_Search_ID","value":"800200"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167205":{"preferredName":"Sunvozertinib","code":"C167205","definitions":[{"definition":"An orally available, irreversible, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that shows similar activity against certain activating mutations, including exon 20 insertions (exon20ins), with potential antineoplastic activity. Upon oral administration,sunvozertinib binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. In contrast to other agents active against exon20ins mutations, sunvozertinib appears to be more selective against mutated EGFR than wild-type (wt) EGFR. This may lessen wtEGFR-related dose-limiting toxicity and may allow for the administration of the desired therapeutic dose of sunvozertinib.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sunvozertinib","termGroup":"PT","termSource":"NCI"},{"termName":"DZD 9008","termGroup":"CN","termSource":"NCI"},{"termName":"DZD-9008","termGroup":"CN","termSource":"NCI"},{"termName":"DZD9008","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/HER2 Inhibitor DZD9008","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2370013-12-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L1Q2K5JYO8"},{"name":"Maps_To","value":"EGFR/HER2 Inhibitor DZD9008"},{"name":"NCI_Drug_Dictionary_ID","value":"800418"},{"name":"NCI_META_CUI","value":"CL972432"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800418"},{"name":"PDQ_Open_Trial_Search_ID","value":"800418"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173165":{"preferredName":"Ficerafusp Alfa","code":"C173165","definitions":[{"definition":"A bifunctional monoclonal antibody targeting both the receptor tyrosine kinase epidermal growth factor receptor (EGFR) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration of ficerafusp alfa, the anti-EGFR moiety targets, binds to and prevents activation of EGFR-mediated signaling. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. The anti-TGFb moiety targets and binds to TGFb, thereby preventing the activation of TGFb-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGFb is overactivated. EGFR and TGFb, mutated and/or overexpressed on the surfaces of various tumor cell types, play key roles in tumor cell proliferation and progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ficerafusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-EGFR/TGFb Bispecific Monoclonal Antibody BCA101","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-EGFR/TGFb Monoclonal Antibody BCA101","termGroup":"SY","termSource":"NCI"},{"termName":"BCA 101","termGroup":"CN","termSource":"NCI"},{"termName":"BCA-101","termGroup":"CN","termSource":"NCI"},{"termName":"BCA101","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR/TGFb Fusion Monoclonal Antibody BCA101","termGroup":"SY","termSource":"NCI"},{"termName":"FMAB2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2764727-44-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LZ88YF62H2"},{"name":"Maps_To","value":"EGFR/TGFb Fusion Monoclonal Antibody BCA101"},{"name":"NCI_Drug_Dictionary_ID","value":"802059"},{"name":"NCI_META_CUI","value":"CL1407043"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802059"},{"name":"PDQ_Open_Trial_Search_ID","value":"802059"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C173436":{"preferredName":"EGFR/VEGFR/RET Inhibitor HA121-28","code":"C173436","definitions":[{"definition":"An orally available inhibitor of the epidermal growth factor receptor (EGFR), the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET) and vascular endothelial growth factor receptor (VEGFR), with potential anti-angiogenic and antineoplastic activities. Upon oral administration of HA121-28, this agent targets, binds to and inhibits the activity of EGFR, RET and VEGFR. This prevents EGFR-, RET- and VEGFR-mediated signaling, and may lead to the induction of apoptosis and inhibition of tumor growth in EGFR-, RET- and VEGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Dysregulation of RET activity plays a key role in the development and progression of a variety of cancers. Expression of VEGFR is upregulated in a variety of tumor cell types; it plays a key role in the migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EGFR/VEGFR/RET Inhibitor HA121-28","termGroup":"PT","termSource":"NCI"},{"termName":"HA 121-28","termGroup":"CN","termSource":"NCI"},{"termName":"HA-121 28","termGroup":"CN","termSource":"NCI"},{"termName":"HA121-28","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EGFR/VEGFR/RET Inhibitor HA121-28"},{"name":"NCI_Drug_Dictionary_ID","value":"801763"},{"name":"NCI_META_CUI","value":"CL1407411"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801763"},{"name":"PDQ_Open_Trial_Search_ID","value":"801763"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168790":{"preferredName":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641","code":"C168790","definitions":[{"definition":"An oncolytic adenoviral vector, a transgene-modified variant of enadenotucirev (EnAd), that expresses a bi-specific T-cell activator molecule FAP-TAc together with immune enhancer molecules C-X-C motif chemokine 9 (CXCL9), C-X-C motif chemokine 10 (CXCL10) and interferon alpha (IFNalpha), with potential immunomodulating and antineoplastic activities. Upon administration of NG-641, EnAd specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses FAP-TAc. The locally expressed FAP-TAc targets and binds to both fibroblast activating protein (FAP) on cancer associated fibroblasts (CAFs) and CD3 on T-cells. This leads to T-cell activation and T-cell mediated killing of CAFs in tumor stroma. NG-641 also encodes the transgenes CXCL9, CXCL10 and IFNalpha. The production of CXCL9, CXCL10 and IFNalpha leads to the recruitment and further activation of T-cells, enhancing the overall immune response and cancer cell killing. FAP, a cell surface glycoprotein, is overexpressed on tumor-associated fibroblasts but minimally expressed on normal, healthy cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641","termGroup":"PT","termSource":"NCI"},{"termName":"NG 641","termGroup":"CN","termSource":"NCI"},{"termName":"NG-641","termGroup":"CN","termSource":"NCI"},{"termName":"NG641","termGroup":"CN","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector Expressing FAP/CD3 Bispecific Molecule NG-641","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Adenoviral Vector-expressing FAP/CD3 Bispecific FAP-TAc NG-641","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L93WSG9AAU"},{"name":"Maps_To","value":"Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641"},{"name":"NCI_Drug_Dictionary_ID","value":"800703"},{"name":"NCI_META_CUI","value":"CL1378696"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800703"},{"name":"PDQ_Open_Trial_Search_ID","value":"800703"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173879":{"preferredName":"Encapsulated Rapamycin","code":"C173879","definitions":[{"definition":"An orally bioavailable nanoparticle-based formulation composed of sub-micron particles of the macrolide antibiotic rapamycin incorporated into a pH-sensitive poly(methyl methacrylate) polymer, with potential immunomodulating and antineoplastic activities. Upon oral administration of the encapsulated rapamycin, the nanoparticle specifically delivers rapamycin at the tumor site. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR), a key regulatory kinase. This may suppress mTORC1 activity. In addition, inhibition of mTOR may modulate central memory CD8 T cells, CD3+/CD56+ natural killer (NK) cells and CD8 T-cell responses. This may kill tumor cells. Compared to the administration of rapamycin alone, this formulation improves oral bioavailability of rapamycin with more consistent rapamycin levels, thereby allowing for administration of lower rapamycin dosage, which improves and minimizes rapamycin's toxicity. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Encapsulated Rapamycin","termGroup":"PT","termSource":"NCI"},{"termName":"Encapsulated Sirolimus","termGroup":"SY","termSource":"NCI"},{"termName":"eRapa (TM)","termGroup":"CN","termSource":"NCI"},{"termName":"Microencapsulated Rapamycin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Encapsulated Rapamycin"},{"name":"NCI_Drug_Dictionary_ID","value":"802399"},{"name":"NCI_META_CUI","value":"CL1407680"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802399"},{"name":"PDQ_Open_Trial_Search_ID","value":"802399"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175447":{"preferredName":"Vodudeutentan Sodium","code":"C175447","definitions":[{"definition":"An antagonist of the immune checkpoint endothelin B receptor (ETBR; EDNRB), with potential immunomodulating and antineoplastic activities. Upon administration, the ETBR blocker ENB 003 selectively targets and binds to ETBR expressed on tumor cells. This prevents ETBR-mediated signaling and may abrogate the immunosuppressive tumor microenvironment (TME), may enhance a T-cell mediated anti-tumor immune response and may inhibit proliferation of ETBR-expressing tumor cells. ETBR, a G-protein coupled receptor, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis. It also plays a role in tumor immunosuppression and blocks T-cell trafficking.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vodudeutentan Sodium","termGroup":"PT","termSource":"NCI"},{"termName":"ENB 003","termGroup":"CN","termSource":"NCI"},{"termName":"ENB-003","termGroup":"CN","termSource":"NCI"},{"termName":"ENB003","termGroup":"CN","termSource":"NCI"},{"termName":"Endothelin B Receptor Blocker ENB 003","termGroup":"SY","termSource":"NCI"},{"termName":"ETBR Blocker ENB 003","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2364572-10-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"AAY8R26VDX"},{"name":"Maps_To","value":"Endothelin B Receptor Blocker ENB 003"},{"name":"NCI_Drug_Dictionary_ID","value":"802784"},{"name":"NCI_META_CUI","value":"CL1412807"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802784"},{"name":"PDQ_Open_Trial_Search_ID","value":"802784"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172990":{"preferredName":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240","code":"C172990","definitions":[{"definition":"A preparation of allogeneic, off-the-shelf (OTS) red blood cells (RBCs) engineered to express both the co-stimulatory molecule tumor necrosis factor ligand superfamily (TNFSF) member 9 (TNFSF9; 4-1BBL) and a fusion protein composed of the trans-presented cytokine interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) (IL-15TP) with potential modulating and antineoplastic activities. CD34+ hematopoietic precursor cells (HPC) are collected by apheresis from a healthy O negative donor, purified, and engineered with a lentiviral vector to express 4-1BBL and IL-15TP. The cells are then further expanded and differentiated until the nucleus is ejected, resulting in a mature reticulocyte. Upon administration of the engineered red blood cells co-expressing 4-1BBL and IL-15TP RTX-240, the RBCs express both 4-1BBL and IL-15TP on their cell surfaces. 4-1BBL and IL-15TP bind to and subsequently induce the proliferation and activation of natural killer (NK) cells and T-cells. This enhances the secretion of cytokine interferon-gamma (IFN-g) and results in the induction of an anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Red Cells Expressing 4-1BBL and IL-15TP","termGroup":"SY","termSource":"NCI"},{"termName":"Engineered RBCs Co-expressing 4-1BBL and IL-15TP RTX-240","termGroup":"SY","termSource":"NCI"},{"termName":"RTX 240","termGroup":"CN","termSource":"NCI"},{"termName":"RTX-240","termGroup":"CN","termSource":"NCI"},{"termName":"RTX240","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240"},{"name":"NCI_Drug_Dictionary_ID","value":"802047"},{"name":"NCI_META_CUI","value":"CL1406781"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802047"},{"name":"PDQ_Open_Trial_Search_ID","value":"802047"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173707":{"preferredName":"Engineered Toxin Body Targeting CD38 TAK-169","code":"C173707","definitions":[{"definition":"An engineered toxin body (ETB) containing a single chain variable fragment (scFv) from an antibody targeting the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) that is fused to a cytotoxic payload composed of the enzymatically active, de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration, the anti-CD38 scFv moiety of TAK-169 specifically targets and binds to CD38-expressing tumor cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and removes an adenine nucleobase from the 28S RNA component of the 60S ribosomal subunit.of ribosomes This prevents ribosome activity,  This inhibits protein synthesis and leads to apoptosis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineered Toxin Body Targeting CD38 TAK-169","termGroup":"PT","termSource":"NCI"},{"termName":"CD38-targeted ETB TAK-169","termGroup":"SY","termSource":"NCI"},{"termName":"ETB Targeting CD38 TAK-169","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 169","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-169","termGroup":"CN","termSource":"NCI"},{"termName":"TAK169","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineered Toxin Body Targeting CD38 TAK-169"},{"name":"NCI_Drug_Dictionary_ID","value":"802255"},{"name":"NCI_META_CUI","value":"CL1407530"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802255"},{"name":"PDQ_Open_Trial_Search_ID","value":"802255"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174460":{"preferredName":"EP2/EP4 Antagonist TPST-1495","code":"C174460","definitions":[{"definition":"An orally bioavailable, dual antagonist of the human prostaglandin E2 receptor subtypes 2 (EP2) and 4 (EP4), with potential immunomodulating and antineoplastic activities. Upon oral administration, the EP2/EP4 antagonist TPST-1495 selectively targets and binds to EP2 and EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP2 and EP4. This prevents the activation of EP2 and EP4, and inhibits PGE2-EP2/EP4-mediated signaling. This inhibits PGE2-driven immune suppression by preventing the PGE2-mediated inhibition of anti-tumor immune effector cells in the tumor microenvironment (TME), such as natural killer (NK) cells, T-lymphocytes, dendritic cells (DCs) and M1 macrophages, and blocking the PGE2-mediated increase in suppressive immune cells, such as myeloid derived suppressor cells (MDSCs), M2 macrophages, and regulatory T cells (Tregs). This inhibits the proliferation of tumor cells in which the PGE2-EP2/4 signaling pathway is over-activated. EP2 and EP4, G protein-coupled receptors (GPCRs) that are overexpressed in certain types of cancers, promote tumor cell proliferation, invasion, survival, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP2/EP4 Antagonist TPST-1495","termGroup":"PT","termSource":"NCI"},{"termName":"Dual EP2/4 Antagonist TPST-1495","termGroup":"SY","termSource":"NCI"},{"termName":"PGE2 EP2/EP4 Receptor Antagonist TPST-1495","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 Receptor EP2/EP4 Antagonist TPST-1495","termGroup":"SY","termSource":"NCI"},{"termName":"TPST 1495","termGroup":"CN","termSource":"NCI"},{"termName":"TPST-1495","termGroup":"CN","termSource":"NCI"},{"termName":"TPST1495","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EP2/EP4 Antagonist TPST-1495"},{"name":"NCI_Drug_Dictionary_ID","value":"803116"},{"name":"NCI_META_CUI","value":"CL1412010"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803116"},{"name":"PDQ_Open_Trial_Search_ID","value":"803116"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173520":{"preferredName":"EP4 Antagonist INV-1120","code":"C173520","definitions":[{"definition":"A small molecule and antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist INV-1120 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EP4 Antagonist INV-1120","termGroup":"PT","termSource":"NCI"},{"termName":"EP4 Receptor Antagonist INV-1120","termGroup":"SY","termSource":"NCI"},{"termName":"INV 1120","termGroup":"CN","termSource":"NCI"},{"termName":"INV-1120","termGroup":"CN","termSource":"NCI"},{"termName":"INV1120","termGroup":"CN","termSource":"NCI"},{"termName":"PGE2 Receptor Antagonist INV-1120","termGroup":"SY","termSource":"NCI"},{"termName":"Prostaglandin E2 Receptor Antagonist INV-1120","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EP4 Antagonist INV-1120"},{"name":"NCI_Drug_Dictionary_ID","value":"802232"},{"name":"NCI_META_CUI","value":"CL1407506"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802232"},{"name":"PDQ_Open_Trial_Search_ID","value":"802232"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171425":{"preferredName":"EphA2-targeting Bicycle Toxin Conjugate BT5528","code":"C171425","definitions":[{"definition":"A bicyclic peptide targeting Ephrin receptor A2 (EphA2) and conjugated, through an inert sarcosine spacer chain and a valine-citrulline cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon administration of the EphA2-targeting bicycle toxin conjugate BT5528, this agent targets and binds to EphA2-expressing tumor cells. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAE binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types. EphA2 expression is associated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EphA2-targeting Bicycle Toxin Conjugate BT5528","termGroup":"PT","termSource":"NCI"},{"termName":"Bicycle BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"Bicycle Toxin Conjugate-targeting EphA2 BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"Bicyclic Peptide Conjugate BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"BT 5528","termGroup":"CN","termSource":"NCI"},{"termName":"BT-5528","termGroup":"CN","termSource":"NCI"},{"termName":"BT5528","termGroup":"CN","termSource":"NCI"},{"termName":"BTC BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"EphA2-targeting BTC BT5528","termGroup":"SY","termSource":"NCI"},{"termName":"EphA2-targeting-MMAE Bicycle Toxin BT5528","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EphA2-targeting Bicycle Toxin Conjugate BT5528"},{"name":"NCI_Drug_Dictionary_ID","value":"801972"},{"name":"NCI_META_CUI","value":"CL1405523"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801972"},{"name":"PDQ_Open_Trial_Search_ID","value":"801972"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172805":{"preferredName":"ERK1/2 Inhibitor HH2710","code":"C172805","definitions":[{"definition":"An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERK1/2 inhibitor HH2710 specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor HH2710","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor HH2710","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor HH2710","termGroup":"SY","termSource":"NCI"},{"termName":"HH 2710","termGroup":"CN","termSource":"NCI"},{"termName":"HH-2710","termGroup":"CN","termSource":"NCI"},{"termName":"HH2710","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor HH2710"},{"name":"NCI_Drug_Dictionary_ID","value":"802029"},{"name":"NCI_META_CUI","value":"CL1406865"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802029"},{"name":"PDQ_Open_Trial_Search_ID","value":"802029"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174203":{"preferredName":"ERK1/2 Inhibitor JSI-1187","code":"C174203","definitions":[{"definition":"An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERK1/2 inhibitor JSI-1187 specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ERK1/2 Inhibitor JSI-1187","termGroup":"PT","termSource":"NCI"},{"termName":"ERK Inhibitor JSI-1187","termGroup":"SY","termSource":"NCI"},{"termName":"Extracellular Signal-regulated Kinase 1/2 Inhibitor JSI-1187","termGroup":"SY","termSource":"NCI"},{"termName":"JSI 1187","termGroup":"CN","termSource":"NCI"},{"termName":"JSI-1187","termGroup":"CN","termSource":"NCI"},{"termName":"JSI1187","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ERK1/2 Inhibitor JSI-1187"},{"name":"NCI_Drug_Dictionary_ID","value":"801859"},{"name":"NCI_META_CUI","value":"CL1407830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801859"},{"name":"PDQ_Open_Trial_Search_ID","value":"801859"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173523":{"preferredName":"Extended Release Metformin Hydrochloride","code":"C173523","definitions":[{"definition":"An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin, with antihyperglycemic and potential prostate-cancer protective and antineoplastic activities. Upon oral administration, metformin targets and inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. This lowers blood glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. It also reduces cyclin D1. This inhibits cancer cell proliferation. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Also, metformin reduces hyperinsulinemia which may contribute to an anti-tumor effect. Metformin may increase the prostate-specific antigen (PSA) doubling time and may lower serum PSA levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extended Release Metformin Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"ER Metformin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Extended-release Metformin Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"Glucophage XR","termGroup":"BR","termSource":"NCI"},{"termName":"Glumetza","termGroup":"BR","termSource":"NCI"},{"termName":"Metformin Hydrochloride Extended Release","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extended Release Metformin Hydrochloride"},{"name":"NCI_Drug_Dictionary_ID","value":"802233"},{"name":"NCI_META_CUI","value":"CL1407513"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802233"},{"name":"PDQ_Open_Trial_Search_ID","value":"802233"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173698":{"preferredName":"EZH1/2 Inhibitor HH2853","code":"C173698","definitions":[{"definition":"An orally bioavailable inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, EZH1/2 inhibitor HH2853 inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"EZH1/2 Inhibitor HH2853","termGroup":"PT","termSource":"NCI"},{"termName":"EZH1 and EZH2 Inhibitor HH2853","termGroup":"SY","termSource":"NCI"},{"termName":"HH 2853","termGroup":"CN","termSource":"NCI"},{"termName":"HH-2853","termGroup":"CN","termSource":"NCI"},{"termName":"HH2853","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"EZH1/2 Inhibitor HH2853"},{"name":"NCI_Drug_Dictionary_ID","value":"802064"},{"name":"NCI_META_CUI","value":"CL1407522"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802064"},{"name":"PDQ_Open_Trial_Search_ID","value":"802064"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167347":{"preferredName":"Tulmimetostat","code":"C167347","definitions":[{"definition":"An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, tulmimetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tulmimetostat","termGroup":"PT","termSource":"NCI"},{"termName":"1,3-Benzodioxole-5-carboxamide, 7-chloro-N-((1,2-dihydro-6-methyl-4-(methylthio)-2-oxo-3-pyridinyl)methyl)-2-(trans-4-(3-methoxy-1-azetidinyl)cyclohexyl)-2,4-dimethyl-, (2R)-","termGroup":"SN","termSource":"NCI"},{"termName":"CPI 0209","termGroup":"CN","termSource":"NCI"},{"termName":"CPI-0209","termGroup":"CN","termSource":"NCI"},{"termName":"CPI0209","termGroup":"CN","termSource":"NCI"},{"termName":"EZH2 Inhibitor CPI-0209","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2567686-02-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"OUQ4N85Z0B"},{"name":"Maps_To","value":"EZH2 inhibitor CPI-0209"},{"name":"NCI_Drug_Dictionary_ID","value":"800217"},{"name":"NCI_META_CUI","value":"CL972321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800217"},{"name":"PDQ_Open_Trial_Search_ID","value":"800217"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172193":{"preferredName":"FAK/ALK/ROS1 Inhibitor APG-2449","code":"C172193","definitions":[{"definition":"An orally available kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and the receptor tyrosine kinase C-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon administration, ALK/FAK/ROS1 inhibitor APG-2449 selectively binds to and inhibits ALK, FAK and ROS1 kinases. The inhibition leads to disruption of ALK-, FAK- and ROS1-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and ROS1-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAK/ALK/ROS1 Inhibitor APG-2449","termGroup":"PT","termSource":"NCI"},{"termName":"APG 2449","termGroup":"CN","termSource":"NCI"},{"termName":"APG-2449","termGroup":"CN","termSource":"NCI"},{"termName":"APG2449","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8L976E3N4N"},{"name":"Maps_To","value":"FAK/ALK/ROS1 Inhibitor APG-2449"},{"name":"NCI_Drug_Dictionary_ID","value":"801583"},{"name":"NCI_META_CUI","value":"CL1406284"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801583"},{"name":"PDQ_Open_Trial_Search_ID","value":"801583"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170894":{"preferredName":"FAP/4-1BB-targeting DARPin MP0310","code":"C170894","definitions":[{"definition":"A designed ankyrin repeat proteins (DARPin)-based agent targeting the tumor-associated protein fibroblast  activation protein (FAP) and the T-cell co-stimulatory immune receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunomodulating and antineoplastic activities. Upon administration, the FAP/4-1BB-targeting DARPin MP0310 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer associated fibroblasts in the majority of solid tumors. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAP/4-1BB-targeting DARPin MP0310","termGroup":"PT","termSource":"NCI"},{"termName":"AMG 506","termGroup":"CN","termSource":"NCI"},{"termName":"FAP x 4-1BB-targeting DARPin MP0310","termGroup":"SY","termSource":"NCI"},{"termName":"FAP/4-1BB-targeting Designed Ankyrin Repeat Protein MP0310","termGroup":"SY","termSource":"NCI"},{"termName":"MP 0310","termGroup":"CN","termSource":"NCI"},{"termName":"MP-0310","termGroup":"CN","termSource":"NCI"},{"termName":"MP0310","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FAP/4-1BB-targeting DARPin MP0310"},{"name":"NCI_Drug_Dictionary_ID","value":"800803"},{"name":"NCI_META_CUI","value":"CL1383054"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800803"},{"name":"PDQ_Open_Trial_Search_ID","value":"800803"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175490":{"preferredName":"FAP/4-1BB-targeting Fusion Protein RO7122290","code":"C175490","definitions":[{"definition":"A bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. Upon administration, the FAP/4-1BB-targeting fusion protein RO7122290 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer-associated fibroblasts in the majority of solid tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FAP/4-1BB-targeting Fusion Protein RO7122290","termGroup":"PT","termSource":"NCI"},{"termName":"RO 7122290","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7122290","termGroup":"CN","termSource":"NCI"},{"termName":"RO7122290","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FAP/4-1BB-targeting Fusion Protein RO7122290"},{"name":"NCI_Drug_Dictionary_ID","value":"803283"},{"name":"NCI_META_CUI","value":"CL1412832"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803283"},{"name":"PDQ_Open_Trial_Search_ID","value":"803283"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167326":{"preferredName":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells","code":"C167326","definitions":[{"definition":"A donor graft derived from allogeneic filgrastim (granulocyte-colony stimulating factor; G-CSF)-mobilized peripheral blood cells (MPBC) that have been incubated with the recombinant human Fas ligand (FasL) APO010 ex vivo, and that can potentially be used for immune reconstitution purposes. The incubation of the hematopoietic stem cell graft with the apoptotic mediator Fas ligand (FasL) selectively induces apoptosis of mature T-cells which express high levels of Fas receptor, such as T stem cell memory (TSCM), T central memory (TCM), and T effector memory (TEM) cells and the pro-inflammatory T-helper cells (Th) Th1 and Th17 subsets while sparing CD34-positive stem and progenitor cells. Upon washing and further ex vivo preparations, and upon allogeneic hematopoietic stem cell transplantation (HSCT) with the FasL-treated allogeneic MPBCs, these cells provide hematopoietic cell recovery, preserve the graft-versus-leukemia (GvL) effects, and may prevent graft-versus-host disease (GvHD).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic Apograft Stem Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Apograft-incubated Mobilized Peripheral Blood Stem Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Apograft-treated Allogeneic MPBCs","termGroup":"SY","termSource":"NCI"},{"termName":"Apograft-treated MPBCs","termGroup":"SY","termSource":"NCI"},{"termName":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cell Product","termGroup":"SY","termSource":"NCI"},{"termName":"FasL-treated Mobilized Peripheral Blood Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells"},{"name":"NCI_META_CUI","value":"CL972303"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170762":{"preferredName":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11","code":"C170762","definitions":[{"definition":"A Fc-engineered agonistic antibody targeting the human B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, 2141-V11 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11","termGroup":"PT","termSource":"NCI"},{"termName":"2141 V-11","termGroup":"CN","termSource":"NCI"},{"termName":"2141 V11","termGroup":"CN","termSource":"NCI"},{"termName":"2141-V11","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-CD40 Agonist Antibody 2141-V11","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-CD40 Agonistic Antibody 2141-V11","termGroup":"SY","termSource":"NCI"},{"termName":"Fc-engineered Anti-CD40 Agonistic Antibody 2141-V11","termGroup":"SY","termSource":"NCI"},{"termName":"Fc-enhanced Anti-CD40 Antibody 2141-V11","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fc-engineered Anti-CD40 Agonist Antibody 2141-V11"},{"name":"NCI_Drug_Dictionary_ID","value":"800787"},{"name":"NCI_META_CUI","value":"CL1383172"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800787"},{"name":"PDQ_Open_Trial_Search_ID","value":"800787"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175469":{"preferredName":"Fenretinide Phospholipid Suspension ST-001","code":"C175469","definitions":[{"definition":"An intravenous formulation composed of a phospholipid suspension of nanoparticles containing the synthetic retinoid derivative fenretinide, with potential antineoplastic activity. Upon intravenous administration, fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in susceptible tumor cell types. Fenretinide also binds to and inhibits the activity of mammalian target of rapamycin (mTOR), which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Independent of RAR activation and mTOR inhibition, this agent may also modulate gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fenretinide Phospholipid Suspension ST-001","termGroup":"PT","termSource":"NCI"},{"termName":"nanoFenretinide ST-001","termGroup":"SY","termSource":"NCI"},{"termName":"ST 001","termGroup":"CN","termSource":"NCI"},{"termName":"ST-001","termGroup":"CN","termSource":"NCI"},{"termName":"ST001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fenretinide Phospholipid Suspension ST-001"},{"name":"NCI_Drug_Dictionary_ID","value":"802915"},{"name":"NCI_META_CUI","value":"CL1412852"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802915"},{"name":"PDQ_Open_Trial_Search_ID","value":"802915"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173964":{"preferredName":"FGFR Inhibitor CPL304110","code":"C173964","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor CPL304110 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR Inhibitor CPL304110","termGroup":"PT","termSource":"NCI"},{"termName":"CPL 304110","termGroup":"CN","termSource":"NCI"},{"termName":"CPL-304110","termGroup":"CN","termSource":"NCI"},{"termName":"CPL304110","termGroup":"CN","termSource":"NCI"},{"termName":"PG19","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR Inhibitor CPL304110"},{"name":"NCI_Drug_Dictionary_ID","value":"802158"},{"name":"NCI_META_CUI","value":"CL1407848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802158"},{"name":"PDQ_Open_Trial_Search_ID","value":"802158"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175460":{"preferredName":"FGFR/CSF-1R Inhibitor 3D185","code":"C175460","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon administration, FGFR/CSF-1R inhibitor 3D185 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-mediated signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. 3D185 also targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FGFR/CSF-1R Inhibitor 3D185","termGroup":"PT","termSource":"NCI"},{"termName":"3D 185","termGroup":"CN","termSource":"NCI"},{"termName":"3D-185","termGroup":"CN","termSource":"NCI"},{"termName":"3D185","termGroup":"CN","termSource":"NCI"},{"termName":"HH185","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FGFR/CSF-1R Inhibitor 3D185"},{"name":"NCI_Drug_Dictionary_ID","value":"802839"},{"name":"NCI_META_CUI","value":"CL1412860"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802839"},{"name":"PDQ_Open_Trial_Search_ID","value":"802839"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174208":{"preferredName":"Lirafugratinib","code":"C174208","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lirafugratinib","termGroup":"PT","termSource":"NCI"},{"termName":"FGFR2 Inhibitor RLY-4008","termGroup":"SY","termSource":"NCI"},{"termName":"Fibroblast Growth Factor Receptor 2 Inhibitor RLY-4008","termGroup":"SY","termSource":"NCI"},{"termName":"RLY 4008","termGroup":"CN","termSource":"NCI"},{"termName":"RLY-4008","termGroup":"CN","termSource":"NCI"},{"termName":"RLY4008","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2549174-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7HY6IMH87S"},{"name":"Maps_To","value":"FGFR2 Inhibitor RLY-4008"},{"name":"NCI_Drug_Dictionary_ID","value":"803114"},{"name":"NCI_META_CUI","value":"CL1411775"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803114"},{"name":"PDQ_Open_Trial_Search_ID","value":"803114"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174049":{"preferredName":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01","code":"C174049","definitions":[{"definition":"An oncolytic vaccinia virus (VV; VACV) genetically engineered to express an Fms-like tyrosine kinase 3 (Flt3) ligand, an antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the human pro-inflammatory cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon administration of the Flt3 ligand/anti-CTLA-4 antibody/IL-12 engineered oncolytic VV RIVAL-01, the virus preferentially targets, infects and replicates in tumor cells, causing oncolysis. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. In addition, the Flt3 ligand, the anti-ctla-4 antibody and IL-12 are expressed by the VV in the cancer cells and may activate the immune system within the tumor microenvironment (TME), thereby stimulating both innate and adaptive immune responses. The anti-CTLA-4 antibody targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation, which promotes T-cell activation. Flt3 ligand binds to the Flt3 tyrosine kinase receptor and promotes Flt3 signaling which plays an important role in expanding the population of antigen-presenting dendritic cells (DCs). IL-12 activates natural killer cells (NKs), induces the secretion of interferon-gamma and promotes CD8 cytotoxic T-cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01","termGroup":"PT","termSource":"NCI"},{"termName":"Engineered Oncolytic Vaccinia Virus TBio-6517","termGroup":"SY","termSource":"NCI"},{"termName":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic VV RIVAL-01","termGroup":"SY","termSource":"NCI"},{"termName":"RIVAL 01","termGroup":"CN","termSource":"NCI"},{"termName":"RIVAL-01","termGroup":"CN","termSource":"NCI"},{"termName":"RIVAL01","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-605","termGroup":"CN","termSource":"NCI"},{"termName":"TBio 6517","termGroup":"CN","termSource":"NCI"},{"termName":"TBio-6517","termGroup":"CN","termSource":"NCI"},{"termName":"TBio6517","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01"},{"name":"NCI_Drug_Dictionary_ID","value":"802460"},{"name":"NCI_META_CUI","value":"CL1407953"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802460"},{"name":"PDQ_Open_Trial_Search_ID","value":"802460"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C174517":{"preferredName":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279","code":"C174517","definitions":[{"definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration of FLT3/FGFR dual kinase inhibitor MAX-40279, this agent binds to and inhibits both FGFR and FLT3, including FLT3 mutant forms, which results in the inhibition of FGFR/FLT3-mediated signal transduction pathways. This inhibits proliferation in FGFR/FLT3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases, is upregulated in many tumor cell types. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. They both play key roles in cellular proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279","termGroup":"PT","termSource":"NCI"},{"termName":"FLT3/FGFR Kinase Inhibitor MAX-40279","termGroup":"SY","termSource":"NCI"},{"termName":"Max 4","termGroup":"CN","termSource":"NCI"},{"termName":"MAX 40279","termGroup":"CN","termSource":"NCI"},{"termName":"MAX-40279","termGroup":"CN","termSource":"NCI"},{"termName":"MAX-40279-01","termGroup":"CN","termSource":"NCI"},{"termName":"MAX40279","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2070931-57-4"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"DL772G3NN7"},{"name":"Maps_To","value":"FLT3/FGFR Dual Kinase Inhibitor MAX-40279"},{"name":"NCI_Drug_Dictionary_ID","value":"802333"},{"name":"NCI_META_CUI","value":"CL1412016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802333"},{"name":"PDQ_Open_Trial_Search_ID","value":"802333"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172195":{"preferredName":"FLT3/KIT/CSF1R Inhibitor NMS-03592088","code":"C172195","definitions":[{"definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), the mast/stem cell factor receptor c-Kit (SCFR; KIT) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic and immunomodulating activities Upon administration, FLT3/KIT/CSF1R inhibitor NMS-03592088 binds to and inhibits the activity of FLT3, KIT and CSF1R. This prevents FLT3, KIT and CSF1R-mediated signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3, KIT and CSF1R. In addition, NMS-03592088 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), NMS-03592088 inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemia (AML), and plays a key role in tumor cell proliferation. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FLT3/KIT/CSF1R Inhibitor NMS-03592088","termGroup":"PT","termSource":"NCI"},{"termName":"NMS 03592088","termGroup":"CN","termSource":"NCI"},{"termName":"NMS P088","termGroup":"CN","termSource":"NCI"},{"termName":"NMS-03592088","termGroup":"CN","termSource":"NCI"},{"termName":"NMS03592088","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"FLT3/KIT/CSF1R Inhibitor NMS-03592088"},{"name":"NCI_Drug_Dictionary_ID","value":"801585"},{"name":"NCI_META_CUI","value":"CL1406095"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801585"},{"name":"PDQ_Open_Trial_Search_ID","value":"801585"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C120100":{"preferredName":"Fluorine F 18 Ara-G","code":"C120100","definitions":[{"definition":"A radioconjugate composed of the guanosine analog arabinosyl guanine (Ara-G), a high-affinity substrate for both cytoplasmic deoxycytidine kinase (DCK) and mitochondrial deoxyguanosine kinase (dGK), labeled with fluorine F 18, that can potentially be used as a tracer for imaging of activated T-lymphocytes during positron emission tomography (PET). Upon administration, fluorine F 18 ara-G is taken up by and accumulates in activated T-lymphocytes with high levels of DCK and dGK. After phosphorylation by DCK and dGK, the 18F moiety can be visualized by PET imaging. Fluorine F 18 ara-G can potentially be used as an imaging agent to detect anti-tumor immune responses and to predict the therapeutic efficacy of immunotherapies. DCK and dGK, both nucleoside salvage pathway enzymes, are overexpressed in activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fluorine F 18 Ara-G","termGroup":"PT","termSource":"NCI"},{"termName":"(18F)F-Arag","termGroup":"SY","termSource":"NCI"},{"termName":"18F-F-Ara-G","termGroup":"SY","termSource":"NCI"},{"termName":"2'-Deoxy-2'-[18F]Fluoro-9-beta-D-arabinofuranosylguanine","termGroup":"SN","termSource":"NCI"},{"termName":"2-Amino-9-((2R,3S,4R,5R)-3-fluoranyl-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6-one","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]-AraG","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]F-ara-G","termGroup":"SY","termSource":"NCI"},{"termName":"[18F]F-AraG","termGroup":"SY","termSource":"NCI"},{"termName":"F-ARAG F-18","termGroup":"SY","termSource":"NCI"},{"termName":"VisAcT","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1268848-88-9"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"X96PT3B08G"},{"name":"Maps_To","value":"Fluorine F 18 Ara-G"},{"name":"NCI_Drug_Dictionary_ID","value":"767684"},{"name":"PDQ_Closed_Trial_Search_ID","value":"767684"},{"name":"PDQ_Open_Trial_Search_ID","value":"767684"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C3896947"}]}}{"C175475":{"preferredName":"Foritinib Succinate","code":"C175475","definitions":[{"definition":"The succinate salt form of foritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, foritinib targets, binds to and inhibits the activity of ALK and ROS1, which leads to the disruption of ALK- and ROS1-mediated signaling and the inhibition of cell growth in ALK- and ROS1-expressing tumor cells. In addition, foritinib is able to cross the blood brain barrier. ALK and ROS1, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Foritinib Succinate","termGroup":"PT","termSource":"NCI"},{"termName":"SAF 189s","termGroup":"CN","termSource":"NCI"},{"termName":"SAF-189s","termGroup":"CN","termSource":"NCI"},{"termName":"SAF189s","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Foritinib Succinate"},{"name":"NCI_Drug_Dictionary_ID","value":"802918"},{"name":"NCI_META_CUI","value":"CL1412842"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802918"},{"name":"PDQ_Open_Trial_Search_ID","value":"802918"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165626":{"preferredName":"G Protein-coupled Estrogen Receptor Agonist LNS8801","code":"C165626","definitions":[{"definition":"An orally bioavailable selective agonist of the G protein-coupled estrogen receptor (G protein-coupled estrogen receptor 1; GPER; GPER1; GPR30), with potential immunomodulating and antineoplastic activities. Upon oral administration, LNS8801 targets, binds to and activates GPER. This activates GPER-mediated signaling and suppresses the expression of various tumor-associated genes, such as c-Myc and programmed cell death-ligand 1 (PD-L1). This leads to an inhibition of tumor cell proliferation. GPER activation may also induce immune memory. GPER is a membrane protein and a member of the G-protein coupled receptors (GPCRs) that are widely distributed in various tissues. GPER is a tumor suppressor in a wide range of cell cancer types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"G Protein-coupled Estrogen Receptor Agonist LNS8801","termGroup":"PT","termSource":"NCI"},{"termName":"GPER Agonist LNS8801","termGroup":"SY","termSource":"NCI"},{"termName":"LNS 8801","termGroup":"CN","termSource":"NCI"},{"termName":"LNS-8801","termGroup":"CN","termSource":"NCI"},{"termName":"LNS8801","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"925419-53-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TFS4QE36ZG"},{"name":"Maps_To","value":"G Protein-coupled Estrogen Receptor Agonist LNS8801"},{"name":"NCI_Drug_Dictionary_ID","value":"799991"},{"name":"NCI_META_CUI","value":"CL978801"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799991"},{"name":"PDQ_Open_Trial_Search_ID","value":"799991"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165650":{"preferredName":"Gallium-based Bone Resorption Inhibitor AP-002","code":"C165650","definitions":[{"definition":"An orally bioavailable gallium (Ga)-based small molecule agent with potential anti-bone resorption and antineoplastic activities. Upon oral administration, AP-002 selectively inhibits osteoclast differentiation and bone resorption, and may promote the growth of osteoblasts thereby improving the skeletal sequelae of bony metastases which include pain, spinal cord compression, fractures and hypercalcemia of malignancy. Additionally, AP-002 may, through an as of yet undescribed mechanism of action, directly target and kill bone tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gallium-based Bone Resorption Inhibitor AP-002","termGroup":"PT","termSource":"NCI"},{"termName":"AP 002","termGroup":"CN","termSource":"NCI"},{"termName":"AP-002","termGroup":"CN","termSource":"NCI"},{"termName":"AP002","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"14642-34-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"R3G3HB38O4"},{"name":"Maps_To","value":"Gallium-based Bone Resorption Inhibitor AP-002"},{"name":"NCI_Drug_Dictionary_ID","value":"800117"},{"name":"NCI_META_CUI","value":"CL978946"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800117"},{"name":"PDQ_Open_Trial_Search_ID","value":"800117"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172199":{"preferredName":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine","code":"C172199","definitions":[{"definition":"An orally bioavailable, immunotherapeutic vaccine composed of hydrolyzed and formulated glioblastoma multiforme (GBM) antigens and alloantigens derived from a pool of patients' cancer cells in the blood and samples of tumor tissues, with potential immunomodulating and antineoplastic activities. Upon oral administration of the GBM antigens and alloantigens immunotherapeutic vaccine, the GBM antigens and alloantigens may stimulate the host immune system via antigen-presenting cells (APCs) lining the gut to mount an immune response against tumor cells expressing these antigens. This may lead to tumor cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"V-Boost","termGroup":"BR","termSource":"NCI"},{"termName":"V-Boost Immunitor","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"GBM Antigens and Alloantigens Immunotherapeutic Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"801582"},{"name":"NCI_META_CUI","value":"CL1406091"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801582"},{"name":"PDQ_Open_Trial_Search_ID","value":"801582"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171371":{"preferredName":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum","code":"C171371","definitions":[{"definition":"A live, genetically modified probiotic bacteria Bifidobacterium longum (B. longum) engineered to deliver genetic material encoding the human pro-inflammatory transgene interleukin-12 (IL-12), with potential immunoactivating activity. Upon administration of genetically modified IL-12 transgene-encoding B. longum, the bacteria selectively colonize hypoxic tumor tissues and deliver plasmid DNA encoding the IL-12 transgene within the tumor microenvironment (TME). IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum","termGroup":"PT","termSource":"NCI"},{"termName":"bacTRL-IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"Bifidobacterium longum Encoding IL-12","termGroup":"SY","termSource":"NCI"},{"termName":"Genetically Modified IL-12 Transgene-encoding Bifidobacterium longum","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum"},{"name":"NCI_Drug_Dictionary_ID","value":"801308"},{"name":"NCI_META_CUI","value":"CL1405492"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801308"},{"name":"PDQ_Open_Trial_Search_ID","value":"801308"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C148486":{"preferredName":"Glofitamab","code":"C148486","definitions":[{"definition":"A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glofitamab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859","termGroup":"SY","termSource":"NCI"},{"termName":"Columvi","termGroup":"BR","termSource":"NCI"},{"termName":"Glofitamab-gxbm","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7082859","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7082859","termGroup":"CN","termSource":"NCI"},{"termName":"RO7082859","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy."},{"name":"CAS_Registry","value":"2229047-91-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"06P3KLK2J8"},{"name":"Maps_To","value":"Glofitamab"},{"name":"NCI_Drug_Dictionary_ID","value":"792571"},{"name":"NCI_META_CUI","value":"CL551055"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792571"},{"name":"PDQ_Open_Trial_Search_ID","value":"792571"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165612":{"preferredName":"Glutaminase-1 Inhibitor IACS-6274","code":"C165612","definitions":[{"definition":"An orally bioavailable inhibitor of the metabolic enzyme glutaminase-1 (GLS1), with potential antineoplastic and immunostimulating activities. Upon oral administration, IACS-6274 selectively targets, binds to and inhibits human GLS1, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Glutaminase-1 Inhibitor IACS-6274","termGroup":"PT","termSource":"NCI"},{"termName":"GLS1 Inhibitor IACS-6274","termGroup":"SY","termSource":"NCI"},{"termName":"IACS 6274","termGroup":"CN","termSource":"NCI"},{"termName":"IACS-6274","termGroup":"CN","termSource":"NCI"},{"termName":"IACS6274","termGroup":"CN","termSource":"NCI"},{"termName":"IPN 60090","termGroup":"CN","termSource":"NCI"},{"termName":"IPN-60090","termGroup":"CN","termSource":"NCI"},{"termName":"IPN60090","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1874231-60-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O6ZT4D087I"},{"name":"Maps_To","value":"Glutaminase Inhibitor IPN60090"},{"name":"NCI_Drug_Dictionary_ID","value":"799989"},{"name":"NCI_META_CUI","value":"CL978797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799989"},{"name":"PDQ_Open_Trial_Search_ID","value":"799989"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174038":{"preferredName":"Sirpiglenastat","code":"C174038","definitions":[{"definition":"A broad acting glutamine antagonist, with potential immunomodulatory and antineoplastic activities. Upon administration, DON (6-Diazo-5-oxo-L-norleucine), the active moiety of sirpiglenastat, irreversibly inhibits multiple enzymes involved in glutamine metabolism. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors rely heavily on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, blocking glutamine metabolism leads to the accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon tumor cell death. As glutamine is essential for T-cell generation, DON may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells. The conversion of sirpiglenastat to the active moiety DON occurs primarily in tumor cells, allowing glutamine metabolism in healthy cells which may lessen adverse effects.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sirpiglenastat","termGroup":"PT","termSource":"NCI"},{"termName":"(S)-Isopropyl 2-((S)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate","termGroup":"SY","termSource":"NCI"},{"termName":"DRP 104","termGroup":"CN","termSource":"NCI"},{"termName":"DRP-104","termGroup":"CN","termSource":"NCI"},{"termName":"DRP104","termGroup":"CN","termSource":"NCI"},{"termName":"Glutamine Antagonist DRP-104","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2079939-05-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9GGE6A0ZMK"},{"name":"Maps_To","value":"Glutamine Antagonist DRP-104"},{"name":"NCI_Drug_Dictionary_ID","value":"802458"},{"name":"NCI_META_CUI","value":"CL1407906"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802458"},{"name":"PDQ_Open_Trial_Search_ID","value":"802458"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174039":{"preferredName":"HER2 Inhibitor DZD1516","code":"C174039","definitions":[{"definition":"An orally bioavailable, blood brain barrier (BBB) penetrable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor DZD1516 selectively binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Inhibitor DZD1516","termGroup":"PT","termSource":"NCI"},{"termName":"DZD 1516","termGroup":"CN","termSource":"NCI"},{"termName":"DZD-1516","termGroup":"CN","termSource":"NCI"},{"termName":"DZD1516","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HER2 Inhibitor DZD1516"},{"name":"NCI_Drug_Dictionary_ID","value":"802459"},{"name":"NCI_META_CUI","value":"CL1407916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802459"},{"name":"PDQ_Open_Trial_Search_ID","value":"802459"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172279":{"preferredName":"HER2 Tri-specific Natural Killer Cell Engager DF1001","code":"C172279","definitions":[{"definition":"An engineered molecule based on tri-specific natural killer (NK) cell engager therapies (TriNKET) that is directed against human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential immunostimulating and antineoplastic activities. Upon administration, HER2 tri-specific NK cell engager DF1001 targets and binds to HER2 on tumor cells and simultaneously binds to NK cells, thereby bringing HER2-expressing tumor cells and NK cells together, which stimulates the NK cells and results in the selective NK cell-mediated tumor cell lysis of HER2-expressing tumor cells. The binding of HER2-expressing tumor cells and NK cells may also lead to the activation of T-cells and B-cells, potentiating the immune response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HER2 Tri-specific Natural Killer Cell Engager DF1001","termGroup":"PT","termSource":"NCI"},{"termName":"DF 1001","termGroup":"CN","termSource":"NCI"},{"termName":"DF-1001","termGroup":"CN","termSource":"NCI"},{"termName":"DF1001","termGroup":"CN","termSource":"NCI"},{"termName":"HER2 Tri-specific NK Cell Engager DF1001","termGroup":"SY","termSource":"NCI"},{"termName":"Tri-specific Natural Killer Cell Engager DF1001","termGroup":"SY","termSource":"NCI"},{"termName":"Tri-specific NK Cell Engager DF1001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"7DGR11S93X"},{"name":"Maps_To","value":"HER2 Tri-specific Natural Killer Cell Engager DF1001"},{"name":"NCI_Drug_Dictionary_ID","value":"801897"},{"name":"NCI_META_CUI","value":"CL1406166"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801897"},{"name":"PDQ_Open_Trial_Search_ID","value":"801897"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174010":{"preferredName":"Pertuzumab Zuvotolimod","code":"C174010","definitions":[{"definition":"An immunotherapeutic composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a Toll-like receptor 8 (TLR8; CD288) agonist, with potential immunostimulating and antineoplastic activities. Upon intravenous administration pertuzumab zuvotolimod, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells, thereby localizing the TLR8 agonist directly to the tumor site. In turn, the TLR8 agonist moiety binds to TLR8 expressed on myeloid cells within the tumor microenvironment (TME). This activates myeloid cells, including tumor-associated macrophages (TAMs), myeloid cell-derived suppressive cells (MDSCs), and conventional dendritic cells (cDCs). This may lead to the activation of nuclear factor NF-kappa-B, the production of pro-inflammatory cytokines and chemokines, macrophage-induced tumor cell killing, inflammasome activation, activation of cytolytic natural killer (NK) cells and neutrophils, and the induction of a Th1-weighted anti-tumor immune response. It also reverses the suppression of senescent naive and tumor-specific T-cells, and enhances the anti-tumor cytotoxic T-lymphocyte (CTL) immune response. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pertuzumab Zuvotolimod","termGroup":"PT","termSource":"NCI"},{"termName":"HER2-directed TLR8 Agonist SBT6050","termGroup":"SY","termSource":"NCI"},{"termName":"HER2-directed TLR8 ImmunoTAC SBT6050","termGroup":"SY","termSource":"NCI"},{"termName":"ImmunoTAC SBT6050","termGroup":"SY","termSource":"NCI"},{"termName":"SBT 6050","termGroup":"CN","termSource":"NCI"},{"termName":"SBT-6050","termGroup":"CN","termSource":"NCI"},{"termName":"SBT6050","termGroup":"CN","termSource":"NCI"},{"termName":"TLR8 Agonist-HER2-directed Monoclonal Antibody Conjugate SBT6050","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2500674-05-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"H4LR6V1LWG"},{"name":"Maps_To","value":"HER2-directed TLR8 Agonist SBT6050"},{"name":"NCI_Drug_Dictionary_ID","value":"802452"},{"name":"NCI_META_CUI","value":"CL1407923"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802452"},{"name":"PDQ_Open_Trial_Search_ID","value":"802452"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170918":{"preferredName":"Zifcasiran","code":"C170918","definitions":[{"definition":"An RNA interference (RNAi) targeting hypoxia-inducible factor 2alpha (HIF-2a), with potential antineoplastic activity. Upon administration, zifcasiran binds to and neutralizes mRNA HIF2a, thereby preventing the production of HIF2a. This may lead to an inhibition of tumor cell proliferation. HIF2a, overexpressed in certain cell types, plays a key role in proliferation, progression and metastasis of tumors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zifcasiran","termGroup":"PT","termSource":"NCI"},{"termName":"ADS-007","termGroup":"CN","termSource":"NCI"},{"termName":"ARO HIF2","termGroup":"CN","termSource":"NCI"},{"termName":"ARO-HIF2","termGroup":"CN","termSource":"NCI"},{"termName":"AROHIF2","termGroup":"CN","termSource":"NCI"},{"termName":"HIF2a RNAi ARO-HIF2","termGroup":"SY","termSource":"NCI"},{"termName":"RNA Interference Therapeutic ARO-HIF2","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted RNAi Molecule ARO-HIF2","termGroup":"SY","termSource":"NCI"},{"termName":"TRiM ARO-HIF2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2437257-11-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"5G6HL9K2G4"},{"name":"Maps_To","value":"HIF2a RNAi ARO-HIF2"},{"name":"NCI_Drug_Dictionary_ID","value":"801198"},{"name":"NCI_META_CUI","value":"CL1383073"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801198"},{"name":"PDQ_Open_Trial_Search_ID","value":"801198"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173149":{"preferredName":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202","code":"C173149","definitions":[{"definition":"A cancer vaccine consisting of replication-attenuated arenavirus encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV 16 E6/E7-encoding arenavirus vaccine HB-202 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202","termGroup":"PT","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine HB-202","termGroup":"SY","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine-expressing HPV 16 E7E6 HB-202","termGroup":"SY","termSource":"NCI"},{"termName":"HB 202","termGroup":"CN","termSource":"NCI"},{"termName":"HB-202","termGroup":"CN","termSource":"NCI"},{"termName":"HB-202 Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HB202","termGroup":"CN","termSource":"NCI"},{"termName":"TT2-E7E6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"O4E1IFK37Y"},{"name":"Maps_To","value":"HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202"},{"name":"NCI_Drug_Dictionary_ID","value":"802056"},{"name":"NCI_META_CUI","value":"CL1407016"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802056"},{"name":"PDQ_Open_Trial_Search_ID","value":"802056"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167349":{"preferredName":"HPV E6/E7-encoding Arenavirus Vaccine HB-201","code":"C167349","definitions":[{"definition":"A cancer vaccine consisting of a replication-attenuated arenavirus lymphocytic choriomeningitis virus (LCMV) encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV E6/E7-encoding arenavirus vaccine HB-201 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV E6/E7-encoding Arenavirus Vaccine HB-201","termGroup":"PT","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine HB-201","termGroup":"SY","termSource":"NCI"},{"termName":"Arenavirus Vector-based Vaccine-expressing HPV 16 E7E6 HB-201","termGroup":"SY","termSource":"NCI"},{"termName":"HB 201","termGroup":"CN","termSource":"NCI"},{"termName":"HB-201","termGroup":"CN","termSource":"NCI"},{"termName":"HB-201 Cancer Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"HB201","termGroup":"CN","termSource":"NCI"},{"termName":"TT1-E7E6","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4B96SSC9KJ"},{"name":"Maps_To","value":"HPV E6/E7-encoding Arenavirus Vaccine HB-201"},{"name":"NCI_Drug_Dictionary_ID","value":"800472"},{"name":"NCI_META_CUI","value":"CL972322"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800472"},{"name":"PDQ_Open_Trial_Search_ID","value":"800472"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173718":{"preferredName":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107","code":"C173718","definitions":[{"definition":"A DNA vaccine consisting of plasmids encoding E6 and E7 genes of human papilloma virus subtype 6 (HPV-6) and 11 (HPV-11), with potential immunostimulating and antineoplastic activities. Upon administration via intramuscular electroporation, the HPV-6/11-targeted DNA plasmid vaccine INO-3107 expresses the HPV-6/11 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing HPV6 and/or HPV11 E6 and E7 proteins, resulting in tumor cell lysis. HPV-6/11 infections are associated with aerodigestive malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107","termGroup":"PT","termSource":"NCI"},{"termName":"HPV-6/11-targeting Immunotherapeutic Vaccine INO-3107","termGroup":"SY","termSource":"NCI"},{"termName":"HPV6/11-targeted DNA Plasmid Immunotherapeutic INO-3107","termGroup":"SY","termSource":"NCI"},{"termName":"INO 3107","termGroup":"CN","termSource":"NCI"},{"termName":"INO-3107","termGroup":"CN","termSource":"NCI"},{"termName":"INO3107","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HPV6/11-targeted DNA Plasmid Vaccine INO-3107"},{"name":"NCI_Drug_Dictionary_ID","value":"802021"},{"name":"NCI_META_CUI","value":"CL1407562"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802021"},{"name":"PDQ_Open_Trial_Search_ID","value":"802021"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173550":{"preferredName":"Hsp90 Inhibitor TQB3474","code":"C173550","definitions":[{"definition":"An inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration, Hsp90 inhibitor TQB3474 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90 Inhibitor TQB3474","termGroup":"PT","termSource":"NCI"},{"termName":"Heat Shock Protein 90 Inhibitor TQB3474","termGroup":"SY","termSource":"NCI"},{"termName":"TQB 3474","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3474","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3474","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hsp90 Inhibitor TQB3474"},{"name":"NCI_Drug_Dictionary_ID","value":"801900"},{"name":"NCI_META_CUI","value":"CL1407320"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801900"},{"name":"PDQ_Open_Trial_Search_ID","value":"801900"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172190":{"preferredName":"Hsp90-targeted Photosensitizer HS-201","code":"C172190","definitions":[{"definition":"A conjugate consisting of a heat shock protein 90 (Hsp90) inhibitor connected via a linker to verteporfin, a photosensitizing agent, with potential imaging, photodynamic and antineoplastic activities. Upon administration, the Hsp90 inhibitor moiety of HS-201 selectively binds to the Hsp90 ATP binding domain in tumor cells and HS-201 accumulates in tumor cells. The verteporfin moiety of HS-201 allows for visualization and photodynamic therapy of the tumors. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins. Verteporfin is a synthetic photosensitizer with photodynamic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hsp90-targeted Photosensitizer HS-201","termGroup":"PT","termSource":"NCI"},{"termName":"HS 201","termGroup":"CN","termSource":"NCI"},{"termName":"HS-201","termGroup":"CN","termSource":"NCI"},{"termName":"HS201","termGroup":"CN","termSource":"NCI"},{"termName":"Hsp90 Inhibitor-linked Verteporfin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hsp90-targeted Photosensitizer HS-201"},{"name":"NCI_Drug_Dictionary_ID","value":"801530"},{"name":"NCI_META_CUI","value":"CL1406287"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801530"},{"name":"PDQ_Open_Trial_Search_ID","value":"801530"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173339":{"preferredName":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab","code":"C173339","definitions":[{"definition":"A ready-to-use fixed-dose combination of pertuzumab and trastuzumab, both recombinant humanized monoclonal antibodies directed against the tyrosine kinase receptor (TKR) human epidermal growth factor receptor 2 (HER2; HER-2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-zzxf, a biosimilar of the recombinant form of the naturally occurring endoglycosidase hyaluronidase, with antineoplastic activity that can be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-zzxf temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows both pertuzumab and trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of both antibodies into the bloodstream. Pertuzumab targets and binds to the extracellular dimerization domain (subdomain II) of HER2 and blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4. This inhibits ligand-initiated intracellular signaling and prevents the activation of the mitogen-activated protein (MAP) kinase and the phosphoinositide 3-kinase (PI3K) signaling pathways, leading to growth arrest and apoptosis in HER2-overexpressing tumor cells, respectively. Trastuzumab targets and binds to subdomain IV of HER2 and inhibits ligand-independent, HER2 mediated cell proliferation and inhibits the PI3K signaling pathway in HER2-overexpressing tumor cells. Both antibodies induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab","termGroup":"PT","termSource":"NCI"},{"termName":"Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","termGroup":"SY","termSource":"NCI"},{"termName":"Pertuzumab/Trastuzumab/Hyaluronidase-zzxf","termGroup":"SY","termSource":"NCI"},{"termName":"Phesgo","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"HER2 overexpressing breast cancer"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"Maps_To","value":"Hyaluronidase-zzxf/Pertuzumab/Trastuzumab"},{"name":"NCI_Drug_Dictionary_ID","value":"801876"},{"name":"NCI_META_CUI","value":"CL1636756"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801876"},{"name":"PDQ_Open_Trial_Search_ID","value":"801876"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175542":{"preferredName":"Crelosidenib","code":"C175542","definitions":[{"definition":"An orally available inhibitor of mutant form of the isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including the substitution mutation at arginine (R) in position 132, IDH1(R132), with potential antineoplastic activity. Upon oral administration, crelosidenib specifically and covalently binds to and modifies a single cysteine (Cys269) in the allosteric binding pocket of mutant forms of IDH1, thereby inactivating IDH1. This inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This depletes 2-HG levels, prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing mutant forms of IDH1. In addition, crelosidenib has the ability to cross the blood-brain barrier (BBB). IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crelosidenib","termGroup":"PT","termSource":"NCI"},{"termName":"IDH1 Inhibitor LY3410738","termGroup":"SY","termSource":"NCI"},{"termName":"IDH1 Mutant Inhibitor LY3410738","termGroup":"SY","termSource":"NCI"},{"termName":"LY 3410738","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3410738","termGroup":"CN","termSource":"NCI"},{"termName":"LY3410738","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2230263-60-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"A4DU555RMD"},{"name":"Maps_To","value":"IDH1 Mutant Inhibitor LY3410738"},{"name":"NCI_Drug_Dictionary_ID","value":"803295"},{"name":"NCI_META_CUI","value":"CL1412892"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803295"},{"name":"PDQ_Open_Trial_Search_ID","value":"803295"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171343":{"preferredName":"IDO/TDO Inhibitor LY-01013","code":"C171343","definitions":[{"definition":"An orally bioavailable, small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor LY-01013 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, LY-01013 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO/TDO Inhibitor LY-01013","termGroup":"PT","termSource":"NCI"},{"termName":"LPM 3480226","termGroup":"CN","termSource":"NCI"},{"termName":"LPM-3480226","termGroup":"CN","termSource":"NCI"},{"termName":"LPM3480226","termGroup":"CN","termSource":"NCI"},{"termName":"LY 01013","termGroup":"CN","termSource":"NCI"},{"termName":"LY-01013","termGroup":"CN","termSource":"NCI"},{"termName":"LY01013","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO/TDO Inhibitor LY-01013"},{"name":"NCI_Drug_Dictionary_ID","value":"801300"},{"name":"NCI_META_CUI","value":"CL1405462"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801300"},{"name":"PDQ_Open_Trial_Search_ID","value":"801300"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168808":{"preferredName":"IDO1/TDO2 Inhibitor M4112","code":"C168808","definitions":[{"definition":"An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor M4112 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (Kyn). This inhibits the IDO1/TDO2-Kyn-AhR pathway and abrogates AhR activation. This prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME), and may restore the immune response by stimulating a cytotoxic T-lymphocyte (CTL) immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types and plays a key role in immunosuppression. Its expression is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDO1/TDO2 Inhibitor M4112","termGroup":"PT","termSource":"NCI"},{"termName":"Indoleamine 2,3-Dioxygenase-1/Tryptophan 2,3-Dioxygenase 2 Inhibitor M4112","termGroup":"SY","termSource":"NCI"},{"termName":"M 4112","termGroup":"CN","termSource":"NCI"},{"termName":"M-4112","termGroup":"CN","termSource":"NCI"},{"termName":"M4112","termGroup":"CN","termSource":"NCI"},{"termName":"MS201408-0005","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDO1/TDO2 Inhibitor M4112"},{"name":"NCI_Drug_Dictionary_ID","value":"800701"},{"name":"NCI_META_CUI","value":"CL1378711"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800701"},{"name":"PDQ_Open_Trial_Search_ID","value":"800701"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166375":{"preferredName":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000","code":"C166375","definitions":[{"definition":"An immunotherapeutic agent utilizing mRNA to encode the cytokines interleukin-12sc (IL-12sc), interleukin-15sushi (IL-15sushi), interferon alpha (IFNa) and granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based immunotherapeutic agent SAR441000, mRNA is picked up by nearby cells, translated and released into the local tumor microenvironment (TME). Secretion of these cytokines activate the immune system by promoting the activation of natural killer cells (NKs) and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in an immune-mediated destruction of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000","termGroup":"PT","termSource":"NCI"},{"termName":"BNT 131","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-131","termGroup":"CN","termSource":"NCI"},{"termName":"BNT131","termGroup":"CN","termSource":"NCI"},{"termName":"SAR 441000","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-441000","termGroup":"CN","termSource":"NCI"},{"termName":"SAR441000","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000"},{"name":"NCI_Drug_Dictionary_ID","value":"800230"},{"name":"NCI_META_CUI","value":"CL971627"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800230"},{"name":"PDQ_Open_Trial_Search_ID","value":"800230"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170893":{"preferredName":"Inactivated Oncolytic Virus Particle GEN0101","code":"C170893","definitions":[{"definition":"An inactivated, non-replicating particle of hemagglutinating virus of Japan (HVJ), an oncolytic virus of the paramyxovirus family, with potential immunostimulating and antineoplastic activities. Upon intracutaneous administration, GEN0101 targets and binds to the cytosolic nucleic acid receptor retinoic acid-inducible gene I (RIG-I). This induces RIG-I-mediated signaling and a potent innate immune response against tumor cells, leading to the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTL), and apoptosis in tumor cells. GEN0101 also activates dendritic cells (DCs) to produce cytokine interleukin-6 (IL-6), suppressing the function of regulatory T cells (Treg), a negative regulator of immune responses. The suppression of Treg activity helps maintain the induced immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inactivated Oncolytic Virus Particle GEN0101","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 0101","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-0101","termGroup":"CN","termSource":"NCI"},{"termName":"GEN0101","termGroup":"CN","termSource":"NCI"},{"termName":"HVJ-E","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated Hemagglutinating Virus of Japan Envelope GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated Hemagglutinating Virus of Japan Envelope Immunotherapy GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated HVJ Particle GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated HVJ-E GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Inactivated HVJ-E Immunotherapy GEN0101","termGroup":"SY","termSource":"NCI"},{"termName":"Non-replicating Oncolytic Virus Particle GEN0101","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Inactivated Oncolytic Virus Particle GEN0101"},{"name":"NCI_Drug_Dictionary_ID","value":"800846"},{"name":"NCI_META_CUI","value":"CL1383056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800846"},{"name":"PDQ_Open_Trial_Search_ID","value":"800846"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171392":{"preferredName":"Individualized MVA-based Vaccine TG4050","code":"C171392","definitions":[{"definition":"An off-the-shelf (OTS) individualized vaccine comprised of a modified Vaccinia virus Ankara (MVA) viral vector encoding tumor-specific neoantigens (TSNAs), with potential immunostimulatory and antineoplastic activities. Following administration of the individualized MVA-based vaccine TG4050, the neoantigens are expressed and presented to the immune system, which induces the activation of a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the patient-specific neoantigens.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Individualized MVA-based Vaccine TG4050","termGroup":"PT","termSource":"NCI"},{"termName":"MVA-Neoantigen Vaccine TG4050","termGroup":"SY","termSource":"NCI"},{"termName":"Neoantigen-expressing MVA-based Vaccine TG4050","termGroup":"SY","termSource":"NCI"},{"termName":"TG 4050","termGroup":"CN","termSource":"NCI"},{"termName":"TG-4050","termGroup":"CN","termSource":"NCI"},{"termName":"TG4050","termGroup":"CN","termSource":"NCI"},{"termName":"TG4050 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Individualized MVA-based Vaccine TG4050"},{"name":"NCI_Drug_Dictionary_ID","value":"801297"},{"name":"NCI_META_CUI","value":"CL1405501"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801297"},{"name":"PDQ_Open_Trial_Search_ID","value":"801297"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172187":{"preferredName":"iNKT Cell Agonist ABX196","code":"C172187","definitions":[{"definition":"A synthetic glycolipid agonist for natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon infusion of the iNKT cell agonist ABX196, this agent targets and binds to iNKTs, thereby activating iNKTs. In turn, iNKTs recognize CD1d-restricted lipid ligands, which are expressed on certain tumor cells, and secrete large amounts of various cytokines. This may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iNKT Cell Agonist ABX196","termGroup":"PT","termSource":"NCI"},{"termName":"ABX 196","termGroup":"CN","termSource":"NCI"},{"termName":"ABX-196","termGroup":"CN","termSource":"NCI"},{"termName":"ABX196","termGroup":"CN","termSource":"NCI"},{"termName":"Invariant NKT Cell Agonist ABX196","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1161877-58-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"SOI87F7GN2"},{"name":"Maps_To","value":"iNKT Cell Agonist ABX196"},{"name":"NCI_Drug_Dictionary_ID","value":"801520"},{"name":"NCI_META_CUI","value":"CL1406290"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801520"},{"name":"PDQ_Open_Trial_Search_ID","value":"801520"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173371":{"preferredName":"Interleukin-12-Fc Fusion Protein DF6002","code":"C173371","definitions":[{"definition":"A fusion protein composed of human interleukin-12 (IL-12) fused to a Fc fragment, with potential immunomodulatory and antineoplastic activities. Upon administration of IL-12-Fc fusion protein DF6002, the IL-12 moiety binds to the IL-12 receptor. This may activate the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-12-Fc Fusion Protein DF6002","termGroup":"PT","termSource":"NCI"},{"termName":"DF 6002","termGroup":"CN","termSource":"NCI"},{"termName":"DF-6002","termGroup":"CN","termSource":"NCI"},{"termName":"DF6002","termGroup":"CN","termSource":"NCI"},{"termName":"IL-12-Fc Fusion Protein DF6002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interleukin-12-Fc Fusion Protein DF6002"},{"name":"NCI_Drug_Dictionary_ID","value":"801838"},{"name":"NCI_META_CUI","value":"CL1407203"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801838"},{"name":"PDQ_Open_Trial_Search_ID","value":"801838"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171385":{"preferredName":"Interleukin-15 Agonist Fusion Protein SHR1501","code":"C171385","definitions":[{"definition":"A human Fc fusion protein composed of the cytokine interleukin (IL)-15 cross-linked with the high-affinity binding sushi domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activity. Upon administration, SHR-1501 activates and increases the levels of natural killer (NK) cells and memory CD8+ T-cells without stimulating regulatory T-cells (Tregs). The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. SHR1501 is more potent than unmodified IL-15 and does not require endogenous IL-15Ra for its action. The Fc moiety allows for an extended half-life of SHR-1501 while cross linking IL-15 with IL-15Ra sushi domain improves stability.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-15 Agonist Fusion Protein SHR1501","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15 Agonist Fusion Protein SHR1501","termGroup":"SY","termSource":"NCI"},{"termName":"IL-15 Super-agonist SHR1501","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SHR1501","termGroup":"SY","termSource":"NCI"},{"termName":"SHR 1501","termGroup":"CN","termSource":"NCI"},{"termName":"SHR-1501","termGroup":"CN","termSource":"NCI"},{"termName":"SHR1501","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S4NL6N7DWD"},{"name":"Maps_To","value":"Interleukin-15 Agonist Fusion Protein SHR1501"},{"name":"NCI_Drug_Dictionary_ID","value":"801247"},{"name":"NCI_META_CUI","value":"CL1405483"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801247"},{"name":"PDQ_Open_Trial_Search_ID","value":"801247"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172075":{"preferredName":"Interleukin-15 Fusion Protein BJ-001","code":"C172075","definitions":[{"definition":"A human fusion protein composed of the cytokine interleukin (IL)-15 linked with an integrins-targeting moiety, with potential antineoplastic activity. Upon subcutaneous administration, the integrins-targeting moiety of BJ-001 targets tumor cells that overexpress integrins such as alpha v beta 3 (avb3), alpha v beta 5 (avb5) and alpha v beta 6 (avb6) and the IL-15 moiety binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) cells and CD8+ T-lymphocytes. This activates and increases the levels of NK cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T- and NK cell development, activation and proliferation. Integrins are involved in tumor growth, angiogenesis, and metastasis and they are overexpressed in a variety of tumor cell types. The linkage of the two moieties may limit the effects of IL-15 to the local tumor microenvironment (TME), increasing efficacy while reducing systemic toxicities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-15 Fusion Protein BJ-001","termGroup":"PT","termSource":"NCI"},{"termName":"BJ 001","termGroup":"CN","termSource":"NCI"},{"termName":"BJ-001","termGroup":"CN","termSource":"NCI"},{"termName":"BJ001","termGroup":"CN","termSource":"NCI"},{"termName":"IL-15 Fusion Protein BJ-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interleukin-15 Fusion Protein BJ-001"},{"name":"NCI_Drug_Dictionary_ID","value":"802006"},{"name":"NCI_META_CUI","value":"CL1406211"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802006"},{"name":"PDQ_Open_Trial_Search_ID","value":"802006"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170890":{"preferredName":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306","code":"C170890","definitions":[{"definition":"An interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain, with potential antineoplastic activity. Upon administration, XmAb24306 stimulates the proliferation of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. XmAb24306 does not require endogenous IL-15Ra for its activation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306","termGroup":"PT","termSource":"NCI"},{"termName":"IL15/IL15Ra Complex-Fc Fusion Protein XmAb24306","termGroup":"SY","termSource":"NCI"},{"termName":"IL15/IL15Ra-Fc Fusion Protein XmAb24306","termGroup":"SY","termSource":"NCI"},{"termName":"RO 7310729","termGroup":"CN","termSource":"NCI"},{"termName":"RO-7310729","termGroup":"CN","termSource":"NCI"},{"termName":"RO7310729","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb 24306","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb-24306","termGroup":"CN","termSource":"NCI"},{"termName":"XmAb24306","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306"},{"name":"NCI_Drug_Dictionary_ID","value":"801195"},{"name":"NCI_META_CUI","value":"CL1383037"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801195"},{"name":"PDQ_Open_Trial_Search_ID","value":"801195"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170516":{"preferredName":"Nanrilkefusp Alfa","code":"C170516","definitions":[{"definition":"A human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activities. Upon administration, nanrilkefusp alfa activates and increases the levels of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. Nanrilkefusp alfa is more potent than unmodified IL-15 and does not require endogenous IL-15Ra for its action.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nanrilkefusp Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15/IL-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101","termGroup":"SY","termSource":"NCI"},{"termName":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SOT101","termGroup":"SY","termSource":"NCI"},{"termName":"RLI 15","termGroup":"CN","termSource":"NCI"},{"termName":"RLI-15","termGroup":"CN","termSource":"NCI"},{"termName":"RLI15","termGroup":"CN","termSource":"NCI"},{"termName":"SO C101","termGroup":"CN","termSource":"NCI"},{"termName":"SO-C101","termGroup":"CN","termSource":"NCI"},{"termName":"SOC101","termGroup":"CN","termSource":"NCI"},{"termName":"SOT 101","termGroup":"CN","termSource":"NCI"},{"termName":"SOT-101","termGroup":"CN","termSource":"NCI"},{"termName":"SOT101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1416390-27-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"UM4VY7ZEC9"},{"name":"Maps_To","value":"Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101"},{"name":"NCI_Drug_Dictionary_ID","value":"801174"},{"name":"NCI_META_CUI","value":"CL1382942"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801174"},{"name":"PDQ_Open_Trial_Search_ID","value":"801174"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171348":{"preferredName":"Iodine I 131 IPA","code":"C171348","definitions":[{"definition":"A radioconjugate consisting of the tumor-specific amino acid derivative 4-iodo-L-phenylalanine labeled with iodine I 131, a beta emitting radionuclide, with potential antineoplastic activity. Upon administration, iodine I 131 IPA actively crosses the blood-brain barrier and accumulates specifically in gliomas, via the amino acid transport system l-amino acid transporter 1 (LAT1) over-expressed in malignant glioma cells. where it delivers a cytotoxic dose of beta radiation. Cells that are exposed to radiation may also release potent toxins into the intracellular environment, leading to radiation-induced biological bystander effects (RIBBE) and killing cells not directly exposed to the radiation. Iodine I 131 IPA may also act synergistically with external irradiation due to its radiosensitizing property.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Iodine I 131 IPA","termGroup":"PT","termSource":"NCI"},{"termName":"131I-IPA","termGroup":"SY","termSource":"NCI"},{"termName":"4-[131I]iodo-L-phenylalanine","termGroup":"SY","termSource":"NCI"},{"termName":"4-L-[131I]iodo-phenylalanine","termGroup":"SY","termSource":"NCI"},{"termName":"I-131 IPA","termGroup":"SY","termSource":"NCI"},{"termName":"Iodine-131 IPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Iodine I 131 IPA"},{"name":"NCI_Drug_Dictionary_ID","value":"801303"},{"name":"NCI_META_CUI","value":"CL1405459"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801303"},{"name":"PDQ_Open_Trial_Search_ID","value":"801303"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170800":{"preferredName":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","code":"C170800","definitions":[{"definition":"An allogeneic, off-the-shelf, chimeric antigen receptor (CAR)-natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a NK cell-specific anti-CD19 CAR, a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF), with potential immunostimulatory and antineoplastic activities. Upon administration, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15RF enhances the cytotoxic effect of the NK cells and the activated anti-tumor T-cells. When used in combination with monoclonal antibodies, the hnCD16 Fc receptor of FT596 binds to the Fc portion of tumor cell-bound monoclonal antibodies, leading to NK cell activation, cytokine secretion and enhanced antibody-dependent cellular cytotoxicity (ADCC). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","termGroup":"PT","termSource":"NCI"},{"termName":"FT 596","termGroup":"CN","termSource":"NCI"},{"termName":"FT-596","termGroup":"CN","termSource":"NCI"},{"termName":"FT596","termGroup":"CN","termSource":"NCI"},{"termName":"Induced Pluripotent Stem Cell-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596","termGroup":"SY","termSource":"NCI"},{"termName":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-Natural Killer Cells FT596","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596"},{"name":"NCI_Drug_Dictionary_ID","value":"801177"},{"name":"NCI_META_CUI","value":"CL1383208"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801177"},{"name":"PDQ_Open_Trial_Search_ID","value":"801177"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165639":{"preferredName":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130","code":"C165639","definitions":[{"definition":"An allogeneic irradiated human lung cancer cell vaccine expressing a fusion protein composed of the OX40 ligand (OX40L) linked to an immunoglobulin (Ig) (OX40L-Ig), with potential immunomodulating and antineoplastic activities. Upon intradermal administration of irradiated allogeneic human lung cancer cells expressing OX40L-Ig vaccine HS-130, the irradiated lung cancer cells continuously express OX40L-Ig. OX40L may then target, bind to and activate its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40; CD134), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, and induces the proliferation and activation of memory and effector T-lymphocytes against the human lung cancer cells. In turn, this promotes a CTL-mediated immune response against the endogenous lung cancer cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130","termGroup":"PT","termSource":"NCI"},{"termName":"HS 130","termGroup":"CN","termSource":"NCI"},{"termName":"HS-130","termGroup":"CN","termSource":"NCI"},{"termName":"HS130","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130"},{"name":"NCI_Drug_Dictionary_ID","value":"799760"},{"name":"NCI_META_CUI","value":"CL978790"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799760"},{"name":"PDQ_Open_Trial_Search_ID","value":"799760"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172200":{"preferredName":"JAK Inhibitor","code":"C172200","definitions":[{"definition":"A substance that inhibits the biological action of tyrosine-protein kinase JAK1, an enzyme that plays a key role in certain types of cancer and cytokine signaling","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JAK Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Janus Kinase Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JAK Inhibitor"},{"name":"NCI_Drug_Dictionary_ID","value":"802011"},{"name":"NCI_META_CUI","value":"CL1406090"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802011"},{"name":"PDQ_Open_Trial_Search_ID","value":"802011"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168608":{"preferredName":"Kanitinib","code":"C168608","definitions":[{"definition":"A tyrosine kinase inhibitor targeting the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR; MET) and vascular endothelial growth factor receptor 2 (VEGFR2), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, kanitinib targets and binds to c-Met and VEGFR2, thereby disrupting c-Met- and VEGFR2-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met and/or VEGFR2 protein. c-Met and VEGFR2 are both overexpressed in many tumor cell types and play key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Kanitinib","termGroup":"PT","termSource":"NCI"},{"termName":"CX 1003","termGroup":"CN","termSource":"NCI"},{"termName":"CX-1003","termGroup":"CN","termSource":"NCI"},{"termName":"CX1003","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kanitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"800350"},{"name":"NCI_META_CUI","value":"CL972814"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800350"},{"name":"PDQ_Open_Trial_Search_ID","value":"800350"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173995":{"preferredName":"Divarasib","code":"C173995","definitions":[{"definition":"An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Divarasib","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 6036","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-6036","termGroup":"CN","termSource":"NCI"},{"termName":"GDC6036","termGroup":"CN","termSource":"NCI"},{"termName":"KRAS G12C Inhibitor GDC-6036","termGroup":"SY","termSource":"NCI"},{"termName":"RG 6330","termGroup":"CN","termSource":"NCI"},{"termName":"RG-6330","termGroup":"CN","termSource":"NCI"},{"termName":"RG6330","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2417917-17-8"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"E6S21PVT91"},{"name":"Maps_To","value":"KRAS G12C Inhibitor GDC-6036"},{"name":"NCI_Drug_Dictionary_ID","value":"802450"},{"name":"NCI_META_CUI","value":"CL1407880"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802450"},{"name":"PDQ_Open_Trial_Search_ID","value":"802450"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166410":{"preferredName":"KRAS G12C Inhibitor LY3499446","code":"C166410","definitions":[{"definition":"An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, LY3499446 targets and covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRAS G12C Inhibitor LY3499446","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3499446","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3499446","termGroup":"CN","termSource":"NCI"},{"termName":"LY3499446","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2409131-50-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QZJ1I2EN1V"},{"name":"Maps_To","value":"KRAS G12C Inhibitor LY3499446"},{"name":"NCI_Drug_Dictionary_ID","value":"800237"},{"name":"NCI_META_CUI","value":"CL971660"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800237"},{"name":"PDQ_Open_Trial_Search_ID","value":"800237"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167157":{"preferredName":"KRAS G12C Inhibitor JNJ-74699157","code":"C167157","definitions":[{"definition":"An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"KRAS G12C Inhibitor JNJ-74699157","termGroup":"PT","termSource":"NCI"},{"termName":"ARS 3248","termGroup":"CN","termSource":"NCI"},{"termName":"ARS-3248","termGroup":"CN","termSource":"NCI"},{"termName":"ARS3248","termGroup":"CN","termSource":"NCI"},{"termName":"G12C Mutant KRAS Protein Inhibitor JNJ-74699157","termGroup":"SY","termSource":"NCI"},{"termName":"JNJ 74699157","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-74699157","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ74699157","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"KRASG12C Inhibitor JNJ-74699157"},{"name":"NCI_Drug_Dictionary_ID","value":"800416"},{"name":"NCI_META_CUI","value":"CL972386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800416"},{"name":"PDQ_Open_Trial_Search_ID","value":"800416"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173559":{"preferredName":"LAIR-2 Fusion Protein NC410","code":"C173559","definitions":[{"definition":"A fusion protein of leukocyte-associated immunoglobulin (Ig)-like receptor (LAIR)-2, a high-affinity collagen receptor, with potential immunomodulatory and antineoplastic activities. Upon administration, LAIR-2 fusion protein NC410 binds to the ligand collagen of LAIR-1 (CD305), thereby blocking the binding of LAIR-1 to its ligand collagen and inhibiting LAIR-1-mediated immune suppression. This may result in enhanced T-cell and dendritic cell (DC) activities, and cytotoxic T-lymphocyte (CTL) and anti-tumor immune responses. LAIR-1, a collagen-receptor and an inhibitory immune receptor belonging to the Ig superfamily, is expressed on many peripheral blood mononuclear cells (PBMC) including T-cells and DCs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LAIR-2 Fusion Protein NC410","termGroup":"PT","termSource":"NCI"},{"termName":"Leukocyte-associated Immunoglobulin-like Receptor-2 Fusion Protein NC410","termGroup":"SY","termSource":"NCI"},{"termName":"NC 410","termGroup":"CN","termSource":"NCI"},{"termName":"NC-410","termGroup":"CN","termSource":"NCI"},{"termName":"NC410","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LAIR-2 Fusion Protein NC410"},{"name":"NCI_Drug_Dictionary_ID","value":"801912"},{"name":"NCI_META_CUI","value":"CL1407327"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801912"},{"name":"PDQ_Open_Trial_Search_ID","value":"801912"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172062":{"preferredName":"Larotinib Mesylate","code":"C172062","definitions":[{"definition":"The mesylate salt form of larotinib, a reversible pan-ErbB inhibitor with potential antineoplastic activity. Upon administration, larotinib binds to and inhibits ErbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing ErbB. The ErbB protein family, also called the epidermal growth factor receptor (EGFR) family, plays major roles in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Larotinib Mesylate","termGroup":"PT","termSource":"NCI"},{"termName":"Z 650","termGroup":"CN","termSource":"NCI"},{"termName":"Z-650","termGroup":"CN","termSource":"NCI"},{"termName":"Z650","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Larotinib Mesylate"},{"name":"NCI_Drug_Dictionary_ID","value":"801495"},{"name":"NCI_META_CUI","value":"CL1406186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801495"},{"name":"PDQ_Open_Trial_Search_ID","value":"801495"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165685":{"preferredName":"Lilotomab","code":"C165685","definitions":[{"definition":"A murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. Upon administration, lilotomab both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lilotomab","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-CD37 Monoclonal Antibody HH1","termGroup":"SY","termSource":"NCI"},{"termName":"HH1","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1453362-55-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"58I6YNR7BV"},{"name":"Maps_To","value":"Lilotomab"},{"name":"NCI_Drug_Dictionary_ID","value":"800126"},{"name":"NCI_META_CUI","value":"CL978919"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800126"},{"name":"PDQ_Open_Trial_Search_ID","value":"800126"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170753":{"preferredName":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006","code":"C170753","definitions":[{"definition":"A biodegradable, lyophilized lipid nanoparticle (LNP) encapsulating small interfering ribonucleic acid (siRNA) directed against glutathione S-transferase P (GSTP), with potential antineoplastic activity. Upon administration of LNP encapsulating GSTP siRNA NBF-006, the LNP formulation delivers the siRNA particles to the tumor cells where the GSTP siRNA targets and binds to GSTP mRNA. This results in the inhibition of the translation and expression of GSTP and may inhibit proliferation of KRAS-overexpressing tumor cells. GSTP, an enzyme overexpressed in many tumor cell types, is involved in modulating MAP kinase-related cell-signaling pathways.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006","termGroup":"PT","termSource":"NCI"},{"termName":"Lipid Nanoparticle Encapsulating GSTP siRNA NBF-006","termGroup":"SY","termSource":"NCI"},{"termName":"NBF 006","termGroup":"CN","termSource":"NCI"},{"termName":"NBF-006","termGroup":"CN","termSource":"NCI"},{"termName":"NBF006","termGroup":"CN","termSource":"NCI"},{"termName":"siRNA-based Lipid Nanoparticle NBF-006","termGroup":"SY","termSource":"NCI"},{"termName":"siRNA-based LNP NBF-006","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006"},{"name":"NCI_Drug_Dictionary_ID","value":"800779"},{"name":"NCI_META_CUI","value":"CL1383151"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800779"},{"name":"PDQ_Open_Trial_Search_ID","value":"800779"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170743":{"preferredName":"Liposomal Bcl-2 Antisense Oligonucleotide BP1002","code":"C170743","definitions":[{"definition":"A liposomal-based nanoparticle composed of an uncharged P-ethoxy antisense oligodeoxynucleotide (ODN) targeting Bcl-2 mRNA and incorporated in liposomes, with potential antineoplastic activity. Upon administration of liposomal Bcl-2 antisense oligonucleotide BP1002, this agent targets and hybridizes with Bcl-2 mRNA and inhibits the expression of Bcl-2 protein. This may induce tumor cell apoptosis of Bcl2-overexpressing tumor cells and may decrease tumor cell proliferation. Bcl2, a protein involved in regulating programmed cell death, is overexpressed in a wide variety of tumors. It promotes cellular survival and inhibits apoptosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposomal Bcl-2 Antisense Oligonucleotide BP1002","termGroup":"PT","termSource":"NCI"},{"termName":"BP 1002","termGroup":"CN","termSource":"NCI"},{"termName":"BP-100-1.02","termGroup":"CN","termSource":"NCI"},{"termName":"BP-1002","termGroup":"CN","termSource":"NCI"},{"termName":"BP1002","termGroup":"CN","termSource":"NCI"},{"termName":"L-Bcl-2 Antisense Oligonucleotide BP1002","termGroup":"SY","termSource":"NCI"},{"termName":"Liposomal Bcl-2 Antisense BP1002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposomal Bcl-2 Antisense Oligonucleotide  BP1002"},{"name":"NCI_Drug_Dictionary_ID","value":"800679"},{"name":"NCI_META_CUI","value":"CL1383140"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800679"},{"name":"PDQ_Open_Trial_Search_ID","value":"800679"},{"name":"Semantic_Type","value":"Nucleic Acid, Nucleoside, or Nucleotide"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174421":{"preferredName":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1","code":"C174421","definitions":[{"definition":"A vaccine consisting of messenger RNA (mRNA) encoding three tumor-associated antigens (TAAs) specific for ovarian cancer that are encapsulated in liposomes, with potential immunomodulating and antineoplastic activities. Upon administration of the liposome-encapsulated TAAs mRNA vaccine W_ova1, the liposomes bind to the plasma membrane of cells and release the mRNA into the cells. The mRNA is then translated by ribosomes to produce the TAAs. The TAAs are presented to the immune system which may activate both humoral and cellular immune responses against the ovarian cancer cells expressing these TAAs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1","termGroup":"PT","termSource":"NCI"},{"termName":"BNT-115","termGroup":"CN","termSource":"NCI"},{"termName":"Liposome Formulated mRNA Vaccine W_ova1","termGroup":"SY","termSource":"NCI"},{"termName":"mRNA Vaccine W_ova1","termGroup":"SY","termSource":"NCI"},{"termName":"W_ova1","termGroup":"CN","termSource":"NCI"},{"termName":"W_ova1 Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liposome-encapsulated TAAs mRNA Vaccine W_ova1"},{"name":"NCI_Drug_Dictionary_ID","value":"802273"},{"name":"NCI_META_CUI","value":"CL1411979"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802273"},{"name":"PDQ_Open_Trial_Search_ID","value":"802273"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172395":{"preferredName":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes","code":"C172395","definitions":[{"definition":"A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A02:01/24:02/11:01-restricted Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Upon administration, the autologous LMP1/LMP2/EBNA1-specific, HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001 recognize and bind to HLA-presented EBV peptides, which may promote cell death and inhibit the growth of tumor cells expressing LMP1, LMP2 or EBNA1. LMP1, LMP2, and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes","termGroup":"PT","termSource":"NCI"},{"termName":"LMP2 Antigen-specific TCR T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes"},{"name":"NCI_Drug_Dictionary_ID","value":"801627"},{"name":"NCI_META_CUI","value":"CL1406351"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801627"},{"name":"PDQ_Open_Trial_Search_ID","value":"801627"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169060":{"preferredName":"LMP7 Inhibitor M3258","code":"C169060","definitions":[{"definition":"An orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, Beta5i, PSMB8), a chymotrypsin-like, proteolytic subunit of the immunoproteasome, with potential antineoplastic activity. Upon oral administration, LMP7 inhibitor M3258 targets and inhibits the proteolytic activity of the LMP7 subunit of immunoproteasome, thereby blocking its deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. Proteasomes are large multi-subunit protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated, thereby restoring protein homeostasis. Unlike the constitutive proteasome, which is expressed in most tissues, immunoproteasome is specifically present in normal and malignant hematopoietic cells, including multiple myeloma. Immunoproteasome degrades ubiquitinated proteins, generates peptides for presentation on MHC class I, and plays a key role in the adaptive immune response and inflammatory diseases.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LMP7 Inhibitor M3258","termGroup":"PT","termSource":"NCI"},{"termName":"Immunoproteasome Inhibitor M3258","termGroup":"SY","termSource":"NCI"},{"termName":"M 3258","termGroup":"CN","termSource":"NCI"},{"termName":"M-3258","termGroup":"CN","termSource":"NCI"},{"termName":"M3258","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LMP7 Inhibitor M3258"},{"name":"NCI_Drug_Dictionary_ID","value":"800618"},{"name":"NCI_META_CUI","value":"CL1378863"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800618"},{"name":"PDQ_Open_Trial_Search_ID","value":"800618"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171102":{"preferredName":"LRP5 Antagonist BI 905681","code":"C171102","definitions":[{"definition":"An antagonist of the lipoprotein receptor-related protein (LRP) 5, with potential antineoplastic and immunomodulating activities. Upon administration, LRP5 antagonist BI 905681 targets and binds to LRP5, thereby blocking the binding of Wnt ligands to LRP5. This prevents the formation of the serpentine receptor Frizzled (FZD)-Wnt-LRP5 trimeric complex and prevents the inactivation of the beta-catenin degradation complex, which leads to beta-catenin degradation. This inhibits the Wnt/beta-catenin signaling pathway, prevents the beta-catenin-mediated activation of Wnt target genes, and inhibits the proliferation and survival of Wnt/beta-catenin-driven tumor cells. In addition, inhibition of Wnt signaling by BI 905681 prevents Wnt-mediated immune escape, thereby re-activating the immune system, specifically inducing the activation of dendritic cells (DCs) and activation as well as infiltration of cytotoxic T-cells into the tumor tissue. The FZD-Wnt-LRP5 trimeric complex induces phosphorylation of LRP5 intracellular domain leading to inactivation of the beta-catenin degradation complex, allowing beta-catenin accumulation; stabilized beta-catenin enters the nucleus and acts as a transcriptional activator of Wnt target genes. Wnt/beta-catenin signaling plays a key role in tumor cell proliferation and survival, and resistance to immunotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LRP5 Antagonist BI 905681","termGroup":"PT","termSource":"NCI"},{"termName":"BI 905681","termGroup":"CN","termSource":"NCI"},{"termName":"BI-905681","termGroup":"CN","termSource":"NCI"},{"termName":"BI905681","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LRP5 Antagonist BI 905681"},{"name":"NCI_Drug_Dictionary_ID","value":"802154"},{"name":"NCI_META_CUI","value":"CL1405341"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802154"},{"name":"PDQ_Open_Trial_Search_ID","value":"802154"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173722":{"preferredName":"LSD1 Inhibitor SYHA1807","code":"C173722","definitions":[{"definition":"An orally available inhibitor of lysine-specific demethylase 1 (LSD1; KDM1A), with potential antineoplastic activity. Upon oral administration, LSD1 inhibitor SYHA1807 targets, binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1 is overexpressed in a number of tumor cell types. LSD1 acts on histone H3 as a transcription co-repressor through demethylation of lysine 4 (H3K4) or as a transcription co-activator through demethylation of lysine 9 (H3K9).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"LSD1 Inhibitor SYHA1807","termGroup":"PT","termSource":"NCI"},{"termName":"Lysine-specific Demethylase 1 Inhibitor SYHA1807","termGroup":"SY","termSource":"NCI"},{"termName":"SYHA 1807","termGroup":"CN","termSource":"NCI"},{"termName":"SYHA-1807","termGroup":"CN","termSource":"NCI"},{"termName":"SYHA1807","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"LSD1 Inhibitor SYHA1807"},{"name":"NCI_Drug_Dictionary_ID","value":"801980"},{"name":"NCI_META_CUI","value":"CL1407574"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801980"},{"name":"PDQ_Open_Trial_Search_ID","value":"801980"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174423":{"preferredName":"Lutetium Lu 177-DTPA-omburtamab","code":"C174423","definitions":[{"definition":"A radioimmunoconjugate consisting of omburtamab, a murine immunoglobulin G1 (IgG1) antibody directed against the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3, CD276), conjugated, via the chelating agent diethylenetriaminepentaacetic acid (DTPA), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intracerebroventricular administration of lutetium Lu 177-DTPA-omburtamab, the omburtamab moiety binds to B7-H3 expressed on certain tumor cells. Upon binding, lutetium Lu 177-DTPA-omburtamab delivers a cytotoxic dose of beta radiation to B7-H3-expressing cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lutetium Lu 177-DTPA-omburtamab","termGroup":"PT","termSource":"NCI"},{"termName":"177Lu-DTPA-omburtamab","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lutetium Lu 177-DTPA-omburtamab"},{"name":"NCI_Drug_Dictionary_ID","value":"802279"},{"name":"NCI_META_CUI","value":"CL1411985"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802279"},{"name":"PDQ_Open_Trial_Search_ID","value":"802279"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174518":{"preferredName":"Maackia amurensis Seed Lectin","code":"C174518","definitions":[{"definition":"A preparation of lectin extracted from the seeds of Maackia amurensis, with potential antineoplastic activity. Upon administration, Maackia amurensis seed lectin (MASL) may target and bind to podoplanin (PDPN), thereby blocking the activation of PDPN by endogenous ligands. This may inhibit tumor cell growth, migration and metastasis that result from PDPN activation. PDPN, a transmembrane receptor glycoprotein that is overexpressed in some cancer types, promotes tumor cell migration, invasion, and metastasis upon activation by various endogenous ligands.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maackia amurensis Seed Lectin","termGroup":"PT","termSource":"NCI"},{"termName":"MASL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Maackia amurensis Seed Lectin"},{"name":"NCI_Drug_Dictionary_ID","value":"802340"},{"name":"NCI_META_CUI","value":"CL1412017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802340"},{"name":"PDQ_Open_Trial_Search_ID","value":"802340"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166141":{"preferredName":"Macrocycle-bridged STING Agonist E7766","code":"C166141","definitions":[{"definition":"An agonist of macrocycle-bridged stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, macrocycle-bridged STING agonist (MBSA) E7766 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Compared to conventional STING agonists, MBSA E7766 allows for conformational rigidity of the unique macrocycle bridge which enhances its stability and STING affinity, thereby increasing its efficacy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macrocycle-bridged STING Agonist E7766","termGroup":"PT","termSource":"NCI"},{"termName":"E 7766","termGroup":"CN","termSource":"NCI"},{"termName":"E-7766","termGroup":"CN","termSource":"NCI"},{"termName":"E7766","termGroup":"CN","termSource":"NCI"},{"termName":"MBSA E7766","termGroup":"SY","termSource":"NCI"},{"termName":"Stimulator of Interferon Genes Agonist E7766","termGroup":"SY","termSource":"NCI"},{"termName":"Sting Agonist E7766","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"J81GDR86J9"},{"name":"Maps_To","value":"Macrocycle-bridged STING Agonist E7766"},{"name":"NCI_Drug_Dictionary_ID","value":"799924"},{"name":"NCI_META_CUI","value":"CL979196"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799924"},{"name":"PDQ_Open_Trial_Search_ID","value":"799924"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174139":{"preferredName":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells","code":"C174139","definitions":[{"definition":"A preparation of autologous CD4- and CD8-positive T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets the human melanoma-associated antigen A1 (MAGE-A1), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A1-specific TCR-transduced autologous T-cells bind to tumor cells expressing MAGE-A1, which may halt the growth of and kill MAGE-A1-expressing cancer cells. MAGE-A1 is a tumor-associated antigen (TAA) overexpressed by a variety of cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells","termGroup":"PT","termSource":"NCI"},{"termName":"MAGE-A1-specific T Cell Receptor-transduced Autologous CD8+ and CD4+ T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"MAGE-A1-specific TCR-transduced Autologous T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802464"},{"name":"NCI_META_CUI","value":"CL1407779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802464"},{"name":"PDQ_Open_Trial_Search_ID","value":"802464"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174400":{"preferredName":"MCL-1 Inhibitor ABBV-467","code":"C174400","definitions":[{"definition":"An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor ABBV-467 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MCL-1 Inhibitor ABBV-467","termGroup":"PT","termSource":"NCI"},{"termName":"ABBV 467","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV-467","termGroup":"CN","termSource":"NCI"},{"termName":"ABBV467","termGroup":"CN","termSource":"NCI"},{"termName":"Myeloid Cell Leukemia-1 Inhibitor ABBV-467","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MCL-1 Inhibitor ABBV-467"},{"name":"NCI_Drug_Dictionary_ID","value":"802326"},{"name":"NCI_META_CUI","value":"CL1411952"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802326"},{"name":"PDQ_Open_Trial_Search_ID","value":"802326"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171616":{"preferredName":"MDM2 Inhibitor AMGMDS3","code":"C171616","definitions":[{"definition":"An inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon administration, MDM2 inhibitor AMGMDS3 binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MDM2 Inhibitor AMGMDS3","termGroup":"PT","termSource":"NCI"},{"termName":"2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"AMGMDS3","termGroup":"CN","termSource":"NCI"},{"termName":"Q59770979","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MDM2 Inhibitor AMGMDS3"},{"name":"NCI_META_CUI","value":"CL1405838"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172382":{"preferredName":"MEK 1/2 Inhibitor FCN-159","code":"C172382","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration, MEK 1/2 Inhibitor FCN-159 selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEK 1/2 Inhibitor FCN-159","termGroup":"PT","termSource":"NCI"},{"termName":"FCN 159","termGroup":"CN","termSource":"NCI"},{"termName":"FCN-159","termGroup":"CN","termSource":"NCI"},{"termName":"FCN159","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor FCN-159","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MEK 1/2 Inhibitor FCN-159"},{"name":"NCI_Drug_Dictionary_ID","value":"801657"},{"name":"NCI_META_CUI","value":"CL1406509"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801657"},{"name":"PDQ_Open_Trial_Search_ID","value":"801657"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173437":{"preferredName":"Tunlametinib","code":"C173437","definitions":[{"definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon administration, tunlametinib selectively binds to and inhibits the activity of MEK, preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a threonine/tyrosine kinase, plays a key role in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tunlametinib","termGroup":"PT","termSource":"NCI"},{"termName":"4-Fluoro-5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-6-benzothiazolecarboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"6-Benzothiazolecarboxamide, 4-fluoro-5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-","termGroup":"SN","termSource":"NCI"},{"termName":"HL 085","termGroup":"CN","termSource":"NCI"},{"termName":"HL-085","termGroup":"CN","termSource":"NCI"},{"termName":"HL085","termGroup":"CN","termSource":"NCI"},{"termName":"MEK Inhibitor HL-085","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1801756-06-8"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"IF25NR1PV3"},{"name":"Maps_To","value":"MEK Inhibitor HL-085"},{"name":"NCI_Drug_Dictionary_ID","value":"801764"},{"name":"NCI_META_CUI","value":"CL1407412"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801764"},{"name":"PDQ_Open_Trial_Search_ID","value":"801764"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165776":{"preferredName":"Revumenib","code":"C165776","definitions":[{"definition":"An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Revumenib","termGroup":"PT","termSource":"NCI"},{"termName":"Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)-","termGroup":"SN","termSource":"NCI"},{"termName":"Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613","termGroup":"SY","termSource":"NCI"},{"termName":"Menin-MLL Inhibitor SNDX-5613","termGroup":"SY","termSource":"NCI"},{"termName":"Menin-MLL Interaction Inhibitor SNDX-5613","termGroup":"SY","termSource":"NCI"},{"termName":"SNDX 5613","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX-5613","termGroup":"CN","termSource":"NCI"},{"termName":"SNDX5613","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2169919-21-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LZ0M43NNF2"},{"name":"Maps_To","value":"Menin-MLL Interaction Inhibitor SNDX-5613"},{"name":"NCI_Drug_Dictionary_ID","value":"800199"},{"name":"NCI_META_CUI","value":"CL978854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800199"},{"name":"PDQ_Open_Trial_Search_ID","value":"800199"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167188":{"preferredName":"Davutamig","code":"C167188","definitions":[{"definition":"A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, davutamig targets and binds to two different, non-overlapping epitopes on MET expressed on thd tumor cell surface, thereby forming unique davutamig-MET complexes. The binding of davutamig to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Davutamig","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-c-Met Bispecific Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"MET x MET Bispecific Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"METxMET Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"METxMET Bispecific Antibody REGN5093","termGroup":"SY","termSource":"NCI"},{"termName":"REGN 5093","termGroup":"CN","termSource":"NCI"},{"termName":"REGN-5093","termGroup":"CN","termSource":"NCI"},{"termName":"REGN5093","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2648058-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"N2H0RP6IHR"},{"name":"Maps_To","value":"MET x MET Bispecific Antibody REGN5093"},{"name":"NCI_Drug_Dictionary_ID","value":"800420"},{"name":"NCI_META_CUI","value":"CL972415"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800420"},{"name":"PDQ_Open_Trial_Search_ID","value":"800420"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168544":{"preferredName":"Metarrestin","code":"C168544","definitions":[{"definition":"An orally available small molecule inhibitor of perinucleolar compartment (PNC), with potential antineoplastic activities. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon oral administration, metarrestin disrupts the structure of PNC and inhibits RNA polymerase (Pol) I transcription. This leads to the reduction in the prevalence of PNC in cancer cells and decrease in tumor growth and spread. PNC is a subnuclear structure and a phenotypic marker of metastatic cancer cells. A high PNC prevalence has been associated with disease progression and poor patient outcomes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Metarrestin","termGroup":"PT","termSource":"NCI"},{"termName":"ML 246","termGroup":"CN","termSource":"NCI"},{"termName":"ML-246","termGroup":"CN","termSource":"NCI"},{"termName":"ML246","termGroup":"CN","termSource":"NCI"},{"termName":"Trans-4-(7-benzyl-4-imino-5,6-diphenylpyrrolo[2,3-d]pyrimidin-3-yl)cyclohexan-1-ol","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1443414-10-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"Q6A9F9DSX5"},{"name":"Maps_To","value":"Metarrestin"},{"name":"NCI_Drug_Dictionary_ID","value":"800687"},{"name":"NCI_META_CUI","value":"CL972873"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800687"},{"name":"PDQ_Open_Trial_Search_ID","value":"800687"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173446":{"preferredName":"Methylcantharidimide","code":"C173446","definitions":[{"definition":"An orally bioavailable derivative of the terpenoid cantharidin, which is a natural toxin extracted from blister beetles, with potential antineoplastic activity. Although the exact mechanism of action through which methylcantharidimide exerts its effect has yet to be fully elucidated, this agent, upon oral administration, may exert a direct tumor cell killing effect in susceptible tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylcantharidimide","termGroup":"PT","termSource":"NCI"},{"termName":"N-methylcantharidimide","termGroup":"SY","termSource":"NCI"},{"termName":"NMC","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"76970-78-0"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"62T9S2Y75E"},{"name":"Maps_To","value":"Methylcantharidimide"},{"name":"NCI_Drug_Dictionary_ID","value":"801753"},{"name":"NCI_META_CUI","value":"CL1407421"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801753"},{"name":"PDQ_Open_Trial_Search_ID","value":"801753"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171422":{"preferredName":"Microbiome GEN-001","code":"C171422","definitions":[{"definition":"A microbiome therapeutic composed of a single-strain bacterium, isolated from the gut of healthy donors, with potential anti-tumor and immunomodulating activities. Upon oral administration, the metabolites of GEN-001 may activate dendritic cells and macrophages in the gut and increase the expression of the cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15), which stimulates the proliferation of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. GEN-001 may improve therapeutic responses to other therapies, such as anti-PD-1 therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microbiome GEN-001","termGroup":"PT","termSource":"NCI"},{"termName":"GEN 001","termGroup":"CN","termSource":"NCI"},{"termName":"GEN-001","termGroup":"CN","termSource":"NCI"},{"termName":"GEN001","termGroup":"CN","termSource":"NCI"},{"termName":"Microbiome-based Therapeutic GEN-001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microbiome GEN-001"},{"name":"NCI_Drug_Dictionary_ID","value":"801465"},{"name":"NCI_META_CUI","value":"CL1405526"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801465"},{"name":"PDQ_Open_Trial_Search_ID","value":"801465"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165646":{"preferredName":"Microbiome-derived Peptide Vaccine EO2401","code":"C165646","definitions":[{"definition":"A donor-derived, off-the-shelf, microbiome therapeutic cancer peptide vaccine composed of three bacterial onco-mimics, immunogenic microbiome-derived peptides that are highly homologous to tumor-associated antigens (TAAs), that are obtained and selected from the human gut microbiome and are specific for brain tumors, including glioblastoma, with potential immunomodulating and antineoplastic activities. The three microbiome-derived bacterial antigens in EO2401 mimic three TAAs that are highly expressed by brain tumors. Upon administration of microbiome-derived peptide vaccine EO2401, the peptides are taken up by and presented on dendritic cells (DCs) to T-cells. As the presented antigens display molecular mimicry with selected TAAs on brain cancer cells, a memory T-cell and cytotoxic T-lymphocyte (CTL)-mediated immune response may be mounted against the TAAs expressed on the brain cancer cells, thereby eradicating the brain cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microbiome-derived Peptide Vaccine EO2401","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Vaccine EO2401","termGroup":"SY","termSource":"NCI"},{"termName":"EO 2401","termGroup":"CN","termSource":"NCI"},{"termName":"EO-2401","termGroup":"CN","termSource":"NCI"},{"termName":"EO2401","termGroup":"CN","termSource":"NCI"},{"termName":"Microbial-derived Peptide Vaccine EO2401","termGroup":"SY","termSource":"NCI"},{"termName":"Microbiome-derived Therapeutic Cancer Vaccine EO2401","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microbiome-derived Peptide Vaccine EO2401"},{"name":"NCI_Drug_Dictionary_ID","value":"799761"},{"name":"NCI_META_CUI","value":"CL978949"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799761"},{"name":"PDQ_Open_Trial_Search_ID","value":"799761"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167362":{"preferredName":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208","code":"C167362","definitions":[{"definition":"A booster cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) Bavarian Nordic (MVA-BN) strain encoding the oncogenic human papillomavirus types 16 (HPV16) and 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of MVA-vectored HPV16/18 vaccine JNJ-65195208, and after the administration of the prime vaccine(s) adenovirus serotype 26 (Ad26)-expressing HPV16 vaccine JNJ-63682918 and/or Ad26-expressing HPV18 vaccine JNJ-63682931, this vaccine further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16/18 proteins, resulting in tumor cell lysis. HPV16/18 infection plays a key role in the development of a variety of cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208","termGroup":"PT","termSource":"NCI"},{"termName":"JNJ 65195208","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ-65195208","termGroup":"CN","termSource":"NCI"},{"termName":"JNJ65195208","termGroup":"CN","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara-HPV16/18 JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA BN HPV16/18 JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-HPV16/18 Vaccine JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-vectored HPV16/18 Vaccine JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA-vectored Vaccine JNJ-65195208","termGroup":"SY","termSource":"NCI"},{"termName":"MVA.HPV16/18 JNJ-65195208","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208"},{"name":"NCI_META_CUI","value":"CL972336"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174519":{"preferredName":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells","code":"C174519","definitions":[{"definition":"A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) loaded with the human tumor-associated antigens (TAAs) mucin-1 (MUC1) and Wilms tumor protein 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon vaccination, the MUC-1/WT1 peptide-primed autologous DCs expose the immune system to MUC1 and WT1 peptides and may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against MUC1 and WT1-expressing cancer cells, which could result in cancer cell lysis. MUC1 and WT1, are overexpressed in a variety of tumor types and play an important role in tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells","termGroup":"PT","termSource":"NCI"},{"termName":"MUC-1/WT1 Peptide-loaded Autologous Dendritic Cells","termGroup":"SY","termSource":"NCI"},{"termName":"MUC-1/WT1 Peptide-primed Autologous DCs","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MUC-1/WT1 Peptide-primed Autologous Dendritic Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802334"},{"name":"NCI_META_CUI","value":"CL1411835"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802334"},{"name":"PDQ_Open_Trial_Search_ID","value":"802334"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173525":{"preferredName":"Multi-epitope HER2 Peptide Vaccine TPIV100","code":"C173525","definitions":[{"definition":"A cancer peptide vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. Upon administration of the multi-epitope HER2 peptide vaccine TPIV100, the four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types. To enhance immunity, the peptides are admixed with the adjuvant granulocyte macrophage-colony-stimulating factor (GM-CSF).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Multi-epitope HER2 Peptide Vaccine TPIV100","termGroup":"PT","termSource":"NCI"},{"termName":"HER2/Neu Peptide Vaccine TPIV100","termGroup":"SY","termSource":"NCI"},{"termName":"Peptide Vaccine TPIV100","termGroup":"SY","termSource":"NCI"},{"termName":"TPIV 100","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV-100","termGroup":"CN","termSource":"NCI"},{"termName":"TPIV100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Multi-epitope HER2 Peptide Vaccine TPIV100"},{"name":"NCI_Drug_Dictionary_ID","value":"802235"},{"name":"NCI_META_CUI","value":"CL1407515"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802235"},{"name":"PDQ_Open_Trial_Search_ID","value":"802235"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175526":{"preferredName":"Muscadine Grape Extract","code":"C175526","definitions":[{"definition":"An extract derived from the Muscadine grape (Vitis rotundifolia), with potential anti-inflammatory, antioxidant, anti-lipidemic and chemopreventive activities. The muscadine grape extract (MGE) contains numerous phytochemicals including hydrolyzable tannins and flavonoids, such as resveratrol, anthocyanin 3,5-diglucosides, quercetin, ellagic acid, myricetin, and kaempferol glycosides. Upon administration, the active components in the MGE scavenge free radicals, protect against oxidation of low-density lipoprotein (LDL), and inhibit cell damage due to reactive oxygen species (ROS). This inhibits oxidative stress and protects against DNA damage. MGE also inhibits enzymes involved in inflammation, cell replication and DNA synthesis, and induces the expression of anti-oxidant enzymes. The active ingredients may also inhibit certain signaling pathways upregulated in some tumor cell types, eventually leading to apoptosis and a reduction in tumor cell proliferation. MGE may also boost energy and prevent fatigue.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Muscadine Grape Extract","termGroup":"PT","termSource":"NCI"},{"termName":"MGE","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Muscadine Grape Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"803286"},{"name":"NCI_META_CUI","value":"CL1412905"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803286"},{"name":"PDQ_Open_Trial_Search_ID","value":"803286"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173552":{"preferredName":"MVA-BN Smallpox Vaccine","code":"C173552","definitions":[{"definition":"A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, with potential antineoplastic activity. Upon intratumoral administration, MVA-BN smallpox vaccine may induce both cellular and humoral immune responses, which may lead to tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MVA-BN Smallpox Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"Imvamune","termGroup":"FB","termSource":"NCI"},{"termName":"Imvanex","termGroup":"FB","termSource":"NCI"},{"termName":"JYNNEOS","termGroup":"BR","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara - Bavarian Nordic Smallpox Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"Modified Vaccinia Ankara Smallpox Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"MVA Smallpox Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1026718-04-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"TU8J357395"},{"name":"Maps_To","value":"MVA-BN Smallpox Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"801908"},{"name":"NCI_META_CUI","value":"CL1407321"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801908"},{"name":"PDQ_Open_Trial_Search_ID","value":"801908"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173438":{"preferredName":"N-dihydrogalactochitosan","code":"C173438","definitions":[{"definition":"A carbohyrate polymer in which galactose molecules are attached to the amino groups of the glucosamine polymer chitosan, with potential imunostimulating activity. After a tumor ablation and upon intratumoral injection directly into the location of the ablated tumor, N-dihydrogalactochitosan may trigger a tumor-specific systemic immune response when exposed to tumor-associated neoantigens that are liberated by tumor ablation. This may kill tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"N-dihydrogalactochitosan","termGroup":"PT","termSource":"NCI"},{"termName":"IP 001","termGroup":"CN","termSource":"NCI"},{"termName":"IP-001","termGroup":"CN","termSource":"NCI"},{"termName":"IP001","termGroup":"CN","termSource":"NCI"},{"termName":"N-dihydro-galacto-chitosan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N-dihydrogalactochitosan"},{"name":"NCI_Drug_Dictionary_ID","value":"801765"},{"name":"NCI_META_CUI","value":"CL1407413"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801765"},{"name":"PDQ_Open_Trial_Search_ID","value":"801765"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170752":{"preferredName":"Oligo-fucoidan","code":"C170752","definitions":[{"definition":"A sulfated polysaccharide low-molecular-weight fucoidan, with potential antioxidant, anti-inflammatory, antiproliferative, anti-angiogenic and pro-apoptotic activities. Upon administration of oligo-fucoidan, this agent seems to exert numerous effects through various mechanisms of action, some of which remain to be fully elucidated. Oligo-fucoidan induces cell cycle arrest, activates caspases, induces apoptosis, and inhibits tumor cell proliferation in susceptible tumor cells. It also increases the expression of tumor suppressors, such as p53, while decreasing levels of certain tumor promoters. Oligo-fucoidan also promotes the degradation of transforming growth factor-beta (TGFb) receptor and the inhibition of epithelial-mesenchymal transition (EMT). It prevents tumor progression, alters tumor microenvironment (TME) and decreases the tumor-promoting M2 macrophages in the TME. Oligo-fucoidan has anti-inflammatory effects that suppress the expression of nitric oxide synthase (iNOS), cyclooxygenase (COX)-2 and monocyte chemoattractant protein-1 (MCP-1/CCL2), and decrease the production of certain pro-inflammatory cytokines, such as interleukin-1beta (IL-1b) and tumor necrosis factor (TNF)-alpha (TNFa). This agent may also suppress angiogenic activity by inhibiting vascular endothelial growth factor (VEGF) receptor expression and VEGF-induced endothelial cell proliferation. As an antioxidant, this agent protects cells against oxidative stress by scavenging superoxide radicals and induces the expression of the anti-oxidant nuclear factor erythroid-2-related factor 2 and that of its target gene, superoxide dismutase; and prevents reactive oxidative species (ROS) generation in cancer cells and ROS release into the TME. Fucoidan also has immune-modulatory effects and enhances the proliferation of natural killer (NKs) cells and cytotoxic T-cells (CTLs).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oligo-fucoidan","termGroup":"PT","termSource":"NCI"},{"termName":"Low-molecular-weight Fucoidan","termGroup":"SY","termSource":"NCI"},{"termName":"Oligo Fucoidan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oligo-fucoidan"},{"name":"NCI_Drug_Dictionary_ID","value":"800738"},{"name":"NCI_META_CUI","value":"CL1383150"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800738"},{"name":"PDQ_Open_Trial_Search_ID","value":"800738"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168607":{"preferredName":"Oncolytic Adenovirus ORCA-010","code":"C168607","definitions":[{"definition":"A replication competent, oncolytic adenovirus serotype 5 (Ad5) that has been modified with a delta24 (d24) deletion, an incorporation of an RGD-4C motif in the Ad fiber protein, and an insertion of the T1 mutation in E3/19K gene, with potential oncolytic activity. Upon administration, oncolytic adenovirus ORCA-010 binds to specific Ad3 receptors that are highly expressed on certain tumor cells. This results in the replication of oncolytic adenovirus Ad5/3-delta24 in tumor cells and induces tumor cell lysis which may potentially result in the activation of a systemic immune response against tumor-associated antigens (TAAs). The Ad5/3-delta24 has a 24 base pair deletion in constant region 2 of the E1A gene which allows for selective replication in cells that are defective in the retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (CDKN2A or p16INK4a). As most tumor cells are defective in the Rb/p16 pathway, this virus selectively replicates in these cells. The RGD-4C motif is a 9-amino acid peptide that binds to various and enhances viral-cell receptor binding by allowing for a Coxsackie-adenovirus receptor (CAR)-independent infection of tumor cells, which is the natural route of viral binding, as CAR expression is often deficient on cancer cells. As integrins are often overexpressed on tumor cell surfaces, integrin receptor binding enhances tumor cells binding and infection by the Ad. The T1 mutation enhances the Ad5 release from tumor cells and promotes spreading throughout the tumor, thereby enhancing anti-tumor activity. The T1 mutation, a single Adenine insertion at position 445 of the nucleotide sequence of the E3/19K gene of Adenovirus, creates a truncated E3/19K protein that is relocated to the plasma membrane due to the disruption of its ER retention signal. This increases plasma membrane permeability and enhances the release of Ad5.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Adenovirus ORCA-010","termGroup":"PT","termSource":"NCI"},{"termName":"Modified Ad5 ORCA-010","termGroup":"SY","termSource":"NCI"},{"termName":"ORCA 010","termGroup":"CN","termSource":"NCI"},{"termName":"ORCA-010","termGroup":"CN","termSource":"NCI"},{"termName":"ORCA010","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Adenovirus ORCA-010"},{"name":"NCI_Drug_Dictionary_ID","value":"800320"},{"name":"NCI_META_CUI","value":"CL972811"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800320"},{"name":"PDQ_Open_Trial_Search_ID","value":"800320"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C171540":{"preferredName":"Oncolytic Herpes Simplex Virus-1 ONCR-177","code":"C171540","definitions":[{"definition":"A recombinant, genetically modified, microRNA (miRNA)-attenuated oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. In ONCR-177, a dual bidirectional promoter enables the expression of five different transgenes: the natural killer (NK) cell and T-cell activating cytokine interleuin-12 (IL-12), the chemokines C-C motif chemokine 4 (CCL4) and the extracellular domain of the Fms-related tyrosine kinase 3 ligand (FLT3LG), to allow for expansion and recruitment of classical dendritic cells (DCs), and antagonists to the immune checkpoints programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to counter T cell exhaustion. Upon intra-tumoral administration, the oncolytic HSV-1 ONCR-177 specifically targets, infects and selectively replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles then infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. In addition, the expressed transgenes that are released upon tumor cell lysis induce a systemic tumor-specific immune response and activate NKs, DCs and cytotoxic T-lymphocytes (CTLs) while inhibiting regulatory T-cells (Tregs). This further kills nearby non-infected tumor cells. In ONCR-177, the neurovirulence gene ICP34.5 allows for potent oncolysis, even in the presence of host cell antiviral responses. To ensure selective replication and oncolysis in cancer cells while attenuating replication in healthy tissue, tissue specific miRNA-binding cassettes (miR-T) are inserted into early genes essential for viral replication. In addition, UL37 mutation suppresses latent infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Herpes Simplex Virus-1 ONCR-177","termGroup":"PT","termSource":"NCI"},{"termName":"oHSV-1 ONCR-177","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic HSV-1 ONCR-177","termGroup":"SY","termSource":"NCI"},{"termName":"ONCR 177","termGroup":"CN","termSource":"NCI"},{"termName":"ONCR-177","termGroup":"CN","termSource":"NCI"},{"termName":"ONCR177","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"83P3OQ67ZT"},{"name":"Maps_To","value":"Oncolytic Herpes Simplex Virus-1 ONCR-177"},{"name":"NCI_Drug_Dictionary_ID","value":"802000"},{"name":"NCI_META_CUI","value":"CL1405762"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802000"},{"name":"PDQ_Open_Trial_Search_ID","value":"802000"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C175473":{"preferredName":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","code":"C175473","definitions":[{"definition":"A genetically engineered oncolytic herpes simplex virus type 1 (oHSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12) and an antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intratumoral administration, oHSV-1 expressing IL-12 and anti-PD-1 antibody T3011 infects and replicates in tumor cells causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In addition, oHSV-1 expressing IL-12 and anti-PD-1 antibody T3011 promotes the secretion of IL-12 and anti-PD-1 antibody by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Anti-PD-1 antibody targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","termGroup":"PT","termSource":"NCI"},{"termName":"MVR-T3011","termGroup":"CN","termSource":"NCI"},{"termName":"oHSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic HSV-1 Expressing IL-12 and PD-1 Antibody T3011","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic HSV-1 Expressing IL-12/Anti-PD-1 Antibody T3011","termGroup":"SY","termSource":"NCI"},{"termName":"T 3011","termGroup":"CN","termSource":"NCI"},{"termName":"T-3011","termGroup":"CN","termSource":"NCI"},{"termName":"T3011","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011"},{"name":"NCI_Drug_Dictionary_ID","value":"802928"},{"name":"NCI_META_CUI","value":"CL1412848"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802928"},{"name":"PDQ_Open_Trial_Search_ID","value":"802928"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173889":{"preferredName":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein","code":"C173889","definitions":[{"definition":"An attenuated oncolytic Edmonston (Ed) strain of measles virus (MV) encoding the N-terminus of the human lambda immunoglobulin light chain containing the Helicobacter pylori neutrophil-activating protein (NAP), with potential immunostimulating and antineoplastic activities. Upon administration, the oncolytic measles virus encoding H. pylori NAP selectively infects and replicates in tumor cells, leading to syncytia formation and tumor cell lysis. The expressed NAP, a toll-like receptor-2 (TLR2) agonist, may stimulate the secretion of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1 and IL-6, leading to local inflammatory reaction in the tumor microenvironment (TME). H. pylori NAP, a bacterial antigen and potent immunomodulator, may enhance the antitumor effect of oncolytic MV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein","termGroup":"PT","termSource":"NCI"},{"termName":"MV Encoding NAP","termGroup":"SY","termSource":"NCI"},{"termName":"MV-s-NAP","termGroup":"SY","termSource":"NCI"},{"termName":"Oncolytic Measles Virus Encoding H. pylori NAP","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein"},{"name":"NCI_Drug_Dictionary_ID","value":"802401"},{"name":"NCI_META_CUI","value":"CL1407687"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802401"},{"name":"PDQ_Open_Trial_Search_ID","value":"802401"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"Semantic_Type","value":"Virus"}]}}{"C172098":{"preferredName":"Oxaliplatin Eluting Beads","code":"C172098","definitions":[{"definition":"A formulation of drug-eluting beads (DEB) consisting of polymeric microbeads impregnated with the organoplatinum complex and alkylating agent oxaliplatin, with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with oxaliplatin. During transarterial chemoembolization (TACE) in the hepatic artery, the oxaliplatin eluting beads occlude tumor blood vessels that feed the tumor and induce ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature. The beads release cytotoxic oxaliplatin locally, which may result in oxaliplatin-mediated inhibition of tumor cell proliferation through formation of both inter- and intra-strand platinum-DNA crosslinks, and the inhibition of DNA replication.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oxaliplatin Eluting Beads","termGroup":"PT","termSource":"NCI"},{"termName":"CalliSpheres Drug-Eluting Beads with Oxaliplatin","termGroup":"SY","termSource":"NCI"},{"termName":"DEB with Oxaliplatin","termGroup":"SY","termSource":"NCI"},{"termName":"Deboxa","termGroup":"SY","termSource":"NCI"},{"termName":"Drug-Eluting Beads with Oxaliplatin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oxaliplatin Eluting Beads"},{"name":"NCI_Drug_Dictionary_ID","value":"801475"},{"name":"NCI_META_CUI","value":"CL1406222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801475"},{"name":"PDQ_Open_Trial_Search_ID","value":"801475"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167257":{"preferredName":"p97 Inhibitor CB-5339","code":"C167257","definitions":[{"definition":"An orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including ER-associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p97 Inhibitor CB-5339","termGroup":"PT","termSource":"NCI"},{"termName":"CB 5339","termGroup":"CN","termSource":"NCI"},{"termName":"CB-5339","termGroup":"CN","termSource":"NCI"},{"termName":"CB5339","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p97 Inhibitor CB-5339"},{"name":"NCI_Drug_Dictionary_ID","value":"800449"},{"name":"NCI_META_CUI","value":"CL972245"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800449"},{"name":"PDQ_Open_Trial_Search_ID","value":"800449"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167262":{"preferredName":"p97 Inhibitor CB-5339 Tosylate","code":"C167262","definitions":[{"definition":"The tosylate salt of  CB-5339, an orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including endoplasmic reticulum associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"p97 Inhibitor CB-5339 Tosylate","termGroup":"PT","termSource":"NCI"},{"termName":"CB 5339 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"CB-5339 Tosylate","termGroup":"SY","termSource":"NCI"},{"termName":"CB5339 Tosylate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p97 Inhibitor CB-5339 Tosylate"},{"name":"NCI_Drug_Dictionary_ID","value":"800450"},{"name":"NCI_META_CUI","value":"CL972249"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800450"},{"name":"PDQ_Open_Trial_Search_ID","value":"800450"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166138":{"preferredName":"Pan-KRAS Inhibitor BI 1701963","code":"C166138","definitions":[{"definition":"An orally available protein-protein interaction (PPI) inhibitor that targets the guanine nucleotide exchange factor Son of sevenless homolog 1 (SOS1), with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BI 1701963 selectively targets and binds to SOS1, thereby preventing the interaction of SOS1 with Kirsten rat sarcoma viral oncogene homolog (KRAS) in the guanosine diphosphate (GDP)-bound 'off' state, which is the inactivated state of KRAS. This abrogates the exchange of RAS-bound GDP for guanosine triphosphate (GTP) and prevents the formation of GTP-loaded KRAS, which is the activated 'on' state of KRAS. This prevents activation of downstream RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway by GTP-loaded KRAS. This inhibits mutant KRAS-dependent signaling and may inhibit growth and survival of KRAS-expressing tumor cells. KRAS is a member of the RAS family of oncogenes that is mutated in many cancer cell types. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, survival, invasion, and metastasis. SOS1 regulates the KRAS GDP-GTP cycle and promotes nucleotide exchange and formation of 'active' KRAS-GTP.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pan-KRAS Inhibitor BI 1701963","termGroup":"PT","termSource":"NCI"},{"termName":"BI 1701963","termGroup":"CN","termSource":"NCI"},{"termName":"BI-1701963","termGroup":"CN","termSource":"NCI"},{"termName":"BI1701963","termGroup":"CN","termSource":"NCI"},{"termName":"PPI Inhibitor BI 1701963","termGroup":"SY","termSource":"NCI"},{"termName":"Protein-protein Interaction Inhibitor BI 1701963","termGroup":"SY","termSource":"NCI"},{"termName":"SOS1:KRAS Interaction Inhibitor BI 1701963","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pan-KRAS Inhibitor BI 1701963"},{"name":"NCI_Drug_Dictionary_ID","value":"799903"},{"name":"NCI_META_CUI","value":"CL979206"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799903"},{"name":"PDQ_Open_Trial_Search_ID","value":"799903"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165567":{"preferredName":"Zipalertinib","code":"C165567","definitions":[{"definition":"An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), with potential antineoplastic activity. CLN-081 is also active against other EGFR mutations including exon 19 deletions (exon19del), L858R, and T790M, as well as the less common G719X, L861Q and S768I mutations. Upon administration, zipalertinib specifically and covalently binds to and inhibits a variety of EGFR mutations, with particularly high selectivity against EGFR Ex20ins, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CLN-081 may have therapeutic benefits in tumors with EGFR Ex20ins, as most EGFR mutant-selective inhibitors are not active against EGFR Ex20ins. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zipalertinib","termGroup":"PT","termSource":"NCI"},{"termName":"CLN 081","termGroup":"CN","termSource":"NCI"},{"termName":"CLN-081","termGroup":"CN","termSource":"NCI"},{"termName":"CLN081","termGroup":"CN","termSource":"NCI"},{"termName":"EGFR Mutant-specific Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"Mutation-specific EGFR TKI TAS6417","termGroup":"SY","termSource":"NCI"},{"termName":"Pan- EGFR Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-mutation-selective EGFR Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"Pan-mutation-selective EGFR Tyrosine Kinase Inhibitor CLN-081","termGroup":"SY","termSource":"NCI"},{"termName":"TAS 6417","termGroup":"CN","termSource":"NCI"},{"termName":"TAS-6417","termGroup":"CN","termSource":"NCI"},{"termName":"TAS6417","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1661854-97-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"T4YMU8TW9H"},{"name":"Maps_To","value":"Pan-mutation-selective EGFR Inhibitor CLN-081"},{"name":"NCI_Drug_Dictionary_ID","value":"799981"},{"name":"NCI_META_CUI","value":"CL978830"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799981"},{"name":"PDQ_Open_Trial_Search_ID","value":"799981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172394":{"preferredName":"Boditrectinib","code":"C172394","definitions":[{"definition":"An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, boditrectinib specifically targets and binds to TRK, TRK mutations and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC). This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Boditrectinib","termGroup":"PT","termSource":"NCI"},{"termName":"AUM-601","termGroup":"CN","termSource":"NCI"},{"termName":"CHC 2014","termGroup":"CN","termSource":"NCI"},{"termName":"CHC-2014","termGroup":"CN","termSource":"NCI"},{"termName":"HL5101","termGroup":"CN","termSource":"NCI"},{"termName":"NOV 1601","termGroup":"CN","termSource":"NCI"},{"termName":"NOV-1601","termGroup":"CN","termSource":"NCI"},{"termName":"NOV1601","termGroup":"CN","termSource":"NCI"},{"termName":"Pan-TRK Inhibitor NOV1601","termGroup":"SY","termSource":"NCI"},{"termName":"TRK Inhibitor NOV1601","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1940165-80-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"M359MC7QGE"},{"name":"Maps_To","value":"Pan-TRK Inhibitor NOV1601"},{"name":"NCI_Drug_Dictionary_ID","value":"801625"},{"name":"NCI_META_CUI","value":"CL1406349"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801625"},{"name":"PDQ_Open_Trial_Search_ID","value":"801625"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168601":{"preferredName":"Senaparib","code":"C168601","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, senaparib selectively binds to PARP 1 and 2 and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Senaparib","termGroup":"PT","termSource":"NCI"},{"termName":"IMP 4297","termGroup":"CN","termSource":"NCI"},{"termName":"IMP-4297","termGroup":"CN","termSource":"NCI"},{"termName":"IMP4297","termGroup":"CN","termSource":"NCI"},{"termName":"PARP 1/2 Inhibitor IMP4297","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1401682-78-7"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"MNZ4OP95CF"},{"name":"Maps_To","value":"PARP 1/2 Inhibitor IMP4297"},{"name":"NCI_Drug_Dictionary_ID","value":"800374"},{"name":"NCI_META_CUI","value":"CL972916"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800374"},{"name":"PDQ_Open_Trial_Search_ID","value":"800374"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167278":{"preferredName":"PARP Inhibitor NMS-03305293","code":"C167278","definitions":[{"definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, PARP inhibitor NMS-03305293 selectively binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PARP Inhibitor NMS-03305293","termGroup":"PT","termSource":"NCI"},{"termName":"NMS 03305293","termGroup":"CN","termSource":"NCI"},{"termName":"NMS-03305293","termGroup":"CN","termSource":"NCI"},{"termName":"NMS03305293","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PARP Inhibitor NMS-03305293"},{"name":"NCI_Drug_Dictionary_ID","value":"802331"},{"name":"NCI_META_CUI","value":"CL972264"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802331"},{"name":"PDQ_Open_Trial_Search_ID","value":"802331"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170764":{"preferredName":"Atamparib","code":"C170764","definitions":[{"definition":"An orally available small molecule inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration,atamparib selectively binds to PARP7 and restores interferon (type 1) signaling.  This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atamparib","termGroup":"PT","termSource":"NCI"},{"termName":"PARP7 Inhibitor RBN-2397","termGroup":"SY","termSource":"NCI"},{"termName":"RBN 2397","termGroup":"CN","termSource":"NCI"},{"termName":"RBN-2397","termGroup":"CN","termSource":"NCI"},{"termName":"RBN2397","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2381037-82-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"B1MW2ME77A"},{"name":"Maps_To","value":"PARP7 Inhibitor RBN-2397"},{"name":"NCI_Drug_Dictionary_ID","value":"800790"},{"name":"NCI_META_CUI","value":"CL1383178"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800790"},{"name":"PDQ_Open_Trial_Search_ID","value":"800790"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166387":{"preferredName":"Parsaclisib Hydrochloride","code":"C166387","definitions":[{"definition":"The hydrochloride salt form of parsaclisib, an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Parsaclisib Hydrochloride","termGroup":"PT","termSource":"NCI"},{"termName":"(4R)-4-(3-((1S)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-onehydrochloric Acid (1:1)","termGroup":"SN","termSource":"NCI"},{"termName":"2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, Hydrochloride (1:1), (4R)-","termGroup":"SY","termSource":"NCI"},{"termName":"INCB 50465 Hydrochloride","termGroup":"SY","termSource":"NCI"},{"termName":"INCB050465 Hydrochloride","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1995889-48-9"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"S0GJ8VM4P9"},{"name":"Maps_To","value":"Parsaclisib Hydrochloride"},{"name":"NCI_META_CUI","value":"CL971639"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167207":{"preferredName":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201","code":"C167207","definitions":[{"definition":"A T-regulatory (Treg) cell donor graft that has been partially engineered by depleting all the T-cells and then enriching the graft with infusions of conventional T-cells, Tregs and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors, with potential immunomodulating activity. Upon administration of the partially engineered T-regulatory cell donor graft TRGFT-201 following myeloablation, the allograft may induce tolerance in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) as treatment for hematologic malignancies.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201","termGroup":"PT","termSource":"NCI"},{"termName":"Orca-T","termGroup":"BR","termSource":"NCI"},{"termName":"Partially Engineered and Enriched Treg Donor Graft TRGFT-201","termGroup":"SY","termSource":"NCI"},{"termName":"T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"TregGraft","termGroup":"BR","termSource":"NCI"},{"termName":"TRGFT 201","termGroup":"CN","termSource":"NCI"},{"termName":"TRGFT-201","termGroup":"CN","termSource":"NCI"},{"termName":"TRGFT201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Partially Engineered T-regulatory Cell Donor Graft TRGFT-201"},{"name":"NCI_Drug_Dictionary_ID","value":"800419"},{"name":"NCI_META_CUI","value":"CL972434"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800419"},{"name":"PDQ_Open_Trial_Search_ID","value":"800419"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170900":{"preferredName":"PD-L1 Inhibitor GS-4224","code":"C170900","definitions":[{"definition":"An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory, anti-viral and antineoplastic activities. Upon administration, PD-L1 inhibitor GS-4224 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. It may also enhance hepatitis B virus (HBV)-specific CD8+ T-cell function, thereby killing HBV-infected cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells. It is also upregulated in HBV-positive patients and contributes to immune dysfunction against HBV infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1 Inhibitor GS-4224","termGroup":"PT","termSource":"NCI"},{"termName":"GS 4224","termGroup":"CN","termSource":"NCI"},{"termName":"GS-4224","termGroup":"CN","termSource":"NCI"},{"termName":"GS4224","termGroup":"CN","termSource":"NCI"},{"termName":"PD-1 Ligand 1 Inhibitor GS-4224","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-L1 Inhibitor GS-4224"},{"name":"NCI_Drug_Dictionary_ID","value":"800806"},{"name":"NCI_META_CUI","value":"CL1383048"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800806"},{"name":"PDQ_Open_Trial_Search_ID","value":"800806"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174020":{"preferredName":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480","code":"C174020","definitions":[{"definition":"A recombinant, trispecific monovalent antibody-based molecule targeting the human programmed death-ligand 1 (PD-L1), 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and human serum albumin (HSA), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. PD-L1/4-1BB/HSA trispecific fusion protein NM21-1480 consists of three monovalent antibody Fvs specific for PD-L1, HSA and 4-1BB fused in a single chain. Upon administration, PD-L1/4-1BB/HSA trispecific fusion protein NM21-1480 simultaneously targets and binds to a membrane-distal epitope of 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. The simultaneous binding to PD-L1 enables clustering of 4-1BB and thereby allows for conditional stimulation of 4-1BB signaling in the tumor microenvironment (TME) only upon binding to PD-L1 on tumor cells. 4-1BB activation results in T-cell stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, NM21-1480 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. HSA fusion prolongs the half-life of NM21-1480. The conditional activation of 4-1BB signaling prevents systemic T-cell activation and lowers toxicity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480","termGroup":"PT","termSource":"NCI"},{"termName":"alphaPD-L1/4-1BB/HSA NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"alphaPD-L1/alpha4-1BB/alphaHSA NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"ND 021","termGroup":"CN","termSource":"NCI"},{"termName":"ND-021","termGroup":"CN","termSource":"NCI"},{"termName":"ND021","termGroup":"CN","termSource":"NCI"},{"termName":"NM21 1480","termGroup":"CN","termSource":"NCI"},{"termName":"NM21-1480","termGroup":"CN","termSource":"NCI"},{"termName":"NM211480","termGroup":"CN","termSource":"NCI"},{"termName":"PD-L1/4-1BB/HSA Trispecific scDb-scFv NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"PD-L1/4-1BB/HSA Trispecific scMATCH3 NM21-1480","termGroup":"SY","termSource":"NCI"},{"termName":"Trispecific Anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) scFv Fusion Protein NM21-1480","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"E6OIF2QOI3"},{"name":"Maps_To","value":"PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480"},{"name":"NCI_Drug_Dictionary_ID","value":"802455"},{"name":"NCI_META_CUI","value":"CL1407921"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802455"},{"name":"PDQ_Open_Trial_Search_ID","value":"802455"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167334":{"preferredName":"Pegylated SN-38 Conjugate PLX038","code":"C167334","definitions":[{"definition":"A pegylated conjugate of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon administration, the proprietary linker slowly releases SN-38 from the pegylated SN-38 conjugate PLX038. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Compared with irinotecan, this formulation allows higher accumulation in solid tumors due to its nanoparticle size and long half-life.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pegylated SN-38 Conjugate PLX038","termGroup":"PT","termSource":"NCI"},{"termName":"Pegylated SN-38 PLX038","termGroup":"SY","termSource":"NCI"},{"termName":"PLX 038","termGroup":"CN","termSource":"NCI"},{"termName":"PLX-038","termGroup":"CN","termSource":"NCI"},{"termName":"PLX038","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pegylated SN-38 Conjugate PLX038"},{"name":"NCI_Drug_Dictionary_ID","value":"800470"},{"name":"NCI_META_CUI","value":"CL972311"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800470"},{"name":"PDQ_Open_Trial_Search_ID","value":"800470"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173152":{"preferredName":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC","code":"C173152","definitions":[{"definition":"A peptide-based, personalized cancer therapeutic vaccine consisting of up to 8 patient-specific tumor peptides, which are immunogenic and unique to the patient's tumor and identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), with potential immunomodulating and antineoplastic activities. Upon administration, personalized and adjusted neoantigen peptide vaccine PANDA-VAC stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens. The vaccine may be adjusted after initial therapy according to sequencing data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC","termGroup":"PT","termSource":"NCI"},{"termName":"PANDA-VAC","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen Peptide Vaccine PANDA-VAC","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen Peptide-poly-ICLC Vaccine PANDA-VAC","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC"},{"name":"NCI_Drug_Dictionary_ID","value":"802057"},{"name":"NCI_META_CUI","value":"CL1407017"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802057"},{"name":"PDQ_Open_Trial_Search_ID","value":"802057"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171430":{"preferredName":"Personalized Neoantigen DNA Vaccine GNOS-PV01","code":"C171430","definitions":[{"definition":"A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon administration of GNOS-PV01, the patient-specific neoantigens are translated in cells and elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. Each patient specific formulation may contain multiple DNA plasmids, and each plasmid may contain multiple neoantigen DNA sequences, allowing the delivery of multiple neoantigen DNA sequences simultaneously.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoantigen DNA Vaccine GNOS-PV01","termGroup":"PT","termSource":"NCI"},{"termName":"GNOS-PV01","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen Vaccine GNOS-PV01","termGroup":"SY","termSource":"NCI"},{"termName":"Personalized Neoantigen-based Vaccine GNOS-PV01","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoantigen DNA Vaccine GNOS-PV01"},{"name":"NCI_Drug_Dictionary_ID","value":"801973"},{"name":"NCI_META_CUI","value":"CL1405519"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801973"},{"name":"PDQ_Open_Trial_Search_ID","value":"801973"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170950":{"preferredName":"Personalized Neoantigen DNA Vaccine GNOS-PVO2","code":"C170950","definitions":[{"definition":"A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon intradermal delivery by electroporation of GNOS-PVO2, the patient-specific neoantigens are translated in cells and elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. Each patient specific formulation may contain multiple DNA plasmids, and each plasmid may contain multiple neoantigen DNA sequences, allowing the delivery of multiple neoantigen DNA sequences simultaneously.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personalized Neoantigen DNA Vaccine GNOS-PVO2","termGroup":"PT","termSource":"NCI"},{"termName":"GNOS-PVO2","termGroup":"CN","termSource":"NCI"},{"termName":"Neoantigen Vaccine GNOS-PVO2","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personalized Neoantigen DNA Vaccine GNOS-PVO2"},{"name":"NCI_Drug_Dictionary_ID","value":"801211"},{"name":"NCI_META_CUI","value":"CL1383225"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801211"},{"name":"PDQ_Open_Trial_Search_ID","value":"801211"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172822":{"preferredName":"Photodynamic Compound TLD-1433","code":"C172822","definitions":[{"definition":"A non-toxic ruthenium-based coordination-complex and photosensitizer, with potential antineoplastic activity upon photodynamic therapy (PDT). Upon intravesical administration, light-activated photodynamic compound (PDC) TLD-1433 targets and binds to transferrin (Tf) and is subsequently taken up by Tf receptors which are located on tumor cells. Upon exposure to green light (525nm), TLD-1433 becomes activated locally and induces the generation of reactive oxygen species (ROS) and singlet oxygen. The release of free radicals may induce apoptosis and destroy the tumor cells. Cancer cells have many more Tf receptors than normal cells,","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Photodynamic Compound TLD-1433","termGroup":"PT","termSource":"NCI"},{"termName":"PDC TLD-1433","termGroup":"SY","termSource":"NCI"},{"termName":"TLD 1433","termGroup":"CN","termSource":"NCI"},{"termName":"TLD-1433","termGroup":"CN","termSource":"NCI"},{"termName":"TLD1433","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1471479-22-7"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"L59D69SZN5"},{"name":"Maps_To","value":"Photodynamic Compound TLD-1433"},{"name":"NCI_Drug_Dictionary_ID","value":"801697"},{"name":"NCI_META_CUI","value":"CL1406854"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801697"},{"name":"PDQ_Open_Trial_Search_ID","value":"801697"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171387":{"preferredName":"Plasmid DNA Vaccine pING-hHER3FL","code":"C171387","definitions":[{"definition":"A plasmid DNA cancer vaccine encoding the tumor-associated antigen (TAA) human epidermal growth factor receptor type-3 (HER-3; HER3), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the plasmid DNA vaccine pING-hHER3FL and after cellular uptake by muscle cells, the plasmid DNA expresses HER-3 which, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-3. HER-3 plays a key role in tumor cell proliferation and its overexpression is associated with poor prognosis. HER-3 is associated with tumor cell resistance to anti-HER-2 therapeutics.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plasmid DNA Vaccine pING-hHER3FL","termGroup":"PT","termSource":"NCI"},{"termName":"pING-hHER3FL","termGroup":"CN","termSource":"NCI"},{"termName":"pING-hHER3FL Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Plasmid DNA Vaccine pING-hHER3FL"},{"name":"NCI_Drug_Dictionary_ID","value":"801289"},{"name":"NCI_META_CUI","value":"CL1405505"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801289"},{"name":"PDQ_Open_Trial_Search_ID","value":"801289"},{"name":"Semantic_Type","value":"Gene or Genome"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175536":{"preferredName":"pNGVL4a-CRT-E6E7L2 DNA Vaccine","code":"C175536","definitions":[{"definition":"A therapeutic DNA vaccine encoding human calreticulin (CRT) linked to human papillomavirus (HPV) type 16 E6, E7, and L2 proteins, with potential immunomodulating and antineoplastic activities. Upon administration via intramuscular injection with electroporation, the pNGVL4a-CRT-E6E7L2 DNA vaccine expresses HPV16 E6, E7 and L2 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response and humoral immune responses against tumor cells expressing these proteins, resulting in tumor cell lysis and tumor cell death. In addition, HPV16 L2-specific neutralizing antibody may prevent a broad spectrum of HPV infections and HPV-associated cancers. The heat shock protein CRT may potentiate MHC class I presentation to antigen-specific CD8-positive T-cells, enhancing the induction of cellular immunity and the potency of the vaccine.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pNGVL4a-CRT-E6E7L2 DNA Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"pNGVL4a-CRT-E6E7L2","termGroup":"CN","termSource":"NCI"},{"termName":"pNGVL4a-CRTE6E7L2","termGroup":"CN","termSource":"NCI"},{"termName":"pNGVL4aCRTE6E7L2","termGroup":"CN","termSource":"NCI"},{"termName":"pNGVL4aCRTE6E7L2 DNA Vaccine","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pNGVL4a-CRT-E6E7L2 DNA Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"803294"},{"name":"NCI_META_CUI","value":"CL1412894"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803294"},{"name":"PDQ_Open_Trial_Search_ID","value":"803294"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172205":{"preferredName":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2","code":"C172205","definitions":[{"definition":"A cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential immunostimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. HPV16 L2/E6/E7 fusion protein TA-CIN vaccine is a recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\\E6\\E7). Upon administration, this boost vaccine may stimulate the immune system to generate HPV16 E6\\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2","termGroup":"PT","termSource":"NCI"},{"termName":"PVX 2","termGroup":"CN","termSource":"NCI"},{"termName":"PVX-2","termGroup":"CN","termSource":"NCI"},{"termName":"PVX2","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2"},{"name":"NCI_Drug_Dictionary_ID","value":"801534"},{"name":"NCI_META_CUI","value":"CL1406087"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801534"},{"name":"PDQ_Open_Trial_Search_ID","value":"801534"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165666":{"preferredName":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255","code":"C165666","definitions":[{"definition":"A long-acting formulation composed of the human cytokine interleukin-15 (IL-15) that is conjugated by polymers, with potential immunomodulating and anti-tumor activities. Upon administration of polymer-conjugated IL-15 receptor agonist NKTR-255, the IL-15 moiety targets and binds to the alpha subunit of the IL-15 receptor on natural killer (NK) and T-cells, thereby activating the IL-15-mediated pathway. This leads to the expansion and activation of natural killer (NK) cells and memory CD8+ T-cells, thereby enhancing the anti-tumor activity of NKs and long-term memory T-lymphocyte immune responses. This may increase tumor cell killing and decrease tumor cell proliferation. In addition, NKTR-255 may, when combined with a tumor-directed antibody, enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. IL-15 is a pro-inflammatory cytokine that plays a key role in the regulation of T- and NK cell activation, proliferation and promotion of their anti-tumor effects. Compared to IL-15 alone, the polymer formulation allows for increased retention at the tumor site and reduced clearance, thereby increasing the effect of IL-15.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255","termGroup":"PT","termSource":"NCI"},{"termName":"IL-15 Receptor Agonist NKTR-255","termGroup":"SY","termSource":"NCI"},{"termName":"Long-acting Polymer-engineered IL-15 Conjugate NKTR-255","termGroup":"SY","termSource":"NCI"},{"termName":"NKTR 255","termGroup":"CN","termSource":"NCI"},{"termName":"NKTR-255","termGroup":"CN","termSource":"NCI"},{"termName":"NKTR255","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Polymer-conjugated IL-15 Receptor Agonist NKTR-255"},{"name":"NCI_Drug_Dictionary_ID","value":"800122"},{"name":"NCI_META_CUI","value":"CL978933"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800122"},{"name":"PDQ_Open_Trial_Search_ID","value":"800122"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172189":{"preferredName":"Porcupine Inhibitor XNW7201","code":"C172189","definitions":[{"definition":"An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, PORCN inhibitor XNW7201 targets, binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. PORCN, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers and plays a key role in cancer cell survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Porcupine Inhibitor XNW7201","termGroup":"PT","termSource":"NCI"},{"termName":"PORCN Inhibitor XNW7201","termGroup":"SY","termSource":"NCI"},{"termName":"XNW 7201","termGroup":"CN","termSource":"NCI"},{"termName":"XNW-7201","termGroup":"CN","termSource":"NCI"},{"termName":"XNW7201","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Porcupine Inhibitor XNW7201"},{"name":"NCI_Drug_Dictionary_ID","value":"801526"},{"name":"NCI_META_CUI","value":"CL1406288"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801526"},{"name":"PDQ_Open_Trial_Search_ID","value":"801526"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C169105":{"preferredName":"PPAR Alpha Antagonist TPST-1120","code":"C169105","definitions":[{"definition":"An orally bioavailable, small molecule, selective and competitive antagonist of peroxisome proliferator activated receptor alpha (PPARa), with potential immunomodulating and antineoplastic activities. Upon oral administration, TPST-1120 targets, binds to and blocks the activity of PPARa, thereby blocking transcription of PPARa target genes leading to an intracellular metabolism shift from fatty acid oxidation (FAO) to glycolysis in FAO-dependent tumors and reducing the production of fatty acids in the tumor microenvironment (TME). As fatty acids are essential for tumor cell growth in FAO-dependent tumor cells and are needed for the metabolism of suppressive immune cells in the TME, including regulatory T-cells (Tregs), reducing the amount of fatty acids leads to a direct killing of FAO-dependent tumor cells. It also skews macrophages from the immune suppressive M2 phenotype to an effector M1 phenotype and facilitates the cytotoxicity of immune effector cells, thereby stimulating an anti-tumor immune response and further killing tumor cells. TPST-1120 also restores the natural inhibitor of angiogenesis thrombospondin-1 (TSP-1) and stimulator of interferon genes (STING) in the TME. PPARa, a ligand-activated nuclear transcription factor and metabolic checkpoint, regulates the expression of FAO genes and lipid metabolism. It plays a key role in immunosuppression in the TME. FAO is a metabolic pathway essential to tumor growth, survival and immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PPAR Alpha Antagonist TPST-1120","termGroup":"PT","termSource":"NCI"},{"termName":"Peroxisome Proliferator Activated Receptor Alpha Antagonist TPST-1120","termGroup":"SY","termSource":"NCI"},{"termName":"PPARA Antagonist TPST-1120","termGroup":"SY","termSource":"NCI"},{"termName":"PPARalpha Antagonist TPST-1120","termGroup":"SY","termSource":"NCI"},{"termName":"TPST 1120","termGroup":"CN","termSource":"NCI"},{"termName":"TPST-1120","termGroup":"CN","termSource":"NCI"},{"termName":"TPST1120","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PPAR Alpha Antagonist TPST-1120"},{"name":"NCI_Drug_Dictionary_ID","value":"800961"},{"name":"NCI_META_CUI","value":"CL1382244"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800961"},{"name":"PDQ_Open_Trial_Search_ID","value":"800961"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168531":{"preferredName":"PRMT5 Inhibitor PRT811","code":"C168531","definitions":[{"definition":"An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration, PRMT5 inhibitor PRT811 selectively binds to PRMT5 and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PRMT5 Inhibitor PRT811","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Arginine Methyltransferase 5 Inhibitor PRT811","termGroup":"SY","termSource":"NCI"},{"termName":"PRT 811","termGroup":"CN","termSource":"NCI"},{"termName":"PRT-811","termGroup":"CN","termSource":"NCI"},{"termName":"PRT811","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PRMT5 Inhibitor PRT811"},{"name":"NCI_Drug_Dictionary_ID","value":"800369"},{"name":"NCI_META_CUI","value":"CL972859"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800369"},{"name":"PDQ_Open_Trial_Search_ID","value":"800369"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166122":{"preferredName":"Ifebemtinib","code":"C166122","definitions":[{"definition":"An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) with potential antineoplastic activity. Upon oral administration, ifebemtinib targets and inhibits, in an adenosine triphosphate (ATP)-competitive manner, PTK2. This prevents PTK2-mediated downstream signaling and inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells. The cytoplasmic tyrosine kinase PTK2, a signal transducer for integrins overexpressed in various tumor cell types, is involved in tumor cell invasion, migration and proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ifebemtinib","termGroup":"PT","termSource":"NCI"},{"termName":"BI 853520","termGroup":"CN","termSource":"NCI"},{"termName":"BI-853520","termGroup":"CN","termSource":"NCI"},{"termName":"BI853520","termGroup":"CN","termSource":"NCI"},{"termName":"FAK1 Inhibitor IN10018","termGroup":"SY","termSource":"NCI"},{"termName":"IN 10018","termGroup":"CN","termSource":"NCI"},{"termName":"IN-10018","termGroup":"CN","termSource":"NCI"},{"termName":"IN10018","termGroup":"CN","termSource":"NCI"},{"termName":"Protein Tyrosine Kinase 2 Inhibitor BI 853520","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Tyrosine Kinase 2 Inhibitor IN10018","termGroup":"SY","termSource":"NCI"},{"termName":"PTK2 Inhibitor IN10018","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1227948-82-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"C57O858DKU"},{"name":"Maps_To","value":"Protein Tyrosine Kinase 2 Inhibitor IN10018"},{"name":"NCI_Drug_Dictionary_ID","value":"699455"},{"name":"NCI_META_CUI","value":"CL979217"},{"name":"PDQ_Closed_Trial_Search_ID","value":"699455"},{"name":"PDQ_Open_Trial_Search_ID","value":"699455"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175380":{"preferredName":"Pyruvate Kinase M2 Isoform Activator TP-1454","code":"C175380","definitions":[{"definition":"An orally bioavailable activator of pyruvate kinase M2 isoform (PKM2), with potential immunomodulating and antineoplastic activities. Upon oral administration, PKM2 activator TP-1454 locks PKM2 into the active tetrameric form. This may prevent the production of glycolytic intermediates by the less active dimer form of PKM2, depleting the supply of glycolytic intermediates which are needed for tumor cell growth. This may also inhibit immune suppression mediated by the dimer form of PKM2. Altogether, this may slow tumor cell growth and enhance anti-tumor immune responses, thereby inhibiting tumor cell proliferation. PKM2, the predominant PK isoform found in tumor cells, is responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pyruvate Kinase M2 Isoform Activator TP-1454","termGroup":"PT","termSource":"NCI"},{"termName":"PKM2 Activator TP-1454","termGroup":"SY","termSource":"NCI"},{"termName":"TP 1454","termGroup":"CN","termSource":"NCI"},{"termName":"TP-1454","termGroup":"CN","termSource":"NCI"},{"termName":"TP1454","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pyruvate Kinase M2 Isoform Activator TP-1454"},{"name":"NCI_Drug_Dictionary_ID","value":"803280"},{"name":"NCI_META_CUI","value":"CL1412698"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803280"},{"name":"PDQ_Open_Trial_Search_ID","value":"803280"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170742":{"preferredName":"Recombinant Bacterial Minicells VAX014","code":"C170742","definitions":[{"definition":"A population of recombinant bacterial minicells (rBMCs) engineered to express the alpha3beta1 (a3b1) and alpha5beta1 (a5b1) integrin-targeting invasion and that contain a bacterial protein toxin, perfringolysin O (PFO), with potential antineoplastic activity. Upon intravesical administration, VAX014 selectively targets and binds to tumor cells expressing un-ligated a3b1 and/or a5b1 integrins and delivers PFO, leading to destabilization of tumor cell membranes and tumor cell lysis. By targeting un-ligated a3b1 and/or a5b1 integrins, VAX014 selectively targets tumor cells over normal cells, with potentially less adverse effects in comparison with first generation integrin-targeted therapies.      ","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Bacterial Minicells VAX014","termGroup":"PT","termSource":"NCI"},{"termName":"rBMCs VAX014","termGroup":"SY","termSource":"NCI"},{"termName":"VAX 014","termGroup":"CN","termSource":"NCI"},{"termName":"VAX-014","termGroup":"CN","termSource":"NCI"},{"termName":"VAX-IP","termGroup":"SY","termSource":"NCI"},{"termName":"VAX-IP Minicells","termGroup":"SY","termSource":"NCI"},{"termName":"VAX014","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Bacterial Minicells VAX014"},{"name":"NCI_Drug_Dictionary_ID","value":"801175"},{"name":"NCI_META_CUI","value":"CL1383139"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801175"},{"name":"PDQ_Open_Trial_Search_ID","value":"801175"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168605":{"preferredName":"Recombinant Human Papillomavirus 11-valent Vaccine","code":"C168605","definitions":[{"definition":"A recombinant, 11-valent, human papillomavirus (HPV) vaccine, produced in Hansenula polymorpha, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant HPV 11-valent vaccine may generate humoral and cellular immunity against the 11 undisclosed types of HPV antigens, thereby preventing cervical infection upon exposure to these 11 types of HPV. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Human Papillomavirus 11-valent Vaccine","termGroup":"PT","termSource":"NCI"},{"termName":"11-valent Recombinant HPV Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"11-valent Recombinant Human Papillomavirus Vaccine","termGroup":"SY","termSource":"NCI"},{"termName":"11-valent Recombinant Human Papillomavirus Vaccine (Hansenula polymorpha)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Human Papillomavirus 11-valent Vaccine"},{"name":"NCI_Drug_Dictionary_ID","value":"800414"},{"name":"NCI_META_CUI","value":"CL972920"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800414"},{"name":"PDQ_Open_Trial_Search_ID","value":"800414"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170907":{"preferredName":"Rilunermin Alfa","code":"C170907","definitions":[{"definition":"A recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L), with potential pro-apoptotic and antineoplastic activities. The binding of TRAIL to the Trimer-Tag allows TRAIL to form a stable covalently-linked homotrimer. Upon administration rilunermin alfa targets, binds to and trimerizes the TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby activating caspases and inducing apoptosis in TRAIL-R1/R2-expressing tumor cells. TRAIL, a homotrimeric type II transmembrane protein and member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types; The induction of receptor trimerization is needed for the initiation of the apoptotic signaling pathway. The TRAIL-Trimer retains similar bioactivity and receptor binding kinetics as native TRAIL but has more favorable pharmacokinetics and antitumor activity than native TRAIL.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rilunermin Alfa","termGroup":"PT","termSource":"NCI"},{"termName":"Recombinant Human TRAIL-Trimer Fusion Protein SCB-313","termGroup":"SY","termSource":"NCI"},{"termName":"Recombinant TNF-related Apoptosis-inducing Ligand-trimer Fusion Protein SCB-313","termGroup":"SY","termSource":"NCI"},{"termName":"SCB 313","termGroup":"CN","termSource":"NCI"},{"termName":"SCB-313","termGroup":"CN","termSource":"NCI"},{"termName":"SCB313","termGroup":"CN","termSource":"NCI"},{"termName":"TRAIL-Trimer Fusion Protein SCB-313","termGroup":"SY","termSource":"NCI"},{"termName":"TRAIL-Trimer SCB-313","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9XNC6EH85J"},{"name":"Maps_To","value":"Recombinant Human TRAIL-Trimer Fusion Protein SCB-313"},{"name":"NCI_Drug_Dictionary_ID","value":"800842"},{"name":"NCI_META_CUI","value":"CL1383053"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800842"},{"name":"PDQ_Open_Trial_Search_ID","value":"800842"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171377":{"preferredName":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301","code":"C171377","definitions":[{"definition":"A glyco-engineered heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization (ECD) domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, recombinant humanized anti-HER-2 bispecific monoclonal antibody MBS301 simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2. This prevents the activation of HER-2 signaling pathways. Also, by binding to HER-2, MBS301 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301","termGroup":"PT","termSource":"NCI"},{"termName":"Bispecific Anti-HER2 Antibody MBS301","termGroup":"SY","termSource":"NCI"},{"termName":"MBS 301","termGroup":"CN","termSource":"NCI"},{"termName":"MBS-301","termGroup":"CN","termSource":"NCI"},{"termName":"MBS301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301"},{"name":"NCI_Drug_Dictionary_ID","value":"801299"},{"name":"NCI_META_CUI","value":"CL1405488"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801299"},{"name":"PDQ_Open_Trial_Search_ID","value":"801299"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167210":{"preferredName":"Enbezotinib","code":"C167210","definitions":[{"definition":"An orally bioavailable selective dual inhibitor of fusions and mutations involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (ret) and the src family tyrosine kinases, with potential antineoplastic activity. Upon oral administration, enbezotinib specifically targets and binds to ret mutants and ret-containing fusion products. This results in an inhibition of cell growth of tumor cells that exhibit increased ret activity. By inhibiting src kinase-mediated signaling and reducing the src-initiated recruitment of multiple receptor tyrosine kinases involved in bypass resistance, enbezotinib may be able to overcome tumor resistance which may increase its therapeutic effect. Ret overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of ret tyrosine kinase activity in various cancer cell types; dysregulation of ret activity plays a key role in the development and progression of these cancers. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis. Src upregulation is seen in tumors with acquired resistance to RET inhibitors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Enbezotinib","termGroup":"PT","termSource":"NCI"},{"termName":"(3aR,11S,20aS)-7-Fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-17,19-metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one","termGroup":"SN","termSource":"NCI"},{"termName":"17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aR,11S,20aS)-","termGroup":"SN","termSource":"NCI"},{"termName":"RET/SRC Inhibitor TPX-0046","termGroup":"SY","termSource":"NCI"},{"termName":"RET/SRC Tyrosine Kinase Inhibitor TPX-0046","termGroup":"SY","termSource":"NCI"},{"termName":"TPX 0046","termGroup":"CN","termSource":"NCI"},{"termName":"TPX-0046","termGroup":"CN","termSource":"NCI"},{"termName":"TPX0046","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2359649-81-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"F6EVK907XR"},{"name":"Maps_To","value":"RET/SRC Inhibitor TPX-0046"},{"name":"NCI_Drug_Dictionary_ID","value":"802260"},{"name":"NCI_META_CUI","value":"CL972435"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802260"},{"name":"PDQ_Open_Trial_Search_ID","value":"802260"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172380":{"preferredName":"ROBO1-targeted BiCAR-NKT Cells","code":"C172380","definitions":[{"definition":"A preparation of natural killer T (NKT) cells engineered to express a chimeric antigen receptor (CAR) specific for roundabout homolog 1 (ROBO1, Robo1), with potential immunostimulating and antineoplastic activities. Upon administration, the ROBO1-targeted BiCAR-NK/T cells target and bind to ROBO1 expressed on the surface of tumor cells. This induces selective toxicity in ROBO1-expressing tumor cells. ROBO1, a member of the axon guidance receptor family, is often overexpressed in a variety of tumor types. It is involved in axon guidance, cell proliferation, cell motility and angiogenesis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ROBO1-targeted BiCAR-NKT Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Anti-ROBO1 BiCAR-NK/T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ROBO1 CAR-NK/T Cells","termGroup":"SY","termSource":"NCI"},{"termName":"ROBO1-targeted Bi-CAR-NK/T Cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"ROBO1-targeted BiCAR-NKT Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"801656"},{"name":"NCI_META_CUI","value":"CL1406507"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801656"},{"name":"PDQ_Open_Trial_Search_ID","value":"801656"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166135":{"preferredName":"RSK1-4 Inhibitor PMD-026","code":"C166135","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine kinase p90 ribosomal S6 kinase (p90RSK; RSK) subtypes 1-4, with high selectivity for RSK subtype 2 (RSK2), with potential antineoplastic activity. Upon administration of the RSK1-4 inhibitor PMD-026, this agent targets and inhibits the RSK subtypes, thereby inhibiting RSK-mediated signaling. This prevents the phosphorylation and activation of the transcription factor Y-box binding protein-1 (YB-1) and leads to cell cycle arrest, an induction of apoptosis, and an inhibition of tumor cell proliferation in RSK-expressing tumor cells. RSK is overexpressed in a variety of cancers, especially in triple negative breast cancer (TNBC). It plays a key role in tumor cell proliferation, differentiation, survival, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"RSK1-4 Inhibitor PMD-026","termGroup":"PT","termSource":"NCI"},{"termName":"PMD 026","termGroup":"CN","termSource":"NCI"},{"termName":"PMD-026","termGroup":"CN","termSource":"NCI"},{"termName":"PMD026","termGroup":"CN","termSource":"NCI"},{"termName":"RSK Inhibitor PMD-026","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"RSK1-4 Inhibitor PMD-026"},{"name":"NCI_Drug_Dictionary_ID","value":"799807"},{"name":"NCI_META_CUI","value":"CL979208"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799807"},{"name":"PDQ_Open_Trial_Search_ID","value":"799807"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173373":{"preferredName":"Ruthenium-based Small Molecule Therapeutic BOLD-100","code":"C173373","definitions":[{"definition":"A ruthenium-based, small molecule that selectively inhibits stress-induced upregulation of GRP78, with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, BOLD-100 may selectively inhibit stress-induced upregulation of GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking GRP78-induced suppression of apoptotic pathways. This may lead to the induction of tumor cell apoptosis and slow tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types. Its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ruthenium-based Small Molecule Therapeutic BOLD-100","termGroup":"PT","termSource":"NCI"},{"termName":"BOLD 100","termGroup":"CN","termSource":"NCI"},{"termName":"BOLD-100","termGroup":"CN","termSource":"NCI"},{"termName":"BOLD100","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ruthenium-based Small Molecule Therapeutic BOLD-100"},{"name":"NCI_Drug_Dictionary_ID","value":"801840"},{"name":"NCI_META_CUI","value":"CL1407205"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801840"},{"name":"PDQ_Open_Trial_Search_ID","value":"801840"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170746":{"preferredName":"SDF-1 Receptor Antagonist PTX-9908","code":"C170746","definitions":[{"definition":"A stromal cell-derived factor 1 (SDF-1; CXCL12) analog and inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, PTX-9908 selectively targets and binds to CXCR4, thereby preventing the binding of CXCR4 to its ligand SDF-1. This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. The G protein-coupled receptor CXCR4, which is overexpressed in several tumor cell types, promotes tumor angiogenesis, tumor cell proliferation, survival, invasion and metastasis. SDF-1, a major chemotactic factor, plays a key role in mediating cell trafficking via selective binding to CXCR4.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SDF-1 Receptor Antagonist PTX-9908","termGroup":"PT","termSource":"NCI"},{"termName":"CTCE 9908","termGroup":"CN","termSource":"NCI"},{"termName":"CTCE-9908","termGroup":"CN","termSource":"NCI"},{"termName":"CTCE9908","termGroup":"CN","termSource":"NCI"},{"termName":"CXCR4 Antagonist CTCE-9908","termGroup":"SY","termSource":"NCI"},{"termName":"PTX 9908","termGroup":"CN","termSource":"NCI"},{"termName":"PTX-9908","termGroup":"CN","termSource":"NCI"},{"termName":"PTX9908","termGroup":"CN","termSource":"NCI"},{"termName":"SDF-1 Analog PTX-9908","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1030384-98-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"NF0BX95A31"},{"name":"Maps_To","value":"SDF-1 Receptor Antagonist PTX-9908"},{"name":"NCI_Drug_Dictionary_ID","value":"800729"},{"name":"NCI_META_CUI","value":"CL1383156"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800729"},{"name":"PDQ_Open_Trial_Search_ID","value":"800729"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168606":{"preferredName":"Selective Estrogen Receptor Degrader LX-039","code":"C168606","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD LX-039 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Selective Estrogen Receptor Degrader LX-039","termGroup":"PT","termSource":"NCI"},{"termName":"LX 039","termGroup":"CN","termSource":"NCI"},{"termName":"LX-039","termGroup":"CN","termSource":"NCI"},{"termName":"LX039","termGroup":"CN","termSource":"NCI"},{"termName":"SERD LX-039","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader LX-039"},{"name":"NCI_Drug_Dictionary_ID","value":"800319"},{"name":"NCI_META_CUI","value":"CL972812"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800319"},{"name":"PDQ_Open_Trial_Search_ID","value":"800319"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174042":{"preferredName":"Imlunestrant","code":"C174042","definitions":[{"definition":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Imlunestrant","termGroup":"PT","termSource":"NCI"},{"termName":"LY 3484356","termGroup":"CN","termSource":"NCI"},{"termName":"LY-3484356","termGroup":"CN","termSource":"NCI"},{"termName":"LY3484356","termGroup":"CN","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader LY3484356","termGroup":"SY","termSource":"NCI"},{"termName":"SERD LY3484356","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2408840-26-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9CXQ3PF69U"},{"name":"Maps_To","value":"Selective Estrogen Receptor Degrader LY3484356"},{"name":"NCI_Drug_Dictionary_ID","value":"802339"},{"name":"NCI_META_CUI","value":"CL1407918"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802339"},{"name":"PDQ_Open_Trial_Search_ID","value":"802339"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167267":{"preferredName":"SERD ZN-c5","code":"C167267","definitions":[{"definition":"An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD ZN-c5 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SERD ZN-c5","termGroup":"PT","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Degrader ZN-c5","termGroup":"SY","termSource":"NCI"},{"termName":"Selective Estrogen Receptor Downregulator ZN-c5","termGroup":"SY","termSource":"NCI"},{"termName":"ZN c5","termGroup":"CN","termSource":"NCI"},{"termName":"ZN-c5","termGroup":"CN","termSource":"NCI"},{"termName":"ZNc5","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SERD ZN-c5"},{"name":"NCI_Drug_Dictionary_ID","value":"802322"},{"name":"NCI_META_CUI","value":"CL972255"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802322"},{"name":"PDQ_Open_Trial_Search_ID","value":"802322"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171384":{"preferredName":"Shenqi Fuzheng Injection SQ001","code":"C171384","definitions":[{"definition":"An injectable formulation composed of the two Chinese medicinal herbs Radix astragali, the root of astragalus membranaceus (huangqi) and Radix codonopsis, the root of Codonopsis pilosula (dangshen), with potential antineoplastic adjuvant and chemoprotective activities that may prevent cancer-related fatigue. Although the exact mechanisms by which shenqi fuzheng injection (SFI) have yet to be fully elucidated, the herbs may improve tumor response and/or reduce the toxicity of certain chemotherapeutics when administered together. It may also alleviate chemotherapy-associated immunosuppression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Shenqi Fuzheng Injection SQ001","termGroup":"PT","termSource":"NCI"},{"termName":"SFI","termGroup":"AB","termSource":"NCI"},{"termName":"SQ 001","termGroup":"CN","termSource":"NCI"},{"termName":"SQ-001","termGroup":"CN","termSource":"NCI"},{"termName":"SQ001","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Shenqi Fuzheng Injection SQ001"},{"name":"NCI_Drug_Dictionary_ID","value":"801246"},{"name":"NCI_META_CUI","value":"CL1405484"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801246"},{"name":"PDQ_Open_Trial_Search_ID","value":"801246"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172988":{"preferredName":"SHP2 Inhibitor RLY-1971","code":"C172988","definitions":[{"definition":"An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor RLY-1971 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SHP2 Inhibitor RLY-1971","termGroup":"PT","termSource":"NCI"},{"termName":"GDC 1971","termGroup":"CN","termSource":"NCI"},{"termName":"GDC-1971","termGroup":"CN","termSource":"NCI"},{"termName":"GDC1971","termGroup":"CN","termSource":"NCI"},{"termName":"RLY 1971","termGroup":"CN","termSource":"NCI"},{"termName":"RLY-1971","termGroup":"CN","termSource":"NCI"},{"termName":"RLY1971","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SHP2 Inhibitor RLY-1971"},{"name":"NCI_Drug_Dictionary_ID","value":"802046"},{"name":"NCI_META_CUI","value":"CL1406779"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802046"},{"name":"PDQ_Open_Trial_Search_ID","value":"802046"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C170763":{"preferredName":"Simmitinib","code":"C170763","definitions":[{"definition":"An orally bioavailable inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), and colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antiangiogenic and antineoplastic activities. Upon oral administration, simmitinib binds to and inhibits the activities of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR2, and CSF1R are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Simmitinib","termGroup":"PT","termSource":"NCI"},{"termName":"SOMCL-15-290","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Simmitinib"},{"name":"NCI_Drug_Dictionary_ID","value":"800788"},{"name":"NCI_META_CUI","value":"CL1383173"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800788"},{"name":"PDQ_Open_Trial_Search_ID","value":"800788"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174171":{"preferredName":"SIRPa-4-1BBL Fusion Protein DSP107","code":"C174171","definitions":[{"definition":"A bi-functional, trimeric, fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) fused to a 4-1BB ligand (4-1BBL), with potential immune checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, the SIRPa-4-1BBL fusion protein DSP107 selectively targets and binds to both CD47 expressed on tumor cells and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) expressed on T-cells and natural killer (NK) cells. Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of 4-1BBL to 4-1BB activates 4-1BB-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as NK-mediated tumor cell killing. The crosslinking specifically enables the activation of 4-1BB-mediated signaling in T-cells and NK cells in the tumor microenvironment (TME), allowing targeted immune responses in the TME. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIRPa-4-1BBL Fusion Protein DSP107","termGroup":"PT","termSource":"NCI"},{"termName":"CD172a-4-1BBL Trimeric Fusion Protein DSP107","termGroup":"SY","termSource":"NCI"},{"termName":"DSP 107","termGroup":"CN","termSource":"NCI"},{"termName":"DSP-107","termGroup":"CN","termSource":"NCI"},{"termName":"DSP107","termGroup":"CN","termSource":"NCI"},{"termName":"SIRPa-4-1BBL DSP107","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-4-1BBL Dual Signaling Protein DSP107","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SIRPa-4-1BBL Fusion Protein DSP107"},{"name":"NCI_Drug_Dictionary_ID","value":"802479"},{"name":"NCI_META_CUI","value":"CL1407805"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802479"},{"name":"PDQ_Open_Trial_Search_ID","value":"802479"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173706":{"preferredName":"SIRPa-Fc-CD40L Fusion Protein SL-172154","code":"C173706","definitions":[{"definition":"A bi-functional fusion protein consisting of the extracellular domains (ECDs) of human signal-regulatory protein alpha (SIRPalpha; SIRPa; CD172a) and CD40 ligand (CD40L; CD154; TRAP; TNFSF5) linked via a human Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the SIRPa-Fc-CD40L fusion protein SL-172154 selectively targets and binds to both CD47 expressed on tumor cells and CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family, expressed on antigen-presenting cells (APCs). Binding to CD47 blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. The binding of CD40L to CD40 activates CD40, increases CD40-mediated signaling and induces proliferation and activation of B-lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived dendritic cells (moDCs), and leads to the secretion of inflammatory cytokines. This activates the immune system to induce the proliferation and activation of cytotoxic T-lymphocytes (CTLs) against tumor cells. The crosslinking specifically enhances antigen presentation to CD8+ and CD4+ T lymphocytes and tumor cell phagocytosis by the APC. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"SIRPa-Fc-CD40L Fusion Protein SL-172154","termGroup":"PT","termSource":"NCI"},{"termName":"CD172a-Fc-CD40L Chimeric Protein SL-172154","termGroup":"SY","termSource":"NCI"},{"termName":"SIRPa-Fc-CD40L SL-172154","termGroup":"SY","termSource":"NCI"},{"termName":"SL 172154","termGroup":"CN","termSource":"NCI"},{"termName":"SL-172154","termGroup":"CN","termSource":"NCI"},{"termName":"SL172154","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"SIRPa-Fc-CD40L Fusion Protein SL-172154"},{"name":"NCI_Drug_Dictionary_ID","value":"801935"},{"name":"NCI_META_CUI","value":"CL1407529"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801935"},{"name":"PDQ_Open_Trial_Search_ID","value":"801935"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C111571":{"preferredName":"Spanlecortemlocel","code":"C111571","definitions":[{"definition":"A preparation of allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) expanded in culture with the stimulatory cytokines stem cell factor (SCF; Kit ligand; mast cell growth factor; MGF), FMS-like tyrosine kinase 3 ligand (Flt3L), interleukin 6 (IL-6), and thrombopoietin, in the presence of an aryl hydrocarbon receptor (AHR) antagonist LHD221 (StemRegenin-1; SR-1), with potential to improve hematopoietic recovery following myeloablative conditioning. Upon administration of Spanlecortemlocel, these cells increase and restore the number of HSPCs, which may prevent or decrease the risk of infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation. LHD221, an AHR antagonist facilitates the expansion of CD34-positive hematopoietic progenitors and impedes HSPC differentiation during cytokine-driven expansion in culture.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spanlecortemlocel","termGroup":"PT","termSource":"NCI"},{"termName":"Allogeneic UCB-derived HSPCs MGTA 456","termGroup":"SY","termSource":"NCI"},{"termName":"Allogeneic Umbilical Cord Blood-derived Hematopoietic Stem and Progenitor Cells MGTA-456","termGroup":"SY","termSource":"NCI"},{"termName":"Expanded Umbilical Cord Blood Product HSC835","termGroup":"SY","termSource":"NCI"},{"termName":"HSC 835","termGroup":"CN","termSource":"NCI"},{"termName":"HSC835","termGroup":"CN","termSource":"NCI"},{"termName":"MGTA 456","termGroup":"CN","termSource":"NCI"},{"termName":"MGTA-456","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"D8O38M043D"},{"name":"Maps_To","value":"Spanlecortemlocel"},{"name":"NCI_Drug_Dictionary_ID","value":"752075"},{"name":"NCI_META_CUI","value":"CL453979"},{"name":"PDQ_Closed_Trial_Search_ID","value":"752075"},{"name":"PDQ_Open_Trial_Search_ID","value":"752075"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175512":{"preferredName":"Emidurdar","code":"C175512","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/arginine-rich splicing factor protein kinase 1 (SRPK1) and the ATP-binding cassette sub-family G member 2 (ABCG2), with potential chemosensitizing and antineoplastic activities. Upon oral administration, emidurdar targets, binds to and inhibits the activity of SRPK1 and ABCG2. Inhibition of the cellular efflux pump ABCG2 by emidurdar prevents the efflux of co-administered chemotherapeutic agents from cancer cells. This may abrogate cancer cell drug resistance and may re-sensitize cancer cells to the chemotherapeutic agents. Inhibition of SRPK1 kinase by emidurdar inhibits the SRPK1-mediated phosphorylation of splicing factors rich in serine/arginine domains, thereby inhibiting the activation of proteins that are involved in the regulation of alternative splicing. This may inhibit cancer cell proliferation. SRPK1 is upregulated in various cancer cell types. Its upregulation is correlated with higher tumor staging, grading, and shorter survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Emidurdar","termGroup":"PT","termSource":"NCI"},{"termName":"Endovion","termGroup":"SY","termSource":"NCI"},{"termName":"N-(4-bromo-2-(1h-1,2,3,4-tetrazol-5-yl)phenyl)-N'-(3,5-bis(trifluoromethyl)phenyl)urea","termGroup":"SN","termSource":"NCI"},{"termName":"NS 3728","termGroup":"CN","termSource":"NCI"},{"termName":"NS-3728","termGroup":"CN","termSource":"NCI"},{"termName":"NS3728","termGroup":"CN","termSource":"NCI"},{"termName":"SCO 101","termGroup":"CN","termSource":"NCI"},{"termName":"SCO-101","termGroup":"CN","termSource":"NCI"},{"termName":"SCO101","termGroup":"CN","termSource":"NCI"},{"termName":"SRPK1/ABCG2 Inhibitor SCO-101","termGroup":"SY","termSource":"NCI"},{"termName":"Urea, N-(3,5-bis(trifluoromethyl)phenyl)-N'-(4-bromo-2-(1H-tetrazol-5-yl)phenyl)-","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"265646-85-3"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"943YH53W21"},{"name":"Maps_To","value":"SRPK1/ABCG2 Inhibitor SCO-101"},{"name":"NCI_Drug_Dictionary_ID","value":"803025"},{"name":"NCI_META_CUI","value":"CL1412867"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803025"},{"name":"PDQ_Open_Trial_Search_ID","value":"803025"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167292":{"preferredName":"STING Agonist BMS-986301","code":"C167292","definitions":[{"definition":"An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon administration, STING agonist BMS-986301 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist BMS-986301","termGroup":"PT","termSource":"NCI"},{"termName":"BMS 986301","termGroup":"CN","termSource":"NCI"},{"termName":"BMS-986301","termGroup":"CN","termSource":"NCI"},{"termName":"BMS986301","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist BMS-986301"},{"name":"NCI_Drug_Dictionary_ID","value":"800468"},{"name":"NCI_META_CUI","value":"CL972276"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800468"},{"name":"PDQ_Open_Trial_Search_ID","value":"800468"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165748":{"preferredName":"STING Agonist GSK3745417","code":"C165748","definitions":[{"definition":"An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist GSK3745417 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist GSK3745417","termGroup":"PT","termSource":"NCI"},{"termName":"GSK 3745417","termGroup":"CN","termSource":"NCI"},{"termName":"GSK-3745417","termGroup":"CN","termSource":"NCI"},{"termName":"GSK3745417","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist GSK3745417"},{"name":"NCI_Drug_Dictionary_ID","value":"800130"},{"name":"NCI_META_CUI","value":"CL978866"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800130"},{"name":"PDQ_Open_Trial_Search_ID","value":"800130"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165655":{"preferredName":"STING Agonist IMSA101","code":"C165655","definitions":[{"definition":"A small molecule analogue of cyclic GMP-AMP (cGAMP) that acts as an agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173) with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING agonist IMSA101 binds to STING and activates STING-mediated pathways. This activates the immune response through the activation of certain immune cells which induces the expression of pro-inflammatory cytokines and chemokines, promotes tumor-associated antigen (TAA) processing and presentation by dendritic cells (DCs) and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist IMSA101","termGroup":"PT","termSource":"NCI"},{"termName":"IMSA 101","termGroup":"CN","termSource":"NCI"},{"termName":"IMSA-101","termGroup":"CN","termSource":"NCI"},{"termName":"IMSA101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist IMSA101"},{"name":"NCI_Drug_Dictionary_ID","value":"800118"},{"name":"NCI_META_CUI","value":"CL978957"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800118"},{"name":"PDQ_Open_Trial_Search_ID","value":"800118"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165566":{"preferredName":"STING Agonist SB 11285","code":"C165566","definitions":[{"definition":"An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist SB 11285 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING Agonist SB 11285","termGroup":"PT","termSource":"NCI"},{"termName":"SB 11285","termGroup":"CN","termSource":"NCI"},{"termName":"SB-11285","termGroup":"CN","termSource":"NCI"},{"termName":"SB11285","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING Agonist SB 11285"},{"name":"NCI_Drug_Dictionary_ID","value":"799980"},{"name":"NCI_META_CUI","value":"CL978836"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799980"},{"name":"PDQ_Open_Trial_Search_ID","value":"799980"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173377":{"preferredName":"Dazostinag Disodium","code":"C173377","definitions":[{"definition":"The disodium salt form of dazostinag, an agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, dazostinag targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dazostinag Disodium","termGroup":"PT","termSource":"NCI"},{"termName":"STING Agonist TAK-676","termGroup":"SY","termSource":"NCI"},{"termName":"TAK 676","termGroup":"CN","termSource":"NCI"},{"termName":"TAK-676","termGroup":"CN","termSource":"NCI"},{"termName":"TAK676","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2553413-93-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"GQ7GWR7ISX"},{"name":"Maps_To","value":"STING Agonist TAK-676"},{"name":"NCI_Drug_Dictionary_ID","value":"801843"},{"name":"NCI_META_CUI","value":"CL1407199"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801843"},{"name":"PDQ_Open_Trial_Search_ID","value":"801843"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167270":{"preferredName":"STING-expressing E. coli SYNB1891","code":"C167270","definitions":[{"definition":"A non-pathogenic strain of Escherichia coli (E. coli) bacteria that has been engineered to express stimulator of interferon genes (STING; transmembrane protein 173; TMEM173) protein, with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING-expressing E. coli SYNB1891 are engulfed by antigen presenting cells (APCs) within the tumor. STING-mediated pathways within the APCs are then activated resulting in a type I interferon (IFN) response which promotes initiation and propagation of tumor-specific T-cell responses. In addition, the bacterial component of SYNB1891 may further stimulate the innate immune system via Toll-like receptors (TLRs) which may enhance the magnitude of the overall immune response. STING, a transmembrane protein that activates immune cells in the tumor microenvironment (TME), plays a key role in the activation of the innate immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"STING-expressing E. coli SYNB1891","termGroup":"PT","termSource":"NCI"},{"termName":"STING-expressing Escherichia coli strain SYNB1891","termGroup":"SY","termSource":"NCI"},{"termName":"SYNB 1891","termGroup":"CN","termSource":"NCI"},{"termName":"SYNB-1891","termGroup":"CN","termSource":"NCI"},{"termName":"SYNB1891","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"STING-expressing E. coli SYNB1891"},{"name":"NCI_Drug_Dictionary_ID","value":"800451"},{"name":"NCI_META_CUI","value":"CL972256"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800451"},{"name":"PDQ_Open_Trial_Search_ID","value":"800451"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173664":{"preferredName":"Rucosopasem Manganese","code":"C173664","definitions":[{"definition":"A mimetic of the enzyme superoxide dismutase (SOD) that may potentially be used to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). Upon administration, rucosopasem manganese may mimic native SODs and catalyze the formation of molecular oxygen and hydrogen peroxide from the burst of superoxide anion present in the irradiated tissues upon radiation. As hydrogen peroxide is less toxic than superoxide to normal tissues, but more toxic to cancer cells, this may increase the anti-cancer efficacy of SBRT and decrease its damage to normal tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rucosopasem Manganese","termGroup":"PT","termSource":"NCI"},{"termName":"Avasopasem Manganese Dipropionate","termGroup":"SY","termSource":"NCI"},{"termName":"GC 4711 ","termGroup":"CN","termSource":"NCI"},{"termName":"GC-4711 ","termGroup":"CN","termSource":"NCI"},{"termName":"GC4711 ","termGroup":"CN","termSource":"NCI"},{"termName":"SOD Mimetic GC4711","termGroup":"SY","termSource":"NCI"},{"termName":"Superoxide Dismutase Mimetic GC4711","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2248030-85-3"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"FW5T90VM32"},{"name":"Maps_To","value":"Superoxide Dismutase Mimetic GC4711"},{"name":"NCI_Drug_Dictionary_ID","value":"802254"},{"name":"NCI_META_CUI","value":"CL1407386"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802254"},{"name":"PDQ_Open_Trial_Search_ID","value":"802254"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166377":{"preferredName":"Synthetic Plumbagin PCUR-101","code":"C166377","definitions":[{"definition":"A synthetic form of the plant-derived medicinal agent, plumbagin, with potential antineoplastic activity.  Plumbagin may act by inhibiting the expression of protein kinase C epsilon (PKCe), signal transducers and activators of transcription 3 phosphorylation (Stat3), protein kinase B (AKT), and certain epithelial-to-mesenchymal transition (EMT) markers, including vimentin and slug. This results in possible inhibition of proliferation in susceptible tumor cells.  PKCe, Stat3, AKT, and the EMT markers vimentin and slug have been linked to the induction and progression of prostate cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Synthetic Plumbagin PCUR-101","termGroup":"PT","termSource":"NCI"},{"termName":"PCUR 101","termGroup":"CN","termSource":"NCI"},{"termName":"PCUR-101","termGroup":"CN","termSource":"NCI"},{"termName":"PCUR101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"481-42-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"YAS4TBQ4OQ"},{"name":"Maps_To","value":"Synthetic Plumbagin PCUR-101"},{"name":"NCI_Drug_Dictionary_ID","value":"792711"},{"name":"NCI_META_CUI","value":"CL971629"},{"name":"PDQ_Closed_Trial_Search_ID","value":"792711"},{"name":"PDQ_Open_Trial_Search_ID","value":"792711"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C174060":{"preferredName":"Basroparib","code":"C174060","definitions":[{"definition":"An orally bioavailable inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme tankyrase, with potential antineoplastic activity. Upon administration, basroparib selectively binds to and inhibits the activity of tankyrase. This may block the tankyrase-mediated poly(ADP-ribosyl)ation of multiple target proteins including various tumor suppressors. This may include the blockage of the poly(ADP-ribosyl)ation and destabilization of AXIN, a negative regulator of beta-catenin, and prevents Wnt/beta-catenin signaling. This may inhibit the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. Tankyrase, a member of the PARP family, plays an important role in the regulation of the Wnt/beta-catenin signaling pathway, tumor suppressors, as well as telomere maintenance and mitosis regulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Basroparib","termGroup":"PT","termSource":"NCI"},{"termName":"STP 1002","termGroup":"CN","termSource":"NCI"},{"termName":"STP-1002","termGroup":"CN","termSource":"NCI"},{"termName":"STP1002","termGroup":"CN","termSource":"NCI"},{"termName":"Tankyrase Inhibitor STP1002","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1858179-75-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P5LYN8CD74"},{"name":"Maps_To","value":"Tankyrase Inhibitor STP1002"},{"name":"NCI_Drug_Dictionary_ID","value":"802474"},{"name":"NCI_META_CUI","value":"CL1407962"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802474"},{"name":"PDQ_Open_Trial_Search_ID","value":"802474"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173370":{"preferredName":"TGF-beta Receptor 1 Kinase Inhibitor SH3051","code":"C173370","definitions":[{"definition":"An orally bioavailable, small molecule inhibitor of the serine/threonine kinase transforming growth factor-beta (TGF-beta) receptor 1 (TGFbR1; activin receptor-like kinase 5; ALK5), with potential antineoplastic and immunomodulating activities. Upon administration, TGFbR1 inhibitor SH3051 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of tumor cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME and cancer cell progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGF-beta Receptor 1 Kinase Inhibitor SH3051","termGroup":"PT","termSource":"NCI"},{"termName":"SH 3051","termGroup":"CN","termSource":"NCI"},{"termName":"SH-3051","termGroup":"CN","termSource":"NCI"},{"termName":"SH3051","termGroup":"CN","termSource":"NCI"},{"termName":"TGFbR1 Inhibitor SH3051","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TGF-beta Receptor 1 Kinase Inhibitor SH3051"},{"name":"NCI_Drug_Dictionary_ID","value":"801834"},{"name":"NCI_META_CUI","value":"CL1407202"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801834"},{"name":"PDQ_Open_Trial_Search_ID","value":"801834"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172107":{"preferredName":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027","code":"C172107","definitions":[{"definition":"An orally bioavailable inhibitor of the serine/threonine kinase transforming growth factor-beta receptor 1 (TGFbR1; activin receptor-like kinase 5; ALK5), with potential antineoplastic and immunomodulating activities. Upon administration, TGF-betaR1 inhibitor YL-13027 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME and cancer cell progression.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027","termGroup":"PT","termSource":"NCI"},{"termName":"TGFbR1 Inhibitor YL-13027","termGroup":"SY","termSource":"NCI"},{"termName":"YL 13027","termGroup":"CN","termSource":"NCI"},{"termName":"YL-13027","termGroup":"CN","termSource":"NCI"},{"termName":"YL13027","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TGF-beta Receptor 1 Kinase Inhibitor YL-13027"},{"name":"NCI_Drug_Dictionary_ID","value":"801356"},{"name":"NCI_META_CUI","value":"CL1406216"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801356"},{"name":"PDQ_Open_Trial_Search_ID","value":"801356"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165621":{"preferredName":"Therapeutic Cancer Vaccine ATP128","code":"C165621","definitions":[{"definition":"A self-adjuvanted chimeric recombinant protein vaccine, based on the self-adjuvanting KISIMA immunization platform, composed of three components: the 42 residue fragment Z12, a cell penetrating peptide (CPP) derived from the ZEBRA protein transduction domain, a toll-like receptor (TLR) peptide agonist as an adjuvant and a chimeric cargo, a multiple antigenic domain (MAD; MultiE), that contains an as of yet not disclosed amount of major histocompatibility class (MHC)-restricted peptides derived from as of yet undisclosed tumor-associated antigens (TAAs) that are specific for colorectal cancer (CRC) patients, with potential immunomodulating and antineoplastic activities. Upon administration of ATP128, the Z12 moiety targets, binds to and penetrates antigen-presenting cells (APCs), specifically dendritic cells (DCs) and promotes the loading of the epitopes into the DCs and transports antigenic cargoes into both endosomal and cytosolic compartments. Upon processing and antigen presentation by MHC II and I, the immune system is stimulated and activates specific CD4+ and CD8+ T-cells, respectively, against the multi-epitopes specific for the CRC cells, thereby killing the CRC cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Cancer Vaccine ATP128","termGroup":"PT","termSource":"NCI"},{"termName":"ATP 128","termGroup":"CN","termSource":"NCI"},{"termName":"ATP-128","termGroup":"CN","termSource":"NCI"},{"termName":"ATP128","termGroup":"CN","termSource":"NCI"},{"termName":"Z12-MultiE/TLR Agonist Domain ATP128","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Therapeutic Cancer Vaccine ATP128"},{"name":"NCI_Drug_Dictionary_ID","value":"799990"},{"name":"NCI_META_CUI","value":"CL978804"},{"name":"PDQ_Closed_Trial_Search_ID","value":"799990"},{"name":"PDQ_Open_Trial_Search_ID","value":"799990"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Immunologic Factor"}]}}{"C168996":{"preferredName":"Thorium Th 227 Trastuzumab Corixetan","code":"C168996","definitions":[{"definition":"A radioimmunoconjugate consisting of trastuzumab, a monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 trastuzumab corixetan, the trastuzumab moiety targets and specifically binds to HER2 on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thorium Th 227 Trastuzumab Corixetan","termGroup":"PT","termSource":"NCI"},{"termName":"227Th Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"227Th Trastuzumab Corixetan","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2701439","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2701439","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2701439","termGroup":"CN","termSource":"NCI"},{"termName":"HER2-TTC","termGroup":"SY","termSource":"NCI"},{"termName":"Th 227 Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Th-227-Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 MOAB BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Anti-HER2 Monoclonal Antibody BAY2701439","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Corixetan Thorium Th-227","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"QC6MLG1NN6"},{"name":"Maps_To","value":"Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439"},{"name":"NCI_Drug_Dictionary_ID","value":"800871"},{"name":"NCI_META_CUI","value":"CL1378806"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800871"},{"name":"PDQ_Open_Trial_Search_ID","value":"800871"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C175301":{"preferredName":"Thorium Th 227 Pelgifatamab Corixetan","code":"C175301","definitions":[{"definition":"A radioimmunoconjugate consisting of pelgifatamab, a monoclonal antibody targeting the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), conjugated to the chelator corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 pelgifatamab corixetan, the pelgifatamab moiety targets and specifically binds to PSMA on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing PSMA. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thorium Th 227 Pelgifatamab Corixetan","termGroup":"PT","termSource":"NCI"},{"termName":"227Th-Pelgifatamab Corixetan","termGroup":"SY","termSource":"NCI"},{"termName":"BAY 2315497","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-2315497","termGroup":"CN","termSource":"NCI"},{"termName":"BAY2315497","termGroup":"CN","termSource":"NCI"},{"termName":"PSMA-targeted Thorium-227 Conjugate BAY-2315497","termGroup":"SY","termSource":"NCI"},{"termName":"PSMA-TTC BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Targeted Thorium Conjugate BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium Th 227 Monoclonal Antibody BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Anti-PSMA Monoclonal Antibody BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Antibody-chelator Conjugate BAY 2315497","termGroup":"SY","termSource":"NCI"},{"termName":"Thorium-227 Labeled Immunoconjugate BAY-2315497","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497"},{"name":"NCI_Drug_Dictionary_ID","value":"803273"},{"name":"NCI_META_CUI","value":"CL1412652"},{"name":"PDQ_Closed_Trial_Search_ID","value":"803273"},{"name":"PDQ_Open_Trial_Search_ID","value":"803273"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C168609":{"preferredName":"Thymidylate Synthase Inhibitor CX1106","code":"C168609","definitions":[{"definition":"A thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon administration, TS inhibitor CX1106 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thymidylate Synthase Inhibitor CX1106","termGroup":"PT","termSource":"NCI"},{"termName":"CX 1106","termGroup":"CN","termSource":"NCI"},{"termName":"CX-1106","termGroup":"CN","termSource":"NCI"},{"termName":"CX1106","termGroup":"CN","termSource":"NCI"},{"termName":"TS Inhibitor CX1106","termGroup":"SY","termSource":"NCI"},{"termName":"TSI CX1106","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Thymidylate Synthase Inhibitor CX1106"},{"name":"NCI_Drug_Dictionary_ID","value":"800351"},{"name":"NCI_META_CUI","value":"CL972813"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800351"},{"name":"PDQ_Open_Trial_Search_ID","value":"800351"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173891":{"preferredName":"Dargistotug","code":"C173891","definitions":[{"definition":"An inhibitor of T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), a co-inhibitory molecule and immune checkpoint inhibitor, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dargistotug targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dargistotug","termGroup":"PT","termSource":"NCI"},{"termName":"M 6223","termGroup":"CN","termSource":"NCI"},{"termName":"M-6223","termGroup":"CN","termSource":"NCI"},{"termName":"M6223","termGroup":"CN","termSource":"NCI"},{"termName":"TIGIT Inhibitor M6223","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2649362-29-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"4O3LRM3I5J"},{"name":"Maps_To","value":"TIGIT Inhibitor M6223"},{"name":"NCI_Drug_Dictionary_ID","value":"802403"},{"name":"NCI_META_CUI","value":"CL1407689"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802403"},{"name":"PDQ_Open_Trial_Search_ID","value":"802403"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167350":{"preferredName":"TLR7 agonist BNT411","code":"C167350","definitions":[{"definition":"A Toll-like receptor (TLR) 7 agonist with potential immunostimulating and antitumor activities. Upon administration, TLR7 agonist BNT411 binds to and activates TLR7. This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells, B cells, and innate immune cells including natural killer (NK) cells and macrophages. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR7 agonist BNT411","termGroup":"PT","termSource":"NCI"},{"termName":"BNT 411","termGroup":"CN","termSource":"NCI"},{"termName":"BNT-411","termGroup":"CN","termSource":"NCI"},{"termName":"BNT411","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TLR7 agonist BNT411"},{"name":"NCI_Drug_Dictionary_ID","value":"800313"},{"name":"NCI_META_CUI","value":"CL972325"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800313"},{"name":"PDQ_Open_Trial_Search_ID","value":"800313"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C166362":{"preferredName":"TLR7 Agonist LHC165","code":"C166362","definitions":[{"definition":"A benzonapthyridine Toll-like receptor (TLR) 7 agonist that is adsorbed to aluminum hydroxide with immunostimulating and potential antitumor activities. Upon intratumoral administration of TLR7 agonist LHC165, the agent is slowly released and targets, binds to and activates TLR7.  This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells and natural killer (NK) cells, the blockage of the suppressive function of regulatory T cells (Tregs), and the production of interferon alpha (IFNa).  TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR7 Agonist LHC165","termGroup":"PT","termSource":"NCI"},{"termName":"LHC 165","termGroup":"CN","termSource":"NCI"},{"termName":"LHC-165","termGroup":"CN","termSource":"NCI"},{"termName":"LHC165","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1258595-14-0"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"RD02U4QLM1"},{"name":"Maps_To","value":"TLR7 Agonist LHC165"},{"name":"NCI_Drug_Dictionary_ID","value":"800232"},{"name":"NCI_META_CUI","value":"CL971618"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800232"},{"name":"PDQ_Open_Trial_Search_ID","value":"800232"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173965":{"preferredName":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells","code":"C173965","definitions":[{"definition":"A mixed preparation of allogeneic T-lymphocytes that have been genetically modified to express either a chimeric antigen receptor (CAR) specific for the antigen transmembrane 4 L six family member 1 (TM4SF1) (CART-TM4SF1) or a CAR specific for epithelial cell adhesion molecule (EpCAM) (CART-EpCAM), with potential immunostimulating and antineoplastic activities. Upon administration of the TM4SF1-CAR/EpCAM-CAR-expressing autologous T cells, the TM4SF1-CAR-expressing autologous T-cells specifically recognize and bind to TM4SF1-expressing tumor cells and the EpCAM-CAR-expressing autologous T-cells specifically recognize and bind to EpCAM-expressing tumor cells, resulting in tumor cell lysis. TM4SF1 and EpCAM are expressed by a variety of tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells","termGroup":"PT","termSource":"NCI"},{"termName":"Autologous CART-TM4SF1 Cells/CART-EpCAM Cells","termGroup":"SY","termSource":"NCI"},{"termName":"Autologous TM4SF1-targeting CAR T-cells and EpCAM-targeting CAR T-cells","termGroup":"SY","termSource":"NCI"},{"termName":"TM4SF1-CAR Autologous T-cells/EpCAM-CAR Autologous T-cells","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells"},{"name":"NCI_Drug_Dictionary_ID","value":"802161"},{"name":"NCI_META_CUI","value":"CL1407843"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802161"},{"name":"PDQ_Open_Trial_Search_ID","value":"802161"},{"name":"Semantic_Type","value":"Cell"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173549":{"preferredName":"Tolebrutinib","code":"C173549","definitions":[{"definition":"An orally bioavailable, brain-penetrant, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, tolebrutinib is able to cross the blood-brain barrier and inhibits the activity of BTK both peripherally and in the central nervous system (CNS). This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway, and the resulting immune activation and inflammation. The inhibition of BTK activity also prevents microglial inflammatory signaling in the CNS, and the resulting immune activation, neuroinflammation and neurodegeneration. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. In addition to B cells, BTK is also expressed in innate immune cells, including macrophages and microglia, and plays an important role in the regulation of microglial inflammatory signaling.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tolebrutinib","termGroup":"PT","termSource":"NCI"},{"termName":"Bruton's Tyrosine Kinase Inhibitor SAR442168","termGroup":"SY","termSource":"NCI"},{"termName":"BTK Inhibitor SAR442168","termGroup":"SY","termSource":"NCI"},{"termName":"SAR 442168","termGroup":"CN","termSource":"NCI"},{"termName":"SAR-442168","termGroup":"CN","termSource":"NCI"},{"termName":"SAR442168","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"1971920-73-6"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"8CZ82ZYY9X"},{"name":"Maps_To","value":"Tolebrutinib"},{"name":"NCI_Drug_Dictionary_ID","value":"801899"},{"name":"NCI_META_CUI","value":"CL1407319"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801899"},{"name":"PDQ_Open_Trial_Search_ID","value":"801899"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173363":{"preferredName":"Topotecan Sustained-release Episcleral Plaque","code":"C173363","definitions":[{"definition":"An episcleral plaque containing sustained-release (SR) topotecan, a semisynthetic derivative of camptothecin and a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic activity. Upon local application of the topotecan SR episcleral plaque to the eye, topotecan is released in a sustained manner and inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The episcleral plaque allows for local delivery of topotecan for the potential treatment of retinoblastoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Topotecan Sustained-release Episcleral Plaque","termGroup":"PT","termSource":"NCI"},{"termName":"Chemoplaque","termGroup":"BR","termSource":"NCI"},{"termName":"Episcleral Topotecan","termGroup":"SY","termSource":"NCI"},{"termName":"SR Topotecan Episcleral Plaque","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained Release Episcleral Topotecan","termGroup":"SY","termSource":"NCI"},{"termName":"Sustained-release Topotecan Episcleral Plaque","termGroup":"SY","termSource":"NCI"},{"termName":"Topotecan SR Episcleral Plaque","termGroup":"SY","termSource":"NCI"},{"termName":"Transscleral Topotecan","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Topotecan Sustained-release Episcleral Plaque"},{"name":"NCI_Drug_Dictionary_ID","value":"801808"},{"name":"NCI_META_CUI","value":"CL1407190"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801808"},{"name":"PDQ_Open_Trial_Search_ID","value":"801808"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172821":{"preferredName":"Trastuzumab/MMAF Antibody-drug Conjugate IKS014","code":"C172821","definitions":[{"definition":"An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting the tumor-associated antigen (TAA) epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), site-specifically conjugated, via a tumor-selective beta-glucuronide linker, to the auristatin analog and potent microtubule inhibitor monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of trastuzumab/MMAF ADC IKS014, the trastuzumab moiety targets and binds to HER2 expressed on tumor cells. Upon binding, internalization and linker cleavage, MMAF is released. MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab/MMAF Antibody-drug Conjugate IKS014","termGroup":"PT","termSource":"NCI"},{"termName":"ADC FS-1502","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-HER2 ADC FS-1502","termGroup":"SY","termSource":"NCI"},{"termName":"Antibody-drug Conjugate FS-1502","termGroup":"SY","termSource":"NCI"},{"termName":"FS 1502","termGroup":"CN","termSource":"NCI"},{"termName":"FS-1502","termGroup":"CN","termSource":"NCI"},{"termName":"FS1502","termGroup":"CN","termSource":"NCI"},{"termName":"IKS 014","termGroup":"CN","termSource":"NCI"},{"termName":"IKS-014","termGroup":"CN","termSource":"NCI"},{"termName":"IKS014","termGroup":"CN","termSource":"NCI"},{"termName":"LCB 14","termGroup":"CN","termSource":"NCI"},{"termName":"LCB-14","termGroup":"CN","termSource":"NCI"},{"termName":"LCB14","termGroup":"CN","termSource":"NCI"},{"termName":"LCB14-0110","termGroup":"CN","termSource":"NCI"},{"termName":"Trastuzumab MMAF","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab Monomethyl Auristatin F","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab/MMAF ADC IKS014","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Trastuzumab Monomethyl Auristatin F"},{"name":"NCI_Drug_Dictionary_ID","value":"801696"},{"name":"NCI_META_CUI","value":"CL1406855"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801696"},{"name":"PDQ_Open_Trial_Search_ID","value":"801696"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172388":{"preferredName":"Trastuzumab Imbotolimod","code":"C172388","definitions":[{"definition":"An immune stimulating antibody conjugate (ISAC) consisting of trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, conjugated to a Toll-like receptor (TLR) 7/8 dual agonist, with potential immunostimulating and antineoplastic activities. Upon administration of trastuzumab imbotolimod, the trastuzumab moiety targets and binds to HER2 expressed on tumor cells and, simultaneously, the TLR 7/8 dual agonist moiety targets, binds to and activates TLR7/8 expressed on antigen-presenting cells (APCs), specifically dendritic cells (DCs), in the tumor microenvironment (TME). The trastuzumab binding to the tumor cells causes the engulfment of the trastuzumab imbotolimod-bound tumor cells by tumor-associated myeloid (TAM) cells and the TAMs travel to the lymph nodes. The DCs activated by the TLR7/8 agonist causes the activation of TLR7/8-mediated pathways, and stimulates the maturation and activation of DCs, thereby re-activating the immune system against the tumor cells. Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses against tumor-associated antigens (TAAs), which lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation. HER2 is overexpressed by a variety of tumor cell types.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Trastuzumab Imbotolimod","termGroup":"PT","termSource":"NCI"},{"termName":"BDC 1001","termGroup":"CN","termSource":"NCI"},{"termName":"BDC-1001","termGroup":"CN","termSource":"NCI"},{"termName":"BDC1001","termGroup":"CN","termSource":"NCI"},{"termName":"Immune Stimulating Antibody Conjugate BDC-1001","termGroup":"SY","termSource":"NCI"},{"termName":"ISAC BDC-1001","termGroup":"SY","termSource":"NCI"},{"termName":"Trastuzumab-TLR 7/8 Agonist BDC-1001","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2643926-85-4"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"LNG8RG3NMF"},{"name":"Maps_To","value":"Trastuzumab-TLR 7/8 Agonist BDC-1001"},{"name":"NCI_Drug_Dictionary_ID","value":"802017"},{"name":"NCI_META_CUI","value":"CL1406514"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802017"},{"name":"PDQ_Open_Trial_Search_ID","value":"802017"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C126803":{"preferredName":"Tris-acryl Gelatin Microspheres","code":"C126803","definitions":[{"definition":"An embolic particle composed of water-soluble, compressible, nonabsorbable microspheres composed of tris-acryl gelatin, with potential use for embolization. Upon administration, the tris-acryl gelatin microspheres (TAGM) serve as an embolic agent before surgery for highly vascularized areas, such as those seen in certain tumors, by penetrating into the blood vessel system and blocking blood flow. These microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as drug delivery vehicles during embolization of tumor vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tris-acryl Gelatin Microspheres","termGroup":"PT","termSource":"NCI"},{"termName":"Embospheres","termGroup":"BR","termSource":"NCI"},{"termName":"TAGM","termGroup":"AB","termSource":"NCI"},{"termName":"Trisacryl Gelatin Microspheres","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tris-acryl Gelatin Microspheres"},{"name":"NCI_Drug_Dictionary_ID","value":"780376"},{"name":"PDQ_Closed_Trial_Search_ID","value":"780376"},{"name":"PDQ_Open_Trial_Search_ID","value":"780376"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1566001"}]}}{"C173560":{"preferredName":"TRK Inhibitor TQB3558","code":"C173560","definitions":[{"definition":"An orally available inhibitor of tropomyosin receptor kinase (Trk), with potential antineoplastic activity. Upon oral administration, Trk inhibitor TQB3558 targets and binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation. This may lead to apoptosis of Trk-expressing tumor cells and the inhibition of tumor cell proliferation in Trk-expressing tumors. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TRK Inhibitor TQB3558","termGroup":"PT","termSource":"NCI"},{"termName":"TQB 3558","termGroup":"CN","termSource":"NCI"},{"termName":"TQB-3558","termGroup":"CN","termSource":"NCI"},{"termName":"TQB3558","termGroup":"CN","termSource":"NCI"},{"termName":"Tropomyosin Receptor Kinase Inhibitor TQB3558","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TRK Inhibitor TQB3558"},{"name":"NCI_Drug_Dictionary_ID","value":"801913"},{"name":"NCI_META_CUI","value":"CL1407328"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801913"},{"name":"PDQ_Open_Trial_Search_ID","value":"801913"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C172843":{"preferredName":"Ursolic Acid","code":"C172843","definitions":[{"definition":"A pentacyclic triterpenoid found in various fruits, vegetables and medicinal herbs, with a variety of potential pharmacologic activities including anti-inflammatory, antioxidative, antiviral, serum lipid-lowering, and antineoplastic activities. Upon administration, ursolic acid may promote apoptosis and inhibit cancer cell proliferation through multiple mechanisms. This may include the regulation of mitochondrial function through various pathways including the ROCK/PTEN and p53 pathways, the suppression of the nuclear factor-kappa B (NF-kB) pathways, and the increase in caspase-3, caspase-8 and caspase-9 activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ursolic Acid","termGroup":"PT","termSource":"NCI"},{"termName":"(3beta)-3-Hydroxyurs-12-en-28-oic Acid","termGroup":"SN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"77-52-1"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"P3M2575F3F"},{"name":"Maps_To","value":"Ursolic Acid"},{"name":"NCI_Drug_Dictionary_ID","value":"801981"},{"name":"NCI_META_CUI","value":"CL1406899"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801981"},{"name":"PDQ_Open_Trial_Search_ID","value":"801981"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C167064":{"preferredName":"Azenosertib","code":"C167064","definitions":[{"definition":"An inhibitor of the tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu) with potential antineoplastic sensitizing activity. Although the exact mechanism of action by which this agent inhibits Wee1 has yet to be disclosed, upon administration of ZN-c3, this agent targets and inhibits Wee1. Inhibition of Wee1 promotes both premature mitosis and a prolonged mitotic arrest leading to cell death in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, upon treatment with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis; it negatively regulates the G2 checkpoint by disallowing entry into mitosis in response to DNA damage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Azenosertib","termGroup":"PT","termSource":"NCI"},{"termName":"Wee1 Inhibitor ZN-c3","termGroup":"SY","termSource":"NCI"},{"termName":"ZN c3","termGroup":"CN","termSource":"NCI"},{"termName":"ZN-c3","termGroup":"CN","termSource":"NCI"},{"termName":"ZNc3","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2376146-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"9J13XU96Z1"},{"name":"Maps_To","value":"Wee1 Inhibitor ZN-c3"},{"name":"NCI_Drug_Dictionary_ID","value":"802182"},{"name":"NCI_META_CUI","value":"CL972056"},{"name":"PDQ_Closed_Trial_Search_ID","value":"802182"},{"name":"PDQ_Open_Trial_Search_ID","value":"802182"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C173426":{"preferredName":"Wee1 Kinase Inhibitor Debio 0123","code":"C173426","definitions":[{"definition":"An orally bioavailable inhibitor of the human tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu), with potential antineoplastic sensitizing activity. Upon oral administration of Debio 0123, this agent targets, binds to and inhibits Wee1. Inhibition of Wee1 inhibits Cdk1 (Cdc2) phosphorylation, promotes both premature mitosis and a prolonged mitotic arrest, which results in the accumulation of unrepaired DNA damage. This leads to apoptosis in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, especially in combination with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis. The Wee1 tyrosine kinase is activated upon DNA damage and regulates the G2-M and S cell cycle checkpoints.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Wee1 Kinase Inhibitor Debio 0123","termGroup":"PT","termSource":"NCI"},{"termName":"Debio 0123","termGroup":"CN","termSource":"NCI"},{"termName":"Debio-0123","termGroup":"CN","termSource":"NCI"},{"termName":"Debio0123","termGroup":"CN","termSource":"NCI"},{"termName":"Wee1 Inhibitor Debio 0123","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wee1 Kinase Inhibitor Debio 0123"},{"name":"NCI_Drug_Dictionary_ID","value":"801754"},{"name":"NCI_META_CUI","value":"CL1407441"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801754"},{"name":"PDQ_Open_Trial_Search_ID","value":"801754"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C171173":{"preferredName":"Gruticibart","code":"C171173","definitions":[{"definition":"A humanized anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, gruticibart targets and binds to the apple 2 domain of FXI, thereby preventing the binding of FXI to factor XIIa (FXIIa). This blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT), and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gruticibart","termGroup":"PT","termSource":"NCI"},{"termName":"AB 023","termGroup":"CN","termSource":"NCI"},{"termName":"AB-023","termGroup":"CN","termSource":"NCI"},{"termName":"AB023","termGroup":"CN","termSource":"NCI"},{"termName":"Anti-factor XI Monoclonal Antibody Xisomab 3G3","termGroup":"SY","termSource":"NCI"},{"termName":"Anti-FXI Antibody Xisomab 3G3","termGroup":"SY","termSource":"NCI"},{"termName":"Xisomab 3G3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2704554-77-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"K8A4DG9RWV"},{"name":"Maps_To","value":"Xisomab 3G3"},{"name":"NCI_Drug_Dictionary_ID","value":"801969"},{"name":"NCI_META_CUI","value":"CL1405388"},{"name":"PDQ_Closed_Trial_Search_ID","value":"801969"},{"name":"PDQ_Open_Trial_Search_ID","value":"801969"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C165746":{"preferredName":"Zotatifin","code":"C165746","definitions":[{"definition":"A selective inhibitor of the eukaryotic translation initiation factor 4A (eIF4A), with potential antineoplastic activity. Upon administration of zotatifin, this agent targets and binds to elF4A, and promotes eIF4A binding to mRNA with specific polypurine motifs within their 5'-untranslated region (5'-UTR), leading to the formation of a stable sequence-specific ternary complex with eIF4A and mRNA (elF4A- zotatifin-mRNA). This results in the translational repression of key oncogenes and anti-apoptotic proteins involved in tumor cell proliferation, survival and metastasis, such as KRAS, Myc, myeloid cell leukemia-1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), cyclin-dependent kinase (CDK) 4 and 6, cyclin D, fibroblast growth factor receptor (FGFR) 1 and 2, human epidermal growth factor receptor 2 (HER2; ERBB2), and beta-catenin. The inhibition of the expression of these oncogenes leads to the inhibition of various oncogenic signal transduction pathways. This inhibits proliferation and induces apoptosis in tumor cells. eIF4A, a RNA helicase and the rate-limiting component of the eukaryotic translation initiation complex, catalyzes the ATP-dependent unwinding of RNA duplexes and facilitates 43S ribosome scanning within the 5'-UTR. elF4A is activated by various oncogenic signaling pathways, including RAS/mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)/AKT pathways, and regulates the translation of oncogenes and tumor survival factors with complex secondary structures within the 5'-UTRs that are required for tumor cell proliferation, survival and metastasis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Zotatifin","termGroup":"PT","termSource":"NCI"},{"termName":"4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)benzonitrile","termGroup":"SN","termSource":"NCI"},{"termName":"eFT 226","termGroup":"CN","termSource":"NCI"},{"termName":"eFT-226","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"2098191-53-6"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"2EWN8Z05CN"},{"name":"Maps_To","value":"Zotatifin"},{"name":"NCI_Drug_Dictionary_ID","value":"800362"},{"name":"NCI_META_CUI","value":"CL978864"},{"name":"PDQ_Closed_Trial_Search_ID","value":"800362"},{"name":"PDQ_Open_Trial_Search_ID","value":"800362"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C66721":{"preferredName":"Levoleucovorin Calcium","code":"C66721","definitions":[{"definition":"A drug used to lessen the toxic effects of substances that block the action of folic acid, especially the anticancer drug methotrexate. Calcium levoleucovorin is used to treat some types of anemia and is also used with fluorouracil to treat colorectal cancer. It is also being studied in the treatment of other types of cancer and other conditions. Calcium levoleucovorin is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A levo isoform of leucovorin calcium with antineoplastic activity. Levoleucovorin is an active metabolite of folic acid, which does not require metabolism by dihydrofolate reductase. This agent counteracts the toxic effects of other folic acid derivative agents, rescuing the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Levoleucovorin Calcium","termGroup":"PT","termSource":"NCI"},{"termName":"Fusilev","termGroup":"BR","termSource":"NCI"},{"termName":"Isovorin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Colorectal Cancer"},{"name":"CAS_Registry","value":"80433-71-2"},{"name":"Chemical_Formula","value":"C20H21N7O7.Ca"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"778XL6VBS8"},{"name":"Legacy Concept Name","value":"Levoleucovorin_Calcium"},{"name":"Maps_To","value":"Levoleucovorin Calcium"},{"name":"NCI_Drug_Dictionary_ID","value":"748638"},{"name":"PDQ_Closed_Trial_Search_ID","value":"748638"},{"name":"PDQ_Open_Trial_Search_ID","value":"748638"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1881372"}]}}{"C2703":{"preferredName":"Mistletoe Extract","code":"C2703","definitions":[{"definition":"A substance that comes from the mistletoe plant and that is being studied as a treatment for cancer. A lectin is a complex molecule that has both protein and sugars. Lectins are able to bind to the outside of a cell and cause biochemical changes in it. Lectins are made by both animals and plants.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"An extract of the whole plant Viscum album (mistletoe) with potential biological response modifier (BRM) activity. Mistletoe extract may both stimulate the antitumoral functions of the immune system and have a direct toxic effect on tumor cells. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mistletoe Extract","termGroup":"PT","termSource":"NCI"},{"termName":"Abnobaviscum","termGroup":"FB","termSource":"NCI"},{"termName":"Apotheker Bauer's Misteltinktur","termGroup":"FB","termSource":"NCI"},{"termName":"Cefalektin","termGroup":"FB","termSource":"NCI"},{"termName":"Eurixor","termGroup":"FB","termSource":"NCI"},{"termName":"Helixor","termGroup":"FB","termSource":"NCI"},{"termName":"Iscador","termGroup":"FB","termSource":"NCI"},{"termName":"Isorel","termGroup":"FB","termSource":"NCI"},{"termName":"Isugran","termGroup":"FB","termSource":"NCI"},{"termName":"Lektinol","termGroup":"FB","termSource":"NCI"},{"termName":"Mistel Curarina","termGroup":"FB","termSource":"NCI"},{"termName":"Mistel- Krautertabletten","termGroup":"FB","termSource":"NCI"},{"termName":"Mistelol-Kapseln","termGroup":"FB","termSource":"NCI"},{"termName":"Plenosol N","termGroup":"FB","termSource":"NCI"},{"termName":"Viscum","termGroup":"SY","termSource":"NCI"},{"termName":"Viscum Album Extract","termGroup":"SY","termSource":"NCI"},{"termName":"Viscysat","termGroup":"FB","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"84929-55-5"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"BK9092J5MP"},{"name":"Legacy Concept Name","value":"Mistletoe_Extract"},{"name":"Maps_To","value":"Mistletoe Extract"},{"name":"NCI_Drug_Dictionary_ID","value":"41724"},{"name":"PDQ_Closed_Trial_Search_ID","value":"41724"},{"name":"PDQ_Open_Trial_Search_ID","value":"41724"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0062189"}]}}{"C80971":{"preferredName":"Canakinumab","code":"C80971","definitions":[{"definition":"A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Canakinumab","termGroup":"PT","termSource":"NCI"},{"termName":"ACZ885","termGroup":"CN","termSource":"NCI"},{"termName":"Ilaris","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"cryopyrin-associated periodic syndrome, Muckle-Wells syndrome, rheumatoid arthritis"},{"name":"Accepted_Therapeutic_Use_For","value":"Muckle-Wells syndrome, rheumatoid arthritis, other inflammatory conditions"},{"name":"CAS_Registry","value":"914613-48-2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"37CQ2C7X93"},{"name":"Legacy Concept Name","value":"Canakinumab"},{"name":"Maps_To","value":"Canakinumab"},{"name":"NCI_Drug_Dictionary_ID","value":"795723"},{"name":"PDQ_Closed_Trial_Search_ID","value":"795723"},{"name":"PDQ_Open_Trial_Search_ID","value":"795723"},{"name":"Semantic_Type","value":"Immunologic Factor"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2718773"}]}}{"C77995":{"preferredName":"Rivaroxaban","code":"C77995","definitions":[{"definition":"An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Rivaroxaban","termGroup":"PT","termSource":"NCI"},{"termName":"5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)- 1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide","termGroup":"SN","termSource":"NCI"},{"termName":"BAY 59 7939","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 59-7939","termGroup":"CN","termSource":"NCI"},{"termName":"BAY 597939","termGroup":"CN","termSource":"NCI"},{"termName":"BAY-59-7939","termGroup":"CN","termSource":"NCI"},{"termName":"BAY597939","termGroup":"CN","termSource":"NCI"},{"termName":"Xarelto","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Deep Vein Thrombosis Prophylaxis"},{"name":"CAS_Registry","value":"366789-02-8"},{"name":"Chemical_Formula","value":"C19H18ClN3O5S"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"9NDF7JZ4M3"},{"name":"Legacy Concept Name","value":"Rivaroxaban"},{"name":"Maps_To","value":"Rivaroxaban"},{"name":"NCI_Drug_Dictionary_ID","value":"701565"},{"name":"PDQ_Closed_Trial_Search_ID","value":"701565"},{"name":"PDQ_Open_Trial_Search_ID","value":"701565"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1739768"}]}}{"C74084":{"preferredName":"TLR9 Agonist SD-101","code":"C74084","definitions":[{"definition":"A proprietary oligonucleotide with immunostimulatory activity. Immunostimulatory phosphorothiolate oligodeoxyribonucleotide SD-101 targets Toll-Like Receptor 9 (TLR9) found on a specialized subset of dendritic cells. The interaction of TLR9 with SD-101, in conjunction with an allergen or antigen, induces activation of memory T helper cells 1 (Th1) against a specific pathogen or allergen, thereby leading to long-lasting therapeutic effects. Furthermore, this agent does not cause a generalized activation of the immune system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TLR9 Agonist SD-101","termGroup":"PT","termSource":"NCI"},{"termName":"ISS-ODN SD-101","termGroup":"AB","termSource":"NCI"},{"termName":"SD-101","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"TLR9_Agonist_SD-101"},{"name":"Maps_To","value":"TLR9 Agonist SD-101"},{"name":"NCI_Drug_Dictionary_ID","value":"706877"},{"name":"PDQ_Closed_Trial_Search_ID","value":"706877"},{"name":"PDQ_Open_Trial_Search_ID","value":"706877"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C2348637"}]}}{"C1729":{"preferredName":"CT2584","code":"C1729","definitions":[{"definition":"A lipid metabolism and phosphatidic acid modulator, with potential antineoplastic activity. Upon administration, CT-2584 inhibits phospholipid signaling which may inhibit tumor cell proliferation.","type":"DEFINITION","source":"NCI"},{"definition":"A substance that is being studied in the treatment of cancer. It may prevent the growth of blood vessels from surrounding tissue into a solid tumor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"CT2584","termGroup":"PT","termSource":"NCI"},{"termName":"1-(11-(dodecylamino)-10-hydroxyundecyl)-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione","termGroup":"SN","termSource":"NCI"},{"termName":"1-(11-Dodecylamino-10-Hydroxyundecyl)-3,7-Dimethylxanthine","termGroup":"SN","termSource":"NCI"},{"termName":"Apra","termGroup":"BR","termSource":"NCI"},{"termName":"CT-2584","termGroup":"CN","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"166981-13-1"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"67E5N3R22H"},{"name":"Legacy Concept Name","value":"CT2584_HMS"},{"name":"Maps_To","value":"CT2584"},{"name":"NCI_Drug_Dictionary_ID","value":"42509"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0539091"}]}}{"C179426":{"preferredName":"Ancient DNA Isolation","code":"C179426","definitions":[{"definition":"Any method that extracts and purifies DNA from ancient, historical, mummified or fossilized biological samples.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ancient DNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"aDNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"aDNA Isolation","termGroup":"SY","termSource":"NCI"},{"termName":"aDNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"aDNA Purification","termGroup":"SY","termSource":"NCI"},{"termName":"Ancient DNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"Ancient DNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"Ancient DNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"aDNA Preparation Type"},{"name":"NCI_META_CUI","value":"CL1662202"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179428":{"preferredName":"AllPrep FFPE DNA Isolation","code":"C179428","definitions":[{"definition":"A method that extracts and purifies DNA from formalin-fixed paraffin-embedded samples using the proprietary AllPrep kit (Qiagen).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AllPrep FFPE DNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"AllPrep FFPE DNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep FFPE DNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep FFPE DNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allprep FFPE DNA"},{"name":"NCI_META_CUI","value":"CL1662198"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179430":{"preferredName":"AllPrep RNA Isolation","code":"C179430","definitions":[{"definition":"A method to isolate total RNA from a biospecimen that uses the proprietary AllPrep RNeasy MinElute spin column (Qiagen).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"AllPrep RNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"AllPrep RNA Extraction","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep RNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"AllPrep RNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allprep RNA Extraction"},{"name":"NCI_META_CUI","value":"CL1662200"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179431":{"preferredName":"Chemical Lysis DNA Extraction","code":"C179431","definitions":[{"definition":"Any method of DNA extraction that uses chemicals, rather than mechanical or enzymatic means, to disrupt the cells in the sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chemical Lysis DNA Extraction","termGroup":"PT","termSource":"NCI"},{"termName":"Chemical Lysis DNA Preparation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chemical Lysis DNA Extraction"},{"name":"NCI_META_CUI","value":"CL1662199"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179436":{"preferredName":"FFPE MicroRNA Isolation","code":"C179436","definitions":[{"definition":"A method that extracts RNA from formalin-fixed paraffin-embedded samples and then isolates the microRNA fraction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FFPE MicroRNA Isolation","termGroup":"PT","termSource":"NCI"},{"termName":"FFPE miRNA Fractionation","termGroup":"SY","termSource":"NCI"},{"termName":"FFPE miRNA Isolation","termGroup":"SY","termSource":"NCI"},{"termName":"FFPE miRNA Preparation","termGroup":"SY","termSource":"NCI"},{"termName":"FFPE miRNA Purification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HighPure miRNA (Allprep DNA) FFPE RNA"},{"name":"NCI_META_CUI","value":"CL1662204"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C179449":{"preferredName":"Pre-extracted DNA Received by TSS Indicator","code":"C179449","definitions":[{"definition":"An indication that a DNA sample received by the tissue sample coordination site (TSS) had been isolated by the site that initially collected the tissue samples from the subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-extracted DNA Received by TSS Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Pre-extracted DNA Received by Tissue Sample Coordination Site","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pre-extracted DNA received by TSS"},{"name":"NCI_META_CUI","value":"CL1662309"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C3038":{"preferredName":"Fever","code":"C3038","definitions":[{"definition":"A disorder characterized by elevation of the body's temperature above the upper limit of normal.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"An increase in body temperature above normal (98.6 degrees F), usually caused by disease.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Elevation of body temperature above normal due to inflammatory or immune responses.","type":"DEFINITION","source":"NCI"},{"definition":"Elevation of body temperature above normal due to the bodies own responses.","type":"ALT_DEFINITION","source":"FDA","qualifiers":[{"type":"attribution","value":"CDRH"}]},{"definition":"Elevation of body temperature above normal due to the production of more heat than the body is able to dissipate.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Temperature greater than or equal to 100.4 degrees F (38.0 degrees C)","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"The elevation of the body's temperature above the upper limit of normal, usually taken as 37.7 degrees Celsius.","type":"ALT_DEFINITION","source":"ACC/AHA"}],"synonyms":[{"termName":"Fever","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTCAE"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"FDA_Table","value":"Patient Code (Appendix B)"},{"name":"Legacy Concept Name","value":"Fever"},{"name":"Maps_To","value":"Fever"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C0015967"},{"name":"Use_For","value":"Pyrogenic"},{"name":"Use_For","value":"Pyrogenic reaction"},{"name":"Use_For","value":"Reaction, pyrogenic"},{"name":"xRef","value":"IMDRF:E230101"}]}}{"C3279":{"preferredName":"Night Sweats","code":"C3279","definitions":[{"definition":"Nocturnal perspiration that is unrelated to environmental temperature.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Perspiration experienced nocturnally that is unrelated to environmental temperature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Night Sweats","termGroup":"PT","termSource":"NCI"},{"termName":"Night Sweating","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Night_Sweating"},{"name":"Maps_To","value":"Night sweats"},{"name":"Maps_To","value":"Night Sweats"},{"name":"Semantic_Type","value":"Sign or Symptom"},{"name":"UMLS_CUI","value":"C0028081"}]}}{"C3445":{"preferredName":"Weight Loss","code":"C3445","definitions":[{"definition":"A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"A reduction in total body weight.","type":"DEFINITION","source":"NCI"},{"definition":"A reduction in total body weight.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Weight Loss","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Weight_Loss"},{"name":"Maps_To","value":"Weight loss"},{"name":"Maps_To","value":"Weight Loss"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1262477"}]}}{"C16237":{"preferredName":"Validation","code":"C16237","definitions":[{"definition":"Process of establishing suitability to purpose. NOTE: Validation is accomplished by planning how to measure and/or evaluate suitability to purpose; then executing the plan and documenting the results. [ICH E6] See also software validation, data validation, psychometric validation, criterion validation (COA), content validation (COA), construct validation (COA).","type":"ALT_DEFINITION","source":"CDISC-GLOSS"},{"definition":"The act of validating; finding or testing the truth of something.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Validation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC-GLOSS"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Validation"},{"name":"Maps_To","value":"Validation"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C1519941"}]}}{"C48227":{"preferredName":"Lost To Follow-Up","code":"C48227","definitions":[{"definition":"The loss or lack of continuation of a subject to follow-up.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The loss or lack of continuation of subject participation after a study has officially closed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lost To Follow-Up","termGroup":"PT","termSource":"NCI"},{"termName":"Lost To Follow-up","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Lost_To_Follow_Up"},{"name":"Maps_To","value":"lost to follow-up"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1302313"}]}}{"C202277":{"preferredName":"Affymetrix Genome-Wide Human SNP Array 6.0","code":"C202277","definitions":[{"definition":"A proprietary system comprised of a single microarray with over 900,000 single nucleotide polymorphisms (SNPs) for genome-wide profiling and approximately 945,000 non-polymorphic probes for detection of copy number variation across a genomic sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Affymetrix Genome-Wide Human SNP Array 6.0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Affymetrix SNP 6.0"},{"name":"NCI_META_CUI","value":"CL1921237"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C182456":{"preferredName":"Comma Separated Values Format","code":"C182456","definitions":[{"definition":"A text file format that separates data elements with commas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Comma Separated Values Format","termGroup":"PT","termSource":"NCI"},{"termName":"Comma-separated Values Format","termGroup":"SY","termSource":"NCI"},{"termName":"CSV","termGroup":"AB","termSource":"NCI"},{"termName":"CSV Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CSV"},{"name":"NCI_META_CUI","value":"CL1771138"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184763":{"preferredName":"Hierarchical Data Format 5","code":"C184763","definitions":[{"definition":"A hierarchical, filesystem-like data format that can store metadata in the form of user-defined, named attributes, which are attached to groups and datasets, and representations of images and tables built up using datasets, groups and attributes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hierarchical Data Format 5","termGroup":"PT","termSource":"NCI"},{"termName":"HDF5","termGroup":"AB","termSource":"NCI"},{"termName":"Hierarchical Data Format Version 5","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"HDF5"},{"name":"NCI_META_CUI","value":"CL1773084"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184778":{"preferredName":"MEX Format","code":"C184778","definitions":[{"definition":"A minimal base ASCII file format to facilitate the exchange of data matrices.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MEX Format","termGroup":"PT","termSource":"NCI"},{"termName":"Market Exchange Format","termGroup":"SY","termSource":"NCI"},{"termName":"Matrix Market Exchange Format","termGroup":"SY","termSource":"NCI"},{"termName":"MEX","termGroup":"SY","termSource":"NCI"},{"termName":"MM Exchange Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The MEX format can be used to represent the gene-barcode matrix output generated by a Cell Ranger sequence analysis pipeline. (https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/output/matrices)"},{"name":"Maps_To","value":"MEX"},{"name":"NCI_META_CUI","value":"CL1773103"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C93207":{"preferredName":"DNA Gene-expression Microarray","code":"C93207","definitions":[{"definition":"A process that allows thousands of pieces of DNA that are fixed to a glass slide to be analyzed at one time. It is used to identify the genes (pieces of DNA) in specific cells or tissue that are actively used to make RNA, which then may be used to make proteins.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"DNA Gene-expression Microarray","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Expression Array"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C2985495"}]}}{"C204352":{"preferredName":"Genomic Variant Call Format","code":"C204352","definitions":[{"definition":"A text file format used for storing gene sequence variations. It is a type of variant call format that has a record for all sites, whether there is a variant call there or not. The format includes metrics of the confidence that positions are actually non-variant vs. a factor of minimum read-depth and genotype quality.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genomic Variant Call Format","termGroup":"PT","termSource":"NCI"},{"termName":"Genomic VCF","termGroup":"SY","termSource":"NCI"},{"termName":"GVCF","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"gVCF"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C97927":{"preferredName":"Gene Variant","code":"C97927","definitions":[{"definition":"A variation in the nucleic acid sequence of a specific gene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Variant","termGroup":"PT","termSource":"NCI"},{"termName":"Gene Mutant","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Mutation","termGroup":"SY","termSource":"NCI"},{"termName":"Gene Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Simple Nucleotide Variation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0678941"}]}}{"C47845":{"preferredName":"FASTA Format","code":"C47845","definitions":[{"definition":"A text-based format for representing either nucleotide sequences or peptide sequences. It consists of a single-line description, followed by lines of sequence data.  Sequences are represented in the standard IUPAC-IUB (International Union of Pure and Applied Chemistry-International Union of Biochemistry Commission on Biochemical Nomenclature) single letter amino acid and nucleic acid base codes. It is an extension of the FAST-P (protein) and FAST-N (nucleotide) alignment tools.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"FASTA Format","termGroup":"PT","termSource":"NCI"},{"termName":"FASTA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"FASTA_Format"},{"name":"Maps_To","value":"FASTA"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1708003"}]}}{"C184749":{"preferredName":"BEDPE Format","code":"C184749","definitions":[{"definition":"A text file format used to store genomic paired-end sequencing data that includes coordinates and associated metadata.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BEDPE Format","termGroup":"PT","termSource":"NCI"},{"termName":"BEDPE","termGroup":"AB","termSource":"NCI"},{"termName":"Browser Extensible Data Paired-End Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BEDPE"},{"name":"NCI_META_CUI","value":"CL1773066"},{"name":"PubMedID_Primary_Reference","value":"17087822"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184761":{"preferredName":"Genome Variation Format","code":"C184761","definitions":[{"definition":"A tab-delimited nine-column file to describe nucleotide sequence variation data. The Genome Variation Format (GVF) is based on the Generic Feature Format Version 3 (GFF3) but the GVF specifies additional text format constraints and allows for additional attributes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genome Variation Format","termGroup":"PT","termSource":"NCI"},{"termName":"GVF","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The nine columns in a GVF file are as follows: 1) the sequence identifier where the variant is located (seqid), 2) the source for the variation data (source), 3) the type of variation as described by a code or term from the Sequence Ontology (type), 4) the integer representing the start coordinate of the sequence (start), 5) an integer representing the end coordinate of the sequence (end), 6) the quality score for the sequencing run (score), 7) the nucleotide strand where the variant was found (strand), 8) an integer representing the start of the next codon from the 5' end of the sequence (phase) and 9) feature attributes (attributes). (https://github.com/The-Sequence-Ontology/Specifications/blob/master/gvf.md)"},{"name":"Maps_To","value":"GVF"},{"name":"NCI_META_CUI","value":"CL1773086"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184769":{"preferredName":"JSON Format","code":"C184769","definitions":[{"definition":"A common open standard file format and data interchange format that uses human-readable text consisting of attribute-value pairs and arrays to store and transmit data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"JSON Format","termGroup":"PT","termSource":"NCI"},{"termName":"JavaScript Object Notation","termGroup":"SY","termSource":"NCI"},{"termName":"JavaScript Object Notation Format","termGroup":"SY","termSource":"NCI"},{"termName":"JSON","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"JSON"},{"name":"NCI_META_CUI","value":"CL1773094"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C64783":{"preferredName":"Gram per Deciliter","code":"C64783","definitions":[{"definition":"A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Gram per Deciliter","termGroup":"PT","termSource":"NCI"},{"termName":"g%","termGroup":"AB","termSource":"NCI"},{"termName":"g/dL","termGroup":"AB","termSource":"NCI"},{"termName":"Gram Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Gram-Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Gram/Deciliter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_Deciliter"},{"name":"Maps_To","value":"g/dL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439267"}]}}{"C64572":{"preferredName":"Microgram per Milliliter","code":"C64572","definitions":[{"definition":"A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of concentration or mass density equal to one microgram of substance per milliliter of solution or one milligram of substance per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Microgram per Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"g/m3","termGroup":"AB","termSource":"NCI"},{"termName":"Gram per Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"gram/cubic meter","termGroup":"SY","termSource":"NCI"},{"termName":"mcg/mL","termGroup":"AB","termSource":"NCI"},{"termName":"mg/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"mg/L","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram/Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Cubic Decimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Liter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanogram per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"ng/uL","termGroup":"AB","termSource":"NCI"},{"termName":"ug/mL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Gram_per_Cubic_Meter"},{"name":"Maps_To","value":"mcg/mL"},{"name":"Maps_To","value":"mg/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439268"}]}}{"C64387":{"preferredName":"Millimole per Liter","code":"C64387","definitions":[{"definition":"A unit of concentration (molarity unit) equal to one millimole of solute per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Millimole per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"amol/fL","termGroup":"AB","termSource":"NCI"},{"termName":"Attomole per Femtoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Femtomole per Picoliter","termGroup":"SY","termSource":"NCI"},{"termName":"fmol/pL","termGroup":"AB","termSource":"NCI"},{"termName":"Micromole per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"Millimolar","termGroup":"SY","termSource":"NCI"},{"termName":"Millimole/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"mmol/L","termGroup":"AB","termSource":"NCI"},{"termName":"Mole per Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanomole per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"nmol/uL","termGroup":"AB","termSource":"NCI"},{"termName":"Picomole per Nanoliter","termGroup":"SY","termSource":"NCI"},{"termName":"pmol/nL","termGroup":"AB","termSource":"NCI"},{"termName":"umol/mL","termGroup":"AB","termSource":"NCI"},{"termName":"ymol/zL","termGroup":"AB","termSource":"NCI"},{"termName":"Yoctomole per Zeptoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Zeptomole per Attoliter","termGroup":"SY","termSource":"NCI"},{"termName":"zmol/aL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Millimole_per_Liter"},{"name":"Maps_To","value":"mmol/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1532563"}]}}{"C105522":{"preferredName":"Unit Per Gram Hemoglobin","code":"C105522","definitions":[{"definition":"A unit of concentration (biologic activity) equal to one unit of substance per gram of hemoglobin.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of hemoglobin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unit Per Gram Hemoglobin","termGroup":"PT","termSource":"NCI"},{"termName":"U/g Hemoglobin","termGroup":"SY","termSource":"NCI"},{"termName":"U/g HGB","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"U/g Hb"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C3642223"}]}}{"C77607":{"preferredName":"Unit per Milliliter","code":"C77607","definitions":[{"definition":"A unit of substance content expressed in unit(s) per milliliter.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An arbitrary unit of substance content expressed in unit(s) per milliliter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unit per Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"U/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Unit/Milliliter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Unit_per_Milliliter"},{"name":"Maps_To","value":"U/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C2945590"}]}}{"C67456":{"preferredName":"Unit per Liter","code":"C67456","definitions":[{"definition":"A unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unit per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"Microunit per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"Milliunit per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"mU/mL","termGroup":"AB","termSource":"NCI"},{"termName":"U/L","termGroup":"AB","termSource":"NCI"},{"termName":"Unit/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"uU/uL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Unit_per_Liter"},{"name":"Maps_To","value":"U/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439339"}]}}{"C67397":{"preferredName":"Microkatal per Liter","code":"C67397","definitions":[{"definition":"Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.","type":"DEFINITION","source":"NCI"},{"definition":"Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Microkatal per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"akat/pL","termGroup":"AB","termSource":"NCI"},{"termName":"Attokatal per Picoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Femtokatal per Nanoliter","termGroup":"SY","termSource":"NCI"},{"termName":"fkat/nL","termGroup":"AB","termSource":"NCI"},{"termName":"Microkatal/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanokatal per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"nkat/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Picokatal per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"pkat/uL","termGroup":"AB","termSource":"NCI"},{"termName":"ukat/L","termGroup":"AB","termSource":"NCI"},{"termName":"ykat/aL","termGroup":"AB","termSource":"NCI"},{"termName":"Yoctokatal per Attoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Zeptokatal per Femtoliter","termGroup":"SY","termSource":"NCI"},{"termName":"zkat/fL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Microkatal_per_Liter"},{"name":"Maps_To","value":"ukat/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1881822"}]}}{"C48508":{"preferredName":"Micromole per Liter","code":"C48508","definitions":[{"definition":"A concentration of 1/1,000,000 (one millionth) molecular weight per liter (mol/L).","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A unit of concentration (molarity unit) equal to one micromole of solute per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of concentration (molarity unit) equal to one one-millionth of a mole (10E-6 mole) of solute per one liter of solution.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Micromole per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"amol/pL","termGroup":"AB","termSource":"NCI"},{"termName":"Attomole per Picoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Femtomole per Nanoliter","termGroup":"SY","termSource":"NCI"},{"termName":"fmol/nL","termGroup":"AB","termSource":"NCI"},{"termName":"mcmol/L","termGroup":"AB","termSource":"NCI"},{"termName":"Micromolar","termGroup":"SY","termSource":"NCI"},{"termName":"Nanomole per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"nmol/mL","termGroup":"AB","termSource":"NCI"},{"termName":"Picomole per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"pmol/uL","termGroup":"AB","termSource":"NCI"},{"termName":"umol/L","termGroup":"AB","termSource":"NCI"},{"termName":"Zeptomole per Femtoliter","termGroup":"SY","termSource":"NCI"},{"termName":"zmol/fL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Micromolar"},{"name":"Maps_To","value":"umol/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439300"}]}}{"C67244":{"preferredName":"Thousand Cells per Microliter","code":"C67244","definitions":[{"definition":"A unit of cell concentration expressed as a number of cells in thousands per unit volume equal to one microliter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thousand Cells per Microliter","termGroup":"PT","termSource":"NCI"},{"termName":"10^3 Cells/uL","termGroup":"SY","termSource":"NCI"},{"termName":"10^3{Cells}/uL","termGroup":"SY","termSource":"NCI"},{"termName":"10E3 Cells/uL","termGroup":"SY","termSource":"NCI"},{"termName":"Thousand Cells/cu mm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Thousand_Cells_per_Microliter"},{"name":"Maps_To","value":"x10^3 cells/mcL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1883312"}]}}{"C67249":{"preferredName":"Billion Cells per Liter","code":"C67249","definitions":[{"definition":"A unit of cell concentration expressed as a number of cells in billions per unit volume equal to one liter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Billion Cells per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"10^9 Cells/L","termGroup":"SY","termSource":"NCI"},{"termName":"10^9{Cells}/L","termGroup":"SY","termSource":"NCI"},{"termName":"10E9 Cells/L","termGroup":"SY","termSource":"NCI"},{"termName":"Billion Cells/Liter","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Billion_Cells_per_Liter"},{"name":"Maps_To","value":"x10^9 cells/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0456524"}]}}{"C65104":{"preferredName":"Square Millimeter","code":"C65104","definitions":[{"definition":"A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.(NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Square Millimeter","termGroup":"PT","termSource":"NCI"},{"termName":"Millimeter Squared","termGroup":"SY","termSource":"NCI"},{"termName":"mm2","termGroup":"AB","termSource":"NCI"},{"termName":"sq. mm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Square_Millimeter"},{"name":"Maps_To","value":"mm^2"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0456786"}]}}{"C184780":{"preferredName":"Milliunits per Mole Hemoglobin","code":"C184780","definitions":[{"definition":"A unit of concentration equal to the concentration in milliunits of substance per mole of hemoglobin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Milliunits per Mole Hemoglobin","termGroup":"PT","termSource":"NCI"},{"termName":"mU/mol Hb","termGroup":"SY","termSource":"NCI"},{"termName":"mU/mol Hemoglobin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"mU/mol Hb"},{"name":"NCI_META_CUI","value":"CL1773101"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C67306":{"preferredName":"Microgram per Liter","code":"C67306","definitions":[{"definition":"A unit of concentration or mass density equal to one nanogram of substance per milliliter of solution or one microgram of substance per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microgram per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"mcg/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"mcg/L","termGroup":"AB","termSource":"NCI"},{"termName":"mg/m3","termGroup":"AB","termSource":"NCI"},{"termName":"Microgram per Cubic Decimeter","termGroup":"SY","termSource":"NCI"},{"termName":"Microgram/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"Milligram per Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanogram per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"ng/mL","termGroup":"AB","termSource":"NCI"},{"termName":"pg/uL","termGroup":"AB","termSource":"NCI"},{"termName":"Picogram per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"ug/dm3","termGroup":"AB","termSource":"NCI"},{"termName":"ug/L","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Microgram_per_Liter"},{"name":"Maps_To","value":"mcg/L"},{"name":"Maps_To","value":"ng/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439275"}]}}{"C48570":{"preferredName":"Percent Unit","code":"C48570","definitions":[{"definition":"A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Percent Unit","termGroup":"PT","termSource":"NCI"},{"termName":"%","termGroup":"AB","termSource":"NCI"},{"termName":"Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Percentage","termGroup":"SY","termSource":"NCI"},{"termName":"Unit of Percent","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Percent_Unit"},{"name":"Maps_To","value":"percent"},{"name":"NCI_META_CUI","value":"CL343029"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C74919":{"preferredName":"Cells per Milliliter","code":"C74919","definitions":[{"definition":"A unit of cell concentration expressed in cells per unit of volume equal to one milliliter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cells per Milliliter","termGroup":"PT","termSource":"NCI"},{"termName":"cells/cm3","termGroup":"SY","termSource":"NCI"},{"termName":"Cells/Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"Cells/mL","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cells_per_Milliliter"},{"name":"Maps_To","value":"cells/mL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C2699156"}]}}{"C48579":{"preferredName":"International Unit","code":"C48579","definitions":[{"definition":"A unit used to measure the activity of many vitamins, hormones, enzymes, and drugs. An IU is the amount of a substance that has a certain biological effect. For each substance there is an international agreement on the biological effect that is expected for 1 IU.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The unitage assigned by the WHO (World Health Organization) to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization, to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.(NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"International Unit","termGroup":"PT","termSource":"NCI"},{"termName":"F2","termGroup":"AB","termSource":"NCI"},{"termName":"International Unit of Biological Activity","termGroup":"SY","termSource":"NCI"},{"termName":"International Units","termGroup":"SY","termSource":"NCI"},{"termName":"IU","termGroup":"AB","termSource":"NCI"},{"termName":"Unit International","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"International_Unit_of_Biological_Activity"},{"name":"Maps_To","value":"IU"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439453"}]}}{"C67432":{"preferredName":"Nanomole per Liter","code":"C67432","definitions":[{"definition":"A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of concentration (molarity unit) equal to one nanomole of solute per liter of solution.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Nanomole per Liter","termGroup":"PT","termSource":"NCI"},{"termName":"amol/nL","termGroup":"AB","termSource":"NCI"},{"termName":"Attomole per Nanoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Femtomole per Microliter","termGroup":"SY","termSource":"NCI"},{"termName":"fmol/mcL","termGroup":"AB","termSource":"NCI"},{"termName":"fmol/uL","termGroup":"AB","termSource":"NCI"},{"termName":"Micromole per Cubic Meter","termGroup":"SY","termSource":"NCI"},{"termName":"Nanomole/Liter","termGroup":"SY","termSource":"NCI"},{"termName":"nmol/L","termGroup":"AB","termSource":"NCI"},{"termName":"Picomole per Milliliter","termGroup":"SY","termSource":"NCI"},{"termName":"pmol/mL","termGroup":"AB","termSource":"NCI"},{"termName":"umol/m3","termGroup":"AB","termSource":"NCI"},{"termName":"ymol/fL","termGroup":"AB","termSource":"NCI"},{"termName":"Yoctomole per Femtoliter","termGroup":"SY","termSource":"NCI"},{"termName":"Zeptomole per Picoliter","termGroup":"SY","termSource":"NCI"},{"termName":"zmol/pL","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Nanomole_per_Liter"},{"name":"Maps_To","value":"nmol/L"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439282"}]}}{"C42535":{"preferredName":"Second","code":"C42535","definitions":[{"definition":"A unit of time, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour.","type":"DEFINITION","source":"NCI"},{"definition":"The base unit of time in the International System of Units (SI) equal to the duration of 9,192,631,770 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the cesium 133 atom in its ground state at 0 K.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Second","termGroup":"PT","termSource":"NCI"},{"termName":"s","termGroup":"AB","termSource":"NCI"},{"termName":"sec","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"DesignNote","value":"Abbreviation Sec. is acceptable in non-scientific usage only."},{"name":"Legacy Concept Name","value":"Second_Unit_of_Time"},{"name":"Maps_To","value":"Seconds"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0457385"}]}}{"C67251":{"preferredName":"Million Cells per Microliter","code":"C67251","definitions":[{"definition":"A unit of cell concentration expressed as a number of cells in millions per unit volume equal to one microliter.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Million Cells per Microliter","termGroup":"PT","termSource":"NCI"},{"termName":"10^6 Cells/uL","termGroup":"SY","termSource":"NCI"},{"termName":"10^6{Cells}/uL","termGroup":"SY","termSource":"NCI"},{"termName":"10E6 cells/uL","termGroup":"SY","termSource":"NCI"},{"termName":"Million Cells/cu mm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Million_Cells_per_Microliter"},{"name":"Maps_To","value":"x10^6 cells/mcL"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C1881842"}]}}{"C36015":{"preferredName":"Asbestos Body","code":"C36015","synonyms":[{"termName":"Asbestos Body","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Asbestos_Body"},{"name":"Maps_To","value":"Asbestos bodies"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0333598"}]}}{"C34584":{"preferredName":"Endocervical Polyp","code":"C34584","definitions":[{"definition":"A polyp that arises from the endocervix. It is characterized by the presence of endocervical glands and a fibrovascular stroma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Endocervical Polyp","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endocervical_Polyp"},{"name":"Maps_To","value":"Benign endocervical polyp"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0014126"}]}}{"C180523":{"preferredName":"Clostridium difficile Infection","code":"C180523","definitions":[{"definition":"A bacterial infection caused by Clostridium difficile (Clostridioides difficile), which is a spore-forming, toxin-producing Gram-positive anaerobic bacillus that is transmitted by the fecal-oral route. Infection may cause symptoms ranging from diarrhea to life-threatening inflammation of the colon, and risk factors include use of antibiotic medication, advanced age, and hospital or long-term care facility admission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clostridium difficile Infection","termGroup":"PT","termSource":"NCI"},{"termName":"C. diff Infection","termGroup":"SY","termSource":"NCI"},{"termName":"Clostridioides difficile Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clostridioides difficile (c. diff)"},{"name":"NCI_META_CUI","value":"CL1663067"},{"name":"Semantic_Type","value":"Disease or Syndrome"}]}}{"C147558":{"preferredName":"Platinum-Resistant Disease","code":"C147558","definitions":[{"definition":"A finding indicating that a cancer is resistant to platinum therapy. For non-gynecologic cancers, the terms \"platinum-resistant\" and \"platinum-refractory\" are used interchangeably. For gynecologic cancers, it refers to cancer progression between one and six months of completing the last platinum therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Platinum-Resistant Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Platinum-Resistant","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Platinum-resistant"},{"name":"NCI_META_CUI","value":"CL545408"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188349":{"preferredName":"Percent Follicular Component Less than or Equal to 10 Percent","code":"C188349","definitions":[{"definition":"A semi-quantitative microscopic finding indicating that less than or equal to 10 percent of the area of a tissue section has follicular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Percent Follicular Component Less than or Equal to 10 Percent","termGroup":"PT","termSource":"NCI"},{"termName":"Percent Follicular Component Less than or Equal to 10%","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Percent follicular component <= 10%"},{"name":"NCI_META_CUI","value":"CL1793618"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188350":{"preferredName":"Percent Follicular Component Greater than 10 Percent","code":"C188350","definitions":[{"definition":"A semi-quantitative microscopic finding indicating more than 10 percent of the area of a tissue section has follicular structures.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Percent Follicular Component Greater than 10 Percent","termGroup":"PT","termSource":"NCI"},{"termName":"Percent Follicular Component Greater than 10%","termGroup":"SY","termSource":"NCI"},{"termName":"Percent Follicular Component More than 10 Percent","termGroup":"SY","termSource":"NCI"},{"termName":"Percent Follicular Component More than 10%","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Percent follicular component > 10%"},{"name":"NCI_META_CUI","value":"CL1793617"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188351":{"preferredName":"PD-L1 Combined Positive Score 20","code":"C188351","definitions":[{"definition":"A quantitative immunohistochemical finding indicating that the number of all PD-L1-expressing cells divided by the total number of viable tumor cells in a sample multiplied by 100 is 20.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PD-L1 Combined Positive Score 20","termGroup":"PT","termSource":"NCI"},{"termName":"CD274 CPS 20","termGroup":"SY","termSource":"NCI"},{"termName":"PD-L1 CPS 20","termGroup":"SY","termSource":"NCI"},{"termName":"PDL1 CPS 20","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"PD-L1 CPS (223C LDT) - 20%"},{"name":"NCI_META_CUI","value":"CL1793616"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C198920":{"preferredName":"Concordant Bone Marrow Histology","code":"C198920","definitions":[{"definition":"A finding, usually associated with lymphoma with bone marrow involvement, where the morphology observed in the bone marrow is the same as that found in the primary nodal site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Concordant Bone Marrow Histology","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone marrow concordant histology"},{"name":"NCI_META_CUI","value":"CL1906365"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198921":{"preferredName":"Discordant Bone Marrow Histology","code":"C198921","definitions":[{"definition":"A finding, usually associated with lymphoma with bone marrow involvement, where the morphology observed in the bone marrow is different from that found in the primary nodal site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Discordant Bone Marrow Histology","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Bone marrow discordant histology"},{"name":"NCI_META_CUI","value":"CL1906364"},{"name":"Semantic_Type","value":"Finding"}]}}{"C6433":{"preferredName":"Endometrial Polyp","code":"C6433","definitions":[{"definition":"A benign nodular lesion protruding above the surface of the endometrium. It is composed of a fibrous stroma that contains thick-walled blood vessels and dilated endometrial glands. Polypectomy is the treatment of choice. Only few cases with recurrence have been reported.","type":"DEFINITION","source":"NCI"},{"definition":"A benign polypoid neoplasm of the endometrium projecting into the endometrial cavity.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Endometrial Polyp","termGroup":"PT","termSource":"NCI"},{"termName":"Endometrial Stromal Polyp","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of Endometrium","termGroup":"SY","termSource":"NCI"},{"termName":"Polyp of the Endometrium","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Endometrial_Polyp"},{"name":"Maps_To","value":"Endometrial polyp"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1704273"}]}}{"C111025":{"preferredName":"Extravascular Matrix Loops","code":"C111025","definitions":[{"definition":"A microscopic finding indicating the presence or absence of extravascular matrix loops in uveal melanoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extravascular Matrix Loops","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extravascular Matrix Loops"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3830280"}]}}{"C111024":{"preferredName":"Presence of Extravascular Matrix Patterns","code":"C111024","definitions":[{"definition":"A microscopic finding indicating the presence of patterns formed by malignant cells outside the blood vessel circulation in uveal melanoma.  The patterns are detectable using PAS stain without counterstaining with hematoxylin.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Presence of Extravascular Matrix Patterns","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Complex Extravascular Matrix Patterns"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828484"}]}}{"C14167":{"preferredName":"Poorly Differentiated","code":"C14167","definitions":[{"definition":"Describes tumor cells that generally have lost most of the appearance of normal cells. They tend to grow and spread.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated","termGroup":"PT","termSource":"NCI"},{"termName":"G3","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated"},{"name":"Maps_To","value":"Poorly Differentiated"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205617"}]}}{"C14171":{"preferredName":"Well Differentiated","code":"C14171","definitions":[{"definition":"Describes tumor cells that generally retain the appearance of normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Well Differentiated","termGroup":"PT","termSource":"NCI"},{"termName":"G1","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Well_Differentiated"},{"name":"Maps_To","value":"Well Differentiated"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205615"}]}}{"C49069":{"preferredName":"Open","code":"C49069","definitions":[{"definition":"Affording unobstructed entrance and exit; affording free passage or access; accessible to all.","type":"DEFINITION","source":"NCI"},{"definition":"Visible; not closed.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Open","termGroup":"PT","termSource":"NCI"},{"termName":"Opened","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Open"},{"name":"Maps_To","value":"open"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0175566"}]}}{"C42729":{"preferredName":"Review","code":"C42729","definitions":[{"definition":"The act of appraisal, evaluation, or analysis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Review","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Review"},{"name":"Maps_To","value":"review"},{"name":"NCI_META_CUI","value":"CL1412614"},{"name":"Semantic_Type","value":"Activity"}]}}{"C25695":{"preferredName":"Submission","code":"C25695","definitions":[{"definition":"The act of referring for judgment or consideration by others; the act of handing over something.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Submission","termGroup":"PT","termSource":"NCI"},{"termName":"Submitted","termGroup":"AD","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Submitted"},{"name":"Maps_To","value":"submitted"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1515023"}]}}{"C48177":{"preferredName":"Processing","code":"C48177","definitions":[{"definition":"The act of preparing or putting through a prescribed procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Processing","termGroup":"PT","termSource":"NCI"},{"termName":"Processing Technique","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Processing_Technique"},{"name":"Maps_To","value":"processing"},{"name":"Semantic_Type","value":"Research Activity"},{"name":"UMLS_CUI","value":"C1709694"}]}}{"C49070":{"preferredName":"Closed","code":"C49070","definitions":[{"definition":"Not affording passage or access; blocked against entry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Closed","termGroup":"PT","termSource":"NCI"},{"termName":"Close","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Closed"},{"name":"Maps_To","value":"closed"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0587267"}]}}{"C184772":{"preferredName":"Legacy Project","code":"C184772","definitions":[{"definition":"An indication that project information or documentation has been deprecated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Legacy Project","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"legacy"},{"name":"NCI_META_CUI","value":"CL1773093"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184788":{"preferredName":"Processed Project","code":"C184788","definitions":[{"definition":"An indication that information or documentation associated with a project has been processed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Processed Project","termGroup":"PT","termSource":"NCI"},{"termName":"Project Processed","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"processed"},{"name":"NCI_META_CUI","value":"CL1773314"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C62669":{"preferredName":"Proteomic Profiling","code":"C62669","definitions":[{"definition":"A laboratory procedure that determines both the identity and levels of expression of the proteins in a biological sample or specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Proteomic Profiling","termGroup":"PT","termSource":"NCI"},{"termName":"Protein Expression Profiling","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Proteomic_Profiling"},{"name":"Maps_To","value":"Proteome Profiling"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1327760"}]}}{"C63480":{"preferredName":"Protein Expression Analysis","code":"C63480","definitions":[{"definition":"Any method of protein detection that can be used to quantify the level of a protein in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Expression Analysis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Protein_Expression_Analysis"},{"name":"Maps_To","value":"Protein Expression Quantification"},{"name":"Semantic_Type","value":"Laboratory Procedure"},{"name":"UMLS_CUI","value":"C1882495"}]}}{"C48329":{"preferredName":"Green","code":"C48329","definitions":[{"definition":"The hue of that portion of the visible spectrum lying between yellow and blue, evoked in the human observer by radiant energy with wavelengths of approximately 490 to 570 nanometers; any of a group of colors that may vary in lightness and saturation and whose hue is that of the emerald or somewhat less yellow than that of growing grass.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Green","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Green"},{"name":"Maps_To","value":"Green"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0332583"}]}}{"C48326":{"preferredName":"Red","code":"C48326","definitions":[{"definition":"The hue of the long-wave end of the visible spectrum, evoked in the human observer by radiant energy with wavelengths of approximately 630 to 750 nanometers; any of a group of colors that may vary in lightness and saturation and whose hue resembles that of blood","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Red","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Red"},{"name":"Maps_To","value":"Red"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1260956"}]}}{"C153189":{"preferredName":"Transcriptomics","code":"C153189","definitions":[{"definition":"A study of the complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transcriptomics","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transcriptome Profiling"},{"name":"NCI_META_CUI","value":"CL554319"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"}]}}{"C38267":{"preferredName":"Intrathecal Route of Administration","code":"C38267","definitions":[{"definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","type":"DEFINITION","source":"NCI"},{"definition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product through the dura to the subarachnoid cavity.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Intrathecal Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intrathecal","termGroup":"SY","termSource":"NCI"},{"termName":"IT","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intrathecal_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intrathecal"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C0677897"}]}}{"C38276":{"preferredName":"Intravenous Route of Administration","code":"C38276","definitions":[{"definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","type":"DEFINITION","source":"NCI"},{"definition":"Administration within or into a vein or veins. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into a vein.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Intravenous Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intravenous","termGroup":"SY","termSource":"NCI"},{"termName":"IV","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intravenous_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intravenous Route of Administration"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522726"}]}}{"C38288":{"preferredName":"Oral Route of Administration","code":"C38288","definitions":[{"definition":"Administration to or by way of the mouth. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Taking a medicinal product by means of swallowing.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Oral Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Oral","termGroup":"SY","termSource":"NCI"},{"termName":"Orally","termGroup":"SY","termSource":"NCI"},{"termName":"Per Os","termGroup":"SY","termSource":"NCI"},{"termName":"PO","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Oral_Route_of_Drug_administration"},{"name":"Maps_To","value":"Oral"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1527415"}]}}{"C38248":{"preferredName":"Intrahepatic Route of Administration","code":"C38248","definitions":[{"definition":"Administration into the liver.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Intrahepatic route of drug administration is a method of drug delivery within the liver, predominantly via hepatic vein or artery. Regimen might be more beneficial then systemic one by delivering a higher dose of drug to the liver and reducing overall systemic exposure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intrahepatic Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"IH","termGroup":"AB","termSource":"NCI"},{"termName":"Intrahepatic","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Intrahepatic_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intrahepatic"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1512952"}]}}{"C28161":{"preferredName":"Intramuscular Route of Administration","code":"C28161","definitions":[{"definition":"Administration within a muscle. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into muscular tissue.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"Intramuscular injection is a route of drug administration via injection into muscle tissue. Aqueous or oleaginous solutions and emulsions or suspensions may be administered. Absorption rates, delay in availability of the drug to the systemic circulation, and duration of effect are perfusion-limited, depend on molecular size of the agent, volume, and osmolarity of the drug solution, fat content of the injection site, and patient physical activity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intramuscular Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"IM","termGroup":"AB","termSource":"NCI"},{"termName":"INTRAMUSCULAR","termGroup":"SY","termSource":"NCI"},{"termName":"Intramuscular Injection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"OORO"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intramuscular_Injection"},{"name":"Maps_To","value":"Intramuscular"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C1556154"}]}}{"C38258":{"preferredName":"Intraperitoneal Route of Administration","code":"C38258","definitions":[{"definition":"A method of delivering fluids and drugs directly into the abdominal cavity through a thin tube.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Administration of a drug via injection or infusion of a substance into the peritoneum, where it is absorbed by the lining.","type":"DEFINITION","source":"NCI"},{"definition":"Administration within the peritoneal cavity. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into the peritoneal cavity.","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Intraperitoneal Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intraperitoneal","termGroup":"SY","termSource":"NCI"},{"termName":"Intraperitoneal Infusion","termGroup":"SY","termSource":"NCI"},{"termName":"IP","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intraperitoneal_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intraperitoneal"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522583"}]}}{"C38269":{"preferredName":"Intratumoral Route of Administration","code":"C38269","definitions":[{"definition":"Administration within a tumor. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Injection of a medicinal product into a tumor.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"The administration of a drug within or introduced directly into a tumor. Method allows to achieve high concentration of the agent in the tumor and delay drug release in systemic circulation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intratumoral Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"I-TUMOR","termGroup":"AB","termSource":"NCI"},{"termName":"Intratumor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intratumoral_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intratumoral"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1517565"}]}}{"C38278":{"preferredName":"Intravesical Route of Administration","code":"C38278","definitions":[{"definition":"Administration of a medicinal product to the urinary bladder.","type":"ALT_DEFINITION","source":"EDQM-HC"},{"definition":"Administration within the bladder. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The administration of a drug within the urinary bladder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intravesical Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"I-VESIC","termGroup":"AB","termSource":"NCI"},{"termName":"Intravesical","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Intravesical_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Intravesical"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522448"}]}}{"C38299":{"preferredName":"Subcutaneous Route of Administration","code":"C38299","definitions":[{"definition":"Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL. (FDA)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Drug administration beneath the skin. It provides for relatively slow, sustained release of the drug. The rate of absorption into the blood is perfusion-limited, proportional to the amount of drug at the site and can be enhanced by chemical or physical stimulation of blood flow. Subcutaneous administration minimizes the risks associated with intravascular injection: for subcutaneous infusions, external and implantable pumps are used.","type":"DEFINITION","source":"NCI"},{"definition":"Injection of a medicinal product directly underneath the skin, i.e. subdermally","type":"ALT_DEFINITION","source":"EDQM-HC"}],"synonyms":[{"termName":"Subcutaneous Route of Administration","termGroup":"PT","termSource":"NCI"},{"termName":"SC","termGroup":"AB","termSource":"NCI"},{"termName":"Subcutaneous","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"EDQM-HC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"FDA_Table","value":"Route of Administration (C-DRG-00301)"},{"name":"Legacy Concept Name","value":"Subcutaneous_Route_of_Drug_Administration"},{"name":"Maps_To","value":"Subcutaneous"},{"name":"Semantic_Type","value":"Functional Concept"},{"name":"UMLS_CUI","value":"C1522438"}]}}{"C111017":{"preferredName":"Amber","code":"C111017","definitions":[{"definition":"A yellowish-orange color.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amber","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Amber"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3714553"}]}}{"C48333":{"preferredName":"Blue","code":"C48333","definitions":[{"definition":"The hue of that portion of the visible spectrum lying between green and indigo, evoked in the human observer by radiant energy with wavelengths of approximately 420 to 490 nanometers; any of a group of colors that may vary in lightness and saturation, whose hue is that of a clear daytime sky.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Blue","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Blue"},{"name":"Maps_To","value":"Blue"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1260957"}]}}{"C48332":{"preferredName":"Brown","code":"C48332","definitions":[{"definition":"Any of a group of colors between red and yellow in hue that are medium to low in lightness and low to moderate in saturation.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Brown","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Brown"},{"name":"Maps_To","value":"Brown"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0678579"}]}}{"C48324":{"preferredName":"Gray","code":"C48324","definitions":[{"definition":"An achromatic color of any lightness between the extremes of black and white.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"American Heritage Dictionary - Bartelby.com"}]}],"synonyms":[{"termName":"Gray","termGroup":"PT","termSource":"NCI"},{"termName":"Gray Color","termGroup":"SY","termSource":"NCI"},{"termName":"Grey","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_Table","value":"SPL Color (C-DRG-00927)"},{"name":"Legacy Concept Name","value":"Gray_Color"},{"name":"Maps_To","value":"Gray"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1269776"}]}}{"C111018":{"preferredName":"Hazel","code":"C111018","definitions":[{"definition":"A color that consists of brown-gold and green.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hazel","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hazel"},{"name":"NCI_META_CUI","value":"CL455349"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C157431":{"preferredName":"Red and Violet","code":"C157431","definitions":[{"definition":"The combination of red and violet colors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Red and Violet","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Red & Violet"},{"name":"NCI_META_CUI","value":"CL937124"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C160244":{"preferredName":"Other Eye Color","code":"C160244","definitions":[{"definition":"The color of the eye was identified in the study but is not present in the form.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Eye Color","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other"},{"name":"NCI_META_CUI","value":"CL971190"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C111066":{"preferredName":"Orchiopexy","code":"C111066","definitions":[{"definition":"A surgical procedure in which an undescended testis is fixated inside the scrotum.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Orchiopexy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Orchiopexy"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0194907"}]}}{"C184803":{"preferredName":"Spontaneous Descent of Undescended Testis","code":"C184803","definitions":[{"definition":"An indication that a subject previously diagnosed with undescended testicle experienced spontaneous resolution without intervention.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Spontaneous Descent of Undescended Testis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spontaneous Descent"},{"name":"NCI_META_CUI","value":"CL1772997"},{"name":"Semantic_Type","value":"Finding"}]}}{"C156018":{"preferredName":"Archive","code":"C156018","definitions":[{"definition":"A place or collection containing records, documents, or other materials, especially those of historical interest.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Archive","termGroup":"PT","termSource":"NCI"},{"termName":"Archival","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Archive"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0003738"}]}}{"C184805":{"preferredName":"TARGZ Format","code":"C184805","definitions":[{"definition":"An electronic file containing multiple files archived using the Unix-based tape archive (tar) utility and then compressed with the GNU zip (gzip) utility.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TARGZ Format","termGroup":"PT","termSource":"NCI"},{"termName":"tar.gz","termGroup":"SY","termSource":"NCI"},{"termName":"TARGZ","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TARGZ"},{"name":"NCI_META_CUI","value":"CL1772995"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C131459":{"preferredName":"Microsatellite Stable","code":"C131459","definitions":[{"definition":"Indicates that no positive loci have been detected in the microsatellite instability (MSI) biomarkers in a sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microsatellite Stable","termGroup":"PT","termSource":"NCI"},{"termName":"MSI Stable","termGroup":"SY","termSource":"NCI"},{"termName":"MSS","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"MSS"},{"name":"NCI_META_CUI","value":"CL514319"},{"name":"Semantic_Type","value":"Laboratory or Test Result"}]}}{"C60763":{"preferredName":"Supplement","code":"C60763","definitions":[{"definition":"Textual matter that is added onto a publication or document, usually at the end; a section added to a book or document to give further information or to correct errors.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Supplement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Supplement_Document"},{"name":"Maps_To","value":"Supplementary Files"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C1947943"}]}}{"C184767":{"preferredName":"Protein Isoform Measurement","code":"C184767","definitions":[{"definition":"The determination of the amount of a specific protein isoform in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protein Isoform Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Isoform Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Isoform Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"Protein Isoform Quantitation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Isoform Expression Quantification"},{"name":"NCI_META_CUI","value":"CL1773096"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184779":{"preferredName":"MicroRNA Measurement","code":"C184779","definitions":[{"definition":"A determination of the amount of microRNA in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"MicroRNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"MicroRNA Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"miRNA Quantitation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"miRNA Expression Quantification"},{"name":"NCI_META_CUI","value":"CL1773100"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C185075":{"preferredName":"Personal History of Pheochromocytoma or Paraganglioma","code":"C185075","definitions":[{"definition":"An individual history of pheochromocytoma or paraganglioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Pheochromocytoma or Paraganglioma","termGroup":"PT","termSource":"NCI"},{"termName":"History of Pheochromocytoma or Paraganglioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Phenochromocytoma or Paraganglioma"},{"name":"NCI_META_CUI","value":"CL1773130"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C198972":{"preferredName":"Personal History of Colorectal Cancer","code":"C198972","definitions":[{"definition":"An individual history of colorectal cancer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Colorectal Cancer","termGroup":"PT","termSource":"NCI"},{"termName":"History of Colorectal Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Colorectal Cancer"},{"name":"NCI_META_CUI","value":"CL1797588"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C198973":{"preferredName":"Personal History of Low Grade Glioma","code":"C198973","definitions":[{"definition":"An individual history of low grade glioma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Personal History of Low Grade Glioma","termGroup":"PT","termSource":"NCI"},{"termName":"History of Low Grade Glioma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lower Grade Glioma"},{"name":"NCI_META_CUI","value":"CL1906399"},{"name":"Semantic_Type","value":"Clinical Attribute"}]}}{"C184801":{"preferredName":"Somatic Cytogenetic Abnormality Analysis","code":"C184801","definitions":[{"definition":"A technique to detect and/or identify cytogenetic abnormalities in non-germline (somatic) cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Somatic Cytogenetic Abnormality Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Somatic Structural Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Structural Abnormality Analysis","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Structural Variation","termGroup":"SY","termSource":"NCI"},{"termName":"Somatic Structural Variation Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Somatic Structural Variation"},{"name":"NCI_META_CUI","value":"CL1772999"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C2950":{"preferredName":"Cytogenetic Abnormality","code":"C2950","definitions":[{"definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cytogenetic Abnormality","termGroup":"PT","termSource":"NCI"},{"termName":"Aberrant Chromosome","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Abnormalities","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosomal Alterations","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Abnormality","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Alterations","termGroup":"SY","termSource":"NCI"},{"termName":"Chromosome Anomalies","termGroup":"SY","termSource":"NCI"},{"termName":"Cytogenetic Aberration","termGroup":"SY","termSource":"NCI"},{"termName":"Genomic Structural Variation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Chromosomal_Aberration"},{"name":"Maps_To","value":"Structural Alteration"},{"name":"Maps_To","value":"Structural Variation"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0008625"}]}}{"C184762":{"preferredName":"IDAT Format","code":"C184762","definitions":[{"definition":"A proprietary, encrypted XML-based, compressed electronic file format from Illumina Inc. for storing genome-wide profiling data. The data contains a summary of the intensity data generated from each probe used during a sequencing run.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"IDAT Format","termGroup":"PT","termSource":"NCI"},{"termName":"IDAT","termGroup":"SY","termSource":"NCI"},{"termName":"Intensity Data","termGroup":"SY","termSource":"NCI"},{"termName":"Intensity Data Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IDAT"},{"name":"NCI_META_CUI","value":"CL1773087"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184806":{"preferredName":"TBI Format","code":"C184806","definitions":[{"definition":"A tab-delimited file that contains an index for the genome positions in a compressed (zipped) variant call format file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TBI Format","termGroup":"PT","termSource":"NCI"},{"termName":"Tabix","termGroup":"SY","termSource":"NCI"},{"termName":"TBI","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TBI"},{"name":"NCI_META_CUI","value":"CL1772996"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C184741":{"preferredName":"Aggregated Somatic Variation Data","code":"C184741","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has been aggregated across samples or sequencing runs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aggregated Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Aggregated Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aggregated Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773058"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184742":{"preferredName":"Aligned Reads Index","code":"C184742","definitions":[{"definition":"The full-text index utilized to align nucleotide sequencing read data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Reads Index","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aligned Reads Index"},{"name":"NCI_META_CUI","value":"CL1773059"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184745":{"preferredName":"Allele-Specific Copy Number Segment Data","code":"C184745","definitions":[{"definition":"Nucleotide sequence data where repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number of specified alleles in each region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Allele-Specific Copy Number Segment Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Allele-Specific Copy Number Segment"},{"name":"NCI_META_CUI","value":"CL1773070"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184744":{"preferredName":"Copy Number Segment Data","code":"C184744","definitions":[{"definition":"Nucleotide sequence data where repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number for each region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copy Number Segment Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Copy Number Segment"},{"name":"NCI_META_CUI","value":"CL1773073"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184776":{"preferredName":"Masked Copy Number Segment Data","code":"C184776","definitions":[{"definition":"Nucleotide sequence data where the low-quality base calls have been masked and repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number for each region.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Copy Number Segment Data","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Copy Number Segment"},{"name":"NCI_META_CUI","value":"CL1773105"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184746":{"preferredName":"Annotated Somatic Variation Data","code":"C184746","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has been annotated.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Annotated Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Annotated Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Annotated Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773071"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184775":{"preferredName":"Masked Annotated Somatic Variation Data","code":"C184775","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has been annotated and where the low-quality base calls have been masked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Annotated Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Masked Annotated Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Annotated Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773104"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184752":{"preferredName":"Cohort Level Copy Number Scores","code":"C184752","definitions":[{"definition":"The number of DNA sequence copies found over the entire genome of a cohort.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cohort Level Copy Number Scores","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cohort Level Copy Number Scores"},{"name":"NCI_META_CUI","value":"CL1773081"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C181336":{"preferredName":"Number of Gene Copies","code":"C181336","definitions":[{"definition":"The number of replicas of a particular gene sequence in a genome.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The number of replicas of a particular gene sequence in a genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Number of Gene Copies","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gene Level Copy Number"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0178655"}]}}{"C184759":{"preferredName":"Gene Level Copy Number Scores","code":"C184759","definitions":[{"definition":"The number of copies of a specified gene found over an entire genome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Level Copy Number Scores","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gene Level Copy Number Scores"},{"name":"NCI_META_CUI","value":"CL1773088"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184755":{"preferredName":"Differential Gene Expression Level Analysis","code":"C184755","definitions":[{"definition":"The determination and comparison of the levels of gene transcription in a set of at least two biospecimens (often a comparison of expression levels for a diseased- or tumor-derived sample versus a normal sample).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Differential Gene Expression Level Analysis","termGroup":"PT","termSource":"NCI"},{"termName":"Differential Gene Expression","termGroup":"SY","termSource":"NCI"},{"termName":"Differential Gene Expression Analysis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Differential Gene Expression"},{"name":"NCI_META_CUI","value":"CL1773076"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184799":{"preferredName":"Single Cell Data","code":"C184799","definitions":[{"definition":"Any data from investigations or experiments performed on samples derived from single cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Single Cell Data","termGroup":"PT","termSource":"NCI"},{"termName":"Single Cell Analysis Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Single Cell Analysis"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C0597452"}]}}{"C184756":{"preferredName":"Exon RNA Measurement","code":"C184756","definitions":[{"definition":"The determination of the amount of RNA encoded by a specific exon in a biological sample.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exon RNA Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"Exon Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal Quantitation","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal RNA Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Exonal RNA Quantitation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Exon Expression Quantification"},{"name":"NCI_META_CUI","value":"CL1773077"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C135484":{"preferredName":"Gene Expression Level Analysis","code":"C135484","definitions":[{"definition":"The determination of the level of gene transcription in a biological specimen. (CDISC)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gene Expression Level Analysis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gene Expression Quantification"},{"name":"NCI_META_CUI","value":"CL522851"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184802":{"preferredName":"Splice Junction Measurement","code":"C184802","definitions":[{"definition":"A determination of the number of transcript splice junctions based on nucleotide sequencing reads extending across the start and/or end of a junction.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Splice Junction Measurement","termGroup":"PT","termSource":"NCI"},{"termName":"RNA Transcript Splice Junction Measurement","termGroup":"SY","termSource":"NCI"},{"termName":"Splice Junction Quantification","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Splice Junction Quantification"},{"name":"NCI_META_CUI","value":"CL1773000"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184774":{"preferredName":"Masked Intensity Sequencing Data","code":"C184774","definitions":[{"definition":"Sequencing chromatogram data where the low-quality base calls have been masked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Intensity Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Masked Intensity Data","termGroup":"SY","termSource":"NCI"},{"termName":"Masked Intensity Nucleotide Sequencing Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Intensities"},{"name":"NCI_META_CUI","value":"CL1773091"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184777":{"preferredName":"Masked Somatic Variation Data","code":"C184777","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples where the low-quality base calls have been masked.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Masked Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Masked Somatic Mutation Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Masked Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1773102"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184795":{"preferredName":"Raw Somatic Variation Data","code":"C184795","definitions":[{"definition":"Sequence variation data from non-germline cell or tissue samples that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw Somatic Variation Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw Somatic Mutation Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw Somatic Variant Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw Simple Somatic Mutation"},{"name":"NCI_META_CUI","value":"CL1772989"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184793":{"preferredName":"Raw Intensity Sequencing Data","code":"C184793","definitions":[{"definition":"The four-color nucleotide sequencing chromatogram generated by the sequencing instrument that has not been subjected to any normalization, alignment or other data processing steps.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Raw Intensity Sequencing Data","termGroup":"PT","termSource":"NCI"},{"termName":"Raw Nucleic Acid Sequencing Data","termGroup":"SY","termSource":"NCI"},{"termName":"Raw Nucleotide Sequencing Data","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Raw Intensities"},{"name":"NCI_META_CUI","value":"CL1772991"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C206457":{"preferredName":"Somatic Mutation Index File","code":"C206457","definitions":[{"definition":"An electronic data file containing the index for somatic mutation calls.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Somatic Mutation Index File","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Somatic Mutation Index"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C184809":{"preferredName":"Fusion Transcript Sequencing","code":"C184809","definitions":[{"definition":"Transcriptome sequencing where either sequencing reads are aligned to reference genes or genomes and then analyzed by software to identify discordant sequences associated with rearrangements are present or samples are subjected to direct sequencing approaches where either each read pair maps to opposite sides of a chimeric junction or where chimeric transcripts overlapping the fusion junction are identified in the reads.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fusion Transcript Sequencing","termGroup":"PT","termSource":"NCI"},{"termName":"Fusion Transcript Detection","termGroup":"SY","termSource":"NCI"},{"termName":"Transcript Fusion Sequencing","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transcript Fusion"},{"name":"NCI_META_CUI","value":"CL1773006"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C184807":{"preferredName":"TARGET Data Coordinating Center Archive","code":"C184807","definitions":[{"definition":"A storage location for historical digital data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project data coordinating center.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TARGET Data Coordinating Center Archive","termGroup":"PT","termSource":"NCI"},{"termName":"TARGET DCC Archive","termGroup":"SY","termSource":"NCI"},{"termName":"Therapeutically Applicable Research to Generate Effective Treatments Data Coordinating Center Archive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TARGET DCC Archive"},{"name":"NCI_META_CUI","value":"CL1773008"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C184808":{"preferredName":"TCGA Data Coordinating Center Archive","code":"C184808","definitions":[{"definition":"A storage location for historical digital data from The Cancer Genome Atlas (TCGA) project data coordinating center.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TCGA Data Coordinating Center Archive","termGroup":"PT","termSource":"NCI"},{"termName":"TCGA DCC Archive","termGroup":"SY","termSource":"NCI"},{"termName":"The Cancer Genome Atlas Data Coordinating Center Archive","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TCGA DCC Archive"},{"name":"NCI_META_CUI","value":"CL1773009"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C184797":{"preferredName":"Reverse Phase Protein Array","code":"C184797","definitions":[{"definition":"A high-throughput antibody-based functional proteomic microarray that can quantify basal protein expression and characterize as well as quantify post-translational modifications in a series of samples of body fluids or those derived from tissue or cellular lysates. (NCI)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"An antibody-based functional proteomic microarray that can characterize basal protein expression and levels of protein modifications in a series of samples of body fluids or those derived from tissue or cellular lysates.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Reverse Phase Protein Array","termGroup":"PT","termSource":"NCI"},{"termName":"Reverse Phase Protein Microarray","termGroup":"SY","termSource":"NCI"},{"termName":"RPMA","termGroup":"SY","termSource":"NCI"},{"termName":"RPPA","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Reverse Phase Protein Array"},{"name":"Maps_To","value":"RPPA"},{"name":"NCI_META_CUI","value":"CL1772987"},{"name":"Semantic_Type","value":"Molecular Biology Research Technique"}]}}{"C184743":{"preferredName":"Sequence Alignment Workflow","code":"C184743","definitions":[{"definition":"A workflow leveraged to align nucleotide sequencing data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sequence Alignment Workflow","termGroup":"PT","termSource":"NCI"},{"termName":"Nucleotide Sequence Alignment Workflow","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"alignment_workflow"},{"name":"NCI_META_CUI","value":"CL1773072"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C45527":{"preferredName":"Amosite Asbestos","code":"C45527","definitions":[{"definition":"A naturally occurring, fibrous amphibole asbestos mineral with a color ranging from gray to greenish-brown. Amosite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Amosite asbestos is a known human carcinogen. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Amosite Asbestos","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12172-73-5"},{"name":"CHEBI_ID","value":"CHEBI:46678"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"321T905Y7I"},{"name":"Legacy Concept Name","value":"Amosite_Asbestos"},{"name":"Maps_To","value":"Amosite"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0051740"}]}}{"C29816":{"preferredName":"Crocidolite Asbestos","code":"C29816","definitions":[{"definition":"A naturally occurring, blue, fibrous amphibole asbestos mineral. Crocidolite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Crocidolite asbestos is a known human carcinogen. (NCI05)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crocidolite Asbestos","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"12001-28-4"},{"name":"CHEBI_ID","value":"CHEBI:46666"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"CK28D16OLZ"},{"name":"Legacy Concept Name","value":"Crocidolite_Asbestos"},{"name":"Maps_To","value":"Crocidolite"},{"name":"Semantic_Type","value":"Hazardous or Poisonous Substance"},{"name":"UMLS_CUI","value":"C0056502"}]}}{"C521":{"preferredName":"Therapeutic Glucocorticoid","code":"C521","definitions":[{"definition":"Synthetically derived forms of the naturally occurring Glucocorticoids.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Therapeutic Glucocorticoid","termGroup":"PT","termSource":"NCI"},{"termName":"Glucocorticoid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Glucocorticoid"},{"name":"Maps_To","value":"Glucocorticoid"},{"name":"NCI_META_CUI","value":"CL448480"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C530":{"preferredName":"Recombinant Growth Factor","code":"C530","definitions":[{"definition":"Formulated therapeutic proteins that are either isolated from endogenous sources or manufactured in a laboratory.  Growth factors bind to specific receptors expressed by various cell types, thereby stimulating cell differentiation and/or proliferation. (NCI04)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Recombinant Growth Factor","termGroup":"PT","termSource":"NCI"},{"termName":"Growth Agents","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Therapeutic_Growth_Factor"},{"name":"Maps_To","value":"Growth factor"},{"name":"Semantic_Type","value":"Amino Acid, Peptide, or Protein"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C1515377"}]}}{"C62554":{"preferredName":"Poly (ADP-Ribose) Polymerase Inhibitor","code":"C62554","definitions":[{"definition":"A substance that blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. It may cause cancer cells to die. It is a type of targeted therapy.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any substance that inhibits Poly (ADP-Ribose) polymerase, an enzyme involved in detecting DNA single strand breaks and the initiation of DNA repair. Inhibition of Poly (ADP-Ribose) polymerase has direct cytotoxic effects by inhibiting DNA repair and causing cell death.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poly (ADP-Ribose) Polymerase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"PARP Inhibitor","termGroup":"AB","termSource":"NCI"},{"termName":"Poly(ADP-Ribose) Polymerase Inhibitor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:62913"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poly_ADP-Ribose_Polymerase_Inhibitor"},{"name":"Maps_To","value":"PARP inhibitor"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C1882413"}]}}{"C38705":{"preferredName":"Absorbable Gelatin Sponge","code":"C38705","definitions":[{"definition":"A sterile hemostatic agent composed of purified porcine-derived gelatin.  In regional chemotherapy, absorbable gelatin sponge may be used to embolize arteries in the region of a tumor in order to block or retard blood flow; this blockage results in a locally increased concentration of chemotherapeutic agents delivered to the tumor when chemotherapeutic agents are infused into the embolized arterial circulation upstream of the blockage.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Absorbable Gelatin Sponge","termGroup":"PT","termSource":"NCI"},{"termName":"Gelatin Sponge, Absorbable","termGroup":"SY","termSource":"NCI"},{"termName":"Gelfoam","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Homeostasis"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Absorbable_Gelatin_Sponge"},{"name":"Maps_To","value":"Gelfoam"},{"name":"NCI_Drug_Dictionary_ID","value":"355797"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355797"},{"name":"PDQ_Open_Trial_Search_ID","value":"355797"},{"name":"Semantic_Type","value":"Medical Device"},{"name":"UMLS_CUI","value":"C0017238"}]}}{"C487":{"preferredName":"Ethiodized Oil","code":"C487","definitions":[{"definition":"A form of poppy seed oil that contains iodine. Ethiodized oil is given by injection and builds up in the blood and lymph vessels in tumors. It is used for imaging (taking pictures) of the salivary glands and the lymph system. It is also being studied in the imaging of other organs such as the liver, lung, stomach, and thyroid. It is a type of diagnostic imaging agent.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A synthetic iodine addition product of the ethyl ester of the fatty acids of poppy seed oil. Ethiodized oil contains 37% organically bound iodine and is used as a diagnostic radiopaque medium or, labeled with I-131, as an antineoplastic agent. Selectively retained in tumor vessels for long periods, ethiodized oil is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodol can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ethiodized Oil","termGroup":"PT","termSource":"NCI"},{"termName":"Ethiodol","termGroup":"SY","termSource":"NCI"},{"termName":"Iodized Oil","termGroup":"SY","termSource":"NCI"},{"termName":"Lipiodol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Diagnostic imaging, hysterosalpingography and lymphography"},{"name":"CAS_Registry","value":"8008-53-5"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"FDA_UNII_Code","value":"KZW0R0686Q"},{"name":"Legacy Concept Name","value":"Ethiodized_Oil"},{"name":"Maps_To","value":"Lipiodol"},{"name":"NCI_Drug_Dictionary_ID","value":"355795"},{"name":"PDQ_Closed_Trial_Search_ID","value":"355795"},{"name":"PDQ_Open_Trial_Search_ID","value":"355795"},{"name":"Semantic_Type","value":"Indicator, Reagent, or Diagnostic Aid"},{"name":"Semantic_Type","value":"Substance"},{"name":"UMLS_CUI","value":"C0015018"}]}}{"C97233":{"preferredName":"Plastic Embolic Bead","code":"C97233","definitions":[{"definition":"An embolic bead that is made from a plastic-like resin or polymer.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Plastic Embolic Bead","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Plastic Beads"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273295"}]}}{"C71147":{"preferredName":"PVA Microporous Hydrospheres","code":"C71147","definitions":[{"definition":"An embolic material composed of microspheres of polyvinyl alcohol (PVA) polymers. These water-soluble, compressible microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as a drug delivery vehicle during embolization of tumor vasculature.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"PVA Microporous Hydrospheres","termGroup":"PT","termSource":"NCI"},{"termName":"Bead Block Compressible Microspheres","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"PVA_Microporous_Hydrospheres"},{"name":"Maps_To","value":"PVA Particles"},{"name":"NCI_Drug_Dictionary_ID","value":"574044"},{"name":"NCI_META_CUI","value":"CL376222"},{"name":"PDQ_Closed_Trial_Search_ID","value":"574044"},{"name":"PDQ_Open_Trial_Search_ID","value":"574044"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C97230":{"preferredName":"Embolic Bead","code":"C97230","definitions":[{"definition":"An embolic agent that is in the form of a small sphere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Embolic Bead","termGroup":"PT","termSource":"NCI"},{"termName":"Embolization Bead","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Spherical Particles"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C3273292"}]}}{"C188376":{"preferredName":"Secondary Exposure Indicator","code":"C188376","definitions":[{"definition":"An indication that a subject was indirectly exposed to potentially harmful agent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Secondary Exposure Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"Secondary Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Secondary"},{"name":"NCI_META_CUI","value":"CL1794629"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C16929":{"preferredName":"Occupational Exposure","code":"C16929","definitions":[{"definition":"The exposure to agents that occurs as a result of one's occupation.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The exposure to potentially harmful agents that occurs as a result of one's occupation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occupational Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Work-related Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Occupational_Exposure"},{"name":"Maps_To","value":"Occupational"},{"name":"Maps_To","value":"Work"},{"name":"Semantic_Type","value":"Human-caused Phenomenon or Process"},{"name":"UMLS_CUI","value":"C0028798"}]}}{"C202294":{"preferredName":"Home-related Exposure","code":"C202294","definitions":[{"definition":"Exposure to potentially harmful chemical, physical, or biological agents in the home.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Home-related Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Home Exposure","termGroup":"SY","termSource":"NCI"},{"termName":"Household Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Home"},{"name":"NCI_META_CUI","value":"CL1921273"},{"name":"Semantic_Type","value":"Finding"}]}}{"C202295":{"preferredName":"Social Setting-related Exposure","code":"C202295","definitions":[{"definition":"Exposure to potentially harmful chemical, physical, or biological agents when interacting with other individuals.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Social Setting-related Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"Social Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social"},{"name":"NCI_META_CUI","value":"CL1921274"},{"name":"Semantic_Type","value":"Finding"}]}}{"C188386":{"preferredName":"Maximum Tumor Bulk No Known Nodal Involvement","code":"C188386","definitions":[{"definition":"A response indicating that no lymph node involvement was detected when the location of a tumor bulk maximum was examined.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Maximum Tumor Bulk No Known Nodal Involvement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No known nodal involvement"},{"name":"NCI_META_CUI","value":"CL1793628"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C159203":{"preferredName":"Ascites Fluid Sample","code":"C159203","definitions":[{"definition":"A biospecimen of ascitic fluid.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ascites Fluid Sample","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Ascites/peritoneum"},{"name":"NCI_META_CUI","value":"CL951255"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"xRef","value":"UBERON:0007795"}]}}{"C159355":{"preferredName":"Abdominal Peritoneum","code":"C159355","definitions":[{"definition":"A membranous lining of the abdominal cavity and abdominal organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Abdominal Peritoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Abdominal Peritoneum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0817432"}]}}{"C137974":{"preferredName":"Adnexa","code":"C137974","definitions":[{"definition":"An appendage or accessory structure of an adjacent or related organ.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adnexa","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adnexa"},{"name":"NCI_META_CUI","value":"CL524965"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"}]}}{"C32959":{"preferredName":"Left Fallopian Tube","code":"C32959","definitions":[{"definition":"The fallopian tube that extends from the uterus to the ovary in the left side of the pelvic cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Left Fallopian Tube","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Left_Fallopian_Tube"},{"name":"Maps_To","value":"Fallopian Tube, Left"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227902"}]}}{"C33475":{"preferredName":"Right Fallopian Tube","code":"C33475","definitions":[{"definition":"The fallopian tube that extends from the uterus to the ovary in the right side of the pelvic cavity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Right Fallopian Tube","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Fallopian_Tube"},{"name":"Maps_To","value":"Fallopian Tube, Right"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227900"}]}}{"C93180":{"preferredName":"Lower Pole of Kidney","code":"C93180","definitions":[{"definition":"The lowermost portion of the kidney.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The pole of the kidney located in the lowest region of the kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lower Pole of Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Inferior Pole of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Kidney Lower Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Lower Lobe of Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney, Lower Pole"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2985481"}]}}{"C186124":{"preferredName":"Kidney Interpolar Region","code":"C186124","definitions":[{"definition":"The portion of the kidney that is located between the upper and lower poles and contains the renal hilum.","type":"DEFINITION","source":"NCI"},{"definition":"The portion of the kidney that is located between the upper and lower poles and contains the renal hilum.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Kidney Interpolar Region","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney, Middle"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C2326831"}]}}{"C93179":{"preferredName":"Upper Pole of Kidney","code":"C93179","definitions":[{"definition":"The pole of the kidney located in the uppermost region of the kidney.","type":"DEFINITION","source":"NCI"},{"definition":"The uppermost portion of the kidney.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Upper Pole of Kidney","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Upper Lobe","termGroup":"SY","termSource":"NCI"},{"termName":"Superior Pole of Kidney","termGroup":"SY","termSource":"NCI"},{"termName":"Upper Lobe of Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney, Upper Pole"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C2985480"}]}}{"C32969":{"preferredName":"Left Ovary","code":"C32969","definitions":[{"definition":"The ovary that is located in the left side of the pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Left Ovary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Left_Ovary"},{"name":"Maps_To","value":"Ovary, Left"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227874"}]}}{"C33487":{"preferredName":"Right Ovary","code":"C33487","definitions":[{"definition":"The ovary that is located in the right side of the pelvis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Right Ovary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Right_Ovary"},{"name":"Maps_To","value":"Ovary, Right"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227873"}]}}{"C159344":{"preferredName":"Pelvic Peritoneum","code":"C159344","definitions":[{"definition":"A membranous lining of the pelvic organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pelvic Peritoneum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pelvic Peritoneum"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0230295"}]}}{"C33301":{"preferredName":"Perineum","code":"C33301","definitions":[{"definition":"The area located between the anus and vulva in females, and anus and scrotum in males.","type":"DEFINITION","source":"NCI"},{"definition":"The area located between the anus and vulva in females, and anus and scrotum in males. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Perineum","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Perineum"},{"name":"Maps_To","value":"Perineum"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0031066"}]}}{"C173496":{"preferredName":"Peripheral Blood","code":"C173496","definitions":[{"definition":"Blood drawn from a limb.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Blood","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Peripheral blood"},{"name":"Maps_To","value":"Peripheral Blood NOS"},{"name":"Semantic_Type","value":"Body Substance"},{"name":"UMLS_CUI","value":"C0229664"},{"name":"xRef","value":"UBERON:0013756"}]}}{"C12465":{"preferredName":"Peripheral Nervous System","code":"C12465","definitions":[{"definition":"That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Nervous System","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Peripheral_Nervous_System"},{"name":"Maps_To","value":"Peripheral nervous system"},{"name":"Semantic_Type","value":"Body System"},{"name":"UMLS_CUI","value":"C0206417"}]}}{"C26990":{"preferredName":"Transplanted Kidney Complication","code":"C26990","definitions":[{"definition":"A disease or disorder that is associated with a transplanted kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transplanted Kidney Complication","termGroup":"PT","termSource":"NCI"},{"termName":"Complication of Transplanted Kidney","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Transplanted_Kidney_Complication"},{"name":"Maps_To","value":"Transplanted kidney"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1261281"}]}}{"C159213":{"preferredName":"Central Lung Parenchyma Tumor","code":"C159213","definitions":[{"definition":"A response that the parenchyma tumor is in the central lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Lung Parenchyma Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Central Lung"},{"name":"NCI_META_CUI","value":"CL951264"},{"name":"Semantic_Type","value":"Finding"}]}}{"C32671":{"preferredName":"Gastrosplenic Ligament","code":"C32671","definitions":[{"definition":"The portion of the greater omentum between the greater curvature of the stomach and the hilum of the spleen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gastrosplenic Ligament","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Gastrosplenic_Omentum"},{"name":"Maps_To","value":"Gastrosplenic Ligament"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0230230"}]}}{"C159212":{"preferredName":"Peripheral Lung Parenchyma Tumor","code":"C159212","definitions":[{"definition":"A response that the parenchyma tumor is in the peripheral lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Lung Parenchyma Tumor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Lung"},{"name":"NCI_META_CUI","value":"CL951263"},{"name":"Semantic_Type","value":"Finding"}]}}{"C102955":{"preferredName":"Great Blood Vessel","code":"C102955","definitions":[{"definition":"Any of the major arteries or veins attached to the cardiac atria or ventricles.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Any of the major arteries or veins attached to the cardiac atria or ventricles. This includes the aorta, superior and inferior vena cava and the pulmonary arteries and veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Great Blood Vessel","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Great Blood Vessel"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C3641002"}]}}{"C12815":{"preferredName":"Inferior Vena Cava","code":"C12815","definitions":[{"definition":"A large vein that empties into the heart. It carries blood from the legs and feet and from organs in the abdomen and pelvis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A large vein that returns blood from the lower half of the body to the heart.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A large vein that returns blood from the lower half of the body to the heart.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Inferior Vena Cava","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Inferior_Vena_Cava"},{"name":"Maps_To","value":"Inferior Vena Cava"},{"name":"Semantic_Type","value":"Body Part, Organ, or Organ Component"},{"name":"UMLS_CUI","value":"C0042458"}]}}{"C32887":{"preferredName":"Thyroid Gland Isthmus","code":"C32887","definitions":[{"definition":"The narrow, central portion of the thyroid gland that crosses the trachea anteriorly and connects the lateral lobes of the gland. When present, the normal variant pyramidal lobe may extend from the isthmus.","type":"DEFINITION","source":"NCI"},{"definition":"The narrow, central portion of the thyroid gland that crosses the trachea anteriorly and connects the two lobes of the gland. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Thyroid Gland Isthmus","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Thyroid_Gland_Isthmus"},{"name":"Maps_To","value":"Thyroid Gland Isthmus"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0229583"}]}}{"C32488":{"preferredName":"Dura Mater","code":"C32488","definitions":[{"definition":"The outermost, toughest, and most fibrous of the three membranes (meninges) that surround and protect the brain and spinal cord.","type":"DEFINITION","source":"NCI"},{"definition":"The outermost, toughest, and most fibrous of the three membranes (meninges) that surround and protect the brain and spinal cord. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Dura Mater","termGroup":"PT","termSource":"NCI"},{"termName":"Dura","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dura_Mater"},{"name":"Maps_To","value":"Dura Mater"},{"name":"Semantic_Type","value":"Tissue"},{"name":"UMLS_CUI","value":"C0013313"}]}}{"C128572":{"preferredName":"Central Zone of Prostate","code":"C128572","definitions":[{"definition":"This region of the prostate gland that is located between the peripheral and transition zones, surrounding the ejaculatory ducts. It gives rise to a very small percentage of prostate cancers, though these cancers are frequently more aggressive, often resulting in invasion of the seminal vesicles.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Central Zone of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Central zone"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0458698"}]}}{"C157522":{"preferredName":"Overlapping/Multiple Zones of Prostate","code":"C157522","definitions":[{"definition":"A term that indicates involvement of multiple zones of prostate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Overlapping/Multiple Zones of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Overlapping/multiple zones"},{"name":"NCI_META_CUI","value":"CL937104"},{"name":"Semantic_Type","value":"Anatomical Structure"}]}}{"C128570":{"preferredName":"Peripheral Zone of Prostate","code":"C128570","definitions":[{"definition":"The region of the prostate that is located most superficial and posterior as compared to the other prostate zones. It is located closest to the rectum, and is easily palpated on digital rectal exam. This zone of the prostate surrounds the distal urethra, and is the zone of origin for the vast majority of prostatic cancers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Zone of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral zone"},{"name":"Semantic_Type","value":"Body Location or Region"},{"name":"UMLS_CUI","value":"C0458696"}]}}{"C128571":{"preferredName":"Transition Zone of Prostate","code":"C128571","definitions":[{"definition":"The region of the prostate gland that is located deep to both the central and peripheral zones; it surrounds the proximal urethra, and is the zone of the prostate gland that grows throughout life, most often causing a condition called benign prostatic hypertrophy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Transition Zone of Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transition zone"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C1261214"}]}}{"C160198":{"preferredName":"Unknown Tumor Zone","code":"C160198","definitions":[{"definition":"An indication that the tumor zone is unknown.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Unknown Tumor Zone","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Unknown zone"},{"name":"NCI_META_CUI","value":"CL969339"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C191737":{"preferredName":"Affymetrix CEL Format","code":"C191737","definitions":[{"definition":"A type of file that stores the results of intensity calculations of pixel values for DNA microarray image analysis. The data includes an intensity value, standard deviation of the intensity, the number of pixels used to calculate the intensity value, a flag to indicate an outlier as calculated by the algorithm, and a user defined flag indicating whether the feature should be excluded from future analysis. The file also stores the previously stated data for each feature on the probe array.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Affymetrix CEL Format","termGroup":"PT","termSource":"NCI"},{"termName":"Affymetrix CEL","termGroup":"SY","termSource":"NCI"},{"termName":"CEL","termGroup":"SY","termSource":"NCI"},{"termName":"CEL File","termGroup":"SY","termSource":"NCI"},{"termName":"CEL Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CEL"},{"name":"NCI_META_CUI","value":"CL1905198"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C190163":{"preferredName":"BAI File","code":"C190163","definitions":[{"definition":"An index file found in the same directory as the binary alignment map (BAM) file, a compressed binary version of a sequence alignment/map (SAM) file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BAI File","termGroup":"PT","termSource":"NCI"},{"termName":"BAI","termGroup":"SY","termSource":"NCI"},{"termName":"BAM Indexing File","termGroup":"SY","termSource":"NCI"},{"termName":"BAM Indexing Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BAI"},{"name":"NCI_META_CUI","value":"CL1798763"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C198923":{"preferredName":"Daily Drinker","code":"C198923","definitions":[{"definition":"An individual who drinks one or more alcoholic beverages each day.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Daily Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Daily Drinker"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0556339"}]}}{"C198924":{"preferredName":"Weekly Drinker","code":"C198924","definitions":[{"definition":"An individual who drinks alcoholic beverages once a week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Weekly Drinker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Weekly Drinker"},{"name":"NCI_META_CUI","value":"CL1906360"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C3239":{"preferredName":"Monosomy","code":"C3239","definitions":[{"definition":"A chromosomal abnormality consisting of the absence of one chromosome from the normal diploid number.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Monosomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Monosomy"},{"name":"Maps_To","value":"Monosomy"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0026499"}]}}{"C3421":{"preferredName":"Trisomy","code":"C3421","definitions":[{"definition":"A chromosomal abnormality consisting of the presence of one chromosome in addition to the normal diploid number.","type":"DEFINITION","source":"NCI"},{"definition":"The presence of an extra chromosome, resulting in a total of three copies of that chromosome instead of the normal 2 copies (e.g., trisomy 21, or Down syndrome).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Trisomy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Trisomy"},{"name":"Maps_To","value":"Trisomy"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C0041107"}]}}{"C15406":{"preferredName":"Cancer Screening","code":"C15406","definitions":[{"definition":"Clinical testing designed to identify the presence of a specific cancer in an asymptomatic individual or population thought to be at risk of that specific cancer. The intent is to find cancers at the earliest possible stage in their development, in order to improve the chances for disease cure.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The use of any device, marker, or other means for the purpose of detecting the presence of a tumor, usually before there are any symptoms.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cancer Screening","termGroup":"PT","termSource":"NCI"},{"termName":"Cancer Screening for Patients","termGroup":"SY","termSource":"NCI"},{"termName":"Early Cancer Detection","termGroup":"SY","termSource":"NCI"},{"termName":"Screening of Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Cancer_Screening"},{"name":"Maps_To","value":"Screening"},{"name":"Maps_To","value":"Special screening examination for neoplasms"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C0199230"}]}}{"C15719":{"preferredName":"Surveillance","code":"C15719","definitions":[{"definition":"In medicine, the ongoing collection of information about a disease, such as cancer, in a certain group of people. The information collected may include where the disease occurs in a population and whether it affects people of a certain gender, age, or ethnic group.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The systematic collection, analysis, and interpretation of health data on an ongoing basis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Surveillance","termGroup":"PT","termSource":"NCI"},{"termName":"Epidemiology / Surveillance","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Surveillance"},{"name":"Maps_To","value":"Surveillance"},{"name":"NCI_META_CUI","value":"CL426379"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C168447":{"preferredName":"Symptomatic Presentation","code":"C168447","definitions":[{"definition":"A clinical description in which a patient demonstrates evidence of greater than or equal to 1 clinical finding suggestive of underlying pathology.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"A clinical description in which a patient demonstrates evidence of more than one clinical finding suggestive of underlying pathology. (ACC/AHA)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Symptomatic Presentation","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Symptomatic"},{"name":"NCI_META_CUI","value":"CL972723"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198925":{"preferredName":"Agent Orange Exposure","code":"C198925","definitions":[{"definition":"A finding indicating that an individual has been exposed to the herbicide agent orange.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Agent Orange Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agent Orange"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4273835"}]}}{"C198926":{"preferredName":"Aluminum Exposure","code":"C198926","definitions":[{"definition":"A finding indicating that an individual has been exposed to aluminum or aluminum-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aluminum Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Aluminum"},{"name":"NCI_META_CUI","value":"CL1906361"},{"name":"Semantic_Type","value":"Finding"}]}}{"C165476":{"preferredName":"Arsenic Exposure","code":"C165476","definitions":[{"definition":"A finding indicating that an individual has been exposed to arsenic.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Arsenic Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Arsenic"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0238690"}]}}{"C36251":{"preferredName":"Benzene Exposure","code":"C36251","definitions":[{"definition":"Environmental, occupational or consumer-based exposure to benzene, benzene-containing compounds or benzene derivatives.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Benzene Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Benzene_Exposure"},{"name":"Maps_To","value":"Benzene"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0238760"}]}}{"C198927":{"preferredName":"Cadmium Exposure","code":"C198927","definitions":[{"definition":"A finding indicating that an individual has been exposed to cadmium or cadmium-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cadmium Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cadmium"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0238876"}]}}{"C198934":{"preferredName":"Chromium Exposure","code":"C198934","definitions":[{"definition":"A finding indicating that an individual has been exposed to chromium or chromium-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chromium Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chromium"},{"name":"NCI_META_CUI","value":"CL1907621"},{"name":"Semantic_Type","value":"Finding"}]}}{"C157008":{"preferredName":"Coke Oven Emission Exposure","code":"C157008","definitions":[{"definition":"Occupational exposure to gases and particulates produced when coal is processed in a coke oven.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Coke Oven Emission Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Coke Oven Emission"},{"name":"NCI_META_CUI","value":"CL936080"},{"name":"Semantic_Type","value":"Human-caused Phenomenon or Process"}]}}{"C198935":{"preferredName":"Copper Exposure","code":"C198935","definitions":[{"definition":"A finding indicating that an individual has been exposed to copper or copper-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copper Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Copper"},{"name":"NCI_META_CUI","value":"CL1906374"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198936":{"preferredName":"Diesel Exhaust Exposure","code":"C198936","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to volatiles and particulates present in diesel exhaust.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diesel Exhaust Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Diesel Exhaust"},{"name":"NCI_META_CUI","value":"CL1906373"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198937":{"preferredName":"Disinfectant Exposure","code":"C198937","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to epoxy compounds and other volatile chemicals associated with production, handling and use of disinfectants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Disinfectant Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Disinfectant"},{"name":"NCI_META_CUI","value":"CL1906375"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198938":{"preferredName":"Formaldehyde Exposure","code":"C198938","definitions":[{"definition":"A finding indicating that an individual has been exposed to formaldehyde.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Formaldehyde Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Formaldehyde"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0239686"}]}}{"C198939":{"preferredName":"Methylene Chloride Exposure","code":"C198939","definitions":[{"definition":"A finding indicating that an individual has been exposed to methylene chloride.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Methylene Chloride Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"DCM Exposure","termGroup":"SY","termSource":"NCI"},{"termName":"Dichloromethane Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Methylene Chloride"},{"name":"NCI_META_CUI","value":"CL1906370"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198940":{"preferredName":"Crude Oil Exposure","code":"C198940","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to volatiles derived from the organic compounds and polycyclic aromatic hydrocarbons and particulates that are present in crude oil.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Crude Oil Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Oil"},{"name":"NCI_META_CUI","value":"CL1907612"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198941":{"preferredName":"Pesticide Exposure","code":"C198941","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to pesticides.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pesticide Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Pesticide"},{"name":"NCI_META_CUI","value":"CL1906372"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198942":{"preferredName":"Petroleum Hydrocarbon Compound Exposure","code":"C198942","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to the volatile organic compounds and polycyclic aromatic hydrocarbons that are present in and produced during refinement of petroleum products.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Petroleum Hydrocarbon Compound Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Petroleum Hydrocarbon Compound"},{"name":"NCI_META_CUI","value":"CL1906371"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198943":{"preferredName":"Resin Fume Exposure","code":"C198943","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure epoxy compounds and other volatile chemicals associated with production and handling of resins (liquid plastics).","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Resin Fume Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Resin Fumes"},{"name":"NCI_META_CUI","value":"CL1906380"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198944":{"preferredName":"Sodium Borate Exposure","code":"C198944","definitions":[{"definition":"A finding indicating that an individual has been exposed to sodium borate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sodium Borate Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sodium Borate"},{"name":"NCI_META_CUI","value":"CL1906379"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198945":{"preferredName":"Solvent Exposure","code":"C198945","definitions":[{"definition":"Environmental, occupational, or consumer-based exposure to volatiles associated with production, handling and use of chemical solvents.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Solvent Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Solvent"},{"name":"NCI_META_CUI","value":"CL1906382"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198946":{"preferredName":"Tetrachloroethylene Exposure","code":"C198946","definitions":[{"definition":"A finding indicating that an individual has been exposed to tetrachloroethylene.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tetrachloroethylene Exposure","termGroup":"PT","termSource":"NCI"},{"termName":"PCE Exposure","termGroup":"SY","termSource":"NCI"},{"termName":"Perchloroethylene Exposure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tetrachloroethylene"},{"name":"NCI_META_CUI","value":"CL1906381"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198947":{"preferredName":"Toluene Exposure","code":"C198947","definitions":[{"definition":"A finding indicating that an individual has been exposed to toluene or toluene-containing compounds.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Toluene Exposure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Toluene"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0241422"}]}}{"C168758":{"preferredName":"t(10;11)(p11.2;q23)","code":"C168758","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 10 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/ABI1 fusions and acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(10;11)(p11.2;q23)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"t(10;11)(p11.2;q23)"},{"name":"NCI_META_CUI","value":"CL1378668"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C36371":{"preferredName":"t(11;19)(q23.3;p13.1)","code":"C36371","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the long arm (q23.3) of chromosome 11 and the short arm (p13.1) of chromosome 19. It is associated with the development of acute myeloid leukemia with variant MLL translocations and topoisomerase II inhibitor-related acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(11;19)(q23.3;p13.1)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_11_19_q23_p13_1"},{"name":"Maps_To","value":"t(11;19)(q23;p13.1)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515710"}]}}{"C36415":{"preferredName":"t(3;5)(q25;q34)","code":"C36415","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the long arm (q25) of chromosome 3 and the long arm (q34) of chromosome 5. It is associated with the development of acute myeloid leukemia arising from myelodysplastic syndrome, acute myeloid leukemia with multilineage dysplasia, and acute myeloid leukemia with myelodysplasia-related changes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(3;5)(q25;q34)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_3_5_q25_q34"},{"name":"Maps_To","value":"t(3;5)(q25;q34)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515766"}]}}{"C36610":{"preferredName":"t(6;11)(q27;q23)","code":"C36610","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the long arm (q27) of chromosome 6 and the long arm (q23) of chromosome 11. It is associated with the development of de novo acute myeloid leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(6;11)(q27;q23)","termGroup":"PT","termSource":"NCI"},{"termName":"t(6;11)(q27;q23.3)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_6_11_q27_q23"},{"name":"Maps_To","value":"t(6;11)(q27;q23)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515779"}]}}{"C128650":{"preferredName":"t(6;9)","code":"C128650","definitions":[{"definition":"A cytogenetic abnormality that involves a translocation between chromosomes 6 and 9.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(6;9)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"t(6;9)"},{"name":"NCI_META_CUI","value":"CL509592"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C119608":{"preferredName":"t(8;21)","code":"C119608","definitions":[{"definition":"A cytogenetic abnormality that involves a translocation between chromosomes 8 and 21.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(8;21)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"t(8;21)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C3897139"}]}}{"C36370":{"preferredName":"t(9;11)(p21.3;q23.3)","code":"C36370","definitions":[{"definition":"A cytogenetic abnormality that refers to the translocation of the short arm (p21.3) of chromosome 9 and the long arm (q23.3) of chromosome 11. It is associated with the development of acute myeloid leukemia with the MLLT3-MLL fusion gene transcript.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(9;11)(p21.3;q23.3)","termGroup":"PT","termSource":"NCI"},{"termName":"t(9;11)(p22;q23)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"t_9_11_p22_q23"},{"name":"Maps_To","value":"t(9;11)(p22;q23)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C1515800"}]}}{"C128656":{"preferredName":"t(15;17)","code":"C128656","definitions":[{"definition":"A cytogenetic abnormality that involves a translocation between chromosomes 15 and 17.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(15;17)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"t(15;17)"},{"name":"NCI_META_CUI","value":"CL509583"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C128652":{"preferredName":"t(4;11)","code":"C128652","definitions":[{"definition":"A cytogenetic abnormality that involves a translocation between chromosomes 4 and 11.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(4;11)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"t(4;11)"},{"name":"NCI_META_CUI","value":"CL509590"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"}]}}{"C113505":{"preferredName":"t(9;11)","code":"C113505","definitions":[{"definition":"A translocation between chromosome 9 and chromosome 11.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(9;11)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"t(9;11)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C3827870"}]}}{"C117116":{"preferredName":"t(9;22)","code":"C117116","definitions":[{"definition":"A translocation between chromosome 9 and chromosome 22 that may be associated with Philadelphia chromosome and increased susceptibility to several types of leukemia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"t(9;22)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"t(9;22)"},{"name":"Semantic_Type","value":"Cell or Molecular Dysfunction"},{"name":"UMLS_CUI","value":"C3897138"}]}}{"C198952":{"preferredName":"Short Arm of Chromosome","code":"C198952","definitions":[{"definition":"The shorter arm of the chromosome based on the distance from the most distal point to the centromere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Short Arm of Chromosome","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Short Arm","termGroup":"SY","termSource":"NCI"},{"termName":"p Arm","termGroup":"SY","termSource":"NCI"},{"termName":"Proximal Arm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"p"},{"name":"NCI_META_CUI","value":"CL565050"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198953":{"preferredName":"Long Arm of Chromosome","code":"C198953","definitions":[{"definition":"The longer arm of the chromosome based on the distance from the most distal point to the centromere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Long Arm of Chromosome","termGroup":"PT","termSource":"NCI"},{"termName":"Chromosome Long Arm","termGroup":"SY","termSource":"NCI"},{"termName":"Distal Arm","termGroup":"SY","termSource":"NCI"},{"termName":"q Arm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"q"},{"name":"NCI_META_CUI","value":"CL568361"},{"name":"Semantic_Type","value":"Finding"}]}}{"C84637":{"preferredName":"Chronic Pancreatitis","code":"C84637","definitions":[{"definition":"A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Chronic Pancreatitis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chronic Pancreatitis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4014770"}]}}{"C2993":{"preferredName":"Down Syndrome","code":"C2993","definitions":[{"definition":"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. Down syndrome occurs in approximately 1:700 live births. Abnormalities are variable from individual to individual and may include mental retardation, retarded growth, flat hypoplastic face with short nose, prominent epicanthic skin folds, small low-set ears with prominent antihelix, fissured and thickened tongue, laxness of joint ligaments, pelvic dysplasia, broad hands and feet, stubby fingers, transverse palmar crease, lenticular opacities and heart disease. Patients with Down syndrome have an estimated 10 to 30-fold increased risk for leukemia; most have symptoms of Alzheimer's disease by age 40. Also known as trisomy 21 syndrome.","type":"DEFINITION","source":"NCI"},{"definition":"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. This condition is characterized by distinctive facial and physical features: short stature, developmental delay, cardiac defects (atrioventricular septal defect, tetralogy of Fallot), hypo- and hyperthyroidism, autoimmune disease (type 1 diabetes mellitus), and hypogonadism.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A disorder caused by the presence of an extra chromosome 21 and characterized by mental retardation and distinguishing physical features.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Down Syndrome","termGroup":"PT","termSource":"NCI"},{"termName":"Trisomy 21 (Down Syndrome)","termGroup":"SY","termSource":"NCI"},{"termName":"Trisomy 21 Syndrome","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Down_Syndrome"},{"name":"Maps_To","value":"Down Syndrome"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0013080"}]}}{"C154329":{"preferredName":"Smoking","code":"C154329","definitions":[{"definition":"The act of puffing and/or inhaling the combustion products of a substance so as to be tasted and absorbed into the bloodstream.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Smoking","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Smoking"},{"name":"Semantic_Type","value":"Individual Behavior"},{"name":"UMLS_CUI","value":"C0037369"}]}}{"C190189":{"preferredName":"TAR Format","code":"C190189","definitions":[{"definition":"A file format generated by the Unix command-line utility tar (tape archive). It is used for collecting many files into one archive file.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"TAR Format","termGroup":"PT","termSource":"NCI"},{"termName":"Tape Archive File Format","termGroup":"SY","termSource":"NCI"},{"termName":"TAR","termGroup":"SY","termSource":"NCI"},{"termName":"TAR File Format","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"TAR"},{"name":"NCI_META_CUI","value":"CL1799248"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C198955":{"preferredName":"Intermediate Analysis Archive","code":"C198955","definitions":[{"definition":"A preserved or historical dataset comprised of items used in or generated by preliminary or interim data analysis processes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermediate Analysis Archive","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate Analysis Archive"},{"name":"NCI_META_CUI","value":"CL1906384"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C206460":{"preferredName":"Copy Number Variation Model File","code":"C206460","definitions":[{"definition":"An electronic data file containing inferred models for determining genomic copy number alterations in molecular data sets.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Copy Number Variation Model File","termGroup":"PT","termSource":"NCI"},{"termName":"CNV Model File","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"CNV Model"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C198967":{"preferredName":"Extensive Extracapsular Extention","code":"C198967","definitions":[{"definition":"A morphological finding indicating that the tumor cell invasion outside the lymph node capsule was greater than 1 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extensive Extracapsular Extention","termGroup":"PT","termSource":"NCI"},{"termName":"Extensive ECE","termGroup":"SY","termSource":"NCI"},{"termName":"Extensive ECS","termGroup":"SY","termSource":"NCI"},{"termName":"Extensive Extracapsular Spread","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extensive"},{"name":"NCI_META_CUI","value":"CL1906401"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198968":{"preferredName":"Focal Extracapsular Extention","code":"C198968","definitions":[{"definition":"A morphological finding indicating that the tumor cell invasion outside the lymph node capsule was less than or equal to 1 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Focal Extracapsular Extention","termGroup":"PT","termSource":"NCI"},{"termName":"Focal ECE","termGroup":"SY","termSource":"NCI"},{"termName":"Focal ECS","termGroup":"SY","termSource":"NCI"},{"termName":"Focal Extracapsular Spread","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Focal"},{"name":"NCI_META_CUI","value":"CL1906400"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198969":{"preferredName":"Gross Extranodal Extension","code":"C198969","definitions":[{"definition":"An indication that the lymph node metastases of a malignant neoplasm have invaded adjacent organs.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Gross Extranodal Extension","termGroup":"PT","termSource":"NCI"},{"termName":"gENE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Gross Extension"},{"name":"NCI_META_CUI","value":"CL1907630"},{"name":"Semantic_Type","value":"Finding"}]}}{"C198970":{"preferredName":"Microscopic Extranodal Extension","code":"C198970","definitions":[{"definition":"An indication that extension of a malignant neoplasm beyond the lymph node was less than or equal to 2 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Microscopic Extranodal Extension","termGroup":"PT","termSource":"NCI"},{"termName":"miENE","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Microscopic Extension"},{"name":"NCI_META_CUI","value":"CL1906402"},{"name":"Semantic_Type","value":"Finding"}]}}{"C160838":{"preferredName":"Extranodal Tumor Extension Absent","code":"C160838","definitions":[{"definition":"A response that the extranodal tumor extension is absent.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extranodal Tumor Extension Absent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Extranodal Extension"},{"name":"NCI_META_CUI","value":"CL969923"},{"name":"Semantic_Type","value":"Finding"}]}}{"C118962":{"preferredName":"Clinical Trial Censoring","code":"C118962","definitions":[{"definition":"When information on time-to-event is not available due to loss to follow-up or non-occurrence of outcome event before the trial end. The data on that participant is banned or removed from the study data.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical Trial Censoring","termGroup":"PT","termSource":"NCI"},{"termName":"Censoring","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Censored"},{"name":"Semantic_Type","value":"Activity"},{"name":"UMLS_CUI","value":"C3889990"}]}}{"C199218":{"preferredName":"Death without Remission","code":"C199218","definitions":[{"definition":"An indication that a subject died during treatment but had not achieved remission.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Death without Remission","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Death without Remission"},{"name":"NCI_META_CUI","value":"CL1906161"},{"name":"Semantic_Type","value":"Finding"}]}}{"C25499":{"preferredName":"Event","code":"C25499","definitions":[{"definition":"Something that happens at a given place and time.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Event","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Event"},{"name":"Maps_To","value":"Event"},{"name":"Semantic_Type","value":"Event"},{"name":"UMLS_CUI","value":"C0441471"}]}}{"C121972":{"preferredName":"Induction Death","code":"C121972","definitions":[{"definition":"Death of the patient due to the toxic side effects of induction therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Induction Death","termGroup":"PT","termSource":"NCI"},{"termName":"Death After Induction Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Death During Induction Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Induction Death"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C4054731"}]}}{"C70622":{"preferredName":"Primary Induction Failure","code":"C70622","definitions":[{"definition":"A disease status whereby the patient does not achieve a complete remission. It may not be limited to the first/initial course of therapy; it may represent all courses.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Primary Induction Failure","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Primary_Induction_Failure"},{"name":"Maps_To","value":"Induction Failure"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2347677"}]}}{"C95606":{"preferredName":"Second Primary Malignant Neoplasm","code":"C95606","definitions":[{"definition":"A primary malignant neoplasm in a patient who has been already diagnosed with a primary malignant neoplasm in another anatomic site.","type":"DEFINITION","source":"NCI"},{"definition":"Refers to a new primary cancer in a person with a history of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Second Primary Malignant Neoplasm","termGroup":"PT","termSource":"NCI"},{"termName":"Second Primary Cancer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Second Malignant Neoplasm"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0751623"}]}}{"C199151":{"preferredName":"Renal Involvement","code":"C199151","definitions":[{"definition":"A finding indicating the spread of disease to a kidney.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Renal Involvement","termGroup":"PT","termSource":"NCI"},{"termName":"Kidney Involvement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Kidney Involvement"},{"name":"NCI_META_CUI","value":"CL1478078"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199154":{"preferredName":"Liver Involvement","code":"C199154","definitions":[{"definition":"A finding indicating the spread of disease to the liver.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Liver Involvement","termGroup":"PT","termSource":"NCI"},{"termName":"Hepatic Involvement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Liver Involvement"},{"name":"NCI_META_CUI","value":"CL1482212"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199155":{"preferredName":"Lung Involvement","code":"C199155","definitions":[{"definition":"A finding indicating the spread of disease to a lung.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lung Involvement","termGroup":"PT","termSource":"NCI"},{"termName":"Pulmonary Involvement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lung Involvement"},{"name":"NCI_META_CUI","value":"CL1906099"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199157":{"preferredName":"Retroperitoneal Lymph Node Involvement","code":"C199157","definitions":[{"definition":"A finding indicating the spread of disease to a retroperitoneal lymph node.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Retroperitoneal Lymph Node Involvement","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retroperitoneal Lymph Node Involvement"},{"name":"NCI_META_CUI","value":"CL1906101"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199158":{"preferredName":"Vena Cava Involvement or Thrombus","code":"C199158","definitions":[{"definition":"A finding indicating a vena cava thrombus or other evidence of disease spread to the vena cava.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vena Cava Involvement or Thrombus","termGroup":"PT","termSource":"NCI"},{"termName":"Vena Cava Involvement/Thrombus","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vena Cava Involvement/Thrombus"},{"name":"NCI_META_CUI","value":"CL1906100"},{"name":"Semantic_Type","value":"Finding"}]}}{"C206461":{"preferredName":"Localized Extraprostatic Extension","code":"C206461","definitions":[{"definition":"A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to nearby tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Localized Extraprostatic Extension","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extraprostatic Extension, Localized"},{"name":"Semantic_Type","value":"Finding"}]}}{"C206462":{"preferredName":"Extraprostatic Extension with Regional Lymphadenopathy","code":"C206462","definitions":[{"definition":"A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to regional lymph nodes, resulting in enlargement of the affected lymph nodes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraprostatic Extension with Regional Lymphadenopathy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Extraprostatic Extension, Regional Lymphadenopathy"},{"name":"Semantic_Type","value":"Finding"}]}}{"C206463":{"preferredName":"Extraprostatic Extension Absent","code":"C206463","definitions":[{"definition":"An indication that there was no evidence for prostatic capsule invasion or spread in a patient with prostate carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Extraprostatic Extension Absent","termGroup":"PT","termSource":"NCI"},{"termName":"Extraprostatic Extension Negative","termGroup":"SY","termSource":"NCI"},{"termName":"No Evidence of Extraprostatic Extension","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No Evidence of Extraprostatic Extension"},{"name":"Semantic_Type","value":"Finding"}]}}{"C148527":{"preferredName":"Bilateral Modified Radical Neck Dissection","code":"C148527","definitions":[{"definition":"A surgical procedure in which all the bilateral cervical lymph node groups of the neck are removed but the internal jugular veins, sternocleidomastoid muscles, and/or spinal accessory nerves are preserved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Bilateral Modified Radical Neck Dissection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Functional (Limited) Neck Dissection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193866"}]}}{"C51904":{"preferredName":"Modified Radical Neck Dissection","code":"C51904","definitions":[{"definition":"A surgical procedure in which all the ipsilateral cervical lymph node groups of the neck are removed but the internal jugular vein, sternocleidomastoid muscle, and/or spinal accessory nerve are preserved.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Modified Radical Neck Dissection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Modified_Radical_Neck_Dissection"},{"name":"Maps_To","value":"Modified Radical Neck Dissection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0193864"}]}}{"C51759":{"preferredName":"Radical Neck Dissection","code":"C51759","definitions":[{"definition":"A surgical procedure in which all the ipsilateral cervical lymph node groups of the neck, internal jugular vein, sternocleidomastoid muscle, spinal accessory nerve, and submandibular gland are removed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radical Neck Dissection","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Radical_Neck_Dissection"},{"name":"Maps_To","value":"Radical Neck Dissection"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0034542"}]}}{"C198715":{"preferredName":"Administration Professional","code":"C198715","definitions":[{"definition":"Occupations held by individuals who analyze management and organization, administer and develop policies, handle human resources and train and develop staff.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Administration Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Administration Professionals"},{"name":"NCI_META_CUI","value":"CL1905864"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198716":{"preferredName":"Administrative and Specialized Secretary","code":"C198716","definitions":[{"definition":"Occupations held by secretaries who perform administrative duties in the office, and may have specialized knowledge in other professions, such as legal or medical.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Administrative and Specialized Secretary","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Administrative and Specialized Secretaries"},{"name":"NCI_META_CUI","value":"CL1905867"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C97632":{"preferredName":"Farming, Fishing, and Forestry Occupations","code":"C97632","definitions":[{"definition":"A class of professional or vocational positions of employment that involve farming, fishing or forestry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Farming, Fishing, and Forestry Occupations","termGroup":"PT","termSource":"NCI"},{"termName":"Agricultural, Forestry and Fishery Laborer","termGroup":"SY","termSource":"NCI"},{"termName":"Farming, Fishing, and Forestry","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Agricultural, Forestry and Fishery Labourers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C3273533"}]}}{"C198717":{"preferredName":"Animal Producer","code":"C198717","definitions":[{"definition":"Occupations held by individuals who work to propagate species of animals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Animal Producer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Animal Producers"},{"name":"NCI_META_CUI","value":"CL1905866"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198718":{"preferredName":"Architect, Planner, Surveyor and Designer","code":"C198718","definitions":[{"definition":"Occupations held by individuals who plan and design landscapes, building exteriors and interiors, products for manufacture and visual and audiovisual content for the communication of information.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Architect, Planner, Surveyor and Designer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Architects, Planners, Surveyors and Designers"},{"name":"NCI_META_CUI","value":"CL1905876"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198719":{"preferredName":"Armed Forces Occupation, Other Rank","code":"C198719","definitions":[{"definition":"Occupations held by individuals who are part of a community dedicated to protect a geographic location.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Armed Forces Occupation, Other Rank","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Armed Forces Occupations, Other Ranks"},{"name":"NCI_META_CUI","value":"CL1905875"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198720":{"preferredName":"Artistic, Cultural and Culinary Associate Professional","code":"C198720","definitions":[{"definition":"Occupations held by individuals who combine creative skills and technical and cultural knowledge in taking and processing still photographs; design and decoration of theater sets, shop displays and the interiors of homes; preparation of objects for display; maintenance of library and gallery collections, records and cataloging systems; creation of menus and preparation and presentation of food; provision of support for stage, film and television production; and in other areas of artistic and cultural endeavor.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Artistic, Cultural and Culinary Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Artistic, Cultural and Culinary Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905877"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198721":{"preferredName":"Assembler","code":"C198721","definitions":[{"definition":"Occupations held by individuals who assemble prefabricated parts of components to form subassemblies, products and equipment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Assembler","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Assemblers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0558478"}]}}{"C198722":{"preferredName":"Author, Journalist and Linguist","code":"C198722","definitions":[{"definition":"Occupations held by individuals who conceive and create literary works; interpret and communicate news and public affairs through the medial and translate or interpret from one language into another.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Author, Journalist and Linguist","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Authors, Journalists and Linguists"},{"name":"NCI_META_CUI","value":"CL1905872"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198723":{"preferredName":"Blacksmith, Toolmaker and Related Trades Worker","code":"C198723","definitions":[{"definition":"Occupations held by individuals who hammer and forge bars, rods or ingots of iron, steel and other metals to make and repair various kinds of tools, equipment and other articles; set machine tools for operators, or set and operate various machine tools; and polish and sharpen surfaces.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Blacksmith, Toolmaker and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Blacksmiths, Toolmakers and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905871"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198724":{"preferredName":"Building and Housekeeping Supervisor","code":"C198724","definitions":[{"definition":"Occupations held by individuals who build houses, lay bricks, work stone, place concrete, carpenters and joiners.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Building and Housekeeping Supervisor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Building and Housekeeping Supervisors"},{"name":"NCI_META_CUI","value":"CL1905874"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198725":{"preferredName":"Building Finisher and Related Trades Worker","code":"C198725","definitions":[{"definition":"Occupations held by individuals who put the finishing touches on buildings and the trades related to such activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Building Finisher and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Building Finishers and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905873"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198726":{"preferredName":"Building Frame and Related Trades Worker","code":"C198726","definitions":[{"definition":"Occupations held by individuals who lay roofing material, put down floors and set tiles, plaster, insulate, glaze, plumb and pipe fit and work on air conditioning and refrigeration.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Building Frame and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Building Frame and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905883"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198727":{"preferredName":"Business Services Agent","code":"C198727","definitions":[{"definition":"Occupations held by individuals who establish contacts to sell various business services such as advertising space in the media, carry out customs clearance activities, match jobseekers; find workers for employers; arrange contracts or the performance of athletes, entertainers and artists, as well as for the publication of books, the production of plays, or the recording, performance and sale of music; and plan and organize conferences and similar events.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Business Services Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Business Services Agents"},{"name":"NCI_META_CUI","value":"CL1905882"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198728":{"preferredName":"Business Services and Administration Manager","code":"C198728","definitions":[{"definition":"Occupations held by individuals who manage finance, human resources, and policy and planning.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Business Services and Administration Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Business Services and Administration Managers"},{"name":"NCI_META_CUI","value":"CL1905885"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198729":{"preferredName":"Car, Van and Motorcycle Driver","code":"C198729","definitions":[{"definition":"Occupations held by individuals who drive and tend motorcycles, motorized tricycles, cars or vans to transport passengers, materials or goods.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Car, Van and Motorcycle Driver","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Car, Van and Motorcycle Drivers"},{"name":"NCI_META_CUI","value":"CL1905884"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198730":{"preferredName":"Cashier and Ticket Clerk","code":"C198730","definitions":[{"definition":"Occupations held by individuals who operate cash registers, optical price scanners, computers or other equipment to record and accept payment for the purchase of goods, services and admissions in settings such as stores, restaurants and ticket offices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Cashier and Ticket Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cashiers and Ticket Clerks"},{"name":"NCI_META_CUI","value":"CL1905879"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198731":{"preferredName":"Chemical and Photographic Products Plant and Machine Operator","code":"C198731","definitions":[{"definition":"Occupations held by individuals who monitor and operate machines which process a variety of chemicals and other ingredients to produce pharmaceuticals, toiletries, explosives and photographic or other chemical products.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Chemical and Photographic Products Plant and Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Chemical and Photographic Products Plant and Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905878"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198732":{"preferredName":"Child Care Worker and Teachers' Aide","code":"C198732","definitions":[{"definition":"Occupations held by individuals who tend to the care of children and assist teachers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Child Care Worker and Teachers' Aide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Child Care Workers and Teachers' Aides"},{"name":"NCI_META_CUI","value":"CL1905881"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198733":{"preferredName":"Client Information Worker","code":"C198733","definitions":[{"definition":"Occupations held by individuals who advise in the context of travel consulting, contact center information, telephone switchboard operators, hotel receptionists, inquiry clerks, general receptionists and survey and market research interviewers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Client Information Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Client Information Workers"},{"name":"NCI_META_CUI","value":"CL1905880"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198734":{"preferredName":"Commissioned Armed Forces Officer","code":"C198734","definitions":[{"definition":"Occupations held by individuals who have received a commission in the armed forces military. They provide leadership and management to organizational units in the armed forces and/or perform similar tasks to those performed in a variety of civilian occupations outside the armed forces.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Commissioned Armed Forces Officer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Commissioned Armed Forces Officers"},{"name":"NCI_META_CUI","value":"CL1905891"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122440":{"preferredName":"Cooks and Food Preparation Workers","code":"C122440","definitions":[{"definition":"Workers who prepare, season, and cook foods, as well as workers who perform routine tasks under the direction of cooks, chefs, or food service managers.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Cooks and Food Preparation Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Cook","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cooks"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4055181"}]}}{"C80245":{"preferredName":"Artist","code":"C80245","definitions":[{"definition":"One who uses imagination and talent or skill to create works of aesthetic value.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Artist","termGroup":"PT","termSource":"NCI"},{"termName":"Creative and Performing Artist","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Artist"},{"name":"Maps_To","value":"Creative and Performing Artists"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0402043"}]}}{"C198735":{"preferredName":"Database and Network Professional","code":"C198735","definitions":[{"definition":"Occupations held by individuals who design and administrate databases, systems administrators and computer network professionals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Database and Network Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Database and Network Professionals"},{"name":"NCI_META_CUI","value":"CL1905890"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198736":{"preferredName":"Domestic, Hotel and Office Cleaner and Helper","code":"C198736","definitions":[{"definition":"Occupations held by individuals who clean in the home, hotel or office environment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Domestic, Hotel and Office Cleaner and Helper","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Domestic, Hotel and Office Cleaners and Helpers"},{"name":"NCI_META_CUI","value":"CL1905893"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122446":{"preferredName":"Electrical and Electronic Equipment Mechanics, Installers, and Repairers","code":"C122446","definitions":[{"definition":"Workers who install, repair, or replace a variety of electrical equipment in telecommunications, transportation, utilities, and other industries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Electrical and Electronic Equipment Mechanics, Installers, and Repairers","termGroup":"PT","termSource":"NCI"},{"termName":"Electrical Equipment Installer and Repairer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrical Equipment Installers and Repairers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4055072"}]}}{"C198737":{"preferredName":"Electronics and Telecommunications Installer and Repairer","code":"C198737","definitions":[{"definition":"Workers who install or repair a variety of electrical equipment in telecommunications, transportation, utilities, and other industries.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Electronics and Telecommunications Installer and Repairer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electronics and Telecommunications Installers and Repairers"},{"name":"NCI_META_CUI","value":"CL1905892"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198738":{"preferredName":"Electrotechnology Engineer","code":"C198738","definitions":[{"definition":"Occupations held by individuals who conduct research on and design, advise, plan and direct the construction and operation of electronic, electrical and telecommunications systems, components, motors and equipment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Electrotechnology Engineer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Electrotechnology Engineers"},{"name":"NCI_META_CUI","value":"CL1905887"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122447":{"preferredName":"Engineers","code":"C122447","definitions":[{"definition":"A professional practitioner of engineering, concerned with applying scientific knowledge, mathematics, and ingenuity to develop solutions for technical, societal and commercial problems. Engineers design materials, structures, and systems while considering the limitations imposed by practicality, regulation, safety, and cost.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Engineers","termGroup":"PT","termSource":"NCI"},{"termName":"Engineering Professional (Excluding Electrotechnology)","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Engineering Professionals (excluding Electrotechnology)"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0878517"}]}}{"C122452":{"preferredName":"Financial Specialists","code":"C122452","definitions":[{"definition":"Workers who meet with customers to help them determine their short-term and long-term financial goals and provide insurance, investment services, certificates of deposits and other financial instruments. They also contact prospective customers, evaluate costs and revenue, make financial presentations and review business trends.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Financial Specialists","termGroup":"PT","termSource":"NCI"},{"termName":"Finance Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Finance Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054955"}]}}{"C198739":{"preferredName":"Financial and Mathematical Associate Professional","code":"C198739","definitions":[{"definition":"Occupations held by individuals who are securities and finance dealers and brokers, credit and loan officers, accounting associate professionals, statistical, math and related associate professionals, valuers and assessors.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Financial and Mathematical Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Financial and Mathematical Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905886"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198740":{"preferredName":"Fishery Worker, Hunter and Trapper","code":"C198740","definitions":[{"definition":"Workers who gather fish or other aquatic animals for human consumption or other uses and/or hunt and trap wild animals for human consumption, fur, feed, bait, or other purposes.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Fishery Worker, Hunter and Trapper","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Fishery Workers, Hunters and Trappers"},{"name":"NCI_META_CUI","value":"CL1905889"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198741":{"preferredName":"Food and Related Products Machine Operator","code":"C198741","definitions":[{"definition":"Occupations held by individuals who are butchers, fishmongers, and related food preparers bakers, pastry-cooks and confectionery makers; dairy products makers; fruit, vegetable and related preservers, food and beverage tasters and graders, tobacco preparers, and tobacco products makers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Food and Related Products Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Food and Related Products Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905888"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198742":{"preferredName":"Food Preparation Assistant","code":"C198742","definitions":[{"definition":"Occupations held by individuals who set, operate and attend machinery used to slaughter animals and trim meat from carcasses, and to bake, freeze, heat, crush, mix, blend and otherwise process foodstuffs, beverages and tobacco leaves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Food Preparation Assistant","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Food Preparation Assistants"},{"name":"NCI_META_CUI","value":"CL1905898"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198743":{"preferredName":"Food Processing and Related Trades Worker","code":"C198743","definitions":[{"definition":"Occupations held by individuals involved in the manufacturing, transportation or serving of food or food products.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Food Processing and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Food Processing and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905897"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198744":{"preferredName":"Forestry and Related Worker","code":"C198744","definitions":[{"definition":"Occupations held by individuals who plan, organize and perform operations to cultivate, conserve and exploit natural and plantation forests.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Forestry and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Forestry and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905900"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198745":{"preferredName":"Garment and Related Trades Worker","code":"C198745","definitions":[{"definition":"Occupations held by individuals who are tailors, dressmakers, furriers, hatters; garment and related patternmakers and cutters; sewing, embroidery and related workers; upholsterers and related workers; pelt dressers, tanners and fellmongers; and shoemakers and related workers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Garment and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Garment and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905899"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198746":{"preferredName":"General Office Clerk","code":"C198746","definitions":[{"definition":"Occupations held by individuals who perform a range of clerical and administrative tasks according to established procedures.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"General Office Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"General Office Clerks"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335238"}]}}{"C198747":{"preferredName":"Government Regulatory Associate Professional","code":"C198747","definitions":[{"definition":"Occupations held by individuals who work with customs and border inspectors, government tax and excise officials, government social benefits, government licensing, police inspectors and detectives, government regulatory associate professionals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Government Regulatory Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Government Regulatory Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905894"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198748":{"preferredName":"Hairdresser, Beautician and Related Worker","code":"C198748","definitions":[{"definition":"Occupations held by individuals who cut and dress hair, shave and trim beards, give beauty treatments, apply cosmetics and make-up and give other kinds of treatment to individuals in order to improve their appearance.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Hairdresser, Beautician and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hairdressers, Beauticians and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905896"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198749":{"preferredName":"Handicraft Worker","code":"C198749","definitions":[{"definition":"Occupations that rely upon use of the hands, including precision instrument or musical instrument makers and repairers, jewelry makers, potters, signmakers and painters, and workers in wood, textiles, and related materials.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Handicraft Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Handicraft Workers"},{"name":"NCI_META_CUI","value":"CL1905895"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198750":{"preferredName":"Heavy Truck and Bus Driver","code":"C198750","definitions":[{"definition":"Occupations that include driving heavy vehicles such as large buses and trucks.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Heavy Truck and Bus Driver","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Heavy Truck and Bus Drivers"},{"name":"NCI_META_CUI","value":"CL1905905"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198751":{"preferredName":"Hotel and Restaurant Manager","code":"C198751","definitions":[{"definition":"Occupations that comprise hotel and restaurant managers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Hotel and Restaurant Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Hotel and Restaurant Managers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335308"}]}}{"C198752":{"preferredName":"Information and Communications Technology Operations and User Support Technician","code":"C198752","definitions":[{"definition":"Information and communications occupations that include technicians and operators of computer networks, computer systems, internet systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Information and Communications Technology Operations and User Support Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Information and Communications Technology Operations and User Support Technicians"},{"name":"NCI_META_CUI","value":"CL1905907"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198753":{"preferredName":"Information and Communications Technology Service Manager","code":"C198753","definitions":[{"definition":"Workers who supervise the technicians and operators of computer networks, computer systems, internet systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Information and Communications Technology Service Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Information and Communications Technology Service managers"},{"name":"NCI_META_CUI","value":"CL1905906"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198754":{"preferredName":"Keyboard Operator","code":"C198754","definitions":[{"definition":"Clerical support workers that input and process text and data, and prepare, edit and generate documents for storage, processing, publication and transmission.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Keyboard Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Keyboard Operators"},{"name":"NCI_META_CUI","value":"CL1905902"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C97637":{"preferredName":"Legal Occupations","code":"C97637","definitions":[{"definition":"A class of professional or vocational positions of employment that involve legal activities.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Legal Occupations","termGroup":"PT","termSource":"NCI"},{"termName":"Legal Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Legal Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C1277117"}]}}{"C198822":{"preferredName":"Legal, Social and Religious Associate Professional","code":"C198822","definitions":[{"definition":"Professionals who provide technical and practical services and support functions in legal processes and investigations, social and community assistance programs, and religious activities.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Legal, Social and Religious Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Legal, Social and Religious Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1906271"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198755":{"preferredName":"Legislator and Senior Official","code":"C198755","definitions":[{"definition":"Government workers who determine, formulate, advise on and direct the implementation of policies of national, state, regional, or local governments or communities, and of special interest organizations.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Legislator and Senior Official","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Legislators and Senior Officials"},{"name":"NCI_META_CUI","value":"CL1905901"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122473":{"preferredName":"Librarians, Curators, and Archivists","code":"C122473","definitions":[{"definition":"Workers who appraise, edit, and maintain permanent records and historically valuable documents; oversee collections of artwork and historic items; restore objects and documents in museum collections and exhibits, and/or help people find information and conduct research for personal and professional use.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Librarians, Curators, and Archivists","termGroup":"PT","termSource":"NCI"},{"termName":"Librarian, Archivist and Curator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Librarians, Archivists and Curators"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335110"}]}}{"C122474":{"preferredName":"Life Scientists","code":"C122474","definitions":[{"definition":"The group of science professions that include animal scientists, biochemists and biophysicists, epidemiologists, food scientists and technologists, medical scientists, microbiologists, zoologists and wildlife biologists, and soil and plant scientists.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Life Scientists","termGroup":"PT","termSource":"NCI"},{"termName":"Life Science Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Life Science Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054649"}]}}{"C198756":{"preferredName":"Life Science Technician and Related Associate Professional","code":"C198756","definitions":[{"definition":"Technicians and other associates who perform technical tasks connected with research and operations in life sciences, which includes biology, botany, biochemistry, agriculture, and forestry.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Life Science Technician and Related Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Life Science Technicians and Related Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905904"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198757":{"preferredName":"Locomotive Engine Driver and Related Worker","code":"C198757","definitions":[{"definition":"The occupations consisting of locomotive drivers and railway brake, signal, and switch operators.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Locomotive Engine Driver and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Locomotive Engine Drivers and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905903"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198758":{"preferredName":"Machinery Mechanics and Repairer","code":"C198758","definitions":[{"definition":"Occupations involved with the maintenance or repair of machinery.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Machinery Mechanics and Repairer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Machinery Mechanics and Repairers"},{"name":"NCI_META_CUI","value":"CL1905913"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198759":{"preferredName":"Managing Director and Chief Executive","code":"C198759","definitions":[{"definition":"Individuals that formulate and review the policies, and plan, direct, coordinate, and evaluate the overall activities of enterprises or organizations, with the support of other managers, usually within guidelines established by a board of directors or a governing body.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Managing Director and Chief Executive","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Managing Directors and Chief Executives"},{"name":"NCI_META_CUI","value":"CL1905912"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C25392":{"preferredName":"Manufacturer","code":"C25392","definitions":[{"definition":"A person, enterprise, or entity that produces finished goods.","type":"DEFINITION","source":"NCI"},{"definition":"The organization defined as being responsible for creating the product as stated on the package in which the product is supplied.","type":"ALT_DEFINITION","source":"BRIDG 3.0.3"},{"definition":"The organization defined as being responsible for creating the product as stated on the package in which the product is supplied. (BRIDG)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Manufacturer","termGroup":"PT","termSource":"NCI"},{"termName":"Make","termGroup":"SY","termSource":"NCI"},{"termName":"Maker","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturer","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturer Name","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturing","termGroup":"SY","termSource":"NCI"},{"termName":"Manufacturing Laborer","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"BRIDG"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"SeroNet"},{"name":"Legacy Concept Name","value":"Manufacturer_Name"},{"name":"Maps_To","value":"Manufacturing Labourers"},{"name":"Semantic_Type","value":"Intellectual Product"},{"name":"UMLS_CUI","value":"C0947322"}]}}{"C198760":{"preferredName":"Manufacturing, Mining, Construction and Distribution Manager","code":"C198760","definitions":[{"definition":"A manager in charge of manufacturing, mining, or construction and distribution workers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Manufacturing, Mining, Construction and Distribution Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Manufacturing, Mining, Construction and Distribution Managers"},{"name":"NCI_META_CUI","value":"CL1905915"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198761":{"preferredName":"Market Gardener and Crop Grower","code":"C198761","definitions":[{"definition":"Gardeners or growers that raise crops for market.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Market Gardener and Crop Grower","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Market Gardeners and Crop Growers"},{"name":"NCI_META_CUI","value":"CL1905914"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198762":{"preferredName":"Material Recording and Transport Clerk","code":"C198762","definitions":[{"definition":"A clerk for material recording or shipment and receiving of goods.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Material Recording and Transport Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Material Recording and Transport Clerks"},{"name":"NCI_META_CUI","value":"CL1905909"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198763":{"preferredName":"Mathematician, Actuary and Statistician","code":"C198763","definitions":[{"definition":"Mathematicians doing actuarial or statistical work.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mathematician, Actuary and Statistician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mathematicians, Actuaries and Statisticians"},{"name":"NCI_META_CUI","value":"CL1905908"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198764":{"preferredName":"Medical and Pharmaceutical Technician","code":"C198764","definitions":[{"definition":"Technicians in medical or pharmaceutical fields.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Medical and Pharmaceutical Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Medical and Pharmaceutical Technicians"},{"name":"NCI_META_CUI","value":"CL1905911"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C25741":{"preferredName":"Physician","code":"C25741","definitions":[{"definition":"A doctor; a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon.","type":"DEFINITION","source":"NCI"},{"definition":"Medical doctor.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Physician","termGroup":"PT","termSource":"NCI"},{"termName":"Doctor","termGroup":"SY","termSource":"NCI"},{"termName":"DR","termGroup":"AB","termSource":"NCI"},{"termName":"Medical Doctor","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Physician"},{"name":"Maps_To","value":"Medical Doctors"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C0031831"}]}}{"C198765":{"preferredName":"Metal Processing and Finishing Plant Operator","code":"C198765","definitions":[{"definition":"An operator in charge of a metal processor or finishing plant machine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Metal Processing and Finishing Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Metal Processing and Finishing Plant Operators"},{"name":"NCI_META_CUI","value":"CL1905910"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198766":{"preferredName":"Mining and Construction Laborer","code":"C198766","definitions":[{"definition":"Individuals who do hands-on work in mining or construction.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mining and Construction Laborer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mining and Construction Labourers"},{"name":"NCI_META_CUI","value":"CL1905921"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198767":{"preferredName":"Mining and Mineral Processing Plant Operator","code":"C198767","definitions":[{"definition":"An operator in charge of a mining or mineral processing plant machine.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mining and Mineral Processing Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mining and Mineral Processing Plant Operators"},{"name":"NCI_META_CUI","value":"CL1905920"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198768":{"preferredName":"Mining, Manufacturing and Construction Supervisor","code":"C198768","definitions":[{"definition":"Workers who directly supervise and coordinate the activities of mining, manufacturing, or construction workers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mining, Manufacturing and Construction Supervisor","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mining, Manufacturing and Construction Supervisors"},{"name":"NCI_META_CUI","value":"CL1905923"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198769":{"preferredName":"Mixed Crop and Animal Producer","code":"C198769","definitions":[{"definition":"Workers who plan, organize and perform farming operations to breed and raise domesticated or non-domesticated animals for meat or animal products or farmers raising mixed crops.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mixed Crop and Animal Producer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mixed Crop and Animal Producers"},{"name":"NCI_META_CUI","value":"CL1905922"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198770":{"preferredName":"Mobile Plant Operator","code":"C198770","definitions":[{"definition":"Operators that drive backhoes, bulldozers, excavators, front- end loaders, graders, scrapers, skid-steer loaders, rollers and forklift trucks to level, excavate, move and load earth, rock and other material.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Mobile Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mobile Plant Operators"},{"name":"NCI_META_CUI","value":"CL1905917"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198771":{"preferredName":"Non-commissioned Armed Forces Officer","code":"C198771","definitions":[{"definition":"A military enlistee who has achieved sergeant, or equivalent rank.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Non-commissioned Armed Forces Officer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Non-commissioned Armed Forces Officers"},{"name":"NCI_META_CUI","value":"CL1905916"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198772":{"preferredName":"Numerical Clerk","code":"C198772","definitions":[{"definition":"Clerks who do accounting, bookkeeping, statistical, financial, and other numerical data, and take charge of cash transactions incidental to business matters.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Numerical Clerk","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Numerical Clerks"},{"name":"NCI_META_CUI","value":"CL1905919"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198773":{"preferredName":"Nursing and Midwifery Associate Professional","code":"C198773","definitions":[{"definition":"Occupations held by individuals who give assistance in basic nursing and personal care for people who are physically or mentally ill, disabled or infirm, and others in need of care due to potential risks to health including before, during and after childbirth. They generally work under the supervision of, and in support of implementation of health care, treatment and referrals plans established by, medical, nursing, midwifery and other health professionals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Nursing and Midwifery Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nursing and Midwifery Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905918"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"}]}}{"C198774":{"preferredName":"Nursing and Midwifery Professional","code":"C198774","definitions":[{"definition":"Occupations held by individuals who plan, provide or manage basic nursing and personal care for people who are physically or mentally ill, disabled or infirm, and others in need of care due to potential risks to health including before, during and after childbirth. This includes delivery of infants and planning, providing, and managing prenatal and postpartum care, newborn care, and some routine care (such as gynecological exams) for women.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Nursing and Midwifery Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nursing and Midwifery Professionals"},{"name":"NCI_META_CUI","value":"CL1905929"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"}]}}{"C198775":{"preferredName":"Other Clerical Support Worker","code":"C198775","definitions":[{"definition":"A clerical support worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Clerical Support Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Clerical Support Workers"},{"name":"NCI_META_CUI","value":"CL1905928"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198776":{"preferredName":"Other Craft and Related Worker","code":"C198776","definitions":[{"definition":"A craft and related worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Craft and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Craft and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905931"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198777":{"preferredName":"Other Elementary Worker","code":"C198777","definitions":[{"definition":"An elementary worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Elementary Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Elementary Workers"},{"name":"NCI_META_CUI","value":"CL1905930"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198778":{"preferredName":"Other Health Associate Professional","code":"C198778","definitions":[{"definition":"A health associate professional not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Health Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Health Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1905925"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198779":{"preferredName":"Other Health Professional","code":"C198779","definitions":[{"definition":"A health professional not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Health Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Health Professionals"},{"name":"NCI_META_CUI","value":"CL1905924"},{"name":"Semantic_Type","value":"Biomedical Occupation or Discipline"}]}}{"C198780":{"preferredName":"Other Personal Services Worker","code":"C198780","definitions":[{"definition":"A personal service worker not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Personal Services Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Personal Services Workers"},{"name":"NCI_META_CUI","value":"CL1905927"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122555":{"preferredName":"Other Sales and Related Workers","code":"C122555","definitions":[{"definition":"Sales and related workers not specifically identified elsewhere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Sales and Related Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Other Sales Worker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Sales Workers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054293"}]}}{"C198781":{"preferredName":"Other Services Manager","code":"C198781","definitions":[{"definition":"A service manager not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Services Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Services Managers"},{"name":"NCI_META_CUI","value":"CL1905926"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198782":{"preferredName":"Other Stationary Plant and Machine Operator","code":"C198782","definitions":[{"definition":"A stationary plant or machine operator not otherwise listed.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Other Stationary Plant and Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Stationary Plant and Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905937"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122556":{"preferredName":"Other Teachers and Instructors","code":"C122556","definitions":[{"definition":"Teachers and instructors not specifically identified elsewhere.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Other Teachers and Instructors","termGroup":"PT","termSource":"NCI"},{"termName":"Other Teaching Professional","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Other Teaching Professionals"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0401921"}]}}{"C198783":{"preferredName":"Painter, Building Structure Cleaner and Related Trades Worker","code":"C198783","definitions":[{"definition":"Occupations held by individuals who prepare the outer surfaces or interiors of buildings, vehicles or other structures or large manufactured articles and apply paint, wallpaper or fabric, and those who clean exterior surfaces, chimneys and other structures associated with buildings.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Painter, Building Structure Cleaner and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Painters, Building Structure Cleaners and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1905936"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C53420":{"preferredName":"Paramedic","code":"C53420","definitions":[{"definition":"An individual trained and certified to provide all basic and intermediate life support measures in addition to using invasive medical procedures (including intravenous therapy, cardiac defibrillation, administering medications and solutions, and using ventilation devices) as dictated by state law and performed under medical control in case of medical emergencies, hazardous materials exposure, child birth, abuse, fires, flood, accidents, trauma, and psychiatric crises.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Paramedic","termGroup":"PT","termSource":"NCI"},{"termName":"Paramedical Practitioner","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Paramedic"},{"name":"Maps_To","value":"Paramedical Practitioners"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0030450"}]}}{"C198784":{"preferredName":"Personal Care Workers in Health Service","code":"C198784","definitions":[{"definition":"Occupations held by individuals who provide personal care, mobility assistance and help with daily activities to patients, elderly or disabled individuals in health care and residential settings.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Personal Care Workers in Health Service","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Personal Care Workers in Health Services"},{"name":"NCI_META_CUI","value":"CL1905939"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198785":{"preferredName":"Physical and Earth Science Professional","code":"C198785","definitions":[{"definition":"Occupations held by individuals who do research and contribute to the development of concepts, theories, methods and applications of physical sciences, including astronomy, chemistry, geology, meteorology and physics.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Physical and Earth Science Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Physical and Earth Science Professionals"},{"name":"NCI_META_CUI","value":"CL1905938"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198786":{"preferredName":"Physical and Engineering Science Technician","code":"C198786","definitions":[{"definition":"Occupations held by individuals who aid in the research and applications of physical science principles in engineering, technical drawing and manufacturing.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Physical and Engineering Science Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Physical and Engineering Science Technicians"},{"name":"NCI_META_CUI","value":"CL1905933"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198787":{"preferredName":"Primary School and Early Childhood Teacher","code":"C198787","definitions":[{"definition":"Occupations held by individuals who teach a range of subjects at the primary educational level and those who organize educational activities for children younger than primary school age.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Primary School and Early Childhood Teacher","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Primary School and Early Childhood Teachers"},{"name":"NCI_META_CUI","value":"CL1905932"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122501":{"preferredName":"Printing Workers","code":"C122501","definitions":[{"definition":"Printing workers produce print material in three stages: prepress, press, and binding and finishing. They review specifications, calibrate color settings on printers, identify and fix problems with printing equipment, and assemble pages.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Printing Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Printing Trades Worker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Printing Trades Workers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4053770"}]}}{"C198788":{"preferredName":"Process Control Technician","code":"C198788","definitions":[{"definition":"Occupations held by individuals who manage, operate and or maintain equipment and machinery used in complex processes including, electrical power production, waste and water management and treatment, chemical manufacturing, and refining of petroleum, natural gas and metals.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Process Control Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Process Control Technicians"},{"name":"NCI_META_CUI","value":"CL1905935"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198789":{"preferredName":"Production Manager in Agriculture, Forestry and Fishery","code":"C198789","definitions":[{"definition":"Occupations held by individuals who plan, direct and coordinate productivity of large-scale agricultural, horticultural, forestry, aquacultural and fishery operations.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Production Manager in Agriculture, Forestry and Fishery","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Production Managers in Agriculture, Forestry and Fisheries"},{"name":"NCI_META_CUI","value":"CL1905934"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198790":{"preferredName":"Professional Services Manager","code":"C198790","definitions":[{"definition":"Occupations held by individuals who plan, direct and coordinate the provision of social care services (child care, health care, welfare and educational services) and other professional services, and those who are branch managers for institutions that provide financial and insurance services.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Professional Services Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Professional Services Managers"},{"name":"NCI_META_CUI","value":"CL1905944"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C97643":{"preferredName":"Protective Service Occupations","code":"C97643","definitions":[{"definition":"A class of professional or vocational positions of employment that involve protective services.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Protective Service Occupations","termGroup":"PT","termSource":"NCI"},{"termName":"Protective Services","termGroup":"SY","termSource":"NCI"},{"termName":"Protective Services Worker","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Protective Services Workers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0600092"}]}}{"C198791":{"preferredName":"Refuse Worker","code":"C198791","definitions":[{"definition":"Occupations held by individuals who collect, sort, process and recycle garbage from various locations or those that keep streets, parks or other public spaces clean.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Refuse Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Refuse Workers"},{"name":"NCI_META_CUI","value":"CL1905943"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198792":{"preferredName":"Retail and Wholesale Trade Manager","code":"C198792","definitions":[{"definition":"Occupations held by individuals who plan, organize and coordinate the operations for retail and wholesale establishments that sell goods.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Retail and Wholesale Trade Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Retail and Wholesale Trade Managers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0335260"}]}}{"C198793":{"preferredName":"Rubber, Plastic and Paper Products Machine Operator","code":"C198793","definitions":[{"definition":"Occupations held by individuals who operate and monitor machines that blend natural or synthetic rubber compounds and various components to produce various rubber-containing products including the manufacture of composite goods that also include plastic or paper components.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Rubber, Plastic and Paper Products Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Rubber, Plastic and Paper Products Machine Operators"},{"name":"NCI_META_CUI","value":"CL1905945"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198794":{"preferredName":"Sales and Purchasing Agent and Broker","code":"C198794","definitions":[{"definition":"Occupations held by individuals who represent companies, governments or other organizations that buy and sell commodities, goods or insurance or provide shipping and other services to other establishments.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sales and Purchasing Agent and Broker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sales and Purchasing Agents and Brokers"},{"name":"NCI_META_CUI","value":"CL1905941"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198795":{"preferredName":"Sales, Marketing and Development Manager","code":"C198795","definitions":[{"definition":"Occupations held by individuals who plan and manage public relations, sales, marketing and research and development activities for goods and services provided by companies or organizations.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sales, Marketing and Development Manager","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sales, Marketing and Development Managers"},{"name":"NCI_META_CUI","value":"CL1905940"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198796":{"preferredName":"Sales, Marketing and Public Relations Professional","code":"C198796","definitions":[{"definition":"Occupations held by individuals who plan develop, coordinate and implement programs to disseminate information related to organizations, companies, goods or services, and those who promote marketing and sales of goods and services.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sales, Marketing and Public Relations Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sales, Marketing and Public Relations Professionals"},{"name":"NCI_META_CUI","value":"CL1905942"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198797":{"preferredName":"Secondary Education Teacher","code":"C198797","definitions":[{"definition":"Occupations held by individuals who teach one or more subjects at the secondary education level, excluding vocational/occupational subjects.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Secondary Education Teacher","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Secondary Education Teachers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0401908"}]}}{"C198798":{"preferredName":"Secretary (General)","code":"C198798","definitions":[{"definition":"Occupations held by individuals who provide a range of administrative support services. This may include use of word processing equipment to transcribe and format correspondence, dictated or draft minutes and reports and other documents to conform to business rules, handling of incoming and outgoing mail and other correspondence, organizing and filing of documents, and surveying and recording of requests for meetings, appointments and staff leave.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Secretary (General)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Secretaries (general)"},{"name":"NCI_META_CUI","value":"CL1905951"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198799":{"preferredName":"Sheet and Structural Metal Worker, Molder and Welder, and Related Worker","code":"C198799","definitions":[{"definition":"Occupations held by individuals who make molds and cores for casting metal, those who cast, weld, shape or repair metals or objects made of metals (such as sheet metals), and those who install, construct, maintain and repair heavy metal-containing structures and equipment.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sheet and Structural Metal Worker, Molder and Welder, and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sheet and Structural Metal Workers, Moulders and Welders, and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905950"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198800":{"preferredName":"Ship and Aircraft Controller and Technician","code":"C198800","definitions":[{"definition":"Occupations held by individuals who manage the operation of all equipment used on board a ship, boat or aircraft, those who command, pilot, navigate, control and/or direct the movement of ships, boats or aircraft, and those who develop and maintain navigation systems for ships, boats or aircraft and air traffic control systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Ship and Aircraft Controller and Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ship and Aircraft Controllers and Technicians"},{"name":"NCI_META_CUI","value":"CL1905953"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198801":{"preferredName":"Ships' Deck Crew and Related Worker","code":"C198801","definitions":[{"definition":"Occupations held by individuals who carry out duties associated with being on board ships and other watercraft.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Ships' Deck Crew and Related Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Ships' Deck Crews and Related Workers"},{"name":"NCI_META_CUI","value":"CL1905952"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C75553":{"preferredName":"Salesperson","code":"C75553","definitions":[{"definition":"A person employed to sell goods or services especially to customers in a store or to customers that are visited within a geographic area.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Salesperson","termGroup":"PT","termSource":"NCI"},{"termName":"Sales","termGroup":"SY","termSource":"NCI"},{"termName":"Selling Occupation","termGroup":"SY","termSource":"NCI"},{"termName":"Shop Salesperson","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Salesperson"},{"name":"Maps_To","value":"Shop Salespersons"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C0402546"}]}}{"C198802":{"preferredName":"Social and Religious Professional","code":"C198802","definitions":[{"definition":"Occupations held by individuals who research, analyze, improve or develop theories regarding historical and current events, those who apply solutions to philosophical, political, economic and social problems and those who provide social services to meet the needs of individuals or families in the community.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Social and Religious Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Social and Religious Professionals"},{"name":"NCI_META_CUI","value":"CL1905947"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198803":{"preferredName":"Software and Applications Developer and Analyst","code":"C198803","definitions":[{"definition":"Occupations held by individuals who research, plan, design, write, test, improve, analyze or set requirements for technology systems and their components, which includes hardware, software and other applications.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Software and Applications Developer and Analyst","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Software and Applications Developers and Analysts"},{"name":"NCI_META_CUI","value":"CL1905946"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198804":{"preferredName":"Sports and Fitness Worker","code":"C198804","definitions":[{"definition":"Occupations held by individuals who provide instruction and promote participation in exercise, sports and other recreational activities, those who train for and compete in sporting events, those who provide performance enhancement training and/or coaching for those participating in sports, and those who organize and officiate sporting events.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Sports and Fitness Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Sports and Fitness Workers"},{"name":"NCI_META_CUI","value":"CL1905949"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198805":{"preferredName":"Street and Market Salesperson","code":"C198805","definitions":[{"definition":"Occupations held by individuals who are permitted to sell goods or prepare and sell hot or cold food and beverages from stalls in public places such as streets or markets.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Street and Market Salesperson","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Street and Market Salespersons"},{"name":"NCI_META_CUI","value":"CL1905948"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198806":{"preferredName":"Street and Related Service Worker","code":"C198806","definitions":[{"definition":"Occupations held by individuals who provide on the spot services in public places including shoe, car and windshield cleaning, running errands and handing out leaflets or other publications.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Street and Related Service Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Street and Related Service Workers"},{"name":"NCI_META_CUI","value":"CL1906255"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198807":{"preferredName":"Street Vendor (Excluding Food)","code":"C198807","definitions":[{"definition":"Occupations held by individuals who sell goods and products (excluding food) in streets and public places or by going house to house.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Street Vendor (Excluding Food)","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Street Vendors (excluding Food)"},{"name":"NCI_META_CUI","value":"CL1906254"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198808":{"preferredName":"Subsistence Crop Farmer","code":"C198808","definitions":[{"definition":"Occupations held by individuals who grow and harvest field-grown crops and edible products from other plants to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Crop Farmer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Crop Farmers"},{"name":"NCI_META_CUI","value":"CL1906257"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198809":{"preferredName":"Subsistence Fisherman, Hunter, Trapper and Gatherer","code":"C198809","definitions":[{"definition":"Occupations held by individuals who gather wild plants for food or medicinal purposes, hunt and trap animals, and catch fish and other aquatic animals to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Fisherman, Hunter, Trapper and Gatherer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Fishers, Hunters, Trappers and Gatherers"},{"name":"NCI_META_CUI","value":"CL1906256"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198810":{"preferredName":"Subsistence Livestock Farmer","code":"C198810","definitions":[{"definition":"Occupations held by individuals who breed, raise and tend livestock to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Livestock Farmer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Livestock Farmers"},{"name":"NCI_META_CUI","value":"CL1906251"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198811":{"preferredName":"Subsistence Mixed Crop and Livestock Farmer","code":"C198811","definitions":[{"definition":"Occupations held by individuals who breed, raise and tend livestock and who grow and harvest field-grown crops and edible products from other plants to provide food and shelter for themselves and their family and, in some cases, acquire a minimum level of income for the household.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Subsistence Mixed Crop and Livestock Farmer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Subsistence Mixed Crop and Livestock Farmers"},{"name":"NCI_META_CUI","value":"CL1906250"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198812":{"preferredName":"Telecommunications and Broadcasting Technician","code":"C198812","definitions":[{"definition":"Occupations held by individuals who ensure all technical equipment for recording, editing and transmission of radio and television broadcasts or other telecommunication signals remains functional. This also includes those who design, develop and perform research for telecommunication systems.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Telecommunications and Broadcasting Technician","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Telecommunications and Broadcasting Technicians"},{"name":"NCI_META_CUI","value":"CL1906253"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122451":{"preferredName":"Financial Clerks","code":"C122451","definitions":[{"definition":"Workers who do administrative work for financial institutions or within the financial industries.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Financial Clerks","termGroup":"PT","termSource":"NCI"},{"termName":"Teller, Money Collector and Related Clerk","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Tellers, Money Collectors and Related Clerks"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054956"}]}}{"C198813":{"preferredName":"Textile, Fur and Leather Products Machine Operator","code":"C198813","definitions":[{"definition":"Occupations held by individuals who operate machinery to prepare, process and chemically treat raw textiles, leather and fur products, those who process yarn or thread to manufacture fabrics, and those who use machines to process textiles, leather, fur, yarn, thread or fabrics in the production or repair of items such as: footwear, baggage, rugs/carpets, handbags or garments.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Textile, Fur and Leather Products Machine Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Textile, Fur and Leather Products Machine Operators"},{"name":"NCI_META_CUI","value":"CL1906252"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198814":{"preferredName":"Traditional and Complementary Medicine Associate Professional","code":"C198814","definitions":[{"definition":"Occupations held by individuals who assist in the providence of health care-related services based on traditional and/or complementary medical practices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Traditional and Complementary Medicine Associate Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Traditional and Complementary Medicine Associate Professionals"},{"name":"NCI_META_CUI","value":"CL1906263"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198815":{"preferredName":"Traditional and Complementary Medicine Professional","code":"C198815","definitions":[{"definition":"Occupations held by individuals who provide health care-related services based on traditional and/or complementary medical practices.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Traditional and Complementary Medicine Professional","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Traditional and Complementary Medicine Professionals"},{"name":"NCI_META_CUI","value":"CL1906262"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198816":{"preferredName":"Transport and Storage Laborer","code":"C198816","definitions":[{"definition":"Occupations held by individuals who operate and drive vehicles to transport passengers, goods and or freight, those who pack, carry, load and hand deliver goods and freight, and those who stock shelves.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Transport and Storage Laborer","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Transport and Storage Labourers"},{"name":"NCI_META_CUI","value":"CL1906265"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198817":{"preferredName":"Travel Attendant, Conductor and Guide","code":"C198817","definitions":[{"definition":"Occupations held by individuals who provide services in connection with travel or tours/excursions. The services may include provision of information for and during travel, and the collection or issuance of tickets to, ensuring safety of, and serving of food/refreshments to passengers.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Travel Attendant, Conductor and Guide","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Travel Attendants, Conductors and Guides"},{"name":"NCI_META_CUI","value":"CL1906264"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122499":{"preferredName":"Postsecondary Teachers","code":"C122499","definitions":[{"definition":"Postsecondary teachers instruct students in a wide variety of academic and vocational subjects beyond the high school level. They also conduct research and publish scholarly papers and books.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Postsecondary Teachers","termGroup":"PT","termSource":"NCI"},{"termName":"University and Higher Education Teacher","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"University and Higher Education Teachers"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054161"}]}}{"C198818":{"preferredName":"Vehicle, Window, Laundry and Other Hand Cleaning Worker","code":"C198818","definitions":[{"definition":"Occupations held by individuals who clean windows, building surfaces, vehicles or textiles by hand.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Vehicle, Window, Laundry and Other Hand Cleaning Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vehicle, Window, Laundry and Other Hand Cleaning Workers"},{"name":"NCI_META_CUI","value":"CL1906259"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C82470":{"preferredName":"Veterinarian","code":"C82470","definitions":[{"definition":"An individual licensed to practice veterinary medicine, usually with a doctorate degree.","type":"ALT_DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Veterinarian","termGroup":"PT","termSource":"NCI"},{"termName":"Veterinarian","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Veterinarian"},{"name":"Maps_To","value":"Veterinarians"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C0242856"}]}}{"C82473":{"preferredName":"Veterinary Staff","code":"C82473","synonyms":[{"termName":"Veterinary Staff","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Veterinary_Staff"},{"name":"Maps_To","value":"Veterinary Technicians and Assistants"},{"name":"Semantic_Type","value":"Professional or Occupational Group"},{"name":"UMLS_CUI","value":"C2826215"}]}}{"C198819":{"preferredName":"Vocational Education Teacher","code":"C198819","definitions":[{"definition":"Occupations held by individuals who teach or provide instruction in vocational or occupational subjects to adults and senior students in secondary schools, colleges and institutions of further education.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Vocational Education Teacher","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Vocational education teachers"},{"name":"NCI_META_CUI","value":"CL1906258"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C122460":{"preferredName":"Food and Beverage Serving Workers","code":"C122460","definitions":[{"definition":"Workers who perform a variety of customer service, food preparation, and cleaning duties in restaurants, cafeterias, and other eating and drinking establishments.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Food and Beverage Serving Workers","termGroup":"PT","termSource":"NCI"},{"termName":"Waiter and Bartender","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Waiters and Bartenders"},{"name":"Semantic_Type","value":"Occupation or Discipline"},{"name":"UMLS_CUI","value":"C4054937"}]}}{"C198820":{"preferredName":"Wood Processing and Papermaking Plant Operator","code":"C198820","definitions":[{"definition":"Occupations held by individuals who operate machinery to produce products from raw lumber including wood veneer, plywood, pulp and paper.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Wood Processing and Papermaking Plant Operator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood Processing and Papermaking Plant Operators"},{"name":"NCI_META_CUI","value":"CL1906261"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C198821":{"preferredName":"Wood Treater, Cabinet-maker and Related Trades Worker","code":"C198821","definitions":[{"definition":"Occupations held by individuals who are involved in the preservation and treatment of wood, in the construction, decoration and repair of wooden furniture and other wooden products, and in the assembly, operation and maintenance of woodworking machines and tools.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"International Standard Classification of Occupations 2008"}]}],"synonyms":[{"termName":"Wood Treater, Cabinet-maker and Related Trades Worker","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Wood Treaters, Cabinet-makers and Related Trades Workers"},{"name":"NCI_META_CUI","value":"CL1906260"},{"name":"Semantic_Type","value":"Occupation or Discipline"}]}}{"C199161":{"preferredName":"Lesion with Diameter Greater than 20 mm","code":"C199161","definitions":[{"definition":"A semi-quantitative finding indicating that the largest diameter for a lesion is greater than 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lesion with Diameter Greater than 20 mm","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":">20 mm"},{"name":"NCI_META_CUI","value":"CL1906111"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199163":{"preferredName":"Lesion with Diameter at Least 1 mm and at Most 10 mm","code":"C199163","definitions":[{"definition":"A semi-quantitative finding indicating that the largest diameter for a lesion was at least 1 mm and at most 10 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lesion with Diameter at Least 1 mm and at Most 10 mm","termGroup":"PT","termSource":"NCI"},{"termName":"Lesion with Diameter 1-10 mm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1-10 mm"},{"name":"NCI_META_CUI","value":"CL1906105"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199164":{"preferredName":"Lesion with Diameter at Least 11 mm and at Most 20 mm","code":"C199164","definitions":[{"definition":"A semi-quantitative finding indicating that the largest diameter for a lesion was at least 11 mm and at most 20 mm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lesion with Diameter at Least 11 mm and at Most 20 mm","termGroup":"PT","termSource":"NCI"},{"termName":"Lesion with Diameter 11-20 mm","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"11-20 mm"},{"name":"NCI_META_CUI","value":"CL1906104"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199165":{"preferredName":"Macroscopic Disease Negative","code":"C199165","definitions":[{"definition":"An indication that macroscopic evidence of disease was not detected.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Macroscopic Disease Negative","termGroup":"PT","termSource":"NCI"},{"termName":"No Macroscopic Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"No macroscopic disease"},{"name":"NCI_META_CUI","value":"CL1906107"},{"name":"Semantic_Type","value":"Finding"}]}}{"C199177":{"preferredName":"Biochemical Assessment Indicator","code":"C199177","definitions":[{"definition":"An indication that a finding or diagnosis was assigned based on biochemical test results.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Biochemical Assessment Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Biochemical Assessment"},{"name":"NCI_META_CUI","value":"CL1906127"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C199179":{"preferredName":"Clinical and Biochemical Assessments Indicator","code":"C199179","definitions":[{"definition":"An indication that a finding or diagnosis was assigned based on both clinical observations and biochemical test results.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical and Biochemical Assessments Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Both Clinical and Biochemical Assessments"},{"name":"NCI_META_CUI","value":"CL1906121"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C199178":{"preferredName":"Clinical Assessment Indicator","code":"C199178","definitions":[{"definition":"An indication that a finding or diagnosis was assigned based on clinical observations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Clinical Assessment Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Clinical Assessment"},{"name":"NCI_META_CUI","value":"CL1906126"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C113215":{"preferredName":"Androgen Excess","code":"C113215","definitions":[{"definition":"Excessive secretion of androgens by the adrenal glands and/or gonads.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Excessive secretion of androgens from the adrenal glands or gonads. Clinical manifestations may include virilization.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]}],"synonyms":[{"termName":"Androgen Excess","termGroup":"PT","termSource":"NCI"},{"termName":"Hyperandrogenism","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Androgen Excess"},{"name":"Maps_To","value":"Hyperandrogenism"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0206081"}]}}{"C113208":{"preferredName":"Hypercortisolemia","code":"C113208","definitions":[{"definition":"Abnormally high level of cortisol in the blood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Abnormally high levels of cortisol in the blood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hypercortisolemia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Cortisol Excess"},{"name":"Maps_To","value":"Hypercortisolemia"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0001622"}]}}{"C113344":{"preferredName":"Hyperestrogenism","code":"C113344","definitions":[{"definition":"Abnormally high level of estrogen.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"Abnormally high level of estrogen.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Hyperestrogenism","termGroup":"PT","termSource":"NCI"},{"termName":"Estrogen Excess","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Estrogen Excess"},{"name":"Maps_To","value":"Hyperestrogenism"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0154209"}]}}{"C35064":{"preferredName":"Hereditary Hemorrhagic Telangiectasia","code":"C35064","definitions":[{"definition":"An autosomal dominant hereditary disorder caused by mutations in the ACVRL1, ENG, and SMAD4 genes. It is characterized by the presence of telangiectasias in the skin, mucous membranes, lungs, brain, liver, and gastrointestinal tract. It results in hemorrhages from the affected areas.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hereditary Hemorrhagic Telangiectasia","termGroup":"PT","termSource":"NCI"},{"termName":"Osler-Weber-Rendu Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Telangiectasia, Hereditary Hemorrahagic, of Rendu, Osler","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"Cellosaurus"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Legacy Concept Name","value":"Hereditary_Hemorrhagic_Telangiectasia"},{"name":"Maps_To","value":"Hereditary Hemorrhagic Telangiectasia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0039445"}]}}{"C3101":{"preferredName":"Genetic Disorder","code":"C3101","definitions":[{"definition":"Genetic diseases are diseases in which inherited genes predispose to increased risk. The genetic disorders associated with cancer often result from an alteration or mutation in a single gene. The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer. Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Genetic Disorder","termGroup":"PT","termSource":"NCI"},{"termName":"Genetic Condition","termGroup":"SY","termSource":"NCI"},{"termName":"Hereditary Diseases","termGroup":"SY","termSource":"NCI"},{"termName":"Inherited Disease","termGroup":"SY","termSource":"NCI"},{"termName":"Molecular Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Genetic_Disorder"},{"name":"Maps_To","value":"Inherited Genetic Syndrome, NOS"},{"name":"Semantic_Type","value":"Congenital Abnormality"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0019247"}]}}{"C198986":{"preferredName":"Mineralocorticoid Excess","code":"C198986","definitions":[{"definition":"A finding indicating that the concentration of mineralocorticoids in a sample is greater than normal values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mineralocorticoid Excess","termGroup":"PT","termSource":"NCI"},{"termName":"Mineralocorticoids Excess","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mineralocorticoids Excess"},{"name":"NCI_META_CUI","value":"CL1906416"},{"name":"Semantic_Type","value":"Finding"}]}}{"C84932":{"preferredName":"Neurocysticercosis","code":"C84932","definitions":[{"definition":"A central nervous system infection that results from the inactive parenchymal or ventricular stage of Taenia solium. While many infections are asymptomatic, seizures are the most common symptom.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Neurocysticercosis","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Neurocysticercosis"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0338437"}]}}{"C85051":{"preferredName":"Rubella Infection","code":"C85051","definitions":[{"definition":"A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.","type":"DEFINITION","source":"NCI"},{"definition":"An infection that is caused by the rubella virus; it is characterized by a descending, non-coalescing macular or maculopapular rash and, generally, a mild systemic illness.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Rubella Infection","termGroup":"PT","termSource":"NCI"},{"termName":"German Measles","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Rubella"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0035920"}]}}{"C131437":{"preferredName":"Nodular Goiter","code":"C131437","definitions":[{"definition":"Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nodular Goiter","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Thyroid Nodular Hyperplasia"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018023"}]}}{"C164008":{"preferredName":"CD38-targeting Agent","code":"C164008","definitions":[{"definition":"Any agent that targets CD38.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"CD38-targeting Agent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"NCI_META_CUI","value":"CL977220"},{"name":"Semantic_Type","value":"Classification"},{"name":"Semantic_Type","value":"Pharmacologic Substance"}]}}{"C199216":{"preferredName":"Peripheral Blood Components","code":"C199216","definitions":[{"definition":"A specimen containing undefined components from peripheral blood collected from an experimental subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Peripheral Blood Components","termGroup":"PT","termSource":"NCI"},{"termName":"Peripheral Blood Components, NOS","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Peripheral Blood Components, NOS"},{"name":"NCI_META_CUI","value":"CL1906159"},{"name":"Semantic_Type","value":"Body Substance"}]}}{"C39298":{"preferredName":"Adolescence","code":"C39298","definitions":[{"definition":"A human life stage that begins at twelve years of age and continues until twenty-one complete years of age, generally marked by the beginning of puberty and lasting to the beginning of adulthood.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A human life stage that begins at twelve years of age and continues until twenty-one complete years of age, generally marked by the beginning of puberty and lasting to the beginning of adulthood.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Adolescence","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Adolescence"},{"name":"Maps_To","value":"Adolescence"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0001578"}]}}{"C199314":{"preferredName":"Adulthood","code":"C199314","definitions":[{"definition":"A time period in the human lifespan when full physical and intellectual maturity have been attained, which generally follows adolescence.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adulthood","termGroup":"PT","termSource":"NCI"},{"termName":"Adult Life Stage","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Adulthood"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0700597"}]}}{"C89345":{"preferredName":"Childhood","code":"C89345","definitions":[{"definition":"A time period that begins at the beginning of the human embryonic stage and continues until the end of adolescence.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"NICHD"}]},{"definition":"A time period that begins at the beginning of the human embryonic stage and continues until the end of adolescence.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Childhood","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Childhood"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0231335"}]}}{"C16033":{"preferredName":"Follow-Up","code":"C16033","definitions":[{"definition":"Monitoring a person's health over time after treatment. This includes keeping track of the health of people who participate in a clinical study or clinical trial for a period of time, both during the study and after the study ends.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The process by which information about the health status of a subject is obtained after the subject is no longer receiving study medication.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Follow-Up","termGroup":"PT","termSource":"NCI"},{"termName":"Active Follow-up","termGroup":"SY","termSource":"NCI"},{"termName":"Follow Up","termGroup":"SY","termSource":"NCI"},{"termName":"Followup","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Follow-up"},{"name":"Maps_To","value":"Follow-up"},{"name":"Semantic_Type","value":"Health Care Activity"},{"name":"UMLS_CUI","value":"C1522577"}]}}{"C199315":{"preferredName":"Last Contact Event Occurrence Indicator","code":"C199315","definitions":[{"definition":"An indication that an individual has had their last contact event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Last Contact Event Occurrence Indicator","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Last Contact"},{"name":"NCI_META_CUI","value":"CL1906249"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C158707":{"preferredName":"Post-Adjuvant Therapy","code":"C158707","definitions":[{"definition":"Therapy administered after to the initial therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post-Adjuvant Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post Adjuvant Therapy"},{"name":"NCI_META_CUI","value":"CL950738"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C199316":{"preferredName":"After Hormone Therapy","code":"C199316","definitions":[{"definition":"Relating to or occurring after hormone therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"After Hormone Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Post Hormone Therapy","termGroup":"SY","termSource":"NCI"},{"termName":"Post-Hormone Therapy","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post Hormone Therapy"},{"name":"NCI_META_CUI","value":"CL1906244"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C158753":{"preferredName":"Post-secondary Therapy","code":"C158753","definitions":[{"definition":"Therapy administered after the second treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Post-secondary Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Post Secondary Therapy"},{"name":"NCI_META_CUI","value":"CL950719"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"}]}}{"C28006":{"preferredName":"Postoperative","code":"C28006","definitions":[{"definition":"After surgery.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Relating to or occurring during the period immediately following a surgical operation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Postoperative","termGroup":"PT","termSource":"NCI"},{"termName":"Post-Operative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Postoperative"},{"name":"Maps_To","value":"Postoperative"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0032790"}]}}{"C54732":{"preferredName":"Preoperative","code":"C54732","definitions":[{"definition":"Relating to or occurring during the period immediately before a surgical operation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Preoperative","termGroup":"PT","termSource":"NCI"},{"termName":"Pre-operative","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Preoperative"},{"name":"Maps_To","value":"Preoperative"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0445204"}]}}{"C199317":{"preferredName":"Pre-Diagnosis","code":"C199317","definitions":[{"definition":"Relating to or occurring before a diagnosis was received.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Diagnosis","termGroup":"PT","termSource":"NCI"},{"termName":"Before Diagnosis","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Diagnostic","termGroup":"SY","termSource":"NCI"},{"termName":"Prior to Diagnosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prior to Diagnosis"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C0332132"}]}}{"C54734":{"preferredName":"Pre-Therapy","code":"C54734","definitions":[{"definition":"Occurring before a therapeutic procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Therapy","termGroup":"PT","termSource":"NCI"},{"termName":"Before Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Pre-Treatment","termGroup":"SY","termSource":"NCI"},{"termName":"Pretreatment","termGroup":"SY","termSource":"NCI"},{"termName":"Prior to Treatment","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Pre-Therapy"},{"name":"Maps_To","value":"Prior to Treatment"},{"name":"Semantic_Type","value":"Temporal Concept"},{"name":"UMLS_CUI","value":"C1882440"}]}}{"C158754":{"preferredName":"Progression of Disease at Recurrence","code":"C158754","definitions":[{"definition":"At the time of the progression or recurrence of a disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Progression of Disease at Recurrence","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Recurrence/Progression"},{"name":"NCI_META_CUI","value":"CL950720"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C200432":{"preferredName":"Within 3 Months of Surgery","code":"C200432","definitions":[{"definition":"Occurring within the period 3 months prior to or 3 months following a surgical procedure.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Within 3 Months of Surgery","termGroup":"PT","termSource":"NCI"},{"termName":"Within Three Months of Surgery","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Within 3 Months of Surgery"},{"name":"NCI_META_CUI","value":"CL1907443"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C206464":{"preferredName":"Prior to Adjuvant Therapy","code":"C206464","definitions":[{"definition":"Occurring before the administration of adjuvant therapy.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Prior to Adjuvant Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prior to Adjuvant Therapy"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C206465":{"preferredName":"Within 2 Months After Completion of First-Course Treatment","code":"C206465","definitions":[{"definition":"Occurring within the 2 months that follow the completion of a first course of treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Within 2 Months After Completion of First-Course Treatment","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Within 2 Months After Completion of First-Course Treatment"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C199318":{"preferredName":"End of Consolidation Therapy Occurrence Indicator","code":"C199318","definitions":[{"definition":"An indication that consolidation therapy has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Consolidation Therapy Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Consolidation Therapy Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Consolidation Therapy"},{"name":"NCI_META_CUI","value":"CL1906246"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199320":{"preferredName":"End of Treatment Course 1 Occurrence Indicator","code":"C199320","definitions":[{"definition":"An indication that the first treatment course has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Treatment Course 1 Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Treatment Course 1 Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Treatment Course 1"},{"name":"NCI_META_CUI","value":"CL1906738"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199321":{"preferredName":"End of Treatment Course 2 Occurrence Indicator","code":"C199321","definitions":[{"definition":"An indication that the second treatment course has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Treatment Course 2 Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Treatment Course 2 Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Treatment Course 2"},{"name":"NCI_META_CUI","value":"CL1906737"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199319":{"preferredName":"End of Treatment Course Occurrence Indicator","code":"C199319","definitions":[{"definition":"An indication that a treatment course has been completed.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"End of Treatment Course Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"End of Treatment Course Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"End of Treatment Course"},{"name":"NCI_META_CUI","value":"CL1906245"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199322":{"preferredName":"First Complete Response Occurrence Indicator","code":"C199322","definitions":[{"definition":"An indication that the first observation of a complete disease response has occurred.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"First Complete Response Occurrence Indicator","termGroup":"PT","termSource":"NCI"},{"termName":"First Complete Response Indicator","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"First Complete Response"},{"name":"NCI_META_CUI","value":"CL1906740"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C199323":{"preferredName":"Pre-Procurement","code":"C199323","definitions":[{"definition":"Relating to or occurring before obtaining goods, services, supplies, specimens, equipment or other required materials.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Procurement","termGroup":"PT","termSource":"NCI"},{"termName":"Prior to Procurement","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prior to Procurement"},{"name":"NCI_META_CUI","value":"CL1906739"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C199324":{"preferredName":"Pre-Registration","code":"C199324","definitions":[{"definition":"Relating to or occurring before registration into a study or trial.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Pre-Registration","termGroup":"PT","termSource":"NCI"},{"termName":"Prior to Registration","termGroup":"SY","termSource":"NCI"},{"termName":"Prior to Study/Trial Registration","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Prior to Study Registration"},{"name":"NCI_META_CUI","value":"CL1906734"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C199325":{"preferredName":"Four Tumor Grade Evaluation Tiers","code":"C199325","definitions":[{"definition":"Four clinical evidence tiers were present in the system used to evaluate the tumor grade for a subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Four Tumor Grade Evaluation Tiers","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Four Tier"},{"name":"NCI_META_CUI","value":"CL1906733"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C199326":{"preferredName":"Three Tumor Grade Evaluation Tiers","code":"C199326","definitions":[{"definition":"Three clinical evidence tiers were present in the system used to evaluate the tumor grade for a subject.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Three Tumor Grade Evaluation Tiers","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Three Tier"},{"name":"NCI_META_CUI","value":"CL1906736"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C13087":{"preferredName":"Apex of the Prostate","code":"C13087","definitions":[{"definition":"The lowest part of the prostate gland adjacent to the superior fascia of the urogenital diaphragm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Apex of the Prostate","termGroup":"PT","termSource":"NCI"},{"termName":"Apex of Prostate","termGroup":"SY","termSource":"NCI"},{"termName":"Apical Prostate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Apex_of_the_Prostate"},{"name":"Maps_To","value":"Apex"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227959"}]}}{"C13088":{"preferredName":"Base of the Prostate","code":"C13088","definitions":[{"definition":"The uppermost part of the prostate gland adjacent to the bladder wall.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Base of the Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Base_of_the_Prostate"},{"name":"Maps_To","value":"Base"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227958"}]}}{"C13094":{"preferredName":"Middle Lobe of the Prostate","code":"C13094","definitions":[{"definition":"The upper, smaller part of the prostate between the ejaculatory ducts and the urethra.","type":"DEFINITION","source":"NCI"},{"definition":"The upper, smaller part of the prostate between the ejaculatory ducts and the urethra. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Middle Lobe of the Prostate","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Middle_Lobe_of_the_Prostate"},{"name":"Maps_To","value":"Middle"},{"name":"Semantic_Type","value":"Anatomical Structure"},{"name":"UMLS_CUI","value":"C0227972"}]}}{"C54566":{"preferredName":"Fourth","code":"C54566","definitions":[{"definition":"Following the third position in an ordering or series; coming next after the third and just before the fifth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fourth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fourth"},{"name":"Maps_To","value":"4th"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205438"}]}}{"C54567":{"preferredName":"Fifth","code":"C54567","definitions":[{"definition":"Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Fifth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Fifth"},{"name":"Maps_To","value":"5th"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205439"}]}}{"C54568":{"preferredName":"Sixth","code":"C54568","definitions":[{"definition":"Following the fifth position in an ordering or series; coming next after the fifth and just before the seventh in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sixth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sixth"},{"name":"Maps_To","value":"6th"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205440"}]}}{"C133531":{"preferredName":"Seventh","code":"C133531","definitions":[{"definition":"Following the sixth position in an ordering or series; coming next after the sixth and just before the eighth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Seventh","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"7th"},{"name":"Semantic_Type","value":"Conceptual Entity"},{"name":"UMLS_CUI","value":"C0205441"}]}}{"C133533":{"preferredName":"Eighth","code":"C133533","definitions":[{"definition":"Following the seventh position in an ordering or series; coming next after the seventh and just before the ninth in position.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Eighth","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"8th"},{"name":"NCI_META_CUI","value":"CL521180"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C35962":{"preferredName":"Atypical Mitotic Figures","code":"C35962","definitions":[{"definition":"A morphologic finding indicating the presence of atypical mitoses in malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Atypical Mitotic Figures","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Atypical_Mitotic_Figures"},{"name":"Maps_To","value":"Atypical Mitotic Figures"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1332352"}]}}{"C199327":{"preferredName":"Presence of Clear Cytoplasm Less than or Equal to 25 Percent","code":"C199327","definitions":[{"definition":"A finding indicating that less than or equal to 25 percent of the cells in a sample have clear or vacuolated cytoplasm.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Presence of Clear Cytoplasm Less than or Equal to 25 Percent","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Cytoplasm presence <= to 25%"},{"name":"NCI_META_CUI","value":"CL1906735"},{"name":"Semantic_Type","value":"Finding"}]}}{"C35903":{"preferredName":"Diffuse Pattern","code":"C35903","definitions":[{"definition":"A morphologic architectural pattern in which a cellular population is distributed in a relatively uniform fashion throughout a specified tissue area; not focal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Pattern","termGroup":"PT","termSource":"NCI"},{"termName":"Diffuse Architectural Pattern","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Pattern"},{"name":"Maps_To","value":"Diffuse Architecture"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1333299"}]}}{"C199328":{"preferredName":"Tumor Capsule Invasion Present","code":"C199328","definitions":[{"definition":"A morphologic finding indicating that tumor cells have infiltrated the surrounding capsule of connective tissue and invaded nearby tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Tumor Capsule Invasion Present","termGroup":"PT","termSource":"NCI"},{"termName":"Tumor Capsule Invasion","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Invasion of Tumor Capsule"},{"name":"NCI_META_CUI","value":"CL1906742"},{"name":"Semantic_Type","value":"Finding"}]}}{"C54007":{"preferredName":"More than 5 Mitoses per 50 HPF","code":"C54007","definitions":[{"definition":"A morphologic finding indicating the presence of more than five mitotic figures per fifty high power fields in a cellular infiltrate.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"More than 5 Mitoses per 50 HPF","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"More_than_5_Mitoses_per_50HPF"},{"name":"Maps_To","value":"Mitotic Rate > 5/50 HPF"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1709073"}]}}{"C36184":{"preferredName":"Necrotic Change","code":"C36184","definitions":[{"definition":"A finding indicating the presence of cellular necrosis in a tissue specimen.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Necrotic Change","termGroup":"PT","termSource":"NCI"},{"termName":"Necrosis","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICDC"},{"name":"Legacy Concept Name","value":"Necrotic_Change"},{"name":"Maps_To","value":"Necrosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1334928"}]}}{"C104011":{"preferredName":"Nuclear Grade III or IV","code":"C104011","definitions":[{"definition":"Nuclear pleomorphism in tumor cells defined either as grade III or IV.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Nuclear Grade III or IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Nuclear Grade III or IV"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C3641689"}]}}{"C39615":{"preferredName":"Sinusoidal Infiltration","code":"C39615","definitions":[{"definition":"A microscopic finding indicating the invasion of sinusoidal spaces by malignant cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sinusoidal Infiltration","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Sinusoidal_Infiltration"},{"name":"Maps_To","value":"Sinusoid Invasion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1519333"}]}}{"C47849":{"preferredName":"Venous Invasion","code":"C47849","definitions":[{"definition":"A term referring to the presence of tumor emboli or tumor masses within veins.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Venous Invasion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Venous_Invasion"},{"name":"Maps_To","value":"Venous Invasion"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1710625"}]}}{"C94812":{"preferredName":"Clark Level I","code":"C94812","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma is confined to the epidermis and does not invade the dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that is found only in the epidermis (outer layer of skin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level I","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"I"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986693"}]}}{"C94813":{"preferredName":"Clark Level II","code":"C94813","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded part of the papillary dermis but the malignant cellular infiltrate has not reached the papillary-reticular dermis interface.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread from the epidermis (outer layer of skin) down into the papillary dermis (the thin top layer of the dermis).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level II","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"II"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986694"}]}}{"C94814":{"preferredName":"Clark Level III","code":"C94814","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded the entire thickness of the papillary dermis but the malignant cellular infiltrate does not extend into the reticular dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread down through the papillary dermis (the thin top layer of the dermis) but not into the reticular dermis (the thick bottom layer of the dermis).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level III","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"III"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986695"}]}}{"C94815":{"preferredName":"Clark Level IV","code":"C94815","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded the reticular dermis.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread down into the reticular dermis (the thick bottom layer of the dermis).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level IV","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"IV"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986696"}]}}{"C94816":{"preferredName":"Clark Level V","code":"C94816","definitions":[{"definition":"A morphologic finding indicating that the cutaneous melanoma has invaded the subcutaneous tissue.","type":"DEFINITION","source":"NCI"},{"definition":"Melanoma that has spread down into the subcutaneous tissue (tissue beneath the skin).","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Clark Level V","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"V"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C2986697"}]}}{"C159746":{"preferredName":"College Completion","code":"C159746","definitions":[{"definition":"Completion of education at an institution of higher education created to educate and grant degrees; often a part of a university.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Indicates that a person has attended college and receive a degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"College Completion","termGroup":"PT","termSource":"NCI"},{"termName":"College Degree","termGroup":"SY","termSource":"NCI"},{"termName":"College Graduate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"College Degree"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0682187"}]}}{"C67136":{"preferredName":"High School Completion","code":"C67136","definitions":[{"definition":"Completed secondary education through 12th or 13th grade as required by the school system.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Indicates that a person has attended high school and has received a high school diploma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"High School Completion","termGroup":"PT","termSource":"NCI"},{"termName":"High School","termGroup":"SY","termSource":"NCI"},{"termName":"High School Diploma Received","termGroup":"SY","termSource":"NCI"},{"termName":"High School Graduate","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"High_School_Graduate"},{"name":"Maps_To","value":"High School Graduate or GED"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0870649"}]}}{"C67135":{"preferredName":"General Equivalency Diploma Completion","code":"C67135","definitions":[{"definition":"Indicates that a person has received a General Equivalency Diploma in lieu of a high school diploma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"General Equivalency Diploma Completion","termGroup":"PT","termSource":"NCI"},{"termName":"GED","termGroup":"AB","termSource":"NCI"},{"termName":"GED or Equivalent","termGroup":"SY","termSource":"NCI"},{"termName":"General Equivalency Diploma","termGroup":"SY","termSource":"NCI"},{"termName":"General Equivalency Diploma Received","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"General_Equivalency_Diploma"},{"name":"Maps_To","value":"High School Graduate or GED"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1880947"}]}}{"C70558":{"preferredName":"Professional Doctorate Degree Completion","code":"C70558","definitions":[{"definition":"Indicates that a person has received a degree allowing them to practice a profession, such as law, medicine, music, or ministry.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Professional Doctorate Degree Completion","termGroup":"PT","termSource":"NCI"},{"termName":"Professional Doctoral Degree","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctoral Degree Completion","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctoral Degree Received","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctorate Degree","termGroup":"SY","termSource":"NCI"},{"termName":"Professional Doctorate Degree Received","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Professional_Doctorate_Degree_Completion"},{"name":"Maps_To","value":"Professional or Graduate Degree"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C2347690"}]}}{"C168226":{"preferredName":"Graduate Studies Completion","code":"C168226","definitions":[{"definition":"Completion of a program of study of at least the full-time equivalent of greater than or equal to 1 academic years of work beyond the bachelor's degree.","type":"ALT_DEFINITION","source":"ACC/AHA"},{"definition":"Indicates that a person has completed a graduate studies program beyond a bachelor's degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Graduate Studies Completion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Professional or Graduate Degree"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0013630"}]}}{"C198650":{"preferredName":"Some High School, No Diploma","code":"C198650","definitions":[{"definition":"Indicates that a person has attended high school, but not to completion and did not receive a diploma. The person may have dropped out in or after 9th, 10th, or 11th grade.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Some High School, No Diploma","termGroup":"PT","termSource":"NCI"},{"termName":"Attended High School","termGroup":"SY","termSource":"NCI"},{"termName":"Some High School","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Some High School or Less"},{"name":"NCI_META_CUI","value":"CL1905805"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C67141":{"preferredName":"Vocational Program Completion","code":"C67141","definitions":[{"definition":"Indicates that a person has attended or received a degree from an occupational, technical, or vocational program as their highest level of educational achievement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Vocational Program Completion","termGroup":"PT","termSource":"NCI"},{"termName":"Vocational Degree","termGroup":"SY","termSource":"NCI"},{"termName":"Vocational Degree Completion","termGroup":"SY","termSource":"NCI"},{"termName":"Vocational Degree Received","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Vocational_Degree"},{"name":"Maps_To","value":"Vocational College or Some College"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1883542"}]}}{"C67137":{"preferredName":"Some College Completion","code":"C67137","definitions":[{"definition":"Indicates that a person has attended college but that they did not receive any degree.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Some College Completion","termGroup":"PT","termSource":"NCI"},{"termName":"Some College","termGroup":"SY","termSource":"NCI"},{"termName":"Some College Attendence","termGroup":"SY","termSource":"NCI"},{"termName":"Some College, No Degree","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Legacy Concept Name","value":"Some_College"},{"name":"Maps_To","value":"Vocational College or Some College"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C1883065"}]}}{"C104028":{"preferredName":"cM0 ENSAT Staging Finding v7","code":"C104028","definitions":[{"definition":"Adrenal cancer with no involvement of distant organs or tissues. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cM0 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641706"}]}}{"C104029":{"preferredName":"cM1 ENSAT Staging Finding v7","code":"C104029","definitions":[{"definition":"Adrenal cancer with involvement of distant organs or tissues such as liver, bone or brain. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"cM1 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"M1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641707"}]}}{"C104024":{"preferredName":"pN0 ENSAT Staging Finding v7","code":"C104024","definitions":[{"definition":"Adrenal cancer with no involvement of regional lymph nodes. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN0 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N0"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641702"}]}}{"C104025":{"preferredName":"pN1 ENSAT Staging Finding v7","code":"C104025","definitions":[{"definition":"Adrenal cancer with involvement of regional lymph nodes. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pN1 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"N1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641703"}]}}{"C104031":{"preferredName":"ENSAT Stage I Adrenal Cortical Carcinoma","code":"C104031","definitions":[{"definition":"Stage I includes: T1, N0, M0.  Tumor 5 cm or less in greatest dimension. The tumor has not invaded the surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues.  (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage I Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage I Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage I"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641709"}]}}{"C104032":{"preferredName":"ENSAT Stage II Adrenal Cortical Carcinoma","code":"C104032","definitions":[{"definition":"Stage II includes: T2, N0, M0. Tumor greater than 5 cm. The tumor has not invaded surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues. (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage II Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage II Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage II"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641710"}]}}{"C104033":{"preferredName":"ENSAT Stage III Adrenal Cortical Carcinoma","code":"C104033","definitions":[{"definition":"Stage III includes: T3/T4, N0/N1, M0.  Tumor of any size that has spread to the fat outside the adrenal gland or into nearby organs or tissues and/or has spread to the regional lymph nodes. (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage III Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage III Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage III"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641711"}]}}{"C104034":{"preferredName":"ENSAT Stage IV Adrenal Cortical Carcinoma","code":"C104034","definitions":[{"definition":"Stage IV includes: Any T, Any N, M1. Tumor of any size that involves distant organs such as liver, bone or brain. The tumor may or may not involve nearby organs, tissues or lymph nodes. (ENSAT 7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"ENSAT Stage IV Adrenal Cortical Carcinoma","termGroup":"PT","termSource":"NCI"},{"termName":"ENSAT Stage IV Adrenal Cortex Carcinoma","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Stage IV"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C3641712"}]}}{"C104019":{"preferredName":"pT1 ENSAT Staging Finding v7","code":"C104019","definitions":[{"definition":"Adrenal cancer with tumor size equal or less than 5.0 cm.  There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT1 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T1"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641697"}]}}{"C104020":{"preferredName":"pT2 ENSAT Staging Finding v7","code":"C104020","definitions":[{"definition":"Adrenal cancer with tumor size more than 5.0 cm. There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT2 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T2"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641698"}]}}{"C104021":{"preferredName":"pT3 ENSAT Staging Finding v7","code":"C104021","definitions":[{"definition":"Adrenal cancer with tumor of any size.  There is invasion of the fat that surrounds the adrenal gland. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT3 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T3"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641699"}]}}{"C104022":{"preferredName":"pT4 ENSAT Staging Finding v7","code":"C104022","definitions":[{"definition":"Adrenal cancer with tumor of any size.  There is invasion of nearby organs such as the kidney, pancreas, spleen or liver. (7th Ed, 2009)","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"pT4 ENSAT Staging Finding v7","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"T4"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3641700"}]}}{"C51776":{"preferredName":"Divorced","code":"C51776","definitions":[{"definition":"Indicates a person whose marriage has been legally dissolved and has not remarried.","type":"DEFINITION","source":"NCI"},{"definition":"Marriage contract has been declared dissolved and inactive. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Divorced","termGroup":"PT","termSource":"NCI"},{"termName":"Divorced Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Divorced_Status"},{"name":"Maps_To","value":"Divorced"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0012828"}]}}{"C51773":{"preferredName":"Married","code":"C51773","definitions":[{"definition":"A current marriage contract is active. (HL7)","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"Indicates a person currently joined in a legally binding matrimonial union.  Classify common law marriage as married.  Includes married couples living together and not living together.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Married","termGroup":"PT","termSource":"NCI"},{"termName":"Married Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Married_Status"},{"name":"Maps_To","value":"Married"},{"name":"NCI_META_CUI","value":"CL355270"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C51774":{"preferredName":"Never Married","code":"C51774","definitions":[{"definition":"Indicates a person who has never been married or whose marriages have been annulled.","type":"DEFINITION","source":"NCI"},{"definition":"No marriage contract has ever been entered. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Never Married","termGroup":"PT","termSource":"NCI"},{"termName":"Never Married Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Never_Married_Status"},{"name":"Maps_To","value":"Never Married"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0027952"}]}}{"C156541":{"preferredName":"Separated","code":"C156541","definitions":[{"definition":"A person who is separated from their spouse, whether or not there is a legal arrangement.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A person who is separated from their spouse, whether or not there is a legal arrangement.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Separated","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Separated"},{"name":"NCI_META_CUI","value":"CL935649"},{"name":"Semantic_Type","value":"Organism Attribute"}]}}{"C51775":{"preferredName":"Widowed","code":"C51775","definitions":[{"definition":"Indicates a person who is no longer married because of the death of his/her spouse and has not remarried.","type":"DEFINITION","source":"NCI"},{"definition":"The spouse has died. (HL7)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Widowed","termGroup":"PT","termSource":"NCI"},{"termName":"Widowed Status","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HL7"},{"name":"Legacy Concept Name","value":"Widowed_Status"},{"name":"Maps_To","value":"Widowed"},{"name":"Semantic_Type","value":"Organism Attribute"},{"name":"UMLS_CUI","value":"C0206275"}]}}{"C93286":{"preferredName":"Radiologic Examination","code":"C93286","definitions":[{"definition":"A test that uses radiation or other imaging procedures to find signs of cancer or other abnormalities.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"The use of x-rays, or other radiologic imaging modalities, for visualizing body spaces and organs, usually for diagnosis or screening of disease.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Radiologic Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Radiologic Exam","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Radiologic"},{"name":"Semantic_Type","value":"Diagnostic Procedure"},{"name":"UMLS_CUI","value":"C2985535"}]}}{"C200433":{"preferredName":"Sonographic Examination","code":"C200433","definitions":[{"definition":"A medical examination of the internal anatomy of a subject using high-frequency sound waves to generate images.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Sonographic Examination","termGroup":"PT","termSource":"NCI"},{"termName":"Echographic Examination","termGroup":"SY","termSource":"NCI"},{"termName":"Ultrasonographic Examination","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Echographic"},{"name":"NCI_META_CUI","value":"CL1907442"},{"name":"Semantic_Type","value":"Diagnostic Procedure"}]}}{"C49668":{"preferredName":"Centimeter","code":"C49668","definitions":[{"definition":"A basic unit of length equal to one hundredth of a meter or approximately 0.393700787 inch.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.","type":"DEFINITION","source":"NCI"},{"definition":"A measure of length in the metric system. There are 100 centimeters in a meter and 2 1/2 centimeters in an inch.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Centimeter","termGroup":"PT","termSource":"NCI"},{"termName":"cm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"NCPDP"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Contributing_Source","value":"UCUM"},{"name":"Legacy Concept Name","value":"Centimeter"},{"name":"Maps_To","value":"Centimeters"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0475210"}]}}{"C28251":{"preferredName":"Millimeter","code":"C28251","definitions":[{"definition":"A measure of length in the metric system. A millimeter is one thousandth of a meter. There are 25 millimeters in an inch.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A metric unit of length equal to one thousandth of a meter (10E-3 meter) or approximately 0.03937 inch.","type":"DEFINITION","source":"NCI"},{"definition":"A unit of measure equal to one thousandth of a meter. (NCI)","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Millimeter","termGroup":"PT","termSource":"NCI"},{"termName":"mm","termGroup":"AB","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"ICH"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"UCUM"},{"name":"FDA_Table","value":"Potency (C-DRG-00501)"},{"name":"Legacy Concept Name","value":"Millimeter"},{"name":"Maps_To","value":"Millimeters"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0439200"}]}}{"C51137":{"preferredName":"Deep Lesion","code":"C51137","definitions":[{"definition":"A lesion that has invaded into or beyond the deep fascia.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Deep Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Deep_Lesion"},{"name":"Maps_To","value":"Deep"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1707653"}]}}{"C36109":{"preferredName":"Superficial Lesion","code":"C36109","definitions":[{"definition":"A lesion with limited invasion of deeper tissues.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Superficial Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Superficial_Lesion"},{"name":"Maps_To","value":"Superficial"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1336528"}]}}{"C64942":{"preferredName":"Few","code":"C64942","definitions":[{"definition":"An indefinite but relatively small number.","type":"DEFINITION","source":"NCI","qualifiers":[{"type":"attribution","value":"WordNet"}]}],"synonyms":[{"termName":"Few","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Few"},{"name":"Maps_To","value":"Few"},{"name":"Semantic_Type","value":"Quantitative Concept"},{"name":"UMLS_CUI","value":"C0205388"}]}}{"C78728":{"preferredName":"Many","code":"C78728","definitions":[{"definition":"An indefinite large quantity that is considered to be greater than several.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Many","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Many"},{"name":"Maps_To","value":"Many"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0439064"}]}}{"C61376":{"preferredName":"Moderate","code":"C61376","definitions":[{"definition":"Middling or intermediate in degree, quality or extent.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"The quality of being within reasonable or average limits; not excessive or extreme.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Moderate","termGroup":"PT","termSource":"NCI"},{"termName":"Moderately","termGroup":"AD","termSource":"NCI"},{"termName":"Moderation","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"DIPG/DMG"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PRO-CTCAE"},{"name":"Legacy Concept Name","value":"Moderation"},{"name":"Maps_To","value":"Moderate"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C0205081"}]}}{"C47826":{"preferredName":"Diffuse Lesion","code":"C47826","definitions":[{"definition":"A lesion that is not confined to the primary site.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diffuse Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diffuse_Lesion"},{"name":"Maps_To","value":"Diffuse"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1707743"}]}}{"C54253":{"preferredName":"Dome-Shaped Lesion","code":"C54253","definitions":[{"definition":"A lesion having the shape of a dome.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Dome-Shaped Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Dome-Shaped_Lesion"},{"name":"Maps_To","value":"Dome"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1711316"}]}}{"C111029":{"preferredName":"Mushroom-Shaped Lesion","code":"C111029","definitions":[{"definition":"A lesion having the shape of a mushroom.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Mushroom-Shaped Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Mushroom"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828878"}]}}{"C3415":{"preferredName":"Thyroid Gland Nodule","code":"C3415","definitions":[{"definition":"A discrete tissue mass in the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"A nodular lesion that develops in the thyroid gland.  Causes include adenoma, thyroiditis, fluid-filled cyst, multinodular goiter, and carcinoma.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Thyroid Gland Nodule","termGroup":"PT","termSource":"NCI"},{"termName":"Nodule of the Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Nodule of the Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Nodule of Thyroid","termGroup":"SY","termSource":"NCI"},{"termName":"Nodule of Thyroid Gland","termGroup":"SY","termSource":"NCI"},{"termName":"Thyroid Nodule","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Thyroid_Nodule"},{"name":"Maps_To","value":"Benign Thyroid Nodule"},{"name":"Neoplastic_Status","value":"Benign"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C0040137"}]}}{"C26785":{"preferredName":"Goiter","code":"C26785","definitions":[{"definition":"An enlarged thyroid. It may be caused by too little iodine in the diet or by other conditions. Most goiters are not cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing.","type":"DEFINITION","source":"NCI"},{"definition":"Enlargement of the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Goiter","termGroup":"PT","termSource":"NCI"},{"termName":"Thyromegaly","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Goiter"},{"name":"Maps_To","value":"Goiter"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231190"}]}}{"C3071":{"preferredName":"Graves Disease","code":"C3071","definitions":[{"definition":"An autoimmune condition characterized by excessive immunoglobulin stimulation of the thyroid gland resulting in hyperthyroidism.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Graves Disease","termGroup":"PT","termSource":"NCI"},{"termName":"Graves' Disease","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Graves_Disease"},{"name":"Maps_To","value":"Graves' Disease"},{"name":"Maps_To","value":"Graves' disease"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0018213"}]}}{"C48259":{"preferredName":"Hyperparathyroidism","code":"C48259","definitions":[{"definition":"A condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Elevated concentration of parathyroid hormone. Causes include conditions originating within the parathyroid glands (primary), in response to hypocalcemia and hyperphosphatemia (secondary), and renal disease (tertiary). Characteristics may include polyuria, polydipsia, constipation, lethargy, cognitive dysfunction, hypercalciuria, nephrolithiasis, and bone demineralization or reduced bone mineral density.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Hyperparathyroidism","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Hyperparathyroidism"},{"name":"Maps_To","value":"Hyperparathyroidism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0020502"}]}}{"C3123":{"preferredName":"Hyperthyroidism","code":"C3123","definitions":[{"definition":"A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.","type":"ALT_DEFINITION","source":"CTCAE"},{"definition":"Increased secretion of thyroid hormone(s) by the thyroid gland.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.","type":"DEFINITION","source":"NCI"},{"definition":"Too much thyroid hormone. Symptoms include weight loss, chest pain, cramps, diarrhea, and nervousness.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Hyperthyroidism","termGroup":"PT","termSource":"NCI"},{"termName":"Overactive Thyroid","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"MedDRA"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Hyperthyroidism"},{"name":"Maps_To","value":"Hyperthyroidism"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C4231189"}]}}{"C102532":{"preferredName":"Lymphoid Hyperplasia","code":"C102532","definitions":[{"definition":"A benign or malignant, diffuse and/or follicular lymphocytic proliferation.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Lymphoid Hyperplasia","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Lymphoid Hyperplasia"},{"name":"Semantic_Type","value":"Pathologic Function"},{"name":"UMLS_CUI","value":"C0333997"}]}}{"C202212":{"preferredName":"Exercised Five or More Days per Week","code":"C202212","definitions":[{"definition":"A response indicating that a subject exercised 5 or more days per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exercised Five or More Days per Week","termGroup":"PT","termSource":"NCI"},{"termName":"Exercised 5 or More Days per Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"5 or More Days"},{"name":"NCI_META_CUI","value":"CL1921179"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C202213":{"preferredName":"Exercised Three to Four Days per Week","code":"C202213","definitions":[{"definition":"A response indicating that a subject exercised 3 to 4 days per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exercised Three to Four Days per Week","termGroup":"PT","termSource":"NCI"},{"termName":"Exercised 3 to 4 Days per Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3 to 4 Days"},{"name":"NCI_META_CUI","value":"CL1921180"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C202214":{"preferredName":"Exercised One to Two Days per Week","code":"C202214","definitions":[{"definition":"A response indicating that a subject exercised 1 to 2 days per week.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Exercised One to Two Days per Week","termGroup":"PT","termSource":"NCI"},{"termName":"Exercised 1 to 2 Days per Week","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1 to 2 Days"},{"name":"NCI_META_CUI","value":"CL1921177"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C202215":{"preferredName":"0-30 Days","code":"C202215","definitions":[{"definition":"A time period between 0 and 30 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"0-30 Days","termGroup":"PT","termSource":"NCI"},{"termName":"Zero to Thirty Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0-30 Days"},{"name":"NCI_META_CUI","value":"CL1921178"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C202216":{"preferredName":"31-90 Days","code":"C202216","definitions":[{"definition":"A time period between 31 and 90 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"31-90 Days","termGroup":"PT","termSource":"NCI"},{"termName":"Thirty One to Ninety Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"31-90 Days"},{"name":"NCI_META_CUI","value":"CL1921188"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C202217":{"preferredName":"91-180 Days","code":"C202217","definitions":[{"definition":"A time period between 91 and 180 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"91-180 Days","termGroup":"PT","termSource":"NCI"},{"termName":"Ninety One to One Hundred Eighty Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"91-180 Days"},{"name":"NCI_META_CUI","value":"CL1921189"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C202218":{"preferredName":"Greater than or Equal to 181 Days","code":"C202218","definitions":[{"definition":"A time period of at least 181 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Greater than or Equal to 181 Days","termGroup":"PT","termSource":"NCI"},{"termName":">=181 Days","termGroup":"SY","termSource":"NCI"},{"termName":"At Least 181 Days","termGroup":"SY","termSource":"NCI"},{"termName":"Greater than or Equal to One Hundred Eighty One Days","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":">=181 Days"},{"name":"NCI_META_CUI","value":"CL1921187"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C36132":{"preferredName":"Poorly Differentiated Lesion","code":"C36132","definitions":[{"definition":"A lesion comprised of neoplastic cells that generally have lost most of the morphological features that are indicative of normal cells.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poorly Differentiated Lesion","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Poorly_Differentiated_Lesion"},{"name":"Maps_To","value":"Poorly differentiated"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1335443"}]}}{"C62710":{"preferredName":"Immunoglobulin Therapy","code":"C62710","definitions":[{"definition":"The use of immunoglobulins in the treatment of any disease or disorder.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Immunoglobulin Therapy","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Immunoglobulin_Therapy"},{"name":"Maps_To","value":"Immunoglobulin"},{"name":"Semantic_Type","value":"Therapeutic or Preventive Procedure"},{"name":"UMLS_CUI","value":"C0021022"}]}}{"C112014":{"preferredName":"Myasthenia Gravis Foundation of America Class I","code":"C112014","definitions":[{"definition":"Myasthenia gravis presenting with any ocular weakness; may have weakness of eye closure. All other muscles strength is normal.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class I","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class I","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class I"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828874"}]}}{"C112015":{"preferredName":"Myasthenia Gravis Foundation of America Class II","code":"C112015","definitions":[{"definition":"Myasthenia gravis presenting with mild weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class II","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class II","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class II"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828872"}]}}{"C112016":{"preferredName":"Myasthenia Gravis Foundation of America Class III","code":"C112016","definitions":[{"definition":"Myasthenia gravis presenting with moderate weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class III","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class III","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class III"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828871"}]}}{"C112017":{"preferredName":"Myasthenia Gravis Foundation of America Class IV","code":"C112017","definitions":[{"definition":"Myasthenia gravis presenting with severe weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class IV","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class IV","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class IV"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828870"}]}}{"C112018":{"preferredName":"Myasthenia Gravis Foundation of America Class V","code":"C112018","definitions":[{"definition":"Myasthenia gravis presenting with severe muscle weakness that requires intubation, with or without mechanical ventilation, except when employed during routine postoperative management.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Myasthenia Gravis Foundation of America Class V","termGroup":"PT","termSource":"NCI"},{"termName":"MGFA Class V","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Class V"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3828869"}]}}{"C198":{"preferredName":"Acetaminophen","code":"C198","definitions":[{"definition":"A drug that reduces pain and fever (but not inflammation).  It belongs to the family of drugs called analgesics.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Acetaminophen","termGroup":"PT","termSource":"NCI"},{"termName":"4-Hydroxyacetanilide","termGroup":"SN","termSource":"NCI"},{"termName":"APAP","termGroup":"AB","termSource":"NCI"},{"termName":"N-(4-Hydroxyphenyl)acetamide","termGroup":"SN","termSource":"NCI"},{"termName":"Paracetamol","termGroup":"SY","termSource":"NCI"},{"termName":"Tylenol","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"CAS_Registry","value":"103-90-2"},{"name":"CHEBI_ID","value":"CHEBI:46195"},{"name":"Chemical_Formula","value":"C8H9NO2"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"362O9ITL9D"},{"name":"Legacy Concept Name","value":"Acetaminophen"},{"name":"Maps_To","value":"Acetaminophen"},{"name":"NCI_Drug_Dictionary_ID","value":"39129"},{"name":"NSC Number","value":"109028"},{"name":"NSC Number","value":"3991"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39129"},{"name":"PDQ_Open_Trial_Search_ID","value":"39129"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0000970"}]}}{"C287":{"preferredName":"Aspirin","code":"C287","definitions":[{"definition":"A drug that reduces pain, fever, inflammation, and blood clotting. Aspirin belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is also being studied in cancer prevention.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Acetylsalicylic acid decreases synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aspirin","termGroup":"PT","termSource":"NCI"},{"termName":"2-(Acetyloxy)benzoic Acid","termGroup":"SN","termSource":"NCI"},{"termName":"Acetylsalicylic Acid","termGroup":"SY","termSource":"NCI"},{"termName":"ASA","termGroup":"AB","termSource":"NCI"},{"termName":"Aspergum","termGroup":"BR","termSource":"NCI"},{"termName":"Ecotrin","termGroup":"BR","termSource":"NCI"},{"termName":"Empirin","termGroup":"BR","termSource":"NCI"},{"termName":"Entericin","termGroup":"BR","termSource":"NCI"},{"termName":"Extren","termGroup":"BR","termSource":"NCI"},{"termName":"Measurin","termGroup":"BR","termSource":"NCI"}],"additionalProperties":[{"name":"Accepted_Therapeutic_Use_For","value":"Mild to moderate pain; fever; prevention of arterial and venous thrombosis"},{"name":"CAS_Registry","value":"50-78-2"},{"name":"CHEBI_ID","value":"CHEBI:15365"},{"name":"Chemical_Formula","value":"C9H8O4"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"HemOnc"},{"name":"FDA_UNII_Code","value":"R16CO5Y76E"},{"name":"Legacy Concept Name","value":"Acetylsalicylic_Acid"},{"name":"Maps_To","value":"Aspirin"},{"name":"NCI_Drug_Dictionary_ID","value":"39152"},{"name":"NSC Number","value":"406186"},{"name":"PDQ_Closed_Trial_Search_ID","value":"39152"},{"name":"PDQ_Open_Trial_Search_ID","value":"39152"},{"name":"Semantic_Type","value":"Organic Chemical"},{"name":"Semantic_Type","value":"Pharmacologic Substance"},{"name":"UMLS_CUI","value":"C0004057"}]}}{"C1655":{"preferredName":"HMG-CoA Reductase Inhibitor","code":"C1655","definitions":[{"definition":"An HMG-CoA reductase inhibitor (\"statin\"). Lipid-lowering medications with proven ASCVD benefits.","type":"ALT_DEFINITION","source":"ACC/AHA","qualifiers":[{"type":"attribution","value":"SARS2"}]},{"definition":"Any of a group of drugs that lower the amount of cholesterol and certain fats in the blood. Statins inhibit a key enzyme that helps make cholesterol. Statin drugs are being studied in the prevention and treatment of cancer.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"Any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Inhibition of HMG-CoA reductase acts to lower plasma cholesterol and lipoprotein levels.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"HMG-CoA Reductase Inhibitor","termGroup":"PT","termSource":"NCI"},{"termName":"Hydroxymethylglutaryl CoenzymeA Reductase Inhibitors","termGroup":"SY","termSource":"NCI"},{"termName":"Statin","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"CHEBI_ID","value":"CHEBI:35664"},{"name":"Contributing_Source","value":"ACC/AHA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"HMG-CoA_Reductase_Inhibitor"},{"name":"Maps_To","value":"Statin, NOS"},{"name":"Semantic_Type","value":"Chemical Viewed Functionally"},{"name":"UMLS_CUI","value":"C0360714"}]}}{"C202296":{"preferredName":"Continuous Oxygen Administration","code":"C202296","definitions":[{"definition":"Long-term administration of supplementary oxygen at a constant rate using a continuous flow device.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Continuous Oxygen Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Continuous O2 Administration","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Continuous"},{"name":"NCI_META_CUI","value":"CL1921286"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C202297":{"preferredName":"Intermittent Oxygen Administration","code":"C202297","definitions":[{"definition":"Administration of supplementary oxygen over a short period of time using a non-continuous flow device.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermittent Oxygen Administration","termGroup":"PT","termSource":"NCI"},{"termName":"Intermittent O2 Administration","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermittent"},{"name":"NCI_META_CUI","value":"CL1921287"},{"name":"Semantic_Type","value":"Health Care Activity"}]}}{"C114095":{"preferredName":"Full Term Birth","code":"C114095","definitions":[{"definition":"Birth at 39 weeks and 0 days through 40 weeks and 6 days gestation.","type":"ALT_DEFINITION","source":"NICHD"},{"definition":"Birth at 39 weeks and 0 days through 40 weeks and 6 days.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Full Term Birth","termGroup":"PT","termSource":"NCI"},{"termName":"Full Term","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Full Term Birth, NOS"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C3814420"}]}}{"C2959":{"preferredName":"Complication","code":"C2959","definitions":[{"definition":"Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure.","type":"DEFINITION","source":"NCI"},{"definition":"In medicine, a medical problem that occurs during a disease, or after a procedure or treatment. The complication may be caused by the disease, procedure, or treatment or may be unrelated to them.","type":"ALT_DEFINITION","source":"NCI-GLOSS"}],"synonyms":[{"termName":"Complication","termGroup":"PT","termSource":"NCI"},{"termName":"Medical Complication","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Legacy Concept Name","value":"Complication"},{"name":"Maps_To","value":"Adverse Event/Complications"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C0009566"}]}}{"C202267":{"preferredName":"Treatment not Administered per the Discretion of the Health Care Provider","code":"C202267","definitions":[{"definition":"The treatment was not administered per the discretion of the health care provider.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Treatment not Administered per the Discretion of the Health Care Provider","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Not Done per Treating Physician's Discretion"},{"name":"NCI_META_CUI","value":"CL1921260"},{"name":"Semantic_Type","value":"Idea or Concept"}]}}{"C192979":{"preferredName":"Refusal of Treatment by Patient","code":"C192979","definitions":[{"definition":"An indication that the patient has refused treatment.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Refusal of Treatment by Patient","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"mCode"},{"name":"Contributing_Source","value":"OORO"},{"name":"Maps_To","value":"Participant Refusal"},{"name":"Semantic_Type","value":"Idea or Concept"},{"name":"UMLS_CUI","value":"C0040809"}]}}{"C185642":{"preferredName":"Scheduling Issue","code":"C185642","definitions":[{"definition":"A problem scheduling an event.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Scheduling Issue","termGroup":"PT","termSource":"NCI"},{"termName":"Scheduling Problem","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Maps_To","value":"Scheduling Problems"},{"name":"NCI_META_CUI","value":"CL1773880"},{"name":"Semantic_Type","value":"Phenomenon or Process"}]}}{"C40412":{"preferredName":"Ineligibility","code":"C40412","definitions":[{"definition":"The state or quality of being disqualified by law, rule, or provision.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Ineligibility","termGroup":"PT","termSource":"NCI"},{"termName":"Ineligible","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTDC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Ineligibility"},{"name":"Maps_To","value":"Patient Ineligible"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1512714"}]}}{"C123276":{"preferredName":"BK Virus Infection","code":"C123276","definitions":[{"definition":"An infection caused by the BK virus. It usually causes an asymptomatic infection, except in immunocompromised individuals where it may cause nephropathy or hemorrhagic cystitis.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"BK Virus Infection","termGroup":"PT","termSource":"NCI"},{"termName":"BK Viral Infection","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"BK Virus"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C1096691"}]}}{"C4922":{"preferredName":"Diverticulosis","code":"C4922","definitions":[{"definition":"A condition marked by small sacs or pouches in the walls of a hollow organ, such as the colon. These sacs can become inflamed and cause a condition called diverticulitis.","type":"ALT_DEFINITION","source":"NCI-GLOSS"},{"definition":"A finding indicating the presence of multiple pouches, usually in the colonic or gastric wall.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Diverticulosis","termGroup":"PT","termSource":"NCI"},{"termName":"Diverticular Disorder","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Diverticulosis"},{"name":"Maps_To","value":"Diverticulosis"},{"name":"Semantic_Type","value":"Finding"},{"name":"UMLS_CUI","value":"C1510475"}]}}{"C94575":{"preferredName":"Scarlet Fever","code":"C94575","definitions":[{"definition":"A streptococcal infection, mainly occurring among children, that is characterized by a red skin rash, sore throat, and fever.","type":"DEFINITION","source":"NCI"},{"definition":"An erythematous, fine, papular rash  that is associated with Streptococcal pharyngitis.","type":"ALT_DEFINITION","source":"NICHD"}],"synonyms":[{"termName":"Scarlet Fever","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"NICHD"},{"name":"Maps_To","value":"Scarlet Fever"},{"name":"Semantic_Type","value":"Disease or Syndrome"},{"name":"UMLS_CUI","value":"C0036285"}]}}{"C202268":{"preferredName":"Three Point Scale for Staining Intensity","code":"C202268","definitions":[{"definition":"A scale for staining intensity with three values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Three Point Scale for Staining Intensity","termGroup":"PT","termSource":"NCI"},{"termName":"3 Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"3 Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"},{"termName":"3-Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"3-Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The values in a 3 point scale could be either 0, 1+ and 2+ or 1+, 2+ and 3+."},{"name":"Maps_To","value":"3 Point Scale"},{"name":"NCI_META_CUI","value":"CL1921257"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C202269":{"preferredName":"Four Point Scale for Staining Intensity","code":"C202269","definitions":[{"definition":"A scale for staining intensity with four values.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Four Point Scale for Staining Intensity","termGroup":"PT","termSource":"NCI"},{"termName":"4 Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"4 Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"},{"termName":"4-Point Scale for Staining","termGroup":"SY","termSource":"NCI"},{"termName":"4-Point Scale for Staining Intensity","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The values in a 4 point scale could be either 0, 1+, 2+ and 3+, or 1+, 2+, 3+ and 4+."},{"name":"Maps_To","value":"4 Point Scale"},{"name":"NCI_META_CUI","value":"CL1921258"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C186199":{"preferredName":"Staining Intensity 0","code":"C186199","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity 0","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"0"},{"name":"NCI_META_CUI","value":"CL1778742"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C186200":{"preferredName":"Staining Intensity 1+","code":"C186200","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity 1+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"1+"},{"name":"NCI_META_CUI","value":"CL1778743"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C186201":{"preferredName":"Staining Intensity 2+","code":"C186201","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.","type":"DEFINITION","source":"NCI"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Staining Intensity 2+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"2+"},{"name":"NCI_META_CUI","value":"CL1778671"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C186202":{"preferredName":"Staining Intensity 3+","code":"C186202","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.","type":"ALT_DEFINITION","source":"CDISC"},{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity 3+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"3+"},{"name":"NCI_META_CUI","value":"CL1778672"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C202273":{"preferredName":"Staining Intensity 4+","code":"C202273","definitions":[{"definition":"A measurement of the amount or proportion of tissue or cells that have a staining intensity of 4+.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Staining Intensity 4+","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"4+"},{"name":"NCI_META_CUI","value":"CL1921241"},{"name":"Semantic_Type","value":"Laboratory Procedure"}]}}{"C202276":{"preferredName":"Once a Week for at Least a Year","code":"C202276","definitions":[{"definition":"An indication that something was scheduled, or occurred, once a week for at least a year.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Once a Week for at Least a Year","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Once a Week for at Least a Year"},{"name":"NCI_META_CUI","value":"CL1921236"},{"name":"Semantic_Type","value":"Temporal Concept"}]}}{"C151974":{"preferredName":"Occasionally","code":"C151974","definitions":[{"definition":"Not frequently or regularly.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Occasionally","termGroup":"PT","termSource":"NCI"},{"termName":"Occasionally","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PRO-CTCAE"},{"name":"Maps_To","value":"Occasionally"},{"name":"NCI_META_CUI","value":"CL553196"},{"name":"Semantic_Type","value":"Quantitative Concept"}]}}{"C172572":{"preferredName":"Never Dosed","code":"C172572","definitions":[{"definition":"An indication that a subject has not ever been dosed with the study treatment or investigational product.","type":"DEFINITION","source":"NCI"},{"definition":"An indication that a subject has not ever been dosed with the study treatment or investigational product.","type":"ALT_DEFINITION","source":"CDISC"}],"synonyms":[{"termName":"Never Dosed","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CDISC"},{"name":"NCI_META_CUI","value":"CL1406672"},{"name":"Semantic_Type","value":"Qualitative Concept"}]}}{"C160757":{"preferredName":"Favorable CALGB Criteria","code":"C160757","definitions":[{"definition":"A rating for AML by CALGB which indicates the outlook on the patient recovery is favored towards recovery.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Favorable CALGB Criteria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Favorable"},{"name":"NCI_META_CUI","value":"CL969801"},{"name":"Semantic_Type","value":"Finding"}]}}{"C160758":{"preferredName":"Intermediate CALGB Criteria","code":"C160758","definitions":[{"definition":"A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered between favorable and poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Intermediate CALGB Criteria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Intermediate/Normal"},{"name":"NCI_META_CUI","value":"CL969800"},{"name":"Semantic_Type","value":"Finding"}]}}{"C160759":{"preferredName":"Poor CALGB Criteria","code":"C160759","definitions":[{"definition":"A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered poor.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Poor CALGB Criteria","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CPTAC"},{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Poor"},{"name":"NCI_META_CUI","value":"CL971180"},{"name":"Semantic_Type","value":"Finding"}]}}{"C206459":{"preferredName":"Germline Mutation Index File","code":"C206459","definitions":[{"definition":"An electronic data file containing the index for germline mutation calls.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Germline Mutation Index File","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"Germline Mutation Index"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C158623":{"preferredName":"Greater Than or Equal to Four","code":"C158623","synonyms":[{"termName":"Greater Than or Equal to Four","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"4+"},{"name":"NCI_META_CUI","value":"CL950656"},{"name":"Semantic_Type","value":"Intellectual Product"}]}}{"C206467":{"preferredName":"GeneChip Human Genome U133 Plus 2.0 Array","code":"C206467","definitions":[{"definition":"A proprietary, next-generation transcriptome profiling, microarray chip developed by Affymetrix that can be leveraged to analyze the expression level of over 47,000 human transcripts, including those in the U133A array.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GeneChip Human Genome U133 Plus 2.0 Array","termGroup":"PT","termSource":"NCI"},{"termName":"GeneChip U133 Plus 2.0 Array","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The GeneChip human genome U133 Plus 2.0 array design is based on sequence clusters from two UniGene database builds 133 and 159 (April 20, 2001 and January 25, 2003, respectively) with further refinement based on analysis and comparison with a number of other publicly available databases."},{"name":"Maps_To","value":"GeneChip U133 Plus 2.0"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C206468":{"preferredName":"GeneChip Human Genome U133A Array","code":"C206468","definitions":[{"definition":"A proprietary, next-generation transcriptome profiling, microarray chip developed by Affymetrix that can be leveraged to analyze the expression level of 18,400 human transcripts and variants.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"GeneChip Human Genome U133A Array","termGroup":"PT","termSource":"NCI"},{"termName":"GeneChip HG-U133A Array","termGroup":"SY","termSource":"NCI"},{"termName":"GeneChip U133A Array","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"DesignNote","value":"The GeneChip human genome U133A array design is based on sequence clusters from the UniGene database build 133 (April 20, 2001) with further refinement based on analysis and comparison with a number of other publicly available databases."},{"name":"Maps_To","value":"GeneChip U133A"},{"name":"Semantic_Type","value":"Manufactured Object"}]}}{"C27886":{"preferredName":"Type 1 Papillary Renal Cell Carcinoma","code":"C27886","definitions":[{"definition":"A papillary renal cell carcinoma characterized by the presence of papillae covered by small cells with scant amount of cytoplasm. The cells are arranged in a single layer on the basement membrane of the papillae.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Type 1 Papillary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Type_1_Papillary_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Type 1"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336839"}]}}{"C27887":{"preferredName":"Type 2 Papillary Renal Cell Carcinoma","code":"C27887","definitions":[{"definition":"A papillary renal cell carcinoma characterized by the presence of papillae covered by cells of a higher nuclear grade as compared to type 1 papillary renal cell carcinoma. The cells have eosinophilic cytoplasm and pseudostratified nuclei.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Type 2 Papillary Renal Cell Carcinoma","termGroup":"PT","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"CTRP"},{"name":"Contributing_Source","value":"GDC"},{"name":"Legacy Concept Name","value":"Type_2_Papillary_Renal_Cell_Carcinoma"},{"name":"Maps_To","value":"Type 2"},{"name":"Neoplastic_Status","value":"Malignant"},{"name":"Semantic_Type","value":"Neoplastic Process"},{"name":"UMLS_CUI","value":"C1336840"}]}}{"C53260":{"preferredName":"Adverse Event Definitely Related to Intervention","code":"C53260","definitions":[{"definition":"A characteristic used to qualify the adverse event as certainly related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to medical intervention, and which cannot be explained by concurrent disease or other interventions. The response to withdrawal of the medical product (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adverse Event Definitely Related to Intervention","termGroup":"PT","termSource":"NCI"},{"termName":"Certain","termGroup":"SY","termSource":"NCI"},{"termName":"Definite","termGroup":"SY","termSource":"NCI"},{"termName":"Definite Attribution","termGroup":"SY","termSource":"NCI"},{"termName":"Definitely Related to Intervention","termGroup":"SY","termSource":"NCI"},{"termName":"Related","termGroup":"SY","termSource":"NCI"},{"termName":"Related Attribution","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"It is recognized that this stringent definition will lead to very few reports meeting the criteria, but this is useful because of the special value of such reports. It is considered that time relationships between drug administration and the onset and course of the adverse event are important in causality analysis. So also is the consideration of confounding features, but due weight must placed on the known pharmacological and other characteristics of the drug product being considered. Sometimes the clinical phenomena described will also be sufficiently specific to allow a confident causality assessment in the absence of confounding features and with appropriate time relationships (WHO)."},{"name":"Legacy Concept Name","value":"Definitely_Related_to_Intervention"},{"name":"Maps_To","value":"Definitely"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1704787"}]}}{"C53258":{"preferredName":"Adverse Event Possibly Related to Intervention","code":"C53258","definitions":[{"definition":"A characteristic indicating that an adverse event may be related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adverse Event Possibly Related to Intervention","termGroup":"PT","termSource":"NCI"},{"termName":"Possible","termGroup":"SY","termSource":"NCI"},{"termName":"Possible Attribution","termGroup":"SY","termSource":"NCI"},{"termName":"Possibly Related","termGroup":"SY","termSource":"NCI"},{"termName":"Possibly Related to Intervention","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"This is the definition to be used when drug causality is one of other possible causes for the described clinical event (WHO)."},{"name":"Legacy Concept Name","value":"Possibly_Related_to_Intervention"},{"name":"Maps_To","value":"Possibly"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1705910"}]}}{"C53259":{"preferredName":"Adverse Event Probably Related to Intervention","code":"C53259","definitions":[{"definition":"A characteristic used to qualify the adverse event as likely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to the medical intervention, unlikely to be attributed to concurrent disease or other medical interventions, and which follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adverse Event Probably Related to Intervention","termGroup":"PT","termSource":"NCI"},{"termName":"Likely Related","termGroup":"SY","termSource":"NCI"},{"termName":"Probable Attribution","termGroup":"SY","termSource":"NCI"},{"termName":"Probably Related","termGroup":"SY","termSource":"NCI"},{"termName":"Probably Related to Intervention","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"OORO"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"This definition has less stringent wording than for \"certain\" and does not necessitate prior knowledge of drug characteristics or clinical adverse reaction phenomena. As stated no rechallenge information is needed, but confounding drug administration underlying disease must be absent (WHO)."},{"name":"Legacy Concept Name","value":"Probably_Related_to_Intervention"},{"name":"Maps_To","value":"Probably"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1709683"}]}}{"C53257":{"preferredName":"Adverse Event Unlikely Related to Intervention","code":"C53257","definitions":[{"definition":"A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adverse Event Unlikely Related to Intervention","termGroup":"PT","termSource":"NCI"},{"termName":"Doubtful Attribution","termGroup":"SY","termSource":"NCI"},{"termName":"Unlikely","termGroup":"SY","termSource":"NCI"},{"termName":"Unlikely Adverse Event Attribution to Product or Procedure","termGroup":"SY","termSource":"NCI"},{"termName":"Unlikely Attribution","termGroup":"SY","termSource":"NCI"},{"termName":"Unlikely Related","termGroup":"SY","termSource":"NCI"},{"termName":"Unlikely Related to Intervention","termGroup":"SY","termSource":"NCI"},{"termName":"Unlikley Adverse Event Attribution to Product or Procedure","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"FDA"},{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"DesignNote","value":"This definition is intended to be used when the exclusion of drug causality of a clinical event seems most plausible (WHO)."},{"name":"Legacy Concept Name","value":"Unlikely_Related_to_Intervention"},{"name":"Maps_To","value":"Unlikely"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1710571"}]}}{"C53256":{"preferredName":"Adverse Event Unrelated to Intervention","code":"C53256","definitions":[{"definition":"A characteristic used to qualify the adverse event as clearly not related to the medical intervention.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Adverse Event Unrelated to Intervention","termGroup":"PT","termSource":"NCI"},{"termName":"Unrelated","termGroup":"SY","termSource":"NCI"},{"termName":"Unrelated Attribution","termGroup":"SY","termSource":"NCI"},{"termName":"Unrelated to Intervention","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Contributing_Source","value":"PCDC"},{"name":"Legacy Concept Name","value":"Unrelated_to_Intervention"},{"name":"Maps_To","value":"Unrelated"},{"name":"Semantic_Type","value":"Qualitative Concept"},{"name":"UMLS_CUI","value":"C1704623"}]}}{"C206483":{"preferredName":"Aligned Read Coverage 16x","code":"C206483","definitions":[{"definition":"The extent of coverage for aligned reads was 16x.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Read Coverage 16x","termGroup":"PT","termSource":"NCI"},{"termName":"Aligned Read Depth 16x","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"16"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C206481":{"preferredName":"Aligned Read Coverage 10-25x","code":"C206481","definitions":[{"definition":"The range of coverage for aligned reads was between 10x and 25x.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Read Coverage 10-25x","termGroup":"PT","termSource":"NCI"},{"termName":"Aligned Read Depth 10-25x","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"10x-25x"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C206482":{"preferredName":"Aligned Read Coverage Greater than or Equal to 150x","code":"C206482","definitions":[{"definition":"The range of coverage for aligned reads was greater than or equal to 150x.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Read Coverage Greater than or Equal to 150x","termGroup":"PT","termSource":"NCI"},{"termName":"Aligned Read Depth Greater than or Equal to 150x","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"150x+"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}{"C206484":{"preferredName":"Aligned Read Coverage 25-150x","code":"C206484","definitions":[{"definition":"The range of coverage for aligned reads was between 25x and 150x.","type":"DEFINITION","source":"NCI"}],"synonyms":[{"termName":"Aligned Read Coverage 25-150x","termGroup":"PT","termSource":"NCI"},{"termName":"Aligned Read Depth 25-150x","termGroup":"SY","termSource":"NCI"}],"additionalProperties":[{"name":"Contributing_Source","value":"GDC"},{"name":"Maps_To","value":"25x-150x"},{"name":"Semantic_Type","value":"Conceptual Entity"}]}}
\ No newline at end of file